cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
HNSC	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	33.96	3.15e-128	9.65e-121	1.2	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	33.13	1.08e-124	3.29e-118	1.21	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	33.13	1.08e-124	3.29e-118	1.21	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	32.62	1.73e-122	2.31e-116	1.2	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	32.61	1.97e-122	2.31e-116	1.22	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	32.61	1.97e-122	2.31e-116	1.22	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	32.46	8.59e-122	9.74e-116	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	32.34	2.71e-121	2.96e-115	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	32.22	9.2e-121	9.71e-115	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	32.16	1.69e-120	1.73e-114	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-30.89	6.37e-115	1.93e-109	-1.16	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-30.58	1.51e-113	4.32e-108	-1.14	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	30.47	4.58e-113	1.3e-107	1.2	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	30.32	2.06e-112	5.72e-107	1.16	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-30.31	2.21e-112	5.99e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-30.31	2.21e-112	5.99e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-30.29	2.83e-112	7.53e-107	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	30.22	5.67e-112	1.48e-106	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	30.22	5.67e-112	1.48e-106	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-30.16	1.04e-111	2.62e-106	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-30.16	1.04e-111	2.62e-106	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	30.13	1.52e-111	3.79e-106	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-29.97	7.56e-111	1.87e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-29.93	1.14e-110	2.78e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-29.83	3.32e-110	8e-105	-1.16	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-29.78	5.32e-110	1.27e-104	-1.11	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-29.65	1.99e-109	4.68e-104	-1.17	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-29.65	1.99e-109	4.68e-104	-1.17	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	28.8	1.28e-105	2.91e-100	1.06	0.8	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.74	2.36e-105	5.32e-100	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-28.74	2.51e-105	5.58e-100	-1.07	-0.8	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-28.67	4.93e-105	1.09e-99	-1.07	-0.8	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	28.67	5.3e-105	1.16e-99	1.08	0.8	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	28.64	6.92e-105	1.46e-99	1.08	0.8	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	28.62	8.24e-105	1.7e-99	1.07	0.8	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	28.62	8.24e-105	1.7e-99	1.07	0.8	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	28.55	1.86e-104	3.18e-99	1.07	0.8	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	28.54	2.02e-104	3.43e-99	1.07	0.8	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	28.5	2.96e-104	4.98e-99	1.07	0.8	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	28.46	4.5e-104	7.06e-99	1.07	0.8	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	28.46	4.62e-104	7.21e-99	1.07	0.8	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	28.43	6.21e-104	9.66e-99	1.07	0.8	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	28.35	1.46e-103	2.23e-98	1.15	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	28.31	2.24e-103	3.4e-98	0.89	0.79	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	28.28	2.85e-103	4.28e-98	1.06	0.79	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	28.28	2.85e-103	4.28e-98	1.06	0.79	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	28.24	4.63e-103	6.89e-98	1.06	0.79	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	28.24	4.63e-103	6.89e-98	1.06	0.79	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-28.22	5.56e-103	8.22e-98	-1.05	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	28.15	1.1e-102	1.61e-97	1.06	0.79	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	28.15	1.1e-102	1.61e-97	1.06	0.79	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	28.15	1.16e-102	1.69e-97	1.06	0.79	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	28.08	2.28e-102	3.25e-97	1.06	0.79	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	28	5.71e-102	7.6e-97	1.06	0.79	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	27.69	1.41e-100	1.83e-95	1.06	0.79	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	27.69	1.41e-100	1.83e-95	1.06	0.79	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	27.67	1.75e-100	2.27e-95	1.06	0.79	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	27.66	1.9e-100	2.46e-95	1.07	0.79	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	27.63	2.63e-100	3.39e-95	1.06	0.79	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	27.44	2e-99	2.49e-94	1.14	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	27.44	2e-99	2.49e-94	1.14	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	27.43	2.31e-99	2.86e-94	1.05	0.79	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	27.41	2.65e-99	3.26e-94	1.06	0.79	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	27.4	2.96e-99	3.61e-94	1.06	0.79	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	27.39	3.27e-99	3.97e-94	1.06	0.79	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	27.37	4.06e-99	4.77e-94	1.05	0.78	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	27.36	4.43e-99	5.12e-94	1.05	0.78	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	27.36	4.43e-99	5.12e-94	1.05	0.78	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	27.33	6.15e-99	7.08e-94	1.05	0.78	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	27.31	7.41e-99	8.5e-94	1.05	0.78	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	27.31	7.51e-99	8.58e-94	1.04	0.78	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	27.29	9.46e-99	1.07e-93	1.06	0.78	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	27.28	1.1e-98	1.25e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	27.24	1.67e-98	1.88e-93	1.05	0.78	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	27.23	1.77e-98	1.98e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.16	3.78e-98	4.2e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.16	3.78e-98	4.2e-93	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	27.14	4.84e-98	5.33e-93	1.05	0.78	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	27.11	6.52e-98	7.16e-93	1.12	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	27.1	6.99e-98	7.64e-93	1.04	0.78	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	27.04	1.28e-97	1.39e-92	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	27.04	1.41e-97	1.52e-92	1.07	0.78	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	27.02	1.71e-97	1.84e-92	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	27.01	1.78e-97	1.91e-92	1.05	0.78	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	27.01	1.83e-97	1.95e-92	1.05	0.78	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	27.01	1.83e-97	1.95e-92	1.05	0.78	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	26.95	3.5e-97	3.71e-92	1.04	0.78	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	26.93	4.35e-97	4.59e-92	1.06	0.78	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	26.9	6.11e-97	6.43e-92	0.87	0.78	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
HNSC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	26.88	7.04e-97	7.38e-92	1.03	0.78	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
HNSC	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	26.77	2.31e-96	2.39e-91	1.13	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	26.68	6.26e-96	6.47e-91	0.87	0.78	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	26.6	1.43e-95	1.47e-90	1.04	0.78	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-26.54	2.73e-95	2.77e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-26.54	2.73e-95	2.77e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-26.53	3.09e-95	3.09e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-26.53	3.09e-95	3.09e-90	-0.87	-0.78	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-26.51	3.58e-95	3.57e-90	-1.04	-0.78	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-26.5	4.25e-95	4.22e-90	-0.87	-0.77	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	26.35	2.07e-94	2.04e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
HNSC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-26.31	2.99e-94	2.92e-89	-1.03	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-26.3	3.24e-94	3.15e-89	-0.91	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	26.3	3.46e-94	3.35e-89	0.85	0.77	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	26.27	4.72e-94	4.56e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	26.26	4.93e-94	4.7e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	26.26	4.93e-94	4.7e-89	0.86	0.77	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	26.06	4.41e-93	4.14e-88	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	26.06	4.51e-93	4.23e-88	1.03	0.77	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	25.97	1.15e-92	1.08e-87	0.86	0.77	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	25.88	2.79e-92	2.59e-87	1.14	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-25.85	3.89e-92	3.6e-87	-1.09	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	25.81	6.13e-92	5.63e-87	0.86	0.77	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	25.7	1.96e-91	1.78e-86	0.85	0.77	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	25.7	1.96e-91	1.78e-86	0.85	0.77	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	25.62	4.66e-91	4.23e-86	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	25.61	5.14e-91	4.65e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-25.61	5.36e-91	4.84e-86	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	25.59	6.57e-91	5.91e-86	1.03	0.76	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	25.57	7.87e-91	7.06e-86	1.11	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	25.55	9.8e-91	8.74e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	25.55	9.8e-91	8.74e-86	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-25.49	1.79e-90	1.58e-85	-1.11	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-25.49	1.79e-90	1.58e-85	-1.11	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-25.44	3.31e-90	2.92e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	25.42	3.76e-90	3.31e-85	0.84	0.76	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	25.34	9.34e-90	8.12e-85	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-25.34	9.34e-90	8.12e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-25.34	9.34e-90	8.12e-85	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
HNSC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	25.31	1.26e-89	1.08e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	25.28	1.84e-89	1.58e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	25.26	2.2e-89	1.87e-84	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	25.23	3.14e-89	2.65e-84	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-25.19	4.5e-89	3.78e-84	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	25.18	5e-89	4.17e-84	1.01	0.76	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	25.18	5e-89	4.17e-84	1.01	0.76	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-25.18	5.07e-89	4.22e-84	-1.05	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	25.15	6.94e-89	5.76e-84	0.89	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	25.14	8e-89	6.62e-84	1.03	0.76	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	25.13	8.34e-89	6.88e-84	1.04	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	25.12	1e-88	8.26e-84	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
HNSC	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	25.09	1.3e-88	1.07e-83	1.01	0.76	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-25.07	1.66e-88	1.36e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	25.06	1.86e-88	1.52e-83	1.03	0.76	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	25.04	2.3e-88	1.88e-83	0.85	0.76	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-25.04	2.34e-88	1.9e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-25.04	2.34e-88	1.9e-83	-1.09	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	25.03	2.57e-88	2.08e-83	0.86	0.76	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-24.98	4.46e-88	3.59e-83	-0.84	-0.76	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	24.97	4.8e-88	3.84e-83	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	24.94	6.93e-88	5.54e-83	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-24.88	1.23e-87	9.82e-83	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-24.87	1.43e-87	1.14e-82	-0.84	-0.75	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	24.82	2.47e-87	1.94e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	24.76	4.54e-87	3.55e-82	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	24.74	5.87e-87	4.59e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	24.74	5.89e-87	4.59e-82	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	24.67	1.24e-86	9.62e-82	1.1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	24.66	1.3e-86	1e-81	0.84	0.75	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	24.62	2.08e-86	1.59e-81	1.01	0.75	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	24.62	2.08e-86	1.59e-81	1.01	0.75	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
HNSC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-24.6	2.49e-86	1.9e-81	-1.01	-0.75	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
HNSC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-24.59	2.72e-86	2.06e-81	-1.02	-0.75	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	24.59	2.85e-86	2.16e-81	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-24.55	4.25e-86	3.2e-81	-0.83	-0.75	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	24.47	1.03e-85	7.64e-81	0.99	0.75	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	24.35	3.8e-85	2.75e-80	1.09	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	24.34	4.06e-85	2.93e-80	1	0.75	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	24.34	4.06e-85	2.93e-80	1	0.75	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	24.27	8.53e-85	6.1e-80	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	24.25	1.09e-84	7.69e-80	0.99	0.75	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	24.25	1.09e-84	7.69e-80	0.99	0.75	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	24.22	1.55e-84	1.09e-79	0.99	0.75	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	24.22	1.55e-84	1.09e-79	0.99	0.75	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	24.19	2.09e-84	1.46e-79	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	24.18	2.47e-84	1.72e-79	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	24.17	2.68e-84	1.86e-79	1	0.75	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	24.17	2.68e-84	1.86e-79	1	0.75	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	24.15	3.2e-84	2.21e-79	0.99	0.75	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	24.13	3.97e-84	2.73e-79	0.99	0.74	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	24.13	3.97e-84	2.73e-79	0.99	0.74	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	24.12	4.28e-84	2.92e-79	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	24.08	6.8e-84	4.62e-79	0.99	0.74	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	24.04	1.08e-83	7.34e-79	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	24	1.66e-83	1.12e-78	0.99	0.74	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	23.98	2.01e-83	1.35e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	23.95	2.69e-83	1.8e-78	0.99	0.74	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-23.95	2.78e-83	1.85e-78	-0.9	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	23.94	2.96e-83	1.97e-78	0.99	0.74	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	23.93	3.57e-83	2.36e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	23.93	3.57e-83	2.36e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	23.89	5.04e-83	3.31e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	23.89	5.36e-83	3.51e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	23.89	5.44e-83	3.53e-78	0.99	0.74	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	23.89	5.44e-83	3.53e-78	0.99	0.74	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	23.88	6.11e-83	3.97e-78	0.99	0.74	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	23.85	8.18e-83	5.29e-78	0.99	0.74	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	23.85	8.54e-83	5.51e-78	1	0.74	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	23.84	8.81e-83	5.66e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	23.84	8.81e-83	5.66e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	23.84	9.41e-83	6.03e-78	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	23.83	1.01e-82	6.43e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	23.83	1.02e-82	6.49e-78	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	23.82	1.07e-82	6.82e-78	0.99	0.74	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	23.81	1.32e-82	8.39e-78	0.98	0.74	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	23.8	1.36e-82	8.54e-78	0.99	0.74	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	23.79	1.61e-82	1.01e-77	0.99	0.74	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	23.79	1.61e-82	1.01e-77	0.99	0.74	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	23.78	1.71e-82	1.07e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	23.77	1.98e-82	1.23e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	23.77	2.02e-82	1.26e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	23.76	2.22e-82	1.38e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	23.75	2.39e-82	1.48e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	23.75	2.39e-82	1.48e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	23.73	2.97e-82	1.83e-77	0.98	0.74	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	23.72	3.28e-82	2.02e-77	0.99	0.74	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	23.72	3.35e-82	2.05e-77	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	23.7	3.97e-82	2.42e-77	0.98	0.74	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	23.7	3.97e-82	2.42e-77	0.98	0.74	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	23.7	4.16e-82	2.53e-77	0.98	0.74	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	23.7	4.3e-82	2.61e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	23.7	4.3e-82	2.61e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	23.68	5.14e-82	3.11e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	23.67	5.45e-82	3.29e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	23.66	6.02e-82	3.61e-77	0.98	0.74	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	23.66	6.02e-82	3.61e-77	0.98	0.74	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	23.66	6.46e-82	3.87e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	23.66	6.51e-82	3.89e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	23.66	6.51e-82	3.89e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	23.65	6.84e-82	4.08e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	23.64	8.04e-82	4.77e-77	0.98	0.74	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	23.63	8.8e-82	5.21e-77	0.88	0.74	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	23.62	9.69e-82	5.73e-77	0.98	0.74	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	23.61	1.12e-81	6.62e-77	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	23.54	2.24e-81	1.3e-76	0.98	0.74	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	23.53	2.46e-81	1.43e-76	0.98	0.74	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	23.52	2.74e-81	1.58e-76	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-23.52	2.86e-81	1.65e-76	-1.04	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	23.52	3.01e-81	1.73e-76	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	23.52	3.01e-81	1.73e-76	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	23.5	3.51e-81	2.01e-76	0.99	0.74	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-23.49	3.82e-81	2.18e-76	-0.98	-0.74	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	23.45	5.99e-81	3.42e-76	0.98	0.74	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	23.44	6.51e-81	3.7e-76	0.97	0.74	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	23.44	6.78e-81	3.84e-76	0.98	0.74	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	23.44	6.78e-81	3.84e-76	0.98	0.74	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	23.42	8.19e-81	4.62e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	23.42	8.3e-81	4.68e-76	0.98	0.73	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	23.39	1.11e-80	6.22e-76	0.97	0.73	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	23.38	1.36e-80	7.54e-76	0.98	0.73	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	23.36	1.64e-80	9e-76	0.97	0.73	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	23.32	2.61e-80	1.43e-75	0.97	0.73	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	23.31	2.83e-80	1.54e-75	1	0.73	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	23.3	2.97e-80	1.62e-75	0.97	0.73	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	23.27	4.26e-80	2.31e-75	0.97	0.73	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	23.27	4.26e-80	2.31e-75	0.97	0.73	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	23.27	4.48e-80	2.43e-75	0.97	0.73	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	23.24	5.91e-80	3.18e-75	0.97	0.73	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	23.21	8.13e-80	4.34e-75	1	0.73	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	23.21	8.13e-80	4.34e-75	1	0.73	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	23.19	1.02e-79	5.43e-75	0.92	0.73	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	23.14	1.72e-79	9.04e-75	0.97	0.73	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	23.14	1.72e-79	9.04e-75	0.97	0.73	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	23.13	1.95e-79	1.02e-74	0.83	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	23.12	2.19e-79	1.14e-74	0.97	0.73	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	23.1	2.8e-79	1.45e-74	0.84	0.73	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	23.09	2.93e-79	1.52e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	23.09	2.97e-79	1.53e-74	0.97	0.73	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	23.09	2.97e-79	1.53e-74	0.97	0.73	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	23.09	3.06e-79	1.56e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	23.07	3.53e-79	1.79e-74	0.97	0.73	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	23.07	3.53e-79	1.79e-74	0.97	0.73	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	23.07	3.61e-79	1.83e-74	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	23.07	3.7e-79	1.87e-74	0.96	0.73	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	23.06	4.16e-79	2.1e-74	0.99	0.73	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	23.05	4.53e-79	2.28e-74	0.97	0.73	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	23.04	5.38e-79	2.71e-74	0.97	0.73	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	23.03	5.44e-79	2.73e-74	0.97	0.73	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	23.03	5.67e-79	2.83e-74	0.97	0.73	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	22.97	1.07e-78	5.28e-74	0.99	0.73	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	22.95	1.41e-78	6.97e-74	0.96	0.73	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	22.94	1.45e-78	7.11e-74	0.99	0.73	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	22.94	1.56e-78	7.67e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	22.94	1.56e-78	7.67e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	22.93	1.67e-78	8.18e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	22.93	1.7e-78	8.32e-74	0.97	0.73	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	22.92	1.89e-78	9.23e-74	0.96	0.73	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	22.92	1.97e-78	9.6e-74	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	22.91	2.13e-78	1.03e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	22.9	2.34e-78	1.13e-73	0.99	0.73	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	22.9	2.36e-78	1.14e-73	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	22.89	2.46e-78	1.18e-73	0.97	0.73	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	22.89	2.48e-78	1.19e-73	0.96	0.73	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	22.88	2.74e-78	1.31e-73	0.82	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	22.86	3.63e-78	1.73e-73	0.96	0.73	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	22.84	4.42e-78	2.09e-73	0.99	0.73	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	22.8	7.2e-78	3.39e-73	0.96	0.73	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	22.78	8.33e-78	3.89e-73	0.96	0.73	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	22.78	8.75e-78	4.08e-73	1	0.73	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	22.77	9.33e-78	4.35e-73	0.99	0.73	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	22.76	1.02e-77	4.71e-73	0.96	0.73	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	22.74	1.24e-77	5.75e-73	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	22.74	1.31e-77	6e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	22.74	1.36e-77	6.25e-73	0.96	0.72	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	22.73	1.46e-77	6.66e-73	0.79	0.72	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-22.73	1.47e-77	6.68e-73	-0.88	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	22.73	1.47e-77	6.68e-73	0.96	0.72	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	22.73	1.47e-77	6.68e-73	0.96	0.72	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	22.71	1.73e-77	7.84e-73	0.95	0.72	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	22.71	1.74e-77	7.85e-73	0.96	0.72	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
HNSC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	22.71	1.79e-77	8e-73	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-22.7	2.02e-77	9.01e-73	-0.89	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	22.69	2.28e-77	1.02e-72	0.99	0.72	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	22.68	2.6e-77	1.15e-72	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	22.68	2.61e-77	1.15e-72	0.99	0.72	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	22.67	2.91e-77	1.28e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	22.63	4.08e-77	1.8e-72	0.96	0.72	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
HNSC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	22.63	4.25e-77	1.87e-72	1.05	0.72	Shingles;	chr7:38346957	chr7:38343894~38350022:-
HNSC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	22.61	5.4e-77	2.37e-72	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	22.59	6.89e-77	3.01e-72	0.96	0.72	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	22.57	8.3e-77	3.62e-72	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	22.56	8.88e-77	3.84e-72	0.95	0.72	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	22.55	1.04e-76	4.49e-72	0.98	0.72	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	22.55	1.05e-76	4.51e-72	0.99	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	22.54	1.14e-76	4.9e-72	1	0.72	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	22.51	1.58e-76	6.77e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	22.51	1.61e-76	6.87e-72	0.96	0.72	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	22.51	1.61e-76	6.87e-72	0.96	0.72	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	22.5	1.69e-76	7.2e-72	0.95	0.72	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	22.49	1.97e-76	8.39e-72	0.82	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	22.48	2.11e-76	8.96e-72	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	22.48	2.23e-76	9.43e-72	0.99	0.72	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	22.48	2.23e-76	9.43e-72	0.99	0.72	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-22.47	2.51e-76	1.06e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-22.4	4.9e-76	2.04e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	22.39	5.68e-76	2.36e-71	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	22.39	5.68e-76	2.36e-71	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	22.36	7.85e-76	3.26e-71	0.96	0.72	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	22.36	8.16e-76	3.38e-71	0.96	0.72	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	22.36	8.24e-76	3.41e-71	0.97	0.72	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
HNSC	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	22.36	8.28e-76	3.42e-71	0.95	0.72	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-22.34	9.95e-76	4.11e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-22.32	1.19e-75	4.89e-71	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	22.32	1.23e-75	5.05e-71	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	22.32	1.25e-75	5.11e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	22.31	1.35e-75	5.51e-71	0.99	0.72	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-22.31	1.4e-75	5.74e-71	-1.05	-0.72	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	22.3	1.51e-75	6.14e-71	0.94	0.72	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	22.3	1.59e-75	6.46e-71	0.96	0.72	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	22.27	2.2e-75	8.92e-71	0.82	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	22.26	2.28e-75	9.18e-71	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	22.25	2.49e-75	1e-70	0.86	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	22.24	3.07e-75	1.23e-70	0.97	0.72	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	22.23	3.11e-75	1.25e-70	0.89	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	22.23	3.37e-75	1.35e-70	0.98	0.72	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	22.21	3.86e-75	1.54e-70	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	22.21	4.01e-75	1.6e-70	0.95	0.72	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-22.21	4.2e-75	1.67e-70	-0.88	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	22.2	4.58e-75	1.82e-70	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	22.19	5.12e-75	2.03e-70	0.97	0.72	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	22.17	5.97e-75	2.36e-70	0.95	0.72	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-22.15	7.91e-75	3.12e-70	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-22.15	7.91e-75	3.12e-70	-0.89	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	22.13	1.01e-74	3.98e-70	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	22.12	1.05e-74	4.12e-70	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	22.12	1.11e-74	4.35e-70	0.9	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	22.12	1.11e-74	4.36e-70	0.98	0.72	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	22.11	1.22e-74	4.77e-70	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-22.08	1.57e-74	6.06e-70	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	22.08	1.58e-74	6.06e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	22.06	2.15e-74	8.23e-70	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	22.05	2.38e-74	9.11e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-22.02	3.13e-74	1.2e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-22.01	3.69e-74	1.41e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-22	4.07e-74	1.55e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	21.99	4.41e-74	1.67e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	21.99	4.41e-74	1.67e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	21.98	4.67e-74	1.76e-69	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-21.98	4.72e-74	1.78e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	21.98	5.1e-74	1.92e-69	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	21.97	5.14e-74	1.93e-69	0.97	0.71	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	21.97	5.19e-74	1.95e-69	0.96	0.71	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	21.96	6.24e-74	2.33e-69	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	21.96	6.24e-74	2.33e-69	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	21.94	7.26e-74	2.71e-69	0.96	0.71	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	21.93	8.09e-74	3.01e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-21.93	8.49e-74	3.15e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-21.92	9.58e-74	3.55e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-21.92	9.74e-74	3.61e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	21.91	9.94e-74	3.68e-69	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-21.89	1.23e-73	4.52e-69	-0.81	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	21.89	1.32e-73	4.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-21.89	1.32e-73	4.82e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-21.89	1.32e-73	4.82e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-21.88	1.41e-73	5.14e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	21.88	1.51e-73	5.5e-69	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	21.87	1.63e-73	5.93e-69	0.82	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-21.87	1.66e-73	6.02e-69	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	21.87	1.67e-73	6.05e-69	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	21.86	1.7e-73	6.15e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	21.86	1.77e-73	6.41e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	21.86	1.77e-73	6.41e-69	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-21.86	1.8e-73	6.5e-69	-0.94	-0.71	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	21.84	2.19e-73	7.89e-69	1.04	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	21.83	2.46e-73	8.85e-69	0.95	0.71	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-21.83	2.49e-73	8.96e-69	-0.96	-0.71	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-21.83	2.53e-73	9.08e-69	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	21.82	2.72e-73	9.71e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	21.82	2.75e-73	9.82e-69	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-21.82	2.83e-73	1.01e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	21.82	2.83e-73	1.01e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	21.81	2.95e-73	1.05e-68	0.96	0.71	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	21.81	2.95e-73	1.05e-68	0.96	0.71	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	21.79	3.73e-73	1.31e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	21.79	3.73e-73	1.31e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	21.79	3.98e-73	1.4e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-21.76	5.4e-73	1.9e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	21.75	5.92e-73	2.08e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	21.75	6.13e-73	2.14e-68	0.89	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	21.74	6.65e-73	2.32e-68	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	21.73	6.92e-73	2.41e-68	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-21.73	7.33e-73	2.55e-68	-0.89	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-21.73	7.35e-73	2.55e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-21.73	7.35e-73	2.55e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-21.72	8.35e-73	2.89e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	21.72	8.47e-73	2.93e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	21.71	8.65e-73	2.99e-68	0.96	0.71	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-21.71	8.81e-73	3.03e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-21.71	9.49e-73	3.25e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	21.7	9.7e-73	3.32e-68	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	21.69	1.1e-72	3.72e-68	0.95	0.71	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	21.69	1.1e-72	3.72e-68	0.95	0.71	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-21.69	1.14e-72	3.86e-68	-0.8	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	21.69	1.15e-72	3.88e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	21.69	1.17e-72	3.96e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
HNSC	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	21.68	1.29e-72	4.36e-68	0.97	0.71	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-21.67	1.34e-72	4.48e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	21.66	1.6e-72	5.34e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	21.66	1.6e-72	5.34e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	21.65	1.66e-72	5.54e-68	0.96	0.71	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-21.65	1.78e-72	5.93e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-21.65	1.78e-72	5.93e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	21.64	1.84e-72	6.13e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-21.64	2.03e-72	6.74e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	21.62	2.34e-72	7.76e-68	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	21.62	2.48e-72	8.23e-68	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-21.62	2.49e-72	8.25e-68	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-21.61	2.7e-72	8.91e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-21.61	2.81e-72	9.26e-68	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	21.59	3.4e-72	1.12e-67	0.88	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	21.58	3.89e-72	1.28e-67	0.95	0.71	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	21.57	4.09e-72	1.34e-67	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	21.57	4.24e-72	1.39e-67	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	21.57	4.27e-72	1.39e-67	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	21.57	4.33e-72	1.41e-67	0.89	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-21.56	4.62e-72	1.51e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-21.54	5.55e-72	1.8e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	21.54	5.85e-72	1.9e-67	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	21.54	5.87e-72	1.9e-67	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-21.52	7.36e-72	2.38e-67	-0.88	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-21.49	9.56e-72	3.09e-67	-0.87	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	21.47	1.16e-71	3.76e-67	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-21.45	1.45e-71	4.68e-67	-0.89	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	21.45	1.51e-71	4.87e-67	0.89	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	21.45	1.57e-71	5.04e-67	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-21.43	1.79e-71	5.7e-67	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-21.43	1.79e-71	5.7e-67	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	21.42	2.02e-71	6.4e-67	0.96	0.7	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	21.41	2.26e-71	7.16e-67	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	21.41	2.43e-71	7.64e-67	0.96	0.7	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-21.4	2.68e-71	8.45e-67	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.39	2.93e-71	9.19e-67	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-21.36	4e-71	1.25e-66	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	21.31	6.64e-71	2.07e-66	1.01	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	21.3	7.74e-71	2.42e-66	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	21.28	9.22e-71	2.87e-66	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	21.28	9.22e-71	2.87e-66	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	21.26	1.25e-70	3.85e-66	0.96	0.7	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-21.25	1.32e-70	4.08e-66	-0.87	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	21.25	1.35e-70	4.16e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	21.25	1.35e-70	4.16e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	21.24	1.41e-70	4.31e-66	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	21.24	1.43e-70	4.39e-66	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.22	1.77e-70	5.42e-66	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-21.22	1.78e-70	5.43e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-21.21	1.98e-70	6.02e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-21.21	1.98e-70	6.02e-66	-0.88	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-21.21	2.14e-70	6.51e-66	-0.94	-0.7	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-21.12	5.62e-70	1.7e-65	-0.86	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-21.11	6.2e-70	1.87e-65	-0.83	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	21.1	6.75e-70	2.02e-65	0.95	0.7	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	21.09	7.29e-70	2.18e-65	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	21.09	7.41e-70	2.22e-65	0.94	0.7	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	21.09	7.73e-70	2.31e-65	0.95	0.7	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-21.03	1.48e-69	4.41e-65	-0.79	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	20.99	2.1e-69	6.2e-65	0.87	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	20.99	2.3e-69	6.79e-65	0.98	0.7	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-20.97	2.67e-69	7.9e-65	-0.86	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-20.97	2.7e-69	7.96e-65	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-20.94	3.6e-69	1.05e-64	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	20.93	4.02e-69	1.18e-64	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	20.93	4.27e-69	1.25e-64	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-20.92	4.63e-69	1.35e-64	-1.01	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-20.92	4.79e-69	1.39e-64	-1.01	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-20.91	5.41e-69	1.57e-64	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	20.9	5.65e-69	1.64e-64	0.86	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	20.89	6.35e-69	1.83e-64	0.78	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-20.89	6.85e-69	1.97e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-20.89	6.85e-69	1.97e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	20.87	8.46e-69	2.42e-64	0.93	0.69	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-20.86	9.12e-69	2.61e-64	-0.86	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-20.85	1.03e-68	2.93e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	20.84	1.13e-68	3.21e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-20.83	1.2e-68	3.4e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-20.83	1.2e-68	3.4e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	20.83	1.29e-68	3.63e-64	0.85	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-20.83	1.3e-68	3.68e-64	-1.01	-0.69	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	20.82	1.35e-68	3.82e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	20.81	1.5e-68	4.21e-64	0.84	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	20.81	1.56e-68	4.4e-64	0.97	0.69	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-20.8	1.76e-68	4.93e-64	-0.99	-0.69	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-20.79	2.01e-68	5.63e-64	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-20.76	2.68e-68	7.48e-64	-1.02	-0.69	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	20.75	3.02e-68	8.42e-64	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	20.71	4.33e-68	1.2e-63	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	20.71	4.62e-68	1.28e-63	0.94	0.69	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	20.7	4.9e-68	1.36e-63	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	20.7	5.35e-68	1.48e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	20.69	5.55e-68	1.54e-63	0.97	0.69	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	20.68	5.98e-68	1.65e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	20.68	6.56e-68	1.81e-63	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-20.66	7.54e-68	2.07e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	20.66	7.59e-68	2.08e-63	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	20.66	8.17e-68	2.23e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-20.65	9e-68	2.45e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-20.62	1.24e-67	3.35e-63	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-20.61	1.32e-67	3.56e-63	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	20.61	1.33e-67	3.58e-63	0.95	0.69	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-20.6	1.51e-67	4.07e-63	-0.99	-0.69	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-20.59	1.62e-67	4.35e-63	-1.02	-0.69	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-20.59	1.62e-67	4.35e-63	-1.02	-0.69	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	20.59	1.7e-67	4.55e-63	0.97	0.69	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-20.59	1.71e-67	4.56e-63	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	20.59	1.71e-67	4.56e-63	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	20.58	1.79e-67	4.76e-63	0.97	0.69	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	20.58	1.88e-67	5e-63	0.95	0.69	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-20.57	2.13e-67	5.65e-63	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	20.56	2.21e-67	5.86e-63	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	20.54	2.95e-67	7.81e-63	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	20.54	2.95e-67	7.81e-63	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	20.54	2.95e-67	7.81e-63	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
HNSC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	20.54	3.02e-67	7.98e-63	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	20.52	3.63e-67	9.56e-63	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	20.51	3.99e-67	1.05e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-20.51	4.07e-67	1.07e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	20.51	4.07e-67	1.07e-62	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	20.5	4.27e-67	1.12e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	20.5	4.27e-67	1.12e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	20.5	4.33e-67	1.13e-62	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-20.5	4.34e-67	1.13e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-20.5	4.65e-67	1.21e-62	-0.78	-0.69	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	20.49	5.01e-67	1.3e-62	0.93	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-20.48	5.45e-67	1.42e-62	-0.97	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
HNSC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-20.48	5.65e-67	1.47e-62	-0.83	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	20.48	5.67e-67	1.47e-62	0.84	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	20.47	5.81e-67	1.51e-62	0.93	0.69	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-20.46	6.7e-67	1.73e-62	-0.99	-0.69	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-20.45	7.38e-67	1.9e-62	-1.02	-0.69	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	20.44	8.1e-67	2.07e-62	0.83	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	20.44	8.12e-67	2.08e-62	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	20.41	1.22e-66	3.11e-62	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	20.41	1.22e-66	3.11e-62	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-20.4	1.29e-66	3.27e-62	-0.94	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-20.39	1.48e-66	3.75e-62	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	20.39	1.51e-66	3.82e-62	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-20.38	1.61e-66	4.07e-62	-0.78	-0.69	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-20.37	1.83e-66	4.62e-62	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-20.37	1.85e-66	4.66e-62	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	20.33	2.73e-66	6.87e-62	0.83	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-20.33	2.78e-66	6.98e-62	-0.85	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-20.31	3.56e-66	8.83e-62	-0.98	-0.68	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-20.3	3.7e-66	9.18e-62	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	20.29	4.16e-66	1.03e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-20.29	4.24e-66	1.05e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	20.29	4.47e-66	1.1e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-20.28	4.56e-66	1.12e-61	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	20.28	4.73e-66	1.16e-61	0.97	0.68	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	20.28	4.99e-66	1.22e-61	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	20.27	5.08e-66	1.24e-61	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	20.26	6.1e-66	1.49e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	20.26	6.1e-66	1.49e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.25	6.47e-66	1.58e-61	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	20.23	7.77e-66	1.88e-61	0.94	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	20.23	7.9e-66	1.91e-61	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	20.23	7.94e-66	1.92e-61	0.84	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-20.23	7.98e-66	1.93e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-20.23	7.98e-66	1.93e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	20.23	8.52e-66	2.05e-61	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.22	8.95e-66	2.15e-61	-0.82	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	20.22	9.42e-66	2.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	20.22	9.42e-66	2.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-20.21	9.96e-66	2.38e-61	-0.82	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	20.2	1.13e-65	2.7e-61	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-20.2	1.17e-65	2.78e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-20.19	1.24e-65	2.95e-61	-0.92	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-20.18	1.36e-65	3.24e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-20.18	1.38e-65	3.28e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-20.18	1.38e-65	3.28e-61	-0.84	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-20.17	1.63e-65	3.86e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-20.17	1.63e-65	3.86e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-20.17	1.65e-65	3.9e-61	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-20.16	1.78e-65	4.22e-61	-0.93	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	20.16	1.8e-65	4.26e-61	0.78	0.68	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-20.13	2.3e-65	5.41e-61	-0.91	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
HNSC	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-20.13	2.5e-65	5.87e-61	-0.93	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
HNSC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	20.11	3.1e-65	7.25e-61	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-20.1	3.21e-65	7.52e-61	-0.87	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-20.09	3.55e-65	8.26e-61	-0.91	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-20.09	3.76e-65	8.73e-61	-0.83	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.08	3.94e-65	9.11e-61	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	20.07	4.74e-65	1.09e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	20.07	4.74e-65	1.09e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	20.05	5.5e-65	1.27e-60	0.93	0.68	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	20.05	5.98e-65	1.38e-60	0.78	0.68	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	20.03	6.87e-65	1.58e-60	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-20.02	7.76e-65	1.78e-60	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-20.02	8.12e-65	1.86e-60	-0.87	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	20.02	8.34e-65	1.9e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	20.01	8.65e-65	1.97e-60	0.78	0.68	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	20	9.35e-65	2.13e-60	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	20	9.48e-65	2.15e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	20	9.76e-65	2.21e-60	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	19.99	1.12e-64	2.53e-60	0.88	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	19.95	1.71e-64	3.83e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	19.95	1.71e-64	3.83e-60	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	19.95	1.72e-64	3.86e-60	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-19.93	2.02e-64	4.52e-60	-0.77	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
HNSC	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	19.91	2.5e-64	5.58e-60	0.92	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	19.9	2.86e-64	6.37e-60	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	19.89	3.2e-64	7.11e-60	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-19.87	4.08e-64	9.04e-60	-1	-0.68	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	19.85	4.96e-64	1.1e-59	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
HNSC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-19.84	5.43e-64	1.2e-59	-0.82	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	19.83	6.05e-64	1.33e-59	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	19.81	7.79e-64	1.71e-59	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	19.8	8.64e-64	1.89e-59	0.92	0.68	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-19.79	9.4e-64	2.06e-59	-0.92	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	19.78	1.03e-63	2.24e-59	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	19.75	1.52e-63	3.3e-59	0.82	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	19.73	1.86e-63	4.02e-59	0.92	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
HNSC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	19.71	2.16e-63	4.66e-59	0.78	0.67	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	19.69	2.94e-63	6.32e-59	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	19.66	3.78e-63	8.12e-59	0.94	0.67	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	19.65	4.07e-63	8.74e-59	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	19.65	4.37e-63	9.35e-59	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	19.6	7.42e-63	1.58e-58	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	19.57	1.02e-62	2.17e-58	0.92	0.67	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	19.56	1.15e-62	2.45e-58	0.76	0.67	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	19.55	1.32e-62	2.8e-58	0.9	0.67	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	19.54	1.33e-62	2.82e-58	0.83	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	19.53	1.57e-62	3.33e-58	0.88	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	19.51	1.89e-62	4e-58	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	19.49	2.49e-62	5.26e-58	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-19.48	2.61e-62	5.51e-58	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
HNSC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-19.47	2.93e-62	6.14e-58	-0.83	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	19.47	3.03e-62	6.35e-58	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	19.46	3.49e-62	7.32e-58	0.92	0.67	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	19.43	4.71e-62	9.85e-58	0.94	0.67	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	19.42	4.9e-62	1.03e-57	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	19.41	5.42e-62	1.13e-57	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	19.39	6.71e-62	1.4e-57	0.93	0.67	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	19.39	7.17e-62	1.49e-57	0.85	0.67	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	19.37	8.49e-62	1.77e-57	0.82	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	19.37	8.84e-62	1.84e-57	0.92	0.67	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	19.37	8.84e-62	1.84e-57	0.92	0.67	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	19.37	8.87e-62	1.84e-57	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	19.36	1e-61	2.07e-57	0.77	0.67	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	19.34	1.18e-61	2.45e-57	0.76	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-19.3	1.89e-61	3.91e-57	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	19.29	1.99e-61	4.11e-57	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	19.27	2.56e-61	5.28e-57	0.83	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	19.26	2.78e-61	5.72e-57	0.95	0.67	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
HNSC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-19.26	2.96e-61	6.09e-57	-0.82	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-19.25	3.04e-61	6.25e-57	-1.01	-0.67	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	19.22	4.34e-61	8.9e-57	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	19.18	6.8e-61	1.39e-56	0.76	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-19.16	8.62e-61	1.76e-56	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	19.16	8.72e-61	1.78e-56	0.82	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	19.15	9.7e-61	1.98e-56	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	19.08	2e-60	4.03e-56	0.82	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	19.07	2.24e-60	4.52e-56	0.87	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	19.04	3.2e-60	6.43e-56	0.92	0.66	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	19.01	4.32e-60	8.66e-56	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
HNSC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	18.98	5.92e-60	1.18e-55	0.85	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
HNSC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	18.96	7.4e-60	1.47e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-18.95	7.63e-60	1.52e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	18.95	7.76e-60	1.54e-55	0.75	0.66	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	18.94	9.18e-60	1.82e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-18.94	9.33e-60	1.85e-55	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-18.94	9.33e-60	1.85e-55	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	18.92	1.1e-59	2.16e-55	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-18.9	1.34e-59	2.63e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-18.88	1.68e-59	3.3e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-18.88	1.79e-59	3.5e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-18.83	2.84e-59	5.56e-55	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	18.82	3.09e-59	6.04e-55	0.92	0.66	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	18.81	3.7e-59	7.2e-55	0.93	0.66	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	18.78	5.11e-59	9.94e-55	0.91	0.66	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	18.73	8.78e-59	1.69e-54	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	18.72	9.36e-59	1.8e-54	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
HNSC	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	18.72	9.45e-59	1.82e-54	0.83	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	18.72	9.53e-59	1.84e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.71	1.08e-58	2.08e-54	0.74	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
HNSC	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	18.7	1.14e-58	2.19e-54	0.93	0.65	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
HNSC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	18.69	1.32e-58	2.53e-54	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-18.68	1.51e-58	2.89e-54	-0.96	-0.65	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-18.67	1.61e-58	3.08e-54	-0.97	-0.65	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	18.67	1.62e-58	3.11e-54	0.94	0.65	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
HNSC	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	18.67	1.68e-58	3.2e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	18.67	1.68e-58	3.2e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	18.64	2.24e-58	4.23e-54	0.89	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-18.6	3.42e-58	6.39e-54	-0.78	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-18.6	3.54e-58	6.62e-54	-0.88	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
HNSC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	18.58	4.25e-58	7.91e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	18.58	4.25e-58	7.91e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	18.57	4.82e-58	8.93e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	18.57	4.9e-58	9.06e-54	0.74	0.65	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	18.53	7.3e-58	1.34e-53	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	18.51	8.92e-58	1.63e-53	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	18.5	9.77e-58	1.78e-53	0.91	0.65	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-18.5	1.03e-57	1.89e-53	-0.86	-0.65	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	18.44	1.81e-57	3.28e-53	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	18.43	2.03e-57	3.68e-53	0.76	0.65	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	18.36	4.53e-57	8.17e-53	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.35	4.99e-57	8.96e-53	0.91	0.65	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	18.34	5.71e-57	1.02e-52	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	18.31	7.27e-57	1.3e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-18.31	7.68e-57	1.37e-52	-0.91	-0.65	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	18.3	8.54e-57	1.52e-52	0.73	0.65	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	18.29	9.03e-57	1.61e-52	0.9	0.65	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-18.26	1.26e-56	2.24e-52	-0.73	-0.65	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	18.25	1.52e-56	2.7e-52	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
HNSC	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-18.22	2.1e-56	3.71e-52	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
HNSC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	18.2	2.36e-56	4.17e-52	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	18.2	2.36e-56	4.17e-52	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.2	2.49e-56	4.38e-52	0.9	0.64	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
HNSC	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	18.18	2.93e-56	5.16e-52	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
HNSC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-18.18	3.08e-56	5.41e-52	-0.82	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
HNSC	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	18.17	3.43e-56	6.02e-52	0.93	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-18.13	5.37e-56	9.38e-52	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	18.07	9.54e-56	1.66e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	18.03	1.56e-55	2.71e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	18.01	1.81e-55	3.13e-51	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-18.01	1.85e-55	3.21e-51	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	18	2.1e-55	3.63e-51	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
HNSC	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-18	2.17e-55	3.75e-51	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	17.97	2.76e-55	4.75e-51	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-17.97	2.9e-55	5e-51	-0.74	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
HNSC	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-17.91	5.71e-55	9.81e-51	-0.86	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
HNSC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	17.9	6.24e-55	1.07e-50	0.89	0.64	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	17.86	8.87e-55	1.51e-50	0.73	0.64	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	17.85	1.07e-54	1.83e-50	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-17.85	1.07e-54	1.83e-50	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	17.82	1.38e-54	2.34e-50	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
HNSC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	17.78	2.17e-54	3.68e-50	0.86	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
HNSC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	17.78	2.23e-54	3.78e-50	0.88	0.64	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	17.77	2.45e-54	4.14e-50	0.75	0.64	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	17.73	3.66e-54	6.2e-50	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-17.7	5.14e-54	8.68e-50	-0.7	-0.63	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-17.69	5.72e-54	9.66e-50	-0.86	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
HNSC	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-17.66	7.85e-54	1.32e-49	-0.85	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.65	8.63e-54	1.45e-49	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
HNSC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-17.63	1.04e-53	1.75e-49	-1.03	-0.63	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-17.59	1.69e-53	2.83e-49	-0.78	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	17.58	1.89e-53	3.17e-49	0.78	0.63	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	17.55	2.52e-53	4.21e-49	0.77	0.63	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	17.5	4.13e-53	6.89e-49	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	17.42	9.92e-53	1.64e-48	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	17.4	1.24e-52	2.03e-48	0.73	0.63	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	17.38	1.46e-52	2.38e-48	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-17.36	1.85e-52	3.01e-48	-0.8	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
HNSC	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-17.35	2.17e-52	3.52e-48	-0.93	-0.63	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	17.33	2.59e-52	4.18e-48	0.8	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
HNSC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	17.31	3.21e-52	5.16e-48	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	17.31	3.21e-52	5.16e-48	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-17.31	3.35e-52	5.39e-48	-0.76	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-17.3	3.44e-52	5.52e-48	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
HNSC	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-17.3	3.47e-52	5.56e-48	-0.91	-0.62	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	17.3	3.55e-52	5.69e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-17.28	4.16e-52	6.66e-48	-0.76	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	17.28	4.31e-52	6.89e-48	0.9	0.62	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
HNSC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	17.26	5.21e-52	8.31e-48	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	17.25	5.89e-52	9.37e-48	0.83	0.62	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
HNSC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	17.25	6.07e-52	9.65e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	17.25	6.28e-52	9.99e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	17.2	1.02e-51	1.61e-47	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	17.2	1.07e-51	1.68e-47	0.73	0.62	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	17.15	1.68e-51	2.61e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	17.15	1.7e-51	2.62e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	17.11	2.57e-51	3.94e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-17.1	2.81e-51	4.3e-47	-0.76	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	17.1	3.07e-51	4.68e-47	0.75	0.62	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	17.07	3.95e-51	6.03e-47	0.76	0.62	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	17.07	4.22e-51	6.42e-47	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	17.07	4.22e-51	6.42e-47	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-17.06	4.5e-51	6.85e-47	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
HNSC	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	17.05	4.77e-51	7.24e-47	0.88	0.62	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
HNSC	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	17.05	4.77e-51	7.24e-47	0.88	0.62	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-17.04	5.56e-51	8.41e-47	-0.7	-0.62	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	17.01	7.64e-51	1.15e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	17	8.5e-51	1.28e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-16.99	9.42e-51	1.41e-46	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	16.98	9.9e-51	1.48e-46	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-16.98	1.08e-50	1.62e-46	-0.7	-0.62	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-16.95	1.5e-50	2.23e-46	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	16.95	1.5e-50	2.23e-46	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	16.94	1.61e-50	2.39e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-16.93	1.76e-50	2.61e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	16.92	1.94e-50	2.88e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-16.92	1.94e-50	2.88e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	16.91	2.06e-50	3.05e-46	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-16.91	2.13e-50	3.15e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-16.91	2.2e-50	3.24e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	16.91	2.2e-50	3.24e-46	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-16.9	2.43e-50	3.58e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-16.9	2.43e-50	3.58e-46	-0.69	-0.62	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-16.9	2.53e-50	3.72e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-16.9	2.53e-50	3.72e-46	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	16.86	3.79e-50	5.54e-46	0.75	0.62	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	16.85	4.11e-50	6e-46	0.76	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	16.85	4.12e-50	6.01e-46	0.68	0.61	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	16.82	5.32e-50	7.73e-46	0.72	0.61	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-16.82	5.7e-50	8.28e-46	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	16.82	5.7e-50	8.28e-46	0.76	0.61	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	16.82	5.73e-50	8.32e-46	0.77	0.61	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	16.81	6.06e-50	8.78e-46	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
HNSC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	16.81	6.51e-50	9.41e-46	0.74	0.61	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-16.8	6.78e-50	9.8e-46	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	16.79	7.79e-50	1.12e-45	0.73	0.61	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	16.78	8.16e-50	1.18e-45	0.72	0.61	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	16.78	8.71e-50	1.25e-45	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-16.78	8.75e-50	1.26e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-16.78	8.75e-50	1.26e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	16.76	1.05e-49	1.5e-45	0.68	0.61	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	16.75	1.12e-49	1.6e-45	0.68	0.61	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	16.75	1.12e-49	1.61e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-16.71	1.75e-49	2.5e-45	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-16.7	1.88e-49	2.67e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-16.7	1.9e-49	2.7e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-16.7	1.98e-49	2.81e-45	-0.69	-0.61	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-16.66	3.15e-49	4.44e-45	-0.75	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-16.63	3.96e-49	5.56e-45	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	16.63	4.13e-49	5.78e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	16.63	4.13e-49	5.78e-45	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-16.6	5.61e-49	7.83e-45	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-16.58	6.72e-49	9.36e-45	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-16.58	7.03e-49	9.78e-45	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	16.56	8.92e-49	1.24e-44	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	16.56	8.94e-49	1.24e-44	0.75	0.61	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-16.52	1.25e-48	1.73e-44	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	16.5	1.67e-48	2.29e-44	0.7	0.61	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-16.49	1.69e-48	2.33e-44	-0.73	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	16.46	2.54e-48	3.48e-44	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	16.44	2.85e-48	3.9e-44	0.75	0.61	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	16.44	2.86e-48	3.91e-44	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-16.44	3.09e-48	4.21e-44	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-16.42	3.64e-48	4.94e-44	-0.62	-0.61	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-16.42	3.64e-48	4.94e-44	-0.62	-0.61	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
HNSC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	16.42	3.81e-48	5.17e-44	0.91	0.6	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
HNSC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	16.41	4.08e-48	5.54e-44	0.74	0.6	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-16.4	4.78e-48	6.46e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-16.4	4.78e-48	6.46e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
HNSC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	16.39	4.88e-48	6.59e-44	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	16.39	5.13e-48	6.91e-44	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-16.38	5.45e-48	7.33e-44	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	16.38	5.56e-48	7.48e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-16.38	5.59e-48	7.51e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	16.38	5.85e-48	7.85e-44	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-16.36	7.01e-48	9.39e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-16.36	7.01e-48	9.39e-44	-0.62	-0.6	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-16.35	7.95e-48	1.06e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-16.35	7.95e-48	1.06e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-16.34	8.28e-48	1.1e-43	-0.99	-0.6	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-16.33	9.03e-48	1.2e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	16.33	9.65e-48	1.28e-43	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	16.31	1.16e-47	1.53e-43	0.62	0.6	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.31	1.22e-47	1.62e-43	-0.89	-0.6	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-16.28	1.53e-47	2.01e-43	-0.71	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-16.27	1.82e-47	2.39e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-16.27	1.82e-47	2.39e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-16.27	1.84e-47	2.42e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-16.26	2.06e-47	2.7e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-16.24	2.49e-47	3.26e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-16.24	2.49e-47	3.26e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	16.23	2.57e-47	3.36e-43	0.67	0.6	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-16.23	2.57e-47	3.36e-43	-0.67	-0.6	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-16.23	2.64e-47	3.45e-43	-0.67	-0.6	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
HNSC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	16.21	3.45e-47	4.49e-43	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-16.19	4.16e-47	5.41e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-16.19	4.16e-47	5.41e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.63	-0.6	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-16.17	4.81e-47	6.22e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	16.17	5.18e-47	6.69e-43	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
HNSC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	16.17	5.22e-47	6.74e-43	0.74	0.6	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-16.16	5.79e-47	7.46e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-16.14	6.74e-47	8.64e-43	-0.62	-0.6	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	16.14	7e-47	8.96e-43	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
HNSC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-16.13	7.48e-47	9.56e-43	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-16.12	8.25e-47	1.05e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	16.12	8.31e-47	1.06e-42	0.68	0.6	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-16.11	9.37e-47	1.19e-42	-0.67	-0.6	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
HNSC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	16.11	9.53e-47	1.21e-42	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	16.1	1.02e-46	1.3e-42	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-16.09	1.15e-46	1.46e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-16.09	1.2e-46	1.52e-42	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-16.08	1.22e-46	1.54e-42	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	16.08	1.33e-46	1.69e-42	0.65	0.6	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	16.08	1.34e-46	1.69e-42	0.73	0.6	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
HNSC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	16.07	1.39e-46	1.76e-42	0.81	0.6	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-16.07	1.46e-46	1.85e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
HNSC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	16.05	1.82e-46	2.3e-42	0.88	0.6	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
HNSC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	16.04	1.94e-46	2.44e-42	0.75	0.6	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	16.04	2.04e-46	2.57e-42	0.9	0.6	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-16.03	2.17e-46	2.73e-42	-0.62	-0.6	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-16.01	2.72e-46	3.39e-42	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-16	2.9e-46	3.61e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-16	2.9e-46	3.61e-42	-0.63	-0.6	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-15.97	3.86e-46	4.79e-42	-0.63	-0.59	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-15.97	3.95e-46	4.89e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	15.95	4.82e-46	5.96e-42	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	15.94	5.64e-46	6.91e-42	1.06	0.59	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	15.94	5.71e-46	6.99e-42	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-15.93	5.9e-46	7.2e-42	-0.62	-0.59	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-15.93	6.09e-46	7.42e-42	-0.61	-0.59	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	15.91	7.66e-46	9.3e-42	0.49	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	15.9	8.26e-46	1e-41	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-15.89	9.11e-46	1.1e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-15.89	9.27e-46	1.12e-41	-0.63	-0.59	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-15.88	9.88e-46	1.19e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-15.88	1.05e-45	1.26e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-15.87	1.08e-45	1.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	15.86	1.2e-45	1.44e-41	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-15.85	1.34e-45	1.59e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	15.85	1.42e-45	1.68e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-15.85	1.44e-45	1.7e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	15.85	1.45e-45	1.72e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-15.84	1.58e-45	1.87e-41	-0.64	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
HNSC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-15.84	1.62e-45	1.91e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	15.83	1.68e-45	1.98e-41	0.48	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
HNSC	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-15.83	1.69e-45	1.99e-41	-0.75	-0.59	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-15.83	1.71e-45	2.02e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-15.83	1.78e-45	2.09e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-15.82	1.94e-45	2.28e-41	-0.7	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-15.82	1.95e-45	2.29e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-15.82	1.97e-45	2.31e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-15.82	1.97e-45	2.31e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-15.8	2.24e-45	2.61e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-15.8	2.24e-45	2.61e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-15.8	2.38e-45	2.77e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-15.77	3.14e-45	3.62e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	15.77	3.18e-45	3.66e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	15.77	3.18e-45	3.66e-41	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-15.76	3.58e-45	4.11e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-15.76	3.58e-45	4.11e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-15.74	4.13e-45	4.72e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-15.74	4.3e-45	4.89e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-15.74	4.31e-45	4.91e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-15.74	4.43e-45	5.03e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-15.73	4.89e-45	5.54e-41	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-15.72	5.26e-45	5.9e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-15.72	5.47e-45	6.1e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	15.71	5.67e-45	6.33e-41	0.49	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	15.71	5.94e-45	6.63e-41	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
HNSC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-15.68	7.85e-45	8.68e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-15.68	7.85e-45	8.68e-41	-0.61	-0.59	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-15.68	8.12e-45	8.96e-41	-0.62	-0.59	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-15.68	8.39e-45	9.25e-41	-0.71	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
HNSC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	15.66	9.51e-45	1.04e-40	0.91	0.59	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
HNSC	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-15.66	9.79e-45	1.07e-40	-0.74	-0.59	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-15.66	1e-44	1.1e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-15.66	1e-44	1.1e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-15.66	1.02e-44	1.11e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-15.65	1.09e-44	1.18e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-15.65	1.15e-44	1.24e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	15.64	1.26e-44	1.36e-40	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-15.63	1.32e-44	1.42e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-15.62	1.45e-44	1.54e-40	-0.61	-0.59	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	15.61	1.58e-44	1.68e-40	0.61	0.59	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	15.6	1.76e-44	1.86e-40	0.48	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-15.6	1.84e-44	1.95e-40	-0.6	-0.59	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.6	1.88e-44	1.99e-40	0.66	0.59	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-15.6	1.89e-44	2e-40	-0.62	-0.59	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-15.58	2.28e-44	2.39e-40	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.58	2.31e-44	2.42e-40	-0.66	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-15.57	2.37e-44	2.48e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-15.55	3.12e-44	3.2e-40	-0.73	-0.58	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-15.54	3.36e-44	3.45e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-15.53	3.94e-44	4.03e-40	-0.64	-0.58	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-15.52	4.15e-44	4.24e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-15.52	4.29e-44	4.37e-40	-0.75	-0.58	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-15.51	4.59e-44	4.67e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-15.51	4.59e-44	4.67e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-15.49	5.88e-44	5.97e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	15.46	7.37e-44	7.46e-40	0.48	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	15.46	7.38e-44	7.47e-40	0.48	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
HNSC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-15.43	1.03e-43	1.03e-39	-0.62	-0.58	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-15.43	1.09e-43	1.09e-39	-0.75	-0.58	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-15.42	1.15e-43	1.15e-39	-0.61	-0.58	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
HNSC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-15.42	1.2e-43	1.2e-39	-0.81	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
HNSC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-15.41	1.23e-43	1.23e-39	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-15.41	1.23e-43	1.23e-39	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
HNSC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	15.4	1.48e-43	1.47e-39	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	15.39	1.58e-43	1.57e-39	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.38	1.69e-43	1.68e-39	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	15.38	1.74e-43	1.73e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
HNSC	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	15.37	2.03e-43	2.01e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	15.36	2.06e-43	2.03e-39	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
HNSC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-15.32	3.36e-43	3.27e-39	-0.64	-0.58	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-15.32	3.36e-43	3.27e-39	-0.64	-0.58	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-15.32	3.4e-43	3.3e-39	-0.6	-0.58	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
HNSC	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	15.31	3.63e-43	3.52e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	15.31	3.67e-43	3.55e-39	0.67	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	15.31	3.75e-43	3.63e-39	0.8	0.58	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	15.3	3.89e-43	3.73e-39	0.64	0.58	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-15.3	3.89e-43	3.73e-39	-0.64	-0.58	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	15.3	3.94e-43	3.77e-39	0.84	0.58	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-15.29	4.41e-43	4.19e-39	-0.64	-0.58	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.29	4.5e-43	4.28e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.27	5.56e-43	5.24e-39	-0.74	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
HNSC	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	15.27	5.56e-43	5.24e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-15.26	5.9e-43	5.56e-39	-0.64	-0.58	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-15.26	6.13e-43	5.76e-39	-0.64	-0.58	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-15.26	6.13e-43	5.76e-39	-0.64	-0.58	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	15.25	6.6e-43	6.19e-39	0.85	0.58	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-15.23	7.78e-43	7.28e-39	-0.64	-0.58	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-15.23	7.78e-43	7.28e-39	-0.64	-0.58	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
HNSC	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	15.23	7.99e-43	7.47e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
HNSC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-15.22	8.59e-43	8.03e-39	-0.7	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
HNSC	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	15.21	9.72e-43	9.06e-39	0.46	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	15.21	9.87e-43	9.19e-39	0.47	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-15.21	1e-42	9.31e-39	-0.63	-0.58	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-15.21	1e-42	9.31e-39	-0.63	-0.58	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-15.2	1.1e-42	1.02e-38	-0.63	-0.58	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
HNSC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-15.19	1.2e-42	1.11e-38	-0.68	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-15.19	1.26e-42	1.17e-38	-0.64	-0.57	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	15.18	1.4e-42	1.3e-38	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-15.17	1.56e-42	1.44e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-15.16	1.6e-42	1.47e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	15.16	1.67e-42	1.53e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-15.15	1.83e-42	1.68e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-15.15	1.86e-42	1.71e-38	-0.62	-0.57	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-15.14	2.04e-42	1.87e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-15.13	2.16e-42	1.97e-38	-0.64	-0.57	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-15.13	2.23e-42	2.04e-38	-0.64	-0.57	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-15.13	2.29e-42	2.09e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-15.13	2.3e-42	2.1e-38	-0.64	-0.57	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-15.12	2.39e-42	2.18e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-15.12	2.39e-42	2.18e-38	-0.69	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	15.12	2.42e-42	2.21e-38	0.75	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	15.11	2.8e-42	2.52e-38	0.64	0.57	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-15.11	2.8e-42	2.52e-38	-0.64	-0.57	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-15.1	3.02e-42	2.7e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	15.1	3.03e-42	2.7e-38	0.63	0.57	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	15.1	3.09e-42	2.76e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
HNSC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-15.09	3.24e-42	2.89e-38	-0.64	-0.57	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-15.09	3.37e-42	3e-38	-0.64	-0.57	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	15.07	4.29e-42	3.8e-38	0.63	0.57	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	15.07	4.31e-42	3.81e-38	0.63	0.57	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	15.07	4.31e-42	3.81e-38	0.63	0.57	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	15.05	5.37e-42	4.74e-38	0.61	0.57	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
HNSC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	15.04	5.39e-42	4.74e-38	0.68	0.57	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	15.04	5.6e-42	4.93e-38	0.62	0.57	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	15.04	5.87e-42	5.15e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
HNSC	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	15.04	5.87e-42	5.15e-38	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	15.04	5.91e-42	5.19e-38	0.63	0.57	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-15.03	6.42e-42	5.62e-38	-0.63	-0.57	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.02	6.78e-42	5.93e-38	0.65	0.57	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	15.02	7.08e-42	6.18e-38	0.63	0.57	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-15.02	7.12e-42	6.21e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	15	8.12e-42	7.04e-38	0.63	0.57	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	15	8.34e-42	7.23e-38	0.63	0.57	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-14.99	9.16e-42	7.92e-38	-0.64	-0.57	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	14.98	1.03e-41	8.87e-38	0.64	0.57	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-14.98	1.08e-41	9.24e-38	-0.64	-0.57	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-14.97	1.12e-41	9.61e-38	-0.64	-0.57	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-14.97	1.2e-41	1.02e-37	-0.63	-0.57	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-14.97	1.21e-41	1.03e-37	-0.64	-0.57	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-14.96	1.22e-41	1.04e-37	-0.63	-0.57	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-14.96	1.31e-41	1.11e-37	-0.59	-0.57	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	14.96	1.33e-41	1.13e-37	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
HNSC	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	14.96	1.34e-41	1.14e-37	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
HNSC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	14.95	1.45e-41	1.23e-37	0.65	0.57	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
HNSC	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	14.95	1.45e-41	1.23e-37	0.46	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
HNSC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-14.94	1.55e-41	1.3e-37	-0.63	-0.57	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-14.94	1.55e-41	1.3e-37	-0.63	-0.57	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	14.93	1.68e-41	1.41e-37	0.63	0.57	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	14.93	1.68e-41	1.41e-37	0.63	0.57	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	14.92	1.85e-41	1.54e-37	0.63	0.57	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	14.91	2.02e-41	1.68e-37	0.63	0.57	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-14.91	2.05e-41	1.7e-37	-0.63	-0.57	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-14.9	2.44e-41	2.01e-37	-0.67	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	14.9	2.46e-41	2.03e-37	0.64	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	14.88	2.75e-41	2.26e-37	0.63	0.57	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-14.84	4.51e-41	3.66e-37	-0.6	-0.57	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66430152	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4717292	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66430611	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420591	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66447394	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66448930	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66449417	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66453720	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66456608	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66457499	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66458866	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs35149210	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66464938	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66464969	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2042133	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66466935	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66467918	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961155	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66468308	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7789768	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66473993	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66474502	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1363055	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66478288	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66479319	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7789554	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66481051	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4717300	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66482393	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66485627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66487937	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66489212	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66490572	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000179406.6	LINC00174	-14.82	5.29e-41	4.25e-37	-0.73	-0.57	Aortic root size;	chr7:66493638	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	14.82	5.52e-41	4.43e-37	0.62	0.57	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	14.81	5.74e-41	4.6e-37	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.81	5.8e-41	4.65e-37	0.63	0.57	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12532998	ENSG00000179406.6	LINC00174	-14.8	6.5e-41	5.19e-37	-0.73	-0.57	Aortic root size;	chr7:66502472	chr7:66376044~66401338:-
HNSC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-14.79	7.06e-41	5.63e-37	-0.72	-0.56	Breast cancer;	chr11:743813	chr11:779617~780755:+
HNSC	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-14.78	7.56e-41	6.02e-37	-0.46	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
HNSC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	14.78	7.77e-41	6.19e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-14.78	8.24e-41	6.54e-37	-0.64	-0.56	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66473171	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66494889	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718357	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66495891	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66499076	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs12533997	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66500390	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs12698523	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503126	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6970030	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503692	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66503891	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs3735148	ENSG00000179406.6	LINC00174	-14.78	8.27e-41	6.55e-37	-0.72	-0.56	Aortic root size;	chr7:66506022	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000179406.6	LINC00174	-14.77	9.05e-41	7.15e-37	-0.73	-0.56	Aortic root size;	chr7:66508888	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000179406.6	LINC00174	-14.77	9.05e-41	7.15e-37	-0.73	-0.56	Aortic root size;	chr7:66511647	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000179406.6	LINC00174	-14.75	1.1e-40	8.71e-37	-0.72	-0.56	Aortic root size;	chr7:66457471	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs11974219	ENSG00000179406.6	LINC00174	14.75	1.11e-40	8.72e-37	0.73	0.56	Aortic root size;	chr7:66182423	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs55962648	ENSG00000179406.6	LINC00174	14.75	1.11e-40	8.77e-37	0.73	0.56	Aortic root size;	chr7:66160764	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs875971	ENSG00000179406.6	LINC00174	14.74	1.15e-40	9.03e-37	0.73	0.56	Aortic root size;	chr7:66152608	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-14.74	1.19e-40	9.36e-37	-0.46	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
HNSC	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	14.74	1.21e-40	9.52e-37	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs1565531	ENSG00000179406.6	LINC00174	14.74	1.25e-40	9.77e-37	0.73	0.56	Aortic root size;	chr7:66198126	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6957199	ENSG00000179406.6	LINC00174	-14.73	1.26e-40	9.88e-37	-0.72	-0.56	Aortic root size;	chr7:66513532	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000179406.6	LINC00174	14.73	1.35e-40	1.06e-36	0.73	0.56	Aortic root size;	chr7:66165644	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	14.72	1.38e-40	1.08e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-14.71	1.6e-40	1.25e-36	-0.71	-0.56	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.71	1.65e-40	1.29e-36	0.73	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-14.71	1.65e-40	1.29e-36	-0.52	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	14.7	1.76e-40	1.37e-36	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
HNSC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-14.7	1.84e-40	1.43e-36	-0.63	-0.56	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
HNSC	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	14.69	1.95e-40	1.52e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs2077593	ENSG00000179406.6	LINC00174	-14.69	1.98e-40	1.55e-36	-0.72	-0.56	Aortic root size;	chr7:66427543	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000179406.6	LINC00174	-14.69	2.06e-40	1.6e-36	-0.72	-0.56	Aortic root size;	chr7:66444024	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	14.68	2.19e-40	1.71e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
HNSC	cis	rs875971	1	rs6963646	ENSG00000179406.6	LINC00174	14.67	2.44e-40	1.89e-36	0.72	0.56	Aortic root size;	chr7:66220780	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000179406.6	LINC00174	14.67	2.49e-40	1.93e-36	0.72	0.56	Aortic root size;	chr7:66224822	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7781698	ENSG00000179406.6	LINC00174	-14.66	2.64e-40	2.04e-36	-0.72	-0.56	Aortic root size;	chr7:66431325	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	14.66	2.66e-40	2.06e-36	0.76	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
HNSC	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	14.66	2.73e-40	2.11e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	14.65	2.98e-40	2.3e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000179406.6	LINC00174	-14.63	3.6e-40	2.77e-36	-0.72	-0.56	Aortic root size;	chr7:66506273	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000179406.6	LINC00174	-14.62	3.98e-40	3.06e-36	-0.72	-0.56	Aortic root size;	chr7:66379575	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778722	ENSG00000179406.6	LINC00174	-14.62	3.98e-40	3.06e-36	-0.72	-0.56	Aortic root size;	chr7:66379841	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000179406.6	LINC00174	-14.62	4.06e-40	3.12e-36	-0.72	-0.56	Aortic root size;	chr7:66377234	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.62	4.14e-40	3.17e-36	0.62	0.56	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	14.62	4.15e-40	3.18e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs778726	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66363744	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778723	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66364510	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66366357	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778685	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66371189	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778682	ENSG00000179406.6	LINC00174	-14.61	4.27e-40	3.27e-36	-0.72	-0.56	Aortic root size;	chr7:66372947	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778721	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66380410	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778712	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66384991	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778710	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66389847	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs778708	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66391332	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778706	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66395437	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs778700	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66401463	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778699	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66403303	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778696	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66405826	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs778694	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66406571	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs778692	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66407462	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718343	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409301	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs4718344	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409394	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1968225	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66409786	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66415618	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66415707	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6460295	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66417741	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000179406.6	LINC00174	-14.61	4.46e-40	3.39e-36	-0.72	-0.56	Aortic root size;	chr7:66418217	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-14.61	4.54e-40	3.46e-36	-0.62	-0.56	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709595	ENSG00000179406.6	LINC00174	-14.56	7.02e-40	5.28e-36	-0.72	-0.56	Aortic root size;	chr7:66352346	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs811880	ENSG00000179406.6	LINC00174	-14.56	7.02e-40	5.28e-36	-0.72	-0.56	Aortic root size;	chr7:66353659	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	14.56	7.12e-40	5.35e-36	0.62	0.56	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	14.56	7.26e-40	5.46e-36	0.62	0.56	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718307	ENSG00000179406.6	LINC00174	14.55	7.94e-40	5.96e-36	0.72	0.56	Aortic root size;	chr7:66146001	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7801282	ENSG00000179406.6	LINC00174	14.55	7.94e-40	5.96e-36	0.72	0.56	Aortic root size;	chr7:66148700	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000179406.6	LINC00174	-14.55	8.25e-40	6.19e-36	-0.72	-0.56	Aortic root size;	chr7:66455949	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	14.55	8.31e-40	6.23e-36	0.52	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	14.54	9.29e-40	6.95e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-14.52	1.12e-39	8.38e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	14.51	1.21e-39	9.03e-36	0.62	0.56	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-14.51	1.25e-39	9.33e-36	-0.63	-0.56	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	14.5	1.3e-39	9.71e-36	0.64	0.56	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-14.5	1.31e-39	9.74e-36	-0.52	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
HNSC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	14.5	1.38e-39	1.03e-35	0.63	0.56	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
HNSC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-14.49	1.47e-39	1.09e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs3981131	ENSG00000179406.6	LINC00174	-14.47	1.75e-39	1.3e-35	-0.71	-0.56	Aortic root size;	chr7:66486690	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	14.47	1.78e-39	1.32e-35	0.74	0.56	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
HNSC	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	14.47	1.89e-39	1.39e-35	0.81	0.56	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	14.46	1.97e-39	1.46e-35	0.62	0.56	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	14.46	2.02e-39	1.49e-35	0.73	0.56	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.45	2.09e-39	1.54e-35	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
HNSC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	14.43	2.58e-39	1.9e-35	0.62	0.56	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	14.43	2.76e-39	2.02e-35	0.61	0.56	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.43	2.76e-39	2.02e-35	0.61	0.56	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709597	ENSG00000179406.6	LINC00174	14.42	2.86e-39	2.1e-35	0.73	0.56	Aortic root size;	chr7:66360996	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-14.42	2.89e-39	2.11e-35	-0.68	-0.56	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	14.42	2.99e-39	2.18e-35	1.12	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.42	3.01e-39	2.19e-35	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	14.42	3.08e-39	2.25e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-14.41	3.22e-39	2.34e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-14.41	3.22e-39	2.34e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
HNSC	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	14.41	3.24e-39	2.36e-35	0.8	0.55	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.41	3.35e-39	2.43e-35	-1.05	-0.55	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000179406.6	LINC00174	14.4	3.61e-39	2.62e-35	0.72	0.55	Aortic root size;	chr7:66278036	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-14.4	3.7e-39	2.68e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	14.4	3.76e-39	2.72e-35	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	14.4	3.76e-39	2.72e-35	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	14.38	4.32e-39	3.11e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000179406.6	LINC00174	14.38	4.39e-39	3.15e-35	0.72	0.55	Aortic root size;	chr7:66278221	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000179406.6	LINC00174	14.38	4.39e-39	3.15e-35	0.72	0.55	Aortic root size;	chr7:66298631	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-14.38	4.46e-39	3.2e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-14.38	4.46e-39	3.2e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
HNSC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-14.38	4.57e-39	3.28e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-14.38	4.57e-39	3.28e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-14.37	4.82e-39	3.46e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000179406.6	LINC00174	14.36	5.2e-39	3.73e-35	0.71	0.55	Aortic root size;	chr7:66282799	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000179406.6	LINC00174	14.36	5.2e-39	3.73e-35	0.71	0.55	Aortic root size;	chr7:66316668	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2087647	ENSG00000179406.6	LINC00174	14.36	5.25e-39	3.76e-35	0.72	0.55	Aortic root size;	chr7:66128201	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	14.36	5.31e-39	3.8e-35	1.11	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-14.36	5.31e-39	3.81e-35	-0.61	-0.55	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-14.36	5.58e-39	4e-35	-1.1	-0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs6958484	ENSG00000179406.6	LINC00174	14.35	5.76e-39	4.12e-35	0.72	0.55	Aortic root size;	chr7:66134459	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-14.35	6.16e-39	4.4e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	14.35	6.22e-39	4.44e-35	0.83	0.55	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	14.34	6.49e-39	4.63e-35	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	14.34	6.49e-39	4.63e-35	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-14.34	6.82e-39	4.86e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
HNSC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	14.32	7.98e-39	5.67e-35	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
HNSC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-14.32	8.17e-39	5.79e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
HNSC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-14.32	8.17e-39	5.79e-35	-0.68	-0.55	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
HNSC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-14.32	8.18e-39	5.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-14.32	8.18e-39	5.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
HNSC	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-14.32	8.26e-39	5.85e-35	-0.67	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-14.31	8.91e-39	6.3e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000179406.6	LINC00174	14.31	9.38e-39	6.62e-35	0.71	0.55	Aortic root size;	chr7:66333558	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6460292	ENSG00000179406.6	LINC00174	14.31	9.38e-39	6.62e-35	0.71	0.55	Aortic root size;	chr7:66345088	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000179406.6	LINC00174	14.29	1.06e-38	7.48e-35	0.71	0.55	Aortic root size;	chr7:66122550	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-14.29	1.11e-38	7.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-14.29	1.11e-38	7.8e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-14.28	1.23e-38	8.68e-35	-0.62	-0.55	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
HNSC	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.27	1.27e-38	8.96e-35	-0.71	-0.55	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	14.27	1.28e-38	8.99e-35	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
HNSC	cis	rs875971	1	rs6946143	ENSG00000179406.6	LINC00174	-14.27	1.34e-38	9.4e-35	-0.72	-0.55	Aortic root size;	chr7:66114735	chr7:66376044~66401338:-
HNSC	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-14.27	1.34e-38	9.4e-35	-0.45	-0.55	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	14.27	1.34e-38	9.41e-35	0.61	0.55	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	14.27	1.36e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	14.27	1.37e-38	9.56e-35	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	14.27	1.38e-38	9.68e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-14.26	1.48e-38	1.03e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-14.24	1.73e-38	1.2e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-14.23	1.9e-38	1.32e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs6945843	ENSG00000179406.6	LINC00174	14.22	2.09e-38	1.45e-34	0.71	0.55	Aortic root size;	chr7:66269796	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-14.22	2.15e-38	1.49e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
HNSC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	14.22	2.17e-38	1.51e-34	0.63	0.55	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	14.22	2.21e-38	1.53e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
HNSC	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.22	2.29e-38	1.58e-34	-1.05	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.21	2.43e-38	1.68e-34	-1.02	-0.55	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
HNSC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-14.21	2.43e-38	1.69e-34	-0.63	-0.55	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
HNSC	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	14.21	2.45e-38	1.69e-34	0.51	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000179406.6	LINC00174	-14.2	2.69e-38	1.86e-34	-0.71	-0.55	Aortic root size;	chr7:66450629	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1981798	ENSG00000179406.6	LINC00174	-14.2	2.69e-38	1.86e-34	-0.71	-0.55	Aortic root size;	chr7:66489916	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-14.2	2.77e-38	1.91e-34	-0.67	-0.55	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-14.18	3.12e-38	2.15e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-14.18	3.17e-38	2.18e-34	-0.68	-0.55	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
HNSC	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	14.18	3.21e-38	2.21e-34	0.67	0.55	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
HNSC	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.18	3.26e-38	2.24e-34	-1.06	-0.55	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
HNSC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-14.18	3.29e-38	2.26e-34	-0.83	-0.55	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
HNSC	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-14.18	3.35e-38	2.3e-34	-0.67	-0.55	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
HNSC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	14.18	3.39e-38	2.33e-34	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
HNSC	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.17	3.59e-38	2.46e-34	-0.7	-0.55	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-14.17	3.62e-38	2.48e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-14.17	3.64e-38	2.49e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
HNSC	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	14.17	3.65e-38	2.5e-34	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	14.16	3.9e-38	2.67e-34	1.1	0.55	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-14.16	3.91e-38	2.68e-34	-0.59	-0.55	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	14.16	4.08e-38	2.79e-34	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	14.16	4.08e-38	2.79e-34	1.1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-14.15	4.24e-38	2.9e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
HNSC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-14.15	4.29e-38	2.93e-34	-0.58	-0.55	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
HNSC	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-14.15	4.46e-38	3.03e-34	-0.62	-0.55	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs6958271	ENSG00000179406.6	LINC00174	-14.15	4.5e-38	3.06e-34	-0.71	-0.55	Aortic root size;	chr7:66514344	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6958277	ENSG00000179406.6	LINC00174	-14.15	4.5e-38	3.06e-34	-0.71	-0.55	Aortic root size;	chr7:66514362	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	14.14	4.68e-38	3.18e-34	0.74	0.55	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-14.14	4.69e-38	3.18e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	14.14	4.82e-38	3.27e-34	0.63	0.55	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000179406.6	LINC00174	14.14	5.09e-38	3.45e-34	0.72	0.55	Aortic root size;	chr7:66182595	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1540651	ENSG00000179406.6	LINC00174	14.14	5.09e-38	3.45e-34	0.72	0.55	Aortic root size;	chr7:66185134	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000179406.6	LINC00174	14.13	5.22e-38	3.54e-34	0.71	0.55	Aortic root size;	chr7:66239589	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	14.13	5.3e-38	3.59e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
HNSC	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-14.13	5.39e-38	3.65e-34	-0.68	-0.55	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
HNSC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-14.13	5.56e-38	3.77e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	14.13	5.57e-38	3.77e-34	0.64	0.55	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs11971949	ENSG00000179406.6	LINC00174	14.13	5.58e-38	3.77e-34	0.72	0.55	Aortic root size;	chr7:66161027	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	14.12	5.68e-38	3.84e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-14.12	5.87e-38	3.96e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-14.12	6e-38	4.05e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
HNSC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-14.12	6e-38	4.05e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-14.12	6e-38	4.05e-34	-0.67	-0.55	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
HNSC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-14.12	6.1e-38	4.11e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-14.12	6.13e-38	4.13e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-14.12	6.16e-38	4.15e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	14.11	6.29e-38	4.2e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
HNSC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	14.11	6.38e-38	4.26e-34	0.66	0.55	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	14.11	6.43e-38	4.28e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	14.11	6.51e-38	4.33e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	14.11	6.53e-38	4.35e-34	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
HNSC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-14.11	6.65e-38	4.42e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000231760.4	RP11-350J20.5	14.11	6.67e-38	4.43e-34	0.75	0.55	Lung cancer;	chr6:149863746	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-14.1	6.91e-38	4.58e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
HNSC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-14.1	6.96e-38	4.61e-34	-0.88	-0.55	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-14.1	7.02e-38	4.65e-34	-0.58	-0.55	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000179406.6	LINC00174	-14.1	7.14e-38	4.72e-34	-0.71	-0.55	Aortic root size;	chr7:66508681	chr7:66376044~66401338:-
HNSC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.22e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.22e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.24e-38	4.78e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-14.1	7.24e-38	4.78e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-14.1	7.45e-38	4.92e-34	-0.65	-0.55	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	14.1	7.49e-38	4.94e-34	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
HNSC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-14.1	7.5e-38	4.95e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-14.09	7.63e-38	5.03e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-14.09	7.63e-38	5.03e-34	-0.63	-0.55	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	14.09	7.97e-38	5.25e-34	0.63	0.55	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
HNSC	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-14.09	8.17e-38	5.38e-34	-0.45	-0.55	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
HNSC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	14.09	8.19e-38	5.39e-34	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-14.08	8.46e-38	5.57e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	14.08	8.66e-38	5.69e-34	0.62	0.55	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	14.08	8.85e-38	5.82e-34	0.66	0.55	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-14.08	9.22e-38	6.06e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-14.07	9.94e-38	6.5e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
HNSC	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-14.07	9.95e-38	6.5e-34	-0.68	-0.55	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	14.07	1e-37	6.55e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-14.07	1.02e-37	6.65e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	14.06	1.09e-37	7.09e-34	0.67	0.55	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	14.06	1.09e-37	7.09e-34	0.67	0.55	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	14.06	1.1e-37	7.16e-34	0.67	0.55	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-14.06	1.13e-37	7.35e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-14.06	1.13e-37	7.35e-34	-0.64	-0.55	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
HNSC	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-14.05	1.14e-37	7.39e-34	-0.63	-0.55	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-14.05	1.14e-37	7.41e-34	-0.6	-0.55	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
HNSC	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	14.05	1.15e-37	7.48e-34	0.67	0.55	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	14.05	1.15e-37	7.5e-34	1.12	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
HNSC	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	14.05	1.19e-37	7.74e-34	0.52	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.05	1.22e-37	7.95e-34	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
HNSC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-14.04	1.26e-37	8.19e-34	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-14.04	1.26e-37	8.19e-34	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.04	1.27e-37	8.25e-34	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
HNSC	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-14.04	1.28e-37	8.28e-34	-1.04	-0.54	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
HNSC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-14.04	1.29e-37	8.35e-34	-0.61	-0.54	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-14.04	1.3e-37	8.44e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-14.04	1.32e-37	8.51e-34	-0.63	-0.54	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-14.03	1.4e-37	9.04e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
HNSC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-14.03	1.42e-37	9.18e-34	-0.63	-0.54	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
HNSC	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-14.03	1.47e-37	9.48e-34	-0.69	-0.54	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
HNSC	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-14.02	1.53e-37	9.9e-34	-0.7	-0.54	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	14.02	1.65e-37	1.06e-33	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	14.02	1.66e-37	1.07e-33	0.73	0.54	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
HNSC	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-14.02	1.67e-37	1.08e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.73e-37	1.12e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.82e-37	1.17e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-14.01	1.82e-37	1.17e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-14	1.87e-37	1.2e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-14	1.87e-37	1.2e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-14	1.94e-37	1.24e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-14	1.94e-37	1.24e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	14	1.94e-37	1.25e-33	0.65	0.54	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-14	1.95e-37	1.25e-33	-0.75	-0.54	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-14	1.99e-37	1.27e-33	-0.61	-0.54	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14	2e-37	1.28e-33	-1.03	-0.54	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
HNSC	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	14	2.03e-37	1.3e-33	0.61	0.54	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
HNSC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-14	2.03e-37	1.3e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-14	2.04e-37	1.31e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-14	2.05e-37	1.31e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-13.99	2.13e-37	1.36e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs6979382	ENSG00000179406.6	LINC00174	-13.99	2.17e-37	1.38e-33	-0.71	-0.54	Aortic root size;	chr7:66421388	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6961990	ENSG00000179406.6	LINC00174	-13.99	2.17e-37	1.38e-33	-0.71	-0.54	Aortic root size;	chr7:66423583	chr7:66376044~66401338:-
HNSC	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	13.99	2.2e-37	1.4e-33	0.67	0.54	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	13.99	2.2e-37	1.4e-33	0.67	0.54	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	13.99	2.25e-37	1.43e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-13.99	2.26e-37	1.44e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	13.98	2.45e-37	1.56e-33	0.66	0.54	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
HNSC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	13.98	2.49e-37	1.58e-33	0.62	0.54	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
HNSC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	13.98	2.5e-37	1.59e-33	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
HNSC	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	13.97	2.55e-37	1.62e-33	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
HNSC	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-13.97	2.58e-37	1.63e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
HNSC	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-13.96	2.81e-37	1.78e-33	-1.02	-0.54	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000179406.6	LINC00174	13.96	2.87e-37	1.81e-33	0.71	0.54	Aortic root size;	chr7:66313559	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-13.96	3.03e-37	1.91e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-13.95	3.17e-37	2e-33	-0.61	-0.54	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-13.95	3.34e-37	2.11e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000179406.6	LINC00174	-13.94	3.52e-37	2.22e-33	-0.71	-0.54	Aortic root size;	chr7:66061661	chr7:66376044~66401338:-
HNSC	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-13.93	3.78e-37	2.38e-33	-0.68	-0.54	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
HNSC	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-13.93	3.84e-37	2.42e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	13.93	3.92e-37	2.47e-33	0.62	0.54	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	13.92	4.15e-37	2.61e-33	0.6	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
HNSC	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	13.92	4.36e-37	2.74e-33	1.1	0.54	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	13.91	4.71e-37	2.95e-33	0.73	0.54	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-13.91	4.92e-37	3.08e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-13.91	4.92e-37	3.08e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-13.9	5.07e-37	3.17e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	13.9	5.12e-37	3.21e-33	0.73	0.54	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs6956179	ENSG00000179406.6	LINC00174	13.9	5.14e-37	3.22e-33	0.69	0.54	Aortic root size;	chr7:66341672	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-13.9	5.25e-37	3.28e-33	-0.6	-0.54	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000179406.6	LINC00174	13.9	5.4e-37	3.37e-33	0.71	0.54	Aortic root size;	chr7:66228355	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000179406.6	LINC00174	13.9	5.4e-37	3.37e-33	0.71	0.54	Aortic root size;	chr7:66249983	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	13.9	5.48e-37	3.42e-33	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
HNSC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-13.89	5.53e-37	3.45e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-13.89	5.74e-37	3.57e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-13.89	5.87e-37	3.66e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-13.89	5.87e-37	3.66e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000179406.6	LINC00174	-13.89	6.09e-37	3.78e-33	-0.71	-0.54	Aortic root size;	chr7:66349822	chr7:66376044~66401338:-
HNSC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-13.88	6.27e-37	3.88e-33	-0.6	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.88	6.38e-37	3.95e-33	-0.6	-0.54	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	13.88	6.47e-37	4e-33	0.64	0.54	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
HNSC	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	13.88	6.7e-37	4.14e-33	0.78	0.54	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
HNSC	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-13.87	7.08e-37	4.37e-33	-0.62	-0.54	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	13.87	7.21e-37	4.45e-33	0.69	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
HNSC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	13.87	7.32e-37	4.51e-33	1.08	0.54	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-13.87	7.4e-37	4.56e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
HNSC	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-13.86	7.62e-37	4.7e-33	-0.67	-0.54	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
HNSC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-13.86	7.62e-37	4.7e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-13.86	8.02e-37	4.93e-33	-0.62	-0.54	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
HNSC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-13.85	8.32e-37	5.11e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-13.85	8.72e-37	5.36e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	13.85	8.88e-37	5.45e-33	0.51	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
HNSC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.58e-37	5.87e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.58e-37	5.87e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-13.84	9.69e-37	5.93e-33	-0.63	-0.54	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
HNSC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-13.84	9.9e-37	6.06e-33	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	13.84	9.92e-37	6.07e-33	0.5	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-13.83	1e-36	6.14e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-13.83	1.01e-36	6.18e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13.83	1.07e-36	6.55e-33	-1.05	-0.54	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
HNSC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-13.83	1.09e-36	6.64e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-13.82	1.13e-36	6.87e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000179406.6	LINC00174	-13.82	1.13e-36	6.88e-33	-0.7	-0.54	Aortic root size;	chr7:66062213	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs160635	ENSG00000179406.6	LINC00174	-13.82	1.13e-36	6.88e-33	-0.7	-0.54	Aortic root size;	chr7:66063931	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-13.81	1.25e-36	7.59e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-13.81	1.25e-36	7.59e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-13.81	1.3e-36	7.92e-33	-0.71	-0.54	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	13.81	1.32e-36	7.99e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	13.81	1.32e-36	7.99e-33	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
HNSC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-13.81	1.34e-36	8.15e-33	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-13.8	1.35e-36	8.16e-33	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-13.8	1.41e-36	8.57e-33	-0.61	-0.54	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-13.8	1.46e-36	8.85e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-13.79	1.49e-36	9e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-13.79	1.51e-36	9.12e-33	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-13.79	1.6e-36	9.66e-33	-0.6	-0.54	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-13.79	1.64e-36	9.87e-33	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	13.78	1.75e-36	1.05e-32	1.06	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
HNSC	cis	rs875971	1	rs937495	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66314811	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2036264	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66334917	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs7783613	ENSG00000179406.6	LINC00174	13.78	1.77e-36	1.07e-32	0.7	0.54	Aortic root size;	chr7:66340274	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-13.78	1.81e-36	1.09e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-13.77	1.81e-36	1.09e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-13.77	1.81e-36	1.09e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-13.77	1.86e-36	1.11e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-13.77	1.87e-36	1.12e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-13.77	1.88e-36	1.13e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs2220626	ENSG00000179406.6	LINC00174	13.77	1.9e-36	1.13e-32	0.71	0.54	Aortic root size;	chr7:66081075	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-13.77	1.92e-36	1.14e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000179406.6	LINC00174	13.77	1.97e-36	1.18e-32	0.7	0.54	Aortic root size;	chr7:66297976	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66070046	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1183245	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66076198	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1144895	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66076320	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1144894	ENSG00000179406.6	LINC00174	13.76	2.05e-36	1.22e-32	0.71	0.54	Aortic root size;	chr7:66077907	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-13.76	2.07e-36	1.23e-32	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
HNSC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-13.76	2.08e-36	1.24e-32	-0.62	-0.54	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
HNSC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-13.76	2.08e-36	1.24e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	13.76	2.18e-36	1.29e-32	0.65	0.54	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	13.76	2.18e-36	1.29e-32	0.65	0.54	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-13.75	2.3e-36	1.36e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
HNSC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	13.75	2.35e-36	1.39e-32	1.09	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	13.75	2.36e-36	1.4e-32	0.64	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-13.74	2.65e-36	1.57e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-13.72	2.98e-36	1.75e-32	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
HNSC	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-13.72	3.22e-36	1.89e-32	-0.62	-0.54	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.8	rs427557	ENSG00000179406.6	LINC00174	-13.72	3.24e-36	1.9e-32	-0.71	-0.54	Aortic root size;	chr7:66054263	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs587360	ENSG00000179406.6	LINC00174	-13.72	3.24e-36	1.9e-32	-0.71	-0.54	Aortic root size;	chr7:66057711	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-13.72	3.25e-36	1.91e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-13.71	3.38e-36	1.98e-32	-0.68	-0.54	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.83	rs427575	ENSG00000179406.6	LINC00174	-13.71	3.52e-36	2.06e-32	-0.71	-0.54	Aortic root size;	chr7:66054232	chr7:66376044~66401338:-
HNSC	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	13.71	3.58e-36	2.1e-32	0.78	0.54	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
HNSC	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-13.7	3.67e-36	2.15e-32	-0.5	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-13.7	3.72e-36	2.18e-32	-0.68	-0.54	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
HNSC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-13.7	3.8e-36	2.22e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-13.7	3.8e-36	2.22e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-13.7	3.86e-36	2.26e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-13.7	3.86e-36	2.26e-32	-0.7	-0.54	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-13.69	4e-36	2.33e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-13.69	4e-36	2.33e-32	-0.66	-0.54	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-13.69	4.01e-36	2.34e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-13.69	4.01e-36	2.34e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-13.69	4.02e-36	2.34e-32	-0.67	-0.54	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	13.69	4.07e-36	2.37e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	13.69	4.07e-36	2.37e-32	0.73	0.54	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-13.69	4.16e-36	2.42e-32	-0.65	-0.54	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs1167411	ENSG00000179406.6	LINC00174	13.69	4.34e-36	2.52e-32	0.71	0.54	Aortic root size;	chr7:66074277	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	13.68	4.38e-36	2.55e-32	0.72	0.54	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-13.68	4.4e-36	2.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-13.68	4.4e-36	2.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-13.68	4.4e-36	2.55e-32	-0.6	-0.53	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
HNSC	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-13.68	4.47e-36	2.59e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	13.68	4.52e-36	2.62e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-13.68	4.58e-36	2.65e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-13.68	4.6e-36	2.66e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-13.68	4.71e-36	2.72e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-13.68	4.71e-36	2.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	13.68	4.78e-36	2.76e-32	0.65	0.53	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	13.68	4.81e-36	2.78e-32	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-13.67	4.97e-36	2.87e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-13.67	5.09e-36	2.94e-32	-0.6	-0.53	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-13.67	5.3e-36	3.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-13.66	5.41e-36	3.12e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-13.66	5.52e-36	3.17e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs1167612	ENSG00000179406.6	LINC00174	13.66	5.53e-36	3.18e-32	0.71	0.53	Aortic root size;	chr7:66102989	chr7:66376044~66401338:-
HNSC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-13.66	5.56e-36	3.2e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-13.66	5.56e-36	3.2e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-13.66	5.72e-36	3.28e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	13.66	5.76e-36	3.31e-32	0.72	0.53	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-13.65	5.93e-36	3.4e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-13.65	6.12e-36	3.5e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-13.65	6.13e-36	3.51e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-13.65	6.21e-36	3.55e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	13.65	6.29e-36	3.6e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	13.65	6.29e-36	3.6e-32	0.73	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-13.65	6.29e-36	3.6e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-13.64	6.53e-36	3.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-13.64	6.53e-36	3.73e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-13.64	6.67e-36	3.79e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-13.64	7.05e-36	4e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-13.63	7.39e-36	4.19e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	13.63	7.58e-36	4.3e-32	0.72	0.53	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.564	rs313804	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049635	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.662	rs448725	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049641	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.658	rs432667	ENSG00000179406.6	LINC00174	-13.63	7.65e-36	4.34e-32	-0.7	-0.53	Aortic root size;	chr7:66049646	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-13.63	7.69e-36	4.36e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
HNSC	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.63	7.72e-36	4.37e-32	1	0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
HNSC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-13.63	7.81e-36	4.42e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
HNSC	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-13.63	7.84e-36	4.44e-32	-0.44	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
HNSC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	13.62	8.07e-36	4.57e-32	0.6	0.53	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-13.62	8.33e-36	4.71e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	13.62	8.36e-36	4.72e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
HNSC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-13.62	8.37e-36	4.73e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-13.62	8.37e-36	4.73e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
HNSC	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	13.61	8.78e-36	4.95e-32	0.76	0.53	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-13.61	8.89e-36	5.01e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-13.61	8.95e-36	5.04e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-13.61	9.18e-36	5.17e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-13.61	9.19e-36	5.17e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-13.61	9.44e-36	5.31e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-13.61	9.49e-36	5.34e-32	-0.69	-0.53	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-13.6	9.6e-36	5.4e-32	-0.6	-0.53	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
HNSC	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-13.6	9.65e-36	5.42e-32	-0.44	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
HNSC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-13.6	9.72e-36	5.46e-32	-0.59	-0.53	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-13.6	9.9e-36	5.55e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-13.6	1e-35	5.61e-32	-0.69	-0.53	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-13.6	1e-35	5.62e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-13.6	1e-35	5.62e-32	-0.65	-0.53	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-13.6	1.01e-35	5.66e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-13.6	1.01e-35	5.66e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-13.59	1.06e-35	5.93e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-13.59	1.08e-35	6.03e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-13.59	1.08e-35	6.05e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-13.59	1.09e-35	6.06e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-13.59	1.09e-35	6.06e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-13.59	1.1e-35	6.12e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-13.59	1.1e-35	6.13e-32	-0.7	-0.53	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-13.59	1.11e-35	6.19e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-13.59	1.12e-35	6.26e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-13.59	1.15e-35	6.38e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.964	rs697969	ENSG00000179406.6	LINC00174	13.58	1.17e-35	6.51e-32	0.7	0.53	Aortic root size;	chr7:66093491	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs1182882	ENSG00000179406.6	LINC00174	13.58	1.17e-35	6.51e-32	0.7	0.53	Aortic root size;	chr7:66097076	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-13.58	1.18e-35	6.57e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-13.58	1.18e-35	6.57e-32	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-13.58	1.18e-35	6.57e-32	-0.71	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-13.58	1.22e-35	6.8e-32	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	13.58	1.24e-35	6.91e-32	0.69	0.53	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-13.57	1.35e-35	7.47e-32	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-13.57	1.36e-35	7.55e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-13.57	1.37e-35	7.57e-32	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
HNSC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-13.57	1.39e-35	7.67e-32	-0.98	-0.53	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
HNSC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-13.56	1.44e-35	7.97e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	13.56	1.54e-35	8.52e-32	0.54	0.53	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-13.55	1.57e-35	8.66e-32	-0.65	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
HNSC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-13.55	1.62e-35	8.93e-32	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-13.55	1.66e-35	9.13e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-13.54	1.79e-35	9.88e-32	-0.67	-0.53	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	13.54	1.8e-35	9.92e-32	0.55	0.53	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
HNSC	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-13.54	1.81e-35	9.94e-32	-0.66	-0.53	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
HNSC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-13.54	1.81e-35	9.94e-32	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-13.54	1.82e-35	9.99e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-13.54	1.83e-35	1e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
HNSC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.54	1.84e-35	1.01e-31	0.64	0.53	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
HNSC	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-13.54	1.88e-35	1.03e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-13.53	1.95e-35	1.07e-31	-0.67	-0.53	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-13.53	1.95e-35	1.07e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-13.53	1.96e-35	1.07e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-13.53	1.98e-35	1.09e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
HNSC	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	13.53	2.03e-35	1.11e-31	0.77	0.53	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.53	2.1e-35	1.15e-31	0.72	0.53	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
HNSC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	13.52	2.13e-35	1.17e-31	0.63	0.53	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-13.52	2.14e-35	1.17e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
HNSC	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	13.52	2.18e-35	1.19e-31	0.75	0.53	Migraine;	chr16:75350086	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-13.52	2.2e-35	1.2e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	13.52	2.21e-35	1.2e-31	0.72	0.53	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	13.52	2.27e-35	1.23e-31	0.59	0.53	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-13.52	2.27e-35	1.23e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-13.52	2.27e-35	1.23e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-13.52	2.3e-35	1.25e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
HNSC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-13.51	2.34e-35	1.27e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-13.51	2.38e-35	1.29e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	13.51	2.42e-35	1.31e-31	0.72	0.53	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
HNSC	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-13.51	2.49e-35	1.35e-31	-0.68	-0.53	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
HNSC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-13.51	2.5e-35	1.36e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-13.51	2.51e-35	1.36e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
HNSC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.5	2.62e-35	1.41e-31	-0.64	-0.53	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
HNSC	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-13.5	2.64e-35	1.42e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-13.5	2.71e-35	1.46e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-13.5	2.74e-35	1.48e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
HNSC	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	13.49	2.81e-35	1.51e-31	0.64	0.53	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	13.49	2.81e-35	1.51e-31	0.64	0.53	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
HNSC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	13.49	2.93e-35	1.57e-31	0.65	0.53	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-13.49	2.97e-35	1.59e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-13.49	2.99e-35	1.61e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
HNSC	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-13.49	3.01e-35	1.62e-31	-0.43	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
HNSC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-13.49	3.04e-35	1.63e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-13.49	3.04e-35	1.63e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
HNSC	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-13.49	3.08e-35	1.65e-31	-0.5	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
HNSC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.48	3.12e-35	1.67e-31	-0.64	-0.53	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
HNSC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-13.48	3.15e-35	1.68e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	13.48	3.16e-35	1.69e-31	0.61	0.53	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-13.48	3.21e-35	1.71e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-13.48	3.22e-35	1.72e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-13.48	3.22e-35	1.72e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-13.48	3.28e-35	1.75e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-13.47	3.5e-35	1.86e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-13.47	3.59e-35	1.91e-31	-0.65	-0.53	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	13.47	3.6e-35	1.91e-31	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
HNSC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-13.47	3.75e-35	1.99e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	13.46	3.9e-35	2.07e-31	0.59	0.53	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-13.46	3.92e-35	2.08e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-13.46	3.99e-35	2.12e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-13.46	4e-35	2.12e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-13.46	4.03e-35	2.14e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-13.46	4.05e-35	2.15e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-13.46	4.05e-35	2.15e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-13.45	4.18e-35	2.22e-31	-0.59	-0.53	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-13.45	4.22e-35	2.24e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-13.45	4.33e-35	2.29e-31	-0.66	-0.53	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-13.45	4.41e-35	2.33e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-13.45	4.41e-35	2.33e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-13.45	4.46e-35	2.36e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-13.45	4.46e-35	2.36e-31	-0.64	-0.53	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	13.44	4.59e-35	2.42e-31	0.59	0.53	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
HNSC	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	13.44	4.73e-35	2.49e-31	0.5	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-13.44	4.77e-35	2.52e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	13.44	4.85e-35	2.56e-31	0.62	0.53	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
HNSC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.44	4.91e-35	2.59e-31	-0.64	-0.53	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
HNSC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-13.44	4.98e-35	2.62e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-13.44	5.04e-35	2.65e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-13.43	5.07e-35	2.67e-31	-0.59	-0.53	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-13.43	5.28e-35	2.78e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-13.43	5.48e-35	2.88e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-13.43	5.5e-35	2.89e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-13.42	5.65e-35	2.96e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	13.42	5.72e-35	3e-31	0.59	0.53	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-13.42	5.82e-35	3.05e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-13.42	5.84e-35	3.06e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-13.42	5.93e-35	3.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-13.41	6.72e-35	3.51e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-13.4	7.1e-35	3.7e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-13.4	7.12e-35	3.71e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-13.4	7.24e-35	3.77e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-13.4	7.24e-35	3.77e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-13.4	7.36e-35	3.83e-31	-0.71	-0.53	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	13.4	7.39e-35	3.84e-31	0.76	0.53	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
HNSC	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-13.39	7.75e-35	4.02e-31	-0.67	-0.53	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-13.39	7.77e-35	4.03e-31	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-13.39	8.17e-35	4.23e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-13.38	8.35e-35	4.32e-31	-0.59	-0.53	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-13.38	8.35e-35	4.32e-31	-0.59	-0.53	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-13.38	8.4e-35	4.34e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-13.38	8.4e-35	4.34e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-13.38	8.43e-35	4.36e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-13.38	8.73e-35	4.51e-31	-0.55	-0.53	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
HNSC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-13.38	8.76e-35	4.52e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-13.38	9e-35	4.64e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-13.38	9.01e-35	4.65e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-13.37	9.2e-35	4.75e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	13.37	9.49e-35	4.89e-31	0.62	0.53	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	13.37	9.71e-35	5.01e-31	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-13.37	9.94e-35	5.11e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
HNSC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	13.36	1e-34	5.14e-31	0.63	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-13.36	1.01e-34	5.17e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-13.36	1.01e-34	5.19e-31	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	13.36	1.02e-34	5.22e-31	0.51	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-13.36	1.03e-34	5.27e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-13.36	1.03e-34	5.27e-31	-0.7	-0.53	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-13.36	1.03e-34	5.27e-31	-1.04	-0.53	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
HNSC	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-13.36	1.04e-34	5.3e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	13.36	1.05e-34	5.35e-31	0.65	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-13.36	1.05e-34	5.36e-31	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	13.36	1.05e-34	5.38e-31	0.58	0.53	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
HNSC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	13.36	1.06e-34	5.41e-31	0.64	0.53	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
HNSC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-13.36	1.06e-34	5.41e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-13.36	1.06e-34	5.41e-31	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-13.35	1.11e-34	5.65e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-13.35	1.13e-34	5.77e-31	-0.54	-0.53	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-13.35	1.16e-34	5.88e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-13.35	1.17e-34	5.94e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
HNSC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	13.35	1.17e-34	5.95e-31	0.54	0.53	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-13.35	1.17e-34	5.95e-31	-0.58	-0.53	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-13.35	1.18e-34	5.99e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-13.35	1.18e-34	5.99e-31	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-13.35	1.2e-34	6.1e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-13.34	1.22e-34	6.16e-31	-0.61	-0.53	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
HNSC	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-13.34	1.22e-34	6.16e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-13.34	1.22e-34	6.18e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
HNSC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.34	1.26e-34	6.36e-31	-0.64	-0.53	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
HNSC	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-13.34	1.29e-34	6.52e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-13.34	1.31e-34	6.6e-31	-0.68	-0.53	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-13.33	1.37e-34	6.86e-31	-0.69	-0.53	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	13.33	1.38e-34	6.91e-31	0.5	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	13.33	1.4e-34	7.02e-31	0.58	0.53	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	13.33	1.4e-34	7.04e-31	0.51	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
HNSC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-13.33	1.45e-34	7.26e-31	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
HNSC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.33	1.45e-34	7.29e-31	-0.63	-0.52	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
HNSC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.33	1.45e-34	7.29e-31	-0.63	-0.52	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-34	7.3e-31	-0.64	-0.52	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-34	7.3e-31	-0.64	-0.52	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
HNSC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-13.32	1.54e-34	7.72e-31	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	13.32	1.58e-34	7.89e-31	0.58	0.52	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	13.32	1.58e-34	7.89e-31	0.58	0.52	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-13.31	1.64e-34	8.21e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-13.31	1.66e-34	8.29e-31	-0.68	-0.52	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-13.31	1.71e-34	8.51e-31	-0.69	-0.52	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
HNSC	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-13.31	1.74e-34	8.69e-31	-0.61	-0.52	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	13.3	1.85e-34	9.22e-31	0.58	0.52	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-13.3	1.87e-34	9.32e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
HNSC	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	13.29	2.03e-34	1.01e-30	0.62	0.52	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-13.29	2.11e-34	1.05e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	13.29	2.13e-34	1.05e-30	0.66	0.52	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-13.29	2.15e-34	1.06e-30	-0.62	-0.52	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-13.29	2.15e-34	1.06e-30	-0.62	-0.52	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
HNSC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-13.29	2.17e-34	1.07e-30	-0.84	-0.52	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
HNSC	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	13.29	2.17e-34	1.07e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-13.28	2.2e-34	1.09e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-13.28	2.26e-34	1.12e-30	-0.5	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-13.28	2.27e-34	1.12e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-13.28	2.27e-34	1.12e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	13.28	2.28e-34	1.13e-30	0.58	0.52	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
HNSC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-13.28	2.31e-34	1.14e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
HNSC	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	13.28	2.35e-34	1.16e-30	0.67	0.52	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
HNSC	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-13.28	2.35e-34	1.16e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-13.28	2.35e-34	1.16e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-13.27	2.41e-34	1.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
HNSC	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-13.27	2.43e-34	1.2e-30	-0.69	-0.52	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-13.27	2.45e-34	1.2e-30	-0.59	-0.52	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	13.27	2.58e-34	1.26e-30	0.58	0.52	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	13.27	2.61e-34	1.28e-30	0.58	0.52	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-13.26	2.65e-34	1.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-13.26	2.65e-34	1.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	13.26	2.68e-34	1.31e-30	0.59	0.52	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	13.26	2.69e-34	1.32e-30	0.58	0.52	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	13.26	2.79e-34	1.36e-30	0.58	0.52	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	13.26	2.8e-34	1.36e-30	0.59	0.52	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-13.26	2.84e-34	1.38e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-13.26	2.86e-34	1.39e-30	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-13.26	2.87e-34	1.4e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-13.26	2.9e-34	1.41e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	13.25	2.94e-34	1.43e-30	0.54	0.52	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
HNSC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-13.25	2.95e-34	1.44e-30	-0.65	-0.52	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
HNSC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-13.25	2.98e-34	1.45e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-13.25	2.98e-34	1.45e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
HNSC	cis	rs875971	1	rs7792762	ENSG00000179406.6	LINC00174	-13.25	3.11e-34	1.51e-30	-0.69	-0.52	Aortic root size;	chr7:66539151	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-13.25	3.15e-34	1.53e-30	-0.59	-0.52	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
HNSC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	13.24	3.23e-34	1.57e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
HNSC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-13.24	3.23e-34	1.57e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
HNSC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-13.24	3.26e-34	1.58e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-13.24	3.26e-34	1.58e-30	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-13.24	3.41e-34	1.65e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-13.24	3.44e-34	1.67e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-13.24	3.44e-34	1.67e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
HNSC	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	13.24	3.44e-34	1.67e-30	0.59	0.52	Breast cancer;	chr11:750849	chr11:779617~780755:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-13.24	3.5e-34	1.69e-30	-0.59	-0.52	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-13.23	3.55e-34	1.72e-30	-0.65	-0.52	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
HNSC	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-13.23	3.68e-34	1.78e-30	-0.74	-0.52	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
HNSC	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	13.23	3.69e-34	1.78e-30	0.68	0.52	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000216906.2	RP11-350J20.9	13.23	3.73e-34	1.8e-30	0.68	0.52	Lung cancer;	chr6:149863746	chr6:149904243~149906418:+
HNSC	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	13.23	3.86e-34	1.86e-30	0.68	0.52	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-13.22	3.93e-34	1.89e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-13.22	3.96e-34	1.91e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
HNSC	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-13.22	3.99e-34	1.93e-30	-0.58	-0.52	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
HNSC	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-13.22	4.07e-34	1.96e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000179406.6	LINC00174	13.22	4.14e-34	1.99e-30	0.69	0.52	Aortic root size;	chr7:66722728	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-13.22	4.16e-34	2e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-13.21	4.4e-34	2.11e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
HNSC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-13.21	4.4e-34	2.11e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-13.21	4.41e-34	2.12e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-13.21	4.54e-34	2.18e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-13.2	4.76e-34	2.28e-30	-0.58	-0.52	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
HNSC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	13.2	4.86e-34	2.33e-30	0.61	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-13.2	4.9e-34	2.34e-30	-0.58	-0.52	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-13.2	4.98e-34	2.38e-30	-0.58	-0.52	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-13.2	5.01e-34	2.4e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-13.2	5.01e-34	2.4e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-13.19	5.26e-34	2.51e-30	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-13.19	5.47e-34	2.61e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-13.19	5.67e-34	2.7e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-13.18	5.79e-34	2.76e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-13.18	5.79e-34	2.76e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-13.18	5.85e-34	2.78e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
HNSC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	13.18	5.91e-34	2.82e-30	0.59	0.52	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
HNSC	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-13.18	5.95e-34	2.83e-30	-0.58	-0.52	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
HNSC	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-13.18	6.12e-34	2.91e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-13.18	6.19e-34	2.94e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-13.18	6.21e-34	2.95e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-13.17	6.34e-34	3.01e-30	-0.58	-0.52	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
HNSC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-13.17	6.5e-34	3.09e-30	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-13.17	6.51e-34	3.09e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	13.17	6.71e-34	3.18e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-13.17	6.73e-34	3.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-13.17	6.73e-34	3.19e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-13.16	7.1e-34	3.36e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-13.16	7.2e-34	3.41e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-13.16	7.2e-34	3.41e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-13.16	7.21e-34	3.41e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-13.16	7.21e-34	3.41e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-13.16	7.5e-34	3.55e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-13.15	7.71e-34	3.64e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-13.15	7.72e-34	3.65e-30	-0.54	-0.52	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-13.15	7.95e-34	3.75e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-13.14	8.47e-34	3.99e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	13.14	8.5e-34	4e-30	0.75	0.52	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000179406.6	LINC00174	13.14	8.55e-34	4.02e-30	0.68	0.52	Aortic root size;	chr7:66653261	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-13.14	8.57e-34	4.03e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-13.14	8.6e-34	4.04e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-13.14	8.6e-34	4.04e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-13.14	8.82e-34	4.14e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-13.14	8.82e-34	4.14e-30	-0.58	-0.52	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-13.14	8.86e-34	4.16e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-13.14	9.07e-34	4.25e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-13.14	9.07e-34	4.25e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-13.13	9.63e-34	4.51e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-13.13	1e-33	4.68e-30	-0.53	-0.52	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
HNSC	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	13.12	1.05e-33	4.88e-30	0.5	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs697970	ENSG00000179406.6	LINC00174	13.12	1.05e-33	4.88e-30	0.7	0.52	Aortic root size;	chr7:66095065	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	13.12	1.05e-33	4.92e-30	0.69	0.52	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	13.12	1.1e-33	5.12e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-13.11	1.16e-33	5.41e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-13.11	1.17e-33	5.47e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-13.11	1.21e-33	5.65e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
HNSC	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-13.1	1.26e-33	5.87e-30	-0.49	-0.52	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-13.1	1.26e-33	5.88e-30	-0.57	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
HNSC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	13.1	1.27e-33	5.88e-30	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-13.1	1.28e-33	5.93e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	13.1	1.29e-33	6e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
HNSC	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-13.1	1.29e-33	6e-30	-0.61	-0.52	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
HNSC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-13.1	1.3e-33	6.02e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000179406.6	LINC00174	-13.1	1.31e-33	6.08e-30	-0.68	-0.52	Aortic root size;	chr7:66691927	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-13.1	1.36e-33	6.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-13.1	1.36e-33	6.3e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	13.09	1.4e-33	6.49e-30	0.63	0.52	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-13.09	1.42e-33	6.58e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-13.09	1.45e-33	6.72e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-13.09	1.45e-33	6.72e-30	-0.71	-0.52	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-13.09	1.47e-33	6.8e-30	-0.59	-0.52	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-13.09	1.47e-33	6.8e-30	-0.59	-0.52	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	13.09	1.47e-33	6.81e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	13.09	1.5e-33	6.93e-30	0.53	0.52	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-13.08	1.53e-33	7.07e-30	-0.59	-0.52	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66731484	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs974239	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66748504	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66749580	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000179406.6	LINC00174	-13.08	1.55e-33	7.17e-30	-0.68	-0.52	Aortic root size;	chr7:66759510	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs10244498	ENSG00000179406.6	LINC00174	-13.08	1.56e-33	7.18e-30	-0.68	-0.52	Aortic root size;	chr7:66651069	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	13.08	1.64e-33	7.55e-30	0.65	0.52	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
HNSC	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-13.07	1.66e-33	7.66e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.7e-33	7.81e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.72e-33	7.91e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.72e-33	7.91e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-13.07	1.74e-33	8e-30	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	13.07	1.77e-33	8.13e-30	0.65	0.52	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	13.07	1.77e-33	8.13e-30	0.54	0.52	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	13.07	1.78e-33	8.18e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-13.06	1.86e-33	8.53e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-13.06	1.86e-33	8.53e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-13.06	1.91e-33	8.75e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-13.06	1.92e-33	8.81e-30	-0.62	-0.52	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-13.06	1.92e-33	8.81e-30	-0.62	-0.52	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
HNSC	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-13.06	1.93e-33	8.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-13.06	1.93e-33	8.85e-30	-0.7	-0.52	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-13.06	1.96e-33	8.98e-30	-0.66	-0.52	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-13.06	1.97e-33	9e-30	-0.6	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-13.06	1.97e-33	9.03e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-13.06	1.99e-33	9.08e-30	-0.62	-0.52	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-13.05	2.03e-33	9.3e-30	-0.58	-0.52	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-13.05	2.06e-33	9.42e-30	-0.67	-0.52	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-13.05	2.07e-33	9.45e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-13.05	2.07e-33	9.45e-30	-0.68	-0.52	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
HNSC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	13.05	2.09e-33	9.55e-30	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000179406.6	LINC00174	-13.05	2.13e-33	9.71e-30	-0.68	-0.52	Aortic root size;	chr7:66765873	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	13.05	2.16e-33	9.83e-30	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-13.05	2.17e-33	9.87e-30	-0.69	-0.52	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
HNSC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-13.05	2.18e-33	9.91e-30	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
HNSC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
HNSC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-13.04	2.28e-33	1.04e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-13.04	2.31e-33	1.05e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
HNSC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-13.04	2.31e-33	1.05e-29	-0.59	-0.52	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-13.04	2.38e-33	1.08e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-13.04	2.38e-33	1.08e-29	-0.66	-0.52	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-13.03	2.44e-33	1.11e-29	-0.58	-0.52	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-13.03	2.45e-33	1.11e-29	-0.58	-0.52	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-13.03	2.49e-33	1.13e-29	-0.58	-0.52	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
HNSC	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-13.03	2.56e-33	1.16e-29	-0.67	-0.52	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-13.03	2.6e-33	1.17e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	13.03	2.61e-33	1.18e-29	0.59	0.52	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	13.03	2.63e-33	1.19e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
HNSC	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-13.02	2.76e-33	1.25e-29	-0.66	-0.52	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-13.02	2.84e-33	1.27e-29	-0.58	-0.52	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	13.02	2.84e-33	1.27e-29	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	13.02	2.86e-33	1.28e-29	0.7	0.52	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-13.02	2.88e-33	1.29e-29	-0.49	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	13.02	2.94e-33	1.31e-29	0.66	0.52	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
HNSC	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	13.01	3.05e-33	1.37e-29	0.42	0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-13.01	3.11e-33	1.39e-29	-0.58	-0.52	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-13.01	3.2e-33	1.43e-29	-0.67	-0.52	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-13	3.25e-33	1.45e-29	-0.58	-0.52	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-13	3.28e-33	1.46e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-13	3.3e-33	1.47e-29	-0.58	-0.52	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	13	3.37e-33	1.5e-29	0.79	0.52	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-13	3.45e-33	1.53e-29	-0.58	-0.52	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-13	3.49e-33	1.55e-29	-0.58	-0.52	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-13	3.51e-33	1.56e-29	-0.58	-0.52	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-12.99	3.6e-33	1.6e-29	-0.69	-0.52	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
HNSC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-12.99	3.69e-33	1.63e-29	-0.63	-0.52	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
HNSC	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	12.99	3.79e-33	1.67e-29	0.7	0.52	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	12.99	3.79e-33	1.67e-29	0.7	0.52	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000179406.6	LINC00174	-12.99	3.81e-33	1.68e-29	-0.68	-0.52	Aortic root size;	chr7:66719456	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-12.99	3.9e-33	1.72e-29	-0.66	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
HNSC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-12.99	3.92e-33	1.73e-29	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	12.98	4.05e-33	1.79e-29	0.58	0.51	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-12.98	4.15e-33	1.83e-29	-0.58	-0.51	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-12.98	4.15e-33	1.83e-29	-0.58	-0.51	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-12.98	4.28e-33	1.89e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-12.98	4.31e-33	1.9e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	12.97	4.38e-33	1.93e-29	0.98	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-12.97	4.57e-33	2.01e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
HNSC	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-12.97	4.63e-33	2.04e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-12.97	4.74e-33	2.08e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-12.96	4.83e-33	2.12e-29	-0.53	-0.51	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
HNSC	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-12.96	4.92e-33	2.16e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-12.96	4.99e-33	2.19e-29	-0.58	-0.51	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-12.96	4.99e-33	2.19e-29	-0.58	-0.51	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-12.95	5.24e-33	2.3e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-12.95	5.29e-33	2.32e-29	-0.58	-0.51	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-12.95	5.33e-33	2.33e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
HNSC	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	12.95	5.4e-33	2.36e-29	0.71	0.51	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
HNSC	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	12.95	5.41e-33	2.37e-29	0.71	0.51	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
HNSC	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	12.95	5.53e-33	2.42e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	12.95	5.54e-33	2.42e-29	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
HNSC	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	12.95	5.72e-33	2.5e-29	0.41	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-12.94	5.84e-33	2.55e-29	-0.58	-0.51	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-12.94	6.12e-33	2.67e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	12.94	6.14e-33	2.68e-29	0.8	0.51	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	12.94	6.14e-33	2.68e-29	0.76	0.51	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-12.94	6.26e-33	2.73e-29	-0.58	-0.51	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	12.94	6.31e-33	2.75e-29	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs709596	ENSG00000179406.6	LINC00174	-12.93	6.35e-33	2.77e-29	-0.68	-0.51	Aortic root size;	chr7:66360926	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-12.93	6.66e-33	2.9e-29	-0.58	-0.51	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
HNSC	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	12.92	7.11e-33	3.09e-29	0.7	0.51	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	12.92	7.27e-33	3.16e-29	0.71	0.51	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	12.92	7.42e-33	3.22e-29	0.65	0.51	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	12.92	7.49e-33	3.25e-29	0.62	0.51	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-12.92	7.61e-33	3.31e-29	-0.62	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	12.92	7.65e-33	3.32e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000179406.6	LINC00174	-12.91	7.67e-33	3.33e-29	-0.68	-0.51	Aortic root size;	chr7:66728097	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	12.91	7.82e-33	3.4e-29	0.66	0.51	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-12.91	7.96e-33	3.46e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	12.91	7.99e-33	3.47e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	12.91	7.99e-33	3.47e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
HNSC	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	12.91	8e-33	3.47e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	12.91	8.19e-33	3.55e-29	0.63	0.51	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
HNSC	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	12.91	8.19e-33	3.55e-29	0.65	0.51	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
HNSC	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	12.91	8.22e-33	3.56e-29	0.63	0.51	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
HNSC	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-12.91	8.27e-33	3.58e-29	-0.58	-0.51	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
HNSC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	12.91	8.38e-33	3.62e-29	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	12.9	8.79e-33	3.8e-29	0.69	0.51	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	12.9	8.85e-33	3.83e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	12.9	8.85e-33	3.83e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
HNSC	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-12.9	9.22e-33	3.98e-29	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000179406.6	LINC00174	-12.9	9.26e-33	3.99e-29	-0.68	-0.51	Aortic root size;	chr7:66495270	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-12.9	9.26e-33	4e-29	-0.58	-0.51	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-12.89	9.41e-33	4.05e-29	-0.63	-0.51	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
HNSC	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-12.89	9.6e-33	4.13e-29	-0.59	-0.51	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
HNSC	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-12.89	9.64e-33	4.15e-29	-0.93	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-12.89	9.64e-33	4.15e-29	-0.93	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
HNSC	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	12.89	9.66e-33	4.15e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
HNSC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-12.89	9.68e-33	4.16e-29	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
HNSC	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-12.89	1.01e-32	4.33e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	12.89	1.02e-32	4.37e-29	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	12.89	1.02e-32	4.37e-29	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
HNSC	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-12.88	1.05e-32	4.52e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-12.88	1.05e-32	4.52e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-12.88	1.08e-32	4.64e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
HNSC	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	12.88	1.1e-32	4.71e-29	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-12.87	1.16e-32	4.96e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	12.87	1.16e-32	4.99e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	12.87	1.17e-32	5.01e-29	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-12.87	1.18e-32	5.04e-29	-0.58	-0.51	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-12.87	1.22e-32	5.24e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-12.87	1.23e-32	5.25e-29	-0.65	-0.51	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000179406.6	LINC00174	-12.86	1.24e-32	5.29e-29	-0.7	-0.51	Aortic root size;	chr7:66210141	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-12.86	1.26e-32	5.38e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	12.85	1.36e-32	5.81e-29	0.66	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-12.85	1.37e-32	5.84e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
HNSC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-12.85	1.38e-32	5.87e-29	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	12.85	1.43e-32	6.09e-29	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
HNSC	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-12.85	1.43e-32	6.11e-29	-0.66	-0.51	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	12.85	1.47e-32	6.27e-29	0.58	0.51	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	12.84	1.5e-32	6.39e-29	0.58	0.51	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1544549	ENSG00000179406.6	LINC00174	12.84	1.52e-32	6.48e-29	0.68	0.51	Aortic root size;	chr7:66625676	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420820	ENSG00000179406.6	LINC00174	12.84	1.52e-32	6.48e-29	0.68	0.51	Aortic root size;	chr7:66626920	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	12.84	1.53e-32	6.5e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	12.84	1.56e-32	6.65e-29	0.58	0.51	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	12.84	1.58e-32	6.7e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
HNSC	cis	rs17270561	0.541	rs17586946	ENSG00000272462.2	U91328.19	-12.84	1.61e-32	6.83e-29	-0.62	-0.51	Iron status biomarkers;	chr6:25938825	chr6:25992662~26001775:+
HNSC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	12.83	1.72e-32	7.29e-29	0.58	0.51	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	12.83	1.79e-32	7.58e-29	0.58	0.51	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	12.83	1.79e-32	7.6e-29	0.62	0.51	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
HNSC	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-12.82	1.86e-32	7.88e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-12.82	1.86e-32	7.88e-29	-0.68	-0.51	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-12.82	1.88e-32	7.97e-29	-0.57	-0.51	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	12.82	1.92e-32	8.14e-29	0.62	0.51	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-12.81	2e-32	8.45e-29	-0.58	-0.51	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-12.81	2e-32	8.46e-29	-0.67	-0.51	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
HNSC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	12.81	2.02e-32	8.53e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
HNSC	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	12.81	2.17e-32	9.15e-29	0.62	0.51	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-12.8	2.22e-32	9.36e-29	-0.76	-0.51	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	12.8	2.22e-32	9.37e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	12.8	2.22e-32	9.37e-29	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	12.8	2.23e-32	9.39e-29	0.71	0.51	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	12.8	2.28e-32	9.6e-29	0.62	0.51	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000179406.6	LINC00174	-12.8	2.29e-32	9.66e-29	-0.68	-0.51	Aortic root size;	chr7:66450996	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000179406.6	LINC00174	-12.8	2.29e-32	9.66e-29	-0.68	-0.51	Aortic root size;	chr7:66450999	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	12.8	2.33e-32	9.82e-29	0.58	0.51	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	12.8	2.35e-32	9.87e-29	0.58	0.51	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	12.8	2.35e-32	9.87e-29	0.58	0.51	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-12.8	2.36e-32	9.91e-29	-0.65	-0.51	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000179406.6	LINC00174	-12.8	2.37e-32	9.97e-29	-0.68	-0.51	Aortic root size;	chr7:66364304	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	12.8	2.39e-32	1.01e-28	0.58	0.51	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	12.8	2.39e-32	1.01e-28	0.58	0.51	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-12.8	2.4e-32	1.01e-28	-0.58	-0.51	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	12.8	2.4e-32	1.01e-28	0.64	0.51	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-12.79	2.41e-32	1.01e-28	-0.58	-0.51	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-12.79	2.41e-32	1.01e-28	-0.58	-0.51	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	12.79	2.5e-32	1.05e-28	0.58	0.51	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
HNSC	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-12.79	2.52e-32	1.06e-28	-0.59	-0.51	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
HNSC	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	12.79	2.56e-32	1.08e-28	0.49	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	12.79	2.61e-32	1.1e-28	0.48	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
HNSC	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-12.78	2.68e-32	1.12e-28	-0.62	-0.51	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
HNSC	cis	rs12216125	0.537	rs12207059	ENSG00000272462.2	U91328.19	-12.78	2.68e-32	1.12e-28	-0.62	-0.51	Iron status biomarkers;	chr6:25922157	chr6:25992662~26001775:+
HNSC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-12.78	2.68e-32	1.12e-28	-0.91	-0.51	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-12.78	2.69e-32	1.13e-28	-0.91	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-12.78	2.7e-32	1.13e-28	-0.66	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
HNSC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	12.78	2.7e-32	1.13e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-12.78	2.75e-32	1.15e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-12.78	2.81e-32	1.18e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-12.78	2.81e-32	1.18e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-12.78	2.83e-32	1.18e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	12.78	2.86e-32	1.2e-28	0.71	0.51	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	12.78	2.87e-32	1.2e-28	0.62	0.51	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-12.77	2.94e-32	1.23e-28	-0.66	-0.51	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-12.77	2.96e-32	1.23e-28	-0.57	-0.51	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	12.77	2.98e-32	1.24e-28	0.58	0.51	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	12.77	3e-32	1.25e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
HNSC	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	12.77	3.02e-32	1.26e-28	0.48	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
HNSC	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-12.77	3.03e-32	1.26e-28	-0.62	-0.51	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
HNSC	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-12.77	3.07e-32	1.28e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
HNSC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	12.77	3.13e-32	1.3e-28	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-12.77	3.2e-32	1.33e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
HNSC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	12.76	3.25e-32	1.35e-28	0.58	0.51	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
HNSC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-12.76	3.25e-32	1.35e-28	-0.91	-0.51	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
HNSC	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	12.76	3.31e-32	1.38e-28	0.56	0.51	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	12.76	3.33e-32	1.38e-28	0.66	0.51	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	12.76	3.33e-32	1.38e-28	0.66	0.51	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	12.76	3.34e-32	1.39e-28	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-12.76	3.45e-32	1.43e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-12.76	3.51e-32	1.46e-28	-0.58	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000179406.6	LINC00174	12.76	3.52e-32	1.46e-28	0.68	0.51	Aortic root size;	chr7:66517644	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	12.75	3.65e-32	1.52e-28	0.58	0.51	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
HNSC	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-12.75	3.69e-32	1.53e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	12.75	3.71e-32	1.54e-28	0.58	0.51	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	12.75	3.71e-32	1.54e-28	0.58	0.51	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000179406.6	LINC00174	12.75	3.72e-32	1.54e-28	0.68	0.51	Aortic root size;	chr7:66146364	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	12.75	3.78e-32	1.57e-28	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-12.75	3.8e-32	1.57e-28	-0.58	-0.51	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-12.75	3.8e-32	1.57e-28	-0.58	-0.51	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
HNSC	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	12.75	3.83e-32	1.59e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
HNSC	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-12.74	3.88e-32	1.61e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-12.74	3.9e-32	1.61e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-12.74	4e-32	1.66e-28	-0.55	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-12.74	4.04e-32	1.67e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
HNSC	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	12.74	4.05e-32	1.67e-28	0.72	0.51	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-12.74	4.07e-32	1.68e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000179406.6	LINC00174	-12.74	4.11e-32	1.7e-28	-0.68	-0.51	Aortic root size;	chr7:66499741	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000179406.6	LINC00174	-12.74	4.11e-32	1.7e-28	-0.68	-0.51	Aortic root size;	chr7:66503987	chr7:66376044~66401338:-
HNSC	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	12.74	4.23e-32	1.75e-28	0.72	0.51	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
HNSC	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	12.73	4.33e-32	1.79e-28	0.62	0.51	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	12.73	4.4e-32	1.81e-28	0.62	0.51	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
HNSC	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	12.73	4.5e-32	1.85e-28	0.59	0.51	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	12.73	4.57e-32	1.88e-28	0.68	0.51	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	12.73	4.57e-32	1.88e-28	0.75	0.51	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-12.73	4.58e-32	1.89e-28	-0.53	-0.51	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000179406.6	LINC00174	-12.72	4.81e-32	1.98e-28	-0.68	-0.51	Aortic root size;	chr7:66507579	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000179406.6	LINC00174	-12.72	4.94e-32	2.03e-28	-0.68	-0.51	Aortic root size;	chr7:66511623	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-12.72	5.04e-32	2.07e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
HNSC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	12.71	5.17e-32	2.12e-28	0.57	0.51	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	12.71	5.17e-32	2.12e-28	0.57	0.51	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-12.71	5.21e-32	2.14e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	12.71	5.21e-32	2.14e-28	0.57	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000179406.6	LINC00174	12.71	5.29e-32	2.17e-28	0.68	0.51	Aortic root size;	chr7:66775021	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	12.71	5.36e-32	2.2e-28	0.59	0.51	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	12.71	5.36e-32	2.2e-28	0.59	0.51	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-12.71	5.46e-32	2.24e-28	-0.65	-0.51	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
HNSC	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-12.71	5.49e-32	2.25e-28	-0.49	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
HNSC	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-12.7	5.94e-32	2.43e-28	-0.67	-0.51	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-12.7	6.14e-32	2.51e-28	-0.52	-0.51	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000179406.6	LINC00174	-12.7	6.19e-32	2.53e-28	-0.68	-0.51	Aortic root size;	chr7:66518542	chr7:66376044~66401338:-
HNSC	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-12.7	6.2e-32	2.53e-28	-0.65	-0.51	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000179406.6	LINC00174	-12.69	6.36e-32	2.6e-28	-0.68	-0.51	Aortic root size;	chr7:66426474	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-12.69	6.85e-32	2.79e-28	-0.64	-0.51	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	12.68	7.11e-32	2.9e-28	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.68	7.13e-32	2.9e-28	-0.93	-0.51	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
HNSC	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	12.68	7.54e-32	3.06e-28	0.59	0.51	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-12.67	7.64e-32	3.1e-28	-0.59	-0.51	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	12.67	7.81e-32	3.17e-28	0.57	0.51	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
HNSC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	12.67	7.92e-32	3.21e-28	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-12.67	7.95e-32	3.23e-28	-0.66	-0.51	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
HNSC	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	12.67	7.99e-32	3.24e-28	0.6	0.51	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	12.67	7.99e-32	3.24e-28	0.65	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	12.67	8.12e-32	3.29e-28	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	12.66	8.32e-32	3.37e-28	0.56	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
HNSC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	12.65	9.83e-32	3.97e-28	0.59	0.51	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
HNSC	cis	rs10853057	0.85	rs62065479	ENSG00000214174.7	AMZ2P1	12.65	9.98e-32	4.03e-28	0.82	0.51	White matter microstructure (global fractional anisotropy);	chr17:65002593	chr17:64966550~64975576:-
HNSC	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	12.65	9.98e-32	4.03e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	12.65	9.98e-32	4.03e-28	0.62	0.51	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-12.65	1e-31	4.05e-28	-0.48	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	12.64	1.03e-31	4.17e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	12.64	1.04e-31	4.2e-28	0.57	0.5	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-12.64	1.05e-31	4.24e-28	-0.95	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	12.64	1.07e-31	4.31e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
HNSC	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-12.64	1.09e-31	4.4e-28	-0.93	-0.5	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-12.63	1.15e-31	4.62e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.862	rs908915	ENSG00000179406.6	LINC00174	12.63	1.18e-31	4.75e-28	0.68	0.5	Aortic root size;	chr7:66149664	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-12.63	1.19e-31	4.8e-28	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
HNSC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-12.63	1.2e-31	4.83e-28	-0.53	-0.5	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
HNSC	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-12.63	1.21e-31	4.84e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
HNSC	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	12.63	1.21e-31	4.86e-28	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
HNSC	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-12.62	1.23e-31	4.93e-28	-0.96	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
HNSC	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-12.62	1.24e-31	4.96e-28	-0.6	-0.5	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-12.62	1.24e-31	4.96e-28	-0.6	-0.5	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
HNSC	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000179406.6	LINC00174	-12.62	1.27e-31	5.09e-28	-0.67	-0.5	Aortic root size;	chr7:66713615	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	12.61	1.35e-31	5.39e-28	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-12.61	1.37e-31	5.5e-28	-0.58	-0.5	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-12.61	1.37e-31	5.5e-28	-0.77	-0.5	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
HNSC	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-12.61	1.38e-31	5.52e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	12.61	1.42e-31	5.69e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	12.6	1.51e-31	6.01e-28	0.65	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66180374	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66180412	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66187797	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66189328	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66192326	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000179406.6	LINC00174	12.6	1.53e-31	6.1e-28	0.68	0.5	Aortic root size;	chr7:66192910	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	12.6	1.56e-31	6.24e-28	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-12.6	1.57e-31	6.25e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
HNSC	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-12.6	1.57e-31	6.25e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	12.6	1.59e-31	6.32e-28	0.76	0.5	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	12.59	1.62e-31	6.44e-28	0.58	0.5	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
HNSC	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-12.59	1.62e-31	6.44e-28	-0.67	-0.5	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	12.59	1.62e-31	6.45e-28	0.66	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	12.59	1.63e-31	6.47e-28	0.78	0.5	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	12.59	1.65e-31	6.53e-28	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
HNSC	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-12.59	1.67e-31	6.61e-28	-0.93	-0.5	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.59	1.74e-31	6.88e-28	-0.95	-0.5	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
HNSC	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.58	1.8e-31	7.11e-28	-0.92	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000179406.6	LINC00174	-12.58	1.83e-31	7.24e-28	-0.67	-0.5	Aortic root size;	chr7:66377141	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000179406.6	LINC00174	-12.58	1.83e-31	7.24e-28	-0.67	-0.5	Aortic root size;	chr7:66379576	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.58	1.84e-31	7.28e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.58	1.84e-31	7.28e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-12.58	1.88e-31	7.43e-28	-0.66	-0.5	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
HNSC	cis	rs875971	0.83	rs778715	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66384222	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs809025	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66384832	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778702	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66399848	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66407690	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000179406.6	LINC00174	-12.58	1.89e-31	7.44e-28	-0.67	-0.5	Aortic root size;	chr7:66418748	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000179406.6	LINC00174	-12.57	1.97e-31	7.79e-28	-0.68	-0.5	Aortic root size;	chr7:66371107	chr7:66376044~66401338:-
HNSC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	12.57	1.99e-31	7.84e-28	0.6	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	12.57	2e-31	7.91e-28	0.57	0.5	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	12.57	2.13e-31	8.39e-28	0.77	0.5	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	12.57	2.13e-31	8.39e-28	0.77	0.5	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs778686	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66370923	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778684	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66371416	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778680	ENSG00000179406.6	LINC00174	-12.56	2.17e-31	8.54e-28	-0.68	-0.5	Aortic root size;	chr7:66375427	chr7:66376044~66401338:-
HNSC	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-12.56	2.18e-31	8.57e-28	-0.58	-0.5	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
HNSC	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	12.56	2.21e-31	8.71e-28	0.56	0.5	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-12.56	2.26e-31	8.88e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	12.55	2.4e-31	9.43e-28	0.97	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
HNSC	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	12.55	2.41e-31	9.49e-28	0.62	0.5	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	12.55	2.49e-31	9.77e-28	0.59	0.5	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	12.55	2.53e-31	9.94e-28	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-12.55	2.56e-31	1e-27	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
HNSC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	12.55	2.57e-31	1.01e-27	0.57	0.5	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
HNSC	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	12.54	2.65e-31	1.04e-27	0.56	0.5	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	12.54	2.65e-31	1.04e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
HNSC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	12.54	2.68e-31	1.05e-27	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-12.54	2.68e-31	1.05e-27	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	12.54	2.69e-31	1.05e-27	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.862	rs880166	ENSG00000179406.6	LINC00174	12.54	2.69e-31	1.05e-27	0.68	0.5	Aortic root size;	chr7:66205775	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	12.54	2.72e-31	1.06e-27	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	12.54	2.73e-31	1.07e-27	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
HNSC	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	12.54	2.74e-31	1.07e-27	0.58	0.5	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	12.54	2.76e-31	1.08e-27	0.57	0.5	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-12.54	2.78e-31	1.09e-27	-0.75	-0.5	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-12.54	2.78e-31	1.09e-27	-0.63	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-12.53	2.92e-31	1.14e-27	-0.68	-0.5	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
HNSC	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-12.53	3.1e-31	1.21e-27	-0.59	-0.5	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
HNSC	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-12.52	3.24e-31	1.26e-27	-0.48	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	12.52	3.34e-31	1.3e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
HNSC	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-12.51	3.45e-31	1.34e-27	-0.56	-0.5	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
HNSC	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	12.51	3.65e-31	1.42e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-12.51	3.66e-31	1.42e-27	-0.58	-0.5	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	12.51	3.75e-31	1.46e-27	0.78	0.5	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000179406.6	LINC00174	12.5	3.8e-31	1.48e-27	0.68	0.5	Aortic root size;	chr7:66154117	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000179406.6	LINC00174	12.5	3.8e-31	1.48e-27	0.68	0.5	Aortic root size;	chr7:66163889	chr7:66376044~66401338:-
HNSC	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-12.5	3.82e-31	1.48e-27	-0.59	-0.5	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-12.5	3.85e-31	1.49e-27	-0.76	-0.5	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
HNSC	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-12.5	3.86e-31	1.5e-27	-0.58	-0.5	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	12.5	3.94e-31	1.53e-27	0.55	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
HNSC	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	12.5	3.98e-31	1.54e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-12.5	4.03e-31	1.56e-27	-0.75	-0.5	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
HNSC	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-12.5	4.06e-31	1.57e-27	-0.47	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000179406.6	LINC00174	12.5	4.06e-31	1.57e-27	0.67	0.5	Aortic root size;	chr7:66344119	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-12.5	4.12e-31	1.6e-27	-0.57	-0.5	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-12.5	4.12e-31	1.6e-27	-0.57	-0.5	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	12.5	4.13e-31	1.6e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	12.5	4.13e-31	1.6e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
HNSC	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-12.49	4.53e-31	1.75e-27	-0.61	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	12.48	4.59e-31	1.77e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	12.48	4.67e-31	1.8e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	12.48	4.71e-31	1.81e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
HNSC	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	12.48	4.74e-31	1.82e-27	0.48	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.48	4.81e-31	1.85e-27	-0.93	-0.5	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-12.48	4.91e-31	1.89e-27	-0.57	-0.5	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-12.47	5.06e-31	1.95e-27	-0.57	-0.5	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-12.47	5.06e-31	1.95e-27	-0.57	-0.5	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-12.47	5.39e-31	2.07e-27	-0.58	-0.5	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-12.47	5.4e-31	2.08e-27	-0.95	-0.5	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
HNSC	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	12.47	5.47e-31	2.1e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-12.47	5.48e-31	2.1e-27	-0.52	-0.5	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
HNSC	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-12.46	5.56e-31	2.13e-27	-0.95	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
HNSC	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	12.46	5.56e-31	2.14e-27	0.61	0.5	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	12.46	5.79e-31	2.22e-27	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	12.46	5.91e-31	2.26e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	12.46	5.96e-31	2.28e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
HNSC	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-12.45	6.17e-31	2.36e-27	-0.67	-0.5	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
HNSC	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	12.45	6.34e-31	2.42e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
HNSC	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	12.45	6.46e-31	2.47e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	12.45	6.61e-31	2.52e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
HNSC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-12.44	6.71e-31	2.56e-27	-0.57	-0.5	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
HNSC	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	12.44	6.98e-31	2.66e-27	0.62	0.5	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-12.44	6.98e-31	2.66e-27	-0.62	-0.5	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	12.44	7.08e-31	2.69e-27	0.63	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	12.44	7.11e-31	2.71e-27	0.62	0.5	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	12.44	7.18e-31	2.73e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-12.43	7.31e-31	2.78e-27	-0.53	-0.5	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	12.43	7.41e-31	2.81e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
HNSC	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	12.43	7.7e-31	2.93e-27	0.4	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
HNSC	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-12.43	7.71e-31	2.93e-27	-0.57	-0.5	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-12.43	7.93e-31	3.01e-27	-0.57	-0.5	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	12.42	8.25e-31	3.13e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	12.42	8.7e-31	3.29e-27	0.62	0.5	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	12.42	8.72e-31	3.3e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
HNSC	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	12.41	8.83e-31	3.34e-27	0.61	0.5	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	12.41	9.24e-31	3.49e-27	0.53	0.5	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
HNSC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	12.41	9.36e-31	3.54e-27	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
HNSC	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	12.4	9.68e-31	3.65e-27	0.56	0.5	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
HNSC	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	12.4	9.83e-31	3.71e-27	0.6	0.5	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000179406.6	LINC00174	12.4	1.01e-30	3.8e-27	0.67	0.5	Aortic root size;	chr7:66150410	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000179406.6	LINC00174	-12.4	1.02e-30	3.83e-27	-0.67	-0.5	Aortic root size;	chr7:66255897	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	12.4	1.02e-30	3.86e-27	0.64	0.5	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
HNSC	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-12.39	1.11e-30	4.17e-27	-0.65	-0.5	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
HNSC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	12.39	1.13e-30	4.24e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-12.38	1.19e-30	4.47e-27	-0.52	-0.5	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	12.38	1.23e-30	4.61e-27	0.64	0.5	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	12.38	1.27e-30	4.75e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
HNSC	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	12.38	1.27e-30	4.76e-27	0.62	0.5	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	12.37	1.28e-30	4.82e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	12.37	1.3e-30	4.86e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-12.37	1.35e-30	5.05e-27	-0.9	-0.5	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-12.37	1.39e-30	5.21e-27	-0.93	-0.5	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	12.37	1.39e-30	5.21e-27	0.75	0.5	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000179406.6	LINC00174	12.37	1.39e-30	5.21e-27	0.67	0.5	Aortic root size;	chr7:66228350	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000179406.6	LINC00174	12.37	1.39e-30	5.21e-27	0.67	0.5	Aortic root size;	chr7:66250256	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	12.37	1.39e-30	5.21e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	12.35	1.55e-30	5.8e-27	0.61	0.5	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
HNSC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	12.35	1.57e-30	5.87e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	12.35	1.58e-30	5.88e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs778734	ENSG00000179406.6	LINC00174	-12.35	1.6e-30	5.96e-27	-0.67	-0.5	Aortic root size;	chr7:66349862	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	12.35	1.64e-30	6.12e-27	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	12.35	1.66e-30	6.2e-27	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
HNSC	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-12.34	1.72e-30	6.42e-27	-0.52	-0.5	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	12.34	1.75e-30	6.51e-27	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	12.34	1.79e-30	6.64e-27	0.6	0.5	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	12.34	1.82e-30	6.75e-27	0.75	0.5	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
HNSC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	12.33	1.9e-30	7.07e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	12.33	1.98e-30	7.35e-27	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	12.33	1.98e-30	7.36e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	12.33	1.99e-30	7.38e-27	0.61	0.5	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
HNSC	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	12.33	1.99e-30	7.38e-27	0.58	0.5	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-12.33	2.01e-30	7.46e-27	-0.52	-0.5	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
HNSC	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.33	2.04e-30	7.57e-27	-0.93	-0.5	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	12.32	2.08e-30	7.71e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	12.32	2.09e-30	7.73e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	12.32	2.1e-30	7.77e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	12.32	2.1e-30	7.77e-27	0.64	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
HNSC	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.32	2.11e-30	7.79e-27	0.96	0.5	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000179406.6	LINC00174	12.32	2.13e-30	7.89e-27	0.67	0.5	Aortic root size;	chr7:66256452	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	12.32	2.18e-30	8.05e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	12.32	2.18e-30	8.05e-27	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	12.32	2.2e-30	8.12e-27	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	12.31	2.25e-30	8.31e-27	0.62	0.5	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
HNSC	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	12.31	2.26e-30	8.35e-27	0.57	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
HNSC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	12.31	2.29e-30	8.45e-27	0.57	0.5	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-12.31	2.33e-30	8.59e-27	-0.95	-0.5	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	12.3	2.48e-30	9.14e-27	0.64	0.49	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
HNSC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-12.3	2.63e-30	9.7e-27	-0.57	-0.49	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-12.3	2.65e-30	9.77e-27	-0.93	-0.49	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	12.29	2.8e-30	1.03e-26	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	12.29	2.8e-30	1.03e-26	0.57	0.49	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	12.29	2.8e-30	1.03e-26	0.57	0.49	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-12.29	2.85e-30	1.05e-26	-0.92	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-12.29	2.85e-30	1.05e-26	-0.92	-0.49	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	12.29	2.88e-30	1.06e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
HNSC	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-12.28	3.08e-30	1.13e-26	-0.55	-0.49	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
HNSC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	12.28	3.08e-30	1.13e-26	0.57	0.49	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-12.28	3.11e-30	1.14e-26	-0.63	-0.49	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
HNSC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-12.28	3.24e-30	1.19e-26	-0.9	-0.49	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
HNSC	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-12.27	3.34e-30	1.22e-26	-0.61	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
HNSC	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-12.27	3.37e-30	1.23e-26	-0.52	-0.49	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	12.27	3.38e-30	1.23e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	12.27	3.54e-30	1.29e-26	0.75	0.49	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66279745	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66284091	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66285177	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66294786	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66335210	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66339430	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66340379	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000179406.6	LINC00174	12.27	3.56e-30	1.3e-26	0.67	0.49	Aortic root size;	chr7:66347979	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	12.27	3.58e-30	1.31e-26	0.49	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	12.27	3.58e-30	1.31e-26	0.49	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
HNSC	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-12.26	3.72e-30	1.35e-26	-0.6	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000179406.6	LINC00174	12.26	3.82e-30	1.39e-26	0.67	0.49	Aortic root size;	chr7:66136231	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000179406.6	LINC00174	12.26	3.82e-30	1.39e-26	0.67	0.49	Aortic root size;	chr7:66143495	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	12.26	3.83e-30	1.39e-26	0.63	0.49	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
HNSC	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	12.25	3.96e-30	1.44e-26	0.48	0.49	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000179406.6	LINC00174	12.25	3.97e-30	1.44e-26	0.66	0.49	Aortic root size;	chr7:66263424	chr7:66376044~66401338:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	12.25	3.97e-30	1.44e-26	0.57	0.49	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	12.25	3.97e-30	1.44e-26	0.57	0.49	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-12.25	4.01e-30	1.46e-26	-0.95	-0.49	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66271195	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66272999	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66274686	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66274896	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs949930	ENSG00000179406.6	LINC00174	12.25	4.02e-30	1.46e-26	0.66	0.49	Aortic root size;	chr7:66301835	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	12.25	4.09e-30	1.48e-26	0.94	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	12.25	4.11e-30	1.49e-26	0.78	0.49	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-12.25	4.21e-30	1.53e-26	-0.57	-0.49	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000179406.6	LINC00174	12.25	4.26e-30	1.55e-26	0.67	0.49	Aortic root size;	chr7:66312922	chr7:66376044~66401338:-
HNSC	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	12.25	4.28e-30	1.55e-26	0.61	0.49	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	12.24	4.36e-30	1.58e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	12.24	4.45e-30	1.61e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	12.24	4.56e-30	1.65e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
HNSC	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-12.23	4.79e-30	1.73e-26	-0.66	-0.49	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	12.23	4.88e-30	1.77e-26	0.65	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
HNSC	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-12.23	5.07e-30	1.83e-26	-0.52	-0.49	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	12.22	5.59e-30	2.02e-26	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	12.22	5.67e-30	2.05e-26	0.61	0.49	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
HNSC	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	12.22	5.67e-30	2.05e-26	0.61	0.49	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
HNSC	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-12.21	5.88e-30	2.12e-26	-0.52	-0.49	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-12.21	5.88e-30	2.12e-26	-0.52	-0.49	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
HNSC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	12.21	6.08e-30	2.19e-26	0.67	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	12.21	6.18e-30	2.23e-26	0.56	0.49	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-12.21	6.27e-30	2.26e-26	-0.58	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	12.2	6.58e-30	2.37e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
HNSC	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	12.2	6.68e-30	2.4e-26	0.48	0.49	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
HNSC	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-12.2	6.71e-30	2.41e-26	-0.52	-0.49	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	12.19	6.99e-30	2.51e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-12.19	7.1e-30	2.55e-26	-0.47	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
HNSC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	12.19	7.29e-30	2.62e-26	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-12.18	7.75e-30	2.78e-26	-0.74	-0.49	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs778720	ENSG00000179406.6	LINC00174	12.18	7.79e-30	2.8e-26	0.65	0.49	Aortic root size;	chr7:66381288	chr7:66376044~66401338:-
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-12.18	7.97e-30	2.86e-26	-0.51	-0.49	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
HNSC	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	12.18	7.97e-30	2.86e-26	0.54	0.49	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	12.17	8.51e-30	3.05e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
HNSC	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.17	8.98e-30	3.22e-26	0.61	0.49	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
HNSC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	12.16	9.41e-30	3.37e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
HNSC	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	12.16	9.54e-30	3.41e-26	0.61	0.49	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000179406.6	LINC00174	12.15	1.03e-29	3.7e-26	0.67	0.49	Aortic root size;	chr7:66197749	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000179406.6	LINC00174	12.15	1.03e-29	3.7e-26	0.67	0.49	Aortic root size;	chr7:66197774	chr7:66376044~66401338:-
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-12.15	1.04e-29	3.71e-26	-0.56	-0.49	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
HNSC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	12.15	1.04e-29	3.73e-26	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
HNSC	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-12.15	1.06e-29	3.78e-26	-0.61	-0.49	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
HNSC	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-12.15	1.07e-29	3.8e-26	-0.52	-0.49	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
HNSC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-12.14	1.14e-29	4.07e-26	-0.59	-0.49	Height;	chr11:118703207	chr11:118704607~118750263:+
HNSC	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-12.14	1.14e-29	4.08e-26	-0.52	-0.49	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	12.14	1.16e-29	4.13e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-12.14	1.17e-29	4.18e-26	-0.56	-0.49	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
HNSC	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-12.13	1.2e-29	4.28e-26	-0.52	-0.49	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	12.13	1.3e-29	4.62e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-12.12	1.32e-29	4.7e-26	-0.52	-0.49	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	12.12	1.34e-29	4.77e-26	0.71	0.49	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
HNSC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-12.12	1.38e-29	4.92e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
HNSC	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-12.11	1.46e-29	5.19e-26	-0.64	-0.49	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	12.11	1.48e-29	5.24e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	12.11	1.52e-29	5.38e-26	0.57	0.49	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	12.11	1.57e-29	5.58e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
HNSC	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-12.1	1.65e-29	5.84e-26	-0.64	-0.49	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
HNSC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	12.1	1.68e-29	5.95e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-12.1	1.68e-29	5.96e-26	-0.56	-0.49	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000179406.6	LINC00174	12.09	1.74e-29	6.18e-26	0.66	0.49	Aortic root size;	chr7:66204077	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-12.09	1.78e-29	6.29e-26	-0.59	-0.49	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.861	rs801215	ENSG00000179406.6	LINC00174	12.09	1.8e-29	6.37e-26	0.66	0.49	Aortic root size;	chr7:66546951	chr7:66376044~66401338:-
HNSC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-12.09	1.81e-29	6.42e-26	-0.59	-0.49	Height;	chr11:118703185	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-12.09	1.81e-29	6.42e-26	-0.59	-0.49	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
HNSC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	12.09	1.85e-29	6.53e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-12.08	2.01e-29	7.08e-26	-0.96	-0.49	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-12.08	2.05e-29	7.25e-26	-0.56	-0.49	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
HNSC	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	12.07	2.1e-29	7.42e-26	0.68	0.49	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
HNSC	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.07	2.16e-29	7.61e-26	0.61	0.49	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-12.07	2.18e-29	7.67e-26	-0.72	-0.49	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000179406.6	LINC00174	12.07	2.23e-29	7.84e-26	0.66	0.49	Aortic root size;	chr7:66221457	chr7:66376044~66401338:-
HNSC	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	12.07	2.23e-29	7.84e-26	0.61	0.49	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	12.07	2.23e-29	7.84e-26	0.61	0.49	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
HNSC	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	12.07	2.25e-29	7.93e-26	0.6	0.49	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
HNSC	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-12.07	2.26e-29	7.95e-26	-0.58	-0.49	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
HNSC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-12.07	2.27e-29	8e-26	-0.56	-0.49	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
HNSC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	12.07	2.28e-29	8.01e-26	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-12.06	2.35e-29	8.28e-26	-0.56	-0.49	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-12.06	2.37e-29	8.33e-26	-0.52	-0.49	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	12.06	2.39e-29	8.41e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	12.06	2.41e-29	8.46e-26	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	12.06	2.52e-29	8.85e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	12.05	2.54e-29	8.9e-26	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
HNSC	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	12.05	2.58e-29	9.04e-26	0.52	0.49	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000179406.6	LINC00174	-12.05	2.6e-29	9.13e-26	-0.66	-0.49	Aortic root size;	chr7:66471587	chr7:66376044~66401338:-
HNSC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-12.05	2.67e-29	9.35e-26	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
HNSC	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	12.05	2.74e-29	9.6e-26	0.6	0.49	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	12.05	2.74e-29	9.61e-26	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	12.04	2.78e-29	9.71e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-12.04	2.86e-29	1e-25	-0.57	-0.49	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-12.04	2.89e-29	1.01e-25	-0.56	-0.49	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	12.04	2.9e-29	1.01e-25	0.56	0.49	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	12.04	2.91e-29	1.02e-25	0.66	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	12.04	2.97e-29	1.04e-25	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	12.04	2.98e-29	1.04e-25	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000179406.6	LINC00174	12.03	3.04e-29	1.06e-25	0.67	0.49	Aortic root size;	chr7:66261628	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000179406.6	LINC00174	12.03	3.11e-29	1.09e-25	0.66	0.49	Aortic root size;	chr7:66218330	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	12.03	3.12e-29	1.09e-25	0.66	0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	12.03	3.14e-29	1.1e-25	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000179406.6	LINC00174	12.03	3.2e-29	1.12e-25	0.66	0.49	Aortic root size;	chr7:66108909	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000179406.6	LINC00174	12.03	3.27e-29	1.14e-25	0.66	0.49	Aortic root size;	chr7:66110906	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000179406.6	LINC00174	12.03	3.27e-29	1.14e-25	0.66	0.49	Aortic root size;	chr7:66115179	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-12.03	3.33e-29	1.16e-25	-0.61	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-12.03	3.33e-29	1.16e-25	-0.52	-0.49	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.37e-29	1.17e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.37e-29	1.17e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-12.02	3.4e-29	1.18e-25	-0.46	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
HNSC	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
HNSC	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
HNSC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-12.02	3.56e-29	1.24e-25	-0.56	-0.49	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
HNSC	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-12.02	3.56e-29	1.24e-25	-0.51	-0.49	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-12.02	3.57e-29	1.24e-25	-0.52	-0.49	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-12.02	3.64e-29	1.27e-25	-0.52	-0.49	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-12.02	3.64e-29	1.27e-25	-0.52	-0.49	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-12.01	3.71e-29	1.29e-25	-0.51	-0.49	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000179406.6	LINC00174	-12.01	3.94e-29	1.37e-25	-0.65	-0.49	Aortic root size;	chr7:66502354	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	12	4.13e-29	1.43e-25	0.64	0.49	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
HNSC	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-12	4.14e-29	1.44e-25	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
HNSC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-12	4.18e-29	1.45e-25	-0.61	-0.49	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
HNSC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-11.99	4.4e-29	1.53e-25	-1.19	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000179406.6	LINC00174	-11.99	4.66e-29	1.62e-25	-0.65	-0.49	Aortic root size;	chr7:66503250	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000179406.6	LINC00174	-11.99	4.66e-29	1.62e-25	-0.65	-0.49	Aortic root size;	chr7:66504118	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	11.99	4.68e-29	1.62e-25	0.47	0.49	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
HNSC	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-11.98	4.86e-29	1.68e-25	-0.51	-0.48	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
HNSC	cis	rs17270561	0.541	rs2009610	ENSG00000272462.2	U91328.19	-11.98	5.01e-29	1.73e-25	-0.61	-0.48	Iron status biomarkers;	chr6:25966840	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000179406.6	LINC00174	11.98	5.07e-29	1.75e-25	0.67	0.48	Aortic root size;	chr7:66089398	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	11.97	5.71e-29	1.97e-25	0.96	0.48	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-11.97	5.78e-29	1.99e-25	-0.51	-0.48	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
HNSC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	11.96	5.98e-29	2.06e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	11.95	6.66e-29	2.29e-25	0.6	0.48	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
HNSC	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	11.94	7.01e-29	2.41e-25	0.54	0.48	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000179406.6	LINC00174	11.94	7.03e-29	2.42e-25	0.65	0.48	Aortic root size;	chr7:66226259	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000179406.6	LINC00174	11.94	7.24e-29	2.49e-25	0.64	0.48	Aortic root size;	chr7:66221942	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-11.93	7.69e-29	2.64e-25	-0.59	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-11.93	7.82e-29	2.69e-25	-0.52	-0.48	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	11.93	8.06e-29	2.76e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
HNSC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-11.93	8.38e-29	2.87e-25	-0.56	-0.48	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-11.92	8.54e-29	2.93e-25	-0.56	-0.48	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-11.92	8.54e-29	2.93e-25	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	11.92	8.92e-29	3.05e-25	0.54	0.48	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
HNSC	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-11.92	8.95e-29	3.06e-25	-0.57	-0.48	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	11.91	9.2e-29	3.15e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	11.91	9.2e-29	3.15e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000179406.6	LINC00174	11.91	9.25e-29	3.17e-25	0.66	0.48	Aortic root size;	chr7:66119713	chr7:66376044~66401338:-
HNSC	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-11.91	9.25e-29	3.17e-25	-0.59	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
HNSC	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	11.91	9.5e-29	3.25e-25	0.96	0.48	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	11.9	1.02e-28	3.5e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
HNSC	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-11.9	1.03e-28	3.5e-25	-0.51	-0.48	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	11.9	1.03e-28	3.5e-25	0.56	0.48	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
HNSC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-11.89	1.16e-28	3.94e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-11.89	1.16e-28	3.95e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
HNSC	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-11.89	1.18e-28	4.02e-25	-0.57	-0.48	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
HNSC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	11.89	1.18e-28	4.03e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	11.88	1.22e-28	4.14e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66521661	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66522725	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66523623	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66529742	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66534311	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66534333	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000179406.6	LINC00174	-11.88	1.27e-28	4.31e-25	-0.65	-0.48	Aortic root size;	chr7:66540947	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66552518	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs13536	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66554203	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801209	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66554403	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801206	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66556979	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801204	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66557934	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801203	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66558025	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs801202	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66558942	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs801195	ENSG00000179406.6	LINC00174	11.88	1.27e-28	4.31e-25	0.65	0.48	Aortic root size;	chr7:66561128	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	11.88	1.3e-28	4.38e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	11.88	1.3e-28	4.4e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-11.88	1.32e-28	4.45e-25	-0.55	-0.48	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-11.88	1.32e-28	4.45e-25	-0.55	-0.48	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	11.88	1.32e-28	4.45e-25	0.66	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-11.87	1.38e-28	4.67e-25	-0.69	-0.48	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
HNSC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-11.87	1.41e-28	4.75e-25	-0.56	-0.48	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-11.87	1.42e-28	4.8e-25	-0.56	-0.48	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	11.87	1.43e-28	4.8e-25	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-11.87	1.43e-28	4.83e-25	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-11.87	1.45e-28	4.87e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-11.86	1.48e-28	4.97e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
HNSC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	11.86	1.5e-28	5.06e-25	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
HNSC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-11.86	1.51e-28	5.07e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
HNSC	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-11.86	1.53e-28	5.16e-25	-0.51	-0.48	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
HNSC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	11.86	1.58e-28	5.32e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	11.86	1.58e-28	5.32e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
HNSC	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	11.85	1.61e-28	5.4e-25	0.62	0.48	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
HNSC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-11.85	1.61e-28	5.4e-25	-0.55	-0.48	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000179406.6	LINC00174	-11.85	1.61e-28	5.41e-25	-0.65	-0.48	Aortic root size;	chr7:66595884	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	11.85	1.68e-28	5.63e-25	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
HNSC	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	11.85	1.71e-28	5.75e-25	0.65	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	11.85	1.71e-28	5.75e-25	0.65	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
HNSC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	11.85	1.73e-28	5.79e-25	0.58	0.48	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-11.85	1.74e-28	5.85e-25	-0.58	-0.48	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	11.84	1.75e-28	5.87e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	11.84	1.76e-28	5.91e-25	0.78	0.48	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
HNSC	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-11.84	1.85e-28	6.22e-25	-0.84	-0.48	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	11.84	1.87e-28	6.28e-25	0.53	0.48	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	11.84	1.89e-28	6.34e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-11.83	1.92e-28	6.44e-25	-0.56	-0.48	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000179406.6	LINC00174	-11.83	1.94e-28	6.48e-25	-0.65	-0.48	Aortic root size;	chr7:66376625	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs778711	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66386670	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66387354	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778707	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66392040	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778705	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66396128	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs778697	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66405439	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66413674	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000179406.6	LINC00174	-11.83	1.96e-28	6.55e-25	-0.65	-0.48	Aortic root size;	chr7:66421313	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-11.83	2e-28	6.67e-25	-0.55	-0.48	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
HNSC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	11.83	2.01e-28	6.72e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
HNSC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-11.82	2.1e-28	7.03e-25	-0.8	-0.48	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000179406.6	LINC00174	11.82	2.12e-28	7.07e-25	0.65	0.48	Aortic root size;	chr7:66331639	chr7:66376044~66401338:-
HNSC	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-11.82	2.17e-28	7.24e-25	-0.61	-0.48	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	11.82	2.21e-28	7.37e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
HNSC	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-11.82	2.22e-28	7.4e-25	-0.64	-0.48	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
HNSC	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-11.82	2.25e-28	7.49e-25	-0.51	-0.48	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	11.81	2.33e-28	7.76e-25	0.62	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-11.81	2.41e-28	8.02e-25	-0.6	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
HNSC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	11.81	2.45e-28	8.15e-25	0.56	0.48	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
HNSC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	11.81	2.45e-28	8.15e-25	0.56	0.48	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	11.79	2.78e-28	9.23e-25	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	11.79	2.81e-28	9.33e-25	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-11.79	2.87e-28	9.49e-25	-0.5	-0.48	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	11.79	2.92e-28	9.65e-25	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-11.79	2.97e-28	9.81e-25	-0.51	-0.48	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
HNSC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-11.78	3.05e-28	1.01e-24	-0.63	-0.48	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000179406.6	LINC00174	-11.78	3.08e-28	1.02e-24	-0.65	-0.48	Aortic root size;	chr7:66444034	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	11.78	3.14e-28	1.04e-24	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000179406.6	LINC00174	11.77	3.35e-28	1.1e-24	0.65	0.48	Aortic root size;	chr7:66253949	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	11.77	3.44e-28	1.13e-24	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	11.77	3.44e-28	1.13e-24	0.45	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
HNSC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-11.77	3.44e-28	1.13e-24	-0.58	-0.48	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.862	rs801194	ENSG00000179406.6	LINC00174	11.77	3.48e-28	1.14e-24	0.65	0.48	Aortic root size;	chr7:66563508	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000179406.6	LINC00174	11.77	3.48e-28	1.14e-24	0.65	0.48	Aortic root size;	chr7:66576460	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-11.77	3.51e-28	1.15e-24	-0.84	-0.48	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
HNSC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	11.77	3.58e-28	1.17e-24	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	11.76	3.78e-28	1.24e-24	0.46	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	11.76	3.78e-28	1.24e-24	0.46	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000179406.6	LINC00174	11.76	3.8e-28	1.25e-24	0.66	0.48	Aortic root size;	chr7:66100371	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	11.76	3.82e-28	1.25e-24	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	11.76	3.82e-28	1.25e-24	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.88e-28	1.27e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.91e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.91e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.92e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-11.76	3.92e-28	1.28e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
HNSC	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-11.76	3.97e-28	1.3e-24	-0.52	-0.48	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
HNSC	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-11.75	3.99e-28	1.3e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-11.75	3.99e-28	1.3e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
HNSC	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	11.75	4.01e-28	1.31e-24	0.6	0.48	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
HNSC	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	11.75	4.09e-28	1.33e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
HNSC	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	11.75	4.1e-28	1.34e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
HNSC	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	11.75	4.16e-28	1.36e-24	0.51	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-11.75	4.23e-28	1.38e-24	-0.72	-0.48	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
HNSC	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-11.75	4.34e-28	1.41e-24	-0.51	-0.48	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
HNSC	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	11.74	4.41e-28	1.44e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000179406.6	LINC00174	11.74	4.44e-28	1.45e-24	0.65	0.48	Aortic root size;	chr7:66345205	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000179406.6	LINC00174	11.74	4.49e-28	1.46e-24	0.64	0.48	Aortic root size;	chr7:66658097	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000179406.6	LINC00174	-11.74	4.69e-28	1.52e-24	-0.65	-0.48	Aortic root size;	chr7:66423483	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	11.74	4.77e-28	1.55e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
HNSC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	11.73	4.81e-28	1.56e-24	0.79	0.48	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
HNSC	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	11.73	4.82e-28	1.57e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
HNSC	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-11.73	4.92e-28	1.6e-24	-0.91	-0.48	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	11.73	5e-28	1.63e-24	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
HNSC	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-11.73	5.12e-28	1.66e-24	-0.59	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs778736	ENSG00000179406.6	LINC00174	-11.73	5.17e-28	1.68e-24	-0.65	-0.48	Aortic root size;	chr7:66348861	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66278783	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66280771	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66325720	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66330724	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66331087	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000179406.6	LINC00174	11.73	5.17e-28	1.68e-24	0.65	0.48	Aortic root size;	chr7:66343621	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	11.73	5.18e-28	1.68e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	11.73	5.18e-28	1.68e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	11.73	5.18e-28	1.68e-24	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000179406.6	LINC00174	11.72	5.36e-28	1.74e-24	0.65	0.48	Aortic root size;	chr7:66604815	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66602045	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66606209	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66612917	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66614048	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000179406.6	LINC00174	11.71	5.75e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66615658	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66271055	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66300017	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66301466	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66301574	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66304099	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66306492	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66315542	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000179406.6	LINC00174	11.71	5.77e-28	1.86e-24	0.65	0.48	Aortic root size;	chr7:66329809	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-11.71	5.89e-28	1.9e-24	-0.46	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000179406.6	LINC00174	11.71	5.95e-28	1.92e-24	0.65	0.48	Aortic root size;	chr7:66308872	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	11.71	5.96e-28	1.92e-24	0.53	0.48	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	11.71	5.98e-28	1.93e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	11.71	6.15e-28	1.98e-24	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66735006	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66735318	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66736127	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66737884	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66744266	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66752983	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66753209	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000179406.6	LINC00174	-11.7	6.43e-28	2.06e-24	-0.64	-0.48	Aortic root size;	chr7:66758701	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-11.7	6.45e-28	2.07e-24	-0.55	-0.48	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66091121	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66091949	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs709609	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66095574	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66096890	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000179406.6	LINC00174	11.7	6.67e-28	2.14e-24	0.66	0.48	Aortic root size;	chr7:66100405	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-11.69	7.05e-28	2.25e-24	-0.56	-0.48	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.18e-28	2.29e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.31e-28	2.33e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.31e-28	2.33e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-11.69	7.35e-28	2.34e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-11.69	7.39e-28	2.36e-24	-0.55	-0.48	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	11.69	7.41e-28	2.36e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
HNSC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-11.69	7.44e-28	2.37e-24	-0.54	-0.48	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000179406.6	LINC00174	11.69	7.54e-28	2.4e-24	0.64	0.48	Aortic root size;	chr7:66592017	chr7:66376044~66401338:-
HNSC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	11.68	7.62e-28	2.43e-24	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
HNSC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	11.68	8e-28	2.54e-24	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-11.68	8e-28	2.54e-24	-0.45	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-11.68	8.21e-28	2.61e-24	-0.55	-0.48	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-11.68	8.21e-28	2.61e-24	-0.55	-0.48	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	11.67	8.28e-28	2.63e-24	0.57	0.48	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-11.67	8.38e-28	2.66e-24	-0.56	-0.48	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	11.67	8.41e-28	2.67e-24	0.44	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66578155	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66583979	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66584691	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000179406.6	LINC00174	11.67	8.43e-28	2.67e-24	0.64	0.48	Aortic root size;	chr7:66586277	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-11.67	8.5e-28	2.7e-24	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000179406.6	LINC00174	11.67	8.84e-28	2.8e-24	0.65	0.48	Aortic root size;	chr7:66617736	chr7:66376044~66401338:-
HNSC	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
HNSC	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-11.67	8.89e-28	2.81e-24	-0.5	-0.48	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66651104	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs881285	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66654433	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66655048	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66656082	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66656898	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000179406.6	LINC00174	11.67	8.95e-28	2.83e-24	0.64	0.48	Aortic root size;	chr7:66657397	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000179406.6	LINC00174	-11.67	9.01e-28	2.84e-24	-0.64	-0.48	Aortic root size;	chr7:66695835	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.591	rs721717	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66665305	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66667525	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000179406.6	LINC00174	11.67	9.01e-28	2.84e-24	0.64	0.48	Aortic root size;	chr7:66670470	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	11.67	9.01e-28	2.85e-24	0.64	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-11.66	9.44e-28	2.98e-24	-0.54	-0.47	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	11.66	9.62e-28	3.03e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	11.66	9.75e-28	3.07e-24	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000179406.6	LINC00174	11.66	9.8e-28	3.08e-24	0.64	0.47	Aortic root size;	chr7:66595806	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66713338	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66716086	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000179406.6	LINC00174	-11.65	9.93e-28	3.12e-24	-0.64	-0.47	Aortic root size;	chr7:66724256	chr7:66376044~66401338:-
HNSC	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-11.65	1.01e-27	3.17e-24	-0.9	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	11.65	1.04e-27	3.25e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	11.65	1.07e-27	3.35e-24	0.56	0.47	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	11.65	1.08e-27	3.39e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	11.65	1.08e-27	3.39e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
HNSC	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-11.64	1.1e-27	3.46e-24	-0.59	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
HNSC	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-11.64	1.13e-27	3.56e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
HNSC	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	11.64	1.16e-27	3.64e-24	0.59	0.47	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-11.62	1.38e-27	4.32e-24	-0.56	-0.47	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-11.62	1.38e-27	4.32e-24	-0.56	-0.47	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000179406.6	LINC00174	-11.62	1.39e-27	4.34e-24	-0.64	-0.47	Aortic root size;	chr7:66699045	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000179406.6	LINC00174	-11.62	1.39e-27	4.34e-24	-0.64	-0.47	Aortic root size;	chr7:66701485	chr7:66376044~66401338:-
HNSC	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-11.62	1.4e-27	4.37e-24	-0.89	-0.47	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
HNSC	cis	rs17270561	0.887	rs717551	ENSG00000272462.2	U91328.19	-11.62	1.4e-27	4.38e-24	-0.6	-0.47	Iron status biomarkers;	chr6:25855396	chr6:25992662~26001775:+
HNSC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	11.62	1.41e-27	4.39e-24	0.58	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
HNSC	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	11.61	1.44e-27	4.47e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-11.61	1.5e-27	4.66e-24	-0.55	-0.47	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	11.61	1.51e-27	4.7e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
HNSC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	11.61	1.51e-27	4.7e-24	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
HNSC	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-11.61	1.52e-27	4.72e-24	-0.93	-0.47	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	11.61	1.56e-27	4.83e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	11.6	1.62e-27	5.04e-24	0.62	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
HNSC	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	11.6	1.63e-27	5.06e-24	0.45	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.6	1.71e-27	5.29e-24	-0.62	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	11.59	1.76e-27	5.46e-24	0.55	0.47	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	11.59	1.78e-27	5.5e-24	0.44	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-11.58	1.91e-27	5.91e-24	-0.55	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-11.58	1.91e-27	5.91e-24	-0.55	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000179406.6	LINC00174	11.58	2e-27	6.16e-24	0.64	0.47	Aortic root size;	chr7:66266868	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000179406.6	LINC00174	11.58	2e-27	6.16e-24	0.64	0.47	Aortic root size;	chr7:66268272	chr7:66376044~66401338:-
HNSC	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-11.58	2.02e-27	6.23e-24	-0.49	-0.47	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000179406.6	LINC00174	-11.58	2.03e-27	6.27e-24	-0.64	-0.47	Aortic root size;	chr7:66768636	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	11.57	2.14e-27	6.6e-24	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-11.57	2.19e-27	6.74e-24	-0.55	-0.47	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-11.57	2.19e-27	6.74e-24	-0.55	-0.47	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	11.57	2.22e-27	6.84e-24	0.53	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-11.56	2.26e-27	6.94e-24	-0.56	-0.47	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-11.56	2.26e-27	6.94e-24	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-11.56	2.27e-27	6.99e-24	-0.55	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-11.56	2.32e-27	7.14e-24	-0.56	-0.47	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	11.56	2.41e-27	7.38e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
HNSC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-11.56	2.44e-27	7.47e-24	-0.56	-0.47	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	11.55	2.46e-27	7.53e-24	0.55	0.47	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
HNSC	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	11.55	2.49e-27	7.63e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
HNSC	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.55	2.49e-27	7.63e-24	-0.9	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-11.55	2.51e-27	7.69e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
HNSC	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	11.55	2.66e-27	8.14e-24	0.64	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
HNSC	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-11.55	2.69e-27	8.21e-24	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
HNSC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	11.54	2.69e-27	8.23e-24	0.56	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
HNSC	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-11.54	2.73e-27	8.34e-24	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
HNSC	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-11.54	2.77e-27	8.44e-24	-0.5	-0.47	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
HNSC	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-11.54	2.92e-27	8.89e-24	-0.54	-0.47	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
HNSC	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-11.53	2.95e-27	8.99e-24	-0.61	-0.47	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-11.53	3.05e-27	9.27e-24	-0.55	-0.47	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
HNSC	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-11.52	3.33e-27	1.01e-23	-0.89	-0.47	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	11.51	3.63e-27	1.1e-23	0.53	0.47	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-11.51	3.72e-27	1.13e-23	-0.55	-0.47	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-11.51	3.8e-27	1.15e-23	-0.55	-0.47	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	11.51	3.8e-27	1.15e-23	0.45	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	11.5	3.88e-27	1.17e-23	0.51	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-11.5	4.04e-27	1.22e-23	-0.52	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
HNSC	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-11.5	4.14e-27	1.25e-23	-0.5	-0.47	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
HNSC	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-11.49	4.27e-27	1.29e-23	-0.46	-0.47	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-11.49	4.27e-27	1.29e-23	-0.55	-0.47	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
HNSC	cis	rs17270561	0.887	rs12201170	ENSG00000272462.2	U91328.19	-11.49	4.51e-27	1.36e-23	-0.6	-0.47	Iron status biomarkers;	chr6:25866019	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-11.49	4.56e-27	1.37e-23	-0.56	-0.47	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	11.48	4.72e-27	1.42e-23	0.55	0.47	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	11.48	4.8e-27	1.44e-23	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	11.48	4.94e-27	1.48e-23	0.56	0.47	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	11.48	4.95e-27	1.49e-23	0.6	0.47	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
HNSC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	11.48	4.95e-27	1.49e-23	0.88	0.47	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
HNSC	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	11.47	5.08e-27	1.52e-23	0.47	0.47	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
HNSC	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	11.47	5.21e-27	1.56e-23	0.52	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
HNSC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-11.47	5.3e-27	1.59e-23	-0.48	-0.47	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
HNSC	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	11.47	5.37e-27	1.61e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	11.47	5.37e-27	1.61e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
HNSC	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	11.47	5.46e-27	1.63e-23	0.47	0.47	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
HNSC	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-11.46	5.66e-27	1.69e-23	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
HNSC	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	11.46	5.71e-27	1.71e-23	0.63	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
HNSC	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	11.46	5.72e-27	1.71e-23	0.76	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
HNSC	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	11.46	5.83e-27	1.74e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
HNSC	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	11.46	5.95e-27	1.78e-23	0.47	0.47	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
HNSC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	11.46	6.01e-27	1.79e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
HNSC	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	11.45	6.21e-27	1.85e-23	0.61	0.47	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	11.45	6.45e-27	1.92e-23	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
HNSC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-11.44	7.11e-27	2.12e-23	-0.55	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
HNSC	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-11.43	7.41e-27	2.2e-23	-0.5	-0.47	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
HNSC	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-11.43	7.59e-27	2.26e-23	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
HNSC	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-11.43	7.68e-27	2.28e-23	-0.44	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-11.43	7.73e-27	2.29e-23	-0.45	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
HNSC	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-11.43	7.83e-27	2.32e-23	-0.85	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
HNSC	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-11.42	8.33e-27	2.47e-23	-0.59	-0.47	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	11.42	8.34e-27	2.47e-23	0.55	0.47	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	11.42	8.6e-27	2.55e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	11.42	8.61e-27	2.55e-23	0.53	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	11.42	8.66e-27	2.56e-23	0.51	0.47	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
HNSC	cis	rs17270561	1	rs12211184	ENSG00000272462.2	U91328.19	-11.41	8.88e-27	2.63e-23	-0.58	-0.47	Iron status biomarkers;	chr6:25823546	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-11.41	9e-27	2.66e-23	-0.5	-0.47	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
HNSC	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	11.41	9.25e-27	2.74e-23	0.49	0.47	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000179406.6	LINC00174	-11.41	9.45e-27	2.79e-23	-0.63	-0.47	Aortic root size;	chr7:66774601	chr7:66376044~66401338:-
HNSC	cis	rs17270561	1	rs79867288	ENSG00000272462.2	U91328.19	-11.41	9.46e-27	2.79e-23	-0.59	-0.47	Iron status biomarkers;	chr6:25828188	chr6:25992662~26001775:+
HNSC	cis	rs17270561	1	rs12200962	ENSG00000272462.2	U91328.19	-11.41	9.46e-27	2.79e-23	-0.59	-0.47	Iron status biomarkers;	chr6:25828758	chr6:25992662~26001775:+
HNSC	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-11.4	9.68e-27	2.86e-23	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	11.4	9.8e-27	2.89e-23	0.59	0.47	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
HNSC	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	11.4	9.94e-27	2.93e-23	0.59	0.47	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
HNSC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	11.4	9.98e-27	2.94e-23	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
HNSC	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	11.38	1.17e-26	3.44e-23	0.63	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.56	0.47	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	11.38	1.21e-26	3.55e-23	0.55	0.47	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
HNSC	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-11.38	1.22e-26	3.57e-23	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
HNSC	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-11.38	1.22e-26	3.59e-23	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
HNSC	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-11.37	1.24e-26	3.65e-23	-0.5	-0.47	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
HNSC	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-11.37	1.27e-26	3.73e-23	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
HNSC	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	11.37	1.29e-26	3.79e-23	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
HNSC	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	11.37	1.32e-26	3.87e-23	0.46	0.47	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
HNSC	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-11.37	1.33e-26	3.9e-23	-0.6	-0.47	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000179406.6	LINC00174	11.36	1.36e-26	3.98e-23	0.64	0.47	Aortic root size;	chr7:66643422	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-11.36	1.38e-26	4.05e-23	-0.53	-0.47	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	11.36	1.4e-26	4.11e-23	0.55	0.47	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	11.36	1.47e-26	4.28e-23	0.55	0.47	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-11.36	1.47e-26	4.29e-23	-0.56	-0.47	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	11.36	1.49e-26	4.34e-23	0.55	0.47	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	11.36	1.49e-26	4.34e-23	0.55	0.47	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
HNSC	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-11.35	1.5e-26	4.38e-23	-0.6	-0.47	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
HNSC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	11.35	1.51e-26	4.4e-23	0.48	0.47	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	11.35	1.52e-26	4.44e-23	0.55	0.47	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-11.35	1.56e-26	4.56e-23	-0.53	-0.46	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
HNSC	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	11.35	1.61e-26	4.7e-23	0.49	0.46	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
HNSC	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-11.34	1.63e-26	4.75e-23	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
HNSC	cis	rs11650106	0.529	rs35391268	ENSG00000266992.1	DHX40P1	-11.33	1.92e-26	5.57e-23	-0.55	-0.46	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:59976009~60002384:-
HNSC	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	11.31	2.13e-26	6.17e-23	0.51	0.46	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-11.31	2.19e-26	6.33e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
HNSC	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	11.31	2.22e-26	6.43e-23	0.59	0.46	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-11.31	2.22e-26	6.43e-23	-0.59	-0.46	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66634237	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66640176	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000179406.6	LINC00174	11.31	2.27e-26	6.56e-23	0.63	0.46	Aortic root size;	chr7:66640211	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	11.31	2.29e-26	6.62e-23	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
HNSC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.3	2.34e-26	6.78e-23	1.05	0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-11.3	2.4e-26	6.94e-23	-0.55	-0.46	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-11.3	2.42e-26	7e-23	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-11.3	2.44e-26	7.03e-23	-0.55	-0.46	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-11.3	2.44e-26	7.03e-23	-0.55	-0.46	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-11.3	2.46e-26	7.1e-23	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
HNSC	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-11.3	2.47e-26	7.12e-23	-0.5	-0.46	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	11.29	2.58e-26	7.43e-23	0.44	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-11.29	2.68e-26	7.72e-23	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
HNSC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.29	2.68e-26	7.72e-23	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
HNSC	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-11.29	2.76e-26	7.94e-23	-0.49	-0.46	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-11.29	2.77e-26	7.96e-23	-0.49	-0.46	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-11.29	2.77e-26	7.97e-23	-0.49	-0.46	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	11.28	2.81e-26	8.07e-23	0.55	0.46	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	11.28	2.81e-26	8.07e-23	0.58	0.46	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	11.28	2.87e-26	8.24e-23	0.55	0.46	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-11.28	2.9e-26	8.33e-23	-0.53	-0.46	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	11.28	2.91e-26	8.34e-23	0.55	0.46	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
HNSC	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-11.28	2.92e-26	8.38e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	11.28	2.96e-26	8.48e-23	0.51	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
HNSC	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-11.28	2.96e-26	8.49e-23	-0.49	-0.46	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-11.28	2.96e-26	8.49e-23	-0.49	-0.46	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
HNSC	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.98e-26	8.53e-23	-0.58	-0.46	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	11.27	3.11e-26	8.9e-23	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-11.27	3.16e-26	9.04e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-11.27	3.16e-26	9.04e-23	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
HNSC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-11.27	3.32e-26	9.5e-23	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	11.26	3.33e-26	9.53e-23	0.5	0.46	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
HNSC	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	11.26	3.51e-26	1e-22	0.63	0.46	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
HNSC	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.54e-26	1.01e-22	-0.58	-0.46	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	11.26	3.54e-26	1.01e-22	0.56	0.46	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	11.26	3.57e-26	1.02e-22	0.55	0.46	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	11.25	3.65e-26	1.04e-22	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.25	3.67e-26	1.05e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
HNSC	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	11.25	3.72e-26	1.06e-22	0.48	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
HNSC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	11.25	3.74e-26	1.07e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.25	3.74e-26	1.07e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
HNSC	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-11.25	3.83e-26	1.09e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-11.25	3.84e-26	1.09e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
HNSC	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-11.25	3.94e-26	1.12e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.04e-26	1.15e-22	-0.57	-0.46	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
HNSC	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	11.24	4.11e-26	1.17e-22	0.56	0.46	Height;	chr11:118758322	chr11:118704607~118750263:+
HNSC	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.12e-26	1.17e-22	-0.59	-0.46	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.32e-26	1.23e-22	-0.57	-0.46	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	11.24	4.34e-26	1.24e-22	0.56	0.46	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	11.23	4.38e-26	1.25e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-11.23	4.39e-26	1.25e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
HNSC	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-11.23	4.4e-26	1.25e-22	-0.56	-0.46	Height;	chr11:118760944	chr11:118704607~118750263:+
HNSC	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-11.23	4.42e-26	1.26e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.44e-26	1.26e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.62e-26	1.31e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.62e-26	1.31e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.23	4.64e-26	1.32e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.23	4.66e-26	1.32e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
HNSC	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-11.23	4.68e-26	1.33e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-11.23	4.68e-26	1.33e-22	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
HNSC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.22	4.81e-26	1.36e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	11.22	4.9e-26	1.39e-22	0.55	0.46	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-11.22	4.92e-26	1.39e-22	-0.56	-0.46	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-11.22	5.08e-26	1.44e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-11.22	5.08e-26	1.44e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	11.22	5.18e-26	1.46e-22	0.55	0.46	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	11.21	5.23e-26	1.48e-22	0.5	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	11.21	5.34e-26	1.51e-22	0.51	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
HNSC	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-11.21	5.43e-26	1.53e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	11.21	5.64e-26	1.59e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
HNSC	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-11.2	5.84e-26	1.65e-22	-0.49	-0.46	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
HNSC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-11.2	5.96e-26	1.68e-22	-0.56	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
HNSC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.2	5.97e-26	1.68e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.2	6.06e-26	1.7e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.2	6.19e-26	1.74e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
HNSC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	11.19	6.41e-26	1.8e-22	0.48	0.46	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
HNSC	cis	rs1865760	0.534	rs2032444	ENSG00000272462.2	U91328.19	-11.19	6.43e-26	1.81e-22	-0.48	-0.46	Height;	chr6:26046516	chr6:25992662~26001775:+
HNSC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.19	6.45e-26	1.81e-22	-0.9	-0.46	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
HNSC	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-11.19	6.66e-26	1.87e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-11.19	6.66e-26	1.87e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
HNSC	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-11.18	7.02e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-11.18	7.04e-26	1.97e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-11.18	7.32e-26	2.05e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
HNSC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	11.18	7.32e-26	2.05e-22	0.48	0.46	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000179406.6	LINC00174	11.18	7.37e-26	2.06e-22	0.63	0.46	Aortic root size;	chr7:66641888	chr7:66376044~66401338:-
HNSC	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-11.17	7.49e-26	2.1e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-11.17	7.49e-26	2.1e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
HNSC	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	11.17	7.62e-26	2.13e-22	0.5	0.46	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	11.17	7.7e-26	2.15e-22	0.55	0.46	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-11.17	8.07e-26	2.26e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
HNSC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-11.17	8.11e-26	2.27e-22	-0.53	-0.46	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
HNSC	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.16	8.21e-26	2.29e-22	-0.9	-0.46	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.16	8.21e-26	2.29e-22	-0.9	-0.46	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
HNSC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	11.16	8.32e-26	2.33e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	11.16	8.32e-26	2.33e-22	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
HNSC	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-11.16	8.36e-26	2.34e-22	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	11.16	8.5e-26	2.37e-22	0.55	0.46	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-11.16	8.7e-26	2.43e-22	-0.56	-0.46	Height;	chr11:118737823	chr11:118704607~118750263:+
HNSC	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-11.16	8.77e-26	2.45e-22	-0.49	-0.46	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-11.16	8.78e-26	2.45e-22	-0.54	-0.46	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-11.16	8.82e-26	2.46e-22	-0.56	-0.46	Height;	chr11:118747911	chr11:118704607~118750263:+
HNSC	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-11.16	8.83e-26	2.46e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	11.15	8.89e-26	2.48e-22	0.54	0.46	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-11.15	8.89e-26	2.48e-22	-0.54	-0.46	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
HNSC	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	11.15	8.93e-26	2.49e-22	0.6	0.46	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	11.15	9.11e-26	2.54e-22	0.48	0.46	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
HNSC	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-11.15	9.12e-26	2.54e-22	-0.56	-0.46	Height;	chr11:118773873	chr11:118704607~118750263:+
HNSC	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-11.15	9.22e-26	2.57e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	11.15	9.26e-26	2.58e-22	0.55	0.46	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	11.15	9.46e-26	2.63e-22	0.5	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
HNSC	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	11.15	9.48e-26	2.64e-22	0.59	0.46	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
HNSC	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-11.15	9.51e-26	2.64e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-11.15	9.51e-26	2.64e-22	-0.51	-0.46	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
HNSC	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	11.15	9.57e-26	2.66e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	11.14	9.81e-26	2.72e-22	0.55	0.46	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	11.14	9.92e-26	2.75e-22	0.56	0.46	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-11.14	9.98e-26	2.77e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	11.14	1.02e-25	2.84e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	11.14	1.02e-25	2.84e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
HNSC	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-11.14	1.03e-25	2.87e-22	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
HNSC	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	11.14	1.04e-25	2.89e-22	0.62	0.46	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-11.14	1.05e-25	2.91e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-11.14	1.05e-25	2.91e-22	-0.5	-0.46	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
HNSC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-11.13	1.09e-25	3.03e-22	-0.51	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
HNSC	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-11.13	1.13e-25	3.14e-22	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
HNSC	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	11.12	1.18e-25	3.26e-22	0.48	0.46	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	11.12	1.18e-25	3.27e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	11.12	1.19e-25	3.29e-22	0.44	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	11.11	1.28e-25	3.54e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.11	1.28e-25	3.54e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.11	1.29e-25	3.57e-22	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	11.11	1.3e-25	3.59e-22	0.54	0.46	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	11.11	1.3e-25	3.59e-22	0.54	0.46	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
HNSC	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-11.11	1.37e-25	3.78e-22	-0.49	-0.46	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
HNSC	cis	rs6867032	0.527	rs4975777	ENSG00000249731.1	RP11-259O2.3	-11.1	1.44e-25	3.97e-22	-0.63	-0.46	Gut microbiome composition (winter);	chr5:1973210	chr5:1968094~1969013:+
HNSC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-11.1	1.45e-25	4e-22	-0.56	-0.46	Height;	chr11:118764443	chr11:118704607~118750263:+
HNSC	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	11.1	1.48e-25	4.08e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
HNSC	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-11.1	1.49e-25	4.11e-22	-0.48	-0.46	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-11.1	1.49e-25	4.11e-22	-0.48	-0.46	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	11.09	1.55e-25	4.27e-22	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
HNSC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-11.08	1.7e-25	4.66e-22	-0.56	-0.46	Breast cancer;	chr11:825777	chr11:779617~780755:+
HNSC	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	11.08	1.78e-25	4.87e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
HNSC	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.85e-25	5.07e-22	-0.56	-0.46	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	11.07	1.86e-25	5.09e-22	0.54	0.46	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	11.07	1.86e-25	5.09e-22	0.54	0.46	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	11.07	1.87e-25	5.13e-22	0.54	0.46	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
HNSC	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.88e-25	5.15e-22	-0.57	-0.46	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-11.07	1.88e-25	5.15e-22	-0.62	-0.46	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	11.07	1.88e-25	5.16e-22	0.53	0.46	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.89e-25	5.16e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
HNSC	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-11.07	1.89e-25	5.17e-22	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
HNSC	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.94e-25	5.29e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
HNSC	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.96e-25	5.36e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
HNSC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-11.05	2.18e-25	5.95e-22	-0.56	-0.46	Height;	chr11:118761813	chr11:118704607~118750263:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-11.05	2.22e-25	6.04e-22	-0.54	-0.46	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-11.05	2.28e-25	6.22e-22	-0.44	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	11.05	2.3e-25	6.26e-22	0.61	0.46	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	11.04	2.36e-25	6.44e-22	0.63	0.46	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-11.04	2.4e-25	6.54e-22	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-11.04	2.42e-25	6.59e-22	-0.46	-0.45	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-11.04	2.44e-25	6.65e-22	-0.54	-0.45	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-11.04	2.45e-25	6.68e-22	-0.56	-0.45	Height;	chr11:118746590	chr11:118704607~118750263:+
HNSC	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-11.04	2.49e-25	6.79e-22	-0.5	-0.45	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000179406.6	LINC00174	-11.04	2.51e-25	6.84e-22	-0.62	-0.45	Aortic root size;	chr7:66762495	chr7:66376044~66401338:-
HNSC	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-11.04	2.52e-25	6.85e-22	-0.55	-0.45	Height;	chr11:118737916	chr11:118704607~118750263:+
HNSC	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-11.03	2.57e-25	6.99e-22	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
HNSC	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-11.03	2.7e-25	7.35e-22	-0.49	-0.45	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
HNSC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-11.03	2.75e-25	7.48e-22	-0.56	-0.45	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
HNSC	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-11.03	2.76e-25	7.51e-22	-0.56	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
HNSC	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-11.03	2.77e-25	7.52e-22	-0.48	-0.45	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
HNSC	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	11.02	2.82e-25	7.66e-22	0.44	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
HNSC	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	11.02	2.83e-25	7.69e-22	0.59	0.45	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-11.02	2.83e-25	7.7e-22	-0.44	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
HNSC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-11.02	2.89e-25	7.84e-22	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
HNSC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-11.02	2.95e-25	7.99e-22	-0.56	-0.45	Height;	chr11:118742526	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-11.02	2.99e-25	8.1e-22	-0.55	-0.45	Height;	chr11:118749988	chr11:118704607~118750263:+
HNSC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-11.02	3e-25	8.13e-22	-0.52	-0.45	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
HNSC	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-11.02	3.03e-25	8.21e-22	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	11.02	3.05e-25	8.26e-22	0.54	0.45	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-11.01	3.16e-25	8.55e-22	-0.5	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
HNSC	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-11.01	3.17e-25	8.59e-22	-0.48	-0.45	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	11.01	3.18e-25	8.61e-22	0.54	0.45	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	11.01	3.2e-25	8.65e-22	0.6	0.45	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	11.01	3.29e-25	8.89e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-11.01	3.32e-25	8.97e-22	-0.62	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
HNSC	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	11	3.35e-25	9.04e-22	0.48	0.45	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-11	3.38e-25	9.12e-22	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	11	3.44e-25	9.28e-22	0.56	0.45	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
HNSC	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	11	3.48e-25	9.39e-22	0.52	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	11	3.49e-25	9.43e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	11	3.49e-25	9.43e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11	3.52e-25	9.51e-22	0.52	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
HNSC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	11	3.55e-25	9.57e-22	0.66	0.45	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	11	3.62e-25	9.75e-22	0.63	0.45	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
HNSC	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	11	3.63e-25	9.79e-22	0.48	0.45	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
HNSC	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-11	3.63e-25	9.8e-22	-0.47	-0.45	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	10.99	3.72e-25	1e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	10.99	3.8e-25	1.02e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	10.99	3.8e-25	1.02e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	10.99	3.83e-25	1.03e-21	0.49	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-10.99	3.83e-25	1.03e-21	-0.54	-0.45	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-10.99	3.86e-25	1.04e-21	-0.54	-0.45	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	10.99	3.93e-25	1.06e-21	0.54	0.45	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
HNSC	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-10.99	3.98e-25	1.07e-21	-0.53	-0.45	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
HNSC	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-10.98	4.03e-25	1.08e-21	-0.57	-0.45	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-10.98	4.03e-25	1.08e-21	-0.57	-0.45	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
HNSC	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-10.98	4.04e-25	1.09e-21	-0.41	-0.45	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
HNSC	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	10.98	4.05e-25	1.09e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	10.98	4.09e-25	1.1e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	10.98	4.25e-25	1.14e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
HNSC	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-10.98	4.26e-25	1.14e-21	-0.47	-0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-10.98	4.29e-25	1.15e-21	-0.6	-0.45	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-10.98	4.35e-25	1.17e-21	-0.53	-0.45	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
HNSC	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-10.97	4.37e-25	1.17e-21	-0.49	-0.45	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-10.97	4.59e-25	1.23e-21	-0.48	-0.45	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
HNSC	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	10.96	4.76e-25	1.27e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-10.96	5.18e-25	1.38e-21	-0.53	-0.45	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	10.95	5.19e-25	1.39e-21	0.54	0.45	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	10.95	5.33e-25	1.42e-21	0.63	0.45	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	10.95	5.33e-25	1.42e-21	0.63	0.45	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
HNSC	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-10.95	5.35e-25	1.43e-21	-0.5	-0.45	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-10.95	5.37e-25	1.43e-21	-0.54	-0.45	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	10.95	5.37e-25	1.43e-21	0.54	0.45	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-10.95	5.4e-25	1.44e-21	-0.53	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
HNSC	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-10.95	5.4e-25	1.44e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
HNSC	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-10.95	5.45e-25	1.45e-21	-0.57	-0.45	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
HNSC	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-10.95	5.49e-25	1.46e-21	-0.62	-0.45	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-10.95	5.5e-25	1.47e-21	-0.56	-0.45	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.672	rs2291248	ENSG00000279233.1	RP11-158L12.4	10.95	5.56e-25	1.48e-21	0.47	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125134762	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.95	5.58e-25	1.49e-21	0.51	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
HNSC	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	10.94	5.72e-25	1.52e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
HNSC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	10.94	5.8e-25	1.54e-21	0.67	0.45	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	10.94	5.81e-25	1.55e-21	0.58	0.45	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-10.94	5.91e-25	1.57e-21	-0.53	-0.45	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-10.94	5.91e-25	1.57e-21	-0.53	-0.45	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
HNSC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	10.94	5.96e-25	1.59e-21	0.53	0.45	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
HNSC	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-10.94	5.98e-25	1.59e-21	-0.54	-0.45	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
HNSC	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	10.93	6.28e-25	1.67e-21	0.48	0.45	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-10.93	6.33e-25	1.68e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-10.93	6.33e-25	1.68e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	10.93	6.52e-25	1.73e-21	0.49	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
HNSC	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.92	6.77e-25	1.8e-21	0.5	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	10.92	6.79e-25	1.8e-21	0.54	0.45	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	10.92	6.79e-25	1.8e-21	0.54	0.45	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
HNSC	cis	rs17270561	1	rs17270561	ENSG00000272462.2	U91328.19	10.92	6.81e-25	1.81e-21	0.53	0.45	Iron status biomarkers;	chr6:25820211	chr6:25992662~26001775:+
HNSC	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-10.92	6.9e-25	1.83e-21	-0.36	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
HNSC	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	10.92	7.01e-25	1.86e-21	0.48	0.45	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	10.92	7.06e-25	1.87e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	10.92	7.07e-25	1.87e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-10.92	7.09e-25	1.88e-21	-0.5	-0.45	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	10.91	7.37e-25	1.95e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-10.91	7.52e-25	1.99e-21	-0.56	-0.45	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	10.91	7.85e-25	2.08e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-10.9	8.12e-25	2.14e-21	-0.53	-0.45	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	10.9	8.39e-25	2.21e-21	0.5	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
HNSC	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.9	8.7e-25	2.29e-21	0.5	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	10.9	8.7e-25	2.29e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
HNSC	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-10.9	8.75e-25	2.31e-21	-0.53	-0.45	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
HNSC	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	10.89	8.79e-25	2.32e-21	0.49	0.45	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	10.89	8.86e-25	2.33e-21	0.59	0.45	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-10.89	9.26e-25	2.43e-21	-0.53	-0.45	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-10.89	9.3e-25	2.45e-21	-1.06	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	10.89	9.52e-25	2.5e-21	0.53	0.45	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	10.89	9.53e-25	2.5e-21	0.61	0.45	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	10.88	9.61e-25	2.53e-21	0.54	0.45	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
HNSC	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-10.88	9.71e-25	2.55e-21	-0.48	-0.45	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
HNSC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	10.88	1e-24	2.64e-21	0.66	0.45	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-10.88	1.03e-24	2.69e-21	-0.54	-0.45	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	10.88	1.04e-24	2.72e-21	0.54	0.45	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	10.87	1.05e-24	2.75e-21	0.44	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
HNSC	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	10.87	1.05e-24	2.75e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	10.87	1.05e-24	2.75e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
HNSC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	10.87	1.07e-24	2.79e-21	0.51	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
HNSC	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	10.87	1.08e-24	2.83e-21	0.45	0.45	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
HNSC	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	10.86	1.17e-24	3.06e-21	0.47	0.45	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-10.86	1.18e-24	3.08e-21	-0.61	-0.45	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-10.86	1.21e-24	3.16e-21	-0.57	-0.45	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	10.86	1.22e-24	3.17e-21	0.54	0.45	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
HNSC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	10.86	1.22e-24	3.19e-21	0.52	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
HNSC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-10.86	1.23e-24	3.21e-21	-0.5	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	10.85	1.26e-24	3.27e-21	0.54	0.45	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	10.85	1.26e-24	3.27e-21	0.54	0.45	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-10.85	1.26e-24	3.28e-21	-0.47	-0.45	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-10.85	1.27e-24	3.3e-21	-0.61	-0.45	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-10.85	1.27e-24	3.3e-21	-0.61	-0.45	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-10.85	1.27e-24	3.31e-21	-0.47	-0.45	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	10.85	1.29e-24	3.37e-21	0.53	0.45	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
HNSC	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	10.85	1.31e-24	3.4e-21	0.61	0.45	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	10.85	1.34e-24	3.47e-21	0.53	0.45	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-10.85	1.34e-24	3.47e-21	-0.47	-0.45	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-10.85	1.34e-24	3.47e-21	-0.47	-0.45	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	10.85	1.34e-24	3.48e-21	0.61	0.45	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	10.85	1.34e-24	3.48e-21	0.58	0.45	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	10.85	1.35e-24	3.51e-21	0.54	0.45	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
HNSC	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-10.84	1.36e-24	3.53e-21	-0.44	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
HNSC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-10.84	1.41e-24	3.64e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
HNSC	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	10.84	1.44e-24	3.73e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	10.84	1.44e-24	3.73e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
HNSC	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	10.84	1.45e-24	3.76e-21	0.45	0.45	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
HNSC	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	10.84	1.47e-24	3.8e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-10.84	1.47e-24	3.81e-21	-0.52	-0.45	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
HNSC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-10.84	1.48e-24	3.82e-21	-0.47	-0.45	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-10.83	1.5e-24	3.89e-21	-0.56	-0.45	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	10.83	1.55e-24	4e-21	0.49	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
HNSC	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	10.83	1.56e-24	4.03e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-10.83	1.58e-24	4.07e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-10.82	1.63e-24	4.22e-21	-0.56	-0.45	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	10.82	1.66e-24	4.27e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
HNSC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-10.82	1.66e-24	4.27e-21	-0.46	-0.45	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	10.82	1.69e-24	4.36e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000179406.6	LINC00174	-10.81	1.78e-24	4.57e-21	-0.63	-0.45	Aortic root size;	chr7:66544233	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	10.81	1.81e-24	4.66e-21	0.59	0.45	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	10.81	1.81e-24	4.66e-21	0.59	0.45	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	10.81	1.82e-24	4.68e-21	0.5	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
HNSC	cis	rs6867032	0.527	rs4246752	ENSG00000249731.1	RP11-259O2.3	-10.81	1.82e-24	4.69e-21	-0.62	-0.45	Gut microbiome composition (winter);	chr5:1975461	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	10.81	1.82e-24	4.69e-21	0.58	0.45	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	10.81	1.82e-24	4.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	10.81	1.82e-24	4.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	10.81	1.83e-24	4.71e-21	0.58	0.45	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-10.81	1.86e-24	4.78e-21	-0.46	-0.45	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-10.81	1.88e-24	4.83e-21	-0.47	-0.45	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	10.81	1.88e-24	4.84e-21	0.61	0.45	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-10.81	1.92e-24	4.92e-21	-0.47	-0.45	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-10.81	1.92e-24	4.92e-21	-0.47	-0.45	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	10.81	1.92e-24	4.92e-21	0.53	0.45	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-10.81	1.92e-24	4.92e-21	-0.53	-0.45	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	10.8	1.95e-24	5.01e-21	0.54	0.45	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
HNSC	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-10.8	1.96e-24	5.03e-21	-0.61	-0.45	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.8	1.97e-24	5.04e-21	0.58	0.45	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-10.8	1.98e-24	5.08e-21	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
HNSC	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-10.8	2e-24	5.12e-21	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.8	2.01e-24	5.15e-21	-0.59	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
HNSC	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-10.8	2.1e-24	5.37e-21	-0.48	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	10.79	2.16e-24	5.53e-21	0.54	0.45	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
HNSC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.79	2.16e-24	5.53e-21	0.56	0.45	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
HNSC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-10.79	2.19e-24	5.61e-21	-0.47	-0.45	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-10.79	2.22e-24	5.66e-21	-0.57	-0.45	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	10.79	2.22e-24	5.68e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
HNSC	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	10.79	2.25e-24	5.73e-21	0.47	0.45	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-10.79	2.27e-24	5.79e-21	-0.47	-0.45	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
HNSC	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	10.79	2.28e-24	5.81e-21	0.6	0.45	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	10.79	2.28e-24	5.81e-21	0.6	0.45	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	10.79	2.29e-24	5.83e-21	0.59	0.45	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-10.78	2.31e-24	5.9e-21	-0.47	-0.45	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-10.78	2.31e-24	5.9e-21	-0.47	-0.45	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-10.78	2.35e-24	6e-21	-0.61	-0.45	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	10.78	2.36e-24	6.01e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	10.78	2.38e-24	6.07e-21	0.53	0.45	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	10.78	2.38e-24	6.07e-21	0.53	0.45	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
HNSC	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	10.78	2.39e-24	6.1e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	10.78	2.39e-24	6.1e-21	0.61	0.45	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-10.78	2.42e-24	6.17e-21	-0.55	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-10.78	2.42e-24	6.17e-21	-0.46	-0.45	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	10.78	2.46e-24	6.25e-21	0.6	0.45	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	10.77	2.53e-24	6.43e-21	0.61	0.45	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
HNSC	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	10.77	2.54e-24	6.47e-21	0.55	0.45	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
HNSC	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-10.77	2.6e-24	6.6e-21	-0.56	-0.45	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-10.77	2.6e-24	6.6e-21	-0.56	-0.45	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	10.77	2.63e-24	6.69e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	10.77	2.65e-24	6.73e-21	0.59	0.45	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-10.77	2.7e-24	6.86e-21	-0.47	-0.45	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	10.77	2.72e-24	6.9e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	10.76	2.73e-24	6.94e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-10.76	2.74e-24	6.96e-21	-0.53	-0.45	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	10.76	2.75e-24	6.99e-21	0.53	0.45	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
HNSC	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	10.76	2.82e-24	7.14e-21	0.47	0.45	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-10.76	2.86e-24	7.25e-21	-0.61	-0.45	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-10.76	2.86e-24	7.25e-21	-0.61	-0.45	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-10.76	2.88e-24	7.29e-21	-0.47	-0.45	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.94e-24	7.45e-21	-0.56	-0.45	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	10.75	2.98e-24	7.56e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	10.75	3e-24	7.6e-21	0.42	0.45	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
HNSC	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-10.75	3.03e-24	7.67e-21	-0.49	-0.45	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
HNSC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-10.75	3.1e-24	7.84e-21	-0.86	-0.45	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
HNSC	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-10.75	3.12e-24	7.89e-21	-0.56	-0.45	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
HNSC	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	10.75	3.14e-24	7.95e-21	0.64	0.45	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
HNSC	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-10.75	3.18e-24	8.04e-21	-0.55	-0.45	Height;	chr11:118791319	chr11:118704607~118750263:+
HNSC	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	10.75	3.2e-24	8.08e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	10.75	3.2e-24	8.08e-21	0.61	0.45	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-10.75	3.21e-24	8.11e-21	-0.57	-0.45	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	10.74	3.28e-24	8.29e-21	0.62	0.45	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
HNSC	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-10.74	3.29e-24	8.29e-21	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	10.74	3.39e-24	8.54e-21	0.49	0.45	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
HNSC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	10.74	3.53e-24	8.89e-21	0.67	0.44	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
HNSC	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-10.73	3.55e-24	8.94e-21	-0.59	-0.44	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	10.73	3.6e-24	9.07e-21	0.56	0.44	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-10.73	3.61e-24	9.09e-21	-0.6	-0.44	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
HNSC	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-10.73	3.67e-24	9.24e-21	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
HNSC	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	10.73	3.69e-24	9.29e-21	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-10.73	3.71e-24	9.34e-21	-0.49	-0.44	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
HNSC	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	10.73	3.79e-24	9.53e-21	0.47	0.44	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
HNSC	cis	rs1865760	0.622	rs9968910	ENSG00000272462.2	U91328.19	-10.73	3.8e-24	9.55e-21	-0.47	-0.44	Height;	chr6:26071867	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.622	rs10946807	ENSG00000272462.2	U91328.19	-10.73	3.8e-24	9.55e-21	-0.47	-0.44	Height;	chr6:26079410	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-10.72	3.88e-24	9.76e-21	-0.61	-0.44	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	10.72	3.95e-24	9.92e-21	0.61	0.44	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	10.72	3.95e-24	9.92e-21	0.61	0.44	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-10.72	4.11e-24	1.03e-20	-0.46	-0.44	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	10.72	4.12e-24	1.03e-20	0.57	0.44	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	10.71	4.22e-24	1.06e-20	0.46	0.44	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	10.71	4.25e-24	1.06e-20	0.46	0.44	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-10.71	4.41e-24	1.11e-20	-0.61	-0.44	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
HNSC	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-10.71	4.47e-24	1.12e-20	-0.56	-0.44	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
HNSC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	10.71	4.47e-24	1.12e-20	0.46	0.44	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
HNSC	cis	rs34375054	0.672	rs2291247	ENSG00000279233.1	RP11-158L12.4	10.71	4.55e-24	1.14e-20	0.47	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125134407	chr12:125138245~125141711:+
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000179406.6	LINC00174	-10.7	4.65e-24	1.16e-20	-0.61	-0.44	Aortic root size;	chr7:66773096	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-10.7	4.67e-24	1.17e-20	-0.6	-0.44	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
HNSC	cis	rs12216125	0.801	rs56107510	ENSG00000272462.2	U91328.19	-10.7	4.68e-24	1.17e-20	-0.47	-0.44	Iron status biomarkers;	chr6:25987208	chr6:25992662~26001775:+
HNSC	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	10.7	4.69e-24	1.17e-20	0.47	0.44	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
HNSC	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-10.7	4.72e-24	1.18e-20	-0.52	-0.44	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
HNSC	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-10.7	4.73e-24	1.18e-20	-0.61	-0.44	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	10.7	4.77e-24	1.19e-20	0.5	0.44	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
HNSC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	10.7	4.82e-24	1.21e-20	0.55	0.44	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
HNSC	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	10.7	4.88e-24	1.22e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
HNSC	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	10.69	5.03e-24	1.25e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-10.69	5.19e-24	1.29e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
HNSC	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	10.69	5.3e-24	1.32e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.47e-24	1.36e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.47e-24	1.36e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.68	5.48e-24	1.36e-20	0.49	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
HNSC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	10.68	5.54e-24	1.38e-20	0.55	0.44	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-10.68	5.66e-24	1.41e-20	-0.61	-0.44	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
HNSC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	10.68	5.72e-24	1.42e-20	0.46	0.44	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.74e-24	1.43e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	10.68	5.88e-24	1.46e-20	0.4	0.44	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
HNSC	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-10.68	5.93e-24	1.48e-20	-0.56	-0.44	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
HNSC	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-10.67	6.08e-24	1.51e-20	-0.48	-0.44	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
HNSC	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-10.67	6.08e-24	1.51e-20	-0.48	-0.44	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
HNSC	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	10.67	6.19e-24	1.53e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-10.67	6.32e-24	1.57e-20	-0.6	-0.44	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	10.67	6.35e-24	1.57e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
HNSC	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	10.67	6.39e-24	1.58e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-10.67	6.4e-24	1.59e-20	-0.59	-0.44	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
HNSC	cis	rs6867032	0.527	rs1017924	ENSG00000249731.1	RP11-259O2.3	10.66	6.91e-24	1.71e-20	0.61	0.44	Gut microbiome composition (winter);	chr5:1976073	chr5:1968094~1969013:+
HNSC	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	10.66	6.92e-24	1.71e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
HNSC	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-10.66	7.05e-24	1.74e-20	-0.55	-0.44	Height;	chr11:118786602	chr11:118704607~118750263:+
HNSC	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-10.65	7.14e-24	1.76e-20	-0.48	-0.44	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
HNSC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	10.65	7.28e-24	1.8e-20	0.85	0.44	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
HNSC	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.65	7.38e-24	1.82e-20	-0.53	-0.44	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
HNSC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	10.65	7.41e-24	1.83e-20	0.55	0.44	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
HNSC	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-10.65	7.44e-24	1.83e-20	-0.59	-0.44	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-10.65	7.57e-24	1.87e-20	-0.61	-0.44	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
HNSC	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-10.65	7.64e-24	1.88e-20	-0.56	-0.44	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
HNSC	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-10.64	7.78e-24	1.92e-20	-0.6	-0.44	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
HNSC	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-10.64	7.92e-24	1.95e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
HNSC	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-10.64	7.92e-24	1.95e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
HNSC	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	10.64	7.93e-24	1.95e-20	0.59	0.44	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
HNSC	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	10.64	7.99e-24	1.97e-20	0.48	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
HNSC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-10.64	8.02e-24	1.98e-20	-0.46	-0.44	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
HNSC	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-10.64	8.03e-24	1.98e-20	-0.6	-0.44	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
HNSC	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-10.64	8.23e-24	2.03e-20	-0.53	-0.44	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
HNSC	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	10.64	8.26e-24	2.03e-20	0.63	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	10.64	8.4e-24	2.07e-20	0.6	0.44	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-10.63	8.51e-24	2.09e-20	-0.59	-0.44	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
HNSC	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	10.63	8.54e-24	2.1e-20	0.64	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
HNSC	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	10.63	8.71e-24	2.14e-20	0.43	0.44	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
HNSC	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-10.63	8.72e-24	2.14e-20	-0.35	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
HNSC	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	10.63	8.87e-24	2.18e-20	0.6	0.44	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	10.63	8.95e-24	2.2e-20	0.43	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	10.63	8.97e-24	2.2e-20	0.61	0.44	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-10.63	8.98e-24	2.2e-20	-0.6	-0.44	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
HNSC	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-10.63	9.06e-24	2.22e-20	-0.55	-0.44	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
HNSC	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.63	9.08e-24	2.23e-20	0.48	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
HNSC	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-10.63	9.18e-24	2.25e-20	-0.59	-0.44	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	10.62	9.23e-24	2.26e-20	0.86	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	10.62	9.49e-24	2.32e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
HNSC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	10.62	9.51e-24	2.33e-20	0.56	0.44	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
HNSC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-10.62	9.55e-24	2.34e-20	-0.46	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	10.62	9.64e-24	2.36e-20	0.6	0.44	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-10.62	9.72e-24	2.38e-20	-0.54	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
HNSC	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	10.62	9.74e-24	2.38e-20	0.5	0.44	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
HNSC	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-10.62	9.95e-24	2.43e-20	-0.59	-0.44	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
HNSC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	10.61	1e-23	2.45e-20	0.54	0.44	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
HNSC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-10.61	1.01e-23	2.47e-20	-0.55	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	10.61	1.03e-23	2.53e-20	0.6	0.44	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	10.61	1.07e-23	2.62e-20	0.4	0.44	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
HNSC	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-10.61	1.08e-23	2.64e-20	-0.56	-0.44	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
HNSC	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	10.61	1.09e-23	2.65e-20	0.6	0.44	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-10.6	1.12e-23	2.73e-20	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-10.6	1.15e-23	2.8e-20	-0.55	-0.44	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-10.6	1.15e-23	2.8e-20	-0.55	-0.44	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	10.59	1.21e-23	2.94e-20	0.6	0.44	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.26e-23	3.07e-20	-0.55	-0.44	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-10.59	1.27e-23	3.08e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-10.59	1.27e-23	3.08e-20	-0.58	-0.44	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
HNSC	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-10.59	1.29e-23	3.14e-20	-0.59	-0.44	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	10.59	1.29e-23	3.14e-20	0.57	0.44	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
HNSC	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-10.59	1.29e-23	3.14e-20	-0.6	-0.44	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	10.58	1.3e-23	3.15e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	10.58	1.34e-23	3.26e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	10.58	1.35e-23	3.27e-20	0.53	0.44	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
HNSC	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.37e-23	3.33e-20	-0.55	-0.44	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-10.58	1.38e-23	3.34e-20	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
HNSC	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	10.58	1.38e-23	3.35e-20	0.6	0.44	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
HNSC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	10.58	1.38e-23	3.36e-20	0.55	0.44	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
HNSC	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	10.58	1.4e-23	3.4e-20	0.62	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	10.58	1.41e-23	3.42e-20	0.61	0.44	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-10.57	1.44e-23	3.48e-20	-0.49	-0.44	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
HNSC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
HNSC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
HNSC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	10.57	1.46e-23	3.53e-20	0.54	0.44	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
HNSC	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	10.57	1.49e-23	3.61e-20	0.48	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
HNSC	cis	rs6867032	0.834	rs10043083	ENSG00000249731.1	RP11-259O2.3	-10.57	1.5e-23	3.62e-20	-0.55	-0.44	Gut microbiome composition (winter);	chr5:1995573	chr5:1968094~1969013:+
HNSC	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	10.57	1.5e-23	3.63e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	10.57	1.5e-23	3.63e-20	0.53	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
HNSC	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-10.57	1.52e-23	3.67e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
HNSC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	10.57	1.53e-23	3.69e-20	0.86	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
HNSC	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	10.56	1.54e-23	3.73e-20	0.6	0.44	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	10.56	1.58e-23	3.81e-20	0.61	0.44	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-10.56	1.59e-23	3.85e-20	-0.55	-0.44	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-10.56	1.61e-23	3.88e-20	-0.58	-0.44	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
HNSC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-10.56	1.61e-23	3.89e-20	-0.53	-0.44	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
HNSC	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	10.56	1.62e-23	3.9e-20	0.6	0.44	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	10.56	1.66e-23	3.98e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.06e-20	-0.6	-0.44	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
HNSC	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.07e-20	-0.59	-0.44	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-10.55	1.69e-23	4.07e-20	-0.58	-0.44	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
HNSC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	10.55	1.7e-23	4.09e-20	0.85	0.44	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
HNSC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	10.55	1.73e-23	4.14e-20	0.63	0.44	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
HNSC	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.55	1.73e-23	4.16e-20	-0.52	-0.44	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
HNSC	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.74e-23	4.17e-20	-0.55	-0.44	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-10.55	1.74e-23	4.18e-20	-0.6	-0.44	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	10.55	1.75e-23	4.19e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	10.55	1.76e-23	4.21e-20	0.57	0.44	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	10.55	1.78e-23	4.27e-20	0.61	0.44	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
HNSC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	10.55	1.79e-23	4.29e-20	0.45	0.44	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.81e-23	4.33e-20	-0.54	-0.44	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-10.55	1.81e-23	4.33e-20	-0.54	-0.44	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000179406.6	LINC00174	10.55	1.81e-23	4.34e-20	0.55	0.44	Aortic root size;	chr7:66622178	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000179406.6	LINC00174	10.55	1.81e-23	4.34e-20	0.55	0.44	Aortic root size;	chr7:66622208	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	10.55	1.82e-23	4.37e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
HNSC	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-10.55	1.83e-23	4.37e-20	-0.48	-0.44	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
HNSC	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-10.54	1.85e-23	4.43e-20	-0.55	-0.44	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	10.54	1.87e-23	4.47e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	10.54	1.87e-23	4.48e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
HNSC	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	10.54	1.89e-23	4.53e-20	0.58	0.44	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000179406.6	LINC00174	-10.54	1.93e-23	4.62e-20	-0.55	-0.44	Aortic root size;	chr7:66519618	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000179406.6	LINC00174	-10.54	1.93e-23	4.62e-20	-0.55	-0.44	Aortic root size;	chr7:66521858	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	10.54	1.96e-23	4.68e-20	0.6	0.44	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	10.54	1.98e-23	4.73e-20	0.6	0.44	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	10.53	2e-23	4.77e-20	0.58	0.44	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-10.53	2.03e-23	4.84e-20	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000179406.6	LINC00174	-10.53	2.03e-23	4.86e-20	-0.55	-0.44	Aortic root size;	chr7:66542376	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801217	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66545590	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs801216	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66546680	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801211	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66550702	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs801205	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66557157	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.617	rs810400	ENSG00000179406.6	LINC00174	10.53	2.03e-23	4.86e-20	0.55	0.44	Aortic root size;	chr7:66557902	chr7:66376044~66401338:-
HNSC	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-10.53	2.06e-23	4.91e-20	-0.58	-0.44	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	10.53	2.07e-23	4.95e-20	0.6	0.44	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	10.53	2.08e-23	4.96e-20	0.45	0.44	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	10.53	2.11e-23	5.03e-20	0.53	0.44	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
HNSC	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	10.53	2.14e-23	5.11e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	10.53	2.14e-23	5.11e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
HNSC	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-10.52	2.17e-23	5.18e-20	-0.58	-0.44	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000179406.6	LINC00174	-10.52	2.18e-23	5.19e-20	-0.55	-0.44	Aortic root size;	chr7:66540031	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000179406.6	LINC00174	-10.52	2.18e-23	5.19e-20	-0.55	-0.44	Aortic root size;	chr7:66540165	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	10.52	2.2e-23	5.22e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	10.52	2.21e-23	5.25e-20	0.6	0.44	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
HNSC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-10.52	2.22e-23	5.27e-20	-0.52	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
HNSC	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.22e-23	5.27e-20	-0.55	-0.44	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	10.52	2.25e-23	5.35e-20	0.45	0.44	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
HNSC	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.26e-23	5.35e-20	-0.54	-0.44	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-10.52	2.31e-23	5.48e-20	-0.55	-0.44	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-10.52	2.35e-23	5.58e-20	-0.58	-0.44	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-10.51	2.4e-23	5.7e-20	-0.41	-0.44	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
HNSC	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	10.51	2.44e-23	5.78e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
HNSC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	10.51	2.47e-23	5.86e-20	0.54	0.44	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-10.51	2.52e-23	5.97e-20	-0.58	-0.44	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
HNSC	cis	rs1865760	0.534	rs72834629	ENSG00000272462.2	U91328.19	-10.51	2.55e-23	6.04e-20	-0.46	-0.44	Height;	chr6:26022804	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	10.51	2.55e-23	6.04e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	10.51	2.55e-23	6.05e-20	0.58	0.44	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	10.5	2.61e-23	6.19e-20	0.58	0.44	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-10.5	2.67e-23	6.32e-20	-0.58	-0.44	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
HNSC	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	10.5	2.79e-23	6.59e-20	0.6	0.44	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	10.5	2.79e-23	6.6e-20	0.58	0.44	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	10.5	2.81e-23	6.64e-20	0.58	0.44	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
HNSC	cis	rs6867032	0.695	rs3902820	ENSG00000249731.1	RP11-259O2.3	-10.49	2.9e-23	6.86e-20	-0.55	-0.44	Gut microbiome composition (winter);	chr5:2000216	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	10.49	2.91e-23	6.87e-20	0.6	0.44	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	10.49	3.03e-23	7.16e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	10.48	3.08e-23	7.28e-20	0.59	0.44	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
HNSC	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	10.48	3.09e-23	7.29e-20	0.35	0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
HNSC	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.16e-23	7.46e-20	-0.55	-0.44	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.19e-23	7.51e-20	-0.55	-0.44	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.19e-23	7.51e-20	-0.55	-0.44	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	10.48	3.2e-23	7.54e-20	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
HNSC	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-10.48	3.21e-23	7.56e-20	-0.54	-0.44	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	10.48	3.21e-23	7.57e-20	0.41	0.44	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-10.48	3.22e-23	7.59e-20	-0.53	-0.44	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
HNSC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	10.48	3.24e-23	7.63e-20	0.4	0.44	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
HNSC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	10.48	3.27e-23	7.71e-20	0.73	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
HNSC	cis	rs6952407	1	rs6952407	ENSG00000179406.6	LINC00174	10.48	3.31e-23	7.79e-20	0.55	0.44	Cotinine glucuronidation;	chr7:66580525	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-10.48	3.32e-23	7.82e-20	-0.58	-0.44	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
HNSC	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-10.48	3.33e-23	7.84e-20	-0.58	-0.44	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-10.47	3.42e-23	8.04e-20	-0.6	-0.44	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	10.47	3.42e-23	8.04e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	10.47	3.42e-23	8.04e-20	0.61	0.44	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-10.47	3.44e-23	8.09e-20	-0.55	-0.44	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	10.47	3.49e-23	8.2e-20	0.59	0.44	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	10.47	3.49e-23	8.2e-20	0.59	0.44	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	10.47	3.49e-23	8.21e-20	0.45	0.44	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	10.47	3.53e-23	8.29e-20	0.6	0.44	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	10.47	3.57e-23	8.38e-20	0.87	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	10.47	3.58e-23	8.41e-20	0.57	0.44	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	10.47	3.61e-23	8.48e-20	0.49	0.44	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-10.47	3.62e-23	8.5e-20	-0.55	-0.44	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	10.46	3.66e-23	8.59e-20	0.46	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
HNSC	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	10.46	3.67e-23	8.61e-20	0.45	0.44	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	10.46	3.68e-23	8.64e-20	0.6	0.44	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	10.46	3.7e-23	8.68e-20	0.59	0.44	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.46	3.7e-23	8.68e-20	0.57	0.44	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.72e-23	8.72e-20	-0.54	-0.44	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
HNSC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	10.46	3.74e-23	8.77e-20	0.84	0.44	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-10.46	3.75e-23	8.78e-20	-0.58	-0.44	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	10.46	3.8e-23	8.91e-20	0.6	0.44	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	10.46	3.82e-23	8.95e-20	0.6	0.44	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000179406.6	LINC00174	-10.46	3.82e-23	8.95e-20	-0.55	-0.44	Aortic root size;	chr7:66746023	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000179406.6	LINC00174	10.46	3.83e-23	8.97e-20	0.55	0.44	Aortic root size;	chr7:66619753	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	10.46	3.83e-23	8.97e-20	0.6	0.44	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	10.46	3.83e-23	8.97e-20	0.6	0.44	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	10.46	3.84e-23	9e-20	0.5	0.44	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
HNSC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	10.46	3.85e-23	9.01e-20	0.45	0.44	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
HNSC	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.86e-23	9.05e-20	-0.53	-0.44	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.93e-23	9.2e-20	-0.54	-0.44	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-10.46	3.93e-23	9.2e-20	-0.54	-0.44	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	10.45	3.96e-23	9.26e-20	0.55	0.44	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
HNSC	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	10.45	4e-23	9.36e-20	0.5	0.44	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
HNSC	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	10.45	4.07e-23	9.51e-20	0.58	0.44	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-10.45	4.07e-23	9.52e-20	-0.62	-0.44	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
HNSC	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	10.45	4.09e-23	9.56e-20	0.5	0.44	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
HNSC	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	10.45	4.12e-23	9.62e-20	0.6	0.44	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-10.45	4.22e-23	9.86e-20	-0.57	-0.44	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-10.45	4.25e-23	9.92e-20	-0.54	-0.44	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
HNSC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	10.45	4.26e-23	9.95e-20	0.45	0.44	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	10.45	4.27e-23	9.97e-20	0.6	0.44	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-10.45	4.31e-23	1e-19	-0.54	-0.44	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
HNSC	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	10.44	4.32e-23	1.01e-19	0.6	0.44	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	10.44	4.33e-23	1.01e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
HNSC	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	10.44	4.36e-23	1.02e-19	0.41	0.44	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
HNSC	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	10.44	4.38e-23	1.02e-19	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
HNSC	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	10.44	4.39e-23	1.02e-19	0.58	0.44	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	10.44	4.4e-23	1.02e-19	0.59	0.44	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	10.44	4.4e-23	1.02e-19	0.59	0.44	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	10.44	4.41e-23	1.02e-19	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	10.44	4.47e-23	1.04e-19	0.6	0.44	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	10.44	4.47e-23	1.04e-19	0.6	0.44	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-10.44	4.52e-23	1.05e-19	-0.54	-0.43	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
HNSC	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	10.44	4.57e-23	1.06e-19	0.53	0.43	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
HNSC	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-10.44	4.59e-23	1.06e-19	-0.58	-0.43	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	10.44	4.62e-23	1.07e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
HNSC	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-10.44	4.63e-23	1.07e-19	-0.35	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
HNSC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	10.44	4.63e-23	1.07e-19	0.54	0.43	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
HNSC	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	10.44	4.63e-23	1.07e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
HNSC	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.72e-23	1.09e-19	-0.55	-0.43	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	10.43	4.77e-23	1.1e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
HNSC	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	10.43	4.85e-23	1.12e-19	0.54	0.43	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
HNSC	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-10.43	4.92e-23	1.13e-19	-0.54	-0.43	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
HNSC	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-10.43	4.98e-23	1.15e-19	-0.58	-0.43	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-10.43	4.98e-23	1.15e-19	-0.58	-0.43	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
HNSC	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-10.43	5.04e-23	1.16e-19	-0.53	-0.43	Height;	chr11:118808920	chr11:118704607~118750263:+
HNSC	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.43	5.06e-23	1.16e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.13e-23	1.18e-19	-0.54	-0.43	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000179406.6	LINC00174	10.42	5.14e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66603522	chr7:66376044~66401338:-
HNSC	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.42	5.23e-23	1.2e-19	0.48	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
HNSC	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	10.42	5.31e-23	1.22e-19	0.57	0.43	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
HNSC	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	10.42	5.38e-23	1.24e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	10.42	5.38e-23	1.24e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
HNSC	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.47e-23	1.26e-19	-0.54	-0.43	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	10.42	5.52e-23	1.27e-19	0.59	0.43	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-10.42	5.56e-23	1.28e-19	-0.55	-0.43	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
HNSC	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-10.41	5.63e-23	1.29e-19	-0.54	-0.43	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	10.41	5.71e-23	1.31e-19	0.6	0.43	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66566965	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs801190	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66568046	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66571204	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66571411	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000179406.6	LINC00174	10.41	5.9e-23	1.35e-19	0.54	0.43	Aortic root size;	chr7:66572000	chr7:66376044~66401338:-
HNSC	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	10.41	5.92e-23	1.36e-19	0.45	0.43	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
HNSC	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	10.41	5.94e-23	1.36e-19	0.49	0.43	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
HNSC	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-10.41	6.01e-23	1.38e-19	-0.58	-0.43	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
HNSC	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-10.41	6.05e-23	1.38e-19	-0.54	-0.43	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	10.41	6.05e-23	1.38e-19	0.59	0.43	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	10.4	6.06e-23	1.39e-19	0.59	0.43	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
HNSC	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-10.4	6.08e-23	1.39e-19	-0.54	-0.43	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000179406.6	LINC00174	10.4	6.18e-23	1.41e-19	0.55	0.43	Aortic root size;	chr7:66606610	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-10.4	6.19e-23	1.42e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	10.39	6.66e-23	1.52e-19	0.49	0.43	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
HNSC	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-10.39	6.66e-23	1.52e-19	-0.46	-0.43	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
HNSC	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-10.39	6.69e-23	1.53e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
HNSC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	10.39	6.76e-23	1.54e-19	0.84	0.43	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	10.39	6.78e-23	1.55e-19	0.57	0.43	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	10.39	6.78e-23	1.55e-19	0.57	0.43	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-10.39	6.84e-23	1.56e-19	-0.53	-0.43	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
HNSC	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	10.38	7.29e-23	1.66e-19	0.56	0.43	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-10.38	7.3e-23	1.66e-19	-0.58	-0.43	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
HNSC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	10.38	7.51e-23	1.71e-19	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
HNSC	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	10.38	7.54e-23	1.72e-19	0.59	0.43	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	10.38	7.59e-23	1.73e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
HNSC	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-10.38	7.66e-23	1.75e-19	-0.54	-0.43	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.623	rs12216125	ENSG00000272462.2	U91328.19	-10.38	7.73e-23	1.76e-19	-0.45	-0.43	Height;	chr6:25997230	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-10.38	7.78e-23	1.77e-19	-0.56	-0.43	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
HNSC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	10.38	7.82e-23	1.78e-19	0.55	0.43	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
HNSC	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-10.37	7.87e-23	1.79e-19	-0.58	-0.43	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	10.37	7.93e-23	1.81e-19	0.59	0.43	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000179406.6	LINC00174	10.37	7.96e-23	1.81e-19	0.55	0.43	Aortic root size;	chr7:66581737	chr7:66376044~66401338:-
HNSC	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	10.37	8.02e-23	1.83e-19	0.49	0.43	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	10.37	8.11e-23	1.84e-19	0.55	0.43	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	10.37	8.37e-23	1.9e-19	0.56	0.43	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	10.37	8.42e-23	1.91e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
HNSC	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	10.37	8.49e-23	1.93e-19	0.54	0.43	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
HNSC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	10.36	8.61e-23	1.95e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	10.36	8.64e-23	1.96e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
HNSC	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-10.36	8.66e-23	1.96e-19	-0.46	-0.43	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
HNSC	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	10.36	8.67e-23	1.96e-19	0.59	0.43	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	10.36	8.69e-23	1.97e-19	0.48	0.43	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66749023	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2659889	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66752125	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs3800812	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66758474	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs4279493	ENSG00000179406.6	LINC00174	-10.36	8.74e-23	1.98e-19	-0.55	-0.43	Aortic root size;	chr7:66761633	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	10.36	8.8e-23	1.98e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-10.36	8.82e-23	1.99e-19	-0.59	-0.43	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000179406.6	LINC00174	-10.36	8.82e-23	1.99e-19	-0.55	-0.43	Aortic root size;	chr7:66765184	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	10.36	9.02e-23	2.03e-19	0.58	0.43	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
HNSC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	10.36	9.14e-23	2.06e-19	0.84	0.43	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
HNSC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	10.36	9.25e-23	2.08e-19	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
HNSC	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-10.36	9.27e-23	2.09e-19	-0.54	-0.43	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
HNSC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-10.36	9.27e-23	2.09e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
HNSC	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	10.35	9.29e-23	2.09e-19	0.5	0.43	Depression;	chr6:28240757	chr6:28176188~28176674:+
HNSC	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	10.35	9.47e-23	2.13e-19	0.61	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
HNSC	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	10.35	9.49e-23	2.13e-19	0.4	0.43	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
HNSC	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	10.35	9.67e-23	2.17e-19	0.57	0.43	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000179406.6	LINC00174	10.35	9.71e-23	2.18e-19	0.54	0.43	Aortic root size;	chr7:66565625	chr7:66376044~66401338:-
HNSC	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-10.35	9.71e-23	2.18e-19	-0.57	-0.43	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
HNSC	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	10.35	9.79e-23	2.2e-19	0.42	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
HNSC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	10.35	9.79e-23	2.2e-19	0.4	0.43	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
HNSC	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	10.35	9.88e-23	2.22e-19	0.62	0.43	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
HNSC	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-10.35	9.89e-23	2.22e-19	-0.54	-0.43	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	10.35	1e-22	2.25e-19	0.58	0.43	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	10.35	1.01e-22	2.26e-19	0.4	0.43	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.686	rs12210098	ENSG00000272462.2	U91328.19	-10.34	1.02e-22	2.29e-19	-0.44	-0.43	Height;	chr6:25963738	chr6:25992662~26001775:+
HNSC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	10.34	1.03e-22	2.3e-19	0.44	0.43	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
HNSC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	10.34	1.03e-22	2.31e-19	0.84	0.43	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	10.34	1.03e-22	2.32e-19	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000179406.6	LINC00174	10.34	1.04e-22	2.33e-19	0.54	0.43	Aortic root size;	chr7:66595421	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000179406.6	LINC00174	10.34	1.04e-22	2.33e-19	0.54	0.43	Aortic root size;	chr7:66598087	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	10.34	1.04e-22	2.34e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66577454	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66577989	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000179406.6	LINC00174	10.34	1.06e-22	2.38e-19	0.54	0.43	Aortic root size;	chr7:66591816	chr7:66376044~66401338:-
HNSC	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-10.34	1.07e-22	2.39e-19	-0.53	-0.43	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
HNSC	cis	rs1823913	1	rs13019004	ENSG00000227542.1	AC092614.2	10.34	1.08e-22	2.41e-19	0.5	0.43	Obesity-related traits;	chr2:191245493	chr2:191229165~191246172:-
HNSC	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
HNSC	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
HNSC	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-10.34	1.08e-22	2.42e-19	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-10.34	1.09e-22	2.45e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
HNSC	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.1e-22	2.47e-19	-0.54	-0.43	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
HNSC	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	10.33	1.11e-22	2.5e-19	0.59	0.43	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
HNSC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-10.33	1.17e-22	2.62e-19	-0.44	-0.43	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
HNSC	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	10.33	1.17e-22	2.63e-19	0.42	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	10.33	1.19e-22	2.67e-19	0.58	0.43	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	10.33	1.19e-22	2.67e-19	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
HNSC	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	10.32	1.22e-22	2.73e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
HNSC	cis	rs4972806	0.849	rs2857535	ENSG00000226363.3	HAGLROS	-10.32	1.23e-22	2.75e-19	-0.51	-0.43	IgG glycosylation;	chr2:176171483	chr2:176177717~176179008:+
HNSC	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	10.32	1.23e-22	2.75e-19	0.57	0.43	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-10.32	1.25e-22	2.78e-19	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	10.32	1.26e-22	2.8e-19	0.48	0.43	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
HNSC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	10.32	1.27e-22	2.83e-19	0.84	0.43	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
HNSC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	10.32	1.29e-22	2.87e-19	0.47	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	10.32	1.3e-22	2.89e-19	0.56	0.43	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	10.31	1.31e-22	2.91e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
HNSC	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	10.31	1.31e-22	2.92e-19	0.59	0.43	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
HNSC	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-10.31	1.32e-22	2.94e-19	-0.54	-0.43	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
HNSC	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-10.31	1.39e-22	3.09e-19	-0.56	-0.43	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
HNSC	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-10.31	1.39e-22	3.09e-19	-0.57	-0.43	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000179406.6	LINC00174	10.31	1.39e-22	3.09e-19	0.54	0.43	Aortic root size;	chr7:66589419	chr7:66376044~66401338:-
HNSC	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	10.31	1.39e-22	3.09e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
HNSC	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-10.31	1.4e-22	3.11e-19	-0.56	-0.43	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000179406.6	LINC00174	10.31	1.41e-22	3.14e-19	0.54	0.43	Aortic root size;	chr7:66624003	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-10.31	1.42e-22	3.15e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66686466	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66687725	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66692033	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707836	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66695448	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs4717310	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66696020	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66696803	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs1553609	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66732152	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs1553610	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66732246	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707845	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66733811	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707850	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66738883	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66740595	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7783924	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66744070	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7789184	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66745208	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2707854	ENSG00000179406.6	LINC00174	-10.3	1.43e-22	3.18e-19	-0.55	-0.43	Aortic root size;	chr7:66747610	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66651646	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs6975195	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66659787	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs3857688	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66662819	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2286684	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66664843	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66664856	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs10274773	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66668591	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7785213	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66673991	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs11773829	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66676087	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66682191	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2003301	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66682669	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs7788576	ENSG00000179406.6	LINC00174	10.3	1.43e-22	3.18e-19	0.55	0.43	Aortic root size;	chr7:66683315	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	10.3	1.44e-22	3.18e-19	0.57	0.43	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
HNSC	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-10.3	1.45e-22	3.21e-19	-0.56	-0.43	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
HNSC	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-10.3	1.46e-22	3.23e-19	-0.59	-0.43	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
HNSC	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	10.3	1.47e-22	3.26e-19	0.56	0.43	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
HNSC	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	10.3	1.48e-22	3.28e-19	0.61	0.43	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
HNSC	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	10.3	1.48e-22	3.29e-19	0.58	0.43	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	10.3	1.49e-22	3.29e-19	0.5	0.43	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
HNSC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-10.3	1.49e-22	3.3e-19	-0.52	-0.43	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
HNSC	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-10.3	1.52e-22	3.36e-19	-0.45	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	10.3	1.53e-22	3.39e-19	0.86	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	10.29	1.56e-22	3.45e-19	0.54	0.43	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-10.29	1.56e-22	3.46e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-10.29	1.56e-22	3.46e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-10.29	1.59e-22	3.51e-19	-0.47	-0.43	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
HNSC	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	10.29	1.59e-22	3.52e-19	0.5	0.43	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
HNSC	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	10.29	1.59e-22	3.52e-19	0.57	0.43	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs2659912	ENSG00000179406.6	LINC00174	-10.29	1.6e-22	3.53e-19	-0.55	-0.43	Aortic root size;	chr7:66693012	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	10.29	1.64e-22	3.62e-19	0.55	0.43	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
HNSC	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	10.29	1.65e-22	3.65e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
HNSC	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	10.28	1.7e-22	3.74e-19	0.57	0.43	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	10.28	1.7e-22	3.76e-19	0.55	0.43	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000179406.6	LINC00174	-10.28	1.71e-22	3.78e-19	-0.55	-0.43	Aortic root size;	chr7:66686365	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	10.28	1.72e-22	3.8e-19	0.55	0.43	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	10.28	1.72e-22	3.8e-19	0.55	0.43	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-10.28	1.74e-22	3.84e-19	-0.59	-0.43	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	10.28	1.75e-22	3.86e-19	0.59	0.43	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	10.28	1.76e-22	3.89e-19	0.5	0.43	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
HNSC	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	10.28	1.76e-22	3.89e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
HNSC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	10.28	1.8e-22	3.98e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000179406.6	LINC00174	10.28	1.81e-22	3.98e-19	0.54	0.43	Aortic root size;	chr7:66586553	chr7:66376044~66401338:-
HNSC	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	10.28	1.82e-22	4e-19	0.61	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
HNSC	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	10.27	1.84e-22	4.06e-19	0.4	0.43	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
HNSC	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	10.27	1.86e-22	4.09e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000179406.6	LINC00174	-10.27	1.87e-22	4.12e-19	-0.55	-0.43	Aortic root size;	chr7:66777606	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	10.27	1.89e-22	4.16e-19	0.47	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	10.27	1.91e-22	4.19e-19	0.58	0.43	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
HNSC	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-10.27	1.91e-22	4.2e-19	-0.47	-0.43	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
HNSC	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.96e-22	4.3e-19	-0.53	-0.43	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
HNSC	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.96e-22	4.3e-19	-0.53	-0.43	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000179406.6	LINC00174	-10.27	1.96e-22	4.3e-19	-0.55	-0.43	Aortic root size;	chr7:66777742	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	10.27	1.97e-22	4.33e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	10.26	2e-22	4.39e-19	0.59	0.43	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.26	2e-22	4.4e-19	0.54	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000179406.6	LINC00174	-10.26	2.01e-22	4.42e-19	-0.54	-0.43	Aortic root size;	chr7:66711400	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.26	2.02e-22	4.44e-19	0.56	0.43	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	10.26	2.02e-22	4.44e-19	0.57	0.43	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-10.26	2.04e-22	4.48e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
HNSC	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	10.26	2.04e-22	4.49e-19	0.52	0.43	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	10.26	2.09e-22	4.59e-19	0.58	0.43	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
HNSC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	10.26	2.12e-22	4.66e-19	0.86	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
HNSC	cis	rs6867032	0.57	rs13166888	ENSG00000249731.1	RP11-259O2.3	-10.26	2.13e-22	4.69e-19	-0.59	-0.43	Gut microbiome composition (winter);	chr5:1982852	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	10.26	2.14e-22	4.69e-19	0.57	0.43	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	10.26	2.14e-22	4.71e-19	0.54	0.43	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
HNSC	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-10.26	2.15e-22	4.72e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-10.26	2.15e-22	4.72e-19	-0.57	-0.43	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
HNSC	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-10.25	2.22e-22	4.86e-19	-0.45	-0.43	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
HNSC	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	10.25	2.25e-22	4.92e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	10.25	2.25e-22	4.92e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
HNSC	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-10.25	2.26e-22	4.95e-19	-0.53	-0.43	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
HNSC	cis	rs1933112	1	rs1024176	ENSG00000227777.1	RP4-738P11.3	-10.25	2.27e-22	4.96e-19	-0.48	-0.43	Blood protein levels;	chr1:168556865	chr1:168542737~168543354:+
HNSC	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	10.25	2.28e-22	4.99e-19	0.48	0.43	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
HNSC	cis	rs801193	1	rs2659906	ENSG00000179406.6	LINC00174	-10.25	2.28e-22	4.99e-19	-0.54	-0.43	Aortic root size;	chr7:66700323	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000179406.6	LINC00174	-10.25	2.28e-22	4.99e-19	-0.54	-0.43	Aortic root size;	chr7:66721734	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	10.24	2.38e-22	5.2e-19	0.58	0.43	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	5.22e-19	0.55	0.43	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	10.24	2.4e-22	5.25e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-10.24	2.45e-22	5.35e-19	-0.53	-0.43	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
HNSC	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	10.24	2.53e-22	5.53e-19	0.58	0.43	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.24	2.53e-22	5.53e-19	0.55	0.43	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
HNSC	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	10.24	2.55e-22	5.57e-19	0.6	0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	10.23	2.57e-22	5.61e-19	0.54	0.43	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	10.23	2.57e-22	5.61e-19	0.54	0.43	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-10.23	2.57e-22	5.61e-19	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
HNSC	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-10.23	2.61e-22	5.69e-19	-0.53	-0.43	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
HNSC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	10.23	2.66e-22	5.8e-19	0.48	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
HNSC	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	10.23	2.67e-22	5.82e-19	0.61	0.43	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-10.23	2.69e-22	5.87e-19	-0.61	-0.43	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
HNSC	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-10.23	2.7e-22	5.89e-19	-0.58	-0.43	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	10.22	2.88e-22	6.26e-19	0.57	0.43	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.9e-22	6.3e-19	-0.54	-0.43	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
HNSC	cis	rs17270561	0.779	rs1165200	ENSG00000272462.2	U91328.19	10.22	2.98e-22	6.47e-19	0.49	0.43	Iron status biomarkers;	chr6:25874984	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-10.22	3.01e-22	6.55e-19	-0.59	-0.43	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
HNSC	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-10.22	3.03e-22	6.58e-19	-0.6	-0.43	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-10.22	3.03e-22	6.59e-19	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	10.21	3.05e-22	6.64e-19	0.54	0.43	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	10.21	3.07e-22	6.67e-19	0.57	0.43	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	10.21	3.09e-22	6.71e-19	0.57	0.43	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	10.21	3.12e-22	6.77e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	10.21	3.14e-22	6.81e-19	0.61	0.43	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
HNSC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	10.21	3.17e-22	6.87e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	10.21	3.23e-22	7.01e-19	0.47	0.43	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	10.21	3.29e-22	7.13e-19	0.57	0.43	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	10.2	3.3e-22	7.16e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000179406.6	LINC00174	10.2	3.34e-22	7.24e-19	0.54	0.43	Aortic root size;	chr7:66629021	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	10.2	3.34e-22	7.24e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	10.2	3.34e-22	7.24e-19	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	10.2	3.35e-22	7.25e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000179406.6	LINC00174	-10.2	3.36e-22	7.26e-19	-0.55	-0.43	Calcium levels;	chr7:65837419	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-10.2	3.36e-22	7.26e-19	-0.51	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
HNSC	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	10.2	3.37e-22	7.29e-19	0.47	0.43	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	10.2	3.5e-22	7.56e-19	0.58	0.43	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	10.2	3.53e-22	7.63e-19	0.57	0.43	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	10.2	3.53e-22	7.63e-19	0.57	0.43	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-10.19	3.61e-22	7.8e-19	-0.53	-0.43	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	10.19	3.62e-22	7.83e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
HNSC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	10.19	3.65e-22	7.88e-19	0.83	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	10.19	3.7e-22	7.99e-19	0.55	0.43	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	10.19	3.72e-22	8.02e-19	0.49	0.43	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.19	3.76e-22	8.12e-19	0.57	0.43	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	10.19	3.77e-22	8.14e-19	0.6	0.43	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	10.19	3.77e-22	8.15e-19	0.55	0.43	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	10.19	3.84e-22	8.28e-19	0.85	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
HNSC	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	10.18	3.93e-22	8.47e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
HNSC	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-10.18	3.95e-22	8.51e-19	-0.47	-0.43	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	10.18	3.98e-22	8.59e-19	0.55	0.43	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	10.18	4e-22	8.62e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-10.18	4.08e-22	8.79e-19	-0.54	-0.43	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
HNSC	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	10.18	4.09e-22	8.82e-19	0.51	0.43	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
HNSC	cis	rs801193	1	rs62466793	ENSG00000179406.6	LINC00174	-10.17	4.25e-22	9.16e-19	-0.54	-0.43	Aortic root size;	chr7:66726530	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs62466794	ENSG00000179406.6	LINC00174	-10.17	4.25e-22	9.16e-19	-0.54	-0.43	Aortic root size;	chr7:66726592	chr7:66376044~66401338:-
HNSC	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	10.17	4.26e-22	9.16e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
HNSC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	10.17	4.26e-22	9.18e-19	0.45	0.43	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	10.17	4.27e-22	9.19e-19	0.62	0.43	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-10.17	4.28e-22	9.21e-19	-0.6	-0.43	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000179406.6	LINC00174	10.17	4.32e-22	9.28e-19	0.53	0.43	Aortic root size;	chr7:66570949	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	10.17	4.32e-22	9.28e-19	0.54	0.43	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
HNSC	cis	rs801193	1	rs10234018	ENSG00000179406.6	LINC00174	10.17	4.33e-22	9.29e-19	0.54	0.43	Aortic root size;	chr7:66681297	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	10.17	4.33e-22	9.3e-19	0.57	0.43	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	10.17	4.42e-22	9.48e-19	0.57	0.43	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000179406.6	LINC00174	-10.17	4.43e-22	9.5e-19	-0.54	-0.43	Aortic root size;	chr7:66712111	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	10.17	4.49e-22	9.63e-19	0.57	0.43	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	10.17	4.5e-22	9.66e-19	0.48	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	10.17	4.52e-22	9.69e-19	0.55	0.43	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	10.17	4.57e-22	9.79e-19	0.56	0.43	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	10.17	4.57e-22	9.79e-19	0.54	0.43	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	10.17	4.58e-22	9.8e-19	0.57	0.43	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	10.17	4.58e-22	9.81e-19	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
HNSC	cis	rs801193	1	rs3778909	ENSG00000179406.6	LINC00174	-10.16	4.72e-22	1.01e-18	-0.54	-0.43	Aortic root size;	chr7:66790659	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-10.16	4.74e-22	1.01e-18	-0.54	-0.43	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-10.16	4.74e-22	1.01e-18	-0.59	-0.43	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
HNSC	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-10.16	4.79e-22	1.02e-18	-0.47	-0.43	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-10.16	4.85e-22	1.04e-18	-0.47	-0.43	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	10.16	4.91e-22	1.05e-18	0.54	0.43	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	10.16	4.91e-22	1.05e-18	0.63	0.43	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-10.16	4.93e-22	1.05e-18	-0.53	-0.43	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
HNSC	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	10.16	4.99e-22	1.06e-18	0.57	0.43	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	10.16	4.99e-22	1.06e-18	0.57	0.43	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	10.16	4.99e-22	1.06e-18	0.39	0.43	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
HNSC	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-10.16	5e-22	1.07e-18	-0.55	-0.43	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	10.15	5.09e-22	1.09e-18	0.54	0.43	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
HNSC	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-10.15	5.19e-22	1.11e-18	-1	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	10.15	5.21e-22	1.11e-18	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
HNSC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-10.15	5.23e-22	1.11e-18	-0.52	-0.43	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	10.15	5.27e-22	1.12e-18	0.59	0.43	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
HNSC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	10.15	5.32e-22	1.13e-18	0.46	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
HNSC	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-10.15	5.37e-22	1.14e-18	-0.57	-0.43	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
HNSC	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	10.15	5.37e-22	1.14e-18	0.58	0.43	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	10.15	5.37e-22	1.14e-18	0.58	0.43	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
HNSC	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	10.15	5.44e-22	1.16e-18	0.53	0.42	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	10.15	5.44e-22	1.16e-18	0.54	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
HNSC	cis	rs17270561	0.887	rs9358870	ENSG00000272462.2	U91328.19	-10.15	5.45e-22	1.16e-18	-0.51	-0.42	Iron status biomarkers;	chr6:25718982	chr6:25992662~26001775:+
HNSC	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-10.14	5.48e-22	1.17e-18	-0.56	-0.42	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
HNSC	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	10.14	5.57e-22	1.18e-18	0.53	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	10.14	5.58e-22	1.19e-18	0.54	0.42	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	10.14	5.58e-22	1.19e-18	0.54	0.42	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	10.14	5.64e-22	1.2e-18	0.54	0.42	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	10.14	5.64e-22	1.2e-18	0.54	0.42	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	10.14	5.87e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	10.14	5.9e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	10.14	5.9e-22	1.25e-18	0.54	0.42	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	10.13	5.96e-22	1.27e-18	0.54	0.42	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	10.13	6.02e-22	1.28e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
HNSC	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	10.13	6.06e-22	1.29e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.13	6.09e-22	1.29e-18	0.54	0.42	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	10.13	6.11e-22	1.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
HNSC	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	10.13	6.15e-22	1.3e-18	0.58	0.42	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	10.13	6.16e-22	1.31e-18	0.54	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000179406.6	LINC00174	-10.13	6.18e-22	1.31e-18	-0.54	-0.42	Aortic root size;	chr7:66535945	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.13	6.23e-22	1.32e-18	0.54	0.42	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	10.13	6.25e-22	1.33e-18	0.54	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.12	6.5e-22	1.38e-18	0.54	0.42	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	10.12	6.51e-22	1.38e-18	0.49	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	10.12	6.6e-22	1.4e-18	0.54	0.42	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000179406.6	LINC00174	-10.12	6.66e-22	1.41e-18	-0.54	-0.42	Aortic root size;	chr7:66763745	chr7:66376044~66401338:-
HNSC	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	10.12	6.78e-22	1.43e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
HNSC	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	10.12	6.86e-22	1.45e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
HNSC	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	10.12	6.87e-22	1.45e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
HNSC	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	10.12	6.9e-22	1.46e-18	0.51	0.42	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	10.12	6.9e-22	1.46e-18	0.53	0.42	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.12	6.9e-22	1.46e-18	0.54	0.42	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	10.12	6.97e-22	1.47e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-10.12	6.99e-22	1.48e-18	-0.54	-0.42	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.12	7e-22	1.48e-18	0.55	0.42	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	10.11	7.06e-22	1.49e-18	0.55	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
HNSC	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	10.11	7.07e-22	1.49e-18	0.57	0.42	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
HNSC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-10.11	7.11e-22	1.5e-18	-0.49	-0.42	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
HNSC	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	10.11	7.23e-22	1.53e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
HNSC	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	10.11	7.35e-22	1.55e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	10.11	7.41e-22	1.56e-18	0.53	0.42	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	10.11	7.41e-22	1.56e-18	0.53	0.42	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	10.11	7.46e-22	1.57e-18	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	10.11	7.51e-22	1.58e-18	0.53	0.42	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
HNSC	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	10.11	7.52e-22	1.58e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
HNSC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-10.11	7.62e-22	1.6e-18	-0.53	-0.42	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
HNSC	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	10.1	7.67e-22	1.61e-18	0.48	0.42	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
HNSC	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-10.1	7.72e-22	1.63e-18	-0.49	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
HNSC	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	10.1	7.83e-22	1.65e-18	0.57	0.42	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	10.1	7.83e-22	1.65e-18	0.57	0.42	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-10.1	7.88e-22	1.66e-18	-0.6	-0.42	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-10.1	7.91e-22	1.66e-18	-0.72	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
HNSC	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-10.1	7.98e-22	1.68e-18	-0.47	-0.42	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	10.1	8.01e-22	1.69e-18	0.54	0.42	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
HNSC	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	10.1	8.11e-22	1.71e-18	0.52	0.42	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
HNSC	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	10.1	8.26e-22	1.74e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	10.1	8.26e-22	1.74e-18	0.6	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
HNSC	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	10.09	8.42e-22	1.77e-18	0.57	0.42	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
HNSC	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-10.09	8.45e-22	1.78e-18	-0.51	-0.42	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
HNSC	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	10.09	8.46e-22	1.78e-18	0.51	0.42	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
HNSC	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-10.09	8.48e-22	1.78e-18	-0.63	-0.42	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
HNSC	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-10.09	8.52e-22	1.79e-18	-0.51	-0.42	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
HNSC	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	10.09	8.54e-22	1.8e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	10.09	8.54e-22	1.8e-18	0.46	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
HNSC	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-10.09	8.55e-22	1.8e-18	-0.52	-0.42	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
HNSC	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	10.09	8.56e-22	1.8e-18	0.55	0.42	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	10.09	8.58e-22	1.8e-18	0.56	0.42	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	10.09	8.65e-22	1.82e-18	0.57	0.42	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000179406.6	LINC00174	-10.09	8.66e-22	1.82e-18	-0.54	-0.42	Aortic root size;	chr7:65827777	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	10.09	8.66e-22	1.82e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
HNSC	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-10.09	8.76e-22	1.84e-18	-0.46	-0.42	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
HNSC	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	10.09	8.92e-22	1.87e-18	0.55	0.42	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
HNSC	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-10.09	9.02e-22	1.89e-18	-0.51	-0.42	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	10.08	9.08e-22	1.91e-18	0.54	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	10.08	9.13e-22	1.92e-18	0.58	0.42	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	10.08	9.16e-22	1.92e-18	0.59	0.42	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.08	9.24e-22	1.94e-18	0.56	0.42	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000179406.6	LINC00174	10.08	9.25e-22	1.94e-18	0.53	0.42	Aortic root size;	chr7:66633495	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000179406.6	LINC00174	10.08	9.25e-22	1.94e-18	0.53	0.42	Aortic root size;	chr7:66638707	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	10.08	9.27e-22	1.94e-18	0.82	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000179406.6	LINC00174	-10.08	9.28e-22	1.95e-18	-0.54	-0.42	Aortic root size;	chr7:66517181	chr7:66376044~66401338:-
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	10.08	9.32e-22	1.95e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	10.08	9.33e-22	1.96e-18	0.53	0.42	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
HNSC	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-10.08	9.39e-22	1.97e-18	-0.46	-0.42	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
HNSC	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	10.08	9.44e-22	1.98e-18	0.46	0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	10.08	9.5e-22	1.99e-18	0.58	0.42	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
HNSC	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	10.07	9.98e-22	2.09e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	10.07	1e-21	2.1e-18	0.53	0.42	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.07	1e-21	2.1e-18	0.55	0.42	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
HNSC	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	10.07	1e-21	2.1e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
HNSC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	10.07	1.01e-21	2.11e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-10.07	1.02e-21	2.13e-18	-0.53	-0.42	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
HNSC	cis	rs1933112	1	rs2223583	ENSG00000227777.1	RP4-738P11.3	-10.07	1.03e-21	2.15e-18	-0.47	-0.42	Blood protein levels;	chr1:168556178	chr1:168542737~168543354:+
HNSC	cis	rs1933112	0.966	rs4656605	ENSG00000227777.1	RP4-738P11.3	-10.07	1.03e-21	2.15e-18	-0.47	-0.42	Blood protein levels;	chr1:168556659	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	10.07	1.03e-21	2.16e-18	0.53	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
HNSC	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-10.07	1.05e-21	2.2e-18	-0.46	-0.42	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
HNSC	cis	rs12594515	0.548	rs55932467	ENSG00000273972.1	CTD-2306A12.1	-10.07	1.05e-21	2.2e-18	-0.58	-0.42	Weight;Waist circumference;	chr15:45704926	chr15:45702640~45703183:+
HNSC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	10.07	1.06e-21	2.2e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
HNSC	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	10.06	1.09e-21	2.27e-18	0.53	0.42	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
HNSC	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	10.06	1.1e-21	2.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
HNSC	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-10.06	1.15e-21	2.39e-18	-0.52	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
HNSC	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-10.06	1.15e-21	2.4e-18	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
HNSC	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	10.05	1.18e-21	2.46e-18	0.55	0.42	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	10.05	1.19e-21	2.47e-18	0.56	0.42	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	10.05	1.19e-21	2.47e-18	0.56	0.42	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.05	1.2e-21	2.49e-18	0.53	0.42	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-10.05	1.2e-21	2.49e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.05	1.2e-21	2.5e-18	0.54	0.42	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
HNSC	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	10.05	1.21e-21	2.51e-18	0.51	0.42	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
HNSC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-10.05	1.23e-21	2.55e-18	-0.8	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.55e-18	0.54	0.42	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.05	1.23e-21	2.56e-18	0.53	0.42	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	10.05	1.24e-21	2.57e-18	0.54	0.42	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	10.05	1.24e-21	2.57e-18	0.54	0.42	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	10.05	1.25e-21	2.6e-18	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.58	0.42	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.57	0.42	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	10.05	1.25e-21	2.6e-18	0.57	0.42	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	10.05	1.25e-21	2.6e-18	0.54	0.42	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	10.04	1.26e-21	2.62e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
HNSC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-10.04	1.27e-21	2.63e-18	-0.82	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
HNSC	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	10.04	1.27e-21	2.64e-18	0.52	0.42	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
HNSC	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	10.04	1.27e-21	2.64e-18	0.53	0.42	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
HNSC	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-10.04	1.29e-21	2.67e-18	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
HNSC	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	10.04	1.29e-21	2.67e-18	0.55	0.42	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	10.04	1.3e-21	2.69e-18	0.53	0.42	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
HNSC	cis	rs35955747	0.539	rs738685	ENSG00000236132.1	CTA-440B3.1	10.04	1.3e-21	2.7e-18	0.46	0.42	Neutrophil count;Sum basophil neutrophil counts;	chr22:31636292	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	10.04	1.31e-21	2.72e-18	0.54	0.42	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
HNSC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-10.04	1.32e-21	2.73e-18	-0.81	-0.42	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	10.04	1.36e-21	2.82e-18	0.53	0.42	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
HNSC	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	10.03	1.37e-21	2.85e-18	0.52	0.42	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
HNSC	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-10.03	1.39e-21	2.88e-18	-0.54	-0.42	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	10.03	1.4e-21	2.9e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	10.03	1.4e-21	2.9e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
HNSC	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-10.03	1.4e-21	2.9e-18	-0.41	-0.42	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
HNSC	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	10.03	1.41e-21	2.92e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.93e-18	0.53	0.42	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	10.03	1.42e-21	2.93e-18	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	10.03	1.42e-21	2.94e-18	0.53	0.42	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	10.03	1.43e-21	2.95e-18	0.53	0.42	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	10.03	1.45e-21	2.99e-18	0.53	0.42	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	10.03	1.45e-21	2.99e-18	0.53	0.42	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	10.03	1.47e-21	3.05e-18	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	10.03	1.49e-21	3.07e-18	0.53	0.42	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	10.03	1.49e-21	3.07e-18	0.47	0.42	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
HNSC	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-10.02	1.5e-21	3.1e-18	-0.47	-0.42	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-10.02	1.5e-21	3.1e-18	-0.47	-0.42	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
HNSC	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-10.02	1.51e-21	3.12e-18	-0.34	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	10.02	1.51e-21	3.12e-18	0.61	0.42	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	10.02	1.51e-21	3.12e-18	0.61	0.42	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	10.02	1.53e-21	3.16e-18	0.56	0.42	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	10.02	1.56e-21	3.22e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	10.02	1.56e-21	3.22e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.02	1.57e-21	3.24e-18	0.53	0.42	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
HNSC	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-10.02	1.57e-21	3.24e-18	-0.51	-0.42	Height;	chr11:118781100	chr11:118704607~118750263:+
HNSC	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	10.02	1.57e-21	3.24e-18	0.34	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
HNSC	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	10.02	1.57e-21	3.25e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
HNSC	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	10.02	1.58e-21	3.26e-18	0.69	0.42	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.02	1.59e-21	3.27e-18	0.54	0.42	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	10.02	1.6e-21	3.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	10.02	1.6e-21	3.3e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	10.02	1.6e-21	3.3e-18	0.55	0.42	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
HNSC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-10.02	1.62e-21	3.33e-18	-0.54	-0.42	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000179406.6	LINC00174	-10.01	1.63e-21	3.36e-18	-0.54	-0.42	Calcium levels;	chr7:65892789	chr7:66376044~66401338:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-10.01	1.66e-21	3.41e-18	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
HNSC	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-10.01	1.7e-21	3.49e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000179406.6	LINC00174	-10.01	1.72e-21	3.53e-18	-0.54	-0.42	Calcium levels;	chr7:65853042	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000179406.6	LINC00174	-10.01	1.73e-21	3.56e-18	-0.54	-0.42	Calcium levels;	chr7:65872915	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	10	1.76e-21	3.62e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	10	1.76e-21	3.62e-18	0.53	0.42	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
HNSC	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	10	1.77e-21	3.63e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
HNSC	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	10	1.77e-21	3.63e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
HNSC	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-10	1.77e-21	3.63e-18	-0.34	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	10	1.8e-21	3.69e-18	0.53	0.42	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	10	1.8e-21	3.69e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
HNSC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	10	1.82e-21	3.74e-18	0.81	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
HNSC	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-10	1.83e-21	3.75e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
HNSC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-10	1.83e-21	3.76e-18	-0.54	-0.42	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
HNSC	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	10	1.84e-21	3.77e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	10	1.84e-21	3.77e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
HNSC	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10	1.88e-21	3.86e-18	-1.06	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
HNSC	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	9.99	1.92e-21	3.94e-18	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	9.99	1.94e-21	3.96e-18	0.53	0.42	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	9.99	1.94e-21	3.98e-18	0.57	0.42	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
HNSC	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	9.99	1.95e-21	3.99e-18	0.5	0.42	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
HNSC	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	9.99	1.96e-21	4.01e-18	0.71	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
HNSC	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-9.99	1.96e-21	4.01e-18	-0.39	-0.42	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	9.99	1.96e-21	4.02e-18	0.53	0.42	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
HNSC	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	9.99	1.98e-21	4.04e-18	0.57	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
HNSC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	9.99	1.98e-21	4.05e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	9.99	1.98e-21	4.05e-18	0.86	0.42	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
HNSC	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	9.99	1.98e-21	4.06e-18	0.53	0.42	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	9.99	1.99e-21	4.07e-18	0.53	0.42	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	9.99	2.01e-21	4.11e-18	0.53	0.42	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	9.99	2.02e-21	4.12e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
HNSC	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	9.99	2.04e-21	4.16e-18	0.54	0.42	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-9.99	2.05e-21	4.18e-18	-0.51	-0.42	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	9.99	2.05e-21	4.19e-18	0.53	0.42	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	9.99	2.05e-21	4.19e-18	0.53	0.42	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-9.98	2.14e-21	4.36e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
HNSC	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-9.98	2.15e-21	4.38e-18	-0.56	-0.42	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
HNSC	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	9.98	2.15e-21	4.4e-18	0.59	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000179406.6	LINC00174	9.98	2.17e-21	4.42e-18	0.53	0.42	Aortic root size;	chr7:66666129	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2659909	ENSG00000179406.6	LINC00174	-9.98	2.17e-21	4.42e-18	-0.53	-0.42	Aortic root size;	chr7:66695292	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	9.98	2.18e-21	4.44e-18	0.53	0.42	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
HNSC	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	9.98	2.2e-21	4.49e-18	0.53	0.42	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	9.98	2.21e-21	4.51e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	9.98	2.22e-21	4.53e-18	0.54	0.42	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	9.98	2.23e-21	4.54e-18	0.59	0.42	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
HNSC	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	9.98	2.23e-21	4.55e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
HNSC	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-9.98	2.23e-21	4.55e-18	-0.39	-0.42	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-9.98	2.24e-21	4.56e-18	-0.58	-0.42	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
HNSC	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	9.98	2.26e-21	4.6e-18	0.57	0.42	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	9.97	2.27e-21	4.62e-18	0.46	0.42	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
HNSC	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-9.97	2.27e-21	4.62e-18	-0.58	-0.42	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-9.97	2.27e-21	4.63e-18	-0.53	-0.42	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.97	2.3e-21	4.68e-18	0.53	0.42	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-9.97	2.32e-21	4.72e-18	-0.54	-0.42	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-9.97	2.34e-21	4.76e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.54	0.42	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.53	0.42	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	9.97	2.43e-21	4.94e-18	0.53	0.42	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	9.97	2.44e-21	4.96e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	9.97	2.44e-21	4.96e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	9.97	2.45e-21	4.97e-18	0.61	0.42	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
HNSC	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-9.96	2.48e-21	5.04e-18	-0.51	-0.42	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
HNSC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-9.96	2.51e-21	5.09e-18	-0.54	-0.42	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
HNSC	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	9.96	2.55e-21	5.17e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	9.96	2.56e-21	5.19e-18	0.53	0.42	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	9.96	2.56e-21	5.19e-18	0.53	0.42	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	9.96	2.57e-21	5.23e-18	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	9.96	2.6e-21	5.27e-18	0.47	0.42	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-9.96	2.61e-21	5.29e-18	-0.48	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
HNSC	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	9.96	2.61e-21	5.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	9.96	2.61e-21	5.3e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	9.96	2.62e-21	5.31e-18	0.53	0.42	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	9.96	2.64e-21	5.35e-18	0.87	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	9.96	2.66e-21	5.39e-18	0.6	0.42	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	9.96	2.66e-21	5.39e-18	0.58	0.42	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	9.96	2.66e-21	5.39e-18	0.54	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-9.95	2.68e-21	5.43e-18	-0.51	-0.42	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000179406.6	LINC00174	9.95	2.7e-21	5.46e-18	0.53	0.42	Aortic root size;	chr7:66642265	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	9.95	2.7e-21	5.47e-18	0.53	0.42	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
HNSC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-9.95	2.72e-21	5.5e-18	-0.52	-0.42	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.95	2.72e-21	5.5e-18	0.53	0.42	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	9.95	2.82e-21	5.7e-18	0.42	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	9.94	2.92e-21	5.9e-18	0.41	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	9.94	2.92e-21	5.91e-18	0.53	0.42	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	9.94	2.97e-21	5.99e-18	0.54	0.42	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
HNSC	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
HNSC	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	9.94	2.99e-21	6.03e-18	0.54	0.42	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
HNSC	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	9.94	3e-21	6.06e-18	0.75	0.42	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	9.94	3.04e-21	6.14e-18	0.52	0.42	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	9.94	3.05e-21	6.15e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	9.94	3.05e-21	6.16e-18	0.53	0.42	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
HNSC	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-9.94	3.06e-21	6.17e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
HNSC	cis	rs1933112	1	rs1933112	ENSG00000227777.1	RP4-738P11.3	-9.94	3.07e-21	6.2e-18	-0.47	-0.42	Blood protein levels;	chr1:168552179	chr1:168542737~168543354:+
HNSC	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	9.93	3.15e-21	6.36e-18	0.57	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	9.93	3.22e-21	6.49e-18	0.46	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
HNSC	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-9.93	3.22e-21	6.49e-18	-0.33	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-9.93	3.35e-21	6.75e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
HNSC	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	9.93	3.36e-21	6.76e-18	0.88	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
HNSC	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	9.93	3.38e-21	6.8e-18	0.53	0.42	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	9.93	3.38e-21	6.81e-18	0.53	0.42	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
HNSC	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	9.93	3.38e-21	6.81e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	9.93	3.39e-21	6.82e-18	0.55	0.42	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	9.93	3.39e-21	6.82e-18	0.55	0.42	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
HNSC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-9.93	3.4e-21	6.84e-18	-0.56	-0.42	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
HNSC	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	9.92	3.47e-21	6.98e-18	0.75	0.42	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-9.92	3.53e-21	7.1e-18	-0.52	-0.42	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
HNSC	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-9.92	3.54e-21	7.11e-18	-0.49	-0.42	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
HNSC	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	9.92	3.67e-21	7.37e-18	0.63	0.42	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
HNSC	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	9.91	3.73e-21	7.48e-18	0.38	0.42	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-9.91	3.74e-21	7.52e-18	-0.59	-0.42	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	9.91	3.78e-21	7.59e-18	0.52	0.42	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-9.91	3.78e-21	7.59e-18	-0.53	-0.42	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs10753777	ENSG00000227777.1	RP4-738P11.3	-9.91	3.8e-21	7.63e-18	-0.47	-0.42	Blood protein levels;	chr1:168558549	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	9.91	3.85e-21	7.73e-18	0.52	0.42	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	9.91	3.86e-21	7.73e-18	0.53	0.42	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
HNSC	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-9.91	3.87e-21	7.75e-18	-0.53	-0.42	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-9.91	3.95e-21	7.92e-18	-0.53	-0.42	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
HNSC	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	9.91	4.01e-21	8.03e-18	0.53	0.42	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
HNSC	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-9.91	4.03e-21	8.06e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
HNSC	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	9.9	4.03e-21	8.07e-18	0.39	0.42	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.9	4.04e-21	8.09e-18	0.54	0.42	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	9.9	4.12e-21	8.23e-18	0.53	0.42	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	9.9	4.15e-21	8.3e-18	0.53	0.42	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.9	4.15e-21	8.3e-18	0.53	0.42	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000179406.6	LINC00174	-9.9	4.19e-21	8.38e-18	-0.53	-0.42	Aortic root size;	chr7:65827018	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	9.9	4.2e-21	8.39e-18	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	9.9	4.23e-21	8.46e-18	0.55	0.42	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
HNSC	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-9.9	4.24e-21	8.47e-18	-0.63	-0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	9.9	4.26e-21	8.5e-18	0.53	0.42	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	9.9	4.29e-21	8.55e-18	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	9.9	4.29e-21	8.55e-18	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.89	4.4e-21	8.77e-18	0.54	0.42	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
HNSC	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-9.89	4.47e-21	8.92e-18	-0.92	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
HNSC	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	9.89	4.48e-21	8.93e-18	0.56	0.42	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
HNSC	cis	rs1933112	1	rs1024177	ENSG00000227777.1	RP4-738P11.3	-9.89	4.48e-21	8.94e-18	-0.47	-0.42	Blood protein levels;	chr1:168557477	chr1:168542737~168543354:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000179406.6	LINC00174	9.89	4.5e-21	8.97e-18	0.53	0.42	Calcium levels;	chr7:65808508	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	9.89	4.62e-21	9.2e-18	0.5	0.42	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	9.89	4.74e-21	9.42e-18	0.78	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	9.88	4.76e-21	9.47e-18	0.53	0.42	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	9.88	4.76e-21	9.47e-18	0.53	0.42	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	9.88	4.8e-21	9.53e-18	0.56	0.42	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	9.88	4.8e-21	9.53e-18	0.56	0.42	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
HNSC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-9.88	4.83e-21	9.6e-18	-0.55	-0.42	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
HNSC	cis	rs17711722	1	rs17711722	ENSG00000179406.6	LINC00174	9.88	4.83e-21	9.6e-18	0.54	0.42	Calcium levels;	chr7:65806210	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.88	4.85e-21	9.64e-18	0.54	0.42	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
HNSC	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	9.88	4.89e-21	9.72e-18	0.55	0.42	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	9.88	4.92e-21	9.77e-18	0.48	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
HNSC	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	9.88	4.95e-21	9.83e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	9.88	4.95e-21	9.83e-18	0.46	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.88	5.03e-21	9.98e-18	0.54	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	9.88	5.06e-21	1e-17	0.46	0.42	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	9.88	5.08e-21	1.01e-17	0.6	0.42	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-9.88	5.09e-21	1.01e-17	-0.82	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
HNSC	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	9.88	5.09e-21	1.01e-17	0.63	0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
HNSC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	9.88	5.11e-21	1.01e-17	0.56	0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
HNSC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	9.88	5.12e-21	1.01e-17	0.59	0.42	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
HNSC	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	9.88	5.15e-21	1.02e-17	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
HNSC	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-9.87	5.18e-21	1.03e-17	-0.55	-0.42	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
HNSC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-9.87	5.18e-21	1.03e-17	-0.53	-0.42	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
HNSC	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	9.87	5.23e-21	1.04e-17	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
HNSC	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	9.87	5.24e-21	1.04e-17	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
HNSC	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	9.87	5.25e-21	1.04e-17	0.53	0.42	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
HNSC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	9.87	5.27e-21	1.04e-17	0.46	0.42	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
HNSC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-9.87	5.32e-21	1.05e-17	-0.5	-0.42	Height;	chr11:118809363	chr11:118704607~118750263:+
HNSC	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	9.87	5.36e-21	1.06e-17	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	9.87	5.38e-21	1.07e-17	0.53	0.42	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	9.87	5.39e-21	1.07e-17	0.54	0.42	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
HNSC	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	9.87	5.46e-21	1.08e-17	0.5	0.42	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	9.87	5.46e-21	1.08e-17	0.5	0.42	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	9.87	5.46e-21	1.08e-17	0.54	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	9.87	5.46e-21	1.08e-17	0.54	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	9.87	5.48e-21	1.08e-17	0.46	0.42	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	9.87	5.49e-21	1.09e-17	0.53	0.42	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
HNSC	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	9.87	5.53e-21	1.09e-17	0.74	0.42	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-9.87	5.59e-21	1.11e-17	-0.64	-0.42	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
HNSC	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-9.86	5.62e-21	1.11e-17	-0.51	-0.42	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-9.86	5.62e-21	1.11e-17	-0.51	-0.42	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
HNSC	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	9.86	5.64e-21	1.11e-17	0.54	0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	9.86	5.65e-21	1.12e-17	0.59	0.42	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	9.86	5.7e-21	1.12e-17	0.53	0.42	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	9.86	5.7e-21	1.12e-17	0.53	0.42	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	9.86	5.7e-21	1.12e-17	0.56	0.42	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	9.86	5.71e-21	1.13e-17	0.53	0.42	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	9.86	5.71e-21	1.13e-17	0.53	0.42	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
HNSC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	9.86	5.77e-21	1.14e-17	0.83	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	9.86	5.89e-21	1.16e-17	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	9.86	5.92e-21	1.17e-17	0.55	0.42	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	9.86	6.05e-21	1.19e-17	0.52	0.41	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs1933109	ENSG00000227777.1	RP4-738P11.3	-9.86	6.07e-21	1.2e-17	-0.47	-0.41	Blood protein levels;	chr1:168554386	chr1:168542737~168543354:+
HNSC	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	9.85	6.14e-21	1.21e-17	0.5	0.41	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-9.85	6.14e-21	1.21e-17	-0.5	-0.41	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	9.85	6.26e-21	1.23e-17	0.53	0.41	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	9.85	6.26e-21	1.23e-17	0.53	0.41	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	9.85	6.31e-21	1.24e-17	0.53	0.41	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	9.85	6.31e-21	1.24e-17	0.52	0.41	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	9.85	6.31e-21	1.24e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.85	6.35e-21	1.25e-17	0.54	0.41	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-9.85	6.37e-21	1.25e-17	-0.59	-0.41	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-9.85	6.37e-21	1.25e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
HNSC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	9.85	6.37e-21	1.25e-17	0.6	0.41	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000179406.6	LINC00174	-9.85	6.44e-21	1.27e-17	-0.53	-0.41	Aortic root size;	chr7:66376994	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	9.85	6.44e-21	1.27e-17	0.57	0.41	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	9.85	6.55e-21	1.29e-17	0.53	0.41	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
HNSC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
HNSC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
HNSC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-9.85	6.58e-21	1.29e-17	-0.55	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
HNSC	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	9.84	6.67e-21	1.31e-17	0.78	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
HNSC	cis	rs1933112	1	rs1933110	ENSG00000227777.1	RP4-738P11.3	-9.84	6.69e-21	1.31e-17	-0.47	-0.41	Blood protein levels;	chr1:168554217	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	9.84	6.78e-21	1.33e-17	0.59	0.41	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
HNSC	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-9.84	6.91e-21	1.35e-17	-0.52	-0.41	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	9.84	6.92e-21	1.36e-17	0.5	0.41	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
HNSC	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	9.84	6.93e-21	1.36e-17	0.56	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
HNSC	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	9.84	6.96e-21	1.37e-17	0.45	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
HNSC	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	9.84	6.97e-21	1.37e-17	0.4	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
HNSC	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-9.83	7.26e-21	1.42e-17	-0.63	-0.41	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.83	7.36e-21	1.44e-17	0.54	0.41	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-9.83	7.37e-21	1.44e-17	-0.52	-0.41	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	9.83	7.39e-21	1.45e-17	0.53	0.41	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	9.83	7.47e-21	1.46e-17	0.53	0.41	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000179406.6	LINC00174	-9.83	7.53e-21	1.47e-17	-0.53	-0.41	Aortic root size;	chr7:65930047	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	9.83	7.59e-21	1.48e-17	0.48	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
HNSC	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-9.82	7.83e-21	1.53e-17	-0.48	-0.41	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000179406.6	LINC00174	-9.82	7.84e-21	1.53e-17	-0.53	-0.41	Calcium levels;	chr7:65903721	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	9.82	7.92e-21	1.55e-17	0.53	0.41	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	9.82	7.92e-21	1.55e-17	0.53	0.41	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-9.82	7.96e-21	1.55e-17	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-9.82	8.1e-21	1.58e-17	-0.53	-0.41	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	9.82	8.15e-21	1.59e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
HNSC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	9.82	8.16e-21	1.59e-17	0.43	0.41	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-9.82	8.19e-21	1.6e-17	-0.49	-0.41	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
HNSC	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	9.82	8.25e-21	1.61e-17	0.4	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000179406.6	LINC00174	-9.82	8.26e-21	1.61e-17	-0.53	-0.41	Aortic root size;	chr7:65871069	chr7:66376044~66401338:-
HNSC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-9.82	8.27e-21	1.61e-17	-0.43	-0.41	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
HNSC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	9.82	8.42e-21	1.64e-17	0.47	0.41	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
HNSC	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	9.82	8.42e-21	1.64e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
HNSC	cis	rs1933112	1	rs1933104	ENSG00000227777.1	RP4-738P11.3	-9.81	8.54e-21	1.67e-17	-0.47	-0.41	Blood protein levels;	chr1:168559648	chr1:168542737~168543354:+
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	9.81	8.67e-21	1.69e-17	0.52	0.41	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-9.81	8.71e-21	1.7e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	9.81	8.84e-21	1.72e-17	0.52	0.41	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	9.81	8.84e-21	1.72e-17	0.52	0.41	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-9.81	8.85e-21	1.72e-17	-0.43	-0.41	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	9.81	9.08e-21	1.77e-17	0.5	0.41	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
HNSC	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	9.8	9.3e-21	1.81e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.8	9.34e-21	1.82e-17	0.54	0.41	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	9.8	9.35e-21	1.82e-17	0.53	0.41	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	9.8	9.45e-21	1.84e-17	0.53	0.41	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-9.8	9.5e-21	1.85e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
HNSC	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-9.8	9.5e-21	1.85e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
HNSC	cis	rs6867032	0.958	rs9312970	ENSG00000249731.1	RP11-259O2.3	-9.8	9.64e-21	1.87e-17	-0.51	-0.41	Gut microbiome composition (winter);	chr5:2002301	chr5:1968094~1969013:+
HNSC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	9.8	9.77e-21	1.9e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000179406.6	LINC00174	-9.8	9.87e-21	1.92e-17	-0.52	-0.41	Aortic root size;	chr7:66407695	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	9.79	1e-20	1.94e-17	0.38	0.41	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	9.79	1e-20	1.94e-17	0.53	0.41	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
HNSC	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-9.79	1.02e-20	1.98e-17	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	9.79	1.02e-20	1.98e-17	0.54	0.41	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
HNSC	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-9.79	1.03e-20	2e-17	-0.93	-0.41	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-9.79	1.03e-20	2.01e-17	-0.51	-0.41	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	9.79	1.06e-20	2.06e-17	0.44	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	9.79	1.07e-20	2.08e-17	0.53	0.41	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs10918925	ENSG00000227777.1	RP4-738P11.3	9.79	1.07e-20	2.08e-17	0.47	0.41	Blood protein levels;	chr1:168556009	chr1:168542737~168543354:+
HNSC	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	9.78	1.09e-20	2.11e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	9.78	1.1e-20	2.13e-17	0.53	0.41	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.78	1.1e-20	2.13e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
HNSC	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	9.78	1.11e-20	2.14e-17	0.55	0.41	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	9.78	1.13e-20	2.18e-17	0.53	0.41	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	9.78	1.13e-20	2.19e-17	0.52	0.41	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	9.78	1.14e-20	2.2e-17	0.46	0.41	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
HNSC	cis	rs11763147	1	rs11763147	ENSG00000179406.6	LINC00174	9.78	1.16e-20	2.25e-17	0.53	0.41	Corneal structure;	chr7:65861834	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	9.78	1.17e-20	2.27e-17	0.53	0.41	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	9.78	1.17e-20	2.27e-17	0.52	0.41	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	9.78	1.17e-20	2.27e-17	0.52	0.41	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	9.78	1.17e-20	2.27e-17	0.52	0.41	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
HNSC	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	9.77	1.18e-20	2.29e-17	0.39	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
HNSC	cis	rs1933112	1	rs2179500	ENSG00000227777.1	RP4-738P11.3	-9.77	1.18e-20	2.29e-17	-0.47	-0.41	Blood protein levels;	chr1:168546589	chr1:168542737~168543354:+
HNSC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-9.77	1.19e-20	2.29e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
HNSC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-9.77	1.2e-20	2.31e-17	-0.53	-0.41	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
HNSC	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-9.77	1.2e-20	2.31e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
HNSC	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	9.77	1.22e-20	2.36e-17	0.57	0.41	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
HNSC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	9.77	1.24e-20	2.39e-17	0.47	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
HNSC	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-9.77	1.27e-20	2.45e-17	-0.49	-0.41	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
HNSC	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-9.77	1.28e-20	2.46e-17	-0.49	-0.41	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
HNSC	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-9.76	1.29e-20	2.48e-17	-0.55	-0.41	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	9.76	1.29e-20	2.49e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
HNSC	cis	rs6867032	0.917	rs10474733	ENSG00000249731.1	RP11-259O2.3	-9.76	1.3e-20	2.51e-17	-0.51	-0.41	Gut microbiome composition (winter);	chr5:2004046	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	9.76	1.32e-20	2.54e-17	0.52	0.41	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	9.76	1.33e-20	2.56e-17	0.47	0.41	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	9.76	1.33e-20	2.57e-17	0.55	0.41	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	9.76	1.34e-20	2.58e-17	0.52	0.41	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	9.76	1.34e-20	2.59e-17	0.41	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-9.76	1.35e-20	2.6e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
HNSC	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	9.76	1.35e-20	2.6e-17	0.51	0.41	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
HNSC	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-9.76	1.37e-20	2.63e-17	-0.33	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
HNSC	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-9.76	1.38e-20	2.66e-17	-0.49	-0.41	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	9.75	1.39e-20	2.67e-17	0.53	0.41	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	9.75	1.42e-20	2.73e-17	0.53	0.41	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
HNSC	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-9.75	1.44e-20	2.77e-17	-0.55	-0.41	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-9.75	1.46e-20	2.8e-17	-0.55	-0.41	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
HNSC	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	9.75	1.46e-20	2.81e-17	0.87	0.41	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	9.75	1.48e-20	2.85e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
HNSC	cis	rs1933112	1	rs7529824	ENSG00000227777.1	RP4-738P11.3	-9.74	1.52e-20	2.92e-17	-0.47	-0.41	Blood protein levels;	chr1:168531220	chr1:168542737~168543354:+
HNSC	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	9.74	1.55e-20	2.97e-17	0.53	0.41	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-9.74	1.55e-20	2.97e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	9.74	1.56e-20	2.99e-17	0.52	0.41	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-9.74	1.56e-20	3e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-9.74	1.56e-20	3e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	9.73	1.64e-20	3.14e-17	0.52	0.41	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	9.73	1.65e-20	3.16e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	9.73	1.65e-20	3.17e-17	0.52	0.41	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
HNSC	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-9.73	1.68e-20	3.21e-17	-0.44	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
HNSC	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-9.73	1.69e-20	3.23e-17	-0.49	-0.41	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	9.73	1.71e-20	3.27e-17	0.51	0.41	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
HNSC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	9.73	1.73e-20	3.31e-17	0.59	0.41	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.73	1.74e-20	3.32e-17	0.61	0.41	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-9.73	1.75e-20	3.35e-17	-0.59	-0.41	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	9.72	1.79e-20	3.42e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	9.72	1.79e-20	3.42e-17	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	9.72	1.8e-20	3.43e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
HNSC	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-9.72	1.82e-20	3.48e-17	-0.54	-0.41	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	9.72	1.86e-20	3.54e-17	0.53	0.41	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	9.72	1.87e-20	3.57e-17	0.53	0.41	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	9.72	1.89e-20	3.6e-17	0.45	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-9.72	1.9e-20	3.63e-17	-0.63	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000179406.6	LINC00174	-9.71	1.93e-20	3.67e-17	-0.52	-0.41	Calcium levels;	chr7:65975383	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000179406.6	LINC00174	-9.71	1.97e-20	3.75e-17	-0.53	-0.41	Aortic root size;	chr7:65832759	chr7:66376044~66401338:-
HNSC	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-9.71	2.02e-20	3.85e-17	-0.54	-0.41	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
HNSC	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-9.71	2.02e-20	3.85e-17	-0.54	-0.41	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-9.71	2.03e-20	3.86e-17	-0.52	-0.41	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	9.71	2.06e-20	3.91e-17	0.52	0.41	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	9.71	2.06e-20	3.91e-17	0.52	0.41	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	9.71	2.08e-20	3.96e-17	0.52	0.41	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	9.71	2.08e-20	3.96e-17	0.52	0.41	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	9.71	2.08e-20	3.96e-17	0.51	0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	9.7	2.17e-20	4.13e-17	0.52	0.41	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.7	2.2e-20	4.18e-17	0.53	0.41	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	9.7	2.2e-20	4.18e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-9.7	2.2e-20	4.18e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-9.7	2.2e-20	4.18e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
HNSC	cis	rs1933112	1	rs2223582	ENSG00000227777.1	RP4-738P11.3	-9.7	2.24e-20	4.24e-17	-0.47	-0.41	Blood protein levels;	chr1:168537297	chr1:168542737~168543354:+
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	9.69	2.27e-20	4.29e-17	0.55	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	9.69	2.32e-20	4.39e-17	0.52	0.41	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	9.69	2.32e-20	4.39e-17	0.52	0.41	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	9.69	2.39e-20	4.51e-17	0.46	0.41	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
HNSC	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-9.69	2.43e-20	4.58e-17	-0.48	-0.41	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
HNSC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-9.69	2.43e-20	4.6e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.46e-20	4.64e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
HNSC	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-9.68	2.48e-20	4.68e-17	-0.77	-0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
HNSC	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	9.68	2.48e-20	4.69e-17	0.44	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-9.68	2.48e-20	4.69e-17	-0.42	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
HNSC	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-9.68	2.5e-20	4.72e-17	-0.5	-0.41	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
HNSC	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	9.68	2.52e-20	4.76e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	9.68	2.64e-20	4.97e-17	0.51	0.41	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
HNSC	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	9.68	2.65e-20	5e-17	0.52	0.41	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
HNSC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	9.67	2.68e-20	5.05e-17	0.6	0.41	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
HNSC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.69e-20	5.07e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000179406.6	LINC00174	-9.67	2.74e-20	5.16e-17	-0.52	-0.41	Aortic root size;	chr7:65943052	chr7:66376044~66401338:-
HNSC	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	9.67	2.79e-20	5.25e-17	0.73	0.41	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
HNSC	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	9.67	2.81e-20	5.29e-17	0.51	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	9.67	2.86e-20	5.38e-17	0.46	0.41	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
HNSC	cis	rs1933112	1	rs7514168	ENSG00000227777.1	RP4-738P11.3	-9.67	2.86e-20	5.38e-17	-0.46	-0.41	Blood protein levels;	chr1:168561499	chr1:168542737~168543354:+
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-9.66	2.93e-20	5.5e-17	-0.56	-0.41	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	9.66	3.01e-20	5.64e-17	0.52	0.41	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	9.66	3.01e-20	5.64e-17	0.46	0.41	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.66	3.07e-20	5.76e-17	0.57	0.41	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
HNSC	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	9.66	3.1e-20	5.82e-17	0.56	0.41	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
HNSC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	9.66	3.11e-20	5.83e-17	0.59	0.41	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-9.65	3.16e-20	5.92e-17	-0.6	-0.41	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
HNSC	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	9.65	3.17e-20	5.95e-17	0.39	0.41	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-9.65	3.19e-20	5.97e-17	-0.52	-0.41	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
HNSC	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	9.65	3.26e-20	6.11e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
HNSC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-9.65	3.26e-20	6.11e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	9.65	3.28e-20	6.15e-17	0.52	0.41	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	9.65	3.28e-20	6.15e-17	0.52	0.41	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
HNSC	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	9.65	3.3e-20	6.18e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
HNSC	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	9.65	3.3e-20	6.18e-17	0.45	0.41	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-9.65	3.3e-20	6.18e-17	-0.58	-0.41	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
HNSC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	9.65	3.31e-20	6.19e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
HNSC	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	9.65	3.33e-20	6.22e-17	0.46	0.41	Temperament;	chr17:13996939	chr17:14024514~14025488:+
HNSC	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	9.65	3.39e-20	6.35e-17	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	9.64	3.41e-20	6.37e-17	0.44	0.41	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
HNSC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-9.64	3.41e-20	6.38e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-9.64	3.48e-20	6.5e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
HNSC	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-9.64	3.51e-20	6.57e-17	-0.48	-0.41	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-9.64	3.51e-20	6.57e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	9.64	3.54e-20	6.61e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000179406.6	LINC00174	-9.64	3.54e-20	6.62e-17	-0.52	-0.41	Aortic root size;	chr7:65931217	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	9.64	3.56e-20	6.64e-17	0.52	0.41	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	9.64	3.6e-20	6.73e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	9.64	3.62e-20	6.76e-17	0.52	0.41	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	9.64	3.62e-20	6.76e-17	0.52	0.41	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-9.64	3.65e-20	6.82e-17	-0.52	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
HNSC	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-9.64	3.66e-20	6.83e-17	-0.44	-0.41	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
HNSC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-9.63	3.79e-20	7.06e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-9.63	3.84e-20	7.15e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	9.63	3.84e-20	7.16e-17	0.52	0.41	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000179406.6	LINC00174	9.63	3.97e-20	7.39e-17	0.52	0.41	Aortic root size;	chr7:66301001	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	9.62	4.02e-20	7.48e-17	0.56	0.41	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	9.62	4.07e-20	7.57e-17	0.51	0.41	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000179406.6	LINC00174	9.62	4.09e-20	7.61e-17	0.52	0.41	Aortic root size;	chr7:66682114	chr7:66376044~66401338:-
HNSC	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-9.62	4.18e-20	7.77e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-9.62	4.18e-20	7.77e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000179406.6	LINC00174	-9.62	4.3e-20	8e-17	-0.53	-0.41	Aortic root size;	chr7:65963835	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	9.61	4.42e-20	8.21e-17	0.53	0.41	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-9.61	4.42e-20	8.21e-17	-0.4	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
HNSC	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-9.61	4.44e-20	8.25e-17	-0.49	-0.41	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-9.61	4.47e-20	8.29e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	9.61	4.53e-20	8.41e-17	0.51	0.41	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-9.61	4.66e-20	8.65e-17	-0.59	-0.41	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
HNSC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-9.61	4.69e-20	8.69e-17	-0.41	-0.41	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
HNSC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.6	4.71e-20	8.72e-17	-0.42	-0.41	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.6	4.71e-20	8.73e-17	0.42	0.41	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
HNSC	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	9.6	4.73e-20	8.76e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-9.6	4.78e-20	8.86e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-9.6	4.78e-20	8.86e-17	-0.53	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	9.6	4.82e-20	8.93e-17	0.62	0.41	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
HNSC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	9.6	4.83e-20	8.94e-17	0.45	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
HNSC	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-9.6	4.87e-20	9.01e-17	-0.49	-0.41	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
HNSC	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-9.6	4.9e-20	9.06e-17	-0.46	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	9.6	4.9e-20	9.06e-17	0.51	0.41	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-9.6	4.91e-20	9.08e-17	-0.47	-0.41	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
HNSC	cis	rs1933112	0.808	rs55863344	ENSG00000227777.1	RP4-738P11.3	-9.6	4.91e-20	9.08e-17	-0.47	-0.41	Blood protein levels;	chr1:168542884	chr1:168542737~168543354:+
HNSC	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	9.6	4.91e-20	9.08e-17	0.63	0.41	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
HNSC	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-9.59	5.11e-20	9.45e-17	-0.48	-0.41	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	9.59	5.18e-20	9.57e-17	0.39	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
HNSC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-9.59	5.26e-20	9.72e-17	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
HNSC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-9.59	5.27e-20	9.74e-17	-0.46	-0.41	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
HNSC	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	9.59	5.32e-20	9.82e-17	0.44	0.41	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
HNSC	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-9.59	5.35e-20	9.88e-17	-0.46	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
HNSC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	9.59	5.37e-20	9.92e-17	0.41	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	9.59	5.41e-20	9.98e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-9.59	5.44e-20	1e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
HNSC	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-9.59	5.46e-20	1.01e-16	-0.54	-0.41	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
HNSC	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	9.58	5.57e-20	1.03e-16	0.49	0.41	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
HNSC	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-9.58	5.58e-20	1.03e-16	-0.56	-0.41	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
HNSC	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-9.58	5.6e-20	1.03e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-9.58	5.6e-20	1.03e-16	-0.47	-0.41	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
HNSC	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.58	5.61e-20	1.03e-16	-0.44	-0.41	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
HNSC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-9.58	5.62e-20	1.03e-16	-0.42	-0.41	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
HNSC	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	9.58	5.69e-20	1.05e-16	0.44	0.41	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
HNSC	cis	rs1933112	0.9	rs7519937	ENSG00000227777.1	RP4-738P11.3	-9.58	5.88e-20	1.08e-16	-0.47	-0.41	Blood protein levels;	chr1:168535403	chr1:168542737~168543354:+
HNSC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-9.58	5.99e-20	1.1e-16	-0.51	-0.41	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-9.58	5.99e-20	1.1e-16	-0.46	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	9.57	6.04e-20	1.11e-16	0.46	0.41	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
HNSC	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-9.57	6.19e-20	1.14e-16	-0.44	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
HNSC	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	9.57	6.2e-20	1.14e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
HNSC	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	9.57	6.22e-20	1.14e-16	0.44	0.4	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000179406.6	LINC00174	9.57	6.26e-20	1.15e-16	0.51	0.4	Aortic root size;	chr7:66682123	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	9.57	6.31e-20	1.16e-16	0.4	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	9.56	6.52e-20	1.2e-16	0.53	0.4	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000179406.6	LINC00174	9.56	6.56e-20	1.2e-16	0.51	0.4	Aortic root size;	chr7:66039646	chr7:66376044~66401338:-
HNSC	cis	rs1933112	1	rs1323534	ENSG00000227777.1	RP4-738P11.3	-9.56	6.58e-20	1.21e-16	-0.47	-0.4	Blood protein levels;	chr1:168534039	chr1:168542737~168543354:+
HNSC	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	9.56	6.61e-20	1.21e-16	0.87	0.4	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	9.56	6.62e-20	1.22e-16	0.44	0.4	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9.56	6.63e-20	1.22e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
HNSC	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-9.56	6.68e-20	1.23e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9.56	6.78e-20	1.24e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
HNSC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-9.56	6.84e-20	1.26e-16	-0.56	-0.4	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
HNSC	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-9.56	6.85e-20	1.26e-16	-0.56	-0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
HNSC	cis	rs875971	0.522	rs781144	ENSG00000179406.6	LINC00174	-9.56	6.86e-20	1.26e-16	-0.51	-0.4	Aortic root size;	chr7:65975357	chr7:66376044~66401338:-
HNSC	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	9.56	6.89e-20	1.26e-16	0.52	0.4	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
HNSC	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-9.56	6.9e-20	1.26e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
HNSC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	9.56	6.95e-20	1.27e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000179406.6	LINC00174	-9.56	7.01e-20	1.28e-16	-0.52	-0.4	Calcium levels;	chr7:65996954	chr7:66376044~66401338:-
HNSC	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	9.56	7.03e-20	1.29e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	9.55	7.17e-20	1.31e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
HNSC	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-9.55	7.18e-20	1.32e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
HNSC	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.55	7.21e-20	1.32e-16	0.46	0.4	Depression;	chr6:28327262	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-9.55	7.33e-20	1.34e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-9.55	7.41e-20	1.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-9.55	7.41e-20	1.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
HNSC	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	9.55	7.44e-20	1.36e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
HNSC	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-9.55	7.48e-20	1.37e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
HNSC	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	9.55	7.5e-20	1.37e-16	0.52	0.4	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
HNSC	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	9.55	7.56e-20	1.38e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
HNSC	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-9.55	7.57e-20	1.38e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000179406.6	LINC00174	9.55	7.62e-20	1.39e-16	0.52	0.4	Aortic root size;	chr7:65800193	chr7:66376044~66401338:-
HNSC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-9.54	7.64e-20	1.39e-16	-0.46	-0.4	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
HNSC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-9.54	7.79e-20	1.42e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000179406.6	LINC00174	9.54	7.91e-20	1.44e-16	0.51	0.4	Aortic root size;	chr7:66174736	chr7:66376044~66401338:-
HNSC	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.54	7.99e-20	1.46e-16	0.52	0.4	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000179406.6	LINC00174	-9.54	8.05e-20	1.47e-16	-0.51	-0.4	Aortic root size;	chr7:65966699	chr7:66376044~66401338:-
HNSC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	9.54	8.06e-20	1.47e-16	0.54	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
HNSC	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-9.54	8.11e-20	1.48e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
HNSC	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	9.54	8.11e-20	1.48e-16	0.47	0.4	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	9.54	8.14e-20	1.48e-16	0.51	0.4	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-9.54	8.17e-20	1.49e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	9.54	8.18e-20	1.49e-16	0.51	0.4	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	9.53	8.47e-20	1.54e-16	0.52	0.4	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
HNSC	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-9.53	8.47e-20	1.54e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
HNSC	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-9.53	8.47e-20	1.54e-16	-0.53	-0.4	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
HNSC	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-9.53	8.47e-20	1.54e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	9.53	8.55e-20	1.55e-16	0.51	0.4	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	9.53	8.61e-20	1.56e-16	0.52	0.4	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
HNSC	cis	rs1933112	1	rs1040509	ENSG00000227777.1	RP4-738P11.3	-9.53	8.63e-20	1.57e-16	-0.45	-0.4	Blood protein levels;	chr1:168531746	chr1:168542737~168543354:+
HNSC	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.53	8.66e-20	1.57e-16	-0.47	-0.4	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
HNSC	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	9.53	8.74e-20	1.59e-16	0.44	0.4	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
HNSC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-9.53	8.76e-20	1.59e-16	-0.52	-0.4	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	9.53	8.78e-20	1.6e-16	0.56	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
HNSC	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-9.53	8.83e-20	1.6e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
HNSC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	9.53	8.94e-20	1.62e-16	0.57	0.4	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
HNSC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	9.53	8.94e-20	1.62e-16	0.54	0.4	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	9.53	8.95e-20	1.62e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
HNSC	cis	rs801193	1	rs13239306	ENSG00000179406.6	LINC00174	9.53	8.97e-20	1.63e-16	0.52	0.4	Aortic root size;	chr7:66671030	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-9.53	8.97e-20	1.63e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
HNSC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.52	9.01e-20	1.63e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
HNSC	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	9.52	9.12e-20	1.65e-16	0.48	0.4	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	9.52	9.16e-20	1.66e-16	0.52	0.4	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-9.52	9.19e-20	1.67e-16	-0.46	-0.4	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
HNSC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	9.52	9.28e-20	1.68e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	9.52	9.44e-20	1.71e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000179406.6	LINC00174	-9.52	9.44e-20	1.71e-16	-0.52	-0.4	Calcium levels;	chr7:65974892	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000179406.6	LINC00174	-9.52	9.45e-20	1.71e-16	-0.51	-0.4	Aortic root size;	chr7:66771620	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	9.52	9.47e-20	1.71e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
HNSC	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-9.52	9.47e-20	1.71e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-9.52	9.47e-20	1.71e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
HNSC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	9.52	9.54e-20	1.73e-16	0.68	0.4	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-9.52	9.69e-20	1.75e-16	-0.6	-0.4	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-9.52	9.69e-20	1.75e-16	-0.6	-0.4	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
HNSC	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-9.51	9.82e-20	1.78e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-9.51	9.9e-20	1.79e-16	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
HNSC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-9.51	9.9e-20	1.79e-16	-0.51	-0.4	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
HNSC	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.51	9.95e-20	1.8e-16	-0.44	-0.4	Temperament;	chr17:14007232	chr17:14024514~14025488:+
HNSC	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	9.51	1.03e-19	1.87e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
HNSC	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.51	1.04e-19	1.88e-16	0.49	0.4	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66042405	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66048109	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000179406.6	LINC00174	9.51	1.04e-19	1.88e-16	0.51	0.4	Aortic root size;	chr7:66048321	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	9.51	1.04e-19	1.89e-16	0.52	0.4	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
HNSC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-9.51	1.05e-19	1.89e-16	-0.37	-0.4	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
HNSC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	9.51	1.05e-19	1.9e-16	0.51	0.4	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	9.51	1.05e-19	1.9e-16	0.44	0.4	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
HNSC	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	9.51	1.05e-19	1.9e-16	0.43	0.4	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
HNSC	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-9.5	1.06e-19	1.91e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	9.5	1.06e-19	1.92e-16	0.6	0.4	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
HNSC	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	9.5	1.07e-19	1.93e-16	0.43	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000179406.6	LINC00174	9.5	1.07e-19	1.93e-16	0.51	0.4	Aortic root size;	chr7:66144830	chr7:66376044~66401338:-
HNSC	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-9.5	1.07e-19	1.94e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
HNSC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	9.5	1.11e-19	2e-16	0.52	0.4	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
HNSC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-9.5	1.11e-19	2e-16	-0.42	-0.4	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	9.5	1.13e-19	2.03e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
HNSC	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	9.5	1.13e-19	2.04e-16	0.47	0.4	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
HNSC	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	9.49	1.17e-19	2.11e-16	0.43	0.4	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
HNSC	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	9.49	1.17e-19	2.12e-16	0.49	0.4	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-9.49	1.18e-19	2.12e-16	-0.58	-0.4	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
HNSC	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	9.49	1.19e-19	2.15e-16	0.5	0.4	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	9.49	1.19e-19	2.15e-16	0.51	0.4	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	9.49	1.24e-19	2.23e-16	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
HNSC	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-9.48	1.24e-19	2.23e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-9.48	1.24e-19	2.23e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
HNSC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-9.48	1.27e-19	2.29e-16	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
HNSC	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-9.48	1.28e-19	2.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
HNSC	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-9.48	1.29e-19	2.31e-16	-0.46	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
HNSC	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-9.48	1.29e-19	2.32e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-9.48	1.29e-19	2.32e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-9.48	1.3e-19	2.34e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
HNSC	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-9.48	1.32e-19	2.37e-16	-0.5	-0.4	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
HNSC	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-9.48	1.34e-19	2.4e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.651	rs313829	ENSG00000179406.6	LINC00174	9.48	1.34e-19	2.41e-16	0.59	0.4	Aortic root size;	chr7:66087510	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000173295.6	FAM86B3P	9.48	1.34e-19	2.41e-16	0.45	0.4	Mood instability;	chr8:8279561	chr8:8228595~8244865:+
HNSC	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	9.47	1.35e-19	2.43e-16	0.48	0.4	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
HNSC	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	9.47	1.38e-19	2.48e-16	0.59	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
HNSC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	9.47	1.39e-19	2.49e-16	0.53	0.4	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	9.47	1.4e-19	2.51e-16	0.72	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
HNSC	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	9.47	1.4e-19	2.51e-16	0.72	0.4	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	9.47	1.42e-19	2.55e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
HNSC	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-9.47	1.43e-19	2.57e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	9.47	1.44e-19	2.58e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	9.47	1.45e-19	2.59e-16	0.51	0.4	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
HNSC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.47	1.45e-19	2.59e-16	0.52	0.4	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	9.47	1.45e-19	2.6e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
HNSC	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	9.46	1.48e-19	2.65e-16	0.52	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	9.46	1.48e-19	2.66e-16	0.51	0.4	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
HNSC	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.46	1.49e-19	2.66e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
HNSC	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-9.46	1.5e-19	2.69e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	9.46	1.52e-19	2.72e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
HNSC	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-9.46	1.52e-19	2.72e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	9.46	1.54e-19	2.76e-16	0.53	0.4	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
HNSC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.46	1.55e-19	2.76e-16	-0.42	-0.4	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.46	1.55e-19	2.76e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
HNSC	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-9.45	1.59e-19	2.84e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
HNSC	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-9.45	1.59e-19	2.84e-16	-0.58	-0.4	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	9.45	1.6e-19	2.86e-16	0.56	0.4	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
HNSC	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-9.45	1.62e-19	2.88e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
HNSC	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	9.45	1.64e-19	2.92e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
HNSC	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	9.45	1.64e-19	2.92e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
HNSC	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-9.45	1.65e-19	2.94e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	9.45	1.65e-19	2.94e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	9.45	1.65e-19	2.94e-16	0.5	0.4	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
HNSC	cis	rs6867032	0.874	rs4975786	ENSG00000249731.1	RP11-259O2.3	-9.45	1.69e-19	3.01e-16	-0.52	-0.4	Gut microbiome composition (winter);	chr5:2004610	chr5:1968094~1969013:+
HNSC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	9.45	1.7e-19	3.03e-16	0.41	0.4	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	9.45	1.7e-19	3.03e-16	0.41	0.4	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
HNSC	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-9.44	1.73e-19	3.07e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	9.44	1.76e-19	3.13e-16	0.51	0.4	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	9.44	1.78e-19	3.17e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-9.44	1.81e-19	3.21e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
HNSC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.44	1.81e-19	3.22e-16	-0.42	-0.4	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
HNSC	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	9.44	1.83e-19	3.26e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	9.44	1.83e-19	3.26e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
HNSC	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-9.43	1.85e-19	3.3e-16	-0.52	-0.4	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
HNSC	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-9.43	1.86e-19	3.3e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
HNSC	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	9.43	1.86e-19	3.31e-16	0.46	0.4	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
HNSC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-9.43	1.88e-19	3.33e-16	-0.47	-0.4	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	9.43	1.92e-19	3.42e-16	0.52	0.4	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	9.43	1.93e-19	3.43e-16	0.57	0.4	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000173295.6	FAM86B3P	9.43	1.96e-19	3.47e-16	0.45	0.4	Mood instability;	chr8:8283379	chr8:8228595~8244865:+
HNSC	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-9.43	1.96e-19	3.47e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	9.43	1.96e-19	3.47e-16	0.45	0.4	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
HNSC	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	9.43	1.96e-19	3.48e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	9.43	1.96e-19	3.48e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000179406.6	LINC00174	-9.43	1.99e-19	3.52e-16	-0.5	-0.4	Aortic root size;	chr7:66688114	chr7:66376044~66401338:-
HNSC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-9.42	2.03e-19	3.6e-16	-0.38	-0.4	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-9.42	2.03e-19	3.6e-16	-0.38	-0.4	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	9.42	2.04e-19	3.6e-16	0.45	0.4	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
HNSC	cis	rs6867032	0.839	rs4314451	ENSG00000249731.1	RP11-259O2.3	-9.42	2.04e-19	3.61e-16	-0.51	-0.4	Gut microbiome composition (winter);	chr5:2001745	chr5:1968094~1969013:+
HNSC	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	9.42	2.08e-19	3.68e-16	0.39	0.4	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
HNSC	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-9.42	2.09e-19	3.7e-16	-0.53	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
HNSC	cis	rs801193	1	rs17566701	ENSG00000179406.6	LINC00174	-9.42	2.09e-19	3.7e-16	-0.51	-0.4	Aortic root size;	chr7:66728196	chr7:66376044~66401338:-
HNSC	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	9.42	2.1e-19	3.72e-16	0.49	0.4	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
HNSC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	9.42	2.12e-19	3.75e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
HNSC	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-9.42	2.15e-19	3.8e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-9.42	2.15e-19	3.8e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
HNSC	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	9.41	2.17e-19	3.84e-16	0.52	0.4	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
HNSC	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-9.41	2.18e-19	3.85e-16	-0.58	-0.4	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
HNSC	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-9.41	2.26e-19	3.99e-16	-0.46	-0.4	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
HNSC	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-9.41	2.26e-19	4e-16	-0.38	-0.4	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
HNSC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-9.41	2.28e-19	4.02e-16	-0.5	-0.4	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
HNSC	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-9.41	2.32e-19	4.09e-16	-0.38	-0.4	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
HNSC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	9.41	2.34e-19	4.13e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
HNSC	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-9.41	2.35e-19	4.14e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
HNSC	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	9.4	2.4e-19	4.23e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
HNSC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-9.4	2.46e-19	4.33e-16	-0.5	-0.4	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
HNSC	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-9.4	2.46e-19	4.34e-16	-0.52	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
HNSC	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-9.4	2.47e-19	4.35e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
HNSC	cis	rs5769707	0.935	rs739239	ENSG00000188511.11	C22orf34	9.4	2.49e-19	4.38e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49414524~49657542:-
HNSC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.4	2.5e-19	4.4e-16	-0.42	-0.4	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
HNSC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	9.4	2.51e-19	4.42e-16	0.52	0.4	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
HNSC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-9.4	2.52e-19	4.43e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
HNSC	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	9.39	2.59e-19	4.55e-16	0.5	0.4	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
HNSC	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-9.39	2.59e-19	4.55e-16	-0.52	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-9.39	2.61e-19	4.6e-16	-0.51	-0.4	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
HNSC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	9.39	2.63e-19	4.63e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
HNSC	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-9.39	2.67e-19	4.69e-16	-0.54	-0.4	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
HNSC	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	9.39	2.72e-19	4.78e-16	0.58	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
HNSC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	9.38	2.76e-19	4.85e-16	0.45	0.4	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	9.38	2.77e-19	4.87e-16	0.45	0.4	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	9.38	2.78e-19	4.88e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	9.38	2.79e-19	4.89e-16	0.53	0.4	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
HNSC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.38	2.8e-19	4.91e-16	-0.41	-0.4	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
HNSC	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	9.38	2.83e-19	4.95e-16	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
HNSC	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-9.38	2.83e-19	4.96e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-9.38	2.85e-19	4.99e-16	-0.51	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
HNSC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	9.38	2.86e-19	5e-16	0.56	0.4	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000179406.6	LINC00174	9.38	2.86e-19	5.01e-16	0.51	0.4	Aortic root size;	chr7:66113790	chr7:66376044~66401338:-
HNSC	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-9.38	2.88e-19	5.04e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
HNSC	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	9.38	2.92e-19	5.11e-16	0.45	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
HNSC	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-9.37	3.11e-19	5.43e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
HNSC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.37	3.13e-19	5.47e-16	-0.41	-0.4	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-9.37	3.17e-19	5.54e-16	-0.56	-0.4	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
HNSC	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	9.37	3.22e-19	5.62e-16	0.43	0.4	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
HNSC	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	9.37	3.22e-19	5.62e-16	0.37	0.4	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
HNSC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.36	3.24e-19	5.66e-16	-0.41	-0.4	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
HNSC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	9.36	3.28e-19	5.73e-16	0.44	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
HNSC	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	9.36	3.31e-19	5.77e-16	0.43	0.4	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	9.36	3.31e-19	5.77e-16	0.43	0.4	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.874	rs9616714	ENSG00000188511.11	C22orf34	9.36	3.32e-19	5.79e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49414524~49657542:-
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	9.36	3.35e-19	5.84e-16	0.53	0.4	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
HNSC	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-9.36	3.37e-19	5.88e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-9.36	3.4e-19	5.93e-16	-0.46	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-9.36	3.4e-19	5.93e-16	-0.46	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.36	3.44e-19	5.99e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	9.36	3.47e-19	6.04e-16	0.43	0.4	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
HNSC	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-9.36	3.5e-19	6.09e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000179406.6	LINC00174	-9.35	3.51e-19	6.11e-16	-0.5	-0.4	Aortic root size;	chr7:65967557	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	9.35	3.52e-19	6.13e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
HNSC	cis	rs6867032	0.917	rs10474734	ENSG00000249731.1	RP11-259O2.3	9.35	3.55e-19	6.17e-16	0.5	0.4	Gut microbiome composition (winter);	chr5:2004094	chr5:1968094~1969013:+
HNSC	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-9.35	3.55e-19	6.17e-16	-0.47	-0.4	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-9.35	3.57e-19	6.21e-16	-0.5	-0.4	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
HNSC	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	9.35	3.58e-19	6.21e-16	0.47	0.4	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	9.35	3.58e-19	6.21e-16	0.47	0.4	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
HNSC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	9.35	3.6e-19	6.25e-16	0.54	0.4	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
HNSC	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-9.35	3.61e-19	6.28e-16	-0.44	-0.4	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
HNSC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.35	3.62e-19	6.29e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-9.35	3.68e-19	6.39e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
HNSC	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	9.35	3.68e-19	6.4e-16	0.38	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
HNSC	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	9.35	3.7e-19	6.41e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	9.35	3.7e-19	6.41e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
HNSC	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	9.35	3.7e-19	6.41e-16	0.45	0.4	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
HNSC	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.35	3.7e-19	6.42e-16	-0.43	-0.4	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
HNSC	cis	rs6867032	0.834	rs4526149	ENSG00000249731.1	RP11-259O2.3	-9.35	3.71e-19	6.43e-16	-0.53	-0.4	Gut microbiome composition (winter);	chr5:1990052	chr5:1968094~1969013:+
HNSC	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	9.35	3.73e-19	6.47e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
HNSC	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-9.35	3.79e-19	6.58e-16	-0.5	-0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
HNSC	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	9.34	3.8e-19	6.59e-16	0.47	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
HNSC	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-9.34	3.89e-19	6.74e-16	-0.52	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
HNSC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.34	3.95e-19	6.84e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
HNSC	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	9.34	3.97e-19	6.87e-16	0.45	0.4	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-9.34	3.97e-19	6.88e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-9.34	3.97e-19	6.88e-16	-0.43	-0.4	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
HNSC	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-9.34	3.98e-19	6.88e-16	-0.45	-0.4	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
HNSC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-9.34	4.01e-19	6.93e-16	-0.47	-0.4	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
HNSC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	9.34	4.03e-19	6.96e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
HNSC	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	9.34	4.06e-19	7.02e-16	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	9.34	4.06e-19	7.02e-16	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000179406.6	LINC00174	9.34	4.09e-19	7.07e-16	0.5	0.4	Aortic root size;	chr7:66032447	chr7:66376044~66401338:-
HNSC	cis	rs801193	1	rs2055682	ENSG00000179406.6	LINC00174	-9.33	4.11e-19	7.1e-16	-0.51	-0.4	Aortic root size;	chr7:66795302	chr7:66376044~66401338:-
HNSC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	9.33	4.13e-19	7.14e-16	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	9.33	4.14e-19	7.15e-16	0.43	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
HNSC	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-9.33	4.16e-19	7.17e-16	-0.51	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
HNSC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
HNSC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.33	4.21e-19	7.26e-16	-0.41	-0.4	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
HNSC	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	9.33	4.37e-19	7.53e-16	0.51	0.4	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
HNSC	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-9.33	4.4e-19	7.58e-16	-0.48	-0.4	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
HNSC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	9.33	4.4e-19	7.58e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
HNSC	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	9.33	4.43e-19	7.64e-16	0.43	0.4	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
HNSC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.33	4.45e-19	7.66e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
HNSC	cis	rs4972806	0.775	rs2857534	ENSG00000226363.3	HAGLROS	-9.32	4.52e-19	7.79e-16	-0.47	-0.4	IgG glycosylation;	chr2:176170948	chr2:176177717~176179008:+
HNSC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	9.32	4.55e-19	7.82e-16	0.55	0.4	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
HNSC	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-9.32	4.63e-19	7.96e-16	-0.44	-0.4	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.32	4.68e-19	8.04e-16	-0.44	-0.4	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	9.32	4.69e-19	8.06e-16	0.39	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
HNSC	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-9.32	4.75e-19	8.15e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
HNSC	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-9.32	4.82e-19	8.27e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
HNSC	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-9.31	4.85e-19	8.32e-16	-0.52	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
HNSC	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-9.31	4.93e-19	8.46e-16	-0.49	-0.4	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
HNSC	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	9.31	4.97e-19	8.52e-16	0.48	0.4	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	9.31	5e-19	8.58e-16	0.5	0.4	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	9.31	5e-19	8.58e-16	0.5	0.4	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
HNSC	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-9.31	5.03e-19	8.63e-16	-0.45	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
HNSC	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-9.31	5.07e-19	8.68e-16	-0.43	-0.4	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
HNSC	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	9.31	5.09e-19	8.72e-16	0.48	0.4	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
HNSC	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-9.31	5.1e-19	8.73e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
HNSC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-9.31	5.11e-19	8.75e-16	-0.77	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
HNSC	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-9.31	5.13e-19	8.78e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	9.31	5.2e-19	8.91e-16	0.43	0.4	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
HNSC	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	9.31	5.21e-19	8.92e-16	0.51	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
HNSC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	9.3	5.25e-19	8.98e-16	0.52	0.4	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	9.3	5.26e-19	8.98e-16	0.5	0.4	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
HNSC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-9.3	5.27e-19	9.01e-16	-0.46	-0.4	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
HNSC	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-9.3	5.34e-19	9.12e-16	-0.38	-0.4	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
HNSC	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-9.3	5.39e-19	9.2e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-9.3	5.39e-19	9.2e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
HNSC	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-9.3	5.42e-19	9.25e-16	-0.59	-0.4	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-9.3	5.42e-19	9.25e-16	-0.59	-0.4	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
HNSC	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-9.3	5.52e-19	9.42e-16	-0.42	-0.4	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
HNSC	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-9.3	5.54e-19	9.45e-16	-0.56	-0.4	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
HNSC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.3	5.55e-19	9.47e-16	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-9.3	5.56e-19	9.48e-16	-0.46	-0.4	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
HNSC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	9.3	5.58e-19	9.51e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
HNSC	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	9.29	5.66e-19	9.64e-16	0.46	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
HNSC	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-9.29	5.83e-19	9.93e-16	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
HNSC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	9.29	5.91e-19	1.01e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
HNSC	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-9.29	5.99e-19	1.02e-15	-0.47	-0.39	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	9.29	6.05e-19	1.03e-15	0.53	0.39	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-9.28	6.16e-19	1.05e-15	-0.54	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
HNSC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	9.28	6.18e-19	1.05e-15	0.6	0.39	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
HNSC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.28	6.19e-19	1.05e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	9.28	6.24e-19	1.06e-15	0.52	0.39	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
HNSC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	9.28	6.32e-19	1.07e-15	0.52	0.39	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
HNSC	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-9.28	6.32e-19	1.07e-15	-0.43	-0.39	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-9.28	6.32e-19	1.07e-15	-0.43	-0.39	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
HNSC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	9.28	6.41e-19	1.09e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
HNSC	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	9.28	6.42e-19	1.09e-15	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
HNSC	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	9.28	6.44e-19	1.09e-15	0.42	0.39	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	9.28	6.47e-19	1.1e-15	0.51	0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-9.28	6.47e-19	1.1e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
HNSC	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-9.28	6.54e-19	1.11e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
HNSC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.28	6.61e-19	1.12e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
HNSC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	9.27	6.63e-19	1.12e-15	0.52	0.39	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
HNSC	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	9.27	6.68e-19	1.13e-15	0.76	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
HNSC	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-9.27	6.7e-19	1.14e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-9.27	6.7e-19	1.14e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
HNSC	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	9.27	6.76e-19	1.15e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
HNSC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	9.27	6.84e-19	1.16e-15	0.59	0.39	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
HNSC	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-9.27	6.85e-19	1.16e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
HNSC	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-9.27	6.85e-19	1.16e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
HNSC	cis	rs16885979	1	rs17682328	ENSG00000224984.1	RP11-524H19.2	-9.27	6.92e-19	1.17e-15	-0.99	-0.39	Daytime sleep phenotypes;	chr6:54845278	chr6:54840118~54840855:-
HNSC	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-9.27	6.92e-19	1.17e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
HNSC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-9.27	7.02e-19	1.19e-15	-0.45	-0.39	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
HNSC	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	9.27	7.05e-19	1.19e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	9.27	7.05e-19	1.19e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
HNSC	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	9.27	7.07e-19	1.2e-15	0.59	0.39	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
HNSC	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-9.27	7.1e-19	1.2e-15	-0.47	-0.39	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
HNSC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-9.26	7.2e-19	1.22e-15	-0.41	-0.39	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
HNSC	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	9.26	7.2e-19	1.22e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
HNSC	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-9.26	7.28e-19	1.23e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
HNSC	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-9.26	7.36e-19	1.24e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
HNSC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	9.26	7.42e-19	1.25e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-9.26	7.52e-19	1.27e-15	-0.56	-0.39	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
HNSC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	9.26	7.63e-19	1.29e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-9.26	7.67e-19	1.29e-15	-0.56	-0.39	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-9.26	7.67e-19	1.29e-15	-0.56	-0.39	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
HNSC	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-9.26	7.75e-19	1.31e-15	-0.38	-0.39	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
HNSC	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	9.25	7.76e-19	1.31e-15	0.48	0.39	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
HNSC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	9.25	7.76e-19	1.31e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-9.25	7.94e-19	1.34e-15	-0.51	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
HNSC	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	9.25	8e-19	1.35e-15	0.43	0.39	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
HNSC	cis	rs6867032	0.527	rs4371796	ENSG00000249731.1	RP11-259O2.3	-9.25	8.03e-19	1.35e-15	-0.58	-0.39	Gut microbiome composition (winter);	chr5:1977671	chr5:1968094~1969013:+
HNSC	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	9.25	8.13e-19	1.37e-15	0.5	0.39	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-9.25	8.2e-19	1.38e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
HNSC	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-9.25	8.24e-19	1.39e-15	-0.54	-0.39	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
HNSC	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-9.25	8.33e-19	1.4e-15	-0.47	-0.39	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
HNSC	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	9.25	8.39e-19	1.41e-15	0.43	0.39	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
HNSC	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-9.24	8.41e-19	1.42e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000179406.6	LINC00174	-9.24	8.47e-19	1.43e-15	-0.51	-0.39	Calcium levels;	chr7:65941231	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-9.24	8.49e-19	1.43e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-9.24	8.49e-19	1.43e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-9.24	8.58e-19	1.44e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
HNSC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	9.24	8.68e-19	1.46e-15	0.56	0.39	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	9.24	8.74e-19	1.47e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	9.24	8.74e-19	1.47e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
HNSC	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	9.24	8.77e-19	1.48e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
HNSC	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-9.24	8.82e-19	1.48e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
HNSC	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-9.24	9.01e-19	1.51e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
HNSC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-9.24	9.02e-19	1.52e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
HNSC	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-9.24	9.05e-19	1.52e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000179406.6	LINC00174	-9.24	9.07e-19	1.52e-15	-0.51	-0.39	Aortic root size;	chr7:65951183	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	9.23	9.13e-19	1.53e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
HNSC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	9.23	9.17e-19	1.54e-15	0.55	0.39	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
HNSC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-9.23	9.2e-19	1.55e-15	-0.37	-0.39	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-9.23	9.2e-19	1.55e-15	-0.37	-0.39	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000179406.6	LINC00174	-9.23	9.24e-19	1.55e-15	-0.51	-0.39	Aortic root size;	chr7:65964026	chr7:66376044~66401338:-
HNSC	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	9.23	9.25e-19	1.55e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	9.23	9.25e-19	1.55e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
HNSC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-9.23	9.28e-19	1.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-9.23	9.28e-19	1.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
HNSC	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-9.23	9.3e-19	1.56e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	9.23	9.39e-19	1.58e-15	0.52	0.39	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000179406.6	LINC00174	-9.23	9.44e-19	1.58e-15	-0.5	-0.39	Aortic root size;	chr7:66789659	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	9.23	9.48e-19	1.59e-15	0.53	0.39	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-9.23	9.48e-19	1.59e-15	-0.45	-0.39	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-9.23	9.48e-19	1.59e-15	-0.45	-0.39	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
HNSC	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	9.23	9.63e-19	1.61e-15	0.45	0.39	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
HNSC	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	9.23	9.64e-19	1.62e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
HNSC	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-9.23	9.72e-19	1.63e-15	-0.59	-0.39	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
HNSC	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-9.23	9.76e-19	1.63e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
HNSC	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-9.22	9.83e-19	1.65e-15	-0.52	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
HNSC	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-9.22	9.83e-19	1.65e-15	-0.52	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
HNSC	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	9.22	9.83e-19	1.65e-15	0.42	0.39	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
HNSC	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	9.22	9.89e-19	1.66e-15	0.45	0.39	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
HNSC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	9.22	9.9e-19	1.66e-15	0.41	0.39	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
HNSC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.22	9.94e-19	1.66e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000179406.6	LINC00174	-9.22	9.95e-19	1.67e-15	-0.49	-0.39	Aortic root size;	chr7:66631041	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	9.22	9.95e-19	1.67e-15	0.5	0.39	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	9.22	9.99e-19	1.67e-15	0.42	0.39	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
HNSC	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	9.22	1.01e-18	1.69e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
HNSC	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-9.22	1.01e-18	1.69e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
HNSC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	9.22	1.02e-18	1.7e-15	0.51	0.39	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000179406.6	LINC00174	9.22	1.02e-18	1.7e-15	0.51	0.39	Aortic root size;	chr7:66120784	chr7:66376044~66401338:-
HNSC	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	9.22	1.03e-18	1.73e-15	0.39	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000179406.6	LINC00174	-9.22	1.04e-18	1.74e-15	-0.51	-0.39	Calcium levels;	chr7:65967580	chr7:66376044~66401338:-
HNSC	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-9.22	1.06e-18	1.76e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
HNSC	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	9.22	1.06e-18	1.77e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
HNSC	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-9.21	1.07e-18	1.78e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
HNSC	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	9.21	1.07e-18	1.78e-15	0.42	0.39	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
HNSC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	9.21	1.08e-18	1.8e-15	0.41	0.39	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
HNSC	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	9.21	1.08e-18	1.81e-15	0.51	0.39	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-9.21	1.1e-18	1.84e-15	-0.5	-0.39	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-9.21	1.11e-18	1.85e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	9.21	1.11e-18	1.85e-15	0.6	0.39	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-9.21	1.13e-18	1.89e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	9.21	1.14e-18	1.89e-15	0.51	0.39	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
HNSC	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-9.2	1.15e-18	1.92e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-9.2	1.16e-18	1.93e-15	-0.58	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
HNSC	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	9.2	1.18e-18	1.97e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
HNSC	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-9.2	1.19e-18	1.98e-15	-0.54	-0.39	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
HNSC	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	9.2	1.2e-18	1.99e-15	0.43	0.39	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
HNSC	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-9.2	1.22e-18	2.03e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
HNSC	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	9.2	1.23e-18	2.04e-15	0.42	0.39	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
HNSC	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-9.2	1.23e-18	2.05e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
HNSC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	9.2	1.23e-18	2.05e-15	0.52	0.39	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
HNSC	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-9.2	1.24e-18	2.06e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
HNSC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
HNSC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
HNSC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.2	1.24e-18	2.06e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
HNSC	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	9.2	1.24e-18	2.06e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
HNSC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	9.19	1.25e-18	2.08e-15	0.48	0.39	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
HNSC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-9.19	1.26e-18	2.1e-15	-0.52	-0.39	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	9.19	1.27e-18	2.11e-15	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
HNSC	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-9.19	1.27e-18	2.11e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
HNSC	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-9.19	1.27e-18	2.11e-15	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-9.19	1.28e-18	2.13e-15	-0.5	-0.39	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
HNSC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	9.19	1.28e-18	2.13e-15	0.71	0.39	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.19	1.3e-18	2.15e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	9.19	1.31e-18	2.17e-15	0.5	0.39	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
HNSC	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-9.19	1.32e-18	2.18e-15	-0.49	-0.39	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
HNSC	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-9.19	1.32e-18	2.18e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
HNSC	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.19	1.33e-18	2.2e-15	-0.5	-0.39	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
HNSC	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	9.19	1.34e-18	2.21e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
HNSC	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-9.19	1.34e-18	2.23e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
HNSC	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-9.19	1.35e-18	2.23e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
HNSC	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-9.18	1.35e-18	2.24e-15	-0.52	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.18	1.35e-18	2.24e-15	0.46	0.39	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
HNSC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-9.18	1.36e-18	2.25e-15	-0.49	-0.39	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-9.18	1.36e-18	2.26e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
HNSC	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-9.18	1.4e-18	2.31e-15	-0.43	-0.39	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
HNSC	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	9.18	1.4e-18	2.31e-15	0.49	0.39	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
HNSC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	9.18	1.41e-18	2.33e-15	0.66	0.39	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
HNSC	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-9.18	1.41e-18	2.33e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
HNSC	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-9.18	1.43e-18	2.36e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
HNSC	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-9.18	1.43e-18	2.36e-15	-0.49	-0.39	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
HNSC	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-9.18	1.43e-18	2.36e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
HNSC	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	9.18	1.43e-18	2.37e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
HNSC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-9.18	1.44e-18	2.37e-15	-0.37	-0.39	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
HNSC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-9.18	1.44e-18	2.38e-15	-0.41	-0.39	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
HNSC	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	9.17	1.46e-18	2.41e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
HNSC	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-9.17	1.5e-18	2.47e-15	-0.52	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
HNSC	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	9.17	1.51e-18	2.48e-15	0.42	0.39	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
HNSC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.17	1.51e-18	2.48e-15	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
HNSC	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	9.17	1.51e-18	2.49e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
HNSC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.17	1.54e-18	2.53e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.17	1.54e-18	2.54e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
HNSC	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-9.17	1.55e-18	2.55e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
HNSC	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	9.17	1.56e-18	2.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	9.17	1.56e-18	2.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-9.16	1.58e-18	2.6e-15	-0.49	-0.39	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	9.16	1.59e-18	2.62e-15	0.51	0.39	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
HNSC	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-9.16	1.6e-18	2.63e-15	-0.37	-0.39	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-9.16	1.6e-18	2.63e-15	-0.37	-0.39	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
HNSC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.16	1.61e-18	2.64e-15	-0.4	-0.39	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
HNSC	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-9.16	1.63e-18	2.68e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
HNSC	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-9.16	1.63e-18	2.68e-15	-0.45	-0.39	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
HNSC	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	9.16	1.64e-18	2.7e-15	0.44	0.39	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-9.16	1.64e-18	2.7e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-9.16	1.66e-18	2.72e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000179406.6	LINC00174	9.16	1.69e-18	2.78e-15	0.51	0.39	Aortic root size;	chr7:66836124	chr7:66376044~66401338:-
HNSC	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	9.16	1.7e-18	2.78e-15	0.35	0.39	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
HNSC	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-9.16	1.7e-18	2.79e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
HNSC	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-9.16	1.7e-18	2.79e-15	-0.47	-0.39	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
HNSC	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-9.16	1.7e-18	2.79e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-9.16	1.7e-18	2.79e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-9.15	1.71e-18	2.8e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-9.15	1.72e-18	2.82e-15	-0.49	-0.39	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	9.15	1.73e-18	2.83e-15	0.38	0.39	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
HNSC	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	9.15	1.73e-18	2.84e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
HNSC	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	9.15	1.76e-18	2.88e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	9.15	1.76e-18	2.88e-15	0.38	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
HNSC	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-9.15	1.76e-18	2.88e-15	-0.43	-0.39	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
HNSC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.15	1.76e-18	2.89e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
HNSC	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-9.15	1.76e-18	2.89e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-9.15	1.77e-18	2.89e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	9.15	1.79e-18	2.92e-15	0.42	0.39	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-9.15	1.8e-18	2.95e-15	-0.42	-0.39	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-9.15	1.83e-18	3e-15	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-9.15	1.84e-18	3.01e-15	-0.52	-0.39	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
HNSC	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-9.14	1.85e-18	3.03e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
HNSC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-9.14	1.86e-18	3.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-9.14	1.86e-18	3.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000179406.6	LINC00174	9.14	1.87e-18	3.06e-15	0.5	0.39	Aortic root size;	chr7:65950660	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.14	1.88e-18	3.08e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-9.14	1.89e-18	3.09e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
HNSC	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.14	1.91e-18	3.12e-15	-0.47	-0.39	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
HNSC	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-9.14	1.91e-18	3.13e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000173295.6	FAM86B3P	9.14	1.92e-18	3.14e-15	0.45	0.39	Neuroticism;	chr8:8241055	chr8:8228595~8244865:+
HNSC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-9.14	1.97e-18	3.21e-15	-0.37	-0.39	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
HNSC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-9.14	1.99e-18	3.25e-15	-0.39	-0.39	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
HNSC	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	9.13	2.01e-18	3.29e-15	0.45	0.39	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
HNSC	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	9.13	2.02e-18	3.3e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
HNSC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-9.13	2.02e-18	3.3e-15	-0.37	-0.39	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
HNSC	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-9.13	2.03e-18	3.31e-15	-0.5	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
HNSC	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-9.13	2.03e-18	3.31e-15	-0.6	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
HNSC	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-9.13	2.03e-18	3.31e-15	-0.6	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	9.13	2.04e-18	3.32e-15	0.4	0.39	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
HNSC	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	9.13	2.06e-18	3.36e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	9.13	2.07e-18	3.37e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
HNSC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-9.13	2.15e-18	3.5e-15	-0.44	-0.39	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
HNSC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-9.12	2.16e-18	3.51e-15	-0.44	-0.39	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
HNSC	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-9.12	2.16e-18	3.52e-15	-0.43	-0.39	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
HNSC	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.12	2.16e-18	3.52e-15	0.44	0.39	Depression;	chr6:28317705	chr6:28176188~28176674:+
HNSC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	9.12	2.23e-18	3.62e-15	0.49	0.39	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-9.12	2.24e-18	3.64e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-9.12	2.25e-18	3.65e-15	-0.46	-0.39	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.12	2.28e-18	3.7e-15	0.44	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
HNSC	cis	rs16885979	1	rs9357819	ENSG00000224984.1	RP11-524H19.2	9.12	2.29e-18	3.71e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54843279	chr6:54840118~54840855:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	9.11	2.36e-18	3.83e-15	0.42	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
HNSC	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	9.11	2.36e-18	3.83e-15	0.51	0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000179406.6	LINC00174	-9.11	2.36e-18	3.83e-15	-0.5	-0.39	Aortic root size;	chr7:66014585	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000179406.6	LINC00174	-9.11	2.36e-18	3.83e-15	-0.5	-0.39	Calcium levels;	chr7:66014891	chr7:66376044~66401338:-
HNSC	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-9.11	2.37e-18	3.85e-15	-0.45	-0.39	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	9.11	2.38e-18	3.86e-15	0.52	0.39	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-9.11	2.4e-18	3.88e-15	-0.42	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
HNSC	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	9.11	2.4e-18	3.88e-15	0.43	0.39	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
HNSC	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-9.11	2.4e-18	3.89e-15	-0.37	-0.39	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-9.11	2.41e-18	3.91e-15	-0.37	-0.39	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
HNSC	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	9.11	2.45e-18	3.97e-15	0.49	0.39	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	9.11	2.45e-18	3.97e-15	0.49	0.39	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
HNSC	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-9.11	2.45e-18	3.97e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
HNSC	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	9.11	2.46e-18	3.99e-15	0.41	0.39	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-9.11	2.47e-18	4e-15	-0.49	-0.39	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-9.11	2.5e-18	4.04e-15	-0.45	-0.39	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
HNSC	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-9.11	2.5e-18	4.04e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-9.11	2.51e-18	4.06e-15	-0.44	-0.39	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
HNSC	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.11	2.52e-18	4.07e-15	0.44	0.39	Depression;	chr6:28323463	chr6:28176188~28176674:+
HNSC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
HNSC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-9.1	2.55e-18	4.12e-15	-0.37	-0.39	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
HNSC	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-9.1	2.55e-18	4.13e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
HNSC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-9.1	2.56e-18	4.15e-15	-0.41	-0.39	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-9.1	2.57e-18	4.15e-15	-0.49	-0.39	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-9.1	2.58e-18	4.18e-15	-0.44	-0.39	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
HNSC	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	9.1	2.59e-18	4.19e-15	0.44	0.39	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
HNSC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	9.1	2.62e-18	4.23e-15	0.43	0.39	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
HNSC	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	9.1	2.62e-18	4.23e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
HNSC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-9.1	2.63e-18	4.25e-15	-0.41	-0.39	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-9.1	2.66e-18	4.3e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	9.1	2.69e-18	4.33e-15	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
HNSC	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	9.1	2.69e-18	4.34e-15	0.47	0.39	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
HNSC	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-9.1	2.69e-18	4.34e-15	-0.44	-0.39	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-9.1	2.7e-18	4.35e-15	-0.44	-0.39	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
HNSC	cis	rs16885979	1	rs17749547	ENSG00000224984.1	RP11-524H19.2	9.1	2.71e-18	4.37e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54845642	chr6:54840118~54840855:-
HNSC	cis	rs16885979	0.793	rs62412648	ENSG00000224984.1	RP11-524H19.2	9.1	2.71e-18	4.37e-15	0.93	0.39	Daytime sleep phenotypes;	chr6:54847061	chr6:54840118~54840855:-
HNSC	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	9.09	2.78e-18	4.49e-15	0.42	0.39	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
HNSC	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-9.09	2.79e-18	4.49e-15	-0.51	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
HNSC	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	9.09	2.79e-18	4.5e-15	0.43	0.39	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-9.09	2.8e-18	4.52e-15	-0.41	-0.39	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
HNSC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	9.09	2.84e-18	4.58e-15	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-9.09	2.85e-18	4.59e-15	-0.49	-0.39	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	9.09	2.93e-18	4.71e-15	0.41	0.39	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
HNSC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	9.08	2.97e-18	4.78e-15	0.51	0.39	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
HNSC	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	9.08	2.98e-18	4.79e-15	0.56	0.39	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
HNSC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.08	3e-18	4.82e-15	-0.4	-0.39	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-9.08	3.02e-18	4.85e-15	-0.49	-0.39	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
HNSC	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-9.08	3.06e-18	4.92e-15	-0.3	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
HNSC	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-9.08	3.07e-18	4.93e-15	-0.45	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
HNSC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-9.08	3.09e-18	4.96e-15	-0.51	-0.39	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
HNSC	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-9.08	3.1e-18	4.97e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
HNSC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-9.08	3.11e-18	4.99e-15	-0.53	-0.39	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-9.08	3.11e-18	5e-15	-0.49	-0.39	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-9.08	3.12e-18	5.01e-15	-0.44	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
HNSC	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-9.08	3.16e-18	5.07e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
HNSC	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-9.08	3.16e-18	5.08e-15	-0.51	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
HNSC	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	9.08	3.19e-18	5.12e-15	0.43	0.39	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	9.08	3.19e-18	5.12e-15	0.43	0.39	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
HNSC	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-9.07	3.2e-18	5.14e-15	-0.44	-0.39	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
HNSC	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-9.07	3.2e-18	5.14e-15	-0.44	-0.39	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	9.07	3.21e-18	5.15e-15	0.46	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	9.07	3.22e-18	5.17e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
HNSC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	9.07	3.24e-18	5.19e-15	0.53	0.39	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-9.07	3.27e-18	5.24e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
HNSC	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	9.07	3.31e-18	5.31e-15	0.46	0.39	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
HNSC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.06	3.47e-18	5.56e-15	-0.4	-0.39	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000179406.6	LINC00174	-9.06	3.5e-18	5.61e-15	-0.5	-0.39	Aortic root size;	chr7:66008093	chr7:66376044~66401338:-
HNSC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	9.06	3.56e-18	5.7e-15	0.44	0.39	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-9.06	3.57e-18	5.72e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
HNSC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	9.06	3.59e-18	5.74e-15	0.51	0.39	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
HNSC	cis	rs131777	0.563	rs5770927	ENSG00000205559.3	CHKB-AS1	-9.06	3.62e-18	5.78e-15	-0.43	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590516	chr22:50583026~50583877:+
HNSC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-9.06	3.62e-18	5.79e-15	-0.4	-0.39	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	9.06	3.63e-18	5.8e-15	0.4	0.39	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000179406.6	LINC00174	-9.06	3.67e-18	5.87e-15	-0.49	-0.39	Aortic root size;	chr7:66008701	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-9.06	3.71e-18	5.93e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-9.05	3.75e-18	5.98e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	9.05	3.77e-18	6.02e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
HNSC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	9.05	3.8e-18	6.07e-15	0.51	0.39	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
HNSC	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	9.05	3.8e-18	6.07e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
HNSC	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.05	3.85e-18	6.14e-15	-0.42	-0.39	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.05	3.85e-18	6.14e-15	-0.42	-0.39	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
HNSC	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-9.05	3.85e-18	6.15e-15	-0.49	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
HNSC	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	9.05	3.9e-18	6.22e-15	0.72	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
HNSC	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-9.05	3.9e-18	6.23e-15	-0.52	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
HNSC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	9.05	3.91e-18	6.24e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
HNSC	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	9.05	3.92e-18	6.26e-15	0.45	0.39	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
HNSC	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-9.05	3.98e-18	6.35e-15	-0.59	-0.39	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-9.04	4.04e-18	6.44e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	9.04	4.12e-18	6.56e-15	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
HNSC	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.04	4.17e-18	6.64e-15	0.44	0.39	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
HNSC	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	9.04	4.17e-18	6.64e-15	0.33	0.39	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
HNSC	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-9.04	4.2e-18	6.69e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000179406.6	LINC00174	9.04	4.24e-18	6.76e-15	0.49	0.39	Aortic root size;	chr7:66018255	chr7:66376044~66401338:-
HNSC	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-9.04	4.26e-18	6.78e-15	-0.45	-0.39	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
HNSC	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-9.04	4.27e-18	6.79e-15	-0.5	-0.39	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
HNSC	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	9.03	4.39e-18	6.97e-15	0.37	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
HNSC	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-9.03	4.51e-18	7.17e-15	-0.35	-0.39	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
HNSC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-9.03	4.59e-18	7.29e-15	-0.5	-0.39	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
HNSC	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	9.03	4.6e-18	7.29e-15	0.42	0.39	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.844	rs732465	ENSG00000179406.6	LINC00174	-9.03	4.6e-18	7.29e-15	-0.48	-0.39	Aortic root size;	chr7:66533463	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.03	4.66e-18	7.39e-15	0.44	0.39	Depression;	chr6:28301886	chr6:28176188~28176674:+
HNSC	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	9.03	4.66e-18	7.39e-15	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
HNSC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	9.02	4.74e-18	7.5e-15	0.54	0.39	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	9.02	4.74e-18	7.51e-15	0.52	0.39	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000179406.6	LINC00174	-9.02	4.75e-18	7.53e-15	-0.49	-0.39	Aortic root size;	chr7:65998108	chr7:66376044~66401338:-
HNSC	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	9.02	4.8e-18	7.6e-15	0.45	0.39	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
HNSC	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-9.02	4.81e-18	7.61e-15	-0.53	-0.39	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
HNSC	cis	rs2006771	0.81	rs4820988	ENSG00000236132.1	CTA-440B3.1	9.02	4.84e-18	7.66e-15	0.43	0.39	Nonsyndromic cleft lip with cleft palate;	chr22:31669821	chr22:31816379~31817491:-
HNSC	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-9.02	4.85e-18	7.68e-15	-0.44	-0.39	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
HNSC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	9.02	4.86e-18	7.69e-15	0.43	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
HNSC	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-9.02	4.87e-18	7.7e-15	-0.5	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
HNSC	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	9.02	4.87e-18	7.7e-15	0.45	0.39	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
HNSC	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-9.02	5.02e-18	7.93e-15	-0.51	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-9.02	5.08e-18	8.03e-15	-0.44	-0.39	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
HNSC	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	9.01	5.12e-18	8.09e-15	0.41	0.38	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
HNSC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	9.01	5.23e-18	8.25e-15	0.54	0.38	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
HNSC	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-9.01	5.24e-18	8.26e-15	-0.43	-0.38	Temperament;	chr17:14013482	chr17:14024514~14025488:+
HNSC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-9.01	5.29e-18	8.34e-15	-0.44	-0.38	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	9.01	5.29e-18	8.34e-15	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
HNSC	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	9.01	5.31e-18	8.36e-15	0.43	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
HNSC	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-9.01	5.34e-18	8.42e-15	-0.45	-0.38	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
HNSC	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	9.01	5.34e-18	8.42e-15	0.46	0.38	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
HNSC	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-9.01	5.39e-18	8.49e-15	-0.45	-0.38	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
HNSC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	9.01	5.41e-18	8.53e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
HNSC	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	9.01	5.48e-18	8.63e-15	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-9	5.52e-18	8.69e-15	-0.49	-0.38	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	9	5.56e-18	8.75e-15	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000179406.6	LINC00174	9	5.61e-18	8.83e-15	0.54	0.38	Aortic root size;	chr7:66143851	chr7:66376044~66401338:-
HNSC	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-9	5.69e-18	8.94e-15	-0.3	-0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
HNSC	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-9	5.7e-18	8.96e-15	-0.42	-0.38	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
HNSC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	9	5.76e-18	9.05e-15	0.53	0.38	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
HNSC	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-9	5.83e-18	9.15e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-9	5.83e-18	9.15e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
HNSC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-9	5.83e-18	9.16e-15	-0.48	-0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
HNSC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	9	5.83e-18	9.16e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
HNSC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	9	5.83e-18	9.16e-15	0.53	0.38	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
HNSC	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9	5.89e-18	9.25e-15	-0.41	-0.38	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
HNSC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-9	5.94e-18	9.32e-15	-0.5	-0.38	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
HNSC	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-8.99	5.99e-18	9.39e-15	-0.42	-0.38	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
HNSC	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-8.99	6.06e-18	9.49e-15	-0.62	-0.38	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-8.99	6.09e-18	9.5e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
HNSC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	8.99	6.21e-18	9.68e-15	0.53	0.38	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-8.99	6.28e-18	9.79e-15	-0.51	-0.38	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
HNSC	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-8.99	6.36e-18	9.9e-15	-0.37	-0.38	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
HNSC	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-8.99	6.39e-18	9.95e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
HNSC	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	8.99	6.4e-18	9.97e-15	0.51	0.38	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
HNSC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.98	6.48e-18	1.01e-14	-0.4	-0.38	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
HNSC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	8.98	6.56e-18	1.02e-14	0.53	0.38	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-8.98	6.65e-18	1.03e-14	-0.42	-0.38	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-8.98	6.74e-18	1.05e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
HNSC	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	8.98	6.74e-18	1.05e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	8.98	6.77e-18	1.05e-14	0.48	0.38	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
HNSC	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-8.98	6.81e-18	1.06e-14	-0.41	-0.38	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
HNSC	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.98	6.91e-18	1.07e-14	0.42	0.38	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
HNSC	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-8.97	6.95e-18	1.08e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
HNSC	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-8.97	6.95e-18	1.08e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
HNSC	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-8.97	6.96e-18	1.08e-14	-0.53	-0.38	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-8.97	6.96e-18	1.08e-14	-0.53	-0.38	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
HNSC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-8.97	6.96e-18	1.08e-14	-0.41	-0.38	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
HNSC	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	8.97	7.03e-18	1.09e-14	0.4	0.38	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
HNSC	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	8.97	7.05e-18	1.09e-14	0.43	0.38	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	8.97	7.12e-18	1.1e-14	0.4	0.38	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	8.97	7.15e-18	1.11e-14	0.44	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-8.97	7.21e-18	1.12e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000179406.6	LINC00174	8.97	7.22e-18	1.12e-14	0.5	0.38	Aortic root size;	chr7:66597493	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	8.97	7.23e-18	1.12e-14	0.48	0.38	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
HNSC	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	8.97	7.27e-18	1.12e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-8.97	7.27e-18	1.13e-14	-0.49	-0.38	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
HNSC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.97	7.27e-18	1.13e-14	-0.4	-0.38	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.97	7.27e-18	1.13e-14	-0.4	-0.38	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
HNSC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	8.97	7.33e-18	1.13e-14	0.41	0.38	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	8.97	7.35e-18	1.14e-14	0.42	0.38	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
HNSC	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.97	7.42e-18	1.15e-14	-0.35	-0.38	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-8.97	7.5e-18	1.16e-14	-0.42	-0.38	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
HNSC	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	8.96	7.82e-18	1.21e-14	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.96	7.84e-18	1.21e-14	-0.52	-0.38	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
HNSC	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-8.95	8.11e-18	1.25e-14	-0.35	-0.38	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	8.95	8.18e-18	1.26e-14	0.43	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
HNSC	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-8.95	8.19e-18	1.26e-14	-0.59	-0.38	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
HNSC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.95	8.31e-18	1.28e-14	0.4	0.38	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
HNSC	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	8.95	8.35e-18	1.29e-14	0.49	0.38	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-8.95	8.35e-18	1.29e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
HNSC	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-8.95	8.4e-18	1.29e-14	-0.37	-0.38	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
HNSC	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	8.95	8.65e-18	1.33e-14	0.49	0.38	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
HNSC	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-8.95	8.71e-18	1.34e-14	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-8.95	8.75e-18	1.35e-14	-0.49	-0.38	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-8.94	8.84e-18	1.36e-14	-0.43	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-8.94	8.84e-18	1.36e-14	-0.43	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
HNSC	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.94	8.85e-18	1.36e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
HNSC	cis	rs2834288	0.618	rs9977699	ENSG00000237945.6	LINC00649	-8.94	8.86e-18	1.36e-14	-0.47	-0.38	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33915534~33977691:+
HNSC	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	8.94	8.95e-18	1.38e-14	0.46	0.38	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
HNSC	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-8.94	8.96e-18	1.38e-14	-0.5	-0.38	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
HNSC	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	8.94	9.02e-18	1.39e-14	0.45	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
HNSC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	8.94	9.04e-18	1.39e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-8.94	9.11e-18	1.4e-14	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	8.94	9.12e-18	1.4e-14	0.55	0.38	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
HNSC	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	8.94	9.22e-18	1.42e-14	0.46	0.38	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-8.94	9.32e-18	1.43e-14	-0.49	-0.38	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-8.94	9.34e-18	1.43e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
HNSC	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-8.94	9.45e-18	1.45e-14	-0.3	-0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	8.93	9.47e-18	1.45e-14	0.53	0.38	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
HNSC	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	8.93	9.54e-18	1.46e-14	0.53	0.38	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
HNSC	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	8.93	9.59e-18	1.47e-14	0.37	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
HNSC	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	8.93	9.59e-18	1.47e-14	0.37	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
HNSC	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-8.93	9.66e-18	1.48e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-8.93	9.66e-18	1.48e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
HNSC	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.93	9.72e-18	1.49e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-8.93	9.87e-18	1.51e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
HNSC	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-8.93	1e-17	1.53e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-8.93	1e-17	1.54e-14	-0.44	-0.38	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
HNSC	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-8.93	1.01e-17	1.55e-14	-0.46	-0.38	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
HNSC	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-8.92	1.03e-17	1.57e-14	-0.42	-0.38	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	8.92	1.03e-17	1.57e-14	0.52	0.38	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
HNSC	cis	rs9402743	0.775	rs4504492	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135648536	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs2876312	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135648714	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9483862	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135649541	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494315	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135649778	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.816	rs9402738	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135652112	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.74	rs9494318	ENSG00000217482.2	HMGB1P17	8.92	1.03e-17	1.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135653519	chr6:135636086~135636713:-
HNSC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.92	1.04e-17	1.58e-14	0.4	0.38	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
HNSC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.92	1.04e-17	1.58e-14	0.4	0.38	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-8.92	1.04e-17	1.59e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-8.92	1.04e-17	1.6e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
HNSC	cis	rs9402743	0.775	rs9494322	ENSG00000217482.2	HMGB1P17	-8.92	1.05e-17	1.6e-14	-0.42	-0.38	Systemic lupus erythematosus;	chr6:135660922	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.92	1.05e-17	1.6e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	8.92	1.08e-17	1.65e-14	0.44	0.38	Depression;	chr6:28303421	chr6:28176188~28176674:+
HNSC	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-8.92	1.09e-17	1.66e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-8.92	1.09e-17	1.66e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
HNSC	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	8.92	1.09e-17	1.67e-14	0.4	0.38	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	8.91	1.1e-17	1.68e-14	0.65	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
HNSC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	8.91	1.11e-17	1.69e-14	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
HNSC	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-8.91	1.11e-17	1.7e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-8.91	1.11e-17	1.7e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-8.91	1.12e-17	1.7e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-8.91	1.12e-17	1.7e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
HNSC	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-8.91	1.13e-17	1.72e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
HNSC	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	8.91	1.14e-17	1.73e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
HNSC	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-8.91	1.14e-17	1.74e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.91	1.15e-17	1.76e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
HNSC	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-8.91	1.16e-17	1.77e-14	-0.43	-0.38	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000179406.6	LINC00174	-8.91	1.17e-17	1.78e-14	-0.56	-0.38	Aortic root size;	chr7:66175760	chr7:66376044~66401338:-
HNSC	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	8.91	1.18e-17	1.79e-14	0.74	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
HNSC	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.9	1.19e-17	1.82e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	8.9	1.2e-17	1.83e-14	0.49	0.38	Depression;	chr6:28086929	chr6:28115628~28116551:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000179406.6	LINC00174	8.9	1.21e-17	1.85e-14	0.48	0.38	Aortic root size;	chr7:66605533	chr7:66376044~66401338:-
HNSC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	8.9	1.22e-17	1.85e-14	0.4	0.38	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-8.9	1.22e-17	1.86e-14	-0.49	-0.38	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
HNSC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-8.9	1.23e-17	1.87e-14	-0.44	-0.38	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-8.9	1.24e-17	1.88e-14	-0.4	-0.38	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000179406.6	LINC00174	8.9	1.24e-17	1.88e-14	0.48	0.38	Aortic root size;	chr7:66603880	chr7:66376044~66401338:-
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000179406.6	LINC00174	8.9	1.24e-17	1.89e-14	0.48	0.38	Aortic root size;	chr7:66605597	chr7:66376044~66401338:-
HNSC	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	8.9	1.25e-17	1.89e-14	0.47	0.38	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-8.9	1.25e-17	1.89e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
HNSC	cis	rs1933112	0.9	rs1040508	ENSG00000227777.1	RP4-738P11.3	-8.9	1.26e-17	1.91e-14	-0.43	-0.38	Blood protein levels;	chr1:168531512	chr1:168542737~168543354:+
HNSC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	8.9	1.26e-17	1.91e-14	0.4	0.38	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	8.9	1.28e-17	1.95e-14	0.42	0.38	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
HNSC	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-8.89	1.3e-17	1.97e-14	-0.44	-0.38	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
HNSC	cis	rs875971	0.543	rs801191	ENSG00000179406.6	LINC00174	8.89	1.31e-17	1.98e-14	0.48	0.38	Aortic root size;	chr7:66567968	chr7:66376044~66401338:-
HNSC	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-8.89	1.31e-17	1.98e-14	-0.52	-0.38	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
HNSC	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	8.89	1.31e-17	1.98e-14	0.47	0.38	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
HNSC	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	8.89	1.31e-17	1.98e-14	0.47	0.38	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
HNSC	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-8.89	1.31e-17	1.99e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-8.89	1.33e-17	2.01e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-8.89	1.35e-17	2.04e-14	-0.43	-0.38	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
HNSC	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-8.89	1.35e-17	2.05e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
HNSC	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-8.89	1.35e-17	2.05e-14	-0.41	-0.38	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
HNSC	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	8.89	1.36e-17	2.06e-14	0.5	0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
HNSC	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-8.89	1.37e-17	2.08e-14	-0.42	-0.38	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-8.89	1.37e-17	2.08e-14	-0.42	-0.38	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
HNSC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	8.89	1.38e-17	2.08e-14	0.4	0.38	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
HNSC	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-8.89	1.38e-17	2.09e-14	-0.54	-0.38	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.89	1.39e-17	2.1e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-8.88	1.41e-17	2.14e-14	-0.49	-0.38	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
HNSC	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.88	1.42e-17	2.14e-14	-0.47	-0.38	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-8.88	1.42e-17	2.14e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-8.88	1.42e-17	2.14e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
HNSC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-8.88	1.46e-17	2.21e-14	-0.36	-0.38	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
HNSC	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-8.88	1.46e-17	2.21e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
HNSC	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.88	1.47e-17	2.21e-14	0.43	0.38	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
HNSC	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-8.88	1.48e-17	2.23e-14	-0.42	-0.38	Migraine;	chr4:56937339	chr4:56960927~56961373:-
HNSC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-8.88	1.48e-17	2.23e-14	-0.51	-0.38	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
HNSC	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.88	1.48e-17	2.23e-14	-0.47	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
HNSC	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.88	1.5e-17	2.26e-14	-0.42	-0.38	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-8.87	1.51e-17	2.28e-14	-0.5	-0.38	Depression;	chr6:28135913	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	8.87	1.51e-17	2.28e-14	0.34	0.38	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
HNSC	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-8.87	1.51e-17	2.28e-14	-0.52	-0.38	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
HNSC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-8.87	1.52e-17	2.3e-14	-0.44	-0.38	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
HNSC	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-8.87	1.53e-17	2.31e-14	-0.52	-0.38	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
HNSC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	8.87	1.54e-17	2.32e-14	0.53	0.38	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
HNSC	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	8.87	1.54e-17	2.32e-14	0.43	0.38	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-8.87	1.55e-17	2.33e-14	-0.5	-0.38	Depression;	chr6:28071808	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-8.87	1.57e-17	2.36e-14	-0.4	-0.38	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-8.87	1.57e-17	2.36e-14	-0.51	-0.38	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
HNSC	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	8.87	1.6e-17	2.41e-14	0.41	0.38	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-8.87	1.6e-17	2.41e-14	-0.42	-0.38	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
HNSC	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-8.87	1.61e-17	2.42e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
HNSC	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-8.86	1.63e-17	2.44e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	8.86	1.63e-17	2.45e-14	0.43	0.38	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.86	1.64e-17	2.47e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.86	1.64e-17	2.47e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-8.86	1.65e-17	2.47e-14	-0.52	-0.38	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-8.86	1.65e-17	2.48e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-8.86	1.67e-17	2.5e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	8.86	1.67e-17	2.5e-14	0.44	0.38	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
HNSC	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-8.86	1.67e-17	2.51e-14	-0.45	-0.38	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
HNSC	cis	rs801193	0.773	rs801207	ENSG00000179406.6	LINC00174	8.86	1.67e-17	2.51e-14	0.48	0.38	Aortic root size;	chr7:66555603	chr7:66376044~66401338:-
HNSC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	8.86	1.68e-17	2.52e-14	0.52	0.38	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
HNSC	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	8.86	1.69e-17	2.54e-14	0.41	0.38	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
HNSC	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	8.86	1.72e-17	2.58e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	8.86	1.72e-17	2.58e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-8.86	1.73e-17	2.6e-14	-0.51	-0.38	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
HNSC	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.86	1.75e-17	2.62e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
HNSC	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-8.85	1.75e-17	2.63e-14	-0.52	-0.38	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
HNSC	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-8.85	1.77e-17	2.65e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
HNSC	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-8.85	1.77e-17	2.65e-14	-0.5	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-8.85	1.77e-17	2.66e-14	-0.53	-0.38	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
HNSC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	8.85	1.78e-17	2.66e-14	0.53	0.38	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
HNSC	cis	rs7615952	1	rs7615952	ENSG00000241288.6	RP11-379B18.5	8.85	1.81e-17	2.71e-14	0.5	0.38	Blood pressure (smoking interaction);	chr3:125930560	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-8.85	1.83e-17	2.73e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
HNSC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-8.85	1.84e-17	2.75e-14	-0.43	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
HNSC	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	8.85	1.85e-17	2.77e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
HNSC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	8.85	1.86e-17	2.78e-14	0.43	0.38	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
HNSC	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-8.85	1.87e-17	2.8e-14	-0.5	-0.38	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
HNSC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	8.85	1.88e-17	2.81e-14	0.52	0.38	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
HNSC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	8.85	1.89e-17	2.82e-14	0.51	0.38	Depression;	chr6:28110525	chr6:28115628~28116551:+
HNSC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	8.84	1.9e-17	2.84e-14	0.4	0.38	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.84	1.9e-17	2.84e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
HNSC	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-8.84	1.91e-17	2.85e-14	-0.4	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-8.84	1.91e-17	2.85e-14	-0.41	-0.38	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
HNSC	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-8.84	1.92e-17	2.86e-14	-0.45	-0.38	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-8.84	1.95e-17	2.91e-14	-0.5	-0.38	Depression;	chr6:28110254	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-8.84	1.97e-17	2.94e-14	-0.42	-0.38	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
HNSC	cis	rs9402743	0.577	rs111373814	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135644459	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.608	rs6918917	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135644473	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs56071012	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646213	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs56976899	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646262	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.673	rs9494312	ENSG00000217482.2	HMGB1P17	8.84	1.97e-17	2.94e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135646826	chr6:135636086~135636713:-
HNSC	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	8.84	1.98e-17	2.96e-14	0.42	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
HNSC	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	8.84	2.01e-17	3e-14	0.46	0.38	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
HNSC	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.83	2.05e-17	3.06e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	8.83	2.09e-17	3.11e-14	0.43	0.38	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
HNSC	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	8.83	2.13e-17	3.16e-14	0.46	0.38	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
HNSC	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	8.83	2.13e-17	3.17e-14	0.47	0.38	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	8.83	2.13e-17	3.17e-14	0.43	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
HNSC	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	8.83	2.15e-17	3.2e-14	0.41	0.38	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
HNSC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	8.83	2.16e-17	3.21e-14	0.47	0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-8.83	2.16e-17	3.21e-14	-0.5	-0.38	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.83	2.17e-17	3.22e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-8.83	2.17e-17	3.23e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
HNSC	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	8.83	2.2e-17	3.27e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	8.83	2.2e-17	3.27e-14	0.64	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
HNSC	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.83	2.2e-17	3.27e-14	0.42	0.38	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
HNSC	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-8.82	2.21e-17	3.29e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000179406.6	LINC00174	8.82	2.23e-17	3.32e-14	0.48	0.38	Aortic root size;	chr7:66597948	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000179406.6	LINC00174	8.82	2.25e-17	3.35e-14	0.48	0.38	Aortic root size;	chr7:66580095	chr7:66376044~66401338:-
HNSC	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-8.82	2.26e-17	3.36e-14	-0.45	-0.38	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-8.82	2.28e-17	3.38e-14	-0.5	-0.38	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
HNSC	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	8.82	2.28e-17	3.39e-14	0.43	0.38	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-8.82	2.29e-17	3.4e-14	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
HNSC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-8.82	2.29e-17	3.41e-14	-0.45	-0.38	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
HNSC	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	8.82	2.3e-17	3.42e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000179406.6	LINC00174	8.82	2.33e-17	3.46e-14	0.48	0.38	Aortic root size;	chr7:66594188	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000179406.6	LINC00174	8.82	2.33e-17	3.46e-14	0.48	0.38	Aortic root size;	chr7:66596151	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28123153	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28124529	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28127577	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-8.82	2.36e-17	3.51e-14	-0.5	-0.38	Depression;	chr6:28131566	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-8.82	2.37e-17	3.51e-14	-0.4	-0.38	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
HNSC	cis	rs16885979	1	rs9396000	ENSG00000224984.1	RP11-524H19.2	8.81	2.39e-17	3.54e-14	0.9	0.38	Daytime sleep phenotypes;	chr6:54841785	chr6:54840118~54840855:-
HNSC	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	8.81	2.4e-17	3.56e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
HNSC	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	8.81	2.41e-17	3.57e-14	0.49	0.38	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
HNSC	cis	rs9402743	0.775	rs7742843	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135654681	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494319	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135655122	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6916924	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656563	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6916825	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656739	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6917005	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135656842	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494320	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135657576	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs2068394	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135658279	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494321	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135658892	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.781	rs6935190	ENSG00000217482.2	HMGB1P17	8.81	2.41e-17	3.57e-14	0.42	0.38	Systemic lupus erythematosus;	chr6:135659553	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082231	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082261	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28082984	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28083994	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28084025	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-8.81	2.41e-17	3.57e-14	-0.49	-0.38	Depression;	chr6:28085319	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-8.81	2.41e-17	3.58e-14	-0.4	-0.38	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-8.81	2.45e-17	3.62e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
HNSC	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-8.81	2.45e-17	3.62e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
HNSC	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-8.81	2.47e-17	3.66e-14	-0.43	-0.38	Temperament;	chr17:14007316	chr17:14024514~14025488:+
HNSC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.81	2.48e-17	3.67e-14	0.42	0.38	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28074687	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28076559	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28076704	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28078391	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28080757	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-8.81	2.5e-17	3.69e-14	-0.49	-0.38	Depression;	chr6:28080760	chr6:28115628~28116551:+
HNSC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	8.81	2.52e-17	3.72e-14	0.4	0.38	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
HNSC	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	8.81	2.52e-17	3.72e-14	0.5	0.38	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.81	2.54e-17	3.75e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-8.8	2.59e-17	3.82e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
HNSC	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.8	2.59e-17	3.82e-14	0.34	0.38	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
HNSC	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-8.8	2.59e-17	3.82e-14	-0.38	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
HNSC	cis	rs9402743	0.673	rs9483860	ENSG00000217482.2	HMGB1P17	-8.8	2.61e-17	3.85e-14	-0.42	-0.38	Systemic lupus erythematosus;	chr6:135646872	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28111382	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28111650	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28112175	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28113851	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28114487	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28114933	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28115743	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Depression;	chr6:28116411	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-8.8	2.65e-17	3.9e-14	-0.5	-0.38	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
HNSC	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-8.8	2.66e-17	3.92e-14	-0.47	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.8	2.67e-17	3.94e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000179406.6	LINC00174	8.8	2.67e-17	3.94e-14	0.47	0.38	Aortic root size;	chr7:66601386	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	8.8	2.68e-17	3.95e-14	0.35	0.38	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.673	rs9483858	ENSG00000217482.2	HMGB1P17	8.8	2.7e-17	3.98e-14	0.43	0.38	Systemic lupus erythematosus;	chr6:135642670	chr6:135636086~135636713:-
HNSC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8.8	2.71e-17	4e-14	-0.44	-0.38	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
HNSC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-8.8	2.71e-17	4e-14	-0.5	-0.38	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
HNSC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	8.8	2.72e-17	4.01e-14	0.4	0.38	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
HNSC	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-8.8	2.74e-17	4.03e-14	-0.57	-0.38	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
HNSC	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	8.8	2.74e-17	4.04e-14	0.52	0.38	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
HNSC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	8.8	2.77e-17	4.07e-14	0.4	0.38	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
HNSC	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-8.79	2.82e-17	4.15e-14	-0.42	-0.38	Temperament;	chr17:14007198	chr17:14024514~14025488:+
HNSC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.79	2.83e-17	4.16e-14	-0.42	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
HNSC	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	8.79	2.84e-17	4.18e-14	0.8	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-8.79	2.86e-17	4.2e-14	-0.49	-0.38	Depression;	chr6:28070115	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-8.79	2.86e-17	4.2e-14	-0.49	-0.38	Depression;	chr6:28071237	chr6:28115628~28116551:+
HNSC	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	8.79	2.86e-17	4.21e-14	0.45	0.38	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
HNSC	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	8.79	2.86e-17	4.21e-14	0.45	0.38	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-8.79	2.87e-17	4.21e-14	-0.5	-0.38	Depression;	chr6:28113616	chr6:28115628~28116551:+
HNSC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-8.79	2.9e-17	4.26e-14	-0.43	-0.38	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-8.79	2.95e-17	4.34e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
HNSC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
HNSC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-8.79	2.96e-17	4.34e-14	-0.43	-0.38	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
HNSC	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-8.78	3.01e-17	4.42e-14	-0.41	-0.38	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
HNSC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-8.78	3.06e-17	4.49e-14	-0.43	-0.38	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
HNSC	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-8.78	3.07e-17	4.5e-14	-0.48	-0.38	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
HNSC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.78	3.08e-17	4.52e-14	0.41	0.38	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
HNSC	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	8.78	3.1e-17	4.55e-14	0.45	0.38	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
HNSC	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	8.78	3.1e-17	4.55e-14	0.45	0.38	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
HNSC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-8.78	3.13e-17	4.58e-14	-0.43	-0.38	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-8.78	3.14e-17	4.6e-14	-0.43	-0.38	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
HNSC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	8.78	3.15e-17	4.61e-14	0.62	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
HNSC	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-8.78	3.16e-17	4.62e-14	-0.4	-0.38	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
HNSC	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	8.78	3.2e-17	4.68e-14	0.46	0.38	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
HNSC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-8.78	3.21e-17	4.69e-14	-0.43	-0.38	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-8.78	3.21e-17	4.69e-14	-0.43	-0.38	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
HNSC	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-8.78	3.21e-17	4.7e-14	-0.36	-0.38	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
HNSC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-8.77	3.35e-17	4.89e-14	-0.43	-0.38	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-8.77	3.36e-17	4.91e-14	-0.35	-0.38	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
HNSC	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-8.77	3.37e-17	4.92e-14	-0.48	-0.38	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
HNSC	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	8.77	3.38e-17	4.93e-14	0.4	0.38	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
HNSC	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	8.77	3.39e-17	4.95e-14	0.42	0.38	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-8.77	3.41e-17	4.98e-14	-0.45	-0.38	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-8.77	3.42e-17	4.99e-14	-0.47	-0.38	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
HNSC	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-8.77	3.43e-17	5.01e-14	-0.48	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-8.77	3.46e-17	5.05e-14	-0.5	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
HNSC	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-8.77	3.47e-17	5.06e-14	-0.4	-0.38	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	8.77	3.48e-17	5.08e-14	0.48	0.38	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
HNSC	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-8.76	3.49e-17	5.09e-14	-0.45	-0.38	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-8.76	3.5e-17	5.11e-14	-0.43	-0.38	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-8.76	3.52e-17	5.13e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
HNSC	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	8.76	3.54e-17	5.16e-14	0.49	0.38	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
HNSC	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-8.76	3.56e-17	5.18e-14	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
HNSC	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-8.76	3.56e-17	5.19e-14	-0.42	-0.38	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
HNSC	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-8.76	3.58e-17	5.21e-14	-0.36	-0.38	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
HNSC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-8.76	3.65e-17	5.31e-14	-0.43	-0.38	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
HNSC	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-8.76	3.7e-17	5.38e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
HNSC	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-8.76	3.7e-17	5.38e-14	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
HNSC	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
HNSC	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	8.76	3.71e-17	5.39e-14	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
HNSC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-8.76	3.72e-17	5.41e-14	-0.54	-0.38	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-8.76	3.72e-17	5.41e-14	-0.5	-0.38	Depression;	chr6:28133900	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	8.76	3.72e-17	5.41e-14	0.4	0.38	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	8.76	3.72e-17	5.42e-14	0.4	0.38	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-8.75	3.8e-17	5.52e-14	-0.5	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-8.75	3.84e-17	5.57e-14	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-8.75	3.84e-17	5.57e-14	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
HNSC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-8.75	3.85e-17	5.59e-14	-0.43	-0.38	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-8.75	3.85e-17	5.59e-14	-0.43	-0.38	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
HNSC	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-8.75	3.87e-17	5.62e-14	-0.49	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
HNSC	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	8.75	3.87e-17	5.62e-14	0.39	0.38	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
HNSC	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.75	3.89e-17	5.66e-14	0.38	0.38	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	8.75	3.91e-17	5.68e-14	0.26	0.38	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
HNSC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-8.75	3.95e-17	5.74e-14	-0.52	-0.38	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
HNSC	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	8.75	3.98e-17	5.77e-14	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
HNSC	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-8.75	3.99e-17	5.8e-14	-0.45	-0.38	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-8.75	4.02e-17	5.83e-14	-0.43	-0.38	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
HNSC	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-8.75	4.03e-17	5.84e-14	-0.45	-0.38	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.75	4.03e-17	5.85e-14	0.52	0.38	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
HNSC	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.74	4.06e-17	5.88e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.74	4.06e-17	5.88e-14	-0.35	-0.38	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8.74	4.11e-17	5.95e-14	0.43	0.38	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
HNSC	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	8.74	4.13e-17	5.98e-14	0.41	0.38	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
HNSC	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-8.74	4.15e-17	6.02e-14	-0.48	-0.38	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-8.74	4.16e-17	6.03e-14	-0.48	-0.37	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
HNSC	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-8.74	4.17e-17	6.04e-14	-0.42	-0.37	Migraine;	chr4:56943905	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.74	4.18e-17	6.05e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	8.74	4.18e-17	6.06e-14	0.41	0.37	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
HNSC	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	8.74	4.26e-17	6.16e-14	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
HNSC	cis	rs12922040	0.607	rs8059739	ENSG00000263335.1	AF001548.5	-8.74	4.29e-17	6.2e-14	-0.48	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15726674~15732993:+
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28136698	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28136856	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28137418	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-8.74	4.32e-17	6.24e-14	-0.49	-0.37	Depression;	chr6:28138363	chr6:28115628~28116551:+
HNSC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-8.74	4.33e-17	6.26e-14	-0.4	-0.37	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	8.74	4.34e-17	6.27e-14	0.4	0.37	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	8.74	4.34e-17	6.27e-14	0.26	0.37	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-8.74	4.34e-17	6.27e-14	-0.49	-0.37	Depression;	chr6:28126588	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-8.74	4.34e-17	6.27e-14	-0.49	-0.37	Depression;	chr6:28126953	chr6:28115628~28116551:+
HNSC	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-8.73	4.39e-17	6.34e-14	-0.42	-0.37	Migraine;	chr4:56940917	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-8.73	4.39e-17	6.34e-14	-0.42	-0.37	Migraine;	chr4:56957291	chr4:56960927~56961373:-
HNSC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	8.73	4.39e-17	6.35e-14	0.36	0.37	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
HNSC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-8.73	4.41e-17	6.37e-14	-0.43	-0.37	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
HNSC	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	8.73	4.43e-17	6.4e-14	0.39	0.37	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-8.73	4.43e-17	6.41e-14	-0.49	-0.37	Depression;	chr6:28079011	chr6:28115628~28116551:+
HNSC	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-8.73	4.44e-17	6.41e-14	-0.43	-0.37	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
HNSC	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-8.73	4.44e-17	6.41e-14	-0.43	-0.37	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
HNSC	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-8.73	4.44e-17	6.42e-14	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
HNSC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-8.73	4.45e-17	6.43e-14	-0.43	-0.37	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	8.73	4.47e-17	6.46e-14	0.26	0.37	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
HNSC	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-8.73	4.57e-17	6.6e-14	-0.49	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-8.73	4.7e-17	6.78e-14	-0.49	-0.37	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
HNSC	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	8.72	4.76e-17	6.86e-14	0.48	0.37	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
HNSC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-8.72	4.82e-17	6.94e-14	-0.52	-0.37	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
HNSC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	8.72	4.84e-17	6.97e-14	0.41	0.37	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	8.72	4.86e-17	6.99e-14	0.26	0.37	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
HNSC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-8.72	4.86e-17	7e-14	-0.44	-0.37	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	8.72	4.87e-17	7.01e-14	0.5	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
HNSC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-8.72	4.89e-17	7.03e-14	-0.38	-0.37	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
HNSC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-8.72	4.91e-17	7.07e-14	-0.45	-0.37	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
HNSC	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-8.72	4.94e-17	7.11e-14	-0.48	-0.37	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-8.72	4.94e-17	7.11e-14	-0.48	-0.37	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
HNSC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.72	4.97e-17	7.14e-14	-0.43	-0.37	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	8.72	5.01e-17	7.2e-14	0.26	0.37	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
HNSC	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	8.72	5.01e-17	7.2e-14	0.4	0.37	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
HNSC	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	8.72	5.03e-17	7.23e-14	0.48	0.37	Height;	chr6:109391084	chr6:109382795~109383666:+
HNSC	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-8.72	5.04e-17	7.24e-14	-0.41	-0.37	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
HNSC	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-8.72	5.07e-17	7.29e-14	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
HNSC	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	8.72	5.08e-17	7.31e-14	0.39	0.37	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-8.71	5.15e-17	7.4e-14	-0.5	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
HNSC	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	8.71	5.17e-17	7.43e-14	0.5	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
HNSC	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	8.71	5.2e-17	7.46e-14	0.4	0.37	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
HNSC	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	8.71	5.28e-17	7.58e-14	0.4	0.37	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
HNSC	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	8.71	5.29e-17	7.6e-14	0.48	0.37	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
HNSC	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-8.71	5.32e-17	7.63e-14	-0.38	-0.37	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
HNSC	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-8.71	5.34e-17	7.66e-14	-0.41	-0.37	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
HNSC	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-8.71	5.35e-17	7.67e-14	-0.42	-0.37	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
HNSC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	8.71	5.39e-17	7.73e-14	0.62	0.37	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
HNSC	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-8.71	5.42e-17	7.77e-14	-0.39	-0.37	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
HNSC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	8.71	5.44e-17	7.79e-14	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
HNSC	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	8.71	5.45e-17	7.82e-14	0.44	0.37	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
HNSC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-8.7	5.6e-17	8.02e-14	-0.43	-0.37	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
HNSC	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-8.7	5.6e-17	8.02e-14	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
HNSC	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.7	5.63e-17	8.06e-14	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
HNSC	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	8.7	5.66e-17	8.11e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Depression;	chr6:28138981	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-8.7	5.71e-17	8.17e-14	-0.49	-0.37	Depression;	chr6:28139012	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-8.7	5.89e-17	8.42e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
HNSC	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-8.69	5.95e-17	8.52e-14	-0.49	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
HNSC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.03e-17	8.63e-14	-0.4	-0.37	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
HNSC	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	8.69	6.04e-17	8.64e-14	0.41	0.37	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-8.69	6.07e-17	8.68e-14	-0.43	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	8.69	6.12e-17	8.74e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
HNSC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.15e-17	8.79e-14	-0.39	-0.37	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000268592.3	RAET1E-AS1	8.69	6.15e-17	8.79e-14	0.53	0.37	Lung cancer;	chr6:149863746	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.22e-17	8.87e-14	-0.39	-0.37	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
HNSC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-8.69	6.24e-17	8.9e-14	-0.43	-0.37	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-8.69	6.24e-17	8.9e-14	-0.43	-0.37	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-8.69	6.29e-17	8.97e-14	-0.43	-0.37	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
HNSC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-8.69	6.31e-17	9e-14	-0.43	-0.37	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-8.69	6.32e-17	9.01e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
HNSC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-8.69	6.33e-17	9.03e-14	-0.43	-0.37	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.34e-17	9.04e-14	-0.4	-0.37	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-8.69	6.34e-17	9.04e-14	-0.4	-0.37	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
HNSC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-8.69	6.36e-17	9.07e-14	-0.42	-0.37	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
HNSC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-8.68	6.4e-17	9.12e-14	-0.43	-0.37	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	8.68	6.42e-17	9.14e-14	0.5	0.37	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
HNSC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-8.68	6.45e-17	9.18e-14	-0.43	-0.37	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
HNSC	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	8.68	6.46e-17	9.2e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
HNSC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-8.68	6.48e-17	9.22e-14	-0.49	-0.37	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
HNSC	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-8.68	6.51e-17	9.26e-14	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
HNSC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8.68	6.52e-17	9.28e-14	-0.43	-0.37	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-8.68	6.53e-17	9.3e-14	-0.43	-0.37	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000179406.6	LINC00174	-8.68	6.54e-17	9.31e-14	-0.48	-0.37	Aortic root size;	chr7:65960907	chr7:66376044~66401338:-
HNSC	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	8.68	6.65e-17	9.45e-14	0.47	0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
HNSC	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	8.68	6.65e-17	9.45e-14	0.4	0.37	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-8.68	6.65e-17	9.46e-14	-0.57	-0.37	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-8.68	6.65e-17	9.46e-14	-0.57	-0.37	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
HNSC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-8.68	6.69e-17	9.51e-14	-0.4	-0.37	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
HNSC	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	8.68	6.72e-17	9.54e-14	0.4	0.37	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
HNSC	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	8.68	6.73e-17	9.56e-14	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-8.68	6.84e-17	9.71e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
HNSC	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-8.67	6.93e-17	9.83e-14	-0.42	-0.37	Migraine;	chr4:56956882	chr4:56960927~56961373:-
HNSC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-8.67	6.97e-17	9.89e-14	-0.43	-0.37	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-8.67	7.08e-17	1e-13	-0.43	-0.37	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
HNSC	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	8.67	7.13e-17	1.01e-13	0.37	0.37	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
HNSC	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	8.67	7.13e-17	1.01e-13	0.38	0.37	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
HNSC	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	8.67	7.13e-17	1.01e-13	0.38	0.37	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
HNSC	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.67	7.17e-17	1.02e-13	0.75	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
HNSC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-8.67	7.2e-17	1.02e-13	-0.43	-0.37	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
HNSC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-8.67	7.33e-17	1.04e-13	-0.39	-0.37	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
HNSC	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	8.67	7.42e-17	1.05e-13	0.38	0.37	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
HNSC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-8.66	7.47e-17	1.06e-13	-0.51	-0.37	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
HNSC	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.66	7.49e-17	1.06e-13	0.56	0.37	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
HNSC	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-8.66	7.68e-17	1.08e-13	-0.42	-0.37	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
HNSC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.66	7.69e-17	1.09e-13	-0.43	-0.37	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
HNSC	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	8.66	7.69e-17	1.09e-13	0.48	0.37	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
HNSC	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-8.66	7.81e-17	1.1e-13	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
HNSC	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	8.66	7.87e-17	1.11e-13	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-8.66	7.91e-17	1.12e-13	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
HNSC	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	8.66	7.95e-17	1.12e-13	0.4	0.37	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28096855	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28099759	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28100648	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28104824	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-8.66	8.02e-17	1.13e-13	-0.49	-0.37	Depression;	chr6:28107222	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-8.65	8.1e-17	1.14e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
HNSC	cis	rs9402743	0.775	rs2179724	ENSG00000217482.2	HMGB1P17	8.65	8.12e-17	1.14e-13	0.42	0.37	Systemic lupus erythematosus;	chr6:135647928	chr6:135636086~135636713:-
HNSC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	8.65	8.34e-17	1.18e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
HNSC	cis	rs7404843	0.925	rs12600043	ENSG00000263065.1	AF001548.6	8.65	8.48e-17	1.19e-13	0.67	0.37	Testicular germ cell tumor;	chr16:15446095	chr16:15741151~15741791:+
HNSC	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	8.65	8.64e-17	1.22e-13	0.38	0.37	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
HNSC	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-8.64	8.69e-17	1.22e-13	-0.41	-0.37	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
HNSC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-8.64	8.75e-17	1.23e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	8.64	8.93e-17	1.26e-13	0.4	0.37	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-8.64	8.96e-17	1.26e-13	-0.49	-0.37	Depression;	chr6:28108492	chr6:28115628~28116551:+
HNSC	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	8.64	8.97e-17	1.26e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
HNSC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-8.64	9.01e-17	1.27e-13	-0.44	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
HNSC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-8.64	9.03e-17	1.27e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-8.64	9.05e-17	1.27e-13	-0.49	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
HNSC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-8.64	9.07e-17	1.27e-13	-0.43	-0.37	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
HNSC	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-8.64	9.26e-17	1.3e-13	-0.45	-0.37	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-8.64	9.34e-17	1.31e-13	-0.49	-0.37	Depression;	chr6:28096077	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-8.63	9.41e-17	1.32e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
HNSC	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-8.63	9.41e-17	1.32e-13	-0.69	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
HNSC	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	8.63	9.43e-17	1.32e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
HNSC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-8.63	9.56e-17	1.34e-13	-0.42	-0.37	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
HNSC	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	8.63	9.57e-17	1.34e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-8.63	9.57e-17	1.34e-13	-0.43	-0.37	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-8.63	9.76e-17	1.37e-13	-0.49	-0.37	Depression;	chr6:28139876	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-8.63	9.76e-17	1.37e-13	-0.49	-0.37	Depression;	chr6:28139998	chr6:28115628~28116551:+
HNSC	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-8.63	9.83e-17	1.38e-13	-0.41	-0.37	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
HNSC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8.63	9.87e-17	1.38e-13	0.42	0.37	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
HNSC	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	8.63	9.89e-17	1.38e-13	0.49	0.37	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000179406.6	LINC00174	-8.63	9.96e-17	1.39e-13	-0.47	-0.37	Aortic root size;	chr7:66737443	chr7:66376044~66401338:-
HNSC	cis	rs1865760	0.963	rs9356991	ENSG00000272462.2	U91328.19	-8.63	1e-16	1.4e-13	-0.37	-0.37	Height;	chr6:25901530	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-8.63	1e-16	1.4e-13	-0.42	-0.37	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-8.63	1e-16	1.4e-13	-0.42	-0.37	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
HNSC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-8.62	1.02e-16	1.43e-13	-0.42	-0.37	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
HNSC	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	8.62	1.03e-16	1.44e-13	0.33	0.37	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
HNSC	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	8.62	1.03e-16	1.44e-13	0.49	0.37	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-8.62	1.04e-16	1.44e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-8.62	1.04e-16	1.44e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
HNSC	cis	rs2834288	0.645	rs2032313	ENSG00000237945.6	LINC00649	8.62	1.04e-16	1.45e-13	0.45	0.37	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	8.62	1.05e-16	1.46e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	8.62	1.05e-16	1.46e-13	0.44	0.37	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
HNSC	cis	rs10256972	0.63	rs10282584	ENSG00000225146.1	AC073957.15	8.62	1.05e-16	1.47e-13	0.43	0.37	Endometriosis;Longevity;	chr7:1041806	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-8.62	1.05e-16	1.47e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-8.62	1.05e-16	1.47e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-8.62	1.05e-16	1.47e-13	-0.4	-0.37	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
HNSC	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-8.62	1.07e-16	1.49e-13	-0.36	-0.37	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
HNSC	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	8.62	1.07e-16	1.49e-13	0.45	0.37	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
HNSC	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	8.62	1.08e-16	1.51e-13	0.47	0.37	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	8.62	1.08e-16	1.51e-13	0.5	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
HNSC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-8.61	1.09e-16	1.52e-13	-0.43	-0.37	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-8.61	1.09e-16	1.52e-13	-0.4	-0.37	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-8.61	1.11e-16	1.54e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
HNSC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-8.61	1.11e-16	1.55e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-8.61	1.11e-16	1.55e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
HNSC	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	8.61	1.11e-16	1.55e-13	0.42	0.37	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.61	1.12e-16	1.56e-13	0.39	0.37	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
HNSC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-8.61	1.13e-16	1.57e-13	-0.43	-0.37	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
HNSC	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-8.61	1.14e-16	1.58e-13	-0.48	-0.37	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-8.61	1.15e-16	1.59e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-8.61	1.16e-16	1.6e-13	-0.41	-0.37	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
HNSC	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	8.61	1.16e-16	1.61e-13	0.38	0.37	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.61	1.17e-16	1.62e-13	0.42	0.37	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
HNSC	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	8.6	1.17e-16	1.62e-13	0.46	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
HNSC	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-8.6	1.18e-16	1.63e-13	-0.42	-0.37	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
HNSC	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-8.6	1.18e-16	1.63e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
HNSC	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	8.6	1.18e-16	1.64e-13	0.61	0.37	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	8.6	1.2e-16	1.66e-13	0.5	0.37	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
HNSC	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-8.6	1.2e-16	1.66e-13	-0.41	-0.37	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
HNSC	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.6	1.2e-16	1.66e-13	-0.34	-0.37	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
HNSC	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	8.6	1.2e-16	1.67e-13	0.42	0.37	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	8.6	1.21e-16	1.68e-13	0.41	0.37	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
HNSC	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-8.6	1.22e-16	1.69e-13	-0.41	-0.37	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-8.6	1.22e-16	1.69e-13	-0.41	-0.37	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
HNSC	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	8.6	1.22e-16	1.69e-13	0.38	0.37	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	8.6	1.23e-16	1.7e-13	0.42	0.37	Depression;	chr6:28363475	chr6:28176188~28176674:+
HNSC	cis	rs1865760	1	rs2071301	ENSG00000272462.2	U91328.19	-8.6	1.26e-16	1.74e-13	-0.37	-0.37	Height;	chr6:25914035	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-8.6	1.26e-16	1.74e-13	-0.42	-0.37	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-8.59	1.28e-16	1.76e-13	-0.42	-0.37	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
HNSC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	8.59	1.28e-16	1.76e-13	0.38	0.37	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
HNSC	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	8.59	1.28e-16	1.77e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
HNSC	cis	rs1865760	1	rs6938233	ENSG00000272462.2	U91328.19	-8.59	1.28e-16	1.77e-13	-0.37	-0.37	Height;	chr6:25913849	chr6:25992662~26001775:+
HNSC	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	8.59	1.29e-16	1.78e-13	0.42	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
HNSC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-8.59	1.31e-16	1.8e-13	-0.42	-0.37	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-8.59	1.31e-16	1.8e-13	-0.42	-0.37	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	8.59	1.31e-16	1.81e-13	0.4	0.37	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
HNSC	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-8.59	1.31e-16	1.81e-13	-0.43	-0.37	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
HNSC	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-8.59	1.32e-16	1.82e-13	-0.4	-0.37	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
HNSC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-8.59	1.32e-16	1.82e-13	-0.43	-0.37	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-8.59	1.33e-16	1.83e-13	-0.25	-0.37	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
HNSC	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	8.59	1.33e-16	1.83e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	8.59	1.33e-16	1.83e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
HNSC	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	8.59	1.34e-16	1.85e-13	0.69	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
HNSC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.85e-13	-0.43	-0.37	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.85e-13	-0.43	-0.37	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-8.59	1.35e-16	1.86e-13	-0.43	-0.37	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
HNSC	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-8.59	1.35e-16	1.86e-13	-0.4	-0.37	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
HNSC	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	8.59	1.35e-16	1.86e-13	0.4	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
HNSC	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-8.59	1.36e-16	1.87e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.59	1.36e-16	1.87e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
HNSC	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	8.58	1.36e-16	1.87e-13	0.4	0.37	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
HNSC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-8.58	1.37e-16	1.88e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
HNSC	cis	rs1865760	0.566	rs2858993	ENSG00000272462.2	U91328.19	-8.58	1.37e-16	1.89e-13	-0.36	-0.37	Height;	chr6:26087628	chr6:25992662~26001775:+
HNSC	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	8.58	1.38e-16	1.9e-13	0.43	0.37	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-8.58	1.4e-16	1.92e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	8.58	1.41e-16	1.93e-13	0.47	0.37	Height;	chr6:109464011	chr6:109382795~109383666:+
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000276710.3	CSPG4P8	-8.58	1.42e-16	1.95e-13	-0.41	-0.37	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82459472~82477258:+
HNSC	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	8.58	1.43e-16	1.95e-13	0.39	0.37	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
HNSC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	8.58	1.43e-16	1.96e-13	0.61	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
HNSC	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	8.58	1.44e-16	1.98e-13	0.4	0.37	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
HNSC	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.58	1.45e-16	1.99e-13	-0.43	-0.37	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	8.58	1.46e-16	2e-13	0.35	0.37	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
HNSC	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-8.57	1.47e-16	2.01e-13	-0.48	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.57	1.48e-16	2.03e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.775	rs12196952	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135662235	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs9494323	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135663249	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs6917604	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135664161	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.775	rs7768645	ENSG00000217482.2	HMGB1P17	8.57	1.49e-16	2.04e-13	0.41	0.37	Systemic lupus erythematosus;	chr6:135664656	chr6:135636086~135636713:-
HNSC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-8.57	1.5e-16	2.05e-13	-0.43	-0.37	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
HNSC	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-8.57	1.5e-16	2.05e-13	-0.49	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
HNSC	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-8.57	1.51e-16	2.06e-13	-0.46	-0.37	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
HNSC	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-8.57	1.51e-16	2.06e-13	-0.41	-0.37	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
HNSC	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	8.57	1.51e-16	2.07e-13	0.76	0.37	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
HNSC	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	8.57	1.52e-16	2.08e-13	0.42	0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
HNSC	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-8.57	1.52e-16	2.08e-13	-0.5	-0.37	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
HNSC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	8.57	1.53e-16	2.09e-13	0.45	0.37	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
HNSC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	8.57	1.53e-16	2.09e-13	0.4	0.37	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-8.57	1.54e-16	2.11e-13	-0.42	-0.37	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
HNSC	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	8.57	1.58e-16	2.15e-13	0.75	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
HNSC	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	8.56	1.59e-16	2.17e-13	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
HNSC	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	8.56	1.6e-16	2.18e-13	0.4	0.37	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-8.56	1.61e-16	2.19e-13	-0.47	-0.37	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
HNSC	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-8.56	1.62e-16	2.21e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
HNSC	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-8.56	1.64e-16	2.23e-13	-0.42	-0.37	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
HNSC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-8.56	1.64e-16	2.24e-13	-0.43	-0.37	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-8.56	1.64e-16	2.24e-13	-0.43	-0.37	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
HNSC	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	8.56	1.65e-16	2.25e-13	0.4	0.37	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	8.56	1.65e-16	2.25e-13	0.4	0.37	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-8.56	1.65e-16	2.25e-13	-0.58	-0.37	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
HNSC	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-8.56	1.67e-16	2.28e-13	-0.4	-0.37	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
HNSC	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-8.56	1.69e-16	2.31e-13	-0.4	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
HNSC	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	8.55	1.71e-16	2.32e-13	0.38	0.37	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	8.55	1.72e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
HNSC	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	8.55	1.73e-16	2.35e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
HNSC	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	8.55	1.73e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	8.55	1.73e-16	2.35e-13	0.4	0.37	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
HNSC	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.55	1.73e-16	2.35e-13	-0.39	-0.37	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
HNSC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-8.55	1.73e-16	2.36e-13	-0.38	-0.37	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
HNSC	cis	rs6951245	0.872	rs75280240	ENSG00000224079.1	AC091729.7	-8.55	1.74e-16	2.37e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1074450~1078036:+
HNSC	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-8.55	1.74e-16	2.37e-13	-0.64	-0.37	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
HNSC	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-8.55	1.74e-16	2.37e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
HNSC	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	8.55	1.74e-16	2.37e-13	0.4	0.37	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
HNSC	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-8.55	1.78e-16	2.42e-13	-0.48	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
HNSC	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.55	1.82e-16	2.47e-13	0.47	0.37	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
HNSC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	8.55	1.82e-16	2.47e-13	0.37	0.37	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
HNSC	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.5e-13	0.37	0.37	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-8.54	1.85e-16	2.5e-13	-0.46	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
HNSC	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.54	1.85e-16	2.51e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	8.54	1.85e-16	2.51e-13	0.46	0.37	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
HNSC	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	8.54	1.87e-16	2.53e-13	0.4	0.37	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
HNSC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-8.54	1.87e-16	2.53e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
HNSC	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-8.54	1.88e-16	2.55e-13	-0.44	-0.37	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
HNSC	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.54	1.88e-16	2.55e-13	0.75	0.37	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
HNSC	cis	rs6951245	1	rs6951245	ENSG00000224079.1	AC091729.7	-8.54	1.88e-16	2.55e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1074450~1078036:+
HNSC	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-8.54	1.91e-16	2.58e-13	-0.54	-0.37	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
HNSC	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	8.54	1.92e-16	2.59e-13	0.41	0.37	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
HNSC	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-8.54	1.92e-16	2.59e-13	-0.45	-0.37	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	8.54	1.93e-16	2.61e-13	0.42	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
HNSC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-8.54	1.93e-16	2.61e-13	-0.39	-0.37	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-8.54	1.93e-16	2.62e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
HNSC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-8.54	1.94e-16	2.62e-13	-0.39	-0.37	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	8.54	1.95e-16	2.63e-13	0.46	0.37	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
HNSC	cis	rs6867032	0.958	rs4246754	ENSG00000249731.1	RP11-259O2.3	8.54	1.95e-16	2.64e-13	0.46	0.37	Gut microbiome composition (winter);	chr5:2014662	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.53	1.98e-16	2.67e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.53	1.98e-16	2.67e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.53	1.99e-16	2.68e-13	0.42	0.37	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
HNSC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-8.53	1.99e-16	2.69e-13	-0.73	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
HNSC	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	8.53	2e-16	2.7e-13	0.46	0.37	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
HNSC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-8.53	2e-16	2.7e-13	-0.39	-0.37	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.53	2e-16	2.7e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
HNSC	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.53	2.01e-16	2.72e-13	0.75	0.37	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
HNSC	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.53	2.02e-16	2.72e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000179406.6	LINC00174	-8.53	2.04e-16	2.74e-13	-0.55	-0.37	Aortic root size;	chr7:66174841	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.53	2.05e-16	2.76e-13	0.42	0.37	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	8.53	2.06e-16	2.78e-13	0.42	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-8.53	2.06e-16	2.78e-13	-0.49	-0.37	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	8.53	2.08e-16	2.8e-13	0.38	0.37	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
HNSC	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	8.53	2.08e-16	2.8e-13	0.48	0.37	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-8.53	2.1e-16	2.82e-13	-0.42	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
HNSC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-8.53	2.12e-16	2.85e-13	-0.42	-0.37	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
HNSC	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-8.53	2.13e-16	2.86e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	8.52	2.17e-16	2.91e-13	0.47	0.37	Height;	chr6:109498751	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	8.52	2.17e-16	2.91e-13	0.47	0.37	Height;	chr6:109500687	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	8.52	2.18e-16	2.92e-13	0.39	0.37	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
HNSC	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8.52	2.18e-16	2.93e-13	0.47	0.37	Height;	chr6:109407238	chr6:109382795~109383666:+
HNSC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-8.52	2.19e-16	2.93e-13	-0.39	-0.37	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
HNSC	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	8.52	2.2e-16	2.95e-13	0.43	0.37	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-8.52	2.21e-16	2.96e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
HNSC	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-8.52	2.21e-16	2.97e-13	-0.39	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
HNSC	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-8.52	2.22e-16	2.98e-13	-0.74	-0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
HNSC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-8.52	2.22e-16	2.98e-13	-0.39	-0.37	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
HNSC	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-8.52	2.24e-16	3e-13	-0.41	-0.37	Migraine;	chr4:56950140	chr4:56960927~56961373:-
HNSC	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	8.52	2.24e-16	3e-13	0.46	0.37	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
HNSC	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	8.52	2.28e-16	3.05e-13	0.4	0.37	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	8.52	2.29e-16	3.07e-13	0.52	0.37	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-8.52	2.29e-16	3.07e-13	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
HNSC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	8.51	2.32e-16	3.1e-13	0.39	0.37	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
HNSC	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	8.51	2.33e-16	3.11e-13	0.4	0.37	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
HNSC	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	8.51	2.33e-16	3.12e-13	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
HNSC	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-8.51	2.34e-16	3.12e-13	-0.42	-0.37	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
HNSC	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	8.51	2.34e-16	3.13e-13	0.42	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
HNSC	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-8.51	2.35e-16	3.14e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
HNSC	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-8.51	2.36e-16	3.15e-13	-0.42	-0.37	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
HNSC	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-8.51	2.38e-16	3.18e-13	-0.4	-0.37	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
HNSC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-8.51	2.41e-16	3.22e-13	-0.42	-0.37	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-8.51	2.42e-16	3.23e-13	-0.42	-0.37	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
HNSC	cis	rs1865760	0.964	rs6932113	ENSG00000272462.2	U91328.19	-8.51	2.43e-16	3.24e-13	-0.37	-0.37	Height;	chr6:25912870	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-8.51	2.43e-16	3.24e-13	-0.39	-0.37	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-8.5	2.48e-16	3.31e-13	-0.35	-0.37	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	8.5	2.49e-16	3.32e-13	0.46	0.37	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
HNSC	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	8.5	2.49e-16	3.32e-13	0.38	0.37	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
HNSC	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.5	2.49e-16	3.33e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.5	2.49e-16	3.33e-13	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28089816	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28090857	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28091439	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28091659	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28092227	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28093966	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-8.5	2.52e-16	3.35e-13	-0.49	-0.37	Depression;	chr6:28094014	chr6:28115628~28116551:+
HNSC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-8.5	2.53e-16	3.37e-13	-0.43	-0.37	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-8.5	2.55e-16	3.4e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-8.5	2.56e-16	3.4e-13	-0.34	-0.37	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	8.5	2.56e-16	3.42e-13	0.41	0.37	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
HNSC	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	8.5	2.57e-16	3.43e-13	0.61	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
HNSC	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	8.5	2.58e-16	3.43e-13	0.42	0.37	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	8.5	2.58e-16	3.43e-13	0.38	0.37	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	8.5	2.58e-16	3.43e-13	0.38	0.37	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-8.5	2.59e-16	3.44e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	8.5	2.6e-16	3.46e-13	0.42	0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
HNSC	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	8.5	2.62e-16	3.49e-13	0.4	0.37	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000179406.6	LINC00174	-8.5	2.63e-16	3.5e-13	-0.54	-0.37	Aortic root size;	chr7:66169164	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000179406.6	LINC00174	-8.5	2.63e-16	3.5e-13	-0.54	-0.37	Aortic root size;	chr7:66182290	chr7:66376044~66401338:-
HNSC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	8.5	2.63e-16	3.5e-13	0.35	0.37	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
HNSC	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.5	2.64e-16	3.51e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
HNSC	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-8.5	2.64e-16	3.51e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	8.5	2.65e-16	3.52e-13	0.48	0.37	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
HNSC	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	8.5	2.66e-16	3.54e-13	0.44	0.37	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.532	rs2794719	ENSG00000272462.2	U91328.19	-8.49	2.71e-16	3.6e-13	-0.36	-0.37	Height;	chr6:26088662	chr6:25992662~26001775:+
HNSC	cis	rs6951245	1	rs11763020	ENSG00000224079.1	AC091729.7	-8.49	2.72e-16	3.61e-13	-0.61	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1074450~1078036:+
HNSC	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-8.49	2.73e-16	3.62e-13	-0.47	-0.37	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	8.49	2.74e-16	3.63e-13	0.34	0.37	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
HNSC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-8.49	2.74e-16	3.63e-13	-0.5	-0.37	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-8.49	2.74e-16	3.63e-13	-0.5	-0.37	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
HNSC	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	8.49	2.77e-16	3.67e-13	0.42	0.37	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
HNSC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	8.49	2.78e-16	3.69e-13	0.37	0.37	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	8.49	2.78e-16	3.69e-13	0.37	0.37	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
HNSC	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	8.49	2.78e-16	3.69e-13	0.39	0.37	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	8.49	2.79e-16	3.7e-13	0.4	0.37	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-8.49	2.79e-16	3.7e-13	-0.48	-0.37	Depression;	chr6:28139049	chr6:28115628~28116551:+
HNSC	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-8.49	2.81e-16	3.72e-13	-0.34	-0.37	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
HNSC	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	8.49	2.81e-16	3.73e-13	0.54	0.37	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
HNSC	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-8.49	2.82e-16	3.74e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
HNSC	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-8.49	2.84e-16	3.76e-13	-0.41	-0.37	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-8.49	2.86e-16	3.78e-13	-0.39	-0.37	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
HNSC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	8.49	2.87e-16	3.8e-13	0.47	0.37	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	8.48	2.88e-16	3.81e-13	0.46	0.37	Height;	chr6:109462738	chr6:109382795~109383666:+
HNSC	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-8.48	2.93e-16	3.88e-13	-0.47	-0.37	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
HNSC	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	8.48	2.95e-16	3.89e-13	0.43	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.48	2.95e-16	3.9e-13	-0.54	-0.37	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
HNSC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-8.48	2.96e-16	3.92e-13	-0.42	-0.37	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
HNSC	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	8.48	2.99e-16	3.95e-13	0.4	0.37	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
HNSC	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8.48	3e-16	3.96e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8.48	3e-16	3.96e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
HNSC	cis	rs1865760	0.566	rs9379825	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083643	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9467672	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083676	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9295688	ENSG00000272462.2	U91328.19	-8.48	3e-16	3.97e-13	-0.36	-0.37	Height;	chr6:26083989	chr6:25992662~26001775:+
HNSC	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-8.48	3.03e-16	4e-13	-0.42	-0.37	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
HNSC	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-8.48	3.04e-16	4.01e-13	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
HNSC	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	8.48	3.04e-16	4.02e-13	0.38	0.37	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
HNSC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	8.48	3.05e-16	4.02e-13	0.46	0.37	Height;	chr6:109392096	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	8.48	3.06e-16	4.04e-13	0.46	0.37	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
HNSC	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	8.48	3.06e-16	4.04e-13	0.44	0.37	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
HNSC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	8.48	3.07e-16	4.05e-13	0.47	0.37	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
HNSC	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	8.48	3.08e-16	4.06e-13	0.46	0.37	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
HNSC	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	8.48	3.08e-16	4.06e-13	0.48	0.37	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	8.48	3.08e-16	4.06e-13	0.48	0.37	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
HNSC	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	8.48	3.08e-16	4.07e-13	0.44	0.37	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
HNSC	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-8.48	3.09e-16	4.08e-13	-0.43	-0.37	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.47	3.11e-16	4.09e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-8.47	3.11e-16	4.1e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-8.47	3.12e-16	4.11e-13	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
HNSC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-8.47	3.12e-16	4.11e-13	-0.39	-0.37	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
HNSC	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.47	3.13e-16	4.12e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.47	3.13e-16	4.12e-13	-0.55	-0.37	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	4.13e-13	-0.46	-0.37	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
HNSC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-8.47	3.16e-16	4.16e-13	-0.42	-0.37	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
HNSC	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-8.47	3.17e-16	4.18e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
HNSC	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	8.47	3.17e-16	4.18e-13	0.38	0.36	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
HNSC	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	8.47	3.18e-16	4.19e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-8.47	3.19e-16	4.2e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
HNSC	cis	rs875971	0.545	rs316316	ENSG00000179406.6	LINC00174	8.47	3.19e-16	4.2e-13	0.54	0.36	Aortic root size;	chr7:66149270	chr7:66376044~66401338:-
HNSC	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-8.47	3.22e-16	4.23e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
HNSC	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	8.47	3.24e-16	4.26e-13	0.38	0.36	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
HNSC	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	8.47	3.24e-16	4.26e-13	0.45	0.36	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
HNSC	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	8.47	3.27e-16	4.3e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.566	rs2051544	ENSG00000272462.2	U91328.19	-8.47	3.28e-16	4.31e-13	-0.36	-0.36	Height;	chr6:26070865	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-8.47	3.28e-16	4.31e-13	-0.42	-0.36	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
HNSC	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-8.47	3.3e-16	4.34e-13	-0.42	-0.36	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
HNSC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-8.47	3.31e-16	4.35e-13	-0.41	-0.36	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
HNSC	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.47	3.33e-16	4.38e-13	-0.55	-0.36	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
HNSC	cis	rs9402743	0.775	rs12210389	ENSG00000217482.2	HMGB1P17	8.47	3.34e-16	4.38e-13	0.41	0.36	Systemic lupus erythematosus;	chr6:135661977	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-8.46	3.36e-16	4.42e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-8.46	3.37e-16	4.42e-13	-0.35	-0.36	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
HNSC	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	8.46	3.39e-16	4.46e-13	0.4	0.36	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
HNSC	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-8.46	3.4e-16	4.47e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-8.46	3.4e-16	4.47e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
HNSC	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	8.46	3.41e-16	4.48e-13	0.46	0.36	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
HNSC	cis	rs7615952	0.673	rs3811677	ENSG00000241288.6	RP11-379B18.5	-8.46	3.44e-16	4.51e-13	-0.53	-0.36	Blood pressure (smoking interaction);	chr3:125929237	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.932	rs3811679	ENSG00000241288.6	RP11-379B18.5	-8.46	3.44e-16	4.51e-13	-0.53	-0.36	Blood pressure (smoking interaction);	chr3:125929440	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	8.46	3.48e-16	4.56e-13	0.46	0.36	Height;	chr6:109465777	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-8.46	3.48e-16	4.56e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.928	rs9295673	ENSG00000272462.2	U91328.19	-8.46	3.5e-16	4.58e-13	-0.37	-0.36	Height;	chr6:25911866	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-8.46	3.52e-16	4.62e-13	-0.39	-0.36	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
HNSC	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-8.46	3.53e-16	4.63e-13	-0.52	-0.36	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
HNSC	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-8.46	3.54e-16	4.64e-13	-0.4	-0.36	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
HNSC	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-8.46	3.55e-16	4.65e-13	-0.43	-0.36	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
HNSC	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-8.45	3.61e-16	4.73e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
HNSC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	8.45	3.63e-16	4.74e-13	0.46	0.36	Height;	chr6:109383239	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	8.45	3.63e-16	4.74e-13	0.46	0.36	Height;	chr6:109383248	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	8.45	3.63e-16	4.74e-13	0.46	0.36	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
HNSC	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-8.45	3.63e-16	4.75e-13	-0.39	-0.36	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
HNSC	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-8.45	3.65e-16	4.77e-13	-0.42	-0.36	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	8.45	3.65e-16	4.78e-13	0.46	0.36	Height;	chr6:109384807	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	8.45	3.66e-16	4.78e-13	0.44	0.36	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
HNSC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	8.45	3.67e-16	4.79e-13	0.41	0.36	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
HNSC	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	8.45	3.68e-16	4.81e-13	0.44	0.36	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-8.45	3.68e-16	4.81e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	8.45	3.69e-16	4.82e-13	0.47	0.36	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
HNSC	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-8.45	3.7e-16	4.83e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-8.45	3.71e-16	4.84e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
HNSC	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	8.45	3.72e-16	4.85e-13	0.43	0.36	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-8.45	3.75e-16	4.9e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.932	rs6438948	ENSG00000241288.6	RP11-379B18.5	8.45	3.79e-16	4.95e-13	0.48	0.36	Blood pressure (smoking interaction);	chr3:125931202	chr3:125827238~125916384:-
HNSC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-8.45	3.83e-16	4.99e-13	-0.54	-0.36	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
HNSC	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109494148	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109494760	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109495102	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	8.45	3.84e-16	5e-13	0.47	0.36	Height;	chr6:109496680	chr6:109382795~109383666:+
HNSC	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	8.45	3.84e-16	5.01e-13	0.45	0.36	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	8.45	3.86e-16	5.03e-13	0.48	0.36	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
HNSC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.44	3.88e-16	5.06e-13	0.4	0.36	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
HNSC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	8.44	3.93e-16	5.12e-13	0.52	0.36	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
HNSC	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.44	3.94e-16	5.13e-13	-0.42	-0.36	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
HNSC	cis	rs7615952	0.932	rs7629977	ENSG00000241288.6	RP11-379B18.5	-8.44	4e-16	5.21e-13	-0.5	-0.36	Blood pressure (smoking interaction);	chr3:125930730	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.932	rs7630077	ENSG00000241288.6	RP11-379B18.5	-8.44	4e-16	5.21e-13	-0.5	-0.36	Blood pressure (smoking interaction);	chr3:125930833	chr3:125827238~125916384:-
HNSC	cis	rs1865760	0.566	rs9379821	ENSG00000272462.2	U91328.19	-8.44	4e-16	5.21e-13	-0.36	-0.36	Height;	chr6:26054040	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9358902	ENSG00000272462.2	U91328.19	-8.44	4e-16	5.21e-13	-0.36	-0.36	Height;	chr6:26058342	chr6:25992662~26001775:+
HNSC	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-8.44	4.04e-16	5.25e-13	-0.43	-0.36	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-8.44	4.04e-16	5.25e-13	-0.43	-0.36	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
HNSC	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-8.44	4.07e-16	5.3e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-8.44	4.08e-16	5.3e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-8.44	4.1e-16	5.32e-13	-0.41	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
HNSC	cis	rs2006771	0.836	rs7285777	ENSG00000236132.1	CTA-440B3.1	8.44	4.12e-16	5.35e-13	0.4	0.36	Nonsyndromic cleft lip with cleft palate;	chr22:31586255	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.43	4.2e-16	5.45e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.43	4.2e-16	5.45e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
HNSC	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	8.43	4.26e-16	5.53e-13	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
HNSC	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-8.43	4.32e-16	5.61e-13	-0.47	-0.36	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-8.43	4.32e-16	5.61e-13	-0.47	-0.36	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
HNSC	cis	rs1865760	0.516	rs9393684	ENSG00000272462.2	U91328.19	-8.43	4.34e-16	5.63e-13	-0.36	-0.36	Height;	chr6:26075303	chr6:25992662~26001775:+
HNSC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.43	4.35e-16	5.64e-13	0.4	0.36	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
HNSC	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	8.43	4.38e-16	5.68e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
HNSC	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-8.43	4.42e-16	5.72e-13	-0.47	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
HNSC	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-8.43	4.42e-16	5.73e-13	-0.43	-0.36	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
HNSC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	8.43	4.43e-16	5.74e-13	0.38	0.36	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-8.43	4.43e-16	5.74e-13	-0.48	-0.36	Depression;	chr6:28091242	chr6:28115628~28116551:+
HNSC	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-8.43	4.46e-16	5.77e-13	-0.42	-0.36	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
HNSC	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	8.43	4.46e-16	5.77e-13	0.36	0.36	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
HNSC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-8.43	4.46e-16	5.77e-13	-0.49	-0.36	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
HNSC	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	8.43	4.47e-16	5.79e-13	0.46	0.36	Height;	chr6:109497088	chr6:109382795~109383666:+
HNSC	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	8.43	4.47e-16	5.79e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	8.43	4.47e-16	5.79e-13	0.41	0.36	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-8.43	4.48e-16	5.8e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
HNSC	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	8.43	4.48e-16	5.8e-13	0.47	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
HNSC	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	8.43	4.49e-16	5.81e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.508	rs9379820	ENSG00000272462.2	U91328.19	-8.42	4.5e-16	5.82e-13	-0.36	-0.36	Height;	chr6:26049696	chr6:25992662~26001775:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-8.42	4.51e-16	5.84e-13	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-8.42	4.51e-16	5.84e-13	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
HNSC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	8.42	4.52e-16	5.85e-13	0.46	0.36	Height;	chr6:109383848	chr6:109382795~109383666:+
HNSC	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	8.42	4.55e-16	5.88e-13	0.61	0.36	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
HNSC	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-8.42	4.64e-16	5.99e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
HNSC	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	8.42	4.65e-16	6.01e-13	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	8.42	4.7e-16	6.07e-13	0.48	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
HNSC	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	8.42	4.74e-16	6.12e-13	0.58	0.36	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
HNSC	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-8.42	4.74e-16	6.12e-13	-0.39	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
HNSC	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-8.42	4.75e-16	6.14e-13	-0.32	-0.36	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	8.42	4.79e-16	6.18e-13	0.42	0.36	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
HNSC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	8.42	4.79e-16	6.19e-13	0.4	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
HNSC	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-8.42	4.8e-16	6.19e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-8.42	4.8e-16	6.19e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
HNSC	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-8.42	4.83e-16	6.23e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
HNSC	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	8.41	4.86e-16	6.26e-13	0.44	0.36	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	8.41	4.86e-16	6.26e-13	0.44	0.36	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
HNSC	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-8.41	4.9e-16	6.31e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-8.41	4.91e-16	6.33e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-8.41	4.93e-16	6.35e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	8.41	5e-16	6.44e-13	0.44	0.36	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
HNSC	cis	rs1865760	0.566	rs10807006	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26048524	chr6:25992662~26001775:+
HNSC	cis	rs12216125	0.554	rs6942196	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Iron status biomarkers;	chr6:26072576	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1539183	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26074823	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs9295686	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26081755	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.532	rs9295687	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26082482	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs4529296	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26082907	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1971509	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26085549	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.532	rs2006736	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26085789	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs1800702	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26086235	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.566	rs2794720	ENSG00000272462.2	U91328.19	-8.41	5.03e-16	6.47e-13	-0.35	-0.36	Height;	chr6:26086974	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-8.41	5.03e-16	6.48e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	8.41	5.05e-16	6.5e-13	0.37	0.36	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	8.41	5.05e-16	6.5e-13	0.37	0.36	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000276710.3	CSPG4P8	-8.41	5.05e-16	6.5e-13	-0.4	-0.36	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82459472~82477258:+
HNSC	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.41	5.05e-16	6.5e-13	-0.33	-0.36	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
HNSC	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-8.41	5.11e-16	6.57e-13	-0.43	-0.36	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
HNSC	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	8.41	5.13e-16	6.6e-13	0.39	0.36	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.41	5.16e-16	6.63e-13	0.34	0.36	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
HNSC	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	8.41	5.16e-16	6.64e-13	0.45	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	8.41	5.16e-16	6.64e-13	0.45	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-8.41	5.17e-16	6.64e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.41	5.17e-16	6.65e-13	0.4	0.36	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.41	5.17e-16	6.65e-13	0.4	0.36	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
HNSC	cis	rs7615952	0.932	rs1976458	ENSG00000241288.6	RP11-379B18.5	-8.41	5.21e-16	6.69e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125928669	chr3:125827238~125916384:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000179406.6	LINC00174	-8.4	5.21e-16	6.69e-13	-0.54	-0.36	Aortic root size;	chr7:66168318	chr7:66376044~66401338:-
HNSC	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-8.4	5.25e-16	6.75e-13	-0.4	-0.36	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
HNSC	cis	rs7615952	0.741	rs13314845	ENSG00000241288.6	RP11-379B18.5	-8.4	5.27e-16	6.77e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125925939	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.733	rs13314847	ENSG00000241288.6	RP11-379B18.5	-8.4	5.27e-16	6.77e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125925945	chr3:125827238~125916384:-
HNSC	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.4	5.28e-16	6.77e-13	0.4	0.36	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
HNSC	cis	rs9341808	0.718	rs9343971	ENSG00000272129.1	RP11-250B2.6	8.4	5.3e-16	6.81e-13	0.43	0.36	Sitting height ratio;	chr6:80172339	chr6:80355424~80356859:+
HNSC	cis	rs1865760	0.566	rs7772312	ENSG00000272462.2	U91328.19	-8.4	5.33e-16	6.84e-13	-0.35	-0.36	Height;	chr6:26049388	chr6:25992662~26001775:+
HNSC	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-8.4	5.35e-16	6.86e-13	-0.48	-0.36	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-8.4	5.37e-16	6.88e-13	-0.38	-0.36	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
HNSC	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	8.4	5.41e-16	6.94e-13	0.42	0.36	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
HNSC	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	8.4	5.48e-16	7.02e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	8.4	5.48e-16	7.02e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
HNSC	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	8.4	5.49e-16	7.03e-13	0.48	0.36	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-8.4	5.5e-16	7.05e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
HNSC	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-8.4	5.51e-16	7.06e-13	-0.37	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
HNSC	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-8.4	5.59e-16	7.16e-13	-0.45	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
HNSC	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	8.39	5.67e-16	7.26e-13	0.46	0.36	Height;	chr6:109454233	chr6:109382795~109383666:+
HNSC	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.39	5.7e-16	7.29e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
HNSC	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.39	5.7e-16	7.29e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
HNSC	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	8.39	5.74e-16	7.34e-13	0.41	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
HNSC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	8.39	5.76e-16	7.37e-13	0.39	0.36	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
HNSC	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	8.39	5.79e-16	7.4e-13	0.44	0.36	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
HNSC	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	8.39	5.79e-16	7.4e-13	0.44	0.36	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
HNSC	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.39	5.82e-16	7.43e-13	0.47	0.36	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-8.39	5.82e-16	7.44e-13	-0.39	-0.36	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
HNSC	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	8.39	5.83e-16	7.45e-13	0.49	0.36	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
HNSC	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-8.39	5.85e-16	7.48e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
HNSC	cis	rs1865760	1	rs6905887	ENSG00000272462.2	U91328.19	-8.39	5.88e-16	7.5e-13	-0.36	-0.36	Height;	chr6:25911875	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-8.39	5.9e-16	7.54e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	8.39	5.92e-16	7.56e-13	0.44	0.36	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
HNSC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	8.39	5.96e-16	7.61e-13	0.46	0.36	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	8.39	5.97e-16	7.62e-13	0.46	0.36	Height;	chr6:109382188	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-8.39	5.98e-16	7.63e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
HNSC	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-8.39	6e-16	7.65e-13	-0.42	-0.36	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
HNSC	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-8.39	6e-16	7.66e-13	-0.46	-0.36	Height;	chr6:109497253	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	8.39	6.03e-16	7.68e-13	0.44	0.36	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000179406.6	LINC00174	8.38	6.05e-16	7.71e-13	0.54	0.36	Aortic root size;	chr7:66152984	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs316306	ENSG00000179406.6	LINC00174	8.38	6.05e-16	7.71e-13	0.54	0.36	Aortic root size;	chr7:66153687	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.866	rs1976459	ENSG00000241288.6	RP11-379B18.5	-8.38	6.1e-16	7.78e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125928643	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	8.38	6.1e-16	7.78e-13	0.45	0.36	Height;	chr6:109393881	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-8.38	6.11e-16	7.78e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.38	6.17e-16	7.85e-13	0.54	0.36	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.38	6.17e-16	7.85e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
HNSC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	8.38	6.17e-16	7.86e-13	0.39	0.36	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
HNSC	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-8.38	6.18e-16	7.87e-13	-0.37	-0.36	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-8.38	6.22e-16	7.91e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	8.38	6.29e-16	8e-13	0.45	0.36	Height;	chr6:109391534	chr6:109382795~109383666:+
HNSC	cis	rs7615952	0.932	rs13086087	ENSG00000241288.6	RP11-379B18.5	-8.38	6.29e-16	8e-13	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125927438	chr3:125827238~125916384:-
HNSC	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-8.38	6.31e-16	8.02e-13	-0.38	-0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
HNSC	cis	rs9341808	0.718	rs9448908	ENSG00000272129.1	RP11-250B2.6	8.38	6.31e-16	8.03e-13	0.43	0.36	Sitting height ratio;	chr6:80188352	chr6:80355424~80356859:+
HNSC	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	8.38	6.32e-16	8.03e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-8.38	6.32e-16	8.04e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	8.38	6.33e-16	8.04e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-8.38	6.33e-16	8.04e-13	-0.55	-0.36	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
HNSC	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-8.38	6.34e-16	8.06e-13	-0.38	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
HNSC	cis	rs1865760	1	rs3799372	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25922083	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.963	rs1540273	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25923930	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9358895	ENSG00000272462.2	U91328.19	-8.38	6.35e-16	8.07e-13	-0.36	-0.36	Height;	chr6:25924427	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs7757666	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25902398	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs6910138	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25904124	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs6910174	ENSG00000272462.2	U91328.19	-8.38	6.38e-16	8.1e-13	-0.36	-0.36	Height;	chr6:25904186	chr6:25992662~26001775:+
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-8.38	6.38e-16	8.11e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-8.38	6.38e-16	8.11e-13	-0.41	-0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
HNSC	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-8.38	6.39e-16	8.12e-13	-0.42	-0.36	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	8.38	6.41e-16	8.14e-13	0.38	0.36	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
HNSC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	8.38	6.42e-16	8.15e-13	0.45	0.36	Height;	chr6:109390116	chr6:109382795~109383666:+
HNSC	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	8.38	6.42e-16	8.16e-13	0.77	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
HNSC	cis	rs1865760	1	rs9467636	ENSG00000272462.2	U91328.19	-8.38	6.42e-16	8.16e-13	-0.36	-0.36	Height;	chr6:25919321	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9358893	ENSG00000272462.2	U91328.19	-8.38	6.42e-16	8.16e-13	-0.36	-0.36	Height;	chr6:25921533	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-8.38	6.44e-16	8.17e-13	-0.39	-0.36	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
HNSC	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	8.38	6.46e-16	8.19e-13	0.49	0.36	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
HNSC	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	8.37	6.54e-16	8.29e-13	0.38	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
HNSC	cis	rs1865760	1	rs7739966	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25905812	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs56118523	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25908747	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs12209482	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25909001	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.963	rs3846838	ENSG00000272462.2	U91328.19	-8.37	6.6e-16	8.36e-13	-0.36	-0.36	Height;	chr6:25911547	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	8.37	6.65e-16	8.43e-13	0.37	0.36	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
HNSC	cis	rs6951245	0.872	rs11768895	ENSG00000224079.1	AC091729.7	-8.37	6.67e-16	8.45e-13	-0.57	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024055	chr7:1074450~1078036:+
HNSC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-8.37	6.68e-16	8.46e-13	-0.46	-0.36	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
HNSC	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	8.37	6.71e-16	8.51e-13	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
HNSC	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	8.37	6.72e-16	8.51e-13	0.41	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
HNSC	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-8.37	6.74e-16	8.54e-13	-0.32	-0.36	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
HNSC	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-8.37	6.75e-16	8.56e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
HNSC	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-8.37	6.75e-16	8.56e-13	-0.41	-0.36	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
HNSC	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-8.37	6.77e-16	8.58e-13	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
HNSC	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-8.37	6.78e-16	8.58e-13	-0.4	-0.36	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
HNSC	cis	rs1865760	0.929	rs1816546	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25938024	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.786	rs1436308	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25939339	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.929	rs1436307	ENSG00000272462.2	U91328.19	-8.37	6.81e-16	8.62e-13	-0.36	-0.36	Height;	chr6:25939495	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.37	6.82e-16	8.64e-13	0.41	0.36	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
HNSC	cis	rs1865760	1	rs9393675	ENSG00000272462.2	U91328.19	-8.37	6.83e-16	8.64e-13	-0.37	-0.36	Height;	chr6:25929888	chr6:25992662~26001775:+
HNSC	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	8.37	6.84e-16	8.66e-13	0.47	0.36	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
HNSC	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	8.37	6.86e-16	8.68e-13	0.41	0.36	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	8.37	6.87e-16	8.7e-13	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	8.37	6.88e-16	8.7e-13	0.45	0.36	Height;	chr6:109390638	chr6:109382795~109383666:+
HNSC	cis	rs12216125	0.549	rs9358905	ENSG00000272462.2	U91328.19	-8.37	6.9e-16	8.73e-13	-0.35	-0.36	Iron status biomarkers;	chr6:26077611	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-8.37	6.94e-16	8.77e-13	-0.46	-0.36	Height;	chr6:109501793	chr6:109382795~109383666:+
HNSC	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-8.37	6.97e-16	8.82e-13	-0.34	-0.36	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
HNSC	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.37	6.98e-16	8.83e-13	0.46	0.36	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
HNSC	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	8.36	7.01e-16	8.86e-13	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
HNSC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	8.36	7.01e-16	8.86e-13	0.48	0.36	Depression;	chr6:28142370	chr6:28115628~28116551:+
HNSC	cis	rs1865760	1	rs7770139	ENSG00000272462.2	U91328.19	-8.36	7.01e-16	8.87e-13	-0.36	-0.36	Height;	chr6:25925595	chr6:25992662~26001775:+
HNSC	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	8.36	7.03e-16	8.89e-13	0.4	0.36	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-8.36	7.07e-16	8.94e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.964	rs3799373	ENSG00000272462.2	U91328.19	-8.36	7.09e-16	8.96e-13	-0.36	-0.36	Height;	chr6:25928945	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs9348698	ENSG00000272462.2	U91328.19	-8.36	7.09e-16	8.96e-13	-0.36	-0.36	Height;	chr6:25929461	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	8.36	7.12e-16	8.99e-13	0.43	0.36	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	8.36	7.12e-16	8.99e-13	0.43	0.36	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-8.36	7.13e-16	9e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
HNSC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	8.36	7.19e-16	9.07e-13	0.46	0.36	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
HNSC	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.36	7.2e-16	9.08e-13	-0.54	-0.36	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
HNSC	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	8.36	7.22e-16	9.1e-13	0.43	0.36	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	8.36	7.22e-16	9.1e-13	0.43	0.36	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
HNSC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	8.36	7.25e-16	9.14e-13	0.43	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66158946	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66160135	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66161064	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66164012	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000179406.6	LINC00174	-8.36	7.29e-16	9.19e-13	-0.54	-0.36	Aortic root size;	chr7:66166374	chr7:66376044~66401338:-
HNSC	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	8.36	7.3e-16	9.19e-13	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
HNSC	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	8.36	7.3e-16	9.2e-13	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-8.36	7.31e-16	9.2e-13	-0.35	-0.36	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-8.36	7.37e-16	9.28e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
HNSC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-8.36	7.38e-16	9.29e-13	-0.48	-0.36	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
HNSC	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	8.36	7.4e-16	9.31e-13	0.47	0.36	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	8.36	7.4e-16	9.31e-13	0.33	0.36	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	8.36	7.4e-16	9.32e-13	0.37	0.36	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	8.36	7.41e-16	9.33e-13	0.46	0.36	Height;	chr6:109443332	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	8.36	7.42e-16	9.34e-13	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	8.36	7.42e-16	9.34e-13	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
HNSC	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	8.36	7.44e-16	9.36e-13	0.42	0.36	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
HNSC	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-8.36	7.45e-16	9.37e-13	-0.43	-0.36	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
HNSC	cis	rs6951245	0.935	rs11763765	ENSG00000224079.1	AC091729.7	-8.36	7.45e-16	9.37e-13	-0.6	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs11766669	ENSG00000224079.1	AC091729.7	-8.36	7.45e-16	9.37e-13	-0.6	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-8.36	7.45e-16	9.37e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.516	rs9295684	ENSG00000272462.2	U91328.19	-8.36	7.5e-16	9.43e-13	-0.35	-0.36	Height;	chr6:26069441	chr6:25992662~26001775:+
HNSC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-8.36	7.5e-16	9.43e-13	-0.42	-0.36	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
HNSC	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	8.36	7.51e-16	9.44e-13	0.46	0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
HNSC	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	8.36	7.52e-16	9.46e-13	0.41	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
HNSC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	8.36	7.53e-16	9.47e-13	0.41	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
HNSC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	8.35	7.56e-16	9.51e-13	0.51	0.36	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
HNSC	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-8.35	7.58e-16	9.53e-13	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.566	rs2032445	ENSG00000272462.2	U91328.19	-8.35	7.58e-16	9.53e-13	-0.35	-0.36	Height;	chr6:26044584	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	8.35	7.62e-16	9.57e-13	0.43	0.36	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
HNSC	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	8.35	7.67e-16	9.63e-13	0.39	0.36	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-8.35	7.68e-16	9.65e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	8.35	7.72e-16	9.69e-13	0.39	0.36	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
HNSC	cis	rs1865760	0.892	rs9379806	ENSG00000272462.2	U91328.19	-8.35	7.72e-16	9.7e-13	-0.36	-0.36	Height;	chr6:25940730	chr6:25992662~26001775:+
HNSC	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	8.35	7.72e-16	9.7e-13	0.46	0.36	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
HNSC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8.35	7.73e-16	9.71e-13	0.41	0.36	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8.35	7.73e-16	9.71e-13	0.41	0.36	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
HNSC	cis	rs10256972	0.626	rs62433138	ENSG00000225146.1	AC073957.15	8.35	7.78e-16	9.77e-13	0.41	0.36	Endometriosis;Longevity;	chr7:1011241	chr7:1029025~1043891:+
HNSC	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-8.35	7.79e-16	9.78e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
HNSC	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	8.35	7.8e-16	9.79e-13	0.47	0.36	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.35	7.9e-16	9.91e-13	0.33	0.36	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
HNSC	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	8.35	7.93e-16	9.95e-13	0.41	0.36	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28140454	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28141189	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-8.35	7.94e-16	9.96e-13	-0.48	-0.36	Depression;	chr6:28141484	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-8.35	7.96e-16	9.99e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	8.35	7.98e-16	1e-12	0.41	0.36	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
HNSC	cis	rs35955747	0.601	rs5749302	ENSG00000236132.1	CTA-440B3.1	-8.35	7.98e-16	1e-12	-0.4	-0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31554632	chr22:31816379~31817491:-
HNSC	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-8.35	8.04e-16	1.01e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
HNSC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	8.35	8.05e-16	1.01e-12	0.41	0.36	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-8.34	8.12e-16	1.02e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-8.34	8.12e-16	1.02e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-8.34	8.14e-16	1.02e-12	-0.4	-0.36	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.34	8.17e-16	1.02e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	8.34	8.19e-16	1.03e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	8.34	8.19e-16	1.03e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
HNSC	cis	rs7104764	0.879	rs511744	ENSG00000277290.1	RP11-326C3.16	-8.34	8.2e-16	1.03e-12	-0.36	-0.36	Menarche (age at onset);	chr11:219089	chr11:243099~243483:-
HNSC	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-8.34	8.28e-16	1.04e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
HNSC	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	8.34	8.28e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	8.34	8.29e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	8.34	8.3e-16	1.04e-12	0.41	0.36	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
HNSC	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	8.34	8.31e-16	1.04e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	8.34	8.31e-16	1.04e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
HNSC	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	8.34	8.32e-16	1.04e-12	0.4	0.36	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
HNSC	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-8.34	8.34e-16	1.04e-12	-0.37	-0.36	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-8.34	8.35e-16	1.04e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.8	rs13086460	ENSG00000241288.6	RP11-379B18.5	-8.34	8.44e-16	1.06e-12	-0.52	-0.36	Blood pressure (smoking interaction);	chr3:125927574	chr3:125827238~125916384:-
HNSC	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	8.34	8.48e-16	1.06e-12	0.43	0.36	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	8.34	8.48e-16	1.06e-12	0.43	0.36	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
HNSC	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	8.34	8.48e-16	1.06e-12	0.34	0.36	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
HNSC	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-8.34	8.48e-16	1.06e-12	-0.34	-0.36	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
HNSC	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-8.34	8.51e-16	1.06e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
HNSC	cis	rs1865760	1	rs1865760	ENSG00000272462.2	U91328.19	-8.34	8.53e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25916751	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.34	8.55e-16	1.07e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
HNSC	cis	rs1865760	1	rs3830057	ENSG00000272462.2	U91328.19	-8.34	8.59e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25918282	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs3752421	ENSG00000272462.2	U91328.19	-8.34	8.59e-16	1.07e-12	-0.36	-0.36	Height;	chr6:25918460	chr6:25992662~26001775:+
HNSC	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	8.34	8.64e-16	1.08e-12	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
HNSC	cis	rs7048146	0.899	rs7032590	ENSG00000213539.4	YBX1P6	8.34	8.64e-16	1.08e-12	0.43	0.36	Vascular brain injury;	chr9:109575480	chr9:109532830~109534332:-
HNSC	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-8.34	8.67e-16	1.08e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
HNSC	cis	rs1865760	0.566	rs9348706	ENSG00000272462.2	U91328.19	-8.33	8.75e-16	1.09e-12	-0.35	-0.36	Height;	chr6:26065253	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-8.33	8.8e-16	1.1e-12	-0.34	-0.36	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-8.33	8.81e-16	1.1e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000276710.3	CSPG4P8	-8.33	8.84e-16	1.1e-12	-0.4	-0.36	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82459472~82477258:+
HNSC	cis	rs2179367	1	rs2179367	ENSG00000231760.4	RP11-350J20.5	8.33	8.87e-16	1.11e-12	0.47	0.36	Dupuytren's disease;	chr6:149441401	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000179406.6	LINC00174	-8.33	8.88e-16	1.11e-12	-0.52	-0.36	Aortic root size;	chr7:66169334	chr7:66376044~66401338:-
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-8.33	8.91e-16	1.11e-12	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
HNSC	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.33	8.92e-16	1.11e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.33	8.94e-16	1.11e-12	0.42	0.36	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.33	8.94e-16	1.11e-12	0.42	0.36	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.59	rs4706841	ENSG00000272129.1	RP11-250B2.6	8.33	8.97e-16	1.12e-12	0.42	0.36	Sitting height ratio;	chr6:80348110	chr6:80355424~80356859:+
HNSC	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	8.33	9.03e-16	1.12e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
HNSC	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	8.33	9.05e-16	1.13e-12	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	8.33	9.07e-16	1.13e-12	0.45	0.36	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	8.33	9.12e-16	1.13e-12	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
HNSC	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	8.33	9.2e-16	1.15e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-8.33	9.25e-16	1.15e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.964	rs1324084	ENSG00000272462.2	U91328.19	-8.33	9.28e-16	1.15e-12	-0.36	-0.36	Height;	chr6:25914906	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	8.33	9.3e-16	1.16e-12	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.566	rs2032443	ENSG00000272462.2	U91328.19	-8.33	9.3e-16	1.16e-12	-0.35	-0.36	Height;	chr6:26046574	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.516	rs9358903	ENSG00000272462.2	U91328.19	-8.33	9.35e-16	1.16e-12	-0.35	-0.36	Height;	chr6:26061721	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-8.33	9.36e-16	1.16e-12	-0.38	-0.36	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
HNSC	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	8.33	9.37e-16	1.16e-12	0.44	0.36	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
HNSC	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-8.33	9.38e-16	1.17e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
HNSC	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.32	9.43e-16	1.17e-12	0.47	0.36	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000179406.6	LINC00174	8.32	9.44e-16	1.17e-12	0.54	0.36	Aortic root size;	chr7:66154218	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	8.32	9.44e-16	1.17e-12	0.38	0.36	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.32	9.45e-16	1.17e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	8.32	9.5e-16	1.18e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	8.32	9.53e-16	1.18e-12	0.37	0.36	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
HNSC	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-8.32	9.56e-16	1.19e-12	-0.42	-0.36	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
HNSC	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-8.32	9.58e-16	1.19e-12	-0.58	-0.36	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-8.32	9.59e-16	1.19e-12	-0.57	-0.36	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-8.32	9.59e-16	1.19e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	8.32	9.6e-16	1.19e-12	0.33	0.36	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-8.32	9.6e-16	1.19e-12	-0.4	-0.36	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
HNSC	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-8.32	9.66e-16	1.2e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-8.32	9.66e-16	1.2e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
HNSC	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-8.32	9.73e-16	1.21e-12	-0.38	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
HNSC	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	8.32	9.77e-16	1.21e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
HNSC	cis	rs7404843	0.778	rs72774864	ENSG00000263065.1	AF001548.6	8.32	9.78e-16	1.21e-12	0.66	0.36	Testicular germ cell tumor;	chr16:15418465	chr16:15741151~15741791:+
HNSC	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-8.32	9.82e-16	1.22e-12	-0.34	-0.36	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
HNSC	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	8.32	9.9e-16	1.23e-12	0.45	0.36	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	8.32	9.9e-16	1.23e-12	0.45	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
HNSC	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-8.32	9.9e-16	1.23e-12	-0.35	-0.36	Height;	chr6:26071497	chr6:25992662~26001775:+
HNSC	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	8.32	9.92e-16	1.23e-12	0.44	0.36	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
HNSC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-8.32	9.92e-16	1.23e-12	-0.41	-0.36	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
HNSC	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	8.32	9.95e-16	1.23e-12	0.47	0.36	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
HNSC	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-8.32	1e-15	1.24e-12	-0.41	-0.36	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
HNSC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	8.32	1e-15	1.24e-12	0.4	0.36	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
HNSC	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-8.32	1e-15	1.24e-12	-0.41	-0.36	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
HNSC	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	8.32	1.01e-15	1.25e-12	0.46	0.36	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
HNSC	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	8.31	1.01e-15	1.25e-12	0.56	0.36	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
HNSC	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-8.31	1.01e-15	1.25e-12	-0.39	-0.36	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-8.31	1.01e-15	1.26e-12	-0.57	-0.36	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	8.31	1.02e-15	1.26e-12	0.38	0.36	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	8.31	1.03e-15	1.27e-12	0.41	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
HNSC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.03e-15	1.28e-12	-0.42	-0.36	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.03e-15	1.28e-12	-0.42	-0.36	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-8.31	1.04e-15	1.28e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
HNSC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.31	1.04e-15	1.28e-12	-0.42	-0.36	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-8.31	1.04e-15	1.29e-12	-0.38	-0.36	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-8.31	1.05e-15	1.3e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
HNSC	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-8.31	1.05e-15	1.3e-12	-0.42	-0.36	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
HNSC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-8.31	1.06e-15	1.31e-12	-0.4	-0.36	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	8.31	1.06e-15	1.31e-12	0.46	0.36	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	8.31	1.06e-15	1.31e-12	0.51	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
HNSC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-8.31	1.07e-15	1.32e-12	-0.39	-0.36	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000276710.3	CSPG4P8	-8.31	1.07e-15	1.32e-12	-0.39	-0.36	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82459472~82477258:+
HNSC	cis	rs2276314	0.857	rs28540805	ENSG00000278986.1	RP11-723J4.3	-8.31	1.07e-15	1.32e-12	-0.47	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36062012	chr18:35972151~35973916:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	8.31	1.08e-15	1.33e-12	0.4	0.36	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.08e-15	1.33e-12	-0.42	-0.36	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.31	1.08e-15	1.33e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
HNSC	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-8.31	1.08e-15	1.34e-12	-0.31	-0.36	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-8.31	1.09e-15	1.34e-12	-0.38	-0.36	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
HNSC	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.31	1.09e-15	1.34e-12	0.46	0.36	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
HNSC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	8.3	1.09e-15	1.35e-12	0.37	0.36	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	8.3	1.09e-15	1.35e-12	0.37	0.36	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-8.3	1.1e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	8.3	1.1e-15	1.36e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
HNSC	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-8.3	1.1e-15	1.36e-12	-0.44	-0.36	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
HNSC	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-8.3	1.11e-15	1.36e-12	-0.38	-0.36	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-8.3	1.11e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-8.3	1.11e-15	1.36e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
HNSC	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	8.3	1.11e-15	1.37e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.927	rs6915834	ENSG00000272462.2	U91328.19	-8.3	1.11e-15	1.37e-12	-0.36	-0.36	Height;	chr6:25935199	chr6:25992662~26001775:+
HNSC	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-8.3	1.12e-15	1.38e-12	-0.39	-0.36	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
HNSC	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	8.3	1.12e-15	1.38e-12	0.45	0.36	Height;	chr6:109470427	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	8.3	1.12e-15	1.38e-12	0.45	0.36	Height;	chr6:109470900	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.516	rs9393683	ENSG00000272462.2	U91328.19	-8.3	1.13e-15	1.39e-12	-0.35	-0.36	Height;	chr6:26065970	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.964	rs9379802	ENSG00000272462.2	U91328.19	-8.3	1.13e-15	1.39e-12	-0.36	-0.36	Height;	chr6:25933670	chr6:25992662~26001775:+
HNSC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-8.3	1.14e-15	1.4e-12	-0.42	-0.36	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
HNSC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-8.3	1.14e-15	1.4e-12	-0.42	-0.36	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
HNSC	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-8.3	1.14e-15	1.4e-12	-0.32	-0.36	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
HNSC	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	8.3	1.14e-15	1.4e-12	0.47	0.36	Height;	chr6:109424139	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-8.3	1.15e-15	1.41e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	8.3	1.15e-15	1.42e-12	0.54	0.36	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	8.3	1.15e-15	1.42e-12	0.54	0.36	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-8.3	1.15e-15	1.42e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
HNSC	cis	rs1021993	0.868	rs906351	ENSG00000231648.1	RP11-372M18.2	-8.3	1.16e-15	1.42e-12	-0.48	-0.36	Gut microbiome composition (winter);	chr1:209354580	chr1:209367662~209379690:+
HNSC	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-8.3	1.16e-15	1.42e-12	-0.45	-0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
HNSC	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-8.3	1.17e-15	1.43e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
HNSC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	8.3	1.17e-15	1.43e-12	0.41	0.36	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000179406.6	LINC00174	-8.3	1.17e-15	1.43e-12	-0.54	-0.36	Aortic root size;	chr7:66622723	chr7:66376044~66401338:-
HNSC	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	8.3	1.17e-15	1.44e-12	0.37	0.36	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	8.3	1.17e-15	1.44e-12	0.46	0.36	Height;	chr6:109447092	chr6:109382795~109383666:+
HNSC	cis	rs7404843	0.852	rs111259294	ENSG00000263065.1	AF001548.6	8.29	1.17e-15	1.44e-12	0.66	0.36	Testicular germ cell tumor;	chr16:15418073	chr16:15741151~15741791:+
HNSC	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-8.29	1.18e-15	1.45e-12	-0.36	-0.36	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
HNSC	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-8.29	1.18e-15	1.45e-12	-0.4	-0.36	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-8.29	1.19e-15	1.45e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-8.29	1.19e-15	1.46e-12	-0.48	-0.36	Depression;	chr6:28140307	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.29	1.19e-15	1.46e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
HNSC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	8.29	1.2e-15	1.46e-12	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-8.29	1.2e-15	1.47e-12	-0.38	-0.36	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-8.29	1.2e-15	1.47e-12	-0.38	-0.36	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000179406.6	LINC00174	-8.29	1.2e-15	1.47e-12	-0.53	-0.36	Aortic root size;	chr7:66193792	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	8.29	1.21e-15	1.47e-12	0.46	0.36	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
HNSC	cis	rs1865760	0.516	rs10807007	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Height;	chr6:26048703	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.516	rs9379819	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Height;	chr6:26049591	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.892	rs2328903	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.36	-0.36	Height;	chr6:25935537	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.892	rs6456705	ENSG00000272462.2	U91328.19	-8.29	1.21e-15	1.48e-12	-0.36	-0.36	Height;	chr6:25935828	chr6:25992662~26001775:+
HNSC	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-8.29	1.21e-15	1.48e-12	-0.35	-0.36	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
HNSC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-8.29	1.23e-15	1.5e-12	-0.4	-0.36	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
HNSC	cis	rs7942368	1	rs1440978	ENSG00000255100.1	RP11-21L23.3	8.29	1.23e-15	1.51e-12	0.45	0.36	Endometriosis;	chr11:76765236	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-8.29	1.23e-15	1.51e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-8.29	1.23e-15	1.51e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
HNSC	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-8.29	1.24e-15	1.51e-12	-0.4	-0.36	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
HNSC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-8.29	1.24e-15	1.52e-12	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
HNSC	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-8.29	1.24e-15	1.52e-12	-0.39	-0.36	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
HNSC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-8.29	1.25e-15	1.52e-12	-0.39	-0.36	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	8.29	1.26e-15	1.53e-12	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
HNSC	cis	rs875971	0.545	rs316324	ENSG00000179406.6	LINC00174	8.29	1.26e-15	1.53e-12	0.54	0.36	Aortic root size;	chr7:66145627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs316323	ENSG00000179406.6	LINC00174	8.29	1.26e-15	1.53e-12	0.54	0.36	Aortic root size;	chr7:66146002	chr7:66376044~66401338:-
HNSC	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.29	1.26e-15	1.53e-12	0.46	0.36	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.29	1.26e-15	1.53e-12	0.46	0.36	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
HNSC	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	8.28	1.26e-15	1.54e-12	0.48	0.36	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
HNSC	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	8.28	1.27e-15	1.55e-12	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
HNSC	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.28	1.27e-15	1.55e-12	0.47	0.36	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
HNSC	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	8.28	1.28e-15	1.56e-12	0.42	0.36	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-8.28	1.28e-15	1.56e-12	-0.52	-0.36	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-8.28	1.28e-15	1.56e-12	-0.38	-0.36	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
HNSC	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-8.28	1.28e-15	1.56e-12	-0.41	-0.36	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	8.28	1.29e-15	1.57e-12	0.4	0.36	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
HNSC	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	8.28	1.29e-15	1.57e-12	0.45	0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-8.28	1.3e-15	1.59e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-8.28	1.31e-15	1.59e-12	-0.38	-0.36	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	8.28	1.32e-15	1.6e-12	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
HNSC	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	8.28	1.32e-15	1.61e-12	0.47	0.36	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
HNSC	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	8.28	1.32e-15	1.61e-12	0.47	0.36	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-8.28	1.33e-15	1.62e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
HNSC	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	8.28	1.34e-15	1.63e-12	0.39	0.36	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
HNSC	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	8.28	1.34e-15	1.63e-12	0.45	0.36	Height;	chr6:109476101	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	8.27	1.36e-15	1.65e-12	0.37	0.36	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	8.27	1.36e-15	1.65e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.27	1.37e-15	1.66e-12	0.41	0.36	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
HNSC	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	8.27	1.37e-15	1.66e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
HNSC	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	8.27	1.38e-15	1.67e-12	0.41	0.36	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
HNSC	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-8.27	1.39e-15	1.68e-12	-0.43	-0.36	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
HNSC	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.27	1.39e-15	1.69e-12	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.27	1.39e-15	1.69e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.27	1.39e-15	1.69e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
HNSC	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	8.27	1.4e-15	1.69e-12	0.46	0.36	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
HNSC	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	8.27	1.4e-15	1.69e-12	0.47	0.36	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-8.27	1.41e-15	1.7e-12	-0.55	-0.36	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
HNSC	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	8.27	1.41e-15	1.71e-12	0.41	0.36	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
HNSC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-8.27	1.42e-15	1.71e-12	-0.37	-0.36	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
HNSC	cis	rs35955747	0.714	rs5997989	ENSG00000236132.1	CTA-440B3.1	8.27	1.42e-15	1.71e-12	0.39	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31443964	chr22:31816379~31817491:-
HNSC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	8.27	1.42e-15	1.72e-12	0.36	0.36	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
HNSC	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	8.27	1.42e-15	1.72e-12	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
HNSC	cis	rs9402743	0.816	rs9402737	ENSG00000217482.2	HMGB1P17	8.27	1.43e-15	1.72e-12	0.41	0.36	Systemic lupus erythematosus;	chr6:135651778	chr6:135636086~135636713:-
HNSC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	8.27	1.43e-15	1.73e-12	0.36	0.36	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	8.27	1.43e-15	1.73e-12	0.44	0.36	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-8.27	1.44e-15	1.74e-12	-0.32	-0.36	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
HNSC	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	8.27	1.46e-15	1.76e-12	0.41	0.36	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
HNSC	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	8.26	1.46e-15	1.77e-12	0.53	0.36	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
HNSC	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-8.26	1.47e-15	1.78e-12	-0.43	-0.36	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
HNSC	cis	rs7942368	1	rs12282785	ENSG00000255100.1	RP11-21L23.3	8.26	1.48e-15	1.78e-12	0.45	0.36	Endometriosis;	chr11:76764986	chr11:76782581~76783062:-
HNSC	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	8.26	1.48e-15	1.78e-12	0.41	0.36	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	8.26	1.48e-15	1.78e-12	0.36	0.36	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
HNSC	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-8.26	1.48e-15	1.79e-12	-0.46	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-8.26	1.49e-15	1.8e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	8.26	1.5e-15	1.8e-12	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
HNSC	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	8.26	1.5e-15	1.8e-12	0.4	0.36	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
HNSC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	8.26	1.5e-15	1.81e-12	0.51	0.36	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
HNSC	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-8.26	1.51e-15	1.82e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
HNSC	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-8.26	1.51e-15	1.82e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
HNSC	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	8.26	1.53e-15	1.84e-12	0.43	0.36	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	8.26	1.53e-15	1.84e-12	0.37	0.36	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
HNSC	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	8.26	1.54e-15	1.85e-12	0.4	0.36	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
HNSC	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	8.26	1.54e-15	1.86e-12	0.45	0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000248787.1	RP11-666A20.4	-8.25	1.57e-15	1.89e-12	-0.54	-0.36	Blood pressure (smoking interaction);	chr3:125880231	chr3:125908005~125910272:-
HNSC	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	8.25	1.57e-15	1.89e-12	0.47	0.36	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
HNSC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-8.25	1.58e-15	1.9e-12	-0.48	-0.36	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
HNSC	cis	rs35955747	0.689	rs5997988	ENSG00000236132.1	CTA-440B3.1	8.25	1.58e-15	1.9e-12	0.39	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31442099	chr22:31816379~31817491:-
HNSC	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	8.25	1.58e-15	1.9e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-8.25	1.58e-15	1.9e-12	-0.45	-0.36	Height;	chr6:109432968	chr6:109382795~109383666:+
HNSC	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	8.25	1.58e-15	1.91e-12	0.4	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
HNSC	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	8.25	1.59e-15	1.92e-12	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
HNSC	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.25	1.6e-15	1.92e-12	0.38	0.36	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.25	1.6e-15	1.92e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.25	1.6e-15	1.92e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
HNSC	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	8.25	1.6e-15	1.93e-12	0.43	0.36	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	8.25	1.6e-15	1.93e-12	0.43	0.36	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-8.25	1.61e-15	1.93e-12	-0.41	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
HNSC	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-8.25	1.61e-15	1.93e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
HNSC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	8.25	1.61e-15	1.94e-12	0.42	0.36	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	8.25	1.62e-15	1.94e-12	0.36	0.36	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	8.25	1.62e-15	1.94e-12	0.36	0.36	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-8.25	1.62e-15	1.95e-12	-0.51	-0.36	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
HNSC	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109747411	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109748819	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109749564	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	8.25	1.62e-15	1.95e-12	0.48	0.36	Height;	chr6:109763331	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.25	1.62e-15	1.95e-12	0.38	0.36	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
HNSC	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-8.25	1.63e-15	1.96e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
HNSC	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-8.25	1.63e-15	1.96e-12	-0.27	-0.36	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
HNSC	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	8.25	1.63e-15	1.96e-12	0.4	0.36	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
HNSC	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-8.25	1.64e-15	1.97e-12	-0.42	-0.36	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
HNSC	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	8.25	1.64e-15	1.97e-12	0.47	0.36	Height;	chr6:109374782	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-8.25	1.64e-15	1.97e-12	-0.36	-0.36	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	8.25	1.64e-15	1.97e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-8.25	1.65e-15	1.98e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-8.25	1.65e-15	1.98e-12	-0.45	-0.36	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-8.25	1.67e-15	2e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
HNSC	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	8.25	1.68e-15	2.01e-12	0.47	0.36	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
HNSC	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	8.25	1.68e-15	2.01e-12	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	8.25	1.68e-15	2.02e-12	0.4	0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
HNSC	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	8.25	1.68e-15	2.02e-12	0.42	0.36	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	8.25	1.68e-15	2.02e-12	0.42	0.36	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
HNSC	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-8.25	1.69e-15	2.02e-12	-0.38	-0.36	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
HNSC	cis	rs7942368	0.941	rs10899279	ENSG00000255100.1	RP11-21L23.3	8.24	1.69e-15	2.03e-12	0.45	0.36	Endometriosis;	chr11:76766200	chr11:76782581~76783062:-
HNSC	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	8.24	1.7e-15	2.04e-12	0.46	0.36	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.24	1.7e-15	2.04e-12	0.54	0.36	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
HNSC	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	8.24	1.71e-15	2.04e-12	0.45	0.36	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
HNSC	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-8.24	1.71e-15	2.05e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	8.24	1.71e-15	2.05e-12	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.24	1.71e-15	2.05e-12	-0.53	-0.36	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
HNSC	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	8.24	1.71e-15	2.05e-12	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	8.24	1.72e-15	2.06e-12	0.4	0.36	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
HNSC	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	8.24	1.73e-15	2.07e-12	0.39	0.36	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
HNSC	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-8.24	1.73e-15	2.07e-12	-0.48	-0.36	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
HNSC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-8.24	1.73e-15	2.08e-12	-0.37	-0.36	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-8.24	1.73e-15	2.08e-12	-0.38	-0.36	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
HNSC	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	8.24	1.74e-15	2.08e-12	0.43	0.36	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-8.24	1.74e-15	2.09e-12	-0.48	-0.36	Depression;	chr6:28180209	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-8.24	1.76e-15	2.11e-12	-0.38	-0.36	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
HNSC	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-8.24	1.77e-15	2.11e-12	-0.38	-0.36	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-8.24	1.77e-15	2.12e-12	-0.36	-0.36	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
HNSC	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-8.24	1.77e-15	2.12e-12	-0.43	-0.36	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
HNSC	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-8.24	1.78e-15	2.13e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-8.24	1.78e-15	2.13e-12	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
HNSC	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-8.24	1.78e-15	2.13e-12	-0.41	-0.36	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
HNSC	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-8.24	1.78e-15	2.13e-12	-0.33	-0.36	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
HNSC	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-8.24	1.78e-15	2.13e-12	-0.39	-0.36	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
HNSC	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-8.24	1.79e-15	2.14e-12	-0.55	-0.36	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
HNSC	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	8.24	1.8e-15	2.15e-12	0.41	0.36	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
HNSC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
HNSC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-8.24	1.81e-15	2.17e-12	-0.37	-0.36	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000254340.1	RP11-10A14.3	8.24	1.82e-15	2.17e-12	0.44	0.36	Joint mobility (Beighton score);	chr8:9012918	chr8:9141424~9145435:+
HNSC	cis	rs1865760	1	rs2071299	ENSG00000272462.2	U91328.19	-8.23	1.82e-15	2.17e-12	-0.36	-0.36	Height;	chr6:25914573	chr6:25992662~26001775:+
HNSC	cis	rs1865760	1	rs2071298	ENSG00000272462.2	U91328.19	-8.23	1.82e-15	2.17e-12	-0.36	-0.36	Height;	chr6:25914673	chr6:25992662~26001775:+
HNSC	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	8.23	1.82e-15	2.17e-12	0.44	0.36	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
HNSC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	8.23	1.82e-15	2.18e-12	0.36	0.36	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
HNSC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	8.23	1.82e-15	2.18e-12	0.36	0.36	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
HNSC	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	8.23	1.82e-15	2.18e-12	0.55	0.36	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
HNSC	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.23	1.83e-15	2.19e-12	0.41	0.36	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	8.23	1.83e-15	2.19e-12	0.42	0.36	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	8.23	1.83e-15	2.19e-12	0.42	0.36	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
HNSC	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-8.23	1.84e-15	2.2e-12	-0.44	-0.36	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	8.23	1.86e-15	2.22e-12	0.44	0.36	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-8.23	1.86e-15	2.22e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	8.23	1.87e-15	2.23e-12	0.55	0.36	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	8.23	1.87e-15	2.23e-12	0.55	0.36	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
HNSC	cis	rs7404843	0.777	rs6498552	ENSG00000263065.1	AF001548.6	-8.23	1.87e-15	2.23e-12	-0.63	-0.36	Testicular germ cell tumor;	chr16:15446044	chr16:15741151~15741791:+
HNSC	cis	rs7404843	0.85	rs6498553	ENSG00000263065.1	AF001548.6	-8.23	1.87e-15	2.23e-12	-0.63	-0.36	Testicular germ cell tumor;	chr16:15446045	chr16:15741151~15741791:+
HNSC	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	8.23	1.88e-15	2.24e-12	0.41	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
HNSC	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-8.23	1.88e-15	2.24e-12	-0.44	-0.36	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
HNSC	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	8.23	1.88e-15	2.25e-12	0.46	0.36	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-8.23	1.9e-15	2.27e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-8.23	1.9e-15	2.27e-12	-0.34	-0.36	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	8.23	1.91e-15	2.28e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	8.23	1.92e-15	2.28e-12	0.43	0.36	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	8.23	1.92e-15	2.28e-12	0.43	0.36	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-8.23	1.93e-15	2.3e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	8.23	1.94e-15	2.31e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-8.23	1.95e-15	2.32e-12	-0.44	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000223648.3	IGHV3-64	8.23	1.95e-15	2.32e-12	0.29	0.36	Kawasaki disease;	chr14:106656426	chr14:106643132~106658258:-
HNSC	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	8.23	1.95e-15	2.32e-12	0.43	0.36	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	8.23	1.95e-15	2.32e-12	0.43	0.36	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-8.22	1.97e-15	2.34e-12	-0.33	-0.36	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-8.22	1.97e-15	2.35e-12	-0.32	-0.36	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28145952	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28147378	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28147406	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28148143	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28149979	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28151096	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28152885	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28153120	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28154567	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28156691	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28158424	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159056	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159666	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159843	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159925	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28159932	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28161802	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28162053	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28162598	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28163375	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28163759	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164580	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164825	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28164948	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28165025	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28165528	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28168434	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169019	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169249	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169676	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169755	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28169791	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-8.22	1.98e-15	2.35e-12	-0.48	-0.36	Depression;	chr6:28170075	chr6:28115628~28116551:+
HNSC	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	8.22	1.98e-15	2.35e-12	0.41	0.36	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
HNSC	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-8.22	1.98e-15	2.36e-12	-0.54	-0.36	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
HNSC	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	8.22	1.98e-15	2.36e-12	0.38	0.36	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
HNSC	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	8.22	1.99e-15	2.36e-12	0.4	0.36	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
HNSC	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	8.22	2e-15	2.38e-12	0.43	0.36	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
HNSC	cis	rs7048146	1	rs7046565	ENSG00000213539.4	YBX1P6	8.22	2.02e-15	2.39e-12	0.41	0.36	Vascular brain injury;	chr9:109539940	chr9:109532830~109534332:-
HNSC	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-8.22	2.02e-15	2.39e-12	-0.4	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
HNSC	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	8.22	2.02e-15	2.39e-12	0.45	0.36	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
HNSC	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-8.22	2.02e-15	2.4e-12	-0.41	-0.36	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
HNSC	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	8.22	2.03e-15	2.4e-12	0.47	0.36	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
HNSC	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.22	2.04e-15	2.42e-12	0.45	0.36	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	8.22	2.04e-15	2.42e-12	0.38	0.36	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-8.22	2.04e-15	2.42e-12	-0.38	-0.36	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-8.22	2.05e-15	2.42e-12	-0.45	-0.36	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	8.22	2.05e-15	2.43e-12	0.46	0.36	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	8.22	2.06e-15	2.43e-12	0.55	0.36	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	8.22	2.06e-15	2.44e-12	0.4	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	8.22	2.07e-15	2.45e-12	0.4	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-8.22	2.07e-15	2.45e-12	-0.44	-0.36	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
HNSC	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	8.22	2.08e-15	2.46e-12	0.43	0.36	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	8.22	2.08e-15	2.46e-12	0.43	0.36	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
HNSC	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-8.22	2.09e-15	2.47e-12	-0.48	-0.36	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
HNSC	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	8.22	2.09e-15	2.48e-12	0.36	0.36	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	8.22	2.1e-15	2.48e-12	0.45	0.36	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
HNSC	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	8.22	2.1e-15	2.48e-12	0.41	0.36	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	8.21	2.1e-15	2.49e-12	0.41	0.36	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	8.21	2.13e-15	2.52e-12	0.4	0.36	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
HNSC	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-8.21	2.14e-15	2.53e-12	-0.56	-0.36	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.21	2.14e-15	2.53e-12	0.41	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.21	2.15e-15	2.54e-12	-0.41	-0.36	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
HNSC	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-8.21	2.15e-15	2.55e-12	-0.34	-0.36	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
HNSC	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
HNSC	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118856460	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118856623	chr11:118704607~118750263:+
HNSC	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-8.21	2.15e-15	2.55e-12	-0.44	-0.36	Height;	chr11:118857611	chr11:118704607~118750263:+
HNSC	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	8.21	2.17e-15	2.56e-12	0.43	0.36	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
HNSC	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-8.21	2.17e-15	2.56e-12	-0.42	-0.36	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	8.21	2.17e-15	2.57e-12	0.44	0.36	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
HNSC	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	8.21	2.17e-15	2.57e-12	0.43	0.36	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000276710.3	CSPG4P8	-8.21	2.19e-15	2.59e-12	-0.39	-0.36	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82459472~82477258:+
HNSC	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-8.21	2.19e-15	2.59e-12	-0.4	-0.36	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-8.21	2.19e-15	2.59e-12	-0.34	-0.36	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-8.21	2.19e-15	2.59e-12	-0.39	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
HNSC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	8.21	2.2e-15	2.59e-12	0.42	0.36	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
HNSC	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	8.21	2.2e-15	2.6e-12	0.43	0.36	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
HNSC	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	8.21	2.21e-15	2.61e-12	0.41	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
HNSC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-8.21	2.24e-15	2.65e-12	-0.37	-0.35	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
HNSC	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	8.21	2.25e-15	2.66e-12	0.47	0.35	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.21	2.26e-15	2.66e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
HNSC	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-8.21	2.26e-15	2.66e-12	-0.41	-0.35	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
HNSC	cis	rs10256972	0.647	rs10233430	ENSG00000225146.1	AC073957.15	8.21	2.26e-15	2.66e-12	0.4	0.35	Endometriosis;Longevity;	chr7:1012028	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-8.2	2.26e-15	2.67e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-8.2	2.27e-15	2.67e-12	-0.41	-0.35	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	8.2	2.27e-15	2.67e-12	0.42	0.35	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	8.2	2.27e-15	2.68e-12	0.43	0.35	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-8.2	2.27e-15	2.68e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	8.2	2.28e-15	2.69e-12	0.44	0.35	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
HNSC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	8.2	2.29e-15	2.7e-12	0.42	0.35	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-8.2	2.29e-15	2.7e-12	-0.4	-0.35	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	8.2	2.29e-15	2.7e-12	0.46	0.35	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
HNSC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	8.2	2.3e-15	2.7e-12	0.37	0.35	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	8.2	2.3e-15	2.7e-12	0.37	0.35	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.532	rs1061482	ENSG00000272462.2	U91328.19	-8.2	2.3e-15	2.71e-12	-0.35	-0.35	Height;	chr6:26086471	chr6:25992662~26001775:+
HNSC	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	8.2	2.3e-15	2.71e-12	0.46	0.35	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
HNSC	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	8.2	2.31e-15	2.72e-12	0.54	0.35	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
HNSC	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-8.2	2.31e-15	2.72e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
HNSC	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	8.2	2.31e-15	2.73e-12	0.55	0.35	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	8.2	2.31e-15	2.73e-12	0.55	0.35	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
HNSC	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-8.2	2.32e-15	2.73e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
HNSC	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	8.2	2.33e-15	2.74e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	8.2	2.34e-15	2.75e-12	0.35	0.35	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
HNSC	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	8.2	2.34e-15	2.75e-12	0.39	0.35	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.76e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
HNSC	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	8.2	2.35e-15	2.76e-12	0.46	0.35	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
HNSC	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-8.2	2.35e-15	2.76e-12	-0.37	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-8.2	2.35e-15	2.77e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-8.2	2.4e-15	2.82e-12	-0.38	-0.35	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000276710.3	CSPG4P8	-8.2	2.41e-15	2.83e-12	-0.39	-0.35	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82459472~82477258:+
HNSC	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-8.2	2.41e-15	2.83e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
HNSC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-8.2	2.41e-15	2.84e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
HNSC	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-8.2	2.42e-15	2.84e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
HNSC	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.19	2.43e-15	2.86e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
HNSC	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-8.19	2.43e-15	2.86e-12	-0.38	-0.35	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
HNSC	cis	rs9402743	0.748	rs11754958	ENSG00000217482.2	HMGB1P17	8.19	2.43e-15	2.86e-12	0.42	0.35	Systemic lupus erythematosus;	chr6:135651462	chr6:135636086~135636713:-
HNSC	cis	rs6969780	0.63	rs3735530	ENSG00000233429.8	HOTAIRM1	-8.19	2.44e-15	2.87e-12	-0.45	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150363	chr7:27095647~27100265:+
HNSC	cis	rs7942368	0.818	rs10793194	ENSG00000255100.1	RP11-21L23.3	8.19	2.45e-15	2.88e-12	0.45	0.35	Endometriosis;	chr11:76764685	chr11:76782581~76783062:-
HNSC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	8.19	2.45e-15	2.88e-12	0.43	0.35	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
HNSC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-8.19	2.46e-15	2.88e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-8.19	2.46e-15	2.88e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	8.19	2.46e-15	2.89e-12	0.4	0.35	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
HNSC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.19	2.46e-15	2.89e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.19	2.46e-15	2.89e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-8.19	2.47e-15	2.9e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
HNSC	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	8.19	2.47e-15	2.9e-12	0.4	0.35	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	8.19	2.48e-15	2.91e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
HNSC	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	8.19	2.48e-15	2.91e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-8.19	2.48e-15	2.91e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-8.19	2.48e-15	2.91e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.49e-15	2.92e-12	-0.38	-0.35	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
HNSC	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	8.19	2.49e-15	2.92e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	8.19	2.49e-15	2.92e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-8.19	2.49e-15	2.92e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
HNSC	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	8.19	2.51e-15	2.94e-12	0.44	0.35	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
HNSC	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.19	2.53e-15	2.96e-12	-0.4	-0.35	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	8.19	2.53e-15	2.96e-12	0.42	0.35	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
HNSC	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	8.19	2.53e-15	2.96e-12	0.71	0.35	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
HNSC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-8.19	2.54e-15	2.97e-12	-0.39	-0.35	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
HNSC	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-8.19	2.54e-15	2.97e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
HNSC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	8.19	2.55e-15	2.98e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.19	2.56e-15	2.99e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
HNSC	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	8.19	2.58e-15	3.01e-12	0.43	0.35	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
HNSC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-8.19	2.58e-15	3.01e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-8.19	2.58e-15	3.01e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
HNSC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-8.19	2.59e-15	3.03e-12	-0.41	-0.35	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
HNSC	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.61e-15	3.05e-12	-0.38	-0.35	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-8.19	2.61e-15	3.05e-12	-0.48	-0.35	Depression;	chr6:28176973	chr6:28115628~28116551:+
HNSC	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-8.19	2.61e-15	3.05e-12	-0.6	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
HNSC	cis	rs1865760	0.929	rs9358896	ENSG00000272462.2	U91328.19	-8.19	2.61e-15	3.05e-12	-0.35	-0.35	Height;	chr6:25942969	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.19	2.61e-15	3.05e-12	-0.41	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	8.18	2.62e-15	3.06e-12	0.4	0.35	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
HNSC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.18	2.62e-15	3.06e-12	-0.41	-0.35	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	8.18	2.63e-15	3.07e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
HNSC	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	8.18	2.63e-15	3.08e-12	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
HNSC	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-8.18	2.64e-15	3.08e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
HNSC	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-8.18	2.64e-15	3.08e-12	-0.4	-0.35	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
HNSC	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-8.18	2.64e-15	3.09e-12	-0.46	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	8.18	2.66e-15	3.1e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
HNSC	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.13e-12	0.38	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.18	2.69e-15	3.14e-12	0.37	0.35	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
HNSC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-8.18	2.69e-15	3.14e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
HNSC	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	8.18	2.7e-15	3.15e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	8.18	2.73e-15	3.17e-12	0.55	0.35	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	8.18	2.73e-15	3.17e-12	0.55	0.35	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.18	2.73e-15	3.18e-12	0.37	0.35	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	8.18	2.74e-15	3.19e-12	0.41	0.35	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	8.18	2.74e-15	3.19e-12	0.41	0.35	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
HNSC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-8.18	2.74e-15	3.19e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
HNSC	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-8.18	2.75e-15	3.2e-12	-0.41	-0.35	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
HNSC	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-8.18	2.75e-15	3.2e-12	-0.38	-0.35	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
HNSC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-8.18	2.76e-15	3.21e-12	-0.38	-0.35	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
HNSC	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-8.18	2.77e-15	3.22e-12	-0.38	-0.35	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-8.18	2.77e-15	3.22e-12	-0.38	-0.35	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
HNSC	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	8.18	2.77e-15	3.22e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
HNSC	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	8.18	2.78e-15	3.23e-12	0.38	0.35	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
HNSC	cis	rs9399135	0.967	rs11757577	ENSG00000232876.1	CTA-212D2.2	-8.18	2.78e-15	3.23e-12	-0.42	-0.35	Red blood cell count;	chr6:135070327	chr6:135055033~135060550:+
HNSC	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	8.18	2.79e-15	3.24e-12	0.47	0.35	Height;	chr6:109740895	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-8.18	2.79e-15	3.25e-12	-0.48	-0.35	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
HNSC	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	8.18	2.79e-15	3.25e-12	0.42	0.35	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
HNSC	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.18	2.79e-15	3.25e-12	0.37	0.35	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
HNSC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	8.18	2.81e-15	3.26e-12	0.45	0.35	Height;	chr6:109440234	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.82	rs9348697	ENSG00000272462.2	U91328.19	-8.17	2.81e-15	3.27e-12	-0.35	-0.35	Height;	chr6:25890606	chr6:25992662~26001775:+
HNSC	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	8.17	2.82e-15	3.27e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.82e-15	3.28e-12	-0.38	-0.35	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.82e-15	3.28e-12	-0.38	-0.35	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	8.17	2.83e-15	3.28e-12	0.47	0.35	Depression;	chr6:28167882	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	8.17	2.83e-15	3.29e-12	0.45	0.35	Height;	chr6:109477209	chr6:109382795~109383666:+
HNSC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	8.17	2.84e-15	3.3e-12	0.36	0.35	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	8.17	2.86e-15	3.32e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	8.17	2.86e-15	3.32e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
HNSC	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	8.17	2.86e-15	3.32e-12	0.54	0.35	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
HNSC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	8.17	2.87e-15	3.33e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
HNSC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	8.17	2.88e-15	3.34e-12	0.42	0.35	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
HNSC	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	8.17	2.9e-15	3.36e-12	0.46	0.35	Height;	chr6:109494237	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	8.17	2.9e-15	3.36e-12	0.46	0.35	Height;	chr6:109496073	chr6:109382795~109383666:+
HNSC	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-8.17	2.93e-15	3.4e-12	-0.41	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
HNSC	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	8.17	2.93e-15	3.4e-12	0.38	0.35	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
HNSC	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	8.17	2.94e-15	3.41e-12	0.45	0.35	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
HNSC	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-8.17	2.94e-15	3.41e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	8.17	2.96e-15	3.43e-12	0.37	0.35	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-8.17	2.96e-15	3.43e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-8.17	2.96e-15	3.43e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
HNSC	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-8.17	2.96e-15	3.43e-12	-0.44	-0.35	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
HNSC	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-8.17	2.97e-15	3.44e-12	-0.37	-0.35	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000254340.1	RP11-10A14.3	8.17	2.97e-15	3.44e-12	0.44	0.35	Joint mobility (Beighton score);	chr8:9014200	chr8:9141424~9145435:+
HNSC	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	8.17	2.97e-15	3.44e-12	0.55	0.35	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	8.17	2.97e-15	3.44e-12	0.55	0.35	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-8.17	2.98e-15	3.45e-12	-0.55	-0.35	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
HNSC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-8.17	2.99e-15	3.46e-12	-0.38	-0.35	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
HNSC	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.17	2.99e-15	3.46e-12	0.37	0.35	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
HNSC	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	8.17	2.99e-15	3.47e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
HNSC	cis	rs1865760	0.929	rs2876693	ENSG00000272462.2	U91328.19	-8.17	3e-15	3.47e-12	-0.35	-0.35	Height;	chr6:25954206	chr6:25992662~26001775:+
HNSC	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-8.17	3.01e-15	3.48e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	8.17	3.02e-15	3.49e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
HNSC	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-8.16	3.02e-15	3.5e-12	-0.46	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-8.16	3.05e-15	3.53e-12	-0.38	-0.35	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	8.16	3.06e-15	3.54e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
HNSC	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	8.16	3.07e-15	3.55e-12	0.42	0.35	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000276710.3	CSPG4P8	-8.16	3.08e-15	3.56e-12	-0.39	-0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82459472~82477258:+
HNSC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-8.16	3.08e-15	3.56e-12	-0.38	-0.35	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
HNSC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-8.16	3.08e-15	3.56e-12	-0.39	-0.35	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
HNSC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.09e-15	3.57e-12	-0.38	-0.35	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000179406.6	LINC00174	8.16	3.09e-15	3.57e-12	0.53	0.35	Aortic root size;	chr7:66123233	chr7:66376044~66401338:-
HNSC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-8.16	3.09e-15	3.58e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	8.16	3.1e-15	3.58e-12	0.55	0.35	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000179406.6	LINC00174	-8.16	3.11e-15	3.59e-12	-0.53	-0.35	Aortic root size;	chr7:66358032	chr7:66376044~66401338:-
HNSC	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	8.16	3.13e-15	3.61e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	8.16	3.15e-15	3.63e-12	0.41	0.35	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
HNSC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	8.16	3.15e-15	3.64e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
HNSC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.17e-15	3.66e-12	-0.38	-0.35	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	8.16	3.18e-15	3.66e-12	0.37	0.35	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-8.16	3.19e-15	3.68e-12	-0.38	-0.35	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
HNSC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	8.16	3.19e-15	3.68e-12	0.44	0.35	Height;	chr6:109397362	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-8.16	3.19e-15	3.68e-12	-0.37	-0.35	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-8.16	3.2e-15	3.69e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-8.16	3.2e-15	3.69e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
HNSC	cis	rs1021993	0.818	rs906349	ENSG00000231648.1	RP11-372M18.2	-8.16	3.21e-15	3.7e-12	-0.48	-0.35	Gut microbiome composition (winter);	chr1:209354783	chr1:209367662~209379690:+
HNSC	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-8.16	3.22e-15	3.71e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-8.16	3.22e-15	3.71e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-8.16	3.22e-15	3.71e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
HNSC	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	8.16	3.23e-15	3.72e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
HNSC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-8.16	3.25e-15	3.74e-12	-0.4	-0.35	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-8.15	3.25e-15	3.75e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-8.15	3.26e-15	3.75e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
HNSC	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	8.15	3.26e-15	3.76e-12	0.45	0.35	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
HNSC	cis	rs2834288	0.959	rs2834294	ENSG00000237945.6	LINC00649	-8.15	3.26e-15	3.76e-12	-0.43	-0.35	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33915534~33977691:+
HNSC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	8.15	3.27e-15	3.76e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-8.15	3.27e-15	3.77e-12	-0.35	-0.35	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-8.15	3.28e-15	3.78e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
HNSC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	8.15	3.29e-15	3.78e-12	0.42	0.35	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
HNSC	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	8.15	3.29e-15	3.79e-12	0.43	0.35	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
HNSC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	8.15	3.3e-15	3.8e-12	0.36	0.35	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	8.15	3.3e-15	3.8e-12	0.46	0.35	Depression;	chr6:28109824	chr6:28115628~28116551:+
HNSC	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-8.15	3.31e-15	3.8e-12	-0.47	-0.35	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-8.15	3.31e-15	3.8e-12	-0.47	-0.35	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
HNSC	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.15	3.31e-15	3.8e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
HNSC	cis	rs1865760	1	rs2071297	ENSG00000272462.2	U91328.19	8.15	3.32e-15	3.82e-12	0.35	0.35	Height;	chr6:25924285	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.45	0.35	Height;	chr6:109507364	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.45	0.35	Height;	chr6:109507366	chr6:109382795~109383666:+
HNSC	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	8.15	3.33e-15	3.83e-12	0.48	0.35	Height;	chr6:109747119	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-8.15	3.34e-15	3.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	8.15	3.34e-15	3.84e-12	0.46	0.35	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	8.15	3.37e-15	3.87e-12	0.37	0.35	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000179406.6	LINC00174	-8.15	3.37e-15	3.87e-12	-0.53	-0.35	Aortic root size;	chr7:66249708	chr7:66376044~66401338:-
HNSC	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	8.15	3.37e-15	3.87e-12	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
HNSC	cis	rs1865760	0.865	rs1541987	ENSG00000272462.2	U91328.19	8.15	3.37e-15	3.87e-12	0.35	0.35	Height;	chr6:25950169	chr6:25992662~26001775:+
HNSC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	8.15	3.37e-15	3.88e-12	0.42	0.35	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
HNSC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	8.15	3.37e-15	3.88e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	8.15	3.39e-15	3.89e-12	0.49	0.35	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-8.15	3.4e-15	3.91e-12	-0.33	-0.35	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	8.15	3.4e-15	3.91e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	8.15	3.41e-15	3.92e-12	0.36	0.35	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	8.15	3.41e-15	3.92e-12	0.45	0.35	Height;	chr6:109375548	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	8.15	3.41e-15	3.92e-12	0.53	0.35	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
HNSC	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-8.15	3.42e-15	3.92e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	8.15	3.42e-15	3.93e-12	0.39	0.35	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28173770	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28174809	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-8.15	3.44e-15	3.94e-12	-0.47	-0.35	Depression;	chr6:28175233	chr6:28115628~28116551:+
HNSC	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	8.15	3.44e-15	3.95e-12	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
HNSC	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	8.15	3.46e-15	3.97e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
HNSC	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	8.15	3.46e-15	3.97e-12	0.4	0.35	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-8.15	3.46e-15	3.97e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
HNSC	cis	rs10256972	0.669	rs10229964	ENSG00000225146.1	AC073957.15	8.15	3.47e-15	3.98e-12	0.4	0.35	Endometriosis;Longevity;	chr7:1012140	chr7:1029025~1043891:+
HNSC	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	8.15	3.49e-15	4e-12	0.44	0.35	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
HNSC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	8.14	3.5e-15	4.01e-12	0.37	0.35	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	8.14	3.5e-15	4.01e-12	0.39	0.35	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-8.14	3.51e-15	4.02e-12	-0.4	-0.35	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
HNSC	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-8.14	3.56e-15	4.08e-12	-0.49	-0.35	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
HNSC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	8.14	3.57e-15	4.08e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
HNSC	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	8.14	3.57e-15	4.09e-12	0.46	0.35	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	8.14	3.57e-15	4.09e-12	0.46	0.35	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
HNSC	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-8.14	3.59e-15	4.11e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
HNSC	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	8.14	3.6e-15	4.12e-12	0.44	0.35	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
HNSC	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	8.14	3.61e-15	4.13e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
HNSC	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	8.14	3.61e-15	4.13e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
HNSC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-8.14	3.61e-15	4.13e-12	-0.38	-0.35	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
HNSC	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-8.14	3.61e-15	4.13e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
HNSC	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	8.14	3.62e-15	4.14e-12	0.42	0.35	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
HNSC	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	8.14	3.62e-15	4.14e-12	0.45	0.35	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
HNSC	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	8.14	3.62e-15	4.14e-12	0.46	0.35	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
HNSC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-8.14	3.62e-15	4.14e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
HNSC	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-8.14	3.63e-15	4.15e-12	-0.56	-0.35	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-8.14	3.63e-15	4.15e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-8.14	3.64e-15	4.16e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
HNSC	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.14	3.65e-15	4.17e-12	-0.38	-0.35	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
HNSC	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	8.14	3.66e-15	4.18e-12	0.41	0.35	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
HNSC	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-8.14	3.67e-15	4.19e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
HNSC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-8.14	3.67e-15	4.19e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-8.14	3.67e-15	4.19e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
HNSC	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-8.14	3.68e-15	4.2e-12	-0.41	-0.35	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-8.14	3.68e-15	4.2e-12	-0.41	-0.35	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	8.14	3.68e-15	4.21e-12	0.46	0.35	Height;	chr6:109741670	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.14	3.69e-15	4.21e-12	0.37	0.35	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.14	3.69e-15	4.21e-12	0.37	0.35	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
HNSC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	8.14	3.7e-15	4.22e-12	0.37	0.35	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
HNSC	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-8.14	3.71e-15	4.23e-12	-0.33	-0.35	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
HNSC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	8.14	3.71e-15	4.24e-12	0.42	0.35	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
HNSC	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	8.14	3.72e-15	4.24e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
HNSC	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	8.14	3.72e-15	4.25e-12	0.4	0.35	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
HNSC	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-8.14	3.72e-15	4.25e-12	-0.35	-0.35	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
HNSC	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	8.14	3.74e-15	4.27e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	8.14	3.75e-15	4.28e-12	0.41	0.35	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
HNSC	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-8.13	3.76e-15	4.29e-12	-0.54	-0.35	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
HNSC	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.13	3.76e-15	4.29e-12	-0.38	-0.35	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.13	3.76e-15	4.29e-12	-0.38	-0.35	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	8.13	3.76e-15	4.29e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	8.13	3.77e-15	4.3e-12	0.55	0.35	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	8.13	3.77e-15	4.3e-12	0.55	0.35	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
HNSC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-8.13	3.77e-15	4.3e-12	-0.41	-0.35	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
HNSC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-8.13	3.77e-15	4.3e-12	-0.41	-0.35	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
HNSC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-8.13	3.78e-15	4.31e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-8.13	3.78e-15	4.31e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
HNSC	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-8.13	3.79e-15	4.32e-12	-0.33	-0.35	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
HNSC	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-8.13	3.79e-15	4.32e-12	-0.33	-0.35	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
HNSC	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	8.13	3.81e-15	4.35e-12	0.54	0.35	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	8.13	3.82e-15	4.36e-12	0.54	0.35	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
HNSC	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-8.13	3.83e-15	4.36e-12	-0.38	-0.35	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-8.13	3.83e-15	4.36e-12	-0.38	-0.35	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
HNSC	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	8.13	3.84e-15	4.37e-12	0.4	0.35	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-8.13	3.84e-15	4.38e-12	-0.4	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	8.13	3.86e-15	4.4e-12	0.55	0.35	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	8.13	3.88e-15	4.42e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-8.13	3.9e-15	4.44e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
HNSC	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	8.13	3.9e-15	4.44e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-8.13	3.9e-15	4.44e-12	-0.41	-0.35	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
HNSC	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	8.13	3.91e-15	4.45e-12	0.38	0.35	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	8.13	3.91e-15	4.46e-12	0.37	0.35	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
HNSC	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	8.13	3.92e-15	4.46e-12	0.38	0.35	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
HNSC	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-8.13	3.93e-15	4.47e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	8.13	3.94e-15	4.48e-12	0.36	0.35	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
HNSC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	8.13	3.94e-15	4.48e-12	0.42	0.35	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
HNSC	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	8.13	3.95e-15	4.49e-12	0.59	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
HNSC	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.13	3.95e-15	4.49e-12	-0.38	-0.35	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
HNSC	cis	rs1865760	1	rs3799371	ENSG00000272462.2	U91328.19	8.13	3.95e-15	4.49e-12	0.35	0.35	Height;	chr6:25912588	chr6:25992662~26001775:+
HNSC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-8.13	3.96e-15	4.5e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
HNSC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-8.13	3.97e-15	4.51e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
HNSC	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	8.13	3.97e-15	4.52e-12	0.44	0.35	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
HNSC	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	8.13	3.97e-15	4.52e-12	0.41	0.35	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
HNSC	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	8.13	3.99e-15	4.53e-12	0.4	0.35	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	8.13	3.99e-15	4.53e-12	0.4	0.35	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.13	3.99e-15	4.54e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
HNSC	cis	rs35955747	0.714	rs4820048	ENSG00000236132.1	CTA-440B3.1	8.13	3.99e-15	4.54e-12	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31458384	chr22:31816379~31817491:-
HNSC	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-8.13	4e-15	4.55e-12	-0.34	-0.35	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-8.13	4e-15	4.55e-12	-0.34	-0.35	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
HNSC	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	8.13	4.01e-15	4.55e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
HNSC	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-8.13	4.02e-15	4.56e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-8.13	4.02e-15	4.57e-12	-0.65	-0.35	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-8.13	4.02e-15	4.57e-12	-0.65	-0.35	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	8.13	4.04e-15	4.58e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-8.12	4.05e-15	4.59e-12	-0.33	-0.35	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
HNSC	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-8.12	4.05e-15	4.6e-12	-0.34	-0.35	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-8.12	4.05e-15	4.6e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	8.12	4.05e-15	4.6e-12	0.44	0.35	Height;	chr6:109402736	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	8.12	4.05e-15	4.6e-12	0.44	0.35	Height;	chr6:109403734	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	8.12	4.11e-15	4.66e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	8.12	4.11e-15	4.66e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	8.12	4.11e-15	4.66e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
HNSC	cis	rs7048146	0.966	rs7046719	ENSG00000213539.4	YBX1P6	8.12	4.13e-15	4.68e-12	0.41	0.35	Vascular brain injury;	chr9:109540085	chr9:109532830~109534332:-
HNSC	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	8.12	4.15e-15	4.7e-12	0.36	0.35	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
HNSC	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-8.12	4.17e-15	4.72e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	8.12	4.17e-15	4.73e-12	0.42	0.35	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
HNSC	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-8.12	4.18e-15	4.74e-12	-0.39	-0.35	Temperament;	chr17:14018109	chr17:14024514~14025488:+
HNSC	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-8.12	4.21e-15	4.76e-12	-0.33	-0.35	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-8.12	4.21e-15	4.76e-12	-0.33	-0.35	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
HNSC	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-8.12	4.24e-15	4.8e-12	-0.4	-0.35	Temperament;	chr17:14075460	chr17:14024514~14025488:+
HNSC	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	8.12	4.26e-15	4.82e-12	0.42	0.35	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-8.12	4.28e-15	4.84e-12	-0.41	-0.35	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
HNSC	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-8.12	4.28e-15	4.85e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-8.12	4.28e-15	4.85e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
HNSC	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	8.12	4.29e-15	4.86e-12	0.4	0.35	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
HNSC	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-8.12	4.31e-15	4.88e-12	-0.58	-0.35	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	8.12	4.32e-15	4.88e-12	0.54	0.35	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
HNSC	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	8.12	4.34e-15	4.91e-12	0.44	0.35	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
HNSC	cis	rs7942368	1	rs10160660	ENSG00000255100.1	RP11-21L23.3	8.11	4.35e-15	4.92e-12	0.45	0.35	Endometriosis;	chr11:76763493	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000179406.6	LINC00174	-8.11	4.35e-15	4.92e-12	-0.52	-0.35	Aortic root size;	chr7:66258859	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.11	4.39e-15	4.96e-12	0.37	0.35	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-8.11	4.4e-15	4.97e-12	-0.47	-0.35	Depression;	chr6:28144784	chr6:28115628~28116551:+
HNSC	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	8.11	4.4e-15	4.98e-12	0.42	0.35	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-8.11	4.4e-15	4.98e-12	-0.39	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
HNSC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-8.11	4.43e-15	5.01e-12	-0.37	-0.35	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	8.11	4.43e-15	5.01e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
HNSC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	8.11	4.43e-15	5.01e-12	0.42	0.35	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
HNSC	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-8.11	4.48e-15	5.06e-12	-0.38	-0.35	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
HNSC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Depression;	chr6:28399886	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	8.11	4.49e-15	5.07e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	8.11	4.49e-15	5.07e-12	0.37	0.35	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-8.11	4.49e-15	5.07e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
HNSC	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-8.11	4.49e-15	5.07e-12	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
HNSC	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-8.11	4.5e-15	5.08e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-8.11	4.5e-15	5.08e-12	-0.33	-0.35	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
HNSC	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-8.11	4.5e-15	5.08e-12	-0.4	-0.35	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	8.11	4.51e-15	5.08e-12	0.42	0.35	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
HNSC	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.11	4.51e-15	5.09e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-8.11	4.52e-15	5.1e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-8.11	4.54e-15	5.12e-12	-0.64	-0.35	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
HNSC	cis	rs7048146	0.966	rs4978824	ENSG00000213539.4	YBX1P6	8.11	4.55e-15	5.13e-12	0.41	0.35	Vascular brain injury;	chr9:109540112	chr9:109532830~109534332:-
HNSC	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-8.11	4.56e-15	5.14e-12	-0.34	-0.35	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
HNSC	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-8.11	4.56e-15	5.14e-12	-0.41	-0.35	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.964	rs9295677	ENSG00000272462.2	U91328.19	-8.11	4.57e-15	5.15e-12	-0.35	-0.35	Height;	chr6:25933484	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	8.11	4.57e-15	5.15e-12	0.4	0.35	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	8.11	4.58e-15	5.16e-12	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
HNSC	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	8.11	4.58e-15	5.16e-12	0.46	0.35	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
HNSC	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-8.11	4.58e-15	5.17e-12	-0.34	-0.35	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-8.11	4.58e-15	5.17e-12	-0.34	-0.35	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-8.11	4.59e-15	5.17e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
HNSC	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-8.11	4.6e-15	5.18e-12	-0.49	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
HNSC	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	8.11	4.61e-15	5.19e-12	0.4	0.35	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	8.11	4.62e-15	5.2e-12	0.4	0.35	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
HNSC	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-8.11	4.63e-15	5.22e-12	-0.37	-0.35	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
HNSC	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	8.1	4.66e-15	5.25e-12	0.42	0.35	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	8.1	4.66e-15	5.25e-12	0.42	0.35	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	8.1	4.67e-15	5.25e-12	0.41	0.35	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	8.1	4.67e-15	5.25e-12	0.41	0.35	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	8.1	4.7e-15	5.28e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
HNSC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-8.1	4.7e-15	5.29e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
HNSC	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-8.1	4.71e-15	5.29e-12	-0.45	-0.35	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
HNSC	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-8.1	4.71e-15	5.3e-12	-0.4	-0.35	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
HNSC	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	8.1	4.74e-15	5.33e-12	0.39	0.35	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
HNSC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	8.1	4.75e-15	5.34e-12	0.42	0.35	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
HNSC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	8.1	4.75e-15	5.34e-12	0.36	0.35	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
HNSC	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	8.1	4.78e-15	5.37e-12	0.43	0.35	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	8.1	4.78e-15	5.37e-12	0.43	0.35	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
HNSC	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	8.1	4.82e-15	5.41e-12	0.54	0.35	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	8.1	4.82e-15	5.42e-12	0.45	0.35	Height;	chr6:109498586	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	8.1	4.82e-15	5.42e-12	0.45	0.35	Height;	chr6:109499759	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-8.1	4.82e-15	5.42e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
HNSC	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-8.1	4.83e-15	5.43e-12	-0.56	-0.35	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-8.1	4.86e-15	5.46e-12	-0.41	-0.35	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
HNSC	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-8.1	4.87e-15	5.47e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-8.1	4.92e-15	5.52e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-8.1	4.92e-15	5.52e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
HNSC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	8.1	4.92e-15	5.52e-12	0.42	0.35	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
HNSC	cis	rs7404843	0.704	rs112251447	ENSG00000263065.1	AF001548.6	8.1	4.92e-15	5.52e-12	0.66	0.35	Testicular germ cell tumor;	chr16:15428015	chr16:15741151~15741791:+
HNSC	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	8.1	4.92e-15	5.53e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	8.1	4.94e-15	5.54e-12	0.44	0.35	Height;	chr6:109405536	chr6:109382795~109383666:+
HNSC	cis	rs1865760	0.865	rs1115920	ENSG00000272462.2	U91328.19	-8.1	4.95e-15	5.56e-12	-0.35	-0.35	Height;	chr6:25953799	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467645	ENSG00000272462.2	U91328.19	-8.1	4.95e-15	5.56e-12	-0.35	-0.35	Height;	chr6:25954948	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	8.1	4.96e-15	5.57e-12	0.34	0.35	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
HNSC	cis	rs1865760	0.827	rs9295680	ENSG00000272462.2	U91328.19	-8.1	4.98e-15	5.58e-12	-0.35	-0.35	Height;	chr6:25943875	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.827	rs9295681	ENSG00000272462.2	U91328.19	-8.1	4.98e-15	5.58e-12	-0.35	-0.35	Height;	chr6:25943889	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-8.1	4.99e-15	5.6e-12	-0.34	-0.35	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	8.09	5.02e-15	5.62e-12	0.38	0.35	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
HNSC	cis	rs7942368	0.941	rs1465900	ENSG00000255100.1	RP11-21L23.3	8.09	5.03e-15	5.64e-12	0.45	0.35	Endometriosis;	chr11:76762094	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-8.09	5.04e-15	5.64e-12	-0.33	-0.35	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-8.09	5.06e-15	5.67e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
HNSC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-8.09	5.07e-15	5.67e-12	-0.37	-0.35	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
HNSC	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-8.09	5.08e-15	5.69e-12	-0.57	-0.35	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
HNSC	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	8.09	5.08e-15	5.69e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-8.09	5.09e-15	5.7e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
HNSC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-8.09	5.1e-15	5.7e-12	-0.41	-0.35	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
HNSC	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-8.09	5.14e-15	5.76e-12	-0.42	-0.35	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	8.09	5.15e-15	5.76e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
HNSC	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	8.09	5.16e-15	5.78e-12	0.4	0.35	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.09	5.19e-15	5.81e-12	0.52	0.35	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
HNSC	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-8.09	5.2e-15	5.81e-12	-0.36	-0.35	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
HNSC	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-8.09	5.2e-15	5.81e-12	-0.55	-0.35	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
HNSC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	8.09	5.21e-15	5.83e-12	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
HNSC	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-8.09	5.21e-15	5.83e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
HNSC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	8.09	5.23e-15	5.85e-12	0.4	0.35	Depression;	chr6:28314871	chr6:28176188~28176674:+
HNSC	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.09	5.24e-15	5.86e-12	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-8.09	5.26e-15	5.88e-12	-0.37	-0.35	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
HNSC	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	8.09	5.27e-15	5.89e-12	0.39	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
HNSC	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-8.09	5.27e-15	5.89e-12	-0.4	-0.35	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-8.09	5.27e-15	5.89e-12	-0.4	-0.35	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
HNSC	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	8.09	5.27e-15	5.89e-12	0.44	0.35	Height;	chr6:109424122	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-8.09	5.3e-15	5.93e-12	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
HNSC	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	8.09	5.34e-15	5.97e-12	0.39	0.35	Temperament;	chr17:14068990	chr17:14024514~14025488:+
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	8.09	5.36e-15	5.99e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-8.09	5.37e-15	6e-12	-0.4	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-8.09	5.38e-15	6.01e-12	-0.41	-0.35	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-8.08	5.39e-15	6.02e-12	-0.4	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
HNSC	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	8.08	5.41e-15	6.05e-12	0.44	0.35	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-8.08	5.44e-15	6.08e-12	-0.42	-0.35	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
HNSC	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	8.08	5.47e-15	6.11e-12	0.37	0.35	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-8.08	5.49e-15	6.13e-12	-0.4	-0.35	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-8.08	5.5e-15	6.14e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
HNSC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-8.08	5.5e-15	6.14e-12	-0.38	-0.35	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
HNSC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-8.08	5.51e-15	6.15e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-8.08	5.51e-15	6.15e-12	-0.33	-0.35	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-8.08	5.51e-15	6.15e-12	-0.33	-0.35	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
HNSC	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-8.08	5.52e-15	6.16e-12	-0.41	-0.35	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
HNSC	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	8.08	5.53e-15	6.17e-12	0.45	0.35	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
HNSC	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	8.08	5.56e-15	6.2e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
HNSC	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	8.08	5.56e-15	6.2e-12	0.54	0.35	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	8.08	5.56e-15	6.2e-12	0.54	0.35	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
HNSC	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	8.08	5.57e-15	6.21e-12	0.4	0.35	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	8.08	5.57e-15	6.21e-12	0.4	0.35	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	8.08	5.57e-15	6.21e-12	0.4	0.35	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
HNSC	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	8.08	5.59e-15	6.23e-12	0.4	0.35	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-8.08	5.61e-15	6.25e-12	-0.43	-0.35	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
HNSC	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	8.08	5.64e-15	6.28e-12	0.41	0.35	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-8.08	5.64e-15	6.28e-12	-0.47	-0.35	Depression;	chr6:28143758	chr6:28115628~28116551:+
HNSC	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	8.08	5.67e-15	6.31e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	8.08	5.67e-15	6.31e-12	0.48	0.35	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-8.08	5.7e-15	6.35e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-8.08	5.72e-15	6.37e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	8.08	5.74e-15	6.39e-12	0.37	0.35	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
HNSC	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	8.08	5.74e-15	6.39e-12	0.34	0.35	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
HNSC	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-8.08	5.75e-15	6.4e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-8.08	5.77e-15	6.42e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
HNSC	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	8.08	5.78e-15	6.43e-12	0.7	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
HNSC	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	8.07	5.8e-15	6.45e-12	0.64	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
HNSC	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	8.07	5.89e-15	6.54e-12	0.4	0.35	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
HNSC	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	8.07	5.9e-15	6.55e-12	0.44	0.35	Height;	chr6:109360263	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	8.07	5.93e-15	6.59e-12	0.46	0.35	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
HNSC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	8.07	5.94e-15	6.6e-12	0.42	0.35	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	8.07	5.94e-15	6.6e-12	0.42	0.35	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
HNSC	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	8.07	5.94e-15	6.6e-12	0.39	0.35	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
HNSC	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	8.07	5.96e-15	6.62e-12	0.36	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
HNSC	cis	rs7048146	1	rs7030085	ENSG00000213539.4	YBX1P6	8.07	5.98e-15	6.63e-12	0.41	0.35	Vascular brain injury;	chr9:109539735	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs7021839	ENSG00000213539.4	YBX1P6	8.07	6e-15	6.66e-12	0.41	0.35	Vascular brain injury;	chr9:109538257	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816832	ENSG00000213539.4	YBX1P6	8.07	6e-15	6.66e-12	0.41	0.35	Vascular brain injury;	chr9:109538494	chr9:109532830~109534332:-
HNSC	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	8.07	6e-15	6.66e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	8.07	6e-15	6.66e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
HNSC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-8.07	6e-15	6.66e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
HNSC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	8.07	6.04e-15	6.7e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
HNSC	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-8.07	6.04e-15	6.7e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
HNSC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-8.07	6.04e-15	6.7e-12	-0.42	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
HNSC	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	8.07	6.04e-15	6.7e-12	0.46	0.35	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
HNSC	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	8.07	6.05e-15	6.71e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
HNSC	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	8.07	6.06e-15	6.72e-12	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
HNSC	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	8.07	6.07e-15	6.72e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
HNSC	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-8.07	6.09e-15	6.75e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	8.07	6.09e-15	6.75e-12	0.4	0.35	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
HNSC	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	8.07	6.09e-15	6.75e-12	0.39	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
HNSC	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	8.07	6.11e-15	6.77e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
HNSC	cis	rs1865760	0.929	rs12195653	ENSG00000272462.2	U91328.19	-8.07	6.12e-15	6.78e-12	-0.35	-0.35	Height;	chr6:25958393	chr6:25992662~26001775:+
HNSC	cis	rs7048146	0.966	rs10816829	ENSG00000213539.4	YBX1P6	8.07	6.13e-15	6.79e-12	0.41	0.35	Vascular brain injury;	chr9:109536396	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs12336499	ENSG00000213539.4	YBX1P6	8.07	6.13e-15	6.79e-12	0.41	0.35	Vascular brain injury;	chr9:109537967	chr9:109532830~109534332:-
HNSC	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-8.07	6.13e-15	6.79e-12	-0.44	-0.35	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
HNSC	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-8.07	6.15e-15	6.81e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-8.07	6.15e-15	6.81e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	8.07	6.2e-15	6.86e-12	0.54	0.35	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-8.07	6.21e-15	6.87e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-8.07	6.21e-15	6.87e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-8.06	6.22e-15	6.89e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
HNSC	cis	rs7048146	1	rs7048146	ENSG00000213539.4	YBX1P6	8.06	6.24e-15	6.91e-12	0.41	0.35	Vascular brain injury;	chr9:109537042	chr9:109532830~109534332:-
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-8.06	6.25e-15	6.91e-12	-0.37	-0.35	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.06	6.27e-15	6.94e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	8.06	6.28e-15	6.94e-12	0.39	0.35	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
HNSC	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	8.06	6.28e-15	6.95e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
HNSC	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	8.06	6.31e-15	6.98e-12	0.34	0.35	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
HNSC	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	8.06	6.31e-15	6.98e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-8.06	6.31e-15	6.98e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-8.06	6.32e-15	6.99e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	8.06	6.38e-15	7.05e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	8.06	6.38e-15	7.05e-12	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-8.06	6.38e-15	7.06e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-8.06	6.38e-15	7.06e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-8.06	6.43e-15	7.1e-12	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
HNSC	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-8.06	6.49e-15	7.17e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	8.06	6.5e-15	7.18e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109425054	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109426518	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109427644	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	8.06	6.52e-15	7.19e-12	0.44	0.35	Height;	chr6:109430292	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-8.06	6.52e-15	7.19e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.06	6.53e-15	7.2e-12	0.36	0.35	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
HNSC	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	8.06	6.53e-15	7.21e-12	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
HNSC	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-8.06	6.54e-15	7.22e-12	-0.37	-0.35	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000179406.6	LINC00174	-8.06	6.57e-15	7.25e-12	-0.53	-0.35	Aortic root size;	chr7:66518628	chr7:66376044~66401338:-
HNSC	cis	rs7048146	1	rs10979904	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538136	chr9:109532830~109534332:-
HNSC	cis	rs7048146	1	rs7022179	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538280	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816831	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538337	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816833	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538551	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10816834	ENSG00000213539.4	YBX1P6	8.06	6.59e-15	7.27e-12	0.41	0.35	Vascular brain injury;	chr9:109538626	chr9:109532830~109534332:-
HNSC	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	8.06	6.59e-15	7.27e-12	0.45	0.35	Height;	chr6:109367528	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	8.06	6.59e-15	7.27e-12	0.45	0.35	Height;	chr6:109368704	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	8.06	6.6e-15	7.28e-12	0.44	0.35	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	8.06	6.61e-15	7.28e-12	0.42	0.35	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	8.06	6.61e-15	7.28e-12	0.37	0.35	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
HNSC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	8.06	6.62e-15	7.29e-12	0.42	0.35	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	8.06	6.62e-15	7.3e-12	0.41	0.35	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
HNSC	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-8.06	6.64e-15	7.31e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-8.06	6.64e-15	7.31e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	8.06	6.66e-15	7.34e-12	0.4	0.35	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
HNSC	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.06	6.68e-15	7.35e-12	-0.38	-0.35	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
HNSC	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-8.05	6.69e-15	7.37e-12	-0.31	-0.35	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
HNSC	cis	rs454422	0.812	rs13041190	ENSG00000275632.1	RP5-967N21.11	8.05	6.7e-15	7.37e-12	0.38	0.35	HIV-1 viral setpoint;	chr20:5980812	chr20:6000418~6000941:+
HNSC	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	8.05	6.72e-15	7.39e-12	0.54	0.35	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
HNSC	cis	rs7048146	0.966	rs4978401	ENSG00000213539.4	YBX1P6	-8.05	6.76e-15	7.43e-12	-0.4	-0.35	Vascular brain injury;	chr9:109540631	chr9:109532830~109534332:-
HNSC	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-8.05	6.76e-15	7.44e-12	-0.34	-0.35	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
HNSC	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	8.05	6.77e-15	7.45e-12	0.42	0.35	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
HNSC	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-8.05	6.79e-15	7.47e-12	-0.41	-0.35	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-8.05	6.79e-15	7.47e-12	-0.41	-0.35	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
HNSC	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	8.05	6.81e-15	7.49e-12	0.42	0.35	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	8.05	6.82e-15	7.5e-12	0.42	0.35	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
HNSC	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	8.05	6.84e-15	7.53e-12	0.42	0.35	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
HNSC	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	8.05	6.86e-15	7.54e-12	0.54	0.35	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
HNSC	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.05	6.88e-15	7.56e-12	-0.38	-0.35	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	8.05	6.89e-15	7.57e-12	0.42	0.35	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	8.05	6.89e-15	7.57e-12	0.42	0.35	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.05	6.9e-15	7.58e-12	-0.55	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
HNSC	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.05	6.9e-15	7.58e-12	0.37	0.35	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-8.05	6.92e-15	7.6e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
HNSC	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-8.05	6.92e-15	7.6e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	8.05	6.94e-15	7.62e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
HNSC	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	8.05	6.97e-15	7.66e-12	0.54	0.35	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
HNSC	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	8.05	6.98e-15	7.66e-12	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
HNSC	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.05	6.98e-15	7.67e-12	-0.38	-0.35	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
HNSC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-8.05	6.99e-15	7.67e-12	-0.43	-0.35	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.05	7.01e-15	7.69e-12	-0.38	-0.35	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.05	7.01e-15	7.69e-12	-0.38	-0.35	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000179406.6	LINC00174	-8.05	7.02e-15	7.7e-12	-0.51	-0.35	Aortic root size;	chr7:66172694	chr7:66376044~66401338:-
HNSC	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	8.05	7.06e-15	7.75e-12	0.48	0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-8.05	7.09e-15	7.78e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-8.05	7.12e-15	7.81e-12	-0.34	-0.35	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	8.05	7.14e-15	7.84e-12	0.46	0.35	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
HNSC	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	8.05	7.15e-15	7.84e-12	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
HNSC	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	8.05	7.16e-15	7.85e-12	0.44	0.35	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
HNSC	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-8.04	7.2e-15	7.89e-12	-0.38	-0.35	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-8.04	7.21e-15	7.9e-12	-0.33	-0.35	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.713	rs2013063	ENSG00000272462.2	U91328.19	-8.04	7.22e-15	7.92e-12	-0.34	-0.35	Height;	chr6:25993870	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-8.04	7.23e-15	7.92e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	8.04	7.25e-15	7.94e-12	0.45	0.35	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
HNSC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	8.04	7.26e-15	7.94e-12	0.41	0.35	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
HNSC	cis	rs7048146	0.966	rs10979907	ENSG00000213539.4	YBX1P6	8.04	7.26e-15	7.95e-12	0.41	0.35	Vascular brain injury;	chr9:109541739	chr9:109532830~109534332:-
HNSC	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-8.04	7.27e-15	7.96e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
HNSC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	8.04	7.27e-15	7.96e-12	0.41	0.35	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
HNSC	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	8.04	7.29e-15	7.98e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
HNSC	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-8.04	7.31e-15	8e-12	-0.38	-0.35	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-8.04	7.32e-15	8.01e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
HNSC	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	8.04	7.38e-15	8.07e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-8.04	7.41e-15	8.09e-12	-0.37	-0.35	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
HNSC	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-8.04	7.42e-15	8.1e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.566	rs9358904	ENSG00000272462.2	U91328.19	-8.04	7.44e-15	8.13e-12	-0.34	-0.35	Height;	chr6:26068338	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-8.04	7.44e-15	8.13e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-8.04	7.44e-15	8.13e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
HNSC	cis	rs17270561	0.666	rs4712976	ENSG00000272462.2	U91328.19	-8.04	7.44e-15	8.13e-12	-0.37	-0.35	Iron status biomarkers;	chr6:25841975	chr6:25992662~26001775:+
HNSC	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	8.04	7.45e-15	8.14e-12	0.4	0.35	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	8.04	7.47e-15	8.16e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
HNSC	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	8.04	7.48e-15	8.17e-12	0.42	0.35	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	8.04	7.52e-15	8.21e-12	0.33	0.35	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	8.04	7.53e-15	8.22e-12	0.49	0.35	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
HNSC	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-8.04	7.56e-15	8.26e-12	-0.45	-0.35	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
HNSC	cis	rs7048146	0.899	rs12550929	ENSG00000213539.4	YBX1P6	8.04	7.58e-15	8.27e-12	0.41	0.35	Vascular brain injury;	chr9:109541072	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.966	rs10979906	ENSG00000213539.4	YBX1P6	8.04	7.58e-15	8.27e-12	0.41	0.35	Vascular brain injury;	chr9:109541401	chr9:109532830~109534332:-
HNSC	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-8.04	7.59e-15	8.28e-12	-0.49	-0.35	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
HNSC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	8.04	7.63e-15	8.32e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
HNSC	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-8.04	7.64e-15	8.33e-12	-0.43	-0.35	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
HNSC	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.04	7.65e-15	8.35e-12	0.37	0.35	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
HNSC	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-8.04	7.66e-15	8.35e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	8.04	7.68e-15	8.38e-12	0.36	0.35	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
HNSC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	8.04	7.68e-15	8.38e-12	0.39	0.35	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
HNSC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	8.04	7.69e-15	8.38e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-8.04	7.7e-15	8.39e-12	-0.52	-0.35	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
HNSC	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-8.04	7.71e-15	8.4e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-8.03	7.75e-15	8.45e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	8.03	7.76e-15	8.45e-12	0.36	0.35	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	8.03	7.78e-15	8.47e-12	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
HNSC	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	8.03	7.78e-15	8.48e-12	0.42	0.35	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
HNSC	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	8.03	7.8e-15	8.5e-12	0.41	0.35	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
HNSC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-8.03	7.82e-15	8.51e-12	-0.44	-0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	8.03	7.84e-15	8.54e-12	0.4	0.35	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
HNSC	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	8.03	7.86e-15	8.55e-12	0.41	0.35	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
HNSC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.03	7.87e-15	8.57e-12	0.41	0.35	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-8.03	7.9e-15	8.6e-12	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
HNSC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	8.03	7.93e-15	8.63e-12	0.4	0.35	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
HNSC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	8.03	7.93e-15	8.63e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
HNSC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-8.03	7.96e-15	8.66e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
HNSC	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	8.03	7.97e-15	8.68e-12	0.44	0.35	Height;	chr6:109458989	chr6:109382795~109383666:+
HNSC	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	8.03	8.01e-15	8.71e-12	0.45	0.35	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
HNSC	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-8.03	8.03e-15	8.73e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
HNSC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	8.03	8.03e-15	8.74e-12	0.36	0.35	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
HNSC	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-8.03	8.06e-15	8.76e-12	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
HNSC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	8.03	8.06e-15	8.77e-12	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	8.03	8.1e-15	8.81e-12	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
HNSC	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-8.03	8.1e-15	8.81e-12	-0.47	-0.35	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
HNSC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-8.03	8.12e-15	8.83e-12	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
HNSC	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-8.03	8.12e-15	8.83e-12	-0.34	-0.35	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-8.03	8.13e-15	8.84e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-8.03	8.13e-15	8.84e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
HNSC	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-8.03	8.17e-15	8.88e-12	-0.34	-0.35	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
HNSC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-8.03	8.21e-15	8.93e-12	-0.36	-0.35	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	8.03	8.22e-15	8.93e-12	0.32	0.35	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	8.03	8.25e-15	8.96e-12	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	8.03	8.26e-15	8.97e-12	0.38	0.35	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-8.02	8.38e-15	9.1e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-8.02	8.38e-15	9.1e-12	-0.55	-0.35	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
HNSC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	8.02	8.41e-15	9.13e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
HNSC	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-8.02	8.45e-15	9.17e-12	-0.53	-0.35	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	8.02	8.48e-15	9.2e-12	0.48	0.35	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-8.02	8.48e-15	9.21e-12	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	8.02	8.49e-15	9.22e-12	0.32	0.35	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
HNSC	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-8.02	8.5e-15	9.22e-12	-0.34	-0.35	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000179406.6	LINC00174	-8.02	8.52e-15	9.24e-12	-0.53	-0.35	Aortic root size;	chr7:66283366	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000179406.6	LINC00174	-8.02	8.52e-15	9.24e-12	-0.53	-0.35	Aortic root size;	chr7:66327797	chr7:66376044~66401338:-
HNSC	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	8.02	8.57e-15	9.29e-12	0.42	0.35	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	8.02	8.58e-15	9.3e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
HNSC	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-8.02	8.58e-15	9.3e-12	-0.55	-0.35	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
HNSC	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-8.02	8.58e-15	9.3e-12	-0.55	-0.35	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
HNSC	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	8.02	8.6e-15	9.32e-12	0.54	0.35	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	8.02	8.62e-15	9.34e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
HNSC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-8.02	8.64e-15	9.36e-12	-0.37	-0.35	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
HNSC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	8.02	8.65e-15	9.37e-12	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
HNSC	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-8.02	8.65e-15	9.37e-12	-0.54	-0.35	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-8.02	8.66e-15	9.38e-12	-0.44	-0.35	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
HNSC	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-8.02	8.71e-15	9.43e-12	-0.43	-0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
HNSC	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-8.02	8.73e-15	9.45e-12	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
HNSC	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	8.02	8.74e-15	9.47e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	8.02	8.75e-15	9.48e-12	0.48	0.35	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-8.02	8.79e-15	9.52e-12	-0.52	-0.35	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	8.02	8.81e-15	9.53e-12	0.33	0.35	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
HNSC	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	8.02	8.85e-15	9.58e-12	0.4	0.35	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
HNSC	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	8.02	8.87e-15	9.61e-12	0.41	0.35	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	8.02	8.88e-15	9.61e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	8.02	8.88e-15	9.61e-12	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	8.01	8.91e-15	9.64e-12	0.44	0.35	Height;	chr6:109409679	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	8.01	8.91e-15	9.64e-12	0.44	0.35	Height;	chr6:109424305	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	8.01	8.93e-15	9.66e-12	0.28	0.35	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
HNSC	cis	rs7048146	0.899	rs1330846	ENSG00000213539.4	YBX1P6	-8.01	8.96e-15	9.69e-12	-0.41	-0.35	Vascular brain injury;	chr9:109574668	chr9:109532830~109534332:-
HNSC	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
HNSC	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	8.01	8.98e-15	9.71e-12	0.43	0.35	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
HNSC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-8.01	8.99e-15	9.72e-12	-0.56	-0.35	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-8.01	8.99e-15	9.72e-12	-0.43	-0.35	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
HNSC	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-8.01	9.01e-15	9.74e-12	-0.44	-0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
HNSC	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8.01	9.03e-15	9.76e-12	-0.4	-0.35	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	8.01	9.05e-15	9.78e-12	0.48	0.35	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	8.01	9.05e-15	9.78e-12	0.48	0.35	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	8.01	9.06e-15	9.79e-12	0.48	0.35	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	8.01	9.15e-15	9.88e-12	0.46	0.35	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	8.01	9.15e-15	9.88e-12	0.46	0.35	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	8.01	9.22e-15	9.95e-12	0.33	0.35	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
HNSC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-8.01	9.22e-15	9.95e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-8.01	9.22e-15	9.96e-12	-0.53	-0.35	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
HNSC	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-8.01	9.25e-15	9.98e-12	-0.42	-0.35	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
HNSC	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	8.01	9.28e-15	1e-11	0.45	0.35	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
HNSC	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	8.01	9.32e-15	1.01e-11	0.35	0.35	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
HNSC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-8.01	9.37e-15	1.01e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-8.01	9.37e-15	1.01e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-8.01	9.38e-15	1.01e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-8.01	9.39e-15	1.01e-11	-0.45	-0.35	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	8.01	9.44e-15	1.02e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
HNSC	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.01	9.48e-15	1.02e-11	0.39	0.35	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	8.01	9.5e-15	1.02e-11	0.48	0.35	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
HNSC	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	8.01	9.5e-15	1.02e-11	0.4	0.35	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
HNSC	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	8.01	9.51e-15	1.02e-11	0.38	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
HNSC	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	8.01	9.51e-15	1.02e-11	0.54	0.35	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	8.01	9.52e-15	1.02e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
HNSC	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	8.01	9.54e-15	1.03e-11	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
HNSC	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	8	9.6e-15	1.03e-11	0.36	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
HNSC	cis	rs1021993	0.868	rs6661759	ENSG00000231648.1	RP11-372M18.2	-8	9.61e-15	1.03e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209357454	chr1:209367662~209379690:+
HNSC	cis	rs9341808	0.754	rs6918172	ENSG00000272129.1	RP11-250B2.6	8	9.62e-15	1.03e-11	0.41	0.35	Sitting height ratio;	chr6:80309525	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8	9.63e-15	1.04e-11	-0.38	-0.35	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
HNSC	cis	rs7048146	0.966	rs4978825	ENSG00000213539.4	YBX1P6	-8	9.64e-15	1.04e-11	-0.4	-0.35	Vascular brain injury;	chr9:109540184	chr9:109532830~109534332:-
HNSC	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	8	9.65e-15	1.04e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	8	9.68e-15	1.04e-11	0.39	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-8	9.69e-15	1.04e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
HNSC	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	8	9.7e-15	1.04e-11	0.41	0.35	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
HNSC	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	8	9.7e-15	1.04e-11	0.41	0.35	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
HNSC	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	8	9.7e-15	1.04e-11	0.54	0.35	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
HNSC	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-8	9.71e-15	1.04e-11	-0.47	-0.35	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
HNSC	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	8	9.71e-15	1.04e-11	0.41	0.35	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	8	9.71e-15	1.04e-11	0.41	0.35	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	8	9.73e-15	1.05e-11	0.24	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	8	9.79e-15	1.05e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8	9.8e-15	1.05e-11	-0.4	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
HNSC	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	8	9.82e-15	1.06e-11	0.4	0.35	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-8	9.85e-15	1.06e-11	-0.57	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-8	9.85e-15	1.06e-11	-0.24	-0.35	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8	9.85e-15	1.06e-11	-0.65	-0.35	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
HNSC	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8	9.92e-15	1.07e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	8	9.94e-15	1.07e-11	0.48	0.35	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	8	9.94e-15	1.07e-11	0.31	0.35	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
HNSC	cis	rs1865760	0.865	rs9467652	ENSG00000272462.2	U91328.19	-8	9.98e-15	1.07e-11	-0.34	-0.35	Height;	chr6:25958899	chr6:25992662~26001775:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	8	9.99e-15	1.07e-11	0.4	0.35	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
HNSC	cis	rs6867032	1	rs10462750	ENSG00000249731.1	RP11-259O2.3	8	1e-14	1.08e-11	0.42	0.35	Gut microbiome composition (winter);	chr5:2012849	chr5:1968094~1969013:+
HNSC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	8	1.01e-14	1.08e-11	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
HNSC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	8	1.01e-14	1.08e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
HNSC	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8	1.01e-14	1.09e-11	0.41	0.35	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	8	1.02e-14	1.09e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-8	1.02e-14	1.09e-11	-0.44	-0.35	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-8	1.02e-14	1.09e-11	-0.39	-0.35	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
HNSC	cis	rs1865760	0.713	rs7766342	ENSG00000272462.2	U91328.19	-8	1.02e-14	1.09e-11	-0.34	-0.35	Height;	chr6:25990446	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.713	rs9461229	ENSG00000272462.2	U91328.19	-8	1.02e-14	1.09e-11	-0.34	-0.35	Height;	chr6:25992051	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	8	1.02e-14	1.1e-11	0.46	0.35	Height;	chr6:109642186	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	8	1.02e-14	1.1e-11	0.4	0.35	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	8	1.02e-14	1.1e-11	0.4	0.35	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	7.99	1.03e-14	1.1e-11	0.41	0.35	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
HNSC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-7.99	1.03e-14	1.1e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
HNSC	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.99	1.03e-14	1.11e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
HNSC	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-7.99	1.04e-14	1.11e-11	-0.49	-0.35	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000179406.6	LINC00174	-7.99	1.04e-14	1.11e-11	-0.52	-0.35	Aortic root size;	chr7:66302237	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	7.99	1.04e-14	1.11e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
HNSC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.99	1.04e-14	1.12e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	7.99	1.04e-14	1.12e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
HNSC	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-7.99	1.05e-14	1.12e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
HNSC	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-7.99	1.05e-14	1.12e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
HNSC	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-7.99	1.05e-14	1.12e-11	-0.4	-0.35	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
HNSC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-7.99	1.05e-14	1.12e-11	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
HNSC	cis	rs1865760	0.568	rs2032450	ENSG00000272462.2	U91328.19	-7.99	1.05e-14	1.12e-11	-0.34	-0.35	Height;	chr6:25992886	chr6:25992662~26001775:+
HNSC	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-7.99	1.05e-14	1.12e-11	-0.53	-0.35	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
HNSC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	7.99	1.06e-14	1.13e-11	0.39	0.35	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
HNSC	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	7.99	1.06e-14	1.13e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	7.99	1.06e-14	1.13e-11	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
HNSC	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.99	1.06e-14	1.14e-11	0.4	0.35	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
HNSC	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	7.99	1.07e-14	1.14e-11	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	7.99	1.07e-14	1.14e-11	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
HNSC	cis	rs35955747	0.633	rs5998002	ENSG00000236132.1	CTA-440B3.1	7.99	1.07e-14	1.14e-11	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485183	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	7.99	1.07e-14	1.14e-11	0.33	0.35	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
HNSC	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	7.99	1.08e-14	1.15e-11	0.32	0.35	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
HNSC	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-7.99	1.08e-14	1.16e-11	-0.37	-0.35	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
HNSC	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-7.99	1.09e-14	1.16e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-7.99	1.09e-14	1.16e-11	-0.57	-0.35	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-7.99	1.09e-14	1.16e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-7.99	1.09e-14	1.16e-11	-0.37	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
HNSC	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	7.99	1.09e-14	1.16e-11	0.4	0.35	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	7.99	1.09e-14	1.17e-11	0.38	0.35	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
HNSC	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-7.99	1.09e-14	1.17e-11	-0.31	-0.35	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
HNSC	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-7.99	1.1e-14	1.17e-11	-0.41	-0.35	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-7.99	1.1e-14	1.17e-11	-0.41	-0.35	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
HNSC	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	7.99	1.1e-14	1.17e-11	0.43	0.35	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
HNSC	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	7.99	1.1e-14	1.18e-11	0.38	0.35	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000179406.6	LINC00174	-7.98	1.11e-14	1.19e-11	-0.52	-0.35	Aortic root size;	chr7:66301366	chr7:66376044~66401338:-
HNSC	cis	rs35955747	0.533	rs5998004	ENSG00000236132.1	CTA-440B3.1	7.98	1.11e-14	1.19e-11	0.38	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485843	chr22:31816379~31817491:-
HNSC	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	7.98	1.11e-14	1.19e-11	0.44	0.35	Height;	chr6:109490935	chr6:109382795~109383666:+
HNSC	cis	rs7048146	0.966	rs4978826	ENSG00000213539.4	YBX1P6	7.98	1.12e-14	1.19e-11	0.4	0.35	Vascular brain injury;	chr9:109540221	chr9:109532830~109534332:-
HNSC	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	7.98	1.12e-14	1.2e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-7.98	1.12e-14	1.2e-11	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
HNSC	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-7.98	1.13e-14	1.21e-11	-0.51	-0.35	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
HNSC	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	7.98	1.13e-14	1.21e-11	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	7.98	1.13e-14	1.21e-11	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-7.98	1.13e-14	1.21e-11	-0.33	-0.35	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
HNSC	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	7.98	1.13e-14	1.21e-11	0.7	0.35	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
HNSC	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-7.98	1.13e-14	1.21e-11	-0.4	-0.35	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-7.98	1.13e-14	1.21e-11	-0.44	-0.35	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-7.98	1.14e-14	1.22e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-7.98	1.14e-14	1.22e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-7.98	1.14e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-7.98	1.15e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-7.98	1.15e-14	1.22e-11	-0.33	-0.35	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
HNSC	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-7.98	1.15e-14	1.22e-11	-0.4	-0.35	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
HNSC	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-7.98	1.15e-14	1.22e-11	-0.4	-0.35	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
HNSC	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.98	1.15e-14	1.23e-11	-0.53	-0.35	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
HNSC	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	7.98	1.15e-14	1.23e-11	0.43	0.35	Height;	chr6:109361200	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	7.98	1.16e-14	1.23e-11	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
HNSC	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	7.98	1.16e-14	1.23e-11	0.4	0.35	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
HNSC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.98	1.16e-14	1.23e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-7.98	1.16e-14	1.24e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
HNSC	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	7.98	1.18e-14	1.25e-11	0.44	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
HNSC	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	7.98	1.18e-14	1.26e-11	0.4	0.35	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
HNSC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	7.98	1.18e-14	1.26e-11	0.36	0.35	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
HNSC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-7.98	1.18e-14	1.26e-11	-0.35	-0.35	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.26e-11	0.33	0.35	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-7.97	1.19e-14	1.27e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
HNSC	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-7.97	1.19e-14	1.27e-11	-0.41	-0.35	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
HNSC	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	7.97	1.19e-14	1.27e-11	0.41	0.35	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
HNSC	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-7.97	1.19e-14	1.27e-11	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
HNSC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.97	1.19e-14	1.27e-11	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.27e-11	0.36	0.35	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.97	1.19e-14	1.27e-11	0.36	0.35	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	7.97	1.2e-14	1.28e-11	0.39	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-7.97	1.21e-14	1.28e-11	-0.39	-0.35	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	7.97	1.21e-14	1.29e-11	0.46	0.35	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
HNSC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-7.97	1.21e-14	1.29e-11	-0.35	-0.35	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-7.97	1.22e-14	1.3e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109646187	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109652694	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	7.97	1.22e-14	1.3e-11	0.46	0.35	Height;	chr6:109655791	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	7.97	1.22e-14	1.3e-11	0.38	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-7.97	1.23e-14	1.31e-11	-0.46	-0.35	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
HNSC	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-7.97	1.23e-14	1.31e-11	-0.48	-0.35	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
HNSC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-7.97	1.23e-14	1.31e-11	-0.36	-0.35	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.865	rs9467647	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957414	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs10946800	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957545	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467648	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25957705	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467650	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25958007	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9467651	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.31e-11	-0.34	-0.35	Height;	chr6:25958029	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-7.97	1.24e-14	1.31e-11	-0.39	-0.35	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	7.97	1.24e-14	1.31e-11	0.39	0.35	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	7.97	1.24e-14	1.31e-11	0.39	0.35	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
HNSC	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-7.97	1.24e-14	1.32e-11	-0.34	-0.35	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-7.97	1.24e-14	1.32e-11	-0.33	-0.35	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.786	rs2164487	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.32e-11	-0.35	-0.35	Height;	chr6:25950572	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs6929805	ENSG00000272462.2	U91328.19	-7.97	1.24e-14	1.32e-11	-0.35	-0.35	Height;	chr6:25950606	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-7.97	1.24e-14	1.32e-11	-0.37	-0.35	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-7.97	1.26e-14	1.33e-11	-0.45	-0.35	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-7.97	1.26e-14	1.33e-11	-0.37	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
HNSC	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-7.97	1.26e-14	1.33e-11	-0.34	-0.35	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-7.97	1.26e-14	1.34e-11	-0.33	-0.35	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.827	rs9461227	ENSG00000272462.2	U91328.19	-7.97	1.27e-14	1.34e-11	-0.34	-0.35	Height;	chr6:25960587	chr6:25992662~26001775:+
HNSC	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	7.97	1.27e-14	1.34e-11	0.52	0.35	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	7.96	1.27e-14	1.35e-11	0.44	0.35	Height;	chr6:109358227	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	7.96	1.28e-14	1.36e-11	0.4	0.35	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
HNSC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	7.96	1.28e-14	1.36e-11	0.39	0.35	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	7.96	1.29e-14	1.37e-11	0.48	0.35	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
HNSC	cis	rs1021993	0.868	rs906350	ENSG00000231648.1	RP11-372M18.2	-7.96	1.29e-14	1.37e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209354763	chr1:209367662~209379690:+
HNSC	cis	rs6951245	0.608	rs10252234	ENSG00000224079.1	AC091729.7	-7.96	1.29e-14	1.37e-11	-0.45	-0.35	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074745	chr7:1074450~1078036:+
HNSC	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-7.96	1.3e-14	1.37e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
HNSC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-7.96	1.3e-14	1.38e-11	-0.38	-0.35	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
HNSC	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	7.96	1.31e-14	1.38e-11	0.4	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
HNSC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-7.96	1.31e-14	1.38e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
HNSC	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.96	1.31e-14	1.39e-11	0.4	0.35	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
HNSC	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-7.96	1.31e-14	1.39e-11	-0.37	-0.35	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
HNSC	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-7.96	1.32e-14	1.39e-11	-0.47	-0.35	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	7.96	1.32e-14	1.39e-11	0.39	0.35	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.865	rs2164485	ENSG00000272462.2	U91328.19	-7.96	1.32e-14	1.39e-11	-0.35	-0.35	Height;	chr6:25951878	chr6:25992662~26001775:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-7.96	1.32e-14	1.4e-11	-0.39	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
HNSC	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-7.96	1.32e-14	1.4e-11	-0.34	-0.35	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-7.96	1.33e-14	1.4e-11	-0.33	-0.35	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
HNSC	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-7.96	1.34e-14	1.41e-11	-0.37	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
HNSC	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	7.96	1.34e-14	1.42e-11	0.42	0.35	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
HNSC	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-7.96	1.34e-14	1.42e-11	-0.37	-0.35	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
HNSC	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-7.96	1.34e-14	1.42e-11	-0.54	-0.35	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
HNSC	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	7.96	1.34e-14	1.42e-11	0.4	0.35	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
HNSC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-7.96	1.35e-14	1.43e-11	-0.36	-0.35	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-7.96	1.35e-14	1.43e-11	-0.51	-0.35	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-7.96	1.36e-14	1.44e-11	-0.39	-0.35	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	7.96	1.36e-14	1.44e-11	0.33	0.35	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-7.96	1.36e-14	1.44e-11	-0.33	-0.35	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.713	rs6928951	ENSG00000272462.2	U91328.19	-7.96	1.36e-14	1.44e-11	-0.34	-0.35	Height;	chr6:25995326	chr6:25992662~26001775:+
HNSC	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.37e-14	1.44e-11	-0.37	-0.35	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
HNSC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.95	1.37e-14	1.44e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	7.95	1.37e-14	1.44e-11	0.48	0.35	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	7.95	1.37e-14	1.44e-11	0.48	0.35	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.95	1.37e-14	1.45e-11	0.39	0.35	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
HNSC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.95	1.37e-14	1.45e-11	-0.38	-0.35	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
HNSC	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-7.95	1.38e-14	1.46e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
HNSC	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-7.95	1.38e-14	1.46e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
HNSC	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	7.95	1.38e-14	1.46e-11	0.37	0.35	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	7.95	1.38e-14	1.46e-11	0.43	0.35	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-7.95	1.39e-14	1.46e-11	-0.37	-0.35	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-7.95	1.39e-14	1.47e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.39e-14	1.47e-11	-0.37	-0.35	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-7.95	1.4e-14	1.47e-11	-0.32	-0.35	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	7.95	1.4e-14	1.47e-11	0.38	0.35	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-7.95	1.4e-14	1.47e-11	-0.33	-0.35	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000179406.6	LINC00174	-7.95	1.41e-14	1.48e-11	-0.52	-0.35	Aortic root size;	chr7:66228193	chr7:66376044~66401338:-
HNSC	cis	rs1021993	0.868	rs6685498	ENSG00000231648.1	RP11-372M18.2	-7.95	1.41e-14	1.48e-11	-0.47	-0.35	Gut microbiome composition (winter);	chr1:209357487	chr1:209367662~209379690:+
HNSC	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	7.95	1.42e-14	1.49e-11	0.4	0.35	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-7.95	1.42e-14	1.49e-11	-0.4	-0.35	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.95	1.42e-14	1.49e-11	0.49	0.35	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
HNSC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.95	1.43e-14	1.5e-11	-0.37	-0.35	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	7.95	1.43e-14	1.5e-11	0.48	0.35	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000179406.6	LINC00174	-7.95	1.43e-14	1.5e-11	-0.52	-0.35	Aortic root size;	chr7:66511428	chr7:66376044~66401338:-
HNSC	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.44e-14	1.51e-11	-0.37	-0.35	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-7.95	1.44e-14	1.51e-11	-0.44	-0.35	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-7.95	1.44e-14	1.51e-11	-0.37	-0.35	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	7.95	1.45e-14	1.52e-11	0.46	0.35	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
HNSC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-7.95	1.45e-14	1.52e-11	-0.38	-0.35	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
HNSC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-7.95	1.45e-14	1.53e-11	-0.53	-0.35	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
HNSC	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	7.95	1.45e-14	1.53e-11	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
HNSC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-7.95	1.45e-14	1.53e-11	-0.37	-0.35	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
HNSC	cis	rs6969780	0.722	rs4722666	ENSG00000233429.8	HOTAIRM1	-7.95	1.45e-14	1.53e-11	-0.44	-0.35	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157982	chr7:27095647~27100265:+
HNSC	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	7.95	1.45e-14	1.53e-11	0.36	0.35	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
HNSC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.95	1.46e-14	1.53e-11	-0.38	-0.35	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
HNSC	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	7.95	1.46e-14	1.53e-11	0.41	0.35	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
HNSC	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-7.95	1.46e-14	1.53e-11	-0.36	-0.35	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
HNSC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	7.95	1.46e-14	1.53e-11	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	7.95	1.46e-14	1.54e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	7.95	1.46e-14	1.54e-11	0.49	0.35	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	7.95	1.46e-14	1.54e-11	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
HNSC	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-7.94	1.47e-14	1.54e-11	-0.46	-0.35	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
HNSC	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.94	1.47e-14	1.54e-11	-0.46	-0.35	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
HNSC	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	7.94	1.47e-14	1.55e-11	0.39	0.35	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
HNSC	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	7.94	1.47e-14	1.55e-11	0.43	0.35	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
HNSC	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	7.94	1.48e-14	1.55e-11	0.39	0.35	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	7.94	1.48e-14	1.55e-11	0.38	0.35	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	7.94	1.48e-14	1.56e-11	0.43	0.35	Height;	chr6:109367335	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	7.94	1.48e-14	1.56e-11	0.43	0.35	Height;	chr6:109368228	chr6:109382795~109383666:+
HNSC	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	7.94	1.48e-14	1.56e-11	0.37	0.35	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
HNSC	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	7.94	1.48e-14	1.56e-11	0.57	0.35	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
HNSC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.94	1.48e-14	1.56e-11	-0.36	-0.35	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
HNSC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.56e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.882	rs2378584	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620290	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.733	rs34767248	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620428	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.882	rs17163301	ENSG00000272750.1	RP11-378J18.8	-7.94	1.49e-14	1.57e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620749	chr1:222658867~222661512:-
HNSC	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	7.94	1.5e-14	1.57e-11	0.4	0.34	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
HNSC	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-7.94	1.5e-14	1.57e-11	-0.82	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	7.94	1.5e-14	1.57e-11	0.33	0.34	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	7.94	1.5e-14	1.57e-11	0.33	0.34	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-7.94	1.51e-14	1.58e-11	-0.41	-0.34	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
HNSC	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	7.94	1.51e-14	1.58e-11	0.7	0.34	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
HNSC	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	7.94	1.51e-14	1.58e-11	0.4	0.34	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.94	1.51e-14	1.59e-11	0.36	0.34	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.94	1.52e-14	1.59e-11	-0.53	-0.34	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
HNSC	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	7.94	1.52e-14	1.59e-11	0.53	0.34	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
HNSC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.94	1.52e-14	1.59e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000179406.6	LINC00174	-7.94	1.52e-14	1.59e-11	-0.53	-0.34	Aortic root size;	chr7:66441589	chr7:66376044~66401338:-
HNSC	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	7.94	1.52e-14	1.59e-11	0.39	0.34	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-7.94	1.52e-14	1.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
HNSC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-7.94	1.53e-14	1.6e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
HNSC	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	7.94	1.53e-14	1.6e-11	0.41	0.34	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
HNSC	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	7.94	1.53e-14	1.6e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	7.94	1.53e-14	1.61e-11	0.4	0.34	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-7.94	1.54e-14	1.61e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
HNSC	cis	rs35955747	0.633	rs4541328	ENSG00000236132.1	CTA-440B3.1	7.94	1.54e-14	1.61e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31500186	chr22:31816379~31817491:-
HNSC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-7.94	1.54e-14	1.62e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-7.94	1.54e-14	1.62e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
HNSC	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-7.94	1.55e-14	1.62e-11	-0.35	-0.34	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-7.94	1.55e-14	1.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	7.94	1.56e-14	1.63e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-7.94	1.56e-14	1.63e-11	-0.34	-0.34	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
HNSC	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	7.94	1.56e-14	1.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-7.94	1.56e-14	1.63e-11	-0.34	-0.34	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-7.94	1.57e-14	1.64e-11	-0.4	-0.34	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
HNSC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	7.94	1.57e-14	1.64e-11	0.35	0.34	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
HNSC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	7.94	1.57e-14	1.64e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	7.94	1.57e-14	1.64e-11	0.48	0.34	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-7.94	1.57e-14	1.64e-11	-0.4	-0.34	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-7.94	1.57e-14	1.64e-11	-0.32	-0.34	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	7.93	1.58e-14	1.65e-11	0.38	0.34	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	7.93	1.58e-14	1.65e-11	0.38	0.34	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
HNSC	cis	rs6951245	0.935	rs79067319	ENSG00000224079.1	AC091729.7	-7.93	1.58e-14	1.65e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000179406.6	LINC00174	7.93	1.58e-14	1.65e-11	0.52	0.34	Aortic root size;	chr7:66603142	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.528	rs801213	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66549931	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs801212	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66550643	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs801199	ENSG00000179406.6	LINC00174	7.93	1.59e-14	1.66e-11	0.52	0.34	Aortic root size;	chr7:66560286	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66534641	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66536353	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000179406.6	LINC00174	-7.93	1.59e-14	1.66e-11	-0.52	-0.34	Aortic root size;	chr7:66537035	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	7.93	1.59e-14	1.66e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-7.93	1.59e-14	1.66e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
HNSC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	7.93	1.6e-14	1.67e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	1.67e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-7.93	1.61e-14	1.68e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-7.93	1.61e-14	1.68e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
HNSC	cis	rs1021993	0.868	rs6674309	ENSG00000231648.1	RP11-372M18.2	-7.93	1.61e-14	1.68e-11	-0.47	-0.34	Gut microbiome composition (winter);	chr1:209357483	chr1:209367662~209379690:+
HNSC	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	7.93	1.61e-14	1.68e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-7.93	1.62e-14	1.69e-11	-0.33	-0.34	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-7.93	1.62e-14	1.69e-11	-0.33	-0.34	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	7.93	1.62e-14	1.69e-11	0.39	0.34	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	7.93	1.62e-14	1.69e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
HNSC	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	7.93	1.62e-14	1.69e-11	0.43	0.34	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	7.93	1.63e-14	1.7e-11	0.39	0.34	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
HNSC	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	7.93	1.63e-14	1.7e-11	0.42	0.34	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-7.93	1.63e-14	1.7e-11	-0.33	-0.34	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-7.93	1.63e-14	1.7e-11	-0.33	-0.34	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-7.93	1.64e-14	1.7e-11	-0.4	-0.34	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
HNSC	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	7.93	1.64e-14	1.71e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
HNSC	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	7.93	1.65e-14	1.72e-11	0.42	0.34	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
HNSC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	7.93	1.65e-14	1.72e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	7.93	1.65e-14	1.72e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	7.93	1.65e-14	1.72e-11	0.33	0.34	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-7.93	1.65e-14	1.72e-11	-0.4	-0.34	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
HNSC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	7.93	1.67e-14	1.73e-11	0.44	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
HNSC	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	7.93	1.67e-14	1.73e-11	0.43	0.34	Height;	chr6:109354092	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-7.93	1.67e-14	1.74e-11	-0.53	-0.34	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
HNSC	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	7.93	1.67e-14	1.74e-11	0.44	0.34	Height;	chr6:109506513	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	7.93	1.68e-14	1.74e-11	0.52	0.34	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.93	1.68e-14	1.75e-11	-0.4	-0.34	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
HNSC	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	7.93	1.68e-14	1.75e-11	0.33	0.34	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	7.93	1.68e-14	1.75e-11	0.37	0.34	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
HNSC	cis	rs1865760	0.865	rs4478388	ENSG00000272462.2	U91328.19	-7.92	1.69e-14	1.76e-11	-0.34	-0.34	Height;	chr6:25953405	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-7.92	1.7e-14	1.76e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
HNSC	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-7.92	1.71e-14	1.77e-11	-0.4	-0.34	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	7.92	1.71e-14	1.78e-11	0.4	0.34	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000179406.6	LINC00174	7.92	1.71e-14	1.78e-11	0.52	0.34	Aortic root size;	chr7:66620931	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	7.92	1.72e-14	1.79e-11	0.48	0.34	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
HNSC	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-7.92	1.73e-14	1.79e-11	-0.54	-0.34	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	7.92	1.73e-14	1.79e-11	0.48	0.34	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-7.92	1.74e-14	1.8e-11	-0.4	-0.34	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
HNSC	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-7.92	1.74e-14	1.8e-11	-0.33	-0.34	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
HNSC	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.92	1.74e-14	1.8e-11	-0.41	-0.34	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
HNSC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-7.92	1.75e-14	1.82e-11	-0.42	-0.34	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-7.92	1.76e-14	1.82e-11	-0.32	-0.34	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
HNSC	cis	rs6867032	1	rs28392808	ENSG00000249731.1	RP11-259O2.3	7.92	1.76e-14	1.82e-11	0.41	0.34	Gut microbiome composition (winter);	chr5:2013363	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs16902318	ENSG00000249731.1	RP11-259O2.3	7.92	1.76e-14	1.82e-11	0.41	0.34	Gut microbiome composition (winter);	chr5:2013454	chr5:1968094~1969013:+
HNSC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.92	1.77e-14	1.83e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
HNSC	cis	rs6951245	0.872	rs74360401	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs118132455	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78628466	ENSG00000224079.1	AC091729.7	-7.92	1.77e-14	1.84e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1074450~1078036:+
HNSC	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-7.92	1.79e-14	1.86e-11	-0.37	-0.34	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	7.92	1.81e-14	1.87e-11	0.48	0.34	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
HNSC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	7.91	1.83e-14	1.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	7.91	1.83e-14	1.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
HNSC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.91	1.83e-14	1.9e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
HNSC	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	7.91	1.83e-14	1.9e-11	0.41	0.34	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
HNSC	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	7.91	1.83e-14	1.9e-11	0.42	0.34	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
HNSC	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	7.91	1.84e-14	1.9e-11	0.41	0.34	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-7.91	1.85e-14	1.91e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
HNSC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-7.91	1.86e-14	1.92e-11	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	7.91	1.86e-14	1.93e-11	0.48	0.34	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	7.91	1.86e-14	1.93e-11	0.48	0.34	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
HNSC	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	7.91	1.86e-14	1.93e-11	0.35	0.34	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
HNSC	cis	rs6951245	1	rs11768761	ENSG00000224079.1	AC091729.7	-7.91	1.87e-14	1.93e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	1.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
HNSC	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	7.91	1.89e-14	1.95e-11	0.45	0.34	Height;	chr6:109446727	chr6:109382795~109383666:+
HNSC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	7.91	1.89e-14	1.96e-11	0.37	0.34	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
HNSC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-7.91	1.89e-14	1.96e-11	-0.37	-0.34	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
HNSC	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-7.91	1.9e-14	1.96e-11	-0.43	-0.34	Height;	chr6:109360458	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	7.91	1.9e-14	1.96e-11	0.47	0.34	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.91	1.9e-14	1.96e-11	-0.37	-0.34	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
HNSC	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-7.91	1.91e-14	1.97e-11	-0.37	-0.34	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-7.91	1.91e-14	1.97e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	7.91	1.91e-14	1.97e-11	0.49	0.34	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	7.91	1.91e-14	1.97e-11	0.49	0.34	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
HNSC	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.91	1.91e-14	1.98e-11	0.39	0.34	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
HNSC	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-7.91	1.92e-14	1.98e-11	-0.45	-0.34	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
HNSC	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-7.91	1.92e-14	1.98e-11	-0.42	-0.34	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
HNSC	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-7.91	1.92e-14	1.98e-11	-0.42	-0.34	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
HNSC	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	7.91	1.94e-14	2e-11	0.32	0.34	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	7.91	1.94e-14	2e-11	0.39	0.34	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
HNSC	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	7.9	1.95e-14	2.01e-11	0.43	0.34	Height;	chr6:109370741	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	7.9	1.95e-14	2.01e-11	0.43	0.34	Height;	chr6:109371524	chr6:109382795~109383666:+
HNSC	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-7.9	1.95e-14	2.01e-11	-0.41	-0.34	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
HNSC	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-7.9	1.95e-14	2.02e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
HNSC	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-7.9	1.95e-14	2.02e-11	-0.49	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
HNSC	cis	rs6969780	0.722	rs983185	ENSG00000233429.8	HOTAIRM1	-7.9	1.96e-14	2.02e-11	-0.44	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148988	chr7:27095647~27100265:+
HNSC	cis	rs1865760	0.713	rs1130000	ENSG00000272462.2	U91328.19	-7.9	1.96e-14	2.02e-11	-0.34	-0.34	Height;	chr6:25985168	chr6:25992662~26001775:+
HNSC	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	7.9	1.96e-14	2.02e-11	0.42	0.34	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
HNSC	cis	rs35955747	0.659	rs11704494	ENSG00000236132.1	CTA-440B3.1	7.9	1.97e-14	2.03e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31517285	chr22:31816379~31817491:-
HNSC	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	7.9	1.99e-14	2.05e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-7.9	1.99e-14	2.05e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000219392.1	RP1-265C24.5	-7.9	1.99e-14	2.05e-11	-0.49	-0.34	Parkinson's disease;	chr6:28134687	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.9	1.99e-14	2.06e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
HNSC	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-7.9	2e-14	2.06e-11	-0.38	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	7.9	2e-14	2.06e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-7.9	2.01e-14	2.07e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
HNSC	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	7.9	2.02e-14	2.08e-11	0.45	0.34	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
HNSC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.9	2.03e-14	2.09e-11	0.38	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
HNSC	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	7.9	2.03e-14	2.09e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000179406.6	LINC00174	-7.9	2.03e-14	2.09e-11	-0.52	-0.34	Aortic root size;	chr7:66216128	chr7:66376044~66401338:-
HNSC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.9	2.03e-14	2.09e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
HNSC	cis	rs6969780	0.63	rs10238095	ENSG00000233429.8	HOTAIRM1	-7.9	2.04e-14	2.1e-11	-0.44	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157024	chr7:27095647~27100265:+
HNSC	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	7.9	2.04e-14	2.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	7.9	2.04e-14	2.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
HNSC	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	7.9	2.04e-14	2.1e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000179406.6	LINC00174	-7.9	2.05e-14	2.11e-11	-0.52	-0.34	Aortic root size;	chr7:66353241	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.11e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	7.9	2.06e-14	2.12e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	7.9	2.06e-14	2.12e-11	0.44	0.34	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
HNSC	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	7.9	2.07e-14	2.12e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	7.9	2.07e-14	2.13e-11	0.47	0.34	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
HNSC	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-7.9	2.07e-14	2.13e-11	-0.42	-0.34	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
HNSC	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	7.9	2.07e-14	2.13e-11	0.36	0.34	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	7.89	2.1e-14	2.16e-11	0.37	0.34	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
HNSC	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-7.89	2.1e-14	2.16e-11	-0.47	-0.34	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
HNSC	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.89	2.1e-14	2.16e-11	0.39	0.34	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
HNSC	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	7.89	2.12e-14	2.17e-11	0.4	0.34	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
HNSC	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	7.89	2.12e-14	2.18e-11	0.36	0.34	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	7.89	2.12e-14	2.18e-11	0.47	0.34	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
HNSC	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-7.89	2.13e-14	2.18e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
HNSC	cis	rs7048146	0.932	rs1576590	ENSG00000213539.4	YBX1P6	7.89	2.13e-14	2.19e-11	0.41	0.34	Vascular brain injury;	chr9:109542883	chr9:109532830~109534332:-
HNSC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.89	2.14e-14	2.2e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
HNSC	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-7.89	2.14e-14	2.2e-11	-0.42	-0.34	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-7.89	2.14e-14	2.2e-11	-0.48	-0.34	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	7.89	2.15e-14	2.2e-11	0.33	0.34	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-7.89	2.15e-14	2.2e-11	-0.52	-0.34	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
HNSC	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-7.89	2.15e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-7.89	2.16e-14	2.22e-11	-0.33	-0.34	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-7.89	2.17e-14	2.22e-11	-0.47	-0.34	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	7.89	2.17e-14	2.23e-11	0.34	0.34	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
HNSC	cis	rs7048146	0.966	rs1576591	ENSG00000213539.4	YBX1P6	7.89	2.18e-14	2.23e-11	0.4	0.34	Vascular brain injury;	chr9:109542724	chr9:109532830~109534332:-
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-7.89	2.19e-14	2.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-7.89	2.19e-14	2.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
HNSC	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-7.89	2.19e-14	2.25e-11	-0.36	-0.34	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-7.89	2.2e-14	2.25e-11	-0.37	-0.34	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	7.89	2.2e-14	2.25e-11	0.32	0.34	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	7.89	2.21e-14	2.26e-11	0.41	0.34	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.566	rs9366634	ENSG00000272462.2	U91328.19	-7.89	2.21e-14	2.26e-11	-0.34	-0.34	Height;	chr6:26072168	chr6:25992662~26001775:+
HNSC	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	7.89	2.22e-14	2.27e-11	0.4	0.34	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
HNSC	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.89	2.22e-14	2.27e-11	-0.43	-0.34	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
HNSC	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-7.89	2.22e-14	2.28e-11	-0.43	-0.34	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	7.89	2.23e-14	2.28e-11	0.48	0.34	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	7.89	2.23e-14	2.28e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
HNSC	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	7.89	2.23e-14	2.29e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	7.88	2.25e-14	2.3e-11	0.48	0.34	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
HNSC	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	7.88	2.25e-14	2.3e-11	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
HNSC	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-7.88	2.26e-14	2.31e-11	-0.37	-0.34	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
HNSC	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	7.88	2.26e-14	2.31e-11	0.43	0.34	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
HNSC	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-7.88	2.26e-14	2.31e-11	-0.33	-0.34	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-7.88	2.26e-14	2.31e-11	-0.33	-0.34	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	7.88	2.27e-14	2.32e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.88	2.29e-14	2.33e-11	0.45	0.34	Height;	chr6:109546439	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	7.88	2.29e-14	2.34e-11	0.41	0.34	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
HNSC	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	7.88	2.3e-14	2.34e-11	0.37	0.34	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
HNSC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-7.88	2.3e-14	2.34e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
HNSC	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.88	2.3e-14	2.35e-11	-0.46	-0.34	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
HNSC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	7.88	2.3e-14	2.35e-11	0.35	0.34	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
HNSC	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-7.88	2.31e-14	2.35e-11	-0.37	-0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
HNSC	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	7.88	2.31e-14	2.36e-11	0.44	0.34	Height;	chr6:109501402	chr6:109382795~109383666:+
HNSC	cis	rs7404843	1	rs7404843	ENSG00000263065.1	AF001548.6	-7.88	2.32e-14	2.37e-11	-0.63	-0.34	Testicular germ cell tumor;	chr16:15436851	chr16:15741151~15741791:+
HNSC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	7.88	2.32e-14	2.37e-11	0.37	0.34	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
HNSC	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-7.88	2.32e-14	2.37e-11	-0.37	-0.34	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
HNSC	cis	rs7048146	1	rs1411690	ENSG00000213539.4	YBX1P6	7.88	2.33e-14	2.38e-11	0.4	0.34	Vascular brain injury;	chr9:109542827	chr9:109532830~109534332:-
HNSC	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	7.88	2.34e-14	2.38e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
HNSC	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-7.88	2.34e-14	2.38e-11	-0.39	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
HNSC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.88	2.35e-14	2.39e-11	-0.41	-0.34	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
HNSC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.88	2.35e-14	2.4e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
HNSC	cis	rs7404843	0.925	rs72774861	ENSG00000263065.1	AF001548.6	7.88	2.35e-14	2.4e-11	0.63	0.34	Testicular germ cell tumor;	chr16:15415777	chr16:15741151~15741791:+
HNSC	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	7.88	2.36e-14	2.4e-11	0.35	0.34	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-7.88	2.36e-14	2.4e-11	-0.33	-0.34	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	7.88	2.37e-14	2.41e-11	0.32	0.34	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	7.88	2.37e-14	2.41e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	7.88	2.38e-14	2.42e-11	0.46	0.34	Height;	chr6:109732518	chr6:109382795~109383666:+
HNSC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	7.88	2.38e-14	2.42e-11	0.39	0.34	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
HNSC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-7.88	2.38e-14	2.43e-11	-0.36	-0.34	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	7.88	2.38e-14	2.43e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-7.88	2.39e-14	2.44e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	7.88	2.4e-14	2.44e-11	0.48	0.34	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
HNSC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.88	2.4e-14	2.44e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	7.88	2.4e-14	2.44e-11	0.36	0.34	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	7.88	2.41e-14	2.45e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
HNSC	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	7.87	2.41e-14	2.45e-11	0.45	0.34	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
HNSC	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-7.87	2.41e-14	2.45e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
HNSC	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	7.87	2.41e-14	2.45e-11	0.36	0.34	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.87	2.42e-14	2.46e-11	0.36	0.34	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	7.87	2.42e-14	2.46e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
HNSC	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	7.87	2.42e-14	2.46e-11	0.39	0.34	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	7.87	2.42e-14	2.46e-11	0.39	0.34	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	7.87	2.42e-14	2.46e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
HNSC	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	7.87	2.43e-14	2.46e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	7.87	2.43e-14	2.47e-11	0.32	0.34	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-7.87	2.43e-14	2.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-7.87	2.43e-14	2.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-7.87	2.43e-14	2.47e-11	-0.34	-0.34	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.571	rs160641	ENSG00000179406.6	LINC00174	7.87	2.44e-14	2.48e-11	0.52	0.34	Aortic root size;	chr7:66112359	chr7:66376044~66401338:-
HNSC	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-7.87	2.45e-14	2.48e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
HNSC	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-7.87	2.45e-14	2.49e-11	-0.36	-0.34	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-7.87	2.46e-14	2.5e-11	-0.32	-0.34	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
HNSC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	7.87	2.47e-14	2.51e-11	0.37	0.34	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
HNSC	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-7.87	2.48e-14	2.51e-11	-0.44	-0.34	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	7.87	2.49e-14	2.52e-11	0.47	0.34	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
HNSC	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	7.87	2.5e-14	2.53e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
HNSC	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	7.87	2.5e-14	2.54e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
HNSC	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-7.87	2.51e-14	2.55e-11	-0.34	-0.34	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	7.87	2.52e-14	2.56e-11	0.47	0.34	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-7.87	2.54e-14	2.57e-11	-0.38	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	7.87	2.54e-14	2.57e-11	0.47	0.34	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	7.87	2.55e-14	2.58e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	7.87	2.56e-14	2.59e-11	0.44	0.34	Height;	chr6:109501429	chr6:109382795~109383666:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	7.87	2.57e-14	2.6e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
HNSC	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	7.87	2.58e-14	2.61e-11	0.41	0.34	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-7.86	2.59e-14	2.62e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
HNSC	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-7.86	2.59e-14	2.62e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
HNSC	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-7.86	2.59e-14	2.62e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
HNSC	cis	rs454422	0.812	rs236118	ENSG00000275632.1	RP5-967N21.11	7.86	2.6e-14	2.63e-11	0.37	0.34	HIV-1 viral setpoint;	chr20:5957561	chr20:6000418~6000941:+
HNSC	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	7.86	2.61e-14	2.63e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	7.86	2.61e-14	2.64e-11	0.41	0.34	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	7.86	2.61e-14	2.64e-11	0.41	0.34	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
HNSC	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	7.86	2.61e-14	2.64e-11	0.53	0.34	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	7.86	2.62e-14	2.65e-11	0.32	0.34	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	7.86	2.63e-14	2.66e-11	0.47	0.34	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	7.86	2.63e-14	2.66e-11	0.47	0.34	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
HNSC	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-7.86	2.63e-14	2.66e-11	-0.37	-0.34	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
HNSC	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	7.86	2.64e-14	2.66e-11	0.4	0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
HNSC	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-7.86	2.64e-14	2.67e-11	-0.35	-0.34	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-7.86	2.64e-14	2.67e-11	-0.35	-0.34	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-7.86	2.64e-14	2.67e-11	-0.4	-0.34	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000179406.6	LINC00174	7.86	2.64e-14	2.67e-11	0.51	0.34	Aortic root size;	chr7:66579422	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	7.86	2.65e-14	2.68e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
HNSC	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	7.86	2.65e-14	2.68e-11	0.36	0.34	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
HNSC	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-7.86	2.66e-14	2.68e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
HNSC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	7.86	2.66e-14	2.69e-11	0.35	0.34	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
HNSC	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	7.86	2.67e-14	2.69e-11	0.37	0.34	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
HNSC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-7.86	2.67e-14	2.7e-11	-0.41	-0.34	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
HNSC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	7.86	2.68e-14	2.7e-11	0.39	0.34	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
HNSC	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	7.86	2.69e-14	2.71e-11	0.57	0.34	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
HNSC	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-7.86	2.69e-14	2.71e-11	-0.4	-0.34	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	7.86	2.7e-14	2.72e-11	0.32	0.34	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	7.86	2.7e-14	2.73e-11	0.47	0.34	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-7.86	2.7e-14	2.73e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
HNSC	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-7.86	2.71e-14	2.73e-11	-0.5	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
HNSC	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	7.86	2.74e-14	2.76e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
HNSC	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	7.86	2.75e-14	2.77e-11	0.45	0.34	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-7.86	2.76e-14	2.77e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
HNSC	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	7.86	2.76e-14	2.78e-11	0.41	0.34	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	7.86	2.76e-14	2.78e-11	0.47	0.34	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	7.86	2.76e-14	2.78e-11	0.47	0.34	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.86	2.77e-14	2.79e-11	0.24	0.34	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
HNSC	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	7.85	2.77e-14	2.79e-11	0.39	0.34	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
HNSC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	7.85	2.77e-14	2.79e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	7.85	2.78e-14	2.79e-11	0.32	0.34	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	7.85	2.78e-14	2.79e-11	0.32	0.34	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	7.85	2.78e-14	2.8e-11	0.37	0.34	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.85	2.79e-14	2.81e-11	0.48	0.34	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-7.85	2.79e-14	2.81e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
HNSC	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-7.85	2.8e-14	2.81e-11	-0.4	-0.34	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	7.85	2.8e-14	2.81e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
HNSC	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-7.85	2.8e-14	2.82e-11	-0.39	-0.34	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
HNSC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.85	2.8e-14	2.82e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	7.85	2.8e-14	2.82e-11	0.47	0.34	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	7.85	2.81e-14	2.83e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
HNSC	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-7.85	2.83e-14	2.84e-11	-0.47	-0.34	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
HNSC	cis	rs6969780	0.524	rs12530948	ENSG00000233429.8	HOTAIRM1	-7.85	2.83e-14	2.85e-11	-0.48	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161639	chr7:27095647~27100265:+
HNSC	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	7.85	2.83e-14	2.85e-11	0.45	0.34	Height;	chr6:109738307	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	7.85	2.83e-14	2.85e-11	0.45	0.34	Height;	chr6:109738751	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	7.85	2.84e-14	2.85e-11	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
HNSC	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-7.85	2.84e-14	2.85e-11	-0.35	-0.34	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
HNSC	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	7.85	2.84e-14	2.85e-11	0.57	0.34	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-7.85	2.84e-14	2.85e-11	-0.33	-0.34	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
HNSC	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-7.85	2.85e-14	2.86e-11	-0.39	-0.34	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
HNSC	cis	rs6951245	1	rs76833820	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs28379681	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs28399710	ENSG00000224079.1	AC091729.7	-7.85	2.85e-14	2.86e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1074450~1078036:+
HNSC	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	7.85	2.86e-14	2.87e-11	0.39	0.34	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	7.85	2.86e-14	2.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	7.85	2.87e-14	2.88e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	7.85	2.87e-14	2.88e-11	0.4	0.34	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
HNSC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-7.85	2.88e-14	2.89e-11	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
HNSC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-7.85	2.88e-14	2.89e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
HNSC	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	7.85	2.88e-14	2.89e-11	0.42	0.34	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	7.85	2.89e-14	2.89e-11	0.47	0.34	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	7.85	2.89e-14	2.89e-11	0.47	0.34	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	7.85	2.9e-14	2.91e-11	0.4	0.34	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
HNSC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-7.85	2.92e-14	2.92e-11	-0.53	-0.34	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
HNSC	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-7.85	2.92e-14	2.93e-11	-0.45	-0.34	Height;	chr6:109731677	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	7.85	2.92e-14	2.93e-11	0.47	0.34	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
HNSC	cis	rs1021993	0.868	rs6674103	ENSG00000231648.1	RP11-372M18.2	-7.85	2.93e-14	2.94e-11	-0.46	-0.34	Gut microbiome composition (winter);	chr1:209357293	chr1:209367662~209379690:+
HNSC	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	7.85	2.94e-14	2.94e-11	0.47	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
HNSC	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	7.85	2.95e-14	2.96e-11	0.4	0.34	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	7.85	2.96e-14	2.96e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
HNSC	cis	rs2579103	0.507	rs1371082	ENSG00000258183.4	RP11-753N8.1	-7.85	2.96e-14	2.96e-11	-0.4	-0.34	Body mass index;	chr12:90288307	chr12:90280894~90300340:+
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-7.84	2.99e-14	2.99e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	7.84	2.99e-14	2.99e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	7.84	3e-14	3e-11	0.47	0.34	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	7.84	3.01e-14	3.01e-11	0.47	0.34	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-7.84	3.01e-14	3.01e-11	-0.42	-0.34	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	7.84	3.03e-14	3.03e-11	0.47	0.34	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
HNSC	cis	rs35955747	0.677	rs4820974	ENSG00000236132.1	CTA-440B3.1	7.84	3.03e-14	3.03e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31473481	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	7.84	3.06e-14	3.05e-11	0.47	0.34	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-7.84	3.06e-14	3.05e-11	-0.39	-0.34	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
HNSC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.84	3.07e-14	3.06e-11	0.4	0.34	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-7.84	3.09e-14	3.08e-11	-0.4	-0.34	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
HNSC	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-7.84	3.09e-14	3.08e-11	-0.47	-0.34	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
HNSC	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-7.84	3.09e-14	3.08e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000173295.6	FAM86B3P	7.84	3.1e-14	3.09e-11	0.37	0.34	Neuroticism;	chr8:8460377	chr8:8228595~8244865:+
HNSC	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	7.84	3.1e-14	3.1e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-7.84	3.11e-14	3.1e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
HNSC	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	7.84	3.13e-14	3.12e-11	0.45	0.34	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-7.84	3.13e-14	3.12e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	7.84	3.14e-14	3.13e-11	0.48	0.34	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-7.84	3.14e-14	3.13e-11	-0.32	-0.34	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-7.84	3.16e-14	3.15e-11	-0.51	-0.34	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
HNSC	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-7.84	3.18e-14	3.17e-11	-0.33	-0.34	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
HNSC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	7.83	3.2e-14	3.18e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-7.83	3.2e-14	3.19e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	7.83	3.22e-14	3.21e-11	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
HNSC	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	7.83	3.22e-14	3.21e-11	0.44	0.34	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.83	3.23e-14	3.21e-11	0.44	0.34	Height;	chr6:109357369	chr6:109382795~109383666:+
HNSC	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-7.83	3.23e-14	3.22e-11	-0.34	-0.34	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
HNSC	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-7.83	3.23e-14	3.22e-11	-0.41	-0.34	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109608105	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109618620	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109620772	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109634150	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	7.83	3.25e-14	3.23e-11	0.45	0.34	Height;	chr6:109640141	chr6:109382795~109383666:+
HNSC	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	7.83	3.25e-14	3.23e-11	0.41	0.34	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-7.83	3.27e-14	3.25e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-7.83	3.31e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-7.83	3.31e-14	3.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
HNSC	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	7.83	3.31e-14	3.29e-11	0.39	0.34	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	7.83	3.31e-14	3.29e-11	0.39	0.34	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	7.83	3.31e-14	3.29e-11	0.36	0.34	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	7.83	3.31e-14	3.29e-11	0.36	0.34	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
HNSC	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	7.83	3.31e-14	3.29e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	7.83	3.31e-14	3.29e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
HNSC	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	7.83	3.32e-14	3.3e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	7.83	3.32e-14	3.3e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-7.83	3.32e-14	3.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-7.83	3.32e-14	3.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
HNSC	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-7.83	3.32e-14	3.3e-11	-0.38	-0.34	Migraine;	chr4:56879297	chr4:56960927~56961373:-
HNSC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.83	3.33e-14	3.3e-11	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
HNSC	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	7.83	3.34e-14	3.32e-11	0.4	0.34	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-7.83	3.34e-14	3.32e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-7.83	3.35e-14	3.32e-11	-0.33	-0.34	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	7.83	3.35e-14	3.32e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-7.83	3.36e-14	3.33e-11	-0.36	-0.34	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
HNSC	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.83	3.36e-14	3.34e-11	0.44	0.34	Height;	chr6:109551060	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	7.83	3.38e-14	3.35e-11	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
HNSC	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	7.83	3.38e-14	3.35e-11	0.4	0.34	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-7.83	3.38e-14	3.35e-11	-0.32	-0.34	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-7.83	3.38e-14	3.35e-11	-0.32	-0.34	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
HNSC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.83	3.38e-14	3.35e-11	-0.37	-0.34	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
HNSC	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-7.83	3.39e-14	3.36e-11	-0.42	-0.34	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-7.83	3.41e-14	3.37e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
HNSC	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-7.83	3.41e-14	3.38e-11	-0.36	-0.34	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
HNSC	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	7.83	3.42e-14	3.39e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
HNSC	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	7.82	3.42e-14	3.39e-11	0.39	0.34	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
HNSC	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-7.82	3.43e-14	3.4e-11	-0.39	-0.34	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
HNSC	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-7.82	3.45e-14	3.41e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	7.82	3.45e-14	3.42e-11	0.32	0.34	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-7.82	3.46e-14	3.43e-11	-0.25	-0.34	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	7.82	3.46e-14	3.43e-11	0.47	0.34	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	7.82	3.46e-14	3.43e-11	0.47	0.34	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000179406.6	LINC00174	-7.82	3.47e-14	3.43e-11	-0.54	-0.34	Aortic root size;	chr7:66311140	chr7:66376044~66401338:-
HNSC	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-7.82	3.48e-14	3.44e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-7.82	3.51e-14	3.47e-11	-0.32	-0.34	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	7.82	3.52e-14	3.48e-11	0.39	0.34	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-7.82	3.52e-14	3.48e-11	-0.32	-0.34	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
HNSC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	7.82	3.53e-14	3.49e-11	0.37	0.34	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
HNSC	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-7.82	3.54e-14	3.49e-11	-0.33	-0.34	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
HNSC	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	7.82	3.54e-14	3.5e-11	0.39	0.34	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-7.82	3.56e-14	3.52e-11	-0.4	-0.34	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-7.82	3.56e-14	3.52e-11	-0.4	-0.34	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
HNSC	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-7.82	3.57e-14	3.53e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
HNSC	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	7.82	3.58e-14	3.53e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
HNSC	cis	rs6951245	1	rs28528096	ENSG00000224079.1	AC091729.7	-7.82	3.58e-14	3.54e-11	-0.59	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1074450~1078036:+
HNSC	cis	rs7615952	1	rs9289275	ENSG00000241288.6	RP11-379B18.5	-7.82	3.58e-14	3.54e-11	-0.48	-0.34	Blood pressure (smoking interaction);	chr3:125929816	chr3:125827238~125916384:-
HNSC	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	7.82	3.58e-14	3.54e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
HNSC	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-7.82	3.59e-14	3.54e-11	-0.36	-0.34	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
HNSC	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	7.82	3.59e-14	3.54e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-7.82	3.59e-14	3.55e-11	-0.44	-0.34	Height;	chr6:109531713	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	7.82	3.59e-14	3.55e-11	0.45	0.34	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
HNSC	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	7.82	3.59e-14	3.55e-11	0.45	0.34	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
HNSC	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	7.82	3.6e-14	3.55e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	7.82	3.6e-14	3.55e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
HNSC	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	7.82	3.6e-14	3.55e-11	0.42	0.34	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
HNSC	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-7.82	3.61e-14	3.56e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
HNSC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-7.82	3.61e-14	3.57e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
HNSC	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-7.82	3.62e-14	3.58e-11	-0.4	-0.34	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.545	rs313828	ENSG00000179406.6	LINC00174	7.82	3.63e-14	3.58e-11	0.53	0.34	Aortic root size;	chr7:66087627	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.571	rs160647	ENSG00000179406.6	LINC00174	7.82	3.63e-14	3.58e-11	0.53	0.34	Aortic root size;	chr7:66089365	chr7:66376044~66401338:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	7.82	3.63e-14	3.58e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
HNSC	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-7.82	3.64e-14	3.59e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
HNSC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	7.82	3.65e-14	3.6e-11	0.36	0.34	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	7.82	3.65e-14	3.6e-11	0.47	0.34	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	7.82	3.65e-14	3.6e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
HNSC	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-7.82	3.65e-14	3.6e-11	-0.87	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
HNSC	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	7.82	3.66e-14	3.6e-11	0.41	0.34	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	7.82	3.66e-14	3.6e-11	0.44	0.34	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
HNSC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-7.82	3.66e-14	3.61e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
HNSC	cis	rs35955747	0.633	rs1916	ENSG00000236132.1	CTA-440B3.1	-7.82	3.67e-14	3.61e-11	-0.37	-0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31496135	chr22:31816379~31817491:-
HNSC	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	7.81	3.67e-14	3.62e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
HNSC	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-7.81	3.68e-14	3.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-7.81	3.68e-14	3.62e-11	-0.4	-0.34	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
HNSC	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	7.81	3.68e-14	3.63e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	7.81	3.71e-14	3.66e-11	0.47	0.34	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
HNSC	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	7.81	3.71e-14	3.66e-11	0.42	0.34	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
HNSC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	7.81	3.72e-14	3.66e-11	0.45	0.34	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
HNSC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-7.81	3.72e-14	3.66e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	7.81	3.72e-14	3.66e-11	0.36	0.34	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	7.81	3.72e-14	3.66e-11	0.36	0.34	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
HNSC	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-7.81	3.73e-14	3.67e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
HNSC	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-7.81	3.73e-14	3.67e-11	-0.36	-0.34	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	7.81	3.73e-14	3.67e-11	0.32	0.34	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-7.81	3.75e-14	3.68e-11	-0.36	-0.34	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-7.81	3.75e-14	3.68e-11	-0.36	-0.34	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
HNSC	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-7.81	3.75e-14	3.69e-11	-0.43	-0.34	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	7.81	3.78e-14	3.71e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
HNSC	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	7.81	3.78e-14	3.71e-11	0.45	0.34	Height;	chr6:109739615	chr6:109382795~109383666:+
HNSC	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-7.81	3.78e-14	3.71e-11	-0.45	-0.34	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
HNSC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.81	3.79e-14	3.73e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.47	0.34	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.47	0.34	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	7.81	3.8e-14	3.74e-11	0.46	0.34	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.865	rs9393677	ENSG00000272462.2	U91328.19	-7.81	3.81e-14	3.74e-11	-0.34	-0.34	Height;	chr6:25945587	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.865	rs9393678	ENSG00000272462.2	U91328.19	-7.81	3.81e-14	3.74e-11	-0.34	-0.34	Height;	chr6:25945591	chr6:25992662~26001775:+
HNSC	cis	rs9595066	0.627	rs9562538	ENSG00000227258.4	SMIM2-AS1	7.81	3.82e-14	3.75e-11	0.59	0.34	Schizophrenia;	chr13:44183532	chr13:44110451~44240517:+
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	7.81	3.82e-14	3.75e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	7.81	3.83e-14	3.76e-11	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
HNSC	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	7.81	3.83e-14	3.76e-11	0.4	0.34	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-7.81	3.84e-14	3.77e-11	-0.32	-0.34	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.81	3.86e-14	3.79e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
HNSC	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	7.81	3.88e-14	3.81e-11	0.4	0.34	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
HNSC	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	7.81	3.9e-14	3.83e-11	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
HNSC	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-7.81	3.9e-14	3.83e-11	-0.32	-0.34	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
HNSC	cis	rs6951245	0.935	rs112554101	ENSG00000224079.1	AC091729.7	-7.81	3.91e-14	3.84e-11	-0.54	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1074450~1078036:+
HNSC	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	7.81	3.92e-14	3.85e-11	0.38	0.34	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	7.81	3.92e-14	3.85e-11	0.38	0.34	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-7.8	3.95e-14	3.88e-11	-0.33	-0.34	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	7.8	3.96e-14	3.88e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	7.8	3.96e-14	3.88e-11	0.48	0.34	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
HNSC	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	7.8	3.96e-14	3.88e-11	0.42	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000179406.6	LINC00174	-7.8	3.98e-14	3.91e-11	-0.52	-0.34	Aortic root size;	chr7:66276638	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000179406.6	LINC00174	-7.8	4e-14	3.92e-11	-0.51	-0.34	Aortic root size;	chr7:66390342	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000179406.6	LINC00174	-7.8	4e-14	3.92e-11	-0.51	-0.34	Aortic root size;	chr7:66479399	chr7:66376044~66401338:-
HNSC	cis	rs6951245	1	rs76804143	ENSG00000224079.1	AC091729.7	-7.8	4e-14	3.92e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1074450~1078036:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000276710.3	CSPG4P8	-7.8	4e-14	3.92e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82459472~82477258:+
HNSC	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	7.8	4.01e-14	3.93e-11	0.41	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
HNSC	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	7.8	4.01e-14	3.93e-11	0.39	0.34	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
HNSC	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	7.8	4.02e-14	3.93e-11	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000179406.6	LINC00174	7.8	4.02e-14	3.94e-11	0.53	0.34	Aortic root size;	chr7:66086944	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-7.8	4.02e-14	3.94e-11	-0.32	-0.34	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
HNSC	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-7.8	4.02e-14	3.94e-11	-0.41	-0.34	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
HNSC	cis	rs7404843	0.925	rs72774861	ENSG00000263335.1	AF001548.5	7.8	4.04e-14	3.95e-11	0.68	0.34	Testicular germ cell tumor;	chr16:15415777	chr16:15726674~15732993:+
HNSC	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	7.8	4.04e-14	3.95e-11	0.45	0.34	Height;	chr6:109693890	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	7.8	4.04e-14	3.95e-11	0.45	0.34	Height;	chr6:109694672	chr6:109382795~109383666:+
HNSC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.8	4.04e-14	3.95e-11	0.48	0.34	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
HNSC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	7.8	4.05e-14	3.96e-11	0.43	0.34	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
HNSC	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	7.8	4.05e-14	3.96e-11	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
HNSC	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-7.8	4.06e-14	3.97e-11	-0.33	-0.34	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	7.8	4.06e-14	3.98e-11	0.48	0.34	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	7.8	4.06e-14	3.98e-11	0.23	0.34	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	7.8	4.07e-14	3.98e-11	0.36	0.34	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
HNSC	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-7.8	4.07e-14	3.99e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
HNSC	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	7.8	4.07e-14	3.99e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
HNSC	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	7.8	4.07e-14	3.99e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
HNSC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	7.8	4.08e-14	3.99e-11	0.36	0.34	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-7.8	4.08e-14	3.99e-11	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	7.8	4.09e-14	4e-11	0.32	0.34	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
HNSC	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	7.8	4.1e-14	4.01e-11	0.36	0.34	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
HNSC	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	7.8	4.11e-14	4.02e-11	0.47	0.34	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	7.8	4.11e-14	4.02e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-7.8	4.11e-14	4.02e-11	-0.35	-0.34	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
HNSC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-7.8	4.14e-14	4.04e-11	-0.41	-0.34	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000179406.6	LINC00174	-7.8	4.15e-14	4.06e-11	-0.52	-0.34	Aortic root size;	chr7:66215323	chr7:66376044~66401338:-
HNSC	cis	rs6867032	1	rs16902321	ENSG00000249731.1	RP11-259O2.3	7.8	4.17e-14	4.08e-11	0.4	0.34	Gut microbiome composition (winter);	chr5:2015034	chr5:1968094~1969013:+
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.48	0.34	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.48	0.34	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	7.8	4.18e-14	4.09e-11	0.47	0.34	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
HNSC	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	7.8	4.19e-14	4.09e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
HNSC	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	7.8	4.19e-14	4.09e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
HNSC	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-7.8	4.19e-14	4.09e-11	-0.35	-0.34	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	7.8	4.19e-14	4.09e-11	0.32	0.34	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	7.8	4.19e-14	4.09e-11	0.32	0.34	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	7.8	4.21e-14	4.11e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	7.79	4.23e-14	4.13e-11	0.36	0.34	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-7.79	4.23e-14	4.13e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	7.79	4.24e-14	4.14e-11	0.47	0.34	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
HNSC	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	7.79	4.25e-14	4.14e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-7.79	4.25e-14	4.15e-11	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-7.79	4.28e-14	4.18e-11	-0.39	-0.34	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	7.79	4.28e-14	4.18e-11	0.48	0.34	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	7.79	4.29e-14	4.19e-11	0.35	0.34	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
HNSC	cis	rs6951245	1	rs74369356	ENSG00000224079.1	AC091729.7	-7.79	4.3e-14	4.19e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1074450~1078036:+
HNSC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	7.79	4.31e-14	4.2e-11	0.35	0.34	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
HNSC	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-7.79	4.31e-14	4.21e-11	-0.39	-0.34	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
HNSC	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	7.79	4.32e-14	4.21e-11	0.55	0.34	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.79	4.34e-14	4.23e-11	0.32	0.34	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
HNSC	cis	rs9402743	0.775	rs12198378	ENSG00000217482.2	HMGB1P17	7.79	4.34e-14	4.23e-11	0.39	0.34	Systemic lupus erythematosus;	chr6:135662479	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-7.79	4.34e-14	4.23e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	7.79	4.35e-14	4.24e-11	0.35	0.34	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
HNSC	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	7.79	4.36e-14	4.25e-11	0.4	0.34	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
HNSC	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	7.79	4.37e-14	4.26e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-7.79	4.38e-14	4.26e-11	-0.37	-0.34	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-7.79	4.38e-14	4.26e-11	-0.37	-0.34	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
HNSC	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-7.79	4.38e-14	4.27e-11	-0.49	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
HNSC	cis	rs1865760	0.663	rs9467656	ENSG00000272462.2	U91328.19	-7.79	4.39e-14	4.27e-11	-0.33	-0.34	Height;	chr6:25993331	chr6:25992662~26001775:+
HNSC	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-7.79	4.39e-14	4.28e-11	-0.41	-0.34	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
HNSC	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.79	4.4e-14	4.29e-11	0.38	0.34	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
HNSC	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-7.79	4.41e-14	4.3e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
HNSC	cis	rs1865760	0.566	rs2032449	ENSG00000272462.2	U91328.19	-7.79	4.41e-14	4.3e-11	-0.33	-0.34	Height;	chr6:26026371	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-7.79	4.42e-14	4.3e-11	-0.39	-0.34	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
HNSC	cis	rs6951245	1	rs77083167	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs74347384	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78308415	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs75493422	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs118059236	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113858334	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79765398	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79443843	ENSG00000224079.1	AC091729.7	-7.79	4.42e-14	4.3e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	7.79	4.42e-14	4.31e-11	0.32	0.34	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.79	4.43e-14	4.31e-11	-0.45	-0.34	Depression;	chr6:28096845	chr6:28115628~28116551:+
HNSC	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.79	4.43e-14	4.31e-11	0.38	0.34	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
HNSC	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.79	4.45e-14	4.33e-11	0.35	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
HNSC	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	7.79	4.45e-14	4.33e-11	0.34	0.34	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
HNSC	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	7.79	4.47e-14	4.35e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
HNSC	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	7.79	4.48e-14	4.36e-11	0.33	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
HNSC	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	7.79	4.49e-14	4.37e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
HNSC	cis	rs35955747	0.633	rs5998012	ENSG00000236132.1	CTA-440B3.1	7.79	4.5e-14	4.38e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31493858	chr22:31816379~31817491:-
HNSC	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	7.78	4.53e-14	4.41e-11	0.41	0.34	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
HNSC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.78	4.54e-14	4.42e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
HNSC	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-7.78	4.57e-14	4.44e-11	-0.37	-0.34	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	7.78	4.58e-14	4.45e-11	0.35	0.34	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-7.78	4.58e-14	4.46e-11	-0.35	-0.34	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-7.78	4.6e-14	4.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-7.78	4.6e-14	4.47e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	7.78	4.6e-14	4.47e-11	0.47	0.34	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	7.78	4.6e-14	4.47e-11	0.47	0.34	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	7.78	4.62e-14	4.49e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-7.78	4.63e-14	4.5e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-7.78	4.63e-14	4.5e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
HNSC	cis	rs7048146	0.966	rs1411691	ENSG00000213539.4	YBX1P6	7.78	4.63e-14	4.5e-11	0.39	0.34	Vascular brain injury;	chr9:109542444	chr9:109532830~109534332:-
HNSC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	7.78	4.63e-14	4.5e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
HNSC	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	7.78	4.64e-14	4.5e-11	0.48	0.34	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
HNSC	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-7.78	4.64e-14	4.5e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-7.78	4.64e-14	4.5e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	7.78	4.64e-14	4.51e-11	0.47	0.34	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
HNSC	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	7.78	4.65e-14	4.51e-11	0.39	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	7.78	4.65e-14	4.51e-11	0.24	0.34	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
HNSC	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-7.78	4.66e-14	4.52e-11	-0.39	-0.34	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
HNSC	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	7.78	4.67e-14	4.53e-11	0.38	0.34	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-7.78	4.67e-14	4.54e-11	-0.41	-0.34	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-7.78	4.68e-14	4.54e-11	-0.42	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	7.78	4.69e-14	4.55e-11	0.46	0.34	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
HNSC	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-7.78	4.7e-14	4.56e-11	-0.53	-0.34	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
HNSC	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	7.78	4.72e-14	4.58e-11	0.35	0.34	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.78	4.73e-14	4.59e-11	-0.32	-0.34	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	7.78	4.74e-14	4.59e-11	0.36	0.34	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	7.78	4.74e-14	4.59e-11	0.36	0.34	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
HNSC	cis	rs6969780	0.722	rs985652	ENSG00000233429.8	HOTAIRM1	-7.78	4.74e-14	4.6e-11	-0.43	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27158464	chr7:27095647~27100265:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	7.78	4.75e-14	4.61e-11	0.47	0.34	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	7.78	4.77e-14	4.62e-11	0.46	0.34	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	7.78	4.77e-14	4.62e-11	0.25	0.34	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
HNSC	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-7.78	4.79e-14	4.64e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
HNSC	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-7.78	4.79e-14	4.64e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	7.78	4.8e-14	4.65e-11	0.46	0.34	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
HNSC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	7.78	4.8e-14	4.66e-11	0.48	0.34	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
HNSC	cis	rs6969780	0.673	rs2301721	ENSG00000233429.8	HOTAIRM1	-7.78	4.82e-14	4.67e-11	-0.43	-0.34	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156494	chr7:27095647~27100265:+
HNSC	cis	rs6951245	1	rs1997243	ENSG00000224079.1	AC091729.7	-7.78	4.82e-14	4.67e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77760339	ENSG00000224079.1	AC091729.7	-7.78	4.82e-14	4.67e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	7.78	4.84e-14	4.69e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	7.78	4.84e-14	4.69e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
HNSC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-7.78	4.86e-14	4.71e-11	-0.41	-0.34	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
HNSC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-7.78	4.86e-14	4.71e-11	-0.41	-0.34	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
HNSC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	7.78	4.86e-14	4.71e-11	0.35	0.34	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-7.77	4.87e-14	4.72e-11	-0.47	-0.34	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
HNSC	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	7.77	4.88e-14	4.72e-11	0.4	0.34	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
HNSC	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-7.77	4.89e-14	4.74e-11	-0.4	-0.34	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	7.77	4.89e-14	4.74e-11	0.32	0.34	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	7.77	4.89e-14	4.74e-11	0.32	0.34	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	7.77	4.9e-14	4.75e-11	0.56	0.34	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
HNSC	cis	rs1865760	0.865	rs9467641	ENSG00000272462.2	U91328.19	-7.77	4.92e-14	4.76e-11	-0.34	-0.34	Height;	chr6:25947008	chr6:25992662~26001775:+
HNSC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	7.77	4.93e-14	4.77e-11	0.41	0.34	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000179406.6	LINC00174	-7.77	4.94e-14	4.78e-11	-0.52	-0.34	Aortic root size;	chr7:66280619	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	7.77	4.94e-14	4.78e-11	0.46	0.34	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
HNSC	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-7.77	4.96e-14	4.8e-11	-0.4	-0.34	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
HNSC	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
HNSC	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	7.77	4.96e-14	4.8e-11	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	7.77	4.97e-14	4.81e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-7.77	4.97e-14	4.81e-11	-0.57	-0.34	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
HNSC	cis	rs9341808	0.727	rs1324120	ENSG00000272129.1	RP11-250B2.6	7.77	4.98e-14	4.82e-11	0.41	0.34	Sitting height ratio;	chr6:80266408	chr6:80355424~80356859:+
HNSC	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-7.77	4.98e-14	4.82e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	7.77	4.99e-14	4.82e-11	0.35	0.34	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.77	5e-14	4.84e-11	-0.38	-0.34	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
HNSC	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	7.77	5e-14	4.84e-11	0.52	0.34	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	7.77	5.03e-14	4.86e-11	0.46	0.34	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	7.77	5.03e-14	4.86e-11	0.46	0.34	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	7.77	5.03e-14	4.87e-11	0.32	0.34	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	7.77	5.03e-14	4.87e-11	0.24	0.34	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
HNSC	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-7.77	5.04e-14	4.87e-11	-0.42	-0.34	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
HNSC	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	7.77	5.04e-14	4.87e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	7.77	5.04e-14	4.88e-11	0.44	0.34	Height;	chr6:109676091	chr6:109382795~109383666:+
HNSC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	7.77	5.04e-14	4.88e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
HNSC	cis	rs7942368	0.941	rs10793195	ENSG00000255100.1	RP11-21L23.3	7.77	5.07e-14	4.9e-11	0.43	0.34	Endometriosis;	chr11:76793688	chr11:76782581~76783062:-
HNSC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	7.77	5.07e-14	4.9e-11	0.39	0.34	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
HNSC	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	7.77	5.1e-14	4.93e-11	0.36	0.34	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
HNSC	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.77	5.12e-14	4.94e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
HNSC	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-7.77	5.13e-14	4.95e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
HNSC	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-7.77	5.13e-14	4.96e-11	-0.39	-0.34	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
HNSC	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	7.77	5.16e-14	4.97e-11	0.4	0.34	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
HNSC	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-7.77	5.17e-14	4.99e-11	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
HNSC	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	7.77	5.2e-14	5.02e-11	0.35	0.34	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
HNSC	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-7.76	5.21e-14	5.03e-11	-0.37	-0.34	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-7.76	5.21e-14	5.03e-11	-0.37	-0.34	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
HNSC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	7.76	5.24e-14	5.05e-11	0.35	0.34	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	7.76	5.24e-14	5.05e-11	0.38	0.34	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	7.76	5.24e-14	5.06e-11	0.47	0.34	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.566	rs3752420	ENSG00000272462.2	U91328.19	-7.76	5.26e-14	5.07e-11	-0.33	-0.34	Height;	chr6:26026907	chr6:25992662~26001775:+
HNSC	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	7.76	5.26e-14	5.07e-11	0.37	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
HNSC	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	7.76	5.26e-14	5.07e-11	0.41	0.34	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	7.76	5.27e-14	5.08e-11	0.43	0.34	Depression;	chr6:28205232	chr6:28115628~28116551:+
HNSC	cis	rs867371	1	rs7166570	ENSG00000276710.3	CSPG4P8	-7.76	5.27e-14	5.08e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82459472~82477258:+
HNSC	cis	rs6951245	1	rs113575110	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs1881123	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs77569514	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11770909	ENSG00000224079.1	AC091729.7	-7.76	5.28e-14	5.09e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1074450~1078036:+
HNSC	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-7.76	5.3e-14	5.11e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
HNSC	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	7.76	5.31e-14	5.11e-11	0.39	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
HNSC	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-7.76	5.31e-14	5.12e-11	-0.36	-0.34	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
HNSC	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	7.76	5.31e-14	5.12e-11	0.38	0.34	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.76	5.33e-14	5.13e-11	-0.45	-0.34	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
HNSC	cis	rs12439619	0.508	rs17354842	ENSG00000276710.3	CSPG4P8	7.76	5.33e-14	5.13e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82459472~82477258:+
HNSC	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-7.76	5.34e-14	5.14e-11	-0.39	-0.34	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-7.76	5.35e-14	5.15e-11	-0.39	-0.34	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
HNSC	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-7.76	5.35e-14	5.15e-11	-0.45	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
HNSC	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	7.76	5.35e-14	5.15e-11	0.35	0.34	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
HNSC	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-7.76	5.36e-14	5.16e-11	-0.34	-0.34	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-7.76	5.36e-14	5.16e-11	-0.34	-0.34	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
HNSC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	7.76	5.38e-14	5.17e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	7.76	5.38e-14	5.18e-11	0.46	0.34	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	7.76	5.38e-14	5.18e-11	0.46	0.34	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-7.76	5.39e-14	5.18e-11	-0.41	-0.34	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
HNSC	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	7.76	5.39e-14	5.19e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
HNSC	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	7.76	5.4e-14	5.2e-11	0.44	0.34	Height;	chr6:109592105	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	7.76	5.4e-14	5.2e-11	0.32	0.34	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	7.76	5.42e-14	5.21e-11	0.39	0.34	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-7.76	5.42e-14	5.21e-11	-0.32	-0.34	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.76	5.43e-14	5.22e-11	0.36	0.34	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
HNSC	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	5.22e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	5.22e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
HNSC	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	7.76	5.44e-14	5.23e-11	0.37	0.34	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
HNSC	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	7.76	5.44e-14	5.23e-11	0.38	0.34	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
HNSC	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	7.76	5.44e-14	5.23e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
HNSC	cis	rs6951245	1	rs78896566	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79422648	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs113119264	ENSG00000224079.1	AC091729.7	-7.76	5.45e-14	5.24e-11	-0.58	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1074450~1078036:+
HNSC	cis	rs1021993	0.868	rs906347	ENSG00000231648.1	RP11-372M18.2	-7.76	5.47e-14	5.26e-11	-0.46	-0.34	Gut microbiome composition (winter);	chr1:209355062	chr1:209367662~209379690:+
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-7.76	5.47e-14	5.26e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
HNSC	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	7.76	5.48e-14	5.27e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
HNSC	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.76	5.48e-14	5.27e-11	-0.36	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
HNSC	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	7.76	5.51e-14	5.29e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	7.76	5.51e-14	5.29e-11	0.46	0.34	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
HNSC	cis	rs7404843	0.704	rs112251447	ENSG00000263335.1	AF001548.5	7.76	5.51e-14	5.29e-11	0.7	0.34	Testicular germ cell tumor;	chr16:15428015	chr16:15726674~15732993:+
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	7.76	5.52e-14	5.3e-11	0.47	0.34	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	7.76	5.52e-14	5.3e-11	0.47	0.34	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.76	5.53e-14	5.31e-11	0.43	0.34	Height;	chr6:109634847	chr6:109382795~109383666:+
HNSC	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-7.76	5.55e-14	5.33e-11	-0.33	-0.34	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
HNSC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.76	5.55e-14	5.33e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
HNSC	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	7.76	5.56e-14	5.33e-11	0.33	0.34	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
HNSC	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	7.76	5.57e-14	5.35e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	7.75	5.61e-14	5.39e-11	0.44	0.34	Height;	chr6:109672088	chr6:109382795~109383666:+
HNSC	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	7.75	5.62e-14	5.39e-11	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
HNSC	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	7.75	5.63e-14	5.39e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	7.75	5.63e-14	5.39e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	7.75	5.66e-14	5.42e-11	0.46	0.34	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
HNSC	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	7.75	5.67e-14	5.44e-11	0.4	0.34	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
HNSC	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	7.75	5.68e-14	5.45e-11	0.4	0.34	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-7.75	5.68e-14	5.45e-11	-0.32	-0.34	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	7.75	5.68e-14	5.45e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
HNSC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.75	5.69e-14	5.45e-11	0.39	0.34	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	7.75	5.71e-14	5.47e-11	0.46	0.34	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	7.75	5.71e-14	5.47e-11	0.46	0.34	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-7.75	5.73e-14	5.49e-11	-0.39	-0.34	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
HNSC	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-7.75	5.74e-14	5.5e-11	-0.34	-0.34	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
HNSC	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	7.75	5.74e-14	5.5e-11	0.43	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000179406.6	LINC00174	7.75	5.75e-14	5.5e-11	0.43	0.34	Aortic root size;	chr7:66316659	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.52	rs160645	ENSG00000179406.6	LINC00174	7.75	5.75e-14	5.51e-11	0.53	0.34	Aortic root size;	chr7:66091320	chr7:66376044~66401338:-
HNSC	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-7.75	5.77e-14	5.53e-11	-0.4	-0.34	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
HNSC	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-7.75	5.8e-14	5.55e-11	-0.41	-0.34	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
HNSC	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	7.75	5.8e-14	5.55e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-7.75	5.8e-14	5.56e-11	-0.37	-0.34	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-7.75	5.83e-14	5.58e-11	-0.32	-0.34	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
HNSC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-7.75	5.83e-14	5.58e-11	-0.53	-0.34	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
HNSC	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	7.75	5.85e-14	5.59e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000179406.6	LINC00174	-7.75	5.85e-14	5.59e-11	-0.52	-0.34	Aortic root size;	chr7:66226662	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	7.75	5.86e-14	5.6e-11	0.35	0.34	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
HNSC	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-7.75	5.87e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
HNSC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.75	5.87e-14	5.61e-11	0.39	0.34	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
HNSC	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-7.75	5.88e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
HNSC	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-7.75	5.88e-14	5.61e-11	-0.34	-0.34	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	7.75	5.89e-14	5.62e-11	0.47	0.34	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs11657053	ENSG00000267151.3	RP11-100E5.2	7.75	5.91e-14	5.64e-11	0.44	0.34	Menopause (age at onset);	chr17:43039112	chr17:43444707~43451200:+
HNSC	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-7.75	5.93e-14	5.66e-11	-0.42	-0.34	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
HNSC	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-7.75	5.94e-14	5.67e-11	-0.38	-0.34	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
HNSC	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	7.75	5.96e-14	5.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-7.74	5.99e-14	5.72e-11	-0.34	-0.34	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
HNSC	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-7.74	6e-14	5.73e-11	-0.39	-0.34	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	7.74	6e-14	5.73e-11	0.46	0.34	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-7.74	6.02e-14	5.74e-11	-0.32	-0.34	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
HNSC	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-7.74	6.03e-14	5.76e-11	-0.37	-0.34	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
HNSC	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	7.74	6.04e-14	5.76e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
HNSC	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	7.74	6.05e-14	5.77e-11	0.35	0.34	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000179406.6	LINC00174	7.74	6.07e-14	5.79e-11	0.53	0.34	Aortic root size;	chr7:66100789	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	7.74	6.08e-14	5.8e-11	0.46	0.34	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs12951869	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43035550	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43037366	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000267151.3	RP11-100E5.2	7.74	6.08e-14	5.8e-11	0.44	0.34	Menopause (age at onset);	chr17:43038698	chr17:43444707~43451200:+
HNSC	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-7.74	6.08e-14	5.8e-11	-0.39	-0.34	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
HNSC	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	7.74	6.12e-14	5.83e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
HNSC	cis	rs7404843	0.925	rs7404803	ENSG00000263065.1	AF001548.6	-7.74	6.13e-14	5.84e-11	-0.62	-0.34	Testicular germ cell tumor;	chr16:15436597	chr16:15741151~15741791:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	7.74	6.13e-14	5.85e-11	0.45	0.34	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000173295.6	FAM86B3P	-7.74	6.14e-14	5.85e-11	-0.36	-0.34	Joint mobility (Beighton score);	chr8:9183348	chr8:8228595~8244865:+
HNSC	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	7.74	6.17e-14	5.88e-11	0.38	0.34	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
HNSC	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	7.74	6.18e-14	5.89e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	7.74	6.19e-14	5.9e-11	0.38	0.34	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
HNSC	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-7.74	6.2e-14	5.9e-11	-0.52	-0.34	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
HNSC	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	7.74	6.23e-14	5.93e-11	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-7.74	6.24e-14	5.94e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-7.74	6.24e-14	5.94e-11	-0.33	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
HNSC	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	7.74	6.25e-14	5.94e-11	0.34	0.34	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
HNSC	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	7.74	6.25e-14	5.95e-11	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-7.74	6.26e-14	5.96e-11	-0.32	-0.34	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	7.74	6.26e-14	5.96e-11	0.32	0.34	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.74	6.27e-14	5.96e-11	0.24	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
HNSC	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	7.74	6.29e-14	5.98e-11	0.42	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	7.74	6.31e-14	6e-11	0.38	0.34	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
HNSC	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	7.74	6.31e-14	6e-11	0.35	0.34	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
HNSC	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	7.74	6.33e-14	6.02e-11	0.51	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
HNSC	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	7.74	6.34e-14	6.03e-11	0.36	0.34	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	7.74	6.34e-14	6.03e-11	0.35	0.34	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.587	rs78609792	ENSG00000231648.1	RP11-372M18.2	-7.74	6.35e-14	6.04e-11	-0.57	-0.34	Gut microbiome composition (winter);	chr1:209372669	chr1:209367662~209379690:+
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	7.74	6.36e-14	6.05e-11	0.35	0.34	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
HNSC	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	7.74	6.38e-14	6.07e-11	0.4	0.34	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	7.74	6.4e-14	6.08e-11	0.24	0.34	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
HNSC	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	7.73	6.44e-14	6.11e-11	0.39	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
HNSC	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	7.73	6.45e-14	6.12e-11	0.35	0.34	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
HNSC	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	7.73	6.49e-14	6.16e-11	0.35	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
HNSC	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	7.73	6.5e-14	6.17e-11	0.39	0.34	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000179406.6	LINC00174	7.73	6.51e-14	6.18e-11	0.52	0.34	Aortic root size;	chr7:66156017	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	7.73	6.51e-14	6.18e-11	0.47	0.34	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	7.73	6.53e-14	6.19e-11	0.42	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
HNSC	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-7.73	6.55e-14	6.21e-11	-0.37	-0.34	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	7.73	6.56e-14	6.23e-11	0.24	0.34	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	7.73	6.6e-14	6.26e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
HNSC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-7.73	6.61e-14	6.27e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
HNSC	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	7.73	6.62e-14	6.28e-11	0.38	0.34	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	7.73	6.64e-14	6.3e-11	0.35	0.34	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
HNSC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-7.73	6.65e-14	6.31e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
HNSC	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	7.73	6.69e-14	6.34e-11	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
HNSC	cis	rs7942368	1	rs1440977	ENSG00000255100.1	RP11-21L23.3	7.73	6.69e-14	6.34e-11	0.42	0.34	Endometriosis;	chr11:76765385	chr11:76782581~76783062:-
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	7.73	6.72e-14	6.37e-11	0.47	0.34	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-7.73	6.73e-14	6.38e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	7.73	6.73e-14	6.38e-11	0.46	0.34	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
HNSC	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-7.73	6.75e-14	6.39e-11	-0.33	-0.34	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000179406.6	LINC00174	-7.73	6.79e-14	6.43e-11	-0.52	-0.34	Aortic root size;	chr7:66221293	chr7:66376044~66401338:-
HNSC	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	7.73	6.79e-14	6.43e-11	0.35	0.34	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	7.73	6.79e-14	6.43e-11	0.35	0.34	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
HNSC	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	7.73	6.8e-14	6.44e-11	0.41	0.34	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	7.73	6.8e-14	6.44e-11	0.41	0.34	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	7.73	6.81e-14	6.45e-11	0.44	0.34	Height;	chr6:109507271	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	7.73	6.83e-14	6.46e-11	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
HNSC	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-7.73	6.83e-14	6.46e-11	-0.39	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	7.73	6.85e-14	6.49e-11	0.48	0.34	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
HNSC	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	7.73	6.85e-14	6.49e-11	0.38	0.34	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
HNSC	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.73	6.85e-14	6.49e-11	0.43	0.34	Height;	chr6:109586733	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	7.72	6.89e-14	6.52e-11	0.35	0.34	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.72	6.89e-14	6.52e-11	0.35	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
HNSC	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	7.72	6.92e-14	6.54e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
HNSC	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	7.72	6.92e-14	6.54e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-7.72	6.93e-14	6.55e-11	-0.38	-0.34	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
HNSC	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-7.72	6.93e-14	6.55e-11	-0.32	-0.34	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-7.72	6.94e-14	6.55e-11	-0.43	-0.34	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	7.72	6.95e-14	6.56e-11	0.52	0.34	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	7.72	6.95e-14	6.56e-11	0.52	0.34	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	7.72	6.96e-14	6.57e-11	0.46	0.34	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
HNSC	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	7.72	6.97e-14	6.58e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	7.72	6.97e-14	6.58e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
HNSC	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-7.72	7.02e-14	6.62e-11	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
HNSC	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	7.72	7.03e-14	6.63e-11	0.25	0.34	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	7.72	7.04e-14	6.64e-11	0.47	0.34	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	7.72	7.04e-14	6.65e-11	0.47	0.34	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
HNSC	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	7.72	7.05e-14	6.65e-11	0.56	0.34	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	7.72	7.06e-14	6.66e-11	0.38	0.34	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	7.72	7.06e-14	6.66e-11	0.46	0.34	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	7.72	7.09e-14	6.69e-11	0.24	0.34	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	7.72	7.09e-14	6.69e-11	0.24	0.34	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	7.72	7.1e-14	6.69e-11	0.47	0.34	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	7.72	7.1e-14	6.69e-11	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
HNSC	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-7.72	7.1e-14	6.7e-11	-0.33	-0.34	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-7.72	7.13e-14	6.73e-11	-0.38	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	7.72	7.13e-14	6.73e-11	0.46	0.34	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	7.72	7.14e-14	6.73e-11	0.47	0.34	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	7.72	7.14e-14	6.73e-11	0.39	0.34	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-7.72	7.16e-14	6.75e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
HNSC	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	7.72	7.17e-14	6.76e-11	0.42	0.34	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
HNSC	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	7.72	7.18e-14	6.76e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
HNSC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	7.72	7.19e-14	6.77e-11	0.36	0.34	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
HNSC	cis	rs17270561	0.636	rs6456694	ENSG00000272462.2	U91328.19	-7.72	7.2e-14	6.78e-11	-0.35	-0.34	Iron status biomarkers;	chr6:25712666	chr6:25992662~26001775:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	7.72	7.21e-14	6.79e-11	0.24	0.34	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
HNSC	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	7.72	7.21e-14	6.8e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-7.72	7.23e-14	6.81e-11	-0.35	-0.34	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-7.72	7.28e-14	6.85e-11	-0.32	-0.34	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-7.72	7.29e-14	6.86e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	7.72	7.32e-14	6.89e-11	0.47	0.34	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
HNSC	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	7.72	7.34e-14	6.9e-11	0.39	0.34	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	7.72	7.36e-14	6.92e-11	0.46	0.34	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	7.72	7.36e-14	6.92e-11	0.46	0.34	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	7.71	7.41e-14	6.97e-11	0.46	0.34	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	7.71	7.45e-14	7.01e-11	0.46	0.34	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
HNSC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	7.71	7.47e-14	7.02e-11	0.39	0.34	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
HNSC	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	7.71	7.47e-14	7.02e-11	0.35	0.34	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
HNSC	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-7.71	7.48e-14	7.03e-11	-0.46	-0.34	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	7.71	7.48e-14	7.03e-11	0.47	0.34	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	7.71	7.5e-14	7.05e-11	0.46	0.34	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	7.71	7.52e-14	7.06e-11	0.34	0.34	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	7.71	7.52e-14	7.07e-11	0.35	0.34	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
HNSC	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	7.71	7.53e-14	7.07e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
HNSC	cis	rs11079757	0.604	rs72823425	ENSG00000262879.4	RP11-156P1.3	7.71	7.58e-14	7.12e-11	0.43	0.34	Erythema nodosum in inflammatory bowel disease;	chr17:47111303	chr17:46984045~47100323:-
HNSC	cis	rs6951245	1	rs2363286	ENSG00000224079.1	AC091729.7	-7.71	7.59e-14	7.13e-11	-0.57	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	7.71	7.62e-14	7.15e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-7.71	7.63e-14	7.17e-11	-0.38	-0.34	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-7.71	7.64e-14	7.17e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
HNSC	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-7.71	7.65e-14	7.18e-11	-0.46	-0.34	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
HNSC	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-7.71	7.66e-14	7.19e-11	-0.38	-0.34	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
HNSC	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	7.71	7.68e-14	7.2e-11	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
HNSC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	7.71	7.7e-14	7.21e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-7.71	7.7e-14	7.21e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-7.71	7.7e-14	7.21e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	7.71	7.75e-14	7.26e-11	0.32	0.34	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000245958.5	RP11-33B1.1	-7.71	7.76e-14	7.27e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119401102	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-7.71	7.78e-14	7.28e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
HNSC	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	7.71	7.83e-14	7.33e-11	0.34	0.34	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
HNSC	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.71	7.84e-14	7.34e-11	0.37	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
HNSC	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-7.71	7.84e-14	7.34e-11	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
HNSC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.71	7.85e-14	7.35e-11	0.36	0.34	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
HNSC	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109558247	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109564443	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109571489	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.71	7.86e-14	7.36e-11	0.44	0.34	Height;	chr6:109576414	chr6:109382795~109383666:+
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-7.71	7.9e-14	7.39e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-7.71	7.9e-14	7.39e-11	-0.31	-0.34	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
HNSC	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	7.7	7.92e-14	7.41e-11	0.35	0.34	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	7.7	7.96e-14	7.44e-11	0.47	0.34	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-7.7	7.97e-14	7.45e-11	-0.38	-0.34	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
HNSC	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-7.7	7.99e-14	7.47e-11	-0.48	-0.34	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	7.7	7.99e-14	7.47e-11	0.24	0.34	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
HNSC	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	7.7	8.03e-14	7.5e-11	0.44	0.34	Height;	chr6:109690255	chr6:109382795~109383666:+
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000276710.3	CSPG4P8	-7.7	8.04e-14	7.51e-11	-0.38	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82459472~82477258:+
HNSC	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	7.7	8.06e-14	7.53e-11	0.39	0.34	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
HNSC	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-7.7	8.07e-14	7.54e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
HNSC	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-7.7	8.1e-14	7.56e-11	-0.37	-0.34	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
HNSC	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-7.7	8.1e-14	7.56e-11	-0.37	-0.34	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
HNSC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.7	8.1e-14	7.57e-11	-0.36	-0.34	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
HNSC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.7	8.1e-14	7.57e-11	-0.36	-0.34	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
HNSC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-7.7	8.11e-14	7.58e-11	-0.36	-0.34	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
HNSC	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.7	8.13e-14	7.59e-11	0.3	0.34	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
HNSC	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-7.7	8.14e-14	7.6e-11	-0.31	-0.34	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	7.7	8.18e-14	7.63e-11	0.46	0.34	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
HNSC	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	7.7	8.18e-14	7.64e-11	0.36	0.34	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	7.7	8.19e-14	7.65e-11	0.47	0.34	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-7.7	8.3e-14	7.74e-11	-0.3	-0.34	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
HNSC	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-7.7	8.3e-14	7.74e-11	-0.37	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
HNSC	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	7.7	8.31e-14	7.74e-11	0.4	0.34	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
HNSC	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-7.7	8.31e-14	7.75e-11	-0.42	-0.34	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	7.7	8.31e-14	7.75e-11	0.24	0.34	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
HNSC	cis	rs6951245	0.938	rs112425403	ENSG00000224079.1	AC091729.7	-7.7	8.31e-14	7.75e-11	-0.57	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1074450~1078036:+
HNSC	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	7.7	8.32e-14	7.76e-11	0.47	0.34	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	7.7	8.35e-14	7.78e-11	0.23	0.34	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
HNSC	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	7.7	8.35e-14	7.79e-11	0.4	0.34	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
HNSC	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	7.7	8.38e-14	7.81e-11	0.37	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-7.7	8.43e-14	7.85e-11	-0.3	-0.34	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	7.7	8.47e-14	7.89e-11	0.39	0.34	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	7.7	8.47e-14	7.89e-11	0.39	0.34	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-7.7	8.47e-14	7.89e-11	-0.32	-0.34	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
HNSC	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	7.69	8.49e-14	7.9e-11	0.39	0.34	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-7.69	8.49e-14	7.9e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
HNSC	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	7.69	8.5e-14	7.91e-11	0.42	0.34	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
HNSC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	7.69	8.51e-14	7.92e-11	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-7.69	8.52e-14	7.93e-11	-0.32	-0.34	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-7.69	8.57e-14	7.97e-11	-0.32	-0.34	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	7.69	8.63e-14	8.03e-11	0.39	0.34	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-7.69	8.63e-14	8.03e-11	-0.46	-0.34	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	7.69	8.64e-14	8.03e-11	0.32	0.34	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	7.69	8.64e-14	8.03e-11	0.46	0.34	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
HNSC	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-7.69	8.67e-14	8.07e-11	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
HNSC	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
HNSC	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	7.69	8.68e-14	8.07e-11	0.39	0.34	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	7.69	8.68e-14	8.07e-11	0.46	0.34	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
HNSC	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-7.69	8.68e-14	8.07e-11	-0.61	-0.34	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	7.69	8.68e-14	8.07e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
HNSC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-7.69	8.72e-14	8.11e-11	-0.37	-0.34	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
HNSC	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	7.69	8.74e-14	8.12e-11	0.37	0.34	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
HNSC	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	7.69	8.76e-14	8.14e-11	0.36	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
HNSC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-7.69	8.79e-14	8.17e-11	-0.35	-0.34	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-7.69	8.79e-14	8.17e-11	-0.35	-0.34	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
HNSC	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	7.69	8.82e-14	8.2e-11	0.38	0.34	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-7.69	8.82e-14	8.2e-11	-0.41	-0.34	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	7.69	8.83e-14	8.2e-11	0.39	0.34	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
HNSC	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-7.69	8.83e-14	8.2e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
HNSC	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-7.69	8.87e-14	8.24e-11	-0.48	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
HNSC	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-7.69	8.87e-14	8.24e-11	-0.39	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	7.69	8.9e-14	8.26e-11	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
HNSC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	7.69	8.92e-14	8.29e-11	0.37	0.34	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	7.69	8.96e-14	8.32e-11	0.46	0.34	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	7.69	8.96e-14	8.32e-11	0.46	0.34	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	7.69	8.97e-14	8.33e-11	0.35	0.34	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
HNSC	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	7.69	8.99e-14	8.34e-11	0.44	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	7.69	8.99e-14	8.35e-11	0.24	0.34	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
HNSC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-7.69	9e-14	8.36e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	7.69	9.05e-14	8.4e-11	0.24	0.34	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
HNSC	cis	rs1865760	0.663	rs9348704	ENSG00000272462.2	U91328.19	-7.69	9.07e-14	8.41e-11	-0.33	-0.34	Height;	chr6:26000165	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	7.69	9.08e-14	8.42e-11	0.47	0.34	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-7.68	9.1e-14	8.44e-11	-0.34	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	7.68	9.12e-14	8.46e-11	0.47	0.34	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
HNSC	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	7.68	9.14e-14	8.47e-11	0.37	0.34	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
HNSC	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-7.68	9.19e-14	8.52e-11	-0.38	-0.34	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
HNSC	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	7.68	9.2e-14	8.53e-11	0.43	0.33	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
HNSC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-7.68	9.21e-14	8.53e-11	-0.37	-0.33	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
HNSC	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	7.68	9.21e-14	8.54e-11	0.42	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	7.68	9.23e-14	8.55e-11	0.47	0.33	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-7.68	9.23e-14	8.55e-11	-0.32	-0.33	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
HNSC	cis	rs9341808	0.621	rs2322627	ENSG00000272129.1	RP11-250B2.6	7.68	9.25e-14	8.58e-11	0.4	0.33	Sitting height ratio;	chr6:80096624	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	7.68	9.26e-14	8.58e-11	0.35	0.33	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	7.68	9.3e-14	8.61e-11	0.43	0.33	Height;	chr6:109358652	chr6:109382795~109383666:+
HNSC	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	7.68	9.3e-14	8.62e-11	0.43	0.33	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	7.68	9.31e-14	8.63e-11	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
HNSC	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.32e-14	8.63e-11	-0.36	-0.33	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
HNSC	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	7.68	9.34e-14	8.65e-11	0.36	0.33	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.47	0.33	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	7.68	9.37e-14	8.68e-11	0.46	0.33	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
HNSC	cis	rs131777	0.576	rs131758	ENSG00000205559.3	CHKB-AS1	-7.68	9.38e-14	8.68e-11	-0.37	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50578653	chr22:50583026~50583877:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	7.68	9.42e-14	8.72e-11	0.24	0.33	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
HNSC	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	7.68	9.44e-14	8.73e-11	0.39	0.33	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-7.68	9.45e-14	8.75e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
HNSC	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-7.68	9.46e-14	8.76e-11	-0.43	-0.33	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	7.68	9.47e-14	8.76e-11	0.46	0.33	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	7.68	9.47e-14	8.76e-11	0.46	0.33	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
HNSC	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-7.68	9.48e-14	8.77e-11	-0.35	-0.33	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
HNSC	cis	rs1865760	0.929	rs9467646	ENSG00000272462.2	U91328.19	-7.68	9.49e-14	8.78e-11	-0.33	-0.33	Height;	chr6:25957180	chr6:25992662~26001775:+
HNSC	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-7.68	9.51e-14	8.79e-11	-0.39	-0.33	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
HNSC	cis	rs1865760	0.865	rs1436306	ENSG00000272462.2	U91328.19	-7.68	9.53e-14	8.81e-11	-0.34	-0.33	Height;	chr6:25948193	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	7.68	9.56e-14	8.84e-11	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-7.68	9.56e-14	8.84e-11	-0.32	-0.33	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	7.68	9.58e-14	8.86e-11	0.46	0.33	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000179406.6	LINC00174	-7.68	9.58e-14	8.86e-11	-0.51	-0.33	Aortic root size;	chr7:66234510	chr7:66376044~66401338:-
HNSC	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-7.68	9.58e-14	8.86e-11	-0.47	-0.33	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-7.68	9.58e-14	8.86e-11	-0.47	-0.33	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-7.68	9.59e-14	8.86e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.6e-14	8.87e-11	-0.38	-0.33	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000267151.3	RP11-100E5.2	7.68	9.63e-14	8.9e-11	0.44	0.33	Menopause (age at onset);	chr17:43028755	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	7.68	9.65e-14	8.92e-11	0.32	0.33	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
HNSC	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	7.68	9.71e-14	8.97e-11	0.37	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
HNSC	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.77e-14	9.02e-11	-0.36	-0.33	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
HNSC	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	7.67	9.77e-14	9.02e-11	0.38	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
HNSC	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109526846	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109533040	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	7.67	9.77e-14	9.02e-11	0.44	0.33	Height;	chr6:109534269	chr6:109382795~109383666:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	7.67	9.77e-14	9.02e-11	0.39	0.33	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
HNSC	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-7.67	9.8e-14	9.05e-11	-0.5	-0.33	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-7.67	9.81e-14	9.06e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
HNSC	cis	rs7942368	1	rs10437754	ENSG00000255100.1	RP11-21L23.3	7.67	9.81e-14	9.06e-11	0.42	0.33	Endometriosis;	chr11:76766823	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-7.67	9.85e-14	9.08e-11	-0.31	-0.33	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-7.67	9.86e-14	9.09e-11	-0.37	-0.33	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
HNSC	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.87e-14	9.1e-11	-0.38	-0.33	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	7.67	9.88e-14	9.11e-11	0.36	0.33	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	7.67	9.9e-14	9.12e-11	0.38	0.33	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-7.67	9.91e-14	9.13e-11	-0.23	-0.33	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-7.67	9.96e-14	9.18e-11	-0.24	-0.33	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
HNSC	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	7.67	1e-13	9.21e-11	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	7.67	1e-13	9.23e-11	0.35	0.33	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
HNSC	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.67	1e-13	9.25e-11	0.44	0.33	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
HNSC	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	7.67	1.01e-13	9.31e-11	0.38	0.33	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
HNSC	cis	rs7942368	0.941	rs10899283	ENSG00000255100.1	RP11-21L23.3	7.67	1.01e-13	9.33e-11	0.42	0.33	Endometriosis;	chr11:76794158	chr11:76782581~76783062:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-7.67	1.02e-13	9.36e-11	-0.36	-0.33	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	7.67	1.02e-13	9.38e-11	0.24	0.33	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
HNSC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-7.67	1.03e-13	9.42e-11	-0.52	-0.33	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
HNSC	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	7.67	1.03e-13	9.45e-11	0.35	0.33	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
HNSC	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	7.67	1.03e-13	9.48e-11	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	7.67	1.03e-13	9.48e-11	0.46	0.33	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.844	rs4846770	ENSG00000272750.1	RP11-378J18.8	-7.67	1.04e-13	9.51e-11	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622227	chr1:222658867~222661512:-
HNSC	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	7.67	1.04e-13	9.52e-11	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
HNSC	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-7.67	1.04e-13	9.55e-11	-0.56	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	7.67	1.04e-13	9.55e-11	0.46	0.33	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-7.67	1.04e-13	9.55e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	7.67	1.04e-13	9.58e-11	0.46	0.33	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	7.66	1.04e-13	9.59e-11	0.46	0.33	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
HNSC	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-7.66	1.05e-13	9.59e-11	-0.42	-0.33	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-7.66	1.05e-13	9.59e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
HNSC	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-7.66	1.05e-13	9.61e-11	-0.35	-0.33	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
HNSC	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-7.66	1.05e-13	9.61e-11	-0.51	-0.33	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	7.66	1.05e-13	9.61e-11	0.24	0.33	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
HNSC	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-7.66	1.05e-13	9.62e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-7.66	1.05e-13	9.65e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
HNSC	cis	rs1865760	0.663	rs9379815	ENSG00000272462.2	U91328.19	-7.66	1.05e-13	9.67e-11	-0.33	-0.33	Height;	chr6:25979888	chr6:25992662~26001775:+
HNSC	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	7.66	1.06e-13	9.7e-11	0.37	0.33	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
HNSC	cis	rs1021993	0.545	rs1006316	ENSG00000231648.1	RP11-372M18.2	-7.66	1.06e-13	9.76e-11	-0.56	-0.33	Gut microbiome composition (winter);	chr1:209377116	chr1:209367662~209379690:+
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	7.66	1.07e-13	9.77e-11	0.46	0.33	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	7.66	1.07e-13	9.8e-11	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000248787.1	RP11-666A20.4	-7.66	1.07e-13	9.82e-11	-0.5	-0.33	Blood pressure (smoking interaction);	chr3:125912928	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-7.66	1.07e-13	9.84e-11	-0.32	-0.33	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	7.66	1.07e-13	9.85e-11	0.38	0.33	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	7.66	1.08e-13	9.86e-11	0.35	0.33	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.87e-11	-0.32	-0.33	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	7.66	1.08e-13	9.88e-11	0.36	0.33	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
HNSC	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	7.66	1.08e-13	9.9e-11	0.4	0.33	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	7.66	1.08e-13	9.9e-11	0.4	0.33	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.91e-11	-0.29	-0.33	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-7.66	1.08e-13	9.91e-11	-0.29	-0.33	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-7.66	1.08e-13	9.92e-11	-0.61	-0.33	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	7.66	1.08e-13	9.93e-11	0.4	0.33	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	7.66	1.09e-13	9.94e-11	0.44	0.33	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
HNSC	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-7.66	1.09e-13	9.95e-11	-0.36	-0.33	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	7.66	1.09e-13	9.99e-11	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
HNSC	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	7.66	1.09e-13	9.99e-11	0.42	0.33	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-7.66	1.09e-13	1e-10	-0.29	-0.33	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
HNSC	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.66	1.09e-13	1e-10	0.41	0.33	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
HNSC	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	7.66	1.1e-13	1.01e-10	0.4	0.33	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
HNSC	cis	rs6951245	0.882	rs11764817	ENSG00000224079.1	AC091729.7	-7.66	1.1e-13	1.01e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-7.66	1.1e-13	1.01e-10	-0.29	-0.33	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	7.66	1.1e-13	1.01e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	7.66	1.1e-13	1.01e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	7.66	1.11e-13	1.01e-10	0.44	0.33	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
HNSC	cis	rs1021993	0.868	rs6685289	ENSG00000231648.1	RP11-372M18.2	-7.66	1.11e-13	1.02e-10	-0.46	-0.33	Gut microbiome composition (winter);	chr1:209357324	chr1:209367662~209379690:+
HNSC	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-7.66	1.12e-13	1.02e-10	-0.34	-0.33	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	7.66	1.12e-13	1.02e-10	0.25	0.33	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
HNSC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	7.65	1.12e-13	1.02e-10	0.36	0.33	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	7.65	1.13e-13	1.03e-10	0.38	0.33	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	7.65	1.13e-13	1.03e-10	0.38	0.33	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000179406.6	LINC00174	7.65	1.13e-13	1.03e-10	0.53	0.33	Aortic root size;	chr7:66101095	chr7:66376044~66401338:-
HNSC	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-7.65	1.13e-13	1.03e-10	-0.38	-0.33	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
HNSC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-7.65	1.13e-13	1.04e-10	-0.52	-0.33	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
HNSC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-7.65	1.13e-13	1.04e-10	-0.41	-0.33	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
HNSC	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.65	1.13e-13	1.04e-10	-0.38	-0.33	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
HNSC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.65	1.13e-13	1.04e-10	-0.36	-0.33	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
HNSC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.65	1.13e-13	1.04e-10	-0.36	-0.33	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	7.65	1.13e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	7.65	1.13e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	7.65	1.14e-13	1.04e-10	0.46	0.33	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
HNSC	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	7.65	1.14e-13	1.04e-10	0.41	0.33	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-7.65	1.14e-13	1.04e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	7.65	1.14e-13	1.04e-10	0.23	0.33	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
HNSC	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	7.65	1.14e-13	1.04e-10	0.35	0.33	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
HNSC	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-7.65	1.14e-13	1.04e-10	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
HNSC	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-7.65	1.14e-13	1.04e-10	-0.39	-0.33	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
HNSC	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.65	1.14e-13	1.04e-10	-0.33	-0.33	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-7.65	1.15e-13	1.05e-10	-0.64	-0.33	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
HNSC	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	7.65	1.15e-13	1.05e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	7.65	1.15e-13	1.05e-10	0.23	0.33	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-7.65	1.15e-13	1.05e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
HNSC	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	7.65	1.15e-13	1.05e-10	0.34	0.33	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
HNSC	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	7.65	1.15e-13	1.05e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
HNSC	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-7.65	1.16e-13	1.05e-10	-0.38	-0.33	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
HNSC	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	7.65	1.16e-13	1.05e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
HNSC	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-7.65	1.16e-13	1.06e-10	-0.39	-0.33	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
HNSC	cis	rs6969780	0.524	rs875898	ENSG00000233429.8	HOTAIRM1	-7.65	1.16e-13	1.06e-10	-0.43	-0.33	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161286	chr7:27095647~27100265:+
HNSC	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	7.65	1.16e-13	1.06e-10	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
HNSC	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	7.65	1.16e-13	1.06e-10	0.48	0.33	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
HNSC	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.65	1.16e-13	1.06e-10	0.43	0.33	Height;	chr6:109584789	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-7.65	1.16e-13	1.06e-10	-0.32	-0.33	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
HNSC	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	7.65	1.17e-13	1.06e-10	0.37	0.33	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	7.65	1.17e-13	1.06e-10	0.37	0.33	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
HNSC	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	7.65	1.17e-13	1.07e-10	0.41	0.33	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
HNSC	cis	rs6951245	0.706	rs28483034	ENSG00000224079.1	AC091729.7	-7.65	1.17e-13	1.07e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1074450~1078036:+
HNSC	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	7.65	1.17e-13	1.07e-10	0.44	0.33	Height;	chr6:109706740	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-7.65	1.18e-13	1.07e-10	-0.4	-0.33	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	7.65	1.18e-13	1.07e-10	0.35	0.33	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
HNSC	cis	rs1865760	0.588	rs9467658	ENSG00000272462.2	U91328.19	-7.65	1.18e-13	1.07e-10	-0.33	-0.33	Height;	chr6:26010653	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	7.65	1.18e-13	1.08e-10	0.32	0.33	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	7.65	1.19e-13	1.08e-10	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-7.65	1.19e-13	1.08e-10	-0.46	-0.33	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs36036395	ENSG00000267151.3	RP11-100E5.2	7.65	1.19e-13	1.08e-10	0.44	0.33	Menopause (age at onset);	chr17:43029280	chr17:43444707~43451200:+
HNSC	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	7.65	1.19e-13	1.08e-10	0.33	0.33	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
HNSC	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	7.65	1.19e-13	1.09e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-7.65	1.2e-13	1.09e-10	-0.32	-0.33	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
HNSC	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	7.65	1.2e-13	1.09e-10	0.37	0.33	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	7.65	1.2e-13	1.09e-10	0.37	0.33	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-7.64	1.2e-13	1.09e-10	-0.32	-0.33	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
HNSC	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	7.64	1.2e-13	1.09e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	7.64	1.21e-13	1.1e-10	0.36	0.33	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-7.64	1.21e-13	1.1e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.48	0.33	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.46	0.33	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	7.64	1.21e-13	1.1e-10	0.46	0.33	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
HNSC	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-7.64	1.22e-13	1.11e-10	-0.51	-0.33	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
HNSC	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	7.64	1.22e-13	1.11e-10	0.34	0.33	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
HNSC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	7.64	1.22e-13	1.11e-10	0.37	0.33	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
HNSC	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	7.64	1.23e-13	1.11e-10	0.37	0.33	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
HNSC	cis	rs9341808	0.718	rs2179842	ENSG00000272129.1	RP11-250B2.6	7.64	1.23e-13	1.12e-10	0.4	0.33	Sitting height ratio;	chr6:80269336	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000179406.6	LINC00174	-7.64	1.23e-13	1.12e-10	-0.51	-0.33	Aortic root size;	chr7:66255529	chr7:66376044~66401338:-
HNSC	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	7.64	1.24e-13	1.12e-10	0.36	0.33	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	7.64	1.24e-13	1.12e-10	0.25	0.33	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
HNSC	cis	rs6867032	1	rs6867032	ENSG00000249731.1	RP11-259O2.3	-7.64	1.24e-13	1.12e-10	-0.4	-0.33	Gut microbiome composition (winter);	chr5:2014989	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	7.64	1.24e-13	1.12e-10	0.32	0.33	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
HNSC	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	7.64	1.24e-13	1.13e-10	0.37	0.33	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
HNSC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	7.64	1.24e-13	1.13e-10	0.32	0.33	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66318029	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66325577	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000179406.6	LINC00174	-7.64	1.24e-13	1.13e-10	-0.52	-0.33	Aortic root size;	chr7:66339619	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	7.64	1.24e-13	1.13e-10	0.46	0.33	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
HNSC	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	7.64	1.24e-13	1.13e-10	0.41	0.33	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
HNSC	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-7.64	1.25e-13	1.14e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-7.64	1.25e-13	1.14e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
HNSC	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	7.64	1.25e-13	1.14e-10	0.34	0.33	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-7.64	1.26e-13	1.14e-10	-0.63	-0.33	Gout;	chr7:66654674	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-7.64	1.26e-13	1.14e-10	-0.63	-0.33	Gout;	chr7:66661502	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.64	1.26e-13	1.14e-10	-0.31	-0.33	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.64	1.26e-13	1.15e-10	0.47	0.33	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-7.64	1.26e-13	1.15e-10	-0.32	-0.33	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
HNSC	cis	rs1933112	0.624	rs1933107	ENSG00000227777.1	RP4-738P11.3	-7.64	1.26e-13	1.15e-10	-0.37	-0.33	Blood protein levels;	chr1:168555657	chr1:168542737~168543354:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000267151.3	RP11-100E5.2	7.64	1.27e-13	1.15e-10	0.44	0.33	Menopause (age at onset);	chr17:43024814	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	7.64	1.28e-13	1.16e-10	0.23	0.33	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	7.64	1.28e-13	1.16e-10	0.46	0.33	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	7.63	1.29e-13	1.17e-10	0.46	0.33	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	7.63	1.29e-13	1.17e-10	0.46	0.33	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
HNSC	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-7.63	1.3e-13	1.18e-10	-0.4	-0.33	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000179406.6	LINC00174	7.63	1.3e-13	1.18e-10	0.51	0.33	Aortic root size;	chr7:66624178	chr7:66376044~66401338:-
HNSC	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	7.63	1.3e-13	1.18e-10	0.32	0.33	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
HNSC	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	7.63	1.3e-13	1.18e-10	0.35	0.33	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
HNSC	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-7.63	1.3e-13	1.18e-10	-0.35	-0.33	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
HNSC	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.63	1.3e-13	1.18e-10	-0.31	-0.33	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	7.63	1.3e-13	1.18e-10	0.47	0.33	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	7.63	1.31e-13	1.18e-10	0.34	0.33	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
HNSC	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	7.63	1.31e-13	1.18e-10	0.61	0.33	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
HNSC	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	7.63	1.31e-13	1.19e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
HNSC	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-7.63	1.32e-13	1.19e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-7.63	1.32e-13	1.19e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
HNSC	cis	rs1799949	1	rs72829113	ENSG00000267151.3	RP11-100E5.2	7.63	1.32e-13	1.19e-10	0.44	0.33	Menopause (age at onset);	chr17:43029818	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000267151.3	RP11-100E5.2	7.63	1.32e-13	1.19e-10	0.44	0.33	Menopause (age at onset);	chr17:43030645	chr17:43444707~43451200:+
HNSC	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	1.19e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	7.63	1.33e-13	1.2e-10	0.39	0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-7.63	1.33e-13	1.2e-10	-0.38	-0.33	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
HNSC	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	7.63	1.33e-13	1.21e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
HNSC	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-7.63	1.34e-13	1.21e-10	-0.42	-0.33	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
HNSC	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
HNSC	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	7.63	1.34e-13	1.21e-10	0.4	0.33	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
HNSC	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-7.63	1.34e-13	1.21e-10	-0.81	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
HNSC	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-7.63	1.34e-13	1.21e-10	-0.46	-0.33	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	7.63	1.34e-13	1.21e-10	0.23	0.33	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
HNSC	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	7.63	1.35e-13	1.22e-10	0.39	0.33	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
HNSC	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	7.63	1.35e-13	1.22e-10	0.37	0.33	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
HNSC	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-7.63	1.36e-13	1.22e-10	-0.43	-0.33	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
HNSC	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-7.63	1.36e-13	1.23e-10	-0.43	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
HNSC	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-7.63	1.36e-13	1.23e-10	-0.35	-0.33	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
HNSC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-7.63	1.36e-13	1.23e-10	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-7.63	1.36e-13	1.23e-10	-0.44	-0.33	Depression;	chr6:28206179	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	7.63	1.37e-13	1.23e-10	0.23	0.33	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	7.63	1.37e-13	1.23e-10	0.45	0.33	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
HNSC	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-7.63	1.37e-13	1.24e-10	-0.37	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
HNSC	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-7.63	1.37e-13	1.24e-10	-0.31	-0.33	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
HNSC	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	7.63	1.38e-13	1.24e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	7.63	1.38e-13	1.24e-10	0.24	0.33	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	7.62	1.38e-13	1.24e-10	0.38	0.33	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.24e-10	0.46	0.33	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
HNSC	cis	rs9402743	0.781	rs9494326	ENSG00000217482.2	HMGB1P17	7.62	1.38e-13	1.25e-10	0.37	0.33	Systemic lupus erythematosus;	chr6:135673400	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	7.62	1.38e-13	1.25e-10	0.46	0.33	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
HNSC	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-7.62	1.39e-13	1.25e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
HNSC	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	7.62	1.39e-13	1.25e-10	0.37	0.33	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	7.62	1.39e-13	1.25e-10	0.37	0.33	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
HNSC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.62	1.39e-13	1.25e-10	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.62	1.39e-13	1.25e-10	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
HNSC	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	7.62	1.39e-13	1.25e-10	0.38	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
HNSC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	7.62	1.4e-13	1.26e-10	0.38	0.33	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-7.62	1.4e-13	1.26e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
HNSC	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	7.62	1.4e-13	1.26e-10	0.38	0.33	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	7.62	1.4e-13	1.27e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-7.62	1.41e-13	1.27e-10	-0.35	-0.33	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
HNSC	cis	rs1799949	1	rs2298862	ENSG00000267151.3	RP11-100E5.2	7.62	1.41e-13	1.27e-10	0.44	0.33	Menopause (age at onset);	chr17:43024671	chr17:43444707~43451200:+
HNSC	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7.62	1.41e-13	1.27e-10	0.38	0.33	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-7.62	1.41e-13	1.27e-10	-0.46	-0.33	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
HNSC	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	7.62	1.42e-13	1.27e-10	0.4	0.33	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-7.62	1.42e-13	1.28e-10	-0.4	-0.33	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
HNSC	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-7.62	1.42e-13	1.28e-10	-0.42	-0.33	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
HNSC	cis	rs7404843	1	rs7404843	ENSG00000263335.1	AF001548.5	-7.62	1.42e-13	1.28e-10	-0.68	-0.33	Testicular germ cell tumor;	chr16:15436851	chr16:15726674~15732993:+
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	7.62	1.42e-13	1.28e-10	0.46	0.33	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	7.62	1.42e-13	1.28e-10	0.46	0.33	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	7.62	1.44e-13	1.29e-10	0.46	0.33	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
HNSC	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	7.62	1.44e-13	1.29e-10	0.37	0.33	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
HNSC	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-7.62	1.44e-13	1.3e-10	-0.46	-0.33	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
HNSC	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	7.62	1.44e-13	1.3e-10	0.4	0.33	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	7.62	1.44e-13	1.3e-10	0.47	0.33	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-7.62	1.44e-13	1.3e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-7.62	1.45e-13	1.3e-10	-0.5	-0.33	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	7.62	1.45e-13	1.31e-10	0.36	0.33	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.62	1.46e-13	1.31e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	7.62	1.46e-13	1.31e-10	0.23	0.33	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
HNSC	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-7.62	1.47e-13	1.32e-10	-0.31	-0.33	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-7.62	1.47e-13	1.32e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	7.62	1.47e-13	1.33e-10	0.47	0.33	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
HNSC	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	7.61	1.48e-13	1.33e-10	0.38	0.33	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	7.61	1.48e-13	1.33e-10	0.46	0.33	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-7.61	1.49e-13	1.34e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
HNSC	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.49e-13	1.34e-10	-0.38	-0.33	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-7.61	1.49e-13	1.34e-10	-0.37	-0.33	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-7.61	1.49e-13	1.34e-10	-0.37	-0.33	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
HNSC	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	7.61	1.49e-13	1.34e-10	0.39	0.33	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	7.61	1.5e-13	1.34e-10	0.24	0.33	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	7.61	1.5e-13	1.34e-10	0.46	0.33	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	7.61	1.5e-13	1.34e-10	0.46	0.33	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66275908	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66302477	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000179406.6	LINC00174	-7.61	1.5e-13	1.35e-10	-0.51	-0.33	Aortic root size;	chr7:66305392	chr7:66376044~66401338:-
HNSC	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-7.61	1.5e-13	1.35e-10	-0.42	-0.33	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
HNSC	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	7.61	1.5e-13	1.35e-10	0.36	0.33	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	7.61	1.51e-13	1.35e-10	0.38	0.33	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
HNSC	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	7.61	1.51e-13	1.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
HNSC	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.61	1.51e-13	1.36e-10	0.38	0.33	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
HNSC	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	7.61	1.51e-13	1.36e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
HNSC	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	7.61	1.52e-13	1.36e-10	0.36	0.33	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
HNSC	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	7.61	1.52e-13	1.36e-10	0.34	0.33	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
HNSC	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	7.61	1.52e-13	1.37e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
HNSC	cis	rs7942368	1	rs7933092	ENSG00000255100.1	RP11-21L23.3	7.61	1.52e-13	1.37e-10	0.42	0.33	Endometriosis;	chr11:76764444	chr11:76782581~76783062:-
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	7.61	1.53e-13	1.37e-10	0.46	0.33	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	7.61	1.53e-13	1.37e-10	0.46	0.33	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
HNSC	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-7.61	1.53e-13	1.37e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
HNSC	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	7.61	1.53e-13	1.37e-10	0.51	0.33	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
HNSC	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	7.61	1.53e-13	1.37e-10	0.52	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
HNSC	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	7.61	1.53e-13	1.37e-10	0.37	0.33	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
HNSC	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	7.61	1.53e-13	1.37e-10	0.37	0.33	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
HNSC	cis	rs12439619	0.693	rs9944185	ENSG00000276710.3	CSPG4P8	-7.61	1.53e-13	1.38e-10	-0.4	-0.33	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82459472~82477258:+
HNSC	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-7.61	1.54e-13	1.38e-10	-0.41	-0.33	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	7.61	1.54e-13	1.38e-10	0.46	0.33	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	7.61	1.54e-13	1.38e-10	0.46	0.33	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000179406.6	LINC00174	-7.61	1.54e-13	1.38e-10	-0.52	-0.33	Aortic root size;	chr7:66249202	chr7:66376044~66401338:-
HNSC	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-7.61	1.56e-13	1.39e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-7.61	1.56e-13	1.4e-10	-0.44	-0.33	Depression;	chr6:28184805	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.61	1.57e-13	1.4e-10	-0.33	-0.33	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
HNSC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.61	1.57e-13	1.4e-10	0.35	0.33	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
HNSC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	7.61	1.57e-13	1.4e-10	0.38	0.33	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	7.61	1.57e-13	1.4e-10	0.38	0.33	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
HNSC	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	7.61	1.57e-13	1.41e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
HNSC	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.58e-13	1.41e-10	-0.37	-0.33	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	7.61	1.58e-13	1.41e-10	0.46	0.33	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	7.61	1.58e-13	1.41e-10	0.46	0.33	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000173295.6	FAM86B3P	7.6	1.58e-13	1.42e-10	0.39	0.33	Joint mobility (Beighton score);	chr8:9014200	chr8:8228595~8244865:+
HNSC	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	7.6	1.59e-13	1.42e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
HNSC	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-7.6	1.59e-13	1.42e-10	-0.48	-0.33	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
HNSC	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	7.6	1.6e-13	1.43e-10	0.44	0.33	Height;	chr6:109706514	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	7.6	1.6e-13	1.43e-10	0.24	0.33	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.6	1.6e-13	1.43e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
HNSC	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	7.6	1.6e-13	1.43e-10	0.38	0.33	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
HNSC	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	7.6	1.6e-13	1.43e-10	0.45	0.33	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
HNSC	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	7.6	1.6e-13	1.43e-10	0.37	0.33	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
HNSC	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-7.6	1.62e-13	1.45e-10	-0.42	-0.33	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	7.6	1.62e-13	1.45e-10	0.42	0.33	Depression;	chr6:28187640	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	7.6	1.62e-13	1.45e-10	0.23	0.33	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	7.6	1.62e-13	1.45e-10	0.38	0.33	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	7.6	1.62e-13	1.45e-10	0.34	0.33	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
HNSC	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	7.6	1.63e-13	1.45e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	7.6	1.63e-13	1.46e-10	0.32	0.33	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.6	1.64e-13	1.46e-10	-0.51	-0.33	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	7.6	1.65e-13	1.48e-10	0.46	0.33	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
HNSC	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	7.6	1.65e-13	1.48e-10	0.46	0.33	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	7.6	1.66e-13	1.48e-10	0.23	0.33	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
HNSC	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-7.6	1.66e-13	1.48e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	7.6	1.66e-13	1.48e-10	0.23	0.33	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
HNSC	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	7.6	1.66e-13	1.49e-10	0.42	0.33	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
HNSC	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.6	1.67e-13	1.49e-10	0.38	0.33	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	7.6	1.67e-13	1.49e-10	0.45	0.33	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	7.6	1.69e-13	1.51e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
HNSC	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-7.59	1.7e-13	1.52e-10	-0.35	-0.33	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-7.59	1.7e-13	1.52e-10	-0.35	-0.33	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
HNSC	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	7.59	1.7e-13	1.52e-10	0.4	0.33	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
HNSC	cis	rs6951245	0.832	rs10266519	ENSG00000224079.1	AC091729.7	-7.59	1.71e-13	1.52e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1074450~1078036:+
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	7.59	1.71e-13	1.53e-10	0.46	0.33	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	7.59	1.71e-13	1.53e-10	0.31	0.33	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
HNSC	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	7.59	1.71e-13	1.53e-10	0.45	0.33	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
HNSC	cis	rs454422	0.767	rs236126	ENSG00000275632.1	RP5-967N21.11	7.59	1.72e-13	1.53e-10	0.37	0.33	HIV-1 viral setpoint;	chr20:5997495	chr20:6000418~6000941:+
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	7.59	1.72e-13	1.53e-10	0.45	0.33	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-7.59	1.72e-13	1.53e-10	-0.37	-0.33	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	7.59	1.72e-13	1.54e-10	0.38	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-7.59	1.72e-13	1.54e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
HNSC	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-7.59	1.73e-13	1.54e-10	-0.46	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
HNSC	cis	rs2579103	0.507	rs10777241	ENSG00000258183.4	RP11-753N8.1	7.59	1.73e-13	1.54e-10	0.38	0.33	Body mass index;	chr12:90279410	chr12:90280894~90300340:+
HNSC	cis	rs7048146	0.899	rs4595205	ENSG00000213539.4	YBX1P6	7.59	1.74e-13	1.55e-10	0.39	0.33	Vascular brain injury;	chr9:109575965	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.899	rs4978836	ENSG00000213539.4	YBX1P6	7.59	1.74e-13	1.55e-10	0.39	0.33	Vascular brain injury;	chr9:109576701	chr9:109532830~109534332:-
HNSC	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-7.59	1.75e-13	1.55e-10	-0.34	-0.33	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
HNSC	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.59	1.76e-13	1.56e-10	0.43	0.33	Height;	chr6:109588639	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.59	1.76e-13	1.56e-10	0.43	0.33	Height;	chr6:109589051	chr6:109382795~109383666:+
HNSC	cis	rs6951245	0.678	rs28600085	ENSG00000224079.1	AC091729.7	-7.59	1.76e-13	1.57e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1074450~1078036:+
HNSC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.59	1.76e-13	1.57e-10	0.39	0.33	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
HNSC	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.59	1.76e-13	1.57e-10	-0.31	-0.33	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
HNSC	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-7.59	1.77e-13	1.57e-10	-0.32	-0.33	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000179406.6	LINC00174	7.59	1.77e-13	1.58e-10	0.52	0.33	Aortic root size;	chr7:66066855	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-7.59	1.78e-13	1.58e-10	-0.31	-0.33	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
HNSC	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-7.59	1.78e-13	1.58e-10	-0.46	-0.33	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	7.59	1.79e-13	1.59e-10	0.23	0.33	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	7.59	1.79e-13	1.59e-10	0.23	0.33	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	7.59	1.79e-13	1.59e-10	0.43	0.33	Height;	chr6:109347707	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	7.59	1.79e-13	1.59e-10	0.45	0.33	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-7.59	1.8e-13	1.59e-10	-0.38	-0.33	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
HNSC	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	7.59	1.8e-13	1.6e-10	0.43	0.33	Height;	chr6:109518783	chr6:109382795~109383666:+
HNSC	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-7.59	1.81e-13	1.6e-10	-0.31	-0.33	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	7.59	1.81e-13	1.61e-10	0.4	0.33	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
HNSC	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
HNSC	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-7.59	1.81e-13	1.61e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
HNSC	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	7.58	1.81e-13	1.61e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
HNSC	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	7.58	1.82e-13	1.61e-10	0.39	0.33	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	7.58	1.82e-13	1.62e-10	0.24	0.33	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
HNSC	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.82e-13	1.62e-10	-0.37	-0.33	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
HNSC	cis	rs17270561	0.697	rs9366633	ENSG00000272462.2	U91328.19	-7.58	1.83e-13	1.62e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25837826	chr6:25992662~26001775:+
HNSC	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	7.58	1.83e-13	1.63e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
HNSC	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	7.58	1.83e-13	1.63e-10	0.39	0.33	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
HNSC	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	7.58	1.84e-13	1.63e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
HNSC	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	7.58	1.84e-13	1.63e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
HNSC	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-7.58	1.84e-13	1.64e-10	-0.36	-0.33	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
HNSC	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	7.58	1.85e-13	1.64e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	7.58	1.85e-13	1.64e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.58	1.85e-13	1.64e-10	0.36	0.33	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-7.58	1.86e-13	1.65e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
HNSC	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-7.58	1.86e-13	1.65e-10	-0.36	-0.33	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
HNSC	cis	rs1021993	0.545	rs1006317	ENSG00000231648.1	RP11-372M18.2	-7.58	1.86e-13	1.65e-10	-0.58	-0.33	Gut microbiome composition (winter);	chr1:209379291	chr1:209367662~209379690:+
HNSC	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	7.58	1.87e-13	1.65e-10	0.4	0.33	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
HNSC	cis	rs6951245	0.786	rs77943789	ENSG00000224079.1	AC091729.7	-7.58	1.87e-13	1.66e-10	-0.52	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1074450~1078036:+
HNSC	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-7.58	1.87e-13	1.66e-10	-0.41	-0.33	Height;	chr11:118855938	chr11:118704607~118750263:+
HNSC	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-7.58	1.88e-13	1.67e-10	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
HNSC	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	7.58	1.88e-13	1.67e-10	0.39	0.33	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
HNSC	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-7.58	1.88e-13	1.67e-10	-0.4	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-7.58	1.89e-13	1.67e-10	-0.43	-0.33	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-7.58	1.89e-13	1.68e-10	-0.33	-0.33	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
HNSC	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.89e-13	1.68e-10	-0.38	-0.33	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
HNSC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.58	1.9e-13	1.68e-10	-0.35	-0.33	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
HNSC	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-7.58	1.9e-13	1.68e-10	-0.34	-0.33	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
HNSC	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	7.58	1.92e-13	1.7e-10	0.37	0.33	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000241288.6	RP11-379B18.5	-7.58	1.92e-13	1.7e-10	-0.55	-0.33	Blood pressure (smoking interaction);	chr3:125886628	chr3:125827238~125916384:-
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	7.58	1.92e-13	1.7e-10	0.48	0.33	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
HNSC	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	7.58	1.93e-13	1.7e-10	0.42	0.33	Height;	chr6:109351795	chr6:109382795~109383666:+
HNSC	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	7.58	1.93e-13	1.71e-10	0.37	0.33	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
HNSC	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	7.58	1.94e-13	1.71e-10	0.39	0.33	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	7.58	1.94e-13	1.71e-10	0.46	0.33	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000179406.6	LINC00174	7.57	1.94e-13	1.72e-10	0.5	0.33	Aortic root size;	chr7:66575494	chr7:66376044~66401338:-
HNSC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.57	1.95e-13	1.72e-10	-0.35	-0.33	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
HNSC	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	7.57	1.95e-13	1.72e-10	0.47	0.33	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
HNSC	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	7.57	1.95e-13	1.73e-10	0.36	0.33	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	7.57	1.96e-13	1.73e-10	0.46	0.33	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	7.57	1.96e-13	1.73e-10	0.46	0.33	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
HNSC	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	7.57	1.97e-13	1.74e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
HNSC	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-7.57	1.98e-13	1.75e-10	-0.29	-0.33	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
HNSC	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	7.57	1.98e-13	1.75e-10	0.41	0.33	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
HNSC	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-7.57	1.99e-13	1.76e-10	-0.31	-0.33	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
HNSC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	7.57	2e-13	1.76e-10	0.36	0.33	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	7.57	2e-13	1.77e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
HNSC	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	7.57	2.01e-13	1.77e-10	0.41	0.33	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
HNSC	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	7.57	2.01e-13	1.77e-10	0.41	0.33	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
HNSC	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.57	2.01e-13	1.77e-10	-0.32	-0.33	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
HNSC	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-7.57	2.01e-13	1.78e-10	-0.39	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
HNSC	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	7.57	2.01e-13	1.78e-10	0.38	0.33	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-7.57	2.02e-13	1.78e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	7.57	2.02e-13	1.78e-10	0.37	0.33	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-7.57	2.03e-13	1.79e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	7.57	2.03e-13	1.79e-10	0.36	0.33	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	7.57	2.04e-13	1.79e-10	0.36	0.33	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-7.57	2.04e-13	1.8e-10	-0.31	-0.33	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-7.57	2.04e-13	1.8e-10	-0.45	-0.33	Depression;	chr6:28192182	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	7.57	2.05e-13	1.8e-10	0.43	0.33	Height;	chr6:109503623	chr6:109382795~109383666:+
HNSC	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7.57	2.05e-13	1.81e-10	0.41	0.33	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.57	2.05e-13	1.81e-10	0.24	0.33	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
HNSC	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	7.57	2.06e-13	1.81e-10	0.4	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	7.57	2.07e-13	1.82e-10	0.23	0.33	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
HNSC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	7.56	2.08e-13	1.83e-10	0.61	0.33	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-7.56	2.08e-13	1.83e-10	-0.38	-0.33	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
HNSC	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	7.56	2.08e-13	1.83e-10	0.42	0.33	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
HNSC	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-7.56	2.09e-13	1.83e-10	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	7.56	2.09e-13	1.84e-10	0.31	0.33	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	7.56	2.1e-13	1.85e-10	0.36	0.33	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	7.56	2.1e-13	1.85e-10	0.31	0.33	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-7.56	2.1e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-7.56	2.11e-13	1.85e-10	-0.43	-0.33	Depression;	chr6:28205175	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-7.56	2.11e-13	1.85e-10	-0.31	-0.33	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
HNSC	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	7.56	2.11e-13	1.86e-10	0.34	0.33	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
HNSC	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-7.56	2.13e-13	1.87e-10	-0.39	-0.33	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
HNSC	cis	rs7626444	1	rs7626444	ENSG00000272359.1	U4	-7.56	2.13e-13	1.87e-10	-0.38	-0.33	Monocyte count;	chr3:196778031	chr3:196747192~196747324:-
HNSC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	7.56	2.13e-13	1.87e-10	0.33	0.33	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	7.56	2.13e-13	1.87e-10	0.45	0.33	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-7.56	2.13e-13	1.87e-10	-0.42	-0.33	Depression;	chr6:28201380	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	7.56	2.14e-13	1.87e-10	0.37	0.33	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	7.56	2.14e-13	1.88e-10	0.51	0.33	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.56	2.15e-13	1.89e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-7.56	2.15e-13	1.89e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
HNSC	cis	rs6471393	0.929	rs56108220	ENSG00000253848.1	RP11-10N23.5	7.56	2.16e-13	1.9e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93736965	chr8:93741193~93744534:+
HNSC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-7.56	2.17e-13	1.91e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
HNSC	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-7.56	2.18e-13	1.91e-10	-0.31	-0.33	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
HNSC	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-7.56	2.19e-13	1.92e-10	-0.31	-0.33	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
HNSC	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	7.56	2.2e-13	1.93e-10	0.39	0.33	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
HNSC	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-7.56	2.2e-13	1.93e-10	-0.35	-0.33	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
HNSC	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	7.56	2.2e-13	1.93e-10	0.34	0.33	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
HNSC	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-7.56	2.22e-13	1.94e-10	-0.4	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
HNSC	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	7.56	2.23e-13	1.95e-10	0.41	0.33	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
HNSC	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
HNSC	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-7.56	2.23e-13	1.95e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	7.55	2.23e-13	1.95e-10	0.31	0.33	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
HNSC	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-7.55	2.23e-13	1.96e-10	-0.48	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	7.55	2.24e-13	1.96e-10	0.46	0.33	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.55	2.25e-13	1.97e-10	0.23	0.33	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-7.55	2.26e-13	1.98e-10	-0.29	-0.33	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
HNSC	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-7.55	2.26e-13	1.98e-10	-0.34	-0.33	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
HNSC	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-7.55	2.26e-13	1.98e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
HNSC	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.27e-13	1.99e-10	-0.36	-0.33	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
HNSC	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-7.55	2.28e-13	1.99e-10	-0.47	-0.33	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
HNSC	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	7.55	2.29e-13	2.01e-10	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	7.55	2.29e-13	2.01e-10	0.48	0.33	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	7.55	2.3e-13	2.01e-10	0.46	0.33	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-7.55	2.31e-13	2.02e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	7.55	2.31e-13	2.02e-10	0.23	0.33	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
HNSC	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	7.55	2.32e-13	2.03e-10	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
HNSC	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	7.55	2.32e-13	2.03e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.32e-13	2.03e-10	-0.37	-0.33	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
HNSC	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-7.55	2.32e-13	2.03e-10	-0.31	-0.33	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	7.55	2.33e-13	2.03e-10	0.23	0.33	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
HNSC	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	7.55	2.34e-13	2.04e-10	0.34	0.33	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	7.55	2.34e-13	2.05e-10	0.32	0.33	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	7.55	2.35e-13	2.06e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-7.55	2.36e-13	2.06e-10	-0.33	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	7.55	2.36e-13	2.07e-10	0.45	0.33	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.37e-13	2.07e-10	-0.37	-0.33	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
HNSC	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-7.55	2.37e-13	2.07e-10	-0.34	-0.33	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
HNSC	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-7.55	2.38e-13	2.08e-10	-0.34	-0.33	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000179406.6	LINC00174	-7.55	2.38e-13	2.08e-10	-0.51	-0.33	Aortic root size;	chr7:66536825	chr7:66376044~66401338:-
HNSC	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-7.54	2.39e-13	2.08e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
HNSC	cis	rs7942368	1	rs1440979	ENSG00000255100.1	RP11-21L23.3	7.54	2.4e-13	2.1e-10	0.42	0.33	Endometriosis;	chr11:76784085	chr11:76782581~76783062:-
HNSC	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-7.54	2.41e-13	2.1e-10	-0.32	-0.33	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
HNSC	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-7.54	2.41e-13	2.1e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
HNSC	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	7.54	2.41e-13	2.11e-10	0.34	0.33	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
HNSC	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	7.54	2.41e-13	2.11e-10	0.41	0.33	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
HNSC	cis	rs1799949	1	rs915945	ENSG00000267151.3	RP11-100E5.2	7.54	2.41e-13	2.11e-10	0.44	0.33	Menopause (age at onset);	chr17:43027847	chr17:43444707~43451200:+
HNSC	cis	rs7404843	0.777	rs6498552	ENSG00000263335.1	AF001548.5	-7.54	2.43e-13	2.12e-10	-0.64	-0.33	Testicular germ cell tumor;	chr16:15446044	chr16:15726674~15732993:+
HNSC	cis	rs7404843	0.85	rs6498553	ENSG00000263335.1	AF001548.5	-7.54	2.43e-13	2.12e-10	-0.64	-0.33	Testicular germ cell tumor;	chr16:15446045	chr16:15726674~15732993:+
HNSC	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-7.54	2.43e-13	2.12e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	7.54	2.44e-13	2.13e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.54	2.45e-13	2.13e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.54	2.45e-13	2.13e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.54	2.45e-13	2.14e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
HNSC	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-7.54	2.45e-13	2.14e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
HNSC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	7.54	2.46e-13	2.15e-10	0.34	0.33	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	7.54	2.46e-13	2.15e-10	0.32	0.33	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
HNSC	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-7.54	2.47e-13	2.15e-10	-0.37	-0.33	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
HNSC	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	7.54	2.48e-13	2.16e-10	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
HNSC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-7.54	2.48e-13	2.16e-10	-0.31	-0.33	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
HNSC	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-7.54	2.5e-13	2.18e-10	-0.32	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	7.54	2.51e-13	2.19e-10	0.23	0.33	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
HNSC	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-7.54	2.51e-13	2.19e-10	-0.35	-0.33	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	7.54	2.52e-13	2.19e-10	0.46	0.33	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
HNSC	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-7.54	2.52e-13	2.19e-10	-0.45	-0.33	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
HNSC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-7.54	2.52e-13	2.2e-10	-0.35	-0.33	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
HNSC	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	7.54	2.53e-13	2.2e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
HNSC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-7.54	2.54e-13	2.21e-10	-0.35	-0.33	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	7.54	2.54e-13	2.21e-10	0.33	0.33	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
HNSC	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	7.54	2.55e-13	2.21e-10	0.48	0.33	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
HNSC	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	7.54	2.55e-13	2.22e-10	0.37	0.33	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
HNSC	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	7.54	2.55e-13	2.22e-10	0.37	0.33	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
HNSC	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-7.54	2.55e-13	2.22e-10	-0.32	-0.33	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000254340.1	RP11-10A14.3	7.53	2.56e-13	2.23e-10	0.41	0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:9141424~9145435:+
HNSC	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-7.53	2.56e-13	2.23e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
HNSC	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	7.53	2.57e-13	2.23e-10	0.37	0.33	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
HNSC	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	7.53	2.57e-13	2.23e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
HNSC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-7.53	2.57e-13	2.23e-10	-0.41	-0.33	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
HNSC	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-7.53	2.59e-13	2.25e-10	-0.36	-0.33	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	7.53	2.59e-13	2.25e-10	0.46	0.33	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
HNSC	cis	rs7942368	1	rs1440980	ENSG00000255100.1	RP11-21L23.3	7.53	2.6e-13	2.26e-10	0.42	0.33	Endometriosis;	chr11:76784032	chr11:76782581~76783062:-
HNSC	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	7.53	2.6e-13	2.26e-10	0.37	0.33	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
HNSC	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	7.53	2.61e-13	2.27e-10	0.48	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
HNSC	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	7.53	2.61e-13	2.27e-10	0.49	0.33	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	7.53	2.62e-13	2.28e-10	0.62	0.33	Gout;	chr7:66682070	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	7.53	2.62e-13	2.28e-10	0.62	0.33	Gout;	chr7:66682162	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66679692	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66692349	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66693433	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66694214	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66701371	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66702658	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66706390	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-7.53	2.62e-13	2.28e-10	-0.62	-0.33	Gout;	chr7:66710076	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	7.53	2.63e-13	2.28e-10	0.45	0.33	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	7.53	2.64e-13	2.29e-10	0.34	0.33	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
HNSC	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.53	2.64e-13	2.29e-10	-0.31	-0.33	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	7.53	2.64e-13	2.29e-10	0.24	0.33	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
HNSC	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-7.53	2.65e-13	2.29e-10	-0.36	-0.33	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
HNSC	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	7.53	2.65e-13	2.3e-10	0.41	0.33	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
HNSC	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.53	2.65e-13	2.3e-10	-0.37	-0.33	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
HNSC	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	7.53	2.66e-13	2.3e-10	0.39	0.33	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	7.53	2.66e-13	2.3e-10	0.34	0.33	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-7.53	2.66e-13	2.31e-10	-0.41	-0.33	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	7.53	2.67e-13	2.32e-10	0.62	0.33	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.53	2.68e-13	2.32e-10	0.47	0.33	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
HNSC	cis	rs6471393	0.964	rs3813853	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93740526	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-7.53	2.68e-13	2.32e-10	-0.31	-0.33	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	7.53	2.68e-13	2.32e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
HNSC	cis	rs6471393	0.929	rs4734251	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.929	rs4734252	ENSG00000253848.1	RP11-10N23.5	7.53	2.68e-13	2.32e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:93741193~93744534:+
HNSC	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	7.53	2.69e-13	2.33e-10	0.39	0.33	Height;	chr4:55363436	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-7.53	2.69e-13	2.33e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-7.53	2.7e-13	2.33e-10	-0.38	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-7.53	2.7e-13	2.33e-10	-0.43	-0.33	Depression;	chr6:28198669	chr6:28115628~28116551:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	7.53	2.7e-13	2.33e-10	0.31	0.33	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	7.53	2.7e-13	2.33e-10	0.31	0.33	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	7.53	2.71e-13	2.34e-10	0.35	0.33	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
HNSC	cis	rs6951245	0.744	rs10265758	ENSG00000224079.1	AC091729.7	-7.53	2.71e-13	2.34e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1074450~1078036:+
HNSC	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	7.53	2.71e-13	2.34e-10	0.38	0.33	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
HNSC	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-7.53	2.71e-13	2.35e-10	-0.38	-0.33	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
HNSC	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-7.53	2.71e-13	2.35e-10	-0.9	-0.33	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
HNSC	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-7.53	2.72e-13	2.35e-10	-0.37	-0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000173295.6	FAM86B3P	7.53	2.72e-13	2.35e-10	0.38	0.33	Joint mobility (Beighton score);	chr8:9012918	chr8:8228595~8244865:+
HNSC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.53	2.73e-13	2.36e-10	-0.35	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
HNSC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.53	2.73e-13	2.36e-10	-0.36	-0.33	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	7.53	2.73e-13	2.36e-10	0.45	0.33	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
HNSC	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	7.53	2.73e-13	2.36e-10	0.5	0.33	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000179406.6	LINC00174	7.53	2.73e-13	2.36e-10	0.5	0.33	Aortic root size;	chr7:66622032	chr7:66376044~66401338:-
HNSC	cis	rs1799949	1	rs12942277	ENSG00000267151.3	RP11-100E5.2	7.52	2.75e-13	2.38e-10	0.44	0.33	Menopause (age at onset);	chr17:43035957	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000267151.3	RP11-100E5.2	7.52	2.75e-13	2.38e-10	0.44	0.33	Menopause (age at onset);	chr17:43036769	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	7.52	2.75e-13	2.38e-10	0.35	0.33	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
HNSC	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	7.52	2.75e-13	2.38e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
HNSC	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	7.52	2.76e-13	2.39e-10	0.37	0.33	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	7.52	2.77e-13	2.39e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	7.52	2.79e-13	2.41e-10	0.31	0.33	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
HNSC	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	7.52	2.8e-13	2.42e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	7.52	2.8e-13	2.42e-10	0.23	0.33	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	7.52	2.8e-13	2.42e-10	0.43	0.33	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
HNSC	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-7.52	2.82e-13	2.43e-10	-0.32	-0.33	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
HNSC	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-7.52	2.82e-13	2.44e-10	-0.32	-0.33	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
HNSC	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-7.52	2.82e-13	2.44e-10	-0.49	-0.33	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
HNSC	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.82e-13	2.44e-10	-0.37	-0.33	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
HNSC	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	7.52	2.83e-13	2.45e-10	0.4	0.33	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.52	2.84e-13	2.45e-10	0.36	0.33	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-7.52	2.85e-13	2.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	7.52	2.85e-13	2.46e-10	0.39	0.33	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	7.52	2.85e-13	2.46e-10	0.23	0.33	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	7.52	2.85e-13	2.46e-10	0.37	0.33	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
HNSC	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-7.52	2.85e-13	2.46e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
HNSC	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-7.52	2.85e-13	2.46e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
HNSC	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.52	2.85e-13	2.46e-10	-0.32	-0.33	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
HNSC	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
HNSC	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.86e-13	2.47e-10	-0.37	-0.33	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-7.52	2.87e-13	2.47e-10	-0.62	-0.33	Gout;	chr7:66645053	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000179406.6	LINC00174	7.52	2.87e-13	2.48e-10	0.5	0.33	Aortic root size;	chr7:66592167	chr7:66376044~66401338:-
HNSC	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	7.52	2.88e-13	2.48e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
HNSC	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	7.52	2.88e-13	2.48e-10	0.36	0.33	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
HNSC	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	7.52	2.88e-13	2.48e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
HNSC	cis	rs6867032	1	rs4975794	ENSG00000249731.1	RP11-259O2.3	-7.52	2.88e-13	2.48e-10	-0.4	-0.33	Gut microbiome composition (winter);	chr5:2015216	chr5:1968094~1969013:+
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.52	2.88e-13	2.49e-10	0.23	0.33	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
HNSC	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-7.52	2.89e-13	2.49e-10	-0.31	-0.33	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-7.52	2.89e-13	2.49e-10	-0.31	-0.33	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
HNSC	cis	rs4141404	0.582	rs5753630	ENSG00000236132.1	CTA-440B3.1	-7.52	2.89e-13	2.49e-10	-0.37	-0.33	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31816379~31817491:-
HNSC	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-7.52	2.9e-13	2.5e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
HNSC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	7.52	2.9e-13	2.5e-10	0.4	0.33	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
HNSC	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	7.52	2.9e-13	2.5e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66442783	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66493729	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000179406.6	LINC00174	-7.52	2.91e-13	2.51e-10	-0.49	-0.33	Aortic root size;	chr7:66505541	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	7.52	2.91e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	7.52	2.91e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
HNSC	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	7.52	2.92e-13	2.51e-10	0.39	0.33	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
HNSC	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	7.52	2.92e-13	2.51e-10	0.4	0.33	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	7.52	2.92e-13	2.51e-10	0.45	0.33	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000179406.6	LINC00174	-7.52	2.92e-13	2.52e-10	-0.5	-0.33	Aortic root size;	chr7:66376399	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-7.52	2.92e-13	2.52e-10	-0.63	-0.33	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	7.51	2.94e-13	2.53e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
HNSC	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-7.51	2.96e-13	2.55e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
HNSC	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-7.51	2.97e-13	2.55e-10	-0.43	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
HNSC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	7.51	2.97e-13	2.55e-10	0.4	0.33	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
HNSC	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	7.51	2.97e-13	2.55e-10	0.35	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
HNSC	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	7.51	2.97e-13	2.55e-10	0.34	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
HNSC	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-7.51	2.99e-13	2.57e-10	-0.38	-0.33	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-7.51	3e-13	2.58e-10	-0.54	-0.33	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
HNSC	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-7.51	3e-13	2.58e-10	-0.37	-0.33	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	7.51	3.01e-13	2.58e-10	0.61	0.33	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
HNSC	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	7.51	3.01e-13	2.59e-10	0.34	0.33	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
HNSC	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-7.51	3.01e-13	2.59e-10	-0.33	-0.33	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
HNSC	cis	rs7942368	1	rs1837680	ENSG00000255100.1	RP11-21L23.3	7.51	3.02e-13	2.59e-10	0.41	0.33	Endometriosis;	chr11:76790407	chr11:76782581~76783062:-
HNSC	cis	rs7942368	1	rs4309181	ENSG00000255100.1	RP11-21L23.3	7.51	3.02e-13	2.6e-10	0.41	0.33	Endometriosis;	chr11:76790661	chr11:76782581~76783062:-
HNSC	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	7.51	3.03e-13	2.6e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
HNSC	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.51	3.04e-13	2.61e-10	-0.37	-0.33	Migraine;	chr4:56879851	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.51	3.04e-13	2.61e-10	-0.37	-0.33	Migraine;	chr4:56880007	chr4:56960927~56961373:-
HNSC	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	7.51	3.04e-13	2.61e-10	0.32	0.33	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
HNSC	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.51	3.04e-13	2.61e-10	-0.43	-0.33	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
HNSC	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	7.51	3.05e-13	2.61e-10	0.39	0.33	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
HNSC	cis	rs6951245	0.744	rs10265736	ENSG00000224079.1	AC091729.7	-7.51	3.07e-13	2.63e-10	-0.51	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1074450~1078036:+
HNSC	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	7.51	3.08e-13	2.64e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	7.51	3.08e-13	2.64e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-7.51	3.08e-13	2.65e-10	-0.56	-0.33	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
HNSC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-7.51	3.09e-13	2.65e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
HNSC	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	7.51	3.09e-13	2.65e-10	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	7.51	3.1e-13	2.66e-10	0.59	0.33	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
HNSC	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-7.51	3.11e-13	2.66e-10	-0.51	-0.33	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
HNSC	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-7.51	3.11e-13	2.66e-10	-0.51	-0.33	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
HNSC	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-7.51	3.11e-13	2.66e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
HNSC	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-7.51	3.11e-13	2.66e-10	-0.38	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
HNSC	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.51	3.12e-13	2.67e-10	-0.31	-0.33	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
HNSC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-7.51	3.13e-13	2.68e-10	-0.31	-0.33	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-7.51	3.13e-13	2.68e-10	-0.31	-0.33	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	7.51	3.13e-13	2.68e-10	0.46	0.33	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
HNSC	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	7.5	3.15e-13	2.7e-10	0.34	0.33	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	7.5	3.15e-13	2.7e-10	0.31	0.33	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
HNSC	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	7.5	3.16e-13	2.7e-10	0.43	0.33	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-7.5	3.16e-13	2.7e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	7.5	3.16e-13	2.71e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
HNSC	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-7.5	3.16e-13	2.71e-10	-0.41	-0.33	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	7.5	3.18e-13	2.72e-10	0.45	0.33	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-7.5	3.18e-13	2.72e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-7.5	3.19e-13	2.73e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	7.5	3.2e-13	2.74e-10	0.3	0.33	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
HNSC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	7.5	3.21e-13	2.74e-10	0.4	0.33	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	7.5	3.21e-13	2.74e-10	0.4	0.33	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
HNSC	cis	rs17270561	0.609	rs9358885	ENSG00000272462.2	U91328.19	-7.5	3.21e-13	2.75e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25757796	chr6:25992662~26001775:+
HNSC	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	7.5	3.21e-13	2.75e-10	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
HNSC	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	7.5	3.22e-13	2.75e-10	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
HNSC	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-7.5	3.22e-13	2.75e-10	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
HNSC	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-7.5	3.24e-13	2.77e-10	-0.52	-0.33	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
HNSC	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-7.5	3.24e-13	2.77e-10	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-7.5	3.25e-13	2.77e-10	-0.43	-0.33	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
HNSC	cis	rs7942368	0.878	rs1866843	ENSG00000255100.1	RP11-21L23.3	7.5	3.25e-13	2.78e-10	0.42	0.33	Endometriosis;	chr11:76778292	chr11:76782581~76783062:-
HNSC	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-7.5	3.25e-13	2.78e-10	-0.47	-0.33	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
HNSC	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.5	3.27e-13	2.79e-10	0.41	0.33	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
HNSC	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	7.5	3.27e-13	2.8e-10	0.33	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
HNSC	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-7.5	3.28e-13	2.8e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-7.5	3.28e-13	2.8e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
HNSC	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	7.5	3.28e-13	2.8e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
HNSC	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	7.5	3.29e-13	2.81e-10	0.36	0.33	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
HNSC	cis	rs6951245	1	rs74652290	ENSG00000224079.1	AC091729.7	-7.5	3.3e-13	2.82e-10	-0.56	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1074450~1078036:+
HNSC	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	7.5	3.3e-13	2.82e-10	0.39	0.33	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
HNSC	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-7.5	3.32e-13	2.83e-10	-0.45	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
HNSC	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-7.5	3.33e-13	2.85e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	7.5	3.33e-13	2.85e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
HNSC	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-7.5	3.34e-13	2.85e-10	-0.37	-0.33	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
HNSC	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	7.5	3.34e-13	2.85e-10	0.34	0.33	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
HNSC	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-7.49	3.35e-13	2.86e-10	-0.35	-0.33	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
HNSC	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-7.49	3.36e-13	2.86e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-7.49	3.38e-13	2.88e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
HNSC	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	7.49	3.39e-13	2.89e-10	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
HNSC	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-7.49	3.41e-13	2.91e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	7.49	3.42e-13	2.91e-10	0.36	0.33	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
HNSC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-7.49	3.42e-13	2.91e-10	-0.36	-0.33	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
HNSC	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	7.49	3.42e-13	2.92e-10	0.31	0.33	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
HNSC	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-7.49	3.43e-13	2.92e-10	-0.4	-0.33	Height;	chr11:118859432	chr11:118704607~118750263:+
HNSC	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	7.49	3.44e-13	2.93e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	7.49	3.44e-13	2.93e-10	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	7.49	3.46e-13	2.95e-10	0.45	0.33	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	7.49	3.46e-13	2.95e-10	0.45	0.33	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	7.49	3.47e-13	2.95e-10	0.34	0.33	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	7.49	3.47e-13	2.95e-10	0.34	0.33	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
HNSC	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	7.49	3.47e-13	2.96e-10	0.36	0.33	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
HNSC	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-7.49	3.48e-13	2.96e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
HNSC	cis	rs451417	1	rs236110	ENSG00000275632.1	RP5-967N21.11	7.49	3.48e-13	2.96e-10	0.4	0.33	Menopause (age at onset);	chr20:5952462	chr20:6000418~6000941:+
HNSC	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.49	3.5e-13	2.98e-10	0.4	0.33	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	7.49	3.52e-13	2.99e-10	0.5	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
HNSC	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
HNSC	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-7.49	3.53e-13	3e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	7.49	3.53e-13	3e-10	0.23	0.33	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
HNSC	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	7.49	3.53e-13	3e-10	0.61	0.33	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	7.49	3.55e-13	3.02e-10	0.45	0.33	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	7.49	3.56e-13	3.03e-10	0.23	0.33	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
HNSC	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	7.49	3.56e-13	3.03e-10	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
HNSC	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	7.49	3.56e-13	3.03e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
HNSC	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	7.49	3.57e-13	3.03e-10	0.41	0.33	Height;	chr6:109471826	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	7.49	3.57e-13	3.03e-10	0.42	0.33	Height;	chr6:109346560	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	7.49	3.58e-13	3.04e-10	0.36	0.33	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
HNSC	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	7.49	3.58e-13	3.05e-10	0.37	0.33	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	7.48	3.6e-13	3.06e-10	0.31	0.33	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
HNSC	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	7.48	3.6e-13	3.06e-10	0.37	0.33	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
HNSC	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-7.48	3.61e-13	3.06e-10	-0.46	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
HNSC	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	7.48	3.61e-13	3.07e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
HNSC	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	7.48	3.62e-13	3.07e-10	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	7.48	3.63e-13	3.08e-10	0.41	0.33	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
HNSC	cis	rs6471393	0.929	rs4464937	ENSG00000253848.1	RP11-10N23.5	7.48	3.63e-13	3.09e-10	0.39	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744689	chr8:93741193~93744534:+
HNSC	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-7.48	3.65e-13	3.1e-10	-0.31	-0.33	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
HNSC	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	7.48	3.65e-13	3.1e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	7.48	3.65e-13	3.1e-10	0.61	0.33	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
HNSC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-7.48	3.66e-13	3.11e-10	-0.42	-0.33	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
HNSC	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-7.48	3.66e-13	3.11e-10	-0.47	-0.33	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	-7.48	3.67e-13	3.12e-10	-0.35	-0.33	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	7.48	3.68e-13	3.12e-10	0.23	0.33	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
HNSC	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.69e-13	3.13e-10	-0.37	-0.33	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
HNSC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	7.48	3.71e-13	3.15e-10	0.45	0.33	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
HNSC	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.71e-13	3.15e-10	-0.37	-0.33	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-7.48	3.71e-13	3.15e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	7.48	3.71e-13	3.15e-10	0.47	0.33	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-7.48	3.72e-13	3.16e-10	-0.41	-0.33	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-7.48	3.72e-13	3.16e-10	-0.35	-0.33	Height;	chr6:25872956	chr6:25992662~26001775:+
HNSC	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-7.48	3.72e-13	3.16e-10	-0.42	-0.33	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
HNSC	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	7.48	3.73e-13	3.16e-10	0.39	0.33	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	7.48	3.74e-13	3.17e-10	0.31	0.33	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	7.48	3.74e-13	3.17e-10	0.35	0.33	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
HNSC	cis	rs8062405	0.722	rs28729187	ENSG00000259982.1	CDC37P1	-7.48	3.75e-13	3.18e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28700294~28701540:-
HNSC	cis	rs8062405	0.789	rs28480369	ENSG00000259982.1	CDC37P1	-7.48	3.75e-13	3.18e-10	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28700294~28701540:-
HNSC	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.48	3.75e-13	3.18e-10	0.34	0.33	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
HNSC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	7.48	3.76e-13	3.19e-10	0.35	0.33	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	7.48	3.77e-13	3.19e-10	0.43	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
HNSC	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-7.48	3.77e-13	3.2e-10	-0.55	-0.33	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
HNSC	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.77e-13	3.2e-10	-0.37	-0.33	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	7.48	3.79e-13	3.21e-10	0.61	0.33	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-7.48	3.79e-13	3.21e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
HNSC	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	7.48	3.79e-13	3.21e-10	0.39	0.33	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
HNSC	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-7.48	3.79e-13	3.21e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-7.48	3.79e-13	3.21e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000267151.3	RP11-100E5.2	7.48	3.8e-13	3.22e-10	0.43	0.33	Menopause (age at onset);	chr17:43035667	chr17:43444707~43451200:+
HNSC	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	7.48	3.8e-13	3.22e-10	0.35	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	7.48	3.8e-13	3.22e-10	0.35	0.33	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-7.48	3.8e-13	3.22e-10	-0.53	-0.33	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
HNSC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-7.48	3.82e-13	3.23e-10	-0.35	-0.33	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
HNSC	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-7.48	3.82e-13	3.24e-10	-0.47	-0.33	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
HNSC	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-7.48	3.82e-13	3.24e-10	-0.47	-0.33	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-7.48	3.84e-13	3.25e-10	-0.61	-0.33	Gout;	chr7:66671562	chr7:66654538~66669855:+
HNSC	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.47	3.84e-13	3.25e-10	0.41	0.33	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-7.47	3.85e-13	3.26e-10	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-7.47	3.85e-13	3.26e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-7.47	3.86e-13	3.27e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-7.47	3.87e-13	3.28e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-7.47	3.87e-13	3.28e-10	-0.29	-0.33	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
HNSC	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-7.47	3.87e-13	3.28e-10	-0.42	-0.33	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
HNSC	cis	rs7942368	1	rs10899280	ENSG00000255100.1	RP11-21L23.3	7.47	3.88e-13	3.28e-10	0.41	0.33	Endometriosis;	chr11:76785693	chr11:76782581~76783062:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	7.47	3.9e-13	3.3e-10	0.41	0.33	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
HNSC	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-7.47	3.9e-13	3.3e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
HNSC	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-7.47	3.9e-13	3.3e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	7.47	3.92e-13	3.31e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.47	3.92e-13	3.32e-10	-0.36	-0.33	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-7.47	3.94e-13	3.33e-10	-0.4	-0.33	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000179406.6	LINC00174	-7.47	3.95e-13	3.34e-10	-0.51	-0.33	Aortic root size;	chr7:66370011	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66715944	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66721259	chr7:66654538~66669855:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-7.47	3.95e-13	3.34e-10	-0.61	-0.33	Gout;	chr7:66732812	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	7.47	3.95e-13	3.34e-10	0.62	0.33	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
HNSC	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.34e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	7.47	3.96e-13	3.34e-10	0.61	0.33	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
HNSC	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-7.47	3.96e-13	3.34e-10	-0.42	-0.33	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	7.47	3.96e-13	3.35e-10	0.33	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
HNSC	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	7.47	3.96e-13	3.35e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
HNSC	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-7.47	3.96e-13	3.35e-10	-0.35	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
HNSC	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	7.47	3.98e-13	3.36e-10	0.39	0.33	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	7.47	3.98e-13	3.36e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
HNSC	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	7.47	3.99e-13	3.37e-10	0.36	0.33	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
HNSC	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	7.47	3.99e-13	3.37e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	7.47	4.01e-13	3.39e-10	0.31	0.33	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
HNSC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-7.47	4.02e-13	3.39e-10	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-7.47	4.02e-13	3.39e-10	-0.54	-0.33	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-7.47	4.03e-13	3.4e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
HNSC	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-7.47	4.03e-13	3.4e-10	-0.47	-0.33	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
HNSC	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-7.47	4.04e-13	3.4e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
HNSC	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-7.47	4.04e-13	3.41e-10	-0.36	-0.33	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	7.47	4.05e-13	3.41e-10	0.31	0.33	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	7.47	4.05e-13	3.42e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.47	4.05e-13	3.42e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
HNSC	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-7.47	4.05e-13	3.42e-10	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
HNSC	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	7.47	4.07e-13	3.43e-10	0.54	0.33	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-7.47	4.11e-13	3.46e-10	-0.39	-0.33	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-7.47	4.11e-13	3.46e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
HNSC	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	7.46	4.11e-13	3.47e-10	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	7.46	4.12e-13	3.47e-10	0.61	0.33	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-7.46	4.12e-13	3.47e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
HNSC	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	7.46	4.15e-13	3.49e-10	0.33	0.33	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-7.46	4.15e-13	3.49e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-7.46	4.15e-13	3.49e-10	-0.62	-0.33	Gout;	chr7:66642037	chr7:66654538~66669855:+
HNSC	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-7.46	4.15e-13	3.49e-10	-0.4	-0.33	Height;	chr11:118860890	chr11:118704607~118750263:+
HNSC	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-7.46	4.15e-13	3.49e-10	-0.4	-0.33	Height;	chr11:118861053	chr11:118704607~118750263:+
HNSC	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-7.46	4.16e-13	3.5e-10	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
HNSC	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-7.46	4.16e-13	3.5e-10	-0.4	-0.33	Height;	chr11:118855233	chr11:118704607~118750263:+
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-7.46	4.18e-13	3.51e-10	-0.45	-0.33	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
HNSC	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	7.46	4.18e-13	3.51e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
HNSC	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-7.46	4.19e-13	3.52e-10	-0.33	-0.33	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
HNSC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	7.46	4.2e-13	3.53e-10	0.36	0.33	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	7.46	4.22e-13	3.54e-10	0.4	0.33	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
HNSC	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-7.46	4.22e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
HNSC	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-7.46	4.22e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
HNSC	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	7.46	4.23e-13	3.55e-10	0.35	0.33	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
HNSC	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-7.46	4.23e-13	3.55e-10	-0.47	-0.33	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
HNSC	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	7.46	4.24e-13	3.56e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
HNSC	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-7.46	4.24e-13	3.56e-10	-0.29	-0.33	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	7.46	4.25e-13	3.57e-10	0.37	0.33	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
HNSC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	7.46	4.25e-13	3.57e-10	0.4	0.33	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
HNSC	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	7.46	4.25e-13	3.57e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	7.46	4.26e-13	3.58e-10	0.34	0.33	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-7.46	4.27e-13	3.58e-10	-0.4	-0.33	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-7.46	4.27e-13	3.59e-10	-0.23	-0.33	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
HNSC	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-7.46	4.29e-13	3.6e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
HNSC	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-7.46	4.3e-13	3.61e-10	-0.47	-0.33	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
HNSC	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-7.46	4.3e-13	3.61e-10	-0.41	-0.33	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
HNSC	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.46	4.3e-13	3.61e-10	0.38	0.33	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.46	4.3e-13	3.61e-10	-0.46	-0.33	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
HNSC	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-7.46	4.33e-13	3.63e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-7.46	4.33e-13	3.63e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
HNSC	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	7.46	4.33e-13	3.63e-10	0.36	0.33	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
HNSC	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-7.46	4.33e-13	3.63e-10	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.59	-0.33	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-7.46	4.34e-13	3.64e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
HNSC	cis	rs6061231	0.958	rs2427304	ENSG00000273619.1	RP5-908M14.9	-7.46	4.35e-13	3.64e-10	-0.31	-0.33	Colorectal cancer;	chr20:62378528	chr20:62386303~62386970:-
HNSC	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	7.46	4.35e-13	3.65e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
HNSC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	7.46	4.35e-13	3.65e-10	0.34	0.33	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
HNSC	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	7.46	4.36e-13	3.65e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-7.46	4.36e-13	3.65e-10	-0.42	-0.33	Depression;	chr6:28197321	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-7.46	4.36e-13	3.65e-10	-0.42	-0.33	Depression;	chr6:28197412	chr6:28115628~28116551:+
HNSC	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-7.46	4.37e-13	3.66e-10	-0.45	-0.33	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
HNSC	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-7.46	4.37e-13	3.66e-10	-0.41	-0.33	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
HNSC	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	7.46	4.39e-13	3.67e-10	0.39	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
HNSC	cis	rs1865760	0.566	rs9467663	ENSG00000272462.2	U91328.19	-7.46	4.39e-13	3.67e-10	-0.32	-0.33	Height;	chr6:26021228	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	7.46	4.39e-13	3.67e-10	0.41	0.33	Depression;	chr6:28200948	chr6:28115628~28116551:+
HNSC	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-7.46	4.39e-13	3.67e-10	-0.5	-0.33	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
HNSC	cis	rs7048146	0.832	rs10979945	ENSG00000213539.4	YBX1P6	7.46	4.39e-13	3.67e-10	0.38	0.33	Vascular brain injury;	chr9:109582456	chr9:109532830~109534332:-
HNSC	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	7.45	4.4e-13	3.69e-10	0.41	0.33	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
HNSC	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-7.45	4.42e-13	3.7e-10	-0.38	-0.33	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
HNSC	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	7.45	4.44e-13	3.71e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-7.45	4.44e-13	3.72e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-7.45	4.46e-13	3.73e-10	-0.44	-0.33	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
HNSC	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-7.45	4.47e-13	3.74e-10	-0.4	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
HNSC	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	7.45	4.48e-13	3.74e-10	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
HNSC	cis	rs17270561	0.609	rs1937131	ENSG00000272462.2	U91328.19	7.45	4.48e-13	3.74e-10	0.34	0.33	Iron status biomarkers;	chr6:25744603	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-7.45	4.48e-13	3.75e-10	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
HNSC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7.45	4.48e-13	3.75e-10	0.34	0.33	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
HNSC	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	7.45	4.52e-13	3.78e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
HNSC	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-7.45	4.52e-13	3.78e-10	-0.52	-0.33	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-7.45	4.53e-13	3.79e-10	-0.52	-0.33	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	7.45	4.55e-13	3.8e-10	0.23	0.33	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	7.45	4.57e-13	3.82e-10	0.34	0.33	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
HNSC	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-7.45	4.57e-13	3.82e-10	-0.5	-0.33	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
HNSC	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-7.45	4.57e-13	3.82e-10	-0.5	-0.33	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
HNSC	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	7.45	4.57e-13	3.82e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
HNSC	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-7.45	4.58e-13	3.82e-10	-0.36	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000241288.6	RP11-379B18.5	-7.45	4.58e-13	3.83e-10	-0.42	-0.33	Blood pressure (smoking interaction);	chr3:125991896	chr3:125827238~125916384:-
HNSC	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	7.45	4.58e-13	3.83e-10	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
HNSC	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	7.45	4.59e-13	3.83e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
HNSC	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	7.45	4.59e-13	3.84e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
HNSC	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	7.45	4.59e-13	3.84e-10	0.41	0.33	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
HNSC	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	7.45	4.61e-13	3.85e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	7.45	4.61e-13	3.85e-10	0.44	0.33	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
HNSC	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-7.45	4.63e-13	3.86e-10	-0.37	-0.33	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
HNSC	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	7.45	4.63e-13	3.87e-10	0.39	0.33	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
HNSC	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	7.45	4.67e-13	3.9e-10	0.39	0.33	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	7.45	4.69e-13	3.91e-10	0.37	0.33	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
HNSC	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-7.45	4.7e-13	3.92e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
HNSC	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	7.45	4.7e-13	3.92e-10	0.36	0.33	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-7.44	4.73e-13	3.94e-10	-0.44	-0.33	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
HNSC	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	7.44	4.73e-13	3.94e-10	0.4	0.33	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	7.44	4.73e-13	3.94e-10	0.4	0.33	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-7.44	4.73e-13	3.94e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	7.44	4.74e-13	3.95e-10	0.42	0.33	Depression;	chr6:28199145	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	7.44	4.75e-13	3.95e-10	0.4	0.33	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	7.44	4.75e-13	3.96e-10	0.43	0.33	Height;	chr6:109715504	chr6:109382795~109383666:+
HNSC	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.76e-13	3.96e-10	-0.36	-0.33	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
HNSC	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	7.44	4.77e-13	3.97e-10	0.36	0.33	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	7.44	4.77e-13	3.97e-10	0.45	0.33	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
HNSC	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-7.44	4.77e-13	3.97e-10	-0.62	-0.33	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-7.44	4.78e-13	3.98e-10	-0.43	-0.33	Depression;	chr6:28206812	chr6:28115628~28116551:+
HNSC	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	7.44	4.78e-13	3.98e-10	0.42	0.33	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
HNSC	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	7.44	4.78e-13	3.98e-10	0.33	0.33	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
HNSC	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.44	4.79e-13	3.99e-10	0.36	0.33	Migraine;	chr4:56881468	chr4:56960927~56961373:-
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	7.44	4.8e-13	3.99e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
HNSC	cis	rs6951245	1	rs78185558	ENSG00000224079.1	AC091729.7	-7.44	4.8e-13	3.99e-10	-0.56	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1074450~1078036:+
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	7.44	4.8e-13	3.99e-10	0.23	0.33	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
HNSC	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	7.44	4.83e-13	4.02e-10	0.36	0.33	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.83e-13	4.02e-10	-0.37	-0.33	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.44	4.83e-13	4.02e-10	-0.37	-0.33	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
HNSC	cis	rs1865760	0.516	rs9379818	ENSG00000272462.2	U91328.19	-7.44	4.84e-13	4.02e-10	-0.32	-0.33	Height;	chr6:26022978	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.44	4.85e-13	4.03e-10	-0.43	-0.33	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	7.44	4.85e-13	4.03e-10	0.23	0.33	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
HNSC	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	7.44	4.86e-13	4.04e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
HNSC	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-7.44	4.86e-13	4.04e-10	-0.37	-0.33	Height;	chr3:52994359	chr3:53064283~53065091:-
HNSC	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	7.44	4.87e-13	4.05e-10	0.36	0.33	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	7.44	4.87e-13	4.05e-10	0.36	0.33	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
HNSC	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	7.44	4.88e-13	4.06e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	7.44	4.88e-13	4.06e-10	0.34	0.33	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-7.44	4.89e-13	4.06e-10	-0.38	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
HNSC	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	7.44	4.91e-13	4.08e-10	0.37	0.33	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
HNSC	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-7.44	4.92e-13	4.09e-10	-0.32	-0.33	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
HNSC	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-7.44	4.93e-13	4.1e-10	-0.33	-0.33	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
HNSC	cis	rs7942368	1	rs11236924	ENSG00000255100.1	RP11-21L23.3	7.44	4.95e-13	4.11e-10	0.43	0.33	Endometriosis;	chr11:76756303	chr11:76782581~76783062:-
HNSC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	7.44	4.95e-13	4.11e-10	0.44	0.33	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	7.44	4.97e-13	4.13e-10	0.36	0.33	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	7.44	5e-13	4.15e-10	0.23	0.33	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
HNSC	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-7.44	5e-13	4.15e-10	-0.51	-0.33	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
HNSC	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	7.44	5.03e-13	4.17e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.609	rs9358886	ENSG00000272462.2	U91328.19	-7.44	5.03e-13	4.18e-10	-0.34	-0.33	Iron status biomarkers;	chr6:25758025	chr6:25992662~26001775:+
HNSC	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	7.44	5.03e-13	4.18e-10	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
HNSC	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	7.44	5.04e-13	4.18e-10	0.36	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
HNSC	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-7.43	5.04e-13	4.19e-10	-0.49	-0.33	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
HNSC	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	7.43	5.06e-13	4.2e-10	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
HNSC	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.43	5.07e-13	4.21e-10	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
HNSC	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-7.43	5.07e-13	4.21e-10	-0.37	-0.33	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-7.43	5.09e-13	4.22e-10	-0.51	-0.33	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-7.43	5.09e-13	4.22e-10	-0.6	-0.33	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	7.43	5.09e-13	4.23e-10	0.23	0.33	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
HNSC	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.43	5.13e-13	4.26e-10	0.36	0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
HNSC	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	7.43	5.14e-13	4.26e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	7.43	5.15e-13	4.27e-10	0.23	0.33	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	7.43	5.15e-13	4.27e-10	0.23	0.33	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-7.43	5.15e-13	4.27e-10	-0.4	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
HNSC	cis	rs6844153	0.938	rs77926313	ENSG00000240005.4	RP11-293A21.1	-7.43	5.16e-13	4.28e-10	-0.49	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26965420	chr4:26859806~26860599:-
HNSC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-7.43	5.18e-13	4.29e-10	-0.43	-0.33	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
HNSC	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-7.43	5.18e-13	4.3e-10	-0.32	-0.33	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
HNSC	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-7.43	5.19e-13	4.3e-10	-0.41	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	7.43	5.19e-13	4.3e-10	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
HNSC	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-7.43	5.22e-13	4.33e-10	-0.29	-0.33	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
HNSC	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-7.43	5.23e-13	4.33e-10	-0.49	-0.33	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
HNSC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-7.43	5.28e-13	4.37e-10	-0.36	-0.33	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
HNSC	cis	rs1799949	1	rs11653231	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43179443	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43180313	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43181769	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43185883	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000267151.3	RP11-100E5.2	7.43	5.28e-13	4.37e-10	0.42	0.33	Menopause (age at onset);	chr17:43190296	chr17:43444707~43451200:+
HNSC	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	7.43	5.29e-13	4.38e-10	0.34	0.33	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	7.43	5.29e-13	4.38e-10	0.34	0.33	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
HNSC	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	7.43	5.3e-13	4.39e-10	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-7.43	5.31e-13	4.39e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-7.43	5.32e-13	4.4e-10	-0.61	-0.33	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-7.43	5.32e-13	4.4e-10	-0.33	-0.33	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
HNSC	cis	rs867371	0.929	rs1501371	ENSG00000255769.6	GOLGA2P10	-7.43	5.33e-13	4.41e-10	-0.42	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	7.43	5.35e-13	4.43e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
HNSC	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	7.43	5.37e-13	4.44e-10	0.34	0.32	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	7.43	5.38e-13	4.44e-10	0.33	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
HNSC	cis	rs875971	0.545	rs221986	ENSG00000179406.6	LINC00174	7.43	5.39e-13	4.45e-10	0.51	0.32	Aortic root size;	chr7:66105323	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000241288.6	RP11-379B18.5	-7.43	5.39e-13	4.45e-10	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125989134	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-7.42	5.39e-13	4.46e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
HNSC	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.4e-13	4.46e-10	-0.36	-0.32	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
HNSC	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-7.42	5.4e-13	4.46e-10	-0.45	-0.32	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
HNSC	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-7.42	5.4e-13	4.47e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	7.42	5.41e-13	4.47e-10	0.38	0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
HNSC	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.44e-13	4.5e-10	-0.37	-0.32	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
HNSC	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-7.42	5.45e-13	4.5e-10	-0.37	-0.32	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
HNSC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	7.42	5.46e-13	4.51e-10	0.37	0.32	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
HNSC	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	7.42	5.47e-13	4.52e-10	0.39	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66363676	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66374173	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000179406.6	LINC00174	-7.42	5.48e-13	4.53e-10	-0.5	-0.32	Aortic root size;	chr7:66376216	chr7:66376044~66401338:-
HNSC	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	7.42	5.5e-13	4.54e-10	0.41	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	7.42	5.5e-13	4.54e-10	0.23	0.32	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.42	5.5e-13	4.54e-10	-0.37	-0.32	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	7.42	5.5e-13	4.54e-10	0.32	0.32	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	7.42	5.5e-13	4.54e-10	0.32	0.32	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	7.42	5.55e-13	4.58e-10	0.31	0.32	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
HNSC	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-7.42	5.59e-13	4.62e-10	-0.37	-0.32	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
HNSC	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	7.42	5.61e-13	4.63e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	7.42	5.64e-13	4.65e-10	0.23	0.32	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
HNSC	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	7.42	5.65e-13	4.66e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66387213	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66474464	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66480545	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000179406.6	LINC00174	-7.42	5.66e-13	4.67e-10	-0.49	-0.32	Aortic root size;	chr7:66481592	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-7.42	5.66e-13	4.67e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
HNSC	cis	rs1021993	0.545	rs6681466	ENSG00000231648.1	RP11-372M18.2	-7.42	5.66e-13	4.67e-10	-0.53	-0.32	Gut microbiome composition (winter);	chr1:209355913	chr1:209367662~209379690:+
HNSC	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	7.42	5.69e-13	4.69e-10	0.28	0.32	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
HNSC	cis	rs1021993	0.545	rs55684110	ENSG00000231648.1	RP11-372M18.2	-7.42	5.7e-13	4.69e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209368487	chr1:209367662~209379690:+
HNSC	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-7.42	5.71e-13	4.7e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
HNSC	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	7.42	5.72e-13	4.71e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000267151.3	RP11-100E5.2	7.42	5.73e-13	4.72e-10	0.42	0.32	Menopause (age at onset);	chr17:43368092	chr17:43444707~43451200:+
HNSC	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.42	5.74e-13	4.72e-10	-0.37	-0.32	Migraine;	chr4:56880659	chr4:56960927~56961373:-
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-7.42	5.74e-13	4.72e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
HNSC	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-7.42	5.74e-13	4.73e-10	-0.32	-0.32	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
HNSC	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.42	5.76e-13	4.74e-10	-0.37	-0.32	Migraine;	chr4:56880190	chr4:56960927~56961373:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000179406.6	LINC00174	7.41	5.78e-13	4.76e-10	0.5	0.32	Aortic root size;	chr7:66646886	chr7:66376044~66401338:-
HNSC	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-7.41	5.79e-13	4.76e-10	-0.42	-0.32	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
HNSC	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.41	5.82e-13	4.78e-10	-0.36	-0.32	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	7.41	5.82e-13	4.79e-10	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
HNSC	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	7.41	5.82e-13	4.79e-10	0.41	0.32	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
HNSC	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7.41	5.82e-13	4.79e-10	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	7.41	5.86e-13	4.82e-10	0.6	0.32	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
HNSC	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	7.41	5.86e-13	4.82e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
HNSC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-7.41	5.87e-13	4.82e-10	-0.42	-0.32	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	7.41	5.87e-13	4.83e-10	0.23	0.32	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
HNSC	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-7.41	5.9e-13	4.85e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	7.41	5.9e-13	4.85e-10	0.29	0.32	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
HNSC	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-7.41	5.92e-13	4.86e-10	-0.29	-0.32	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
HNSC	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-7.41	5.93e-13	4.87e-10	-0.35	-0.32	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
HNSC	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-7.41	5.94e-13	4.88e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
HNSC	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-7.41	5.96e-13	4.9e-10	-0.38	-0.32	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
HNSC	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-7.41	5.97e-13	4.9e-10	-0.35	-0.32	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
HNSC	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-7.41	5.98e-13	4.91e-10	-0.47	-0.32	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	7.41	6.01e-13	4.94e-10	0.45	0.32	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
HNSC	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-7.41	6.01e-13	4.94e-10	-0.36	-0.32	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-7.41	6.01e-13	4.94e-10	-0.36	-0.32	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
HNSC	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-7.41	6.05e-13	4.97e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
HNSC	cis	rs451417	1	rs236102	ENSG00000275632.1	RP5-967N21.11	7.41	6.06e-13	4.97e-10	0.39	0.32	Menopause (age at onset);	chr20:5971320	chr20:6000418~6000941:+
HNSC	cis	rs6472866	1	rs6472866	ENSG00000254349.4	FLJ39080	7.41	6.06e-13	4.97e-10	0.36	0.32	Protein quantitative trait loci;	chr8:74600899	chr8:74599775~74823313:+
HNSC	cis	rs6472866	0.967	rs6472867	ENSG00000254349.4	FLJ39080	7.41	6.06e-13	4.97e-10	0.36	0.32	Protein quantitative trait loci;	chr8:74601596	chr8:74599775~74823313:+
HNSC	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	7.41	6.07e-13	4.98e-10	0.39	0.32	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	7.41	6.07e-13	4.98e-10	0.39	0.32	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	7.41	6.07e-13	4.98e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
HNSC	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	7.41	6.07e-13	4.98e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
HNSC	cis	rs9595066	0.627	rs2246432	ENSG00000227258.4	SMIM2-AS1	-7.41	6.07e-13	4.99e-10	-0.49	-0.32	Schizophrenia;	chr13:44182648	chr13:44110451~44240517:+
HNSC	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-7.41	6.08e-13	4.99e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
HNSC	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	7.41	6.08e-13	4.99e-10	0.47	0.32	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
HNSC	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-7.41	6.11e-13	5.01e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
HNSC	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	7.4	6.22e-13	5.1e-10	0.41	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	7.4	6.22e-13	5.1e-10	0.41	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
HNSC	cis	rs7942368	1	rs1837679	ENSG00000255100.1	RP11-21L23.3	7.4	6.22e-13	5.1e-10	0.42	0.32	Endometriosis;	chr11:76790513	chr11:76782581~76783062:-
HNSC	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-7.4	6.23e-13	5.11e-10	-0.34	-0.32	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
HNSC	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-7.4	6.28e-13	5.15e-10	-0.29	-0.32	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
HNSC	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.4	6.29e-13	5.15e-10	0.4	0.32	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
HNSC	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-7.4	6.29e-13	5.15e-10	-0.33	-0.32	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-7.4	6.29e-13	5.16e-10	-0.6	-0.32	Gout;	chr7:66693028	chr7:66654538~66669855:+
HNSC	cis	rs12922040	0.651	rs35288467	ENSG00000263065.1	AF001548.6	-7.4	6.32e-13	5.17e-10	-0.37	-0.32	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15741151~15741791:+
HNSC	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-7.4	6.32e-13	5.18e-10	-0.52	-0.32	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	7.4	6.33e-13	5.18e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
HNSC	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	7.4	6.33e-13	5.19e-10	0.44	0.32	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-7.4	6.34e-13	5.19e-10	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
HNSC	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-7.4	6.35e-13	5.2e-10	-0.3	-0.32	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
HNSC	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-7.4	6.36e-13	5.21e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-7.4	6.36e-13	5.21e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-7.4	6.38e-13	5.22e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
HNSC	cis	rs7942368	0.941	rs11236936	ENSG00000255100.1	RP11-21L23.3	7.4	6.42e-13	5.26e-10	0.41	0.32	Endometriosis;	chr11:76789786	chr11:76782581~76783062:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	7.4	6.44e-13	5.27e-10	0.22	0.32	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
HNSC	cis	rs7048146	0.899	rs7861587	ENSG00000213539.4	YBX1P6	7.4	6.45e-13	5.28e-10	0.38	0.32	Vascular brain injury;	chr9:109584316	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.899	rs884919	ENSG00000213539.4	YBX1P6	7.4	6.45e-13	5.28e-10	0.38	0.32	Vascular brain injury;	chr9:109585693	chr9:109532830~109534332:-
HNSC	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-7.4	6.46e-13	5.29e-10	-0.51	-0.32	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	7.4	6.47e-13	5.29e-10	0.23	0.32	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
HNSC	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-7.4	6.48e-13	5.3e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
HNSC	cis	rs1865760	0.602	rs9467662	ENSG00000272462.2	U91328.19	-7.4	6.48e-13	5.3e-10	-0.32	-0.32	Height;	chr6:26021099	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-7.4	6.49e-13	5.31e-10	-0.43	-0.32	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
HNSC	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-7.4	6.49e-13	5.31e-10	-0.32	-0.32	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
HNSC	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	7.4	6.5e-13	5.32e-10	0.33	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
HNSC	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	7.4	6.51e-13	5.32e-10	0.41	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
HNSC	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-7.4	6.51e-13	5.32e-10	-0.29	-0.32	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
HNSC	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-7.4	6.53e-13	5.34e-10	-0.38	-0.32	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	7.4	6.58e-13	5.38e-10	0.33	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	7.4	6.59e-13	5.39e-10	0.44	0.32	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	7.39	6.61e-13	5.4e-10	0.45	0.32	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
HNSC	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	7.39	6.62e-13	5.41e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000267151.3	RP11-100E5.2	7.39	6.62e-13	5.41e-10	0.42	0.32	Menopause (age at onset);	chr17:43181999	chr17:43444707~43451200:+
HNSC	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-7.39	6.62e-13	5.41e-10	-0.48	-0.32	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
HNSC	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	7.39	6.7e-13	5.47e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
HNSC	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	7.39	6.7e-13	5.47e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	7.39	6.71e-13	5.48e-10	0.46	0.32	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
HNSC	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	7.39	6.71e-13	5.48e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
HNSC	cis	rs35955747	0.633	rs2006771	ENSG00000236132.1	CTA-440B3.1	7.39	6.71e-13	5.48e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31602626	chr22:31816379~31817491:-
HNSC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-7.39	6.72e-13	5.48e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
HNSC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	7.39	6.75e-13	5.51e-10	0.34	0.32	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
HNSC	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-7.39	6.77e-13	5.53e-10	-0.35	-0.32	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	7.39	6.78e-13	5.54e-10	0.23	0.32	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
HNSC	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	7.39	6.8e-13	5.55e-10	0.36	0.32	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	7.39	6.8e-13	5.55e-10	0.36	0.32	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	-7.39	6.8e-13	5.55e-10	-0.35	-0.32	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-7.39	6.81e-13	5.56e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
HNSC	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	7.39	6.82e-13	5.56e-10	0.34	0.32	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
HNSC	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-7.39	6.84e-13	5.58e-10	-0.65	-0.32	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
HNSC	cis	rs875971	0.545	rs1638735	ENSG00000179406.6	LINC00174	-7.39	6.85e-13	5.59e-10	-0.5	-0.32	Aortic root size;	chr7:66630751	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	7.39	6.89e-13	5.62e-10	0.23	0.32	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
HNSC	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-7.39	6.93e-13	5.65e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
HNSC	cis	rs1799949	1	rs2271574	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43175631	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43176801	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43176993	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000267151.3	RP11-100E5.2	7.39	6.93e-13	5.65e-10	0.42	0.32	Menopause (age at onset);	chr17:43177155	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-7.39	6.95e-13	5.67e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-7.39	6.95e-13	5.67e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
HNSC	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-7.39	6.95e-13	5.67e-10	-0.41	-0.32	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
HNSC	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	7.39	6.96e-13	5.68e-10	0.4	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
HNSC	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-7.39	6.99e-13	5.69e-10	-0.37	-0.32	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
HNSC	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-7.39	7e-13	5.71e-10	-0.39	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
HNSC	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-7.39	7e-13	5.71e-10	-0.39	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
HNSC	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	7.39	7.01e-13	5.71e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
HNSC	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-7.39	7.03e-13	5.73e-10	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
HNSC	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	7.39	7.06e-13	5.75e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-7.39	7.06e-13	5.75e-10	-0.43	-0.32	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
HNSC	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	7.38	7.07e-13	5.76e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
HNSC	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	7.38	7.07e-13	5.76e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	7.38	7.07e-13	5.76e-10	0.38	0.32	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
HNSC	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	7.38	7.09e-13	5.77e-10	0.33	0.32	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
HNSC	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	7.38	7.09e-13	5.78e-10	0.34	0.32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
HNSC	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	7.38	7.1e-13	5.78e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
HNSC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	7.38	7.11e-13	5.79e-10	0.42	0.32	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
HNSC	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	7.38	7.12e-13	5.8e-10	0.37	0.32	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
HNSC	cis	rs1865760	0.602	rs2157050	ENSG00000272462.2	U91328.19	-7.38	7.13e-13	5.81e-10	-0.31	-0.32	Height;	chr6:26020203	chr6:25992662~26001775:+
HNSC	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	7.38	7.14e-13	5.81e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-7.38	7.14e-13	5.81e-10	-0.39	-0.32	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
HNSC	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-7.38	7.16e-13	5.83e-10	-0.35	-0.32	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000276710.3	CSPG4P8	-7.38	7.16e-13	5.83e-10	-0.37	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-7.38	7.16e-13	5.83e-10	-0.22	-0.32	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	7.38	7.18e-13	5.84e-10	0.43	0.32	Height;	chr6:109715560	chr6:109382795~109383666:+
HNSC	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-7.38	7.2e-13	5.86e-10	-0.32	-0.32	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	7.38	7.21e-13	5.86e-10	0.35	0.32	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
HNSC	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-7.38	7.21e-13	5.87e-10	-0.38	-0.32	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
HNSC	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	7.38	7.22e-13	5.88e-10	0.53	0.32	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
HNSC	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	7.38	7.29e-13	5.93e-10	0.32	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
HNSC	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	7.38	7.31e-13	5.94e-10	0.41	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
HNSC	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-7.38	7.32e-13	5.95e-10	-0.37	-0.32	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
HNSC	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.38	7.32e-13	5.95e-10	-0.3	-0.32	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
HNSC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	7.38	7.33e-13	5.96e-10	0.39	0.32	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
HNSC	cis	rs10080237	0.564	rs2490230	ENSG00000272129.1	RP11-250B2.6	7.38	7.36e-13	5.98e-10	0.37	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80355424~80356859:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-7.38	7.36e-13	5.98e-10	-0.48	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
HNSC	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-7.38	7.39e-13	6.01e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
HNSC	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-7.38	7.41e-13	6.02e-10	-0.29	-0.32	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-7.38	7.43e-13	6.04e-10	-0.3	-0.32	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-7.38	7.44e-13	6.04e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
HNSC	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-7.38	7.44e-13	6.04e-10	-0.4	-0.32	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
HNSC	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	7.38	7.45e-13	6.05e-10	0.37	0.32	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
HNSC	cis	rs1021993	0.868	rs906348	ENSG00000231648.1	RP11-372M18.2	-7.38	7.46e-13	6.06e-10	-0.44	-0.32	Gut microbiome composition (winter);	chr1:209355001	chr1:209367662~209379690:+
HNSC	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	7.38	7.46e-13	6.06e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
HNSC	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-7.38	7.46e-13	6.06e-10	-0.42	-0.32	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
HNSC	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	7.38	7.47e-13	6.06e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
HNSC	cis	rs904251	0.561	rs4714070	ENSG00000204110.6	RP1-153P14.8	-7.38	7.49e-13	6.08e-10	-0.32	-0.32	Cognitive performance;	chr6:37505422	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	7.38	7.52e-13	6.1e-10	0.3	0.32	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
HNSC	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	7.38	7.52e-13	6.1e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	7.38	7.53e-13	6.11e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
HNSC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-7.38	7.53e-13	6.11e-10	-0.43	-0.32	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.38	7.53e-13	6.11e-10	-0.37	-0.32	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-7.38	7.54e-13	6.12e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	7.38	7.54e-13	6.12e-10	0.45	0.32	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
HNSC	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	7.38	7.54e-13	6.12e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
HNSC	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-7.37	7.56e-13	6.14e-10	-0.32	-0.32	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
HNSC	cis	rs6061231	0.958	rs2379126	ENSG00000273619.1	RP5-908M14.9	-7.37	7.57e-13	6.14e-10	-0.31	-0.32	Colorectal cancer;	chr20:62377949	chr20:62386303~62386970:-
HNSC	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-7.37	7.57e-13	6.14e-10	-0.47	-0.32	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
HNSC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-7.37	7.58e-13	6.15e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-7.37	7.58e-13	6.15e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
HNSC	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-7.37	7.59e-13	6.16e-10	-0.33	-0.32	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
HNSC	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-7.37	7.59e-13	6.16e-10	-0.29	-0.32	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	7.37	7.6e-13	6.16e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	7.37	7.6e-13	6.16e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
HNSC	cis	rs7942368	0.941	rs737185	ENSG00000255100.1	RP11-21L23.3	7.37	7.6e-13	6.16e-10	0.41	0.32	Endometriosis;	chr11:76774314	chr11:76782581~76783062:-
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	7.37	7.6e-13	6.17e-10	0.36	0.32	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
HNSC	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	7.37	7.61e-13	6.17e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
HNSC	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	7.37	7.61e-13	6.17e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-7.37	7.61e-13	6.17e-10	-0.62	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
HNSC	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	7.37	7.61e-13	6.17e-10	0.32	0.32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
HNSC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	7.37	7.62e-13	6.17e-10	0.31	0.32	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	7.37	7.62e-13	6.17e-10	0.31	0.32	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
HNSC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	7.37	7.63e-13	6.18e-10	0.39	0.32	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-7.37	7.65e-13	6.2e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	7.37	7.65e-13	6.2e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	7.37	7.67e-13	6.22e-10	0.46	0.32	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
HNSC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	7.37	7.68e-13	6.23e-10	0.39	0.32	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
HNSC	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-7.37	7.74e-13	6.27e-10	-0.42	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
HNSC	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	7.37	7.79e-13	6.31e-10	0.38	0.32	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
HNSC	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-7.37	7.8e-13	6.32e-10	-0.32	-0.32	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
HNSC	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-7.37	7.81e-13	6.32e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
HNSC	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.83e-13	6.33e-10	-0.37	-0.32	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.83e-13	6.33e-10	-0.37	-0.32	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
HNSC	cis	rs6471393	0.964	rs16916186	ENSG00000253848.1	RP11-10N23.5	7.37	7.83e-13	6.34e-10	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93733158	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-7.37	7.87e-13	6.36e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
HNSC	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-7.37	7.92e-13	6.4e-10	-0.35	-0.32	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
HNSC	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-7.37	7.92e-13	6.41e-10	-0.48	-0.32	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
HNSC	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	7.37	7.93e-13	6.41e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
HNSC	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	7.37	7.94e-13	6.42e-10	0.39	0.32	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
HNSC	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	7.37	7.94e-13	6.42e-10	0.38	0.32	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
HNSC	cis	rs6951245	0.872	rs57068908	ENSG00000224079.1	AC091729.7	-7.37	7.96e-13	6.44e-10	-0.51	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1074450~1078036:+
HNSC	cis	rs17270561	0.666	rs3923725	ENSG00000272462.2	U91328.19	-7.36	8.09e-13	6.53e-10	-0.34	-0.32	Iron status biomarkers;	chr6:25734692	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-7.36	8.11e-13	6.55e-10	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
HNSC	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.13e-13	6.57e-10	-0.34	-0.32	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
HNSC	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	7.36	8.13e-13	6.57e-10	0.59	0.32	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.14e-13	6.58e-10	-0.36	-0.32	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	7.36	8.16e-13	6.59e-10	0.22	0.32	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
HNSC	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	7.36	8.16e-13	6.59e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
HNSC	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-7.36	8.17e-13	6.59e-10	-0.49	-0.32	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
HNSC	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
HNSC	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	7.36	8.17e-13	6.59e-10	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	7.36	8.18e-13	6.6e-10	0.23	0.32	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
HNSC	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	7.36	8.19e-13	6.61e-10	0.35	0.32	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
HNSC	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	7.36	8.19e-13	6.61e-10	0.36	0.32	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
HNSC	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	7.36	8.21e-13	6.62e-10	0.35	0.32	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	7.36	8.21e-13	6.62e-10	0.35	0.32	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
HNSC	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.36	8.21e-13	6.62e-10	-0.42	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	7.36	8.24e-13	6.65e-10	0.23	0.32	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
HNSC	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	7.36	8.28e-13	6.67e-10	0.52	0.32	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
HNSC	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	7.36	8.28e-13	6.67e-10	0.52	0.32	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
HNSC	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	7.36	8.29e-13	6.68e-10	0.36	0.32	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	7.36	8.29e-13	6.68e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
HNSC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	7.36	8.3e-13	6.69e-10	0.44	0.32	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000267151.3	RP11-100E5.2	7.36	8.3e-13	6.69e-10	0.43	0.32	Menopause (age at onset);	chr17:43043008	chr17:43444707~43451200:+
HNSC	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-7.36	8.3e-13	6.69e-10	-0.49	-0.32	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	7.36	8.33e-13	6.71e-10	0.6	0.32	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
HNSC	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	7.36	8.34e-13	6.72e-10	0.37	0.32	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
HNSC	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	7.36	8.36e-13	6.73e-10	0.34	0.32	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
HNSC	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	7.36	8.36e-13	6.73e-10	0.34	0.32	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
HNSC	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	7.36	8.37e-13	6.75e-10	0.37	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
HNSC	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-7.36	8.38e-13	6.75e-10	-0.3	-0.32	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
HNSC	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	7.36	8.38e-13	6.75e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-7.36	8.39e-13	6.76e-10	-0.29	-0.32	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-7.36	8.39e-13	6.76e-10	-0.29	-0.32	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
HNSC	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
HNSC	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
HNSC	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	7.36	8.41e-13	6.77e-10	0.36	0.32	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
HNSC	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	7.36	8.41e-13	6.77e-10	0.36	0.32	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
HNSC	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-7.36	8.41e-13	6.77e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.36	8.42e-13	6.78e-10	-0.37	-0.32	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-7.36	8.43e-13	6.79e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-7.36	8.43e-13	6.79e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
HNSC	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-7.36	8.44e-13	6.8e-10	-0.51	-0.32	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-7.36	8.46e-13	6.81e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
HNSC	cis	rs12439619	0.693	rs28689861	ENSG00000276710.3	CSPG4P8	-7.36	8.46e-13	6.81e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82459472~82477258:+
HNSC	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	7.36	8.47e-13	6.82e-10	0.35	0.32	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	7.36	8.47e-13	6.82e-10	0.35	0.32	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
HNSC	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-7.36	8.49e-13	6.83e-10	-0.34	-0.32	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	7.36	8.51e-13	6.85e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-7.36	8.53e-13	6.86e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-7.36	8.55e-13	6.88e-10	-0.51	-0.32	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-7.36	8.55e-13	6.88e-10	-0.29	-0.32	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
HNSC	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	7.36	8.57e-13	6.89e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
HNSC	cis	rs1799949	1	rs8176126	ENSG00000267151.3	RP11-100E5.2	-7.36	8.58e-13	6.9e-10	-0.41	-0.32	Menopause (age at onset);	chr17:43107032	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-7.36	8.58e-13	6.9e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
HNSC	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	7.36	8.58e-13	6.9e-10	0.37	0.32	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
HNSC	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-7.36	8.59e-13	6.91e-10	-0.46	-0.32	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
HNSC	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-7.36	8.61e-13	6.92e-10	-0.4	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
HNSC	cis	rs4141404	0.604	rs5753625	ENSG00000236132.1	CTA-440B3.1	7.36	8.62e-13	6.93e-10	0.36	0.32	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31816379~31817491:-
HNSC	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-7.36	8.63e-13	6.93e-10	-0.31	-0.32	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-7.36	8.63e-13	6.93e-10	-0.43	-0.32	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
HNSC	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	7.36	8.63e-13	6.94e-10	0.41	0.32	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
HNSC	cis	rs451417	1	rs379418	ENSG00000275632.1	RP5-967N21.11	7.35	8.67e-13	6.96e-10	0.39	0.32	Menopause (age at onset);	chr20:5961561	chr20:6000418~6000941:+
HNSC	cis	rs6951245	0.638	rs74976697	ENSG00000224079.1	AC091729.7	-7.35	8.67e-13	6.97e-10	-0.5	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1074450~1078036:+
HNSC	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-7.35	8.69e-13	6.98e-10	-0.5	-0.32	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
HNSC	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	7.35	8.72e-13	7e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
HNSC	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	7.35	8.74e-13	7.02e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	7.35	8.74e-13	7.02e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
HNSC	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.35	8.74e-13	7.02e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.35	8.74e-13	7.02e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
HNSC	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	7.35	8.75e-13	7.02e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
HNSC	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	7.35	8.75e-13	7.03e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
HNSC	cis	rs451417	1	rs236105	ENSG00000275632.1	RP5-967N21.11	-7.35	8.76e-13	7.03e-10	-0.38	-0.32	Menopause (age at onset);	chr20:5979186	chr20:6000418~6000941:+
HNSC	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-7.35	8.76e-13	7.04e-10	-0.34	-0.32	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
HNSC	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-7.35	8.79e-13	7.05e-10	-0.44	-0.32	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
HNSC	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-7.35	8.85e-13	7.1e-10	-0.32	-0.32	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
HNSC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	7.35	8.86e-13	7.11e-10	0.37	0.32	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	7.35	8.86e-13	7.11e-10	0.23	0.32	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
HNSC	cis	rs6951245	1	rs74785791	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs74366004	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77702926	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs78573577	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76129108	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78523927	ENSG00000224079.1	AC091729.7	-7.35	8.88e-13	7.12e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1074450~1078036:+
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-7.35	8.9e-13	7.14e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
HNSC	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-7.35	8.9e-13	7.14e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
HNSC	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	7.35	8.92e-13	7.15e-10	0.35	0.32	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
HNSC	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-7.35	8.95e-13	7.17e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	7.35	9e-13	7.21e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.35	9.08e-13	7.28e-10	-0.42	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
HNSC	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	7.35	9.09e-13	7.28e-10	0.25	0.32	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-7.35	9.12e-13	7.3e-10	-0.58	-0.32	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.35	9.14e-13	7.32e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	7.35	9.14e-13	7.32e-10	0.37	0.32	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
HNSC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	7.35	9.16e-13	7.34e-10	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
HNSC	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-7.35	9.18e-13	7.35e-10	-0.55	-0.32	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
HNSC	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-7.35	9.19e-13	7.36e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
HNSC	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-7.35	9.21e-13	7.37e-10	-0.32	-0.32	Height;	chr5:36861889	chr5:36666214~36725195:-
HNSC	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-7.34	9.25e-13	7.41e-10	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
HNSC	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-7.34	9.28e-13	7.43e-10	-0.32	-0.32	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-7.34	9.29e-13	7.44e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-7.34	9.3e-13	7.44e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
HNSC	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	7.34	9.39e-13	7.51e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
HNSC	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-7.34	9.4e-13	7.52e-10	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
HNSC	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.44e-13	7.55e-10	-0.36	-0.32	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-7.34	9.45e-13	7.55e-10	-0.42	-0.32	Depression;	chr6:28193021	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-7.34	9.45e-13	7.55e-10	-0.21	-0.32	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
HNSC	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	7.34	9.5e-13	7.59e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.53e-13	7.61e-10	-0.36	-0.32	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	7.34	9.57e-13	7.64e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
HNSC	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-7.34	9.57e-13	7.64e-10	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
HNSC	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-7.34	9.61e-13	7.67e-10	-0.32	-0.32	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
HNSC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.34	9.62e-13	7.68e-10	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
HNSC	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	7.34	9.74e-13	7.77e-10	0.4	0.32	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
HNSC	cis	rs1021993	0.545	rs79212878	ENSG00000231648.1	RP11-372M18.2	-7.34	9.76e-13	7.79e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209374072	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.545	rs80311419	ENSG00000231648.1	RP11-372M18.2	-7.34	9.76e-13	7.79e-10	-0.55	-0.32	Gut microbiome composition (winter);	chr1:209374073	chr1:209367662~209379690:+
HNSC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-7.34	9.79e-13	7.81e-10	-0.38	-0.32	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
HNSC	cis	rs451417	1	rs236120	ENSG00000275632.1	RP5-967N21.11	7.34	9.81e-13	7.82e-10	0.39	0.32	Menopause (age at onset);	chr20:5959003	chr20:6000418~6000941:+
HNSC	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-7.34	9.86e-13	7.86e-10	-0.37	-0.32	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
HNSC	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	7.34	9.87e-13	7.87e-10	0.39	0.32	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
HNSC	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-7.33	9.89e-13	7.88e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
HNSC	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-7.33	9.89e-13	7.89e-10	-0.32	-0.32	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
HNSC	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	7.33	9.9e-13	7.89e-10	0.31	0.32	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
HNSC	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	7.33	9.91e-13	7.9e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
HNSC	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	7.33	9.95e-13	7.92e-10	0.39	0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
HNSC	cis	rs451417	1	rs236115	ENSG00000275632.1	RP5-967N21.11	7.33	1e-12	7.96e-10	0.39	0.32	Menopause (age at onset);	chr20:5954803	chr20:6000418~6000941:+
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	7.33	1e-12	7.97e-10	0.22	0.32	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
HNSC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	7.33	1e-12	7.97e-10	0.35	0.32	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
HNSC	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.33	1e-12	7.97e-10	-0.36	-0.32	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
HNSC	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-7.33	1.01e-12	8.01e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
HNSC	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-7.33	1.01e-12	8.01e-10	-0.6	-0.32	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
HNSC	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-7.33	1.01e-12	8.06e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
HNSC	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	7.33	1.02e-12	8.15e-10	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
HNSC	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	7.33	1.02e-12	8.15e-10	0.39	0.32	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
HNSC	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	7.33	1.03e-12	8.17e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
HNSC	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-7.33	1.03e-12	8.17e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	7.33	1.03e-12	8.18e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	7.33	1.03e-12	8.2e-10	0.22	0.32	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-7.33	1.03e-12	8.21e-10	-0.37	-0.32	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	7.33	1.03e-12	8.21e-10	0.59	0.32	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
HNSC	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-7.33	1.04e-12	8.24e-10	-0.46	-0.32	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	7.33	1.04e-12	8.26e-10	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	7.33	1.04e-12	8.29e-10	0.22	0.32	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
HNSC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.33	1.05e-12	8.3e-10	0.36	0.32	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
HNSC	cis	rs7615952	1	rs7616044	ENSG00000248787.1	RP11-666A20.4	-7.33	1.05e-12	8.3e-10	-0.46	-0.32	Blood pressure (smoking interaction);	chr3:125930511	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs6803160	ENSG00000241288.6	RP11-379B18.5	-7.33	1.05e-12	8.3e-10	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125990711	chr3:125827238~125916384:-
HNSC	cis	rs1021993	0.545	rs17014375	ENSG00000231648.1	RP11-372M18.2	-7.33	1.05e-12	8.32e-10	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209370215	chr1:209367662~209379690:+
HNSC	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-7.33	1.05e-12	8.34e-10	-0.61	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	7.33	1.05e-12	8.34e-10	0.31	0.32	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-7.33	1.05e-12	8.35e-10	-0.39	-0.32	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
HNSC	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-7.33	1.05e-12	8.36e-10	-0.43	-0.32	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
HNSC	cis	rs1021993	0.597	rs2055698	ENSG00000231648.1	RP11-372M18.2	-7.32	1.06e-12	8.38e-10	-0.41	-0.32	Gut microbiome composition (winter);	chr1:209375201	chr1:209367662~209379690:+
HNSC	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.06e-12	8.41e-10	-0.38	-0.32	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.06e-12	8.41e-10	-0.38	-0.32	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
HNSC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-7.32	1.06e-12	8.41e-10	-0.36	-0.32	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
HNSC	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	7.32	1.07e-12	8.45e-10	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
HNSC	cis	rs904251	0.561	rs4714071	ENSG00000204110.6	RP1-153P14.8	-7.32	1.07e-12	8.46e-10	-0.32	-0.32	Cognitive performance;	chr6:37506617	chr6:37507348~37535616:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	7.32	1.07e-12	8.51e-10	0.22	0.32	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
HNSC	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-7.32	1.08e-12	8.53e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
HNSC	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	7.32	1.08e-12	8.56e-10	0.52	0.32	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-7.32	1.08e-12	8.56e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
HNSC	cis	rs6951245	1	rs80212261	ENSG00000224079.1	AC091729.7	-7.32	1.08e-12	8.58e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77346188	ENSG00000224079.1	AC091729.7	-7.32	1.08e-12	8.58e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1074450~1078036:+
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	7.32	1.08e-12	8.58e-10	0.46	0.32	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	7.32	1.08e-12	8.58e-10	0.46	0.32	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-7.32	1.09e-12	8.62e-10	-0.36	-0.32	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
HNSC	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-7.32	1.09e-12	8.64e-10	-0.32	-0.32	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
HNSC	cis	rs6951245	1	rs78158942	ENSG00000224079.1	AC091729.7	-7.32	1.09e-12	8.64e-10	-0.56	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1074450~1078036:+
HNSC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	7.32	1.09e-12	8.64e-10	0.39	0.32	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	7.32	1.09e-12	8.64e-10	0.39	0.32	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
HNSC	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	7.32	1.1e-12	8.68e-10	0.36	0.32	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
HNSC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	7.32	1.1e-12	8.72e-10	0.39	0.32	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
HNSC	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.32	1.1e-12	8.74e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
HNSC	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.32	1.1e-12	8.74e-10	-0.46	-0.32	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
HNSC	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	7.32	1.11e-12	8.76e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
HNSC	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-7.32	1.11e-12	8.78e-10	-0.31	-0.32	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
HNSC	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	7.32	1.11e-12	8.8e-10	0.73	0.32	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-7.32	1.12e-12	8.83e-10	-0.42	-0.32	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
HNSC	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	7.32	1.12e-12	8.85e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
HNSC	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-7.32	1.12e-12	8.89e-10	-0.37	-0.32	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
HNSC	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	7.32	1.13e-12	8.91e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-7.32	1.13e-12	8.91e-10	-0.4	-0.32	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	7.31	1.13e-12	8.94e-10	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
HNSC	cis	rs6951245	0.744	rs1133122	ENSG00000224079.1	AC091729.7	-7.31	1.13e-12	8.94e-10	-0.53	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1074450~1078036:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	8.95e-10	-0.43	-0.32	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	8.95e-10	-0.43	-0.32	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
HNSC	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	7.31	1.13e-12	8.95e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
HNSC	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	7.31	1.13e-12	8.95e-10	0.37	0.32	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
HNSC	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-7.31	1.13e-12	8.96e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs8034801	ENSG00000276710.3	CSPG4P8	-7.31	1.13e-12	8.96e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82459472~82477258:+
HNSC	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	7.31	1.13e-12	8.97e-10	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-7.31	1.14e-12	8.98e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
HNSC	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-7.31	1.14e-12	9.04e-10	-0.39	-0.32	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
HNSC	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	7.31	1.15e-12	9.08e-10	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
HNSC	cis	rs12439619	0.693	rs17269819	ENSG00000276710.3	CSPG4P8	-7.31	1.15e-12	9.09e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82459472~82477258:+
HNSC	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.31	1.15e-12	9.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.31	1.15e-12	9.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-7.31	1.15e-12	9.11e-10	-0.64	-0.32	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	7.31	1.15e-12	9.12e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	7.31	1.16e-12	9.16e-10	0.36	0.32	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-7.31	1.16e-12	9.17e-10	-0.39	-0.32	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
HNSC	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	7.31	1.16e-12	9.19e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
HNSC	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.31	1.17e-12	9.21e-10	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
HNSC	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	7.31	1.17e-12	9.24e-10	0.34	0.32	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
HNSC	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	7.31	1.17e-12	9.26e-10	0.43	0.32	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
HNSC	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-7.31	1.18e-12	9.3e-10	-0.45	-0.32	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
HNSC	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	7.31	1.18e-12	9.32e-10	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-7.31	1.18e-12	9.33e-10	-0.31	-0.32	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
HNSC	cis	rs12439619	0.693	rs7165536	ENSG00000276710.3	CSPG4P8	-7.31	1.19e-12	9.35e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82459472~82477258:+
HNSC	cis	rs7942368	1	rs3758711	ENSG00000255100.1	RP11-21L23.3	7.31	1.19e-12	9.36e-10	0.4	0.32	Endometriosis;	chr11:76784516	chr11:76782581~76783062:-
HNSC	cis	rs6951245	0.706	rs1133116	ENSG00000224079.1	AC091729.7	-7.31	1.19e-12	9.37e-10	-0.53	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1074450~1078036:+
HNSC	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-7.31	1.19e-12	9.37e-10	-0.38	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-7.31	1.19e-12	9.42e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-7.31	1.2e-12	9.46e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-7.31	1.2e-12	9.46e-10	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	7.3	1.21e-12	9.51e-10	0.28	0.32	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
HNSC	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	7.3	1.21e-12	9.53e-10	0.34	0.32	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
HNSC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	7.3	1.21e-12	9.54e-10	0.39	0.32	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
HNSC	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	7.3	1.21e-12	9.54e-10	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
HNSC	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.3	1.21e-12	9.54e-10	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	7.3	1.22e-12	9.57e-10	0.32	0.32	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
HNSC	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	7.3	1.22e-12	9.58e-10	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-7.3	1.22e-12	9.6e-10	-0.41	-0.32	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
HNSC	cis	rs6061231	0.958	rs2427305	ENSG00000273619.1	RP5-908M14.9	-7.3	1.23e-12	9.65e-10	-0.31	-0.32	Colorectal cancer;	chr20:62378693	chr20:62386303~62386970:-
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	7.3	1.23e-12	9.67e-10	0.47	0.32	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
HNSC	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-7.3	1.24e-12	9.75e-10	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
HNSC	cis	rs36423	0.702	rs1205076	ENSG00000266869.1	RP6-114E22.1	7.3	1.24e-12	9.76e-10	0.56	0.32	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71871335	chr14:71848606~71908430:+
HNSC	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-7.3	1.24e-12	9.77e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
HNSC	cis	rs6951245	0.935	rs79143504	ENSG00000224079.1	AC091729.7	-7.3	1.24e-12	9.77e-10	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1074450~1078036:+
HNSC	cis	rs17270561	0.666	rs4712971	ENSG00000272462.2	U91328.19	-7.3	1.24e-12	9.79e-10	-0.33	-0.32	Iron status biomarkers;	chr6:25771672	chr6:25992662~26001775:+
HNSC	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	7.3	1.25e-12	9.84e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
HNSC	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-7.3	1.25e-12	9.86e-10	-0.44	-0.32	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.3	1.26e-12	9.87e-10	-0.3	-0.32	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	7.3	1.26e-12	9.91e-10	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
HNSC	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	7.3	1.27e-12	9.95e-10	0.37	0.32	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
HNSC	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	7.3	1.27e-12	9.97e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	7.3	1.27e-12	9.97e-10	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
HNSC	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	7.3	1.27e-12	1e-09	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
HNSC	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-7.3	1.27e-12	1e-09	-0.37	-0.32	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
HNSC	cis	rs9402743	0.816	rs9494332	ENSG00000217482.2	HMGB1P17	7.3	1.28e-12	1e-09	0.36	0.32	Systemic lupus erythematosus;	chr6:135687470	chr6:135636086~135636713:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	7.3	1.28e-12	1e-09	0.35	0.32	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
HNSC	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	7.3	1.28e-12	1.01e-09	0.35	0.32	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-7.3	1.28e-12	1.01e-09	-0.29	-0.32	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
HNSC	cis	rs1933112	0.527	rs12090218	ENSG00000227777.1	RP4-738P11.3	-7.3	1.29e-12	1.01e-09	-0.36	-0.32	Blood protein levels;	chr1:168529966	chr1:168542737~168543354:+
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000267151.3	RP11-100E5.2	7.29	1.31e-12	1.02e-09	0.41	0.32	Menopause (age at onset);	chr17:43350035	chr17:43444707~43451200:+
HNSC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-7.29	1.31e-12	1.03e-09	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
HNSC	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	7.29	1.31e-12	1.03e-09	0.49	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
HNSC	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	7.29	1.32e-12	1.04e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
HNSC	cis	rs6471393	0.964	rs2914940	ENSG00000253848.1	RP11-10N23.5	7.29	1.32e-12	1.04e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93719598	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-7.29	1.32e-12	1.04e-09	-0.35	-0.32	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-7.29	1.32e-12	1.04e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
HNSC	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.32e-12	1.04e-09	-0.34	-0.32	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	7.29	1.33e-12	1.04e-09	0.22	0.32	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	7.29	1.33e-12	1.04e-09	0.22	0.32	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
HNSC	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	7.29	1.33e-12	1.04e-09	0.37	0.32	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
HNSC	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-7.29	1.33e-12	1.04e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-7.29	1.33e-12	1.04e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
HNSC	cis	rs6951245	0.938	rs11764937	ENSG00000224079.1	AC091729.7	-7.29	1.33e-12	1.05e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs4793229	ENSG00000267151.3	RP11-100E5.2	-7.29	1.33e-12	1.05e-09	-0.41	-0.32	Menopause (age at onset);	chr17:43340966	chr17:43444707~43451200:+
HNSC	cis	rs17270561	0.609	rs9356984	ENSG00000272462.2	U91328.19	7.29	1.34e-12	1.05e-09	0.33	0.32	Iron status biomarkers;	chr6:25725253	chr6:25992662~26001775:+
HNSC	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-7.29	1.34e-12	1.05e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
HNSC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
HNSC	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	7.29	1.34e-12	1.05e-09	0.51	0.32	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
HNSC	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-7.29	1.34e-12	1.05e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
HNSC	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-7.29	1.34e-12	1.05e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
HNSC	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-7.29	1.34e-12	1.05e-09	-0.36	-0.32	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
HNSC	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-7.29	1.34e-12	1.05e-09	-0.49	-0.32	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
HNSC	cis	rs6867032	0.958	rs4975795	ENSG00000249731.1	RP11-259O2.3	7.29	1.35e-12	1.06e-09	0.39	0.32	Gut microbiome composition (winter);	chr5:2015276	chr5:1968094~1969013:+
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-7.29	1.35e-12	1.06e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
HNSC	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	7.29	1.35e-12	1.06e-09	0.45	0.32	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.29	1.36e-12	1.06e-09	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
HNSC	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-7.29	1.36e-12	1.07e-09	-0.35	-0.32	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
HNSC	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
HNSC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	7.29	1.37e-12	1.07e-09	0.44	0.32	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
HNSC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	7.29	1.37e-12	1.07e-09	0.44	0.32	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
HNSC	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	7.29	1.37e-12	1.07e-09	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
HNSC	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	7.28	1.38e-12	1.08e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
HNSC	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-7.28	1.39e-12	1.08e-09	-0.35	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-7.28	1.39e-12	1.09e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
HNSC	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-7.28	1.39e-12	1.09e-09	-0.38	-0.32	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	7.28	1.39e-12	1.09e-09	0.38	0.32	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.28	1.4e-12	1.1e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
HNSC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.28	1.41e-12	1.1e-09	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
HNSC	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-7.28	1.41e-12	1.1e-09	-0.31	-0.32	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
HNSC	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-7.28	1.42e-12	1.11e-09	-0.34	-0.32	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
HNSC	cis	rs6471393	0.964	rs16916191	ENSG00000253848.1	RP11-10N23.5	7.28	1.42e-12	1.11e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93741193~93744534:+
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	7.28	1.42e-12	1.11e-09	0.35	0.32	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-7.28	1.43e-12	1.12e-09	-0.4	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
HNSC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-7.28	1.43e-12	1.12e-09	-0.39	-0.32	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
HNSC	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-7.28	1.43e-12	1.12e-09	-0.35	-0.32	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-7.28	1.44e-12	1.12e-09	-0.29	-0.32	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-7.28	1.44e-12	1.12e-09	-0.29	-0.32	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
HNSC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-7.28	1.44e-12	1.12e-09	-0.35	-0.32	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
HNSC	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-7.28	1.44e-12	1.13e-09	-0.36	-0.32	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	7.28	1.45e-12	1.13e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-7.28	1.45e-12	1.13e-09	-0.58	-0.32	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	7.28	1.46e-12	1.14e-09	0.32	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
HNSC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	7.28	1.46e-12	1.14e-09	0.39	0.32	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
HNSC	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	7.28	1.46e-12	1.14e-09	0.34	0.32	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000179406.6	LINC00174	7.28	1.46e-12	1.14e-09	0.5	0.32	Aortic root size;	chr7:66645977	chr7:66376044~66401338:-
HNSC	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.28	1.46e-12	1.14e-09	-0.43	-0.32	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
HNSC	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-7.28	1.47e-12	1.15e-09	-0.39	-0.32	Height;	chr11:118852670	chr11:118704607~118750263:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000173295.6	FAM86B3P	7.28	1.47e-12	1.15e-09	0.37	0.32	Joint mobility (Beighton score);	chr8:9002766	chr8:8228595~8244865:+
HNSC	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-7.28	1.47e-12	1.15e-09	-0.33	-0.32	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
HNSC	cis	rs1799949	1	rs11653460	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179289	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179580	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000267151.3	RP11-100E5.2	7.28	1.47e-12	1.15e-09	0.42	0.32	Menopause (age at onset);	chr17:43179799	chr17:43444707~43451200:+
HNSC	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.27	1.48e-12	1.15e-09	-0.31	-0.32	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
HNSC	cis	rs6565180	0.926	rs4788413	ENSG00000183604.13	SMG1P5	7.27	1.48e-12	1.15e-09	0.34	0.32	Tonsillectomy;	chr16:30399124	chr16:30267553~30335374:-
HNSC	cis	rs1823913	0.538	rs6732537	ENSG00000227542.1	AC092614.2	7.27	1.48e-12	1.15e-09	0.36	0.32	Obesity-related traits;	chr2:191346755	chr2:191229165~191246172:-
HNSC	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-7.27	1.48e-12	1.16e-09	-0.45	-0.32	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
HNSC	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	7.27	1.48e-12	1.16e-09	0.32	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-7.27	1.49e-12	1.16e-09	-0.31	-0.32	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-7.27	1.49e-12	1.16e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-7.27	1.49e-12	1.16e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
HNSC	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-7.27	1.49e-12	1.16e-09	-0.39	-0.32	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	7.27	1.49e-12	1.16e-09	0.22	0.32	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
HNSC	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	7.27	1.49e-12	1.16e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-7.27	1.49e-12	1.16e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
HNSC	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	7.27	1.5e-12	1.16e-09	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	7.27	1.5e-12	1.17e-09	0.46	0.32	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
HNSC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-7.27	1.5e-12	1.17e-09	-0.39	-0.32	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
HNSC	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	7.27	1.5e-12	1.17e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
HNSC	cis	rs7942368	0.715	rs12788118	ENSG00000255100.1	RP11-21L23.3	7.27	1.5e-12	1.17e-09	0.4	0.32	Endometriosis;	chr11:76783176	chr11:76782581~76783062:-
HNSC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	7.27	1.51e-12	1.17e-09	0.49	0.32	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
HNSC	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-7.27	1.51e-12	1.17e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
HNSC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.27	1.51e-12	1.18e-09	-0.35	-0.32	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
HNSC	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	7.27	1.52e-12	1.18e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.27	1.52e-12	1.18e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.27	1.52e-12	1.18e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
HNSC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-7.27	1.52e-12	1.18e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-7.27	1.52e-12	1.18e-09	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-7.27	1.52e-12	1.18e-09	-0.29	-0.32	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-7.27	1.52e-12	1.18e-09	-0.29	-0.32	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-7.27	1.52e-12	1.18e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	7.27	1.52e-12	1.18e-09	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
HNSC	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	7.27	1.52e-12	1.18e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
HNSC	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	7.27	1.52e-12	1.18e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-7.27	1.53e-12	1.19e-09	-0.21	-0.32	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
HNSC	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	7.27	1.53e-12	1.19e-09	0.31	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
HNSC	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	7.27	1.53e-12	1.19e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-7.27	1.53e-12	1.19e-09	-0.45	-0.32	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
HNSC	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-7.27	1.53e-12	1.19e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
HNSC	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
HNSC	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
HNSC	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-7.27	1.53e-12	1.19e-09	-0.39	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
HNSC	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	7.27	1.54e-12	1.19e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
HNSC	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	7.27	1.54e-12	1.2e-09	0.27	0.32	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
HNSC	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-7.27	1.54e-12	1.2e-09	-0.54	-0.32	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43332285	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43334234	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43336956	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43337648	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43342667	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000267151.3	RP11-100E5.2	7.27	1.54e-12	1.2e-09	0.41	0.32	Menopause (age at onset);	chr17:43344508	chr17:43444707~43451200:+
HNSC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-7.27	1.54e-12	1.2e-09	-0.36	-0.32	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
HNSC	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-7.27	1.55e-12	1.21e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-7.27	1.55e-12	1.21e-09	-0.36	-0.32	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
HNSC	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-7.27	1.57e-12	1.22e-09	-0.36	-0.32	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
HNSC	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-7.27	1.57e-12	1.22e-09	-0.36	-0.32	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
HNSC	cis	rs10791097	0.967	rs10750450	ENSG00000254842.5	RP11-890B15.2	-7.27	1.57e-12	1.22e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130849166	chr11:130844191~130865561:-
HNSC	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-7.27	1.57e-12	1.22e-09	-0.39	-0.32	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
HNSC	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	7.26	1.58e-12	1.22e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
HNSC	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-7.26	1.58e-12	1.22e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
HNSC	cis	rs10791097	1	rs10791098	ENSG00000254842.5	RP11-890B15.2	-7.26	1.58e-12	1.23e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848816	chr11:130844191~130865561:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	7.26	1.59e-12	1.23e-09	0.32	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
HNSC	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-7.26	1.59e-12	1.23e-09	-0.38	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
HNSC	cis	rs4218	0.689	rs11853828	ENSG00000259732.1	RP11-59H7.3	-7.26	1.59e-12	1.23e-09	-0.45	-0.32	Social communication problems;	chr15:59136031	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000254340.1	RP11-10A14.3	7.26	1.59e-12	1.23e-09	0.4	0.32	Joint mobility (Beighton score);	chr8:9009901	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-7.26	1.6e-12	1.24e-09	-0.39	-0.32	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
HNSC	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	7.26	1.6e-12	1.24e-09	0.34	0.32	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
HNSC	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-7.26	1.61e-12	1.25e-09	-0.32	-0.32	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
HNSC	cis	rs7615952	0.932	rs7629977	ENSG00000248787.1	RP11-666A20.4	-7.26	1.61e-12	1.25e-09	-0.47	-0.32	Blood pressure (smoking interaction);	chr3:125930730	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs7630077	ENSG00000248787.1	RP11-666A20.4	-7.26	1.61e-12	1.25e-09	-0.47	-0.32	Blood pressure (smoking interaction);	chr3:125930833	chr3:125908005~125910272:-
HNSC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	7.26	1.62e-12	1.25e-09	0.31	0.32	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	7.26	1.63e-12	1.26e-09	0.51	0.32	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
HNSC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-7.26	1.63e-12	1.26e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-7.26	1.64e-12	1.27e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
HNSC	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-7.26	1.64e-12	1.27e-09	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
HNSC	cis	rs10791097	0.967	rs10791099	ENSG00000254842.5	RP11-890B15.2	-7.26	1.64e-12	1.27e-09	-0.28	-0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848918	chr11:130844191~130865561:-
HNSC	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-7.26	1.64e-12	1.27e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
HNSC	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-7.26	1.64e-12	1.27e-09	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
HNSC	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	7.26	1.66e-12	1.28e-09	0.36	0.32	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
HNSC	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	7.26	1.66e-12	1.28e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
HNSC	cis	rs12439619	0.693	rs4778989	ENSG00000276710.3	CSPG4P8	-7.26	1.66e-12	1.28e-09	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82459472~82477258:+
HNSC	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-7.26	1.67e-12	1.29e-09	-0.35	-0.32	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-7.26	1.67e-12	1.29e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000267151.3	RP11-100E5.2	7.26	1.67e-12	1.29e-09	0.42	0.32	Menopause (age at onset);	chr17:43358297	chr17:43444707~43451200:+
HNSC	cis	rs7048146	0.899	rs13284486	ENSG00000213539.4	YBX1P6	7.26	1.68e-12	1.29e-09	0.37	0.32	Vascular brain injury;	chr9:109586658	chr9:109532830~109534332:-
HNSC	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-7.26	1.68e-12	1.3e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
HNSC	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	7.26	1.68e-12	1.3e-09	0.36	0.32	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.26	1.68e-12	1.3e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.26	1.68e-12	1.3e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
HNSC	cis	rs1799949	1	rs4793197	ENSG00000267151.3	RP11-100E5.2	7.25	1.69e-12	1.3e-09	0.41	0.32	Menopause (age at onset);	chr17:43079885	chr17:43444707~43451200:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-7.25	1.69e-12	1.3e-09	-0.35	-0.32	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-7.25	1.69e-12	1.31e-09	-0.36	-0.32	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
HNSC	cis	rs1021993	0.545	rs17014370	ENSG00000231648.1	RP11-372M18.2	-7.25	1.7e-12	1.31e-09	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209366746	chr1:209367662~209379690:+
HNSC	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	7.25	1.71e-12	1.32e-09	0.53	0.32	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
HNSC	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	7.25	1.71e-12	1.32e-09	0.51	0.32	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
HNSC	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	7.25	1.72e-12	1.32e-09	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	7.25	1.72e-12	1.32e-09	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-7.25	1.72e-12	1.32e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-7.25	1.72e-12	1.33e-09	-0.37	-0.32	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
HNSC	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-7.25	1.72e-12	1.33e-09	-0.36	-0.32	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
HNSC	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-7.25	1.72e-12	1.33e-09	-0.41	-0.32	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
HNSC	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.25	1.73e-12	1.34e-09	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.25	1.73e-12	1.34e-09	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000267151.3	RP11-100E5.2	7.25	1.73e-12	1.34e-09	0.42	0.32	Menopause (age at onset);	chr17:43358815	chr17:43444707~43451200:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.25	1.73e-12	1.34e-09	-0.37	-0.32	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
HNSC	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-7.25	1.74e-12	1.34e-09	-0.35	-0.32	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
HNSC	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-7.25	1.74e-12	1.34e-09	-0.29	-0.32	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
HNSC	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-7.25	1.74e-12	1.34e-09	-0.35	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	7.25	1.75e-12	1.35e-09	0.34	0.32	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
HNSC	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-7.25	1.76e-12	1.35e-09	-0.49	-0.32	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-7.25	1.76e-12	1.35e-09	-0.39	-0.32	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
HNSC	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-7.25	1.76e-12	1.36e-09	-0.39	-0.32	Height;	chr11:118854014	chr11:118704607~118750263:+
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-7.25	1.76e-12	1.36e-09	-0.42	-0.32	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
HNSC	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-7.25	1.76e-12	1.36e-09	-0.26	-0.32	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
HNSC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-7.25	1.77e-12	1.36e-09	-0.42	-0.32	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-7.25	1.77e-12	1.36e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
HNSC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	7.25	1.77e-12	1.36e-09	0.31	0.32	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
HNSC	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	7.25	1.77e-12	1.36e-09	0.38	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
HNSC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	7.25	1.77e-12	1.37e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
HNSC	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-7.25	1.78e-12	1.37e-09	-0.35	-0.32	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-7.25	1.79e-12	1.38e-09	-0.44	-0.32	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
HNSC	cis	rs17270561	0.609	rs9348692	ENSG00000272462.2	U91328.19	-7.25	1.8e-12	1.38e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25720584	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	7.24	1.8e-12	1.39e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
HNSC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-7.24	1.8e-12	1.39e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
HNSC	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-7.24	1.81e-12	1.39e-09	-0.38	-0.32	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
HNSC	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
HNSC	cis	rs6951245	1	rs79327308	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.938	rs117729148	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79617366	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs111899361	ENSG00000224079.1	AC091729.7	-7.24	1.82e-12	1.4e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1074450~1078036:+
HNSC	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-7.24	1.82e-12	1.4e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-7.24	1.82e-12	1.4e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
HNSC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-7.24	1.82e-12	1.4e-09	-0.39	-0.32	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
HNSC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.83e-12	1.41e-09	-0.33	-0.32	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
HNSC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-7.24	1.83e-12	1.41e-09	-0.42	-0.32	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
HNSC	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-7.24	1.84e-12	1.41e-09	-0.34	-0.32	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-7.24	1.84e-12	1.41e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-7.24	1.84e-12	1.41e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
HNSC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	7.24	1.84e-12	1.42e-09	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
HNSC	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-7.24	1.84e-12	1.42e-09	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	7.24	1.85e-12	1.42e-09	0.45	0.32	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-7.24	1.85e-12	1.42e-09	-0.3	-0.32	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-7.24	1.85e-12	1.42e-09	-0.3	-0.32	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
HNSC	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	7.24	1.85e-12	1.42e-09	0.31	0.32	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
HNSC	cis	rs16885979	1	rs12664791	ENSG00000224984.1	RP11-524H19.2	7.24	1.85e-12	1.42e-09	0.7	0.32	Daytime sleep phenotypes;	chr6:54829547	chr6:54840118~54840855:-
HNSC	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-7.24	1.85e-12	1.42e-09	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	7.24	1.85e-12	1.42e-09	0.4	0.32	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-7.24	1.86e-12	1.43e-09	-0.48	-0.32	Depression;	chr6:28103220	chr6:28115628~28116551:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	7.24	1.86e-12	1.43e-09	0.32	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000267151.3	RP11-100E5.2	7.24	1.87e-12	1.43e-09	0.41	0.32	Menopause (age at onset);	chr17:43174070	chr17:43444707~43451200:+
HNSC	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.87e-12	1.43e-09	-0.36	-0.32	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
HNSC	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.87e-12	1.43e-09	-0.36	-0.32	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
HNSC	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	7.24	1.87e-12	1.44e-09	0.35	0.32	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
HNSC	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	7.24	1.87e-12	1.44e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000267151.3	RP11-100E5.2	7.24	1.87e-12	1.44e-09	0.41	0.32	Menopause (age at onset);	chr17:43347551	chr17:43444707~43451200:+
HNSC	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-7.24	1.88e-12	1.44e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
HNSC	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	7.24	1.88e-12	1.44e-09	0.35	0.32	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
HNSC	cis	rs6951245	0.935	rs113365567	ENSG00000224079.1	AC091729.7	-7.24	1.88e-12	1.44e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1074450~1078036:+
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000241288.6	RP11-379B18.5	-7.24	1.88e-12	1.44e-09	-0.42	-0.32	Blood pressure (smoking interaction);	chr3:125987203	chr3:125827238~125916384:-
HNSC	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	7.24	1.88e-12	1.44e-09	0.27	0.32	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
HNSC	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-7.24	1.9e-12	1.45e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-7.24	1.9e-12	1.45e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-7.24	1.9e-12	1.45e-09	-0.38	-0.32	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-7.24	1.9e-12	1.46e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-7.24	1.9e-12	1.46e-09	-0.31	-0.32	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
HNSC	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-7.24	1.91e-12	1.46e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-7.24	1.91e-12	1.46e-09	-0.5	-0.32	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
HNSC	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	7.24	1.91e-12	1.46e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
HNSC	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-7.24	1.91e-12	1.46e-09	-0.41	-0.32	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43350693	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43351298	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000267151.3	RP11-100E5.2	7.24	1.91e-12	1.46e-09	0.41	0.32	Menopause (age at onset);	chr17:43354440	chr17:43444707~43451200:+
HNSC	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	7.24	1.92e-12	1.47e-09	0.35	0.32	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
HNSC	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	7.23	1.93e-12	1.47e-09	0.32	0.32	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	7.23	1.94e-12	1.48e-09	0.35	0.32	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-7.23	1.94e-12	1.48e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	7.23	1.94e-12	1.48e-09	0.39	0.32	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
HNSC	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	7.23	1.94e-12	1.49e-09	0.4	0.32	Height;	chr6:109332929	chr6:109382795~109383666:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	7.23	1.96e-12	1.5e-09	0.57	0.32	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-7.23	1.96e-12	1.5e-09	-0.29	-0.32	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	7.23	1.97e-12	1.5e-09	0.46	0.32	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
HNSC	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-7.23	1.97e-12	1.5e-09	-0.32	-0.32	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	7.23	1.97e-12	1.5e-09	0.47	0.32	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
HNSC	cis	rs7615952	0.741	rs13314845	ENSG00000248787.1	RP11-666A20.4	-7.23	1.98e-12	1.51e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125925939	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.733	rs13314847	ENSG00000248787.1	RP11-666A20.4	-7.23	1.98e-12	1.51e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125925945	chr3:125908005~125910272:-
HNSC	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-7.23	1.99e-12	1.52e-09	-0.34	-0.32	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
HNSC	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-7.23	1.99e-12	1.52e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
HNSC	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	7.23	1.99e-12	1.52e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
HNSC	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	7.23	1.99e-12	1.52e-09	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
HNSC	cis	rs6951245	0.935	rs61753396	ENSG00000224079.1	AC091729.7	-7.23	2e-12	1.52e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.938	rs113642700	ENSG00000224079.1	AC091729.7	-7.23	2e-12	1.52e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	7.23	2e-12	1.53e-09	0.29	0.32	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	-7.23	2.01e-12	1.53e-09	-0.35	-0.32	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
HNSC	cis	rs6471393	0.964	rs2914953	ENSG00000253848.1	RP11-10N23.5	7.23	2.01e-12	1.53e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93730122	chr8:93741193~93744534:+
HNSC	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-7.23	2.01e-12	1.54e-09	-0.39	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
HNSC	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-7.23	2.02e-12	1.54e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-7.23	2.02e-12	1.54e-09	-0.32	-0.32	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-7.23	2.02e-12	1.54e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
HNSC	cis	rs6951245	0.872	rs112309216	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs76161580	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76388414	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs77305932	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs11768486	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11766526	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs76214082	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113146460	ENSG00000224079.1	AC091729.7	-7.23	2.02e-12	1.54e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1074450~1078036:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.23	2.03e-12	1.54e-09	0.37	0.32	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
HNSC	cis	rs9402743	0.816	rs9494327	ENSG00000217482.2	HMGB1P17	7.23	2.03e-12	1.55e-09	0.36	0.32	Systemic lupus erythematosus;	chr6:135674898	chr6:135636086~135636713:-
HNSC	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	7.23	2.03e-12	1.55e-09	0.48	0.32	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
HNSC	cis	rs1799949	1	rs35956818	ENSG00000267151.3	RP11-100E5.2	7.23	2.03e-12	1.55e-09	0.41	0.32	Menopause (age at onset);	chr17:43345617	chr17:43444707~43451200:+
HNSC	cis	rs1865760	0.625	rs9393681	ENSG00000272462.2	U91328.19	-7.23	2.04e-12	1.56e-09	-0.31	-0.32	Height;	chr6:26008032	chr6:25992662~26001775:+
HNSC	cis	rs4978813	0.5	rs12685609	ENSG00000213539.4	YBX1P6	-7.23	2.05e-12	1.56e-09	-0.36	-0.32	Plantar warts;	chr9:109536303	chr9:109532830~109534332:-
HNSC	cis	rs1933112	0.545	rs10429892	ENSG00000227777.1	RP4-738P11.3	-7.23	2.05e-12	1.56e-09	-0.34	-0.32	Blood protein levels;	chr1:168532215	chr1:168542737~168543354:+
HNSC	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	7.23	2.05e-12	1.56e-09	0.27	0.32	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	7.23	2.05e-12	1.56e-09	0.27	0.32	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
HNSC	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-7.23	2.05e-12	1.56e-09	-0.32	-0.32	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-7.23	2.05e-12	1.56e-09	-0.32	-0.32	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
HNSC	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-7.22	2.07e-12	1.57e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43332406	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43337311	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43342017	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43342288	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000267151.3	RP11-100E5.2	7.22	2.07e-12	1.58e-09	0.41	0.32	Menopause (age at onset);	chr17:43344763	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-7.22	2.07e-12	1.58e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
HNSC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-7.22	2.07e-12	1.58e-09	-0.36	-0.32	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
HNSC	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	7.22	2.08e-12	1.58e-09	0.37	0.32	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
HNSC	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	7.22	2.09e-12	1.59e-09	0.27	0.32	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
HNSC	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-7.22	2.09e-12	1.59e-09	-0.39	-0.32	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
HNSC	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	7.22	2.1e-12	1.6e-09	0.48	0.32	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
HNSC	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	7.22	2.11e-12	1.6e-09	0.36	0.32	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	7.22	2.13e-12	1.62e-09	0.29	0.32	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
HNSC	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-7.22	2.13e-12	1.62e-09	-0.37	-0.32	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
HNSC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	7.22	2.14e-12	1.62e-09	0.46	0.32	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
HNSC	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.22	2.15e-12	1.63e-09	0.36	0.32	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
HNSC	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-7.22	2.15e-12	1.63e-09	-0.32	-0.32	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
HNSC	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	7.22	2.15e-12	1.64e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
HNSC	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	7.22	2.15e-12	1.64e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
HNSC	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.22	2.16e-12	1.64e-09	0.43	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	7.22	2.17e-12	1.65e-09	0.35	0.32	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
HNSC	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	7.22	2.17e-12	1.65e-09	0.37	0.32	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
HNSC	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.22	2.17e-12	1.65e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	7.22	2.19e-12	1.66e-09	0.44	0.32	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
HNSC	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-7.22	2.19e-12	1.66e-09	-0.35	-0.32	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
HNSC	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-7.21	2.2e-12	1.67e-09	-0.44	-0.32	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
HNSC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-7.21	2.2e-12	1.67e-09	-0.39	-0.32	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
HNSC	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-7.21	2.2e-12	1.67e-09	-0.29	-0.32	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
HNSC	cis	rs7615952	0.641	rs6438951	ENSG00000241288.6	RP11-379B18.5	-7.21	2.2e-12	1.67e-09	-0.41	-0.32	Blood pressure (smoking interaction);	chr3:125978156	chr3:125827238~125916384:-
HNSC	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.21	2.21e-12	1.67e-09	0.39	0.32	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	7.21	2.23e-12	1.69e-09	0.37	0.32	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
HNSC	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	7.21	2.23e-12	1.69e-09	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
HNSC	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	7.21	2.24e-12	1.7e-09	0.34	0.32	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
HNSC	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	7.21	2.24e-12	1.7e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
HNSC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-7.21	2.25e-12	1.7e-09	-0.6	-0.32	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	7.21	2.25e-12	1.71e-09	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-7.21	2.25e-12	1.71e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
HNSC	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	7.21	2.26e-12	1.71e-09	0.65	0.32	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
HNSC	cis	rs17270561	0.609	rs9358883	ENSG00000272462.2	U91328.19	-7.21	2.26e-12	1.71e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25755287	chr6:25992662~26001775:+
HNSC	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	7.21	2.26e-12	1.71e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000241288.6	RP11-379B18.5	-7.21	2.26e-12	1.71e-09	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:126006108	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000241288.6	RP11-379B18.5	-7.21	2.26e-12	1.71e-09	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:126006716	chr3:125827238~125916384:-
HNSC	cis	rs9402743	1	rs6926161	ENSG00000217482.2	HMGB1P17	7.21	2.26e-12	1.71e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135653341	chr6:135636086~135636713:-
HNSC	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-7.21	2.26e-12	1.71e-09	-0.45	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
HNSC	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	7.21	2.27e-12	1.72e-09	0.34	0.32	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	7.21	2.27e-12	1.72e-09	0.34	0.32	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
HNSC	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-7.21	2.27e-12	1.72e-09	-0.36	-0.32	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
HNSC	cis	rs17270561	0.553	rs9379784	ENSG00000272462.2	U91328.19	-7.21	2.29e-12	1.73e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25725278	chr6:25992662~26001775:+
HNSC	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-7.21	2.29e-12	1.74e-09	-0.36	-0.32	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
HNSC	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	7.21	2.31e-12	1.74e-09	0.31	0.32	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
HNSC	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.21	2.32e-12	1.76e-09	0.44	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.21	2.32e-12	1.76e-09	0.44	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
HNSC	cis	rs1021993	0.545	rs1507336	ENSG00000231648.1	RP11-372M18.2	-7.21	2.33e-12	1.76e-09	-0.56	-0.32	Gut microbiome composition (winter);	chr1:209375580	chr1:209367662~209379690:+
HNSC	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-7.21	2.33e-12	1.76e-09	-0.47	-0.32	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
HNSC	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	7.21	2.34e-12	1.77e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
HNSC	cis	rs9402743	0.811	rs6570024	ENSG00000217482.2	HMGB1P17	7.21	2.34e-12	1.77e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135649186	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.923	rs4896159	ENSG00000217482.2	HMGB1P17	7.21	2.34e-12	1.77e-09	0.34	0.32	Systemic lupus erythematosus;	chr6:135650304	chr6:135636086~135636713:-
HNSC	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	7.21	2.34e-12	1.77e-09	0.29	0.32	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
HNSC	cis	rs451417	1	rs236108	ENSG00000275632.1	RP5-967N21.11	7.21	2.34e-12	1.77e-09	0.39	0.32	Menopause (age at onset);	chr20:5987913	chr20:6000418~6000941:+
HNSC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.2	2.35e-12	1.77e-09	0.29	0.32	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
HNSC	cis	rs2579103	0.708	rs1438988	ENSG00000258183.4	RP11-753N8.1	-7.2	2.36e-12	1.78e-09	-0.44	-0.32	Body mass index;	chr12:90290693	chr12:90280894~90300340:+
HNSC	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-7.2	2.37e-12	1.79e-09	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
HNSC	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.2	2.39e-12	1.8e-09	-0.42	-0.32	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
HNSC	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-7.2	2.39e-12	1.8e-09	-0.33	-0.32	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-7.2	2.39e-12	1.8e-09	-0.31	-0.32	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
HNSC	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	7.2	2.39e-12	1.81e-09	0.37	0.32	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
HNSC	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-7.2	2.39e-12	1.81e-09	-0.33	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
HNSC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.2	2.4e-12	1.81e-09	0.42	0.32	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
HNSC	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.41e-12	1.82e-09	-0.35	-0.32	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
HNSC	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-7.2	2.41e-12	1.82e-09	-0.26	-0.32	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-7.2	2.41e-12	1.82e-09	-0.43	-0.32	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
HNSC	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	7.2	2.42e-12	1.83e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
HNSC	cis	rs7615952	0.673	rs3811677	ENSG00000248787.1	RP11-666A20.4	-7.2	2.43e-12	1.83e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125929237	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs3811679	ENSG00000248787.1	RP11-666A20.4	-7.2	2.43e-12	1.83e-09	-0.48	-0.32	Blood pressure (smoking interaction);	chr3:125929440	chr3:125908005~125910272:-
HNSC	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	7.2	2.43e-12	1.84e-09	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-7.2	2.44e-12	1.84e-09	-0.59	-0.32	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
HNSC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-7.2	2.44e-12	1.84e-09	-0.36	-0.32	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-7.2	2.45e-12	1.85e-09	-0.34	-0.32	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
HNSC	cis	rs17270561	0.609	rs1937132	ENSG00000272462.2	U91328.19	-7.2	2.45e-12	1.85e-09	-0.33	-0.32	Iron status biomarkers;	chr6:25756789	chr6:25992662~26001775:+
HNSC	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	7.2	2.46e-12	1.85e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
HNSC	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	7.2	2.46e-12	1.86e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
HNSC	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	7.2	2.46e-12	1.86e-09	0.42	0.32	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
HNSC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	7.2	2.47e-12	1.86e-09	0.37	0.32	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
HNSC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-7.2	2.47e-12	1.86e-09	-0.41	-0.32	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
HNSC	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	7.2	2.47e-12	1.86e-09	0.33	0.32	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
HNSC	cis	rs7048146	0.7	rs10759351	ENSG00000213539.4	YBX1P6	7.2	2.48e-12	1.87e-09	0.35	0.32	Vascular brain injury;	chr9:109582738	chr9:109532830~109534332:-
HNSC	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-7.2	2.48e-12	1.87e-09	-0.38	-0.32	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-7.2	2.48e-12	1.87e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
HNSC	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	7.2	2.5e-12	1.88e-09	0.32	0.32	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
HNSC	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	7.2	2.5e-12	1.88e-09	0.36	0.32	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	7.2	2.5e-12	1.88e-09	0.36	0.32	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
HNSC	cis	rs1021993	0.62	rs17014326	ENSG00000231648.1	RP11-372M18.2	-7.2	2.5e-12	1.89e-09	-0.39	-0.32	Gut microbiome composition (winter);	chr1:209341940	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	7.2	2.5e-12	1.89e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs9646417	ENSG00000267151.3	RP11-100E5.2	7.19	2.51e-12	1.89e-09	0.41	0.32	Menopause (age at onset);	chr17:43346885	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000267151.3	RP11-100E5.2	7.19	2.51e-12	1.89e-09	0.41	0.32	Menopause (age at onset);	chr17:43347197	chr17:43444707~43451200:+
HNSC	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	7.19	2.51e-12	1.89e-09	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
HNSC	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	7.19	2.52e-12	1.89e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000267151.3	RP11-100E5.2	7.19	2.52e-12	1.9e-09	0.41	0.32	Menopause (age at onset);	chr17:43359227	chr17:43444707~43451200:+
HNSC	cis	rs7615952	0.932	rs6438948	ENSG00000248787.1	RP11-666A20.4	7.19	2.53e-12	1.9e-09	0.44	0.32	Blood pressure (smoking interaction);	chr3:125931202	chr3:125908005~125910272:-
HNSC	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-7.19	2.53e-12	1.91e-09	-0.28	-0.32	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
HNSC	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-7.19	2.54e-12	1.92e-09	-0.36	-0.32	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
HNSC	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.19	2.55e-12	1.92e-09	0.39	0.32	Height;	chr4:55361200	chr4:55363971~55395847:-
HNSC	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	7.19	2.55e-12	1.92e-09	0.46	0.32	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
HNSC	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-7.19	2.56e-12	1.92e-09	-0.36	-0.32	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
HNSC	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.19	2.56e-12	1.92e-09	-0.36	-0.32	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	7.19	2.56e-12	1.92e-09	0.28	0.32	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-7.19	2.56e-12	1.92e-09	-0.38	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
HNSC	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	7.19	2.57e-12	1.93e-09	0.34	0.32	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
HNSC	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	7.19	2.58e-12	1.94e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
HNSC	cis	rs1865760	0.551	rs9461230	ENSG00000272462.2	U91328.19	-7.19	2.59e-12	1.94e-09	-0.31	-0.32	Height;	chr6:26019012	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-7.19	2.59e-12	1.95e-09	-0.32	-0.32	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
HNSC	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-7.19	2.6e-12	1.95e-09	-0.31	-0.32	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
HNSC	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-7.19	2.6e-12	1.95e-09	-0.7	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
HNSC	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	7.19	2.61e-12	1.96e-09	0.4	0.32	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
HNSC	cis	rs10791097	0.967	rs6590512	ENSG00000254842.5	RP11-890B15.2	7.19	2.61e-12	1.96e-09	0.27	0.32	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848021	chr11:130844191~130865561:-
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.19	2.61e-12	1.96e-09	-0.3	-0.32	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-7.19	2.61e-12	1.96e-09	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
HNSC	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-7.19	2.61e-12	1.96e-09	-0.41	-0.32	Height;	chr6:109636120	chr6:109382795~109383666:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000276710.3	CSPG4P8	-7.19	2.62e-12	1.97e-09	-0.37	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	7.19	2.62e-12	1.97e-09	0.22	0.32	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
HNSC	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	7.19	2.64e-12	1.98e-09	0.38	0.32	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
HNSC	cis	rs9595066	0.627	rs4942290	ENSG00000227258.4	SMIM2-AS1	7.19	2.65e-12	1.99e-09	0.53	0.32	Schizophrenia;	chr13:44183203	chr13:44110451~44240517:+
HNSC	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	7.19	2.65e-12	1.99e-09	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
HNSC	cis	rs1799949	1	rs4793231	ENSG00000267151.3	RP11-100E5.2	7.19	2.65e-12	1.99e-09	0.41	0.32	Menopause (age at onset);	chr17:43350101	chr17:43444707~43451200:+
HNSC	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-7.19	2.66e-12	1.99e-09	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
HNSC	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-7.19	2.66e-12	2e-09	-0.33	-0.32	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-7.18	2.68e-12	2e-09	-0.31	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
HNSC	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	7.18	2.68e-12	2e-09	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
HNSC	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-7.18	2.68e-12	2.01e-09	-0.44	-0.32	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.18	2.68e-12	2.01e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
HNSC	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-7.18	2.68e-12	2.01e-09	-0.47	-0.32	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-7.18	2.69e-12	2.01e-09	-0.3	-0.32	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
HNSC	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	7.18	2.69e-12	2.01e-09	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
HNSC	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	7.18	2.69e-12	2.01e-09	0.39	0.32	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
HNSC	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-7.18	2.69e-12	2.01e-09	-0.5	-0.32	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
HNSC	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-7.18	2.7e-12	2.02e-09	-0.45	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.18	2.71e-12	2.03e-09	-0.29	-0.32	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	7.18	2.71e-12	2.03e-09	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000267151.3	RP11-100E5.2	7.18	2.71e-12	2.03e-09	0.4	0.32	Menopause (age at onset);	chr17:43103094	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000267151.3	RP11-100E5.2	7.18	2.71e-12	2.03e-09	0.4	0.32	Menopause (age at onset);	chr17:43106026	chr17:43444707~43451200:+
HNSC	cis	rs6951245	1	rs74887741	ENSG00000224079.1	AC091729.7	-7.18	2.71e-12	2.03e-09	-0.55	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1074450~1078036:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	7.18	2.72e-12	2.04e-09	0.38	0.32	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
HNSC	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-7.18	2.73e-12	2.04e-09	-0.36	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
HNSC	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-7.18	2.73e-12	2.04e-09	-0.29	-0.32	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	7.18	2.73e-12	2.04e-09	0.28	0.32	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
HNSC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-7.18	2.75e-12	2.06e-09	-0.33	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
HNSC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-7.18	2.76e-12	2.06e-09	-0.36	-0.32	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
HNSC	cis	rs6471393	0.964	rs7001808	ENSG00000253848.1	RP11-10N23.5	7.18	2.77e-12	2.07e-09	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93725043	chr8:93741193~93744534:+
HNSC	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	7.18	2.78e-12	2.08e-09	0.36	0.32	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-7.18	2.79e-12	2.09e-09	-0.57	-0.32	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
HNSC	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	7.18	2.81e-12	2.1e-09	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
HNSC	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	7.18	2.81e-12	2.1e-09	0.39	0.32	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
HNSC	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-7.18	2.83e-12	2.11e-09	-0.31	-0.32	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
HNSC	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	7.18	2.83e-12	2.11e-09	0.45	0.32	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
HNSC	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.83e-12	2.12e-09	-0.36	-0.32	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
HNSC	cis	rs1865760	0.519	rs2275904	ENSG00000272462.2	U91328.19	-7.18	2.84e-12	2.12e-09	-0.33	-0.32	Height;	chr6:25767857	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	7.18	2.84e-12	2.12e-09	0.36	0.32	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
HNSC	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	7.18	2.84e-12	2.12e-09	0.46	0.32	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
HNSC	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.85e-12	2.13e-09	-0.35	-0.32	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
HNSC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-7.18	2.85e-12	2.13e-09	-0.41	-0.32	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
HNSC	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	7.17	2.86e-12	2.13e-09	0.48	0.32	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
HNSC	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-7.17	2.86e-12	2.14e-09	-0.34	-0.32	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
HNSC	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-7.17	2.86e-12	2.14e-09	-0.43	-0.32	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
HNSC	cis	rs1021993	0.545	rs76438740	ENSG00000231648.1	RP11-372M18.2	-7.17	2.87e-12	2.14e-09	-0.54	-0.32	Gut microbiome composition (winter);	chr1:209366381	chr1:209367662~209379690:+
HNSC	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	7.17	2.88e-12	2.15e-09	0.41	0.32	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
HNSC	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	7.17	2.89e-12	2.15e-09	0.33	0.32	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
HNSC	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-7.17	2.9e-12	2.16e-09	-0.4	-0.32	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
HNSC	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	7.17	2.91e-12	2.17e-09	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
HNSC	cis	rs61542988	1	rs61542988	ENSG00000228649.7	AC005682.5	7.17	2.91e-12	2.17e-09	0.35	0.31	Fibrinogen levels;	chr7:22842672	chr7:22854178~22861579:+
HNSC	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-7.17	2.92e-12	2.18e-09	-0.5	-0.31	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	7.17	2.93e-12	2.19e-09	0.6	0.31	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
HNSC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-7.17	2.94e-12	2.19e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
HNSC	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	7.17	2.95e-12	2.19e-09	0.45	0.31	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	7.17	2.95e-12	2.19e-09	0.45	0.31	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
HNSC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-7.17	2.95e-12	2.2e-09	-0.4	-0.31	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
HNSC	cis	rs1799949	1	rs16942	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43091983	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43097077	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000267151.3	RP11-100E5.2	7.17	2.95e-12	2.2e-09	0.4	0.31	Menopause (age at onset);	chr17:43099629	chr17:43444707~43451200:+
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.932	rs13086087	ENSG00000248787.1	RP11-666A20.4	-7.17	2.95e-12	2.2e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125927438	chr3:125908005~125910272:-
HNSC	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	7.17	2.95e-12	2.2e-09	0.39	0.31	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
HNSC	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	7.17	2.96e-12	2.21e-09	0.24	0.31	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-7.17	2.96e-12	2.21e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
HNSC	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	7.17	2.97e-12	2.21e-09	0.44	0.31	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
HNSC	cis	rs1021993	0.545	rs17014337	ENSG00000231648.1	RP11-372M18.2	-7.17	2.98e-12	2.22e-09	-0.54	-0.31	Gut microbiome composition (winter);	chr1:209354120	chr1:209367662~209379690:+
HNSC	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	7.17	2.99e-12	2.22e-09	0.38	0.31	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
HNSC	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	7.17	2.99e-12	2.22e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
HNSC	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	7.17	2.99e-12	2.22e-09	0.39	0.31	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	7.17	2.99e-12	2.22e-09	0.44	0.31	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
HNSC	cis	rs6951245	0.745	rs79788515	ENSG00000224079.1	AC091729.7	-7.17	2.99e-12	2.23e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1074450~1078036:+
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000276710.3	CSPG4P8	-7.17	3e-12	2.23e-09	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82459472~82477258:+
HNSC	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-7.17	3e-12	2.23e-09	-0.31	-0.31	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
HNSC	cis	rs1865760	0.566	rs3752419	ENSG00000272462.2	U91328.19	-7.17	3.01e-12	2.24e-09	-0.3	-0.31	Height;	chr6:26027205	chr6:25992662~26001775:+
HNSC	cis	rs1021993	0.553	rs1857966	ENSG00000231648.1	RP11-372M18.2	-7.17	3.04e-12	2.26e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209388370	chr1:209367662~209379690:+
HNSC	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-7.16	3.08e-12	2.29e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-7.16	3.09e-12	2.3e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
HNSC	cis	rs6951245	0.935	rs61910751	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs77434655	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs75398423	ENSG00000224079.1	AC091729.7	-7.16	3.1e-12	2.3e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1074450~1078036:+
HNSC	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	7.16	3.11e-12	2.31e-09	0.27	0.31	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
HNSC	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-7.16	3.12e-12	2.32e-09	-0.39	-0.31	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-7.16	3.12e-12	2.32e-09	-0.31	-0.31	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
HNSC	cis	rs6867032	0.958	rs4975797	ENSG00000249731.1	RP11-259O2.3	7.16	3.16e-12	2.35e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015459	chr5:1968094~1969013:+
HNSC	cis	rs6867032	0.958	rs4975798	ENSG00000249731.1	RP11-259O2.3	7.16	3.16e-12	2.35e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015466	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-7.16	3.17e-12	2.35e-09	-0.3	-0.31	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000276710.3	CSPG4P8	7.16	3.17e-12	2.35e-09	0.37	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	7.16	3.18e-12	2.36e-09	0.58	0.31	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
HNSC	cis	rs7615952	0.8	rs13086460	ENSG00000248787.1	RP11-666A20.4	-7.16	3.18e-12	2.36e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125927574	chr3:125908005~125910272:-
HNSC	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	7.16	3.18e-12	2.36e-09	0.39	0.31	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
HNSC	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.19e-12	2.37e-09	-0.36	-0.31	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
HNSC	cis	rs9402743	0.781	rs10223338	ENSG00000217482.2	HMGB1P17	7.16	3.2e-12	2.38e-09	0.37	0.31	Systemic lupus erythematosus;	chr6:135680889	chr6:135636086~135636713:-
HNSC	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	7.16	3.21e-12	2.38e-09	0.3	0.31	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	7.16	3.21e-12	2.38e-09	0.3	0.31	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
HNSC	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-7.16	3.21e-12	2.38e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.21e-12	2.38e-09	-0.36	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
HNSC	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	7.16	3.22e-12	2.39e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
HNSC	cis	rs4978813	0.5	rs10759345	ENSG00000213539.4	YBX1P6	-7.16	3.22e-12	2.39e-09	-0.36	-0.31	Plantar warts;	chr9:109516765	chr9:109532830~109534332:-
HNSC	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	7.16	3.22e-12	2.39e-09	0.34	0.31	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
HNSC	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-7.16	3.23e-12	2.4e-09	-0.31	-0.31	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	7.16	3.24e-12	2.4e-09	0.44	0.31	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
HNSC	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	7.16	3.25e-12	2.41e-09	0.28	0.31	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
HNSC	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	7.16	3.25e-12	2.41e-09	0.34	0.31	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
HNSC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-7.16	3.25e-12	2.41e-09	-0.36	-0.31	Height;	chr3:53085518	chr3:53064283~53065091:-
HNSC	cis	rs1075265	0.868	rs1877906	ENSG00000233266.1	HMGB1P31	7.15	3.27e-12	2.42e-09	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54136700	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs9646412	ENSG00000267151.3	RP11-100E5.2	7.15	3.27e-12	2.42e-09	0.41	0.31	Menopause (age at onset);	chr17:43348525	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	7.15	3.28e-12	2.43e-09	0.28	0.31	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
HNSC	cis	rs451417	0.841	rs12106220	ENSG00000275632.1	RP5-967N21.11	7.15	3.3e-12	2.44e-09	0.38	0.31	Menopause (age at onset);	chr20:5963609	chr20:6000418~6000941:+
HNSC	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	7.15	3.3e-12	2.44e-09	0.4	0.31	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
HNSC	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	7.15	3.31e-12	2.45e-09	0.24	0.31	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
HNSC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-7.15	3.32e-12	2.45e-09	-0.36	-0.31	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-7.15	3.32e-12	2.46e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
HNSC	cis	rs1021993	0.545	rs4844820	ENSG00000231648.1	RP11-372M18.2	-7.15	3.33e-12	2.46e-09	-0.55	-0.31	Gut microbiome composition (winter);	chr1:209381120	chr1:209367662~209379690:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-7.15	3.33e-12	2.46e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
HNSC	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-7.15	3.33e-12	2.46e-09	-0.46	-0.31	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000254340.1	RP11-10A14.3	7.15	3.37e-12	2.5e-09	0.4	0.31	Joint mobility (Beighton score);	chr8:8995760	chr8:9141424~9145435:+
HNSC	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	7.15	3.4e-12	2.51e-09	0.45	0.31	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
HNSC	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-7.15	3.42e-12	2.53e-09	-0.4	-0.31	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000267151.3	RP11-100E5.2	7.15	3.44e-12	2.54e-09	0.4	0.31	Menopause (age at onset);	chr17:43115033	chr17:43444707~43451200:+
HNSC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-7.15	3.44e-12	2.54e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
HNSC	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	7.15	3.44e-12	2.55e-09	0.45	0.31	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
HNSC	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	7.15	3.44e-12	2.55e-09	0.3	0.31	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
HNSC	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	7.15	3.44e-12	2.55e-09	0.51	0.31	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
HNSC	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	7.15	3.46e-12	2.56e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	7.15	3.46e-12	2.56e-09	0.4	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-7.15	3.47e-12	2.56e-09	-0.34	-0.31	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
HNSC	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-7.14	3.48e-12	2.57e-09	-0.35	-0.31	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
HNSC	cis	rs6867032	1	rs4413568	ENSG00000249731.1	RP11-259O2.3	7.14	3.52e-12	2.6e-09	0.39	0.31	Gut microbiome composition (winter);	chr5:2016780	chr5:1968094~1969013:+
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-7.14	3.53e-12	2.6e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000267151.3	RP11-100E5.2	7.14	3.53e-12	2.61e-09	0.4	0.31	Menopause (age at onset);	chr17:43113759	chr17:43444707~43451200:+
HNSC	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	7.14	3.54e-12	2.62e-09	0.33	0.31	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
HNSC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-7.14	3.57e-12	2.63e-09	-0.39	-0.31	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
HNSC	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	7.14	3.57e-12	2.64e-09	0.45	0.31	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
HNSC	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	7.14	3.58e-12	2.64e-09	0.28	0.31	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000267151.3	RP11-100E5.2	7.14	3.59e-12	2.65e-09	0.4	0.31	Menopause (age at onset);	chr17:43116189	chr17:43444707~43451200:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-7.14	3.6e-12	2.66e-09	-0.3	-0.31	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
HNSC	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-7.14	3.6e-12	2.66e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
HNSC	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-7.14	3.61e-12	2.67e-09	-0.31	-0.31	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
HNSC	cis	rs6867032	1	rs4975796	ENSG00000249731.1	RP11-259O2.3	-7.14	3.62e-12	2.67e-09	-0.38	-0.31	Gut microbiome composition (winter);	chr5:2015406	chr5:1968094~1969013:+
HNSC	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-7.14	3.63e-12	2.68e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-7.14	3.63e-12	2.68e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
HNSC	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-7.14	3.64e-12	2.68e-09	-0.33	-0.31	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
HNSC	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	7.14	3.66e-12	2.69e-09	0.43	0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
HNSC	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-7.14	3.66e-12	2.69e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000276710.3	CSPG4P8	-7.14	3.66e-12	2.7e-09	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82459472~82477258:+
HNSC	cis	rs7115242	0.8	rs493134	ENSG00000280143.1	AP000892.6	7.14	3.67e-12	2.7e-09	0.46	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	7.14	3.67e-12	2.7e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-7.14	3.68e-12	2.71e-09	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
HNSC	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	7.14	3.69e-12	2.72e-09	0.42	0.31	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
HNSC	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	7.14	3.71e-12	2.73e-09	0.45	0.31	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
HNSC	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	7.14	3.71e-12	2.73e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	7.13	3.73e-12	2.74e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
HNSC	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-7.13	3.73e-12	2.75e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
HNSC	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	7.13	3.73e-12	2.75e-09	0.28	0.31	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	7.13	3.74e-12	2.75e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	7.13	3.74e-12	2.75e-09	0.41	0.31	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-7.13	3.74e-12	2.75e-09	-0.41	-0.31	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
HNSC	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-7.13	3.74e-12	2.75e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
HNSC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	7.13	3.74e-12	2.75e-09	0.48	0.31	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	7.13	3.75e-12	2.76e-09	0.28	0.31	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	7.13	3.75e-12	2.76e-09	0.28	0.31	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.591	rs4239252	ENSG00000270977.1	AC015849.16	7.13	3.76e-12	2.76e-09	0.36	0.31	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35893707~35911023:-
HNSC	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-7.13	3.76e-12	2.76e-09	-0.5	-0.31	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
HNSC	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	7.13	3.76e-12	2.77e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
HNSC	cis	rs7615952	0.599	rs66532274	ENSG00000241288.6	RP11-379B18.5	-7.13	3.76e-12	2.77e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:126013002	chr3:125827238~125916384:-
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000267151.3	RP11-100E5.2	7.13	3.76e-12	2.77e-09	0.4	0.31	Menopause (age at onset);	chr17:43083782	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-7.13	3.78e-12	2.78e-09	-0.28	-0.31	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.13	3.78e-12	2.78e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
HNSC	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-7.13	3.79e-12	2.79e-09	-0.37	-0.31	Height;	chr4:55364952	chr4:55363971~55395847:-
HNSC	cis	rs17270561	0.609	rs1892255	ENSG00000272462.2	U91328.19	-7.13	3.81e-12	2.8e-09	-0.33	-0.31	Iron status biomarkers;	chr6:25750126	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1892254	ENSG00000272462.2	U91328.19	-7.13	3.81e-12	2.8e-09	-0.33	-0.31	Iron status biomarkers;	chr6:25750302	chr6:25992662~26001775:+
HNSC	cis	rs6951245	1	rs75488469	ENSG00000224079.1	AC091729.7	-7.13	3.81e-12	2.8e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1074450~1078036:+
HNSC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-7.13	3.82e-12	2.81e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000267151.3	RP11-100E5.2	7.13	3.82e-12	2.81e-09	0.4	0.31	Menopause (age at onset);	chr17:43079499	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176120	ENSG00000267151.3	RP11-100E5.2	7.13	3.82e-12	2.81e-09	0.4	0.31	Menopause (age at onset);	chr17:43109216	chr17:43444707~43451200:+
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-7.13	3.83e-12	2.81e-09	-0.6	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	7.13	3.83e-12	2.81e-09	0.28	0.31	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.545	rs76234951	ENSG00000231648.1	RP11-372M18.2	-7.13	3.83e-12	2.81e-09	-0.55	-0.31	Gut microbiome composition (winter);	chr1:209377881	chr1:209367662~209379690:+
HNSC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-7.13	3.85e-12	2.83e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
HNSC	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-7.13	3.85e-12	2.83e-09	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
HNSC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	7.13	3.85e-12	2.83e-09	0.38	0.31	Height;	chr3:53085313	chr3:53064283~53065091:-
HNSC	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	7.13	3.85e-12	2.83e-09	0.28	0.31	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	7.13	3.85e-12	2.83e-09	0.28	0.31	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	7.13	3.86e-12	2.83e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
HNSC	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-7.13	3.86e-12	2.83e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
HNSC	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-7.13	3.86e-12	2.83e-09	-0.39	-0.31	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-7.13	3.87e-12	2.84e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
HNSC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-7.13	3.87e-12	2.84e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	7.13	3.87e-12	2.84e-09	0.28	0.31	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	7.13	3.87e-12	2.84e-09	0.28	0.31	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
HNSC	cis	rs1912483	0.505	rs3760372	ENSG00000228782.6	CTD-2026D20.3	7.13	3.87e-12	2.84e-09	0.33	0.31	Coronary artery disease;	chr17:47302636	chr17:47450568~47492492:-
HNSC	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	7.13	3.88e-12	2.85e-09	0.46	0.31	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	7.13	3.88e-12	2.85e-09	0.46	0.31	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43177830	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43178007	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000267151.3	RP11-100E5.2	7.13	3.89e-12	2.85e-09	0.41	0.31	Menopause (age at onset);	chr17:43178248	chr17:43444707~43451200:+
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-7.13	3.89e-12	2.86e-09	-0.4	-0.31	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-7.13	3.89e-12	2.86e-09	-0.4	-0.31	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
HNSC	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-7.13	3.9e-12	2.86e-09	-0.46	-0.31	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
HNSC	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	7.13	3.91e-12	2.87e-09	0.31	0.31	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
HNSC	cis	rs1021993	0.597	rs1014817	ENSG00000231648.1	RP11-372M18.2	-7.13	3.91e-12	2.87e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209350319	chr1:209367662~209379690:+
HNSC	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.13	3.92e-12	2.88e-09	-0.32	-0.31	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
HNSC	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	7.13	3.93e-12	2.88e-09	0.34	0.31	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000254340.1	RP11-10A14.3	7.13	3.95e-12	2.89e-09	0.4	0.31	Mean corpuscular volume;	chr8:8994371	chr8:9141424~9145435:+
HNSC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-7.13	3.96e-12	2.9e-09	-0.37	-0.31	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
HNSC	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	7.13	3.96e-12	2.9e-09	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
HNSC	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	7.12	3.98e-12	2.91e-09	0.38	0.31	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000267151.3	RP11-100E5.2	7.12	3.99e-12	2.92e-09	0.4	0.31	Menopause (age at onset);	chr17:43089373	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000267151.3	RP11-100E5.2	7.12	3.99e-12	2.92e-09	0.4	0.31	Menopause (age at onset);	chr17:43089486	chr17:43444707~43451200:+
HNSC	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	7.12	3.99e-12	2.92e-09	0.35	0.31	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
HNSC	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-7.12	3.99e-12	2.92e-09	-0.43	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000267151.3	RP11-100E5.2	7.12	4.01e-12	2.93e-09	0.41	0.31	Menopause (age at onset);	chr17:43358069	chr17:43444707~43451200:+
HNSC	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	7.12	4.01e-12	2.94e-09	0.44	0.31	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
HNSC	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-7.12	4.01e-12	2.94e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	7.12	4.04e-12	2.95e-09	0.27	0.31	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
HNSC	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	7.12	4.04e-12	2.96e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
HNSC	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-7.12	4.05e-12	2.96e-09	-0.45	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
HNSC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	7.12	4.05e-12	2.97e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000267151.3	RP11-100E5.2	7.12	4.08e-12	2.98e-09	0.41	0.31	Menopause (age at onset);	chr17:43178803	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000267151.3	RP11-100E5.2	7.12	4.08e-12	2.98e-09	0.41	0.31	Menopause (age at onset);	chr17:43182732	chr17:43444707~43451200:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	7.12	4.09e-12	2.99e-09	0.29	0.31	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
HNSC	cis	rs1021993	0.597	rs10494922	ENSG00000231648.1	RP11-372M18.2	-7.12	4.09e-12	2.99e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209352085	chr1:209367662~209379690:+
HNSC	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-7.12	4.13e-12	3.02e-09	-0.28	-0.31	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
HNSC	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	7.12	4.14e-12	3.02e-09	0.46	0.31	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
HNSC	cis	rs17270561	0.609	rs7754733	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25744821	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7754814	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745015	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7775354	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745038	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9379789	ENSG00000272462.2	U91328.19	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25745351	chr6:25992662~26001775:+
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.12	4.14e-12	3.03e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
HNSC	cis	rs9341808	0.527	rs7453746	ENSG00000272129.1	RP11-250B2.6	7.12	4.16e-12	3.04e-09	0.37	0.31	Sitting height ratio;	chr6:80100296	chr6:80355424~80356859:+
HNSC	cis	rs7048146	0.899	rs1541092	ENSG00000213539.4	YBX1P6	-7.12	4.16e-12	3.04e-09	-0.37	-0.31	Vascular brain injury;	chr9:109580279	chr9:109532830~109534332:-
HNSC	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.12	4.18e-12	3.05e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-7.12	4.18e-12	3.05e-09	-0.44	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
HNSC	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	7.12	4.19e-12	3.06e-09	0.34	0.31	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
HNSC	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-7.12	4.19e-12	3.06e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
HNSC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	7.12	4.2e-12	3.07e-09	0.31	0.31	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-7.12	4.2e-12	3.07e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
HNSC	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-7.12	4.21e-12	3.07e-09	-0.31	-0.31	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
HNSC	cis	rs17270561	0.609	rs9379783	ENSG00000272462.2	U91328.19	-7.12	4.22e-12	3.08e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25724979	chr6:25992662~26001775:+
HNSC	cis	rs1659258	0.803	rs1258417	ENSG00000232508.1	MRPL45P1	7.12	4.23e-12	3.09e-09	0.66	0.31	Visceral fat;	chr2:88332624	chr2:88364695~88365608:-
HNSC	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-7.12	4.23e-12	3.09e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	7.11	4.24e-12	3.1e-09	0.44	0.31	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
HNSC	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	7.11	4.27e-12	3.11e-09	0.34	0.31	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
HNSC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.11	4.28e-12	3.12e-09	-0.36	-0.31	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
HNSC	cis	rs7615952	0.932	rs1976458	ENSG00000248787.1	RP11-666A20.4	-7.11	4.3e-12	3.13e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125928669	chr3:125908005~125910272:-
HNSC	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-7.11	4.3e-12	3.14e-09	-0.36	-0.31	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
HNSC	cis	rs1799949	1	rs3950989	ENSG00000267151.3	RP11-100E5.2	7.11	4.33e-12	3.15e-09	0.4	0.31	Menopause (age at onset);	chr17:43085936	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000267151.3	RP11-100E5.2	7.11	4.33e-12	3.15e-09	0.4	0.31	Menopause (age at onset);	chr17:43090268	chr17:43444707~43451200:+
HNSC	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	7.11	4.33e-12	3.16e-09	0.36	0.31	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
HNSC	cis	rs2834288	0.536	rs762357	ENSG00000237945.6	LINC00649	7.11	4.34e-12	3.16e-09	0.39	0.31	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33915534~33977691:+
HNSC	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	7.11	4.34e-12	3.16e-09	0.33	0.31	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
HNSC	cis	rs1021993	0.545	rs17014395	ENSG00000231648.1	RP11-372M18.2	-7.11	4.35e-12	3.17e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209375462	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.545	rs17014396	ENSG00000231648.1	RP11-372M18.2	-7.11	4.35e-12	3.17e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209375540	chr1:209367662~209379690:+
HNSC	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	7.11	4.36e-12	3.17e-09	0.37	0.31	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
HNSC	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-7.11	4.37e-12	3.18e-09	-0.31	-0.31	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-7.11	4.37e-12	3.18e-09	-0.31	-0.31	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
HNSC	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-7.11	4.38e-12	3.19e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
HNSC	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	7.11	4.38e-12	3.19e-09	0.4	0.31	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	7.11	4.4e-12	3.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
HNSC	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.4e-12	3.2e-09	-0.36	-0.31	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
HNSC	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.4e-12	3.2e-09	-0.35	-0.31	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
HNSC	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-7.11	4.4e-12	3.2e-09	-0.48	-0.31	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-7.11	4.41e-12	3.21e-09	-0.28	-0.31	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
HNSC	cis	rs1659258	0.892	rs1659259	ENSG00000232508.1	MRPL45P1	7.11	4.41e-12	3.21e-09	0.66	0.31	Visceral fat;	chr2:88360376	chr2:88364695~88365608:-
HNSC	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	7.11	4.43e-12	3.22e-09	0.39	0.31	Height;	chr4:55611014	chr4:55363971~55395847:-
HNSC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-7.11	4.45e-12	3.24e-09	-0.38	-0.31	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	7.11	4.46e-12	3.24e-09	0.28	0.31	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
HNSC	cis	rs7000734	0.687	rs297550	ENSG00000245080.5	RP11-320N21.1	7.11	4.46e-12	3.24e-09	0.45	0.31	Radiation response;	chr8:95089566	chr8:95066808~95073182:-
HNSC	cis	rs62344088	0.59	rs62345236	ENSG00000277812.1	AC021087.1	7.11	4.48e-12	3.25e-09	0.71	0.31	Asthma (childhood onset);	chr5:283404	chr5:262769~262881:+
HNSC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	7.11	4.48e-12	3.26e-09	0.3	0.31	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-7.11	4.49e-12	3.26e-09	-0.39	-0.31	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	7.11	4.5e-12	3.27e-09	0.28	0.31	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-7.11	4.5e-12	3.27e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	7.11	4.5e-12	3.27e-09	0.3	0.31	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
HNSC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	7.11	4.51e-12	3.28e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	7.11	4.51e-12	3.28e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
HNSC	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
HNSC	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	7.1	4.52e-12	3.29e-09	0.27	0.31	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
HNSC	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	7.1	4.52e-12	3.29e-09	0.37	0.31	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
HNSC	cis	rs4141404	0.604	rs2103853	ENSG00000236132.1	CTA-440B3.1	-7.1	4.53e-12	3.29e-09	-0.35	-0.31	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31816379~31817491:-
HNSC	cis	rs740698	0.521	rs9891713	ENSG00000265702.1	RP11-156L14.1	7.1	4.54e-12	3.3e-09	0.37	0.31	Pulse pressure;	chr17:62712044	chr17:62699244~62737922:+
HNSC	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	7.1	4.54e-12	3.3e-09	0.3	0.31	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	7.1	4.54e-12	3.3e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
HNSC	cis	rs9402743	0.962	rs11967412	ENSG00000217482.2	HMGB1P17	7.1	4.56e-12	3.31e-09	0.34	0.31	Systemic lupus erythematosus;	chr6:135648288	chr6:135636086~135636713:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	7.1	4.58e-12	3.32e-09	0.41	0.31	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-7.1	4.59e-12	3.33e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
HNSC	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-7.1	4.59e-12	3.33e-09	-0.38	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.866	rs1976459	ENSG00000248787.1	RP11-666A20.4	-7.1	4.61e-12	3.35e-09	-0.48	-0.31	Blood pressure (smoking interaction);	chr3:125928643	chr3:125908005~125910272:-
HNSC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-7.1	4.61e-12	3.35e-09	-0.4	-0.31	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
HNSC	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-7.1	4.63e-12	3.36e-09	-0.34	-0.31	Temperament;	chr17:14046511	chr17:14024514~14025488:+
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-7.1	4.63e-12	3.36e-09	-0.29	-0.31	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-7.1	4.63e-12	3.36e-09	-0.29	-0.31	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
HNSC	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	7.1	4.63e-12	3.36e-09	0.27	0.31	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
HNSC	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	7.1	4.64e-12	3.37e-09	0.45	0.31	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
HNSC	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-7.1	4.64e-12	3.37e-09	-0.32	-0.31	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	7.1	4.64e-12	3.37e-09	0.43	0.31	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
HNSC	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	7.1	4.65e-12	3.37e-09	0.3	0.31	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
HNSC	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-7.1	4.65e-12	3.37e-09	-0.34	-0.31	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
HNSC	cis	rs6951245	1	rs80094748	ENSG00000224079.1	AC091729.7	-7.1	4.66e-12	3.38e-09	-0.54	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1074450~1078036:+
HNSC	cis	rs9326248	0.53	rs579890	ENSG00000280143.1	AP000892.6	7.1	4.67e-12	3.39e-09	0.47	0.31	Blood protein levels;	chr11:116928247	chr11:117204967~117210292:+
HNSC	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	7.1	4.67e-12	3.39e-09	0.4	0.31	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
HNSC	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-7.1	4.68e-12	3.4e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000267151.3	RP11-100E5.2	7.1	4.69e-12	3.4e-09	0.4	0.31	Menopause (age at onset);	chr17:43161595	chr17:43444707~43451200:+
HNSC	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	7.1	4.71e-12	3.41e-09	0.31	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
HNSC	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-7.1	4.71e-12	3.42e-09	-0.34	-0.31	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
HNSC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-7.1	4.72e-12	3.42e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
HNSC	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	7.1	4.72e-12	3.42e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
HNSC	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	7.1	4.72e-12	3.42e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
HNSC	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	7.1	4.73e-12	3.43e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
HNSC	cis	rs12922040	0.607	rs8059739	ENSG00000263065.1	AF001548.6	-7.1	4.74e-12	3.43e-09	-0.36	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15741151~15741791:+
HNSC	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	7.1	4.75e-12	3.44e-09	0.38	0.31	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
HNSC	cis	rs7115242	0.8	rs519794	ENSG00000280143.1	AP000892.6	7.1	4.77e-12	3.46e-09	0.44	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117204967~117210292:+
HNSC	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	7.1	4.78e-12	3.46e-09	0.3	0.31	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
HNSC	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-7.1	4.78e-12	3.46e-09	-0.34	-0.31	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000267151.3	RP11-100E5.2	7.1	4.79e-12	3.47e-09	0.4	0.31	Menopause (age at onset);	chr17:43165415	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000267151.3	RP11-100E5.2	7.1	4.79e-12	3.47e-09	0.4	0.31	Menopause (age at onset);	chr17:43169829	chr17:43444707~43451200:+
HNSC	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	7.1	4.79e-12	3.47e-09	0.39	0.31	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
HNSC	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	7.1	4.81e-12	3.48e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
HNSC	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	7.1	4.81e-12	3.48e-09	0.28	0.31	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	7.1	4.81e-12	3.48e-09	0.28	0.31	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
HNSC	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-7.09	4.84e-12	3.5e-09	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
HNSC	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	7.09	4.85e-12	3.5e-09	0.38	0.31	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
HNSC	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-7.09	4.86e-12	3.51e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
HNSC	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	7.09	4.87e-12	3.52e-09	0.4	0.31	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
HNSC	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	7.09	4.87e-12	3.52e-09	0.4	0.31	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.09	4.88e-12	3.53e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
HNSC	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	7.09	4.88e-12	3.53e-09	0.29	0.31	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
HNSC	cis	rs17270561	0.585	rs9393663	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25740805	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9366629	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25740988	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.553	rs6456696	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741180	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs6456697	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741206	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs6456698	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741436	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.666	rs4711099	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741581	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711100	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741726	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711101	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741742	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712965	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741794	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.608	rs4711102	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741847	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711103	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25741996	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9379788	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742531	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358879	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742690	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs9358880	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25742933	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4145216	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25743331	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4145217	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25743769	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393665	ENSG00000272462.2	U91328.19	-7.09	4.91e-12	3.54e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25744056	chr6:25992662~26001775:+
HNSC	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	7.09	4.92e-12	3.56e-09	0.61	0.31	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
HNSC	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-7.09	4.95e-12	3.57e-09	-0.32	-0.31	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.09	4.95e-12	3.57e-09	-0.32	-0.31	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
HNSC	cis	rs7942368	1	rs7107409	ENSG00000255100.1	RP11-21L23.3	7.09	4.97e-12	3.59e-09	0.4	0.31	Endometriosis;	chr11:76781151	chr11:76782581~76783062:-
HNSC	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	7.09	4.97e-12	3.59e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
HNSC	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-7.09	4.98e-12	3.6e-09	-0.32	-0.31	Height;	chr2:231516587	chr2:231508426~231514339:-
HNSC	cis	rs9402743	1	rs7739635	ENSG00000217482.2	HMGB1P17	7.09	4.99e-12	3.61e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135676640	chr6:135636086~135636713:-
HNSC	cis	rs6951245	0.832	rs79808627	ENSG00000224079.1	AC091729.7	-7.09	4.99e-12	3.61e-09	-0.5	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-7.09	5e-12	3.61e-09	-0.29	-0.31	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-7.09	5.02e-12	3.63e-09	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
HNSC	cis	rs17270561	0.609	rs9348694	ENSG00000272462.2	U91328.19	-7.09	5.05e-12	3.65e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25753412	chr6:25992662~26001775:+
HNSC	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-7.09	5.06e-12	3.65e-09	-0.31	-0.31	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
HNSC	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-7.09	5.06e-12	3.65e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
HNSC	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-7.09	5.07e-12	3.65e-09	-0.36	-0.31	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
HNSC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	7.09	5.07e-12	3.66e-09	0.41	0.31	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
HNSC	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-7.09	5.08e-12	3.66e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-7.09	5.08e-12	3.66e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
HNSC	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-7.09	5.09e-12	3.67e-09	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
HNSC	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-7.09	5.11e-12	3.68e-09	-0.41	-0.31	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
HNSC	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-7.09	5.11e-12	3.68e-09	-0.41	-0.31	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
HNSC	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-7.09	5.11e-12	3.68e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	7.09	5.12e-12	3.69e-09	0.35	0.31	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
HNSC	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	7.09	5.13e-12	3.7e-09	0.32	0.31	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
HNSC	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-7.09	5.13e-12	3.7e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.09	5.13e-12	3.7e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
HNSC	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.09	5.14e-12	3.7e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
HNSC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	7.09	5.14e-12	3.7e-09	0.41	0.31	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
HNSC	cis	rs9402743	0.962	rs6935033	ENSG00000217482.2	HMGB1P17	7.09	5.14e-12	3.71e-09	0.34	0.31	Systemic lupus erythematosus;	chr6:135659499	chr6:135636086~135636713:-
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43155456	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43155755	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000267151.3	RP11-100E5.2	7.08	5.17e-12	3.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43156257	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000267151.3	RP11-100E5.2	7.08	5.2e-12	3.74e-09	0.4	0.31	Menopause (age at onset);	chr17:43174923	chr17:43444707~43451200:+
HNSC	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	7.08	5.2e-12	3.74e-09	0.45	0.31	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
HNSC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-7.08	5.22e-12	3.76e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-7.08	5.23e-12	3.76e-09	-0.3	-0.31	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	7.08	5.23e-12	3.77e-09	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	7.08	5.24e-12	3.78e-09	0.45	0.31	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000267151.3	RP11-100E5.2	7.08	5.24e-12	3.78e-09	0.4	0.31	Menopause (age at onset);	chr17:43121078	chr17:43444707~43451200:+
HNSC	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-7.08	5.26e-12	3.79e-09	-0.31	-0.31	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
HNSC	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	7.08	5.26e-12	3.79e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
HNSC	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	7.08	5.27e-12	3.79e-09	0.49	0.31	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
HNSC	cis	rs35955747	0.669	rs878718	ENSG00000236132.1	CTA-440B3.1	-7.08	5.27e-12	3.8e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31156716	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.08	5.28e-12	3.8e-09	-0.31	-0.31	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
HNSC	cis	rs2243480	0.706	rs6460257	ENSG00000179406.6	LINC00174	-7.08	5.32e-12	3.83e-09	-0.56	-0.31	Diabetic kidney disease;	chr7:65731813	chr7:66376044~66401338:-
HNSC	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	7.08	5.32e-12	3.83e-09	0.34	0.31	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
HNSC	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	7.08	5.32e-12	3.83e-09	0.39	0.31	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
HNSC	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	7.08	5.34e-12	3.84e-09	0.33	0.31	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
HNSC	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-7.08	5.36e-12	3.85e-09	-0.38	-0.31	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
HNSC	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	7.08	5.36e-12	3.86e-09	0.37	0.31	Depression;	chr6:28363475	chr6:28943877~28944537:+
HNSC	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	7.08	5.36e-12	3.86e-09	0.47	0.31	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
HNSC	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-7.08	5.36e-12	3.86e-09	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
HNSC	cis	rs2579103	0.668	rs825965	ENSG00000258183.4	RP11-753N8.1	-7.08	5.38e-12	3.87e-09	-0.43	-0.31	Body mass index;	chr12:90309031	chr12:90280894~90300340:+
HNSC	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	7.08	5.39e-12	3.88e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
HNSC	cis	rs1021993	0.545	rs60534728	ENSG00000231648.1	RP11-372M18.2	-7.08	5.4e-12	3.89e-09	-0.56	-0.31	Gut microbiome composition (winter);	chr1:209374826	chr1:209367662~209379690:+
HNSC	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.08	5.4e-12	3.89e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-7.08	5.41e-12	3.89e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-7.08	5.41e-12	3.89e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
HNSC	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	7.08	5.43e-12	3.9e-09	0.35	0.31	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
HNSC	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-7.08	5.44e-12	3.91e-09	-0.39	-0.31	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
HNSC	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	7.08	5.44e-12	3.91e-09	0.44	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
HNSC	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-7.08	5.47e-12	3.93e-09	-0.39	-0.31	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
HNSC	cis	rs7942368	0.941	rs10160769	ENSG00000255100.1	RP11-21L23.3	7.07	5.51e-12	3.95e-09	0.39	0.31	Endometriosis;	chr11:76763783	chr11:76782581~76783062:-
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000267151.3	RP11-100E5.2	7.07	5.51e-12	3.96e-09	0.4	0.31	Menopause (age at onset);	chr17:43118649	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000267151.3	RP11-100E5.2	7.07	5.51e-12	3.96e-09	0.4	0.31	Menopause (age at onset);	chr17:43121362	chr17:43444707~43451200:+
HNSC	cis	rs9402743	0.926	rs7762826	ENSG00000217482.2	HMGB1P17	7.07	5.56e-12	3.99e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135654485	chr6:135636086~135636713:-
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-7.07	5.56e-12	3.99e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-7.07	5.56e-12	3.99e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
HNSC	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	7.07	5.57e-12	4e-09	0.45	0.31	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	7.07	5.57e-12	4e-09	0.45	0.31	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
HNSC	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	7.07	5.62e-12	4.04e-09	0.47	0.31	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
HNSC	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	7.07	5.65e-12	4.05e-09	0.28	0.31	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
HNSC	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-7.07	5.66e-12	4.06e-09	-0.46	-0.31	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
HNSC	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-7.07	5.68e-12	4.07e-09	-0.28	-0.31	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
HNSC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-7.07	5.71e-12	4.09e-09	-0.39	-0.31	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
HNSC	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-7.07	5.72e-12	4.1e-09	-0.39	-0.31	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-7.07	5.72e-12	4.1e-09	-0.31	-0.31	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-7.07	5.73e-12	4.11e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
HNSC	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-7.07	5.75e-12	4.12e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
HNSC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.07	5.76e-12	4.13e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
HNSC	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-7.07	5.8e-12	4.15e-09	-0.41	-0.31	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
HNSC	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	7.07	5.81e-12	4.16e-09	0.45	0.31	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
HNSC	cis	rs9326248	0.53	rs473188	ENSG00000280143.1	AP000892.6	7.07	5.82e-12	4.17e-09	0.45	0.31	Blood protein levels;	chr11:116941313	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	7.07	5.83e-12	4.18e-09	0.28	0.31	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
HNSC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-7.07	5.84e-12	4.18e-09	-0.39	-0.31	Height;	chr3:53080524	chr3:53064283~53065091:-
HNSC	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	7.07	5.85e-12	4.19e-09	0.36	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
HNSC	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-7.07	5.85e-12	4.19e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
HNSC	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	7.07	5.86e-12	4.19e-09	0.45	0.31	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	7.07	5.86e-12	4.19e-09	0.45	0.31	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
HNSC	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	7.06	5.87e-12	4.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	7.06	5.87e-12	4.2e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
HNSC	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	7.06	5.87e-12	4.2e-09	0.46	0.31	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
HNSC	cis	rs1021993	0.597	rs2356722	ENSG00000231648.1	RP11-372M18.2	-7.06	5.88e-12	4.21e-09	-0.39	-0.31	Gut microbiome composition (winter);	chr1:209351389	chr1:209367662~209379690:+
HNSC	cis	rs9402743	0.781	rs9494331	ENSG00000217482.2	HMGB1P17	-7.06	5.89e-12	4.21e-09	-0.36	-0.31	Systemic lupus erythematosus;	chr6:135685163	chr6:135636086~135636713:-
HNSC	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	7.06	5.89e-12	4.21e-09	0.37	0.31	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
HNSC	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	7.06	5.89e-12	4.22e-09	0.45	0.31	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
HNSC	cis	rs35955747	0.633	rs5998021	ENSG00000236132.1	CTA-440B3.1	7.06	5.9e-12	4.22e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31511441	chr22:31816379~31817491:-
HNSC	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	7.06	5.91e-12	4.23e-09	0.44	0.31	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
HNSC	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	7.06	5.92e-12	4.23e-09	0.5	0.31	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-7.06	5.92e-12	4.23e-09	-0.37	-0.31	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
HNSC	cis	rs36405	0.5	rs4622450	ENSG00000266869.1	RP6-114E22.1	-7.06	5.95e-12	4.26e-09	-0.4	-0.31	Yang-deficiency constitution;	chr14:71889095	chr14:71848606~71908430:+
HNSC	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-7.06	5.97e-12	4.27e-09	-0.44	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
HNSC	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-7.06	5.98e-12	4.27e-09	-0.48	-0.31	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
HNSC	cis	rs6471393	0.929	rs58575315	ENSG00000253848.1	RP11-10N23.5	7.06	5.98e-12	4.28e-09	0.38	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:93741193~93744534:+
HNSC	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	7.06	6e-12	4.29e-09	0.42	0.31	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.06	6.04e-12	4.32e-09	0.23	0.31	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
HNSC	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-7.06	6.05e-12	4.32e-09	-0.31	-0.31	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
HNSC	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	7.06	6.05e-12	4.32e-09	0.34	0.31	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
HNSC	cis	rs1799949	1	rs8176202	ENSG00000267151.3	RP11-100E5.2	7.06	6.07e-12	4.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43078211	chr17:43444707~43451200:+
HNSC	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	7.06	6.08e-12	4.34e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
HNSC	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	7.06	6.1e-12	4.36e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	7.06	6.1e-12	4.36e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
HNSC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	7.06	6.12e-12	4.37e-09	0.31	0.31	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
HNSC	cis	rs6867032	0.958	rs4463207	ENSG00000249731.1	RP11-259O2.3	7.06	6.12e-12	4.37e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2017004	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs61177713	ENSG00000249731.1	RP11-259O2.3	7.06	6.12e-12	4.37e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2017141	chr5:1968094~1969013:+
HNSC	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-7.06	6.13e-12	4.37e-09	-0.38	-0.31	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
HNSC	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-7.06	6.14e-12	4.38e-09	-0.48	-0.31	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
HNSC	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-7.06	6.16e-12	4.4e-09	-0.31	-0.31	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
HNSC	cis	rs7942368	0.793	rs12273016	ENSG00000255100.1	RP11-21L23.3	-7.06	6.16e-12	4.4e-09	-0.38	-0.31	Endometriosis;	chr11:76779672	chr11:76782581~76783062:-
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	7.06	6.19e-12	4.42e-09	0.37	0.31	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-7.06	6.2e-12	4.42e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
HNSC	cis	rs36423	0.557	rs36457	ENSG00000266869.1	RP6-114E22.1	-7.06	6.24e-12	4.45e-09	-0.46	-0.31	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71864157	chr14:71848606~71908430:+
HNSC	cis	rs17270561	0.609	rs4132072	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25717615	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs7453371	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719028	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7450798	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719052	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712957	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719586	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.666	rs17320090	ENSG00000272462.2	U91328.19	-7.06	6.24e-12	4.45e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25719987	chr6:25992662~26001775:+
HNSC	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-7.06	6.25e-12	4.45e-09	-0.33	-0.31	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
HNSC	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.06	6.26e-12	4.46e-09	-0.33	-0.31	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
HNSC	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	7.05	6.27e-12	4.47e-09	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
HNSC	cis	rs4841097	0.876	rs6601288	ENSG00000173295.6	FAM86B3P	7.05	6.28e-12	4.48e-09	0.36	0.31	Platelet distribution width;	chr8:9085920	chr8:8228595~8244865:+
HNSC	cis	rs6920372	0.731	rs9386799	ENSG00000260273.1	RP11-425D10.10	7.05	6.3e-12	4.49e-09	0.39	0.31	Height;	chr6:109333398	chr6:109382795~109383666:+
HNSC	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-7.05	6.3e-12	4.49e-09	-0.5	-0.31	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
HNSC	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-7.05	6.31e-12	4.49e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
HNSC	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-7.05	6.31e-12	4.5e-09	-0.34	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
HNSC	cis	rs9326248	0.53	rs2513093	ENSG00000280143.1	AP000892.6	7.05	6.33e-12	4.51e-09	0.46	0.31	Blood protein levels;	chr11:116935971	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	7.05	6.34e-12	4.51e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
HNSC	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	7.05	6.34e-12	4.52e-09	0.44	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
HNSC	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-7.05	6.37e-12	4.53e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
HNSC	cis	rs451417	1	rs236125	ENSG00000275632.1	RP5-967N21.11	7.05	6.39e-12	4.55e-09	0.38	0.31	Menopause (age at onset);	chr20:5996328	chr20:6000418~6000941:+
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-7.05	6.4e-12	4.56e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
HNSC	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	7.05	6.41e-12	4.56e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
HNSC	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-7.05	6.43e-12	4.58e-09	-0.34	-0.31	Temperament;	chr17:14048649	chr17:14024514~14025488:+
HNSC	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	7.05	6.46e-12	4.6e-09	0.35	0.31	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-7.05	6.46e-12	4.6e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
HNSC	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-7.05	6.47e-12	4.6e-09	-0.35	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
HNSC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-7.05	6.49e-12	4.62e-09	-0.4	-0.31	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
HNSC	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-7.05	6.49e-12	4.62e-09	-0.39	-0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
HNSC	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	7.05	6.49e-12	4.62e-09	0.78	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	7.05	6.49e-12	4.62e-09	0.78	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
HNSC	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-7.05	6.51e-12	4.63e-09	-0.3	-0.31	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
HNSC	cis	rs2579103	0.708	rs825966	ENSG00000258183.4	RP11-753N8.1	-7.05	6.52e-12	4.64e-09	-0.43	-0.31	Body mass index;	chr12:90309109	chr12:90280894~90300340:+
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.05	6.55e-12	4.66e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
HNSC	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.05	6.58e-12	4.68e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
HNSC	cis	rs7048146	0.51	rs10816827	ENSG00000213539.4	YBX1P6	-7.05	6.61e-12	4.7e-09	-0.35	-0.31	Vascular brain injury;	chr9:109529829	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs10816830	ENSG00000213539.4	YBX1P6	-7.05	6.61e-12	4.7e-09	-0.35	-0.31	Plantar warts;	chr9:109537404	chr9:109532830~109534332:-
HNSC	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-7.05	6.62e-12	4.7e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
HNSC	cis	rs2579103	0.708	rs2579101	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90293325	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.626	rs2579099	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90293578	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2579095	ENSG00000258183.4	RP11-753N8.1	-7.05	6.64e-12	4.72e-09	-0.43	-0.31	Body mass index;	chr12:90294499	chr12:90280894~90300340:+
HNSC	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-7.05	6.65e-12	4.72e-09	-0.5	-0.31	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
HNSC	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-7.05	6.66e-12	4.73e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
HNSC	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-7.05	6.67e-12	4.74e-09	-0.31	-0.31	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
HNSC	cis	rs4218	0.731	rs11539756	ENSG00000259732.1	RP11-59H7.3	-7.04	6.69e-12	4.75e-09	-0.46	-0.31	Social communication problems;	chr15:59136912	chr15:59121034~59133250:+
HNSC	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-7.04	6.7e-12	4.75e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
HNSC	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	7.04	6.71e-12	4.76e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
HNSC	cis	rs1659258	0.803	rs1659248	ENSG00000232508.1	MRPL45P1	-7.04	6.71e-12	4.76e-09	-0.66	-0.31	Visceral fat;	chr2:88335454	chr2:88364695~88365608:-
HNSC	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-7.04	6.71e-12	4.76e-09	-0.38	-0.31	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
HNSC	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.71e-12	4.76e-09	-0.33	-0.31	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
HNSC	cis	rs35955747	0.601	rs7289941	ENSG00000236132.1	CTA-440B3.1	-7.04	6.72e-12	4.77e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31488419	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-7.04	6.73e-12	4.77e-09	-0.31	-0.31	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
HNSC	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	7.04	6.75e-12	4.79e-09	0.41	0.31	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
HNSC	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	7.04	6.77e-12	4.8e-09	0.5	0.31	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
HNSC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
HNSC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-7.04	6.77e-12	4.8e-09	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
HNSC	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	7.04	6.78e-12	4.81e-09	0.38	0.31	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
HNSC	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	7.04	6.78e-12	4.81e-09	0.46	0.31	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
HNSC	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	7.04	6.79e-12	4.81e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
HNSC	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	7.04	6.81e-12	4.83e-09	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
HNSC	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	7.04	6.85e-12	4.85e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
HNSC	cis	rs10791097	0.967	rs10894268	ENSG00000254842.5	RP11-890B15.2	-7.04	6.85e-12	4.85e-09	-0.27	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847258	chr11:130844191~130865561:-
HNSC	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.04	6.86e-12	4.86e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	7.04	6.88e-12	4.87e-09	0.28	0.31	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	7.04	6.88e-12	4.87e-09	0.28	0.31	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-7.04	6.91e-12	4.89e-09	-0.37	-0.31	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
HNSC	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	7.04	6.92e-12	4.9e-09	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000274902.1	RP1-197B17.4	7.04	6.93e-12	4.91e-09	0.81	0.31	Pneumonia;	chr12:47576949	chr12:47731908~47732351:+
HNSC	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.94e-12	4.91e-09	-0.33	-0.31	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
HNSC	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-7.04	6.95e-12	4.92e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-7.04	6.95e-12	4.92e-09	-0.2	-0.31	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
HNSC	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-7.04	6.98e-12	4.94e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
HNSC	cis	rs1021993	0.597	rs10494924	ENSG00000231648.1	RP11-372M18.2	-7.04	6.98e-12	4.94e-09	-0.38	-0.31	Gut microbiome composition (winter);	chr1:209354361	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	7.04	6.98e-12	4.94e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-7.04	7.04e-12	4.98e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
HNSC	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-7.04	7.05e-12	4.99e-09	-0.46	-0.31	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
HNSC	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-7.04	7.09e-12	5.02e-09	-0.71	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs8176234	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43067763	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43067787	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43070445	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000267151.3	RP11-100E5.2	7.04	7.12e-12	5.04e-09	0.4	0.31	Menopause (age at onset);	chr17:43071077	chr17:43444707~43451200:+
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	7.04	7.13e-12	5.04e-09	0.44	0.31	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-7.03	7.13e-12	5.05e-09	-0.27	-0.31	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
HNSC	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	7.03	7.14e-12	5.05e-09	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
HNSC	cis	rs2834288	1	rs2834288	ENSG00000237945.6	LINC00649	7.03	7.17e-12	5.07e-09	0.37	0.31	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33915534~33977691:+
HNSC	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-7.03	7.18e-12	5.08e-09	-0.32	-0.31	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
HNSC	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	7.03	7.2e-12	5.09e-09	0.45	0.31	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	7.03	7.2e-12	5.09e-09	0.45	0.31	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
HNSC	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-7.03	7.2e-12	5.09e-09	-0.29	-0.31	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
HNSC	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	7.03	7.29e-12	5.15e-09	0.36	0.31	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
HNSC	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	7.03	7.29e-12	5.15e-09	0.36	0.31	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
HNSC	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.03	7.3e-12	5.16e-09	-0.32	-0.31	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
HNSC	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	7.03	7.32e-12	5.17e-09	0.34	0.31	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
HNSC	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-7.03	7.33e-12	5.18e-09	-0.49	-0.31	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
HNSC	cis	rs451417	1	rs236122	ENSG00000275632.1	RP5-967N21.11	7.03	7.33e-12	5.18e-09	0.37	0.31	Menopause (age at onset);	chr20:5992882	chr20:6000418~6000941:+
HNSC	cis	rs1021993	0.545	rs79960084	ENSG00000231648.1	RP11-372M18.2	-7.03	7.34e-12	5.18e-09	-0.54	-0.31	Gut microbiome composition (winter);	chr1:209382825	chr1:209367662~209379690:+
HNSC	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-7.03	7.34e-12	5.19e-09	-0.31	-0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
HNSC	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-7.03	7.34e-12	5.19e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
HNSC	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.03	7.35e-12	5.2e-09	-0.35	-0.31	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
HNSC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-7.03	7.37e-12	5.2e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
HNSC	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-7.03	7.37e-12	5.21e-09	-0.4	-0.31	Depression;	chr6:28226851	chr6:28115628~28116551:+
HNSC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	7.03	7.38e-12	5.22e-09	0.35	0.31	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
HNSC	cis	rs35955747	0.87	rs5997986	ENSG00000236132.1	CTA-440B3.1	7.03	7.39e-12	5.22e-09	0.33	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31438953	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	7.03	7.4e-12	5.22e-09	0.37	0.31	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
HNSC	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	7.03	7.4e-12	5.23e-09	0.36	0.31	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
HNSC	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-7.03	7.41e-12	5.23e-09	-0.31	-0.31	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
HNSC	cis	rs6951245	0.872	rs75280240	ENSG00000225146.1	AC073957.15	-7.03	7.42e-12	5.24e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1029025~1043891:+
HNSC	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	7.03	7.43e-12	5.25e-09	0.34	0.31	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
HNSC	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	7.03	7.43e-12	5.25e-09	0.34	0.31	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
HNSC	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	7.03	7.44e-12	5.25e-09	0.52	0.31	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000267151.3	RP11-100E5.2	7.03	7.48e-12	5.28e-09	0.39	0.31	Menopause (age at onset);	chr17:43348533	chr17:43444707~43451200:+
HNSC	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-7.03	7.48e-12	5.28e-09	-0.32	-0.31	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
HNSC	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.03	7.49e-12	5.29e-09	-0.31	-0.31	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
HNSC	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-7.03	7.5e-12	5.29e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-7.03	7.53e-12	5.31e-09	-0.37	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
HNSC	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-7.03	7.54e-12	5.32e-09	-0.37	-0.31	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
HNSC	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
HNSC	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-7.03	7.56e-12	5.33e-09	-0.33	-0.31	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
HNSC	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.02	7.64e-12	5.39e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.02	7.64e-12	5.39e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
HNSC	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	7.02	7.66e-12	5.4e-09	0.46	0.31	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
HNSC	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-7.02	7.68e-12	5.41e-09	-0.38	-0.31	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
HNSC	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	7.02	7.7e-12	5.43e-09	0.37	0.31	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.02	7.73e-12	5.45e-09	0.28	0.31	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
HNSC	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	7.02	7.74e-12	5.45e-09	0.35	0.31	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
HNSC	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-7.02	7.75e-12	5.46e-09	-0.38	-0.31	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-7.02	7.76e-12	5.47e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
HNSC	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	7.02	7.78e-12	5.48e-09	0.46	0.31	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
HNSC	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-7.02	7.79e-12	5.49e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
HNSC	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-7.02	7.79e-12	5.49e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
HNSC	cis	rs6951245	1	rs77868187	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs75016635	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs113066613	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11763793	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11763835	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78861357	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.872	rs76713558	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.748	rs79658522	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.935	rs76525951	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs79683221	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78185801	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs80031817	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs78143408	ENSG00000224079.1	AC091729.7	-7.02	7.84e-12	5.52e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1074450~1078036:+
HNSC	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-7.02	7.86e-12	5.53e-09	-0.31	-0.31	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
HNSC	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	7.02	7.86e-12	5.53e-09	0.44	0.31	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
HNSC	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	7.02	7.89e-12	5.55e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
HNSC	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	7.02	7.89e-12	5.55e-09	0.4	0.31	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
HNSC	cis	rs6471393	0.929	rs62525162	ENSG00000253848.1	RP11-10N23.5	7.02	7.92e-12	5.58e-09	0.37	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:93741193~93744534:+
HNSC	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-7.02	7.93e-12	5.58e-09	-0.45	-0.31	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
HNSC	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-7.02	7.93e-12	5.58e-09	-0.47	-0.31	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
HNSC	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	7.02	7.93e-12	5.58e-09	0.33	0.31	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-7.02	7.95e-12	5.59e-09	-0.3	-0.31	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
HNSC	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	7.02	7.97e-12	5.6e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
HNSC	cis	rs757110	0.803	rs7928810	ENSG00000260196.1	RP1-239B22.5	7.02	8.02e-12	5.64e-09	0.35	0.31	Type 2 diabetes;	chr11:17350896	chr11:17380649~17383531:+
HNSC	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	7.02	8.02e-12	5.64e-09	0.44	0.31	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
HNSC	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-7.02	8.05e-12	5.66e-09	-0.36	-0.31	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
HNSC	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	7.02	8.07e-12	5.67e-09	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-7.02	8.07e-12	5.67e-09	-0.45	-0.31	Depression;	chr6:28267398	chr6:28115628~28116551:+
HNSC	cis	rs451417	1	rs451417	ENSG00000275632.1	RP5-967N21.11	7.02	8.07e-12	5.67e-09	0.37	0.31	Menopause (age at onset);	chr20:5961353	chr20:6000418~6000941:+
HNSC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-7.02	8.08e-12	5.68e-09	-0.47	-0.31	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.02	8.11e-12	5.7e-09	-0.27	-0.31	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
HNSC	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.01	8.13e-12	5.71e-09	-0.32	-0.31	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
HNSC	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	7.01	8.13e-12	5.72e-09	0.38	0.31	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
HNSC	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.01	8.15e-12	5.73e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
HNSC	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-7.01	8.18e-12	5.75e-09	-0.43	-0.31	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
HNSC	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	7.01	8.19e-12	5.75e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	7.01	8.19e-12	5.75e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000267151.3	RP11-100E5.2	7.01	8.19e-12	5.76e-09	0.4	0.31	Menopause (age at onset);	chr17:43365646	chr17:43444707~43451200:+
HNSC	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	7.01	8.2e-12	5.76e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.636	rs9379782	ENSG00000272462.2	U91328.19	-7.01	8.21e-12	5.77e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25714795	chr6:25992662~26001775:+
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000254340.1	RP11-10A14.3	-7.01	8.22e-12	5.77e-09	-0.37	-0.31	Mood instability;	chr8:8937291	chr8:9141424~9145435:+
HNSC	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-7.01	8.23e-12	5.78e-09	-0.36	-0.31	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	7.01	8.24e-12	5.78e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
HNSC	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-7.01	8.24e-12	5.79e-09	-0.38	-0.31	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
HNSC	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	7.01	8.26e-12	5.8e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
HNSC	cis	rs6867032	1	rs4074914	ENSG00000249731.1	RP11-259O2.3	7.01	8.27e-12	5.8e-09	0.39	0.31	Gut microbiome composition (winter);	chr5:2020160	chr5:1968094~1969013:+
HNSC	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-7.01	8.27e-12	5.81e-09	-0.45	-0.31	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
HNSC	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	7.01	8.28e-12	5.81e-09	0.37	0.31	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
HNSC	cis	rs832187	0.64	rs56293138	ENSG00000280620.1	SCAANT1	7.01	8.29e-12	5.82e-09	0.4	0.31	Schizophrenia;	chr3:63903259	chr3:63911518~63911772:-
HNSC	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-7.01	8.36e-12	5.86e-09	-0.39	-0.31	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
HNSC	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-7.01	8.38e-12	5.88e-09	-0.35	-0.31	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
HNSC	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	7.01	8.4e-12	5.89e-09	0.39	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
HNSC	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	7.01	8.42e-12	5.9e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	7.01	8.42e-12	5.9e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
HNSC	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-7.01	8.45e-12	5.93e-09	-0.38	-0.31	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	7.01	8.45e-12	5.93e-09	0.22	0.31	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
HNSC	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	7.01	8.46e-12	5.94e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
HNSC	cis	rs17270561	0.609	rs9379785	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25725985	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358871	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726447	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711095	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726546	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712959	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726829	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712960	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727037	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712961	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727106	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358872	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727289	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9356985	ENSG00000272462.2	U91328.19	-7.01	8.48e-12	5.94e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25727870	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-7.01	8.48e-12	5.95e-09	-0.34	-0.31	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
HNSC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	7.01	8.49e-12	5.95e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.01	8.51e-12	5.97e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	7.01	8.53e-12	5.98e-09	0.22	0.31	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
HNSC	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	7.01	8.54e-12	5.99e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
HNSC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-7.01	8.55e-12	6e-09	-0.33	-0.31	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
HNSC	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-7.01	8.56e-12	6e-09	-0.49	-0.31	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
HNSC	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.28	-0.31	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-7.01	8.58e-12	6.01e-09	-0.27	-0.31	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	7.01	8.61e-12	6.03e-09	0.37	0.31	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
HNSC	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	7.01	8.63e-12	6.05e-09	0.5	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	7	8.67e-12	6.07e-09	0.44	0.31	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
HNSC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-7	8.67e-12	6.07e-09	-0.28	-0.31	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
HNSC	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-7	8.67e-12	6.07e-09	-0.38	-0.31	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
HNSC	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-7	8.68e-12	6.08e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
HNSC	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-7	8.72e-12	6.11e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	7	8.75e-12	6.13e-09	0.32	0.31	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
HNSC	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7	8.77e-12	6.14e-09	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
HNSC	cis	rs2579103	0.63	rs1222451	ENSG00000258183.4	RP11-753N8.1	-7	8.77e-12	6.14e-09	-0.42	-0.31	Body mass index;	chr12:90314445	chr12:90280894~90300340:+
HNSC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-7	8.78e-12	6.14e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
HNSC	cis	rs1799949	1	rs35330014	ENSG00000267151.3	RP11-100E5.2	7	8.78e-12	6.14e-09	0.4	0.31	Menopause (age at onset);	chr17:43060530	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000267151.3	RP11-100E5.2	7	8.78e-12	6.14e-09	0.4	0.31	Menopause (age at onset);	chr17:43063808	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	7	8.82e-12	6.17e-09	0.32	0.31	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
HNSC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-7	8.82e-12	6.17e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
HNSC	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-7	8.85e-12	6.19e-09	-0.44	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
HNSC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	7	8.88e-12	6.21e-09	0.36	0.31	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
HNSC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-7	8.89e-12	6.22e-09	-0.37	-0.31	Height;	chr3:53084188	chr3:53064283~53065091:-
HNSC	cis	rs6867032	1	rs7729761	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015669	chr5:1968094~1969013:+
HNSC	cis	rs6867032	0.687	rs4998338	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015796	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs2129471	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2016122	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs2129472	ENSG00000249731.1	RP11-259O2.3	7	8.89e-12	6.22e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2016133	chr5:1968094~1969013:+
HNSC	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	7	8.9e-12	6.23e-09	0.44	0.31	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
HNSC	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-7	8.91e-12	6.23e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
HNSC	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-7	8.91e-12	6.23e-09	-0.51	-0.31	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
HNSC	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	7	8.92e-12	6.24e-09	0.37	0.31	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
HNSC	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	7	8.94e-12	6.25e-09	0.37	0.31	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
HNSC	cis	rs1799949	1	rs8176318	ENSG00000267151.3	RP11-100E5.2	7	8.95e-12	6.26e-09	0.4	0.31	Menopause (age at onset);	chr17:43045257	chr17:43444707~43451200:+
HNSC	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	7	9e-12	6.29e-09	0.28	0.31	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-7	9.06e-12	6.33e-09	-0.39	-0.31	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
HNSC	cis	rs1799949	1	rs16941	ENSG00000267151.3	RP11-100E5.2	7	9.08e-12	6.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43092418	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000267151.3	RP11-100E5.2	7	9.08e-12	6.34e-09	0.4	0.31	Menopause (age at onset);	chr17:43103085	chr17:43444707~43451200:+
HNSC	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	7	9.1e-12	6.36e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-7	9.12e-12	6.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-7	9.12e-12	6.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
HNSC	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	7	9.12e-12	6.37e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
HNSC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-7	9.15e-12	6.39e-09	-0.37	-0.31	Migraine;	chr4:56852029	chr4:56960927~56961373:-
HNSC	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-7	9.15e-12	6.39e-09	-0.32	-0.31	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	7	9.16e-12	6.4e-09	0.31	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
HNSC	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	7	9.17e-12	6.4e-09	0.33	0.31	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
HNSC	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-7	9.18e-12	6.41e-09	-0.59	-0.31	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
HNSC	cis	rs1799949	1	rs12516	ENSG00000267151.3	RP11-100E5.2	7	9.18e-12	6.41e-09	0.4	0.31	Menopause (age at onset);	chr17:43044391	chr17:43444707~43451200:+
HNSC	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	7	9.21e-12	6.43e-09	0.33	0.31	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
HNSC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	6.99	9.24e-12	6.45e-09	0.36	0.31	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	6.99	9.24e-12	6.45e-09	0.36	0.31	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
HNSC	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-6.99	9.26e-12	6.46e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
HNSC	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	6.99	9.26e-12	6.46e-09	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-6.99	9.27e-12	6.47e-09	-0.27	-0.31	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
HNSC	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-6.99	9.28e-12	6.48e-09	-0.29	-0.31	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
HNSC	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.99	9.29e-12	6.49e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
HNSC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.99	9.29e-12	6.49e-09	0.35	0.31	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
HNSC	cis	rs17270561	0.609	rs9358873	ENSG00000272462.2	U91328.19	-6.99	9.33e-12	6.51e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25731555	chr6:25992662~26001775:+
HNSC	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-6.99	9.33e-12	6.51e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
HNSC	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-6.99	9.36e-12	6.53e-09	-0.32	-0.31	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
HNSC	cis	rs1659258	0.772	rs1659251	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88356679	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.772	rs1659252	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88358323	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs55909126	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88358580	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs1659258	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88360069	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.892	rs3114962	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88361383	chr2:88364695~88365608:-
HNSC	cis	rs1659258	1	rs1659267	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88366167	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.892	rs2679263	ENSG00000232508.1	MRPL45P1	6.99	9.36e-12	6.53e-09	0.65	0.31	Visceral fat;	chr2:88366444	chr2:88364695~88365608:-
HNSC	cis	rs10791097	0.967	rs1944142	ENSG00000254842.5	RP11-890B15.2	-6.99	9.38e-12	6.54e-09	-0.26	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847545	chr11:130844191~130865561:-
HNSC	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-6.99	9.39e-12	6.55e-09	-0.3	-0.31	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-6.99	9.39e-12	6.55e-09	-0.3	-0.31	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
HNSC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	6.99	9.45e-12	6.59e-09	0.37	0.31	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
HNSC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.99	9.46e-12	6.59e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
HNSC	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.99	9.5e-12	6.62e-09	-0.34	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
HNSC	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.99	9.51e-12	6.62e-09	0.44	0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000241288.6	RP11-379B18.5	-6.99	9.55e-12	6.65e-09	-0.51	-0.31	Blood pressure (smoking interaction);	chr3:125905076	chr3:125827238~125916384:-
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	-6.99	9.56e-12	6.66e-09	-0.34	-0.31	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
HNSC	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	6.99	9.59e-12	6.68e-09	0.38	0.31	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
HNSC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	6.99	9.61e-12	6.69e-09	0.47	0.31	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	6.99	9.64e-12	6.71e-09	0.45	0.31	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
HNSC	cis	rs17270561	0.636	rs9393656	ENSG00000272462.2	U91328.19	-6.99	9.67e-12	6.72e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25721831	chr6:25992662~26001775:+
HNSC	cis	rs62344088	0.59	rs62346174	ENSG00000277812.1	AC021087.1	6.99	9.69e-12	6.74e-09	0.8	0.31	Asthma (childhood onset);	chr5:296193	chr5:262769~262881:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	6.99	9.69e-12	6.74e-09	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	6.99	9.72e-12	6.76e-09	0.43	0.31	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-6.99	9.73e-12	6.76e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
HNSC	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	6.99	9.73e-12	6.76e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
HNSC	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-6.99	9.76e-12	6.78e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
HNSC	cis	rs6951245	1	rs6951245	ENSG00000225146.1	AC073957.15	-6.99	9.78e-12	6.8e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1029025~1043891:+
HNSC	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	6.99	9.79e-12	6.8e-09	0.46	0.31	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
HNSC	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-6.99	9.82e-12	6.83e-09	-0.35	-0.31	Height;	chr3:52994990	chr3:53064283~53065091:-
HNSC	cis	rs6951245	0.938	rs78351779	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11761941	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1074450~1078036:+
HNSC	cis	rs6951245	1	rs11767527	ENSG00000224079.1	AC091729.7	-6.99	9.86e-12	6.85e-09	-0.53	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs16940	ENSG00000267151.3	RP11-100E5.2	6.98	9.88e-12	6.86e-09	0.4	0.31	Menopause (age at onset);	chr17:43093220	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000267151.3	RP11-100E5.2	6.98	9.88e-12	6.86e-09	0.4	0.31	Menopause (age at onset);	chr17:43096467	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-6.98	9.91e-12	6.88e-09	-0.27	-0.31	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
HNSC	cis	rs2579103	0.708	rs1371080	ENSG00000258183.4	RP11-753N8.1	-6.98	1e-11	6.96e-09	-0.43	-0.31	Body mass index;	chr12:90288622	chr12:90280894~90300340:+
HNSC	cis	rs6951245	0.935	rs11763765	ENSG00000225146.1	AC073957.15	-6.98	1e-11	6.96e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs11766669	ENSG00000225146.1	AC073957.15	-6.98	1e-11	6.96e-09	-0.51	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1029025~1043891:+
HNSC	cis	rs17270561	0.609	rs4711096	ENSG00000272462.2	U91328.19	-6.98	1e-11	6.96e-09	-0.32	-0.31	Iron status biomarkers;	chr6:25726826	chr6:25992662~26001775:+
HNSC	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-6.98	1e-11	6.97e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-6.98	1e-11	6.97e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
HNSC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	6.98	1.01e-11	6.98e-09	0.38	0.31	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
HNSC	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-6.98	1.01e-11	6.98e-09	-0.3	-0.31	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
HNSC	cis	rs116095464	1	rs55671190	ENSG00000277812.1	AC021087.1	6.98	1.01e-11	7e-09	0.7	0.31	Breast cancer;	chr5:287307	chr5:262769~262881:+
HNSC	cis	rs451417	1	rs236124	ENSG00000275632.1	RP5-967N21.11	6.98	1.02e-11	7.05e-09	0.38	0.31	Menopause (age at onset);	chr20:5995333	chr20:6000418~6000941:+
HNSC	cis	rs7615952	0.611	rs2947646	ENSG00000241288.6	RP11-379B18.5	6.98	1.02e-11	7.06e-09	0.49	0.31	Blood pressure (smoking interaction);	chr3:125874759	chr3:125827238~125916384:-
HNSC	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	6.98	1.02e-11	7.07e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	6.98	1.02e-11	7.09e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
HNSC	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	6.98	1.02e-11	7.09e-09	0.43	0.31	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
HNSC	cis	rs6867032	0.958	rs4505990	ENSG00000249731.1	RP11-259O2.3	6.98	1.03e-11	7.1e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015697	chr5:1968094~1969013:+
HNSC	cis	rs6867032	1	rs4398675	ENSG00000249731.1	RP11-259O2.3	6.98	1.03e-11	7.1e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2015702	chr5:1968094~1969013:+
HNSC	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	6.98	1.03e-11	7.1e-09	0.45	0.31	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
HNSC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-6.98	1.03e-11	7.11e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
HNSC	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-6.98	1.03e-11	7.16e-09	-0.56	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43043694	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43048092	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43051308	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43051574	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43052360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43052373	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000267151.3	RP11-100E5.2	6.98	1.03e-11	7.16e-09	0.4	0.31	Menopause (age at onset);	chr17:43054039	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	6.98	1.04e-11	7.17e-09	0.22	0.31	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	6.98	1.04e-11	7.17e-09	0.22	0.31	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
HNSC	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	6.98	1.04e-11	7.19e-09	0.56	0.31	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
HNSC	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-6.98	1.04e-11	7.19e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
HNSC	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-6.98	1.04e-11	7.19e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-6.98	1.04e-11	7.19e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
HNSC	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	6.98	1.04e-11	7.2e-09	0.38	0.31	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
HNSC	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-6.98	1.04e-11	7.2e-09	-0.33	-0.31	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
HNSC	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-6.98	1.04e-11	7.21e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
HNSC	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-6.98	1.04e-11	7.21e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
HNSC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	6.98	1.04e-11	7.22e-09	0.36	0.31	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
HNSC	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	6.98	1.05e-11	7.23e-09	0.44	0.31	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
HNSC	cis	rs10791097	0.967	rs4366492	ENSG00000254842.5	RP11-890B15.2	-6.98	1.05e-11	7.26e-09	-0.27	-0.31	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130847361	chr11:130844191~130865561:-
HNSC	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-6.97	1.05e-11	7.28e-09	-0.35	-0.31	Height;	chr3:52994045	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-6.97	1.05e-11	7.29e-09	-0.34	-0.31	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-6.97	1.06e-11	7.32e-09	-0.36	-0.31	Height;	chr3:52998472	chr3:53064283~53065091:-
HNSC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-6.97	1.06e-11	7.34e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
HNSC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-6.97	1.06e-11	7.34e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
HNSC	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	6.97	1.07e-11	7.37e-09	0.46	0.31	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
HNSC	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	6.97	1.07e-11	7.37e-09	0.46	0.31	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-6.97	1.07e-11	7.37e-09	-0.49	-0.31	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
HNSC	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	6.97	1.07e-11	7.39e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
HNSC	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-6.97	1.07e-11	7.39e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
HNSC	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	6.97	1.07e-11	7.4e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
HNSC	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-6.97	1.07e-11	7.42e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
HNSC	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	6.97	1.08e-11	7.45e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
HNSC	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-6.97	1.08e-11	7.46e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
HNSC	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	6.97	1.08e-11	7.46e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
HNSC	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	6.97	1.08e-11	7.48e-09	0.45	0.31	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-6.97	1.08e-11	7.49e-09	-0.27	-0.31	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
HNSC	cis	rs1659258	1	rs1258383	ENSG00000232508.1	MRPL45P1	6.97	1.09e-11	7.51e-09	0.64	0.31	Visceral fat;	chr2:88340213	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.803	rs72841297	ENSG00000232508.1	MRPL45P1	6.97	1.09e-11	7.51e-09	0.64	0.31	Visceral fat;	chr2:88347981	chr2:88364695~88365608:-
HNSC	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-6.97	1.09e-11	7.51e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-6.97	1.09e-11	7.53e-09	-0.37	-0.31	Depression;	chr6:28422360	chr6:28176188~28176674:+
HNSC	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	6.97	1.09e-11	7.54e-09	0.34	0.31	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
HNSC	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.97	1.1e-11	7.58e-09	-0.31	-0.31	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
HNSC	cis	rs1799949	1	rs8176133	ENSG00000267151.3	RP11-100E5.2	6.97	1.1e-11	7.58e-09	0.4	0.31	Menopause (age at onset);	chr17:43105441	chr17:43444707~43451200:+
HNSC	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	6.97	1.1e-11	7.59e-09	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
HNSC	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-6.97	1.1e-11	7.61e-09	-0.45	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
HNSC	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-6.97	1.1e-11	7.62e-09	-0.36	-0.31	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
HNSC	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-6.97	1.11e-11	7.62e-09	-0.39	-0.31	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
HNSC	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-6.97	1.11e-11	7.63e-09	-0.37	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs11655505	ENSG00000267151.3	RP11-100E5.2	6.97	1.11e-11	7.65e-09	0.39	0.31	Menopause (age at onset);	chr17:43126360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000267151.3	RP11-100E5.2	6.97	1.11e-11	7.65e-09	0.39	0.31	Menopause (age at onset);	chr17:43127281	chr17:43444707~43451200:+
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	6.97	1.11e-11	7.67e-09	0.39	0.31	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
HNSC	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.97	1.12e-11	7.69e-09	-0.32	-0.31	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-6.97	1.12e-11	7.72e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-6.97	1.12e-11	7.72e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	6.97	1.12e-11	7.72e-09	0.22	0.31	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
HNSC	cis	rs1799949	1	rs4793215	ENSG00000267151.3	RP11-100E5.2	6.96	1.12e-11	7.73e-09	0.4	0.31	Menopause (age at onset);	chr17:43166915	chr17:43444707~43451200:+
HNSC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	6.96	1.13e-11	7.77e-09	0.36	0.31	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
HNSC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	6.96	1.13e-11	7.77e-09	0.36	0.31	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
HNSC	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-6.96	1.13e-11	7.79e-09	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
HNSC	cis	rs6471393	0.798	rs55680024	ENSG00000253848.1	RP11-10N23.5	6.96	1.13e-11	7.79e-09	0.41	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93741193~93744534:+
HNSC	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	6.96	1.13e-11	7.8e-09	0.36	0.31	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.668	rs1222456	ENSG00000258183.4	RP11-753N8.1	-6.96	1.13e-11	7.81e-09	-0.43	-0.31	Body mass index;	chr12:90300134	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-6.96	1.14e-11	7.84e-09	-0.42	-0.31	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-6.96	1.14e-11	7.87e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
HNSC	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-6.96	1.14e-11	7.87e-09	-0.37	-0.31	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
HNSC	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-6.96	1.15e-11	7.88e-09	-0.29	-0.31	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-6.96	1.15e-11	7.9e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
HNSC	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	6.96	1.15e-11	7.9e-09	0.3	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
HNSC	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-6.96	1.15e-11	7.9e-09	-0.48	-0.31	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	6.96	1.15e-11	7.91e-09	0.31	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
HNSC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-6.96	1.15e-11	7.92e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
HNSC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-6.96	1.15e-11	7.92e-09	-0.33	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
HNSC	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.96	1.15e-11	7.92e-09	0.28	0.31	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.96	1.15e-11	7.92e-09	0.28	0.31	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-6.96	1.15e-11	7.92e-09	-0.4	-0.31	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
HNSC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-6.96	1.15e-11	7.93e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
HNSC	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-6.96	1.16e-11	7.95e-09	-0.43	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
HNSC	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-6.96	1.16e-11	7.96e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
HNSC	cis	rs7083	1	rs512188	ENSG00000254851.1	RP11-109L13.1	-6.96	1.16e-11	7.98e-09	-0.39	-0.31	Blood protein levels;	chr11:117255994	chr11:117135528~117138582:+
HNSC	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	6.96	1.17e-11	8.02e-09	0.3	0.31	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
HNSC	cis	rs2579103	0.708	rs1561423	ENSG00000258183.4	RP11-753N8.1	-6.96	1.17e-11	8.05e-09	-0.43	-0.31	Body mass index;	chr12:90280416	chr12:90280894~90300340:+
HNSC	cis	rs440932	0.798	rs330942	ENSG00000254340.1	RP11-10A14.3	6.96	1.17e-11	8.06e-09	0.37	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9141424~9145435:+
HNSC	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-6.96	1.18e-11	8.09e-09	-0.38	-0.31	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
HNSC	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-6.96	1.18e-11	8.09e-09	-0.41	-0.31	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000267151.3	RP11-100E5.2	6.96	1.18e-11	8.1e-09	0.4	0.31	Menopause (age at onset);	chr17:43043756	chr17:43444707~43451200:+
HNSC	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	6.96	1.18e-11	8.1e-09	0.3	0.31	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	6.96	1.18e-11	8.1e-09	0.3	0.31	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
HNSC	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.96	1.19e-11	8.14e-09	0.33	0.31	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
HNSC	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.96	1.19e-11	8.14e-09	0.33	0.31	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-6.96	1.19e-11	8.18e-09	-0.28	-0.31	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
HNSC	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	6.96	1.19e-11	8.18e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.95	1.2e-11	8.22e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
HNSC	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	6.95	1.2e-11	8.22e-09	0.44	0.31	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.23e-09	-0.27	-0.31	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.23e-09	-0.27	-0.31	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
HNSC	cis	rs17214007	0.518	rs56374730	ENSG00000263335.1	AF001548.5	-6.95	1.2e-11	8.25e-09	-0.44	-0.31	Cognitive function;	chr16:15773795	chr16:15726674~15732993:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-6.95	1.2e-11	8.25e-09	-0.27	-0.31	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
HNSC	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-6.95	1.2e-11	8.25e-09	-0.47	-0.31	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
HNSC	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-6.95	1.21e-11	8.29e-09	-0.39	-0.31	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.21e-11	8.29e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
HNSC	cis	rs1659258	0.655	rs3107210	ENSG00000232508.1	MRPL45P1	6.95	1.21e-11	8.29e-09	0.65	0.31	Visceral fat;	chr2:88359241	chr2:88364695~88365608:-
HNSC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	6.95	1.21e-11	8.32e-09	0.36	0.31	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
HNSC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-6.95	1.22e-11	8.33e-09	-0.38	-0.31	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	6.95	1.22e-11	8.33e-09	0.38	0.31	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
HNSC	cis	rs5769707	0.777	rs8141219	ENSG00000188511.11	C22orf34	6.95	1.22e-11	8.34e-09	0.39	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	6.95	1.22e-11	8.35e-09	0.37	0.31	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.599	rs6779141	ENSG00000241288.6	RP11-379B18.5	-6.95	1.22e-11	8.35e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125991152	chr3:125827238~125916384:-
HNSC	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	6.95	1.22e-11	8.35e-09	0.3	0.31	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.22e-11	8.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.22e-11	8.37e-09	-0.33	-0.31	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
HNSC	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	6.95	1.23e-11	8.4e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
HNSC	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-6.95	1.23e-11	8.4e-09	-0.38	-0.31	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-6.95	1.23e-11	8.4e-09	-0.38	-0.31	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
HNSC	cis	rs1799949	1	rs2175957	ENSG00000267151.3	RP11-100E5.2	6.95	1.23e-11	8.42e-09	0.39	0.31	Menopause (age at onset);	chr17:43134805	chr17:43444707~43451200:+
HNSC	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	6.95	1.23e-11	8.43e-09	0.46	0.31	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
HNSC	cis	rs1799949	1	rs4793194	ENSG00000267151.3	RP11-100E5.2	6.95	1.24e-11	8.5e-09	0.39	0.31	Menopause (age at onset);	chr17:43066316	chr17:43444707~43451200:+
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	6.95	1.24e-11	8.5e-09	0.3	0.31	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.95	1.25e-11	8.54e-09	-0.4	-0.31	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43138596	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43140722	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43145975	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43147590	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43147911	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43148782	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000267151.3	RP11-100E5.2	6.95	1.25e-11	8.55e-09	0.39	0.31	Menopause (age at onset);	chr17:43149692	chr17:43444707~43451200:+
HNSC	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	6.95	1.25e-11	8.57e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
HNSC	cis	rs36405	0.5	rs8011906	ENSG00000266869.1	RP6-114E22.1	-6.95	1.26e-11	8.59e-09	-0.38	-0.31	Yang-deficiency constitution;	chr14:71893078	chr14:71848606~71908430:+
HNSC	cis	rs451417	0.643	rs34907229	ENSG00000275632.1	RP5-967N21.11	6.95	1.26e-11	8.6e-09	0.4	0.31	Menopause (age at onset);	chr20:6002207	chr20:6000418~6000941:+
HNSC	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-6.95	1.26e-11	8.62e-09	-0.3	-0.31	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
HNSC	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-6.95	1.26e-11	8.64e-09	-0.39	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
HNSC	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	6.95	1.26e-11	8.64e-09	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-6.95	1.27e-11	8.67e-09	-0.4	-0.31	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
HNSC	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-6.95	1.27e-11	8.69e-09	-0.3	-0.31	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
HNSC	cis	rs1799810	0.899	rs4662726	ENSG00000236682.1	AC068282.3	6.95	1.27e-11	8.71e-09	0.36	0.31	Self-rated health;	chr2:127413086	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-6.94	1.28e-11	8.71e-09	-0.57	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
HNSC	cis	rs7115242	0.8	rs10736487	ENSG00000280143.1	AP000892.6	6.94	1.28e-11	8.71e-09	0.46	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117204967~117210292:+
HNSC	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.94	1.28e-11	8.73e-09	0.29	0.31	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
HNSC	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-6.94	1.28e-11	8.77e-09	-0.4	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
HNSC	cis	rs7615952	0.599	rs12485717	ENSG00000241288.6	RP11-379B18.5	6.94	1.29e-11	8.79e-09	0.4	0.31	Blood pressure (smoking interaction);	chr3:125988232	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-6.94	1.29e-11	8.81e-09	-0.27	-0.31	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
HNSC	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	6.94	1.29e-11	8.81e-09	0.3	0.31	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
HNSC	cis	rs9326248	0.53	rs10750101	ENSG00000280143.1	AP000892.6	6.94	1.29e-11	8.81e-09	0.47	0.31	Blood protein levels;	chr11:117108973	chr11:117204967~117210292:+
HNSC	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	6.94	1.29e-11	8.84e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
HNSC	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	6.94	1.3e-11	8.85e-09	0.45	0.31	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
HNSC	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-6.94	1.3e-11	8.86e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
HNSC	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	6.94	1.3e-11	8.86e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	6.94	1.3e-11	8.86e-09	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-6.94	1.3e-11	8.88e-09	-0.31	-0.31	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
HNSC	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-6.94	1.3e-11	8.89e-09	-0.43	-0.31	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.94	1.3e-11	8.9e-09	0.35	0.31	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
HNSC	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	6.94	1.31e-11	8.9e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
HNSC	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	6.94	1.31e-11	8.94e-09	0.28	0.31	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.558	rs17334039	ENSG00000248787.1	RP11-666A20.4	-6.94	1.31e-11	8.94e-09	-0.45	-0.31	Blood pressure (smoking interaction);	chr3:125821465	chr3:125908005~125910272:-
HNSC	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	6.94	1.31e-11	8.95e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
HNSC	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	6.94	1.31e-11	8.95e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-6.94	1.31e-11	8.96e-09	-0.41	-0.31	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
HNSC	cis	rs6951245	0.554	rs10246354	ENSG00000224079.1	AC091729.7	-6.94	1.32e-11	8.97e-09	-0.42	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1074450~1078036:+
HNSC	cis	rs4978813	0.5	rs7870600	ENSG00000213539.4	YBX1P6	-6.94	1.32e-11	8.97e-09	-0.35	-0.31	Plantar warts;	chr9:109535950	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs58522556	ENSG00000213539.4	YBX1P6	-6.94	1.32e-11	8.97e-09	-0.35	-0.31	Plantar warts;	chr9:109536728	chr9:109532830~109534332:-
HNSC	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	6.94	1.32e-11	8.97e-09	0.46	0.31	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
HNSC	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	6.94	1.32e-11	8.97e-09	0.33	0.31	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
HNSC	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-6.94	1.32e-11	9e-09	-0.32	-0.31	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
HNSC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	6.94	1.32e-11	9.01e-09	0.36	0.31	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
HNSC	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	6.94	1.32e-11	9.01e-09	0.29	0.31	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
HNSC	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-6.94	1.33e-11	9.06e-09	-0.39	-0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
HNSC	cis	rs1799949	1	rs2292595	ENSG00000267151.3	RP11-100E5.2	6.94	1.33e-11	9.08e-09	0.39	0.31	Menopause (age at onset);	chr17:43138657	chr17:43444707~43451200:+
HNSC	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	6.94	1.34e-11	9.09e-09	0.38	0.31	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000267151.3	RP11-100E5.2	6.94	1.34e-11	9.09e-09	0.4	0.31	Menopause (age at onset);	chr17:43158478	chr17:43444707~43451200:+
HNSC	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-6.94	1.34e-11	9.1e-09	-0.29	-0.31	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
HNSC	cis	rs9402743	0.962	rs9321521	ENSG00000217482.2	HMGB1P17	6.94	1.34e-11	9.1e-09	0.33	0.31	Systemic lupus erythematosus;	chr6:135668512	chr6:135636086~135636713:-
HNSC	cis	rs17270561	0.609	rs17267614	ENSG00000272462.2	U91328.19	-6.94	1.34e-11	9.11e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25729799	chr6:25992662~26001775:+
HNSC	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	6.94	1.34e-11	9.11e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
HNSC	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.94	1.34e-11	9.13e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
HNSC	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.94	1.35e-11	9.16e-09	0.3	0.31	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
HNSC	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-6.94	1.35e-11	9.2e-09	-0.31	-0.31	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
HNSC	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-6.94	1.35e-11	9.21e-09	-0.58	-0.31	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
HNSC	cis	rs451417	0.818	rs236103	ENSG00000275632.1	RP5-967N21.11	6.94	1.35e-11	9.21e-09	0.4	0.31	Menopause (age at onset);	chr20:5977341	chr20:6000418~6000941:+
HNSC	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	6.94	1.36e-11	9.22e-09	0.44	0.31	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
HNSC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-6.94	1.36e-11	9.24e-09	-0.4	-0.31	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
HNSC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	6.94	1.36e-11	9.24e-09	0.37	0.31	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-6.94	1.36e-11	9.24e-09	-0.27	-0.31	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
HNSC	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.93	1.36e-11	9.25e-09	0.38	0.31	Height;	chr6:109370985	chr6:109382795~109383666:+
HNSC	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	6.93	1.37e-11	9.29e-09	0.37	0.31	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43122761	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43124230	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000267151.3	RP11-100E5.2	6.93	1.37e-11	9.29e-09	0.39	0.31	Menopause (age at onset);	chr17:43124331	chr17:43444707~43451200:+
HNSC	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-6.93	1.37e-11	9.31e-09	-0.47	-0.31	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
HNSC	cis	rs860295	0.967	rs6665227	ENSG00000203761.5	MSTO2P	-6.93	1.38e-11	9.37e-09	-0.22	-0.31	Body mass index;	chr1:155740669	chr1:155745829~155750137:+
HNSC	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-6.93	1.38e-11	9.37e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
HNSC	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	6.93	1.38e-11	9.39e-09	0.6	0.31	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
HNSC	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-6.93	1.39e-11	9.42e-09	-0.34	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
HNSC	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.44e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
HNSC	cis	rs6867032	1	rs4975802	ENSG00000249731.1	RP11-259O2.3	6.93	1.39e-11	9.46e-09	0.38	0.31	Gut microbiome composition (winter);	chr5:2019636	chr5:1968094~1969013:+
HNSC	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.46e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	6.93	1.39e-11	9.46e-09	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
HNSC	cis	rs6951245	0.58	rs77101766	ENSG00000224079.1	AC091729.7	-6.93	1.4e-11	9.48e-09	-0.41	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1074450~1078036:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000254340.1	RP11-10A14.3	-6.93	1.4e-11	9.49e-09	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9044411	chr8:9141424~9145435:+
HNSC	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-6.93	1.41e-11	9.55e-09	-0.4	-0.31	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-6.93	1.41e-11	9.56e-09	-0.31	-0.31	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
HNSC	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-6.93	1.41e-11	9.58e-09	-0.39	-0.31	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8176083	ENSG00000267151.3	RP11-100E5.2	6.93	1.41e-11	9.58e-09	0.4	0.31	Menopause (age at onset);	chr17:43123134	chr17:43444707~43451200:+
HNSC	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	6.93	1.42e-11	9.6e-09	0.42	0.31	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000267151.3	RP11-100E5.2	6.93	1.42e-11	9.6e-09	0.4	0.31	Menopause (age at onset);	chr17:43357824	chr17:43444707~43451200:+
HNSC	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-6.93	1.42e-11	9.62e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
HNSC	cis	rs889014	1	rs7704555	ENSG00000253768.1	CTB-33O18.1	6.93	1.42e-11	9.66e-09	0.33	0.31	Height;	chr5:173572999	chr5:173562478~173573199:+
HNSC	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-6.93	1.42e-11	9.66e-09	-0.34	-0.31	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
HNSC	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.93	1.42e-11	9.66e-09	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
HNSC	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.69e-09	0.43	0.31	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	6.93	1.43e-11	9.7e-09	0.44	0.31	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.93	1.43e-11	9.71e-09	-0.39	-0.31	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
HNSC	cis	rs2834288	0.608	rs2017190	ENSG00000237945.6	LINC00649	6.93	1.43e-11	9.72e-09	0.39	0.31	Gut microbiota (bacterial taxa);	chr21:33938609	chr21:33915534~33977691:+
HNSC	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	6.93	1.44e-11	9.75e-09	0.3	0.31	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
HNSC	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	6.93	1.44e-11	9.76e-09	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
HNSC	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	6.92	1.45e-11	9.84e-09	0.41	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-6.92	1.45e-11	9.84e-09	-0.39	-0.31	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
HNSC	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-6.92	1.46e-11	9.86e-09	-0.3	-0.31	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
HNSC	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-6.92	1.46e-11	9.9e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
HNSC	cis	rs12935418	1	rs62054589	ENSG00000261061.1	RP11-303E16.2	-6.92	1.46e-11	9.9e-09	-0.44	-0.31	Mean corpuscular volume;	chr16:81035143	chr16:81030770~81031485:+
HNSC	cis	rs12935418	1	rs12935418	ENSG00000261061.1	RP11-303E16.2	-6.92	1.46e-11	9.9e-09	-0.44	-0.31	Mean corpuscular volume;	chr16:81036403	chr16:81030770~81031485:+
HNSC	cis	rs7615952	0.599	rs2270986	ENSG00000241288.6	RP11-379B18.5	-6.92	1.47e-11	9.93e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125982256	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs12496921	ENSG00000241288.6	RP11-379B18.5	-6.92	1.47e-11	9.93e-09	-0.4	-0.31	Blood pressure (smoking interaction);	chr3:125983105	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-6.92	1.47e-11	9.95e-09	-0.3	-0.31	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	6.92	1.47e-11	9.95e-09	0.22	0.31	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
HNSC	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	6.92	1.47e-11	9.96e-09	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
HNSC	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	6.92	1.47e-11	9.96e-09	0.33	0.31	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
HNSC	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	6.92	1.48e-11	1e-08	0.33	0.31	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
HNSC	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	6.92	1.48e-11	1e-08	0.33	0.31	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
HNSC	cis	rs6951245	0.872	rs57068908	ENSG00000225146.1	AC073957.15	-6.92	1.48e-11	1e-08	-0.47	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1029025~1043891:+
HNSC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	6.92	1.48e-11	1e-08	0.33	0.31	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
HNSC	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-6.92	1.49e-11	1.01e-08	-0.33	-0.31	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
HNSC	cis	rs2834288	0.5	rs766423	ENSG00000237945.6	LINC00649	6.92	1.49e-11	1.01e-08	0.38	0.3	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33915534~33977691:+
HNSC	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-6.92	1.5e-11	1.01e-08	-0.31	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
HNSC	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	6.92	1.5e-11	1.01e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
HNSC	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-6.92	1.5e-11	1.01e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
HNSC	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-6.92	1.5e-11	1.01e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
HNSC	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-6.92	1.51e-11	1.02e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
HNSC	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	6.92	1.51e-11	1.02e-08	0.4	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	6.92	1.51e-11	1.02e-08	0.4	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-6.92	1.51e-11	1.02e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
HNSC	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	6.92	1.51e-11	1.02e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
HNSC	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-6.92	1.51e-11	1.02e-08	-0.3	-0.3	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
HNSC	cis	rs7615952	0.688	rs12638224	ENSG00000248787.1	RP11-666A20.4	-6.92	1.51e-11	1.02e-08	-0.45	-0.3	Blood pressure (smoking interaction);	chr3:125822477	chr3:125908005~125910272:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43127865	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43128056	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43128665	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43131360	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000267151.3	RP11-100E5.2	6.92	1.51e-11	1.02e-08	0.39	0.3	Menopause (age at onset);	chr17:43135863	chr17:43444707~43451200:+
HNSC	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	6.92	1.51e-11	1.02e-08	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-6.92	1.51e-11	1.02e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
HNSC	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	6.92	1.52e-11	1.03e-08	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
HNSC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-6.92	1.52e-11	1.03e-08	-0.36	-0.3	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	6.92	1.52e-11	1.03e-08	0.38	0.3	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
HNSC	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	6.92	1.52e-11	1.03e-08	0.49	0.3	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
HNSC	cis	rs7615952	0.599	rs12486459	ENSG00000241288.6	RP11-379B18.5	-6.92	1.52e-11	1.03e-08	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126022622	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs67575510	ENSG00000241288.6	RP11-379B18.5	-6.92	1.52e-11	1.03e-08	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126023512	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.92	1.53e-11	1.04e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
HNSC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	6.92	1.53e-11	1.04e-08	0.34	0.3	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
HNSC	cis	rs17270561	0.609	rs4711097	ENSG00000272462.2	U91328.19	-6.92	1.54e-11	1.04e-08	-0.32	-0.3	Iron status biomarkers;	chr6:25732086	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.608	rs9358875	ENSG00000272462.2	U91328.19	-6.92	1.54e-11	1.04e-08	-0.32	-0.3	Iron status biomarkers;	chr6:25737780	chr6:25992662~26001775:+
HNSC	cis	rs2579103	0.708	rs825981	ENSG00000258183.4	RP11-753N8.1	6.92	1.54e-11	1.04e-08	0.42	0.3	Body mass index;	chr12:90306162	chr12:90280894~90300340:+
HNSC	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-6.92	1.54e-11	1.04e-08	-0.45	-0.3	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
HNSC	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-6.92	1.54e-11	1.04e-08	-0.36	-0.3	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
HNSC	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	6.92	1.54e-11	1.04e-08	0.3	0.3	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
HNSC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	6.91	1.55e-11	1.04e-08	0.31	0.3	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
HNSC	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	6.91	1.55e-11	1.04e-08	0.35	0.3	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
HNSC	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	6.91	1.55e-11	1.05e-08	0.3	0.3	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
HNSC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-6.91	1.56e-11	1.05e-08	-0.32	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
HNSC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-6.91	1.56e-11	1.05e-08	-0.4	-0.3	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
HNSC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	6.91	1.56e-11	1.05e-08	0.36	0.3	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
HNSC	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	6.91	1.56e-11	1.05e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
HNSC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	6.91	1.56e-11	1.05e-08	0.36	0.3	Depression;	chr6:28407125	chr6:28176188~28176674:+
HNSC	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-6.91	1.56e-11	1.05e-08	-0.39	-0.3	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
HNSC	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	6.91	1.57e-11	1.06e-08	0.31	0.3	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	6.91	1.57e-11	1.06e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-6.91	1.57e-11	1.06e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
HNSC	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-6.91	1.57e-11	1.06e-08	-0.38	-0.3	QT interval;	chr16:28845498	chr16:28700294~28701540:-
HNSC	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-6.91	1.57e-11	1.06e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
HNSC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-6.91	1.57e-11	1.06e-08	-0.39	-0.3	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
HNSC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	6.91	1.58e-11	1.06e-08	0.36	0.3	Depression;	chr6:28431469	chr6:28176188~28176674:+
HNSC	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	6.91	1.58e-11	1.06e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	6.91	1.58e-11	1.06e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
HNSC	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	6.91	1.58e-11	1.06e-08	0.44	0.3	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
HNSC	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.91	1.58e-11	1.07e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
HNSC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	6.91	1.58e-11	1.07e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-6.91	1.59e-11	1.07e-08	-0.27	-0.3	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-6.91	1.59e-11	1.07e-08	-0.27	-0.3	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
HNSC	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-6.91	1.6e-11	1.08e-08	-0.39	-0.3	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
HNSC	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.08e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
HNSC	cis	rs2579103	0.708	rs1103370	ENSG00000258183.4	RP11-753N8.1	-6.91	1.61e-11	1.08e-08	-0.42	-0.3	Body mass index;	chr12:90307356	chr12:90280894~90300340:+
HNSC	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	6.91	1.61e-11	1.08e-08	0.34	0.3	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
HNSC	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-6.91	1.61e-11	1.08e-08	-0.31	-0.3	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
HNSC	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-6.91	1.61e-11	1.08e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-6.91	1.61e-11	1.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6.91	1.62e-11	1.09e-08	0.36	0.3	Depression;	chr6:28430971	chr6:28176188~28176674:+
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000255769.6	GOLGA2P10	-6.91	1.63e-11	1.09e-08	-0.48	-0.3	Excessive daytime sleepiness;	chr15:82734974	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-6.91	1.64e-11	1.1e-08	-0.33	-0.3	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-6.91	1.64e-11	1.1e-08	-0.33	-0.3	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
HNSC	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	6.91	1.64e-11	1.1e-08	0.43	0.3	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
HNSC	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-6.91	1.64e-11	1.1e-08	-0.37	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	6.91	1.64e-11	1.1e-08	0.43	0.3	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	6.91	1.64e-11	1.1e-08	0.22	0.3	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	6.91	1.64e-11	1.1e-08	0.22	0.3	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
HNSC	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-6.9	1.65e-11	1.11e-08	-0.37	-0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
HNSC	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-6.9	1.65e-11	1.11e-08	-0.35	-0.3	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
HNSC	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	6.9	1.66e-11	1.12e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-6.9	1.66e-11	1.12e-08	-0.43	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000173295.6	FAM86B3P	6.9	1.66e-11	1.12e-08	0.35	0.3	Joint mobility (Beighton score);	chr8:9009901	chr8:8228595~8244865:+
HNSC	cis	rs1659258	0.772	rs1659265	ENSG00000232508.1	MRPL45P1	6.9	1.66e-11	1.12e-08	0.65	0.3	Visceral fat;	chr2:88363231	chr2:88364695~88365608:-
HNSC	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	6.9	1.67e-11	1.12e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-6.9	1.67e-11	1.12e-08	-0.36	-0.3	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
HNSC	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	6.9	1.68e-11	1.13e-08	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
HNSC	cis	rs7615952	0.688	rs12638240	ENSG00000248787.1	RP11-666A20.4	-6.9	1.68e-11	1.13e-08	-0.45	-0.3	Blood pressure (smoking interaction);	chr3:125822395	chr3:125908005~125910272:-
HNSC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	6.9	1.69e-11	1.13e-08	0.31	0.3	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
HNSC	cis	rs6951245	1	rs11763020	ENSG00000225146.1	AC073957.15	-6.9	1.69e-11	1.14e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1029025~1043891:+
HNSC	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-6.9	1.69e-11	1.14e-08	-0.35	-0.3	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
HNSC	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-6.9	1.7e-11	1.14e-08	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
HNSC	cis	rs1799949	1	rs8070085	ENSG00000267151.3	RP11-100E5.2	-6.9	1.7e-11	1.14e-08	-0.4	-0.3	Menopause (age at onset);	chr17:43189967	chr17:43444707~43451200:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-6.9	1.7e-11	1.14e-08	-0.33	-0.3	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-6.9	1.7e-11	1.14e-08	-0.39	-0.3	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-6.9	1.7e-11	1.14e-08	-0.39	-0.3	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
HNSC	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	6.9	1.7e-11	1.14e-08	0.41	0.3	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
HNSC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-6.9	1.71e-11	1.15e-08	-0.37	-0.3	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
HNSC	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	6.9	1.72e-11	1.15e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
HNSC	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	6.9	1.72e-11	1.15e-08	0.37	0.3	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-6.9	1.72e-11	1.16e-08	-0.36	-0.3	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
HNSC	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	6.9	1.72e-11	1.16e-08	0.43	0.3	Height;	chr6:109387972	chr6:109382795~109383666:+
HNSC	cis	rs1021993	0.545	rs79950910	ENSG00000231648.1	RP11-372M18.2	-6.9	1.73e-11	1.16e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209344553	chr1:209367662~209379690:+
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	6.9	1.73e-11	1.16e-08	0.43	0.3	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-6.9	1.73e-11	1.16e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
HNSC	cis	rs35955747	0.807	rs9619169	ENSG00000236132.1	CTA-440B3.1	6.9	1.73e-11	1.16e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31141356	chr22:31816379~31817491:-
HNSC	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.73e-11	1.16e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
HNSC	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
HNSC	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-6.9	1.73e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000267151.3	RP11-100E5.2	6.9	1.73e-11	1.16e-08	0.4	0.3	Menopause (age at onset);	chr17:43079204	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000267151.3	RP11-100E5.2	6.9	1.73e-11	1.16e-08	0.4	0.3	Menopause (age at onset);	chr17:43082453	chr17:43444707~43451200:+
HNSC	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.9	1.74e-11	1.16e-08	0.32	0.3	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
HNSC	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	6.9	1.74e-11	1.17e-08	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs8176273	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43059636	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43061609	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000267151.3	RP11-100E5.2	6.9	1.74e-11	1.17e-08	0.4	0.3	Menopause (age at onset);	chr17:43061979	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	6.9	1.75e-11	1.17e-08	0.21	0.3	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
HNSC	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	6.9	1.75e-11	1.17e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
HNSC	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.9	1.75e-11	1.17e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
HNSC	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.75e-11	1.17e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.75e-11	1.17e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
HNSC	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-6.9	1.76e-11	1.18e-08	-0.39	-0.3	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.76e-11	1.18e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.76e-11	1.18e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	6.89	1.76e-11	1.18e-08	0.37	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
HNSC	cis	rs4218	0.597	rs12442301	ENSG00000259732.1	RP11-59H7.3	-6.89	1.77e-11	1.18e-08	-0.43	-0.3	Social communication problems;	chr15:59065968	chr15:59121034~59133250:+
HNSC	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	6.89	1.77e-11	1.18e-08	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
HNSC	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-6.89	1.77e-11	1.19e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
HNSC	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	6.89	1.77e-11	1.19e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
HNSC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	6.89	1.77e-11	1.19e-08	0.37	0.3	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
HNSC	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-6.89	1.77e-11	1.19e-08	-0.33	-0.3	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
HNSC	cis	rs36405	0.5	rs11621704	ENSG00000266869.1	RP6-114E22.1	-6.89	1.77e-11	1.19e-08	-0.39	-0.3	Yang-deficiency constitution;	chr14:71888476	chr14:71848606~71908430:+
HNSC	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	6.89	1.77e-11	1.19e-08	0.33	0.3	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-6.89	1.77e-11	1.19e-08	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
HNSC	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-6.89	1.77e-11	1.19e-08	-0.31	-0.3	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
HNSC	cis	rs2579103	0.708	rs2731256	ENSG00000258183.4	RP11-753N8.1	-6.89	1.78e-11	1.19e-08	-0.42	-0.3	Body mass index;	chr12:90289196	chr12:90280894~90300340:+
HNSC	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	6.89	1.78e-11	1.19e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
HNSC	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	6.89	1.78e-11	1.19e-08	0.43	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
HNSC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-6.89	1.78e-11	1.19e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
HNSC	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	6.89	1.78e-11	1.19e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	6.89	1.78e-11	1.19e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
HNSC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-6.89	1.8e-11	1.2e-08	-0.33	-0.3	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
HNSC	cis	rs9402743	0.781	rs2273069	ENSG00000217482.2	HMGB1P17	6.89	1.8e-11	1.2e-08	0.35	0.3	Systemic lupus erythematosus;	chr6:135689660	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.597	rs4821774	ENSG00000211638.2	IGLV8-61	-6.89	1.8e-11	1.21e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22098700~22099212:+
HNSC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-6.89	1.81e-11	1.21e-08	-0.39	-0.3	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
HNSC	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	6.89	1.83e-11	1.22e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
HNSC	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
HNSC	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-6.89	1.84e-11	1.23e-08	-0.51	-0.3	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
HNSC	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-6.89	1.84e-11	1.23e-08	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-6.89	1.84e-11	1.23e-08	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
HNSC	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-6.89	1.84e-11	1.23e-08	-0.45	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
HNSC	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	6.89	1.84e-11	1.23e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
HNSC	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.89	1.85e-11	1.24e-08	-0.48	-0.3	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
HNSC	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-6.89	1.85e-11	1.24e-08	-0.35	-0.3	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
HNSC	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
HNSC	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	6.89	1.86e-11	1.24e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
HNSC	cis	rs10791097	1	rs10791097	ENSG00000254842.5	RP11-890B15.2	6.89	1.86e-11	1.24e-08	0.26	0.3	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130848735	chr11:130844191~130865561:-
HNSC	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	6.89	1.86e-11	1.24e-08	0.44	0.3	Height;	chr6:109381443	chr6:109382795~109383666:+
HNSC	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-6.89	1.86e-11	1.24e-08	-0.32	-0.3	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
HNSC	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	6.89	1.87e-11	1.25e-08	0.35	0.3	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-6.89	1.87e-11	1.25e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-6.89	1.87e-11	1.25e-08	-0.37	-0.3	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-6.88	1.87e-11	1.25e-08	-0.33	-0.3	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-6.88	1.88e-11	1.26e-08	-0.37	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	6.88	1.88e-11	1.26e-08	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
HNSC	cis	rs9341808	0.935	rs2298307	ENSG00000272129.1	RP11-250B2.6	6.88	1.88e-11	1.26e-08	0.36	0.3	Sitting height ratio;	chr6:80106579	chr6:80355424~80356859:+
HNSC	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	6.88	1.89e-11	1.26e-08	0.37	0.3	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-6.88	1.89e-11	1.26e-08	-0.33	-0.3	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
HNSC	cis	rs6471393	0.929	rs62525164	ENSG00000253848.1	RP11-10N23.5	6.88	1.89e-11	1.26e-08	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:93741193~93744534:+
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000267151.3	RP11-100E5.2	6.88	1.89e-11	1.26e-08	0.39	0.3	Menopause (age at onset);	chr17:43154506	chr17:43444707~43451200:+
HNSC	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	6.88	1.89e-11	1.26e-08	0.44	0.3	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
HNSC	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-6.88	1.89e-11	1.26e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-6.88	1.89e-11	1.26e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
HNSC	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-6.88	1.9e-11	1.26e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000173295.6	FAM86B3P	-6.88	1.9e-11	1.26e-08	-0.33	-0.3	Myopia (pathological);	chr8:9111923	chr8:8228595~8244865:+
HNSC	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	6.88	1.9e-11	1.27e-08	0.39	0.3	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	6.88	1.9e-11	1.27e-08	0.28	0.3	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	6.88	1.9e-11	1.27e-08	0.28	0.3	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	6.88	1.91e-11	1.27e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
HNSC	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.88	1.91e-11	1.28e-08	-0.48	-0.3	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
HNSC	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.88	1.91e-11	1.28e-08	-0.48	-0.3	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
HNSC	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	6.88	1.91e-11	1.28e-08	0.34	0.3	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-6.88	1.92e-11	1.28e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
HNSC	cis	rs6951245	1	rs11764748	ENSG00000224079.1	AC091729.7	-6.88	1.92e-11	1.28e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1074450~1078036:+
HNSC	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	6.88	1.92e-11	1.28e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
HNSC	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	6.88	1.92e-11	1.28e-08	0.35	0.3	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
HNSC	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	6.88	1.93e-11	1.28e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	6.88	1.93e-11	1.28e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
HNSC	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	6.88	1.93e-11	1.28e-08	0.36	0.3	Height;	chr4:55370412	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	6.88	1.93e-11	1.28e-08	0.43	0.3	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	6.88	1.93e-11	1.28e-08	0.43	0.3	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
HNSC	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.88	1.93e-11	1.29e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
HNSC	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-6.88	1.93e-11	1.29e-08	-0.33	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
HNSC	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.88	1.94e-11	1.29e-08	-0.48	-0.3	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
HNSC	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-6.88	1.94e-11	1.29e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
HNSC	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-6.88	1.95e-11	1.3e-08	-0.33	-0.3	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
HNSC	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	6.88	1.96e-11	1.3e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
HNSC	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-6.88	1.96e-11	1.3e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
HNSC	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	6.88	1.96e-11	1.3e-08	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
HNSC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-6.88	1.96e-11	1.3e-08	-0.35	-0.3	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	6.88	1.96e-11	1.3e-08	0.29	0.3	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
HNSC	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.88	1.96e-11	1.31e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000267151.3	RP11-100E5.2	6.88	1.97e-11	1.31e-08	0.39	0.3	Menopause (age at onset);	chr17:43070706	chr17:43444707~43451200:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-6.88	1.97e-11	1.31e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-6.88	1.98e-11	1.32e-08	-0.33	-0.3	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-6.88	1.98e-11	1.32e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs8176242	ENSG00000267151.3	RP11-100E5.2	6.88	1.99e-11	1.32e-08	0.39	0.3	Menopause (age at onset);	chr17:43065857	chr17:43444707~43451200:+
HNSC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-6.88	1.99e-11	1.32e-08	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
HNSC	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	6.88	1.99e-11	1.33e-08	0.43	0.3	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
HNSC	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	6.87	2.01e-11	1.33e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
HNSC	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-6.87	2.01e-11	1.33e-08	-0.42	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
HNSC	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	6.87	2.01e-11	1.34e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
HNSC	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-6.87	2.01e-11	1.34e-08	-0.38	-0.3	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
HNSC	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	6.87	2.03e-11	1.35e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
HNSC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	6.87	2.03e-11	1.35e-08	0.36	0.3	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
HNSC	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	6.87	2.03e-11	1.35e-08	0.39	0.3	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
HNSC	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-6.87	2.03e-11	1.35e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
HNSC	cis	rs1021993	1	rs2660640	ENSG00000231648.1	RP11-372M18.2	6.87	2.04e-11	1.36e-08	0.41	0.3	Gut microbiome composition (winter);	chr1:209336845	chr1:209367662~209379690:+
HNSC	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-6.87	2.04e-11	1.36e-08	-0.41	-0.3	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
HNSC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-6.87	2.05e-11	1.36e-08	-0.39	-0.3	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-6.87	2.05e-11	1.36e-08	-0.39	-0.3	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
HNSC	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	6.87	2.06e-11	1.37e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
HNSC	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	6.87	2.06e-11	1.37e-08	0.3	0.3	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
HNSC	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.87	2.06e-11	1.37e-08	-0.46	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
HNSC	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	6.87	2.06e-11	1.37e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
HNSC	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-6.87	2.06e-11	1.37e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
HNSC	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-6.87	2.06e-11	1.37e-08	-0.35	-0.3	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-6.87	2.07e-11	1.37e-08	-0.39	-0.3	Depression;	chr6:28229408	chr6:28115628~28116551:+
HNSC	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-6.87	2.07e-11	1.37e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
HNSC	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-6.87	2.08e-11	1.38e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
HNSC	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	6.87	2.08e-11	1.38e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-6.87	2.08e-11	1.38e-08	-0.28	-0.3	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-6.87	2.08e-11	1.38e-08	-0.28	-0.3	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
HNSC	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	6.87	2.09e-11	1.38e-08	0.37	0.3	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
HNSC	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-6.87	2.09e-11	1.39e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.729	rs1344964	ENSG00000258183.4	RP11-753N8.1	-6.87	2.09e-11	1.39e-08	-0.39	-0.3	Body mass index;	chr12:90276876	chr12:90280894~90300340:+
HNSC	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-6.87	2.1e-11	1.39e-08	-0.31	-0.3	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
HNSC	cis	rs6471393	0.895	rs4255106	ENSG00000253848.1	RP11-10N23.5	6.87	2.1e-11	1.39e-08	0.36	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:93741193~93744534:+
HNSC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	6.87	2.1e-11	1.39e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
HNSC	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	6.87	2.1e-11	1.39e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
HNSC	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-6.87	2.1e-11	1.39e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
HNSC	cis	rs17270561	0.609	rs7754296	ENSG00000272462.2	U91328.19	-6.87	2.11e-11	1.4e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25744650	chr6:25992662~26001775:+
HNSC	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	6.87	2.11e-11	1.4e-08	0.43	0.3	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000267151.3	RP11-100E5.2	6.87	2.12e-11	1.4e-08	0.4	0.3	Menopause (age at onset);	chr17:43049685	chr17:43444707~43451200:+
HNSC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.4e-08	-0.4	-0.3	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-6.87	2.12e-11	1.41e-08	-0.39	-0.3	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
HNSC	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-6.87	2.12e-11	1.41e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-6.87	2.12e-11	1.41e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
HNSC	cis	rs4218	0.597	rs12438962	ENSG00000259732.1	RP11-59H7.3	-6.86	2.13e-11	1.41e-08	-0.43	-0.3	Social communication problems;	chr15:59065694	chr15:59121034~59133250:+
HNSC	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.86	2.13e-11	1.41e-08	-0.48	-0.3	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
HNSC	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.86	2.13e-11	1.41e-08	0.42	0.3	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
HNSC	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	6.86	2.14e-11	1.42e-08	0.38	0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
HNSC	cis	rs1021993	0.545	rs74155473	ENSG00000231648.1	RP11-372M18.2	-6.86	2.14e-11	1.42e-08	-0.5	-0.3	Gut microbiome composition (winter);	chr1:209372518	chr1:209367662~209379690:+
HNSC	cis	rs9326248	0.53	rs588918	ENSG00000280143.1	AP000892.6	6.86	2.14e-11	1.42e-08	0.44	0.3	Blood protein levels;	chr11:116985926	chr11:117204967~117210292:+
HNSC	cis	rs4218	0.551	rs12906212	ENSG00000259732.1	RP11-59H7.3	-6.86	2.14e-11	1.42e-08	-0.44	-0.3	Social communication problems;	chr15:59070556	chr15:59121034~59133250:+
HNSC	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-6.86	2.15e-11	1.42e-08	-0.33	-0.3	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
HNSC	cis	rs62344088	0.744	rs76038312	ENSG00000277812.1	AC021087.1	6.86	2.15e-11	1.42e-08	0.76	0.3	Asthma (childhood onset);	chr5:228890	chr5:262769~262881:+
HNSC	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	6.86	2.15e-11	1.42e-08	0.43	0.3	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	6.86	2.15e-11	1.42e-08	0.28	0.3	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6.86	2.15e-11	1.42e-08	0.36	0.3	Depression;	chr6:28432562	chr6:28176188~28176674:+
HNSC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-6.86	2.16e-11	1.43e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
HNSC	cis	rs2834288	0.536	rs762356	ENSG00000237945.6	LINC00649	6.86	2.16e-11	1.43e-08	0.38	0.3	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33915534~33977691:+
HNSC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.86	2.16e-11	1.43e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
HNSC	cis	rs2579103	0.767	rs1371084	ENSG00000258183.4	RP11-753N8.1	-6.86	2.17e-11	1.43e-08	-0.39	-0.3	Body mass index;	chr12:90273990	chr12:90280894~90300340:+
HNSC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.86	2.17e-11	1.44e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.673	rs35955861	ENSG00000241288.6	RP11-379B18.5	-6.86	2.17e-11	1.44e-08	-0.51	-0.3	Blood pressure (smoking interaction);	chr3:125907358	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.673	rs35001498	ENSG00000241288.6	RP11-379B18.5	-6.86	2.17e-11	1.44e-08	-0.51	-0.3	Blood pressure (smoking interaction);	chr3:125909801	chr3:125827238~125916384:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-6.86	2.17e-11	1.44e-08	-0.45	-0.3	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.895	rs5756985	ENSG00000211638.2	IGLV8-61	-6.86	2.18e-11	1.44e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-6.86	2.19e-11	1.45e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
HNSC	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	6.86	2.19e-11	1.45e-08	0.44	0.3	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
HNSC	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-6.86	2.19e-11	1.45e-08	-0.38	-0.3	Height;	chr3:53070344	chr3:53064283~53065091:-
HNSC	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.86	2.2e-11	1.46e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
HNSC	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-6.86	2.2e-11	1.46e-08	-0.49	-0.3	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
HNSC	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-6.86	2.21e-11	1.46e-08	-0.5	-0.3	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
HNSC	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	6.86	2.21e-11	1.46e-08	0.45	0.3	Depression;	chr6:28262103	chr6:28115628~28116551:+
HNSC	cis	rs2239557	0.608	rs2041186	ENSG00000259065.1	RP5-1021I20.1	-6.86	2.21e-11	1.46e-08	-0.37	-0.3	Common traits (Other);	chr14:73815334	chr14:73787360~73803270:+
HNSC	cis	rs6951245	0.706	rs28685743	ENSG00000224079.1	AC091729.7	-6.86	2.21e-11	1.46e-08	-0.51	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1074450~1078036:+
HNSC	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	6.86	2.22e-11	1.46e-08	0.61	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
HNSC	cis	rs4218	0.597	rs62002544	ENSG00000259732.1	RP11-59H7.3	-6.86	2.22e-11	1.47e-08	-0.44	-0.3	Social communication problems;	chr15:59066663	chr15:59121034~59133250:+
HNSC	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	6.86	2.23e-11	1.47e-08	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
HNSC	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	6.86	2.23e-11	1.47e-08	0.29	0.3	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
HNSC	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	6.86	2.23e-11	1.48e-08	0.29	0.3	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	6.86	2.23e-11	1.48e-08	0.29	0.3	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
HNSC	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	6.86	2.24e-11	1.48e-08	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
HNSC	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	6.86	2.24e-11	1.48e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
HNSC	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	6.86	2.24e-11	1.48e-08	0.35	0.3	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
HNSC	cis	rs1815787	1	rs1815787	ENSG00000280143.1	AP000892.6	6.86	2.24e-11	1.48e-08	0.44	0.3	Subjective well-being;	chr11:117050681	chr11:117204967~117210292:+
HNSC	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	6.86	2.24e-11	1.48e-08	0.38	0.3	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577638	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577671	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000274902.1	RP1-197B17.4	6.86	2.25e-11	1.48e-08	0.78	0.3	Pneumonia;	chr12:47577693	chr12:47731908~47732351:+
HNSC	cis	rs9402743	0.816	rs9494335	ENSG00000217482.2	HMGB1P17	-6.86	2.25e-11	1.49e-08	-0.33	-0.3	Systemic lupus erythematosus;	chr6:135690726	chr6:135636086~135636713:-
HNSC	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	6.86	2.25e-11	1.49e-08	0.29	0.3	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
HNSC	cis	rs17270561	0.609	rs9358878	ENSG00000272462.2	U91328.19	-6.86	2.26e-11	1.49e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740045	chr6:25992662~26001775:+
HNSC	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-6.86	2.26e-11	1.49e-08	-0.55	-0.3	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-6.86	2.26e-11	1.49e-08	-0.55	-0.3	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-6.86	2.26e-11	1.49e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
HNSC	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	6.85	2.27e-11	1.5e-08	0.34	0.3	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
HNSC	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	6.85	2.27e-11	1.5e-08	0.23	0.3	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
HNSC	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	6.85	2.27e-11	1.5e-08	0.23	0.3	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
HNSC	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	6.85	2.27e-11	1.5e-08	0.43	0.3	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	6.85	2.27e-11	1.5e-08	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	6.85	2.27e-11	1.5e-08	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	6.85	2.27e-11	1.5e-08	0.36	0.3	Depression;	chr6:28402301	chr6:28176188~28176674:+
HNSC	cis	rs889014	1	rs7733195	ENSG00000253768.1	CTB-33O18.1	6.85	2.28e-11	1.51e-08	0.32	0.3	Height;	chr5:173567621	chr5:173562478~173573199:+
HNSC	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	-6.85	2.29e-11	1.51e-08	-0.35	-0.3	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
HNSC	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-6.85	2.3e-11	1.52e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-6.85	2.3e-11	1.52e-08	-0.26	-0.3	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
HNSC	cis	rs7048146	0.715	rs34983370	ENSG00000213539.4	YBX1P6	6.85	2.31e-11	1.53e-08	0.36	0.3	Vascular brain injury;	chr9:109586983	chr9:109532830~109534332:-
HNSC	cis	rs1799949	1	rs33926631	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43152446	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43153380	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000267151.3	RP11-100E5.2	6.85	2.32e-11	1.53e-08	0.38	0.3	Menopause (age at onset);	chr17:43153866	chr17:43444707~43451200:+
HNSC	cis	rs2579103	0.708	rs2731260	ENSG00000258183.4	RP11-753N8.1	-6.85	2.32e-11	1.53e-08	-0.42	-0.3	Body mass index;	chr12:90283433	chr12:90280894~90300340:+
HNSC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	6.85	2.32e-11	1.53e-08	0.36	0.3	Depression;	chr6:28399846	chr6:28176188~28176674:+
HNSC	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	6.85	2.32e-11	1.53e-08	0.38	0.3	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
HNSC	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	6.85	2.33e-11	1.53e-08	0.36	0.3	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	6.85	2.33e-11	1.53e-08	0.36	0.3	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-6.85	2.33e-11	1.53e-08	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
HNSC	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.34e-11	1.54e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-6.85	2.34e-11	1.55e-08	-0.44	-0.3	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
HNSC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-6.85	2.35e-11	1.55e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
HNSC	cis	rs2579103	0.595	rs7301703	ENSG00000258183.4	RP11-753N8.1	-6.85	2.35e-11	1.55e-08	-0.39	-0.3	Body mass index;	chr12:90313548	chr12:90280894~90300340:+
HNSC	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.85	2.35e-11	1.55e-08	0.32	0.3	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-6.85	2.35e-11	1.55e-08	-0.21	-0.3	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
HNSC	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	6.85	2.36e-11	1.55e-08	0.25	0.3	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
HNSC	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	6.85	2.36e-11	1.55e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-6.85	2.36e-11	1.56e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	-6.85	2.37e-11	1.56e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
HNSC	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-6.85	2.37e-11	1.56e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-6.85	2.37e-11	1.56e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
HNSC	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	6.85	2.37e-11	1.56e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
HNSC	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-6.85	2.38e-11	1.56e-08	-0.42	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
HNSC	cis	rs1799810	0.899	rs6753288	ENSG00000236682.1	AC068282.3	-6.85	2.39e-11	1.57e-08	-0.36	-0.3	Self-rated health;	chr2:127412323	chr2:127389130~127400580:+
HNSC	cis	rs7115242	0.8	rs7931770	ENSG00000280143.1	AP000892.6	6.85	2.39e-11	1.57e-08	0.44	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.8	rs4245168	ENSG00000280143.1	AP000892.6	6.85	2.39e-11	1.57e-08	0.44	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	6.85	2.4e-11	1.58e-08	0.46	0.3	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
HNSC	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-6.85	2.4e-11	1.58e-08	-0.37	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
HNSC	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-6.85	2.41e-11	1.58e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-6.85	2.41e-11	1.58e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
HNSC	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	6.85	2.41e-11	1.59e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
HNSC	cis	rs2579103	0.63	rs1222610	ENSG00000258183.4	RP11-753N8.1	-6.85	2.41e-11	1.59e-08	-0.41	-0.3	Body mass index;	chr12:90315578	chr12:90280894~90300340:+
HNSC	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	6.84	2.41e-11	1.59e-08	0.32	0.3	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
HNSC	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	6.84	2.44e-11	1.6e-08	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
HNSC	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-6.84	2.44e-11	1.61e-08	-0.56	-0.3	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-6.84	2.44e-11	1.61e-08	-0.29	-0.3	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
HNSC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	6.84	2.45e-11	1.61e-08	0.43	0.3	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
HNSC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-6.84	2.46e-11	1.61e-08	-0.39	-0.3	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
HNSC	cis	rs9326248	0.53	rs7124741	ENSG00000280143.1	AP000892.6	6.84	2.46e-11	1.62e-08	0.47	0.3	Blood protein levels;	chr11:116881503	chr11:117204967~117210292:+
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-6.84	2.47e-11	1.62e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	6.84	2.47e-11	1.63e-08	0.43	0.3	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-6.84	2.48e-11	1.63e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
HNSC	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	6.84	2.48e-11	1.63e-08	0.3	0.3	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
HNSC	cis	rs6471393	0.929	rs62525163	ENSG00000253848.1	RP11-10N23.5	6.84	2.48e-11	1.63e-08	0.36	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:93741193~93744534:+
HNSC	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-6.84	2.48e-11	1.63e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-6.84	2.48e-11	1.63e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
HNSC	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	6.84	2.49e-11	1.63e-08	0.34	0.3	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	6.84	2.49e-11	1.63e-08	0.34	0.3	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
HNSC	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	6.84	2.49e-11	1.64e-08	0.36	0.3	Depression;	chr6:28327262	chr6:28943877~28944537:+
HNSC	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	6.84	2.49e-11	1.64e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
HNSC	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-6.84	2.49e-11	1.64e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
HNSC	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-6.84	2.5e-11	1.64e-08	-0.3	-0.3	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
HNSC	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-6.84	2.5e-11	1.64e-08	-0.37	-0.3	Height;	chr4:55593918	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-6.84	2.52e-11	1.65e-08	-0.27	-0.3	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
HNSC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.84	2.52e-11	1.65e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
HNSC	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	6.84	2.52e-11	1.65e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
HNSC	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	6.84	2.53e-11	1.66e-08	0.31	0.3	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
HNSC	cis	rs17270561	0.609	rs6941933	ENSG00000272462.2	U91328.19	-6.84	2.53e-11	1.66e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745474	chr6:25992662~26001775:+
HNSC	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	6.84	2.54e-11	1.67e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
HNSC	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	6.84	2.54e-11	1.67e-08	0.38	0.3	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	6.84	2.55e-11	1.67e-08	0.43	0.3	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
HNSC	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-6.84	2.55e-11	1.67e-08	-0.47	-0.3	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
HNSC	cis	rs172166	0.637	rs1233708	ENSG00000204709.4	LINC01556	6.84	2.55e-11	1.67e-08	0.37	0.3	Cardiac Troponin-T levels;	chr6:28205441	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	6.84	2.55e-11	1.68e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
HNSC	cis	rs7048146	0.51	rs7859790	ENSG00000213539.4	YBX1P6	-6.84	2.56e-11	1.68e-08	-0.34	-0.3	Vascular brain injury;	chr9:109528203	chr9:109532830~109534332:-
HNSC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6.84	2.56e-11	1.68e-08	-0.41	-0.3	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
HNSC	cis	rs4141404	0.737	rs5998067	ENSG00000236132.1	CTA-440B3.1	6.84	2.56e-11	1.68e-08	0.38	0.3	Paclitaxel-induced neuropathy;	chr22:31647644	chr22:31816379~31817491:-
HNSC	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	6.84	2.57e-11	1.68e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-6.84	2.57e-11	1.68e-08	-0.31	-0.3	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
HNSC	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-6.84	2.57e-11	1.68e-08	-0.28	-0.3	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
HNSC	cis	rs4141404	0.737	rs5998058	ENSG00000236132.1	CTA-440B3.1	-6.84	2.57e-11	1.68e-08	-0.38	-0.3	Paclitaxel-induced neuropathy;	chr22:31610422	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	6.83	2.57e-11	1.69e-08	0.29	0.3	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.83	2.57e-11	1.69e-08	0.28	0.3	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-6.83	2.59e-11	1.7e-08	-0.58	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
HNSC	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.59e-11	1.7e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
HNSC	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-6.83	2.6e-11	1.7e-08	-0.32	-0.3	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
HNSC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	6.83	2.6e-11	1.71e-08	0.36	0.3	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
HNSC	cis	rs2115630	0.645	rs3825877	ENSG00000229212.6	RP11-561C5.4	6.83	2.61e-11	1.71e-08	0.35	0.3	P wave terminal force;	chr15:84631400	chr15:85205440~85234795:-
HNSC	cis	rs2115630	0.645	rs3825878	ENSG00000229212.6	RP11-561C5.4	6.83	2.61e-11	1.71e-08	0.35	0.3	P wave terminal force;	chr15:84631524	chr15:85205440~85234795:-
HNSC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	6.83	2.61e-11	1.71e-08	0.36	0.3	Depression;	chr6:28428413	chr6:28176188~28176674:+
HNSC	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.83	2.62e-11	1.71e-08	-0.48	-0.3	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
HNSC	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-6.83	2.62e-11	1.72e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
HNSC	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	6.83	2.62e-11	1.72e-08	0.4	0.3	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
HNSC	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	6.83	2.63e-11	1.72e-08	0.36	0.3	Depression;	chr6:28323463	chr6:28943877~28944537:+
HNSC	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	6.83	2.64e-11	1.73e-08	0.28	0.3	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
HNSC	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	6.83	2.65e-11	1.73e-08	0.43	0.3	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
HNSC	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	6.83	2.65e-11	1.74e-08	0.37	0.3	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
HNSC	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	6.83	2.66e-11	1.74e-08	0.34	0.3	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	6.83	2.66e-11	1.74e-08	0.34	0.3	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
HNSC	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-6.83	2.66e-11	1.74e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-6.83	2.66e-11	1.74e-08	-0.36	-0.3	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
HNSC	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	6.83	2.66e-11	1.74e-08	0.36	0.3	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
HNSC	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-6.83	2.67e-11	1.75e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
HNSC	cis	rs2286503	0.901	rs10950922	ENSG00000221740.1	SNORD93	6.83	2.67e-11	1.75e-08	0.32	0.3	Fibrinogen;	chr7:22814387	chr7:22856613~22856686:+
HNSC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	6.83	2.68e-11	1.75e-08	0.36	0.3	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
HNSC	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-6.83	2.68e-11	1.75e-08	-0.45	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
HNSC	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.83	2.68e-11	1.76e-08	-0.39	-0.3	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
HNSC	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.83	2.69e-11	1.76e-08	-0.38	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
HNSC	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	6.83	2.69e-11	1.76e-08	0.38	0.3	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
HNSC	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.83	2.69e-11	1.76e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.83	2.69e-11	1.76e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
HNSC	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	6.83	2.7e-11	1.76e-08	0.38	0.3	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
HNSC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	6.83	2.7e-11	1.76e-08	0.36	0.3	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-6.83	2.71e-11	1.77e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
HNSC	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	6.83	2.71e-11	1.77e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
HNSC	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	6.83	2.71e-11	1.77e-08	0.47	0.3	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	6.83	2.72e-11	1.77e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.63	rs825975	ENSG00000258183.4	RP11-753N8.1	6.83	2.72e-11	1.77e-08	0.41	0.3	Body mass index;	chr12:90314725	chr12:90280894~90300340:+
HNSC	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	6.83	2.72e-11	1.78e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	6.83	2.72e-11	1.78e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
HNSC	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-6.83	2.72e-11	1.78e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
HNSC	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-6.83	2.74e-11	1.79e-08	-0.34	-0.3	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
HNSC	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-6.83	2.74e-11	1.79e-08	-0.48	-0.3	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
HNSC	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs2000616	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117045813	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs10750100	ENSG00000280143.1	AP000892.6	6.82	2.74e-11	1.79e-08	0.44	0.3	Blood protein levels;	chr11:117046528	chr11:117204967~117210292:+
HNSC	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-6.82	2.74e-11	1.79e-08	-0.31	-0.3	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
HNSC	cis	rs1799949	1	rs2271573	ENSG00000267151.3	RP11-100E5.2	6.82	2.74e-11	1.79e-08	0.4	0.3	Menopause (age at onset);	chr17:43175604	chr17:43444707~43451200:+
HNSC	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	6.82	2.75e-11	1.79e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
HNSC	cis	rs7083	1	rs588763	ENSG00000254851.1	RP11-109L13.1	6.82	2.75e-11	1.79e-08	0.39	0.3	Blood protein levels;	chr11:117246065	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-6.82	2.75e-11	1.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	6.82	2.75e-11	1.79e-08	0.21	0.3	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
HNSC	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	6.82	2.76e-11	1.8e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
HNSC	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-6.82	2.76e-11	1.8e-08	-0.32	-0.3	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
HNSC	cis	rs1799949	1	rs11652332	ENSG00000267151.3	RP11-100E5.2	6.82	2.77e-11	1.81e-08	0.39	0.3	Menopause (age at onset);	chr17:43143472	chr17:43444707~43451200:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	6.82	2.77e-11	1.81e-08	0.27	0.3	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	6.82	2.77e-11	1.81e-08	0.21	0.3	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
HNSC	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	6.82	2.78e-11	1.81e-08	0.39	0.3	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
HNSC	cis	rs6951245	0.744	rs10275401	ENSG00000224079.1	AC091729.7	-6.82	2.78e-11	1.81e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1074450~1078036:+
HNSC	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	6.82	2.79e-11	1.82e-08	0.38	0.3	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
HNSC	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	6.82	2.79e-11	1.82e-08	0.37	0.3	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
HNSC	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	6.82	2.79e-11	1.82e-08	0.39	0.3	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
HNSC	cis	rs7048146	0.51	rs2210159	ENSG00000213539.4	YBX1P6	-6.82	2.8e-11	1.82e-08	-0.34	-0.3	Vascular brain injury;	chr9:109526297	chr9:109532830~109534332:-
HNSC	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-6.82	2.8e-11	1.82e-08	-0.32	-0.3	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
HNSC	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-6.82	2.8e-11	1.83e-08	-0.35	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
HNSC	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-6.82	2.81e-11	1.83e-08	-0.44	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
HNSC	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.81e-11	1.83e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
HNSC	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	6.82	2.81e-11	1.83e-08	0.31	0.3	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
HNSC	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-6.82	2.82e-11	1.84e-08	-0.35	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
HNSC	cis	rs4218	0.608	rs34859729	ENSG00000259732.1	RP11-59H7.3	-6.82	2.82e-11	1.84e-08	-0.43	-0.3	Social communication problems;	chr15:59070117	chr15:59121034~59133250:+
HNSC	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-6.82	2.82e-11	1.84e-08	-0.48	-0.3	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
HNSC	cis	rs6867032	0.876	rs1552435	ENSG00000249731.1	RP11-259O2.3	6.82	2.83e-11	1.84e-08	0.37	0.3	Gut microbiome composition (winter);	chr5:2018264	chr5:1968094~1969013:+
HNSC	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-6.82	2.83e-11	1.85e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
HNSC	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	6.82	2.84e-11	1.85e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000248787.1	RP11-666A20.4	-6.82	2.85e-11	1.85e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125880966	chr3:125908005~125910272:-
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.85e-11	1.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
HNSC	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-6.82	2.86e-11	1.86e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
HNSC	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	6.82	2.86e-11	1.86e-08	0.35	0.3	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
HNSC	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.86e-11	1.86e-08	-0.37	-0.3	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
HNSC	cis	rs7048146	0.51	rs4978821	ENSG00000213539.4	YBX1P6	-6.82	2.87e-11	1.87e-08	-0.34	-0.3	Vascular brain injury;	chr9:109525661	chr9:109532830~109534332:-
HNSC	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-6.82	2.87e-11	1.87e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
HNSC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.87e-11	1.87e-08	-0.37	-0.3	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-6.82	2.87e-11	1.87e-08	-0.37	-0.3	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
HNSC	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.82	2.88e-11	1.88e-08	0.31	0.3	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.82	2.88e-11	1.88e-08	0.31	0.3	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
HNSC	cis	rs2579103	0.66	rs1438995	ENSG00000258183.4	RP11-753N8.1	6.82	2.89e-11	1.88e-08	0.33	0.3	Body mass index;	chr12:90262833	chr12:90280894~90300340:+
HNSC	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-6.82	2.89e-11	1.88e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
HNSC	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	6.82	2.9e-11	1.89e-08	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.82	2.91e-11	1.89e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
HNSC	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	6.82	2.91e-11	1.89e-08	0.43	0.3	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
HNSC	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	6.82	2.91e-11	1.89e-08	0.28	0.3	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
HNSC	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Migraine;	chr4:56851192	chr4:56960927~56961373:-
HNSC	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Migraine;	chr4:56852087	chr4:56960927~56961373:-
HNSC	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-6.82	2.91e-11	1.89e-08	-0.37	-0.3	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
HNSC	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-6.82	2.91e-11	1.89e-08	-0.32	-0.3	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
HNSC	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-6.82	2.92e-11	1.9e-08	-0.33	-0.3	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
HNSC	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	6.81	2.93e-11	1.9e-08	0.29	0.3	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
HNSC	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-6.81	2.93e-11	1.91e-08	-0.38	-0.3	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-6.81	2.94e-11	1.91e-08	-0.34	-0.3	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
HNSC	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-6.81	2.94e-11	1.91e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
HNSC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-6.81	2.95e-11	1.92e-08	-0.36	-0.3	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
HNSC	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-6.81	2.95e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-6.81	2.95e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
HNSC	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.81	2.96e-11	1.92e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.81	2.96e-11	1.92e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
HNSC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.81	2.96e-11	1.93e-08	0.33	0.3	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
HNSC	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-6.81	2.96e-11	1.93e-08	-0.38	-0.3	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
HNSC	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-6.81	2.96e-11	1.93e-08	-0.38	-0.3	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	6.81	2.97e-11	1.93e-08	0.27	0.3	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
HNSC	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	6.81	2.97e-11	1.93e-08	0.38	0.3	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
HNSC	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.81	2.97e-11	1.93e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
HNSC	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	6.81	2.97e-11	1.93e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
HNSC	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	6.81	2.97e-11	1.93e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
HNSC	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	6.81	2.97e-11	1.93e-08	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
HNSC	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-6.81	2.98e-11	1.93e-08	-0.38	-0.3	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
HNSC	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-6.81	2.98e-11	1.93e-08	-0.37	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	6.81	2.98e-11	1.93e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000173295.6	FAM86B3P	6.81	2.98e-11	1.93e-08	0.34	0.3	Joint mobility (Beighton score);	chr8:9003384	chr8:8228595~8244865:+
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-6.81	2.99e-11	1.94e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
HNSC	cis	rs2579103	0.767	rs1347845	ENSG00000258183.4	RP11-753N8.1	-6.81	3e-11	1.95e-08	-0.39	-0.3	Body mass index;	chr12:90269234	chr12:90280894~90300340:+
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000254340.1	RP11-10A14.3	-6.81	3e-11	1.95e-08	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9226611	chr8:9141424~9145435:+
HNSC	cis	rs5753618	0.504	rs9606847	ENSG00000236132.1	CTA-440B3.1	-6.81	3e-11	1.95e-08	-0.38	-0.3	Colorectal cancer;	chr22:31505803	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9606848	ENSG00000236132.1	CTA-440B3.1	-6.81	3e-11	1.95e-08	-0.38	-0.3	Colorectal cancer;	chr22:31505881	chr22:31816379~31817491:-
HNSC	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	6.81	3e-11	1.95e-08	0.4	0.3	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
HNSC	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	6.81	3.01e-11	1.96e-08	0.42	0.3	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	6.81	3.01e-11	1.96e-08	0.21	0.3	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	6.81	3.01e-11	1.96e-08	0.21	0.3	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
HNSC	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	6.81	3.02e-11	1.96e-08	0.44	0.3	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	6.81	3.02e-11	1.96e-08	0.44	0.3	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-6.81	3.02e-11	1.96e-08	-0.44	-0.3	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
HNSC	cis	rs8177876	0.658	rs11150337	ENSG00000261061.1	RP11-303E16.2	-6.81	3.02e-11	1.96e-08	-0.49	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81030770~81031485:+
HNSC	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	6.81	3.03e-11	1.96e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
HNSC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-6.81	3.03e-11	1.97e-08	-0.39	-0.3	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
HNSC	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	6.81	3.04e-11	1.97e-08	0.33	0.3	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
HNSC	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	6.81	3.05e-11	1.98e-08	0.31	0.3	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
HNSC	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	6.81	3.05e-11	1.98e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
HNSC	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-6.81	3.06e-11	1.98e-08	-0.39	-0.3	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
HNSC	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-6.81	3.07e-11	1.99e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
HNSC	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.81	3.07e-11	1.99e-08	-0.25	-0.3	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-6.81	3.09e-11	2e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
HNSC	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-6.81	3.09e-11	2e-08	-0.37	-0.3	Migraine;	chr4:56853383	chr4:56960927~56961373:-
HNSC	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-6.81	3.09e-11	2e-08	-0.32	-0.3	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
HNSC	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	6.81	3.1e-11	2.01e-08	0.44	0.3	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
HNSC	cis	rs7615952	0.599	rs6766327	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126004834	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs12491577	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126012288	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs1875683	ENSG00000241288.6	RP11-379B18.5	-6.81	3.1e-11	2.01e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126013638	chr3:125827238~125916384:-
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-6.81	3.11e-11	2.01e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.81	3.11e-11	2.01e-08	-0.28	-0.3	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939545	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939563	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000254340.1	RP11-10A14.3	-6.8	3.12e-11	2.02e-08	-0.36	-0.3	Mood instability;	chr8:8939568	chr8:9141424~9145435:+
HNSC	cis	rs6951245	0.554	rs4724294	ENSG00000224079.1	AC091729.7	-6.8	3.12e-11	2.02e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1074450~1078036:+
HNSC	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-6.8	3.12e-11	2.02e-08	-0.28	-0.3	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
HNSC	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	6.8	3.12e-11	2.02e-08	0.37	0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
HNSC	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-6.8	3.12e-11	2.02e-08	-0.41	-0.3	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
HNSC	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.8	3.13e-11	2.02e-08	0.3	0.3	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
HNSC	cis	rs6951245	0.554	rs11544331	ENSG00000224079.1	AC091729.7	-6.8	3.14e-11	2.03e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1074450~1078036:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	6.8	3.14e-11	2.03e-08	0.23	0.3	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-6.8	3.14e-11	2.03e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000248787.1	RP11-666A20.4	-6.8	3.15e-11	2.04e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125880752	chr3:125908005~125910272:-
HNSC	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	6.8	3.15e-11	2.04e-08	0.37	0.3	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
HNSC	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-6.8	3.15e-11	2.04e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-6.8	3.15e-11	2.04e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
HNSC	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	6.8	3.15e-11	2.04e-08	0.43	0.3	Height;	chr6:109403951	chr6:109382795~109383666:+
HNSC	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-6.8	3.16e-11	2.04e-08	-0.48	-0.3	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
HNSC	cis	rs1799949	1	rs2037075	ENSG00000267151.3	RP11-100E5.2	6.8	3.16e-11	2.05e-08	0.39	0.3	Menopause (age at onset);	chr17:43153809	chr17:43444707~43451200:+
HNSC	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.8	3.16e-11	2.05e-08	0.32	0.3	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
HNSC	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-6.8	3.16e-11	2.05e-08	-0.3	-0.3	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
HNSC	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-6.8	3.17e-11	2.05e-08	-0.38	-0.3	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
HNSC	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.8	3.17e-11	2.05e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.8	3.17e-11	2.05e-08	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
HNSC	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-6.8	3.17e-11	2.05e-08	-0.31	-0.3	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
HNSC	cis	rs7819412	0.745	rs4841498	ENSG00000269918.1	AF131215.9	-6.8	3.18e-11	2.05e-08	-0.29	-0.3	Triglycerides;	chr8:11127922	chr8:11104691~11106704:-
HNSC	cis	rs6471393	0.964	rs56282609	ENSG00000253848.1	RP11-10N23.5	6.8	3.18e-11	2.06e-08	0.38	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737852	chr8:93741193~93744534:+
HNSC	cis	rs394563	0.726	rs6942381	ENSG00000231760.4	RP11-350J20.5	-6.8	3.18e-11	2.06e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149341855	chr6:149796151~149826294:-
HNSC	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-6.8	3.18e-11	2.06e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	6.8	3.18e-11	2.06e-08	0.21	0.3	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
HNSC	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-6.8	3.18e-11	2.06e-08	-0.48	-0.3	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
HNSC	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	6.8	3.19e-11	2.06e-08	0.34	0.3	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
HNSC	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.8	3.19e-11	2.06e-08	-0.35	-0.3	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
HNSC	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	6.8	3.2e-11	2.07e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
HNSC	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	6.8	3.2e-11	2.07e-08	0.47	0.3	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
HNSC	cis	rs12439619	0.774	rs2867649	ENSG00000276710.3	CSPG4P8	-6.8	3.2e-11	2.07e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.846	rs28697264	ENSG00000276710.3	CSPG4P8	-6.8	3.2e-11	2.07e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82459472~82477258:+
HNSC	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	6.8	3.21e-11	2.07e-08	0.59	0.3	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
HNSC	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-6.8	3.22e-11	2.08e-08	-0.37	-0.3	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs11657835	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43139936	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43140306	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43150733	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43150923	chr17:43444707~43451200:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000267151.3	RP11-100E5.2	6.8	3.22e-11	2.08e-08	0.39	0.3	Menopause (age at onset);	chr17:43151054	chr17:43444707~43451200:+
HNSC	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.8	3.22e-11	2.08e-08	-0.36	-0.3	Migraine;	chr4:56850720	chr4:56960927~56961373:-
HNSC	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-6.8	3.23e-11	2.09e-08	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
HNSC	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.8	3.23e-11	2.09e-08	0.34	0.3	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	6.8	3.25e-11	2.1e-08	0.36	0.3	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
HNSC	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	6.8	3.25e-11	2.1e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
HNSC	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-6.8	3.25e-11	2.1e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
HNSC	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-6.8	3.26e-11	2.1e-08	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
HNSC	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.8	3.26e-11	2.1e-08	0.3	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
HNSC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.8	3.27e-11	2.11e-08	0.37	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
HNSC	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	6.8	3.28e-11	2.11e-08	0.38	0.3	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
HNSC	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	6.8	3.28e-11	2.12e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
HNSC	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-6.8	3.28e-11	2.12e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
HNSC	cis	rs6951245	0.554	rs75075857	ENSG00000224079.1	AC091729.7	-6.8	3.29e-11	2.12e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-6.8	3.29e-11	2.12e-08	-0.27	-0.3	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	6.8	3.29e-11	2.12e-08	0.27	0.3	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	6.8	3.29e-11	2.12e-08	0.37	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
HNSC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.8	3.3e-11	2.13e-08	0.34	0.3	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
HNSC	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	6.8	3.3e-11	2.13e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
HNSC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	6.8	3.3e-11	2.13e-08	0.39	0.3	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-6.8	3.31e-11	2.13e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
HNSC	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	6.8	3.31e-11	2.13e-08	0.55	0.3	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
HNSC	cis	rs35955747	0.934	rs5994397	ENSG00000236132.1	CTA-440B3.1	6.79	3.32e-11	2.14e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31430164	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	6.79	3.32e-11	2.14e-08	0.22	0.3	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-6.79	3.32e-11	2.14e-08	-0.49	-0.3	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000173295.6	FAM86B3P	6.79	3.33e-11	2.14e-08	0.34	0.3	Systolic blood pressure;	chr8:8488264	chr8:8228595~8244865:+
HNSC	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	6.79	3.34e-11	2.15e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	-6.79	3.35e-11	2.16e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
HNSC	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	6.79	3.35e-11	2.16e-08	0.35	0.3	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
HNSC	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	6.79	3.35e-11	2.16e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.597	rs10431762	ENSG00000259732.1	RP11-59H7.3	-6.79	3.35e-11	2.16e-08	-0.43	-0.3	Social communication problems;	chr15:59066330	chr15:59121034~59133250:+
HNSC	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.79	3.36e-11	2.16e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
HNSC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-6.79	3.37e-11	2.17e-08	-0.31	-0.3	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
HNSC	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	6.79	3.37e-11	2.17e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
HNSC	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	6.79	3.37e-11	2.17e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	6.79	3.37e-11	2.17e-08	0.35	0.3	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000254340.1	RP11-10A14.3	-6.79	3.38e-11	2.17e-08	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9053494	chr8:9141424~9145435:+
HNSC	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	6.79	3.38e-11	2.18e-08	0.54	0.3	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
HNSC	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	6.79	3.38e-11	2.18e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
HNSC	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-6.79	3.39e-11	2.18e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
HNSC	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.79	3.41e-11	2.19e-08	-0.35	-0.3	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-6.79	3.41e-11	2.19e-08	-0.27	-0.3	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	-6.79	3.41e-11	2.19e-08	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-6.79	3.42e-11	2.2e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
HNSC	cis	rs4218	0.543	rs35658945	ENSG00000259732.1	RP11-59H7.3	-6.79	3.42e-11	2.2e-08	-0.4	-0.3	Social communication problems;	chr15:59018053	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.543	rs12050865	ENSG00000259732.1	RP11-59H7.3	-6.79	3.42e-11	2.2e-08	-0.4	-0.3	Social communication problems;	chr15:59020689	chr15:59121034~59133250:+
HNSC	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.79	3.42e-11	2.2e-08	0.32	0.3	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
HNSC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-6.79	3.43e-11	2.2e-08	-0.34	-0.3	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
HNSC	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	6.79	3.44e-11	2.21e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
HNSC	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-6.79	3.46e-11	2.22e-08	-0.33	-0.3	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
HNSC	cis	rs889014	1	rs12517986	ENSG00000253768.1	CTB-33O18.1	-6.79	3.46e-11	2.22e-08	-0.32	-0.3	Height;	chr5:173568157	chr5:173562478~173573199:+
HNSC	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-6.79	3.46e-11	2.22e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
HNSC	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	6.79	3.47e-11	2.23e-08	0.46	0.3	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
HNSC	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	6.79	3.48e-11	2.23e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
HNSC	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-6.79	3.48e-11	2.23e-08	-0.56	-0.3	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
HNSC	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-6.79	3.48e-11	2.24e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-6.79	3.48e-11	2.24e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-6.79	3.49e-11	2.24e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	6.79	3.5e-11	2.25e-08	0.47	0.3	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
HNSC	cis	rs1021993	0.545	rs77070927	ENSG00000231648.1	RP11-372M18.2	-6.79	3.52e-11	2.26e-08	-0.52	-0.3	Gut microbiome composition (winter);	chr1:209356960	chr1:209367662~209379690:+
HNSC	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	6.78	3.53e-11	2.27e-08	0.27	0.3	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	6.78	3.54e-11	2.27e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.78	3.55e-11	2.28e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-6.78	3.55e-11	2.28e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
HNSC	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	6.78	3.55e-11	2.28e-08	0.33	0.3	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000211974.3	IGHV2-70	-6.78	3.55e-11	2.28e-08	-0.39	-0.3	Alzheimer's disease (late onset);	chr14:106670302	chr14:106723574~106724093:-
HNSC	cis	rs7048146	0.899	rs10979957	ENSG00000213539.4	YBX1P6	6.78	3.57e-11	2.29e-08	0.35	0.3	Vascular brain injury;	chr9:109594413	chr9:109532830~109534332:-
HNSC	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.57e-11	2.29e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
HNSC	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-6.78	3.58e-11	2.29e-08	-0.58	-0.3	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
HNSC	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.78	3.58e-11	2.3e-08	-0.3	-0.3	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.78	3.58e-11	2.3e-08	0.34	0.3	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-6.78	3.6e-11	2.31e-08	-0.27	-0.3	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
HNSC	cis	rs1659258	0.772	rs1659256	ENSG00000232508.1	MRPL45P1	6.78	3.6e-11	2.31e-08	0.57	0.3	Visceral fat;	chr2:88358967	chr2:88364695~88365608:-
HNSC	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	6.78	3.6e-11	2.31e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
HNSC	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-6.78	3.6e-11	2.31e-08	-0.34	-0.3	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
HNSC	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.78	3.61e-11	2.31e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
HNSC	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.61e-11	2.31e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.61e-11	2.31e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
HNSC	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	6.78	3.61e-11	2.31e-08	0.36	0.3	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
HNSC	cis	rs17270561	0.609	rs4712964	ENSG00000272462.2	U91328.19	-6.78	3.61e-11	2.31e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740594	chr6:25992662~26001775:+
HNSC	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	6.78	3.61e-11	2.32e-08	0.37	0.3	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
HNSC	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-6.78	3.62e-11	2.32e-08	-0.3	-0.3	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
HNSC	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	6.78	3.62e-11	2.32e-08	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	6.78	3.63e-11	2.32e-08	0.21	0.3	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	6.78	3.63e-11	2.32e-08	0.27	0.3	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
HNSC	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-6.78	3.64e-11	2.33e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
HNSC	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	6.78	3.66e-11	2.34e-08	0.27	0.3	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
HNSC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-6.78	3.66e-11	2.34e-08	-0.39	-0.3	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
HNSC	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	6.78	3.66e-11	2.34e-08	0.43	0.3	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
HNSC	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-6.78	3.66e-11	2.35e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	6.78	3.67e-11	2.35e-08	0.33	0.3	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000248787.1	RP11-666A20.4	-6.78	3.67e-11	2.35e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125886628	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	6.78	3.68e-11	2.35e-08	0.21	0.3	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
HNSC	cis	rs7615952	0.599	rs60847438	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126027162	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.534	rs1503072	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126035848	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.599	rs7631268	ENSG00000241288.6	RP11-379B18.5	-6.78	3.68e-11	2.35e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126036821	chr3:125827238~125916384:-
HNSC	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	6.78	3.68e-11	2.35e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
HNSC	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-6.78	3.69e-11	2.36e-08	-0.49	-0.3	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
HNSC	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-6.78	3.69e-11	2.36e-08	-0.35	-0.3	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
HNSC	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	6.78	3.69e-11	2.36e-08	0.36	0.3	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
HNSC	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	6.78	3.7e-11	2.37e-08	0.38	0.3	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
HNSC	cis	rs6951245	0.507	rs11976805	ENSG00000224079.1	AC091729.7	-6.78	3.7e-11	2.37e-08	-0.39	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1074450~1078036:+
HNSC	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.72e-11	2.38e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
HNSC	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	6.78	3.75e-11	2.4e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
HNSC	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-6.77	3.76e-11	2.4e-08	-0.32	-0.3	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
HNSC	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	6.77	3.77e-11	2.41e-08	0.42	0.3	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
HNSC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-6.77	3.78e-11	2.41e-08	-0.32	-0.3	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
HNSC	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-6.77	3.79e-11	2.42e-08	-0.33	-0.3	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
HNSC	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.77	3.79e-11	2.42e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
HNSC	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	6.77	3.8e-11	2.43e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	6.77	3.81e-11	2.43e-08	0.27	0.3	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
HNSC	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-6.77	3.81e-11	2.43e-08	-0.38	-0.3	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
HNSC	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-6.77	3.82e-11	2.44e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.926	rs5750601	ENSG00000211638.2	IGLV8-61	-6.77	3.82e-11	2.44e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22098700~22099212:+
HNSC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-6.77	3.82e-11	2.44e-08	-0.36	-0.3	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	6.77	3.82e-11	2.44e-08	0.44	0.3	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
HNSC	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	6.77	3.83e-11	2.44e-08	0.43	0.3	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
HNSC	cis	rs1021993	0.545	rs7548184	ENSG00000231648.1	RP11-372M18.2	-6.77	3.83e-11	2.44e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209358255	chr1:209367662~209379690:+
HNSC	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	6.77	3.83e-11	2.44e-08	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
HNSC	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-6.77	3.83e-11	2.45e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	6.77	3.84e-11	2.45e-08	0.27	0.3	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
HNSC	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	6.77	3.84e-11	2.45e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	6.77	3.84e-11	2.45e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
HNSC	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-6.77	3.87e-11	2.47e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000267151.3	RP11-100E5.2	6.77	3.88e-11	2.47e-08	0.39	0.3	Menopause (age at onset);	chr17:43135907	chr17:43444707~43451200:+
HNSC	cis	rs2286503	1	rs2286499	ENSG00000221740.1	SNORD93	6.77	3.89e-11	2.48e-08	0.32	0.3	Fibrinogen;	chr7:22817858	chr7:22856613~22856686:+
HNSC	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	6.77	3.89e-11	2.48e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
HNSC	cis	rs36405	0.5	rs2109273	ENSG00000266869.1	RP6-114E22.1	-6.77	3.89e-11	2.48e-08	-0.38	-0.3	Yang-deficiency constitution;	chr14:71894247	chr14:71848606~71908430:+
HNSC	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-6.77	3.9e-11	2.49e-08	-0.33	-0.3	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
HNSC	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	6.77	3.91e-11	2.49e-08	0.38	0.3	Height;	chr6:109421257	chr6:109382795~109383666:+
HNSC	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.77	3.91e-11	2.49e-08	0.29	0.3	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	6.77	3.91e-11	2.49e-08	0.43	0.3	Height;	chr6:109441837	chr6:109382795~109383666:+
HNSC	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-6.77	3.93e-11	2.5e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-6.77	3.93e-11	2.5e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
HNSC	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-6.77	3.94e-11	2.51e-08	-0.48	-0.3	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
HNSC	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	6.77	3.94e-11	2.51e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-6.77	3.94e-11	2.51e-08	-0.37	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
HNSC	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.77	3.95e-11	2.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.77	3.95e-11	2.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
HNSC	cis	rs71327718	1	rs71327718	ENSG00000241288.6	RP11-379B18.5	-6.77	3.95e-11	2.51e-08	-0.51	-0.3	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125827238~125916384:-
HNSC	cis	rs36405	0.5	rs2013781	ENSG00000266869.1	RP6-114E22.1	-6.77	3.96e-11	2.52e-08	-0.38	-0.3	Yang-deficiency constitution;	chr14:71890603	chr14:71848606~71908430:+
HNSC	cis	rs4218	0.648	rs34407560	ENSG00000259732.1	RP11-59H7.3	-6.77	3.96e-11	2.52e-08	-0.43	-0.3	Social communication problems;	chr15:59073397	chr15:59121034~59133250:+
HNSC	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-6.77	3.97e-11	2.53e-08	-0.3	-0.3	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	6.77	3.97e-11	2.53e-08	0.4	0.3	Height;	chr6:109382524	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-6.77	3.97e-11	2.53e-08	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000173295.6	FAM86B3P	6.77	3.98e-11	2.53e-08	0.33	0.3	Neuroticism;	chr8:8866747	chr8:8228595~8244865:+
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000173295.6	FAM86B3P	6.77	3.98e-11	2.53e-08	0.33	0.3	Neuroticism;	chr8:8866766	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000254340.1	RP11-10A14.3	-6.77	3.98e-11	2.54e-08	-0.36	-0.3	Mood instability;	chr8:8939092	chr8:9141424~9145435:+
HNSC	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	6.77	3.99e-11	2.54e-08	0.33	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-6.76	4e-11	2.55e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-6.76	4e-11	2.55e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
HNSC	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-6.76	4.01e-11	2.55e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	6.76	4.02e-11	2.56e-08	0.27	0.3	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
HNSC	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-6.76	4.02e-11	2.56e-08	-0.4	-0.3	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	-6.76	4.03e-11	2.56e-08	-0.32	-0.3	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
HNSC	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	6.76	4.03e-11	2.56e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	6.76	4.03e-11	2.56e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000254153.1	CTA-398F10.2	6.76	4.03e-11	2.56e-08	0.32	0.3	Mood instability;	chr8:8462594	chr8:8456909~8461337:-
HNSC	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	6.76	4.04e-11	2.57e-08	0.3	0.3	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-6.76	4.04e-11	2.57e-08	-0.36	-0.3	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
HNSC	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	6.76	4.05e-11	2.58e-08	0.37	0.3	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	6.76	4.07e-11	2.59e-08	0.45	0.3	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
HNSC	cis	rs1021993	0.597	rs10494921	ENSG00000231648.1	RP11-372M18.2	-6.76	4.07e-11	2.59e-08	-0.51	-0.3	Gut microbiome composition (winter);	chr1:209340156	chr1:209367662~209379690:+
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	6.76	4.07e-11	2.59e-08	0.34	0.3	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	6.76	4.08e-11	2.59e-08	0.36	0.3	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	6.76	4.08e-11	2.59e-08	0.4	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
HNSC	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	6.76	4.08e-11	2.59e-08	0.71	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-6.76	4.08e-11	2.6e-08	-0.35	-0.3	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-6.76	4.09e-11	2.6e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-6.76	4.09e-11	2.6e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-6.76	4.09e-11	2.6e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000267151.3	RP11-100E5.2	6.76	4.09e-11	2.6e-08	0.38	0.3	Menopause (age at onset);	chr17:43348789	chr17:43444707~43451200:+
HNSC	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	6.76	4.1e-11	2.6e-08	0.37	0.3	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
HNSC	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	6.76	4.1e-11	2.6e-08	0.37	0.3	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
HNSC	cis	rs9326246	0.556	rs662799	ENSG00000254851.1	RP11-109L13.1	-6.76	4.1e-11	2.61e-08	-0.73	-0.3	Coronary artery disease;	chr11:116792991	chr11:117135528~117138582:+
HNSC	cis	rs6951245	0.935	rs79067319	ENSG00000225146.1	AC073957.15	-6.76	4.11e-11	2.61e-08	-0.5	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1029025~1043891:+
HNSC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-6.76	4.11e-11	2.61e-08	-0.37	-0.3	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
HNSC	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	6.76	4.12e-11	2.62e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
HNSC	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-6.76	4.13e-11	2.62e-08	-0.49	-0.3	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
HNSC	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	6.76	4.13e-11	2.62e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-6.76	4.13e-11	2.62e-08	-0.36	-0.3	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	6.76	4.14e-11	2.63e-08	0.23	0.3	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
HNSC	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	6.76	4.15e-11	2.63e-08	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
HNSC	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-6.76	4.15e-11	2.63e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	6.76	4.15e-11	2.64e-08	0.42	0.3	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-6.76	4.16e-11	2.64e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-6.76	4.16e-11	2.64e-08	-0.43	-0.3	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	6.76	4.16e-11	2.64e-08	0.42	0.3	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-6.76	4.16e-11	2.64e-08	-0.26	-0.3	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
HNSC	cis	rs6951245	0.529	rs10262070	ENSG00000224079.1	AC091729.7	-6.76	4.17e-11	2.64e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1074450~1078036:+
HNSC	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	6.76	4.17e-11	2.65e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
HNSC	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-6.76	4.17e-11	2.65e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-6.76	4.17e-11	2.65e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
HNSC	cis	rs36405	0.5	rs17178883	ENSG00000266869.1	RP6-114E22.1	6.76	4.18e-11	2.65e-08	0.38	0.3	Yang-deficiency constitution;	chr14:71888874	chr14:71848606~71908430:+
HNSC	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-6.76	4.19e-11	2.66e-08	-0.33	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
HNSC	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	6.76	4.2e-11	2.66e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
HNSC	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-6.76	4.2e-11	2.66e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	6.76	4.2e-11	2.66e-08	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
HNSC	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-6.76	4.2e-11	2.66e-08	-0.34	-0.3	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6.76	4.21e-11	2.67e-08	-0.27	-0.3	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
HNSC	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.76	4.21e-11	2.67e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
HNSC	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	6.76	4.21e-11	2.67e-08	0.28	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	6.76	4.22e-11	2.67e-08	0.71	0.3	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	6.76	4.22e-11	2.67e-08	0.71	0.3	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-6.76	4.23e-11	2.68e-08	-0.35	-0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
HNSC	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-6.76	4.23e-11	2.68e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-6.76	4.23e-11	2.68e-08	-0.35	-0.3	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
HNSC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-6.76	4.23e-11	2.69e-08	-0.36	-0.3	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
HNSC	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-6.76	4.24e-11	2.69e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	6.76	4.25e-11	2.7e-08	0.27	0.3	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
HNSC	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	6.76	4.25e-11	2.7e-08	0.43	0.3	Height;	chr6:109382480	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-6.76	4.26e-11	2.7e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
HNSC	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-6.76	4.26e-11	2.7e-08	-0.32	-0.3	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
HNSC	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	6.76	4.26e-11	2.7e-08	0.26	0.3	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	6.76	4.26e-11	2.7e-08	0.26	0.3	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
HNSC	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	6.75	4.27e-11	2.71e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
HNSC	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-6.75	4.28e-11	2.71e-08	-0.36	-0.3	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
HNSC	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-6.75	4.28e-11	2.71e-08	-0.42	-0.3	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-6.75	4.29e-11	2.72e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
HNSC	cis	rs4218	0.517	rs71480503	ENSG00000259732.1	RP11-59H7.3	-6.75	4.29e-11	2.72e-08	-0.43	-0.3	Social communication problems;	chr15:59098246	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000254340.1	RP11-10A14.3	-6.75	4.29e-11	2.72e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9050725	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	6.75	4.3e-11	2.72e-08	0.21	0.3	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
HNSC	cis	rs4218	0.648	rs1074702	ENSG00000259732.1	RP11-59H7.3	-6.75	4.31e-11	2.73e-08	-0.43	-0.3	Social communication problems;	chr15:59073900	chr15:59121034~59133250:+
HNSC	cis	rs35955747	0.934	rs131200	ENSG00000236132.1	CTA-440B3.1	-6.75	4.32e-11	2.73e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31307286	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-6.75	4.33e-11	2.74e-08	-0.2	-0.3	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
HNSC	cis	rs7048146	0.51	rs1109477	ENSG00000213539.4	YBX1P6	-6.75	4.33e-11	2.74e-08	-0.34	-0.3	Vascular brain injury;	chr9:109519571	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.51	rs1109478	ENSG00000213539.4	YBX1P6	-6.75	4.33e-11	2.74e-08	-0.34	-0.3	Vascular brain injury;	chr9:109519583	chr9:109532830~109534332:-
HNSC	cis	rs17270561	0.609	rs4712963	ENSG00000272462.2	U91328.19	-6.75	4.34e-11	2.75e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25740274	chr6:25992662~26001775:+
HNSC	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	6.75	4.36e-11	2.76e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000254340.1	RP11-10A14.3	-6.75	4.36e-11	2.76e-08	-0.36	-0.3	Mood instability;	chr8:8937520	chr8:9141424~9145435:+
HNSC	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.37e-11	2.77e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
HNSC	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	6.75	4.38e-11	2.77e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
HNSC	cis	rs35955747	0.838	rs28716	ENSG00000236132.1	CTA-440B3.1	-6.75	4.38e-11	2.77e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334203	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs131209	ENSG00000236132.1	CTA-440B3.1	-6.75	4.38e-11	2.77e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31336475	chr22:31816379~31817491:-
HNSC	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-6.75	4.38e-11	2.77e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-6.75	4.38e-11	2.77e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000254340.1	RP11-10A14.3	-6.75	4.39e-11	2.77e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9050721	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-6.75	4.41e-11	2.79e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
HNSC	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-6.75	4.42e-11	2.8e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
HNSC	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	6.75	4.44e-11	2.8e-08	0.33	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
HNSC	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	6.75	4.44e-11	2.8e-08	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-6.75	4.44e-11	2.8e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
HNSC	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	6.75	4.44e-11	2.81e-08	0.4	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
HNSC	cis	rs394563	0.726	rs6922130	ENSG00000231760.4	RP11-350J20.5	-6.75	4.45e-11	2.81e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149351239	chr6:149796151~149826294:-
HNSC	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-6.75	4.45e-11	2.81e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	6.75	4.45e-11	2.81e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
HNSC	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	6.75	4.45e-11	2.81e-08	0.26	0.3	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	6.75	4.45e-11	2.81e-08	0.26	0.3	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-6.75	4.46e-11	2.82e-08	-0.29	-0.3	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
HNSC	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.75	4.46e-11	2.82e-08	0.31	0.3	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-6.75	4.46e-11	2.82e-08	-0.32	-0.3	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	6.75	4.47e-11	2.82e-08	0.21	0.3	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	6.75	4.47e-11	2.82e-08	0.21	0.3	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
HNSC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.75	4.48e-11	2.83e-08	0.32	0.3	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	6.75	4.48e-11	2.83e-08	0.26	0.3	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
HNSC	cis	rs7404843	0.789	rs222909	ENSG00000263065.1	AF001548.6	6.75	4.48e-11	2.83e-08	0.5	0.3	Testicular germ cell tumor;	chr16:15405432	chr16:15741151~15741791:+
HNSC	cis	rs7083	1	rs655023	ENSG00000254851.1	RP11-109L13.1	6.75	4.49e-11	2.83e-08	0.38	0.3	Blood protein levels;	chr11:117256904	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs505045	ENSG00000254851.1	RP11-109L13.1	6.75	4.49e-11	2.83e-08	0.38	0.3	Blood protein levels;	chr11:117281824	chr11:117135528~117138582:+
HNSC	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	6.75	4.49e-11	2.84e-08	0.37	0.3	Height;	chr3:53072864	chr3:53064283~53065091:-
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-6.75	4.5e-11	2.84e-08	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
HNSC	cis	rs7083	0.905	rs11216338	ENSG00000254851.1	RP11-109L13.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Blood protein levels;	chr11:117261003	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs619772	ENSG00000254851.1	RP11-109L13.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Blood protein levels;	chr11:117268120	chr11:117135528~117138582:+
HNSC	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-6.75	4.52e-11	2.85e-08	-0.44	-0.3	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
HNSC	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	6.75	4.52e-11	2.85e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-6.75	4.52e-11	2.85e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
HNSC	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-6.75	4.53e-11	2.86e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
HNSC	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.54e-11	2.86e-08	-0.33	-0.3	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
HNSC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-6.74	4.55e-11	2.87e-08	-0.46	-0.3	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
HNSC	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	6.74	4.55e-11	2.87e-08	0.43	0.3	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
HNSC	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	6.74	4.55e-11	2.87e-08	0.29	0.3	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
HNSC	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	6.74	4.56e-11	2.87e-08	0.35	0.3	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	6.74	4.63e-11	2.92e-08	0.29	0.3	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
HNSC	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-6.74	4.63e-11	2.92e-08	-0.35	-0.3	Migraine;	chr4:56881195	chr4:56960927~56961373:-
HNSC	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	6.74	4.66e-11	2.94e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000254340.1	RP11-10A14.3	-6.74	4.67e-11	2.94e-08	-0.36	-0.3	Mood instability;	chr8:8939009	chr8:9141424~9145435:+
HNSC	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	6.74	4.67e-11	2.94e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
HNSC	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-6.74	4.68e-11	2.94e-08	-0.37	-0.3	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
HNSC	cis	rs4218	0.648	rs12441973	ENSG00000259732.1	RP11-59H7.3	-6.74	4.68e-11	2.95e-08	-0.42	-0.3	Social communication problems;	chr15:59057016	chr15:59121034~59133250:+
HNSC	cis	rs5753618	0.504	rs5753669	ENSG00000236132.1	CTA-440B3.1	-6.74	4.69e-11	2.95e-08	-0.37	-0.3	Colorectal cancer;	chr22:31509833	chr22:31816379~31817491:-
HNSC	cis	rs7083	1	rs493139	ENSG00000254851.1	RP11-109L13.1	6.74	4.7e-11	2.96e-08	0.38	0.3	Blood protein levels;	chr11:117275233	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-6.74	4.7e-11	2.96e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
HNSC	cis	rs5753618	0.539	rs737888	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31215563	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs1034588	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31220315	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs5753521	ENSG00000236132.1	CTA-440B3.1	6.74	4.7e-11	2.96e-08	0.37	0.3	Colorectal cancer;	chr22:31242041	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	6.74	4.71e-11	2.96e-08	0.43	0.3	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
HNSC	cis	rs6951245	0.58	rs78894484	ENSG00000224079.1	AC091729.7	-6.74	4.71e-11	2.97e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1074450~1078036:+
HNSC	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	6.74	4.72e-11	2.97e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	6.74	4.72e-11	2.97e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
HNSC	cis	rs4218	0.648	rs10851642	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59077909	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.608	rs59282449	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59078881	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.648	rs60285686	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59079829	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.648	rs60741546	ENSG00000259732.1	RP11-59H7.3	-6.74	4.72e-11	2.97e-08	-0.43	-0.3	Social communication problems;	chr15:59079831	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000254340.1	RP11-10A14.3	-6.74	4.73e-11	2.97e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9047129	chr8:9141424~9145435:+
HNSC	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-6.74	4.73e-11	2.98e-08	-0.38	-0.3	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
HNSC	cis	rs9341808	0.539	rs2490253	ENSG00000272129.1	RP11-250B2.6	6.74	4.74e-11	2.98e-08	0.35	0.3	Sitting height ratio;	chr6:80186153	chr6:80355424~80356859:+
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000179406.6	LINC00174	6.74	4.74e-11	2.98e-08	0.38	0.3	Calcium levels;	chr7:66026136	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-6.74	4.74e-11	2.98e-08	-0.19	-0.3	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-6.74	4.75e-11	2.99e-08	-0.28	-0.3	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
HNSC	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	6.74	4.75e-11	2.99e-08	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
HNSC	cis	rs10504130	0.696	rs17284746	ENSG00000272024.1	RP11-546K22.3	-6.74	4.76e-11	2.99e-08	-0.43	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51950284~51950690:+
HNSC	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.74	4.77e-11	3e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
HNSC	cis	rs11089937	0.963	rs2226943	ENSG00000211638.2	IGLV8-61	-6.74	4.77e-11	3e-08	-0.26	-0.3	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22098700~22099212:+
HNSC	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-6.74	4.78e-11	3e-08	-0.34	-0.3	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
HNSC	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	6.74	4.81e-11	3.02e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
HNSC	cis	rs6951245	0.554	rs58210047	ENSG00000224079.1	AC091729.7	-6.74	4.81e-11	3.02e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1074450~1078036:+
HNSC	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-6.74	4.81e-11	3.02e-08	-0.37	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
HNSC	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-6.74	4.81e-11	3.02e-08	-0.45	-0.3	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-6.74	4.81e-11	3.02e-08	-0.29	-0.3	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
HNSC	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	6.74	4.82e-11	3.03e-08	0.4	0.3	Height;	chr6:109387685	chr6:109382795~109383666:+
HNSC	cis	rs5753618	0.504	rs8138525	ENSG00000236132.1	CTA-440B3.1	6.74	4.82e-11	3.03e-08	0.38	0.3	Colorectal cancer;	chr22:31615943	chr22:31816379~31817491:-
HNSC	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	6.74	4.83e-11	3.03e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-6.73	4.84e-11	3.04e-08	-0.29	-0.3	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
HNSC	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	6.73	4.85e-11	3.04e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
HNSC	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-6.73	4.85e-11	3.05e-08	-0.35	-0.3	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000254340.1	RP11-10A14.3	-6.73	4.86e-11	3.05e-08	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9225906	chr8:9141424~9145435:+
HNSC	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-6.73	4.87e-11	3.06e-08	-0.36	-0.3	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
HNSC	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-6.73	4.87e-11	3.06e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	6.73	4.88e-11	3.06e-08	0.27	0.3	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
HNSC	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-6.73	4.88e-11	3.06e-08	-0.36	-0.3	Height;	chr3:52949886	chr3:53064283~53065091:-
HNSC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	6.73	4.88e-11	3.06e-08	0.31	0.3	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
HNSC	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-6.73	4.9e-11	3.07e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
HNSC	cis	rs5769707	0.605	rs2071900	ENSG00000188511.11	C22orf34	6.73	4.92e-11	3.08e-08	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49658527	chr22:49414524~49657542:-
HNSC	cis	rs451417	0.818	rs236117	ENSG00000275632.1	RP5-967N21.11	6.73	4.92e-11	3.09e-08	0.38	0.3	Menopause (age at onset);	chr20:5956529	chr20:6000418~6000941:+
HNSC	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-6.73	4.92e-11	3.09e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
HNSC	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	6.73	4.92e-11	3.09e-08	0.37	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	6.73	4.93e-11	3.09e-08	0.27	0.3	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
HNSC	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	6.73	4.93e-11	3.09e-08	0.83	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
HNSC	cis	rs6471393	0.964	rs2914959	ENSG00000253848.1	RP11-10N23.5	6.73	4.93e-11	3.09e-08	0.4	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93741193~93744534:+
HNSC	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-6.73	4.94e-11	3.09e-08	-0.37	-0.3	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
HNSC	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-6.73	4.94e-11	3.1e-08	-0.29	-0.3	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-6.73	4.94e-11	3.1e-08	-0.29	-0.3	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
HNSC	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.73	4.95e-11	3.1e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
HNSC	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-6.73	4.95e-11	3.1e-08	-0.36	-0.3	Height;	chr3:52967831	chr3:53064283~53065091:-
HNSC	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	6.73	4.96e-11	3.11e-08	0.35	0.3	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-6.73	4.96e-11	3.11e-08	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
HNSC	cis	rs17270561	0.636	rs6923839	ENSG00000272462.2	U91328.19	-6.73	4.96e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745625	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-6.73	4.97e-11	3.11e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
HNSC	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.73	4.97e-11	3.11e-08	-0.28	-0.3	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.73	4.97e-11	3.11e-08	-0.28	-0.3	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
HNSC	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	6.73	4.97e-11	3.11e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-6.73	4.98e-11	3.12e-08	-0.3	-0.3	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	6.73	5e-11	3.13e-08	0.35	0.3	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.73	5e-11	3.13e-08	0.35	0.3	Depression;	chr6:28391932	chr6:28176188~28176674:+
HNSC	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	6.73	5e-11	3.13e-08	0.34	0.3	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
HNSC	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-6.73	5.02e-11	3.14e-08	-0.3	-0.3	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
HNSC	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	6.73	5.02e-11	3.15e-08	0.35	0.3	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-6.73	5.03e-11	3.15e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-6.73	5.03e-11	3.15e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
HNSC	cis	rs7615952	0.599	rs2279821	ENSG00000241288.6	RP11-379B18.5	-6.73	5.03e-11	3.15e-08	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:126015465	chr3:125827238~125916384:-
HNSC	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	6.73	5.05e-11	3.16e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000254340.1	RP11-10A14.3	-6.73	5.06e-11	3.16e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9047352	chr8:9141424~9145435:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	6.73	5.06e-11	3.16e-08	0.26	0.3	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
HNSC	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	6.73	5.08e-11	3.18e-08	0.36	0.3	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
HNSC	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.73	5.09e-11	3.18e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
HNSC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-6.73	5.09e-11	3.18e-08	-0.39	-0.3	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
HNSC	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	6.73	5.09e-11	3.18e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
HNSC	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-6.73	5.1e-11	3.19e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
HNSC	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-6.73	5.11e-11	3.19e-08	-0.31	-0.3	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-6.73	5.11e-11	3.2e-08	-0.29	-0.3	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
HNSC	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	6.73	5.12e-11	3.2e-08	0.35	0.3	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000254340.1	RP11-10A14.3	-6.73	5.13e-11	3.21e-08	-0.38	-0.3	Mean corpuscular volume;	chr8:8993123	chr8:9141424~9145435:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-6.73	5.14e-11	3.21e-08	-0.35	-0.3	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
HNSC	cis	rs1021993	0.545	rs58017268	ENSG00000231648.1	RP11-372M18.2	-6.72	5.16e-11	3.22e-08	-0.53	-0.3	Gut microbiome composition (winter);	chr1:209366729	chr1:209367662~209379690:+
HNSC	cis	rs6951245	0.882	rs56048221	ENSG00000224079.1	AC091729.7	-6.72	5.16e-11	3.22e-08	-0.47	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052897	chr7:1074450~1078036:+
HNSC	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	6.72	5.18e-11	3.24e-08	0.34	0.3	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
HNSC	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	6.72	5.18e-11	3.24e-08	0.36	0.3	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-6.72	5.19e-11	3.24e-08	-0.29	-0.3	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
HNSC	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-6.72	5.19e-11	3.24e-08	-0.36	-0.3	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
HNSC	cis	rs1355223	0.837	rs11600402	ENSG00000271369.1	RP11-350D17.3	-6.72	5.21e-11	3.25e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670204	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.21e-11	3.26e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	6.72	5.22e-11	3.26e-08	0.43	0.3	Height;	chr6:109436760	chr6:109382795~109383666:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000254340.1	RP11-10A14.3	-6.72	5.22e-11	3.26e-08	-0.36	-0.3	Mood instability;	chr8:8937937	chr8:9141424~9145435:+
HNSC	cis	rs67180937	0.677	rs17011666	ENSG00000272750.1	RP11-378J18.8	-6.72	5.23e-11	3.26e-08	-0.36	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222625623	chr1:222658867~222661512:-
HNSC	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	6.72	5.23e-11	3.26e-08	0.36	0.3	Depression;	chr6:28240757	chr6:28943877~28944537:+
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-6.72	5.24e-11	3.27e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
HNSC	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-6.72	5.26e-11	3.28e-08	-0.39	-0.3	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
HNSC	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-6.72	5.28e-11	3.3e-08	-0.41	-0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
HNSC	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	6.72	5.28e-11	3.3e-08	0.56	0.3	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
HNSC	cis	rs7000734	0.637	rs2599706	ENSG00000245080.5	RP11-320N21.1	-6.72	5.3e-11	3.31e-08	-0.42	-0.3	Radiation response;	chr8:95074797	chr8:95066808~95073182:-
HNSC	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-6.72	5.3e-11	3.31e-08	-0.68	-0.3	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
HNSC	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-6.72	5.3e-11	3.31e-08	-0.37	-0.3	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-6.72	5.3e-11	3.31e-08	-0.37	-0.3	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000254153.1	CTA-398F10.2	6.72	5.31e-11	3.31e-08	0.32	0.3	Mood instability;	chr8:8461157	chr8:8456909~8461337:-
HNSC	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-6.72	5.31e-11	3.32e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
HNSC	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-6.72	5.31e-11	3.32e-08	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-6.72	5.34e-11	3.33e-08	-0.29	-0.3	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
HNSC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-6.72	5.34e-11	3.33e-08	-0.35	-0.3	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
HNSC	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-6.72	5.34e-11	3.33e-08	-0.36	-0.3	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
HNSC	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.72	5.35e-11	3.34e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
HNSC	cis	rs17270561	0.636	rs6923367	ENSG00000272462.2	U91328.19	-6.72	5.37e-11	3.35e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745624	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs4145218	ENSG00000272462.2	U91328.19	-6.72	5.37e-11	3.35e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25745855	chr6:25992662~26001775:+
HNSC	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.72	5.39e-11	3.36e-08	-0.35	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
HNSC	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-6.72	5.39e-11	3.36e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
HNSC	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	6.72	5.39e-11	3.36e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	6.72	5.39e-11	3.36e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
HNSC	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	6.72	5.4e-11	3.37e-08	0.35	0.3	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	6.72	5.4e-11	3.37e-08	0.35	0.3	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
HNSC	cis	rs4218	0.813	rs8036907	ENSG00000259732.1	RP11-59H7.3	-6.72	5.4e-11	3.37e-08	-0.4	-0.3	Social communication problems;	chr15:59121144	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.724	rs35168204	ENSG00000259732.1	RP11-59H7.3	-6.72	5.4e-11	3.37e-08	-0.4	-0.3	Social communication problems;	chr15:59121354	chr15:59121034~59133250:+
HNSC	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	6.72	5.42e-11	3.37e-08	0.44	0.3	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	6.72	5.42e-11	3.38e-08	0.71	0.3	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
HNSC	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	6.72	5.43e-11	3.38e-08	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
HNSC	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	6.72	5.43e-11	3.38e-08	0.37	0.3	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
HNSC	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	6.72	5.44e-11	3.39e-08	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
HNSC	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-6.72	5.44e-11	3.39e-08	-0.33	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-6.72	5.44e-11	3.39e-08	-0.33	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
HNSC	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109384228	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109385087	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	6.72	5.46e-11	3.4e-08	0.4	0.3	Height;	chr6:109388256	chr6:109382795~109383666:+
HNSC	cis	rs1355223	0.867	rs7943363	ENSG00000271369.1	RP11-350D17.3	-6.72	5.47e-11	3.4e-08	-0.34	-0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669587	chr11:34709600~34710161:+
HNSC	cis	rs17270561	0.666	rs9356988	ENSG00000272462.2	U91328.19	-6.71	5.48e-11	3.41e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25777253	chr6:25992662~26001775:+
HNSC	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	6.71	5.48e-11	3.41e-08	0.32	0.3	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
HNSC	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	6.71	5.49e-11	3.41e-08	0.58	0.3	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
HNSC	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.71	5.49e-11	3.42e-08	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
HNSC	cis	rs6951245	0.554	rs35126802	ENSG00000224079.1	AC091729.7	-6.71	5.5e-11	3.42e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1074450~1078036:+
HNSC	cis	rs2337406	1	rs17113331	ENSG00000211974.3	IGHV2-70	-6.71	5.5e-11	3.42e-08	-0.36	-0.3	Alzheimer's disease (late onset);	chr14:106703843	chr14:106723574~106724093:-
HNSC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.71	5.5e-11	3.42e-08	-0.36	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
HNSC	cis	rs1865760	0.519	rs4360119	ENSG00000272462.2	U91328.19	-6.71	5.51e-11	3.43e-08	-0.31	-0.3	Height;	chr6:25814846	chr6:25992662~26001775:+
HNSC	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	6.71	5.51e-11	3.43e-08	0.57	0.3	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
HNSC	cis	rs6951245	0.554	rs78999139	ENSG00000224079.1	AC091729.7	-6.71	5.51e-11	3.43e-08	-0.4	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1074450~1078036:+
HNSC	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	6.71	5.53e-11	3.44e-08	0.41	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
HNSC	cis	rs2115630	0.645	rs2292463	ENSG00000229212.6	RP11-561C5.4	6.71	5.54e-11	3.44e-08	0.35	0.3	P wave terminal force;	chr15:84632519	chr15:85205440~85234795:-
HNSC	cis	rs34375054	0.573	rs12823172	ENSG00000279233.1	RP11-158L12.4	6.71	5.55e-11	3.45e-08	0.4	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125161737	chr12:125138245~125141711:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000254340.1	RP11-10A14.3	-6.71	5.55e-11	3.45e-08	-0.36	-0.3	Mood instability;	chr8:8936683	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000254340.1	RP11-10A14.3	-6.71	5.55e-11	3.45e-08	-0.36	-0.3	Mood instability;	chr8:8936944	chr8:9141424~9145435:+
HNSC	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	6.71	5.56e-11	3.46e-08	0.56	0.3	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
HNSC	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	6.71	5.56e-11	3.46e-08	0.38	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-6.71	5.56e-11	3.46e-08	-0.34	-0.3	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	6.71	5.57e-11	3.46e-08	0.33	0.3	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
HNSC	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-6.71	5.57e-11	3.46e-08	-0.38	-0.3	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
HNSC	cis	rs2579103	0.63	rs10506985	ENSG00000258183.4	RP11-753N8.1	-6.71	5.57e-11	3.46e-08	-0.42	-0.3	Body mass index;	chr12:90318265	chr12:90280894~90300340:+
HNSC	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-6.71	5.57e-11	3.46e-08	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	6.71	5.58e-11	3.47e-08	0.71	0.3	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
HNSC	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	6.71	5.6e-11	3.48e-08	0.34	0.3	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
HNSC	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	6.71	5.6e-11	3.48e-08	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	6.71	5.62e-11	3.49e-08	0.23	0.3	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
HNSC	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	6.71	5.63e-11	3.5e-08	0.42	0.3	Height;	chr6:109427303	chr6:109382795~109383666:+
HNSC	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	6.71	5.63e-11	3.5e-08	0.34	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
HNSC	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-6.71	5.63e-11	3.5e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-6.71	5.63e-11	3.5e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
HNSC	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	6.71	5.64e-11	3.51e-08	0.35	0.3	Height;	chr3:53091453	chr3:53064283~53065091:-
HNSC	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-6.71	5.65e-11	3.51e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-6.71	5.65e-11	3.51e-08	-0.19	-0.3	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
HNSC	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.71	5.65e-11	3.51e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
HNSC	cis	rs1021993	0.545	rs4844815	ENSG00000231648.1	RP11-372M18.2	-6.71	5.66e-11	3.52e-08	-0.48	-0.3	Gut microbiome composition (winter);	chr1:209356309	chr1:209367662~209379690:+
HNSC	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.71	5.71e-11	3.54e-08	0.27	0.3	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	6.71	5.72e-11	3.55e-08	0.71	0.3	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
HNSC	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-6.71	5.72e-11	3.55e-08	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000248787.1	RP11-666A20.4	-6.71	5.72e-11	3.55e-08	-0.49	-0.3	Blood pressure (smoking interaction);	chr3:125883870	chr3:125908005~125910272:-
HNSC	cis	rs2235642	0.893	rs2076445	ENSG00000280231.1	LA16c-380F5.3	-6.71	5.72e-11	3.55e-08	-0.36	-0.3	Coronary artery disease;	chr16:1542265	chr16:1553655~1554130:-
HNSC	cis	rs1355223	0.902	rs7102625	ENSG00000271369.1	RP11-350D17.3	6.71	5.73e-11	3.55e-08	0.33	0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34718170	chr11:34709600~34710161:+
HNSC	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	6.71	5.74e-11	3.56e-08	0.36	0.3	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
HNSC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.71	5.74e-11	3.56e-08	-0.33	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
HNSC	cis	rs2579103	0.683	rs10777234	ENSG00000258183.4	RP11-753N8.1	-6.71	5.75e-11	3.57e-08	-0.33	-0.3	Body mass index;	chr12:90213380	chr12:90280894~90300340:+
HNSC	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.71	5.76e-11	3.57e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.71	5.76e-11	3.57e-08	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
HNSC	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	6.71	5.77e-11	3.58e-08	0.47	0.3	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
HNSC	cis	rs12439619	0.768	rs28694364	ENSG00000276710.3	CSPG4P8	-6.71	5.78e-11	3.58e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82459472~82477258:+
HNSC	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	6.71	5.79e-11	3.59e-08	0.44	0.3	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	6.71	5.79e-11	3.59e-08	0.44	0.3	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	6.71	5.8e-11	3.59e-08	0.33	0.3	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
HNSC	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	6.71	5.8e-11	3.59e-08	0.4	0.3	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
HNSC	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	6.71	5.8e-11	3.6e-08	0.34	0.3	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-6.71	5.83e-11	3.61e-08	-0.31	-0.3	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
HNSC	cis	rs1075265	0.564	rs2111851	ENSG00000233266.1	HMGB1P31	6.7	5.84e-11	3.62e-08	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53655030	chr2:54051334~54051760:+
HNSC	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-6.7	5.85e-11	3.62e-08	-0.34	-0.3	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
HNSC	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-6.7	5.86e-11	3.63e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
HNSC	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-6.7	5.86e-11	3.63e-08	-0.35	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
HNSC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-6.7	5.87e-11	3.64e-08	-0.38	-0.3	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
HNSC	cis	rs947583	0.545	rs9494364	ENSG00000217482.2	HMGB1P17	6.7	5.88e-11	3.64e-08	0.34	0.3	Phosphorus levels;	chr6:135759549	chr6:135636086~135636713:-
HNSC	cis	rs7301826	0.504	rs11061164	ENSG00000256250.1	RP11-989F5.1	-6.7	5.88e-11	3.64e-08	-0.32	-0.3	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810606~130812438:+
HNSC	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-6.7	5.9e-11	3.65e-08	-0.45	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
HNSC	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	6.7	5.91e-11	3.66e-08	0.37	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
HNSC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-6.7	5.93e-11	3.67e-08	-0.31	-0.3	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
HNSC	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	6.7	5.94e-11	3.68e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
HNSC	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
HNSC	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	6.7	5.95e-11	3.68e-08	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
HNSC	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-6.7	6e-11	3.71e-08	-0.36	-0.3	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
HNSC	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	6.7	6e-11	3.71e-08	0.4	0.3	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	6.7	6.02e-11	3.72e-08	0.36	0.3	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	6.7	6.04e-11	3.73e-08	0.31	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
HNSC	cis	rs11992162	0.636	rs11250182	ENSG00000206014.6	OR7E161P	6.7	6.04e-11	3.73e-08	0.32	0.3	Monocyte count;	chr8:11950067	chr8:11928597~11929563:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	6.7	6.04e-11	3.73e-08	0.33	0.3	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
HNSC	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.7	6.05e-11	3.74e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
HNSC	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-6.7	6.05e-11	3.74e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
HNSC	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	6.7	6.06e-11	3.74e-08	0.38	0.3	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
HNSC	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	6.7	6.06e-11	3.74e-08	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-6.7	6.07e-11	3.75e-08	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
HNSC	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-6.7	6.08e-11	3.75e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
HNSC	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-6.7	6.08e-11	3.76e-08	-0.4	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	6.7	6.11e-11	3.77e-08	0.43	0.3	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
HNSC	cis	rs2404602	0.692	rs12910382	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76761101	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12911902	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76761234	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs4383105	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76763169	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs7174673	ENSG00000259422.1	RP11-593F23.1	6.7	6.12e-11	3.77e-08	0.34	0.3	Blood metabolite levels;	chr15:76779657	chr15:76174891~76181486:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-6.7	6.12e-11	3.78e-08	-0.29	-0.3	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
HNSC	cis	rs9326248	0.53	rs2155583	ENSG00000280143.1	AP000892.6	6.7	6.13e-11	3.78e-08	0.45	0.3	Blood protein levels;	chr11:117044501	chr11:117204967~117210292:+
HNSC	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	6.7	6.14e-11	3.79e-08	0.54	0.3	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
HNSC	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-6.7	6.17e-11	3.8e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
HNSC	cis	rs7615952	0.641	rs4490307	ENSG00000241288.6	RP11-379B18.5	-6.7	6.18e-11	3.81e-08	-0.38	-0.3	Blood pressure (smoking interaction);	chr3:125993833	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	6.7	6.2e-11	3.82e-08	0.4	0.3	Height;	chr6:109446728	chr6:109382795~109383666:+
HNSC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-6.7	6.2e-11	3.82e-08	-0.32	-0.3	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
HNSC	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	6.69	6.22e-11	3.83e-08	0.36	0.3	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
HNSC	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.69	6.22e-11	3.84e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
HNSC	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-6.69	6.24e-11	3.84e-08	-0.5	-0.3	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
HNSC	cis	rs5753618	0.504	rs5753661	ENSG00000236132.1	CTA-440B3.1	-6.69	6.24e-11	3.85e-08	-0.37	-0.3	Colorectal cancer;	chr22:31503811	chr22:31816379~31817491:-
HNSC	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.69	6.25e-11	3.85e-08	0.31	0.3	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
HNSC	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	6.69	6.26e-11	3.86e-08	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
HNSC	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	6.69	6.28e-11	3.87e-08	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
HNSC	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	6.69	6.28e-11	3.87e-08	0.37	0.3	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
HNSC	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	6.69	6.28e-11	3.87e-08	0.29	0.3	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
HNSC	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-6.69	6.3e-11	3.88e-08	-0.31	-0.3	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
HNSC	cis	rs2579103	0.708	rs825964	ENSG00000258183.4	RP11-753N8.1	6.69	6.32e-11	3.89e-08	0.41	0.3	Body mass index;	chr12:90306962	chr12:90280894~90300340:+
HNSC	cis	rs4141404	0.673	rs1968023	ENSG00000236132.1	CTA-440B3.1	6.69	6.34e-11	3.91e-08	0.41	0.3	Paclitaxel-induced neuropathy;	chr22:31546784	chr22:31816379~31817491:-
HNSC	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-6.69	6.35e-11	3.91e-08	-0.43	-0.3	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
HNSC	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.36e-11	3.92e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
HNSC	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-6.69	6.37e-11	3.92e-08	-0.35	-0.3	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
HNSC	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-6.69	6.38e-11	3.93e-08	-0.29	-0.3	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
HNSC	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.69	6.39e-11	3.93e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
HNSC	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
HNSC	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-6.69	6.4e-11	3.94e-08	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
HNSC	cis	rs6951245	0.638	rs4720486	ENSG00000224079.1	AC091729.7	-6.69	6.4e-11	3.94e-08	-0.39	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1074450~1078036:+
HNSC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	6.69	6.41e-11	3.94e-08	0.37	0.3	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
HNSC	cis	rs2286503	1	rs1029740	ENSG00000221740.1	SNORD93	6.69	6.42e-11	3.95e-08	0.31	0.3	Fibrinogen;	chr7:22833967	chr7:22856613~22856686:+
HNSC	cis	rs4218	0.543	rs2414618	ENSG00000259732.1	RP11-59H7.3	-6.69	6.42e-11	3.95e-08	-0.4	-0.3	Social communication problems;	chr15:59019684	chr15:59121034~59133250:+
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	6.69	6.42e-11	3.95e-08	0.44	0.3	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.43e-11	3.96e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
HNSC	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	6.69	6.43e-11	3.96e-08	0.77	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
HNSC	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.45e-11	3.96e-08	-0.29	-0.3	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-6.69	6.45e-11	3.96e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
HNSC	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-6.69	6.45e-11	3.97e-08	-0.41	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
HNSC	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-6.69	6.46e-11	3.97e-08	-0.39	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
HNSC	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	6.69	6.46e-11	3.97e-08	0.32	0.3	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-6.69	6.47e-11	3.98e-08	-0.42	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
HNSC	cis	rs9341808	0.667	rs2505929	ENSG00000272129.1	RP11-250B2.6	6.69	6.5e-11	3.99e-08	0.34	0.3	Sitting height ratio;	chr6:80124491	chr6:80355424~80356859:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	6.69	6.5e-11	4e-08	0.36	0.3	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
HNSC	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-6.69	6.51e-11	4e-08	-0.32	-0.3	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
HNSC	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	6.69	6.51e-11	4e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
HNSC	cis	rs9402743	0.709	rs9373136	ENSG00000217482.2	HMGB1P17	6.69	6.51e-11	4e-08	0.33	0.3	Systemic lupus erythematosus;	chr6:135617531	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.678	rs965191	ENSG00000217482.2	HMGB1P17	6.69	6.51e-11	4e-08	0.33	0.3	Systemic lupus erythematosus;	chr6:135618363	chr6:135636086~135636713:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-6.69	6.51e-11	4e-08	-0.41	-0.3	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
HNSC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	6.69	6.52e-11	4e-08	0.35	0.3	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
HNSC	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	6.69	6.52e-11	4.01e-08	0.32	0.3	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
HNSC	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-6.69	6.53e-11	4.01e-08	-0.36	-0.3	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
HNSC	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	6.69	6.56e-11	4.03e-08	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-6.69	6.56e-11	4.03e-08	-0.32	-0.3	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
HNSC	cis	rs9907295	0.591	rs8080959	ENSG00000270977.1	AC015849.16	-6.69	6.58e-11	4.04e-08	-0.34	-0.3	Fibroblast growth factor basic levels;	chr17:35813450	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.636	rs4251724	ENSG00000270977.1	AC015849.16	-6.69	6.58e-11	4.04e-08	-0.34	-0.3	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35893707~35911023:-
HNSC	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.69	6.59e-11	4.04e-08	-0.31	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
HNSC	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-6.69	6.59e-11	4.05e-08	-0.36	-0.3	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
HNSC	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.69	6.6e-11	4.05e-08	-0.37	-0.3	Height;	chr3:52992698	chr3:53064283~53065091:-
HNSC	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-6.68	6.61e-11	4.05e-08	-0.37	-0.3	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
HNSC	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	6.68	6.61e-11	4.06e-08	0.35	0.3	Height;	chr4:55387515	chr4:55363971~55395847:-
HNSC	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-6.68	6.61e-11	4.06e-08	-0.24	-0.3	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
HNSC	cis	rs10504130	0.696	rs75833886	ENSG00000272024.1	RP11-546K22.3	-6.68	6.64e-11	4.07e-08	-0.42	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51950284~51950690:+
HNSC	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-6.68	6.65e-11	4.08e-08	-0.36	-0.3	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
HNSC	cis	rs9341808	0.935	rs942381	ENSG00000272129.1	RP11-250B2.6	6.68	6.66e-11	4.08e-08	0.35	0.3	Sitting height ratio;	chr6:80170433	chr6:80355424~80356859:+
HNSC	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	6.68	6.67e-11	4.09e-08	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
HNSC	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	6.68	6.68e-11	4.09e-08	0.29	0.3	Height;	chr2:231516534	chr2:231508426~231514339:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-6.68	6.68e-11	4.09e-08	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
HNSC	cis	rs11089937	0.626	rs9622968	ENSG00000211638.2	IGLV8-61	-6.68	6.7e-11	4.11e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22098700~22099212:+
HNSC	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	6.68	6.71e-11	4.11e-08	0.31	0.3	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
HNSC	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-6.68	6.72e-11	4.12e-08	-0.37	-0.3	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
HNSC	cis	rs35955747	0.902	rs5997938	ENSG00000236132.1	CTA-440B3.1	6.68	6.72e-11	4.12e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31281006	chr22:31816379~31817491:-
HNSC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	6.68	6.73e-11	4.12e-08	0.31	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
HNSC	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	6.68	6.73e-11	4.13e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
HNSC	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-6.68	6.76e-11	4.14e-08	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
HNSC	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	6.68	6.76e-11	4.14e-08	0.71	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
HNSC	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	6.68	6.78e-11	4.15e-08	0.34	0.3	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-6.68	6.78e-11	4.15e-08	-0.34	-0.3	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
HNSC	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	6.68	6.81e-11	4.17e-08	0.28	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
HNSC	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	6.68	6.81e-11	4.17e-08	0.4	0.3	Height;	chr6:109438349	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	6.68	6.81e-11	4.17e-08	0.4	0.3	Height;	chr6:109441033	chr6:109382795~109383666:+
HNSC	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-6.68	6.81e-11	4.17e-08	-0.36	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
HNSC	cis	rs7615952	0.599	rs2333408	ENSG00000241288.6	RP11-379B18.5	-6.68	6.84e-11	4.19e-08	-0.38	-0.3	Blood pressure (smoking interaction);	chr3:126013255	chr3:125827238~125916384:-
HNSC	cis	rs451417	0.818	rs236113	ENSG00000275632.1	RP5-967N21.11	6.68	6.85e-11	4.19e-08	0.37	0.3	Menopause (age at onset);	chr20:5953920	chr20:6000418~6000941:+
HNSC	cis	rs9341808	0.667	rs3805919	ENSG00000272129.1	RP11-250B2.6	6.68	6.85e-11	4.19e-08	0.34	0.3	Sitting height ratio;	chr6:80197092	chr6:80355424~80356859:+
HNSC	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-6.68	6.85e-11	4.19e-08	-0.33	-0.3	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.68	6.85e-11	4.2e-08	0.33	0.3	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	6.68	6.9e-11	4.22e-08	0.7	0.3	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
HNSC	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.68	6.9e-11	4.22e-08	0.4	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
HNSC	cis	rs8054556	0.692	rs12716973	ENSG00000183604.13	SMG1P5	-6.68	6.9e-11	4.22e-08	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr16:29926331	chr16:30267553~30335374:-
HNSC	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.68	6.9e-11	4.22e-08	0.31	0.3	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.68	6.9e-11	4.22e-08	0.31	0.3	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
HNSC	cis	rs17270561	0.609	rs1408271	ENSG00000272462.2	U91328.19	-6.68	6.91e-11	4.23e-08	-0.31	-0.3	Iron status biomarkers;	chr6:25859393	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-6.68	6.91e-11	4.23e-08	-0.46	-0.3	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-6.68	6.95e-11	4.25e-08	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
HNSC	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-6.68	6.95e-11	4.25e-08	-0.36	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
HNSC	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	6.68	6.97e-11	4.26e-08	0.34	0.3	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
HNSC	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	6.68	6.98e-11	4.26e-08	0.44	0.3	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
HNSC	cis	rs7083	0.935	rs529470	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117262092	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs529471	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117262093	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs7111678	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117265090	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs2509210	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117265354	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs673738	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117272865	chr11:117135528~117138582:+
HNSC	cis	rs7083	1	rs495438	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117274011	chr11:117135528~117138582:+
HNSC	cis	rs7083	0.935	rs492151	ENSG00000254851.1	RP11-109L13.1	6.68	6.98e-11	4.27e-08	0.38	0.3	Blood protein levels;	chr11:117275099	chr11:117135528~117138582:+
HNSC	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	6.68	6.98e-11	4.27e-08	0.34	0.3	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
HNSC	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-6.68	7.02e-11	4.29e-08	-0.35	-0.3	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-6.68	7.02e-11	4.29e-08	-0.35	-0.3	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
HNSC	cis	rs12439619	0.81	rs28876157	ENSG00000276710.3	CSPG4P8	-6.67	7.04e-11	4.3e-08	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82459472~82477258:+
HNSC	cis	rs2579103	0.708	rs2579105	ENSG00000258183.4	RP11-753N8.1	-6.67	7.04e-11	4.3e-08	-0.39	-0.3	Body mass index;	chr12:90290980	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2579104	ENSG00000258183.4	RP11-753N8.1	-6.67	7.04e-11	4.3e-08	-0.39	-0.3	Body mass index;	chr12:90291037	chr12:90280894~90300340:+
HNSC	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-6.67	7.05e-11	4.31e-08	-0.26	-0.3	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	6.67	7.06e-11	4.31e-08	0.23	0.3	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
HNSC	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	6.67	7.06e-11	4.31e-08	0.33	0.3	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
HNSC	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	6.67	7.07e-11	4.32e-08	0.35	0.3	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-6.67	7.1e-11	4.34e-08	-0.39	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-6.67	7.1e-11	4.34e-08	-0.39	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
HNSC	cis	rs6951245	0.505	rs56117635	ENSG00000224079.1	AC091729.7	-6.67	7.1e-11	4.34e-08	-0.58	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:990398	chr7:1074450~1078036:+
HNSC	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Depression;	chr6:28399886	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	6.67	7.11e-11	4.34e-08	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	6.67	7.12e-11	4.34e-08	0.43	0.3	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
HNSC	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-6.67	7.12e-11	4.35e-08	-0.36	-0.3	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
HNSC	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-6.67	7.15e-11	4.36e-08	-0.36	-0.3	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
HNSC	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	6.67	7.15e-11	4.36e-08	0.33	0.3	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
HNSC	cis	rs11089937	0.597	rs4145535	ENSG00000211638.2	IGLV8-61	-6.67	7.16e-11	4.37e-08	-0.28	-0.3	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22098700~22099212:+
HNSC	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-6.67	7.17e-11	4.37e-08	-0.4	-0.29	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
HNSC	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	6.67	7.17e-11	4.37e-08	0.38	0.29	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
HNSC	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-6.67	7.18e-11	4.38e-08	-0.31	-0.29	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-6.67	7.18e-11	4.38e-08	-0.28	-0.29	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
HNSC	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-6.67	7.19e-11	4.39e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
HNSC	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-6.67	7.22e-11	4.4e-08	-0.27	-0.29	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	6.67	7.22e-11	4.4e-08	0.43	0.29	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
HNSC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	6.67	7.24e-11	4.41e-08	0.33	0.29	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
HNSC	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-6.67	7.25e-11	4.42e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
HNSC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	6.67	7.26e-11	4.43e-08	0.37	0.29	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
HNSC	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-6.67	7.32e-11	4.46e-08	-0.4	-0.29	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
HNSC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-6.67	7.33e-11	4.46e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
HNSC	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-6.67	7.34e-11	4.47e-08	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
HNSC	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	6.67	7.39e-11	4.5e-08	0.56	0.29	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
HNSC	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-6.67	7.39e-11	4.5e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
HNSC	cis	rs7048146	0.51	rs10759347	ENSG00000213539.4	YBX1P6	-6.67	7.39e-11	4.5e-08	-0.33	-0.29	Vascular brain injury;	chr9:109521455	chr9:109532830~109534332:-
HNSC	cis	rs7615952	0.599	rs67566088	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126050130	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs12495947	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126052855	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs6805074	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126053431	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs4422257	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126055520	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs66520539	ENSG00000241288.6	RP11-379B18.5	-6.67	7.41e-11	4.51e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:126061531	chr3:125827238~125916384:-
HNSC	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	6.67	7.42e-11	4.52e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-6.67	7.43e-11	4.52e-08	-0.29	-0.29	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
HNSC	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	6.67	7.43e-11	4.52e-08	0.37	0.29	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
HNSC	cis	rs17270561	0.609	rs9393655	ENSG00000272462.2	U91328.19	-6.67	7.44e-11	4.53e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25711110	chr6:25992662~26001775:+
HNSC	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	6.67	7.44e-11	4.53e-08	0.42	0.29	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	6.67	7.44e-11	4.53e-08	0.42	0.29	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
HNSC	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-6.67	7.45e-11	4.53e-08	-0.34	-0.29	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
HNSC	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-6.67	7.45e-11	4.53e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
HNSC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-6.67	7.46e-11	4.54e-08	-0.35	-0.29	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000254340.1	RP11-10A14.3	-6.67	7.47e-11	4.54e-08	-0.35	-0.29	Mood instability;	chr8:8934916	chr8:9141424~9145435:+
HNSC	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-6.67	7.47e-11	4.55e-08	-0.31	-0.29	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000267151.3	RP11-100E5.2	6.67	7.48e-11	4.55e-08	0.38	0.29	Menopause (age at onset);	chr17:43218318	chr17:43444707~43451200:+
HNSC	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	6.67	7.48e-11	4.55e-08	0.39	0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-6.67	7.48e-11	4.55e-08	-0.36	-0.29	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
HNSC	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.66	7.48e-11	4.55e-08	0.41	0.29	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
HNSC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.5e-11	4.56e-08	-0.36	-0.29	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-6.66	7.51e-11	4.57e-08	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-6.66	7.53e-11	4.58e-08	-0.28	-0.29	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
HNSC	cis	rs2235642	0.893	rs2076442	ENSG00000280231.1	LA16c-380F5.3	-6.66	7.53e-11	4.58e-08	-0.36	-0.29	Coronary artery disease;	chr16:1541111	chr16:1553655~1554130:-
HNSC	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	6.66	7.54e-11	4.58e-08	0.42	0.29	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
HNSC	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	6.66	7.54e-11	4.58e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
HNSC	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-6.66	7.54e-11	4.58e-08	-0.53	-0.29	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
HNSC	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-6.66	7.55e-11	4.59e-08	-0.42	-0.29	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
HNSC	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-6.66	7.58e-11	4.61e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
HNSC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	6.66	7.61e-11	4.62e-08	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.66	7.61e-11	4.62e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
HNSC	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	6.66	7.61e-11	4.62e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	6.66	7.61e-11	4.63e-08	0.34	0.29	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-6.66	7.62e-11	4.63e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
HNSC	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	6.66	7.63e-11	4.63e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	6.66	7.63e-11	4.64e-08	0.35	0.29	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
HNSC	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-6.66	7.63e-11	4.64e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-6.66	7.63e-11	4.64e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
HNSC	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	6.66	7.64e-11	4.64e-08	0.46	0.29	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
HNSC	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-6.66	7.65e-11	4.65e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.66	7.7e-11	4.68e-08	0.27	0.29	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
HNSC	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	6.66	7.7e-11	4.68e-08	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
HNSC	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.66	7.72e-11	4.68e-08	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
HNSC	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-6.66	7.74e-11	4.69e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
HNSC	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	6.66	7.74e-11	4.69e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	6.66	7.74e-11	4.69e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
HNSC	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	6.66	7.75e-11	4.7e-08	0.35	0.29	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-6.66	7.78e-11	4.72e-08	-0.35	-0.29	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
HNSC	cis	rs4141404	0.651	rs5753723	ENSG00000236132.1	CTA-440B3.1	6.66	7.78e-11	4.72e-08	0.43	0.29	Paclitaxel-induced neuropathy;	chr22:31606308	chr22:31816379~31817491:-
HNSC	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.79e-11	4.72e-08	-0.36	-0.29	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
HNSC	cis	rs7083	1	rs7083	ENSG00000254851.1	RP11-109L13.1	6.66	7.79e-11	4.72e-08	0.38	0.29	Blood protein levels;	chr11:117285836	chr11:117135528~117138582:+
HNSC	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-6.66	7.8e-11	4.73e-08	-0.36	-0.29	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
HNSC	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	6.66	7.8e-11	4.73e-08	0.3	0.29	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
HNSC	cis	rs7615952	0.688	rs17334074	ENSG00000248787.1	RP11-666A20.4	6.66	7.82e-11	4.74e-08	0.43	0.29	Blood pressure (smoking interaction);	chr3:125821617	chr3:125908005~125910272:-
HNSC	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-6.66	7.84e-11	4.75e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000211974.3	IGHV2-70	-6.66	7.84e-11	4.75e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106701309	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000211974.3	IGHV2-70	-6.66	7.85e-11	4.76e-08	-0.38	-0.29	Alzheimer's disease (late onset);	chr14:106667423	chr14:106723574~106724093:-
HNSC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	6.66	7.85e-11	4.76e-08	0.37	0.29	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
HNSC	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.66	7.86e-11	4.76e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
HNSC	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-6.66	7.87e-11	4.77e-08	-0.3	-0.29	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
HNSC	cis	rs4141404	0.64	rs9606854	ENSG00000236132.1	CTA-440B3.1	-6.66	7.9e-11	4.78e-08	-0.41	-0.29	Paclitaxel-induced neuropathy;	chr22:31534581	chr22:31816379~31817491:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	6.66	7.9e-11	4.79e-08	0.47	0.29	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
HNSC	cis	rs4218	0.648	rs12442134	ENSG00000259732.1	RP11-59H7.3	-6.66	7.9e-11	4.79e-08	-0.43	-0.29	Social communication problems;	chr15:59074478	chr15:59121034~59133250:+
HNSC	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	6.66	7.93e-11	4.81e-08	0.29	0.29	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
HNSC	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	6.66	7.94e-11	4.81e-08	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
HNSC	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-6.65	7.96e-11	4.82e-08	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
HNSC	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	6.65	7.97e-11	4.83e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-6.65	7.97e-11	4.83e-08	-0.29	-0.29	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-6.65	7.97e-11	4.83e-08	-0.28	-0.29	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
HNSC	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-6.65	7.98e-11	4.83e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
HNSC	cis	rs4218	0.597	rs62002543	ENSG00000259732.1	RP11-59H7.3	-6.65	7.99e-11	4.84e-08	-0.42	-0.29	Social communication problems;	chr15:59066646	chr15:59121034~59133250:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	6.65	7.99e-11	4.84e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
HNSC	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	6.65	8e-11	4.84e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	6.65	8e-11	4.84e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
HNSC	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.65	8.02e-11	4.85e-08	-0.37	-0.29	Height;	chr3:52989412	chr3:53064283~53065091:-
HNSC	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	6.65	8.02e-11	4.85e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
HNSC	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	6.65	8.03e-11	4.86e-08	0.35	0.29	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
HNSC	cis	rs35955747	0.902	rs2413048	ENSG00000236132.1	CTA-440B3.1	6.65	8.04e-11	4.87e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31290116	chr22:31816379~31817491:-
HNSC	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-6.65	8.05e-11	4.87e-08	-0.46	-0.29	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
HNSC	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-6.65	8.06e-11	4.88e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
HNSC	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	6.65	8.06e-11	4.88e-08	0.32	0.29	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
HNSC	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-6.65	8.07e-11	4.88e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
HNSC	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-6.65	8.07e-11	4.88e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
HNSC	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-6.65	8.12e-11	4.91e-08	-0.38	-0.29	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.65	8.12e-11	4.91e-08	0.35	0.29	Depression;	chr6:28379133	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.65	8.12e-11	4.91e-08	0.35	0.29	Depression;	chr6:28379168	chr6:28176188~28176674:+
HNSC	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-6.65	8.15e-11	4.92e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
HNSC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	6.65	8.15e-11	4.93e-08	0.33	0.29	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
HNSC	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-6.65	8.16e-11	4.93e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
HNSC	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	6.65	8.19e-11	4.95e-08	0.35	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
HNSC	cis	rs35955747	0.838	rs5997887	ENSG00000236132.1	CTA-440B3.1	6.65	8.19e-11	4.95e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31147211	chr22:31816379~31817491:-
HNSC	cis	rs6471393	0.893	rs2976350	ENSG00000253848.1	RP11-10N23.5	-6.65	8.2e-11	4.95e-08	-0.36	-0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716818	chr8:93741193~93744534:+
HNSC	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	6.65	8.2e-11	4.96e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
HNSC	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-6.65	8.21e-11	4.96e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
HNSC	cis	rs1659258	0.541	rs1270162	ENSG00000232508.1	MRPL45P1	-6.65	8.21e-11	4.96e-08	-0.61	-0.29	Visceral fat;	chr2:88351914	chr2:88364695~88365608:-
HNSC	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.65	8.21e-11	4.96e-08	0.29	0.29	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	6.65	8.24e-11	4.98e-08	0.42	0.29	Height;	chr6:109415050	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	6.65	8.24e-11	4.98e-08	0.42	0.29	Height;	chr6:109416945	chr6:109382795~109383666:+
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-6.65	8.25e-11	4.98e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
HNSC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-6.65	8.27e-11	4.99e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-6.65	8.27e-11	4.99e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
HNSC	cis	rs7115242	0.669	rs1241658	ENSG00000280143.1	AP000892.6	6.65	8.28e-11	5e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs511676	ENSG00000280143.1	AP000892.6	6.65	8.28e-11	5e-08	0.44	0.29	Blood protein levels;	chr11:116954168	chr11:117204967~117210292:+
HNSC	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	6.65	8.3e-11	5.01e-08	0.35	0.29	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
HNSC	cis	rs394563	0.559	rs7753269	ENSG00000231760.4	RP11-350J20.5	-6.65	8.3e-11	5.01e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149350224	chr6:149796151~149826294:-
HNSC	cis	rs947583	0.588	rs981580	ENSG00000217482.2	HMGB1P17	6.65	8.34e-11	5.04e-08	0.34	0.29	Phosphorus levels;	chr6:135786492	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-6.65	8.35e-11	5.04e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-6.65	8.35e-11	5.04e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
HNSC	cis	rs9341808	0.935	rs2322633	ENSG00000272129.1	RP11-250B2.6	-6.65	8.36e-11	5.05e-08	-0.34	-0.29	Sitting height ratio;	chr6:80136272	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	6.65	8.36e-11	5.05e-08	0.35	0.29	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
HNSC	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	6.65	8.36e-11	5.05e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-6.65	8.37e-11	5.05e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-6.65	8.37e-11	5.05e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.65	8.37e-11	5.05e-08	0.35	0.29	Depression;	chr6:28386473	chr6:28176188~28176674:+
HNSC	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	6.65	8.38e-11	5.06e-08	0.34	0.29	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
HNSC	cis	rs9341808	0.69	rs2505932	ENSG00000272129.1	RP11-250B2.6	6.65	8.39e-11	5.06e-08	0.34	0.29	Sitting height ratio;	chr6:80129535	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.667	rs2322632	ENSG00000272129.1	RP11-250B2.6	6.65	8.39e-11	5.06e-08	0.34	0.29	Sitting height ratio;	chr6:80135891	chr6:80355424~80356859:+
HNSC	cis	rs11089937	0.825	rs5757012	ENSG00000211638.2	IGLV8-61	-6.65	8.39e-11	5.06e-08	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	6.65	8.39e-11	5.06e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
HNSC	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	6.65	8.4e-11	5.07e-08	0.27	0.29	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
HNSC	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.65	8.4e-11	5.07e-08	0.31	0.29	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
HNSC	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	6.65	8.42e-11	5.08e-08	0.35	0.29	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000267151.3	RP11-100E5.2	6.65	8.42e-11	5.08e-08	0.38	0.29	Menopause (age at onset);	chr17:43127753	chr17:43444707~43451200:+
HNSC	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-6.65	8.43e-11	5.08e-08	-0.35	-0.29	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
HNSC	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-6.65	8.43e-11	5.08e-08	-0.35	-0.29	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
HNSC	cis	rs9326248	0.53	rs2513095	ENSG00000280143.1	AP000892.6	6.65	8.44e-11	5.08e-08	0.44	0.29	Blood protein levels;	chr11:116935553	chr11:117204967~117210292:+
HNSC	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-6.65	8.44e-11	5.09e-08	-0.36	-0.29	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
HNSC	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-6.65	8.45e-11	5.09e-08	-0.37	-0.29	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
HNSC	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-6.65	8.45e-11	5.09e-08	-0.21	-0.29	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	-6.65	8.46e-11	5.1e-08	-0.34	-0.29	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
HNSC	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-6.65	8.46e-11	5.1e-08	-0.37	-0.29	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
HNSC	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	6.65	8.47e-11	5.1e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
HNSC	cis	rs9402743	0.634	rs9494306	ENSG00000217482.2	HMGB1P17	6.64	8.47e-11	5.11e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135622823	chr6:135636086~135636713:-
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-6.64	8.48e-11	5.11e-08	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	6.64	8.49e-11	5.11e-08	0.34	0.29	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-6.64	8.49e-11	5.12e-08	-0.19	-0.29	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
HNSC	cis	rs6471393	0.895	rs58103546	ENSG00000253848.1	RP11-10N23.5	6.64	8.5e-11	5.12e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749483	chr8:93741193~93744534:+
HNSC	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	6.64	8.51e-11	5.13e-08	0.35	0.29	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
HNSC	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	6.64	8.53e-11	5.14e-08	0.4	0.29	Height;	chr6:109407148	chr6:109382795~109383666:+
HNSC	cis	rs4218	0.573	rs4775115	ENSG00000259732.1	RP11-59H7.3	-6.64	8.54e-11	5.14e-08	-0.4	-0.29	Social communication problems;	chr15:59076311	chr15:59121034~59133250:+
HNSC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-6.64	8.54e-11	5.14e-08	-0.34	-0.29	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
HNSC	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-6.64	8.58e-11	5.17e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
HNSC	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	6.64	8.58e-11	5.17e-08	0.31	0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
HNSC	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	6.64	8.59e-11	5.17e-08	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
HNSC	cis	rs9402743	0.67	rs7769840	ENSG00000217482.2	HMGB1P17	-6.64	8.59e-11	5.17e-08	-0.33	-0.29	Systemic lupus erythematosus;	chr6:135605412	chr6:135636086~135636713:-
HNSC	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-6.64	8.62e-11	5.19e-08	-0.35	-0.29	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
HNSC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	6.64	8.63e-11	5.19e-08	0.34	0.29	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
HNSC	cis	rs6081541	0.689	rs6081546	ENSG00000179447.2	RP5-1027G4.3	-6.64	8.65e-11	5.2e-08	-0.36	-0.29	Psychosis (atypical);	chr20:19240785	chr20:19242302~19284596:-
HNSC	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-6.64	8.65e-11	5.2e-08	-0.31	-0.29	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
HNSC	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	6.64	8.66e-11	5.21e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
HNSC	cis	rs2579103	0.63	rs862233	ENSG00000258183.4	RP11-753N8.1	-6.64	8.66e-11	5.21e-08	-0.39	-0.29	Body mass index;	chr12:90312060	chr12:90280894~90300340:+
HNSC	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	6.64	8.67e-11	5.21e-08	0.33	0.29	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.67e-11	5.22e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.67e-11	5.22e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
HNSC	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-6.64	8.67e-11	5.22e-08	-0.33	-0.29	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
HNSC	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.64	8.7e-11	5.23e-08	0.48	0.29	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
HNSC	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	6.64	8.7e-11	5.23e-08	0.34	0.29	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	6.64	8.7e-11	5.23e-08	0.34	0.29	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
HNSC	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-6.64	8.71e-11	5.23e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
HNSC	cis	rs1075265	0.564	rs2160930	ENSG00000233266.1	HMGB1P31	6.64	8.71e-11	5.24e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53655390	chr2:54051334~54051760:+
HNSC	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	6.64	8.73e-11	5.25e-08	0.27	0.29	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
HNSC	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	6.64	8.73e-11	5.25e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
HNSC	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-6.64	8.73e-11	5.25e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
HNSC	cis	rs35955747	0.902	rs12166373	ENSG00000236132.1	CTA-440B3.1	6.64	8.74e-11	5.25e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31304522	chr22:31816379~31817491:-
HNSC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-6.64	8.74e-11	5.25e-08	-0.32	-0.29	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
HNSC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-6.64	8.74e-11	5.25e-08	-0.37	-0.29	QT interval;	chr16:28824579	chr16:28700294~28701540:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	6.64	8.75e-11	5.26e-08	0.33	0.29	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
HNSC	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-6.64	8.78e-11	5.27e-08	-0.36	-0.29	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
HNSC	cis	rs7615952	0.611	rs2947646	ENSG00000248787.1	RP11-666A20.4	6.64	8.78e-11	5.27e-08	0.5	0.29	Blood pressure (smoking interaction);	chr3:125874759	chr3:125908005~125910272:-
HNSC	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	6.64	8.78e-11	5.28e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	6.64	8.78e-11	5.28e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
HNSC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	6.64	8.79e-11	5.28e-08	0.33	0.29	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
HNSC	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-6.64	8.8e-11	5.29e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
HNSC	cis	rs667920	0.512	rs13069695	ENSG00000239213.4	NCK1-AS1	-6.64	8.81e-11	5.29e-08	-0.39	-0.29	Coronary artery disease;	chr3:136572720	chr3:136841726~136862054:-
HNSC	cis	rs6471393	0.964	rs1051914	ENSG00000253848.1	RP11-10N23.5	6.64	8.81e-11	5.29e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93728838	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.964	rs2914952	ENSG00000253848.1	RP11-10N23.5	6.64	8.81e-11	5.29e-08	0.37	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93729524	chr8:93741193~93744534:+
HNSC	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.82e-11	5.3e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.82e-11	5.3e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
HNSC	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-6.64	8.82e-11	5.3e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
HNSC	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-6.64	8.82e-11	5.3e-08	-0.37	-0.29	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
HNSC	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	6.64	8.84e-11	5.3e-08	0.43	0.29	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	6.64	8.85e-11	5.31e-08	0.45	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
HNSC	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-6.64	8.86e-11	5.32e-08	-0.37	-0.29	Height;	chr3:52989619	chr3:53064283~53065091:-
HNSC	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-6.64	8.87e-11	5.32e-08	-0.32	-0.29	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
HNSC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	6.64	8.87e-11	5.32e-08	0.36	0.29	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
HNSC	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-6.64	8.87e-11	5.32e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	6.64	8.87e-11	5.32e-08	0.29	0.29	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
HNSC	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	6.64	8.87e-11	5.32e-08	0.43	0.29	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
HNSC	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-6.64	8.89e-11	5.33e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
HNSC	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-6.64	8.89e-11	5.34e-08	-0.31	-0.29	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-6.64	8.9e-11	5.34e-08	-0.39	-0.29	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
HNSC	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.64	8.9e-11	5.34e-08	0.31	0.29	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-6.64	8.92e-11	5.35e-08	-0.33	-0.29	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
HNSC	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	6.64	8.94e-11	5.36e-08	0.33	0.29	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000254340.1	RP11-10A14.3	6.64	8.96e-11	5.37e-08	0.35	0.29	Joint mobility (Beighton score);	chr8:9044861	chr8:9141424~9145435:+
HNSC	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-6.64	8.97e-11	5.38e-08	-0.35	-0.29	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	6.64	8.98e-11	5.38e-08	0.7	0.29	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
HNSC	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	6.64	8.99e-11	5.39e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000241288.6	RP11-379B18.5	-6.64	9e-11	5.4e-08	-0.51	-0.29	Blood pressure (smoking interaction);	chr3:125883117	chr3:125827238~125916384:-
HNSC	cis	rs9326248	0.53	rs510988	ENSG00000280143.1	AP000892.6	6.63	9.01e-11	5.4e-08	0.44	0.29	Blood protein levels;	chr11:116943088	chr11:117204967~117210292:+
HNSC	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	6.63	9.02e-11	5.41e-08	0.38	0.29	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
HNSC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-6.63	9.02e-11	5.41e-08	-0.37	-0.29	QT interval;	chr16:28857143	chr16:28700294~28701540:-
HNSC	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-6.63	9.03e-11	5.41e-08	-0.31	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
HNSC	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	6.63	9.04e-11	5.42e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
HNSC	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	6.63	9.04e-11	5.42e-08	0.33	0.29	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
HNSC	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-6.63	9.06e-11	5.43e-08	-0.36	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
HNSC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	6.63	9.06e-11	5.43e-08	0.33	0.29	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
HNSC	cis	rs5753618	0.561	rs2283879	ENSG00000236132.1	CTA-440B3.1	6.63	9.1e-11	5.45e-08	0.36	0.29	Colorectal cancer;	chr22:31242462	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2283881	ENSG00000236132.1	CTA-440B3.1	6.63	9.1e-11	5.45e-08	0.36	0.29	Colorectal cancer;	chr22:31242946	chr22:31816379~31817491:-
HNSC	cis	rs2985684	0.948	rs2883437	ENSG00000258568.1	RHOQP1	6.63	9.13e-11	5.47e-08	0.3	0.29	Carotid intima media thickness;	chr14:49564948	chr14:49599994~49600572:+
HNSC	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	6.63	9.13e-11	5.47e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
HNSC	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-6.63	9.14e-11	5.47e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-6.63	9.15e-11	5.48e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
HNSC	cis	rs10504130	0.696	rs77958054	ENSG00000272024.1	RP11-546K22.3	-6.63	9.15e-11	5.48e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51950284~51950690:+
HNSC	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-6.63	9.18e-11	5.5e-08	-0.73	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
HNSC	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-6.63	9.18e-11	5.5e-08	-0.35	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
HNSC	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	6.63	9.18e-11	5.5e-08	0.35	0.29	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
HNSC	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-6.63	9.19e-11	5.5e-08	-0.46	-0.29	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	-6.63	9.19e-11	5.5e-08	-0.34	-0.29	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.576	rs66671308	ENSG00000241288.6	RP11-379B18.5	-6.63	9.2e-11	5.51e-08	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126074683	chr3:125827238~125916384:-
HNSC	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	6.63	9.2e-11	5.51e-08	0.28	0.29	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
HNSC	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-6.63	9.21e-11	5.51e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
HNSC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-6.63	9.22e-11	5.52e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
HNSC	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-6.63	9.23e-11	5.52e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
HNSC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	6.63	9.23e-11	5.52e-08	0.35	0.29	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-6.63	9.24e-11	5.53e-08	-0.28	-0.29	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
HNSC	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-6.63	9.28e-11	5.55e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
HNSC	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-6.63	9.3e-11	5.56e-08	-0.28	-0.29	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
HNSC	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-6.63	9.31e-11	5.57e-08	-0.31	-0.29	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
HNSC	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	6.63	9.32e-11	5.57e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
HNSC	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.63	9.34e-11	5.58e-08	-0.35	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
HNSC	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-6.63	9.35e-11	5.59e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
HNSC	cis	rs1021993	0.545	rs1507331	ENSG00000231648.1	RP11-372M18.2	-6.63	9.35e-11	5.59e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209343552	chr1:209367662~209379690:+
HNSC	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	6.63	9.37e-11	5.6e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
HNSC	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-6.63	9.39e-11	5.61e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
HNSC	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-6.63	9.41e-11	5.62e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
HNSC	cis	rs12439619	0.846	rs7496227	ENSG00000276710.3	CSPG4P8	-6.63	9.41e-11	5.62e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82459472~82477258:+
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-6.63	9.41e-11	5.62e-08	-0.37	-0.29	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.692	rs60658665	ENSG00000259422.1	RP11-593F23.1	6.63	9.43e-11	5.63e-08	0.34	0.29	Blood metabolite levels;	chr15:76750167	chr15:76174891~76181486:-
HNSC	cis	rs7615952	0.599	rs6438955	ENSG00000241288.6	RP11-379B18.5	-6.63	9.45e-11	5.65e-08	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:126011490	chr3:125827238~125916384:-
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-6.63	9.46e-11	5.65e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
HNSC	cis	rs1021993	0.597	rs17014323	ENSG00000231648.1	RP11-372M18.2	-6.63	9.48e-11	5.66e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209340507	chr1:209367662~209379690:+
HNSC	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-6.63	9.49e-11	5.67e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
HNSC	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	6.63	9.49e-11	5.67e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	6.63	9.51e-11	5.68e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
HNSC	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	6.63	9.52e-11	5.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
HNSC	cis	rs35955747	0.869	rs7286648	ENSG00000236132.1	CTA-440B3.1	-6.63	9.54e-11	5.7e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31143628	chr22:31816379~31817491:-
HNSC	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	6.63	9.54e-11	5.7e-08	0.28	0.29	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000254340.1	RP11-10A14.3	-6.63	9.55e-11	5.7e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9011767	chr8:9141424~9145435:+
HNSC	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	6.63	9.55e-11	5.7e-08	0.34	0.29	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
HNSC	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	6.63	9.56e-11	5.71e-08	0.36	0.29	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
HNSC	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	6.63	9.57e-11	5.71e-08	0.46	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
HNSC	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-6.63	9.58e-11	5.72e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
HNSC	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	6.62	9.6e-11	5.73e-08	0.35	0.29	Depression;	chr6:28317705	chr6:28943877~28944537:+
HNSC	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.62	9.61e-11	5.73e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.62	9.61e-11	5.73e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
HNSC	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-6.62	9.61e-11	5.74e-08	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
HNSC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	6.62	9.61e-11	5.74e-08	0.33	0.29	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
HNSC	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-6.62	9.62e-11	5.74e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-6.62	9.62e-11	5.74e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
HNSC	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-6.62	9.62e-11	5.74e-08	-0.29	-0.29	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
HNSC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.62	9.63e-11	5.75e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
HNSC	cis	rs17270561	0.636	rs12194699	ENSG00000272462.2	U91328.19	-6.62	9.64e-11	5.75e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25729001	chr6:25992662~26001775:+
HNSC	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.62	9.65e-11	5.75e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	6.62	9.65e-11	5.76e-08	0.36	0.29	Height;	chr4:55363436	chr4:55387949~55388271:+
HNSC	cis	rs9341808	0.667	rs6938280	ENSG00000272129.1	RP11-250B2.6	6.62	9.66e-11	5.76e-08	0.34	0.29	Sitting height ratio;	chr6:80188065	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	-6.62	9.71e-11	5.79e-08	-0.32	-0.29	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
HNSC	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	6.62	9.75e-11	5.81e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-6.62	9.76e-11	5.82e-08	-0.39	-0.29	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
HNSC	cis	rs17270561	0.609	rs9379786	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25730027	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12203927	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25732462	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12192077	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25732566	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs4711098	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734111	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs4360128	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734330	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3922699	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25734741	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs6924782	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25735588	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs6924794	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25735646	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs3922842	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25736336	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358876	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738728	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs9393661	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738852	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9356986	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738891	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9358877	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739000	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs12663099	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739290	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393662	ENSG00000272462.2	U91328.19	-6.62	9.76e-11	5.82e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25739442	chr6:25992662~26001775:+
HNSC	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	6.62	9.77e-11	5.82e-08	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
HNSC	cis	rs35955747	0.84	rs9621221	ENSG00000236132.1	CTA-440B3.1	6.62	9.77e-11	5.82e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31220183	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs5997919	ENSG00000236132.1	CTA-440B3.1	6.62	9.77e-11	5.82e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31227456	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	6.62	9.77e-11	5.82e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
HNSC	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-6.62	9.81e-11	5.84e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
HNSC	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-6.62	9.81e-11	5.84e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000254340.1	RP11-10A14.3	6.62	9.82e-11	5.85e-08	0.34	0.29	Joint mobility (Beighton score);	chr8:9227785	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	6.62	9.83e-11	5.85e-08	0.38	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
HNSC	cis	rs17270561	0.609	rs9393658	ENSG00000272462.2	U91328.19	-6.62	9.85e-11	5.86e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25730210	chr6:25992662~26001775:+
HNSC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.62	9.85e-11	5.87e-08	-0.36	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-6.62	9.87e-11	5.88e-08	-0.29	-0.29	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
HNSC	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-6.62	9.87e-11	5.88e-08	-0.37	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
HNSC	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.87e-11	5.88e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-6.62	9.92e-11	5.91e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
HNSC	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	6.62	9.94e-11	5.91e-08	0.46	0.29	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-6.62	9.94e-11	5.91e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
HNSC	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	6.62	9.99e-11	5.94e-08	0.33	0.29	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
HNSC	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.62	1e-10	5.95e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-6.62	1e-10	5.95e-08	-0.34	-0.29	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
HNSC	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-6.62	1e-10	5.96e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	6.62	1e-10	5.96e-08	0.7	0.29	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
HNSC	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-6.62	1e-10	5.96e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
HNSC	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	6.62	1.01e-10	5.99e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	6.62	1.01e-10	5.99e-08	0.42	0.29	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	6.62	1.01e-10	5.99e-08	0.42	0.29	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-6.62	1.01e-10	6e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-6.62	1.01e-10	6e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
HNSC	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	6.62	1.01e-10	6e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	6.62	1.01e-10	6e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
HNSC	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-6.62	1.01e-10	6e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
HNSC	cis	rs757110	0.77	rs1557765	ENSG00000260196.1	RP1-239B22.5	6.62	1.01e-10	6.01e-08	0.33	0.29	Type 2 diabetes;	chr11:17382092	chr11:17380649~17383531:+
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-6.62	1.01e-10	6.01e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
HNSC	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-6.62	1.01e-10	6.02e-08	-0.45	-0.29	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
HNSC	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.62	1.01e-10	6.03e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
HNSC	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-6.62	1.02e-10	6.04e-08	-0.33	-0.29	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-6.62	1.02e-10	6.04e-08	-0.33	-0.29	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
HNSC	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.62	1.02e-10	6.05e-08	0.31	0.29	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
HNSC	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-6.62	1.02e-10	6.05e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-6.62	1.02e-10	6.05e-08	-0.36	-0.29	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
HNSC	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-6.62	1.02e-10	6.06e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
HNSC	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	6.61	1.02e-10	6.07e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
HNSC	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.61	1.02e-10	6.08e-08	0.27	0.29	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
HNSC	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	6.61	1.02e-10	6.08e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-6.61	1.03e-10	6.09e-08	-0.28	-0.29	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
HNSC	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	6.61	1.03e-10	6.09e-08	0.7	0.29	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
HNSC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.61	1.03e-10	6.09e-08	0.33	0.29	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
HNSC	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	6.61	1.03e-10	6.09e-08	0.31	0.29	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000254340.1	RP11-10A14.3	-6.61	1.03e-10	6.11e-08	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9226344	chr8:9141424~9145435:+
HNSC	cis	rs4218	0.648	rs877269	ENSG00000259732.1	RP11-59H7.3	-6.61	1.03e-10	6.11e-08	-0.42	-0.29	Social communication problems;	chr15:59081595	chr15:59121034~59133250:+
HNSC	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-6.61	1.03e-10	6.11e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
HNSC	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	6.61	1.03e-10	6.11e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	6.61	1.03e-10	6.12e-08	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
HNSC	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	6.61	1.03e-10	6.12e-08	0.32	0.29	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
HNSC	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-6.61	1.03e-10	6.13e-08	-0.31	-0.29	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
HNSC	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	6.61	1.03e-10	6.13e-08	0.29	0.29	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
HNSC	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.61	1.04e-10	6.14e-08	-0.37	-0.29	Height;	chr3:52991821	chr3:53064283~53065091:-
HNSC	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-6.61	1.04e-10	6.14e-08	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-6.61	1.04e-10	6.15e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	6.61	1.04e-10	6.16e-08	0.34	0.29	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
HNSC	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-6.61	1.04e-10	6.16e-08	-0.31	-0.29	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
HNSC	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	6.61	1.04e-10	6.17e-08	0.26	0.29	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	6.61	1.04e-10	6.18e-08	0.26	0.29	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
HNSC	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-6.61	1.04e-10	6.18e-08	-0.31	-0.29	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	6.61	1.04e-10	6.18e-08	0.36	0.29	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
HNSC	cis	rs189798	1	rs189798	ENSG00000173295.6	FAM86B3P	-6.61	1.04e-10	6.18e-08	-0.34	-0.29	Myopia (pathological);	chr8:9133067	chr8:8228595~8244865:+
HNSC	cis	rs440932	0.887	rs398801	ENSG00000173295.6	FAM86B3P	-6.61	1.04e-10	6.19e-08	-0.36	-0.29	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.667	rs2490241	ENSG00000272129.1	RP11-250B2.6	6.61	1.04e-10	6.19e-08	0.34	0.29	Sitting height ratio;	chr6:80136625	chr6:80355424~80356859:+
HNSC	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	6.19e-08	0.31	0.29	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
HNSC	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
HNSC	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-6.61	1.05e-10	6.2e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
HNSC	cis	rs867371	0.519	rs1566560	ENSG00000276710.3	CSPG4P8	-6.61	1.05e-10	6.2e-08	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82459472~82477258:+
HNSC	cis	rs867371	0.519	rs1566559	ENSG00000276710.3	CSPG4P8	-6.61	1.05e-10	6.2e-08	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82459472~82477258:+
HNSC	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-6.61	1.05e-10	6.2e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-6.61	1.05e-10	6.2e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
HNSC	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-6.61	1.05e-10	6.21e-08	-0.5	-0.29	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
HNSC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-6.61	1.05e-10	6.22e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	6.61	1.05e-10	6.22e-08	0.35	0.29	Depression;	chr6:28303421	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.708	rs1470032	ENSG00000258183.4	RP11-753N8.1	-6.61	1.05e-10	6.22e-08	-0.39	-0.29	Body mass index;	chr12:90277350	chr12:90280894~90300340:+
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47582204	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47582915	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47583112	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000274902.1	RP1-197B17.4	6.61	1.05e-10	6.23e-08	0.77	0.29	Pneumonia;	chr12:47583333	chr12:47731908~47732351:+
HNSC	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	6.61	1.05e-10	6.23e-08	0.51	0.29	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
HNSC	cis	rs8177876	0.57	rs11863158	ENSG00000261061.1	RP11-303E16.2	-6.61	1.05e-10	6.23e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81030770~81031485:+
HNSC	cis	rs7000734	0.598	rs2678841	ENSG00000245080.5	RP11-320N21.1	-6.61	1.05e-10	6.23e-08	-0.43	-0.29	Radiation response;	chr8:95076287	chr8:95066808~95073182:-
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	6.61	1.05e-10	6.24e-08	0.33	0.29	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-6.61	1.06e-10	6.28e-08	-0.37	-0.29	Height;	chr3:53093751	chr3:53064283~53065091:-
HNSC	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	6.61	1.06e-10	6.28e-08	0.31	0.29	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
HNSC	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-6.61	1.06e-10	6.28e-08	-0.33	-0.29	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
HNSC	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	6.61	1.06e-10	6.29e-08	0.32	0.29	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	6.61	1.06e-10	6.29e-08	0.26	0.29	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
HNSC	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-6.61	1.06e-10	6.3e-08	-0.29	-0.29	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-6.61	1.06e-10	6.3e-08	-0.37	-0.29	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000254340.1	RP11-10A14.3	-6.61	1.07e-10	6.31e-08	-0.36	-0.29	Mood instability;	chr8:8938391	chr8:9141424~9145435:+
HNSC	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	6.61	1.07e-10	6.31e-08	0.31	0.29	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000211974.3	IGHV2-70	-6.61	1.07e-10	6.31e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106697724	chr14:106723574~106724093:-
HNSC	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	6.61	1.07e-10	6.32e-08	0.31	0.29	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-6.61	1.07e-10	6.32e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-6.61	1.07e-10	6.32e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
HNSC	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-6.61	1.07e-10	6.32e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.61	1.07e-10	6.32e-08	0.35	0.29	Depression;	chr6:28364057	chr6:28176188~28176674:+
HNSC	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	6.61	1.07e-10	6.34e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
HNSC	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	6.61	1.07e-10	6.35e-08	0.35	0.29	Height;	chr4:55577294	chr4:55363971~55395847:-
HNSC	cis	rs6951245	1	rs78896566	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79422648	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs113119264	ENSG00000225146.1	AC073957.15	-6.61	1.08e-10	6.38e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1029025~1043891:+
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-6.61	1.08e-10	6.38e-08	-0.19	-0.29	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
HNSC	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-6.61	1.08e-10	6.39e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
HNSC	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	6.61	1.08e-10	6.39e-08	0.4	0.29	Height;	chr6:109452743	chr6:109382795~109383666:+
HNSC	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-6.61	1.08e-10	6.41e-08	-0.31	-0.29	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-6.6	1.08e-10	6.41e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
HNSC	cis	rs2579103	0.708	rs2579102	ENSG00000258183.4	RP11-753N8.1	-6.6	1.09e-10	6.42e-08	-0.39	-0.29	Body mass index;	chr12:90291557	chr12:90280894~90300340:+
HNSC	cis	rs17270561	0.609	rs4464787	ENSG00000272462.2	U91328.19	-6.6	1.09e-10	6.43e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25733330	chr6:25992662~26001775:+
HNSC	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.6	1.09e-10	6.43e-08	0.27	0.29	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
HNSC	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.6	1.09e-10	6.44e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
HNSC	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	6.6	1.1e-10	6.48e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
HNSC	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	6.6	1.1e-10	6.48e-08	0.59	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
HNSC	cis	rs451417	1	rs384578	ENSG00000275632.1	RP5-967N21.11	-6.6	1.1e-10	6.48e-08	-0.35	-0.29	Menopause (age at onset);	chr20:6000830	chr20:6000418~6000941:+
HNSC	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-6.6	1.1e-10	6.48e-08	-0.31	-0.29	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
HNSC	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	6.6	1.1e-10	6.49e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-6.6	1.1e-10	6.5e-08	-0.35	-0.29	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
HNSC	cis	rs10504130	0.696	rs76522329	ENSG00000272024.1	RP11-546K22.3	-6.6	1.1e-10	6.51e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51950284~51950690:+
HNSC	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
HNSC	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.6	1.1e-10	6.52e-08	0.27	0.29	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-6.6	1.11e-10	6.55e-08	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
HNSC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-6.6	1.11e-10	6.55e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-6.6	1.11e-10	6.55e-08	-0.29	-0.29	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-6.6	1.11e-10	6.58e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-6.6	1.11e-10	6.58e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
HNSC	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	6.6	1.12e-10	6.59e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
HNSC	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	6.6	1.12e-10	6.59e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
HNSC	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	6.6	1.12e-10	6.59e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
HNSC	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	6.6	1.12e-10	6.59e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	6.6	1.12e-10	6.6e-08	0.7	0.29	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
HNSC	cis	rs35955747	0.902	rs7288735	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283560	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs7288643	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283683	chr22:31816379~31817491:-
HNSC	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	6.6	1.12e-10	6.61e-08	0.52	0.29	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
HNSC	cis	rs5753618	0.509	rs2079431	ENSG00000236132.1	CTA-440B3.1	6.6	1.12e-10	6.61e-08	0.36	0.29	Colorectal cancer;	chr22:31168348	chr22:31816379~31817491:-
HNSC	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	6.6	1.12e-10	6.62e-08	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
HNSC	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-6.6	1.12e-10	6.62e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-6.6	1.12e-10	6.62e-08	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
HNSC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-6.6	1.13e-10	6.64e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-6.6	1.13e-10	6.64e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
HNSC	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	6.6	1.13e-10	6.65e-08	0.41	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-6.6	1.13e-10	6.65e-08	-0.35	-0.29	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
HNSC	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	6.6	1.13e-10	6.66e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
HNSC	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	6.6	1.13e-10	6.67e-08	0.79	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
HNSC	cis	rs4218	0.648	rs8042896	ENSG00000259732.1	RP11-59H7.3	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Social communication problems;	chr15:59067727	chr15:59121034~59133250:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-6.6	1.14e-10	6.69e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
HNSC	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	6.6	1.14e-10	6.69e-08	0.43	0.29	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
HNSC	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.6	1.14e-10	6.69e-08	0.35	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
HNSC	cis	rs9326248	0.53	rs562179	ENSG00000280143.1	AP000892.6	6.6	1.14e-10	6.7e-08	0.43	0.29	Blood protein levels;	chr11:116934488	chr11:117204967~117210292:+
HNSC	cis	rs2579103	0.631	rs2579113	ENSG00000258183.4	RP11-753N8.1	-6.6	1.14e-10	6.7e-08	-0.39	-0.29	Body mass index;	chr12:90288844	chr12:90280894~90300340:+
HNSC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-6.6	1.14e-10	6.71e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
HNSC	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-6.6	1.14e-10	6.71e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
HNSC	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-6.6	1.14e-10	6.72e-08	-0.35	-0.29	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
HNSC	cis	rs17270561	0.609	rs12529272	ENSG00000272462.2	U91328.19	-6.6	1.15e-10	6.74e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25731114	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs9393659	ENSG00000272462.2	U91328.19	-6.6	1.15e-10	6.74e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25731130	chr6:25992662~26001775:+
HNSC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	6.6	1.15e-10	6.76e-08	0.35	0.29	Height;	chr3:53073584	chr3:53064283~53065091:-
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000248787.1	RP11-666A20.4	-6.6	1.15e-10	6.76e-08	-0.42	-0.29	Blood pressure (smoking interaction);	chr3:125834656	chr3:125908005~125910272:-
HNSC	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-6.6	1.15e-10	6.77e-08	-0.37	-0.29	Height;	chr3:53094335	chr3:53064283~53065091:-
HNSC	cis	rs2579103	0.767	rs2579096	ENSG00000258183.4	RP11-753N8.1	-6.6	1.15e-10	6.78e-08	-0.36	-0.29	Body mass index;	chr12:90268478	chr12:90280894~90300340:+
HNSC	cis	rs5753618	0.555	rs5749286	ENSG00000236132.1	CTA-440B3.1	-6.59	1.16e-10	6.79e-08	-0.37	-0.29	Colorectal cancer;	chr22:31504373	chr22:31816379~31817491:-
HNSC	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	6.59	1.16e-10	6.8e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	6.59	1.16e-10	6.8e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
HNSC	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	6.59	1.16e-10	6.8e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
HNSC	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-6.59	1.16e-10	6.81e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
HNSC	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-6.59	1.16e-10	6.81e-08	-0.41	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.59	1.16e-10	6.82e-08	0.27	0.29	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
HNSC	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	6.59	1.16e-10	6.83e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
HNSC	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	6.59	1.16e-10	6.83e-08	0.32	0.29	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
HNSC	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.16e-10	6.84e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.16e-10	6.84e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
HNSC	cis	rs9341808	0.628	rs1892475	ENSG00000272129.1	RP11-250B2.6	6.59	1.17e-10	6.86e-08	0.34	0.29	Sitting height ratio;	chr6:80152496	chr6:80355424~80356859:+
HNSC	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	6.59	1.17e-10	6.87e-08	0.39	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
HNSC	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-6.59	1.17e-10	6.87e-08	-0.41	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
HNSC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	6.59	1.17e-10	6.87e-08	0.33	0.29	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
HNSC	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.87e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.87e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
HNSC	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-6.59	1.17e-10	6.88e-08	-0.43	-0.29	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	6.59	1.17e-10	6.89e-08	0.33	0.29	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.17e-10	6.89e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
HNSC	cis	rs2579103	0.708	rs2731254	ENSG00000258183.4	RP11-753N8.1	-6.59	1.17e-10	6.9e-08	-0.39	-0.29	Body mass index;	chr12:90289830	chr12:90280894~90300340:+
HNSC	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	6.59	1.18e-10	6.91e-08	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
HNSC	cis	rs4218	0.689	rs60262196	ENSG00000259732.1	RP11-59H7.3	-6.59	1.18e-10	6.91e-08	-0.42	-0.29	Social communication problems;	chr15:59088853	chr15:59121034~59133250:+
HNSC	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-6.59	1.18e-10	6.91e-08	-0.42	-0.29	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
HNSC	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	6.59	1.18e-10	6.92e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
HNSC	cis	rs17270561	0.666	rs12209856	ENSG00000272462.2	U91328.19	-6.59	1.18e-10	6.93e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25793445	chr6:25992662~26001775:+
HNSC	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	6.59	1.18e-10	6.93e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
HNSC	cis	rs35955747	0.871	rs2013254	ENSG00000236132.1	CTA-440B3.1	6.59	1.18e-10	6.94e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31294817	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.59	1.18e-10	6.94e-08	0.33	0.29	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
HNSC	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	6.59	1.18e-10	6.94e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
HNSC	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-6.59	1.18e-10	6.95e-08	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	6.59	1.18e-10	6.95e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
HNSC	cis	rs4218	0.648	rs12442086	ENSG00000259732.1	RP11-59H7.3	-6.59	1.19e-10	6.97e-08	-0.42	-0.29	Social communication problems;	chr15:59074364	chr15:59121034~59133250:+
HNSC	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-6.59	1.19e-10	6.97e-08	-0.3	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
HNSC	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-6.59	1.19e-10	6.97e-08	-0.3	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
HNSC	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	6.59	1.19e-10	6.97e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
HNSC	cis	rs35955747	0.902	rs5997932	ENSG00000236132.1	CTA-440B3.1	6.59	1.19e-10	6.99e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31272168	chr22:31816379~31817491:-
HNSC	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	6.59	1.19e-10	6.99e-08	0.29	0.29	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
HNSC	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	6.59	1.19e-10	7e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
HNSC	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-6.59	1.19e-10	7e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.19e-10	7e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
HNSC	cis	rs2404602	0.692	rs34272342	ENSG00000259422.1	RP11-593F23.1	6.59	1.19e-10	7e-08	0.34	0.29	Blood metabolite levels;	chr15:76719935	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs67570291	ENSG00000259422.1	RP11-593F23.1	6.59	1.19e-10	7e-08	0.34	0.29	Blood metabolite levels;	chr15:76728161	chr15:76174891~76181486:-
HNSC	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	6.59	1.19e-10	7.01e-08	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
HNSC	cis	rs35955747	0.869	rs131213	ENSG00000236132.1	CTA-440B3.1	-6.59	1.2e-10	7.01e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31357863	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.902	rs12167361	ENSG00000236132.1	CTA-440B3.1	6.59	1.2e-10	7.02e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31300292	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.652	rs2505940	ENSG00000272129.1	RP11-250B2.6	6.59	1.2e-10	7.04e-08	0.34	0.29	Sitting height ratio;	chr6:80141474	chr6:80355424~80356859:+
HNSC	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-6.59	1.2e-10	7.05e-08	-0.33	-0.29	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
HNSC	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-6.59	1.2e-10	7.05e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
HNSC	cis	rs1021993	1	rs1395747	ENSG00000231648.1	RP11-372M18.2	-6.59	1.21e-10	7.07e-08	-0.4	-0.29	Gut microbiome composition (winter);	chr1:209315219	chr1:209367662~209379690:+
HNSC	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-6.59	1.21e-10	7.07e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
HNSC	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-6.59	1.21e-10	7.07e-08	-0.36	-0.29	Height;	chr3:53064759	chr3:53064283~53065091:-
HNSC	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-6.59	1.21e-10	7.08e-08	-0.38	-0.29	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
HNSC	cis	rs7819412	0.775	rs2001329	ENSG00000269918.1	AF131215.9	-6.59	1.21e-10	7.08e-08	-0.29	-0.29	Triglycerides;	chr8:11129349	chr8:11104691~11106704:-
HNSC	cis	rs8054556	0.765	rs11150574	ENSG00000183604.13	SMG1P5	-6.59	1.21e-10	7.1e-08	-0.29	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30267553~30335374:-
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-6.59	1.21e-10	7.11e-08	-0.42	-0.29	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000254340.1	RP11-10A14.3	-6.59	1.21e-10	7.11e-08	-0.35	-0.29	Mood instability;	chr8:8934707	chr8:9141424~9145435:+
HNSC	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	6.59	1.22e-10	7.12e-08	0.37	0.29	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
HNSC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	6.59	1.22e-10	7.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
HNSC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-6.59	1.22e-10	7.13e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	6.59	1.22e-10	7.13e-08	0.34	0.29	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	6.59	1.22e-10	7.16e-08	0.7	0.29	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	6.59	1.22e-10	7.16e-08	0.7	0.29	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
HNSC	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	6.59	1.22e-10	7.16e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
HNSC	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.22e-10	7.16e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-6.59	1.22e-10	7.16e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
HNSC	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-6.59	1.22e-10	7.17e-08	-0.36	-0.29	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-6.58	1.23e-10	7.19e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-6.58	1.23e-10	7.2e-08	-0.27	-0.29	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-6.58	1.23e-10	7.2e-08	-0.27	-0.29	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
HNSC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	6.58	1.23e-10	7.21e-08	0.33	0.29	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
HNSC	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-6.58	1.23e-10	7.23e-08	-0.33	-0.29	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	6.58	1.24e-10	7.23e-08	0.33	0.29	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
HNSC	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	6.58	1.24e-10	7.25e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
HNSC	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-6.58	1.24e-10	7.25e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
HNSC	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-6.58	1.24e-10	7.25e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
HNSC	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-6.58	1.24e-10	7.25e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
HNSC	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-6.58	1.24e-10	7.26e-08	-0.37	-0.29	Height;	chr3:53007328	chr3:53064283~53065091:-
HNSC	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	6.58	1.24e-10	7.26e-08	0.39	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
HNSC	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-6.58	1.25e-10	7.29e-08	-0.36	-0.29	Height;	chr3:53052712	chr3:53064283~53065091:-
HNSC	cis	rs9326248	0.648	rs11216257	ENSG00000280143.1	AP000892.6	6.58	1.25e-10	7.29e-08	0.34	0.29	Blood protein levels;	chr11:117061845	chr11:117204967~117210292:+
HNSC	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	6.58	1.25e-10	7.29e-08	0.4	0.29	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
HNSC	cis	rs2404602	0.692	rs1471780	ENSG00000259422.1	RP11-593F23.1	6.58	1.25e-10	7.29e-08	0.34	0.29	Blood metabolite levels;	chr15:76734185	chr15:76174891~76181486:-
HNSC	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-6.58	1.25e-10	7.3e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
HNSC	cis	rs12439619	0.846	rs62012003	ENSG00000276710.3	CSPG4P8	-6.58	1.25e-10	7.33e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82459472~82477258:+
HNSC	cis	rs17270561	0.609	rs4131670	ENSG00000272462.2	U91328.19	-6.58	1.25e-10	7.34e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738391	chr6:25992662~26001775:+
HNSC	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	6.58	1.26e-10	7.34e-08	0.43	0.29	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-6.58	1.26e-10	7.34e-08	-0.43	-0.29	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
HNSC	cis	rs2579103	0.668	rs1909552	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90282067	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.708	rs2731261	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90283399	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.668	rs2253621	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90283940	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.668	rs2253289	ENSG00000258183.4	RP11-753N8.1	-6.58	1.26e-10	7.35e-08	-0.39	-0.29	Body mass index;	chr12:90286943	chr12:90280894~90300340:+
HNSC	cis	rs9402743	0.851	rs4896167	ENSG00000217482.2	HMGB1P17	6.58	1.26e-10	7.36e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135693164	chr6:135636086~135636713:-
HNSC	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	6.58	1.26e-10	7.36e-08	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
HNSC	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-6.58	1.26e-10	7.37e-08	-0.37	-0.29	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-6.58	1.26e-10	7.37e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
HNSC	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.27e-10	7.4e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
HNSC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	6.58	1.27e-10	7.4e-08	0.33	0.29	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-6.58	1.27e-10	7.4e-08	-0.36	-0.29	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	6.58	1.27e-10	7.41e-08	0.33	0.29	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-6.58	1.27e-10	7.41e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	-6.58	1.27e-10	7.42e-08	-0.32	-0.29	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
HNSC	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	6.58	1.27e-10	7.45e-08	0.29	0.29	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
HNSC	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-6.58	1.28e-10	7.47e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
HNSC	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-6.58	1.28e-10	7.48e-08	-0.37	-0.29	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
HNSC	cis	rs6951245	0.872	rs74360401	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs118132455	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78628466	ENSG00000225146.1	AC073957.15	-6.58	1.28e-10	7.48e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1029025~1043891:+
HNSC	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	6.58	1.28e-10	7.48e-08	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
HNSC	cis	rs35955747	0.87	rs7289189	ENSG00000236132.1	CTA-440B3.1	6.58	1.28e-10	7.48e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31261196	chr22:31816379~31817491:-
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	6.58	1.29e-10	7.5e-08	0.7	0.29	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
HNSC	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.58	1.29e-10	7.52e-08	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
HNSC	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	6.58	1.29e-10	7.52e-08	0.43	0.29	Depression;	chr6:28253486	chr6:28115628~28116551:+
HNSC	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.29e-10	7.53e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
HNSC	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	6.58	1.29e-10	7.55e-08	0.39	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
HNSC	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-6.58	1.29e-10	7.55e-08	-0.42	-0.29	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
HNSC	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-6.58	1.3e-10	7.55e-08	-0.4	-0.29	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
HNSC	cis	rs5753618	0.504	rs5753671	ENSG00000236132.1	CTA-440B3.1	-6.58	1.3e-10	7.57e-08	-0.37	-0.29	Colorectal cancer;	chr22:31514748	chr22:31816379~31817491:-
HNSC	cis	rs2286503	0.966	rs6949233	ENSG00000221740.1	SNORD93	6.58	1.3e-10	7.57e-08	0.31	0.29	Fibrinogen;	chr7:22818572	chr7:22856613~22856686:+
HNSC	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	6.58	1.3e-10	7.57e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000267151.3	RP11-100E5.2	6.58	1.3e-10	7.58e-08	0.37	0.29	Menopause (age at onset);	chr17:43092919	chr17:43444707~43451200:+
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-6.58	1.3e-10	7.58e-08	-0.35	-0.29	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-6.58	1.3e-10	7.58e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
HNSC	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	6.58	1.3e-10	7.58e-08	0.27	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	6.58	1.3e-10	7.59e-08	0.26	0.29	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
HNSC	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.3e-10	7.59e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-6.58	1.3e-10	7.59e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
HNSC	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-6.58	1.3e-10	7.59e-08	-0.26	-0.29	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
HNSC	cis	rs9402743	0.634	rs4896156	ENSG00000217482.2	HMGB1P17	6.58	1.3e-10	7.6e-08	0.32	0.29	Systemic lupus erythematosus;	chr6:135605725	chr6:135636086~135636713:-
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000274902.1	RP1-197B17.4	6.58	1.3e-10	7.6e-08	0.77	0.29	Pneumonia;	chr12:47584539	chr12:47731908~47732351:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	6.57	1.31e-10	7.6e-08	0.22	0.29	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
HNSC	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	6.57	1.31e-10	7.6e-08	0.39	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
HNSC	cis	rs1021993	0.597	rs17014320	ENSG00000231648.1	RP11-372M18.2	-6.57	1.31e-10	7.65e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209338828	chr1:209367662~209379690:+
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-6.57	1.32e-10	7.66e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
HNSC	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	6.57	1.32e-10	7.67e-08	0.33	0.29	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
HNSC	cis	rs9341808	0.667	rs3828753	ENSG00000272129.1	RP11-250B2.6	6.57	1.32e-10	7.68e-08	0.34	0.29	Sitting height ratio;	chr6:80203029	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.591	rs7741013	ENSG00000272129.1	RP11-250B2.6	6.57	1.32e-10	7.68e-08	0.34	0.29	Sitting height ratio;	chr6:80206613	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	6.57	1.32e-10	7.68e-08	0.22	0.29	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
HNSC	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	6.57	1.32e-10	7.69e-08	0.42	0.29	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000254340.1	RP11-10A14.3	-6.57	1.32e-10	7.7e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9011689	chr8:9141424~9145435:+
HNSC	cis	rs5753618	0.583	rs5749279	ENSG00000236132.1	CTA-440B3.1	-6.57	1.32e-10	7.7e-08	-0.33	-0.29	Colorectal cancer;	chr22:31458223	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.73e-08	0.33	0.29	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.73e-08	0.33	0.29	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
HNSC	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	6.57	1.33e-10	7.73e-08	0.46	0.29	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
HNSC	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	6.57	1.33e-10	7.74e-08	0.34	0.29	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
HNSC	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	6.57	1.33e-10	7.75e-08	0.33	0.29	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
HNSC	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-6.57	1.34e-10	7.78e-08	-0.41	-0.29	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
HNSC	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-6.57	1.34e-10	7.8e-08	-0.29	-0.29	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
HNSC	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-6.57	1.34e-10	7.81e-08	-0.32	-0.29	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
HNSC	cis	rs4218	0.648	rs35769647	ENSG00000259732.1	RP11-59H7.3	-6.57	1.34e-10	7.81e-08	-0.42	-0.29	Social communication problems;	chr15:59081670	chr15:59121034~59133250:+
HNSC	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.85e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
HNSC	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	6.57	1.35e-10	7.85e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-6.57	1.35e-10	7.86e-08	-0.22	-0.29	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
HNSC	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-6.57	1.36e-10	7.88e-08	-0.29	-0.29	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-6.57	1.36e-10	7.88e-08	-0.29	-0.29	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
HNSC	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	6.57	1.36e-10	7.88e-08	0.3	0.29	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
HNSC	cis	rs6951245	1	rs74785791	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs74366004	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77702926	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs78573577	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76129108	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78523927	ENSG00000225146.1	AC073957.15	-6.57	1.36e-10	7.9e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1029025~1043891:+
HNSC	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-6.57	1.36e-10	7.9e-08	-0.37	-0.29	Height;	chr3:53015087	chr3:53064283~53065091:-
HNSC	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-6.57	1.36e-10	7.9e-08	-0.36	-0.29	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
HNSC	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-6.57	1.36e-10	7.91e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
HNSC	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	6.57	1.36e-10	7.92e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
HNSC	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-6.57	1.36e-10	7.93e-08	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
HNSC	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	6.57	1.37e-10	7.95e-08	0.33	0.29	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
HNSC	cis	rs4218	0.648	rs2289895	ENSG00000259732.1	RP11-59H7.3	-6.57	1.37e-10	7.96e-08	-0.41	-0.29	Social communication problems;	chr15:59089570	chr15:59121034~59133250:+
HNSC	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-6.57	1.37e-10	7.98e-08	-0.37	-0.29	Height;	chr3:53009621	chr3:53064283~53065091:-
HNSC	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-6.57	1.38e-10	7.99e-08	-0.38	-0.29	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
HNSC	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-6.57	1.38e-10	8e-08	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-6.57	1.38e-10	8.01e-08	-0.28	-0.29	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-6.57	1.38e-10	8.01e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
HNSC	cis	rs35955747	0.838	rs7285171	ENSG00000236132.1	CTA-440B3.1	6.57	1.38e-10	8.01e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31202381	chr22:31816379~31817491:-
HNSC	cis	rs17270561	0.609	rs1165181	ENSG00000272462.2	U91328.19	-6.57	1.38e-10	8.01e-08	-0.29	-0.29	Iron status biomarkers;	chr6:25825162	chr6:25992662~26001775:+
HNSC	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	6.57	1.38e-10	8.03e-08	0.38	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
HNSC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-6.56	1.39e-10	8.06e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-6.56	1.39e-10	8.06e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
HNSC	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	6.56	1.39e-10	8.06e-08	0.38	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
HNSC	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	6.56	1.39e-10	8.06e-08	0.3	0.29	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000267151.3	RP11-100E5.2	6.56	1.39e-10	8.06e-08	0.38	0.29	Menopause (age at onset);	chr17:43041893	chr17:43444707~43451200:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-6.56	1.39e-10	8.07e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
HNSC	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-6.56	1.39e-10	8.07e-08	-0.56	-0.29	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
HNSC	cis	rs9341808	0.667	rs1575541	ENSG00000272129.1	RP11-250B2.6	6.56	1.39e-10	8.08e-08	0.34	0.29	Sitting height ratio;	chr6:80207768	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-6.56	1.39e-10	8.08e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
HNSC	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.56	1.4e-10	8.1e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.56	1.4e-10	8.1e-08	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000173295.6	FAM86B3P	6.56	1.4e-10	8.1e-08	0.33	0.29	Joint mobility (Beighton score);	chr8:8970227	chr8:8228595~8244865:+
HNSC	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	6.56	1.4e-10	8.14e-08	0.35	0.29	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
HNSC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	6.56	1.41e-10	8.15e-08	0.33	0.29	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
HNSC	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	6.56	1.41e-10	8.17e-08	0.46	0.29	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-6.56	1.41e-10	8.18e-08	-0.36	-0.29	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
HNSC	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-6.56	1.41e-10	8.18e-08	-0.48	-0.29	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
HNSC	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-6.56	1.41e-10	8.19e-08	-0.29	-0.29	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
HNSC	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	6.56	1.42e-10	8.2e-08	0.42	0.29	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
HNSC	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	6.56	1.42e-10	8.21e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
HNSC	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	6.56	1.42e-10	8.23e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
HNSC	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	8.24e-08	0.28	0.29	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
HNSC	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	6.56	1.42e-10	8.24e-08	0.39	0.29	Height;	chr6:109428824	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-6.56	1.43e-10	8.27e-08	-0.24	-0.29	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
HNSC	cis	rs12439619	0.846	rs28470877	ENSG00000276710.3	CSPG4P8	-6.56	1.43e-10	8.27e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82459472~82477258:+
HNSC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.56	1.43e-10	8.3e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	6.56	1.44e-10	8.31e-08	0.33	0.29	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
HNSC	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	6.56	1.44e-10	8.31e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	6.56	1.44e-10	8.31e-08	0.33	0.29	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
HNSC	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-6.56	1.44e-10	8.33e-08	-0.39	-0.29	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
HNSC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-6.56	1.44e-10	8.34e-08	-0.57	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
HNSC	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-6.56	1.44e-10	8.35e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
HNSC	cis	rs17270561	0.666	rs9356987	ENSG00000272462.2	U91328.19	-6.56	1.44e-10	8.35e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25738959	chr6:25992662~26001775:+
HNSC	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-6.56	1.44e-10	8.35e-08	-0.33	-0.29	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
HNSC	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-6.56	1.44e-10	8.35e-08	-0.35	-0.29	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
HNSC	cis	rs7615952	0.641	rs12487875	ENSG00000241288.6	RP11-379B18.5	-6.56	1.45e-10	8.37e-08	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126068381	chr3:125827238~125916384:-
HNSC	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	6.56	1.45e-10	8.38e-08	0.41	0.29	Height;	chr6:109773423	chr6:109382795~109383666:+
HNSC	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-6.56	1.45e-10	8.38e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
HNSC	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	6.56	1.45e-10	8.39e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
HNSC	cis	rs6951245	1	rs113575110	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs1881123	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs77569514	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11770909	ENSG00000225146.1	AC073957.15	-6.56	1.45e-10	8.39e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1029025~1043891:+
HNSC	cis	rs451417	0.73	rs236128	ENSG00000275632.1	RP5-967N21.11	-6.56	1.45e-10	8.4e-08	-0.37	-0.29	Menopause (age at onset);	chr20:5999007	chr20:6000418~6000941:+
HNSC	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-6.56	1.45e-10	8.41e-08	-0.37	-0.29	Height;	chr3:53027969	chr3:53064283~53065091:-
HNSC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-6.56	1.46e-10	8.43e-08	-0.35	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
HNSC	cis	rs2286503	1	rs2286503	ENSG00000221740.1	SNORD93	6.56	1.46e-10	8.43e-08	0.31	0.29	Fibrinogen;	chr7:22816987	chr7:22856613~22856686:+
HNSC	cis	rs2286503	1	rs2286501	ENSG00000221740.1	SNORD93	6.56	1.46e-10	8.43e-08	0.31	0.29	Fibrinogen;	chr7:22817166	chr7:22856613~22856686:+
HNSC	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	6.56	1.46e-10	8.43e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
HNSC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-6.56	1.46e-10	8.43e-08	-0.35	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	6.56	1.46e-10	8.43e-08	0.26	0.29	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	6.56	1.46e-10	8.43e-08	0.26	0.29	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-6.56	1.46e-10	8.44e-08	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
HNSC	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-6.56	1.46e-10	8.44e-08	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
HNSC	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	6.56	1.47e-10	8.47e-08	0.41	0.29	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
HNSC	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-6.56	1.47e-10	8.47e-08	-0.37	-0.29	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000221740.1	SNORD93	6.56	1.47e-10	8.47e-08	0.32	0.29	Fibrinogen;	chr7:22851123	chr7:22856613~22856686:+
HNSC	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	6.56	1.47e-10	8.47e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.555	rs5749291	ENSG00000236132.1	CTA-440B3.1	-6.56	1.47e-10	8.49e-08	-0.37	-0.29	Colorectal cancer;	chr22:31511537	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-6.56	1.47e-10	8.5e-08	-0.35	-0.29	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
HNSC	cis	rs7617773	0.539	rs6779517	ENSG00000228638.1	FCF1P2	-6.55	1.48e-10	8.54e-08	-0.26	-0.29	Coronary artery disease;	chr3:48342898	chr3:48290793~48291375:-
HNSC	cis	rs17270561	0.636	rs1185977	ENSG00000272462.2	U91328.19	-6.55	1.48e-10	8.55e-08	-0.29	-0.29	Iron status biomarkers;	chr6:25828826	chr6:25992662~26001775:+
HNSC	cis	rs11089937	0.857	rs5750578	ENSG00000211638.2	IGLV8-61	-6.55	1.48e-10	8.55e-08	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22098700~22099212:+
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	6.55	1.48e-10	8.55e-08	0.22	0.29	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
HNSC	cis	rs1021993	0.597	rs79455200	ENSG00000231648.1	RP11-372M18.2	-6.55	1.48e-10	8.56e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209334422	chr1:209367662~209379690:+
HNSC	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	6.55	1.48e-10	8.56e-08	0.35	0.29	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-6.55	1.49e-10	8.58e-08	-0.37	-0.29	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
HNSC	cis	rs7942368	0.941	rs12290350	ENSG00000255100.1	RP11-21L23.3	-6.55	1.49e-10	8.59e-08	-0.38	-0.29	Endometriosis;	chr11:76769211	chr11:76782581~76783062:-
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-6.55	1.49e-10	8.6e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
HNSC	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-6.55	1.49e-10	8.6e-08	-0.42	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
HNSC	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	6.55	1.49e-10	8.61e-08	0.39	0.29	Height;	chr6:109429207	chr6:109382795~109383666:+
HNSC	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	6.55	1.5e-10	8.64e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
HNSC	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-6.55	1.5e-10	8.65e-08	-0.33	-0.29	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66715944	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66721259	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	8.65e-08	-0.41	-0.29	Gout;	chr7:66732812	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	6.55	1.5e-10	8.66e-08	0.33	0.29	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-6.55	1.5e-10	8.67e-08	-0.36	-0.29	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
HNSC	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.55	1.5e-10	8.67e-08	0.28	0.29	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
HNSC	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-6.55	1.51e-10	8.68e-08	-0.35	-0.29	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
HNSC	cis	rs35955747	0.902	rs131202	ENSG00000236132.1	CTA-440B3.1	-6.55	1.51e-10	8.68e-08	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31313323	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	6.55	1.51e-10	8.7e-08	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
HNSC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.55	1.51e-10	8.72e-08	-0.32	-0.29	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
HNSC	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	6.55	1.51e-10	8.72e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000274902.1	RP1-197B17.4	6.55	1.51e-10	8.73e-08	0.78	0.29	Pneumonia;	chr12:47578764	chr12:47731908~47732351:+
HNSC	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	6.55	1.52e-10	8.73e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000254340.1	RP11-10A14.3	6.55	1.52e-10	8.74e-08	0.35	0.29	Mood instability;	chr8:8788736	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000267151.3	RP11-100E5.2	6.55	1.52e-10	8.77e-08	0.37	0.29	Menopause (age at onset);	chr17:43352811	chr17:43444707~43451200:+
HNSC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-6.55	1.52e-10	8.78e-08	-0.35	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
HNSC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-6.55	1.52e-10	8.78e-08	-0.35	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
HNSC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-6.55	1.53e-10	8.82e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
HNSC	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.55	1.53e-10	8.82e-08	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
HNSC	cis	rs6951245	1	rs78158942	ENSG00000225146.1	AC073957.15	-6.55	1.54e-10	8.86e-08	-0.5	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1029025~1043891:+
HNSC	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	6.55	1.54e-10	8.87e-08	0.35	0.29	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
HNSC	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	6.55	1.54e-10	8.87e-08	0.58	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
HNSC	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-6.55	1.55e-10	8.89e-08	-0.33	-0.29	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
HNSC	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-6.55	1.55e-10	8.9e-08	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	6.55	1.55e-10	8.91e-08	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
HNSC	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	6.55	1.55e-10	8.92e-08	0.41	0.29	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
HNSC	cis	rs6951245	1	rs1997243	ENSG00000225146.1	AC073957.15	-6.55	1.55e-10	8.92e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77760339	ENSG00000225146.1	AC073957.15	-6.55	1.55e-10	8.92e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1029025~1043891:+
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-6.55	1.55e-10	8.93e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	6.55	1.55e-10	8.93e-08	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-6.55	1.55e-10	8.94e-08	-0.35	-0.29	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
HNSC	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	6.55	1.56e-10	8.95e-08	0.33	0.29	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
HNSC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-6.55	1.56e-10	8.97e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-6.55	1.56e-10	8.97e-08	-0.47	-0.29	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
HNSC	cis	rs4141404	0.818	rs6518737	ENSG00000236132.1	CTA-440B3.1	6.55	1.56e-10	8.99e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31816379~31817491:-
HNSC	cis	rs4141404	0.787	rs11913992	ENSG00000236132.1	CTA-440B3.1	6.55	1.56e-10	8.99e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31816379~31817491:-
HNSC	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-6.55	1.56e-10	8.99e-08	-0.31	-0.29	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
HNSC	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-6.55	1.56e-10	8.99e-08	-0.31	-0.29	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	6.55	1.56e-10	8.99e-08	0.31	0.29	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
HNSC	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	6.54	1.57e-10	9.04e-08	0.3	0.29	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
HNSC	cis	rs2337406	1	rs11850600	ENSG00000211974.3	IGHV2-70	-6.54	1.58e-10	9.05e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106670765	chr14:106723574~106724093:-
HNSC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.54	1.58e-10	9.06e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
HNSC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-6.54	1.58e-10	9.07e-08	-0.35	-0.29	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
HNSC	cis	rs7587476	0.601	rs6715570	ENSG00000229267.2	AC072062.1	6.54	1.58e-10	9.08e-08	0.36	0.29	Neuroblastoma;	chr2:214808716	chr2:214810229~214963274:+
HNSC	cis	rs7083	1	rs644215	ENSG00000254851.1	RP11-109L13.1	6.54	1.58e-10	9.09e-08	0.37	0.29	Blood protein levels;	chr11:117275202	chr11:117135528~117138582:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-6.54	1.59e-10	9.1e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
HNSC	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	6.54	1.59e-10	9.12e-08	0.31	0.29	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
HNSC	cis	rs6951245	1	rs76804143	ENSG00000225146.1	AC073957.15	-6.54	1.59e-10	9.12e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1029025~1043891:+
HNSC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	6.54	1.59e-10	9.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
HNSC	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	6.54	1.59e-10	9.12e-08	0.27	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
HNSC	cis	rs2985684	0.74	rs2883438	ENSG00000258568.1	RHOQP1	6.54	1.59e-10	9.12e-08	0.3	0.29	Carotid intima media thickness;	chr14:49577674	chr14:49599994~49600572:+
HNSC	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.59e-10	9.14e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.59e-10	9.14e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
HNSC	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-6.54	1.59e-10	9.14e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
HNSC	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	6.54	1.59e-10	9.14e-08	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
HNSC	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.54	1.6e-10	9.16e-08	0.34	0.29	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
HNSC	cis	rs6951245	0.938	rs11764937	ENSG00000225146.1	AC073957.15	-6.54	1.6e-10	9.17e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1029025~1043891:+
HNSC	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	6.54	1.6e-10	9.17e-08	0.22	0.29	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-6.54	1.6e-10	9.17e-08	-0.35	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
HNSC	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-6.54	1.6e-10	9.19e-08	-0.51	-0.29	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
HNSC	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.54	1.61e-10	9.23e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
HNSC	cis	rs1021993	0.597	rs4844807	ENSG00000231648.1	RP11-372M18.2	-6.54	1.61e-10	9.23e-08	-0.5	-0.29	Gut microbiome composition (winter);	chr1:209337769	chr1:209367662~209379690:+
HNSC	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	6.54	1.61e-10	9.24e-08	0.42	0.29	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
HNSC	cis	rs8177876	0.822	rs4324141	ENSG00000261061.1	RP11-303E16.2	6.54	1.61e-10	9.25e-08	0.47	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81030770~81031485:+
HNSC	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	6.54	1.61e-10	9.26e-08	0.39	0.29	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
HNSC	cis	rs8177876	0.749	rs935942	ENSG00000261061.1	RP11-303E16.2	6.54	1.62e-10	9.27e-08	0.45	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81030770~81031485:+
HNSC	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	6.54	1.62e-10	9.28e-08	0.31	0.29	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	6.54	1.62e-10	9.28e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	6.54	1.62e-10	9.28e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
HNSC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	6.54	1.62e-10	9.29e-08	0.33	0.29	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	6.54	1.62e-10	9.29e-08	0.33	0.29	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
HNSC	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	6.54	1.62e-10	9.31e-08	0.33	0.29	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-6.54	1.63e-10	9.31e-08	-0.43	-0.29	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	6.54	1.63e-10	9.34e-08	0.32	0.29	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
HNSC	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-6.54	1.63e-10	9.35e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
HNSC	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-6.54	1.63e-10	9.36e-08	-0.41	-0.29	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
HNSC	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	6.54	1.63e-10	9.36e-08	0.29	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
HNSC	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	6.54	1.64e-10	9.38e-08	0.33	0.29	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
HNSC	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.54	1.64e-10	9.39e-08	-0.35	-0.29	Height;	chr3:52971094	chr3:53064283~53065091:-
HNSC	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-6.54	1.64e-10	9.4e-08	-0.28	-0.29	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
HNSC	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-6.54	1.64e-10	9.41e-08	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
HNSC	cis	rs783540	0.542	rs62009945	ENSG00000276710.3	CSPG4P8	6.54	1.64e-10	9.41e-08	0.36	0.29	Schizophrenia;	chr15:82631205	chr15:82459472~82477258:+
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000267151.3	RP11-100E5.2	6.54	1.65e-10	9.42e-08	0.37	0.29	Menopause (age at onset);	chr17:43365383	chr17:43444707~43451200:+
HNSC	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-6.54	1.65e-10	9.42e-08	-0.36	-0.29	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-6.54	1.65e-10	9.43e-08	-0.32	-0.29	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
HNSC	cis	rs8054556	0.74	rs12716975	ENSG00000183604.13	SMG1P5	-6.54	1.65e-10	9.43e-08	-0.29	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30267553~30335374:-
HNSC	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-6.54	1.65e-10	9.44e-08	-0.34	-0.29	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
HNSC	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-6.54	1.65e-10	9.44e-08	-0.56	-0.29	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
HNSC	cis	rs6951245	1	rs11768761	ENSG00000225146.1	AC073957.15	-6.54	1.65e-10	9.44e-08	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1029025~1043891:+
HNSC	cis	rs2579103	0.767	rs1347844	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90269439	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1371085	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90271728	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs2118804	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90272189	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1438992	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90275756	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.728	rs2731270	ENSG00000258183.4	RP11-753N8.1	-6.54	1.65e-10	9.45e-08	-0.36	-0.29	Body mass index;	chr12:90275906	chr12:90280894~90300340:+
HNSC	cis	rs35955747	0.869	rs5753576	ENSG00000236132.1	CTA-440B3.1	-6.54	1.65e-10	9.46e-08	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31361749	chr22:31816379~31817491:-
HNSC	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	6.54	1.65e-10	9.46e-08	0.45	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
HNSC	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	6.54	1.66e-10	9.49e-08	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
HNSC	cis	rs9341808	0.935	rs4706113	ENSG00000272129.1	RP11-250B2.6	6.54	1.66e-10	9.5e-08	0.34	0.29	Sitting height ratio;	chr6:80129598	chr6:80355424~80356859:+
HNSC	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
HNSC	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
HNSC	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	6.54	1.66e-10	9.51e-08	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000267151.3	RP11-100E5.2	-6.54	1.66e-10	9.52e-08	-0.37	-0.29	Menopause (age at onset);	chr17:43176078	chr17:43444707~43451200:+
HNSC	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	6.54	1.66e-10	9.52e-08	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
HNSC	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	6.54	1.66e-10	9.52e-08	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
HNSC	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-6.54	1.67e-10	9.53e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
HNSC	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-6.54	1.67e-10	9.53e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
HNSC	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-6.54	1.67e-10	9.53e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
HNSC	cis	rs4141404	0.818	rs5997897	ENSG00000236132.1	CTA-440B3.1	6.53	1.67e-10	9.54e-08	0.31	0.29	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31816379~31817491:-
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-6.53	1.67e-10	9.54e-08	-0.28	-0.29	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
HNSC	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	6.53	1.67e-10	9.55e-08	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
HNSC	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-6.53	1.67e-10	9.57e-08	-0.3	-0.29	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
HNSC	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	6.53	1.67e-10	9.57e-08	0.33	0.29	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.963	rs5757098	ENSG00000211638.2	IGLV8-61	6.53	1.68e-10	9.59e-08	0.25	0.29	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22098700~22099212:+
HNSC	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	6.53	1.68e-10	9.59e-08	0.37	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
HNSC	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	6.53	1.68e-10	9.59e-08	0.36	0.29	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000211974.3	IGHV2-70	-6.53	1.68e-10	9.61e-08	-0.34	-0.29	Alzheimer's disease (late onset);	chr14:106704924	chr14:106723574~106724093:-
HNSC	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-6.53	1.69e-10	9.63e-08	-0.37	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
HNSC	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-6.53	1.69e-10	9.64e-08	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-6.53	1.69e-10	9.65e-08	-0.28	-0.29	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-6.53	1.69e-10	9.67e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-6.53	1.69e-10	9.67e-08	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
HNSC	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	6.53	1.69e-10	9.67e-08	0.33	0.29	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
HNSC	cis	rs35955747	0.934	rs4820045	ENSG00000236132.1	CTA-440B3.1	6.53	1.69e-10	9.67e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31389983	chr22:31816379~31817491:-
HNSC	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	6.53	1.7e-10	9.68e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	6.53	1.7e-10	9.68e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
HNSC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-6.53	1.7e-10	9.7e-08	-0.31	-0.29	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-6.53	1.7e-10	9.71e-08	-0.41	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
HNSC	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	6.53	1.7e-10	9.71e-08	0.55	0.29	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
HNSC	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-6.53	1.7e-10	9.72e-08	-0.3	-0.29	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
HNSC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-6.53	1.71e-10	9.75e-08	-0.37	-0.29	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
HNSC	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-6.53	1.71e-10	9.75e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
HNSC	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-6.53	1.71e-10	9.76e-08	-0.29	-0.29	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
HNSC	cis	rs4273100	1	rs4924986	ENSG00000265185.4	SNORD3B-1	-6.53	1.71e-10	9.76e-08	-0.44	-0.29	Schizophrenia;	chr17:19339154	chr17:19061912~19062669:+
HNSC	cis	rs8054556	0.513	rs12596042	ENSG00000183604.13	SMG1P5	-6.53	1.71e-10	9.77e-08	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30267553~30335374:-
HNSC	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	6.53	1.71e-10	9.77e-08	0.23	0.29	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
HNSC	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-6.53	1.72e-10	9.8e-08	-0.27	-0.29	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-6.53	1.72e-10	9.8e-08	-0.36	-0.29	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.81e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.81e-08	-0.31	-0.29	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
HNSC	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-6.53	1.72e-10	9.82e-08	-0.43	-0.29	Depression;	chr6:28266819	chr6:28115628~28116551:+
HNSC	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-6.53	1.72e-10	9.83e-08	-0.53	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
HNSC	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-6.53	1.72e-10	9.83e-08	-0.45	-0.29	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.53	1.73e-10	9.84e-08	-0.33	-0.29	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.729	rs11264369	ENSG00000203761.5	MSTO2P	6.53	1.73e-10	9.85e-08	0.22	0.29	Body mass index;	chr1:155390039	chr1:155745829~155750137:+
HNSC	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	6.53	1.73e-10	9.86e-08	0.34	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
HNSC	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-6.53	1.73e-10	9.87e-08	-0.34	-0.29	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
HNSC	cis	rs2337406	1	rs78631692	ENSG00000211974.3	IGHV2-70	-6.53	1.73e-10	9.89e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106709371	chr14:106723574~106724093:-
HNSC	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
HNSC	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	6.53	1.73e-10	9.89e-08	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	6.53	1.74e-10	9.91e-08	0.34	0.29	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
HNSC	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	6.53	1.74e-10	9.92e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
HNSC	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-6.53	1.74e-10	9.92e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-6.53	1.74e-10	9.92e-08	-0.55	-0.29	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-6.53	1.74e-10	9.93e-08	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
HNSC	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-6.53	1.74e-10	9.93e-08	-0.35	-0.29	Height;	chr3:52972039	chr3:53064283~53065091:-
HNSC	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-6.53	1.74e-10	9.94e-08	-0.39	-0.29	Height;	chr6:109444615	chr6:109382795~109383666:+
HNSC	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	6.53	1.75e-10	9.95e-08	0.41	0.29	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-6.53	1.75e-10	9.97e-08	-0.19	-0.29	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-6.53	1.75e-10	9.98e-08	-0.27	-0.29	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-6.53	1.75e-10	9.99e-08	-0.25	-0.29	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-6.53	1.75e-10	9.99e-08	-0.25	-0.29	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
HNSC	cis	rs860295	1	rs708611	ENSG00000203761.5	MSTO2P	6.53	1.76e-10	1e-07	0.21	0.29	Body mass index;	chr1:155773519	chr1:155745829~155750137:+
HNSC	cis	rs9341808	0.667	rs2490251	ENSG00000272129.1	RP11-250B2.6	6.53	1.76e-10	1e-07	0.34	0.29	Sitting height ratio;	chr6:80185447	chr6:80355424~80356859:+
HNSC	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	6.53	1.76e-10	1e-07	0.39	0.29	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
HNSC	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.53	1.76e-10	1e-07	-0.45	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
HNSC	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-6.53	1.76e-10	1e-07	-0.38	-0.29	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
HNSC	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-6.53	1.77e-10	1.01e-07	-0.29	-0.29	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
HNSC	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-6.52	1.77e-10	1.01e-07	-0.32	-0.29	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
HNSC	cis	rs4218	0.648	rs12915899	ENSG00000259732.1	RP11-59H7.3	-6.52	1.77e-10	1.01e-07	-0.41	-0.29	Social communication problems;	chr15:59084332	chr15:59121034~59133250:+
HNSC	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-6.52	1.78e-10	1.01e-07	-0.35	-0.29	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
HNSC	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	6.52	1.78e-10	1.01e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-6.52	1.78e-10	1.01e-07	-0.32	-0.29	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-6.52	1.78e-10	1.01e-07	-0.32	-0.29	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
HNSC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-6.52	1.78e-10	1.01e-07	-0.35	-0.29	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-6.52	1.79e-10	1.02e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
HNSC	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	6.52	1.79e-10	1.02e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
HNSC	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-6.52	1.79e-10	1.02e-07	-0.43	-0.29	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-6.52	1.79e-10	1.02e-07	-0.32	-0.29	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
HNSC	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-6.52	1.79e-10	1.02e-07	-0.37	-0.29	Height;	chr3:53034139	chr3:53064283~53065091:-
HNSC	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-6.52	1.79e-10	1.02e-07	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
HNSC	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
HNSC	cis	rs6951245	1	rs74369356	ENSG00000225146.1	AC073957.15	-6.52	1.79e-10	1.02e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1029025~1043891:+
HNSC	cis	rs9341808	0.667	rs2505944	ENSG00000272129.1	RP11-250B2.6	6.52	1.79e-10	1.02e-07	0.34	0.29	Sitting height ratio;	chr6:80178693	chr6:80355424~80356859:+
HNSC	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-6.52	1.79e-10	1.02e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
HNSC	cis	rs2579103	0.625	rs1726065	ENSG00000258183.4	RP11-753N8.1	-6.52	1.8e-10	1.02e-07	-0.41	-0.29	Body mass index;	chr12:90319369	chr12:90280894~90300340:+
HNSC	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-6.52	1.8e-10	1.02e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
HNSC	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.8e-10	1.03e-07	-0.36	-0.29	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
HNSC	cis	rs6951245	1	rs28528096	ENSG00000225146.1	AC073957.15	-6.52	1.8e-10	1.03e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1029025~1043891:+
HNSC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	6.52	1.81e-10	1.03e-07	0.33	0.29	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
HNSC	cis	rs6951245	0.554	rs10270249	ENSG00000224079.1	AC091729.7	-6.52	1.81e-10	1.03e-07	-0.38	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1074450~1078036:+
HNSC	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.52	1.81e-10	1.03e-07	0.34	0.29	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
HNSC	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-6.52	1.82e-10	1.03e-07	-0.26	-0.29	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-6.52	1.82e-10	1.03e-07	-0.37	-0.29	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
HNSC	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.52	1.82e-10	1.03e-07	-0.35	-0.29	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
HNSC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	6.52	1.82e-10	1.03e-07	0.34	0.29	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
HNSC	cis	rs11089937	0.963	rs5757078	ENSG00000211638.2	IGLV8-61	-6.52	1.82e-10	1.03e-07	-0.25	-0.29	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22098700~22099212:+
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-6.52	1.82e-10	1.03e-07	-0.38	-0.29	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	6.52	1.82e-10	1.04e-07	0.37	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
HNSC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-6.52	1.82e-10	1.04e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
HNSC	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.83e-10	1.04e-07	-0.35	-0.29	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
HNSC	cis	rs6918586	0.658	rs1572982	ENSG00000272462.2	U91328.19	6.52	1.83e-10	1.04e-07	0.27	0.29	Schizophrenia;	chr6:26094139	chr6:25992662~26001775:+
HNSC	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-6.52	1.83e-10	1.04e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
HNSC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	6.52	1.83e-10	1.04e-07	0.27	0.29	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
HNSC	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66679692	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	6.52	1.83e-10	1.04e-07	0.41	0.29	Gout;	chr7:66682070	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	6.52	1.83e-10	1.04e-07	0.41	0.29	Gout;	chr7:66682162	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66692349	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66693433	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66694214	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66701371	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66702658	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66706390	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-6.52	1.83e-10	1.04e-07	-0.41	-0.29	Gout;	chr7:66710076	chr7:66902857~66906297:+
HNSC	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-6.52	1.83e-10	1.04e-07	-0.34	-0.29	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
HNSC	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	6.52	1.84e-10	1.04e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
HNSC	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	6.52	1.84e-10	1.04e-07	0.34	0.29	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
HNSC	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-6.52	1.84e-10	1.04e-07	-0.31	-0.29	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
HNSC	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-6.52	1.84e-10	1.04e-07	-0.31	-0.29	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
HNSC	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-6.52	1.84e-10	1.04e-07	-0.35	-0.29	Height;	chr4:55364952	chr4:55387949~55388271:+
HNSC	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	6.52	1.84e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
HNSC	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	6.52	1.84e-10	1.05e-07	0.42	0.29	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	6.52	1.85e-10	1.05e-07	0.19	0.29	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-6.52	1.85e-10	1.05e-07	-0.37	-0.29	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
HNSC	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-6.52	1.85e-10	1.05e-07	-0.29	-0.29	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
HNSC	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	6.52	1.85e-10	1.05e-07	0.34	0.29	Depression;	chr6:28301886	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	6.52	1.85e-10	1.05e-07	0.42	0.29	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	6.52	1.85e-10	1.05e-07	0.42	0.29	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
HNSC	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	6.52	1.85e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	6.52	1.85e-10	1.05e-07	0.33	0.29	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-6.52	1.85e-10	1.05e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
HNSC	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	6.52	1.86e-10	1.05e-07	0.44	0.29	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
HNSC	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-6.52	1.86e-10	1.05e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
HNSC	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-6.52	1.86e-10	1.05e-07	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
HNSC	cis	rs7819412	0.594	rs7460507	ENSG00000269918.1	AF131215.9	-6.52	1.86e-10	1.06e-07	-0.29	-0.29	Triglycerides;	chr8:11111565	chr8:11104691~11106704:-
HNSC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	6.52	1.87e-10	1.06e-07	0.32	0.29	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
HNSC	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	6.52	1.87e-10	1.06e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
HNSC	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	6.52	1.87e-10	1.06e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
HNSC	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	6.52	1.87e-10	1.06e-07	0.33	0.29	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	6.52	1.87e-10	1.06e-07	0.33	0.29	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-6.52	1.88e-10	1.06e-07	-0.34	-0.29	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
HNSC	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	6.52	1.88e-10	1.06e-07	0.36	0.29	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
HNSC	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	6.52	1.88e-10	1.06e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
HNSC	cis	rs2235642	0.893	rs2076439	ENSG00000280231.1	LA16c-380F5.3	-6.52	1.88e-10	1.07e-07	-0.35	-0.29	Coronary artery disease;	chr16:1537276	chr16:1553655~1554130:-
HNSC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-6.52	1.88e-10	1.07e-07	-0.23	-0.29	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
HNSC	cis	rs2919917	1	rs4739134	ENSG00000254352.1	RP11-578O24.2	6.52	1.88e-10	1.07e-07	0.36	0.29	Lymphocyte counts;	chr8:78643913	chr8:78723796~78724136:-
HNSC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	6.51	1.89e-10	1.07e-07	0.36	0.29	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
HNSC	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	6.51	1.89e-10	1.07e-07	0.33	0.29	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	6.51	1.89e-10	1.07e-07	0.34	0.29	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	6.51	1.89e-10	1.07e-07	0.34	0.29	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
HNSC	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-6.51	1.89e-10	1.07e-07	-0.21	-0.29	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
HNSC	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-6.51	1.89e-10	1.07e-07	-0.21	-0.29	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
HNSC	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.51	1.9e-10	1.08e-07	0.42	0.29	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
HNSC	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	6.51	1.91e-10	1.08e-07	0.33	0.29	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
HNSC	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	6.51	1.91e-10	1.08e-07	0.41	0.29	Height;	chr6:109373851	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	6.51	1.91e-10	1.08e-07	0.41	0.29	Height;	chr6:109375848	chr6:109382795~109383666:+
HNSC	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-6.51	1.91e-10	1.08e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
HNSC	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	6.51	1.91e-10	1.08e-07	0.34	0.29	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
HNSC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.51	1.92e-10	1.08e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.51	1.92e-10	1.08e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
HNSC	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-6.51	1.92e-10	1.09e-07	-0.33	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	6.51	1.92e-10	1.09e-07	0.46	0.29	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
HNSC	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	6.51	1.92e-10	1.09e-07	0.78	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
HNSC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-6.51	1.92e-10	1.09e-07	-0.36	-0.29	QT interval;	chr16:28877088	chr16:28700294~28701540:-
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	6.51	1.93e-10	1.09e-07	0.43	0.29	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
HNSC	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	6.51	1.93e-10	1.09e-07	0.33	0.29	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
HNSC	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.51	1.93e-10	1.09e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
HNSC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6.51	1.93e-10	1.09e-07	0.29	0.29	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
HNSC	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-6.51	1.93e-10	1.09e-07	-0.35	-0.29	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
HNSC	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-6.51	1.93e-10	1.09e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
HNSC	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	6.51	1.93e-10	1.09e-07	0.36	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
HNSC	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.51	1.94e-10	1.09e-07	0.34	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
HNSC	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.51	1.94e-10	1.09e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
HNSC	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-6.51	1.94e-10	1.09e-07	-0.52	-0.29	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
HNSC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-6.51	1.94e-10	1.09e-07	-0.37	-0.29	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
HNSC	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	6.51	1.94e-10	1.09e-07	0.57	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
HNSC	cis	rs7309	0.622	rs4664395	ENSG00000227403.1	AC009299.3	-6.51	1.94e-10	1.1e-07	-0.39	-0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161244739~161249050:+
HNSC	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	6.51	1.95e-10	1.1e-07	0.35	0.29	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
HNSC	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-6.51	1.95e-10	1.1e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
HNSC	cis	rs9402743	1	rs9402743	ENSG00000217482.2	HMGB1P17	6.51	1.95e-10	1.1e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135679896	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.816	rs7757431	ENSG00000217482.2	HMGB1P17	6.51	1.95e-10	1.1e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135680422	chr6:135636086~135636713:-
HNSC	cis	rs2579103	0.728	rs1371088	ENSG00000258183.4	RP11-753N8.1	-6.51	1.95e-10	1.1e-07	-0.36	-0.29	Body mass index;	chr12:90266956	chr12:90280894~90300340:+
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000173295.6	FAM86B3P	6.51	1.96e-10	1.1e-07	0.33	0.29	Neuroticism;	chr8:8866905	chr8:8228595~8244865:+
HNSC	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	6.51	1.96e-10	1.11e-07	0.32	0.29	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
HNSC	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-6.51	1.96e-10	1.11e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
HNSC	cis	rs35955747	0.902	rs11703927	ENSG00000236132.1	CTA-440B3.1	6.51	1.96e-10	1.11e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31248978	chr22:31816379~31817491:-
HNSC	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	6.51	1.96e-10	1.11e-07	0.29	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-6.51	1.96e-10	1.11e-07	-0.34	-0.29	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
HNSC	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-6.51	1.97e-10	1.11e-07	-0.42	-0.29	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
HNSC	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	6.51	1.97e-10	1.11e-07	0.42	0.29	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	6.51	1.97e-10	1.11e-07	0.33	0.29	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	6.51	1.97e-10	1.11e-07	0.33	0.29	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
HNSC	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	6.51	1.97e-10	1.11e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
HNSC	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	6.51	1.97e-10	1.11e-07	0.33	0.29	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
HNSC	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-6.51	1.97e-10	1.11e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
HNSC	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.51	1.97e-10	1.11e-07	0.34	0.29	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
HNSC	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-6.51	1.98e-10	1.12e-07	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
HNSC	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	6.51	1.98e-10	1.12e-07	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
HNSC	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	6.51	1.98e-10	1.12e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
HNSC	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-6.51	1.99e-10	1.12e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
HNSC	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-6.51	1.99e-10	1.12e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
HNSC	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	6.51	2e-10	1.12e-07	0.33	0.29	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
HNSC	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	6.51	2e-10	1.13e-07	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
HNSC	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	6.51	2e-10	1.13e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
HNSC	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-6.5	2e-10	1.13e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
HNSC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.5	2.01e-10	1.13e-07	-0.32	-0.29	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
HNSC	cis	rs860295	1	rs822478	ENSG00000203761.5	MSTO2P	6.5	2.02e-10	1.14e-07	0.21	0.29	Body mass index;	chr1:155824178	chr1:155745829~155750137:+
HNSC	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	6.5	2.02e-10	1.14e-07	0.26	0.29	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
HNSC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	6.5	2.02e-10	1.14e-07	0.45	0.29	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000267151.3	RP11-100E5.2	6.5	2.02e-10	1.14e-07	0.37	0.29	Menopause (age at onset);	chr17:43105117	chr17:43444707~43451200:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	6.5	2.02e-10	1.14e-07	0.22	0.29	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
HNSC	cis	rs2579103	0.767	rs2247166	ENSG00000258183.4	RP11-753N8.1	-6.5	2.03e-10	1.14e-07	-0.36	-0.29	Body mass index;	chr12:90267489	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.767	rs1595601	ENSG00000258183.4	RP11-753N8.1	-6.5	2.03e-10	1.14e-07	-0.36	-0.29	Body mass index;	chr12:90267591	chr12:90280894~90300340:+
HNSC	cis	rs6471393	0.798	rs62525169	ENSG00000253848.1	RP11-10N23.5	6.5	2.03e-10	1.14e-07	0.39	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93741193~93744534:+
HNSC	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	6.5	2.03e-10	1.14e-07	0.46	0.29	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
HNSC	cis	rs8054556	0.74	rs9936474	ENSG00000183604.13	SMG1P5	-6.5	2.03e-10	1.14e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30267553~30335374:-
HNSC	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	6.5	2.03e-10	1.14e-07	0.39	0.29	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-6.5	2.03e-10	1.14e-07	-0.19	-0.29	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
HNSC	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	6.5	2.03e-10	1.14e-07	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
HNSC	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-6.5	2.03e-10	1.14e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
HNSC	cis	rs6951245	1	rs76833820	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs28379681	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs28399710	ENSG00000225146.1	AC073957.15	-6.5	2.03e-10	1.14e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1029025~1043891:+
HNSC	cis	rs35955747	0.902	rs140074	ENSG00000236132.1	CTA-440B3.1	-6.5	2.03e-10	1.15e-07	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31329648	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-6.5	2.04e-10	1.15e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
HNSC	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.5	2.04e-10	1.15e-07	0.34	0.29	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
HNSC	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	6.5	2.04e-10	1.15e-07	0.43	0.29	Depression;	chr6:28261633	chr6:28115628~28116551:+
HNSC	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-6.5	2.04e-10	1.15e-07	-0.36	-0.29	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
HNSC	cis	rs7587476	0.505	rs6435862	ENSG00000229267.2	AC072062.1	6.5	2.05e-10	1.15e-07	0.37	0.29	Neuroblastoma;	chr2:214807822	chr2:214810229~214963274:+
HNSC	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	6.5	2.05e-10	1.15e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.529	rs5749298	ENSG00000236132.1	CTA-440B3.1	-6.5	2.05e-10	1.15e-07	-0.37	-0.29	Colorectal cancer;	chr22:31545046	chr22:31816379~31817491:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000267151.3	RP11-100E5.2	6.5	2.05e-10	1.15e-07	0.37	0.29	Menopause (age at onset);	chr17:43047896	chr17:43444707~43451200:+
HNSC	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-6.5	2.05e-10	1.15e-07	-0.33	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000255769.6	GOLGA2P10	-6.5	2.06e-10	1.16e-07	-0.44	-0.29	Excessive daytime sleepiness;	chr15:82715317	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-6.5	2.06e-10	1.16e-07	-0.28	-0.29	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-6.5	2.07e-10	1.16e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
HNSC	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-6.5	2.07e-10	1.16e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
HNSC	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-6.5	2.07e-10	1.16e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-6.5	2.07e-10	1.16e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
HNSC	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-6.5	2.07e-10	1.16e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
HNSC	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	6.5	2.07e-10	1.16e-07	0.35	0.29	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
HNSC	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	6.5	2.07e-10	1.16e-07	0.34	0.29	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
HNSC	cis	rs12439619	0.846	rs62013464	ENSG00000276710.3	CSPG4P8	-6.5	2.07e-10	1.16e-07	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82459472~82477258:+
HNSC	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-6.5	2.07e-10	1.17e-07	-0.34	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
HNSC	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	6.5	2.07e-10	1.17e-07	0.46	0.29	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
HNSC	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-6.5	2.08e-10	1.17e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
HNSC	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-6.5	2.08e-10	1.17e-07	-0.41	-0.29	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	6.5	2.08e-10	1.17e-07	0.33	0.29	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.08e-10	1.17e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
HNSC	cis	rs5753618	0.504	rs7284622	ENSG00000236132.1	CTA-440B3.1	-6.5	2.08e-10	1.17e-07	-0.36	-0.29	Colorectal cancer;	chr22:31511999	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-6.5	2.09e-10	1.17e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-6.5	2.09e-10	1.17e-07	-0.27	-0.29	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-6.5	2.09e-10	1.17e-07	-0.33	-0.29	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
HNSC	cis	rs35955747	0.902	rs739427	ENSG00000236132.1	CTA-440B3.1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31263115	chr22:31816379~31817491:-
HNSC	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.5	2.09e-10	1.17e-07	0.38	0.29	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
HNSC	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
HNSC	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-6.5	2.09e-10	1.17e-07	-0.32	-0.29	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
HNSC	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	6.5	2.09e-10	1.17e-07	0.34	0.29	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
HNSC	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
HNSC	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	6.5	2.09e-10	1.17e-07	0.42	0.29	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
HNSC	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-6.5	2.09e-10	1.17e-07	-0.37	-0.29	Height;	chr3:53029908	chr3:53064283~53065091:-
HNSC	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	6.5	2.09e-10	1.18e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-6.5	2.09e-10	1.18e-07	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
HNSC	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	6.5	2.09e-10	1.18e-07	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
HNSC	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-6.5	2.1e-10	1.18e-07	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
HNSC	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	6.5	2.1e-10	1.18e-07	0.41	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
HNSC	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	6.5	2.1e-10	1.18e-07	0.44	0.29	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
HNSC	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	6.5	2.1e-10	1.18e-07	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
HNSC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	6.5	2.11e-10	1.18e-07	0.32	0.29	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	6.5	2.11e-10	1.18e-07	0.35	0.29	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
HNSC	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.5	2.11e-10	1.19e-07	-0.36	-0.29	Height;	chr3:52975027	chr3:53064283~53065091:-
HNSC	cis	rs5753618	0.509	rs5997902	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31187021	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs4820951	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31190262	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5749229	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31191232	chr22:31816379~31817491:-
HNSC	cis	rs4141404	0.787	rs4820042	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Paclitaxel-induced neuropathy;	chr22:31193070	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5997912	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31197875	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.509	rs5997913	ENSG00000236132.1	CTA-440B3.1	6.5	2.12e-10	1.19e-07	0.35	0.29	Colorectal cancer;	chr22:31197973	chr22:31816379~31817491:-
HNSC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-6.5	2.12e-10	1.19e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
HNSC	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-6.5	2.12e-10	1.19e-07	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
HNSC	cis	rs8177876	0.658	rs16954505	ENSG00000261061.1	RP11-303E16.2	-6.5	2.13e-10	1.19e-07	-0.5	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81030770~81031485:+
HNSC	cis	rs4218	0.648	rs57361749	ENSG00000259732.1	RP11-59H7.3	-6.5	2.13e-10	1.19e-07	-0.4	-0.29	Social communication problems;	chr15:59091352	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.608	rs16941014	ENSG00000259732.1	RP11-59H7.3	-6.5	2.13e-10	1.19e-07	-0.4	-0.29	Social communication problems;	chr15:59091503	chr15:59121034~59133250:+
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	6.49	2.13e-10	1.19e-07	0.69	0.29	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
HNSC	cis	rs4273100	1	rs16960499	ENSG00000265185.4	SNORD3B-1	6.49	2.13e-10	1.2e-07	0.44	0.29	Schizophrenia;	chr17:19299719	chr17:19061912~19062669:+
HNSC	cis	rs7615952	0.641	rs7632497	ENSG00000241288.6	RP11-379B18.5	-6.49	2.13e-10	1.2e-07	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126064243	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.49	2.13e-10	1.2e-07	-0.27	-0.29	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	6.49	2.13e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-6.49	2.13e-10	1.2e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
HNSC	cis	rs947583	0.588	rs9494360	ENSG00000217482.2	HMGB1P17	6.49	2.14e-10	1.2e-07	0.33	0.29	Phosphorus levels;	chr6:135755906	chr6:135636086~135636713:-
HNSC	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-6.49	2.14e-10	1.2e-07	-0.37	-0.29	Height;	chr3:53097932	chr3:53064283~53065091:-
HNSC	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-6.49	2.14e-10	1.2e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
HNSC	cis	rs5753618	0.509	rs2413033	ENSG00000236132.1	CTA-440B3.1	6.49	2.14e-10	1.2e-07	0.35	0.29	Colorectal cancer;	chr22:31178227	chr22:31816379~31817491:-
HNSC	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	6.49	2.15e-10	1.2e-07	0.33	0.29	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
HNSC	cis	rs2579103	0.66	rs3860258	ENSG00000258183.4	RP11-753N8.1	-6.49	2.15e-10	1.2e-07	-0.38	-0.29	Body mass index;	chr12:90316847	chr12:90280894~90300340:+
HNSC	cis	rs2235642	0.893	rs2076440	ENSG00000280231.1	LA16c-380F5.3	-6.49	2.15e-10	1.2e-07	-0.35	-0.29	Coronary artery disease;	chr16:1537321	chr16:1553655~1554130:-
HNSC	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	6.49	2.15e-10	1.21e-07	0.42	0.29	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
HNSC	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	6.49	2.16e-10	1.21e-07	0.38	0.29	Height;	chr6:109430398	chr6:109382795~109383666:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000267151.3	RP11-100E5.2	-6.49	2.17e-10	1.21e-07	-0.36	-0.29	Menopause (age at onset);	chr17:43091173	chr17:43444707~43451200:+
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-6.49	2.17e-10	1.22e-07	-0.35	-0.29	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
HNSC	cis	rs860295	1	rs860295	ENSG00000203761.5	MSTO2P	6.49	2.18e-10	1.22e-07	0.21	0.29	Body mass index;	chr1:155797917	chr1:155745829~155750137:+
HNSC	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-6.49	2.18e-10	1.22e-07	-0.42	-0.29	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-6.49	2.18e-10	1.22e-07	-0.42	-0.29	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
HNSC	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-6.49	2.19e-10	1.22e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-6.49	2.19e-10	1.22e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
HNSC	cis	rs7615952	1	rs9289275	ENSG00000248787.1	RP11-666A20.4	-6.49	2.19e-10	1.22e-07	-0.43	-0.29	Blood pressure (smoking interaction);	chr3:125929816	chr3:125908005~125910272:-
HNSC	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	6.49	2.2e-10	1.23e-07	0.4	0.29	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
HNSC	cis	rs451417	0.818	rs236111	ENSG00000275632.1	RP5-967N21.11	6.49	2.2e-10	1.23e-07	0.39	0.29	Menopause (age at onset);	chr20:5952889	chr20:6000418~6000941:+
HNSC	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-6.49	2.2e-10	1.23e-07	-0.31	-0.29	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
HNSC	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	6.49	2.21e-10	1.23e-07	0.41	0.29	Height;	chr6:109769861	chr6:109382795~109383666:+
HNSC	cis	rs860295	1	rs822527	ENSG00000203761.5	MSTO2P	6.49	2.21e-10	1.23e-07	0.21	0.29	Body mass index;	chr1:155768262	chr1:155745829~155750137:+
HNSC	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-6.49	2.21e-10	1.24e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
HNSC	cis	rs860295	1	rs10908482	ENSG00000203761.5	MSTO2P	-6.49	2.21e-10	1.24e-07	-0.21	-0.29	Body mass index;	chr1:155744082	chr1:155745829~155750137:+
HNSC	cis	rs4218	0.648	rs58087223	ENSG00000259732.1	RP11-59H7.3	-6.49	2.21e-10	1.24e-07	-0.42	-0.29	Social communication problems;	chr15:59075132	chr15:59121034~59133250:+
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-6.49	2.22e-10	1.24e-07	-0.19	-0.29	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
HNSC	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	6.49	2.22e-10	1.24e-07	0.29	0.29	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-6.49	2.22e-10	1.24e-07	-0.34	-0.29	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
HNSC	cis	rs2579103	0.767	rs1347842	ENSG00000258183.4	RP11-753N8.1	-6.49	2.22e-10	1.24e-07	-0.38	-0.29	Body mass index;	chr12:90270298	chr12:90280894~90300340:+
HNSC	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-6.49	2.23e-10	1.24e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
HNSC	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	6.49	2.23e-10	1.24e-07	0.32	0.29	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
HNSC	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-6.49	2.23e-10	1.25e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
HNSC	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	6.49	2.24e-10	1.25e-07	0.27	0.29	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
HNSC	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	6.49	2.24e-10	1.25e-07	0.33	0.29	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
HNSC	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	6.49	2.25e-10	1.26e-07	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
HNSC	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.49	2.26e-10	1.26e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
HNSC	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	6.49	2.26e-10	1.26e-07	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	6.49	2.26e-10	1.26e-07	0.22	0.29	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	6.48	2.26e-10	1.26e-07	0.32	0.29	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
HNSC	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	6.48	2.27e-10	1.27e-07	0.76	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
HNSC	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	6.48	2.27e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.539	rs2106294	ENSG00000236132.1	CTA-440B3.1	6.48	2.27e-10	1.27e-07	0.35	0.29	Colorectal cancer;	chr22:31249773	chr22:31816379~31817491:-
HNSC	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-6.48	2.27e-10	1.27e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
HNSC	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-6.48	2.28e-10	1.27e-07	-0.33	-0.29	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	6.48	2.28e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	6.48	2.28e-10	1.27e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	6.48	2.28e-10	1.28e-07	0.71	0.29	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
HNSC	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	6.48	2.28e-10	1.28e-07	0.71	0.29	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-6.48	2.28e-10	1.28e-07	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
HNSC	cis	rs6951245	1	rs74652290	ENSG00000225146.1	AC073957.15	-6.48	2.29e-10	1.28e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1029025~1043891:+
HNSC	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-6.48	2.29e-10	1.28e-07	-0.37	-0.29	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
HNSC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-6.48	2.29e-10	1.28e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
HNSC	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-6.48	2.29e-10	1.28e-07	-0.38	-0.29	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
HNSC	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	6.48	2.3e-10	1.28e-07	0.46	0.29	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
HNSC	cis	rs2235642	0.826	rs8048410	ENSG00000280231.1	LA16c-380F5.3	-6.48	2.3e-10	1.28e-07	-0.36	-0.29	Coronary artery disease;	chr16:1564096	chr16:1553655~1554130:-
HNSC	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-6.48	2.3e-10	1.28e-07	-0.45	-0.29	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	6.48	2.31e-10	1.29e-07	0.33	0.29	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.27	0.29	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
HNSC	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.48	2.31e-10	1.29e-07	0.3	0.29	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
HNSC	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-6.48	2.31e-10	1.29e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
HNSC	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-6.48	2.31e-10	1.29e-07	-0.37	-0.29	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.31e-10	1.29e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
HNSC	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.28	0.29	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	6.48	2.31e-10	1.29e-07	0.28	0.29	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
HNSC	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-6.48	2.32e-10	1.29e-07	-0.42	-0.29	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
HNSC	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-6.48	2.32e-10	1.29e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.32e-10	1.29e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.54	rs2329931	ENSG00000211638.2	IGLV8-61	-6.48	2.32e-10	1.29e-07	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.568	rs2876996	ENSG00000211638.2	IGLV8-61	-6.48	2.32e-10	1.29e-07	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22098700~22099212:+
HNSC	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-6.48	2.32e-10	1.29e-07	-0.34	-0.29	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
HNSC	cis	rs11992162	0.636	rs4841642	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11940825	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.636	rs4841646	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11941198	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.613	rs6998690	ENSG00000206014.6	OR7E161P	-6.48	2.33e-10	1.3e-07	-0.31	-0.29	Monocyte count;	chr8:11941287	chr8:11928597~11929563:-
HNSC	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-6.48	2.33e-10	1.3e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	6.48	2.33e-10	1.3e-07	0.33	0.29	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	6.48	2.33e-10	1.3e-07	0.33	0.29	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
HNSC	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	6.48	2.34e-10	1.3e-07	0.48	0.29	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
HNSC	cis	rs11992162	0.569	rs11786149	ENSG00000206014.6	OR7E161P	6.48	2.34e-10	1.3e-07	0.31	0.29	Monocyte count;	chr8:11943309	chr8:11928597~11929563:-
HNSC	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-6.48	2.34e-10	1.3e-07	-0.29	-0.29	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
HNSC	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	6.48	2.34e-10	1.31e-07	0.39	0.29	Height;	chr6:109423238	chr6:109382795~109383666:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	6.48	2.34e-10	1.31e-07	0.41	0.29	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
HNSC	cis	rs394563	0.726	rs6906384	ENSG00000231760.4	RP11-350J20.5	-6.48	2.34e-10	1.31e-07	-0.36	-0.29	Dupuytren's disease;	chr6:149343404	chr6:149796151~149826294:-
HNSC	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-6.48	2.34e-10	1.31e-07	-0.33	-0.29	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
HNSC	cis	rs6471393	0.862	rs11994625	ENSG00000253848.1	RP11-10N23.5	6.48	2.35e-10	1.31e-07	0.36	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93760149	chr8:93741193~93744534:+
HNSC	cis	rs6471393	0.83	rs6981752	ENSG00000253848.1	RP11-10N23.5	6.48	2.35e-10	1.31e-07	0.36	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761046	chr8:93741193~93744534:+
HNSC	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-6.48	2.35e-10	1.31e-07	-0.24	-0.29	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
HNSC	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.48	2.35e-10	1.31e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
HNSC	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	6.48	2.36e-10	1.31e-07	0.35	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
HNSC	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	6.48	2.38e-10	1.32e-07	0.34	0.29	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
HNSC	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	6.48	2.38e-10	1.32e-07	0.42	0.29	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
HNSC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.48	2.39e-10	1.33e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
HNSC	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	6.48	2.39e-10	1.33e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
HNSC	cis	rs9402743	0.702	rs9399150	ENSG00000217482.2	HMGB1P17	6.48	2.39e-10	1.33e-07	0.32	0.29	Systemic lupus erythematosus;	chr6:135599752	chr6:135636086~135636713:-
HNSC	cis	rs7621025	0.69	rs11715257	ENSG00000273486.1	RP11-731C17.2	6.48	2.39e-10	1.33e-07	0.26	0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	6.48	2.39e-10	1.33e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
HNSC	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-6.48	2.39e-10	1.33e-07	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
HNSC	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-6.48	2.39e-10	1.33e-07	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
HNSC	cis	rs9341808	0.667	rs7745301	ENSG00000272129.1	RP11-250B2.6	6.48	2.4e-10	1.33e-07	0.34	0.29	Sitting height ratio;	chr6:80212844	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-6.48	2.4e-10	1.33e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
HNSC	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-6.48	2.4e-10	1.33e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
HNSC	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	6.48	2.4e-10	1.33e-07	0.33	0.29	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
HNSC	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	6.48	2.4e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
HNSC	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.4e-10	1.34e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
HNSC	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-6.48	2.4e-10	1.34e-07	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
HNSC	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	6.47	2.41e-10	1.34e-07	0.33	0.29	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
HNSC	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-6.47	2.42e-10	1.34e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
HNSC	cis	rs8177876	0.822	rs7203546	ENSG00000261061.1	RP11-303E16.2	6.47	2.43e-10	1.35e-07	0.44	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81030770~81031485:+
HNSC	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	6.47	2.43e-10	1.35e-07	0.37	0.29	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
HNSC	cis	rs4273100	0.526	rs2074280	ENSG00000265185.4	SNORD3B-1	6.47	2.43e-10	1.35e-07	0.37	0.29	Schizophrenia;	chr17:19014602	chr17:19061912~19062669:+
HNSC	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	6.47	2.43e-10	1.35e-07	0.45	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-6.47	2.43e-10	1.35e-07	-0.25	-0.29	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
HNSC	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-6.47	2.44e-10	1.35e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
HNSC	cis	rs7083	0.967	rs477269	ENSG00000254851.1	RP11-109L13.1	6.47	2.44e-10	1.35e-07	0.37	0.29	Blood protein levels;	chr11:117267575	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-6.47	2.44e-10	1.36e-07	-0.36	-0.29	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
HNSC	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	6.47	2.44e-10	1.36e-07	0.33	0.29	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.36e-07	0.25	0.29	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.36e-07	0.25	0.29	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
HNSC	cis	rs6951245	1	rs77083167	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs74347384	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78308415	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs75493422	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs118059236	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113858334	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79765398	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79443843	ENSG00000225146.1	AC073957.15	-6.47	2.45e-10	1.36e-07	-0.49	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1029025~1043891:+
HNSC	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-6.47	2.46e-10	1.36e-07	-0.46	-0.29	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
HNSC	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-6.47	2.46e-10	1.36e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
HNSC	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.36e-07	-0.47	-0.29	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.36e-07	-0.47	-0.29	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
HNSC	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
HNSC	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-6.47	2.46e-10	1.37e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
HNSC	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.46e-10	1.37e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
HNSC	cis	rs10791097	0.935	rs4601795	ENSG00000254842.5	RP11-890B15.2	-6.47	2.46e-10	1.37e-07	-0.25	-0.29	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130859535	chr11:130844191~130865561:-
HNSC	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-6.47	2.47e-10	1.37e-07	-0.35	-0.29	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
HNSC	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	6.47	2.47e-10	1.37e-07	0.34	0.29	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
HNSC	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-6.47	2.47e-10	1.37e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
HNSC	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-6.47	2.48e-10	1.37e-07	-0.4	-0.29	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
HNSC	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-6.47	2.48e-10	1.38e-07	-0.32	-0.29	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
HNSC	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-6.47	2.48e-10	1.38e-07	-0.33	-0.29	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-6.47	2.48e-10	1.38e-07	-0.33	-0.29	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
HNSC	cis	rs9402743	0.671	rs2327650	ENSG00000217482.2	HMGB1P17	6.47	2.48e-10	1.38e-07	0.32	0.29	Systemic lupus erythematosus;	chr6:135630279	chr6:135636086~135636713:-
HNSC	cis	rs2579103	0.595	rs3849229	ENSG00000258183.4	RP11-753N8.1	-6.47	2.49e-10	1.38e-07	-0.37	-0.29	Body mass index;	chr12:90317586	chr12:90280894~90300340:+
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000267151.3	RP11-100E5.2	6.47	2.49e-10	1.38e-07	0.37	0.29	Menopause (age at onset);	chr17:43334882	chr17:43444707~43451200:+
HNSC	cis	rs17270561	0.636	rs2070642	ENSG00000272462.2	U91328.19	-6.47	2.49e-10	1.38e-07	-0.29	-0.29	Iron status biomarkers;	chr6:25830984	chr6:25992662~26001775:+
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	6.47	2.49e-10	1.38e-07	0.71	0.29	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
HNSC	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	6.47	2.5e-10	1.38e-07	0.31	0.29	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
HNSC	cis	rs9341808	0.905	rs3805903	ENSG00000272129.1	RP11-250B2.6	6.47	2.51e-10	1.39e-07	0.34	0.29	Sitting height ratio;	chr6:80266112	chr6:80355424~80356859:+
HNSC	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.54e-10	1.4e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
HNSC	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-6.47	2.54e-10	1.41e-07	-0.29	-0.29	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
HNSC	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-6.47	2.54e-10	1.41e-07	-0.29	-0.29	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
HNSC	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	6.47	2.54e-10	1.41e-07	0.33	0.29	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	6.47	2.54e-10	1.41e-07	0.33	0.29	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
HNSC	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-6.47	2.54e-10	1.41e-07	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
HNSC	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	6.47	2.55e-10	1.41e-07	0.42	0.29	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
HNSC	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	6.47	2.55e-10	1.41e-07	0.32	0.29	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	6.46	2.56e-10	1.42e-07	0.71	0.29	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	6.46	2.56e-10	1.42e-07	0.71	0.29	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
HNSC	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-6.46	2.57e-10	1.42e-07	-0.3	-0.29	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
HNSC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-6.46	2.57e-10	1.42e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
HNSC	cis	rs11992162	0.636	rs4841644	ENSG00000206014.6	OR7E161P	-6.46	2.57e-10	1.42e-07	-0.31	-0.29	Monocyte count;	chr8:11940924	chr8:11928597~11929563:-
HNSC	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-6.46	2.58e-10	1.43e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
HNSC	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	6.46	2.58e-10	1.43e-07	0.29	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
HNSC	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	6.46	2.58e-10	1.43e-07	0.36	0.29	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
HNSC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-6.46	2.58e-10	1.43e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-6.46	2.58e-10	1.43e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
HNSC	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	6.46	2.58e-10	1.43e-07	0.4	0.29	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	6.46	2.58e-10	1.43e-07	0.33	0.29	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
HNSC	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6.46	2.58e-10	1.43e-07	0.28	0.29	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6.46	2.58e-10	1.43e-07	0.28	0.29	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
HNSC	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
HNSC	cis	rs9326248	0.53	rs17120139	ENSG00000280143.1	AP000892.6	-6.46	2.59e-10	1.43e-07	-0.45	-0.29	Blood protein levels;	chr11:116903485	chr11:117204967~117210292:+
HNSC	cis	rs6951245	0.554	rs11761322	ENSG00000224079.1	AC091729.7	-6.46	2.59e-10	1.43e-07	-0.38	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
HNSC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	6.46	2.59e-10	1.43e-07	0.3	0.29	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.59e-10	1.43e-07	-0.31	-0.29	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	6.46	2.59e-10	1.43e-07	0.39	0.29	Height;	chr6:109380457	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	6.46	2.59e-10	1.43e-07	0.39	0.29	Height;	chr6:109380990	chr6:109382795~109383666:+
HNSC	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	6.46	2.6e-10	1.44e-07	0.36	0.29	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
HNSC	cis	rs6951245	1	rs2363286	ENSG00000225146.1	AC073957.15	-6.46	2.6e-10	1.44e-07	-0.48	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1029025~1043891:+
HNSC	cis	rs35955747	0.902	rs5997929	ENSG00000236132.1	CTA-440B3.1	6.46	2.6e-10	1.44e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31268046	chr22:31816379~31817491:-
HNSC	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-6.46	2.6e-10	1.44e-07	-0.39	-0.29	Height;	chr6:109380015	chr6:109382795~109383666:+
HNSC	cis	rs6928977	0.896	rs2246943	ENSG00000234084.1	RP3-388E23.2	6.46	2.61e-10	1.44e-07	0.29	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135301568~135307158:+
HNSC	cis	rs9341808	0.667	rs742833	ENSG00000272129.1	RP11-250B2.6	6.46	2.61e-10	1.44e-07	0.33	0.29	Sitting height ratio;	chr6:80211729	chr6:80355424~80356859:+
HNSC	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-6.46	2.61e-10	1.44e-07	-0.41	-0.29	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
HNSC	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-6.46	2.61e-10	1.44e-07	-0.46	-0.29	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
HNSC	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	6.46	2.61e-10	1.44e-07	0.32	0.29	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
HNSC	cis	rs17270561	0.609	rs4711094	ENSG00000272462.2	U91328.19	-6.46	2.62e-10	1.45e-07	-0.29	-0.29	Iron status biomarkers;	chr6:25705946	chr6:25992662~26001775:+
HNSC	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-6.46	2.62e-10	1.45e-07	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
HNSC	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	6.46	2.63e-10	1.45e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
HNSC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	6.46	2.64e-10	1.45e-07	0.33	0.29	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
HNSC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	6.46	2.64e-10	1.45e-07	0.34	0.29	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
HNSC	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	6.46	2.64e-10	1.46e-07	0.26	0.29	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-6.46	2.64e-10	1.46e-07	-0.31	-0.29	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
HNSC	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	6.46	2.64e-10	1.46e-07	0.27	0.29	Asthma;	chr2:102440033	chr2:102438713~102440475:+
HNSC	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	6.46	2.65e-10	1.46e-07	0.34	0.29	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
HNSC	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	6.46	2.65e-10	1.46e-07	0.38	0.29	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	6.46	2.65e-10	1.46e-07	0.38	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
HNSC	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	6.46	2.65e-10	1.46e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
HNSC	cis	rs2404602	0.692	rs4442773	ENSG00000259422.1	RP11-593F23.1	6.46	2.66e-10	1.47e-07	0.33	0.29	Blood metabolite levels;	chr15:76739292	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-6.46	2.67e-10	1.47e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	6.46	2.67e-10	1.47e-07	0.48	0.29	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
HNSC	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-6.46	2.67e-10	1.47e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
HNSC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.46	2.67e-10	1.47e-07	-0.32	-0.29	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
HNSC	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	6.46	2.67e-10	1.47e-07	0.36	0.29	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
HNSC	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	6.46	2.68e-10	1.48e-07	0.31	0.29	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
HNSC	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.46	2.68e-10	1.48e-07	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
HNSC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	6.46	2.68e-10	1.48e-07	0.36	0.29	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
HNSC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-6.46	2.68e-10	1.48e-07	-0.3	-0.29	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
HNSC	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-6.46	2.69e-10	1.48e-07	-0.27	-0.29	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
HNSC	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-6.46	2.69e-10	1.48e-07	-0.38	-0.29	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
HNSC	cis	rs35955747	0.902	rs713947	ENSG00000236132.1	CTA-440B3.1	6.46	2.69e-10	1.48e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31243523	chr22:31816379~31817491:-
HNSC	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-6.46	2.7e-10	1.49e-07	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
HNSC	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-6.46	2.7e-10	1.49e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-6.46	2.7e-10	1.49e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
HNSC	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-6.46	2.71e-10	1.49e-07	-0.41	-0.29	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
HNSC	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	6.46	2.71e-10	1.49e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
HNSC	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-6.46	2.71e-10	1.49e-07	-0.36	-0.29	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
HNSC	cis	rs3743266	0.507	rs56261931	ENSG00000245534.5	RORA-AS1	-6.46	2.71e-10	1.5e-07	-0.44	-0.29	Menarche (age at onset);	chr15:60439419	chr15:60479178~60630637:+
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000173295.6	FAM86B3P	-6.46	2.71e-10	1.5e-07	-0.33	-0.29	Joint mobility (Beighton score);	chr8:9053494	chr8:8228595~8244865:+
HNSC	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-6.45	2.72e-10	1.5e-07	-0.35	-0.29	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	6.45	2.72e-10	1.5e-07	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-6.45	2.72e-10	1.5e-07	-0.37	-0.29	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
HNSC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6.45	2.73e-10	1.5e-07	-0.29	-0.29	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000211974.3	IGHV2-70	-6.45	2.73e-10	1.51e-07	-0.35	-0.29	Alzheimer's disease (late onset);	chr14:106706726	chr14:106723574~106724093:-
HNSC	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	6.45	2.74e-10	1.51e-07	0.33	0.29	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
HNSC	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	6.45	2.74e-10	1.51e-07	0.34	0.29	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
HNSC	cis	rs4639966	0.836	rs4499035	ENSG00000255422.1	AP002954.4	6.45	2.75e-10	1.51e-07	0.4	0.29	Systemic lupus erythematosus;	chr11:118739754	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.836	rs1893029	ENSG00000255422.1	AP002954.4	6.45	2.75e-10	1.51e-07	0.4	0.29	Systemic lupus erythematosus;	chr11:118740117	chr11:118704607~118750263:+
HNSC	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-6.45	2.75e-10	1.51e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-6.45	2.76e-10	1.52e-07	-0.3	-0.29	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
HNSC	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
HNSC	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	6.45	2.76e-10	1.52e-07	0.34	0.29	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
HNSC	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-6.45	2.76e-10	1.52e-07	-0.54	-0.29	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
HNSC	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-6.45	2.76e-10	1.52e-07	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
HNSC	cis	rs4218	0.681	rs34977427	ENSG00000259732.1	RP11-59H7.3	-6.45	2.77e-10	1.52e-07	-0.4	-0.29	Social communication problems;	chr15:59098172	chr15:59121034~59133250:+
HNSC	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	6.45	2.77e-10	1.52e-07	0.38	0.29	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
HNSC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-6.45	2.77e-10	1.52e-07	-0.31	-0.29	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
HNSC	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-6.45	2.77e-10	1.52e-07	-0.23	-0.29	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
HNSC	cis	rs4218	0.648	rs17236453	ENSG00000259732.1	RP11-59H7.3	-6.45	2.77e-10	1.52e-07	-0.4	-0.29	Social communication problems;	chr15:59092156	chr15:59121034~59133250:+
HNSC	cis	rs7615952	0.641	rs7618515	ENSG00000241288.6	RP11-379B18.5	-6.45	2.78e-10	1.53e-07	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:126071735	chr3:125827238~125916384:-
HNSC	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	6.45	2.78e-10	1.53e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
HNSC	cis	rs9402743	1	rs6570026	ENSG00000217482.2	HMGB1P17	6.45	2.79e-10	1.53e-07	0.31	0.29	Systemic lupus erythematosus;	chr6:135670039	chr6:135636086~135636713:-
HNSC	cis	rs4218	0.648	rs12910987	ENSG00000259732.1	RP11-59H7.3	-6.45	2.79e-10	1.53e-07	-0.4	-0.29	Social communication problems;	chr15:59092782	chr15:59121034~59133250:+
HNSC	cis	rs801193	0.613	rs2016325	ENSG00000179406.6	LINC00174	6.45	2.79e-10	1.53e-07	0.37	0.29	Aortic root size;	chr7:66858513	chr7:66376044~66401338:-
HNSC	cis	rs2985684	0.894	rs6572586	ENSG00000258568.1	RHOQP1	6.45	2.79e-10	1.53e-07	0.29	0.29	Carotid intima media thickness;	chr14:49555223	chr14:49599994~49600572:+
HNSC	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	6.45	2.79e-10	1.53e-07	0.33	0.29	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
HNSC	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-6.45	2.79e-10	1.53e-07	-0.27	-0.29	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
HNSC	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-6.45	2.8e-10	1.54e-07	-0.34	-0.29	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
HNSC	cis	rs6471393	0.792	rs7839522	ENSG00000253848.1	RP11-10N23.5	-6.45	2.81e-10	1.54e-07	-0.38	-0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93827906	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-6.45	2.81e-10	1.54e-07	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
HNSC	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-6.45	2.81e-10	1.54e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
HNSC	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-6.45	2.81e-10	1.54e-07	-0.44	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
HNSC	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-6.45	2.81e-10	1.54e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-6.45	2.82e-10	1.55e-07	-0.33	-0.29	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	6.45	2.82e-10	1.55e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	6.45	2.82e-10	1.55e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
HNSC	cis	rs2115630	0.645	rs6496284	ENSG00000229212.6	RP11-561C5.4	6.45	2.82e-10	1.55e-07	0.34	0.29	P wave terminal force;	chr15:84635039	chr15:85205440~85234795:-
HNSC	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	6.45	2.83e-10	1.55e-07	0.38	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
HNSC	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	6.45	2.83e-10	1.55e-07	0.34	0.29	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
HNSC	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	6.45	2.83e-10	1.55e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
HNSC	cis	rs67180937	0.631	rs1909195	ENSG00000272750.1	RP11-378J18.8	-6.45	2.83e-10	1.55e-07	-0.35	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623985	chr1:222658867~222661512:-
HNSC	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	6.45	2.83e-10	1.55e-07	0.36	0.29	Height;	chr4:55611014	chr4:55387949~55388271:+
HNSC	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-6.45	2.84e-10	1.56e-07	-0.44	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
HNSC	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.84e-10	1.56e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
HNSC	cis	rs5753618	0.509	rs5753500	ENSG00000236132.1	CTA-440B3.1	6.45	2.84e-10	1.56e-07	0.35	0.29	Colorectal cancer;	chr22:31182893	chr22:31816379~31817491:-
HNSC	cis	rs9341808	0.667	rs12209624	ENSG00000272129.1	RP11-250B2.6	6.45	2.84e-10	1.56e-07	0.33	0.29	Sitting height ratio;	chr6:80209416	chr6:80355424~80356859:+
HNSC	cis	rs2842992	0.747	rs4709378	ENSG00000237927.1	RP3-393E18.2	-6.45	2.84e-10	1.56e-07	-0.43	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159806403	chr6:159586955~159589169:-
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-6.45	2.84e-10	1.56e-07	-0.26	-0.29	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
HNSC	cis	rs8054556	0.74	rs8052502	ENSG00000183604.13	SMG1P5	-6.45	2.85e-10	1.56e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29918407	chr16:30267553~30335374:-
HNSC	cis	rs2985684	0.894	rs4900928	ENSG00000258568.1	RHOQP1	6.45	2.85e-10	1.56e-07	0.29	0.29	Carotid intima media thickness;	chr14:49554099	chr14:49599994~49600572:+
HNSC	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	6.45	2.85e-10	1.56e-07	0.3	0.29	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	6.45	2.85e-10	1.56e-07	0.42	0.29	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
HNSC	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	6.45	2.86e-10	1.57e-07	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
HNSC	cis	rs453301	0.571	rs330057	ENSG00000254340.1	RP11-10A14.3	-6.45	2.87e-10	1.58e-07	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9232283	chr8:9141424~9145435:+
HNSC	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-6.45	2.88e-10	1.58e-07	-0.31	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
HNSC	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-6.45	2.88e-10	1.58e-07	-0.36	-0.29	Height;	chr3:53047596	chr3:53064283~53065091:-
HNSC	cis	rs2834288	0.535	rs881229	ENSG00000237945.6	LINC00649	6.45	2.88e-10	1.58e-07	0.35	0.29	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33915534~33977691:+
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000224373.3	IGHV4-59	6.45	2.88e-10	1.58e-07	0.19	0.29	Kawasaki disease;	chr14:106664672	chr14:106627249~106627825:-
HNSC	cis	rs757110	0.745	rs10734252	ENSG00000260196.1	RP1-239B22.5	6.45	2.88e-10	1.58e-07	0.32	0.29	Type 2 diabetes;	chr11:17383292	chr11:17380649~17383531:+
HNSC	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.45	2.88e-10	1.58e-07	0.42	0.29	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
HNSC	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	6.44	2.88e-10	1.58e-07	0.35	0.29	QT interval;	chr16:28860645	chr16:28700294~28701540:-
HNSC	cis	rs2286503	0.966	rs2286507	ENSG00000221740.1	SNORD93	6.44	2.89e-10	1.58e-07	0.3	0.29	Fibrinogen;	chr7:22815141	chr7:22856613~22856686:+
HNSC	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.44	2.89e-10	1.58e-07	-0.27	-0.29	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-6.44	2.89e-10	1.58e-07	-0.19	-0.29	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
HNSC	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	6.44	2.89e-10	1.59e-07	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
HNSC	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	6.44	2.9e-10	1.59e-07	0.31	0.29	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
HNSC	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-6.44	2.91e-10	1.59e-07	-0.4	-0.29	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000254153.1	CTA-398F10.2	6.44	2.91e-10	1.6e-07	0.31	0.29	Joint mobility (Beighton score);	chr8:9001207	chr8:8456909~8461337:-
HNSC	cis	rs34526934	0.608	rs34720456	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176162564	chr2:176177717~176179008:+
HNSC	cis	rs34526934	0.608	rs7591820	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163416	chr2:176177717~176179008:+
HNSC	cis	rs34526934	0.608	rs7606110	ENSG00000226363.3	HAGLROS	6.44	2.92e-10	1.6e-07	0.38	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163823	chr2:176177717~176179008:+
HNSC	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-6.44	2.92e-10	1.6e-07	-0.39	-0.29	Height;	chr6:109405874	chr6:109382795~109383666:+
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-6.44	2.93e-10	1.6e-07	-0.36	-0.29	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
HNSC	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-6.44	2.93e-10	1.61e-07	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
HNSC	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-6.44	2.93e-10	1.61e-07	-0.32	-0.29	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
HNSC	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-6.44	2.94e-10	1.61e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
HNSC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	6.44	2.94e-10	1.61e-07	0.36	0.29	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
HNSC	cis	rs394563	0.559	rs7752555	ENSG00000231760.4	RP11-350J20.5	-6.44	2.94e-10	1.61e-07	-0.35	-0.29	Dupuytren's disease;	chr6:149349980	chr6:149796151~149826294:-
HNSC	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-6.44	2.95e-10	1.61e-07	-0.35	-0.29	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
HNSC	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	6.44	2.95e-10	1.62e-07	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000173295.6	FAM86B3P	6.44	2.96e-10	1.62e-07	0.32	0.29	Parkinson's disease;	chr8:8397365	chr8:8228595~8244865:+
HNSC	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-6.44	2.96e-10	1.62e-07	-0.4	-0.29	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.44	2.96e-10	1.62e-07	-0.36	-0.29	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
HNSC	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.44	2.96e-10	1.62e-07	-0.35	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
HNSC	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-6.44	2.96e-10	1.62e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
HNSC	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.44	2.97e-10	1.62e-07	0.42	0.29	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
HNSC	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.44	2.97e-10	1.62e-07	0.42	0.29	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-6.44	2.97e-10	1.62e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
HNSC	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.44	2.97e-10	1.63e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
HNSC	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	6.44	2.98e-10	1.63e-07	0.4	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-6.44	2.98e-10	1.63e-07	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-6.44	2.98e-10	1.63e-07	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000254340.1	RP11-10A14.3	-6.44	2.98e-10	1.63e-07	-0.33	-0.29	Joint mobility (Beighton score);	chr8:9226831	chr8:9141424~9145435:+
HNSC	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-6.44	2.98e-10	1.63e-07	-0.32	-0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
HNSC	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-6.44	2.98e-10	1.63e-07	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
HNSC	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	6.44	2.99e-10	1.64e-07	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-6.44	2.99e-10	1.64e-07	-0.38	-0.29	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
HNSC	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-6.44	2.99e-10	1.64e-07	-0.3	-0.29	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
HNSC	cis	rs6951245	0.58	rs10257426	ENSG00000224079.1	AC091729.7	-6.44	3e-10	1.64e-07	-0.46	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1074450~1078036:+
HNSC	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-6.44	3e-10	1.64e-07	-0.36	-0.29	QT interval;	chr16:28884339	chr16:28700294~28701540:-
HNSC	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	6.44	3e-10	1.64e-07	0.37	0.29	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	6.44	3e-10	1.64e-07	0.32	0.29	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
HNSC	cis	rs5753618	0.561	rs4141404	ENSG00000236132.1	CTA-440B3.1	6.44	3.01e-10	1.64e-07	0.35	0.29	Colorectal cancer;	chr22:31279199	chr22:31816379~31817491:-
HNSC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	6.44	3.01e-10	1.65e-07	0.34	0.29	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	6.44	3.02e-10	1.65e-07	0.32	0.29	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
HNSC	cis	rs5753618	0.504	rs9609329	ENSG00000236132.1	CTA-440B3.1	-6.44	3.02e-10	1.65e-07	-0.36	-0.29	Colorectal cancer;	chr22:31570327	chr22:31816379~31817491:-
HNSC	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-6.44	3.02e-10	1.65e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-6.44	3.02e-10	1.65e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
HNSC	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	6.44	3.02e-10	1.65e-07	0.34	0.29	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
HNSC	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-6.44	3.03e-10	1.65e-07	-0.31	-0.29	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
HNSC	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-6.44	3.03e-10	1.65e-07	-0.41	-0.29	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-6.44	3.03e-10	1.66e-07	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	6.44	3.03e-10	1.66e-07	0.44	0.29	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	6.44	3.04e-10	1.66e-07	0.33	0.29	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
HNSC	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	6.44	3.04e-10	1.66e-07	0.44	0.29	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
HNSC	cis	rs2235642	0.893	rs8051295	ENSG00000280231.1	LA16c-380F5.3	-6.44	3.04e-10	1.66e-07	-0.35	-0.29	Coronary artery disease;	chr16:1538086	chr16:1553655~1554130:-
HNSC	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-6.44	3.04e-10	1.66e-07	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
HNSC	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-6.44	3.04e-10	1.66e-07	-0.36	-0.29	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	6.44	3.05e-10	1.66e-07	0.38	0.29	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	6.44	3.05e-10	1.67e-07	0.43	0.29	Depression;	chr6:28260564	chr6:28115628~28116551:+
HNSC	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	6.43	3.07e-10	1.67e-07	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
HNSC	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	6.43	3.07e-10	1.68e-07	0.39	0.29	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
HNSC	cis	rs8177876	0.749	rs2278025	ENSG00000261061.1	RP11-303E16.2	6.43	3.08e-10	1.68e-07	0.46	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81030770~81031485:+
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-6.43	3.08e-10	1.68e-07	-0.19	-0.29	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
HNSC	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-6.43	3.08e-10	1.68e-07	-0.43	-0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
HNSC	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	6.43	3.09e-10	1.68e-07	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
HNSC	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-6.43	3.09e-10	1.68e-07	-0.35	-0.29	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
HNSC	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.68e-07	-0.41	-0.29	Gout;	chr7:66671562	chr7:66902857~66906297:+
HNSC	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-6.43	3.09e-10	1.68e-07	-0.37	-0.29	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
HNSC	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-6.43	3.09e-10	1.69e-07	-0.53	-0.29	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
HNSC	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-6.43	3.09e-10	1.69e-07	-0.34	-0.29	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
HNSC	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.43	3.1e-10	1.69e-07	-0.34	-0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
HNSC	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-6.43	3.11e-10	1.69e-07	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
HNSC	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	6.43	3.11e-10	1.69e-07	0.22	0.29	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
HNSC	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-6.43	3.11e-10	1.7e-07	-0.42	-0.29	Depression;	chr6:28321008	chr6:28115628~28116551:+
HNSC	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-6.43	3.12e-10	1.7e-07	-0.3	-0.29	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
HNSC	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	6.43	3.12e-10	1.7e-07	0.31	0.29	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	6.43	3.12e-10	1.7e-07	0.31	0.29	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
HNSC	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	6.43	3.12e-10	1.7e-07	0.43	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.12e-10	1.7e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
HNSC	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	6.43	3.13e-10	1.71e-07	0.34	0.29	Height;	chr4:55578154	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
HNSC	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-6.43	3.15e-10	1.71e-07	-0.26	-0.29	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
HNSC	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-6.43	3.15e-10	1.72e-07	-0.35	-0.29	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
HNSC	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	6.43	3.16e-10	1.72e-07	0.25	0.29	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
HNSC	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-6.43	3.16e-10	1.72e-07	-0.43	-0.29	Depression;	chr6:28273304	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-6.43	3.16e-10	1.72e-07	-0.43	-0.29	Depression;	chr6:28275017	chr6:28115628~28116551:+
HNSC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-6.43	3.16e-10	1.72e-07	-0.35	-0.29	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
HNSC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-6.43	3.17e-10	1.73e-07	-0.34	-0.29	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
HNSC	cis	rs2985684	0.625	rs4900931	ENSG00000258568.1	RHOQP1	6.43	3.17e-10	1.73e-07	0.29	0.29	Carotid intima media thickness;	chr14:49556075	chr14:49599994~49600572:+
HNSC	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	6.43	3.17e-10	1.73e-07	0.36	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-6.43	3.18e-10	1.73e-07	-0.35	-0.29	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
HNSC	cis	rs2235642	0.592	rs743963	ENSG00000280231.1	LA16c-380F5.3	-6.43	3.18e-10	1.73e-07	-0.36	-0.29	Coronary artery disease;	chr16:1607349	chr16:1553655~1554130:-
HNSC	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-6.43	3.19e-10	1.73e-07	-0.28	-0.29	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
HNSC	cis	rs757110	0.77	rs11024271	ENSG00000260196.1	RP1-239B22.5	6.43	3.19e-10	1.73e-07	0.32	0.29	Type 2 diabetes;	chr11:17373993	chr11:17380649~17383531:+
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-6.43	3.19e-10	1.73e-07	-0.32	-0.29	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
HNSC	cis	rs7804306	0.826	rs77672302	ENSG00000233264.2	AC006042.8	6.43	3.19e-10	1.74e-07	0.64	0.29	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8048681	chr7:7980312~7982228:+
HNSC	cis	rs2985684	0.894	rs8005990	ENSG00000258568.1	RHOQP1	6.43	3.2e-10	1.74e-07	0.29	0.29	Carotid intima media thickness;	chr14:49555530	chr14:49599994~49600572:+
HNSC	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	6.43	3.21e-10	1.74e-07	0.39	0.29	Height;	chr6:109414295	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	6.43	3.21e-10	1.74e-07	0.39	0.29	Height;	chr6:109416225	chr6:109382795~109383666:+
HNSC	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	6.43	3.21e-10	1.75e-07	0.33	0.29	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
HNSC	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-6.43	3.21e-10	1.75e-07	-0.28	-0.29	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
HNSC	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	6.43	3.22e-10	1.75e-07	0.44	0.29	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-6.43	3.22e-10	1.75e-07	-0.4	-0.29	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	6.43	3.22e-10	1.75e-07	0.31	0.29	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
HNSC	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	6.43	3.22e-10	1.75e-07	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
HNSC	cis	rs35955747	0.838	rs5997900	ENSG00000236132.1	CTA-440B3.1	6.43	3.22e-10	1.75e-07	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31184360	chr22:31816379~31817491:-
HNSC	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-6.43	3.22e-10	1.75e-07	-0.3	-0.29	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
HNSC	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	6.43	3.22e-10	1.75e-07	0.28	0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
HNSC	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.43	3.22e-10	1.75e-07	-0.35	-0.29	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
HNSC	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	6.43	3.23e-10	1.75e-07	0.33	0.29	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
HNSC	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-6.43	3.23e-10	1.75e-07	-0.28	-0.29	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000204709.4	LINC01556	6.43	3.23e-10	1.76e-07	0.37	0.29	Parkinson's disease;	chr6:28046247	chr6:28943877~28944537:+
HNSC	cis	rs12439619	0.846	rs62012056	ENSG00000276710.3	CSPG4P8	-6.43	3.24e-10	1.76e-07	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82459472~82477258:+
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-6.43	3.24e-10	1.76e-07	-0.26	-0.29	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
HNSC	cis	rs2985684	0.841	rs12894785	ENSG00000258568.1	RHOQP1	6.43	3.24e-10	1.76e-07	0.29	0.29	Carotid intima media thickness;	chr14:49583037	chr14:49599994~49600572:+
HNSC	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.43	3.24e-10	1.76e-07	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	6.42	3.26e-10	1.77e-07	0.23	0.28	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
HNSC	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-6.42	3.26e-10	1.77e-07	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
HNSC	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	6.42	3.26e-10	1.77e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000267151.3	RP11-100E5.2	6.42	3.27e-10	1.77e-07	0.37	0.28	Menopause (age at onset);	chr17:43036325	chr17:43444707~43451200:+
HNSC	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	6.42	3.27e-10	1.78e-07	0.29	0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
HNSC	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	6.42	3.28e-10	1.78e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	6.42	3.29e-10	1.78e-07	0.29	0.28	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
HNSC	cis	rs6951245	0.554	rs76243429	ENSG00000224079.1	AC091729.7	-6.42	3.29e-10	1.79e-07	-0.38	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1074450~1078036:+
HNSC	cis	rs6471393	1	rs6997642	ENSG00000253848.1	RP11-10N23.5	-6.42	3.3e-10	1.79e-07	-0.36	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703737	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	6.42	3.3e-10	1.79e-07	0.29	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
HNSC	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-6.42	3.3e-10	1.79e-07	-0.27	-0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
HNSC	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	6.42	3.3e-10	1.79e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
HNSC	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	6.42	3.3e-10	1.79e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	6.42	3.3e-10	1.79e-07	0.33	0.28	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
HNSC	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	6.42	3.31e-10	1.79e-07	0.34	0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
HNSC	cis	rs35955747	0.902	rs7287402	ENSG00000236132.1	CTA-440B3.1	-6.42	3.31e-10	1.79e-07	-0.3	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31258837	chr22:31816379~31817491:-
HNSC	cis	rs12439619	0.739	rs62012046	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.774	rs62012047	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82459472~82477258:+
HNSC	cis	rs12439619	0.81	rs62012049	ENSG00000276710.3	CSPG4P8	-6.42	3.31e-10	1.8e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82459472~82477258:+
HNSC	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-6.42	3.31e-10	1.8e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
HNSC	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	6.42	3.31e-10	1.8e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
HNSC	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-6.42	3.31e-10	1.8e-07	-0.34	-0.28	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000204709.4	LINC01556	6.42	3.32e-10	1.8e-07	0.37	0.28	Parkinson's disease;	chr6:28045839	chr6:28943877~28944537:+
HNSC	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-6.42	3.32e-10	1.8e-07	-0.36	-0.28	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
HNSC	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-6.42	3.32e-10	1.8e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
HNSC	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-6.42	3.32e-10	1.8e-07	-0.41	-0.28	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-6.42	3.33e-10	1.81e-07	-0.41	-0.28	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
HNSC	cis	rs2286503	0.901	rs2286505	ENSG00000221740.1	SNORD93	6.42	3.33e-10	1.81e-07	0.3	0.28	Fibrinogen;	chr7:22815221	chr7:22856613~22856686:+
HNSC	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.42	3.34e-10	1.81e-07	0.3	0.28	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-6.42	3.34e-10	1.81e-07	-0.32	-0.28	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
HNSC	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	6.42	3.34e-10	1.81e-07	0.34	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-6.42	3.34e-10	1.81e-07	-0.28	-0.28	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
HNSC	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	6.42	3.36e-10	1.82e-07	0.36	0.28	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
HNSC	cis	rs757110	0.705	rs10832778	ENSG00000260196.1	RP1-239B22.5	6.42	3.36e-10	1.82e-07	0.32	0.28	Type 2 diabetes;	chr11:17372526	chr11:17380649~17383531:+
HNSC	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-6.42	3.36e-10	1.82e-07	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
HNSC	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-6.42	3.36e-10	1.82e-07	-0.34	-0.28	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
HNSC	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-6.42	3.37e-10	1.82e-07	-0.32	-0.28	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
HNSC	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-6.42	3.37e-10	1.83e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
HNSC	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-6.42	3.37e-10	1.83e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
HNSC	cis	rs17270561	0.609	rs7772382	ENSG00000272462.2	U91328.19	-6.42	3.37e-10	1.83e-07	-0.29	-0.28	Iron status biomarkers;	chr6:25707888	chr6:25992662~26001775:+
HNSC	cis	rs2985684	0.894	rs4900932	ENSG00000258568.1	RHOQP1	6.42	3.38e-10	1.83e-07	0.29	0.28	Carotid intima media thickness;	chr14:49556210	chr14:49599994~49600572:+
HNSC	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	6.42	3.38e-10	1.83e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000211974.3	IGHV2-70	-6.42	3.38e-10	1.83e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106700837	chr14:106723574~106724093:-
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	6.42	3.38e-10	1.83e-07	0.33	0.28	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
HNSC	cis	rs35955747	0.869	rs34873968	ENSG00000236132.1	CTA-440B3.1	6.42	3.39e-10	1.83e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31185787	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.869	rs8143002	ENSG00000236132.1	CTA-440B3.1	6.42	3.39e-10	1.83e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191205	chr22:31816379~31817491:-
HNSC	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	6.42	3.39e-10	1.84e-07	0.31	0.28	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
HNSC	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-6.42	3.39e-10	1.84e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
HNSC	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-6.42	3.39e-10	1.84e-07	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
HNSC	cis	rs9402743	1	rs9389318	ENSG00000217482.2	HMGB1P17	6.42	3.39e-10	1.84e-07	0.31	0.28	Systemic lupus erythematosus;	chr6:135692396	chr6:135636086~135636713:-
HNSC	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-6.42	3.39e-10	1.84e-07	-0.53	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	6.42	3.4e-10	1.84e-07	0.22	0.28	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
HNSC	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	6.42	3.41e-10	1.85e-07	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
HNSC	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	6.42	3.41e-10	1.85e-07	0.34	0.28	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
HNSC	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	6.42	3.43e-10	1.85e-07	0.75	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
HNSC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-6.42	3.43e-10	1.86e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
HNSC	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-6.42	3.43e-10	1.86e-07	-0.44	-0.28	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
HNSC	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-6.42	3.43e-10	1.86e-07	-0.34	-0.28	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
HNSC	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-6.42	3.43e-10	1.86e-07	-0.38	-0.28	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
HNSC	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.42	3.43e-10	1.86e-07	0.27	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
HNSC	cis	rs4639966	0.836	rs10892282	ENSG00000255422.1	AP002954.4	-6.42	3.43e-10	1.86e-07	-0.39	-0.28	Systemic lupus erythematosus;	chr11:118757069	chr11:118704607~118750263:+
HNSC	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	6.42	3.44e-10	1.86e-07	0.34	0.28	Height;	chr4:55587104	chr4:55363971~55395847:-
HNSC	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.42	3.44e-10	1.86e-07	-0.39	-0.28	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-6.42	3.46e-10	1.87e-07	-0.32	-0.28	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
HNSC	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	6.41	3.47e-10	1.87e-07	0.27	0.28	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
HNSC	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.87e-07	-0.38	-0.28	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.41	3.47e-10	1.88e-07	0.29	0.28	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000267151.3	RP11-100E5.2	6.41	3.48e-10	1.88e-07	0.36	0.28	Menopause (age at onset);	chr17:43050671	chr17:43444707~43451200:+
HNSC	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	6.41	3.48e-10	1.88e-07	0.33	0.28	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
HNSC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.41	3.48e-10	1.88e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
HNSC	cis	rs12439619	0.846	rs62012059	ENSG00000276710.3	CSPG4P8	-6.41	3.48e-10	1.88e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82459472~82477258:+
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-6.41	3.48e-10	1.88e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	6.41	3.48e-10	1.88e-07	0.32	0.28	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
HNSC	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	6.41	3.48e-10	1.88e-07	0.37	0.28	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
HNSC	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-6.41	3.49e-10	1.89e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
HNSC	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.41	3.49e-10	1.89e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
HNSC	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-6.41	3.49e-10	1.89e-07	-0.26	-0.28	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.584	rs7215845	ENSG00000270977.1	AC015849.16	-6.41	3.5e-10	1.89e-07	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.591	rs4796128	ENSG00000270977.1	AC015849.16	-6.41	3.5e-10	1.89e-07	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35893707~35911023:-
HNSC	cis	rs1021993	0.645	rs11586524	ENSG00000231648.1	RP11-372M18.2	6.41	3.5e-10	1.89e-07	0.36	0.28	Gut microbiome composition (winter);	chr1:209323188	chr1:209367662~209379690:+
HNSC	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	6.41	3.5e-10	1.89e-07	0.28	0.28	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
HNSC	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-6.41	3.5e-10	1.89e-07	-0.32	-0.28	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000254153.1	CTA-398F10.2	6.41	3.5e-10	1.89e-07	0.3	0.28	Systolic blood pressure;	chr8:8462519	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-6.41	3.51e-10	1.9e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
HNSC	cis	rs4987094	0.505	rs4938011	ENSG00000270179.1	RP11-159N11.4	6.41	3.51e-10	1.9e-07	0.5	0.28	Schizophrenia;	chr11:113376510	chr11:113368478~113369117:+
HNSC	cis	rs11992162	0.56	rs13276386	ENSG00000206014.6	OR7E161P	-6.41	3.52e-10	1.9e-07	-0.31	-0.28	Monocyte count;	chr8:11939912	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.621	rs13268810	ENSG00000206014.6	OR7E161P	-6.41	3.52e-10	1.9e-07	-0.31	-0.28	Monocyte count;	chr8:11939921	chr8:11928597~11929563:-
HNSC	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.41	3.52e-10	1.9e-07	-0.35	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
HNSC	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	6.41	3.53e-10	1.9e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.509	rs5749224	ENSG00000236132.1	CTA-440B3.1	6.41	3.53e-10	1.9e-07	0.35	0.28	Colorectal cancer;	chr22:31162563	chr22:31816379~31817491:-
HNSC	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	6.41	3.53e-10	1.91e-07	0.42	0.28	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
HNSC	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	6.41	3.54e-10	1.91e-07	0.29	0.28	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
HNSC	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	6.41	3.54e-10	1.91e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-6.41	3.55e-10	1.91e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
HNSC	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	6.41	3.55e-10	1.91e-07	0.32	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	6.41	3.55e-10	1.92e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
HNSC	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	6.41	3.56e-10	1.92e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
HNSC	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	6.41	3.56e-10	1.92e-07	0.33	0.28	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
HNSC	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	6.41	3.57e-10	1.92e-07	0.5	0.28	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
HNSC	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-6.41	3.57e-10	1.93e-07	-0.38	-0.28	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
HNSC	cis	rs4218	0.638	rs8042516	ENSG00000259732.1	RP11-59H7.3	-6.41	3.58e-10	1.93e-07	-0.4	-0.28	Social communication problems;	chr15:59067525	chr15:59121034~59133250:+
HNSC	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	6.41	3.58e-10	1.93e-07	0.33	0.28	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-6.41	3.58e-10	1.93e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-6.41	3.58e-10	1.93e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
HNSC	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-6.41	3.58e-10	1.93e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
HNSC	cis	rs8054556	0.73	rs4788190	ENSG00000183604.13	SMG1P5	-6.41	3.58e-10	1.93e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30267553~30335374:-
HNSC	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	6.41	3.59e-10	1.94e-07	0.34	0.28	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
HNSC	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-6.41	3.6e-10	1.94e-07	-0.35	-0.28	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000241288.6	RP11-379B18.5	-6.41	3.61e-10	1.95e-07	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125915924	chr3:125827238~125916384:-
HNSC	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.41	3.62e-10	1.95e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
HNSC	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	6.41	3.63e-10	1.95e-07	0.41	0.28	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
HNSC	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.41	3.63e-10	1.96e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.41	3.63e-10	1.96e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
HNSC	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-6.41	3.63e-10	1.96e-07	-0.35	-0.28	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	6.41	3.63e-10	1.96e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
HNSC	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.41	3.64e-10	1.96e-07	0.3	0.28	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
HNSC	cis	rs7615952	0.576	rs2276726	ENSG00000241288.6	RP11-379B18.5	-6.41	3.66e-10	1.97e-07	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:126107444	chr3:125827238~125916384:-
HNSC	cis	rs6951245	1	rs78185558	ENSG00000225146.1	AC073957.15	-6.41	3.66e-10	1.97e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1029025~1043891:+
HNSC	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	6.4	3.67e-10	1.98e-07	0.32	0.28	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
HNSC	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-6.4	3.68e-10	1.98e-07	-0.34	-0.28	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000173295.6	FAM86B3P	-6.4	3.68e-10	1.98e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9047352	chr8:8228595~8244865:+
HNSC	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	6.4	3.69e-10	1.99e-07	0.38	0.28	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
HNSC	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-6.4	3.69e-10	1.99e-07	-0.32	-0.28	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
HNSC	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-6.4	3.69e-10	1.99e-07	-0.35	-0.28	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-6.4	3.69e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	6.4	3.69e-10	1.99e-07	0.33	0.28	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-6.4	3.7e-10	1.99e-07	-0.41	-0.28	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-6.4	3.7e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-6.4	3.7e-10	1.99e-07	-0.35	-0.28	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
HNSC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-6.4	3.72e-10	2e-07	-0.53	-0.28	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
HNSC	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-6.4	3.73e-10	2e-07	-0.38	-0.28	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
HNSC	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-6.4	3.73e-10	2e-07	-0.38	-0.28	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
HNSC	cis	rs2235642	0.701	rs2281230	ENSG00000280231.1	LA16c-380F5.3	-6.4	3.73e-10	2e-07	-0.36	-0.28	Coronary artery disease;	chr16:1551766	chr16:1553655~1554130:-
HNSC	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.4	3.73e-10	2.01e-07	-0.35	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
HNSC	cis	rs6081541	0.689	rs723768	ENSG00000179447.2	RP5-1027G4.3	-6.4	3.73e-10	2.01e-07	-0.35	-0.28	Psychosis (atypical);	chr20:19234998	chr20:19242302~19284596:-
HNSC	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.4	3.75e-10	2.01e-07	-0.35	-0.28	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-6.4	3.75e-10	2.02e-07	-0.35	-0.28	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-6.4	3.75e-10	2.02e-07	-0.35	-0.28	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-6.4	3.75e-10	2.02e-07	-0.41	-0.28	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000173295.6	FAM86B3P	-6.4	3.76e-10	2.02e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9047129	chr8:8228595~8244865:+
HNSC	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	6.4	3.76e-10	2.02e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
HNSC	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	6.4	3.76e-10	2.02e-07	0.31	0.28	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
HNSC	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.4	3.76e-10	2.02e-07	0.78	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-6.4	3.77e-10	2.03e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-6.4	3.78e-10	2.03e-07	-0.34	-0.28	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
HNSC	cis	rs4841097	0.806	rs6992247	ENSG00000173295.6	FAM86B3P	6.4	3.78e-10	2.03e-07	0.32	0.28	Platelet distribution width;	chr8:9090959	chr8:8228595~8244865:+
HNSC	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-6.4	3.78e-10	2.03e-07	-0.36	-0.28	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	6.4	3.79e-10	2.04e-07	0.24	0.28	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
HNSC	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	6.4	3.79e-10	2.04e-07	0.4	0.28	Height;	chr6:109775693	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-6.4	3.79e-10	2.04e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-6.4	3.8e-10	2.04e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
HNSC	cis	rs2579103	0.708	rs2731266	ENSG00000258183.4	RP11-753N8.1	6.4	3.81e-10	2.05e-07	0.38	0.28	Body mass index;	chr12:90278930	chr12:90280894~90300340:+
HNSC	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-6.4	3.81e-10	2.05e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	6.4	3.81e-10	2.05e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
HNSC	cis	rs2834288	0.535	rs881228	ENSG00000237945.6	LINC00649	6.4	3.82e-10	2.05e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33915534~33977691:+
HNSC	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	6.4	3.82e-10	2.05e-07	0.31	0.28	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
HNSC	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	6.4	3.82e-10	2.05e-07	0.41	0.28	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000173295.6	FAM86B3P	-6.4	3.82e-10	2.05e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9037242	chr8:8228595~8244865:+
HNSC	cis	rs11992162	0.636	rs13265816	ENSG00000206014.6	OR7E161P	-6.4	3.83e-10	2.05e-07	-0.31	-0.28	Monocyte count;	chr8:11939976	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000254153.1	CTA-398F10.2	6.4	3.87e-10	2.08e-07	0.31	0.28	Mood instability;	chr8:8465578	chr8:8456909~8461337:-
HNSC	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-6.4	3.88e-10	2.08e-07	-0.35	-0.28	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
HNSC	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-6.4	3.88e-10	2.08e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
HNSC	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-6.4	3.89e-10	2.08e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
HNSC	cis	rs12935418	0.55	rs35595567	ENSG00000261061.1	RP11-303E16.2	-6.4	3.89e-10	2.08e-07	-0.37	-0.28	Mean corpuscular volume;	chr16:80999761	chr16:81030770~81031485:+
HNSC	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	6.4	3.89e-10	2.09e-07	0.36	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
HNSC	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-6.4	3.89e-10	2.09e-07	-0.24	-0.28	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
HNSC	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	6.4	3.9e-10	2.09e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	6.4	3.9e-10	2.09e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000211974.3	IGHV2-70	-6.4	3.9e-10	2.09e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106790636	chr14:106723574~106724093:-
HNSC	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	6.39	3.91e-10	2.1e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
HNSC	cis	rs9326248	0.53	rs9919599	ENSG00000280143.1	AP000892.6	6.39	3.92e-10	2.1e-07	0.44	0.28	Blood protein levels;	chr11:116874768	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000211974.3	IGHV2-70	-6.39	3.92e-10	2.1e-07	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106706790	chr14:106723574~106724093:-
HNSC	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	6.39	3.93e-10	2.11e-07	0.33	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.39	3.93e-10	2.11e-07	0.38	0.28	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
HNSC	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	6.39	3.93e-10	2.11e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
HNSC	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-6.39	3.93e-10	2.11e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-6.39	3.94e-10	2.11e-07	-0.32	-0.28	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
HNSC	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-6.39	3.94e-10	2.11e-07	-0.4	-0.28	Gout;	chr7:66693028	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	6.39	3.94e-10	2.11e-07	0.27	0.28	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
HNSC	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-6.39	3.95e-10	2.12e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
HNSC	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	6.39	3.95e-10	2.12e-07	0.4	0.28	Height;	chr6:109359125	chr6:109382795~109383666:+
HNSC	cis	rs8054556	0.74	rs10083738	ENSG00000183604.13	SMG1P5	-6.39	3.96e-10	2.12e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30267553~30335374:-
HNSC	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-6.39	3.96e-10	2.12e-07	-0.33	-0.28	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
HNSC	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-6.39	3.96e-10	2.12e-07	-0.28	-0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
HNSC	cis	rs2985684	0.894	rs4581611	ENSG00000258568.1	RHOQP1	6.39	3.97e-10	2.12e-07	0.29	0.28	Carotid intima media thickness;	chr14:49576802	chr14:49599994~49600572:+
HNSC	cis	rs860295	0.966	rs821551	ENSG00000203761.5	MSTO2P	-6.39	3.97e-10	2.13e-07	-0.21	-0.28	Body mass index;	chr1:155718789	chr1:155745829~155750137:+
HNSC	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	6.39	3.97e-10	2.13e-07	0.34	0.28	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
HNSC	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-6.39	3.97e-10	2.13e-07	-0.39	-0.28	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	6.39	3.97e-10	2.13e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
HNSC	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	6.39	3.98e-10	2.13e-07	0.51	0.28	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-6.39	3.98e-10	2.13e-07	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-6.39	3.98e-10	2.13e-07	-0.25	-0.28	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
HNSC	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-6.39	3.98e-10	2.13e-07	-0.31	-0.28	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
HNSC	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-6.39	3.98e-10	2.13e-07	-0.53	-0.28	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
HNSC	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.39	3.98e-10	2.13e-07	0.33	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
HNSC	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	6.39	3.98e-10	2.13e-07	0.27	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
HNSC	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	6.39	4.01e-10	2.15e-07	0.25	0.28	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
HNSC	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	6.39	4.01e-10	2.15e-07	0.56	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
HNSC	cis	rs453301	0.624	rs330060	ENSG00000254340.1	RP11-10A14.3	-6.39	4.01e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9233392	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.624	rs330056	ENSG00000254340.1	RP11-10A14.3	-6.39	4.02e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9232185	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.624	rs330058	ENSG00000254340.1	RP11-10A14.3	-6.39	4.02e-10	2.15e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9232299	chr8:9141424~9145435:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000204709.4	LINC01556	6.39	4.03e-10	2.16e-07	0.36	0.28	Cardiac Troponin-T levels;	chr6:28109596	chr6:28943877~28944537:+
HNSC	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-6.39	4.03e-10	2.16e-07	-0.35	-0.28	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
HNSC	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-6.39	4.05e-10	2.17e-07	-0.35	-0.28	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
HNSC	cis	rs5753618	0.561	rs9606831	ENSG00000236132.1	CTA-440B3.1	-6.39	4.05e-10	2.17e-07	-0.35	-0.28	Colorectal cancer;	chr22:31336526	chr22:31816379~31817491:-
HNSC	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	6.39	4.05e-10	2.17e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	6.39	4.05e-10	2.17e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
HNSC	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
HNSC	cis	rs5753618	0.561	rs714909	ENSG00000236132.1	CTA-440B3.1	-6.39	4.06e-10	2.17e-07	-0.35	-0.28	Colorectal cancer;	chr22:31345081	chr22:31816379~31817491:-
HNSC	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	6.39	4.06e-10	2.17e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
HNSC	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-6.39	4.07e-10	2.17e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-6.39	4.07e-10	2.18e-07	-0.19	-0.28	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-6.39	4.07e-10	2.18e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
HNSC	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-6.39	4.07e-10	2.18e-07	-0.37	-0.28	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
HNSC	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-6.39	4.07e-10	2.18e-07	-0.52	-0.28	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
HNSC	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	6.39	4.07e-10	2.18e-07	0.39	0.28	Height;	chr6:109449796	chr6:109382795~109383666:+
HNSC	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-6.39	4.08e-10	2.18e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.08e-10	2.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
HNSC	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	6.39	4.08e-10	2.18e-07	0.33	0.28	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
HNSC	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-6.39	4.1e-10	2.19e-07	-0.35	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
HNSC	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-6.39	4.1e-10	2.19e-07	-0.35	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
HNSC	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	6.39	4.1e-10	2.19e-07	0.4	0.28	Height;	chr6:109372084	chr6:109382795~109383666:+
HNSC	cis	rs7396835	0.866	rs6589571	ENSG00000280143.1	AP000892.6	6.39	4.1e-10	2.19e-07	0.41	0.28	Quantitative traits;	chr11:116809702	chr11:117204967~117210292:+
HNSC	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	6.39	4.11e-10	2.2e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000211972.2	IGHV3-66	6.39	4.12e-10	2.2e-07	0.22	0.28	Kawasaki disease;	chr14:106711377	chr14:106675017~106675544:-
HNSC	cis	rs1021993	0.672	rs2660641	ENSG00000231648.1	RP11-372M18.2	6.39	4.13e-10	2.21e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209336539	chr1:209367662~209379690:+
HNSC	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-6.39	4.13e-10	2.21e-07	-0.69	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
HNSC	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-6.39	4.13e-10	2.21e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
HNSC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-6.39	4.14e-10	2.21e-07	-0.31	-0.28	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
HNSC	cis	rs11089937	0.857	rs5750580	ENSG00000211638.2	IGLV8-61	-6.38	4.15e-10	2.22e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22098700~22099212:+
HNSC	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-6.38	4.15e-10	2.22e-07	-0.29	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
HNSC	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	6.38	4.15e-10	2.22e-07	0.32	0.28	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-6.38	4.17e-10	2.23e-07	-0.35	-0.28	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-6.38	4.17e-10	2.23e-07	-0.35	-0.28	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-6.38	4.17e-10	2.23e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-6.38	4.17e-10	2.23e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
HNSC	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.38	4.17e-10	2.23e-07	0.28	0.28	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
HNSC	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-6.38	4.18e-10	2.23e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
HNSC	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	6.38	4.18e-10	2.23e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	6.38	4.18e-10	2.23e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
HNSC	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	6.38	4.18e-10	2.23e-07	0.29	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	6.38	4.19e-10	2.23e-07	0.18	0.28	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
HNSC	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	6.38	4.19e-10	2.24e-07	0.45	0.28	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
HNSC	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	6.38	4.19e-10	2.24e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
HNSC	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-6.38	4.19e-10	2.24e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
HNSC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-6.38	4.19e-10	2.24e-07	-0.37	-0.28	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
HNSC	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-6.38	4.2e-10	2.24e-07	-0.33	-0.28	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-6.38	4.2e-10	2.24e-07	-0.25	-0.28	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
HNSC	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-6.38	4.2e-10	2.24e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
HNSC	cis	rs8054556	0.733	rs35467921	ENSG00000183604.13	SMG1P5	-6.38	4.21e-10	2.24e-07	-0.29	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30037232	chr16:30267553~30335374:-
HNSC	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.38	4.21e-10	2.24e-07	0.33	0.28	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
HNSC	cis	rs860295	0.775	rs822505	ENSG00000203761.5	MSTO2P	6.38	4.22e-10	2.25e-07	0.21	0.28	Body mass index;	chr1:155876737	chr1:155745829~155750137:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-6.38	4.22e-10	2.25e-07	-0.19	-0.28	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-6.38	4.22e-10	2.25e-07	-0.34	-0.28	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
HNSC	cis	rs17270561	0.666	rs1937129	ENSG00000272462.2	U91328.19	-6.38	4.23e-10	2.26e-07	-0.28	-0.28	Iron status biomarkers;	chr6:25788904	chr6:25992662~26001775:+
HNSC	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	6.38	4.23e-10	2.26e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-6.38	4.24e-10	2.26e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106790480	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106793065	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106795643	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106795976	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106799722	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000211974.3	IGHV2-70	-6.38	4.25e-10	2.26e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106801091	chr14:106723574~106724093:-
HNSC	cis	rs4273100	1	rs868698	ENSG00000265185.4	SNORD3B-1	6.38	4.25e-10	2.26e-07	0.42	0.28	Schizophrenia;	chr17:19281898	chr17:19061912~19062669:+
HNSC	cis	rs12439619	0.846	rs62011975	ENSG00000276710.3	CSPG4P8	-6.38	4.25e-10	2.27e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82459472~82477258:+
HNSC	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-6.38	4.26e-10	2.27e-07	-0.32	-0.28	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-6.38	4.26e-10	2.27e-07	-0.41	-0.28	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-6.38	4.26e-10	2.27e-07	-0.41	-0.28	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
HNSC	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.38	4.26e-10	2.27e-07	0.28	0.28	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.38	4.26e-10	2.27e-07	0.28	0.28	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
HNSC	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-6.38	4.27e-10	2.27e-07	-0.32	-0.28	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
HNSC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	6.38	4.27e-10	2.27e-07	0.44	0.28	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
HNSC	cis	rs6435862	0.844	rs6720708	ENSG00000229267.2	AC072062.1	6.38	4.27e-10	2.28e-07	0.37	0.28	Neuroblastoma (high-risk);	chr2:214806593	chr2:214810229~214963274:+
HNSC	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	6.38	4.27e-10	2.28e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
HNSC	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	6.38	4.27e-10	2.28e-07	0.4	0.28	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
HNSC	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	6.38	4.27e-10	2.28e-07	0.46	0.28	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
HNSC	cis	rs7615952	0.576	rs2276729	ENSG00000241288.6	RP11-379B18.5	-6.38	4.28e-10	2.28e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107371	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	6.38	4.28e-10	2.28e-07	0.33	0.28	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
HNSC	cis	rs5753618	0.561	rs1858821	ENSG00000236132.1	CTA-440B3.1	6.38	4.28e-10	2.28e-07	0.35	0.28	Colorectal cancer;	chr22:31280468	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.519	rs5997939	ENSG00000236132.1	CTA-440B3.1	6.38	4.28e-10	2.28e-07	0.35	0.28	Colorectal cancer;	chr22:31281144	chr22:31816379~31817491:-
HNSC	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-6.38	4.29e-10	2.28e-07	-0.32	-0.28	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
HNSC	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-6.38	4.29e-10	2.29e-07	-0.36	-0.28	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
HNSC	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-6.38	4.29e-10	2.29e-07	-0.34	-0.28	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
HNSC	cis	rs6951245	0.554	rs79367977	ENSG00000224079.1	AC091729.7	-6.38	4.29e-10	2.29e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1074450~1078036:+
HNSC	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	6.38	4.29e-10	2.29e-07	0.35	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	6.38	4.3e-10	2.29e-07	0.32	0.28	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
HNSC	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	6.38	4.31e-10	2.29e-07	0.22	0.28	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
HNSC	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-6.38	4.31e-10	2.3e-07	-0.4	-0.28	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
HNSC	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	6.38	4.31e-10	2.3e-07	0.33	0.28	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
HNSC	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-6.38	4.32e-10	2.3e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
HNSC	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	6.38	4.32e-10	2.3e-07	0.37	0.28	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000211974.3	IGHV2-70	-6.38	4.32e-10	2.3e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106696601	chr14:106723574~106724093:-
HNSC	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-6.38	4.32e-10	2.3e-07	-0.29	-0.28	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
HNSC	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	6.38	4.33e-10	2.31e-07	0.37	0.28	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
HNSC	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-6.38	4.34e-10	2.31e-07	-0.3	-0.28	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
HNSC	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.38	4.34e-10	2.31e-07	0.27	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
HNSC	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-6.38	4.34e-10	2.31e-07	-0.32	-0.28	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
HNSC	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-6.38	4.35e-10	2.31e-07	-0.37	-0.28	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
HNSC	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	6.38	4.35e-10	2.31e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
HNSC	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-6.38	4.35e-10	2.31e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
HNSC	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-6.38	4.36e-10	2.32e-07	-0.32	-0.28	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
HNSC	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	6.38	4.36e-10	2.32e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
HNSC	cis	rs4141404	0.828	rs2413043	ENSG00000236132.1	CTA-440B3.1	6.38	4.37e-10	2.33e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31252590	chr22:31816379~31817491:-
HNSC	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-6.38	4.38e-10	2.33e-07	-0.32	-0.28	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
HNSC	cis	rs6496044	0.547	rs7173125	ENSG00000259295.5	CSPG4P12	-6.38	4.39e-10	2.34e-07	-0.34	-0.28	Interstitial lung disease;	chr15:85512214	chr15:85191438~85213905:+
HNSC	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.38	4.4e-10	2.34e-07	0.28	0.28	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
HNSC	cis	rs35955747	0.811	rs9606835	ENSG00000236132.1	CTA-440B3.1	-6.38	4.4e-10	2.34e-07	-0.3	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31370974	chr22:31816379~31817491:-
HNSC	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-6.37	4.4e-10	2.34e-07	-0.4	-0.28	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
HNSC	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	6.37	4.4e-10	2.34e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
HNSC	cis	rs7615952	0.576	rs1127717	ENSG00000241288.6	RP11-379B18.5	-6.37	4.41e-10	2.34e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107216	chr3:125827238~125916384:-
HNSC	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-6.37	4.42e-10	2.35e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
HNSC	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	6.37	4.42e-10	2.35e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
HNSC	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-6.37	4.43e-10	2.36e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
HNSC	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	6.37	4.44e-10	2.36e-07	0.46	0.28	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
HNSC	cis	rs7615952	0.611	rs9681518	ENSG00000241288.6	RP11-379B18.5	-6.37	4.44e-10	2.36e-07	-0.47	-0.28	Blood pressure (smoking interaction);	chr3:125896287	chr3:125827238~125916384:-
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.45e-10	2.37e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
HNSC	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	6.37	4.45e-10	2.37e-07	0.4	0.28	Height;	chr6:109360679	chr6:109382795~109383666:+
HNSC	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-6.37	4.47e-10	2.37e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
HNSC	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-6.37	4.47e-10	2.37e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
HNSC	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	6.37	4.47e-10	2.38e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
HNSC	cis	rs2985684	0.894	rs2281837	ENSG00000258568.1	RHOQP1	6.37	4.47e-10	2.38e-07	0.29	0.28	Carotid intima media thickness;	chr14:49598641	chr14:49599994~49600572:+
HNSC	cis	rs8177876	0.822	rs4306521	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs4324142	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs4324143	ENSG00000261061.1	RP11-303E16.2	-6.37	4.47e-10	2.38e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81030770~81031485:+
HNSC	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-6.37	4.48e-10	2.38e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
HNSC	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	6.37	4.48e-10	2.38e-07	0.33	0.28	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-6.37	4.48e-10	2.38e-07	-0.35	-0.28	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-6.37	4.48e-10	2.38e-07	-0.35	-0.28	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	6.37	4.48e-10	2.38e-07	0.31	0.28	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
HNSC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-6.37	4.49e-10	2.38e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-6.37	4.49e-10	2.39e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
HNSC	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	6.37	4.5e-10	2.39e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
HNSC	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-6.37	4.5e-10	2.39e-07	-0.29	-0.28	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
HNSC	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	6.37	4.5e-10	2.39e-07	0.32	0.28	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000254340.1	RP11-10A14.3	-6.37	4.5e-10	2.39e-07	-0.34	-0.28	Mood instability;	chr8:8933743	chr8:9141424~9145435:+
HNSC	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	6.37	4.5e-10	2.39e-07	0.42	0.28	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
HNSC	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-6.37	4.5e-10	2.39e-07	-0.35	-0.28	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
HNSC	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	6.37	4.51e-10	2.39e-07	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	-6.37	4.51e-10	2.39e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-6.37	4.51e-10	2.39e-07	-0.27	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
HNSC	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.37	4.51e-10	2.39e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
HNSC	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-6.37	4.51e-10	2.39e-07	-0.42	-0.28	Depression;	chr6:28329086	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-6.37	4.51e-10	2.39e-07	-0.42	-0.28	Depression;	chr6:28329536	chr6:28115628~28116551:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000255769.6	GOLGA2P10	-6.37	4.51e-10	2.4e-07	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82712096	chr15:82472993~82513950:-
HNSC	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-6.37	4.52e-10	2.4e-07	-0.36	-0.28	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
HNSC	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	6.37	4.52e-10	2.4e-07	0.39	0.28	Height;	chr6:109395761	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-6.37	4.52e-10	2.4e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
HNSC	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	6.37	4.53e-10	2.4e-07	0.28	0.28	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
HNSC	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	6.37	4.55e-10	2.41e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
HNSC	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	6.37	4.55e-10	2.42e-07	0.44	0.28	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
HNSC	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-6.37	4.59e-10	2.43e-07	-0.28	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-6.37	4.59e-10	2.44e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
HNSC	cis	rs11089937	0.864	rs5757041	ENSG00000211638.2	IGLV8-61	-6.37	4.6e-10	2.44e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22098700~22099212:+
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000211974.3	IGHV2-70	-6.37	4.61e-10	2.45e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106780575	chr14:106723574~106724093:-
HNSC	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-6.37	4.61e-10	2.45e-07	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
HNSC	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-6.37	4.62e-10	2.45e-07	-0.35	-0.28	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-6.37	4.62e-10	2.45e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-6.37	4.62e-10	2.45e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
HNSC	cis	rs393155	0.517	rs330050	ENSG00000254340.1	RP11-10A14.3	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Neuroticism;	chr8:9230169	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.571	rs330054	ENSG00000254340.1	RP11-10A14.3	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9230781	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-6.37	4.62e-10	2.45e-07	-0.33	-0.28	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
HNSC	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-6.37	4.63e-10	2.45e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
HNSC	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	6.37	4.64e-10	2.46e-07	0.33	0.28	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
HNSC	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	6.37	4.64e-10	2.46e-07	0.32	0.28	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
HNSC	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.37	4.64e-10	2.46e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.37	4.64e-10	2.46e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
HNSC	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	6.37	4.65e-10	2.47e-07	0.41	0.28	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
HNSC	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.65e-10	2.47e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
HNSC	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	6.37	4.66e-10	2.47e-07	0.28	0.28	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
HNSC	cis	rs17270561	0.583	rs6908713	ENSG00000272462.2	U91328.19	6.37	4.66e-10	2.47e-07	0.29	0.28	Iron status biomarkers;	chr6:25703383	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.583	rs6908407	ENSG00000272462.2	U91328.19	6.37	4.66e-10	2.47e-07	0.29	0.28	Iron status biomarkers;	chr6:25703428	chr6:25992662~26001775:+
HNSC	cis	rs2985684	0.841	rs7158577	ENSG00000258568.1	RHOQP1	6.36	4.67e-10	2.47e-07	0.29	0.28	Carotid intima media thickness;	chr14:49591915	chr14:49599994~49600572:+
HNSC	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-6.36	4.69e-10	2.48e-07	-0.4	-0.28	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-6.36	4.69e-10	2.48e-07	-0.4	-0.28	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
HNSC	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-6.36	4.7e-10	2.49e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
HNSC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	6.36	4.71e-10	2.49e-07	0.31	0.28	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
HNSC	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	6.36	4.71e-10	2.49e-07	0.45	0.28	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
HNSC	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	6.36	4.72e-10	2.5e-07	0.27	0.28	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
HNSC	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	6.36	4.72e-10	2.5e-07	0.33	0.28	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
HNSC	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-6.36	4.73e-10	2.5e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-6.36	4.73e-10	2.5e-07	-0.31	-0.28	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
HNSC	cis	rs8177876	0.822	rs4889225	ENSG00000261061.1	RP11-303E16.2	6.36	4.74e-10	2.51e-07	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81030770~81031485:+
HNSC	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-6.36	4.75e-10	2.51e-07	-0.53	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
HNSC	cis	rs11089937	0.667	rs5757081	ENSG00000211638.2	IGLV8-61	-6.36	4.75e-10	2.51e-07	-0.27	-0.28	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22098700~22099212:+
HNSC	cis	rs8054556	0.787	rs12921753	ENSG00000183604.13	SMG1P5	-6.36	4.76e-10	2.52e-07	-0.29	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30267553~30335374:-
HNSC	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-6.36	4.77e-10	2.52e-07	-0.4	-0.28	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
HNSC	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-6.36	4.77e-10	2.52e-07	-0.24	-0.28	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
HNSC	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	6.36	4.77e-10	2.53e-07	0.39	0.28	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.36	4.78e-10	2.53e-07	-0.38	-0.28	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
HNSC	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	6.36	4.78e-10	2.53e-07	0.33	0.28	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
HNSC	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-6.36	4.8e-10	2.54e-07	-0.4	-0.28	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.36	4.81e-10	2.54e-07	-0.26	-0.28	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
HNSC	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-6.36	4.83e-10	2.55e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
HNSC	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.36	4.83e-10	2.56e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
HNSC	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	6.36	4.84e-10	2.56e-07	0.33	0.28	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
HNSC	cis	rs1021993	0.729	rs2456809	ENSG00000231648.1	RP11-372M18.2	6.36	4.85e-10	2.56e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209314622	chr1:209367662~209379690:+
HNSC	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6.36	4.85e-10	2.56e-07	0.41	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
HNSC	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.36	4.86e-10	2.57e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
HNSC	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-6.36	4.87e-10	2.57e-07	-0.26	-0.28	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
HNSC	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	6.36	4.87e-10	2.57e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	6.36	4.87e-10	2.57e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
HNSC	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	6.36	4.88e-10	2.58e-07	0.33	0.28	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
HNSC	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-6.36	4.88e-10	2.58e-07	-0.34	-0.28	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
HNSC	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	6.36	4.89e-10	2.58e-07	0.45	0.28	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
HNSC	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	6.36	4.89e-10	2.58e-07	0.31	0.28	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-6.36	4.9e-10	2.59e-07	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
HNSC	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	6.36	4.9e-10	2.59e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
HNSC	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	6.36	4.9e-10	2.59e-07	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
HNSC	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	6.36	4.9e-10	2.59e-07	0.38	0.28	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
HNSC	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-6.36	4.9e-10	2.59e-07	-0.35	-0.28	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
HNSC	cis	rs8177876	0.822	rs7206814	ENSG00000261061.1	RP11-303E16.2	6.36	4.9e-10	2.59e-07	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81030770~81031485:+
HNSC	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-6.36	4.91e-10	2.59e-07	-0.36	-0.28	Height;	chr4:55593918	chr4:55387949~55388271:+
HNSC	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-6.36	4.91e-10	2.59e-07	-0.24	-0.28	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.36	4.91e-10	2.59e-07	0.35	0.28	Depression;	chr6:28391932	chr6:28943877~28944537:+
HNSC	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	6.36	4.91e-10	2.59e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
HNSC	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	6.36	4.91e-10	2.59e-07	0.34	0.28	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-6.36	4.92e-10	2.59e-07	-0.4	-0.28	Gout;	chr7:66654674	chr7:66902857~66906297:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-6.36	4.92e-10	2.59e-07	-0.4	-0.28	Gout;	chr7:66661502	chr7:66902857~66906297:+
HNSC	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	6.36	4.92e-10	2.6e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
HNSC	cis	rs1021993	0.672	rs2800929	ENSG00000231648.1	RP11-372M18.2	6.36	4.92e-10	2.6e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209318623	chr1:209367662~209379690:+
HNSC	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	6.36	4.93e-10	2.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	6.36	4.93e-10	2.6e-07	0.66	0.28	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
HNSC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-6.36	4.94e-10	2.6e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
HNSC	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	6.36	4.94e-10	2.61e-07	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
HNSC	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	6.36	4.95e-10	2.61e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
HNSC	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-6.36	4.95e-10	2.61e-07	-0.35	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
HNSC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-6.36	4.96e-10	2.62e-07	-0.35	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
HNSC	cis	rs7819412	0.745	rs4841498	ENSG00000255310.2	AF131215.2	-6.35	4.96e-10	2.62e-07	-0.27	-0.28	Triglycerides;	chr8:11127922	chr8:11107788~11109726:-
HNSC	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	6.35	4.96e-10	2.62e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
HNSC	cis	rs2834288	0.535	rs8132681	ENSG00000237945.6	LINC00649	6.35	4.96e-10	2.62e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33915534~33977691:+
HNSC	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-6.35	4.98e-10	2.63e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-6.35	4.99e-10	2.63e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
HNSC	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	6.35	4.99e-10	2.63e-07	0.33	0.28	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
HNSC	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	6.35	4.99e-10	2.63e-07	0.35	0.28	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
HNSC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	6.35	5e-10	2.63e-07	0.33	0.28	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
HNSC	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	6.35	5e-10	2.63e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	6.35	5e-10	2.63e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
HNSC	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	6.35	5e-10	2.63e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
HNSC	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-6.35	5e-10	2.64e-07	-0.32	-0.28	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
HNSC	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	6.35	5e-10	2.64e-07	0.32	0.28	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
HNSC	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-6.35	5.01e-10	2.64e-07	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
HNSC	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	6.35	5.01e-10	2.64e-07	0.27	0.28	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
HNSC	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	6.35	5.02e-10	2.64e-07	0.39	0.28	Height;	chr6:109454855	chr6:109382795~109383666:+
HNSC	cis	rs9300255	0.739	rs4759415	ENSG00000280120.1	RP11-546D6.3	-6.35	5.02e-10	2.65e-07	-0.25	-0.28	Neutrophil percentage of white cells;	chr12:123259127	chr12:123152324~123153377:-
HNSC	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.35	5.03e-10	2.65e-07	0.24	0.28	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
HNSC	cis	rs9399135	0.773	rs9389263	ENSG00000232876.1	CTA-212D2.2	-6.35	5.03e-10	2.65e-07	-0.34	-0.28	Red blood cell count;	chr6:135079427	chr6:135055033~135060550:+
HNSC	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	6.35	5.03e-10	2.65e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-6.35	5.04e-10	2.66e-07	-0.34	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
HNSC	cis	rs9907295	0.818	rs7211393	ENSG00000270977.1	AC015849.16	-6.35	5.04e-10	2.66e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35893707~35911023:-
HNSC	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-6.35	5.05e-10	2.66e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
HNSC	cis	rs7587476	0.765	rs2121284	ENSG00000229267.2	AC072062.1	6.35	5.05e-10	2.66e-07	0.36	0.28	Neuroblastoma;	chr2:214791536	chr2:214810229~214963274:+
HNSC	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-6.35	5.05e-10	2.66e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
HNSC	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.67e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.67e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
HNSC	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	6.35	5.08e-10	2.67e-07	0.45	0.28	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	6.35	5.08e-10	2.68e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
HNSC	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	6.35	5.09e-10	2.68e-07	0.34	0.28	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
HNSC	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	6.35	5.09e-10	2.68e-07	0.34	0.28	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
HNSC	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-6.35	5.09e-10	2.68e-07	-0.4	-0.28	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
HNSC	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-6.35	5.09e-10	2.68e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
HNSC	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-6.35	5.1e-10	2.68e-07	-0.33	-0.28	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
HNSC	cis	rs17270561	0.609	rs1185976	ENSG00000272462.2	U91328.19	6.35	5.1e-10	2.68e-07	0.28	0.28	Iron status biomarkers;	chr6:25822135	chr6:25992662~26001775:+
HNSC	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	6.35	5.1e-10	2.68e-07	0.4	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
HNSC	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	6.35	5.12e-10	2.7e-07	0.37	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
HNSC	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	6.35	5.13e-10	2.7e-07	0.37	0.28	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
HNSC	cis	rs4639966	0.836	rs7943039	ENSG00000255422.1	AP002954.4	6.35	5.13e-10	2.7e-07	0.39	0.28	Systemic lupus erythematosus;	chr11:118732321	chr11:118704607~118750263:+
HNSC	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	6.35	5.14e-10	2.7e-07	0.32	0.28	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
HNSC	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-6.35	5.14e-10	2.7e-07	-0.4	-0.28	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
HNSC	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	6.35	5.16e-10	2.71e-07	0.26	0.28	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	6.35	5.16e-10	2.71e-07	0.26	0.28	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
HNSC	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.35	5.16e-10	2.72e-07	0.27	0.28	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	6.35	5.17e-10	2.72e-07	0.23	0.28	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
HNSC	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-6.35	5.19e-10	2.73e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
HNSC	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-6.35	5.19e-10	2.73e-07	-0.34	-0.28	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
HNSC	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	6.35	5.2e-10	2.73e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
HNSC	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-6.35	5.2e-10	2.74e-07	-0.31	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
HNSC	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	6.35	5.21e-10	2.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
HNSC	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-6.35	5.22e-10	2.74e-07	-0.41	-0.28	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-6.35	5.22e-10	2.75e-07	-0.33	-0.28	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
HNSC	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	6.35	5.22e-10	2.75e-07	0.27	0.28	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
HNSC	cis	rs2579103	0.708	rs2250237	ENSG00000258183.4	RP11-753N8.1	-6.35	5.23e-10	2.75e-07	-0.38	-0.28	Body mass index;	chr12:90289234	chr12:90280894~90300340:+
HNSC	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-6.35	5.24e-10	2.75e-07	-0.33	-0.28	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
HNSC	cis	rs451417	0.722	rs236189	ENSG00000275632.1	RP5-967N21.11	6.35	5.24e-10	2.76e-07	0.31	0.28	Menopause (age at onset);	chr20:5951544	chr20:6000418~6000941:+
HNSC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	6.35	5.24e-10	2.76e-07	0.32	0.28	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
HNSC	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-6.35	5.26e-10	2.76e-07	-0.3	-0.28	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
HNSC	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-6.35	5.26e-10	2.77e-07	-0.69	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
HNSC	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-6.34	5.27e-10	2.77e-07	-0.28	-0.28	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
HNSC	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	6.34	5.27e-10	2.77e-07	0.31	0.28	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	6.34	5.27e-10	2.77e-07	0.31	0.28	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	6.34	5.27e-10	2.77e-07	0.4	0.28	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
HNSC	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	6.34	5.27e-10	2.77e-07	0.33	0.28	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
HNSC	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-6.34	5.28e-10	2.77e-07	-0.34	-0.28	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
HNSC	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-6.34	5.28e-10	2.78e-07	-0.36	-0.28	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-6.34	5.28e-10	2.78e-07	-0.36	-0.28	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
HNSC	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-6.34	5.29e-10	2.78e-07	-0.38	-0.28	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
HNSC	cis	rs1021993	0.672	rs2254757	ENSG00000231648.1	RP11-372M18.2	6.34	5.29e-10	2.78e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209318648	chr1:209367662~209379690:+
HNSC	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	6.34	5.3e-10	2.78e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	6.34	5.3e-10	2.78e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
HNSC	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	6.34	5.31e-10	2.79e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.539	rs2228619	ENSG00000236132.1	CTA-440B3.1	6.34	5.31e-10	2.79e-07	0.35	0.28	Colorectal cancer;	chr22:31267856	chr22:31816379~31817491:-
HNSC	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-6.34	5.31e-10	2.79e-07	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
HNSC	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	6.34	5.33e-10	2.8e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
HNSC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.34	5.34e-10	2.8e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
HNSC	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	6.34	5.35e-10	2.81e-07	0.32	0.28	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
HNSC	cis	rs2239557	0.885	rs4899502	ENSG00000259065.1	RP5-1021I20.1	6.34	5.36e-10	2.81e-07	0.34	0.28	Common traits (Other);	chr14:74203190	chr14:73787360~73803270:+
HNSC	cis	rs2985684	0.789	rs1957979	ENSG00000258568.1	RHOQP1	6.34	5.36e-10	2.81e-07	0.29	0.28	Carotid intima media thickness;	chr14:49596614	chr14:49599994~49600572:+
HNSC	cis	rs2985684	0.789	rs7161649	ENSG00000258568.1	RHOQP1	6.34	5.36e-10	2.81e-07	0.29	0.28	Carotid intima media thickness;	chr14:49597310	chr14:49599994~49600572:+
HNSC	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.38e-10	2.82e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.34	5.39e-10	2.83e-07	0.32	0.28	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
HNSC	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-6.34	5.39e-10	2.83e-07	-0.29	-0.28	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
HNSC	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-6.34	5.39e-10	2.83e-07	-0.39	-0.28	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-6.34	5.39e-10	2.83e-07	-0.39	-0.28	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-6.34	5.39e-10	2.83e-07	-0.41	-0.28	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
HNSC	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-6.34	5.4e-10	2.83e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
HNSC	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-6.34	5.4e-10	2.83e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
HNSC	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	6.34	5.4e-10	2.83e-07	0.33	0.28	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
HNSC	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-6.34	5.4e-10	2.83e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-6.34	5.4e-10	2.83e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
HNSC	cis	rs7615952	0.576	rs4646759	ENSG00000241288.6	RP11-379B18.5	-6.34	5.4e-10	2.83e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126104103	chr3:125827238~125916384:-
HNSC	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	6.34	5.41e-10	2.83e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
HNSC	cis	rs4141404	0.74	rs9609301	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Paclitaxel-induced neuropathy;	chr22:31499954	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.555	rs9609302	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500001	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9609303	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500323	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.504	rs9606846	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31501585	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.555	rs9609304	ENSG00000236132.1	CTA-440B3.1	-6.34	5.41e-10	2.83e-07	-0.36	-0.28	Colorectal cancer;	chr22:31501809	chr22:31816379~31817491:-
HNSC	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	6.34	5.42e-10	2.84e-07	0.33	0.28	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
HNSC	cis	rs5753618	0.561	rs2078803	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31256866	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2073857	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31262295	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs737684	ENSG00000236132.1	CTA-440B3.1	6.34	5.42e-10	2.84e-07	0.34	0.28	Colorectal cancer;	chr22:31263841	chr22:31816379~31817491:-
HNSC	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	6.34	5.42e-10	2.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
HNSC	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	6.34	5.42e-10	2.84e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
HNSC	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-6.34	5.42e-10	2.84e-07	-0.46	-0.28	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
HNSC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	6.34	5.42e-10	2.84e-07	0.31	0.28	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
HNSC	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	6.34	5.43e-10	2.84e-07	0.32	0.28	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
HNSC	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-6.34	5.43e-10	2.85e-07	-0.35	-0.28	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
HNSC	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-6.34	5.43e-10	2.85e-07	-0.35	-0.28	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
HNSC	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-6.34	5.43e-10	2.85e-07	-0.42	-0.28	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
HNSC	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-6.34	5.44e-10	2.85e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
HNSC	cis	rs189798	0.807	rs330909	ENSG00000173295.6	FAM86B3P	6.34	5.44e-10	2.85e-07	0.34	0.28	Myopia (pathological);	chr8:9137877	chr8:8228595~8244865:+
HNSC	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	6.34	5.45e-10	2.85e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-6.34	5.46e-10	2.86e-07	-0.19	-0.28	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
HNSC	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-6.34	5.46e-10	2.86e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
HNSC	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-6.34	5.47e-10	2.87e-07	-0.36	-0.28	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-6.34	5.48e-10	2.87e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
HNSC	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.34	5.48e-10	2.87e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
HNSC	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	6.34	5.49e-10	2.87e-07	0.27	0.28	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
HNSC	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-6.34	5.49e-10	2.87e-07	-0.21	-0.28	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
HNSC	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
HNSC	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-6.34	5.49e-10	2.88e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
HNSC	cis	rs5769707	0.681	rs916360	ENSG00000188511.11	C22orf34	6.34	5.49e-10	2.88e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49414524~49657542:-
HNSC	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	6.34	5.5e-10	2.88e-07	0.32	0.28	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
HNSC	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-6.34	5.51e-10	2.88e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000211974.3	IGHV2-70	-6.34	5.51e-10	2.88e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106779942	chr14:106723574~106724093:-
HNSC	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	6.34	5.51e-10	2.88e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
HNSC	cis	rs17270561	0.609	rs9467572	ENSG00000272462.2	U91328.19	6.34	5.52e-10	2.89e-07	0.29	0.28	Iron status biomarkers;	chr6:25703898	chr6:25992662~26001775:+
HNSC	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-6.34	5.53e-10	2.89e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-6.34	5.53e-10	2.89e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
HNSC	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-6.34	5.53e-10	2.89e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
HNSC	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.34	5.56e-10	2.9e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
HNSC	cis	rs6951245	0.529	rs76001997	ENSG00000224079.1	AC091729.7	-6.34	5.56e-10	2.91e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1074450~1078036:+
HNSC	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-6.34	5.56e-10	2.91e-07	-0.43	-0.28	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
HNSC	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	6.34	5.56e-10	2.91e-07	0.36	0.28	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
HNSC	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	6.34	5.56e-10	2.91e-07	0.26	0.28	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	6.34	5.56e-10	2.91e-07	0.32	0.28	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.58e-10	2.91e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	6.34	5.58e-10	2.92e-07	0.23	0.28	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
HNSC	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-6.33	5.6e-10	2.93e-07	-0.4	-0.28	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000254153.1	CTA-398F10.2	6.33	5.6e-10	2.93e-07	0.3	0.28	Mood instability;	chr8:8462781	chr8:8456909~8461337:-
HNSC	cis	rs783540	0.521	rs28719490	ENSG00000276710.3	CSPG4P8	-6.33	5.6e-10	2.93e-07	-0.35	-0.28	Schizophrenia;	chr15:82720688	chr15:82459472~82477258:+
HNSC	cis	rs13113518	0.678	rs13149568	ENSG00000273257.1	RP11-177J6.1	6.33	5.61e-10	2.93e-07	0.34	0.28	Height;	chr4:55370412	chr4:55387949~55388271:+
HNSC	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-6.33	5.61e-10	2.93e-07	-0.48	-0.28	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
HNSC	cis	rs7615952	0.736	rs9862893	ENSG00000241288.6	RP11-379B18.5	-6.33	5.61e-10	2.93e-07	-0.44	-0.28	Blood pressure (smoking interaction);	chr3:125968131	chr3:125827238~125916384:-
HNSC	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	6.33	5.62e-10	2.94e-07	0.3	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
HNSC	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	6.33	5.62e-10	2.94e-07	0.32	0.28	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	6.33	5.63e-10	2.94e-07	0.34	0.28	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
HNSC	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	6.33	5.64e-10	2.94e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
HNSC	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	6.33	5.64e-10	2.94e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
HNSC	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	6.33	5.65e-10	2.95e-07	0.25	0.28	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-6.33	5.65e-10	2.95e-07	-0.25	-0.28	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
HNSC	cis	rs7615952	0.512	rs4234285	ENSG00000241288.6	RP11-379B18.5	-6.33	5.65e-10	2.95e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125685633	chr3:125827238~125916384:-
HNSC	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.33	5.65e-10	2.95e-07	0.28	0.28	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
HNSC	cis	rs440932	0.565	rs19334	ENSG00000173295.6	FAM86B3P	6.33	5.68e-10	2.97e-07	0.31	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8228595~8244865:+
HNSC	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-6.33	5.7e-10	2.97e-07	-0.34	-0.28	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
HNSC	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-6.33	5.71e-10	2.98e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
HNSC	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-6.33	5.71e-10	2.98e-07	-0.33	-0.28	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
HNSC	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-6.33	5.72e-10	2.98e-07	-0.4	-0.28	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
HNSC	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-6.33	5.74e-10	2.99e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
HNSC	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-6.33	5.74e-10	2.99e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
HNSC	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	6.33	5.74e-10	3e-07	0.27	0.28	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
HNSC	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	6.33	5.75e-10	3e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
HNSC	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.33	5.75e-10	3e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
HNSC	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.33	5.76e-10	3e-07	0.3	0.28	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
HNSC	cis	rs2239557	0.845	rs11622838	ENSG00000259065.1	RP5-1021I20.1	6.33	5.78e-10	3.02e-07	0.34	0.28	Common traits (Other);	chr14:74202656	chr14:73787360~73803270:+
HNSC	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-6.33	5.78e-10	3.02e-07	-0.35	-0.28	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-6.33	5.79e-10	3.02e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000211974.3	IGHV2-70	6.33	5.79e-10	3.02e-07	0.33	0.28	Rheumatic heart disease;	chr14:106622776	chr14:106723574~106724093:-
HNSC	cis	rs2235642	0.601	rs2235647	ENSG00000280231.1	LA16c-380F5.3	-6.33	5.79e-10	3.02e-07	-0.36	-0.28	Coronary artery disease;	chr16:1551330	chr16:1553655~1554130:-
HNSC	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	6.33	5.79e-10	3.02e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
HNSC	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-6.33	5.8e-10	3.02e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
HNSC	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	6.33	5.8e-10	3.03e-07	0.34	0.28	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
HNSC	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-6.33	5.82e-10	3.04e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
HNSC	cis	rs783540	0.5	rs783541	ENSG00000255769.6	GOLGA2P10	6.33	5.82e-10	3.04e-07	0.4	0.28	Schizophrenia;	chr15:82586310	chr15:82472993~82513950:-
HNSC	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	6.33	5.84e-10	3.04e-07	0.37	0.28	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
HNSC	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-6.33	5.84e-10	3.04e-07	-0.26	-0.28	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
HNSC	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.33	5.85e-10	3.05e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000179406.6	LINC00174	-6.33	5.86e-10	3.05e-07	-0.51	-0.28	Diabetic kidney disease;	chr7:65988305	chr7:66376044~66401338:-
HNSC	cis	rs8177876	0.822	rs9923732	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9925940	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9925943	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9933184	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9926174	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs8052490	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8056972	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs74437879	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs76948085	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs80315956	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs16954572	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9929586	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs9938965	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs7204040	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs7188508	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs28672349	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.818	rs59177227	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs59685942	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs10514515	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1410	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1412	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs1414	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177950	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs8177948	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177940	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.73	rs76656387	ENSG00000261061.1	RP11-303E16.2	-6.33	5.86e-10	3.05e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-6.33	5.86e-10	3.05e-07	-0.34	-0.28	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
HNSC	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-6.33	5.87e-10	3.06e-07	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000267151.3	RP11-100E5.2	6.33	5.88e-10	3.06e-07	0.35	0.28	Menopause (age at onset);	chr17:43368042	chr17:43444707~43451200:+
HNSC	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	6.33	5.88e-10	3.06e-07	0.36	0.28	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
HNSC	cis	rs11992162	0.591	rs34123222	ENSG00000206014.6	OR7E161P	6.33	5.88e-10	3.06e-07	0.31	0.28	Monocyte count;	chr8:11937840	chr8:11928597~11929563:-
HNSC	cis	rs4141404	0.851	rs5749222	ENSG00000236132.1	CTA-440B3.1	6.33	5.9e-10	3.07e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31160773	chr22:31816379~31817491:-
HNSC	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-6.33	5.9e-10	3.07e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
HNSC	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-6.33	5.91e-10	3.07e-07	-0.36	-0.28	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
HNSC	cis	rs2006771	0.818	rs8142376	ENSG00000236132.1	CTA-440B3.1	6.33	5.91e-10	3.08e-07	0.31	0.28	Nonsyndromic cleft lip with cleft palate;	chr22:31605051	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.528	rs57557135	ENSG00000259732.1	RP11-59H7.3	-6.33	5.92e-10	3.08e-07	-0.37	-0.28	Social communication problems;	chr15:59054018	chr15:59121034~59133250:+
HNSC	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-6.33	5.92e-10	3.08e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	6.33	5.93e-10	3.08e-07	0.39	0.28	Depression;	chr6:28192182	chr6:28943877~28944537:+
HNSC	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-6.33	5.93e-10	3.08e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
HNSC	cis	rs7804306	0.826	rs73050951	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8032762	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050956	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036076	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050958	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036162	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050959	ENSG00000233264.2	AC006042.8	6.32	5.93e-10	3.09e-07	0.65	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037069	chr7:7980312~7982228:+
HNSC	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-6.32	5.94e-10	3.09e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
HNSC	cis	rs5753618	0.561	rs9606830	ENSG00000236132.1	CTA-440B3.1	-6.32	5.94e-10	3.09e-07	-0.34	-0.28	Colorectal cancer;	chr22:31321813	chr22:31816379~31817491:-
HNSC	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	6.32	5.94e-10	3.09e-07	0.33	0.28	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
HNSC	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-6.32	5.94e-10	3.09e-07	-0.34	-0.28	Height;	chr3:53069965	chr3:53064283~53065091:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	6.32	5.94e-10	3.09e-07	0.3	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
HNSC	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	6.32	5.95e-10	3.09e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-6.32	5.96e-10	3.1e-07	-0.22	-0.28	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
HNSC	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-6.32	5.96e-10	3.1e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
HNSC	cis	rs4218	0.689	rs34338282	ENSG00000259732.1	RP11-59H7.3	-6.32	5.97e-10	3.1e-07	-0.4	-0.28	Social communication problems;	chr15:59096897	chr15:59121034~59133250:+
HNSC	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.32	5.97e-10	3.11e-07	0.38	0.28	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
HNSC	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-6.32	5.98e-10	3.11e-07	-0.28	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	6.32	6e-10	3.12e-07	0.35	0.28	Depression;	chr6:28430971	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	6.32	6e-10	3.12e-07	0.31	0.28	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
HNSC	cis	rs6951245	0.745	rs79788515	ENSG00000225146.1	AC073957.15	-6.32	6e-10	3.12e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1029025~1043891:+
HNSC	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-6.32	6.01e-10	3.13e-07	-0.34	-0.28	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
HNSC	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	6.32	6.02e-10	3.13e-07	0.27	0.28	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
HNSC	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	6.32	6.04e-10	3.14e-07	0.35	0.28	Height;	chr4:55457922	chr4:55363971~55395847:-
HNSC	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-6.32	6.04e-10	3.14e-07	-0.34	-0.28	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
HNSC	cis	rs1021993	0.672	rs2495295	ENSG00000231648.1	RP11-372M18.2	6.32	6.04e-10	3.14e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209316343	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.672	rs1395752	ENSG00000231648.1	RP11-372M18.2	6.32	6.04e-10	3.14e-07	0.35	0.28	Gut microbiome composition (winter);	chr1:209317090	chr1:209367662~209379690:+
HNSC	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-6.32	6.06e-10	3.15e-07	-0.33	-0.28	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-6.32	6.06e-10	3.15e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
HNSC	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	6.32	6.06e-10	3.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	6.32	6.06e-10	3.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	6.32	6.06e-10	3.15e-07	0.65	0.28	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	6.32	6.06e-10	3.15e-07	0.65	0.28	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
HNSC	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	6.32	6.07e-10	3.15e-07	0.32	0.28	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
HNSC	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-6.32	6.07e-10	3.15e-07	-0.34	-0.28	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
HNSC	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	6.32	6.07e-10	3.15e-07	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.32	6.08e-10	3.16e-07	-0.37	-0.28	Depression;	chr6:28205232	chr6:28943877~28944537:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000267151.3	RP11-100E5.2	-6.32	6.08e-10	3.16e-07	-0.36	-0.28	Menopause (age at onset);	chr17:43367777	chr17:43444707~43451200:+
HNSC	cis	rs5753618	0.554	rs5753648	ENSG00000236132.1	CTA-440B3.1	-6.32	6.08e-10	3.16e-07	-0.37	-0.28	Colorectal cancer;	chr22:31483479	chr22:31816379~31817491:-
HNSC	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	6.32	6.09e-10	3.16e-07	0.25	0.28	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
HNSC	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-6.32	6.11e-10	3.17e-07	-0.27	-0.28	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
HNSC	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.32	6.12e-10	3.18e-07	-0.51	-0.28	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
HNSC	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-6.32	6.12e-10	3.18e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-6.32	6.13e-10	3.18e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
HNSC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
HNSC	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.13e-10	3.18e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
HNSC	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
HNSC	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-6.32	6.13e-10	3.18e-07	-0.32	-0.28	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
HNSC	cis	rs11992162	0.636	rs4841645	ENSG00000206014.6	OR7E161P	6.32	6.14e-10	3.18e-07	0.31	0.28	Monocyte count;	chr8:11941175	chr8:11928597~11929563:-
HNSC	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.32	6.14e-10	3.19e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
HNSC	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	6.32	6.15e-10	3.19e-07	0.33	0.28	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
HNSC	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.32	6.15e-10	3.19e-07	0.28	0.28	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
HNSC	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	6.32	6.16e-10	3.2e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
HNSC	cis	rs2442825	0.508	rs2648545	ENSG00000206573.7	THUMPD3-AS1	-6.32	6.16e-10	3.2e-07	-0.24	-0.28	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9349689~9398579:-
HNSC	cis	rs7404843	0.789	rs222907	ENSG00000263065.1	AF001548.6	6.32	6.17e-10	3.2e-07	0.45	0.28	Testicular germ cell tumor;	chr16:15404950	chr16:15741151~15741791:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-6.32	6.19e-10	3.21e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
HNSC	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-6.32	6.19e-10	3.21e-07	-0.43	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
HNSC	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	6.32	6.2e-10	3.22e-07	0.4	0.28	Height;	chr6:109365409	chr6:109382795~109383666:+
HNSC	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	6.32	6.21e-10	3.22e-07	0.32	0.28	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
HNSC	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-6.32	6.21e-10	3.22e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
HNSC	cis	rs2579103	0.767	rs2731268	ENSG00000258183.4	RP11-753N8.1	-6.32	6.21e-10	3.22e-07	-0.35	-0.28	Body mass index;	chr12:90276679	chr12:90280894~90300340:+
HNSC	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	6.32	6.21e-10	3.22e-07	0.33	0.28	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
HNSC	cis	rs757110	0.77	rs4439492	ENSG00000260196.1	RP1-239B22.5	6.32	6.21e-10	3.22e-07	0.32	0.28	Type 2 diabetes;	chr11:17365186	chr11:17380649~17383531:+
HNSC	cis	rs757110	0.77	rs2051772	ENSG00000260196.1	RP1-239B22.5	6.32	6.21e-10	3.22e-07	0.32	0.28	Type 2 diabetes;	chr11:17368303	chr11:17380649~17383531:+
HNSC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	6.32	6.22e-10	3.23e-07	0.44	0.28	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000173295.6	FAM86B3P	6.32	6.22e-10	3.23e-07	0.32	0.28	Joint mobility (Beighton score);	chr8:8967994	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000173295.6	FAM86B3P	6.32	6.22e-10	3.23e-07	0.32	0.28	Mood instability;	chr8:8968365	chr8:8228595~8244865:+
HNSC	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	6.32	6.22e-10	3.23e-07	0.31	0.28	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-6.32	6.23e-10	3.23e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
HNSC	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-6.32	6.24e-10	3.23e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000267151.3	RP11-100E5.2	6.32	6.24e-10	3.23e-07	0.36	0.28	Menopause (age at onset);	chr17:43160842	chr17:43444707~43451200:+
HNSC	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	6.32	6.24e-10	3.23e-07	0.23	0.28	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
HNSC	cis	rs440932	1	rs378974	ENSG00000173295.6	FAM86B3P	6.32	6.24e-10	3.23e-07	0.34	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.667	rs7746917	ENSG00000272129.1	RP11-250B2.6	6.32	6.25e-10	3.24e-07	0.33	0.28	Sitting height ratio;	chr6:80221786	chr6:80355424~80356859:+
HNSC	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-6.32	6.25e-10	3.24e-07	-0.46	-0.28	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
HNSC	cis	rs4639966	0.836	rs7124498	ENSG00000255422.1	AP002954.4	6.32	6.25e-10	3.24e-07	0.39	0.28	Systemic lupus erythematosus;	chr11:118745544	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.32	6.26e-10	3.24e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
HNSC	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	6.32	6.26e-10	3.24e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
HNSC	cis	rs947583	0.955	rs7760254	ENSG00000217482.2	HMGB1P17	-6.32	6.26e-10	3.24e-07	-0.3	-0.28	Phosphorus levels;	chr6:135811157	chr6:135636086~135636713:-
HNSC	cis	rs757110	0.74	rs10832776	ENSG00000260196.1	RP1-239B22.5	6.32	6.27e-10	3.25e-07	0.32	0.28	Type 2 diabetes;	chr11:17363677	chr11:17380649~17383531:+
HNSC	cis	rs61160187	0.582	rs17444495	ENSG00000215032.2	GNL3LP1	6.32	6.27e-10	3.25e-07	0.32	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60891935~60893577:-
HNSC	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	6.32	6.28e-10	3.25e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.29e-10	3.26e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.32	6.29e-10	3.26e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
HNSC	cis	rs8177876	0.822	rs1563075	ENSG00000261061.1	RP11-303E16.2	-6.32	6.3e-10	3.26e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81030770~81031485:+
HNSC	cis	rs1865760	0.613	rs9358894	ENSG00000272462.2	U91328.19	-6.31	6.3e-10	3.26e-07	-0.27	-0.28	Height;	chr6:25923087	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	6.31	6.31e-10	3.27e-07	0.37	0.28	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
HNSC	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	6.31	6.31e-10	3.27e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
HNSC	cis	rs8054556	0.76	rs11642740	ENSG00000183604.13	SMG1P5	6.31	6.31e-10	3.27e-07	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr16:30049334	chr16:30267553~30335374:-
HNSC	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	6.31	6.32e-10	3.27e-07	0.45	0.28	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
HNSC	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.31	6.34e-10	3.28e-07	0.27	0.28	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
HNSC	cis	rs9907295	0.591	rs4325615	ENSG00000270977.1	AC015849.16	-6.31	6.34e-10	3.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35826379	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.551	rs28595279	ENSG00000270977.1	AC015849.16	-6.31	6.34e-10	3.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35826416	chr17:35893707~35911023:-
HNSC	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-6.31	6.35e-10	3.28e-07	-0.35	-0.28	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
HNSC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-6.31	6.35e-10	3.29e-07	-0.31	-0.28	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	6.31	6.35e-10	3.29e-07	0.22	0.28	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
HNSC	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-6.31	6.35e-10	3.29e-07	-0.24	-0.28	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
HNSC	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-6.31	6.36e-10	3.29e-07	-0.33	-0.28	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
HNSC	cis	rs4218	0.597	rs4775114	ENSG00000259732.1	RP11-59H7.3	-6.31	6.37e-10	3.3e-07	-0.39	-0.28	Social communication problems;	chr15:59059635	chr15:59121034~59133250:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.31	6.39e-10	3.31e-07	0.34	0.28	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
HNSC	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	6.31	6.39e-10	3.31e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
HNSC	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-6.31	6.4e-10	3.31e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
HNSC	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	6.31	6.4e-10	3.31e-07	0.34	0.28	Height;	chr4:55575856	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-6.31	6.4e-10	3.31e-07	-0.41	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
HNSC	cis	rs2834288	0.535	rs7278341	ENSG00000237945.6	LINC00649	6.31	6.42e-10	3.32e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.535	rs7279183	ENSG00000237945.6	LINC00649	6.31	6.42e-10	3.32e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33915534~33977691:+
HNSC	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-6.31	6.42e-10	3.32e-07	-0.3	-0.28	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
HNSC	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.31	6.43e-10	3.33e-07	-0.37	-0.28	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
HNSC	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-6.31	6.45e-10	3.33e-07	-0.38	-0.28	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
HNSC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-6.31	6.46e-10	3.34e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-6.31	6.46e-10	3.34e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
HNSC	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	6.31	6.48e-10	3.35e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
HNSC	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	6.31	6.51e-10	3.36e-07	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
HNSC	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-6.31	6.53e-10	3.37e-07	-0.35	-0.28	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
HNSC	cis	rs1355223	0.867	rs1377495	ENSG00000271369.1	RP11-350D17.3	6.31	6.53e-10	3.37e-07	0.33	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34661415	chr11:34709600~34710161:+
HNSC	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	6.31	6.54e-10	3.38e-07	0.33	0.28	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
HNSC	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	6.31	6.54e-10	3.38e-07	0.37	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
HNSC	cis	rs2834288	0.535	rs9982605	ENSG00000237945.6	LINC00649	6.31	6.54e-10	3.38e-07	0.35	0.28	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33915534~33977691:+
HNSC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	6.31	6.56e-10	3.39e-07	0.33	0.28	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
HNSC	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	6.31	6.56e-10	3.39e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
HNSC	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-6.31	6.57e-10	3.39e-07	-0.3	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
HNSC	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
HNSC	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-6.31	6.58e-10	3.4e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
HNSC	cis	rs9650657	0.53	rs6982381	ENSG00000269918.1	AF131215.9	-6.31	6.59e-10	3.4e-07	-0.28	-0.28	Neuroticism;	chr8:11094990	chr8:11104691~11106704:-
HNSC	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.33	0.28	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	6.31	6.59e-10	3.4e-07	0.35	0.28	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
HNSC	cis	rs1021993	0.545	rs4844809	ENSG00000231648.1	RP11-372M18.2	-6.31	6.6e-10	3.41e-07	-0.46	-0.28	Gut microbiome composition (winter);	chr1:209346427	chr1:209367662~209379690:+
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-6.31	6.6e-10	3.41e-07	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
HNSC	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-6.31	6.61e-10	3.41e-07	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
HNSC	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-6.31	6.61e-10	3.41e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	6.31	6.63e-10	3.42e-07	0.66	0.28	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
HNSC	cis	rs757110	0.648	rs12146443	ENSG00000260196.1	RP1-239B22.5	6.31	6.63e-10	3.42e-07	0.32	0.28	Type 2 diabetes;	chr11:17362951	chr11:17380649~17383531:+
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	6.31	6.64e-10	3.43e-07	0.35	0.28	Depression;	chr6:28432562	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	6.31	6.65e-10	3.43e-07	0.35	0.28	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
HNSC	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	6.31	6.65e-10	3.43e-07	0.36	0.28	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
HNSC	cis	rs8177876	0.731	rs74882687	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.642	rs76909932	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs8177939	ENSG00000261061.1	RP11-303E16.2	-6.31	6.66e-10	3.44e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81030770~81031485:+
HNSC	cis	rs4141404	0.851	rs8135417	ENSG00000236132.1	CTA-440B3.1	6.31	6.68e-10	3.45e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31163269	chr22:31816379~31817491:-
HNSC	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	6.3	6.69e-10	3.45e-07	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
HNSC	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	6.3	6.69e-10	3.45e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
HNSC	cis	rs2404602	0.692	rs1838048	ENSG00000259422.1	RP11-593F23.1	6.3	6.69e-10	3.45e-07	0.32	0.28	Blood metabolite levels;	chr15:76639338	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs56193230	ENSG00000259422.1	RP11-593F23.1	6.3	6.69e-10	3.45e-07	0.32	0.28	Blood metabolite levels;	chr15:76642131	chr15:76174891~76181486:-
HNSC	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	6.3	6.7e-10	3.46e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
HNSC	cis	rs67180937	0.55	rs9441926	ENSG00000272750.1	RP11-378J18.8	-6.3	6.71e-10	3.46e-07	-0.34	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622822	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.589	rs9441835	ENSG00000272750.1	RP11-378J18.8	-6.3	6.71e-10	3.46e-07	-0.34	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622827	chr1:222658867~222661512:-
HNSC	cis	rs9326248	0.53	rs72645460	ENSG00000280143.1	AP000892.6	-6.3	6.71e-10	3.46e-07	-0.44	-0.28	Blood protein levels;	chr11:116900659	chr11:117204967~117210292:+
HNSC	cis	rs7615952	0.546	rs2976733	ENSG00000241288.6	RP11-379B18.5	-6.3	6.73e-10	3.47e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125695294	chr3:125827238~125916384:-
HNSC	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	6.3	6.73e-10	3.47e-07	0.32	0.28	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-6.3	6.73e-10	3.47e-07	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	6.3	6.74e-10	3.47e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
HNSC	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-6.3	6.75e-10	3.48e-07	-0.38	-0.28	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
HNSC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-6.3	6.75e-10	3.48e-07	-0.3	-0.28	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
HNSC	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.3	6.76e-10	3.48e-07	-0.34	-0.28	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
HNSC	cis	rs7615952	0.558	rs7641353	ENSG00000241288.6	RP11-379B18.5	-6.3	6.76e-10	3.48e-07	-0.35	-0.28	Blood pressure (smoking interaction);	chr3:125621035	chr3:125827238~125916384:-
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-6.3	6.76e-10	3.48e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
HNSC	cis	rs757110	0.77	rs11024268	ENSG00000260196.1	RP1-239B22.5	6.3	6.76e-10	3.48e-07	0.32	0.28	Type 2 diabetes;	chr11:17366435	chr11:17380649~17383531:+
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000211974.3	IGHV2-70	-6.3	6.76e-10	3.49e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106700213	chr14:106723574~106724093:-
HNSC	cis	rs8054556	0.692	rs12716972	ENSG00000183604.13	SMG1P5	-6.3	6.77e-10	3.49e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30267553~30335374:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000254153.1	CTA-398F10.2	6.3	6.77e-10	3.49e-07	0.3	0.28	Mood instability;	chr8:8460105	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	6.3	6.77e-10	3.49e-07	0.4	0.28	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
HNSC	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.3	6.77e-10	3.49e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
HNSC	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-6.3	6.78e-10	3.49e-07	-0.42	-0.28	Depression;	chr6:28272137	chr6:28115628~28116551:+
HNSC	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-6.3	6.78e-10	3.49e-07	-0.34	-0.28	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	6.3	6.79e-10	3.5e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
HNSC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	6.3	6.8e-10	3.5e-07	0.32	0.28	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
HNSC	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	6.3	6.81e-10	3.51e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
HNSC	cis	rs8177876	0.642	rs56032321	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs56119129	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs77145371	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.908	rs80187824	ENSG00000261061.1	RP11-303E16.2	-6.3	6.82e-10	3.51e-07	-0.46	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81030770~81031485:+
HNSC	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	6.3	6.83e-10	3.52e-07	0.36	0.28	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	6.3	6.84e-10	3.52e-07	0.66	0.28	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
HNSC	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	6.3	6.84e-10	3.52e-07	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
HNSC	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	6.3	6.84e-10	3.52e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
HNSC	cis	rs4141404	0.851	rs5997893	ENSG00000236132.1	CTA-440B3.1	6.3	6.84e-10	3.52e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31160117	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.3	6.87e-10	3.53e-07	-0.33	-0.28	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000254340.1	RP11-10A14.3	-6.3	6.88e-10	3.54e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9227707	chr8:9141424~9145435:+
HNSC	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-6.3	6.88e-10	3.54e-07	-0.32	-0.28	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.54e-07	0.36	0.28	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
HNSC	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	6.3	6.89e-10	3.54e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
HNSC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.3	6.89e-10	3.54e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
HNSC	cis	rs11992162	0.613	rs56094399	ENSG00000206014.6	OR7E161P	6.3	6.9e-10	3.55e-07	0.31	0.28	Monocyte count;	chr8:11939961	chr8:11928597~11929563:-
HNSC	cis	rs5753618	0.504	rs8142121	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.37	-0.28	Colorectal cancer;	chr22:31486799	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs13054220	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.34	-0.28	Colorectal cancer;	chr22:31308506	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs9609254	ENSG00000236132.1	CTA-440B3.1	-6.3	6.9e-10	3.55e-07	-0.34	-0.28	Colorectal cancer;	chr22:31309956	chr22:31816379~31817491:-
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.9e-10	3.55e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
HNSC	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	6.3	6.91e-10	3.55e-07	0.38	0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
HNSC	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-6.3	6.91e-10	3.55e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
HNSC	cis	rs2286503	1	rs2286498	ENSG00000221740.1	SNORD93	-6.3	6.91e-10	3.55e-07	-0.29	-0.28	Fibrinogen;	chr7:22817885	chr7:22856613~22856686:+
HNSC	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	6.3	6.93e-10	3.56e-07	0.32	0.28	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
HNSC	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	6.3	6.93e-10	3.56e-07	0.32	0.28	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	6.3	6.94e-10	3.56e-07	0.66	0.28	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	6.3	6.94e-10	3.57e-07	0.45	0.28	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
HNSC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	6.3	6.95e-10	3.57e-07	0.31	0.28	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
HNSC	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	6.3	6.95e-10	3.57e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
HNSC	cis	rs9341808	0.935	rs9343974	ENSG00000272129.1	RP11-250B2.6	6.3	6.95e-10	3.57e-07	0.33	0.28	Sitting height ratio;	chr6:80214928	chr6:80355424~80356859:+
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000173295.6	FAM86B3P	-6.3	6.95e-10	3.57e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9036071	chr8:8228595~8244865:+
HNSC	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	6.3	6.95e-10	3.57e-07	0.24	0.28	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	6.3	6.95e-10	3.57e-07	0.24	0.28	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-6.3	6.95e-10	3.57e-07	-0.24	-0.28	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.3	6.96e-10	3.57e-07	0.35	0.28	Depression;	chr6:28379133	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.3	6.96e-10	3.57e-07	0.35	0.28	Depression;	chr6:28379168	chr6:28943877~28944537:+
HNSC	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-6.3	6.98e-10	3.58e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
HNSC	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-6.3	6.98e-10	3.58e-07	-0.3	-0.28	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
HNSC	cis	rs2404602	0.692	rs35077207	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76642965	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs35195096	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76646106	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs34287706	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76650061	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12438540	ENSG00000259422.1	RP11-593F23.1	6.3	6.99e-10	3.59e-07	0.32	0.28	Blood metabolite levels;	chr15:76650872	chr15:76174891~76181486:-
HNSC	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	6.3	7e-10	3.59e-07	0.32	0.28	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
HNSC	cis	rs12439619	0.846	rs62012004	ENSG00000276710.3	CSPG4P8	-6.3	7e-10	3.59e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	6.3	7e-10	3.59e-07	0.39	0.28	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
HNSC	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	6.3	7e-10	3.59e-07	0.31	0.28	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	6.3	7e-10	3.59e-07	0.31	0.28	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
HNSC	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	6.3	7e-10	3.6e-07	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
HNSC	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-6.3	7.02e-10	3.6e-07	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-6.3	7.02e-10	3.6e-07	-0.33	-0.28	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
HNSC	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	6.3	7.02e-10	3.6e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
HNSC	cis	rs2404602	0.692	rs8037005	ENSG00000259422.1	RP11-593F23.1	6.3	7.02e-10	3.6e-07	0.32	0.28	Blood metabolite levels;	chr15:76658768	chr15:76174891~76181486:-
HNSC	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	6.3	7.03e-10	3.61e-07	0.32	0.28	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
HNSC	cis	rs6471393	1	rs6471393	ENSG00000253848.1	RP11-10N23.5	-6.3	7.04e-10	3.61e-07	-0.35	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703063	chr8:93741193~93744534:+
HNSC	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-6.3	7.05e-10	3.62e-07	-0.28	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000254340.1	RP11-10A14.3	-6.3	7.05e-10	3.62e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9226955	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-6.3	7.06e-10	3.62e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
HNSC	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-6.3	7.07e-10	3.63e-07	-0.25	-0.28	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-6.3	7.07e-10	3.63e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-6.3	7.07e-10	3.63e-07	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
HNSC	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	6.3	7.08e-10	3.63e-07	0.39	0.28	Height;	chr6:109465229	chr6:109382795~109383666:+
HNSC	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-6.3	7.08e-10	3.63e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000173295.6	FAM86B3P	-6.3	7.08e-10	3.63e-07	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9009151	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	6.29	7.1e-10	3.64e-07	0.32	0.28	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	6.29	7.11e-10	3.64e-07	0.4	0.28	Height;	chr6:109351533	chr6:109382795~109383666:+
HNSC	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	6.29	7.11e-10	3.64e-07	0.4	0.28	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
HNSC	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	6.29	7.11e-10	3.65e-07	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
HNSC	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	6.29	7.12e-10	3.65e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
HNSC	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	6.29	7.12e-10	3.65e-07	0.36	0.28	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
HNSC	cis	rs8054556	0.656	rs4420550	ENSG00000183604.13	SMG1P5	-6.29	7.15e-10	3.67e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30267553~30335374:-
HNSC	cis	rs1355223	0.844	rs12809046	ENSG00000271369.1	RP11-350D17.3	-6.29	7.15e-10	3.67e-07	-0.33	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726714	chr11:34709600~34710161:+
HNSC	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-6.29	7.16e-10	3.67e-07	-0.52	-0.28	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
HNSC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	6.29	7.16e-10	3.67e-07	0.31	0.28	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-6.29	7.17e-10	3.68e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
HNSC	cis	rs4639966	0.836	rs73001486	ENSG00000255422.1	AP002954.4	6.29	7.18e-10	3.68e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118758655	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.29	7.19e-10	3.68e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.29	7.19e-10	3.68e-07	-0.31	-0.28	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
HNSC	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	6.29	7.19e-10	3.69e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
HNSC	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	6.29	7.19e-10	3.69e-07	0.52	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
HNSC	cis	rs9341808	0.935	rs9448894	ENSG00000272129.1	RP11-250B2.6	6.29	7.2e-10	3.69e-07	0.33	0.28	Sitting height ratio;	chr6:80127536	chr6:80355424~80356859:+
HNSC	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-6.29	7.2e-10	3.69e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
HNSC	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	6.29	7.21e-10	3.69e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	6.29	7.21e-10	3.7e-07	0.31	0.28	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	6.29	7.23e-10	3.7e-07	0.33	0.28	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
HNSC	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	6.29	7.24e-10	3.71e-07	0.37	0.28	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
HNSC	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-6.29	7.25e-10	3.71e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
HNSC	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-6.29	7.25e-10	3.72e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
HNSC	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-6.29	7.26e-10	3.72e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
HNSC	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	6.29	7.26e-10	3.72e-07	0.34	0.28	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
HNSC	cis	rs947583	0.866	rs7759326	ENSG00000217482.2	HMGB1P17	6.29	7.27e-10	3.72e-07	0.31	0.28	Phosphorus levels;	chr6:135816421	chr6:135636086~135636713:-
HNSC	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	6.29	7.28e-10	3.73e-07	0.3	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
HNSC	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-6.29	7.3e-10	3.74e-07	-0.31	-0.28	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
HNSC	cis	rs8177876	0.822	rs8177959	ENSG00000261061.1	RP11-303E16.2	-6.29	7.31e-10	3.74e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	6.29	7.31e-10	3.74e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
HNSC	cis	rs9840812	0.567	rs2655008	ENSG00000273486.1	RP11-731C17.2	6.29	7.31e-10	3.74e-07	0.24	0.28	Fibrinogen levels;	chr3:136404933	chr3:136837338~136839021:-
HNSC	cis	rs7819412	0.775	rs2001329	ENSG00000255310.2	AF131215.2	-6.29	7.31e-10	3.74e-07	-0.27	-0.28	Triglycerides;	chr8:11129349	chr8:11107788~11109726:-
HNSC	cis	rs860295	0.775	rs822509	ENSG00000203761.5	MSTO2P	6.29	7.33e-10	3.75e-07	0.2	0.28	Body mass index;	chr1:155881020	chr1:155745829~155750137:+
HNSC	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	6.29	7.33e-10	3.75e-07	0.27	0.28	Asthma;	chr2:102446466	chr2:102438713~102440475:+
HNSC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	6.29	7.33e-10	3.75e-07	0.32	0.28	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.29	7.33e-10	3.75e-07	0.32	0.28	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
HNSC	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-6.29	7.34e-10	3.75e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
HNSC	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-6.29	7.35e-10	3.76e-07	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
HNSC	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	6.29	7.37e-10	3.77e-07	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
HNSC	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-6.29	7.39e-10	3.78e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
HNSC	cis	rs8054556	0.74	rs4609871	ENSG00000183604.13	SMG1P5	6.29	7.39e-10	3.78e-07	0.26	0.28	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30267553~30335374:-
HNSC	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-6.29	7.39e-10	3.78e-07	-0.31	-0.28	Monocyte count;	chr11:307036	chr11:318640~325631:+
HNSC	cis	rs34526934	0.566	rs9141	ENSG00000226363.3	HAGLROS	6.29	7.41e-10	3.79e-07	0.37	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176173242	chr2:176177717~176179008:+
HNSC	cis	rs7615952	0.576	rs4646763	ENSG00000241288.6	RP11-379B18.5	-6.29	7.41e-10	3.79e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126103286	chr3:125827238~125916384:-
HNSC	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	6.29	7.41e-10	3.79e-07	0.32	0.28	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
HNSC	cis	rs4639966	0.836	rs11217016	ENSG00000255422.1	AP002954.4	6.29	7.42e-10	3.79e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118756440	chr11:118704607~118750263:+
HNSC	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	6.29	7.42e-10	3.79e-07	0.36	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
HNSC	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	6.29	7.44e-10	3.8e-07	0.27	0.28	Asthma;	chr2:102437614	chr2:102438713~102440475:+
HNSC	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-6.29	7.44e-10	3.8e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
HNSC	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	6.29	7.45e-10	3.81e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
HNSC	cis	rs7246657	0.943	rs10404945	ENSG00000276846.1	CTD-3220F14.3	6.29	7.45e-10	3.81e-07	0.38	0.28	Coronary artery calcification;	chr19:37531456	chr19:37314868~37315620:-
HNSC	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-6.29	7.46e-10	3.81e-07	-0.33	-0.28	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
HNSC	cis	rs947583	0.517	rs4896181	ENSG00000217482.2	HMGB1P17	6.29	7.46e-10	3.81e-07	0.29	0.28	Phosphorus levels;	chr6:135788742	chr6:135636086~135636713:-
HNSC	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-6.29	7.47e-10	3.82e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
HNSC	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	6.29	7.48e-10	3.82e-07	0.32	0.28	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
HNSC	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	6.29	7.48e-10	3.82e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
HNSC	cis	rs13056815	1	rs13056815	ENSG00000236132.1	CTA-440B3.1	6.29	7.49e-10	3.82e-07	0.3	0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr22:31272264	chr22:31816379~31817491:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000211974.3	IGHV2-70	-6.29	7.49e-10	3.83e-07	-0.33	-0.28	Rheumatic heart disease;	chr14:106618321	chr14:106723574~106724093:-
HNSC	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-6.29	7.49e-10	3.83e-07	-0.36	-0.28	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-6.29	7.49e-10	3.83e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	6.29	7.49e-10	3.83e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	6.29	7.49e-10	3.83e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
HNSC	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.29	7.5e-10	3.83e-07	0.3	0.28	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
HNSC	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-6.29	7.5e-10	3.83e-07	-0.33	-0.28	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	6.28	7.53e-10	3.84e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
HNSC	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.28	7.53e-10	3.84e-07	0.28	0.28	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
HNSC	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	6.28	7.54e-10	3.84e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.571	rs330048	ENSG00000254340.1	RP11-10A14.3	-6.28	7.54e-10	3.85e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9229768	chr8:9141424~9145435:+
HNSC	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-6.28	7.55e-10	3.85e-07	-0.3	-0.28	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
HNSC	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	6.28	7.56e-10	3.86e-07	0.36	0.28	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
HNSC	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-6.28	7.56e-10	3.86e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
HNSC	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	6.28	7.56e-10	3.86e-07	0.35	0.28	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.57e-10	3.86e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-6.28	7.58e-10	3.86e-07	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
HNSC	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-6.28	7.58e-10	3.87e-07	-0.37	-0.28	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
HNSC	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	6.28	7.59e-10	3.87e-07	0.33	0.28	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
HNSC	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.28	7.59e-10	3.87e-07	0.28	0.28	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
HNSC	cis	rs9341808	0.667	rs10943698	ENSG00000272129.1	RP11-250B2.6	6.28	7.59e-10	3.87e-07	0.32	0.28	Sitting height ratio;	chr6:80224584	chr6:80355424~80356859:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-6.28	7.61e-10	3.88e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-6.28	7.62e-10	3.88e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.62e-10	3.89e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
HNSC	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	6.28	7.63e-10	3.89e-07	0.35	0.28	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
HNSC	cis	rs8012947	0.883	rs8005100	ENSG00000279636.2	LINC00216	-6.28	7.63e-10	3.89e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58271048	chr14:58288033~58289158:+
HNSC	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-6.28	7.64e-10	3.89e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
HNSC	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-6.28	7.65e-10	3.9e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
HNSC	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-6.28	7.67e-10	3.91e-07	-0.32	-0.28	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000173295.6	FAM86B3P	-6.28	7.67e-10	3.91e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9035094	chr8:8228595~8244865:+
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	-6.28	7.67e-10	3.91e-07	-0.33	-0.28	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
HNSC	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-6.28	7.68e-10	3.91e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
HNSC	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	6.28	7.69e-10	3.92e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
HNSC	cis	rs860295	0.775	rs1749410	ENSG00000203761.5	MSTO2P	6.28	7.69e-10	3.92e-07	0.21	0.28	Body mass index;	chr1:155874274	chr1:155745829~155750137:+
HNSC	cis	rs4141404	0.923	rs2413046	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Paclitaxel-induced neuropathy;	chr22:31269923	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2413047	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31270040	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs8135344	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31275946	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.539	rs5997933	ENSG00000236132.1	CTA-440B3.1	6.28	7.73e-10	3.94e-07	0.34	0.28	Colorectal cancer;	chr22:31276766	chr22:31816379~31817491:-
HNSC	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.28	7.74e-10	3.94e-07	0.29	0.28	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
HNSC	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-6.28	7.74e-10	3.94e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
HNSC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.28	7.77e-10	3.95e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-6.28	7.77e-10	3.95e-07	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
HNSC	cis	rs8177876	0.822	rs79926943	ENSG00000261061.1	RP11-303E16.2	-6.28	7.77e-10	3.96e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81030770~81031485:+
HNSC	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-6.28	7.77e-10	3.96e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
HNSC	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-6.28	7.78e-10	3.96e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
HNSC	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.28	7.78e-10	3.96e-07	0.33	0.28	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.28	7.78e-10	3.96e-07	0.33	0.28	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
HNSC	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	6.28	7.78e-10	3.96e-07	0.27	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-6.28	7.78e-10	3.96e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
HNSC	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.79e-10	3.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.79e-10	3.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
HNSC	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	6.28	7.79e-10	3.97e-07	0.45	0.28	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
HNSC	cis	rs783540	0.521	rs28719490	ENSG00000255769.6	GOLGA2P10	-6.28	7.8e-10	3.97e-07	-0.39	-0.28	Schizophrenia;	chr15:82720688	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	6.28	7.8e-10	3.97e-07	0.39	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
HNSC	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-6.28	7.81e-10	3.97e-07	-0.33	-0.28	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
HNSC	cis	rs4218	0.513	rs17302142	ENSG00000259732.1	RP11-59H7.3	-6.28	7.81e-10	3.97e-07	-0.37	-0.28	Social communication problems;	chr15:59053813	chr15:59121034~59133250:+
HNSC	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	6.28	7.81e-10	3.97e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-6.28	7.81e-10	3.97e-07	-0.18	-0.28	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
HNSC	cis	rs947583	0.517	rs9402757	ENSG00000217482.2	HMGB1P17	-6.28	7.82e-10	3.98e-07	-0.29	-0.28	Phosphorus levels;	chr6:135799947	chr6:135636086~135636713:-
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.84e-10	3.99e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-6.28	7.85e-10	3.99e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
HNSC	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-6.28	7.86e-10	4e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-6.28	7.86e-10	4e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
HNSC	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-6.28	7.86e-10	4e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	6.28	7.86e-10	4e-07	0.36	0.28	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
HNSC	cis	rs6918586	0.636	rs198857	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26102189	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198856	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26102480	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198854	ENSG00000272462.2	U91328.19	-6.28	7.87e-10	4e-07	-0.26	-0.28	Schizophrenia;	chr6:26103829	chr6:25992662~26001775:+
HNSC	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-6.28	7.88e-10	4.01e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	6.28	7.89e-10	4.01e-07	0.4	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
HNSC	cis	rs2790457	0.795	rs7903703	ENSG00000254635.4	WAC-AS1	-6.28	7.91e-10	4.02e-07	-0.32	-0.28	Multiple myeloma;	chr10:28646220	chr10:28522652~28532743:-
HNSC	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
HNSC	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-6.28	7.92e-10	4.02e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
HNSC	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-6.28	7.92e-10	4.02e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
HNSC	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.28	7.93e-10	4.03e-07	-0.38	-0.28	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
HNSC	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	6.28	7.94e-10	4.03e-07	0.33	0.28	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
HNSC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-6.28	7.94e-10	4.03e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
HNSC	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	6.28	7.94e-10	4.03e-07	0.32	0.28	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
HNSC	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-6.28	7.94e-10	4.04e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000254340.1	RP11-10A14.3	-6.28	7.95e-10	4.04e-07	-0.33	-0.28	Joint mobility (Beighton score);	chr8:9227399	chr8:9141424~9145435:+
HNSC	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.28	7.95e-10	4.04e-07	0.28	0.28	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
HNSC	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-6.28	7.96e-10	4.04e-07	-0.34	-0.28	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
HNSC	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	6.28	7.96e-10	4.04e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
HNSC	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	6.28	7.97e-10	4.05e-07	0.35	0.28	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000211974.3	IGHV2-70	-6.28	7.98e-10	4.05e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106697010	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000211974.3	IGHV2-70	-6.28	7.98e-10	4.05e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106697140	chr14:106723574~106724093:-
HNSC	cis	rs9907295	0.591	rs78655848	ENSG00000270977.1	AC015849.16	-6.28	7.98e-10	4.05e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35893707~35911023:-
HNSC	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-6.27	8e-10	4.06e-07	-0.37	-0.28	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
HNSC	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	6.27	8e-10	4.06e-07	0.33	0.28	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
HNSC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	6.27	8.03e-10	4.07e-07	0.34	0.28	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
HNSC	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6.27	8.03e-10	4.08e-07	0.33	0.28	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
HNSC	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	6.27	8.04e-10	4.08e-07	0.39	0.28	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
HNSC	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	6.27	8.05e-10	4.08e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
HNSC	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	6.27	8.05e-10	4.08e-07	0.32	0.28	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-6.27	8.08e-10	4.1e-07	-0.33	-0.28	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	6.27	8.11e-10	4.11e-07	0.66	0.28	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	6.27	8.11e-10	4.11e-07	0.66	0.28	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
HNSC	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	6.27	8.12e-10	4.12e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
HNSC	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	6.27	8.15e-10	4.13e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
HNSC	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	6.27	8.16e-10	4.14e-07	0.31	0.28	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
HNSC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-6.27	8.16e-10	4.14e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000173295.6	FAM86B3P	6.27	8.17e-10	4.14e-07	0.32	0.28	Mood instability;	chr8:8865165	chr8:8228595~8244865:+
HNSC	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	6.27	8.17e-10	4.14e-07	0.32	0.28	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
HNSC	cis	rs17270561	0.666	rs1141034	ENSG00000272462.2	U91328.19	-6.27	8.17e-10	4.14e-07	-0.29	-0.28	Iron status biomarkers;	chr6:25780104	chr6:25992662~26001775:+
HNSC	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	6.27	8.18e-10	4.14e-07	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
HNSC	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-6.27	8.19e-10	4.15e-07	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
HNSC	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	6.27	8.2e-10	4.16e-07	0.36	0.28	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	6.27	8.21e-10	4.16e-07	0.38	0.28	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
HNSC	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	6.27	8.22e-10	4.16e-07	0.24	0.28	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
HNSC	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	6.27	8.22e-10	4.16e-07	0.57	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-6.27	8.24e-10	4.17e-07	-0.35	-0.28	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000179406.6	LINC00174	-6.27	8.24e-10	4.17e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66474549	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-6.27	8.25e-10	4.18e-07	-0.33	-0.28	Height;	chr4:55514317	chr4:55363971~55395847:-
HNSC	cis	rs2985684	0.846	rs10150624	ENSG00000258568.1	RHOQP1	6.27	8.25e-10	4.18e-07	0.29	0.28	Carotid intima media thickness;	chr14:49584847	chr14:49599994~49600572:+
HNSC	cis	rs2985684	0.802	rs10150823	ENSG00000258568.1	RHOQP1	6.27	8.25e-10	4.18e-07	0.29	0.28	Carotid intima media thickness;	chr14:49585033	chr14:49599994~49600572:+
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	6.27	8.25e-10	4.18e-07	0.66	0.28	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
HNSC	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.27	8.25e-10	4.18e-07	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
HNSC	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-6.27	8.27e-10	4.19e-07	-0.36	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
HNSC	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-6.27	8.27e-10	4.19e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
HNSC	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	6.27	8.28e-10	4.19e-07	0.22	0.28	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
HNSC	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	6.27	8.28e-10	4.19e-07	0.32	0.28	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
HNSC	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	6.27	8.29e-10	4.2e-07	0.26	0.28	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
HNSC	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-6.27	8.3e-10	4.2e-07	-0.28	-0.28	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
HNSC	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.27	8.31e-10	4.21e-07	0.29	0.28	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
HNSC	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	6.27	8.33e-10	4.21e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	6.27	8.33e-10	4.21e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
HNSC	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-6.27	8.33e-10	4.22e-07	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
HNSC	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-6.27	8.34e-10	4.22e-07	-0.41	-0.28	Depression;	chr6:28311323	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-6.27	8.34e-10	4.22e-07	-0.31	-0.28	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
HNSC	cis	rs4218	0.689	rs12902628	ENSG00000259732.1	RP11-59H7.3	-6.27	8.35e-10	4.22e-07	-0.39	-0.28	Social communication problems;	chr15:59100193	chr15:59121034~59133250:+
HNSC	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	6.27	8.35e-10	4.23e-07	0.32	0.28	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	6.27	8.35e-10	4.23e-07	0.32	0.28	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
HNSC	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-6.27	8.35e-10	4.23e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-6.27	8.36e-10	4.23e-07	-0.18	-0.28	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
HNSC	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-6.27	8.37e-10	4.24e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
HNSC	cis	rs34526934	0.608	rs72927183	ENSG00000226363.3	HAGLROS	6.27	8.37e-10	4.24e-07	0.37	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176169051	chr2:176177717~176179008:+
HNSC	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	6.27	8.39e-10	4.24e-07	0.21	0.28	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
HNSC	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	6.27	8.39e-10	4.24e-07	0.38	0.28	Height;	chr6:109375003	chr6:109382795~109383666:+
HNSC	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.27	8.41e-10	4.25e-07	0.28	0.28	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
HNSC	cis	rs6951245	1	rs77868187	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs75016635	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113066613	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11763793	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11763835	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78861357	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs76713558	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.748	rs79658522	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.935	rs76525951	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79683221	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78185801	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs80031817	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs78143408	ENSG00000225146.1	AC073957.15	-6.27	8.42e-10	4.26e-07	-0.48	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1029025~1043891:+
HNSC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	6.27	8.45e-10	4.27e-07	0.31	0.28	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	6.27	8.45e-10	4.27e-07	0.31	0.28	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
HNSC	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	6.27	8.46e-10	4.28e-07	0.35	0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
HNSC	cis	rs9907295	0.591	rs8069014	ENSG00000270977.1	AC015849.16	-6.27	8.47e-10	4.28e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35893707~35911023:-
HNSC	cis	rs8062405	0.54	rs193628	ENSG00000259982.1	CDC37P1	-6.27	8.47e-10	4.28e-07	-0.3	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28700294~28701540:-
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-6.26	8.49e-10	4.29e-07	-0.34	-0.28	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
HNSC	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-6.26	8.5e-10	4.29e-07	-0.34	-0.28	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
HNSC	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.26	8.5e-10	4.29e-07	0.27	0.28	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
HNSC	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-6.26	8.53e-10	4.31e-07	-0.26	-0.28	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-6.26	8.53e-10	4.31e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
HNSC	cis	rs9890032	0.934	rs3760318	ENSG00000263531.1	RP13-753N3.1	6.26	8.53e-10	4.31e-07	0.33	0.28	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30863921~30864940:-
HNSC	cis	rs7176527	0.796	rs1057946	ENSG00000229212.6	RP11-561C5.4	6.26	8.53e-10	4.31e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85205440~85234795:-
HNSC	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	6.26	8.54e-10	4.31e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66433290	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs67536397	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66482930	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs58669269	ENSG00000179406.6	LINC00174	-6.26	8.55e-10	4.32e-07	-0.59	-0.28	Diabetic kidney disease;	chr7:66486966	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	6.26	8.56e-10	4.32e-07	0.37	0.28	Depression;	chr6:28226851	chr6:28943877~28944537:+
HNSC	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.26	8.57e-10	4.33e-07	0.29	0.28	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
HNSC	cis	rs4388249	0.687	rs10038829	ENSG00000271849.1	CTC-332L22.1	6.26	8.57e-10	4.33e-07	0.37	0.28	Schizophrenia;	chr5:109769002	chr5:109687802~109688329:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	6.26	8.58e-10	4.33e-07	0.22	0.28	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
HNSC	cis	rs6951245	0.938	rs112425403	ENSG00000225146.1	AC073957.15	-6.26	8.58e-10	4.33e-07	-0.46	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1029025~1043891:+
HNSC	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	6.26	8.58e-10	4.33e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.689	rs73418863	ENSG00000259732.1	RP11-59H7.3	-6.26	8.59e-10	4.34e-07	-0.39	-0.28	Social communication problems;	chr15:59098923	chr15:59121034~59133250:+
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	6.26	8.6e-10	4.34e-07	0.66	0.28	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
HNSC	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	6.26	8.61e-10	4.35e-07	0.38	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
HNSC	cis	rs9329221	0.592	rs7832708	ENSG00000269918.1	AF131215.9	6.26	8.61e-10	4.35e-07	0.26	0.28	Neuroticism;	chr8:10332530	chr8:11104691~11106704:-
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	6.26	8.64e-10	4.35e-07	0.39	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-6.26	8.64e-10	4.35e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
HNSC	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-6.26	8.64e-10	4.36e-07	-0.34	-0.28	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
HNSC	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	6.26	8.64e-10	4.36e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
HNSC	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-6.26	8.65e-10	4.36e-07	-0.34	-0.28	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	6.26	8.66e-10	4.36e-07	0.31	0.28	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	6.26	8.66e-10	4.37e-07	0.65	0.28	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-6.26	8.67e-10	4.37e-07	-0.19	-0.28	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
HNSC	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	6.26	8.67e-10	4.37e-07	0.37	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
HNSC	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	6.26	8.67e-10	4.37e-07	0.27	0.28	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
HNSC	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.26	8.68e-10	4.37e-07	0.28	0.28	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
HNSC	cis	rs757110	0.69	rs35271178	ENSG00000260196.1	RP1-239B22.5	6.26	8.68e-10	4.38e-07	0.31	0.28	Type 2 diabetes;	chr11:17389473	chr11:17380649~17383531:+
HNSC	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.26	8.69e-10	4.38e-07	0.28	0.28	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
HNSC	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-6.26	8.69e-10	4.38e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
HNSC	cis	rs9402743	0.641	rs6906211	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135778283	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6906845	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135778363	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.64	rs9494384	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135779072	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6570041	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135780515	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6923513	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135780784	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs4895457	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135783172	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs7764412	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Phosphorus levels;	chr6:135787214	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.667	rs4896179	ENSG00000217482.2	HMGB1P17	6.26	8.69e-10	4.38e-07	0.29	0.28	Systemic lupus erythematosus;	chr6:135788352	chr6:135636086~135636713:-
HNSC	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.26	8.7e-10	4.38e-07	0.39	0.28	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
HNSC	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	6.26	8.7e-10	4.38e-07	0.32	0.28	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
HNSC	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6.26	8.7e-10	4.39e-07	0.33	0.28	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6.26	8.7e-10	4.39e-07	0.33	0.28	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
HNSC	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-6.26	8.71e-10	4.39e-07	-0.34	-0.28	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
HNSC	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-6.26	8.73e-10	4.4e-07	-0.29	-0.28	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
HNSC	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	6.26	8.74e-10	4.4e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
HNSC	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	6.26	8.74e-10	4.4e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
HNSC	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.26	8.75e-10	4.41e-07	-0.44	-0.28	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
HNSC	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-6.26	8.78e-10	4.42e-07	-0.34	-0.28	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
HNSC	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	6.26	8.8e-10	4.43e-07	0.24	0.28	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
HNSC	cis	rs9326248	0.53	rs7121347	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Blood protein levels;	chr11:116996493	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs7114963	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Blood protein levels;	chr11:117005267	chr11:117204967~117210292:+
HNSC	cis	rs7115242	0.72	rs10790169	ENSG00000280143.1	AP000892.6	6.26	8.8e-10	4.43e-07	0.42	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117204967~117210292:+
HNSC	cis	rs4273100	0.834	rs59415593	ENSG00000265185.4	SNORD3B-1	6.26	8.81e-10	4.43e-07	0.42	0.28	Schizophrenia;	chr17:19319911	chr17:19061912~19062669:+
HNSC	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-6.26	8.81e-10	4.44e-07	-0.31	-0.28	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-6.26	8.83e-10	4.44e-07	-0.18	-0.28	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
HNSC	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	6.26	8.83e-10	4.45e-07	0.3	0.28	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
HNSC	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	6.26	8.84e-10	4.45e-07	0.33	0.28	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
HNSC	cis	rs947583	1	rs6570043	ENSG00000217482.2	HMGB1P17	6.26	8.84e-10	4.45e-07	0.31	0.28	Phosphorus levels;	chr6:135812960	chr6:135636086~135636713:-
HNSC	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	6.26	8.84e-10	4.45e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
HNSC	cis	rs4218	0.681	rs35204615	ENSG00000259732.1	RP11-59H7.3	-6.26	8.84e-10	4.45e-07	-0.39	-0.28	Social communication problems;	chr15:59099637	chr15:59121034~59133250:+
HNSC	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	6.26	8.85e-10	4.45e-07	0.32	0.28	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.26	8.85e-10	4.45e-07	-0.36	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
HNSC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.26	8.85e-10	4.46e-07	0.3	0.28	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
HNSC	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	6.26	8.86e-10	4.46e-07	0.7	0.28	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
HNSC	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	6.26	8.88e-10	4.47e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.26	8.9e-10	4.48e-07	0.29	0.28	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
HNSC	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-6.26	8.9e-10	4.48e-07	-0.27	-0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
HNSC	cis	rs35955747	0.871	rs5994392	ENSG00000236132.1	CTA-440B3.1	6.26	8.91e-10	4.48e-07	0.3	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31387920	chr22:31816379~31817491:-
HNSC	cis	rs860295	0.775	rs729022	ENSG00000203761.5	MSTO2P	6.26	8.93e-10	4.49e-07	0.21	0.28	Body mass index;	chr1:155882332	chr1:155745829~155750137:+
HNSC	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	6.26	8.93e-10	4.49e-07	0.38	0.28	Height;	chr6:109480428	chr6:109382795~109383666:+
HNSC	cis	rs4239252	0.929	rs4796116	ENSG00000270977.1	AC015849.16	-6.26	8.94e-10	4.5e-07	-0.32	-0.28	Blood protein levels;	chr17:35841496	chr17:35893707~35911023:-
HNSC	cis	rs4239252	0.929	rs4251791	ENSG00000270977.1	AC015849.16	-6.26	8.94e-10	4.5e-07	-0.32	-0.28	Blood protein levels;	chr17:35845711	chr17:35893707~35911023:-
HNSC	cis	rs858239	0.704	rs466240	ENSG00000226816.2	AC005082.12	-6.26	8.94e-10	4.5e-07	-0.34	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23206013~23208045:+
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-6.26	8.94e-10	4.5e-07	-0.49	-0.28	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
HNSC	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.26	8.97e-10	4.51e-07	-0.35	-0.28	Height;	chr3:52977358	chr3:53064283~53065091:-
HNSC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-6.26	8.99e-10	4.52e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
HNSC	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	6.25	9e-10	4.53e-07	0.4	0.28	Depression;	chr6:28300675	chr6:28115628~28116551:+
HNSC	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	6.25	9.01e-10	4.53e-07	0.32	0.28	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
HNSC	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-6.25	9.03e-10	4.54e-07	-0.28	-0.28	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
HNSC	cis	rs9326248	0.53	rs10790172	ENSG00000280143.1	AP000892.6	6.25	9.03e-10	4.54e-07	0.42	0.28	Blood protein levels;	chr11:117057024	chr11:117204967~117210292:+
HNSC	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.25	9.04e-10	4.54e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000254153.1	CTA-398F10.2	6.25	9.04e-10	4.54e-07	0.31	0.28	Systolic blood pressure;	chr8:8487658	chr8:8456909~8461337:-
HNSC	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	6.25	9.05e-10	4.55e-07	0.33	0.28	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
HNSC	cis	rs1665050	0.571	rs1446238	ENSG00000259732.1	RP11-59H7.3	-6.25	9.05e-10	4.55e-07	-0.37	-0.28	Atopic dermatitis;	chr15:59055558	chr15:59121034~59133250:+
HNSC	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-6.25	9.05e-10	4.55e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
HNSC	cis	rs6951245	1	rs75488469	ENSG00000225146.1	AC073957.15	-6.25	9.06e-10	4.55e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1029025~1043891:+
HNSC	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	6.25	9.06e-10	4.55e-07	0.44	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
HNSC	cis	rs8054556	0.74	rs8059619	ENSG00000183604.13	SMG1P5	-6.25	9.07e-10	4.56e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30267553~30335374:-
HNSC	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	6.25	9.07e-10	4.56e-07	0.32	0.28	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
HNSC	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-6.25	9.09e-10	4.57e-07	-0.35	-0.28	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
HNSC	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-6.25	9.09e-10	4.57e-07	-0.32	-0.28	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
HNSC	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.25	9.1e-10	4.57e-07	0.28	0.28	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
HNSC	cis	rs7615952	0.576	rs6780025	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126096781	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.576	rs6804482	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126096919	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.576	rs12497295	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126099807	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs4646765	ENSG00000241288.6	RP11-379B18.5	-6.25	9.1e-10	4.57e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126101864	chr3:125827238~125916384:-
HNSC	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-6.25	9.11e-10	4.57e-07	-0.37	-0.28	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
HNSC	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	6.25	9.12e-10	4.58e-07	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
HNSC	cis	rs889014	1	rs13183901	ENSG00000253768.1	CTB-33O18.1	6.25	9.12e-10	4.58e-07	0.3	0.28	Height;	chr5:173563489	chr5:173562478~173573199:+
HNSC	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	6.25	9.13e-10	4.58e-07	0.32	0.28	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
HNSC	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-6.25	9.13e-10	4.58e-07	-0.28	-0.28	Height;	chr2:231490121	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-6.25	9.14e-10	4.59e-07	-0.32	-0.28	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
HNSC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-6.25	9.17e-10	4.61e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
HNSC	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-6.25	9.18e-10	4.61e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
HNSC	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	6.25	9.18e-10	4.61e-07	0.34	0.28	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
HNSC	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-6.25	9.21e-10	4.62e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
HNSC	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	6.25	9.22e-10	4.63e-07	0.34	0.28	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
HNSC	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-6.25	9.25e-10	4.64e-07	-0.29	-0.28	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	6.25	9.26e-10	4.65e-07	0.34	0.28	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
HNSC	cis	rs10435719	0.58	rs13260712	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.551	rs13268217	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925100	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.573	rs13264994	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925250	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.573	rs13275808	ENSG00000206014.6	OR7E161P	6.25	9.27e-10	4.65e-07	0.3	0.28	Monocyte count;	chr8:11925306	chr8:11928597~11929563:-
HNSC	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.25	9.29e-10	4.66e-07	0.27	0.28	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
HNSC	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	6.25	9.3e-10	4.66e-07	0.32	0.28	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
HNSC	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-6.25	9.3e-10	4.67e-07	-0.32	-0.28	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	6.25	9.31e-10	4.67e-07	0.22	0.28	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	6.25	9.31e-10	4.67e-07	0.22	0.28	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
HNSC	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	6.25	9.32e-10	4.68e-07	0.29	0.28	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
HNSC	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	6.25	9.32e-10	4.68e-07	0.31	0.28	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
HNSC	cis	rs9341808	0.714	rs4256394	ENSG00000272129.1	RP11-250B2.6	6.25	9.35e-10	4.69e-07	0.32	0.28	Sitting height ratio;	chr6:80172425	chr6:80355424~80356859:+
HNSC	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-6.25	9.35e-10	4.69e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	6.25	9.35e-10	4.69e-07	0.64	0.28	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
HNSC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-6.25	9.36e-10	4.69e-07	-0.32	-0.28	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
HNSC	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	6.25	9.36e-10	4.69e-07	0.28	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
HNSC	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.37e-10	4.7e-07	-0.31	-0.28	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
HNSC	cis	rs11992162	0.573	rs61468577	ENSG00000206014.6	OR7E161P	6.25	9.37e-10	4.7e-07	0.3	0.28	Monocyte count;	chr8:11927416	chr8:11928597~11929563:-
HNSC	cis	rs11992162	0.507	rs60902764	ENSG00000206014.6	OR7E161P	6.25	9.37e-10	4.7e-07	0.3	0.28	Monocyte count;	chr8:11927482	chr8:11928597~11929563:-
HNSC	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	6.25	9.38e-10	4.71e-07	0.35	0.28	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
HNSC	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	6.25	9.39e-10	4.71e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-6.25	9.39e-10	4.71e-07	-0.19	-0.28	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
HNSC	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	6.25	9.4e-10	4.71e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
HNSC	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	6.25	9.4e-10	4.72e-07	0.45	0.28	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
HNSC	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	6.25	9.41e-10	4.72e-07	0.3	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
HNSC	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-6.25	9.41e-10	4.72e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-6.25	9.41e-10	4.72e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
HNSC	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-6.25	9.41e-10	4.72e-07	-0.24	-0.28	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
HNSC	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	6.25	9.43e-10	4.73e-07	0.32	0.28	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-6.25	9.44e-10	4.73e-07	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
HNSC	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-6.25	9.44e-10	4.73e-07	-0.24	-0.28	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
HNSC	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.44e-10	4.73e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.44e-10	4.73e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
HNSC	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	6.25	9.44e-10	4.73e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	6.25	9.45e-10	4.74e-07	0.33	0.28	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
HNSC	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-6.25	9.46e-10	4.74e-07	-0.3	-0.28	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
HNSC	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-6.25	9.46e-10	4.74e-07	-0.24	-0.28	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
HNSC	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.48e-10	4.75e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	6.25	9.5e-10	4.76e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
HNSC	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.25	9.52e-10	4.77e-07	0.4	0.28	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
HNSC	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-6.25	9.53e-10	4.77e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
HNSC	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-6.25	9.54e-10	4.78e-07	-0.28	-0.28	Height;	chr2:231559006	chr2:231508426~231514339:-
HNSC	cis	rs4218	0.689	rs12907187	ENSG00000259732.1	RP11-59H7.3	-6.24	9.54e-10	4.78e-07	-0.39	-0.28	Social communication problems;	chr15:59100607	chr15:59121034~59133250:+
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000267151.3	RP11-100E5.2	6.24	9.54e-10	4.78e-07	0.36	0.28	Menopause (age at onset);	chr17:43125170	chr17:43444707~43451200:+
HNSC	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-6.24	9.55e-10	4.78e-07	-0.47	-0.28	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-6.24	9.55e-10	4.78e-07	-0.47	-0.28	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
HNSC	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	6.24	9.55e-10	4.78e-07	0.36	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
HNSC	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	6.24	9.56e-10	4.79e-07	0.44	0.28	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
HNSC	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6.24	9.56e-10	4.79e-07	0.33	0.28	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
HNSC	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	6.24	9.61e-10	4.81e-07	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
HNSC	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	6.24	9.64e-10	4.82e-07	0.32	0.28	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-6.24	9.64e-10	4.83e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
HNSC	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	6.24	9.65e-10	4.83e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	6.24	9.66e-10	4.84e-07	0.19	0.28	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
HNSC	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-6.24	9.67e-10	4.84e-07	-0.33	-0.28	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000173295.6	FAM86B3P	6.24	9.67e-10	4.84e-07	0.32	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8228595~8244865:+
HNSC	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-6.24	9.71e-10	4.86e-07	-0.29	-0.28	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-6.24	9.71e-10	4.86e-07	-0.43	-0.28	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
HNSC	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	6.24	9.75e-10	4.88e-07	0.38	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
HNSC	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-6.24	9.78e-10	4.89e-07	-0.42	-0.28	Depression;	chr6:28283207	chr6:28115628~28116551:+
HNSC	cis	rs7201929	0.959	rs35725751	ENSG00000259982.1	CDC37P1	-6.24	9.79e-10	4.89e-07	-0.36	-0.28	QT interval;	chr16:28834263	chr16:28700294~28701540:-
HNSC	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	6.24	9.79e-10	4.9e-07	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
HNSC	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-6.24	9.79e-10	4.9e-07	-0.38	-0.28	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
HNSC	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-6.24	9.8e-10	4.9e-07	-0.32	-0.28	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
HNSC	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-6.24	9.81e-10	4.9e-07	-0.41	-0.28	Depression;	chr6:28331910	chr6:28115628~28116551:+
HNSC	cis	rs35955747	0.869	rs131219	ENSG00000236132.1	CTA-440B3.1	-6.24	9.81e-10	4.91e-07	-0.29	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31364264	chr22:31816379~31817491:-
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000204709.4	LINC01556	6.24	9.82e-10	4.91e-07	0.36	0.28	Parkinson's disease;	chr6:28048140	chr6:28943877~28944537:+
HNSC	cis	rs2985684	0.948	rs4900925	ENSG00000258568.1	RHOQP1	-6.24	9.82e-10	4.91e-07	-0.29	-0.28	Carotid intima media thickness;	chr14:49545607	chr14:49599994~49600572:+
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	6.24	9.82e-10	4.91e-07	0.65	0.28	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-6.24	9.82e-10	4.91e-07	-0.33	-0.28	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
HNSC	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	6.24	9.83e-10	4.91e-07	0.25	0.28	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	6.24	9.83e-10	4.92e-07	0.44	0.28	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	6.24	9.83e-10	4.92e-07	0.44	0.28	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	6.24	9.84e-10	4.92e-07	0.42	0.28	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
HNSC	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	6.24	9.84e-10	4.92e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
HNSC	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	6.24	9.86e-10	4.93e-07	0.26	0.28	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
HNSC	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-6.24	9.86e-10	4.93e-07	-0.34	-0.28	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
HNSC	cis	rs12439619	0.846	rs62010071	ENSG00000276710.3	CSPG4P8	-6.24	9.89e-10	4.94e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82459472~82477258:+
HNSC	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-6.24	9.92e-10	4.96e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-6.24	9.93e-10	4.96e-07	-0.18	-0.28	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-6.24	9.93e-10	4.96e-07	-0.19	-0.28	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
HNSC	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-6.24	9.94e-10	4.97e-07	-0.37	-0.28	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
HNSC	cis	rs947583	0.517	rs6570039	ENSG00000217482.2	HMGB1P17	6.24	9.95e-10	4.97e-07	0.29	0.28	Phosphorus levels;	chr6:135775602	chr6:135636086~135636713:-
HNSC	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	6.24	9.96e-10	4.97e-07	0.38	0.28	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
HNSC	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-6.24	9.97e-10	4.98e-07	-0.29	-0.28	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
HNSC	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	6.24	9.98e-10	4.98e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000211974.3	IGHV2-70	-6.24	1e-09	5e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106667442	chr14:106723574~106724093:-
HNSC	cis	rs2834288	0.535	rs7275560	ENSG00000237945.6	LINC00649	-6.24	1e-09	5e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.535	rs2834306	ENSG00000237945.6	LINC00649	-6.24	1e-09	5e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33915534~33977691:+
HNSC	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-6.24	1e-09	5.01e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
HNSC	cis	rs6471393	0.964	rs10504930	ENSG00000253848.1	RP11-10N23.5	-6.24	1e-09	5.01e-07	-0.33	-0.28	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732585	chr8:93741193~93744534:+
HNSC	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-6.24	1e-09	5.01e-07	-0.32	-0.28	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
HNSC	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	6.24	1e-09	5.01e-07	0.78	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
HNSC	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	6.24	1.01e-09	5.02e-07	0.39	0.28	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
HNSC	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-6.24	1.01e-09	5.02e-07	-0.33	-0.28	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
HNSC	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	6.24	1.01e-09	5.02e-07	0.37	0.28	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
HNSC	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	6.24	1.01e-09	5.03e-07	0.43	0.28	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
HNSC	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-6.24	1.01e-09	5.03e-07	-0.37	-0.28	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
HNSC	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	6.24	1.01e-09	5.04e-07	0.36	0.28	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
HNSC	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	6.24	1.01e-09	5.04e-07	0.34	0.28	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
HNSC	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-6.24	1.01e-09	5.04e-07	-0.32	-0.28	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
HNSC	cis	rs2985684	0.846	rs11157693	ENSG00000258568.1	RHOQP1	6.24	1.01e-09	5.05e-07	0.28	0.28	Carotid intima media thickness;	chr14:49581708	chr14:49599994~49600572:+
HNSC	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	6.23	1.01e-09	5.05e-07	0.34	0.28	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
HNSC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	6.23	1.01e-09	5.05e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
HNSC	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	6.23	1.01e-09	5.06e-07	0.33	0.28	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
HNSC	cis	rs1865760	0.613	rs9379805	ENSG00000272462.2	U91328.19	-6.23	1.02e-09	5.07e-07	-0.26	-0.28	Height;	chr6:25938536	chr6:25992662~26001775:+
HNSC	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	6.23	1.02e-09	5.08e-07	0.37	0.28	Height;	chr6:109486036	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-6.23	1.02e-09	5.08e-07	-0.35	-0.28	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
HNSC	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
HNSC	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	6.23	1.02e-09	5.09e-07	0.31	0.28	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-6.23	1.02e-09	5.09e-07	-0.31	-0.28	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	6.23	1.02e-09	5.09e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
HNSC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	6.23	1.02e-09	5.09e-07	0.32	0.28	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
HNSC	cis	rs9907295	0.591	rs4251749	ENSG00000270977.1	AC015849.16	-6.23	1.02e-09	5.1e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35823421	chr17:35893707~35911023:-
HNSC	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-6.23	1.02e-09	5.1e-07	-0.27	-0.28	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
HNSC	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-6.23	1.02e-09	5.11e-07	-0.36	-0.28	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	6.23	1.02e-09	5.11e-07	0.22	0.28	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	6.23	1.02e-09	5.11e-07	0.47	0.28	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
HNSC	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-6.23	1.03e-09	5.12e-07	-0.4	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
HNSC	cis	rs5753618	0.504	rs9609296	ENSG00000236132.1	CTA-440B3.1	-6.23	1.03e-09	5.12e-07	-0.36	-0.28	Colorectal cancer;	chr22:31495798	chr22:31816379~31817491:-
HNSC	cis	rs2834288	0.535	rs4816469	ENSG00000237945.6	LINC00649	6.23	1.03e-09	5.12e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33915534~33977691:+
HNSC	cis	rs12935418	0.83	rs7188549	ENSG00000261061.1	RP11-303E16.2	-6.23	1.03e-09	5.12e-07	-0.38	-0.28	Mean corpuscular volume;	chr16:81016371	chr16:81030770~81031485:+
HNSC	cis	rs4639966	0.836	rs7130875	ENSG00000255422.1	AP002954.4	6.23	1.03e-09	5.13e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118742965	chr11:118704607~118750263:+
HNSC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-6.23	1.03e-09	5.13e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
HNSC	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.23	1.03e-09	5.13e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.23	1.03e-09	5.13e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
HNSC	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	6.23	1.03e-09	5.13e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
HNSC	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-6.23	1.03e-09	5.14e-07	-0.26	-0.28	Asthma;	chr2:102438096	chr2:102438713~102440475:+
HNSC	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-6.23	1.03e-09	5.15e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
HNSC	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-6.23	1.03e-09	5.15e-07	-0.39	-0.28	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
HNSC	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.23	1.03e-09	5.15e-07	0.33	0.28	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
HNSC	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-6.23	1.04e-09	5.15e-07	-0.29	-0.28	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
HNSC	cis	rs7048146	0.668	rs2150260	ENSG00000213539.4	YBX1P6	6.23	1.04e-09	5.16e-07	0.31	0.28	Vascular brain injury;	chr9:109511914	chr9:109532830~109534332:-
HNSC	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-6.23	1.04e-09	5.16e-07	-0.32	-0.28	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
HNSC	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-6.23	1.04e-09	5.18e-07	-0.33	-0.28	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000254153.1	CTA-398F10.2	6.23	1.04e-09	5.19e-07	0.29	0.28	Neuroticism;	chr8:8461340	chr8:8456909~8461337:-
HNSC	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-6.23	1.04e-09	5.19e-07	-0.32	-0.28	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-6.23	1.04e-09	5.19e-07	-0.32	-0.28	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
HNSC	cis	rs6951245	0.935	rs61753396	ENSG00000225146.1	AC073957.15	-6.23	1.04e-09	5.19e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.938	rs113642700	ENSG00000225146.1	AC073957.15	-6.23	1.04e-09	5.19e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1029025~1043891:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000254153.1	CTA-398F10.2	6.23	1.04e-09	5.19e-07	0.29	0.28	Neuroticism;	chr8:8461672	chr8:8456909~8461337:-
HNSC	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	6.23	1.05e-09	5.2e-07	0.4	0.28	Height;	chr6:109762861	chr6:109382795~109383666:+
HNSC	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	6.23	1.05e-09	5.2e-07	0.33	0.28	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
HNSC	cis	rs1355223	0.902	rs12801509	ENSG00000271369.1	RP11-350D17.3	-6.23	1.05e-09	5.21e-07	-0.32	-0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725789	chr11:34709600~34710161:+
HNSC	cis	rs5753618	0.561	rs4603880	ENSG00000236132.1	CTA-440B3.1	-6.23	1.05e-09	5.21e-07	-0.34	-0.28	Colorectal cancer;	chr22:31348735	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs9609264	ENSG00000236132.1	CTA-440B3.1	-6.23	1.05e-09	5.21e-07	-0.34	-0.28	Colorectal cancer;	chr22:31350733	chr22:31816379~31817491:-
HNSC	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	5.21e-07	-0.24	-0.28	Height;	chr11:118703185	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	5.21e-07	-0.24	-0.28	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	6.23	1.05e-09	5.21e-07	0.38	0.28	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
HNSC	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-6.23	1.05e-09	5.21e-07	-0.43	-0.28	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
HNSC	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-6.23	1.05e-09	5.22e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
HNSC	cis	rs2108622	0.64	rs58858790	ENSG00000267453.5	AC004791.2	-6.23	1.05e-09	5.22e-07	-0.35	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15851993~15864904:-
HNSC	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-6.23	1.05e-09	5.23e-07	-0.33	-0.28	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
HNSC	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	6.23	1.05e-09	5.23e-07	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
HNSC	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	6.23	1.05e-09	5.23e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	6.23	1.05e-09	5.24e-07	0.36	0.28	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	6.23	1.05e-09	5.24e-07	0.36	0.28	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
HNSC	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-6.23	1.05e-09	5.25e-07	-0.31	-0.28	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.23	1.06e-09	5.25e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
HNSC	cis	rs9840812	0.637	rs698270	ENSG00000273486.1	RP11-731C17.2	6.23	1.06e-09	5.25e-07	0.25	0.28	Fibrinogen levels;	chr3:136390670	chr3:136837338~136839021:-
HNSC	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-6.23	1.06e-09	5.27e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-6.23	1.06e-09	5.27e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
HNSC	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	6.23	1.06e-09	5.27e-07	0.33	0.28	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
HNSC	cis	rs4218	0.517	rs2899640	ENSG00000259732.1	RP11-59H7.3	-6.23	1.07e-09	5.31e-07	-0.38	-0.28	Social communication problems;	chr15:59060281	chr15:59121034~59133250:+
HNSC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	6.23	1.07e-09	5.31e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	-6.23	1.07e-09	5.31e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	6.23	1.07e-09	5.31e-07	0.35	0.28	Depression;	chr6:28386473	chr6:28943877~28944537:+
HNSC	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	6.23	1.07e-09	5.31e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
HNSC	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	6.23	1.07e-09	5.32e-07	0.36	0.28	Height;	chr6:109415411	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.07e-09	5.32e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
HNSC	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.07e-09	5.32e-07	-0.34	-0.28	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-6.23	1.07e-09	5.32e-07	-0.4	-0.28	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-6.23	1.07e-09	5.32e-07	-0.4	-0.28	Gout;	chr7:66642037	chr7:66902857~66906297:+
HNSC	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-6.23	1.07e-09	5.33e-07	-0.4	-0.28	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
HNSC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	6.23	1.07e-09	5.33e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	6.22	1.07e-09	5.33e-07	0.21	0.28	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
HNSC	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	6.22	1.08e-09	5.34e-07	0.45	0.28	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
HNSC	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	6.22	1.08e-09	5.35e-07	0.33	0.28	Height;	chr4:55573424	chr4:55363971~55395847:-
HNSC	cis	rs2834288	0.535	rs4816468	ENSG00000237945.6	LINC00649	6.22	1.08e-09	5.35e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33915534~33977691:+
HNSC	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	6.22	1.08e-09	5.35e-07	0.27	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
HNSC	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	6.22	1.08e-09	5.36e-07	0.28	0.28	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
HNSC	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	6.22	1.08e-09	5.36e-07	0.3	0.28	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
HNSC	cis	rs4639966	0.836	rs3825057	ENSG00000255422.1	AP002954.4	6.22	1.08e-09	5.37e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118752276	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.836	rs11217014	ENSG00000255422.1	AP002954.4	6.22	1.08e-09	5.37e-07	0.38	0.28	Systemic lupus erythematosus;	chr11:118755577	chr11:118704607~118750263:+
HNSC	cis	rs5753618	0.561	rs2040533	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31283124	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs5753543	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31289472	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs2413049	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31290158	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs715510	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31294542	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs737887	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31300629	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.561	rs4820963	ENSG00000236132.1	CTA-440B3.1	6.22	1.08e-09	5.37e-07	0.34	0.28	Colorectal cancer;	chr22:31302180	chr22:31816379~31817491:-
HNSC	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.22	1.08e-09	5.38e-07	0.28	0.28	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
HNSC	cis	rs11992162	0.56	rs7846248	ENSG00000206014.6	OR7E161P	-6.22	1.08e-09	5.38e-07	-0.3	-0.28	Monocyte count;	chr8:11936540	chr8:11928597~11929563:-
HNSC	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	6.22	1.08e-09	5.38e-07	0.37	0.28	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
HNSC	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	6.22	1.09e-09	5.39e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	6.22	1.09e-09	5.39e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
HNSC	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	6.22	1.09e-09	5.39e-07	0.3	0.28	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
HNSC	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-6.22	1.09e-09	5.39e-07	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
HNSC	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	6.22	1.09e-09	5.39e-07	0.32	0.28	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
HNSC	cis	rs6951245	0.935	rs61910751	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs77434655	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs75398423	ENSG00000225146.1	AC073957.15	-6.22	1.09e-09	5.4e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1029025~1043891:+
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	-6.22	1.09e-09	5.4e-07	-0.32	-0.28	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
HNSC	cis	rs9901225	1	rs9901225	ENSG00000108785.7	HSD17B1P1	-6.22	1.09e-09	5.4e-07	-0.28	-0.28	Colorectal or endometrial cancer;	chr17:42603793	chr17:42546764~42548706:+
HNSC	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	6.22	1.09e-09	5.42e-07	0.3	0.28	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-6.22	1.09e-09	5.42e-07	-0.42	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
HNSC	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	6.22	1.09e-09	5.42e-07	0.26	0.28	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
HNSC	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	6.22	1.1e-09	5.43e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
HNSC	cis	rs2985684	0.802	rs8015368	ENSG00000258568.1	RHOQP1	6.22	1.1e-09	5.43e-07	0.28	0.28	Carotid intima media thickness;	chr14:49553792	chr14:49599994~49600572:+
HNSC	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-6.22	1.1e-09	5.43e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-6.22	1.1e-09	5.43e-07	-0.49	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
HNSC	cis	rs2834288	0.535	rs8129694	ENSG00000237945.6	LINC00649	-6.22	1.1e-09	5.44e-07	-0.34	-0.28	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33915534~33977691:+
HNSC	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-6.22	1.1e-09	5.44e-07	-0.3	-0.28	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
HNSC	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	6.22	1.1e-09	5.44e-07	0.33	0.28	Height;	chr4:55570843	chr4:55363971~55395847:-
HNSC	cis	rs9907295	0.591	rs11650668	ENSG00000270977.1	AC015849.16	-6.22	1.1e-09	5.45e-07	-0.32	-0.28	Fibroblast growth factor basic levels;	chr17:35822045	chr17:35893707~35911023:-
HNSC	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	6.22	1.1e-09	5.46e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
HNSC	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	6.22	1.1e-09	5.47e-07	0.3	0.28	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
HNSC	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	6.22	1.1e-09	5.47e-07	0.55	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
HNSC	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-6.22	1.1e-09	5.47e-07	-0.31	-0.28	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
HNSC	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	6.22	1.1e-09	5.47e-07	0.35	0.28	Height;	chr4:55482360	chr4:55363971~55395847:-
HNSC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-6.22	1.11e-09	5.48e-07	-0.31	-0.28	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-6.22	1.11e-09	5.48e-07	-0.31	-0.28	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
HNSC	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-6.22	1.11e-09	5.48e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
HNSC	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	6.22	1.11e-09	5.48e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
HNSC	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	6.22	1.11e-09	5.48e-07	0.33	0.28	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
HNSC	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-6.22	1.11e-09	5.48e-07	-0.24	-0.28	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
HNSC	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-6.22	1.11e-09	5.48e-07	-0.24	-0.28	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
HNSC	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.48e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
HNSC	cis	rs7048146	0.668	rs6477708	ENSG00000213539.4	YBX1P6	6.22	1.11e-09	5.49e-07	0.31	0.28	Vascular brain injury;	chr9:109513462	chr9:109532830~109534332:-
HNSC	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	6.22	1.11e-09	5.49e-07	0.35	0.28	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
HNSC	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	6.22	1.11e-09	5.49e-07	0.3	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
HNSC	cis	rs4218	0.689	rs35555888	ENSG00000259732.1	RP11-59H7.3	-6.22	1.11e-09	5.49e-07	-0.39	-0.28	Social communication problems;	chr15:59093935	chr15:59121034~59133250:+
HNSC	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	6.22	1.11e-09	5.49e-07	0.24	0.28	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
HNSC	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-6.22	1.11e-09	5.49e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
HNSC	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	6.22	1.11e-09	5.49e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
HNSC	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-6.22	1.11e-09	5.5e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
HNSC	cis	rs757110	0.834	rs1002226	ENSG00000260196.1	RP1-239B22.5	6.22	1.11e-09	5.51e-07	0.31	0.28	Type 2 diabetes;	chr11:17384070	chr11:17380649~17383531:+
HNSC	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.51e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	6.22	1.11e-09	5.51e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
HNSC	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-6.22	1.12e-09	5.52e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	6.22	1.12e-09	5.52e-07	0.31	0.28	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.512	rs1077621	ENSG00000241288.6	RP11-379B18.5	-6.22	1.12e-09	5.53e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126100956	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-6.22	1.12e-09	5.53e-07	-0.25	-0.28	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
HNSC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	6.22	1.12e-09	5.53e-07	0.31	0.28	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	6.22	1.12e-09	5.53e-07	0.31	0.28	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
HNSC	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	6.22	1.12e-09	5.54e-07	0.36	0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
HNSC	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	6.22	1.12e-09	5.54e-07	0.31	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
HNSC	cis	rs2286503	0.839	rs2240728	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22812880	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs1054471	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22813024	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2240726	ENSG00000221740.1	SNORD93	6.22	1.12e-09	5.54e-07	0.3	0.28	Fibrinogen;	chr7:22813516	chr7:22856613~22856686:+
HNSC	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-6.22	1.12e-09	5.54e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-6.22	1.12e-09	5.54e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
HNSC	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	6.22	1.12e-09	5.54e-07	0.26	0.28	Asthma;	chr2:102446780	chr2:102438713~102440475:+
HNSC	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	6.22	1.12e-09	5.55e-07	0.3	0.28	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	6.22	1.12e-09	5.55e-07	0.3	0.28	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
HNSC	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-6.22	1.12e-09	5.56e-07	-0.32	-0.28	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
HNSC	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	6.22	1.12e-09	5.56e-07	0.31	0.28	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
HNSC	cis	rs35955747	0.902	rs4820961	ENSG00000236132.1	CTA-440B3.1	6.22	1.12e-09	5.56e-07	0.3	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283463	chr22:31816379~31817491:-
HNSC	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-6.22	1.13e-09	5.57e-07	-0.28	-0.28	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-6.22	1.13e-09	5.57e-07	-0.28	-0.28	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
HNSC	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-6.22	1.13e-09	5.58e-07	-0.33	-0.28	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
HNSC	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
HNSC	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-6.22	1.13e-09	5.58e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
HNSC	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	6.22	1.13e-09	5.58e-07	0.47	0.28	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
HNSC	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.58e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.58e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
HNSC	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-6.22	1.13e-09	5.58e-07	-0.52	-0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
HNSC	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-6.22	1.13e-09	5.58e-07	-0.32	-0.28	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
HNSC	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	6.22	1.13e-09	5.58e-07	0.3	0.28	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
HNSC	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	6.22	1.13e-09	5.59e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
HNSC	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-6.22	1.13e-09	5.59e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-6.22	1.13e-09	5.59e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
HNSC	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-6.22	1.13e-09	5.59e-07	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
HNSC	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	6.22	1.13e-09	5.59e-07	0.33	0.28	Height;	chr4:55440988	chr4:55363971~55395847:-
HNSC	cis	rs6951245	1	rs884977	ENSG00000224079.1	AC091729.7	-6.22	1.14e-09	5.61e-07	-0.43	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1074450~1078036:+
HNSC	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.14e-09	5.61e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.22	1.14e-09	5.61e-07	0.38	0.28	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
HNSC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	6.22	1.14e-09	5.61e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
HNSC	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	6.22	1.14e-09	5.61e-07	0.38	0.28	Height;	chr6:109479396	chr6:109382795~109383666:+
HNSC	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	6.22	1.14e-09	5.62e-07	0.34	0.28	Depression;	chr6:28428413	chr6:28943877~28944537:+
HNSC	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-6.22	1.14e-09	5.62e-07	-0.39	-0.28	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
HNSC	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-6.21	1.14e-09	5.63e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
HNSC	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-6.21	1.14e-09	5.63e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
HNSC	cis	rs7567389	0.812	rs6710496	ENSG00000236682.1	AC068282.3	6.21	1.14e-09	5.63e-07	0.34	0.28	Self-rated health;	chr2:127218798	chr2:127389130~127400580:+
HNSC	cis	rs2834288	0.535	rs13049489	ENSG00000237945.6	LINC00649	6.21	1.14e-09	5.64e-07	0.34	0.28	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33915534~33977691:+
HNSC	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	5.64e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	6.21	1.14e-09	5.65e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
HNSC	cis	rs7048146	0.668	rs1411682	ENSG00000213539.4	YBX1P6	6.21	1.14e-09	5.65e-07	0.31	0.28	Vascular brain injury;	chr9:109514077	chr9:109532830~109534332:-
HNSC	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-6.21	1.15e-09	5.66e-07	-0.34	-0.28	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
HNSC	cis	rs6951245	0.872	rs112309216	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs76161580	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76388414	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77305932	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.872	rs11768486	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11766526	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs76214082	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs113146460	ENSG00000225146.1	AC073957.15	-6.21	1.15e-09	5.66e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1029025~1043891:+
HNSC	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-6.21	1.15e-09	5.66e-07	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
HNSC	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-6.21	1.15e-09	5.66e-07	-0.28	-0.28	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	-6.21	1.15e-09	5.67e-07	-0.31	-0.28	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
HNSC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.21	1.15e-09	5.67e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
HNSC	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	6.21	1.15e-09	5.67e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000179406.6	LINC00174	-6.21	1.15e-09	5.68e-07	-0.58	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66376044~66401338:-
HNSC	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	6.21	1.15e-09	5.69e-07	0.32	0.28	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
HNSC	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	6.21	1.16e-09	5.7e-07	0.4	0.28	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
HNSC	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	6.21	1.16e-09	5.71e-07	0.31	0.28	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	6.21	1.16e-09	5.74e-07	0.36	0.28	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.17e-09	5.74e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-6.21	1.17e-09	5.75e-07	-0.35	-0.28	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
HNSC	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	6.21	1.17e-09	5.75e-07	0.44	0.28	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
HNSC	cis	rs4239252	0.929	rs4251787	ENSG00000270977.1	AC015849.16	-6.21	1.17e-09	5.75e-07	-0.32	-0.28	Blood protein levels;	chr17:35845577	chr17:35893707~35911023:-
HNSC	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-6.21	1.17e-09	5.75e-07	-0.32	-0.28	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	-6.21	1.17e-09	5.77e-07	-0.31	-0.28	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
HNSC	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.21	1.17e-09	5.77e-07	0.29	0.28	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	6.21	1.17e-09	5.78e-07	0.65	0.28	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
HNSC	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-6.21	1.17e-09	5.78e-07	-0.4	-0.28	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
HNSC	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-6.21	1.17e-09	5.78e-07	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
HNSC	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	6.21	1.18e-09	5.79e-07	0.32	0.28	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
HNSC	cis	rs4657482	0.572	rs4656466	ENSG00000236364.3	RP11-525G13.2	6.21	1.18e-09	5.8e-07	0.29	0.28	Testicular germ cell tumor;	chr1:165900130	chr1:165890795~165900683:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-6.21	1.18e-09	5.81e-07	-0.18	-0.28	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
HNSC	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-6.21	1.18e-09	5.82e-07	-0.4	-0.28	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
HNSC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	6.21	1.18e-09	5.83e-07	0.31	0.28	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	6.21	1.18e-09	5.83e-07	0.31	0.28	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
HNSC	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	6.21	1.18e-09	5.83e-07	0.3	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
HNSC	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-6.21	1.19e-09	5.84e-07	-0.34	-0.28	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
HNSC	cis	rs4218	0.701	rs56375269	ENSG00000259732.1	RP11-59H7.3	-6.21	1.19e-09	5.84e-07	-0.38	-0.28	Social communication problems;	chr15:59137741	chr15:59121034~59133250:+
HNSC	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	6.21	1.19e-09	5.84e-07	0.32	0.28	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
HNSC	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	6.21	1.19e-09	5.84e-07	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
HNSC	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	6.21	1.19e-09	5.86e-07	0.36	0.28	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-6.21	1.19e-09	5.86e-07	-0.18	-0.28	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
HNSC	cis	rs7615952	0.673	rs9821905	ENSG00000241288.6	RP11-379B18.5	6.21	1.19e-09	5.87e-07	0.43	0.28	Blood pressure (smoking interaction);	chr3:125902007	chr3:125827238~125916384:-
HNSC	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-6.21	1.19e-09	5.87e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
HNSC	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-6.21	1.19e-09	5.87e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	6.21	1.19e-09	5.88e-07	0.21	0.28	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	6.21	1.2e-09	5.88e-07	0.34	0.28	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
HNSC	cis	rs7615952	0.641	rs61048217	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089062	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs60839048	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089095	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs7640158	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089168	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.641	rs2365019	ENSG00000241288.6	RP11-379B18.5	-6.21	1.2e-09	5.89e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126089292	chr3:125827238~125916384:-
HNSC	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	6.21	1.2e-09	5.89e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
HNSC	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-6.21	1.2e-09	5.9e-07	-0.4	-0.28	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
HNSC	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	6.21	1.2e-09	5.9e-07	0.39	0.28	Height;	chr6:109573151	chr6:109382795~109383666:+
HNSC	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	6.21	1.2e-09	5.9e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
HNSC	cis	rs7804306	0.826	rs17566854	ENSG00000233264.2	AC006042.8	6.21	1.2e-09	5.9e-07	0.59	0.28	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7993887	chr7:7980312~7982228:+
HNSC	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	6.21	1.2e-09	5.9e-07	0.33	0.28	Height;	chr4:55540928	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	6.21	1.2e-09	5.9e-07	0.65	0.28	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
HNSC	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	6.21	1.2e-09	5.91e-07	0.3	0.28	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	6.21	1.2e-09	5.92e-07	0.33	0.28	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	6.21	1.2e-09	5.92e-07	0.33	0.28	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
HNSC	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-6.21	1.2e-09	5.92e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-6.21	1.2e-09	5.92e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
HNSC	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.21	1.21e-09	5.93e-07	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
HNSC	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-6.21	1.21e-09	5.93e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
HNSC	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	6.21	1.21e-09	5.93e-07	0.35	0.28	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
HNSC	cis	rs947583	0.517	rs9376147	ENSG00000217482.2	HMGB1P17	6.2	1.21e-09	5.93e-07	0.29	0.28	Phosphorus levels;	chr6:135774774	chr6:135636086~135636713:-
HNSC	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.2	1.21e-09	5.94e-07	-0.29	-0.28	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-6.2	1.21e-09	5.94e-07	-0.32	-0.28	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
HNSC	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	6.2	1.21e-09	5.95e-07	0.38	0.28	Height;	chr6:109469907	chr6:109382795~109383666:+
HNSC	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	6.2	1.21e-09	5.95e-07	0.36	0.28	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000204709.4	LINC01556	6.2	1.21e-09	5.95e-07	0.36	0.28	Parkinson's disease;	chr6:28045632	chr6:28943877~28944537:+
HNSC	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-6.2	1.21e-09	5.95e-07	-0.27	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-6.2	1.21e-09	5.96e-07	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
HNSC	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.2	1.21e-09	5.96e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
HNSC	cis	rs9548119	0.941	rs9576404	ENSG00000223685.4	LINC00571	-6.2	1.21e-09	5.96e-07	-0.45	-0.28	Self-rated health;	chr13:37953276	chr13:38050817~38143232:-
HNSC	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-6.2	1.21e-09	5.97e-07	-0.32	-0.28	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
HNSC	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-6.2	1.22e-09	5.97e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	6.2	1.22e-09	5.97e-07	0.3	0.28	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
HNSC	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.22e-09	5.97e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
HNSC	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-6.2	1.22e-09	5.97e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-6.2	1.22e-09	5.97e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
HNSC	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-6.2	1.22e-09	5.98e-07	-0.54	-0.28	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000254153.1	CTA-398F10.2	6.2	1.22e-09	5.98e-07	0.29	0.28	Systolic blood pressure;	chr8:8461832	chr8:8456909~8461337:-
HNSC	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	6.2	1.22e-09	5.98e-07	0.3	0.28	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
HNSC	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-6.2	1.22e-09	5.99e-07	-0.36	-0.28	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
HNSC	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	6.2	1.22e-09	5.99e-07	0.31	0.28	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
HNSC	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-6.2	1.22e-09	6e-07	-0.33	-0.28	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
HNSC	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	6.2	1.22e-09	6e-07	0.65	0.28	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
HNSC	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-6.2	1.23e-09	6.02e-07	-0.3	-0.28	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
HNSC	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.2	1.23e-09	6.03e-07	0.29	0.28	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
HNSC	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-6.2	1.23e-09	6.04e-07	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
HNSC	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.2	1.23e-09	6.04e-07	0.27	0.28	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
HNSC	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	6.2	1.23e-09	6.04e-07	0.69	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	6.2	1.23e-09	6.04e-07	0.69	0.28	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
HNSC	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.2	1.23e-09	6.04e-07	0.33	0.28	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
HNSC	cis	rs8177876	0.822	rs1563077	ENSG00000261061.1	RP11-303E16.2	-6.2	1.23e-09	6.05e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	6.2	1.24e-09	6.06e-07	0.32	0.28	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
HNSC	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-6.2	1.24e-09	6.06e-07	-0.29	-0.28	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
HNSC	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-6.2	1.24e-09	6.06e-07	-0.25	-0.28	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
HNSC	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.24e-09	6.07e-07	-0.32	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.24e-09	6.07e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
HNSC	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-6.2	1.24e-09	6.07e-07	-0.34	-0.28	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
HNSC	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.2	1.24e-09	6.08e-07	-0.37	-0.28	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
HNSC	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-6.2	1.24e-09	6.08e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
HNSC	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	6.2	1.24e-09	6.09e-07	0.38	0.28	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
HNSC	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	6.2	1.25e-09	6.12e-07	0.31	0.28	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
HNSC	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	6.2	1.25e-09	6.12e-07	0.31	0.28	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
HNSC	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-6.2	1.25e-09	6.13e-07	-0.39	-0.28	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
HNSC	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-6.2	1.25e-09	6.13e-07	-0.34	-0.28	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
HNSC	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-6.2	1.25e-09	6.13e-07	-0.36	-0.28	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
HNSC	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-6.2	1.25e-09	6.13e-07	-0.34	-0.28	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.2	1.25e-09	6.14e-07	-0.33	-0.28	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
HNSC	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	6.2	1.25e-09	6.15e-07	0.34	0.28	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
HNSC	cis	rs8054556	0.74	rs12444978	ENSG00000183604.13	SMG1P5	-6.2	1.26e-09	6.15e-07	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30267553~30335374:-
HNSC	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-6.2	1.26e-09	6.15e-07	-0.29	-0.28	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	6.2	1.26e-09	6.16e-07	0.36	0.28	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
HNSC	cis	rs2985684	0.948	rs6572592	ENSG00000258568.1	RHOQP1	6.2	1.26e-09	6.17e-07	0.28	0.28	Carotid intima media thickness;	chr14:49614153	chr14:49599994~49600572:+
HNSC	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-6.2	1.26e-09	6.18e-07	-0.37	-0.28	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
HNSC	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	6.2	1.26e-09	6.18e-07	0.39	0.28	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
HNSC	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-6.2	1.26e-09	6.19e-07	-0.33	-0.28	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
HNSC	cis	rs9840812	0.596	rs571513	ENSG00000273486.1	RP11-731C17.2	6.2	1.27e-09	6.21e-07	0.24	0.28	Fibrinogen levels;	chr3:136376193	chr3:136837338~136839021:-
HNSC	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-6.2	1.27e-09	6.23e-07	-0.35	-0.28	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
HNSC	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	6.2	1.27e-09	6.23e-07	0.33	0.28	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
HNSC	cis	rs11992162	0.613	rs6601634	ENSG00000206014.6	OR7E161P	6.2	1.27e-09	6.23e-07	0.3	0.28	Monocyte count;	chr8:11948947	chr8:11928597~11929563:-
HNSC	cis	rs1659258	0.803	rs1258412	ENSG00000232508.1	MRPL45P1	-6.19	1.28e-09	6.27e-07	-0.54	-0.28	Visceral fat;	chr2:88318068	chr2:88364695~88365608:-
HNSC	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-6.19	1.28e-09	6.28e-07	-0.34	-0.28	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
HNSC	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	6.19	1.28e-09	6.28e-07	0.39	0.28	Height;	chr6:109339681	chr6:109382795~109383666:+
HNSC	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-6.19	1.28e-09	6.28e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
HNSC	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	6.19	1.29e-09	6.31e-07	0.3	0.28	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	6.19	1.29e-09	6.31e-07	0.3	0.28	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
HNSC	cis	rs4639966	0.836	rs7110526	ENSG00000255422.1	AP002954.4	6.19	1.29e-09	6.31e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118762824	chr11:118704607~118750263:+
HNSC	cis	rs4639966	0.797	rs11217021	ENSG00000255422.1	AP002954.4	6.19	1.29e-09	6.31e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118770119	chr11:118704607~118750263:+
HNSC	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-6.19	1.29e-09	6.32e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
HNSC	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-6.19	1.29e-09	6.32e-07	-0.28	-0.28	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
HNSC	cis	rs8012947	0.916	rs28411823	ENSG00000279636.2	LINC00216	-6.19	1.29e-09	6.32e-07	-0.34	-0.28	Alcohol consumption in current drinkers;	chr14:58239891	chr14:58288033~58289158:+
HNSC	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	6.19	1.29e-09	6.33e-07	0.34	0.28	Depression;	chr6:28431469	chr6:28943877~28944537:+
HNSC	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.19	1.3e-09	6.33e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.19	1.3e-09	6.33e-07	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
HNSC	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	6.19	1.3e-09	6.33e-07	0.36	0.28	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
HNSC	cis	rs61542988	0.532	rs12673996	ENSG00000228649.7	AC005682.5	6.19	1.3e-09	6.33e-07	0.34	0.28	Fibrinogen levels;	chr7:22793781	chr7:22854178~22861579:+
HNSC	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	6.19	1.3e-09	6.34e-07	0.32	0.28	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
HNSC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.34e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.34e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
HNSC	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	6.19	1.3e-09	6.34e-07	0.38	0.28	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	6.19	1.3e-09	6.34e-07	0.34	0.28	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
HNSC	cis	rs71327718	1	rs71327718	ENSG00000248787.1	RP11-666A20.4	-6.19	1.3e-09	6.35e-07	-0.5	-0.28	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125908005~125910272:-
HNSC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.35e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.576	rs4646748	ENSG00000241288.6	RP11-379B18.5	-6.19	1.3e-09	6.35e-07	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:126107486	chr3:125827238~125916384:-
HNSC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.19	1.3e-09	6.35e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
HNSC	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-6.19	1.3e-09	6.35e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
HNSC	cis	rs5753618	0.561	rs4820043	ENSG00000236132.1	CTA-440B3.1	6.19	1.3e-09	6.36e-07	0.34	0.28	Colorectal cancer;	chr22:31251108	chr22:31816379~31817491:-
HNSC	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	6.19	1.3e-09	6.36e-07	0.3	0.28	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
HNSC	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-6.19	1.3e-09	6.36e-07	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
HNSC	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-6.19	1.31e-09	6.38e-07	-0.22	-0.28	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
HNSC	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	6.19	1.31e-09	6.38e-07	0.36	0.28	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
HNSC	cis	rs9840812	0.522	rs711976	ENSG00000273486.1	RP11-731C17.2	6.19	1.31e-09	6.38e-07	0.25	0.28	Fibrinogen levels;	chr3:136510180	chr3:136837338~136839021:-
HNSC	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-6.19	1.31e-09	6.39e-07	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
HNSC	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.39e-07	0.3	0.28	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	6.19	1.31e-09	6.39e-07	0.36	0.28	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	6.19	1.31e-09	6.39e-07	0.36	0.28	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
HNSC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.19	1.31e-09	6.4e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
HNSC	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	6.19	1.31e-09	6.4e-07	0.43	0.28	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
HNSC	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	6.19	1.31e-09	6.4e-07	0.3	0.28	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
HNSC	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28248708	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28250019	chr6:28115628~28116551:+
HNSC	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-6.19	1.31e-09	6.4e-07	-0.41	-0.28	Depression;	chr6:28250421	chr6:28115628~28116551:+
HNSC	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	6.19	1.31e-09	6.4e-07	0.49	0.28	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
HNSC	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.31e-09	6.4e-07	-0.3	-0.28	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
HNSC	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	6.19	1.31e-09	6.41e-07	0.25	0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
HNSC	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	6.19	1.31e-09	6.41e-07	0.32	0.28	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
HNSC	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-6.19	1.31e-09	6.41e-07	-0.26	-0.28	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
HNSC	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-6.19	1.31e-09	6.41e-07	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
HNSC	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-6.19	1.31e-09	6.41e-07	-0.38	-0.28	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
HNSC	cis	rs7819412	0.594	rs7460507	ENSG00000255310.2	AF131215.2	-6.19	1.32e-09	6.42e-07	-0.27	-0.28	Triglycerides;	chr8:11111565	chr8:11107788~11109726:-
HNSC	cis	rs2985684	0.894	rs7152110	ENSG00000258568.1	RHOQP1	6.19	1.32e-09	6.42e-07	0.28	0.28	Carotid intima media thickness;	chr14:49551500	chr14:49599994~49600572:+
HNSC	cis	rs453301	0.653	rs7853	ENSG00000254153.1	CTA-398F10.2	6.19	1.32e-09	6.43e-07	0.31	0.28	Joint mobility (Beighton score);	chr8:9033304	chr8:8456909~8461337:-
HNSC	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-6.19	1.32e-09	6.43e-07	-0.34	-0.28	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
HNSC	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	6.19	1.32e-09	6.44e-07	0.26	0.28	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
HNSC	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.19	1.32e-09	6.44e-07	0.29	0.28	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
HNSC	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-6.19	1.32e-09	6.44e-07	-0.29	-0.28	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
HNSC	cis	rs9326248	0.53	rs6589589	ENSG00000280143.1	AP000892.6	6.19	1.32e-09	6.44e-07	0.42	0.28	Blood protein levels;	chr11:117061712	chr11:117204967~117210292:+
HNSC	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	6.19	1.32e-09	6.44e-07	0.3	0.28	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
HNSC	cis	rs9907295	0.591	rs6505496	ENSG00000270977.1	AC015849.16	-6.19	1.32e-09	6.45e-07	-0.33	-0.28	Fibroblast growth factor basic levels;	chr17:35802063	chr17:35893707~35911023:-
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-6.19	1.33e-09	6.47e-07	-0.21	-0.28	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
HNSC	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-6.19	1.33e-09	6.48e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
HNSC	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	6.19	1.33e-09	6.5e-07	0.38	0.28	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
HNSC	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-6.19	1.33e-09	6.5e-07	-0.28	-0.28	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
HNSC	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	6.19	1.34e-09	6.51e-07	0.32	0.28	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	6.19	1.34e-09	6.51e-07	0.34	0.28	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
HNSC	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	6.19	1.34e-09	6.51e-07	0.27	0.28	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
HNSC	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	6.19	1.34e-09	6.51e-07	0.27	0.28	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
HNSC	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.19	1.34e-09	6.52e-07	-0.21	-0.28	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
HNSC	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-6.19	1.34e-09	6.53e-07	-0.33	-0.28	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
HNSC	cis	rs6951245	0.938	rs78351779	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11761941	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs11767527	ENSG00000225146.1	AC073957.15	-6.19	1.34e-09	6.53e-07	-0.47	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1029025~1043891:+
HNSC	cis	rs2579103	0.809	rs34691361	ENSG00000258183.4	RP11-753N8.1	-6.19	1.34e-09	6.53e-07	-0.33	-0.28	Body mass index;	chr12:90202116	chr12:90280894~90300340:+
HNSC	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-6.19	1.34e-09	6.54e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
HNSC	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-6.19	1.34e-09	6.54e-07	-0.33	-0.28	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-6.19	1.35e-09	6.56e-07	-0.34	-0.28	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
HNSC	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	6.19	1.35e-09	6.56e-07	0.38	0.28	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
HNSC	cis	rs4141404	0.757	rs5749272	ENSG00000236132.1	CTA-440B3.1	6.19	1.35e-09	6.56e-07	0.3	0.28	Paclitaxel-induced neuropathy;	chr22:31434365	chr22:31816379~31817491:-
HNSC	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-6.19	1.35e-09	6.57e-07	-0.37	-0.28	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	6.19	1.35e-09	6.58e-07	0.32	0.28	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
HNSC	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	6.19	1.35e-09	6.59e-07	0.42	0.28	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
HNSC	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	6.19	1.35e-09	6.59e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
HNSC	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	6.19	1.35e-09	6.59e-07	0.29	0.28	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
HNSC	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	6.19	1.35e-09	6.59e-07	0.3	0.28	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
HNSC	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	6.19	1.36e-09	6.6e-07	0.3	0.28	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	6.19	1.36e-09	6.6e-07	0.3	0.28	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
HNSC	cis	rs2404602	0.692	rs34478400	ENSG00000259422.1	RP11-593F23.1	6.18	1.36e-09	6.61e-07	0.32	0.28	Blood metabolite levels;	chr15:76631169	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	6.18	1.36e-09	6.61e-07	0.41	0.28	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
HNSC	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-6.18	1.36e-09	6.62e-07	-0.27	-0.28	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
HNSC	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-6.18	1.36e-09	6.62e-07	-0.68	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	6.18	1.36e-09	6.62e-07	0.35	0.28	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	6.18	1.36e-09	6.62e-07	0.35	0.28	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
HNSC	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-6.18	1.36e-09	6.62e-07	-0.23	-0.28	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	6.18	1.36e-09	6.63e-07	0.23	0.28	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	6.18	1.36e-09	6.64e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	6.18	1.36e-09	6.64e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
HNSC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	6.18	1.37e-09	6.64e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
HNSC	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-6.18	1.37e-09	6.64e-07	-0.29	-0.28	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
HNSC	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-6.18	1.37e-09	6.64e-07	-0.37	-0.28	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-6.18	1.37e-09	6.65e-07	-0.34	-0.28	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	6.18	1.37e-09	6.65e-07	0.32	0.28	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
HNSC	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.18	1.37e-09	6.66e-07	-0.24	-0.28	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
HNSC	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	6.18	1.37e-09	6.66e-07	0.33	0.28	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
HNSC	cis	rs2337406	1	rs17113276	ENSG00000211974.3	IGHV2-70	6.18	1.37e-09	6.67e-07	0.33	0.28	Alzheimer's disease (late onset);	chr14:106683485	chr14:106723574~106724093:-
HNSC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.18	1.37e-09	6.67e-07	-0.3	-0.28	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
HNSC	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	6.18	1.38e-09	6.69e-07	0.26	0.28	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-6.18	1.38e-09	6.69e-07	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
HNSC	cis	rs2337406	1	rs1858677	ENSG00000211974.3	IGHV2-70	-6.18	1.38e-09	6.69e-07	-0.33	-0.28	Alzheimer's disease (late onset);	chr14:106706828	chr14:106723574~106724093:-
HNSC	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-6.18	1.38e-09	6.69e-07	-0.26	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000211974.3	IGHV2-70	-6.18	1.38e-09	6.7e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106669877	chr14:106723574~106724093:-
HNSC	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-6.18	1.38e-09	6.7e-07	-0.3	-0.28	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
HNSC	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-6.18	1.38e-09	6.7e-07	-0.31	-0.28	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
HNSC	cis	rs4639966	0.758	rs11217013	ENSG00000255422.1	AP002954.4	6.18	1.38e-09	6.71e-07	0.37	0.28	Systemic lupus erythematosus;	chr11:118754210	chr11:118704607~118750263:+
HNSC	cis	rs7824557	0.547	rs4512344	ENSG00000269918.1	AF131215.9	-6.18	1.38e-09	6.71e-07	-0.27	-0.28	Retinal vascular caliber;	chr8:11221272	chr8:11104691~11106704:-
HNSC	cis	rs7404843	0.789	rs222909	ENSG00000263335.1	AF001548.5	6.18	1.38e-09	6.71e-07	0.5	0.28	Testicular germ cell tumor;	chr16:15405432	chr16:15726674~15732993:+
HNSC	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-6.18	1.38e-09	6.71e-07	-0.26	-0.28	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
HNSC	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-6.18	1.38e-09	6.71e-07	-0.29	-0.28	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
HNSC	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-6.18	1.38e-09	6.71e-07	-0.29	-0.28	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
HNSC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	6.18	1.38e-09	6.72e-07	0.31	0.28	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
HNSC	cis	rs4657482	0.606	rs3790665	ENSG00000236364.3	RP11-525G13.2	6.18	1.38e-09	6.72e-07	0.29	0.28	Testicular germ cell tumor;	chr1:165900834	chr1:165890795~165900683:-
HNSC	cis	rs1021993	0.597	rs1395753	ENSG00000231648.1	RP11-372M18.2	-6.18	1.38e-09	6.72e-07	-0.46	-0.28	Gut microbiome composition (winter);	chr1:209317182	chr1:209367662~209379690:+
HNSC	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	6.18	1.39e-09	6.75e-07	0.3	0.27	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
HNSC	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-6.18	1.39e-09	6.75e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
HNSC	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-6.18	1.39e-09	6.76e-07	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
HNSC	cis	rs4657482	0.607	rs473222	ENSG00000236364.3	RP11-525G13.2	-6.18	1.39e-09	6.76e-07	-0.28	-0.27	Testicular germ cell tumor;	chr1:165907341	chr1:165890795~165900683:-
HNSC	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	6.18	1.39e-09	6.77e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	6.18	1.39e-09	6.77e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
HNSC	cis	rs4218	0.597	rs12438208	ENSG00000259732.1	RP11-59H7.3	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Social communication problems;	chr15:59057715	chr15:59121034~59133250:+
HNSC	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-6.18	1.4e-09	6.78e-07	-0.37	-0.27	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-6.18	1.4e-09	6.78e-07	-0.37	-0.27	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
HNSC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.4e-09	6.78e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
HNSC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.4e-09	6.78e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
HNSC	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-6.18	1.4e-09	6.78e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
HNSC	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	6.18	1.4e-09	6.79e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
HNSC	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-6.18	1.4e-09	6.8e-07	-0.4	-0.27	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6.18	1.4e-09	6.8e-07	0.36	0.27	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
HNSC	cis	rs9813712	0.953	rs7619208	ENSG00000249846.5	RP11-77P16.4	-6.18	1.4e-09	6.82e-07	-0.33	-0.27	Response to amphetamines;	chr3:130258163	chr3:130112550~130120579:+
HNSC	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	6.18	1.41e-09	6.82e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
HNSC	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-6.18	1.41e-09	6.82e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
HNSC	cis	rs6471393	0.83	rs57803852	ENSG00000253848.1	RP11-10N23.5	6.18	1.41e-09	6.83e-07	0.33	0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761156	chr8:93741193~93744534:+
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	6.18	1.41e-09	6.84e-07	0.36	0.27	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	6.18	1.41e-09	6.84e-07	0.36	0.27	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
HNSC	cis	rs5753618	0.583	rs71324184	ENSG00000236132.1	CTA-440B3.1	-6.18	1.41e-09	6.85e-07	-0.32	-0.27	Colorectal cancer;	chr22:31356075	chr22:31816379~31817491:-
HNSC	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-6.18	1.41e-09	6.86e-07	-0.39	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
HNSC	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-6.18	1.41e-09	6.86e-07	-0.3	-0.27	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
HNSC	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	6.18	1.42e-09	6.86e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
HNSC	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	6.18	1.42e-09	6.86e-07	0.25	0.27	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
HNSC	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.18	1.42e-09	6.86e-07	-0.24	-0.27	Height;	chr11:118703207	chr11:118791254~118793137:+
HNSC	cis	rs4657482	0.607	rs3790671	ENSG00000236364.3	RP11-525G13.2	6.18	1.42e-09	6.87e-07	0.29	0.27	Testicular germ cell tumor;	chr1:165904085	chr1:165890795~165900683:-
HNSC	cis	rs4657482	0.607	rs3790672	ENSG00000236364.3	RP11-525G13.2	-6.18	1.42e-09	6.87e-07	-0.29	-0.27	Testicular germ cell tumor;	chr1:165904155	chr1:165890795~165900683:-
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	6.18	1.42e-09	6.87e-07	0.37	0.27	Depression;	chr6:28229408	chr6:28943877~28944537:+
HNSC	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-6.18	1.42e-09	6.89e-07	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
HNSC	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-6.18	1.43e-09	6.91e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
HNSC	cis	rs8012947	0.877	rs12879675	ENSG00000279636.2	LINC00216	-6.18	1.43e-09	6.93e-07	-0.34	-0.27	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58288033~58289158:+
HNSC	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	6.18	1.43e-09	6.93e-07	0.61	0.27	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
HNSC	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-6.18	1.43e-09	6.93e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
HNSC	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-6.18	1.43e-09	6.94e-07	-0.26	-0.27	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-6.18	1.43e-09	6.94e-07	-0.26	-0.27	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
HNSC	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-6.18	1.43e-09	6.95e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
HNSC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	6.18	1.43e-09	6.95e-07	0.31	0.27	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	6.18	1.43e-09	6.95e-07	0.31	0.27	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
HNSC	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-6.18	1.44e-09	6.96e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
HNSC	cis	rs6951245	1	rs80212261	ENSG00000225146.1	AC073957.15	-6.17	1.44e-09	6.97e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs77346188	ENSG00000225146.1	AC073957.15	-6.17	1.44e-09	6.97e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1029025~1043891:+
HNSC	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	6.17	1.44e-09	6.97e-07	0.33	0.27	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
HNSC	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	6.17	1.44e-09	6.98e-07	0.36	0.27	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
HNSC	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	6.17	1.44e-09	6.98e-07	0.33	0.27	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
HNSC	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	6.17	1.44e-09	6.99e-07	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
HNSC	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-6.17	1.45e-09	7.01e-07	-0.39	-0.27	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000229212.6	RP11-561C5.4	6.17	1.45e-09	7.01e-07	0.32	0.27	P wave terminal force;	chr15:84654022	chr15:85205440~85234795:-
HNSC	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	6.17	1.45e-09	7.01e-07	0.26	0.27	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	6.17	1.45e-09	7.01e-07	0.22	0.27	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
HNSC	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.17	1.45e-09	7.03e-07	0.37	0.27	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
HNSC	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	6.17	1.45e-09	7.03e-07	0.36	0.27	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
HNSC	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	6.17	1.45e-09	7.03e-07	0.46	0.27	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
HNSC	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-6.17	1.45e-09	7.03e-07	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-6.17	1.45e-09	7.03e-07	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
HNSC	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	6.17	1.45e-09	7.03e-07	0.46	0.27	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
HNSC	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.17	1.45e-09	7.03e-07	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
HNSC	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	6.17	1.45e-09	7.04e-07	0.3	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
HNSC	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-6.17	1.46e-09	7.07e-07	-0.33	-0.27	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
HNSC	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-6.17	1.46e-09	7.08e-07	-0.31	-0.27	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
HNSC	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-6.17	1.47e-09	7.09e-07	-0.32	-0.27	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
HNSC	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	6.17	1.47e-09	7.11e-07	0.34	0.27	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
HNSC	cis	rs35955747	0.869	rs5997909	ENSG00000236132.1	CTA-440B3.1	6.17	1.47e-09	7.11e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31195242	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.689	rs12900369	ENSG00000259732.1	RP11-59H7.3	-6.17	1.47e-09	7.12e-07	-0.39	-0.27	Social communication problems;	chr15:59099254	chr15:59121034~59133250:+
HNSC	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-6.17	1.47e-09	7.12e-07	-0.29	-0.27	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
HNSC	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	6.17	1.47e-09	7.12e-07	0.32	0.27	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
HNSC	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-6.17	1.48e-09	7.14e-07	-0.25	-0.27	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
HNSC	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	6.17	1.48e-09	7.14e-07	0.3	0.27	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
HNSC	cis	rs8054556	0.76	rs12598856	ENSG00000183604.13	SMG1P5	-6.17	1.48e-09	7.15e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30267553~30335374:-
HNSC	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-6.17	1.48e-09	7.16e-07	-0.41	-0.27	Depression;	chr6:28251883	chr6:28115628~28116551:+
HNSC	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	6.17	1.48e-09	7.16e-07	0.29	0.27	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
HNSC	cis	rs11992162	0.597	rs6996342	ENSG00000206014.6	OR7E161P	6.17	1.48e-09	7.16e-07	0.3	0.27	Monocyte count;	chr8:11927032	chr8:11928597~11929563:-
HNSC	cis	rs9326248	0.53	rs2000615	ENSG00000280143.1	AP000892.6	6.17	1.48e-09	7.17e-07	0.42	0.27	Blood protein levels;	chr11:117045103	chr11:117204967~117210292:+
HNSC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-6.17	1.48e-09	7.17e-07	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-6.17	1.48e-09	7.17e-07	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
HNSC	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-6.17	1.48e-09	7.18e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-6.17	1.48e-09	7.18e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
HNSC	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	6.17	1.48e-09	7.18e-07	0.27	0.27	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
HNSC	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	6.17	1.49e-09	7.18e-07	0.31	0.27	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
HNSC	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.17	1.49e-09	7.18e-07	0.28	0.27	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
HNSC	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-6.17	1.49e-09	7.18e-07	-0.32	-0.27	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
HNSC	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	6.17	1.49e-09	7.19e-07	0.31	0.27	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
HNSC	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-6.17	1.49e-09	7.19e-07	-0.3	-0.27	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
HNSC	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	6.17	1.49e-09	7.2e-07	0.36	0.27	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000173295.6	FAM86B3P	-6.17	1.49e-09	7.21e-07	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9015783	chr8:8228595~8244865:+
HNSC	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-6.17	1.49e-09	7.21e-07	-0.3	-0.27	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
HNSC	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.17	1.49e-09	7.22e-07	0.27	0.27	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
HNSC	cis	rs9341808	0.667	rs2490244	ENSG00000272129.1	RP11-250B2.6	6.17	1.49e-09	7.22e-07	0.32	0.27	Sitting height ratio;	chr6:80181395	chr6:80355424~80356859:+
HNSC	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	6.17	1.49e-09	7.22e-07	0.25	0.27	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
HNSC	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-6.17	1.5e-09	7.22e-07	-0.32	-0.27	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
HNSC	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	6.17	1.5e-09	7.24e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
HNSC	cis	rs440932	1	rs440932	ENSG00000173295.6	FAM86B3P	6.17	1.5e-09	7.26e-07	0.33	0.27	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8228595~8244865:+
HNSC	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	6.17	1.51e-09	7.27e-07	0.36	0.27	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	6.17	1.51e-09	7.27e-07	0.36	0.27	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
HNSC	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-6.17	1.51e-09	7.28e-07	-0.37	-0.27	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
HNSC	cis	rs9329221	0.682	rs6982308	ENSG00000269918.1	AF131215.9	-6.17	1.51e-09	7.28e-07	-0.27	-0.27	Neuroticism;	chr8:10336262	chr8:11104691~11106704:-
HNSC	cis	rs7209700	0.662	rs8066295	ENSG00000228782.6	CTD-2026D20.3	6.17	1.51e-09	7.28e-07	0.29	0.27	IgG glycosylation;	chr17:47270837	chr17:47450568~47492492:-
HNSC	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-6.17	1.51e-09	7.29e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
HNSC	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-6.17	1.51e-09	7.29e-07	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
HNSC	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-6.17	1.51e-09	7.29e-07	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-6.17	1.52e-09	7.31e-07	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	6.17	1.52e-09	7.32e-07	0.27	0.27	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
HNSC	cis	rs6928977	0.675	rs11154803	ENSG00000234084.1	RP3-388E23.2	-6.17	1.52e-09	7.32e-07	-0.28	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135301568~135307158:+
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-6.17	1.52e-09	7.32e-07	-0.34	-0.27	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	6.17	1.52e-09	7.32e-07	0.37	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
HNSC	cis	rs9402743	0.666	rs9385737	ENSG00000217482.2	HMGB1P17	6.17	1.52e-09	7.33e-07	0.29	0.27	Systemic lupus erythematosus;	chr6:135759379	chr6:135636086~135636713:-
HNSC	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	6.17	1.52e-09	7.33e-07	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
HNSC	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	6.17	1.52e-09	7.33e-07	0.38	0.27	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
HNSC	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
HNSC	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	6.17	1.52e-09	7.34e-07	0.34	0.27	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
HNSC	cis	rs11992162	0.591	rs35657308	ENSG00000206014.6	OR7E161P	6.17	1.52e-09	7.34e-07	0.29	0.27	Monocyte count;	chr8:11946893	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	6.17	1.52e-09	7.35e-07	0.33	0.27	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000254153.1	CTA-398F10.2	-6.17	1.53e-09	7.36e-07	-0.3	-0.27	Systolic blood pressure;	chr8:8480709	chr8:8456909~8461337:-
HNSC	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-6.16	1.53e-09	7.37e-07	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
HNSC	cis	rs8054556	0.787	rs12325400	ENSG00000183604.13	SMG1P5	-6.16	1.53e-09	7.37e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-6.16	1.53e-09	7.37e-07	-0.27	-0.27	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000241288.6	RP11-379B18.5	-6.16	1.53e-09	7.37e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125916896	chr3:125827238~125916384:-
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	6.16	1.53e-09	7.38e-07	0.31	0.27	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	6.16	1.53e-09	7.38e-07	0.32	0.27	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	6.16	1.53e-09	7.38e-07	0.21	0.27	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
HNSC	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	6.16	1.53e-09	7.39e-07	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
HNSC	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-6.16	1.53e-09	7.39e-07	-0.38	-0.27	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
HNSC	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.53e-09	7.39e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.53e-09	7.39e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
HNSC	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	6.16	1.54e-09	7.42e-07	0.68	0.27	Breast cancer;	chr5:349183	chr5:262769~262881:+
HNSC	cis	rs6951245	1	rs884977	ENSG00000225146.1	AC073957.15	-6.16	1.54e-09	7.43e-07	-0.42	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1029025~1043891:+
HNSC	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	6.16	1.54e-09	7.43e-07	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
HNSC	cis	rs2235642	0.505	rs56359342	ENSG00000280231.1	LA16c-380F5.3	-6.16	1.54e-09	7.43e-07	-0.34	-0.27	Coronary artery disease;	chr16:1604947	chr16:1553655~1554130:-
HNSC	cis	rs7824557	0.547	rs2409749	ENSG00000269918.1	AF131215.9	-6.16	1.54e-09	7.44e-07	-0.27	-0.27	Retinal vascular caliber;	chr8:11221440	chr8:11104691~11106704:-
HNSC	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.16	1.55e-09	7.44e-07	0.36	0.27	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.16	1.55e-09	7.44e-07	0.36	0.27	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-6.16	1.55e-09	7.47e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-6.16	1.55e-09	7.47e-07	-0.37	-0.27	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	6.16	1.56e-09	7.49e-07	0.63	0.27	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
HNSC	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-6.16	1.56e-09	7.52e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
HNSC	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-6.16	1.56e-09	7.52e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
HNSC	cis	rs9611519	0.78	rs3171692	ENSG00000235513.1	RP4-756G23.5	6.16	1.56e-09	7.53e-07	0.29	0.27	Neuroticism;	chr22:41246208	chr22:41209122~41217627:-
HNSC	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	6.16	1.56e-09	7.53e-07	0.26	0.27	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
HNSC	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	6.16	1.57e-09	7.54e-07	0.31	0.27	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
HNSC	cis	rs7617773	0.539	rs12486944	ENSG00000228638.1	FCF1P2	-6.16	1.57e-09	7.55e-07	-0.24	-0.27	Coronary artery disease;	chr3:48348526	chr3:48290793~48291375:-
HNSC	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	6.16	1.57e-09	7.55e-07	0.34	0.27	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.16	1.57e-09	7.55e-07	0.26	0.27	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
HNSC	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	6.16	1.57e-09	7.56e-07	0.32	0.27	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
HNSC	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-6.16	1.57e-09	7.57e-07	-0.36	-0.27	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000267151.3	RP11-100E5.2	6.16	1.57e-09	7.57e-07	0.35	0.27	Menopause (age at onset);	chr17:43127544	chr17:43444707~43451200:+
HNSC	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	6.16	1.57e-09	7.57e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
HNSC	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	6.16	1.57e-09	7.57e-07	0.36	0.27	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	6.16	1.57e-09	7.58e-07	0.38	0.27	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
HNSC	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-6.16	1.58e-09	7.58e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-6.16	1.58e-09	7.58e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000211974.3	IGHV2-70	-6.16	1.58e-09	7.59e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106704673	chr14:106723574~106724093:-
HNSC	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	6.16	1.58e-09	7.6e-07	0.31	0.27	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
HNSC	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-6.16	1.58e-09	7.6e-07	-0.33	-0.27	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-6.16	1.58e-09	7.6e-07	-0.33	-0.27	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
HNSC	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	6.16	1.58e-09	7.6e-07	0.31	0.27	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
HNSC	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	6.16	1.58e-09	7.61e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	6.16	1.58e-09	7.61e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
HNSC	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-6.16	1.58e-09	7.61e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
HNSC	cis	rs17270561	0.636	rs9348696	ENSG00000272462.2	U91328.19	-6.16	1.58e-09	7.61e-07	-0.28	-0.27	Iron status biomarkers;	chr6:25781710	chr6:25992662~26001775:+
HNSC	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	6.16	1.58e-09	7.61e-07	0.36	0.27	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	6.16	1.59e-09	7.62e-07	0.31	0.27	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
HNSC	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	6.16	1.59e-09	7.63e-07	0.28	0.27	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
HNSC	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.59e-09	7.64e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
HNSC	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	6.16	1.59e-09	7.64e-07	0.32	0.27	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
HNSC	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	6.16	1.59e-09	7.65e-07	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
HNSC	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-6.16	1.59e-09	7.65e-07	-0.32	-0.27	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	6.16	1.59e-09	7.65e-07	0.49	0.27	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
HNSC	cis	rs9326248	0.53	rs7950364	ENSG00000280143.1	AP000892.6	6.16	1.59e-09	7.65e-07	0.41	0.27	Blood protein levels;	chr11:117028170	chr11:117204967~117210292:+
HNSC	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-6.16	1.59e-09	7.65e-07	-0.46	-0.27	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
HNSC	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.16	1.59e-09	7.66e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
HNSC	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	6.16	1.59e-09	7.66e-07	0.26	0.27	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000254153.1	CTA-398F10.2	-6.16	1.6e-09	7.7e-07	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9037960	chr8:8456909~8461337:-
HNSC	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	6.16	1.6e-09	7.7e-07	0.27	0.27	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
HNSC	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-6.16	1.6e-09	7.71e-07	-0.36	-0.27	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
HNSC	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	6.16	1.6e-09	7.71e-07	0.37	0.27	Height;	chr6:109357908	chr6:109382795~109383666:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-6.16	1.6e-09	7.71e-07	-0.18	-0.27	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	6.16	1.61e-09	7.72e-07	0.24	0.27	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	6.16	1.61e-09	7.73e-07	0.22	0.27	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
HNSC	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-6.16	1.61e-09	7.75e-07	-0.46	-0.27	Depression;	chr6:28124907	chr6:28115628~28116551:+
HNSC	cis	rs35955747	0.869	rs9621216	ENSG00000236132.1	CTA-440B3.1	6.16	1.61e-09	7.75e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31194222	chr22:31816379~31817491:-
HNSC	cis	rs11648785	0.777	rs12932473	ENSG00000222019.6	URAHP	6.16	1.61e-09	7.75e-07	0.28	0.27	Tanning;	chr16:90033981	chr16:90039761~90047773:-
HNSC	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-6.16	1.62e-09	7.76e-07	-0.36	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
HNSC	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-6.16	1.62e-09	7.76e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
HNSC	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-6.15	1.62e-09	7.77e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
HNSC	cis	rs9525927	0.57	rs7400099	ENSG00000227258.4	SMIM2-AS1	-6.15	1.62e-09	7.77e-07	-0.37	-0.27	Dupuytren's disease;	chr13:44230344	chr13:44110451~44240517:+
HNSC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	6.15	1.62e-09	7.79e-07	0.3	0.27	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
HNSC	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.15	1.62e-09	7.79e-07	0.27	0.27	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	6.15	1.62e-09	7.8e-07	0.31	0.27	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
HNSC	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	6.15	1.62e-09	7.8e-07	0.36	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
HNSC	cis	rs2985684	0.894	rs6572585	ENSG00000258568.1	RHOQP1	6.15	1.63e-09	7.81e-07	0.28	0.27	Carotid intima media thickness;	chr14:49554357	chr14:49599994~49600572:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	6.15	1.63e-09	7.82e-07	0.3	0.27	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	6.15	1.63e-09	7.82e-07	0.3	0.27	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000241288.6	RP11-379B18.5	-6.15	1.63e-09	7.83e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125918136	chr3:125827238~125916384:-
HNSC	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	6.15	1.64e-09	7.85e-07	0.37	0.27	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
HNSC	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.85e-07	0.31	0.27	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	6.15	1.64e-09	7.86e-07	0.3	0.27	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-6.15	1.64e-09	7.88e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
HNSC	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-6.15	1.64e-09	7.88e-07	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
HNSC	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	6.15	1.64e-09	7.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
HNSC	cis	rs9907295	0.591	rs3817655	ENSG00000270977.1	AC015849.16	6.15	1.64e-09	7.89e-07	0.33	0.27	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35893707~35911023:-
HNSC	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	6.15	1.65e-09	7.9e-07	0.32	0.27	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
HNSC	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.15	1.65e-09	7.91e-07	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
HNSC	cis	rs4657482	0.639	rs12045367	ENSG00000236364.3	RP11-525G13.2	6.15	1.65e-09	7.91e-07	0.28	0.27	Testicular germ cell tumor;	chr1:165906735	chr1:165890795~165900683:-
HNSC	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	6.15	1.65e-09	7.91e-07	0.28	0.27	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
HNSC	cis	rs4218	0.597	rs12438962	ENSG00000277144.1	RP11-59H7.4	-6.15	1.65e-09	7.92e-07	-0.37	-0.27	Social communication problems;	chr15:59065694	chr15:59115547~59116089:-
HNSC	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-6.15	1.65e-09	7.92e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	6.15	1.65e-09	7.92e-07	0.34	0.27	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
HNSC	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-6.15	1.66e-09	7.94e-07	-0.35	-0.27	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
HNSC	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.15	1.66e-09	7.94e-07	0.28	0.27	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
HNSC	cis	rs2985684	0.895	rs4900940	ENSG00000258568.1	RHOQP1	6.15	1.66e-09	7.95e-07	0.28	0.27	Carotid intima media thickness;	chr14:49608592	chr14:49599994~49600572:+
HNSC	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	6.15	1.66e-09	7.96e-07	0.33	0.27	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	6.15	1.66e-09	7.96e-07	0.38	0.27	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	6.15	1.66e-09	7.96e-07	0.38	0.27	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
HNSC	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	6.15	1.66e-09	7.97e-07	0.31	0.27	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
HNSC	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	6.15	1.66e-09	7.97e-07	0.33	0.27	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
HNSC	cis	rs7804306	1	rs73050915	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8010614	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs73050929	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8019638	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73050940	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027882	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs56142807	ENSG00000233264.2	AC006042.8	6.15	1.67e-09	7.99e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8028562	chr7:7980312~7982228:+
HNSC	cis	rs11992162	0.551	rs35010200	ENSG00000206014.6	OR7E161P	6.15	1.67e-09	7.99e-07	0.3	0.27	Monocyte count;	chr8:11928146	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-6.15	1.67e-09	8e-07	-0.26	-0.27	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
HNSC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-6.15	1.67e-09	8e-07	-0.3	-0.27	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
HNSC	cis	rs12691307	1	rs12691307	ENSG00000183604.13	SMG1P5	-6.15	1.67e-09	8.01e-07	-0.26	-0.27	Schizophrenia;	chr16:29928556	chr16:30267553~30335374:-
HNSC	cis	rs8177876	0.642	rs12445303	ENSG00000261061.1	RP11-303E16.2	6.15	1.67e-09	8.01e-07	0.44	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81030770~81031485:+
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	6.15	1.67e-09	8.02e-07	0.3	0.27	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
HNSC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	6.15	1.68e-09	8.03e-07	0.31	0.27	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
HNSC	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-6.15	1.68e-09	8.03e-07	-0.33	-0.27	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.68e-09	8.04e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
HNSC	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	6.15	1.69e-09	8.08e-07	0.28	0.27	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
HNSC	cis	rs7048146	0.668	rs7341726	ENSG00000213539.4	YBX1P6	6.15	1.69e-09	8.09e-07	0.31	0.27	Vascular brain injury;	chr9:109513495	chr9:109532830~109534332:-
HNSC	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.69e-09	8.09e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
HNSC	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-6.15	1.69e-09	8.1e-07	-0.44	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
HNSC	cis	rs4639966	0.836	rs11217018	ENSG00000255422.1	AP002954.4	6.15	1.69e-09	8.1e-07	0.37	0.27	Systemic lupus erythematosus;	chr11:118764656	chr11:118704607~118750263:+
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000211974.3	IGHV2-70	-6.15	1.69e-09	8.1e-07	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106699438	chr14:106723574~106724093:-
HNSC	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-6.15	1.69e-09	8.11e-07	-0.28	-0.27	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
HNSC	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-6.15	1.69e-09	8.11e-07	-0.33	-0.27	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
HNSC	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.15	1.69e-09	8.11e-07	0.31	0.27	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.7e-09	8.12e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.15	1.7e-09	8.12e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-6.15	1.7e-09	8.12e-07	-0.31	-0.27	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.609	rs1937127	ENSG00000272462.2	U91328.19	6.15	1.7e-09	8.13e-07	0.28	0.27	Iron status biomarkers;	chr6:25769644	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-6.15	1.7e-09	8.14e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-6.15	1.7e-09	8.14e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
HNSC	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	6.15	1.7e-09	8.14e-07	0.56	0.27	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
HNSC	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-6.15	1.7e-09	8.14e-07	-0.32	-0.27	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.15	1.7e-09	8.16e-07	-0.33	-0.27	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.505	rs61789642	ENSG00000239213.4	NCK1-AS1	-6.15	1.71e-09	8.17e-07	-0.36	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136841726~136862054:-
HNSC	cis	rs7621025	0.505	rs61789643	ENSG00000239213.4	NCK1-AS1	-6.15	1.71e-09	8.17e-07	-0.36	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136841726~136862054:-
HNSC	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	6.15	1.71e-09	8.17e-07	0.37	0.27	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-6.15	1.71e-09	8.17e-07	-0.18	-0.27	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
HNSC	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-6.15	1.71e-09	8.18e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-6.15	1.71e-09	8.2e-07	-0.26	-0.27	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
HNSC	cis	rs9341808	0.667	rs2490239	ENSG00000272129.1	RP11-250B2.6	6.14	1.71e-09	8.21e-07	0.32	0.27	Sitting height ratio;	chr6:80116572	chr6:80355424~80356859:+
HNSC	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-6.14	1.72e-09	8.21e-07	-0.25	-0.27	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
HNSC	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	6.14	1.72e-09	8.22e-07	0.22	0.27	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
HNSC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	6.14	1.72e-09	8.22e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
HNSC	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-6.14	1.72e-09	8.22e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
HNSC	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-6.14	1.72e-09	8.23e-07	-0.37	-0.27	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
HNSC	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	6.14	1.72e-09	8.23e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
HNSC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-6.14	1.72e-09	8.23e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
HNSC	cis	rs9300255	0.739	rs1402275	ENSG00000280120.1	RP11-546D6.3	6.14	1.72e-09	8.23e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123266348	chr12:123152324~123153377:-
HNSC	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	6.14	1.72e-09	8.23e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
HNSC	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.14	1.72e-09	8.24e-07	0.28	0.27	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	6.14	1.72e-09	8.25e-07	0.22	0.27	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
HNSC	cis	rs34526934	0.565	rs34729309	ENSG00000226363.3	HAGLROS	6.14	1.72e-09	8.25e-07	0.36	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176169393	chr2:176177717~176179008:+
HNSC	cis	rs6928977	0.832	rs2614286	ENSG00000234084.1	RP3-388E23.2	-6.14	1.72e-09	8.25e-07	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371533	chr6:135301568~135307158:+
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-6.14	1.73e-09	8.26e-07	-0.18	-0.27	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
HNSC	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	6.14	1.73e-09	8.26e-07	0.32	0.27	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
HNSC	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-6.14	1.73e-09	8.27e-07	-0.35	-0.27	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
HNSC	cis	rs6951245	1	rs79327308	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.938	rs117729148	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs79617366	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1029025~1043891:+
HNSC	cis	rs6951245	1	rs111899361	ENSG00000225146.1	AC073957.15	-6.14	1.73e-09	8.27e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1029025~1043891:+
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-6.14	1.73e-09	8.28e-07	-0.4	-0.27	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
HNSC	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	6.14	1.73e-09	8.29e-07	0.29	0.27	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
HNSC	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-6.14	1.73e-09	8.29e-07	-0.23	-0.27	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	6.14	1.73e-09	8.29e-07	0.32	0.27	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
HNSC	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-6.14	1.74e-09	8.3e-07	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	6.14	1.74e-09	8.3e-07	0.35	0.27	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
HNSC	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-6.14	1.74e-09	8.3e-07	-0.27	-0.27	Height;	chr2:231539118	chr2:231508426~231514339:-
HNSC	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-6.14	1.74e-09	8.3e-07	-0.38	-0.27	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
HNSC	cis	rs35955747	0.869	rs28715	ENSG00000236132.1	CTA-440B3.1	-6.14	1.74e-09	8.31e-07	-0.29	-0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334183	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	6.14	1.74e-09	8.31e-07	0.37	0.27	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
HNSC	cis	rs7621025	0.617	rs12637102	ENSG00000273486.1	RP11-731C17.2	6.14	1.74e-09	8.32e-07	0.25	0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136837338~136839021:-
HNSC	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-6.14	1.74e-09	8.32e-07	-0.36	-0.27	Height;	chr6:109485060	chr6:109382795~109383666:+
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-6.14	1.74e-09	8.33e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	6.14	1.74e-09	8.33e-07	0.18	0.27	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
HNSC	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-6.14	1.74e-09	8.34e-07	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
HNSC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-6.14	1.75e-09	8.35e-07	-0.28	-0.27	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
HNSC	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	6.14	1.75e-09	8.36e-07	0.32	0.27	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-6.14	1.75e-09	8.36e-07	-0.24	-0.27	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	6.14	1.75e-09	8.36e-07	0.22	0.27	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	6.14	1.75e-09	8.36e-07	0.22	0.27	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
HNSC	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-6.14	1.75e-09	8.37e-07	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
HNSC	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	6.14	1.76e-09	8.39e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	6.14	1.76e-09	8.39e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
HNSC	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	6.14	1.76e-09	8.39e-07	0.3	0.27	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
HNSC	cis	rs7804306	0.826	rs73049290	ENSG00000233264.2	AC006042.8	6.14	1.76e-09	8.4e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7992584	chr7:7980312~7982228:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000211972.2	IGHV3-66	6.14	1.76e-09	8.4e-07	0.21	0.27	Kawasaki disease;	chr14:106697673	chr14:106675017~106675544:-
HNSC	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.14	1.76e-09	8.41e-07	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
HNSC	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-6.14	1.77e-09	8.44e-07	-0.34	-0.27	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
HNSC	cis	rs8177876	0.822	rs4889231	ENSG00000261061.1	RP11-303E16.2	6.14	1.77e-09	8.44e-07	0.43	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81030770~81031485:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000233609.3	RP11-62H7.2	6.14	1.77e-09	8.45e-07	0.26	0.27	Joint mobility (Beighton score);	chr8:8967994	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000233609.3	RP11-62H7.2	6.14	1.77e-09	8.45e-07	0.26	0.27	Mood instability;	chr8:8968365	chr8:8961200~8979025:+
HNSC	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-6.14	1.77e-09	8.45e-07	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
HNSC	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	6.14	1.77e-09	8.46e-07	0.32	0.27	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
HNSC	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.14	1.78e-09	8.49e-07	0.33	0.27	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000267151.3	RP11-100E5.2	6.14	1.78e-09	8.5e-07	0.35	0.27	Menopause (age at onset);	chr17:43074658	chr17:43444707~43451200:+
HNSC	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	6.14	1.78e-09	8.51e-07	0.33	0.27	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-6.14	1.78e-09	8.51e-07	-0.21	-0.27	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
HNSC	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	6.14	1.78e-09	8.51e-07	0.34	0.27	Depression;	chr6:28399846	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	6.14	1.79e-09	8.52e-07	0.41	0.27	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
HNSC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.14	1.79e-09	8.52e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
HNSC	cis	rs2985684	0.894	rs10147029	ENSG00000258568.1	RHOQP1	-6.14	1.79e-09	8.55e-07	-0.27	-0.27	Carotid intima media thickness;	chr14:49553514	chr14:49599994~49600572:+
HNSC	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.14	1.79e-09	8.55e-07	0.27	0.27	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-6.14	1.8e-09	8.56e-07	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
HNSC	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	6.14	1.8e-09	8.56e-07	0.3	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
HNSC	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	6.14	1.8e-09	8.56e-07	0.32	0.27	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.14	1.8e-09	8.57e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
HNSC	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	6.14	1.8e-09	8.58e-07	0.34	0.27	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
HNSC	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.14	1.8e-09	8.59e-07	0.31	0.27	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
HNSC	cis	rs860295	0.836	rs35615695	ENSG00000203761.5	MSTO2P	6.14	1.8e-09	8.59e-07	0.2	0.27	Body mass index;	chr1:155531223	chr1:155745829~155750137:+
HNSC	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	6.14	1.8e-09	8.6e-07	0.36	0.27	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
HNSC	cis	rs889014	1	rs889014	ENSG00000253768.1	CTB-33O18.1	6.14	1.81e-09	8.62e-07	0.29	0.27	Height;	chr5:173557111	chr5:173562478~173573199:+
HNSC	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	6.14	1.81e-09	8.63e-07	0.25	0.27	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
HNSC	cis	rs8177876	0.822	rs804902	ENSG00000261061.1	RP11-303E16.2	-6.14	1.81e-09	8.63e-07	-0.42	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	6.14	1.81e-09	8.64e-07	0.32	0.27	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	6.14	1.81e-09	8.64e-07	0.32	0.27	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
HNSC	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-6.14	1.82e-09	8.66e-07	-0.34	-0.27	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
HNSC	cis	rs860295	0.871	rs11582072	ENSG00000203761.5	MSTO2P	6.14	1.82e-09	8.66e-07	0.2	0.27	Body mass index;	chr1:155507779	chr1:155745829~155750137:+
HNSC	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	6.13	1.82e-09	8.67e-07	0.37	0.27	Height;	chr6:109359747	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	6.13	1.82e-09	8.67e-07	0.37	0.27	Height;	chr6:109361318	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	6.13	1.82e-09	8.68e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
HNSC	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
HNSC	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	6.13	1.82e-09	8.69e-07	0.34	0.27	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
HNSC	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-6.13	1.82e-09	8.69e-07	-0.32	-0.27	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
HNSC	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	6.13	1.83e-09	8.71e-07	0.37	0.27	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
HNSC	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-6.13	1.83e-09	8.71e-07	-0.33	-0.27	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
HNSC	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	6.13	1.83e-09	8.71e-07	0.35	0.27	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
HNSC	cis	rs947583	0.588	rs9321532	ENSG00000217482.2	HMGB1P17	-6.13	1.83e-09	8.72e-07	-0.3	-0.27	Phosphorus levels;	chr6:135791078	chr6:135636086~135636713:-
HNSC	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-6.13	1.83e-09	8.73e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
HNSC	cis	rs1021993	0.672	rs2843173	ENSG00000231648.1	RP11-372M18.2	6.13	1.83e-09	8.73e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209313696	chr1:209367662~209379690:+
HNSC	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-6.13	1.83e-09	8.73e-07	-0.27	-0.27	Height;	chr2:231543307	chr2:231508426~231514339:-
HNSC	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-6.13	1.84e-09	8.74e-07	-0.46	-0.27	Depression;	chr6:28119105	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-6.13	1.84e-09	8.76e-07	-0.43	-0.27	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
HNSC	cis	rs2337406	1	rs78857163	ENSG00000211974.3	IGHV2-70	-6.13	1.84e-09	8.76e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106707435	chr14:106723574~106724093:-
HNSC	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-6.13	1.85e-09	8.78e-07	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
HNSC	cis	rs4218	0.689	rs28391430	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.78e-07	-0.38	-0.27	Social communication problems;	chr15:59100318	chr15:59121034~59133250:+
HNSC	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	6.13	1.85e-09	8.78e-07	0.32	0.27	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000276710.3	CSPG4P8	-6.13	1.85e-09	8.79e-07	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82459472~82477258:+
HNSC	cis	rs6951245	0.572	rs11559183	ENSG00000224079.1	AC091729.7	-6.13	1.85e-09	8.79e-07	-0.58	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:997389	chr7:1074450~1078036:+
HNSC	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	6.13	1.85e-09	8.79e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
HNSC	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	6.13	1.85e-09	8.79e-07	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
HNSC	cis	rs4218	0.689	rs28514475	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.8e-07	-0.38	-0.27	Social communication problems;	chr15:59099896	chr15:59121034~59133250:+
HNSC	cis	rs4218	0.689	rs28610479	ENSG00000259732.1	RP11-59H7.3	-6.13	1.85e-09	8.8e-07	-0.38	-0.27	Social communication problems;	chr15:59099906	chr15:59121034~59133250:+
HNSC	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-6.13	1.85e-09	8.8e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
HNSC	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.13	1.85e-09	8.81e-07	0.28	0.27	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-6.13	1.85e-09	8.81e-07	-0.33	-0.27	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
HNSC	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	6.13	1.86e-09	8.82e-07	0.26	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
HNSC	cis	rs9300255	0.739	rs1969354	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123257229	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs1533703	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123257546	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs4759371	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123258016	chr12:123152324~123153377:-
HNSC	cis	rs63406760	1	rs63406760	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:123258146	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs2337934	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123260812	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.698	rs4759416	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123261810	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.739	rs4759417	ENSG00000280120.1	RP11-546D6.3	6.13	1.86e-09	8.82e-07	0.24	0.27	Neutrophil percentage of white cells;	chr12:123261963	chr12:123152324~123153377:-
HNSC	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-6.13	1.86e-09	8.82e-07	-0.35	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
HNSC	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	6.13	1.86e-09	8.83e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
HNSC	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	6.13	1.86e-09	8.83e-07	0.36	0.27	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-6.13	1.86e-09	8.83e-07	-0.36	-0.27	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
HNSC	cis	rs6951245	1	rs80094748	ENSG00000225146.1	AC073957.15	-6.13	1.86e-09	8.83e-07	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1029025~1043891:+
HNSC	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-6.13	1.86e-09	8.84e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
HNSC	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-6.13	1.86e-09	8.84e-07	-0.44	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
HNSC	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-6.13	1.86e-09	8.85e-07	-0.51	-0.27	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
HNSC	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-6.13	1.87e-09	8.86e-07	-0.27	-0.27	Height;	chr2:231556448	chr2:231508426~231514339:-
HNSC	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-6.13	1.87e-09	8.86e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
HNSC	cis	rs6951245	0.935	rs79143504	ENSG00000225146.1	AC073957.15	-6.13	1.87e-09	8.87e-07	-0.47	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1029025~1043891:+
HNSC	cis	rs17270561	0.636	rs9393671	ENSG00000272462.2	U91328.19	6.13	1.87e-09	8.87e-07	0.27	0.27	Iron status biomarkers;	chr6:25788961	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1179086	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25791517	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs1165157	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25792022	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1165156	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25792750	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs1165155	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25795349	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.636	rs1165216	ENSG00000272462.2	U91328.19	-6.13	1.87e-09	8.87e-07	-0.27	-0.27	Iron status biomarkers;	chr6:25797743	chr6:25992662~26001775:+
HNSC	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	6.13	1.87e-09	8.88e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-6.13	1.87e-09	8.89e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-6.13	1.87e-09	8.89e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
HNSC	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-6.13	1.87e-09	8.89e-07	-0.37	-0.27	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
HNSC	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-6.13	1.88e-09	8.91e-07	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
HNSC	cis	rs2790457	0.958	rs2532741	ENSG00000254635.4	WAC-AS1	-6.13	1.88e-09	8.91e-07	-0.32	-0.27	Multiple myeloma;	chr10:28574879	chr10:28522652~28532743:-
HNSC	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-6.13	1.88e-09	8.91e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
HNSC	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-6.13	1.88e-09	8.93e-07	-0.32	-0.27	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-6.13	1.88e-09	8.93e-07	-0.32	-0.27	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
HNSC	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	6.13	1.88e-09	8.94e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
HNSC	cis	rs3743266	0.507	rs34092508	ENSG00000245534.5	RORA-AS1	-6.13	1.88e-09	8.94e-07	-0.43	-0.27	Menarche (age at onset);	chr15:60430780	chr15:60479178~60630637:+
HNSC	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-6.13	1.89e-09	8.96e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
HNSC	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-6.13	1.89e-09	8.96e-07	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
HNSC	cis	rs988913	1	rs960834	ENSG00000224984.1	RP11-524H19.2	6.13	1.89e-09	8.97e-07	0.31	0.27	Menarche (age at onset);	chr6:54958633	chr6:54840118~54840855:-
HNSC	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	6.13	1.89e-09	8.97e-07	0.31	0.27	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
HNSC	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-6.13	1.89e-09	8.98e-07	-0.32	-0.27	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
HNSC	cis	rs8054556	0.787	rs11649274	ENSG00000183604.13	SMG1P5	-6.13	1.89e-09	8.98e-07	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30267553~30335374:-
HNSC	cis	rs7804306	0.826	rs56017154	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7995282	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049293	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999017	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049297	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999429	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049300	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8002315	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs58348680	ENSG00000233264.2	AC006042.8	6.13	1.89e-09	8.98e-07	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8005655	chr7:7980312~7982228:+
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	6.13	1.89e-09	8.99e-07	0.43	0.27	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-6.13	1.89e-09	8.99e-07	-0.18	-0.27	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
HNSC	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-6.13	1.89e-09	8.99e-07	-0.37	-0.27	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-6.13	1.9e-09	8.99e-07	-0.32	-0.27	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	-6.13	1.9e-09	8.99e-07	-0.31	-0.27	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
HNSC	cis	rs2404602	0.692	rs36070630	ENSG00000259422.1	RP11-593F23.1	6.13	1.9e-09	9e-07	0.32	0.27	Blood metabolite levels;	chr15:76656918	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-6.13	1.9e-09	9.01e-07	-0.32	-0.27	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
HNSC	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-6.13	1.9e-09	9.01e-07	-0.44	-0.27	Depression;	chr6:28129415	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.13	1.9e-09	9.01e-07	-0.37	-0.27	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
HNSC	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	6.13	1.9e-09	9.01e-07	0.59	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
HNSC	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	6.13	1.9e-09	9.01e-07	0.3	0.27	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	6.13	1.9e-09	9.01e-07	0.3	0.27	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
HNSC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	6.13	1.91e-09	9.04e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
HNSC	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	6.13	1.91e-09	9.04e-07	0.33	0.27	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
HNSC	cis	rs2115630	0.653	rs61394864	ENSG00000229212.6	RP11-561C5.4	6.13	1.91e-09	9.05e-07	0.31	0.27	P wave terminal force;	chr15:84626943	chr15:85205440~85234795:-
HNSC	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	6.13	1.91e-09	9.05e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	6.13	1.91e-09	9.05e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
HNSC	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	6.13	1.91e-09	9.05e-07	0.35	0.27	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	6.13	1.91e-09	9.05e-07	0.32	0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
HNSC	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-6.13	1.91e-09	9.06e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-6.13	1.91e-09	9.06e-07	-0.34	-0.27	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	6.13	1.92e-09	9.08e-07	0.63	0.27	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
HNSC	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-6.13	1.92e-09	9.09e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
HNSC	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-6.13	1.92e-09	9.09e-07	-0.34	-0.27	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
HNSC	cis	rs1865760	0.613	rs9379801	ENSG00000272462.2	U91328.19	-6.13	1.92e-09	9.09e-07	-0.25	-0.27	Height;	chr6:25901483	chr6:25992662~26001775:+
HNSC	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	6.13	1.92e-09	9.1e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	6.13	1.92e-09	9.1e-07	0.29	0.27	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000211974.3	IGHV2-70	-6.13	1.92e-09	9.11e-07	-0.31	-0.27	Rheumatic heart disease;	chr14:106619987	chr14:106723574~106724093:-
HNSC	cis	rs667920	0.512	rs13065626	ENSG00000239213.4	NCK1-AS1	-6.13	1.92e-09	9.11e-07	-0.34	-0.27	Coronary artery disease;	chr3:136575915	chr3:136841726~136862054:-
HNSC	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	6.13	1.93e-09	9.12e-07	0.3	0.27	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
HNSC	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	6.13	1.93e-09	9.12e-07	0.32	0.27	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
HNSC	cis	rs6081541	0.622	rs6035257	ENSG00000179447.2	RP5-1027G4.3	6.12	1.93e-09	9.13e-07	0.34	0.27	Psychosis (atypical);	chr20:19224067	chr20:19242302~19284596:-
HNSC	cis	rs6081541	0.622	rs6035259	ENSG00000179447.2	RP5-1027G4.3	6.12	1.93e-09	9.13e-07	0.34	0.27	Psychosis (atypical);	chr20:19225349	chr20:19242302~19284596:-
HNSC	cis	rs950776	0.695	rs1878399	ENSG00000261762.1	RP11-650L12.2	-6.12	1.93e-09	9.13e-07	-0.32	-0.27	Sudden cardiac arrest;	chr15:78619661	chr15:78589123~78591276:-
HNSC	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-6.12	1.93e-09	9.14e-07	-0.4	-0.27	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-6.12	1.93e-09	9.14e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-6.12	1.93e-09	9.14e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
HNSC	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	6.12	1.93e-09	9.15e-07	0.31	0.27	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
HNSC	cis	rs4218	0.648	rs35460138	ENSG00000259732.1	RP11-59H7.3	-6.12	1.94e-09	9.16e-07	-0.38	-0.27	Social communication problems;	chr15:59093200	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000254153.1	CTA-398F10.2	6.12	1.94e-09	9.18e-07	0.31	0.27	Joint mobility (Beighton score);	chr8:9034711	chr8:8456909~8461337:-
HNSC	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-6.12	1.94e-09	9.18e-07	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
HNSC	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-6.12	1.94e-09	9.19e-07	-0.33	-0.27	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
HNSC	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	6.12	1.94e-09	9.19e-07	0.36	0.27	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
HNSC	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-6.12	1.94e-09	9.19e-07	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
HNSC	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	6.12	1.95e-09	9.21e-07	0.29	0.27	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
HNSC	cis	rs947583	0.955	rs927330	ENSG00000217482.2	HMGB1P17	-6.12	1.95e-09	9.21e-07	-0.3	-0.27	Phosphorus levels;	chr6:135810618	chr6:135636086~135636713:-
HNSC	cis	rs4852324	0.536	rs17009553	ENSG00000217702.2	RP11-287D1.4	-6.12	1.95e-09	9.21e-07	-0.68	-0.27	Systemic lupus erythematosus;	chr2:73992908	chr2:74130583~74135395:+
HNSC	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-6.12	1.95e-09	9.21e-07	-0.31	-0.27	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	6.12	1.95e-09	9.24e-07	0.31	0.27	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs4149468	ENSG00000179406.6	LINC00174	-6.12	1.96e-09	9.25e-07	-0.57	-0.27	Diabetic kidney disease;	chr7:66360703	chr7:66376044~66401338:-
HNSC	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	6.12	1.96e-09	9.25e-07	0.34	0.27	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	6.12	1.96e-09	9.25e-07	0.34	0.27	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
HNSC	cis	rs11992162	0.55	rs61426048	ENSG00000206014.6	OR7E161P	6.12	1.96e-09	9.26e-07	0.3	0.27	Monocyte count;	chr8:11927447	chr8:11928597~11929563:-
HNSC	cis	rs11089937	0.626	rs4821784	ENSG00000211638.2	IGLV8-61	-6.12	1.96e-09	9.27e-07	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22098700~22099212:+
HNSC	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	6.12	1.96e-09	9.27e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
HNSC	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-6.12	1.96e-09	9.27e-07	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
HNSC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.12	1.97e-09	9.29e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
HNSC	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-6.12	1.97e-09	9.3e-07	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
HNSC	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	6.12	1.97e-09	9.3e-07	0.43	0.27	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	6.12	1.97e-09	9.3e-07	0.32	0.27	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-6.12	1.97e-09	9.31e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
HNSC	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-6.12	1.97e-09	9.32e-07	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
HNSC	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-6.12	1.97e-09	9.32e-07	-0.22	-0.27	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
HNSC	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	6.12	1.97e-09	9.33e-07	0.33	0.27	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
HNSC	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	6.12	1.98e-09	9.33e-07	0.24	0.27	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
HNSC	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.33e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-6.12	1.98e-09	9.35e-07	-0.34	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
HNSC	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	6.12	1.98e-09	9.36e-07	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
HNSC	cis	rs6928977	0.66	rs9321508	ENSG00000217482.2	HMGB1P17	-6.12	1.98e-09	9.37e-07	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135556839	chr6:135636086~135636713:-
HNSC	cis	rs34526934	0.608	rs13017511	ENSG00000226363.3	HAGLROS	6.12	1.98e-09	9.37e-07	0.36	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176170667	chr2:176177717~176179008:+
HNSC	cis	rs947583	0.617	rs56048607	ENSG00000217482.2	HMGB1P17	6.12	1.98e-09	9.37e-07	0.3	0.27	Phosphorus levels;	chr6:135699171	chr6:135636086~135636713:-
HNSC	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	6.12	1.99e-09	9.38e-07	0.34	0.27	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
HNSC	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.12	1.99e-09	9.38e-07	-0.32	-0.27	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
HNSC	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-6.12	1.99e-09	9.38e-07	-0.28	-0.27	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-6.12	1.99e-09	9.41e-07	-0.32	-0.27	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
HNSC	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	6.12	1.99e-09	9.41e-07	0.31	0.27	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-6.12	2e-09	9.42e-07	-0.33	-0.27	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	6.12	2e-09	9.43e-07	0.34	0.27	Depression;	chr6:28402301	chr6:28943877~28944537:+
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000211974.3	IGHV2-70	6.12	2e-09	9.44e-07	0.31	0.27	Rheumatic heart disease;	chr14:106630317	chr14:106723574~106724093:-
HNSC	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	6.12	2e-09	9.45e-07	0.33	0.27	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
HNSC	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-6.12	2.01e-09	9.47e-07	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
HNSC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.12	2.01e-09	9.48e-07	-0.3	-0.27	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
HNSC	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-6.12	2.01e-09	9.48e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
HNSC	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	6.12	2.01e-09	9.48e-07	0.3	0.27	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000173295.6	FAM86B3P	-6.12	2.01e-09	9.49e-07	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8228595~8244865:+
HNSC	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	6.12	2.02e-09	9.5e-07	0.37	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
HNSC	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	6.12	2.02e-09	9.52e-07	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000254340.1	RP11-10A14.3	-6.12	2.02e-09	9.52e-07	-0.33	-0.27	Joint mobility (Beighton score);	chr8:8936097	chr8:9141424~9145435:+
HNSC	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	6.12	2.02e-09	9.53e-07	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	6.12	2.02e-09	9.53e-07	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
HNSC	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	6.12	2.02e-09	9.53e-07	0.29	0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
HNSC	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-6.12	2.03e-09	9.55e-07	-0.25	-0.27	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
HNSC	cis	rs35955747	0.778	rs9609263	ENSG00000236132.1	CTA-440B3.1	6.12	2.03e-09	9.55e-07	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31349288	chr22:31816379~31817491:-
HNSC	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-6.12	2.03e-09	9.55e-07	-0.31	-0.27	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
HNSC	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	6.12	2.03e-09	9.56e-07	0.33	0.27	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
HNSC	cis	rs7819412	0.745	rs2898260	ENSG00000269918.1	AF131215.9	-6.12	2.03e-09	9.57e-07	-0.27	-0.27	Triglycerides;	chr8:11081980	chr8:11104691~11106704:-
HNSC	cis	rs638893	0.673	rs538645	ENSG00000255422.1	AP002954.4	6.12	2.04e-09	9.59e-07	0.38	0.27	Vitiligo;	chr11:118840360	chr11:118704607~118750263:+
HNSC	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	6.12	2.04e-09	9.6e-07	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
HNSC	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-6.12	2.04e-09	9.6e-07	-0.32	-0.27	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
HNSC	cis	rs11089937	1	rs11089937	ENSG00000211638.2	IGLV8-61	-6.12	2.04e-09	9.6e-07	-0.24	-0.27	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22098700~22099212:+
HNSC	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-6.12	2.04e-09	9.6e-07	-0.3	-0.27	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	6.12	2.04e-09	9.61e-07	0.64	0.27	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
HNSC	cis	rs4141404	0.706	rs5753698	ENSG00000236132.1	CTA-440B3.1	-6.11	2.04e-09	9.62e-07	-0.35	-0.27	Paclitaxel-induced neuropathy;	chr22:31574068	chr22:31816379~31817491:-
HNSC	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	6.11	2.04e-09	9.62e-07	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
HNSC	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	6.11	2.05e-09	9.63e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
HNSC	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	6.11	2.05e-09	9.63e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
HNSC	cis	rs1021993	0.672	rs2247066	ENSG00000231648.1	RP11-372M18.2	6.11	2.05e-09	9.63e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209300349	chr1:209367662~209379690:+
HNSC	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-6.11	2.05e-09	9.65e-07	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
HNSC	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	6.11	2.05e-09	9.65e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
HNSC	cis	rs1021993	0.672	rs2660634	ENSG00000231648.1	RP11-372M18.2	6.11	2.05e-09	9.66e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209309668	chr1:209367662~209379690:+
HNSC	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.05e-09	9.66e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
HNSC	cis	rs1021993	0.672	rs2660633	ENSG00000231648.1	RP11-372M18.2	6.11	2.06e-09	9.68e-07	0.34	0.27	Gut microbiome composition (winter);	chr1:209313307	chr1:209367662~209379690:+
HNSC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	6.11	2.06e-09	9.7e-07	0.3	0.27	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
HNSC	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	6.11	2.06e-09	9.7e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
HNSC	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-6.11	2.06e-09	9.71e-07	-0.32	-0.27	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-6.11	2.06e-09	9.71e-07	-0.32	-0.27	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
HNSC	cis	rs3743266	0.507	rs62003261	ENSG00000245534.5	RORA-AS1	-6.11	2.07e-09	9.72e-07	-0.44	-0.27	Menarche (age at onset);	chr15:60469290	chr15:60479178~60630637:+
HNSC	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-6.11	2.07e-09	9.73e-07	-0.38	-0.27	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
HNSC	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	6.11	2.07e-09	9.73e-07	0.29	0.27	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
HNSC	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.74e-07	0.37	0.27	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	6.11	2.07e-09	9.75e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
HNSC	cis	rs6951245	0.935	rs113365567	ENSG00000225146.1	AC073957.15	-6.11	2.07e-09	9.75e-07	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1029025~1043891:+
HNSC	cis	rs9525927	0.57	rs9316074	ENSG00000227258.4	SMIM2-AS1	6.11	2.07e-09	9.75e-07	0.39	0.27	Dupuytren's disease;	chr13:44229045	chr13:44110451~44240517:+
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.07e-09	9.75e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
HNSC	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	6.11	2.07e-09	9.75e-07	0.3	0.27	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
HNSC	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	6.11	2.07e-09	9.75e-07	0.36	0.27	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
HNSC	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	6.11	2.07e-09	9.75e-07	0.3	0.27	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
HNSC	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-6.11	2.08e-09	9.77e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
HNSC	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.11	2.09e-09	9.8e-07	0.36	0.27	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
HNSC	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.09e-09	9.81e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
HNSC	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	6.11	2.09e-09	9.81e-07	0.33	0.27	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
HNSC	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-6.11	2.09e-09	9.82e-07	-0.36	-0.27	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
HNSC	cis	rs2115630	0.691	rs61322921	ENSG00000229212.6	RP11-561C5.4	6.11	2.09e-09	9.83e-07	0.31	0.27	P wave terminal force;	chr15:84620407	chr15:85205440~85234795:-
HNSC	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	6.11	2.09e-09	9.83e-07	0.32	0.27	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
HNSC	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	6.11	2.09e-09	9.84e-07	0.3	0.27	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
HNSC	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	6.11	2.09e-09	9.84e-07	0.26	0.27	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
HNSC	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.1e-09	9.85e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.1e-09	9.85e-07	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
HNSC	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-6.11	2.1e-09	9.86e-07	-0.33	-0.27	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
HNSC	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	6.11	2.1e-09	9.86e-07	0.34	0.27	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
HNSC	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	6.11	2.1e-09	9.87e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
HNSC	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	6.11	2.1e-09	9.88e-07	0.26	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000254153.1	CTA-398F10.2	6.11	2.1e-09	9.88e-07	0.3	0.27	Systolic blood pressure;	chr8:8488071	chr8:8456909~8461337:-
HNSC	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	6.11	2.1e-09	9.88e-07	0.37	0.27	Height;	chr6:109482392	chr6:109382795~109383666:+
HNSC	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-6.11	2.11e-09	9.89e-07	-0.32	-0.27	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.11	2.11e-09	9.89e-07	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
HNSC	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	6.11	2.11e-09	9.89e-07	0.36	0.27	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
HNSC	cis	rs1865760	0.613	rs9295674	ENSG00000272462.2	U91328.19	-6.11	2.11e-09	9.9e-07	-0.25	-0.27	Height;	chr6:25912114	chr6:25992662~26001775:+
HNSC	cis	rs17214007	0.627	rs28593034	ENSG00000263335.1	AF001548.5	-6.11	2.11e-09	9.91e-07	-0.43	-0.27	Cognitive function;	chr16:15597329	chr16:15726674~15732993:+
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-6.11	2.11e-09	9.92e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-6.11	2.11e-09	9.93e-07	-0.42	-0.27	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	6.11	2.11e-09	9.93e-07	0.29	0.27	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
HNSC	cis	rs11969893	0.85	rs12664068	ENSG00000270987.1	RP3-467N11.2	6.11	2.12e-09	9.93e-07	0.74	0.27	Economic and political preferences (immigration/crime);	chr6:100914222	chr6:100889603~100890338:+
HNSC	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-6.11	2.12e-09	9.95e-07	-0.31	-0.27	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
HNSC	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	6.11	2.12e-09	9.96e-07	0.36	0.27	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
HNSC	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	6.11	2.12e-09	9.97e-07	0.3	0.27	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
HNSC	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	6.11	2.13e-09	9.98e-07	0.34	0.27	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
HNSC	cis	rs9611519	0.78	rs5751072	ENSG00000235513.1	RP4-756G23.5	6.11	2.13e-09	9.98e-07	0.28	0.27	Neuroticism;	chr22:41260505	chr22:41209122~41217627:-
HNSC	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.11	2.13e-09	1e-06	0.35	0.27	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000254153.1	CTA-398F10.2	-6.11	2.13e-09	1e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9032588	chr8:8456909~8461337:-
HNSC	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	6.11	2.13e-09	1e-06	0.55	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000211972.2	IGHV3-66	6.11	2.14e-09	1e-06	0.21	0.27	Kawasaki disease;	chr14:106711838	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.11	2.14e-09	1.01e-06	-0.37	-0.27	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
HNSC	cis	rs12439619	0.705	rs4778665	ENSG00000276710.3	CSPG4P8	-6.11	2.14e-09	1.01e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82459472~82477258:+
HNSC	cis	rs2235642	0.533	rs2667679	ENSG00000280231.1	LA16c-380F5.3	-6.11	2.15e-09	1.01e-06	-0.34	-0.27	Coronary artery disease;	chr16:1604945	chr16:1553655~1554130:-
HNSC	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.15e-09	1.01e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
HNSC	cis	rs12922040	1	rs12922040	ENSG00000263065.1	AF001548.6	-6.11	2.15e-09	1.01e-06	-0.32	-0.27	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15741151~15741791:+
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000173295.6	FAM86B3P	-6.11	2.15e-09	1.01e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9032531	chr8:8228595~8244865:+
HNSC	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-6.11	2.15e-09	1.01e-06	-0.2	-0.27	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
HNSC	cis	rs8054556	0.692	rs4424923	ENSG00000183604.13	SMG1P5	-6.11	2.15e-09	1.01e-06	-0.26	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30267553~30335374:-
HNSC	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	6.11	2.16e-09	1.01e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
HNSC	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-6.11	2.16e-09	1.01e-06	-0.43	-0.27	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-6.11	2.16e-09	1.01e-06	-0.29	-0.27	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
HNSC	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-6.11	2.16e-09	1.01e-06	-0.32	-0.27	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-6.11	2.16e-09	1.01e-06	-0.32	-0.27	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
HNSC	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	6.11	2.16e-09	1.01e-06	0.35	0.27	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
HNSC	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	6.11	2.16e-09	1.01e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
HNSC	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	6.1	2.16e-09	1.01e-06	0.25	0.27	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
HNSC	cis	rs1865760	0.515	rs2003208	ENSG00000272462.2	U91328.19	-6.1	2.17e-09	1.01e-06	-0.25	-0.27	Height;	chr6:25940491	chr6:25992662~26001775:+
HNSC	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-6.1	2.17e-09	1.01e-06	-0.27	-0.27	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.1	2.17e-09	1.01e-06	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
HNSC	cis	rs2404602	0.669	rs12148877	ENSG00000259422.1	RP11-593F23.1	6.1	2.17e-09	1.02e-06	0.32	0.27	Blood metabolite levels;	chr15:76627618	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.692	rs12902452	ENSG00000259422.1	RP11-593F23.1	6.1	2.17e-09	1.02e-06	0.32	0.27	Blood metabolite levels;	chr15:76629124	chr15:76174891~76181486:-
HNSC	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.1	2.17e-09	1.02e-06	0.27	0.27	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
HNSC	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-6.1	2.17e-09	1.02e-06	-0.32	-0.27	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
HNSC	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	6.1	2.17e-09	1.02e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
HNSC	cis	rs6928977	0.66	rs12214269	ENSG00000217482.2	HMGB1P17	-6.1	2.18e-09	1.02e-06	-0.3	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135525380	chr6:135636086~135636713:-
HNSC	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	6.1	2.18e-09	1.02e-06	0.38	0.27	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
HNSC	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-6.1	2.18e-09	1.02e-06	-0.42	-0.27	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
HNSC	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	6.1	2.19e-09	1.02e-06	0.26	0.27	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
HNSC	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-6.1	2.19e-09	1.02e-06	-0.3	-0.27	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
HNSC	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	6.1	2.19e-09	1.02e-06	0.26	0.27	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
HNSC	cis	rs2337406	1	rs11850709	ENSG00000211974.3	IGHV2-70	-6.1	2.19e-09	1.03e-06	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106670844	chr14:106723574~106724093:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.1	2.19e-09	1.03e-06	0.3	0.27	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
HNSC	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	6.1	2.19e-09	1.03e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
HNSC	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	6.1	2.19e-09	1.03e-06	0.23	0.27	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
HNSC	cis	rs7396835	0.866	rs7927820	ENSG00000280143.1	AP000892.6	6.1	2.2e-09	1.03e-06	0.38	0.27	Quantitative traits;	chr11:116811440	chr11:117204967~117210292:+
HNSC	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	6.1	2.2e-09	1.03e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
HNSC	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-6.1	2.2e-09	1.03e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
HNSC	cis	rs9341808	0.667	rs2476826	ENSG00000272129.1	RP11-250B2.6	6.1	2.2e-09	1.03e-06	0.32	0.27	Sitting height ratio;	chr6:80166347	chr6:80355424~80356859:+
HNSC	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-6.1	2.2e-09	1.03e-06	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
HNSC	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-6.1	2.2e-09	1.03e-06	-0.31	-0.27	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-6.1	2.2e-09	1.03e-06	-0.31	-0.27	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
HNSC	cis	rs2286503	0.839	rs4722189	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22820855	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.809	rs4719716	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22821750	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270108	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22822512	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270107	ENSG00000221740.1	SNORD93	6.1	2.2e-09	1.03e-06	0.3	0.27	Fibrinogen;	chr7:22822564	chr7:22856613~22856686:+
HNSC	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-6.1	2.2e-09	1.03e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
HNSC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	6.1	2.21e-09	1.03e-06	0.33	0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
HNSC	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-6.1	2.21e-09	1.03e-06	-0.4	-0.27	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
HNSC	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	6.1	2.21e-09	1.03e-06	0.33	0.27	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
HNSC	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-6.1	2.21e-09	1.03e-06	-0.33	-0.27	Height;	chr4:55514317	chr4:55387949~55388271:+
HNSC	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	6.1	2.21e-09	1.03e-06	0.25	0.27	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000179406.6	LINC00174	-6.1	2.22e-09	1.04e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160648	ENSG00000179406.6	LINC00174	-6.1	2.22e-09	1.04e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000254340.1	RP11-10A14.3	-6.1	2.22e-09	1.04e-06	-0.33	-0.27	Mood instability;	chr8:8932549	chr8:9141424~9145435:+
HNSC	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	6.1	2.22e-09	1.04e-06	0.33	0.27	Height;	chr4:55548666	chr4:55363971~55395847:-
HNSC	cis	rs5753618	0.539	rs5753596	ENSG00000236132.1	CTA-440B3.1	6.1	2.22e-09	1.04e-06	0.31	0.27	Colorectal cancer;	chr22:31391486	chr22:31816379~31817491:-
HNSC	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-6.1	2.22e-09	1.04e-06	-0.31	-0.27	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
HNSC	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	6.1	2.22e-09	1.04e-06	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
HNSC	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-6.1	2.22e-09	1.04e-06	-0.32	-0.27	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	6.1	2.23e-09	1.04e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
HNSC	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-6.1	2.23e-09	1.04e-06	-0.21	-0.27	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
HNSC	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	6.1	2.23e-09	1.04e-06	0.3	0.27	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
HNSC	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-6.1	2.23e-09	1.04e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
HNSC	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	6.1	2.23e-09	1.04e-06	0.25	0.27	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	6.1	2.23e-09	1.04e-06	0.25	0.27	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
HNSC	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	6.1	2.23e-09	1.04e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
HNSC	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-6.1	2.23e-09	1.04e-06	-0.33	-0.27	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000179406.6	LINC00174	6.1	2.24e-09	1.05e-06	0.35	0.27	Calcium levels;	chr7:66040056	chr7:66376044~66401338:-
HNSC	cis	rs9300255	0.739	rs10846491	ENSG00000280120.1	RP11-546D6.3	6.1	2.24e-09	1.05e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123268945	chr12:123152324~123153377:-
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-6.1	2.24e-09	1.05e-06	-0.18	-0.27	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
HNSC	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	6.1	2.24e-09	1.05e-06	0.34	0.27	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
HNSC	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-6.1	2.24e-09	1.05e-06	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
HNSC	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-6.1	2.24e-09	1.05e-06	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
HNSC	cis	rs9611519	0.78	rs5751071	ENSG00000235513.1	RP4-756G23.5	6.1	2.25e-09	1.05e-06	0.28	0.27	Neuroticism;	chr22:41260328	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	6.1	2.25e-09	1.05e-06	0.3	0.27	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
HNSC	cis	rs5753618	0.509	rs1034589	ENSG00000236132.1	CTA-440B3.1	6.1	2.25e-09	1.05e-06	0.33	0.27	Colorectal cancer;	chr22:31183247	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-6.1	2.25e-09	1.05e-06	-0.29	-0.27	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	6.1	2.25e-09	1.05e-06	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
HNSC	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-6.1	2.25e-09	1.05e-06	-0.33	-0.27	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
HNSC	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-6.1	2.25e-09	1.05e-06	-0.34	-0.27	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-6.1	2.25e-09	1.05e-06	-0.34	-0.27	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	6.1	2.25e-09	1.05e-06	0.21	0.27	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
HNSC	cis	rs2579103	0.624	rs1371081	ENSG00000258183.4	RP11-753N8.1	-6.1	2.26e-09	1.05e-06	-0.4	-0.27	Body mass index;	chr12:90288436	chr12:90280894~90300340:+
HNSC	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	6.1	2.26e-09	1.05e-06	0.36	0.27	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	6.1	2.26e-09	1.05e-06	0.36	0.27	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-6.1	2.26e-09	1.05e-06	-0.33	-0.27	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
HNSC	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.1	2.26e-09	1.05e-06	0.27	0.27	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	6.1	2.26e-09	1.06e-06	0.21	0.27	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.1	2.26e-09	1.06e-06	-0.31	-0.27	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
HNSC	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-6.1	2.26e-09	1.06e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-6.1	2.27e-09	1.06e-06	-0.31	-0.27	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.555	rs1415296	ENSG00000223787.2	RP4-593M8.1	-6.1	2.27e-09	1.06e-06	-0.37	-0.27	Multiple sclerosis;	chr1:92624919	chr1:92580476~92580821:-
HNSC	cis	rs9481169	0.557	rs2179070	ENSG00000255389.1	C6orf3	-6.1	2.27e-09	1.06e-06	-0.49	-0.27	Inflammatory skin disease;	chr6:111564549	chr6:111599875~111602295:+
HNSC	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	6.1	2.27e-09	1.06e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
HNSC	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	6.1	2.27e-09	1.06e-06	0.39	0.27	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
HNSC	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	6.1	2.27e-09	1.06e-06	0.36	0.27	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
HNSC	cis	rs860295	0.775	rs822508	ENSG00000203761.5	MSTO2P	-6.1	2.27e-09	1.06e-06	-0.2	-0.27	Body mass index;	chr1:155880767	chr1:155745829~155750137:+
HNSC	cis	rs7826238	0.502	rs10503377	ENSG00000173295.6	FAM86B3P	6.1	2.28e-09	1.06e-06	0.34	0.27	Systolic blood pressure;	chr8:8520912	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	6.1	2.28e-09	1.07e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
HNSC	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	6.1	2.28e-09	1.07e-06	0.31	0.27	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.1	2.29e-09	1.07e-06	-0.31	-0.27	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-6.1	2.29e-09	1.07e-06	-0.18	-0.27	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
HNSC	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.1	2.29e-09	1.07e-06	0.28	0.27	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
HNSC	cis	rs4657482	0.607	rs10494449	ENSG00000236364.3	RP11-525G13.2	6.1	2.29e-09	1.07e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165914066	chr1:165890795~165900683:-
HNSC	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-6.1	2.29e-09	1.07e-06	-0.53	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
HNSC	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	6.1	2.29e-09	1.07e-06	0.3	0.27	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
HNSC	cis	rs2235642	0.525	rs2667688	ENSG00000280231.1	LA16c-380F5.3	-6.1	2.29e-09	1.07e-06	-0.38	-0.27	Coronary artery disease;	chr16:1511445	chr16:1553655~1554130:-
HNSC	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-6.1	2.29e-09	1.07e-06	-0.33	-0.27	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-6.09	2.29e-09	1.07e-06	-0.39	-0.27	Gout;	chr7:66645053	chr7:66902857~66906297:+
HNSC	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-6.09	2.29e-09	1.07e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
HNSC	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-6.09	2.3e-09	1.07e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
HNSC	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	6.09	2.3e-09	1.07e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
HNSC	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
HNSC	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-6.09	2.3e-09	1.07e-06	-0.34	-0.27	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
HNSC	cis	rs1355223	0.902	rs11607035	ENSG00000271369.1	RP11-350D17.3	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697364	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.3e-09	1.07e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
HNSC	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.09	2.3e-09	1.07e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-6.09	2.3e-09	1.07e-06	-0.32	-0.27	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.31e-09	1.08e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
HNSC	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	6.09	2.31e-09	1.08e-06	0.3	0.27	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
HNSC	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-6.09	2.31e-09	1.08e-06	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
HNSC	cis	rs5753618	0.583	rs5753632	ENSG00000236132.1	CTA-440B3.1	-6.09	2.31e-09	1.08e-06	-0.32	-0.27	Colorectal cancer;	chr22:31467111	chr22:31816379~31817491:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-6.09	2.31e-09	1.08e-06	-0.32	-0.27	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
HNSC	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	6.09	2.31e-09	1.08e-06	0.23	0.27	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
HNSC	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-6.09	2.31e-09	1.08e-06	-0.35	-0.27	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
HNSC	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	1.08e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
HNSC	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	6.09	2.32e-09	1.08e-06	0.3	0.27	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
HNSC	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	6.09	2.32e-09	1.08e-06	0.25	0.27	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
HNSC	cis	rs8177876	0.597	rs1048194	ENSG00000261061.1	RP11-303E16.2	6.09	2.32e-09	1.08e-06	0.48	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81030770~81031485:+
HNSC	cis	rs6928977	0.675	rs12206850	ENSG00000217482.2	HMGB1P17	6.09	2.32e-09	1.08e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135636086~135636713:-
HNSC	cis	rs9611519	0.78	rs1983631	ENSG00000235513.1	RP4-756G23.5	6.09	2.32e-09	1.08e-06	0.29	0.27	Neuroticism;	chr22:41248070	chr22:41209122~41217627:-
HNSC	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-6.09	2.32e-09	1.08e-06	-0.37	-0.27	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
HNSC	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	6.09	2.32e-09	1.08e-06	0.3	0.27	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
HNSC	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-6.09	2.33e-09	1.08e-06	-0.32	-0.27	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
HNSC	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-6.09	2.33e-09	1.08e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
HNSC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	6.09	2.33e-09	1.08e-06	0.3	0.27	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
HNSC	cis	rs9840812	0.535	rs695983	ENSG00000273486.1	RP11-731C17.2	6.09	2.33e-09	1.08e-06	0.22	0.27	Fibrinogen levels;	chr3:136345705	chr3:136837338~136839021:-
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-6.09	2.33e-09	1.09e-06	-0.4	-0.27	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
HNSC	cis	rs7396835	0.741	rs7396851	ENSG00000280143.1	AP000892.6	-6.09	2.33e-09	1.09e-06	-0.36	-0.27	Quantitative traits;	chr11:116813448	chr11:117204967~117210292:+
HNSC	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.09e-06	0.3	0.27	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
HNSC	cis	rs11969893	0.85	rs9791284	ENSG00000270987.1	RP3-467N11.2	6.09	2.34e-09	1.09e-06	0.74	0.27	Economic and political preferences (immigration/crime);	chr6:100906010	chr6:100889603~100890338:+
HNSC	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	6.09	2.34e-09	1.09e-06	0.42	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.09	2.34e-09	1.09e-06	0.32	0.27	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
HNSC	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	6.09	2.35e-09	1.09e-06	0.33	0.27	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
HNSC	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-6.09	2.35e-09	1.09e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-6.09	2.35e-09	1.09e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
HNSC	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-6.09	2.35e-09	1.09e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
HNSC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
HNSC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000267151.3	RP11-100E5.2	-6.09	2.35e-09	1.09e-06	-0.35	-0.27	Menopause (age at onset);	chr17:43185455	chr17:43444707~43451200:+
HNSC	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-6.09	2.35e-09	1.09e-06	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
HNSC	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	6.09	2.35e-09	1.09e-06	0.39	0.27	Height;	chr6:109764163	chr6:109382795~109383666:+
HNSC	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	6.09	2.35e-09	1.09e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
HNSC	cis	rs2579103	0.651	rs865438	ENSG00000258183.4	RP11-753N8.1	-6.09	2.35e-09	1.1e-06	-0.4	-0.27	Body mass index;	chr12:90309334	chr12:90280894~90300340:+
HNSC	cis	rs1355223	0.902	rs61881050	ENSG00000271369.1	RP11-350D17.3	-6.09	2.35e-09	1.1e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34698202	chr11:34709600~34710161:+
HNSC	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-6.09	2.35e-09	1.1e-06	-0.33	-0.27	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
HNSC	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-6.09	2.36e-09	1.1e-06	-0.37	-0.27	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
HNSC	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.09	2.36e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
HNSC	cis	rs6918586	0.658	rs198838	ENSG00000272462.2	U91328.19	6.09	2.36e-09	1.1e-06	0.25	0.27	Schizophrenia;	chr6:26113112	chr6:25992662~26001775:+
HNSC	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-6.09	2.36e-09	1.1e-06	-0.3	-0.27	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
HNSC	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	6.09	2.37e-09	1.1e-06	0.32	0.27	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	6.09	2.37e-09	1.1e-06	0.21	0.27	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
HNSC	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	6.09	2.37e-09	1.1e-06	0.37	0.27	Height;	chr6:109354040	chr6:109382795~109383666:+
HNSC	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	6.09	2.37e-09	1.1e-06	0.54	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
HNSC	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-6.09	2.37e-09	1.1e-06	-0.28	-0.27	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
HNSC	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	6.09	2.37e-09	1.1e-06	0.29	0.27	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
HNSC	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-6.09	2.37e-09	1.1e-06	-0.32	-0.27	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	6.09	2.38e-09	1.1e-06	0.3	0.27	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
HNSC	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	6.09	2.38e-09	1.11e-06	0.32	0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
HNSC	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	6.09	2.38e-09	1.11e-06	0.31	0.27	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
HNSC	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	6.09	2.38e-09	1.11e-06	0.3	0.27	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
HNSC	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-6.09	2.39e-09	1.11e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
HNSC	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.09	2.39e-09	1.11e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000211972.2	IGHV3-66	6.09	2.39e-09	1.11e-06	0.21	0.27	Kawasaki disease;	chr14:106775695	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000211972.2	IGHV3-66	6.09	2.39e-09	1.11e-06	0.21	0.27	Kawasaki disease;	chr14:106775735	chr14:106675017~106675544:-
HNSC	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.09	2.39e-09	1.11e-06	0.26	0.27	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	6.09	2.39e-09	1.11e-06	0.33	0.27	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
HNSC	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-6.09	2.39e-09	1.11e-06	-0.3	-0.27	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
HNSC	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	6.09	2.39e-09	1.11e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
HNSC	cis	rs4218	0.681	rs58335303	ENSG00000259732.1	RP11-59H7.3	-6.09	2.39e-09	1.11e-06	-0.38	-0.27	Social communication problems;	chr15:59073206	chr15:59121034~59133250:+
HNSC	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	6.09	2.4e-09	1.11e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
HNSC	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-6.09	2.4e-09	1.11e-06	-0.3	-0.27	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
HNSC	cis	rs3743266	0.507	rs11637887	ENSG00000245534.5	RORA-AS1	-6.09	2.4e-09	1.11e-06	-0.44	-0.27	Menarche (age at onset);	chr15:60473017	chr15:60479178~60630637:+
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	6.09	2.4e-09	1.11e-06	0.34	0.27	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
HNSC	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	6.09	2.4e-09	1.12e-06	0.3	0.27	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
HNSC	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-6.09	2.4e-09	1.12e-06	-0.33	-0.27	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
HNSC	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	6.09	2.4e-09	1.12e-06	0.42	0.27	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
HNSC	cis	rs1355223	1	rs1355222	ENSG00000271369.1	RP11-350D17.3	-6.09	2.4e-09	1.12e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737169	chr11:34709600~34710161:+
HNSC	cis	rs2286503	0.839	rs2270105	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22822848	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs2270103	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22823103	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.839	rs10276099	ENSG00000221740.1	SNORD93	6.09	2.41e-09	1.12e-06	0.3	0.27	Fibrinogen;	chr7:22823331	chr7:22856613~22856686:+
HNSC	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	6.09	2.41e-09	1.12e-06	0.28	0.27	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
HNSC	cis	rs2842992	0.747	rs4709379	ENSG00000237927.1	RP3-393E18.2	-6.09	2.41e-09	1.12e-06	-0.41	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159806498	chr6:159586955~159589169:-
HNSC	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	6.09	2.41e-09	1.12e-06	0.24	0.27	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
HNSC	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-6.09	2.41e-09	1.12e-06	-0.34	-0.27	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
HNSC	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.09	2.41e-09	1.12e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
HNSC	cis	rs1865760	0.593	rs2097273	ENSG00000272462.2	U91328.19	-6.09	2.42e-09	1.12e-06	-0.25	-0.27	Height;	chr6:25941082	chr6:25992662~26001775:+
HNSC	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-6.09	2.42e-09	1.12e-06	-0.28	-0.27	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
HNSC	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-6.09	2.42e-09	1.12e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
HNSC	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.09	2.42e-09	1.13e-06	0.27	0.27	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
HNSC	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	6.09	2.43e-09	1.13e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	6.08	2.43e-09	1.13e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
HNSC	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	6.08	2.43e-09	1.13e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	6.08	2.43e-09	1.13e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
HNSC	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-6.08	2.43e-09	1.13e-06	-0.31	-0.27	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-6.08	2.43e-09	1.13e-06	-0.31	-0.27	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.08	2.44e-09	1.13e-06	0.34	0.27	Depression;	chr6:28364057	chr6:28943877~28944537:+
HNSC	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	6.08	2.44e-09	1.13e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
HNSC	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-6.08	2.44e-09	1.13e-06	-0.36	-0.27	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
HNSC	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-6.08	2.44e-09	1.13e-06	-0.39	-0.27	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
HNSC	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-6.08	2.45e-09	1.13e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
HNSC	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	6.08	2.45e-09	1.13e-06	0.24	0.27	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	6.08	2.45e-09	1.13e-06	0.24	0.27	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
HNSC	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-6.08	2.45e-09	1.14e-06	-0.54	-0.27	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
HNSC	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	6.08	2.45e-09	1.14e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-6.08	2.45e-09	1.14e-06	-0.18	-0.27	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
HNSC	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.08	2.46e-09	1.14e-06	0.32	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
HNSC	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	6.08	2.46e-09	1.14e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	6.08	2.47e-09	1.15e-06	0.3	0.27	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
HNSC	cis	rs1355223	1	rs1396883	ENSG00000271369.1	RP11-350D17.3	-6.08	2.47e-09	1.15e-06	-0.32	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34735900	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	6.08	2.47e-09	1.15e-06	0.37	0.27	Depression;	chr6:28206812	chr6:28943877~28944537:+
HNSC	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.08	2.47e-09	1.15e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-6.08	2.48e-09	1.15e-06	-0.29	-0.27	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
HNSC	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
HNSC	cis	rs9907295	0.591	rs2291299	ENSG00000270977.1	AC015849.16	-6.08	2.48e-09	1.15e-06	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35864402	chr17:35893707~35911023:-
HNSC	cis	rs7615952	0.576	rs2276727	ENSG00000241288.6	RP11-379B18.5	-6.08	2.48e-09	1.15e-06	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:126107400	chr3:125827238~125916384:-
HNSC	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	6.08	2.48e-09	1.15e-06	0.33	0.27	Height;	chr4:55544621	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.08	2.49e-09	1.15e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
HNSC	cis	rs947583	0.588	rs9321530	ENSG00000217482.2	HMGB1P17	6.08	2.49e-09	1.15e-06	0.3	0.27	Phosphorus levels;	chr6:135790941	chr6:135636086~135636713:-
HNSC	cis	rs4803480	0.678	rs3745936	ENSG00000270164.1	LINC01480	-6.08	2.5e-09	1.16e-06	-0.23	-0.27	Schizophrenia;	chr19:41586462	chr19:41535183~41536904:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-6.08	2.5e-09	1.16e-06	-0.26	-0.27	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-6.08	2.5e-09	1.16e-06	-0.26	-0.27	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
HNSC	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-6.08	2.5e-09	1.16e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
HNSC	cis	rs9611565	0.506	rs7364221	ENSG00000235513.1	RP4-756G23.5	6.08	2.51e-09	1.16e-06	0.28	0.27	Vitiligo;	chr22:41254186	chr22:41209122~41217627:-
HNSC	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-6.08	2.51e-09	1.16e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
HNSC	cis	rs6928977	0.932	rs6914831	ENSG00000234084.1	RP3-388E23.2	6.08	2.51e-09	1.16e-06	0.28	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135301568~135307158:+
HNSC	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	6.08	2.51e-09	1.16e-06	0.48	0.27	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
HNSC	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	6.08	2.51e-09	1.16e-06	0.33	0.27	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
HNSC	cis	rs172166	0.769	rs149965	ENSG00000204709.4	LINC01556	6.08	2.51e-09	1.16e-06	0.36	0.27	Cardiac Troponin-T levels;	chr6:28050911	chr6:28943877~28944537:+
HNSC	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-6.08	2.52e-09	1.16e-06	-0.24	-0.27	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	6.08	2.52e-09	1.17e-06	0.21	0.27	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-6.08	2.52e-09	1.17e-06	-0.32	-0.27	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
HNSC	cis	rs6928977	0.714	rs11154801	ENSG00000217482.2	HMGB1P17	6.08	2.52e-09	1.17e-06	0.31	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135636086~135636713:-
HNSC	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	6.08	2.52e-09	1.17e-06	0.34	0.27	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-6.08	2.53e-09	1.17e-06	-0.23	-0.27	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	6.08	2.54e-09	1.17e-06	0.35	0.27	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
HNSC	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	6.08	2.54e-09	1.17e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
HNSC	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	6.08	2.54e-09	1.18e-06	0.31	0.27	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
HNSC	cis	rs4657482	0.606	rs4657490	ENSG00000236364.3	RP11-525G13.2	6.08	2.55e-09	1.18e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165900453	chr1:165890795~165900683:-
HNSC	cis	rs7630852	1	rs7626440	ENSG00000272359.1	U4	-6.08	2.55e-09	1.18e-06	-0.29	-0.27	Eosinophil counts;	chr3:196778019	chr3:196747192~196747324:-
HNSC	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-6.08	2.55e-09	1.18e-06	-0.32	-0.27	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	-6.08	2.55e-09	1.18e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
HNSC	cis	rs4218	0.608	rs34859729	ENSG00000277144.1	RP11-59H7.4	-6.08	2.56e-09	1.18e-06	-0.37	-0.27	Social communication problems;	chr15:59070117	chr15:59115547~59116089:-
HNSC	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-6.08	2.56e-09	1.18e-06	-0.34	-0.27	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
HNSC	cis	rs4218	0.587	rs1446237	ENSG00000259732.1	RP11-59H7.3	-6.08	2.56e-09	1.18e-06	-0.36	-0.27	Social communication problems;	chr15:59052603	chr15:59121034~59133250:+
HNSC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-6.08	2.56e-09	1.18e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
HNSC	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109415123	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109416903	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	6.08	2.56e-09	1.18e-06	0.35	0.27	Height;	chr6:109417941	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000211974.3	IGHV2-70	-6.08	2.57e-09	1.19e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106805386	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000211974.3	IGHV2-70	-6.08	2.57e-09	1.19e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106806185	chr14:106723574~106724093:-
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000276710.3	CSPG4P8	-6.08	2.57e-09	1.19e-06	-0.38	-0.27	Excessive daytime sleepiness;	chr15:82734974	chr15:82459472~82477258:+
HNSC	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	6.08	2.57e-09	1.19e-06	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
HNSC	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	6.08	2.57e-09	1.19e-06	0.3	0.27	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
HNSC	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-6.07	2.58e-09	1.19e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
HNSC	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	6.07	2.58e-09	1.19e-06	0.35	0.27	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
HNSC	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-6.07	2.59e-09	1.19e-06	-0.32	-0.27	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
HNSC	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
HNSC	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-6.07	2.59e-09	1.2e-06	-0.25	-0.27	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
HNSC	cis	rs9907295	0.591	rs6505498	ENSG00000270977.1	AC015849.16	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35803047	chr17:35893707~35911023:-
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-6.07	2.59e-09	1.2e-06	-0.32	-0.27	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
HNSC	cis	rs7617773	0.78	rs9846818	ENSG00000228638.1	FCF1P2	-6.07	2.6e-09	1.2e-06	-0.25	-0.27	Coronary artery disease;	chr3:48334195	chr3:48290793~48291375:-
HNSC	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	6.07	2.6e-09	1.2e-06	0.34	0.27	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
HNSC	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-6.07	2.6e-09	1.2e-06	-0.41	-0.27	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
HNSC	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-6.07	2.6e-09	1.2e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
HNSC	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	6.07	2.6e-09	1.2e-06	0.33	0.27	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
HNSC	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-6.07	2.6e-09	1.2e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
HNSC	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	6.07	2.6e-09	1.2e-06	0.31	0.27	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	6.07	2.6e-09	1.2e-06	0.37	0.27	Height;	chr6:109352730	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	6.07	2.6e-09	1.2e-06	0.37	0.27	Height;	chr6:109353355	chr6:109382795~109383666:+
HNSC	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	6.07	2.6e-09	1.2e-06	0.32	0.27	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
HNSC	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	6.07	2.6e-09	1.2e-06	0.32	0.27	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
HNSC	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	6.07	2.6e-09	1.2e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-6.07	2.6e-09	1.2e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	6.07	2.6e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
HNSC	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	6.07	2.6e-09	1.2e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	6.07	2.6e-09	1.2e-06	0.64	0.27	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
HNSC	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	6.07	2.6e-09	1.2e-06	0.36	0.27	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
HNSC	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.07	2.61e-09	1.2e-06	-0.3	-0.27	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	6.07	2.61e-09	1.2e-06	0.21	0.27	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000211974.3	IGHV2-70	-6.07	2.61e-09	1.2e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106790663	chr14:106723574~106724093:-
HNSC	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.07	2.61e-09	1.21e-06	0.3	0.27	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
HNSC	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-6.07	2.62e-09	1.21e-06	-0.34	-0.27	Depression;	chr6:28422360	chr6:28943877~28944537:+
HNSC	cis	rs2243480	1	rs709607	ENSG00000179406.6	LINC00174	6.07	2.62e-09	1.21e-06	0.51	0.27	Diabetic kidney disease;	chr7:65984554	chr7:66376044~66401338:-
HNSC	cis	rs1021993	0.621	rs2246571	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296326	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.553	rs5008730	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296662	chr1:209367662~209379690:+
HNSC	cis	rs1021993	0.645	rs5008731	ENSG00000231648.1	RP11-372M18.2	6.07	2.62e-09	1.21e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209296665	chr1:209367662~209379690:+
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-6.07	2.62e-09	1.21e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
HNSC	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-6.07	2.63e-09	1.21e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
HNSC	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-6.07	2.63e-09	1.21e-06	-0.31	-0.27	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
HNSC	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.07	2.63e-09	1.21e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.07	2.63e-09	1.21e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
HNSC	cis	rs7927592	0.83	rs11228240	ENSG00000212093.1	AP000807.1	6.07	2.63e-09	1.21e-06	0.33	0.27	Total body bone mineral density;	chr11:68450822	chr11:68506083~68506166:-
HNSC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	6.07	2.63e-09	1.21e-06	0.3	0.27	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
HNSC	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	6.07	2.63e-09	1.21e-06	0.42	0.27	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
HNSC	cis	rs6928977	0.675	rs9399148	ENSG00000217482.2	HMGB1P17	-6.07	2.63e-09	1.21e-06	-0.3	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135636086~135636713:-
HNSC	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-6.07	2.63e-09	1.21e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	6.07	2.63e-09	1.21e-06	0.34	0.27	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
HNSC	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-6.07	2.63e-09	1.21e-06	-0.34	-0.27	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
HNSC	cis	rs6504622	0.818	rs758391	ENSG00000262879.4	RP11-156P1.3	6.07	2.64e-09	1.21e-06	0.29	0.27	Orofacial clefts;	chr17:46939875	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	6.07	2.64e-09	1.21e-06	0.3	0.27	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	6.07	2.64e-09	1.22e-06	0.37	0.27	Height;	chr6:109366911	chr6:109382795~109383666:+
HNSC	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-6.07	2.65e-09	1.22e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
HNSC	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.07	2.65e-09	1.22e-06	0.3	0.27	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
HNSC	cis	rs2985684	0.894	rs2354439	ENSG00000258568.1	RHOQP1	6.07	2.65e-09	1.22e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552699	chr14:49599994~49600572:+
HNSC	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	6.07	2.66e-09	1.22e-06	0.35	0.27	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
HNSC	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
HNSC	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
HNSC	cis	rs7819412	0.775	rs6601564	ENSG00000269918.1	AF131215.9	-6.07	2.66e-09	1.22e-06	-0.27	-0.27	Triglycerides;	chr8:11124541	chr8:11104691~11106704:-
HNSC	cis	rs2985684	0.841	rs2281836	ENSG00000258568.1	RHOQP1	6.07	2.66e-09	1.23e-06	0.28	0.27	Carotid intima media thickness;	chr14:49598999	chr14:49599994~49600572:+
HNSC	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	6.07	2.66e-09	1.23e-06	0.36	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
HNSC	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	6.07	2.66e-09	1.23e-06	0.37	0.27	Height;	chr6:109347085	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	6.07	2.66e-09	1.23e-06	0.37	0.27	Height;	chr6:109347277	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.667	rs1408292	ENSG00000272129.1	RP11-250B2.6	6.07	2.67e-09	1.23e-06	0.32	0.27	Sitting height ratio;	chr6:80174189	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.628	rs2490245	ENSG00000272129.1	RP11-250B2.6	6.07	2.67e-09	1.23e-06	0.32	0.27	Sitting height ratio;	chr6:80182710	chr6:80355424~80356859:+
HNSC	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	6.07	2.67e-09	1.23e-06	0.37	0.27	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
HNSC	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	6.07	2.67e-09	1.23e-06	0.33	0.27	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
HNSC	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	6.07	2.67e-09	1.23e-06	0.26	0.27	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	6.07	2.68e-09	1.23e-06	0.35	0.27	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
HNSC	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-6.07	2.68e-09	1.23e-06	-0.27	-0.27	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
HNSC	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-6.07	2.68e-09	1.23e-06	-0.55	-0.27	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
HNSC	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-6.07	2.68e-09	1.24e-06	-0.23	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000211974.3	IGHV2-70	-6.07	2.68e-09	1.24e-06	-0.3	-0.27	Rheumatic heart disease;	chr14:106644643	chr14:106723574~106724093:-
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000267151.3	RP11-100E5.2	6.07	2.69e-09	1.24e-06	0.35	0.27	Menopause (age at onset);	chr17:43132725	chr17:43444707~43451200:+
HNSC	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-6.07	2.69e-09	1.24e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	6.07	2.7e-09	1.24e-06	0.33	0.27	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.07	2.7e-09	1.24e-06	0.35	0.27	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.07	2.7e-09	1.24e-06	0.35	0.27	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
HNSC	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109420812	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109422189	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109423330	chr6:109382795~109383666:+
HNSC	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	6.07	2.7e-09	1.24e-06	0.35	0.27	Height;	chr6:109423487	chr6:109382795~109383666:+
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000254153.1	CTA-398F10.2	6.07	2.7e-09	1.24e-06	0.29	0.27	Joint mobility (Beighton score);	chr8:8979093	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000179406.6	LINC00174	-6.07	2.71e-09	1.24e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66500146	chr7:66376044~66401338:-
HNSC	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.07	2.71e-09	1.25e-06	0.3	0.27	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000211972.2	IGHV3-66	6.07	2.71e-09	1.25e-06	0.21	0.27	Kawasaki disease;	chr14:106777570	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-6.07	2.71e-09	1.25e-06	-0.32	-0.27	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
HNSC	cis	rs7617773	0.539	rs13069884	ENSG00000228638.1	FCF1P2	-6.07	2.72e-09	1.25e-06	-0.24	-0.27	Coronary artery disease;	chr3:48339658	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs2017859	ENSG00000228638.1	FCF1P2	-6.07	2.72e-09	1.25e-06	-0.24	-0.27	Coronary artery disease;	chr3:48340771	chr3:48290793~48291375:-
HNSC	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	6.07	2.72e-09	1.25e-06	0.32	0.27	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
HNSC	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-6.07	2.72e-09	1.25e-06	-0.28	-0.27	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
HNSC	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-6.07	2.72e-09	1.25e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
HNSC	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-6.07	2.72e-09	1.25e-06	-0.37	-0.27	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
HNSC	cis	rs4218	0.689	rs2121237	ENSG00000259732.1	RP11-59H7.3	-6.06	2.73e-09	1.25e-06	-0.38	-0.27	Social communication problems;	chr15:59091888	chr15:59121034~59133250:+
HNSC	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-6.06	2.73e-09	1.26e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-6.06	2.73e-09	1.26e-06	-0.25	-0.27	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
HNSC	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-6.06	2.74e-09	1.26e-06	-0.32	-0.27	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
HNSC	cis	rs9402743	0.598	rs2327654	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135758303	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs6933668	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135760013	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs7756751	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135761314	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.703	rs6570030	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135761688	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs6909996	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135763365	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs9399164	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135765408	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.517	rs4385331	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Phosphorus levels;	chr6:135772025	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.641	rs9402752	ENSG00000217482.2	HMGB1P17	6.06	2.74e-09	1.26e-06	0.28	0.27	Systemic lupus erythematosus;	chr6:135772549	chr6:135636086~135636713:-
HNSC	cis	rs9611519	0.78	rs9611528	ENSG00000235513.1	RP4-756G23.5	6.06	2.74e-09	1.26e-06	0.28	0.27	Neuroticism;	chr22:41252498	chr22:41209122~41217627:-
HNSC	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-6.06	2.74e-09	1.26e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
HNSC	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	6.06	2.74e-09	1.26e-06	0.32	0.27	Height;	chr4:55532542	chr4:55363971~55395847:-
HNSC	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-6.06	2.75e-09	1.26e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	6.06	2.75e-09	1.26e-06	0.31	0.27	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
HNSC	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-6.06	2.75e-09	1.26e-06	-0.34	-0.27	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-6.06	2.75e-09	1.26e-06	-0.34	-0.27	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
HNSC	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	6.06	2.75e-09	1.26e-06	0.23	0.27	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
HNSC	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	6.06	2.76e-09	1.27e-06	0.3	0.27	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.06	2.76e-09	1.27e-06	-0.36	-0.27	Depression;	chr6:28199145	chr6:28943877~28944537:+
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	6.06	2.76e-09	1.27e-06	0.18	0.27	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
HNSC	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	6.06	2.76e-09	1.27e-06	0.37	0.27	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
HNSC	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	6.06	2.76e-09	1.27e-06	0.26	0.27	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
HNSC	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	6.06	2.77e-09	1.27e-06	0.29	0.27	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-6.06	2.77e-09	1.27e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-6.06	2.77e-09	1.27e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	6.06	2.77e-09	1.27e-06	0.18	0.27	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
HNSC	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	6.06	2.77e-09	1.27e-06	0.33	0.27	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
HNSC	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-6.06	2.78e-09	1.27e-06	-0.3	-0.27	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
HNSC	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.06	2.78e-09	1.28e-06	0.3	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
HNSC	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-6.06	2.78e-09	1.28e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
HNSC	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-6.06	2.78e-09	1.28e-06	-0.31	-0.27	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
HNSC	cis	rs1355223	0.902	rs11605785	ENSG00000271369.1	RP11-350D17.3	-6.06	2.78e-09	1.28e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729840	chr11:34709600~34710161:+
HNSC	cis	rs6928977	0.675	rs7759971	ENSG00000217482.2	HMGB1P17	6.06	2.78e-09	1.28e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135636086~135636713:-
HNSC	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	6.06	2.78e-09	1.28e-06	0.27	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
HNSC	cis	rs947583	0.517	rs7756915	ENSG00000217482.2	HMGB1P17	6.06	2.78e-09	1.28e-06	0.28	0.27	Phosphorus levels;	chr6:135798177	chr6:135636086~135636713:-
HNSC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.06	2.79e-09	1.28e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
HNSC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.06	2.79e-09	1.28e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-6.06	2.79e-09	1.28e-06	-0.3	-0.27	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
HNSC	cis	rs17270561	0.609	rs7746502	ENSG00000272462.2	U91328.19	6.06	2.79e-09	1.28e-06	0.27	0.27	Iron status biomarkers;	chr6:25718534	chr6:25992662~26001775:+
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	6.06	2.79e-09	1.28e-06	0.21	0.27	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-6.06	2.79e-09	1.28e-06	-0.32	-0.27	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
HNSC	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-6.06	2.8e-09	1.29e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
HNSC	cis	rs7819412	0.538	rs4523214	ENSG00000269918.1	AF131215.9	-6.06	2.8e-09	1.29e-06	-0.27	-0.27	Triglycerides;	chr8:11113263	chr8:11104691~11106704:-
HNSC	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	6.06	2.81e-09	1.29e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-6.06	2.81e-09	1.29e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
HNSC	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	6.06	2.81e-09	1.29e-06	0.3	0.27	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
HNSC	cis	rs11648785	0.747	rs3743826	ENSG00000222019.6	URAHP	6.06	2.81e-09	1.29e-06	0.28	0.27	Tanning;	chr16:90027806	chr16:90039761~90047773:-
HNSC	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	6.06	2.81e-09	1.29e-06	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
HNSC	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.06	2.81e-09	1.29e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
HNSC	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.06	2.81e-09	1.29e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
HNSC	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-6.06	2.82e-09	1.29e-06	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	6.06	2.82e-09	1.29e-06	0.26	0.27	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
HNSC	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-6.06	2.83e-09	1.29e-06	-0.35	-0.27	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
HNSC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.06	2.83e-09	1.3e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
HNSC	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
HNSC	cis	rs6928977	0.675	rs58761508	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.631	rs9385726	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.637	rs9647635	ENSG00000217482.2	HMGB1P17	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135636086~135636713:-
HNSC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-6.06	2.83e-09	1.3e-06	-0.31	-0.27	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
HNSC	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	6.06	2.84e-09	1.3e-06	0.31	0.27	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
HNSC	cis	rs8054556	0.692	rs7201384	ENSG00000183604.13	SMG1P5	-6.06	2.84e-09	1.3e-06	-0.26	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30267553~30335374:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000179406.6	LINC00174	-6.06	2.84e-09	1.3e-06	-0.56	-0.27	Diabetic kidney disease;	chr7:66357373	chr7:66376044~66401338:-
HNSC	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-6.06	2.85e-09	1.3e-06	-0.32	-0.27	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
HNSC	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	6.06	2.85e-09	1.3e-06	0.37	0.27	Height;	chr6:109371573	chr6:109382795~109383666:+
HNSC	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-6.06	2.85e-09	1.31e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
HNSC	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	6.06	2.85e-09	1.31e-06	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
HNSC	cis	rs9300255	0.602	rs1790095	ENSG00000280120.1	RP11-546D6.3	6.06	2.85e-09	1.31e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123196675	chr12:123152324~123153377:-
HNSC	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-6.06	2.86e-09	1.31e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
HNSC	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-6.06	2.86e-09	1.31e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
HNSC	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	6.06	2.86e-09	1.31e-06	0.35	0.27	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
HNSC	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-6.06	2.86e-09	1.31e-06	-0.32	-0.27	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
HNSC	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	6.06	2.86e-09	1.31e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
HNSC	cis	rs4657482	0.607	rs10918309	ENSG00000236364.3	RP11-525G13.2	6.06	2.87e-09	1.31e-06	0.28	0.27	Testicular germ cell tumor;	chr1:165904791	chr1:165890795~165900683:-
HNSC	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.06	2.87e-09	1.31e-06	0.3	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
HNSC	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	6.06	2.87e-09	1.31e-06	0.38	0.27	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	6.06	2.87e-09	1.31e-06	0.38	0.27	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
HNSC	cis	rs7396835	0.8	rs6589572	ENSG00000280143.1	AP000892.6	6.06	2.87e-09	1.31e-06	0.38	0.27	Quantitative traits;	chr11:116810847	chr11:117204967~117210292:+
HNSC	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-6.06	2.87e-09	1.31e-06	-0.31	-0.27	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	6.06	2.88e-09	1.32e-06	0.26	0.27	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
HNSC	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	6.06	2.88e-09	1.32e-06	0.22	0.27	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
HNSC	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	6.06	2.88e-09	1.32e-06	0.31	0.27	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
HNSC	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.06	2.88e-09	1.32e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
HNSC	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	6.06	2.89e-09	1.32e-06	0.36	0.27	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
HNSC	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	6.05	2.89e-09	1.32e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	6.05	2.89e-09	1.32e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-6.05	2.89e-09	1.32e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-6.05	2.89e-09	1.32e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-6.05	2.89e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-6.05	2.9e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-6.05	2.9e-09	1.32e-06	-0.35	-0.27	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
HNSC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	6.05	2.9e-09	1.33e-06	0.28	0.27	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-6.05	2.91e-09	1.33e-06	-0.25	-0.27	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
HNSC	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	6.05	2.91e-09	1.33e-06	0.39	0.27	Depression;	chr6:28254038	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-6.05	2.91e-09	1.33e-06	-0.17	-0.27	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
HNSC	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	6.05	2.91e-09	1.33e-06	0.45	0.27	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
HNSC	cis	rs2834288	0.536	rs8129513	ENSG00000237945.6	LINC00649	6.05	2.91e-09	1.33e-06	0.33	0.27	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33915534~33977691:+
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	6.05	2.91e-09	1.33e-06	0.22	0.27	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
HNSC	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-6.05	2.92e-09	1.33e-06	-0.29	-0.27	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-6.05	2.92e-09	1.33e-06	-0.33	-0.27	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
HNSC	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-6.05	2.92e-09	1.33e-06	-0.32	-0.27	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	6.05	2.92e-09	1.33e-06	0.32	0.27	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
HNSC	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	6.05	2.92e-09	1.33e-06	0.36	0.27	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-6.05	2.92e-09	1.34e-06	-0.4	-0.27	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	6.05	2.92e-09	1.34e-06	0.39	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
HNSC	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.94e-09	1.34e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
HNSC	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-6.05	2.94e-09	1.34e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-6.05	2.94e-09	1.34e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
HNSC	cis	rs6604026	0.555	rs11805007	ENSG00000223787.2	RP4-593M8.1	6.05	2.94e-09	1.34e-06	0.37	0.27	Multiple sclerosis;	chr1:92616633	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs56044027	ENSG00000223787.2	RP4-593M8.1	6.05	2.94e-09	1.34e-06	0.37	0.27	Multiple sclerosis;	chr1:92617137	chr1:92580476~92580821:-
HNSC	cis	rs6928977	0.896	rs2614285	ENSG00000234084.1	RP3-388E23.2	6.05	2.94e-09	1.34e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371480	chr6:135301568~135307158:+
HNSC	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-6.05	2.94e-09	1.34e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-6.05	2.94e-09	1.34e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
HNSC	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	6.05	2.94e-09	1.34e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
HNSC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	6.05	2.95e-09	1.35e-06	0.31	0.27	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
HNSC	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
HNSC	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-6.05	2.95e-09	1.35e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
HNSC	cis	rs9840812	0.637	rs698270	ENSG00000239213.4	NCK1-AS1	6.05	2.95e-09	1.35e-06	0.26	0.27	Fibrinogen levels;	chr3:136390670	chr3:136841726~136862054:-
HNSC	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-6.05	2.95e-09	1.35e-06	-0.34	-0.27	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.583	rs7765833	ENSG00000272462.2	U91328.19	-6.05	2.95e-09	1.35e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25712205	chr6:25992662~26001775:+
HNSC	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	6.05	2.96e-09	1.35e-06	0.37	0.27	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
HNSC	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-6.05	2.96e-09	1.35e-06	-0.29	-0.27	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
HNSC	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	6.05	2.96e-09	1.35e-06	0.27	0.27	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
HNSC	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	6.05	2.96e-09	1.35e-06	0.25	0.27	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	6.05	2.96e-09	1.35e-06	0.25	0.27	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
HNSC	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	6.05	2.96e-09	1.35e-06	0.33	0.27	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
HNSC	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	6.05	2.96e-09	1.35e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
HNSC	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-6.05	2.97e-09	1.35e-06	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
HNSC	cis	rs67981189	0.529	rs8181986	ENSG00000274818.1	RP1-292L20.3	6.05	2.97e-09	1.36e-06	0.33	0.27	Schizophrenia;	chr14:71115527	chr14:70906657~70907111:-
HNSC	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-6.05	2.97e-09	1.36e-06	-0.33	-0.27	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
HNSC	cis	rs6051080	1	rs6051080	ENSG00000204556.4	CTD-2514C3.1	-6.05	2.98e-09	1.36e-06	-0.34	-0.27	Colorectal or endometrial cancer;	chr20:25995038	chr20:26018832~26020684:+
HNSC	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.05	2.98e-09	1.36e-06	0.26	0.27	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
HNSC	cis	rs7980687	0.574	rs10744149	ENSG00000280120.1	RP11-546D6.3	6.05	2.98e-09	1.36e-06	0.24	0.27	Head circumference (infant);Educational attainment;Height;	chr12:123223943	chr12:123152324~123153377:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	6.05	2.98e-09	1.36e-06	0.31	0.27	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-6.05	2.98e-09	1.36e-06	-0.29	-0.27	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
HNSC	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-6.05	2.98e-09	1.36e-06	-0.35	-0.27	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
HNSC	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-6.05	2.98e-09	1.36e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
HNSC	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-6.05	2.99e-09	1.36e-06	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-6.05	2.99e-09	1.36e-06	-0.32	-0.27	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
HNSC	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	6.05	2.99e-09	1.36e-06	0.31	0.27	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	6.05	2.99e-09	1.36e-06	0.31	0.27	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
HNSC	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	6.05	2.99e-09	1.36e-06	0.51	0.27	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	6.05	2.99e-09	1.36e-06	0.51	0.27	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
HNSC	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.99e-09	1.36e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
HNSC	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	6.05	2.99e-09	1.36e-06	0.5	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
HNSC	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	6.05	2.99e-09	1.36e-06	0.21	0.27	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
HNSC	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-6.05	2.99e-09	1.37e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
HNSC	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.05	3e-09	1.37e-06	0.3	0.27	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
HNSC	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-6.05	3e-09	1.37e-06	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
HNSC	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	6.05	3e-09	1.37e-06	0.4	0.27	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000173295.6	FAM86B3P	-6.05	3.01e-09	1.37e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9033292	chr8:8228595~8244865:+
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000173295.6	FAM86B3P	-6.05	3.01e-09	1.37e-06	-0.3	-0.27	Myopia (pathological);Myopia;	chr8:9033866	chr8:8228595~8244865:+
HNSC	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-6.05	3.01e-09	1.37e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
HNSC	cis	rs947583	0.517	rs9376144	ENSG00000217482.2	HMGB1P17	6.05	3.01e-09	1.37e-06	0.28	0.27	Phosphorus levels;	chr6:135756247	chr6:135636086~135636713:-
HNSC	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-6.05	3.01e-09	1.37e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
HNSC	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-6.05	3.01e-09	1.37e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
HNSC	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	6.05	3.02e-09	1.38e-06	0.25	0.27	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.05	3.02e-09	1.38e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
HNSC	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.05	3.02e-09	1.38e-06	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-6.05	3.02e-09	1.38e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
HNSC	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	6.05	3.03e-09	1.38e-06	0.32	0.27	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
HNSC	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-6.05	3.03e-09	1.38e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-6.05	3.03e-09	1.38e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
HNSC	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	6.05	3.03e-09	1.38e-06	0.33	0.27	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
HNSC	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-6.05	3.03e-09	1.38e-06	-0.46	-0.27	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000254340.1	RP11-10A14.3	6.05	3.03e-09	1.38e-06	0.33	0.27	Mood instability;	chr8:8795379	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-6.05	3.04e-09	1.38e-06	-0.32	-0.27	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
HNSC	cis	rs6951245	1	rs74887741	ENSG00000225146.1	AC073957.15	-6.05	3.04e-09	1.38e-06	-0.46	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1029025~1043891:+
HNSC	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-6.05	3.04e-09	1.39e-06	-0.28	-0.27	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
HNSC	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-6.05	3.04e-09	1.39e-06	-0.38	-0.27	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
HNSC	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	6.05	3.04e-09	1.39e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
HNSC	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-6.05	3.04e-09	1.39e-06	-0.33	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
HNSC	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-6.05	3.05e-09	1.39e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
HNSC	cis	rs6928977	0.538	rs17064702	ENSG00000217482.2	HMGB1P17	6.05	3.05e-09	1.39e-06	0.31	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135636086~135636713:-
HNSC	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	6.05	3.05e-09	1.39e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
HNSC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	6.05	3.05e-09	1.39e-06	0.36	0.27	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
HNSC	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	6.05	3.05e-09	1.39e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	6.05	3.05e-09	1.39e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	6.05	3.06e-09	1.39e-06	0.31	0.27	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
HNSC	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-6.05	3.06e-09	1.39e-06	-0.36	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
HNSC	cis	rs2985684	0.948	rs11623263	ENSG00000258568.1	RHOQP1	6.04	3.06e-09	1.39e-06	0.28	0.27	Carotid intima media thickness;	chr14:49616577	chr14:49599994~49600572:+
HNSC	cis	rs17270561	0.583	rs12662869	ENSG00000272462.2	U91328.19	6.04	3.06e-09	1.39e-06	0.27	0.27	Iron status biomarkers;	chr6:25784253	chr6:25992662~26001775:+
HNSC	cis	rs947583	0.517	rs9494390	ENSG00000217482.2	HMGB1P17	6.04	3.06e-09	1.39e-06	0.28	0.27	Phosphorus levels;	chr6:135794875	chr6:135636086~135636713:-
HNSC	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	6.04	3.06e-09	1.39e-06	0.41	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-6.04	3.07e-09	1.4e-06	-0.4	-0.27	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
HNSC	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	6.04	3.07e-09	1.4e-06	0.35	0.27	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
HNSC	cis	rs7048146	0.668	rs10124300	ENSG00000213539.4	YBX1P6	-6.04	3.07e-09	1.4e-06	-0.29	-0.27	Vascular brain injury;	chr9:109515460	chr9:109532830~109534332:-
HNSC	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	6.04	3.07e-09	1.4e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
HNSC	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	6.04	3.07e-09	1.4e-06	0.36	0.27	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
HNSC	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-6.04	3.08e-09	1.4e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
HNSC	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-6.04	3.08e-09	1.4e-06	-0.3	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
HNSC	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-6.04	3.08e-09	1.4e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-6.04	3.08e-09	1.4e-06	-0.22	-0.27	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	6.04	3.08e-09	1.4e-06	0.33	0.27	Height;	chr4:55542243	chr4:55363971~55395847:-
HNSC	cis	rs2985684	0.846	rs4476096	ENSG00000258568.1	RHOQP1	6.04	3.09e-09	1.41e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552673	chr14:49599994~49600572:+
HNSC	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-6.04	3.09e-09	1.41e-06	-0.36	-0.27	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
HNSC	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-6.04	3.1e-09	1.41e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
HNSC	cis	rs9300255	0.602	rs1790126	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123199016	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs1716182	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123201580	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1402274	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123201677	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs11057192	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123208873	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2682434	ENSG00000280120.1	RP11-546D6.3	6.04	3.1e-09	1.41e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123210177	chr12:123152324~123153377:-
HNSC	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	6.04	3.1e-09	1.41e-06	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
HNSC	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	6.04	3.1e-09	1.41e-06	0.37	0.27	Height;	chr6:109352852	chr6:109382795~109383666:+
HNSC	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	6.04	3.11e-09	1.41e-06	0.3	0.27	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
HNSC	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-6.04	3.11e-09	1.41e-06	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
HNSC	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	6.04	3.11e-09	1.41e-06	0.31	0.27	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.896	rs2614287	ENSG00000234084.1	RP3-388E23.2	6.04	3.11e-09	1.41e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135301568~135307158:+
HNSC	cis	rs2834288	0.5	rs7283594	ENSG00000237945.6	LINC00649	-6.04	3.11e-09	1.41e-06	-0.33	-0.27	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33915534~33977691:+
HNSC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	6.04	3.12e-09	1.42e-06	0.34	0.27	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
HNSC	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-6.04	3.12e-09	1.42e-06	-0.32	-0.27	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
HNSC	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-6.04	3.12e-09	1.42e-06	-0.34	-0.27	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
HNSC	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-6.04	3.13e-09	1.42e-06	-0.36	-0.27	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000179406.6	LINC00174	-6.04	3.13e-09	1.42e-06	-0.57	-0.27	Diabetic kidney disease;	chr7:66500834	chr7:66376044~66401338:-
HNSC	cis	rs7209700	0.662	rs8080254	ENSG00000228782.6	CTD-2026D20.3	6.04	3.13e-09	1.42e-06	0.29	0.27	IgG glycosylation;	chr17:47270526	chr17:47450568~47492492:-
HNSC	cis	rs8054556	0.787	rs1140239	ENSG00000183604.13	SMG1P5	-6.04	3.13e-09	1.42e-06	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30267553~30335374:-
HNSC	cis	rs5753618	0.539	rs695438	ENSG00000236132.1	CTA-440B3.1	-6.04	3.14e-09	1.42e-06	-0.31	-0.27	Colorectal cancer;	chr22:31415890	chr22:31816379~31817491:-
HNSC	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	6.04	3.14e-09	1.43e-06	0.34	0.27	Depression;	chr6:28407125	chr6:28943877~28944537:+
HNSC	cis	rs5753618	0.539	rs4820962	ENSG00000236132.1	CTA-440B3.1	6.04	3.14e-09	1.43e-06	0.33	0.27	Colorectal cancer;	chr22:31293965	chr22:31816379~31817491:-
HNSC	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-6.04	3.14e-09	1.43e-06	-0.34	-0.27	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.636	rs1575535	ENSG00000272462.2	U91328.19	-6.04	3.14e-09	1.43e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25809681	chr6:25992662~26001775:+
HNSC	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.04	3.15e-09	1.43e-06	0.31	0.27	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	6.04	3.15e-09	1.43e-06	0.31	0.27	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
HNSC	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55490176	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55490228	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	6.04	3.15e-09	1.43e-06	0.32	0.27	Height;	chr4:55491150	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-6.04	3.16e-09	1.43e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
HNSC	cis	rs7209700	0.662	rs8074094	ENSG00000228782.6	CTD-2026D20.3	-6.04	3.16e-09	1.43e-06	-0.29	-0.27	IgG glycosylation;	chr17:47270655	chr17:47450568~47492492:-
HNSC	cis	rs947583	0.573	rs12191817	ENSG00000217482.2	HMGB1P17	6.04	3.16e-09	1.43e-06	0.3	0.27	Phosphorus levels;	chr6:135702608	chr6:135636086~135636713:-
HNSC	cis	rs2134046	0.555	rs11854483	ENSG00000255769.6	GOLGA2P10	-6.04	3.17e-09	1.44e-06	-0.32	-0.27	Cognitive ability;	chr15:82267217	chr15:82472993~82513950:-
HNSC	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-6.04	3.17e-09	1.44e-06	-0.33	-0.27	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
HNSC	cis	rs9840812	0.522	rs699165	ENSG00000273486.1	RP11-731C17.2	6.04	3.17e-09	1.44e-06	0.24	0.27	Fibrinogen levels;	chr3:136505855	chr3:136837338~136839021:-
HNSC	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-6.04	3.17e-09	1.44e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
HNSC	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	6.04	3.17e-09	1.44e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
HNSC	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	6.04	3.18e-09	1.44e-06	0.36	0.27	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
HNSC	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	6.04	3.18e-09	1.44e-06	0.32	0.27	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
HNSC	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	6.04	3.18e-09	1.44e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	6.04	3.18e-09	1.44e-06	0.21	0.27	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
HNSC	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	6.04	3.18e-09	1.44e-06	0.34	0.27	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
HNSC	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	6.04	3.18e-09	1.44e-06	0.33	0.27	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	6.04	3.18e-09	1.44e-06	0.33	0.27	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
HNSC	cis	rs11648785	0.735	rs868372	ENSG00000222019.6	URAHP	6.04	3.19e-09	1.45e-06	0.27	0.27	Tanning;	chr16:90031587	chr16:90039761~90047773:-
HNSC	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	6.04	3.19e-09	1.45e-06	0.28	0.27	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000276710.3	CSPG4P8	6.04	3.19e-09	1.45e-06	0.3	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82459472~82477258:+
HNSC	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	6.04	3.19e-09	1.45e-06	0.3	0.27	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
HNSC	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	6.04	3.19e-09	1.45e-06	0.31	0.27	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
HNSC	cis	rs947583	0.588	rs2208574	ENSG00000217482.2	HMGB1P17	6.04	3.2e-09	1.45e-06	0.3	0.27	Phosphorus levels;	chr6:135754479	chr6:135636086~135636713:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-6.04	3.2e-09	1.45e-06	-0.32	-0.27	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-6.04	3.2e-09	1.45e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
HNSC	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.04	3.2e-09	1.45e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-6.04	3.2e-09	1.45e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
HNSC	cis	rs2286503	0.839	rs4722188	ENSG00000221740.1	SNORD93	6.04	3.2e-09	1.45e-06	0.3	0.27	Fibrinogen;	chr7:22820592	chr7:22856613~22856686:+
HNSC	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	6.04	3.2e-09	1.45e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	6.04	3.2e-09	1.45e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
HNSC	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	6.04	3.21e-09	1.46e-06	0.27	0.27	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
HNSC	cis	rs67981189	0.529	rs2810097	ENSG00000274818.1	RP1-292L20.3	-6.04	3.21e-09	1.46e-06	-0.32	-0.27	Schizophrenia;	chr14:70967397	chr14:70906657~70907111:-
HNSC	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
HNSC	cis	rs1355223	1	rs11602909	ENSG00000271369.1	RP11-350D17.3	-6.04	3.22e-09	1.46e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746456	chr11:34709600~34710161:+
HNSC	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	6.04	3.22e-09	1.46e-06	0.32	0.27	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-6.04	3.22e-09	1.46e-06	-0.39	-0.27	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
HNSC	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
HNSC	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	6.04	3.22e-09	1.46e-06	0.33	0.27	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
HNSC	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	6.04	3.22e-09	1.46e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	6.04	3.22e-09	1.46e-06	0.35	0.27	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
HNSC	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-6.04	3.23e-09	1.46e-06	-0.43	-0.27	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	6.04	3.23e-09	1.47e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
HNSC	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-6.04	3.24e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55528801	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55529387	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	6.03	3.25e-09	1.47e-06	0.32	0.27	Height;	chr4:55529786	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-6.03	3.25e-09	1.47e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-6.03	3.25e-09	1.47e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-6.03	3.25e-09	1.47e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-6.03	3.25e-09	1.47e-06	-0.32	-0.27	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
HNSC	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	6.03	3.25e-09	1.47e-06	0.35	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-6.03	3.26e-09	1.47e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
HNSC	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	6.03	3.26e-09	1.47e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-6.03	3.26e-09	1.48e-06	-0.31	-0.27	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
HNSC	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	6.03	3.27e-09	1.48e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
HNSC	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	6.03	3.27e-09	1.48e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
HNSC	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-6.03	3.27e-09	1.48e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
HNSC	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	6.03	3.28e-09	1.48e-06	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	6.03	3.28e-09	1.48e-06	0.34	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
HNSC	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	6.03	3.28e-09	1.48e-06	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000211974.3	IGHV2-70	-6.03	3.28e-09	1.49e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106807164	chr14:106723574~106724093:-
HNSC	cis	rs7819412	0.668	rs920047	ENSG00000269918.1	AF131215.9	-6.03	3.29e-09	1.49e-06	-0.27	-0.27	Triglycerides;	chr8:11229966	chr8:11104691~11106704:-
HNSC	cis	rs11648785	0.777	rs4433810	ENSG00000222019.6	URAHP	6.03	3.29e-09	1.49e-06	0.28	0.27	Tanning;	chr16:90032058	chr16:90039761~90047773:-
HNSC	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	6.03	3.29e-09	1.49e-06	0.3	0.27	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
HNSC	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-6.03	3.3e-09	1.49e-06	-0.37	-0.27	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.03	3.3e-09	1.49e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.03	3.3e-09	1.49e-06	0.37	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
HNSC	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-6.03	3.3e-09	1.49e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
HNSC	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
HNSC	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
HNSC	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	6.03	3.3e-09	1.49e-06	0.32	0.27	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
HNSC	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	6.03	3.31e-09	1.5e-06	0.31	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
HNSC	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-6.03	3.32e-09	1.5e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	6.03	3.32e-09	1.5e-06	0.42	0.27	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
HNSC	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	6.03	3.32e-09	1.5e-06	0.3	0.27	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
HNSC	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-6.03	3.32e-09	1.5e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-6.03	3.32e-09	1.5e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
HNSC	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-6.03	3.32e-09	1.5e-06	-0.33	-0.27	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-6.03	3.32e-09	1.5e-06	-0.33	-0.27	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
HNSC	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	6.03	3.33e-09	1.5e-06	0.32	0.27	Height;	chr4:55465165	chr4:55363971~55395847:-
HNSC	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	6.03	3.33e-09	1.5e-06	0.33	0.27	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
HNSC	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-6.03	3.33e-09	1.5e-06	-0.32	-0.27	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
HNSC	cis	rs7209700	0.632	rs11657963	ENSG00000228782.6	CTD-2026D20.3	-6.03	3.33e-09	1.5e-06	-0.28	-0.27	IgG glycosylation;	chr17:47270167	chr17:47450568~47492492:-
HNSC	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-6.03	3.33e-09	1.51e-06	-0.32	-0.27	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
HNSC	cis	rs9907295	0.591	rs9908928	ENSG00000270977.1	AC015849.16	-6.03	3.34e-09	1.51e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35893707~35911023:-
HNSC	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-6.03	3.34e-09	1.51e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-6.03	3.34e-09	1.51e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
HNSC	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	6.03	3.34e-09	1.51e-06	0.41	0.27	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
HNSC	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-6.03	3.35e-09	1.51e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-6.03	3.35e-09	1.51e-06	-0.34	-0.27	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
HNSC	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	6.03	3.35e-09	1.51e-06	0.31	0.27	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
HNSC	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	6.03	3.35e-09	1.51e-06	0.33	0.27	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
HNSC	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	6.03	3.36e-09	1.51e-06	0.3	0.27	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
HNSC	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.03	3.37e-09	1.52e-06	-0.4	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-6.03	3.37e-09	1.52e-06	-0.32	-0.27	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-6.03	3.37e-09	1.52e-06	-0.32	-0.27	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
HNSC	cis	rs9300255	0.596	rs10773002	ENSG00000280120.1	RP11-546D6.3	-6.03	3.38e-09	1.52e-06	-0.23	-0.27	Neutrophil percentage of white cells;	chr12:123262414	chr12:123152324~123153377:-
HNSC	cis	rs17214007	0.518	rs8047940	ENSG00000263335.1	AF001548.5	-6.03	3.38e-09	1.52e-06	-0.4	-0.27	Cognitive function;	chr16:15691787	chr16:15726674~15732993:+
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	-6.03	3.38e-09	1.53e-06	-0.3	-0.27	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
HNSC	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-6.03	3.38e-09	1.53e-06	-0.33	-0.27	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
HNSC	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-6.03	3.38e-09	1.53e-06	-0.34	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000224373.3	IGHV4-59	6.03	3.39e-09	1.53e-06	0.17	0.27	Kawasaki disease;	chr14:106656426	chr14:106627249~106627825:-
HNSC	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-6.03	3.39e-09	1.53e-06	-0.23	-0.27	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
HNSC	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-6.03	3.39e-09	1.53e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
HNSC	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-6.03	3.39e-09	1.53e-06	-0.37	-0.27	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
HNSC	cis	rs1012068	0.686	rs5998176	ENSG00000236132.1	CTA-440B3.1	-6.03	3.4e-09	1.53e-06	-0.31	-0.27	Chronic hepatitis C infection;	chr22:31922107	chr22:31816379~31817491:-
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000254340.1	RP11-10A14.3	-6.03	3.4e-09	1.53e-06	-0.33	-0.27	Joint mobility (Beighton score);	chr8:8935272	chr8:9141424~9145435:+
HNSC	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	6.03	3.4e-09	1.53e-06	0.25	0.27	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
HNSC	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	6.03	3.41e-09	1.54e-06	0.22	0.27	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
HNSC	cis	rs35955747	0.869	rs8141987	ENSG00000236132.1	CTA-440B3.1	6.03	3.42e-09	1.54e-06	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191169	chr22:31816379~31817491:-
HNSC	cis	rs35955747	0.869	rs8142988	ENSG00000236132.1	CTA-440B3.1	6.03	3.42e-09	1.54e-06	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191172	chr22:31816379~31817491:-
HNSC	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
HNSC	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	6.03	3.42e-09	1.54e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
HNSC	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-6.03	3.42e-09	1.54e-06	-0.37	-0.27	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
HNSC	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-6.03	3.43e-09	1.55e-06	-0.37	-0.27	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
HNSC	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-6.03	3.43e-09	1.55e-06	-0.33	-0.27	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
HNSC	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	6.03	3.43e-09	1.55e-06	0.34	0.27	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000173295.6	FAM86B3P	-6.03	3.43e-09	1.55e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9017276	chr8:8228595~8244865:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000254153.1	CTA-398F10.2	6.03	3.43e-09	1.55e-06	0.28	0.27	Neuroticism;	chr8:8460377	chr8:8456909~8461337:-
HNSC	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.02	3.44e-09	1.55e-06	-0.31	-0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
HNSC	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-6.02	3.44e-09	1.55e-06	-0.41	-0.27	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	6.02	3.44e-09	1.55e-06	0.33	0.27	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
HNSC	cis	rs2985684	1	rs8014170	ENSG00000258568.1	RHOQP1	6.02	3.44e-09	1.55e-06	0.28	0.27	Carotid intima media thickness;	chr14:49604976	chr14:49599994~49600572:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	6.02	3.45e-09	1.55e-06	0.25	0.27	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	6.02	3.45e-09	1.56e-06	0.21	0.27	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-6.02	3.46e-09	1.56e-06	-0.32	-0.27	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000173295.6	FAM86B3P	-6.02	3.46e-09	1.56e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9016136	chr8:8228595~8244865:+
HNSC	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-6.02	3.46e-09	1.56e-06	-0.33	-0.27	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
HNSC	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-6.02	3.47e-09	1.56e-06	-0.34	-0.27	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	6.02	3.47e-09	1.56e-06	0.21	0.27	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
HNSC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-6.02	3.48e-09	1.57e-06	-0.28	-0.27	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-6.02	3.48e-09	1.57e-06	-0.26	-0.27	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	6.02	3.49e-09	1.57e-06	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-6.02	3.5e-09	1.57e-06	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
HNSC	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-6.02	3.5e-09	1.57e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
HNSC	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-6.02	3.5e-09	1.58e-06	-0.24	-0.27	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
HNSC	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	6.02	3.5e-09	1.58e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
HNSC	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-6.02	3.51e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
HNSC	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-6.02	3.51e-09	1.58e-06	-0.36	-0.27	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
HNSC	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.51e-09	1.58e-06	-0.35	-0.27	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
HNSC	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-6.02	3.51e-09	1.58e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
HNSC	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	6.02	3.52e-09	1.58e-06	0.37	0.27	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000173295.6	FAM86B3P	6.02	3.52e-09	1.58e-06	0.3	0.27	Neuroticism;	chr8:8866141	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	6.02	3.52e-09	1.58e-06	0.33	0.27	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-6.02	3.52e-09	1.58e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
HNSC	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-6.02	3.53e-09	1.59e-06	-0.3	-0.27	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	6.02	3.53e-09	1.59e-06	0.21	0.27	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-6.02	3.54e-09	1.59e-06	-0.32	-0.27	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-6.02	3.54e-09	1.59e-06	-0.32	-0.27	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-6.02	3.54e-09	1.59e-06	-0.18	-0.27	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
HNSC	cis	rs8177876	0.731	rs4889227	ENSG00000261061.1	RP11-303E16.2	6.02	3.54e-09	1.59e-06	0.42	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81030770~81031485:+
HNSC	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	6.02	3.54e-09	1.59e-06	0.25	0.27	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
HNSC	cis	rs8177876	0.658	rs12444747	ENSG00000261061.1	RP11-303E16.2	-6.02	3.55e-09	1.6e-06	-0.5	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81030770~81031485:+
HNSC	cis	rs1355223	0.902	rs34751755	ENSG00000271369.1	RP11-350D17.3	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34672696	chr11:34709600~34710161:+
HNSC	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-6.02	3.56e-09	1.6e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	6.02	3.56e-09	1.6e-06	0.35	0.27	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	6.02	3.56e-09	1.6e-06	0.35	0.27	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-6.02	3.56e-09	1.6e-06	-0.31	-0.27	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
HNSC	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-6.02	3.56e-09	1.6e-06	-0.33	-0.27	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
HNSC	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-6.02	3.57e-09	1.6e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-6.02	3.58e-09	1.61e-06	-0.35	-0.27	Depression;	chr6:28187640	chr6:28943877~28944537:+
HNSC	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	6.02	3.58e-09	1.61e-06	0.3	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	6.02	3.58e-09	1.61e-06	0.3	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
HNSC	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.02	3.58e-09	1.61e-06	0.3	0.27	Depression;	chr6:28273214	chr6:28176188~28176674:+
HNSC	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.02	3.58e-09	1.61e-06	0.3	0.27	Depression;	chr6:28273215	chr6:28176188~28176674:+
HNSC	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.02	3.58e-09	1.61e-06	0.39	0.27	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
HNSC	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-6.02	3.59e-09	1.61e-06	-0.32	-0.27	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-6.02	3.59e-09	1.61e-06	-0.18	-0.27	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
HNSC	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	6.02	3.6e-09	1.62e-06	0.31	0.27	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	6.02	3.6e-09	1.62e-06	0.38	0.27	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-6.02	3.6e-09	1.62e-06	-0.17	-0.27	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	6.02	3.61e-09	1.62e-06	0.32	0.27	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
HNSC	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.61e-09	1.62e-06	-0.34	-0.27	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
HNSC	cis	rs189798	0.807	rs12785	ENSG00000173295.6	FAM86B3P	6.02	3.61e-09	1.62e-06	0.33	0.27	Myopia (pathological);	chr8:9137426	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-6.02	3.61e-09	1.62e-06	-0.32	-0.27	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	6.02	3.61e-09	1.62e-06	0.35	0.27	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-6.02	3.62e-09	1.62e-06	-0.25	-0.27	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
HNSC	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-6.02	3.62e-09	1.63e-06	-0.34	-0.27	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
HNSC	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	6.02	3.62e-09	1.63e-06	0.3	0.27	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
HNSC	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-6.02	3.62e-09	1.63e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
HNSC	cis	rs440932	1	rs365309	ENSG00000173295.6	FAM86B3P	-6.02	3.63e-09	1.63e-06	-0.32	-0.27	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8228595~8244865:+
HNSC	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	6.02	3.63e-09	1.63e-06	0.39	0.27	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	6.02	3.63e-09	1.63e-06	0.21	0.27	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
HNSC	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-6.02	3.63e-09	1.63e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
HNSC	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-6.01	3.64e-09	1.63e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	-6.01	3.65e-09	1.64e-06	-0.31	-0.27	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
HNSC	cis	rs831571	0.649	rs831556	ENSG00000280620.1	SCAANT1	-6.01	3.65e-09	1.64e-06	-0.37	-0.27	Type 2 diabetes;	chr3:64036017	chr3:63911518~63911772:-
HNSC	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-6.01	3.65e-09	1.64e-06	-0.33	-0.27	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
HNSC	cis	rs867371	0.614	rs1814739	ENSG00000255769.6	GOLGA2P10	-6.01	3.65e-09	1.64e-06	-0.37	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82472993~82513950:-
HNSC	cis	rs6918586	0.658	rs198840	ENSG00000272462.2	U91328.19	-6.01	3.65e-09	1.64e-06	-0.25	-0.27	Schizophrenia;	chr6:26111936	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-6.01	3.66e-09	1.64e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
HNSC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.01	3.66e-09	1.64e-06	-0.29	-0.27	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
HNSC	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-6.01	3.66e-09	1.64e-06	-0.3	-0.27	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
HNSC	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	6.01	3.66e-09	1.64e-06	0.32	0.27	Height;	chr4:55460485	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	6.01	3.67e-09	1.65e-06	0.25	0.27	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	6.01	3.67e-09	1.65e-06	0.25	0.27	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
HNSC	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-6.01	3.67e-09	1.65e-06	-0.52	-0.27	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
HNSC	cis	rs9611519	0.78	rs2235849	ENSG00000235513.1	RP4-756G23.5	6.01	3.68e-09	1.65e-06	0.28	0.27	Neuroticism;	chr22:41257536	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	6.01	3.68e-09	1.65e-06	0.3	0.27	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-6.01	3.69e-09	1.65e-06	-0.18	-0.27	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-6.01	3.69e-09	1.65e-06	-0.18	-0.27	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
HNSC	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-6.01	3.69e-09	1.66e-06	-0.32	-0.27	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
HNSC	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-6.01	3.69e-09	1.66e-06	-0.34	-0.27	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
HNSC	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-6.01	3.7e-09	1.66e-06	-0.31	-0.27	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	6.01	3.7e-09	1.66e-06	0.18	0.27	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
HNSC	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-6.01	3.7e-09	1.66e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
HNSC	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-6.01	3.71e-09	1.66e-06	-0.39	-0.27	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.66e-06	0.36	0.27	Depression;	chr6:28193021	chr6:28943877~28944537:+
HNSC	cis	rs6918586	0.658	rs198843	ENSG00000272462.2	U91328.19	-6.01	3.72e-09	1.67e-06	-0.25	-0.27	Schizophrenia;	chr6:26110086	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.594	rs198842	ENSG00000272462.2	U91328.19	-6.01	3.72e-09	1.67e-06	-0.25	-0.27	Schizophrenia;	chr6:26111220	chr6:25992662~26001775:+
HNSC	cis	rs17270561	0.609	rs7746609	ENSG00000272462.2	U91328.19	6.01	3.72e-09	1.67e-06	0.27	0.27	Iron status biomarkers;	chr6:25727768	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-6.01	3.72e-09	1.67e-06	-0.36	-0.27	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
HNSC	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-6.01	3.73e-09	1.67e-06	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
HNSC	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	6.01	3.74e-09	1.67e-06	0.3	0.27	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
HNSC	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	6.01	3.74e-09	1.67e-06	0.33	0.27	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
HNSC	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-6.01	3.74e-09	1.67e-06	-0.39	-0.27	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
HNSC	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-6.01	3.74e-09	1.68e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
HNSC	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.01	3.74e-09	1.68e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-6.01	3.75e-09	1.68e-06	-0.4	-0.27	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
HNSC	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-6.01	3.75e-09	1.68e-06	-0.29	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
HNSC	cis	rs8054556	0.787	rs12935701	ENSG00000183604.13	SMG1P5	-6.01	3.75e-09	1.68e-06	-0.27	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30267553~30335374:-
HNSC	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-6.01	3.75e-09	1.68e-06	-0.22	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
HNSC	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-6.01	3.75e-09	1.68e-06	-0.22	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
HNSC	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	6.01	3.76e-09	1.68e-06	0.3	0.27	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
HNSC	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	6.01	3.76e-09	1.68e-06	0.36	0.27	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
HNSC	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	6.01	3.76e-09	1.68e-06	0.32	0.27	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
HNSC	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-6.01	3.76e-09	1.69e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000254340.1	RP11-10A14.3	-6.01	3.78e-09	1.69e-06	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:9141424~9145435:+
HNSC	cis	rs2337406	1	rs74090714	ENSG00000211974.3	IGHV2-70	-6.01	3.78e-09	1.69e-06	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106691225	chr14:106723574~106724093:-
HNSC	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-6.01	3.78e-09	1.69e-06	-0.3	-0.27	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
HNSC	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	6.01	3.78e-09	1.69e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
HNSC	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-6.01	3.78e-09	1.69e-06	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
HNSC	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	6.01	3.79e-09	1.7e-06	0.35	0.27	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
HNSC	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	6.01	3.79e-09	1.7e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
HNSC	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	6.01	3.79e-09	1.7e-06	0.37	0.27	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
HNSC	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-6.01	3.79e-09	1.7e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
HNSC	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	6.01	3.8e-09	1.7e-06	0.28	0.27	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
HNSC	cis	rs4218	0.543	rs4775110	ENSG00000259732.1	RP11-59H7.3	-6.01	3.8e-09	1.7e-06	-0.35	-0.27	Social communication problems;	chr15:59023685	chr15:59121034~59133250:+
HNSC	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
HNSC	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	6.01	3.8e-09	1.7e-06	0.36	0.27	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
HNSC	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	6.01	3.8e-09	1.7e-06	0.3	0.27	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
HNSC	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	6.01	3.8e-09	1.7e-06	0.35	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
HNSC	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	6.01	3.8e-09	1.7e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
HNSC	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	6.01	3.8e-09	1.7e-06	0.3	0.27	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
HNSC	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	6.01	3.8e-09	1.7e-06	0.37	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
HNSC	cis	rs9341808	0.714	rs9448911	ENSG00000272129.1	RP11-250B2.6	6.01	3.81e-09	1.7e-06	0.31	0.27	Sitting height ratio;	chr6:80204142	chr6:80355424~80356859:+
HNSC	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	6.01	3.81e-09	1.7e-06	0.38	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
HNSC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-6.01	3.81e-09	1.7e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	6.01	3.81e-09	1.7e-06	0.21	0.27	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
HNSC	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	6.01	3.81e-09	1.7e-06	0.34	0.27	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
HNSC	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-6.01	3.81e-09	1.71e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
HNSC	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	6.01	3.81e-09	1.71e-06	0.2	0.27	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
HNSC	cis	rs6918586	0.658	rs198809	ENSG00000272462.2	U91328.19	-6.01	3.82e-09	1.71e-06	-0.25	-0.27	Schizophrenia;	chr6:26128538	chr6:25992662~26001775:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-6.01	3.82e-09	1.71e-06	-0.32	-0.27	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
HNSC	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	6.01	3.82e-09	1.71e-06	0.34	0.27	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
HNSC	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	6.01	3.82e-09	1.71e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
HNSC	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-6.01	3.82e-09	1.71e-06	-0.4	-0.27	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
HNSC	cis	rs9341808	0.591	rs6454147	ENSG00000272129.1	RP11-250B2.6	6.01	3.82e-09	1.71e-06	0.31	0.27	Sitting height ratio;	chr6:80206611	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.628	rs9294172	ENSG00000272129.1	RP11-250B2.6	6.01	3.82e-09	1.71e-06	0.31	0.27	Sitting height ratio;	chr6:80208844	chr6:80355424~80356859:+
HNSC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-6.01	3.82e-09	1.71e-06	-0.31	-0.27	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
HNSC	cis	rs8177876	0.554	rs56286107	ENSG00000261061.1	RP11-303E16.2	-6.01	3.83e-09	1.71e-06	-0.5	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81030770~81031485:+
HNSC	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-6.01	3.83e-09	1.71e-06	-0.33	-0.27	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
HNSC	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-6.01	3.83e-09	1.71e-06	-0.34	-0.27	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-6.01	3.83e-09	1.71e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-6.01	3.84e-09	1.71e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
HNSC	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	6.01	3.85e-09	1.72e-06	0.29	0.27	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	6	3.85e-09	1.72e-06	0.31	0.27	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
HNSC	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-6	3.85e-09	1.72e-06	-0.37	-0.27	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
HNSC	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-6	3.85e-09	1.72e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	6	3.86e-09	1.72e-06	0.21	0.27	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
HNSC	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	6	3.86e-09	1.73e-06	0.38	0.27	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
HNSC	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	6	3.87e-09	1.73e-06	0.36	0.27	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
HNSC	cis	rs4639966	0.723	rs11217022	ENSG00000255422.1	AP002954.4	6	3.87e-09	1.73e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118770897	chr11:118704607~118750263:+
HNSC	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-6	3.87e-09	1.73e-06	-0.25	-0.27	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
HNSC	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-6	3.87e-09	1.73e-06	-0.32	-0.27	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
HNSC	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	6	3.88e-09	1.73e-06	0.35	0.27	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
HNSC	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
HNSC	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6	3.89e-09	1.74e-06	0.3	0.27	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
HNSC	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	6	3.89e-09	1.74e-06	0.33	0.27	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
HNSC	cis	rs6928977	0.675	rs6908428	ENSG00000217482.2	HMGB1P17	6	3.9e-09	1.74e-06	0.3	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135636086~135636713:-
HNSC	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	6	3.9e-09	1.74e-06	0.37	0.27	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
HNSC	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	6	3.91e-09	1.74e-06	0.31	0.27	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
HNSC	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	6	3.91e-09	1.74e-06	0.27	0.27	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
HNSC	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6	3.91e-09	1.75e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000211974.3	IGHV2-70	6	3.91e-09	1.75e-06	0.31	0.27	Alzheimer's disease (late onset);	chr14:106650277	chr14:106723574~106724093:-
HNSC	cis	rs6928977	0.896	rs2746429	ENSG00000234084.1	RP3-388E23.2	6	3.91e-09	1.75e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352146	chr6:135301568~135307158:+
HNSC	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	6	3.92e-09	1.75e-06	0.32	0.27	Height;	chr4:55527164	chr4:55363971~55395847:-
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000248787.1	RP11-666A20.4	-6	3.92e-09	1.75e-06	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125883117	chr3:125908005~125910272:-
HNSC	cis	rs4218	0.551	rs12906212	ENSG00000277144.1	RP11-59H7.4	-6	3.92e-09	1.75e-06	-0.37	-0.27	Social communication problems;	chr15:59070556	chr15:59115547~59116089:-
HNSC	cis	rs6604026	0.555	rs3790450	ENSG00000223787.2	RP4-593M8.1	6	3.93e-09	1.75e-06	0.36	0.27	Multiple sclerosis;	chr1:92625508	chr1:92580476~92580821:-
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-6	3.93e-09	1.75e-06	-0.4	-0.27	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
HNSC	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	6	3.93e-09	1.75e-06	0.25	0.27	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
HNSC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	6	3.94e-09	1.76e-06	0.3	0.27	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
HNSC	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	6	3.94e-09	1.76e-06	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
HNSC	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	6	3.94e-09	1.76e-06	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
HNSC	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	6	3.95e-09	1.76e-06	0.27	0.27	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
HNSC	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-6	3.95e-09	1.76e-06	-0.38	-0.27	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-6	3.95e-09	1.76e-06	-0.33	-0.27	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-6	3.95e-09	1.76e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
HNSC	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	6	3.96e-09	1.77e-06	0.33	0.27	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
HNSC	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6	3.96e-09	1.77e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
HNSC	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6	3.98e-09	1.77e-06	0.31	0.27	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
HNSC	cis	rs6918586	0.658	rs198844	ENSG00000272462.2	U91328.19	-6	3.98e-09	1.78e-06	-0.25	-0.27	Schizophrenia;	chr6:26108054	chr6:25992662~26001775:+
HNSC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-6	3.98e-09	1.78e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
HNSC	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-6	3.98e-09	1.78e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-6	3.98e-09	1.78e-06	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-6	3.99e-09	1.78e-06	-0.32	-0.27	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
HNSC	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	6	3.99e-09	1.78e-06	0.33	0.27	Height;	chr4:55532542	chr4:55387949~55388271:+
HNSC	cis	rs1355223	1	rs11604069	ENSG00000271369.1	RP11-350D17.3	-6	4e-09	1.78e-06	-0.31	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742704	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-6	4e-09	1.78e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
HNSC	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-6	4e-09	1.78e-06	-0.35	-0.27	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
HNSC	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	6	4e-09	1.78e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
HNSC	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-6	4e-09	1.78e-06	-0.26	-0.27	Height;	chr2:231541633	chr2:231508426~231514339:-
HNSC	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	6	4.01e-09	1.79e-06	0.35	0.27	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000267151.3	RP11-100E5.2	6	4.02e-09	1.79e-06	0.34	0.27	Menopause (age at onset);	chr17:43222443	chr17:43444707~43451200:+
HNSC	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	6	4.03e-09	1.8e-06	0.2	0.27	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
HNSC	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-6	4.03e-09	1.8e-06	-0.34	-0.27	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-6	4.03e-09	1.8e-06	-0.34	-0.27	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
HNSC	cis	rs17270561	0.609	rs1165211	ENSG00000272462.2	U91328.19	-6	4.04e-09	1.8e-06	-0.26	-0.27	Iron status biomarkers;	chr6:25800694	chr6:25992662~26001775:+
HNSC	cis	rs1021993	0.672	rs2843167	ENSG00000231648.1	RP11-372M18.2	-6	4.04e-09	1.8e-06	-0.33	-0.27	Gut microbiome composition (winter);	chr1:209339552	chr1:209367662~209379690:+
HNSC	cis	rs9907295	0.636	rs4251703	ENSG00000270977.1	AC015849.16	-6	4.04e-09	1.8e-06	-0.31	-0.27	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35893707~35911023:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-6	4.04e-09	1.8e-06	-0.41	-0.27	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
HNSC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-6	4.05e-09	1.8e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-6	4.05e-09	1.8e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
HNSC	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-6	4.05e-09	1.8e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
HNSC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	6	4.05e-09	1.8e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	6	4.05e-09	1.8e-06	0.21	0.27	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-6	4.05e-09	1.8e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	6	4.05e-09	1.81e-06	0.27	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
HNSC	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	6	4.05e-09	1.81e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
HNSC	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	6	4.06e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	6	4.07e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	6	4.07e-09	1.81e-06	0.25	0.27	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
HNSC	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-5.99	4.08e-09	1.81e-06	-0.41	-0.27	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
HNSC	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.36	0.27	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.36	0.27	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
HNSC	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-5.99	4.08e-09	1.82e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000254340.1	RP11-10A14.3	5.99	4.08e-09	1.82e-06	0.33	0.27	Mood instability;	chr8:8828344	chr8:9141424~9145435:+
HNSC	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	1.82e-06	0.3	0.27	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-5.99	4.08e-09	1.82e-06	-0.39	-0.27	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
HNSC	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	5.99	4.09e-09	1.82e-06	0.3	0.27	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
HNSC	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	5.99	4.09e-09	1.82e-06	0.35	0.27	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-5.99	4.09e-09	1.82e-06	-0.31	-0.27	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
HNSC	cis	rs6928977	0.675	rs7750586	ENSG00000234084.1	RP3-388E23.2	5.99	4.09e-09	1.82e-06	0.28	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135301568~135307158:+
HNSC	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.99	4.09e-09	1.82e-06	-0.39	-0.27	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-5.99	4.09e-09	1.82e-06	-0.32	-0.27	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	5.99	4.1e-09	1.82e-06	0.21	0.27	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	5.99	4.1e-09	1.82e-06	0.21	0.27	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
HNSC	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-5.99	4.1e-09	1.82e-06	-0.34	-0.27	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
HNSC	cis	rs7617773	0.501	rs12185901	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48341429	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs13082217	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48341774	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs11706939	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48342502	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs11130165	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48343231	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.539	rs1471217	ENSG00000228638.1	FCF1P2	-5.99	4.1e-09	1.82e-06	-0.24	-0.27	Coronary artery disease;	chr3:48343405	chr3:48290793~48291375:-
HNSC	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-5.99	4.1e-09	1.83e-06	-0.32	-0.27	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
HNSC	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	5.99	4.11e-09	1.83e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
HNSC	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-5.99	4.11e-09	1.83e-06	-0.48	-0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
HNSC	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-5.99	4.11e-09	1.83e-06	-0.32	-0.27	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	5.99	4.11e-09	1.83e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
HNSC	cis	rs2115630	1	rs2115630	ENSG00000229212.6	RP11-561C5.4	5.99	4.11e-09	1.83e-06	0.31	0.27	P wave terminal force;	chr15:84821285	chr15:85205440~85234795:-
HNSC	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-5.99	4.11e-09	1.83e-06	-0.41	-0.27	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
HNSC	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	5.99	4.11e-09	1.83e-06	0.37	0.27	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
HNSC	cis	rs6928977	0.896	rs2614259	ENSG00000234084.1	RP3-388E23.2	5.99	4.11e-09	1.83e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356114	chr6:135301568~135307158:+
HNSC	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	5.99	4.12e-09	1.83e-06	0.31	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
HNSC	cis	rs11992162	0.551	rs59191504	ENSG00000206014.6	OR7E161P	5.99	4.12e-09	1.83e-06	0.29	0.27	Monocyte count;	chr8:11927572	chr8:11928597~11929563:-
HNSC	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-5.99	4.12e-09	1.83e-06	-0.23	-0.27	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-5.99	4.12e-09	1.83e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
HNSC	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	5.99	4.12e-09	1.83e-06	0.29	0.27	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
HNSC	cis	rs11992162	0.56	rs13256329	ENSG00000206014.6	OR7E161P	5.99	4.13e-09	1.83e-06	0.29	0.27	Monocyte count;	chr8:11924705	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.638	rs67146188	ENSG00000206014.6	OR7E161P	5.99	4.13e-09	1.83e-06	0.29	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11928597~11929563:-
HNSC	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.99	4.13e-09	1.84e-06	0.3	0.27	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	5.99	4.13e-09	1.84e-06	0.43	0.27	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
HNSC	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	5.99	4.13e-09	1.84e-06	0.32	0.27	Height;	chr4:55493557	chr4:55363971~55395847:-
HNSC	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-5.99	4.14e-09	1.84e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000267151.3	RP11-100E5.2	5.99	4.14e-09	1.84e-06	0.35	0.27	Menopause (age at onset);	chr17:43042868	chr17:43444707~43451200:+
HNSC	cis	rs853679	1	rs6905391	ENSG00000219392.1	RP1-265C24.5	-5.99	4.14e-09	1.84e-06	-0.4	-0.27	Depression;	chr6:28294909	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.896	rs9321501	ENSG00000234084.1	RP3-388E23.2	5.99	4.15e-09	1.84e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-5.99	4.15e-09	1.84e-06	-0.32	-0.27	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
HNSC	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-5.99	4.15e-09	1.84e-06	-0.33	-0.27	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
HNSC	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	5.99	4.15e-09	1.85e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000173295.6	FAM86B3P	-5.99	4.16e-09	1.85e-06	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9012868	chr8:8228595~8244865:+
HNSC	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-5.99	4.16e-09	1.85e-06	-0.47	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
HNSC	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	5.99	4.16e-09	1.85e-06	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
HNSC	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-5.99	4.16e-09	1.85e-06	-0.25	-0.27	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
HNSC	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.99	4.17e-09	1.85e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.99	4.17e-09	1.85e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
HNSC	cis	rs2235642	0.653	rs7197288	ENSG00000280231.1	LA16c-380F5.3	-5.99	4.17e-09	1.85e-06	-0.33	-0.27	Coronary artery disease;	chr16:1604752	chr16:1553655~1554130:-
HNSC	cis	rs11992162	0.508	rs7003792	ENSG00000206014.6	OR7E161P	5.99	4.17e-09	1.85e-06	0.29	0.27	Monocyte count;	chr8:11923955	chr8:11928597~11929563:-
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.85e-06	0.36	0.27	Depression;	chr6:28205175	chr6:28943877~28944537:+
HNSC	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-5.99	4.18e-09	1.86e-06	-0.38	-0.27	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
HNSC	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.99	4.18e-09	1.86e-06	0.34	0.27	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
HNSC	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	5.99	4.18e-09	1.86e-06	0.27	0.27	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
HNSC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	5.99	4.19e-09	1.86e-06	0.3	0.27	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
HNSC	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	5.99	4.19e-09	1.86e-06	0.32	0.27	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
HNSC	cis	rs4218	0.597	rs12438111	ENSG00000259732.1	RP11-59H7.3	-5.99	4.2e-09	1.86e-06	-0.37	-0.27	Social communication problems;	chr15:59057540	chr15:59121034~59133250:+
HNSC	cis	rs2115630	1	rs2879828	ENSG00000229212.6	RP11-561C5.4	5.99	4.22e-09	1.87e-06	0.31	0.27	P wave terminal force;	chr15:84818746	chr15:85205440~85234795:-
HNSC	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.99	4.22e-09	1.87e-06	0.3	0.27	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
HNSC	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-5.99	4.22e-09	1.87e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-5.99	4.22e-09	1.87e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
HNSC	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	5.99	4.22e-09	1.87e-06	0.41	0.27	Height;	chr6:109409645	chr6:109382795~109383666:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	-5.99	4.23e-09	1.87e-06	-0.29	-0.27	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-5.99	4.23e-09	1.87e-06	-0.32	-0.27	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
HNSC	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	5.99	4.23e-09	1.88e-06	0.36	0.27	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
HNSC	cis	rs6928977	0.896	rs2064431	ENSG00000234084.1	RP3-388E23.2	5.99	4.23e-09	1.88e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135301568~135307158:+
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-5.99	4.24e-09	1.88e-06	-0.31	-0.27	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
HNSC	cis	rs4639966	0.684	rs487177	ENSG00000255422.1	AP002954.4	5.99	4.24e-09	1.88e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118786588	chr11:118704607~118750263:+
HNSC	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	5.99	4.24e-09	1.88e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
HNSC	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-5.99	4.24e-09	1.88e-06	-0.39	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
HNSC	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-5.99	4.25e-09	1.88e-06	-0.32	-0.27	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-5.99	4.25e-09	1.88e-06	-0.32	-0.27	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
HNSC	cis	rs9300255	0.568	rs3018098	ENSG00000280120.1	RP11-546D6.3	5.99	4.25e-09	1.88e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123170265	chr12:123152324~123153377:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-5.99	4.25e-09	1.88e-06	-0.39	-0.27	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
HNSC	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	5.99	4.25e-09	1.88e-06	0.3	0.27	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
HNSC	cis	rs6928977	0.675	rs12206850	ENSG00000234084.1	RP3-388E23.2	-5.99	4.25e-09	1.88e-06	-0.28	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135301568~135307158:+
HNSC	cis	rs465969	0.744	rs34659678	ENSG00000255389.1	C6orf3	-5.99	4.26e-09	1.88e-06	-0.5	-0.27	Psoriasis;	chr6:111567337	chr6:111599875~111602295:+
HNSC	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
HNSC	cis	rs6918586	0.658	rs198803	ENSG00000272462.2	U91328.19	-5.99	4.26e-09	1.89e-06	-0.25	-0.27	Schizophrenia;	chr6:26134824	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	5.99	4.26e-09	1.89e-06	0.36	0.27	Depression;	chr6:28197321	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	5.99	4.26e-09	1.89e-06	0.36	0.27	Depression;	chr6:28197412	chr6:28943877~28944537:+
HNSC	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-5.99	4.26e-09	1.89e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
HNSC	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-5.99	4.26e-09	1.89e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
HNSC	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	5.99	4.26e-09	1.89e-06	0.36	0.27	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
HNSC	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-5.99	4.27e-09	1.89e-06	-0.38	-0.27	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
HNSC	cis	rs2985684	0.948	rs12897941	ENSG00000258568.1	RHOQP1	5.99	4.28e-09	1.9e-06	0.27	0.27	Carotid intima media thickness;	chr14:49549983	chr14:49599994~49600572:+
HNSC	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-5.99	4.28e-09	1.9e-06	-0.33	-0.27	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-5.99	4.28e-09	1.9e-06	-0.33	-0.27	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
HNSC	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	5.99	4.28e-09	1.9e-06	0.28	0.27	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
HNSC	cis	rs35955747	0.777	rs5997895	ENSG00000236132.1	CTA-440B3.1	5.99	4.29e-09	1.9e-06	0.28	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31170187	chr22:31816379~31817491:-
HNSC	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-5.99	4.3e-09	1.9e-06	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
HNSC	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-5.99	4.3e-09	1.9e-06	-0.47	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
HNSC	cis	rs11846409	1	rs11846409	ENSG00000211974.3	IGHV2-70	-5.99	4.3e-09	1.9e-06	-0.31	-0.27	Rheumatic heart disease;	chr14:106645692	chr14:106723574~106724093:-
HNSC	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	5.99	4.31e-09	1.91e-06	0.37	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	5.99	4.31e-09	1.91e-06	0.37	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
HNSC	cis	rs6471393	0.861	rs2976372	ENSG00000253848.1	RP11-10N23.5	-5.99	4.31e-09	1.91e-06	-0.34	-0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93690797	chr8:93741193~93744534:+
HNSC	cis	rs9300255	0.602	rs1727306	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123181148	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.512	rs2851436	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123182807	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs1716157	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123185926	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs10772995	ENSG00000280120.1	RP11-546D6.3	5.99	4.31e-09	1.91e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123187214	chr12:123152324~123153377:-
HNSC	cis	rs4218	0.619	rs10851643	ENSG00000259732.1	RP11-59H7.3	-5.99	4.31e-09	1.91e-06	-0.35	-0.27	Social communication problems;	chr15:59102985	chr15:59121034~59133250:+
HNSC	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	5.98	4.32e-09	1.91e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000173295.6	FAM86B3P	-5.98	4.32e-09	1.91e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9035087	chr8:8228595~8244865:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-5.98	4.32e-09	1.91e-06	-0.31	-0.27	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	5.98	4.33e-09	1.91e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
HNSC	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	5.98	4.33e-09	1.92e-06	0.34	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
HNSC	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	5.98	4.33e-09	1.92e-06	0.36	0.27	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	5.98	4.34e-09	1.92e-06	0.32	0.27	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
HNSC	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	5.98	4.34e-09	1.92e-06	0.38	0.27	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
HNSC	cis	rs7209700	0.662	rs11656865	ENSG00000228782.6	CTD-2026D20.3	-5.98	4.34e-09	1.92e-06	-0.28	-0.27	IgG glycosylation;	chr17:47269123	chr17:47450568~47492492:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	5.98	4.34e-09	1.92e-06	0.3	0.27	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
HNSC	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-5.98	4.34e-09	1.92e-06	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
HNSC	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	5.98	4.34e-09	1.92e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000254340.1	RP11-10A14.3	-5.98	4.35e-09	1.92e-06	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9226261	chr8:9141424~9145435:+
HNSC	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.98	4.36e-09	1.93e-06	-0.39	-0.27	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
HNSC	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-5.98	4.36e-09	1.93e-06	-0.33	-0.27	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
HNSC	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-5.98	4.36e-09	1.93e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
HNSC	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	5.98	4.37e-09	1.93e-06	0.3	0.27	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
HNSC	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	5.98	4.37e-09	1.93e-06	0.31	0.27	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
HNSC	cis	rs1865760	0.593	rs3903852	ENSG00000272462.2	U91328.19	-5.98	4.38e-09	1.94e-06	-0.25	-0.27	Height;	chr6:25914919	chr6:25992662~26001775:+
HNSC	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	5.98	4.38e-09	1.94e-06	0.34	0.27	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000211974.3	IGHV2-70	-5.98	4.39e-09	1.94e-06	-0.3	-0.27	Rheumatic heart disease;	chr14:106637687	chr14:106723574~106724093:-
HNSC	cis	rs11154801	0.696	rs4432992	ENSG00000217482.2	HMGB1P17	5.98	4.39e-09	1.94e-06	0.31	0.27	Multiple sclerosis;	chr6:135612356	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs13132420	ENSG00000273257.1	RP11-177J6.1	-5.98	4.39e-09	1.94e-06	-0.32	-0.27	Height;	chr4:55526646	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	5.98	4.4e-09	1.94e-06	0.32	0.27	Height;	chr4:55387515	chr4:55387949~55388271:+
HNSC	cis	rs7674212	0.537	rs2623060	ENSG00000246560.2	RP11-10L12.4	5.98	4.4e-09	1.94e-06	0.3	0.27	Type 2 diabetes;	chr4:103126347	chr4:102828055~102844075:+
HNSC	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-5.98	4.4e-09	1.94e-06	-0.38	-0.27	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-5.98	4.41e-09	1.95e-06	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
HNSC	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	5.98	4.41e-09	1.95e-06	0.39	0.27	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
HNSC	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	5.98	4.41e-09	1.95e-06	0.39	0.27	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
HNSC	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.98	4.41e-09	1.95e-06	-0.33	-0.27	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-5.98	4.41e-09	1.95e-06	-0.33	-0.27	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.41e-09	1.95e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
HNSC	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-5.98	4.42e-09	1.95e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-5.98	4.42e-09	1.95e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
HNSC	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.98	4.42e-09	1.95e-06	0.38	0.27	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
HNSC	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-5.98	4.42e-09	1.95e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
HNSC	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-5.98	4.43e-09	1.95e-06	-0.38	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
HNSC	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-5.98	4.43e-09	1.95e-06	-0.38	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
HNSC	cis	rs7402982	0.625	rs4966009	ENSG00000278022.1	RP11-35O15.2	-5.98	4.43e-09	1.96e-06	-0.31	-0.27	Birth weight;	chr15:98660267	chr15:98660210~98660668:+
HNSC	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-5.98	4.43e-09	1.96e-06	-0.34	-0.27	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
HNSC	cis	rs17270561	0.583	rs7749149	ENSG00000272462.2	U91328.19	-5.98	4.43e-09	1.96e-06	-0.27	-0.27	Iron status biomarkers;	chr6:25780911	chr6:25992662~26001775:+
HNSC	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-5.98	4.44e-09	1.96e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
HNSC	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.98	4.45e-09	1.96e-06	0.41	0.27	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
HNSC	cis	rs13126694	0.744	rs10005901	ENSG00000248429.4	RP11-597D13.9	5.98	4.45e-09	1.96e-06	0.3	0.27	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158170752~158202877:+
HNSC	cis	rs860295	0.871	rs6688636	ENSG00000203761.5	MSTO2P	5.98	4.45e-09	1.97e-06	0.2	0.27	Body mass index;	chr1:155509106	chr1:155745829~155750137:+
HNSC	cis	rs4639966	0.756	rs61219050	ENSG00000255422.1	AP002954.4	5.98	4.46e-09	1.97e-06	0.37	0.27	Systemic lupus erythematosus;	chr11:118777915	chr11:118704607~118750263:+
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000173295.6	FAM86B3P	-5.98	4.47e-09	1.97e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9012154	chr8:8228595~8244865:+
HNSC	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-5.98	4.48e-09	1.98e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
HNSC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.98	4.48e-09	1.98e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000211974.3	IGHV2-70	-5.98	4.49e-09	1.98e-06	-0.32	-0.27	Alzheimer's disease (late onset);	chr14:106786097	chr14:106723574~106724093:-
HNSC	cis	rs947583	0.588	rs6925090	ENSG00000217482.2	HMGB1P17	5.98	4.49e-09	1.98e-06	0.29	0.27	Phosphorus levels;	chr6:135795339	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	5.98	4.49e-09	1.98e-06	0.33	0.27	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-5.98	4.5e-09	1.98e-06	-0.21	-0.27	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
HNSC	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	5.98	4.5e-09	1.98e-06	0.29	0.27	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs981792	ENSG00000221740.1	SNORD93	5.98	4.5e-09	1.98e-06	0.29	0.27	Fibrinogen;	chr7:22822020	chr7:22856613~22856686:+
HNSC	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.5e-09	1.99e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
HNSC	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	5.98	4.51e-09	1.99e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	5.98	4.51e-09	1.99e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
HNSC	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-5.98	4.51e-09	1.99e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
HNSC	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	5.98	4.51e-09	1.99e-06	0.3	0.27	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
HNSC	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-5.98	4.51e-09	1.99e-06	-0.33	-0.27	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
HNSC	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-5.98	4.52e-09	1.99e-06	-0.32	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
HNSC	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	5.98	4.52e-09	1.99e-06	0.29	0.27	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
HNSC	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	5.98	4.53e-09	2e-06	0.3	0.27	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
HNSC	cis	rs9326248	0.53	rs10732856	ENSG00000280143.1	AP000892.6	5.98	4.54e-09	2e-06	0.4	0.27	Blood protein levels;	chr11:117036397	chr11:117204967~117210292:+
HNSC	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	5.98	4.54e-09	2e-06	0.35	0.27	Height;	chr6:109350642	chr6:109382795~109383666:+
HNSC	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	5.98	4.54e-09	2e-06	0.28	0.27	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	5.98	4.55e-09	2e-06	0.21	0.27	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
HNSC	cis	rs17270561	0.609	rs1165208	ENSG00000272462.2	U91328.19	-5.98	4.55e-09	2.01e-06	-0.26	-0.27	Iron status biomarkers;	chr6:25803676	chr6:25992662~26001775:+
HNSC	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-5.98	4.56e-09	2.01e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-5.98	4.56e-09	2.01e-06	-0.37	-0.27	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
HNSC	cis	rs13113518	0.812	rs2035692	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55528801	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs4507426	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55529387	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	5.98	4.56e-09	2.01e-06	0.33	0.27	Height;	chr4:55529786	chr4:55387949~55388271:+
HNSC	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-5.98	4.56e-09	2.01e-06	-0.36	-0.27	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
HNSC	cis	rs9525927	0.625	rs9533801	ENSG00000227258.4	SMIM2-AS1	5.98	4.56e-09	2.01e-06	0.4	0.27	Dupuytren's disease;	chr13:44242433	chr13:44110451~44240517:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-5.97	4.57e-09	2.01e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
HNSC	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	5.97	4.57e-09	2.02e-06	0.27	0.27	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000211972.2	IGHV3-66	5.97	4.57e-09	2.02e-06	0.21	0.27	Kawasaki disease;	chr14:106716993	chr14:106675017~106675544:-
HNSC	cis	rs6504622	1	rs4968286	ENSG00000262879.4	RP11-156P1.3	-5.97	4.58e-09	2.02e-06	-0.29	-0.27	Orofacial clefts;	chr17:46940279	chr17:46984045~47100323:-
HNSC	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	5.97	4.58e-09	2.02e-06	0.33	0.27	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	5.97	4.58e-09	2.02e-06	0.33	0.27	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
HNSC	cis	rs6951245	0.572	rs75818004	ENSG00000224079.1	AC091729.7	-5.97	4.59e-09	2.02e-06	-0.57	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1007936	chr7:1074450~1078036:+
HNSC	cis	rs6951245	0.572	rs75083636	ENSG00000224079.1	AC091729.7	-5.97	4.59e-09	2.02e-06	-0.57	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1011164	chr7:1074450~1078036:+
HNSC	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	5.97	4.59e-09	2.02e-06	0.43	0.27	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
HNSC	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	5.97	4.59e-09	2.02e-06	0.3	0.27	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
HNSC	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	5.97	4.59e-09	2.02e-06	0.27	0.27	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
HNSC	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.59e-09	2.02e-06	-0.32	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-5.97	4.59e-09	2.02e-06	-0.31	-0.27	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
HNSC	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	5.97	4.59e-09	2.02e-06	0.3	0.27	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
HNSC	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-5.97	4.6e-09	2.02e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
HNSC	cis	rs6928977	0.896	rs1012645	ENSG00000234084.1	RP3-388E23.2	5.97	4.6e-09	2.02e-06	0.27	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135301568~135307158:+
HNSC	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	5.97	4.6e-09	2.02e-06	0.29	0.27	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
HNSC	cis	rs7819412	0.811	rs2409691	ENSG00000269918.1	AF131215.9	-5.97	4.61e-09	2.03e-06	-0.26	-0.27	Triglycerides;	chr8:11085766	chr8:11104691~11106704:-
HNSC	cis	rs9341808	0.558	rs3805911	ENSG00000272129.1	RP11-250B2.6	5.97	4.61e-09	2.03e-06	0.31	0.27	Sitting height ratio;	chr6:80224279	chr6:80355424~80356859:+
HNSC	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	5.97	4.61e-09	2.03e-06	0.32	0.27	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
HNSC	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.97	4.62e-09	2.03e-06	0.28	0.27	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
HNSC	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	5.97	4.63e-09	2.04e-06	0.28	0.27	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
HNSC	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	5.97	4.65e-09	2.04e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
HNSC	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	5.97	4.65e-09	2.05e-06	0.28	0.27	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
HNSC	cis	rs2834288	0.7	rs2834298	ENSG00000237945.6	LINC00649	-5.97	4.65e-09	2.05e-06	-0.34	-0.27	Gut microbiota (bacterial taxa);	chr21:33911251	chr21:33915534~33977691:+
HNSC	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	5.97	4.66e-09	2.05e-06	0.34	0.27	Height;	chr4:55566291	chr4:55363971~55395847:-
HNSC	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-5.97	4.66e-09	2.05e-06	-0.32	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
HNSC	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-5.97	4.67e-09	2.05e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
HNSC	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	5.97	4.67e-09	2.05e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
HNSC	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	5.97	4.67e-09	2.05e-06	0.74	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
HNSC	cis	rs2985684	0.948	rs12886130	ENSG00000258568.1	RHOQP1	5.97	4.67e-09	2.05e-06	0.28	0.27	Carotid intima media thickness;	chr14:49616035	chr14:49599994~49600572:+
HNSC	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-5.97	4.68e-09	2.06e-06	-0.36	-0.27	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
HNSC	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	5.97	4.68e-09	2.06e-06	0.32	0.27	Height;	chr4:55561053	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	5.97	4.68e-09	2.06e-06	0.32	0.27	Height;	chr4:55564241	chr4:55363971~55395847:-
HNSC	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-5.97	4.68e-09	2.06e-06	-0.29	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
HNSC	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	5.97	4.68e-09	2.06e-06	0.32	0.27	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	5.97	4.68e-09	2.06e-06	0.32	0.27	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
HNSC	cis	rs1799949	1	rs35070007	ENSG00000267151.3	RP11-100E5.2	-5.97	4.68e-09	2.06e-06	-0.34	-0.27	Menopause (age at onset);	chr17:43164730	chr17:43444707~43451200:+
HNSC	cis	rs710913	0.966	rs3738676	ENSG00000182109.6	RP11-69E11.4	5.97	4.68e-09	2.06e-06	0.26	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39522280~39546187:-
HNSC	cis	rs4218	0.635	rs10431792	ENSG00000259732.1	RP11-59H7.3	-5.97	4.68e-09	2.06e-06	-0.37	-0.27	Social communication problems;	chr15:59066181	chr15:59121034~59133250:+
HNSC	cis	rs9341808	0.667	rs3805913	ENSG00000272129.1	RP11-250B2.6	5.97	4.69e-09	2.06e-06	0.31	0.27	Sitting height ratio;	chr6:80217605	chr6:80355424~80356859:+
HNSC	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	5.97	4.69e-09	2.06e-06	0.3	0.27	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
HNSC	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	5.97	4.69e-09	2.06e-06	0.29	0.27	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
HNSC	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-5.97	4.69e-09	2.06e-06	-0.3	-0.27	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
HNSC	cis	rs11992162	0.967	rs10088415	ENSG00000206014.6	OR7E161P	5.97	4.7e-09	2.06e-06	0.28	0.27	Monocyte count;	chr8:11973316	chr8:11928597~11929563:-
HNSC	cis	rs7804306	0.826	rs73049252	ENSG00000233264.2	AC006042.8	5.97	4.7e-09	2.06e-06	0.6	0.27	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7976971	chr7:7980312~7982228:+
HNSC	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	5.97	4.7e-09	2.07e-06	0.21	0.27	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	5.97	4.7e-09	2.07e-06	0.34	0.27	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	5.97	4.71e-09	2.07e-06	0.41	0.27	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
HNSC	cis	rs1865760	0.593	rs9393676	ENSG00000272462.2	U91328.19	-5.97	4.71e-09	2.07e-06	-0.25	-0.27	Height;	chr6:25936716	chr6:25992662~26001775:+
HNSC	cis	rs1865760	0.593	rs9295678	ENSG00000272462.2	U91328.19	-5.97	4.71e-09	2.07e-06	-0.25	-0.27	Height;	chr6:25936805	chr6:25992662~26001775:+
HNSC	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	5.97	4.72e-09	2.07e-06	0.3	0.27	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
HNSC	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-5.97	4.72e-09	2.07e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.97	4.72e-09	2.07e-06	-0.31	-0.27	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	5.97	4.72e-09	2.07e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
HNSC	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-5.97	4.73e-09	2.08e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
HNSC	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	5.97	4.73e-09	2.08e-06	0.35	0.27	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
HNSC	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-5.97	4.73e-09	2.08e-06	-0.34	-0.27	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
HNSC	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-5.97	4.73e-09	2.08e-06	-0.31	-0.27	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
HNSC	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-5.97	4.73e-09	2.08e-06	-0.37	-0.27	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
HNSC	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	5.97	4.74e-09	2.08e-06	0.35	0.27	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
HNSC	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	5.97	4.75e-09	2.08e-06	0.31	0.27	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
HNSC	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	5.97	4.75e-09	2.08e-06	0.31	0.27	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
HNSC	cis	rs1021993	0.672	rs1876409	ENSG00000231648.1	RP11-372M18.2	5.97	4.75e-09	2.09e-06	0.34	0.27	Gut microbiome composition (winter);	chr1:209307758	chr1:209367662~209379690:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-5.97	4.75e-09	2.09e-06	-0.29	-0.27	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
HNSC	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	5.97	4.76e-09	2.09e-06	0.3	0.27	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
HNSC	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	5.97	4.76e-09	2.09e-06	0.24	0.27	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
HNSC	cis	rs6951245	0.572	rs79396168	ENSG00000224079.1	AC091729.7	-5.97	4.76e-09	2.09e-06	-0.56	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1009292	chr7:1074450~1078036:+
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000254340.1	RP11-10A14.3	5.97	4.77e-09	2.09e-06	0.33	0.27	Mood instability;	chr8:8846820	chr8:9141424~9145435:+
HNSC	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	5.97	4.77e-09	2.09e-06	0.31	0.27	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
HNSC	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	5.97	4.77e-09	2.09e-06	0.22	0.27	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
HNSC	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	5.97	4.78e-09	2.1e-06	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
HNSC	cis	rs17772222	0.582	rs11625009	ENSG00000258789.1	RP11-507K2.3	5.97	4.78e-09	2.1e-06	0.3	0.27	Coronary artery calcification;	chr14:88521018	chr14:88551597~88552493:+
HNSC	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	5.97	4.79e-09	2.1e-06	0.36	0.27	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
HNSC	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	5.97	4.81e-09	2.11e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.97	4.81e-09	2.11e-06	-0.32	-0.27	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000276710.3	CSPG4P8	-5.97	4.82e-09	2.11e-06	-0.28	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82459472~82477258:+
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000211970.3	IGHV4-61	-5.97	4.83e-09	2.12e-06	-0.18	-0.27	Kawasaki disease;	chr14:106711838	chr14:106639119~106639657:-
HNSC	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	5.97	4.83e-09	2.12e-06	0.34	0.27	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
HNSC	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.97	4.83e-09	2.12e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
HNSC	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	5.96	4.84e-09	2.12e-06	0.32	0.27	Height;	chr4:55489895	chr4:55363971~55395847:-
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-5.96	4.84e-09	2.12e-06	-0.38	-0.27	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
HNSC	cis	rs9326248	0.569	rs11216161	ENSG00000280143.1	AP000892.6	5.96	4.85e-09	2.12e-06	0.37	0.27	Blood protein levels;	chr11:116850485	chr11:117204967~117210292:+
HNSC	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	5.96	4.85e-09	2.13e-06	0.31	0.27	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
HNSC	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-5.96	4.85e-09	2.13e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-5.96	4.85e-09	2.13e-06	-0.39	-0.27	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
HNSC	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	5.96	4.85e-09	2.13e-06	0.35	0.27	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
HNSC	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-5.96	4.85e-09	2.13e-06	-0.27	-0.27	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
HNSC	cis	rs2286503	0.78	rs1304431	ENSG00000221740.1	SNORD93	5.96	4.85e-09	2.13e-06	0.29	0.27	Fibrinogen;	chr7:22825793	chr7:22856613~22856686:+
HNSC	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	5.96	4.86e-09	2.13e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
HNSC	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	5.96	4.86e-09	2.13e-06	0.45	0.27	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-5.96	4.86e-09	2.13e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
HNSC	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-5.96	4.87e-09	2.13e-06	-0.33	-0.27	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	5.96	4.87e-09	2.13e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
HNSC	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-5.96	4.87e-09	2.13e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	5.96	4.88e-09	2.14e-06	0.21	0.27	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.932	rs6931735	ENSG00000234084.1	RP3-388E23.2	-5.96	4.88e-09	2.14e-06	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135301568~135307158:+
HNSC	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	5.96	4.88e-09	2.14e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	5.96	4.88e-09	2.14e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
HNSC	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-5.96	4.9e-09	2.15e-06	-0.33	-0.27	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
HNSC	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-5.96	4.9e-09	2.15e-06	-0.33	-0.27	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
HNSC	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	5.96	4.9e-09	2.15e-06	0.23	0.27	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
HNSC	cis	rs7824557	0.524	rs7835318	ENSG00000269918.1	AF131215.9	-5.96	4.91e-09	2.15e-06	-0.26	-0.27	Retinal vascular caliber;	chr8:11096364	chr8:11104691~11106704:-
HNSC	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	5.96	4.92e-09	2.15e-06	0.33	0.27	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
HNSC	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-5.96	4.92e-09	2.16e-06	-0.37	-0.27	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.675	rs6908428	ENSG00000234084.1	RP3-388E23.2	-5.96	4.92e-09	2.16e-06	-0.27	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135301568~135307158:+
HNSC	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	5.96	4.93e-09	2.16e-06	0.33	0.27	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
HNSC	cis	rs116095464	1	rs3777237	ENSG00000277812.1	AC021087.1	5.96	4.93e-09	2.16e-06	0.63	0.27	Breast cancer;	chr5:307526	chr5:262769~262881:+
HNSC	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.96	4.94e-09	2.16e-06	-0.34	-0.27	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
HNSC	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-5.96	4.94e-09	2.16e-06	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	5.96	4.94e-09	2.16e-06	0.3	0.27	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	5.96	4.94e-09	2.16e-06	0.33	0.27	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
HNSC	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	5.96	4.95e-09	2.16e-06	0.31	0.27	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	5.96	4.95e-09	2.16e-06	0.31	0.27	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
HNSC	cis	rs7824557	0.505	rs2736313	ENSG00000269918.1	AF131215.9	5.96	4.95e-09	2.17e-06	0.26	0.27	Retinal vascular caliber;	chr8:11229433	chr8:11104691~11106704:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	5.96	4.95e-09	2.17e-06	0.3	0.27	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
HNSC	cis	rs1479119	0.78	rs7971776	ENSG00000180861.8	LINC01559	5.96	4.95e-09	2.17e-06	0.36	0.27	Intelligence (multi-trait analysis);	chr12:13347962	chr12:13371089~13387167:-
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-5.96	4.96e-09	2.17e-06	-0.29	-0.27	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
HNSC	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-5.96	4.96e-09	2.17e-06	-0.24	-0.27	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
HNSC	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-5.96	4.96e-09	2.17e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-5.96	4.96e-09	2.17e-06	-0.25	-0.27	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.96	4.96e-09	2.17e-06	0.3	0.27	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
HNSC	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-5.96	4.96e-09	2.17e-06	-0.35	-0.27	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-5.96	4.96e-09	2.17e-06	-0.35	-0.27	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
HNSC	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-5.96	4.96e-09	2.17e-06	-0.42	-0.27	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	5.96	4.98e-09	2.18e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
HNSC	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	5.96	4.98e-09	2.18e-06	0.29	0.27	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
HNSC	cis	rs1021993	0.62	rs1395748	ENSG00000231648.1	RP11-372M18.2	5.96	4.98e-09	2.18e-06	0.33	0.27	Gut microbiome composition (winter);	chr1:209302600	chr1:209367662~209379690:+
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-5.96	4.98e-09	2.18e-06	-0.3	-0.27	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
HNSC	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	5.96	4.99e-09	2.18e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
HNSC	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	5.96	4.99e-09	2.18e-06	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
HNSC	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-5.96	5.03e-09	2.2e-06	-0.39	-0.27	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
HNSC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-5.96	5.03e-09	2.2e-06	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
HNSC	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-5.96	5.03e-09	2.2e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-5.96	5.03e-09	2.2e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
HNSC	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	5.96	5.03e-09	2.2e-06	0.27	0.27	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
HNSC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.96	5.03e-09	2.2e-06	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
HNSC	cis	rs2579103	0.767	rs1545179	ENSG00000258183.4	RP11-753N8.1	-5.96	5.04e-09	2.2e-06	-0.37	-0.27	Body mass index;	chr12:90273213	chr12:90280894~90300340:+
HNSC	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-5.96	5.06e-09	2.21e-06	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
HNSC	cis	rs9300255	0.544	rs2049114	ENSG00000280120.1	RP11-546D6.3	5.96	5.06e-09	2.21e-06	0.25	0.27	Neutrophil percentage of white cells;	chr12:123172791	chr12:123152324~123153377:-
HNSC	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-5.96	5.06e-09	2.21e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
HNSC	cis	rs6918586	0.658	rs198837	ENSG00000272462.2	U91328.19	5.96	5.07e-09	2.21e-06	0.25	0.27	Schizophrenia;	chr6:26113170	chr6:25992662~26001775:+
HNSC	cis	rs1021993	1	rs1021993	ENSG00000231648.1	RP11-372M18.2	-5.96	5.07e-09	2.21e-06	-0.37	-0.27	Gut microbiome composition (winter);	chr1:209339028	chr1:209367662~209379690:+
HNSC	cis	rs2834288	0.7	rs2834299	ENSG00000237945.6	LINC00649	-5.96	5.07e-09	2.22e-06	-0.36	-0.27	Gut microbiota (bacterial taxa);	chr21:33912198	chr21:33915534~33977691:+
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.96	5.08e-09	2.22e-06	-0.38	-0.27	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
HNSC	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-5.96	5.08e-09	2.22e-06	-0.33	-0.27	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
HNSC	cis	rs7402982	0.647	rs34038360	ENSG00000278022.1	RP11-35O15.2	-5.96	5.08e-09	2.22e-06	-0.31	-0.27	Birth weight;	chr15:98658344	chr15:98660210~98660668:+
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	5.96	5.08e-09	2.22e-06	0.31	0.27	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
HNSC	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	5.96	5.1e-09	2.23e-06	0.33	0.27	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
HNSC	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	5.96	5.1e-09	2.23e-06	0.33	0.27	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
HNSC	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55486718	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55495262	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55502504	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55508982	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55509442	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	5.96	5.1e-09	2.23e-06	0.32	0.27	Height;	chr4:55510177	chr4:55363971~55395847:-
HNSC	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-5.96	5.1e-09	2.23e-06	-0.33	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
HNSC	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	5.96	5.1e-09	2.23e-06	0.3	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	5.96	5.11e-09	2.23e-06	0.32	0.27	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
HNSC	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-5.96	5.11e-09	2.23e-06	-0.33	-0.27	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-5.96	5.11e-09	2.23e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
HNSC	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.95	5.12e-09	2.24e-06	0.34	0.27	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
HNSC	cis	rs6604026	0.624	rs11800409	ENSG00000223787.2	RP4-593M8.1	5.95	5.12e-09	2.24e-06	0.37	0.27	Multiple sclerosis;	chr1:92715456	chr1:92580476~92580821:-
HNSC	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-5.95	5.13e-09	2.24e-06	-0.33	-0.27	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
HNSC	cis	rs947583	0.517	rs9376148	ENSG00000217482.2	HMGB1P17	5.95	5.14e-09	2.24e-06	0.28	0.27	Phosphorus levels;	chr6:135777362	chr6:135636086~135636713:-
HNSC	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-5.95	5.15e-09	2.25e-06	-0.27	-0.27	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-5.95	5.15e-09	2.25e-06	-0.32	-0.27	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
HNSC	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	5.95	5.15e-09	2.25e-06	0.35	0.27	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
HNSC	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	5.95	5.15e-09	2.25e-06	0.49	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
HNSC	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	5.95	5.15e-09	2.25e-06	0.34	0.27	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	5.95	5.16e-09	2.25e-06	0.3	0.27	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
HNSC	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.95	5.16e-09	2.25e-06	0.26	0.27	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
HNSC	cis	rs2834288	0.5	rs2834304	ENSG00000273102.1	AP000569.9	5.95	5.17e-09	2.25e-06	0.28	0.27	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33967101~33968573:-
HNSC	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	5.95	5.17e-09	2.25e-06	0.32	0.27	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
HNSC	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-5.95	5.17e-09	2.26e-06	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
HNSC	cis	rs9300255	0.602	rs1716172	ENSG00000280120.1	RP11-546D6.3	5.95	5.18e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123228165	chr12:123152324~123153377:-
HNSC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-5.95	5.19e-09	2.26e-06	-0.32	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
HNSC	cis	rs9300255	0.602	rs4372492	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123212810	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.627	rs1727325	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Head circumference (infant);Educational attainment;Height;	chr12:123213785	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.51	rs1727323	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123214243	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716160	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123215678	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1727320	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123215929	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1790131	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123216463	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs1790130	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123216723	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2682431	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123218679	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2851450	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123218954	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs1790101	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123220297	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1790102	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123220343	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1626899	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123223516	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs10846486	ENSG00000280120.1	RP11-546D6.3	5.95	5.19e-09	2.26e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123225380	chr12:123152324~123153377:-
HNSC	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	5.95	5.19e-09	2.26e-06	0.36	0.27	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
HNSC	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-5.95	5.2e-09	2.26e-06	-0.33	-0.27	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
HNSC	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	5.95	5.2e-09	2.27e-06	0.34	0.27	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
HNSC	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	5.95	5.2e-09	2.27e-06	0.36	0.27	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
HNSC	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	5.95	5.2e-09	2.27e-06	0.31	0.27	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
HNSC	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-5.95	5.2e-09	2.27e-06	-0.33	-0.27	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
HNSC	cis	rs189798	0.807	rs330905	ENSG00000173295.6	FAM86B3P	5.95	5.21e-09	2.27e-06	0.31	0.27	Myopia (pathological);	chr8:9136041	chr8:8228595~8244865:+
HNSC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.95	5.22e-09	2.27e-06	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
HNSC	cis	rs2834288	0.7	rs2834292	ENSG00000237945.6	LINC00649	-5.95	5.22e-09	2.27e-06	-0.35	-0.27	Gut microbiota (bacterial taxa);	chr21:33901909	chr21:33915534~33977691:+
HNSC	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-5.95	5.22e-09	2.28e-06	-0.32	-0.27	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
HNSC	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55514802	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55516548	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55516744	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55517185	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	5.95	5.22e-09	2.28e-06	0.32	0.27	Height;	chr4:55522229	chr4:55363971~55395847:-
HNSC	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	5.95	5.22e-09	2.28e-06	0.3	0.27	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
HNSC	cis	rs757110	0.868	rs5219	ENSG00000260196.1	RP1-239B22.5	5.95	5.22e-09	2.28e-06	0.31	0.27	Type 2 diabetes;	chr11:17388025	chr11:17380649~17383531:+
HNSC	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	5.95	5.23e-09	2.28e-06	0.4	0.27	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
HNSC	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	5.95	5.24e-09	2.28e-06	0.3	0.27	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
HNSC	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.95	5.24e-09	2.28e-06	0.3	0.27	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-5.95	5.24e-09	2.28e-06	-0.32	-0.27	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
HNSC	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-5.95	5.24e-09	2.28e-06	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
HNSC	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	5.95	5.25e-09	2.29e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	5.95	5.25e-09	2.29e-06	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	5.95	5.25e-09	2.29e-06	0.34	0.27	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
HNSC	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	5.95	5.26e-09	2.29e-06	0.2	0.27	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
HNSC	cis	rs9300255	0.602	rs1716164	ENSG00000280120.1	RP11-546D6.3	5.95	5.27e-09	2.29e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123179113	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1727300	ENSG00000280120.1	RP11-546D6.3	5.95	5.27e-09	2.29e-06	0.24	0.27	Neutrophil percentage of white cells;	chr12:123179658	chr12:123152324~123153377:-
HNSC	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-5.95	5.27e-09	2.29e-06	-0.37	-0.27	Depression;	chr6:27871968	chr6:28115628~28116551:+
HNSC	cis	rs9914544	1	rs7223231	ENSG00000264885.1	RP11-815I9.4	-5.95	5.27e-09	2.29e-06	-0.28	-0.27	Educational attainment (years of education);	chr17:18908533	chr17:18667629~18669461:-
HNSC	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5.95	5.27e-09	2.3e-06	0.41	0.27	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
HNSC	cis	rs2985684	0.894	rs4900927	ENSG00000258568.1	RHOQP1	5.95	5.28e-09	2.3e-06	0.27	0.27	Carotid intima media thickness;	chr14:49552023	chr14:49599994~49600572:+
HNSC	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	5.95	5.3e-09	2.31e-06	0.3	0.27	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	5.95	5.31e-09	2.31e-06	0.34	0.27	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
HNSC	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	5.95	5.31e-09	2.31e-06	0.29	0.27	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	5.95	5.31e-09	2.31e-06	0.29	0.27	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
HNSC	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-5.95	5.32e-09	2.32e-06	-0.33	-0.27	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-5.95	5.32e-09	2.32e-06	-0.33	-0.27	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
HNSC	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	5.95	5.32e-09	2.32e-06	0.3	0.27	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
HNSC	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	5.95	5.33e-09	2.32e-06	0.3	0.27	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
HNSC	cis	rs8177876	1	rs8177876	ENSG00000261061.1	RP11-303E16.2	-5.95	5.33e-09	2.32e-06	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81030770~81031485:+
HNSC	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-5.95	5.33e-09	2.32e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
HNSC	cis	rs7674212	0.57	rs2711898	ENSG00000246560.2	RP11-10L12.4	5.95	5.34e-09	2.32e-06	0.3	0.27	Type 2 diabetes;	chr4:103141914	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5.95	5.34e-09	2.32e-06	0.35	0.27	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	5.95	5.34e-09	2.32e-06	0.23	0.27	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
HNSC	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-5.95	5.34e-09	2.32e-06	-0.31	-0.27	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
HNSC	cis	rs3738814	0.529	rs761422	ENSG00000186715.9	MST1L	-5.95	5.34e-09	2.33e-06	-0.22	-0.27	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16754910~16770237:-
HNSC	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5.95	5.35e-09	2.33e-06	-0.27	-0.27	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
HNSC	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-5.95	5.35e-09	2.33e-06	-0.32	-0.27	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
HNSC	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	5.95	5.36e-09	2.33e-06	0.32	0.27	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
HNSC	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	5.95	5.36e-09	2.33e-06	0.26	0.27	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
HNSC	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-5.95	5.36e-09	2.33e-06	-0.23	-0.27	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
HNSC	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	5.95	5.36e-09	2.33e-06	0.28	0.27	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
HNSC	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	5.95	5.36e-09	2.33e-06	0.32	0.27	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
HNSC	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.95	5.36e-09	2.33e-06	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.95	5.36e-09	2.33e-06	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
HNSC	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	5.95	5.37e-09	2.33e-06	0.27	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-5.95	5.38e-09	2.34e-06	-0.17	-0.27	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
HNSC	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-5.95	5.38e-09	2.34e-06	-0.31	-0.27	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
HNSC	cis	rs13126694	0.744	rs10027000	ENSG00000248429.4	RP11-597D13.9	5.95	5.38e-09	2.34e-06	0.3	0.27	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158170752~158202877:+
HNSC	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	5.95	5.38e-09	2.34e-06	0.35	0.27	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
HNSC	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	5.95	5.38e-09	2.34e-06	0.3	0.27	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
HNSC	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	5.95	5.38e-09	2.34e-06	0.33	0.27	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-5.95	5.39e-09	2.34e-06	-0.31	-0.27	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-5.95	5.39e-09	2.34e-06	-0.31	-0.27	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
HNSC	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	5.95	5.39e-09	2.34e-06	0.32	0.27	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
HNSC	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-5.95	5.39e-09	2.34e-06	-0.32	-0.27	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	5.95	5.39e-09	2.34e-06	0.35	0.27	Depression;	chr6:28201380	chr6:28943877~28944537:+
HNSC	cis	rs2579103	0.838	rs2579115	ENSG00000258183.4	RP11-753N8.1	-5.95	5.4e-09	2.35e-06	-0.33	-0.27	Body mass index;	chr12:90214973	chr12:90280894~90300340:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-5.95	5.4e-09	2.35e-06	-0.17	-0.27	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-5.95	5.4e-09	2.35e-06	-0.17	-0.27	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
HNSC	cis	rs2071303	0.836	rs198835	ENSG00000272462.2	U91328.19	-5.95	5.41e-09	2.35e-06	-0.25	-0.27	Intelligence (multi-trait analysis);	chr6:26113766	chr6:25992662~26001775:+
HNSC	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-5.95	5.41e-09	2.35e-06	-0.33	-0.27	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
HNSC	cis	rs454422	0.857	rs236106	ENSG00000275632.1	RP5-967N21.11	5.95	5.41e-09	2.35e-06	0.27	0.27	HIV-1 viral setpoint;	chr20:5980045	chr20:6000418~6000941:+
HNSC	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	5.95	5.42e-09	2.35e-06	0.54	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
HNSC	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-5.94	5.42e-09	2.36e-06	-0.33	-0.27	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
HNSC	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	5.94	5.44e-09	2.36e-06	0.33	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
HNSC	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	5.94	5.44e-09	2.36e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	5.94	5.44e-09	2.36e-06	0.29	0.27	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
HNSC	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-5.94	5.45e-09	2.37e-06	-0.27	-0.27	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
HNSC	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-5.94	5.45e-09	2.37e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-5.94	5.45e-09	2.37e-06	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
HNSC	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	5.94	5.47e-09	2.37e-06	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
HNSC	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	5.94	5.47e-09	2.37e-06	0.36	0.27	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	5.94	5.47e-09	2.37e-06	0.36	0.27	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
HNSC	cis	rs4218	0.648	rs877269	ENSG00000277144.1	RP11-59H7.4	-5.94	5.47e-09	2.38e-06	-0.36	-0.27	Social communication problems;	chr15:59081595	chr15:59115547~59116089:-
HNSC	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-5.94	5.47e-09	2.38e-06	-0.36	-0.27	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
HNSC	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.49e-09	2.38e-06	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
HNSC	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.94	5.49e-09	2.38e-06	-0.35	-0.27	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.94	5.49e-09	2.38e-06	-0.35	-0.27	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	5.94	5.49e-09	2.39e-06	0.36	0.27	Depression;	chr6:28184805	chr6:28943877~28944537:+
HNSC	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5.94	5.5e-09	2.39e-06	0.2	0.27	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
HNSC	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.94	5.51e-09	2.39e-06	-0.36	-0.27	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
HNSC	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-5.94	5.52e-09	2.39e-06	-0.31	-0.27	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000244479.5	OR2A1-AS1	5.94	5.52e-09	2.4e-06	0.4	0.27	Obesity-related traits;	chr7:144076758	chr7:144251264~144356181:-
HNSC	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	5.94	5.52e-09	2.4e-06	0.49	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	5.94	5.53e-09	2.4e-06	0.33	0.27	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	-5.94	5.53e-09	2.4e-06	-0.3	-0.27	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
HNSC	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-5.94	5.53e-09	2.4e-06	-0.35	-0.27	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
HNSC	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-5.94	5.53e-09	2.4e-06	-0.29	-0.27	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000267151.3	RP11-100E5.2	5.94	5.53e-09	2.4e-06	0.34	0.27	Menopause (age at onset);	chr17:43112722	chr17:43444707~43451200:+
HNSC	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	5.94	5.54e-09	2.4e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	5.94	5.54e-09	2.41e-06	0.33	0.27	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
HNSC	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-5.94	5.56e-09	2.41e-06	-0.25	-0.27	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-5.94	5.56e-09	2.41e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-5.94	5.56e-09	2.41e-06	-0.18	-0.27	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
HNSC	cis	rs2115630	0.691	rs8040066	ENSG00000229212.6	RP11-561C5.4	5.94	5.58e-09	2.42e-06	0.3	0.27	P wave terminal force;	chr15:84633234	chr15:85205440~85234795:-
HNSC	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	5.94	5.58e-09	2.42e-06	0.42	0.27	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
HNSC	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-5.94	5.59e-09	2.42e-06	-0.24	-0.27	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
HNSC	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	5.94	5.59e-09	2.42e-06	0.32	0.27	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
HNSC	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	5.94	5.59e-09	2.42e-06	0.32	0.27	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-5.94	5.59e-09	2.42e-06	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
HNSC	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-5.94	5.59e-09	2.42e-06	-0.31	-0.27	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
HNSC	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-5.94	5.59e-09	2.42e-06	-0.34	-0.27	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
HNSC	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-5.94	5.61e-09	2.43e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-5.94	5.63e-09	2.44e-06	-0.31	-0.26	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-5.94	5.63e-09	2.44e-06	-0.31	-0.26	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-5.94	5.64e-09	2.44e-06	-0.17	-0.26	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
HNSC	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	5.94	5.64e-09	2.44e-06	0.33	0.26	Height;	chr4:55570843	chr4:55387949~55388271:+
HNSC	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-5.94	5.64e-09	2.44e-06	-0.31	-0.26	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
HNSC	cis	rs9840812	0.592	rs12489577	ENSG00000273486.1	RP11-731C17.2	5.94	5.64e-09	2.44e-06	0.23	0.26	Fibrinogen levels;	chr3:136494303	chr3:136837338~136839021:-
HNSC	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	5.94	5.64e-09	2.44e-06	0.32	0.26	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
HNSC	cis	rs1355223	0.934	rs5010670	ENSG00000271369.1	RP11-350D17.3	-5.94	5.65e-09	2.45e-06	-0.31	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745102	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-5.94	5.65e-09	2.45e-06	-0.17	-0.26	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
HNSC	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.94	5.66e-09	2.45e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
HNSC	cis	rs35306767	0.953	rs11253509	ENSG00000229869.1	RP11-363N22.2	-5.94	5.66e-09	2.45e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:918366	chr10:933026~942743:+
HNSC	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-5.94	5.66e-09	2.45e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-5.94	5.66e-09	2.45e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
HNSC	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-5.94	5.66e-09	2.45e-06	-0.31	-0.26	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
HNSC	cis	rs1479119	0.78	rs1479114	ENSG00000180861.8	LINC01559	-5.94	5.66e-09	2.45e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr12:13347305	chr12:13371089~13387167:-
HNSC	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-5.94	5.67e-09	2.45e-06	-0.25	-0.26	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
HNSC	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-5.94	5.67e-09	2.45e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
HNSC	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-5.94	5.67e-09	2.45e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
HNSC	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.94	5.67e-09	2.46e-06	-0.28	-0.26	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	5.94	5.67e-09	2.46e-06	0.4	0.26	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	5.94	5.68e-09	2.46e-06	0.29	0.26	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
HNSC	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.94	5.68e-09	2.46e-06	0.2	0.26	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-5.94	5.69e-09	2.46e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000179406.6	LINC00174	-5.94	5.69e-09	2.46e-06	-0.57	-0.26	Diabetic kidney disease;	chr7:66591724	chr7:66376044~66401338:-
HNSC	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	5.94	5.7e-09	2.47e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
HNSC	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-5.94	5.71e-09	2.47e-06	-0.36	-0.26	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
HNSC	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	5.94	5.71e-09	2.47e-06	0.29	0.26	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
HNSC	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-5.94	5.71e-09	2.47e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
HNSC	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	5.94	5.72e-09	2.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	5.94	5.72e-09	2.48e-06	0.3	0.26	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000179406.6	LINC00174	5.94	5.73e-09	2.48e-06	0.34	0.26	Calcium levels;	chr7:66045710	chr7:66376044~66401338:-
HNSC	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	5.94	5.73e-09	2.48e-06	0.3	0.26	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
HNSC	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.94	5.73e-09	2.48e-06	0.3	0.26	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
HNSC	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	5.94	5.73e-09	2.48e-06	0.36	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	5.94	5.73e-09	2.48e-06	0.36	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
HNSC	cis	rs2286503	0.78	rs2240727	ENSG00000221740.1	SNORD93	5.93	5.73e-09	2.48e-06	0.29	0.26	Fibrinogen;	chr7:22812893	chr7:22856613~22856686:+
HNSC	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.93	5.74e-09	2.48e-06	-0.26	-0.26	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
HNSC	cis	rs12935418	0.83	rs7195459	ENSG00000261061.1	RP11-303E16.2	-5.93	5.74e-09	2.49e-06	-0.37	-0.26	Mean corpuscular volume;	chr16:81016376	chr16:81030770~81031485:+
HNSC	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-5.93	5.75e-09	2.49e-06	-0.43	-0.26	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
HNSC	cis	rs783540	0.5	rs7178459	ENSG00000276710.3	CSPG4P8	-5.93	5.75e-09	2.49e-06	-0.33	-0.26	Schizophrenia;	chr15:82729632	chr15:82459472~82477258:+
HNSC	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	5.93	5.75e-09	2.49e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
HNSC	cis	rs6604026	0.555	rs34812295	ENSG00000223787.2	RP4-593M8.1	5.93	5.77e-09	2.49e-06	0.36	0.26	Multiple sclerosis;	chr1:92606712	chr1:92580476~92580821:-
HNSC	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	5.93	5.79e-09	2.5e-06	0.3	0.26	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
HNSC	cis	rs35306767	0.903	rs12761424	ENSG00000229869.1	RP11-363N22.2	-5.93	5.79e-09	2.5e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:921355	chr10:933026~942743:+
HNSC	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.93	5.79e-09	2.5e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000211972.2	IGHV3-66	5.93	5.79e-09	2.5e-06	0.2	0.26	Kawasaki disease;	chr14:106781682	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000211972.2	IGHV3-66	5.93	5.79e-09	2.5e-06	0.2	0.26	Kawasaki disease;	chr14:106781820	chr14:106675017~106675544:-
HNSC	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-5.93	5.79e-09	2.5e-06	-0.23	-0.26	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
HNSC	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-5.93	5.8e-09	2.51e-06	-0.29	-0.26	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
HNSC	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	5.93	5.81e-09	2.51e-06	0.4	0.26	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
HNSC	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-5.93	5.81e-09	2.51e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
HNSC	cis	rs76934034	0.522	rs117488236	ENSG00000237840.5	FAM21FP	-5.93	5.82e-09	2.51e-06	-0.44	-0.26	Prostate cancer;	chr10:45546587	chr10:45706431~45727231:-
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000267151.3	RP11-100E5.2	5.93	5.82e-09	2.52e-06	0.34	0.26	Menopause (age at onset);	chr17:43053924	chr17:43444707~43451200:+
HNSC	cis	rs4218	0.648	rs35769647	ENSG00000277144.1	RP11-59H7.4	-5.93	5.83e-09	2.52e-06	-0.36	-0.26	Social communication problems;	chr15:59081670	chr15:59115547~59116089:-
HNSC	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	5.93	5.83e-09	2.52e-06	0.3	0.26	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
HNSC	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	5.93	5.83e-09	2.52e-06	0.28	0.26	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
HNSC	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	5.93	5.83e-09	2.52e-06	0.29	0.26	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	5.93	5.84e-09	2.52e-06	0.33	0.26	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
HNSC	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	5.93	5.84e-09	2.52e-06	0.27	0.26	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
HNSC	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	5.93	5.85e-09	2.53e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
HNSC	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-5.93	5.85e-09	2.53e-06	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	5.93	5.85e-09	2.53e-06	0.35	0.26	Depression;	chr6:28198669	chr6:28943877~28944537:+
HNSC	cis	rs155076	0.666	rs2015241	ENSG00000233325.3	MIPEPP3	-5.93	5.85e-09	2.53e-06	-0.43	-0.26	White matter hyperintensity burden;	chr13:21314115	chr13:21298139~21306373:+
HNSC	cis	rs13113518	0.783	rs1586555	ENSG00000273257.1	RP11-177J6.1	5.93	5.85e-09	2.53e-06	0.33	0.26	Height;	chr4:55587104	chr4:55387949~55388271:+
HNSC	cis	rs2235642	0.525	rs8048290	ENSG00000280231.1	LA16c-380F5.3	-5.93	5.86e-09	2.53e-06	-0.37	-0.26	Coronary artery disease;	chr16:1512025	chr16:1553655~1554130:-
HNSC	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-5.93	5.86e-09	2.53e-06	-0.31	-0.26	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
HNSC	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.93	5.87e-09	2.53e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
HNSC	cis	rs7804306	0.826	rs73049270	ENSG00000233264.2	AC006042.8	5.93	5.87e-09	2.53e-06	0.59	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982015	chr7:7980312~7982228:+
HNSC	cis	rs7804306	0.826	rs73049276	ENSG00000233264.2	AC006042.8	5.93	5.87e-09	2.53e-06	0.59	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982385	chr7:7980312~7982228:+
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	5.93	5.87e-09	2.53e-06	0.21	0.26	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
HNSC	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	5.93	5.87e-09	2.53e-06	0.29	0.26	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	5.93	5.87e-09	2.54e-06	0.23	0.26	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
HNSC	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-5.93	5.88e-09	2.54e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
HNSC	cis	rs947583	0.573	rs12202212	ENSG00000217482.2	HMGB1P17	5.93	5.88e-09	2.54e-06	0.3	0.26	Phosphorus levels;	chr6:135698009	chr6:135636086~135636713:-
HNSC	cis	rs4218	0.648	rs12441973	ENSG00000277144.1	RP11-59H7.4	-5.93	5.88e-09	2.54e-06	-0.35	-0.26	Social communication problems;	chr15:59057016	chr15:59115547~59116089:-
HNSC	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	5.93	5.88e-09	2.54e-06	0.3	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-5.93	5.89e-09	2.54e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-5.93	5.89e-09	2.54e-06	-0.31	-0.26	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.871	rs6696888	ENSG00000203761.5	MSTO2P	5.93	5.89e-09	2.54e-06	0.2	0.26	Body mass index;	chr1:155539091	chr1:155745829~155750137:+
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	5.93	5.9e-09	2.54e-06	0.34	0.26	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
HNSC	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	5.93	5.9e-09	2.54e-06	0.36	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
HNSC	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	5.93	5.9e-09	2.55e-06	0.32	0.26	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
HNSC	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	5.93	5.9e-09	2.55e-06	0.33	0.26	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
HNSC	cis	rs1799949	1	rs8077486	ENSG00000267151.3	RP11-100E5.2	5.93	5.9e-09	2.55e-06	0.34	0.26	Menopause (age at onset);	chr17:43060788	chr17:43444707~43451200:+
HNSC	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-5.93	5.9e-09	2.55e-06	-0.32	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
HNSC	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	5.93	5.9e-09	2.55e-06	0.23	0.26	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
HNSC	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	5.93	5.9e-09	2.55e-06	0.3	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-5.93	5.91e-09	2.55e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
HNSC	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	5.93	5.91e-09	2.55e-06	0.24	0.26	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-5.93	5.91e-09	2.55e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-5.93	5.91e-09	2.55e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
HNSC	cis	rs36405	0.5	rs8003168	ENSG00000266869.1	RP6-114E22.1	-5.93	5.91e-09	2.55e-06	-0.33	-0.26	Yang-deficiency constitution;	chr14:71896671	chr14:71848606~71908430:+
HNSC	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	5.93	5.93e-09	2.56e-06	0.35	0.26	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
HNSC	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-5.93	5.93e-09	2.56e-06	-0.31	-0.26	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.93	5.94e-09	2.56e-06	0.37	0.26	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
HNSC	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.93	5.94e-09	2.56e-06	0.31	0.26	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
HNSC	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	5.93	5.95e-09	2.56e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
HNSC	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-5.93	5.95e-09	2.57e-06	-0.33	-0.26	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
HNSC	cis	rs6918586	0.658	rs13161	ENSG00000272462.2	U91328.19	-5.93	5.95e-09	2.57e-06	-0.25	-0.26	Schizophrenia;	chr6:26114474	chr6:25992662~26001775:+
HNSC	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.93	5.96e-09	2.57e-06	0.38	0.26	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
HNSC	cis	rs1021993	0.672	rs906353	ENSG00000231648.1	RP11-372M18.2	5.93	5.96e-09	2.57e-06	0.33	0.26	Gut microbiome composition (winter);	chr1:209294177	chr1:209367662~209379690:+
HNSC	cis	rs6918586	0.658	rs198814	ENSG00000272462.2	U91328.19	-5.93	5.96e-09	2.57e-06	-0.25	-0.26	Schizophrenia;	chr6:26127531	chr6:25992662~26001775:+
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000173295.6	FAM86B3P	-5.93	5.96e-09	2.57e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9011767	chr8:8228595~8244865:+
HNSC	cis	rs189798	0.738	rs330908	ENSG00000173295.6	FAM86B3P	5.93	5.97e-09	2.58e-06	0.31	0.26	Myopia (pathological);	chr8:9137656	chr8:8228595~8244865:+
HNSC	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-5.93	5.98e-09	2.58e-06	-0.36	-0.26	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
HNSC	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	5.93	5.98e-09	2.58e-06	0.27	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
HNSC	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	5.93	5.99e-09	2.58e-06	0.38	0.26	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
HNSC	cis	rs2834288	0.666	rs2834293	ENSG00000237945.6	LINC00649	-5.93	6e-09	2.59e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33903905	chr21:33915534~33977691:+
HNSC	cis	rs4388249	0.696	rs31600	ENSG00000271849.1	CTC-332L22.1	5.93	6.01e-09	2.59e-06	0.37	0.26	Schizophrenia;	chr5:109670675	chr5:109687802~109688329:-
HNSC	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-5.93	6.01e-09	2.59e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
HNSC	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	5.93	6.01e-09	2.59e-06	0.35	0.26	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
HNSC	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-5.93	6.02e-09	2.6e-06	-0.34	-0.26	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-5.93	6.02e-09	2.6e-06	-0.34	-0.26	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
HNSC	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-5.93	6.04e-09	2.6e-06	-0.37	-0.26	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
HNSC	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	5.93	6.05e-09	2.61e-06	0.29	0.26	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
HNSC	cis	rs7617773	0.539	rs2017858	ENSG00000228638.1	FCF1P2	-5.93	6.05e-09	2.61e-06	-0.24	-0.26	Coronary artery disease;	chr3:48340792	chr3:48290793~48291375:-
HNSC	cis	rs2006771	0.74	rs8140312	ENSG00000236132.1	CTA-440B3.1	-5.93	6.05e-09	2.61e-06	-0.29	-0.26	Nonsyndromic cleft lip with cleft palate;	chr22:31609608	chr22:31816379~31817491:-
HNSC	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-5.93	6.05e-09	2.61e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
HNSC	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-5.93	6.06e-09	2.61e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
HNSC	cis	rs6918586	0.616	rs198836	ENSG00000272462.2	U91328.19	-5.93	6.06e-09	2.61e-06	-0.25	-0.26	Schizophrenia;	chr6:26113388	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.616	rs1056314	ENSG00000272462.2	U91328.19	5.93	6.06e-09	2.61e-06	0.25	0.26	Schizophrenia;	chr6:26114425	chr6:25992662~26001775:+
HNSC	cis	rs4218	0.648	rs10851642	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59077909	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.608	rs59282449	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59078881	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.648	rs60285686	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59079829	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.648	rs60741546	ENSG00000277144.1	RP11-59H7.4	-5.92	6.07e-09	2.62e-06	-0.37	-0.26	Social communication problems;	chr15:59079831	chr15:59115547~59116089:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.92	6.07e-09	2.62e-06	0.26	0.26	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.92	6.07e-09	2.62e-06	0.26	0.26	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	5.92	6.08e-09	2.62e-06	0.33	0.26	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
HNSC	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.11e-09	2.63e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
HNSC	cis	rs10435719	0.746	rs58007588	ENSG00000206014.6	OR7E161P	-5.92	6.11e-09	2.63e-06	-0.29	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:11928597~11929563:-
HNSC	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.92	6.12e-09	2.63e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
HNSC	cis	rs8177876	0.822	rs56198248	ENSG00000261061.1	RP11-303E16.2	-5.92	6.12e-09	2.63e-06	-0.49	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81030770~81031485:+
HNSC	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-5.92	6.12e-09	2.63e-06	-0.44	-0.26	Depression;	chr6:28139579	chr6:28115628~28116551:+
HNSC	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-5.92	6.12e-09	2.64e-06	-0.52	-0.26	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
HNSC	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	5.92	6.12e-09	2.64e-06	0.29	0.26	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
HNSC	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-5.92	6.13e-09	2.64e-06	-0.31	-0.26	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-5.92	6.13e-09	2.64e-06	-0.31	-0.26	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	5.92	6.14e-09	2.64e-06	0.31	0.26	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
HNSC	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	5.92	6.14e-09	2.64e-06	0.41	0.26	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
HNSC	cis	rs4218	0.597	rs4775114	ENSG00000277144.1	RP11-59H7.4	-5.92	6.15e-09	2.65e-06	-0.35	-0.26	Social communication problems;	chr15:59059635	chr15:59115547~59116089:-
HNSC	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	5.92	6.15e-09	2.65e-06	0.35	0.26	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	5.92	6.16e-09	2.65e-06	0.29	0.26	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	5.92	6.16e-09	2.65e-06	0.29	0.26	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
HNSC	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-5.92	6.16e-09	2.65e-06	-0.31	-0.26	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
HNSC	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.92	6.16e-09	2.65e-06	0.25	0.26	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
HNSC	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-5.92	6.16e-09	2.65e-06	-0.36	-0.26	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-5.92	6.17e-09	2.65e-06	-0.28	-0.26	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	5.92	6.18e-09	2.66e-06	0.32	0.26	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
HNSC	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-5.92	6.19e-09	2.66e-06	-0.33	-0.26	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-5.92	6.19e-09	2.66e-06	-0.33	-0.26	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
HNSC	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-5.92	6.19e-09	2.66e-06	-0.27	-0.26	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
HNSC	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-5.92	6.19e-09	2.66e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
HNSC	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	5.92	6.21e-09	2.67e-06	0.35	0.26	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	5.92	6.21e-09	2.67e-06	0.35	0.26	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
HNSC	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	5.92	6.21e-09	2.67e-06	0.36	0.26	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-5.92	6.23e-09	2.68e-06	-0.37	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
HNSC	cis	rs2836950	0.501	rs1474490	ENSG00000255568.3	BRWD1-AS2	-5.92	6.24e-09	2.68e-06	-0.22	-0.26	Menarche (age at onset);	chr21:39344210	chr21:39313935~39314962:+
HNSC	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	5.92	6.24e-09	2.68e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
HNSC	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.92	6.24e-09	2.68e-06	-0.39	-0.26	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
HNSC	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	5.92	6.25e-09	2.69e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
HNSC	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.717	rs9806227	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43387917	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs12323999	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43390917	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2584702	ENSG00000205771.5	CATSPER2P1	-5.92	6.26e-09	2.69e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43392716	chr15:43726918~43747094:-
HNSC	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-5.92	6.26e-09	2.69e-06	-0.31	-0.26	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
HNSC	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-5.92	6.27e-09	2.69e-06	-0.32	-0.26	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
HNSC	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	5.92	6.27e-09	2.69e-06	0.36	0.26	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
HNSC	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	5.92	6.27e-09	2.7e-06	0.32	0.26	Height;	chr4:55483718	chr4:55363971~55395847:-
HNSC	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-5.92	6.27e-09	2.7e-06	-0.35	-0.26	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
HNSC	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-5.92	6.28e-09	2.7e-06	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
HNSC	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	5.92	6.29e-09	2.7e-06	0.34	0.26	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
HNSC	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	5.92	6.29e-09	2.7e-06	0.3	0.26	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-5.92	6.29e-09	2.7e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-5.92	6.3e-09	2.71e-06	-0.32	-0.26	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
HNSC	cis	rs9300255	0.544	rs1790100	ENSG00000280120.1	RP11-546D6.3	5.92	6.31e-09	2.71e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123172178	chr12:123152324~123153377:-
HNSC	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	5.92	6.31e-09	2.71e-06	0.29	0.26	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
HNSC	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-5.92	6.31e-09	2.71e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
HNSC	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.92	6.32e-09	2.71e-06	0.36	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
HNSC	cis	rs6472866	0.679	rs1425771	ENSG00000254349.4	FLJ39080	-5.92	6.33e-09	2.72e-06	-0.28	-0.26	Protein quantitative trait loci;	chr8:74593494	chr8:74599775~74823313:+
HNSC	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-5.92	6.33e-09	2.72e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
HNSC	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-5.92	6.34e-09	2.72e-06	-0.35	-0.26	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
HNSC	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-5.92	6.35e-09	2.73e-06	-0.31	-0.26	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
HNSC	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-5.92	6.35e-09	2.73e-06	-0.23	-0.26	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
HNSC	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	5.92	6.35e-09	2.73e-06	0.41	0.26	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	-5.92	6.36e-09	2.73e-06	-0.3	-0.26	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
HNSC	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	5.92	6.37e-09	2.73e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
HNSC	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	5.92	6.37e-09	2.73e-06	0.26	0.26	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
HNSC	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-5.92	6.37e-09	2.73e-06	-0.31	-0.26	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
HNSC	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-5.92	6.38e-09	2.74e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
HNSC	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-5.92	6.39e-09	2.74e-06	-0.43	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
HNSC	cis	rs2404602	0.716	rs2404736	ENSG00000259422.1	RP11-593F23.1	5.92	6.39e-09	2.74e-06	0.3	0.26	Blood metabolite levels;	chr15:76583602	chr15:76174891~76181486:-
HNSC	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-5.92	6.4e-09	2.75e-06	-0.31	-0.26	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
HNSC	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	5.92	6.4e-09	2.75e-06	0.29	0.26	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
HNSC	cis	rs2880765	0.546	rs8042776	ENSG00000259295.5	CSPG4P12	5.92	6.4e-09	2.75e-06	0.32	0.26	Coronary artery disease;	chr15:85512398	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	5.92	6.4e-09	2.75e-06	0.33	0.26	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
HNSC	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	5.92	6.41e-09	2.75e-06	0.32	0.26	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
HNSC	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-5.92	6.42e-09	2.75e-06	-0.28	-0.26	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
HNSC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-5.91	6.42e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-5.91	6.42e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-5.91	6.43e-09	2.76e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
HNSC	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.91	6.43e-09	2.76e-06	0.32	0.26	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	5.91	6.44e-09	2.76e-06	0.3	0.26	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
HNSC	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	5.91	6.44e-09	2.76e-06	0.55	0.26	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
HNSC	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-5.91	6.45e-09	2.76e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
HNSC	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	5.91	6.45e-09	2.77e-06	0.26	0.26	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000248787.1	RP11-666A20.4	-5.91	6.45e-09	2.77e-06	-0.48	-0.26	Blood pressure (smoking interaction);	chr3:125915924	chr3:125908005~125910272:-
HNSC	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	5.91	6.45e-09	2.77e-06	0.34	0.26	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
HNSC	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-5.91	6.46e-09	2.77e-06	-0.32	-0.26	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
HNSC	cis	rs9300255	0.596	rs1727331	ENSG00000280120.1	RP11-546D6.3	-5.91	6.46e-09	2.77e-06	-0.23	-0.26	Neutrophil percentage of white cells;	chr12:123234332	chr12:123152324~123153377:-
HNSC	cis	rs8177876	0.915	rs12444974	ENSG00000261061.1	RP11-303E16.2	-5.91	6.46e-09	2.77e-06	-0.46	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81030770~81031485:+
HNSC	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-5.91	6.47e-09	2.77e-06	-0.31	-0.26	Height;	chr4:55477866	chr4:55363971~55395847:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	5.91	6.47e-09	2.77e-06	0.21	0.26	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
HNSC	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-5.91	6.47e-09	2.78e-06	-0.37	-0.26	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-5.91	6.47e-09	2.78e-06	-0.37	-0.26	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000254153.1	CTA-398F10.2	5.91	6.47e-09	2.78e-06	0.3	0.26	Joint mobility (Beighton score);	chr8:9045624	chr8:8456909~8461337:-
HNSC	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	5.91	6.49e-09	2.78e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
HNSC	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-5.91	6.49e-09	2.78e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
HNSC	cis	rs73186030	1	rs73186030	ENSG00000272758.4	RP11-299J3.8	5.91	6.49e-09	2.78e-06	0.39	0.26	Serum parathyroid hormone levels;	chr3:122294618	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	5.91	6.49e-09	2.78e-06	0.2	0.26	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	5.91	6.49e-09	2.78e-06	0.2	0.26	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
HNSC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-5.91	6.5e-09	2.78e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-5.91	6.5e-09	2.78e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000211972.2	IGHV3-66	5.91	6.5e-09	2.79e-06	0.2	0.26	Kawasaki disease;	chr14:106780451	chr14:106675017~106675544:-
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	5.91	6.5e-09	2.79e-06	0.29	0.26	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
HNSC	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	5.91	6.5e-09	2.79e-06	0.32	0.26	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
HNSC	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-5.91	6.52e-09	2.79e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
HNSC	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-5.91	6.52e-09	2.8e-06	-0.3	-0.26	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
HNSC	cis	rs9611519	0.78	rs9611527	ENSG00000235513.1	RP4-756G23.5	5.91	6.53e-09	2.8e-06	0.28	0.26	Neuroticism;	chr22:41248424	chr22:41209122~41217627:-
HNSC	cis	rs189798	0.807	rs330912	ENSG00000173295.6	FAM86B3P	5.91	6.53e-09	2.8e-06	0.33	0.26	Myopia (pathological);	chr8:9138784	chr8:8228595~8244865:+
HNSC	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.91	6.53e-09	2.8e-06	0.24	0.26	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-5.91	6.53e-09	2.8e-06	-0.31	-0.26	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
HNSC	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	5.91	6.53e-09	2.8e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
HNSC	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.91	6.54e-09	2.8e-06	-0.33	-0.26	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	5.91	6.55e-09	2.81e-06	0.41	0.26	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	-5.91	6.56e-09	2.81e-06	-0.29	-0.26	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
HNSC	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	5.91	6.56e-09	2.81e-06	0.36	0.26	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
HNSC	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-5.91	6.57e-09	2.81e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-5.91	6.57e-09	2.81e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
HNSC	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.91	6.57e-09	2.82e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
HNSC	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	5.91	6.58e-09	2.82e-06	0.31	0.26	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
HNSC	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.91	6.58e-09	2.82e-06	-0.39	-0.26	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
HNSC	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-5.91	6.59e-09	2.82e-06	-0.32	-0.26	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
HNSC	cis	rs13113518	0.812	rs56055342	ENSG00000273257.1	RP11-177J6.1	5.91	6.59e-09	2.82e-06	0.33	0.26	Height;	chr4:55540928	chr4:55387949~55388271:+
HNSC	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-5.91	6.59e-09	2.82e-06	-0.23	-0.26	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
HNSC	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	5.91	6.59e-09	2.82e-06	0.33	0.26	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
HNSC	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-5.91	6.6e-09	2.82e-06	-0.31	-0.26	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-5.91	6.6e-09	2.83e-06	-0.3	-0.26	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
HNSC	cis	rs7804306	0.826	rs113537684	ENSG00000233264.2	AC006042.8	5.91	6.61e-09	2.83e-06	0.58	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7985192	chr7:7980312~7982228:+
HNSC	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	5.91	6.61e-09	2.83e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
HNSC	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.91	6.61e-09	2.83e-06	0.35	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
HNSC	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-5.91	6.62e-09	2.83e-06	-0.35	-0.26	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
HNSC	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.91	6.62e-09	2.83e-06	0.3	0.26	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
HNSC	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	5.91	6.62e-09	2.83e-06	0.34	0.26	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
HNSC	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-5.91	6.62e-09	2.83e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-5.91	6.63e-09	2.84e-06	-0.31	-0.26	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
HNSC	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	5.91	6.63e-09	2.84e-06	0.32	0.26	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
HNSC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-5.91	6.63e-09	2.84e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
HNSC	cis	rs9300255	0.544	rs1716175	ENSG00000280120.1	RP11-546D6.3	5.91	6.64e-09	2.84e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123173841	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-5.91	6.65e-09	2.84e-06	-0.27	-0.26	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
HNSC	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	5.91	6.65e-09	2.84e-06	0.32	0.26	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
HNSC	cis	rs9840812	0.637	rs667920	ENSG00000273486.1	RP11-731C17.2	5.91	6.65e-09	2.84e-06	0.24	0.26	Fibrinogen levels;	chr3:136350630	chr3:136837338~136839021:-
HNSC	cis	rs60617249	0.507	rs34591416	ENSG00000228204.2	RP4-724E13.2	5.91	6.65e-09	2.84e-06	0.33	0.26	Major depression and alcohol dependence;	chr7:50872830	chr7:50866747~51022990:+
HNSC	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	5.91	6.65e-09	2.84e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
HNSC	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.91	6.65e-09	2.85e-06	0.24	0.26	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
HNSC	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	5.91	6.66e-09	2.85e-06	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
HNSC	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-5.91	6.67e-09	2.85e-06	-0.37	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
HNSC	cis	rs9840812	0.623	rs4678433	ENSG00000273486.1	RP11-731C17.2	5.91	6.67e-09	2.85e-06	0.23	0.26	Fibrinogen levels;	chr3:136546840	chr3:136837338~136839021:-
HNSC	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	5.91	6.67e-09	2.85e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
HNSC	cis	rs6604026	0.557	rs72724515	ENSG00000223787.2	RP4-593M8.1	5.91	6.68e-09	2.86e-06	0.36	0.26	Multiple sclerosis;	chr1:92585519	chr1:92580476~92580821:-
HNSC	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	5.91	6.68e-09	2.86e-06	0.31	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
HNSC	cis	rs2286503	0.752	rs6461669	ENSG00000221740.1	SNORD93	5.91	6.68e-09	2.86e-06	0.29	0.26	Fibrinogen;	chr7:22818447	chr7:22856613~22856686:+
HNSC	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-5.91	6.68e-09	2.86e-06	-0.31	-0.26	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	5.91	6.69e-09	2.86e-06	0.25	0.26	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
HNSC	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	5.91	6.69e-09	2.86e-06	0.35	0.26	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	5.91	6.71e-09	2.87e-06	0.3	0.26	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
HNSC	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-5.91	6.71e-09	2.87e-06	-0.33	-0.26	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-5.91	6.71e-09	2.87e-06	-0.33	-0.26	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
HNSC	cis	rs6969780	0.778	rs61384251	ENSG00000233429.8	HOTAIRM1	5.91	6.71e-09	2.87e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106583	chr7:27095647~27100265:+
HNSC	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	5.91	6.72e-09	2.87e-06	0.31	0.26	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
HNSC	cis	rs7615952	0.512	rs2979351	ENSG00000241288.6	RP11-379B18.5	-5.91	6.72e-09	2.87e-06	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:125644755	chr3:125827238~125916384:-
HNSC	cis	rs9291683	0.552	rs3796832	ENSG00000250413.1	RP11-448G15.1	-5.91	6.72e-09	2.87e-06	-0.33	-0.26	Bone mineral density;	chr4:10014241	chr4:10006482~10009725:+
HNSC	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-5.91	6.72e-09	2.87e-06	-0.24	-0.26	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
HNSC	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	5.91	6.74e-09	2.88e-06	0.47	0.26	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
HNSC	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	5.91	6.74e-09	2.88e-06	0.36	0.26	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
HNSC	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-5.91	6.74e-09	2.88e-06	-0.31	-0.26	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
HNSC	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.91	6.74e-09	2.88e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
HNSC	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	5.91	6.76e-09	2.89e-06	0.31	0.26	Height;	chr4:55578787	chr4:55363971~55395847:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000254153.1	CTA-398F10.2	5.91	6.76e-09	2.89e-06	0.29	0.26	Systolic blood pressure;	chr8:8486617	chr8:8456909~8461337:-
HNSC	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-5.91	6.76e-09	2.89e-06	-0.23	-0.26	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
HNSC	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-5.91	6.77e-09	2.89e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
HNSC	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.91	6.77e-09	2.89e-06	0.49	0.26	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
HNSC	cis	rs526231	0.756	rs556560	ENSG00000175749.11	EIF3KP1	-5.91	6.77e-09	2.89e-06	-0.32	-0.26	Primary biliary cholangitis;	chr5:103288223	chr5:103032376~103033031:+
HNSC	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	5.91	6.78e-09	2.89e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	5.91	6.78e-09	2.89e-06	0.28	0.26	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
HNSC	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-5.91	6.79e-09	2.9e-06	-0.31	-0.26	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
HNSC	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-5.91	6.79e-09	2.9e-06	-0.34	-0.26	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
HNSC	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	5.9	6.8e-09	2.9e-06	0.23	0.26	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
HNSC	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-5.9	6.8e-09	2.9e-06	-0.41	-0.26	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
HNSC	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	5.9	6.8e-09	2.9e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	5.9	6.8e-09	2.9e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
HNSC	cis	rs6928977	0.932	rs6935146	ENSG00000234084.1	RP3-388E23.2	-5.9	6.81e-09	2.91e-06	-0.26	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135301568~135307158:+
HNSC	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.81e-09	2.91e-06	-0.32	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
HNSC	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	5.9	6.82e-09	2.91e-06	0.27	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
HNSC	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-5.9	6.82e-09	2.91e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
HNSC	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	5.9	6.82e-09	2.91e-06	0.29	0.26	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-5.9	6.82e-09	2.91e-06	-0.17	-0.26	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
HNSC	cis	rs2115630	1	rs6496452	ENSG00000229212.6	RP11-561C5.4	5.9	6.83e-09	2.91e-06	0.3	0.26	P wave terminal force;	chr15:84829414	chr15:85205440~85234795:-
HNSC	cis	rs9914544	0.932	rs11870265	ENSG00000264885.1	RP11-815I9.4	-5.9	6.83e-09	2.92e-06	-0.28	-0.26	Educational attainment (years of education);	chr17:18917672	chr17:18667629~18669461:-
HNSC	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	5.9	6.85e-09	2.92e-06	0.42	0.26	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
HNSC	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-5.9	6.85e-09	2.92e-06	-0.37	-0.26	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
HNSC	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-5.9	6.86e-09	2.93e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
HNSC	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-5.9	6.86e-09	2.93e-06	-0.26	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
HNSC	cis	rs56080343	0.748	rs56190986	ENSG00000275759.1	RP11-131L12.3	-5.9	6.86e-09	2.93e-06	-0.53	-0.26	Neuroticism;	chr12:118408458	chr12:118428281~118428870:+
HNSC	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	5.9	6.87e-09	2.93e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
HNSC	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	5.9	6.87e-09	2.93e-06	0.36	0.26	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
HNSC	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-5.9	6.87e-09	2.93e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-5.9	6.87e-09	2.93e-06	-0.17	-0.26	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
HNSC	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	5.9	6.88e-09	2.93e-06	0.34	0.26	Height;	chr4:55501955	chr4:55363971~55395847:-
HNSC	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	5.9	6.89e-09	2.94e-06	0.32	0.26	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
HNSC	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-5.9	6.89e-09	2.94e-06	-0.34	-0.26	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
HNSC	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-5.9	6.89e-09	2.94e-06	-0.2	-0.26	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
HNSC	cis	rs9300255	0.62	rs1716173	ENSG00000280120.1	RP11-546D6.3	5.9	6.89e-09	2.94e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123176174	chr12:123152324~123153377:-
HNSC	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-5.9	6.9e-09	2.94e-06	-0.31	-0.26	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.783	rs13111128	ENSG00000273257.1	RP11-177J6.1	5.9	6.91e-09	2.95e-06	0.33	0.26	Height;	chr4:55578154	chr4:55387949~55388271:+
HNSC	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-5.9	6.91e-09	2.95e-06	-0.4	-0.26	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
HNSC	cis	rs6918586	0.615	rs198841	ENSG00000272462.2	U91328.19	-5.9	6.92e-09	2.95e-06	-0.25	-0.26	Schizophrenia;	chr6:26111443	chr6:25992662~26001775:+
HNSC	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-5.9	6.92e-09	2.95e-06	-0.3	-0.26	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
HNSC	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-5.9	6.93e-09	2.95e-06	-0.38	-0.26	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
HNSC	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	5.9	6.94e-09	2.96e-06	0.3	0.26	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
HNSC	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	5.9	6.95e-09	2.96e-06	0.31	0.26	Height;	chr4:55409063	chr4:55363971~55395847:-
HNSC	cis	rs9611519	0.754	rs4820435	ENSG00000235513.1	RP4-756G23.5	5.9	6.95e-09	2.96e-06	0.28	0.26	Neuroticism;	chr22:41256842	chr22:41209122~41217627:-
HNSC	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	5.9	6.96e-09	2.97e-06	0.36	0.26	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	5.9	6.96e-09	2.97e-06	0.2	0.26	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
HNSC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-5.9	6.96e-09	2.97e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-5.9	6.97e-09	2.97e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
HNSC	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-5.9	6.97e-09	2.97e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
HNSC	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	5.9	6.97e-09	2.97e-06	0.25	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
HNSC	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	5.9	6.98e-09	2.97e-06	0.4	0.26	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
HNSC	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-5.9	6.98e-09	2.97e-06	-0.34	-0.26	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
HNSC	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5.9	6.98e-09	2.97e-06	-0.2	-0.26	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
HNSC	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	5.9	6.98e-09	2.97e-06	0.38	0.26	Height;	chr6:109732047	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.98e-09	2.97e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
HNSC	cis	rs6928977	0.675	rs7750586	ENSG00000217482.2	HMGB1P17	-5.9	6.98e-09	2.98e-06	-0.29	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-5.9	6.99e-09	2.98e-06	-0.33	-0.26	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-5.9	7e-09	2.98e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
HNSC	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-5.9	7e-09	2.98e-06	-0.32	-0.26	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-5.9	7e-09	2.98e-06	-0.21	-0.26	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
HNSC	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	5.9	7.03e-09	2.99e-06	0.32	0.26	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
HNSC	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-5.9	7.03e-09	2.99e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
HNSC	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-5.9	7.03e-09	2.99e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	5.9	7.03e-09	2.99e-06	0.33	0.26	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
HNSC	cis	rs8054556	0.74	rs3924855	ENSG00000183604.13	SMG1P5	-5.9	7.04e-09	3e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30267553~30335374:-
HNSC	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	5.9	7.04e-09	3e-06	0.25	0.26	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-5.9	7.05e-09	3e-06	-0.31	-0.26	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
HNSC	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	5.9	7.05e-09	3e-06	0.3	0.26	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
HNSC	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-5.9	7.06e-09	3e-06	-0.43	-0.26	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
HNSC	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.9	7.06e-09	3.01e-06	0.3	0.26	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
HNSC	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-5.9	7.06e-09	3.01e-06	-0.31	-0.26	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	5.9	7.06e-09	3.01e-06	0.32	0.26	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	5.9	7.07e-09	3.01e-06	0.34	0.26	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
HNSC	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	5.9	7.07e-09	3.01e-06	0.36	0.26	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
HNSC	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-5.9	7.07e-09	3.01e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
HNSC	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-5.9	7.08e-09	3.01e-06	-0.26	-0.26	Height;	chr2:231549981	chr2:231508426~231514339:-
HNSC	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	5.9	7.08e-09	3.01e-06	0.29	0.26	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
HNSC	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	5.9	7.09e-09	3.01e-06	0.29	0.26	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
HNSC	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	5.9	7.09e-09	3.02e-06	0.31	0.26	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000254153.1	CTA-398F10.2	5.9	7.09e-09	3.02e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9002766	chr8:8456909~8461337:-
HNSC	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	5.9	7.1e-09	3.02e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
HNSC	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	5.9	7.1e-09	3.02e-06	0.41	0.26	Height;	chr6:109455700	chr6:109382795~109383666:+
HNSC	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-5.9	7.11e-09	3.02e-06	-0.31	-0.26	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
HNSC	cis	rs6918586	0.636	rs198817	ENSG00000272462.2	U91328.19	-5.9	7.11e-09	3.02e-06	-0.25	-0.26	Schizophrenia;	chr6:26126296	chr6:25992662~26001775:+
HNSC	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-5.9	7.12e-09	3.03e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
HNSC	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	-5.9	7.12e-09	3.03e-06	-0.29	-0.26	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
HNSC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	5.9	7.12e-09	3.03e-06	0.27	0.26	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
HNSC	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-5.9	7.12e-09	3.03e-06	-0.31	-0.26	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	5.9	7.15e-09	3.04e-06	0.3	0.26	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
HNSC	cis	rs11992162	0.967	rs4841661	ENSG00000206014.6	OR7E161P	-5.9	7.15e-09	3.04e-06	-0.28	-0.26	Monocyte count;	chr8:11975260	chr8:11928597~11929563:-
HNSC	cis	rs6867032	0.527	rs13190594	ENSG00000249731.1	RP11-259O2.3	5.9	7.16e-09	3.04e-06	0.29	0.26	Gut microbiome composition (winter);	chr5:2012360	chr5:1968094~1969013:+
HNSC	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-5.9	7.16e-09	3.04e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
HNSC	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	5.9	7.16e-09	3.04e-06	0.35	0.26	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	5.9	7.16e-09	3.04e-06	0.35	0.26	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
HNSC	cis	rs2439831	1	rs2254321	ENSG00000205771.5	CATSPER2P1	-5.9	7.17e-09	3.05e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43415344	chr15:43726918~43747094:-
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-5.9	7.18e-09	3.05e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
HNSC	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-5.9	7.18e-09	3.05e-06	-0.39	-0.26	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
HNSC	cis	rs8012947	1	rs61450169	ENSG00000279636.2	LINC00216	5.9	7.18e-09	3.05e-06	0.32	0.26	Alcohol consumption in current drinkers;	chr14:58246142	chr14:58288033~58289158:+
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000211974.3	IGHV2-70	-5.89	7.19e-09	3.06e-06	-0.34	-0.26	Alzheimer's disease (late onset);	chr14:106767918	chr14:106723574~106724093:-
HNSC	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-5.89	7.2e-09	3.06e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
HNSC	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-5.89	7.2e-09	3.06e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000276710.3	CSPG4P8	-5.89	7.2e-09	3.06e-06	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82459472~82477258:+
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000276710.3	CSPG4P8	-5.89	7.2e-09	3.06e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82459472~82477258:+
HNSC	cis	rs11846409	0.799	rs10467899	ENSG00000211974.3	IGHV2-70	-5.89	7.21e-09	3.06e-06	-0.3	-0.26	Rheumatic heart disease;	chr14:106644012	chr14:106723574~106724093:-
HNSC	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-5.89	7.22e-09	3.07e-06	-0.31	-0.26	Height;	chr4:55487920	chr4:55363971~55395847:-
HNSC	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-5.89	7.22e-09	3.07e-06	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000254153.1	CTA-398F10.2	5.89	7.22e-09	3.07e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9005011	chr8:8456909~8461337:-
HNSC	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-5.89	7.23e-09	3.07e-06	-0.36	-0.26	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
HNSC	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5.89	7.23e-09	3.07e-06	-0.36	-0.26	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
HNSC	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	5.89	7.23e-09	3.07e-06	0.24	0.26	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
HNSC	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	5.89	7.23e-09	3.07e-06	0.28	0.26	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
HNSC	cis	rs1012068	1	rs1012068	ENSG00000236132.1	CTA-440B3.1	-5.89	7.24e-09	3.07e-06	-0.31	-0.26	Chronic hepatitis C infection;	chr22:31869917	chr22:31816379~31817491:-
HNSC	cis	rs7115242	0.844	rs645258	ENSG00000280143.1	AP000892.6	5.89	7.24e-09	3.07e-06	0.49	0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117204967~117210292:+
HNSC	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-5.89	7.24e-09	3.08e-06	-0.34	-0.26	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
HNSC	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-5.89	7.26e-09	3.08e-06	-0.35	-0.26	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
HNSC	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	5.89	7.27e-09	3.09e-06	0.29	0.26	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000173295.6	FAM86B3P	-5.89	7.27e-09	3.09e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9018719	chr8:8228595~8244865:+
HNSC	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	5.89	7.27e-09	3.09e-06	0.3	0.26	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
HNSC	cis	rs7819412	0.805	rs2409710	ENSG00000269918.1	AF131215.9	-5.89	7.28e-09	3.09e-06	-0.26	-0.26	Triglycerides;	chr8:11122311	chr8:11104691~11106704:-
HNSC	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	5.89	7.28e-09	3.09e-06	0.4	0.26	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	5.89	7.28e-09	3.09e-06	0.4	0.26	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
HNSC	cis	rs2404602	0.669	rs8036703	ENSG00000259422.1	RP11-593F23.1	5.89	7.29e-09	3.09e-06	0.3	0.26	Blood metabolite levels;	chr15:76658699	chr15:76174891~76181486:-
HNSC	cis	rs2134046	0.587	rs11854289	ENSG00000255769.6	GOLGA2P10	5.89	7.3e-09	3.1e-06	0.31	0.26	Cognitive ability;	chr15:82266461	chr15:82472993~82513950:-
HNSC	cis	rs7617773	0.539	rs17593974	ENSG00000228638.1	FCF1P2	-5.89	7.31e-09	3.1e-06	-0.23	-0.26	Coronary artery disease;	chr3:48345844	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.514	rs11130166	ENSG00000228638.1	FCF1P2	-5.89	7.31e-09	3.1e-06	-0.23	-0.26	Coronary artery disease;	chr3:48346566	chr3:48290793~48291375:-
HNSC	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	5.89	7.31e-09	3.1e-06	0.31	0.26	Height;	chr4:55537960	chr4:55363971~55395847:-
HNSC	cis	rs988913	0.957	rs1910350	ENSG00000224984.1	RP11-524H19.2	5.89	7.33e-09	3.11e-06	0.3	0.26	Menarche (age at onset);	chr6:54987664	chr6:54840118~54840855:-
HNSC	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.89	7.34e-09	3.11e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
HNSC	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	5.89	7.34e-09	3.11e-06	0.3	0.26	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
HNSC	cis	rs2404602	0.692	rs7163397	ENSG00000259422.1	RP11-593F23.1	5.89	7.36e-09	3.12e-06	0.3	0.26	Blood metabolite levels;	chr15:76647974	chr15:76174891~76181486:-
HNSC	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	5.89	7.36e-09	3.12e-06	0.36	0.26	Height;	chr6:109582583	chr6:109382795~109383666:+
HNSC	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	5.89	7.36e-09	3.12e-06	0.31	0.26	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	5.89	7.36e-09	3.12e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
HNSC	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-5.89	7.36e-09	3.12e-06	-0.34	-0.26	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
HNSC	cis	rs950169	0.526	rs698620	ENSG00000229212.6	RP11-561C5.4	5.89	7.37e-09	3.12e-06	0.3	0.26	Schizophrenia;	chr15:84633977	chr15:85205440~85234795:-
HNSC	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-5.89	7.38e-09	3.13e-06	-0.29	-0.26	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
HNSC	cis	rs7819412	0.749	rs11991118	ENSG00000269918.1	AF131215.9	5.89	7.38e-09	3.13e-06	0.26	0.26	Triglycerides;	chr8:11081763	chr8:11104691~11106704:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-5.89	7.38e-09	3.13e-06	-0.29	-0.26	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
HNSC	cis	rs7824557	0.547	rs6601570	ENSG00000269918.1	AF131215.9	-5.89	7.39e-09	3.13e-06	-0.26	-0.26	Retinal vascular caliber;	chr8:11221858	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	5.89	7.39e-09	3.13e-06	0.32	0.26	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
HNSC	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-5.89	7.39e-09	3.13e-06	-0.35	-0.26	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-5.89	7.4e-09	3.14e-06	-0.3	-0.26	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-5.89	7.4e-09	3.14e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-5.89	7.4e-09	3.14e-06	-0.35	-0.26	Depression;	chr6:28200948	chr6:28943877~28944537:+
HNSC	cis	rs2834288	0.5	rs881231	ENSG00000273102.1	AP000569.9	5.89	7.41e-09	3.14e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33967101~33968573:-
HNSC	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	5.89	7.41e-09	3.14e-06	0.32	0.26	Height;	chr4:55436423	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000276691.1	RP5-1057I20.5	5.89	7.41e-09	3.14e-06	0.47	0.26	Pneumonia;	chr12:47717273	chr12:47788426~47788971:+
HNSC	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	5.89	7.43e-09	3.15e-06	0.4	0.26	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
HNSC	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	5.89	7.43e-09	3.15e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
HNSC	cis	rs2834288	0.5	rs766425	ENSG00000273102.1	AP000569.9	5.89	7.43e-09	3.15e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33967101~33968573:-
HNSC	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-5.89	7.43e-09	3.15e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
HNSC	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-5.89	7.44e-09	3.15e-06	-0.31	-0.26	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
HNSC	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	5.89	7.45e-09	3.16e-06	0.25	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
HNSC	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.89	7.45e-09	3.16e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
HNSC	cis	rs6951245	0.872	rs11768895	ENSG00000225146.1	AC073957.15	-5.89	7.46e-09	3.16e-06	-0.41	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024055	chr7:1029025~1043891:+
HNSC	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-5.89	7.46e-09	3.16e-06	-0.3	-0.26	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
HNSC	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-5.89	7.47e-09	3.17e-06	-0.27	-0.26	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
HNSC	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	5.89	7.5e-09	3.18e-06	0.34	0.26	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
HNSC	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.89	7.5e-09	3.18e-06	0.3	0.26	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
HNSC	cis	rs9300255	0.537	rs1727334	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123229689	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.639	rs941306	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123230566	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs941305	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123230719	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.639	rs1716171	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123231829	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1716170	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123231966	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.679	rs4759409	ENSG00000280120.1	RP11-546D6.3	5.89	7.5e-09	3.18e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123235038	chr12:123152324~123153377:-
HNSC	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-5.89	7.51e-09	3.18e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
HNSC	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-5.89	7.52e-09	3.18e-06	-0.31	-0.26	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
HNSC	cis	rs6918586	0.636	rs198816	ENSG00000272462.2	U91328.19	-5.89	7.54e-09	3.19e-06	-0.25	-0.26	Schizophrenia;	chr6:26126956	chr6:25992662~26001775:+
HNSC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-5.89	7.54e-09	3.19e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-5.89	7.55e-09	3.19e-06	-0.41	-0.26	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
HNSC	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-5.89	7.55e-09	3.2e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
HNSC	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	5.89	7.55e-09	3.2e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
HNSC	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-5.89	7.56e-09	3.2e-06	-0.38	-0.26	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
HNSC	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-5.89	7.56e-09	3.2e-06	-0.31	-0.26	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	5.89	7.56e-09	3.2e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000254340.1	RP11-10A14.3	5.89	7.57e-09	3.2e-06	0.33	0.26	Mood instability;	chr8:8786764	chr8:9141424~9145435:+
HNSC	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-5.89	7.57e-09	3.2e-06	-0.34	-0.26	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
HNSC	cis	rs889014	0.751	rs11742399	ENSG00000253768.1	CTB-33O18.1	5.89	7.57e-09	3.2e-06	0.29	0.26	Height;	chr5:173551352	chr5:173562478~173573199:+
HNSC	cis	rs8177876	0.841	rs117310590	ENSG00000261061.1	RP11-303E16.2	-5.89	7.58e-09	3.21e-06	-0.48	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81030770~81031485:+
HNSC	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	5.89	7.6e-09	3.21e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
HNSC	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	5.89	7.6e-09	3.22e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-5.89	7.6e-09	3.22e-06	-0.29	-0.26	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
HNSC	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-5.88	7.61e-09	3.22e-06	-0.44	-0.26	Depression;	chr6:28076050	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-5.88	7.61e-09	3.22e-06	-0.44	-0.26	Depression;	chr6:28085045	chr6:28115628~28116551:+
HNSC	cis	rs673078	0.562	rs61944672	ENSG00000275409.1	RP11-131L12.4	-5.88	7.62e-09	3.22e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118450123	chr12:118430147~118430699:+
HNSC	cis	rs7615952	0.641	rs12488180	ENSG00000241288.6	RP11-379B18.5	-5.88	7.63e-09	3.23e-06	-0.34	-0.26	Blood pressure (smoking interaction);	chr3:126063393	chr3:125827238~125916384:-
HNSC	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-5.88	7.63e-09	3.23e-06	-0.28	-0.26	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
HNSC	cis	rs3743266	0.507	rs9630426	ENSG00000245534.5	RORA-AS1	-5.88	7.63e-09	3.23e-06	-0.42	-0.26	Menarche (age at onset);	chr15:60446854	chr15:60479178~60630637:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-5.88	7.64e-09	3.23e-06	-0.25	-0.26	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
HNSC	cis	rs13113518	0.812	rs13140173	ENSG00000273257.1	RP11-177J6.1	5.88	7.65e-09	3.23e-06	0.32	0.26	Height;	chr4:55527164	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-5.88	7.65e-09	3.23e-06	-0.2	-0.26	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
HNSC	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	5.88	7.66e-09	3.24e-06	0.28	0.26	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
HNSC	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-5.88	7.66e-09	3.24e-06	-0.36	-0.26	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
HNSC	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.66e-09	3.24e-06	-0.32	-0.26	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-5.88	7.68e-09	3.25e-06	-0.31	-0.26	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000228039.3	KB-1125A3.10	5.88	7.69e-09	3.25e-06	0.33	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-5.88	7.69e-09	3.25e-06	-0.31	-0.26	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
HNSC	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	5.88	7.69e-09	3.25e-06	0.32	0.26	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
HNSC	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-5.88	7.69e-09	3.25e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
HNSC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.88	7.69e-09	3.25e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
HNSC	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	5.88	7.69e-09	3.25e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	5.88	7.69e-09	3.25e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	5.88	7.7e-09	3.25e-06	0.4	0.26	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
HNSC	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-5.88	7.7e-09	3.26e-06	-0.44	-0.26	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000179406.6	LINC00174	-5.88	7.7e-09	3.26e-06	-0.57	-0.26	Diabetic kidney disease;	chr7:66528779	chr7:66376044~66401338:-
HNSC	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	5.88	7.71e-09	3.26e-06	0.36	0.26	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
HNSC	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	5.88	7.71e-09	3.26e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
HNSC	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.88	7.71e-09	3.26e-06	-0.2	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
HNSC	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-5.88	7.72e-09	3.26e-06	-0.41	-0.26	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
HNSC	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-5.88	7.72e-09	3.26e-06	-0.31	-0.26	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	5.88	7.73e-09	3.26e-06	0.36	0.26	Depression;	chr6:28206179	chr6:28943877~28944537:+
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000276691.1	RP5-1057I20.5	5.88	7.73e-09	3.26e-06	0.47	0.26	Pneumonia;	chr12:47716040	chr12:47788426~47788971:+
HNSC	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	5.88	7.74e-09	3.27e-06	0.34	0.26	Height;	chr4:55361200	chr4:55387949~55388271:+
HNSC	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	5.88	7.74e-09	3.27e-06	0.36	0.26	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
HNSC	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	5.88	7.74e-09	3.27e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
HNSC	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	5.88	7.74e-09	3.27e-06	0.33	0.26	Height;	chr4:55573424	chr4:55387949~55388271:+
HNSC	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-5.88	7.76e-09	3.28e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
HNSC	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	5.88	7.77e-09	3.28e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
HNSC	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	5.88	7.77e-09	3.28e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
HNSC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	5.88	7.77e-09	3.28e-06	0.29	0.26	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
HNSC	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.88	7.77e-09	3.28e-06	0.35	0.26	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
HNSC	cis	rs9840812	0.691	rs1070232	ENSG00000273486.1	RP11-731C17.2	5.88	7.77e-09	3.28e-06	0.23	0.26	Fibrinogen levels;	chr3:136529245	chr3:136837338~136839021:-
HNSC	cis	rs17507216	1	rs3850610	ENSG00000276710.3	CSPG4P8	5.88	7.79e-09	3.29e-06	0.32	0.26	Excessive daytime sleepiness;	chr15:82552642	chr15:82459472~82477258:+
HNSC	cis	rs889014	1	rs6885032	ENSG00000253768.1	CTB-33O18.1	5.88	7.8e-09	3.29e-06	0.28	0.26	Height;	chr5:173556276	chr5:173562478~173573199:+
HNSC	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-5.88	7.8e-09	3.29e-06	-0.31	-0.26	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
HNSC	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-5.88	7.8e-09	3.29e-06	-0.37	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	5.88	7.82e-09	3.3e-06	0.33	0.26	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
HNSC	cis	rs11846409	0.521	rs10143547	ENSG00000211974.3	IGHV2-70	-5.88	7.83e-09	3.3e-06	-0.3	-0.26	Rheumatic heart disease;	chr14:106644638	chr14:106723574~106724093:-
HNSC	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-5.88	7.83e-09	3.3e-06	-0.17	-0.26	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
HNSC	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	5.88	7.83e-09	3.31e-06	0.3	0.26	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.57	rs6810571	ENSG00000246560.2	RP11-10L12.4	5.88	7.83e-09	3.31e-06	0.3	0.26	Type 2 diabetes;	chr4:103165630	chr4:102828055~102844075:+
HNSC	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	5.88	7.84e-09	3.31e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
HNSC	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	5.88	7.84e-09	3.31e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
HNSC	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	5.88	7.84e-09	3.31e-06	0.33	0.26	Height;	chr6:109355573	chr6:109382795~109383666:+
HNSC	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	5.88	7.85e-09	3.31e-06	0.35	0.26	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000267151.3	RP11-100E5.2	5.88	7.85e-09	3.31e-06	0.34	0.26	Menopause (age at onset);	chr17:43126099	chr17:43444707~43451200:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000267151.3	RP11-100E5.2	5.88	7.85e-09	3.31e-06	0.34	0.26	Menopause (age at onset);	chr17:43126899	chr17:43444707~43451200:+
HNSC	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	5.88	7.86e-09	3.31e-06	0.35	0.26	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000254153.1	CTA-398F10.2	-5.88	7.87e-09	3.32e-06	-0.29	-0.26	Mood instability;	chr8:8460307	chr8:8456909~8461337:-
HNSC	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	5.88	7.89e-09	3.32e-06	0.33	0.26	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
HNSC	cis	rs4218	0.597	rs12442301	ENSG00000277144.1	RP11-59H7.4	-5.88	7.89e-09	3.33e-06	-0.35	-0.26	Social communication problems;	chr15:59065968	chr15:59115547~59116089:-
HNSC	cis	rs947583	0.517	rs6935371	ENSG00000217482.2	HMGB1P17	5.88	7.89e-09	3.33e-06	0.28	0.26	Phosphorus levels;	chr6:135779380	chr6:135636086~135636713:-
HNSC	cis	rs9693857	1	rs9693857	ENSG00000254340.1	RP11-10A14.3	-5.88	7.89e-09	3.33e-06	-0.32	-0.26	Systolic blood pressure;	chr8:9409607	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs778729	ENSG00000179406.6	LINC00174	-5.88	7.9e-09	3.33e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66359432	chr7:66376044~66401338:-
HNSC	cis	rs6918586	0.658	rs198819	ENSG00000272462.2	U91328.19	-5.88	7.9e-09	3.33e-06	-0.25	-0.26	Schizophrenia;	chr6:26124202	chr6:25992662~26001775:+
HNSC	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-5.88	7.91e-09	3.33e-06	-0.31	-0.26	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-5.88	7.91e-09	3.33e-06	-0.31	-0.26	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
HNSC	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	5.88	7.91e-09	3.34e-06	0.32	0.26	Height;	chr4:55561218	chr4:55363971~55395847:-
HNSC	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	5.88	7.92e-09	3.34e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
HNSC	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-5.88	7.92e-09	3.34e-06	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	5.88	7.92e-09	3.34e-06	0.26	0.26	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
HNSC	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	5.88	7.93e-09	3.34e-06	0.36	0.26	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-5.88	7.93e-09	3.34e-06	-0.31	-0.26	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	5.88	7.94e-09	3.35e-06	0.23	0.26	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
HNSC	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-5.88	7.95e-09	3.35e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
HNSC	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	5.88	7.95e-09	3.35e-06	0.32	0.26	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
HNSC	cis	rs7309	0.622	rs4664395	ENSG00000235724.7	AC009299.2	-5.88	7.95e-09	3.35e-06	-0.32	-0.26	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161222785~161308303:-
HNSC	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs2615539	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103159949	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	5.88	7.96e-09	3.35e-06	0.3	0.26	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
HNSC	cis	rs6918586	0.658	rs198813	ENSG00000272462.2	U91328.19	-5.88	7.96e-09	3.35e-06	-0.25	-0.26	Schizophrenia;	chr6:26127998	chr6:25992662~26001775:+
HNSC	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	5.88	7.96e-09	3.35e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	5.88	7.96e-09	3.35e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
HNSC	cis	rs9300255	0.51	rs1790133	ENSG00000280120.1	RP11-546D6.3	5.88	7.96e-09	3.35e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123213971	chr12:123152324~123153377:-
HNSC	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-5.88	7.96e-09	3.35e-06	-0.3	-0.26	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
HNSC	cis	rs4218	0.597	rs10431762	ENSG00000277144.1	RP11-59H7.4	-5.88	7.96e-09	3.35e-06	-0.36	-0.26	Social communication problems;	chr15:59066330	chr15:59115547~59116089:-
HNSC	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	5.88	7.97e-09	3.36e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
HNSC	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-5.88	7.97e-09	3.36e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
HNSC	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	5.88	7.98e-09	3.36e-06	0.31	0.26	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
HNSC	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-5.88	7.98e-09	3.36e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-5.88	7.99e-09	3.37e-06	-0.25	-0.26	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
HNSC	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-5.88	8e-09	3.37e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
HNSC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-5.88	8e-09	3.37e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-5.88	8e-09	3.37e-06	-0.31	-0.26	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-5.88	8e-09	3.37e-06	-0.17	-0.26	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
HNSC	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-5.88	8.01e-09	3.37e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
HNSC	cis	rs2834288	0.7	rs731061	ENSG00000237945.6	LINC00649	-5.88	8.01e-09	3.37e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33902937	chr21:33915534~33977691:+
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-5.88	8.02e-09	3.38e-06	-0.23	-0.26	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
HNSC	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.88	8.02e-09	3.38e-06	0.26	0.26	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
HNSC	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-5.88	8.02e-09	3.38e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
HNSC	cis	rs67981189	0.501	rs2810104	ENSG00000274818.1	RP1-292L20.3	5.87	8.05e-09	3.39e-06	0.31	0.26	Schizophrenia;	chr14:70958096	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	5.87	8.06e-09	3.39e-06	0.32	0.26	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
HNSC	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.87	8.06e-09	3.39e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
HNSC	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-5.87	8.06e-09	3.39e-06	-0.3	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
HNSC	cis	rs7567389	0.889	rs1504136	ENSG00000236682.1	AC068282.3	5.87	8.06e-09	3.39e-06	0.32	0.26	Self-rated health;	chr2:127219542	chr2:127389130~127400580:+
HNSC	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-5.87	8.06e-09	3.39e-06	-0.31	-0.26	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-5.87	8.07e-09	3.4e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	5.87	8.08e-09	3.4e-06	0.33	0.26	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	5.87	8.08e-09	3.4e-06	0.32	0.26	Depression;	chr6:28086929	chr6:28161781~28169594:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000179406.6	LINC00174	-5.87	8.09e-09	3.4e-06	-0.35	-0.26	Calcium levels;	chr7:65806798	chr7:66376044~66401338:-
HNSC	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	5.87	8.09e-09	3.4e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
HNSC	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	5.87	8.09e-09	3.4e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
HNSC	cis	rs860295	0.676	rs2666826	ENSG00000203761.5	MSTO2P	-5.87	8.09e-09	3.4e-06	-0.19	-0.26	Body mass index;	chr1:155688294	chr1:155745829~155750137:+
HNSC	cis	rs6504622	1	rs4968285	ENSG00000262879.4	RP11-156P1.3	-5.87	8.1e-09	3.41e-06	-0.28	-0.26	Orofacial clefts;	chr17:46938266	chr17:46984045~47100323:-
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	5.87	8.1e-09	3.41e-06	0.32	0.26	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	5.87	8.1e-09	3.41e-06	0.33	0.26	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
HNSC	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	5.87	8.11e-09	3.41e-06	0.32	0.26	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
HNSC	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.87	8.11e-09	3.41e-06	-0.35	-0.26	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
HNSC	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-5.87	8.11e-09	3.41e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	5.87	8.12e-09	3.41e-06	0.36	0.26	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
HNSC	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-5.87	8.12e-09	3.41e-06	-0.3	-0.26	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
HNSC	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-5.87	8.12e-09	3.41e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
HNSC	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	5.87	8.14e-09	3.42e-06	0.29	0.26	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
HNSC	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	5.87	8.15e-09	3.43e-06	0.25	0.26	Asthma;	chr2:102410644	chr2:102438713~102440475:+
HNSC	cis	rs667920	0.575	rs9861150	ENSG00000273486.1	RP11-731C17.2	5.87	8.16e-09	3.43e-06	0.26	0.26	Coronary artery disease;	chr3:136464478	chr3:136837338~136839021:-
HNSC	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-5.87	8.16e-09	3.43e-06	-0.33	-0.26	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	5.87	8.18e-09	3.44e-06	0.33	0.26	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	5.87	8.18e-09	3.44e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
HNSC	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-5.87	8.19e-09	3.44e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
HNSC	cis	rs2834288	0.7	rs6517196	ENSG00000237945.6	LINC00649	-5.87	8.2e-09	3.44e-06	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr21:33905116	chr21:33915534~33977691:+
HNSC	cis	rs5753618	0.504	rs5753659	ENSG00000236132.1	CTA-440B3.1	-5.87	8.2e-09	3.44e-06	-0.34	-0.26	Colorectal cancer;	chr22:31497627	chr22:31816379~31817491:-
HNSC	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	5.87	8.2e-09	3.45e-06	0.33	0.26	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	5.87	8.21e-09	3.45e-06	0.21	0.26	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-5.87	8.22e-09	3.45e-06	-0.31	-0.26	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-5.87	8.22e-09	3.45e-06	-0.31	-0.26	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
HNSC	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	5.87	8.22e-09	3.45e-06	0.36	0.26	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	5.87	8.22e-09	3.45e-06	0.36	0.26	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
HNSC	cis	rs6604026	0.522	rs12756786	ENSG00000223787.2	RP4-593M8.1	5.87	8.23e-09	3.45e-06	0.36	0.26	Multiple sclerosis;	chr1:92579398	chr1:92580476~92580821:-
HNSC	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-5.87	8.24e-09	3.46e-06	-0.31	-0.26	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
HNSC	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-5.87	8.25e-09	3.46e-06	-0.38	-0.26	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-5.87	8.26e-09	3.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
HNSC	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.26e-09	3.47e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
HNSC	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-5.87	8.26e-09	3.47e-06	-0.29	-0.26	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
HNSC	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	5.87	8.27e-09	3.47e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
HNSC	cis	rs2834288	0.5	rs881230	ENSG00000273102.1	AP000569.9	5.87	8.28e-09	3.47e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33967101~33968573:-
HNSC	cis	rs860295	0.836	rs1360554	ENSG00000203761.5	MSTO2P	5.87	8.28e-09	3.47e-06	0.19	0.26	Body mass index;	chr1:155503565	chr1:155745829~155750137:+
HNSC	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	5.87	8.28e-09	3.47e-06	0.36	0.26	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.87	8.31e-09	3.48e-06	-0.32	-0.26	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
HNSC	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.87	8.31e-09	3.49e-06	0.3	0.26	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
HNSC	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-5.87	8.32e-09	3.49e-06	-0.36	-0.26	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
HNSC	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-5.87	8.32e-09	3.49e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
HNSC	cis	rs9329221	0.967	rs7005363	ENSG00000269918.1	AF131215.9	-5.87	8.33e-09	3.49e-06	-0.26	-0.26	Neuroticism;	chr8:10426238	chr8:11104691~11106704:-
HNSC	cis	rs9840812	0.592	rs1711161	ENSG00000273486.1	RP11-731C17.2	5.87	8.33e-09	3.49e-06	0.23	0.26	Fibrinogen levels;	chr3:136361695	chr3:136837338~136839021:-
HNSC	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	5.87	8.34e-09	3.49e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.675	rs11154803	ENSG00000217482.2	HMGB1P17	5.87	8.34e-09	3.5e-06	0.29	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135636086~135636713:-
HNSC	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	5.87	8.35e-09	3.5e-06	0.23	0.26	Height;	chr11:118758322	chr11:118791254~118793137:+
HNSC	cis	rs9300255	0.679	rs10772998	ENSG00000280120.1	RP11-546D6.3	5.87	8.35e-09	3.5e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123236630	chr12:123152324~123153377:-
HNSC	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	5.87	8.35e-09	3.5e-06	0.29	0.26	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-5.87	8.35e-09	3.5e-06	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
HNSC	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	5.87	8.35e-09	3.5e-06	0.35	0.26	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
HNSC	cis	rs6928977	0.863	rs2223803	ENSG00000234084.1	RP3-388E23.2	5.87	8.35e-09	3.5e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135301568~135307158:+
HNSC	cis	rs67981189	0.529	rs2158996	ENSG00000274818.1	RP1-292L20.3	5.87	8.37e-09	3.51e-06	0.32	0.26	Schizophrenia;	chr14:71062882	chr14:70906657~70907111:-
HNSC	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	5.87	8.37e-09	3.51e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
HNSC	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-5.87	8.38e-09	3.51e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
HNSC	cis	rs7819412	0.838	rs3021494	ENSG00000269918.1	AF131215.9	-5.87	8.39e-09	3.51e-06	-0.26	-0.26	Triglycerides;	chr8:11126024	chr8:11104691~11106704:-
HNSC	cis	rs11992162	0.548	rs4841631	ENSG00000206014.6	OR7E161P	5.87	8.4e-09	3.52e-06	0.28	0.26	Monocyte count;	chr8:11924159	chr8:11928597~11929563:-
HNSC	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-5.87	8.4e-09	3.52e-06	-0.25	-0.26	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-5.87	8.4e-09	3.52e-06	-0.25	-0.26	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-5.87	8.41e-09	3.52e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
HNSC	cis	rs860295	0.702	rs1325908	ENSG00000203761.5	MSTO2P	-5.87	8.41e-09	3.52e-06	-0.2	-0.26	Body mass index;	chr1:155443513	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55490176	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55490228	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	5.87	8.42e-09	3.52e-06	0.32	0.26	Height;	chr4:55491150	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.675	rs58761508	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.631	rs9385726	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.637	rs9647635	ENSG00000234084.1	RP3-388E23.2	5.87	8.42e-09	3.52e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-5.87	8.42e-09	3.52e-06	-0.31	-0.26	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
HNSC	cis	rs10435719	0.867	rs62493601	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.753	rs9694940	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.78	rs9692662	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs9693925	ENSG00000206014.6	OR7E161P	-5.87	8.42e-09	3.52e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:11928597~11929563:-
HNSC	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	5.87	8.42e-09	3.53e-06	0.35	0.26	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
HNSC	cis	rs6867032	0.527	rs9312971	ENSG00000249731.1	RP11-259O2.3	5.87	8.42e-09	3.53e-06	0.29	0.26	Gut microbiome composition (winter);	chr5:2012774	chr5:1968094~1969013:+
HNSC	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	5.87	8.45e-09	3.54e-06	0.5	0.26	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
HNSC	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.87	8.45e-09	3.54e-06	-0.37	-0.26	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
HNSC	cis	rs9914544	0.966	rs9906795	ENSG00000264885.1	RP11-815I9.4	-5.87	8.46e-09	3.54e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18913427	chr17:18667629~18669461:-
HNSC	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-5.87	8.46e-09	3.54e-06	-0.31	-0.26	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
HNSC	cis	rs17270561	0.583	rs6926425	ENSG00000272462.2	U91328.19	-5.87	8.46e-09	3.54e-06	-0.26	-0.26	Iron status biomarkers;	chr6:25785076	chr6:25992662~26001775:+
HNSC	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	5.87	8.46e-09	3.54e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
HNSC	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	5.87	8.47e-09	3.54e-06	0.4	0.26	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
HNSC	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-5.87	8.47e-09	3.55e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
HNSC	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
HNSC	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-5.87	8.49e-09	3.55e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
HNSC	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	5.87	8.49e-09	3.55e-06	0.36	0.26	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
HNSC	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-5.87	8.51e-09	3.56e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
HNSC	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-5.86	8.52e-09	3.56e-06	-0.31	-0.26	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
HNSC	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.86	8.52e-09	3.56e-06	0.31	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
HNSC	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	5.86	8.52e-09	3.56e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
HNSC	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.86	8.52e-09	3.56e-06	0.3	0.26	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
HNSC	cis	rs6928977	0.896	rs2614284	ENSG00000234084.1	RP3-388E23.2	5.86	8.52e-09	3.56e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135301568~135307158:+
HNSC	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	5.86	8.53e-09	3.57e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	5.86	8.53e-09	3.57e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
HNSC	cis	rs804280	0.543	rs13261205	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11933707	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.867	rs34465618	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.867	rs34583868	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.518	rs34266352	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11933953	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.542	rs36100659	ENSG00000206014.6	OR7E161P	-5.86	8.55e-09	3.58e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934144	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-5.86	8.56e-09	3.58e-06	-0.31	-0.26	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-5.86	8.56e-09	3.58e-06	-0.31	-0.26	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
HNSC	cis	rs4657482	0.606	rs2241965	ENSG00000236364.3	RP11-525G13.2	5.86	8.56e-09	3.58e-06	0.26	0.26	Testicular germ cell tumor;	chr1:165896457	chr1:165890795~165900683:-
HNSC	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	5.86	8.57e-09	3.58e-06	0.36	0.26	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-5.86	8.57e-09	3.58e-06	-0.3	-0.26	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
HNSC	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-5.86	8.58e-09	3.59e-06	-0.33	-0.26	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
HNSC	cis	rs9341808	0.6	rs2505930	ENSG00000272129.1	RP11-250B2.6	5.86	8.58e-09	3.59e-06	0.31	0.26	Sitting height ratio;	chr6:80127341	chr6:80355424~80356859:+
HNSC	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-5.86	8.59e-09	3.59e-06	-0.3	-0.26	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
HNSC	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.86	8.63e-09	3.61e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
HNSC	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	5.86	8.63e-09	3.61e-06	0.32	0.26	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	5.86	8.63e-09	3.61e-06	0.32	0.26	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
HNSC	cis	rs2579103	0.809	rs1978864	ENSG00000258183.4	RP11-753N8.1	-5.86	8.63e-09	3.61e-06	-0.32	-0.26	Body mass index;	chr12:90232279	chr12:90280894~90300340:+
HNSC	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	5.86	8.64e-09	3.61e-06	0.31	0.26	Height;	chr4:55452921	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-5.86	8.65e-09	3.62e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-5.86	8.66e-09	3.62e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
HNSC	cis	rs60617249	0.507	rs34790261	ENSG00000228204.2	RP4-724E13.2	5.86	8.66e-09	3.62e-06	0.33	0.26	Major depression and alcohol dependence;	chr7:50880125	chr7:50866747~51022990:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-5.86	8.67e-09	3.62e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
HNSC	cis	rs4218	0.517	rs71480503	ENSG00000277144.1	RP11-59H7.4	-5.86	8.67e-09	3.62e-06	-0.36	-0.26	Social communication problems;	chr15:59098246	chr15:59115547~59116089:-
HNSC	cis	rs2439831	0.867	rs2243434	ENSG00000205771.5	CATSPER2P1	-5.86	8.68e-09	3.62e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43397669	chr15:43726918~43747094:-
HNSC	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	5.86	8.68e-09	3.62e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
HNSC	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-5.86	8.68e-09	3.63e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
HNSC	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-5.86	8.68e-09	3.63e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
HNSC	cis	rs2579103	0.965	rs2579106	ENSG00000258183.4	RP11-753N8.1	-5.86	8.69e-09	3.63e-06	-0.35	-0.26	Body mass index;	chr12:90234453	chr12:90280894~90300340:+
HNSC	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-5.86	8.7e-09	3.63e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
HNSC	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	5.86	8.7e-09	3.63e-06	0.34	0.26	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
HNSC	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	5.86	8.71e-09	3.64e-06	0.3	0.26	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
HNSC	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	5.86	8.72e-09	3.64e-06	0.2	0.26	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
HNSC	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-5.86	8.72e-09	3.64e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
HNSC	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	5.86	8.73e-09	3.64e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
HNSC	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-5.86	8.73e-09	3.64e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
HNSC	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.86	8.74e-09	3.65e-06	0.31	0.26	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.86	8.74e-09	3.65e-06	0.31	0.26	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
HNSC	cis	rs4218	0.597	rs62002544	ENSG00000277144.1	RP11-59H7.4	-5.86	8.74e-09	3.65e-06	-0.36	-0.26	Social communication problems;	chr15:59066663	chr15:59115547~59116089:-
HNSC	cis	rs9300255	0.739	rs11057210	ENSG00000280120.1	RP11-546D6.3	5.86	8.74e-09	3.65e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123249252	chr12:123152324~123153377:-
HNSC	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	5.86	8.75e-09	3.65e-06	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000254340.1	RP11-10A14.3	-5.86	8.75e-09	3.65e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8936144	chr8:9141424~9145435:+
HNSC	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-5.86	8.76e-09	3.65e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
HNSC	cis	rs804280	0.542	rs35647515	ENSG00000206014.6	OR7E161P	-5.86	8.76e-09	3.65e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934120	chr8:11928597~11929563:-
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	5.86	8.76e-09	3.66e-06	0.27	0.26	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
HNSC	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	5.86	8.77e-09	3.66e-06	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
HNSC	cis	rs1012068	0.686	rs5994451	ENSG00000236132.1	CTA-440B3.1	-5.86	8.77e-09	3.66e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31927525	chr22:31816379~31817491:-
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000173295.6	FAM86B3P	-5.86	8.78e-09	3.66e-06	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9011689	chr8:8228595~8244865:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66521515	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13237037	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66532895	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1796228	ENSG00000179406.6	LINC00174	-5.86	8.79e-09	3.66e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66568097	chr7:66376044~66401338:-
HNSC	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-5.86	8.79e-09	3.67e-06	-0.24	-0.26	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
HNSC	cis	rs17214007	0.518	rs35694612	ENSG00000263335.1	AF001548.5	-5.86	8.8e-09	3.67e-06	-0.39	-0.26	Cognitive function;	chr16:15674392	chr16:15726674~15732993:+
HNSC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-5.86	8.8e-09	3.67e-06	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
HNSC	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-5.86	8.8e-09	3.67e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
HNSC	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-5.86	8.81e-09	3.67e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
HNSC	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	5.86	8.83e-09	3.68e-06	0.5	0.26	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
HNSC	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	5.86	8.83e-09	3.68e-06	0.29	0.26	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
HNSC	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.86	8.84e-09	3.69e-06	-0.35	-0.26	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
HNSC	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	5.86	8.86e-09	3.69e-06	0.2	0.26	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
HNSC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-5.86	8.87e-09	3.7e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
HNSC	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-5.86	8.87e-09	3.7e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
HNSC	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	5.86	8.88e-09	3.7e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-5.86	8.88e-09	3.7e-06	-0.3	-0.26	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
HNSC	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-5.86	8.89e-09	3.7e-06	-0.22	-0.26	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-5.86	8.89e-09	3.7e-06	-0.22	-0.26	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
HNSC	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-5.86	8.89e-09	3.7e-06	-0.31	-0.26	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
HNSC	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-5.86	8.91e-09	3.71e-06	-0.21	-0.26	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
HNSC	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-5.86	8.92e-09	3.72e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
HNSC	cis	rs8031584	0.672	rs17227989	ENSG00000260382.1	RP11-540B6.2	5.86	8.94e-09	3.72e-06	0.38	0.26	Huntington's disease progression;	chr15:31001571	chr15:30882267~30883231:-
HNSC	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-5.86	8.95e-09	3.73e-06	-0.23	-0.26	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
HNSC	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-5.86	8.96e-09	3.73e-06	-0.25	-0.26	Asthma;	chr2:102399682	chr2:102438713~102440475:+
HNSC	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	5.86	8.96e-09	3.73e-06	0.32	0.26	Height;	chr4:55575856	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	5.86	8.96e-09	3.73e-06	0.21	0.26	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.675	rs7759971	ENSG00000234084.1	RP3-388E23.2	-5.86	8.96e-09	3.73e-06	-0.27	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135301568~135307158:+
HNSC	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-5.86	8.97e-09	3.74e-06	-0.31	-0.26	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66370832	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778679	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66375924	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778704	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66398480	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66407358	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs778691	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66408105	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13235972	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66418618	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34192067	ENSG00000179406.6	LINC00174	-5.86	8.98e-09	3.74e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66422670	chr7:66376044~66401338:-
HNSC	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	5.86	8.98e-09	3.74e-06	0.3	0.26	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
HNSC	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-5.86	8.99e-09	3.74e-06	-0.33	-0.26	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	5.86	9e-09	3.75e-06	0.2	0.26	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
HNSC	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.85	9.01e-09	3.75e-06	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
HNSC	cis	rs67981189	0.529	rs17093738	ENSG00000274818.1	RP1-292L20.3	5.85	9.01e-09	3.75e-06	0.32	0.26	Schizophrenia;	chr14:71119931	chr14:70906657~70907111:-
HNSC	cis	rs947583	0.573	rs9494336	ENSG00000217482.2	HMGB1P17	5.85	9.02e-09	3.75e-06	0.3	0.26	Phosphorus levels;	chr6:135694749	chr6:135636086~135636713:-
HNSC	cis	rs7209700	0.547	rs11657517	ENSG00000228782.6	CTD-2026D20.3	-5.85	9.02e-09	3.75e-06	-0.28	-0.26	IgG glycosylation;	chr17:47266347	chr17:47450568~47492492:-
HNSC	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5.85	9.02e-09	3.75e-06	0.19	0.26	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
HNSC	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-5.85	9.02e-09	3.76e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
HNSC	cis	rs740698	0.522	rs1024653	ENSG00000265702.1	RP11-156L14.1	-5.85	9.03e-09	3.76e-06	-0.32	-0.26	Pulse pressure;	chr17:62714457	chr17:62699244~62737922:+
HNSC	cis	rs860295	0.841	rs7556102	ENSG00000203761.5	MSTO2P	5.85	9.04e-09	3.76e-06	0.19	0.26	Body mass index;	chr1:155398412	chr1:155745829~155750137:+
HNSC	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	5.85	9.05e-09	3.77e-06	0.32	0.26	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
HNSC	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.85	9.06e-09	3.77e-06	-0.29	-0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
HNSC	cis	rs1355223	0.902	rs35032224	ENSG00000271369.1	RP11-350D17.3	-5.85	9.06e-09	3.77e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676607	chr11:34709600~34710161:+
HNSC	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	5.85	9.06e-09	3.77e-06	0.32	0.26	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
HNSC	cis	rs7819412	0.745	rs2898260	ENSG00000255310.2	AF131215.2	-5.85	9.07e-09	3.78e-06	-0.25	-0.26	Triglycerides;	chr8:11081980	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	5.85	9.08e-09	3.78e-06	0.32	0.26	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	5.85	9.09e-09	3.78e-06	0.35	0.26	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
HNSC	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	5.85	9.09e-09	3.78e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
HNSC	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	5.85	9.09e-09	3.78e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
HNSC	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.09e-09	3.78e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.09e-09	3.78e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
HNSC	cis	rs9341808	0.538	rs615585	ENSG00000272129.1	RP11-250B2.6	-5.85	9.09e-09	3.78e-06	-0.31	-0.26	Sitting height ratio;	chr6:80276436	chr6:80355424~80356859:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	5.85	9.11e-09	3.79e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	5.85	9.11e-09	3.79e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
HNSC	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	5.85	9.12e-09	3.79e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
HNSC	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-5.85	9.12e-09	3.79e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
HNSC	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	5.85	9.13e-09	3.79e-06	0.31	0.26	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
HNSC	cis	rs9326248	0.569	rs10047459	ENSG00000280143.1	AP000892.6	5.85	9.14e-09	3.8e-06	0.36	0.26	Blood protein levels;	chr11:116851110	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-5.85	9.14e-09	3.8e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
HNSC	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-5.85	9.14e-09	3.8e-06	-0.26	-0.26	Height;	chr2:231551270	chr2:231508426~231514339:-
HNSC	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-5.85	9.14e-09	3.8e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
HNSC	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-5.85	9.14e-09	3.8e-06	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
HNSC	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-5.85	9.16e-09	3.81e-06	-0.32	-0.26	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000254340.1	RP11-10A14.3	5.85	9.18e-09	3.82e-06	0.32	0.26	Mood instability;	chr8:8797017	chr8:9141424~9145435:+
HNSC	cis	rs2579103	0.898	rs1583700	ENSG00000258183.4	RP11-753N8.1	-5.85	9.19e-09	3.82e-06	-0.32	-0.26	Body mass index;	chr12:90206076	chr12:90280894~90300340:+
HNSC	cis	rs6604026	0.695	rs11164801	ENSG00000223787.2	RP4-593M8.1	5.85	9.19e-09	3.82e-06	0.34	0.26	Multiple sclerosis;	chr1:92737621	chr1:92580476~92580821:-
HNSC	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	5.85	9.22e-09	3.83e-06	0.35	0.26	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
HNSC	cis	rs9840812	0.623	rs1394092	ENSG00000273486.1	RP11-731C17.2	5.85	9.22e-09	3.83e-06	0.22	0.26	Fibrinogen levels;	chr3:136477229	chr3:136837338~136839021:-
HNSC	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-5.85	9.23e-09	3.84e-06	-0.24	-0.26	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	-5.85	9.23e-09	3.84e-06	-0.3	-0.26	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
HNSC	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-5.85	9.23e-09	3.84e-06	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
HNSC	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.23e-09	3.84e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
HNSC	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.85	9.25e-09	3.84e-06	0.32	0.26	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
HNSC	cis	rs860295	0.65	rs28662267	ENSG00000203761.5	MSTO2P	-5.85	9.25e-09	3.84e-06	-0.2	-0.26	Body mass index;	chr1:155710658	chr1:155745829~155750137:+
HNSC	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	5.85	9.26e-09	3.85e-06	0.28	0.26	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
HNSC	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-5.85	9.26e-09	3.85e-06	-0.36	-0.26	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-5.85	9.26e-09	3.85e-06	-0.3	-0.26	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
HNSC	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	5.85	9.27e-09	3.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000267151.3	RP11-100E5.2	5.85	9.29e-09	3.86e-06	0.33	0.26	Menopause (age at onset);	chr17:43135128	chr17:43444707~43451200:+
HNSC	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	5.85	9.29e-09	3.86e-06	0.36	0.26	Height;	chr6:109655182	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	5.85	9.29e-09	3.86e-06	0.36	0.26	Height;	chr6:109656105	chr6:109382795~109383666:+
HNSC	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	5.85	9.29e-09	3.86e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	5.85	9.29e-09	3.86e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.5	rs7178459	ENSG00000255769.6	GOLGA2P10	-5.85	9.3e-09	3.86e-06	-0.36	-0.26	Schizophrenia;	chr15:82729632	chr15:82472993~82513950:-
HNSC	cis	rs4218	0.813	rs8036907	ENSG00000277144.1	RP11-59H7.4	-5.85	9.31e-09	3.86e-06	-0.34	-0.26	Social communication problems;	chr15:59121144	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.724	rs35168204	ENSG00000277144.1	RP11-59H7.4	-5.85	9.31e-09	3.86e-06	-0.34	-0.26	Social communication problems;	chr15:59121354	chr15:59115547~59116089:-
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	5.85	9.31e-09	3.87e-06	0.29	0.26	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
HNSC	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	5.85	9.32e-09	3.87e-06	0.37	0.26	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-5.85	9.32e-09	3.87e-06	-0.33	-0.26	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	5.85	9.34e-09	3.88e-06	0.33	0.26	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
HNSC	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-5.85	9.34e-09	3.88e-06	-0.31	-0.26	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
HNSC	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	5.85	9.35e-09	3.88e-06	0.27	0.26	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
HNSC	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	5.85	9.35e-09	3.88e-06	0.36	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
HNSC	cis	rs603446	0.678	rs664059	ENSG00000254851.1	RP11-109L13.1	-5.85	9.36e-09	3.88e-06	-0.33	-0.26	Triglycerides;	chr11:116771421	chr11:117135528~117138582:+
HNSC	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	5.85	9.36e-09	3.88e-06	0.29	0.26	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	5.85	9.36e-09	3.89e-06	0.31	0.26	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
HNSC	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-5.85	9.36e-09	3.89e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.38e-09	3.89e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.85	9.38e-09	3.89e-06	0.32	0.26	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
HNSC	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-5.85	9.38e-09	3.89e-06	-0.38	-0.26	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
HNSC	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	5.85	9.38e-09	3.89e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
HNSC	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.85	9.39e-09	3.89e-06	-0.41	-0.26	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
HNSC	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	5.85	9.39e-09	3.89e-06	0.36	0.26	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	5.85	9.39e-09	3.89e-06	0.33	0.26	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	5.85	9.39e-09	3.9e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	5.85	9.39e-09	3.9e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
HNSC	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	5.85	9.4e-09	3.9e-06	0.36	0.26	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
HNSC	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-5.85	9.4e-09	3.9e-06	-0.33	-0.26	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-5.85	9.4e-09	3.9e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000179406.6	LINC00174	-5.85	9.4e-09	3.9e-06	-0.56	-0.26	Gout;	chr7:66645053	chr7:66376044~66401338:-
HNSC	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	5.85	9.41e-09	3.9e-06	0.32	0.26	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
HNSC	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-5.85	9.41e-09	3.9e-06	-0.31	-0.26	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-5.85	9.41e-09	3.9e-06	-0.31	-0.26	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
HNSC	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	5.85	9.42e-09	3.9e-06	0.19	0.26	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
HNSC	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-5.85	9.44e-09	3.91e-06	-0.31	-0.26	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-5.85	9.44e-09	3.91e-06	-0.31	-0.26	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
HNSC	cis	rs757110	0.866	rs5215	ENSG00000260196.1	RP1-239B22.5	5.85	9.44e-09	3.91e-06	0.29	0.26	Type 2 diabetes;	chr11:17387083	chr11:17380649~17383531:+
HNSC	cis	rs858239	0.863	rs466225	ENSG00000226816.2	AC005082.12	5.85	9.44e-09	3.91e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23206013~23208045:+
HNSC	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	5.85	9.44e-09	3.91e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	5.85	9.44e-09	3.91e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
HNSC	cis	rs10435719	0.805	rs13269417	ENSG00000206014.6	OR7E161P	-5.85	9.45e-09	3.92e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11928597~11929563:-
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	5.85	9.45e-09	3.92e-06	0.29	0.26	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
HNSC	cis	rs454422	1	rs236104	ENSG00000275632.1	RP5-967N21.11	5.85	9.46e-09	3.92e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5978314	chr20:6000418~6000941:+
HNSC	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-5.85	9.46e-09	3.92e-06	-0.33	-0.26	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
HNSC	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	5.85	9.47e-09	3.92e-06	0.33	0.26	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-5.85	9.47e-09	3.92e-06	-0.32	-0.26	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
HNSC	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	5.85	9.48e-09	3.93e-06	0.43	0.26	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
HNSC	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	5.85	9.49e-09	3.93e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
HNSC	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	5.85	9.51e-09	3.94e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	5.85	9.51e-09	3.94e-06	0.3	0.26	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-5.84	9.52e-09	3.94e-06	-0.27	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.84	9.53e-09	3.95e-06	0.32	0.26	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
HNSC	cis	rs10504130	0.66	rs6473666	ENSG00000272024.1	RP11-546K22.3	-5.84	9.53e-09	3.95e-06	-0.34	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51950284~51950690:+
HNSC	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-5.84	9.55e-09	3.95e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
HNSC	cis	rs508487	0.537	rs5072	ENSG00000280143.1	AP000892.6	5.84	9.55e-09	3.95e-06	0.47	0.26	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117204967~117210292:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	5.84	9.55e-09	3.95e-06	0.29	0.26	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
HNSC	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-5.84	9.55e-09	3.96e-06	-0.32	-0.26	Height;	chr4:55477866	chr4:55387949~55388271:+
HNSC	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	5.84	9.56e-09	3.96e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	5.84	9.56e-09	3.96e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
HNSC	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	5.84	9.56e-09	3.96e-06	0.33	0.26	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-5.84	9.56e-09	3.96e-06	-0.17	-0.26	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
HNSC	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	5.84	9.57e-09	3.96e-06	0.19	0.26	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
HNSC	cis	rs2579103	0.867	rs10745527	ENSG00000258183.4	RP11-753N8.1	-5.84	9.57e-09	3.96e-06	-0.32	-0.26	Body mass index;	chr12:90215240	chr12:90280894~90300340:+
HNSC	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	5.84	9.58e-09	3.97e-06	0.31	0.26	Depression;	chr6:28314871	chr6:28943877~28944537:+
HNSC	cis	rs6479901	0.501	rs7084396	ENSG00000232075.1	MRPL35P2	-5.84	9.59e-09	3.97e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63634317~63634827:-
HNSC	cis	rs13113518	0.783	rs12510400	ENSG00000273257.1	RP11-177J6.1	5.84	9.59e-09	3.97e-06	0.33	0.26	Height;	chr4:55577294	chr4:55387949~55388271:+
HNSC	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	5.84	9.59e-09	3.97e-06	0.28	0.26	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
HNSC	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.84	9.6e-09	3.97e-06	0.29	0.26	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000179406.6	LINC00174	-5.84	9.6e-09	3.97e-06	-0.34	-0.26	Calcium levels;	chr7:65977808	chr7:66376044~66401338:-
HNSC	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-5.84	9.6e-09	3.97e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-5.84	9.6e-09	3.97e-06	-0.32	-0.26	Depression;	chr6:28079011	chr6:28161781~28169594:+
HNSC	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	5.84	9.6e-09	3.97e-06	0.55	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
HNSC	cis	rs3743266	0.507	rs10162677	ENSG00000245534.5	RORA-AS1	-5.84	9.61e-09	3.98e-06	-0.42	-0.26	Menarche (age at onset);	chr15:60456369	chr15:60479178~60630637:+
HNSC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
HNSC	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-5.84	9.63e-09	3.98e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
HNSC	cis	rs858239	0.712	rs199650	ENSG00000226816.2	AC005082.12	-5.84	9.63e-09	3.98e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23206013~23208045:+
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-5.84	9.64e-09	3.99e-06	-0.3	-0.26	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
HNSC	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	5.84	9.64e-09	3.99e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
HNSC	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.84	9.65e-09	3.99e-06	-0.35	-0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
HNSC	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-5.84	9.65e-09	3.99e-06	-0.37	-0.26	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
HNSC	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-5.84	9.67e-09	4e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-5.84	9.67e-09	4e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
HNSC	cis	rs12922040	1	rs2075516	ENSG00000263065.1	AF001548.6	5.84	9.67e-09	4e-06	0.31	0.26	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15741151~15741791:+
HNSC	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-5.84	9.68e-09	4e-06	-0.34	-0.26	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
HNSC	cis	rs10506328	0.689	rs4759348	ENSG00000248265.1	FLJ12825	5.84	9.69e-09	4.01e-06	0.33	0.26	Mean platelet volume;	chr12:54236733	chr12:54058254~54122234:+
HNSC	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.84	9.7e-09	4.01e-06	-0.38	-0.26	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
HNSC	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	5.84	9.7e-09	4.01e-06	0.31	0.26	Height;	chr4:55574959	chr4:55363971~55395847:-
HNSC	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-5.84	9.7e-09	4.01e-06	-0.33	-0.26	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	5.84	9.71e-09	4.01e-06	0.34	0.26	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
HNSC	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.84	9.71e-09	4.01e-06	-0.35	-0.26	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
HNSC	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.84	9.71e-09	4.01e-06	-0.35	-0.26	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
HNSC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-5.84	9.72e-09	4.02e-06	-0.27	-0.26	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
HNSC	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-5.84	9.72e-09	4.02e-06	-0.23	-0.26	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
HNSC	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-5.84	9.72e-09	4.02e-06	-0.31	-0.26	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
HNSC	cis	rs17507216	1	rs17507216	ENSG00000276710.3	CSPG4P8	5.84	9.73e-09	4.02e-06	0.34	0.26	Excessive daytime sleepiness;	chr15:82558175	chr15:82459472~82477258:+
HNSC	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-5.84	9.73e-09	4.02e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000254153.1	CTA-398F10.2	5.84	9.74e-09	4.02e-06	0.29	0.26	Mood instability;	chr8:8482967	chr8:8456909~8461337:-
HNSC	cis	rs2834288	0.666	rs762188	ENSG00000237945.6	LINC00649	-5.84	9.74e-09	4.03e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902206	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.7	rs731059	ENSG00000237945.6	LINC00649	-5.84	9.74e-09	4.03e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902813	chr21:33915534~33977691:+
HNSC	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	5.84	9.75e-09	4.03e-06	0.3	0.26	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
HNSC	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-5.84	9.75e-09	4.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
HNSC	cis	rs947583	0.913	rs2027516	ENSG00000217482.2	HMGB1P17	5.84	9.75e-09	4.03e-06	0.29	0.26	Phosphorus levels;	chr6:135810750	chr6:135636086~135636713:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	5.84	9.75e-09	4.03e-06	0.2	0.26	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
HNSC	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	5.84	9.75e-09	4.03e-06	0.35	0.26	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	5.84	9.75e-09	4.03e-06	0.35	0.26	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
HNSC	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-5.84	9.75e-09	4.03e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
HNSC	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-5.84	9.77e-09	4.03e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
HNSC	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	5.84	9.77e-09	4.03e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
HNSC	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	5.84	9.78e-09	4.04e-06	0.32	0.26	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000173295.6	FAM86B3P	-5.84	9.78e-09	4.04e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9028444	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-5.84	9.78e-09	4.04e-06	-0.31	-0.26	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
HNSC	cis	rs2286503	0.78	rs12113458	ENSG00000221740.1	SNORD93	5.84	9.78e-09	4.04e-06	0.29	0.26	Fibrinogen;	chr7:22816009	chr7:22856613~22856686:+
HNSC	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-5.84	9.79e-09	4.04e-06	-0.23	-0.26	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
HNSC	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	5.84	9.79e-09	4.04e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	5.84	9.79e-09	4.04e-06	0.28	0.26	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
HNSC	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	5.84	9.8e-09	4.05e-06	0.27	0.26	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000179406.6	LINC00174	-5.84	9.81e-09	4.05e-06	-0.56	-0.26	Gout;	chr7:66654674	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000179406.6	LINC00174	-5.84	9.81e-09	4.05e-06	-0.56	-0.26	Gout;	chr7:66661502	chr7:66376044~66401338:-
HNSC	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-5.84	9.81e-09	4.05e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-5.84	9.81e-09	4.05e-06	-0.33	-0.26	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
HNSC	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-5.84	9.82e-09	4.05e-06	-0.33	-0.26	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
HNSC	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-5.84	9.82e-09	4.05e-06	-0.41	-0.26	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
HNSC	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-5.84	9.82e-09	4.05e-06	-0.31	-0.26	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-5.84	9.83e-09	4.06e-06	-0.31	-0.26	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
HNSC	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-5.84	9.83e-09	4.06e-06	-0.41	-0.26	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
HNSC	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-5.84	9.83e-09	4.06e-06	-0.33	-0.26	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-5.84	9.84e-09	4.06e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
HNSC	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-5.84	9.86e-09	4.07e-06	-0.29	-0.26	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
HNSC	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-5.84	9.86e-09	4.07e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-5.84	9.86e-09	4.07e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
HNSC	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	5.84	9.87e-09	4.07e-06	0.27	0.26	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
HNSC	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109613205	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109617741	chr6:109382795~109383666:+
HNSC	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	5.84	9.88e-09	4.08e-06	0.36	0.26	Height;	chr6:109619295	chr6:109382795~109383666:+
HNSC	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-5.84	9.88e-09	4.08e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-5.84	9.88e-09	4.08e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	5.84	9.88e-09	4.08e-06	0.2	0.26	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
HNSC	cis	rs6969780	0.778	rs2465276	ENSG00000233429.8	HOTAIRM1	5.84	9.88e-09	4.08e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106098	chr7:27095647~27100265:+
HNSC	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-5.84	9.89e-09	4.08e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
HNSC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.84	9.89e-09	4.08e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	5.84	9.9e-09	4.08e-06	0.28	0.26	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
HNSC	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	5.84	9.9e-09	4.08e-06	0.29	0.26	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
HNSC	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-5.84	9.9e-09	4.08e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
HNSC	cis	rs8177876	0.658	rs16954513	ENSG00000261061.1	RP11-303E16.2	-5.84	9.91e-09	4.09e-06	-0.48	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81030770~81031485:+
HNSC	cis	rs6928977	0.675	rs9399148	ENSG00000234084.1	RP3-388E23.2	5.84	9.91e-09	4.09e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135301568~135307158:+
HNSC	cis	rs4218	0.648	rs34407560	ENSG00000277144.1	RP11-59H7.4	-5.84	9.91e-09	4.09e-06	-0.36	-0.26	Social communication problems;	chr15:59073397	chr15:59115547~59116089:-
HNSC	cis	rs947583	0.588	rs9494389	ENSG00000217482.2	HMGB1P17	5.84	9.93e-09	4.1e-06	0.29	0.26	Phosphorus levels;	chr6:135794369	chr6:135636086~135636713:-
HNSC	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-5.84	9.94e-09	4.1e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
HNSC	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	5.84	9.94e-09	4.1e-06	0.28	0.26	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
HNSC	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-5.84	9.95e-09	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000233609.3	RP11-62H7.2	-5.84	9.95e-09	4.1e-06	-0.25	-0.26	Mood instability;	chr8:8937937	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000254340.1	RP11-10A14.3	-5.84	9.95e-09	4.1e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8935833	chr8:9141424~9145435:+
HNSC	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-5.84	9.96e-09	4.11e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
HNSC	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-5.84	9.96e-09	4.11e-06	-0.3	-0.26	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
HNSC	cis	rs4218	0.597	rs62002543	ENSG00000277144.1	RP11-59H7.4	-5.84	9.97e-09	4.11e-06	-0.35	-0.26	Social communication problems;	chr15:59066646	chr15:59115547~59116089:-
HNSC	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	5.84	9.97e-09	4.11e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
HNSC	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	5.84	9.98e-09	4.12e-06	0.3	0.26	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
HNSC	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	5.84	9.98e-09	4.12e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
HNSC	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	5.84	9.99e-09	4.12e-06	0.34	0.26	Height;	chr6:109478720	chr6:109382795~109383666:+
HNSC	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55452295	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55454900	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55454938	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	5.84	9.99e-09	4.12e-06	0.31	0.26	Height;	chr4:55455102	chr4:55363971~55395847:-
HNSC	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	5.84	1e-08	4.12e-06	0.41	0.26	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-5.84	1e-08	4.12e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-5.84	1e-08	4.12e-06	-0.41	-0.26	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
HNSC	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	5.84	1e-08	4.12e-06	0.3	0.26	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	5.84	1e-08	4.13e-06	0.33	0.26	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	5.84	1e-08	4.14e-06	0.34	0.26	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
HNSC	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-5.84	1e-08	4.14e-06	-0.35	-0.26	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-5.84	1e-08	4.14e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-5.84	1.01e-08	4.14e-06	-0.33	-0.26	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
HNSC	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.84	1.01e-08	4.14e-06	0.31	0.26	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
HNSC	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-5.84	1.01e-08	4.14e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	5.84	1.01e-08	4.14e-06	0.3	0.26	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
HNSC	cis	rs4218	0.648	rs2289895	ENSG00000277144.1	RP11-59H7.4	-5.83	1.01e-08	4.15e-06	-0.35	-0.26	Social communication problems;	chr15:59089570	chr15:59115547~59116089:-
HNSC	cis	rs11089937	0.626	rs11089933	ENSG00000211638.2	IGLV8-61	-5.83	1.01e-08	4.15e-06	-0.26	-0.26	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22098700~22099212:+
HNSC	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	5.83	1.01e-08	4.15e-06	0.25	0.26	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
HNSC	cis	rs2439831	0.867	rs3213991	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.16e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43378082	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7163245	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.16e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43379096	chr15:43726918~43747094:-
HNSC	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	5.83	1.01e-08	4.16e-06	0.32	0.26	Height;	chr4:55460485	chr4:55387949~55388271:+
HNSC	cis	rs2439831	1	rs690263	ENSG00000205771.5	CATSPER2P1	-5.83	1.01e-08	4.17e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43412267	chr15:43726918~43747094:-
HNSC	cis	rs4218	0.648	rs1074702	ENSG00000277144.1	RP11-59H7.4	-5.83	1.01e-08	4.17e-06	-0.36	-0.26	Social communication problems;	chr15:59073900	chr15:59115547~59116089:-
HNSC	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.83	1.01e-08	4.18e-06	-0.34	-0.26	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	5.83	1.02e-08	4.18e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
HNSC	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-5.83	1.02e-08	4.19e-06	-0.26	-0.26	Height;	chr2:231553603	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-5.83	1.02e-08	4.19e-06	-0.32	-0.26	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-5.83	1.02e-08	4.2e-06	-0.17	-0.26	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
HNSC	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	5.83	1.02e-08	4.2e-06	0.36	0.26	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
HNSC	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	5.83	1.02e-08	4.2e-06	0.29	0.26	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
HNSC	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-5.83	1.02e-08	4.2e-06	-0.4	-0.26	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
HNSC	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	5.83	1.02e-08	4.2e-06	0.32	0.26	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
HNSC	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	5.83	1.02e-08	4.2e-06	0.29	0.26	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
HNSC	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-5.83	1.02e-08	4.2e-06	-0.24	-0.26	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
HNSC	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	5.83	1.02e-08	4.2e-06	0.34	0.26	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
HNSC	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-5.83	1.02e-08	4.2e-06	-0.36	-0.26	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
HNSC	cis	rs1355223	0.872	rs12785367	ENSG00000271369.1	RP11-350D17.3	-5.83	1.02e-08	4.21e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34693722	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs11819839	ENSG00000271369.1	RP11-350D17.3	-5.83	1.02e-08	4.21e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34694231	chr11:34709600~34710161:+
HNSC	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-5.83	1.02e-08	4.21e-06	-0.52	-0.26	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
HNSC	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	5.83	1.02e-08	4.22e-06	0.34	0.26	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
HNSC	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	5.83	1.03e-08	4.23e-06	0.27	0.26	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
HNSC	cis	rs9402743	0.632	rs7773035	ENSG00000217482.2	HMGB1P17	5.83	1.03e-08	4.23e-06	0.28	0.26	Systemic lupus erythematosus;	chr6:135784743	chr6:135636086~135636713:-
HNSC	cis	rs6604026	0.555	rs67646822	ENSG00000223787.2	RP4-593M8.1	5.83	1.03e-08	4.23e-06	0.36	0.26	Multiple sclerosis;	chr1:92643406	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.661	rs72724555	ENSG00000223787.2	RP4-593M8.1	5.83	1.03e-08	4.23e-06	0.36	0.26	Multiple sclerosis;	chr1:92645318	chr1:92580476~92580821:-
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000254340.1	RP11-10A14.3	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Joint mobility (Beighton score);	chr8:8935355	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000173295.6	FAM86B3P	-5.83	1.03e-08	4.24e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9026993	chr8:8228595~8244865:+
HNSC	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
HNSC	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	5.83	1.03e-08	4.24e-06	0.31	0.26	Height;	chr4:55582068	chr4:55363971~55395847:-
HNSC	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	5.83	1.03e-08	4.24e-06	0.35	0.26	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082231	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082261	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28082984	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28083994	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28084025	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-5.83	1.03e-08	4.24e-06	-0.32	-0.26	Depression;	chr6:28085319	chr6:28161781~28169594:+
HNSC	cis	rs189798	0.807	rs9949	ENSG00000173295.6	FAM86B3P	5.83	1.03e-08	4.24e-06	0.34	0.26	Myopia (pathological);	chr8:9137002	chr8:8228595~8244865:+
HNSC	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-5.83	1.03e-08	4.24e-06	-0.27	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
HNSC	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	5.83	1.03e-08	4.25e-06	0.34	0.26	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
HNSC	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	5.83	1.04e-08	4.26e-06	0.28	0.26	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
HNSC	cis	rs9914544	1	rs1737944	ENSG00000264885.1	RP11-815I9.4	-5.83	1.04e-08	4.26e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18937120	chr17:18667629~18669461:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-5.83	1.04e-08	4.26e-06	-0.4	-0.26	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
HNSC	cis	rs6918586	0.658	rs198830	ENSG00000272462.2	U91328.19	-5.83	1.04e-08	4.26e-06	-0.25	-0.26	Schizophrenia;	chr6:26118018	chr6:25992662~26001775:+
HNSC	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	5.83	1.04e-08	4.27e-06	0.32	0.26	Height;	chr4:55493557	chr4:55387949~55388271:+
HNSC	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	5.83	1.04e-08	4.27e-06	0.34	0.26	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
HNSC	cis	rs6928977	0.66	rs9389301	ENSG00000217482.2	HMGB1P17	-5.83	1.04e-08	4.27e-06	-0.29	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135549844	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-5.83	1.04e-08	4.27e-06	-0.32	-0.26	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
HNSC	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	5.83	1.04e-08	4.27e-06	0.34	0.26	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
HNSC	cis	rs7587476	0.906	rs2734674	ENSG00000229267.2	AC072062.1	5.83	1.04e-08	4.28e-06	0.36	0.26	Neuroblastoma;	chr2:214794171	chr2:214810229~214963274:+
HNSC	cis	rs2115630	1	rs7183401	ENSG00000229212.6	RP11-561C5.4	5.83	1.04e-08	4.28e-06	0.29	0.26	P wave terminal force;	chr15:84828713	chr15:85205440~85234795:-
HNSC	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-5.83	1.04e-08	4.28e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
HNSC	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	5.83	1.04e-08	4.28e-06	0.27	0.26	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-5.83	1.04e-08	4.29e-06	-0.37	-0.26	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
HNSC	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	5.83	1.04e-08	4.29e-06	0.36	0.26	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
HNSC	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-5.83	1.04e-08	4.29e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	5.83	1.04e-08	4.29e-06	0.29	0.26	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	5.83	1.04e-08	4.29e-06	0.29	0.26	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
HNSC	cis	rs61542988	0.57	rs62448267	ENSG00000228649.7	AC005682.5	5.83	1.05e-08	4.29e-06	0.33	0.26	Fibrinogen levels;	chr7:22782882	chr7:22854178~22861579:+
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-5.83	1.05e-08	4.29e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.29e-06	0.32	0.26	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
HNSC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	5.83	1.05e-08	4.3e-06	0.3	0.26	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
HNSC	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	5.83	1.05e-08	4.3e-06	0.29	0.26	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
HNSC	cis	rs7819412	0.745	rs28464654	ENSG00000269918.1	AF131215.9	-5.83	1.05e-08	4.3e-06	-0.26	-0.26	Triglycerides;	chr8:11223156	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.745	rs28591576	ENSG00000269918.1	AF131215.9	-5.83	1.05e-08	4.3e-06	-0.26	-0.26	Triglycerides;	chr8:11223166	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.3e-06	0.32	0.26	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
HNSC	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.83	1.05e-08	4.3e-06	0.19	0.26	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
HNSC	cis	rs35955747	0.749	rs2027982	ENSG00000236132.1	CTA-440B3.1	5.83	1.05e-08	4.31e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31197449	chr22:31816379~31817491:-
HNSC	cis	rs4218	0.648	rs12910987	ENSG00000277144.1	RP11-59H7.4	-5.83	1.05e-08	4.31e-06	-0.35	-0.26	Social communication problems;	chr15:59092782	chr15:59115547~59116089:-
HNSC	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-5.83	1.05e-08	4.32e-06	-0.51	-0.26	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	5.83	1.05e-08	4.32e-06	0.32	0.26	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
HNSC	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-5.83	1.06e-08	4.33e-06	-0.33	-0.26	Height;	chr6:109417511	chr6:109382795~109383666:+
HNSC	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-5.83	1.06e-08	4.33e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
HNSC	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	5.83	1.06e-08	4.33e-06	0.32	0.26	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
HNSC	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-5.83	1.06e-08	4.34e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	5.83	1.06e-08	4.34e-06	0.33	0.26	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
HNSC	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	5.83	1.06e-08	4.34e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000173295.6	FAM86B3P	-5.83	1.06e-08	4.34e-06	-0.29	-0.26	Mood instability;	chr8:8938391	chr8:8228595~8244865:+
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000211974.3	IGHV2-70	-5.83	1.06e-08	4.34e-06	-0.29	-0.26	Rheumatic heart disease;	chr14:106631568	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	5.83	1.06e-08	4.34e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
HNSC	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	5.83	1.06e-08	4.34e-06	0.37	0.26	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
HNSC	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	5.83	1.06e-08	4.35e-06	0.3	0.26	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
HNSC	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	5.83	1.06e-08	4.35e-06	0.23	0.26	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
HNSC	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-5.83	1.06e-08	4.35e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.543	rs8027536	ENSG00000259732.1	RP11-59H7.3	-5.83	1.06e-08	4.35e-06	-0.33	-0.26	Social communication problems;	chr15:59022364	chr15:59121034~59133250:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000179406.6	LINC00174	-5.83	1.06e-08	4.35e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1267818	ENSG00000179406.6	LINC00174	-5.83	1.06e-08	4.35e-06	-0.56	-0.26	Gout;	chr7:66642037	chr7:66376044~66401338:-
HNSC	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-5.83	1.06e-08	4.35e-06	-0.29	-0.26	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
HNSC	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-5.83	1.06e-08	4.35e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
HNSC	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.83	1.06e-08	4.35e-06	-0.34	-0.26	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
HNSC	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-5.83	1.06e-08	4.36e-06	-0.23	-0.26	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
HNSC	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-5.83	1.06e-08	4.36e-06	-0.37	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-5.83	1.06e-08	4.36e-06	-0.25	-0.26	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
HNSC	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	5.83	1.06e-08	4.36e-06	0.32	0.26	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
HNSC	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	5.83	1.06e-08	4.36e-06	0.32	0.26	Height;	chr4:55544621	chr4:55387949~55388271:+
HNSC	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-5.83	1.06e-08	4.36e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
HNSC	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	5.83	1.06e-08	4.36e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
HNSC	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	5.82	1.07e-08	4.37e-06	0.33	0.26	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
HNSC	cis	rs988913	1	rs6902422	ENSG00000224984.1	RP11-524H19.2	-5.82	1.07e-08	4.37e-06	-0.29	-0.26	Menarche (age at onset);	chr6:54946412	chr6:54840118~54840855:-
HNSC	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.82	1.07e-08	4.37e-06	0.49	0.26	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
HNSC	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.37e-06	0.36	0.26	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.37e-06	0.36	0.26	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
HNSC	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	5.82	1.07e-08	4.37e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
HNSC	cis	rs4218	0.689	rs12440692	ENSG00000259732.1	RP11-59H7.3	-5.82	1.07e-08	4.38e-06	-0.36	-0.26	Social communication problems;	chr15:59090671	chr15:59121034~59133250:+
HNSC	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	5.82	1.07e-08	4.38e-06	0.27	0.26	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
HNSC	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-5.82	1.07e-08	4.38e-06	-0.22	-0.26	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	5.82	1.07e-08	4.38e-06	0.29	0.26	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
HNSC	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	5.82	1.07e-08	4.39e-06	0.31	0.26	Height;	chr4:55430730	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	5.82	1.07e-08	4.39e-06	0.31	0.26	Height;	chr4:55430740	chr4:55363971~55395847:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-5.82	1.07e-08	4.39e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-5.82	1.07e-08	4.39e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-5.82	1.07e-08	4.39e-06	-0.32	-0.26	Depression;	chr6:28126588	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-5.82	1.07e-08	4.39e-06	-0.32	-0.26	Depression;	chr6:28126953	chr6:28161781~28169594:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	5.82	1.07e-08	4.39e-06	0.27	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
HNSC	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	5.82	1.07e-08	4.4e-06	0.35	0.26	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	5.82	1.07e-08	4.4e-06	0.3	0.26	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.82	1.08e-08	4.41e-06	0.31	0.26	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-5.82	1.08e-08	4.41e-06	-0.39	-0.26	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
HNSC	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-5.82	1.08e-08	4.41e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
HNSC	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	5.82	1.08e-08	4.42e-06	0.32	0.26	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
HNSC	cis	rs13043901	0.539	rs6097480	ENSG00000197670.6	RP4-724E16.2	-5.82	1.08e-08	4.42e-06	-0.25	-0.26	Type 2 diabetes (age of onset);	chr20:53560021	chr20:53552770~53575863:+
HNSC	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-5.82	1.08e-08	4.42e-06	-0.32	-0.26	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
HNSC	cis	rs6604026	0.555	rs11589122	ENSG00000223787.2	RP4-593M8.1	5.82	1.08e-08	4.43e-06	0.36	0.26	Multiple sclerosis;	chr1:92618346	chr1:92580476~92580821:-
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	5.82	1.08e-08	4.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	5.82	1.08e-08	4.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.82	1.08e-08	4.43e-06	0.23	0.26	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
HNSC	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-5.82	1.08e-08	4.43e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
HNSC	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	5.82	1.08e-08	4.44e-06	0.29	0.26	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	5.82	1.08e-08	4.44e-06	0.2	0.26	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	5.82	1.08e-08	4.44e-06	0.29	0.26	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
HNSC	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	5.82	1.08e-08	4.44e-06	0.31	0.26	Height;	chr4:55459921	chr4:55363971~55395847:-
HNSC	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-5.82	1.08e-08	4.44e-06	-0.32	-0.26	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
HNSC	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-5.82	1.08e-08	4.44e-06	-0.31	-0.26	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-5.82	1.08e-08	4.44e-06	-0.31	-0.26	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
HNSC	cis	rs1355223	1	rs11601923	ENSG00000271369.1	RP11-350D17.3	-5.82	1.09e-08	4.45e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742807	chr11:34709600~34710161:+
HNSC	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	5.82	1.09e-08	4.45e-06	0.34	0.26	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
HNSC	cis	rs2243480	1	rs1267820	ENSG00000179406.6	LINC00174	-5.82	1.09e-08	4.45e-06	-0.56	-0.26	Diabetic kidney disease;	chr7:66585308	chr7:66376044~66401338:-
HNSC	cis	rs3206736	0.548	rs1649221	ENSG00000197085.10	NPSR1-AS1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34948146	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.529	rs1649225	ENSG00000197085.10	NPSR1-AS1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34952064	chr7:34346512~34871582:-
HNSC	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-5.82	1.09e-08	4.45e-06	-0.32	-0.26	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
HNSC	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-5.82	1.09e-08	4.46e-06	-0.26	-0.26	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
HNSC	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-5.82	1.09e-08	4.46e-06	-0.26	-0.26	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
HNSC	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	5.82	1.09e-08	4.46e-06	0.67	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
HNSC	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	5.82	1.09e-08	4.47e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-5.82	1.09e-08	4.47e-06	-0.17	-0.26	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
HNSC	cis	rs5753618	0.583	rs5753639	ENSG00000236132.1	CTA-440B3.1	5.82	1.09e-08	4.47e-06	0.31	0.26	Colorectal cancer;	chr22:31474414	chr22:31816379~31817491:-
HNSC	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	5.82	1.09e-08	4.48e-06	0.33	0.26	Height;	chr4:55415153	chr4:55363971~55395847:-
HNSC	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	5.82	1.09e-08	4.48e-06	0.34	0.26	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
HNSC	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-5.82	1.09e-08	4.48e-06	-0.32	-0.26	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
HNSC	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	5.82	1.09e-08	4.48e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
HNSC	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.82	1.1e-08	4.48e-06	0.31	0.26	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
HNSC	cis	rs1865760	0.613	rs7749342	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.48e-06	-0.25	-0.26	Height;	chr6:25920037	chr6:25992662~26001775:+
HNSC	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	5.82	1.1e-08	4.49e-06	0.29	0.26	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
HNSC	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	5.82	1.1e-08	4.49e-06	0.4	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
HNSC	cis	rs1865760	0.573	rs7450342	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.49e-06	-0.25	-0.26	Height;	chr6:25919252	chr6:25992662~26001775:+
HNSC	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	5.82	1.1e-08	4.5e-06	0.36	0.26	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
HNSC	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	5.82	1.1e-08	4.5e-06	0.32	0.26	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
HNSC	cis	rs4218	0.648	rs57361749	ENSG00000277144.1	RP11-59H7.4	-5.82	1.1e-08	4.5e-06	-0.35	-0.26	Social communication problems;	chr15:59091352	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.608	rs16941014	ENSG00000277144.1	RP11-59H7.4	-5.82	1.1e-08	4.5e-06	-0.35	-0.26	Social communication problems;	chr15:59091503	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	5.82	1.1e-08	4.5e-06	0.4	0.26	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
HNSC	cis	rs1800562	1	rs1800562	ENSG00000272462.2	U91328.19	-5.82	1.1e-08	4.5e-06	-0.49	-0.26	Hematology traits;Iron status biomarkers (transferrin levels);Iron status biomarkers;Red blood cell count;Red blood cell traits;Mean corpuscular volume;Iron status biomarkers (ferritin levels);Iron status biomarkers (transferrin saturation);Diastolic blood pressure;Cholesterol, total;Cardiovascular disease risk factors;Hematocrit;Alcohol consumption (transferrin glycosylation);Hemoglobin;Iron status biomarkers (iron levels);Hematological parameters;LDL cholesterol;Mean corpuscular hemoglobin;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hepcidin levels;	chr6:26092913	chr6:25992662~26001775:+
HNSC	cis	rs8054556	0.751	rs11642430	ENSG00000183604.13	SMG1P5	-5.82	1.1e-08	4.51e-06	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30267553~30335374:-
HNSC	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	5.82	1.1e-08	4.51e-06	0.23	0.26	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-5.82	1.1e-08	4.51e-06	-0.32	-0.26	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000254153.1	CTA-398F10.2	5.82	1.1e-08	4.52e-06	0.29	0.26	Mood instability;	chr8:8483595	chr8:8456909~8461337:-
HNSC	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	5.82	1.11e-08	4.52e-06	0.32	0.26	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
HNSC	cis	rs4218	0.648	rs17236453	ENSG00000277144.1	RP11-59H7.4	-5.82	1.11e-08	4.52e-06	-0.35	-0.26	Social communication problems;	chr15:59092156	chr15:59115547~59116089:-
HNSC	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	5.82	1.11e-08	4.52e-06	0.28	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
HNSC	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.82	1.11e-08	4.53e-06	0.31	0.26	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
HNSC	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	5.82	1.11e-08	4.53e-06	0.55	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
HNSC	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	5.82	1.11e-08	4.53e-06	0.23	0.26	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
HNSC	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-5.82	1.11e-08	4.53e-06	-0.23	-0.26	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
HNSC	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	5.82	1.11e-08	4.54e-06	0.31	0.26	Height;	chr4:55450812	chr4:55363971~55395847:-
HNSC	cis	rs1021993	0.857	rs1395756	ENSG00000231648.1	RP11-372M18.2	5.82	1.11e-08	4.54e-06	0.36	0.26	Gut microbiome composition (winter);	chr1:209290352	chr1:209367662~209379690:+
HNSC	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	5.82	1.11e-08	4.54e-06	0.37	0.26	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
HNSC	cis	rs2286503	0.78	rs929464	ENSG00000221740.1	SNORD93	5.82	1.11e-08	4.54e-06	0.29	0.26	Fibrinogen;	chr7:22835151	chr7:22856613~22856686:+
HNSC	cis	rs7615952	0.512	rs2979336	ENSG00000241288.6	RP11-379B18.5	-5.82	1.11e-08	4.54e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125638626	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	5.82	1.11e-08	4.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
HNSC	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-5.82	1.11e-08	4.55e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
HNSC	cis	rs2439831	0.717	rs10518820	ENSG00000205771.5	CATSPER2P1	-5.82	1.11e-08	4.55e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43596778	chr15:43726918~43747094:-
HNSC	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-5.82	1.11e-08	4.55e-06	-0.36	-0.26	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
HNSC	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.82	1.11e-08	4.55e-06	0.31	0.26	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
HNSC	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.82	1.11e-08	4.55e-06	-0.21	-0.26	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
HNSC	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-5.82	1.11e-08	4.55e-06	-0.26	-0.26	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.82	1.11e-08	4.55e-06	0.25	0.26	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
HNSC	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-5.82	1.12e-08	4.55e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-5.82	1.12e-08	4.56e-06	-0.17	-0.26	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
HNSC	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	5.82	1.12e-08	4.56e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
HNSC	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-5.82	1.12e-08	4.56e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
HNSC	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.56e-06	0.34	0.26	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
HNSC	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-5.82	1.12e-08	4.56e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
HNSC	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	5.82	1.12e-08	4.56e-06	0.36	0.26	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
HNSC	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.56e-06	0.35	0.26	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
HNSC	cis	rs78773383	0.505	rs10033019	ENSG00000249207.1	RP11-360F5.1	5.82	1.12e-08	4.57e-06	0.3	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39112677~39126818:-
HNSC	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-5.82	1.12e-08	4.57e-06	-0.34	-0.26	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
HNSC	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	5.82	1.12e-08	4.57e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000179406.6	LINC00174	-5.82	1.12e-08	4.57e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66376044~66401338:-
HNSC	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	5.82	1.12e-08	4.57e-06	0.35	0.26	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.66	rs2614263	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.57e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135636086~135636713:-
HNSC	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-5.82	1.12e-08	4.58e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
HNSC	cis	rs9341808	0.905	rs9343977	ENSG00000272129.1	RP11-250B2.6	5.82	1.12e-08	4.58e-06	0.31	0.26	Sitting height ratio;	chr6:80257284	chr6:80355424~80356859:+
HNSC	cis	rs6928977	0.66	rs2614267	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.58e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135636086~135636713:-
HNSC	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.59e-06	0.35	0.26	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	5.82	1.12e-08	4.59e-06	0.35	0.26	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-5.82	1.12e-08	4.59e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
HNSC	cis	rs6928977	0.66	rs2757647	ENSG00000217482.2	HMGB1P17	-5.82	1.12e-08	4.59e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135636086~135636713:-
HNSC	cis	rs9341808	0.519	rs4446525	ENSG00000272129.1	RP11-250B2.6	-5.82	1.12e-08	4.59e-06	-0.31	-0.26	Sitting height ratio;	chr6:80314336	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.538	rs613588	ENSG00000272129.1	RP11-250B2.6	-5.82	1.13e-08	4.59e-06	-0.31	-0.26	Sitting height ratio;	chr6:80269211	chr6:80355424~80356859:+
HNSC	cis	rs7615952	0.512	rs4679430	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639049	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs34651730	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639796	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs2979334	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125639980	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs11929125	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125640599	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs11921452	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125640906	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.512	rs2922175	ENSG00000241288.6	RP11-379B18.5	-5.82	1.13e-08	4.59e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125642516	chr3:125827238~125916384:-
HNSC	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-5.82	1.13e-08	4.59e-06	-0.31	-0.26	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
HNSC	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-5.81	1.13e-08	4.59e-06	-0.29	-0.26	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
HNSC	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-5.81	1.13e-08	4.59e-06	-0.29	-0.26	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
HNSC	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-5.81	1.13e-08	4.6e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
HNSC	cis	rs6928977	0.66	rs9373131	ENSG00000217482.2	HMGB1P17	-5.81	1.13e-08	4.6e-06	-0.28	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135636086~135636713:-
HNSC	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-5.81	1.13e-08	4.6e-06	-0.31	-0.26	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
HNSC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-5.81	1.13e-08	4.6e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
HNSC	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55461320	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55462689	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55463606	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55466010	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55467308	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55470266	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55470874	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55474259	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	5.81	1.13e-08	4.61e-06	0.31	0.26	Height;	chr4:55475130	chr4:55363971~55395847:-
HNSC	cis	rs6928977	0.714	rs11154801	ENSG00000234084.1	RP3-388E23.2	-5.81	1.13e-08	4.61e-06	-0.27	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135301568~135307158:+
HNSC	cis	rs330048	0.51	rs11784654	ENSG00000254340.1	RP11-10A14.3	-5.81	1.13e-08	4.61e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr8:9112101	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-5.81	1.13e-08	4.61e-06	-0.31	-0.26	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
HNSC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.81	1.13e-08	4.61e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	5.81	1.13e-08	4.62e-06	0.2	0.26	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
HNSC	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	5.81	1.13e-08	4.62e-06	0.36	0.26	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
HNSC	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.63e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
HNSC	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-5.81	1.14e-08	4.63e-06	-0.37	-0.26	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	5.81	1.14e-08	4.63e-06	0.3	0.26	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
HNSC	cis	rs7617773	0.539	rs13094496	ENSG00000228638.1	FCF1P2	-5.81	1.14e-08	4.63e-06	-0.23	-0.26	Coronary artery disease;	chr3:48345560	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	5.81	1.14e-08	4.63e-06	0.17	0.26	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	5.81	1.14e-08	4.64e-06	0.2	0.26	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
HNSC	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	5.81	1.14e-08	4.65e-06	0.34	0.26	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	5.81	1.14e-08	4.65e-06	0.34	0.26	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
HNSC	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-5.81	1.14e-08	4.65e-06	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-5.81	1.14e-08	4.65e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	5.81	1.14e-08	4.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
HNSC	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	5.81	1.14e-08	4.66e-06	0.19	0.26	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
HNSC	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-5.81	1.14e-08	4.66e-06	-0.36	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-5.81	1.15e-08	4.66e-06	-0.34	-0.26	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-5.81	1.15e-08	4.66e-06	-0.34	-0.26	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
HNSC	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	5.81	1.15e-08	4.66e-06	0.29	0.26	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
HNSC	cis	rs6928977	0.826	rs9321502	ENSG00000234084.1	RP3-388E23.2	5.81	1.15e-08	4.67e-06	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135335114	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.538	rs9494290	ENSG00000217482.2	HMGB1P17	5.81	1.15e-08	4.67e-06	0.3	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135636086~135636713:-
HNSC	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-5.81	1.15e-08	4.67e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
HNSC	cis	rs7806994	1	rs7806994	ENSG00000226278.1	PSPHP1	-5.81	1.15e-08	4.67e-06	-0.36	-0.26	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55764797~55773288:+
HNSC	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	5.81	1.15e-08	4.67e-06	0.24	0.26	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
HNSC	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	4.67e-06	-0.41	-0.26	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
HNSC	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-5.81	1.15e-08	4.67e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-5.81	1.15e-08	4.67e-06	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	5.81	1.15e-08	4.68e-06	0.28	0.26	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
HNSC	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	5.81	1.15e-08	4.68e-06	0.25	0.26	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
HNSC	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	5.81	1.15e-08	4.68e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
HNSC	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-5.81	1.15e-08	4.68e-06	-0.29	-0.26	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
HNSC	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-5.81	1.15e-08	4.69e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
HNSC	cis	rs11992162	0.591	rs4240678	ENSG00000206014.6	OR7E161P	5.81	1.15e-08	4.69e-06	0.28	0.26	Monocyte count;	chr8:11944917	chr8:11928597~11929563:-
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-5.81	1.15e-08	4.69e-06	-0.17	-0.26	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
HNSC	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-5.81	1.15e-08	4.69e-06	-0.23	-0.26	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	5.81	1.15e-08	4.69e-06	0.2	0.26	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
HNSC	cis	rs1355223	0.902	rs1539250	ENSG00000271369.1	RP11-350D17.3	-5.81	1.15e-08	4.69e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721228	chr11:34709600~34710161:+
HNSC	cis	rs6951245	0.572	rs73259905	ENSG00000224079.1	AC091729.7	-5.81	1.15e-08	4.69e-06	-0.53	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:983728	chr7:1074450~1078036:+
HNSC	cis	rs2579103	0.898	rs1371089	ENSG00000258183.4	RP11-753N8.1	-5.81	1.16e-08	4.7e-06	-0.32	-0.26	Body mass index;	chr12:90214751	chr12:90280894~90300340:+
HNSC	cis	rs5753618	0.504	rs9609297	ENSG00000236132.1	CTA-440B3.1	-5.81	1.16e-08	4.7e-06	-0.35	-0.26	Colorectal cancer;	chr22:31497745	chr22:31816379~31817491:-
HNSC	cis	rs440932	0.798	rs330942	ENSG00000173295.6	FAM86B3P	5.81	1.16e-08	4.7e-06	0.29	0.26	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8228595~8244865:+
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-5.81	1.16e-08	4.71e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.51	rs73105819	ENSG00000276691.1	RP5-1057I20.5	5.81	1.16e-08	4.71e-06	0.45	0.26	Pneumonia;	chr12:47727190	chr12:47788426~47788971:+
HNSC	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	5.81	1.16e-08	4.71e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
HNSC	cis	rs9914544	1	rs8066385	ENSG00000264885.1	RP11-815I9.4	-5.81	1.16e-08	4.71e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18857820	chr17:18667629~18669461:-
HNSC	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-5.81	1.16e-08	4.71e-06	-0.36	-0.26	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000254153.1	CTA-398F10.2	5.81	1.16e-08	4.71e-06	0.29	0.26	Joint mobility (Beighton score);	chr8:9043712	chr8:8456909~8461337:-
HNSC	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.81	1.16e-08	4.71e-06	-0.37	-0.26	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
HNSC	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	5.81	1.16e-08	4.71e-06	0.32	0.26	Height;	chr4:55409063	chr4:55387949~55388271:+
HNSC	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	5.81	1.16e-08	4.72e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
HNSC	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	5.81	1.16e-08	4.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
HNSC	cis	rs35963943	0.625	rs11713263	ENSG00000228956.7	SATB1-AS1	-5.81	1.16e-08	4.72e-06	-0.32	-0.26	Lymphocyte counts;	chr3:18678418	chr3:18445024~18920401:+
HNSC	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-5.81	1.16e-08	4.73e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
HNSC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-5.81	1.16e-08	4.73e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	5.81	1.16e-08	4.73e-06	0.32	0.26	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
HNSC	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-5.81	1.17e-08	4.74e-06	-0.38	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
HNSC	cis	rs5753618	0.607	rs5753621	ENSG00000236132.1	CTA-440B3.1	-5.81	1.17e-08	4.74e-06	-0.32	-0.26	Colorectal cancer;	chr22:31451661	chr22:31816379~31817491:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	5.81	1.17e-08	4.74e-06	0.28	0.26	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
HNSC	cis	rs867371	0.929	rs1501371	ENSG00000276710.3	CSPG4P8	-5.81	1.17e-08	4.74e-06	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82459472~82477258:+
HNSC	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.75e-06	-0.26	-0.26	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
HNSC	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.75e-06	-0.26	-0.26	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
HNSC	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-5.81	1.17e-08	4.75e-06	-0.25	-0.26	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
HNSC	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-5.81	1.17e-08	4.75e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.81	1.17e-08	4.75e-06	-0.34	-0.26	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
HNSC	cis	rs9300255	0.602	rs1716177	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170910	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.508	rs1716176	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170920	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1790098	ENSG00000280120.1	RP11-546D6.3	5.81	1.17e-08	4.76e-06	0.24	0.26	Neutrophil percentage of white cells;	chr12:123170934	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	5.81	1.17e-08	4.76e-06	0.33	0.26	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
HNSC	cis	rs12030196	0.536	rs2716130	ENSG00000230812.4	LINC01358	5.81	1.17e-08	4.76e-06	0.25	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59021456	chr1:59020387~59044614:+
HNSC	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-5.81	1.17e-08	4.76e-06	-0.74	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
HNSC	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.17e-08	4.76e-06	-0.26	-0.26	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-5.81	1.17e-08	4.76e-06	-0.31	-0.26	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
HNSC	cis	rs1355223	0.902	rs704744	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715014	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs836466	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715819	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1773910	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34719706	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1539251	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721225	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs836462	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721716	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs1773908	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721833	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs860712	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721947	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs2226113	ENSG00000271369.1	RP11-350D17.3	-5.81	1.17e-08	4.77e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724742	chr11:34709600~34710161:+
HNSC	cis	rs1355223	1	rs11601205	ENSG00000271369.1	RP11-350D17.3	-5.81	1.18e-08	4.77e-06	-0.3	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746932	chr11:34709600~34710161:+
HNSC	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	5.81	1.18e-08	4.78e-06	0.34	0.26	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
HNSC	cis	rs155076	0.711	rs9550724	ENSG00000233325.3	MIPEPP3	-5.81	1.18e-08	4.78e-06	-0.42	-0.26	White matter hyperintensity burden;	chr13:21310891	chr13:21298139~21306373:+
HNSC	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-5.81	1.18e-08	4.78e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
HNSC	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	5.81	1.18e-08	4.78e-06	0.25	0.26	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
HNSC	cis	rs7402982	0.625	rs7179841	ENSG00000278022.1	RP11-35O15.2	-5.81	1.18e-08	4.78e-06	-0.31	-0.26	Birth weight;	chr15:98661423	chr15:98660210~98660668:+
HNSC	cis	rs1355223	0.902	rs11603774	ENSG00000271369.1	RP11-350D17.3	-5.81	1.18e-08	4.79e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34711344	chr11:34709600~34710161:+
HNSC	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	5.81	1.18e-08	4.8e-06	0.27	0.26	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
HNSC	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-5.81	1.18e-08	4.8e-06	-0.26	-0.26	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
HNSC	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-5.81	1.18e-08	4.8e-06	-0.23	-0.26	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
HNSC	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	5.81	1.18e-08	4.81e-06	0.35	0.26	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
HNSC	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	5.81	1.18e-08	4.81e-06	0.32	0.26	Height;	chr4:55465165	chr4:55387949~55388271:+
HNSC	cis	rs9907295	0.748	rs2526328	ENSG00000270977.1	AC015849.16	-5.81	1.19e-08	4.81e-06	-0.35	-0.26	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35893707~35911023:-
HNSC	cis	rs1012068	0.662	rs11703779	ENSG00000236132.1	CTA-440B3.1	-5.81	1.19e-08	4.81e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31926398	chr22:31816379~31817491:-
HNSC	cis	rs10435719	0.867	rs35778860	ENSG00000206014.6	OR7E161P	-5.81	1.19e-08	4.81e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:11928597~11929563:-
HNSC	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-5.81	1.19e-08	4.82e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-5.81	1.19e-08	4.82e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	5.81	1.19e-08	4.82e-06	0.38	0.26	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
HNSC	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	5.8	1.19e-08	4.83e-06	0.32	0.26	Height;	chr4:55489895	chr4:55387949~55388271:+
HNSC	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-5.8	1.19e-08	4.83e-06	-0.25	-0.26	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
HNSC	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	5.8	1.19e-08	4.83e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
HNSC	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-5.8	1.19e-08	4.83e-06	-0.26	-0.26	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
HNSC	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	5.8	1.19e-08	4.84e-06	0.28	0.26	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
HNSC	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-5.8	1.19e-08	4.84e-06	-0.31	-0.26	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
HNSC	cis	rs35306767	0.953	rs35693858	ENSG00000229869.1	RP11-363N22.2	-5.8	1.19e-08	4.84e-06	-0.35	-0.26	Eosinophil percentage of granulocytes;	chr10:933873	chr10:933026~942743:+
HNSC	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	5.8	1.19e-08	4.84e-06	0.34	0.26	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
HNSC	cis	rs2762353	0.526	rs12215823	ENSG00000272462.2	U91328.19	-5.8	1.2e-08	4.85e-06	-0.25	-0.26	Blood metabolite levels;	chr6:25725846	chr6:25992662~26001775:+
HNSC	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	5.8	1.2e-08	4.85e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
HNSC	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55476736	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55477426	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	5.8	1.2e-08	4.85e-06	0.31	0.26	Height;	chr4:55477545	chr4:55363971~55395847:-
HNSC	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5.8	1.2e-08	4.85e-06	0.31	0.26	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
HNSC	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-5.8	1.2e-08	4.86e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
HNSC	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	5.8	1.2e-08	4.86e-06	0.36	0.26	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
HNSC	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55486718	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55495262	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55502504	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55508982	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55509442	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.86e-06	0.32	0.26	Height;	chr4:55510177	chr4:55387949~55388271:+
HNSC	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-5.8	1.2e-08	4.87e-06	-0.34	-0.26	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
HNSC	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	5.8	1.2e-08	4.87e-06	0.32	0.26	Height;	chr4:55548666	chr4:55387949~55388271:+
HNSC	cis	rs75422866	0.51	rs73105818	ENSG00000276691.1	RP5-1057I20.5	5.8	1.2e-08	4.87e-06	0.45	0.26	Pneumonia;	chr12:47726538	chr12:47788426~47788971:+
HNSC	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	5.8	1.2e-08	4.87e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
HNSC	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	5.8	1.2e-08	4.88e-06	0.32	0.26	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
HNSC	cis	rs6918586	0.658	rs198825	ENSG00000272462.2	U91328.19	-5.8	1.21e-08	4.88e-06	-0.24	-0.26	Schizophrenia;	chr6:26122274	chr6:25992662~26001775:+
HNSC	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	5.8	1.21e-08	4.88e-06	0.27	0.26	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
HNSC	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-5.8	1.21e-08	4.89e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
HNSC	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531150	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531218	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	5.8	1.21e-08	4.89e-06	0.31	0.26	Height;	chr4:55531811	chr4:55363971~55395847:-
HNSC	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-5.8	1.21e-08	4.9e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-5.8	1.21e-08	4.9e-06	-0.36	-0.26	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
HNSC	cis	rs9300255	0.739	rs1980252	ENSG00000280120.1	RP11-546D6.3	5.8	1.21e-08	4.91e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123260631	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716167	ENSG00000280120.1	RP11-546D6.3	-5.8	1.21e-08	4.91e-06	-0.24	-0.26	Neutrophil percentage of white cells;	chr12:123166615	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	5.8	1.21e-08	4.92e-06	0.32	0.26	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
HNSC	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.8	1.22e-08	4.93e-06	-0.68	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
HNSC	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	5.8	1.22e-08	4.93e-06	0.27	0.26	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
HNSC	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.8	1.22e-08	4.93e-06	-0.29	-0.26	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
HNSC	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-5.8	1.22e-08	4.93e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
HNSC	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.8	1.22e-08	4.93e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
HNSC	cis	rs7630852	1	rs9852432	ENSG00000272359.1	U4	-5.8	1.22e-08	4.94e-06	-0.28	-0.26	Eosinophil counts;	chr3:196780210	chr3:196747192~196747324:-
HNSC	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-5.8	1.22e-08	4.94e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-5.8	1.22e-08	4.94e-06	-0.3	-0.26	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
HNSC	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	5.8	1.22e-08	4.94e-06	0.25	0.26	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
HNSC	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-5.8	1.22e-08	4.94e-06	-0.33	-0.26	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000276710.3	CSPG4P8	-5.8	1.22e-08	4.94e-06	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	5.8	1.22e-08	4.94e-06	0.4	0.26	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
HNSC	cis	rs3206736	0.548	rs328902	ENSG00000197085.10	NPSR1-AS1	-5.8	1.22e-08	4.94e-06	-0.33	-0.26	Diastolic blood pressure;	chr7:34981231	chr7:34346512~34871582:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-5.8	1.22e-08	4.94e-06	-0.36	-0.26	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
HNSC	cis	rs2579103	1	rs2731277	ENSG00000258183.4	RP11-753N8.1	-5.8	1.22e-08	4.94e-06	-0.34	-0.26	Body mass index;	chr12:90230184	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2579103	ENSG00000258183.4	RP11-753N8.1	-5.8	1.22e-08	4.94e-06	-0.34	-0.26	Body mass index;	chr12:90239730	chr12:90280894~90300340:+
HNSC	cis	rs13126694	0.901	rs4691460	ENSG00000248429.4	RP11-597D13.9	-5.8	1.22e-08	4.95e-06	-0.29	-0.26	Blood osmolality (transformed sodium);	chr4:158138279	chr4:158170752~158202877:+
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	5.8	1.22e-08	4.95e-06	0.32	0.26	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531150	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531218	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	5.8	1.22e-08	4.95e-06	0.32	0.26	Height;	chr4:55531811	chr4:55387949~55388271:+
HNSC	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-5.8	1.22e-08	4.95e-06	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
HNSC	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	5.8	1.22e-08	4.95e-06	0.3	0.26	Height;	chr4:55479996	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	5.8	1.22e-08	4.95e-06	0.3	0.26	Height;	chr4:55482317	chr4:55363971~55395847:-
HNSC	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	5.8	1.23e-08	4.96e-06	0.37	0.26	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
HNSC	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-5.8	1.23e-08	4.97e-06	-0.31	-0.26	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
HNSC	cis	rs9914544	1	rs28436199	ENSG00000264885.1	RP11-815I9.4	-5.8	1.23e-08	4.97e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18848417	chr17:18667629~18669461:-
HNSC	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	5.8	1.23e-08	4.97e-06	0.29	0.26	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
HNSC	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	5.8	1.23e-08	4.98e-06	0.34	0.26	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
HNSC	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-5.8	1.23e-08	4.98e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
HNSC	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-5.8	1.23e-08	4.98e-06	-0.37	-0.26	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
HNSC	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-5.8	1.23e-08	4.98e-06	-0.42	-0.26	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-5.8	1.23e-08	4.98e-06	-0.37	-0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
HNSC	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.8	1.24e-08	4.99e-06	0.32	0.26	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
HNSC	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-5.8	1.24e-08	4.99e-06	-0.36	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
HNSC	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-5.8	1.24e-08	4.99e-06	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
HNSC	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	5.8	1.24e-08	4.99e-06	0.33	0.26	Height;	chr4:55401306	chr4:55363971~55395847:-
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	5.8	1.24e-08	5e-06	0.66	0.26	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
HNSC	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-5.8	1.24e-08	5e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
HNSC	cis	rs62344088	1	rs7710931	ENSG00000277812.1	AC021087.1	5.8	1.24e-08	5.01e-06	0.72	0.26	Asthma (childhood onset);	chr5:152171	chr5:262769~262881:+
HNSC	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	5.8	1.24e-08	5.01e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	5.8	1.24e-08	5.01e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
HNSC	cis	rs9840812	0.623	rs9854084	ENSG00000273486.1	RP11-731C17.2	5.8	1.24e-08	5.01e-06	0.23	0.26	Fibrinogen levels;	chr3:136475901	chr3:136837338~136839021:-
HNSC	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-5.8	1.24e-08	5.01e-06	-0.3	-0.26	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
HNSC	cis	rs9907295	0.591	rs2107538	ENSG00000270977.1	AC015849.16	-5.8	1.24e-08	5.01e-06	-0.3	-0.26	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35893707~35911023:-
HNSC	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	5.8	1.24e-08	5.02e-06	0.31	0.26	Height;	chr4:55437438	chr4:55363971~55395847:-
HNSC	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	5.8	1.24e-08	5.02e-06	0.35	0.26	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
HNSC	cis	rs5753618	0.583	rs9606843	ENSG00000236132.1	CTA-440B3.1	-5.8	1.25e-08	5.03e-06	-0.33	-0.26	Colorectal cancer;	chr22:31457385	chr22:31816379~31817491:-
HNSC	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.25e-08	5.03e-06	-0.32	-0.26	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
HNSC	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-5.8	1.25e-08	5.03e-06	-0.32	-0.26	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
HNSC	cis	rs988913	1	rs1393776	ENSG00000224984.1	RP11-524H19.2	-5.8	1.25e-08	5.03e-06	-0.29	-0.26	Menarche (age at onset);	chr6:54898220	chr6:54840118~54840855:-
HNSC	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	5.8	1.25e-08	5.03e-06	0.33	0.26	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-5.8	1.25e-08	5.03e-06	-0.17	-0.26	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000179406.6	LINC00174	-5.8	1.25e-08	5.03e-06	-0.34	-0.26	Calcium levels;	chr7:65800652	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	5.8	1.25e-08	5.03e-06	0.31	0.26	Height;	chr4:55407965	chr4:55363971~55395847:-
HNSC	cis	rs9300255	0.699	rs11057204	ENSG00000280120.1	RP11-546D6.3	5.8	1.25e-08	5.03e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123241280	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.62	rs7313483	ENSG00000280120.1	RP11-546D6.3	5.8	1.25e-08	5.03e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123242287	chr12:123152324~123153377:-
HNSC	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	5.8	1.25e-08	5.04e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
HNSC	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5.8	1.25e-08	5.04e-06	0.31	0.26	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
HNSC	cis	rs9840812	0.623	rs6794351	ENSG00000273486.1	RP11-731C17.2	5.8	1.25e-08	5.05e-06	0.22	0.26	Fibrinogen levels;	chr3:136573437	chr3:136837338~136839021:-
HNSC	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	5.8	1.25e-08	5.05e-06	0.34	0.26	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
HNSC	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.8	1.25e-08	5.05e-06	0.24	0.26	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
HNSC	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.25e-08	5.05e-06	-0.32	-0.26	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
HNSC	cis	rs4218	0.517	rs2899640	ENSG00000277144.1	RP11-59H7.4	-5.8	1.25e-08	5.06e-06	-0.34	-0.26	Social communication problems;	chr15:59060281	chr15:59115547~59116089:-
HNSC	cis	rs9840812	0.728	rs12630999	ENSG00000273486.1	RP11-731C17.2	5.8	1.26e-08	5.06e-06	0.22	0.26	Fibrinogen levels;	chr3:136582085	chr3:136837338~136839021:-
HNSC	cis	rs757110	0.866	rs5213	ENSG00000260196.1	RP1-239B22.5	5.8	1.26e-08	5.06e-06	0.3	0.26	Type 2 diabetes;	chr11:17386857	chr11:17380649~17383531:+
HNSC	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.26e-08	5.06e-06	-0.32	-0.26	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
HNSC	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	5.8	1.26e-08	5.06e-06	0.33	0.26	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
HNSC	cis	rs9341808	0.538	rs667097	ENSG00000272129.1	RP11-250B2.6	-5.8	1.26e-08	5.07e-06	-0.31	-0.26	Sitting height ratio;	chr6:80269226	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-5.8	1.26e-08	5.07e-06	-0.31	-0.26	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
HNSC	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-5.8	1.26e-08	5.07e-06	-0.36	-0.26	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-5.8	1.26e-08	5.07e-06	-0.36	-0.26	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
HNSC	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-5.79	1.26e-08	5.07e-06	-0.35	-0.26	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
HNSC	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	5.79	1.26e-08	5.07e-06	0.33	0.26	Height;	chr6:109350188	chr6:109382795~109383666:+
HNSC	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-5.79	1.26e-08	5.08e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
HNSC	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	5.79	1.26e-08	5.1e-06	0.3	0.26	Height;	chr4:55479069	chr4:55363971~55395847:-
HNSC	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.79	1.27e-08	5.1e-06	0.35	0.26	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
HNSC	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-5.79	1.27e-08	5.11e-06	-0.49	-0.26	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
HNSC	cis	rs4852324	0.536	rs13387174	ENSG00000217702.2	RP11-287D1.4	5.79	1.27e-08	5.11e-06	0.63	0.26	Systemic lupus erythematosus;	chr2:73979558	chr2:74130583~74135395:+
HNSC	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	5.79	1.27e-08	5.12e-06	0.35	0.26	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
HNSC	cis	rs454422	1	rs2326680	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5962309	chr20:6000418~6000941:+
HNSC	cis	rs454422	1	rs409035	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5963003	chr20:6000418~6000941:+
HNSC	cis	rs454422	1	rs454422	ENSG00000275632.1	RP5-967N21.11	5.79	1.27e-08	5.12e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5963047	chr20:6000418~6000941:+
HNSC	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	5.79	1.27e-08	5.12e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
HNSC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-5.79	1.27e-08	5.12e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
HNSC	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-5.79	1.27e-08	5.13e-06	-0.35	-0.26	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-5.79	1.27e-08	5.13e-06	-0.3	-0.26	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
HNSC	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	5.79	1.27e-08	5.13e-06	0.3	0.26	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
HNSC	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-5.79	1.27e-08	5.13e-06	-0.29	-0.26	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
HNSC	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	5.79	1.28e-08	5.13e-06	0.34	0.26	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
HNSC	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	5.79	1.28e-08	5.14e-06	0.36	0.26	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	5.79	1.28e-08	5.14e-06	0.21	0.26	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
HNSC	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	5.79	1.28e-08	5.14e-06	0.3	0.26	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
HNSC	cis	rs7674212	0.51	rs55715738	ENSG00000246560.2	RP11-10L12.4	5.79	1.28e-08	5.14e-06	0.29	0.26	Type 2 diabetes;	chr4:103209032	chr4:102828055~102844075:+
HNSC	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-5.79	1.28e-08	5.16e-06	-0.5	-0.26	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
HNSC	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-5.79	1.28e-08	5.16e-06	-0.36	-0.26	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	5.79	1.28e-08	5.16e-06	0.32	0.26	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	5.79	1.28e-08	5.17e-06	0.31	0.26	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.79	1.29e-08	5.17e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
HNSC	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	5.79	1.29e-08	5.17e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
HNSC	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-5.79	1.29e-08	5.18e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
HNSC	cis	rs2985684	1	rs3007030	ENSG00000258568.1	RHOQP1	5.79	1.29e-08	5.18e-06	0.27	0.26	Carotid intima media thickness;	chr14:49619845	chr14:49599994~49600572:+
HNSC	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-5.79	1.29e-08	5.19e-06	-0.33	-0.26	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-5.79	1.29e-08	5.19e-06	-0.33	-0.26	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
HNSC	cis	rs9300255	0.602	rs1716168	ENSG00000280120.1	RP11-546D6.3	-5.79	1.29e-08	5.19e-06	-0.23	-0.26	Neutrophil percentage of white cells;	chr12:123167419	chr12:123152324~123153377:-
HNSC	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	5.79	1.29e-08	5.19e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
HNSC	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	5.79	1.29e-08	5.19e-06	0.34	0.26	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
HNSC	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-5.79	1.29e-08	5.19e-06	-0.34	-0.26	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	5.79	1.29e-08	5.19e-06	0.32	0.26	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	5.79	1.29e-08	5.2e-06	0.32	0.26	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
HNSC	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	5.2e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
HNSC	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	5.79	1.29e-08	5.2e-06	0.25	0.26	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
HNSC	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-5.79	1.3e-08	5.21e-06	-0.3	-0.26	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
HNSC	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-5.79	1.3e-08	5.21e-06	-0.39	-0.26	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
HNSC	cis	rs2483058	0.767	rs11579993	ENSG00000261000.1	RP11-534L20.5	5.79	1.3e-08	5.22e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206445529	chr1:206503948~206504456:+
HNSC	cis	rs2762353	0.526	rs3936052	ENSG00000272462.2	U91328.19	-5.79	1.3e-08	5.22e-06	-0.25	-0.26	Blood metabolite levels;	chr6:25715306	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-5.79	1.3e-08	5.22e-06	-0.32	-0.26	Depression;	chr6:28133900	chr6:28161781~28169594:+
HNSC	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.79	1.3e-08	5.22e-06	-0.34	-0.26	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
HNSC	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-5.79	1.3e-08	5.23e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
HNSC	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-5.79	1.3e-08	5.23e-06	-0.34	-0.26	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
HNSC	cis	rs61542988	0.57	rs62448268	ENSG00000228649.7	AC005682.5	5.79	1.3e-08	5.23e-06	0.34	0.26	Fibrinogen levels;	chr7:22789845	chr7:22854178~22861579:+
HNSC	cis	rs7587476	0.638	rs34358404	ENSG00000229267.2	AC072062.1	-5.79	1.3e-08	5.23e-06	-0.38	-0.26	Neuroblastoma;	chr2:214794730	chr2:214810229~214963274:+
HNSC	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-5.79	1.3e-08	5.23e-06	-0.28	-0.26	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
HNSC	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-5.79	1.3e-08	5.23e-06	-0.27	-0.26	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-5.79	1.3e-08	5.23e-06	-0.27	-0.26	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
HNSC	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	5.79	1.3e-08	5.23e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
HNSC	cis	rs9650657	0.53	rs6982381	ENSG00000255310.2	AF131215.2	-5.79	1.31e-08	5.25e-06	-0.25	-0.26	Neuroticism;	chr8:11094990	chr8:11107788~11109726:-
HNSC	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	5.79	1.31e-08	5.25e-06	0.34	0.26	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
HNSC	cis	rs9341808	0.538	rs9443742	ENSG00000272129.1	RP11-250B2.6	-5.79	1.31e-08	5.25e-06	-0.3	-0.26	Sitting height ratio;	chr6:80307212	chr6:80355424~80356859:+
HNSC	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-5.79	1.31e-08	5.26e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
HNSC	cis	rs4141404	0.851	rs9606833	ENSG00000236132.1	CTA-440B3.1	-5.79	1.31e-08	5.26e-06	-0.36	-0.26	Paclitaxel-induced neuropathy;	chr22:31354027	chr22:31816379~31817491:-
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	5.79	1.31e-08	5.27e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
HNSC	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	5.79	1.31e-08	5.28e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
HNSC	cis	rs9840812	0.691	rs833752	ENSG00000273486.1	RP11-731C17.2	5.79	1.32e-08	5.29e-06	0.23	0.26	Fibrinogen levels;	chr3:136536327	chr3:136837338~136839021:-
HNSC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.79	1.32e-08	5.29e-06	-0.27	-0.26	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
HNSC	cis	rs11992162	0.529	rs6995037	ENSG00000206014.6	OR7E161P	5.79	1.32e-08	5.29e-06	0.28	0.26	Monocyte count;	chr8:11923378	chr8:11928597~11929563:-
HNSC	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	5.79	1.32e-08	5.31e-06	0.28	0.26	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
HNSC	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	5.79	1.32e-08	5.31e-06	0.33	0.26	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
HNSC	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	5.79	1.32e-08	5.31e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
HNSC	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	5.79	1.32e-08	5.31e-06	0.41	0.26	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
HNSC	cis	rs3206736	0.548	rs167893	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35003121	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.52	rs328934	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35004114	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328936	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35007967	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.521	rs329232	ENSG00000197085.10	NPSR1-AS1	-5.79	1.33e-08	5.32e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35015339	chr7:34346512~34871582:-
HNSC	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.79	1.33e-08	5.32e-06	-0.37	-0.26	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
HNSC	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	5.79	1.33e-08	5.32e-06	0.34	0.26	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	5.79	1.33e-08	5.32e-06	0.34	0.26	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
HNSC	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	5.79	1.33e-08	5.33e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
HNSC	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	5.79	1.33e-08	5.33e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
HNSC	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	5.79	1.33e-08	5.33e-06	0.29	0.26	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	5.79	1.33e-08	5.33e-06	0.29	0.26	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-5.79	1.33e-08	5.33e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
HNSC	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	5.79	1.33e-08	5.33e-06	0.25	0.26	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
HNSC	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-5.78	1.33e-08	5.34e-06	-0.3	-0.26	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	5.78	1.33e-08	5.34e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
HNSC	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	5.78	1.33e-08	5.34e-06	0.28	0.26	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
HNSC	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	5.78	1.33e-08	5.34e-06	0.33	0.26	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
HNSC	cis	rs2976388	0.507	rs7813604	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.33e-08	5.34e-06	-0.26	-0.26	Urinary tract infection frequency;	chr8:142756644	chr8:142702252~142726973:-
HNSC	cis	rs61542988	0.532	rs10240168	ENSG00000228649.7	AC005682.5	5.78	1.33e-08	5.35e-06	0.31	0.26	Fibrinogen levels;	chr7:22779715	chr7:22854178~22861579:+
HNSC	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	5.78	1.33e-08	5.35e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
HNSC	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	5.78	1.34e-08	5.36e-06	0.34	0.26	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
HNSC	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-5.78	1.34e-08	5.37e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
HNSC	cis	rs1021993	0.857	rs1553622	ENSG00000231648.1	RP11-372M18.2	-5.78	1.34e-08	5.37e-06	-0.35	-0.26	Gut microbiome composition (winter);	chr1:209290515	chr1:209367662~209379690:+
HNSC	cis	rs6504622	0.875	rs3785888	ENSG00000262879.4	RP11-156P1.3	-5.78	1.34e-08	5.37e-06	-0.28	-0.26	Orofacial clefts;	chr17:46928337	chr17:46984045~47100323:-
HNSC	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	5.78	1.34e-08	5.37e-06	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
HNSC	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-5.78	1.34e-08	5.38e-06	-0.3	-0.26	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
HNSC	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-5.78	1.35e-08	5.4e-06	-0.36	-0.26	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
HNSC	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-5.78	1.35e-08	5.4e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
HNSC	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-5.78	1.35e-08	5.4e-06	-0.39	-0.26	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
HNSC	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-5.78	1.35e-08	5.4e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
HNSC	cis	rs783540	0.5	rs7163840	ENSG00000276710.3	CSPG4P8	5.78	1.35e-08	5.41e-06	0.31	0.26	Schizophrenia;	chr15:82729551	chr15:82459472~82477258:+
HNSC	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-5.78	1.35e-08	5.41e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
HNSC	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	5.78	1.35e-08	5.41e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	5.78	1.35e-08	5.42e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
HNSC	cis	rs6604026	0.555	rs34734076	ENSG00000223787.2	RP4-593M8.1	5.78	1.35e-08	5.42e-06	0.36	0.26	Multiple sclerosis;	chr1:92613901	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs11807962	ENSG00000223787.2	RP4-593M8.1	5.78	1.35e-08	5.42e-06	0.36	0.26	Multiple sclerosis;	chr1:92614721	chr1:92580476~92580821:-
HNSC	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	5.78	1.36e-08	5.43e-06	0.36	0.26	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
HNSC	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-5.78	1.36e-08	5.44e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
HNSC	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-5.78	1.36e-08	5.44e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	5.45e-06	-0.31	-0.26	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
HNSC	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	5.78	1.36e-08	5.45e-06	0.47	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
HNSC	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	5.78	1.36e-08	5.45e-06	0.47	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
HNSC	cis	rs61542988	0.535	rs10807813	ENSG00000228649.7	AC005682.5	5.78	1.36e-08	5.45e-06	0.34	0.26	Fibrinogen levels;	chr7:22790342	chr7:22854178~22861579:+
HNSC	cis	rs2179367	0.632	rs10155766	ENSG00000216906.2	RP11-350J20.9	5.78	1.36e-08	5.45e-06	0.38	0.26	Dupuytren's disease;	chr6:149364577	chr6:149904243~149906418:+
HNSC	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	5.78	1.36e-08	5.45e-06	0.34	0.26	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
HNSC	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-5.78	1.36e-08	5.46e-06	-0.44	-0.26	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
HNSC	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	5.78	1.36e-08	5.46e-06	0.21	0.26	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
HNSC	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-5.78	1.36e-08	5.46e-06	-0.22	-0.26	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	5.78	1.36e-08	5.46e-06	0.66	0.26	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
HNSC	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	5.78	1.36e-08	5.46e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
HNSC	cis	rs2579103	0.898	rs2263480	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90222950	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731251	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90227881	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731278	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90230046	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs1371086	ENSG00000258183.4	RP11-753N8.1	-5.78	1.37e-08	5.46e-06	-0.34	-0.26	Body mass index;	chr12:90231669	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-5.78	1.37e-08	5.47e-06	-0.4	-0.26	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
HNSC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-5.78	1.37e-08	5.47e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.47e-06	0.32	0.26	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	5.78	1.37e-08	5.48e-06	0.4	0.26	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
HNSC	cis	rs889014	0.751	rs4867720	ENSG00000253768.1	CTB-33O18.1	5.78	1.37e-08	5.48e-06	0.29	0.26	Height;	chr5:173552560	chr5:173562478~173573199:+
HNSC	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55514802	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55516548	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55516744	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55517185	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	5.78	1.37e-08	5.48e-06	0.32	0.26	Height;	chr4:55522229	chr4:55387949~55388271:+
HNSC	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-5.78	1.37e-08	5.49e-06	-0.23	-0.26	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
HNSC	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-5.78	1.37e-08	5.49e-06	-0.26	-0.26	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	5.78	1.37e-08	5.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
HNSC	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	5.78	1.37e-08	5.49e-06	0.29	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000267151.3	RP11-100E5.2	-5.78	1.37e-08	5.49e-06	-0.33	-0.26	Menopause (age at onset);	chr17:43165879	chr17:43444707~43451200:+
HNSC	cis	rs2179367	0.632	rs9498325	ENSG00000216906.2	RP11-350J20.9	5.78	1.37e-08	5.49e-06	0.38	0.26	Dupuytren's disease;	chr6:149345993	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498326	ENSG00000216906.2	RP11-350J20.9	5.78	1.37e-08	5.49e-06	0.38	0.26	Dupuytren's disease;	chr6:149346112	chr6:149904243~149906418:+
HNSC	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	5.78	1.37e-08	5.5e-06	0.29	0.26	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-5.78	1.37e-08	5.5e-06	-0.4	-0.26	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
HNSC	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.5e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.5e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
HNSC	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	5.78	1.38e-08	5.5e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
HNSC	cis	rs2579103	1	rs1579669	ENSG00000258183.4	RP11-753N8.1	-5.78	1.38e-08	5.5e-06	-0.34	-0.26	Body mass index;	chr12:90216068	chr12:90280894~90300340:+
HNSC	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-5.78	1.38e-08	5.5e-06	-0.31	-0.26	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
HNSC	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-5.78	1.38e-08	5.5e-06	-0.33	-0.26	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
HNSC	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-5.78	1.38e-08	5.51e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
HNSC	cis	rs4218	0.648	rs12442134	ENSG00000277144.1	RP11-59H7.4	-5.78	1.38e-08	5.51e-06	-0.36	-0.26	Social communication problems;	chr15:59074478	chr15:59115547~59116089:-
HNSC	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.38e-08	5.51e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
HNSC	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	5.78	1.38e-08	5.51e-06	0.32	0.26	Depression;	chr6:28142370	chr6:28161781~28169594:+
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	5.78	1.38e-08	5.51e-06	0.32	0.26	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	5.78	1.38e-08	5.51e-06	0.32	0.26	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
HNSC	cis	rs1355223	0.902	rs10501134	ENSG00000271369.1	RP11-350D17.3	-5.78	1.38e-08	5.51e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34727590	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.902	rs7130325	ENSG00000271369.1	RP11-350D17.3	-5.78	1.38e-08	5.51e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729412	chr11:34709600~34710161:+
HNSC	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.52e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.78	1.38e-08	5.52e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
HNSC	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-5.78	1.38e-08	5.52e-06	-0.26	-0.26	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
HNSC	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	5.78	1.38e-08	5.52e-06	0.35	0.26	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
HNSC	cis	rs17507216	1	rs17158413	ENSG00000276710.3	CSPG4P8	-5.78	1.38e-08	5.52e-06	-0.33	-0.26	Excessive daytime sleepiness;	chr15:82566658	chr15:82459472~82477258:+
HNSC	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	5.78	1.38e-08	5.53e-06	0.31	0.26	Height;	chr4:55450662	chr4:55363971~55395847:-
HNSC	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-5.78	1.38e-08	5.53e-06	-0.36	-0.26	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
HNSC	cis	rs2976388	0.507	rs13259549	ENSG00000253741.1	CTD-2292P10.4	-5.78	1.38e-08	5.53e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142757101	chr8:142702252~142726973:-
HNSC	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-5.78	1.39e-08	5.55e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
HNSC	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	5.78	1.39e-08	5.55e-06	0.35	0.26	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	5.78	1.39e-08	5.55e-06	0.35	0.26	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
HNSC	cis	rs2115630	1	rs4633690	ENSG00000229212.6	RP11-561C5.4	5.78	1.39e-08	5.56e-06	0.3	0.26	P wave terminal force;	chr15:84818729	chr15:85205440~85234795:-
HNSC	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-5.78	1.39e-08	5.56e-06	-0.31	-0.26	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	5.78	1.39e-08	5.56e-06	0.2	0.26	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
HNSC	cis	rs4699052	1	rs6533059	ENSG00000246560.2	RP11-10L12.4	5.78	1.39e-08	5.56e-06	0.3	0.26	Testicular germ cell tumor;	chr4:103212219	chr4:102828055~102844075:+
HNSC	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-5.78	1.39e-08	5.57e-06	-0.36	-0.26	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-5.78	1.39e-08	5.57e-06	-0.36	-0.26	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
HNSC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.78	1.4e-08	5.57e-06	-0.32	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
HNSC	cis	rs1864400	0.645	rs10899787	ENSG00000273008.1	RP11-351D16.3	5.78	1.4e-08	5.57e-06	0.36	0.26	Hirschsprung disease;	chr10:43254696	chr10:43136824~43138334:-
HNSC	cis	rs1021993	0.953	rs925077	ENSG00000231648.1	RP11-372M18.2	5.78	1.4e-08	5.57e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209335907	chr1:209367662~209379690:+
HNSC	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	5.78	1.4e-08	5.57e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
HNSC	cis	rs9329221	0.592	rs7832708	ENSG00000255310.2	AF131215.2	5.78	1.4e-08	5.58e-06	0.24	0.26	Neuroticism;	chr8:10332530	chr8:11107788~11109726:-
HNSC	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-5.78	1.4e-08	5.58e-06	-0.26	-0.26	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	5.78	1.4e-08	5.58e-06	0.32	0.26	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	5.78	1.4e-08	5.58e-06	0.3	0.26	Height;	chr4:55476159	chr4:55363971~55395847:-
HNSC	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.78	1.4e-08	5.58e-06	-0.21	-0.26	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
HNSC	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	5.78	1.4e-08	5.59e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-5.78	1.4e-08	5.59e-06	-0.17	-0.26	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
HNSC	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-5.78	1.4e-08	5.6e-06	-0.34	-0.26	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
HNSC	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-5.78	1.4e-08	5.6e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
HNSC	cis	rs3206736	0.548	rs1637675	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34960880	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs1637676	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34960947	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.514	rs1637679	ENSG00000197085.10	NPSR1-AS1	-5.78	1.4e-08	5.6e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34961410	chr7:34346512~34871582:-
HNSC	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	5.78	1.4e-08	5.6e-06	0.35	0.26	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
HNSC	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-5.78	1.4e-08	5.6e-06	-0.3	-0.26	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
HNSC	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	5.78	1.4e-08	5.6e-06	0.31	0.26	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
HNSC	cis	rs9341808	0.519	rs676311	ENSG00000272129.1	RP11-250B2.6	-5.78	1.4e-08	5.61e-06	-0.31	-0.26	Sitting height ratio;	chr6:80280033	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	5.78	1.4e-08	5.61e-06	0.32	0.26	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
HNSC	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	5.78	1.41e-08	5.61e-06	0.3	0.26	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	5.78	1.41e-08	5.61e-06	0.31	0.26	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000248787.1	RP11-666A20.4	-5.78	1.41e-08	5.61e-06	-0.47	-0.26	Blood pressure (smoking interaction);	chr3:125916896	chr3:125908005~125910272:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.77	1.41e-08	5.61e-06	0.28	0.26	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
HNSC	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.77	1.41e-08	5.61e-06	0.35	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
HNSC	cis	rs4218	0.593	rs8040456	ENSG00000259732.1	RP11-59H7.3	-5.77	1.41e-08	5.62e-06	-0.35	-0.26	Social communication problems;	chr15:59063904	chr15:59121034~59133250:+
HNSC	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	5.77	1.41e-08	5.62e-06	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
HNSC	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	5.77	1.41e-08	5.63e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
HNSC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28074687	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28076559	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28076704	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28078391	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28080757	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-5.77	1.41e-08	5.63e-06	-0.32	-0.26	Depression;	chr6:28080760	chr6:28161781~28169594:+
HNSC	cis	rs8054556	0.787	rs12444108	ENSG00000183604.13	SMG1P5	-5.77	1.41e-08	5.64e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30267553~30335374:-
HNSC	cis	rs60617249	0.507	rs71540279	ENSG00000228204.2	RP4-724E13.2	5.77	1.42e-08	5.65e-06	0.32	0.26	Major depression and alcohol dependence;	chr7:50909215	chr7:50866747~51022990:+
HNSC	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.77	1.42e-08	5.65e-06	0.34	0.26	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
HNSC	cis	rs7402982	0.625	rs4966011	ENSG00000278022.1	RP11-35O15.2	-5.77	1.42e-08	5.65e-06	-0.3	-0.26	Birth weight;	chr15:98660777	chr15:98660210~98660668:+
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	5.77	1.42e-08	5.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-5.77	1.42e-08	5.65e-06	-0.28	-0.26	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-5.77	1.42e-08	5.66e-06	-0.31	-0.26	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
HNSC	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	5.77	1.42e-08	5.67e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
HNSC	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-5.77	1.42e-08	5.67e-06	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
HNSC	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-5.77	1.42e-08	5.67e-06	-0.31	-0.26	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-5.77	1.42e-08	5.67e-06	-0.31	-0.26	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-5.77	1.43e-08	5.69e-06	-0.31	-0.26	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
HNSC	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-5.77	1.43e-08	5.69e-06	-0.37	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
HNSC	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-5.77	1.43e-08	5.69e-06	-0.35	-0.26	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
HNSC	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-5.77	1.43e-08	5.69e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
HNSC	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-5.77	1.43e-08	5.71e-06	-0.42	-0.26	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
HNSC	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	5.77	1.43e-08	5.71e-06	0.29	0.26	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
HNSC	cis	rs10446497	0.585	rs13074050	ENSG00000272359.1	U4	5.77	1.43e-08	5.71e-06	0.31	0.26	Schizophrenia;	chr3:196816270	chr3:196747192~196747324:-
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	5.77	1.43e-08	5.71e-06	0.32	0.26	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
HNSC	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.43e-08	5.72e-06	-0.32	-0.26	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	5.77	1.43e-08	5.72e-06	0.32	0.26	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
HNSC	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	5.77	1.44e-08	5.72e-06	0.28	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
HNSC	cis	rs7819412	0.805	rs4333549	ENSG00000269918.1	AF131215.9	-5.77	1.44e-08	5.72e-06	-0.26	-0.26	Triglycerides;	chr8:11122051	chr8:11104691~11106704:-
HNSC	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.44e-08	5.73e-06	-0.32	-0.26	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
HNSC	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-5.77	1.44e-08	5.73e-06	-0.37	-0.26	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
HNSC	cis	rs7630852	1	rs7630852	ENSG00000272359.1	U4	-5.77	1.44e-08	5.74e-06	-0.28	-0.26	Eosinophil counts;	chr3:196781680	chr3:196747192~196747324:-
HNSC	cis	rs11846409	0.655	rs79296226	ENSG00000211974.3	IGHV2-70	5.77	1.44e-08	5.74e-06	0.3	0.26	Rheumatic heart disease;	chr14:106650436	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000211974.3	IGHV2-70	5.77	1.44e-08	5.74e-06	0.31	0.26	Alzheimer's disease (late onset);	chr14:106650408	chr14:106723574~106724093:-
HNSC	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-5.77	1.44e-08	5.74e-06	-0.37	-0.26	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
HNSC	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	5.77	1.44e-08	5.75e-06	0.3	0.26	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	5.77	1.44e-08	5.75e-06	0.32	0.26	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000257433.4	RP1-197B17.3	5.77	1.44e-08	5.75e-06	0.68	0.26	Pneumonia;	chr12:47578764	chr12:47706085~47742294:+
HNSC	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	5.77	1.45e-08	5.76e-06	0.33	0.26	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.77	1.45e-08	5.76e-06	0.32	0.26	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
HNSC	cis	rs1021993	1	rs2660642	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209321498	chr1:209367662~209379690:+
HNSC	cis	rs1021993	1	rs1027823	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209338109	chr1:209367662~209379690:+
HNSC	cis	rs1021993	1	rs1027821	ENSG00000231648.1	RP11-372M18.2	5.77	1.45e-08	5.76e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209338541	chr1:209367662~209379690:+
HNSC	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	5.77	1.45e-08	5.76e-06	0.39	0.26	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
HNSC	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	5.77	1.45e-08	5.76e-06	0.31	0.26	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
HNSC	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	5.77	1.45e-08	5.77e-06	0.29	0.26	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000254340.1	RP11-10A14.3	5.77	1.45e-08	5.77e-06	0.32	0.26	Mood instability;	chr8:8865165	chr8:9141424~9145435:+
HNSC	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	5.77	1.45e-08	5.78e-06	0.36	0.26	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
HNSC	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	5.77	1.45e-08	5.78e-06	0.26	0.26	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
HNSC	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	5.77	1.45e-08	5.78e-06	0.3	0.26	Height;	chr4:55479339	chr4:55363971~55395847:-
HNSC	cis	rs7617773	0.563	rs62263035	ENSG00000228638.1	FCF1P2	-5.77	1.45e-08	5.78e-06	-0.23	-0.26	Coronary artery disease;	chr3:48350079	chr3:48290793~48291375:-
HNSC	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-5.77	1.45e-08	5.78e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-5.77	1.45e-08	5.78e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
HNSC	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	5.77	1.45e-08	5.78e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
HNSC	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.77	1.45e-08	5.79e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
HNSC	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.77	1.46e-08	5.8e-06	0.32	0.26	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
HNSC	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	5.77	1.46e-08	5.8e-06	0.31	0.26	Height;	chr4:55540912	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	5.77	1.46e-08	5.8e-06	0.31	0.26	Height;	chr4:55540972	chr4:55363971~55395847:-
HNSC	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	5.77	1.46e-08	5.81e-06	0.24	0.26	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
HNSC	cis	rs67180937	0.535	rs3008615	ENSG00000272750.1	RP11-378J18.8	5.77	1.46e-08	5.81e-06	0.34	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623242	chr1:222658867~222661512:-
HNSC	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-5.77	1.46e-08	5.81e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
HNSC	cis	rs454422	1	rs6053816	ENSG00000275632.1	RP5-967N21.11	5.77	1.46e-08	5.82e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5990104	chr20:6000418~6000941:+
HNSC	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	5.77	1.46e-08	5.82e-06	0.33	0.26	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
HNSC	cis	rs2286503	0.78	rs2286506	ENSG00000221740.1	SNORD93	5.77	1.46e-08	5.83e-06	0.29	0.26	Fibrinogen;	chr7:22815196	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.752	rs2286504	ENSG00000221740.1	SNORD93	5.77	1.46e-08	5.83e-06	0.29	0.26	Fibrinogen;	chr7:22815228	chr7:22856613~22856686:+
HNSC	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	5.77	1.47e-08	5.83e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
HNSC	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	5.77	1.47e-08	5.83e-06	0.26	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
HNSC	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-5.77	1.47e-08	5.83e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
HNSC	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	5.77	1.47e-08	5.83e-06	0.27	0.26	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
HNSC	cis	rs2483058	0.767	rs61817176	ENSG00000261000.1	RP11-534L20.5	5.77	1.47e-08	5.84e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206447682	chr1:206503948~206504456:+
HNSC	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	5.77	1.47e-08	5.84e-06	0.32	0.26	Height;	chr4:55542243	chr4:55387949~55388271:+
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000267151.3	RP11-100E5.2	5.77	1.47e-08	5.85e-06	0.34	0.26	Menopause (age at onset);	chr17:43324652	chr17:43444707~43451200:+
HNSC	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	5.77	1.47e-08	5.85e-06	0.25	0.26	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
HNSC	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.77	1.47e-08	5.85e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.77	1.47e-08	5.85e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
HNSC	cis	rs67981189	0.558	rs56043821	ENSG00000274818.1	RP1-292L20.3	5.77	1.47e-08	5.85e-06	0.32	0.26	Schizophrenia;	chr14:71103835	chr14:70906657~70907111:-
HNSC	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-5.77	1.47e-08	5.85e-06	-0.32	-0.26	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
HNSC	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-5.77	1.47e-08	5.85e-06	-0.32	-0.26	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
HNSC	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-5.77	1.47e-08	5.86e-06	-0.42	-0.26	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
HNSC	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-5.77	1.47e-08	5.86e-06	-0.33	-0.26	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
HNSC	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-5.77	1.47e-08	5.86e-06	-0.29	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	5.77	1.47e-08	5.86e-06	0.31	0.26	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
HNSC	cis	rs6951245	1	rs11764748	ENSG00000225146.1	AC073957.15	-5.77	1.48e-08	5.87e-06	-0.42	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1029025~1043891:+
HNSC	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-5.77	1.48e-08	5.87e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
HNSC	cis	rs867371	0.929	rs7173852	ENSG00000276710.3	CSPG4P8	-5.77	1.48e-08	5.87e-06	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82459472~82477258:+
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	5.77	1.48e-08	5.88e-06	0.31	0.26	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	5.77	1.48e-08	5.88e-06	0.28	0.26	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
HNSC	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	5.77	1.48e-08	5.89e-06	0.32	0.26	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
HNSC	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-5.77	1.48e-08	5.89e-06	-0.45	-0.26	Depression;	chr6:28246920	chr6:28115628~28116551:+
HNSC	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	5.77	1.48e-08	5.9e-06	0.34	0.26	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-5.77	1.48e-08	5.9e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.77	1.48e-08	5.9e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
HNSC	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	5.76	1.49e-08	5.91e-06	0.33	0.26	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
HNSC	cis	rs10435719	0.764	rs10103485	ENSG00000206014.6	OR7E161P	-5.76	1.49e-08	5.92e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:11928597~11929563:-
HNSC	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	5.76	1.49e-08	5.92e-06	0.27	0.26	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	5.76	1.49e-08	5.92e-06	0.63	0.26	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
HNSC	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	5.76	1.49e-08	5.92e-06	0.63	0.26	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
HNSC	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	5.76	1.49e-08	5.93e-06	0.31	0.26	Height;	chr4:55479069	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	5.76	1.49e-08	5.93e-06	0.32	0.26	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.51	rs35784744	ENSG00000276691.1	RP5-1057I20.5	5.76	1.49e-08	5.93e-06	0.45	0.26	Pneumonia;	chr12:47729646	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.541	rs12425816	ENSG00000276691.1	RP5-1057I20.5	5.76	1.49e-08	5.93e-06	0.45	0.26	Pneumonia;	chr12:47731419	chr12:47788426~47788971:+
HNSC	cis	rs2579103	0.867	rs10735280	ENSG00000258183.4	RP11-753N8.1	-5.76	1.49e-08	5.93e-06	-0.31	-0.26	Body mass index;	chr12:90248932	chr12:90280894~90300340:+
HNSC	cis	rs9840812	0.861	rs645040	ENSG00000239213.4	NCK1-AS1	-5.76	1.49e-08	5.93e-06	-0.24	-0.26	Fibrinogen levels;	chr3:136207780	chr3:136841726~136862054:-
HNSC	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-5.76	1.49e-08	5.94e-06	-0.41	-0.26	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
HNSC	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102426252	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102427407	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102427715	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102431747	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102432120	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102432614	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	5.76	1.5e-08	5.94e-06	0.25	0.26	Asthma;	chr2:102433405	chr2:102438713~102440475:+
HNSC	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	5.76	1.5e-08	5.94e-06	0.35	0.26	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
HNSC	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	5.76	1.5e-08	5.95e-06	0.29	0.26	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
HNSC	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	5.76	1.5e-08	5.95e-06	0.36	0.26	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
HNSC	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	5.76	1.5e-08	5.95e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	5.76	1.5e-08	5.95e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
HNSC	cis	rs804280	0.542	rs34117651	ENSG00000206014.6	OR7E161P	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934108	chr8:11928597~11929563:-
HNSC	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-5.76	1.5e-08	5.95e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
HNSC	cis	rs2439831	0.867	rs28729853	ENSG00000205771.5	CATSPER2P1	-5.76	1.5e-08	5.96e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43381482	chr15:43726918~43747094:-
HNSC	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-5.76	1.5e-08	5.96e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	5.76	1.5e-08	5.96e-06	0.32	0.26	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	5.76	1.5e-08	5.96e-06	0.32	0.26	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	5.76	1.5e-08	5.97e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
HNSC	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-5.76	1.5e-08	5.97e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
HNSC	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-5.76	1.5e-08	5.97e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
HNSC	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-5.76	1.51e-08	5.98e-06	-0.25	-0.26	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
HNSC	cis	rs3206736	0.548	rs328939	ENSG00000197085.10	NPSR1-AS1	-5.76	1.51e-08	5.98e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35010615	chr7:34346512~34871582:-
HNSC	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	5.76	1.51e-08	5.98e-06	0.47	0.26	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
HNSC	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-5.76	1.51e-08	5.98e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
HNSC	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5.76	1.51e-08	5.98e-06	0.37	0.26	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	5.76	1.51e-08	5.98e-06	0.28	0.26	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
HNSC	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-5.76	1.51e-08	5.98e-06	-0.35	-0.26	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
HNSC	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-5.76	1.51e-08	5.99e-06	-0.29	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
HNSC	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-5.76	1.51e-08	5.99e-06	-0.33	-0.26	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
HNSC	cis	rs9341808	0.538	rs623048	ENSG00000272129.1	RP11-250B2.6	-5.76	1.51e-08	6e-06	-0.3	-0.26	Sitting height ratio;	chr6:80272199	chr6:80355424~80356859:+
HNSC	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-5.76	1.51e-08	6e-06	-0.44	-0.26	Depression;	chr6:28159062	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.932	rs6931735	ENSG00000231028.7	LINC00271	-5.76	1.52e-08	6.01e-06	-0.3	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135497801~135716055:+
HNSC	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	5.76	1.52e-08	6.02e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
HNSC	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.76	1.52e-08	6.03e-06	0.31	0.26	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
HNSC	cis	rs5753618	0.561	rs5753609	ENSG00000236132.1	CTA-440B3.1	-5.76	1.52e-08	6.03e-06	-0.3	-0.26	Colorectal cancer;	chr22:31423226	chr22:31816379~31817491:-
HNSC	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-5.76	1.52e-08	6.03e-06	-0.36	-0.26	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-5.76	1.52e-08	6.03e-06	-0.33	-0.26	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	5.76	1.52e-08	6.03e-06	0.32	0.26	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	5.76	1.52e-08	6.03e-06	0.32	0.26	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.76	1.52e-08	6.04e-06	-0.35	-0.26	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
HNSC	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	5.76	1.52e-08	6.04e-06	0.37	0.26	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
HNSC	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-5.76	1.53e-08	6.05e-06	-0.33	-0.26	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
HNSC	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	5.76	1.53e-08	6.05e-06	0.33	0.26	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
HNSC	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-5.76	1.53e-08	6.05e-06	-0.29	-0.26	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
HNSC	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-5.76	1.53e-08	6.05e-06	-0.33	-0.26	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000248787.1	RP11-666A20.4	-5.76	1.53e-08	6.05e-06	-0.47	-0.26	Blood pressure (smoking interaction);	chr3:125918136	chr3:125908005~125910272:-
HNSC	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	5.76	1.53e-08	6.06e-06	0.32	0.26	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
HNSC	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	5.76	1.53e-08	6.07e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
HNSC	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5.76	1.54e-08	6.08e-06	0.31	0.26	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
HNSC	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	5.76	1.54e-08	6.08e-06	0.4	0.26	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
HNSC	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	5.76	1.54e-08	6.09e-06	0.3	0.26	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
HNSC	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-5.76	1.54e-08	6.09e-06	-0.3	-0.26	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
HNSC	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	5.76	1.54e-08	6.09e-06	0.27	0.26	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
HNSC	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	5.76	1.54e-08	6.09e-06	0.47	0.26	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
HNSC	cis	rs8054556	0.787	rs11642612	ENSG00000183604.13	SMG1P5	-5.76	1.54e-08	6.09e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30267553~30335374:-
HNSC	cis	rs8054556	0.787	rs11150581	ENSG00000183604.13	SMG1P5	-5.76	1.54e-08	6.09e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30267553~30335374:-
HNSC	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	5.76	1.54e-08	6.1e-06	0.28	0.26	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
HNSC	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	5.76	1.54e-08	6.11e-06	0.34	0.26	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	5.76	1.54e-08	6.11e-06	0.34	0.26	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
HNSC	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	5.76	1.54e-08	6.11e-06	0.35	0.26	Height;	chr6:109530435	chr6:109382795~109383666:+
HNSC	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-5.76	1.54e-08	6.11e-06	-0.31	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
HNSC	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5.76	1.55e-08	6.12e-06	0.26	0.26	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5.76	1.55e-08	6.12e-06	0.26	0.26	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
HNSC	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-5.76	1.55e-08	6.12e-06	-0.34	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
HNSC	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	5.76	1.55e-08	6.12e-06	0.3	0.26	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	5.76	1.55e-08	6.12e-06	0.3	0.26	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
HNSC	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	5.76	1.55e-08	6.13e-06	0.28	0.26	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
HNSC	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-5.76	1.55e-08	6.13e-06	-0.23	-0.26	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
HNSC	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.76	1.55e-08	6.13e-06	-0.37	-0.26	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	5.76	1.55e-08	6.13e-06	0.31	0.26	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
HNSC	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	5.76	1.55e-08	6.14e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
HNSC	cis	rs4218	0.689	rs60262196	ENSG00000277144.1	RP11-59H7.4	-5.76	1.55e-08	6.15e-06	-0.36	-0.26	Social communication problems;	chr15:59088853	chr15:59115547~59116089:-
HNSC	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-5.76	1.55e-08	6.15e-06	-0.3	-0.26	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
HNSC	cis	rs35306767	0.953	rs12354639	ENSG00000229869.1	RP11-363N22.2	-5.76	1.55e-08	6.15e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:917741	chr10:933026~942743:+
HNSC	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-5.76	1.55e-08	6.15e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
HNSC	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-5.76	1.56e-08	6.16e-06	-0.23	-0.26	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
HNSC	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-5.76	1.56e-08	6.16e-06	-0.36	-0.26	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
HNSC	cis	rs2243480	1	rs1618893	ENSG00000179406.6	LINC00174	-5.76	1.56e-08	6.16e-06	-0.5	-0.26	Diabetic kidney disease;	chr7:66631132	chr7:66376044~66401338:-
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28123153	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28124529	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28127577	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-5.76	1.56e-08	6.16e-06	-0.32	-0.26	Depression;	chr6:28131566	chr6:28161781~28169594:+
HNSC	cis	rs7630852	0.965	rs4256169	ENSG00000272359.1	U4	-5.76	1.56e-08	6.16e-06	-0.28	-0.26	Eosinophil counts;	chr3:196785852	chr3:196747192~196747324:-
HNSC	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-5.76	1.56e-08	6.17e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
HNSC	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	5.76	1.56e-08	6.17e-06	0.26	0.26	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
HNSC	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-5.76	1.56e-08	6.17e-06	-0.32	-0.26	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
HNSC	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
HNSC	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-5.76	1.56e-08	6.17e-06	-0.4	-0.26	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
HNSC	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-5.76	1.56e-08	6.17e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
HNSC	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-5.76	1.56e-08	6.18e-06	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
HNSC	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	5.76	1.56e-08	6.18e-06	0.36	0.26	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
HNSC	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-5.76	1.56e-08	6.18e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
HNSC	cis	rs4218	0.543	rs11852461	ENSG00000259732.1	RP11-59H7.3	-5.76	1.56e-08	6.18e-06	-0.33	-0.26	Social communication problems;	chr15:59021728	chr15:59121034~59133250:+
HNSC	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-5.76	1.56e-08	6.18e-06	-0.37	-0.26	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
HNSC	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-5.76	1.57e-08	6.19e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000254340.1	RP11-10A14.3	5.76	1.57e-08	6.19e-06	0.31	0.26	Mood instability;	chr8:8783635	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.76	1.57e-08	6.19e-06	0.3	0.26	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
HNSC	cis	rs2006771	0.765	rs6518752	ENSG00000236132.1	CTA-440B3.1	-5.76	1.57e-08	6.2e-06	-0.28	-0.26	Nonsyndromic cleft lip with cleft palate;	chr22:31603141	chr22:31816379~31817491:-
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-5.76	1.57e-08	6.2e-06	-0.3	-0.26	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
HNSC	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-5.76	1.57e-08	6.21e-06	-0.3	-0.26	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.555	rs11591094	ENSG00000223787.2	RP4-593M8.1	5.75	1.57e-08	6.21e-06	0.36	0.26	Multiple sclerosis;	chr1:92649899	chr1:92580476~92580821:-
HNSC	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	5.75	1.57e-08	6.22e-06	0.27	0.26	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
HNSC	cis	rs8054556	0.708	rs2278557	ENSG00000183604.13	SMG1P5	-5.75	1.57e-08	6.22e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30082458	chr16:30267553~30335374:-
HNSC	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-5.75	1.58e-08	6.22e-06	-0.3	-0.26	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
HNSC	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	5.75	1.58e-08	6.23e-06	0.36	0.26	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
HNSC	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	5.75	1.58e-08	6.23e-06	0.31	0.26	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
HNSC	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	5.75	1.58e-08	6.25e-06	0.39	0.26	Height;	chr6:109479488	chr6:109382795~109383666:+
HNSC	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-5.75	1.58e-08	6.25e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
HNSC	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-5.75	1.58e-08	6.26e-06	-0.34	-0.26	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
HNSC	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	5.75	1.59e-08	6.26e-06	0.34	0.26	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-5.75	1.59e-08	6.26e-06	-0.32	-0.26	Depression;	chr6:28096077	chr6:28161781~28169594:+
HNSC	cis	rs2898681	0.618	rs7677726	ENSG00000248375.1	RP11-177B4.1	5.75	1.59e-08	6.26e-06	0.48	0.26	Optic nerve measurement (cup area);	chr4:52873095	chr4:52720081~52720831:-
HNSC	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-5.75	1.59e-08	6.26e-06	-0.3	-0.26	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000276710.3	CSPG4P8	-5.75	1.59e-08	6.27e-06	-0.27	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82459472~82477258:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000179406.6	LINC00174	5.75	1.59e-08	6.27e-06	0.54	0.26	Diabetic kidney disease;	chr7:66324467	chr7:66376044~66401338:-
HNSC	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	5.75	1.59e-08	6.27e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	5.75	1.59e-08	6.27e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
HNSC	cis	rs7819412	0.775	rs34094119	ENSG00000269918.1	AF131215.9	-5.75	1.59e-08	6.27e-06	-0.25	-0.26	Triglycerides;	chr8:11078388	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	5.75	1.59e-08	6.28e-06	0.32	0.26	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
HNSC	cis	rs6951245	0.572	rs80133931	ENSG00000224079.1	AC091729.7	-5.75	1.59e-08	6.28e-06	-0.56	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:987650	chr7:1074450~1078036:+
HNSC	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	5.75	1.59e-08	6.28e-06	0.35	0.26	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	5.75	1.59e-08	6.28e-06	0.21	0.26	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
HNSC	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	5.75	1.59e-08	6.28e-06	0.32	0.26	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
HNSC	cis	rs35955747	0.722	rs5997898	ENSG00000236132.1	CTA-440B3.1	5.75	1.59e-08	6.29e-06	0.28	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31176977	chr22:31816379~31817491:-
HNSC	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	5.75	1.59e-08	6.29e-06	0.34	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
HNSC	cis	rs4141404	0.816	rs5749227	ENSG00000236132.1	CTA-440B3.1	5.75	1.6e-08	6.3e-06	0.36	0.26	Paclitaxel-induced neuropathy;	chr22:31185180	chr22:31816379~31817491:-
HNSC	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	5.75	1.6e-08	6.3e-06	0.35	0.26	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
HNSC	cis	rs4218	0.648	rs12915899	ENSG00000277144.1	RP11-59H7.4	-5.75	1.6e-08	6.31e-06	-0.35	-0.26	Social communication problems;	chr15:59084332	chr15:59115547~59116089:-
HNSC	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	5.75	1.6e-08	6.31e-06	0.34	0.26	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
HNSC	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-5.75	1.6e-08	6.31e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000233609.3	RP11-62H7.2	5.75	1.6e-08	6.31e-06	0.25	0.26	Joint mobility (Beighton score);	chr8:8970227	chr8:8961200~8979025:+
HNSC	cis	rs2483058	0.796	rs11120291	ENSG00000261000.1	RP11-534L20.5	5.75	1.6e-08	6.31e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206442751	chr1:206503948~206504456:+
HNSC	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	5.75	1.6e-08	6.31e-06	0.36	0.26	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
HNSC	cis	rs35306767	0.953	rs34405399	ENSG00000229869.1	RP11-363N22.2	-5.75	1.6e-08	6.32e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:935075	chr10:933026~942743:+
HNSC	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-5.75	1.6e-08	6.33e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
HNSC	cis	rs7819412	0.775	rs4841489	ENSG00000269918.1	AF131215.9	-5.75	1.6e-08	6.33e-06	-0.25	-0.26	Triglycerides;	chr8:11079301	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.775	rs4841490	ENSG00000269918.1	AF131215.9	-5.75	1.6e-08	6.33e-06	-0.25	-0.26	Triglycerides;	chr8:11079381	chr8:11104691~11106704:-
HNSC	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-5.75	1.61e-08	6.34e-06	-0.41	-0.26	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
HNSC	cis	rs2985684	1	rs2985696	ENSG00000258568.1	RHOQP1	5.75	1.61e-08	6.34e-06	0.27	0.26	Carotid intima media thickness;	chr14:49628195	chr14:49599994~49600572:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	5.75	1.61e-08	6.34e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.75	1.61e-08	6.34e-06	-0.28	-0.26	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
HNSC	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-5.75	1.61e-08	6.35e-06	-0.37	-0.26	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
HNSC	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	5.75	1.61e-08	6.35e-06	0.31	0.26	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
HNSC	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-5.75	1.61e-08	6.36e-06	-0.36	-0.26	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
HNSC	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
HNSC	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	5.75	1.61e-08	6.36e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
HNSC	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-5.75	1.61e-08	6.36e-06	-0.32	-0.26	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.75	1.62e-08	6.37e-06	-0.29	-0.26	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
HNSC	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-5.75	1.62e-08	6.38e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-5.75	1.62e-08	6.38e-06	-0.31	-0.26	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
HNSC	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	5.75	1.62e-08	6.39e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
HNSC	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-5.75	1.62e-08	6.39e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
HNSC	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	5.75	1.62e-08	6.4e-06	0.23	0.26	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
HNSC	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	5.75	1.62e-08	6.4e-06	0.35	0.26	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
HNSC	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	5.75	1.62e-08	6.4e-06	0.34	0.26	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000254340.1	RP11-10A14.3	5.75	1.63e-08	6.4e-06	0.33	0.26	Recombination measurement;	chr8:9228513	chr8:9141424~9145435:+
HNSC	cis	rs2179367	0.632	rs9498324	ENSG00000216906.2	RP11-350J20.9	5.75	1.63e-08	6.4e-06	0.38	0.26	Dupuytren's disease;	chr6:149338973	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs55826712	ENSG00000216906.2	RP11-350J20.9	5.75	1.63e-08	6.4e-06	0.38	0.26	Dupuytren's disease;	chr6:149344716	chr6:149904243~149906418:+
HNSC	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	5.75	1.63e-08	6.41e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	5.75	1.63e-08	6.41e-06	0.34	0.26	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
HNSC	cis	rs4140799	0.78	rs10137642	ENSG00000266869.1	RP6-114E22.1	-5.75	1.63e-08	6.42e-06	-0.31	-0.26	Neuroticism;	chr14:71738604	chr14:71848606~71908430:+
HNSC	cis	rs4218	0.541	rs1374155	ENSG00000259732.1	RP11-59H7.3	-5.75	1.63e-08	6.43e-06	-0.34	-0.26	Social communication problems;	chr15:59030630	chr15:59121034~59133250:+
HNSC	cis	rs6951245	0.572	rs74791540	ENSG00000224079.1	AC091729.7	-5.75	1.63e-08	6.43e-06	-0.54	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1022277	chr7:1074450~1078036:+
HNSC	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-5.75	1.63e-08	6.43e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
HNSC	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-5.75	1.64e-08	6.44e-06	-0.26	-0.26	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
HNSC	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-5.75	1.64e-08	6.44e-06	-0.48	-0.26	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
HNSC	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	5.75	1.64e-08	6.45e-06	0.35	0.26	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
HNSC	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	5.75	1.64e-08	6.45e-06	0.35	0.26	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
HNSC	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	5.75	1.64e-08	6.45e-06	0.35	0.26	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	5.75	1.64e-08	6.45e-06	0.35	0.26	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
HNSC	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-5.75	1.64e-08	6.45e-06	-0.27	-0.26	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	5.75	1.64e-08	6.45e-06	0.21	0.26	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
HNSC	cis	rs17507216	0.591	rs7163848	ENSG00000276710.3	CSPG4P8	-5.75	1.64e-08	6.45e-06	-0.36	-0.26	Excessive daytime sleepiness;	chr15:82729563	chr15:82459472~82477258:+
HNSC	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-5.75	1.64e-08	6.46e-06	-0.33	-0.26	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-5.75	1.64e-08	6.47e-06	-0.31	-0.26	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
HNSC	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-5.75	1.64e-08	6.47e-06	-0.3	-0.26	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-5.75	1.64e-08	6.47e-06	-0.3	-0.26	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-5.75	1.64e-08	6.47e-06	-0.32	-0.26	Depression;	chr6:28071808	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-5.75	1.65e-08	6.48e-06	-0.31	-0.26	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-5.75	1.65e-08	6.48e-06	-0.31	-0.26	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
HNSC	cis	rs9914544	1	rs9916245	ENSG00000264885.1	RP11-815I9.4	-5.75	1.65e-08	6.49e-06	-0.27	-0.26	Educational attainment (years of education);	chr17:18863512	chr17:18667629~18669461:-
HNSC	cis	rs11089937	1	rs6001121	ENSG00000211638.2	IGLV8-61	-5.75	1.65e-08	6.49e-06	-0.22	-0.26	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22098700~22099212:+
HNSC	cis	rs9341808	0.6	rs668329	ENSG00000272129.1	RP11-250B2.6	-5.75	1.65e-08	6.5e-06	-0.31	-0.26	Sitting height ratio;	chr6:80258861	chr6:80355424~80356859:+
HNSC	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	5.75	1.65e-08	6.51e-06	0.31	0.26	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
HNSC	cis	rs9840812	0.655	rs696516	ENSG00000273486.1	RP11-731C17.2	5.75	1.65e-08	6.51e-06	0.22	0.26	Fibrinogen levels;	chr3:136348936	chr3:136837338~136839021:-
HNSC	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-5.75	1.66e-08	6.51e-06	-0.25	-0.26	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-5.75	1.66e-08	6.52e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
HNSC	cis	rs3206736	0.548	rs1637673	ENSG00000197085.10	NPSR1-AS1	-5.74	1.66e-08	6.55e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34958238	chr7:34346512~34871582:-
HNSC	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	5.74	1.67e-08	6.55e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	5.74	1.67e-08	6.55e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
HNSC	cis	rs2243480	1	rs2707844	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1796220	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66597113	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2707831	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Diabetic kidney disease;	chr7:66597524	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1638731	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66679692	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs1882655	ENSG00000179406.6	LINC00174	5.74	1.67e-08	6.55e-06	0.55	0.26	Gout;	chr7:66682070	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000179406.6	LINC00174	5.74	1.67e-08	6.55e-06	0.55	0.26	Gout;	chr7:66682162	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659913	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66692349	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2659911	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66693433	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707838	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66694214	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs60326618	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66701371	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707830	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66702658	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2707828	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66706390	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000179406.6	LINC00174	-5.74	1.67e-08	6.55e-06	-0.55	-0.26	Gout;	chr7:66710076	chr7:66376044~66401338:-
HNSC	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-5.74	1.67e-08	6.55e-06	-0.3	-0.26	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
HNSC	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	5.74	1.67e-08	6.56e-06	0.27	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
HNSC	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	5.74	1.67e-08	6.56e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
HNSC	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	5.74	1.67e-08	6.57e-06	0.35	0.26	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
HNSC	cis	rs1355223	0.816	rs2136506	ENSG00000271369.1	RP11-350D17.3	-5.74	1.67e-08	6.57e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726713	chr11:34709600~34710161:+
HNSC	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-5.74	1.67e-08	6.57e-06	-0.37	-0.26	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-5.74	1.67e-08	6.58e-06	-0.32	-0.26	Depression;	chr6:28091242	chr6:28161781~28169594:+
HNSC	cis	rs2235642	0.785	rs1057983	ENSG00000280231.1	LA16c-380F5.3	-5.74	1.68e-08	6.58e-06	-0.31	-0.26	Coronary artery disease;	chr16:1610273	chr16:1553655~1554130:-
HNSC	cis	rs6928977	0.86	rs2746432	ENSG00000234084.1	RP3-388E23.2	5.74	1.68e-08	6.59e-06	0.26	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135375459	chr6:135301568~135307158:+
HNSC	cis	rs9329221	0.617	rs483916	ENSG00000254340.1	RP11-10A14.3	-5.74	1.68e-08	6.59e-06	-0.29	-0.26	Neuroticism;	chr8:9936091	chr8:9141424~9145435:+
HNSC	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-5.74	1.68e-08	6.6e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
HNSC	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-5.74	1.68e-08	6.62e-06	-0.35	-0.26	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
HNSC	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	5.74	1.69e-08	6.62e-06	0.38	0.26	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-5.74	1.69e-08	6.62e-06	-0.15	-0.26	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
HNSC	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	5.74	1.69e-08	6.62e-06	0.29	0.26	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
HNSC	cis	rs11532322	1	rs11532322	ENSG00000280120.1	RP11-546D6.3	5.74	1.69e-08	6.63e-06	0.22	0.26	Schizophrenia;	chr12:123246876	chr12:123152324~123153377:-
HNSC	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-5.74	1.69e-08	6.63e-06	-0.23	-0.26	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
HNSC	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	5.74	1.69e-08	6.63e-06	0.28	0.26	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
HNSC	cis	rs6604026	0.589	rs67026262	ENSG00000223787.2	RP4-593M8.1	5.74	1.69e-08	6.63e-06	0.36	0.26	Multiple sclerosis;	chr1:92646070	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs67876779	ENSG00000223787.2	RP4-593M8.1	5.74	1.69e-08	6.63e-06	0.36	0.26	Multiple sclerosis;	chr1:92646308	chr1:92580476~92580821:-
HNSC	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-5.74	1.69e-08	6.63e-06	-0.24	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
HNSC	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	5.74	1.69e-08	6.64e-06	0.3	0.26	Height;	chr4:55515118	chr4:55363971~55395847:-
HNSC	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-5.74	1.69e-08	6.65e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
HNSC	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-5.74	1.69e-08	6.65e-06	-0.41	-0.26	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
HNSC	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	5.74	1.69e-08	6.65e-06	0.3	0.26	Height;	chr4:55485974	chr4:55363971~55395847:-
HNSC	cis	rs1355223	0.902	rs12802120	ENSG00000271369.1	RP11-350D17.3	-5.74	1.7e-08	6.66e-06	-0.29	-0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726103	chr11:34709600~34710161:+
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000206014.6	OR7E161P	-5.74	1.7e-08	6.68e-06	-0.28	-0.26	Neuroticism;	chr8:11939481	chr8:11928597~11929563:-
HNSC	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	5.74	1.7e-08	6.68e-06	0.35	0.26	Height;	chr6:109581800	chr6:109382795~109383666:+
HNSC	cis	rs6604026	0.778	rs11164820	ENSG00000223787.2	RP4-593M8.1	-5.74	1.7e-08	6.69e-06	-0.36	-0.26	Multiple sclerosis;	chr1:92815231	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-5.74	1.7e-08	6.69e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-5.74	1.7e-08	6.69e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
HNSC	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.74	1.7e-08	6.69e-06	0.28	0.26	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-5.74	1.71e-08	6.69e-06	-0.29	-0.26	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
HNSC	cis	rs75422866	0.51	rs73105829	ENSG00000276691.1	RP5-1057I20.5	5.74	1.71e-08	6.69e-06	0.45	0.26	Pneumonia;	chr12:47734162	chr12:47788426~47788971:+
HNSC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	5.74	1.71e-08	6.7e-06	0.32	0.26	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
HNSC	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	5.74	1.71e-08	6.71e-06	0.37	0.26	Height;	chr6:109737797	chr6:109382795~109383666:+
HNSC	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	5.74	1.71e-08	6.71e-06	0.25	0.26	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
HNSC	cis	rs1012068	0.686	rs4820996	ENSG00000236132.1	CTA-440B3.1	-5.74	1.71e-08	6.72e-06	-0.3	-0.26	Chronic hepatitis C infection;	chr22:31928044	chr22:31816379~31817491:-
HNSC	cis	rs2179367	0.586	rs62426088	ENSG00000216906.2	RP11-350J20.9	5.74	1.72e-08	6.73e-06	0.38	0.26	Dupuytren's disease;	chr6:149339301	chr6:149904243~149906418:+
HNSC	cis	rs2579103	0.898	rs2579119	ENSG00000258183.4	RP11-753N8.1	-5.74	1.72e-08	6.73e-06	-0.31	-0.26	Body mass index;	chr12:90212163	chr12:90280894~90300340:+
HNSC	cis	rs9813712	0.953	rs6782280	ENSG00000249846.5	RP11-77P16.4	5.74	1.72e-08	6.73e-06	0.31	0.26	Response to amphetamines;	chr3:130245370	chr3:130112550~130120579:+
HNSC	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	5.74	1.72e-08	6.74e-06	0.28	0.26	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
HNSC	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	5.74	1.72e-08	6.75e-06	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
HNSC	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-5.74	1.72e-08	6.75e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
HNSC	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-5.74	1.72e-08	6.75e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
HNSC	cis	rs1021993	0.556	rs2153043	ENSG00000231648.1	RP11-372M18.2	5.74	1.72e-08	6.75e-06	0.36	0.26	Gut microbiome composition (winter);	chr1:209252959	chr1:209367662~209379690:+
HNSC	cis	rs9341808	0.519	rs3805878	ENSG00000272129.1	RP11-250B2.6	5.74	1.72e-08	6.76e-06	0.3	0.26	Sitting height ratio;	chr6:80304138	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000233609.3	RP11-62H7.2	-5.74	1.72e-08	6.76e-06	-0.25	-0.26	Mood instability;	chr8:8938391	chr8:8961200~8979025:+
HNSC	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55429416	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55430596	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	5.74	1.72e-08	6.76e-06	0.3	0.26	Height;	chr4:55431595	chr4:55363971~55395847:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000179406.6	LINC00174	-5.74	1.72e-08	6.76e-06	-0.34	-0.26	Calcium levels;	chr7:65829754	chr7:66376044~66401338:-
HNSC	cis	rs62344088	1	rs7715867	ENSG00000277812.1	AC021087.1	5.74	1.72e-08	6.76e-06	0.71	0.26	Asthma (childhood onset);	chr5:128944	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs73022563	ENSG00000277812.1	AC021087.1	5.74	1.72e-08	6.76e-06	0.71	0.26	Asthma (childhood onset);	chr5:140698	chr5:262769~262881:+
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	5.74	1.73e-08	6.77e-06	0.23	0.26	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
HNSC	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	5.74	1.73e-08	6.77e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
HNSC	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	5.74	1.73e-08	6.78e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
HNSC	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	5.74	1.73e-08	6.78e-06	0.3	0.26	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000254340.1	RP11-10A14.3	5.74	1.73e-08	6.78e-06	0.31	0.26	Mood instability;	chr8:8803028	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-5.74	1.73e-08	6.78e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000254340.1	RP11-10A14.3	-5.74	1.73e-08	6.79e-06	-0.31	-0.26	Mean corpuscular volume;	chr8:8996725	chr8:9141424~9145435:+
HNSC	cis	rs4141404	0.923	rs2413035	ENSG00000236132.1	CTA-440B3.1	5.74	1.74e-08	6.8e-06	0.32	0.26	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	5.74	1.74e-08	6.8e-06	0.32	0.26	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	5.74	1.74e-08	6.8e-06	0.32	0.26	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000254340.1	RP11-10A14.3	5.74	1.74e-08	6.8e-06	0.32	0.26	Mood instability;	chr8:8786428	chr8:9141424~9145435:+
HNSC	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-5.74	1.74e-08	6.8e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
HNSC	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-5.74	1.74e-08	6.8e-06	-0.22	-0.26	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
HNSC	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-5.74	1.74e-08	6.8e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
HNSC	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	5.74	1.74e-08	6.81e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
HNSC	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	5.74	1.74e-08	6.81e-06	0.28	0.26	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-5.74	1.74e-08	6.81e-06	-0.17	-0.26	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
HNSC	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-5.74	1.74e-08	6.81e-06	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	5.74	1.74e-08	6.81e-06	0.23	0.26	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
HNSC	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-5.74	1.74e-08	6.82e-06	-0.29	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
HNSC	cis	rs9525927	0.625	rs4941488	ENSG00000227258.4	SMIM2-AS1	5.74	1.74e-08	6.82e-06	0.37	0.26	Dupuytren's disease;	chr13:44243622	chr13:44110451~44240517:+
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28096855	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28099759	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28100648	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28104824	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-5.74	1.74e-08	6.82e-06	-0.32	-0.26	Depression;	chr6:28107222	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	5.74	1.74e-08	6.83e-06	0.31	0.26	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-5.74	1.74e-08	6.83e-06	-0.28	-0.26	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
HNSC	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	5.74	1.75e-08	6.83e-06	0.29	0.26	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
HNSC	cis	rs9341808	1	rs1359239	ENSG00000272129.1	RP11-250B2.6	5.74	1.75e-08	6.84e-06	0.31	0.26	Sitting height ratio;	chr6:80246429	chr6:80355424~80356859:+
HNSC	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-5.74	1.75e-08	6.84e-06	-0.33	-0.26	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
HNSC	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	5.74	1.75e-08	6.84e-06	0.29	0.26	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
HNSC	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.74	1.75e-08	6.84e-06	-0.36	-0.26	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
HNSC	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-5.74	1.75e-08	6.85e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
HNSC	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.74	1.75e-08	6.85e-06	-0.37	-0.26	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
HNSC	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	5.74	1.75e-08	6.85e-06	0.28	0.26	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
HNSC	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-5.74	1.75e-08	6.85e-06	-0.22	-0.26	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	5.74	1.75e-08	6.85e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
HNSC	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	5.74	1.75e-08	6.85e-06	0.46	0.26	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
HNSC	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-5.74	1.75e-08	6.86e-06	-0.34	-0.26	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-5.73	1.75e-08	6.87e-06	-0.17	-0.26	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
HNSC	cis	rs9341808	0.622	rs682482	ENSG00000272129.1	RP11-250B2.6	-5.73	1.75e-08	6.87e-06	-0.31	-0.26	Sitting height ratio;	chr6:80251422	chr6:80355424~80356859:+
HNSC	cis	rs2579103	0.898	rs2731224	ENSG00000258183.4	RP11-753N8.1	-5.73	1.76e-08	6.87e-06	-0.32	-0.26	Body mass index;	chr12:90202115	chr12:90280894~90300340:+
HNSC	cis	rs6918586	0.615	rs198824	ENSG00000272462.2	U91328.19	-5.73	1.76e-08	6.87e-06	-0.24	-0.26	Schizophrenia;	chr6:26122555	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198821	ENSG00000272462.2	U91328.19	-5.73	1.76e-08	6.87e-06	-0.24	-0.26	Schizophrenia;	chr6:26123401	chr6:25992662~26001775:+
HNSC	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55487368	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55489310	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55491628	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55495801	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55496737	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55496933	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55497842	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55500224	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501629	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501726	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55501788	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55504176	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55504201	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55506498	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55507248	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55507729	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55508587	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55509367	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	5.73	1.76e-08	6.87e-06	0.3	0.26	Height;	chr4:55510352	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	5.73	1.76e-08	6.87e-06	0.27	0.26	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	5.73	1.76e-08	6.88e-06	0.25	0.26	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
HNSC	cis	rs7819412	0.807	rs4840542	ENSG00000269918.1	AF131215.9	-5.73	1.76e-08	6.89e-06	-0.25	-0.26	Triglycerides;	chr8:11087299	chr8:11104691~11106704:-
HNSC	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	5.73	1.76e-08	6.89e-06	0.36	0.26	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
HNSC	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	5.73	1.76e-08	6.89e-06	0.36	0.26	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	5.73	1.76e-08	6.9e-06	0.29	0.26	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	5.73	1.76e-08	6.9e-06	0.32	0.26	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
HNSC	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-5.73	1.77e-08	6.9e-06	-0.22	-0.26	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
HNSC	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	5.73	1.77e-08	6.91e-06	0.31	0.26	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
HNSC	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	5.73	1.77e-08	6.91e-06	0.31	0.26	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	5.73	1.77e-08	6.91e-06	0.3	0.26	Height;	chr4:55501479	chr4:55363971~55395847:-
HNSC	cis	rs189798	0.738	rs330911	ENSG00000173295.6	FAM86B3P	5.73	1.77e-08	6.91e-06	0.31	0.26	Myopia (pathological);	chr8:9138763	chr8:8228595~8244865:+
HNSC	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	5.73	1.77e-08	6.92e-06	0.34	0.26	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
HNSC	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	5.73	1.77e-08	6.93e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
HNSC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-5.73	1.78e-08	6.94e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.73	1.78e-08	6.94e-06	0.27	0.26	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
HNSC	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-5.73	1.78e-08	6.94e-06	-0.35	-0.26	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
HNSC	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	5.73	1.78e-08	6.94e-06	0.32	0.26	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
HNSC	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-5.73	1.78e-08	6.95e-06	-0.4	-0.26	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
HNSC	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-5.73	1.78e-08	6.95e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
HNSC	cis	rs2834288	0.7	rs2409502	ENSG00000237945.6	LINC00649	-5.73	1.78e-08	6.95e-06	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr21:33902431	chr21:33915534~33977691:+
HNSC	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-5.73	1.78e-08	6.95e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
HNSC	cis	rs1865760	0.534	rs1541988	ENSG00000272462.2	U91328.19	-5.73	1.78e-08	6.95e-06	-0.24	-0.26	Height;	chr6:25950576	chr6:25992662~26001775:+
HNSC	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-5.73	1.78e-08	6.95e-06	-0.36	-0.26	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
HNSC	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	5.73	1.78e-08	6.96e-06	0.27	0.26	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
HNSC	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-5.73	1.79e-08	6.98e-06	-0.32	-0.26	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-5.73	1.79e-08	6.99e-06	-0.18	-0.26	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
HNSC	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-5.73	1.79e-08	7e-06	-0.29	-0.26	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
HNSC	cis	rs67180937	0.583	rs3008614	ENSG00000272750.1	RP11-378J18.8	5.73	1.79e-08	7e-06	0.34	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622794	chr1:222658867~222661512:-
HNSC	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	5.73	1.79e-08	7.01e-06	0.31	0.26	Height;	chr4:55479996	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	5.73	1.79e-08	7.01e-06	0.31	0.26	Height;	chr4:55482317	chr4:55387949~55388271:+
HNSC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	5.73	1.79e-08	7.01e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
HNSC	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	5.73	1.8e-08	7.01e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
HNSC	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	5.73	1.8e-08	7.02e-06	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
HNSC	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	5.73	1.8e-08	7.02e-06	0.46	0.26	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
HNSC	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-5.73	1.8e-08	7.02e-06	-0.39	-0.26	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
HNSC	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-5.73	1.8e-08	7.02e-06	-0.28	-0.26	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
HNSC	cis	rs7674212	0.512	rs2720462	ENSG00000246560.2	RP11-10L12.4	5.73	1.8e-08	7.03e-06	0.29	0.26	Type 2 diabetes;	chr4:103135053	chr4:102828055~102844075:+
HNSC	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	5.73	1.81e-08	7.05e-06	0.25	0.26	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
HNSC	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-5.73	1.81e-08	7.05e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
HNSC	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-5.73	1.81e-08	7.06e-06	-0.3	-0.26	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
HNSC	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	7.06e-06	-0.35	-0.26	Depression;	chr6:28230678	chr6:28115628~28116551:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	5.73	1.81e-08	7.06e-06	0.28	0.26	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
HNSC	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	5.73	1.81e-08	7.06e-06	0.31	0.26	Height;	chr4:55459921	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	5.73	1.81e-08	7.06e-06	0.32	0.26	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	5.73	1.81e-08	7.07e-06	0.3	0.26	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
HNSC	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	5.73	1.81e-08	7.08e-06	0.25	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
HNSC	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	5.73	1.82e-08	7.09e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
HNSC	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	5.73	1.82e-08	7.09e-06	0.27	0.26	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
HNSC	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-5.73	1.82e-08	7.09e-06	-0.34	-0.26	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
HNSC	cis	rs6604026	0.589	rs12738833	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92653561	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs11578098	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92653853	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.589	rs11800771	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92661552	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs68160001	ENSG00000223787.2	RP4-593M8.1	5.73	1.82e-08	7.09e-06	0.36	0.26	Multiple sclerosis;	chr1:92668018	chr1:92580476~92580821:-
HNSC	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-5.73	1.82e-08	7.09e-06	-0.32	-0.26	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
HNSC	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	5.73	1.82e-08	7.1e-06	0.32	0.26	Height;	chr4:55483718	chr4:55387949~55388271:+
HNSC	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-5.73	1.82e-08	7.1e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-5.73	1.82e-08	7.1e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
HNSC	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	5.73	1.82e-08	7.11e-06	0.28	0.26	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
HNSC	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-5.73	1.83e-08	7.12e-06	-0.22	-0.26	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
HNSC	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-5.73	1.83e-08	7.12e-06	-0.35	-0.26	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
HNSC	cis	rs9341808	0.667	rs806783	ENSG00000272129.1	RP11-250B2.6	-5.73	1.83e-08	7.13e-06	-0.31	-0.26	Sitting height ratio;	chr6:80233226	chr6:80355424~80356859:+
HNSC	cis	rs4218	0.701	rs7174277	ENSG00000259732.1	RP11-59H7.3	-5.73	1.83e-08	7.13e-06	-0.32	-0.26	Social communication problems;	chr15:59150390	chr15:59121034~59133250:+
HNSC	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	5.73	1.83e-08	7.14e-06	0.28	0.26	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	5.73	1.83e-08	7.14e-06	0.28	0.26	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
HNSC	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	5.73	1.83e-08	7.14e-06	0.28	0.26	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
HNSC	cis	rs8054556	0.787	rs35105141	ENSG00000183604.13	SMG1P5	-5.73	1.83e-08	7.14e-06	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30267553~30335374:-
HNSC	cis	rs454422	1	rs236121	ENSG00000275632.1	RP5-967N21.11	5.73	1.83e-08	7.14e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5991948	chr20:6000418~6000941:+
HNSC	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-5.73	1.83e-08	7.14e-06	-0.23	-0.26	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
HNSC	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-5.73	1.83e-08	7.15e-06	-0.33	-0.26	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
HNSC	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	5.73	1.84e-08	7.15e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
HNSC	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-5.73	1.84e-08	7.15e-06	-0.2	-0.26	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
HNSC	cis	rs9302065	0.529	rs2992904	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305919	chr13:95310830~95310955:-
HNSC	cis	rs9302065	0.529	rs2993582	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305927	chr13:95310830~95310955:-
HNSC	cis	rs9302065	0.565	rs2992905	ENSG00000223298.1	RNY3P8	5.73	1.84e-08	7.16e-06	0.26	0.26	Blood metabolite levels;	chr13:95305936	chr13:95310830~95310955:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-5.73	1.84e-08	7.16e-06	-0.15	-0.26	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	5.73	1.84e-08	7.17e-06	0.31	0.26	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
HNSC	cis	rs1021993	1	rs2174775	ENSG00000231648.1	RP11-372M18.2	5.73	1.84e-08	7.17e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209311422	chr1:209367662~209379690:+
HNSC	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	5.73	1.84e-08	7.18e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
HNSC	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-5.73	1.84e-08	7.18e-06	-0.3	-0.26	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	5.73	1.84e-08	7.18e-06	0.3	0.26	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
HNSC	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	5.73	1.84e-08	7.18e-06	0.3	0.26	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
HNSC	cis	rs757110	0.745	rs2074311	ENSG00000260196.1	RP1-239B22.5	5.73	1.84e-08	7.18e-06	0.29	0.26	Type 2 diabetes;	chr11:17400313	chr11:17380649~17383531:+
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000254153.1	CTA-398F10.2	5.73	1.84e-08	7.18e-06	0.29	0.26	Neuroticism;	chr8:8241055	chr8:8456909~8461337:-
HNSC	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	5.73	1.84e-08	7.18e-06	0.66	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
HNSC	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	5.73	1.84e-08	7.18e-06	0.31	0.26	Height;	chr4:55515118	chr4:55387949~55388271:+
HNSC	cis	rs9402743	0.632	rs6570040	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135779557	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs7754830	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135779904	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs2104133	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135781149	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.597	rs9483880	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135781474	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4895458	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135783235	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896178	ENSG00000217482.2	HMGB1P17	5.73	1.84e-08	7.18e-06	0.27	0.26	Systemic lupus erythematosus;	chr6:135783957	chr6:135636086~135636713:-
HNSC	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	5.73	1.85e-08	7.19e-06	0.37	0.26	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
HNSC	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	5.73	1.85e-08	7.19e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-5.73	1.85e-08	7.19e-06	-0.31	-0.26	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-5.73	1.85e-08	7.19e-06	-0.31	-0.26	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
HNSC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	5.73	1.85e-08	7.19e-06	0.32	0.26	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-5.73	1.85e-08	7.19e-06	-0.17	-0.26	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
HNSC	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.73	1.85e-08	7.2e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.73	1.85e-08	7.2e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	5.73	1.85e-08	7.21e-06	0.62	0.26	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
HNSC	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	5.72	1.86e-08	7.22e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
HNSC	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	5.72	1.86e-08	7.22e-06	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
HNSC	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-5.72	1.86e-08	7.23e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
HNSC	cis	rs6951245	0.572	rs79396675	ENSG00000224079.1	AC091729.7	-5.72	1.86e-08	7.23e-06	-0.54	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1015411	chr7:1074450~1078036:+
HNSC	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-5.72	1.86e-08	7.23e-06	-0.36	-0.26	Depression;	chr6:28231053	chr6:28115628~28116551:+
HNSC	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	5.72	1.86e-08	7.23e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
HNSC	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-5.72	1.87e-08	7.26e-06	-0.27	-0.26	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
HNSC	cis	rs6604026	0.59	rs35612297	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92688538	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs2051841	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92690638	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs72724574	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92692547	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs11577426	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92694681	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs12756698	ENSG00000223787.2	RP4-593M8.1	5.72	1.87e-08	7.26e-06	0.36	0.26	Multiple sclerosis;	chr1:92697243	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-5.72	1.87e-08	7.26e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-5.72	1.87e-08	7.26e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
HNSC	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	5.72	1.87e-08	7.27e-06	0.3	0.26	Height;	chr4:55511198	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	5.72	1.87e-08	7.27e-06	0.3	0.26	Height;	chr4:55526514	chr4:55363971~55395847:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-5.72	1.87e-08	7.27e-06	-0.17	-0.26	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
HNSC	cis	rs11992162	1	rs11994417	ENSG00000206014.6	OR7E161P	-5.72	1.87e-08	7.28e-06	-0.28	-0.26	Monocyte count;	chr8:11975753	chr8:11928597~11929563:-
HNSC	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-5.72	1.87e-08	7.29e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
HNSC	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	5.72	1.87e-08	7.29e-06	0.36	0.26	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-5.72	1.88e-08	7.29e-06	-0.19	-0.26	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
HNSC	cis	rs2985684	1	rs2985697	ENSG00000258568.1	RHOQP1	5.72	1.88e-08	7.3e-06	0.27	0.26	Carotid intima media thickness;	chr14:49626184	chr14:49599994~49600572:+
HNSC	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-5.72	1.88e-08	7.3e-06	-0.31	-0.26	Height;	chr4:55487920	chr4:55387949~55388271:+
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	5.72	1.88e-08	7.3e-06	0.17	0.26	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
HNSC	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	5.72	1.88e-08	7.3e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	5.72	1.88e-08	7.3e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
HNSC	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	5.72	1.88e-08	7.3e-06	0.26	0.26	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.72	1.88e-08	7.3e-06	-0.3	-0.26	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
HNSC	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	5.72	1.88e-08	7.3e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
HNSC	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-5.72	1.88e-08	7.31e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
HNSC	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	5.72	1.88e-08	7.32e-06	0.25	0.26	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
HNSC	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-5.72	1.88e-08	7.32e-06	-0.55	-0.26	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
HNSC	cis	rs62344088	1	rs10037843	ENSG00000277812.1	AC021087.1	5.72	1.89e-08	7.34e-06	0.71	0.26	Asthma (childhood onset);	chr5:119963	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs13436694	ENSG00000277812.1	AC021087.1	5.72	1.89e-08	7.34e-06	0.71	0.26	Asthma (childhood onset);	chr5:122767	chr5:262769~262881:+
HNSC	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
HNSC	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-5.72	1.89e-08	7.35e-06	-0.37	-0.26	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
HNSC	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55515292	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55518776	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55518922	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55520278	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55523835	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55524246	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55525589	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	5.72	1.89e-08	7.35e-06	0.3	0.26	Height;	chr4:55525781	chr4:55363971~55395847:-
HNSC	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	5.72	1.89e-08	7.36e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
HNSC	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-5.72	1.9e-08	7.36e-06	-0.37	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
HNSC	cis	rs783540	0.5	rs7163840	ENSG00000255769.6	GOLGA2P10	5.72	1.9e-08	7.37e-06	0.35	0.26	Schizophrenia;	chr15:82729551	chr15:82472993~82513950:-
HNSC	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	5.72	1.9e-08	7.37e-06	0.34	0.26	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
HNSC	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.37e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
HNSC	cis	rs9813712	0.953	rs9847910	ENSG00000249846.5	RP11-77P16.4	5.72	1.9e-08	7.37e-06	0.31	0.26	Response to amphetamines;	chr3:130248174	chr3:130112550~130120579:+
HNSC	cis	rs2579103	0.782	rs2579132	ENSG00000258183.4	RP11-753N8.1	-5.72	1.9e-08	7.38e-06	-0.32	-0.26	Body mass index;	chr12:90201954	chr12:90280894~90300340:+
HNSC	cis	rs1355223	0.966	rs11602318	ENSG00000271369.1	RP11-350D17.3	5.72	1.9e-08	7.38e-06	0.3	0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745436	chr11:34709600~34710161:+
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000211974.3	IGHV2-70	-5.72	1.9e-08	7.38e-06	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106656649	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.72	1.9e-08	7.38e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
HNSC	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-5.72	1.9e-08	7.39e-06	-0.28	-0.26	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
HNSC	cis	rs2243480	1	rs4718317	ENSG00000179406.6	LINC00174	5.72	1.9e-08	7.39e-06	0.53	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66376044~66401338:-
HNSC	cis	rs9840812	0.906	rs61791757	ENSG00000239213.4	NCK1-AS1	-5.72	1.9e-08	7.39e-06	-0.25	-0.26	Fibrinogen levels;	chr3:136186483	chr3:136841726~136862054:-
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	5.72	1.91e-08	7.4e-06	0.2	0.26	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
HNSC	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	5.72	1.91e-08	7.41e-06	0.24	0.26	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	5.72	1.91e-08	7.41e-06	0.24	0.26	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
HNSC	cis	rs5753618	0.583	rs2273249	ENSG00000236132.1	CTA-440B3.1	-5.72	1.91e-08	7.41e-06	-0.32	-0.26	Colorectal cancer;	chr22:31440500	chr22:31816379~31817491:-
HNSC	cis	rs7819412	0.745	rs7017567	ENSG00000269918.1	AF131215.9	-5.72	1.91e-08	7.43e-06	-0.25	-0.26	Triglycerides;	chr8:11076189	chr8:11104691~11106704:-
HNSC	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	5.72	1.91e-08	7.43e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
HNSC	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-5.72	1.91e-08	7.43e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	5.72	1.91e-08	7.43e-06	0.32	0.26	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
HNSC	cis	rs1908814	0.504	rs7830734	ENSG00000206014.6	OR7E161P	-5.72	1.92e-08	7.44e-06	-0.28	-0.26	Neuroticism;	chr8:11938130	chr8:11928597~11929563:-
HNSC	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	5.72	1.92e-08	7.44e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
HNSC	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-5.72	1.92e-08	7.44e-06	-0.3	-0.26	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
HNSC	cis	rs860295	0.557	rs348196	ENSG00000203761.5	MSTO2P	-5.72	1.92e-08	7.44e-06	-0.2	-0.26	Body mass index;	chr1:155697170	chr1:155745829~155750137:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-5.72	1.92e-08	7.45e-06	-0.31	-0.26	Depression;	chr6:28070115	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-5.72	1.92e-08	7.45e-06	-0.31	-0.26	Depression;	chr6:28071237	chr6:28161781~28169594:+
HNSC	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-5.72	1.92e-08	7.45e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
HNSC	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	5.72	1.92e-08	7.46e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	5.72	1.92e-08	7.46e-06	0.23	0.26	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
HNSC	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-5.72	1.92e-08	7.47e-06	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
HNSC	cis	rs9840812	0.655	rs4452981	ENSG00000273486.1	RP11-731C17.2	5.72	1.93e-08	7.47e-06	0.22	0.26	Fibrinogen levels;	chr3:136588925	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	5.72	1.93e-08	7.48e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
HNSC	cis	rs6918586	0.658	rs198829	ENSG00000272462.2	U91328.19	-5.72	1.93e-08	7.48e-06	-0.24	-0.26	Schizophrenia;	chr6:26118665	chr6:25992662~26001775:+
HNSC	cis	rs6918586	0.658	rs198828	ENSG00000272462.2	U91328.19	-5.72	1.93e-08	7.48e-06	-0.24	-0.26	Schizophrenia;	chr6:26119231	chr6:25992662~26001775:+
HNSC	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	5.72	1.93e-08	7.48e-06	0.46	0.26	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	5.72	1.93e-08	7.48e-06	0.46	0.26	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
HNSC	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	5.72	1.93e-08	7.48e-06	0.24	0.26	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
HNSC	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-5.72	1.93e-08	7.49e-06	-0.32	-0.26	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-5.72	1.93e-08	7.49e-06	-0.32	-0.26	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-5.72	1.93e-08	7.49e-06	-0.31	-0.26	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
HNSC	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-5.72	1.93e-08	7.49e-06	-0.27	-0.26	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
HNSC	cis	rs454422	0.767	rs236119	ENSG00000275632.1	RP5-967N21.11	5.72	1.93e-08	7.49e-06	0.27	0.26	HIV-1 viral setpoint;	chr20:5958008	chr20:6000418~6000941:+
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.72	1.93e-08	7.49e-06	0.27	0.26	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
HNSC	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	5.72	1.93e-08	7.5e-06	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
HNSC	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	5.72	1.93e-08	7.5e-06	0.23	0.26	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-5.72	1.93e-08	7.5e-06	-0.18	-0.26	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
HNSC	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	5.72	1.94e-08	7.51e-06	0.36	0.26	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66715944	chr7:66376044~66401338:-
HNSC	cis	rs1499614	1	rs2141924	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66721259	chr7:66376044~66401338:-
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000179406.6	LINC00174	-5.72	1.94e-08	7.51e-06	-0.55	-0.26	Gout;	chr7:66732812	chr7:66376044~66401338:-
HNSC	cis	rs2579103	0.898	rs1583699	ENSG00000258183.4	RP11-753N8.1	-5.72	1.94e-08	7.51e-06	-0.31	-0.26	Body mass index;	chr12:90206198	chr12:90280894~90300340:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	5.72	1.94e-08	7.53e-06	0.2	0.26	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	5.72	1.95e-08	7.54e-06	0.32	0.26	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.72	1.95e-08	7.54e-06	0.27	0.26	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
HNSC	cis	rs2179367	0.632	rs10872636	ENSG00000216906.2	RP11-350J20.9	5.72	1.95e-08	7.54e-06	0.38	0.26	Dupuytren's disease;	chr6:149353678	chr6:149904243~149906418:+
HNSC	cis	rs6918586	0.658	rs198826	ENSG00000272462.2	U91328.19	5.72	1.95e-08	7.54e-06	0.24	0.26	Schizophrenia;	chr6:26120925	chr6:25992662~26001775:+
HNSC	cis	rs3206736	0.548	rs1186721	ENSG00000197085.10	NPSR1-AS1	-5.72	1.95e-08	7.55e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34934990	chr7:34346512~34871582:-
HNSC	cis	rs10504130	0.542	rs1589079	ENSG00000272024.1	RP11-546K22.3	-5.72	1.95e-08	7.55e-06	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51950284~51950690:+
HNSC	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-5.72	1.95e-08	7.56e-06	-0.25	-0.26	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
HNSC	cis	rs2579103	0.617	rs61924675	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90208613	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.867	rs2118805	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90209168	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.838	rs2043850	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90209938	chr12:90280894~90300340:+
HNSC	cis	rs2579103	0.898	rs2731229	ENSG00000258183.4	RP11-753N8.1	-5.72	1.95e-08	7.57e-06	-0.31	-0.26	Body mass index;	chr12:90211096	chr12:90280894~90300340:+
HNSC	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	5.72	1.95e-08	7.57e-06	0.34	0.26	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
HNSC	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	5.72	1.95e-08	7.57e-06	0.34	0.26	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
HNSC	cis	rs6604026	0.624	rs12731107	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92701772	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11803097	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92705932	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs12749786	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92706367	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs72724586	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92707620	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs72724587	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92707653	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs34305407	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92708658	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs35311203	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92712910	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs12749480	ENSG00000223787.2	RP4-593M8.1	5.72	1.96e-08	7.58e-06	0.36	0.26	Multiple sclerosis;	chr1:92714968	chr1:92580476~92580821:-
HNSC	cis	rs35306767	0.904	rs10904584	ENSG00000229869.1	RP11-363N22.2	-5.72	1.96e-08	7.58e-06	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr10:937807	chr10:933026~942743:+
HNSC	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	5.72	1.96e-08	7.58e-06	0.35	0.26	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
HNSC	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	5.72	1.96e-08	7.58e-06	0.33	0.26	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
HNSC	cis	rs9341808	0.558	rs2490234	ENSG00000272129.1	RP11-250B2.6	5.71	1.96e-08	7.58e-06	0.3	0.26	Sitting height ratio;	chr6:80107249	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-5.71	1.96e-08	7.59e-06	-0.31	-0.26	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	5.71	1.96e-08	7.6e-06	0.32	0.26	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
HNSC	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.71	1.96e-08	7.6e-06	-0.31	-0.26	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
HNSC	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	5.71	1.96e-08	7.6e-06	0.31	0.26	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
HNSC	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-5.71	1.97e-08	7.62e-06	-0.26	-0.26	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
HNSC	cis	rs6604026	0.624	rs11578004	ENSG00000223787.2	RP4-593M8.1	5.71	1.97e-08	7.62e-06	0.35	0.26	Multiple sclerosis;	chr1:92726707	chr1:92580476~92580821:-
HNSC	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-5.71	1.97e-08	7.62e-06	-0.3	-0.26	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
HNSC	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	5.71	1.97e-08	7.62e-06	0.3	0.26	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-5.71	1.97e-08	7.62e-06	-0.17	-0.26	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
HNSC	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-5.71	1.97e-08	7.62e-06	-0.33	-0.26	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
HNSC	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	5.71	1.97e-08	7.62e-06	0.23	0.26	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	5.71	1.97e-08	7.62e-06	0.32	0.26	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
HNSC	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-5.71	1.97e-08	7.62e-06	-0.29	-0.26	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
HNSC	cis	rs11648785	0.59	rs10431948	ENSG00000222019.6	URAHP	-5.71	1.97e-08	7.63e-06	-0.24	-0.26	Tanning;	chr16:90033163	chr16:90039761~90047773:-
HNSC	cis	rs4948102	0.597	rs12669623	ENSG00000226278.1	PSPHP1	-5.71	1.97e-08	7.63e-06	-0.28	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55764797~55773288:+
HNSC	cis	rs1355223	0.902	rs1258470	ENSG00000271369.1	RP11-350D17.3	5.71	1.97e-08	7.64e-06	0.29	0.26	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34707718	chr11:34709600~34710161:+
HNSC	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-5.71	1.98e-08	7.64e-06	-0.33	-0.26	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
HNSC	cis	rs3206736	0.556	rs1649235	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.64e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34964270	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.514	rs1649236	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.64e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34964522	chr7:34346512~34871582:-
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	5.71	1.98e-08	7.64e-06	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
HNSC	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-5.71	1.98e-08	7.65e-06	-0.3	-0.26	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
HNSC	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-5.71	1.98e-08	7.66e-06	-0.33	-0.26	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-5.71	1.98e-08	7.66e-06	-0.33	-0.26	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
HNSC	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-5.71	1.98e-08	7.66e-06	-0.3	-0.26	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000211974.3	IGHV2-70	5.71	1.98e-08	7.67e-06	0.29	0.26	Rheumatic heart disease;	chr14:106630013	chr14:106723574~106724093:-
HNSC	cis	rs3206736	0.556	rs328924	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34996092	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328925	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:34997715	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328929	ENSG00000197085.10	NPSR1-AS1	-5.71	1.98e-08	7.67e-06	-0.32	-0.26	Diastolic blood pressure;	chr7:35000426	chr7:34346512~34871582:-
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.71	1.99e-08	7.68e-06	0.27	0.26	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
HNSC	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	5.71	1.99e-08	7.7e-06	0.28	0.26	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
HNSC	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	5.71	2e-08	7.71e-06	0.35	0.26	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
HNSC	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	5.71	2e-08	7.72e-06	0.32	0.26	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
HNSC	cis	rs6918586	0.658	rs198822	ENSG00000272462.2	U91328.19	-5.71	2e-08	7.72e-06	-0.24	-0.26	Schizophrenia;	chr6:26123311	chr6:25992662~26001775:+
HNSC	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-5.71	2e-08	7.73e-06	-0.28	-0.26	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
HNSC	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	5.71	2e-08	7.73e-06	0.35	0.26	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
HNSC	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	5.71	2.01e-08	7.77e-06	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
HNSC	cis	rs804280	0.509	rs13268030	ENSG00000206014.6	OR7E161P	-5.71	2.01e-08	7.77e-06	-0.27	-0.26	Myopia (pathological);	chr8:11925564	chr8:11928597~11929563:-
HNSC	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	5.71	2.01e-08	7.77e-06	0.31	0.26	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
HNSC	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55476736	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55477426	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	5.71	2.01e-08	7.77e-06	0.31	0.26	Height;	chr4:55477545	chr4:55387949~55388271:+
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000233609.3	RP11-62H7.2	-5.71	2.01e-08	7.77e-06	-0.25	-0.26	Joint mobility (Beighton score);	chr8:8935355	chr8:8961200~8979025:+
HNSC	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-5.71	2.01e-08	7.78e-06	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
HNSC	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	5.71	2.02e-08	7.78e-06	0.34	0.26	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
HNSC	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	5.71	2.02e-08	7.78e-06	0.34	0.26	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	5.71	2.02e-08	7.78e-06	0.23	0.26	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.71	2.02e-08	7.79e-06	0.27	0.26	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
HNSC	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	5.71	2.02e-08	7.8e-06	0.34	0.26	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
HNSC	cis	rs4140799	0.839	rs8015004	ENSG00000266869.1	RP6-114E22.1	5.71	2.02e-08	7.8e-06	0.31	0.26	Neuroticism;	chr14:71706696	chr14:71848606~71908430:+
HNSC	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-5.71	2.02e-08	7.8e-06	-0.4	-0.26	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
HNSC	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	5.71	2.03e-08	7.82e-06	0.32	0.26	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	5.71	2.03e-08	7.82e-06	0.32	0.26	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
HNSC	cis	rs2834288	0.5	rs2834305	ENSG00000273102.1	AP000569.9	5.71	2.03e-08	7.82e-06	0.27	0.26	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.5	rs7277248	ENSG00000273102.1	AP000569.9	5.71	2.03e-08	7.82e-06	0.27	0.26	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33967101~33968573:-
HNSC	cis	rs9300255	0.568	rs1790108	ENSG00000280120.1	RP11-546D6.3	5.71	2.03e-08	7.83e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123152294	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.51	rs1790109	ENSG00000280120.1	RP11-546D6.3	5.71	2.03e-08	7.83e-06	0.23	0.26	Neutrophil percentage of white cells;	chr12:123153205	chr12:123152324~123153377:-
HNSC	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	5.71	2.03e-08	7.83e-06	0.32	0.26	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	5.71	2.03e-08	7.83e-06	0.32	0.26	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
HNSC	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	5.71	2.03e-08	7.83e-06	0.4	0.26	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
HNSC	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	5.71	2.03e-08	7.83e-06	0.3	0.26	Height;	chr4:55484534	chr4:55363971~55395847:-
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Depression;	chr6:28138981	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-5.71	2.03e-08	7.84e-06	-0.32	-0.26	Depression;	chr6:28139012	chr6:28161781~28169594:+
HNSC	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-5.71	2.03e-08	7.84e-06	-0.33	-0.26	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	5.71	2.03e-08	7.84e-06	0.32	0.26	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
HNSC	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	5.71	2.03e-08	7.84e-06	0.27	0.26	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
HNSC	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	5.71	2.04e-08	7.86e-06	0.34	0.26	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
HNSC	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-5.71	2.04e-08	7.86e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
HNSC	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	5.71	2.04e-08	7.86e-06	0.36	0.26	Height;	chr6:109333018	chr6:109382795~109383666:+
HNSC	cis	rs9341808	0.6	rs590641	ENSG00000272129.1	RP11-250B2.6	5.71	2.04e-08	7.87e-06	0.3	0.26	Sitting height ratio;	chr6:80256766	chr6:80355424~80356859:+
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	5.71	2.04e-08	7.87e-06	0.32	0.26	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	5.71	2.05e-08	7.89e-06	0.33	0.26	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
HNSC	cis	rs7160336	0.641	rs17782448	ENSG00000259065.1	RP5-1021I20.1	-5.71	2.05e-08	7.89e-06	-0.3	-0.26	Blood protein levels;	chr14:74215998	chr14:73787360~73803270:+
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000173295.6	FAM86B3P	5.71	2.05e-08	7.89e-06	0.28	0.26	Mood instability;	chr8:8817815	chr8:8228595~8244865:+
HNSC	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-5.71	2.05e-08	7.89e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-5.71	2.05e-08	7.89e-06	-0.39	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
HNSC	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	5.71	2.05e-08	7.89e-06	0.29	0.26	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
HNSC	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	5.71	2.05e-08	7.9e-06	0.37	0.26	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
HNSC	cis	rs9302065	0.565	rs2992908	ENSG00000223298.1	RNY3P8	5.71	2.05e-08	7.9e-06	0.26	0.26	Blood metabolite levels;	chr13:95308346	chr13:95310830~95310955:-
HNSC	cis	rs75422866	0.51	rs73105845	ENSG00000276691.1	RP5-1057I20.5	5.71	2.05e-08	7.9e-06	0.46	0.26	Pneumonia;	chr12:47741824	chr12:47788426~47788971:+
HNSC	cis	rs8177876	0.731	rs74878296	ENSG00000261061.1	RP11-303E16.2	-5.71	2.05e-08	7.91e-06	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81030770~81031485:+
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	5.71	2.05e-08	7.92e-06	0.27	0.26	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
HNSC	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.71	2.06e-08	7.92e-06	0.45	0.26	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
HNSC	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-5.71	2.06e-08	7.92e-06	-0.26	-0.26	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
HNSC	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	5.71	2.06e-08	7.92e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
HNSC	cis	rs10504130	0.569	rs7820177	ENSG00000272024.1	RP11-546K22.3	-5.71	2.06e-08	7.93e-06	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	5.71	2.06e-08	7.94e-06	0.32	0.26	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
HNSC	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	5.71	2.06e-08	7.94e-06	0.27	0.26	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
HNSC	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55461320	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55462689	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55463606	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55466010	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55467308	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55470266	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55470874	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55474259	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	5.71	2.06e-08	7.95e-06	0.31	0.26	Height;	chr4:55475130	chr4:55387949~55388271:+
HNSC	cis	rs1021993	0.674	rs937874	ENSG00000231648.1	RP11-372M18.2	5.71	2.07e-08	7.96e-06	0.35	0.26	Gut microbiome composition (winter);	chr1:209326036	chr1:209367662~209379690:+
HNSC	cis	rs7819412	0.594	rs17724226	ENSG00000269918.1	AF131215.9	-5.71	2.07e-08	7.96e-06	-0.26	-0.26	Triglycerides;	chr8:11111416	chr8:11104691~11106704:-
HNSC	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	5.7	2.07e-08	7.98e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-5.7	2.07e-08	7.98e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	5.7	2.08e-08	8e-06	0.31	0.26	Height;	chr4:55476159	chr4:55387949~55388271:+
HNSC	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	5.7	2.08e-08	8e-06	0.25	0.26	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
HNSC	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	5.7	2.08e-08	8e-06	0.29	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
HNSC	cis	rs9840812	0.592	rs900048	ENSG00000273486.1	RP11-731C17.2	5.7	2.08e-08	8e-06	0.22	0.26	Fibrinogen levels;	chr3:136500088	chr3:136837338~136839021:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-5.7	2.08e-08	8.01e-06	-0.17	-0.26	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
HNSC	cis	rs6951245	0.572	rs79489623	ENSG00000224079.1	AC091729.7	-5.7	2.08e-08	8.01e-06	-0.55	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005996	chr7:1074450~1078036:+
HNSC	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	5.7	2.08e-08	8.01e-06	0.27	0.26	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
HNSC	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-5.7	2.08e-08	8.02e-06	-0.33	-0.26	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
HNSC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-5.7	2.08e-08	8.02e-06	-0.32	-0.26	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
HNSC	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	5.7	2.08e-08	8.02e-06	0.31	0.26	Height;	chr4:55589624	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	5.7	2.09e-08	8.02e-06	0.32	0.26	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
HNSC	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-5.7	2.09e-08	8.04e-06	-0.37	-0.26	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
HNSC	cis	rs4218	0.588	rs9788719	ENSG00000259732.1	RP11-59H7.3	-5.7	2.09e-08	8.04e-06	-0.33	-0.26	Social communication problems;	chr15:59028920	chr15:59121034~59133250:+
HNSC	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-5.7	2.09e-08	8.04e-06	-0.29	-0.26	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
HNSC	cis	rs4218	0.569	rs73418864	ENSG00000259732.1	RP11-59H7.3	-5.7	2.09e-08	8.05e-06	-0.35	-0.26	Social communication problems;	chr15:59098996	chr15:59121034~59133250:+
HNSC	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-5.7	2.09e-08	8.05e-06	-0.35	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
HNSC	cis	rs9341808	0.558	rs2322635	ENSG00000272129.1	RP11-250B2.6	5.7	2.09e-08	8.05e-06	0.3	0.26	Sitting height ratio;	chr6:80187493	chr6:80355424~80356859:+
HNSC	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	5.7	2.1e-08	8.06e-06	0.31	0.26	Height;	chr4:55485974	chr4:55387949~55388271:+
HNSC	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-5.7	2.1e-08	8.07e-06	-0.22	-0.26	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-5.7	2.1e-08	8.07e-06	-0.22	-0.26	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
HNSC	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-5.7	2.1e-08	8.07e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
HNSC	cis	rs67981189	0.529	rs61990387	ENSG00000274818.1	RP1-292L20.3	5.7	2.1e-08	8.07e-06	0.31	0.26	Schizophrenia;	chr14:71024850	chr14:70906657~70907111:-
HNSC	cis	rs7209700	0.547	rs7219925	ENSG00000228782.6	CTD-2026D20.3	-5.7	2.1e-08	8.07e-06	-0.27	-0.26	IgG glycosylation;	chr17:47264274	chr17:47450568~47492492:-
HNSC	cis	rs9300255	0.596	rs11057207	ENSG00000280120.1	RP11-546D6.3	5.7	2.1e-08	8.08e-06	0.22	0.26	Neutrophil percentage of white cells;	chr12:123246344	chr12:123152324~123153377:-
HNSC	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-5.7	2.1e-08	8.08e-06	-0.29	-0.26	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-5.7	2.1e-08	8.08e-06	-0.29	-0.26	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
HNSC	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	5.7	2.1e-08	8.09e-06	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
HNSC	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	5.7	2.11e-08	8.1e-06	0.48	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-5.7	2.11e-08	8.1e-06	-0.36	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
HNSC	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-5.7	2.11e-08	8.1e-06	-0.36	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000179406.6	LINC00174	-5.7	2.11e-08	8.11e-06	-0.54	-0.26	Diabetic kidney disease;	chr7:66105184	chr7:66376044~66401338:-
HNSC	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	5.7	2.11e-08	8.11e-06	0.34	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
HNSC	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-5.7	2.11e-08	8.12e-06	-0.31	-0.26	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.7	2.11e-08	8.12e-06	0.27	0.26	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
HNSC	cis	rs2115630	0.967	rs8028490	ENSG00000229212.6	RP11-561C5.4	5.7	2.11e-08	8.13e-06	0.29	0.26	P wave terminal force;	chr15:84734657	chr15:85205440~85234795:-
HNSC	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	5.7	2.12e-08	8.15e-06	0.27	0.26	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
HNSC	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-5.7	2.12e-08	8.16e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
HNSC	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-5.7	2.12e-08	8.16e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
HNSC	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	5.7	2.13e-08	8.16e-06	0.29	0.26	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
HNSC	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
HNSC	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	5.7	2.13e-08	8.16e-06	0.4	0.26	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
HNSC	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-5.7	2.13e-08	8.16e-06	-0.25	-0.26	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
HNSC	cis	rs804280	0.517	rs7815179	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	Myopia (pathological);	chr8:11934539	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.871	rs7815186	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs7833079	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	Neuroticism;	chr8:11934620	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs7815595	ENSG00000206014.6	OR7E161P	-5.7	2.13e-08	8.16e-06	-0.28	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11928597~11929563:-
HNSC	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-5.7	2.13e-08	8.17e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	5.7	2.13e-08	8.17e-06	0.31	0.26	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
HNSC	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-5.7	2.13e-08	8.17e-06	-0.32	-0.26	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
HNSC	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-5.7	2.13e-08	8.18e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
HNSC	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-5.7	2.13e-08	8.18e-06	-0.24	-0.26	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	5.7	2.13e-08	8.19e-06	0.32	0.26	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.624	rs34202284	ENSG00000223787.2	RP4-593M8.1	-5.7	2.13e-08	8.19e-06	-0.35	-0.26	Multiple sclerosis;	chr1:92694445	chr1:92580476~92580821:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-5.7	2.14e-08	8.2e-06	-0.32	-0.26	Depression;	chr6:28139049	chr6:28161781~28169594:+
HNSC	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-5.7	2.14e-08	8.21e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
HNSC	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	5.7	2.14e-08	8.21e-06	0.25	0.25	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-5.7	2.14e-08	8.21e-06	-0.28	-0.25	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
HNSC	cis	rs2742234	0.541	rs10793427	ENSG00000273008.1	RP11-351D16.3	5.7	2.14e-08	8.22e-06	0.35	0.25	Hirschsprung disease;	chr10:43251995	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	5.7	2.14e-08	8.22e-06	0.32	0.25	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	5.7	2.14e-08	8.22e-06	0.32	0.25	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
HNSC	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-5.7	2.15e-08	8.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	5.7	2.15e-08	8.25e-06	0.32	0.25	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.7	2.15e-08	8.25e-06	0.31	0.25	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000179406.6	LINC00174	-5.7	2.15e-08	8.25e-06	-0.33	-0.25	Calcium levels;	chr7:65751755	chr7:66376044~66401338:-
HNSC	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55574959	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55551447	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55551845	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55553396	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	5.7	2.15e-08	8.26e-06	0.31	0.25	Height;	chr4:55554025	chr4:55387949~55388271:+
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	5.7	2.15e-08	8.26e-06	0.62	0.25	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	5.7	2.15e-08	8.26e-06	0.62	0.25	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
HNSC	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-5.7	2.16e-08	8.27e-06	-0.33	-0.25	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
HNSC	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-5.7	2.16e-08	8.29e-06	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-5.7	2.16e-08	8.29e-06	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	5.7	2.16e-08	8.29e-06	0.32	0.25	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
HNSC	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	5.7	2.17e-08	8.32e-06	0.27	0.25	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
HNSC	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-5.7	2.17e-08	8.32e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-5.7	2.17e-08	8.32e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
HNSC	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-5.7	2.17e-08	8.33e-06	-0.33	-0.25	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
HNSC	cis	rs35306767	0.953	rs7908138	ENSG00000229869.1	RP11-363N22.2	-5.7	2.17e-08	8.33e-06	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:917038	chr10:933026~942743:+
HNSC	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-5.7	2.17e-08	8.34e-06	-0.25	-0.25	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
HNSC	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	5.7	2.18e-08	8.34e-06	0.3	0.25	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
HNSC	cis	rs11648785	0.777	rs3785183	ENSG00000222019.6	URAHP	5.7	2.18e-08	8.35e-06	0.25	0.25	Tanning;	chr16:90029153	chr16:90039761~90047773:-
HNSC	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	5.7	2.18e-08	8.35e-06	0.47	0.25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
HNSC	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	5.7	2.18e-08	8.35e-06	0.48	0.25	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	5.7	2.18e-08	8.36e-06	0.32	0.25	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	5.7	2.18e-08	8.36e-06	0.32	0.25	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
HNSC	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-5.7	2.18e-08	8.36e-06	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-5.7	2.18e-08	8.36e-06	-0.27	-0.25	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
HNSC	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.7	2.18e-08	8.37e-06	0.37	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
HNSC	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.69	2.19e-08	8.38e-06	0.25	0.25	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	5.69	2.19e-08	8.38e-06	0.25	0.25	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-5.69	2.19e-08	8.38e-06	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.872	rs74091715	ENSG00000211974.3	IGHV2-70	-5.69	2.19e-08	8.38e-06	-0.29	-0.25	Rheumatic heart disease;	chr14:106637731	chr14:106723574~106724093:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.69	2.19e-08	8.39e-06	0.27	0.25	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
HNSC	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	5.69	2.19e-08	8.39e-06	0.33	0.25	Height;	chr4:55413708	chr4:55363971~55395847:-
HNSC	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	5.69	2.19e-08	8.39e-06	0.5	0.25	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
HNSC	cis	rs6951245	0.572	rs112072378	ENSG00000224079.1	AC091729.7	-5.69	2.19e-08	8.4e-06	-0.54	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999764	chr7:1074450~1078036:+
HNSC	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	5.69	2.19e-08	8.41e-06	0.31	0.25	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
HNSC	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	5.69	2.2e-08	8.41e-06	0.25	0.25	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
HNSC	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	5.69	2.2e-08	8.42e-06	0.35	0.25	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	5.69	2.2e-08	8.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
HNSC	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	5.69	2.2e-08	8.42e-06	0.3	0.25	Height;	chr4:55425312	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	5.69	2.2e-08	8.42e-06	0.28	0.25	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
HNSC	cis	rs4218	0.648	rs58087223	ENSG00000277144.1	RP11-59H7.4	-5.69	2.2e-08	8.43e-06	-0.35	-0.25	Social communication problems;	chr15:59075132	chr15:59115547~59116089:-
HNSC	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	5.69	2.2e-08	8.43e-06	0.32	0.25	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
HNSC	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	5.69	2.2e-08	8.44e-06	0.32	0.25	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
HNSC	cis	rs2579103	1	rs2918621	ENSG00000258183.4	RP11-753N8.1	-5.69	2.2e-08	8.44e-06	-0.33	-0.25	Body mass index;	chr12:90213775	chr12:90280894~90300340:+
HNSC	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	5.69	2.2e-08	8.44e-06	0.3	0.25	Height;	chr4:55589624	chr4:55363971~55395847:-
HNSC	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-5.69	2.21e-08	8.44e-06	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
HNSC	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	5.69	2.21e-08	8.44e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	5.69	2.21e-08	8.44e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
HNSC	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	5.69	2.21e-08	8.45e-06	0.35	0.25	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
HNSC	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
HNSC	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-5.69	2.21e-08	8.45e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
HNSC	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-5.69	2.21e-08	8.45e-06	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
HNSC	cis	rs11992162	0.967	rs10108320	ENSG00000206014.6	OR7E161P	5.69	2.21e-08	8.45e-06	0.26	0.25	Monocyte count;	chr8:11974754	chr8:11928597~11929563:-
HNSC	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	5.69	2.21e-08	8.46e-06	0.34	0.25	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
HNSC	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	5.69	2.21e-08	8.46e-06	0.35	0.25	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.69	2.21e-08	8.46e-06	0.27	0.25	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
HNSC	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	5.69	2.21e-08	8.47e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.69	2.21e-08	8.48e-06	0.27	0.25	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
HNSC	cis	rs13126694	0.744	rs10049927	ENSG00000248429.4	RP11-597D13.9	5.69	2.21e-08	8.48e-06	0.29	0.25	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158170752~158202877:+
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-5.69	2.22e-08	8.48e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	5.69	2.22e-08	8.48e-06	0.29	0.25	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
HNSC	cis	rs950776	0.79	rs2067808	ENSG00000261762.1	RP11-650L12.2	5.69	2.22e-08	8.49e-06	0.31	0.25	Sudden cardiac arrest;	chr15:78619438	chr15:78589123~78591276:-
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	5.69	2.22e-08	8.49e-06	0.2	0.25	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000257433.4	RP1-197B17.3	5.69	2.22e-08	8.5e-06	0.67	0.25	Pneumonia;	chr12:47584539	chr12:47706085~47742294:+
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.69	2.22e-08	8.5e-06	0.27	0.25	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
HNSC	cis	rs6604026	0.555	rs34221961	ENSG00000223787.2	RP4-593M8.1	5.69	2.22e-08	8.51e-06	0.35	0.25	Multiple sclerosis;	chr1:92615337	chr1:92580476~92580821:-
HNSC	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-5.69	2.22e-08	8.51e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-5.69	2.22e-08	8.51e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
HNSC	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	5.69	2.23e-08	8.52e-06	0.34	0.25	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
HNSC	cis	rs7404843	0.733	rs153003	ENSG00000263065.1	AF001548.6	5.69	2.23e-08	8.52e-06	0.4	0.25	Testicular germ cell tumor;	chr16:15397543	chr16:15741151~15741791:+
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	5.69	2.23e-08	8.53e-06	0.27	0.25	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
HNSC	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-5.69	2.23e-08	8.53e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000211972.2	IGHV3-66	5.69	2.23e-08	8.53e-06	0.2	0.25	Kawasaki disease;	chr14:106716897	chr14:106675017~106675544:-
HNSC	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-5.69	2.23e-08	8.54e-06	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
HNSC	cis	rs2579103	1	rs2043852	ENSG00000258183.4	RP11-753N8.1	-5.69	2.24e-08	8.55e-06	-0.34	-0.25	Body mass index;	chr12:90195659	chr12:90280894~90300340:+
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	5.69	2.24e-08	8.56e-06	0.31	0.25	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	5.69	2.24e-08	8.57e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
HNSC	cis	rs35306767	0.953	rs1106064	ENSG00000229869.1	RP11-363N22.2	-5.69	2.24e-08	8.57e-06	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:911271	chr10:933026~942743:+
HNSC	cis	rs8054556	0.787	rs12325539	ENSG00000183604.13	SMG1P5	-5.69	2.24e-08	8.58e-06	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30267553~30335374:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000254153.1	CTA-398F10.2	5.69	2.24e-08	8.58e-06	0.28	0.25	Mood instability;	chr8:8484905	chr8:8456909~8461337:-
HNSC	cis	rs2810114	0.76	rs2810105	ENSG00000274818.1	RP1-292L20.3	-5.69	2.24e-08	8.58e-06	-0.31	-0.25	Alcohol dependence;	chr14:70957934	chr14:70906657~70907111:-
HNSC	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	2.25e-08	8.58e-06	-0.28	-0.25	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
HNSC	cis	rs9341808	0.519	rs607130	ENSG00000272129.1	RP11-250B2.6	-5.69	2.25e-08	8.59e-06	-0.3	-0.25	Sitting height ratio;	chr6:80289516	chr6:80355424~80356859:+
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000211974.3	IGHV2-70	-5.69	2.25e-08	8.6e-06	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106810329	chr14:106723574~106724093:-
HNSC	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-5.69	2.25e-08	8.6e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
HNSC	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	5.69	2.25e-08	8.6e-06	0.31	0.25	Height;	chr4:55534166	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	5.69	2.25e-08	8.6e-06	0.31	0.25	Height;	chr4:55534180	chr4:55387949~55388271:+
HNSC	cis	rs2742234	0.541	rs11238490	ENSG00000273008.1	RP11-351D16.3	5.69	2.25e-08	8.62e-06	0.35	0.25	Hirschsprung disease;	chr10:43252150	chr10:43136824~43138334:-
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-5.69	2.26e-08	8.62e-06	-0.31	-0.25	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
HNSC	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	5.69	2.26e-08	8.63e-06	0.46	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
HNSC	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	5.69	2.26e-08	8.63e-06	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
HNSC	cis	rs4356203	0.933	rs12801545	ENSG00000260196.1	RP1-239B22.5	5.69	2.27e-08	8.66e-06	0.28	0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17380649~17383531:+
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000244479.5	OR2A1-AS1	5.69	2.27e-08	8.66e-06	0.38	0.25	Obesity-related traits;	chr7:144057308	chr7:144251264~144356181:-
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	5.69	2.27e-08	8.66e-06	0.32	0.25	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	5.69	2.27e-08	8.66e-06	0.32	0.25	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
HNSC	cis	rs9840812	0.691	rs7621025	ENSG00000273486.1	RP11-731C17.2	5.69	2.27e-08	8.66e-06	0.22	0.25	Fibrinogen levels;	chr3:136553404	chr3:136837338~136839021:-
HNSC	cis	rs9840812	0.728	rs6439646	ENSG00000273486.1	RP11-731C17.2	5.69	2.27e-08	8.66e-06	0.22	0.25	Fibrinogen levels;	chr3:136554721	chr3:136837338~136839021:-
HNSC	cis	rs2834288	0.575	rs2239564	ENSG00000237945.6	LINC00649	-5.69	2.27e-08	8.67e-06	-0.33	-0.25	Gut microbiota (bacterial taxa);	chr21:33908245	chr21:33915534~33977691:+
HNSC	cis	rs2483058	0.739	rs963893	ENSG00000261000.1	RP11-534L20.5	5.69	2.27e-08	8.67e-06	0.25	0.25	Cholesterol and Triglycerides;	chr1:206452351	chr1:206503948~206504456:+
HNSC	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	5.69	2.27e-08	8.68e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
HNSC	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	5.69	2.27e-08	8.68e-06	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
HNSC	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-5.69	2.27e-08	8.68e-06	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
HNSC	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	5.69	2.28e-08	8.69e-06	0.35	0.25	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
HNSC	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	5.69	2.28e-08	8.69e-06	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
HNSC	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	5.69	2.28e-08	8.69e-06	0.28	0.25	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
HNSC	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	5.69	2.28e-08	8.7e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
HNSC	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-5.69	2.28e-08	8.7e-06	-0.26	-0.25	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
HNSC	cis	rs9402743	0.6	rs9376151	ENSG00000217482.2	HMGB1P17	5.69	2.28e-08	8.71e-06	0.27	0.25	Systemic lupus erythematosus;	chr6:135789599	chr6:135636086~135636713:-
HNSC	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-5.69	2.29e-08	8.72e-06	-0.31	-0.25	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
HNSC	cis	rs860295	0.871	rs12724079	ENSG00000203761.5	MSTO2P	5.69	2.29e-08	8.72e-06	0.19	0.25	Body mass index;	chr1:155464151	chr1:155745829~155750137:+
HNSC	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-5.69	2.29e-08	8.73e-06	-0.36	-0.25	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
HNSC	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-5.69	2.29e-08	8.74e-06	-0.33	-0.25	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
HNSC	cis	rs35306767	0.953	rs1539174	ENSG00000229869.1	RP11-363N22.2	-5.69	2.29e-08	8.75e-06	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:928930	chr10:933026~942743:+
HNSC	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-5.69	2.3e-08	8.76e-06	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
HNSC	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	5.69	2.3e-08	8.77e-06	0.3	0.25	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
HNSC	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-5.69	2.3e-08	8.77e-06	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
HNSC	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-5.69	2.3e-08	8.77e-06	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
HNSC	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	5.69	2.3e-08	8.77e-06	0.31	0.25	Height;	chr4:55537960	chr4:55387949~55388271:+
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	5.69	2.3e-08	8.77e-06	0.25	0.25	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
HNSC	cis	rs2579103	0.782	rs1583701	ENSG00000258183.4	RP11-753N8.1	-5.69	2.3e-08	8.78e-06	-0.31	-0.25	Body mass index;	chr12:90205824	chr12:90280894~90300340:+
HNSC	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-5.69	2.3e-08	8.79e-06	-0.3	-0.25	Height;	chr4:55537550	chr4:55363971~55395847:-
HNSC	cis	rs2976388	0.647	rs2585174	ENSG00000253741.1	CTD-2292P10.4	-5.69	2.31e-08	8.79e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142700626	chr8:142702252~142726973:-
HNSC	cis	rs2579103	0.898	rs35018904	ENSG00000258183.4	RP11-753N8.1	-5.69	2.31e-08	8.79e-06	-0.31	-0.25	Body mass index;	chr12:90202113	chr12:90280894~90300340:+
HNSC	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	5.69	2.31e-08	8.79e-06	0.26	0.25	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
HNSC	cis	rs2579103	0.898	rs10777237	ENSG00000258183.4	RP11-753N8.1	5.69	2.31e-08	8.79e-06	0.31	0.25	Body mass index;	chr12:90249747	chr12:90280894~90300340:+
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.69	2.31e-08	8.79e-06	-0.27	-0.25	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
HNSC	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.69	2.31e-08	8.8e-06	-0.28	-0.25	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.68	2.31e-08	8.8e-06	-0.34	-0.25	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
HNSC	cis	rs4144743	0.641	rs67696888	ENSG00000228782.6	CTD-2026D20.3	-5.68	2.31e-08	8.8e-06	-0.33	-0.25	Body mass index;	chr17:47277750	chr17:47450568~47492492:-
HNSC	cis	rs9300255	0.55	rs10772997	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123235333	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs11057202	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123236228	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.566	rs10744150	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.8e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123237067	chr12:123152324~123153377:-
HNSC	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	5.68	2.31e-08	8.81e-06	0.35	0.25	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
HNSC	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	5.68	2.31e-08	8.81e-06	0.31	0.25	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
HNSC	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	5.68	2.31e-08	8.81e-06	0.25	0.25	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	5.68	2.31e-08	8.81e-06	0.25	0.25	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
HNSC	cis	rs9302065	0.565	rs2993585	ENSG00000223298.1	RNY3P8	5.68	2.31e-08	8.82e-06	0.26	0.25	Blood metabolite levels;	chr13:95309712	chr13:95310830~95310955:-
HNSC	cis	rs9300255	0.596	rs1568427	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123254131	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.539	rs1969355	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123257514	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10734900	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123258898	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10734901	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123258900	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs10732573	ENSG00000280120.1	RP11-546D6.3	5.68	2.31e-08	8.82e-06	0.22	0.25	Neutrophil percentage of white cells;	chr12:123259336	chr12:123152324~123153377:-
HNSC	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-5.68	2.32e-08	8.83e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
HNSC	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	5.68	2.32e-08	8.83e-06	0.26	0.25	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
HNSC	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-5.68	2.32e-08	8.84e-06	-0.3	-0.25	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.86e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
HNSC	cis	rs60617249	0.501	rs4446688	ENSG00000228204.2	RP4-724E13.2	5.68	2.33e-08	8.88e-06	0.32	0.25	Major depression and alcohol dependence;	chr7:50925780	chr7:50866747~51022990:+
HNSC	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	5.68	2.33e-08	8.88e-06	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
HNSC	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-5.68	2.33e-08	8.88e-06	-0.24	-0.25	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
HNSC	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.89e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-5.68	2.33e-08	8.89e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	5.68	2.33e-08	8.89e-06	0.32	0.25	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
HNSC	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	5.68	2.34e-08	8.9e-06	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
HNSC	cis	rs8177876	0.915	rs4889233	ENSG00000261061.1	RP11-303E16.2	5.68	2.34e-08	8.9e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.915	rs11866124	ENSG00000261061.1	RP11-303E16.2	5.68	2.34e-08	8.9e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81030770~81031485:+
HNSC	cis	rs3738443	0.672	rs6691539	ENSG00000259865.1	RP11-488L18.10	5.68	2.34e-08	8.91e-06	0.2	0.25	Alcohol dependence;	chr1:247209370	chr1:247187281~247188526:-
HNSC	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-5.68	2.34e-08	8.92e-06	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000274576.2	IGHV2-70	-5.68	2.34e-08	8.92e-06	-0.25	-0.25	Rheumatic heart disease;	chr14:106644643	chr14:106770577~106771020:-
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000206014.6	OR7E161P	-5.68	2.34e-08	8.92e-06	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11928597~11929563:-
HNSC	cis	rs10256972	0.967	rs7799110	ENSG00000225146.1	AC073957.15	5.68	2.34e-08	8.92e-06	0.3	0.25	Endometriosis;Longevity;	chr7:999429	chr7:1029025~1043891:+
HNSC	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-5.68	2.34e-08	8.92e-06	-0.39	-0.25	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
HNSC	cis	rs9300255	0.568	rs1627724	ENSG00000280120.1	RP11-546D6.3	5.68	2.35e-08	8.93e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123154033	chr12:123152324~123153377:-
HNSC	cis	rs7402982	0.625	rs4966008	ENSG00000278022.1	RP11-35O15.2	5.68	2.35e-08	8.93e-06	0.3	0.25	Birth weight;	chr15:98660216	chr15:98660210~98660668:+
HNSC	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	5.68	2.35e-08	8.93e-06	0.28	0.25	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
HNSC	cis	rs9611519	0.78	rs2235850	ENSG00000235513.1	RP4-756G23.5	5.68	2.35e-08	8.93e-06	0.26	0.25	Neuroticism;	chr22:41261622	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	5.68	2.35e-08	8.94e-06	0.31	0.25	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
HNSC	cis	rs9302065	0.565	rs2993584	ENSG00000223298.1	RNY3P8	5.68	2.35e-08	8.94e-06	0.26	0.25	Blood metabolite levels;	chr13:95309424	chr13:95310830~95310955:-
HNSC	cis	rs1355223	0.902	rs12802323	ENSG00000271369.1	RP11-350D17.3	-5.68	2.35e-08	8.94e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726192	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-5.68	2.35e-08	8.95e-06	-0.32	-0.25	Depression;	chr6:28139876	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-5.68	2.35e-08	8.95e-06	-0.32	-0.25	Depression;	chr6:28139998	chr6:28161781~28169594:+
HNSC	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5.68	2.35e-08	8.95e-06	0.32	0.25	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
HNSC	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	5.68	2.35e-08	8.95e-06	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
HNSC	cis	rs11846409	0.932	rs74091721	ENSG00000211974.3	IGHV2-70	-5.68	2.35e-08	8.95e-06	-0.29	-0.25	Rheumatic heart disease;	chr14:106638262	chr14:106723574~106724093:-
HNSC	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-5.68	2.35e-08	8.95e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
HNSC	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.68	2.35e-08	8.95e-06	-0.33	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
HNSC	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	5.68	2.35e-08	8.95e-06	0.33	0.25	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.96e-06	0.31	0.25	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
HNSC	cis	rs9611519	1	rs5758267	ENSG00000235513.1	RP4-756G23.5	-5.68	2.36e-08	8.97e-06	-0.27	-0.25	Neuroticism;	chr22:41223346	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	5.68	2.36e-08	8.97e-06	0.31	0.25	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	5.68	2.36e-08	8.98e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	5.68	2.36e-08	8.98e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-5.68	2.36e-08	8.99e-06	-0.18	-0.25	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
HNSC	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-5.68	2.36e-08	8.99e-06	-0.31	-0.25	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
HNSC	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-5.68	2.37e-08	9e-06	-0.24	-0.25	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
HNSC	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	5.68	2.37e-08	9.01e-06	0.35	0.25	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000211972.2	IGHV3-66	5.68	2.37e-08	9.02e-06	0.2	0.25	Kawasaki disease;	chr14:106708947	chr14:106675017~106675544:-
HNSC	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-5.68	2.37e-08	9.02e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
HNSC	cis	rs2483058	0.767	rs10779631	ENSG00000261000.1	RP11-534L20.5	5.68	2.37e-08	9.02e-06	0.25	0.25	Cholesterol and Triglycerides;	chr1:206448943	chr1:206503948~206504456:+
HNSC	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	5.68	2.37e-08	9.02e-06	0.36	0.25	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
HNSC	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-5.68	2.37e-08	9.02e-06	-0.24	-0.25	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
HNSC	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	5.68	2.37e-08	9.02e-06	0.25	0.25	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
HNSC	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	5.68	2.38e-08	9.05e-06	0.26	0.25	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	5.68	2.38e-08	9.05e-06	0.21	0.25	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-5.68	2.38e-08	9.06e-06	-0.27	-0.25	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-5.68	2.38e-08	9.06e-06	-0.15	-0.25	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-5.68	2.38e-08	9.06e-06	-0.15	-0.25	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
HNSC	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	5.68	2.38e-08	9.06e-06	0.27	0.25	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
HNSC	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	5.68	2.39e-08	9.07e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
HNSC	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-5.68	2.39e-08	9.08e-06	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
HNSC	cis	rs9813712	0.904	rs6439223	ENSG00000249846.5	RP11-77P16.4	5.68	2.39e-08	9.08e-06	0.3	0.25	Response to amphetamines;	chr3:130256697	chr3:130112550~130120579:+
HNSC	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-5.68	2.39e-08	9.09e-06	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
HNSC	cis	rs5753618	0.583	rs5753628	ENSG00000236132.1	CTA-440B3.1	-5.68	2.39e-08	9.1e-06	-0.33	-0.25	Colorectal cancer;	chr22:31464336	chr22:31816379~31817491:-
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000206014.6	OR7E161P	-5.68	2.4e-08	9.1e-06	-0.27	-0.25	Neuroticism;	chr8:11936935	chr8:11928597~11929563:-
HNSC	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	5.68	2.4e-08	9.1e-06	0.38	0.25	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-5.68	2.4e-08	9.1e-06	-0.17	-0.25	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28136698	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28136856	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28137418	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-5.68	2.4e-08	9.1e-06	-0.32	-0.25	Depression;	chr6:28138363	chr6:28161781~28169594:+
HNSC	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-5.68	2.4e-08	9.11e-06	-0.23	-0.25	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
HNSC	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-5.68	2.4e-08	9.11e-06	-0.37	-0.25	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
HNSC	cis	rs9914544	0.966	rs1737943	ENSG00000264885.1	RP11-815I9.4	5.68	2.4e-08	9.11e-06	0.27	0.25	Educational attainment (years of education);	chr17:18938277	chr17:18667629~18669461:-
HNSC	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-5.68	2.4e-08	9.11e-06	-0.32	-0.25	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
HNSC	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-5.68	2.4e-08	9.11e-06	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
HNSC	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-5.68	2.4e-08	9.12e-06	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
HNSC	cis	rs8177876	0.686	rs804897	ENSG00000261061.1	RP11-303E16.2	5.68	2.4e-08	9.13e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81030770~81031485:+
HNSC	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-5.68	2.41e-08	9.14e-06	-0.22	-0.25	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
HNSC	cis	rs13113518	0.812	rs12500456	ENSG00000273257.1	RP11-177J6.1	5.68	2.41e-08	9.14e-06	0.32	0.25	Height;	chr4:55561053	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.783	rs2171618	ENSG00000273257.1	RP11-177J6.1	5.68	2.41e-08	9.14e-06	0.32	0.25	Height;	chr4:55564241	chr4:55387949~55388271:+
HNSC	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-5.68	2.41e-08	9.14e-06	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
HNSC	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.41e-08	9.15e-06	-0.32	-0.25	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
HNSC	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	5.68	2.41e-08	9.15e-06	0.24	0.25	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	5.68	2.41e-08	9.16e-06	0.31	0.25	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	5.68	2.41e-08	9.16e-06	0.31	0.25	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
HNSC	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	5.68	2.41e-08	9.17e-06	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
HNSC	cis	rs4218	0.648	rs12442086	ENSG00000277144.1	RP11-59H7.4	-5.68	2.42e-08	9.17e-06	-0.35	-0.25	Social communication problems;	chr15:59074364	chr15:59115547~59116089:-
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	5.68	2.42e-08	9.18e-06	0.27	0.25	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	5.68	2.42e-08	9.18e-06	0.31	0.25	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
HNSC	cis	rs73186030	0.764	rs34408666	ENSG00000272758.4	RP11-299J3.8	5.68	2.42e-08	9.19e-06	0.36	0.25	Serum parathyroid hormone levels;	chr3:122262762	chr3:122416207~122443180:+
HNSC	cis	rs2579103	1	rs2408222	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90208355	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2731228	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90211011	chr12:90280894~90300340:+
HNSC	cis	rs2579103	1	rs2579121	ENSG00000258183.4	RP11-753N8.1	-5.68	2.42e-08	9.19e-06	-0.33	-0.25	Body mass index;	chr12:90211227	chr12:90280894~90300340:+
HNSC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	5.68	2.43e-08	9.21e-06	0.21	0.25	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
HNSC	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	5.68	2.43e-08	9.22e-06	0.31	0.25	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	5.68	2.43e-08	9.22e-06	0.31	0.25	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.68	2.43e-08	9.22e-06	-0.23	-0.25	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
HNSC	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55439652	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55440643	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441110	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441567	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55441907	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55442184	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55442875	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55444253	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55446869	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	5.68	2.43e-08	9.22e-06	0.3	0.25	Height;	chr4:55447523	chr4:55363971~55395847:-
HNSC	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-5.68	2.43e-08	9.22e-06	-0.22	-0.25	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
HNSC	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-5.68	2.43e-08	9.22e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
HNSC	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-5.68	2.43e-08	9.22e-06	-0.24	-0.25	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
HNSC	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	5.67	2.44e-08	9.26e-06	0.35	0.25	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
HNSC	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-5.67	2.44e-08	9.26e-06	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
HNSC	cis	rs8012947	0.916	rs11851552	ENSG00000279636.2	LINC00216	5.67	2.44e-08	9.27e-06	0.32	0.25	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58288033~58289158:+
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	5.67	2.44e-08	9.27e-06	0.31	0.25	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
HNSC	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-5.67	2.44e-08	9.27e-06	-0.32	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
HNSC	cis	rs8054556	1	rs11901	ENSG00000183604.13	SMG1P5	-5.67	2.45e-08	9.27e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4318227	ENSG00000183604.13	SMG1P5	-5.67	2.45e-08	9.27e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30267553~30335374:-
HNSC	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	5.67	2.45e-08	9.27e-06	0.35	0.25	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
HNSC	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-5.67	2.45e-08	9.28e-06	-0.35	-0.25	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	5.67	2.45e-08	9.29e-06	0.2	0.25	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
HNSC	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-5.67	2.45e-08	9.29e-06	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
HNSC	cis	rs7621025	0.554	rs1471740	ENSG00000273486.1	RP11-731C17.2	5.67	2.45e-08	9.3e-06	0.22	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136837338~136839021:-
HNSC	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	5.67	2.45e-08	9.3e-06	0.32	0.25	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
HNSC	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	5.67	2.46e-08	9.31e-06	0.3	0.25	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28089816	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28090857	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28091439	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28091659	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28092227	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28093966	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-5.67	2.46e-08	9.31e-06	-0.32	-0.25	Depression;	chr6:28094014	chr6:28161781~28169594:+
HNSC	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55554380	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55554456	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	5.67	2.46e-08	9.31e-06	0.31	0.25	Height;	chr4:55559957	chr4:55387949~55388271:+
HNSC	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	5.67	2.46e-08	9.32e-06	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
HNSC	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.67	2.46e-08	9.32e-06	-0.36	-0.25	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
HNSC	cis	rs11992162	0.597	rs7011924	ENSG00000206014.6	OR7E161P	5.67	2.46e-08	9.33e-06	0.28	0.25	Monocyte count;	chr8:11923084	chr8:11928597~11929563:-
HNSC	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-5.67	2.46e-08	9.33e-06	-0.32	-0.25	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
HNSC	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-5.67	2.47e-08	9.36e-06	-0.24	-0.25	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
HNSC	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-5.67	2.47e-08	9.36e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
HNSC	cis	rs6951245	0.572	rs60918895	ENSG00000224079.1	AC091729.7	-5.67	2.47e-08	9.37e-06	-0.51	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999400	chr7:1074450~1078036:+
HNSC	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.67	2.47e-08	9.37e-06	-0.31	-0.25	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
HNSC	cis	rs667920	0.512	rs13065626	ENSG00000273486.1	RP11-731C17.2	-5.67	2.47e-08	9.37e-06	-0.3	-0.25	Coronary artery disease;	chr3:136575915	chr3:136837338~136839021:-
HNSC	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	5.67	2.47e-08	9.37e-06	0.35	0.25	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
HNSC	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-5.67	2.47e-08	9.37e-06	-0.31	-0.25	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	5.67	2.48e-08	9.38e-06	0.31	0.25	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	5.67	2.48e-08	9.38e-06	0.31	0.25	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
HNSC	cis	rs155076	0.711	rs4770131	ENSG00000233325.3	MIPEPP3	-5.67	2.48e-08	9.38e-06	-0.41	-0.25	White matter hyperintensity burden;	chr13:21323329	chr13:21298139~21306373:+
HNSC	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-5.67	2.48e-08	9.38e-06	-0.22	-0.25	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-5.67	2.48e-08	9.38e-06	-0.22	-0.25	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
HNSC	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55534788	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55535489	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55536421	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55537080	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	5.67	2.48e-08	9.39e-06	0.31	0.25	Height;	chr4:55538228	chr4:55387949~55388271:+
HNSC	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-5.67	2.48e-08	9.39e-06	-0.39	-0.25	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
HNSC	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-5.67	2.48e-08	9.4e-06	-0.28	-0.25	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
HNSC	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	5.67	2.49e-08	9.41e-06	0.3	0.25	Height;	chr4:55534166	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	5.67	2.49e-08	9.41e-06	0.3	0.25	Height;	chr4:55534180	chr4:55363971~55395847:-
HNSC	cis	rs9840812	0.861	rs687339	ENSG00000239213.4	NCK1-AS1	5.67	2.49e-08	9.41e-06	0.24	0.25	Fibrinogen levels;	chr3:136213517	chr3:136841726~136862054:-
HNSC	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	5.67	2.49e-08	9.42e-06	0.29	0.25	Migraine;	chr4:56861145	chr4:56960927~56961373:-
HNSC	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	5.67	2.49e-08	9.42e-06	0.39	0.25	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
HNSC	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	5.67	2.49e-08	9.42e-06	0.39	0.25	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
HNSC	cis	rs3206736	0.548	rs328896	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34977610	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328900	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34980668	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328901	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34980839	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328904	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34981564	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328908	ENSG00000197085.10	NPSR1-AS1	-5.67	2.49e-08	9.42e-06	-0.32	-0.25	Diastolic blood pressure;	chr7:34986396	chr7:34346512~34871582:-
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	5.67	2.49e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
HNSC	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-5.67	2.49e-08	9.42e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
HNSC	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-5.67	2.49e-08	9.42e-06	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
HNSC	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-5.67	2.49e-08	9.42e-06	-0.47	-0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
HNSC	cis	rs8054556	1	rs3814881	ENSG00000183604.13	SMG1P5	-5.67	2.5e-08	9.42e-06	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30267553~30335374:-
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.42e-06	0.31	0.25	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
HNSC	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	5.67	2.5e-08	9.43e-06	0.45	0.25	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
HNSC	cis	rs6951245	0.935	rs112554101	ENSG00000225146.1	AC073957.15	-5.67	2.5e-08	9.43e-06	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1029025~1043891:+
HNSC	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	5.67	2.5e-08	9.43e-06	0.31	0.25	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.5e-08	9.43e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.5e-08	9.43e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
HNSC	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.67	2.5e-08	9.45e-06	0.36	0.25	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
HNSC	cis	rs9300255	0.602	rs2510885	ENSG00000280120.1	RP11-546D6.3	5.67	2.5e-08	9.46e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123130266	chr12:123152324~123153377:-
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-5.67	2.51e-08	9.47e-06	-0.32	-0.25	Depression;	chr6:28108492	chr6:28161781~28169594:+
HNSC	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.67	2.51e-08	9.48e-06	-0.31	-0.25	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
HNSC	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	5.67	2.51e-08	9.48e-06	0.36	0.25	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
HNSC	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-5.67	2.51e-08	9.49e-06	-0.29	-0.25	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
HNSC	cis	rs5753618	0.583	rs2273251	ENSG00000236132.1	CTA-440B3.1	-5.67	2.52e-08	9.5e-06	-0.32	-0.25	Colorectal cancer;	chr22:31447581	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000249244.1	RP11-548H18.2	5.67	2.52e-08	9.53e-06	0.31	0.25	Corneal astigmatism;	chr4:119401102	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	5.67	2.53e-08	9.53e-06	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
HNSC	cis	rs1355223	0.902	rs1258468	ENSG00000271369.1	RP11-350D17.3	-5.67	2.53e-08	9.54e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708184	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.872	rs1258466	ENSG00000271369.1	RP11-350D17.3	-5.67	2.53e-08	9.54e-06	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708519	chr11:34709600~34710161:+
HNSC	cis	rs804280	0.509	rs13276433	ENSG00000206014.6	OR7E161P	-5.67	2.53e-08	9.54e-06	-0.27	-0.25	Myopia (pathological);	chr8:11925527	chr8:11928597~11929563:-
HNSC	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-5.67	2.53e-08	9.54e-06	-0.25	-0.25	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	5.67	2.53e-08	9.55e-06	0.29	0.25	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
HNSC	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	5.67	2.53e-08	9.55e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
HNSC	cis	rs13126694	0.744	rs7691516	ENSG00000248429.4	RP11-597D13.9	5.67	2.53e-08	9.56e-06	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158170752~158202877:+
HNSC	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-5.67	2.53e-08	9.56e-06	-0.23	-0.25	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
HNSC	cis	rs9341808	0.667	rs583426	ENSG00000272129.1	RP11-250B2.6	-5.67	2.53e-08	9.56e-06	-0.3	-0.25	Sitting height ratio;	chr6:80236970	chr6:80355424~80356859:+
HNSC	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-5.67	2.53e-08	9.56e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
HNSC	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.67	2.54e-08	9.57e-06	0.3	0.25	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
HNSC	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	5.67	2.54e-08	9.57e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-5.67	2.54e-08	9.58e-06	-0.17	-0.25	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
HNSC	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	5.67	2.54e-08	9.58e-06	0.31	0.25	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
HNSC	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	5.67	2.54e-08	9.58e-06	0.26	0.25	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
HNSC	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-5.67	2.54e-08	9.59e-06	-0.3	-0.25	Height;	chr4:55547636	chr4:55363971~55395847:-
HNSC	cis	rs6928977	0.66	rs2757643	ENSG00000217482.2	HMGB1P17	5.67	2.54e-08	9.59e-06	0.27	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135636086~135636713:-
HNSC	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-5.67	2.54e-08	9.59e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-5.67	2.54e-08	9.59e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
HNSC	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	5.67	2.54e-08	9.59e-06	0.3	0.25	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
HNSC	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-5.67	2.54e-08	9.59e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
HNSC	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	5.67	2.55e-08	9.63e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
HNSC	cis	rs9300255	0.537	rs1618679	ENSG00000280120.1	RP11-546D6.3	5.67	2.55e-08	9.63e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123166167	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1621194	ENSG00000280120.1	RP11-546D6.3	5.67	2.55e-08	9.63e-06	0.23	0.25	Neutrophil percentage of white cells;	chr12:123166471	chr12:123152324~123153377:-
HNSC	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	5.67	2.55e-08	9.64e-06	0.24	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	5.67	2.55e-08	9.64e-06	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
HNSC	cis	rs947583	0.588	rs9494355	ENSG00000217482.2	HMGB1P17	5.67	2.56e-08	9.64e-06	0.29	0.25	Phosphorus levels;	chr6:135743579	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs12216021	ENSG00000217482.2	HMGB1P17	5.67	2.56e-08	9.64e-06	0.29	0.25	Phosphorus levels;	chr6:135752789	chr6:135636086~135636713:-
HNSC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	5.67	2.56e-08	9.65e-06	0.21	0.25	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
HNSC	cis	rs8177876	0.915	rs6420421	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs5023849	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.841	rs5023850	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094755	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.915	rs5023852	ENSG00000261061.1	RP11-303E16.2	5.67	2.56e-08	9.65e-06	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094800	chr16:81030770~81031485:+
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	5.67	2.56e-08	9.65e-06	0.2	0.25	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
HNSC	cis	rs9300255	0.83	rs28413626	ENSG00000280120.1	RP11-546D6.3	-5.67	2.56e-08	9.66e-06	-0.23	-0.25	Neutrophil percentage of white cells;	chr12:123376905	chr12:123152324~123153377:-
HNSC	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-5.67	2.56e-08	9.66e-06	-0.32	-0.25	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
HNSC	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.67	2.57e-08	9.68e-06	-0.27	-0.25	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
HNSC	cis	rs1021993	1	rs2660643	ENSG00000231648.1	RP11-372M18.2	5.67	2.57e-08	9.68e-06	0.35	0.25	Gut microbiome composition (winter);	chr1:209299094	chr1:209367662~209379690:+
HNSC	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-5.67	2.57e-08	9.68e-06	-0.25	-0.25	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
HNSC	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	5.67	2.57e-08	9.69e-06	0.27	0.25	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
HNSC	cis	rs9813712	0.909	rs1453257	ENSG00000249846.5	RP11-77P16.4	-5.67	2.57e-08	9.69e-06	-0.3	-0.25	Response to amphetamines;	chr3:130258730	chr3:130112550~130120579:+
HNSC	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-5.67	2.57e-08	9.7e-06	-0.2	-0.25	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
HNSC	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-5.67	2.57e-08	9.7e-06	-0.22	-0.25	Height;	chr11:118760944	chr11:118791254~118793137:+
HNSC	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	5.67	2.57e-08	9.7e-06	0.31	0.25	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
HNSC	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-5.67	2.57e-08	9.7e-06	-0.2	-0.25	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
HNSC	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-5.66	2.57e-08	9.7e-06	-0.32	-0.25	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-5.66	2.58e-08	9.71e-06	-0.31	-0.25	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
HNSC	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-5.66	2.58e-08	9.71e-06	-0.32	-0.25	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
HNSC	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-5.66	2.58e-08	9.71e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000206014.6	OR7E161P	5.66	2.58e-08	9.73e-06	0.27	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	5.66	2.58e-08	9.74e-06	0.3	0.25	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
HNSC	cis	rs1933112	0.5	rs1998510	ENSG00000227777.1	RP4-738P11.3	-5.66	2.59e-08	9.74e-06	-0.35	-0.25	Blood protein levels;	chr1:168533924	chr1:168542737~168543354:+
HNSC	cis	rs1933112	0.5	rs4656599	ENSG00000227777.1	RP4-738P11.3	-5.66	2.59e-08	9.74e-06	-0.35	-0.25	Blood protein levels;	chr1:168534148	chr1:168542737~168543354:+
HNSC	cis	rs2810114	0.916	rs2810099	ENSG00000274818.1	RP1-292L20.3	-5.66	2.59e-08	9.77e-06	-0.31	-0.25	Alcohol dependence;	chr14:70965704	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.57	rs67188216	ENSG00000274818.1	RP1-292L20.3	5.66	2.59e-08	9.77e-06	0.31	0.25	Schizophrenia;	chr14:71042607	chr14:70906657~70907111:-
HNSC	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-5.66	2.59e-08	9.77e-06	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
HNSC	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-5.66	2.6e-08	9.78e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	5.66	2.6e-08	9.78e-06	0.32	0.25	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	5.66	2.6e-08	9.78e-06	0.32	0.25	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
HNSC	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-5.66	2.6e-08	9.79e-06	-0.31	-0.25	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
HNSC	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	5.66	2.6e-08	9.8e-06	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
HNSC	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	5.66	2.6e-08	9.81e-06	0.36	0.25	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
HNSC	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55434518	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55435912	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55436576	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55436985	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	5.66	2.61e-08	9.81e-06	0.3	0.25	Height;	chr4:55439472	chr4:55363971~55395847:-
HNSC	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	5.66	2.61e-08	9.81e-06	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
HNSC	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	5.66	2.61e-08	9.81e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
HNSC	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	5.66	2.61e-08	9.82e-06	0.24	0.25	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
HNSC	cis	rs2579103	0.898	rs2118806	ENSG00000258183.4	RP11-753N8.1	-5.66	2.61e-08	9.83e-06	-0.31	-0.25	Body mass index;	chr12:90207532	chr12:90280894~90300340:+
HNSC	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-5.66	2.61e-08	9.83e-06	-0.48	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-5.66	2.61e-08	9.83e-06	-0.48	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
HNSC	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	5.66	2.61e-08	9.84e-06	0.66	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
HNSC	cis	rs4699052	0.787	rs2169508	ENSG00000246560.2	RP11-10L12.4	5.66	2.62e-08	9.86e-06	0.29	0.25	Testicular germ cell tumor;	chr4:103145733	chr4:102828055~102844075:+
HNSC	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	5.66	2.62e-08	9.87e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
HNSC	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	5.66	2.63e-08	9.88e-06	0.34	0.25	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.896	rs2064430	ENSG00000234084.1	RP3-388E23.2	-5.66	2.63e-08	9.89e-06	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135321618	chr6:135301568~135307158:+
HNSC	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	5.66	2.63e-08	9.89e-06	0.27	0.25	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	5.66	2.63e-08	9.9e-06	0.31	0.25	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
HNSC	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	5.66	2.63e-08	9.9e-06	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
HNSC	cis	rs67981189	0.529	rs2810096	ENSG00000274818.1	RP1-292L20.3	-5.66	2.63e-08	9.9e-06	-0.31	-0.25	Schizophrenia;	chr14:70968583	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs17108808	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70974835	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.501	rs3829954	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70988823	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs17108862	ENSG00000274818.1	RP1-292L20.3	5.66	2.63e-08	9.9e-06	0.31	0.25	Schizophrenia;	chr14:70997949	chr14:70906657~70907111:-
HNSC	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-5.66	2.63e-08	9.91e-06	-0.23	-0.25	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
HNSC	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-5.66	2.64e-08	9.91e-06	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000179406.6	LINC00174	-5.66	2.64e-08	9.91e-06	-0.55	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160633	ENSG00000179406.6	LINC00174	-5.66	2.64e-08	9.91e-06	-0.55	-0.25	Diabetic kidney disease;	chr7:66063241	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.66	2.64e-08	9.92e-06	0.27	0.25	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
HNSC	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	5.66	2.64e-08	9.92e-06	0.3	0.25	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
HNSC	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-5.66	2.64e-08	9.92e-06	-0.25	-0.25	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
HNSC	cis	rs3096299	0.629	rs12929744	ENSG00000274627.1	RP11-104N10.2	5.66	2.64e-08	9.93e-06	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89427172	chr16:89516797~89522217:+
HNSC	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	5.66	2.64e-08	9.94e-06	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
HNSC	cis	rs7115242	0.8	rs1320668	ENSG00000280143.1	AP000892.6	5.66	2.65e-08	9.95e-06	0.38	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117204967~117210292:+
HNSC	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	5.66	2.65e-08	9.95e-06	0.27	0.25	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000276710.3	CSPG4P8	-5.66	2.65e-08	9.95e-06	-0.27	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82459472~82477258:+
HNSC	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-5.66	2.65e-08	9.95e-06	-0.49	-0.25	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
HNSC	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	5.66	2.65e-08	9.96e-06	0.31	0.25	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-5.66	2.65e-08	9.97e-06	-0.39	-0.25	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
HNSC	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-5.66	2.66e-08	9.99e-06	-0.32	-0.25	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
HNSC	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-5.66	2.66e-08	9.99e-06	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
HNSC	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-5.66	2.66e-08	1e-05	-0.33	-0.25	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
HNSC	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	5.66	2.66e-08	1e-05	0.31	0.25	Height;	chr4:55511198	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	5.66	2.66e-08	1e-05	0.31	0.25	Height;	chr4:55526514	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.832	rs9402703	ENSG00000234084.1	RP3-388E23.2	5.66	2.66e-08	1e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135325097	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.597	rs9483879	ENSG00000217482.2	HMGB1P17	5.66	2.67e-08	1e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135778024	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9494383	ENSG00000217482.2	HMGB1P17	5.66	2.67e-08	1e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135778026	chr6:135636086~135636713:-
HNSC	cis	rs9611565	0.506	rs1984839	ENSG00000235513.1	RP4-756G23.5	5.66	2.67e-08	1e-05	0.27	0.25	Vitiligo;	chr22:41289933	chr22:41209122~41217627:-
HNSC	cis	rs7980687	0.628	rs2102949	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123192216	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.596	rs4460848	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123193263	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.628	rs2851443	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123209703	chr12:123152324~123153377:-
HNSC	cis	rs7980687	0.596	rs1727319	ENSG00000280120.1	RP11-546D6.3	5.66	2.67e-08	1e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123216806	chr12:123152324~123153377:-
HNSC	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55551447	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55551845	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55553396	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	5.66	2.67e-08	1e-05	0.3	0.25	Height;	chr4:55554025	chr4:55363971~55395847:-
HNSC	cis	rs9611519	0.78	rs2284079	ENSG00000235513.1	RP4-756G23.5	5.66	2.67e-08	1e-05	0.26	0.25	Neuroticism;	chr22:41262628	chr22:41209122~41217627:-
HNSC	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-5.66	2.67e-08	1e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-5.66	2.67e-08	1e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	5.66	2.67e-08	1e-05	0.27	0.25	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.66	2.68e-08	1e-05	-0.27	-0.25	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
HNSC	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.66	2.68e-08	1.01e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
HNSC	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	5.66	2.68e-08	1.01e-05	0.21	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
HNSC	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	5.66	2.68e-08	1.01e-05	0.35	0.25	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
HNSC	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55487368	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55489310	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55491628	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55495801	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55496737	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55496933	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55497842	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55500224	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501629	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501726	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55501788	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55504176	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55504201	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55506498	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55507248	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55507729	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55508587	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55509367	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	5.66	2.68e-08	1.01e-05	0.31	0.25	Height;	chr4:55510352	chr4:55387949~55388271:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.66	2.68e-08	1.01e-05	0.27	0.25	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
HNSC	cis	rs8012947	0.917	rs2145600	ENSG00000279636.2	LINC00216	5.66	2.68e-08	1.01e-05	0.33	0.25	Alcohol consumption in current drinkers;	chr14:58284184	chr14:58288033~58289158:+
HNSC	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	5.66	2.68e-08	1.01e-05	0.27	0.25	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	5.66	2.69e-08	1.01e-05	0.31	0.25	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	5.66	2.69e-08	1.01e-05	0.31	0.25	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.589	rs11800848	ENSG00000223787.2	RP4-593M8.1	5.66	2.69e-08	1.01e-05	0.35	0.25	Multiple sclerosis;	chr1:92662370	chr1:92580476~92580821:-
HNSC	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	5.66	2.69e-08	1.01e-05	0.46	0.25	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
HNSC	cis	rs9300255	0.596	rs7304782	ENSG00000280120.1	RP11-546D6.3	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Neutrophil percentage of white cells;	chr12:123234897	chr12:123152324~123153377:-
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-5.66	2.7e-08	1.01e-05	-0.22	-0.25	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-5.66	2.7e-08	1.01e-05	-0.3	-0.25	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
HNSC	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	5.66	2.7e-08	1.01e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.66	2.7e-08	1.01e-05	0.27	0.25	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
HNSC	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-5.66	2.7e-08	1.01e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-5.66	2.7e-08	1.01e-05	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
HNSC	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	5.66	2.7e-08	1.01e-05	0.4	0.25	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
HNSC	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-5.66	2.71e-08	1.02e-05	-0.31	-0.25	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
HNSC	cis	rs9813712	0.953	rs1453258	ENSG00000249846.5	RP11-77P16.4	5.66	2.71e-08	1.02e-05	0.3	0.25	Response to amphetamines;	chr3:130256454	chr3:130112550~130120579:+
HNSC	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	5.66	2.71e-08	1.02e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	5.66	2.71e-08	1.02e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
HNSC	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	5.66	2.71e-08	1.02e-05	0.37	0.25	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000211972.2	IGHV3-66	5.66	2.71e-08	1.02e-05	0.2	0.25	Kawasaki disease;	chr14:106779713	chr14:106675017~106675544:-
HNSC	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-5.65	2.72e-08	1.02e-05	-0.3	-0.25	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-5.65	2.72e-08	1.02e-05	-0.3	-0.25	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-5.65	2.73e-08	1.02e-05	-0.17	-0.25	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
HNSC	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	5.65	2.73e-08	1.02e-05	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
HNSC	cis	rs988913	0.958	rs1503140	ENSG00000224984.1	RP11-524H19.2	5.65	2.73e-08	1.02e-05	0.29	0.25	Menarche (age at onset);	chr6:54945968	chr6:54840118~54840855:-
HNSC	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-5.65	2.73e-08	1.02e-05	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
HNSC	cis	rs61542988	0.57	rs10950919	ENSG00000228649.7	AC005682.5	5.65	2.73e-08	1.02e-05	0.32	0.25	Fibrinogen levels;	chr7:22794202	chr7:22854178~22861579:+
HNSC	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55534788	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55535489	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55536421	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55537080	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55538228	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	5.65	2.74e-08	1.03e-05	0.3	0.25	Height;	chr4:55451489	chr4:55363971~55395847:-
HNSC	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-5.65	2.75e-08	1.03e-05	-0.31	-0.25	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
HNSC	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	5.65	2.75e-08	1.03e-05	0.32	0.25	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
HNSC	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-5.65	2.75e-08	1.03e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
HNSC	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-5.65	2.76e-08	1.03e-05	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-5.65	2.76e-08	1.03e-05	-0.25	-0.25	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000253893.2	FAM85B	5.65	2.76e-08	1.03e-05	0.33	0.25	Neuroticism;	chr8:8504313	chr8:8167819~8226614:-
HNSC	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	5.65	2.76e-08	1.03e-05	0.31	0.25	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-5.65	2.77e-08	1.04e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
HNSC	cis	rs4140799	0.789	rs1204988	ENSG00000266869.1	RP6-114E22.1	5.65	2.77e-08	1.04e-05	0.31	0.25	Neuroticism;	chr14:71745231	chr14:71848606~71908430:+
HNSC	cis	rs1355223	1	rs11607300	ENSG00000271369.1	RP11-350D17.3	-5.65	2.77e-08	1.04e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737772	chr11:34709600~34710161:+
HNSC	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	5.65	2.77e-08	1.04e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
HNSC	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-5.65	2.77e-08	1.04e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
HNSC	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	5.65	2.77e-08	1.04e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
HNSC	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	5.65	2.77e-08	1.04e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
HNSC	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-5.65	2.77e-08	1.04e-05	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-5.65	2.77e-08	1.04e-05	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
HNSC	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	5.65	2.78e-08	1.04e-05	0.31	0.25	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
HNSC	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-5.65	2.78e-08	1.04e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
HNSC	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-5.65	2.78e-08	1.04e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	5.65	2.78e-08	1.04e-05	0.33	0.25	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	5.65	2.78e-08	1.04e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	5.65	2.78e-08	1.04e-05	0.33	0.25	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.65	2.78e-08	1.04e-05	-0.27	-0.25	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
HNSC	cis	rs6928977	0.932	rs6914831	ENSG00000231028.7	LINC00271	5.65	2.79e-08	1.04e-05	0.3	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135497801~135716055:+
HNSC	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-5.65	2.79e-08	1.04e-05	-0.24	-0.25	Asthma;	chr2:102394777	chr2:102438713~102440475:+
HNSC	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-5.65	2.79e-08	1.04e-05	-0.29	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
HNSC	cis	rs2976388	0.525	rs2016749	ENSG00000253741.1	CTD-2292P10.4	5.65	2.79e-08	1.04e-05	0.25	0.25	Urinary tract infection frequency;	chr8:142754700	chr8:142702252~142726973:-
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	5.65	2.8e-08	1.05e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
HNSC	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-5.65	2.8e-08	1.05e-05	-0.22	-0.25	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
HNSC	cis	rs10435719	0.834	rs11250176	ENSG00000206014.6	OR7E161P	-5.65	2.8e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11928597~11929563:-
HNSC	cis	rs6928977	0.832	rs2327613	ENSG00000234084.1	RP3-388E23.2	5.65	2.8e-08	1.05e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341234	chr6:135301568~135307158:+
HNSC	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-5.65	2.8e-08	1.05e-05	-0.3	-0.25	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
HNSC	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	5.65	2.8e-08	1.05e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
HNSC	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-5.65	2.8e-08	1.05e-05	-0.22	-0.25	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
HNSC	cis	rs61542988	0.797	rs4329182	ENSG00000228649.7	AC005682.5	5.65	2.8e-08	1.05e-05	0.3	0.25	Fibrinogen levels;	chr7:22843002	chr7:22854178~22861579:+
HNSC	cis	rs61542988	0.756	rs5013587	ENSG00000228649.7	AC005682.5	5.65	2.8e-08	1.05e-05	0.3	0.25	Fibrinogen levels;	chr7:22843041	chr7:22854178~22861579:+
HNSC	cis	rs2579103	0.898	rs6538231	ENSG00000258183.4	RP11-753N8.1	-5.65	2.8e-08	1.05e-05	-0.31	-0.25	Body mass index;	chr12:90205038	chr12:90280894~90300340:+
HNSC	cis	rs9840812	0.592	rs35418151	ENSG00000273486.1	RP11-731C17.2	5.65	2.81e-08	1.05e-05	0.22	0.25	Fibrinogen levels;	chr3:136443779	chr3:136837338~136839021:-
HNSC	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
HNSC	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.65	2.81e-08	1.05e-05	-0.36	-0.25	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
HNSC	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	5.65	2.81e-08	1.05e-05	0.28	0.25	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-5.65	2.82e-08	1.05e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
HNSC	cis	rs10435719	0.647	rs10092605	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:11928597~11929563:-
HNSC	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-5.65	2.82e-08	1.05e-05	-0.32	-0.25	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
HNSC	cis	rs1908814	0.516	rs10113062	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11935740	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10113145	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11935786	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs4367597	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11936020	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.899	rs9329251	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.773	rs7842810	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs7812563	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11936979	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13281077	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11937305	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13281315	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11937346	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs4840597	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Neuroticism;	chr8:11938559	chr8:11928597~11929563:-
HNSC	cis	rs804280	0.509	rs4841639	ENSG00000206014.6	OR7E161P	-5.65	2.82e-08	1.05e-05	-0.27	-0.25	Myopia (pathological);	chr8:11938584	chr8:11928597~11929563:-
HNSC	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	5.65	2.82e-08	1.05e-05	0.31	0.25	Height;	chr4:55541259	chr4:55387949~55388271:+
HNSC	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	5.65	2.82e-08	1.05e-05	0.24	0.25	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
HNSC	cis	rs638893	0.617	rs4938558	ENSG00000255422.1	AP002954.4	-5.65	2.82e-08	1.05e-05	-0.35	-0.25	Vitiligo;	chr11:118847220	chr11:118704607~118750263:+
HNSC	cis	rs6471393	0.861	rs2976374	ENSG00000253848.1	RP11-10N23.5	5.65	2.82e-08	1.05e-05	0.32	0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93691945	chr8:93741193~93744534:+
HNSC	cis	rs2579103	0.867	rs11105539	ENSG00000258183.4	RP11-753N8.1	-5.65	2.82e-08	1.05e-05	-0.31	-0.25	Body mass index;	chr12:90208768	chr12:90280894~90300340:+
HNSC	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	5.65	2.82e-08	1.05e-05	0.35	0.25	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
HNSC	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	5.65	2.83e-08	1.06e-05	0.31	0.25	Height;	chr4:55548261	chr4:55387949~55388271:+
HNSC	cis	rs889014	0.679	rs11742377	ENSG00000253768.1	CTB-33O18.1	5.65	2.83e-08	1.06e-05	0.28	0.25	Height;	chr5:173551281	chr5:173562478~173573199:+
HNSC	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-5.65	2.83e-08	1.06e-05	-0.29	-0.25	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-5.65	2.83e-08	1.06e-05	-0.16	-0.25	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-5.65	2.83e-08	1.06e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000206014.6	OR7E161P	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11928597~11929563:-
HNSC	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000206014.6	OR7E161P	-5.65	2.83e-08	1.06e-05	-0.27	-0.25	Myopia (pathological);	chr8:11929423	chr8:11928597~11929563:-
HNSC	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-5.65	2.83e-08	1.06e-05	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
HNSC	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	5.65	2.83e-08	1.06e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
HNSC	cis	rs889014	0.724	rs11745770	ENSG00000253768.1	CTB-33O18.1	5.65	2.83e-08	1.06e-05	0.28	0.25	Height;	chr5:173551101	chr5:173562478~173573199:+
HNSC	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-5.65	2.84e-08	1.06e-05	-0.34	-0.25	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000211974.3	IGHV2-70	-5.65	2.84e-08	1.06e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106665764	chr14:106723574~106724093:-
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.65	2.84e-08	1.06e-05	0.3	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	5.65	2.84e-08	1.06e-05	0.31	0.25	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000179406.6	LINC00174	-5.65	2.84e-08	1.06e-05	-0.54	-0.25	Gout;	chr7:66693028	chr7:66376044~66401338:-
HNSC	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-5.65	2.85e-08	1.06e-05	-0.36	-0.25	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
HNSC	cis	rs9402743	0.632	rs9399167	ENSG00000217482.2	HMGB1P17	5.65	2.85e-08	1.06e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135792678	chr6:135636086~135636713:-
HNSC	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	5.65	2.85e-08	1.06e-05	0.28	0.25	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
HNSC	cis	rs804280	0.509	rs10109241	ENSG00000206014.6	OR7E161P	-5.65	2.85e-08	1.06e-05	-0.27	-0.25	Myopia (pathological);	chr8:11927476	chr8:11928597~11929563:-
HNSC	cis	rs7819412	0.775	rs11773990	ENSG00000269918.1	AF131215.9	-5.65	2.85e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077572	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000254153.1	CTA-398F10.2	-5.65	2.85e-08	1.07e-05	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9044914	chr8:8456909~8461337:-
HNSC	cis	rs9300255	0.602	rs1727314	ENSG00000280120.1	RP11-546D6.3	5.65	2.86e-08	1.07e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123156117	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs2682429	ENSG00000280120.1	RP11-546D6.3	5.65	2.86e-08	1.07e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123158408	chr12:123152324~123153377:-
HNSC	cis	rs7819412	0.775	rs4545055	ENSG00000269918.1	AF131215.9	-5.65	2.86e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077856	chr8:11104691~11106704:-
HNSC	cis	rs7819412	0.775	rs2898257	ENSG00000269918.1	AF131215.9	-5.65	2.86e-08	1.07e-05	-0.25	-0.25	Triglycerides;	chr8:11077858	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-5.65	2.86e-08	1.07e-05	-0.31	-0.25	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
HNSC	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	5.65	2.86e-08	1.07e-05	0.35	0.25	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	5.65	2.86e-08	1.07e-05	0.35	0.25	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
HNSC	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	5.65	2.86e-08	1.07e-05	0.43	0.25	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
HNSC	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-5.65	2.86e-08	1.07e-05	-0.31	-0.25	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
HNSC	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	5.65	2.86e-08	1.07e-05	0.31	0.25	Height;	chr4:55540912	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	5.65	2.86e-08	1.07e-05	0.31	0.25	Height;	chr4:55540972	chr4:55387949~55388271:+
HNSC	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-5.65	2.86e-08	1.07e-05	-0.32	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
HNSC	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-5.65	2.86e-08	1.07e-05	-0.32	-0.25	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-5.64	2.87e-08	1.07e-05	-0.31	-0.25	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
HNSC	cis	rs6604026	0.555	rs1333743	ENSG00000223787.2	RP4-593M8.1	5.64	2.87e-08	1.07e-05	0.35	0.25	Multiple sclerosis;	chr1:92600617	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.555	rs11808092	ENSG00000223787.2	RP4-593M8.1	5.64	2.87e-08	1.07e-05	0.35	0.25	Multiple sclerosis;	chr1:92607671	chr1:92580476~92580821:-
HNSC	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.64	2.88e-08	1.07e-05	-0.28	-0.25	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	5.64	2.88e-08	1.07e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-5.64	2.88e-08	1.07e-05	-0.16	-0.25	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
HNSC	cis	rs10791097	0.765	rs7943757	ENSG00000254842.5	RP11-890B15.2	-5.64	2.88e-08	1.07e-05	-0.22	-0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130846262	chr11:130844191~130865561:-
HNSC	cis	rs1012068	0.921	rs5994442	ENSG00000236132.1	CTA-440B3.1	-5.64	2.88e-08	1.08e-05	-0.3	-0.25	Chronic hepatitis C infection;	chr22:31875946	chr22:31816379~31817491:-
HNSC	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-5.64	2.89e-08	1.08e-05	-0.29	-0.25	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
HNSC	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	5.64	2.89e-08	1.08e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
HNSC	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.64	2.89e-08	1.08e-05	0.27	0.25	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
HNSC	cis	rs9300255	0.602	rs2851438	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123159142	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.568	rs1047158	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123159509	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1051431	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123161256	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1727296	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123163178	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1716165	ENSG00000280120.1	RP11-546D6.3	5.64	2.9e-08	1.08e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123164334	chr12:123152324~123153377:-
HNSC	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-5.64	2.9e-08	1.08e-05	-0.24	-0.25	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
HNSC	cis	rs9341808	1	rs9341808	ENSG00000272129.1	RP11-250B2.6	5.64	2.9e-08	1.08e-05	0.3	0.25	Sitting height ratio;	chr6:80243540	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-5.64	2.9e-08	1.08e-05	-0.3	-0.25	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
HNSC	cis	rs7209700	0.547	rs10514919	ENSG00000228782.6	CTD-2026D20.3	-5.64	2.91e-08	1.08e-05	-0.27	-0.25	IgG glycosylation;	chr17:47264763	chr17:47450568~47492492:-
HNSC	cis	rs804280	0.509	rs9886639	ENSG00000206014.6	OR7E161P	-5.64	2.91e-08	1.09e-05	-0.27	-0.25	Myopia (pathological);	chr8:11927020	chr8:11928597~11929563:-
HNSC	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.64	2.91e-08	1.09e-05	0.28	0.25	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	5.64	2.91e-08	1.09e-05	0.23	0.25	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	5.64	2.92e-08	1.09e-05	0.31	0.25	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-5.64	2.92e-08	1.09e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
HNSC	cis	rs10446497	0.61	rs12497046	ENSG00000272359.1	U4	5.64	2.92e-08	1.09e-05	0.3	0.25	Schizophrenia;	chr3:196816775	chr3:196747192~196747324:-
HNSC	cis	rs6928977	0.514	rs2757635	ENSG00000217482.2	HMGB1P17	-5.64	2.92e-08	1.09e-05	-0.27	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135636086~135636713:-
HNSC	cis	rs3747113	0.913	rs34999116	ENSG00000128262.7	POM121L9P	-5.64	2.92e-08	1.09e-05	-0.3	-0.25	Gut microbiome composition (summer);	chr22:24418657	chr22:24251828~24265525:+
HNSC	cis	rs2115630	1	rs6496441	ENSG00000229212.6	RP11-561C5.4	5.64	2.93e-08	1.09e-05	0.29	0.25	P wave terminal force;	chr15:84820117	chr15:85205440~85234795:-
HNSC	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55515292	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55518776	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55518922	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55520278	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55523835	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55524246	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55525589	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	5.64	2.93e-08	1.09e-05	0.31	0.25	Height;	chr4:55525781	chr4:55387949~55388271:+
HNSC	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.64	2.93e-08	1.09e-05	-0.35	-0.25	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
HNSC	cis	rs2579103	0.898	rs1347850	ENSG00000258183.4	RP11-753N8.1	-5.64	2.93e-08	1.09e-05	-0.31	-0.25	Body mass index;	chr12:90211819	chr12:90280894~90300340:+
HNSC	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	5.64	2.93e-08	1.09e-05	0.26	0.25	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	5.64	2.94e-08	1.09e-05	0.23	0.25	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-5.64	2.94e-08	1.09e-05	-0.23	-0.25	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
HNSC	cis	rs867371	0.614	rs7183805	ENSG00000255769.6	GOLGA2P10	-5.64	2.94e-08	1.09e-05	-0.35	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82472993~82513950:-
HNSC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	5.64	2.95e-08	1.1e-05	0.29	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
HNSC	cis	rs10242455	0.702	rs41385645	ENSG00000078319.8	PMS2P1	-5.64	2.95e-08	1.1e-05	-0.47	-0.25	Blood metabolite levels;	chr7:99376415	chr7:100320992~100341908:-
HNSC	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-5.64	2.95e-08	1.1e-05	-0.58	-0.25	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
HNSC	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-5.64	2.96e-08	1.1e-05	-0.27	-0.25	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-5.64	2.96e-08	1.1e-05	-0.42	-0.25	Depression;	chr6:28111963	chr6:28115628~28116551:+
HNSC	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	5.64	2.96e-08	1.1e-05	0.26	0.25	Height;	chr2:46624894	chr2:46668870~46670778:+
HNSC	cis	rs9813712	0.953	rs1453256	ENSG00000249846.5	RP11-77P16.4	-5.64	2.96e-08	1.1e-05	-0.3	-0.25	Response to amphetamines;	chr3:130258787	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.953	rs935916	ENSG00000249846.5	RP11-77P16.4	-5.64	2.96e-08	1.1e-05	-0.3	-0.25	Response to amphetamines;	chr3:130258931	chr3:130112550~130120579:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-5.64	2.96e-08	1.1e-05	-0.17	-0.25	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
HNSC	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	5.64	2.97e-08	1.11e-05	0.28	0.25	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	5.64	2.97e-08	1.11e-05	0.28	0.25	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
HNSC	cis	rs2145598	0.967	rs12892257	ENSG00000279636.2	LINC00216	-5.64	2.98e-08	1.11e-05	-0.28	-0.25	Coronary artery disease;	chr14:58266030	chr14:58288033~58289158:+
HNSC	cis	rs8177876	0.658	rs889516	ENSG00000261061.1	RP11-303E16.2	5.64	2.98e-08	1.11e-05	0.42	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr16:81030770~81031485:+
HNSC	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	5.64	2.98e-08	1.11e-05	0.3	0.25	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
HNSC	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-5.64	2.98e-08	1.11e-05	-0.43	-0.25	Depression;	chr6:28223052	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-5.64	2.98e-08	1.11e-05	-0.43	-0.25	Depression;	chr6:28223279	chr6:28115628~28116551:+
HNSC	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	5.64	2.98e-08	1.11e-05	0.3	0.25	Height;	chr4:55546002	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	5.64	2.98e-08	1.11e-05	0.3	0.25	Height;	chr4:55546378	chr4:55363971~55395847:-
HNSC	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	5.64	2.98e-08	1.11e-05	0.62	0.25	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
HNSC	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	5.64	2.98e-08	1.11e-05	0.34	0.25	Height;	chr6:109640682	chr6:109382795~109383666:+
HNSC	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-5.64	2.98e-08	1.11e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
HNSC	cis	rs6604026	0.624	rs11164814	ENSG00000223787.2	RP4-593M8.1	5.64	2.99e-08	1.11e-05	0.35	0.25	Multiple sclerosis;	chr1:92795816	chr1:92580476~92580821:-
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47582204	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47582915	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47583112	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000257433.4	RP1-197B17.3	5.64	2.99e-08	1.11e-05	0.66	0.25	Pneumonia;	chr12:47583333	chr12:47706085~47742294:+
HNSC	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-5.64	2.99e-08	1.11e-05	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-5.64	2.99e-08	1.11e-05	-0.3	-0.25	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
HNSC	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.64	2.99e-08	1.11e-05	0.36	0.25	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
HNSC	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	5.64	2.99e-08	1.11e-05	0.29	0.25	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	5.64	2.99e-08	1.11e-05	0.29	0.25	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
HNSC	cis	rs6928977	0.932	rs11154799	ENSG00000234084.1	RP3-388E23.2	5.64	2.99e-08	1.11e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr6:135301568~135307158:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-5.64	3e-08	1.11e-05	-0.32	-0.25	Depression;	chr6:28140307	chr6:28161781~28169594:+
HNSC	cis	rs1355223	0.872	rs913204	ENSG00000271369.1	RP11-350D17.3	5.64	3e-08	1.11e-05	0.3	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34684677	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	5.64	3e-08	1.12e-05	0.2	0.25	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	5.64	3e-08	1.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	5.64	3e-08	1.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.64	3e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
HNSC	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102404807	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102407218	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
HNSC	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.64	3.01e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.64	3.01e-08	1.12e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	5.64	3.01e-08	1.12e-05	0.2	0.25	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
HNSC	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102374753	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102379885	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102381261	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102381819	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102382514	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102382943	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102394452	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102399227	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102402540	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102402571	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102403325	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	5.64	3.01e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102403679	chr2:102438713~102440475:+
HNSC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	5.64	3.01e-08	1.12e-05	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	5.64	3.01e-08	1.12e-05	0.28	0.25	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
HNSC	cis	rs2145598	0.967	rs6573194	ENSG00000279636.2	LINC00216	-5.64	3.01e-08	1.12e-05	-0.28	-0.25	Coronary artery disease;	chr14:58246196	chr14:58288033~58289158:+
HNSC	cis	rs8177876	0.915	rs1563072	ENSG00000261061.1	RP11-303E16.2	5.64	3.01e-08	1.12e-05	0.44	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.841	rs874437	ENSG00000261061.1	RP11-303E16.2	5.64	3.01e-08	1.12e-05	0.44	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81030770~81031485:+
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000206014.6	OR7E161P	-5.64	3.02e-08	1.12e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11928597~11929563:-
HNSC	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-5.64	3.02e-08	1.12e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
HNSC	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	5.64	3.02e-08	1.12e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	5.64	3.02e-08	1.12e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000254153.1	CTA-398F10.2	5.64	3.02e-08	1.12e-05	0.27	0.25	Systolic blood pressure;	chr8:8462453	chr8:8456909~8461337:-
HNSC	cis	rs9341808	0.644	rs62408577	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232307	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.644	rs76102095	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232309	chr6:80355424~80356859:+
HNSC	cis	rs9341808	0.644	rs59371711	ENSG00000272129.1	RP11-250B2.6	-5.64	3.03e-08	1.12e-05	-0.3	-0.25	Sitting height ratio;	chr6:80232310	chr6:80355424~80356859:+
HNSC	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102388870	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102389644	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	5.64	3.03e-08	1.12e-05	0.24	0.25	Asthma;	chr2:102389988	chr2:102438713~102440475:+
HNSC	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55554380	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55554456	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	5.64	3.03e-08	1.12e-05	0.3	0.25	Height;	chr4:55559957	chr4:55363971~55395847:-
HNSC	cis	rs3206736	0.548	rs329236	ENSG00000197085.10	NPSR1-AS1	-5.64	3.03e-08	1.12e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35016654	chr7:34346512~34871582:-
HNSC	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-5.64	3.03e-08	1.13e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
HNSC	cis	rs2179367	0.632	rs12211357	ENSG00000216906.2	RP11-350J20.9	5.63	3.04e-08	1.13e-05	0.37	0.25	Dupuytren's disease;	chr6:149331148	chr6:149904243~149906418:+
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.63	3.04e-08	1.13e-05	0.31	0.25	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
HNSC	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-5.63	3.04e-08	1.13e-05	-0.29	-0.25	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
HNSC	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-5.63	3.05e-08	1.13e-05	-0.33	-0.25	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
HNSC	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
HNSC	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-5.63	3.05e-08	1.13e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	5.63	3.05e-08	1.13e-05	0.31	0.25	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	5.63	3.05e-08	1.13e-05	0.31	0.25	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000254340.1	RP11-10A14.3	-5.63	3.06e-08	1.13e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9183348	chr8:9141424~9145435:+
HNSC	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-5.63	3.06e-08	1.14e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
HNSC	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	5.63	3.06e-08	1.14e-05	0.29	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
HNSC	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-5.63	3.06e-08	1.14e-05	-0.24	-0.25	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-5.63	3.06e-08	1.14e-05	-0.24	-0.25	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
HNSC	cis	rs67180937	0.583	rs3008616	ENSG00000272750.1	RP11-378J18.8	5.63	3.07e-08	1.14e-05	0.33	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623831	chr1:222658867~222661512:-
HNSC	cis	rs889014	0.751	rs7712664	ENSG00000253768.1	CTB-33O18.1	5.63	3.07e-08	1.14e-05	0.28	0.25	Height;	chr5:173551663	chr5:173562478~173573199:+
HNSC	cis	rs1499614	1	rs2707832	ENSG00000179406.6	LINC00174	-5.63	3.07e-08	1.14e-05	-0.54	-0.25	Gout;	chr7:66671562	chr7:66376044~66401338:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	5.63	3.07e-08	1.14e-05	0.2	0.25	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
HNSC	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-5.63	3.07e-08	1.14e-05	-0.32	-0.25	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
HNSC	cis	rs9402743	0.632	rs9399166	ENSG00000217482.2	HMGB1P17	5.63	3.07e-08	1.14e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135776762	chr6:135636086~135636713:-
HNSC	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	5.63	3.08e-08	1.14e-05	0.26	0.25	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	5.63	3.08e-08	1.14e-05	0.26	0.25	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
HNSC	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	5.63	3.08e-08	1.14e-05	0.32	0.25	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
HNSC	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	5.63	3.08e-08	1.14e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs6958420	ENSG00000179406.6	LINC00174	5.63	3.08e-08	1.14e-05	0.53	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	5.63	3.08e-08	1.14e-05	0.32	0.25	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
HNSC	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-5.63	3.08e-08	1.14e-05	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
HNSC	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-5.63	3.08e-08	1.14e-05	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
HNSC	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-5.63	3.08e-08	1.14e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.63	3.09e-08	1.14e-05	0.27	0.25	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
HNSC	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	5.63	3.09e-08	1.14e-05	0.34	0.25	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
HNSC	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	5.63	3.09e-08	1.14e-05	0.37	0.25	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
HNSC	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.63	3.09e-08	1.15e-05	-0.27	-0.25	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
HNSC	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	5.63	3.09e-08	1.15e-05	0.29	0.25	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
HNSC	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	5.63	3.09e-08	1.15e-05	0.35	0.25	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
HNSC	cis	rs75422866	0.51	rs73105803	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47722135	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs73105812	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47724404	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs74733564	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47724644	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.51	rs73105814	ENSG00000276691.1	RP5-1057I20.5	5.63	3.09e-08	1.15e-05	0.44	0.25	Pneumonia;	chr12:47725817	chr12:47788426~47788971:+
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.31	0.25	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.32	0.25	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	5.63	3.1e-08	1.15e-05	0.32	0.25	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
HNSC	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	5.63	3.1e-08	1.15e-05	0.31	0.25	Height;	chr4:55561218	chr4:55387949~55388271:+
HNSC	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-5.63	3.1e-08	1.15e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
HNSC	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-5.63	3.1e-08	1.15e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
HNSC	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-5.63	3.1e-08	1.15e-05	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
HNSC	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.63	3.1e-08	1.15e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
HNSC	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	5.63	3.1e-08	1.15e-05	0.3	0.25	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
HNSC	cis	rs947583	1	rs7742626	ENSG00000217482.2	HMGB1P17	-5.63	3.11e-08	1.15e-05	-0.29	-0.25	Phosphorus levels;	chr6:135811358	chr6:135636086~135636713:-
HNSC	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	5.63	3.11e-08	1.15e-05	0.4	0.25	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
HNSC	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	5.63	3.11e-08	1.15e-05	0.31	0.25	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
HNSC	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
HNSC	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	5.63	3.11e-08	1.15e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
HNSC	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-5.63	3.12e-08	1.16e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
HNSC	cis	rs8012947	0.917	rs57044214	ENSG00000279636.2	LINC00216	5.63	3.12e-08	1.16e-05	0.31	0.25	Alcohol consumption in current drinkers;	chr14:58367191	chr14:58288033~58289158:+
HNSC	cis	rs6928977	0.733	rs9321500	ENSG00000234084.1	RP3-388E23.2	5.63	3.12e-08	1.16e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320231	chr6:135301568~135307158:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	5.63	3.12e-08	1.16e-05	0.31	0.25	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
HNSC	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-5.63	3.12e-08	1.16e-05	-0.23	-0.25	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
HNSC	cis	rs6714900	0.588	rs11675048	ENSG00000234896.1	OR7E62P	-5.63	3.12e-08	1.16e-05	-0.31	-0.25	Blood protein levels;	chr2:71065534	chr2:71055527~71056003:+
HNSC	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	5.63	3.12e-08	1.16e-05	0.31	0.25	Height;	chr4:55484534	chr4:55387949~55388271:+
HNSC	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.63	3.12e-08	1.16e-05	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
HNSC	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-5.63	3.12e-08	1.16e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-5.63	3.12e-08	1.16e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
HNSC	cis	rs4140799	0.816	rs1204995	ENSG00000266869.1	RP6-114E22.1	5.63	3.13e-08	1.16e-05	0.31	0.25	Neuroticism;	chr14:71721133	chr14:71848606~71908430:+
HNSC	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-5.63	3.13e-08	1.16e-05	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
HNSC	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-5.63	3.13e-08	1.16e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
HNSC	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.63	3.13e-08	1.16e-05	-0.37	-0.25	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
HNSC	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	5.63	3.14e-08	1.16e-05	0.26	0.25	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
HNSC	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-5.63	3.14e-08	1.16e-05	-0.34	-0.25	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
HNSC	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-5.63	3.14e-08	1.16e-05	-0.31	-0.25	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-5.63	3.14e-08	1.16e-05	-0.31	-0.25	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
HNSC	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	5.63	3.14e-08	1.16e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
HNSC	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	5.63	3.14e-08	1.16e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	5.63	3.14e-08	1.16e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
HNSC	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-5.63	3.14e-08	1.16e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
HNSC	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
HNSC	cis	rs2985684	0.779	rs12160	ENSG00000258568.1	RHOQP1	5.63	3.14e-08	1.16e-05	0.26	0.25	Carotid intima media thickness;	chr14:49625214	chr14:49599994~49600572:+
HNSC	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
HNSC	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.63	3.14e-08	1.16e-05	-0.27	-0.25	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
HNSC	cis	rs330048	0.545	rs11774353	ENSG00000254340.1	RP11-10A14.3	5.63	3.15e-08	1.17e-05	0.31	0.25	Systemic lupus erythematosus;	chr8:9295617	chr8:9141424~9145435:+
HNSC	cis	rs5758659	1	rs134900	ENSG00000227370.1	RP4-669P10.19	-5.63	3.15e-08	1.17e-05	-0.24	-0.25	Cognitive function;	chr22:42287337	chr22:42132543~42132998:+
HNSC	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	5.63	3.15e-08	1.17e-05	0.35	0.25	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7778911	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1979823	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10807701	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1499613	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1553174	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10950032	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1392104	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718333	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7792391	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs10247526	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000179406.6	LINC00174	5.63	3.16e-08	1.17e-05	0.53	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	5.63	3.16e-08	1.17e-05	0.32	0.25	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
HNSC	cis	rs7980687	0.657	rs2851447	ENSG00000280120.1	RP11-546D6.3	5.63	3.16e-08	1.17e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123180566	chr12:123152324~123153377:-
HNSC	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-5.63	3.16e-08	1.17e-05	-0.32	-0.25	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
HNSC	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-5.63	3.16e-08	1.17e-05	-0.28	-0.25	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
HNSC	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	5.63	3.17e-08	1.17e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
HNSC	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	5.63	3.17e-08	1.17e-05	0.24	0.25	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	5.63	3.17e-08	1.17e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-5.63	3.17e-08	1.17e-05	-0.31	-0.25	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.529	rs2526857	ENSG00000274818.1	RP1-292L20.3	-5.63	3.17e-08	1.17e-05	-0.31	-0.25	Schizophrenia;	chr14:70945909	chr14:70906657~70907111:-
HNSC	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	5.63	3.17e-08	1.17e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	5.63	3.17e-08	1.17e-05	0.2	0.25	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
HNSC	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	5.63	3.17e-08	1.17e-05	0.3	0.25	Height;	chr4:55541259	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-5.63	3.18e-08	1.17e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
HNSC	cis	rs7396835	1	rs7396835	ENSG00000280143.1	AP000892.6	5.63	3.18e-08	1.17e-05	0.33	0.25	Quantitative traits;	chr11:116813312	chr11:117204967~117210292:+
HNSC	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	5.63	3.18e-08	1.18e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
HNSC	cis	rs7819412	0.811	rs2409691	ENSG00000255310.2	AF131215.2	-5.63	3.18e-08	1.18e-05	-0.24	-0.25	Triglycerides;	chr8:11085766	chr8:11107788~11109726:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	5.63	3.18e-08	1.18e-05	0.2	0.25	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	5.63	3.18e-08	1.18e-05	0.31	0.25	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
HNSC	cis	rs1012068	0.662	rs5753816	ENSG00000236132.1	CTA-440B3.1	-5.63	3.18e-08	1.18e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31916856	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-5.63	3.19e-08	1.18e-05	-0.15	-0.25	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-5.63	3.19e-08	1.18e-05	-0.15	-0.25	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
HNSC	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-5.63	3.19e-08	1.18e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
HNSC	cis	rs11648785	0.506	rs7191175	ENSG00000222019.6	URAHP	-5.63	3.19e-08	1.18e-05	-0.23	-0.25	Tanning;	chr16:90028869	chr16:90039761~90047773:-
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-5.63	3.19e-08	1.18e-05	-0.19	-0.25	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
HNSC	cis	rs13126694	0.839	rs66490968	ENSG00000248429.4	RP11-597D13.9	5.62	3.2e-08	1.18e-05	0.29	0.25	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158170752~158202877:+
HNSC	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	5.62	3.2e-08	1.18e-05	0.27	0.25	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
HNSC	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.21e-08	1.19e-05	-0.25	-0.25	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
HNSC	cis	rs11648785	0.747	rs12920767	ENSG00000222019.6	URAHP	5.62	3.21e-08	1.19e-05	0.25	0.25	Tanning;	chr16:90028162	chr16:90039761~90047773:-
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-5.62	3.21e-08	1.19e-05	-0.32	-0.25	Depression;	chr6:28135913	chr6:28161781~28169594:+
HNSC	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-5.62	3.21e-08	1.19e-05	-0.27	-0.25	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
HNSC	cis	rs13113518	0.934	rs10866425	ENSG00000273257.1	RP11-177J6.1	5.62	3.22e-08	1.19e-05	0.31	0.25	Height;	chr4:55582068	chr4:55387949~55388271:+
HNSC	cis	rs35306767	0.953	rs11253521	ENSG00000229869.1	RP11-363N22.2	-5.62	3.22e-08	1.19e-05	-0.32	-0.25	Eosinophil percentage of granulocytes;	chr10:930476	chr10:933026~942743:+
HNSC	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	5.62	3.22e-08	1.19e-05	0.34	0.25	Height;	chr6:109340338	chr6:109382795~109383666:+
HNSC	cis	rs61542988	0.606	rs4722185	ENSG00000228649.7	AC005682.5	5.62	3.22e-08	1.19e-05	0.33	0.25	Fibrinogen levels;	chr7:22793092	chr7:22854178~22861579:+
HNSC	cis	rs3206736	0.548	rs329240	ENSG00000197085.10	NPSR1-AS1	5.62	3.23e-08	1.19e-05	0.31	0.25	Diastolic blood pressure;	chr7:35018828	chr7:34346512~34871582:-
HNSC	cis	rs9611519	0.857	rs4820434	ENSG00000235513.1	RP4-756G23.5	5.62	3.23e-08	1.19e-05	0.28	0.25	Neuroticism;	chr22:41241115	chr22:41209122~41217627:-
HNSC	cis	rs1865760	0.555	rs2051541	ENSG00000272462.2	U91328.19	5.62	3.23e-08	1.19e-05	0.24	0.25	Height;	chr6:25944983	chr6:25992662~26001775:+
HNSC	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-5.62	3.23e-08	1.19e-05	-0.3	-0.25	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-5.62	3.23e-08	1.19e-05	-0.3	-0.25	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
HNSC	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-5.62	3.23e-08	1.19e-05	-0.31	-0.25	Depression;	chr6:28251492	chr6:28115628~28116551:+
HNSC	cis	rs9929218	0.52	rs1078621	ENSG00000260459.2	FTLP14	5.62	3.23e-08	1.19e-05	0.34	0.25	Colorectal cancer;	chr16:68745093	chr16:68822587~68823070:+
HNSC	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.62	3.23e-08	1.19e-05	0.36	0.25	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
HNSC	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	5.62	3.24e-08	1.19e-05	0.25	0.25	Height;	chr5:37025769	chr5:36666214~36725195:-
HNSC	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.62	3.24e-08	1.19e-05	-0.37	-0.25	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
HNSC	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-5.62	3.24e-08	1.2e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
HNSC	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-5.62	3.24e-08	1.2e-05	-0.29	-0.25	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
HNSC	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-5.62	3.24e-08	1.2e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
HNSC	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	5.62	3.25e-08	1.2e-05	0.65	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
HNSC	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	5.62	3.25e-08	1.2e-05	0.24	0.25	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
HNSC	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	5.62	3.25e-08	1.2e-05	0.22	0.25	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
HNSC	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.62	3.25e-08	1.2e-05	-0.33	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
HNSC	cis	rs2115630	1	rs58581703	ENSG00000229212.6	RP11-561C5.4	5.62	3.26e-08	1.2e-05	0.29	0.25	P wave terminal force;	chr15:84733704	chr15:85205440~85234795:-
HNSC	cis	rs11992162	0.967	rs10112888	ENSG00000206014.6	OR7E161P	-5.62	3.26e-08	1.2e-05	-0.27	-0.25	Monocyte count;	chr8:11972699	chr8:11928597~11929563:-
HNSC	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-5.62	3.26e-08	1.2e-05	-0.27	-0.25	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
HNSC	cis	rs4141404	0.851	rs5749248	ENSG00000236132.1	CTA-440B3.1	5.62	3.26e-08	1.2e-05	0.35	0.25	Paclitaxel-induced neuropathy;	chr22:31287725	chr22:31816379~31817491:-
HNSC	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-5.62	3.26e-08	1.2e-05	-0.37	-0.25	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-5.62	3.26e-08	1.2e-05	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
HNSC	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-5.62	3.26e-08	1.2e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
HNSC	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	5.62	3.27e-08	1.21e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	5.62	3.27e-08	1.21e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
HNSC	cis	rs2985684	0.948	rs4900925	ENSG00000278009.1	RP11-649E7.8	-5.62	3.27e-08	1.21e-05	-0.33	-0.25	Carotid intima media thickness;	chr14:49545607	chr14:49601011~49601124:-
HNSC	cis	rs9402743	0.634	rs9321512	ENSG00000217482.2	HMGB1P17	-5.62	3.27e-08	1.21e-05	-0.27	-0.25	Systemic lupus erythematosus;	chr6:135603299	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-5.62	3.27e-08	1.21e-05	-0.17	-0.25	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	5.62	3.27e-08	1.21e-05	0.31	0.25	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000211974.3	IGHV2-70	-5.62	3.27e-08	1.21e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106662151	chr14:106723574~106724093:-
HNSC	cis	rs2235642	0.859	rs9927529	ENSG00000280231.1	LA16c-380F5.3	-5.62	3.28e-08	1.21e-05	-0.31	-0.25	Coronary artery disease;	chr16:1569487	chr16:1553655~1554130:-
HNSC	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	5.62	3.28e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
HNSC	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-5.62	3.28e-08	1.21e-05	-0.44	-0.25	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
HNSC	cis	rs5758659	1	rs134873	ENSG00000227370.1	RP4-669P10.19	-5.62	3.28e-08	1.21e-05	-0.24	-0.25	Cognitive function;	chr22:42261560	chr22:42132543~42132998:+
HNSC	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-5.62	3.29e-08	1.21e-05	-0.29	-0.25	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
HNSC	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	5.62	3.29e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	5.62	3.29e-08	1.21e-05	0.27	0.25	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
HNSC	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	5.62	3.29e-08	1.21e-05	0.24	0.25	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
HNSC	cis	rs9611519	0.808	rs5751074	ENSG00000235513.1	RP4-756G23.5	5.62	3.29e-08	1.21e-05	0.26	0.25	Neuroticism;	chr22:41269718	chr22:41209122~41217627:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000204709.4	LINC01556	5.62	3.29e-08	1.21e-05	0.35	0.25	Parkinson's disease;	chr6:28046819	chr6:28943877~28944537:+
HNSC	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-5.62	3.29e-08	1.21e-05	-0.43	-0.25	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
HNSC	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-5.62	3.29e-08	1.21e-05	-0.35	-0.25	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
HNSC	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-5.62	3.29e-08	1.21e-05	-0.28	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
HNSC	cis	rs9341808	0.519	rs59232999	ENSG00000272129.1	RP11-250B2.6	-5.62	3.3e-08	1.21e-05	-0.3	-0.25	Sitting height ratio;	chr6:80309066	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.62	3.31e-08	1.22e-05	-0.3	-0.25	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.529	rs61990379	ENSG00000274818.1	RP1-292L20.3	5.62	3.31e-08	1.22e-05	0.3	0.25	Schizophrenia;	chr14:71000353	chr14:70906657~70907111:-
HNSC	cis	rs4925386	0.559	rs2427291	ENSG00000273619.1	RP5-908M14.9	-5.62	3.31e-08	1.22e-05	-0.28	-0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346268	chr20:62386303~62386970:-
HNSC	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	5.62	3.31e-08	1.22e-05	0.35	0.25	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
HNSC	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	5.62	3.31e-08	1.22e-05	0.35	0.25	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
HNSC	cis	rs11154801	0.634	rs6941396	ENSG00000217482.2	HMGB1P17	5.62	3.32e-08	1.22e-05	0.3	0.25	Multiple sclerosis;	chr6:135606388	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	5.62	3.32e-08	1.22e-05	0.3	0.25	Height;	chr4:55548261	chr4:55363971~55395847:-
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	5.62	3.32e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
HNSC	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-5.62	3.33e-08	1.22e-05	-0.3	-0.25	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
HNSC	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55452853	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55454154	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55455650	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55457027	chr4:55363971~55395847:-
HNSC	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	5.62	3.33e-08	1.22e-05	0.3	0.25	Height;	chr4:55457086	chr4:55363971~55395847:-
HNSC	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	5.62	3.33e-08	1.22e-05	0.4	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
HNSC	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-5.62	3.33e-08	1.23e-05	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
HNSC	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-5.62	3.33e-08	1.23e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	5.62	3.33e-08	1.23e-05	0.21	0.25	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
HNSC	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	5.62	3.33e-08	1.23e-05	0.45	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
HNSC	cis	rs7209700	0.547	rs16941776	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	IgG glycosylation;	chr17:47265775	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.547	rs16941780	ENSG00000228782.6	CTD-2026D20.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	IgG glycosylation;	chr17:47265817	chr17:47450568~47492492:-
HNSC	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-5.62	3.33e-08	1.23e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
HNSC	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-5.62	3.33e-08	1.23e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	5.62	3.34e-08	1.23e-05	0.32	0.25	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000211974.3	IGHV2-70	-5.62	3.34e-08	1.23e-05	-0.3	-0.25	Alzheimer's disease (late onset);	chr14:106793907	chr14:106723574~106724093:-
HNSC	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	5.62	3.35e-08	1.23e-05	0.32	0.25	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
HNSC	cis	rs330048	0.561	rs330088	ENSG00000254340.1	RP11-10A14.3	5.62	3.35e-08	1.23e-05	0.31	0.25	Systemic lupus erythematosus;	chr8:9292236	chr8:9141424~9145435:+
HNSC	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	5.62	3.35e-08	1.23e-05	0.24	0.25	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
HNSC	cis	rs9402743	0.632	rs6570038	ENSG00000217482.2	HMGB1P17	5.62	3.35e-08	1.23e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135775465	chr6:135636086~135636713:-
HNSC	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	5.62	3.35e-08	1.23e-05	0.3	0.25	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
HNSC	cis	rs11846409	0.932	rs756588	ENSG00000211974.3	IGHV2-70	5.62	3.35e-08	1.23e-05	0.29	0.25	Rheumatic heart disease;	chr14:106632316	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.86	rs55745256	ENSG00000211974.3	IGHV2-70	-5.62	3.35e-08	1.23e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632365	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs731013	ENSG00000211974.3	IGHV2-70	-5.62	3.35e-08	1.23e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632481	chr14:106723574~106724093:-
HNSC	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-5.62	3.35e-08	1.23e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
HNSC	cis	rs60617249	0.507	rs12718990	ENSG00000228204.2	RP4-724E13.2	5.62	3.36e-08	1.24e-05	0.32	0.25	Major depression and alcohol dependence;	chr7:50906089	chr7:50866747~51022990:+
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	5.62	3.36e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-5.62	3.37e-08	1.24e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
HNSC	cis	rs7824557	0.547	rs2409749	ENSG00000255310.2	AF131215.2	-5.62	3.38e-08	1.24e-05	-0.24	-0.25	Retinal vascular caliber;	chr8:11221440	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	5.62	3.38e-08	1.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
HNSC	cis	rs2976388	0.647	rs1048831	ENSG00000253741.1	CTD-2292P10.4	-5.61	3.38e-08	1.24e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142700440	chr8:142702252~142726973:-
HNSC	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-5.61	3.38e-08	1.24e-05	-0.29	-0.25	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
HNSC	cis	rs9525927	0.521	rs4942298	ENSG00000227258.4	SMIM2-AS1	5.61	3.38e-08	1.24e-05	0.34	0.25	Dupuytren's disease;	chr13:44224486	chr13:44110451~44240517:+
HNSC	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	5.61	3.4e-08	1.25e-05	0.4	0.25	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	5.61	3.4e-08	1.25e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
HNSC	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-5.61	3.4e-08	1.25e-05	-0.37	-0.25	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
HNSC	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	5.61	3.4e-08	1.25e-05	0.31	0.25	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
HNSC	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	5.61	3.4e-08	1.25e-05	0.29	0.25	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
HNSC	cis	rs9813712	0.571	rs9824426	ENSG00000249846.5	RP11-77P16.4	-5.61	3.41e-08	1.25e-05	-0.27	-0.25	Response to amphetamines;	chr3:130226115	chr3:130112550~130120579:+
HNSC	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	5.61	3.41e-08	1.25e-05	0.55	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
HNSC	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-5.61	3.41e-08	1.25e-05	-0.32	-0.25	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
HNSC	cis	rs4218	0.648	rs8042896	ENSG00000277144.1	RP11-59H7.4	-5.61	3.41e-08	1.25e-05	-0.34	-0.25	Social communication problems;	chr15:59067727	chr15:59115547~59116089:-
HNSC	cis	rs7980687	0.628	rs1727332	ENSG00000280120.1	RP11-546D6.3	5.61	3.41e-08	1.25e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123233754	chr12:123152324~123153377:-
HNSC	cis	rs6928977	0.5	rs12211833	ENSG00000217482.2	HMGB1P17	5.61	3.42e-08	1.26e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	5.61	3.42e-08	1.26e-05	0.31	0.25	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
HNSC	cis	rs3206736	0.548	rs329229	ENSG00000197085.10	NPSR1-AS1	-5.61	3.42e-08	1.26e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35014417	chr7:34346512~34871582:-
HNSC	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-5.61	3.43e-08	1.26e-05	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
HNSC	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	5.61	3.43e-08	1.26e-05	0.27	0.25	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
HNSC	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-5.61	3.43e-08	1.26e-05	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
HNSC	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	5.61	3.43e-08	1.26e-05	0.36	0.25	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
HNSC	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	5.61	3.43e-08	1.26e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
HNSC	cis	rs6951245	0.572	rs73264028	ENSG00000224079.1	AC091729.7	-5.61	3.44e-08	1.26e-05	-0.5	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005819	chr7:1074450~1078036:+
HNSC	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-5.61	3.44e-08	1.26e-05	-0.27	-0.25	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	5.61	3.45e-08	1.27e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
HNSC	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-5.61	3.45e-08	1.27e-05	-0.24	-0.25	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-5.61	3.45e-08	1.27e-05	-0.36	-0.25	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
HNSC	cis	rs1355223	0.833	rs11032804	ENSG00000271369.1	RP11-350D17.3	-5.61	3.45e-08	1.27e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659051	chr11:34709600~34710161:+
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	5.61	3.46e-08	1.27e-05	0.31	0.25	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	5.61	3.46e-08	1.27e-05	0.31	0.25	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
HNSC	cis	rs9813712	0.818	rs11718381	ENSG00000249846.5	RP11-77P16.4	5.61	3.46e-08	1.27e-05	0.3	0.25	Response to amphetamines;	chr3:130222660	chr3:130112550~130120579:+
HNSC	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.61	3.46e-08	1.27e-05	-0.2	-0.25	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
HNSC	cis	rs988913	1	rs6926997	ENSG00000224984.1	RP11-524H19.2	5.61	3.46e-08	1.27e-05	0.28	0.25	Menarche (age at onset);	chr6:54952528	chr6:54840118~54840855:-
HNSC	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	5.61	3.47e-08	1.27e-05	0.3	0.25	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
HNSC	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	5.61	3.47e-08	1.27e-05	0.36	0.25	Height;	chr6:109712525	chr6:109382795~109383666:+
HNSC	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	5.61	3.47e-08	1.27e-05	0.24	0.25	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
HNSC	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	5.61	3.47e-08	1.27e-05	0.27	0.25	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
HNSC	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	5.61	3.47e-08	1.27e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
HNSC	cis	rs7674212	0.539	rs6854709	ENSG00000246560.2	RP11-10L12.4	5.61	3.47e-08	1.27e-05	0.29	0.25	Type 2 diabetes;	chr4:103208629	chr4:102828055~102844075:+
HNSC	cis	rs11846409	0.932	rs731012	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632578	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs731011	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632619	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs10138537	ENSG00000211974.3	IGHV2-70	-5.61	3.47e-08	1.27e-05	-0.29	-0.25	Rheumatic heart disease;	chr14:106632778	chr14:106723574~106724093:-
HNSC	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	5.61	3.48e-08	1.28e-05	0.34	0.25	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
HNSC	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	5.61	3.48e-08	1.28e-05	0.2	0.25	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
HNSC	cis	rs1355223	0.902	rs286858	ENSG00000271369.1	RP11-350D17.3	5.61	3.48e-08	1.28e-05	0.29	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34695810	chr11:34709600~34710161:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	5.61	3.48e-08	1.28e-05	0.27	0.25	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
HNSC	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	5.61	3.48e-08	1.28e-05	0.26	0.25	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	5.61	3.48e-08	1.28e-05	0.26	0.25	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
HNSC	cis	rs4657482	0.962	rs10800164	ENSG00000236364.3	RP11-525G13.2	-5.61	3.48e-08	1.28e-05	-0.25	-0.25	Testicular germ cell tumor;	chr1:165889117	chr1:165890795~165900683:-
HNSC	cis	rs8054556	1	rs4583255	ENSG00000183604.13	SMG1P5	-5.61	3.48e-08	1.28e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30267553~30335374:-
HNSC	cis	rs9341808	0.5	rs2322629	ENSG00000272129.1	RP11-250B2.6	5.61	3.48e-08	1.28e-05	0.3	0.25	Sitting height ratio;	chr6:80101823	chr6:80355424~80356859:+
HNSC	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-5.61	3.49e-08	1.28e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
HNSC	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.61	3.49e-08	1.28e-05	0.32	0.25	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
HNSC	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	5.61	3.49e-08	1.28e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
HNSC	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	5.61	3.49e-08	1.28e-05	0.26	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
HNSC	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	5.61	3.49e-08	1.28e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
HNSC	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-5.61	3.5e-08	1.28e-05	-0.24	-0.25	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
HNSC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	5.61	3.5e-08	1.28e-05	0.29	0.25	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
HNSC	cis	rs7160336	0.738	rs11849883	ENSG00000259065.1	RP5-1021I20.1	5.61	3.5e-08	1.28e-05	0.29	0.25	Blood protein levels;	chr14:74010633	chr14:73787360~73803270:+
HNSC	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	5.61	3.5e-08	1.28e-05	0.28	0.25	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
HNSC	cis	rs2179367	0.632	rs9498332	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149367490	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498333	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149368196	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498334	ENSG00000216906.2	RP11-350J20.9	5.61	3.5e-08	1.28e-05	0.37	0.25	Dupuytren's disease;	chr6:149370902	chr6:149904243~149906418:+
HNSC	cis	rs6604026	0.59	rs11810217	ENSG00000223787.2	RP4-593M8.1	5.61	3.51e-08	1.29e-05	0.35	0.25	Multiple sclerosis;	chr1:92682820	chr1:92580476~92580821:-
HNSC	cis	rs11810217	0.718	rs114225281	ENSG00000223787.2	RP4-593M8.1	5.61	3.51e-08	1.29e-05	0.35	0.25	Multiple sclerosis;	chr1:92685669	chr1:92580476~92580821:-
HNSC	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	5.61	3.51e-08	1.29e-05	0.37	0.25	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
HNSC	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	5.61	3.51e-08	1.29e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	5.61	3.51e-08	1.29e-05	0.31	0.25	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
HNSC	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-5.61	3.51e-08	1.29e-05	-0.35	-0.25	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-5.61	3.51e-08	1.29e-05	-0.35	-0.25	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
HNSC	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	5.61	3.51e-08	1.29e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
HNSC	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Height;	chr4:55546002	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Height;	chr4:55546378	chr4:55387949~55388271:+
HNSC	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-5.61	3.52e-08	1.29e-05	-0.35	-0.25	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
HNSC	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.61	3.52e-08	1.29e-05	0.27	0.25	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
HNSC	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	5.61	3.52e-08	1.29e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
HNSC	cis	rs9329221	0.935	rs3750310	ENSG00000269918.1	AF131215.9	-5.61	3.52e-08	1.29e-05	-0.24	-0.25	Neuroticism;	chr8:10425916	chr8:11104691~11106704:-
HNSC	cis	rs9402743	0.632	rs6900101	ENSG00000217482.2	HMGB1P17	5.61	3.52e-08	1.29e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135773766	chr6:135636086~135636713:-
HNSC	cis	rs6918586	0.681	rs198831	ENSG00000272462.2	U91328.19	-5.61	3.52e-08	1.29e-05	-0.24	-0.25	Schizophrenia;	chr6:26116768	chr6:25992662~26001775:+
HNSC	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	5.61	3.52e-08	1.29e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
HNSC	cis	rs4140799	0.78	rs1204992	ENSG00000266869.1	RP6-114E22.1	5.61	3.52e-08	1.29e-05	0.31	0.25	Neuroticism;	chr14:71731794	chr14:71848606~71908430:+
HNSC	cis	rs2579103	0.898	rs2165039	ENSG00000258183.4	RP11-753N8.1	5.61	3.53e-08	1.29e-05	0.31	0.25	Body mass index;	chr12:90207656	chr12:90280894~90300340:+
HNSC	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-5.61	3.53e-08	1.29e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
HNSC	cis	rs7980687	0.657	rs10744151	ENSG00000280120.1	RP11-546D6.3	5.61	3.53e-08	1.29e-05	0.22	0.25	Head circumference (infant);Educational attainment;Height;	chr12:123239188	chr12:123152324~123153377:-
HNSC	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-5.61	3.53e-08	1.29e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.61	3.53e-08	1.29e-05	0.31	0.25	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
HNSC	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	5.61	3.54e-08	1.29e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	5.61	3.54e-08	1.3e-05	0.31	0.25	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
HNSC	cis	rs947583	0.588	rs11753333	ENSG00000217482.2	HMGB1P17	5.61	3.54e-08	1.3e-05	0.3	0.25	Phosphorus levels;	chr6:135715788	chr6:135636086~135636713:-
HNSC	cis	rs11089937	0.963	rs2073454	ENSG00000211638.2	IGLV8-61	-5.61	3.54e-08	1.3e-05	-0.22	-0.25	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22098700~22099212:+
HNSC	cis	rs1355223	0.867	rs3818514	ENSG00000271369.1	RP11-350D17.3	-5.61	3.55e-08	1.3e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34658506	chr11:34709600~34710161:+
HNSC	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	5.61	3.55e-08	1.3e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
HNSC	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	5.61	3.55e-08	1.3e-05	0.42	0.25	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	5.61	3.55e-08	1.3e-05	0.23	0.25	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
HNSC	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	5.61	3.56e-08	1.3e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
HNSC	cis	rs853679	1	rs735765	ENSG00000204709.4	LINC01556	5.61	3.56e-08	1.3e-05	0.42	0.25	Depression;	chr6:28202519	chr6:28943877~28944537:+
HNSC	cis	rs9813712	0.526	rs62281641	ENSG00000249846.5	RP11-77P16.4	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Response to amphetamines;	chr3:130235668	chr3:130112550~130120579:+
HNSC	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
HNSC	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-5.61	3.56e-08	1.3e-05	-0.27	-0.25	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
HNSC	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	5.61	3.56e-08	1.3e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
HNSC	cis	rs35306767	0.807	rs11253513	ENSG00000229869.1	RP11-363N22.2	-5.61	3.57e-08	1.3e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:922510	chr10:933026~942743:+
HNSC	cis	rs35306767	0.953	rs12259338	ENSG00000229869.1	RP11-363N22.2	-5.61	3.57e-08	1.3e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:923437	chr10:933026~942743:+
HNSC	cis	rs947583	0.588	rs12201044	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135743303	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs7748386	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135750576	chr6:135636086~135636713:-
HNSC	cis	rs947583	0.588	rs12202435	ENSG00000217482.2	HMGB1P17	5.6	3.57e-08	1.3e-05	0.29	0.25	Phosphorus levels;	chr6:135752622	chr6:135636086~135636713:-
HNSC	cis	rs9914544	1	rs6502677	ENSG00000264885.1	RP11-815I9.4	-5.6	3.57e-08	1.31e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18900345	chr17:18667629~18669461:-
HNSC	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.6	3.58e-08	1.31e-05	-0.37	-0.25	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
HNSC	cis	rs9291683	0.546	rs10939672	ENSG00000250413.1	RP11-448G15.1	-5.6	3.58e-08	1.31e-05	-0.31	-0.25	Bone mineral density;	chr4:10050512	chr4:10006482~10009725:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000254153.1	CTA-398F10.2	5.6	3.59e-08	1.31e-05	0.28	0.25	Neuroticism;	chr8:8480637	chr8:8456909~8461337:-
HNSC	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	5.6	3.59e-08	1.31e-05	0.35	0.25	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
HNSC	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	5.6	3.59e-08	1.31e-05	0.24	0.25	Height;	chr5:36887793	chr5:36666214~36725195:-
HNSC	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	5.6	3.59e-08	1.31e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
HNSC	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.6	3.59e-08	1.31e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.6	3.59e-08	1.31e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000206014.6	OR7E161P	-5.6	3.59e-08	1.31e-05	-0.27	-0.25	Neuroticism;	chr8:11939219	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000206014.6	OR7E161P	-5.6	3.59e-08	1.31e-05	-0.27	-0.25	Neuroticism;	chr8:11939586	chr8:11928597~11929563:-
HNSC	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	5.6	3.59e-08	1.31e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
HNSC	cis	rs763567	1	rs763567	ENSG00000271811.1	RP1-79C4.4	-5.6	3.59e-08	1.31e-05	-0.28	-0.25	Tonsillectomy;	chr1:170596864	chr1:170667381~170669425:+
HNSC	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-5.6	3.59e-08	1.31e-05	-0.3	-0.25	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
HNSC	cis	rs9341808	0.538	rs9343980	ENSG00000272129.1	RP11-250B2.6	-5.6	3.6e-08	1.32e-05	-0.29	-0.25	Sitting height ratio;	chr6:80313715	chr6:80355424~80356859:+
HNSC	cis	rs5753618	0.583	rs7287267	ENSG00000236132.1	CTA-440B3.1	-5.6	3.6e-08	1.32e-05	-0.3	-0.25	Colorectal cancer;	chr22:31352429	chr22:31816379~31817491:-
HNSC	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	5.6	3.6e-08	1.32e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
HNSC	cis	rs6951245	0.572	rs73264010	ENSG00000224079.1	AC091729.7	-5.6	3.6e-08	1.32e-05	-0.5	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1000841	chr7:1074450~1078036:+
HNSC	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	5.6	3.6e-08	1.32e-05	0.26	0.25	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
HNSC	cis	rs9341808	0.519	rs3805872	ENSG00000272129.1	RP11-250B2.6	-5.6	3.6e-08	1.32e-05	-0.3	-0.25	Sitting height ratio;	chr6:80325385	chr6:80355424~80356859:+
HNSC	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.6	3.61e-08	1.32e-05	-0.27	-0.25	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
HNSC	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	5.6	3.61e-08	1.32e-05	0.3	0.25	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
HNSC	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-5.6	3.61e-08	1.32e-05	-0.37	-0.25	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
HNSC	cis	rs6928977	0.86	rs3827780	ENSG00000234084.1	RP3-388E23.2	5.6	3.62e-08	1.32e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135388622	chr6:135301568~135307158:+
HNSC	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	5.6	3.62e-08	1.32e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	5.6	3.62e-08	1.32e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
HNSC	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-5.6	3.62e-08	1.32e-05	-0.31	-0.25	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
HNSC	cis	rs9341808	0.538	rs7756067	ENSG00000272129.1	RP11-250B2.6	-5.6	3.62e-08	1.32e-05	-0.29	-0.25	Sitting height ratio;	chr6:80310077	chr6:80355424~80356859:+
HNSC	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-5.6	3.63e-08	1.33e-05	-0.31	-0.25	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
HNSC	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-5.6	3.63e-08	1.33e-05	-0.28	-0.25	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	5.6	3.63e-08	1.33e-05	0.2	0.25	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-5.6	3.64e-08	1.33e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
HNSC	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-5.6	3.64e-08	1.33e-05	-0.43	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
HNSC	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.64e-08	1.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
HNSC	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-5.6	3.64e-08	1.33e-05	-0.27	-0.25	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
HNSC	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
HNSC	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
HNSC	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-5.6	3.65e-08	1.33e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
HNSC	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-5.6	3.65e-08	1.33e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
HNSC	cis	rs2033711	0.654	rs734380	ENSG00000269473.1	CTD-2619J13.19	5.6	3.65e-08	1.33e-05	0.31	0.25	Uric acid clearance;	chr19:58387596	chr19:58440448~58445849:+
HNSC	cis	rs4763879	0.54	rs741200	ENSG00000256673.1	RP11-599J14.2	5.6	3.65e-08	1.33e-05	0.24	0.25	Type 1 diabetes;	chr12:9717819	chr12:9398355~9414851:-
HNSC	cis	rs6928977	0.86	rs2757649	ENSG00000231028.7	LINC00271	-5.6	3.65e-08	1.33e-05	-0.29	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135497801~135716055:+
HNSC	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	5.6	3.65e-08	1.33e-05	0.29	0.25	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
HNSC	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	5.6	3.65e-08	1.33e-05	0.31	0.25	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
HNSC	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	5.6	3.66e-08	1.34e-05	0.36	0.25	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
HNSC	cis	rs9611519	0.761	rs35445172	ENSG00000235513.1	RP4-756G23.5	5.6	3.66e-08	1.34e-05	0.26	0.25	Neuroticism;	chr22:41264297	chr22:41209122~41217627:-
HNSC	cis	rs860295	0.557	rs10796944	ENSG00000203761.5	MSTO2P	-5.6	3.66e-08	1.34e-05	-0.21	-0.25	Body mass index;	chr1:155446537	chr1:155745829~155750137:+
HNSC	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-5.6	3.67e-08	1.34e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
HNSC	cis	rs9341808	0.538	rs620147	ENSG00000272129.1	RP11-250B2.6	-5.6	3.67e-08	1.34e-05	-0.29	-0.25	Sitting height ratio;	chr6:80282373	chr6:80355424~80356859:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-5.6	3.67e-08	1.34e-05	-0.22	-0.25	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	5.6	3.67e-08	1.34e-05	0.31	0.25	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28140454	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28141189	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	1.34e-05	-0.32	-0.25	Depression;	chr6:28141484	chr6:28161781~28169594:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
HNSC	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	5.6	3.68e-08	1.34e-05	0.25	0.25	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	5.6	3.68e-08	1.34e-05	0.25	0.25	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
HNSC	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-5.6	3.68e-08	1.34e-05	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
HNSC	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	5.6	3.69e-08	1.34e-05	0.26	0.25	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
HNSC	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	5.6	3.69e-08	1.35e-05	0.27	0.25	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
HNSC	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.6	3.69e-08	1.35e-05	-0.35	-0.25	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	5.6	3.69e-08	1.35e-05	0.3	0.25	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
HNSC	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-5.6	3.7e-08	1.35e-05	-0.35	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
HNSC	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.6	3.7e-08	1.35e-05	-0.2	-0.25	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
HNSC	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	5.6	3.7e-08	1.35e-05	0.31	0.25	Height;	chr4:55407965	chr4:55387949~55388271:+
HNSC	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-5.6	3.71e-08	1.35e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
HNSC	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-5.6	3.71e-08	1.35e-05	-0.32	-0.25	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
HNSC	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-5.6	3.71e-08	1.35e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
HNSC	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.6	3.71e-08	1.35e-05	-0.4	-0.25	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
HNSC	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	5.6	3.71e-08	1.35e-05	0.29	0.25	Height;	chr4:55456620	chr4:55363971~55395847:-
HNSC	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-5.6	3.71e-08	1.35e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	5.6	3.71e-08	1.35e-05	0.34	0.25	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	5.6	3.71e-08	1.35e-05	0.3	0.25	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
HNSC	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
HNSC	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-5.6	3.71e-08	1.35e-05	-0.26	-0.25	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
HNSC	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	5.6	3.72e-08	1.35e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
HNSC	cis	rs3206736	0.548	rs1649238	ENSG00000197085.10	NPSR1-AS1	5.6	3.72e-08	1.36e-05	0.31	0.25	Diastolic blood pressure;	chr7:34964905	chr7:34346512~34871582:-
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-5.6	3.72e-08	1.36e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
HNSC	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-5.6	3.72e-08	1.36e-05	-0.3	-0.25	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
HNSC	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma;	chr2:102423587	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma;	chr2:102423717	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	5.6	3.72e-08	1.36e-05	0.24	0.25	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
HNSC	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.6	3.73e-08	1.36e-05	-0.28	-0.25	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
HNSC	cis	rs75422866	0.51	rs75424057	ENSG00000276691.1	RP5-1057I20.5	5.6	3.73e-08	1.36e-05	0.44	0.25	Pneumonia;	chr12:47737294	chr12:47788426~47788971:+
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	5.6	3.73e-08	1.36e-05	0.31	0.25	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
HNSC	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.6	3.74e-08	1.36e-05	-0.27	-0.25	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
HNSC	cis	rs2268667	0.509	rs7521189	ENSG00000223653.4	RP11-131L23.1	-5.6	3.74e-08	1.36e-05	-0.32	-0.25	Asymmetrical dimethylarginine levels;	chr1:85423913	chr1:85276715~85448124:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-5.6	3.75e-08	1.37e-05	-0.17	-0.25	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
HNSC	cis	rs5758659	0.904	rs134877	ENSG00000227370.1	RP4-669P10.19	-5.6	3.75e-08	1.37e-05	-0.24	-0.25	Cognitive function;	chr22:42266365	chr22:42132543~42132998:+
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-5.6	3.75e-08	1.37e-05	-0.3	-0.25	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
HNSC	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.6	3.75e-08	1.37e-05	-0.22	-0.25	Height;	chr11:118761813	chr11:118791254~118793137:+
HNSC	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-5.6	3.75e-08	1.37e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	5.6	3.75e-08	1.37e-05	0.31	0.25	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
HNSC	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-5.6	3.75e-08	1.37e-05	-0.29	-0.25	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
HNSC	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	5.6	3.76e-08	1.37e-05	0.22	0.25	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
HNSC	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.76e-08	1.37e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-5.6	3.76e-08	1.37e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
HNSC	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	5.6	3.76e-08	1.37e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
HNSC	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	5.59	3.77e-08	1.37e-05	0.31	0.25	Height;	chr4:55578787	chr4:55387949~55388271:+
HNSC	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-5.59	3.77e-08	1.37e-05	-0.3	-0.25	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.649	rs12617968	ENSG00000234818.1	AC092687.5	5.59	3.77e-08	1.37e-05	0.53	0.25	Prostate cancer;	chr2:10581819	chr2:10589166~10604830:+
HNSC	cis	rs60617249	0.55	rs13309489	ENSG00000228204.2	RP4-724E13.2	5.59	3.77e-08	1.37e-05	0.32	0.25	Major depression and alcohol dependence;	chr7:50943627	chr7:50866747~51022990:+
HNSC	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-5.59	3.77e-08	1.37e-05	-0.28	-0.25	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
HNSC	cis	rs503425	0.818	rs2508922	ENSG00000255422.1	AP002954.4	5.59	3.78e-08	1.38e-05	0.35	0.25	Systemic lupus erythematosus;	chr11:118810379	chr11:118704607~118750263:+
HNSC	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-5.59	3.78e-08	1.38e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-5.59	3.78e-08	1.38e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
HNSC	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	5.59	3.78e-08	1.38e-05	0.31	0.25	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
HNSC	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	5.59	3.78e-08	1.38e-05	0.31	0.25	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
HNSC	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.38e-05	-0.31	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.38e-05	-0.31	-0.25	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
HNSC	cis	rs11992162	0.597	rs7016320	ENSG00000206014.6	OR7E161P	5.59	3.79e-08	1.38e-05	0.27	0.25	Monocyte count;	chr8:11923543	chr8:11928597~11929563:-
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000254340.1	RP11-10A14.3	5.59	3.79e-08	1.38e-05	0.31	0.25	Mood instability;	chr8:8410553	chr8:9141424~9145435:+
HNSC	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
HNSC	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
HNSC	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	5.59	3.79e-08	1.38e-05	0.27	0.25	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
HNSC	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-5.59	3.79e-08	1.38e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
HNSC	cis	rs7819412	0.634	rs6987767	ENSG00000269918.1	AF131215.9	5.59	3.79e-08	1.38e-05	0.25	0.25	Triglycerides;	chr8:11052556	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	5.59	3.79e-08	1.38e-05	0.2	0.25	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	5.59	3.8e-08	1.38e-05	0.24	0.25	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
HNSC	cis	rs6604026	0.59	rs111807611	ENSG00000223787.2	RP4-593M8.1	5.59	3.8e-08	1.38e-05	0.35	0.25	Multiple sclerosis;	chr1:92687707	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-5.59	3.8e-08	1.38e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000206014.6	OR7E161P	5.59	3.8e-08	1.38e-05	0.27	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11928597~11929563:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000179406.6	LINC00174	-5.59	3.8e-08	1.38e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66038513	chr7:66376044~66401338:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.59	3.81e-08	1.39e-05	-0.27	-0.25	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
HNSC	cis	rs1355223	1	rs2221720	ENSG00000271369.1	RP11-350D17.3	5.59	3.81e-08	1.39e-05	0.27	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34733374	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	5.59	3.81e-08	1.39e-05	0.27	0.25	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000211974.3	IGHV2-70	5.59	3.81e-08	1.39e-05	0.28	0.25	Rheumatic heart disease;	chr14:106629835	chr14:106723574~106724093:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000206014.6	OR7E161P	-5.59	3.82e-08	1.39e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11928597~11929563:-
HNSC	cis	rs503425	1	rs503425	ENSG00000255422.1	AP002954.4	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118822018	chr11:118704607~118750263:+
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Depression;	chr6:28231986	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-5.59	3.82e-08	1.39e-05	-0.35	-0.25	Depression;	chr6:28232159	chr6:28115628~28116551:+
HNSC	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	5.59	3.82e-08	1.39e-05	0.33	0.25	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
HNSC	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	5.59	3.82e-08	1.39e-05	0.34	0.25	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
HNSC	cis	rs7819412	0.538	rs4523214	ENSG00000255310.2	AF131215.2	-5.59	3.82e-08	1.39e-05	-0.24	-0.25	Triglycerides;	chr8:11113263	chr8:11107788~11109726:-
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	5.59	3.83e-08	1.39e-05	0.57	0.25	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	5.59	3.83e-08	1.39e-05	0.31	0.25	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
HNSC	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.59	3.83e-08	1.39e-05	0.3	0.25	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
HNSC	cis	rs2243480	1	rs2420171	ENSG00000179406.6	LINC00174	5.59	3.83e-08	1.39e-05	0.53	0.25	Diabetic kidney disease;	chr7:66172773	chr7:66376044~66401338:-
HNSC	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.59	3.84e-08	1.4e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	5.59	3.84e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-5.59	3.84e-08	1.4e-05	-0.16	-0.25	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-5.59	3.84e-08	1.4e-05	-0.16	-0.25	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
HNSC	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	5.59	3.84e-08	1.4e-05	0.23	0.25	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
HNSC	cis	rs5753618	0.583	rs738657	ENSG00000236132.1	CTA-440B3.1	-5.59	3.85e-08	1.4e-05	-0.3	-0.25	Colorectal cancer;	chr22:31445763	chr22:31816379~31817491:-
HNSC	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-5.59	3.85e-08	1.4e-05	-0.27	-0.25	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	5.59	3.85e-08	1.4e-05	0.3	0.25	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	5.59	3.85e-08	1.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
HNSC	cis	rs7674212	0.57	rs2711899	ENSG00000246560.2	RP11-10L12.4	5.59	3.85e-08	1.4e-05	0.28	0.25	Type 2 diabetes;	chr4:103141257	chr4:102828055~102844075:+
HNSC	cis	rs10256972	0.967	rs4723338	ENSG00000225146.1	AC073957.15	5.59	3.85e-08	1.4e-05	0.29	0.25	Endometriosis;Longevity;	chr7:996605	chr7:1029025~1043891:+
HNSC	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	5.59	3.85e-08	1.4e-05	0.27	0.25	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
HNSC	cis	rs988913	1	rs9370342	ENSG00000224984.1	RP11-524H19.2	5.59	3.86e-08	1.4e-05	0.28	0.25	Menarche (age at onset);	chr6:54955872	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9370343	ENSG00000224984.1	RP11-524H19.2	5.59	3.86e-08	1.4e-05	0.28	0.25	Menarche (age at onset);	chr6:54955878	chr6:54840118~54840855:-
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-5.59	3.86e-08	1.4e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
HNSC	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-5.59	3.86e-08	1.4e-05	-0.28	-0.25	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
HNSC	cis	rs9341808	0.622	rs684283	ENSG00000272129.1	RP11-250B2.6	-5.59	3.87e-08	1.4e-05	-0.3	-0.25	Sitting height ratio;	chr6:80257600	chr6:80355424~80356859:+
HNSC	cis	rs7665090	0.728	rs228628	ENSG00000246560.2	RP11-10L12.4	-5.59	3.87e-08	1.4e-05	-0.29	-0.25	Primary biliary cholangitis;	chr4:102652166	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.692	rs228629	ENSG00000246560.2	RP11-10L12.4	-5.59	3.87e-08	1.4e-05	-0.29	-0.25	Primary biliary cholangitis;	chr4:102652220	chr4:102828055~102844075:+
HNSC	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	5.59	3.87e-08	1.41e-05	0.26	0.25	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
HNSC	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-5.59	3.88e-08	1.41e-05	-0.32	-0.25	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
HNSC	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-5.59	3.88e-08	1.41e-05	-0.3	-0.25	Height;	chr4:55537550	chr4:55387949~55388271:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000254153.1	CTA-398F10.2	5.59	3.88e-08	1.41e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9027656	chr8:8456909~8461337:-
HNSC	cis	rs9914544	1	rs67411574	ENSG00000264885.1	RP11-815I9.4	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18894024	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.966	rs7210746	ENSG00000264885.1	RP11-815I9.4	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18895280	chr17:18667629~18669461:-
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	5.59	3.89e-08	1.41e-05	0.31	0.25	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	5.59	3.89e-08	1.41e-05	0.31	0.25	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000254153.1	CTA-398F10.2	-5.59	3.89e-08	1.41e-05	-0.27	-0.25	Neuroticism;	chr8:8237241	chr8:8456909~8461337:-
HNSC	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	5.59	3.89e-08	1.41e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
HNSC	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	5.59	3.89e-08	1.41e-05	0.29	0.25	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	5.59	3.89e-08	1.41e-05	0.29	0.25	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
HNSC	cis	rs1012068	0.662	rs4820994	ENSG00000236132.1	CTA-440B3.1	-5.59	3.89e-08	1.41e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31915633	chr22:31816379~31817491:-
HNSC	cis	rs526231	0.857	rs415657	ENSG00000175749.11	EIF3KP1	-5.59	3.89e-08	1.41e-05	-0.31	-0.25	Primary biliary cholangitis;	chr5:103329295	chr5:103032376~103033031:+
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000276710.3	CSPG4P8	5.59	3.9e-08	1.41e-05	0.26	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82459472~82477258:+
HNSC	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-5.59	3.9e-08	1.41e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-5.59	3.9e-08	1.42e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
HNSC	cis	rs60617249	0.602	rs34709117	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50930485	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.55	rs13235836	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50931626	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.55	rs71540281	ENSG00000228204.2	RP4-724E13.2	5.59	3.9e-08	1.42e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50936419	chr7:50866747~51022990:+
HNSC	cis	rs2834288	0.7	rs731060	ENSG00000237945.6	LINC00649	-5.59	3.91e-08	1.42e-05	-0.32	-0.25	Gut microbiota (bacterial taxa);	chr21:33902624	chr21:33915534~33977691:+
HNSC	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-5.59	3.91e-08	1.42e-05	-0.33	-0.25	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
HNSC	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-5.59	3.91e-08	1.42e-05	-0.35	-0.25	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
HNSC	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	5.59	3.91e-08	1.42e-05	0.45	0.25	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	5.59	3.91e-08	1.42e-05	0.22	0.25	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
HNSC	cis	rs9840812	0.769	rs1711171	ENSG00000273486.1	RP11-731C17.2	5.59	3.92e-08	1.42e-05	0.22	0.25	Fibrinogen levels;	chr3:136301699	chr3:136837338~136839021:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000173295.6	FAM86B3P	-5.59	3.92e-08	1.42e-05	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9025061	chr8:8228595~8244865:+
HNSC	cis	rs2115630	1	rs8037423	ENSG00000229212.6	RP11-561C5.4	5.59	3.92e-08	1.42e-05	0.29	0.25	P wave terminal force;	chr15:84812263	chr15:85205440~85234795:-
HNSC	cis	rs7160336	0.728	rs4899488	ENSG00000259065.1	RP5-1021I20.1	5.59	3.92e-08	1.42e-05	0.29	0.25	Blood protein levels;	chr14:74008147	chr14:73787360~73803270:+
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	5.59	3.92e-08	1.42e-05	0.57	0.25	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
HNSC	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.59	3.92e-08	1.42e-05	-0.27	-0.25	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	5.59	3.92e-08	1.42e-05	0.3	0.25	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
HNSC	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-5.59	3.93e-08	1.42e-05	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-5.59	3.93e-08	1.42e-05	-0.27	-0.25	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-5.59	3.93e-08	1.42e-05	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	5.59	3.93e-08	1.42e-05	0.27	0.25	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
HNSC	cis	rs35306767	0.953	rs12762973	ENSG00000229869.1	RP11-363N22.2	-5.59	3.93e-08	1.43e-05	-0.35	-0.25	Eosinophil percentage of granulocytes;	chr10:914821	chr10:933026~942743:+
HNSC	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-5.59	3.93e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
HNSC	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	5.59	3.93e-08	1.43e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
HNSC	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	5.59	3.93e-08	1.43e-05	0.26	0.25	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
HNSC	cis	rs8054556	1	rs6565173	ENSG00000183604.13	SMG1P5	-5.59	3.93e-08	1.43e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30267553~30335374:-
HNSC	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	5.59	3.93e-08	1.43e-05	0.22	0.25	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-5.59	3.94e-08	1.43e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
HNSC	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	5.59	3.94e-08	1.43e-05	0.32	0.25	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
HNSC	cis	rs1355223	0.902	rs680727	ENSG00000271369.1	RP11-350D17.3	5.59	3.95e-08	1.43e-05	0.29	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682899	chr11:34709600~34710161:+
HNSC	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.59	3.95e-08	1.43e-05	-0.27	-0.25	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.59	3.95e-08	1.43e-05	-0.27	-0.25	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
HNSC	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-5.59	3.95e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-5.59	3.95e-08	1.43e-05	-0.33	-0.25	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
HNSC	cis	rs10504130	0.569	rs16916966	ENSG00000272024.1	RP11-546K22.3	-5.59	3.95e-08	1.43e-05	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51930769	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	5.59	3.95e-08	1.43e-05	0.31	0.25	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	5.59	3.95e-08	1.43e-05	0.31	0.25	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
HNSC	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-5.59	3.96e-08	1.43e-05	-0.45	-0.25	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
HNSC	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	5.59	3.96e-08	1.44e-05	0.26	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	5.59	3.96e-08	1.44e-05	0.19	0.25	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
HNSC	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	5.59	3.96e-08	1.44e-05	0.44	0.25	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-5.59	3.96e-08	1.44e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
HNSC	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-5.59	3.96e-08	1.44e-05	-0.22	-0.25	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
HNSC	cis	rs77204473	0.744	rs12420725	ENSG00000254851.1	RP11-109L13.1	5.59	3.97e-08	1.44e-05	0.4	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117146814	chr11:117135528~117138582:+
HNSC	cis	rs988913	1	rs6922186	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54946294	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs6929930	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54947912	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs6902245	ENSG00000224984.1	RP11-524H19.2	5.59	3.97e-08	1.44e-05	0.28	0.25	Menarche (age at onset);	chr6:54948208	chr6:54840118~54840855:-
HNSC	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	5.59	3.97e-08	1.44e-05	0.27	0.25	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
HNSC	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-5.59	3.97e-08	1.44e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000211974.3	IGHV2-70	5.59	3.97e-08	1.44e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106648903	chr14:106723574~106724093:-
HNSC	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-5.58	3.98e-08	1.44e-05	-0.22	-0.25	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
HNSC	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	5.58	3.98e-08	1.44e-05	0.3	0.25	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
HNSC	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	5.58	3.98e-08	1.44e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
HNSC	cis	rs7824557	0.547	rs4512344	ENSG00000255310.2	AF131215.2	-5.58	3.99e-08	1.44e-05	-0.24	-0.25	Retinal vascular caliber;	chr8:11221272	chr8:11107788~11109726:-
HNSC	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	5.58	3.99e-08	1.44e-05	0.22	0.25	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
HNSC	cis	rs67981189	0.529	rs2526858	ENSG00000274818.1	RP1-292L20.3	-5.58	3.99e-08	1.44e-05	-0.31	-0.25	Schizophrenia;	chr14:70945623	chr14:70906657~70907111:-
HNSC	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	5.58	3.99e-08	1.45e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
HNSC	cis	rs12817211	0.536	rs3184122	ENSG00000272368.2	RP4-605O3.4	-5.58	4e-08	1.45e-05	-0.25	-0.25	Colorectal or endometrial cancer;	chr12:50176344	chr12:50112197~50165618:+
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.31	0.25	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	5.58	4e-08	1.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
HNSC	cis	rs73186030	0.925	rs1801725	ENSG00000272758.4	RP11-299J3.8	5.58	4e-08	1.45e-05	0.36	0.25	Serum parathyroid hormone levels;	chr3:122284910	chr3:122416207~122443180:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	5.58	4e-08	1.45e-05	0.27	0.25	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
HNSC	cis	rs9329221	0.682	rs6982308	ENSG00000255310.2	AF131215.2	-5.58	4.01e-08	1.45e-05	-0.24	-0.25	Neuroticism;	chr8:10336262	chr8:11107788~11109726:-
HNSC	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-5.58	4.01e-08	1.45e-05	-0.27	-0.25	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
HNSC	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-5.58	4.01e-08	1.45e-05	-0.28	-0.25	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
HNSC	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	5.58	4.01e-08	1.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs2279458	ENSG00000273257.1	RP11-177J6.1	5.58	4.02e-08	1.45e-05	0.31	0.25	Height;	chr4:55562653	chr4:55387949~55388271:+
HNSC	cis	rs3738443	0.52	rs1771932	ENSG00000259865.1	RP11-488L18.10	5.58	4.02e-08	1.45e-05	0.2	0.25	Alcohol dependence;	chr1:247218747	chr1:247187281~247188526:-
HNSC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-5.58	4.02e-08	1.46e-05	-0.3	-0.25	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
HNSC	cis	rs5753618	0.583	rs7285619	ENSG00000236132.1	CTA-440B3.1	-5.58	4.03e-08	1.46e-05	-0.31	-0.25	Colorectal cancer;	chr22:31446568	chr22:31816379~31817491:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-5.58	4.03e-08	1.46e-05	-0.17	-0.25	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
HNSC	cis	rs947583	0.588	rs721366	ENSG00000217482.2	HMGB1P17	5.58	4.03e-08	1.46e-05	0.3	0.25	Phosphorus levels;	chr6:135713061	chr6:135636086~135636713:-
HNSC	cis	rs67981189	0.529	rs8014273	ENSG00000274818.1	RP1-292L20.3	5.58	4.04e-08	1.46e-05	0.3	0.25	Schizophrenia;	chr14:71043113	chr14:70906657~70907111:-
HNSC	cis	rs8054556	1	rs4788200	ENSG00000183604.13	SMG1P5	-5.58	4.04e-08	1.46e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788201	ENSG00000183604.13	SMG1P5	-5.58	4.04e-08	1.46e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30267553~30335374:-
HNSC	cis	rs9329221	0.935	rs3750311	ENSG00000269918.1	AF131215.9	-5.58	4.04e-08	1.46e-05	-0.24	-0.25	Neuroticism;	chr8:10426092	chr8:11104691~11106704:-
HNSC	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-5.58	4.04e-08	1.46e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
HNSC	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	5.58	4.04e-08	1.46e-05	0.31	0.25	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
HNSC	cis	rs2904967	0.636	rs239253	ENSG00000254614.2	AP003068.23	-5.58	4.04e-08	1.46e-05	-0.36	-0.25	Mean corpuscular volume;	chr11:65217272	chr11:65177606~65181834:-
HNSC	cis	rs4140799	0.816	rs1204997	ENSG00000266869.1	RP6-114E22.1	5.58	4.04e-08	1.46e-05	0.3	0.25	Neuroticism;	chr14:71716592	chr14:71848606~71908430:+
HNSC	cis	rs17507216	0.718	rs72753931	ENSG00000255769.6	GOLGA2P10	-5.58	4.05e-08	1.46e-05	-0.41	-0.25	Excessive daytime sleepiness;	chr15:82721485	chr15:82472993~82513950:-
HNSC	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	5.58	4.05e-08	1.47e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
HNSC	cis	rs9611519	0.964	rs4820428	ENSG00000235513.1	RP4-756G23.5	-5.58	4.05e-08	1.47e-05	-0.27	-0.25	Neuroticism;	chr22:41141585	chr22:41209122~41217627:-
HNSC	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-5.58	4.05e-08	1.47e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
HNSC	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	5.58	4.05e-08	1.47e-05	0.31	0.25	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
HNSC	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-5.58	4.06e-08	1.47e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-5.58	4.06e-08	1.47e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
HNSC	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-5.58	4.06e-08	1.47e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
HNSC	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-5.58	4.06e-08	1.47e-05	-0.29	-0.25	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
HNSC	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-5.58	4.06e-08	1.47e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
HNSC	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-5.58	4.06e-08	1.47e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
HNSC	cis	rs988913	1	rs9382402	ENSG00000224984.1	RP11-524H19.2	5.58	4.06e-08	1.47e-05	0.28	0.25	Menarche (age at onset);	chr6:54944695	chr6:54840118~54840855:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000179406.6	LINC00174	-5.58	4.07e-08	1.47e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66376044~66401338:-
HNSC	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	5.58	4.07e-08	1.47e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
HNSC	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-5.58	4.07e-08	1.47e-05	-0.35	-0.25	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
HNSC	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	5.58	4.08e-08	1.47e-05	0.34	0.25	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
HNSC	cis	rs2243480	1	rs6964245	ENSG00000179406.6	LINC00174	5.58	4.08e-08	1.47e-05	0.53	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66376044~66401338:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	5.58	4.08e-08	1.48e-05	0.22	0.25	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
HNSC	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	5.58	4.08e-08	1.48e-05	0.26	0.25	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	5.58	4.09e-08	1.48e-05	0.31	0.25	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	5.58	4.09e-08	1.48e-05	0.31	0.25	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000254153.1	CTA-398F10.2	5.58	4.09e-08	1.48e-05	0.28	0.25	Neuroticism;	chr8:8287918	chr8:8456909~8461337:-
HNSC	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	5.58	4.09e-08	1.48e-05	0.32	0.25	Height;	chr4:55457922	chr4:55387949~55388271:+
HNSC	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	5.58	4.09e-08	1.48e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28057501	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28057708	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28058299	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28058358	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28059910	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28060612	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28060704	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28062059	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000204709.4	LINC01556	5.58	4.09e-08	1.48e-05	0.34	0.25	Parkinson's disease;	chr6:28062721	chr6:28943877~28944537:+
HNSC	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-5.58	4.1e-08	1.48e-05	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-5.58	4.1e-08	1.48e-05	-0.22	-0.25	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
HNSC	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	5.58	4.1e-08	1.48e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	5.58	4.1e-08	1.48e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
HNSC	cis	rs2243480	1	rs6964530	ENSG00000179406.6	LINC00174	5.58	4.1e-08	1.48e-05	0.53	0.25	Diabetic kidney disease;	chr7:66253864	chr7:66376044~66401338:-
HNSC	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.58	4.1e-08	1.48e-05	0.33	0.25	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
HNSC	cis	rs36093844	0.752	rs17744699	ENSG00000279742.1	RP11-700A24.1	-5.58	4.1e-08	1.48e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886120	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs17817343	ENSG00000279742.1	RP11-700A24.1	-5.58	4.1e-08	1.48e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887269	chr11:85852557~85854943:-
HNSC	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	5.58	4.1e-08	1.48e-05	0.27	0.25	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
HNSC	cis	rs6981523	0.517	rs13251510	ENSG00000269918.1	AF131215.9	-5.58	4.11e-08	1.48e-05	-0.25	-0.25	Neuroticism;	chr8:11059464	chr8:11104691~11106704:-
HNSC	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma;	chr2:102419319	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma;	chr2:102419875	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	5.58	4.11e-08	1.48e-05	0.24	0.25	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
HNSC	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	5.58	4.11e-08	1.48e-05	0.23	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	5.58	4.11e-08	1.48e-05	0.23	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
HNSC	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-5.58	4.11e-08	1.48e-05	-0.3	-0.25	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
HNSC	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-5.58	4.12e-08	1.49e-05	-0.27	-0.25	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
HNSC	cis	rs2268667	0.565	rs6657732	ENSG00000223653.4	RP11-131L23.1	-5.58	4.12e-08	1.49e-05	-0.32	-0.25	Asymmetrical dimethylarginine levels;	chr1:85408812	chr1:85276715~85448124:+
HNSC	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-5.58	4.12e-08	1.49e-05	-0.21	-0.25	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	5.58	4.12e-08	1.49e-05	0.23	0.25	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
HNSC	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-5.58	4.12e-08	1.49e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	5.58	4.12e-08	1.49e-05	0.2	0.25	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
HNSC	cis	rs783540	0.632	rs17356528	ENSG00000255769.6	GOLGA2P10	5.58	4.12e-08	1.49e-05	0.33	0.25	Schizophrenia;	chr15:82636799	chr15:82472993~82513950:-
HNSC	cis	rs2985684	0.947	rs1952013	ENSG00000258568.1	RHOQP1	5.58	4.13e-08	1.49e-05	0.26	0.25	Carotid intima media thickness;	chr14:49620639	chr14:49599994~49600572:+
HNSC	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	5.58	4.13e-08	1.49e-05	0.31	0.25	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
HNSC	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-5.58	4.13e-08	1.49e-05	-0.3	-0.25	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
HNSC	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-5.58	4.14e-08	1.49e-05	-0.26	-0.25	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
HNSC	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-5.58	4.14e-08	1.49e-05	-0.3	-0.25	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
HNSC	cis	rs889014	0.751	rs6891923	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552180	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs4868286	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552257	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs6892270	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552321	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.646	rs4867719	ENSG00000253768.1	CTB-33O18.1	5.58	4.14e-08	1.49e-05	0.27	0.25	Height;	chr5:173552491	chr5:173562478~173573199:+
HNSC	cis	rs6472866	0.622	rs10957727	ENSG00000254349.4	FLJ39080	5.58	4.14e-08	1.5e-05	0.28	0.25	Protein quantitative trait loci;	chr8:74585958	chr8:74599775~74823313:+
HNSC	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-5.58	4.15e-08	1.5e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
HNSC	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-5.58	4.15e-08	1.5e-05	-0.3	-0.25	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-5.58	4.15e-08	1.5e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
HNSC	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.58	4.16e-08	1.5e-05	-0.27	-0.25	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
HNSC	cis	rs9402743	0.634	rs6570018	ENSG00000217482.2	HMGB1P17	5.58	4.16e-08	1.5e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135602218	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs9494294	ENSG00000217482.2	HMGB1P17	5.58	4.16e-08	1.5e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135603460	chr6:135636086~135636713:-
HNSC	cis	rs9302065	0.565	rs2992910	ENSG00000223298.1	RNY3P8	5.58	4.16e-08	1.5e-05	0.26	0.25	Blood metabolite levels;	chr13:95309962	chr13:95310830~95310955:-
HNSC	cis	rs6951245	0.882	rs11764817	ENSG00000225146.1	AC073957.15	-5.58	4.16e-08	1.5e-05	-0.38	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1029025~1043891:+
HNSC	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-5.58	4.17e-08	1.5e-05	-0.29	-0.25	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
HNSC	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-5.58	4.17e-08	1.5e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	5.58	4.17e-08	1.51e-05	0.19	0.25	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
HNSC	cis	rs77204473	1	rs1135663	ENSG00000254851.1	RP11-109L13.1	5.58	4.17e-08	1.51e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116918121	chr11:117135528~117138582:+
HNSC	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-5.58	4.17e-08	1.51e-05	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
HNSC	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.18e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.18e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
HNSC	cis	rs6928977	0.896	rs2246943	ENSG00000231028.7	LINC00271	5.58	4.18e-08	1.51e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135497801~135716055:+
HNSC	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-5.58	4.18e-08	1.51e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
HNSC	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	5.58	4.18e-08	1.51e-05	0.64	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
HNSC	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	5.58	4.19e-08	1.51e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000206014.6	OR7E161P	-5.58	4.19e-08	1.51e-05	-0.27	-0.25	Neuroticism;	chr8:11939165	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000206014.6	OR7E161P	-5.58	4.19e-08	1.51e-05	-0.27	-0.25	Neuroticism;	chr8:11939166	chr8:11928597~11929563:-
HNSC	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	5.58	4.19e-08	1.51e-05	0.28	0.25	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
HNSC	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.58	4.19e-08	1.51e-05	0.54	0.25	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	5.58	4.19e-08	1.51e-05	0.31	0.25	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	5.58	4.19e-08	1.51e-05	0.31	0.25	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
HNSC	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-5.58	4.19e-08	1.51e-05	-0.32	-0.25	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
HNSC	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	5.57	4.19e-08	1.51e-05	0.35	0.25	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
HNSC	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	5.57	4.19e-08	1.51e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000233609.3	RP11-62H7.2	-5.57	4.2e-08	1.51e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9018719	chr8:8961200~8979025:+
HNSC	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.2e-08	1.51e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
HNSC	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-5.57	4.2e-08	1.52e-05	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-5.57	4.21e-08	1.52e-05	-0.36	-0.25	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
HNSC	cis	rs1355223	1	rs12792532	ENSG00000271369.1	RP11-350D17.3	-5.57	4.21e-08	1.52e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34744235	chr11:34709600~34710161:+
HNSC	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	5.57	4.21e-08	1.52e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
HNSC	cis	rs2985684	0.894	rs6572585	ENSG00000278009.1	RP11-649E7.8	5.57	4.21e-08	1.52e-05	0.33	0.25	Carotid intima media thickness;	chr14:49554357	chr14:49601011~49601124:-
HNSC	cis	rs9300255	0.51	rs1790086	ENSG00000280120.1	RP11-546D6.3	5.57	4.22e-08	1.52e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123187971	chr12:123152324~123153377:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	5.57	4.22e-08	1.52e-05	0.2	0.25	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
HNSC	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	5.57	4.23e-08	1.52e-05	0.29	0.25	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
HNSC	cis	rs1355223	1	rs1355223	ENSG00000271369.1	RP11-350D17.3	-5.57	4.23e-08	1.52e-05	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742932	chr11:34709600~34710161:+
HNSC	cis	rs7674212	0.539	rs6821617	ENSG00000246560.2	RP11-10L12.4	5.57	4.23e-08	1.52e-05	0.28	0.25	Type 2 diabetes;	chr4:103207253	chr4:102828055~102844075:+
HNSC	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	5.57	4.23e-08	1.52e-05	0.28	0.25	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
HNSC	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	5.57	4.23e-08	1.52e-05	0.28	0.25	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
HNSC	cis	rs526231	0.644	rs35797	ENSG00000175749.11	EIF3KP1	-5.57	4.23e-08	1.52e-05	-0.31	-0.25	Primary biliary cholangitis;	chr5:103278626	chr5:103032376~103033031:+
HNSC	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	5.57	4.23e-08	1.53e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
HNSC	cis	rs9611519	0.78	rs1535048	ENSG00000235513.1	RP4-756G23.5	5.57	4.24e-08	1.53e-05	0.27	0.25	Neuroticism;	chr22:41288089	chr22:41209122~41217627:-
HNSC	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	5.57	4.24e-08	1.53e-05	0.35	0.25	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
HNSC	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-5.57	4.24e-08	1.53e-05	-0.35	-0.25	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
HNSC	cis	rs6993244	1	rs6993244	ENSG00000254153.1	CTA-398F10.2	5.57	4.24e-08	1.53e-05	0.28	0.25	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8456909~8461337:-
HNSC	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-5.57	4.24e-08	1.53e-05	-0.35	-0.25	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
HNSC	cis	rs9302065	0.565	rs2993586	ENSG00000223298.1	RNY3P8	5.57	4.24e-08	1.53e-05	0.26	0.25	Blood metabolite levels;	chr13:95310324	chr13:95310830~95310955:-
HNSC	cis	rs673078	1	rs673078	ENSG00000275409.1	RP11-131L12.4	5.57	4.25e-08	1.53e-05	0.36	0.25	Glucose homeostasis traits;	chr12:118353636	chr12:118430147~118430699:+
HNSC	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	5.57	4.25e-08	1.53e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
HNSC	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	5.57	4.25e-08	1.53e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
HNSC	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-5.57	4.26e-08	1.53e-05	-0.35	-0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
HNSC	cis	rs7674212	0.541	rs11727498	ENSG00000246560.2	RP11-10L12.4	5.57	4.26e-08	1.53e-05	0.29	0.25	Type 2 diabetes;	chr4:103179830	chr4:102828055~102844075:+
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000223648.3	IGHV3-64	5.57	4.26e-08	1.53e-05	0.2	0.25	Kawasaki disease;	chr14:106711377	chr14:106643132~106658258:-
HNSC	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-5.57	4.26e-08	1.53e-05	-0.37	-0.25	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
HNSC	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	5.57	4.26e-08	1.53e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
HNSC	cis	rs3206736	0.548	rs329242	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35020055	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs329243	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35020104	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs7779894	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35021897	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs10243141	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35022954	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs57315957	ENSG00000197085.10	NPSR1-AS1	-5.57	4.27e-08	1.54e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35023207	chr7:34346512~34871582:-
HNSC	cis	rs4218	0.597	rs12438208	ENSG00000277144.1	RP11-59H7.4	-5.57	4.27e-08	1.54e-05	-0.33	-0.25	Social communication problems;	chr15:59057715	chr15:59115547~59116089:-
HNSC	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558258	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558259	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	5.57	4.27e-08	1.54e-05	0.31	0.25	Height;	chr4:55558261	chr4:55387949~55388271:+
HNSC	cis	rs5753618	0.583	rs5753631	ENSG00000236132.1	CTA-440B3.1	-5.57	4.28e-08	1.54e-05	-0.32	-0.25	Colorectal cancer;	chr22:31467036	chr22:31816379~31817491:-
HNSC	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.28e-08	1.54e-05	-0.31	-0.25	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
HNSC	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	5.57	4.28e-08	1.54e-05	0.3	0.25	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
HNSC	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	5.57	4.28e-08	1.54e-05	0.4	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.57	4.28e-08	1.54e-05	0.21	0.25	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
HNSC	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-5.57	4.29e-08	1.54e-05	-0.29	-0.25	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
HNSC	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	5.57	4.29e-08	1.54e-05	0.26	0.25	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
HNSC	cis	rs4657482	0.64	rs10918304	ENSG00000236364.3	RP11-525G13.2	5.57	4.29e-08	1.54e-05	0.25	0.25	Testicular germ cell tumor;	chr1:165895450	chr1:165890795~165900683:-
HNSC	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-5.57	4.29e-08	1.54e-05	-0.21	-0.25	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
HNSC	cis	rs9611519	1	rs5758264	ENSG00000235513.1	RP4-756G23.5	5.57	4.29e-08	1.55e-05	0.26	0.25	Neuroticism;	chr22:41220280	chr22:41209122~41217627:-
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-5.57	4.29e-08	1.55e-05	-0.16	-0.25	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
HNSC	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	5.57	4.3e-08	1.55e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
HNSC	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-5.57	4.3e-08	1.55e-05	-0.35	-0.25	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-5.57	4.3e-08	1.55e-05	-0.15	-0.25	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
HNSC	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-5.57	4.3e-08	1.55e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
HNSC	cis	rs6928977	0.896	rs2614257	ENSG00000234084.1	RP3-388E23.2	5.57	4.3e-08	1.55e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135301568~135307158:+
HNSC	cis	rs5753618	0.583	rs8138596	ENSG00000236132.1	CTA-440B3.1	-5.57	4.3e-08	1.55e-05	-0.31	-0.25	Colorectal cancer;	chr22:31390975	chr22:31816379~31817491:-
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	5.57	4.31e-08	1.55e-05	0.31	0.25	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
HNSC	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	5.57	4.31e-08	1.55e-05	0.32	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
HNSC	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	5.57	4.31e-08	1.55e-05	0.3	0.25	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-5.57	4.32e-08	1.55e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.57	4.32e-08	1.55e-05	0.27	0.25	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
HNSC	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-5.57	4.32e-08	1.55e-05	-0.24	-0.25	Asthma;	chr2:102374909	chr2:102438713~102440475:+
HNSC	cis	rs9402743	0.634	rs2327646	ENSG00000217482.2	HMGB1P17	5.57	4.32e-08	1.55e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135597186	chr6:135636086~135636713:-
HNSC	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	5.57	4.32e-08	1.55e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
HNSC	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	5.57	4.32e-08	1.55e-05	0.67	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
HNSC	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-5.57	4.32e-08	1.55e-05	-0.29	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
HNSC	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	5.57	4.33e-08	1.55e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
HNSC	cis	rs2579103	0.651	rs2731275	ENSG00000258183.4	RP11-753N8.1	5.57	4.33e-08	1.56e-05	0.35	0.25	Body mass index;	chr12:90249822	chr12:90280894~90300340:+
HNSC	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	5.57	4.34e-08	1.56e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
HNSC	cis	rs2115630	0.967	rs10438428	ENSG00000229212.6	RP11-561C5.4	5.57	4.34e-08	1.56e-05	0.29	0.25	P wave terminal force;	chr15:84787514	chr15:85205440~85234795:-
HNSC	cis	rs9611519	0.964	rs5995992	ENSG00000235513.1	RP4-756G23.5	5.57	4.34e-08	1.56e-05	0.28	0.25	Neuroticism;	chr22:41091214	chr22:41209122~41217627:-
HNSC	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	5.57	4.34e-08	1.56e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
HNSC	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	5.57	4.35e-08	1.56e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
HNSC	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	5.57	4.35e-08	1.56e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
HNSC	cis	rs9341808	0.935	rs1535825	ENSG00000272129.1	RP11-250B2.6	-5.57	4.35e-08	1.56e-05	-0.29	-0.25	Sitting height ratio;	chr6:80228869	chr6:80355424~80356859:+
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-5.57	4.35e-08	1.56e-05	-0.16	-0.25	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	5.57	4.35e-08	1.56e-05	0.22	0.25	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.57	4.36e-08	1.56e-05	0.27	0.25	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
HNSC	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-5.57	4.36e-08	1.57e-05	-0.33	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
HNSC	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.57	4.36e-08	1.57e-05	-0.24	-0.25	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
HNSC	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.36e-08	1.57e-05	-0.31	-0.25	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
HNSC	cis	rs988913	1	rs1503142	ENSG00000224984.1	RP11-524H19.2	5.57	4.37e-08	1.57e-05	0.28	0.25	Menarche (age at onset);	chr6:54954150	chr6:54840118~54840855:-
HNSC	cis	rs8032939	0.533	rs16967103	ENSG00000259747.1	RP11-275I4.2	-5.57	4.37e-08	1.57e-05	-0.31	-0.25	Rheumatoid arthritis;	chr15:38606989	chr15:38671847~38689191:+
HNSC	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-5.57	4.38e-08	1.57e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
HNSC	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-5.57	4.38e-08	1.57e-05	-0.3	-0.25	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
HNSC	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-5.57	4.38e-08	1.57e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
HNSC	cis	rs35306767	0.953	rs10904581	ENSG00000229869.1	RP11-363N22.2	-5.57	4.38e-08	1.57e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:918745	chr10:933026~942743:+
HNSC	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	5.57	4.39e-08	1.58e-05	0.3	0.25	Height;	chr4:55570311	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-5.57	4.39e-08	1.58e-05	-0.3	-0.25	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
HNSC	cis	rs6867032	0.527	rs13162781	ENSG00000249731.1	RP11-259O2.3	5.57	4.39e-08	1.58e-05	0.28	0.25	Gut microbiome composition (winter);	chr5:2012121	chr5:1968094~1969013:+
HNSC	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-5.57	4.39e-08	1.58e-05	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	5.57	4.4e-08	1.58e-05	0.31	0.25	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
HNSC	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-5.57	4.4e-08	1.58e-05	-0.24	-0.25	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
HNSC	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-5.57	4.4e-08	1.58e-05	-0.31	-0.25	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	5.57	4.4e-08	1.58e-05	0.31	0.25	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000254153.1	CTA-398F10.2	5.57	4.41e-08	1.58e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9003384	chr8:8456909~8461337:-
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5.57	4.41e-08	1.58e-05	0.27	0.25	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
HNSC	cis	rs7617773	0.963	rs12495221	ENSG00000228638.1	FCF1P2	5.57	4.41e-08	1.58e-05	0.23	0.25	Coronary artery disease;	chr3:48137688	chr3:48290793~48291375:-
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-5.57	4.42e-08	1.59e-05	-0.31	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
HNSC	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	5.56	4.43e-08	1.59e-05	0.24	0.25	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-5.56	4.43e-08	1.59e-05	-0.17	-0.25	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	5.56	4.43e-08	1.59e-05	0.28	0.25	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
HNSC	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	5.56	4.44e-08	1.59e-05	0.32	0.25	Height;	chr6:109403287	chr6:109382795~109383666:+
HNSC	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-5.56	4.44e-08	1.59e-05	-0.35	-0.25	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
HNSC	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	5.56	4.44e-08	1.59e-05	0.3	0.25	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs11488879	ENSG00000254174.1	IGHV1-12	5.56	4.44e-08	1.59e-05	0.21	0.25	Alzheimer's disease (late onset);	chr14:106786097	chr14:106122420~106122709:-
HNSC	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	5.56	4.44e-08	1.59e-05	0.36	0.25	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
HNSC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-5.56	4.45e-08	1.59e-05	-0.3	-0.25	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
HNSC	cis	rs6918586	0.557	rs198827	ENSG00000272462.2	U91328.19	-5.56	4.45e-08	1.6e-05	-0.23	-0.25	Schizophrenia;	chr6:26120774	chr6:25992662~26001775:+
HNSC	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
HNSC	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	5.56	4.45e-08	1.6e-05	0.33	0.25	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	5.56	4.45e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	5.56	4.45e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
HNSC	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	5.56	4.46e-08	1.6e-05	0.2	0.25	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
HNSC	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	5.56	4.46e-08	1.6e-05	0.29	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.56	4.46e-08	1.6e-05	0.27	0.25	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
HNSC	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.56	4.46e-08	1.6e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
HNSC	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-5.56	4.46e-08	1.6e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	5.56	4.47e-08	1.6e-05	0.2	0.25	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
HNSC	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-5.56	4.47e-08	1.6e-05	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	5.56	4.47e-08	1.6e-05	0.31	0.25	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
HNSC	cis	rs9611565	0.506	rs2024566	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41301334	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.506	rs2024567	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41303202	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.506	rs4822020	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41304199	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.732	rs1883826	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Neuroticism;	chr22:41307424	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.525	rs9611549	ENSG00000235513.1	RP4-756G23.5	5.56	4.47e-08	1.6e-05	0.27	0.25	Vitiligo;	chr22:41309905	chr22:41209122~41217627:-
HNSC	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.56	4.48e-08	1.6e-05	-0.22	-0.25	Height;	chr11:118764443	chr11:118791254~118793137:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000179406.6	LINC00174	-5.56	4.48e-08	1.6e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66136229	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.632	rs9485389	ENSG00000216906.2	RP11-350J20.9	-5.56	4.49e-08	1.61e-05	-0.37	-0.25	Dupuytren's disease;	chr6:149420078	chr6:149904243~149906418:+
HNSC	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-5.56	4.5e-08	1.61e-05	-0.25	-0.25	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
HNSC	cis	rs2834288	0.613	rs2040113	ENSG00000273102.1	AP000569.9	5.56	4.5e-08	1.61e-05	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33967101~33968573:-
HNSC	cis	rs3206736	0.548	rs6963995	ENSG00000197085.10	NPSR1-AS1	-5.56	4.5e-08	1.61e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35018737	chr7:34346512~34871582:-
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-5.56	4.5e-08	1.61e-05	-0.16	-0.25	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-5.56	4.5e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
HNSC	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	5.56	4.5e-08	1.61e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
HNSC	cis	rs1012068	0.624	rs4820997	ENSG00000236132.1	CTA-440B3.1	-5.56	4.5e-08	1.61e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31928154	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.56	4.5e-08	1.61e-05	-0.32	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
HNSC	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-5.56	4.5e-08	1.61e-05	-0.28	-0.25	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
HNSC	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	5.56	4.51e-08	1.61e-05	0.36	0.25	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
HNSC	cis	rs2115630	0.967	rs11073731	ENSG00000229212.6	RP11-561C5.4	5.56	4.52e-08	1.62e-05	0.29	0.25	P wave terminal force;	chr15:84811882	chr15:85205440~85234795:-
HNSC	cis	rs4218	0.638	rs8042516	ENSG00000277144.1	RP11-59H7.4	-5.56	4.52e-08	1.62e-05	-0.33	-0.25	Social communication problems;	chr15:59067525	chr15:59115547~59116089:-
HNSC	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-5.56	4.53e-08	1.62e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
HNSC	cis	rs13126694	0.744	rs7682867	ENSG00000248429.4	RP11-597D13.9	5.56	4.53e-08	1.62e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158170752~158202877:+
HNSC	cis	rs7819412	0.775	rs6601564	ENSG00000255310.2	AF131215.2	-5.56	4.53e-08	1.62e-05	-0.24	-0.25	Triglycerides;	chr8:11124541	chr8:11107788~11109726:-
HNSC	cis	rs11648785	0.526	rs4530137	ENSG00000222019.6	URAHP	5.56	4.54e-08	1.62e-05	0.23	0.25	Tanning;	chr16:90028093	chr16:90039761~90047773:-
HNSC	cis	rs2337406	0.587	rs2583291	ENSG00000211974.3	IGHV2-70	5.56	4.54e-08	1.62e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106649293	chr14:106723574~106724093:-
HNSC	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.56	4.54e-08	1.62e-05	-0.28	-0.25	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
HNSC	cis	rs4699052	1	rs7661702	ENSG00000246560.2	RP11-10L12.4	5.56	4.55e-08	1.63e-05	0.28	0.25	Testicular germ cell tumor;	chr4:103218972	chr4:102828055~102844075:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-5.56	4.55e-08	1.63e-05	-0.16	-0.25	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
HNSC	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	5.56	4.55e-08	1.63e-05	0.28	0.25	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
HNSC	cis	rs9291683	0.655	rs55941493	ENSG00000250413.1	RP11-448G15.1	5.56	4.56e-08	1.63e-05	0.31	0.25	Bone mineral density;	chr4:10098717	chr4:10006482~10009725:+
HNSC	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	5.56	4.56e-08	1.63e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	5.56	4.56e-08	1.63e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	5.56	4.56e-08	1.63e-05	0.31	0.25	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
HNSC	cis	rs9300255	0.602	rs1790116	ENSG00000280120.1	RP11-546D6.3	5.56	4.56e-08	1.63e-05	0.23	0.25	Neutrophil percentage of white cells;	chr12:123133997	chr12:123152324~123153377:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000254153.1	CTA-398F10.2	5.56	4.56e-08	1.63e-05	0.28	0.25	Mean corpuscular volume;	chr8:8994371	chr8:8456909~8461337:-
HNSC	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-5.56	4.57e-08	1.63e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000204709.4	LINC01556	5.56	4.57e-08	1.63e-05	0.34	0.25	Parkinson's disease;	chr6:28056708	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000204709.4	LINC01556	5.56	4.57e-08	1.63e-05	0.34	0.25	Parkinson's disease;	chr6:28056792	chr6:28943877~28944537:+
HNSC	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	5.56	4.57e-08	1.63e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
HNSC	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.56	4.58e-08	1.64e-05	-0.31	-0.25	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
HNSC	cis	rs2337406	0.866	rs4280141	ENSG00000211974.3	IGHV2-70	5.56	4.59e-08	1.64e-05	0.29	0.25	Alzheimer's disease (late onset);	chr14:106780476	chr14:106723574~106724093:-
HNSC	cis	rs7617773	0.963	rs9822496	ENSG00000228638.1	FCF1P2	-5.56	4.59e-08	1.64e-05	-0.23	-0.25	Coronary artery disease;	chr3:48139843	chr3:48290793~48291375:-
HNSC	cis	rs4218	0.541	rs8030323	ENSG00000259732.1	RP11-59H7.3	-5.56	4.59e-08	1.64e-05	-0.34	-0.25	Social communication problems;	chr15:59048048	chr15:59121034~59133250:+
HNSC	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
HNSC	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
HNSC	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-5.56	4.62e-08	1.65e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
HNSC	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	5.56	4.62e-08	1.65e-05	0.23	0.25	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
HNSC	cis	rs1355223	1	rs35365094	ENSG00000271369.1	RP11-350D17.3	-5.56	4.62e-08	1.65e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746243	chr11:34709600~34710161:+
HNSC	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	5.56	4.62e-08	1.65e-05	0.31	0.25	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
HNSC	cis	rs2033711	0.811	rs9304814	ENSG00000269473.1	CTD-2619J13.19	5.56	4.62e-08	1.65e-05	0.31	0.25	Uric acid clearance;	chr19:58440444	chr19:58440448~58445849:+
HNSC	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.56	4.63e-08	1.65e-05	-0.36	-0.25	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
HNSC	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.56	4.63e-08	1.65e-05	-0.24	-0.25	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
HNSC	cis	rs9402743	0.634	rs2327647	ENSG00000217482.2	HMGB1P17	-5.56	4.63e-08	1.65e-05	-0.27	-0.25	Systemic lupus erythematosus;	chr6:135597296	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	5.56	4.64e-08	1.65e-05	0.27	0.25	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
HNSC	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-5.56	4.65e-08	1.66e-05	-0.24	-0.25	Asthma;	chr2:102393077	chr2:102438713~102440475:+
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	5.56	4.65e-08	1.66e-05	0.61	0.25	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	5.56	4.65e-08	1.66e-05	0.61	0.25	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
HNSC	cis	rs5753618	0.583	rs2899164	ENSG00000236132.1	CTA-440B3.1	-5.56	4.65e-08	1.66e-05	-0.31	-0.25	Colorectal cancer;	chr22:31394303	chr22:31816379~31817491:-
HNSC	cis	rs8054556	1	rs11150580	ENSG00000183604.13	SMG1P5	-5.56	4.66e-08	1.66e-05	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30267553~30335374:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	5.56	4.67e-08	1.66e-05	0.2	0.25	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
HNSC	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-5.56	4.67e-08	1.67e-05	-0.27	-0.25	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
HNSC	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-5.56	4.67e-08	1.67e-05	-0.24	-0.25	Asthma;	chr2:102377873	chr2:102438713~102440475:+
HNSC	cis	rs1012068	0.92	rs5994443	ENSG00000236132.1	CTA-440B3.1	-5.55	4.67e-08	1.67e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31879367	chr22:31816379~31817491:-
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	5.55	4.67e-08	1.67e-05	0.61	0.25	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
HNSC	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	5.55	4.67e-08	1.67e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-5.55	4.68e-08	1.67e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	5.55	4.68e-08	1.67e-05	0.16	0.25	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
HNSC	cis	rs2115630	0.905	rs1975277	ENSG00000229212.6	RP11-561C5.4	5.55	4.69e-08	1.67e-05	0.29	0.25	P wave terminal force;	chr15:84786327	chr15:85205440~85234795:-
HNSC	cis	rs72807246	0.54	rs72807258	ENSG00000228701.1	TNKS2-AS1	5.55	4.69e-08	1.67e-05	0.46	0.25	Breast cancer;	chr10:92209153	chr10:91782839~91798291:-
HNSC	cis	rs9813712	0.953	rs896822	ENSG00000249846.5	RP11-77P16.4	-5.55	4.69e-08	1.67e-05	-0.3	-0.25	Response to amphetamines;	chr3:130259987	chr3:130112550~130120579:+
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	5.55	4.69e-08	1.67e-05	0.31	0.25	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
HNSC	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-5.55	4.7e-08	1.67e-05	-0.4	-0.25	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
HNSC	cis	rs4218	0.871	rs2414621	ENSG00000259732.1	RP11-59H7.3	-5.55	4.7e-08	1.68e-05	-0.32	-0.25	Social communication problems;	chr15:59142129	chr15:59121034~59133250:+
HNSC	cis	rs17428076	0.836	rs57718990	ENSG00000228389.1	AC068039.4	-5.55	4.7e-08	1.68e-05	-0.3	-0.25	Myopia;	chr2:171806104	chr2:171773482~171775844:+
HNSC	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	5.55	4.7e-08	1.68e-05	0.37	0.25	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
HNSC	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	5.55	4.7e-08	1.68e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
HNSC	cis	rs9341808	0.538	rs12176343	ENSG00000272129.1	RP11-250B2.6	-5.55	4.71e-08	1.68e-05	-0.3	-0.25	Sitting height ratio;	chr6:80317670	chr6:80355424~80356859:+
HNSC	cis	rs13126694	0.71	rs6847800	ENSG00000248429.4	RP11-597D13.9	5.55	4.71e-08	1.68e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158170752~158202877:+
HNSC	cis	rs9840812	0.728	rs12635723	ENSG00000273486.1	RP11-731C17.2	5.55	4.71e-08	1.68e-05	0.22	0.25	Fibrinogen levels;	chr3:136581890	chr3:136837338~136839021:-
HNSC	cis	rs1823913	0.614	rs1947457	ENSG00000227542.1	AC092614.2	5.55	4.71e-08	1.68e-05	0.49	0.25	Obesity-related traits;	chr2:191298970	chr2:191229165~191246172:-
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.55	4.71e-08	1.68e-05	-0.27	-0.25	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-5.55	4.72e-08	1.68e-05	-0.28	-0.25	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
HNSC	cis	rs2115630	1	rs55646601	ENSG00000229212.6	RP11-561C5.4	5.55	4.72e-08	1.68e-05	0.29	0.25	P wave terminal force;	chr15:84780337	chr15:85205440~85234795:-
HNSC	cis	rs3733585	0.762	rs6449217	ENSG00000250413.1	RP11-448G15.1	-5.55	4.72e-08	1.68e-05	-0.31	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10007527	chr4:10006482~10009725:+
HNSC	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	5.55	4.73e-08	1.69e-05	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	5.55	4.74e-08	1.69e-05	0.31	0.25	Depression;	chr6:28109824	chr6:28161781~28169594:+
HNSC	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-5.55	4.74e-08	1.69e-05	-0.29	-0.25	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000179406.6	LINC00174	5.55	4.74e-08	1.69e-05	0.54	0.25	Diabetic kidney disease;	chr7:66170692	chr7:66376044~66401338:-
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	5.55	4.74e-08	1.69e-05	0.27	0.25	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
HNSC	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
HNSC	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-5.55	4.74e-08	1.69e-05	-0.24	-0.25	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
HNSC	cis	rs7819412	0.749	rs11991118	ENSG00000255310.2	AF131215.2	5.55	4.75e-08	1.69e-05	0.24	0.25	Triglycerides;	chr8:11081763	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.55	4.75e-08	1.69e-05	-0.33	-0.25	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
HNSC	cis	rs9402743	0.634	rs9483853	ENSG00000217482.2	HMGB1P17	5.55	4.75e-08	1.69e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135595767	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs4394233	ENSG00000217482.2	HMGB1P17	5.55	4.75e-08	1.69e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135596752	chr6:135636086~135636713:-
HNSC	cis	rs9813712	1	rs57804141	ENSG00000249846.5	RP11-77P16.4	5.55	4.75e-08	1.69e-05	0.3	0.25	Response to amphetamines;	chr3:130243669	chr3:130112550~130120579:+
HNSC	cis	rs6928977	0.897	rs2246852	ENSG00000234084.1	RP3-388E23.2	5.55	4.75e-08	1.69e-05	0.26	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135301568~135307158:+
HNSC	cis	rs348196	0.672	rs670876	ENSG00000203761.5	MSTO2P	-5.55	4.76e-08	1.69e-05	-0.19	-0.25	Breast cancer;	chr1:155701887	chr1:155745829~155750137:+
HNSC	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.55	4.76e-08	1.7e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
HNSC	cis	rs2579103	0.898	rs1438993	ENSG00000258183.4	RP11-753N8.1	-5.55	4.77e-08	1.7e-05	-0.31	-0.25	Body mass index;	chr12:90203038	chr12:90280894~90300340:+
HNSC	cis	rs9813712	0.78	rs55929137	ENSG00000249846.5	RP11-77P16.4	5.55	4.77e-08	1.7e-05	0.3	0.25	Response to amphetamines;	chr3:130236002	chr3:130112550~130120579:+
HNSC	cis	rs7630852	0.841	rs9325377	ENSG00000272359.1	U4	-5.55	4.77e-08	1.7e-05	-0.27	-0.25	Eosinophil counts;	chr3:196779282	chr3:196747192~196747324:-
HNSC	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.55	4.78e-08	1.7e-05	-0.26	-0.25	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-5.55	4.78e-08	1.7e-05	-0.15	-0.25	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
HNSC	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	5.55	4.78e-08	1.7e-05	0.24	0.25	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
HNSC	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	5.55	4.78e-08	1.7e-05	0.27	0.25	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
HNSC	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	5.55	4.79e-08	1.7e-05	0.66	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
HNSC	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	5.55	4.79e-08	1.7e-05	0.35	0.25	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
HNSC	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-5.55	4.79e-08	1.7e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
HNSC	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.71e-05	-0.43	-0.25	Depression;	chr6:28173682	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.71e-05	-0.43	-0.25	Depression;	chr6:28175340	chr6:28115628~28116551:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-5.55	4.8e-08	1.71e-05	-0.34	-0.25	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-5.55	4.8e-08	1.71e-05	-0.3	-0.25	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
HNSC	cis	rs7160336	0.568	rs10146294	ENSG00000259065.1	RP5-1021I20.1	-5.55	4.81e-08	1.71e-05	-0.29	-0.25	Blood protein levels;	chr14:74214679	chr14:73787360~73803270:+
HNSC	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-5.55	4.81e-08	1.71e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
HNSC	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-5.55	4.81e-08	1.71e-05	-0.4	-0.25	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
HNSC	cis	rs9611565	0.506	rs1883825	ENSG00000235513.1	RP4-756G23.5	5.55	4.81e-08	1.71e-05	0.26	0.25	Vitiligo;	chr22:41307404	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.525	rs1883827	ENSG00000235513.1	RP4-756G23.5	5.55	4.81e-08	1.71e-05	0.26	0.25	Vitiligo;	chr22:41307575	chr22:41209122~41217627:-
HNSC	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	5.55	4.82e-08	1.71e-05	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
HNSC	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	5.55	4.82e-08	1.71e-05	0.36	0.25	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28111382	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28111650	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28112175	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28113851	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28114487	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28114933	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28115743	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Depression;	chr6:28116411	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-5.55	4.82e-08	1.71e-05	-0.31	-0.25	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
HNSC	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-5.55	4.82e-08	1.71e-05	-0.29	-0.25	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
HNSC	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	5.55	4.83e-08	1.71e-05	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
HNSC	cis	rs6604026	0.624	rs11164816	ENSG00000223787.2	RP4-593M8.1	5.55	4.83e-08	1.72e-05	0.35	0.25	Multiple sclerosis;	chr1:92795941	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11581705	ENSG00000223787.2	RP4-593M8.1	5.55	4.83e-08	1.72e-05	0.35	0.25	Multiple sclerosis;	chr1:92796459	chr1:92580476~92580821:-
HNSC	cis	rs12701220	0.744	rs2030958	ENSG00000229043.2	AC091729.9	-5.55	4.84e-08	1.72e-05	-0.37	-0.25	Bronchopulmonary dysplasia;	chr7:1036374	chr7:1160374~1165267:+
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-5.55	4.85e-08	1.72e-05	-0.29	-0.25	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
HNSC	cis	rs6604026	0.59	rs12743005	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92727181	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs35526187	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92732610	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11805698	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92737695	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs35241270	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92739957	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs12746893	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92745319	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11164803	ENSG00000223787.2	RP4-593M8.1	5.55	4.85e-08	1.72e-05	0.34	0.25	Multiple sclerosis;	chr1:92746363	chr1:92580476~92580821:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000179406.6	LINC00174	5.55	4.85e-08	1.72e-05	0.53	0.25	Diabetic kidney disease;	chr7:66219914	chr7:66376044~66401338:-
HNSC	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.55	4.86e-08	1.72e-05	-0.36	-0.25	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
HNSC	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	5.55	4.86e-08	1.73e-05	0.38	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	5.55	4.86e-08	1.73e-05	0.22	0.25	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
HNSC	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	5.55	4.87e-08	1.73e-05	0.28	0.25	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
HNSC	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-5.55	4.87e-08	1.73e-05	-0.29	-0.25	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
HNSC	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-5.55	4.87e-08	1.73e-05	-0.28	-0.25	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-5.55	4.87e-08	1.73e-05	-0.28	-0.25	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
HNSC	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-5.55	4.87e-08	1.73e-05	-0.34	-0.25	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-5.55	4.87e-08	1.73e-05	-0.36	-0.25	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
HNSC	cis	rs2985684	1	rs2147712	ENSG00000258568.1	RHOQP1	5.55	4.87e-08	1.73e-05	0.26	0.25	Carotid intima media thickness;	chr14:49624966	chr14:49599994~49600572:+
HNSC	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	5.55	4.87e-08	1.73e-05	0.24	0.25	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
HNSC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	5.55	4.88e-08	1.73e-05	0.31	0.25	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
HNSC	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-5.55	4.89e-08	1.74e-05	-0.34	-0.25	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
HNSC	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	5.55	4.89e-08	1.74e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
HNSC	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-5.55	4.89e-08	1.74e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
HNSC	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.55	4.89e-08	1.74e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
HNSC	cis	rs7621025	0.69	rs11715257	ENSG00000239213.4	NCK1-AS1	5.55	4.9e-08	1.74e-05	0.23	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.645	rs13068119	ENSG00000273486.1	RP11-731C17.2	-5.55	4.9e-08	1.74e-05	-0.23	-0.25	Fibrinogen levels;	chr3:136487527	chr3:136837338~136839021:-
HNSC	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	5.55	4.9e-08	1.74e-05	0.43	0.25	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.55	4.9e-08	1.74e-05	0.29	0.25	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	5.55	4.9e-08	1.74e-05	0.35	0.25	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-5.55	4.9e-08	1.74e-05	-0.36	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
HNSC	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-5.55	4.9e-08	1.74e-05	-0.24	-0.25	Asthma;	chr2:102392894	chr2:102438713~102440475:+
HNSC	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-5.55	4.9e-08	1.74e-05	-0.36	-0.25	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
HNSC	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	5.55	4.9e-08	1.74e-05	0.22	0.25	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
HNSC	cis	rs1355223	0.902	rs286861	ENSG00000271369.1	RP11-350D17.3	-5.55	4.91e-08	1.74e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34696877	chr11:34709600~34710161:+
HNSC	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-5.55	4.91e-08	1.74e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
HNSC	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-5.55	4.92e-08	1.74e-05	-0.29	-0.25	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
HNSC	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	5.55	4.92e-08	1.74e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	5.55	4.92e-08	1.74e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
HNSC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-5.55	4.92e-08	1.74e-05	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
HNSC	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	5.55	4.92e-08	1.74e-05	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
HNSC	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102418383	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102411180	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102411191	chr2:102438713~102440475:+
HNSC	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412435	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412461	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102412524	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102415109	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102415289	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	5.55	4.92e-08	1.74e-05	0.24	0.25	Asthma;	chr2:102417501	chr2:102438713~102440475:+
HNSC	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	5.55	4.92e-08	1.75e-05	0.3	0.25	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
HNSC	cis	rs4388249	0.687	rs10041575	ENSG00000271849.1	CTC-332L22.1	-5.55	4.92e-08	1.75e-05	-0.34	-0.25	Schizophrenia;	chr5:109768576	chr5:109687802~109688329:-
HNSC	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	5.54	4.93e-08	1.75e-05	0.3	0.25	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
HNSC	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-5.54	4.93e-08	1.75e-05	-0.28	-0.25	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
HNSC	cis	rs2115630	0.755	rs7169629	ENSG00000229212.6	RP11-561C5.4	-5.54	4.93e-08	1.75e-05	-0.28	-0.25	P wave terminal force;	chr15:84648043	chr15:85205440~85234795:-
HNSC	cis	rs4218	0.871	rs2414621	ENSG00000277144.1	RP11-59H7.4	-5.54	4.94e-08	1.75e-05	-0.3	-0.25	Social communication problems;	chr15:59142129	chr15:59115547~59116089:-
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	5.54	4.94e-08	1.75e-05	0.31	0.25	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
HNSC	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-5.54	4.94e-08	1.75e-05	-0.35	-0.25	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
HNSC	cis	rs9402743	0.597	rs9385729	ENSG00000217482.2	HMGB1P17	5.54	4.94e-08	1.75e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135600001	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-5.54	4.95e-08	1.75e-05	-0.17	-0.25	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000254153.1	CTA-398F10.2	5.54	4.95e-08	1.75e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:8995760	chr8:8456909~8461337:-
HNSC	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-5.54	4.95e-08	1.76e-05	-0.36	-0.25	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	5.54	4.95e-08	1.76e-05	0.25	0.25	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
HNSC	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.54	4.96e-08	1.76e-05	0.33	0.25	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
HNSC	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	5.54	4.96e-08	1.76e-05	0.25	0.25	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
HNSC	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.54	4.96e-08	1.76e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
HNSC	cis	rs8035957	0.522	rs56083426	ENSG00000259747.1	RP11-275I4.2	-5.54	4.97e-08	1.76e-05	-0.31	-0.25	Type 1 diabetes;	chr15:38606558	chr15:38671847~38689191:+
HNSC	cis	rs2483058	0.767	rs4127124	ENSG00000261000.1	RP11-534L20.5	5.54	4.97e-08	1.76e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206451019	chr1:206503948~206504456:+
HNSC	cis	rs11846409	0.629	rs76295389	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Rheumatic heart disease;	chr14:106650437	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.698	rs71419854	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Rheumatic heart disease;	chr14:106650440	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.5	rs71419855	ENSG00000211974.3	IGHV2-70	5.54	4.97e-08	1.76e-05	0.3	0.25	Alzheimer's disease (late onset);	chr14:106650444	chr14:106723574~106724093:-
HNSC	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.54	4.97e-08	1.76e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
HNSC	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	5.54	4.97e-08	1.76e-05	0.33	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
HNSC	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	5.54	4.97e-08	1.76e-05	0.33	0.25	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
HNSC	cis	rs11154801	0.732	rs13202115	ENSG00000217482.2	HMGB1P17	5.54	4.98e-08	1.76e-05	0.28	0.25	Multiple sclerosis;	chr6:135604386	chr6:135636086~135636713:-
HNSC	cis	rs67981189	0.519	rs2526879	ENSG00000274818.1	RP1-292L20.3	-5.54	4.98e-08	1.76e-05	-0.3	-0.25	Schizophrenia;	chr14:70910501	chr14:70906657~70907111:-
HNSC	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-5.54	4.99e-08	1.77e-05	-0.53	-0.25	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
HNSC	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-5.54	4.99e-08	1.77e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
HNSC	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-5.54	4.99e-08	1.77e-05	-0.36	-0.25	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
HNSC	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	5.54	4.99e-08	1.77e-05	0.29	0.25	Height;	chr4:55545574	chr4:55363971~55395847:-
HNSC	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.54	4.99e-08	1.77e-05	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
HNSC	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-5.54	4.99e-08	1.77e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
HNSC	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-5.54	5e-08	1.77e-05	-0.29	-0.25	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
HNSC	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	5.54	5e-08	1.77e-05	0.62	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
HNSC	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	5.54	5e-08	1.77e-05	0.24	0.25	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
HNSC	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	5.54	5e-08	1.77e-05	0.2	0.25	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
HNSC	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-5.54	5.01e-08	1.77e-05	-0.27	-0.25	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
HNSC	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	5.54	5.01e-08	1.77e-05	0.27	0.25	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
HNSC	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-5.54	5.03e-08	1.78e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-5.54	5.03e-08	1.78e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
HNSC	cis	rs6928977	0.86	rs2746438	ENSG00000234084.1	RP3-388E23.2	5.54	5.03e-08	1.78e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135301568~135307158:+
HNSC	cis	rs988913	0.958	rs9475078	ENSG00000224984.1	RP11-524H19.2	5.54	5.03e-08	1.78e-05	0.28	0.25	Menarche (age at onset);	chr6:54944791	chr6:54840118~54840855:-
HNSC	cis	rs2439831	0.681	rs2242067	ENSG00000205771.5	CATSPER2P1	-5.54	5.04e-08	1.78e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43407105	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-5.54	5.04e-08	1.78e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.54	5.05e-08	1.79e-05	0.25	0.25	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
HNSC	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-5.54	5.05e-08	1.79e-05	-0.32	-0.25	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
HNSC	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	5.54	5.05e-08	1.79e-05	0.27	0.25	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
HNSC	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.54	5.05e-08	1.79e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
HNSC	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.54	5.06e-08	1.79e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
HNSC	cis	rs3206736	0.548	rs328937	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35009519	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328940	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35010752	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs328942	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35012203	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs329233	ENSG00000197085.10	NPSR1-AS1	-5.54	5.06e-08	1.79e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35016219	chr7:34346512~34871582:-
HNSC	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	5.54	5.07e-08	1.79e-05	0.32	0.25	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
HNSC	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.54	5.07e-08	1.79e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	5.54	5.07e-08	1.79e-05	0.31	0.25	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
HNSC	cis	rs2179367	0.632	rs763590	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149398831	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs17506789	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149399710	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.586	rs34097428	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149399822	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498344	ENSG00000216906.2	RP11-350J20.9	5.54	5.07e-08	1.79e-05	0.37	0.25	Dupuytren's disease;	chr6:149401053	chr6:149904243~149906418:+
HNSC	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	5.54	5.08e-08	1.8e-05	0.25	0.25	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
HNSC	cis	rs34421088	0.576	rs2572437	ENSG00000255310.2	AF131215.2	-5.54	5.08e-08	1.8e-05	-0.26	-0.25	Neuroticism;	chr8:11240932	chr8:11107788~11109726:-
HNSC	cis	rs2524005	1	rs2524005	ENSG00000243753.4	HLA-L	-5.54	5.08e-08	1.8e-05	-0.36	-0.25	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30259584~30293014:+
HNSC	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	5.54	5.08e-08	1.8e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
HNSC	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.54	5.09e-08	1.8e-05	-0.35	-0.25	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
HNSC	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.54	5.09e-08	1.8e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-5.54	5.09e-08	1.8e-05	-0.26	-0.25	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
HNSC	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-5.54	5.09e-08	1.8e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	5.54	5.09e-08	1.8e-05	0.31	0.25	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
HNSC	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-5.54	5.09e-08	1.8e-05	-0.24	-0.25	Asthma;	chr2:102374328	chr2:102438713~102440475:+
HNSC	cis	rs34245511	1	rs34245511	ENSG00000272368.2	RP4-605O3.4	-5.54	5.1e-08	1.8e-05	-0.24	-0.25	Colorectal cancer;	chr12:50179650	chr12:50112197~50165618:+
HNSC	cis	rs7819412	0.936	rs7814499	ENSG00000269918.1	AF131215.9	-5.54	5.1e-08	1.8e-05	-0.25	-0.25	Triglycerides;	chr8:11183138	chr8:11104691~11106704:-
HNSC	cis	rs6604026	0.589	rs34250288	ENSG00000223787.2	RP4-593M8.1	5.54	5.12e-08	1.81e-05	0.35	0.25	Multiple sclerosis;	chr1:92792062	chr1:92580476~92580821:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000254340.1	RP11-10A14.3	5.54	5.12e-08	1.81e-05	0.3	0.25	Mood instability;	chr8:8804171	chr8:9141424~9145435:+
HNSC	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	5.54	5.12e-08	1.81e-05	0.34	0.25	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
HNSC	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-5.54	5.12e-08	1.81e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
HNSC	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	5.54	5.13e-08	1.81e-05	0.43	0.25	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
HNSC	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	5.54	5.13e-08	1.81e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
HNSC	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-5.54	5.13e-08	1.81e-05	-0.29	-0.25	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
HNSC	cis	rs1355223	0.902	rs286862	ENSG00000271369.1	RP11-350D17.3	5.54	5.13e-08	1.81e-05	0.28	0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697232	chr11:34709600~34710161:+
HNSC	cis	rs9300255	0.602	rs1727294	ENSG00000280120.1	RP11-546D6.3	5.54	5.13e-08	1.81e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123131967	chr12:123152324~123153377:-
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	5.54	5.13e-08	1.81e-05	0.61	0.25	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	5.54	5.13e-08	1.81e-05	0.3	0.25	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
HNSC	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-5.54	5.13e-08	1.81e-05	-0.31	-0.25	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
HNSC	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	5.54	5.14e-08	1.82e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	5.54	5.14e-08	1.82e-05	0.34	0.25	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
HNSC	cis	rs6928977	0.932	rs11154798	ENSG00000234084.1	RP3-388E23.2	-5.54	5.15e-08	1.82e-05	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr6:135301568~135307158:+
HNSC	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-5.54	5.15e-08	1.82e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
HNSC	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	5.54	5.15e-08	1.82e-05	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
HNSC	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.54	5.17e-08	1.83e-05	0.48	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	5.54	5.17e-08	1.83e-05	0.34	0.25	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
HNSC	cis	rs822354	1	rs822354	ENSG00000226652.2	PSMD10P2	5.54	5.18e-08	1.83e-05	0.28	0.25	Adiponectin levels;	chr3:186762417	chr3:186760693~186762050:+
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000233609.3	RP11-62H7.2	5.54	5.18e-08	1.83e-05	0.24	0.25	Joint mobility (Beighton score);	chr8:9003920	chr8:8961200~8979025:+
HNSC	cis	rs6604026	0.555	rs12743520	ENSG00000223787.2	RP4-593M8.1	5.54	5.19e-08	1.83e-05	0.35	0.25	Multiple sclerosis;	chr1:92571555	chr1:92580476~92580821:-
HNSC	cis	rs860295	0.812	rs2297775	ENSG00000203761.5	MSTO2P	5.54	5.19e-08	1.83e-05	0.19	0.25	Body mass index;	chr1:155765221	chr1:155745829~155750137:+
HNSC	cis	rs2179367	0.632	rs62426068	ENSG00000216906.2	RP11-350J20.9	5.54	5.19e-08	1.83e-05	0.36	0.25	Dupuytren's disease;	chr6:149325795	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs62426069	ENSG00000216906.2	RP11-350J20.9	5.54	5.19e-08	1.83e-05	0.36	0.25	Dupuytren's disease;	chr6:149325804	chr6:149904243~149906418:+
HNSC	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	5.54	5.19e-08	1.83e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
HNSC	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-5.53	5.2e-08	1.84e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
HNSC	cis	rs2483058	0.767	rs2336939	ENSG00000261000.1	RP11-534L20.5	5.53	5.21e-08	1.84e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206446827	chr1:206503948~206504456:+
HNSC	cis	rs8177876	0.749	rs12927239	ENSG00000261061.1	RP11-303E16.2	-5.53	5.21e-08	1.84e-05	-0.4	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81030770~81031485:+
HNSC	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-5.53	5.21e-08	1.84e-05	-0.32	-0.25	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
HNSC	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	5.53	5.22e-08	1.84e-05	0.33	0.25	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
HNSC	cis	rs889014	0.751	rs6891807	ENSG00000253768.1	CTB-33O18.1	5.53	5.23e-08	1.84e-05	0.27	0.25	Height;	chr5:173551858	chr5:173562478~173573199:+
HNSC	cis	rs889014	0.751	rs34151159	ENSG00000253768.1	CTB-33O18.1	5.53	5.23e-08	1.84e-05	0.27	0.25	Height;	chr5:173551868	chr5:173562478~173573199:+
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211972.2	IGHV3-66	5.53	5.23e-08	1.84e-05	0.19	0.25	Kawasaki disease;	chr14:106799309	chr14:106675017~106675544:-
HNSC	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-5.53	5.23e-08	1.85e-05	-0.31	-0.25	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
HNSC	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-5.53	5.23e-08	1.85e-05	-0.23	-0.25	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
HNSC	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-5.53	5.23e-08	1.85e-05	-0.23	-0.25	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-5.53	5.23e-08	1.85e-05	-0.3	-0.25	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
HNSC	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	5.53	5.23e-08	1.85e-05	0.3	0.25	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	5.53	5.24e-08	1.85e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
HNSC	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	5.53	5.24e-08	1.85e-05	0.27	0.25	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000254340.1	RP11-10A14.3	-5.53	5.24e-08	1.85e-05	-0.31	-0.25	Recombination measurement;	chr8:9213523	chr8:9141424~9145435:+
HNSC	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-5.53	5.24e-08	1.85e-05	-0.22	-0.25	Height;	chr11:118747911	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-5.53	5.25e-08	1.85e-05	-0.31	-0.25	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
HNSC	cis	rs7048146	0.531	rs34302146	ENSG00000213539.4	YBX1P6	5.53	5.25e-08	1.85e-05	0.33	0.25	Vascular brain injury;	chr9:109521469	chr9:109532830~109534332:-
HNSC	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-5.53	5.25e-08	1.85e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
HNSC	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-5.53	5.26e-08	1.85e-05	-0.4	-0.25	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
HNSC	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-5.53	5.26e-08	1.85e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
HNSC	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	5.53	5.26e-08	1.85e-05	0.34	0.25	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
HNSC	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	5.53	5.26e-08	1.86e-05	0.3	0.25	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
HNSC	cis	rs9525927	0.57	rs9533797	ENSG00000227258.4	SMIM2-AS1	5.53	5.26e-08	1.86e-05	0.33	0.25	Dupuytren's disease;	chr13:44225232	chr13:44110451~44240517:+
HNSC	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.53	5.26e-08	1.86e-05	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
HNSC	cis	rs60617249	0.507	rs10486745	ENSG00000228204.2	RP4-724E13.2	5.53	5.27e-08	1.86e-05	0.31	0.25	Major depression and alcohol dependence;	chr7:50914829	chr7:50866747~51022990:+
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	5.53	5.27e-08	1.86e-05	0.27	0.25	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
HNSC	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.53	5.28e-08	1.86e-05	0.35	0.25	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
HNSC	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	5.53	5.28e-08	1.86e-05	0.24	0.25	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
HNSC	cis	rs4978813	0.5	rs4978817	ENSG00000213539.4	YBX1P6	5.53	5.28e-08	1.86e-05	0.3	0.25	Plantar warts;	chr9:109509525	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.5	rs34590358	ENSG00000213539.4	YBX1P6	5.53	5.28e-08	1.86e-05	0.3	0.25	Plantar warts;	chr9:109510284	chr9:109532830~109534332:-
HNSC	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-5.53	5.28e-08	1.86e-05	-0.32	-0.25	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
HNSC	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-5.53	5.3e-08	1.87e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
HNSC	cis	rs860295	0.557	rs12091730	ENSG00000203761.5	MSTO2P	-5.53	5.3e-08	1.87e-05	-0.21	-0.25	Body mass index;	chr1:155587180	chr1:155745829~155750137:+
HNSC	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	5.53	5.3e-08	1.87e-05	0.26	0.25	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-5.53	5.3e-08	1.87e-05	-0.15	-0.25	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
HNSC	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	5.53	5.3e-08	1.87e-05	0.35	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
HNSC	cis	rs9402743	0.634	rs7765113	ENSG00000217482.2	HMGB1P17	5.53	5.3e-08	1.87e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135598935	chr6:135636086~135636713:-
HNSC	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	5.53	5.3e-08	1.87e-05	0.28	0.25	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
HNSC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	5.53	5.31e-08	1.87e-05	0.31	0.25	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
HNSC	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-5.53	5.31e-08	1.87e-05	-0.29	-0.25	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
HNSC	cis	rs6604026	0.778	rs11810111	ENSG00000223787.2	RP4-593M8.1	5.53	5.32e-08	1.87e-05	0.35	0.25	Multiple sclerosis;	chr1:92813212	chr1:92580476~92580821:-
HNSC	cis	rs1933112	0.5	rs7543171	ENSG00000227777.1	RP4-738P11.3	-5.53	5.32e-08	1.87e-05	-0.35	-0.25	Blood protein levels;	chr1:168535895	chr1:168542737~168543354:+
HNSC	cis	rs7000734	0.874	rs2599726	ENSG00000245080.5	RP11-320N21.1	-5.53	5.32e-08	1.88e-05	-0.35	-0.25	Radiation response;	chr8:95120544	chr8:95066808~95073182:-
HNSC	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.53	5.33e-08	1.88e-05	0.31	0.25	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
HNSC	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	5.53	5.33e-08	1.88e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	5.53	5.33e-08	1.88e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
HNSC	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-5.53	5.33e-08	1.88e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
HNSC	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-5.53	5.33e-08	1.88e-05	-0.34	-0.25	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
HNSC	cis	rs9402743	0.634	rs9494289	ENSG00000217482.2	HMGB1P17	5.53	5.33e-08	1.88e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135594751	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.863	rs7772681	ENSG00000234084.1	RP3-388E23.2	-5.53	5.33e-08	1.88e-05	-0.25	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135327875	chr6:135301568~135307158:+
HNSC	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	5.53	5.33e-08	1.88e-05	0.33	0.25	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
HNSC	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	5.53	5.35e-08	1.88e-05	0.27	0.25	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
HNSC	cis	rs9611519	0.964	rs2179744	ENSG00000235513.1	RP4-756G23.5	5.53	5.35e-08	1.88e-05	0.26	0.25	Neuroticism;	chr22:41225710	chr22:41209122~41217627:-
HNSC	cis	rs9611519	1	rs5758268	ENSG00000235513.1	RP4-756G23.5	5.53	5.35e-08	1.88e-05	0.26	0.25	Neuroticism;	chr22:41226415	chr22:41209122~41217627:-
HNSC	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	5.53	5.35e-08	1.88e-05	0.22	0.25	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
HNSC	cis	rs4657482	0.606	rs3790655	ENSG00000236364.3	RP11-525G13.2	5.53	5.36e-08	1.89e-05	0.25	0.25	Testicular germ cell tumor;	chr1:165893086	chr1:165890795~165900683:-
HNSC	cis	rs61542988	0.57	rs7781074	ENSG00000228649.7	AC005682.5	-5.53	5.36e-08	1.89e-05	-0.32	-0.25	Fibrinogen levels;	chr7:22786741	chr7:22854178~22861579:+
HNSC	cis	rs1021993	0.953	rs950890	ENSG00000231648.1	RP11-372M18.2	5.53	5.37e-08	1.89e-05	0.33	0.25	Gut microbiome composition (winter);	chr1:209309472	chr1:209367662~209379690:+
HNSC	cis	rs2834288	0.7	rs11088263	ENSG00000237945.6	LINC00649	-5.53	5.37e-08	1.89e-05	-0.32	-0.25	Gut microbiota (bacterial taxa);	chr21:33918486	chr21:33915534~33977691:+
HNSC	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	5.53	5.37e-08	1.89e-05	0.27	0.25	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
HNSC	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	5.53	5.38e-08	1.89e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
HNSC	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-5.53	5.38e-08	1.9e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
HNSC	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	5.53	5.38e-08	1.9e-05	0.27	0.25	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
HNSC	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-5.53	5.39e-08	1.9e-05	-0.3	-0.25	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
HNSC	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	5.53	5.39e-08	1.9e-05	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
HNSC	cis	rs10504130	0.569	rs11775587	ENSG00000272024.1	RP11-546K22.3	5.53	5.4e-08	1.9e-05	0.34	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51950284~51950690:+
HNSC	cis	rs783540	0.632	rs17356528	ENSG00000276710.3	CSPG4P8	5.53	5.4e-08	1.9e-05	0.29	0.25	Schizophrenia;	chr15:82636799	chr15:82459472~82477258:+
HNSC	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-5.53	5.4e-08	1.9e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-5.53	5.4e-08	1.9e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	5.53	5.41e-08	1.9e-05	0.31	0.25	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
HNSC	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-5.53	5.41e-08	1.91e-05	-0.39	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
HNSC	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	5.53	5.42e-08	1.91e-05	0.37	0.25	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
HNSC	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	5.53	5.43e-08	1.91e-05	0.3	0.25	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
HNSC	cis	rs783540	0.656	rs783524	ENSG00000276710.3	CSPG4P8	5.53	5.44e-08	1.91e-05	0.29	0.25	Schizophrenia;	chr15:82615393	chr15:82459472~82477258:+
HNSC	cis	rs783540	0.592	rs2567632	ENSG00000276710.3	CSPG4P8	5.53	5.44e-08	1.91e-05	0.29	0.25	Schizophrenia;	chr15:82616053	chr15:82459472~82477258:+
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	5.53	5.44e-08	1.91e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
HNSC	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000254340.1	RP11-10A14.3	5.53	5.44e-08	1.91e-05	0.3	0.25	Mood instability;	chr8:8410803	chr8:9141424~9145435:+
HNSC	cis	rs988913	0.957	rs2397177	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54969335	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9382404	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54970420	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7764641	ENSG00000224984.1	RP11-524H19.2	5.53	5.44e-08	1.91e-05	0.28	0.25	Menarche (age at onset);	chr6:54970671	chr6:54840118~54840855:-
HNSC	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-5.53	5.46e-08	1.92e-05	-0.35	-0.25	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
HNSC	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-5.53	5.46e-08	1.92e-05	-0.35	-0.25	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	5.53	5.46e-08	1.92e-05	0.3	0.25	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
HNSC	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-5.53	5.46e-08	1.92e-05	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
HNSC	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	5.53	5.47e-08	1.92e-05	0.35	0.25	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
HNSC	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	5.53	5.47e-08	1.92e-05	0.41	0.25	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	5.53	5.48e-08	1.93e-05	0.3	0.25	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	5.53	5.48e-08	1.93e-05	0.31	0.25	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
HNSC	cis	rs8031584	0.678	rs35098644	ENSG00000260382.1	RP11-540B6.2	5.52	5.49e-08	1.93e-05	0.31	0.25	Huntington's disease progression;	chr15:30853237	chr15:30882267~30883231:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000173295.6	FAM86B3P	-5.52	5.49e-08	1.93e-05	-0.29	-0.25	Recombination measurement;	chr8:9213523	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	5.52	5.5e-08	1.93e-05	0.3	0.25	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
HNSC	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-5.52	5.5e-08	1.93e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
HNSC	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	5.52	5.5e-08	1.93e-05	0.3	0.25	Height;	chr4:55501479	chr4:55387949~55388271:+
HNSC	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	5.52	5.5e-08	1.93e-05	0.55	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
HNSC	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	5.52	5.51e-08	1.94e-05	0.43	0.25	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
HNSC	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	5.52	5.51e-08	1.94e-05	0.35	0.25	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
HNSC	cis	rs7209700	0.788	rs12949936	ENSG00000228782.6	CTD-2026D20.3	-5.52	5.52e-08	1.94e-05	-0.26	-0.25	IgG glycosylation;	chr17:47295056	chr17:47450568~47492492:-
HNSC	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	5.52	5.52e-08	1.94e-05	0.63	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
HNSC	cis	rs11154801	0.589	rs6924066	ENSG00000217482.2	HMGB1P17	5.52	5.52e-08	1.94e-05	0.28	0.25	Multiple sclerosis;	chr6:135598006	chr6:135636086~135636713:-
HNSC	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.52	5.54e-08	1.95e-05	-0.31	-0.25	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
HNSC	cis	rs2243480	1	rs6460260	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65750468	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6460261	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65750593	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000179406.6	LINC00174	5.52	5.55e-08	1.95e-05	0.53	0.25	Diabetic kidney disease;	chr7:65751112	chr7:66376044~66401338:-
HNSC	cis	rs988913	1	rs9382408	ENSG00000224984.1	RP11-524H19.2	5.52	5.55e-08	1.95e-05	0.28	0.25	Menarche (age at onset);	chr6:54972186	chr6:54840118~54840855:-
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000206014.6	OR7E161P	-5.52	5.55e-08	1.95e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11928597~11929563:-
HNSC	cis	rs8054556	1	rs3935873	ENSG00000183604.13	SMG1P5	5.52	5.55e-08	1.95e-05	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:30267553~30335374:-
HNSC	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	5.52	5.56e-08	1.95e-05	0.25	0.25	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
HNSC	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	5.52	5.56e-08	1.95e-05	0.19	0.25	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
HNSC	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	5.52	5.57e-08	1.95e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	5.52	5.57e-08	1.95e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-5.52	5.57e-08	1.96e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
HNSC	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	5.52	5.57e-08	1.96e-05	0.23	0.25	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
HNSC	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5.52	5.58e-08	1.96e-05	-0.28	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
HNSC	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.52	5.58e-08	1.96e-05	0.3	0.25	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000233609.3	RP11-62H7.2	-5.52	5.58e-08	1.96e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9047352	chr8:8961200~8979025:+
HNSC	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.52	5.58e-08	1.96e-05	-0.33	-0.25	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
HNSC	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-5.52	5.59e-08	1.96e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
HNSC	cis	rs11648785	0.506	rs3743829	ENSG00000222019.6	URAHP	5.52	5.59e-08	1.96e-05	0.23	0.25	Tanning;	chr16:90027561	chr16:90039761~90047773:-
HNSC	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.52	5.6e-08	1.97e-05	-0.28	-0.25	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
HNSC	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	5.52	5.61e-08	1.97e-05	0.27	0.25	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
HNSC	cis	rs10435719	0.867	rs6999030	ENSG00000206014.6	OR7E161P	-5.52	5.61e-08	1.97e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11928597~11929563:-
HNSC	cis	rs10435719	0.834	rs6985792	ENSG00000206014.6	OR7E161P	-5.52	5.61e-08	1.97e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11928597~11929563:-
HNSC	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	5.52	5.61e-08	1.97e-05	0.33	0.25	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
HNSC	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	5.52	5.61e-08	1.97e-05	0.25	0.25	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
HNSC	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-5.52	5.61e-08	1.97e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000233609.3	RP11-62H7.2	-5.52	5.62e-08	1.97e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9047129	chr8:8961200~8979025:+
HNSC	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.62e-08	1.97e-05	-0.38	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.62e-08	1.97e-05	-0.38	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
HNSC	cis	rs947583	0.573	rs55789102	ENSG00000217482.2	HMGB1P17	5.52	5.63e-08	1.97e-05	0.27	0.25	Phosphorus levels;	chr6:135699954	chr6:135636086~135636713:-
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000254340.1	RP11-10A14.3	5.52	5.63e-08	1.97e-05	0.3	0.25	Joint mobility (Beighton score);	chr8:8970227	chr8:9141424~9145435:+
HNSC	cis	rs503425	0.546	rs540716	ENSG00000255422.1	AP002954.4	5.52	5.63e-08	1.97e-05	0.34	0.25	Systemic lupus erythematosus;	chr11:118814306	chr11:118704607~118750263:+
HNSC	cis	rs9650657	0.547	rs11250099	ENSG00000269918.1	AF131215.9	5.52	5.64e-08	1.98e-05	0.24	0.25	Neuroticism;	chr8:10961147	chr8:11104691~11106704:-
HNSC	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-5.52	5.64e-08	1.98e-05	-0.26	-0.25	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
HNSC	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-5.52	5.64e-08	1.98e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	5.52	5.65e-08	1.98e-05	0.28	0.25	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
HNSC	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	5.52	5.65e-08	1.98e-05	0.38	0.25	Height;	chr6:109369898	chr6:109382795~109383666:+
HNSC	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-5.52	5.65e-08	1.98e-05	-0.23	-0.25	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-5.52	5.66e-08	1.98e-05	-0.16	-0.25	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
HNSC	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.52	5.66e-08	1.98e-05	0.33	0.25	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
HNSC	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	5.52	5.66e-08	1.98e-05	0.25	0.25	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
HNSC	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-5.52	5.66e-08	1.98e-05	-0.33	-0.25	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
HNSC	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-5.52	5.66e-08	1.98e-05	-0.32	-0.25	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
HNSC	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	5.52	5.67e-08	1.99e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	5.52	5.67e-08	1.99e-05	0.3	0.25	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	5.52	5.67e-08	1.99e-05	0.3	0.25	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
HNSC	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	5.52	5.67e-08	1.99e-05	0.4	0.25	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
HNSC	cis	rs2243480	1	rs1499614	ENSG00000179406.6	LINC00174	-5.52	5.67e-08	1.99e-05	-0.53	-0.25	Diabetic kidney disease;	chr7:66265811	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	5.52	5.68e-08	1.99e-05	0.27	0.25	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	5.52	5.69e-08	2e-05	0.27	0.25	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
HNSC	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.52	5.7e-08	2e-05	-0.3	-0.25	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
HNSC	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-5.52	5.7e-08	2e-05	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
HNSC	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	5.52	5.7e-08	2e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
HNSC	cis	rs9291683	0.62	rs4444830	ENSG00000250413.1	RP11-448G15.1	5.52	5.7e-08	2e-05	0.32	0.25	Bone mineral density;	chr4:10123195	chr4:10006482~10009725:+
HNSC	cis	rs2243480	1	rs160652	ENSG00000179406.6	LINC00174	-5.52	5.7e-08	2e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66073444	chr7:66376044~66401338:-
HNSC	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-5.52	5.71e-08	2e-05	-0.28	-0.25	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
HNSC	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	5.52	5.71e-08	2e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
HNSC	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	5.52	5.71e-08	2e-05	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
HNSC	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	5.52	5.72e-08	2e-05	0.26	0.25	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
HNSC	cis	rs75920871	0.528	rs11216255	ENSG00000254851.1	RP11-109L13.1	5.52	5.72e-08	2e-05	0.34	0.25	Subjective well-being;	chr11:117059279	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	5.52	5.73e-08	2e-05	0.3	0.25	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
HNSC	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	5.52	5.73e-08	2.01e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
HNSC	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	5.52	5.73e-08	2.01e-05	0.37	0.25	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	5.52	5.73e-08	2.01e-05	0.37	0.25	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
HNSC	cis	rs5758511	0.689	rs45441993	ENSG00000226450.2	CYP2D8P	5.52	5.73e-08	2.01e-05	0.26	0.25	Birth weight;	chr22:42075734	chr22:42149886~42155001:-
HNSC	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	5.52	5.75e-08	2.01e-05	0.35	0.25	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
HNSC	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-5.52	5.75e-08	2.01e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000211974.3	IGHV2-70	5.52	5.76e-08	2.02e-05	0.28	0.25	Alzheimer's disease (late onset);	chr14:106649674	chr14:106723574~106724093:-
HNSC	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-5.52	5.76e-08	2.02e-05	-0.37	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
HNSC	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	5.52	5.76e-08	2.02e-05	0.3	0.25	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.624	rs111281067	ENSG00000223787.2	RP4-593M8.1	5.52	5.77e-08	2.02e-05	0.35	0.25	Multiple sclerosis;	chr1:92790096	chr1:92580476~92580821:-
HNSC	cis	rs67981189	0.519	rs2526853	ENSG00000274818.1	RP1-292L20.3	-5.52	5.77e-08	2.02e-05	-0.3	-0.25	Schizophrenia;	chr14:70949235	chr14:70906657~70907111:-
HNSC	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-5.52	5.77e-08	2.02e-05	-0.24	-0.25	Asthma;	chr2:102401592	chr2:102438713~102440475:+
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	-5.52	5.77e-08	2.02e-05	-0.27	-0.25	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
HNSC	cis	rs13126694	0.933	rs6830475	ENSG00000248429.4	RP11-597D13.9	5.52	5.78e-08	2.02e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158155527	chr4:158170752~158202877:+
HNSC	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	5.51	5.79e-08	2.02e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
HNSC	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-5.51	5.79e-08	2.03e-05	-0.3	-0.25	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
HNSC	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	5.51	5.8e-08	2.03e-05	0.27	0.25	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
HNSC	cis	rs9402743	0.671	rs6901733	ENSG00000217482.2	HMGB1P17	5.51	5.8e-08	2.03e-05	0.28	0.25	Systemic lupus erythematosus;	chr6:135619407	chr6:135636086~135636713:-
HNSC	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	5.51	5.8e-08	2.03e-05	0.3	0.25	Height;	chr4:55479339	chr4:55387949~55388271:+
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000206014.6	OR7E161P	-5.51	5.8e-08	2.03e-05	-0.27	-0.25	Neuroticism;	chr8:11942522	chr8:11928597~11929563:-
HNSC	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	5.51	5.81e-08	2.03e-05	0.3	0.25	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
HNSC	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-5.51	5.81e-08	2.03e-05	-0.33	-0.25	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000254153.1	CTA-398F10.2	5.51	5.81e-08	2.03e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9026395	chr8:8456909~8461337:-
HNSC	cis	rs2483058	0.739	rs3860302	ENSG00000261000.1	RP11-534L20.5	5.51	5.82e-08	2.04e-05	0.24	0.25	Cholesterol and Triglycerides;	chr1:206451299	chr1:206503948~206504456:+
HNSC	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	5.51	5.82e-08	2.04e-05	0.33	0.25	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
HNSC	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-5.51	5.83e-08	2.04e-05	-0.23	-0.25	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
HNSC	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-5.51	5.83e-08	2.04e-05	-0.29	-0.25	Height;	chr4:55526646	chr4:55363971~55395847:-
HNSC	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	5.51	5.84e-08	2.04e-05	0.26	0.25	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
HNSC	cis	rs2179367	0.632	rs66672129	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149334387	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498322	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149335950	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498323	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149336077	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12204793	ENSG00000216906.2	RP11-350J20.9	5.51	5.84e-08	2.04e-05	0.36	0.25	Dupuytren's disease;	chr6:149340102	chr6:149904243~149906418:+
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	5.51	5.85e-08	2.04e-05	0.19	0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
HNSC	cis	rs6604026	0.624	rs59864761	ENSG00000223787.2	RP4-593M8.1	5.51	5.85e-08	2.04e-05	0.35	0.25	Multiple sclerosis;	chr1:92791656	chr1:92580476~92580821:-
HNSC	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	5.51	5.85e-08	2.04e-05	0.25	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	5.51	5.85e-08	2.04e-05	0.6	0.25	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
HNSC	cis	rs2115630	0.875	rs8039472	ENSG00000229212.6	RP11-561C5.4	5.51	5.85e-08	2.05e-05	0.29	0.25	P wave terminal force;	chr15:84818413	chr15:85205440~85234795:-
HNSC	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.51	5.86e-08	2.05e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
HNSC	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	5.51	5.86e-08	2.05e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	5.51	5.86e-08	2.05e-05	0.28	0.25	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
HNSC	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-5.51	5.86e-08	2.05e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
HNSC	cis	rs35306767	0.953	rs35174953	ENSG00000229869.1	RP11-363N22.2	-5.51	5.86e-08	2.05e-05	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:915251	chr10:933026~942743:+
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-5.51	5.86e-08	2.05e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66108952	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313820	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66109479	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160639	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66115000	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313824	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66116220	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs186378	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66117071	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160637	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.52	-0.25	Diabetic kidney disease;	chr7:66119331	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000179406.6	LINC00174	-5.51	5.87e-08	2.05e-05	-0.54	-0.25	Diabetic kidney disease;	chr7:66055509	chr7:66376044~66401338:-
HNSC	cis	rs7000734	0.916	rs172469	ENSG00000245080.5	RP11-320N21.1	-5.51	5.88e-08	2.05e-05	-0.35	-0.25	Radiation response;	chr8:95120167	chr8:95066808~95073182:-
HNSC	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-5.51	5.89e-08	2.06e-05	-0.35	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
HNSC	cis	rs6604026	0.624	rs34761380	ENSG00000223787.2	RP4-593M8.1	5.51	5.89e-08	2.06e-05	0.34	0.25	Multiple sclerosis;	chr1:92731928	chr1:92580476~92580821:-
HNSC	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	5.51	5.9e-08	2.06e-05	0.32	0.25	Height;	chr6:109332622	chr6:109382795~109383666:+
HNSC	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-5.51	5.9e-08	2.06e-05	-0.22	-0.25	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
HNSC	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-5.51	5.9e-08	2.06e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
HNSC	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	5.51	5.91e-08	2.06e-05	0.3	0.25	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
HNSC	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	5.51	5.91e-08	2.06e-05	0.24	0.25	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
HNSC	cis	rs7160336	0.738	rs7145427	ENSG00000259065.1	RP5-1021I20.1	5.51	5.91e-08	2.06e-05	0.28	0.25	Blood protein levels;	chr14:74016745	chr14:73787360~73803270:+
HNSC	cis	rs9402743	0.634	rs6923032	ENSG00000217482.2	HMGB1P17	5.51	5.91e-08	2.06e-05	0.28	0.25	Systemic lupus erythematosus;	chr6:135597708	chr6:135636086~135636713:-
HNSC	cis	rs7777677	0.925	rs4726540	ENSG00000244273.1	PGBD4P1	-5.51	5.91e-08	2.07e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142722358~142722764:+
HNSC	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-5.51	5.92e-08	2.07e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
HNSC	cis	rs13126694	0.71	rs13137826	ENSG00000248429.4	RP11-597D13.9	5.51	5.92e-08	2.07e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158170752~158202877:+
HNSC	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	5.51	5.92e-08	2.07e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
HNSC	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-5.51	5.93e-08	2.07e-05	-0.21	-0.25	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
HNSC	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	5.51	5.93e-08	2.07e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	5.51	5.93e-08	2.07e-05	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
HNSC	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-5.51	5.93e-08	2.07e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
HNSC	cis	rs5758659	1	rs134882	ENSG00000227370.1	RP4-669P10.19	-5.51	5.94e-08	2.07e-05	-0.24	-0.25	Cognitive function;	chr22:42274959	chr22:42132543~42132998:+
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	5.51	5.94e-08	2.07e-05	0.3	0.25	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-5.51	5.94e-08	2.08e-05	-0.31	-0.25	Depression;	chr6:28113616	chr6:28161781~28169594:+
HNSC	cis	rs860295	0.871	rs34632540	ENSG00000203761.5	MSTO2P	5.51	5.94e-08	2.08e-05	0.18	0.25	Body mass index;	chr1:155642406	chr1:155745829~155750137:+
HNSC	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.51	5.95e-08	2.08e-05	-0.24	-0.25	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-5.51	5.95e-08	2.08e-05	-0.38	-0.25	Depression;	chr6:28235522	chr6:28115628~28116551:+
HNSC	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	5.51	5.95e-08	2.08e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs10278195	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35024847	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs17793874	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35025946	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs59505449	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35026240	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs73110554	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35026919	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs73110557	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35028445	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs17793929	ENSG00000197085.10	NPSR1-AS1	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35029368	chr7:34346512~34871582:-
HNSC	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-5.51	5.96e-08	2.08e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
HNSC	cis	rs330048	0.525	rs10112237	ENSG00000254340.1	RP11-10A14.3	-5.51	5.96e-08	2.08e-05	-0.31	-0.25	Systemic lupus erythematosus;	chr8:9215219	chr8:9141424~9145435:+
HNSC	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	5.51	5.96e-08	2.08e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	5.51	5.96e-08	2.08e-05	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
HNSC	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-5.51	5.97e-08	2.08e-05	-0.29	-0.25	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
HNSC	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-5.51	5.97e-08	2.08e-05	-0.34	-0.25	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
HNSC	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	5.51	5.97e-08	2.08e-05	0.27	0.25	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
HNSC	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-5.51	5.98e-08	2.09e-05	-0.24	-0.25	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
HNSC	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-5.51	5.98e-08	2.09e-05	-0.24	-0.25	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
HNSC	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.51	5.98e-08	2.09e-05	-0.27	-0.25	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
HNSC	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	5.51	5.98e-08	2.09e-05	0.29	0.25	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
HNSC	cis	rs7615952	0.558	rs7641353	ENSG00000248787.1	RP11-666A20.4	-5.51	5.98e-08	2.09e-05	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125621035	chr3:125908005~125910272:-
HNSC	cis	rs9840812	0.906	rs61791757	ENSG00000273486.1	RP11-731C17.2	-5.51	5.98e-08	2.09e-05	-0.23	-0.25	Fibrinogen levels;	chr3:136186483	chr3:136837338~136839021:-
HNSC	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	5.51	5.98e-08	2.09e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
HNSC	cis	rs17507216	1	rs17356118	ENSG00000276710.3	CSPG4P8	-5.51	5.99e-08	2.09e-05	-0.32	-0.25	Excessive daytime sleepiness;	chr15:82569149	chr15:82459472~82477258:+
HNSC	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	5.51	5.99e-08	2.09e-05	0.36	0.25	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
HNSC	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	5.51	5.99e-08	2.09e-05	0.35	0.25	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
HNSC	cis	rs5758511	0.508	rs2413667	ENSG00000226450.2	CYP2D8P	5.51	5.99e-08	2.09e-05	0.25	0.25	Birth weight;	chr22:42076233	chr22:42149886~42155001:-
HNSC	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-5.51	5.99e-08	2.09e-05	-0.28	-0.25	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
HNSC	cis	rs4141404	0.748	rs2232176	ENSG00000236132.1	CTA-440B3.1	5.51	6e-08	2.09e-05	0.3	0.25	Paclitaxel-induced neuropathy;	chr22:31140147	chr22:31816379~31817491:-
HNSC	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-5.51	6e-08	2.09e-05	-0.33	-0.25	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
HNSC	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-5.51	6e-08	2.09e-05	-0.33	-0.25	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
HNSC	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	5.51	6.01e-08	2.1e-05	0.26	0.25	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
HNSC	cis	rs35306767	0.953	rs12259801	ENSG00000229869.1	RP11-363N22.2	-5.51	6.02e-08	2.1e-05	-0.34	-0.25	Eosinophil percentage of granulocytes;	chr10:913366	chr10:933026~942743:+
HNSC	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-5.51	6.02e-08	2.1e-05	-0.33	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
HNSC	cis	rs9402743	0.717	rs6930773	ENSG00000217482.2	HMGB1P17	5.51	6.03e-08	2.1e-05	0.26	0.25	Systemic lupus erythematosus;	chr6:135694363	chr6:135636086~135636713:-
HNSC	cis	rs10256972	0.967	rs1881122	ENSG00000225146.1	AC073957.15	5.51	6.03e-08	2.1e-05	0.29	0.25	Endometriosis;Longevity;	chr7:1001310	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	5.51	6.03e-08	2.1e-05	0.31	0.25	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
HNSC	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-5.51	6.04e-08	2.11e-05	-0.33	-0.25	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
HNSC	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	5.51	6.04e-08	2.11e-05	0.35	0.25	Height;	chr6:109713188	chr6:109382795~109383666:+
HNSC	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	5.51	6.04e-08	2.11e-05	0.31	0.25	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
HNSC	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-5.51	6.05e-08	2.11e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
HNSC	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-5.51	6.06e-08	2.11e-05	-0.4	-0.25	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
HNSC	cis	rs9300255	0.602	rs1727316	ENSG00000280120.1	RP11-546D6.3	5.51	6.06e-08	2.11e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123134056	chr12:123152324~123153377:-
HNSC	cis	rs2179367	0.632	rs6920383	ENSG00000216906.2	RP11-350J20.9	5.51	6.06e-08	2.11e-05	0.36	0.25	Dupuytren's disease;	chr6:149356361	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs11155645	ENSG00000216906.2	RP11-350J20.9	5.51	6.06e-08	2.11e-05	0.36	0.25	Dupuytren's disease;	chr6:149360056	chr6:149904243~149906418:+
HNSC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-5.51	6.06e-08	2.11e-05	-0.2	-0.25	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-5.51	6.07e-08	2.12e-05	-0.2	-0.25	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-5.51	6.07e-08	2.12e-05	-0.2	-0.25	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-5.51	6.07e-08	2.12e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
HNSC	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	5.51	6.07e-08	2.12e-05	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
HNSC	cis	rs7674212	0.57	rs6813563	ENSG00000246560.2	RP11-10L12.4	5.51	6.08e-08	2.12e-05	0.28	0.25	Type 2 diabetes;	chr4:103177953	chr4:102828055~102844075:+
HNSC	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	5.51	6.08e-08	2.12e-05	0.23	0.25	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
HNSC	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-5.51	6.08e-08	2.12e-05	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
HNSC	cis	rs6693567	0.565	rs11205355	ENSG00000228126.1	FALEC	-5.51	6.08e-08	2.12e-05	-0.3	-0.25	Migraine;	chr1:150279918	chr1:150515757~150518032:+
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	5.51	6.09e-08	2.12e-05	0.31	0.25	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.5	6.1e-08	2.13e-05	0.26	0.25	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
HNSC	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	5.5	6.11e-08	2.13e-05	0.32	0.25	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	5.5	6.11e-08	2.13e-05	0.33	0.25	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
HNSC	cis	rs7160336	0.738	rs35579176	ENSG00000259065.1	RP5-1021I20.1	5.5	6.11e-08	2.13e-05	0.28	0.25	Blood protein levels;	chr14:74013601	chr14:73787360~73803270:+
HNSC	cis	rs7777677	0.925	rs4726542	ENSG00000244273.1	PGBD4P1	-5.5	6.11e-08	2.13e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142722358~142722764:+
HNSC	cis	rs67981189	0.529	rs2526868	ENSG00000274818.1	RP1-292L20.3	-5.5	6.12e-08	2.13e-05	-0.3	-0.25	Schizophrenia;	chr14:70923672	chr14:70906657~70907111:-
HNSC	cis	rs7829975	1	rs7829975	ENSG00000254153.1	CTA-398F10.2	-5.5	6.12e-08	2.13e-05	-0.28	-0.25	Mood instability;	chr8:8690607	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000254153.1	CTA-398F10.2	5.5	6.12e-08	2.13e-05	0.28	0.25	Joint mobility (Beighton score);	chr8:9014200	chr8:8456909~8461337:-
HNSC	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	5.5	6.12e-08	2.13e-05	0.23	0.25	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
HNSC	cis	rs10256972	0.9	rs7812072	ENSG00000225146.1	AC073957.15	5.5	6.13e-08	2.13e-05	0.29	0.25	Endometriosis;Longevity;	chr7:1014226	chr7:1029025~1043891:+
HNSC	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-5.5	6.13e-08	2.13e-05	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000204709.4	LINC01556	5.5	6.13e-08	2.13e-05	0.34	0.25	Parkinson's disease;	chr6:28047791	chr6:28943877~28944537:+
HNSC	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	5.5	6.14e-08	2.14e-05	0.27	0.25	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
HNSC	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.5	6.15e-08	2.14e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.5	6.15e-08	2.14e-05	-0.32	-0.25	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
HNSC	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-5.5	6.15e-08	2.14e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
HNSC	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-5.5	6.15e-08	2.14e-05	-0.26	-0.25	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
HNSC	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-5.5	6.16e-08	2.14e-05	-0.38	-0.25	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
HNSC	cis	rs35306767	0.953	rs10904583	ENSG00000229869.1	RP11-363N22.2	-5.5	6.16e-08	2.14e-05	-0.33	-0.25	Eosinophil percentage of granulocytes;	chr10:937558	chr10:933026~942743:+
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-5.5	6.16e-08	2.14e-05	-0.27	-0.25	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
HNSC	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	5.5	6.16e-08	2.14e-05	0.33	0.25	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
HNSC	cis	rs6928977	0.932	rs11154798	ENSG00000231028.7	LINC00271	-5.5	6.16e-08	2.15e-05	-0.28	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr6:135497801~135716055:+
HNSC	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-5.5	6.16e-08	2.15e-05	-0.29	-0.25	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
HNSC	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	5.5	6.16e-08	2.15e-05	0.26	0.25	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-5.5	6.17e-08	2.15e-05	-0.22	-0.25	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
HNSC	cis	rs1355223	0.768	rs11032806	ENSG00000271369.1	RP11-350D17.3	-5.5	6.17e-08	2.15e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670758	chr11:34709600~34710161:+
HNSC	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-5.5	6.17e-08	2.15e-05	-0.28	-0.25	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
HNSC	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	5.5	6.17e-08	2.15e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
HNSC	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-5.5	6.18e-08	2.15e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-5.5	6.18e-08	2.15e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-5.5	6.18e-08	2.15e-05	-0.22	-0.25	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
HNSC	cis	rs7048146	0.531	rs12554939	ENSG00000213539.4	YBX1P6	5.5	6.18e-08	2.15e-05	0.33	0.25	Vascular brain injury;	chr9:109529001	chr9:109532830~109534332:-
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	5.5	6.19e-08	2.15e-05	0.29	0.25	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-5.5	6.19e-08	2.15e-05	-0.29	-0.25	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
HNSC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	5.5	6.2e-08	2.16e-05	0.2	0.25	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	5.5	6.2e-08	2.16e-05	0.3	0.25	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	-5.5	6.2e-08	2.16e-05	-0.28	-0.25	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
HNSC	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
HNSC	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
HNSC	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.5	6.2e-08	2.16e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
HNSC	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	5.5	6.21e-08	2.16e-05	0.27	0.25	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
HNSC	cis	rs4218	0.734	rs12912071	ENSG00000259732.1	RP11-59H7.3	-5.5	6.21e-08	2.16e-05	-0.31	-0.25	Social communication problems;	chr15:59150951	chr15:59121034~59133250:+
HNSC	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-5.5	6.21e-08	2.16e-05	-0.3	-0.25	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-5.5	6.21e-08	2.16e-05	-0.22	-0.25	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
HNSC	cis	rs950776	0.695	rs8025188	ENSG00000261762.1	RP11-650L12.2	-5.5	6.22e-08	2.16e-05	-0.28	-0.25	Sudden cardiac arrest;	chr15:78619936	chr15:78589123~78591276:-
HNSC	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	5.5	6.23e-08	2.16e-05	0.27	0.25	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
HNSC	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.5	6.23e-08	2.16e-05	-0.23	-0.25	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
HNSC	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	5.5	6.23e-08	2.17e-05	0.18	0.25	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
HNSC	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-5.5	6.24e-08	2.17e-05	-0.4	-0.25	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
HNSC	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	5.5	6.24e-08	2.17e-05	0.26	0.25	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
HNSC	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	5.5	6.25e-08	2.17e-05	0.21	0.25	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
HNSC	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	5.5	6.25e-08	2.17e-05	0.26	0.25	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000254340.1	RP11-10A14.3	-5.5	6.25e-08	2.17e-05	-0.31	-0.25	Recombination measurement;	chr8:9202567	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.625	rs4900931	ENSG00000278009.1	RP11-649E7.8	5.5	6.25e-08	2.17e-05	0.32	0.25	Carotid intima media thickness;	chr14:49556075	chr14:49601011~49601124:-
HNSC	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-5.5	6.25e-08	2.17e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-5.5	6.25e-08	2.17e-05	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-5.5	6.26e-08	2.17e-05	-0.15	-0.25	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
HNSC	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	5.5	6.26e-08	2.17e-05	0.28	0.25	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
HNSC	cis	rs9311676	0.502	rs4681676	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Systemic lupus erythematosus;	chr3:58314070	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs6445969	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Red blood cell count;	chr3:58315609	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs4681677	ENSG00000273493.1	RP11-80H18.4	-5.5	6.26e-08	2.18e-05	-0.31	-0.25	Red blood cell count;	chr3:58316313	chr3:58329965~58330118:+
HNSC	cis	rs6928977	0.932	rs11154799	ENSG00000231028.7	LINC00271	5.5	6.26e-08	2.18e-05	0.29	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr6:135497801~135716055:+
HNSC	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	5.5	6.26e-08	2.18e-05	0.29	0.25	Height;	chr4:55451955	chr4:55363971~55395847:-
HNSC	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	5.5	6.27e-08	2.18e-05	0.21	0.25	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
HNSC	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	5.5	6.27e-08	2.18e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
HNSC	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-5.5	6.27e-08	2.18e-05	-0.43	-0.25	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
HNSC	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	5.5	6.28e-08	2.18e-05	0.31	0.25	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
HNSC	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-5.5	6.28e-08	2.18e-05	-0.31	-0.25	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
HNSC	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	5.5	6.28e-08	2.18e-05	0.25	0.25	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
HNSC	cis	rs17428076	0.793	rs3765167	ENSG00000228389.1	AC068039.4	-5.5	6.28e-08	2.18e-05	-0.3	-0.25	Myopia;	chr2:171837434	chr2:171773482~171775844:+
HNSC	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	5.5	6.3e-08	2.19e-05	0.28	0.25	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
HNSC	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	5.5	6.3e-08	2.19e-05	0.39	0.25	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.5	6.3e-08	2.19e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
HNSC	cis	rs804280	0.509	rs12719915	ENSG00000206014.6	OR7E161P	5.5	6.31e-08	2.19e-05	0.26	0.25	Myopia (pathological);	chr8:11928746	chr8:11928597~11929563:-
HNSC	cis	rs9840812	0.637	rs667920	ENSG00000239213.4	NCK1-AS1	5.5	6.31e-08	2.19e-05	0.23	0.25	Fibrinogen levels;	chr3:136350630	chr3:136841726~136862054:-
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	5.5	6.31e-08	2.19e-05	0.3	0.25	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	5.5	6.32e-08	2.19e-05	0.22	0.25	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
HNSC	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.5	6.33e-08	2.2e-05	0.49	0.25	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
HNSC	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.5	6.33e-08	2.2e-05	-0.36	-0.25	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
HNSC	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.5	6.33e-08	2.2e-05	0.28	0.25	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
HNSC	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-5.5	6.33e-08	2.2e-05	-0.29	-0.25	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
HNSC	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	5.5	6.34e-08	2.2e-05	0.3	0.25	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
HNSC	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	5.5	6.34e-08	2.2e-05	0.35	0.25	Height;	chr6:109708527	chr6:109382795~109383666:+
HNSC	cis	rs2243480	1	rs383402	ENSG00000179406.6	LINC00174	5.5	6.35e-08	2.2e-05	0.51	0.25	Diabetic kidney disease;	chr7:66121666	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.515	rs7630575	ENSG00000241288.6	RP11-379B18.5	-5.5	6.36e-08	2.21e-05	-0.32	-0.25	Blood pressure (smoking interaction);	chr3:125963487	chr3:125827238~125916384:-
HNSC	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	5.5	6.36e-08	2.21e-05	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935587	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935631	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000206014.6	OR7E161P	-5.5	6.36e-08	2.21e-05	-0.27	-0.25	Neuroticism;	chr8:11935669	chr8:11928597~11929563:-
HNSC	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	5.5	6.36e-08	2.21e-05	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
HNSC	cis	rs9840812	0.598	rs33999043	ENSG00000273486.1	RP11-731C17.2	5.5	6.36e-08	2.21e-05	0.25	0.25	Fibrinogen levels;	chr3:136381198	chr3:136837338~136839021:-
HNSC	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-5.5	6.37e-08	2.21e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
HNSC	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-5.5	6.37e-08	2.21e-05	-0.33	-0.25	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
HNSC	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-5.5	6.38e-08	2.21e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
HNSC	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-5.5	6.38e-08	2.21e-05	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
HNSC	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-5.5	6.38e-08	2.21e-05	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
HNSC	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	5.5	6.38e-08	2.21e-05	0.28	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	5.5	6.38e-08	2.21e-05	0.6	0.25	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	5.5	6.38e-08	2.21e-05	0.6	0.25	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000204709.4	LINC01556	5.5	6.38e-08	2.21e-05	0.34	0.25	Parkinson's disease;	chr6:28053997	chr6:28943877~28944537:+
HNSC	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.5	6.38e-08	2.21e-05	-0.27	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
HNSC	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-5.5	6.39e-08	2.22e-05	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
HNSC	cis	rs889014	0.679	rs4868287	ENSG00000253768.1	CTB-33O18.1	5.5	6.39e-08	2.22e-05	0.27	0.25	Height;	chr5:173552624	chr5:173562478~173573199:+
HNSC	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	5.5	6.39e-08	2.22e-05	0.29	0.25	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
HNSC	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	5.5	6.4e-08	2.22e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
HNSC	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	5.5	6.4e-08	2.22e-05	0.27	0.25	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	5.5	6.4e-08	2.22e-05	0.27	0.25	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs1186716	ENSG00000197085.10	NPSR1-AS1	-5.5	6.4e-08	2.22e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:34931073	chr7:34346512~34871582:-
HNSC	cis	rs10504130	0.66	rs6473666	ENSG00000253844.1	RP11-546K22.1	-5.5	6.4e-08	2.22e-05	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51961458~52022974:+
HNSC	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	5.5	6.41e-08	2.22e-05	0.33	0.25	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
HNSC	cis	rs2179367	0.632	rs11155640	ENSG00000216906.2	RP11-350J20.9	5.5	6.41e-08	2.22e-05	0.36	0.25	Dupuytren's disease;	chr6:149323648	chr6:149904243~149906418:+
HNSC	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.5	6.41e-08	2.22e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
HNSC	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	5.5	6.41e-08	2.22e-05	0.26	0.25	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
HNSC	cis	rs10463554	0.501	rs6860813	ENSG00000175749.11	EIF3KP1	5.5	6.41e-08	2.22e-05	0.31	0.25	Parkinson's disease;	chr5:103353125	chr5:103032376~103033031:+
HNSC	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-5.5	6.42e-08	2.23e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
HNSC	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.5	6.42e-08	2.23e-05	-0.27	-0.25	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
HNSC	cis	rs17428076	0.793	rs3765166	ENSG00000228389.1	AC068039.4	-5.5	6.42e-08	2.23e-05	-0.3	-0.25	Myopia;	chr2:171837270	chr2:171773482~171775844:+
HNSC	cis	rs5753618	0.561	rs5749265	ENSG00000236132.1	CTA-440B3.1	-5.5	6.43e-08	2.23e-05	-0.31	-0.25	Colorectal cancer;	chr22:31400911	chr22:31816379~31817491:-
HNSC	cis	rs11648785	0.735	rs12926012	ENSG00000222019.6	URAHP	5.5	6.43e-08	2.23e-05	0.26	0.25	Tanning;	chr16:90029595	chr16:90039761~90047773:-
HNSC	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	5.5	6.43e-08	2.23e-05	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	5.5	6.43e-08	2.23e-05	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
HNSC	cis	rs3930017	0.513	rs3930018	ENSG00000242435.1	UPK3BP1	5.49	6.45e-08	2.23e-05	0.29	0.25	Body mass index;	chr7:77091318	chr7:77004662~77005774:+
HNSC	cis	rs13126694	0.744	rs28635553	ENSG00000248429.4	RP11-597D13.9	5.49	6.45e-08	2.24e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158170752~158202877:+
HNSC	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-5.49	6.46e-08	2.24e-05	-0.32	-0.25	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-5.49	6.46e-08	2.24e-05	-0.32	-0.25	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	5.49	6.46e-08	2.24e-05	0.31	0.25	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
HNSC	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	5.49	6.47e-08	2.24e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000211974.3	IGHV2-70	-5.49	6.47e-08	2.24e-05	-0.27	-0.25	Alzheimer's disease (late onset);	chr14:106631885	chr14:106723574~106724093:-
HNSC	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.49	6.48e-08	2.24e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
HNSC	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-5.49	6.48e-08	2.24e-05	-0.33	-0.25	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
HNSC	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	5.49	6.48e-08	2.24e-05	0.27	0.25	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
HNSC	cis	rs11089937	0.895	rs5756985	ENSG00000211639.2	IGLV4-60	5.49	6.48e-08	2.25e-05	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22162199~22162681:+
HNSC	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-5.49	6.49e-08	2.25e-05	-0.35	-0.25	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
HNSC	cis	rs67981189	0.529	rs2526872	ENSG00000274818.1	RP1-292L20.3	-5.49	6.49e-08	2.25e-05	-0.3	-0.25	Schizophrenia;	chr14:70918168	chr14:70906657~70907111:-
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000206014.6	OR7E161P	-5.49	6.49e-08	2.25e-05	-0.27	-0.25	Neuroticism;	chr8:11935465	chr8:11928597~11929563:-
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000206014.6	OR7E161P	-5.49	6.49e-08	2.25e-05	-0.27	-0.25	Neuroticism;	chr8:11935469	chr8:11928597~11929563:-
HNSC	cis	rs1021993	1	rs1507341	ENSG00000231648.1	RP11-372M18.2	5.49	6.49e-08	2.25e-05	0.34	0.25	Gut microbiome composition (winter);	chr1:209299505	chr1:209367662~209379690:+
HNSC	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	5.49	6.49e-08	2.25e-05	0.31	0.25	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
HNSC	cis	rs9611519	0.78	rs9611542	ENSG00000235513.1	RP4-756G23.5	5.49	6.49e-08	2.25e-05	0.27	0.25	Neuroticism;	chr22:41281313	chr22:41209122~41217627:-
HNSC	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-5.49	6.5e-08	2.25e-05	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
HNSC	cis	rs1355223	0.867	rs7944030	ENSG00000271369.1	RP11-350D17.3	-5.49	6.51e-08	2.25e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670191	chr11:34709600~34710161:+
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-5.49	6.51e-08	2.25e-05	-0.17	-0.25	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-5.49	6.51e-08	2.25e-05	-0.17	-0.25	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
HNSC	cis	rs5753618	0.583	rs5749268	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31413166	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs34545960	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31416476	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs5749270	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.31	-0.25	Colorectal cancer;	chr22:31416867	chr22:31816379~31817491:-
HNSC	cis	rs1012068	0.581	rs5753817	ENSG00000236132.1	CTA-440B3.1	-5.49	6.51e-08	2.25e-05	-0.29	-0.25	Chronic hepatitis C infection;	chr22:31917741	chr22:31816379~31817491:-
HNSC	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-5.49	6.51e-08	2.26e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000254153.1	CTA-398F10.2	5.49	6.52e-08	2.26e-05	0.27	0.25	Neuroticism;	chr8:8237204	chr8:8456909~8461337:-
HNSC	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	5.49	6.52e-08	2.26e-05	0.26	0.25	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
HNSC	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	5.49	6.53e-08	2.26e-05	0.29	0.25	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	5.49	6.53e-08	2.26e-05	0.29	0.25	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
HNSC	cis	rs9813712	0.953	rs9871734	ENSG00000249846.5	RP11-77P16.4	5.49	6.53e-08	2.26e-05	0.28	0.25	Response to amphetamines;	chr3:130240756	chr3:130112550~130120579:+
HNSC	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	5.49	6.53e-08	2.26e-05	0.33	0.25	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
HNSC	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	5.49	6.54e-08	2.26e-05	0.32	0.25	Height;	chr4:55482360	chr4:55387949~55388271:+
HNSC	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	5.49	6.54e-08	2.26e-05	0.28	0.25	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
HNSC	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-5.49	6.55e-08	2.27e-05	-0.28	-0.25	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
HNSC	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	5.49	6.55e-08	2.27e-05	0.3	0.25	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
HNSC	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-5.49	6.55e-08	2.27e-05	-0.28	-0.25	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
HNSC	cis	rs2810114	0.916	rs2526851	ENSG00000274818.1	RP1-292L20.3	-5.49	6.56e-08	2.27e-05	-0.3	-0.25	Alcohol dependence;	chr14:70949563	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.529	rs2526850	ENSG00000274818.1	RP1-292L20.3	-5.49	6.56e-08	2.27e-05	-0.3	-0.25	Schizophrenia;	chr14:70950532	chr14:70906657~70907111:-
HNSC	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-5.49	6.56e-08	2.27e-05	-0.29	-0.25	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
HNSC	cis	rs1908814	0.51	rs57655799	ENSG00000206014.6	OR7E161P	-5.49	6.57e-08	2.27e-05	-0.26	-0.25	Neuroticism;	chr8:11924908	chr8:11928597~11929563:-
HNSC	cis	rs36093844	0.747	rs17817314	ENSG00000279742.1	RP11-700A24.1	-5.49	6.57e-08	2.27e-05	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883929	chr11:85852557~85854943:-
HNSC	cis	rs2579103	1	rs1438994	ENSG00000258183.4	RP11-753N8.1	-5.49	6.58e-08	2.28e-05	-0.33	-0.25	Body mass index;	chr12:90200612	chr12:90280894~90300340:+
HNSC	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	5.49	6.58e-08	2.28e-05	0.42	0.25	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
HNSC	cis	rs2834288	0.5	rs2051189	ENSG00000273102.1	AP000569.9	5.49	6.59e-08	2.28e-05	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33967101~33968573:-
HNSC	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-5.49	6.59e-08	2.28e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-5.49	6.59e-08	2.28e-05	-0.32	-0.25	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
HNSC	cis	rs9525927	0.625	rs9567395	ENSG00000227258.4	SMIM2-AS1	5.49	6.6e-08	2.28e-05	0.38	0.25	Dupuytren's disease;	chr13:44249337	chr13:44110451~44240517:+
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
HNSC	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	5.49	6.6e-08	2.28e-05	0.6	0.25	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
HNSC	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	5.49	6.6e-08	2.28e-05	0.2	0.25	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
HNSC	cis	rs9402743	0.632	rs9389329	ENSG00000217482.2	HMGB1P17	-5.49	6.61e-08	2.28e-05	-0.26	-0.25	Systemic lupus erythematosus;	chr6:135777966	chr6:135636086~135636713:-
HNSC	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-5.49	6.62e-08	2.29e-05	-0.31	-0.25	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
HNSC	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-5.49	6.62e-08	2.29e-05	-0.24	-0.25	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
HNSC	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	5.49	6.62e-08	2.29e-05	0.32	0.25	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
HNSC	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	5.49	6.63e-08	2.29e-05	0.37	0.25	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
HNSC	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-5.49	6.63e-08	2.29e-05	-0.29	-0.25	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
HNSC	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-5.49	6.63e-08	2.29e-05	-0.35	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
HNSC	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-5.49	6.63e-08	2.29e-05	-0.4	-0.25	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
HNSC	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	5.49	6.63e-08	2.29e-05	0.35	0.25	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
HNSC	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.49	6.64e-08	2.3e-05	0.36	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
HNSC	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	5.49	6.65e-08	2.3e-05	0.23	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
HNSC	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	5.49	6.66e-08	2.3e-05	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
HNSC	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-5.49	6.67e-08	2.3e-05	-0.31	-0.25	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
HNSC	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	5.49	6.67e-08	2.31e-05	0.24	0.25	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
HNSC	cis	rs11976020	1	rs11976020	ENSG00000225648.4	SBDSP1	-5.49	6.67e-08	2.31e-05	-0.29	-0.25	Educational attainment (years of education);	chr7:72782785	chr7:72829425~72836701:+
HNSC	cis	rs2243480	1	rs160646	ENSG00000179406.6	LINC00174	-5.49	6.67e-08	2.31e-05	-0.51	-0.25	Diabetic kidney disease;	chr7:66091293	chr7:66376044~66401338:-
HNSC	cis	rs13073817	0.563	rs949606	ENSG00000228956.7	SATB1-AS1	5.49	6.67e-08	2.31e-05	0.26	0.25	Crohn's disease;	chr3:18628685	chr3:18445024~18920401:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2420170	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6958289	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7804223	ENSG00000179406.6	LINC00174	5.49	6.68e-08	2.31e-05	0.52	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66376044~66401338:-
HNSC	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-5.49	6.68e-08	2.31e-05	-0.4	-0.25	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
HNSC	cis	rs9914544	1	rs1634409	ENSG00000264885.1	RP11-815I9.4	-5.49	6.69e-08	2.31e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18932864	chr17:18667629~18669461:-
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-5.49	6.69e-08	2.31e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
HNSC	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-5.49	6.7e-08	2.31e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-5.49	6.7e-08	2.31e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
HNSC	cis	rs4968361	0.892	rs67028302	ENSG00000266992.1	DHX40P1	5.49	6.7e-08	2.31e-05	0.44	0.25	Schizophrenia;	chr17:59443342	chr17:59976009~60002384:-
HNSC	cis	rs860295	0.756	rs7546258	ENSG00000203761.5	MSTO2P	-5.49	6.7e-08	2.31e-05	-0.19	-0.25	Body mass index;	chr1:155728854	chr1:155745829~155750137:+
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000233609.3	RP11-62H7.2	-5.49	6.7e-08	2.31e-05	-0.24	-0.25	Joint mobility (Beighton score);	chr8:8935272	chr8:8961200~8979025:+
HNSC	cis	rs2834288	0.734	rs9984514	ENSG00000237945.6	LINC00649	5.49	6.7e-08	2.31e-05	0.31	0.25	Gut microbiota (bacterial taxa);	chr21:33892370	chr21:33915534~33977691:+
HNSC	cis	rs7819412	1	rs7819412	ENSG00000269918.1	AF131215.9	5.49	6.71e-08	2.32e-05	0.24	0.25	Triglycerides;	chr8:11187652	chr8:11104691~11106704:-
HNSC	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-5.49	6.71e-08	2.32e-05	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
HNSC	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	5.49	6.71e-08	2.32e-05	0.29	0.25	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
HNSC	cis	rs71520386	0.607	rs4308627	ENSG00000221740.1	SNORD93	-5.49	6.71e-08	2.32e-05	-0.29	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22856613~22856686:+
HNSC	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-5.49	6.71e-08	2.32e-05	-0.24	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
HNSC	cis	rs13126694	0.649	rs4615226	ENSG00000248429.4	RP11-597D13.9	5.49	6.72e-08	2.32e-05	0.27	0.25	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158170752~158202877:+
HNSC	cis	rs5758659	0.935	rs134879	ENSG00000227370.1	RP4-669P10.19	-5.49	6.74e-08	2.33e-05	-0.24	-0.25	Cognitive function;	chr22:42268195	chr22:42132543~42132998:+
HNSC	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	5.49	6.74e-08	2.33e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
HNSC	cis	rs9329221	0.617	rs615632	ENSG00000254340.1	RP11-10A14.3	-5.49	6.74e-08	2.33e-05	-0.29	-0.25	Neuroticism;	chr8:9938811	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	5.49	6.74e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
HNSC	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-5.49	6.74e-08	2.33e-05	-0.24	-0.25	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
HNSC	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-5.49	6.74e-08	2.33e-05	-0.31	-0.25	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	5.49	6.75e-08	2.33e-05	0.6	0.25	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
HNSC	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	5.49	6.76e-08	2.33e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
HNSC	cis	rs61160187	0.582	rs4700407	ENSG00000215032.2	GNL3LP1	-5.49	6.76e-08	2.33e-05	-0.27	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60891935~60893577:-
HNSC	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-5.49	6.76e-08	2.33e-05	-0.21	-0.25	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
HNSC	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	5.49	6.76e-08	2.33e-05	0.33	0.25	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.923	rs9322225	ENSG00000223701.3	RAET1E-AS1	5.49	6.77e-08	2.33e-05	0.27	0.25	Lung cancer;	chr6:149863746	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	5.49	6.77e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	5.49	6.77e-08	2.33e-05	0.31	0.25	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
HNSC	cis	rs10027350	0.964	rs2302565	ENSG00000281501.1	SEPSECS-AS1	5.49	6.77e-08	2.34e-05	0.31	0.25	Childhood ear infection;	chr4:25144685	chr4:25160641~25201440:+
HNSC	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-5.49	6.77e-08	2.34e-05	-0.27	-0.25	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
HNSC	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-5.49	6.77e-08	2.34e-05	-0.31	-0.25	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000248787.1	RP11-666A20.4	-5.49	6.77e-08	2.34e-05	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125987203	chr3:125908005~125910272:-
HNSC	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46629946	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46630262	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-5.49	6.77e-08	2.34e-05	-0.26	-0.25	Height;	chr2:46631182	chr2:46668870~46670778:+
HNSC	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-5.49	6.78e-08	2.34e-05	-0.39	-0.25	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
HNSC	cis	rs7777677	0.925	rs6969951	ENSG00000244273.1	PGBD4P1	5.49	6.78e-08	2.34e-05	0.26	0.25	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142722358~142722764:+
HNSC	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	5.49	6.79e-08	2.34e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	5.48	6.79e-08	2.34e-05	0.31	0.25	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
HNSC	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	5.48	6.79e-08	2.34e-05	0.25	0.25	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	5.48	6.79e-08	2.34e-05	0.25	0.25	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	5.48	6.8e-08	2.35e-05	0.22	0.25	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
HNSC	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-5.48	6.81e-08	2.35e-05	-0.29	-0.25	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
HNSC	cis	rs10028773	0.632	rs34481394	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327219	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.666	rs35231872	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327221	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.7	rs35653026	ENSG00000249244.1	RP11-548H18.2	5.48	6.81e-08	2.35e-05	0.31	0.25	Educational attainment;	chr4:119327223	chr4:119391831~119395335:-
HNSC	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	5.48	6.82e-08	2.35e-05	0.33	0.25	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-5.48	6.82e-08	2.35e-05	-0.26	-0.25	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
HNSC	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	5.48	6.82e-08	2.35e-05	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
HNSC	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	5.48	6.83e-08	2.35e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
HNSC	cis	rs7824557	0.524	rs7835318	ENSG00000255310.2	AF131215.2	-5.48	6.83e-08	2.35e-05	-0.23	-0.25	Retinal vascular caliber;	chr8:11096364	chr8:11107788~11109726:-
HNSC	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	5.48	6.84e-08	2.36e-05	0.18	0.25	Breast size;	chr12:9232939	chr12:9277235~9313241:+
HNSC	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	6.84e-08	2.36e-05	-0.27	-0.25	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
HNSC	cis	rs9611519	0.78	rs9611546	ENSG00000235513.1	RP4-756G23.5	5.48	6.85e-08	2.36e-05	0.27	0.25	Neuroticism;	chr22:41302538	chr22:41209122~41217627:-
HNSC	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	5.48	6.85e-08	2.36e-05	0.37	0.25	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
HNSC	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-5.48	6.86e-08	2.36e-05	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
HNSC	cis	rs7824557	0.505	rs2736313	ENSG00000255310.2	AF131215.2	5.48	6.86e-08	2.36e-05	0.24	0.25	Retinal vascular caliber;	chr8:11229433	chr8:11107788~11109726:-
HNSC	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	5.48	6.86e-08	2.36e-05	0.26	0.25	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
HNSC	cis	rs11969893	0.85	rs9485417	ENSG00000270987.1	RP3-467N11.2	-5.48	6.87e-08	2.37e-05	-0.62	-0.25	Economic and political preferences (immigration/crime);	chr6:100852162	chr6:100889603~100890338:+
HNSC	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	5.48	6.87e-08	2.37e-05	0.23	0.25	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
HNSC	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	5.48	6.87e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	5.48	6.87e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
HNSC	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	5.48	6.87e-08	2.37e-05	0.38	0.25	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
HNSC	cis	rs11992162	0.933	rs10108075	ENSG00000206014.6	OR7E161P	-5.48	6.88e-08	2.37e-05	-0.27	-0.25	Monocyte count;	chr8:11974570	chr8:11928597~11929563:-
HNSC	cis	rs9611519	1	rs2273085	ENSG00000235513.1	RP4-756G23.5	5.48	6.88e-08	2.37e-05	0.26	0.25	Neuroticism;	chr22:41219372	chr22:41209122~41217627:-
HNSC	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	5.48	6.89e-08	2.37e-05	0.29	0.25	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
HNSC	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-5.48	6.89e-08	2.37e-05	-0.22	-0.25	Height;	chr11:118773873	chr11:118791254~118793137:+
HNSC	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	5.48	6.89e-08	2.37e-05	0.28	0.25	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
HNSC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.48	6.89e-08	2.37e-05	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.48	6.89e-08	2.37e-05	0.3	0.25	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000173295.6	FAM86B3P	-5.48	6.89e-08	2.37e-05	-0.29	-0.25	Recombination measurement;	chr8:9212778	chr8:8228595~8244865:+
HNSC	cis	rs2179367	0.632	rs56924465	ENSG00000216906.2	RP11-350J20.9	5.48	6.89e-08	2.37e-05	0.36	0.25	Dupuytren's disease;	chr6:149350270	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.568	rs62426092	ENSG00000216906.2	RP11-350J20.9	5.48	6.89e-08	2.37e-05	0.36	0.25	Dupuytren's disease;	chr6:149352720	chr6:149904243~149906418:+
HNSC	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.48	6.9e-08	2.38e-05	-0.26	-0.25	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
HNSC	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	5.48	6.91e-08	2.38e-05	0.31	0.25	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
HNSC	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-5.48	6.91e-08	2.38e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
HNSC	cis	rs9650657	0.529	rs10108618	ENSG00000269918.1	AF131215.9	-5.48	6.91e-08	2.38e-05	-0.24	-0.25	Neuroticism;	chr8:11095582	chr8:11104691~11106704:-
HNSC	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	5.48	6.92e-08	2.38e-05	0.26	0.25	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
HNSC	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-5.48	6.92e-08	2.38e-05	-0.32	-0.25	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
HNSC	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	5.48	6.92e-08	2.38e-05	0.21	0.25	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
HNSC	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	5.48	6.92e-08	2.38e-05	0.28	0.25	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
HNSC	cis	rs947583	0.71	rs6570045	ENSG00000217482.2	HMGB1P17	5.48	6.94e-08	2.39e-05	0.27	0.25	Phosphorus levels;	chr6:135815734	chr6:135636086~135636713:-
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28052201	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28053036	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000204709.4	LINC01556	5.48	6.94e-08	2.39e-05	0.34	0.25	Parkinson's disease;	chr6:28053042	chr6:28943877~28944537:+
HNSC	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	6.94e-08	2.39e-05	-0.27	-0.25	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
HNSC	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-5.48	6.95e-08	2.39e-05	-0.24	-0.25	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
HNSC	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-5.48	6.96e-08	2.39e-05	-0.26	-0.25	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	5.48	6.96e-08	2.39e-05	0.27	0.25	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	5.48	6.96e-08	2.4e-05	0.14	0.25	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-5.48	6.97e-08	2.4e-05	-0.31	-0.25	Depression;	chr6:28110254	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000254153.1	CTA-398F10.2	5.48	6.98e-08	2.4e-05	0.27	0.25	Mood instability;	chr8:8515975	chr8:8456909~8461337:-
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	5.48	6.98e-08	2.4e-05	0.31	0.25	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
HNSC	cis	rs667920	0.512	rs13069695	ENSG00000273486.1	RP11-731C17.2	-5.48	6.99e-08	2.4e-05	-0.31	-0.25	Coronary artery disease;	chr3:136572720	chr3:136837338~136839021:-
HNSC	cis	rs860295	0.812	rs10908481	ENSG00000203761.5	MSTO2P	-5.48	6.99e-08	2.41e-05	-0.19	-0.25	Body mass index;	chr1:155743859	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.812	rs4278368	ENSG00000203761.5	MSTO2P	-5.48	6.99e-08	2.41e-05	-0.19	-0.25	Body mass index;	chr1:155752766	chr1:155745829~155750137:+
HNSC	cis	rs17428076	0.831	rs3821093	ENSG00000228389.1	AC068039.4	-5.48	7.02e-08	2.41e-05	-0.3	-0.25	Myopia;	chr2:171838077	chr2:171773482~171775844:+
HNSC	cis	rs2439831	0.764	rs12324584	ENSG00000205771.5	CATSPER2P1	-5.48	7.02e-08	2.41e-05	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43391248	chr15:43726918~43747094:-
HNSC	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-5.48	7.02e-08	2.41e-05	-0.27	-0.25	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-5.48	7.03e-08	2.42e-05	-0.16	-0.25	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
HNSC	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	5.48	7.03e-08	2.42e-05	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
HNSC	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	5.48	7.03e-08	2.42e-05	0.34	0.25	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	5.48	7.03e-08	2.42e-05	0.34	0.25	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
HNSC	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-5.48	7.03e-08	2.42e-05	-0.34	-0.25	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
HNSC	cis	rs860295	0.557	rs11264372	ENSG00000203761.5	MSTO2P	-5.48	7.04e-08	2.42e-05	-0.19	-0.25	Body mass index;	chr1:155443139	chr1:155745829~155750137:+
HNSC	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-5.48	7.04e-08	2.42e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
HNSC	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	5.48	7.05e-08	2.42e-05	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
HNSC	cis	rs9813712	0.597	rs11711883	ENSG00000249846.5	RP11-77P16.4	-5.48	7.05e-08	2.42e-05	-0.26	-0.25	Response to amphetamines;	chr3:130241367	chr3:130112550~130120579:+
HNSC	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	5.48	7.06e-08	2.43e-05	0.35	0.25	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
HNSC	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-5.48	7.06e-08	2.43e-05	-0.25	-0.25	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
HNSC	cis	rs9525927	0.625	rs9533802	ENSG00000227258.4	SMIM2-AS1	5.48	7.07e-08	2.43e-05	0.36	0.25	Dupuytren's disease;	chr13:44245923	chr13:44110451~44240517:+
HNSC	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	5.48	7.07e-08	2.43e-05	0.28	0.25	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
HNSC	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-5.48	7.08e-08	2.43e-05	-0.23	-0.25	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
HNSC	cis	rs9611519	0.964	rs20551	ENSG00000235513.1	RP4-756G23.5	5.48	7.08e-08	2.43e-05	0.28	0.25	Neuroticism;	chr22:41152004	chr22:41209122~41217627:-
HNSC	cis	rs5758659	1	rs134869	ENSG00000227370.1	RP4-669P10.19	-5.48	7.09e-08	2.43e-05	-0.24	-0.25	Cognitive function;	chr22:42256068	chr22:42132543~42132998:+
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-5.48	7.09e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
HNSC	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-5.48	7.1e-08	2.44e-05	-0.29	-0.25	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	5.48	7.1e-08	2.44e-05	0.27	0.25	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
HNSC	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	5.48	7.1e-08	2.44e-05	0.35	0.25	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
HNSC	cis	rs9402743	0.634	rs66513771	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135603885	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.634	rs7774974	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135604248	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.538	rs6570019	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs6570020	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135604607	chr6:135636086~135636713:-
HNSC	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-5.48	7.11e-08	2.44e-05	-0.3	-0.25	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
HNSC	cis	rs9402743	0.634	rs7767072	ENSG00000217482.2	HMGB1P17	5.48	7.11e-08	2.44e-05	0.27	0.25	Systemic lupus erythematosus;	chr6:135593899	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-5.48	7.12e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-5.48	7.12e-08	2.44e-05	-0.16	-0.25	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-5.48	7.12e-08	2.44e-05	-0.14	-0.25	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
HNSC	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	5.48	7.12e-08	2.44e-05	0.37	0.25	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	5.48	7.12e-08	2.44e-05	0.37	0.25	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
HNSC	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.48	7.12e-08	2.44e-05	-0.27	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-5.48	7.12e-08	2.45e-05	-0.34	-0.25	Depression;	chr6:28240414	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-5.48	7.12e-08	2.45e-05	-0.34	-0.25	Depression;	chr6:28240780	chr6:28115628~28116551:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	5.48	7.13e-08	2.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	5.48	7.15e-08	2.45e-05	0.3	0.25	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
HNSC	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.48	7.16e-08	2.46e-05	-0.27	-0.25	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
HNSC	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	5.47	7.16e-08	2.46e-05	0.41	0.25	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	5.47	7.16e-08	2.46e-05	0.3	0.25	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
HNSC	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.47	7.17e-08	2.46e-05	0.25	0.25	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
HNSC	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-5.47	7.17e-08	2.46e-05	-0.23	-0.25	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
HNSC	cis	rs62344088	1	rs10042022	ENSG00000277812.1	AC021087.1	5.47	7.17e-08	2.46e-05	0.71	0.25	Asthma (childhood onset);	chr5:113956	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs76792440	ENSG00000277812.1	AC021087.1	5.47	7.17e-08	2.46e-05	0.71	0.25	Asthma (childhood onset);	chr5:114459	chr5:262769~262881:+
HNSC	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.47	7.18e-08	2.46e-05	-0.27	-0.25	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
HNSC	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	5.47	7.19e-08	2.47e-05	0.55	0.25	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-5.47	7.19e-08	2.47e-05	-0.29	-0.25	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
HNSC	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	5.47	7.19e-08	2.47e-05	0.29	0.25	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
HNSC	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-5.47	7.2e-08	2.47e-05	-0.31	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
HNSC	cis	rs34421088	0.576	rs2572437	ENSG00000269918.1	AF131215.9	-5.47	7.2e-08	2.47e-05	-0.26	-0.25	Neuroticism;	chr8:11240932	chr8:11104691~11106704:-
HNSC	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-5.47	7.21e-08	2.47e-05	-0.28	-0.25	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
HNSC	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	5.47	7.22e-08	2.47e-05	0.25	0.25	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
HNSC	cis	rs6604026	0.555	rs36114576	ENSG00000223787.2	RP4-593M8.1	5.47	7.22e-08	2.48e-05	0.35	0.25	Multiple sclerosis;	chr1:92671999	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.59	rs11809055	ENSG00000223787.2	RP4-593M8.1	5.47	7.22e-08	2.48e-05	0.35	0.25	Multiple sclerosis;	chr1:92675107	chr1:92580476~92580821:-
HNSC	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	5.47	7.22e-08	2.48e-05	0.29	0.25	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
HNSC	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-5.47	7.23e-08	2.48e-05	-0.31	-0.25	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
HNSC	cis	rs9840812	0.559	rs6439640	ENSG00000273486.1	RP11-731C17.2	5.47	7.23e-08	2.48e-05	0.25	0.25	Fibrinogen levels;	chr3:136466838	chr3:136837338~136839021:-
HNSC	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	5.47	7.23e-08	2.48e-05	0.23	0.25	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
HNSC	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	5.47	7.23e-08	2.48e-05	0.23	0.25	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
HNSC	cis	rs10462794	0.661	rs16873568	ENSG00000260763.1	RP11-445O3.3	5.47	7.23e-08	2.48e-05	0.36	0.25	DNA methylation (variation);	chr5:4523737	chr5:4436850~4440259:-
HNSC	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	5.47	7.23e-08	2.48e-05	0.3	0.25	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
HNSC	cis	rs2115630	0.967	rs12595786	ENSG00000229212.6	RP11-561C5.4	5.47	7.24e-08	2.48e-05	0.28	0.25	P wave terminal force;	chr15:84793439	chr15:85205440~85234795:-
HNSC	cis	rs67981189	0.529	rs8010063	ENSG00000274818.1	RP1-292L20.3	5.47	7.24e-08	2.48e-05	0.3	0.25	Schizophrenia;	chr14:71043408	chr14:70906657~70907111:-
HNSC	cis	rs9987353	0.544	rs2929469	ENSG00000254340.1	RP11-10A14.3	5.47	7.24e-08	2.48e-05	0.31	0.25	Recombination measurement;	chr8:9205146	chr8:9141424~9145435:+
HNSC	cis	rs9914544	1	rs1634411	ENSG00000264885.1	RP11-815I9.4	-5.47	7.24e-08	2.48e-05	-0.27	-0.25	Educational attainment (years of education);	chr17:18930497	chr17:18667629~18669461:-
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000254153.1	CTA-398F10.2	5.47	7.24e-08	2.48e-05	0.25	0.25	Neuroticism;	chr8:8314210	chr8:8456909~8461337:-
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000254174.1	IGHV1-12	5.47	7.24e-08	2.48e-05	0.2	0.25	Alzheimer's disease (late onset);	chr14:106646735	chr14:106122420~106122709:-
HNSC	cis	rs7209700	0.547	rs61131650	ENSG00000228782.6	CTD-2026D20.3	-5.47	7.24e-08	2.48e-05	-0.27	-0.25	IgG glycosylation;	chr17:47266961	chr17:47450568~47492492:-
HNSC	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-5.47	7.25e-08	2.49e-05	-0.43	-0.25	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
HNSC	cis	rs9300255	0.568	rs1790090	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123148877	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs949142	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123149496	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs884548	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123149575	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.537	rs2695482	ENSG00000280120.1	RP11-546D6.3	5.47	7.25e-08	2.49e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123138627	chr12:123152324~123153377:-
HNSC	cis	rs603446	0.967	rs180350	ENSG00000254851.1	RP11-109L13.1	-5.47	7.26e-08	2.49e-05	-0.33	-0.25	Triglycerides;	chr11:116739332	chr11:117135528~117138582:+
HNSC	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	5.47	7.28e-08	2.5e-05	0.28	0.25	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
HNSC	cis	rs6604026	0.624	rs35038369	ENSG00000223787.2	RP4-593M8.1	5.47	7.28e-08	2.5e-05	0.34	0.25	Multiple sclerosis;	chr1:92765411	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.624	rs11585590	ENSG00000223787.2	RP4-593M8.1	5.47	7.28e-08	2.5e-05	0.34	0.25	Multiple sclerosis;	chr1:92766823	chr1:92580476~92580821:-
HNSC	cis	rs7665090	0.87	rs228627	ENSG00000246560.2	RP11-10L12.4	-5.47	7.31e-08	2.5e-05	-0.28	-0.25	Primary biliary cholangitis;	chr4:102651925	chr4:102828055~102844075:+
HNSC	cis	rs13126694	0.744	rs4077776	ENSG00000248429.4	RP11-597D13.9	5.47	7.31e-08	2.5e-05	0.28	0.25	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158170752~158202877:+
HNSC	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-5.47	7.32e-08	2.51e-05	-0.28	-0.25	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
HNSC	cis	rs7777677	0.925	rs73543808	ENSG00000244273.1	PGBD4P1	-5.47	7.32e-08	2.51e-05	-0.26	-0.25	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142722358~142722764:+
HNSC	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	5.47	7.33e-08	2.51e-05	0.3	0.25	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	5.47	7.33e-08	2.51e-05	0.18	0.25	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
HNSC	cis	rs1799949	0.587	rs1824890	ENSG00000267151.3	RP11-100E5.2	5.47	7.33e-08	2.51e-05	0.36	0.25	Menopause (age at onset);	chr17:43344536	chr17:43444707~43451200:+
HNSC	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-5.47	7.34e-08	2.51e-05	-0.29	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
HNSC	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-5.47	7.34e-08	2.51e-05	-0.31	-0.25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
HNSC	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-5.47	7.34e-08	2.51e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
HNSC	cis	rs2985684	0.894	rs4900932	ENSG00000278009.1	RP11-649E7.8	5.47	7.35e-08	2.52e-05	0.32	0.25	Carotid intima media thickness;	chr14:49556210	chr14:49601011~49601124:-
HNSC	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-5.47	7.35e-08	2.52e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-5.47	7.35e-08	2.52e-05	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
HNSC	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-5.47	7.35e-08	2.52e-05	-0.31	-0.25	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
HNSC	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	5.47	7.36e-08	2.52e-05	0.36	0.25	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
HNSC	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	5.47	7.38e-08	2.53e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	5.47	7.38e-08	2.53e-05	0.24	0.25	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
HNSC	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	5.47	7.39e-08	2.53e-05	0.34	0.25	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
HNSC	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	5.47	7.4e-08	2.53e-05	0.33	0.25	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
HNSC	cis	rs6928977	0.86	rs2614266	ENSG00000234084.1	RP3-388E23.2	5.47	7.4e-08	2.53e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135301568~135307158:+
HNSC	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	5.47	7.41e-08	2.53e-05	0.41	0.25	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
HNSC	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	5.47	7.41e-08	2.53e-05	0.32	0.25	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
HNSC	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.47	7.41e-08	2.54e-05	-0.27	-0.25	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
HNSC	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	5.47	7.42e-08	2.54e-05	0.45	0.25	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
HNSC	cis	rs8040855	0.542	rs2342122	ENSG00000259774.1	RP11-182J1.13	-5.47	7.43e-08	2.54e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85185304	chr15:84422618~84425882:+
HNSC	cis	rs8040855	0.644	rs2342120	ENSG00000259774.1	RP11-182J1.13	-5.47	7.43e-08	2.54e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85185589	chr15:84422618~84425882:+
HNSC	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	5.47	7.43e-08	2.54e-05	0.27	0.25	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
HNSC	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	5.47	7.43e-08	2.54e-05	0.31	0.25	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.668	rs920047	ENSG00000255310.2	AF131215.2	-5.47	7.43e-08	2.54e-05	-0.24	-0.25	Triglycerides;	chr8:11229966	chr8:11107788~11109726:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	5.47	7.44e-08	2.54e-05	0.22	0.25	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
HNSC	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	5.47	7.44e-08	2.54e-05	0.35	0.25	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
HNSC	cis	rs7617773	0.539	rs13087050	ENSG00000228638.1	FCF1P2	-5.47	7.44e-08	2.54e-05	-0.22	-0.25	Coronary artery disease;	chr3:48351310	chr3:48290793~48291375:-
HNSC	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-5.47	7.44e-08	2.54e-05	-0.2	-0.25	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
HNSC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	5.47	7.44e-08	2.54e-05	0.3	0.25	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
HNSC	cis	rs3206736	0.548	rs73110562	ENSG00000197085.10	NPSR1-AS1	-5.47	7.45e-08	2.55e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35030311	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs10254796	ENSG00000197085.10	NPSR1-AS1	-5.47	7.45e-08	2.55e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:35031323	chr7:34346512~34871582:-
HNSC	cis	rs1355223	0.902	rs1453387	ENSG00000271369.1	RP11-350D17.3	-5.47	7.45e-08	2.55e-05	-0.28	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34686351	chr11:34709600~34710161:+
HNSC	cis	rs2179367	0.632	rs12154153	ENSG00000216906.2	RP11-350J20.9	5.47	7.47e-08	2.55e-05	0.36	0.25	Dupuytren's disease;	chr6:149401686	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs55836833	ENSG00000216906.2	RP11-350J20.9	5.47	7.47e-08	2.55e-05	0.36	0.25	Dupuytren's disease;	chr6:149403736	chr6:149904243~149906418:+
HNSC	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-5.47	7.48e-08	2.56e-05	-0.35	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
HNSC	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-5.47	7.48e-08	2.56e-05	-0.32	-0.25	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-5.47	7.48e-08	2.56e-05	-0.32	-0.25	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-5.47	7.49e-08	2.56e-05	-0.28	-0.25	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
HNSC	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	5.47	7.49e-08	2.56e-05	0.18	0.25	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
HNSC	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-5.47	7.5e-08	2.56e-05	-0.28	-0.25	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
HNSC	cis	rs9987353	0.522	rs2929466	ENSG00000254340.1	RP11-10A14.3	-5.47	7.5e-08	2.56e-05	-0.3	-0.25	Recombination measurement;	chr8:9206389	chr8:9141424~9145435:+
HNSC	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	5.47	7.5e-08	2.56e-05	0.28	0.25	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
HNSC	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.47	7.5e-08	2.56e-05	0.24	0.25	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-5.47	7.51e-08	2.56e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.66	rs9321508	ENSG00000234084.1	RP3-388E23.2	5.47	7.51e-08	2.57e-05	0.25	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135556839	chr6:135301568~135307158:+
HNSC	cis	rs6714900	0.619	rs7580273	ENSG00000234896.1	OR7E62P	5.47	7.52e-08	2.57e-05	0.29	0.25	Blood protein levels;	chr2:71049568	chr2:71055527~71056003:+
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-5.47	7.52e-08	2.57e-05	-0.24	-0.25	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
HNSC	cis	rs8054556	0.787	rs3814877	ENSG00000183604.13	SMG1P5	-5.47	7.53e-08	2.57e-05	-0.24	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30267553~30335374:-
HNSC	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	5.47	7.53e-08	2.57e-05	0.42	0.25	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	5.47	7.54e-08	2.57e-05	0.3	0.25	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000179406.6	LINC00174	5.47	7.54e-08	2.58e-05	0.32	0.25	Calcium levels;	chr7:65733651	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	5.47	7.54e-08	2.58e-05	0.3	0.25	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
HNSC	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	5.47	7.54e-08	2.58e-05	0.3	0.25	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-5.47	7.55e-08	2.58e-05	-0.29	-0.25	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
HNSC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5.46	7.55e-08	2.58e-05	0.27	0.25	Height;	chr3:53073764	chr3:53064283~53065091:-
HNSC	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	5.46	7.55e-08	2.58e-05	0.28	0.25	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
HNSC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-5.46	7.55e-08	2.58e-05	-0.27	-0.25	Height;	chr3:53074760	chr3:53064283~53065091:-
HNSC	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	5.46	7.55e-08	2.58e-05	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
HNSC	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-5.46	7.55e-08	2.58e-05	-0.35	-0.25	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
HNSC	cis	rs577676	0.533	rs10800529	ENSG00000271811.1	RP1-79C4.4	5.46	7.56e-08	2.58e-05	0.27	0.25	Prevalent atrial fibrillation;	chr1:170600902	chr1:170667381~170669425:+
HNSC	cis	rs4218	0.541	rs8030246	ENSG00000259732.1	RP11-59H7.3	-5.46	7.56e-08	2.58e-05	-0.33	-0.25	Social communication problems;	chr15:59049447	chr15:59121034~59133250:+
HNSC	cis	rs9611519	1	rs9611520	ENSG00000235513.1	RP4-756G23.5	5.46	7.56e-08	2.58e-05	0.27	0.25	Neuroticism;	chr22:41217299	chr22:41209122~41217627:-
HNSC	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	5.46	7.58e-08	2.59e-05	0.28	0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-5.46	7.58e-08	2.59e-05	-0.16	-0.25	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
HNSC	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-5.46	7.58e-08	2.59e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
HNSC	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	5.46	7.59e-08	2.59e-05	0.23	0.25	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
HNSC	cis	rs9300255	0.602	rs1106241	ENSG00000280120.1	RP11-546D6.3	5.46	7.59e-08	2.59e-05	0.22	0.25	Neutrophil percentage of white cells;	chr12:123142469	chr12:123152324~123153377:-
HNSC	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	5.46	7.6e-08	2.59e-05	0.3	0.25	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
HNSC	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	5.46	7.6e-08	2.59e-05	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
HNSC	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	5.46	7.61e-08	2.6e-05	0.28	0.25	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
HNSC	cis	rs71520386	0.607	rs11767419	ENSG00000221740.1	SNORD93	-5.46	7.61e-08	2.6e-05	-0.28	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22856613~22856686:+
HNSC	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	5.46	7.61e-08	2.6e-05	0.27	0.25	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
HNSC	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-5.46	7.62e-08	2.6e-05	-0.34	-0.25	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
HNSC	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-5.46	7.62e-08	2.6e-05	-0.26	-0.25	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
HNSC	cis	rs520525	0.927	rs583006	ENSG00000271811.1	RP1-79C4.4	5.46	7.63e-08	2.6e-05	0.29	0.25	Atrial fibrillation;	chr1:170659247	chr1:170667381~170669425:+
HNSC	cis	rs3733585	0.699	rs4621431	ENSG00000250413.1	RP11-448G15.1	5.46	7.64e-08	2.61e-05	0.3	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9945966	chr4:10006482~10009725:+
HNSC	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-5.46	7.64e-08	2.61e-05	-0.23	-0.25	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
HNSC	cis	rs6928977	0.896	rs2614287	ENSG00000231028.7	LINC00271	5.46	7.65e-08	2.61e-05	0.28	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135497801~135716055:+
HNSC	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
HNSC	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-5.46	7.65e-08	2.61e-05	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
HNSC	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	5.46	7.65e-08	2.61e-05	0.35	0.25	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
HNSC	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	5.46	7.66e-08	2.61e-05	0.23	0.25	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
HNSC	cis	rs3206736	0.593	rs328923	ENSG00000197085.10	NPSR1-AS1	-5.46	7.66e-08	2.61e-05	-0.31	-0.25	Diastolic blood pressure;	chr7:34996083	chr7:34346512~34871582:-
HNSC	cis	rs6928977	0.932	rs6935146	ENSG00000231028.7	LINC00271	-5.46	7.66e-08	2.61e-05	-0.28	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135497801~135716055:+
HNSC	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-5.46	7.67e-08	2.61e-05	-0.44	-0.25	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000254153.1	CTA-398F10.2	5.46	7.68e-08	2.62e-05	0.27	0.25	Mood instability;	chr8:8516446	chr8:8456909~8461337:-
HNSC	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-5.46	7.68e-08	2.62e-05	-0.24	-0.25	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
HNSC	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-5.46	7.69e-08	2.62e-05	-0.28	-0.25	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000254153.1	CTA-398F10.2	5.46	7.69e-08	2.62e-05	0.27	0.25	Mood instability;	chr8:8527137	chr8:8456909~8461337:-
HNSC	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.7e-08	2.62e-05	-0.3	-0.25	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	5.46	7.7e-08	2.63e-05	0.29	0.25	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
HNSC	cis	rs14027	0.883	rs16893027	ENSG00000279347.1	RP11-85I17.2	-5.46	7.71e-08	2.63e-05	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119838736~119840385:-
HNSC	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	5.46	7.71e-08	2.63e-05	0.4	0.25	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
HNSC	cis	rs9813712	0.818	rs16845853	ENSG00000249846.5	RP11-77P16.4	5.46	7.71e-08	2.63e-05	0.28	0.24	Response to amphetamines;	chr3:130229587	chr3:130112550~130120579:+
HNSC	cis	rs7617773	0.563	rs13082269	ENSG00000228638.1	FCF1P2	-5.46	7.71e-08	2.63e-05	-0.22	-0.24	Coronary artery disease;	chr3:48350784	chr3:48290793~48291375:-
HNSC	cis	rs36093844	0.752	rs7121363	ENSG00000279742.1	RP11-700A24.1	-5.46	7.71e-08	2.63e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85864067	chr11:85852557~85854943:-
HNSC	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	5.46	7.72e-08	2.63e-05	0.3	0.24	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
HNSC	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	5.46	7.72e-08	2.63e-05	0.28	0.24	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
HNSC	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-5.46	7.74e-08	2.64e-05	-0.31	-0.24	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
HNSC	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5.46	7.74e-08	2.64e-05	-0.39	-0.24	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
HNSC	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	5.46	7.75e-08	2.64e-05	0.3	0.24	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
HNSC	cis	rs526231	0.786	rs171695	ENSG00000175749.11	EIF3KP1	5.46	7.76e-08	2.64e-05	0.3	0.24	Primary biliary cholangitis;	chr5:103296339	chr5:103032376~103033031:+
HNSC	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	5.46	7.76e-08	2.64e-05	0.28	0.24	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
HNSC	cis	rs4718428	1	rs4718428	ENSG00000179406.6	LINC00174	-5.46	7.77e-08	2.65e-05	-0.33	-0.24	Corneal structure;	chr7:66956459	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	5.46	7.77e-08	2.65e-05	0.3	0.24	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
HNSC	cis	rs7615952	0.515	rs4441610	ENSG00000241288.6	RP11-379B18.5	-5.46	7.77e-08	2.65e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125962464	chr3:125827238~125916384:-
HNSC	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-5.46	7.78e-08	2.65e-05	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-5.46	7.78e-08	2.65e-05	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
HNSC	cis	rs9650657	0.589	rs6985109	ENSG00000269918.1	AF131215.9	5.46	7.78e-08	2.65e-05	0.24	0.24	Neuroticism;	chr8:10904075	chr8:11104691~11106704:-
HNSC	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-5.46	7.79e-08	2.65e-05	-0.4	-0.24	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
HNSC	cis	rs1908814	0.516	rs4841641	ENSG00000206014.6	OR7E161P	-5.46	7.79e-08	2.65e-05	-0.26	-0.24	Neuroticism;	chr8:11940718	chr8:11928597~11929563:-
HNSC	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	5.46	7.79e-08	2.65e-05	0.3	0.24	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
HNSC	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.46	7.79e-08	2.65e-05	-0.2	-0.24	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
HNSC	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.46	7.79e-08	2.65e-05	-0.2	-0.24	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
HNSC	cis	rs2058059	0.636	rs2961005	ENSG00000225648.4	SBDSP1	5.46	7.8e-08	2.65e-05	0.33	0.24	Subcutaneous adipose tissue;	chr7:72675517	chr7:72829425~72836701:+
HNSC	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	5.46	7.8e-08	2.66e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
HNSC	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	5.46	7.82e-08	2.66e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
HNSC	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	5.46	7.83e-08	2.66e-05	0.28	0.24	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
HNSC	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	5.46	7.83e-08	2.66e-05	0.19	0.24	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
HNSC	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-5.46	7.83e-08	2.67e-05	-0.29	-0.24	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
HNSC	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-5.46	7.84e-08	2.67e-05	-0.28	-0.24	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-5.46	7.84e-08	2.67e-05	-0.28	-0.24	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
HNSC	cis	rs947583	1	rs947583	ENSG00000217482.2	HMGB1P17	5.46	7.84e-08	2.67e-05	0.29	0.24	Phosphorus levels;	chr6:135812521	chr6:135636086~135636713:-
HNSC	cis	rs5753618	0.583	rs5753601	ENSG00000236132.1	CTA-440B3.1	-5.46	7.85e-08	2.67e-05	-0.31	-0.24	Colorectal cancer;	chr22:31402273	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs5753612	ENSG00000236132.1	CTA-440B3.1	-5.46	7.85e-08	2.67e-05	-0.31	-0.24	Colorectal cancer;	chr22:31425493	chr22:31816379~31817491:-
HNSC	cis	rs2115630	1	rs56074163	ENSG00000229212.6	RP11-561C5.4	5.46	7.85e-08	2.67e-05	0.28	0.24	P wave terminal force;	chr15:84808101	chr15:85205440~85234795:-
HNSC	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-5.46	7.86e-08	2.68e-05	-0.31	-0.24	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
HNSC	cis	rs6928977	0.86	rs2746438	ENSG00000231028.7	LINC00271	5.46	7.86e-08	2.68e-05	0.29	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135497801~135716055:+
HNSC	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-5.46	7.86e-08	2.68e-05	-0.22	-0.24	Height;	chr11:118746590	chr11:118791254~118793137:+
HNSC	cis	rs988913	1	rs1393772	ENSG00000224984.1	RP11-524H19.2	5.46	7.87e-08	2.68e-05	0.28	0.24	Menarche (age at onset);	chr6:54973590	chr6:54840118~54840855:-
HNSC	cis	rs8054556	1	rs4788209	ENSG00000183604.13	SMG1P5	-5.46	7.88e-08	2.68e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788210	ENSG00000183604.13	SMG1P5	-5.46	7.88e-08	2.68e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30267553~30335374:-
HNSC	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-5.46	7.88e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.46	7.88e-08	2.68e-05	0.26	0.24	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
HNSC	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	5.46	7.88e-08	2.68e-05	0.34	0.24	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
HNSC	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-5.46	7.89e-08	2.68e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
HNSC	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-5.46	7.89e-08	2.68e-05	-0.24	-0.24	Height;	chr5:37005003	chr5:36666214~36725195:-
HNSC	cis	rs6928977	0.5	rs3734213	ENSG00000217482.2	HMGB1P17	5.46	7.9e-08	2.69e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135636086~135636713:-
HNSC	cis	rs6928977	0.5	rs6941629	ENSG00000217482.2	HMGB1P17	5.46	7.9e-08	2.69e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135636086~135636713:-
HNSC	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-5.46	7.9e-08	2.69e-05	-0.28	-0.24	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
HNSC	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-5.46	7.9e-08	2.69e-05	-0.49	-0.24	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
HNSC	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	5.46	7.9e-08	2.69e-05	0.27	0.24	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
HNSC	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-5.46	7.9e-08	2.69e-05	-0.3	-0.24	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
HNSC	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-5.46	7.9e-08	2.69e-05	-0.4	-0.24	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-5.46	7.91e-08	2.69e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000267151.3	RP11-100E5.2	5.46	7.91e-08	2.69e-05	0.31	0.24	Menopause (age at onset);	chr17:43058379	chr17:43444707~43451200:+
HNSC	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	5.46	7.93e-08	2.7e-05	0.28	0.24	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
HNSC	cis	rs6931421	0.8	rs12662365	ENSG00000272129.1	RP11-250B2.6	5.46	7.93e-08	2.7e-05	0.32	0.24	Sitting height ratio;	chr6:80195672	chr6:80355424~80356859:+
HNSC	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	5.46	7.94e-08	2.7e-05	0.28	0.24	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	5.46	7.94e-08	2.7e-05	0.28	0.24	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
HNSC	cis	rs988913	1	rs1503136	ENSG00000224984.1	RP11-524H19.2	5.46	7.94e-08	2.7e-05	0.28	0.24	Menarche (age at onset);	chr6:54987167	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.597	rs9399162	ENSG00000217482.2	HMGB1P17	5.46	7.95e-08	2.7e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135759368	chr6:135636086~135636713:-
HNSC	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	5.46	7.95e-08	2.7e-05	0.23	0.24	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
HNSC	cis	rs2179367	0.632	rs9485384	ENSG00000216906.2	RP11-350J20.9	5.46	7.95e-08	2.7e-05	0.36	0.24	Dupuytren's disease;	chr6:149328808	chr6:149904243~149906418:+
HNSC	cis	rs2985684	1	rs1957977	ENSG00000258568.1	RHOQP1	5.46	7.95e-08	2.7e-05	0.25	0.24	Carotid intima media thickness;	chr14:49623885	chr14:49599994~49600572:+
HNSC	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-5.46	7.95e-08	2.7e-05	-0.33	-0.24	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
HNSC	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	5.45	7.96e-08	2.71e-05	0.27	0.24	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	5.45	7.96e-08	2.71e-05	0.27	0.24	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
HNSC	cis	rs72615157	0.613	rs56089143	ENSG00000078319.8	PMS2P1	-5.45	7.96e-08	2.71e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100222221	chr7:100320992~100341908:-
HNSC	cis	rs9840812	0.861	rs687339	ENSG00000273486.1	RP11-731C17.2	5.45	7.97e-08	2.71e-05	0.22	0.24	Fibrinogen levels;	chr3:136213517	chr3:136837338~136839021:-
HNSC	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-5.45	7.97e-08	2.71e-05	-0.28	-0.24	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
HNSC	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-5.45	7.97e-08	2.71e-05	-0.33	-0.24	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
HNSC	cis	rs4295623	0.553	rs11250163	ENSG00000269918.1	AF131215.9	5.45	7.97e-08	2.71e-05	0.24	0.24	Morning vs. evening chronotype;	chr8:11738928	chr8:11104691~11106704:-
HNSC	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.45	7.98e-08	2.71e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
HNSC	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-5.45	7.99e-08	2.71e-05	-0.32	-0.24	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
HNSC	cis	rs6693567	0.565	rs12739706	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Migraine;	chr1:150289240	chr1:150515757~150518032:+
HNSC	cis	rs3754214	0.823	rs10888579	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr1:150289512	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs7544900	ENSG00000228126.1	FALEC	-5.45	7.99e-08	2.71e-05	-0.3	-0.24	Migraine;	chr1:150289918	chr1:150515757~150518032:+
HNSC	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	5.45	8e-08	2.72e-05	0.28	0.24	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
HNSC	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	5.45	8e-08	2.72e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
HNSC	cis	rs13126694	0.682	rs6536288	ENSG00000248429.4	RP11-597D13.9	-5.45	8.01e-08	2.72e-05	-0.27	-0.24	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158170752~158202877:+
HNSC	cis	rs1908814	0.503	rs34657250	ENSG00000206014.6	OR7E161P	5.45	8.02e-08	2.72e-05	0.27	0.24	Neuroticism;	chr8:11937864	chr8:11928597~11929563:-
HNSC	cis	rs12817211	0.536	rs9364	ENSG00000272368.2	RP4-605O3.4	5.45	8.03e-08	2.73e-05	0.24	0.24	Colorectal or endometrial cancer;	chr12:50176736	chr12:50112197~50165618:+
HNSC	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-5.45	8.04e-08	2.73e-05	-0.34	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
HNSC	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
HNSC	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	5.45	8.04e-08	2.73e-05	0.28	0.24	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
HNSC	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-5.45	8.05e-08	2.74e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-5.45	8.05e-08	2.74e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000254153.1	CTA-398F10.2	5.45	8.05e-08	2.74e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:9012918	chr8:8456909~8461337:-
HNSC	cis	rs783540	0.656	rs783524	ENSG00000255769.6	GOLGA2P10	5.45	8.07e-08	2.74e-05	0.32	0.24	Schizophrenia;	chr15:82615393	chr15:82472993~82513950:-
HNSC	cis	rs783540	0.592	rs2567632	ENSG00000255769.6	GOLGA2P10	5.45	8.07e-08	2.74e-05	0.32	0.24	Schizophrenia;	chr15:82616053	chr15:82472993~82513950:-
HNSC	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-5.45	8.07e-08	2.74e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-5.45	8.08e-08	2.74e-05	-0.17	-0.24	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	5.45	8.08e-08	2.74e-05	0.3	0.24	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.802	rs2614276	ENSG00000234084.1	RP3-388E23.2	5.45	8.08e-08	2.74e-05	0.26	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135360566	chr6:135301568~135307158:+
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-5.45	8.08e-08	2.74e-05	-0.3	-0.24	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
HNSC	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	5.45	8.09e-08	2.74e-05	0.27	0.24	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
HNSC	cis	rs6928977	0.869	rs6912933	ENSG00000234084.1	RP3-388E23.2	5.45	8.09e-08	2.74e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306396	chr6:135301568~135307158:+
HNSC	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	5.45	8.09e-08	2.75e-05	0.25	0.24	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-5.45	8.09e-08	2.75e-05	-0.15	-0.24	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
HNSC	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	5.45	8.1e-08	2.75e-05	0.26	0.24	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-5.45	8.1e-08	2.75e-05	-0.16	-0.24	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
HNSC	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	5.45	8.1e-08	2.75e-05	0.3	0.24	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000226314.6	ZNF192P1	-5.45	8.11e-08	2.75e-05	-0.33	-0.24	Parkinson's disease;	chr6:28134687	chr6:28161781~28169594:+
HNSC	cis	rs8054556	0.647	rs8048433	ENSG00000183604.13	SMG1P5	-5.45	8.11e-08	2.75e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30267553~30335374:-
HNSC	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	5.45	8.12e-08	2.76e-05	0.29	0.24	Height;	chr4:55562653	chr4:55363971~55395847:-
HNSC	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-5.45	8.12e-08	2.76e-05	-0.18	-0.24	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	5.45	8.13e-08	2.76e-05	0.32	0.24	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000206014.6	OR7E161P	-5.45	8.13e-08	2.76e-05	-0.26	-0.24	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11928597~11929563:-
HNSC	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-5.45	8.14e-08	2.76e-05	-0.28	-0.24	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
HNSC	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.45	8.14e-08	2.76e-05	0.25	0.24	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
HNSC	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	8.15e-08	2.76e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
HNSC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	5.45	8.16e-08	2.77e-05	0.29	0.24	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
HNSC	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	5.45	8.16e-08	2.77e-05	0.44	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
HNSC	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-5.45	8.17e-08	2.77e-05	-0.31	-0.24	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
HNSC	cis	rs5758659	1	rs5758660	ENSG00000227370.1	RP4-669P10.19	-5.45	8.17e-08	2.77e-05	-0.24	-0.24	Cognitive function;	chr22:42227712	chr22:42132543~42132998:+
HNSC	cis	rs8054556	1	rs4787486	ENSG00000183604.13	SMG1P5	-5.45	8.17e-08	2.77e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30267553~30335374:-
HNSC	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	5.45	8.19e-08	2.78e-05	0.26	0.24	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
HNSC	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	5.45	8.19e-08	2.78e-05	0.25	0.24	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	5.45	8.2e-08	2.78e-05	0.3	0.24	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
HNSC	cis	rs4356203	1	rs4356203	ENSG00000260196.1	RP1-239B22.5	5.45	8.2e-08	2.78e-05	0.26	0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17380649~17383531:+
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28241324	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28241753	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-5.45	8.2e-08	2.78e-05	-0.34	-0.24	Depression;	chr6:28242515	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.66	rs2757643	ENSG00000234084.1	RP3-388E23.2	-5.45	8.21e-08	2.78e-05	-0.24	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135301568~135307158:+
HNSC	cis	rs7773987	1	rs7773987	ENSG00000234084.1	RP3-388E23.2	5.45	8.21e-08	2.78e-05	0.25	0.24	Selective IgA deficiency;	chr6:135386348	chr6:135301568~135307158:+
HNSC	cis	rs2579103	0.867	rs2731222	ENSG00000258183.4	RP11-753N8.1	-5.45	8.22e-08	2.79e-05	-0.31	-0.24	Body mass index;	chr12:90201606	chr12:90280894~90300340:+
HNSC	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-5.45	8.23e-08	2.79e-05	-0.27	-0.24	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
HNSC	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	5.45	8.23e-08	2.79e-05	0.28	0.24	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000254340.1	RP11-10A14.3	5.45	8.23e-08	2.79e-05	0.3	0.24	Mood instability;	chr8:8402935	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	5.45	8.24e-08	2.79e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
HNSC	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-5.45	8.25e-08	2.79e-05	-0.28	-0.24	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
HNSC	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	5.45	8.25e-08	2.8e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
HNSC	cis	rs2179367	0.632	rs11155650	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149407613	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs11155651	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149408146	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs7896	ENSG00000216906.2	RP11-350J20.9	5.45	8.26e-08	2.8e-05	0.36	0.24	Dupuytren's disease;	chr6:149410340	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	5.45	8.27e-08	2.8e-05	0.28	0.24	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
HNSC	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	5.45	8.28e-08	2.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
HNSC	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	5.45	8.28e-08	2.81e-05	0.23	0.24	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
HNSC	cis	rs1933112	0.5	rs34328291	ENSG00000227777.1	RP4-738P11.3	-5.45	8.28e-08	2.81e-05	-0.34	-0.24	Blood protein levels;	chr1:168545108	chr1:168542737~168543354:+
HNSC	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	5.45	8.29e-08	2.81e-05	0.33	0.24	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
HNSC	cis	rs8054556	1	rs7204797	ENSG00000183604.13	SMG1P5	-5.45	8.31e-08	2.81e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30267553~30335374:-
HNSC	cis	rs1908814	0.541	rs7824267	ENSG00000206014.6	OR7E161P	-5.45	8.31e-08	2.81e-05	-0.27	-0.24	Neuroticism;	chr8:11936770	chr8:11928597~11929563:-
HNSC	cis	rs2985684	0.894	rs6572586	ENSG00000278009.1	RP11-649E7.8	5.45	8.31e-08	2.82e-05	0.32	0.24	Carotid intima media thickness;	chr14:49555223	chr14:49601011~49601124:-
HNSC	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	5.45	8.31e-08	2.82e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
HNSC	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.45	8.32e-08	2.82e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
HNSC	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	5.45	8.33e-08	2.82e-05	0.29	0.24	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
HNSC	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	5.45	8.33e-08	2.82e-05	0.36	0.24	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs59820585	ENSG00000216906.2	RP11-350J20.9	5.45	8.33e-08	2.82e-05	0.36	0.24	Dupuytren's disease;	chr6:149350249	chr6:149904243~149906418:+
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000233609.3	RP11-62H7.2	5.45	8.34e-08	2.82e-05	0.24	0.24	Joint mobility (Beighton score);	chr8:9003384	chr8:8961200~8979025:+
HNSC	cis	rs5753618	0.583	rs7293171	ENSG00000236132.1	CTA-440B3.1	-5.45	8.34e-08	2.82e-05	-0.31	-0.24	Colorectal cancer;	chr22:31406338	chr22:31816379~31817491:-
HNSC	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-5.45	8.34e-08	2.82e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
HNSC	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-5.45	8.35e-08	2.83e-05	-0.3	-0.24	Height;	chr4:55547636	chr4:55387949~55388271:+
HNSC	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	5.45	8.35e-08	2.83e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
HNSC	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	5.45	8.35e-08	2.83e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
HNSC	cis	rs7819412	0.875	rs6981523	ENSG00000269918.1	AF131215.9	-5.45	8.37e-08	2.83e-05	-0.24	-0.24	Triglycerides;	chr8:11204283	chr8:11104691~11106704:-
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000248787.1	RP11-666A20.4	-5.45	8.37e-08	2.83e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000248787.1	RP11-666A20.4	-5.45	8.37e-08	2.83e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125908005~125910272:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-5.45	8.37e-08	2.83e-05	-0.22	-0.24	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
HNSC	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	5.45	8.37e-08	2.83e-05	0.33	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
HNSC	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-5.44	8.39e-08	2.84e-05	-0.32	-0.24	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
HNSC	cis	rs1665050	0.545	rs59540276	ENSG00000259732.1	RP11-59H7.3	-5.44	8.39e-08	2.84e-05	-0.33	-0.24	Atopic dermatitis;	chr15:59037559	chr15:59121034~59133250:+
HNSC	cis	rs7674212	0.541	rs2720458	ENSG00000246560.2	RP11-10L12.4	5.44	8.4e-08	2.84e-05	0.28	0.24	Type 2 diabetes;	chr4:103131806	chr4:102828055~102844075:+
HNSC	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	5.44	8.41e-08	2.84e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	5.44	8.41e-08	2.84e-05	0.29	0.24	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000179406.6	LINC00174	-5.44	8.41e-08	2.84e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66376044~66401338:-
HNSC	cis	rs2985684	0.894	rs8005990	ENSG00000278009.1	RP11-649E7.8	5.44	8.41e-08	2.84e-05	0.32	0.24	Carotid intima media thickness;	chr14:49555530	chr14:49601011~49601124:-
HNSC	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	5.44	8.41e-08	2.85e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
HNSC	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	5.44	8.41e-08	2.85e-05	0.3	0.24	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
HNSC	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	5.44	8.42e-08	2.85e-05	0.37	0.24	Height;	chr6:109352277	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.587	rs2516889	ENSG00000254174.1	IGHV1-12	-5.44	8.42e-08	2.85e-05	-0.2	-0.24	Alzheimer's disease (late onset);	chr14:106648903	chr14:106122420~106122709:-
HNSC	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	5.44	8.43e-08	2.85e-05	0.31	0.24	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
HNSC	cis	rs9611519	0.929	rs11090039	ENSG00000235513.1	RP4-756G23.5	5.44	8.43e-08	2.85e-05	0.28	0.24	Neuroticism;	chr22:41100796	chr22:41209122~41217627:-
HNSC	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	5.44	8.43e-08	2.85e-05	0.27	0.24	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
HNSC	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	5.44	8.43e-08	2.85e-05	0.27	0.24	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
HNSC	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-5.44	8.43e-08	2.85e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
HNSC	cis	rs783540	0.609	rs803686	ENSG00000276710.3	CSPG4P8	5.44	8.44e-08	2.85e-05	0.29	0.24	Schizophrenia;	chr15:82550590	chr15:82459472~82477258:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.44	8.45e-08	2.86e-05	0.23	0.24	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
HNSC	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	5.44	8.45e-08	2.86e-05	0.3	0.24	Height;	chr4:55430730	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	5.44	8.45e-08	2.86e-05	0.3	0.24	Height;	chr4:55430740	chr4:55387949~55388271:+
HNSC	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-5.44	8.46e-08	2.86e-05	-0.23	-0.24	Height;	chr5:36904297	chr5:36666214~36725195:-
HNSC	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-5.44	8.46e-08	2.86e-05	-0.31	-0.24	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
HNSC	cis	rs9291683	0.509	rs10939671	ENSG00000250413.1	RP11-448G15.1	-5.44	8.47e-08	2.86e-05	-0.3	-0.24	Bone mineral density;	chr4:10049191	chr4:10006482~10009725:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66121618	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316313	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66128561	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316312	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66131504	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs419603	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66132354	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs387676	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66133233	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13310597	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66133553	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs431076	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66135333	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2257790	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66135463	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2460422	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66136518	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316334	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66137139	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316332	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66139312	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316330	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66140385	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316329	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66143429	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316326	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66144466	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316325	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66144531	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316321	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66146626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316318	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66147917	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316317	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66148650	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs316304	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66151907	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2465120	ENSG00000179406.6	LINC00174	-5.44	8.47e-08	2.86e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66155987	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66157859	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66158142	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718309	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66162777	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6460274	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66163497	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7787230	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66164112	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66170354	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6974723	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66172952	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs9769882	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66177938	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6966322	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66181767	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4145008	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66182524	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718315	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66183554	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs4718316	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66183744	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1873494	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66184912	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6959002	ENSG00000179406.6	LINC00174	5.44	8.47e-08	2.86e-05	0.52	0.24	Diabetic kidney disease;	chr7:66185509	chr7:66376044~66401338:-
HNSC	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	5.44	8.47e-08	2.86e-05	0.35	0.24	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
HNSC	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	5.44	8.48e-08	2.86e-05	0.27	0.24	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
HNSC	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-5.44	8.48e-08	2.86e-05	-0.24	-0.24	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
HNSC	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	5.44	8.48e-08	2.87e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
HNSC	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.44	8.49e-08	2.87e-05	-0.22	-0.24	Height;	chr11:118791319	chr11:118791254~118793137:+
HNSC	cis	rs831571	0.876	rs56363381	ENSG00000280620.1	SCAANT1	5.44	8.5e-08	2.87e-05	0.4	0.24	Type 2 diabetes;	chr3:64071001	chr3:63911518~63911772:-
HNSC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	5.44	8.5e-08	2.87e-05	0.31	0.24	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
HNSC	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.44	8.5e-08	2.87e-05	0.3	0.24	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
HNSC	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	5.44	8.52e-08	2.88e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
HNSC	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	5.44	8.52e-08	2.88e-05	0.3	0.24	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
HNSC	cis	rs17428076	0.836	rs3770455	ENSG00000228389.1	AC068039.4	-5.44	8.52e-08	2.88e-05	-0.3	-0.24	Myopia;	chr2:171811385	chr2:171773482~171775844:+
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	5.44	8.53e-08	2.88e-05	0.3	0.24	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000254174.1	IGHV1-12	5.44	8.54e-08	2.88e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779234	chr14:106122420~106122709:-
HNSC	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	5.44	8.55e-08	2.89e-05	0.31	0.24	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
HNSC	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	5.44	8.55e-08	2.89e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
HNSC	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-5.44	8.56e-08	2.89e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
HNSC	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-5.44	8.56e-08	2.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
HNSC	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-5.44	8.57e-08	2.89e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
HNSC	cis	rs4648739	0.613	rs13303201	ENSG00000268575.1	RP1-283E3.8	5.44	8.57e-08	2.89e-05	0.24	0.24	Severe influenza A (H1N1) infection;	chr1:1972273	chr1:1702736~1737688:-
HNSC	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-5.44	8.57e-08	2.89e-05	-0.27	-0.24	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
HNSC	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	5.44	8.57e-08	2.89e-05	0.27	0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
HNSC	cis	rs4699052	0.928	rs2126473	ENSG00000246560.2	RP11-10L12.4	5.44	8.57e-08	2.89e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103220376	chr4:102828055~102844075:+
HNSC	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	5.44	8.58e-08	2.9e-05	0.27	0.24	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
HNSC	cis	rs3206736	0.548	rs328891	ENSG00000197085.10	NPSR1-AS1	-5.44	8.59e-08	2.9e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34973905	chr7:34346512~34871582:-
HNSC	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-5.44	8.59e-08	2.9e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
HNSC	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	5.44	8.59e-08	2.9e-05	0.29	0.24	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-5.44	8.61e-08	2.9e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
HNSC	cis	rs155076	1	rs12870992	ENSG00000233325.3	MIPEPP3	-5.44	8.63e-08	2.91e-05	-0.43	-0.24	White matter hyperintensity burden;	chr13:21271880	chr13:21298139~21306373:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000254153.1	CTA-398F10.2	5.44	8.64e-08	2.91e-05	0.27	0.24	Neuroticism;	chr8:8240557	chr8:8456909~8461337:-
HNSC	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.44	8.65e-08	2.92e-05	0.27	0.24	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
HNSC	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-5.44	8.65e-08	2.92e-05	-0.26	-0.24	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
HNSC	cis	rs7819412	0.838	rs3021494	ENSG00000255310.2	AF131215.2	-5.44	8.65e-08	2.92e-05	-0.24	-0.24	Triglycerides;	chr8:11126024	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000204709.4	LINC01556	5.44	8.65e-08	2.92e-05	0.34	0.24	Parkinson's disease;	chr6:28055973	chr6:28943877~28944537:+
HNSC	cis	rs11969893	0.85	rs9386260	ENSG00000270987.1	RP3-467N11.2	5.44	8.66e-08	2.92e-05	0.62	0.24	Economic and political preferences (immigration/crime);	chr6:100881552	chr6:100889603~100890338:+
HNSC	cis	rs7160336	0.738	rs66941731	ENSG00000259065.1	RP5-1021I20.1	5.44	8.66e-08	2.92e-05	0.28	0.24	Blood protein levels;	chr14:74026538	chr14:73787360~73803270:+
HNSC	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	5.44	8.67e-08	2.92e-05	0.47	0.24	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
HNSC	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	5.44	8.67e-08	2.92e-05	0.28	0.24	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
HNSC	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	5.44	8.68e-08	2.93e-05	0.36	0.24	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
HNSC	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	8.7e-08	2.93e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
HNSC	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	5.44	8.7e-08	2.93e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
HNSC	cis	rs9291683	0.546	rs4575994	ENSG00000250413.1	RP11-448G15.1	-5.44	8.7e-08	2.93e-05	-0.3	-0.24	Bone mineral density;	chr4:9996355	chr4:10006482~10009725:+
HNSC	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	8.71e-08	2.94e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
HNSC	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	5.44	8.73e-08	2.94e-05	0.29	0.24	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
HNSC	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	5.44	8.73e-08	2.94e-05	0.28	0.24	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
HNSC	cis	rs3806843	0.766	rs801399	ENSG00000202515.1	VTRNA1-3	5.44	8.74e-08	2.94e-05	0.27	0.24	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140726158~140726246:+
HNSC	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	5.44	8.74e-08	2.94e-05	0.32	0.24	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
HNSC	cis	rs9840812	0.598	rs1145101	ENSG00000273486.1	RP11-731C17.2	5.44	8.74e-08	2.94e-05	0.25	0.24	Fibrinogen levels;	chr3:136350444	chr3:136837338~136839021:-
HNSC	cis	rs9611519	0.828	rs4822008	ENSG00000235513.1	RP4-756G23.5	5.44	8.74e-08	2.95e-05	0.27	0.24	Neuroticism;	chr22:41143202	chr22:41209122~41217627:-
HNSC	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-5.44	8.74e-08	2.95e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
HNSC	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-5.44	8.74e-08	2.95e-05	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
HNSC	cis	rs2179367	0.632	rs12196750	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149413335	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.552	rs11155652	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149417849	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12209364	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418062	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9322179	ENSG00000216906.2	RP11-350J20.9	5.44	8.75e-08	2.95e-05	0.36	0.24	Dupuytren's disease;	chr6:149418664	chr6:149904243~149906418:+
HNSC	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.44	8.75e-08	2.95e-05	-0.39	-0.24	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
HNSC	cis	rs17428076	0.793	rs7584258	ENSG00000228389.1	AC068039.4	-5.44	8.76e-08	2.95e-05	-0.3	-0.24	Myopia;	chr2:171803326	chr2:171773482~171775844:+
HNSC	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.44	8.76e-08	2.95e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-5.44	8.76e-08	2.95e-05	-0.14	-0.24	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
HNSC	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-5.44	8.76e-08	2.95e-05	-0.26	-0.24	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	5.44	8.77e-08	2.95e-05	0.59	0.24	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
HNSC	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-5.44	8.77e-08	2.95e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
HNSC	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.44	8.78e-08	2.96e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
HNSC	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	5.44	8.78e-08	2.96e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-5.44	8.78e-08	2.96e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
HNSC	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	5.44	8.79e-08	2.96e-05	0.3	0.24	Height;	chr4:55436423	chr4:55387949~55388271:+
HNSC	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	5.44	8.79e-08	2.96e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	5.44	8.79e-08	2.96e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
HNSC	cis	rs6604026	0.555	rs4642892	ENSG00000223787.2	RP4-593M8.1	5.44	8.8e-08	2.96e-05	0.35	0.24	Multiple sclerosis;	chr1:92628570	chr1:92580476~92580821:-
HNSC	cis	rs9300255	0.602	rs1616131	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135291	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs1616181	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135309	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.569	rs1790115	ENSG00000280120.1	RP11-546D6.3	5.44	8.8e-08	2.96e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135723	chr12:123152324~123153377:-
HNSC	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	5.44	8.81e-08	2.97e-05	0.33	0.24	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
HNSC	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	5.44	8.81e-08	2.97e-05	0.29	0.24	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	5.44	8.82e-08	2.97e-05	0.2	0.24	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
HNSC	cis	rs6928977	0.896	rs2746425	ENSG00000234084.1	RP3-388E23.2	5.44	8.82e-08	2.97e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135343227	chr6:135301568~135307158:+
HNSC	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-5.44	8.82e-08	2.97e-05	-0.36	-0.24	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
HNSC	cis	rs4938303	0.633	rs528806	ENSG00000254851.1	RP11-109L13.1	5.44	8.82e-08	2.97e-05	0.44	0.24	Triglycerides;	chr11:116659197	chr11:117135528~117138582:+
HNSC	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	5.44	8.82e-08	2.97e-05	0.36	0.24	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
HNSC	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	5.43	8.86e-08	2.98e-05	0.42	0.24	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
HNSC	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	5.43	8.86e-08	2.98e-05	0.42	0.24	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-5.43	8.86e-08	2.98e-05	-0.16	-0.24	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000254340.1	RP11-10A14.3	5.43	8.86e-08	2.98e-05	0.29	0.24	Mood instability;	chr8:8404114	chr8:9141424~9145435:+
HNSC	cis	rs8054556	1	rs3814880	ENSG00000183604.13	SMG1P5	-5.43	8.87e-08	2.98e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30267553~30335374:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-5.43	8.88e-08	2.99e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778702	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779073	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779163	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000254174.1	IGHV1-12	5.43	8.88e-08	2.99e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106779174	chr14:106122420~106122709:-
HNSC	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-5.43	8.89e-08	2.99e-05	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
HNSC	cis	rs4252134	0.551	rs6926947	ENSG00000231863.1	RP3-428L16.1	-5.43	8.89e-08	2.99e-05	-0.32	-0.24	Giant cell arteritis;	chr6:160851644	chr6:160931080~160969771:+
HNSC	cis	rs4699052	0.963	rs11943325	ENSG00000246560.2	RP11-10L12.4	5.43	8.9e-08	2.99e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103257236	chr4:102828055~102844075:+
HNSC	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.43	8.9e-08	2.99e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	5.43	8.9e-08	2.99e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
HNSC	cis	rs8054556	1	rs12921996	ENSG00000183604.13	SMG1P5	-5.43	8.91e-08	3e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30267553~30335374:-
HNSC	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-5.43	8.91e-08	3e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
HNSC	cis	rs9813712	0.574	rs62281647	ENSG00000249846.5	RP11-77P16.4	-5.43	8.91e-08	3e-05	-0.26	-0.24	Response to amphetamines;	chr3:130242670	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.597	rs62281648	ENSG00000249846.5	RP11-77P16.4	-5.43	8.91e-08	3e-05	-0.26	-0.24	Response to amphetamines;	chr3:130244794	chr3:130112550~130120579:+
HNSC	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	5.43	8.91e-08	3e-05	0.62	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
HNSC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	5.43	8.92e-08	3e-05	0.29	0.24	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
HNSC	cis	rs783540	0.681	rs1259178	ENSG00000276710.3	CSPG4P8	5.43	8.92e-08	3e-05	0.28	0.24	Schizophrenia;	chr15:82603127	chr15:82459472~82477258:+
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-5.43	8.93e-08	3e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
HNSC	cis	rs2579103	0.898	rs4842510	ENSG00000258183.4	RP11-753N8.1	-5.43	8.93e-08	3e-05	-0.3	-0.24	Body mass index;	chr12:90199640	chr12:90280894~90300340:+
HNSC	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	5.43	8.93e-08	3e-05	0.26	0.24	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
HNSC	cis	rs6928977	0.86	rs2746426	ENSG00000234084.1	RP3-388E23.2	5.43	8.93e-08	3e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135345294	chr6:135301568~135307158:+
HNSC	cis	rs2985684	0.901	rs7146248	ENSG00000258568.1	RHOQP1	5.43	8.94e-08	3.01e-05	0.25	0.24	Carotid intima media thickness;	chr14:49645349	chr14:49599994~49600572:+
HNSC	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	5.43	8.94e-08	3.01e-05	0.26	0.24	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
HNSC	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-5.43	8.95e-08	3.01e-05	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
HNSC	cis	rs6928977	0.832	rs2746427	ENSG00000234084.1	RP3-388E23.2	5.43	8.95e-08	3.01e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135347959	chr6:135301568~135307158:+
HNSC	cis	rs9813712	0.672	rs73210789	ENSG00000249846.5	RP11-77P16.4	5.43	8.95e-08	3.01e-05	0.29	0.24	Response to amphetamines;	chr3:130243418	chr3:130112550~130120579:+
HNSC	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-5.43	8.96e-08	3.01e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
HNSC	cis	rs6928977	0.86	rs2746433	ENSG00000234084.1	RP3-388E23.2	5.43	8.96e-08	3.01e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135301568~135307158:+
HNSC	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-5.43	8.97e-08	3.01e-05	-0.35	-0.24	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
HNSC	cis	rs2179367	0.632	rs9498321	ENSG00000216906.2	RP11-350J20.9	5.43	8.97e-08	3.01e-05	0.35	0.24	Dupuytren's disease;	chr6:149322573	chr6:149904243~149906418:+
HNSC	cis	rs651386	0.506	rs12027180	ENSG00000271811.1	RP1-79C4.4	5.43	8.97e-08	3.02e-05	0.28	0.24	Atrial fibrillation;	chr1:170594064	chr1:170667381~170669425:+
HNSC	cis	rs2411233	0.967	rs11856829	ENSG00000259278.1	RP11-62C7.2	5.43	8.97e-08	3.02e-05	0.39	0.24	Platelet count;	chr15:38985580	chr15:39019233~39024918:+
HNSC	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-5.43	8.97e-08	3.02e-05	-0.32	-0.24	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
HNSC	cis	rs4978813	0.5	rs11791965	ENSG00000213539.4	YBX1P6	5.43	8.98e-08	3.02e-05	0.29	0.24	Plantar warts;	chr9:109515083	chr9:109532830~109534332:-
HNSC	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-5.43	8.99e-08	3.02e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
HNSC	cis	rs2985684	0.748	rs2985686	ENSG00000258568.1	RHOQP1	5.43	8.99e-08	3.02e-05	0.25	0.24	Carotid intima media thickness;	chr14:49633965	chr14:49599994~49600572:+
HNSC	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	5.43	8.99e-08	3.02e-05	0.42	0.24	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
HNSC	cis	rs655720	1	rs655720	ENSG00000273486.1	RP11-731C17.2	5.43	8.99e-08	3.02e-05	0.2	0.24	Coronary artery disease;	chr3:136384425	chr3:136837338~136839021:-
HNSC	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.43	8.99e-08	3.02e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
HNSC	cis	rs13126694	0.71	rs4631100	ENSG00000248429.4	RP11-597D13.9	5.43	9e-08	3.02e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158170752~158202877:+
HNSC	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	5.43	9e-08	3.02e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.504	rs10093053	ENSG00000269918.1	AF131215.9	-5.43	9e-08	3.03e-05	-0.24	-0.24	Neuroticism;	chr8:11179678	chr8:11104691~11106704:-
HNSC	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-5.43	9.01e-08	3.03e-05	-0.38	-0.24	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
HNSC	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	5.43	9.01e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	5.43	9.02e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	5.43	9.02e-08	3.03e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
HNSC	cis	rs4218	0.573	rs4775115	ENSG00000277144.1	RP11-59H7.4	-5.43	9.02e-08	3.03e-05	-0.31	-0.24	Social communication problems;	chr15:59076311	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	5.43	9.03e-08	3.03e-05	0.26	0.24	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	5.43	9.04e-08	3.04e-05	0.29	0.24	Height;	chr4:55533481	chr4:55387949~55388271:+
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000233609.3	RP11-62H7.2	5.43	9.04e-08	3.04e-05	0.24	0.24	Mean corpuscular volume;	chr8:8994371	chr8:8961200~8979025:+
HNSC	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-5.43	9.05e-08	3.04e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
HNSC	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	5.43	9.06e-08	3.04e-05	0.25	0.24	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
HNSC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	5.43	9.06e-08	3.04e-05	0.2	0.24	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
HNSC	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-5.43	9.06e-08	3.04e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
HNSC	cis	rs783540	0.656	rs783538	ENSG00000276710.3	CSPG4P8	5.43	9.07e-08	3.05e-05	0.29	0.24	Schizophrenia;	chr15:82584394	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	5.43	9.07e-08	3.05e-05	0.26	0.24	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	5.43	9.07e-08	3.05e-05	0.26	0.24	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs328895	ENSG00000197085.10	NPSR1-AS1	-5.43	9.07e-08	3.05e-05	-0.31	-0.24	Diastolic blood pressure;	chr7:34976775	chr7:34346512~34871582:-
HNSC	cis	rs3206736	0.548	rs2021177	ENSG00000197085.10	NPSR1-AS1	-5.43	9.07e-08	3.05e-05	-0.31	-0.24	Diastolic blood pressure;	chr7:34980576	chr7:34346512~34871582:-
HNSC	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	5.43	9.07e-08	3.05e-05	0.27	0.24	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
HNSC	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-5.43	9.08e-08	3.05e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
HNSC	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-5.43	9.08e-08	3.05e-05	-0.45	-0.24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
HNSC	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-5.43	9.09e-08	3.05e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
HNSC	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-5.43	9.1e-08	3.06e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-5.43	9.1e-08	3.06e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
HNSC	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	5.43	9.11e-08	3.06e-05	0.28	0.24	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
HNSC	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	5.43	9.11e-08	3.06e-05	0.27	0.24	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
HNSC	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-5.43	9.11e-08	3.06e-05	-0.38	-0.24	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
HNSC	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-5.43	9.12e-08	3.06e-05	-0.27	-0.24	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-5.43	9.12e-08	3.06e-05	-0.27	-0.24	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	5.43	9.12e-08	3.06e-05	0.3	0.24	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	5.43	9.12e-08	3.06e-05	0.3	0.24	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
HNSC	cis	rs4968361	0.892	rs68025251	ENSG00000266992.1	DHX40P1	5.43	9.13e-08	3.07e-05	0.44	0.24	Schizophrenia;	chr17:59442071	chr17:59976009~60002384:-
HNSC	cis	rs9914544	0.933	rs11871889	ENSG00000264885.1	RP11-815I9.4	-5.43	9.14e-08	3.07e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18868112	chr17:18667629~18669461:-
HNSC	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	5.43	9.14e-08	3.07e-05	0.3	0.24	Height;	chr4:55570311	chr4:55387949~55388271:+
HNSC	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	5.43	9.14e-08	3.07e-05	0.27	0.24	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
HNSC	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.43	9.15e-08	3.07e-05	-0.24	-0.24	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-5.43	9.15e-08	3.07e-05	-0.14	-0.24	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
HNSC	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	5.43	9.15e-08	3.07e-05	0.33	0.24	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	5.43	9.16e-08	3.07e-05	0.19	0.24	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
HNSC	cis	rs7819412	0.634	rs4841485	ENSG00000269918.1	AF131215.9	5.43	9.16e-08	3.07e-05	0.25	0.24	Triglycerides;	chr8:11052426	chr8:11104691~11106704:-
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	5.43	9.16e-08	3.07e-05	0.3	0.24	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	5.43	9.16e-08	3.07e-05	0.3	0.24	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
HNSC	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.43	9.16e-08	3.07e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
HNSC	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	5.43	9.16e-08	3.08e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
HNSC	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-5.43	9.17e-08	3.08e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000254153.1	CTA-398F10.2	-5.43	9.17e-08	3.08e-05	-0.27	-0.24	Mood instability;	chr8:8726362	chr8:8456909~8461337:-
HNSC	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5.43	9.17e-08	3.08e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-5.43	9.18e-08	3.08e-05	-0.27	-0.24	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
HNSC	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	5.43	9.19e-08	3.08e-05	0.31	0.24	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
HNSC	cis	rs6604026	0.624	rs35705463	ENSG00000223787.2	RP4-593M8.1	5.43	9.19e-08	3.08e-05	0.34	0.24	Multiple sclerosis;	chr1:92767766	chr1:92580476~92580821:-
HNSC	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	5.43	9.19e-08	3.08e-05	0.34	0.24	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
HNSC	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-5.43	9.2e-08	3.09e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000229212.6	RP11-561C5.4	-5.43	9.2e-08	3.09e-05	-0.35	-0.24	Schizophrenia;	chr15:84250623	chr15:85205440~85234795:-
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000254174.1	IGHV1-12	5.43	9.2e-08	3.09e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106776118	chr14:106122420~106122709:-
HNSC	cis	rs8054556	1	rs11150579	ENSG00000183604.13	SMG1P5	-5.43	9.21e-08	3.09e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs9924686	ENSG00000183604.13	SMG1P5	-5.43	9.21e-08	3.09e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30267553~30335374:-
HNSC	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	5.43	9.21e-08	3.09e-05	0.28	0.24	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
HNSC	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-5.43	9.22e-08	3.09e-05	-0.27	-0.24	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
HNSC	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-5.43	9.22e-08	3.09e-05	-0.26	-0.24	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
HNSC	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	5.43	9.22e-08	3.09e-05	0.34	0.24	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
HNSC	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	5.43	9.22e-08	3.09e-05	0.23	0.24	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
HNSC	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	5.43	9.22e-08	3.09e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	5.43	9.23e-08	3.09e-05	0.59	0.24	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
HNSC	cis	rs860295	0.812	rs12081192	ENSG00000203761.5	MSTO2P	-5.43	9.23e-08	3.1e-05	-0.19	-0.24	Body mass index;	chr1:155768253	chr1:155745829~155750137:+
HNSC	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	5.43	9.24e-08	3.1e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
HNSC	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-5.43	9.24e-08	3.1e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
HNSC	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.43	9.25e-08	3.1e-05	-0.3	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
HNSC	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-5.43	9.25e-08	3.1e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
HNSC	cis	rs9650657	0.504	rs7813802	ENSG00000269918.1	AF131215.9	5.43	9.25e-08	3.1e-05	0.24	0.24	Neuroticism;	chr8:11176467	chr8:11104691~11106704:-
HNSC	cis	rs11846409	0.932	rs10151046	ENSG00000211974.3	IGHV2-70	-5.43	9.26e-08	3.1e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106633095	chr14:106723574~106724093:-
HNSC	cis	rs9611565	0.569	rs6002328	ENSG00000235513.1	RP4-756G23.5	5.43	9.26e-08	3.1e-05	0.26	0.24	Vitiligo;	chr22:41314030	chr22:41209122~41217627:-
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000254174.1	IGHV1-12	5.43	9.26e-08	3.1e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106810329	chr14:106122420~106122709:-
HNSC	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	5.43	9.26e-08	3.1e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	5.43	9.27e-08	3.11e-05	0.3	0.24	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
HNSC	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	5.43	9.27e-08	3.11e-05	0.27	0.24	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
HNSC	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-5.43	9.28e-08	3.11e-05	-0.31	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
HNSC	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	5.43	9.29e-08	3.11e-05	0.28	0.24	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
HNSC	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-5.43	9.29e-08	3.11e-05	-0.23	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
HNSC	cis	rs3733585	0.736	rs4543113	ENSG00000250413.1	RP11-448G15.1	-5.43	9.29e-08	3.11e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10006681	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	5.43	9.3e-08	3.12e-05	0.3	0.24	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-5.43	9.31e-08	3.12e-05	-0.34	-0.24	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
HNSC	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.43	9.31e-08	3.12e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
HNSC	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-5.43	9.32e-08	3.12e-05	-0.29	-0.24	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28145952	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28147378	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28147406	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28148143	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28149979	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28151096	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28152885	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28153120	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28154567	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28156691	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28158424	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159056	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159666	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159843	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159925	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28159932	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28161802	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28162053	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28162598	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28163375	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28163759	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164580	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164825	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28164948	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28165025	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28165528	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28168434	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169019	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169249	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169676	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169755	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28169791	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-5.43	9.32e-08	3.12e-05	-0.31	-0.24	Depression;	chr6:28170075	chr6:28161781~28169594:+
HNSC	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	5.42	9.33e-08	3.12e-05	0.27	0.24	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
HNSC	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	5.42	9.33e-08	3.12e-05	0.32	0.24	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
HNSC	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	5.42	9.33e-08	3.13e-05	0.3	0.24	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
HNSC	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-5.42	9.33e-08	3.13e-05	-0.27	-0.24	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-5.42	9.33e-08	3.13e-05	-0.27	-0.24	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
HNSC	cis	rs9291683	0.546	rs13120348	ENSG00000250413.1	RP11-448G15.1	5.42	9.34e-08	3.13e-05	0.3	0.24	Bone mineral density;	chr4:10051531	chr4:10006482~10009725:+
HNSC	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	5.42	9.34e-08	3.13e-05	0.3	0.24	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	5.42	9.34e-08	3.13e-05	0.19	0.24	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
HNSC	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-5.42	9.35e-08	3.13e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
HNSC	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.42	9.35e-08	3.13e-05	0.33	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
HNSC	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	5.42	9.36e-08	3.13e-05	0.26	0.24	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
HNSC	cis	rs4699052	0.963	rs6533078	ENSG00000246560.2	RP11-10L12.4	5.42	9.36e-08	3.13e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103290999	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs7672802	ENSG00000246560.2	RP11-10L12.4	5.42	9.36e-08	3.13e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103291076	chr4:102828055~102844075:+
HNSC	cis	rs603446	0.967	rs3741301	ENSG00000254851.1	RP11-109L13.1	-5.42	9.37e-08	3.14e-05	-0.33	-0.24	Triglycerides;	chr11:116760675	chr11:117135528~117138582:+
HNSC	cis	rs4140799	0.816	rs1204996	ENSG00000266869.1	RP6-114E22.1	5.42	9.38e-08	3.14e-05	0.3	0.24	Neuroticism;	chr14:71719967	chr14:71848606~71908430:+
HNSC	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-5.42	9.38e-08	3.14e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
HNSC	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-5.42	9.38e-08	3.14e-05	-0.24	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
HNSC	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-5.42	9.39e-08	3.14e-05	-0.32	-0.24	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
HNSC	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-5.42	9.39e-08	3.14e-05	-0.28	-0.24	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
HNSC	cis	rs1355223	0.867	rs7943755	ENSG00000271369.1	RP11-350D17.3	-5.42	9.39e-08	3.14e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669904	chr11:34709600~34710161:+
HNSC	cis	rs6928977	0.896	rs2179779	ENSG00000234084.1	RP3-388E23.2	5.42	9.4e-08	3.15e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135328678	chr6:135301568~135307158:+
HNSC	cis	rs3754214	0.857	rs9126	ENSG00000228126.1	FALEC	-5.42	9.4e-08	3.15e-05	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr1:150286988	chr1:150515757~150518032:+
HNSC	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-5.42	9.4e-08	3.15e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
HNSC	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-5.42	9.4e-08	3.15e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	5.42	9.4e-08	3.15e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	5.42	9.4e-08	3.15e-05	0.22	0.24	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
HNSC	cis	rs1355223	0.902	rs6484726	ENSG00000271369.1	RP11-350D17.3	-5.42	9.41e-08	3.15e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676011	chr11:34709600~34710161:+
HNSC	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	5.42	9.41e-08	3.15e-05	0.18	0.24	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	5.42	9.42e-08	3.15e-05	0.3	0.24	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
HNSC	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-5.42	9.43e-08	3.15e-05	-0.27	-0.24	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
HNSC	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-5.42	9.43e-08	3.15e-05	-0.27	-0.24	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000249244.1	RP11-548H18.2	5.42	9.43e-08	3.15e-05	0.28	0.24	Corneal astigmatism;	chr4:119230297	chr4:119391831~119395335:-
HNSC	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	5.42	9.43e-08	3.16e-05	0.33	0.24	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	5.42	9.44e-08	3.16e-05	0.29	0.24	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
HNSC	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	5.42	9.44e-08	3.16e-05	0.28	0.24	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
HNSC	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	5.42	9.44e-08	3.16e-05	0.25	0.24	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
HNSC	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-5.42	9.46e-08	3.16e-05	-0.21	-0.24	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.507	rs12678938	ENSG00000269918.1	AF131215.9	-5.42	9.47e-08	3.17e-05	-0.24	-0.24	Neuroticism;	chr8:10159459	chr8:11104691~11106704:-
HNSC	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	5.42	9.47e-08	3.17e-05	0.33	0.24	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
HNSC	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-5.42	9.47e-08	3.17e-05	-0.28	-0.24	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
HNSC	cis	rs4218	0.648	rs35460138	ENSG00000277144.1	RP11-59H7.4	-5.42	9.47e-08	3.17e-05	-0.32	-0.24	Social communication problems;	chr15:59093200	chr15:59115547~59116089:-
HNSC	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	5.42	9.48e-08	3.17e-05	0.28	0.24	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
HNSC	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	5.42	9.49e-08	3.17e-05	0.28	0.24	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	5.42	9.49e-08	3.17e-05	0.28	0.24	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
HNSC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-5.42	9.5e-08	3.18e-05	-0.26	-0.24	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000211974.3	IGHV2-70	-5.42	9.5e-08	3.18e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106638433	chr14:106723574~106724093:-
HNSC	cis	rs9611519	1	rs9611510	ENSG00000235513.1	RP4-756G23.5	5.42	9.51e-08	3.18e-05	0.27	0.24	Neuroticism;	chr22:41173120	chr22:41209122~41217627:-
HNSC	cis	rs7980687	0.527	rs1626703	ENSG00000280120.1	RP11-546D6.3	5.42	9.53e-08	3.18e-05	0.21	0.24	Head circumference (infant);Educational attainment;Height;	chr12:123226288	chr12:123152324~123153377:-
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	5.42	9.53e-08	3.19e-05	0.3	0.24	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
HNSC	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	5.42	9.54e-08	3.19e-05	0.33	0.24	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
HNSC	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-5.42	9.55e-08	3.19e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-5.42	9.55e-08	3.19e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	5.42	9.56e-08	3.19e-05	0.31	0.24	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
HNSC	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-5.42	9.57e-08	3.2e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
HNSC	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	5.42	9.58e-08	3.2e-05	0.29	0.24	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
HNSC	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	5.42	9.58e-08	3.2e-05	0.24	0.24	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
HNSC	cis	rs950169	0.84	rs72748702	ENSG00000229212.6	RP11-561C5.4	-5.42	9.59e-08	3.2e-05	-0.34	-0.24	Schizophrenia;	chr15:84246494	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.922	rs4338765	ENSG00000229212.6	RP11-561C5.4	-5.42	9.59e-08	3.2e-05	-0.34	-0.24	Schizophrenia;	chr15:84248084	chr15:85205440~85234795:-
HNSC	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-5.42	9.6e-08	3.21e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.42	9.6e-08	3.21e-05	-0.2	-0.24	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-5.42	9.61e-08	3.21e-05	-0.28	-0.24	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
HNSC	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	5.42	9.62e-08	3.21e-05	0.27	0.24	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
HNSC	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558258	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558259	chr4:55363971~55395847:-
HNSC	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	5.42	9.62e-08	3.21e-05	0.29	0.24	Height;	chr4:55558261	chr4:55363971~55395847:-
HNSC	cis	rs11648785	0.62	rs10153134	ENSG00000222019.6	URAHP	5.42	9.62e-08	3.21e-05	0.23	0.24	Tanning;	chr16:90024691	chr16:90039761~90047773:-
HNSC	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-5.42	9.62e-08	3.21e-05	-0.31	-0.24	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
HNSC	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-5.42	9.63e-08	3.22e-05	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000233609.3	RP11-62H7.2	-5.42	9.64e-08	3.22e-05	-0.24	-0.24	Joint mobility (Beighton score);	chr8:8935833	chr8:8961200~8979025:+
HNSC	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	5.42	9.64e-08	3.22e-05	0.42	0.24	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
HNSC	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	5.42	9.64e-08	3.22e-05	0.42	0.24	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
HNSC	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	5.42	9.65e-08	3.22e-05	0.23	0.24	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
HNSC	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-5.42	9.66e-08	3.22e-05	-0.37	-0.24	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
HNSC	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.42	9.68e-08	3.23e-05	0.36	0.24	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	5.42	9.68e-08	3.23e-05	0.22	0.24	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
HNSC	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	5.42	9.68e-08	3.23e-05	0.35	0.24	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	5.42	9.68e-08	3.23e-05	0.35	0.24	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
HNSC	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.42	9.69e-08	3.23e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-5.42	9.69e-08	3.24e-05	-0.16	-0.24	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
HNSC	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	5.42	9.7e-08	3.24e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	5.42	9.7e-08	3.24e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
HNSC	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-5.42	9.7e-08	3.24e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
HNSC	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-5.42	9.7e-08	3.24e-05	-0.21	-0.24	Height;	chr11:118749988	chr11:118791254~118793137:+
HNSC	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-5.42	9.7e-08	3.24e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
HNSC	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-5.42	9.7e-08	3.24e-05	-0.28	-0.24	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
HNSC	cis	rs656319	0.513	rs34990153	ENSG00000269918.1	AF131215.9	-5.42	9.71e-08	3.24e-05	-0.25	-0.24	Myopia (pathological);	chr8:10138879	chr8:11104691~11106704:-
HNSC	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	5.42	9.72e-08	3.24e-05	0.27	0.24	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	5.42	9.72e-08	3.24e-05	0.27	0.24	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
HNSC	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	5.42	9.73e-08	3.24e-05	0.26	0.24	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
HNSC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-5.42	9.73e-08	3.25e-05	-0.2	-0.24	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
HNSC	cis	rs3738443	0.52	rs6699577	ENSG00000259865.1	RP11-488L18.10	5.42	9.73e-08	3.25e-05	0.19	0.24	Alcohol dependence;	chr1:247224152	chr1:247187281~247188526:-
HNSC	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-5.42	9.75e-08	3.25e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
HNSC	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	5.42	9.75e-08	3.25e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	5.42	9.75e-08	3.25e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	5.42	9.76e-08	3.26e-05	0.3	0.24	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	5.42	9.76e-08	3.26e-05	0.19	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
HNSC	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-5.42	9.78e-08	3.26e-05	-0.3	-0.24	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
HNSC	cis	rs6714900	0.589	rs12993301	ENSG00000234896.1	OR7E62P	-5.42	9.78e-08	3.26e-05	-0.29	-0.24	Blood protein levels;	chr2:71055392	chr2:71055527~71056003:+
HNSC	cis	rs8054556	1	rs10871451	ENSG00000183604.13	SMG1P5	-5.42	9.78e-08	3.26e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30267553~30335374:-
HNSC	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-5.42	9.79e-08	3.26e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
HNSC	cis	rs9611519	1	rs9611505	ENSG00000235513.1	RP4-756G23.5	5.42	9.8e-08	3.27e-05	0.27	0.24	Neuroticism;	chr22:41144275	chr22:41209122~41217627:-
HNSC	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-5.42	9.8e-08	3.27e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
HNSC	cis	rs2115630	0.967	rs11073702	ENSG00000229212.6	RP11-561C5.4	5.42	9.81e-08	3.27e-05	0.28	0.24	P wave terminal force;	chr15:84766840	chr15:85205440~85234795:-
HNSC	cis	rs1012068	0.581	rs5749339	ENSG00000236132.1	CTA-440B3.1	5.42	9.81e-08	3.27e-05	0.29	0.24	Chronic hepatitis C infection;	chr22:31919749	chr22:31816379~31817491:-
HNSC	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.42	9.81e-08	3.27e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
HNSC	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-5.42	9.81e-08	3.27e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
HNSC	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	5.42	9.82e-08	3.27e-05	0.3	0.24	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
HNSC	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-5.42	9.82e-08	3.27e-05	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
HNSC	cis	rs2404602	0.536	rs1587381	ENSG00000259422.1	RP11-593F23.1	5.41	9.83e-08	3.28e-05	0.28	0.24	Blood metabolite levels;	chr15:76477279	chr15:76174891~76181486:-
HNSC	cis	rs3806843	0.931	rs13168670	ENSG00000202515.1	VTRNA1-3	-5.41	9.85e-08	3.28e-05	-0.27	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140726158~140726246:+
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	5.41	9.85e-08	3.28e-05	0.2	0.24	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
HNSC	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	5.41	9.85e-08	3.28e-05	0.35	0.24	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
HNSC	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	5.41	9.88e-08	3.29e-05	0.27	0.24	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
HNSC	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-5.41	9.88e-08	3.29e-05	-0.28	-0.24	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
HNSC	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	5.41	9.89e-08	3.29e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
HNSC	cis	rs4141404	0.748	rs2232170	ENSG00000236132.1	CTA-440B3.1	5.41	9.89e-08	3.3e-05	0.3	0.24	Paclitaxel-induced neuropathy;	chr22:31141136	chr22:31816379~31817491:-
HNSC	cis	rs9611519	1	rs4820433	ENSG00000235513.1	RP4-756G23.5	5.41	9.89e-08	3.3e-05	0.26	0.24	Neuroticism;	chr22:41211061	chr22:41209122~41217627:-
HNSC	cis	rs9611519	1	rs3818003	ENSG00000235513.1	RP4-756G23.5	5.41	9.89e-08	3.3e-05	0.26	0.24	Neuroticism;	chr22:41213686	chr22:41209122~41217627:-
HNSC	cis	rs2985684	0.894	rs4900928	ENSG00000278009.1	RP11-649E7.8	5.41	9.9e-08	3.3e-05	0.32	0.24	Carotid intima media thickness;	chr14:49554099	chr14:49601011~49601124:-
HNSC	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-5.41	9.91e-08	3.3e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
HNSC	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-5.41	9.91e-08	3.3e-05	-0.31	-0.24	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
HNSC	cis	rs10256972	1	rs10256972	ENSG00000225146.1	AC073957.15	-5.41	9.92e-08	3.3e-05	-0.28	-0.24	Endometriosis;Longevity;	chr7:999367	chr7:1029025~1043891:+
HNSC	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-5.41	9.93e-08	3.31e-05	-0.26	-0.24	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
HNSC	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	5.41	9.94e-08	3.31e-05	0.27	0.24	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	5.41	9.94e-08	3.31e-05	0.59	0.24	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
HNSC	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	5.41	9.95e-08	3.31e-05	0.28	0.24	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
HNSC	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	5.41	9.95e-08	3.31e-05	0.32	0.24	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
HNSC	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-5.41	9.96e-08	3.32e-05	-0.26	-0.24	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
HNSC	cis	rs8040855	0.644	rs4635318	ENSG00000259774.1	RP11-182J1.13	-5.41	9.96e-08	3.32e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85183506	chr15:84422618~84425882:+
HNSC	cis	rs8032939	0.533	rs17574546	ENSG00000259747.1	RP11-275I4.2	5.41	9.96e-08	3.32e-05	0.31	0.24	Rheumatoid arthritis;	chr15:38610275	chr15:38671847~38689191:+
HNSC	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	5.41	9.97e-08	3.32e-05	0.3	0.24	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
HNSC	cis	rs2058059	0.551	rs13225871	ENSG00000225648.4	SBDSP1	-5.41	9.97e-08	3.32e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72573203	chr7:72829425~72836701:+
HNSC	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-5.41	9.97e-08	3.32e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-5.41	9.97e-08	3.32e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	5.41	9.97e-08	3.32e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
HNSC	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-5.41	9.98e-08	3.32e-05	-0.28	-0.24	Height;	chr2:46617930	chr2:46668870~46670778:+
HNSC	cis	rs17428076	0.715	rs788164	ENSG00000228389.1	AC068039.4	5.41	9.98e-08	3.32e-05	0.29	0.24	Myopia;	chr2:172048662	chr2:171773482~171775844:+
HNSC	cis	rs72615157	0.612	rs7786505	ENSG00000078319.8	PMS2P1	-5.41	9.99e-08	3.33e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100219962	chr7:100320992~100341908:-
HNSC	cis	rs72615157	0.664	rs6953580	ENSG00000078319.8	PMS2P1	-5.41	9.99e-08	3.33e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr7:100227652	chr7:100320992~100341908:-
HNSC	cis	rs8035957	0.564	rs17651741	ENSG00000259747.1	RP11-275I4.2	-5.41	1e-07	3.33e-05	-0.32	-0.24	Type 1 diabetes;	chr15:38577465	chr15:38671847~38689191:+
HNSC	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-5.41	1e-07	3.33e-05	-0.42	-0.24	Depression;	chr6:28200565	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	5.41	1e-07	3.33e-05	0.25	0.24	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	5.41	1e-07	3.33e-05	0.25	0.24	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
HNSC	cis	rs748404	0.534	rs489509	ENSG00000205771.5	CATSPER2P1	-5.41	1e-07	3.33e-05	-0.31	-0.24	Lung cancer;	chr15:43294709	chr15:43726918~43747094:-
HNSC	cis	rs4947019	0.688	rs9487119	ENSG00000260273.1	RP11-425D10.10	5.41	1e-07	3.34e-05	0.68	0.24	Hematological parameters;	chr6:109464954	chr6:109382795~109383666:+
HNSC	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.41	1e-07	3.34e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
HNSC	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-5.41	1e-07	3.34e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
HNSC	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-5.41	1e-07	3.34e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
HNSC	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	5.41	1.01e-07	3.35e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
HNSC	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-5.41	1.01e-07	3.35e-05	-0.28	-0.24	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
HNSC	cis	rs2235642	0.621	rs2667665	ENSG00000280231.1	LA16c-380F5.3	-5.41	1.01e-07	3.35e-05	-0.32	-0.24	Coronary artery disease;	chr16:1519523	chr16:1553655~1554130:-
HNSC	cis	rs4947019	0.614	rs117663805	ENSG00000260273.1	RP11-425D10.10	5.41	1.01e-07	3.35e-05	0.68	0.24	Hematological parameters;	chr6:109455712	chr6:109382795~109383666:+
HNSC	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-5.41	1.01e-07	3.35e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
HNSC	cis	rs7580658	0.75	rs6761391	ENSG00000236682.1	AC068282.3	-5.41	1.01e-07	3.35e-05	-0.28	-0.24	Protein C levels;	chr2:127396708	chr2:127389130~127400580:+
HNSC	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-5.41	1.01e-07	3.35e-05	-0.22	-0.24	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
HNSC	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-5.41	1.01e-07	3.35e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
HNSC	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	5.41	1.01e-07	3.35e-05	0.27	0.24	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
HNSC	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	5.41	1.01e-07	3.35e-05	0.27	0.24	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
HNSC	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-5.41	1.01e-07	3.35e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	5.41	1.01e-07	3.36e-05	0.31	0.24	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
HNSC	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.41	1.01e-07	3.36e-05	-0.31	-0.24	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
HNSC	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	5.41	1.01e-07	3.36e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	5.41	1.01e-07	3.36e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
HNSC	cis	rs7674212	0.541	rs4699050	ENSG00000246560.2	RP11-10L12.4	5.41	1.01e-07	3.36e-05	0.28	0.24	Type 2 diabetes;	chr4:103193140	chr4:102828055~102844075:+
HNSC	cis	rs7674212	0.541	rs17217473	ENSG00000246560.2	RP11-10L12.4	5.41	1.01e-07	3.36e-05	0.28	0.24	Type 2 diabetes;	chr4:103193585	chr4:102828055~102844075:+
HNSC	cis	rs6928977	0.66	rs12214269	ENSG00000234084.1	RP3-388E23.2	5.41	1.01e-07	3.37e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135525380	chr6:135301568~135307158:+
HNSC	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-5.41	1.01e-07	3.37e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
HNSC	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.41	1.01e-07	3.37e-05	-0.27	-0.24	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
HNSC	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	5.41	1.01e-07	3.37e-05	0.23	0.24	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
HNSC	cis	rs6693567	0.565	rs10888578	ENSG00000228126.1	FALEC	-5.41	1.01e-07	3.37e-05	-0.29	-0.24	Migraine;	chr1:150288580	chr1:150515757~150518032:+
HNSC	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-5.41	1.02e-07	3.38e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
HNSC	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	5.41	1.02e-07	3.38e-05	0.28	0.24	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
HNSC	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-5.41	1.02e-07	3.38e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
HNSC	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	5.41	1.02e-07	3.38e-05	0.34	0.24	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
HNSC	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	5.41	1.02e-07	3.38e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
HNSC	cis	rs2115630	1	rs1030863	ENSG00000229212.6	RP11-561C5.4	5.41	1.02e-07	3.38e-05	0.28	0.24	P wave terminal force;	chr15:84739404	chr15:85205440~85234795:-
HNSC	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-5.41	1.02e-07	3.38e-05	-0.46	-0.24	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	5.41	1.02e-07	3.38e-05	0.3	0.24	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	5.41	1.02e-07	3.38e-05	0.3	0.24	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	5.41	1.02e-07	3.38e-05	0.31	0.24	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
HNSC	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
HNSC	cis	rs61160187	0.582	rs17332824	ENSG00000215032.2	GNL3LP1	-5.41	1.02e-07	3.39e-05	-0.27	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60891935~60893577:-
HNSC	cis	rs1355223	0.752	rs17293467	ENSG00000271369.1	RP11-350D17.3	-5.41	1.02e-07	3.39e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655813	chr11:34709600~34710161:+
HNSC	cis	rs9840812	0.773	rs1154988	ENSG00000239213.4	NCK1-AS1	-5.41	1.02e-07	3.39e-05	-0.23	-0.24	Fibrinogen levels;	chr3:136206349	chr3:136841726~136862054:-
HNSC	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	5.41	1.02e-07	3.39e-05	0.29	0.24	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
HNSC	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-5.41	1.02e-07	3.4e-05	-0.28	-0.24	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
HNSC	cis	rs116095464	1	rs7723693	ENSG00000277812.1	AC021087.1	5.41	1.02e-07	3.4e-05	0.52	0.24	Breast cancer;	chr5:305917	chr5:262769~262881:+
HNSC	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	5.41	1.02e-07	3.4e-05	0.3	0.24	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	5.41	1.02e-07	3.4e-05	0.26	0.24	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
HNSC	cis	rs9650657	0.504	rs2409724	ENSG00000269918.1	AF131215.9	-5.41	1.02e-07	3.4e-05	-0.25	-0.24	Neuroticism;	chr8:11184133	chr8:11104691~11106704:-
HNSC	cis	rs5753618	0.583	rs5753615	ENSG00000236132.1	CTA-440B3.1	-5.41	1.02e-07	3.4e-05	-0.3	-0.24	Colorectal cancer;	chr22:31432041	chr22:31816379~31817491:-
HNSC	cis	rs11992162	0.967	rs7461062	ENSG00000206014.6	OR7E161P	-5.41	1.02e-07	3.4e-05	-0.26	-0.24	Monocyte count;	chr8:11974439	chr8:11928597~11929563:-
HNSC	cis	rs9402743	0.631	rs9376112	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135606862	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.635	rs9373135	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135611101	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs2143681	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135611867	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs9376113	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135612254	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6934482	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135612363	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402724	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135614046	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.564	rs2327649	ENSG00000217482.2	HMGB1P17	5.41	1.03e-07	3.41e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615097	chr6:135636086~135636713:-
HNSC	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-5.41	1.03e-07	3.41e-05	-0.28	-0.24	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
HNSC	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.41	1.03e-07	3.41e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
HNSC	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	5.41	1.03e-07	3.41e-05	0.25	0.24	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
HNSC	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-5.41	1.03e-07	3.41e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
HNSC	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-5.41	1.03e-07	3.41e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
HNSC	cis	rs8040855	0.644	rs7495437	ENSG00000259774.1	RP11-182J1.13	-5.41	1.03e-07	3.42e-05	-0.3	-0.24	Bulimia nervosa;	chr15:85183059	chr15:84422618~84425882:+
HNSC	cis	rs9813712	1	rs9864582	ENSG00000249846.5	RP11-77P16.4	5.41	1.03e-07	3.42e-05	0.29	0.24	Response to amphetamines;	chr3:130251619	chr3:130112550~130120579:+
HNSC	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5.41	1.03e-07	3.42e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
HNSC	cis	rs7777677	0.925	rs4726546	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs6960743	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs6956756	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.889	rs6975391	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs9655661	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.888	rs9655574	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.963	rs4726550	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.963	rs7796324	ENSG00000244273.1	PGBD4P1	-5.41	1.03e-07	3.42e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142722358~142722764:+
HNSC	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-5.41	1.03e-07	3.42e-05	-0.3	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
HNSC	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	5.41	1.03e-07	3.42e-05	0.28	0.24	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.41	1.03e-07	3.42e-05	0.26	0.24	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	5.41	1.03e-07	3.43e-05	0.29	0.24	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
HNSC	cis	rs1008375	0.931	rs3775926	ENSG00000249502.1	AC006160.5	-5.41	1.03e-07	3.43e-05	-0.27	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598214	chr4:17587467~17614571:-
HNSC	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-5.41	1.03e-07	3.43e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
HNSC	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	5.41	1.03e-07	3.43e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
HNSC	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	5.41	1.03e-07	3.43e-05	0.34	0.24	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
HNSC	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	5.41	1.03e-07	3.43e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
HNSC	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	5.41	1.03e-07	3.43e-05	0.3	0.24	Height;	chr4:55437438	chr4:55387949~55388271:+
HNSC	cis	rs9291683	0.546	rs6829727	ENSG00000250413.1	RP11-448G15.1	-5.41	1.03e-07	3.43e-05	-0.31	-0.24	Bone mineral density;	chr4:10050048	chr4:10006482~10009725:+
HNSC	cis	rs860818	0.793	rs10230879	ENSG00000226816.2	AC005082.12	-5.41	1.04e-07	3.43e-05	-0.65	-0.24	Initial pursuit acceleration;	chr7:23158939	chr7:23206013~23208045:+
HNSC	cis	rs6928977	0.863	rs2614255	ENSG00000234084.1	RP3-388E23.2	5.41	1.04e-07	3.43e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135342443	chr6:135301568~135307158:+
HNSC	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	5.41	1.04e-07	3.44e-05	0.33	0.24	Height;	chr6:109331033	chr6:109382795~109383666:+
HNSC	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-5.4	1.04e-07	3.44e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
HNSC	cis	rs6604026	0.885	rs12738964	ENSG00000223787.2	RP4-593M8.1	5.4	1.04e-07	3.44e-05	0.34	0.24	Multiple sclerosis;	chr1:92808893	chr1:92580476~92580821:-
HNSC	cis	rs9611519	0.894	rs9623320	ENSG00000235513.1	RP4-756G23.5	5.4	1.04e-07	3.44e-05	0.27	0.24	Neuroticism;	chr22:41082478	chr22:41209122~41217627:-
HNSC	cis	rs13126694	0.71	rs6848159	ENSG00000248429.4	RP11-597D13.9	-5.4	1.04e-07	3.44e-05	-0.27	-0.24	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158170752~158202877:+
HNSC	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000254153.1	CTA-398F10.2	-5.4	1.04e-07	3.45e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8456909~8461337:-
HNSC	cis	rs8054556	1	rs11150577	ENSG00000183604.13	SMG1P5	-5.4	1.04e-07	3.45e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-5.4	1.04e-07	3.45e-05	-0.24	-0.24	Height;	chr5:37022673	chr5:36666214~36725195:-
HNSC	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	5.4	1.04e-07	3.45e-05	0.27	0.24	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-5.4	1.04e-07	3.45e-05	-0.22	-0.24	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
HNSC	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.4	1.04e-07	3.45e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
HNSC	cis	rs763121	0.776	rs4820346	ENSG00000273076.1	RP3-508I15.22	-5.4	1.04e-07	3.45e-05	-0.26	-0.24	Menopause (age at onset);	chr22:38729069	chr22:38743495~38743910:+
HNSC	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	5.4	1.04e-07	3.45e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
HNSC	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	5.4	1.04e-07	3.46e-05	0.23	0.24	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
HNSC	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.4	1.04e-07	3.46e-05	-0.22	-0.24	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
HNSC	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-5.4	1.04e-07	3.46e-05	-0.32	-0.24	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
HNSC	cis	rs3806843	0.966	rs2563265	ENSG00000202515.1	VTRNA1-3	5.4	1.05e-07	3.46e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140726158~140726246:+
HNSC	cis	rs1355223	0.902	rs7129089	ENSG00000271369.1	RP11-350D17.3	-5.4	1.05e-07	3.47e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34678152	chr11:34709600~34710161:+
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000229212.6	RP11-561C5.4	-5.4	1.05e-07	3.47e-05	-0.34	-0.24	Schizophrenia;	chr15:84251244	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000229212.6	RP11-561C5.4	-5.4	1.05e-07	3.47e-05	-0.34	-0.24	Schizophrenia;	chr15:84254768	chr15:85205440~85234795:-
HNSC	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	5.4	1.05e-07	3.47e-05	0.3	0.24	Height;	chr4:55440988	chr4:55387949~55388271:+
HNSC	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-5.4	1.05e-07	3.47e-05	-0.24	-0.24	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
HNSC	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-5.4	1.05e-07	3.47e-05	-0.31	-0.24	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
HNSC	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-5.4	1.05e-07	3.48e-05	-0.22	-0.24	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
HNSC	cis	rs6928977	0.896	rs2746421	ENSG00000234084.1	RP3-388E23.2	5.4	1.05e-07	3.48e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135340491	chr6:135301568~135307158:+
HNSC	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-5.4	1.05e-07	3.49e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
HNSC	cis	rs6928977	0.863	rs2746430	ENSG00000234084.1	RP3-388E23.2	5.4	1.05e-07	3.49e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352154	chr6:135301568~135307158:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-5.4	1.05e-07	3.49e-05	-0.22	-0.24	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	5.4	1.05e-07	3.49e-05	0.26	0.24	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	5.4	1.05e-07	3.49e-05	0.26	0.24	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
HNSC	cis	rs1056107	0.966	rs4979094	ENSG00000225513.1	RP11-165N19.2	-5.4	1.05e-07	3.49e-05	-0.26	-0.24	Colorectal cancer;	chr9:112283837	chr9:112173522~112173971:-
HNSC	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-5.4	1.05e-07	3.49e-05	-0.29	-0.24	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
HNSC	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-5.4	1.05e-07	3.49e-05	-0.25	-0.24	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
HNSC	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.4	1.05e-07	3.49e-05	0.29	0.24	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	5.4	1.05e-07	3.49e-05	0.3	0.24	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
HNSC	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	5.4	1.05e-07	3.49e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-5.4	1.05e-07	3.49e-05	-0.22	-0.24	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
HNSC	cis	rs2179367	0.632	rs9498335	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149372648	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	5.4	1.06e-07	3.49e-05	0.35	0.24	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
HNSC	cis	rs6928977	0.86	rs2614266	ENSG00000231028.7	LINC00271	5.4	1.06e-07	3.49e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135497801~135716055:+
HNSC	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-5.4	1.06e-07	3.5e-05	-0.3	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	5.4	1.06e-07	3.5e-05	0.33	0.24	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
HNSC	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	5.4	1.06e-07	3.5e-05	0.34	0.24	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
HNSC	cis	rs860295	0.65	rs2993207	ENSG00000203761.5	MSTO2P	5.4	1.06e-07	3.5e-05	0.18	0.24	Body mass index;	chr1:155903523	chr1:155745829~155750137:+
HNSC	cis	rs6928977	0.827	rs2614265	ENSG00000234084.1	RP3-388E23.2	5.4	1.06e-07	3.5e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135394237	chr6:135301568~135307158:+
HNSC	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.4	1.06e-07	3.51e-05	0.35	0.24	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
HNSC	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-5.4	1.06e-07	3.52e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
HNSC	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-5.4	1.06e-07	3.52e-05	-0.42	-0.24	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
HNSC	cis	rs17507216	0.958	rs28648832	ENSG00000276710.3	CSPG4P8	-5.4	1.06e-07	3.52e-05	-0.31	-0.24	Excessive daytime sleepiness;	chr15:82567642	chr15:82459472~82477258:+
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-5.4	1.06e-07	3.52e-05	-0.22	-0.24	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
HNSC	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-5.4	1.06e-07	3.52e-05	-0.28	-0.24	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
HNSC	cis	rs2243480	1	rs2462569	ENSG00000179406.6	LINC00174	5.4	1.06e-07	3.52e-05	0.5	0.24	Diabetic kidney disease;	chr7:66009859	chr7:66376044~66401338:-
HNSC	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-5.4	1.06e-07	3.52e-05	-0.33	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
HNSC	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	5.4	1.07e-07	3.53e-05	0.4	0.24	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-5.4	1.07e-07	3.53e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
HNSC	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	5.4	1.07e-07	3.53e-05	0.42	0.24	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
HNSC	cis	rs7824557	0.547	rs2409745	ENSG00000269918.1	AF131215.9	5.4	1.07e-07	3.53e-05	0.24	0.24	Retinal vascular caliber;	chr8:11219126	chr8:11104691~11106704:-
HNSC	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.4	1.07e-07	3.53e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
HNSC	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	5.4	1.07e-07	3.53e-05	0.27	0.24	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
HNSC	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-5.4	1.07e-07	3.54e-05	-0.3	-0.24	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
HNSC	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-5.4	1.07e-07	3.54e-05	-0.31	-0.24	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
HNSC	cis	rs5758511	0.508	rs58099562	ENSG00000226450.2	CYP2D8P	5.4	1.07e-07	3.54e-05	0.25	0.24	Birth weight;	chr22:42057768	chr22:42149886~42155001:-
HNSC	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-5.4	1.07e-07	3.55e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
HNSC	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	5.4	1.07e-07	3.55e-05	0.29	0.24	Height;	chr4:55425312	chr4:55387949~55388271:+
HNSC	cis	rs8177876	0.731	rs79546329	ENSG00000261061.1	RP11-303E16.2	-5.4	1.07e-07	3.55e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103636	chr16:81030770~81031485:+
HNSC	cis	rs8177876	0.731	rs12448806	ENSG00000261061.1	RP11-303E16.2	-5.4	1.07e-07	3.55e-05	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104597	chr16:81030770~81031485:+
HNSC	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-5.4	1.07e-07	3.55e-05	-0.28	-0.24	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
HNSC	cis	rs7819412	0.806	rs2409689	ENSG00000269918.1	AF131215.9	-5.4	1.07e-07	3.55e-05	-0.24	-0.24	Triglycerides;	chr8:11075358	chr8:11104691~11106704:-
HNSC	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	5.4	1.07e-07	3.55e-05	0.3	0.24	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
HNSC	cis	rs6928977	0.66	rs9373131	ENSG00000234084.1	RP3-388E23.2	5.4	1.07e-07	3.55e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135301568~135307158:+
HNSC	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-5.4	1.07e-07	3.55e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
HNSC	cis	rs5758659	0.967	rs5751250	ENSG00000227370.1	RP4-669P10.19	-5.4	1.08e-07	3.56e-05	-0.23	-0.24	Cognitive function;	chr22:42243639	chr22:42132543~42132998:+
HNSC	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	5.4	1.08e-07	3.56e-05	0.18	0.24	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
HNSC	cis	rs10256972	0.678	rs6962989	ENSG00000225146.1	AC073957.15	-5.4	1.08e-07	3.56e-05	-0.43	-0.24	Endometriosis;Longevity;	chr7:977876	chr7:1029025~1043891:+
HNSC	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-5.4	1.08e-07	3.56e-05	-0.24	-0.24	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
HNSC	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	5.4	1.08e-07	3.57e-05	0.23	0.24	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
HNSC	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.4	1.08e-07	3.57e-05	-0.27	-0.24	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
HNSC	cis	rs4218	0.689	rs12902628	ENSG00000277144.1	RP11-59H7.4	-5.4	1.08e-07	3.57e-05	-0.32	-0.24	Social communication problems;	chr15:59100193	chr15:59115547~59116089:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-5.4	1.08e-07	3.57e-05	-0.34	-0.24	Depression;	chr6:28242910	chr6:28115628~28116551:+
HNSC	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-5.4	1.08e-07	3.58e-05	-0.29	-0.24	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
HNSC	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	5.4	1.08e-07	3.58e-05	0.3	0.24	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
HNSC	cis	rs4937076	0.51	rs13424	ENSG00000254967.5	RP11-680F20.6	-5.4	1.08e-07	3.58e-05	-0.27	-0.24	Primary tooth development (time to first tooth eruption);	chr11:125957058	chr11:125950116~125956319:+
HNSC	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.4	1.08e-07	3.58e-05	-0.27	-0.24	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000254153.1	CTA-398F10.2	5.4	1.08e-07	3.58e-05	0.27	0.24	Mood instability;	chr8:8525195	chr8:8456909~8461337:-
HNSC	cis	rs2439831	0.867	rs2242068	ENSG00000205771.5	CATSPER2P1	-5.4	1.08e-07	3.58e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43407106	chr15:43726918~43747094:-
HNSC	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-5.4	1.08e-07	3.58e-05	-0.23	-0.24	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
HNSC	cis	rs12468226	1	rs7565875	ENSG00000226261.1	AC064836.3	5.4	1.09e-07	3.59e-05	0.35	0.24	Urate levels;	chr2:202516412	chr2:202336024~202336727:-
HNSC	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-5.4	1.09e-07	3.59e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
HNSC	cis	rs72727394	0.51	rs56165729	ENSG00000259747.1	RP11-275I4.2	-5.4	1.09e-07	3.59e-05	-0.33	-0.24	Crohn's disease;	chr15:38627978	chr15:38671847~38689191:+
HNSC	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	5.4	1.09e-07	3.59e-05	0.25	0.24	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
HNSC	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	5.4	1.09e-07	3.59e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	5.4	1.09e-07	3.59e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
HNSC	cis	rs6714900	0.588	rs2287331	ENSG00000234896.1	OR7E62P	-5.4	1.09e-07	3.59e-05	-0.29	-0.24	Blood protein levels;	chr2:71067422	chr2:71055527~71056003:+
HNSC	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-5.4	1.09e-07	3.59e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-5.4	1.09e-07	3.59e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
HNSC	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	5.4	1.09e-07	3.59e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
HNSC	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	5.4	1.09e-07	3.6e-05	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
HNSC	cis	rs860295	0.812	rs12024257	ENSG00000203761.5	MSTO2P	-5.4	1.09e-07	3.6e-05	-0.19	-0.24	Body mass index;	chr1:155810745	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.812	rs6657670	ENSG00000203761.5	MSTO2P	-5.4	1.09e-07	3.6e-05	-0.19	-0.24	Body mass index;	chr1:155818076	chr1:155745829~155750137:+
HNSC	cis	rs8054556	1	rs9925915	ENSG00000183604.13	SMG1P5	-5.4	1.09e-07	3.6e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:30267553~30335374:-
HNSC	cis	rs2579103	0.898	rs2118807	ENSG00000258183.4	RP11-753N8.1	-5.4	1.09e-07	3.6e-05	-0.3	-0.24	Body mass index;	chr12:90205569	chr12:90280894~90300340:+
HNSC	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-5.4	1.09e-07	3.6e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000254153.1	CTA-398F10.2	5.39	1.09e-07	3.61e-05	0.26	0.24	Neuroticism;	chr8:8237439	chr8:8456909~8461337:-
HNSC	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	5.39	1.09e-07	3.61e-05	0.26	0.24	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
HNSC	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-5.39	1.09e-07	3.61e-05	-0.23	-0.24	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000254153.1	CTA-398F10.2	-5.39	1.09e-07	3.61e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9037242	chr8:8456909~8461337:-
HNSC	cis	rs2810114	1	rs2810114	ENSG00000274818.1	RP1-292L20.3	-5.39	1.09e-07	3.61e-05	-0.3	-0.24	Alcohol dependence;	chr14:70928887	chr14:70906657~70907111:-
HNSC	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	5.39	1.09e-07	3.61e-05	0.28	0.24	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
HNSC	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-5.39	1.1e-07	3.61e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	5.39	1.1e-07	3.62e-05	0.29	0.24	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
HNSC	cis	rs2032447	0.613	rs6456708	ENSG00000272462.2	U91328.19	-5.39	1.1e-07	3.62e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26032619	chr6:25992662~26001775:+
HNSC	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	5.39	1.1e-07	3.62e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
HNSC	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.39	1.1e-07	3.63e-05	0.32	0.24	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-5.39	1.1e-07	3.63e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
HNSC	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	5.39	1.1e-07	3.63e-05	0.26	0.24	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
HNSC	cis	rs7819412	0.806	rs6980856	ENSG00000269918.1	AF131215.9	5.39	1.1e-07	3.63e-05	0.24	0.24	Triglycerides;	chr8:11080750	chr8:11104691~11106704:-
HNSC	cis	rs17428076	0.836	rs12053046	ENSG00000228389.1	AC068039.4	-5.39	1.1e-07	3.64e-05	-0.29	-0.24	Myopia;	chr2:171816889	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-5.39	1.1e-07	3.64e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
HNSC	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	5.39	1.1e-07	3.64e-05	0.27	0.24	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
HNSC	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-5.39	1.1e-07	3.64e-05	-0.3	-0.24	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
HNSC	cis	rs10504130	0.569	rs35032384	ENSG00000272024.1	RP11-546K22.3	-5.39	1.1e-07	3.64e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51950284~51950690:+
HNSC	cis	rs2933343	0.7	rs1680779	ENSG00000261159.1	RP11-723O4.9	5.39	1.1e-07	3.64e-05	0.24	0.24	IgG glycosylation;	chr3:128895927	chr3:128859716~128860526:-
HNSC	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	5.39	1.1e-07	3.64e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	5.39	1.1e-07	3.64e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
HNSC	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-5.39	1.1e-07	3.64e-05	-0.22	-0.24	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-5.39	1.1e-07	3.64e-05	-0.22	-0.24	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
HNSC	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	5.39	1.1e-07	3.64e-05	0.24	0.24	Height;	chr5:36941665	chr5:36666214~36725195:-
HNSC	cis	rs6928977	0.863	rs2179780	ENSG00000234084.1	RP3-388E23.2	5.39	1.11e-07	3.65e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135329128	chr6:135301568~135307158:+
HNSC	cis	rs9300255	0.537	rs1619561	ENSG00000280120.1	RP11-546D6.3	5.39	1.11e-07	3.65e-05	0.22	0.24	Neutrophil percentage of white cells;	chr12:123135721	chr12:123152324~123153377:-
HNSC	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.39	1.11e-07	3.65e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
HNSC	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-5.39	1.11e-07	3.65e-05	-0.24	-0.24	Height;	chr5:37019252	chr5:36666214~36725195:-
HNSC	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-5.39	1.11e-07	3.65e-05	-0.22	-0.24	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
HNSC	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	5.39	1.11e-07	3.66e-05	0.3	0.24	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.66e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777532	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.66e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777533	chr14:106122420~106122709:-
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	5.39	1.11e-07	3.66e-05	0.3	0.24	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	5.39	1.11e-07	3.66e-05	0.3	0.24	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	5.39	1.11e-07	3.66e-05	0.28	0.24	Height;	chr4:55533481	chr4:55363971~55395847:-
HNSC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	5.39	1.11e-07	3.67e-05	0.3	0.24	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
HNSC	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-5.39	1.11e-07	3.67e-05	-0.34	-0.24	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
HNSC	cis	rs5758659	1	rs5751255	ENSG00000227370.1	RP4-669P10.19	-5.39	1.11e-07	3.67e-05	-0.23	-0.24	Cognitive function;	chr22:42252402	chr22:42132543~42132998:+
HNSC	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	5.39	1.11e-07	3.67e-05	0.25	0.24	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
HNSC	cis	rs11773103	0.881	rs11771569	ENSG00000224046.1	AC005076.5	5.39	1.12e-07	3.68e-05	0.45	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87208752	chr7:87151423~87152420:-
HNSC	cis	rs860295	0.627	rs11264410	ENSG00000203761.5	MSTO2P	-5.39	1.12e-07	3.68e-05	-0.19	-0.24	Body mass index;	chr1:155775558	chr1:155745829~155750137:+
HNSC	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-5.39	1.12e-07	3.68e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
HNSC	cis	rs2483058	0.767	rs11809494	ENSG00000261000.1	RP11-534L20.5	5.39	1.12e-07	3.68e-05	0.23	0.24	Cholesterol and Triglycerides;	chr1:206450521	chr1:206503948~206504456:+
HNSC	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-5.39	1.12e-07	3.69e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-5.39	1.12e-07	3.69e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
HNSC	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-5.39	1.12e-07	3.69e-05	-0.28	-0.24	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
HNSC	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	5.39	1.12e-07	3.69e-05	0.39	0.24	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	5.39	1.12e-07	3.69e-05	0.39	0.24	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
HNSC	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	5.39	1.12e-07	3.69e-05	0.34	0.24	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
HNSC	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	5.39	1.12e-07	3.69e-05	0.27	0.24	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
HNSC	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-5.39	1.12e-07	3.69e-05	-0.24	-0.24	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
HNSC	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	5.39	1.12e-07	3.69e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
HNSC	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	5.39	1.12e-07	3.69e-05	0.23	0.24	Asthma;	chr2:102418659	chr2:102438713~102440475:+
HNSC	cis	rs6928977	0.86	rs2757649	ENSG00000234084.1	RP3-388E23.2	-5.39	1.12e-07	3.69e-05	-0.25	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135301568~135307158:+
HNSC	cis	rs6714900	0.619	rs7593893	ENSG00000234896.1	OR7E62P	-5.39	1.12e-07	3.69e-05	-0.28	-0.24	Blood protein levels;	chr2:71049433	chr2:71055527~71056003:+
HNSC	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-5.39	1.12e-07	3.7e-05	-0.34	-0.24	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
HNSC	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-5.39	1.12e-07	3.7e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
HNSC	cis	rs3747113	0.732	rs11704465	ENSG00000128262.7	POM121L9P	-5.39	1.12e-07	3.7e-05	-0.28	-0.24	Gut microbiome composition (summer);	chr22:24466629	chr22:24251828~24265525:+
HNSC	cis	rs73198271	0.74	rs964771	ENSG00000173295.6	FAM86B3P	5.39	1.12e-07	3.7e-05	0.31	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8228595~8244865:+
HNSC	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-5.39	1.12e-07	3.7e-05	-0.3	-0.24	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000254153.1	CTA-398F10.2	-5.39	1.12e-07	3.7e-05	-0.26	-0.24	Mood instability;	chr8:8933743	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-5.39	1.13e-07	3.71e-05	-0.34	-0.24	Depression;	chr6:28237724	chr6:28115628~28116551:+
HNSC	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	5.39	1.13e-07	3.71e-05	0.27	0.24	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
HNSC	cis	rs2337406	0.587	rs2516886	ENSG00000254174.1	IGHV1-12	-5.39	1.13e-07	3.71e-05	-0.19	-0.24	Alzheimer's disease (late onset);	chr14:106649674	chr14:106122420~106122709:-
HNSC	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	5.39	1.13e-07	3.71e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
HNSC	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	5.39	1.13e-07	3.71e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
HNSC	cis	rs651386	0.529	rs722597	ENSG00000271811.1	RP1-79C4.4	5.39	1.13e-07	3.72e-05	0.27	0.24	Atrial fibrillation;	chr1:170607914	chr1:170667381~170669425:+
HNSC	cis	rs9291683	0.668	rs2241474	ENSG00000250413.1	RP11-448G15.1	-5.39	1.13e-07	3.72e-05	-0.3	-0.24	Bone mineral density;	chr4:10084391	chr4:10006482~10009725:+
HNSC	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.39	1.13e-07	3.72e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
HNSC	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-5.39	1.13e-07	3.72e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	5.39	1.13e-07	3.72e-05	0.3	0.24	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
HNSC	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-5.39	1.13e-07	3.72e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-5.39	1.13e-07	3.72e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
HNSC	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	5.39	1.13e-07	3.72e-05	0.32	0.24	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
HNSC	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	5.39	1.13e-07	3.72e-05	0.58	0.24	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
HNSC	cis	rs7819412	0.66	rs7462931	ENSG00000269918.1	AF131215.9	-5.39	1.13e-07	3.73e-05	-0.25	-0.24	Triglycerides;	chr8:11052833	chr8:11104691~11106704:-
HNSC	cis	rs860295	0.702	rs11264381	ENSG00000203761.5	MSTO2P	5.39	1.13e-07	3.73e-05	0.19	0.24	Body mass index;	chr1:155552781	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55452295	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55454900	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55454938	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	5.39	1.13e-07	3.73e-05	0.3	0.24	Height;	chr4:55455102	chr4:55387949~55388271:+
HNSC	cis	rs7621025	0.691	rs4678438	ENSG00000273486.1	RP11-731C17.2	5.39	1.13e-07	3.73e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136837338~136839021:-
HNSC	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-5.39	1.13e-07	3.73e-05	-0.26	-0.24	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000254340.1	RP11-10A14.3	5.39	1.13e-07	3.73e-05	0.3	0.24	Recombination measurement;	chr8:9205517	chr8:9141424~9145435:+
HNSC	cis	rs17270561	0.541	rs17586946	ENSG00000272810.1	U91328.22	-5.39	1.13e-07	3.73e-05	-0.27	-0.24	Iron status biomarkers;	chr6:25938825	chr6:26013241~26013757:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	5.39	1.13e-07	3.73e-05	0.3	0.24	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
HNSC	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-5.39	1.14e-07	3.74e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
HNSC	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-5.39	1.14e-07	3.74e-05	-0.2	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
HNSC	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-5.39	1.14e-07	3.74e-05	-0.2	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-5.39	1.14e-07	3.74e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
HNSC	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-5.39	1.14e-07	3.74e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
HNSC	cis	rs5758659	1	rs5758659	ENSG00000227370.1	RP4-669P10.19	-5.39	1.14e-07	3.75e-05	-0.23	-0.24	Cognitive function;	chr22:42225997	chr22:42132543~42132998:+
HNSC	cis	rs6928977	0.86	rs2614264	ENSG00000234084.1	RP3-388E23.2	-5.39	1.14e-07	3.75e-05	-0.24	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135301568~135307158:+
HNSC	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	5.39	1.14e-07	3.75e-05	0.26	0.24	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
HNSC	cis	rs4699052	0.963	rs11097804	ENSG00000246560.2	RP11-10L12.4	5.39	1.14e-07	3.75e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103293980	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.928	rs4456958	ENSG00000246560.2	RP11-10L12.4	5.39	1.14e-07	3.75e-05	0.29	0.24	Testicular germ cell tumor;	chr4:103294175	chr4:102828055~102844075:+
HNSC	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-5.39	1.14e-07	3.75e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
HNSC	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-5.39	1.14e-07	3.75e-05	-0.31	-0.24	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
HNSC	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.39	1.14e-07	3.76e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
HNSC	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-5.39	1.14e-07	3.76e-05	-0.3	-0.24	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
HNSC	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-5.39	1.14e-07	3.76e-05	-0.23	-0.24	Breast cancer;	chr11:743813	chr11:781645~782105:+
HNSC	cis	rs60617249	0.519	rs2107695	ENSG00000228204.2	RP4-724E13.2	5.39	1.14e-07	3.76e-05	0.28	0.24	Major depression and alcohol dependence;	chr7:50882640	chr7:50866747~51022990:+
HNSC	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	5.39	1.14e-07	3.76e-05	0.26	0.24	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	5.39	1.14e-07	3.76e-05	0.3	0.24	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
HNSC	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-5.39	1.14e-07	3.76e-05	-0.35	-0.24	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
HNSC	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-5.39	1.14e-07	3.76e-05	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
HNSC	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	5.39	1.14e-07	3.77e-05	0.32	0.24	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
HNSC	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Height;	chr2:46627225	chr2:46668870~46670778:+
HNSC	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	5.39	1.15e-07	3.77e-05	0.23	0.24	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28173770	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28174809	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-5.39	1.15e-07	3.77e-05	-0.31	-0.24	Depression;	chr6:28175233	chr6:28161781~28169594:+
HNSC	cis	rs4699052	1	rs4699052	ENSG00000246560.2	RP11-10L12.4	5.39	1.15e-07	3.77e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103216633	chr4:102828055~102844075:+
HNSC	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-5.39	1.15e-07	3.77e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
HNSC	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-5.39	1.15e-07	3.77e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
HNSC	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	5.39	1.15e-07	3.77e-05	0.25	0.24	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
HNSC	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	5.39	1.15e-07	3.77e-05	0.27	0.24	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
HNSC	cis	rs9914544	1	rs9914544	ENSG00000264885.1	RP11-815I9.4	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18884515	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.966	rs9915346	ENSG00000264885.1	RP11-815I9.4	-5.39	1.15e-07	3.77e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18884618	chr17:18667629~18669461:-
HNSC	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
HNSC	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
HNSC	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-5.39	1.15e-07	3.78e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
HNSC	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-5.39	1.15e-07	3.78e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-5.39	1.15e-07	3.78e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
HNSC	cis	rs656319	0.607	rs35437983	ENSG00000269918.1	AF131215.9	-5.39	1.15e-07	3.78e-05	-0.25	-0.24	Myopia (pathological);	chr8:10147543	chr8:11104691~11106704:-
HNSC	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
HNSC	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-5.39	1.15e-07	3.78e-05	-0.21	-0.24	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-5.38	1.15e-07	3.78e-05	-0.15	-0.24	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
HNSC	cis	rs2243480	1	rs4718269	ENSG00000179406.6	LINC00174	5.38	1.15e-07	3.78e-05	0.51	0.24	Diabetic kidney disease;	chr7:65735810	chr7:66376044~66401338:-
HNSC	cis	rs860295	0.836	rs6684889	ENSG00000203761.5	MSTO2P	5.38	1.15e-07	3.79e-05	0.18	0.24	Body mass index;	chr1:155457271	chr1:155745829~155750137:+
HNSC	cis	rs1355223	0.902	rs448016	ENSG00000271369.1	RP11-350D17.3	5.38	1.15e-07	3.79e-05	0.28	0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34685046	chr11:34709600~34710161:+
HNSC	cis	rs889014	0.724	rs10062678	ENSG00000253768.1	CTB-33O18.1	5.38	1.15e-07	3.79e-05	0.27	0.24	Height;	chr5:173545046	chr5:173562478~173573199:+
HNSC	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	5.38	1.15e-07	3.79e-05	0.28	0.24	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
HNSC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	5.38	1.15e-07	3.79e-05	0.31	0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
HNSC	cis	rs11648785	0.59	rs4324129	ENSG00000222019.6	URAHP	5.38	1.15e-07	3.79e-05	0.23	0.24	Tanning;	chr16:90032653	chr16:90039761~90047773:-
HNSC	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.38	1.15e-07	3.79e-05	0.24	0.24	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
HNSC	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
HNSC	cis	rs1008375	0.966	rs3775927	ENSG00000249502.1	AC006160.5	-5.38	1.16e-07	3.8e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598271	chr4:17587467~17614571:-
HNSC	cis	rs8054556	1	rs11642046	ENSG00000183604.13	SMG1P5	-5.38	1.16e-07	3.8e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30267553~30335374:-
HNSC	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	5.38	1.16e-07	3.8e-05	0.23	0.24	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
HNSC	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
HNSC	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-5.38	1.16e-07	3.8e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
HNSC	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
HNSC	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.8e-05	0.26	0.24	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
HNSC	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-5.38	1.16e-07	3.81e-05	-0.29	-0.24	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
HNSC	cis	rs10256972	0.605	rs10251094	ENSG00000224079.1	AC091729.7	-5.38	1.16e-07	3.82e-05	-0.45	-0.24	Endometriosis;Longevity;	chr7:977447	chr7:1074450~1078036:+
HNSC	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-5.38	1.16e-07	3.82e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.8	rs76663264	ENSG00000279742.1	RP11-700A24.1	-5.38	1.16e-07	3.82e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867412	chr11:85852557~85854943:-
HNSC	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.82e-05	0.26	0.24	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	5.38	1.16e-07	3.82e-05	0.26	0.24	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
HNSC	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-5.38	1.16e-07	3.82e-05	-0.31	-0.24	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
HNSC	cis	rs7617773	0.539	rs35460860	ENSG00000228638.1	FCF1P2	-5.38	1.16e-07	3.82e-05	-0.22	-0.24	Coronary artery disease;	chr3:48350595	chr3:48290793~48291375:-
HNSC	cis	rs6951245	0.832	rs79808627	ENSG00000225146.1	AC073957.15	-5.38	1.17e-07	3.83e-05	-0.38	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1029025~1043891:+
HNSC	cis	rs860818	1	rs858254	ENSG00000226816.2	AC005082.12	5.38	1.17e-07	3.83e-05	0.6	0.24	Initial pursuit acceleration;	chr7:23177584	chr7:23206013~23208045:+
HNSC	cis	rs9300255	0.602	rs1727315	ENSG00000280120.1	RP11-546D6.3	-5.38	1.17e-07	3.83e-05	-0.22	-0.24	Neutrophil percentage of white cells;	chr12:123154383	chr12:123152324~123153377:-
HNSC	cis	rs1355223	0.752	rs896856	ENSG00000271369.1	RP11-350D17.3	-5.38	1.17e-07	3.83e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655295	chr11:34709600~34710161:+
HNSC	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	5.38	1.17e-07	3.83e-05	0.27	0.24	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
HNSC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-5.38	1.17e-07	3.84e-05	-0.2	-0.24	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
HNSC	cis	rs783540	0.609	rs803686	ENSG00000255769.6	GOLGA2P10	5.38	1.17e-07	3.84e-05	0.32	0.24	Schizophrenia;	chr15:82550590	chr15:82472993~82513950:-
HNSC	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-5.38	1.17e-07	3.85e-05	-0.26	-0.24	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
HNSC	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-5.38	1.17e-07	3.85e-05	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	5.38	1.17e-07	3.85e-05	0.19	0.24	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
HNSC	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	5.38	1.17e-07	3.85e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
HNSC	cis	rs67981189	0.546	rs2810075	ENSG00000274818.1	RP1-292L20.3	-5.38	1.17e-07	3.85e-05	-0.3	-0.24	Schizophrenia;	chr14:70908363	chr14:70906657~70907111:-
HNSC	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-5.38	1.17e-07	3.85e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
HNSC	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	5.38	1.17e-07	3.85e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783113	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783133	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000211974.3	IGHV2-70	-5.38	1.18e-07	3.86e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783374	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	5.38	1.18e-07	3.86e-05	0.26	0.24	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	5.38	1.18e-07	3.86e-05	0.26	0.24	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
HNSC	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-5.38	1.18e-07	3.86e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-5.38	1.18e-07	3.87e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
HNSC	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.38	1.18e-07	3.87e-05	-0.39	-0.24	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
HNSC	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	5.38	1.18e-07	3.87e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
HNSC	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.38	1.18e-07	3.87e-05	0.21	0.24	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
HNSC	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-5.38	1.18e-07	3.87e-05	-0.29	-0.24	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
HNSC	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.38	1.18e-07	3.87e-05	-0.23	-0.24	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
HNSC	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	5.38	1.18e-07	3.87e-05	0.3	0.24	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
HNSC	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	5.38	1.18e-07	3.88e-05	0.29	0.24	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
HNSC	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	5.38	1.18e-07	3.88e-05	0.27	0.24	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	5.38	1.18e-07	3.88e-05	0.27	0.24	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
HNSC	cis	rs4699052	1	rs6533060	ENSG00000246560.2	RP11-10L12.4	5.38	1.18e-07	3.88e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103218839	chr4:102828055~102844075:+
HNSC	cis	rs3806843	0.735	rs801183	ENSG00000202515.1	VTRNA1-3	-5.38	1.18e-07	3.88e-05	-0.27	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140726158~140726246:+
HNSC	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-5.38	1.19e-07	3.89e-05	-0.22	-0.24	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-5.38	1.19e-07	3.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-5.38	1.19e-07	3.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
HNSC	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	5.38	1.19e-07	3.89e-05	0.3	0.24	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
HNSC	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.38	1.19e-07	3.89e-05	0.29	0.24	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
HNSC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-5.38	1.19e-07	3.9e-05	-0.2	-0.24	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
HNSC	cis	rs4699052	0.963	rs6816055	ENSG00000246560.2	RP11-10L12.4	5.38	1.19e-07	3.9e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103222003	chr4:102828055~102844075:+
HNSC	cis	rs950169	0.881	rs150965	ENSG00000229212.6	RP11-561C5.4	-5.38	1.19e-07	3.9e-05	-0.34	-0.24	Schizophrenia;	chr15:84537296	chr15:85205440~85234795:-
HNSC	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-5.38	1.19e-07	3.9e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
HNSC	cis	rs60617249	0.507	rs12718991	ENSG00000228204.2	RP4-724E13.2	5.38	1.19e-07	3.9e-05	0.31	0.24	Major depression and alcohol dependence;	chr7:50917570	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.507	rs17725573	ENSG00000228204.2	RP4-724E13.2	5.38	1.19e-07	3.9e-05	0.31	0.24	Major depression and alcohol dependence;	chr7:50918320	chr7:50866747~51022990:+
HNSC	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-5.38	1.19e-07	3.91e-05	-0.31	-0.24	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
HNSC	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	5.38	1.19e-07	3.91e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
HNSC	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	5.38	1.19e-07	3.91e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	5.38	1.19e-07	3.91e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
HNSC	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	5.38	1.19e-07	3.91e-05	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
HNSC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-5.38	1.19e-07	3.91e-05	-0.2	-0.24	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
HNSC	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	5.38	1.19e-07	3.91e-05	0.33	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
HNSC	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-5.38	1.19e-07	3.91e-05	-0.33	-0.24	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
HNSC	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-5.38	1.19e-07	3.91e-05	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000204709.4	LINC01556	5.38	1.19e-07	3.91e-05	0.35	0.24	Depression;	chr6:28237724	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	5.38	1.2e-07	3.92e-05	0.26	0.24	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
HNSC	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55429416	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55430596	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	5.38	1.2e-07	3.92e-05	0.29	0.24	Height;	chr4:55431595	chr4:55387949~55388271:+
HNSC	cis	rs526231	0.824	rs253755	ENSG00000175749.11	EIF3KP1	5.38	1.2e-07	3.92e-05	0.3	0.24	Primary biliary cholangitis;	chr5:103295232	chr5:103032376~103033031:+
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000254153.1	CTA-398F10.2	5.38	1.2e-07	3.92e-05	0.26	0.24	Mood instability;	chr8:8726834	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	5.38	1.2e-07	3.93e-05	0.2	0.24	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	5.38	1.2e-07	3.93e-05	0.29	0.24	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
HNSC	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	5.38	1.2e-07	3.93e-05	0.32	0.24	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
HNSC	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-5.38	1.2e-07	3.93e-05	-0.27	-0.24	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
HNSC	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-5.38	1.2e-07	3.93e-05	-0.28	-0.24	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	5.38	1.2e-07	3.93e-05	0.29	0.24	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
HNSC	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-5.38	1.2e-07	3.93e-05	-0.31	-0.24	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
HNSC	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	5.38	1.2e-07	3.93e-05	0.36	0.24	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
HNSC	cis	rs3733585	0.673	rs6840802	ENSG00000250413.1	RP11-448G15.1	-5.38	1.2e-07	3.94e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964009	chr4:10006482~10009725:+
HNSC	cis	rs860295	0.812	rs3820594	ENSG00000203761.5	MSTO2P	-5.38	1.2e-07	3.94e-05	-0.19	-0.24	Body mass index;	chr1:155859720	chr1:155745829~155750137:+
HNSC	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-5.38	1.2e-07	3.94e-05	-0.34	-0.24	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
HNSC	cis	rs9650657	0.537	rs4841457	ENSG00000269918.1	AF131215.9	-5.38	1.2e-07	3.94e-05	-0.24	-0.24	Neuroticism;	chr8:10916001	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	5.38	1.21e-07	3.94e-05	0.19	0.24	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-5.38	1.21e-07	3.94e-05	-0.29	-0.24	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.38	1.21e-07	3.94e-05	0.23	0.24	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-5.38	1.21e-07	3.95e-05	-0.14	-0.24	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000254153.1	CTA-398F10.2	-5.38	1.21e-07	3.95e-05	-0.27	-0.24	Mood instability;	chr8:8723898	chr8:8456909~8461337:-
HNSC	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-5.38	1.21e-07	3.95e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
HNSC	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-5.38	1.21e-07	3.95e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
HNSC	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-5.38	1.21e-07	3.95e-05	-0.31	-0.24	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
HNSC	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-5.38	1.21e-07	3.95e-05	-0.31	-0.24	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
HNSC	cis	rs988913	1	rs6941796	ENSG00000224984.1	RP11-524H19.2	5.38	1.21e-07	3.96e-05	0.27	0.24	Menarche (age at onset);	chr6:54972823	chr6:54840118~54840855:-
HNSC	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-5.37	1.21e-07	3.97e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
HNSC	cis	rs5753618	0.583	rs8141150	ENSG00000236132.1	CTA-440B3.1	-5.37	1.21e-07	3.97e-05	-0.3	-0.24	Colorectal cancer;	chr22:31404350	chr22:31816379~31817491:-
HNSC	cis	rs5753618	0.583	rs9606839	ENSG00000236132.1	CTA-440B3.1	-5.37	1.21e-07	3.97e-05	-0.3	-0.24	Colorectal cancer;	chr22:31406724	chr22:31816379~31817491:-
HNSC	cis	rs7048146	0.509	rs7020545	ENSG00000213539.4	YBX1P6	5.37	1.21e-07	3.97e-05	0.34	0.24	Vascular brain injury;	chr9:109567309	chr9:109532830~109534332:-
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-5.37	1.21e-07	3.97e-05	-0.15	-0.24	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
HNSC	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	5.37	1.21e-07	3.97e-05	0.26	0.24	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
HNSC	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	5.37	1.21e-07	3.97e-05	0.3	0.24	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
HNSC	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	5.37	1.21e-07	3.97e-05	0.26	0.24	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	5.37	1.22e-07	3.97e-05	0.26	0.24	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
HNSC	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
HNSC	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-5.37	1.22e-07	3.98e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
HNSC	cis	rs11846409	0.932	rs731012	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632578	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs731011	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632619	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs10138537	ENSG00000274576.2	IGHV2-70	-5.37	1.22e-07	3.98e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632778	chr14:106770577~106771020:-
HNSC	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
HNSC	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	5.37	1.22e-07	3.98e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
HNSC	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-5.37	1.22e-07	3.98e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
HNSC	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	5.37	1.22e-07	3.99e-05	0.21	0.24	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
HNSC	cis	rs9813712	0.855	rs6806152	ENSG00000249846.5	RP11-77P16.4	-5.37	1.22e-07	3.99e-05	-0.29	-0.24	Response to amphetamines;	chr3:130245358	chr3:130112550~130120579:+
HNSC	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	5.37	1.22e-07	3.99e-05	0.32	0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
HNSC	cis	rs526231	0.764	rs2116755	ENSG00000175749.11	EIF3KP1	5.37	1.22e-07	3.99e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103314187	chr5:103032376~103033031:+
HNSC	cis	rs526231	0.764	rs372564	ENSG00000175749.11	EIF3KP1	5.37	1.22e-07	3.99e-05	0.31	0.24	Primary biliary cholangitis;	chr5:103314823	chr5:103032376~103033031:+
HNSC	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-5.37	1.22e-07	3.99e-05	-0.23	-0.24	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
HNSC	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-5.37	1.22e-07	3.99e-05	-0.31	-0.24	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
HNSC	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-5.37	1.22e-07	4e-05	-0.3	-0.24	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
HNSC	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-5.37	1.22e-07	4e-05	-0.27	-0.24	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
HNSC	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	5.37	1.23e-07	4.01e-05	0.26	0.24	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	5.37	1.23e-07	4.01e-05	0.26	0.24	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
HNSC	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.37	1.23e-07	4.01e-05	0.26	0.24	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
HNSC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	5.37	1.23e-07	4.01e-05	0.3	0.24	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
HNSC	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-5.37	1.23e-07	4.01e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-5.37	1.23e-07	4.01e-05	-0.14	-0.24	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
HNSC	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
HNSC	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	5.37	1.23e-07	4.02e-05	0.29	0.24	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
HNSC	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-5.37	1.23e-07	4.02e-05	-0.3	-0.24	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-5.37	1.23e-07	4.02e-05	-0.16	-0.24	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
HNSC	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-5.37	1.23e-07	4.02e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
HNSC	cis	rs10435719	0.902	rs7459983	ENSG00000206014.6	OR7E161P	-5.37	1.23e-07	4.02e-05	-0.26	-0.24	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11928597~11929563:-
HNSC	cis	rs2404602	0.536	rs11072599	ENSG00000259422.1	RP11-593F23.1	5.37	1.23e-07	4.02e-05	0.28	0.24	Blood metabolite levels;	chr15:76482167	chr15:76174891~76181486:-
HNSC	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	5.37	1.23e-07	4.03e-05	0.26	0.24	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
HNSC	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	5.37	1.23e-07	4.03e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-5.37	1.23e-07	4.03e-05	-0.19	-0.24	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
HNSC	cis	rs2337406	0.789	rs9324095	ENSG00000254174.1	IGHV1-12	5.37	1.24e-07	4.03e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106795885	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs58154560	ENSG00000254174.1	IGHV1-12	5.37	1.24e-07	4.03e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106799601	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs756588	ENSG00000274576.2	IGHV2-70	5.37	1.24e-07	4.03e-05	0.24	0.24	Rheumatic heart disease;	chr14:106632316	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.86	rs55745256	ENSG00000274576.2	IGHV2-70	-5.37	1.24e-07	4.03e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632365	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs731013	ENSG00000274576.2	IGHV2-70	-5.37	1.24e-07	4.03e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106632481	chr14:106770577~106771020:-
HNSC	cis	rs4140799	0.845	rs2286135	ENSG00000266869.1	RP6-114E22.1	5.37	1.24e-07	4.03e-05	0.3	0.24	Neuroticism;	chr14:71703041	chr14:71848606~71908430:+
HNSC	cis	rs3733585	0.638	rs28715627	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956516	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs17245436	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956545	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.638	rs17185835	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956556	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs17185870	ENSG00000250413.1	RP11-448G15.1	5.37	1.24e-07	4.04e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956590	chr4:10006482~10009725:+
HNSC	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	5.37	1.24e-07	4.04e-05	0.29	0.24	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-5.37	1.24e-07	4.04e-05	-0.15	-0.24	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
HNSC	cis	rs9402743	0.671	rs6925684	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615740	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6905536	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615865	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs6905555	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135615894	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402725	ENSG00000217482.2	HMGB1P17	5.37	1.24e-07	4.05e-05	0.27	0.24	Systemic lupus erythematosus;	chr6:135616509	chr6:135636086~135636713:-
HNSC	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-5.37	1.24e-07	4.05e-05	-0.43	-0.24	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
HNSC	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	5.37	1.24e-07	4.05e-05	0.27	0.24	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
HNSC	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	5.37	1.24e-07	4.05e-05	0.64	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
HNSC	cis	rs72949976	0.511	rs11903721	ENSG00000270659.1	RP11-105N14.1	5.37	1.24e-07	4.06e-05	0.24	0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213152028	chr2:213152970~213153659:+
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-5.37	1.25e-07	4.06e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
HNSC	cis	rs7630852	0.965	rs6774504	ENSG00000272359.1	U4	5.37	1.25e-07	4.07e-05	0.26	0.24	Eosinophil counts;	chr3:196784021	chr3:196747192~196747324:-
HNSC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
HNSC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
HNSC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-5.37	1.25e-07	4.07e-05	-0.2	-0.24	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
HNSC	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-5.37	1.25e-07	4.07e-05	-0.31	-0.24	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-5.37	1.25e-07	4.07e-05	-0.31	-0.24	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
HNSC	cis	rs116095464	1	rs2721025	ENSG00000277812.1	AC021087.1	5.37	1.25e-07	4.07e-05	0.55	0.24	Breast cancer;	chr5:347329	chr5:262769~262881:+
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-5.37	1.25e-07	4.08e-05	-0.29	-0.24	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
HNSC	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	5.37	1.25e-07	4.08e-05	0.3	0.24	Height;	chr4:55452921	chr4:55387949~55388271:+
HNSC	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-5.37	1.25e-07	4.08e-05	-0.28	-0.24	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
HNSC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	5.37	1.25e-07	4.08e-05	0.3	0.24	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
HNSC	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	5.37	1.25e-07	4.09e-05	0.29	0.24	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
HNSC	cis	rs860295	0.812	rs11264413	ENSG00000203761.5	MSTO2P	-5.37	1.25e-07	4.09e-05	-0.19	-0.24	Body mass index;	chr1:155818865	chr1:155745829~155750137:+
HNSC	cis	rs6928977	0.863	rs9389286	ENSG00000234084.1	RP3-388E23.2	5.37	1.25e-07	4.09e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135319827	chr6:135301568~135307158:+
HNSC	cis	rs3733585	0.699	rs6449171	ENSG00000250413.1	RP11-448G15.1	-5.37	1.25e-07	4.09e-05	-0.29	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964374	chr4:10006482~10009725:+
HNSC	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	5.37	1.25e-07	4.09e-05	0.29	0.24	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
HNSC	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	5.37	1.25e-07	4.09e-05	0.26	0.24	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
HNSC	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-5.37	1.26e-07	4.09e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
HNSC	cis	rs889014	0.751	rs11742164	ENSG00000253768.1	CTB-33O18.1	-5.37	1.26e-07	4.1e-05	-0.26	-0.24	Height;	chr5:173550708	chr5:173562478~173573199:+
HNSC	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	5.37	1.26e-07	4.11e-05	0.26	0.24	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
HNSC	cis	rs7777677	1	rs7777677	ENSG00000244273.1	PGBD4P1	-5.37	1.26e-07	4.11e-05	-0.26	-0.24	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142722358~142722764:+
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	5.37	1.26e-07	4.11e-05	0.29	0.24	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
HNSC	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	5.37	1.26e-07	4.11e-05	0.3	0.24	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	5.37	1.26e-07	4.11e-05	0.26	0.24	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
HNSC	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	5.37	1.26e-07	4.11e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	5.37	1.26e-07	4.11e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
HNSC	cis	rs2439831	1	rs2467426	ENSG00000205771.5	CATSPER2P1	-5.37	1.26e-07	4.11e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43697320	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-5.37	1.26e-07	4.12e-05	-0.27	-0.24	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
HNSC	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-5.37	1.26e-07	4.12e-05	-0.23	-0.24	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
HNSC	cis	rs822354	1	rs822355	ENSG00000226652.2	PSMD10P2	5.37	1.26e-07	4.12e-05	0.26	0.24	Adiponectin levels;	chr3:186762334	chr3:186760693~186762050:+
HNSC	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	5.37	1.27e-07	4.12e-05	0.27	0.24	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
HNSC	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	5.37	1.27e-07	4.12e-05	0.27	0.24	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
HNSC	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	5.37	1.27e-07	4.13e-05	0.29	0.24	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
HNSC	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	5.37	1.27e-07	4.13e-05	0.27	0.24	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
HNSC	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	5.37	1.27e-07	4.14e-05	0.27	0.24	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
HNSC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.37	1.27e-07	4.14e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.37	1.27e-07	4.14e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
HNSC	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	5.37	1.27e-07	4.14e-05	0.21	0.24	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	-5.37	1.27e-07	4.14e-05	-0.28	-0.24	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
HNSC	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-5.37	1.27e-07	4.14e-05	-0.26	-0.24	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
HNSC	cis	rs9840812	0.769	rs483465	ENSG00000273486.1	RP11-731C17.2	5.37	1.27e-07	4.15e-05	0.21	0.24	Fibrinogen levels;	chr3:136329135	chr3:136837338~136839021:-
HNSC	cis	rs3738443	0.545	rs12566906	ENSG00000259865.1	RP11-488L18.10	5.37	1.27e-07	4.15e-05	0.19	0.24	Alcohol dependence;	chr1:247224904	chr1:247187281~247188526:-
HNSC	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	5.37	1.27e-07	4.15e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
HNSC	cis	rs11846409	0.932	rs60659763	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634172	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs57080270	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634215	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs60917084	ENSG00000211974.3	IGHV2-70	-5.37	1.28e-07	4.15e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634621	chr14:106723574~106724093:-
HNSC	cis	rs4252134	0.615	rs73029749	ENSG00000231863.1	RP3-428L16.1	-5.37	1.28e-07	4.16e-05	-0.32	-0.24	Giant cell arteritis;	chr6:160847379	chr6:160931080~160969771:+
HNSC	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-5.36	1.28e-07	4.16e-05	-0.27	-0.24	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
HNSC	cis	rs2058059	0.511	rs66624667	ENSG00000225648.4	SBDSP1	-5.36	1.28e-07	4.16e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72565634	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.551	rs58608277	ENSG00000225648.4	SBDSP1	-5.36	1.28e-07	4.16e-05	-0.35	-0.24	Subcutaneous adipose tissue;	chr7:72567083	chr7:72829425~72836701:+
HNSC	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	5.36	1.28e-07	4.16e-05	0.29	0.24	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	5.36	1.28e-07	4.17e-05	0.32	0.24	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
HNSC	cis	rs2243480	1	rs34703416	ENSG00000179406.6	LINC00174	-5.36	1.28e-07	4.17e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65835655	chr7:66376044~66401338:-
HNSC	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	5.36	1.28e-07	4.17e-05	0.36	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	5.36	1.28e-07	4.17e-05	0.29	0.24	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
HNSC	cis	rs6951245	0.572	rs74791540	ENSG00000225146.1	AC073957.15	-5.36	1.28e-07	4.17e-05	-0.5	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1022277	chr7:1029025~1043891:+
HNSC	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	5.36	1.28e-07	4.17e-05	0.26	0.24	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
HNSC	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	5.36	1.28e-07	4.17e-05	0.28	0.24	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
HNSC	cis	rs9341808	0.519	rs660888	ENSG00000272129.1	RP11-250B2.6	5.36	1.28e-07	4.17e-05	0.28	0.24	Sitting height ratio;	chr6:80273495	chr6:80355424~80356859:+
HNSC	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-5.36	1.28e-07	4.18e-05	-0.26	-0.24	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
HNSC	cis	rs71520386	0.632	rs12535331	ENSG00000221740.1	SNORD93	5.36	1.28e-07	4.18e-05	0.28	0.24	Fibrinogen levels;	chr7:22838485	chr7:22856613~22856686:+
HNSC	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	5.36	1.29e-07	4.18e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
HNSC	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	5.36	1.29e-07	4.18e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
HNSC	cis	rs11846409	0.932	rs61233250	ENSG00000211974.3	IGHV2-70	-5.36	1.29e-07	4.19e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106634072	chr14:106723574~106724093:-
HNSC	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	5.36	1.29e-07	4.19e-05	0.25	0.24	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
HNSC	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-5.36	1.29e-07	4.19e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
HNSC	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-5.36	1.29e-07	4.2e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
HNSC	cis	rs988913	1	rs6941291	ENSG00000224984.1	RP11-524H19.2	5.36	1.29e-07	4.2e-05	0.27	0.24	Menarche (age at onset);	chr6:54972578	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.632	rs6570029	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135757894	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9399161	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135759326	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.665	rs6933507	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135760018	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.665	rs4896172	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135760664	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs6570031	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762018	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896173	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762413	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896174	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762421	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs4896175	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135762568	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs2093330	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763534	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.632	rs9389324	ENSG00000217482.2	HMGB1P17	5.36	1.29e-07	4.2e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135765375	chr6:135636086~135636713:-
HNSC	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-5.36	1.29e-07	4.2e-05	-0.25	-0.24	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
HNSC	cis	rs9611519	1	rs2057070	ENSG00000235513.1	RP4-756G23.5	5.36	1.29e-07	4.21e-05	0.27	0.24	Neuroticism;	chr22:41168283	chr22:41209122~41217627:-
HNSC	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.36	1.29e-07	4.21e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
HNSC	cis	rs9341808	0.5	rs806851	ENSG00000272129.1	RP11-250B2.6	-5.36	1.29e-07	4.21e-05	-0.28	-0.24	Sitting height ratio;	chr6:80321114	chr6:80355424~80356859:+
HNSC	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	5.36	1.3e-07	4.21e-05	0.29	0.24	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
HNSC	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	5.36	1.3e-07	4.21e-05	0.29	0.24	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
HNSC	cis	rs792448	0.501	rs2307128	ENSG00000226251.4	RP11-15I11.3	-5.36	1.3e-07	4.22e-05	-0.28	-0.24	White blood cell count (basophil);	chr1:212226474	chr1:212225278~212238977:-
HNSC	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-5.36	1.3e-07	4.22e-05	-0.3	-0.24	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-5.36	1.3e-07	4.22e-05	-0.14	-0.24	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
HNSC	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-5.36	1.3e-07	4.22e-05	-0.3	-0.24	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.36	1.3e-07	4.22e-05	-0.27	-0.24	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
HNSC	cis	rs9907295	0.892	rs55950249	ENSG00000270977.1	AC015849.16	-5.36	1.3e-07	4.22e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35903948	chr17:35893707~35911023:-
HNSC	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	5.36	1.3e-07	4.23e-05	0.26	0.24	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
HNSC	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	5.36	1.3e-07	4.23e-05	0.27	0.24	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
HNSC	cis	rs860295	0.702	rs4971095	ENSG00000203761.5	MSTO2P	5.36	1.3e-07	4.23e-05	0.18	0.24	Body mass index;	chr1:155636433	chr1:155745829~155750137:+
HNSC	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	5.36	1.3e-07	4.23e-05	0.24	0.24	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	5.36	1.3e-07	4.23e-05	0.24	0.24	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
HNSC	cis	rs2179367	0.632	rs11155649	ENSG00000216906.2	RP11-350J20.9	5.36	1.3e-07	4.24e-05	0.35	0.24	Dupuytren's disease;	chr6:149405830	chr6:149904243~149906418:+
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000233609.3	RP11-62H7.2	-5.36	1.3e-07	4.24e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9037242	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	5.36	1.3e-07	4.24e-05	0.3	0.24	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
HNSC	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-5.36	1.3e-07	4.24e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
HNSC	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	5.36	1.31e-07	4.24e-05	0.31	0.24	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
HNSC	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	5.36	1.31e-07	4.25e-05	0.36	0.24	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
HNSC	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	5.36	1.31e-07	4.25e-05	0.23	0.24	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
HNSC	cis	rs860295	0.702	rs10908479	ENSG00000203761.5	MSTO2P	-5.36	1.31e-07	4.26e-05	-0.18	-0.24	Body mass index;	chr1:155673612	chr1:155745829~155750137:+
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000211974.3	IGHV2-70	-5.36	1.31e-07	4.26e-05	-0.29	-0.24	Alzheimer's disease (late onset);	chr14:106779306	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-5.36	1.31e-07	4.27e-05	-0.14	-0.24	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-5.36	1.32e-07	4.28e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	5.36	1.32e-07	4.29e-05	0.29	0.24	Height;	chr4:55545574	chr4:55387949~55388271:+
HNSC	cis	rs3733585	0.753	rs12500805	ENSG00000250413.1	RP11-448G15.1	-5.36	1.32e-07	4.29e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10006482~10009725:+
HNSC	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	5.36	1.32e-07	4.29e-05	0.35	0.24	Height;	chr6:109618283	chr6:109382795~109383666:+
HNSC	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	5.36	1.32e-07	4.3e-05	0.25	0.24	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
HNSC	cis	rs2008905	1	rs2008905	ENSG00000260196.1	RP1-239B22.5	5.36	1.32e-07	4.3e-05	0.26	0.24	Schizophrenia;	chr11:17163076	chr11:17380649~17383531:+
HNSC	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	5.36	1.32e-07	4.3e-05	0.27	0.24	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
HNSC	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	5.36	1.32e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	5.36	1.33e-07	4.3e-05	0.24	0.24	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
HNSC	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.36	1.33e-07	4.3e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
HNSC	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	5.36	1.33e-07	4.3e-05	0.29	0.24	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
HNSC	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-5.36	1.33e-07	4.3e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-5.36	1.33e-07	4.31e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
HNSC	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-5.36	1.33e-07	4.31e-05	-0.34	-0.24	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
HNSC	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	4.31e-05	0.42	0.24	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
HNSC	cis	rs2834288	0.734	rs1557269	ENSG00000237945.6	LINC00649	-5.36	1.33e-07	4.31e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33894091	chr21:33915534~33977691:+
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	5.36	1.33e-07	4.31e-05	0.57	0.24	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	5.36	1.33e-07	4.31e-05	0.57	0.24	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
HNSC	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	5.36	1.33e-07	4.31e-05	0.2	0.24	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
HNSC	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	5.36	1.33e-07	4.31e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
HNSC	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-5.36	1.33e-07	4.31e-05	-0.21	-0.24	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
HNSC	cis	rs4140799	0.874	rs10132111	ENSG00000266869.1	RP6-114E22.1	5.36	1.33e-07	4.31e-05	0.29	0.24	Neuroticism;	chr14:71705701	chr14:71848606~71908430:+
HNSC	cis	rs224090	0.523	rs12220700	ENSG00000238280.1	RP11-436D10.3	-5.36	1.33e-07	4.31e-05	-0.3	-0.24	Crohn's disease;	chr10:62801746	chr10:62793562~62805887:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000254153.1	CTA-398F10.2	5.36	1.33e-07	4.32e-05	0.26	0.24	Mood instability;	chr8:8237348	chr8:8456909~8461337:-
HNSC	cis	rs7819412	0.807	rs10105315	ENSG00000269918.1	AF131215.9	-5.36	1.33e-07	4.32e-05	-0.24	-0.24	Triglycerides;	chr8:11074693	chr8:11104691~11106704:-
HNSC	cis	rs9543976	0.614	rs4885308	ENSG00000261553.4	RP11-29G8.3	-5.36	1.33e-07	4.32e-05	-0.49	-0.24	Diabetic retinopathy;	chr13:75532357	chr13:75549773~75807120:+
HNSC	cis	rs783540	0.681	rs1259178	ENSG00000255769.6	GOLGA2P10	5.36	1.33e-07	4.33e-05	0.31	0.24	Schizophrenia;	chr15:82603127	chr15:82472993~82513950:-
HNSC	cis	rs860295	0.702	rs2175391	ENSG00000203761.5	MSTO2P	5.36	1.33e-07	4.33e-05	0.18	0.24	Body mass index;	chr1:155655811	chr1:155745829~155750137:+
HNSC	cis	rs7048146	0.509	rs10979937	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567759	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs72748673	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567809	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs72748674	ENSG00000213539.4	YBX1P6	5.36	1.33e-07	4.33e-05	0.34	0.24	Vascular brain injury;	chr9:109567816	chr9:109532830~109534332:-
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	5.36	1.33e-07	4.33e-05	0.2	0.24	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
HNSC	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	5.36	1.34e-07	4.33e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	5.36	1.34e-07	4.33e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
HNSC	cis	rs9300255	0.507	rs1615350	ENSG00000280120.1	RP11-546D6.3	5.36	1.34e-07	4.33e-05	0.21	0.24	Neutrophil percentage of white cells;	chr12:123165788	chr12:123152324~123153377:-
HNSC	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	5.36	1.34e-07	4.33e-05	0.3	0.24	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
HNSC	cis	rs9840812	0.623	rs4678433	ENSG00000239213.4	NCK1-AS1	5.36	1.34e-07	4.33e-05	0.22	0.24	Fibrinogen levels;	chr3:136546840	chr3:136841726~136862054:-
HNSC	cis	rs6928977	0.796	rs2179781	ENSG00000234084.1	RP3-388E23.2	5.36	1.34e-07	4.33e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135398362	chr6:135301568~135307158:+
HNSC	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-5.36	1.34e-07	4.34e-05	-0.4	-0.24	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
HNSC	cis	rs8054556	1	rs3814884	ENSG00000183604.13	SMG1P5	-5.36	1.34e-07	4.34e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30267553~30335374:-
HNSC	cis	rs4699052	1	rs7694190	ENSG00000246560.2	RP11-10L12.4	5.36	1.34e-07	4.34e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103246860	chr4:102828055~102844075:+
HNSC	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.36	1.34e-07	4.34e-05	-0.24	-0.24	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
HNSC	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	5.36	1.34e-07	4.35e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
HNSC	cis	rs9840812	0.61	rs34967300	ENSG00000273486.1	RP11-731C17.2	-5.36	1.34e-07	4.35e-05	-0.23	-0.24	Fibrinogen levels;	chr3:136549976	chr3:136837338~136839021:-
HNSC	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	5.36	1.34e-07	4.35e-05	0.36	0.24	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
HNSC	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-5.36	1.34e-07	4.35e-05	-0.31	-0.24	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
HNSC	cis	rs783540	0.656	rs783538	ENSG00000255769.6	GOLGA2P10	5.36	1.34e-07	4.35e-05	0.32	0.24	Schizophrenia;	chr15:82584394	chr15:82472993~82513950:-
HNSC	cis	rs10256972	0.869	rs4720158	ENSG00000225146.1	AC073957.15	5.36	1.34e-07	4.35e-05	0.28	0.24	Endometriosis;Longevity;	chr7:1000689	chr7:1029025~1043891:+
HNSC	cis	rs9402743	0.671	rs6901733	ENSG00000234084.1	RP3-388E23.2	-5.36	1.34e-07	4.36e-05	-0.25	-0.24	Systemic lupus erythematosus;	chr6:135619407	chr6:135301568~135307158:+
HNSC	cis	rs2790457	0.771	rs2800737	ENSG00000254635.4	WAC-AS1	-5.36	1.34e-07	4.36e-05	-0.26	-0.24	Multiple myeloma;	chr10:28654143	chr10:28522652~28532743:-
HNSC	cis	rs9907295	0.901	rs4795096	ENSG00000270977.1	AC015849.16	-5.36	1.34e-07	4.36e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35888821	chr17:35893707~35911023:-
HNSC	cis	rs2115630	1	rs10220733	ENSG00000229212.6	RP11-561C5.4	5.36	1.34e-07	4.36e-05	0.28	0.24	P wave terminal force;	chr15:84737633	chr15:85205440~85234795:-
HNSC	cis	rs1355223	0.833	rs286885	ENSG00000271369.1	RP11-350D17.3	5.36	1.34e-07	4.36e-05	0.27	0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34665799	chr11:34709600~34710161:+
HNSC	cis	rs7819412	0.805	rs2409710	ENSG00000255310.2	AF131215.2	-5.36	1.34e-07	4.36e-05	-0.23	-0.24	Triglycerides;	chr8:11122311	chr8:11107788~11109726:-
HNSC	cis	rs860295	0.702	rs12239100	ENSG00000203761.5	MSTO2P	-5.35	1.34e-07	4.36e-05	-0.19	-0.24	Body mass index;	chr1:155458685	chr1:155745829~155750137:+
HNSC	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	5.35	1.35e-07	4.36e-05	0.25	0.24	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	5.35	1.35e-07	4.36e-05	0.25	0.24	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
HNSC	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-5.35	1.35e-07	4.36e-05	-0.27	-0.24	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
HNSC	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	5.35	1.35e-07	4.36e-05	0.3	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
HNSC	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Height;	chr5:37053874	chr5:36666214~36725195:-
HNSC	cis	rs9402743	0.632	rs2104132	ENSG00000217482.2	HMGB1P17	5.35	1.35e-07	4.37e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763810	chr6:135636086~135636713:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000204709.4	LINC01556	5.35	1.35e-07	4.37e-05	0.35	0.24	Depression;	chr6:28242910	chr6:28943877~28944537:+
HNSC	cis	rs6693567	0.565	rs6685252	ENSG00000228126.1	FALEC	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Migraine;	chr1:150287533	chr1:150515757~150518032:+
HNSC	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
HNSC	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	5.35	1.35e-07	4.37e-05	0.6	0.24	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
HNSC	cis	rs17428076	0.874	rs17581347	ENSG00000228389.1	AC068039.4	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Myopia;	chr2:171826091	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs17581361	ENSG00000228389.1	AC068039.4	-5.35	1.35e-07	4.37e-05	-0.29	-0.24	Myopia;	chr2:171826102	chr2:171773482~171775844:+
HNSC	cis	rs9611519	0.894	rs13053242	ENSG00000235513.1	RP4-756G23.5	5.35	1.35e-07	4.37e-05	0.27	0.24	Neuroticism;	chr22:41063482	chr22:41209122~41217627:-
HNSC	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	5.35	1.35e-07	4.37e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
HNSC	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-5.35	1.35e-07	4.37e-05	-0.23	-0.24	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
HNSC	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	5.35	1.35e-07	4.38e-05	0.28	0.24	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
HNSC	cis	rs2834288	0.613	rs2834297	ENSG00000273102.1	AP000569.9	-5.35	1.35e-07	4.38e-05	-0.25	-0.24	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33967101~33968573:-
HNSC	cis	rs6430553	0.964	rs1530556	ENSG00000224043.6	CCNT2-AS1	-5.35	1.35e-07	4.38e-05	-0.28	-0.24	Blood metabolite levels;	chr2:134842164	chr2:134735464~134918710:-
HNSC	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	5.35	1.35e-07	4.38e-05	0.26	0.24	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	5.35	1.35e-07	4.38e-05	0.26	0.24	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
HNSC	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-5.35	1.35e-07	4.39e-05	-0.28	-0.24	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
HNSC	cis	rs2255336	0.938	rs17549004	ENSG00000245648.1	RP11-277P12.20	-5.35	1.36e-07	4.39e-05	-0.42	-0.24	Blood protein levels;	chr12:10410024	chr12:10363769~10398506:+
HNSC	cis	rs1008375	0.966	rs3796812	ENSG00000249502.1	AC006160.5	-5.35	1.36e-07	4.39e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580428	chr4:17587467~17614571:-
HNSC	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	5.35	1.36e-07	4.39e-05	0.57	0.24	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
HNSC	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	5.35	1.36e-07	4.4e-05	0.24	0.24	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
HNSC	cis	rs6928977	0.66	rs9389301	ENSG00000234084.1	RP3-388E23.2	5.35	1.36e-07	4.4e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135549844	chr6:135301568~135307158:+
HNSC	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	5.35	1.36e-07	4.41e-05	0.3	0.24	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	5.35	1.36e-07	4.41e-05	0.3	0.24	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	5.35	1.36e-07	4.41e-05	0.29	0.24	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	5.35	1.36e-07	4.41e-05	0.29	0.24	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
HNSC	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-5.35	1.36e-07	4.42e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
HNSC	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	5.35	1.36e-07	4.42e-05	0.26	0.24	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
HNSC	cis	rs3206736	0.548	rs329235	ENSG00000197085.10	NPSR1-AS1	5.35	1.36e-07	4.42e-05	0.29	0.24	Diastolic blood pressure;	chr7:35016554	chr7:34346512~34871582:-
HNSC	cis	rs8054556	1	rs9932196	ENSG00000183604.13	SMG1P5	-5.35	1.37e-07	4.42e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:30267553~30335374:-
HNSC	cis	rs11846409	0.932	rs73378155	ENSG00000211974.3	IGHV2-70	-5.35	1.37e-07	4.42e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637840	chr14:106723574~106724093:-
HNSC	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	5.35	1.37e-07	4.43e-05	0.7	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
HNSC	cis	rs490608	0.628	rs678157	ENSG00000203761.5	MSTO2P	-5.35	1.37e-07	4.43e-05	-0.18	-0.24	Inflammatory bowel disease;	chr1:155688550	chr1:155745829~155750137:+
HNSC	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-5.35	1.37e-07	4.43e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
HNSC	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.35	1.37e-07	4.43e-05	-0.3	-0.24	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
HNSC	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	5.35	1.37e-07	4.43e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
HNSC	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	5.35	1.37e-07	4.43e-05	0.26	0.24	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
HNSC	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	5.35	1.37e-07	4.44e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
HNSC	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	4.44e-05	0.26	0.24	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
HNSC	cis	rs1008375	0.966	rs28441502	ENSG00000249502.1	AC006160.5	-5.35	1.37e-07	4.44e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17596761	chr4:17587467~17614571:-
HNSC	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-5.35	1.38e-07	4.45e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-5.35	1.38e-07	4.45e-05	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
HNSC	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-5.35	1.38e-07	4.45e-05	-0.39	-0.24	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
HNSC	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.35	1.38e-07	4.46e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000179406.6	LINC00174	-5.35	1.38e-07	4.46e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65963465	chr7:66376044~66401338:-
HNSC	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.35	1.38e-07	4.47e-05	-0.33	-0.24	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
HNSC	cis	rs9611519	0.929	rs9611509	ENSG00000235513.1	RP4-756G23.5	5.35	1.38e-07	4.47e-05	0.27	0.24	Neuroticism;	chr22:41169823	chr22:41209122~41217627:-
HNSC	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
HNSC	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.38e-07	4.47e-05	-0.24	-0.24	Height;	chr5:37023796	chr5:36666214~36725195:-
HNSC	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	5.35	1.38e-07	4.47e-05	0.25	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
HNSC	cis	rs1012068	0.541	rs11703587	ENSG00000236132.1	CTA-440B3.1	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Chronic hepatitis C infection;	chr22:31926428	chr22:31816379~31817491:-
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.35	1.38e-07	4.47e-05	-0.29	-0.24	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.582	rs11783950	ENSG00000173295.6	FAM86B3P	-5.35	1.38e-07	4.47e-05	-0.28	-0.24	Mood instability;	chr8:8740321	chr8:8228595~8244865:+
HNSC	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	5.35	1.38e-07	4.48e-05	0.35	0.24	Height;	chr6:109564272	chr6:109382795~109383666:+
HNSC	cis	rs860295	0.702	rs12025532	ENSG00000203761.5	MSTO2P	-5.35	1.38e-07	4.48e-05	-0.19	-0.24	Body mass index;	chr1:155399511	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.678	rs12563627	ENSG00000203761.5	MSTO2P	5.35	1.38e-07	4.48e-05	0.18	0.24	Body mass index;	chr1:155893175	chr1:155745829~155750137:+
HNSC	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
HNSC	cis	rs9611519	0.929	rs2064560	ENSG00000235513.1	RP4-756G23.5	5.35	1.39e-07	4.48e-05	0.27	0.24	Neuroticism;	chr22:41134036	chr22:41209122~41217627:-
HNSC	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	5.35	1.39e-07	4.48e-05	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
HNSC	cis	rs9611519	0.894	rs9611486	ENSG00000235513.1	RP4-756G23.5	5.35	1.39e-07	4.48e-05	0.27	0.24	Neuroticism;	chr22:41062780	chr22:41209122~41217627:-
HNSC	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	5.35	1.39e-07	4.48e-05	0.26	0.24	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
HNSC	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-5.35	1.39e-07	4.48e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
HNSC	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-5.35	1.39e-07	4.48e-05	-0.23	-0.24	Height;	chr5:36925633	chr5:36666214~36725195:-
HNSC	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	5.35	1.39e-07	4.48e-05	0.31	0.24	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
HNSC	cis	rs13126694	0.682	rs4504305	ENSG00000248429.4	RP11-597D13.9	5.35	1.39e-07	4.48e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158170752~158202877:+
HNSC	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-5.35	1.39e-07	4.49e-05	-0.42	-0.24	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000254153.1	CTA-398F10.2	-5.35	1.39e-07	4.49e-05	-0.25	-0.24	Mood instability;	chr8:8967348	chr8:8456909~8461337:-
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	5.35	1.39e-07	4.49e-05	0.3	0.24	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.932	rs4896143	ENSG00000231028.7	LINC00271	5.35	1.39e-07	4.49e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135313962	chr6:135497801~135716055:+
HNSC	cis	rs2337406	1	rs78857163	ENSG00000254174.1	IGHV1-12	5.35	1.39e-07	4.49e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106707435	chr14:106122420~106122709:-
HNSC	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	5.35	1.39e-07	4.49e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
HNSC	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-5.35	1.39e-07	4.5e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
HNSC	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	5.35	1.39e-07	4.5e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
HNSC	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	5.35	1.39e-07	4.5e-05	0.3	0.24	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
HNSC	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-5.35	1.39e-07	4.5e-05	-0.21	-0.24	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	5.35	1.39e-07	4.5e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	5.35	1.39e-07	4.5e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
HNSC	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	5.35	1.4e-07	4.51e-05	0.26	0.24	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
HNSC	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-5.35	1.4e-07	4.51e-05	-0.31	-0.24	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
HNSC	cis	rs4723738	0.693	rs6462818	ENSG00000227191.5	TRGC2	-5.35	1.4e-07	4.51e-05	-0.18	-0.24	Treatment response for severe sepsis;	chr7:38211435	chr7:38239580~38368091:-
HNSC	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-5.35	1.4e-07	4.51e-05	-0.21	-0.24	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
HNSC	cis	rs7617773	0.925	rs6442105	ENSG00000228638.1	FCF1P2	5.35	1.4e-07	4.51e-05	0.23	0.24	Coronary artery disease;	chr3:48140836	chr3:48290793~48291375:-
HNSC	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	5.35	1.4e-07	4.52e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000179406.6	LINC00174	-5.35	1.4e-07	4.52e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66021736	chr7:66376044~66401338:-
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	5.35	1.4e-07	4.52e-05	0.54	0.24	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
HNSC	cis	rs2762353	0.526	rs9461203	ENSG00000272462.2	U91328.19	5.35	1.4e-07	4.53e-05	0.23	0.24	Blood metabolite levels;	chr6:25710327	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.526	rs6912391	ENSG00000272462.2	U91328.19	5.35	1.4e-07	4.53e-05	0.23	0.24	Blood metabolite levels;	chr6:25710535	chr6:25992662~26001775:+
HNSC	cis	rs5758659	0.967	rs5758670	ENSG00000227370.1	RP4-669P10.19	-5.35	1.4e-07	4.53e-05	-0.23	-0.24	Cognitive function;	chr22:42240681	chr22:42132543~42132998:+
HNSC	cis	rs7819412	1	rs2409722	ENSG00000269918.1	AF131215.9	-5.35	1.4e-07	4.53e-05	-0.24	-0.24	Triglycerides;	chr8:11182307	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs34815098	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65827267	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7456042	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65834791	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35735127	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65835436	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000179406.6	LINC00174	-5.35	1.41e-07	4.54e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:65841418	chr7:66376044~66401338:-
HNSC	cis	rs2179367	0.632	rs12197598	ENSG00000216906.2	RP11-350J20.9	5.35	1.41e-07	4.54e-05	0.35	0.24	Dupuytren's disease;	chr6:149385418	chr6:149904243~149906418:+
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000254174.1	IGHV1-12	5.35	1.41e-07	4.54e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777623	chr14:106122420~106122709:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000233609.3	RP11-62H7.2	5.35	1.41e-07	4.54e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9044861	chr8:8961200~8979025:+
HNSC	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-5.35	1.41e-07	4.54e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
HNSC	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-5.35	1.41e-07	4.54e-05	-0.29	-0.24	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
HNSC	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	5.35	1.41e-07	4.55e-05	0.28	0.24	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
HNSC	cis	rs7621025	0.617	rs12637102	ENSG00000239213.4	NCK1-AS1	5.35	1.41e-07	4.55e-05	0.23	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136841726~136862054:-
HNSC	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	5.35	1.41e-07	4.55e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
HNSC	cis	rs11846409	0.932	rs74091728	ENSG00000211974.3	IGHV2-70	-5.35	1.41e-07	4.55e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106638762	chr14:106723574~106724093:-
HNSC	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-5.35	1.41e-07	4.55e-05	-0.23	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
HNSC	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-5.35	1.41e-07	4.56e-05	-0.21	-0.24	Height;	chr11:118737916	chr11:118791254~118793137:+
HNSC	cis	rs988913	1	rs2221334	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54969743	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs4715492	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54970380	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7765236	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54970769	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs1503134	ENSG00000224984.1	RP11-524H19.2	5.35	1.41e-07	4.56e-05	0.27	0.24	Menarche (age at onset);	chr6:54971426	chr6:54840118~54840855:-
HNSC	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-5.35	1.41e-07	4.56e-05	-0.29	-0.24	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-5.35	1.41e-07	4.56e-05	-0.29	-0.24	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
HNSC	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	5.35	1.41e-07	4.56e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
HNSC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	5.35	1.41e-07	4.56e-05	0.3	0.24	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	5.35	1.41e-07	4.56e-05	0.3	0.24	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
HNSC	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-5.35	1.42e-07	4.57e-05	-0.29	-0.24	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
HNSC	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	5.35	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
HNSC	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5.34	1.42e-07	4.57e-05	-0.31	-0.24	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5.34	1.42e-07	4.57e-05	-0.31	-0.24	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
HNSC	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	5.34	1.42e-07	4.57e-05	0.33	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
HNSC	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	5.34	1.42e-07	4.57e-05	0.26	0.24	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
HNSC	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-5.34	1.42e-07	4.58e-05	-0.25	-0.24	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
HNSC	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	5.34	1.42e-07	4.58e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
HNSC	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-5.34	1.42e-07	4.58e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
HNSC	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	5.34	1.42e-07	4.59e-05	0.33	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
HNSC	cis	rs6928977	0.5	rs9494308	ENSG00000217482.2	HMGB1P17	-5.34	1.42e-07	4.59e-05	-0.27	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135636086~135636713:-
HNSC	cis	rs17507216	0.628	rs28607761	ENSG00000276710.3	CSPG4P8	-5.34	1.43e-07	4.6e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82715317	chr15:82459472~82477258:+
HNSC	cis	rs889014	0.751	rs6891528	ENSG00000253768.1	CTB-33O18.1	-5.34	1.43e-07	4.6e-05	-0.26	-0.24	Height;	chr5:173551902	chr5:173562478~173573199:+
HNSC	cis	rs13126694	0.744	rs28477319	ENSG00000248429.4	RP11-597D13.9	5.34	1.43e-07	4.6e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158170752~158202877:+
HNSC	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-5.34	1.43e-07	4.6e-05	-0.32	-0.24	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	5.34	1.43e-07	4.61e-05	0.29	0.24	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
HNSC	cis	rs1665050	0.571	rs1446238	ENSG00000277144.1	RP11-59H7.4	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Atopic dermatitis;	chr15:59055558	chr15:59115547~59116089:-
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	5.34	1.43e-07	4.61e-05	0.54	0.24	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
HNSC	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
HNSC	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5.34	1.43e-07	4.61e-05	-0.39	-0.24	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000204709.4	LINC01556	5.34	1.43e-07	4.61e-05	0.34	0.24	Parkinson's disease;	chr6:28065745	chr6:28943877~28944537:+
HNSC	cis	rs4239252	0.725	rs1994182	ENSG00000270977.1	AC015849.16	5.34	1.43e-07	4.61e-05	0.28	0.24	Blood protein levels;	chr17:35760685	chr17:35893707~35911023:-
HNSC	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-5.34	1.43e-07	4.61e-05	-0.21	-0.24	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-5.34	1.43e-07	4.61e-05	-0.21	-0.24	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
HNSC	cis	rs4140799	0.845	rs2286136	ENSG00000266869.1	RP6-114E22.1	-5.34	1.43e-07	4.61e-05	-0.3	-0.24	Neuroticism;	chr14:71701978	chr14:71848606~71908430:+
HNSC	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	5.34	1.43e-07	4.61e-05	0.26	0.24	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
HNSC	cis	rs1355223	0.872	rs7112608	ENSG00000271369.1	RP11-350D17.3	-5.34	1.43e-07	4.61e-05	-0.28	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677722	chr11:34709600~34710161:+
HNSC	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	5.34	1.43e-07	4.61e-05	0.31	0.24	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	5.34	1.43e-07	4.62e-05	0.29	0.24	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
HNSC	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	5.34	1.43e-07	4.62e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
HNSC	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-5.34	1.43e-07	4.62e-05	-0.23	-0.24	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
HNSC	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	5.34	1.43e-07	4.62e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000179406.6	LINC00174	-5.34	1.44e-07	4.62e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66013324	chr7:66376044~66401338:-
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000173295.6	FAM86B3P	-5.34	1.44e-07	4.63e-05	-0.3	-0.24	Neuroticism;	chr8:8504313	chr8:8228595~8244865:+
HNSC	cis	rs7824557	0.547	rs6601570	ENSG00000255310.2	AF131215.2	-5.34	1.44e-07	4.63e-05	-0.23	-0.24	Retinal vascular caliber;	chr8:11221858	chr8:11107788~11109726:-
HNSC	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-5.34	1.44e-07	4.63e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
HNSC	cis	rs988913	1	rs9382407	ENSG00000224984.1	RP11-524H19.2	5.34	1.44e-07	4.63e-05	0.27	0.24	Menarche (age at onset);	chr6:54971840	chr6:54840118~54840855:-
HNSC	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	5.34	1.44e-07	4.63e-05	0.27	0.24	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
HNSC	cis	rs9611519	1	rs9611519	ENSG00000235513.1	RP4-756G23.5	5.34	1.44e-07	4.64e-05	0.27	0.24	Neuroticism;	chr22:41217184	chr22:41209122~41217627:-
HNSC	cis	rs2337406	0.866	rs8012619	ENSG00000254174.1	IGHV1-12	5.34	1.44e-07	4.64e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106793907	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74090151	ENSG00000211974.3	IGHV2-70	-5.34	1.44e-07	4.64e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106785377	chr14:106723574~106724093:-
HNSC	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	5.34	1.44e-07	4.64e-05	0.26	0.24	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
HNSC	cis	rs1008375	0.966	rs1860591	ENSG00000249502.1	AC006160.5	-5.34	1.44e-07	4.64e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575706	chr4:17587467~17614571:-
HNSC	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	5.34	1.44e-07	4.65e-05	0.38	0.24	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-5.34	1.44e-07	4.65e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
HNSC	cis	rs3733585	0.673	rs9994937	ENSG00000250413.1	RP11-448G15.1	5.34	1.44e-07	4.65e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9963175	chr4:10006482~10009725:+
HNSC	cis	rs2115630	0.905	rs6496401	ENSG00000229212.6	RP11-561C5.4	5.34	1.44e-07	4.65e-05	0.28	0.24	P wave terminal force;	chr15:84754562	chr15:85205440~85234795:-
HNSC	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-5.34	1.45e-07	4.65e-05	-0.33	-0.24	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
HNSC	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-5.34	1.45e-07	4.66e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
HNSC	cis	rs7621025	0.691	rs9845762	ENSG00000273486.1	RP11-731C17.2	5.34	1.45e-07	4.66e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136837338~136839021:-
HNSC	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	5.34	1.45e-07	4.66e-05	0.38	0.24	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
HNSC	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	5.34	1.45e-07	4.66e-05	0.28	0.24	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
HNSC	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	5.34	1.45e-07	4.66e-05	0.18	0.24	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-5.34	1.45e-07	4.66e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
HNSC	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-5.34	1.45e-07	4.67e-05	-0.31	-0.24	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
HNSC	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	5.34	1.45e-07	4.67e-05	0.27	0.24	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
HNSC	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-5.34	1.45e-07	4.67e-05	-0.27	-0.24	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
HNSC	cis	rs6540731	0.967	rs2884512	ENSG00000226251.4	RP11-15I11.3	-5.34	1.45e-07	4.67e-05	-0.28	-0.24	Intelligence (childhood);	chr1:212229848	chr1:212225278~212238977:-
HNSC	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-5.34	1.45e-07	4.67e-05	-0.41	-0.24	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
HNSC	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.34	1.45e-07	4.68e-05	0.26	0.24	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
HNSC	cis	rs2834288	0.734	rs9984662	ENSG00000237945.6	LINC00649	5.34	1.45e-07	4.68e-05	0.3	0.24	Gut microbiota (bacterial taxa);	chr21:33892504	chr21:33915534~33977691:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-5.34	1.45e-07	4.68e-05	-0.28	-0.24	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
HNSC	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	5.34	1.45e-07	4.68e-05	0.24	0.24	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
HNSC	cis	rs9907295	0.901	rs9909416	ENSG00000270977.1	AC015849.16	-5.34	1.45e-07	4.68e-05	-0.32	-0.24	Fibroblast growth factor basic levels;	chr17:35870979	chr17:35893707~35911023:-
HNSC	cis	rs792448	0.545	rs6679796	ENSG00000226251.4	RP11-15I11.3	-5.34	1.45e-07	4.68e-05	-0.27	-0.24	White blood cell count (basophil);	chr1:212229182	chr1:212225278~212238977:-
HNSC	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	5.34	1.45e-07	4.68e-05	0.3	0.24	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
HNSC	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-5.34	1.46e-07	4.68e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
HNSC	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.34	1.46e-07	4.68e-05	0.26	0.24	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	5.34	1.46e-07	4.68e-05	0.21	0.24	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
HNSC	cis	rs9329221	0.741	rs13264066	ENSG00000254340.1	RP11-10A14.3	-5.34	1.46e-07	4.7e-05	-0.29	-0.24	Neuroticism;	chr8:9946565	chr8:9141424~9145435:+
HNSC	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-5.34	1.46e-07	4.7e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000179406.6	LINC00174	-5.34	1.46e-07	4.7e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65922691	chr7:66376044~66401338:-
HNSC	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-5.34	1.46e-07	4.7e-05	-0.22	-0.24	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
HNSC	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	5.34	1.46e-07	4.7e-05	0.21	0.24	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
HNSC	cis	rs9329221	0.741	rs9650622	ENSG00000254340.1	RP11-10A14.3	-5.34	1.46e-07	4.7e-05	-0.29	-0.24	Neuroticism;	chr8:9946782	chr8:9141424~9145435:+
HNSC	cis	rs6928977	1	rs6928977	ENSG00000231028.7	LINC00271	5.34	1.46e-07	4.71e-05	0.29	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135497801~135716055:+
HNSC	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-5.34	1.46e-07	4.71e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000276710.3	CSPG4P8	-5.34	1.47e-07	4.71e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82714435	chr15:82459472~82477258:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-5.34	1.47e-07	4.72e-05	-0.22	-0.24	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
HNSC	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-5.34	1.47e-07	4.72e-05	-0.23	-0.24	Height;	chr5:36941456	chr5:36666214~36725195:-
HNSC	cis	rs988913	1	rs6922438	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976585	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs1503135	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976874	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9349741	ENSG00000224984.1	RP11-524H19.2	5.34	1.47e-07	4.73e-05	0.27	0.24	Menarche (age at onset);	chr6:54976911	chr6:54840118~54840855:-
HNSC	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	5.34	1.47e-07	4.73e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	5.34	1.47e-07	4.73e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000211974.3	IGHV2-70	-5.34	1.47e-07	4.73e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106780983	chr14:106723574~106724093:-
HNSC	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-5.34	1.47e-07	4.73e-05	-0.39	-0.24	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
HNSC	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	5.34	1.47e-07	4.74e-05	0.26	0.24	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
HNSC	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	5.34	1.47e-07	4.74e-05	0.23	0.24	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66007799	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781156	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66014154	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781150	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66015986	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781149	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66016297	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs451396	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66019087	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1167613	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66022452	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1715235	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66023407	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313798	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66028044	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313799	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66029343	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35396113	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66030474	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313807	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034494	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313809	ENSG00000179406.6	LINC00174	-5.34	1.47e-07	4.74e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034996	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	5.34	1.47e-07	4.74e-05	0.26	0.24	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
HNSC	cis	rs7048146	0.531	rs10979908	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542257	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs10979909	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542258	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs10979910	ENSG00000213539.4	YBX1P6	5.34	1.48e-07	4.75e-05	0.31	0.24	Vascular brain injury;	chr9:109542340	chr9:109532830~109534332:-
HNSC	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	5.34	1.48e-07	4.75e-05	0.3	0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
HNSC	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-5.34	1.48e-07	4.75e-05	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
HNSC	cis	rs1056107	0.966	rs7041688	ENSG00000225513.1	RP11-165N19.2	-5.34	1.48e-07	4.75e-05	-0.26	-0.24	Colorectal cancer;	chr9:112272619	chr9:112173522~112173971:-
HNSC	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	5.34	1.48e-07	4.75e-05	0.32	0.24	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
HNSC	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-5.34	1.48e-07	4.75e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-5.34	1.48e-07	4.75e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000274576.2	IGHV2-70	-5.34	1.48e-07	4.76e-05	-0.24	-0.24	Rheumatic heart disease;	chr14:106619987	chr14:106770577~106771020:-
HNSC	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-5.34	1.48e-07	4.76e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
HNSC	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	5.34	1.48e-07	4.76e-05	0.29	0.24	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
HNSC	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	5.34	1.48e-07	4.76e-05	0.29	0.24	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
HNSC	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	5.34	1.48e-07	4.76e-05	0.3	0.24	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
HNSC	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-5.34	1.48e-07	4.76e-05	-0.33	-0.24	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
HNSC	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
HNSC	cis	rs17428076	0.793	rs12622772	ENSG00000228389.1	AC068039.4	-5.34	1.48e-07	4.76e-05	-0.29	-0.24	Myopia;	chr2:171769227	chr2:171773482~171775844:+
HNSC	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	5.34	1.48e-07	4.77e-05	0.34	0.24	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
HNSC	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-5.34	1.49e-07	4.78e-05	-0.33	-0.24	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
HNSC	cis	rs2742234	0.541	rs12220534	ENSG00000273008.1	RP11-351D16.3	-5.34	1.49e-07	4.78e-05	-0.3	-0.24	Hirschsprung disease;	chr10:43238858	chr10:43136824~43138334:-
HNSC	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	5.34	1.49e-07	4.78e-05	0.29	0.24	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
HNSC	cis	rs7615952	0.546	rs2976733	ENSG00000248787.1	RP11-666A20.4	-5.34	1.49e-07	4.78e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125695294	chr3:125908005~125910272:-
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	5.34	1.49e-07	4.78e-05	0.19	0.24	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
HNSC	cis	rs4218	0.528	rs57557135	ENSG00000277144.1	RP11-59H7.4	-5.34	1.49e-07	4.79e-05	-0.3	-0.24	Social communication problems;	chr15:59054018	chr15:59115547~59116089:-
HNSC	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	5.33	1.49e-07	4.79e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
HNSC	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-5.33	1.49e-07	4.79e-05	-0.21	-0.24	Height;	chr11:118786602	chr11:118791254~118793137:+
HNSC	cis	rs6723108	0.603	rs1592	ENSG00000224043.6	CCNT2-AS1	-5.33	1.49e-07	4.79e-05	-0.3	-0.24	Type 2 diabetes;	chr2:134964573	chr2:134735464~134918710:-
HNSC	cis	rs3733585	0.699	rs17245723	ENSG00000250413.1	RP11-448G15.1	5.33	1.49e-07	4.79e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9960594	chr4:10006482~10009725:+
HNSC	cis	rs7819412	0.875	rs6981523	ENSG00000255310.2	AF131215.2	-5.33	1.49e-07	4.8e-05	-0.23	-0.24	Triglycerides;	chr8:11204283	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-5.33	1.49e-07	4.8e-05	-0.14	-0.24	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
HNSC	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	5.33	1.5e-07	4.8e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-5.33	1.5e-07	4.8e-05	-0.14	-0.24	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000211974.3	IGHV2-70	-5.33	1.5e-07	4.8e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106782459	chr14:106723574~106724093:-
HNSC	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	5.33	1.5e-07	4.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	5.33	1.5e-07	4.8e-05	0.21	0.24	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
HNSC	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	5.33	1.5e-07	4.81e-05	0.25	0.24	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
HNSC	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.33	1.5e-07	4.81e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
HNSC	cis	rs3733585	0.699	rs10001964	ENSG00000250413.1	RP11-448G15.1	5.33	1.5e-07	4.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957651	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.637	rs6850684	ENSG00000250413.1	RP11-448G15.1	5.33	1.5e-07	4.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962756	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	5.33	1.5e-07	4.82e-05	0.36	0.24	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
HNSC	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	5.33	1.5e-07	4.82e-05	0.35	0.24	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
HNSC	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-5.33	1.5e-07	4.82e-05	-0.21	-0.24	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
HNSC	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-5.33	1.5e-07	4.83e-05	-0.27	-0.24	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
HNSC	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-5.33	1.5e-07	4.83e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
HNSC	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	5.33	1.5e-07	4.83e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
HNSC	cis	rs2303759	0.958	rs1465697	ENSG00000268686.1	AC010524.2	-5.33	1.51e-07	4.83e-05	-0.29	-0.24	Multiple sclerosis;	chr19:49333989	chr19:49368705~49388081:-
HNSC	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-5.33	1.51e-07	4.83e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
HNSC	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-5.33	1.51e-07	4.84e-05	-0.42	-0.24	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
HNSC	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	5.33	1.51e-07	4.84e-05	0.3	0.24	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
HNSC	cis	rs860295	0.665	rs12028416	ENSG00000203761.5	MSTO2P	-5.33	1.51e-07	4.84e-05	-0.19	-0.24	Body mass index;	chr1:155431370	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.629	rs12026638	ENSG00000203761.5	MSTO2P	-5.33	1.51e-07	4.84e-05	-0.19	-0.24	Body mass index;	chr1:155431469	chr1:155745829~155750137:+
HNSC	cis	rs1218582	0.772	rs10908448	ENSG00000270361.1	RP11-307C12.13	5.33	1.51e-07	4.84e-05	0.26	0.24	Prostate cancer;	chr1:154910068	chr1:154937370~154938059:+
HNSC	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	5.33	1.51e-07	4.84e-05	0.41	0.24	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	5.33	1.51e-07	4.84e-05	0.41	0.24	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
HNSC	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	5.33	1.51e-07	4.84e-05	0.27	0.24	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
HNSC	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-5.33	1.51e-07	4.85e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	5.33	1.51e-07	4.85e-05	0.29	0.24	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
HNSC	cis	rs17428076	0.793	rs72881938	ENSG00000228389.1	AC068039.4	-5.33	1.51e-07	4.85e-05	-0.29	-0.24	Myopia;	chr2:171772242	chr2:171773482~171775844:+
HNSC	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	5.33	1.51e-07	4.85e-05	0.27	0.24	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
HNSC	cis	rs3733585	0.699	rs6449158	ENSG00000250413.1	RP11-448G15.1	5.33	1.51e-07	4.85e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958835	chr4:10006482~10009725:+
HNSC	cis	rs4218	0.689	rs35555888	ENSG00000277144.1	RP11-59H7.4	-5.33	1.52e-07	4.86e-05	-0.32	-0.24	Social communication problems;	chr15:59093935	chr15:59115547~59116089:-
HNSC	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	5.33	1.52e-07	4.86e-05	0.26	0.24	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	5.33	1.52e-07	4.86e-05	0.26	0.24	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	5.33	1.52e-07	4.87e-05	0.15	0.24	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
HNSC	cis	rs67981189	0.542	rs17109053	ENSG00000274818.1	RP1-292L20.3	5.33	1.52e-07	4.87e-05	0.29	0.24	Schizophrenia;	chr14:71142981	chr14:70906657~70907111:-
HNSC	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	5.33	1.52e-07	4.87e-05	0.3	0.24	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
HNSC	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	5.33	1.52e-07	4.87e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	5.33	1.52e-07	4.87e-05	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
HNSC	cis	rs1218582	0.772	rs6683557	ENSG00000270361.1	RP11-307C12.13	-5.33	1.52e-07	4.87e-05	-0.26	-0.24	Prostate cancer;	chr1:154879831	chr1:154937370~154938059:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000254174.1	IGHV1-12	5.33	1.52e-07	4.87e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106122420~106122709:-
HNSC	cis	rs8040855	0.621	rs6496796	ENSG00000259774.1	RP11-182J1.13	-5.33	1.52e-07	4.88e-05	-0.3	-0.24	Bulimia nervosa;	chr15:85183617	chr15:84422618~84425882:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	5.33	1.52e-07	4.89e-05	0.19	0.24	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-5.33	1.52e-07	4.89e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
HNSC	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	5.33	1.53e-07	4.89e-05	0.24	0.24	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
HNSC	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	5.33	1.53e-07	4.89e-05	0.27	0.24	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
HNSC	cis	rs28475163	0.958	rs7395116	ENSG00000255328.1	RP11-326C3.12	-5.33	1.53e-07	4.89e-05	-0.3	-0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:327171~330122:+
HNSC	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-5.33	1.53e-07	4.89e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
HNSC	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-5.33	1.53e-07	4.89e-05	-0.27	-0.24	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
HNSC	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.89e-05	0.25	0.24	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
HNSC	cis	rs988913	1	rs988913	ENSG00000224984.1	RP11-524H19.2	5.33	1.53e-07	4.9e-05	0.27	0.24	Menarche (age at onset);	chr6:54891510	chr6:54840118~54840855:-
HNSC	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.33	1.53e-07	4.9e-05	-0.24	-0.24	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
HNSC	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.9e-05	0.27	0.24	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
HNSC	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	5.33	1.53e-07	4.9e-05	0.27	0.24	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
HNSC	cis	rs17594362	1	rs12869969	ENSG00000229473.2	RGS17P1	5.33	1.53e-07	4.9e-05	0.36	0.24	Multiple sclerosis;	chr13:41566204	chr13:40992779~40993331:-
HNSC	cis	rs860295	0.702	rs56675301	ENSG00000203761.5	MSTO2P	-5.33	1.53e-07	4.91e-05	-0.19	-0.24	Body mass index;	chr1:155394536	chr1:155745829~155750137:+
HNSC	cis	rs10504130	0.502	rs16916968	ENSG00000253844.1	RP11-546K22.1	-5.33	1.53e-07	4.91e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51931851	chr8:51961458~52022974:+
HNSC	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-5.33	1.53e-07	4.91e-05	-0.36	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
HNSC	cis	rs180730	0.5	rs6810734	ENSG00000251609.2	SETP12	5.33	1.53e-07	4.92e-05	0.29	0.24	Fasting plasma glucose;	chr4:120935625	chr4:120895494~120897083:-
HNSC	cis	rs8177876	0.915	rs6420418	ENSG00000261061.1	RP11-303E16.2	5.33	1.54e-07	4.92e-05	0.39	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094409	chr16:81030770~81031485:+
HNSC	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.33	1.54e-07	4.92e-05	0.23	0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
HNSC	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-5.33	1.54e-07	4.92e-05	-0.3	-0.24	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000179406.6	LINC00174	5.33	1.54e-07	4.92e-05	0.51	0.24	Diabetic kidney disease;	chr7:65928187	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65917585	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34933526	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65918212	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34577383	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65920739	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6949812	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65922114	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs6970243	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65923503	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7794661	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65924743	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs7795242	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925107	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925372	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35058610	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65925938	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2177703	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65926730	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35432774	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65928032	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs56985706	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929575	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs60683927	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929781	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs58062456	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65929865	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34529418	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.92e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65938222	chr7:66376044~66401338:-
HNSC	cis	rs1971762	0.545	rs6580949	ENSG00000270175.1	RP11-793H13.11	-5.33	1.54e-07	4.93e-05	-0.2	-0.24	Height;	chr12:53530509	chr12:53500162~53500936:-
HNSC	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	5.33	1.54e-07	4.93e-05	0.29	0.24	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
HNSC	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.33	1.54e-07	4.93e-05	-0.26	-0.24	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000179406.6	LINC00174	-5.33	1.54e-07	4.93e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66034886	chr7:66376044~66401338:-
HNSC	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-5.33	1.54e-07	4.93e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
HNSC	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	5.33	1.54e-07	4.94e-05	0.24	0.24	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
HNSC	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	5.33	1.54e-07	4.94e-05	0.31	0.24	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-5.33	1.54e-07	4.94e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
HNSC	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-5.33	1.55e-07	4.95e-05	-0.26	-0.24	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
HNSC	cis	rs2243480	1	rs4718270	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.95e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65737415	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.95e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65739282	chr7:66376044~66401338:-
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000248787.1	RP11-666A20.4	-5.33	1.55e-07	4.95e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125989134	chr3:125908005~125910272:-
HNSC	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	5.33	1.55e-07	4.95e-05	0.27	0.24	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
HNSC	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-5.33	1.55e-07	4.96e-05	-0.23	-0.24	Height;	chr5:37072722	chr5:36666214~36725195:-
HNSC	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-5.33	1.55e-07	4.96e-05	-0.26	-0.24	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-5.33	1.55e-07	4.96e-05	-0.26	-0.24	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
HNSC	cis	rs12742923	0.534	rs323962	ENSG00000236268.4	LINC01361	-5.33	1.55e-07	4.96e-05	-0.28	-0.24	HIV-associated dementia;	chr1:83152534	chr1:82973882~82986208:-
HNSC	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.33	1.55e-07	4.97e-05	-0.3	-0.24	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
HNSC	cis	rs9611519	0.964	rs2092563	ENSG00000235513.1	RP4-756G23.5	5.33	1.55e-07	4.97e-05	0.27	0.24	Neuroticism;	chr22:41196673	chr22:41209122~41217627:-
HNSC	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.33	1.55e-07	4.97e-05	-0.31	-0.24	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	5.33	1.55e-07	4.97e-05	0.58	0.24	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
HNSC	cis	rs2243480	1	rs73142121	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65846219	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65847191	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35825738	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65853040	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34702770	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65879836	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000179406.6	LINC00174	-5.33	1.55e-07	4.97e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65892097	chr7:66376044~66401338:-
HNSC	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	5.33	1.55e-07	4.97e-05	0.21	0.24	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
HNSC	cis	rs860295	0.702	rs10796946	ENSG00000203761.5	MSTO2P	-5.33	1.55e-07	4.97e-05	-0.19	-0.24	Body mass index;	chr1:155459699	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.676	rs10908466	ENSG00000203761.5	MSTO2P	-5.33	1.55e-07	4.97e-05	-0.19	-0.24	Body mass index;	chr1:155459934	chr1:155745829~155750137:+
HNSC	cis	rs1056107	0.966	rs1538770	ENSG00000225513.1	RP11-165N19.2	-5.33	1.55e-07	4.97e-05	-0.25	-0.24	Colorectal cancer;	chr9:112300069	chr9:112173522~112173971:-
HNSC	cis	rs11846409	0.932	rs28617526	ENSG00000211974.3	IGHV2-70	-5.33	1.55e-07	4.97e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637322	chr14:106723574~106724093:-
HNSC	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-5.33	1.56e-07	4.97e-05	-0.3	-0.24	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
HNSC	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	5.33	1.56e-07	4.98e-05	0.25	0.24	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
HNSC	cis	rs4388249	0.687	rs2300995	ENSG00000271849.1	CTC-332L22.1	-5.33	1.56e-07	4.99e-05	-0.32	-0.24	Schizophrenia;	chr5:109746724	chr5:109687802~109688329:-
HNSC	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	5.33	1.56e-07	4.99e-05	0.27	0.24	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.34	0.24	Depression;	chr6:28240414	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.34	0.24	Depression;	chr6:28240780	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	5.33	1.56e-07	4.99e-05	0.29	0.24	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	5.33	1.56e-07	4.99e-05	0.29	0.24	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000204709.4	LINC01556	5.33	1.56e-07	4.99e-05	0.32	0.24	Parkinson's disease;	chr6:27999496	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	5.33	1.56e-07	4.99e-05	0.24	0.24	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
HNSC	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-5.33	1.56e-07	4.99e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
HNSC	cis	rs1555322	0.872	rs2425048	ENSG00000126005.14	MMP24-AS1	-5.33	1.56e-07	5e-05	-0.48	-0.24	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35216462~35278131:-
HNSC	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-5.33	1.56e-07	5e-05	-0.3	-0.24	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
HNSC	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-5.33	1.56e-07	5e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
HNSC	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	5.33	1.57e-07	5e-05	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	5.33	1.57e-07	5.01e-05	0.19	0.24	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
HNSC	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	5.33	1.57e-07	5.01e-05	0.29	0.24	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
HNSC	cis	rs6928977	0.896	rs2614257	ENSG00000231028.7	LINC00271	5.33	1.57e-07	5.01e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135497801~135716055:+
HNSC	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-5.33	1.57e-07	5.01e-05	-0.27	-0.24	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
HNSC	cis	rs9907295	0.901	rs11652536	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35891043	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs9789051	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892000	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs3809769	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892484	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs76016589	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35892923	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796124	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35893280	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs11656556	ENSG00000270977.1	AC015849.16	-5.33	1.57e-07	5.02e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894090	chr17:35893707~35911023:-
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000211974.3	IGHV2-70	-5.33	1.57e-07	5.02e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781132	chr14:106723574~106724093:-
HNSC	cis	rs2115630	1	rs11073730	ENSG00000229212.6	RP11-561C5.4	5.33	1.57e-07	5.02e-05	0.28	0.24	P wave terminal force;	chr15:84811365	chr15:85205440~85234795:-
HNSC	cis	rs10027350	0.964	rs10026230	ENSG00000281501.1	SEPSECS-AS1	5.33	1.57e-07	5.02e-05	0.3	0.24	Childhood ear infection;	chr4:25135784	chr4:25160641~25201440:+
HNSC	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	5.32	1.57e-07	5.02e-05	0.27	0.24	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
HNSC	cis	rs6928977	0.832	rs9402703	ENSG00000231028.7	LINC00271	5.32	1.57e-07	5.03e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135325097	chr6:135497801~135716055:+
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	5.32	1.58e-07	5.03e-05	0.29	0.24	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.04e-05	0.26	0.24	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	5.32	1.58e-07	5.04e-05	0.14	0.24	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
HNSC	cis	rs202072	0.729	rs202038	ENSG00000215022.6	RP1-257A7.4	5.32	1.58e-07	5.04e-05	0.35	0.24	HIV-1 viral setpoint;	chr6:13288416	chr6:13264861~13295586:-
HNSC	cis	rs9914544	1	rs1037036	ENSG00000264885.1	RP11-815I9.4	-5.32	1.58e-07	5.04e-05	-0.26	-0.24	Educational attainment (years of education);	chr17:18860764	chr17:18667629~18669461:-
HNSC	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	5.32	1.58e-07	5.04e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
HNSC	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	5.32	1.58e-07	5.05e-05	0.39	0.24	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
HNSC	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.05e-05	0.27	0.24	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	5.32	1.58e-07	5.05e-05	0.26	0.24	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
HNSC	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	5.32	1.58e-07	5.05e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
HNSC	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	5.32	1.58e-07	5.05e-05	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
HNSC	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-5.32	1.58e-07	5.05e-05	-0.28	-0.24	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28241324	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28241753	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000204709.4	LINC01556	5.32	1.58e-07	5.05e-05	0.34	0.24	Depression;	chr6:28242515	chr6:28943877~28944537:+
HNSC	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.32	1.58e-07	5.06e-05	0.25	0.24	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781327	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781363	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781364	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781722	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781883	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000211974.3	IGHV2-70	-5.32	1.58e-07	5.06e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781942	chr14:106723574~106724093:-
HNSC	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-5.32	1.59e-07	5.06e-05	-0.32	-0.24	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
HNSC	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-5.32	1.59e-07	5.06e-05	-0.3	-0.24	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
HNSC	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	5.32	1.59e-07	5.07e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
HNSC	cis	rs6693567	0.516	rs7554686	ENSG00000228126.1	FALEC	-5.32	1.59e-07	5.07e-05	-0.29	-0.24	Migraine;	chr1:150293199	chr1:150515757~150518032:+
HNSC	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-5.32	1.59e-07	5.08e-05	-0.27	-0.24	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.08e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.08e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
HNSC	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	5.32	1.59e-07	5.08e-05	0.31	0.24	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
HNSC	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	5.32	1.59e-07	5.09e-05	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-5.32	1.59e-07	5.09e-05	-0.14	-0.24	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
HNSC	cis	rs71520386	0.632	rs1029738	ENSG00000221740.1	SNORD93	-5.32	1.6e-07	5.09e-05	-0.28	-0.24	Fibrinogen levels;	chr7:22834428	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs9654968	ENSG00000221740.1	SNORD93	-5.32	1.6e-07	5.09e-05	-0.28	-0.24	Fibrinogen levels;	chr7:22836697	chr7:22856613~22856686:+
HNSC	cis	rs9525927	0.625	rs9562541	ENSG00000227258.4	SMIM2-AS1	5.32	1.6e-07	5.09e-05	0.35	0.24	Dupuytren's disease;	chr13:44249190	chr13:44110451~44240517:+
HNSC	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-5.32	1.6e-07	5.09e-05	-0.3	-0.24	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
HNSC	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-5.32	1.6e-07	5.09e-05	-0.23	-0.24	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
HNSC	cis	rs10256972	0.933	rs35696159	ENSG00000225146.1	AC073957.15	5.32	1.6e-07	5.1e-05	0.28	0.24	Endometriosis;Longevity;	chr7:1007558	chr7:1029025~1043891:+
HNSC	cis	rs8032939	0.533	rs17652674	ENSG00000259747.1	RP11-275I4.2	-5.32	1.6e-07	5.1e-05	-0.3	-0.24	Rheumatoid arthritis;	chr15:38608111	chr15:38671847~38689191:+
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	5.32	1.6e-07	5.1e-05	0.28	0.24	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
HNSC	cis	rs7927592	0.645	rs7950900	ENSG00000212093.1	AP000807.1	5.32	1.6e-07	5.1e-05	0.26	0.24	Total body bone mineral density;	chr11:68526077	chr11:68506083~68506166:-
HNSC	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.32	1.6e-07	5.1e-05	-0.31	-0.24	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	5.32	1.6e-07	5.11e-05	0.57	0.24	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
HNSC	cis	rs9840812	0.522	rs699165	ENSG00000239213.4	NCK1-AS1	5.32	1.6e-07	5.11e-05	0.23	0.24	Fibrinogen levels;	chr3:136505855	chr3:136841726~136862054:-
HNSC	cis	rs10027350	1	rs10027350	ENSG00000281501.1	SEPSECS-AS1	5.32	1.6e-07	5.11e-05	0.3	0.24	Childhood ear infection;	chr4:25130872	chr4:25160641~25201440:+
HNSC	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-5.32	1.6e-07	5.11e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-5.32	1.6e-07	5.11e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
HNSC	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-5.32	1.6e-07	5.12e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
HNSC	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.32	1.6e-07	5.12e-05	0.48	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
HNSC	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-5.32	1.61e-07	5.12e-05	-0.27	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
HNSC	cis	rs933688	1	rs1895448	ENSG00000281357.1	ARRDC3-AS1	5.32	1.61e-07	5.12e-05	0.35	0.24	Smoking behavior;	chr5:91448037	chr5:91380349~91439085:+
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	5.32	1.61e-07	5.12e-05	0.29	0.24	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
HNSC	cis	rs988913	1	rs9382403	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54960889	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9349740	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54960910	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7744592	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54961547	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs7753255	ENSG00000224984.1	RP11-524H19.2	5.32	1.61e-07	5.13e-05	0.27	0.24	Menarche (age at onset);	chr6:54968175	chr6:54840118~54840855:-
HNSC	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-5.32	1.61e-07	5.13e-05	-0.22	-0.24	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
HNSC	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	5.32	1.61e-07	5.13e-05	0.31	0.24	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
HNSC	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	5.32	1.61e-07	5.14e-05	0.41	0.24	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
HNSC	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-5.32	1.61e-07	5.14e-05	-0.21	-0.24	Height;	chr11:118742526	chr11:118791254~118793137:+
HNSC	cis	rs9813712	1	rs9813712	ENSG00000249846.5	RP11-77P16.4	5.32	1.61e-07	5.14e-05	0.28	0.24	Response to amphetamines;	chr3:130252258	chr3:130112550~130120579:+
HNSC	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-5.32	1.61e-07	5.14e-05	-0.27	-0.24	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
HNSC	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	5.32	1.61e-07	5.14e-05	0.31	0.24	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
HNSC	cis	rs9921338	0.961	rs7200667	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.924	rs7202024	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs7206017	ENSG00000263080.1	RP11-485G7.5	5.32	1.61e-07	5.15e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11341809~11345211:-
HNSC	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-5.32	1.61e-07	5.15e-05	-0.26	-0.24	Height;	chr2:46640019	chr2:46668870~46670778:+
HNSC	cis	rs9840812	0.598	rs33999043	ENSG00000239213.4	NCK1-AS1	5.32	1.62e-07	5.15e-05	0.26	0.24	Fibrinogen levels;	chr3:136381198	chr3:136841726~136862054:-
HNSC	cis	rs3736485	0.808	rs28485410	ENSG00000259438.1	CTD-2650P22.1	5.32	1.62e-07	5.15e-05	0.24	0.24	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51657688	chr15:52010999~52019095:-
HNSC	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-5.32	1.62e-07	5.15e-05	-0.25	-0.24	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
HNSC	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	5.32	1.62e-07	5.16e-05	0.26	0.24	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
HNSC	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	5.32	1.62e-07	5.16e-05	0.24	0.24	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	5.32	1.62e-07	5.16e-05	0.24	0.24	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
HNSC	cis	rs9921338	0.961	rs11545336	ENSG00000263080.1	RP11-485G7.5	5.32	1.62e-07	5.16e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11341809~11345211:-
HNSC	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	5.32	1.62e-07	5.16e-05	0.19	0.24	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
HNSC	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-5.32	1.62e-07	5.16e-05	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
HNSC	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-5.32	1.62e-07	5.16e-05	-0.35	-0.24	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
HNSC	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-5.32	1.62e-07	5.17e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
HNSC	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-5.32	1.62e-07	5.17e-05	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-5.32	1.62e-07	5.17e-05	-0.3	-0.24	Depression;	chr6:28180209	chr6:28161781~28169594:+
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000173295.6	FAM86B3P	-5.32	1.63e-07	5.18e-05	-0.29	-0.24	Recombination measurement;	chr8:9208000	chr8:8228595~8244865:+
HNSC	cis	rs7819412	0.775	rs34094119	ENSG00000255310.2	AF131215.2	-5.32	1.63e-07	5.18e-05	-0.23	-0.24	Triglycerides;	chr8:11078388	chr8:11107788~11109726:-
HNSC	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.18e-05	0.26	0.24	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
HNSC	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-5.32	1.63e-07	5.18e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
HNSC	cis	rs9840812	0.69	rs1618069	ENSG00000273486.1	RP11-731C17.2	5.32	1.63e-07	5.18e-05	0.21	0.24	Fibrinogen levels;	chr3:136308303	chr3:136837338~136839021:-
HNSC	cis	rs950169	0.887	rs220333	ENSG00000229212.6	RP11-561C5.4	-5.32	1.63e-07	5.18e-05	-0.33	-0.24	Schizophrenia;	chr15:84547902	chr15:85205440~85234795:-
HNSC	cis	rs638893	0.617	rs2156750	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118848545	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.561	rs2156749	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118848696	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs7116715	ENSG00000255422.1	AP002954.4	-5.32	1.63e-07	5.18e-05	-0.34	-0.24	Vitiligo;	chr11:118849033	chr11:118704607~118750263:+
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	5.32	1.63e-07	5.18e-05	0.59	0.24	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
HNSC	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.18e-05	0.26	0.24	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
HNSC	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.32	1.63e-07	5.18e-05	-0.24	-0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
HNSC	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-5.32	1.63e-07	5.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
HNSC	cis	rs1056107	0.931	rs6575	ENSG00000225513.1	RP11-165N19.2	-5.32	1.63e-07	5.19e-05	-0.26	-0.24	Colorectal cancer;	chr9:112218687	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.797	rs4979087	ENSG00000225513.1	RP11-165N19.2	-5.32	1.63e-07	5.19e-05	-0.26	-0.24	Colorectal cancer;	chr9:112179920	chr9:112173522~112173971:-
HNSC	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	5.32	1.63e-07	5.19e-05	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
HNSC	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	5.32	1.63e-07	5.19e-05	0.29	0.24	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000254174.1	IGHV1-12	5.32	1.63e-07	5.2e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106805386	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000254174.1	IGHV1-12	5.32	1.63e-07	5.2e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106806185	chr14:106122420~106122709:-
HNSC	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	5.32	1.63e-07	5.2e-05	0.29	0.24	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
HNSC	cis	rs9341808	0.519	rs7771593	ENSG00000272129.1	RP11-250B2.6	-5.32	1.63e-07	5.2e-05	-0.29	-0.24	Sitting height ratio;	chr6:80326410	chr6:80355424~80356859:+
HNSC	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	5.32	1.63e-07	5.2e-05	0.26	0.24	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
HNSC	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	5.32	1.64e-07	5.21e-05	0.29	0.24	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
HNSC	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	5.32	1.64e-07	5.21e-05	0.26	0.24	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-5.32	1.64e-07	5.21e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
HNSC	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-5.32	1.64e-07	5.21e-05	-0.26	-0.24	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
HNSC	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	5.32	1.64e-07	5.21e-05	0.3	0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
HNSC	cis	rs712039	0.565	rs1714987	ENSG00000276054.1	RP11-378E13.3	5.32	1.64e-07	5.21e-05	0.33	0.24	Tuberculosis;	chr17:37386072	chr17:37386886~37387926:+
HNSC	cis	rs2235642	1	rs2076438	ENSG00000280231.1	LA16c-380F5.3	-5.32	1.64e-07	5.21e-05	-0.29	-0.24	Coronary artery disease;	chr16:1534617	chr16:1553655~1554130:-
HNSC	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	5.32	1.64e-07	5.22e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
HNSC	cis	rs988913	1	rs9367600	ENSG00000224984.1	RP11-524H19.2	5.32	1.64e-07	5.22e-05	0.27	0.24	Menarche (age at onset);	chr6:54973179	chr6:54840118~54840855:-
HNSC	cis	rs9402743	0.671	rs9373137	ENSG00000217482.2	HMGB1P17	5.32	1.64e-07	5.22e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135629059	chr6:135636086~135636713:-
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000248787.1	RP11-666A20.4	-5.32	1.64e-07	5.22e-05	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125991896	chr3:125908005~125910272:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.22e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106780074	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.23e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778385	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000254174.1	IGHV1-12	5.32	1.64e-07	5.23e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778427	chr14:106122420~106122709:-
HNSC	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-5.32	1.64e-07	5.23e-05	-0.34	-0.24	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
HNSC	cis	rs2579103	0.898	rs2579127	ENSG00000258183.4	RP11-753N8.1	-5.32	1.64e-07	5.23e-05	-0.3	-0.24	Body mass index;	chr12:90204420	chr12:90280894~90300340:+
HNSC	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-5.32	1.64e-07	5.23e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
HNSC	cis	rs1355223	1	rs1355221	ENSG00000271369.1	RP11-350D17.3	-5.32	1.65e-07	5.23e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737062	chr11:34709600~34710161:+
HNSC	cis	rs13126694	0.679	rs4072170	ENSG00000248429.4	RP11-597D13.9	5.32	1.65e-07	5.24e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158170752~158202877:+
HNSC	cis	rs7819412	0.775	rs4841489	ENSG00000255310.2	AF131215.2	-5.32	1.65e-07	5.24e-05	-0.23	-0.24	Triglycerides;	chr8:11079301	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.775	rs4841490	ENSG00000255310.2	AF131215.2	-5.32	1.65e-07	5.24e-05	-0.23	-0.24	Triglycerides;	chr8:11079381	chr8:11107788~11109726:-
HNSC	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-5.32	1.65e-07	5.24e-05	-0.39	-0.24	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
HNSC	cis	rs4218	0.681	rs34977427	ENSG00000277144.1	RP11-59H7.4	-5.32	1.65e-07	5.24e-05	-0.32	-0.24	Social communication problems;	chr15:59098172	chr15:59115547~59116089:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66043558	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs437889	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044247	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs402418	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044482	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66044512	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs431318	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66046610	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313803	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66049744	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs313802	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66051386	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66052736	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs458291	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.24e-05	-0.52	-0.24	Diabetic kidney disease;	chr7:66055492	chr7:66376044~66401338:-
HNSC	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-5.32	1.65e-07	5.25e-05	-0.32	-0.24	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
HNSC	cis	rs2243480	1	rs11538349	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65956884	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35542501	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65966228	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65973566	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs781142	ENSG00000179406.6	LINC00174	-5.32	1.65e-07	5.25e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65973791	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	5.32	1.65e-07	5.25e-05	0.3	0.24	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
HNSC	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	5.32	1.65e-07	5.25e-05	0.23	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
HNSC	cis	rs3206736	0.548	rs10265125	ENSG00000197085.10	NPSR1-AS1	-5.32	1.65e-07	5.25e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35021524	chr7:34346512~34871582:-
HNSC	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-5.32	1.65e-07	5.25e-05	-0.24	-0.24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
HNSC	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	5.32	1.65e-07	5.26e-05	0.26	0.24	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
HNSC	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-5.32	1.65e-07	5.26e-05	-0.24	-0.24	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
HNSC	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-5.32	1.65e-07	5.26e-05	-0.24	-0.24	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
HNSC	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-5.31	1.66e-07	5.27e-05	-0.24	-0.24	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
HNSC	cis	rs7615952	0.599	rs66532274	ENSG00000248787.1	RP11-666A20.4	-5.31	1.66e-07	5.27e-05	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126013002	chr3:125908005~125910272:-
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-5.31	1.66e-07	5.27e-05	-0.3	-0.24	Depression;	chr6:28176973	chr6:28161781~28169594:+
HNSC	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.31	1.66e-07	5.28e-05	0.25	0.24	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
HNSC	cis	rs442309	0.532	rs10995301	ENSG00000238280.1	RP11-436D10.3	5.31	1.66e-07	5.28e-05	0.3	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62747535	chr10:62793562~62805887:-
HNSC	cis	rs2179367	0.632	rs11155642	ENSG00000216906.2	RP11-350J20.9	5.31	1.66e-07	5.28e-05	0.35	0.24	Dupuytren's disease;	chr6:149332984	chr6:149904243~149906418:+
HNSC	cis	rs889014	0.751	rs12520258	ENSG00000253768.1	CTB-33O18.1	-5.31	1.66e-07	5.28e-05	-0.26	-0.24	Height;	chr5:173553711	chr5:173562478~173573199:+
HNSC	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	5.31	1.66e-07	5.29e-05	0.26	0.24	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
HNSC	cis	rs67981189	0.529	rs61990380	ENSG00000274818.1	RP1-292L20.3	5.31	1.66e-07	5.29e-05	0.29	0.24	Schizophrenia;	chr14:71005229	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	5.31	1.66e-07	5.29e-05	0.29	0.24	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
HNSC	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-5.31	1.66e-07	5.29e-05	-0.24	-0.24	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
HNSC	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	5.31	1.67e-07	5.29e-05	0.27	0.24	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
HNSC	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	5.31	1.67e-07	5.29e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
HNSC	cis	rs2243480	1	rs2243480	ENSG00000179406.6	LINC00174	-5.31	1.67e-07	5.29e-05	-0.5	-0.24	Diabetic kidney disease;	chr7:66134209	chr7:66376044~66401338:-
HNSC	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	5.31	1.67e-07	5.3e-05	0.26	0.24	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
HNSC	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	5.31	1.67e-07	5.3e-05	0.23	0.24	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
HNSC	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-5.31	1.67e-07	5.31e-05	-0.33	-0.24	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
HNSC	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	5.31	1.67e-07	5.31e-05	0.22	0.24	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
HNSC	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	5.31	1.67e-07	5.31e-05	0.44	0.24	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
HNSC	cis	rs7615952	0.736	rs9862893	ENSG00000248787.1	RP11-666A20.4	-5.31	1.67e-07	5.31e-05	-0.4	-0.24	Blood pressure (smoking interaction);	chr3:125968131	chr3:125908005~125910272:-
HNSC	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	5.31	1.67e-07	5.32e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	5.31	1.67e-07	5.32e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
HNSC	cis	rs8054556	0.967	rs11150576	ENSG00000183604.13	SMG1P5	-5.31	1.67e-07	5.32e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30267553~30335374:-
HNSC	cis	rs9840812	0.596	rs571513	ENSG00000239213.4	NCK1-AS1	5.31	1.68e-07	5.32e-05	0.22	0.24	Fibrinogen levels;	chr3:136376193	chr3:136841726~136862054:-
HNSC	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	5.31	1.68e-07	5.32e-05	0.37	0.24	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	5.31	1.68e-07	5.32e-05	0.37	0.24	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
HNSC	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-5.31	1.68e-07	5.33e-05	-0.3	-0.24	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000204709.4	LINC01556	5.31	1.68e-07	5.33e-05	0.32	0.24	Parkinson's disease;	chr6:27997725	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000204709.4	LINC01556	5.31	1.68e-07	5.33e-05	0.32	0.24	Parkinson's disease;	chr6:27999813	chr6:28943877~28944537:+
HNSC	cis	rs9840812	0.522	rs711976	ENSG00000239213.4	NCK1-AS1	5.31	1.68e-07	5.34e-05	0.23	0.24	Fibrinogen levels;	chr3:136510180	chr3:136841726~136862054:-
HNSC	cis	rs4699052	0.507	rs6533085	ENSG00000246560.2	RP11-10L12.4	5.31	1.68e-07	5.34e-05	0.3	0.24	Testicular germ cell tumor;	chr4:103360429	chr4:102828055~102844075:+
HNSC	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	5.31	1.68e-07	5.34e-05	0.23	0.24	Height;	chr5:37041491	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	5.31	1.68e-07	5.34e-05	0.29	0.24	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
HNSC	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	5.31	1.68e-07	5.35e-05	0.26	0.24	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-5.31	1.68e-07	5.35e-05	-0.14	-0.24	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
HNSC	cis	rs11969893	1	rs60993915	ENSG00000270987.1	RP3-467N11.2	5.31	1.69e-07	5.35e-05	0.65	0.24	Economic and political preferences (immigration/crime);	chr6:101132273	chr6:100889603~100890338:+
HNSC	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-5.31	1.69e-07	5.35e-05	-0.26	-0.24	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
HNSC	cis	rs1355223	0.867	rs11821793	ENSG00000271369.1	RP11-350D17.3	-5.31	1.69e-07	5.36e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659915	chr11:34709600~34710161:+
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000274576.2	IGHV2-70	5.31	1.69e-07	5.36e-05	0.23	0.24	Rheumatic heart disease;	chr14:106630013	chr14:106770577~106771020:-
HNSC	cis	rs9987353	0.62	rs34455383	ENSG00000173295.6	FAM86B3P	-5.31	1.69e-07	5.36e-05	-0.3	-0.24	Recombination measurement;	chr8:9208948	chr8:8228595~8244865:+
HNSC	cis	rs860295	0.702	rs2025669	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155387818	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs12081067	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155389191	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs10908465	ENSG00000203761.5	MSTO2P	-5.31	1.69e-07	5.37e-05	-0.19	-0.24	Body mass index;	chr1:155419897	chr1:155745829~155750137:+
HNSC	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	5.31	1.69e-07	5.37e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
HNSC	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	5.31	1.69e-07	5.37e-05	0.31	0.24	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
HNSC	cis	rs1008375	0.966	rs7658240	ENSG00000249502.1	AC006160.5	5.31	1.69e-07	5.37e-05	0.27	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587327	chr4:17587467~17614571:-
HNSC	cis	rs17270561	0.514	rs10946805	ENSG00000272810.1	U91328.22	-5.31	1.69e-07	5.38e-05	-0.27	-0.24	Iron status biomarkers;	chr6:26077663	chr6:26013241~26013757:+
HNSC	cis	rs3733585	0.775	rs13124007	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.566	rs13144709	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10042558	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13110307	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10042740	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.566	rs13122689	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043024	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13129453	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043160	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs12504565	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10043521	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs7442336	ENSG00000250413.1	RP11-448G15.1	-5.31	1.7e-07	5.38e-05	-0.3	-0.24	Bone mineral density;	chr4:10044159	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs28613263	ENSG00000250413.1	RP11-448G15.1	5.31	1.7e-07	5.38e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9963256	chr4:10006482~10009725:+
HNSC	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55439652	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55440643	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441110	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441567	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55441907	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55442184	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55442875	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55444253	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55446869	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	5.31	1.7e-07	5.39e-05	0.29	0.24	Height;	chr4:55447523	chr4:55387949~55388271:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-5.31	1.7e-07	5.39e-05	-0.3	-0.24	Depression;	chr6:28143758	chr6:28161781~28169594:+
HNSC	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	5.31	1.7e-07	5.4e-05	0.26	0.24	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	5.31	1.7e-07	5.4e-05	0.26	0.24	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
HNSC	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-5.31	1.7e-07	5.4e-05	-0.23	-0.24	Height;	chr5:36911514	chr5:36666214~36725195:-
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-5.31	1.7e-07	5.4e-05	-0.29	-0.24	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
HNSC	cis	rs1971762	0.527	rs6580952	ENSG00000270175.1	RP11-793H13.11	-5.31	1.7e-07	5.4e-05	-0.2	-0.24	Height;	chr12:53543668	chr12:53500162~53500936:-
HNSC	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	5.31	1.7e-07	5.41e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
HNSC	cis	rs10504130	0.542	rs1589079	ENSG00000253844.1	RP11-546K22.1	-5.31	1.71e-07	5.41e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51961458~52022974:+
HNSC	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	5.31	1.71e-07	5.41e-05	0.22	0.24	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
HNSC	cis	rs17428076	0.874	rs12614709	ENSG00000228389.1	AC068039.4	-5.31	1.71e-07	5.41e-05	-0.29	-0.24	Myopia;	chr2:171824362	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs62182372	ENSG00000228389.1	AC068039.4	-5.31	1.71e-07	5.41e-05	-0.29	-0.24	Myopia;	chr2:171827977	chr2:171773482~171775844:+
HNSC	cis	rs17270561	0.562	rs12199626	ENSG00000272810.1	U91328.22	-5.31	1.71e-07	5.42e-05	-0.28	-0.24	Iron status biomarkers;	chr6:26013376	chr6:26013241~26013757:+
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	-5.31	1.71e-07	5.42e-05	-0.27	-0.24	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
HNSC	cis	rs11170631	0.504	rs10128880	ENSG00000270175.1	RP11-793H13.11	-5.31	1.71e-07	5.42e-05	-0.2	-0.24	Height;	chr12:53533999	chr12:53500162~53500936:-
HNSC	cis	rs7617773	0.963	rs12494304	ENSG00000228638.1	FCF1P2	5.31	1.71e-07	5.42e-05	0.22	0.24	Coronary artery disease;	chr3:48136539	chr3:48290793~48291375:-
HNSC	cis	rs1552244	1	rs6789156	ENSG00000180385.7	EMC3-AS1	5.31	1.71e-07	5.42e-05	0.28	0.24	Alzheimer's disease;	chr3:10082436	chr3:9986893~10006990:+
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	5.31	1.71e-07	5.42e-05	0.57	0.24	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
HNSC	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-5.31	1.71e-07	5.42e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-5.31	1.71e-07	5.42e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
HNSC	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	5.31	1.71e-07	5.42e-05	0.29	0.24	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
HNSC	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-5.31	1.71e-07	5.43e-05	-0.24	-0.24	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
HNSC	cis	rs6540731	1	rs11119884	ENSG00000226251.4	RP11-15I11.3	-5.31	1.71e-07	5.43e-05	-0.28	-0.24	Intelligence (childhood);	chr1:212226804	chr1:212225278~212238977:-
HNSC	cis	rs35306767	0.953	rs11253517	ENSG00000229869.1	RP11-363N22.2	5.31	1.71e-07	5.43e-05	0.33	0.24	Eosinophil percentage of granulocytes;	chr10:924584	chr10:933026~942743:+
HNSC	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	5.31	1.71e-07	5.43e-05	0.27	0.24	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000233609.3	RP11-62H7.2	5.31	1.71e-07	5.43e-05	0.24	0.24	Joint mobility (Beighton score);	chr8:8995760	chr8:8961200~8979025:+
HNSC	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	5.31	1.71e-07	5.43e-05	0.25	0.24	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
HNSC	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	5.31	1.71e-07	5.43e-05	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
HNSC	cis	rs1008375	0.931	rs1860592	ENSG00000249502.1	AC006160.5	-5.31	1.71e-07	5.43e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575405	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000233609.3	RP11-62H7.2	-5.31	1.72e-07	5.44e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8961200~8979025:+
HNSC	cis	rs7083	0.653	rs573442	ENSG00000254851.1	RP11-109L13.1	5.31	1.72e-07	5.44e-05	0.32	0.24	Blood protein levels;	chr11:117307204	chr11:117135528~117138582:+
HNSC	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	5.31	1.72e-07	5.44e-05	0.25	0.24	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
HNSC	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-5.31	1.72e-07	5.45e-05	-0.26	-0.24	Height;	chr2:46641180	chr2:46668870~46670778:+
HNSC	cis	rs11969893	0.85	rs9390697	ENSG00000270987.1	RP3-467N11.2	5.31	1.72e-07	5.46e-05	0.61	0.24	Economic and political preferences (immigration/crime);	chr6:100846555	chr6:100889603~100890338:+
HNSC	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	5.31	1.73e-07	5.47e-05	0.29	0.24	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	5.31	1.73e-07	5.47e-05	0.28	0.24	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
HNSC	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	5.31	1.73e-07	5.47e-05	0.24	0.24	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
HNSC	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-5.31	1.73e-07	5.47e-05	-0.28	-0.24	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
HNSC	cis	rs7515577	0.588	rs17380378	ENSG00000223787.2	RP4-593M8.1	5.31	1.73e-07	5.48e-05	0.52	0.24	Cholesterol, total;	chr1:92580420	chr1:92580476~92580821:-
HNSC	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	5.31	1.73e-07	5.48e-05	0.21	0.24	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
HNSC	cis	rs11773103	1	rs73206984	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87182209	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208507	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87192492	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs11773103	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87192664	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.867	rs73208517	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87198251	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208522	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87198863	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208537	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87200814	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73208546	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87203799	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs117742735	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87205452	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73210234	ENSG00000224046.1	AC005076.5	5.31	1.73e-07	5.49e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87211844	chr7:87151423~87152420:-
HNSC	cis	rs7617773	0.963	rs12493256	ENSG00000228638.1	FCF1P2	5.31	1.74e-07	5.49e-05	0.22	0.24	Coronary artery disease;	chr3:48135257	chr3:48290793~48291375:-
HNSC	cis	rs1008375	0.9	rs1003413	ENSG00000249502.1	AC006160.5	5.31	1.74e-07	5.49e-05	0.27	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580819	chr4:17587467~17614571:-
HNSC	cis	rs6928977	0.897	rs2746431	ENSG00000234084.1	RP3-388E23.2	5.31	1.74e-07	5.5e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366063	chr6:135301568~135307158:+
HNSC	cis	rs4718428	1	rs1830070	ENSG00000179406.6	LINC00174	-5.31	1.74e-07	5.5e-05	-0.32	-0.24	Corneal structure;	chr7:66884684	chr7:66376044~66401338:-
HNSC	cis	rs17507216	0.718	rs4779034	ENSG00000276710.3	CSPG4P8	-5.31	1.74e-07	5.5e-05	-0.32	-0.24	Excessive daytime sleepiness;	chr15:82576799	chr15:82459472~82477258:+
HNSC	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	5.31	1.74e-07	5.51e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
HNSC	cis	rs10504130	0.502	rs10087958	ENSG00000272024.1	RP11-546K22.3	-5.31	1.74e-07	5.51e-05	-0.31	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51950284~51950690:+
HNSC	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	5.31	1.74e-07	5.51e-05	0.22	0.24	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
HNSC	cis	rs13126694	0.617	rs10008900	ENSG00000248429.4	RP11-597D13.9	5.31	1.74e-07	5.51e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158170752~158202877:+
HNSC	cis	rs1056107	0.966	rs7869209	ENSG00000225513.1	RP11-165N19.2	-5.3	1.74e-07	5.52e-05	-0.25	-0.24	Colorectal cancer;	chr9:112301133	chr9:112173522~112173971:-
HNSC	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	5.3	1.74e-07	5.52e-05	0.45	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
HNSC	cis	rs1355223	0.867	rs1869360	ENSG00000271369.1	RP11-350D17.3	-5.3	1.74e-07	5.52e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677043	chr11:34709600~34710161:+
HNSC	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-5.3	1.74e-07	5.52e-05	-0.3	-0.24	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
HNSC	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	5.3	1.75e-07	5.52e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
HNSC	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	5.3	1.75e-07	5.53e-05	0.28	0.24	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
HNSC	cis	rs116095464	1	rs6879758	ENSG00000277812.1	AC021087.1	5.3	1.75e-07	5.53e-05	0.55	0.24	Breast cancer;	chr5:350162	chr5:262769~262881:+
HNSC	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-5.3	1.75e-07	5.53e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-5.3	1.75e-07	5.53e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
HNSC	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	5.3	1.75e-07	5.53e-05	0.32	0.24	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
HNSC	cis	rs988913	1	rs9367601	ENSG00000224984.1	RP11-524H19.2	5.3	1.75e-07	5.53e-05	0.27	0.24	Menarche (age at onset);	chr6:54974364	chr6:54840118~54840855:-
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000211974.3	IGHV2-70	-5.3	1.75e-07	5.53e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106665591	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-5.3	1.75e-07	5.53e-05	-0.16	-0.24	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
HNSC	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-5.3	1.75e-07	5.54e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
HNSC	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	5.3	1.75e-07	5.54e-05	0.31	0.24	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
HNSC	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
HNSC	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.3	1.76e-07	5.55e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
HNSC	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	5.3	1.76e-07	5.55e-05	0.3	0.24	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	5.3	1.76e-07	5.56e-05	0.29	0.24	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-5.3	1.76e-07	5.56e-05	-0.14	-0.24	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
HNSC	cis	rs10462794	0.661	rs4702804	ENSG00000260763.1	RP11-445O3.3	-5.3	1.76e-07	5.56e-05	-0.35	-0.24	DNA methylation (variation);	chr5:4526310	chr5:4436850~4440259:-
HNSC	cis	rs6928977	0.66	rs2614267	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.56e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135301568~135307158:+
HNSC	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	5.3	1.76e-07	5.56e-05	0.3	0.24	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
HNSC	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	5.3	1.76e-07	5.57e-05	0.34	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
HNSC	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-5.3	1.76e-07	5.57e-05	-0.21	-0.24	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
HNSC	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	5.3	1.76e-07	5.57e-05	0.28	0.24	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
HNSC	cis	rs6928977	0.66	rs2757647	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.57e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135301568~135307158:+
HNSC	cis	rs7048146	0.509	rs7021081	ENSG00000213539.4	YBX1P6	5.3	1.76e-07	5.57e-05	0.31	0.24	Vascular brain injury;	chr9:109537580	chr9:109532830~109534332:-
HNSC	cis	rs6928977	0.66	rs2614263	ENSG00000234084.1	RP3-388E23.2	5.3	1.76e-07	5.57e-05	0.24	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135301568~135307158:+
HNSC	cis	rs2834288	0.734	rs743336	ENSG00000237945.6	LINC00649	-5.3	1.76e-07	5.57e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33893080	chr21:33915534~33977691:+
HNSC	cis	rs2834288	0.734	rs743337	ENSG00000237945.6	LINC00649	-5.3	1.76e-07	5.57e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33893220	chr21:33915534~33977691:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000233609.3	RP11-62H7.2	5.3	1.76e-07	5.57e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9034711	chr8:8961200~8979025:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	5.3	1.77e-07	5.58e-05	0.21	0.24	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
HNSC	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-5.3	1.77e-07	5.58e-05	-0.23	-0.24	Height;	chr5:36882917	chr5:36666214~36725195:-
HNSC	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-5.3	1.77e-07	5.58e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000215302.7	CTD-3092A11.1	-5.3	1.77e-07	5.58e-05	-0.52	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30470779~30507623:+
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-5.3	1.77e-07	5.58e-05	-0.16	-0.24	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000254153.1	CTA-398F10.2	-5.3	1.77e-07	5.58e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9032531	chr8:8456909~8461337:-
HNSC	cis	rs2337406	0.714	rs115401799	ENSG00000211974.3	IGHV2-70	-5.3	1.77e-07	5.58e-05	-0.3	-0.24	Alzheimer's disease (late onset);	chr14:106813739	chr14:106723574~106724093:-
HNSC	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-5.3	1.77e-07	5.58e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
HNSC	cis	rs2115630	0.791	rs2008262	ENSG00000229212.6	RP11-561C5.4	5.3	1.77e-07	5.59e-05	0.29	0.24	P wave terminal force;	chr15:84762039	chr15:85205440~85234795:-
HNSC	cis	rs12468226	1	rs6739198	ENSG00000226261.1	AC064836.3	5.3	1.77e-07	5.59e-05	0.34	0.24	Urate levels;	chr2:202492273	chr2:202336024~202336727:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-5.3	1.77e-07	5.59e-05	-0.16	-0.24	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
HNSC	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	5.3	1.77e-07	5.59e-05	0.3	0.24	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	5.3	1.77e-07	5.59e-05	0.24	0.24	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
HNSC	cis	rs17428076	0.874	rs17615262	ENSG00000228389.1	AC068039.4	-5.3	1.77e-07	5.59e-05	-0.29	-0.24	Myopia;	chr2:171826971	chr2:171773482~171775844:+
HNSC	cis	rs2235642	1	rs2235642	ENSG00000280231.1	LA16c-380F5.3	-5.3	1.77e-07	5.59e-05	-0.29	-0.24	Coronary artery disease;	chr16:1534865	chr16:1553655~1554130:-
HNSC	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	5.3	1.77e-07	5.6e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
HNSC	cis	rs9402743	0.597	rs34266043	ENSG00000217482.2	HMGB1P17	5.3	1.77e-07	5.6e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135763663	chr6:135636086~135636713:-
HNSC	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-5.3	1.78e-07	5.6e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-5.3	1.78e-07	5.6e-05	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
HNSC	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.3	1.78e-07	5.61e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
HNSC	cis	rs7824557	0.507	rs7010590	ENSG00000269918.1	AF131215.9	5.3	1.78e-07	5.61e-05	0.24	0.24	Retinal vascular caliber;	chr8:11205373	chr8:11104691~11106704:-
HNSC	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-5.3	1.78e-07	5.61e-05	-0.27	-0.24	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
HNSC	cis	rs9840812	0.591	rs1291921	ENSG00000273486.1	RP11-731C17.2	5.3	1.78e-07	5.62e-05	0.2	0.24	Fibrinogen levels;	chr3:136317384	chr3:136837338~136839021:-
HNSC	cis	rs9326248	0.53	rs11216171	ENSG00000280143.1	AP000892.6	5.3	1.78e-07	5.62e-05	0.28	0.24	Blood protein levels;	chr11:116878397	chr11:117204967~117210292:+
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106780669	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781183	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106781256	chr14:106723574~106724093:-
HNSC	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	5.3	1.78e-07	5.62e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
HNSC	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	5.3	1.78e-07	5.62e-05	0.29	0.24	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
HNSC	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	5.3	1.78e-07	5.62e-05	0.28	0.24	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	5.3	1.78e-07	5.62e-05	0.28	0.24	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000211974.3	IGHV2-70	-5.3	1.78e-07	5.62e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779632	chr14:106723574~106724093:-
HNSC	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	5.3	1.78e-07	5.63e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	5.3	1.78e-07	5.63e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
HNSC	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	5.3	1.78e-07	5.63e-05	0.31	0.24	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65940221	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35046236	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65943626	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs36068983	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65944004	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs68189316	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65944182	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000179406.6	LINC00174	-5.3	1.79e-07	5.63e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65947955	chr7:66376044~66401338:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	5.3	1.79e-07	5.63e-05	0.21	0.24	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
HNSC	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	5.3	1.79e-07	5.64e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
HNSC	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5.3	1.79e-07	5.64e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
HNSC	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-5.3	1.79e-07	5.64e-05	-0.27	-0.24	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-5.3	1.79e-07	5.65e-05	-0.3	-0.24	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
HNSC	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-5.3	1.79e-07	5.65e-05	-0.22	-0.24	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
HNSC	cis	rs7804306	0.826	rs35567393	ENSG00000233264.2	AC006042.8	5.3	1.79e-07	5.65e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8033938	chr7:7980312~7982228:+
HNSC	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-5.3	1.79e-07	5.65e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-5.3	1.79e-07	5.65e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
HNSC	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-5.3	1.79e-07	5.65e-05	-0.21	-0.24	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
HNSC	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	5.3	1.79e-07	5.66e-05	0.28	0.24	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
HNSC	cis	rs9840812	0.598	rs1145101	ENSG00000239213.4	NCK1-AS1	5.3	1.8e-07	5.66e-05	0.26	0.24	Fibrinogen levels;	chr3:136350444	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.728	rs12635723	ENSG00000239213.4	NCK1-AS1	5.3	1.8e-07	5.66e-05	0.22	0.24	Fibrinogen levels;	chr3:136581890	chr3:136841726~136862054:-
HNSC	cis	rs3206736	0.548	rs2108690	ENSG00000197085.10	NPSR1-AS1	-5.3	1.8e-07	5.67e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35043197	chr7:34346512~34871582:-
HNSC	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-5.3	1.8e-07	5.67e-05	-0.29	-0.24	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
HNSC	cis	rs11773103	1	rs73204890	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87148422	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs55834411	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87148864	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73204892	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87149381	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73204895	ENSG00000224046.1	AC005076.5	5.3	1.8e-07	5.67e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87149801	chr7:87151423~87152420:-
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000233609.3	RP11-62H7.2	-5.3	1.8e-07	5.67e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9035094	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	5.3	1.8e-07	5.68e-05	0.29	0.24	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-5.3	1.8e-07	5.68e-05	-0.25	-0.24	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
HNSC	cis	rs1971762	0.527	rs9737721	ENSG00000270175.1	RP11-793H13.11	-5.3	1.81e-07	5.69e-05	-0.21	-0.24	Height;	chr12:53680912	chr12:53500162~53500936:-
HNSC	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-5.3	1.81e-07	5.7e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
HNSC	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	5.3	1.81e-07	5.7e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
HNSC	cis	rs2115630	1	rs11854313	ENSG00000229212.6	RP11-561C5.4	5.3	1.81e-07	5.7e-05	0.27	0.24	P wave terminal force;	chr15:84760817	chr15:85205440~85234795:-
HNSC	cis	rs11969893	0.85	rs9498418	ENSG00000270987.1	RP3-467N11.2	5.3	1.81e-07	5.7e-05	0.58	0.24	Economic and political preferences (immigration/crime);	chr6:100883962	chr6:100889603~100890338:+
HNSC	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	5.3	1.81e-07	5.7e-05	0.32	0.24	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
HNSC	cis	rs6604026	1	rs6657809	ENSG00000223787.2	RP4-593M8.1	5.3	1.81e-07	5.71e-05	0.31	0.24	Multiple sclerosis;	chr1:92827506	chr1:92580476~92580821:-
HNSC	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-5.3	1.81e-07	5.71e-05	-0.27	-0.24	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
HNSC	cis	rs7048146	0.509	rs55796394	ENSG00000213539.4	YBX1P6	5.3	1.81e-07	5.71e-05	0.31	0.24	Vascular brain injury;	chr9:109538348	chr9:109532830~109534332:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	5.3	1.81e-07	5.71e-05	0.26	0.24	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
HNSC	cis	rs6604026	0.885	rs17614449	ENSG00000223787.2	RP4-593M8.1	5.3	1.81e-07	5.72e-05	0.33	0.24	Multiple sclerosis;	chr1:92810377	chr1:92580476~92580821:-
HNSC	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	5.3	1.82e-07	5.72e-05	0.29	0.24	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	5.3	1.82e-07	5.72e-05	0.28	0.24	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
HNSC	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	5.3	1.82e-07	5.72e-05	0.21	0.24	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
HNSC	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	5.3	1.82e-07	5.73e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
HNSC	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-5.3	1.82e-07	5.74e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	5.3	1.82e-07	5.74e-05	0.21	0.24	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
HNSC	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	5.3	1.82e-07	5.74e-05	0.43	0.24	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
HNSC	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-5.3	1.82e-07	5.74e-05	-0.27	-0.24	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-5.3	1.83e-07	5.75e-05	-0.16	-0.24	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
HNSC	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-5.3	1.83e-07	5.75e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000179406.6	LINC00174	-5.3	1.83e-07	5.75e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65999249	chr7:66376044~66401338:-
HNSC	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55434518	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55435912	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55436576	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55436985	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	5.3	1.83e-07	5.75e-05	0.29	0.24	Height;	chr4:55439472	chr4:55387949~55388271:+
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-5.3	1.83e-07	5.76e-05	-0.3	-0.24	Depression;	chr6:28096845	chr6:28161781~28169594:+
HNSC	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-5.3	1.83e-07	5.77e-05	-0.31	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-5.3	1.83e-07	5.77e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
HNSC	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	5.3	1.83e-07	5.77e-05	0.26	0.24	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
HNSC	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-5.3	1.83e-07	5.77e-05	-0.23	-0.24	Height;	chr5:36880769	chr5:36666214~36725195:-
HNSC	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	5.3	1.83e-07	5.77e-05	0.25	0.24	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
HNSC	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	5.29	1.84e-07	5.78e-05	0.24	0.24	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
HNSC	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	5.29	1.84e-07	5.78e-05	0.24	0.24	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
HNSC	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.78e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
HNSC	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	5.29	1.84e-07	5.79e-05	0.28	0.24	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
HNSC	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-5.29	1.84e-07	5.79e-05	-0.25	-0.24	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
HNSC	cis	rs12935418	0.673	rs2602428	ENSG00000261061.1	RP11-303E16.2	5.29	1.84e-07	5.79e-05	0.27	0.24	Mean corpuscular volume;	chr16:81028566	chr16:81030770~81031485:+
HNSC	cis	rs8032939	0.533	rs72729306	ENSG00000259747.1	RP11-275I4.2	-5.29	1.84e-07	5.8e-05	-0.3	-0.24	Rheumatoid arthritis;	chr15:38606887	chr15:38671847~38689191:+
HNSC	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-5.29	1.85e-07	5.81e-05	-0.24	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
HNSC	cis	rs3733585	0.598	rs28677023	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956702	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.664	rs28602527	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956703	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6815001	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957038	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6849729	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957108	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6850143	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957300	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6844316	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957353	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6834893	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957499	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6844787	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957609	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.648	rs28513781	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957710	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4515163	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957979	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs62294331	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958265	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs62294332	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958365	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs57574512	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958558	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs7699609	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9959435	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4588456	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962271	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6836706	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.81e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962627	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	5.29	1.85e-07	5.81e-05	0.31	0.24	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-5.29	1.85e-07	5.81e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-5.29	1.85e-07	5.81e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
HNSC	cis	rs9341808	0.538	rs7747327	ENSG00000272129.1	RP11-250B2.6	-5.29	1.85e-07	5.81e-05	-0.28	-0.24	Sitting height ratio;	chr6:80326057	chr6:80355424~80356859:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000254153.1	CTA-398F10.2	-5.29	1.85e-07	5.82e-05	-0.26	-0.24	Mood instability;	chr8:8934916	chr8:8456909~8461337:-
HNSC	cis	rs3733585	0.673	rs10018204	ENSG00000250413.1	RP11-448G15.1	5.29	1.85e-07	5.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9962946	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	5.29	1.85e-07	5.82e-05	0.3	0.24	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
HNSC	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-5.29	1.85e-07	5.82e-05	-0.24	-0.24	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
HNSC	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	5.29	1.85e-07	5.83e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
HNSC	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	5.29	1.86e-07	5.83e-05	0.22	0.24	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
HNSC	cis	rs1008375	0.9	rs4698622	ENSG00000249502.1	AC006160.5	-5.29	1.86e-07	5.83e-05	-0.27	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587934	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000254153.1	CTA-398F10.2	-5.29	1.86e-07	5.84e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9033292	chr8:8456909~8461337:-
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000254153.1	CTA-398F10.2	-5.29	1.86e-07	5.84e-05	-0.26	-0.24	Myopia (pathological);Myopia;	chr8:9033866	chr8:8456909~8461337:-
HNSC	cis	rs5758265	1	rs5758265	ENSG00000235513.1	RP4-756G23.5	5.29	1.86e-07	5.84e-05	0.25	0.24	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr22:41209122~41217627:-
HNSC	cis	rs9840812	0.861	rs511154	ENSG00000239213.4	NCK1-AS1	5.29	1.86e-07	5.84e-05	0.23	0.24	Fibrinogen levels;	chr3:136232079	chr3:136841726~136862054:-
HNSC	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	5.29	1.86e-07	5.84e-05	0.29	0.24	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
HNSC	cis	rs9907295	0.818	rs11653204	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894538	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.792	rs4796125	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35894847	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs74622050	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35895939	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs79730543	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35896537	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796127	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35899127	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs11868801	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35900047	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796130	ENSG00000270977.1	AC015849.16	-5.29	1.86e-07	5.84e-05	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35904264	chr17:35893707~35911023:-
HNSC	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	5.29	1.86e-07	5.85e-05	0.34	0.24	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
HNSC	cis	rs3733585	0.699	rs6449159	ENSG00000250413.1	RP11-448G15.1	5.29	1.86e-07	5.85e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958874	chr4:10006482~10009725:+
HNSC	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-5.29	1.86e-07	5.85e-05	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
HNSC	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-5.29	1.86e-07	5.85e-05	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
HNSC	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-5.29	1.87e-07	5.86e-05	-0.29	-0.24	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
HNSC	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
HNSC	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
HNSC	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	5.29	1.87e-07	5.87e-05	0.29	0.24	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
HNSC	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	5.29	1.87e-07	5.87e-05	0.27	0.24	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
HNSC	cis	rs7824557	0.534	rs10092549	ENSG00000269918.1	AF131215.9	-5.29	1.87e-07	5.88e-05	-0.24	-0.24	Retinal vascular caliber;	chr8:11231570	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-5.29	1.87e-07	5.88e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
HNSC	cis	rs9402743	0.671	rs9376115	ENSG00000217482.2	HMGB1P17	-5.29	1.87e-07	5.88e-05	-0.26	-0.24	Systemic lupus erythematosus;	chr6:135616579	chr6:135636086~135636713:-
HNSC	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.29	1.87e-07	5.89e-05	0.24	0.24	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
HNSC	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	5.29	1.87e-07	5.89e-05	0.37	0.24	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
HNSC	cis	rs9813712	0.574	rs35856399	ENSG00000249846.5	RP11-77P16.4	-5.29	1.87e-07	5.89e-05	-0.25	-0.24	Response to amphetamines;	chr3:130241961	chr3:130112550~130120579:+
HNSC	cis	rs7665090	0.87	rs228625	ENSG00000246560.2	RP11-10L12.4	-5.29	1.88e-07	5.89e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102651594	chr4:102828055~102844075:+
HNSC	cis	rs2243480	1	rs10807702	ENSG00000179406.6	LINC00174	-5.29	1.88e-07	5.9e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66302856	chr7:66376044~66401338:-
HNSC	cis	rs7621025	0.586	rs12330725	ENSG00000273486.1	RP11-731C17.2	-5.29	1.88e-07	5.9e-05	-0.2	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136837338~136839021:-
HNSC	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-5.29	1.88e-07	5.9e-05	-0.3	-0.24	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
HNSC	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-5.29	1.88e-07	5.9e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
HNSC	cis	rs11773103	1	rs73206905	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87155307	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.867	rs73206912	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87159075	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73206916	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87159697	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73206937	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87166076	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs55750589	ENSG00000224046.1	AC005076.5	5.29	1.88e-07	5.9e-05	0.46	0.24	Bipolar disorder or major depressive disorder (combined);	chr7:87168929	chr7:87151423~87152420:-
HNSC	cis	rs4388249	0.578	rs427691	ENSG00000271849.1	CTC-332L22.1	-5.29	1.88e-07	5.9e-05	-0.35	-0.24	Schizophrenia;	chr5:109678809	chr5:109687802~109688329:-
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000254340.1	RP11-10A14.3	-5.29	1.88e-07	5.91e-05	-0.31	-0.24	Recombination measurement;	chr8:9212778	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.894	rs7152110	ENSG00000278009.1	RP11-649E7.8	5.29	1.88e-07	5.91e-05	0.31	0.24	Carotid intima media thickness;	chr14:49551500	chr14:49601011~49601124:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000254174.1	IGHV1-12	5.29	1.88e-07	5.91e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106777984	chr14:106122420~106122709:-
HNSC	cis	rs792448	0.545	rs7519168	ENSG00000226251.4	RP11-15I11.3	5.29	1.88e-07	5.91e-05	0.27	0.24	White blood cell count (basophil);	chr1:212220043	chr1:212225278~212238977:-
HNSC	cis	rs3806843	0.838	rs2262567	ENSG00000202515.1	VTRNA1-3	5.29	1.89e-07	5.92e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140726158~140726246:+
HNSC	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	5.29	1.89e-07	5.92e-05	0.29	0.24	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	5.29	1.89e-07	5.92e-05	0.3	0.24	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000179406.6	LINC00174	-5.29	1.89e-07	5.93e-05	-0.5	-0.24	Diabetic kidney disease;	chr7:66146246	chr7:66376044~66401338:-
HNSC	cis	rs4218	0.681	rs12913177	ENSG00000259732.1	RP11-59H7.3	5.29	1.89e-07	5.93e-05	0.34	0.24	Social communication problems;	chr15:59066273	chr15:59121034~59133250:+
HNSC	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.29	1.89e-07	5.93e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
HNSC	cis	rs1008375	0.966	rs6825133	ENSG00000249502.1	AC006160.5	-5.29	1.89e-07	5.94e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576153	chr4:17587467~17614571:-
HNSC	cis	rs9611519	1	rs5751069	ENSG00000235513.1	RP4-756G23.5	5.29	1.89e-07	5.94e-05	0.26	0.24	Neuroticism;	chr22:41231771	chr22:41209122~41217627:-
HNSC	cis	rs3743266	0.613	rs10851681	ENSG00000245534.5	RORA-AS1	-5.29	1.89e-07	5.94e-05	-0.3	-0.24	Menarche (age at onset);	chr15:60439939	chr15:60479178~60630637:+
HNSC	cis	rs4787491	0.658	rs11647753	ENSG00000183604.13	SMG1P5	5.29	1.89e-07	5.95e-05	0.23	0.24	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30267553~30335374:-
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-5.29	1.89e-07	5.95e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
HNSC	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	5.29	1.9e-07	5.95e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
HNSC	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	5.29	1.9e-07	5.95e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
HNSC	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-5.29	1.9e-07	5.95e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
HNSC	cis	rs638893	0.588	rs4936440	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118849975	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.588	rs4938566	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118850480	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs4938567	ENSG00000255422.1	AP002954.4	-5.29	1.9e-07	5.96e-05	-0.33	-0.24	Vitiligo;	chr11:118850540	chr11:118704607~118750263:+
HNSC	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	5.29	1.9e-07	5.96e-05	0.25	0.24	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000211974.3	IGHV2-70	-5.29	1.9e-07	5.96e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777984	chr14:106723574~106724093:-
HNSC	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-5.29	1.9e-07	5.96e-05	-0.27	-0.24	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
HNSC	cis	rs7819412	0.594	rs17724226	ENSG00000255310.2	AF131215.2	-5.29	1.9e-07	5.97e-05	-0.24	-0.24	Triglycerides;	chr8:11111416	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	5.29	1.9e-07	5.97e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
HNSC	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	5.29	1.91e-07	5.98e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000254340.1	RP11-10A14.3	5.29	1.91e-07	5.98e-05	0.3	0.24	Neuroticism;	chr8:8866905	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	5.29	1.91e-07	5.99e-05	0.29	0.24	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
HNSC	cis	rs6604026	0.885	rs66649041	ENSG00000223787.2	RP4-593M8.1	5.29	1.91e-07	5.99e-05	0.33	0.24	Multiple sclerosis;	chr1:92809328	chr1:92580476~92580821:-
HNSC	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	5.29	1.91e-07	5.99e-05	0.31	0.24	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
HNSC	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	5.29	1.91e-07	6e-05	0.29	0.24	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	5.29	1.91e-07	6e-05	0.25	0.24	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
HNSC	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-5.29	1.91e-07	6e-05	-0.28	-0.24	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
HNSC	cis	rs7804306	1	rs13222718	ENSG00000233264.2	AC006042.8	5.29	1.92e-07	6e-05	0.43	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974690	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs34438930	ENSG00000233264.2	AC006042.8	5.29	1.92e-07	6e-05	0.43	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974740	chr7:7980312~7982228:+
HNSC	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.29	1.92e-07	6.01e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
HNSC	cis	rs3754214	0.836	rs12023277	ENSG00000228126.1	FALEC	5.29	1.92e-07	6.02e-05	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr1:150494261	chr1:150515757~150518032:+
HNSC	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	5.29	1.92e-07	6.02e-05	0.25	0.24	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
HNSC	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	5.29	1.92e-07	6.02e-05	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	5.29	1.92e-07	6.02e-05	0.21	0.24	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
HNSC	cis	rs9611519	0.894	rs8136923	ENSG00000235513.1	RP4-756G23.5	5.29	1.92e-07	6.03e-05	0.27	0.24	Neuroticism;	chr22:41074518	chr22:41209122~41217627:-
HNSC	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	5.29	1.92e-07	6.03e-05	0.31	0.24	Height;	chr4:55415153	chr4:55387949~55388271:+
HNSC	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	5.29	1.92e-07	6.03e-05	0.29	0.24	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
HNSC	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	5.29	1.92e-07	6.03e-05	0.29	0.24	Height;	chr4:55456620	chr4:55387949~55388271:+
HNSC	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	5.29	1.93e-07	6.04e-05	0.35	0.24	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
HNSC	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-5.29	1.93e-07	6.04e-05	-0.27	-0.24	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
HNSC	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	5.29	1.93e-07	6.04e-05	0.41	0.24	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000211974.3	IGHV2-70	-5.29	1.93e-07	6.04e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779385	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-5.29	1.93e-07	6.05e-05	-0.23	-0.24	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
HNSC	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	5.29	1.93e-07	6.05e-05	0.24	0.24	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
HNSC	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	5.29	1.93e-07	6.05e-05	0.31	0.24	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
HNSC	cis	rs7610312	0.681	rs7610449	ENSG00000273493.1	RP11-80H18.4	-5.29	1.93e-07	6.05e-05	-0.29	-0.24	Red blood cell count;	chr3:58334231	chr3:58329965~58330118:+
HNSC	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-5.29	1.93e-07	6.05e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
HNSC	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-5.28	1.93e-07	6.06e-05	-0.24	-0.24	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-5.28	1.94e-07	6.06e-05	-0.14	-0.24	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
HNSC	cis	rs860295	0.812	rs12407800	ENSG00000203761.5	MSTO2P	-5.28	1.94e-07	6.07e-05	-0.18	-0.24	Body mass index;	chr1:155790951	chr1:155745829~155750137:+
HNSC	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	5.28	1.94e-07	6.07e-05	0.29	0.24	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
HNSC	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-5.28	1.94e-07	6.08e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
HNSC	cis	rs4803480	1	rs7255679	ENSG00000270164.1	LINC01480	-5.28	1.95e-07	6.09e-05	-0.22	-0.24	Schizophrenia;	chr19:41557611	chr19:41535183~41536904:+
HNSC	cis	rs860295	0.615	rs656737	ENSG00000203761.5	MSTO2P	5.28	1.95e-07	6.1e-05	0.18	0.24	Body mass index;	chr1:155908104	chr1:155745829~155750137:+
HNSC	cis	rs3747113	0.732	rs28360612	ENSG00000128262.7	POM121L9P	-5.28	1.95e-07	6.1e-05	-0.27	-0.24	Gut microbiome composition (summer);	chr22:24487250	chr22:24251828~24265525:+
HNSC	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	5.28	1.95e-07	6.1e-05	0.26	0.24	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
HNSC	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.1e-05	0.24	0.24	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
HNSC	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-5.28	1.95e-07	6.1e-05	-0.23	-0.24	Height;	chr5:36878678	chr5:36666214~36725195:-
HNSC	cis	rs860295	0.702	rs10908470	ENSG00000203761.5	MSTO2P	-5.28	1.95e-07	6.11e-05	-0.18	-0.24	Body mass index;	chr1:155557222	chr1:155745829~155750137:+
HNSC	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-5.28	1.95e-07	6.11e-05	-0.37	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
HNSC	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	5.28	1.95e-07	6.11e-05	0.24	0.24	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
HNSC	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	5.28	1.95e-07	6.12e-05	0.25	0.24	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
HNSC	cis	rs2286503	0.752	rs59538378	ENSG00000221740.1	SNORD93	5.28	1.95e-07	6.12e-05	0.26	0.24	Fibrinogen;	chr7:22837478	chr7:22856613~22856686:+
HNSC	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-5.28	1.96e-07	6.12e-05	-0.33	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	5.28	1.96e-07	6.13e-05	0.29	0.24	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000211974.3	IGHV2-70	-5.28	1.96e-07	6.13e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777532	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000211974.3	IGHV2-70	-5.28	1.96e-07	6.13e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777533	chr14:106723574~106724093:-
HNSC	cis	rs4218	0.513	rs17302142	ENSG00000277144.1	RP11-59H7.4	-5.28	1.96e-07	6.14e-05	-0.3	-0.24	Social communication problems;	chr15:59053813	chr15:59115547~59116089:-
HNSC	cis	rs4947019	0.688	rs9480965	ENSG00000260273.1	RP11-425D10.10	5.28	1.96e-07	6.14e-05	0.68	0.24	Hematological parameters;	chr6:109478281	chr6:109382795~109383666:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	5.28	1.96e-07	6.14e-05	0.22	0.24	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000254153.1	CTA-398F10.2	-5.28	1.96e-07	6.14e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9035094	chr8:8456909~8461337:-
HNSC	cis	rs7000734	0.958	rs1561715	ENSG00000245080.5	RP11-320N21.1	5.28	1.97e-07	6.15e-05	0.32	0.24	Radiation response;	chr8:95107686	chr8:95066808~95073182:-
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000254153.1	CTA-398F10.2	-5.28	1.97e-07	6.15e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8456909~8461337:-
HNSC	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.28	1.97e-07	6.15e-05	0.25	0.24	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
HNSC	cis	rs7160336	0.713	rs7161293	ENSG00000259065.1	RP5-1021I20.1	5.28	1.97e-07	6.16e-05	0.28	0.24	Blood protein levels;	chr14:74031655	chr14:73787360~73803270:+
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000254340.1	RP11-10A14.3	-5.28	1.97e-07	6.16e-05	-0.28	-0.24	Neuroticism;	chr8:8869294	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	-5.28	1.97e-07	6.17e-05	-0.27	-0.24	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
HNSC	cis	rs9341808	0.538	rs688867	ENSG00000272129.1	RP11-250B2.6	5.28	1.97e-07	6.18e-05	0.28	0.24	Sitting height ratio;	chr6:80229511	chr6:80355424~80356859:+
HNSC	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-5.28	1.98e-07	6.18e-05	-0.27	-0.24	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
HNSC	cis	rs13073817	0.563	rs4130090	ENSG00000228956.7	SATB1-AS1	5.28	1.98e-07	6.19e-05	0.25	0.24	Crohn's disease;	chr3:18630565	chr3:18445024~18920401:+
HNSC	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	5.28	1.98e-07	6.19e-05	0.25	0.24	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
HNSC	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	5.28	1.98e-07	6.2e-05	0.27	0.24	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
HNSC	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-5.28	1.98e-07	6.2e-05	-0.26	-0.24	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
HNSC	cis	rs7535099	0.954	rs3790431	ENSG00000224570.1	RP11-430H12.2	-5.28	1.99e-07	6.21e-05	-0.31	-0.24	Blood protein levels;	chr1:65570345	chr1:65576129~65578380:-
HNSC	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-5.28	1.99e-07	6.21e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
HNSC	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	5.28	1.99e-07	6.22e-05	0.18	0.24	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
HNSC	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-5.28	1.99e-07	6.22e-05	-0.33	-0.24	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-5.28	1.99e-07	6.23e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
HNSC	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	5.28	1.99e-07	6.23e-05	0.31	0.24	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
HNSC	cis	rs2337406	0.866	rs74092511	ENSG00000211974.3	IGHV2-70	-5.28	1.99e-07	6.23e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779234	chr14:106723574~106724093:-
HNSC	cis	rs9907295	0.688	rs9754	ENSG00000270977.1	AC015849.16	-5.28	1.99e-07	6.23e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35934827	chr17:35893707~35911023:-
HNSC	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.28	1.99e-07	6.23e-05	0.26	0.24	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
HNSC	cis	rs3733585	0.673	rs6843873	ENSG00000250413.1	RP11-448G15.1	5.28	2e-07	6.24e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9957164	chr4:10006482~10009725:+
HNSC	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	5.28	2e-07	6.24e-05	0.26	0.24	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
HNSC	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-5.28	2e-07	6.24e-05	-0.39	-0.24	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
HNSC	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-5.28	2e-07	6.25e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-5.28	2e-07	6.25e-05	-0.28	-0.24	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000254153.1	CTA-398F10.2	5.28	2e-07	6.26e-05	0.25	0.24	Systolic blood pressure;	chr8:8297953	chr8:8456909~8461337:-
HNSC	cis	rs17270561	0.525	rs12201678	ENSG00000272810.1	U91328.22	-5.28	2e-07	6.26e-05	-0.28	-0.24	Iron status biomarkers;	chr6:25978765	chr6:26013241~26013757:+
HNSC	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-5.28	2e-07	6.26e-05	-0.3	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
HNSC	cis	rs6867032	0.527	rs13153217	ENSG00000249731.1	RP11-259O2.3	-5.28	2.01e-07	6.27e-05	-0.26	-0.24	Gut microbiome composition (winter);	chr5:2012674	chr5:1968094~1969013:+
HNSC	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	5.28	2.01e-07	6.27e-05	0.28	0.24	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
HNSC	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	5.28	2.01e-07	6.27e-05	0.32	0.24	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
HNSC	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-5.28	2.01e-07	6.27e-05	-0.3	-0.24	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
HNSC	cis	rs2243480	1	rs313814	ENSG00000179406.6	LINC00174	-5.28	2.01e-07	6.27e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:66038306	chr7:66376044~66401338:-
HNSC	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-5.28	2.01e-07	6.27e-05	-0.3	-0.24	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
HNSC	cis	rs4218	0.681	rs35204615	ENSG00000277144.1	RP11-59H7.4	-5.28	2.01e-07	6.28e-05	-0.32	-0.24	Social communication problems;	chr15:59099637	chr15:59115547~59116089:-
HNSC	cis	rs4699052	0.963	rs6533066	ENSG00000246560.2	RP11-10L12.4	5.28	2.01e-07	6.28e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103242450	chr4:102828055~102844075:+
HNSC	cis	rs7048146	0.509	rs7020926	ENSG00000213539.4	YBX1P6	-5.28	2.01e-07	6.28e-05	-0.33	-0.24	Vascular brain injury;	chr9:109567512	chr9:109532830~109534332:-
HNSC	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	5.28	2.01e-07	6.28e-05	0.29	0.24	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
HNSC	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	5.28	2.01e-07	6.28e-05	0.25	0.24	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
HNSC	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-5.28	2.01e-07	6.28e-05	-0.27	-0.24	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	5.28	2.02e-07	6.29e-05	0.25	0.24	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	5.28	2.02e-07	6.29e-05	0.25	0.24	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
HNSC	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-5.28	2.02e-07	6.29e-05	-0.36	-0.24	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
HNSC	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-5.28	2.02e-07	6.3e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-5.28	2.02e-07	6.3e-05	-0.23	-0.24	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	5.28	2.02e-07	6.31e-05	0.28	0.24	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
HNSC	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-5.28	2.02e-07	6.31e-05	-0.3	-0.24	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
HNSC	cis	rs7617773	0.963	rs6766754	ENSG00000228638.1	FCF1P2	5.28	2.02e-07	6.31e-05	0.22	0.24	Coronary artery disease;	chr3:48141099	chr3:48290793~48291375:-
HNSC	cis	rs7617773	0.832	rs6775114	ENSG00000228638.1	FCF1P2	5.28	2.02e-07	6.31e-05	0.22	0.24	Coronary artery disease;	chr3:48141130	chr3:48290793~48291375:-
HNSC	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	5.28	2.02e-07	6.32e-05	0.24	0.24	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
HNSC	cis	rs7048146	0.509	rs10979936	ENSG00000213539.4	YBX1P6	5.28	2.03e-07	6.33e-05	0.34	0.24	Vascular brain injury;	chr9:109566227	chr9:109532830~109534332:-
HNSC	cis	rs9650657	0.504	rs10109167	ENSG00000269918.1	AF131215.9	-5.28	2.03e-07	6.33e-05	-0.24	-0.24	Neuroticism;	chr8:11176016	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.863	rs2223803	ENSG00000231028.7	LINC00271	5.28	2.03e-07	6.33e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135497801~135716055:+
HNSC	cis	rs35542019	1	rs35542019	ENSG00000237945.6	LINC00649	5.28	2.03e-07	6.33e-05	0.29	0.24	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33915534~33977691:+
HNSC	cis	rs3736485	0.808	rs55982453	ENSG00000259438.1	CTD-2650P22.1	5.28	2.03e-07	6.34e-05	0.24	0.24	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659048	chr15:52010999~52019095:-
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000254174.1	IGHV1-12	5.28	2.03e-07	6.34e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106778230	chr14:106122420~106122709:-
HNSC	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	5.28	2.03e-07	6.34e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
HNSC	cis	rs867371	0.571	rs2654222	ENSG00000255769.6	GOLGA2P10	5.27	2.04e-07	6.35e-05	0.33	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82137496	chr15:82472993~82513950:-
HNSC	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-5.27	2.04e-07	6.35e-05	-0.24	-0.24	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
HNSC	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.27	2.04e-07	6.35e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
HNSC	cis	rs2243480	1	rs34136756	ENSG00000179406.6	LINC00174	-5.27	2.04e-07	6.36e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65916269	chr7:66376044~66401338:-
HNSC	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	5.27	2.04e-07	6.36e-05	0.28	0.24	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	5.27	2.04e-07	6.36e-05	0.28	0.24	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
HNSC	cis	rs8054556	0.967	rs7193532	ENSG00000183604.13	SMG1P5	-5.27	2.04e-07	6.36e-05	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.04e-07	6.36e-05	-0.23	-0.24	Height;	chr5:37068442	chr5:36666214~36725195:-
HNSC	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-5.27	2.04e-07	6.36e-05	-0.21	-0.24	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
HNSC	cis	rs36423	0.748	rs28138	ENSG00000266869.1	RP6-114E22.1	-5.27	2.04e-07	6.37e-05	-0.39	-0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71891970	chr14:71848606~71908430:+
HNSC	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.04e-07	6.37e-05	-0.23	-0.24	Height;	chr5:37061159	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	5.27	2.04e-07	6.37e-05	0.29	0.24	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
HNSC	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	5.27	2.04e-07	6.37e-05	0.26	0.24	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
HNSC	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
HNSC	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	5.27	2.05e-07	6.37e-05	0.4	0.24	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
HNSC	cis	rs1008375	0.966	rs3775924	ENSG00000249502.1	AC006160.5	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584361	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs4698621	ENSG00000249502.1	AC006160.5	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585942	chr4:17587467~17614571:-
HNSC	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-5.27	2.05e-07	6.38e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000254153.1	CTA-398F10.2	-5.27	2.05e-07	6.38e-05	-0.26	-0.24	Mood instability;	chr8:8934707	chr8:8456909~8461337:-
HNSC	cis	rs9329221	0.502	rs11777364	ENSG00000269918.1	AF131215.9	5.27	2.05e-07	6.39e-05	0.23	0.24	Neuroticism;	chr8:10431036	chr8:11104691~11106704:-
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000211974.3	IGHV2-70	-5.27	2.05e-07	6.39e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777623	chr14:106723574~106724093:-
HNSC	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	5.27	2.05e-07	6.39e-05	0.26	0.24	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
HNSC	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-5.27	2.06e-07	6.41e-05	-0.23	-0.24	Height;	chr5:37045739	chr5:36666214~36725195:-
HNSC	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	5.27	2.06e-07	6.41e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
HNSC	cis	rs6928977	0.896	rs2614284	ENSG00000231028.7	LINC00271	5.27	2.06e-07	6.41e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135497801~135716055:+
HNSC	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	5.27	2.06e-07	6.41e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
HNSC	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	5.27	2.06e-07	6.42e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
HNSC	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	5.27	2.06e-07	6.42e-05	0.32	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-5.27	2.06e-07	6.43e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
HNSC	cis	rs393155	0.517	rs330050	ENSG00000254153.1	CTA-398F10.2	-5.27	2.06e-07	6.43e-05	-0.25	-0.24	Neuroticism;	chr8:9230169	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.571	rs330054	ENSG00000254153.1	CTA-398F10.2	-5.27	2.06e-07	6.43e-05	-0.25	-0.24	Joint mobility (Beighton score);	chr8:9230781	chr8:8456909~8461337:-
HNSC	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-5.27	2.06e-07	6.43e-05	-0.32	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
HNSC	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-5.27	2.06e-07	6.43e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
HNSC	cis	rs10504130	0.502	rs10087958	ENSG00000253844.1	RP11-546K22.1	-5.27	2.06e-07	6.43e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51961458~52022974:+
HNSC	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-5.27	2.06e-07	6.43e-05	-0.3	-0.24	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
HNSC	cis	rs4699052	0.507	rs10005997	ENSG00000246560.2	RP11-10L12.4	5.27	2.06e-07	6.43e-05	0.3	0.24	Testicular germ cell tumor;	chr4:103380554	chr4:102828055~102844075:+
HNSC	cis	rs9921338	0.887	rs6498183	ENSG00000263080.1	RP11-485G7.5	5.27	2.07e-07	6.44e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11341809~11345211:-
HNSC	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	5.27	2.07e-07	6.44e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
HNSC	cis	rs4218	0.689	rs12907187	ENSG00000277144.1	RP11-59H7.4	-5.27	2.07e-07	6.44e-05	-0.32	-0.24	Social communication problems;	chr15:59100607	chr15:59115547~59116089:-
HNSC	cis	rs7610312	0.583	rs2056119	ENSG00000273493.1	RP11-80H18.4	-5.27	2.07e-07	6.44e-05	-0.29	-0.24	Red blood cell count;	chr3:58323666	chr3:58329965~58330118:+
HNSC	cis	rs36093844	0.8	rs17744711	ENSG00000279742.1	RP11-700A24.1	-5.27	2.07e-07	6.45e-05	-0.34	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85889681	chr11:85852557~85854943:-
HNSC	cis	rs9650657	0.547	rs11250099	ENSG00000255310.2	AF131215.2	5.27	2.07e-07	6.45e-05	0.22	0.24	Neuroticism;	chr8:10961147	chr8:11107788~11109726:-
HNSC	cis	rs4388249	0.687	rs2301002	ENSG00000271849.1	CTC-332L22.1	-5.27	2.07e-07	6.45e-05	-0.32	-0.24	Schizophrenia;	chr5:109766130	chr5:109687802~109688329:-
HNSC	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-5.27	2.07e-07	6.45e-05	-0.22	-0.24	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
HNSC	cis	rs36093844	0.8	rs112468922	ENSG00000279742.1	RP11-700A24.1	-5.27	2.07e-07	6.45e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865651	chr11:85852557~85854943:-
HNSC	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	5.27	2.08e-07	6.46e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
HNSC	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-5.27	2.08e-07	6.47e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
HNSC	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	5.27	2.08e-07	6.47e-05	0.27	0.24	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
HNSC	cis	rs9840812	0.861	rs1153871	ENSG00000239213.4	NCK1-AS1	5.27	2.08e-07	6.47e-05	0.23	0.24	Fibrinogen levels;	chr3:136235757	chr3:136841726~136862054:-
HNSC	cis	rs9907295	0.688	rs4795101	ENSG00000270977.1	AC015849.16	-5.27	2.08e-07	6.48e-05	-0.33	-0.24	Fibroblast growth factor basic levels;	chr17:35932989	chr17:35893707~35911023:-
HNSC	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-5.27	2.08e-07	6.48e-05	-0.33	-0.24	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
HNSC	cis	rs13126694	0.62	rs6844184	ENSG00000248429.4	RP11-597D13.9	5.27	2.08e-07	6.48e-05	0.27	0.24	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158170752~158202877:+
HNSC	cis	rs3806843	0.868	rs2262573	ENSG00000202515.1	VTRNA1-3	5.27	2.08e-07	6.49e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140726158~140726246:+
HNSC	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-5.27	2.09e-07	6.49e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106778702	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779073	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779163	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	6.49e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106779174	chr14:106723574~106724093:-
HNSC	cis	rs8012947	0.916	rs78350060	ENSG00000279636.2	LINC00216	5.27	2.09e-07	6.49e-05	0.3	0.24	Alcohol consumption in current drinkers;	chr14:58381595	chr14:58288033~58289158:+
HNSC	cis	rs36423	0.748	rs36415	ENSG00000266869.1	RP6-114E22.1	-5.27	2.09e-07	6.5e-05	-0.39	-0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71888958	chr14:71848606~71908430:+
HNSC	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-5.27	2.09e-07	6.5e-05	-0.42	-0.24	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
HNSC	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	5.27	2.09e-07	6.51e-05	0.26	0.24	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	5.27	2.09e-07	6.51e-05	0.26	0.24	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
HNSC	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-5.27	2.09e-07	6.51e-05	-0.34	-0.24	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-5.27	2.1e-07	6.53e-05	-0.3	-0.24	Depression;	chr6:28144784	chr6:28161781~28169594:+
HNSC	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-5.27	2.1e-07	6.53e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
HNSC	cis	rs1008375	0.966	rs3796813	ENSG00000249502.1	AC006160.5	-5.27	2.1e-07	6.53e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17590025	chr4:17587467~17614571:-
HNSC	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-5.27	2.1e-07	6.53e-05	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
HNSC	cis	rs2179367	0.537	rs6911411	ENSG00000216906.2	RP11-350J20.9	5.27	2.1e-07	6.53e-05	0.36	0.24	Dupuytren's disease;	chr6:149366954	chr6:149904243~149906418:+
HNSC	cis	rs860295	0.676	rs11264374	ENSG00000203761.5	MSTO2P	-5.27	2.1e-07	6.54e-05	-0.19	-0.24	Body mass index;	chr1:155451721	chr1:155745829~155750137:+
HNSC	cis	rs6928977	1	rs6928977	ENSG00000234084.1	RP3-388E23.2	5.27	2.1e-07	6.54e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135301568~135307158:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-5.27	2.1e-07	6.54e-05	-0.14	-0.24	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
HNSC	cis	rs860295	0.702	rs10796943	ENSG00000203761.5	MSTO2P	-5.27	2.11e-07	6.55e-05	-0.19	-0.24	Body mass index;	chr1:155444938	chr1:155745829~155750137:+
HNSC	cis	rs7535099	1	rs7524458	ENSG00000224570.1	RP11-430H12.2	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Blood protein levels;	chr1:65585217	chr1:65576129~65578380:-
HNSC	cis	rs7535099	1	rs7535099	ENSG00000224570.1	RP11-430H12.2	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Blood protein levels;	chr1:65585314	chr1:65576129~65578380:-
HNSC	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-5.27	2.11e-07	6.55e-05	-0.21	-0.24	Height;	chr11:118737823	chr11:118791254~118793137:+
HNSC	cis	rs741738	1	rs741738	ENSG00000251661.3	RP11-326C3.11	-5.27	2.11e-07	6.55e-05	-0.31	-0.24	Granulocyte percentage of myeloid white cells;	chr11:309508	chr11:318640~325631:+
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	5.27	2.11e-07	6.55e-05	0.28	0.24	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000254340.1	RP11-10A14.3	5.27	2.11e-07	6.56e-05	0.29	0.24	Mood instability;	chr8:8516446	chr8:9141424~9145435:+
HNSC	cis	rs2985684	0.802	rs8015368	ENSG00000278009.1	RP11-649E7.8	5.27	2.11e-07	6.56e-05	0.3	0.24	Carotid intima media thickness;	chr14:49553792	chr14:49601011~49601124:-
HNSC	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-5.27	2.11e-07	6.57e-05	-0.44	-0.24	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-5.27	2.11e-07	6.57e-05	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
HNSC	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-5.27	2.11e-07	6.57e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
HNSC	cis	rs712039	0.565	rs1714988	ENSG00000276054.1	RP11-378E13.3	5.27	2.11e-07	6.57e-05	0.34	0.24	Tuberculosis;	chr17:37387113	chr17:37386886~37387926:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000233609.3	RP11-62H7.2	5.27	2.12e-07	6.58e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9001207	chr8:8961200~8979025:+
HNSC	cis	rs3206736	0.548	rs73110545	ENSG00000197085.10	NPSR1-AS1	-5.27	2.12e-07	6.58e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:35024182	chr7:34346512~34871582:-
HNSC	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-5.27	2.12e-07	6.58e-05	-0.33	-0.24	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
HNSC	cis	rs9291683	0.935	rs1860911	ENSG00000250413.1	RP11-448G15.1	-5.27	2.12e-07	6.58e-05	-0.29	-0.24	Bone mineral density;	chr4:10273433	chr4:10006482~10009725:+
HNSC	cis	rs1933112	0.5	rs1123864	ENSG00000227777.1	RP4-738P11.3	-5.27	2.12e-07	6.6e-05	-0.33	-0.24	Blood protein levels;	chr1:168559223	chr1:168542737~168543354:+
HNSC	cis	rs7777677	0.925	rs6956269	ENSG00000244273.1	PGBD4P1	-5.27	2.12e-07	6.6e-05	-0.25	-0.24	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142722358~142722764:+
HNSC	cis	rs7777677	0.925	rs4726547	ENSG00000244273.1	PGBD4P1	-5.27	2.12e-07	6.6e-05	-0.25	-0.24	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142722358~142722764:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000179406.6	LINC00174	-5.27	2.12e-07	6.6e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66376044~66401338:-
HNSC	cis	rs7809950	0.817	rs2712224	ENSG00000238832.1	snoU109	-5.27	2.13e-07	6.61e-05	-0.35	-0.24	Coronary artery disease;	chr7:107540790	chr7:107603363~107603507:+
HNSC	cis	rs2834288	0.734	rs8126592	ENSG00000237945.6	LINC00649	-5.27	2.13e-07	6.61e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33895961	chr21:33915534~33977691:+
HNSC	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-5.27	2.13e-07	6.61e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-5.27	2.13e-07	6.61e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
HNSC	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	5.27	2.13e-07	6.61e-05	0.3	0.24	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
HNSC	cis	rs6723108	0.517	rs6729702	ENSG00000224043.6	CCNT2-AS1	-5.27	2.13e-07	6.62e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134844586	chr2:134735464~134918710:-
HNSC	cis	rs5758659	1	rs5758677	ENSG00000227370.1	RP4-669P10.19	-5.27	2.13e-07	6.62e-05	-0.23	-0.24	Cognitive function;	chr22:42247033	chr22:42132543~42132998:+
HNSC	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	5.27	2.13e-07	6.62e-05	0.33	0.24	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
HNSC	cis	rs7048146	0.509	rs12554926	ENSG00000213539.4	YBX1P6	5.27	2.13e-07	6.62e-05	0.34	0.24	Vascular brain injury;	chr9:109567975	chr9:109532830~109534332:-
HNSC	cis	rs2243480	1	rs1404147	ENSG00000179406.6	LINC00174	-5.27	2.13e-07	6.63e-05	-0.46	-0.24	Diabetic kidney disease;	chr7:65799537	chr7:66376044~66401338:-
HNSC	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	5.27	2.13e-07	6.63e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
HNSC	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	5.27	2.13e-07	6.63e-05	0.33	0.24	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
HNSC	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-5.27	2.14e-07	6.63e-05	-0.28	-0.24	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
HNSC	cis	rs1971762	0.527	rs6580950	ENSG00000270175.1	RP11-793H13.11	-5.27	2.14e-07	6.63e-05	-0.2	-0.24	Height;	chr12:53532872	chr12:53500162~53500936:-
HNSC	cis	rs28475163	1	rs28475163	ENSG00000255328.1	RP11-326C3.12	5.27	2.14e-07	6.64e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:327143	chr11:327171~330122:+
HNSC	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	5.27	2.14e-07	6.64e-05	0.3	0.24	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
HNSC	cis	rs6693567	0.565	rs3754214	ENSG00000228126.1	FALEC	5.27	2.14e-07	6.64e-05	0.29	0.24	Migraine;	chr1:150506147	chr1:150515757~150518032:+
HNSC	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	5.27	2.14e-07	6.65e-05	0.3	0.24	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
HNSC	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	5.27	2.14e-07	6.65e-05	0.25	0.24	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
HNSC	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-5.27	2.14e-07	6.65e-05	-0.21	-0.24	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
HNSC	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	5.27	2.14e-07	6.65e-05	0.31	0.24	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
HNSC	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-5.26	2.14e-07	6.65e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
HNSC	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	5.26	2.15e-07	6.66e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
HNSC	cis	rs4699052	0.963	rs4698890	ENSG00000246560.2	RP11-10L12.4	5.26	2.15e-07	6.66e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103260721	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs2061646	ENSG00000246560.2	RP11-10L12.4	5.26	2.15e-07	6.66e-05	0.28	0.24	Testicular germ cell tumor;	chr4:103262737	chr4:102828055~102844075:+
HNSC	cis	rs7819412	0.745	rs28464654	ENSG00000255310.2	AF131215.2	-5.26	2.15e-07	6.66e-05	-0.23	-0.24	Triglycerides;	chr8:11223156	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.745	rs28591576	ENSG00000255310.2	AF131215.2	-5.26	2.15e-07	6.66e-05	-0.23	-0.24	Triglycerides;	chr8:11223166	chr8:11107788~11109726:-
HNSC	cis	rs13434995	0.796	rs2412664	ENSG00000273257.1	RP11-177J6.1	5.26	2.15e-07	6.66e-05	0.36	0.24	Adiponectin levels;	chr4:55591220	chr4:55387949~55388271:+
HNSC	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	5.26	2.15e-07	6.67e-05	0.54	0.24	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	5.26	2.15e-07	6.67e-05	0.54	0.24	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
HNSC	cis	rs8032939	0.533	rs56249992	ENSG00000259747.1	RP11-275I4.2	-5.26	2.15e-07	6.67e-05	-0.31	-0.24	Rheumatoid arthritis;	chr15:38611683	chr15:38671847~38689191:+
HNSC	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-5.26	2.15e-07	6.67e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
HNSC	cis	rs7615952	0.512	rs4234285	ENSG00000248787.1	RP11-666A20.4	-5.26	2.15e-07	6.67e-05	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125685633	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-5.26	2.15e-07	6.67e-05	-0.29	-0.24	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
HNSC	cis	rs7048146	0.577	rs10979952	ENSG00000213539.4	YBX1P6	5.26	2.15e-07	6.68e-05	0.27	0.24	Vascular brain injury;	chr9:109587348	chr9:109532830~109534332:-
HNSC	cis	rs1218582	0.772	rs10796934	ENSG00000270361.1	RP11-307C12.13	-5.26	2.15e-07	6.68e-05	-0.26	-0.24	Prostate cancer;	chr1:154877003	chr1:154937370~154938059:+
HNSC	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	5.26	2.15e-07	6.68e-05	0.25	0.24	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
HNSC	cis	rs933688	1	rs2059208	ENSG00000281357.1	ARRDC3-AS1	5.26	2.16e-07	6.69e-05	0.33	0.24	Smoking behavior;	chr5:91436248	chr5:91380349~91439085:+
HNSC	cis	rs10256972	0.605	rs10251094	ENSG00000225146.1	AC073957.15	-5.26	2.16e-07	6.69e-05	-0.43	-0.24	Endometriosis;Longevity;	chr7:977447	chr7:1029025~1043891:+
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000276710.3	CSPG4P8	-5.26	2.16e-07	6.7e-05	-0.33	-0.24	Excessive daytime sleepiness;	chr15:82712096	chr15:82459472~82477258:+
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000211974.3	IGHV2-70	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106723574~106724093:-
HNSC	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-5.26	2.16e-07	6.7e-05	-0.25	-0.24	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
HNSC	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-5.26	2.16e-07	6.7e-05	-0.28	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
HNSC	cis	rs7120173	0.571	rs634044	ENSG00000254851.1	RP11-109L13.1	-5.26	2.16e-07	6.71e-05	-0.39	-0.24	Visceral adipose tissue adjusted for BMI;	chr11:116881842	chr11:117135528~117138582:+
HNSC	cis	rs3733585	0.699	rs6449174	ENSG00000250413.1	RP11-448G15.1	5.26	2.16e-07	6.71e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964798	chr4:10006482~10009725:+
HNSC	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	5.26	2.16e-07	6.71e-05	0.26	0.24	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
HNSC	cis	rs6540731	1	rs951623	ENSG00000226251.4	RP11-15I11.3	-5.26	2.17e-07	6.72e-05	-0.27	-0.24	Intelligence (childhood);	chr1:212225720	chr1:212225278~212238977:-
HNSC	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	5.26	2.17e-07	6.72e-05	0.29	0.24	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000211974.3	IGHV2-70	-5.26	2.17e-07	6.72e-05	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106783991	chr14:106723574~106724093:-
HNSC	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	5.26	2.17e-07	6.73e-05	0.26	0.24	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
HNSC	cis	rs67981189	0.758	rs221921	ENSG00000274818.1	RP1-292L20.3	-5.26	2.17e-07	6.73e-05	-0.28	-0.24	Schizophrenia;	chr14:71119411	chr14:70906657~70907111:-
HNSC	cis	rs9402743	0.671	rs9373138	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.74e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135630343	chr6:135636086~135636713:-
HNSC	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-5.26	2.18e-07	6.74e-05	-0.23	-0.24	Height;	chr5:36999896	chr5:36666214~36725195:-
HNSC	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-5.26	2.18e-07	6.74e-05	-0.27	-0.24	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
HNSC	cis	rs10504130	0.696	rs60796336	ENSG00000253844.1	RP11-546K22.1	-5.26	2.18e-07	6.75e-05	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51961458~52022974:+
HNSC	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	5.26	2.18e-07	6.75e-05	0.33	0.24	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
HNSC	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	5.26	2.18e-07	6.75e-05	0.25	0.24	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
HNSC	cis	rs9402743	0.671	rs9399151	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135617920	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9376116	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135618763	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs4896157	ENSG00000217482.2	HMGB1P17	5.26	2.18e-07	6.75e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135620981	chr6:135636086~135636713:-
HNSC	cis	rs4140799	0.805	rs757744	ENSG00000266869.1	RP6-114E22.1	5.26	2.18e-07	6.75e-05	0.29	0.24	Neuroticism;	chr14:71731056	chr14:71848606~71908430:+
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000254174.1	IGHV1-12	5.26	2.18e-07	6.76e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106807164	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs28378201	ENSG00000211974.3	IGHV2-70	-5.26	2.18e-07	6.76e-05	-0.27	-0.24	Rheumatic heart disease;	chr14:106637262	chr14:106723574~106724093:-
HNSC	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-5.26	2.18e-07	6.76e-05	-0.21	-0.24	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
HNSC	cis	rs1008375	0.866	rs12233712	ENSG00000249502.1	AC006160.5	-5.26	2.18e-07	6.76e-05	-0.26	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17568440	chr4:17587467~17614571:-
HNSC	cis	rs14027	0.512	rs7010808	ENSG00000279347.1	RP11-85I17.2	-5.26	2.18e-07	6.77e-05	-0.2	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712216	chr8:119838736~119840385:-
HNSC	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	5.26	2.18e-07	6.77e-05	0.24	0.24	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
HNSC	cis	rs6928977	0.832	rs2327613	ENSG00000231028.7	LINC00271	5.26	2.19e-07	6.77e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341234	chr6:135497801~135716055:+
HNSC	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-5.26	2.19e-07	6.78e-05	-0.24	-0.24	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	5.26	2.19e-07	6.78e-05	0.24	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
HNSC	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-5.26	2.19e-07	6.78e-05	-0.32	-0.24	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000254174.1	IGHV1-12	5.26	2.19e-07	6.78e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106790636	chr14:106122420~106122709:-
HNSC	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	5.26	2.19e-07	6.78e-05	0.25	0.24	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	5.26	2.19e-07	6.78e-05	0.25	0.24	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
HNSC	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-5.26	2.19e-07	6.79e-05	-0.32	-0.24	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
HNSC	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-5.26	2.19e-07	6.79e-05	-0.26	-0.24	Height;	chr2:46616492	chr2:46668870~46670778:+
HNSC	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-5.26	2.19e-07	6.8e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
HNSC	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	5.26	2.2e-07	6.8e-05	0.35	0.24	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
HNSC	cis	rs17507216	0.718	rs4779033	ENSG00000276710.3	CSPG4P8	5.26	2.2e-07	6.8e-05	0.33	0.24	Excessive daytime sleepiness;	chr15:82576634	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.8e-05	0.26	0.24	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.8e-05	0.26	0.24	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
HNSC	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	5.26	2.2e-07	6.8e-05	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
HNSC	cis	rs860295	0.702	rs12746592	ENSG00000203761.5	MSTO2P	-5.26	2.2e-07	6.8e-05	-0.18	-0.24	Body mass index;	chr1:155536176	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs10752611	ENSG00000203761.5	MSTO2P	-5.26	2.2e-07	6.8e-05	-0.18	-0.24	Body mass index;	chr1:155539316	chr1:155745829~155750137:+
HNSC	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-5.26	2.2e-07	6.8e-05	-0.27	-0.24	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
HNSC	cis	rs71520386	0.632	rs9692432	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829244	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs9691076	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22829742	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs71520387	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830057	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs10224244	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22830455	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs28526185	ENSG00000221740.1	SNORD93	-5.26	2.2e-07	6.81e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22831699	chr7:22856613~22856686:+
HNSC	cis	rs7819412	0.875	rs11250121	ENSG00000269918.1	AF131215.9	-5.26	2.2e-07	6.81e-05	-0.24	-0.24	Triglycerides;	chr8:11202802	chr8:11104691~11106704:-
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	5.26	2.2e-07	6.81e-05	0.26	0.24	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
HNSC	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	5.26	2.2e-07	6.81e-05	0.26	0.24	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
HNSC	cis	rs2337406	0.789	rs60000589	ENSG00000254174.1	IGHV1-12	5.26	2.2e-07	6.82e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106782459	chr14:106122420~106122709:-
HNSC	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	5.26	2.2e-07	6.82e-05	0.36	0.24	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
HNSC	cis	rs10504130	0.569	rs7820177	ENSG00000253844.1	RP11-546K22.1	-5.26	2.2e-07	6.82e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51961458~52022974:+
HNSC	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	5.26	2.2e-07	6.82e-05	0.25	0.24	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
HNSC	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-5.26	2.21e-07	6.83e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
HNSC	cis	rs10946940	0.965	rs9393830	ENSG00000219392.1	RP1-265C24.5	-5.26	2.21e-07	6.83e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr6:27619248	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.86	rs2746433	ENSG00000231028.7	LINC00271	5.26	2.21e-07	6.83e-05	0.28	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135497801~135716055:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.84e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.84e-05	-0.28	-0.24	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
HNSC	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-5.26	2.21e-07	6.84e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	5.26	2.21e-07	6.85e-05	0.19	0.24	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	5.26	2.21e-07	6.85e-05	0.25	0.24	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000204709.4	LINC01556	-5.26	2.22e-07	6.86e-05	-0.32	-0.24	Parkinson's disease;	chr6:28002253	chr6:28943877~28944537:+
HNSC	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-5.26	2.22e-07	6.87e-05	-0.32	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
HNSC	cis	rs7733403	1	rs7733403	ENSG00000202515.1	VTRNA1-3	-5.26	2.22e-07	6.88e-05	-0.26	-0.24	Schizophrenia;	chr5:140774630	chr5:140726158~140726246:+
HNSC	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-5.26	2.22e-07	6.88e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
HNSC	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-5.26	2.23e-07	6.88e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
HNSC	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	5.26	2.23e-07	6.88e-05	0.28	0.24	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
HNSC	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	5.26	2.23e-07	6.88e-05	0.24	0.24	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
HNSC	cis	rs712039	0.652	rs2946340	ENSG00000276054.1	RP11-378E13.3	5.26	2.23e-07	6.89e-05	0.34	0.24	Tuberculosis;	chr17:37392762	chr17:37386886~37387926:+
HNSC	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	5.26	2.23e-07	6.89e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000179406.6	LINC00174	5.26	2.23e-07	6.9e-05	0.5	0.24	Diabetic kidney disease;	chr7:66139635	chr7:66376044~66401338:-
HNSC	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	5.26	2.23e-07	6.9e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
HNSC	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-5.26	2.23e-07	6.9e-05	-0.24	-0.24	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
HNSC	cis	rs9813712	0.953	rs9883455	ENSG00000249846.5	RP11-77P16.4	-5.26	2.23e-07	6.9e-05	-0.28	-0.24	Response to amphetamines;	chr3:130260088	chr3:130112550~130120579:+
HNSC	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	5.26	2.24e-07	6.92e-05	0.27	0.24	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
HNSC	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-5.26	2.24e-07	6.92e-05	-0.2	-0.24	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-5.26	2.24e-07	6.92e-05	-0.2	-0.24	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
HNSC	cis	rs13217239	0.646	rs7451149	ENSG00000224843.5	LINC00240	5.26	2.24e-07	6.93e-05	0.23	0.24	Schizophrenia;	chr6:27089739	chr6:26956992~27023924:+
HNSC	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-5.26	2.24e-07	6.93e-05	-0.29	-0.24	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
HNSC	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-5.26	2.24e-07	6.93e-05	-0.3	-0.24	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
HNSC	cis	rs3805389	0.504	rs17725163	ENSG00000273257.1	RP11-177J6.1	5.26	2.24e-07	6.93e-05	0.36	0.24	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55387949~55388271:+
HNSC	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.26	2.24e-07	6.93e-05	-0.24	-0.24	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	5.26	2.25e-07	6.94e-05	0.25	0.24	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
HNSC	cis	rs5758659	1	rs134902	ENSG00000227370.1	RP4-669P10.19	-5.26	2.25e-07	6.95e-05	-0.23	-0.24	Cognitive function;	chr22:42287991	chr22:42132543~42132998:+
HNSC	cis	rs9907295	0.685	rs4796131	ENSG00000270977.1	AC015849.16	-5.26	2.25e-07	6.95e-05	-0.35	-0.24	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35893707~35911023:-
HNSC	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-5.26	2.26e-07	6.97e-05	-0.37	-0.24	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
HNSC	cis	rs11992162	0.967	rs11250185	ENSG00000206014.6	OR7E161P	-5.25	2.26e-07	6.97e-05	-0.26	-0.24	Monocyte count;	chr8:11975614	chr8:11928597~11929563:-
HNSC	cis	rs11992162	1	rs12334769	ENSG00000206014.6	OR7E161P	-5.25	2.26e-07	6.97e-05	-0.26	-0.24	Monocyte count;	chr8:11975652	chr8:11928597~11929563:-
HNSC	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	5.25	2.26e-07	6.97e-05	0.24	0.24	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
HNSC	cis	rs651386	0.505	rs10919441	ENSG00000271811.1	RP1-79C4.4	5.25	2.26e-07	6.98e-05	0.26	0.24	Atrial fibrillation;	chr1:170609948	chr1:170667381~170669425:+
HNSC	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55452853	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55454154	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55455650	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55457027	chr4:55387949~55388271:+
HNSC	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	5.25	2.26e-07	6.98e-05	0.29	0.24	Height;	chr4:55457086	chr4:55387949~55388271:+
HNSC	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	5.25	2.26e-07	6.98e-05	0.37	0.24	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
HNSC	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	5.25	2.26e-07	6.99e-05	0.27	0.24	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
HNSC	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	5.25	2.26e-07	6.99e-05	0.35	0.24	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
HNSC	cis	rs5758511	0.508	rs28715885	ENSG00000226450.2	CYP2D8P	5.25	2.26e-07	6.99e-05	0.24	0.24	Birth weight;	chr22:42045087	chr22:42149886~42155001:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000179406.6	LINC00174	5.25	2.26e-07	7e-05	0.49	0.24	Diabetic kidney disease;	chr7:66144214	chr7:66376044~66401338:-
HNSC	cis	rs7688540	0.771	rs10005733	ENSG00000211553.1	AC253576.2	-5.25	2.27e-07	7e-05	-0.33	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:136461~136568:+
HNSC	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-5.25	2.27e-07	7e-05	-0.27	-0.24	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
HNSC	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	5.25	2.27e-07	7.01e-05	0.29	0.24	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
HNSC	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.25	2.27e-07	7.01e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.25	2.27e-07	7.01e-05	-0.22	-0.24	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
HNSC	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-5.25	2.27e-07	7.01e-05	-0.35	-0.24	Height;	chr6:109625358	chr6:109382795~109383666:+
HNSC	cis	rs4218	0.689	rs11853828	ENSG00000277144.1	RP11-59H7.4	-5.25	2.27e-07	7.02e-05	-0.32	-0.24	Social communication problems;	chr15:59136031	chr15:59115547~59116089:-
HNSC	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-5.25	2.27e-07	7.02e-05	-0.29	-0.24	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
HNSC	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-5.25	2.27e-07	7.02e-05	-0.32	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
HNSC	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-5.25	2.28e-07	7.03e-05	-0.28	-0.24	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
HNSC	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-5.25	2.28e-07	7.03e-05	-0.25	-0.24	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
HNSC	cis	rs17428076	0.836	rs57775770	ENSG00000228389.1	AC068039.4	-5.25	2.28e-07	7.03e-05	-0.28	-0.24	Myopia;	chr2:171831221	chr2:171773482~171775844:+
HNSC	cis	rs638893	0.617	rs4938564	ENSG00000255422.1	AP002954.4	-5.25	2.28e-07	7.03e-05	-0.34	-0.24	Vitiligo;	chr11:118849881	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.617	rs11217059	ENSG00000255422.1	AP002954.4	-5.25	2.28e-07	7.03e-05	-0.34	-0.24	Vitiligo;	chr11:118852378	chr11:118704607~118750263:+
HNSC	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-5.25	2.28e-07	7.03e-05	-0.26	-0.24	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
HNSC	cis	rs860295	0.812	rs7556519	ENSG00000203761.5	MSTO2P	-5.25	2.28e-07	7.04e-05	-0.18	-0.24	Body mass index;	chr1:155857755	chr1:155745829~155750137:+
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-5.25	2.28e-07	7.04e-05	-0.28	-0.24	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
HNSC	cis	rs2337406	0.789	rs60390024	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781327	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092532	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781363	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092534	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781364	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092535	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781722	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs74092537	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781883	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.81	rs74092538	ENSG00000254174.1	IGHV1-12	5.25	2.28e-07	7.05e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106781942	chr14:106122420~106122709:-
HNSC	cis	rs7621025	0.755	rs1017881	ENSG00000273486.1	RP11-731C17.2	5.25	2.28e-07	7.05e-05	0.2	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000254153.1	CTA-398F10.2	5.25	2.29e-07	7.05e-05	0.25	0.24	Mood instability;	chr8:8933634	chr8:8456909~8461337:-
HNSC	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-5.25	2.29e-07	7.05e-05	-0.25	-0.24	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
HNSC	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-5.25	2.29e-07	7.06e-05	-0.19	-0.24	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
HNSC	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-5.25	2.29e-07	7.06e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
HNSC	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-5.25	2.29e-07	7.06e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106790480	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106793065	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106795643	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106795976	chr14:106122420~106122709:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Kawasaki disease;	chr14:106799309	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106799722	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000254174.1	IGHV1-12	5.25	2.29e-07	7.07e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106801091	chr14:106122420~106122709:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	5.25	2.29e-07	7.07e-05	0.29	0.24	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
HNSC	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-5.25	2.29e-07	7.07e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
HNSC	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	5.25	2.29e-07	7.07e-05	0.24	0.24	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000229212.6	RP11-561C5.4	-5.25	2.29e-07	7.08e-05	-0.34	-0.24	Schizophrenia;	chr15:84387097	chr15:85205440~85234795:-
HNSC	cis	rs792448	0.527	rs11119887	ENSG00000226251.4	RP11-15I11.3	-5.25	2.29e-07	7.08e-05	-0.27	-0.24	White blood cell count (basophil);	chr1:212234220	chr1:212225278~212238977:-
HNSC	cis	rs2243480	1	rs59794892	ENSG00000179406.6	LINC00174	-5.25	2.3e-07	7.08e-05	-0.51	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66376044~66401338:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	5.25	2.3e-07	7.08e-05	0.29	0.24	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
HNSC	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-5.25	2.3e-07	7.09e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
HNSC	cis	rs1355223	0.752	rs17359064	ENSG00000271369.1	RP11-350D17.3	-5.25	2.3e-07	7.1e-05	-0.27	-0.24	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34652337	chr11:34709600~34710161:+
HNSC	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-5.25	2.31e-07	7.11e-05	-0.32	-0.24	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
HNSC	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5.25	2.31e-07	7.12e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
HNSC	cis	rs7610312	0.681	rs6445971	ENSG00000273493.1	RP11-80H18.4	-5.25	2.31e-07	7.12e-05	-0.29	-0.24	Red blood cell count;	chr3:58328597	chr3:58329965~58330118:+
HNSC	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-5.25	2.31e-07	7.13e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-5.25	2.31e-07	7.13e-05	-0.33	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
HNSC	cis	rs17428076	0.751	rs788168	ENSG00000228389.1	AC068039.4	-5.25	2.32e-07	7.14e-05	-0.29	-0.24	Myopia;	chr2:172053071	chr2:171773482~171775844:+
HNSC	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	5.25	2.32e-07	7.15e-05	0.26	0.24	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
HNSC	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-5.25	2.32e-07	7.15e-05	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
HNSC	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.25	2.32e-07	7.16e-05	0.33	0.24	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
HNSC	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-5.25	2.32e-07	7.16e-05	-0.36	-0.24	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-5.25	2.32e-07	7.16e-05	-0.21	-0.24	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	5.25	2.32e-07	7.16e-05	0.24	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
HNSC	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-5.25	2.32e-07	7.17e-05	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-5.25	2.32e-07	7.17e-05	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
HNSC	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.28	-0.24	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.28	-0.24	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
HNSC	cis	rs71520386	0.53	rs10256628	ENSG00000221740.1	SNORD93	-5.25	2.33e-07	7.17e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22856613~22856686:+
HNSC	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-5.25	2.33e-07	7.17e-05	-0.27	-0.24	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
HNSC	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	5.25	2.33e-07	7.17e-05	0.58	0.24	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	5.25	2.33e-07	7.17e-05	0.58	0.24	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
HNSC	cis	rs3206736	0.548	rs1649224	ENSG00000197085.10	NPSR1-AS1	-5.25	2.33e-07	7.17e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34951384	chr7:34346512~34871582:-
HNSC	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	5.25	2.33e-07	7.18e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
HNSC	cis	rs6928977	0.896	rs9321501	ENSG00000231028.7	LINC00271	5.25	2.33e-07	7.18e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135497801~135716055:+
HNSC	cis	rs925255	0.967	rs10199829	ENSG00000270210.1	RP11-373D23.3	5.25	2.33e-07	7.18e-05	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28380044	chr2:28425945~28426719:+
HNSC	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	5.25	2.33e-07	7.18e-05	0.22	0.24	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
HNSC	cis	rs3733585	0.699	rs6852441	ENSG00000250413.1	RP11-448G15.1	5.25	2.33e-07	7.19e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9972120	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.725	rs6449201	ENSG00000250413.1	RP11-448G15.1	5.25	2.33e-07	7.19e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9972270	chr4:10006482~10009725:+
HNSC	cis	rs860295	0.702	rs5005770	ENSG00000203761.5	MSTO2P	5.25	2.33e-07	7.19e-05	0.18	0.24	Body mass index;	chr1:155375252	chr1:155745829~155750137:+
HNSC	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-5.25	2.33e-07	7.19e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
HNSC	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	5.25	2.33e-07	7.19e-05	0.27	0.24	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
HNSC	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	5.25	2.34e-07	7.19e-05	0.27	0.24	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
HNSC	cis	rs5758659	0.714	rs5758578	ENSG00000227370.1	RP4-669P10.19	5.25	2.34e-07	7.21e-05	0.23	0.24	Cognitive function;	chr22:42094288	chr22:42132543~42132998:+
HNSC	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-5.25	2.34e-07	7.21e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
HNSC	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-5.25	2.34e-07	7.21e-05	-0.3	-0.24	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
HNSC	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	5.25	2.34e-07	7.21e-05	0.26	0.24	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
HNSC	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	5.25	2.34e-07	7.21e-05	0.26	0.24	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
HNSC	cis	rs9291683	0.935	rs1860910	ENSG00000250413.1	RP11-448G15.1	-5.25	2.34e-07	7.22e-05	-0.29	-0.24	Bone mineral density;	chr4:10273846	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.546	rs13139055	ENSG00000250413.1	RP11-448G15.1	-5.25	2.34e-07	7.22e-05	-0.29	-0.24	Bone mineral density;	chr4:10037300	chr4:10006482~10009725:+
HNSC	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	5.25	2.35e-07	7.23e-05	0.25	0.24	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
HNSC	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-5.25	2.35e-07	7.23e-05	-0.25	-0.24	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
HNSC	cis	rs11969893	0.85	rs9404058	ENSG00000270987.1	RP3-467N11.2	5.25	2.35e-07	7.23e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100875202	chr6:100889603~100890338:+
HNSC	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	5.25	2.35e-07	7.23e-05	0.28	0.24	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.745	rs6601569	ENSG00000269918.1	AF131215.9	-5.25	2.35e-07	7.24e-05	-0.25	-0.24	Triglycerides;	chr8:11216069	chr8:11104691~11106704:-
HNSC	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-5.25	2.35e-07	7.24e-05	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
HNSC	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	5.25	2.36e-07	7.25e-05	0.27	0.24	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
HNSC	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	5.25	2.36e-07	7.25e-05	0.29	0.24	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
HNSC	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-5.25	2.36e-07	7.26e-05	-0.25	-0.24	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
HNSC	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	5.25	2.36e-07	7.26e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	5.25	2.36e-07	7.26e-05	0.28	0.24	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
HNSC	cis	rs6928977	0.896	rs2064431	ENSG00000231028.7	LINC00271	5.25	2.36e-07	7.26e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135497801~135716055:+
HNSC	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	5.25	2.36e-07	7.27e-05	0.25	0.24	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	5.25	2.36e-07	7.27e-05	0.25	0.24	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
HNSC	cis	rs2337406	1	rs17112416	ENSG00000254174.1	IGHV1-12	-5.25	2.36e-07	7.27e-05	-0.2	-0.24	Alzheimer's disease (late onset);	chr14:106686773	chr14:106122420~106122709:-
HNSC	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	5.25	2.36e-07	7.27e-05	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
HNSC	cis	rs7665090	0.743	rs228626	ENSG00000246560.2	RP11-10L12.4	-5.25	2.36e-07	7.27e-05	-0.27	-0.24	Primary biliary cholangitis;	chr4:102651789	chr4:102828055~102844075:+
HNSC	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	5.25	2.37e-07	7.28e-05	0.27	0.24	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
HNSC	cis	rs3806843	0.966	rs6891559	ENSG00000202515.1	VTRNA1-3	-5.25	2.37e-07	7.29e-05	-0.26	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs11741994	ENSG00000202515.1	VTRNA1-3	-5.25	2.37e-07	7.29e-05	-0.26	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140726158~140726246:+
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000233609.3	RP11-62H7.2	-5.25	2.37e-07	7.3e-05	-0.23	-0.24	Joint mobility (Beighton score);	chr8:9053494	chr8:8961200~8979025:+
HNSC	cis	rs2337406	0.866	rs111881598	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783113	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61164979	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783133	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs61419485	ENSG00000254174.1	IGHV1-12	5.24	2.38e-07	7.3e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783374	chr14:106122420~106122709:-
HNSC	cis	rs9840812	0.728	rs12630999	ENSG00000239213.4	NCK1-AS1	5.24	2.38e-07	7.31e-05	0.21	0.24	Fibrinogen levels;	chr3:136582085	chr3:136841726~136862054:-
HNSC	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	5.24	2.38e-07	7.31e-05	0.19	0.24	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
HNSC	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-5.24	2.38e-07	7.31e-05	-0.28	-0.24	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-5.24	2.38e-07	7.31e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
HNSC	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	5.24	2.38e-07	7.31e-05	0.28	0.24	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
HNSC	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	5.24	2.38e-07	7.32e-05	0.25	0.24	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
HNSC	cis	rs638893	0.617	rs7103314	ENSG00000255422.1	AP002954.4	-5.24	2.38e-07	7.32e-05	-0.34	-0.24	Vitiligo;	chr11:118852828	chr11:118704607~118750263:+
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000249244.1	RP11-548H18.2	-5.24	2.38e-07	7.33e-05	-0.27	-0.24	Corneal astigmatism;	chr4:119212557	chr4:119391831~119395335:-
HNSC	cis	rs2904524	0.748	rs11178226	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70409894	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.748	rs11178227	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70409970	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.748	rs11178228	ENSG00000257815.4	RP11-611E13.2	-5.24	2.39e-07	7.33e-05	-0.3	-0.24	Amyotrophic lateral sclerosis (age of onset);	chr12:70410290	chr12:69904033~70243360:-
HNSC	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	5.24	2.39e-07	7.33e-05	0.28	0.24	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
HNSC	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.39e-07	7.34e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-5.24	2.39e-07	7.34e-05	-0.3	-0.24	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
HNSC	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	5.24	2.39e-07	7.35e-05	0.25	0.24	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-5.24	2.39e-07	7.35e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
HNSC	cis	rs6928977	0.86	rs2614264	ENSG00000217482.2	HMGB1P17	5.24	2.39e-07	7.35e-05	0.25	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135636086~135636713:-
HNSC	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	5.24	2.39e-07	7.35e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
HNSC	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	5.24	2.39e-07	7.35e-05	0.29	0.24	Height;	chr4:55450812	chr4:55387949~55388271:+
HNSC	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-5.24	2.39e-07	7.36e-05	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-5.24	2.39e-07	7.36e-05	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	5.24	2.4e-07	7.37e-05	0.28	0.24	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-5.24	2.4e-07	7.38e-05	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-5.24	2.4e-07	7.38e-05	-0.14	-0.24	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-5.24	2.4e-07	7.38e-05	-0.22	-0.24	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
HNSC	cis	rs6928977	0.896	rs1012645	ENSG00000231028.7	LINC00271	5.24	2.41e-07	7.39e-05	0.27	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135497801~135716055:+
HNSC	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.24	2.41e-07	7.39e-05	0.27	0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
HNSC	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	5.24	2.41e-07	7.39e-05	0.27	0.24	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	5.24	2.41e-07	7.39e-05	0.25	0.24	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
HNSC	cis	rs6693567	0.545	rs12049177	ENSG00000228126.1	FALEC	5.24	2.41e-07	7.39e-05	0.29	0.24	Migraine;	chr1:150501861	chr1:150515757~150518032:+
HNSC	cis	rs1008375	0.646	rs13103430	ENSG00000249502.1	AC006160.5	5.24	2.41e-07	7.39e-05	0.26	0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565732	chr4:17587467~17614571:-
HNSC	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-5.24	2.41e-07	7.39e-05	-0.28	-0.24	Height;	chr2:46609767	chr2:46668870~46670778:+
HNSC	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.24	2.41e-07	7.39e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
HNSC	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.24	2.41e-07	7.4e-05	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
HNSC	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-5.24	2.41e-07	7.4e-05	-0.58	-0.24	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
HNSC	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-5.24	2.41e-07	7.41e-05	-0.38	-0.24	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
HNSC	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.24	2.41e-07	7.41e-05	0.32	0.24	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
HNSC	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	5.24	2.41e-07	7.41e-05	0.3	0.24	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
HNSC	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-5.24	2.41e-07	7.41e-05	-0.32	-0.24	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
HNSC	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	5.24	2.41e-07	7.41e-05	0.38	0.24	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
HNSC	cis	rs72949976	0.646	rs11681232	ENSG00000270659.1	RP11-105N14.1	-5.24	2.41e-07	7.41e-05	-0.23	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168278	chr2:213152970~213153659:+
HNSC	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-5.24	2.42e-07	7.41e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
HNSC	cis	rs9840812	0.592	rs12489577	ENSG00000239213.4	NCK1-AS1	5.24	2.42e-07	7.42e-05	0.22	0.24	Fibrinogen levels;	chr3:136494303	chr3:136841726~136862054:-
HNSC	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-5.24	2.42e-07	7.42e-05	-0.34	-0.24	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
HNSC	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.24	2.42e-07	7.42e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
HNSC	cis	rs42490	0.589	rs39772	ENSG00000251136.7	RP11-37B2.1	-5.24	2.42e-07	7.42e-05	-0.2	-0.24	Leprosy;	chr8:89831636	chr8:89609409~89757727:-
HNSC	cis	rs2657294	0.603	rs11543	ENSG00000233313.2	HMGA1P5	-5.24	2.42e-07	7.43e-05	-0.26	-0.24	Pneumonia;	chr10:75210855	chr10:75276376~75276646:-
HNSC	cis	rs8054556	1	rs4787489	ENSG00000183604.13	SMG1P5	-5.24	2.43e-07	7.44e-05	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30267553~30335374:-
HNSC	cis	rs17428076	0.874	rs62182373	ENSG00000228389.1	AC068039.4	-5.24	2.43e-07	7.44e-05	-0.28	-0.24	Myopia;	chr2:171829045	chr2:171773482~171775844:+
HNSC	cis	rs5758511	0.514	rs5751211	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42090052	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs3985938	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42115723	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5751221	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42120362	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5758586	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42121467	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs5751222	ENSG00000226450.2	CYP2D8P	5.24	2.43e-07	7.44e-05	0.24	0.24	Birth weight;	chr22:42121918	chr22:42149886~42155001:-
HNSC	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-5.24	2.43e-07	7.45e-05	-0.28	-0.24	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
HNSC	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	5.24	2.43e-07	7.45e-05	0.29	0.24	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-5.24	2.43e-07	7.45e-05	-0.29	-0.24	Depression;	chr6:28197321	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-5.24	2.43e-07	7.45e-05	-0.29	-0.24	Depression;	chr6:28197412	chr6:28161781~28169594:+
HNSC	cis	rs7621025	0.505	rs61789642	ENSG00000273486.1	RP11-731C17.2	-5.24	2.43e-07	7.45e-05	-0.3	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136837338~136839021:-
HNSC	cis	rs7621025	0.505	rs61789643	ENSG00000273486.1	RP11-731C17.2	-5.24	2.43e-07	7.45e-05	-0.3	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136837338~136839021:-
HNSC	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	5.24	2.43e-07	7.45e-05	0.24	0.24	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
HNSC	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.43e-07	7.45e-05	-0.26	-0.24	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
HNSC	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	5.24	2.43e-07	7.46e-05	0.21	0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
HNSC	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	5.24	2.43e-07	7.46e-05	0.33	0.24	Height;	chr6:109694120	chr6:109382795~109383666:+
HNSC	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	5.24	2.44e-07	7.47e-05	0.29	0.24	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
HNSC	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-5.24	2.44e-07	7.47e-05	-0.27	-0.24	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000254153.1	CTA-398F10.2	5.24	2.44e-07	7.48e-05	0.25	0.24	Neuroticism;	chr8:8312614	chr8:8456909~8461337:-
HNSC	cis	rs1555322	0.872	rs6579227	ENSG00000126005.14	MMP24-AS1	-5.24	2.44e-07	7.48e-05	-0.49	-0.24	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35216462~35278131:-
HNSC	cis	rs4699052	0.963	rs11097801	ENSG00000246560.2	RP11-10L12.4	5.24	2.44e-07	7.48e-05	0.27	0.24	Testicular germ cell tumor;	chr4:103229166	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs56144793	ENSG00000246560.2	RP11-10L12.4	5.24	2.44e-07	7.48e-05	0.27	0.24	Testicular germ cell tumor;	chr4:103229496	chr4:102828055~102844075:+
HNSC	cis	rs6964833	0.872	rs4717903	ENSG00000184616.8	AC004166.6	5.24	2.44e-07	7.48e-05	0.29	0.24	Menarche (age at onset);	chr7:74653827	chr7:74906673~74913256:-
HNSC	cis	rs4218	0.597	rs12438111	ENSG00000277144.1	RP11-59H7.4	-5.24	2.44e-07	7.49e-05	-0.31	-0.24	Social communication problems;	chr15:59057540	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.636	rs4775116	ENSG00000277144.1	RP11-59H7.4	5.24	2.44e-07	7.49e-05	0.28	0.24	Social communication problems;	chr15:59135608	chr15:59115547~59116089:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	5.24	2.44e-07	7.49e-05	0.21	0.24	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
HNSC	cis	rs4218	0.689	rs34338282	ENSG00000277144.1	RP11-59H7.4	-5.24	2.45e-07	7.5e-05	-0.32	-0.24	Social communication problems;	chr15:59096897	chr15:59115547~59116089:-
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-5.24	2.45e-07	7.5e-05	-0.29	-0.24	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
HNSC	cis	rs72772090	0.908	rs17086588	ENSG00000248734.2	CTD-2260A17.1	5.24	2.45e-07	7.51e-05	0.33	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96784777~96785999:+
HNSC	cis	rs9840812	0.645	rs9883916	ENSG00000273486.1	RP11-731C17.2	5.24	2.45e-07	7.51e-05	0.22	0.24	Fibrinogen levels;	chr3:136489946	chr3:136837338~136839021:-
HNSC	cis	rs10504130	0.569	rs16916966	ENSG00000253844.1	RP11-546K22.1	-5.24	2.45e-07	7.51e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51930769	chr8:51961458~52022974:+
HNSC	cis	rs9921338	0.961	rs7199821	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs77552156	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs4781069	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs7187870	ENSG00000263080.1	RP11-485G7.5	5.24	2.45e-07	7.52e-05	0.26	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11341809~11345211:-
HNSC	cis	rs7804306	1	rs35641104	ENSG00000233264.2	AC006042.8	5.24	2.45e-07	7.52e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046289	chr7:7980312~7982228:+
HNSC	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	5.24	2.45e-07	7.52e-05	0.47	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
HNSC	cis	rs2985684	0.894	rs2281837	ENSG00000278009.1	RP11-649E7.8	5.24	2.46e-07	7.52e-05	0.31	0.24	Carotid intima media thickness;	chr14:49598641	chr14:49601011~49601124:-
HNSC	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	5.24	2.46e-07	7.53e-05	0.25	0.24	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
HNSC	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	5.24	2.46e-07	7.53e-05	0.26	0.24	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
HNSC	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	5.24	2.46e-07	7.54e-05	0.36	0.24	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
HNSC	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-5.24	2.46e-07	7.54e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
HNSC	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-5.24	2.46e-07	7.54e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
HNSC	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.24	2.46e-07	7.54e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.24	2.46e-07	7.54e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
HNSC	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-5.24	2.46e-07	7.55e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
HNSC	cis	rs3808502	0.527	rs2736374	ENSG00000269918.1	AF131215.9	-5.24	2.47e-07	7.55e-05	-0.25	-0.24	Neuroticism;	chr8:11256319	chr8:11104691~11106704:-
HNSC	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	5.24	2.47e-07	7.55e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
HNSC	cis	rs11846409	0.932	rs2015469	ENSG00000211974.3	IGHV2-70	-5.24	2.47e-07	7.55e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106631857	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs56167903	ENSG00000211974.3	IGHV2-70	-5.24	2.47e-07	7.55e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106632070	chr14:106723574~106724093:-
HNSC	cis	rs11969893	0.85	rs9498409	ENSG00000270987.1	RP3-467N11.2	5.24	2.47e-07	7.56e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100852090	chr6:100889603~100890338:+
HNSC	cis	rs11969893	0.85	rs3734351	ENSG00000270987.1	RP3-467N11.2	5.24	2.47e-07	7.56e-05	0.6	0.24	Economic and political preferences (immigration/crime);	chr6:100859255	chr6:100889603~100890338:+
HNSC	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	5.24	2.47e-07	7.56e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	5.24	2.47e-07	7.56e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-5.24	2.47e-07	7.56e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
HNSC	cis	rs9341808	0.519	rs684251	ENSG00000272129.1	RP11-250B2.6	-5.24	2.47e-07	7.57e-05	-0.28	-0.24	Sitting height ratio;	chr6:80257620	chr6:80355424~80356859:+
HNSC	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.24	2.48e-07	7.58e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
HNSC	cis	rs17428076	0.874	rs72885529	ENSG00000228389.1	AC068039.4	-5.24	2.48e-07	7.58e-05	-0.28	-0.24	Myopia;	chr2:171827522	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.874	rs72885532	ENSG00000228389.1	AC068039.4	-5.24	2.48e-07	7.58e-05	-0.28	-0.24	Myopia;	chr2:171827523	chr2:171773482~171775844:+
HNSC	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-5.24	2.48e-07	7.58e-05	-0.25	-0.24	Height;	chr2:46615271	chr2:46668870~46670778:+
HNSC	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	5.24	2.48e-07	7.58e-05	0.33	0.24	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
HNSC	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	5.24	2.48e-07	7.58e-05	0.28	0.24	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
HNSC	cis	rs950169	0.922	rs11630507	ENSG00000229212.6	RP11-561C5.4	-5.24	2.48e-07	7.58e-05	-0.33	-0.24	Schizophrenia;	chr15:84552494	chr15:85205440~85234795:-
HNSC	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	5.24	2.48e-07	7.59e-05	0.25	0.24	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
HNSC	cis	rs9907295	0.748	rs4251719	ENSG00000270977.1	AC015849.16	-5.24	2.48e-07	7.59e-05	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35893707~35911023:-
HNSC	cis	rs10462794	0.661	rs16873538	ENSG00000260763.1	RP11-445O3.3	-5.24	2.48e-07	7.59e-05	-0.34	-0.24	DNA methylation (variation);	chr5:4515701	chr5:4436850~4440259:-
HNSC	cis	rs2337406	0.866	rs8015361	ENSG00000254174.1	IGHV1-12	5.24	2.48e-07	7.59e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106783991	chr14:106122420~106122709:-
HNSC	cis	rs1933112	0.5	rs12049040	ENSG00000227777.1	RP4-738P11.3	5.24	2.48e-07	7.59e-05	0.33	0.24	Blood protein levels;	chr1:168552377	chr1:168542737~168543354:+
HNSC	cis	rs7115242	0.567	rs10047462	ENSG00000280143.1	AP000892.6	5.24	2.48e-07	7.6e-05	0.41	0.24	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117204967~117210292:+
HNSC	cis	rs4218	0.689	rs12900369	ENSG00000277144.1	RP11-59H7.4	-5.24	2.48e-07	7.6e-05	-0.31	-0.24	Social communication problems;	chr15:59099254	chr15:59115547~59116089:-
HNSC	cis	rs7048146	0.509	rs12551462	ENSG00000213539.4	YBX1P6	5.24	2.48e-07	7.6e-05	0.33	0.24	Vascular brain injury;	chr9:109568279	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs34738162	ENSG00000213539.4	YBX1P6	5.24	2.48e-07	7.6e-05	0.33	0.24	Vascular brain injury;	chr9:109568706	chr9:109532830~109534332:-
HNSC	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	5.24	2.49e-07	7.6e-05	0.28	0.24	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	5.24	2.49e-07	7.6e-05	0.28	0.24	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
HNSC	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	5.24	2.49e-07	7.62e-05	0.28	0.24	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
HNSC	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-5.24	2.49e-07	7.63e-05	-0.29	-0.24	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
HNSC	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.24	2.49e-07	7.63e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
HNSC	cis	rs9813712	0.571	rs9855777	ENSG00000249846.5	RP11-77P16.4	5.24	2.5e-07	7.64e-05	0.25	0.24	Response to amphetamines;	chr3:130214805	chr3:130112550~130120579:+
HNSC	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	5.24	2.5e-07	7.64e-05	0.29	0.24	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
HNSC	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.23	2.5e-07	7.64e-05	0.24	0.24	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
HNSC	cis	rs3806843	0.868	rs2262574	ENSG00000202515.1	VTRNA1-3	5.23	2.5e-07	7.65e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140726158~140726246:+
HNSC	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-5.23	2.5e-07	7.65e-05	-0.25	-0.24	Height;	chr2:46635327	chr2:46668870~46670778:+
HNSC	cis	rs9611519	0.828	rs28814423	ENSG00000235513.1	RP4-756G23.5	5.23	2.5e-07	7.65e-05	0.26	0.24	Neuroticism;	chr22:41056297	chr22:41209122~41217627:-
HNSC	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-5.23	2.5e-07	7.66e-05	-0.22	-0.24	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000229212.6	RP11-561C5.4	-5.23	2.5e-07	7.66e-05	-0.33	-0.24	Schizophrenia;	chr15:84571037	chr15:85205440~85234795:-
HNSC	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-5.23	2.51e-07	7.66e-05	-0.31	-0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
HNSC	cis	rs4388249	0.687	rs2300998	ENSG00000271849.1	CTC-332L22.1	-5.23	2.51e-07	7.66e-05	-0.31	-0.24	Schizophrenia;	chr5:109747421	chr5:109687802~109688329:-
HNSC	cis	rs638893	0.617	rs4938561	ENSG00000255422.1	AP002954.4	-5.23	2.51e-07	7.66e-05	-0.33	-0.24	Vitiligo;	chr11:118847776	chr11:118704607~118750263:+
HNSC	cis	rs9525927	0.625	rs4942301	ENSG00000227258.4	SMIM2-AS1	5.23	2.51e-07	7.66e-05	0.32	0.24	Dupuytren's disease;	chr13:44237111	chr13:44110451~44240517:+
HNSC	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.23	2.51e-07	7.66e-05	0.25	0.24	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
HNSC	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	5.23	2.51e-07	7.67e-05	0.31	0.24	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
HNSC	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	5.23	2.51e-07	7.68e-05	0.28	0.24	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
HNSC	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	5.23	2.51e-07	7.68e-05	0.26	0.24	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
HNSC	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	5.23	2.51e-07	7.68e-05	0.26	0.24	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
HNSC	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-5.23	2.51e-07	7.68e-05	-0.25	-0.24	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
HNSC	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	5.23	2.52e-07	7.69e-05	0.33	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
HNSC	cis	rs879620	1	rs2531995	ENSG00000262888.1	RP11-462G12.2	-5.23	2.52e-07	7.69e-05	-0.28	-0.24	Hip circumference;Body mass index;	chr16:3963466	chr16:3931217~3946305:-
HNSC	cis	rs9402743	0.671	rs7767066	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135623970	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.598	rs9483856	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135624088	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.635	rs9376118	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135624521	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs742738	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135625301	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9402728	ENSG00000217482.2	HMGB1P17	5.23	2.52e-07	7.69e-05	0.26	0.24	Systemic lupus erythematosus;	chr6:135626450	chr6:135636086~135636713:-
HNSC	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-5.23	2.52e-07	7.7e-05	-0.19	-0.24	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-5.23	2.52e-07	7.7e-05	-0.19	-0.24	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
HNSC	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-5.23	2.52e-07	7.7e-05	-0.28	-0.24	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
HNSC	cis	rs9813712	0.953	rs6439222	ENSG00000249846.5	RP11-77P16.4	5.23	2.52e-07	7.7e-05	0.29	0.24	Response to amphetamines;	chr3:130256298	chr3:130112550~130120579:+
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-5.23	2.52e-07	7.7e-05	-0.14	-0.24	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
HNSC	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	5.23	2.52e-07	7.71e-05	0.26	0.24	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
HNSC	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	5.23	2.52e-07	7.71e-05	0.29	0.24	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
HNSC	cis	rs17428076	0.874	rs62182374	ENSG00000228389.1	AC068039.4	-5.23	2.53e-07	7.71e-05	-0.28	-0.24	Myopia;	chr2:171829172	chr2:171773482~171775844:+
HNSC	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.72e-05	0.24	0.24	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
HNSC	cis	rs2337406	1	rs1858677	ENSG00000254174.1	IGHV1-12	5.23	2.53e-07	7.72e-05	0.19	0.24	Alzheimer's disease (late onset);	chr14:106706828	chr14:106122420~106122709:-
HNSC	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	5.23	2.53e-07	7.72e-05	0.25	0.24	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
HNSC	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	5.23	2.53e-07	7.72e-05	0.26	0.24	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
HNSC	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-5.23	2.53e-07	7.73e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
HNSC	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-5.23	2.53e-07	7.73e-05	-0.31	-0.24	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
HNSC	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	5.23	2.53e-07	7.73e-05	0.24	0.24	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
HNSC	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-5.23	2.53e-07	7.73e-05	-0.29	-0.24	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
HNSC	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	5.23	2.53e-07	7.73e-05	0.26	0.24	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
HNSC	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-5.23	2.54e-07	7.74e-05	-0.45	-0.24	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
HNSC	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	5.23	2.54e-07	7.74e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
HNSC	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-5.23	2.54e-07	7.74e-05	-0.22	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
HNSC	cis	rs6928977	0.538	rs17064702	ENSG00000234084.1	RP3-388E23.2	-5.23	2.54e-07	7.74e-05	-0.25	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135301568~135307158:+
HNSC	cis	rs4947019	0.688	rs4946979	ENSG00000260273.1	RP11-425D10.10	5.23	2.54e-07	7.75e-05	0.66	0.24	Hematological parameters;	chr6:109484714	chr6:109382795~109383666:+
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	5.23	2.54e-07	7.75e-05	0.29	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	5.23	2.54e-07	7.75e-05	0.29	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
HNSC	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-5.23	2.54e-07	7.75e-05	-0.23	-0.24	Height;	chr5:37053881	chr5:36666214~36725195:-
HNSC	cis	rs7829975	0.684	rs546603	ENSG00000173295.6	FAM86B3P	-5.23	2.54e-07	7.76e-05	-0.27	-0.24	Mood instability;	chr8:8738328	chr8:8228595~8244865:+
HNSC	cis	rs3806843	0.864	rs2531343	ENSG00000202515.1	VTRNA1-3	5.23	2.55e-07	7.77e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140726158~140726246:+
HNSC	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-5.23	2.55e-07	7.77e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
HNSC	cis	rs1056107	0.931	rs10981316	ENSG00000225513.1	RP11-165N19.2	-5.23	2.55e-07	7.77e-05	-0.25	-0.24	Colorectal cancer;	chr9:112211522	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-5.23	2.55e-07	7.77e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
HNSC	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.23	2.55e-07	7.77e-05	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
HNSC	cis	rs3206736	0.52	rs1637674	ENSG00000197085.10	NPSR1-AS1	-5.23	2.55e-07	7.78e-05	-0.3	-0.24	Diastolic blood pressure;	chr7:34958475	chr7:34346512~34871582:-
HNSC	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.23	2.55e-07	7.78e-05	-0.3	-0.24	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-5.23	2.55e-07	7.78e-05	-0.28	-0.24	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
HNSC	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	5.23	2.56e-07	7.8e-05	0.23	0.24	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
HNSC	cis	rs10504130	0.502	rs877248	ENSG00000253844.1	RP11-546K22.1	-5.23	2.56e-07	7.8e-05	-0.32	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51939074	chr8:51961458~52022974:+
HNSC	cis	rs59406912	1	rs59406912	ENSG00000261485.1	PAN3-AS1	5.23	2.56e-07	7.81e-05	0.38	0.24	Hepcidin/transferrin saturation ratio;	chr13:28269628	chr13:28136843~28138193:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000254174.1	IGHV1-12	5.23	2.56e-07	7.81e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106781123	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000254174.1	IGHV1-12	5.23	2.56e-07	7.81e-05	0.2	0.24	Alzheimer's disease (late onset);	chr14:106781131	chr14:106122420~106122709:-
HNSC	cis	rs3733585	0.699	rs11724510	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9956959	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs28837683	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958184	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6823361	ENSG00000250413.1	RP11-448G15.1	5.23	2.56e-07	7.82e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9961503	chr4:10006482~10009725:+
HNSC	cis	rs9611519	0.929	rs73174660	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41041300	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs12484971	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41043300	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs13055800	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41044420	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs4821991	ENSG00000235513.1	RP4-756G23.5	5.23	2.57e-07	7.82e-05	0.26	0.24	Neuroticism;	chr22:41044679	chr22:41209122~41217627:-
HNSC	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-5.23	2.57e-07	7.83e-05	-0.38	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
HNSC	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	5.23	2.57e-07	7.84e-05	0.43	0.24	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	5.23	2.57e-07	7.84e-05	0.28	0.24	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.803	rs12701432	ENSG00000229043.2	AC091729.9	-5.23	2.57e-07	7.84e-05	-0.32	-0.24	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1160374~1165267:+
HNSC	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-5.23	2.57e-07	7.84e-05	-0.25	-0.24	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
HNSC	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-5.23	2.57e-07	7.84e-05	-0.25	-0.24	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
HNSC	cis	rs4218	0.689	rs73418863	ENSG00000277144.1	RP11-59H7.4	-5.23	2.58e-07	7.86e-05	-0.31	-0.24	Social communication problems;	chr15:59098923	chr15:59115547~59116089:-
HNSC	cis	rs36093844	0.8	rs17817355	ENSG00000279742.1	RP11-700A24.1	-5.23	2.58e-07	7.86e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85888902	chr11:85852557~85854943:-
HNSC	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-5.23	2.58e-07	7.87e-05	-0.25	-0.24	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
HNSC	cis	rs11846409	0.86	rs10150951	ENSG00000211974.3	IGHV2-70	-5.23	2.58e-07	7.87e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106632988	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.86	rs17112419	ENSG00000211974.3	IGHV2-70	-5.23	2.58e-07	7.87e-05	-0.26	-0.24	Rheumatic heart disease;	chr14:106633260	chr14:106723574~106724093:-
HNSC	cis	rs11846409	0.932	rs2583329	ENSG00000211974.3	IGHV2-70	5.23	2.58e-07	7.87e-05	0.26	0.24	Rheumatic heart disease;	chr14:106632971	chr14:106723574~106724093:-
HNSC	cis	rs3733585	0.673	rs6449156	ENSG00000250413.1	RP11-448G15.1	5.23	2.58e-07	7.87e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9955088	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6449157	ENSG00000250413.1	RP11-448G15.1	5.23	2.58e-07	7.87e-05	0.29	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9958818	chr4:10006482~10009725:+
HNSC	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-5.23	2.59e-07	7.88e-05	-0.4	-0.24	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
HNSC	cis	rs9840812	0.728	rs665200	ENSG00000273486.1	RP11-731C17.2	5.23	2.59e-07	7.88e-05	0.2	0.24	Fibrinogen levels;	chr3:136276174	chr3:136837338~136839021:-
HNSC	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.59e-07	7.88e-05	-0.55	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
HNSC	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	5.23	2.59e-07	7.9e-05	0.26	0.24	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
HNSC	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	5.23	2.59e-07	7.9e-05	0.26	0.24	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
HNSC	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	5.23	2.6e-07	7.92e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
HNSC	cis	rs1008375	0.966	rs2315645	ENSG00000249502.1	AC006160.5	-5.23	2.6e-07	7.92e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17578055	chr4:17587467~17614571:-
HNSC	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	5.23	2.6e-07	7.93e-05	0.32	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
HNSC	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	5.23	2.6e-07	7.93e-05	0.29	0.24	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	5.23	2.6e-07	7.93e-05	0.29	0.24	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
HNSC	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-5.23	2.6e-07	7.93e-05	-0.32	-0.24	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
HNSC	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	5.23	2.61e-07	7.93e-05	0.42	0.24	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	5.23	2.61e-07	7.93e-05	0.2	0.24	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	5.23	2.61e-07	7.93e-05	0.2	0.24	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
HNSC	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.23	2.61e-07	7.93e-05	0.25	0.24	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
HNSC	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-5.23	2.61e-07	7.94e-05	-0.23	-0.24	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	5.23	2.61e-07	7.94e-05	0.28	0.24	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
HNSC	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	5.23	2.61e-07	7.94e-05	0.38	0.24	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
HNSC	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-5.23	2.61e-07	7.94e-05	-0.22	-0.24	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
HNSC	cis	rs10504130	0.696	rs76522329	ENSG00000253844.1	RP11-546K22.1	-5.23	2.61e-07	7.95e-05	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51961458~52022974:+
HNSC	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	5.23	2.61e-07	7.95e-05	0.29	0.24	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
HNSC	cis	rs2179367	0.632	rs997682	ENSG00000216906.2	RP11-350J20.9	-5.23	2.61e-07	7.95e-05	-0.35	-0.24	Dupuytren's disease;	chr6:149345484	chr6:149904243~149906418:+
HNSC	cis	rs72949976	0.646	rs1441171	ENSG00000270659.1	RP11-105N14.1	-5.23	2.61e-07	7.95e-05	-0.23	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168913	chr2:213152970~213153659:+
HNSC	cis	rs3206736	0.521	rs6948899	ENSG00000197085.10	NPSR1-AS1	-5.23	2.62e-07	7.96e-05	-0.28	-0.24	Diastolic blood pressure;	chr7:35193190	chr7:34346512~34871582:-
HNSC	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	5.23	2.62e-07	7.97e-05	0.26	0.24	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
HNSC	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.97e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
HNSC	cis	rs2834288	0.734	rs8126669	ENSG00000237945.6	LINC00649	-5.23	2.62e-07	7.98e-05	-0.31	-0.24	Gut microbiota (bacterial taxa);	chr21:33895836	chr21:33915534~33977691:+
HNSC	cis	rs1008375	0.966	rs3775925	ENSG00000249502.1	AC006160.5	-5.23	2.62e-07	7.98e-05	-0.25	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586814	chr4:17587467~17614571:-
HNSC	cis	rs13073817	0.582	rs10865756	ENSG00000228956.7	SATB1-AS1	5.23	2.62e-07	7.98e-05	0.25	0.24	Crohn's disease;	chr3:18653645	chr3:18445024~18920401:+
HNSC	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.98e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	5.23	2.62e-07	7.98e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
HNSC	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.23	2.62e-07	7.98e-05	-0.24	-0.24	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
HNSC	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	5.23	2.62e-07	7.98e-05	0.28	0.24	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	5.23	2.62e-07	7.98e-05	0.28	0.24	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
HNSC	cis	rs7404843	0.733	rs153003	ENSG00000263335.1	AF001548.5	5.23	2.62e-07	7.98e-05	0.41	0.24	Testicular germ cell tumor;	chr16:15397543	chr16:15726674~15732993:+
HNSC	cis	rs3806843	0.9	rs2262576	ENSG00000202515.1	VTRNA1-3	5.23	2.63e-07	7.98e-05	0.26	0.24	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140726158~140726246:+
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	5.23	2.63e-07	7.99e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
HNSC	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	5.23	2.63e-07	7.99e-05	0.41	0.24	Depression;	chr6:28333322	chr6:28943877~28944537:+
HNSC	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	5.22	2.63e-07	8e-05	0.35	0.24	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	5.22	2.63e-07	8e-05	0.35	0.24	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
HNSC	cis	rs9813712	0.83	rs9755184	ENSG00000249846.5	RP11-77P16.4	-5.22	2.63e-07	8e-05	-0.28	-0.24	Response to amphetamines;	chr3:130262278	chr3:130112550~130120579:+
HNSC	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8e-05	0.25	0.24	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
HNSC	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-5.22	2.63e-07	8e-05	-0.34	-0.24	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
HNSC	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8.01e-05	0.25	0.23	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	5.22	2.63e-07	8.01e-05	0.25	0.23	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
HNSC	cis	rs71520386	0.634	rs13240023	ENSG00000221740.1	SNORD93	-5.22	2.64e-07	8.01e-05	-0.27	-0.23	Fibrinogen levels;	chr7:22827874	chr7:22856613~22856686:+
HNSC	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-5.22	2.64e-07	8.01e-05	-0.27	-0.23	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
HNSC	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-5.22	2.64e-07	8.02e-05	-0.27	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
HNSC	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	5.22	2.64e-07	8.02e-05	0.26	0.23	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.894	rs10263252	ENSG00000229043.2	AC091729.9	-5.22	2.64e-07	8.02e-05	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.894	rs2141274	ENSG00000229043.2	AC091729.9	-5.22	2.64e-07	8.02e-05	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:995081	chr7:1160374~1165267:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-5.22	2.64e-07	8.03e-05	-0.27	-0.23	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
HNSC	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	5.22	2.64e-07	8.04e-05	0.3	0.23	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
HNSC	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-5.22	2.65e-07	8.04e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
HNSC	cis	rs7819412	0.875	rs11250121	ENSG00000255310.2	AF131215.2	-5.22	2.65e-07	8.04e-05	-0.23	-0.23	Triglycerides;	chr8:11202802	chr8:11107788~11109726:-
HNSC	cis	rs9813712	0.574	rs11718032	ENSG00000249846.5	RP11-77P16.4	5.22	2.65e-07	8.04e-05	0.24	0.23	Response to amphetamines;	chr3:130257749	chr3:130112550~130120579:+
HNSC	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	5.22	2.65e-07	8.04e-05	0.32	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
HNSC	cis	rs1971762	0.527	rs11170590	ENSG00000270175.1	RP11-793H13.11	-5.22	2.65e-07	8.04e-05	-0.2	-0.23	Height;	chr12:53545129	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.527	rs7972401	ENSG00000270175.1	RP11-793H13.11	-5.22	2.65e-07	8.04e-05	-0.2	-0.23	Height;	chr12:53546262	chr12:53500162~53500936:-
HNSC	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	5.22	2.65e-07	8.05e-05	0.25	0.23	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	5.22	2.65e-07	8.05e-05	0.25	0.23	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
HNSC	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-5.22	2.65e-07	8.05e-05	-0.25	-0.23	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
HNSC	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	5.22	2.65e-07	8.06e-05	0.29	0.23	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
HNSC	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.22	2.65e-07	8.06e-05	-0.22	-0.23	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
HNSC	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-5.22	2.66e-07	8.08e-05	-0.38	-0.23	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
HNSC	cis	rs17772222	0.755	rs12435019	ENSG00000258789.1	RP11-507K2.3	-5.22	2.66e-07	8.08e-05	-0.26	-0.23	Coronary artery calcification;	chr14:88365074	chr14:88551597~88552493:+
HNSC	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	5.22	2.66e-07	8.09e-05	0.25	0.23	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
HNSC	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-5.22	2.67e-07	8.11e-05	-0.25	-0.23	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
HNSC	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	5.22	2.67e-07	8.11e-05	0.35	0.23	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-5.22	2.67e-07	8.12e-05	-0.33	-0.23	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
HNSC	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	5.22	2.67e-07	8.12e-05	0.17	0.23	Breast size;	chr12:9220132	chr12:9277235~9313241:+
HNSC	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-5.22	2.67e-07	8.12e-05	-0.2	-0.23	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
HNSC	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	5.22	2.68e-07	8.13e-05	0.28	0.23	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
HNSC	cis	rs8054556	1	rs4283241	ENSG00000183604.13	SMG1P5	5.22	2.68e-07	8.13e-05	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30267553~30335374:-
HNSC	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-5.22	2.68e-07	8.13e-05	-0.23	-0.23	Height;	chr5:37007527	chr5:36666214~36725195:-
HNSC	cis	rs3733585	0.673	rs116046986	ENSG00000250413.1	RP11-448G15.1	5.22	2.68e-07	8.13e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9956170	chr4:10006482~10009725:+
HNSC	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	5.22	2.68e-07	8.14e-05	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000211974.3	IGHV2-70	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106778230	chr14:106723574~106724093:-
HNSC	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	5.22	2.68e-07	8.14e-05	0.22	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
HNSC	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-5.22	2.68e-07	8.14e-05	-0.23	-0.23	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
HNSC	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000211974.3	IGHV2-70	-5.22	2.68e-07	8.14e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106780074	chr14:106723574~106724093:-
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000204709.4	LINC01556	5.22	2.68e-07	8.15e-05	0.32	0.23	Parkinson's disease;	chr6:28043807	chr6:28943877~28944537:+
HNSC	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	5.22	2.69e-07	8.15e-05	0.25	0.23	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
HNSC	cis	rs2985684	0.894	rs2354439	ENSG00000278009.1	RP11-649E7.8	5.22	2.69e-07	8.15e-05	0.3	0.23	Carotid intima media thickness;	chr14:49552699	chr14:49601011~49601124:-
HNSC	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	5.22	2.69e-07	8.16e-05	0.26	0.23	Temperament;	chr17:13996939	chr17:13756478~14069495:-
HNSC	cis	rs7819412	0.775	rs4545055	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.16e-05	-0.22	-0.23	Triglycerides;	chr8:11077856	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.775	rs2898257	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.16e-05	-0.22	-0.23	Triglycerides;	chr8:11077858	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	5.22	2.69e-07	8.16e-05	0.21	0.23	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
HNSC	cis	rs7819412	0.936	rs7814499	ENSG00000255310.2	AF131215.2	-5.22	2.69e-07	8.17e-05	-0.23	-0.23	Triglycerides;	chr8:11183138	chr8:11107788~11109726:-
HNSC	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-5.22	2.69e-07	8.17e-05	-0.31	-0.23	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
HNSC	cis	rs13126694	0.744	rs4521391	ENSG00000248429.4	RP11-597D13.9	5.22	2.69e-07	8.17e-05	0.27	0.23	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158170752~158202877:+
HNSC	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	5.22	2.7e-07	8.18e-05	0.3	0.23	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
HNSC	cis	rs9907295	1	rs9908011	ENSG00000270977.1	AC015849.16	-5.22	2.7e-07	8.19e-05	-0.36	-0.23	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35893707~35911023:-
HNSC	cis	rs1355223	0.867	rs7925421	ENSG00000271369.1	RP11-350D17.3	-5.22	2.7e-07	8.19e-05	-0.27	-0.23	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34660130	chr11:34709600~34710161:+
HNSC	cis	rs2985684	0.948	rs12897941	ENSG00000278009.1	RP11-649E7.8	5.22	2.7e-07	8.19e-05	0.31	0.23	Carotid intima media thickness;	chr14:49549983	chr14:49601011~49601124:-
HNSC	cis	rs36093844	0.752	rs80193798	ENSG00000279742.1	RP11-700A24.1	-5.22	2.7e-07	8.2e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866486	chr11:85852557~85854943:-
HNSC	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	5.22	2.7e-07	8.2e-05	0.23	0.23	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
HNSC	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	5.22	2.71e-07	8.21e-05	0.28	0.23	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
HNSC	cis	rs7819412	0.775	rs11773990	ENSG00000255310.2	AF131215.2	-5.22	2.71e-07	8.21e-05	-0.22	-0.23	Triglycerides;	chr8:11077572	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	5.22	2.71e-07	8.21e-05	0.28	0.23	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
HNSC	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.22	2.71e-07	8.22e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
HNSC	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-5.22	2.71e-07	8.23e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
HNSC	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	5.22	2.71e-07	8.23e-05	0.25	0.23	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
HNSC	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	5.22	2.72e-07	8.23e-05	0.23	0.23	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
HNSC	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-5.22	2.72e-07	8.23e-05	-0.3	-0.23	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
HNSC	cis	rs8054556	1	rs4788197	ENSG00000183604.13	SMG1P5	-5.22	2.72e-07	8.23e-05	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs4788198	ENSG00000183604.13	SMG1P5	-5.22	2.72e-07	8.23e-05	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30267553~30335374:-
HNSC	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	5.22	2.72e-07	8.24e-05	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
HNSC	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	5.22	2.72e-07	8.24e-05	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
HNSC	cis	rs14027	0.512	rs6997976	ENSG00000279347.1	RP11-85I17.2	5.22	2.72e-07	8.24e-05	0.2	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119722044	chr8:119838736~119840385:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-5.22	2.72e-07	8.24e-05	-0.28	-0.23	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
HNSC	cis	rs2898290	0.5	rs11998678	ENSG00000206014.6	OR7E161P	5.22	2.72e-07	8.24e-05	0.26	0.23	Systolic blood pressure;	chr8:11972641	chr8:11928597~11929563:-
HNSC	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-5.22	2.73e-07	8.26e-05	-0.33	-0.23	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-5.22	2.73e-07	8.26e-05	-0.33	-0.23	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
HNSC	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	5.22	2.73e-07	8.26e-05	0.26	0.23	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
HNSC	cis	rs860818	1	rs858256	ENSG00000226816.2	AC005082.12	5.22	2.73e-07	8.27e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23176017	chr7:23206013~23208045:+
HNSC	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	5.22	2.73e-07	8.28e-05	0.23	0.23	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	5.22	2.73e-07	8.28e-05	0.55	0.23	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	5.22	2.73e-07	8.28e-05	0.55	0.23	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
HNSC	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	5.22	2.73e-07	8.28e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
HNSC	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-5.22	2.73e-07	8.28e-05	-0.24	-0.23	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
HNSC	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	5.22	2.73e-07	8.29e-05	0.42	0.23	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
HNSC	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-5.22	2.74e-07	8.29e-05	-0.28	-0.23	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-5.22	2.74e-07	8.29e-05	-0.28	-0.23	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000254340.1	RP11-10A14.3	-5.22	2.74e-07	8.3e-05	-0.28	-0.23	Mood instability;	chr8:8400509	chr8:9141424~9145435:+
HNSC	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-5.22	2.74e-07	8.3e-05	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
HNSC	cis	rs4388249	0.687	rs10059767	ENSG00000271849.1	CTC-332L22.1	-5.22	2.74e-07	8.31e-05	-0.32	-0.23	Schizophrenia;	chr5:109765049	chr5:109687802~109688329:-
HNSC	cis	rs330048	0.545	rs11249913	ENSG00000254340.1	RP11-10A14.3	-5.22	2.75e-07	8.31e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr8:9286011	chr8:9141424~9145435:+
HNSC	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	5.22	2.75e-07	8.32e-05	0.26	0.23	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
HNSC	cis	rs453301	0.506	rs686189	ENSG00000254340.1	RP11-10A14.3	-5.22	2.75e-07	8.32e-05	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8766127	chr8:9141424~9145435:+
HNSC	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	5.22	2.75e-07	8.32e-05	0.32	0.23	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-5.22	2.75e-07	8.33e-05	-0.14	-0.23	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
HNSC	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	5.22	2.75e-07	8.33e-05	0.26	0.23	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
HNSC	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	5.22	2.75e-07	8.33e-05	0.36	0.23	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
HNSC	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	5.22	2.75e-07	8.33e-05	0.36	0.23	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
HNSC	cis	rs9813712	0.597	rs1453255	ENSG00000249846.5	RP11-77P16.4	-5.22	2.75e-07	8.33e-05	-0.25	-0.23	Response to amphetamines;	chr3:130258815	chr3:130112550~130120579:+
HNSC	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-5.22	2.75e-07	8.33e-05	-0.21	-0.23	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
HNSC	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-5.22	2.75e-07	8.34e-05	-0.24	-0.23	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
HNSC	cis	rs17270561	0.525	rs10484432	ENSG00000272810.1	U91328.22	-5.22	2.76e-07	8.34e-05	-0.27	-0.23	Iron status biomarkers;	chr6:26008648	chr6:26013241~26013757:+
HNSC	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	5.22	2.76e-07	8.35e-05	0.25	0.23	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
HNSC	cis	rs1008375	0.9	rs6812675	ENSG00000249502.1	AC006160.5	-5.22	2.76e-07	8.35e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17595926	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.9	rs4698625	ENSG00000249502.1	AC006160.5	-5.22	2.76e-07	8.35e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17597877	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-5.22	2.76e-07	8.35e-05	-0.23	-0.23	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000254340.1	RP11-10A14.3	5.22	2.76e-07	8.36e-05	0.29	0.23	Neuroticism;	chr8:8866141	chr8:9141424~9145435:+
HNSC	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-5.22	2.76e-07	8.36e-05	-0.44	-0.23	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
HNSC	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-5.22	2.76e-07	8.36e-05	-0.32	-0.23	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
HNSC	cis	rs36093844	0.66	rs12274717	ENSG00000279742.1	RP11-700A24.1	-5.22	2.76e-07	8.37e-05	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866671	chr11:85852557~85854943:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000274576.2	IGHV2-70	-5.22	2.76e-07	8.37e-05	-0.24	-0.23	Rheumatic heart disease;	chr14:106618321	chr14:106770577~106771020:-
HNSC	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	5.22	2.77e-07	8.37e-05	0.23	0.23	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
HNSC	cis	rs2058059	0.594	rs3015907	ENSG00000225648.4	SBDSP1	-5.22	2.77e-07	8.38e-05	-0.32	-0.23	Subcutaneous adipose tissue;	chr7:72670647	chr7:72829425~72836701:+
HNSC	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	5.21	2.77e-07	8.38e-05	0.27	0.23	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
HNSC	cis	rs1008375	0.898	rs2079892	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575540	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.931	rs10019482	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576456	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs4698619	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579332	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs10939736	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	8.38e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579994	chr4:17587467~17614571:-
HNSC	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-5.21	2.77e-07	8.39e-05	-0.29	-0.23	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
HNSC	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	5.21	2.77e-07	8.39e-05	0.25	0.23	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	5.21	2.77e-07	8.39e-05	0.25	0.23	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
HNSC	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	5.21	2.77e-07	8.4e-05	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
HNSC	cis	rs10462794	0.661	rs16873561	ENSG00000260763.1	RP11-445O3.3	-5.21	2.78e-07	8.4e-05	-0.34	-0.23	DNA methylation (variation);	chr5:4521189	chr5:4436850~4440259:-
HNSC	cis	rs13113518	0.507	rs4549456	ENSG00000273257.1	RP11-177J6.1	5.21	2.78e-07	8.41e-05	0.27	0.23	Height;	chr4:55398586	chr4:55387949~55388271:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000254174.1	IGHV1-12	5.21	2.78e-07	8.41e-05	0.2	0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106122420~106122709:-
HNSC	cis	rs933688	0.941	rs2887007	ENSG00000281357.1	ARRDC3-AS1	5.21	2.78e-07	8.41e-05	0.34	0.23	Smoking behavior;	chr5:91444714	chr5:91380349~91439085:+
HNSC	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	5.21	2.78e-07	8.41e-05	0.28	0.23	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
HNSC	cis	rs5758511	0.508	rs2854827	ENSG00000226450.2	CYP2D8P	5.21	2.78e-07	8.42e-05	0.22	0.23	Birth weight;	chr22:42065914	chr22:42149886~42155001:-
HNSC	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	5.21	2.78e-07	8.42e-05	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
HNSC	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	5.21	2.79e-07	8.43e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000254153.1	CTA-398F10.2	-5.21	2.79e-07	8.43e-05	-0.27	-0.23	Mean corpuscular volume;	chr8:8993123	chr8:8456909~8461337:-
HNSC	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-5.21	2.8e-07	8.45e-05	-0.35	-0.23	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
HNSC	cis	rs2033711	0.905	rs1077420	ENSG00000269473.1	CTD-2619J13.19	5.21	2.8e-07	8.46e-05	0.29	0.23	Uric acid clearance;	chr19:58457508	chr19:58440448~58445849:+
HNSC	cis	rs7171171	0.718	rs56279249	ENSG00000259747.1	RP11-275I4.2	-5.21	2.8e-07	8.46e-05	-0.33	-0.23	Type 1 diabetes;	chr15:38623112	chr15:38671847~38689191:+
HNSC	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-5.21	2.8e-07	8.46e-05	-0.27	-0.23	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
HNSC	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.8e-07	8.46e-05	-0.23	-0.23	Height;	chr5:36865567	chr5:36666214~36725195:-
HNSC	cis	rs8062405	0.722	rs28729187	ENSG00000251417.2	RP11-1348G14.4	5.21	2.8e-07	8.47e-05	0.28	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615645	chr16:28802743~28817828:+
HNSC	cis	rs8062405	0.789	rs28480369	ENSG00000251417.2	RP11-1348G14.4	5.21	2.8e-07	8.47e-05	0.28	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615683	chr16:28802743~28817828:+
HNSC	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-5.21	2.8e-07	8.47e-05	-0.25	-0.23	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
HNSC	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	5.21	2.8e-07	8.47e-05	0.25	0.23	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
HNSC	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	5.21	2.8e-07	8.48e-05	0.26	0.23	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
HNSC	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	5.21	2.8e-07	8.48e-05	0.25	0.23	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
HNSC	cis	rs1012068	0.96	rs12167583	ENSG00000236132.1	CTA-440B3.1	-5.21	2.81e-07	8.48e-05	-0.28	-0.23	Chronic hepatitis C infection;	chr22:31873725	chr22:31816379~31817491:-
HNSC	cis	rs2235642	0.551	rs1966171	ENSG00000280231.1	LA16c-380F5.3	-5.21	2.81e-07	8.49e-05	-0.31	-0.23	Coronary artery disease;	chr16:1512803	chr16:1553655~1554130:-
HNSC	cis	rs3733585	0.699	rs6449172	ENSG00000250413.1	RP11-448G15.1	5.21	2.81e-07	8.49e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9964412	chr4:10006482~10009725:+
HNSC	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-5.21	2.81e-07	8.49e-05	-0.23	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
HNSC	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-5.21	2.81e-07	8.49e-05	-0.35	-0.23	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
HNSC	cis	rs1008375	0.966	rs2010053	ENSG00000249502.1	AC006160.5	-5.21	2.81e-07	8.5e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17582183	chr4:17587467~17614571:-
HNSC	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	5.21	2.82e-07	8.52e-05	0.27	0.23	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
HNSC	cis	rs8032939	0.533	rs72729314	ENSG00000259747.1	RP11-275I4.2	-5.21	2.82e-07	8.53e-05	-0.31	-0.23	Rheumatoid arthritis;	chr15:38613933	chr15:38671847~38689191:+
HNSC	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-5.21	2.82e-07	8.53e-05	-0.24	-0.23	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	5.21	2.83e-07	8.54e-05	0.29	0.23	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
HNSC	cis	rs4699052	0.928	rs2169511	ENSG00000246560.2	RP11-10L12.4	5.21	2.83e-07	8.54e-05	0.28	0.23	Testicular germ cell tumor;	chr4:103271423	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.963	rs6849319	ENSG00000246560.2	RP11-10L12.4	5.21	2.83e-07	8.54e-05	0.28	0.23	Testicular germ cell tumor;	chr4:103271585	chr4:102828055~102844075:+
HNSC	cis	rs3733585	0.699	rs6856127	ENSG00000250413.1	RP11-448G15.1	5.21	2.83e-07	8.54e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9963819	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	5.21	2.83e-07	8.55e-05	0.28	0.23	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
HNSC	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-5.21	2.83e-07	8.55e-05	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
HNSC	cis	rs860295	0.812	rs12131079	ENSG00000203761.5	MSTO2P	5.21	2.84e-07	8.56e-05	0.18	0.23	Body mass index;	chr1:155349877	chr1:155745829~155750137:+
HNSC	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	5.21	2.84e-07	8.57e-05	0.3	0.23	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
HNSC	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.21	2.84e-07	8.57e-05	0.39	0.23	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
HNSC	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	5.21	2.84e-07	8.57e-05	0.33	0.23	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
HNSC	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	5.21	2.84e-07	8.57e-05	0.35	0.23	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
HNSC	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-5.21	2.84e-07	8.57e-05	-0.26	-0.23	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
HNSC	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	5.21	2.84e-07	8.58e-05	0.35	0.23	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
HNSC	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-5.21	2.84e-07	8.58e-05	-0.2	-0.23	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
HNSC	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	5.21	2.84e-07	8.58e-05	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
HNSC	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	5.21	2.85e-07	8.6e-05	0.23	0.23	Height;	chr5:36948260	chr5:36666214~36725195:-
HNSC	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-5.21	2.85e-07	8.6e-05	-0.36	-0.23	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
HNSC	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	5.21	2.85e-07	8.61e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
HNSC	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	5.21	2.85e-07	8.61e-05	0.18	0.23	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
HNSC	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.85e-07	8.61e-05	-0.23	-0.23	Height;	chr5:37046524	chr5:36666214~36725195:-
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000276710.3	CSPG4P8	-5.21	2.86e-07	8.62e-05	-0.33	-0.23	Excessive daytime sleepiness;	chr15:82708330	chr15:82459472~82477258:+
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	5.21	2.86e-07	8.63e-05	0.3	0.23	Depression;	chr6:28167882	chr6:28161781~28169594:+
HNSC	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-5.21	2.86e-07	8.63e-05	-0.22	-0.23	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
HNSC	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-5.21	2.86e-07	8.63e-05	-0.46	-0.23	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
HNSC	cis	rs4141404	0.561	rs5994376	ENSG00000236132.1	CTA-440B3.1	5.21	2.86e-07	8.64e-05	0.25	0.23	Paclitaxel-induced neuropathy;	chr22:31167569	chr22:31816379~31817491:-
HNSC	cis	rs1075232	1	rs9672214	ENSG00000215302.7	CTD-3092A11.1	-5.21	2.86e-07	8.64e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30470779~30507623:+
HNSC	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	5.21	2.86e-07	8.64e-05	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
HNSC	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	5.21	2.87e-07	8.66e-05	0.26	0.23	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000254340.1	RP11-10A14.3	-5.21	2.87e-07	8.66e-05	-0.3	-0.23	Recombination measurement;	chr8:9208015	chr8:9141424~9145435:+
HNSC	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	5.21	2.87e-07	8.66e-05	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
HNSC	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-5.21	2.87e-07	8.66e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
HNSC	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	5.21	2.87e-07	8.67e-05	0.25	0.23	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-5.21	2.87e-07	8.67e-05	-0.29	-0.23	Depression;	chr6:28198669	chr6:28161781~28169594:+
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	5.21	2.87e-07	8.67e-05	0.28	0.23	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
HNSC	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	5.21	2.88e-07	8.67e-05	0.28	0.23	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	5.21	2.88e-07	8.67e-05	0.28	0.23	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
HNSC	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-5.21	2.88e-07	8.68e-05	-0.56	-0.23	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
HNSC	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-5.21	2.88e-07	8.68e-05	-0.23	-0.23	Height;	chr5:36968438	chr5:36666214~36725195:-
HNSC	cis	rs4388249	0.687	rs6877418	ENSG00000271849.1	CTC-332L22.1	-5.21	2.88e-07	8.69e-05	-0.32	-0.23	Schizophrenia;	chr5:109738408	chr5:109687802~109688329:-
HNSC	cis	rs2337406	0.587	rs10129888	ENSG00000254174.1	IGHV1-12	5.21	2.88e-07	8.69e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106647421	chr14:106122420~106122709:-
HNSC	cis	rs9840812	0.559	rs6439640	ENSG00000239213.4	NCK1-AS1	5.21	2.88e-07	8.7e-05	0.26	0.23	Fibrinogen levels;	chr3:136466838	chr3:136841726~136862054:-
HNSC	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	5.21	2.88e-07	8.7e-05	0.25	0.23	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	5.21	2.88e-07	8.7e-05	0.25	0.23	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
HNSC	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-5.21	2.88e-07	8.7e-05	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
HNSC	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	5.21	2.89e-07	8.7e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
HNSC	cis	rs348196	0.767	rs12744132	ENSG00000203761.5	MSTO2P	-5.21	2.89e-07	8.71e-05	-0.19	-0.23	Breast cancer;	chr1:155693535	chr1:155745829~155750137:+
HNSC	cis	rs17507216	0.718	rs7165690	ENSG00000276710.3	CSPG4P8	-5.21	2.89e-07	8.71e-05	-0.33	-0.23	Excessive daytime sleepiness;	chr15:82654804	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	5.21	2.89e-07	8.71e-05	0.25	0.23	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	5.21	2.89e-07	8.71e-05	0.25	0.23	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
HNSC	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	5.21	2.89e-07	8.71e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
HNSC	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-5.21	2.89e-07	8.71e-05	-0.24	-0.23	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000254340.1	RP11-10A14.3	5.21	2.89e-07	8.71e-05	0.28	0.23	Mood instability;	chr8:8401202	chr8:9141424~9145435:+
HNSC	cis	rs3206736	0.548	rs329234	ENSG00000197085.10	NPSR1-AS1	-5.21	2.89e-07	8.71e-05	-0.29	-0.23	Diastolic blood pressure;	chr7:35016268	chr7:34346512~34871582:-
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000204709.4	LINC01556	5.21	2.89e-07	8.71e-05	0.32	0.23	Parkinson's disease;	chr6:28004655	chr6:28943877~28944537:+
HNSC	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-5.21	2.89e-07	8.71e-05	-0.19	-0.23	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
HNSC	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	5.21	2.89e-07	8.72e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
HNSC	cis	rs17270561	0.541	rs2009610	ENSG00000272810.1	U91328.22	-5.21	2.89e-07	8.72e-05	-0.27	-0.23	Iron status biomarkers;	chr6:25966840	chr6:26013241~26013757:+
HNSC	cis	rs3806843	0.9	rs2337984	ENSG00000202515.1	VTRNA1-3	5.21	2.89e-07	8.72e-05	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140726158~140726246:+
HNSC	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-5.21	2.9e-07	8.73e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
HNSC	cis	rs8177876	0.749	rs11865207	ENSG00000261061.1	RP11-303E16.2	-5.21	2.9e-07	8.74e-05	-0.36	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81030770~81031485:+
HNSC	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	5.21	2.91e-07	8.76e-05	0.44	0.23	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
HNSC	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	5.21	2.91e-07	8.76e-05	0.31	0.23	Height;	chr4:55501955	chr4:55387949~55388271:+
HNSC	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-5.21	2.91e-07	8.76e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000254340.1	RP11-10A14.3	-5.21	2.91e-07	8.77e-05	-0.29	-0.23	Mood instability;	chr8:8516047	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-5.21	2.91e-07	8.78e-05	-0.27	-0.23	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
HNSC	cis	rs7789940	0.951	rs7787526	ENSG00000231087.2	FDPSP7	-5.2	2.91e-07	8.78e-05	-0.29	-0.23	Multiple sclerosis;	chr7:76318236	chr7:76968197~76969250:-
HNSC	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	8.78e-05	0.58	0.23	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
HNSC	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-5.2	2.91e-07	8.78e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
HNSC	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	5.2	2.91e-07	8.78e-05	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	5.2	2.91e-07	8.78e-05	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
HNSC	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	5.2	2.91e-07	8.78e-05	0.29	0.23	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
HNSC	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-5.2	2.92e-07	8.8e-05	-0.24	-0.23	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
HNSC	cis	rs4218	0.689	rs2121237	ENSG00000277144.1	RP11-59H7.4	-5.2	2.92e-07	8.81e-05	-0.31	-0.23	Social communication problems;	chr15:59091888	chr15:59115547~59116089:-
HNSC	cis	rs17507216	0.671	rs28582623	ENSG00000276710.3	CSPG4P8	-5.2	2.92e-07	8.81e-05	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82577381	chr15:82459472~82477258:+
HNSC	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	5.2	2.92e-07	8.81e-05	0.25	0.23	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	5.2	2.92e-07	8.81e-05	0.25	0.23	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
HNSC	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	5.2	2.93e-07	8.81e-05	0.28	0.23	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
HNSC	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	5.2	2.93e-07	8.82e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	5.2	2.93e-07	8.82e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
HNSC	cis	rs7590368	0.926	rs12623588	ENSG00000272275.1	RP11-791G15.2	-5.2	2.93e-07	8.82e-05	-0.3	-0.23	Educational attainment (years of education);	chr2:10817486	chr2:10767875~10770058:-
HNSC	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-5.2	2.93e-07	8.83e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
HNSC	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	5.2	2.93e-07	8.83e-05	0.38	0.23	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
HNSC	cis	rs6693567	0.565	rs10157197	ENSG00000228126.1	FALEC	-5.2	2.93e-07	8.83e-05	-0.29	-0.23	Migraine;	chr1:150278225	chr1:150515757~150518032:+
HNSC	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	5.2	2.93e-07	8.84e-05	0.25	0.23	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
HNSC	cis	rs11846409	0.86	rs74091720	ENSG00000211974.3	IGHV2-70	-5.2	2.94e-07	8.85e-05	-0.26	-0.23	Rheumatic heart disease;	chr14:106638192	chr14:106723574~106724093:-
HNSC	cis	rs67981189	0.579	rs2240533	ENSG00000274818.1	RP1-292L20.3	5.2	2.94e-07	8.85e-05	0.28	0.23	Schizophrenia;	chr14:71074309	chr14:70906657~70907111:-
HNSC	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-5.2	2.94e-07	8.86e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
HNSC	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	5.2	2.94e-07	8.86e-05	0.22	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
HNSC	cis	rs3206736	0.548	rs1559959	ENSG00000197085.10	NPSR1-AS1	-5.2	2.95e-07	8.88e-05	-0.3	-0.23	Diastolic blood pressure;	chr7:35034755	chr7:34346512~34871582:-
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000223648.3	IGHV3-64	5.2	2.95e-07	8.88e-05	0.19	0.23	Kawasaki disease;	chr14:106711838	chr14:106643132~106658258:-
HNSC	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-5.2	2.95e-07	8.88e-05	-0.4	-0.23	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
HNSC	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	5.2	2.95e-07	8.88e-05	0.4	0.23	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
HNSC	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	5.2	2.95e-07	8.89e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
HNSC	cis	rs9813712	0.571	rs6795143	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130224355	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.571	rs9289366	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130225267	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.571	rs9289367	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130225286	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.571	rs9289368	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130225562	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.571	rs6774141	ENSG00000249846.5	RP11-77P16.4	-5.2	2.95e-07	8.89e-05	-0.25	-0.23	Response to amphetamines;	chr3:130225599	chr3:130112550~130120579:+
HNSC	cis	rs454422	1	rs6053815	ENSG00000275632.1	RP5-967N21.11	5.2	2.96e-07	8.89e-05	0.24	0.23	HIV-1 viral setpoint;	chr20:5989792	chr20:6000418~6000941:+
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	5.2	2.96e-07	8.89e-05	0.19	0.23	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
HNSC	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-5.2	2.96e-07	8.89e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
HNSC	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-5.2	2.96e-07	8.89e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
HNSC	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-5.2	2.96e-07	8.89e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
HNSC	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-5.2	2.96e-07	8.89e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
HNSC	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-5.2	2.96e-07	8.89e-05	-0.23	-0.23	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	5.2	2.96e-07	8.89e-05	0.19	0.23	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
HNSC	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-5.2	2.96e-07	8.9e-05	-0.25	-0.23	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
HNSC	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-5.2	2.96e-07	8.9e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
HNSC	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-5.2	2.96e-07	8.9e-05	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
HNSC	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	5.2	2.96e-07	8.91e-05	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
HNSC	cis	rs1075232	1	rs4450360	ENSG00000215302.7	CTD-3092A11.1	-5.2	2.96e-07	8.91e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30470779~30507623:+
HNSC	cis	rs1075232	1	rs72722847	ENSG00000215302.7	CTD-3092A11.1	-5.2	2.96e-07	8.91e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30470779~30507623:+
HNSC	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	5.2	2.97e-07	8.93e-05	0.25	0.23	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
HNSC	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-5.2	2.97e-07	8.93e-05	-0.29	-0.23	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
HNSC	cis	rs1707322	1	rs7539800	ENSG00000234329.1	RP11-767N6.2	-5.2	2.97e-07	8.93e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45651039~45651826:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000233609.3	RP11-62H7.2	-5.2	2.97e-07	8.94e-05	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9032531	chr8:8961200~8979025:+
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000211972.2	IGHV3-66	5.2	2.97e-07	8.94e-05	0.17	0.23	Kawasaki disease;	chr14:106676288	chr14:106675017~106675544:-
HNSC	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-5.2	2.97e-07	8.94e-05	-0.23	-0.23	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
HNSC	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	5.2	2.98e-07	8.95e-05	0.24	0.23	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
HNSC	cis	rs728616	0.867	rs56198874	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.98e-07	8.95e-05	-0.55	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs17884637	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.98e-07	8.95e-05	-0.55	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79663088~79826594:-
HNSC	cis	rs2268667	0.511	rs1874807	ENSG00000223653.4	RP11-131L23.1	-5.2	2.98e-07	8.95e-05	-0.3	-0.23	Asymmetrical dimethylarginine levels;	chr1:85313710	chr1:85276715~85448124:+
HNSC	cis	rs2337406	0.587	rs2583291	ENSG00000254174.1	IGHV1-12	-5.2	2.98e-07	8.96e-05	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106649293	chr14:106122420~106122709:-
HNSC	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	5.2	2.98e-07	8.96e-05	0.25	0.23	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
HNSC	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-5.2	2.98e-07	8.96e-05	-0.29	-0.23	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
HNSC	cis	rs3733585	0.577	rs28558552	ENSG00000250413.1	RP11-448G15.1	5.2	2.98e-07	8.97e-05	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9963289	chr4:10006482~10009725:+
HNSC	cis	rs1707322	1	rs10890350	ENSG00000234329.1	RP11-767N6.2	5.2	2.98e-07	8.97e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45651039~45651826:-
HNSC	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	5.2	2.99e-07	8.98e-05	0.24	0.23	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
HNSC	cis	rs2337406	0.587	rs10139664	ENSG00000254174.1	IGHV1-12	5.2	2.99e-07	8.98e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106647254	chr14:106122420~106122709:-
HNSC	cis	rs7819412	0.807	rs4840542	ENSG00000255310.2	AF131215.2	-5.2	2.99e-07	8.98e-05	-0.22	-0.23	Triglycerides;	chr8:11087299	chr8:11107788~11109726:-
HNSC	cis	rs3806843	0.766	rs801176	ENSG00000202515.1	VTRNA1-3	-5.2	2.99e-07	8.98e-05	-0.26	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr5:140726158~140726246:+
HNSC	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	5.2	2.99e-07	8.98e-05	0.35	0.23	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	5.2	2.99e-07	8.98e-05	0.35	0.23	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
HNSC	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	5.2	2.99e-07	8.98e-05	0.23	0.23	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
HNSC	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-5.2	2.99e-07	8.98e-05	-0.28	-0.23	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-5.2	2.99e-07	8.98e-05	-0.28	-0.23	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
HNSC	cis	rs1008375	0.966	rs1476836	ENSG00000249502.1	AC006160.5	-5.2	2.99e-07	8.98e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17583391	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.898	rs7670500	ENSG00000249502.1	AC006160.5	-5.2	2.99e-07	8.98e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585334	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs7675735	ENSG00000249502.1	AC006160.5	-5.2	2.99e-07	8.98e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585514	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.898	rs4698620	ENSG00000249502.1	AC006160.5	-5.2	2.99e-07	8.98e-05	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585738	chr4:17587467~17614571:-
HNSC	cis	rs9650657	0.504	rs10108347	ENSG00000269918.1	AF131215.9	-5.2	2.99e-07	8.99e-05	-0.23	-0.23	Neuroticism;	chr8:11176008	chr8:11104691~11106704:-
HNSC	cis	rs7777677	0.925	rs2156964	ENSG00000244273.1	PGBD4P1	-5.2	2.99e-07	9e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142722358~142722764:+
HNSC	cis	rs2033711	0.622	rs975947	ENSG00000269473.1	CTD-2619J13.19	5.2	2.99e-07	9e-05	0.29	0.23	Uric acid clearance;	chr19:58386826	chr19:58440448~58445849:+
HNSC	cis	rs13126694	0.778	rs12503001	ENSG00000248429.4	RP11-597D13.9	5.2	2.99e-07	9e-05	0.26	0.23	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158170752~158202877:+
HNSC	cis	rs6674176	0.597	rs9326136	ENSG00000237950.1	RP11-7O11.3	-5.2	3e-07	9e-05	-0.26	-0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43924720	chr1:43944370~43946551:-
HNSC	cis	rs9611519	0.929	rs73174657	ENSG00000235513.1	RP4-756G23.5	5.2	3e-07	9.01e-05	0.26	0.23	Neuroticism;	chr22:41038154	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs9611474	ENSG00000235513.1	RP4-756G23.5	5.2	3e-07	9.01e-05	0.26	0.23	Neuroticism;	chr22:41038854	chr22:41209122~41217627:-
HNSC	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-5.2	3e-07	9.02e-05	-0.38	-0.23	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
HNSC	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.2	3.01e-07	9.03e-05	0.23	0.23	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
HNSC	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	5.2	3.01e-07	9.03e-05	0.29	0.23	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
HNSC	cis	rs2337406	1	rs3858878	ENSG00000254174.1	IGHV1-12	5.2	3.01e-07	9.04e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106688061	chr14:106122420~106122709:-
HNSC	cis	rs5758659	0.714	rs5751216	ENSG00000227370.1	RP4-669P10.19	5.2	3.01e-07	9.04e-05	0.23	0.23	Cognitive function;	chr22:42112933	chr22:42132543~42132998:+
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000254340.1	RP11-10A14.3	-5.2	3.01e-07	9.04e-05	-0.3	-0.23	Recombination measurement;	chr8:9208000	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-5.2	3.01e-07	9.04e-05	-0.28	-0.23	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
HNSC	cis	rs75422866	0.867	rs73104155	ENSG00000276691.1	RP5-1057I20.5	5.2	3.01e-07	9.05e-05	0.44	0.23	Pneumonia;	chr12:47700790	chr12:47788426~47788971:+
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-5.2	3.02e-07	9.06e-05	-0.29	-0.23	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
HNSC	cis	rs1355223	0.902	rs12800220	ENSG00000271369.1	RP11-350D17.3	-5.2	3.02e-07	9.06e-05	-0.26	-0.23	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34680070	chr11:34709600~34710161:+
HNSC	cis	rs75422866	0.867	rs117388682	ENSG00000276691.1	RP5-1057I20.5	5.2	3.02e-07	9.06e-05	0.43	0.23	Pneumonia;	chr12:47599713	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs79113930	ENSG00000276691.1	RP5-1057I20.5	5.2	3.02e-07	9.06e-05	0.43	0.23	Pneumonia;	chr12:47600628	chr12:47788426~47788971:+
HNSC	cis	rs7615952	0.599	rs6803160	ENSG00000248787.1	RP11-666A20.4	-5.2	3.02e-07	9.07e-05	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125990711	chr3:125908005~125910272:-
HNSC	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	5.2	3.02e-07	9.07e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
HNSC	cis	rs3733585	0.781	rs6449183	ENSG00000250413.1	RP11-448G15.1	5.2	3.02e-07	9.07e-05	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10006482~10009725:+
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000254340.1	RP11-10A14.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Neuroticism;	chr8:8866747	chr8:9141424~9145435:+
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000254340.1	RP11-10A14.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Neuroticism;	chr8:8866766	chr8:9141424~9145435:+
HNSC	cis	rs67981189	0.821	rs34257131	ENSG00000274818.1	RP1-292L20.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Schizophrenia;	chr14:71053723	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.821	rs12896370	ENSG00000274818.1	RP1-292L20.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Schizophrenia;	chr14:71054623	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.821	rs2286310	ENSG00000274818.1	RP1-292L20.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Schizophrenia;	chr14:71056888	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.821	rs61990419	ENSG00000274818.1	RP1-292L20.3	5.2	3.03e-07	9.08e-05	0.28	0.23	Schizophrenia;	chr14:71069570	chr14:70906657~70907111:-
HNSC	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-5.2	3.03e-07	9.09e-05	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
HNSC	cis	rs7048146	0.509	rs7042082	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109568854	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs7026037	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109568991	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.531	rs7042569	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109569211	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs35139900	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109569369	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs13297930	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109569740	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs35993367	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109570047	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs35464144	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109570129	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs34314233	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109570232	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs7873812	ENSG00000213539.4	YBX1P6	5.2	3.03e-07	9.09e-05	0.33	0.23	Vascular brain injury;	chr9:109571971	chr9:109532830~109534332:-
HNSC	cis	rs13126694	0.778	rs7692254	ENSG00000248429.4	RP11-597D13.9	5.2	3.03e-07	9.09e-05	0.26	0.23	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158170752~158202877:+
HNSC	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	5.2	3.03e-07	9.1e-05	0.26	0.23	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
HNSC	cis	rs4853525	0.59	rs10198852	ENSG00000235852.1	AC005540.3	5.2	3.03e-07	9.1e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863606	chr2:190880797~190882059:-
HNSC	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-5.2	3.03e-07	9.1e-05	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
HNSC	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	5.2	3.03e-07	9.1e-05	0.25	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
HNSC	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	5.2	3.04e-07	9.11e-05	0.35	0.23	Height;	chr6:109645257	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000211974.3	IGHV2-70	-5.2	3.04e-07	9.11e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106778385	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000211974.3	IGHV2-70	-5.2	3.04e-07	9.11e-05	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106778427	chr14:106723574~106724093:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000254340.1	RP11-10A14.3	5.2	3.04e-07	9.11e-05	0.28	0.23	Mood instability;	chr8:8401607	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs465359	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66093177	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs462853	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66093180	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160644	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66093199	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs160642	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66093386	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66100154	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000179406.6	LINC00174	-5.2	3.04e-07	9.12e-05	-0.48	-0.23	Diabetic kidney disease;	chr7:66100518	chr7:66376044~66401338:-
HNSC	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	5.2	3.04e-07	9.12e-05	0.25	0.23	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
HNSC	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	5.2	3.04e-07	9.12e-05	0.24	0.23	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
HNSC	cis	rs7209700	1	rs7209700	ENSG00000228782.6	CTD-2026D20.3	-5.2	3.04e-07	9.13e-05	-0.24	-0.23	IgG glycosylation;	chr17:47273752	chr17:47450568~47492492:-
HNSC	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	5.2	3.04e-07	9.13e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
HNSC	cis	rs6723108	0.517	rs7580655	ENSG00000224043.6	CCNT2-AS1	-5.2	3.04e-07	9.13e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134869605	chr2:134735464~134918710:-
HNSC	cis	rs17428076	0.793	rs56275355	ENSG00000228389.1	AC068039.4	-5.2	3.05e-07	9.13e-05	-0.29	-0.23	Myopia;	chr2:171853670	chr2:171773482~171775844:+
HNSC	cis	rs13113518	0.51	rs11732723	ENSG00000273257.1	RP11-177J6.1	-5.2	3.05e-07	9.13e-05	-0.27	-0.23	Height;	chr4:55424391	chr4:55387949~55388271:+
HNSC	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	5.2	3.05e-07	9.14e-05	0.17	0.23	Breast size;	chr12:9228263	chr12:9277235~9313241:+
HNSC	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-5.2	3.05e-07	9.14e-05	-0.27	-0.23	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
HNSC	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-5.2	3.05e-07	9.15e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
HNSC	cis	rs11773103	0.881	rs74759656	ENSG00000224046.1	AC005076.5	5.2	3.05e-07	9.16e-05	0.45	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87130844	chr7:87151423~87152420:-
HNSC	cis	rs4699052	1	rs4699055	ENSG00000246560.2	RP11-10L12.4	5.2	3.05e-07	9.16e-05	0.27	0.23	Testicular germ cell tumor;	chr4:103233343	chr4:102828055~102844075:+
HNSC	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.16e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.16e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
HNSC	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.16e-05	-0.27	-0.23	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.16e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.16e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
HNSC	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	5.2	3.06e-07	9.16e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	5.2	3.06e-07	9.16e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
HNSC	cis	rs4664293	0.74	rs12464577	ENSG00000226266.5	AC009961.3	5.2	3.06e-07	9.17e-05	0.25	0.23	Monocyte percentage of white cells;	chr2:159816321	chr2:159670708~159712435:-
HNSC	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-5.2	3.06e-07	9.17e-05	-0.27	-0.23	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
HNSC	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-5.2	3.06e-07	9.17e-05	-0.24	-0.23	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-5.2	3.06e-07	9.17e-05	-0.14	-0.23	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-5.2	3.06e-07	9.17e-05	-0.14	-0.23	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-5.2	3.06e-07	9.17e-05	-0.14	-0.23	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	5.2	3.06e-07	9.18e-05	0.22	0.23	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
HNSC	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	5.19	3.06e-07	9.18e-05	0.23	0.23	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
HNSC	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-5.19	3.06e-07	9.18e-05	-0.23	-0.23	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
HNSC	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	5.19	3.07e-07	9.18e-05	0.27	0.23	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	5.19	3.07e-07	9.18e-05	0.27	0.23	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
HNSC	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	5.19	3.07e-07	9.19e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000204709.4	LINC01556	5.19	3.07e-07	9.19e-05	0.31	0.23	Parkinson's disease;	chr6:28002926	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000204709.4	LINC01556	5.19	3.07e-07	9.19e-05	0.31	0.23	Parkinson's disease;	chr6:28002927	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000204709.4	LINC01556	5.19	3.07e-07	9.19e-05	0.31	0.23	Parkinson's disease;	chr6:28007039	chr6:28943877~28944537:+
HNSC	cis	rs17214007	0.735	rs2075513	ENSG00000263335.1	AF001548.5	-5.19	3.07e-07	9.19e-05	-0.36	-0.23	Cognitive function;	chr16:15782614	chr16:15726674~15732993:+
HNSC	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	5.19	3.07e-07	9.19e-05	0.33	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
HNSC	cis	rs72727394	0.51	rs72729320	ENSG00000259747.1	RP11-275I4.2	-5.19	3.07e-07	9.2e-05	-0.33	-0.23	Crohn's disease;	chr15:38624511	chr15:38671847~38689191:+
HNSC	cis	rs1008375	0.932	rs6449315	ENSG00000249502.1	AC006160.5	-5.19	3.08e-07	9.21e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17588596	chr4:17587467~17614571:-
HNSC	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	5.19	3.08e-07	9.21e-05	0.33	0.23	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	5.19	3.08e-07	9.21e-05	0.33	0.23	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	5.19	3.08e-07	9.21e-05	0.33	0.23	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
HNSC	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	5.19	3.08e-07	9.22e-05	0.21	0.23	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
HNSC	cis	rs11992162	1	rs7460395	ENSG00000206014.6	OR7E161P	-5.19	3.08e-07	9.22e-05	-0.26	-0.23	Monocyte count;	chr8:11977866	chr8:11928597~11929563:-
HNSC	cis	rs8012947	0.916	rs8004077	ENSG00000279636.2	LINC00216	5.19	3.08e-07	9.23e-05	0.29	0.23	Alcohol consumption in current drinkers;	chr14:58380013	chr14:58288033~58289158:+
HNSC	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-5.19	3.08e-07	9.23e-05	-0.29	-0.23	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
HNSC	cis	rs1218582	0.772	rs11264282	ENSG00000270361.1	RP11-307C12.13	-5.19	3.08e-07	9.24e-05	-0.25	-0.23	Prostate cancer;	chr1:154894894	chr1:154937370~154938059:+
HNSC	cis	rs9987353	0.62	rs34455383	ENSG00000254340.1	RP11-10A14.3	-5.19	3.09e-07	9.24e-05	-0.31	-0.23	Recombination measurement;	chr8:9208948	chr8:9141424~9145435:+
HNSC	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-5.19	3.09e-07	9.24e-05	-0.24	-0.23	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
HNSC	cis	rs5758659	0.714	rs5758589	ENSG00000227370.1	RP4-669P10.19	5.19	3.09e-07	9.24e-05	0.23	0.23	Cognitive function;	chr22:42122378	chr22:42132543~42132998:+
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	5.19	3.09e-07	9.25e-05	0.21	0.23	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
HNSC	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-5.19	3.09e-07	9.25e-05	-0.3	-0.23	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-5.19	3.09e-07	9.25e-05	-0.3	-0.23	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
HNSC	cis	rs9611519	1	rs6002271	ENSG00000235513.1	RP4-756G23.5	5.19	3.09e-07	9.25e-05	0.26	0.23	Neuroticism;	chr22:41170591	chr22:41209122~41217627:-
HNSC	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-5.19	3.09e-07	9.26e-05	-0.29	-0.23	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
HNSC	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-5.19	3.09e-07	9.26e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
HNSC	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-5.19	3.1e-07	9.27e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
HNSC	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-5.19	3.1e-07	9.27e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
HNSC	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.19	3.1e-07	9.27e-05	-0.29	-0.23	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
HNSC	cis	rs860295	0.65	rs12027412	ENSG00000203761.5	MSTO2P	5.19	3.1e-07	9.27e-05	0.17	0.23	Body mass index;	chr1:155939139	chr1:155745829~155750137:+
HNSC	cis	rs9611519	0.929	rs926914	ENSG00000235513.1	RP4-756G23.5	5.19	3.1e-07	9.28e-05	0.26	0.23	Neuroticism;	chr22:41022150	chr22:41209122~41217627:-
HNSC	cis	rs712039	1	rs712039	ENSG00000276054.1	RP11-378E13.3	5.19	3.1e-07	9.28e-05	0.29	0.23	Tuberculosis;	chr17:37490447	chr17:37386886~37387926:+
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000254174.1	IGHV1-12	5.19	3.1e-07	9.29e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106779306	chr14:106122420~106122709:-
HNSC	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-5.19	3.1e-07	9.29e-05	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-5.19	3.1e-07	9.29e-05	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-5.19	3.1e-07	9.29e-05	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-5.19	3.1e-07	9.29e-05	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
HNSC	cis	rs6928977	0.896	rs2746429	ENSG00000231028.7	LINC00271	5.19	3.1e-07	9.29e-05	0.27	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352146	chr6:135497801~135716055:+
HNSC	cis	rs465969	0.744	rs574056	ENSG00000255389.1	C6orf3	-5.19	3.11e-07	9.29e-05	-0.44	-0.23	Psoriasis;	chr6:111305787	chr6:111599875~111602295:+
HNSC	cis	rs6951245	0.786	rs77943789	ENSG00000225146.1	AC073957.15	-5.19	3.11e-07	9.3e-05	-0.36	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1029025~1043891:+
HNSC	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.19	3.11e-07	9.3e-05	0.28	0.23	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
HNSC	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	5.19	3.11e-07	9.3e-05	0.27	0.23	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
HNSC	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.19	3.11e-07	9.31e-05	-0.22	-0.23	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
HNSC	cis	rs11969893	0.85	rs9404055	ENSG00000270987.1	RP3-467N11.2	5.19	3.12e-07	9.32e-05	0.56	0.23	Economic and political preferences (immigration/crime);	chr6:100854384	chr6:100889603~100890338:+
HNSC	cis	rs7789940	0.81	rs12533978	ENSG00000231087.2	FDPSP7	-5.19	3.12e-07	9.33e-05	-0.29	-0.23	Multiple sclerosis;	chr7:76314035	chr7:76968197~76969250:-
HNSC	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	5.19	3.12e-07	9.33e-05	0.39	0.23	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
HNSC	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	5.19	3.12e-07	9.33e-05	0.28	0.23	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
HNSC	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	5.19	3.12e-07	9.34e-05	0.25	0.23	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
HNSC	cis	rs71520386	0.632	rs10224419	ENSG00000221740.1	SNORD93	5.19	3.12e-07	9.34e-05	0.27	0.23	Fibrinogen levels;	chr7:22830397	chr7:22856613~22856686:+
HNSC	cis	rs1021993	1	rs2660636	ENSG00000231648.1	RP11-372M18.2	5.19	3.12e-07	9.34e-05	0.32	0.23	Gut microbiome composition (winter);	chr1:209308523	chr1:209367662~209379690:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000254153.1	CTA-398F10.2	5.19	3.13e-07	9.35e-05	0.25	0.23	Joint mobility (Beighton score);	chr8:8977018	chr8:8456909~8461337:-
HNSC	cis	rs7567389	0.576	rs2069902	ENSG00000236682.1	AC068282.3	-5.19	3.13e-07	9.35e-05	-0.29	-0.23	Self-rated health;	chr2:127417287	chr2:127389130~127400580:+
HNSC	cis	rs5758659	0.714	rs2284087	ENSG00000227370.1	RP4-669P10.19	5.19	3.13e-07	9.36e-05	0.23	0.23	Cognitive function;	chr22:42089667	chr22:42132543~42132998:+
HNSC	cis	rs11846409	0.932	rs73378155	ENSG00000274576.2	IGHV2-70	-5.19	3.13e-07	9.37e-05	-0.22	-0.23	Rheumatic heart disease;	chr14:106637840	chr14:106770577~106771020:-
HNSC	cis	rs6714900	0.516	rs6546658	ENSG00000234896.1	OR7E62P	-5.19	3.13e-07	9.37e-05	-0.28	-0.23	Blood protein levels;	chr2:71048652	chr2:71055527~71056003:+
HNSC	cis	rs964184	0.554	rs7118999	ENSG00000254851.1	RP11-109L13.1	-5.19	3.13e-07	9.37e-05	-0.33	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116774559	chr11:117135528~117138582:+
HNSC	cis	rs1707322	1	rs11211190	ENSG00000234329.1	RP11-767N6.2	5.19	3.14e-07	9.37e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs6429580	ENSG00000234329.1	RP11-767N6.2	5.19	3.14e-07	9.37e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45651039~45651826:-
HNSC	cis	rs11976180	1	rs2961144	ENSG00000273234.1	OR2A13P	5.19	3.14e-07	9.38e-05	0.26	0.23	Obesity-related traits;	chr7:144050777	chr7:144142009~144142938:+
HNSC	cis	rs667920	0.575	rs9861150	ENSG00000239213.4	NCK1-AS1	5.19	3.14e-07	9.38e-05	0.24	0.23	Coronary artery disease;	chr3:136464478	chr3:136841726~136862054:-
HNSC	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	5.19	3.14e-07	9.39e-05	0.24	0.23	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000233609.3	RP11-62H7.2	-5.19	3.14e-07	9.39e-05	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9016136	chr8:8961200~8979025:+
HNSC	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	5.19	3.15e-07	9.4e-05	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
HNSC	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-5.19	3.15e-07	9.41e-05	-0.49	-0.23	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
HNSC	cis	rs4664293	0.715	rs13002625	ENSG00000226266.5	AC009961.3	5.19	3.15e-07	9.41e-05	0.24	0.23	Monocyte percentage of white cells;	chr2:159648114	chr2:159670708~159712435:-
HNSC	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	5.19	3.15e-07	9.42e-05	0.28	0.23	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
HNSC	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	5.19	3.15e-07	9.42e-05	0.3	0.23	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
HNSC	cis	rs3806843	0.838	rs2337514	ENSG00000202515.1	VTRNA1-3	5.19	3.15e-07	9.42e-05	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr5:140726158~140726246:+
HNSC	cis	rs2976388	0.692	rs2585175	ENSG00000253741.1	CTD-2292P10.4	-5.19	3.15e-07	9.42e-05	-0.22	-0.23	Urinary tract infection frequency;	chr8:142699871	chr8:142702252~142726973:-
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000204709.4	LINC01556	5.19	3.16e-07	9.43e-05	0.31	0.23	Parkinson's disease;	chr6:28009959	chr6:28943877~28944537:+
HNSC	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	5.19	3.16e-07	9.43e-05	0.31	0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
HNSC	cis	rs2337406	0.866	rs74090151	ENSG00000254174.1	IGHV1-12	5.19	3.16e-07	9.45e-05	0.19	0.23	Alzheimer's disease (late onset);	chr14:106785377	chr14:106122420~106122709:-
HNSC	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	5.19	3.16e-07	9.45e-05	0.54	0.23	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
HNSC	cis	rs36052053	0.908	rs36094641	ENSG00000219700.1	PTCHD3P3	5.19	3.16e-07	9.45e-05	0.38	0.23	Red cell distribution width;	chr6:109282652	chr6:109288571~109290503:-
HNSC	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	5.19	3.16e-07	9.45e-05	0.27	0.23	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
HNSC	cis	rs5758659	0.904	rs5758653	ENSG00000227370.1	RP4-669P10.19	-5.19	3.16e-07	9.45e-05	-0.23	-0.23	Cognitive function;	chr22:42217479	chr22:42132543~42132998:+
HNSC	cis	rs17428076	0.831	rs55957712	ENSG00000228389.1	AC068039.4	-5.19	3.16e-07	9.45e-05	-0.28	-0.23	Myopia;	chr2:171731446	chr2:171773482~171775844:+
HNSC	cis	rs9840812	0.567	rs2655008	ENSG00000239213.4	NCK1-AS1	5.19	3.16e-07	9.45e-05	0.21	0.23	Fibrinogen levels;	chr3:136404933	chr3:136841726~136862054:-
HNSC	cis	rs860295	0.557	rs11264371	ENSG00000203761.5	MSTO2P	-5.19	3.16e-07	9.45e-05	-0.18	-0.23	Body mass index;	chr1:155442246	chr1:155745829~155750137:+
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000173295.6	FAM86B3P	-5.19	3.17e-07	9.45e-05	-0.26	-0.23	Mean corpuscular volume;	chr8:8996725	chr8:8228595~8244865:+
HNSC	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	5.19	3.17e-07	9.46e-05	0.23	0.23	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	5.19	3.17e-07	9.46e-05	0.23	0.23	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	5.19	3.17e-07	9.46e-05	0.23	0.23	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
HNSC	cis	rs1971762	0.509	rs784567	ENSG00000270175.1	RP11-793H13.11	5.19	3.17e-07	9.47e-05	0.2	0.23	Height;	chr12:53500681	chr12:53500162~53500936:-
HNSC	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	5.19	3.17e-07	9.47e-05	0.29	0.23	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
HNSC	cis	rs520525	0.963	rs524877	ENSG00000271811.1	RP1-79C4.4	5.19	3.17e-07	9.47e-05	0.27	0.23	Atrial fibrillation;	chr1:170659294	chr1:170667381~170669425:+
HNSC	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	5.19	3.18e-07	9.48e-05	0.18	0.23	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-5.19	3.18e-07	9.48e-05	-0.28	-0.23	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-5.19	3.18e-07	9.49e-05	-0.36	-0.23	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
HNSC	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-5.19	3.18e-07	9.49e-05	-0.3	-0.23	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
HNSC	cis	rs860295	0.557	rs10796941	ENSG00000203761.5	MSTO2P	-5.19	3.18e-07	9.5e-05	-0.19	-0.23	Body mass index;	chr1:155314470	chr1:155745829~155750137:+
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-5.19	3.18e-07	9.5e-05	-0.14	-0.23	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
HNSC	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	5.19	3.18e-07	9.5e-05	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
HNSC	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-5.19	3.18e-07	9.5e-05	-0.3	-0.23	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	5.19	3.19e-07	9.51e-05	0.56	0.23	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
HNSC	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	5.19	3.19e-07	9.51e-05	0.24	0.23	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	5.19	3.19e-07	9.51e-05	0.24	0.23	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	5.19	3.19e-07	9.51e-05	0.24	0.23	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
HNSC	cis	rs5758511	0.514	rs5758580	ENSG00000226450.2	CYP2D8P	5.19	3.19e-07	9.52e-05	0.23	0.23	Birth weight;	chr22:42097871	chr22:42149886~42155001:-
HNSC	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	5.19	3.19e-07	9.52e-05	0.4	0.23	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
HNSC	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	5.19	3.19e-07	9.52e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
HNSC	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	5.19	3.19e-07	9.52e-05	0.22	0.23	Height;	chr5:37463644	chr5:36666214~36725195:-
HNSC	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	5.19	3.19e-07	9.53e-05	0.27	0.23	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
HNSC	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-5.19	3.19e-07	9.53e-05	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
HNSC	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-5.19	3.2e-07	9.54e-05	-0.3	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-5.19	3.2e-07	9.54e-05	-0.3	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	5.19	3.2e-07	9.54e-05	0.2	0.23	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
HNSC	cis	rs4218	0.543	rs8025246	ENSG00000259732.1	RP11-59H7.3	-5.19	3.2e-07	9.55e-05	-0.29	-0.23	Social communication problems;	chr15:59025814	chr15:59121034~59133250:+
HNSC	cis	rs9611519	0.894	rs9611488	ENSG00000235513.1	RP4-756G23.5	5.19	3.21e-07	9.57e-05	0.26	0.23	Neuroticism;	chr22:41066588	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.894	rs4821998	ENSG00000235513.1	RP4-756G23.5	5.19	3.21e-07	9.57e-05	0.26	0.23	Neuroticism;	chr22:41072269	chr22:41209122~41217627:-
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000233609.3	RP11-62H7.2	-5.19	3.21e-07	9.58e-05	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9017276	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	5.19	3.21e-07	9.58e-05	0.32	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
HNSC	cis	rs75422866	0.867	rs73104152	ENSG00000276691.1	RP5-1057I20.5	5.19	3.22e-07	9.59e-05	0.44	0.23	Pneumonia;	chr12:47699091	chr12:47788426~47788971:+
HNSC	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	5.19	3.22e-07	9.59e-05	0.25	0.23	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
HNSC	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	5.19	3.22e-07	9.59e-05	0.29	0.23	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
HNSC	cis	rs3096299	0.702	rs2086825	ENSG00000274627.1	RP11-104N10.2	5.19	3.22e-07	9.6e-05	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89516797~89522217:+
HNSC	cis	rs4218	0.593	rs8040456	ENSG00000277144.1	RP11-59H7.4	-5.19	3.22e-07	9.6e-05	-0.3	-0.23	Social communication problems;	chr15:59063904	chr15:59115547~59116089:-
HNSC	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	5.19	3.22e-07	9.6e-05	0.28	0.23	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
HNSC	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-5.19	3.22e-07	9.6e-05	-0.26	-0.23	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
HNSC	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-5.19	3.22e-07	9.61e-05	-0.3	-0.23	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
HNSC	cis	rs1971762	0.527	rs4759211	ENSG00000270175.1	RP11-793H13.11	-5.19	3.22e-07	9.61e-05	-0.2	-0.23	Height;	chr12:53537161	chr12:53500162~53500936:-
HNSC	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-5.18	3.22e-07	9.61e-05	-0.28	-0.23	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
HNSC	cis	rs5758659	0.729	rs134866	ENSG00000227370.1	RP4-669P10.19	-5.18	3.23e-07	9.62e-05	-0.22	-0.23	Cognitive function;	chr22:42254657	chr22:42132543~42132998:+
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000254153.1	CTA-398F10.2	-5.18	3.23e-07	9.62e-05	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9226955	chr8:8456909~8461337:-
HNSC	cis	rs2086824	0.702	rs3114896	ENSG00000274627.1	RP11-104N10.2	-5.18	3.23e-07	9.63e-05	-0.23	-0.23	Multiple myeloma (IgH translocation);	chr16:89327154	chr16:89516797~89522217:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000254153.1	CTA-398F10.2	-5.18	3.23e-07	9.64e-05	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9226344	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.653	rs7853	ENSG00000253981.4	ALG1L13P	5.18	3.23e-07	9.64e-05	0.26	0.23	Joint mobility (Beighton score);	chr8:9033304	chr8:8236003~8244667:-
HNSC	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	5.18	3.23e-07	9.64e-05	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	5.18	3.23e-07	9.64e-05	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
HNSC	cis	rs597539	0.652	rs646586	ENSG00000255741.1	RP11-757G1.5	5.18	3.24e-07	9.64e-05	0.32	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68941503~68942852:-
HNSC	cis	rs9863	0.896	rs4765148	ENSG00000269938.1	RP11-214K3.20	-5.18	3.24e-07	9.65e-05	-0.28	-0.23	White blood cell count;	chr12:123994090	chr12:123968023~123968579:-
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-5.18	3.24e-07	9.65e-05	-0.21	-0.23	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
HNSC	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	5.18	3.24e-07	9.65e-05	0.31	0.23	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
HNSC	cis	rs2579103	0.898	rs2731283	ENSG00000258183.4	RP11-753N8.1	-5.18	3.24e-07	9.66e-05	-0.3	-0.23	Body mass index;	chr12:90199771	chr12:90280894~90300340:+
HNSC	cis	rs10504130	0.696	rs79069311	ENSG00000253844.1	RP11-546K22.1	-5.18	3.25e-07	9.67e-05	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51961458~52022974:+
HNSC	cis	rs9527	0.637	rs7085104	ENSG00000236937.2	PTGES3P4	5.18	3.25e-07	9.67e-05	0.3	0.23	Arsenic metabolism;	chr10:102869116	chr10:102845595~102845950:+
HNSC	cis	rs933688	1	rs6865495	ENSG00000281357.1	ARRDC3-AS1	5.18	3.25e-07	9.67e-05	0.34	0.23	Smoking behavior;	chr5:91450607	chr5:91380349~91439085:+
HNSC	cis	rs3743266	0.613	rs1869484	ENSG00000245534.5	RORA-AS1	5.18	3.25e-07	9.67e-05	0.3	0.23	Menarche (age at onset);	chr15:60449864	chr15:60479178~60630637:+
HNSC	cis	rs2998286	0.862	rs2790448	ENSG00000254635.4	WAC-AS1	-5.18	3.25e-07	9.68e-05	-0.31	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.822	rs2807734	ENSG00000254635.4	WAC-AS1	-5.18	3.25e-07	9.68e-05	-0.31	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28522652~28532743:-
HNSC	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	5.18	3.25e-07	9.68e-05	0.25	0.23	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
HNSC	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	5.18	3.25e-07	9.69e-05	0.27	0.23	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
HNSC	cis	rs947583	0.588	rs1033755	ENSG00000217482.2	HMGB1P17	5.18	3.25e-07	9.69e-05	0.26	0.23	Phosphorus levels;	chr6:135749553	chr6:135636086~135636713:-
HNSC	cis	rs4908760	0.773	rs301805	ENSG00000232912.4	RP5-1115A15.1	5.18	3.26e-07	9.69e-05	0.25	0.23	Vitiligo;	chr1:8420956	chr1:8424645~8434838:+
HNSC	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	5.18	3.26e-07	9.71e-05	0.22	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
HNSC	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	5.18	3.26e-07	9.72e-05	0.24	0.23	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
HNSC	cis	rs860295	0.557	rs12035524	ENSG00000203761.5	MSTO2P	-5.18	3.26e-07	9.72e-05	-0.18	-0.23	Body mass index;	chr1:155697311	chr1:155745829~155750137:+
HNSC	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-5.18	3.26e-07	9.72e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
HNSC	cis	rs6430553	0.861	rs12463645	ENSG00000224043.6	CCNT2-AS1	-5.18	3.27e-07	9.72e-05	-0.28	-0.23	Blood metabolite levels;	chr2:134916800	chr2:134735464~134918710:-
HNSC	cis	rs6928977	0.896	rs2614259	ENSG00000231028.7	LINC00271	5.18	3.27e-07	9.72e-05	0.27	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356114	chr6:135497801~135716055:+
HNSC	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-5.18	3.27e-07	9.72e-05	-0.28	-0.23	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
HNSC	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-5.18	3.27e-07	9.73e-05	-0.18	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
HNSC	cis	rs1008375	0.898	rs9998130	ENSG00000249502.1	AC006160.5	-5.18	3.27e-07	9.73e-05	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592282	chr4:17587467~17614571:-
HNSC	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	5.18	3.27e-07	9.73e-05	0.26	0.23	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
HNSC	cis	rs2998286	0.822	rs2807737	ENSG00000254635.4	WAC-AS1	-5.18	3.27e-07	9.74e-05	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28501052	chr10:28522652~28532743:-
HNSC	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	5.18	3.27e-07	9.74e-05	0.31	0.23	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
HNSC	cis	rs7804306	1	rs35425218	ENSG00000233264.2	AC006042.8	5.18	3.27e-07	9.74e-05	0.41	0.23	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7977124	chr7:7980312~7982228:+
HNSC	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-5.18	3.27e-07	9.74e-05	-0.32	-0.23	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
HNSC	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-5.18	3.27e-07	9.75e-05	-0.44	-0.23	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
HNSC	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-5.18	3.27e-07	9.75e-05	-0.28	-0.23	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
HNSC	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	5.18	3.28e-07	9.75e-05	0.25	0.23	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
HNSC	cis	rs860295	0.65	rs625658	ENSG00000203761.5	MSTO2P	5.18	3.28e-07	9.75e-05	0.17	0.23	Body mass index;	chr1:155921254	chr1:155745829~155750137:+
HNSC	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-5.18	3.28e-07	9.76e-05	-0.28	-0.23	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
HNSC	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	5.18	3.28e-07	9.76e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
HNSC	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-5.18	3.28e-07	9.76e-05	-0.28	-0.23	Height;	chr2:46601985	chr2:46668870~46670778:+
HNSC	cis	rs6081541	0.689	rs1547100	ENSG00000179447.2	RP5-1027G4.3	5.18	3.28e-07	9.76e-05	0.29	0.23	Psychosis (atypical);	chr20:19220625	chr20:19242302~19284596:-
HNSC	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	5.18	3.28e-07	9.76e-05	0.29	0.23	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
HNSC	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	5.18	3.28e-07	9.76e-05	0.27	0.23	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000254153.1	CTA-398F10.2	-5.18	3.28e-07	9.77e-05	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9227399	chr8:8456909~8461337:-
HNSC	cis	rs6918586	1	rs6918586	ENSG00000272462.2	U91328.19	5.18	3.29e-07	9.78e-05	0.21	0.23	Schizophrenia;	chr6:26097156	chr6:25992662~26001775:+
HNSC	cis	rs6540731	1	rs6540731	ENSG00000226251.4	RP11-15I11.3	5.18	3.29e-07	9.79e-05	0.26	0.23	Intelligence (childhood);	chr1:212218821	chr1:212225278~212238977:-
HNSC	cis	rs1075232	1	rs56396205	ENSG00000215302.7	CTD-3092A11.1	-5.18	3.29e-07	9.8e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30470779~30507623:+
HNSC	cis	rs1075232	1	rs12438318	ENSG00000215302.7	CTD-3092A11.1	-5.18	3.29e-07	9.8e-05	-0.52	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30470779~30507623:+
HNSC	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	5.18	3.29e-07	9.8e-05	0.28	0.23	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
HNSC	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	5.18	3.3e-07	9.8e-05	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
HNSC	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-5.18	3.3e-07	9.8e-05	-0.23	-0.23	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
HNSC	cis	rs36093844	0.605	rs79719453	ENSG00000279742.1	RP11-700A24.1	-5.18	3.3e-07	9.8e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85871174	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs113529766	ENSG00000279742.1	RP11-700A24.1	-5.18	3.3e-07	9.8e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872358	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.8	rs76464398	ENSG00000279742.1	RP11-700A24.1	-5.18	3.3e-07	9.8e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872855	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs116940726	ENSG00000279742.1	RP11-700A24.1	-5.18	3.3e-07	9.8e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873009	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs1445505	ENSG00000279742.1	RP11-700A24.1	-5.18	3.3e-07	9.8e-05	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873679	chr11:85852557~85854943:-
HNSC	cis	rs77580281	0.526	rs4594540	ENSG00000185065.6	AC000068.5	-5.18	3.3e-07	9.81e-05	-0.25	-0.23	Pediatric bone mineral density (hip);	chr22:19551674	chr22:19447893~19450105:+
HNSC	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	5.18	3.3e-07	9.81e-05	0.28	0.23	Depression;	chr6:28273214	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	5.18	3.3e-07	9.81e-05	0.28	0.23	Depression;	chr6:28273215	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	5.18	3.3e-07	9.82e-05	0.25	0.23	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
HNSC	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-5.18	3.3e-07	9.82e-05	-0.4	-0.23	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
HNSC	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-5.18	3.31e-07	9.85e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
HNSC	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-5.18	3.31e-07	9.85e-05	-0.23	-0.23	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
HNSC	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-5.18	3.32e-07	9.86e-05	-0.24	-0.23	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
HNSC	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-5.18	3.32e-07	9.86e-05	-0.18	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
HNSC	cis	rs6693567	0.545	rs1694380	ENSG00000228126.1	FALEC	5.18	3.32e-07	9.86e-05	0.28	0.23	Migraine;	chr1:150319893	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs1776276	ENSG00000228126.1	FALEC	5.18	3.32e-07	9.86e-05	0.28	0.23	Migraine;	chr1:150320630	chr1:150515757~150518032:+
HNSC	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	5.18	3.32e-07	9.87e-05	0.25	0.23	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
HNSC	cis	rs1908814	0.516	rs11250178	ENSG00000206014.6	OR7E161P	-5.18	3.32e-07	9.87e-05	-0.25	-0.23	Neuroticism;	chr8:11942725	chr8:11928597~11929563:-
HNSC	cis	rs4295623	0.585	rs13259242	ENSG00000269918.1	AF131215.9	-5.18	3.33e-07	9.88e-05	-0.23	-0.23	Morning vs. evening chronotype;	chr8:11735524	chr8:11104691~11106704:-
HNSC	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-5.18	3.33e-07	9.89e-05	-0.25	-0.23	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
HNSC	cis	rs11154801	0.696	rs4432992	ENSG00000234084.1	RP3-388E23.2	-5.18	3.33e-07	9.89e-05	-0.25	-0.23	Multiple sclerosis;	chr6:135612356	chr6:135301568~135307158:+
HNSC	cis	rs12682352	0.65	rs13265731	ENSG00000254340.1	RP11-10A14.3	5.18	3.33e-07	9.89e-05	0.28	0.23	Neuroticism;	chr8:8815810	chr8:9141424~9145435:+
HNSC	cis	rs6928977	0.733	rs9321500	ENSG00000231028.7	LINC00271	5.18	3.33e-07	9.89e-05	0.27	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320231	chr6:135497801~135716055:+
HNSC	cis	rs9525927	0.553	rs2773283	ENSG00000227258.4	SMIM2-AS1	-5.18	3.33e-07	9.89e-05	-0.31	-0.23	Dupuytren's disease;	chr13:44225727	chr13:44110451~44240517:+
HNSC	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-5.18	3.33e-07	9.89e-05	-0.27	-0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
HNSC	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-5.18	3.33e-07	9.89e-05	-0.32	-0.23	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000254153.1	CTA-398F10.2	-5.18	3.33e-07	9.9e-05	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9227707	chr8:8456909~8461337:-
HNSC	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-5.18	3.33e-07	9.9e-05	-0.22	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
HNSC	cis	rs11722228	0.522	rs73212808	ENSG00000250413.1	RP11-448G15.1	-5.18	3.33e-07	9.9e-05	-0.34	-0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10053815	chr4:10006482~10009725:+
HNSC	cis	rs9402743	0.599	rs6919741	ENSG00000217482.2	HMGB1P17	5.18	3.33e-07	9.91e-05	0.26	0.23	Systemic lupus erythematosus;	chr6:135622057	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs9321516	ENSG00000217482.2	HMGB1P17	5.18	3.33e-07	9.91e-05	0.26	0.23	Systemic lupus erythematosus;	chr6:135622150	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.598	rs7761716	ENSG00000217482.2	HMGB1P17	5.18	3.33e-07	9.91e-05	0.26	0.23	Systemic lupus erythematosus;	chr6:135623243	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.671	rs7762139	ENSG00000217482.2	HMGB1P17	5.18	3.33e-07	9.91e-05	0.26	0.23	Systemic lupus erythematosus;	chr6:135623289	chr6:135636086~135636713:-
HNSC	cis	rs17428076	0.83	rs6704590	ENSG00000228389.1	AC068039.4	-5.18	3.34e-07	9.92e-05	-0.29	-0.23	Myopia;	chr2:172013647	chr2:171773482~171775844:+
HNSC	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-5.18	3.34e-07	9.93e-05	-0.2	-0.23	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
HNSC	cis	rs1707322	1	rs4298677	ENSG00000234329.1	RP11-767N6.2	5.18	3.35e-07	9.94e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45651039~45651826:-
HNSC	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-5.18	3.35e-07	9.94e-05	-0.3	-0.23	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
HNSC	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-5.18	3.35e-07	9.95e-05	-0.29	-0.23	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	5.18	3.35e-07	9.95e-05	0.28	0.23	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-5.18	3.35e-07	9.95e-05	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000254340.1	RP11-10A14.3	5.18	3.35e-07	9.95e-05	0.28	0.23	Mood instability;	chr8:8515975	chr8:9141424~9145435:+
HNSC	cis	rs712039	0.652	rs60112577	ENSG00000276054.1	RP11-378E13.3	5.18	3.36e-07	9.97e-05	0.34	0.23	Tuberculosis;	chr17:37473105	chr17:37386886~37387926:+
HNSC	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	5.18	3.36e-07	9.97e-05	0.27	0.23	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	5.18	3.36e-07	9.97e-05	0.28	0.23	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
HNSC	cis	rs1056107	0.931	rs7855376	ENSG00000225513.1	RP11-165N19.2	5.18	3.36e-07	9.97e-05	0.25	0.23	Colorectal cancer;	chr9:112251851	chr9:112173522~112173971:-
HNSC	cis	rs3743266	0.613	rs12442393	ENSG00000245534.5	RORA-AS1	5.18	3.36e-07	9.97e-05	0.3	0.23	Menarche (age at onset);	chr15:60442261	chr15:60479178~60630637:+
HNSC	cis	rs3743266	0.613	rs1063100	ENSG00000245534.5	RORA-AS1	5.18	3.36e-07	9.97e-05	0.3	0.23	Menarche (age at onset);	chr15:60442498	chr15:60479178~60630637:+
HNSC	cis	rs3743266	0.613	rs4775273	ENSG00000245534.5	RORA-AS1	5.18	3.36e-07	9.97e-05	0.3	0.23	Menarche (age at onset);	chr15:60446367	chr15:60479178~60630637:+
HNSC	cis	rs3743266	0.613	rs1869485	ENSG00000245534.5	RORA-AS1	5.18	3.36e-07	9.97e-05	0.3	0.23	Menarche (age at onset);	chr15:60454406	chr15:60479178~60630637:+
HNSC	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	5.18	3.36e-07	9.97e-05	0.39	0.23	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
HNSC	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-5.18	3.36e-07	9.98e-05	-0.36	-0.23	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
HNSC	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	5.18	3.36e-07	9.98e-05	0.35	0.23	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	5.18	3.36e-07	9.98e-05	0.35	0.23	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
HNSC	cis	rs1021993	1	rs1354854	ENSG00000231648.1	RP11-372M18.2	5.18	3.36e-07	9.99e-05	0.32	0.23	Gut microbiome composition (winter);	chr1:209295336	chr1:209367662~209379690:+
HNSC	cis	rs2302464	1	rs58978163	ENSG00000214846.4	RP11-115L11.1	5.18	3.36e-07	9.99e-05	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15726385	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs73123615	ENSG00000214846.4	RP11-115L11.1	5.18	3.36e-07	9.99e-05	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15726553	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs16892276	ENSG00000214846.4	RP11-115L11.1	5.18	3.36e-07	9.99e-05	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15726614	chr4:15730962~15731627:-
HNSC	cis	rs2302464	1	rs60913985	ENSG00000214846.4	RP11-115L11.1	5.18	3.36e-07	9.99e-05	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15726671	chr4:15730962~15731627:-
HNSC	cis	rs1404100	0.51	rs6768480	ENSG00000249274.1	PDLIM1P4	5.18	3.37e-07	9.99e-05	0.28	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99070070	chr3:98782188~98783193:+
HNSC	cis	rs4218	0.689	rs28514475	ENSG00000277144.1	RP11-59H7.4	-5.18	3.37e-07	1e-04	-0.31	-0.23	Social communication problems;	chr15:59099896	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.689	rs28610479	ENSG00000277144.1	RP11-59H7.4	-5.18	3.37e-07	1e-04	-0.31	-0.23	Social communication problems;	chr15:59099906	chr15:59115547~59116089:-
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000224373.3	IGHV4-59	-5.18	3.37e-07	1e-04	-0.13	-0.23	Kawasaki disease;	chr14:106677179	chr14:106627249~106627825:-
HNSC	cis	rs11247915	0.583	rs34058882	ENSG00000236782.4	RP11-96L14.7	-5.18	3.37e-07	1e-04	-0.27	-0.23	Obesity-related traits;	chr1:26333303	chr1:26169947~26171821:-
HNSC	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	5.18	3.37e-07	1e-04	0.35	0.23	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000254174.1	IGHV1-12	5.18	3.38e-07	1e-04	0.2	0.23	Alzheimer's disease (late onset);	chr14:106790663	chr14:106122420~106122709:-
HNSC	cis	rs3733585	0.805	rs882222	ENSG00000250413.1	RP11-448G15.1	-5.18	3.38e-07	1e-04	-0.29	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10006482~10009725:+
HNSC	cis	rs1555322	0.505	rs2254207	ENSG00000126005.14	MMP24-AS1	-5.18	3.38e-07	1e-04	-0.35	-0.23	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35216462~35278131:-
HNSC	cis	rs72727394	0.51	rs55762999	ENSG00000259747.1	RP11-275I4.2	-5.18	3.38e-07	1e-04	-0.31	-0.23	Crohn's disease;	chr15:38622442	chr15:38671847~38689191:+
HNSC	cis	rs3806843	0.966	rs2563261	ENSG00000202515.1	VTRNA1-3	5.18	3.38e-07	1e-04	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr5:140726158~140726246:+
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000204709.4	LINC01556	5.18	3.38e-07	1e-04	0.32	0.23	Parkinson's disease;	chr6:28066257	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000204709.4	LINC01556	5.18	3.38e-07	1e-04	0.32	0.23	Parkinson's disease;	chr6:28066263	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000204709.4	LINC01556	5.18	3.38e-07	1e-04	0.32	0.23	Parkinson's disease;	chr6:28066343	chr6:28943877~28944537:+
HNSC	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-5.18	3.39e-07	1e-04	-0.27	-0.23	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
HNSC	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	5.17	3.39e-07	0.000101	0.28	0.23	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
HNSC	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	5.17	3.39e-07	0.000101	0.35	0.23	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000254174.1	IGHV1-12	5.17	3.39e-07	0.000101	0.2	0.23	Alzheimer's disease (late onset);	chr14:106779942	chr14:106122420~106122709:-
HNSC	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	5.17	3.39e-07	0.000101	0.29	0.23	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
HNSC	cis	rs9291683	0.507	rs3796837	ENSG00000250413.1	RP11-448G15.1	-5.17	3.4e-07	0.000101	-0.29	-0.23	Bone mineral density;	chr4:10009697	chr4:10006482~10009725:+
HNSC	cis	rs2834288	0.5	rs7283594	ENSG00000273102.1	AP000569.9	-5.17	3.4e-07	0.000101	-0.26	-0.23	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33967101~33968573:-
HNSC	cis	rs795484	0.683	rs514826	ENSG00000275409.1	RP11-131L12.4	5.17	3.4e-07	0.000101	0.26	0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118371498	chr12:118430147~118430699:+
HNSC	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	5.17	3.4e-07	0.000101	0.25	0.23	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
HNSC	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	5.17	3.4e-07	0.000101	0.29	0.23	Shingles;	chr7:38346957	chr7:38353715~38354517:-
HNSC	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-5.17	3.4e-07	0.000101	-0.23	-0.23	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
HNSC	cis	rs73222236	1	rs73222236	ENSG00000273486.1	RP11-731C17.2	5.17	3.4e-07	0.000101	0.19	0.23	Coronary artery disease;	chr3:136169800	chr3:136837338~136839021:-
HNSC	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	5.17	3.41e-07	0.000101	0.24	0.23	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
HNSC	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-5.17	3.41e-07	0.000101	-0.23	-0.23	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
HNSC	cis	rs9813712	0.526	rs13065659	ENSG00000249846.5	RP11-77P16.4	-5.17	3.41e-07	0.000101	-0.25	-0.23	Response to amphetamines;	chr3:130231945	chr3:130112550~130120579:+
HNSC	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	5.17	3.42e-07	0.000101	0.25	0.23	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	5.17	3.42e-07	0.000101	0.25	0.23	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
HNSC	cis	rs3806843	0.932	rs2563269	ENSG00000202515.1	VTRNA1-3	5.17	3.42e-07	0.000101	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr5:140726158~140726246:+
HNSC	cis	rs4718428	1	rs12534637	ENSG00000179406.6	LINC00174	-5.17	3.42e-07	0.000101	-0.31	-0.23	Corneal structure;	chr7:66862667	chr7:66376044~66401338:-
HNSC	cis	rs17270561	0.562	rs74293932	ENSG00000272810.1	U91328.22	-5.17	3.42e-07	0.000101	-0.27	-0.23	Iron status biomarkers;	chr6:26014583	chr6:26013241~26013757:+
HNSC	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	5.17	3.42e-07	0.000101	0.24	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
HNSC	cis	rs1707322	1	rs785480	ENSG00000234329.1	RP11-767N6.2	5.17	3.42e-07	0.000101	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45651039~45651826:-
HNSC	cis	rs13113518	0.557	rs13142096	ENSG00000273257.1	RP11-177J6.1	5.17	3.42e-07	0.000101	0.31	0.23	Height;	chr4:55566291	chr4:55387949~55388271:+
HNSC	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-5.17	3.43e-07	0.000102	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
HNSC	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	5.17	3.43e-07	0.000102	0.27	0.23	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
HNSC	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	5.17	3.43e-07	0.000102	0.25	0.23	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	5.17	3.43e-07	0.000102	0.25	0.23	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	5.17	3.43e-07	0.000102	0.25	0.23	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
HNSC	cis	rs62344088	1	rs62344088	ENSG00000277812.1	AC021087.1	5.17	3.44e-07	0.000102	0.64	0.23	Asthma (childhood onset);	chr5:95949	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs7727872	ENSG00000277812.1	AC021087.1	5.17	3.44e-07	0.000102	0.64	0.23	Asthma (childhood onset);	chr5:97818	chr5:262769~262881:+
HNSC	cis	rs62344088	1	rs9986162	ENSG00000277812.1	AC021087.1	5.17	3.44e-07	0.000102	0.64	0.23	Asthma (childhood onset);	chr5:107396	chr5:262769~262881:+
HNSC	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-5.17	3.44e-07	0.000102	-0.23	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
HNSC	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	5.17	3.45e-07	0.000102	0.25	0.23	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	5.17	3.45e-07	0.000102	0.29	0.23	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
HNSC	cis	rs3806843	1	rs10066278	ENSG00000202515.1	VTRNA1-3	-5.17	3.45e-07	0.000102	-0.26	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr5:140726158~140726246:+
HNSC	cis	rs3206736	0.583	rs1649233	ENSG00000197085.10	NPSR1-AS1	-5.17	3.45e-07	0.000102	-0.29	-0.23	Diastolic blood pressure;	chr7:34960847	chr7:34346512~34871582:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	5.17	3.45e-07	0.000102	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
HNSC	cis	rs7615952	0.576	rs2276726	ENSG00000248787.1	RP11-666A20.4	-5.17	3.45e-07	0.000102	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126107444	chr3:125908005~125910272:-
HNSC	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	5.17	3.45e-07	0.000102	0.52	0.23	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	5.17	3.45e-07	0.000102	0.52	0.23	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	5.17	3.45e-07	0.000102	0.52	0.23	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	5.17	3.45e-07	0.000102	0.52	0.23	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
HNSC	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-5.17	3.46e-07	0.000102	-0.23	-0.23	Height;	chr5:37088525	chr5:36666214~36725195:-
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000219392.1	RP1-265C24.5	-5.17	3.46e-07	0.000102	-0.29	-0.23	Parkinson's disease;	chr6:27879739	chr6:28115628~28116551:+
HNSC	cis	rs9291683	0.53	rs882223	ENSG00000250413.1	RP11-448G15.1	-5.17	3.46e-07	0.000102	-0.29	-0.23	Bone mineral density;	chr4:9980001	chr4:10006482~10009725:+
HNSC	cis	rs6479901	0.723	rs7088045	ENSG00000232075.1	MRPL35P2	-5.17	3.47e-07	0.000103	-0.29	-0.23	Intelligence (multi-trait analysis);	chr10:63319637	chr10:63634317~63634827:-
HNSC	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	5.17	3.47e-07	0.000103	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
HNSC	cis	rs6928977	0.832	rs2614286	ENSG00000231028.7	LINC00271	-5.17	3.47e-07	0.000103	-0.27	-0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371533	chr6:135497801~135716055:+
HNSC	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	5.17	3.47e-07	0.000103	0.25	0.23	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
HNSC	cis	rs6496044	0.568	rs2880764	ENSG00000259295.5	CSPG4P12	5.17	3.47e-07	0.000103	0.27	0.23	Interstitial lung disease;	chr15:85513177	chr15:85191438~85213905:+
HNSC	cis	rs6951245	0.832	rs10266519	ENSG00000225146.1	AC073957.15	-5.17	3.47e-07	0.000103	-0.36	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1029025~1043891:+
HNSC	cis	rs7048146	0.509	rs17730738	ENSG00000213539.4	YBX1P6	-5.17	3.47e-07	0.000103	-0.31	-0.23	Vascular brain injury;	chr9:109551618	chr9:109532830~109534332:-
HNSC	cis	rs6479891	0.722	rs4746951	ENSG00000232075.1	MRPL35P2	5.17	3.48e-07	0.000103	0.36	0.23	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63634317~63634827:-
HNSC	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-5.17	3.48e-07	0.000103	-0.21	-0.23	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
HNSC	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	5.17	3.48e-07	0.000103	0.25	0.23	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	5.17	3.48e-07	0.000103	0.25	0.23	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000254153.1	CTA-398F10.2	-5.17	3.48e-07	0.000103	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9041808	chr8:8456909~8461337:-
HNSC	cis	rs2243480	1	rs1964692	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:65989196	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:65996588	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1701750	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:66002158	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1723270	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:66004843	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1701758	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:66005214	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000179406.6	LINC00174	-5.17	3.48e-07	0.000103	-0.5	-0.23	Diabetic kidney disease;	chr7:66005945	chr7:66376044~66401338:-
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-5.17	3.49e-07	0.000103	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
HNSC	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-5.17	3.49e-07	0.000103	-0.22	-0.23	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
HNSC	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-5.17	3.49e-07	0.000103	-0.22	-0.23	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
HNSC	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	5.17	3.49e-07	0.000103	0.32	0.23	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
HNSC	cis	rs712039	0.652	rs853222	ENSG00000276054.1	RP11-378E13.3	5.17	3.49e-07	0.000103	0.34	0.23	Tuberculosis;	chr17:37429923	chr17:37386886~37387926:+
HNSC	cis	rs12701220	0.895	rs3808348	ENSG00000229043.2	AC091729.9	-5.17	3.49e-07	0.000103	-0.35	-0.23	Bronchopulmonary dysplasia;	chr7:988812	chr7:1160374~1165267:+
HNSC	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	5.17	3.49e-07	0.000103	0.24	0.23	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
HNSC	cis	rs10462794	0.661	rs12519041	ENSG00000260763.1	RP11-445O3.3	-5.17	3.5e-07	0.000103	-0.33	-0.23	DNA methylation (variation);	chr5:4519135	chr5:4436850~4440259:-
HNSC	cis	rs1008375	0.797	rs6843530	ENSG00000249502.1	AC006160.5	-5.17	3.5e-07	0.000103	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17591982	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.931	rs10008337	ENSG00000249502.1	AC006160.5	-5.17	3.5e-07	0.000103	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592226	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.898	rs61047804	ENSG00000249502.1	AC006160.5	-5.17	3.5e-07	0.000103	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592342	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.898	rs10008445	ENSG00000249502.1	AC006160.5	-5.17	3.5e-07	0.000103	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592355	chr4:17587467~17614571:-
HNSC	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	5.17	3.5e-07	0.000103	0.24	0.23	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
HNSC	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	5.17	3.5e-07	0.000103	0.27	0.23	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
HNSC	cis	rs2302464	1	rs16892272	ENSG00000214846.4	RP11-115L11.1	5.17	3.5e-07	0.000103	0.53	0.23	Cerebrospinal fluid biomarker levels;	chr4:15726456	chr4:15730962~15731627:-
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	5.17	3.5e-07	0.000103	0.26	0.23	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
HNSC	cis	rs9907295	0.681	rs9912284	ENSG00000270977.1	AC015849.16	-5.17	3.5e-07	0.000103	-0.35	-0.23	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35893707~35911023:-
HNSC	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-5.17	3.5e-07	0.000104	-0.24	-0.23	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-5.17	3.5e-07	0.000104	-0.24	-0.23	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
HNSC	cis	rs3806843	0.808	rs6893708	ENSG00000202515.1	VTRNA1-3	5.17	3.51e-07	0.000104	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr5:140726158~140726246:+
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	5.17	3.51e-07	0.000104	0.21	0.23	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
HNSC	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	5.17	3.51e-07	0.000104	0.25	0.23	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
HNSC	cis	rs2048656	0.535	rs2014514	ENSG00000254340.1	RP11-10A14.3	5.17	3.51e-07	0.000104	0.28	0.23	Schizophrenia;	chr8:9789686	chr8:9141424~9145435:+
HNSC	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	5.17	3.51e-07	0.000104	0.29	0.23	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
HNSC	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-5.17	3.51e-07	0.000104	-0.34	-0.23	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
HNSC	cis	rs6540731	1	rs4500383	ENSG00000226251.4	RP11-15I11.3	-5.17	3.52e-07	0.000104	-0.27	-0.23	Intelligence (childhood);	chr1:212218254	chr1:212225278~212238977:-
HNSC	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-5.17	3.52e-07	0.000104	-0.27	-0.23	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
HNSC	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	5.17	3.52e-07	0.000104	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	5.17	3.52e-07	0.000104	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
HNSC	cis	rs1167832	0.645	rs1167828	ENSG00000127957.15	PMS2P3	-5.17	3.52e-07	0.000104	-0.28	-0.23	Ankle injury;	chr7:75534076	chr7:75502930~75528148:-
HNSC	cis	rs2483058	0.515	rs3849275	ENSG00000261000.1	RP11-534L20.5	-5.17	3.52e-07	0.000104	-0.23	-0.23	Cholesterol and Triglycerides;	chr1:206432315	chr1:206503948~206504456:+
HNSC	cis	rs2235642	0.582	rs8051374	ENSG00000280231.1	LA16c-380F5.3	-5.17	3.53e-07	0.000104	-0.31	-0.23	Coronary artery disease;	chr16:1516283	chr16:1553655~1554130:-
HNSC	cis	rs12986445	0.738	rs7581255	ENSG00000218682.1	AC010150.1	5.17	3.53e-07	0.000104	0.32	0.23	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25825673	chr2:25856461~25856966:-
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-5.17	3.53e-07	0.000104	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	5.17	3.53e-07	0.000104	0.14	0.23	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
HNSC	cis	rs4218	0.689	rs28391430	ENSG00000277144.1	RP11-59H7.4	-5.17	3.53e-07	0.000104	-0.31	-0.23	Social communication problems;	chr15:59100318	chr15:59115547~59116089:-
HNSC	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-5.17	3.53e-07	0.000104	-0.26	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
HNSC	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	5.17	3.53e-07	0.000104	0.24	0.23	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
HNSC	cis	rs36093844	0.752	rs4296062	ENSG00000279742.1	RP11-700A24.1	-5.17	3.54e-07	0.000104	-0.35	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85818140	chr11:85852557~85854943:-
HNSC	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-5.17	3.54e-07	0.000104	-0.24	-0.23	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
HNSC	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	5.17	3.54e-07	0.000105	0.26	0.23	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
HNSC	cis	rs603446	0.967	rs3741300	ENSG00000254851.1	RP11-109L13.1	-5.17	3.54e-07	0.000105	-0.31	-0.23	Triglycerides;	chr11:116760974	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-5.17	3.54e-07	0.000105	-0.21	-0.23	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000229212.6	RP11-561C5.4	-5.17	3.54e-07	0.000105	-0.33	-0.23	Schizophrenia;	chr15:84262447	chr15:85205440~85234795:-
HNSC	cis	rs6723108	0.627	rs2166480	ENSG00000224043.6	CCNT2-AS1	5.17	3.54e-07	0.000105	0.28	0.23	Type 2 diabetes;	chr2:134879768	chr2:134735464~134918710:-
HNSC	cis	rs73198271	0.74	rs3827807	ENSG00000253893.2	FAM85B	5.17	3.54e-07	0.000105	0.32	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8167819~8226614:-
HNSC	cis	rs3806843	0.838	rs2563289	ENSG00000202515.1	VTRNA1-3	5.17	3.55e-07	0.000105	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr5:140726158~140726246:+
HNSC	cis	rs9840812	0.769	rs1279840	ENSG00000239213.4	NCK1-AS1	5.17	3.55e-07	0.000105	0.22	0.23	Fibrinogen levels;	chr3:136287734	chr3:136841726~136862054:-
HNSC	cis	rs3806843	0.657	rs2563283	ENSG00000202515.1	VTRNA1-3	5.17	3.56e-07	0.000105	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.771	rs2563336	ENSG00000202515.1	VTRNA1-3	5.17	3.56e-07	0.000105	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr5:140726158~140726246:+
HNSC	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-5.17	3.56e-07	0.000105	-0.18	-0.23	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000254153.1	CTA-398F10.2	5.17	3.56e-07	0.000105	0.26	0.23	Joint mobility (Beighton score);	chr8:9051726	chr8:8456909~8461337:-
HNSC	cis	rs1799949	0.602	rs8176199	ENSG00000267151.3	RP11-100E5.2	5.17	3.56e-07	0.000105	0.34	0.23	Menopause (age at onset);	chr17:43078507	chr17:43444707~43451200:+
HNSC	cis	rs7617773	1	rs9832957	ENSG00000228638.1	FCF1P2	5.17	3.56e-07	0.000105	0.22	0.23	Coronary artery disease;	chr3:48143776	chr3:48290793~48291375:-
HNSC	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	5.17	3.56e-07	0.000105	0.34	0.23	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
HNSC	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-5.17	3.56e-07	0.000105	-0.23	-0.23	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
HNSC	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	5.17	3.56e-07	0.000105	0.23	0.23	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
HNSC	cis	rs9402743	0.671	rs4896158	ENSG00000217482.2	HMGB1P17	5.17	3.56e-07	0.000105	0.26	0.23	Systemic lupus erythematosus;	chr6:135630087	chr6:135636086~135636713:-
HNSC	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-5.17	3.56e-07	0.000105	-0.42	-0.23	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
HNSC	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	5.17	3.57e-07	0.000105	0.27	0.23	Depression;	chr6:28142370	chr6:28170845~28172521:+
HNSC	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	5.17	3.57e-07	0.000105	0.26	0.23	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
HNSC	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-5.17	3.57e-07	0.000105	-0.25	-0.23	Height;	chr2:46611108	chr2:46668870~46670778:+
HNSC	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-5.16	3.57e-07	0.000105	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
HNSC	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	5.16	3.57e-07	0.000105	0.23	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
HNSC	cis	rs4388249	0.687	rs3797692	ENSG00000271849.1	CTC-332L22.1	-5.16	3.58e-07	0.000106	-0.31	-0.23	Schizophrenia;	chr5:109761985	chr5:109687802~109688329:-
HNSC	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	5.16	3.58e-07	0.000106	0.3	0.23	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
HNSC	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-5.16	3.58e-07	0.000106	-0.3	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
HNSC	cis	rs7829975	0.56	rs56094035	ENSG00000254340.1	RP11-10A14.3	-5.16	3.58e-07	0.000106	-0.3	-0.23	Mood instability;	chr8:8694112	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.539	rs4841012	ENSG00000254340.1	RP11-10A14.3	-5.16	3.58e-07	0.000106	-0.3	-0.23	Mood instability;	chr8:8694200	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.56	rs4841013	ENSG00000254340.1	RP11-10A14.3	-5.16	3.58e-07	0.000106	-0.3	-0.23	Mood instability;	chr8:8694503	chr8:9141424~9145435:+
HNSC	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-5.16	3.59e-07	0.000106	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
HNSC	cis	rs9840812	0.861	rs511154	ENSG00000273486.1	RP11-731C17.2	5.16	3.59e-07	0.000106	0.21	0.23	Fibrinogen levels;	chr3:136232079	chr3:136837338~136839021:-
HNSC	cis	rs853679	0.76	rs9393909	ENSG00000204709.4	LINC01556	-5.16	3.59e-07	0.000106	-0.35	-0.23	Depression;	chr6:28239422	chr6:28943877~28944537:+
HNSC	cis	rs6430553	0.964	rs10496731	ENSG00000224043.6	CCNT2-AS1	-5.16	3.59e-07	0.000106	-0.27	-0.23	Blood metabolite levels;	chr2:134840058	chr2:134735464~134918710:-
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	5.16	3.59e-07	0.000106	0.28	0.23	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
HNSC	cis	rs4853525	0.59	rs12619138	ENSG00000235852.1	AC005540.3	5.16	3.59e-07	0.000106	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865474	chr2:190880797~190882059:-
HNSC	cis	rs10256972	0.678	rs6962989	ENSG00000224079.1	AC091729.7	-5.16	3.6e-07	0.000106	-0.42	-0.23	Endometriosis;Longevity;	chr7:977876	chr7:1074450~1078036:+
HNSC	cis	rs36093844	0.752	rs56396016	ENSG00000279742.1	RP11-700A24.1	-5.16	3.6e-07	0.000106	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885347	chr11:85852557~85854943:-
HNSC	cis	rs287982	0.611	rs79276033	ENSG00000269973.1	RP11-95D17.1	-5.16	3.6e-07	0.000106	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9835868	chr2:9936360~9939590:+
HNSC	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-5.16	3.6e-07	0.000106	-0.28	-0.23	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
HNSC	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-5.16	3.6e-07	0.000106	-0.22	-0.23	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
HNSC	cis	rs11096990	0.793	rs9997050	ENSG00000249207.1	RP11-360F5.1	5.16	3.6e-07	0.000106	0.28	0.23	Cognitive function;	chr4:39301045	chr4:39112677~39126818:-
HNSC	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	5.16	3.6e-07	0.000106	0.39	0.23	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
HNSC	cis	rs180730	0.561	rs3115313	ENSG00000251609.2	SETP12	-5.16	3.61e-07	0.000106	-0.29	-0.23	Fasting plasma glucose;	chr4:120887708	chr4:120895494~120897083:-
HNSC	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	5.16	3.61e-07	0.000106	0.26	0.23	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
HNSC	cis	rs4140799	0.772	rs10133626	ENSG00000266869.1	RP6-114E22.1	5.16	3.61e-07	0.000106	0.28	0.23	Neuroticism;	chr14:71728889	chr14:71848606~71908430:+
HNSC	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	5.16	3.61e-07	0.000106	0.29	0.23	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
HNSC	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	5.16	3.61e-07	0.000107	0.28	0.23	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
HNSC	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-5.16	3.62e-07	0.000107	-0.28	-0.23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
HNSC	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	5.16	3.62e-07	0.000107	0.25	0.23	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000254153.1	CTA-398F10.2	-5.16	3.62e-07	0.000107	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9050721	chr8:8456909~8461337:-
HNSC	cis	rs287982	0.611	rs79083459	ENSG00000269973.1	RP11-95D17.1	-5.16	3.62e-07	0.000107	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9838286	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs112561492	ENSG00000269973.1	RP11-95D17.1	-5.16	3.62e-07	0.000107	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9838991	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs77359699	ENSG00000269973.1	RP11-95D17.1	-5.16	3.62e-07	0.000107	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9839170	chr2:9936360~9939590:+
HNSC	cis	rs6951245	0.572	rs79396675	ENSG00000225146.1	AC073957.15	-5.16	3.63e-07	0.000107	-0.48	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1015411	chr7:1029025~1043891:+
HNSC	cis	rs7083	0.716	rs574603	ENSG00000254851.1	RP11-109L13.1	5.16	3.63e-07	0.000107	0.31	0.23	Blood protein levels;	chr11:117307025	chr11:117135528~117138582:+
HNSC	cis	rs4218	0.531	rs10431791	ENSG00000277144.1	RP11-59H7.4	-5.16	3.63e-07	0.000107	-0.28	-0.23	Social communication problems;	chr15:59055159	chr15:59115547~59116089:-
HNSC	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	5.16	3.63e-07	0.000107	0.35	0.23	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
HNSC	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-5.16	3.63e-07	0.000107	-0.33	-0.23	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
HNSC	cis	rs72615157	0.716	rs75779608	ENSG00000078319.8	PMS2P1	-5.16	3.63e-07	0.000107	-0.3	-0.23	Lung function (FEV1/FVC);	chr7:100171334	chr7:100320992~100341908:-
HNSC	cis	rs2115630	0.846	rs8024538	ENSG00000229212.6	RP11-561C5.4	5.16	3.64e-07	0.000107	0.28	0.23	P wave terminal force;	chr15:84825188	chr15:85205440~85234795:-
HNSC	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	5.16	3.64e-07	0.000107	0.2	0.23	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
HNSC	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-5.16	3.64e-07	0.000107	-0.29	-0.23	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-5.16	3.64e-07	0.000107	-0.29	-0.23	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
HNSC	cis	rs3743266	0.613	rs8027901	ENSG00000245534.5	RORA-AS1	5.16	3.64e-07	0.000107	0.29	0.23	Menarche (age at onset);	chr15:60441265	chr15:60479178~60630637:+
HNSC	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-5.16	3.64e-07	0.000107	-0.2	-0.23	Height;	chr11:118809363	chr11:118791254~118793137:+
HNSC	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	5.16	3.64e-07	0.000107	0.25	0.23	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	5.16	3.64e-07	0.000107	0.28	0.23	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	5.16	3.64e-07	0.000107	0.28	0.23	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
HNSC	cis	rs2998286	0.822	rs2095901	ENSG00000254635.4	WAC-AS1	-5.16	3.64e-07	0.000107	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.862	rs2993990	ENSG00000254635.4	WAC-AS1	-5.16	3.64e-07	0.000107	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28522652~28532743:-
HNSC	cis	rs9329221	0.905	rs28712068	ENSG00000269918.1	AF131215.9	-5.16	3.65e-07	0.000107	-0.23	-0.23	Neuroticism;	chr8:10393635	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.897	rs2746431	ENSG00000231028.7	LINC00271	5.16	3.65e-07	0.000107	0.28	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366063	chr6:135497801~135716055:+
HNSC	cis	rs1218582	0.804	rs4845678	ENSG00000270361.1	RP11-307C12.13	-5.16	3.65e-07	0.000108	-0.25	-0.23	Prostate cancer;	chr1:154880819	chr1:154937370~154938059:+
HNSC	cis	rs8031584	1	rs35239376	ENSG00000260382.1	RP11-540B6.2	5.16	3.66e-07	0.000108	0.31	0.23	Huntington's disease progression;	chr15:30998335	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-5.16	3.66e-07	0.000108	-0.28	-0.23	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
HNSC	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-5.16	3.66e-07	0.000108	-0.28	-0.23	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-5.16	3.66e-07	0.000108	-0.28	-0.23	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
HNSC	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-5.16	3.66e-07	0.000108	-0.18	-0.23	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
HNSC	cis	rs6693567	0.565	rs1260398	ENSG00000228126.1	FALEC	-5.16	3.67e-07	0.000108	-0.28	-0.23	Migraine;	chr1:150307442	chr1:150515757~150518032:+
HNSC	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	5.16	3.67e-07	0.000108	0.27	0.23	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
HNSC	cis	rs2985684	0.846	rs4476096	ENSG00000278009.1	RP11-649E7.8	5.16	3.67e-07	0.000108	0.3	0.23	Carotid intima media thickness;	chr14:49552673	chr14:49601011~49601124:-
HNSC	cis	rs9291683	0.546	rs4529049	ENSG00000250413.1	RP11-448G15.1	-5.16	3.67e-07	0.000108	-0.29	-0.23	Bone mineral density;	chr4:10043765	chr4:10006482~10009725:+
HNSC	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	5.16	3.67e-07	0.000108	0.45	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
HNSC	cis	rs7789940	0.904	rs6953281	ENSG00000231087.2	FDPSP7	-5.16	3.67e-07	0.000108	-0.28	-0.23	Multiple sclerosis;	chr7:76317626	chr7:76968197~76969250:-
HNSC	cis	rs9890032	0.581	rs62070592	ENSG00000263531.1	RP13-753N3.1	5.16	3.68e-07	0.000108	0.28	0.23	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30863921~30864940:-
HNSC	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-5.16	3.68e-07	0.000108	-0.4	-0.23	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
HNSC	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-5.16	3.68e-07	0.000108	-0.22	-0.23	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
HNSC	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-5.16	3.68e-07	0.000108	-0.23	-0.23	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
HNSC	cis	rs2337406	1	rs7145172	ENSG00000254174.1	IGHV1-12	5.16	3.68e-07	0.000108	0.19	0.23	Alzheimer's disease (late onset);	chr14:106704924	chr14:106122420~106122709:-
HNSC	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-5.16	3.68e-07	0.000108	-0.22	-0.23	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
HNSC	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	5.16	3.69e-07	0.000108	0.25	0.23	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
HNSC	cis	rs6674176	0.597	rs3762422	ENSG00000237950.1	RP11-7O11.3	5.16	3.69e-07	0.000109	0.26	0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934860	chr1:43944370~43946551:-
HNSC	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-5.16	3.69e-07	0.000109	-0.23	-0.23	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
HNSC	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	5.16	3.69e-07	0.000109	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
HNSC	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	5.16	3.69e-07	0.000109	0.25	0.23	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
HNSC	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-5.16	3.69e-07	0.000109	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000254153.1	CTA-398F10.2	-5.16	3.7e-07	0.000109	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9050725	chr8:8456909~8461337:-
HNSC	cis	rs9527	0.637	rs7096169	ENSG00000236937.2	PTGES3P4	5.16	3.7e-07	0.000109	0.3	0.23	Arsenic metabolism;	chr10:102858938	chr10:102845595~102845950:+
HNSC	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	5.16	3.7e-07	0.000109	0.26	0.23	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
HNSC	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	5.16	3.7e-07	0.000109	0.35	0.23	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
HNSC	cis	rs603446	0.967	rs180370	ENSG00000254851.1	RP11-109L13.1	-5.16	3.71e-07	0.000109	-0.3	-0.23	Triglycerides;	chr11:116721649	chr11:117135528~117138582:+
HNSC	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	5.16	3.71e-07	0.000109	0.17	0.23	Breast size;	chr12:9219433	chr12:9277235~9313241:+
HNSC	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	5.16	3.71e-07	0.000109	0.17	0.23	Breast size;	chr12:9220266	chr12:9277235~9313241:+
HNSC	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-5.16	3.71e-07	0.000109	-0.23	-0.23	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	5.16	3.71e-07	0.000109	0.19	0.23	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
HNSC	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-5.16	3.71e-07	0.000109	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-5.16	3.71e-07	0.000109	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-5.16	3.71e-07	0.000109	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-5.16	3.71e-07	0.000109	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-5.16	3.71e-07	0.000109	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
HNSC	cis	rs4968361	1	rs4968361	ENSG00000266992.1	DHX40P1	5.16	3.71e-07	0.000109	0.39	0.23	Schizophrenia;	chr17:59425467	chr17:59976009~60002384:-
HNSC	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-5.16	3.71e-07	0.000109	-0.28	-0.23	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
HNSC	cis	rs1799949	0.965	rs6503727	ENSG00000236383.6	LINC00854	-5.16	3.71e-07	0.000109	-0.22	-0.23	Menopause (age at onset);	chr17:43160842	chr17:43216941~43305976:-
HNSC	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	5.16	3.72e-07	0.000109	0.32	0.23	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
HNSC	cis	rs9291683	0.53	rs73227883	ENSG00000250413.1	RP11-448G15.1	-5.16	3.72e-07	0.000109	-0.29	-0.23	Bone mineral density;	chr4:9977655	chr4:10006482~10009725:+
HNSC	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	5.16	3.72e-07	0.000109	0.28	0.23	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
HNSC	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.16	3.72e-07	0.000109	-0.44	-0.23	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000211974.3	IGHV2-70	-5.16	3.73e-07	0.00011	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106781123	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000211974.3	IGHV2-70	-5.16	3.73e-07	0.00011	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106781131	chr14:106723574~106724093:-
HNSC	cis	rs6693567	0.545	rs6664703	ENSG00000228126.1	FALEC	5.16	3.73e-07	0.00011	0.28	0.23	Migraine;	chr1:150486611	chr1:150515757~150518032:+
HNSC	cis	rs13217239	0.646	rs10946898	ENSG00000224843.5	LINC00240	-5.16	3.73e-07	0.00011	-0.23	-0.23	Schizophrenia;	chr6:27036105	chr6:26956992~27023924:+
HNSC	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	5.16	3.73e-07	0.00011	0.31	0.23	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
HNSC	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-5.16	3.73e-07	0.00011	-0.29	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
HNSC	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	5.16	3.73e-07	0.00011	0.24	0.23	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
HNSC	cis	rs9921338	0.961	rs6498185	ENSG00000263080.1	RP11-485G7.5	5.16	3.73e-07	0.00011	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11341809~11345211:-
HNSC	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	5.16	3.73e-07	0.00011	0.32	0.23	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000254153.1	CTA-398F10.2	5.16	3.74e-07	0.00011	0.24	0.23	Joint mobility (Beighton score);	chr8:9227785	chr8:8456909~8461337:-
HNSC	cis	rs3806843	0.9	rs2531341	ENSG00000202515.1	VTRNA1-3	5.16	3.74e-07	0.00011	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.9	rs2531340	ENSG00000202515.1	VTRNA1-3	5.16	3.74e-07	0.00011	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.868	rs2563281	ENSG00000202515.1	VTRNA1-3	5.16	3.74e-07	0.00011	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.9	rs2563280	ENSG00000202515.1	VTRNA1-3	5.16	3.74e-07	0.00011	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr5:140726158~140726246:+
HNSC	cis	rs6693567	0.565	rs12093148	ENSG00000228126.1	FALEC	-5.16	3.74e-07	0.00011	-0.28	-0.23	Migraine;	chr1:150292753	chr1:150515757~150518032:+
HNSC	cis	rs9450351	0.744	rs6900270	ENSG00000203875.9	SNHG5	-5.16	3.74e-07	0.00011	-0.5	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85504789	chr6:85660950~85678736:-
HNSC	cis	rs17428076	0.914	rs72889094	ENSG00000228389.1	AC068039.4	-5.16	3.74e-07	0.00011	-0.29	-0.23	Myopia;	chr2:171938249	chr2:171773482~171775844:+
HNSC	cis	rs9907295	1	rs9900563	ENSG00000270977.1	AC015849.16	-5.16	3.75e-07	0.00011	-0.31	-0.23	Fibroblast growth factor basic levels;	chr17:35908033	chr17:35893707~35911023:-
HNSC	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	5.16	3.75e-07	0.00011	0.28	0.23	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
HNSC	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-5.16	3.75e-07	0.00011	-0.17	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-5.16	3.75e-07	0.00011	-0.17	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
HNSC	cis	rs6964833	1	rs4717907	ENSG00000184616.8	AC004166.6	5.16	3.75e-07	0.00011	0.28	0.23	Menarche (age at onset);	chr7:74672169	chr7:74906673~74913256:-
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000233609.3	RP11-62H7.2	-5.15	3.75e-07	0.00011	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9015783	chr8:8961200~8979025:+
HNSC	cis	rs7809950	0.817	rs2253833	ENSG00000238832.1	snoU109	5.15	3.76e-07	0.00011	0.34	0.23	Coronary artery disease;	chr7:107565224	chr7:107603363~107603507:+
HNSC	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	5.15	3.76e-07	0.00011	0.41	0.23	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
HNSC	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-5.15	3.76e-07	0.00011	-0.27	-0.23	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
HNSC	cis	rs490608	0.608	rs11264360	ENSG00000203761.5	MSTO2P	-5.15	3.76e-07	0.00011	-0.19	-0.23	Inflammatory bowel disease;	chr1:155314795	chr1:155745829~155750137:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000254174.1	IGHV1-12	5.15	3.76e-07	0.00011	0.2	0.23	Alzheimer's disease (late onset);	chr14:106706790	chr14:106122420~106122709:-
HNSC	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	5.15	3.76e-07	0.00011	0.32	0.23	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	5.15	3.76e-07	0.00011	0.24	0.23	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	5.15	3.76e-07	0.00011	0.24	0.23	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	5.15	3.76e-07	0.00011	0.24	0.23	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	5.15	3.76e-07	0.00011	0.24	0.23	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	5.15	3.76e-07	0.00011	0.21	0.23	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
HNSC	cis	rs6061231	0.544	rs2427314	ENSG00000275437.1	RP5-908M14.10	5.15	3.77e-07	0.000111	0.23	0.23	Colorectal cancer;	chr20:62398610	chr20:62402236~62405935:-
HNSC	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-5.15	3.77e-07	0.000111	-0.36	-0.23	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
HNSC	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	5.15	3.77e-07	0.000111	0.33	0.23	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
HNSC	cis	rs6964833	0.935	rs35735900	ENSG00000184616.8	AC004166.6	5.15	3.78e-07	0.000111	0.29	0.23	Menarche (age at onset);	chr7:74651887	chr7:74906673~74913256:-
HNSC	cis	rs17428076	0.709	rs55791993	ENSG00000228389.1	AC068039.4	-5.15	3.78e-07	0.000111	-0.28	-0.23	Myopia;	chr2:172046984	chr2:171773482~171775844:+
HNSC	cis	rs202072	0.818	rs405078	ENSG00000215022.6	RP1-257A7.4	-5.15	3.78e-07	0.000111	-0.32	-0.23	HIV-1 viral setpoint;	chr6:13279635	chr6:13264861~13295586:-
HNSC	cis	rs9813712	0.953	rs12635811	ENSG00000249846.5	RP11-77P16.4	-5.15	3.78e-07	0.000111	-0.28	-0.23	Response to amphetamines;	chr3:130262534	chr3:130112550~130120579:+
HNSC	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	5.15	3.79e-07	0.000111	0.28	0.23	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
HNSC	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	5.15	3.79e-07	0.000111	0.26	0.23	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	5.15	3.79e-07	0.000111	0.26	0.23	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
HNSC	cis	rs17428076	0.918	rs55864623	ENSG00000228389.1	AC068039.4	-5.15	3.79e-07	0.000111	-0.29	-0.23	Myopia;	chr2:171892180	chr2:171773482~171775844:+
HNSC	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-5.15	3.79e-07	0.000111	-0.4	-0.23	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
HNSC	cis	rs988913	0.706	rs1155749	ENSG00000224984.1	RP11-524H19.2	5.15	3.79e-07	0.000111	0.27	0.23	Menarche (age at onset);	chr6:54865585	chr6:54840118~54840855:-
HNSC	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	5.15	3.8e-07	0.000111	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
HNSC	cis	rs2058059	0.636	rs3015906	ENSG00000225648.4	SBDSP1	-5.15	3.8e-07	0.000112	-0.32	-0.23	Subcutaneous adipose tissue;	chr7:72670552	chr7:72829425~72836701:+
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	5.15	3.8e-07	0.000112	0.28	0.23	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	5.15	3.8e-07	0.000112	0.28	0.23	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	5.15	3.8e-07	0.000112	0.28	0.23	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	5.15	3.81e-07	0.000112	0.28	0.23	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
HNSC	cis	rs8054556	1	rs4788204	ENSG00000183604.13	SMG1P5	-5.15	3.81e-07	0.000112	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30267553~30335374:-
HNSC	cis	rs603446	0.935	rs180376	ENSG00000254851.1	RP11-109L13.1	-5.15	3.81e-07	0.000112	-0.3	-0.23	Triglycerides;	chr11:116719323	chr11:117135528~117138582:+
HNSC	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-5.15	3.81e-07	0.000112	-0.23	-0.23	Height;	chr5:36997725	chr5:36666214~36725195:-
HNSC	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	5.15	3.81e-07	0.000112	0.21	0.23	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
HNSC	cis	rs8054556	1	rs4788195	ENSG00000183604.13	SMG1P5	-5.15	3.81e-07	0.000112	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:30267553~30335374:-
HNSC	cis	rs9402743	0.671	rs9399151	ENSG00000234084.1	RP3-388E23.2	-5.15	3.81e-07	0.000112	-0.24	-0.23	Systemic lupus erythematosus;	chr6:135617920	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs9376116	ENSG00000234084.1	RP3-388E23.2	-5.15	3.81e-07	0.000112	-0.24	-0.23	Systemic lupus erythematosus;	chr6:135618763	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs4896157	ENSG00000234084.1	RP3-388E23.2	-5.15	3.81e-07	0.000112	-0.24	-0.23	Systemic lupus erythematosus;	chr6:135620981	chr6:135301568~135307158:+
HNSC	cis	rs3733585	0.638	rs6414766	ENSG00000250413.1	RP11-448G15.1	5.15	3.81e-07	0.000112	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954850	chr4:10006482~10009725:+
HNSC	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	5.15	3.81e-07	0.000112	0.17	0.23	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
HNSC	cis	rs8054556	0.967	rs9932702	ENSG00000183604.13	SMG1P5	-5.15	3.82e-07	0.000112	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29971640	chr16:30267553~30335374:-
HNSC	cis	rs8054556	1	rs9925102	ENSG00000183604.13	SMG1P5	-5.15	3.82e-07	0.000112	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29971827	chr16:30267553~30335374:-
HNSC	cis	rs2985684	0.841	rs7158577	ENSG00000278009.1	RP11-649E7.8	5.15	3.82e-07	0.000112	0.3	0.23	Carotid intima media thickness;	chr14:49591915	chr14:49601011~49601124:-
HNSC	cis	rs36093844	0.8	rs1445504	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873836	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs1445503	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873968	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.698	rs79435802	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874163	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs79814326	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874530	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs75334800	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875538	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs77497327	ENSG00000279742.1	RP11-700A24.1	-5.15	3.82e-07	0.000112	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875898	chr11:85852557~85854943:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000233609.3	RP11-62H7.2	5.15	3.82e-07	0.000112	0.22	0.23	Joint mobility (Beighton score);	chr8:9005011	chr8:8961200~8979025:+
HNSC	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	5.15	3.82e-07	0.000112	0.25	0.23	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
HNSC	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	5.15	3.82e-07	0.000112	0.35	0.23	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
HNSC	cis	rs7615952	0.512	rs2979351	ENSG00000248787.1	RP11-666A20.4	-5.15	3.83e-07	0.000112	-0.3	-0.23	Blood pressure (smoking interaction);	chr3:125644755	chr3:125908005~125910272:-
HNSC	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-5.15	3.83e-07	0.000112	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
HNSC	cis	rs9840812	0.769	rs1279425	ENSG00000273486.1	RP11-731C17.2	5.15	3.84e-07	0.000112	0.2	0.23	Fibrinogen levels;	chr3:136288142	chr3:136837338~136839021:-
HNSC	cis	rs9611519	0.78	rs2235852	ENSG00000235513.1	RP4-756G23.5	5.15	3.84e-07	0.000112	0.24	0.23	Neuroticism;	chr22:41265150	chr22:41209122~41217627:-
HNSC	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-5.15	3.84e-07	0.000113	-0.23	-0.23	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
HNSC	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	5.15	3.84e-07	0.000113	0.28	0.23	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5.15	3.85e-07	0.000113	0.26	0.23	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
HNSC	cis	rs6723108	0.627	rs4954197	ENSG00000224043.6	CCNT2-AS1	-5.15	3.85e-07	0.000113	-0.28	-0.23	Type 2 diabetes;	chr2:134904674	chr2:134735464~134918710:-
HNSC	cis	rs287982	0.611	rs7568330	ENSG00000269973.1	RP11-95D17.1	-5.15	3.86e-07	0.000113	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9835428	chr2:9936360~9939590:+
HNSC	cis	rs2322633	0.515	rs1892474	ENSG00000272129.1	RP11-250B2.6	5.15	3.86e-07	0.000113	0.29	0.23	Height;	chr6:80152632	chr6:80355424~80356859:+
HNSC	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-5.15	3.86e-07	0.000113	-0.3	-0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
HNSC	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-5.15	3.86e-07	0.000113	-0.21	-0.23	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
HNSC	cis	rs925255	0.678	rs6547853	ENSG00000270210.1	RP11-373D23.3	5.15	3.86e-07	0.000113	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28423934	chr2:28425945~28426719:+
HNSC	cis	rs9907295	0.748	rs4251769	ENSG00000270977.1	AC015849.16	-5.15	3.86e-07	0.000113	-0.31	-0.23	Fibroblast growth factor basic levels;	chr17:35837523	chr17:35893707~35911023:-
HNSC	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	5.15	3.86e-07	0.000113	0.24	0.23	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
HNSC	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-5.15	3.86e-07	0.000113	-0.28	-0.23	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
HNSC	cis	rs17428076	0.681	rs788163	ENSG00000228389.1	AC068039.4	-5.15	3.86e-07	0.000113	-0.28	-0.23	Myopia;	chr2:172066831	chr2:171773482~171775844:+
HNSC	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	5.15	3.87e-07	0.000113	0.31	0.23	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
HNSC	cis	rs9840812	0.655	rs696516	ENSG00000239213.4	NCK1-AS1	5.15	3.87e-07	0.000113	0.21	0.23	Fibrinogen levels;	chr3:136348936	chr3:136841726~136862054:-
HNSC	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	5.15	3.87e-07	0.000113	0.35	0.23	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
HNSC	cis	rs860295	0.65	rs12024880	ENSG00000203761.5	MSTO2P	5.15	3.87e-07	0.000113	0.17	0.23	Body mass index;	chr1:155939119	chr1:155745829~155750137:+
HNSC	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-5.15	3.87e-07	0.000113	-0.27	-0.23	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
HNSC	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-5.15	3.87e-07	0.000113	-0.32	-0.23	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
HNSC	cis	rs6430553	0.929	rs1348792	ENSG00000224043.6	CCNT2-AS1	-5.15	3.87e-07	0.000113	-0.27	-0.23	Blood metabolite levels;	chr2:134903288	chr2:134735464~134918710:-
HNSC	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.15	3.88e-07	0.000114	-0.26	-0.23	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
HNSC	cis	rs950169	0.922	rs11635505	ENSG00000229212.6	RP11-561C5.4	5.15	3.88e-07	0.000114	0.32	0.23	Schizophrenia;	chr15:84553803	chr15:85205440~85234795:-
HNSC	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	5.15	3.89e-07	0.000114	0.22	0.23	Height;	chr5:36789552	chr5:36666214~36725195:-
HNSC	cis	rs3805389	0.504	rs10026315	ENSG00000273257.1	RP11-177J6.1	-5.15	3.89e-07	0.000114	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55387949~55388271:+
HNSC	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	5.15	3.89e-07	0.000114	0.2	0.23	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
HNSC	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	5.15	3.89e-07	0.000114	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	5.15	3.89e-07	0.000114	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	5.15	3.89e-07	0.000114	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
HNSC	cis	rs3806843	0.9	rs2563286	ENSG00000202515.1	VTRNA1-3	5.15	3.9e-07	0.000114	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr5:140726158~140726246:+
HNSC	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-5.15	3.9e-07	0.000114	-0.21	-0.23	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
HNSC	cis	rs728616	0.614	rs958865	ENSG00000225484.5	NUTM2B-AS1	-5.15	3.9e-07	0.000114	-0.41	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79663088~79826594:-
HNSC	cis	rs4852324	0.536	rs13390332	ENSG00000217702.2	RP11-287D1.4	5.15	3.9e-07	0.000114	0.54	0.23	Systemic lupus erythematosus;	chr2:73980230	chr2:74130583~74135395:+
HNSC	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-5.15	3.9e-07	0.000114	-0.33	-0.23	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
HNSC	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	5.15	3.9e-07	0.000114	0.31	0.23	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
HNSC	cis	rs947583	0.588	rs12211505	ENSG00000217482.2	HMGB1P17	5.15	3.9e-07	0.000114	0.26	0.23	Phosphorus levels;	chr6:135753683	chr6:135636086~135636713:-
HNSC	cis	rs9863	0.827	rs7305864	ENSG00000269938.1	RP11-214K3.20	-5.15	3.9e-07	0.000114	-0.27	-0.23	White blood cell count;	chr12:123957333	chr12:123968023~123968579:-
HNSC	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-5.15	3.91e-07	0.000114	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
HNSC	cis	rs6674176	0.597	rs12127737	ENSG00000237950.1	RP11-7O11.3	5.15	3.91e-07	0.000114	0.26	0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43936893	chr1:43944370~43946551:-
HNSC	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	5.15	3.91e-07	0.000114	0.32	0.23	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	5.15	3.91e-07	0.000114	0.32	0.23	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
HNSC	cis	rs752590	0.806	rs4849174	ENSG00000274877.1	RP11-65I12.1	-5.15	3.91e-07	0.000114	-0.33	-0.23	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113237595~113240825:+
HNSC	cis	rs36093844	0.8	rs17817331	ENSG00000279742.1	RP11-700A24.1	5.15	3.92e-07	0.000115	0.33	0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884295	chr11:85852557~85854943:-
HNSC	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-5.15	3.92e-07	0.000115	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
HNSC	cis	rs17214007	0.778	rs17213271	ENSG00000263335.1	AF001548.5	-5.15	3.93e-07	0.000115	-0.37	-0.23	Cognitive function;	chr16:15770487	chr16:15726674~15732993:+
HNSC	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-5.15	3.93e-07	0.000115	-0.23	-0.23	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
HNSC	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	5.15	3.93e-07	0.000115	0.29	0.23	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
HNSC	cis	rs2439831	0.867	rs2412778	ENSG00000205771.5	CATSPER2P1	-5.15	3.94e-07	0.000115	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43368784	chr15:43726918~43747094:-
HNSC	cis	rs4927850	1	rs7627868	ENSG00000273009.1	RP11-352G9.1	-5.15	3.94e-07	0.000115	-0.27	-0.23	Pancreatic cancer;	chr3:196026602	chr3:195913078~195913683:-
HNSC	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	5.15	3.94e-07	0.000115	0.33	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
HNSC	cis	rs6693567	0.516	rs519126	ENSG00000228126.1	FALEC	-5.15	3.94e-07	0.000115	-0.28	-0.23	Migraine;	chr1:150316418	chr1:150515757~150518032:+
HNSC	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-5.15	3.94e-07	0.000115	-0.37	-0.23	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
HNSC	cis	rs2115630	0.764	rs11073716	ENSG00000229212.6	RP11-561C5.4	5.14	3.95e-07	0.000115	0.28	0.23	P wave terminal force;	chr15:84792543	chr15:85205440~85234795:-
HNSC	cis	rs6928977	0.514	rs2757635	ENSG00000234084.1	RP3-388E23.2	5.14	3.95e-07	0.000116	0.23	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135301568~135307158:+
HNSC	cis	rs8012947	0.565	rs12891852	ENSG00000279636.2	LINC00216	-5.14	3.95e-07	0.000116	-0.27	-0.23	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58288033~58289158:+
HNSC	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-5.14	3.95e-07	0.000116	-0.28	-0.23	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
HNSC	cis	rs2985684	0.948	rs2883437	ENSG00000278009.1	RP11-649E7.8	5.14	3.95e-07	0.000116	0.3	0.23	Carotid intima media thickness;	chr14:49564948	chr14:49601011~49601124:-
HNSC	cis	rs17772222	0.74	rs7160647	ENSG00000258789.1	RP11-507K2.3	-5.14	3.95e-07	0.000116	-0.26	-0.23	Coronary artery calcification;	chr14:88507340	chr14:88551597~88552493:+
HNSC	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.14	3.95e-07	0.000116	0.2	0.23	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
HNSC	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	5.14	3.96e-07	0.000116	0.29	0.23	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
HNSC	cis	rs17428076	0.749	rs788161	ENSG00000228389.1	AC068039.4	-5.14	3.96e-07	0.000116	-0.28	-0.23	Myopia;	chr2:172061943	chr2:171773482~171775844:+
HNSC	cis	rs860295	0.65	rs4661151	ENSG00000203761.5	MSTO2P	5.14	3.96e-07	0.000116	0.17	0.23	Body mass index;	chr1:155933617	chr1:155745829~155750137:+
HNSC	cis	rs7804306	1	rs35009545	ENSG00000233264.2	AC006042.8	5.14	3.96e-07	0.000116	0.46	0.23	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037223	chr7:7980312~7982228:+
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000173295.6	FAM86B3P	5.14	3.96e-07	0.000116	0.27	0.23	Joint mobility (Beighton score);	chr8:9003920	chr8:8228595~8244865:+
HNSC	cis	rs7048146	0.531	rs12555476	ENSG00000213539.4	YBX1P6	5.14	3.96e-07	0.000116	0.31	0.23	Vascular brain injury;	chr9:109521837	chr9:109532830~109534332:-
HNSC	cis	rs4938303	0.587	rs10892017	ENSG00000254851.1	RP11-109L13.1	5.14	3.97e-07	0.000116	0.34	0.23	Triglycerides;	chr11:116697165	chr11:117135528~117138582:+
HNSC	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-5.14	3.97e-07	0.000116	-0.26	-0.23	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
HNSC	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-5.14	3.97e-07	0.000116	-0.3	-0.23	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
HNSC	cis	rs10462794	0.661	rs16873563	ENSG00000260763.1	RP11-445O3.3	-5.14	3.97e-07	0.000116	-0.34	-0.23	DNA methylation (variation);	chr5:4521716	chr5:4436850~4440259:-
HNSC	cis	rs4657482	0.962	rs4657483	ENSG00000236364.3	RP11-525G13.2	-5.14	3.98e-07	0.000116	-0.22	-0.23	Testicular germ cell tumor;	chr1:165864880	chr1:165890795~165900683:-
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000233609.3	RP11-62H7.2	-5.14	3.98e-07	0.000116	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9012868	chr8:8961200~8979025:+
HNSC	cis	rs4141404	0.512	rs1018490	ENSG00000236132.1	CTA-440B3.1	-5.14	3.98e-07	0.000116	-0.27	-0.23	Paclitaxel-induced neuropathy;	chr22:31600639	chr22:31816379~31817491:-
HNSC	cis	rs853679	0.723	rs1736904	ENSG00000204709.4	LINC01556	5.14	3.98e-07	0.000116	0.3	0.23	Depression;	chr6:28251492	chr6:28943877~28944537:+
HNSC	cis	rs36423	0.668	rs28347	ENSG00000266869.1	RP6-114E22.1	-5.14	3.99e-07	0.000116	-0.39	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71908561	chr14:71848606~71908430:+
HNSC	cis	rs9813712	0.953	rs6804874	ENSG00000249846.5	RP11-77P16.4	5.14	3.99e-07	0.000116	0.28	0.23	Response to amphetamines;	chr3:130257205	chr3:130112550~130120579:+
HNSC	cis	rs2921036	0.545	rs4840975	ENSG00000173295.6	FAM86B3P	-5.14	3.99e-07	0.000116	-0.27	-0.23	Neuroticism;	chr8:8505748	chr8:8228595~8244865:+
HNSC	cis	rs4388249	0.687	rs2416217	ENSG00000271849.1	CTC-332L22.1	-5.14	3.99e-07	0.000117	-0.32	-0.23	Schizophrenia;	chr5:109736510	chr5:109687802~109688329:-
HNSC	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	5.14	4e-07	0.000117	0.32	0.23	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
HNSC	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	5.14	4e-07	0.000117	0.28	0.23	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
HNSC	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	5.14	4e-07	0.000117	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
HNSC	cis	rs9840812	0.769	rs534944	ENSG00000239213.4	NCK1-AS1	5.14	4e-07	0.000117	0.22	0.23	Fibrinogen levels;	chr3:136242189	chr3:136841726~136862054:-
HNSC	cis	rs13113518	1	rs4864993	ENSG00000273257.1	RP11-177J6.1	5.14	4e-07	0.000117	0.28	0.23	Height;	chr4:55450662	chr4:55387949~55388271:+
HNSC	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-5.14	4.01e-07	0.000117	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
HNSC	cis	rs2933343	0.7	rs1683779	ENSG00000261159.1	RP11-723O4.9	5.14	4.01e-07	0.000117	0.24	0.23	IgG glycosylation;	chr3:128923205	chr3:128859716~128860526:-
HNSC	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-5.14	4.01e-07	0.000117	-0.21	-0.23	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
HNSC	cis	rs17507216	0.588	rs4778687	ENSG00000255769.6	GOLGA2P10	-5.14	4.01e-07	0.000117	-0.36	-0.23	Excessive daytime sleepiness;	chr15:82649085	chr15:82472993~82513950:-
HNSC	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-5.14	4.01e-07	0.000117	-0.26	-0.23	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000179406.6	LINC00174	-5.14	4.01e-07	0.000117	-0.5	-0.23	Diabetic kidney disease;	chr7:65918494	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs56291018	ENSG00000179406.6	LINC00174	-5.14	4.01e-07	0.000117	-0.5	-0.23	Diabetic kidney disease;	chr7:65925352	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs36033484	ENSG00000179406.6	LINC00174	-5.14	4.01e-07	0.000117	-0.5	-0.23	Diabetic kidney disease;	chr7:65925571	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34193460	ENSG00000179406.6	LINC00174	-5.14	4.01e-07	0.000117	-0.5	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66376044~66401338:-
HNSC	cis	rs36423	0.748	rs36408	ENSG00000266869.1	RP6-114E22.1	-5.14	4.01e-07	0.000117	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71890558	chr14:71848606~71908430:+
HNSC	cis	rs9840812	0.623	rs1145106	ENSG00000239213.4	NCK1-AS1	5.14	4.02e-07	0.000117	0.21	0.23	Fibrinogen levels;	chr3:136393075	chr3:136841726~136862054:-
HNSC	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	5.14	4.02e-07	0.000117	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000179406.6	LINC00174	-5.14	4.02e-07	0.000117	-0.5	-0.23	Diabetic kidney disease;	chr7:65985932	chr7:66376044~66401338:-
HNSC	cis	rs35306767	0.953	rs11253520	ENSG00000229869.1	RP11-363N22.2	5.14	4.02e-07	0.000117	0.27	0.23	Eosinophil percentage of granulocytes;	chr10:930021	chr10:933026~942743:+
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000223648.3	IGHV3-64	5.14	4.02e-07	0.000117	0.19	0.23	Kawasaki disease;	chr14:106716897	chr14:106643132~106658258:-
HNSC	cis	rs9368481	0.761	rs9379952	ENSG00000224843.5	LINC00240	5.14	4.02e-07	0.000117	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26956992~27023924:+
HNSC	cis	rs1056107	0.931	rs6477903	ENSG00000225513.1	RP11-165N19.2	-5.14	4.02e-07	0.000117	-0.25	-0.23	Colorectal cancer;	chr9:112254581	chr9:112173522~112173971:-
HNSC	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-5.14	4.03e-07	0.000117	-0.24	-0.23	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
HNSC	cis	rs947583	0.588	rs12204523	ENSG00000217482.2	HMGB1P17	5.14	4.03e-07	0.000118	0.26	0.23	Phosphorus levels;	chr6:135753856	chr6:135636086~135636713:-
HNSC	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-5.14	4.03e-07	0.000118	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
HNSC	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-5.14	4.04e-07	0.000118	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
HNSC	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-5.14	4.04e-07	0.000118	-0.29	-0.23	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-5.14	4.04e-07	0.000118	-0.29	-0.23	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
HNSC	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-5.14	4.05e-07	0.000118	-0.37	-0.23	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
HNSC	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-5.14	4.05e-07	0.000118	-0.32	-0.23	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
HNSC	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-5.14	4.05e-07	0.000118	-0.28	-0.23	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
HNSC	cis	rs17270561	0.579	rs10456326	ENSG00000272810.1	U91328.22	-5.14	4.05e-07	0.000118	-0.26	-0.23	Iron status biomarkers;	chr6:25919434	chr6:26013241~26013757:+
HNSC	cis	rs12216125	0.537	rs12207059	ENSG00000272810.1	U91328.22	-5.14	4.05e-07	0.000118	-0.26	-0.23	Iron status biomarkers;	chr6:25922157	chr6:26013241~26013757:+
HNSC	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-5.14	4.05e-07	0.000118	-0.27	-0.23	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
HNSC	cis	rs6674176	0.66	rs6680421	ENSG00000237950.1	RP11-7O11.3	-5.14	4.05e-07	0.000118	-0.27	-0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43943297	chr1:43944370~43946551:-
HNSC	cis	rs1012068	0.695	rs5998152	ENSG00000236132.1	CTA-440B3.1	-5.14	4.05e-07	0.000118	-0.28	-0.23	Chronic hepatitis C infection;	chr22:31867176	chr22:31816379~31817491:-
HNSC	cis	rs9329221	0.905	rs17765901	ENSG00000269918.1	AF131215.9	-5.14	4.06e-07	0.000118	-0.23	-0.23	Neuroticism;	chr8:10391970	chr8:11104691~11106704:-
HNSC	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	5.14	4.06e-07	0.000118	0.21	0.23	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
HNSC	cis	rs1056107	0.931	rs7847972	ENSG00000225513.1	RP11-165N19.2	5.14	4.06e-07	0.000118	0.25	0.23	Colorectal cancer;	chr9:112214590	chr9:112173522~112173971:-
HNSC	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-5.14	4.06e-07	0.000118	-0.37	-0.23	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
HNSC	cis	rs1707322	1	rs12097761	ENSG00000234329.1	RP11-767N6.2	5.14	4.07e-07	0.000119	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45651039~45651826:-
HNSC	cis	rs1218582	0.804	rs4845398	ENSG00000270361.1	RP11-307C12.13	-5.14	4.07e-07	0.000119	-0.25	-0.23	Prostate cancer;	chr1:154886562	chr1:154937370~154938059:+
HNSC	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	5.14	4.07e-07	0.000119	0.25	0.23	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
HNSC	cis	rs2243480	1	rs3885839	ENSG00000179406.6	LINC00174	-5.14	4.07e-07	0.000119	-0.5	-0.23	Diabetic kidney disease;	chr7:65825416	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs3813708	ENSG00000179406.6	LINC00174	-5.14	4.07e-07	0.000119	-0.5	-0.23	Diabetic kidney disease;	chr7:65840645	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs73142122	ENSG00000179406.6	LINC00174	-5.14	4.07e-07	0.000119	-0.5	-0.23	Diabetic kidney disease;	chr7:65846311	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs73142137	ENSG00000179406.6	LINC00174	-5.14	4.07e-07	0.000119	-0.5	-0.23	Diabetic kidney disease;	chr7:65878455	chr7:66376044~66401338:-
HNSC	cis	rs11773103	0.881	rs56378450	ENSG00000224046.1	AC005076.5	5.14	4.07e-07	0.000119	0.46	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87122585	chr7:87151423~87152420:-
HNSC	cis	rs9863	0.898	rs7301953	ENSG00000269938.1	RP11-214K3.20	-5.14	4.08e-07	0.000119	-0.29	-0.23	White blood cell count;	chr12:123921324	chr12:123968023~123968579:-
HNSC	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-5.14	4.08e-07	0.000119	-0.29	-0.23	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-5.14	4.08e-07	0.000119	-0.29	-0.23	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
HNSC	cis	rs2933343	0.7	rs1680788	ENSG00000261159.1	RP11-723O4.9	5.14	4.08e-07	0.000119	0.23	0.23	IgG glycosylation;	chr3:128906475	chr3:128859716~128860526:-
HNSC	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	5.14	4.09e-07	0.000119	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
HNSC	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-5.14	4.09e-07	0.000119	-0.29	-0.23	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
HNSC	cis	rs3736485	0.868	rs9744054	ENSG00000259438.1	CTD-2650P22.1	5.14	4.09e-07	0.000119	0.23	0.23	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51640966	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.932	rs2899477	ENSG00000259438.1	CTD-2650P22.1	5.14	4.09e-07	0.000119	0.23	0.23	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51645504	chr15:52010999~52019095:-
HNSC	cis	rs9287719	0.624	rs6740245	ENSG00000243819.4	RN7SL832P	5.14	4.09e-07	0.000119	0.23	0.23	Prostate cancer;	chr2:10620776	chr2:10690344~10692099:+
HNSC	cis	rs9921338	0.961	rs9936093	ENSG00000263080.1	RP11-485G7.5	5.14	4.09e-07	0.000119	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11341809~11345211:-
HNSC	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-5.14	4.09e-07	0.000119	-0.51	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
HNSC	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-5.14	4.09e-07	0.000119	-0.51	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
HNSC	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-5.14	4.09e-07	0.000119	-0.27	-0.23	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-5.14	4.09e-07	0.000119	-0.27	-0.23	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-5.14	4.09e-07	0.000119	-0.27	-0.23	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
HNSC	cis	rs10462794	0.661	rs62343555	ENSG00000260763.1	RP11-445O3.3	-5.14	4.1e-07	0.000119	-0.34	-0.23	DNA methylation (variation);	chr5:4522357	chr5:4436850~4440259:-
HNSC	cis	rs1707322	1	rs6672115	ENSG00000234329.1	RP11-767N6.2	5.14	4.1e-07	0.000119	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45651039~45651826:-
HNSC	cis	rs2933343	0.7	rs2624910	ENSG00000261159.1	RP11-723O4.9	5.14	4.11e-07	0.00012	0.23	0.23	IgG glycosylation;	chr3:128931432	chr3:128859716~128860526:-
HNSC	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-5.14	4.11e-07	0.00012	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
HNSC	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	5.14	4.11e-07	0.00012	0.29	0.23	Depression;	chr6:28110525	chr6:28161781~28169594:+
HNSC	cis	rs8059260	0.541	rs34361212	ENSG00000274038.1	RP11-66H6.4	-5.14	4.11e-07	0.00012	-0.44	-0.23	Alcohol consumption over the past year;	chr16:11145832	chr16:11056556~11057034:+
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-5.14	4.12e-07	0.00012	-0.15	-0.23	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
HNSC	cis	rs9907295	1	rs9908525	ENSG00000270977.1	AC015849.16	-5.14	4.13e-07	0.00012	-0.36	-0.23	Fibroblast growth factor basic levels;	chr17:35908605	chr17:35893707~35911023:-
HNSC	cis	rs2985684	0.74	rs2883438	ENSG00000278009.1	RP11-649E7.8	5.14	4.13e-07	0.00012	0.3	0.23	Carotid intima media thickness;	chr14:49577674	chr14:49601011~49601124:-
HNSC	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	5.14	4.13e-07	0.00012	0.22	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
HNSC	cis	rs9329221	0.905	rs28507213	ENSG00000269918.1	AF131215.9	-5.14	4.14e-07	0.00012	-0.23	-0.23	Neuroticism;	chr8:10393339	chr8:11104691~11106704:-
HNSC	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-5.14	4.14e-07	0.00012	-0.22	-0.23	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
HNSC	cis	rs10504130	0.502	rs71513552	ENSG00000272024.1	RP11-546K22.3	-5.14	4.14e-07	0.00012	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs34073804	ENSG00000272024.1	RP11-546K22.3	-5.14	4.14e-07	0.00012	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs34319820	ENSG00000272024.1	RP11-546K22.3	-5.14	4.14e-07	0.00012	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51950284~51950690:+
HNSC	cis	rs11247915	0.622	rs4072445	ENSG00000236782.4	RP11-96L14.7	-5.14	4.14e-07	0.00012	-0.27	-0.23	Obesity-related traits;	chr1:26337728	chr1:26169947~26171821:-
HNSC	cis	rs7115242	0.702	rs672058	ENSG00000280143.1	AP000892.6	5.14	4.14e-07	0.000121	0.33	0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117204967~117210292:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-5.14	4.14e-07	0.000121	-0.21	-0.23	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
HNSC	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-5.14	4.15e-07	0.000121	-0.27	-0.23	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
HNSC	cis	rs36093844	0.8	rs79276445	ENSG00000279742.1	RP11-700A24.1	-5.14	4.15e-07	0.000121	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85876784	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.8	rs78681528	ENSG00000279742.1	RP11-700A24.1	-5.14	4.15e-07	0.000121	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85877113	chr11:85852557~85854943:-
HNSC	cis	rs860295	0.702	rs12039893	ENSG00000203761.5	MSTO2P	-5.13	4.15e-07	0.000121	-0.18	-0.23	Body mass index;	chr1:155645024	chr1:155745829~155750137:+
HNSC	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	5.13	4.15e-07	0.000121	0.23	0.23	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	5.13	4.15e-07	0.000121	0.23	0.23	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
HNSC	cis	rs9840812	0.623	rs9854084	ENSG00000239213.4	NCK1-AS1	5.13	4.15e-07	0.000121	0.21	0.23	Fibrinogen levels;	chr3:136475901	chr3:136841726~136862054:-
HNSC	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.13	4.15e-07	0.000121	0.21	0.23	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
HNSC	cis	rs860295	0.614	rs639398	ENSG00000203761.5	MSTO2P	5.13	4.16e-07	0.000121	0.17	0.23	Body mass index;	chr1:155920447	chr1:155745829~155750137:+
HNSC	cis	rs3733585	0.673	rs4311316	ENSG00000250413.1	RP11-448G15.1	-5.13	4.16e-07	0.000121	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954347	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000254153.1	CTA-398F10.2	-5.13	4.16e-07	0.000121	-0.26	-0.23	Mood instability;	chr8:8735335	chr8:8456909~8461337:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000179406.6	LINC00174	-5.13	4.17e-07	0.000121	-0.5	-0.23	Diabetic kidney disease;	chr7:65895144	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35391607	ENSG00000179406.6	LINC00174	-5.13	4.17e-07	0.000121	-0.5	-0.23	Diabetic kidney disease;	chr7:65895842	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs13220979	ENSG00000179406.6	LINC00174	-5.13	4.17e-07	0.000121	-0.5	-0.23	Diabetic kidney disease;	chr7:65898217	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34974928	ENSG00000179406.6	LINC00174	-5.13	4.17e-07	0.000121	-0.5	-0.23	Diabetic kidney disease;	chr7:65899019	chr7:66376044~66401338:-
HNSC	cis	rs10995505	0.589	rs10822140	ENSG00000232075.1	MRPL35P2	-5.13	4.17e-07	0.000121	-0.3	-0.23	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63634317~63634827:-
HNSC	cis	rs1799949	0.587	rs1824890	ENSG00000267681.1	CTD-3199J23.6	-5.13	4.17e-07	0.000121	-0.29	-0.23	Menopause (age at onset);	chr17:43344536	chr17:43144956~43145255:+
HNSC	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	5.13	4.17e-07	0.000121	0.26	0.23	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	5.13	4.17e-07	0.000121	0.28	0.23	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
HNSC	cis	rs1555322	0.872	rs2425046	ENSG00000126005.14	MMP24-AS1	-5.13	4.17e-07	0.000121	-0.46	-0.23	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35216462~35278131:-
HNSC	cis	rs860295	0.65	rs539602	ENSG00000203761.5	MSTO2P	5.13	4.17e-07	0.000121	0.17	0.23	Body mass index;	chr1:155929229	chr1:155745829~155750137:+
HNSC	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-5.13	4.17e-07	0.000121	-0.23	-0.23	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
HNSC	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-5.13	4.18e-07	0.000121	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
HNSC	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-5.13	4.18e-07	0.000121	-0.25	-0.23	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
HNSC	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	5.13	4.18e-07	0.000122	0.18	0.23	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	5.13	4.18e-07	0.000122	0.25	0.23	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
HNSC	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	5.13	4.18e-07	0.000122	0.2	0.23	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
HNSC	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-5.13	4.19e-07	0.000122	-0.27	-0.23	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
HNSC	cis	rs11846409	0.932	rs74091728	ENSG00000274576.2	IGHV2-70	-5.13	4.19e-07	0.000122	-0.23	-0.23	Rheumatic heart disease;	chr14:106638762	chr14:106770577~106771020:-
HNSC	cis	rs3806843	0.868	rs2531345	ENSG00000202515.1	VTRNA1-3	5.13	4.19e-07	0.000122	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr5:140726158~140726246:+
HNSC	cis	rs7824557	0.751	rs2099456	ENSG00000269918.1	AF131215.9	5.13	4.19e-07	0.000122	0.23	0.23	Retinal vascular caliber;	chr8:11269492	chr8:11104691~11106704:-
HNSC	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-5.13	4.19e-07	0.000122	-0.38	-0.23	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
HNSC	cis	rs10504130	0.569	rs12681734	ENSG00000272024.1	RP11-546K22.3	-5.13	4.19e-07	0.000122	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51950284~51950690:+
HNSC	cis	rs9368481	0.729	rs9379950	ENSG00000224843.5	LINC00240	5.13	4.19e-07	0.000122	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26956992~27023924:+
HNSC	cis	rs9368481	1	rs9368481	ENSG00000224843.5	LINC00240	5.13	4.19e-07	0.000122	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.554	rs2754603	ENSG00000224843.5	LINC00240	5.13	4.19e-07	0.000122	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.761	rs9357028	ENSG00000224843.5	LINC00240	5.13	4.19e-07	0.000122	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26956992~27023924:+
HNSC	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-5.13	4.2e-07	0.000122	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
HNSC	cis	rs4218	0.689	rs35066133	ENSG00000277144.1	RP11-59H7.4	-5.13	4.2e-07	0.000122	-0.28	-0.23	Social communication problems;	chr15:59081917	chr15:59115547~59116089:-
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	5.13	4.2e-07	0.000122	0.19	0.23	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
HNSC	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	5.13	4.2e-07	0.000122	0.19	0.23	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
HNSC	cis	rs7000734	0.674	rs13265626	ENSG00000245080.5	RP11-320N21.1	5.13	4.21e-07	0.000122	0.34	0.23	Radiation response;	chr8:95145740	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.674	rs10504941	ENSG00000245080.5	RP11-320N21.1	5.13	4.21e-07	0.000122	0.34	0.23	Radiation response;	chr8:95148686	chr8:95066808~95073182:-
HNSC	cis	rs1971762	0.563	rs7975862	ENSG00000270175.1	RP11-793H13.11	5.13	4.21e-07	0.000122	0.19	0.23	Height;	chr12:53684643	chr12:53500162~53500936:-
HNSC	cis	rs12701220	0.655	rs11489405	ENSG00000229043.2	AC091729.9	-5.13	4.21e-07	0.000122	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:1100256	chr7:1160374~1165267:+
HNSC	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	5.13	4.21e-07	0.000122	0.26	0.23	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	5.13	4.21e-07	0.000122	0.26	0.23	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
HNSC	cis	rs950169	0.922	rs12910334	ENSG00000229212.6	RP11-561C5.4	-5.13	4.22e-07	0.000122	-0.33	-0.23	Schizophrenia;	chr15:84403620	chr15:85205440~85234795:-
HNSC	cis	rs860818	1	rs858287	ENSG00000226816.2	AC005082.12	5.13	4.22e-07	0.000123	0.55	0.23	Initial pursuit acceleration;	chr7:23209594	chr7:23206013~23208045:+
HNSC	cis	rs9907295	1	rs9913488	ENSG00000270977.1	AC015849.16	-5.13	4.22e-07	0.000123	-0.34	-0.23	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9912571	ENSG00000270977.1	AC015849.16	-5.13	4.22e-07	0.000123	-0.34	-0.23	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9912793	ENSG00000270977.1	AC015849.16	-5.13	4.22e-07	0.000123	-0.34	-0.23	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35893707~35911023:-
HNSC	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	5.13	4.22e-07	0.000123	0.23	0.23	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
HNSC	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-5.13	4.22e-07	0.000123	-0.29	-0.23	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
HNSC	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	5.13	4.22e-07	0.000123	0.26	0.23	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
HNSC	cis	rs7000734	0.958	rs4735344	ENSG00000245080.5	RP11-320N21.1	-5.13	4.22e-07	0.000123	-0.32	-0.23	Radiation response;	chr8:95102645	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.958	rs7000568	ENSG00000245080.5	RP11-320N21.1	-5.13	4.22e-07	0.000123	-0.32	-0.23	Radiation response;	chr8:95105012	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.916	rs1975425	ENSG00000245080.5	RP11-320N21.1	-5.13	4.22e-07	0.000123	-0.32	-0.23	Radiation response;	chr8:95107479	chr8:95066808~95073182:-
HNSC	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-5.13	4.22e-07	0.000123	-0.25	-0.23	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
HNSC	cis	rs9813712	0.585	rs10934929	ENSG00000249846.5	RP11-77P16.4	5.13	4.22e-07	0.000123	0.32	0.23	Response to amphetamines;	chr3:130225231	chr3:130112550~130120579:+
HNSC	cis	rs950169	0.84	rs62029595	ENSG00000229212.6	RP11-561C5.4	-5.13	4.23e-07	0.000123	-0.33	-0.23	Schizophrenia;	chr15:84400603	chr15:85205440~85234795:-
HNSC	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	5.13	4.23e-07	0.000123	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-5.13	4.23e-07	0.000123	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-5.13	4.23e-07	0.000123	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-5.13	4.23e-07	0.000123	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-5.13	4.23e-07	0.000123	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
HNSC	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-5.13	4.23e-07	0.000123	-0.36	-0.23	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
HNSC	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	5.13	4.23e-07	0.000123	0.24	0.23	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
HNSC	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	5.13	4.23e-07	0.000123	0.29	0.23	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
HNSC	cis	rs7819412	0.745	rs7017567	ENSG00000255310.2	AF131215.2	-5.13	4.23e-07	0.000123	-0.22	-0.23	Triglycerides;	chr8:11076189	chr8:11107788~11109726:-
HNSC	cis	rs8177876	0.749	rs2549891	ENSG00000261061.1	RP11-303E16.2	5.13	4.23e-07	0.000123	0.35	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81030770~81031485:+
HNSC	cis	rs6964587	0.967	rs34040612	ENSG00000188693.7	CYP51A1-AS1	-5.13	4.23e-07	0.000123	-0.25	-0.23	Breast cancer;	chr7:92169602	chr7:92134604~92180725:+
HNSC	cis	rs712039	0.652	rs8069062	ENSG00000276054.1	RP11-378E13.3	5.13	4.23e-07	0.000123	0.33	0.23	Tuberculosis;	chr17:37469202	chr17:37386886~37387926:+
HNSC	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	5.13	4.24e-07	0.000123	0.28	0.23	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
HNSC	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	5.13	4.24e-07	0.000123	0.33	0.23	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
HNSC	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	5.13	4.24e-07	0.000123	0.28	0.23	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
HNSC	cis	rs728616	0.614	rs726014	ENSG00000225484.5	NUTM2B-AS1	-5.13	4.24e-07	0.000123	-0.41	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:79663088~79826594:-
HNSC	cis	rs4664293	0.625	rs6745448	ENSG00000226266.5	AC009961.3	-5.13	4.24e-07	0.000123	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159699087	chr2:159670708~159712435:-
HNSC	cis	rs4388249	0.687	rs3797689	ENSG00000271849.1	CTC-332L22.1	-5.13	4.24e-07	0.000123	-0.31	-0.23	Schizophrenia;	chr5:109764814	chr5:109687802~109688329:-
HNSC	cis	rs10800713	0.529	rs10919966	ENSG00000260088.1	RP11-92G12.3	5.13	4.24e-07	0.000123	0.41	0.23	Tandem gait;	chr1:200533441	chr1:200669507~200694250:+
HNSC	cis	rs7515577	0.588	rs35846792	ENSG00000223787.2	RP4-593M8.1	5.13	4.24e-07	0.000123	0.51	0.23	Cholesterol, total;	chr1:92505756	chr1:92580476~92580821:-
HNSC	cis	rs7515577	0.588	rs17371561	ENSG00000223787.2	RP4-593M8.1	5.13	4.24e-07	0.000123	0.51	0.23	Cholesterol, total;	chr1:92515682	chr1:92580476~92580821:-
HNSC	cis	rs7515577	0.541	rs75911573	ENSG00000223787.2	RP4-593M8.1	5.13	4.24e-07	0.000123	0.51	0.23	Cholesterol, total;	chr1:92560205	chr1:92580476~92580821:-
HNSC	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	5.13	4.25e-07	0.000123	0.31	0.23	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
HNSC	cis	rs2483058	0.515	rs2987936	ENSG00000261000.1	RP11-534L20.5	-5.13	4.26e-07	0.000123	-0.22	-0.23	Cholesterol and Triglycerides;	chr1:206432728	chr1:206503948~206504456:+
HNSC	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	5.13	4.26e-07	0.000123	0.33	0.23	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
HNSC	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	5.13	4.26e-07	0.000123	0.28	0.23	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
HNSC	cis	rs4141404	0.512	rs2070274	ENSG00000236132.1	CTA-440B3.1	5.13	4.26e-07	0.000123	0.27	0.23	Paclitaxel-induced neuropathy;	chr22:31603237	chr22:31816379~31817491:-
HNSC	cis	rs2985684	0.841	rs2281836	ENSG00000278009.1	RP11-649E7.8	5.13	4.26e-07	0.000123	0.3	0.23	Carotid intima media thickness;	chr14:49598999	chr14:49601011~49601124:-
HNSC	cis	rs75422866	0.867	rs117022227	ENSG00000276691.1	RP5-1057I20.5	5.13	4.26e-07	0.000124	0.43	0.23	Pneumonia;	chr12:47633282	chr12:47788426~47788971:+
HNSC	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	5.13	4.26e-07	0.000124	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
HNSC	cis	rs9287719	0.649	rs6732429	ENSG00000243819.4	RN7SL832P	-5.13	4.27e-07	0.000124	-0.23	-0.23	Prostate cancer;	chr2:10618846	chr2:10690344~10692099:+
HNSC	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	5.13	4.27e-07	0.000124	0.25	0.23	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
HNSC	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	5.13	4.27e-07	0.000124	0.29	0.23	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
HNSC	cis	rs7746199	0.736	rs34105070	ENSG00000219392.1	RP1-265C24.5	-5.13	4.27e-07	0.000124	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28115628~28116551:+
HNSC	cis	rs1008375	0.931	rs2098151	ENSG00000249502.1	AC006160.5	-5.13	4.28e-07	0.000124	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575867	chr4:17587467~17614571:-
HNSC	cis	rs9907295	1	rs11655533	ENSG00000270977.1	AC015849.16	-5.13	4.28e-07	0.000124	-0.34	-0.23	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35893707~35911023:-
HNSC	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	5.13	4.28e-07	0.000124	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
HNSC	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-5.13	4.28e-07	0.000124	-0.2	-0.23	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
HNSC	cis	rs9987353	0.519	rs13276350	ENSG00000254340.1	RP11-10A14.3	-5.13	4.28e-07	0.000124	-0.29	-0.23	Recombination measurement;	chr8:9205647	chr8:9141424~9145435:+
HNSC	cis	rs1008375	0.931	rs6449310	ENSG00000249502.1	AC006160.5	-5.13	4.28e-07	0.000124	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573907	chr4:17587467~17614571:-
HNSC	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	5.13	4.28e-07	0.000124	0.25	0.23	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.739	rs6534130	ENSG00000249244.1	RP11-548H18.2	-5.13	4.28e-07	0.000124	-0.27	-0.23	Corneal astigmatism;	chr4:119210184	chr4:119391831~119395335:-
HNSC	cis	rs858239	0.829	rs2268744	ENSG00000226816.2	AC005082.12	5.13	4.29e-07	0.000124	0.28	0.23	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23206013~23208045:+
HNSC	cis	rs9992667	0.955	rs922334	ENSG00000231160.8	KLF3-AS1	5.13	4.29e-07	0.000124	0.25	0.23	Eosinophil percentage of granulocytes;	chr4:38615137	chr4:38612701~38664883:-
HNSC	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	5.13	4.29e-07	0.000124	0.28	0.23	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
HNSC	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	5.13	4.29e-07	0.000124	0.3	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000254340.1	RP11-10A14.3	5.13	4.29e-07	0.000124	0.28	0.23	Joint mobility (Beighton score);	chr8:8967994	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000254340.1	RP11-10A14.3	5.13	4.29e-07	0.000124	0.28	0.23	Mood instability;	chr8:8968365	chr8:9141424~9145435:+
HNSC	cis	rs7819412	0.659	rs4073948	ENSG00000269918.1	AF131215.9	-5.13	4.3e-07	0.000124	-0.23	-0.23	Triglycerides;	chr8:10915134	chr8:11104691~11106704:-
HNSC	cis	rs4218	0.681	rs1074701	ENSG00000277144.1	RP11-59H7.4	-5.13	4.3e-07	0.000124	-0.29	-0.23	Social communication problems;	chr15:59073862	chr15:59115547~59116089:-
HNSC	cis	rs8032939	0.533	rs61573680	ENSG00000259747.1	RP11-275I4.2	-5.13	4.3e-07	0.000124	-0.29	-0.23	Rheumatoid arthritis;	chr15:38614385	chr15:38671847~38689191:+
HNSC	cis	rs8032939	0.533	rs61109886	ENSG00000259747.1	RP11-275I4.2	-5.13	4.3e-07	0.000124	-0.29	-0.23	Rheumatoid arthritis;	chr15:38614466	chr15:38671847~38689191:+
HNSC	cis	rs10504130	0.696	rs12676835	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs12677407	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs59602923	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs113096282	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.735	rs77362085	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.735	rs12681203	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.735	rs12679287	ENSG00000253844.1	RP11-546K22.1	-5.13	4.3e-07	0.000124	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51961458~52022974:+
HNSC	cis	rs9304742	0.962	rs1808106	ENSG00000213801.4	ZNF816-ZNF321P	5.13	4.3e-07	0.000125	0.26	0.23	Psoriasis;	chr19:52949691	chr19:52927135~52942601:-
HNSC	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	5.13	4.3e-07	0.000125	0.25	0.23	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
HNSC	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-5.13	4.31e-07	0.000125	-0.19	-0.23	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
HNSC	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-5.13	4.31e-07	0.000125	-0.25	-0.23	Height;	chr2:46636733	chr2:46668870~46670778:+
HNSC	cis	rs9450351	0.744	rs2229524	ENSG00000203875.9	SNHG5	-5.13	4.32e-07	0.000125	-0.5	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85489525	chr6:85660950~85678736:-
HNSC	cis	rs17428076	0.793	rs3770448	ENSG00000228389.1	AC068039.4	-5.13	4.32e-07	0.000125	-0.28	-0.23	Myopia;	chr2:171835755	chr2:171773482~171775844:+
HNSC	cis	rs14027	0.512	rs6992632	ENSG00000279347.1	RP11-85I17.2	-5.13	4.32e-07	0.000125	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711969	chr8:119838736~119840385:-
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000229212.6	RP11-561C5.4	-5.13	4.32e-07	0.000125	-0.33	-0.23	Schizophrenia;	chr15:84262270	chr15:85205440~85234795:-
HNSC	cis	rs3733585	0.673	rs7672947	ENSG00000250413.1	RP11-448G15.1	5.13	4.32e-07	0.000125	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9959744	chr4:10006482~10009725:+
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-5.13	4.33e-07	0.000125	-0.18	-0.23	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
HNSC	cis	rs2933343	0.7	rs876754	ENSG00000261159.1	RP11-723O4.9	5.13	4.33e-07	0.000125	0.23	0.23	IgG glycosylation;	chr3:128908910	chr3:128859716~128860526:-
HNSC	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-5.13	4.33e-07	0.000125	-0.27	-0.23	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-5.13	4.33e-07	0.000125	-0.27	-0.23	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-5.13	4.33e-07	0.000125	-0.27	-0.23	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
HNSC	cis	rs2985684	1	rs11157696	ENSG00000258568.1	RHOQP1	-5.13	4.33e-07	0.000125	-0.23	-0.23	Carotid intima media thickness;	chr14:49639028	chr14:49599994~49600572:+
HNSC	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	5.13	4.34e-07	0.000125	0.25	0.23	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
HNSC	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	5.13	4.34e-07	0.000125	0.25	0.23	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
HNSC	cis	rs224090	0.601	rs10761661	ENSG00000238280.1	RP11-436D10.3	-5.13	4.34e-07	0.000126	-0.29	-0.23	Crohn's disease;	chr10:62765375	chr10:62793562~62805887:-
HNSC	cis	rs9543976	0.688	rs56084319	ENSG00000261553.4	RP11-29G8.3	-5.13	4.34e-07	0.000126	-0.45	-0.23	Diabetic retinopathy;	chr13:75536543	chr13:75549773~75807120:+
HNSC	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	5.13	4.34e-07	0.000126	0.31	0.23	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
HNSC	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-5.13	4.34e-07	0.000126	-0.25	-0.23	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
HNSC	cis	rs7246657	0.525	rs1667357	ENSG00000276846.1	CTD-3220F14.3	5.13	4.34e-07	0.000126	0.32	0.23	Coronary artery calcification;	chr19:36993450	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.525	rs1667359	ENSG00000276846.1	CTD-3220F14.3	5.13	4.34e-07	0.000126	0.32	0.23	Coronary artery calcification;	chr19:36995270	chr19:37314868~37315620:-
HNSC	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-5.13	4.35e-07	0.000126	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
HNSC	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-5.13	4.36e-07	0.000126	-0.35	-0.23	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
HNSC	cis	rs3805389	0.504	rs62308708	ENSG00000273257.1	RP11-177J6.1	-5.13	4.36e-07	0.000126	-0.36	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55387949~55388271:+
HNSC	cis	rs4927850	1	rs7627706	ENSG00000273009.1	RP11-352G9.1	-5.13	4.36e-07	0.000126	-0.27	-0.23	Pancreatic cancer;	chr3:196026482	chr3:195913078~195913683:-
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000273009.1	RP11-352G9.1	-5.13	4.36e-07	0.000126	-0.27	-0.23	Pancreatic cancer;	chr3:196026530	chr3:195913078~195913683:-
HNSC	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	5.12	4.36e-07	0.000126	0.27	0.23	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	5.12	4.36e-07	0.000126	0.27	0.23	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
HNSC	cis	rs13126694	0.778	rs10013448	ENSG00000248429.4	RP11-597D13.9	5.12	4.36e-07	0.000126	0.26	0.23	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158170752~158202877:+
HNSC	cis	rs75422866	0.867	rs73104112	ENSG00000274902.1	RP1-197B17.4	5.12	4.37e-07	0.000126	0.51	0.23	Pneumonia;	chr12:47680969	chr12:47731908~47732351:+
HNSC	cis	rs4803480	1	rs4803480	ENSG00000270164.1	LINC01480	-5.12	4.37e-07	0.000126	-0.22	-0.23	Schizophrenia;	chr19:41559909	chr19:41535183~41536904:+
HNSC	cis	rs7829975	0.514	rs2979151	ENSG00000254153.1	CTA-398F10.2	-5.12	4.37e-07	0.000126	-0.25	-0.23	Mood instability;	chr8:8400509	chr8:8456909~8461337:-
HNSC	cis	rs9863	0.896	rs4930722	ENSG00000269938.1	RP11-214K3.20	-5.12	4.37e-07	0.000126	-0.28	-0.23	White blood cell count;	chr12:123938728	chr12:123968023~123968579:-
HNSC	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-5.12	4.37e-07	0.000126	-0.37	-0.23	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
HNSC	cis	rs638893	0.617	rs7933007	ENSG00000255422.1	AP002954.4	5.12	4.38e-07	0.000126	0.32	0.23	Vitiligo;	chr11:118859960	chr11:118704607~118750263:+
HNSC	cis	rs5758511	0.689	rs55906806	ENSG00000226450.2	CYP2D8P	5.12	4.38e-07	0.000127	0.24	0.23	Birth weight;	chr22:42248465	chr22:42149886~42155001:-
HNSC	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	5.12	4.38e-07	0.000127	0.34	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
HNSC	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	5.12	4.38e-07	0.000127	0.29	0.23	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
HNSC	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	5.12	4.38e-07	0.000127	0.3	0.23	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-5.12	4.38e-07	0.000127	-0.29	-0.23	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-5.12	4.38e-07	0.000127	-0.29	-0.23	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
HNSC	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-5.12	4.39e-07	0.000127	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
HNSC	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	5.12	4.39e-07	0.000127	0.25	0.23	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
HNSC	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	5.12	4.39e-07	0.000127	0.3	0.23	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
HNSC	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	5.12	4.39e-07	0.000127	0.26	0.23	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
HNSC	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-5.12	4.39e-07	0.000127	-0.24	-0.23	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-5.12	4.39e-07	0.000127	-0.24	-0.23	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-5.12	4.39e-07	0.000127	-0.24	-0.23	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-5.12	4.39e-07	0.000127	-0.24	-0.23	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-5.12	4.39e-07	0.000127	-0.24	-0.23	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
HNSC	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-5.12	4.39e-07	0.000127	-0.32	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
HNSC	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	5.12	4.39e-07	0.000127	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
HNSC	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	5.12	4.39e-07	0.000127	0.27	0.23	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
HNSC	cis	rs9840812	0.69	rs7628146	ENSG00000239213.4	NCK1-AS1	5.12	4.4e-07	0.000127	0.21	0.23	Fibrinogen levels;	chr3:136279611	chr3:136841726~136862054:-
HNSC	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-5.12	4.4e-07	0.000127	-0.24	-0.23	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
HNSC	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	5.12	4.4e-07	0.000127	0.34	0.23	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
HNSC	cis	rs2058059	0.636	rs3015917	ENSG00000225648.4	SBDSP1	-5.12	4.41e-07	0.000127	-0.31	-0.23	Subcutaneous adipose tissue;	chr7:72679494	chr7:72829425~72836701:+
HNSC	cis	rs4218	0.681	rs17302163	ENSG00000277144.1	RP11-59H7.4	-5.12	4.41e-07	0.000127	-0.29	-0.23	Social communication problems;	chr15:59076773	chr15:59115547~59116089:-
HNSC	cis	rs2286503	0.839	rs2240728	ENSG00000226329.2	AC005682.6	5.12	4.41e-07	0.000127	0.29	0.23	Fibrinogen;	chr7:22812880	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs1054471	ENSG00000226329.2	AC005682.6	5.12	4.41e-07	0.000127	0.29	0.23	Fibrinogen;	chr7:22813024	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs2240726	ENSG00000226329.2	AC005682.6	5.12	4.41e-07	0.000127	0.29	0.23	Fibrinogen;	chr7:22813516	chr7:22863874~22881350:-
HNSC	cis	rs6964587	0.967	rs4626516	ENSG00000188693.7	CYP51A1-AS1	-5.12	4.41e-07	0.000127	-0.25	-0.23	Breast cancer;	chr7:92177839	chr7:92134604~92180725:+
HNSC	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-5.12	4.41e-07	0.000127	-0.2	-0.23	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
HNSC	cis	rs10504130	0.696	rs76717135	ENSG00000253844.1	RP11-546K22.1	-5.12	4.42e-07	0.000127	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs17212256	ENSG00000253844.1	RP11-546K22.1	-5.12	4.42e-07	0.000127	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs12676780	ENSG00000253844.1	RP11-546K22.1	-5.12	4.42e-07	0.000127	-0.35	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51961458~52022974:+
HNSC	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	5.12	4.42e-07	0.000128	0.26	0.23	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000233609.3	RP11-62H7.2	5.12	4.42e-07	0.000128	0.23	0.23	Joint mobility (Beighton score);	chr8:9009901	chr8:8961200~8979025:+
HNSC	cis	rs11170631	0.507	rs12307701	ENSG00000270175.1	RP11-793H13.11	-5.12	4.42e-07	0.000128	-0.2	-0.23	Height;	chr12:53696940	chr12:53500162~53500936:-
HNSC	cis	rs8012947	0.651	rs8008129	ENSG00000279636.2	LINC00216	5.12	4.42e-07	0.000128	0.26	0.23	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58288033~58289158:+
HNSC	cis	rs1008375	0.898	rs7678654	ENSG00000249502.1	AC006160.5	-5.12	4.42e-07	0.000128	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573753	chr4:17587467~17614571:-
HNSC	cis	rs36093844	0.698	rs1445498	ENSG00000279742.1	RP11-700A24.1	-5.12	4.42e-07	0.000128	-0.34	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85815647	chr11:85852557~85854943:-
HNSC	cis	rs1355223	1	rs1396879	ENSG00000271369.1	RP11-350D17.3	-5.12	4.42e-07	0.000128	-0.26	-0.23	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745106	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.607	rs67340775	ENSG00000219392.1	RP1-265C24.5	-5.12	4.43e-07	0.000128	-0.44	-0.23	Depression;	chr6:28336607	chr6:28115628~28116551:+
HNSC	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	5.12	4.43e-07	0.000128	0.2	0.23	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
HNSC	cis	rs7819412	0.74	rs7844536	ENSG00000269918.1	AF131215.9	-5.12	4.43e-07	0.000128	-0.24	-0.23	Triglycerides;	chr8:11176519	chr8:11104691~11106704:-
HNSC	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	5.12	4.44e-07	0.000128	0.25	0.23	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
HNSC	cis	rs3806843	0.9	rs2563287	ENSG00000202515.1	VTRNA1-3	-5.12	4.44e-07	0.000128	-0.25	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr5:140726158~140726246:+
HNSC	cis	rs2548724	0.617	rs62369302	ENSG00000250682.4	LINC00491	5.12	4.44e-07	0.000128	0.3	0.23	Type 2 diabetes;	chr5:102372089	chr5:102609156~102671559:-
HNSC	cis	rs36423	0.748	rs36401	ENSG00000266869.1	RP6-114E22.1	-5.12	4.44e-07	0.000128	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893031	chr14:71848606~71908430:+
HNSC	cis	rs7621025	0.554	rs1471740	ENSG00000239213.4	NCK1-AS1	5.12	4.44e-07	0.000128	0.21	0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136841726~136862054:-
HNSC	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	5.12	4.44e-07	0.000128	0.4	0.23	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	5.12	4.44e-07	0.000128	0.4	0.23	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
HNSC	cis	rs4925386	0.808	rs1760073	ENSG00000273619.1	RP5-908M14.9	5.12	4.44e-07	0.000128	0.21	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62386303~62386970:-
HNSC	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	5.12	4.45e-07	0.000128	0.28	0.23	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
HNSC	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	5.12	4.45e-07	0.000128	0.3	0.23	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
HNSC	cis	rs9291683	0.507	rs6849273	ENSG00000250413.1	RP11-448G15.1	-5.12	4.45e-07	0.000128	-0.28	-0.23	Bone mineral density;	chr4:10019971	chr4:10006482~10009725:+
HNSC	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-5.12	4.45e-07	0.000128	-0.2	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	5.12	4.46e-07	0.000129	0.28	0.23	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	5.12	4.46e-07	0.000129	0.28	0.23	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
HNSC	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	5.12	4.46e-07	0.000129	0.28	0.23	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
HNSC	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-5.12	4.46e-07	0.000129	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-5.12	4.46e-07	0.000129	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-5.12	4.46e-07	0.000129	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-5.12	4.46e-07	0.000129	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-5.12	4.46e-07	0.000129	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
HNSC	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	5.12	4.46e-07	0.000129	0.32	0.23	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	5.12	4.46e-07	0.000129	0.32	0.23	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	5.12	4.46e-07	0.000129	0.32	0.23	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
HNSC	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	5.12	4.46e-07	0.000129	0.26	0.23	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
HNSC	cis	rs36093844	0.8	rs78356210	ENSG00000279742.1	RP11-700A24.1	-5.12	4.46e-07	0.000129	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85870224	chr11:85852557~85854943:-
HNSC	cis	rs2276314	0.512	rs7234973	ENSG00000278986.1	RP11-723J4.3	-5.12	4.46e-07	0.000129	-0.26	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35870373	chr18:35972151~35973916:+
HNSC	cis	rs4763879	0.739	rs7310460	ENSG00000256673.1	RP11-599J14.2	5.12	4.47e-07	0.000129	0.21	0.23	Type 1 diabetes;	chr12:9688177	chr12:9398355~9414851:-
HNSC	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-5.12	4.47e-07	0.000129	-0.26	-0.23	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
HNSC	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-5.12	4.47e-07	0.000129	-0.26	-0.23	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
HNSC	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	5.12	4.47e-07	0.000129	0.34	0.23	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
HNSC	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-5.12	4.47e-07	0.000129	-0.24	-0.23	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
HNSC	cis	rs14027	0.512	rs10095282	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712629	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.512	rs28711081	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119713469	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.512	rs10103886	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119715158	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.512	rs7825803	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119716558	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.512	rs13252708	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718283	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.512	rs6469841	ENSG00000279347.1	RP11-85I17.2	-5.12	4.48e-07	0.000129	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119721889	chr8:119838736~119840385:-
HNSC	cis	rs12682352	0.602	rs1473029	ENSG00000254340.1	RP11-10A14.3	5.12	4.49e-07	0.000129	0.28	0.23	Neuroticism;	chr8:8811407	chr8:9141424~9145435:+
HNSC	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	5.12	4.49e-07	0.000129	0.36	0.23	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
HNSC	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	5.12	4.49e-07	0.000129	0.23	0.23	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
HNSC	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-5.12	4.49e-07	0.000129	-0.23	-0.23	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
HNSC	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-5.12	4.5e-07	0.00013	-0.28	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
HNSC	cis	rs7829975	1	rs7829975	ENSG00000254340.1	RP11-10A14.3	-5.12	4.5e-07	0.00013	-0.29	-0.23	Mood instability;	chr8:8690607	chr8:9141424~9145435:+
HNSC	cis	rs4237845	0.611	rs7298370	ENSG00000257159.1	RP11-58A17.3	5.12	4.5e-07	0.00013	0.27	0.23	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57967058~57968399:+
HNSC	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-5.12	4.5e-07	0.00013	-0.35	-0.23	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-5.12	4.5e-07	0.00013	-0.35	-0.23	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
HNSC	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-5.12	4.5e-07	0.00013	-0.35	-0.23	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
HNSC	cis	rs78905543	0.967	rs4242388	ENSG00000253616.4	RP11-875O11.3	5.12	4.5e-07	0.00013	0.27	0.23	Mean corpuscular volume;	chr8:23075198	chr8:23071377~23074488:-
HNSC	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	5.12	4.5e-07	0.00013	0.2	0.23	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
HNSC	cis	rs7824557	0.507	rs7010590	ENSG00000255310.2	AF131215.2	5.12	4.5e-07	0.00013	0.22	0.23	Retinal vascular caliber;	chr8:11205373	chr8:11107788~11109726:-
HNSC	cis	rs3805389	0.504	rs17781708	ENSG00000273257.1	RP11-177J6.1	5.12	4.5e-07	0.00013	0.36	0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55614902	chr4:55387949~55388271:+
HNSC	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	5.12	4.5e-07	0.00013	0.19	0.23	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	5.12	4.5e-07	0.00013	0.19	0.23	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
HNSC	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	5.12	4.5e-07	0.00013	0.27	0.23	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	5.12	4.51e-07	0.00013	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
HNSC	cis	rs1971762	0.561	rs4759288	ENSG00000270175.1	RP11-793H13.11	-5.12	4.51e-07	0.00013	-0.2	-0.23	Height;	chr12:53690222	chr12:53500162~53500936:-
HNSC	cis	rs2985684	0.894	rs4900927	ENSG00000278009.1	RP11-649E7.8	5.12	4.51e-07	0.00013	0.3	0.23	Carotid intima media thickness;	chr14:49552023	chr14:49601011~49601124:-
HNSC	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-5.12	4.51e-07	0.00013	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
HNSC	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-5.12	4.51e-07	0.00013	-0.27	-0.23	Height;	chr2:46618710	chr2:46668870~46670778:+
HNSC	cis	rs860295	0.58	rs10908463	ENSG00000203761.5	MSTO2P	-5.12	4.51e-07	0.00013	-0.19	-0.23	Body mass index;	chr1:155316467	chr1:155745829~155750137:+
HNSC	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-5.12	4.52e-07	0.00013	-0.26	-0.23	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
HNSC	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-5.12	4.52e-07	0.00013	-0.22	-0.23	Height;	chr5:36954710	chr5:36666214~36725195:-
HNSC	cis	rs287982	0.611	rs77095920	ENSG00000269973.1	RP11-95D17.1	-5.12	4.52e-07	0.00013	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9833092	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs7580521	ENSG00000269973.1	RP11-95D17.1	-5.12	4.52e-07	0.00013	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9835555	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs80336909	ENSG00000269973.1	RP11-95D17.1	-5.12	4.52e-07	0.00013	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9835645	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs76624418	ENSG00000269973.1	RP11-95D17.1	-5.12	4.52e-07	0.00013	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9836389	chr2:9936360~9939590:+
HNSC	cis	rs9907295	0.688	rs4796138	ENSG00000270977.1	AC015849.16	-5.12	4.52e-07	0.00013	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35932791	chr17:35893707~35911023:-
HNSC	cis	rs7115242	0.858	rs6589592	ENSG00000280143.1	AP000892.6	5.12	4.53e-07	0.00013	0.43	0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117204967~117210292:+
HNSC	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	5.12	4.53e-07	0.00013	0.28	0.23	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
HNSC	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	5.12	4.53e-07	0.00013	0.35	0.23	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	5.12	4.53e-07	0.00013	0.35	0.23	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
HNSC	cis	rs1056107	0.931	rs940593	ENSG00000225513.1	RP11-165N19.2	-5.12	4.53e-07	0.00013	-0.25	-0.23	Colorectal cancer;	chr9:112255380	chr9:112173522~112173971:-
HNSC	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	5.12	4.53e-07	0.000131	0.25	0.23	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
HNSC	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	5.12	4.53e-07	0.000131	0.26	0.23	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
HNSC	cis	rs2058059	0.51	rs61567992	ENSG00000225648.4	SBDSP1	-5.12	4.53e-07	0.000131	-0.34	-0.23	Subcutaneous adipose tissue;	chr7:72576332	chr7:72829425~72836701:+
HNSC	cis	rs10995505	0.589	rs2896496	ENSG00000232075.1	MRPL35P2	-5.12	4.53e-07	0.000131	-0.3	-0.23	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63634317~63634827:-
HNSC	cis	rs9329221	0.905	rs17765901	ENSG00000255310.2	AF131215.2	-5.12	4.54e-07	0.000131	-0.22	-0.23	Neuroticism;	chr8:10391970	chr8:11107788~11109726:-
HNSC	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	5.12	4.54e-07	0.000131	0.55	0.23	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
HNSC	cis	rs1971762	0.583	rs7979659	ENSG00000270175.1	RP11-793H13.11	-5.12	4.54e-07	0.000131	-0.2	-0.23	Height;	chr12:53692795	chr12:53500162~53500936:-
HNSC	cis	rs453301	0.571	rs330057	ENSG00000254153.1	CTA-398F10.2	-5.12	4.55e-07	0.000131	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9232283	chr8:8456909~8461337:-
HNSC	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-5.12	4.55e-07	0.000131	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
HNSC	cis	rs9907295	0.688	rs4796135	ENSG00000270977.1	AC015849.16	-5.12	4.55e-07	0.000131	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.688	rs4796136	ENSG00000270977.1	AC015849.16	-5.12	4.55e-07	0.000131	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.688	rs4796137	ENSG00000270977.1	AC015849.16	-5.12	4.55e-07	0.000131	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35893707~35911023:-
HNSC	cis	rs9992667	0.704	rs3900761	ENSG00000231160.8	KLF3-AS1	-5.12	4.55e-07	0.000131	-0.31	-0.23	Eosinophil percentage of granulocytes;	chr4:38609961	chr4:38612701~38664883:-
HNSC	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-5.12	4.56e-07	0.000131	-0.19	-0.23	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
HNSC	cis	rs287982	0.611	rs76011221	ENSG00000269973.1	RP11-95D17.1	-5.12	4.56e-07	0.000131	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9837504	chr2:9936360~9939590:+
HNSC	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-5.12	4.56e-07	0.000131	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-5.12	4.56e-07	0.000131	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-5.12	4.56e-07	0.000131	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-5.12	4.56e-07	0.000131	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
HNSC	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	5.12	4.56e-07	0.000131	0.37	0.23	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
HNSC	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-5.12	4.57e-07	0.000132	-0.2	-0.23	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
HNSC	cis	rs6964587	0.967	rs10953065	ENSG00000188693.7	CYP51A1-AS1	5.12	4.58e-07	0.000132	0.25	0.23	Breast cancer;	chr7:92179601	chr7:92134604~92180725:+
HNSC	cis	rs453301	0.571	rs330048	ENSG00000254153.1	CTA-398F10.2	-5.12	4.58e-07	0.000132	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9229768	chr8:8456909~8461337:-
HNSC	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	5.12	4.58e-07	0.000132	0.36	0.23	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
HNSC	cis	rs4908760	0.757	rs301807	ENSG00000232912.4	RP5-1115A15.1	5.12	4.59e-07	0.000132	0.24	0.23	Vitiligo;	chr1:8424763	chr1:8424645~8434838:+
HNSC	cis	rs7829975	0.684	rs488904	ENSG00000173295.6	FAM86B3P	-5.12	4.59e-07	0.000132	-0.27	-0.23	Mood instability;	chr8:8730061	chr8:8228595~8244865:+
HNSC	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-5.11	4.59e-07	0.000132	-0.22	-0.23	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
HNSC	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-5.11	4.59e-07	0.000132	-0.31	-0.23	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
HNSC	cis	rs2933343	0.729	rs1680794	ENSG00000261159.1	RP11-723O4.9	5.11	4.59e-07	0.000132	0.23	0.23	IgG glycosylation;	chr3:128901547	chr3:128859716~128860526:-
HNSC	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	5.11	4.59e-07	0.000132	0.33	0.23	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
HNSC	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	5.11	4.59e-07	0.000132	0.33	0.23	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
HNSC	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	5.11	4.59e-07	0.000132	0.24	0.23	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	5.11	4.59e-07	0.000132	0.24	0.23	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
HNSC	cis	rs6540731	0.782	rs10436976	ENSG00000226251.4	RP11-15I11.3	-5.11	4.6e-07	0.000132	-0.27	-0.23	Intelligence (childhood);	chr1:212187066	chr1:212225278~212238977:-
HNSC	cis	rs1008375	0.9	rs6851783	ENSG00000249502.1	AC006160.5	-5.11	4.6e-07	0.000132	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576846	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.9	rs7658447	ENSG00000249502.1	AC006160.5	-5.11	4.6e-07	0.000132	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577792	chr4:17587467~17614571:-
HNSC	cis	rs13126694	0.744	rs6821252	ENSG00000248429.4	RP11-597D13.9	5.11	4.6e-07	0.000132	0.26	0.23	Blood osmolality (transformed sodium);	chr4:158076296	chr4:158170752~158202877:+
HNSC	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-5.11	4.6e-07	0.000132	-0.21	-0.23	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
HNSC	cis	rs4218	0.636	rs4775116	ENSG00000259732.1	RP11-59H7.3	5.11	4.6e-07	0.000132	0.29	0.23	Social communication problems;	chr15:59135608	chr15:59121034~59133250:+
HNSC	cis	rs9611519	0.894	rs4821990	ENSG00000235513.1	RP4-756G23.5	5.11	4.6e-07	0.000132	0.25	0.23	Neuroticism;	chr22:41042706	chr22:41209122~41217627:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000233609.3	RP11-62H7.2	-5.11	4.61e-07	0.000132	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9028444	chr8:8961200~8979025:+
HNSC	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-5.11	4.61e-07	0.000132	-0.24	-0.23	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
HNSC	cis	rs36093844	0.8	rs59179556	ENSG00000279742.1	RP11-700A24.1	-5.11	4.61e-07	0.000133	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862854	chr11:85852557~85854943:-
HNSC	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
HNSC	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	5.11	4.61e-07	0.000133	0.4	0.23	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
HNSC	cis	rs13434995	0.945	rs55849318	ENSG00000273257.1	RP11-177J6.1	-5.11	4.61e-07	0.000133	-0.36	-0.23	Adiponectin levels;	chr4:55615826	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.896	rs2614285	ENSG00000231028.7	LINC00271	5.11	4.62e-07	0.000133	0.26	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371480	chr6:135497801~135716055:+
HNSC	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	5.11	4.62e-07	0.000133	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	5.11	4.62e-07	0.000133	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	5.11	4.62e-07	0.000133	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	5.11	4.62e-07	0.000133	0.28	0.23	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs34560516	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65939105	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs57057549	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65946971	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs2961102	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65959671	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs34970380	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65966506	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65966800	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs906134	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65979301	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs1039664	ENSG00000179406.6	LINC00174	-5.11	4.63e-07	0.000133	-0.5	-0.23	Diabetic kidney disease;	chr7:65984729	chr7:66376044~66401338:-
HNSC	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-5.11	4.63e-07	0.000133	-0.2	-0.23	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
HNSC	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	5.11	4.63e-07	0.000133	0.37	0.23	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
HNSC	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	5.11	4.63e-07	0.000133	0.25	0.23	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
HNSC	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	5.11	4.63e-07	0.000133	0.32	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
HNSC	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	5.11	4.63e-07	0.000133	0.25	0.23	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
HNSC	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-5.11	4.63e-07	0.000133	-0.23	-0.23	Height;	chr5:36982949	chr5:36666214~36725195:-
HNSC	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-5.11	4.64e-07	0.000133	-0.29	-0.23	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
HNSC	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	5.11	4.64e-07	0.000133	0.34	0.23	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
HNSC	cis	rs783540	0.521	rs1259176	ENSG00000276710.3	CSPG4P8	5.11	4.64e-07	0.000133	0.28	0.23	Schizophrenia;	chr15:82602149	chr15:82459472~82477258:+
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000233609.3	RP11-62H7.2	5.11	4.64e-07	0.000133	0.23	0.23	Joint mobility (Beighton score);	chr8:9026395	chr8:8961200~8979025:+
HNSC	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-5.11	4.65e-07	0.000133	-0.22	-0.23	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
HNSC	cis	rs6928977	0.896	rs2064430	ENSG00000231028.7	LINC00271	-5.11	4.65e-07	0.000133	-0.26	-0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135321618	chr6:135497801~135716055:+
HNSC	cis	rs11191419	1	rs11191419	ENSG00000236937.2	PTGES3P4	5.11	4.65e-07	0.000133	0.29	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102845595~102845950:+
HNSC	cis	rs11098499	0.739	rs7441137	ENSG00000249244.1	RP11-548H18.2	-5.11	4.65e-07	0.000134	-0.26	-0.23	Corneal astigmatism;	chr4:119212066	chr4:119391831~119395335:-
HNSC	cis	rs7746199	0.736	rs13212093	ENSG00000219392.1	RP1-265C24.5	-5.11	4.66e-07	0.000134	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs34038546	ENSG00000219392.1	RP1-265C24.5	-5.11	4.66e-07	0.000134	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28115628~28116551:+
HNSC	cis	rs141342723	1	rs141342723	ENSG00000219392.1	RP1-265C24.5	-5.11	4.66e-07	0.000134	-0.46	-0.23	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs34543938	ENSG00000219392.1	RP1-265C24.5	-5.11	4.66e-07	0.000134	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs56405707	ENSG00000219392.1	RP1-265C24.5	-5.11	4.66e-07	0.000134	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28115628~28116551:+
HNSC	cis	rs6723108	0.627	rs2197579	ENSG00000224043.6	CCNT2-AS1	-5.11	4.66e-07	0.000134	-0.28	-0.23	Type 2 diabetes;	chr2:134887408	chr2:134735464~134918710:-
HNSC	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	5.11	4.67e-07	0.000134	0.2	0.23	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
HNSC	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	5.11	4.67e-07	0.000134	0.25	0.23	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
HNSC	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	5.11	4.67e-07	0.000134	0.32	0.23	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
HNSC	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	5.11	4.67e-07	0.000134	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
HNSC	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	5.11	4.67e-07	0.000134	0.23	0.23	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
HNSC	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	5.11	4.67e-07	0.000134	0.4	0.23	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
HNSC	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	5.11	4.67e-07	0.000134	0.4	0.23	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
HNSC	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	5.11	4.68e-07	0.000134	0.23	0.23	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
HNSC	cis	rs4664293	0.647	rs7580816	ENSG00000226266.5	AC009961.3	-5.11	4.68e-07	0.000134	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159619370	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs1966530	ENSG00000226266.5	AC009961.3	-5.11	4.68e-07	0.000134	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159620897	chr2:159670708~159712435:-
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000233609.3	RP11-62H7.2	-5.11	4.68e-07	0.000134	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9026993	chr8:8961200~8979025:+
HNSC	cis	rs740698	0.529	rs9895414	ENSG00000265702.1	RP11-156L14.1	-5.11	4.68e-07	0.000134	-0.27	-0.23	Pulse pressure;	chr17:62716038	chr17:62699244~62737922:+
HNSC	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	5.11	4.68e-07	0.000134	0.24	0.23	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
HNSC	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-5.11	4.68e-07	0.000134	-0.29	-0.23	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
HNSC	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-5.11	4.68e-07	0.000134	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-5.11	4.68e-07	0.000134	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
HNSC	cis	rs3733585	0.673	rs4314284	ENSG00000250413.1	RP11-448G15.1	5.11	4.69e-07	0.000135	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954472	chr4:10006482~10009725:+
HNSC	cis	rs9863	0.896	rs12311114	ENSG00000269938.1	RP11-214K3.20	5.11	4.69e-07	0.000135	0.28	0.23	White blood cell count;	chr12:123976156	chr12:123968023~123968579:-
HNSC	cis	rs6540731	1	rs7518329	ENSG00000226251.4	RP11-15I11.3	-5.11	4.69e-07	0.000135	-0.27	-0.23	Intelligence (childhood);	chr1:212225191	chr1:212225278~212238977:-
HNSC	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	5.11	4.69e-07	0.000135	0.28	0.23	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	5.11	4.69e-07	0.000135	0.28	0.23	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
HNSC	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	5.11	4.69e-07	0.000135	0.23	0.23	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
HNSC	cis	rs3806843	0.75	rs2563285	ENSG00000202515.1	VTRNA1-3	5.11	4.69e-07	0.000135	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr5:140726158~140726246:+
HNSC	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-5.11	4.7e-07	0.000135	-0.4	-0.23	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
HNSC	cis	rs4256159	1	rs3935033	ENSG00000228956.7	SATB1-AS1	-5.11	4.7e-07	0.000135	-0.36	-0.23	Crohn's disease;Inflammatory bowel disease;	chr3:18783582	chr3:18445024~18920401:+
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000233609.3	RP11-62H7.2	-5.11	4.7e-07	0.000135	-0.22	-0.23	Joint mobility (Beighton score);	chr8:8936097	chr8:8961200~8979025:+
HNSC	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	5.11	4.7e-07	0.000135	0.28	0.23	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	5.11	4.7e-07	0.000135	0.28	0.23	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	5.11	4.7e-07	0.000135	0.28	0.23	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	5.11	4.7e-07	0.000135	0.28	0.23	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
HNSC	cis	rs442309	0.551	rs1509966	ENSG00000238280.1	RP11-436D10.3	-5.11	4.7e-07	0.000135	-0.27	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62792847	chr10:62793562~62805887:-
HNSC	cis	rs2985684	0.841	rs12894785	ENSG00000278009.1	RP11-649E7.8	5.11	4.7e-07	0.000135	0.3	0.23	Carotid intima media thickness;	chr14:49583037	chr14:49601011~49601124:-
HNSC	cis	rs712039	0.652	rs853227	ENSG00000276054.1	RP11-378E13.3	5.11	4.7e-07	0.000135	0.33	0.23	Tuberculosis;	chr17:37437428	chr17:37386886~37387926:+
HNSC	cis	rs712039	0.652	rs853200	ENSG00000276054.1	RP11-378E13.3	5.11	4.7e-07	0.000135	0.33	0.23	Tuberculosis;	chr17:37444013	chr17:37386886~37387926:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000229212.6	RP11-561C5.4	-5.11	4.71e-07	0.000135	-0.33	-0.23	Schizophrenia;	chr15:84387263	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000229212.6	RP11-561C5.4	-5.11	4.71e-07	0.000135	-0.33	-0.23	Schizophrenia;	chr15:84387606	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000229212.6	RP11-561C5.4	-5.11	4.71e-07	0.000135	-0.33	-0.23	Schizophrenia;	chr15:84387633	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000229212.6	RP11-561C5.4	-5.11	4.71e-07	0.000135	-0.33	-0.23	Schizophrenia;	chr15:84387641	chr15:85205440~85234795:-
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	5.11	4.71e-07	0.000135	0.25	0.23	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
HNSC	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-5.11	4.71e-07	0.000135	-0.32	-0.23	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
HNSC	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	5.11	4.71e-07	0.000135	0.37	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
HNSC	cis	rs1008375	0.9	rs12650220	ENSG00000249502.1	AC006160.5	-5.11	4.71e-07	0.000135	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17593742	chr4:17587467~17614571:-
HNSC	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-5.11	4.71e-07	0.000135	-0.26	-0.23	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-5.11	4.71e-07	0.000135	-0.26	-0.23	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
HNSC	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-5.11	4.71e-07	0.000135	-0.31	-0.23	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
HNSC	cis	rs8040855	0.599	rs8037195	ENSG00000259774.1	RP11-182J1.13	-5.11	4.71e-07	0.000135	-0.27	-0.23	Bulimia nervosa;	chr15:85181455	chr15:84422618~84425882:+
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-5.11	4.72e-07	0.000135	-0.13	-0.23	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
HNSC	cis	rs9506514	0.722	rs10400670	ENSG00000238286.1	SLC35E1P1	5.11	4.72e-07	0.000135	0.25	0.23	Coronary artery calcification;	chr13:20679350	chr13:20607268~20608131:+
HNSC	cis	rs9506514	0.712	rs11838795	ENSG00000238286.1	SLC35E1P1	5.11	4.72e-07	0.000135	0.25	0.23	Coronary artery calcification;	chr13:20684189	chr13:20607268~20608131:+
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	5.11	4.72e-07	0.000135	0.22	0.23	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
HNSC	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	5.11	4.72e-07	0.000135	0.19	0.23	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
HNSC	cis	rs1933112	0.5	rs12021763	ENSG00000227777.1	RP4-738P11.3	-5.11	4.72e-07	0.000135	-0.32	-0.23	Blood protein levels;	chr1:168558845	chr1:168542737~168543354:+
HNSC	cis	rs860818	1	rs858233	ENSG00000226816.2	AC005082.12	5.11	4.72e-07	0.000135	0.57	0.23	Initial pursuit acceleration;	chr7:23201914	chr7:23206013~23208045:+
HNSC	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	5.11	4.73e-07	0.000136	0.24	0.23	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.739	rs9884728	ENSG00000249244.1	RP11-548H18.2	-5.11	4.73e-07	0.000136	-0.26	-0.23	Corneal astigmatism;	chr4:119205924	chr4:119391831~119395335:-
HNSC	cis	rs4657482	0.962	rs10918303	ENSG00000236364.3	RP11-525G13.2	5.11	4.74e-07	0.000136	0.23	0.23	Testicular germ cell tumor;	chr1:165883992	chr1:165890795~165900683:-
HNSC	cis	rs9840812	0.728	rs665200	ENSG00000239213.4	NCK1-AS1	5.11	4.74e-07	0.000136	0.21	0.23	Fibrinogen levels;	chr3:136276174	chr3:136841726~136862054:-
HNSC	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-5.11	4.74e-07	0.000136	-0.43	-0.23	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-5.11	4.74e-07	0.000136	-0.43	-0.23	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
HNSC	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	5.11	4.74e-07	0.000136	0.34	0.23	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
HNSC	cis	rs988913	1	rs9396011	ENSG00000224984.1	RP11-524H19.2	5.11	4.74e-07	0.000136	0.26	0.23	Menarche (age at onset);	chr6:54971941	chr6:54840118~54840855:-
HNSC	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	5.11	4.74e-07	0.000136	0.24	0.23	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
HNSC	cis	rs7621025	0.662	rs3856637	ENSG00000273486.1	RP11-731C17.2	5.11	4.74e-07	0.000136	0.19	0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136672353	chr3:136837338~136839021:-
HNSC	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	5.11	4.74e-07	0.000136	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
HNSC	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	5.11	4.74e-07	0.000136	0.23	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
HNSC	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-5.11	4.75e-07	0.000136	-0.22	-0.23	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-5.11	4.75e-07	0.000136	-0.22	-0.23	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	5.11	4.75e-07	0.000136	0.22	0.23	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
HNSC	cis	rs13434995	0.589	rs499110	ENSG00000273257.1	RP11-177J6.1	-5.11	4.75e-07	0.000136	-0.31	-0.23	Adiponectin levels;	chr4:55381628	chr4:55387949~55388271:+
HNSC	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-5.11	4.75e-07	0.000136	-0.27	-0.23	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-5.11	4.75e-07	0.000136	-0.27	-0.23	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-5.11	4.75e-07	0.000136	-0.27	-0.23	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
HNSC	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-5.11	4.75e-07	0.000136	-0.24	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
HNSC	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	5.11	4.75e-07	0.000136	0.28	0.23	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
HNSC	cis	rs1799949	0.965	rs4793230	ENSG00000236383.6	LINC00854	-5.11	4.75e-07	0.000136	-0.22	-0.23	Menopause (age at onset);	chr17:43350035	chr17:43216941~43305976:-
HNSC	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-5.11	4.75e-07	0.000136	-0.29	-0.23	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
HNSC	cis	rs8077577	0.789	rs62072546	ENSG00000273018.4	CTD-2303H24.2	-5.11	4.75e-07	0.000136	-0.34	-0.23	Obesity-related traits;	chr17:18350525	chr17:18511221~18551705:-
HNSC	cis	rs7000734	0.877	rs2583365	ENSG00000245080.5	RP11-320N21.1	-5.11	4.76e-07	0.000136	-0.32	-0.23	Radiation response;	chr8:95117859	chr8:95066808~95073182:-
HNSC	cis	rs7746199	0.736	rs13210634	ENSG00000219392.1	RP1-265C24.5	-5.11	4.76e-07	0.000136	-0.45	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs13215275	ENSG00000219392.1	RP1-265C24.5	-5.11	4.76e-07	0.000136	-0.45	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28115628~28116551:+
HNSC	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-5.11	4.77e-07	0.000137	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
HNSC	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	5.11	4.77e-07	0.000137	0.23	0.23	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
HNSC	cis	rs3806843	0.568	rs2530232	ENSG00000202515.1	VTRNA1-3	5.11	4.77e-07	0.000137	0.27	0.23	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr5:140726158~140726246:+
HNSC	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-5.11	4.77e-07	0.000137	-0.32	-0.23	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
HNSC	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	5.11	4.77e-07	0.000137	0.25	0.23	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
HNSC	cis	rs950169	0.8	rs34302901	ENSG00000229212.6	RP11-561C5.4	-5.11	4.79e-07	0.000137	-0.32	-0.23	Schizophrenia;	chr15:84567712	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-5.11	4.79e-07	0.000137	-0.24	-0.23	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
HNSC	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	5.11	4.79e-07	0.000137	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
HNSC	cis	rs2551802	0.615	rs17395735	ENSG00000226363.3	HAGLROS	-5.11	4.79e-07	0.000137	-0.3	-0.23	Motion sickness;	chr2:176203052	chr2:176177717~176179008:+
HNSC	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-5.11	4.79e-07	0.000137	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
HNSC	cis	rs36052053	0.908	rs71558363	ENSG00000219700.1	PTCHD3P3	5.11	4.8e-07	0.000137	0.37	0.23	Red cell distribution width;	chr6:109283778	chr6:109288571~109290503:-
HNSC	cis	rs2337406	0.714	rs115401799	ENSG00000254174.1	IGHV1-12	5.11	4.8e-07	0.000137	0.2	0.23	Alzheimer's disease (late onset);	chr14:106813739	chr14:106122420~106122709:-
HNSC	cis	rs9329221	0.683	rs4598253	ENSG00000254340.1	RP11-10A14.3	-5.11	4.8e-07	0.000137	-0.27	-0.23	Neuroticism;	chr8:10032794	chr8:9141424~9145435:+
HNSC	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-5.11	4.8e-07	0.000137	-0.23	-0.23	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
HNSC	cis	rs2439831	0.85	rs524417	ENSG00000205771.5	CATSPER2P1	-5.11	4.8e-07	0.000137	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43480176	chr15:43726918~43747094:-
HNSC	cis	rs1971762	0.583	rs10876485	ENSG00000270175.1	RP11-793H13.11	5.11	4.8e-07	0.000137	0.2	0.23	Height;	chr12:53693864	chr12:53500162~53500936:-
HNSC	cis	rs75422866	0.51	rs73105819	ENSG00000274902.1	RP1-197B17.4	5.11	4.8e-07	0.000137	0.51	0.23	Pneumonia;	chr12:47727190	chr12:47731908~47732351:+
HNSC	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-5.11	4.8e-07	0.000137	-0.26	-0.23	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
HNSC	cis	rs9291683	0.53	rs11723970	ENSG00000250413.1	RP11-448G15.1	-5.11	4.8e-07	0.000137	-0.29	-0.23	Bone mineral density;	chr4:9978838	chr4:10006482~10009725:+
HNSC	cis	rs858239	0.704	rs199657	ENSG00000226816.2	AC005082.12	-5.11	4.8e-07	0.000137	-0.28	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.704	rs199656	ENSG00000226816.2	AC005082.12	-5.11	4.8e-07	0.000137	-0.28	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23206013~23208045:+
HNSC	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-5.11	4.81e-07	0.000138	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
HNSC	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	5.11	4.81e-07	0.000138	0.24	0.23	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	5.11	4.81e-07	0.000138	0.24	0.23	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
HNSC	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-5.11	4.82e-07	0.000138	-0.32	-0.23	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-5.11	4.82e-07	0.000138	-0.32	-0.23	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
HNSC	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	5.11	4.82e-07	0.000138	0.25	0.23	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
HNSC	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-5.1	4.83e-07	0.000138	-0.34	-0.23	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
HNSC	cis	rs6928977	0.5	rs11154810	ENSG00000217482.2	HMGB1P17	-5.1	4.83e-07	0.000138	-0.25	-0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135636086~135636713:-
HNSC	cis	rs11098499	0.739	rs4833612	ENSG00000249244.1	RP11-548H18.2	-5.1	4.83e-07	0.000138	-0.26	-0.23	Corneal astigmatism;	chr4:119226441	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.739	rs10013032	ENSG00000249244.1	RP11-548H18.2	-5.1	4.83e-07	0.000138	-0.26	-0.23	Corneal astigmatism;	chr4:119228264	chr4:119391831~119395335:-
HNSC	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	5.1	4.83e-07	0.000138	0.23	0.23	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
HNSC	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	5.1	4.84e-07	0.000138	0.24	0.23	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-5.1	4.84e-07	0.000138	-0.21	-0.23	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
HNSC	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-5.1	4.84e-07	0.000138	-0.22	-0.23	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-5.1	4.84e-07	0.000138	-0.22	-0.23	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-5.1	4.84e-07	0.000138	-0.22	-0.23	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
HNSC	cis	rs6540731	0.754	rs2358452	ENSG00000226251.4	RP11-15I11.3	-5.1	4.84e-07	0.000138	-0.26	-0.23	Intelligence (childhood);	chr1:212185707	chr1:212225278~212238977:-
HNSC	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	5.1	4.85e-07	0.000139	0.4	0.23	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
HNSC	cis	rs728616	1	rs12414891	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.717	rs12415523	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.764	rs75385771	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs17883671	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs17885031	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs3088308	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs17879726	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.85e-07	0.000139	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79663088~79826594:-
HNSC	cis	rs10027350	0.857	rs3796793	ENSG00000281501.1	SEPSECS-AS1	5.1	4.85e-07	0.000139	0.28	0.23	Childhood ear infection;	chr4:25142945	chr4:25160641~25201440:+
HNSC	cis	rs2904967	0.598	rs2904978	ENSG00000254614.2	AP003068.23	5.1	4.86e-07	0.000139	0.33	0.23	Mean corpuscular volume;	chr11:65233007	chr11:65177606~65181834:-
HNSC	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-5.1	4.86e-07	0.000139	-0.23	-0.23	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
HNSC	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-5.1	4.86e-07	0.000139	-0.23	-0.23	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
HNSC	cis	rs1218582	0.774	rs4845680	ENSG00000270361.1	RP11-307C12.13	-5.1	4.86e-07	0.000139	-0.25	-0.23	Prostate cancer;	chr1:154890719	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.745	rs1580943	ENSG00000270361.1	RP11-307C12.13	-5.1	4.86e-07	0.000139	-0.25	-0.23	Prostate cancer;	chr1:154892649	chr1:154937370~154938059:+
HNSC	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	5.1	4.87e-07	0.000139	0.28	0.23	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
HNSC	cis	rs988913	1	rs9370345	ENSG00000224984.1	RP11-524H19.2	5.1	4.87e-07	0.000139	0.26	0.23	Menarche (age at onset);	chr6:54960369	chr6:54840118~54840855:-
HNSC	cis	rs14027	0.64	rs10096846	ENSG00000279347.1	RP11-85I17.2	-5.1	4.87e-07	0.000139	-0.19	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119760884	chr8:119838736~119840385:-
HNSC	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	5.1	4.88e-07	0.000139	0.27	0.23	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
HNSC	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	5.1	4.88e-07	0.000139	0.39	0.23	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
HNSC	cis	rs10109025	0.67	rs7825690	ENSG00000269918.1	AF131215.9	-5.1	4.88e-07	0.000139	-0.22	-0.23	Joint mobility (Beighton score);	chr8:11000747	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000233609.3	RP11-62H7.2	5.1	4.88e-07	0.000139	0.22	0.23	Joint mobility (Beighton score);	chr8:9002766	chr8:8961200~8979025:+
HNSC	cis	rs9650657	0.562	rs10090444	ENSG00000269918.1	AF131215.9	5.1	4.89e-07	0.00014	0.22	0.23	Neuroticism;	chr8:10887959	chr8:11104691~11106704:-
HNSC	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	5.1	4.89e-07	0.00014	0.35	0.23	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
HNSC	cis	rs71520386	0.632	rs10253651	ENSG00000221740.1	SNORD93	-5.1	4.89e-07	0.00014	-0.26	-0.23	Fibrinogen levels;	chr7:22830564	chr7:22856613~22856686:+
HNSC	cis	rs72772090	0.908	rs11750510	ENSG00000248734.2	CTD-2260A17.1	-5.1	4.9e-07	0.00014	-0.33	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96706391	chr5:96784777~96785999:+
HNSC	cis	rs9607805	1	rs9607805	ENSG00000235513.1	RP4-756G23.5	-5.1	4.9e-07	0.00014	-0.26	-0.23	Neuroticism;	chr22:41458442	chr22:41209122~41217627:-
HNSC	cis	rs36423	0.748	rs36399	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893616	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36398	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893710	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36395	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71895714	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36394	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71895899	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.702	rs36393	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71896009	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36392	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71896044	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36388	ENSG00000266869.1	RP6-114E22.1	-5.1	4.9e-07	0.00014	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71898959	chr14:71848606~71908430:+
HNSC	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	5.1	4.9e-07	0.00014	0.27	0.23	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
HNSC	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	5.1	4.9e-07	0.00014	0.26	0.23	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
HNSC	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	5.1	4.9e-07	0.00014	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
HNSC	cis	rs7746199	0.736	rs10484399	ENSG00000219392.1	RP1-265C24.5	-5.1	4.91e-07	0.00014	-0.44	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000254340.1	RP11-10A14.3	5.1	4.91e-07	0.00014	0.28	0.23	Mood instability;	chr8:8822967	chr8:9141424~9145435:+
HNSC	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-5.1	4.91e-07	0.00014	-0.33	-0.23	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
HNSC	cis	rs9840812	0.691	rs7621025	ENSG00000239213.4	NCK1-AS1	5.1	4.91e-07	0.00014	0.21	0.23	Fibrinogen levels;	chr3:136553404	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.728	rs6439646	ENSG00000239213.4	NCK1-AS1	5.1	4.91e-07	0.00014	0.21	0.23	Fibrinogen levels;	chr3:136554721	chr3:136841726~136862054:-
HNSC	cis	rs4763879	0.778	rs1056151	ENSG00000256673.1	RP11-599J14.2	5.1	4.91e-07	0.00014	0.22	0.23	Type 1 diabetes;	chr12:9698427	chr12:9398355~9414851:-
HNSC	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	5.1	4.91e-07	0.00014	0.23	0.23	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
HNSC	cis	rs9527	1	rs4919690	ENSG00000236937.2	PTGES3P4	-5.1	4.92e-07	0.00014	-0.34	-0.23	Arsenic metabolism;	chr10:102856743	chr10:102845595~102845950:+
HNSC	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	5.1	4.92e-07	0.00014	0.55	0.23	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	5.1	4.92e-07	0.00014	0.55	0.23	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	5.1	4.92e-07	0.00014	0.55	0.23	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
HNSC	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-5.1	4.92e-07	0.000141	-0.29	-0.23	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
HNSC	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-5.1	4.92e-07	0.000141	-0.23	-0.23	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
HNSC	cis	rs12701220	0.857	rs1057558	ENSG00000229043.2	AC091729.9	-5.1	4.93e-07	0.000141	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1160374~1165267:+
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000276710.3	CSPG4P8	-5.1	4.93e-07	0.000141	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82701318	chr15:82459472~82477258:+
HNSC	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	5.1	4.93e-07	0.000141	0.27	0.23	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
HNSC	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-5.1	4.93e-07	0.000141	-0.29	-0.23	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
HNSC	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-5.1	4.93e-07	0.000141	-0.35	-0.23	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
HNSC	cis	rs8059260	0.541	rs35126143	ENSG00000274038.1	RP11-66H6.4	-5.1	4.94e-07	0.000141	-0.47	-0.23	Alcohol consumption over the past year;	chr16:11070455	chr16:11056556~11057034:+
HNSC	cis	rs1218582	0.804	rs869506	ENSG00000270361.1	RP11-307C12.13	-5.1	4.94e-07	0.000141	-0.25	-0.23	Prostate cancer;	chr1:154887105	chr1:154937370~154938059:+
HNSC	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	5.1	4.94e-07	0.000141	0.26	0.23	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
HNSC	cis	rs155076	1	rs261369	ENSG00000233325.3	MIPEPP3	5.1	4.94e-07	0.000141	0.4	0.23	White matter hyperintensity burden;	chr13:21294281	chr13:21298139~21306373:+
HNSC	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	5.1	4.94e-07	0.000141	0.28	0.23	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
HNSC	cis	rs7083	0.716	rs687740	ENSG00000254851.1	RP11-109L13.1	-5.1	4.94e-07	0.000141	-0.31	-0.23	Blood protein levels;	chr11:117306887	chr11:117135528~117138582:+
HNSC	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	5.1	4.94e-07	0.000141	0.57	0.23	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
HNSC	cis	rs7819412	0.805	rs4333549	ENSG00000255310.2	AF131215.2	-5.1	4.94e-07	0.000141	-0.22	-0.23	Triglycerides;	chr8:11122051	chr8:11107788~11109726:-
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000254340.1	RP11-10A14.3	5.1	4.95e-07	0.000141	0.28	0.23	Mood instability;	chr8:8817815	chr8:9141424~9145435:+
HNSC	cis	rs2998286	0.666	rs2491251	ENSG00000254635.4	WAC-AS1	-5.1	4.95e-07	0.000141	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28522652~28532743:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000254153.1	CTA-398F10.2	-5.1	4.95e-07	0.000141	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9025061	chr8:8456909~8461337:-
HNSC	cis	rs3806843	0.735	rs809635	ENSG00000202515.1	VTRNA1-3	5.1	4.95e-07	0.000141	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr5:140726158~140726246:+
HNSC	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-5.1	4.95e-07	0.000141	-0.26	-0.23	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
HNSC	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-5.1	4.95e-07	0.000141	-0.29	-0.23	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
HNSC	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-5.1	4.95e-07	0.000141	-0.25	-0.23	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
HNSC	cis	rs2985684	1	rs2224949	ENSG00000258568.1	RHOQP1	-5.1	4.95e-07	0.000141	-0.23	-0.23	Carotid intima media thickness;	chr14:49629842	chr14:49599994~49600572:+
HNSC	cis	rs860818	1	rs858315	ENSG00000226816.2	AC005082.12	5.1	4.96e-07	0.000141	0.59	0.23	Initial pursuit acceleration;	chr7:23164348	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858314	ENSG00000226816.2	AC005082.12	5.1	4.96e-07	0.000141	0.59	0.23	Initial pursuit acceleration;	chr7:23164932	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858313	ENSG00000226816.2	AC005082.12	5.1	4.96e-07	0.000141	0.59	0.23	Initial pursuit acceleration;	chr7:23165118	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.655	rs6968416	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158042	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs9639457	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158090	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.655	rs6461696	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158225	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6461697	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158468	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs6949272	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158750	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs12700419	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23158881	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs7807516	ENSG00000226816.2	AC005082.12	-5.1	4.96e-07	0.000141	-0.59	-0.23	Initial pursuit acceleration;	chr7:23163147	chr7:23206013~23208045:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-5.1	4.96e-07	0.000141	-0.21	-0.23	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
HNSC	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-5.1	4.96e-07	0.000141	-0.28	-0.23	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
HNSC	cis	rs6061231	0.556	rs6121571	ENSG00000275437.1	RP5-908M14.10	5.1	4.96e-07	0.000141	0.23	0.23	Colorectal cancer;	chr20:62402267	chr20:62402236~62405935:-
HNSC	cis	rs721917	0.629	rs1304463	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.96e-07	0.000141	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79663088~79826594:-
HNSC	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	5.1	4.96e-07	0.000142	0.28	0.23	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000254340.1	RP11-10A14.3	5.1	4.97e-07	0.000142	0.28	0.23	Mood instability;	chr8:8822104	chr8:9141424~9145435:+
HNSC	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-5.1	4.97e-07	0.000142	-0.27	-0.23	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
HNSC	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	5.1	4.98e-07	0.000142	0.33	0.23	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
HNSC	cis	rs6693567	0.545	rs6699093	ENSG00000228126.1	FALEC	-5.1	4.98e-07	0.000142	-0.27	-0.23	Migraine;	chr1:150467975	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs6684939	ENSG00000228126.1	FALEC	-5.1	4.98e-07	0.000142	-0.27	-0.23	Migraine;	chr1:150468087	chr1:150515757~150518032:+
HNSC	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	5.1	4.98e-07	0.000142	0.34	0.23	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
HNSC	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-5.1	4.98e-07	0.000142	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
HNSC	cis	rs2579103	0.63	rs1222611	ENSG00000258183.4	RP11-753N8.1	-5.1	4.98e-07	0.000142	-0.3	-0.23	Body mass index;	chr12:90315884	chr12:90280894~90300340:+
HNSC	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	5.1	4.98e-07	0.000142	0.38	0.23	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
HNSC	cis	rs3733585	0.725	rs10939636	ENSG00000250413.1	RP11-448G15.1	5.1	4.98e-07	0.000142	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9971016	chr4:10006482~10009725:+
HNSC	cis	rs7789940	0.904	rs6948661	ENSG00000231087.2	FDPSP7	-5.1	4.98e-07	0.000142	-0.28	-0.23	Multiple sclerosis;	chr7:76332330	chr7:76968197~76969250:-
HNSC	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	5.1	4.99e-07	0.000142	0.3	0.23	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
HNSC	cis	rs36093844	0.752	rs79516304	ENSG00000279742.1	RP11-700A24.1	-5.1	4.99e-07	0.000142	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836192	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs77197861	ENSG00000279742.1	RP11-700A24.1	-5.1	4.99e-07	0.000142	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836362	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs1445511	ENSG00000279742.1	RP11-700A24.1	-5.1	4.99e-07	0.000142	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837006	chr11:85852557~85854943:-
HNSC	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-5.1	4.99e-07	0.000142	-0.27	-0.23	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
HNSC	cis	rs8062405	0.558	rs231976	ENSG00000251417.2	RP11-1348G14.4	-5.1	5e-07	0.000142	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28802743~28817828:+
HNSC	cis	rs9840812	0.769	rs1279425	ENSG00000239213.4	NCK1-AS1	5.1	5e-07	0.000142	0.21	0.23	Fibrinogen levels;	chr3:136288142	chr3:136841726~136862054:-
HNSC	cis	rs36423	0.668	rs36369	ENSG00000266869.1	RP6-114E22.1	-5.1	5e-07	0.000143	-0.39	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71910726	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.668	rs36368	ENSG00000266869.1	RP6-114E22.1	-5.1	5e-07	0.000143	-0.39	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71910897	chr14:71848606~71908430:+
HNSC	cis	rs3785309	0.519	rs7197253	ENSG00000268836.1	LA16c-OS12.2	-5.1	5e-07	0.000143	-0.38	-0.23	Immature fraction of reticulocytes;	chr16:226550	chr16:185748~186294:-
HNSC	cis	rs330048	0.545	rs11781008	ENSG00000254340.1	RP11-10A14.3	5.1	5e-07	0.000143	0.29	0.23	Systemic lupus erythematosus;	chr8:9295729	chr8:9141424~9145435:+
HNSC	cis	rs3206736	0.549	rs10282424	ENSG00000197085.10	NPSR1-AS1	5.1	5e-07	0.000143	0.3	0.23	Diastolic blood pressure;	chr7:35171523	chr7:34346512~34871582:-
HNSC	cis	rs10995505	0.589	rs1553789	ENSG00000232075.1	MRPL35P2	5.1	5e-07	0.000143	0.3	0.23	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63634317~63634827:-
HNSC	cis	rs3733585	0.673	rs4519796	ENSG00000250413.1	RP11-448G15.1	5.1	5e-07	0.000143	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954312	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4312757	ENSG00000250413.1	RP11-448G15.1	5.1	5e-07	0.000143	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954521	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs6814664	ENSG00000250413.1	RP11-448G15.1	5.1	5e-07	0.000143	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954604	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.588	rs6449154	ENSG00000250413.1	RP11-448G15.1	5.1	5e-07	0.000143	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954780	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.638	rs6449155	ENSG00000250413.1	RP11-448G15.1	5.1	5e-07	0.000143	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954923	chr4:10006482~10009725:+
HNSC	cis	rs62344088	1	rs6880143	ENSG00000277812.1	AC021087.1	5.1	5.01e-07	0.000143	0.58	0.23	Asthma (childhood onset);	chr5:137401	chr5:262769~262881:+
HNSC	cis	rs12997796	1	rs12997796	ENSG00000273080.1	RP11-301O19.1	5.1	5.01e-07	0.000143	0.3	0.23	Schizophrenia;	chr2:86747195	chr2:86195590~86196049:+
HNSC	cis	rs12682352	0.602	rs13260419	ENSG00000254340.1	RP11-10A14.3	5.1	5.01e-07	0.000143	0.28	0.23	Neuroticism;	chr8:8817666	chr8:9141424~9145435:+
HNSC	cis	rs7590368	0.926	rs12621237	ENSG00000272275.1	RP11-791G15.2	5.1	5.01e-07	0.000143	0.29	0.23	Educational attainment (years of education);	chr2:10817412	chr2:10767875~10770058:-
HNSC	cis	rs4657482	0.962	rs4657484	ENSG00000236364.3	RP11-525G13.2	-5.1	5.01e-07	0.000143	-0.22	-0.23	Testicular germ cell tumor;	chr1:165864886	chr1:165890795~165900683:-
HNSC	cis	rs4657482	0.962	rs4657485	ENSG00000236364.3	RP11-525G13.2	-5.1	5.01e-07	0.000143	-0.22	-0.23	Testicular germ cell tumor;	chr1:165865015	chr1:165890795~165900683:-
HNSC	cis	rs9291683	0.566	rs13115776	ENSG00000250413.1	RP11-448G15.1	-5.1	5.01e-07	0.000143	-0.28	-0.23	Bone mineral density;	chr4:10038565	chr4:10006482~10009725:+
HNSC	cis	rs14027	0.577	rs12707876	ENSG00000279347.1	RP11-85I17.2	-5.1	5.02e-07	0.000143	-0.19	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119730143	chr8:119838736~119840385:-
HNSC	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	5.1	5.02e-07	0.000143	0.27	0.23	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
HNSC	cis	rs763121	0.813	rs2179143	ENSG00000273076.1	RP3-508I15.22	5.1	5.02e-07	0.000143	0.22	0.23	Menopause (age at onset);	chr22:38641979	chr22:38743495~38743910:+
HNSC	cis	rs9840812	0.769	rs548288	ENSG00000273486.1	RP11-731C17.2	-5.1	5.02e-07	0.000143	-0.2	-0.23	Fibrinogen levels;	chr3:136250913	chr3:136837338~136839021:-
HNSC	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-5.1	5.02e-07	0.000143	-0.24	-0.23	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
HNSC	cis	rs6964833	1	rs4717906	ENSG00000184616.8	AC004166.6	5.1	5.02e-07	0.000143	0.28	0.23	Menarche (age at onset);	chr7:74671923	chr7:74906673~74913256:-
HNSC	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-5.1	5.03e-07	0.000143	-0.17	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
HNSC	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	5.1	5.03e-07	0.000143	0.32	0.23	Height;	chr4:57019797	chr4:56960927~56961373:-
HNSC	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-5.1	5.03e-07	0.000143	-0.23	-0.23	Height;	chr5:36995103	chr5:36666214~36725195:-
HNSC	cis	rs75422866	0.51	rs73105818	ENSG00000274902.1	RP1-197B17.4	5.1	5.03e-07	0.000143	0.51	0.23	Pneumonia;	chr12:47726538	chr12:47731908~47732351:+
HNSC	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	5.1	5.04e-07	0.000143	0.26	0.23	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
HNSC	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	5.1	5.04e-07	0.000143	0.17	0.23	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
HNSC	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-5.1	5.05e-07	0.000144	-0.22	-0.23	Height;	chr5:36990381	chr5:36666214~36725195:-
HNSC	cis	rs17428076	0.837	rs62182430	ENSG00000228389.1	AC068039.4	-5.1	5.05e-07	0.000144	-0.29	-0.23	Myopia;	chr2:171916327	chr2:171773482~171775844:+
HNSC	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-5.1	5.05e-07	0.000144	-0.28	-0.23	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
HNSC	cis	rs9863	0.931	rs3186071	ENSG00000269938.1	RP11-214K3.20	-5.1	5.06e-07	0.000144	-0.27	-0.23	White blood cell count;	chr12:123944732	chr12:123968023~123968579:-
HNSC	cis	rs6981523	0.517	rs13251510	ENSG00000255310.2	AF131215.2	-5.1	5.06e-07	0.000144	-0.23	-0.23	Neuroticism;	chr8:11059464	chr8:11107788~11109726:-
HNSC	cis	rs62344088	1	rs6872393	ENSG00000277812.1	AC021087.1	-5.1	5.06e-07	0.000144	-0.61	-0.23	Asthma (childhood onset);	chr5:155739	chr5:262769~262881:+
HNSC	cis	rs42490	0.652	rs374957	ENSG00000251136.7	RP11-37B2.1	-5.1	5.06e-07	0.000144	-0.19	-0.23	Leprosy;	chr8:89825402	chr8:89609409~89757727:-
HNSC	cis	rs2933343	0.649	rs1683786	ENSG00000261159.1	RP11-723O4.9	5.1	5.06e-07	0.000144	0.23	0.23	IgG glycosylation;	chr3:128908109	chr3:128859716~128860526:-
HNSC	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-5.1	5.07e-07	0.000144	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-5.1	5.07e-07	0.000144	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-5.1	5.07e-07	0.000144	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-5.1	5.07e-07	0.000144	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-5.1	5.07e-07	0.000144	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
HNSC	cis	rs62344088	1	rs10065373	ENSG00000277812.1	AC021087.1	5.1	5.07e-07	0.000144	0.61	0.23	Asthma (childhood onset);	chr5:106704	chr5:262769~262881:+
HNSC	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	5.1	5.07e-07	0.000144	0.26	0.23	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
HNSC	cis	rs9840812	0.69	rs7628146	ENSG00000273486.1	RP11-731C17.2	5.1	5.07e-07	0.000144	0.2	0.23	Fibrinogen levels;	chr3:136279611	chr3:136837338~136839021:-
HNSC	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-5.1	5.07e-07	0.000144	-0.26	-0.23	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
HNSC	cis	rs9402743	0.632	rs7766804	ENSG00000217482.2	HMGB1P17	5.1	5.07e-07	0.000144	0.25	0.23	Systemic lupus erythematosus;	chr6:135772118	chr6:135636086~135636713:-
HNSC	cis	rs71520386	0.632	rs10254365	ENSG00000221740.1	SNORD93	-5.1	5.07e-07	0.000144	-0.26	-0.23	Fibrinogen levels;	chr7:22825135	chr7:22856613~22856686:+
HNSC	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	5.1	5.07e-07	0.000144	0.27	0.23	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
HNSC	cis	rs2134046	0.555	rs11854483	ENSG00000276710.3	CSPG4P8	-5.09	5.08e-07	0.000144	-0.24	-0.23	Cognitive ability;	chr15:82267217	chr15:82459472~82477258:+
HNSC	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	5.09	5.08e-07	0.000144	0.24	0.23	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
HNSC	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	5.09	5.08e-07	0.000144	0.5	0.23	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
HNSC	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-5.09	5.08e-07	0.000144	-0.23	-0.23	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	5.09	5.08e-07	0.000145	0.21	0.23	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
HNSC	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-5.09	5.08e-07	0.000145	-0.22	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
HNSC	cis	rs577676	0.524	rs601938	ENSG00000271811.1	RP1-79C4.4	5.09	5.08e-07	0.000145	0.26	0.23	Prevalent atrial fibrillation;	chr1:170661118	chr1:170667381~170669425:+
HNSC	cis	rs7789940	1	rs2072435	ENSG00000231087.2	FDPSP7	-5.09	5.08e-07	0.000145	-0.28	-0.23	Multiple sclerosis;	chr7:76329871	chr7:76968197~76969250:-
HNSC	cis	rs860295	0.702	rs10908471	ENSG00000203761.5	MSTO2P	-5.09	5.08e-07	0.000145	-0.18	-0.23	Body mass index;	chr1:155573151	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs10908472	ENSG00000203761.5	MSTO2P	-5.09	5.08e-07	0.000145	-0.18	-0.23	Body mass index;	chr1:155574465	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs11264383	ENSG00000203761.5	MSTO2P	-5.09	5.08e-07	0.000145	-0.18	-0.23	Body mass index;	chr1:155575555	chr1:155745829~155750137:+
HNSC	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-5.09	5.09e-07	0.000145	-0.24	-0.23	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
HNSC	cis	rs516805	0.748	rs6912610	ENSG00000279453.1	RP3-425C14.4	5.09	5.09e-07	0.000145	0.31	0.23	Lymphocyte counts;	chr6:122379961	chr6:122436789~122439223:-
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84390487	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84393989	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84396135	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84399732	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84400482	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84400554	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84400736	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84401537	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84401867	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000229212.6	RP11-561C5.4	-5.09	5.09e-07	0.000145	-0.33	-0.23	Schizophrenia;	chr15:84402196	chr15:85205440~85234795:-
HNSC	cis	rs13073817	0.582	rs13074889	ENSG00000228956.7	SATB1-AS1	5.09	5.09e-07	0.000145	0.24	0.23	Crohn's disease;	chr3:18652999	chr3:18445024~18920401:+
HNSC	cis	rs11098499	0.532	rs4833624	ENSG00000249244.1	RP11-548H18.2	5.09	5.09e-07	0.000145	0.29	0.23	Corneal astigmatism;	chr4:119664342	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.532	rs12512646	ENSG00000249244.1	RP11-548H18.2	5.09	5.09e-07	0.000145	0.29	0.23	Corneal astigmatism;	chr4:119664578	chr4:119391831~119395335:-
HNSC	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	5.09	5.09e-07	0.000145	0.29	0.23	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000173295.6	FAM86B3P	-5.09	5.1e-07	0.000145	-0.26	-0.23	Joint mobility (Beighton score);	chr8:8935833	chr8:8228595~8244865:+
HNSC	cis	rs860295	0.702	rs475550	ENSG00000203761.5	MSTO2P	-5.09	5.1e-07	0.000145	-0.18	-0.23	Body mass index;	chr1:155682290	chr1:155745829~155750137:+
HNSC	cis	rs9907295	0.584	rs2280787	ENSG00000270977.1	AC015849.16	-5.09	5.1e-07	0.000145	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35930046	chr17:35893707~35911023:-
HNSC	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	5.09	5.11e-07	0.000145	0.26	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
HNSC	cis	rs6928977	0.863	rs2614275	ENSG00000234084.1	RP3-388E23.2	5.09	5.11e-07	0.000145	0.24	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135337376	chr6:135301568~135307158:+
HNSC	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	5.09	5.11e-07	0.000145	0.37	0.23	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
HNSC	cis	rs7048146	0.509	rs36049958	ENSG00000213539.4	YBX1P6	5.09	5.11e-07	0.000145	0.33	0.23	Vascular brain injury;	chr9:109568491	chr9:109532830~109534332:-
HNSC	cis	rs3806843	0.648	rs2530233	ENSG00000202515.1	VTRNA1-3	5.09	5.11e-07	0.000145	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr5:140726158~140726246:+
HNSC	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-5.09	5.12e-07	0.000145	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000254153.1	CTA-398F10.2	5.09	5.12e-07	0.000145	0.25	0.23	Joint mobility (Beighton score);	chr8:9044861	chr8:8456909~8461337:-
HNSC	cis	rs72949976	0.646	rs4673731	ENSG00000270659.1	RP11-105N14.1	-5.09	5.12e-07	0.000146	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213163820	chr2:213152970~213153659:+
HNSC	cis	rs72949976	0.646	rs13029384	ENSG00000270659.1	RP11-105N14.1	-5.09	5.12e-07	0.000146	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213164440	chr2:213152970~213153659:+
HNSC	cis	rs72949976	0.606	rs2178756	ENSG00000270659.1	RP11-105N14.1	-5.09	5.12e-07	0.000146	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213166699	chr2:213152970~213153659:+
HNSC	cis	rs287982	0.611	rs80238678	ENSG00000269973.1	RP11-95D17.1	-5.09	5.12e-07	0.000146	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9836053	chr2:9936360~9939590:+
HNSC	cis	rs36423	0.748	rs36376	ENSG00000266869.1	RP6-114E22.1	-5.09	5.12e-07	0.000146	-0.39	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71906084	chr14:71848606~71908430:+
HNSC	cis	rs17270561	0.578	rs76182885	ENSG00000272810.1	U91328.22	-5.09	5.13e-07	0.000146	-0.26	-0.23	Iron status biomarkers;	chr6:25903857	chr6:26013241~26013757:+
HNSC	cis	rs17270561	0.541	rs12192932	ENSG00000272810.1	U91328.22	-5.09	5.13e-07	0.000146	-0.26	-0.23	Iron status biomarkers;	chr6:25911274	chr6:26013241~26013757:+
HNSC	cis	rs12893668	0.572	rs1606	ENSG00000269940.1	RP11-73M18.7	5.09	5.13e-07	0.000146	0.22	0.23	Reticulocyte count;	chr14:103694944	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.543	rs1799796	ENSG00000269940.1	RP11-73M18.7	5.09	5.13e-07	0.000146	0.22	0.23	Reticulocyte count;	chr14:103699590	chr14:103694560~103695170:+
HNSC	cis	rs3811273	0.614	rs7155927	ENSG00000211816.2	TRAV38-1	5.09	5.13e-07	0.000146	0.25	0.23	Periodontal disease-related phenotypes;	chr14:22263097	chr14:22271968~22272563:+
HNSC	cis	rs9813712	0.855	rs10934930	ENSG00000249846.5	RP11-77P16.4	5.09	5.13e-07	0.000146	0.28	0.23	Response to amphetamines;	chr3:130259564	chr3:130112550~130120579:+
HNSC	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	5.09	5.13e-07	0.000146	0.32	0.23	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
HNSC	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	5.09	5.13e-07	0.000146	0.32	0.23	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
HNSC	cis	rs367615	0.918	rs115145487	ENSG00000249476.1	CTD-2587M2.1	5.09	5.14e-07	0.000146	0.31	0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109552445	chr5:109237120~109326369:-
HNSC	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-5.09	5.14e-07	0.000146	-0.22	-0.23	Height;	chr5:36804263	chr5:36666214~36725195:-
HNSC	cis	rs12821008	1	rs12821008	ENSG00000258017.1	RP11-386G11.10	-5.09	5.15e-07	0.000146	-0.27	-0.23	Bone mineral density;	chr12:49080822	chr12:49127782~49147869:+
HNSC	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	5.09	5.15e-07	0.000146	0.27	0.23	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
HNSC	cis	rs860295	0.702	rs12067371	ENSG00000203761.5	MSTO2P	-5.09	5.15e-07	0.000146	-0.18	-0.23	Body mass index;	chr1:155467878	chr1:155745829~155750137:+
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	5.09	5.15e-07	0.000146	0.19	0.23	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000254174.1	IGHV1-12	5.09	5.16e-07	0.000146	0.21	0.23	Alzheimer's disease (late onset);	chr14:106767918	chr14:106122420~106122709:-
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000254340.1	RP11-10A14.3	5.09	5.16e-07	0.000146	0.28	0.23	Joint mobility (Beighton score);	chr8:9003920	chr8:9141424~9145435:+
HNSC	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-5.09	5.16e-07	0.000147	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
HNSC	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-5.09	5.16e-07	0.000147	-0.27	-0.23	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
HNSC	cis	rs9921338	1	rs8049173	ENSG00000263080.1	RP11-485G7.5	5.09	5.16e-07	0.000147	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11341809~11345211:-
HNSC	cis	rs9921338	1	rs8055427	ENSG00000263080.1	RP11-485G7.5	5.09	5.16e-07	0.000147	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11341809~11345211:-
HNSC	cis	rs2933343	0.7	rs1683777	ENSG00000261159.1	RP11-723O4.9	5.09	5.16e-07	0.000147	0.23	0.23	IgG glycosylation;	chr3:128906037	chr3:128859716~128860526:-
HNSC	cis	rs7809950	1	rs10273733	ENSG00000238832.1	snoU109	5.09	5.17e-07	0.000147	0.3	0.23	Coronary artery disease;	chr7:107617676	chr7:107603363~107603507:+
HNSC	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	5.09	5.17e-07	0.000147	0.34	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
HNSC	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	5.09	5.17e-07	0.000147	0.26	0.23	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
HNSC	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-5.09	5.17e-07	0.000147	-0.32	-0.23	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
HNSC	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-5.09	5.18e-07	0.000147	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-5.09	5.18e-07	0.000147	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-5.09	5.18e-07	0.000147	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-5.09	5.18e-07	0.000147	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-5.09	5.18e-07	0.000147	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
HNSC	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	5.09	5.18e-07	0.000147	0.25	0.23	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
HNSC	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-5.09	5.18e-07	0.000147	-0.27	-0.23	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000254153.1	CTA-398F10.2	-5.09	5.18e-07	0.000147	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9047129	chr8:8456909~8461337:-
HNSC	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-5.09	5.18e-07	0.000147	-0.25	-0.23	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
HNSC	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	5.09	5.18e-07	0.000147	0.28	0.23	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
HNSC	cis	rs13073817	0.562	rs7614445	ENSG00000228956.7	SATB1-AS1	5.09	5.18e-07	0.000147	0.24	0.23	Crohn's disease;	chr3:18651172	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.582	rs10780006	ENSG00000228956.7	SATB1-AS1	5.09	5.18e-07	0.000147	0.24	0.23	Crohn's disease;	chr3:18651699	chr3:18445024~18920401:+
HNSC	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-5.09	5.19e-07	0.000147	-0.24	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
HNSC	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	5.09	5.19e-07	0.000147	0.17	0.23	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	5.09	5.19e-07	0.000147	0.17	0.23	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-5.09	5.19e-07	0.000147	-0.17	-0.23	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-5.09	5.19e-07	0.000147	-0.17	-0.23	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000254340.1	RP11-10A14.3	5.09	5.2e-07	0.000147	0.27	0.23	Mood instability;	chr8:8814919	chr8:9141424~9145435:+
HNSC	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	5.09	5.2e-07	0.000148	0.35	0.23	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
HNSC	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-5.09	5.2e-07	0.000148	-0.29	-0.23	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
HNSC	cis	rs72949976	0.646	rs1441169	ENSG00000270659.1	RP11-105N14.1	-5.09	5.2e-07	0.000148	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213168806	chr2:213152970~213153659:+
HNSC	cis	rs2998286	0.862	rs2807740	ENSG00000254635.4	WAC-AS1	-5.09	5.21e-07	0.000148	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28495554	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.862	rs2807738	ENSG00000254635.4	WAC-AS1	-5.09	5.21e-07	0.000148	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28496479	chr10:28522652~28532743:-
HNSC	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-5.09	5.21e-07	0.000148	-0.21	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
HNSC	cis	rs9304742	0.962	rs1044467	ENSG00000213801.4	ZNF816-ZNF321P	5.09	5.21e-07	0.000148	0.26	0.23	Psoriasis;	chr19:52949516	chr19:52927135~52942601:-
HNSC	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	5.09	5.21e-07	0.000148	0.23	0.23	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000254153.1	CTA-398F10.2	-5.09	5.21e-07	0.000148	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9047352	chr8:8456909~8461337:-
HNSC	cis	rs9402743	0.666	rs9373149	ENSG00000217482.2	HMGB1P17	5.09	5.22e-07	0.000148	0.26	0.23	Systemic lupus erythematosus;	chr6:135724264	chr6:135636086~135636713:-
HNSC	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-5.09	5.22e-07	0.000148	-0.38	-0.23	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
HNSC	cis	rs7615952	0.641	rs6438951	ENSG00000248787.1	RP11-666A20.4	-5.09	5.22e-07	0.000148	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125978156	chr3:125908005~125910272:-
HNSC	cis	rs2985684	0.789	rs1957979	ENSG00000278009.1	RP11-649E7.8	5.09	5.22e-07	0.000148	0.3	0.23	Carotid intima media thickness;	chr14:49596614	chr14:49601011~49601124:-
HNSC	cis	rs2985684	0.789	rs7161649	ENSG00000278009.1	RP11-649E7.8	5.09	5.22e-07	0.000148	0.3	0.23	Carotid intima media thickness;	chr14:49597310	chr14:49601011~49601124:-
HNSC	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	5.09	5.23e-07	0.000148	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	5.09	5.23e-07	0.000148	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
HNSC	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	5.09	5.23e-07	0.000148	0.32	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
HNSC	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-5.09	5.23e-07	0.000148	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
HNSC	cis	rs763567	0.935	rs1234275	ENSG00000271811.1	RP1-79C4.4	-5.09	5.23e-07	0.000148	-0.24	-0.23	Tonsillectomy;	chr1:170627117	chr1:170667381~170669425:+
HNSC	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-5.09	5.23e-07	0.000148	-0.26	-0.23	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
HNSC	cis	rs155076	1	rs155076	ENSG00000233325.3	MIPEPP3	5.09	5.23e-07	0.000148	0.39	0.23	White matter hyperintensity burden;	chr13:21295975	chr13:21298139~21306373:+
HNSC	cis	rs12291225	0.585	rs10832242	ENSG00000251991.1	RNU7-49P	-5.09	5.24e-07	0.000149	-0.26	-0.23	Sense of smell;	chr11:14318958	chr11:14478892~14478953:+
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000204709.4	LINC01556	5.09	5.25e-07	0.000149	0.36	0.23	Depression;	chr6:28103220	chr6:28943877~28944537:+
HNSC	cis	rs17818399	0.815	rs35837037	ENSG00000279254.1	RP11-536C12.1	-5.09	5.25e-07	0.000149	-0.26	-0.23	Height;	chr2:46634161	chr2:46668870~46670778:+
HNSC	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-5.09	5.25e-07	0.000149	-0.22	-0.23	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000254174.1	IGHV1-12	5.09	5.25e-07	0.000149	0.19	0.23	Alzheimer's disease (late onset);	chr14:106779632	chr14:106122420~106122709:-
HNSC	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	5.09	5.25e-07	0.000149	0.28	0.23	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
HNSC	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	5.09	5.27e-07	0.000149	0.32	0.23	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
HNSC	cis	rs3015497	0.527	rs2934668	ENSG00000269906.1	RP11-248J18.2	-5.09	5.28e-07	0.00015	-0.31	-0.23	Mean platelet volume;	chr14:50686807	chr14:50662511~50663178:-
HNSC	cis	rs9840812	0.691	rs1070232	ENSG00000239213.4	NCK1-AS1	5.09	5.28e-07	0.00015	0.21	0.23	Fibrinogen levels;	chr3:136529245	chr3:136841726~136862054:-
HNSC	cis	rs14027	0.512	rs13253139	ENSG00000279347.1	RP11-85I17.2	5.09	5.28e-07	0.00015	0.2	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718225	chr8:119838736~119840385:-
HNSC	cis	rs1056107	0.831	rs10125827	ENSG00000225513.1	RP11-165N19.2	5.09	5.29e-07	0.00015	0.24	0.23	Colorectal cancer;	chr9:112182226	chr9:112173522~112173971:-
HNSC	cis	rs9650657	0.589	rs12542037	ENSG00000269918.1	AF131215.9	5.09	5.29e-07	0.00015	0.23	0.23	Neuroticism;	chr8:10900986	chr8:11104691~11106704:-
HNSC	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	5.09	5.29e-07	0.00015	0.2	0.23	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
HNSC	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-5.09	5.3e-07	0.00015	-0.28	-0.23	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
HNSC	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	5.09	5.3e-07	0.00015	0.31	0.23	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
HNSC	cis	rs1056107	0.931	rs7863117	ENSG00000225513.1	RP11-165N19.2	-5.09	5.3e-07	0.00015	-0.25	-0.23	Colorectal cancer;	chr9:112253559	chr9:112173522~112173971:-
HNSC	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-5.09	5.3e-07	0.00015	-0.29	-0.23	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
HNSC	cis	rs1971762	0.545	rs10783586	ENSG00000270175.1	RP11-793H13.11	-5.09	5.31e-07	0.00015	-0.2	-0.23	Height;	chr12:53587037	chr12:53500162~53500936:-
HNSC	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	5.09	5.31e-07	0.00015	0.26	0.23	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
HNSC	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	5.09	5.31e-07	0.00015	0.24	0.23	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
HNSC	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	5.09	5.31e-07	0.00015	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
HNSC	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	5.09	5.31e-07	0.00015	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	5.09	5.31e-07	0.00015	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
HNSC	cis	rs1008375	0.898	rs4698623	ENSG00000249502.1	AC006160.5	-5.09	5.31e-07	0.00015	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17593079	chr4:17587467~17614571:-
HNSC	cis	rs9840812	0.623	rs6794351	ENSG00000239213.4	NCK1-AS1	5.09	5.31e-07	0.00015	0.21	0.23	Fibrinogen levels;	chr3:136573437	chr3:136841726~136862054:-
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000254153.1	CTA-398F10.2	-5.09	5.32e-07	0.00015	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9053798	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000179406.6	LINC00174	-5.09	5.32e-07	0.00015	-0.5	-0.23	Diabetic kidney disease;	chr7:65924813	chr7:66376044~66401338:-
HNSC	cis	rs1056107	0.7	rs10817274	ENSG00000225513.1	RP11-165N19.2	-5.09	5.32e-07	0.000151	-0.25	-0.23	Colorectal cancer;	chr9:112167691	chr9:112173522~112173971:-
HNSC	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-5.09	5.32e-07	0.000151	-0.25	-0.23	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
HNSC	cis	rs10462794	0.661	rs4702801	ENSG00000260763.1	RP11-445O3.3	-5.09	5.33e-07	0.000151	-0.34	-0.23	DNA methylation (variation);	chr5:4522715	chr5:4436850~4440259:-
HNSC	cis	rs9921338	0.961	rs7626	ENSG00000263080.1	RP11-485G7.5	5.09	5.33e-07	0.000151	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11341809~11345211:-
HNSC	cis	rs9402743	0.634	rs6923032	ENSG00000234084.1	RP3-388E23.2	-5.09	5.33e-07	0.000151	-0.24	-0.23	Systemic lupus erythematosus;	chr6:135597708	chr6:135301568~135307158:+
HNSC	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	5.09	5.33e-07	0.000151	0.32	0.23	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
HNSC	cis	rs2834288	0.535	rs7278341	ENSG00000273102.1	AP000569.9	5.08	5.33e-07	0.000151	0.25	0.23	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.535	rs7279183	ENSG00000273102.1	AP000569.9	5.08	5.33e-07	0.000151	0.25	0.23	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33967101~33968573:-
HNSC	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	5.08	5.34e-07	0.000151	0.39	0.23	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
HNSC	cis	rs7048146	0.509	rs12554063	ENSG00000213539.4	YBX1P6	5.08	5.34e-07	0.000151	0.32	0.23	Vascular brain injury;	chr9:109555182	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs4978834	ENSG00000213539.4	YBX1P6	5.08	5.34e-07	0.000151	0.32	0.23	Vascular brain injury;	chr9:109555632	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs67971143	ENSG00000213539.4	YBX1P6	5.08	5.34e-07	0.000151	0.32	0.23	Vascular brain injury;	chr9:109556025	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs11790626	ENSG00000213539.4	YBX1P6	5.08	5.34e-07	0.000151	0.32	0.23	Vascular brain injury;	chr9:109556939	chr9:109532830~109534332:-
HNSC	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	5.08	5.34e-07	0.000151	0.36	0.23	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
HNSC	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	5.08	5.34e-07	0.000151	0.3	0.23	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-5.08	5.35e-07	0.000151	-0.21	-0.23	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
HNSC	cis	rs7824557	0.713	rs6601575	ENSG00000269918.1	AF131215.9	5.08	5.35e-07	0.000151	0.23	0.23	Retinal vascular caliber;	chr8:11240295	chr8:11104691~11106704:-
HNSC	cis	rs4664293	0.609	rs10167143	ENSG00000226266.5	AC009961.3	-5.08	5.35e-07	0.000151	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159606885	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.669	rs13389096	ENSG00000226266.5	AC009961.3	-5.08	5.35e-07	0.000151	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159611246	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.55	rs13388082	ENSG00000226266.5	AC009961.3	-5.08	5.35e-07	0.000151	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159616439	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.582	rs1046496	ENSG00000226266.5	AC009961.3	-5.08	5.35e-07	0.000151	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159616888	chr2:159670708~159712435:-
HNSC	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	5.08	5.35e-07	0.000151	0.25	0.23	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
HNSC	cis	rs9921338	0.961	rs7195536	ENSG00000263080.1	RP11-485G7.5	5.08	5.35e-07	0.000151	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11341809~11345211:-
HNSC	cis	rs4218	0.532	rs17236369	ENSG00000259732.1	RP11-59H7.3	-5.08	5.35e-07	0.000151	-0.28	-0.23	Social communication problems;	chr15:59021656	chr15:59121034~59133250:+
HNSC	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-5.08	5.35e-07	0.000151	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
HNSC	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	5.08	5.36e-07	0.000152	0.28	0.23	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
HNSC	cis	rs3806843	0.706	rs2563302	ENSG00000202515.1	VTRNA1-3	5.08	5.36e-07	0.000152	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr5:140726158~140726246:+
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000211970.3	IGHV4-61	-5.08	5.36e-07	0.000152	-0.14	-0.23	Kawasaki disease;	chr14:106767802	chr14:106639119~106639657:-
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	5.08	5.37e-07	0.000152	0.28	0.23	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
HNSC	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	5.08	5.37e-07	0.000152	0.24	0.23	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
HNSC	cis	rs155076	1	rs195570	ENSG00000233325.3	MIPEPP3	5.08	5.38e-07	0.000152	0.4	0.23	White matter hyperintensity burden;	chr13:21293441	chr13:21298139~21306373:+
HNSC	cis	rs3733585	0.699	rs7658170	ENSG00000250413.1	RP11-448G15.1	-5.08	5.38e-07	0.000152	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9964969	chr4:10006482~10009725:+
HNSC	cis	rs12817211	0.502	rs59262224	ENSG00000272368.2	RP4-605O3.4	-5.08	5.38e-07	0.000152	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50117164	chr12:50112197~50165618:+
HNSC	cis	rs2836974	0.565	rs34304022	ENSG00000255568.3	BRWD1-AS2	5.08	5.38e-07	0.000152	0.26	0.23	Cognitive function;	chr21:39207693	chr21:39313935~39314962:+
HNSC	cis	rs34976449	1	rs34976449	ENSG00000232912.4	RP5-1115A15.1	5.08	5.39e-07	0.000152	0.24	0.23	Lymphocyte counts;	chr1:8438266	chr1:8424645~8434838:+
HNSC	cis	rs3733585	0.648	rs13125029	ENSG00000250413.1	RP11-448G15.1	-5.08	5.39e-07	0.000152	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9980405	chr4:10006482~10009725:+
HNSC	cis	rs4853525	0.59	rs1921910	ENSG00000235852.1	AC005540.3	5.08	5.39e-07	0.000152	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859206	chr2:190880797~190882059:-
HNSC	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	5.08	5.4e-07	0.000152	0.27	0.23	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
HNSC	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	5.08	5.4e-07	0.000152	0.32	0.23	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	5.08	5.4e-07	0.000152	0.32	0.23	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	5.08	5.4e-07	0.000152	0.32	0.23	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	5.08	5.4e-07	0.000152	0.32	0.23	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	5.08	5.4e-07	0.000152	0.32	0.23	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
HNSC	cis	rs12701220	1	rs12701220	ENSG00000229043.2	AC091729.9	-5.08	5.4e-07	0.000153	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:983092	chr7:1160374~1165267:+
HNSC	cis	rs12468226	0.689	rs17651413	ENSG00000226261.1	AC064836.3	5.08	5.4e-07	0.000153	0.35	0.23	Urate levels;	chr2:202104086	chr2:202336024~202336727:-
HNSC	cis	rs12935418	0.616	rs9936366	ENSG00000261061.1	RP11-303E16.2	-5.08	5.41e-07	0.000153	-0.27	-0.23	Mean corpuscular volume;	chr16:81011657	chr16:81030770~81031485:+
HNSC	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-5.08	5.41e-07	0.000153	-0.22	-0.23	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
HNSC	cis	rs3736485	0.808	rs28576876	ENSG00000259438.1	CTD-2650P22.1	5.08	5.41e-07	0.000153	0.23	0.23	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659055	chr15:52010999~52019095:-
HNSC	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	5.08	5.42e-07	0.000153	0.25	0.23	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	5.08	5.42e-07	0.000153	0.25	0.23	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
HNSC	cis	rs5758659	0.716	rs5758661	ENSG00000227370.1	RP4-669P10.19	-5.08	5.42e-07	0.000153	-0.22	-0.23	Cognitive function;	chr22:42228439	chr22:42132543~42132998:+
HNSC	cis	rs9291683	0.526	rs12506122	ENSG00000250413.1	RP11-448G15.1	-5.08	5.42e-07	0.000153	-0.28	-0.23	Bone mineral density;	chr4:10031914	chr4:10006482~10009725:+
HNSC	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	0.000153	0.26	0.23	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
HNSC	cis	rs9863	0.931	rs35825716	ENSG00000269938.1	RP11-214K3.20	-5.08	5.42e-07	0.000153	-0.28	-0.23	White blood cell count;	chr12:123942977	chr12:123968023~123968579:-
HNSC	cis	rs9436116	1	rs9436116	ENSG00000228126.1	FALEC	5.08	5.42e-07	0.000153	0.27	0.23	Morning vs. evening chronotype;	chr1:150482248	chr1:150515757~150518032:+
HNSC	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	5.08	5.42e-07	0.000153	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
HNSC	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	5.08	5.42e-07	0.000153	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
HNSC	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-5.08	5.42e-07	0.000153	-0.25	-0.23	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
HNSC	cis	rs712039	0.652	rs866465	ENSG00000276054.1	RP11-378E13.3	5.08	5.43e-07	0.000153	0.33	0.23	Tuberculosis;	chr17:37499298	chr17:37386886~37387926:+
HNSC	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-5.08	5.43e-07	0.000153	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
HNSC	cis	rs2810114	0.804	rs36567	ENSG00000274818.1	RP1-292L20.3	-5.08	5.43e-07	0.000153	-0.28	-0.23	Alcohol dependence;	chr14:70883900	chr14:70906657~70907111:-
HNSC	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	5.08	5.43e-07	0.000153	0.32	0.23	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
HNSC	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-5.08	5.43e-07	0.000153	-0.27	-0.23	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
HNSC	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-5.08	5.43e-07	0.000153	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
HNSC	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-5.08	5.44e-07	0.000153	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
HNSC	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-5.08	5.44e-07	0.000154	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
HNSC	cis	rs9921338	0.887	rs9926136	ENSG00000263080.1	RP11-485G7.5	5.08	5.45e-07	0.000154	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11341809~11345211:-
HNSC	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-5.08	5.46e-07	0.000154	-0.22	-0.23	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
HNSC	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	5.08	5.46e-07	0.000154	0.25	0.23	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
HNSC	cis	rs2115630	0.754	rs12595321	ENSG00000229212.6	RP11-561C5.4	5.08	5.46e-07	0.000154	0.28	0.23	P wave terminal force;	chr15:84788038	chr15:85205440~85234795:-
HNSC	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	5.08	5.46e-07	0.000154	0.2	0.23	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
HNSC	cis	rs5758659	0.679	rs134870	ENSG00000227370.1	RP4-669P10.19	-5.08	5.47e-07	0.000154	-0.22	-0.23	Cognitive function;	chr22:42256311	chr22:42132543~42132998:+
HNSC	cis	rs721917	0.607	rs4319455	ENSG00000225484.5	NUTM2B-AS1	-5.08	5.47e-07	0.000154	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79663088~79826594:-
HNSC	cis	rs13113518	1	rs4864994	ENSG00000273257.1	RP11-177J6.1	5.08	5.47e-07	0.000154	0.28	0.23	Height;	chr4:55451955	chr4:55387949~55388271:+
HNSC	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	5.08	5.47e-07	0.000154	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
HNSC	cis	rs3733585	0.699	rs7437120	ENSG00000250413.1	RP11-448G15.1	5.08	5.47e-07	0.000154	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9966059	chr4:10006482~10009725:+
HNSC	cis	rs3863381	0.764	rs76875414	ENSG00000277715.1	RP11-651L5.3	5.08	5.47e-07	0.000154	0.35	0.23	Night sleep phenotypes;	chr12:105719367	chr12:106250759~106252786:+
HNSC	cis	rs3733585	0.699	rs13328050	ENSG00000250413.1	RP11-448G15.1	5.08	5.48e-07	0.000154	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9949496	chr4:10006482~10009725:+
HNSC	cis	rs4664293	0.667	rs6432562	ENSG00000226266.5	AC009961.3	-5.08	5.48e-07	0.000155	-0.24	-0.23	Monocyte percentage of white cells;	chr2:159791495	chr2:159670708~159712435:-
HNSC	cis	rs4218	0.681	rs7178935	ENSG00000259732.1	RP11-59H7.3	-5.08	5.48e-07	0.000155	-0.3	-0.23	Social communication problems;	chr15:59075968	chr15:59121034~59133250:+
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000254153.1	CTA-398F10.2	-5.08	5.48e-07	0.000155	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9225906	chr8:8456909~8461337:-
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000254174.1	IGHV1-12	5.08	5.48e-07	0.000155	0.2	0.23	Alzheimer's disease (late onset);	chr14:106667423	chr14:106122420~106122709:-
HNSC	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	5.08	5.48e-07	0.000155	0.28	0.23	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
HNSC	cis	rs1799949	0.965	rs4239149	ENSG00000236383.6	LINC00854	5.08	5.49e-07	0.000155	0.21	0.23	Menopause (age at onset);	chr17:43176078	chr17:43216941~43305976:-
HNSC	cis	rs603446	0.967	rs2849179	ENSG00000254851.1	RP11-109L13.1	-5.08	5.49e-07	0.000155	-0.3	-0.23	Triglycerides;	chr11:116750080	chr11:117135528~117138582:+
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-5.08	5.49e-07	0.000155	-0.24	-0.23	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-5.08	5.49e-07	0.000155	-0.24	-0.23	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	5.08	5.5e-07	0.000155	0.28	0.23	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000173295.6	FAM86B3P	-5.08	5.5e-07	0.000155	-0.28	-0.23	Recombination measurement;	chr8:9208015	chr8:8228595~8244865:+
HNSC	cis	rs12701220	0.948	rs10275712	ENSG00000229043.2	AC091729.9	-5.08	5.5e-07	0.000155	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:1043282	chr7:1160374~1165267:+
HNSC	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	5.08	5.5e-07	0.000155	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
HNSC	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	5.08	5.5e-07	0.000155	0.27	0.23	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
HNSC	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	5.08	5.51e-07	0.000155	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000204709.4	LINC01556	5.08	5.51e-07	0.000155	0.32	0.23	Parkinson's disease;	chr6:28066959	chr6:28943877~28944537:+
HNSC	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	5.08	5.51e-07	0.000155	0.28	0.23	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
HNSC	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	5.08	5.51e-07	0.000155	0.24	0.23	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
HNSC	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5.08	5.52e-07	0.000156	-0.28	-0.23	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
HNSC	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-5.08	5.52e-07	0.000156	-0.26	-0.23	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
HNSC	cis	rs7674212	0.51	rs6856593	ENSG00000246560.2	RP11-10L12.4	5.08	5.52e-07	0.000156	0.27	0.23	Type 2 diabetes;	chr4:103256542	chr4:102828055~102844075:+
HNSC	cis	rs783540	0.521	rs1259176	ENSG00000255769.6	GOLGA2P10	5.08	5.52e-07	0.000156	0.31	0.23	Schizophrenia;	chr15:82602149	chr15:82472993~82513950:-
HNSC	cis	rs12468226	1	rs116635509	ENSG00000226261.1	AC064836.3	5.08	5.52e-07	0.000156	0.34	0.23	Urate levels;	chr2:202460027	chr2:202336024~202336727:-
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000254153.1	CTA-398F10.2	5.08	5.52e-07	0.000156	0.25	0.23	Mood instability;	chr8:8314761	chr8:8456909~8461337:-
HNSC	cis	rs9840812	0.769	rs3755636	ENSG00000239213.4	NCK1-AS1	5.08	5.53e-07	0.000156	0.21	0.23	Fibrinogen levels;	chr3:136249986	chr3:136841726~136862054:-
HNSC	cis	rs9890032	0.532	rs1808257	ENSG00000263531.1	RP13-753N3.1	5.08	5.53e-07	0.000156	0.27	0.23	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30863921~30864940:-
HNSC	cis	rs442309	0.553	rs10995278	ENSG00000238280.1	RP11-436D10.3	-5.08	5.53e-07	0.000156	-0.29	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62694737	chr10:62793562~62805887:-
HNSC	cis	rs4938303	0.633	rs567209	ENSG00000254851.1	RP11-109L13.1	5.08	5.53e-07	0.000156	0.4	0.23	Triglycerides;	chr11:116664111	chr11:117135528~117138582:+
HNSC	cis	rs9840812	0.769	rs1279840	ENSG00000273486.1	RP11-731C17.2	5.08	5.54e-07	0.000156	0.2	0.23	Fibrinogen levels;	chr3:136287734	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	5.08	5.54e-07	0.000156	0.28	0.23	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	5.08	5.54e-07	0.000156	0.28	0.23	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
HNSC	cis	rs712039	0.687	rs11656455	ENSG00000276054.1	RP11-378E13.3	5.08	5.54e-07	0.000156	0.33	0.23	Tuberculosis;	chr17:37411798	chr17:37386886~37387926:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-5.08	5.55e-07	0.000156	-0.28	-0.23	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
HNSC	cis	rs13434995	0.945	rs28473211	ENSG00000273257.1	RP11-177J6.1	-5.08	5.55e-07	0.000156	-0.35	-0.23	Adiponectin levels;	chr4:55615808	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.838	rs73236165	ENSG00000273257.1	RP11-177J6.1	-5.08	5.55e-07	0.000156	-0.35	-0.23	Adiponectin levels;	chr4:55617617	chr4:55387949~55388271:+
HNSC	cis	rs9611519	0.929	rs71327107	ENSG00000235513.1	RP4-756G23.5	5.08	5.55e-07	0.000156	0.27	0.23	Neuroticism;	chr22:41022225	chr22:41209122~41217627:-
HNSC	cis	rs10462794	0.661	rs57263812	ENSG00000260763.1	RP11-445O3.3	-5.08	5.55e-07	0.000156	-0.33	-0.23	DNA methylation (variation);	chr5:4521178	chr5:4436850~4440259:-
HNSC	cis	rs2337406	0.866	rs4773949	ENSG00000254174.1	IGHV1-12	-5.08	5.56e-07	0.000157	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106808070	chr14:106122420~106122709:-
HNSC	cis	rs2243480	1	rs35820085	ENSG00000179406.6	LINC00174	-5.08	5.57e-07	0.000157	-0.49	-0.23	Diabetic kidney disease;	chr7:65977771	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000179406.6	LINC00174	-5.08	5.57e-07	0.000157	-0.49	-0.23	Diabetic kidney disease;	chr7:65970805	chr7:66376044~66401338:-
HNSC	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	5.08	5.57e-07	0.000157	0.22	0.23	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
HNSC	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	5.08	5.57e-07	0.000157	0.28	0.23	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000254174.1	IGHV1-12	5.08	5.58e-07	0.000157	0.19	0.23	Alzheimer's disease (late onset);	chr14:106779385	chr14:106122420~106122709:-
HNSC	cis	rs3863381	0.764	rs78486541	ENSG00000277715.1	RP11-651L5.3	5.08	5.58e-07	0.000157	0.35	0.23	Night sleep phenotypes;	chr12:105719181	chr12:106250759~106252786:+
HNSC	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-5.08	5.58e-07	0.000157	-0.25	-0.23	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
HNSC	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	5.08	5.58e-07	0.000157	0.23	0.23	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
HNSC	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-5.08	5.58e-07	0.000157	-0.22	-0.23	Height;	chr5:36963703	chr5:36666214~36725195:-
HNSC	cis	rs2998286	0.862	rs2807732	ENSG00000254635.4	WAC-AS1	-5.08	5.58e-07	0.000157	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28522652~28532743:-
HNSC	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-5.08	5.59e-07	0.000157	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-5.08	5.59e-07	0.000157	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
HNSC	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-5.08	5.59e-07	0.000157	-0.26	-0.23	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-5.08	5.59e-07	0.000157	-0.28	-0.23	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
HNSC	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-5.08	5.59e-07	0.000157	-0.21	-0.23	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
HNSC	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	5.08	5.6e-07	0.000158	0.26	0.23	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
HNSC	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	5.08	5.6e-07	0.000158	0.23	0.23	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
HNSC	cis	rs860295	0.58	rs11264361	ENSG00000203761.5	MSTO2P	-5.08	5.6e-07	0.000158	-0.19	-0.23	Body mass index;	chr1:155319754	chr1:155745829~155750137:+
HNSC	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	5.07	5.61e-07	0.000158	0.29	0.23	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
HNSC	cis	rs28489187	0.558	rs2474123	ENSG00000223653.4	RP11-131L23.1	5.07	5.61e-07	0.000158	0.3	0.23	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85361769	chr1:85276715~85448124:+
HNSC	cis	rs7615952	0.512	rs2979336	ENSG00000248787.1	RP11-666A20.4	-5.07	5.61e-07	0.000158	-0.3	-0.23	Blood pressure (smoking interaction);	chr3:125638626	chr3:125908005~125910272:-
HNSC	cis	rs2933343	0.7	rs2249514	ENSG00000261159.1	RP11-723O4.9	5.07	5.62e-07	0.000158	0.23	0.23	IgG glycosylation;	chr3:128924969	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.7	rs2630257	ENSG00000261159.1	RP11-723O4.9	5.07	5.62e-07	0.000158	0.23	0.23	IgG glycosylation;	chr3:128925172	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs1680785	ENSG00000261159.1	RP11-723O4.9	5.07	5.62e-07	0.000158	0.23	0.23	IgG glycosylation;	chr3:128925973	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs1680786	ENSG00000261159.1	RP11-723O4.9	5.07	5.62e-07	0.000158	0.23	0.23	IgG glycosylation;	chr3:128925997	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.672	rs1872545	ENSG00000261159.1	RP11-723O4.9	5.07	5.62e-07	0.000158	0.23	0.23	IgG glycosylation;	chr3:128926196	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs1683816	ENSG00000261159.1	RP11-723O4.9	-5.07	5.62e-07	0.000158	-0.23	-0.23	IgG glycosylation;	chr3:128932352	chr3:128859716~128860526:-
HNSC	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	5.07	5.62e-07	0.000158	0.25	0.23	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	5.07	5.62e-07	0.000158	0.28	0.23	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
HNSC	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	5.07	5.62e-07	0.000158	0.25	0.23	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
HNSC	cis	rs9907295	0.818	rs4796112	ENSG00000270977.1	AC015849.16	5.07	5.63e-07	0.000158	0.33	0.23	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35893707~35911023:-
HNSC	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-5.07	5.63e-07	0.000158	-0.35	-0.23	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000254153.1	CTA-398F10.2	5.07	5.63e-07	0.000158	0.25	0.23	Systolic blood pressure;	chr8:8488264	chr8:8456909~8461337:-
HNSC	cis	rs4218	0.681	rs7178935	ENSG00000277144.1	RP11-59H7.4	-5.07	5.63e-07	0.000158	-0.28	-0.23	Social communication problems;	chr15:59075968	chr15:59115547~59116089:-
HNSC	cis	rs1971762	0.527	rs784568	ENSG00000270175.1	RP11-793H13.11	5.07	5.63e-07	0.000159	0.2	0.23	Height;	chr12:53533770	chr12:53500162~53500936:-
HNSC	cis	rs4218	0.638	rs12437587	ENSG00000277144.1	RP11-59H7.4	-5.07	5.63e-07	0.000159	-0.28	-0.23	Social communication problems;	chr15:59072785	chr15:59115547~59116089:-
HNSC	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-5.07	5.63e-07	0.000159	-0.19	-0.23	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
HNSC	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-5.07	5.64e-07	0.000159	-0.26	-0.23	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
HNSC	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-5.07	5.64e-07	0.000159	-0.26	-0.23	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
HNSC	cis	rs9291683	0.62	rs11722946	ENSG00000250413.1	RP11-448G15.1	5.07	5.64e-07	0.000159	0.29	0.23	Bone mineral density;	chr4:10124366	chr4:10006482~10009725:+
HNSC	cis	rs9863	0.931	rs4575361	ENSG00000269938.1	RP11-214K3.20	-5.07	5.65e-07	0.000159	-0.29	-0.23	White blood cell count;	chr12:123925982	chr12:123968023~123968579:-
HNSC	cis	rs3806843	0.518	rs2569188	ENSG00000202515.1	VTRNA1-3	5.07	5.65e-07	0.000159	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140628834	chr5:140726158~140726246:+
HNSC	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	5.07	5.65e-07	0.000159	0.24	0.23	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000233609.3	RP11-62H7.2	-5.07	5.65e-07	0.000159	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9035087	chr8:8961200~8979025:+
HNSC	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	5.07	5.66e-07	0.000159	0.22	0.23	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
HNSC	cis	rs4657482	0.962	rs10918300	ENSG00000236364.3	RP11-525G13.2	5.07	5.66e-07	0.000159	0.22	0.23	Testicular germ cell tumor;	chr1:165873488	chr1:165890795~165900683:-
HNSC	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-5.07	5.66e-07	0.000159	-0.31	-0.23	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
HNSC	cis	rs1799949	0.965	rs9646418	ENSG00000236383.6	LINC00854	-5.07	5.67e-07	0.000159	-0.21	-0.23	Menopause (age at onset);	chr17:43348533	chr17:43216941~43305976:-
HNSC	cis	rs2439831	0.702	rs495175	ENSG00000205771.5	CATSPER2P1	-5.07	5.67e-07	0.000159	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43506486	chr15:43726918~43747094:-
HNSC	cis	rs7809950	0.817	rs2712195	ENSG00000238832.1	snoU109	-5.07	5.67e-07	0.000159	-0.33	-0.23	Coronary artery disease;	chr7:107487051	chr7:107603363~107603507:+
HNSC	cis	rs6693567	0.565	rs8006	ENSG00000228126.1	FALEC	-5.07	5.67e-07	0.000159	-0.27	-0.23	Migraine;	chr1:150308367	chr1:150515757~150518032:+
HNSC	cis	rs3754214	0.857	rs488271	ENSG00000228126.1	FALEC	-5.07	5.67e-07	0.000159	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr1:150312090	chr1:150515757~150518032:+
HNSC	cis	rs3096299	0.838	rs4785561	ENSG00000261574.1	RP1-168P16.2	5.07	5.67e-07	0.00016	0.29	0.23	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89392375~89412564:-
HNSC	cis	rs860818	1	rs1621012	ENSG00000226816.2	AC005082.12	5.07	5.67e-07	0.00016	0.58	0.23	Initial pursuit acceleration;	chr7:23163714	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs1637244	ENSG00000226816.2	AC005082.12	5.07	5.67e-07	0.00016	0.58	0.23	Initial pursuit acceleration;	chr7:23163715	chr7:23206013~23208045:+
HNSC	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	5.07	5.67e-07	0.00016	0.33	0.23	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
HNSC	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-5.07	5.68e-07	0.00016	-0.28	-0.23	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-5.07	5.68e-07	0.00016	-0.28	-0.23	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
HNSC	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	5.07	5.68e-07	0.00016	0.25	0.23	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	5.07	5.68e-07	0.00016	0.25	0.23	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
HNSC	cis	rs7267979	0.657	rs6107073	ENSG00000231081.1	RP4-760C5.3	-5.07	5.68e-07	0.00016	-0.23	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26008791~26010531:-
HNSC	cis	rs9291683	0.51	rs4318649	ENSG00000250413.1	RP11-448G15.1	-5.07	5.69e-07	0.00016	-0.28	-0.23	Bone mineral density;	chr4:10015191	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.746	rs4318650	ENSG00000250413.1	RP11-448G15.1	-5.07	5.69e-07	0.00016	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:10015244	chr4:10006482~10009725:+
HNSC	cis	rs9300255	0.507	rs1727302	ENSG00000280120.1	RP11-546D6.3	5.07	5.69e-07	0.00016	0.2	0.23	Neutrophil percentage of white cells;	chr12:123148383	chr12:123152324~123153377:-
HNSC	cis	rs2985684	0.894	rs10147029	ENSG00000278009.1	RP11-649E7.8	-5.07	5.69e-07	0.00016	-0.29	-0.23	Carotid intima media thickness;	chr14:49553514	chr14:49601011~49601124:-
HNSC	cis	rs4388249	0.687	rs2269204	ENSG00000271849.1	CTC-332L22.1	-5.07	5.69e-07	0.00016	-0.31	-0.23	Schizophrenia;	chr5:109763402	chr5:109687802~109688329:-
HNSC	cis	rs36093844	0.698	rs55951560	ENSG00000279742.1	RP11-700A24.1	-5.07	5.69e-07	0.00016	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837299	chr11:85852557~85854943:-
HNSC	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	5.07	5.7e-07	0.00016	0.25	0.23	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
HNSC	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-5.07	5.7e-07	0.00016	-0.26	-0.23	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
HNSC	cis	rs36093844	0.66	rs895256	ENSG00000279742.1	RP11-700A24.1	-5.07	5.71e-07	0.00016	-0.34	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85824166	chr11:85852557~85854943:-
HNSC	cis	rs3733585	0.673	rs4455410	ENSG00000250413.1	RP11-448G15.1	-5.07	5.71e-07	0.000161	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9951673	chr4:10006482~10009725:+
HNSC	cis	rs2439831	1	rs101094	ENSG00000205771.5	CATSPER2P1	-5.07	5.71e-07	0.000161	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43495124	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2584725	ENSG00000205771.5	CATSPER2P1	-5.07	5.71e-07	0.000161	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43500937	chr15:43726918~43747094:-
HNSC	cis	rs3806843	0.778	rs2531346	ENSG00000202515.1	VTRNA1-3	5.07	5.71e-07	0.000161	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr5:140726158~140726246:+
HNSC	cis	rs853679	0.76	rs2299029	ENSG00000204709.4	LINC01556	5.07	5.71e-07	0.000161	0.33	0.23	Depression;	chr6:28231053	chr6:28943877~28944537:+
HNSC	cis	rs12701220	0.948	rs12690826	ENSG00000229043.2	AC091729.9	-5.07	5.71e-07	0.000161	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:1041982	chr7:1160374~1165267:+
HNSC	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-5.07	5.72e-07	0.000161	-0.2	-0.23	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
HNSC	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-5.07	5.72e-07	0.000161	-0.26	-0.23	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
HNSC	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	5.07	5.72e-07	0.000161	0.24	0.23	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
HNSC	cis	rs9840812	0.655	rs4452981	ENSG00000239213.4	NCK1-AS1	5.07	5.72e-07	0.000161	0.21	0.23	Fibrinogen levels;	chr3:136588925	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.861	rs1153871	ENSG00000273486.1	RP11-731C17.2	5.07	5.72e-07	0.000161	0.21	0.23	Fibrinogen levels;	chr3:136235757	chr3:136837338~136839021:-
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000273009.1	RP11-352G9.1	-5.07	5.72e-07	0.000161	-0.27	-0.23	Pancreatic cancer;	chr3:196024982	chr3:195913078~195913683:-
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000273009.1	RP11-352G9.1	-5.07	5.72e-07	0.000161	-0.27	-0.23	Pancreatic cancer;	chr3:196025389	chr3:195913078~195913683:-
HNSC	cis	rs9548119	0.696	rs9566276	ENSG00000223685.4	LINC00571	-5.07	5.73e-07	0.000161	-0.39	-0.23	Self-rated health;	chr13:37924700	chr13:38050817~38143232:-
HNSC	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-5.07	5.73e-07	0.000161	-0.29	-0.23	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
HNSC	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-5.07	5.73e-07	0.000161	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
HNSC	cis	rs11846409	0.872	rs74091715	ENSG00000274576.2	IGHV2-70	-5.07	5.73e-07	0.000161	-0.23	-0.23	Rheumatic heart disease;	chr14:106637731	chr14:106770577~106771020:-
HNSC	cis	rs6964587	1	rs2097739	ENSG00000188693.7	CYP51A1-AS1	-5.07	5.74e-07	0.000161	-0.24	-0.23	Breast cancer;	chr7:92082152	chr7:92134604~92180725:+
HNSC	cis	rs2985684	0.894	rs4581611	ENSG00000278009.1	RP11-649E7.8	5.07	5.74e-07	0.000161	0.3	0.23	Carotid intima media thickness;	chr14:49576802	chr14:49601011~49601124:-
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	5.07	5.74e-07	0.000161	0.2	0.23	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000233609.3	RP11-62H7.2	5.07	5.74e-07	0.000161	0.21	0.23	Joint mobility (Beighton score);	chr8:8977018	chr8:8961200~8979025:+
HNSC	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-5.07	5.74e-07	0.000161	-0.24	-0.23	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
HNSC	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	5.07	5.74e-07	0.000161	0.26	0.23	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
HNSC	cis	rs11969893	0.649	rs9390699	ENSG00000270987.1	RP3-467N11.2	5.07	5.75e-07	0.000161	0.51	0.23	Economic and political preferences (immigration/crime);	chr6:100858626	chr6:100889603~100890338:+
HNSC	cis	rs697003	0.705	rs701926	ENSG00000231057.3	RP11-122M14.1	-5.07	5.75e-07	0.000161	-0.23	-0.23	Red cell distribution width;	chr1:211678277	chr1:211675762~211690103:+
HNSC	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	5.07	5.75e-07	0.000161	0.24	0.23	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
HNSC	cis	rs9393777	0.777	rs35984974	ENSG00000219392.1	RP1-265C24.5	-5.07	5.75e-07	0.000161	-0.41	-0.23	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28115628~28116551:+
HNSC	cis	rs1056107	0.671	rs7875332	ENSG00000225513.1	RP11-165N19.2	5.07	5.75e-07	0.000162	0.24	0.23	Colorectal cancer;	chr9:112165255	chr9:112173522~112173971:-
HNSC	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	5.07	5.76e-07	0.000162	0.32	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
HNSC	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-5.07	5.76e-07	0.000162	-0.21	-0.23	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
HNSC	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	5.07	5.76e-07	0.000162	0.27	0.23	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000233609.3	RP11-62H7.2	-5.07	5.76e-07	0.000162	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9050721	chr8:8961200~8979025:+
HNSC	cis	rs2998286	0.784	rs2993987	ENSG00000254635.4	WAC-AS1	-5.07	5.76e-07	0.000162	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28511241	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.862	rs2993989	ENSG00000254635.4	WAC-AS1	-5.07	5.76e-07	0.000162	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28522652~28532743:-
HNSC	cis	rs860295	0.702	rs12047756	ENSG00000203761.5	MSTO2P	-5.07	5.77e-07	0.000162	-0.18	-0.23	Body mass index;	chr1:155655153	chr1:155745829~155750137:+
HNSC	cis	rs783540	0.5	rs1313494	ENSG00000276710.3	CSPG4P8	5.07	5.77e-07	0.000162	0.27	0.23	Schizophrenia;	chr15:82605530	chr15:82459472~82477258:+
HNSC	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-5.07	5.77e-07	0.000162	-0.29	-0.23	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
HNSC	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-5.07	5.77e-07	0.000162	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
HNSC	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	5.07	5.78e-07	0.000162	0.4	0.23	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	5.07	5.78e-07	0.000162	0.4	0.23	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
HNSC	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	5.07	5.78e-07	0.000162	0.29	0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
HNSC	cis	rs7000734	0.958	rs1466169	ENSG00000245080.5	RP11-320N21.1	-5.07	5.78e-07	0.000162	-0.31	-0.23	Radiation response;	chr8:95104769	chr8:95066808~95073182:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000233609.3	RP11-62H7.2	-5.07	5.78e-07	0.000162	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9025061	chr8:8961200~8979025:+
HNSC	cis	rs12935418	0.672	rs9923948	ENSG00000261061.1	RP11-303E16.2	-5.07	5.79e-07	0.000162	-0.26	-0.23	Mean corpuscular volume;	chr16:81013814	chr16:81030770~81031485:+
HNSC	cis	rs36093844	0.8	rs75605851	ENSG00000279742.1	RP11-700A24.1	-5.07	5.79e-07	0.000162	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85868988	chr11:85852557~85854943:-
HNSC	cis	rs853679	0.607	rs34661125	ENSG00000219392.1	RP1-265C24.5	-5.07	5.79e-07	0.000162	-0.44	-0.23	Depression;	chr6:28314117	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13190888	ENSG00000219392.1	RP1-265C24.5	-5.07	5.79e-07	0.000162	-0.44	-0.23	Depression;	chr6:28318208	chr6:28115628~28116551:+
HNSC	cis	rs8054556	0.935	rs4788203	ENSG00000183604.13	SMG1P5	-5.07	5.79e-07	0.000162	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:30267553~30335374:-
HNSC	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-5.07	5.79e-07	0.000163	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
HNSC	cis	rs7515577	0.533	rs17578954	ENSG00000223787.2	RP4-593M8.1	5.07	5.79e-07	0.000163	0.52	0.23	Cholesterol, total;	chr1:92300508	chr1:92580476~92580821:-
HNSC	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	5.07	5.8e-07	0.000163	0.28	0.23	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
HNSC	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	5.07	5.8e-07	0.000163	0.28	0.23	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
HNSC	cis	rs11247915	0.622	rs34370465	ENSG00000236782.4	RP11-96L14.7	-5.07	5.8e-07	0.000163	-0.27	-0.23	Obesity-related traits;	chr1:26344118	chr1:26169947~26171821:-
HNSC	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-5.07	5.8e-07	0.000163	-0.26	-0.23	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
HNSC	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-5.07	5.8e-07	0.000163	-0.31	-0.23	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
HNSC	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	5.07	5.8e-07	0.000163	0.24	0.23	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
HNSC	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	5.07	5.8e-07	0.000163	0.34	0.23	Height;	chr6:109548647	chr6:109382795~109383666:+
HNSC	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	5.07	5.81e-07	0.000163	0.28	0.23	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
HNSC	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-5.07	5.81e-07	0.000163	-0.28	-0.23	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
HNSC	cis	rs12986445	0.694	rs13422450	ENSG00000218682.1	AC010150.1	5.07	5.81e-07	0.000163	0.31	0.23	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25859188	chr2:25856461~25856966:-
HNSC	cis	rs12986445	0.793	rs2271664	ENSG00000218682.1	AC010150.1	5.07	5.81e-07	0.000163	0.31	0.23	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25868112	chr2:25856461~25856966:-
HNSC	cis	rs950169	0.922	rs17531523	ENSG00000229212.6	RP11-561C5.4	-5.07	5.81e-07	0.000163	-0.33	-0.23	Schizophrenia;	chr15:84589218	chr15:85205440~85234795:-
HNSC	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-5.07	5.82e-07	0.000163	-0.24	-0.23	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
HNSC	cis	rs6964587	1	rs11981461	ENSG00000188693.7	CYP51A1-AS1	-5.07	5.82e-07	0.000163	-0.24	-0.23	Breast cancer;	chr7:92063348	chr7:92134604~92180725:+
HNSC	cis	rs4295623	0.585	rs34421088	ENSG00000269918.1	AF131215.9	-5.07	5.82e-07	0.000163	-0.22	-0.23	Morning vs. evening chronotype;	chr8:11731533	chr8:11104691~11106704:-
HNSC	cis	rs1075232	1	rs12437749	ENSG00000215302.7	CTD-3092A11.1	-5.07	5.82e-07	0.000163	-0.51	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30470779~30507623:+
HNSC	cis	rs7267979	0.738	rs2892409	ENSG00000231081.1	RP4-760C5.3	-5.07	5.82e-07	0.000163	-0.23	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26008791~26010531:-
HNSC	cis	rs3206736	0.521	rs2057819	ENSG00000197085.10	NPSR1-AS1	-5.07	5.83e-07	0.000163	-0.28	-0.23	Diastolic blood pressure;	chr7:34905259	chr7:34346512~34871582:-
HNSC	cis	rs860295	0.729	rs4971072	ENSG00000203761.5	MSTO2P	5.07	5.83e-07	0.000163	0.18	0.23	Body mass index;	chr1:155304078	chr1:155745829~155750137:+
HNSC	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	5.07	5.83e-07	0.000163	0.37	0.23	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
HNSC	cis	rs6540731	1	rs1389369	ENSG00000226251.4	RP11-15I11.3	-5.07	5.83e-07	0.000164	-0.26	-0.23	Intelligence (childhood);	chr1:212227194	chr1:212225278~212238977:-
HNSC	cis	rs6540731	1	rs1389370	ENSG00000226251.4	RP11-15I11.3	-5.07	5.83e-07	0.000164	-0.26	-0.23	Intelligence (childhood);	chr1:212227275	chr1:212225278~212238977:-
HNSC	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	5.07	5.83e-07	0.000164	0.34	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
HNSC	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	5.07	5.84e-07	0.000164	0.28	0.23	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
HNSC	cis	rs12701220	0.947	rs1007765	ENSG00000229043.2	AC091729.9	-5.07	5.84e-07	0.000164	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:993169	chr7:1160374~1165267:+
HNSC	cis	rs8031584	0.672	rs17815726	ENSG00000260382.1	RP11-540B6.2	-5.07	5.84e-07	0.000164	-0.33	-0.23	Huntington's disease progression;	chr15:31021049	chr15:30882267~30883231:-
HNSC	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-5.07	5.84e-07	0.000164	-0.22	-0.23	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
HNSC	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	5.07	5.84e-07	0.000164	0.24	0.23	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	5.07	5.84e-07	0.000164	0.24	0.23	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
HNSC	cis	rs7829975	0.582	rs11783950	ENSG00000254340.1	RP11-10A14.3	-5.07	5.85e-07	0.000164	-0.28	-0.23	Mood instability;	chr8:8740321	chr8:9141424~9145435:+
HNSC	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	5.07	5.85e-07	0.000164	0.24	0.23	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
HNSC	cis	rs11846409	0.932	rs74091721	ENSG00000274576.2	IGHV2-70	-5.07	5.85e-07	0.000164	-0.23	-0.23	Rheumatic heart disease;	chr14:106638262	chr14:106770577~106771020:-
HNSC	cis	rs13217239	0.646	rs12527111	ENSG00000224843.5	LINC00240	-5.07	5.85e-07	0.000164	-0.22	-0.23	Schizophrenia;	chr6:27038696	chr6:26956992~27023924:+
HNSC	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-5.07	5.85e-07	0.000164	-0.29	-0.23	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000233609.3	RP11-62H7.2	5.07	5.86e-07	0.000164	0.22	0.23	Joint mobility (Beighton score);	chr8:9027656	chr8:8961200~8979025:+
HNSC	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	5.07	5.87e-07	0.000165	0.17	0.23	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
HNSC	cis	rs9929218	0.581	rs4783676	ENSG00000260459.2	FTLP14	5.07	5.88e-07	0.000165	0.3	0.23	Colorectal cancer;	chr16:68767174	chr16:68822587~68823070:+
HNSC	cis	rs1971762	0.583	rs1527068	ENSG00000270175.1	RP11-793H13.11	-5.07	5.88e-07	0.000165	-0.19	-0.23	Height;	chr12:53694904	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.583	rs11170648	ENSG00000270175.1	RP11-793H13.11	-5.07	5.88e-07	0.000165	-0.19	-0.23	Height;	chr12:53695876	chr12:53500162~53500936:-
HNSC	cis	rs950169	0.922	rs62021167	ENSG00000229212.6	RP11-561C5.4	-5.07	5.88e-07	0.000165	-0.32	-0.23	Schizophrenia;	chr15:84574820	chr15:85205440~85234795:-
HNSC	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	5.07	5.89e-07	0.000165	0.25	0.23	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
HNSC	cis	rs1799949	0.965	rs8071278	ENSG00000236383.6	LINC00854	-5.07	5.89e-07	0.000165	-0.22	-0.23	Menopause (age at onset);	chr17:43041893	chr17:43216941~43305976:-
HNSC	cis	rs7746199	0.673	rs72845046	ENSG00000219392.1	RP1-265C24.5	-5.07	5.89e-07	0.000165	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs67652222	ENSG00000219392.1	RP1-265C24.5	-5.07	5.89e-07	0.000165	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28115628~28116551:+
HNSC	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-5.07	5.89e-07	0.000165	-0.29	-0.23	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
HNSC	cis	rs1404100	0.51	rs1038272	ENSG00000249274.1	PDLIM1P4	5.06	5.89e-07	0.000165	0.27	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067685	chr3:98782188~98783193:+
HNSC	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	5.06	5.89e-07	0.000165	0.32	0.23	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
HNSC	cis	rs9402743	0.671	rs9376115	ENSG00000234084.1	RP3-388E23.2	5.06	5.9e-07	0.000165	0.23	0.23	Systemic lupus erythematosus;	chr6:135616579	chr6:135301568~135307158:+
HNSC	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	5.06	5.9e-07	0.000165	0.25	0.23	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
HNSC	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-5.06	5.9e-07	0.000165	-0.36	-0.23	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
HNSC	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-5.06	5.9e-07	0.000165	-0.29	-0.23	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
HNSC	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	5.06	5.9e-07	0.000165	0.27	0.23	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	5.06	5.9e-07	0.000165	0.27	0.23	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
HNSC	cis	rs9840812	0.592	rs900048	ENSG00000239213.4	NCK1-AS1	5.06	5.91e-07	0.000165	0.21	0.23	Fibrinogen levels;	chr3:136500088	chr3:136841726~136862054:-
HNSC	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-5.06	5.91e-07	0.000166	-0.26	-0.23	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
HNSC	cis	rs9611519	0.828	rs9611460	ENSG00000235513.1	RP4-756G23.5	5.06	5.91e-07	0.000166	0.27	0.23	Neuroticism;	chr22:41022293	chr22:41209122~41217627:-
HNSC	cis	rs8177876	0.822	rs8043855	ENSG00000261061.1	RP11-303E16.2	-5.06	5.92e-07	0.000166	-0.34	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089256	chr16:81030770~81031485:+
HNSC	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-5.06	5.92e-07	0.000166	-0.31	-0.23	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
HNSC	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-5.06	5.93e-07	0.000166	-0.28	-0.23	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
HNSC	cis	rs950169	0.922	rs11630760	ENSG00000229212.6	RP11-561C5.4	-5.06	5.93e-07	0.000166	-0.32	-0.23	Schizophrenia;	chr15:84570106	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.887	rs71395453	ENSG00000229212.6	RP11-561C5.4	-5.06	5.93e-07	0.000166	-0.32	-0.23	Schizophrenia;	chr15:84570259	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.922	rs11633075	ENSG00000229212.6	RP11-561C5.4	-5.06	5.93e-07	0.000166	-0.32	-0.23	Schizophrenia;	chr15:84570741	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.922	rs12912934	ENSG00000229212.6	RP11-561C5.4	-5.06	5.93e-07	0.000166	-0.32	-0.23	Schizophrenia;	chr15:84571216	chr15:85205440~85234795:-
HNSC	cis	rs3806843	0.966	rs2563267	ENSG00000202515.1	VTRNA1-3	5.06	5.93e-07	0.000166	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs2563266	ENSG00000202515.1	VTRNA1-3	5.06	5.93e-07	0.000166	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr5:140726158~140726246:+
HNSC	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-5.06	5.94e-07	0.000166	-0.26	-0.23	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000233609.3	RP11-62H7.2	-5.06	5.94e-07	0.000166	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9012154	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.653	rs7853	ENSG00000233609.3	RP11-62H7.2	5.06	5.94e-07	0.000166	0.22	0.23	Joint mobility (Beighton score);	chr8:9033304	chr8:8961200~8979025:+
HNSC	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-5.06	5.94e-07	0.000166	-0.42	-0.23	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	5.06	5.94e-07	0.000166	0.28	0.23	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	5.06	5.94e-07	0.000166	0.28	0.23	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
HNSC	cis	rs73198271	0.681	rs35457364	ENSG00000173295.6	FAM86B3P	-5.06	5.94e-07	0.000166	-0.3	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.681	rs11987924	ENSG00000173295.6	FAM86B3P	-5.06	5.94e-07	0.000166	-0.3	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8228595~8244865:+
HNSC	cis	rs71636778	0.509	rs34217609	ENSG00000260063.1	RP5-968P14.2	-5.06	5.95e-07	0.000166	-0.44	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26681776	chr1:26692132~26694131:-
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-5.06	5.95e-07	0.000166	-0.24	-0.23	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
HNSC	cis	rs6540731	0.967	rs1472226	ENSG00000226251.4	RP11-15I11.3	-5.06	5.95e-07	0.000167	-0.26	-0.23	Intelligence (childhood);	chr1:212229238	chr1:212225278~212238977:-
HNSC	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-5.06	5.95e-07	0.000167	-0.19	-0.23	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
HNSC	cis	rs13217239	0.646	rs11756275	ENSG00000224843.5	LINC00240	5.06	5.95e-07	0.000167	0.22	0.23	Schizophrenia;	chr6:27039334	chr6:26956992~27023924:+
HNSC	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	5.06	5.96e-07	0.000167	0.29	0.23	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
HNSC	cis	rs14027	0.512	rs4871528	ENSG00000279347.1	RP11-85I17.2	5.06	5.96e-07	0.000167	0.19	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119700371	chr8:119838736~119840385:-
HNSC	cis	rs9548119	0.696	rs4943544	ENSG00000223685.4	LINC00571	5.06	5.97e-07	0.000167	0.39	0.23	Self-rated health;	chr13:37900316	chr13:38050817~38143232:-
HNSC	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	5.06	5.97e-07	0.000167	0.34	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
HNSC	cis	rs860295	0.65	rs488079	ENSG00000203761.5	MSTO2P	5.06	5.98e-07	0.000167	0.17	0.23	Body mass index;	chr1:155920790	chr1:155745829~155750137:+
HNSC	cis	rs1971762	0.542	rs12303370	ENSG00000270175.1	RP11-793H13.11	-5.06	5.98e-07	0.000167	-0.19	-0.23	Height;	chr12:53698023	chr12:53500162~53500936:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-5.06	5.98e-07	0.000167	-0.27	-0.23	Depression;	chr6:28139049	chr6:28170845~28172521:+
HNSC	cis	rs9611519	0.929	rs9611469	ENSG00000235513.1	RP4-756G23.5	5.06	5.98e-07	0.000167	0.25	0.23	Neuroticism;	chr22:41037315	chr22:41209122~41217627:-
HNSC	cis	rs4657482	0.962	rs9887956	ENSG00000236364.3	RP11-525G13.2	-5.06	5.98e-07	0.000167	-0.22	-0.23	Testicular germ cell tumor;	chr1:165879976	chr1:165890795~165900683:-
HNSC	cis	rs5758511	0.689	rs62240864	ENSG00000226450.2	CYP2D8P	5.06	5.99e-07	0.000168	0.24	0.23	Birth weight;	chr22:42167883	chr22:42149886~42155001:-
HNSC	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	5.06	5.99e-07	0.000168	0.27	0.23	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
HNSC	cis	rs4699052	0.893	rs4699058	ENSG00000246560.2	RP11-10L12.4	5.06	5.99e-07	0.000168	0.27	0.23	Testicular germ cell tumor;	chr4:103250164	chr4:102828055~102844075:+
HNSC	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.06	5.99e-07	0.000168	0.2	0.23	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.06	5.99e-07	0.000168	0.2	0.23	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
HNSC	cis	rs9921338	0.961	rs7193278	ENSG00000263080.1	RP11-485G7.5	5.06	5.99e-07	0.000168	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11341809~11345211:-
HNSC	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-5.06	6e-07	0.000168	-0.37	-0.23	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
HNSC	cis	rs10504130	0.569	rs4534123	ENSG00000272024.1	RP11-546K22.3	5.06	6.01e-07	0.000168	0.32	0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs13275967	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs13274159	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs4436115	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs4573262	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs11785467	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs34004633	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs12679983	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs12680128	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.53	rs4292674	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs4292675	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs76746661	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs71513549	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.502	rs4321994	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.66	rs79691523	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs12676345	ENSG00000272024.1	RP11-546K22.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51950284~51950690:+
HNSC	cis	rs6951245	0.572	rs79396168	ENSG00000225146.1	AC073957.15	-5.06	6.01e-07	0.000168	-0.48	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1009292	chr7:1029025~1043891:+
HNSC	cis	rs7819412	0.806	rs6980856	ENSG00000255310.2	AF131215.2	5.06	6.01e-07	0.000168	0.22	0.23	Triglycerides;	chr8:11080750	chr8:11107788~11109726:-
HNSC	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-5.06	6.01e-07	0.000168	-0.26	-0.23	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
HNSC	cis	rs1933112	0.5	rs12409982	ENSG00000227777.1	RP4-738P11.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Blood protein levels;	chr1:168553146	chr1:168542737~168543354:+
HNSC	cis	rs1933112	0.5	rs12568619	ENSG00000227777.1	RP4-738P11.3	-5.06	6.01e-07	0.000168	-0.32	-0.23	Blood protein levels;	chr1:168553496	chr1:168542737~168543354:+
HNSC	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-5.06	6.02e-07	0.000168	-0.36	-0.23	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
HNSC	cis	rs3806843	0.9	rs2261651	ENSG00000202515.1	VTRNA1-3	5.06	6.02e-07	0.000168	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr5:140726158~140726246:+
HNSC	cis	rs12935418	0.672	rs9938541	ENSG00000261061.1	RP11-303E16.2	-5.06	6.02e-07	0.000168	-0.26	-0.23	Mean corpuscular volume;	chr16:81011623	chr16:81030770~81031485:+
HNSC	cis	rs9527	0.637	rs12219247	ENSG00000236937.2	PTGES3P4	5.06	6.03e-07	0.000168	0.29	0.23	Arsenic metabolism;	chr10:102853604	chr10:102845595~102845950:+
HNSC	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	5.06	6.03e-07	0.000169	0.29	0.23	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
HNSC	cis	rs36423	0.748	rs36391	ENSG00000266869.1	RP6-114E22.1	-5.06	6.03e-07	0.000169	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71898402	chr14:71848606~71908430:+
HNSC	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	5.06	6.03e-07	0.000169	0.31	0.23	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
HNSC	cis	rs9840812	0.69	rs1618069	ENSG00000239213.4	NCK1-AS1	5.06	6.03e-07	0.000169	0.21	0.23	Fibrinogen levels;	chr3:136308303	chr3:136841726~136862054:-
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000229212.6	RP11-561C5.4	-5.06	6.05e-07	0.000169	-0.32	-0.23	Schizophrenia;	chr15:84557698	chr15:85205440~85234795:-
HNSC	cis	rs1056107	0.931	rs6477905	ENSG00000225513.1	RP11-165N19.2	-5.06	6.05e-07	0.000169	-0.25	-0.23	Colorectal cancer;	chr9:112261381	chr9:112173522~112173971:-
HNSC	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-5.06	6.06e-07	0.000169	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
HNSC	cis	rs13204927	1	rs13204927	ENSG00000219700.1	PTCHD3P3	5.06	6.06e-07	0.000169	0.28	0.23	Mean corpuscular hemoglobin;	chr6:109281587	chr6:109288571~109290503:-
HNSC	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	5.06	6.06e-07	0.000169	0.25	0.23	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000254153.1	CTA-398F10.2	-5.06	6.07e-07	0.00017	-0.25	-0.23	Mood instability;	chr8:8737594	chr8:8456909~8461337:-
HNSC	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	5.06	6.07e-07	0.00017	0.37	0.23	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
HNSC	cis	rs656319	0.58	rs17690549	ENSG00000269918.1	AF131215.9	-5.06	6.07e-07	0.00017	-0.23	-0.23	Myopia (pathological);	chr8:10141028	chr8:11104691~11106704:-
HNSC	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	5.06	6.08e-07	0.00017	0.25	0.23	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
HNSC	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	5.06	6.08e-07	0.00017	0.24	0.23	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
HNSC	cis	rs3002131	0.604	rs11487813	ENSG00000225265.1	TAF1A-AS1	-5.06	6.08e-07	0.00017	-0.31	-0.23	Interleukin-10 levels;	chr1:222563436	chr1:222589825~222593032:+
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	5.06	6.08e-07	0.00017	0.28	0.23	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	5.06	6.08e-07	0.00017	0.28	0.23	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
HNSC	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	5.06	6.09e-07	0.00017	0.21	0.23	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
HNSC	cis	rs7746199	0.736	rs72845070	ENSG00000219392.1	RP1-265C24.5	-5.06	6.09e-07	0.00017	-0.46	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28115628~28116551:+
HNSC	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	5.06	6.09e-07	0.00017	0.26	0.23	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
HNSC	cis	rs36423	0.748	rs36387	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71900629	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36385	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901594	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.66	rs36384	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901638	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.702	rs36383	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71902385	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36381	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71903833	chr14:71848606~71908430:+
HNSC	cis	rs36423	0.748	rs36380	ENSG00000266869.1	RP6-114E22.1	-5.06	6.09e-07	0.00017	-0.37	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71904545	chr14:71848606~71908430:+
HNSC	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-5.06	6.09e-07	0.00017	-0.29	-0.23	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-5.06	6.09e-07	0.00017	-0.29	-0.23	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
HNSC	cis	rs2086824	0.702	rs3114891	ENSG00000274627.1	RP11-104N10.2	5.06	6.1e-07	0.00017	0.22	0.23	Multiple myeloma (IgH translocation);	chr16:89333047	chr16:89516797~89522217:+
HNSC	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	5.06	6.11e-07	0.00017	0.27	0.23	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
HNSC	cis	rs5742933	0.597	rs6761923	ENSG00000253559.1	OSGEPL1-AS1	5.06	6.12e-07	0.000171	0.26	0.23	Ferritin levels;	chr2:189642873	chr2:189762704~189765556:+
HNSC	cis	rs3015497	0.527	rs2934672	ENSG00000269906.1	RP11-248J18.2	-5.06	6.12e-07	0.000171	-0.31	-0.23	Mean platelet volume;	chr14:50685754	chr14:50662511~50663178:-
HNSC	cis	rs9329221	0.683	rs658385	ENSG00000254340.1	RP11-10A14.3	-5.06	6.12e-07	0.000171	-0.27	-0.23	Neuroticism;	chr8:10034667	chr8:9141424~9145435:+
HNSC	cis	rs2187895	0.704	rs1476040	ENSG00000271811.1	RP1-79C4.4	5.06	6.12e-07	0.000171	0.28	0.23	Tonsillectomy;	chr1:170731617	chr1:170667381~170669425:+
HNSC	cis	rs10466239	0.614	rs56214316	ENSG00000230555.2	RP11-517P14.2	5.06	6.12e-07	0.000171	0.29	0.23	Telomere length;	chr10:43365658	chr10:43420738~43422100:+
HNSC	cis	rs520525	0.963	rs600093	ENSG00000271811.1	RP1-79C4.4	5.06	6.13e-07	0.000171	0.26	0.23	Atrial fibrillation;	chr1:170660697	chr1:170667381~170669425:+
HNSC	cis	rs4657482	0.962	rs4657487	ENSG00000236364.3	RP11-525G13.2	5.06	6.13e-07	0.000171	0.23	0.23	Testicular germ cell tumor;	chr1:165866127	chr1:165890795~165900683:-
HNSC	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-5.06	6.13e-07	0.000171	-0.29	-0.23	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
HNSC	cis	rs6693567	0.565	rs1260374	ENSG00000228126.1	FALEC	5.06	6.14e-07	0.000171	0.27	0.23	Migraine;	chr1:150359117	chr1:150515757~150518032:+
HNSC	cis	rs36423	0.702	rs36373	ENSG00000266869.1	RP6-114E22.1	-5.06	6.14e-07	0.000171	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71907901	chr14:71848606~71908430:+
HNSC	cis	rs1008375	0.966	rs3775923	ENSG00000249502.1	AC006160.5	-5.06	6.14e-07	0.000171	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584002	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs3733576	ENSG00000249502.1	AC006160.5	-5.06	6.14e-07	0.000171	-0.26	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585080	chr4:17587467~17614571:-
HNSC	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-5.06	6.15e-07	0.000171	-0.26	-0.23	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
HNSC	cis	rs507080	0.922	rs4936433	ENSG00000278376.1	RP11-158I9.8	5.06	6.15e-07	0.000172	0.21	0.23	Serum metabolite levels;	chr11:118681711	chr11:118791254~118793137:+
HNSC	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	5.06	6.15e-07	0.000172	0.39	0.23	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
HNSC	cis	rs860295	0.702	rs34620961	ENSG00000203761.5	MSTO2P	-5.06	6.15e-07	0.000172	-0.18	-0.23	Body mass index;	chr1:155680036	chr1:155745829~155750137:+
HNSC	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-5.06	6.16e-07	0.000172	-0.28	-0.23	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
HNSC	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-5.06	6.16e-07	0.000172	-0.28	-0.23	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000233609.3	RP11-62H7.2	-5.06	6.16e-07	0.000172	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9050725	chr8:8961200~8979025:+
HNSC	cis	rs7688540	0.771	rs11737268	ENSG00000211553.1	AC253576.2	-5.06	6.16e-07	0.000172	-0.32	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs11726829	ENSG00000211553.1	AC253576.2	-5.06	6.16e-07	0.000172	-0.32	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:136461~136568:+
HNSC	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	5.06	6.17e-07	0.000172	0.22	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
HNSC	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	5.06	6.17e-07	0.000172	0.32	0.23	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
HNSC	cis	rs6964587	1	rs2282972	ENSG00000188693.7	CYP51A1-AS1	-5.06	6.17e-07	0.000172	-0.24	-0.23	Breast cancer;	chr7:92037055	chr7:92134604~92180725:+
HNSC	cis	rs950169	0.84	rs2896002	ENSG00000229212.6	RP11-561C5.4	-5.06	6.17e-07	0.000172	-0.33	-0.23	Schizophrenia;	chr15:84390423	chr15:85205440~85234795:-
HNSC	cis	rs12935418	0.672	rs12448656	ENSG00000261061.1	RP11-303E16.2	-5.06	6.18e-07	0.000172	-0.26	-0.23	Mean corpuscular volume;	chr16:81008876	chr16:81030770~81031485:+
HNSC	cis	rs860295	0.702	rs11264366	ENSG00000203761.5	MSTO2P	-5.06	6.18e-07	0.000172	-0.18	-0.23	Body mass index;	chr1:155365620	chr1:155745829~155750137:+
HNSC	cis	rs453301	0.624	rs330060	ENSG00000254153.1	CTA-398F10.2	-5.06	6.18e-07	0.000172	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9233392	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-5.06	6.19e-07	0.000172	-0.27	-0.23	Depression;	chr6:28140454	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-5.06	6.19e-07	0.000172	-0.27	-0.23	Depression;	chr6:28141189	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-5.06	6.19e-07	0.000172	-0.27	-0.23	Depression;	chr6:28141484	chr6:28170845~28172521:+
HNSC	cis	rs67981189	0.896	rs12100737	ENSG00000274818.1	RP1-292L20.3	-5.06	6.19e-07	0.000172	-0.26	-0.23	Schizophrenia;	chr14:71004383	chr14:70906657~70907111:-
HNSC	cis	rs12817211	0.502	rs7294618	ENSG00000272368.2	RP4-605O3.4	-5.06	6.19e-07	0.000173	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50119192	chr12:50112197~50165618:+
HNSC	cis	rs12817211	0.502	rs7961112	ENSG00000272368.2	RP4-605O3.4	-5.06	6.19e-07	0.000173	-0.22	-0.23	Colorectal or endometrial cancer;	chr12:50119736	chr12:50112197~50165618:+
HNSC	cis	rs9840812	0.817	rs61789561	ENSG00000239213.4	NCK1-AS1	-5.05	6.19e-07	0.000173	-0.24	-0.23	Fibrinogen levels;	chr3:136198785	chr3:136841726~136862054:-
HNSC	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	5.05	6.2e-07	0.000173	0.23	0.23	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
HNSC	cis	rs3733585	0.673	rs7376948	ENSG00000250413.1	RP11-448G15.1	5.05	6.2e-07	0.000173	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953084	chr4:10006482~10009725:+
HNSC	cis	rs9907295	1	rs11650409	ENSG00000270977.1	AC015849.16	5.05	6.2e-07	0.000173	0.33	0.23	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35893707~35911023:-
HNSC	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	5.05	6.2e-07	0.000173	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
HNSC	cis	rs11250098	0.6	rs4240671	ENSG00000269918.1	AF131215.9	5.05	6.2e-07	0.000173	0.22	0.23	Morning vs. evening chronotype;	chr8:10910238	chr8:11104691~11106704:-
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000254340.1	RP11-10A14.3	5.05	6.2e-07	0.000173	0.28	0.23	Mood instability;	chr8:8314761	chr8:9141424~9145435:+
HNSC	cis	rs10504130	0.502	rs877248	ENSG00000272024.1	RP11-546K22.3	-5.05	6.2e-07	0.000173	-0.29	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51939074	chr8:51950284~51950690:+
HNSC	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-5.05	6.21e-07	0.000173	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
HNSC	cis	rs2998286	0.862	rs2185293	ENSG00000254635.4	WAC-AS1	-5.05	6.21e-07	0.000173	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28522652~28532743:-
HNSC	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	5.05	6.21e-07	0.000173	0.31	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
HNSC	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.21e-07	0.000173	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
HNSC	cis	rs10995505	0.589	rs4601646	ENSG00000232075.1	MRPL35P2	-5.05	6.22e-07	0.000173	-0.29	-0.23	Intelligence (multi-trait analysis);	chr10:63120520	chr10:63634317~63634827:-
HNSC	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-5.05	6.22e-07	0.000173	-0.2	-0.23	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
HNSC	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-5.05	6.22e-07	0.000173	-0.24	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
HNSC	cis	rs17428076	0.834	rs6749895	ENSG00000228389.1	AC068039.4	-5.05	6.23e-07	0.000173	-0.28	-0.23	Myopia;	chr2:172010535	chr2:171773482~171775844:+
HNSC	cis	rs656319	0.513	rs3885723	ENSG00000269918.1	AF131215.9	-5.05	6.23e-07	0.000173	-0.23	-0.23	Myopia (pathological);	chr8:10134151	chr8:11104691~11106704:-
HNSC	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-5.05	6.23e-07	0.000174	-0.29	-0.23	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	5.05	6.23e-07	0.000174	0.28	0.23	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
HNSC	cis	rs3736485	0.899	rs7183479	ENSG00000259438.1	CTD-2650P22.1	5.05	6.24e-07	0.000174	0.23	0.23	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51650010	chr15:52010999~52019095:-
HNSC	cis	rs453301	0.624	rs330056	ENSG00000254153.1	CTA-398F10.2	-5.05	6.24e-07	0.000174	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9232185	chr8:8456909~8461337:-
HNSC	cis	rs453301	0.624	rs330058	ENSG00000254153.1	CTA-398F10.2	-5.05	6.24e-07	0.000174	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9232299	chr8:8456909~8461337:-
HNSC	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	5.05	6.25e-07	0.000174	0.27	0.23	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
HNSC	cis	rs9326248	0.559	rs573549	ENSG00000280143.1	AP000892.6	5.05	6.25e-07	0.000174	0.23	0.23	Blood protein levels;	chr11:116865963	chr11:117204967~117210292:+
HNSC	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	5.05	6.25e-07	0.000174	0.31	0.23	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
HNSC	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	5.05	6.25e-07	0.000174	0.31	0.23	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
HNSC	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-5.05	6.25e-07	0.000174	-0.26	-0.23	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
HNSC	cis	rs7819412	0.654	rs34741518	ENSG00000269918.1	AF131215.9	-5.05	6.26e-07	0.000174	-0.22	-0.23	Triglycerides;	chr8:10919350	chr8:11104691~11106704:-
HNSC	cis	rs2834288	0.535	rs881229	ENSG00000273102.1	AP000569.9	5.05	6.26e-07	0.000174	0.25	0.23	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33967101~33968573:-
HNSC	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	5.05	6.26e-07	0.000174	0.27	0.23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
HNSC	cis	rs9650657	0.504	rs2409724	ENSG00000255310.2	AF131215.2	-5.05	6.27e-07	0.000174	-0.22	-0.23	Neuroticism;	chr8:11184133	chr8:11107788~11109726:-
HNSC	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-5.05	6.27e-07	0.000175	-0.28	-0.23	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
HNSC	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-5.05	6.28e-07	0.000175	-0.22	-0.23	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
HNSC	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-5.05	6.28e-07	0.000175	-0.22	-0.23	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
HNSC	cis	rs1218582	0.772	rs906593	ENSG00000270361.1	RP11-307C12.13	-5.05	6.28e-07	0.000175	-0.24	-0.23	Prostate cancer;	chr1:154912779	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs4845689	ENSG00000270361.1	RP11-307C12.13	-5.05	6.28e-07	0.000175	-0.24	-0.23	Prostate cancer;	chr1:154913048	chr1:154937370~154938059:+
HNSC	cis	rs12439619	0.705	rs17354185	ENSG00000276710.3	CSPG4P8	5.05	6.28e-07	0.000175	0.3	0.23	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82459472~82477258:+
HNSC	cis	rs9304742	1	rs9304742	ENSG00000213801.4	ZNF816-ZNF321P	5.05	6.28e-07	0.000175	0.25	0.23	Psoriasis;	chr19:52948038	chr19:52927135~52942601:-
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	5.05	6.29e-07	0.000175	0.18	0.23	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
HNSC	cis	rs1056107	0.931	rs3849123	ENSG00000225513.1	RP11-165N19.2	-5.05	6.29e-07	0.000175	-0.24	-0.23	Colorectal cancer;	chr9:112215901	chr9:112173522~112173971:-
HNSC	cis	rs1008375	0.966	rs10939735	ENSG00000249502.1	AC006160.5	-5.05	6.29e-07	0.000175	-0.25	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577268	chr4:17587467~17614571:-
HNSC	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	5.05	6.29e-07	0.000175	0.37	0.23	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
HNSC	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	5.05	6.3e-07	0.000175	0.26	0.23	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000254340.1	RP11-10A14.3	-5.05	6.3e-07	0.000175	-0.28	-0.23	Mood instability;	chr8:8735335	chr8:9141424~9145435:+
HNSC	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	5.05	6.3e-07	0.000175	0.19	0.23	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
HNSC	cis	rs13126694	0.682	rs9991381	ENSG00000248429.4	RP11-597D13.9	5.05	6.3e-07	0.000175	0.26	0.23	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158170752~158202877:+
HNSC	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-5.05	6.31e-07	0.000175	-0.23	-0.23	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
HNSC	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	5.05	6.31e-07	0.000175	0.25	0.23	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
HNSC	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	5.05	6.32e-07	0.000176	0.2	0.23	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	5.05	6.32e-07	0.000176	0.33	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
HNSC	cis	rs4978813	0.5	rs4978396	ENSG00000213539.4	YBX1P6	5.05	6.32e-07	0.000176	0.27	0.23	Plantar warts;	chr9:109507200	chr9:109532830~109534332:-
HNSC	cis	rs728616	0.614	rs1885552	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs1885551	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs12253608	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.764	rs1885549	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs12245076	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10788319	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs11200859	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887229	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10788321	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61858839	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61858841	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61858842	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887233	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887234	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887235	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs2146192	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs2146191	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887243	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs10887244	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.32e-07	0.000176	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
HNSC	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-5.05	6.33e-07	0.000176	-0.26	-0.23	Height;	chr2:46632247	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-5.05	6.33e-07	0.000176	-0.26	-0.23	Height;	chr2:46633262	chr2:46668870~46670778:+
HNSC	cis	rs4664293	0.647	rs7595044	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159589694	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs12623149	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159590835	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.631	rs6714899	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159592895	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs6714917	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159592942	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs6734085	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159595711	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs4665090	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159597396	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs4635484	ENSG00000226266.5	AC009961.3	-5.05	6.33e-07	0.000176	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159597619	chr2:159670708~159712435:-
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	5.05	6.33e-07	0.000176	0.21	0.23	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
HNSC	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-5.05	6.33e-07	0.000176	-0.23	-0.23	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
HNSC	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-5.05	6.33e-07	0.000176	-0.28	-0.23	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	5.05	6.33e-07	0.000176	0.23	0.23	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
HNSC	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	5.05	6.34e-07	0.000176	0.32	0.23	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
HNSC	cis	rs783540	0.5	rs1313494	ENSG00000255769.6	GOLGA2P10	5.05	6.34e-07	0.000176	0.31	0.23	Schizophrenia;	chr15:82605530	chr15:82472993~82513950:-
HNSC	cis	rs9840812	0.861	rs645040	ENSG00000273486.1	RP11-731C17.2	-5.05	6.34e-07	0.000176	-0.2	-0.23	Fibrinogen levels;	chr3:136207780	chr3:136837338~136839021:-
HNSC	cis	rs60617249	0.526	rs71540282	ENSG00000228204.2	RP4-724E13.2	5.05	6.34e-07	0.000176	0.3	0.23	Major depression and alcohol dependence;	chr7:50940952	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.526	rs34469633	ENSG00000228204.2	RP4-724E13.2	5.05	6.34e-07	0.000176	0.3	0.23	Major depression and alcohol dependence;	chr7:50941890	chr7:50866747~51022990:+
HNSC	cis	rs12935418	0.672	rs12446304	ENSG00000261061.1	RP11-303E16.2	-5.05	6.35e-07	0.000176	-0.26	-0.23	Mean corpuscular volume;	chr16:81012730	chr16:81030770~81031485:+
HNSC	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	5.05	6.35e-07	0.000177	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
HNSC	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	5.05	6.35e-07	0.000177	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
HNSC	cis	rs67981189	0.784	rs58984901	ENSG00000274818.1	RP1-292L20.3	5.05	6.35e-07	0.000177	0.27	0.23	Schizophrenia;	chr14:71085271	chr14:70906657~70907111:-
HNSC	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-5.05	6.36e-07	0.000177	-0.32	-0.23	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
HNSC	cis	rs8062405	0.54	rs480400	ENSG00000251417.2	RP11-1348G14.4	-5.05	6.36e-07	0.000177	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28802743~28817828:+
HNSC	cis	rs4664293	0.647	rs7580539	ENSG00000226266.5	AC009961.3	-5.05	6.36e-07	0.000177	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159589238	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.539	rs7580661	ENSG00000226266.5	AC009961.3	-5.05	6.36e-07	0.000177	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159589326	chr2:159670708~159712435:-
HNSC	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	5.05	6.36e-07	0.000177	0.37	0.23	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
HNSC	cis	rs1218582	0.772	rs4845400	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154900047	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs7528532	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154901964	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs6656435	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154904393	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs4845682	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154904629	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.71	rs4845685	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154905824	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs1976559	ENSG00000270361.1	RP11-307C12.13	-5.05	6.36e-07	0.000177	-0.24	-0.23	Prostate cancer;	chr1:154907312	chr1:154937370~154938059:+
HNSC	cis	rs11846409	0.932	rs10151046	ENSG00000274576.2	IGHV2-70	-5.05	6.36e-07	0.000177	-0.22	-0.23	Rheumatic heart disease;	chr14:106633095	chr14:106770577~106771020:-
HNSC	cis	rs728616	0.717	rs61860016	ENSG00000225484.5	NUTM2B-AS1	-5.05	6.37e-07	0.000177	-0.54	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79663088~79826594:-
HNSC	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-5.05	6.38e-07	0.000177	-0.27	-0.23	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-5.05	6.38e-07	0.000177	-0.27	-0.23	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
HNSC	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	5.05	6.38e-07	0.000177	0.32	0.23	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	5.05	6.38e-07	0.000177	0.2	0.23	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
HNSC	cis	rs9863	0.931	rs11057401	ENSG00000269938.1	RP11-214K3.20	-5.05	6.39e-07	0.000177	-0.27	-0.23	White blood cell count;	chr12:123942759	chr12:123968023~123968579:-
HNSC	cis	rs13217239	0.574	rs9366680	ENSG00000224843.5	LINC00240	-5.05	6.39e-07	0.000177	-0.22	-0.23	Schizophrenia;	chr6:27038344	chr6:26956992~27023924:+
HNSC	cis	rs6540731	1	rs6540735	ENSG00000226251.4	RP11-15I11.3	-5.05	6.39e-07	0.000177	-0.26	-0.23	Intelligence (childhood);	chr1:212227418	chr1:212225278~212238977:-
HNSC	cis	rs6540731	1	rs6657900	ENSG00000226251.4	RP11-15I11.3	-5.05	6.39e-07	0.000177	-0.26	-0.23	Intelligence (childhood);	chr1:212227524	chr1:212225278~212238977:-
HNSC	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-5.05	6.39e-07	0.000177	-0.31	-0.23	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
HNSC	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	5.05	6.39e-07	0.000177	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
HNSC	cis	rs9813712	0.78	rs7625942	ENSG00000249846.5	RP11-77P16.4	5.05	6.39e-07	0.000178	0.27	0.23	Response to amphetamines;	chr3:130232611	chr3:130112550~130120579:+
HNSC	cis	rs4388249	0.687	rs2416218	ENSG00000271849.1	CTC-332L22.1	-5.05	6.39e-07	0.000178	-0.31	-0.23	Schizophrenia;	chr5:109736511	chr5:109687802~109688329:-
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000233609.3	RP11-62H7.2	-5.05	6.4e-07	0.000178	-0.22	-0.23	Joint mobility (Beighton score);	chr8:8936144	chr8:8961200~8979025:+
HNSC	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	5.05	6.4e-07	0.000178	0.29	0.23	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
HNSC	cis	rs4218	0.573	rs16940998	ENSG00000277144.1	RP11-59H7.4	5.05	6.4e-07	0.000178	0.28	0.23	Social communication problems;	chr15:59086095	chr15:59115547~59116089:-
HNSC	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	5.05	6.4e-07	0.000178	0.33	0.23	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
HNSC	cis	rs860295	0.665	rs11264367	ENSG00000203761.5	MSTO2P	-5.05	6.41e-07	0.000178	-0.18	-0.23	Body mass index;	chr1:155367547	chr1:155745829~155750137:+
HNSC	cis	rs9907295	0.688	rs28722787	ENSG00000270977.1	AC015849.16	-5.05	6.41e-07	0.000178	-0.31	-0.23	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35893707~35911023:-
HNSC	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-5.05	6.41e-07	0.000178	-0.29	-0.23	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
HNSC	cis	rs1218582	0.772	rs10908445	ENSG00000270361.1	RP11-307C12.13	5.05	6.41e-07	0.000178	0.25	0.23	Prostate cancer;	chr1:154877114	chr1:154937370~154938059:+
HNSC	cis	rs9402743	0.632	rs6570028	ENSG00000217482.2	HMGB1P17	5.05	6.41e-07	0.000178	0.25	0.23	Systemic lupus erythematosus;	chr6:135754784	chr6:135636086~135636713:-
HNSC	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	5.05	6.41e-07	0.000178	0.19	0.23	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
HNSC	cis	rs1012068	0.881	rs5998168	ENSG00000236132.1	CTA-440B3.1	-5.05	6.42e-07	0.000178	-0.28	-0.23	Chronic hepatitis C infection;	chr22:31901310	chr22:31816379~31817491:-
HNSC	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	5.05	6.42e-07	0.000178	0.22	0.23	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	5.05	6.42e-07	0.000178	0.22	0.23	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	5.05	6.42e-07	0.000178	0.22	0.23	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
HNSC	cis	rs6674176	0.66	rs12726706	ENSG00000237950.1	RP11-7O11.3	5.05	6.42e-07	0.000178	0.26	0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934270	chr1:43944370~43946551:-
HNSC	cis	rs3806843	0.966	rs2563260	ENSG00000202515.1	VTRNA1-3	5.05	6.42e-07	0.000178	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr5:140726158~140726246:+
HNSC	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	5.05	6.42e-07	0.000178	0.24	0.23	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
HNSC	cis	rs9329221	0.905	rs4433149	ENSG00000269918.1	AF131215.9	-5.05	6.42e-07	0.000178	-0.22	-0.23	Neuroticism;	chr8:10391758	chr8:11104691~11106704:-
HNSC	cis	rs2933343	0.7	rs883602	ENSG00000261159.1	RP11-723O4.9	5.05	6.42e-07	0.000178	0.23	0.23	IgG glycosylation;	chr3:128935109	chr3:128859716~128860526:-
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28082231	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28082261	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Parkinson's disease;	chr6:28082269	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28082984	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28083994	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28084025	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000204709.4	LINC01556	5.05	6.43e-07	0.000178	0.31	0.23	Depression;	chr6:28085319	chr6:28943877~28944537:+
HNSC	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	5.05	6.43e-07	0.000178	0.26	0.23	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	5.05	6.43e-07	0.000178	0.26	0.23	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
HNSC	cis	rs2243480	1	rs67728539	ENSG00000179406.6	LINC00174	-5.05	6.43e-07	0.000178	-0.49	-0.23	Diabetic kidney disease;	chr7:65913137	chr7:66376044~66401338:-
HNSC	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-5.05	6.43e-07	0.000178	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.5	rs10143242	ENSG00000224373.3	IGHV4-59	5.05	6.43e-07	0.000179	0.13	0.23	Kawasaki disease;	chr14:106681814	chr14:106627249~106627825:-
HNSC	cis	rs1150668	0.699	rs13408	ENSG00000219392.1	RP1-265C24.5	-5.05	6.43e-07	0.000179	-0.25	-0.23	Pubertal anthropometrics;	chr6:28244970	chr6:28115628~28116551:+
HNSC	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-5.05	6.44e-07	0.000179	-0.22	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
HNSC	cis	rs6723108	0.627	rs766270	ENSG00000224043.6	CCNT2-AS1	-5.05	6.44e-07	0.000179	-0.28	-0.23	Type 2 diabetes;	chr2:134909356	chr2:134735464~134918710:-
HNSC	cis	rs8012947	0.916	rs4901853	ENSG00000279636.2	LINC00216	5.05	6.45e-07	0.000179	0.28	0.23	Alcohol consumption in current drinkers;	chr14:58382581	chr14:58288033~58289158:+
HNSC	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-5.05	6.45e-07	0.000179	-0.27	-0.23	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
HNSC	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	5.05	6.45e-07	0.000179	0.25	0.23	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
HNSC	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	5.05	6.45e-07	0.000179	0.23	0.23	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
HNSC	cis	rs1223397	0.938	rs9395602	ENSG00000215022.6	RP1-257A7.4	-5.05	6.46e-07	0.000179	-0.28	-0.23	Blood pressure;	chr6:13278521	chr6:13264861~13295586:-
HNSC	cis	rs860295	0.776	rs11264362	ENSG00000203761.5	MSTO2P	5.05	6.46e-07	0.000179	0.17	0.23	Body mass index;	chr1:155345824	chr1:155745829~155750137:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000254153.1	CTA-398F10.2	5.05	6.46e-07	0.000179	0.25	0.23	Mood instability;	chr8:8721284	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-5.05	6.46e-07	0.000179	-0.28	-0.23	Depression;	chr6:28193021	chr6:28161781~28169594:+
HNSC	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.46e-07	0.000179	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.46e-07	0.000179	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.46e-07	0.000179	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.46e-07	0.000179	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.46e-07	0.000179	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
HNSC	cis	rs13113518	0.729	rs12641881	ENSG00000273257.1	RP11-177J6.1	5.05	6.47e-07	0.00018	0.3	0.23	Height;	chr4:55401306	chr4:55387949~55388271:+
HNSC	cis	rs9840812	0.769	rs548288	ENSG00000239213.4	NCK1-AS1	-5.05	6.47e-07	0.00018	-0.21	-0.23	Fibrinogen levels;	chr3:136250913	chr3:136841726~136862054:-
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-5.05	6.48e-07	0.00018	-0.27	-0.23	Depression;	chr6:28140307	chr6:28170845~28172521:+
HNSC	cis	rs4295623	0.553	rs34962960	ENSG00000269918.1	AF131215.9	-5.05	6.48e-07	0.00018	-0.23	-0.23	Morning vs. evening chronotype;	chr8:11737088	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.739	rs951570	ENSG00000249244.1	RP11-548H18.2	-5.05	6.48e-07	0.00018	-0.26	-0.23	Corneal astigmatism;	chr4:119229312	chr4:119391831~119395335:-
HNSC	cis	rs1012068	0.961	rs5994441	ENSG00000236132.1	CTA-440B3.1	-5.05	6.49e-07	0.00018	-0.27	-0.23	Chronic hepatitis C infection;	chr22:31870560	chr22:31816379~31817491:-
HNSC	cis	rs17428076	0.872	rs56218609	ENSG00000228389.1	AC068039.4	-5.05	6.49e-07	0.00018	-0.28	-0.23	Myopia;	chr2:171997407	chr2:171773482~171775844:+
HNSC	cis	rs7809950	0.731	rs2712196	ENSG00000238832.1	snoU109	-5.05	6.49e-07	0.00018	-0.33	-0.23	Coronary artery disease;	chr7:107488352	chr7:107603363~107603507:+
HNSC	cis	rs1056107	0.931	rs10981334	ENSG00000225513.1	RP11-165N19.2	-5.05	6.5e-07	0.00018	-0.25	-0.23	Colorectal cancer;	chr9:112262415	chr9:112173522~112173971:-
HNSC	cis	rs71444571	1	rs71444571	ENSG00000280120.1	RP11-546D6.3	-5.05	6.5e-07	0.00018	-0.22	-0.23	Lymphocyte percentage of white cells;	chr12:123286468	chr12:123152324~123153377:-
HNSC	cis	rs36052053	0.908	rs34739891	ENSG00000219700.1	PTCHD3P3	5.05	6.51e-07	0.00018	0.37	0.23	Red cell distribution width;	chr6:109290264	chr6:109288571~109290503:-
HNSC	cis	rs10504130	0.696	rs77958054	ENSG00000253844.1	RP11-546K22.1	-5.04	6.51e-07	0.00018	-0.34	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51961458~52022974:+
HNSC	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.51e-07	0.00018	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.51e-07	0.00018	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
HNSC	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	5.04	6.51e-07	0.00018	0.29	0.23	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
HNSC	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-5.04	6.51e-07	0.000181	-0.27	-0.23	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
HNSC	cis	rs2933343	0.729	rs789231	ENSG00000261159.1	RP11-723O4.9	5.04	6.51e-07	0.000181	0.23	0.23	IgG glycosylation;	chr3:128884004	chr3:128859716~128860526:-
HNSC	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	5.04	6.53e-07	0.000181	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
HNSC	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	5.04	6.53e-07	0.000181	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
HNSC	cis	rs792448	0.545	rs6668866	ENSG00000226251.4	RP11-15I11.3	5.04	6.53e-07	0.000181	0.25	0.23	White blood cell count (basophil);	chr1:212231605	chr1:212225278~212238977:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000254174.1	IGHV1-12	5.04	6.53e-07	0.000181	0.2	0.23	Alzheimer's disease (late onset);	chr14:106697010	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000254174.1	IGHV1-12	5.04	6.53e-07	0.000181	0.2	0.23	Alzheimer's disease (late onset);	chr14:106697140	chr14:106122420~106122709:-
HNSC	cis	rs3736485	0.673	rs8033234	ENSG00000259438.1	CTD-2650P22.1	5.04	6.53e-07	0.000181	0.23	0.23	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51663920	chr15:52010999~52019095:-
HNSC	cis	rs9611519	0.929	rs12484477	ENSG00000235513.1	RP4-756G23.5	5.04	6.54e-07	0.000181	0.25	0.23	Neuroticism;	chr22:41033080	chr22:41209122~41217627:-
HNSC	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	5.04	6.54e-07	0.000181	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
HNSC	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-5.04	6.54e-07	0.000181	-0.26	-0.23	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
HNSC	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-5.04	6.54e-07	0.000181	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-5.04	6.54e-07	0.000181	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-5.04	6.54e-07	0.000181	-0.25	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
HNSC	cis	rs2058059	0.551	rs68044527	ENSG00000225648.4	SBDSP1	-5.04	6.55e-07	0.000181	-0.34	-0.23	Subcutaneous adipose tissue;	chr7:72599814	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.551	rs4473912	ENSG00000225648.4	SBDSP1	-5.04	6.55e-07	0.000181	-0.34	-0.23	Subcutaneous adipose tissue;	chr7:72600851	chr7:72829425~72836701:+
HNSC	cis	rs1218582	0.772	rs2174507	ENSG00000270361.1	RP11-307C12.13	-5.04	6.55e-07	0.000181	-0.24	-0.23	Prostate cancer;	chr1:154915473	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.741	rs4339857	ENSG00000270361.1	RP11-307C12.13	-5.04	6.55e-07	0.000181	-0.24	-0.23	Prostate cancer;	chr1:154916486	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs10796935	ENSG00000270361.1	RP11-307C12.13	-5.04	6.55e-07	0.000181	-0.24	-0.23	Prostate cancer;	chr1:154918887	chr1:154937370~154938059:+
HNSC	cis	rs36093844	0.752	rs75639684	ENSG00000279742.1	RP11-700A24.1	-5.04	6.55e-07	0.000181	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860533	chr11:85852557~85854943:-
HNSC	cis	rs2337406	0.789	rs9324095	ENSG00000211974.3	IGHV2-70	-5.04	6.55e-07	0.000181	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106795885	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.866	rs58154560	ENSG00000211974.3	IGHV2-70	-5.04	6.55e-07	0.000181	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106799601	chr14:106723574~106724093:-
HNSC	cis	rs17428076	0.872	rs62183808	ENSG00000228389.1	AC068039.4	-5.04	6.55e-07	0.000181	-0.28	-0.23	Myopia;	chr2:172015170	chr2:171773482~171775844:+
HNSC	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-5.04	6.56e-07	0.000182	-0.28	-0.23	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
HNSC	cis	rs4218	0.701	rs7174277	ENSG00000277144.1	RP11-59H7.4	-5.04	6.56e-07	0.000182	-0.27	-0.23	Social communication problems;	chr15:59150390	chr15:59115547~59116089:-
HNSC	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-5.04	6.57e-07	0.000182	-0.21	-0.23	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
HNSC	cis	rs9329221	0.905	rs17709397	ENSG00000269918.1	AF131215.9	-5.04	6.57e-07	0.000182	-0.22	-0.23	Neuroticism;	chr8:10392351	chr8:11104691~11106704:-
HNSC	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-5.04	6.58e-07	0.000182	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
HNSC	cis	rs7819412	1	rs2409722	ENSG00000255310.2	AF131215.2	-5.04	6.58e-07	0.000182	-0.22	-0.23	Triglycerides;	chr8:11182307	chr8:11107788~11109726:-
HNSC	cis	rs11969893	0.649	rs9498408	ENSG00000270987.1	RP3-467N11.2	5.04	6.58e-07	0.000182	0.5	0.23	Economic and political preferences (immigration/crime);	chr6:100844464	chr6:100889603~100890338:+
HNSC	cis	rs860295	0.65	rs11264422	ENSG00000203761.5	MSTO2P	5.04	6.58e-07	0.000182	0.17	0.23	Body mass index;	chr1:155938032	chr1:155745829~155750137:+
HNSC	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-5.04	6.6e-07	0.000183	-0.36	-0.23	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
HNSC	cis	rs4853525	0.561	rs11898764	ENSG00000235852.1	AC005540.3	-5.04	6.6e-07	0.000183	-0.31	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190847844	chr2:190880797~190882059:-
HNSC	cis	rs9650657	0.74	rs10481451	ENSG00000269918.1	AF131215.9	-5.04	6.6e-07	0.000183	-0.22	-0.23	Neuroticism;	chr8:10791818	chr8:11104691~11106704:-
HNSC	cis	rs36093844	0.752	rs79734467	ENSG00000279742.1	RP11-700A24.1	-5.04	6.6e-07	0.000183	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860910	chr11:85852557~85854943:-
HNSC	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-5.04	6.6e-07	0.000183	-0.24	-0.23	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
HNSC	cis	rs3805389	0.504	rs10017749	ENSG00000273257.1	RP11-177J6.1	-5.04	6.61e-07	0.000183	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs3805385	ENSG00000273257.1	RP11-177J6.1	-5.04	6.61e-07	0.000183	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs3805386	ENSG00000273257.1	RP11-177J6.1	-5.04	6.61e-07	0.000183	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs3805387	ENSG00000273257.1	RP11-177J6.1	-5.04	6.61e-07	0.000183	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55387949~55388271:+
HNSC	cis	rs3806843	0.9	rs2337983	ENSG00000202515.1	VTRNA1-3	5.04	6.61e-07	0.000183	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr5:140726158~140726246:+
HNSC	cis	rs1218582	0.772	rs4845688	ENSG00000270361.1	RP11-307C12.13	-5.04	6.61e-07	0.000183	-0.24	-0.23	Prostate cancer;	chr1:154911666	chr1:154937370~154938059:+
HNSC	cis	rs75422866	0.867	rs73102195	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47666309	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102201	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47669269	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104103	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47669604	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104104	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47671986	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104111	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47673994	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104115	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47684843	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104116	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47685023	chr12:47788426~47788971:+
HNSC	cis	rs6540731	0.754	rs6679064	ENSG00000226251.4	RP11-15I11.3	-5.04	6.61e-07	0.000183	-0.26	-0.23	Intelligence (childhood);	chr1:212186366	chr1:212225278~212238977:-
HNSC	cis	rs75422866	0.867	rs73113139	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47622826	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.717	rs73113159	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47631318	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.717	rs73113161	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47632361	chr12:47788426~47788971:+
HNSC	cis	rs75422866	1	rs73102120	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47637280	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102125	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47637869	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs12426849	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47638975	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs117950951	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47639794	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs7954764	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47641136	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs12422974	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47644559	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102127	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47645341	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102140	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47647497	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102148	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47648013	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102151	ENSG00000276691.1	RP5-1057I20.5	5.04	6.61e-07	0.000183	0.42	0.23	Pneumonia;	chr12:47648023	chr12:47788426~47788971:+
HNSC	cis	rs10800713	0.779	rs2815289	ENSG00000260088.1	RP11-92G12.3	5.04	6.61e-07	0.000183	0.34	0.23	Tandem gait;	chr1:200610628	chr1:200669507~200694250:+
HNSC	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	5.04	6.61e-07	0.000183	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
HNSC	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	5.04	6.62e-07	0.000183	0.27	0.23	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	5.04	6.63e-07	0.000183	0.27	0.23	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
HNSC	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-5.04	6.64e-07	0.000184	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
HNSC	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	5.04	6.64e-07	0.000184	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
HNSC	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-5.04	6.64e-07	0.000184	-0.27	-0.23	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
HNSC	cis	rs3806843	0.966	rs2337516	ENSG00000202515.1	VTRNA1-3	5.04	6.65e-07	0.000184	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr5:140726158~140726246:+
HNSC	cis	rs7615952	0.599	rs6438955	ENSG00000248787.1	RP11-666A20.4	-5.04	6.65e-07	0.000184	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126011490	chr3:125908005~125910272:-
HNSC	cis	rs6928977	0.896	rs2179779	ENSG00000231028.7	LINC00271	5.04	6.66e-07	0.000184	0.26	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135328678	chr6:135497801~135716055:+
HNSC	cis	rs1167832	0.645	rs1167829	ENSG00000127957.15	PMS2P3	-5.04	6.66e-07	0.000184	-0.27	-0.23	Ankle injury;	chr7:75535697	chr7:75502930~75528148:-
HNSC	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	5.04	6.66e-07	0.000184	0.28	0.23	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
HNSC	cis	rs36052053	0.908	rs1812230	ENSG00000219700.1	PTCHD3P3	5.04	6.66e-07	0.000184	0.37	0.23	Red cell distribution width;	chr6:109268132	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs34854922	ENSG00000219700.1	PTCHD3P3	5.04	6.66e-07	0.000184	0.37	0.23	Red cell distribution width;	chr6:109272953	chr6:109288571~109290503:-
HNSC	cis	rs1218582	0.741	rs10908444	ENSG00000270361.1	RP11-307C12.13	-5.04	6.66e-07	0.000184	-0.24	-0.23	Prostate cancer;	chr1:154867811	chr1:154937370~154938059:+
HNSC	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	5.04	6.67e-07	0.000184	0.24	0.23	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
HNSC	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.04	6.67e-07	0.000184	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
HNSC	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-5.04	6.67e-07	0.000184	-0.28	-0.23	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000173295.6	FAM86B3P	-5.04	6.67e-07	0.000185	-0.26	-0.23	Recombination measurement;	chr8:9202567	chr8:8228595~8244865:+
HNSC	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-5.04	6.68e-07	0.000185	-0.23	-0.23	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
HNSC	cis	rs763121	0.651	rs738249	ENSG00000273076.1	RP3-508I15.22	5.04	6.68e-07	0.000185	0.24	0.23	Menopause (age at onset);	chr22:38641974	chr22:38743495~38743910:+
HNSC	cis	rs6693567	0.565	rs10888584	ENSG00000228126.1	FALEC	5.04	6.68e-07	0.000185	0.28	0.23	Migraine;	chr1:150503930	chr1:150515757~150518032:+
HNSC	cis	rs4713118	0.669	rs200997	ENSG00000219392.1	RP1-265C24.5	-5.04	6.68e-07	0.000185	-0.27	-0.23	Parkinson's disease;	chr6:27844037	chr6:28115628~28116551:+
HNSC	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	5.04	6.68e-07	0.000185	0.21	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
HNSC	cis	rs6940116	1	rs6940116	ENSG00000219392.1	RP1-265C24.5	-5.04	6.68e-07	0.000185	-0.32	-0.23	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28115628~28116551:+
HNSC	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	5.04	6.68e-07	0.000185	0.23	0.23	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
HNSC	cis	rs6723108	0.603	rs10166142	ENSG00000224043.6	CCNT2-AS1	-5.04	6.69e-07	0.000185	-0.28	-0.23	Type 2 diabetes;	chr2:134952752	chr2:134735464~134918710:-
HNSC	cis	rs3733585	0.699	rs10017674	ENSG00000250413.1	RP11-448G15.1	5.04	6.7e-07	0.000185	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9965429	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs7434391	ENSG00000250413.1	RP11-448G15.1	5.04	6.7e-07	0.000185	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9966058	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs6449176	ENSG00000250413.1	RP11-448G15.1	5.04	6.7e-07	0.000185	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9966219	chr4:10006482~10009725:+
HNSC	cis	rs4908760	0.811	rs301806	ENSG00000232912.4	RP5-1115A15.1	5.04	6.7e-07	0.000185	0.24	0.23	Vitiligo;	chr1:8422018	chr1:8424645~8434838:+
HNSC	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	5.04	6.71e-07	0.000185	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
HNSC	cis	rs1971762	0.545	rs10783585	ENSG00000270175.1	RP11-793H13.11	-5.04	6.71e-07	0.000185	-0.2	-0.23	Height;	chr12:53583533	chr12:53500162~53500936:-
HNSC	cis	rs17428076	0.872	rs72892835	ENSG00000228389.1	AC068039.4	-5.04	6.71e-07	0.000185	-0.28	-0.23	Myopia;	chr2:172029711	chr2:171773482~171775844:+
HNSC	cis	rs56114371	0.53	rs2056923	ENSG00000219392.1	RP1-265C24.5	-5.04	6.71e-07	0.000185	-0.33	-0.23	Breast cancer;	chr6:27722160	chr6:28115628~28116551:+
HNSC	cis	rs860818	1	rs858286	ENSG00000226816.2	AC005082.12	5.04	6.72e-07	0.000186	0.54	0.23	Initial pursuit acceleration;	chr7:23209844	chr7:23206013~23208045:+
HNSC	cis	rs9402743	0.671	rs6925684	ENSG00000234084.1	RP3-388E23.2	-5.04	6.72e-07	0.000186	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135615740	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs6905536	ENSG00000234084.1	RP3-388E23.2	-5.04	6.72e-07	0.000186	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135615865	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs6905555	ENSG00000234084.1	RP3-388E23.2	-5.04	6.72e-07	0.000186	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135615894	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs9402725	ENSG00000234084.1	RP3-388E23.2	-5.04	6.72e-07	0.000186	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135616509	chr6:135301568~135307158:+
HNSC	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-5.04	6.72e-07	0.000186	-0.23	-0.23	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
HNSC	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-5.04	6.72e-07	0.000186	-0.23	-0.23	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
HNSC	cis	rs9326248	0.53	rs900012	ENSG00000280143.1	AP000892.6	5.04	6.72e-07	0.000186	0.34	0.23	Blood protein levels;	chr11:117095719	chr11:117204967~117210292:+
HNSC	cis	rs10109025	0.67	rs7825690	ENSG00000255310.2	AF131215.2	-5.04	6.73e-07	0.000186	-0.22	-0.23	Joint mobility (Beighton score);	chr8:11000747	chr8:11107788~11109726:-
HNSC	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	5.04	6.73e-07	0.000186	0.5	0.23	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
HNSC	cis	rs9611519	0.929	rs9611465	ENSG00000235513.1	RP4-756G23.5	5.04	6.73e-07	0.000186	0.25	0.23	Neuroticism;	chr22:41030135	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs9611466	ENSG00000235513.1	RP4-756G23.5	5.04	6.73e-07	0.000186	0.25	0.23	Neuroticism;	chr22:41030295	chr22:41209122~41217627:-
HNSC	cis	rs9611519	0.929	rs4820423	ENSG00000235513.1	RP4-756G23.5	5.04	6.73e-07	0.000186	0.25	0.23	Neuroticism;	chr22:41034334	chr22:41209122~41217627:-
HNSC	cis	rs6540731	1	rs12402397	ENSG00000226251.4	RP11-15I11.3	-5.04	6.73e-07	0.000186	-0.26	-0.23	Intelligence (childhood);	chr1:212222602	chr1:212225278~212238977:-
HNSC	cis	rs10989172	0.714	rs10739798	ENSG00000175611.10	LINC00476	5.04	6.73e-07	0.000186	0.22	0.23	Common carotid intima-media thickness in HIV negative individuals;	chr9:96079335	chr9:95759231~95875977:-
HNSC	cis	rs5758659	0.714	rs5751220	ENSG00000227370.1	RP4-669P10.19	5.04	6.73e-07	0.000186	0.23	0.23	Cognitive function;	chr22:42120201	chr22:42132543~42132998:+
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-5.04	6.74e-07	0.000186	-0.24	-0.23	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
HNSC	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	5.04	6.74e-07	0.000186	0.2	0.23	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	5.04	6.74e-07	0.000186	0.2	0.23	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
HNSC	cis	rs7789940	1	rs76024966	ENSG00000231087.2	FDPSP7	-5.04	6.74e-07	0.000186	-0.27	-0.23	Multiple sclerosis;	chr7:76365704	chr7:76968197~76969250:-
HNSC	cis	rs7789940	1	rs11765693	ENSG00000231087.2	FDPSP7	-5.04	6.75e-07	0.000186	-0.27	-0.23	Multiple sclerosis;	chr7:76356056	chr7:76968197~76969250:-
HNSC	cis	rs7789940	1	rs73140069	ENSG00000231087.2	FDPSP7	-5.04	6.75e-07	0.000186	-0.27	-0.23	Multiple sclerosis;	chr7:76357473	chr7:76968197~76969250:-
HNSC	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	5.04	6.75e-07	0.000186	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000254340.1	RP11-10A14.3	5.04	6.75e-07	0.000187	0.27	0.23	Mood instability;	chr8:8272638	chr8:9141424~9145435:+
HNSC	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	5.04	6.75e-07	0.000187	0.28	0.23	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
HNSC	cis	rs155076	1	rs261432	ENSG00000233325.3	MIPEPP3	5.04	6.76e-07	0.000187	0.39	0.23	White matter hyperintensity burden;	chr13:21291776	chr13:21298139~21306373:+
HNSC	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	5.04	6.76e-07	0.000187	0.24	0.23	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
HNSC	cis	rs9300255	0.739	rs1879380	ENSG00000280120.1	RP11-546D6.3	-5.04	6.76e-07	0.000187	-0.22	-0.23	Neutrophil percentage of white cells;	chr12:123254564	chr12:123152324~123153377:-
HNSC	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	5.04	6.76e-07	0.000187	0.23	0.23	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	5.04	6.76e-07	0.000187	0.23	0.23	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
HNSC	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-5.04	6.76e-07	0.000187	-0.26	-0.23	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
HNSC	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-5.04	6.77e-07	0.000187	-0.52	-0.23	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
HNSC	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-5.04	6.78e-07	0.000187	-0.28	-0.23	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
HNSC	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-5.04	6.78e-07	0.000187	-0.3	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
HNSC	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-5.04	6.78e-07	0.000187	-0.3	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
HNSC	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-5.04	6.78e-07	0.000187	-0.23	-0.23	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-5.04	6.78e-07	0.000187	-0.23	-0.23	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-5.04	6.78e-07	0.000187	-0.23	-0.23	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
HNSC	cis	rs638893	0.588	rs2156755	ENSG00000255422.1	AP002954.4	-5.04	6.78e-07	0.000187	-0.33	-0.23	Vitiligo;	chr11:118855521	chr11:118704607~118750263:+
HNSC	cis	rs9650657	0.617	rs7814795	ENSG00000269918.1	AF131215.9	-5.04	6.78e-07	0.000187	-0.22	-0.23	Neuroticism;	chr8:10661775	chr8:11104691~11106704:-
HNSC	cis	rs9487051	0.621	rs351735	ENSG00000243587.6	C6orf183	5.04	6.78e-07	0.000187	0.24	0.23	Reticulocyte fraction of red cells;	chr6:109184737	chr6:109165833~109271014:+
HNSC	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-5.04	6.79e-07	0.000188	-0.27	-0.23	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000233609.3	RP11-62H7.2	-5.04	6.8e-07	0.000188	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9011767	chr8:8961200~8979025:+
HNSC	cis	rs2179367	0.6	rs1001305	ENSG00000216906.2	RP11-350J20.9	5.04	6.8e-07	0.000188	0.35	0.23	Dupuytren's disease;	chr6:149436808	chr6:149904243~149906418:+
HNSC	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	5.04	6.8e-07	0.000188	0.24	0.23	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
HNSC	cis	rs3733585	0.699	rs7676733	ENSG00000250413.1	RP11-448G15.1	5.04	6.81e-07	0.000188	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9965332	chr4:10006482~10009725:+
HNSC	cis	rs4664293	0.647	rs10198053	ENSG00000226266.5	AC009961.3	-5.04	6.81e-07	0.000188	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159605169	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.669	rs10174515	ENSG00000226266.5	AC009961.3	-5.04	6.81e-07	0.000188	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159605524	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.609	rs12470879	ENSG00000226266.5	AC009961.3	-5.04	6.81e-07	0.000188	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159612116	chr2:159670708~159712435:-
HNSC	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	5.04	6.81e-07	0.000188	0.32	0.23	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
HNSC	cis	rs752590	0.806	rs4849174	ENSG00000189223.12	PAX8-AS1	-5.04	6.81e-07	0.000188	-0.33	-0.23	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113211522~113276581:+
HNSC	cis	rs2657294	0.62	rs4746261	ENSG00000233313.2	HMGA1P5	5.04	6.81e-07	0.000188	0.25	0.23	Pneumonia;	chr10:75085874	chr10:75276376~75276646:-
HNSC	cis	rs2337406	0.866	rs4773949	ENSG00000211974.3	IGHV2-70	5.04	6.82e-07	0.000188	0.25	0.23	Alzheimer's disease (late onset);	chr14:106808070	chr14:106723574~106724093:-
HNSC	cis	rs10791097	0.739	rs735094	ENSG00000254842.5	RP11-890B15.2	-5.04	6.82e-07	0.000188	-0.2	-0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130855214	chr11:130844191~130865561:-
HNSC	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-5.04	6.82e-07	0.000188	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
HNSC	cis	rs7615952	0.576	rs1127717	ENSG00000248787.1	RP11-666A20.4	-5.04	6.82e-07	0.000188	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126107216	chr3:125908005~125910272:-
HNSC	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	5.04	6.82e-07	0.000188	0.26	0.23	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
HNSC	cis	rs36093844	0.752	rs57534090	ENSG00000279742.1	RP11-700A24.1	-5.04	6.82e-07	0.000188	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85861977	chr11:85852557~85854943:-
HNSC	cis	rs77580281	0.507	rs5746767	ENSG00000185065.6	AC000068.5	-5.04	6.82e-07	0.000188	-0.24	-0.23	Pediatric bone mineral density (hip);	chr22:19550681	chr22:19447893~19450105:+
HNSC	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-5.04	6.83e-07	0.000188	-0.54	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
HNSC	cis	rs933688	0.941	rs6452954	ENSG00000281357.1	ARRDC3-AS1	5.04	6.83e-07	0.000188	0.33	0.23	Smoking behavior;	chr5:91439875	chr5:91380349~91439085:+
HNSC	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-5.04	6.83e-07	0.000188	-0.52	-0.23	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
HNSC	cis	rs9329221	0.905	rs4433149	ENSG00000255310.2	AF131215.2	-5.04	6.83e-07	0.000188	-0.21	-0.23	Neuroticism;	chr8:10391758	chr8:11107788~11109726:-
HNSC	cis	rs8012947	0.527	rs1190981	ENSG00000279636.2	LINC00216	-5.04	6.83e-07	0.000188	-0.25	-0.23	Alcohol consumption in current drinkers;	chr14:58348357	chr14:58288033~58289158:+
HNSC	cis	rs11773103	1	rs11971131	ENSG00000224046.1	AC005076.5	5.03	6.84e-07	0.000189	0.43	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87194303	chr7:87151423~87152420:-
HNSC	cis	rs6693567	0.565	rs698914	ENSG00000228126.1	FALEC	5.03	6.84e-07	0.000189	0.27	0.23	Migraine;	chr1:150326292	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs1260403	ENSG00000228126.1	FALEC	5.03	6.84e-07	0.000189	0.27	0.23	Migraine;	chr1:150331196	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs1260385	ENSG00000228126.1	FALEC	5.03	6.84e-07	0.000189	0.27	0.23	Migraine;	chr1:150343909	chr1:150515757~150518032:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000253981.4	ALG1L13P	5.03	6.84e-07	0.000189	0.25	0.23	Mood instability;	chr8:8283379	chr8:8236003~8244667:-
HNSC	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	5.03	6.85e-07	0.000189	0.5	0.23	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
HNSC	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	5.03	6.85e-07	0.000189	0.5	0.23	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
HNSC	cis	rs7085104	0.514	rs284855	ENSG00000236937.2	PTGES3P4	-5.03	6.85e-07	0.000189	-0.28	-0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102845595~102845950:+
HNSC	cis	rs75422866	0.867	rs73102166	ENSG00000276691.1	RP5-1057I20.5	5.03	6.85e-07	0.000189	0.42	0.23	Pneumonia;	chr12:47653769	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102168	ENSG00000276691.1	RP5-1057I20.5	5.03	6.85e-07	0.000189	0.42	0.23	Pneumonia;	chr12:47654010	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102171	ENSG00000276691.1	RP5-1057I20.5	5.03	6.85e-07	0.000189	0.42	0.23	Pneumonia;	chr12:47656077	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs76100981	ENSG00000276691.1	RP5-1057I20.5	5.03	6.85e-07	0.000189	0.42	0.23	Pneumonia;	chr12:47660092	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73102188	ENSG00000276691.1	RP5-1057I20.5	5.03	6.85e-07	0.000189	0.42	0.23	Pneumonia;	chr12:47662993	chr12:47788426~47788971:+
HNSC	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-5.03	6.85e-07	0.000189	-0.27	-0.23	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
HNSC	cis	rs9650657	0.504	rs10093053	ENSG00000255310.2	AF131215.2	-5.03	6.85e-07	0.000189	-0.22	-0.23	Neuroticism;	chr8:11179678	chr8:11107788~11109726:-
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000254153.1	CTA-398F10.2	5.03	6.86e-07	0.000189	0.25	0.23	Joint mobility (Beighton score);	chr8:9009901	chr8:8456909~8461337:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000276710.3	CSPG4P8	-5.03	6.86e-07	0.000189	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82698956	chr15:82459472~82477258:+
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000276710.3	CSPG4P8	-5.03	6.86e-07	0.000189	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82699081	chr15:82459472~82477258:+
HNSC	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	5.03	6.86e-07	0.000189	0.29	0.23	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
HNSC	cis	rs11089937	0.651	rs6001216	ENSG00000211639.2	IGLV4-60	5.03	6.87e-07	0.000189	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22183755	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.651	rs6001217	ENSG00000211639.2	IGLV4-60	5.03	6.87e-07	0.000189	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22183804	chr22:22162199~22162681:+
HNSC	cis	rs1799949	0.965	rs799917	ENSG00000236383.6	LINC00854	-5.03	6.87e-07	0.000189	-0.21	-0.23	Menopause (age at onset);	chr17:43092919	chr17:43216941~43305976:-
HNSC	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	5.03	6.87e-07	0.000189	0.25	0.23	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28074687	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28076559	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28076704	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28078391	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28080757	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000204709.4	LINC01556	5.03	6.87e-07	0.00019	0.31	0.23	Depression;	chr6:28080760	chr6:28943877~28944537:+
HNSC	cis	rs73219805	0.759	rs3758098	ENSG00000228451.3	SDAD1P1	-5.03	6.88e-07	0.00019	-0.4	-0.23	Schizophrenia;	chr8:26381867	chr8:26379259~26382953:-
HNSC	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	5.03	6.88e-07	0.00019	0.26	0.23	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
HNSC	cis	rs72615157	0.634	rs74774557	ENSG00000078319.8	PMS2P1	-5.03	6.89e-07	0.00019	-0.28	-0.23	Lung function (FEV1/FVC);	chr7:100212802	chr7:100320992~100341908:-
HNSC	cis	rs4699052	0.963	rs2085978	ENSG00000246560.2	RP11-10L12.4	5.03	6.89e-07	0.00019	0.27	0.23	Testicular germ cell tumor;	chr4:103272457	chr4:102828055~102844075:+
HNSC	cis	rs6928977	0.863	rs2614275	ENSG00000231028.7	LINC00271	5.03	6.89e-07	0.00019	0.27	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135337376	chr6:135497801~135716055:+
HNSC	cis	rs11638352	1	rs2733221	ENSG00000205771.5	CATSPER2P1	5.03	6.9e-07	0.00019	0.6	0.23	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097672	chr15:43726918~43747094:-
HNSC	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	5.03	6.91e-07	0.00019	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
HNSC	cis	rs1218582	0.772	rs4240874	ENSG00000270361.1	RP11-307C12.13	-5.03	6.91e-07	0.00019	-0.24	-0.23	Prostate cancer;	chr1:154913303	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs4240875	ENSG00000270361.1	RP11-307C12.13	-5.03	6.91e-07	0.00019	-0.24	-0.23	Prostate cancer;	chr1:154913306	chr1:154937370~154938059:+
HNSC	cis	rs7085104	0.572	rs284856	ENSG00000236937.2	PTGES3P4	-5.03	6.92e-07	0.000191	-0.28	-0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102845595~102845950:+
HNSC	cis	rs11756659	0.653	rs185635	ENSG00000272462.2	U91328.19	5.03	6.92e-07	0.000191	0.26	0.23	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:25992662~26001775:+
HNSC	cis	rs6951245	0.572	rs75818004	ENSG00000225146.1	AC073957.15	-5.03	6.92e-07	0.000191	-0.47	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1007936	chr7:1029025~1043891:+
HNSC	cis	rs6951245	0.572	rs75083636	ENSG00000225146.1	AC073957.15	-5.03	6.92e-07	0.000191	-0.47	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1011164	chr7:1029025~1043891:+
HNSC	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	5.03	6.93e-07	0.000191	0.23	0.23	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
HNSC	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	5.03	6.93e-07	0.000191	0.2	0.23	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
HNSC	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-5.03	6.93e-07	0.000191	-0.24	-0.23	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
HNSC	cis	rs7610312	0.681	rs6445972	ENSG00000273493.1	RP11-80H18.4	-5.03	6.93e-07	0.000191	-0.28	-0.23	Red blood cell count;	chr3:58335980	chr3:58329965~58330118:+
HNSC	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-5.03	6.93e-07	0.000191	-0.28	-0.23	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
HNSC	cis	rs9543976	0.614	rs73223948	ENSG00000261553.4	RP11-29G8.3	-5.03	6.94e-07	0.000191	-0.45	-0.23	Diabetic retinopathy;	chr13:75523889	chr13:75549773~75807120:+
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000254174.1	IGHV1-12	5.03	6.94e-07	0.000191	0.2	0.23	Alzheimer's disease (late onset);	chr14:106699438	chr14:106122420~106122709:-
HNSC	cis	rs42490	0.834	rs10102245	ENSG00000251136.7	RP11-37B2.1	5.03	6.95e-07	0.000191	0.2	0.23	Leprosy;	chr8:89638317	chr8:89609409~89757727:-
HNSC	cis	rs1971762	0.504	rs1843318	ENSG00000270175.1	RP11-793H13.11	-5.03	6.95e-07	0.000191	-0.19	-0.23	Height;	chr12:53564293	chr12:53500162~53500936:-
HNSC	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	5.03	6.95e-07	0.000191	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
HNSC	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-5.03	6.96e-07	0.000192	-0.26	-0.23	Height;	chr2:46634872	chr2:46668870~46670778:+
HNSC	cis	rs12935418	0.672	rs12446810	ENSG00000261061.1	RP11-303E16.2	-5.03	6.96e-07	0.000192	-0.26	-0.23	Mean corpuscular volume;	chr16:81009369	chr16:81030770~81031485:+
HNSC	cis	rs6693567	0.545	rs9436009	ENSG00000228126.1	FALEC	5.03	6.96e-07	0.000192	0.27	0.23	Migraine;	chr1:150486950	chr1:150515757~150518032:+
HNSC	cis	rs9840812	0.769	rs1711171	ENSG00000239213.4	NCK1-AS1	5.03	6.97e-07	0.000192	0.21	0.23	Fibrinogen levels;	chr3:136301699	chr3:136841726~136862054:-
HNSC	cis	rs9650657	0.589	rs10107145	ENSG00000269918.1	AF131215.9	-5.03	6.98e-07	0.000192	-0.22	-0.23	Neuroticism;	chr8:10900703	chr8:11104691~11106704:-
HNSC	cis	rs17428076	0.918	rs62183765	ENSG00000228389.1	AC068039.4	-5.03	6.98e-07	0.000192	-0.28	-0.23	Myopia;	chr2:171975512	chr2:171773482~171775844:+
HNSC	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	5.03	6.98e-07	0.000192	0.28	0.23	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
HNSC	cis	rs9907295	0.901	rs74780070	ENSG00000270977.1	AC015849.16	-5.03	6.99e-07	0.000192	-0.38	-0.23	Fibroblast growth factor basic levels;	chr17:35903521	chr17:35893707~35911023:-
HNSC	cis	rs7688540	0.8	rs1578898	ENSG00000211553.1	AC253576.2	-5.03	6.99e-07	0.000192	-0.29	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:136461~136568:+
HNSC	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	5.03	7e-07	0.000193	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
HNSC	cis	rs4218	0.681	rs17302163	ENSG00000259732.1	RP11-59H7.3	-5.03	7.01e-07	0.000193	-0.3	-0.23	Social communication problems;	chr15:59076773	chr15:59121034~59133250:+
HNSC	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-5.03	7.02e-07	0.000193	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
HNSC	cis	rs8040855	0.557	rs9744503	ENSG00000259774.1	RP11-182J1.13	-5.03	7.02e-07	0.000193	-0.27	-0.23	Bulimia nervosa;	chr15:85180986	chr15:84422618~84425882:+
HNSC	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-5.03	7.02e-07	0.000193	-0.25	-0.23	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
HNSC	cis	rs752590	0.65	rs6751201	ENSG00000274877.1	RP11-65I12.1	5.03	7.03e-07	0.000193	0.32	0.23	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113237595~113240825:+
HNSC	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	5.03	7.03e-07	0.000193	0.26	0.23	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
HNSC	cis	rs6964587	1	rs2888851	ENSG00000188693.7	CYP51A1-AS1	-5.03	7.03e-07	0.000193	-0.24	-0.23	Breast cancer;	chr7:92019027	chr7:92134604~92180725:+
HNSC	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-5.03	7.04e-07	0.000194	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
HNSC	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	5.03	7.04e-07	0.000194	0.23	0.23	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
HNSC	cis	rs2933343	0.7	rs6787833	ENSG00000261159.1	RP11-723O4.9	5.03	7.04e-07	0.000194	0.23	0.23	IgG glycosylation;	chr3:128937341	chr3:128859716~128860526:-
HNSC	cis	rs9611519	0.929	rs4820425	ENSG00000235513.1	RP4-756G23.5	5.03	7.04e-07	0.000194	0.25	0.23	Neuroticism;	chr22:41035338	chr22:41209122~41217627:-
HNSC	cis	rs36093844	0.752	rs7127501	ENSG00000279742.1	RP11-700A24.1	-5.03	7.05e-07	0.000194	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853262	chr11:85852557~85854943:-
HNSC	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-5.03	7.05e-07	0.000194	-0.27	-0.23	Height;	chr2:46598887	chr2:46668870~46670778:+
HNSC	cis	rs3863381	0.764	rs75164574	ENSG00000277715.1	RP11-651L5.3	5.03	7.05e-07	0.000194	0.35	0.23	Night sleep phenotypes;	chr12:105718387	chr12:106250759~106252786:+
HNSC	cis	rs17428076	0.958	rs62183762	ENSG00000228389.1	AC068039.4	-5.03	7.05e-07	0.000194	-0.28	-0.23	Myopia;	chr2:171972289	chr2:171773482~171775844:+
HNSC	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-5.03	7.05e-07	0.000194	-0.28	-0.23	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-5.03	7.05e-07	0.000194	-0.28	-0.23	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-5.03	7.05e-07	0.000194	-0.28	-0.23	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
HNSC	cis	rs11773103	1	rs117517262	ENSG00000224046.1	AC005076.5	5.03	7.05e-07	0.000194	0.43	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87309811	chr7:87151423~87152420:-
HNSC	cis	rs763121	0.853	rs5750621	ENSG00000273076.1	RP3-508I15.22	5.03	7.06e-07	0.000194	0.24	0.23	Menopause (age at onset);	chr22:38560161	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750622	ENSG00000273076.1	RP3-508I15.22	5.03	7.06e-07	0.000194	0.24	0.23	Menopause (age at onset);	chr22:38560459	chr22:38743495~38743910:+
HNSC	cis	rs2911132	0.506	rs10037212	ENSG00000248734.2	CTD-2260A17.1	-5.03	7.06e-07	0.000194	-0.24	-0.23	Urate levels (BMI interaction);	chr5:96749072	chr5:96784777~96785999:+
HNSC	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	5.03	7.07e-07	0.000194	0.31	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
HNSC	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-5.03	7.08e-07	0.000195	-0.26	-0.23	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-5.03	7.08e-07	0.000195	-0.26	-0.23	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
HNSC	cis	rs3733585	0.638	rs7377625	ENSG00000250413.1	RP11-448G15.1	5.03	7.08e-07	0.000195	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9951475	chr4:10006482~10009725:+
HNSC	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-5.03	7.08e-07	0.000195	-0.52	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
HNSC	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	5.03	7.08e-07	0.000195	0.36	0.23	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
HNSC	cis	rs3733585	0.699	rs6449179	ENSG00000250413.1	RP11-448G15.1	5.03	7.08e-07	0.000195	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9967493	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs7677710	ENSG00000250413.1	RP11-448G15.1	5.03	7.08e-07	0.000195	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9967893	chr4:10006482~10009725:+
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000229212.6	RP11-561C5.4	-5.03	7.08e-07	0.000195	-0.33	-0.23	Schizophrenia;	chr15:84400409	chr15:85205440~85234795:-
HNSC	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	5.03	7.08e-07	0.000195	0.31	0.23	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
HNSC	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-5.03	7.09e-07	0.000195	-0.24	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
HNSC	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	5.03	7.09e-07	0.000195	0.23	0.23	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	5.03	7.09e-07	0.000195	0.23	0.23	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
HNSC	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	5.03	7.09e-07	0.000195	0.23	0.23	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
HNSC	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	5.03	7.09e-07	0.000195	0.23	0.23	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
HNSC	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-5.03	7.09e-07	0.000195	-0.28	-0.23	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
HNSC	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-5.03	7.09e-07	0.000195	-0.28	-0.23	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
HNSC	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	5.03	7.09e-07	0.000195	0.24	0.23	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
HNSC	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	5.03	7.09e-07	0.000195	0.25	0.23	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
HNSC	cis	rs2337406	1	rs17113331	ENSG00000254174.1	IGHV1-12	5.03	7.1e-07	0.000195	0.19	0.23	Alzheimer's disease (late onset);	chr14:106703843	chr14:106122420~106122709:-
HNSC	cis	rs3805389	0.504	rs10000512	ENSG00000273257.1	RP11-177J6.1	-5.03	7.1e-07	0.000195	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.932	rs4896143	ENSG00000234084.1	RP3-388E23.2	5.03	7.11e-07	0.000195	0.23	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135313962	chr6:135301568~135307158:+
HNSC	cis	rs6479891	0.63	rs10995447	ENSG00000232075.1	MRPL35P2	5.03	7.11e-07	0.000195	0.33	0.23	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63634317~63634827:-
HNSC	cis	rs4140799	0.809	rs1468373	ENSG00000266869.1	RP6-114E22.1	5.03	7.11e-07	0.000195	0.27	0.23	Neuroticism;	chr14:71744039	chr14:71848606~71908430:+
HNSC	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-5.03	7.11e-07	0.000195	-0.36	-0.23	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
HNSC	cis	rs9921338	0.924	rs7204628	ENSG00000263080.1	RP11-485G7.5	5.03	7.12e-07	0.000196	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11341809~11345211:-
HNSC	cis	rs2985684	0.846	rs11157693	ENSG00000278009.1	RP11-649E7.8	5.03	7.12e-07	0.000196	0.29	0.23	Carotid intima media thickness;	chr14:49581708	chr14:49601011~49601124:-
HNSC	cis	rs7246657	0.525	rs997516	ENSG00000276846.1	CTD-3220F14.3	5.03	7.12e-07	0.000196	0.33	0.23	Coronary artery calcification;	chr19:36983362	chr19:37314868~37315620:-
HNSC	cis	rs4657482	0.889	rs10918298	ENSG00000236364.3	RP11-525G13.2	-5.03	7.12e-07	0.000196	-0.22	-0.23	Testicular germ cell tumor;	chr1:165864011	chr1:165890795~165900683:-
HNSC	cis	rs10791097	0.765	rs4622274	ENSG00000254842.5	RP11-890B15.2	-5.03	7.12e-07	0.000196	-0.2	-0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130859591	chr11:130844191~130865561:-
HNSC	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	5.03	7.13e-07	0.000196	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
HNSC	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-5.03	7.13e-07	0.000196	-0.22	-0.23	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
HNSC	cis	rs6540731	1	rs4362041	ENSG00000226251.4	RP11-15I11.3	-5.03	7.13e-07	0.000196	-0.26	-0.23	Intelligence (childhood);	chr1:212227127	chr1:212225278~212238977:-
HNSC	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	5.03	7.14e-07	0.000196	0.2	0.23	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
HNSC	cis	rs9287719	0.649	rs11684537	ENSG00000243819.4	RN7SL832P	5.03	7.14e-07	0.000196	0.23	0.23	Prostate cancer;	chr2:10594706	chr2:10690344~10692099:+
HNSC	cis	rs6430553	0.929	rs3819121	ENSG00000224043.6	CCNT2-AS1	-5.03	7.14e-07	0.000196	-0.27	-0.23	Blood metabolite levels;	chr2:134865290	chr2:134735464~134918710:-
HNSC	cis	rs11969893	0.649	rs12527901	ENSG00000270987.1	RP3-467N11.2	5.03	7.15e-07	0.000196	0.5	0.23	Economic and political preferences (immigration/crime);	chr6:100832559	chr6:100889603~100890338:+
HNSC	cis	rs831571	0.668	rs34723451	ENSG00000280620.1	SCAANT1	5.03	7.15e-07	0.000196	0.36	0.23	Type 2 diabetes;	chr3:64096160	chr3:63911518~63911772:-
HNSC	cis	rs4664293	0.647	rs1425039	ENSG00000226266.5	AC009961.3	-5.03	7.16e-07	0.000196	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159571612	chr2:159670708~159712435:-
HNSC	cis	rs35306767	0.909	rs12264390	ENSG00000229869.1	RP11-363N22.2	-5.03	7.16e-07	0.000197	-0.31	-0.23	Eosinophil percentage of granulocytes;	chr10:913171	chr10:933026~942743:+
HNSC	cis	rs6430553	0.929	rs74265413	ENSG00000224043.6	CCNT2-AS1	-5.03	7.16e-07	0.000197	-0.27	-0.23	Blood metabolite levels;	chr2:134892083	chr2:134735464~134918710:-
HNSC	cis	rs4326844	0.59	rs7967622	ENSG00000248265.1	FLJ12825	5.03	7.17e-07	0.000197	0.28	0.23	Platelet count;	chr12:54284196	chr12:54058254~54122234:+
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000276710.3	CSPG4P8	-5.03	7.17e-07	0.000197	-0.32	-0.23	Excessive daytime sleepiness;	chr15:82695420	chr15:82459472~82477258:+
HNSC	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	5.03	7.17e-07	0.000197	0.24	0.23	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
HNSC	cis	rs13113518	0.507	rs11943456	ENSG00000273257.1	RP11-177J6.1	5.03	7.18e-07	0.000197	0.26	0.23	Height;	chr4:55410167	chr4:55387949~55388271:+
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000254174.1	IGHV1-12	5.03	7.18e-07	0.000197	0.2	0.23	Alzheimer's disease (late onset);	chr14:106696601	chr14:106122420~106122709:-
HNSC	cis	rs950169	0.922	rs2033284	ENSG00000229212.6	RP11-561C5.4	-5.03	7.18e-07	0.000197	-0.32	-0.23	Schizophrenia;	chr15:84391575	chr15:85205440~85234795:-
HNSC	cis	rs867371	0.82	rs12443224	ENSG00000255769.6	GOLGA2P10	-5.03	7.18e-07	0.000197	-0.28	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472993~82513950:-
HNSC	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-5.02	7.19e-07	0.000197	-0.23	-0.23	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
HNSC	cis	rs3863381	0.656	rs57530124	ENSG00000277715.1	RP11-651L5.3	5.02	7.19e-07	0.000197	0.34	0.23	Night sleep phenotypes;	chr12:105708066	chr12:106250759~106252786:+
HNSC	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	5.02	7.19e-07	0.000197	0.3	0.23	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
HNSC	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-5.02	7.2e-07	0.000198	-0.28	-0.23	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
HNSC	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	5.02	7.21e-07	0.000198	0.24	0.23	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
HNSC	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-5.02	7.21e-07	0.000198	-0.3	-0.23	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-5.02	7.21e-07	0.000198	-0.3	-0.23	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
HNSC	cis	rs763567	0.967	rs1234274	ENSG00000271811.1	RP1-79C4.4	5.02	7.22e-07	0.000198	0.24	0.23	Tonsillectomy;	chr1:170627232	chr1:170667381~170669425:+
HNSC	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	5.02	7.22e-07	0.000198	0.29	0.23	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
HNSC	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	5.02	7.22e-07	0.000198	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000254153.1	CTA-398F10.2	5.02	7.23e-07	0.000198	0.24	0.23	Mood instability;	chr8:8446992	chr8:8456909~8461337:-
HNSC	cis	rs939574	1	rs7574937	ENSG00000243910.6	TUBA4B	5.02	7.23e-07	0.000198	0.47	0.23	Platelet distribution width;	chr2:219234609	chr2:219253243~219272188:+
HNSC	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-5.02	7.23e-07	0.000198	-0.29	-0.23	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
HNSC	cis	rs1223397	1	rs1223397	ENSG00000215022.6	RP1-257A7.4	-5.02	7.23e-07	0.000198	-0.28	-0.23	Blood pressure;	chr6:13270713	chr6:13264861~13295586:-
HNSC	cis	rs7789940	0.951	rs7779014	ENSG00000231087.2	FDPSP7	-5.02	7.23e-07	0.000198	-0.27	-0.23	Multiple sclerosis;	chr7:76346269	chr7:76968197~76969250:-
HNSC	cis	rs17507216	0.958	rs72751643	ENSG00000276710.3	CSPG4P8	-5.02	7.23e-07	0.000198	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82559444	chr15:82459472~82477258:+
HNSC	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	5.02	7.24e-07	0.000198	0.24	0.23	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
HNSC	cis	rs2235642	0.533	rs17135391	ENSG00000280231.1	LA16c-380F5.3	-5.02	7.24e-07	0.000198	-0.31	-0.23	Coronary artery disease;	chr16:1555605	chr16:1553655~1554130:-
HNSC	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-5.02	7.24e-07	0.000198	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-5.02	7.24e-07	0.000198	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
HNSC	cis	rs6558530	0.579	rs6558528	ENSG00000253982.1	CTD-2336O2.1	5.02	7.25e-07	0.000199	0.28	0.23	Systolic blood pressure;	chr8:1754897	chr8:1761990~1764502:-
HNSC	cis	rs36052053	0.908	rs13203020	ENSG00000219700.1	PTCHD3P3	5.02	7.25e-07	0.000199	0.36	0.23	Red cell distribution width;	chr6:109263442	chr6:109288571~109290503:-
HNSC	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	5.02	7.26e-07	0.000199	0.31	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
HNSC	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	5.02	7.26e-07	0.000199	0.28	0.23	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
HNSC	cis	rs1479119	0.53	rs17820074	ENSG00000180861.8	LINC01559	-5.02	7.27e-07	0.000199	-0.28	-0.23	Intelligence (multi-trait analysis);	chr12:13362736	chr12:13371089~13387167:-
HNSC	cis	rs7824557	0.724	rs2572398	ENSG00000269918.1	AF131215.9	5.02	7.27e-07	0.000199	0.22	0.23	Retinal vascular caliber;	chr8:11320584	chr8:11104691~11106704:-
HNSC	cis	rs6693567	0.565	rs696615	ENSG00000228126.1	FALEC	5.02	7.27e-07	0.000199	0.27	0.23	Migraine;	chr1:150366512	chr1:150515757~150518032:+
HNSC	cis	rs1799949	0.93	rs34210004	ENSG00000236383.6	LINC00854	-5.02	7.27e-07	0.000199	-0.21	-0.23	Menopause (age at onset);	chr17:43218318	chr17:43216941~43305976:-
HNSC	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	5.02	7.28e-07	2e-04	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	5.02	7.28e-07	2e-04	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	5.02	7.28e-07	2e-04	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
HNSC	cis	rs1218582	0.741	rs11264283	ENSG00000270361.1	RP11-307C12.13	-5.02	7.29e-07	2e-04	-0.24	-0.23	Prostate cancer;	chr1:154897076	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.741	rs10908446	ENSG00000270361.1	RP11-307C12.13	-5.02	7.29e-07	2e-04	-0.24	-0.23	Prostate cancer;	chr1:154897083	chr1:154937370~154938059:+
HNSC	cis	rs9813712	0.596	rs2587988	ENSG00000249846.5	RP11-77P16.4	-5.02	7.29e-07	2e-04	-0.23	-0.23	Response to amphetamines;	chr3:130201415	chr3:130112550~130120579:+
HNSC	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	5.02	7.29e-07	2e-04	0.31	0.23	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
HNSC	cis	rs988913	0.706	rs4715489	ENSG00000224984.1	RP11-524H19.2	5.02	7.3e-07	2e-04	0.26	0.23	Menarche (age at onset);	chr6:54868167	chr6:54840118~54840855:-
HNSC	cis	rs4664293	0.647	rs918969	ENSG00000226266.5	AC009961.3	5.02	7.3e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159610145	chr2:159670708~159712435:-
HNSC	cis	rs853679	0.607	rs67101035	ENSG00000219392.1	RP1-265C24.5	-5.02	7.3e-07	2e-04	-0.45	-0.23	Depression;	chr6:27831109	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.556	rs34706883	ENSG00000219392.1	RP1-265C24.5	-5.02	7.3e-07	2e-04	-0.45	-0.23	Depression;	chr6:27837477	chr6:28115628~28116551:+
HNSC	cis	rs4664293	0.625	rs6760931	ENSG00000226266.5	AC009961.3	5.02	7.3e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159702600	chr2:159670708~159712435:-
HNSC	cis	rs36052053	0.908	rs932222	ENSG00000219700.1	PTCHD3P3	-5.02	7.3e-07	2e-04	-0.35	-0.23	Red cell distribution width;	chr6:109265475	chr6:109288571~109290503:-
HNSC	cis	rs1971762	0.527	rs784562	ENSG00000270175.1	RP11-793H13.11	5.02	7.3e-07	2e-04	0.2	0.23	Height;	chr12:53525916	chr12:53500162~53500936:-
HNSC	cis	rs3733585	0.534	rs7375642	ENSG00000250413.1	RP11-448G15.1	5.02	7.3e-07	2e-04	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953612	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.578	rs6837224	ENSG00000250413.1	RP11-448G15.1	5.02	7.3e-07	2e-04	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953631	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.578	rs4466042	ENSG00000250413.1	RP11-448G15.1	5.02	7.3e-07	2e-04	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953743	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.726	rs4306953	ENSG00000250413.1	RP11-448G15.1	5.02	7.3e-07	2e-04	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9954152	chr4:10006482~10009725:+
HNSC	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-5.02	7.3e-07	2e-04	-0.2	-0.23	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
HNSC	cis	rs9813712	0.571	rs9855426	ENSG00000249846.5	RP11-77P16.4	5.02	7.3e-07	2e-04	0.24	0.23	Response to amphetamines;	chr3:130214475	chr3:130112550~130120579:+
HNSC	cis	rs4141404	0.577	rs2413045	ENSG00000236132.1	CTA-440B3.1	5.02	7.31e-07	2e-04	0.36	0.23	Paclitaxel-induced neuropathy;	chr22:31269876	chr22:31816379~31817491:-
HNSC	cis	rs4664293	0.605	rs6741498	ENSG00000226266.5	AC009961.3	5.02	7.31e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159698111	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	5.02	7.31e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	5.02	7.31e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
HNSC	cis	rs1865760	0.613	rs2071300	ENSG00000272462.2	U91328.19	-5.02	7.32e-07	2e-04	-0.21	-0.23	Height;	chr6:25914344	chr6:25992662~26001775:+
HNSC	cis	rs2243480	1	rs160634	ENSG00000179406.6	LINC00174	5.02	7.32e-07	2e-04	0.47	0.23	Diabetic kidney disease;	chr7:66063677	chr7:66376044~66401338:-
HNSC	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	5.02	7.32e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	5.02	7.32e-07	2e-04	0.23	0.23	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
HNSC	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-5.02	7.32e-07	2e-04	-0.25	-0.23	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
HNSC	cis	rs12468226	0.872	rs1061157	ENSG00000226261.1	AC064836.3	5.02	7.33e-07	0.000201	0.34	0.23	Urate levels;	chr2:202556476	chr2:202336024~202336727:-
HNSC	cis	rs7829975	0.535	rs4841005	ENSG00000254340.1	RP11-10A14.3	-5.02	7.33e-07	0.000201	-0.28	-0.23	Mood instability;	chr8:8643720	chr8:9141424~9145435:+
HNSC	cis	rs9907295	0.786	rs56344830	ENSG00000270977.1	AC015849.16	-5.02	7.33e-07	0.000201	-0.38	-0.23	Fibroblast growth factor basic levels;	chr17:35903951	chr17:35893707~35911023:-
HNSC	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-5.02	7.33e-07	0.000201	-0.26	-0.23	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-5.02	7.33e-07	0.000201	-0.26	-0.23	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-5.02	7.33e-07	0.000201	-0.26	-0.23	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
HNSC	cis	rs655720	1	rs655720	ENSG00000239213.4	NCK1-AS1	5.02	7.35e-07	0.000201	0.2	0.23	Coronary artery disease;	chr3:136384425	chr3:136841726~136862054:-
HNSC	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	5.02	7.35e-07	0.000201	0.23	0.23	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
HNSC	cis	rs2810114	0.834	rs36559	ENSG00000274818.1	RP1-292L20.3	5.02	7.35e-07	0.000201	0.27	0.23	Alcohol dependence;	chr14:70888232	chr14:70906657~70907111:-
HNSC	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	5.02	7.35e-07	0.000201	0.25	0.23	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
HNSC	cis	rs1552244	0.882	rs55962400	ENSG00000180385.7	EMC3-AS1	5.02	7.35e-07	0.000201	0.26	0.23	Alzheimer's disease;	chr3:10002773	chr3:9986893~10006990:+
HNSC	cis	rs1971762	0.583	rs12810378	ENSG00000270175.1	RP11-793H13.11	-5.02	7.36e-07	0.000201	-0.19	-0.23	Height;	chr12:53698054	chr12:53500162~53500936:-
HNSC	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	5.02	7.36e-07	0.000201	0.31	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
HNSC	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	5.02	7.36e-07	0.000201	0.27	0.23	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
HNSC	cis	rs763567	0.81	rs638704	ENSG00000271811.1	RP1-79C4.4	5.02	7.36e-07	0.000201	0.24	0.23	Tonsillectomy;	chr1:170629046	chr1:170667381~170669425:+
HNSC	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	5.02	7.36e-07	0.000201	0.23	0.23	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
HNSC	cis	rs12935418	0.672	rs1453327	ENSG00000261061.1	RP11-303E16.2	5.02	7.37e-07	0.000201	0.24	0.23	Mean corpuscular volume;	chr16:81014959	chr16:81030770~81031485:+
HNSC	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-5.02	7.37e-07	0.000202	-0.29	-0.23	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
HNSC	cis	rs1056107	0.931	rs7875843	ENSG00000225513.1	RP11-165N19.2	-5.02	7.37e-07	0.000202	-0.24	-0.23	Colorectal cancer;	chr9:112256675	chr9:112173522~112173971:-
HNSC	cis	rs11976180	1	rs2951372	ENSG00000273234.1	OR2A13P	-5.02	7.37e-07	0.000202	-0.25	-0.23	Obesity-related traits;	chr7:144052410	chr7:144142009~144142938:+
HNSC	cis	rs4388249	0.687	rs11745926	ENSG00000271849.1	CTC-332L22.1	-5.02	7.38e-07	0.000202	-0.31	-0.23	Schizophrenia;	chr5:109809489	chr5:109687802~109688329:-
HNSC	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	5.02	7.38e-07	0.000202	0.33	0.23	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
HNSC	cis	rs3733585	0.648	rs7378305	ENSG00000250413.1	RP11-448G15.1	5.02	7.38e-07	0.000202	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953269	chr4:10006482~10009725:+
HNSC	cis	rs6964587	1	rs11982047	ENSG00000188693.7	CYP51A1-AS1	-5.02	7.38e-07	0.000202	-0.24	-0.23	Breast cancer;	chr7:92075960	chr7:92134604~92180725:+
HNSC	cis	rs1056107	0.931	rs3849126	ENSG00000225513.1	RP11-165N19.2	-5.02	7.39e-07	0.000202	-0.24	-0.23	Colorectal cancer;	chr9:112261060	chr9:112173522~112173971:-
HNSC	cis	rs75422866	0.867	rs78912815	ENSG00000276691.1	RP5-1057I20.5	5.02	7.39e-07	0.000202	0.42	0.23	Pneumonia;	chr12:47612065	chr12:47788426~47788971:+
HNSC	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	5.02	7.39e-07	0.000202	0.25	0.23	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000254340.1	RP11-10A14.3	5.02	7.39e-07	0.000202	0.27	0.23	Parkinson's disease;	chr8:8399807	chr8:9141424~9145435:+
HNSC	cis	rs11846409	0.932	rs28617526	ENSG00000274576.2	IGHV2-70	-5.02	7.39e-07	0.000202	-0.22	-0.23	Rheumatic heart disease;	chr14:106637322	chr14:106770577~106771020:-
HNSC	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	5.02	7.41e-07	0.000203	0.5	0.23	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	5.02	7.41e-07	0.000203	0.5	0.23	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	5.02	7.41e-07	0.000203	0.5	0.23	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	5.02	7.41e-07	0.000203	0.5	0.23	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
HNSC	cis	rs1056107	0.931	rs6477904	ENSG00000225513.1	RP11-165N19.2	-5.02	7.41e-07	0.000203	-0.24	-0.23	Colorectal cancer;	chr9:112261254	chr9:112173522~112173971:-
HNSC	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	5.02	7.41e-07	0.000203	0.24	0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
HNSC	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	5.02	7.42e-07	0.000203	0.29	0.23	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	5.02	7.42e-07	0.000203	0.28	0.23	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	5.02	7.42e-07	0.000203	0.28	0.23	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000233609.3	RP11-62H7.2	-5.02	7.42e-07	0.000203	-0.22	-0.23	Joint mobility (Beighton score);	chr8:9011689	chr8:8961200~8979025:+
HNSC	cis	rs2985684	0.846	rs10150624	ENSG00000278009.1	RP11-649E7.8	5.02	7.43e-07	0.000203	0.29	0.23	Carotid intima media thickness;	chr14:49584847	chr14:49601011~49601124:-
HNSC	cis	rs2985684	0.802	rs10150823	ENSG00000278009.1	RP11-649E7.8	5.02	7.43e-07	0.000203	0.29	0.23	Carotid intima media thickness;	chr14:49585033	chr14:49601011~49601124:-
HNSC	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	5.02	7.43e-07	0.000203	0.27	0.23	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
HNSC	cis	rs9402743	0.631	rs9376112	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135606862	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.635	rs9373135	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135611101	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs2143681	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135611867	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.564	rs9376113	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135612254	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs6934482	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135612363	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs9402724	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135614046	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.564	rs2327649	ENSG00000234084.1	RP3-388E23.2	-5.02	7.43e-07	0.000203	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135615097	chr6:135301568~135307158:+
HNSC	cis	rs6051080	1	rs6051080	ENSG00000231081.1	RP4-760C5.3	-5.02	7.43e-07	0.000203	-0.23	-0.23	Colorectal or endometrial cancer;	chr20:25995038	chr20:26008791~26010531:-
HNSC	cis	rs10510102	0.623	rs10159856	ENSG00000226864.1	ATE1-AS1	5.02	7.43e-07	0.000203	0.41	0.23	Breast cancer;	chr10:121988292	chr10:121928312~121951965:+
HNSC	cis	rs3743266	0.613	rs7180766	ENSG00000245534.5	RORA-AS1	5.02	7.44e-07	0.000203	0.29	0.23	Menarche (age at onset);	chr15:60482294	chr15:60479178~60630637:+
HNSC	cis	rs6540731	1	rs6540732	ENSG00000226251.4	RP11-15I11.3	5.02	7.44e-07	0.000203	0.27	0.23	Intelligence (childhood);	chr1:212219144	chr1:212225278~212238977:-
HNSC	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-5.02	7.44e-07	0.000203	-0.28	-0.23	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-5.02	7.44e-07	0.000203	-0.28	-0.23	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-5.02	7.44e-07	0.000203	-0.28	-0.23	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
HNSC	cis	rs11773103	0.737	rs73194613	ENSG00000224046.1	AC005076.5	5.02	7.45e-07	0.000203	0.43	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87288601	chr7:87151423~87152420:-
HNSC	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-5.02	7.45e-07	0.000204	-0.2	-0.23	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
HNSC	cis	rs3805389	0.504	rs3805388	ENSG00000273257.1	RP11-177J6.1	-5.02	7.45e-07	0.000204	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55387949~55388271:+
HNSC	cis	rs9907295	0.748	rs11868785	ENSG00000270977.1	AC015849.16	-5.02	7.46e-07	0.000204	-0.3	-0.23	Fibroblast growth factor basic levels;	chr17:35812214	chr17:35893707~35911023:-
HNSC	cis	rs7000734	0.674	rs13275945	ENSG00000245080.5	RP11-320N21.1	5.02	7.47e-07	0.000204	0.34	0.23	Radiation response;	chr8:95146825	chr8:95066808~95073182:-
HNSC	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-5.02	7.47e-07	0.000204	-0.22	-0.23	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
HNSC	cis	rs6674176	0.597	rs4660262	ENSG00000237950.1	RP11-7O11.3	5.02	7.47e-07	0.000204	0.25	0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43916852	chr1:43944370~43946551:-
HNSC	cis	rs4873772	0.735	rs4873437	ENSG00000253330.1	RP11-697N18.3	-5.02	7.47e-07	0.000204	-0.28	-0.23	Lobe attachment (rater-scored or self-reported);	chr8:47531194	chr8:47511034~47512141:-
HNSC	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	5.02	7.47e-07	0.000204	0.29	0.23	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
HNSC	cis	rs4218	0.681	rs1074701	ENSG00000259732.1	RP11-59H7.3	-5.02	7.47e-07	0.000204	-0.29	-0.23	Social communication problems;	chr15:59073862	chr15:59121034~59133250:+
HNSC	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	5.02	7.47e-07	0.000204	0.23	0.23	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	5.02	7.47e-07	0.000204	0.23	0.23	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
HNSC	cis	rs1008375	1	rs1008375	ENSG00000249502.1	AC006160.5	-5.02	7.47e-07	0.000204	-0.24	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17681211	chr4:17587467~17614571:-
HNSC	cis	rs7829975	0.658	rs907181	ENSG00000173295.6	FAM86B3P	5.02	7.48e-07	0.000204	0.25	0.23	Mood instability;	chr8:8845365	chr8:8228595~8244865:+
HNSC	cis	rs10462794	0.661	rs12517672	ENSG00000260763.1	RP11-445O3.3	-5.02	7.48e-07	0.000204	-0.33	-0.23	DNA methylation (variation);	chr5:4520378	chr5:4436850~4440259:-
HNSC	cis	rs42490	0.789	rs51331	ENSG00000251136.7	RP11-37B2.1	-5.02	7.48e-07	0.000204	-0.19	-0.23	Leprosy;	chr8:89801900	chr8:89609409~89757727:-
HNSC	cis	rs3806843	1	rs2098058	ENSG00000202515.1	VTRNA1-3	5.02	7.49e-07	0.000205	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr5:140726158~140726246:+
HNSC	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	5.02	7.49e-07	0.000205	0.24	0.23	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
HNSC	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	5.02	7.49e-07	0.000205	0.24	0.23	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
HNSC	cis	rs1355223	0.934	rs11602669	ENSG00000271369.1	RP11-350D17.3	-5.02	7.5e-07	0.000205	-0.26	-0.23	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673567	chr11:34709600~34710161:+
HNSC	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.02	7.5e-07	0.000205	-0.2	-0.23	Height;	chr11:118808920	chr11:118791254~118793137:+
HNSC	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-5.02	7.5e-07	0.000205	-0.29	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
HNSC	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-5.02	7.5e-07	0.000205	-0.27	-0.23	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
HNSC	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	5.02	7.51e-07	0.000205	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
HNSC	cis	rs11893307	0.566	rs13412750	ENSG00000235852.1	AC005540.3	5.02	7.51e-07	0.000205	0.3	0.23	Mean platelet volume;	chr2:190770232	chr2:190880797~190882059:-
HNSC	cis	rs6540731	1	rs35209719	ENSG00000226251.4	RP11-15I11.3	-5.02	7.51e-07	0.000205	-0.26	-0.23	Intelligence (childhood);	chr1:212228335	chr1:212225278~212238977:-
HNSC	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-5.02	7.52e-07	0.000205	-0.26	-0.23	Height;	chr2:46638595	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-5.02	7.52e-07	0.000205	-0.26	-0.23	Height;	chr2:46638634	chr2:46668870~46670778:+
HNSC	cis	rs6693567	0.507	rs828784	ENSG00000228126.1	FALEC	5.02	7.53e-07	0.000205	0.27	0.23	Migraine;	chr1:150362764	chr1:150515757~150518032:+
HNSC	cis	rs7819412	1	rs7819412	ENSG00000255310.2	AF131215.2	5.02	7.53e-07	0.000206	0.22	0.23	Triglycerides;	chr8:11187652	chr8:11107788~11109726:-
HNSC	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-5.02	7.53e-07	0.000206	-0.27	-0.23	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
HNSC	cis	rs287982	0.611	rs111636862	ENSG00000269973.1	RP11-95D17.1	-5.02	7.54e-07	0.000206	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9840128	chr2:9936360~9939590:+
HNSC	cis	rs7829975	0.508	rs4841006	ENSG00000254340.1	RP11-10A14.3	-5.02	7.54e-07	0.000206	-0.28	-0.23	Mood instability;	chr8:8643964	chr8:9141424~9145435:+
HNSC	cis	rs9300255	0.664	rs7306755	ENSG00000280120.1	RP11-546D6.3	-5.02	7.54e-07	0.000206	-0.22	-0.23	Neutrophil percentage of white cells;	chr12:123283382	chr12:123152324~123153377:-
HNSC	cis	rs860295	0.702	rs11264386	ENSG00000203761.5	MSTO2P	-5.02	7.54e-07	0.000206	-0.18	-0.23	Body mass index;	chr1:155589379	chr1:155745829~155750137:+
HNSC	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-5.02	7.55e-07	0.000206	-0.3	-0.23	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
HNSC	cis	rs853679	0.546	rs35819751	ENSG00000219392.1	RP1-265C24.5	-5.01	7.55e-07	0.000206	-0.44	-0.23	Depression;	chr6:27842791	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13194781	ENSG00000219392.1	RP1-265C24.5	-5.01	7.55e-07	0.000206	-0.44	-0.23	Depression;	chr6:27847861	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs36116761	ENSG00000219392.1	RP1-265C24.5	-5.01	7.55e-07	0.000206	-0.44	-0.23	Depression;	chr6:27850704	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs34194357	ENSG00000219392.1	RP1-265C24.5	-5.01	7.55e-07	0.000206	-0.44	-0.23	Depression;	chr6:27850757	chr6:28115628~28116551:+
HNSC	cis	rs2058059	0.551	rs72608543	ENSG00000225648.4	SBDSP1	-5.01	7.55e-07	0.000206	-0.34	-0.23	Subcutaneous adipose tissue;	chr7:72597693	chr7:72829425~72836701:+
HNSC	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-5.01	7.55e-07	0.000206	-0.19	-0.23	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
HNSC	cis	rs4218	0.681	rs10518996	ENSG00000277144.1	RP11-59H7.4	-5.01	7.55e-07	0.000206	-0.28	-0.23	Social communication problems;	chr15:59085247	chr15:59115547~59116089:-
HNSC	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-5.01	7.56e-07	0.000206	-0.28	-0.23	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
HNSC	cis	rs12291225	0.585	rs11023194	ENSG00000251991.1	RNU7-49P	5.01	7.56e-07	0.000206	0.25	0.23	Sense of smell;	chr11:14348223	chr11:14478892~14478953:+
HNSC	cis	rs11672691	0.67	rs4802119	ENSG00000270164.1	LINC01480	-5.01	7.56e-07	0.000206	-0.21	-0.23	Prostate cancer;	chr19:41484417	chr19:41535183~41536904:+
HNSC	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	5.01	7.56e-07	0.000206	0.29	0.23	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
HNSC	cis	rs4218	0.681	rs58335303	ENSG00000277144.1	RP11-59H7.4	-5.01	7.56e-07	0.000206	-0.3	-0.23	Social communication problems;	chr15:59073206	chr15:59115547~59116089:-
HNSC	cis	rs36093844	0.8	rs2044390	ENSG00000279742.1	RP11-700A24.1	-5.01	7.57e-07	0.000206	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85858791	chr11:85852557~85854943:-
HNSC	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-5.01	7.57e-07	0.000207	-0.28	-0.23	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
HNSC	cis	rs1056107	0.831	rs7856196	ENSG00000225513.1	RP11-165N19.2	-5.01	7.57e-07	0.000207	-0.24	-0.23	Colorectal cancer;	chr9:112181635	chr9:112173522~112173971:-
HNSC	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-5.01	7.58e-07	0.000207	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
HNSC	cis	rs1065852	0.906	rs9611734	ENSG00000226450.2	CYP2D8P	5.01	7.58e-07	0.000207	0.22	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42149886~42155001:-
HNSC	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	5.01	7.58e-07	0.000207	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
HNSC	cis	rs9840812	0.769	rs483465	ENSG00000239213.4	NCK1-AS1	5.01	7.58e-07	0.000207	0.21	0.23	Fibrinogen levels;	chr3:136329135	chr3:136841726~136862054:-
HNSC	cis	rs17428076	0.872	rs6761111	ENSG00000228389.1	AC068039.4	-5.01	7.58e-07	0.000207	-0.28	-0.23	Myopia;	chr2:172018664	chr2:171773482~171775844:+
HNSC	cis	rs9840812	0.691	rs833752	ENSG00000239213.4	NCK1-AS1	5.01	7.59e-07	0.000207	0.21	0.23	Fibrinogen levels;	chr3:136536327	chr3:136841726~136862054:-
HNSC	cis	rs4853525	0.59	rs1921911	ENSG00000235852.1	AC005540.3	5.01	7.59e-07	0.000207	0.31	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855644	chr2:190880797~190882059:-
HNSC	cis	rs1665050	0.652	rs9302206	ENSG00000277144.1	RP11-59H7.4	-5.01	7.59e-07	0.000207	-0.27	-0.23	Atopic dermatitis;	chr15:59017274	chr15:59115547~59116089:-
HNSC	cis	rs10462794	0.661	rs16873555	ENSG00000260763.1	RP11-445O3.3	-5.01	7.59e-07	0.000207	-0.33	-0.23	DNA methylation (variation);	chr5:4517632	chr5:4436850~4440259:-
HNSC	cis	rs860818	1	rs10634	ENSG00000226816.2	AC005082.12	-5.01	7.59e-07	0.000207	-0.53	-0.23	Initial pursuit acceleration;	chr7:23200977	chr7:23206013~23208045:+
HNSC	cis	rs11976180	1	rs2951363	ENSG00000273234.1	OR2A13P	-5.01	7.6e-07	0.000207	-0.25	-0.23	Obesity-related traits;	chr7:144057631	chr7:144142009~144142938:+
HNSC	cis	rs3738443	0.868	rs7546908	ENSG00000259865.1	RP11-488L18.10	-5.01	7.6e-07	0.000207	-0.2	-0.23	Alcohol dependence;	chr1:247200531	chr1:247187281~247188526:-
HNSC	cis	rs6964587	0.934	rs1544377	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92058037	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6951972	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92060132	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6969981	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92060147	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs56072181	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92061143	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10236397	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92062287	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.934	rs73226382	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92063446	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6465347	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92064523	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs10248102	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92070465	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10270598	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92071513	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7800582	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.6e-07	0.000207	-0.24	-0.23	Breast cancer;	chr7:92072032	chr7:92134604~92180725:+
HNSC	cis	rs4237845	0.611	rs4335583	ENSG00000257159.1	RP11-58A17.3	5.01	7.6e-07	0.000207	0.27	0.23	Intelligence (multi-trait analysis);	chr12:57911328	chr12:57967058~57968399:+
HNSC	cis	rs12701220	0.817	rs7798459	ENSG00000229043.2	AC091729.9	-5.01	7.61e-07	0.000207	-0.31	-0.23	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1160374~1165267:+
HNSC	cis	rs2976388	0.632	rs2585139	ENSG00000253741.1	CTD-2292P10.4	-5.01	7.61e-07	0.000207	-0.22	-0.23	Urinary tract infection frequency;	chr8:142726757	chr8:142702252~142726973:-
HNSC	cis	rs11154801	0.634	rs6941396	ENSG00000234084.1	RP3-388E23.2	-5.01	7.61e-07	0.000207	-0.25	-0.23	Multiple sclerosis;	chr6:135606388	chr6:135301568~135307158:+
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000254174.1	IGHV1-12	5.01	7.61e-07	0.000207	0.19	0.23	Alzheimer's disease (late onset);	chr14:106780575	chr14:106122420~106122709:-
HNSC	cis	rs17428076	0.831	rs3736499	ENSG00000228389.1	AC068039.4	-5.01	7.62e-07	0.000208	-0.28	-0.23	Myopia;	chr2:171833908	chr2:171773482~171775844:+
HNSC	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-5.01	7.63e-07	0.000208	-0.22	-0.23	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
HNSC	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-5.01	7.64e-07	0.000208	-0.32	-0.23	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
HNSC	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-5.01	7.64e-07	0.000208	-0.2	-0.23	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
HNSC	cis	rs3733585	0.699	rs7683283	ENSG00000250413.1	RP11-448G15.1	5.01	7.64e-07	0.000208	0.27	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9968350	chr4:10006482~10009725:+
HNSC	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-5.01	7.64e-07	0.000208	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
HNSC	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-5.01	7.64e-07	0.000208	-0.26	-0.23	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
HNSC	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	5.01	7.64e-07	0.000208	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
HNSC	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-5.01	7.65e-07	0.000208	-0.35	-0.23	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
HNSC	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	5.01	7.65e-07	0.000208	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
HNSC	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	5.01	7.65e-07	0.000208	0.31	0.23	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
HNSC	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	5.01	7.65e-07	0.000208	0.26	0.23	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
HNSC	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	5.01	7.65e-07	0.000208	0.23	0.23	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
HNSC	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	5.01	7.67e-07	0.000209	0.26	0.23	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
HNSC	cis	rs9402743	0.599	rs6919741	ENSG00000234084.1	RP3-388E23.2	-5.01	7.68e-07	0.000209	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135622057	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs9321516	ENSG00000234084.1	RP3-388E23.2	-5.01	7.68e-07	0.000209	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135622150	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.598	rs7761716	ENSG00000234084.1	RP3-388E23.2	-5.01	7.68e-07	0.000209	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135623243	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs7762139	ENSG00000234084.1	RP3-388E23.2	-5.01	7.68e-07	0.000209	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135623289	chr6:135301568~135307158:+
HNSC	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	5.01	7.68e-07	0.000209	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
HNSC	cis	rs6723108	0.603	rs3814354	ENSG00000224043.6	CCNT2-AS1	-5.01	7.68e-07	0.000209	-0.28	-0.23	Type 2 diabetes;	chr2:134954087	chr2:134735464~134918710:-
HNSC	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	5.01	7.69e-07	0.000209	0.33	0.23	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
HNSC	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-5.01	7.69e-07	0.000209	-0.28	-0.23	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
HNSC	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	5.01	7.7e-07	0.000209	0.45	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
HNSC	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	5.01	7.71e-07	0.00021	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	5.01	7.71e-07	0.00021	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	5.01	7.71e-07	0.00021	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
HNSC	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	5.01	7.71e-07	0.00021	0.23	0.23	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
HNSC	cis	rs9611565	0.525	rs9611548	ENSG00000235513.1	RP4-756G23.5	5.01	7.71e-07	0.00021	0.25	0.23	Vitiligo;	chr22:41308139	chr22:41209122~41217627:-
HNSC	cis	rs453301	0.506	rs476845	ENSG00000254340.1	RP11-10A14.3	-5.01	7.71e-07	0.00021	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8765367	chr8:9141424~9145435:+
HNSC	cis	rs3733585	0.781	rs57250714	ENSG00000250413.1	RP11-448G15.1	-5.01	7.71e-07	0.00021	-0.28	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9982905	chr4:10006482~10009725:+
HNSC	cis	rs2145598	1	rs10137475	ENSG00000279636.2	LINC00216	-5.01	7.72e-07	0.00021	-0.24	-0.23	Coronary artery disease;	chr14:58331235	chr14:58288033~58289158:+
HNSC	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-5.01	7.72e-07	0.00021	-0.29	-0.23	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-5.01	7.72e-07	0.00021	-0.29	-0.23	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-5.01	7.72e-07	0.00021	-0.29	-0.23	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-5.01	7.72e-07	0.00021	-0.29	-0.23	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
HNSC	cis	rs3733585	0.673	rs4467563	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9951836	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4467564	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9951848	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4292332	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952206	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4292333	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952247	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4447861	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952316	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4459990	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952381	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4495037	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952426	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4627861	ENSG00000250413.1	RP11-448G15.1	5.01	7.73e-07	0.00021	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9952614	chr4:10006482~10009725:+
HNSC	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-5.01	7.73e-07	0.00021	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
HNSC	cis	rs911555	0.504	rs4906340	ENSG00000270108.1	RP11-73M18.6	-5.01	7.73e-07	0.00021	-0.26	-0.23	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103687576~103688127:+
HNSC	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-5.01	7.73e-07	0.00021	-0.32	-0.23	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
HNSC	cis	rs11083475	0.599	rs7250443	ENSG00000269486.2	CTC-360G5.9	5.01	7.74e-07	0.00021	0.25	0.23	Heart rate;	chr19:38776705	chr19:38935297~38938632:-
HNSC	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-5.01	7.74e-07	0.00021	-0.22	-0.23	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
HNSC	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	5.01	7.74e-07	0.00021	0.23	0.23	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
HNSC	cis	rs6693567	0.507	rs4970964	ENSG00000228126.1	FALEC	5.01	7.74e-07	0.00021	0.27	0.23	Migraine;	chr1:150485553	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs4970922	ENSG00000228126.1	FALEC	5.01	7.74e-07	0.00021	0.27	0.23	Migraine;	chr1:150485618	chr1:150515757~150518032:+
HNSC	cis	rs13217239	0.646	rs6937880	ENSG00000224843.5	LINC00240	-5.01	7.74e-07	0.00021	-0.22	-0.23	Schizophrenia;	chr6:27032457	chr6:26956992~27023924:+
HNSC	cis	rs5758659	0.714	rs6002626	ENSG00000227370.1	RP4-669P10.19	5.01	7.75e-07	0.00021	0.23	0.23	Cognitive function;	chr22:42121985	chr22:42132543~42132998:+
HNSC	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-5.01	7.75e-07	0.00021	-0.25	-0.23	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
HNSC	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-5.01	7.75e-07	0.000211	-0.28	-0.23	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-5.01	7.75e-07	0.000211	-0.28	-0.23	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
HNSC	cis	rs9907295	0.818	rs4251737	ENSG00000270977.1	AC015849.16	-5.01	7.75e-07	0.000211	-0.3	-0.23	Fibroblast growth factor basic levels;	chr17:35819814	chr17:35893707~35911023:-
HNSC	cis	rs10504130	0.696	rs17284746	ENSG00000253844.1	RP11-546K22.1	-5.01	7.75e-07	0.000211	-0.34	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51961458~52022974:+
HNSC	cis	rs2179367	0.613	rs12207047	ENSG00000216906.2	RP11-350J20.9	5.01	7.75e-07	0.000211	0.32	0.23	Dupuytren's disease;	chr6:149423496	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.613	rs12207261	ENSG00000216906.2	RP11-350J20.9	5.01	7.75e-07	0.000211	0.32	0.23	Dupuytren's disease;	chr6:149423722	chr6:149904243~149906418:+
HNSC	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	5.01	7.76e-07	0.000211	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
HNSC	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-5.01	7.76e-07	0.000211	-0.28	-0.23	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
HNSC	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	5.01	7.76e-07	0.000211	0.24	0.23	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000204709.4	LINC01556	-5.01	7.76e-07	0.000211	-0.3	-0.23	Depression;	chr6:28086929	chr6:28943877~28944537:+
HNSC	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-5.01	7.76e-07	0.000211	-0.22	-0.23	Height;	chr5:36817237	chr5:36666214~36725195:-
HNSC	cis	rs10462794	0.661	rs12517115	ENSG00000260763.1	RP11-445O3.3	-5.01	7.77e-07	0.000211	-0.32	-0.23	DNA methylation (variation);	chr5:4520107	chr5:4436850~4440259:-
HNSC	cis	rs950169	0.922	rs11638445	ENSG00000229212.6	RP11-561C5.4	-5.01	7.77e-07	0.000211	-0.32	-0.23	Schizophrenia;	chr15:84594463	chr15:85205440~85234795:-
HNSC	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	5.01	7.78e-07	0.000211	0.33	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
HNSC	cis	rs13217239	0.621	rs12527231	ENSG00000224843.5	LINC00240	-5.01	7.78e-07	0.000211	-0.22	-0.23	Schizophrenia;	chr6:27033509	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs12523820	ENSG00000224843.5	LINC00240	-5.01	7.78e-07	0.000211	-0.22	-0.23	Schizophrenia;	chr6:27033723	chr6:26956992~27023924:+
HNSC	cis	rs1125355	0.69	rs62183016	ENSG00000204380.3	AC005042.4	5.01	7.78e-07	0.000211	0.26	0.23	Alzheimer's disease in APOE e4+ carriers;	chr2:158764018	chr2:158658337~158735002:-
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-5.01	7.78e-07	0.000211	-0.27	-0.23	Depression;	chr6:28096845	chr6:28170845~28172521:+
HNSC	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-5.01	7.79e-07	0.000211	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
HNSC	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	5.01	7.79e-07	0.000211	0.28	0.23	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
HNSC	cis	rs7085104	0.684	rs7092690	ENSG00000236937.2	PTGES3P4	5.01	7.79e-07	0.000212	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102845595~102845950:+
HNSC	cis	rs1665050	0.598	rs8041221	ENSG00000277144.1	RP11-59H7.4	-5.01	7.8e-07	0.000212	-0.27	-0.23	Atopic dermatitis;	chr15:59042609	chr15:59115547~59116089:-
HNSC	cis	rs1150668	0.699	rs1531681	ENSG00000219392.1	RP1-265C24.5	-5.01	7.8e-07	0.000212	-0.24	-0.23	Pubertal anthropometrics;	chr6:28259100	chr6:28115628~28116551:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	5.01	7.8e-07	0.000212	0.18	0.23	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
HNSC	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-5.01	7.8e-07	0.000212	-0.22	-0.23	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
HNSC	cis	rs4699052	0.927	rs1870888	ENSG00000246560.2	RP11-10L12.4	5.01	7.8e-07	0.000212	0.26	0.23	Testicular germ cell tumor;	chr4:103248169	chr4:102828055~102844075:+
HNSC	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	5.01	7.8e-07	0.000212	0.27	0.23	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
HNSC	cis	rs4388249	0.659	rs10065099	ENSG00000271849.1	CTC-332L22.1	-5.01	7.8e-07	0.000212	-0.31	-0.23	Schizophrenia;	chr5:109841677	chr5:109687802~109688329:-
HNSC	cis	rs45509595	0.556	rs34409918	ENSG00000219392.1	RP1-265C24.5	-5.01	7.81e-07	0.000212	-0.44	-0.23	Breast cancer;	chr6:27717569	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs13212318	ENSG00000219392.1	RP1-265C24.5	-5.01	7.81e-07	0.000212	-0.44	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28115628~28116551:+
HNSC	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.01	7.81e-07	0.000212	0.2	0.23	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
HNSC	cis	rs13113518	0.812	rs12500601	ENSG00000273257.1	RP11-177J6.1	5.01	7.81e-07	0.000212	0.28	0.23	Height;	chr4:55451489	chr4:55387949~55388271:+
HNSC	cis	rs36423	0.748	rs36375	ENSG00000266869.1	RP6-114E22.1	-5.01	7.82e-07	0.000212	-0.38	-0.23	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71907229	chr14:71848606~71908430:+
HNSC	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	5.01	7.82e-07	0.000212	0.23	0.23	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
HNSC	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	5.01	7.82e-07	0.000212	0.54	0.23	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
HNSC	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-5.01	7.82e-07	0.000212	-0.23	-0.23	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
HNSC	cis	rs73198271	0.74	rs11781430	ENSG00000173295.6	FAM86B3P	-5.01	7.83e-07	0.000212	-0.29	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8228595~8244865:+
HNSC	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	5.01	7.83e-07	0.000213	0.27	0.23	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
HNSC	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	5.01	7.83e-07	0.000213	0.27	0.23	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
HNSC	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-5.01	7.83e-07	0.000213	-0.28	-0.23	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
HNSC	cis	rs6964587	1	rs6970277	ENSG00000188693.7	CYP51A1-AS1	-5.01	7.83e-07	0.000213	-0.24	-0.23	Breast cancer;	chr7:92051341	chr7:92134604~92180725:+
HNSC	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	5.01	7.84e-07	0.000213	0.27	0.23	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.65	rs670523	ENSG00000203761.5	MSTO2P	5.01	7.84e-07	0.000213	0.17	0.23	Body mass index;	chr1:155908941	chr1:155745829~155750137:+
HNSC	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	5.01	7.84e-07	0.000213	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000253981.4	ALG1L13P	5.01	7.85e-07	0.000213	0.25	0.23	Mood instability;	chr8:8279561	chr8:8236003~8244667:-
HNSC	cis	rs8040855	0.579	rs28521166	ENSG00000259774.1	RP11-182J1.13	-5.01	7.86e-07	0.000213	-0.27	-0.23	Bulimia nervosa;	chr15:85184801	chr15:84422618~84425882:+
HNSC	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-5.01	7.86e-07	0.000213	-0.26	-0.23	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
HNSC	cis	rs577676	0.564	rs619699	ENSG00000271811.1	RP1-79C4.4	5.01	7.86e-07	0.000213	0.26	0.23	Prevalent atrial fibrillation;	chr1:170648238	chr1:170667381~170669425:+
HNSC	cis	rs694739	0.726	rs17857342	ENSG00000236935.1	AP003774.1	5.01	7.87e-07	0.000213	0.23	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371433	chr11:64325050~64329504:-
HNSC	cis	rs950027	0.516	rs12916762	ENSG00000259520.4	CTD-2651B20.3	-5.01	7.87e-07	0.000213	-0.26	-0.23	Response to fenofibrate (adiponectin levels);	chr15:45656104	chr15:45251580~45279251:-
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000253981.4	ALG1L13P	5.01	7.87e-07	0.000213	0.25	0.23	Neuroticism;	chr8:8241055	chr8:8236003~8244667:-
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	5.01	7.87e-07	0.000213	0.28	0.23	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
HNSC	cis	rs4388249	0.687	rs2301016	ENSG00000271849.1	CTC-332L22.1	-5.01	7.87e-07	0.000213	-0.31	-0.23	Schizophrenia;	chr5:109807901	chr5:109687802~109688329:-
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000254153.1	CTA-398F10.2	-5.01	7.88e-07	0.000214	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9226831	chr8:8456909~8461337:-
HNSC	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-5.01	7.88e-07	0.000214	-0.22	-0.23	Height;	chr5:36796728	chr5:36666214~36725195:-
HNSC	cis	rs36093844	0.752	rs17817254	ENSG00000279742.1	RP11-700A24.1	-5.01	7.88e-07	0.000214	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853783	chr11:85852557~85854943:-
HNSC	cis	rs287982	0.611	rs78100109	ENSG00000269973.1	RP11-95D17.1	-5.01	7.88e-07	0.000214	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9838280	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs78401890	ENSG00000269973.1	RP11-95D17.1	-5.01	7.88e-07	0.000214	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9838332	chr2:9936360~9939590:+
HNSC	cis	rs287982	0.611	rs75277217	ENSG00000269973.1	RP11-95D17.1	-5.01	7.88e-07	0.000214	-0.31	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9839275	chr2:9936360~9939590:+
HNSC	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	5.01	7.88e-07	0.000214	0.26	0.23	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-5.01	7.89e-07	0.000214	-0.27	-0.23	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
HNSC	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-5.01	7.89e-07	0.000214	-0.25	-0.23	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
HNSC	cis	rs9402743	0.671	rs9373137	ENSG00000234084.1	RP3-388E23.2	-5.01	7.89e-07	0.000214	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135629059	chr6:135301568~135307158:+
HNSC	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-5.01	7.89e-07	0.000214	-0.21	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
HNSC	cis	rs9329221	0.772	rs7824675	ENSG00000269918.1	AF131215.9	-5.01	7.89e-07	0.000214	-0.22	-0.23	Neuroticism;	chr8:10385908	chr8:11104691~11106704:-
HNSC	cis	rs4938303	0.633	rs524467	ENSG00000254851.1	RP11-109L13.1	5.01	7.89e-07	0.000214	0.39	0.23	Triglycerides;	chr11:116658924	chr11:117135528~117138582:+
HNSC	cis	rs6693567	0.507	rs863862	ENSG00000228126.1	FALEC	5.01	7.91e-07	0.000214	0.27	0.23	Migraine;	chr1:150379885	chr1:150515757~150518032:+
HNSC	cis	rs11846409	0.86	rs59055020	ENSG00000211974.3	IGHV2-70	-5.01	7.91e-07	0.000214	-0.25	-0.23	Rheumatic heart disease;	chr14:106631573	chr14:106723574~106724093:-
HNSC	cis	rs6693567	0.565	rs1313569	ENSG00000228126.1	FALEC	5.01	7.91e-07	0.000214	0.27	0.23	Migraine;	chr1:150371695	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs1313568	ENSG00000228126.1	FALEC	5.01	7.91e-07	0.000214	0.27	0.23	Migraine;	chr1:150371704	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs1260457	ENSG00000228126.1	FALEC	5.01	7.91e-07	0.000214	0.27	0.23	Migraine;	chr1:150374898	chr1:150515757~150518032:+
HNSC	cis	rs638893	0.617	rs4938565	ENSG00000255422.1	AP002954.4	5.01	7.92e-07	0.000215	0.32	0.23	Vitiligo;	chr11:118850289	chr11:118704607~118750263:+
HNSC	cis	rs17428076	0.83	rs62183852	ENSG00000228389.1	AC068039.4	-5.01	7.92e-07	0.000215	-0.28	-0.23	Myopia;	chr2:172061483	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.673	rs6737876	ENSG00000228389.1	AC068039.4	-5.01	7.92e-07	0.000215	-0.28	-0.23	Myopia;	chr2:172061948	chr2:171773482~171775844:+
HNSC	cis	rs10129255	0.536	rs17113249	ENSG00000224373.3	IGHV4-59	5.01	7.92e-07	0.000215	0.13	0.23	Kawasaki disease;	chr14:106678273	chr14:106627249~106627825:-
HNSC	cis	rs753274	0.65	rs28497965	ENSG00000267147.2	CTC-548K16.1	-5	7.93e-07	0.000215	-0.28	-0.23	Tumor necrosis factor beta levels;	chr19:14306590	chr19:14333743~14343916:+
HNSC	cis	rs1150668	0.699	rs2394049	ENSG00000219392.1	RP1-265C24.5	-5	7.93e-07	0.000215	-0.25	-0.23	Pubertal anthropometrics;	chr6:28271903	chr6:28115628~28116551:+
HNSC	cis	rs467650	0.517	rs469491	ENSG00000246763.5	RGMB-AS1	5	7.93e-07	0.000215	0.26	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98599799	chr5:98769618~98773469:-
HNSC	cis	rs9650657	0.617	rs28680211	ENSG00000269918.1	AF131215.9	-5	7.94e-07	0.000215	-0.22	-0.23	Neuroticism;	chr8:10661935	chr8:11104691~11106704:-
HNSC	cis	rs7246657	0.525	rs10401417	ENSG00000276846.1	CTD-3220F14.3	5	7.94e-07	0.000215	0.33	0.23	Coronary artery calcification;	chr19:36976638	chr19:37314868~37315620:-
HNSC	cis	rs728616	0.614	rs59169164	ENSG00000225484.5	NUTM2B-AS1	-5	7.94e-07	0.000215	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:79663088~79826594:-
HNSC	cis	rs4657482	0.962	rs6703209	ENSG00000236364.3	RP11-525G13.2	5	7.95e-07	0.000215	0.22	0.23	Testicular germ cell tumor;	chr1:165870907	chr1:165890795~165900683:-
HNSC	cis	rs11121022	0.601	rs707455	ENSG00000269925.1	RP3-467L1.6	5	7.95e-07	0.000215	0.26	0.23	Morning vs. evening chronotype;	chr1:7765251	chr1:7776383~7776775:+
HNSC	cis	rs1971762	0.563	rs10747678	ENSG00000270175.1	RP11-793H13.11	5	7.96e-07	0.000216	0.19	0.23	Height;	chr12:53683903	chr12:53500162~53500936:-
HNSC	cis	rs2033711	0.905	rs893186	ENSG00000269473.1	CTD-2619J13.19	5	7.96e-07	0.000216	0.28	0.23	Uric acid clearance;	chr19:58457812	chr19:58440448~58445849:+
HNSC	cis	rs11089937	0.523	rs4821832	ENSG00000211639.2	IGLV4-60	5	7.96e-07	0.000216	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22188499	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	5	7.96e-07	0.000216	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
HNSC	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	5	7.96e-07	0.000216	0.28	0.23	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000254174.1	IGHV1-12	5	7.96e-07	0.000216	0.2	0.23	Alzheimer's disease (late onset);	chr14:106686309	chr14:106122420~106122709:-
HNSC	cis	rs7746199	0.736	rs17749927	ENSG00000219392.1	RP1-265C24.5	-5	7.96e-07	0.000216	-0.44	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs13192965	ENSG00000219392.1	RP1-265C24.5	-5	7.96e-07	0.000216	-0.44	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28115628~28116551:+
HNSC	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-5	7.97e-07	0.000216	-0.27	-0.23	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
HNSC	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	5	7.97e-07	0.000216	0.24	0.23	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
HNSC	cis	rs13126694	0.778	rs4691454	ENSG00000248429.4	RP11-597D13.9	5	7.97e-07	0.000216	0.25	0.23	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158170752~158202877:+
HNSC	cis	rs4141404	0.74	rs4820946	ENSG00000236132.1	CTA-440B3.1	-5	7.97e-07	0.000216	-0.27	-0.23	Paclitaxel-induced neuropathy;	chr22:31155174	chr22:31816379~31817491:-
HNSC	cis	rs73198271	0.71	rs11779565	ENSG00000253893.2	FAM85B	5	7.97e-07	0.000216	0.3	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8167819~8226614:-
HNSC	cis	rs36093844	0.8	rs11826218	ENSG00000279742.1	RP11-700A24.1	-5	7.97e-07	0.000216	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85857479	chr11:85852557~85854943:-
HNSC	cis	rs36052053	0.908	rs13199388	ENSG00000219700.1	PTCHD3P3	5	7.98e-07	0.000216	0.36	0.23	Red cell distribution width;	chr6:109262897	chr6:109288571~109290503:-
HNSC	cis	rs61160187	0.75	rs1807017	ENSG00000215032.2	GNL3LP1	5	7.98e-07	0.000216	0.26	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60891935~60893577:-
HNSC	cis	rs3733585	0.699	rs7663079	ENSG00000250413.1	RP11-448G15.1	5	7.98e-07	0.000216	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9965147	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs7657340	ENSG00000250413.1	RP11-448G15.1	5	7.98e-07	0.000216	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9965148	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs7663097	ENSG00000250413.1	RP11-448G15.1	5	7.98e-07	0.000216	0.28	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9965167	chr4:10006482~10009725:+
HNSC	cis	rs4218	0.543	rs4775110	ENSG00000277144.1	RP11-59H7.4	-5	7.99e-07	0.000216	-0.28	-0.23	Social communication problems;	chr15:59023685	chr15:59115547~59116089:-
HNSC	cis	rs73198271	0.641	rs34473848	ENSG00000173295.6	FAM86B3P	-5	7.99e-07	0.000217	-0.29	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.601	rs11997731	ENSG00000173295.6	FAM86B3P	-5	7.99e-07	0.000217	-0.29	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8228595~8244865:+
HNSC	cis	rs2337406	1	rs11850600	ENSG00000254174.1	IGHV1-12	5	8e-07	0.000217	0.2	0.23	Alzheimer's disease (late onset);	chr14:106670765	chr14:106122420~106122709:-
HNSC	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	5	8e-07	0.000217	0.31	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.681	rs11987924	ENSG00000253893.2	FAM85B	5	8e-07	0.000217	0.31	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8167819~8226614:-
HNSC	cis	rs5758511	0.689	rs17478227	ENSG00000226450.2	CYP2D8P	-5	8e-07	0.000217	-0.25	-0.23	Birth weight;	chr22:42258321	chr22:42149886~42155001:-
HNSC	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-5	8e-07	0.000217	-0.18	-0.23	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
HNSC	cis	rs9329221	0.905	rs4841329	ENSG00000255310.2	AF131215.2	-5	8.01e-07	0.000217	-0.22	-0.23	Neuroticism;	chr8:10395588	chr8:11107788~11109726:-
HNSC	cis	rs10462794	0.661	rs62343553	ENSG00000260763.1	RP11-445O3.3	-5	8.01e-07	0.000217	-0.32	-0.23	DNA methylation (variation);	chr5:4518337	chr5:4436850~4440259:-
HNSC	cis	rs17772222	0.597	rs17700521	ENSG00000258789.1	RP11-507K2.3	-5	8.01e-07	0.000217	-0.27	-0.23	Coronary artery calcification;	chr14:88849531	chr14:88551597~88552493:+
HNSC	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-5	8.01e-07	0.000217	-0.22	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	5	8.01e-07	0.000217	0.27	0.23	Depression;	chr6:28205232	chr6:28161781~28169594:+
HNSC	cis	rs2145598	1	rs2145598	ENSG00000279636.2	LINC00216	-5	8.01e-07	0.000217	-0.24	-0.23	Coronary artery disease;	chr14:58327283	chr14:58288033~58289158:+
HNSC	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	5	8.02e-07	0.000217	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
HNSC	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-5	8.03e-07	0.000217	-0.26	-0.23	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
HNSC	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	5	8.03e-07	0.000217	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	5	8.03e-07	0.000217	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
HNSC	cis	rs4664293	0.647	rs7587700	ENSG00000226266.5	AC009961.3	-5	8.03e-07	0.000217	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159587809	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.609	rs10209829	ENSG00000226266.5	AC009961.3	-5	8.03e-07	0.000217	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159591113	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs6432539	ENSG00000226266.5	AC009961.3	-5	8.03e-07	0.000217	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159592209	chr2:159670708~159712435:-
HNSC	cis	rs8040855	0.599	rs2342123	ENSG00000259774.1	RP11-182J1.13	5	8.04e-07	0.000217	0.26	0.23	Bulimia nervosa;	chr15:85181918	chr15:84422618~84425882:+
HNSC	cis	rs9450351	0.744	rs6919244	ENSG00000203875.9	SNHG5	-5	8.05e-07	0.000218	-0.5	-0.23	Interferon gamma-induced protein 10 levels;	chr6:86045035	chr6:85660950~85678736:-
HNSC	cis	rs75422866	0.867	rs73104148	ENSG00000276691.1	RP5-1057I20.5	5	8.05e-07	0.000218	0.42	0.23	Pneumonia;	chr12:47696732	chr12:47788426~47788971:+
HNSC	cis	rs9548119	0.696	rs9566273	ENSG00000223685.4	LINC00571	-5	8.05e-07	0.000218	-0.4	-0.23	Self-rated health;	chr13:37906741	chr13:38050817~38143232:-
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-5	8.05e-07	0.000218	-0.27	-0.23	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
HNSC	cis	rs4295623	0.531	rs2898295	ENSG00000269918.1	AF131215.9	-5	8.05e-07	0.000218	-0.22	-0.23	Morning vs. evening chronotype;	chr8:11738460	chr8:11104691~11106704:-
HNSC	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	5	8.05e-07	0.000218	0.43	0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
HNSC	cis	rs2998286	0.784	rs998362	ENSG00000254635.4	WAC-AS1	-5	8.06e-07	0.000218	-0.29	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528129	chr10:28522652~28532743:-
HNSC	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-5	8.06e-07	0.000218	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-5	8.06e-07	0.000218	-0.35	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
HNSC	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	5	8.06e-07	0.000218	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs10890358	ENSG00000234329.1	RP11-767N6.2	5	8.06e-07	0.000218	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45651039~45651826:-
HNSC	cis	rs4218	0.681	rs1867757	ENSG00000277144.1	RP11-59H7.4	-5	8.07e-07	0.000218	-0.28	-0.23	Social communication problems;	chr15:59072315	chr15:59115547~59116089:-
HNSC	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-5	8.07e-07	0.000218	-0.22	-0.23	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000253981.4	ALG1L13P	-5	8.07e-07	0.000218	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9044914	chr8:8236003~8244667:-
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000173295.6	FAM86B3P	-5	8.07e-07	0.000218	-0.25	-0.23	Joint mobility (Beighton score);	chr8:8936097	chr8:8228595~8244865:+
HNSC	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-5	8.07e-07	0.000218	-0.28	-0.23	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
HNSC	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	5	8.07e-07	0.000218	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
HNSC	cis	rs11992162	1	rs11784499	ENSG00000206014.6	OR7E161P	-5	8.08e-07	0.000218	-0.25	-0.23	Monocyte count;	chr8:11977030	chr8:11928597~11929563:-
HNSC	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-5	8.08e-07	0.000218	-0.2	-0.23	Breast cancer;	chr11:825777	chr11:781645~782105:+
HNSC	cis	rs7615952	0.599	rs6766327	ENSG00000248787.1	RP11-666A20.4	-5	8.08e-07	0.000219	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126004834	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs12491577	ENSG00000248787.1	RP11-666A20.4	-5	8.08e-07	0.000219	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126012288	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs1875683	ENSG00000248787.1	RP11-666A20.4	-5	8.08e-07	0.000219	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126013638	chr3:125908005~125910272:-
HNSC	cis	rs1404100	0.51	rs2341683	ENSG00000249274.1	PDLIM1P4	5	8.08e-07	0.000219	0.27	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99069807	chr3:98782188~98783193:+
HNSC	cis	rs7809950	0.817	rs2237678	ENSG00000238832.1	snoU109	-5	8.08e-07	0.000219	-0.33	-0.23	Coronary artery disease;	chr7:107562820	chr7:107603363~107603507:+
HNSC	cis	rs6693567	0.565	rs1776275	ENSG00000228126.1	FALEC	-5	8.09e-07	0.000219	-0.27	-0.23	Migraine;	chr1:150297014	chr1:150515757~150518032:+
HNSC	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	5	8.09e-07	0.000219	0.5	0.23	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
HNSC	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-5	8.09e-07	0.000219	-0.24	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
HNSC	cis	rs13217239	0.572	rs9379958	ENSG00000224843.5	LINC00240	5	8.09e-07	0.000219	0.22	0.23	Schizophrenia;	chr6:27098384	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs9393789	ENSG00000224843.5	LINC00240	5	8.09e-07	0.000219	0.22	0.23	Schizophrenia;	chr6:27099249	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs6456767	ENSG00000224843.5	LINC00240	5	8.09e-07	0.000219	0.22	0.23	Schizophrenia;	chr6:27102764	chr6:26956992~27023924:+
HNSC	cis	rs7809950	0.817	rs62483725	ENSG00000238832.1	snoU109	-5	8.1e-07	0.000219	-0.32	-0.23	Coronary artery disease;	chr7:107561130	chr7:107603363~107603507:+
HNSC	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	5	8.11e-07	0.000219	0.26	0.23	Height;	chr2:46632940	chr2:46668870~46670778:+
HNSC	cis	rs4664293	0.647	rs7576644	ENSG00000226266.5	AC009961.3	-5	8.11e-07	0.000219	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159584947	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs1425042	ENSG00000226266.5	AC009961.3	-5	8.11e-07	0.000219	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159584004	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs7562850	ENSG00000226266.5	AC009961.3	-5	8.11e-07	0.000219	-0.23	-0.23	Monocyte percentage of white cells;	chr2:159585023	chr2:159670708~159712435:-
HNSC	cis	rs9402743	0.702	rs9399150	ENSG00000234084.1	RP3-388E23.2	-5	8.11e-07	0.000219	-0.23	-0.23	Systemic lupus erythematosus;	chr6:135599752	chr6:135301568~135307158:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	5	8.12e-07	0.000219	0.28	0.23	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
HNSC	cis	rs6928977	0.86	rs2746426	ENSG00000231028.7	LINC00271	5	8.12e-07	0.000219	0.26	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135345294	chr6:135497801~135716055:+
HNSC	cis	rs9329221	0.87	rs11777976	ENSG00000255310.2	AF131215.2	-5	8.12e-07	0.000219	-0.22	-0.23	Neuroticism;	chr8:10397892	chr8:11107788~11109726:-
HNSC	cis	rs603446	1	rs1145208	ENSG00000254851.1	RP11-109L13.1	-5	8.12e-07	0.000219	-0.3	-0.23	Triglycerides;	chr11:116767269	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	5	8.12e-07	0.000219	0.29	0.23	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
HNSC	cis	rs6674176	0.66	rs2108202	ENSG00000237950.1	RP11-7O11.3	-5	8.12e-07	0.000219	-0.26	-0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930114	chr1:43944370~43946551:-
HNSC	cis	rs6479901	0.696	rs931972	ENSG00000232075.1	MRPL35P2	-5	8.13e-07	0.00022	-0.3	-0.23	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63634317~63634827:-
HNSC	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-5	8.13e-07	0.00022	-0.28	-0.23	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
HNSC	cis	rs9650657	0.513	rs4841459	ENSG00000269918.1	AF131215.9	-5	8.13e-07	0.00022	-0.22	-0.23	Neuroticism;	chr8:10924932	chr8:11104691~11106704:-
HNSC	cis	rs9300255	0.739	rs6633	ENSG00000280120.1	RP11-546D6.3	-5	8.15e-07	0.00022	-0.22	-0.23	Neutrophil percentage of white cells;	chr12:123261262	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.651	rs2330015	ENSG00000211639.2	IGLV4-60	-5	8.16e-07	0.00022	-0.21	-0.23	Periodontitis (PAL4Q3);	chr22:22182566	chr22:22162199~22162681:+
HNSC	cis	rs2762353	0.526	rs6901027	ENSG00000272462.2	U91328.19	5	8.16e-07	0.00022	0.22	0.23	Blood metabolite levels;	chr6:25708814	chr6:25992662~26001775:+
HNSC	cis	rs9840812	0.861	rs684773	ENSG00000273486.1	RP11-731C17.2	5	8.16e-07	0.00022	0.2	0.23	Fibrinogen levels;	chr3:136237463	chr3:136837338~136839021:-
HNSC	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	5	8.17e-07	0.000221	0.24	0.23	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
HNSC	cis	rs7615952	0.512	rs4679430	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125639049	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs34651730	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125639796	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs2979334	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125639980	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs11929125	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125640599	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs11921452	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125640906	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs2922175	ENSG00000248787.1	RP11-666A20.4	-5	8.18e-07	0.000221	-0.29	-0.23	Blood pressure (smoking interaction);	chr3:125642516	chr3:125908005~125910272:-
HNSC	cis	rs1799949	0.965	rs8067269	ENSG00000236383.6	LINC00854	-5	8.18e-07	0.000221	-0.21	-0.23	Menopause (age at onset);	chr17:43083782	chr17:43216941~43305976:-
HNSC	cis	rs12701220	0.842	rs10236293	ENSG00000229043.2	AC091729.9	-5	8.18e-07	0.000221	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:993001	chr7:1160374~1165267:+
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-5	8.18e-07	0.000221	-0.28	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000254174.1	IGHV1-12	5	8.19e-07	0.000221	0.19	0.23	Alzheimer's disease (late onset);	chr14:106780983	chr14:106122420~106122709:-
HNSC	cis	rs4763879	0.865	rs4763839	ENSG00000256673.1	RP11-599J14.2	5	8.19e-07	0.000221	0.22	0.23	Type 1 diabetes;	chr12:9730104	chr12:9398355~9414851:-
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28082231	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28082261	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28082984	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28083994	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28084025	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-5	8.2e-07	0.000221	-0.26	-0.23	Depression;	chr6:28085319	chr6:28170845~28172521:+
HNSC	cis	rs1218582	0.71	rs4845687	ENSG00000270361.1	RP11-307C12.13	-5	8.2e-07	0.000221	-0.24	-0.23	Prostate cancer;	chr1:154906435	chr1:154937370~154938059:+
HNSC	cis	rs11976180	1	rs1320894	ENSG00000273234.1	OR2A13P	-5	8.2e-07	0.000221	-0.25	-0.23	Obesity-related traits;	chr7:144054709	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2951369	ENSG00000273234.1	OR2A13P	-5	8.2e-07	0.000221	-0.25	-0.23	Obesity-related traits;	chr7:144055545	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2951364	ENSG00000273234.1	OR2A13P	-5	8.2e-07	0.000221	-0.25	-0.23	Obesity-related traits;	chr7:144057390	chr7:144142009~144142938:+
HNSC	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	5	8.21e-07	0.000221	0.2	0.23	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
HNSC	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-5	8.21e-07	0.000222	-0.23	-0.23	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
HNSC	cis	rs4927850	1	rs7614767	ENSG00000226155.1	AC124944.3	-5	8.22e-07	0.000222	-0.26	-0.23	Pancreatic cancer;	chr3:196026580	chr3:195912049~195913986:+
HNSC	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-5	8.22e-07	0.000222	-0.29	-0.23	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
HNSC	cis	rs1799949	0.965	rs11080034	ENSG00000236383.6	LINC00854	-5	8.22e-07	0.000222	-0.21	-0.23	Menopause (age at onset);	chr17:43365646	chr17:43216941~43305976:-
HNSC	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-5	8.22e-07	0.000222	-0.32	-0.23	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
HNSC	cis	rs2235642	0.582	rs11643891	ENSG00000280231.1	LA16c-380F5.3	-5	8.23e-07	0.000222	-0.3	-0.23	Coronary artery disease;	chr16:1515539	chr16:1553655~1554130:-
HNSC	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	5	8.23e-07	0.000222	0.34	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
HNSC	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-5	8.23e-07	0.000222	-0.22	-0.23	Height;	chr5:37081780	chr5:36666214~36725195:-
HNSC	cis	rs170183	0.934	rs35734452	ENSG00000233818.1	AP000695.4	-5	8.23e-07	0.000222	-0.24	-0.23	Bone mineral density;	chr21:36483703	chr21:36445731~36532408:+
HNSC	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-5	8.23e-07	0.000222	-0.24	-0.23	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
HNSC	cis	rs13126694	0.744	rs7656059	ENSG00000248429.4	RP11-597D13.9	5	8.23e-07	0.000222	0.26	0.23	Blood osmolality (transformed sodium);	chr4:158080386	chr4:158170752~158202877:+
HNSC	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	5	8.23e-07	0.000222	0.23	0.23	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
HNSC	cis	rs9487051	0.646	rs351736	ENSG00000243587.6	C6orf183	5	8.24e-07	0.000222	0.24	0.23	Reticulocyte fraction of red cells;	chr6:109184691	chr6:109165833~109271014:+
HNSC	cis	rs6951245	0.572	rs79489623	ENSG00000225146.1	AC073957.15	-5	8.25e-07	0.000222	-0.47	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005996	chr7:1029025~1043891:+
HNSC	cis	rs2911132	0.506	rs7705827	ENSG00000248734.2	CTD-2260A17.1	5	8.26e-07	0.000223	0.24	0.23	Urate levels (BMI interaction);	chr5:96746729	chr5:96784777~96785999:+
HNSC	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-5	8.26e-07	0.000223	-0.29	-0.23	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
HNSC	cis	rs11976180	1	rs1320893	ENSG00000273234.1	OR2A13P	-5	8.27e-07	0.000223	-0.25	-0.23	Obesity-related traits;	chr7:144055019	chr7:144142009~144142938:+
HNSC	cis	rs9929218	0.559	rs55907909	ENSG00000260459.2	FTLP14	5	8.27e-07	0.000223	0.29	0.23	Colorectal cancer;	chr16:68771902	chr16:68822587~68823070:+
HNSC	cis	rs933688	1	rs10073935	ENSG00000281357.1	ARRDC3-AS1	5	8.28e-07	0.000223	0.33	0.23	Smoking behavior;	chr5:91446371	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs10059163	ENSG00000281357.1	ARRDC3-AS1	5	8.28e-07	0.000223	0.33	0.23	Smoking behavior;	chr5:91446627	chr5:91380349~91439085:+
HNSC	cis	rs3015497	0.549	rs10133807	ENSG00000269906.1	RP11-248J18.2	-5	8.28e-07	0.000223	-0.3	-0.23	Mean platelet volume;	chr14:50684804	chr14:50662511~50663178:-
HNSC	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-5	8.29e-07	0.000223	-0.25	-0.23	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
HNSC	cis	rs4718428	1	rs1830070	ENSG00000273142.1	RP11-458F8.4	-5	8.29e-07	0.000223	-0.2	-0.23	Corneal structure;	chr7:66884684	chr7:66902857~66906297:+
HNSC	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	5	8.29e-07	0.000223	0.2	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
HNSC	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5	8.29e-07	0.000224	0.2	0.23	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
HNSC	cis	rs72949976	0.564	rs4673730	ENSG00000270659.1	RP11-105N14.1	-5	8.3e-07	0.000224	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213160112	chr2:213152970~213153659:+
HNSC	cis	rs72949976	0.584	rs13001511	ENSG00000270659.1	RP11-105N14.1	-5	8.3e-07	0.000224	-0.22	-0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213160538	chr2:213152970~213153659:+
HNSC	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	5	8.3e-07	0.000224	0.28	0.23	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
HNSC	cis	rs75422866	0.867	rs73104138	ENSG00000276691.1	RP5-1057I20.5	5	8.3e-07	0.000224	0.42	0.23	Pneumonia;	chr12:47692302	chr12:47788426~47788971:+
HNSC	cis	rs7615952	0.576	rs2276729	ENSG00000248787.1	RP11-666A20.4	-5	8.3e-07	0.000224	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126107371	chr3:125908005~125910272:-
HNSC	cis	rs12291225	0.546	rs12291662	ENSG00000251991.1	RNU7-49P	5	8.3e-07	0.000224	0.25	0.23	Sense of smell;	chr11:14321403	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.545	rs11023187	ENSG00000251991.1	RNU7-49P	5	8.3e-07	0.000224	0.25	0.23	Sense of smell;	chr11:14324013	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.546	rs12795545	ENSG00000251991.1	RNU7-49P	5	8.3e-07	0.000224	0.25	0.23	Sense of smell;	chr11:14334018	chr11:14478892~14478953:+
HNSC	cis	rs1862618	0.853	rs1833896	ENSG00000271828.1	CTD-2310F14.1	5	8.31e-07	0.000224	0.3	0.23	Initial pursuit acceleration;	chr5:56801842	chr5:56927874~56929573:+
HNSC	cis	rs3806843	0.801	rs801170	ENSG00000202515.1	VTRNA1-3	5	8.31e-07	0.000224	0.25	0.23	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr5:140726158~140726246:+
HNSC	cis	rs9921338	0.961	rs7191093	ENSG00000263080.1	RP11-485G7.5	5	8.31e-07	0.000224	0.25	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11341809~11345211:-
HNSC	cis	rs4968361	0.892	rs58003080	ENSG00000266992.1	DHX40P1	5	8.32e-07	0.000224	0.41	0.23	Schizophrenia;	chr17:59437596	chr17:59976009~60002384:-
HNSC	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	5	8.32e-07	0.000224	0.23	0.23	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
HNSC	cis	rs4948102	0.69	rs35844144	ENSG00000226278.1	PSPHP1	-5	8.32e-07	0.000224	-0.26	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr7:55764797~55773288:+
HNSC	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	5	8.32e-07	0.000224	0.34	0.23	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
HNSC	cis	rs1056107	0.931	rs7040713	ENSG00000225513.1	RP11-165N19.2	-5	8.32e-07	0.000224	-0.24	-0.23	Colorectal cancer;	chr9:112255041	chr9:112173522~112173971:-
HNSC	cis	rs1404100	0.531	rs1038271	ENSG00000249274.1	PDLIM1P4	5	8.33e-07	0.000224	0.27	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067399	chr3:98782188~98783193:+
HNSC	cis	rs9329221	0.617	rs483916	ENSG00000233609.3	RP11-62H7.2	-4.99	8.33e-07	0.000224	-0.2	-0.23	Neuroticism;	chr8:9936091	chr8:8961200~8979025:+
HNSC	cis	rs6540731	0.728	rs12746096	ENSG00000226251.4	RP11-15I11.3	-4.99	8.34e-07	0.000225	-0.26	-0.23	Intelligence (childhood);	chr1:212190424	chr1:212225278~212238977:-
HNSC	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-4.99	8.35e-07	0.000225	-0.25	-0.23	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
HNSC	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-4.99	8.35e-07	0.000225	-0.25	-0.23	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
HNSC	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	4.99	8.35e-07	0.000225	0.19	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
HNSC	cis	rs4237845	0.611	rs7978588	ENSG00000257159.1	RP11-58A17.3	4.99	8.35e-07	0.000225	0.27	0.23	Intelligence (multi-trait analysis);	chr12:57911000	chr12:57967058~57968399:+
HNSC	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	4.99	8.36e-07	0.000225	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	4.99	8.36e-07	0.000225	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
HNSC	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-4.99	8.36e-07	0.000225	-0.37	-0.23	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
HNSC	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-4.99	8.37e-07	0.000225	-0.24	-0.23	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	4.99	8.37e-07	0.000225	0.27	0.23	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	4.99	8.37e-07	0.000225	0.27	0.23	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
HNSC	cis	rs12893668	0.514	rs3212090	ENSG00000269940.1	RP11-73M18.7	4.99	8.37e-07	0.000225	0.22	0.23	Reticulocyte count;	chr14:103702526	chr14:103694560~103695170:+
HNSC	cis	rs8040855	0.599	rs1964724	ENSG00000259774.1	RP11-182J1.13	-4.99	8.37e-07	0.000225	-0.27	-0.23	Bulimia nervosa;	chr15:85183269	chr15:84422618~84425882:+
HNSC	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	4.99	8.38e-07	0.000226	0.24	0.23	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	4.99	8.38e-07	0.000226	0.24	0.23	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-4.99	8.38e-07	0.000226	-0.26	-0.23	Depression;	chr6:28139876	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-4.99	8.38e-07	0.000226	-0.26	-0.23	Depression;	chr6:28139998	chr6:28170845~28172521:+
HNSC	cis	rs17428076	0.751	rs1008152	ENSG00000228389.1	AC068039.4	-4.99	8.39e-07	0.000226	-0.28	-0.23	Myopia;	chr2:172047362	chr2:171773482~171775844:+
HNSC	cis	rs763121	0.744	rs5757140	ENSG00000273076.1	RP3-508I15.22	4.99	8.39e-07	0.000226	0.24	0.23	Menopause (age at onset);	chr22:38561008	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.691	rs17009144	ENSG00000249244.1	RP11-548H18.2	-4.99	8.39e-07	0.000226	-0.27	-0.23	Corneal astigmatism;	chr4:119349640	chr4:119391831~119395335:-
HNSC	cis	rs36093844	0.752	rs7943104	ENSG00000279742.1	RP11-700A24.1	-4.99	8.39e-07	0.000226	-0.32	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85834137	chr11:85852557~85854943:-
HNSC	cis	rs3808502	0.527	rs2736374	ENSG00000255310.2	AF131215.2	-4.99	8.39e-07	0.000226	-0.23	-0.23	Neuroticism;	chr8:11256319	chr8:11107788~11109726:-
HNSC	cis	rs7296418	0.961	rs1790106	ENSG00000280120.1	RP11-546D6.3	4.99	8.4e-07	0.000226	0.19	0.23	Platelet count;	chr12:123107049	chr12:123152324~123153377:-
HNSC	cis	rs13073817	0.582	rs7649824	ENSG00000228956.7	SATB1-AS1	4.99	8.4e-07	0.000226	0.23	0.23	Crohn's disease;	chr3:18651134	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.582	rs11128894	ENSG00000228956.7	SATB1-AS1	4.99	8.4e-07	0.000226	0.23	0.23	Crohn's disease;	chr3:18651427	chr3:18445024~18920401:+
HNSC	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-4.99	8.4e-07	0.000226	-0.29	-0.23	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.99	8.41e-07	0.000226	0.28	0.23	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.99	8.41e-07	0.000226	0.28	0.23	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.99	8.41e-07	0.000226	0.28	0.23	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
HNSC	cis	rs7665090	0.755	rs228619	ENSG00000246560.2	RP11-10L12.4	-4.99	8.41e-07	0.000226	-0.26	-0.23	Primary biliary cholangitis;	chr4:102648126	chr4:102828055~102844075:+
HNSC	cis	rs1862618	0.853	rs1862619	ENSG00000271828.1	CTD-2310F14.1	4.99	8.41e-07	0.000226	0.3	0.23	Initial pursuit acceleration;	chr5:56802429	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.853	rs1559282	ENSG00000271828.1	CTD-2310F14.1	4.99	8.41e-07	0.000226	0.3	0.23	Initial pursuit acceleration;	chr5:56803548	chr5:56927874~56929573:+
HNSC	cis	rs7746199	0.736	rs13209332	ENSG00000219392.1	RP1-265C24.5	-4.99	8.41e-07	0.000226	-0.44	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28115628~28116551:+
HNSC	cis	rs3805389	0.504	rs56288855	ENSG00000273257.1	RP11-177J6.1	-4.99	8.41e-07	0.000226	-0.35	-0.23	Waist-to-hip ratio adjusted for body mass index;	chr4:55603178	chr4:55387949~55388271:+
HNSC	cis	rs933688	1	rs10041402	ENSG00000281357.1	ARRDC3-AS1	4.99	8.41e-07	0.000226	0.33	0.23	Smoking behavior;	chr5:91443131	chr5:91380349~91439085:+
HNSC	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	4.99	8.41e-07	0.000226	0.25	0.23	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
HNSC	cis	rs6928977	0.896	rs2746425	ENSG00000231028.7	LINC00271	4.99	8.41e-07	0.000226	0.26	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135343227	chr6:135497801~135716055:+
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	4.99	8.42e-07	0.000226	0.27	0.23	Depression;	chr6:28200948	chr6:28161781~28169594:+
HNSC	cis	rs721917	0.569	rs2247820	ENSG00000225484.5	NUTM2B-AS1	-4.99	8.42e-07	0.000227	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79663088~79826594:-
HNSC	cis	rs6928977	0.832	rs2746427	ENSG00000231028.7	LINC00271	4.99	8.42e-07	0.000227	0.26	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135347959	chr6:135497801~135716055:+
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000254340.1	RP11-10A14.3	4.99	8.42e-07	0.000227	0.27	0.23	Systolic blood pressure;	chr8:8273016	chr8:9141424~9145435:+
HNSC	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-4.99	8.44e-07	0.000227	-0.28	-0.23	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
HNSC	cis	rs12291225	0.585	rs12270374	ENSG00000251991.1	RNU7-49P	4.99	8.44e-07	0.000227	0.26	0.23	Sense of smell;	chr11:14353533	chr11:14478892~14478953:+
HNSC	cis	rs9907295	0.901	rs2107540	ENSG00000270977.1	AC015849.16	-4.99	8.45e-07	0.000227	-0.38	-0.23	Fibroblast growth factor basic levels;	chr17:35893516	chr17:35893707~35911023:-
HNSC	cis	rs6693567	0.565	rs834225	ENSG00000228126.1	FALEC	4.99	8.45e-07	0.000227	0.27	0.23	Migraine;	chr1:150328268	chr1:150515757~150518032:+
HNSC	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	4.99	8.45e-07	0.000227	0.26	0.23	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
HNSC	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-4.99	8.45e-07	0.000227	-0.26	-0.23	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
HNSC	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	4.99	8.45e-07	0.000227	0.28	0.23	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
HNSC	cis	rs7809950	0.817	rs2237671	ENSG00000238832.1	snoU109	-4.99	8.45e-07	0.000227	-0.32	-0.23	Coronary artery disease;	chr7:107491083	chr7:107603363~107603507:+
HNSC	cis	rs9987353	0.522	rs2929466	ENSG00000173295.6	FAM86B3P	-4.99	8.45e-07	0.000227	-0.26	-0.23	Recombination measurement;	chr8:9206389	chr8:8228595~8244865:+
HNSC	cis	rs4938303	0.633	rs12800436	ENSG00000254851.1	RP11-109L13.1	4.99	8.46e-07	0.000227	0.4	0.23	Triglycerides;	chr11:116688086	chr11:117135528~117138582:+
HNSC	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	4.99	8.46e-07	0.000228	0.23	0.23	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
HNSC	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	4.99	8.46e-07	0.000228	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
HNSC	cis	rs763567	0.967	rs473832	ENSG00000271811.1	RP1-79C4.4	4.99	8.46e-07	0.000228	0.24	0.23	Tonsillectomy;	chr1:170640049	chr1:170667381~170669425:+
HNSC	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	4.99	8.47e-07	0.000228	0.37	0.23	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
HNSC	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-4.99	8.47e-07	0.000228	-0.25	-0.23	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
HNSC	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-4.99	8.47e-07	0.000228	-0.46	-0.23	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
HNSC	cis	rs36052053	0.808	rs78799897	ENSG00000219700.1	PTCHD3P3	4.99	8.47e-07	0.000228	0.36	0.23	Red cell distribution width;	chr6:109285941	chr6:109288571~109290503:-
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000204709.4	LINC01556	4.99	8.47e-07	0.000228	0.31	0.23	Parkinson's disease;	chr6:28065618	chr6:28943877~28944537:+
HNSC	cis	rs9907295	0.818	rs9303692	ENSG00000270977.1	AC015849.16	4.99	8.49e-07	0.000228	0.29	0.23	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35893707~35911023:-
HNSC	cis	rs2058059	0.511	rs6970153	ENSG00000225648.4	SBDSP1	-4.99	8.49e-07	0.000228	-0.31	-0.23	Subcutaneous adipose tissue;	chr7:72573610	chr7:72829425~72836701:+
HNSC	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-4.99	8.49e-07	0.000228	-0.21	-0.23	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
HNSC	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-4.99	8.49e-07	0.000228	-0.22	-0.23	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-4.99	8.5e-07	0.000228	-0.26	-0.23	Depression;	chr6:28133900	chr6:28170845~28172521:+
HNSC	cis	rs34787248	1	rs34787248	ENSG00000204709.4	LINC01556	4.99	8.5e-07	0.000228	0.33	0.23	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28943877~28944537:+
HNSC	cis	rs1056107	0.898	rs943620	ENSG00000225513.1	RP11-165N19.2	-4.99	8.5e-07	0.000228	-0.24	-0.23	Colorectal cancer;	chr9:112231228	chr9:112173522~112173971:-
HNSC	cis	rs7615952	0.599	rs2333408	ENSG00000248787.1	RP11-666A20.4	-4.99	8.5e-07	0.000228	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126013255	chr3:125908005~125910272:-
HNSC	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-4.99	8.5e-07	0.000228	-0.29	-0.23	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
HNSC	cis	rs6900992	1	rs6900992	ENSG00000234147.1	RP3-460G2.2	4.99	8.51e-07	0.000229	0.28	0.23	Night sleep phenotypes;	chr6:140700714	chr6:140845958~140852924:-
HNSC	cis	rs7740706	1	rs7740706	ENSG00000234147.1	RP3-460G2.2	4.99	8.51e-07	0.000229	0.28	0.23	Night sleep phenotypes;	chr6:140701399	chr6:140845958~140852924:-
HNSC	cis	rs11893307	0.851	rs62182472	ENSG00000235852.1	AC005540.3	4.99	8.52e-07	0.000229	0.32	0.23	Mean platelet volume;	chr2:190868102	chr2:190880797~190882059:-
HNSC	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	4.99	8.52e-07	0.000229	0.28	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
HNSC	cis	rs651386	0.529	rs576736	ENSG00000271811.1	RP1-79C4.4	4.99	8.52e-07	0.000229	0.24	0.23	Atrial fibrillation;	chr1:170618074	chr1:170667381~170669425:+
HNSC	cis	rs10504130	0.569	rs2069119	ENSG00000272024.1	RP11-546K22.3	-4.99	8.52e-07	0.000229	-0.32	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs35603537	ENSG00000272024.1	RP11-546K22.3	-4.99	8.52e-07	0.000229	-0.32	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	4.99	8.53e-07	0.000229	0.27	0.22	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	4.99	8.53e-07	0.000229	0.27	0.22	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	4.99	8.53e-07	0.000229	0.27	0.22	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	4.99	8.53e-07	0.000229	0.27	0.22	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
HNSC	cis	rs3733585	0.648	rs13103497	ENSG00000250413.1	RP11-448G15.1	-4.99	8.54e-07	0.000229	-0.28	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9977638	chr4:10006482~10009725:+
HNSC	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-4.99	8.54e-07	0.000229	-0.27	-0.22	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
HNSC	cis	rs2058059	0.551	rs1954708	ENSG00000225648.4	SBDSP1	-4.99	8.55e-07	0.00023	-0.33	-0.22	Subcutaneous adipose tissue;	chr7:72621134	chr7:72829425~72836701:+
HNSC	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-4.99	8.55e-07	0.00023	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
HNSC	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-4.99	8.56e-07	0.00023	-0.18	-0.22	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
HNSC	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-4.99	8.56e-07	0.00023	-0.27	-0.22	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
HNSC	cis	rs950169	0.84	rs62019457	ENSG00000229212.6	RP11-561C5.4	-4.99	8.56e-07	0.00023	-0.32	-0.22	Schizophrenia;	chr15:84558911	chr15:85205440~85234795:-
HNSC	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-4.99	8.56e-07	0.00023	-0.28	-0.22	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-4.99	8.56e-07	0.00023	-0.28	-0.22	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
HNSC	cis	rs9863	0.861	rs4765528	ENSG00000269938.1	RP11-214K3.20	4.99	8.57e-07	0.00023	0.3	0.22	White blood cell count;	chr12:123977707	chr12:123968023~123968579:-
HNSC	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	4.99	8.57e-07	0.00023	0.32	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-4.99	8.57e-07	0.00023	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
HNSC	cis	rs2179367	0.6	rs9498354	ENSG00000216906.2	RP11-350J20.9	-4.99	8.58e-07	0.00023	-0.34	-0.22	Dupuytren's disease;	chr6:149441715	chr6:149904243~149906418:+
HNSC	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	4.99	8.58e-07	0.00023	0.26	0.22	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000233609.3	RP11-62H7.2	4.99	8.58e-07	0.00023	0.22	0.22	Joint mobility (Beighton score);	chr8:9014200	chr8:8961200~8979025:+
HNSC	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	4.99	8.58e-07	0.00023	0.33	0.22	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
HNSC	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	4.99	8.58e-07	0.00023	0.33	0.22	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
HNSC	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	4.99	8.58e-07	0.00023	0.33	0.22	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
HNSC	cis	rs7688540	0.76	rs12506250	ENSG00000211553.1	AC253576.2	-4.99	8.59e-07	0.000231	-0.29	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:136461~136568:+
HNSC	cis	rs72843506	0.656	rs28622601	ENSG00000261033.1	RP11-209D14.2	4.99	8.59e-07	0.000231	0.36	0.22	Schizophrenia;	chr17:20055341	chr17:20008051~20009234:-
HNSC	cis	rs6964587	1	rs13231820	ENSG00000188693.7	CYP51A1-AS1	-4.99	8.59e-07	0.000231	-0.24	-0.22	Breast cancer;	chr7:92034215	chr7:92134604~92180725:+
HNSC	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	4.99	8.59e-07	0.000231	0.28	0.22	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
HNSC	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-4.99	8.6e-07	0.000231	-0.26	-0.22	Height;	chr2:46634098	chr2:46668870~46670778:+
HNSC	cis	rs3806843	0.712	rs2530244	ENSG00000202515.1	VTRNA1-3	4.99	8.6e-07	0.000231	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr5:140726158~140726246:+
HNSC	cis	rs728616	0.764	rs12413678	ENSG00000225484.5	NUTM2B-AS1	-4.99	8.6e-07	0.000231	-0.5	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79663088~79826594:-
HNSC	cis	rs860295	0.702	rs11264380	ENSG00000203761.5	MSTO2P	-4.99	8.6e-07	0.000231	-0.17	-0.22	Body mass index;	chr1:155550353	chr1:155745829~155750137:+
HNSC	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	4.99	8.6e-07	0.000231	0.27	0.22	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
HNSC	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-4.99	8.61e-07	0.000231	-0.23	-0.22	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
HNSC	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	4.99	8.61e-07	0.000231	0.29	0.22	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
HNSC	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-4.99	8.61e-07	0.000231	-0.31	-0.22	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
HNSC	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	4.99	8.61e-07	0.000231	0.25	0.22	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
HNSC	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	4.99	8.62e-07	0.000231	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
HNSC	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-4.99	8.62e-07	0.000231	-0.35	-0.22	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
HNSC	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	4.99	8.62e-07	0.000231	0.2	0.22	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
HNSC	cis	rs9840812	0.769	rs576771	ENSG00000273486.1	RP11-731C17.2	4.99	8.63e-07	0.000231	0.19	0.22	Fibrinogen levels;	chr3:136270450	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.772	rs7824675	ENSG00000255310.2	AF131215.2	-4.99	8.63e-07	0.000232	-0.21	-0.22	Neuroticism;	chr8:10385908	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-4.99	8.63e-07	0.000232	-0.27	-0.22	Depression;	chr6:28096077	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	4.99	8.64e-07	0.000232	0.28	0.22	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000254340.1	RP11-10A14.3	4.99	8.64e-07	0.000232	0.27	0.22	Mood instability;	chr8:8821666	chr8:9141424~9145435:+
HNSC	cis	rs2933343	0.729	rs789228	ENSG00000261159.1	RP11-723O4.9	4.99	8.64e-07	0.000232	0.22	0.22	IgG glycosylation;	chr3:128882207	chr3:128859716~128860526:-
HNSC	cis	rs597539	0.552	rs10896384	ENSG00000255741.1	RP11-757G1.5	4.99	8.65e-07	0.000232	0.31	0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68941503~68942852:-
HNSC	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.99	8.65e-07	0.000232	-0.23	-0.22	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
HNSC	cis	rs3863381	0.764	rs77244411	ENSG00000277715.1	RP11-651L5.3	4.99	8.66e-07	0.000232	0.34	0.22	Night sleep phenotypes;	chr12:105708807	chr12:106250759~106252786:+
HNSC	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-4.99	8.66e-07	0.000232	-0.28	-0.22	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
HNSC	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-4.99	8.66e-07	0.000232	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
HNSC	cis	rs3733585	0.638	rs13145554	ENSG00000250413.1	RP11-448G15.1	-4.99	8.66e-07	0.000232	-0.28	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9977965	chr4:10006482~10009725:+
HNSC	cis	rs12935418	0.672	rs9925780	ENSG00000261061.1	RP11-303E16.2	-4.99	8.66e-07	0.000232	-0.26	-0.22	Mean corpuscular volume;	chr16:81011571	chr16:81030770~81031485:+
HNSC	cis	rs916888	0.779	rs199528	ENSG00000260075.1	NSFP1	-4.99	8.66e-07	0.000232	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.821	rs199525	ENSG00000260075.1	NSFP1	-4.99	8.66e-07	0.000232	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46372855~46487141:+
HNSC	cis	rs9907295	0.818	rs11658222	ENSG00000270977.1	AC015849.16	-4.99	8.67e-07	0.000232	-0.33	-0.22	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35893707~35911023:-
HNSC	cis	rs9863	0.931	rs34180676	ENSG00000269938.1	RP11-214K3.20	-4.99	8.67e-07	0.000233	-0.27	-0.22	White blood cell count;	chr12:123946972	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.931	rs7955815	ENSG00000269938.1	RP11-214K3.20	-4.99	8.67e-07	0.000233	-0.27	-0.22	White blood cell count;	chr12:123948159	chr12:123968023~123968579:-
HNSC	cis	rs3806843	0.735	rs801167	ENSG00000202515.1	VTRNA1-3	-4.99	8.68e-07	0.000233	-0.26	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr5:140726158~140726246:+
HNSC	cis	rs9650657	0.529	rs10108618	ENSG00000255310.2	AF131215.2	-4.99	8.69e-07	0.000233	-0.21	-0.22	Neuroticism;	chr8:11095582	chr8:11107788~11109726:-
HNSC	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-4.99	8.69e-07	0.000233	-0.26	-0.22	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
HNSC	cis	rs67340775	0.748	rs13212651	ENSG00000219392.1	RP1-265C24.5	-4.99	8.7e-07	0.000233	-0.44	-0.22	Lung cancer in ever smokers;	chr6:27839207	chr6:28115628~28116551:+
HNSC	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-4.99	8.7e-07	0.000233	-0.24	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
HNSC	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-4.99	8.7e-07	0.000233	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
HNSC	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-4.99	8.71e-07	0.000233	-0.37	-0.22	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
HNSC	cis	rs4664293	0.647	rs6756502	ENSG00000226266.5	AC009961.3	4.99	8.71e-07	0.000233	0.23	0.22	Monocyte percentage of white cells;	chr2:159698072	chr2:159670708~159712435:-
HNSC	cis	rs6964587	1	rs10234434	ENSG00000188693.7	CYP51A1-AS1	-4.99	8.71e-07	0.000233	-0.24	-0.22	Breast cancer;	chr7:92043994	chr7:92134604~92180725:+
HNSC	cis	rs13073817	0.601	rs13085637	ENSG00000228956.7	SATB1-AS1	4.99	8.71e-07	0.000233	0.24	0.22	Crohn's disease;	chr3:18660271	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.526	rs13090941	ENSG00000228956.7	SATB1-AS1	4.99	8.71e-07	0.000233	0.24	0.22	Crohn's disease;	chr3:18660544	chr3:18445024~18920401:+
HNSC	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	4.99	8.71e-07	0.000234	0.2	0.22	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
HNSC	cis	rs11773103	1	rs11762311	ENSG00000224046.1	AC005076.5	4.99	8.71e-07	0.000234	0.43	0.22	Bipolar disorder or major depressive disorder (combined);	chr7:87313509	chr7:87151423~87152420:-
HNSC	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	4.99	8.72e-07	0.000234	0.31	0.22	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	4.99	8.72e-07	0.000234	0.21	0.22	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
HNSC	cis	rs11969893	0.649	rs9485415	ENSG00000270987.1	RP3-467N11.2	4.99	8.73e-07	0.000234	0.5	0.22	Economic and political preferences (immigration/crime);	chr6:100831583	chr6:100889603~100890338:+
HNSC	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	4.99	8.73e-07	0.000234	0.29	0.22	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000233609.3	RP11-62H7.2	4.99	8.73e-07	0.000234	0.22	0.22	Joint mobility (Beighton score);	chr8:9043712	chr8:8961200~8979025:+
HNSC	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	4.99	8.73e-07	0.000234	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	4.99	8.73e-07	0.000234	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
HNSC	cis	rs5758659	0.714	rs133376	ENSG00000227370.1	RP4-669P10.19	-4.99	8.74e-07	0.000234	-0.22	-0.22	Cognitive function;	chr22:42070901	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.653	rs133383	ENSG00000227370.1	RP4-669P10.19	-4.99	8.74e-07	0.000234	-0.22	-0.22	Cognitive function;	chr22:42077599	chr22:42132543~42132998:+
HNSC	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	4.99	8.74e-07	0.000234	0.23	0.22	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-4.99	8.74e-07	0.000234	-0.27	-0.22	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
HNSC	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	4.99	8.74e-07	0.000234	0.26	0.22	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
HNSC	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	4.99	8.75e-07	0.000234	0.26	0.22	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	4.98	8.76e-07	0.000235	0.26	0.22	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
HNSC	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-4.98	8.76e-07	0.000235	-0.22	-0.22	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
HNSC	cis	rs763567	0.967	rs593560	ENSG00000271811.1	RP1-79C4.4	4.98	8.76e-07	0.000235	0.24	0.22	Tonsillectomy;	chr1:170646776	chr1:170667381~170669425:+
HNSC	cis	rs4968361	0.892	rs4968363	ENSG00000266992.1	DHX40P1	4.98	8.76e-07	0.000235	0.43	0.22	Schizophrenia;	chr17:59433712	chr17:59976009~60002384:-
HNSC	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	4.98	8.76e-07	0.000235	0.22	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
HNSC	cis	rs4388249	1	rs3756598	ENSG00000271849.1	CTC-332L22.1	-4.98	8.77e-07	0.000235	-0.34	-0.22	Schizophrenia;	chr5:109698681	chr5:109687802~109688329:-
HNSC	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-4.98	8.77e-07	0.000235	-0.23	-0.22	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-4.98	8.77e-07	0.000235	-0.23	-0.22	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-4.98	8.77e-07	0.000235	-0.23	-0.22	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
HNSC	cis	rs6586111	1	rs7093787	ENSG00000226659.1	RP11-137H2.4	-4.98	8.78e-07	0.000235	-0.27	-0.22	Capecitabine sensitivity;	chr10:80611371	chr10:80529597~80535942:-
HNSC	cis	rs763512	0.504	rs1051838	ENSG00000276054.1	RP11-378E13.3	4.98	8.78e-07	0.000235	0.33	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37510731	chr17:37386886~37387926:+
HNSC	cis	rs1799949	0.965	rs799910	ENSG00000236383.6	LINC00854	-4.98	8.78e-07	0.000235	-0.21	-0.22	Menopause (age at onset);	chr17:43127544	chr17:43216941~43305976:-
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	4.98	8.79e-07	0.000235	0.26	0.22	Depression;	chr6:28086929	chr6:28170845~28172521:+
HNSC	cis	rs9304742	0.821	rs2011496	ENSG00000213801.4	ZNF816-ZNF321P	4.98	8.79e-07	0.000235	0.25	0.22	Psoriasis;	chr19:52952624	chr19:52927135~52942601:-
HNSC	cis	rs11083475	0.607	rs6508816	ENSG00000269486.2	CTC-360G5.9	4.98	8.79e-07	0.000235	0.25	0.22	Heart rate;	chr19:38777143	chr19:38935297~38938632:-
HNSC	cis	rs1971762	0.712	rs7302232	ENSG00000270175.1	RP11-793H13.11	-4.98	8.79e-07	0.000235	-0.2	-0.22	Height;	chr12:53571639	chr12:53500162~53500936:-
HNSC	cis	rs7048146	0.509	rs12551533	ENSG00000213539.4	YBX1P6	4.98	8.8e-07	0.000236	0.3	0.22	Vascular brain injury;	chr9:109547700	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs1571641	ENSG00000213539.4	YBX1P6	4.98	8.8e-07	0.000236	0.3	0.22	Vascular brain injury;	chr9:109548550	chr9:109532830~109534332:-
HNSC	cis	rs7048146	0.509	rs12002415	ENSG00000213539.4	YBX1P6	4.98	8.8e-07	0.000236	0.3	0.22	Vascular brain injury;	chr9:109549114	chr9:109532830~109534332:-
HNSC	cis	rs950776	0.518	rs2869055	ENSG00000261762.1	RP11-650L12.2	-4.98	8.8e-07	0.000236	-0.25	-0.22	Sudden cardiac arrest;	chr15:78530046	chr15:78589123~78591276:-
HNSC	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-4.98	8.8e-07	0.000236	-0.28	-0.22	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
HNSC	cis	rs1056107	0.966	rs10981338	ENSG00000225513.1	RP11-165N19.2	-4.98	8.8e-07	0.000236	-0.25	-0.22	Colorectal cancer;	chr9:112273741	chr9:112173522~112173971:-
HNSC	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-4.98	8.81e-07	0.000236	-0.27	-0.22	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
HNSC	cis	rs6496044	0.568	rs4842888	ENSG00000259295.5	CSPG4P12	-4.98	8.82e-07	0.000236	-0.26	-0.22	Interstitial lung disease;	chr15:85519902	chr15:85191438~85213905:+
HNSC	cis	rs9291683	0.507	rs6845554	ENSG00000250413.1	RP11-448G15.1	-4.98	8.82e-07	0.000236	-0.28	-0.22	Bone mineral density;	chr4:10011549	chr4:10006482~10009725:+
HNSC	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	4.98	8.82e-07	0.000236	0.28	0.22	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
HNSC	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-4.98	8.82e-07	0.000236	-0.3	-0.22	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
HNSC	cis	rs4787491	0.679	rs12933575	ENSG00000183604.13	SMG1P5	-4.98	8.82e-07	0.000236	-0.22	-0.22	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30267553~30335374:-
HNSC	cis	rs1218582	0.772	rs12069356	ENSG00000270361.1	RP11-307C12.13	-4.98	8.82e-07	0.000236	-0.24	-0.22	Prostate cancer;	chr1:154877295	chr1:154937370~154938059:+
HNSC	cis	rs11976180	1	rs2951368	ENSG00000273234.1	OR2A13P	-4.98	8.84e-07	0.000237	-0.25	-0.22	Obesity-related traits;	chr7:144055728	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2961115	ENSG00000273234.1	OR2A13P	-4.98	8.84e-07	0.000237	-0.25	-0.22	Obesity-related traits;	chr7:144056278	chr7:144142009~144142938:+
HNSC	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	4.98	8.84e-07	0.000237	0.27	0.22	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
HNSC	cis	rs9368481	0.761	rs9348746	ENSG00000224843.5	LINC00240	4.98	8.84e-07	0.000237	0.23	0.22	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26956992~27023924:+
HNSC	cis	rs13113518	0.545	rs6810483	ENSG00000273257.1	RP11-177J6.1	4.98	8.85e-07	0.000237	0.26	0.22	Height;	chr4:55424406	chr4:55387949~55388271:+
HNSC	cis	rs11971779	0.7	rs11763942	ENSG00000273391.1	RP11-634H22.1	4.98	8.85e-07	0.000237	0.28	0.22	Diisocyanate-induced asthma;	chr7:139321049	chr7:139359032~139359566:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000254174.1	IGHV1-12	4.98	8.85e-07	0.000237	0.2	0.22	Alzheimer's disease (late onset);	chr14:106670302	chr14:106122420~106122709:-
HNSC	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.98	8.86e-07	0.000237	0.27	0.22	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
HNSC	cis	rs4664293	0.647	rs1425040	ENSG00000226266.5	AC009961.3	-4.98	8.86e-07	0.000237	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159571912	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs11693108	ENSG00000226266.5	AC009961.3	-4.98	8.86e-07	0.000237	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159572076	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs7575924	ENSG00000226266.5	AC009961.3	-4.98	8.86e-07	0.000237	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159573049	chr2:159670708~159712435:-
HNSC	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-4.98	8.86e-07	0.000237	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
HNSC	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-4.98	8.87e-07	0.000237	-0.34	-0.22	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
HNSC	cis	rs2998286	0.862	rs2998285	ENSG00000254635.4	WAC-AS1	4.98	8.87e-07	0.000237	0.29	0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504310	chr10:28522652~28532743:-
HNSC	cis	rs7789940	1	rs758944	ENSG00000231087.2	FDPSP7	-4.98	8.88e-07	0.000237	-0.27	-0.22	Multiple sclerosis;	chr7:76323980	chr7:76968197~76969250:-
HNSC	cis	rs6831352	0.704	rs1800759	ENSG00000263923.1	RP11-571L19.7	-4.98	8.89e-07	0.000238	-0.22	-0.22	Alcohol dependence;	chr4:99144358	chr4:98928897~98994994:+
HNSC	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-4.98	8.89e-07	0.000238	-0.24	-0.22	Height;	chr2:46609300	chr2:46668870~46670778:+
HNSC	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-4.98	8.89e-07	0.000238	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
HNSC	cis	rs6657613	0.815	rs735258	ENSG00000186715.9	MST1L	-4.98	8.89e-07	0.000238	-0.19	-0.22	Hip circumference adjusted for BMI;	chr1:17014651	chr1:16754910~16770237:-
HNSC	cis	rs75422866	0.717	rs73104143	ENSG00000276691.1	RP5-1057I20.5	4.98	8.89e-07	0.000238	0.42	0.22	Pneumonia;	chr12:47693449	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs73104144	ENSG00000276691.1	RP5-1057I20.5	4.98	8.89e-07	0.000238	0.42	0.22	Pneumonia;	chr12:47694390	chr12:47788426~47788971:+
HNSC	cis	rs9907295	0.901	rs56294660	ENSG00000270977.1	AC015849.16	-4.98	8.89e-07	0.000238	-0.37	-0.22	Fibroblast growth factor basic levels;	chr17:35901470	chr17:35893707~35911023:-
HNSC	cis	rs867371	0.826	rs2047678	ENSG00000276710.3	CSPG4P8	-4.98	8.9e-07	0.000238	-0.26	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82459472~82477258:+
HNSC	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	4.98	8.91e-07	0.000238	0.25	0.22	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
HNSC	cis	rs3015497	0.527	rs2934671	ENSG00000269906.1	RP11-248J18.2	-4.98	8.91e-07	0.000238	-0.3	-0.22	Mean platelet volume;	chr14:50686363	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.527	rs2934670	ENSG00000269906.1	RP11-248J18.2	-4.98	8.91e-07	0.000238	-0.3	-0.22	Mean platelet volume;	chr14:50686691	chr14:50662511~50663178:-
HNSC	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	4.98	8.91e-07	0.000238	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
HNSC	cis	rs763567	0.933	rs567328	ENSG00000271811.1	RP1-79C4.4	4.98	8.91e-07	0.000238	0.24	0.22	Tonsillectomy;	chr1:170644728	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.904	rs544478	ENSG00000271811.1	RP1-79C4.4	4.98	8.91e-07	0.000238	0.24	0.22	Tonsillectomy;	chr1:170644901	chr1:170667381~170669425:+
HNSC	cis	rs2548724	0.704	rs62372211	ENSG00000250682.4	LINC00491	4.98	8.91e-07	0.000238	0.3	0.22	Type 2 diabetes;	chr5:102301073	chr5:102609156~102671559:-
HNSC	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-4.98	8.92e-07	0.000238	-0.25	-0.22	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
HNSC	cis	rs9863	0.896	rs34854841	ENSG00000269938.1	RP11-214K3.20	-4.98	8.92e-07	0.000239	-0.27	-0.22	White blood cell count;	chr12:123966957	chr12:123968023~123968579:-
HNSC	cis	rs12893668	0.572	rs4906356	ENSG00000269940.1	RP11-73M18.7	4.98	8.93e-07	0.000239	0.22	0.22	Reticulocyte count;	chr14:103672364	chr14:103694560~103695170:+
HNSC	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-4.98	8.93e-07	0.000239	-0.25	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
HNSC	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-4.98	8.93e-07	0.000239	-0.28	-0.22	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	4.98	8.93e-07	0.000239	0.28	0.22	Depression;	chr6:28199145	chr6:28161781~28169594:+
HNSC	cis	rs763567	0.845	rs492804	ENSG00000271811.1	RP1-79C4.4	4.98	8.94e-07	0.000239	0.24	0.22	Tonsillectomy;	chr1:170643121	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.967	rs654461	ENSG00000271811.1	RP1-79C4.4	4.98	8.94e-07	0.000239	0.24	0.22	Tonsillectomy;	chr1:170644709	chr1:170667381~170669425:+
HNSC	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-4.98	8.94e-07	0.000239	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
HNSC	cis	rs6964833	1	rs17515241	ENSG00000184616.8	AC004166.6	-4.98	8.94e-07	0.000239	-0.28	-0.22	Menarche (age at onset);	chr7:74717695	chr7:74906673~74913256:-
HNSC	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	4.98	8.94e-07	0.000239	0.33	0.22	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	4.98	8.94e-07	0.000239	0.33	0.22	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
HNSC	cis	rs11648785	0.661	rs870856	ENSG00000222019.6	URAHP	4.98	8.94e-07	0.000239	0.22	0.22	Tanning;	chr16:90023055	chr16:90039761~90047773:-
HNSC	cis	rs7789940	0.951	rs73140055	ENSG00000231087.2	FDPSP7	-4.98	8.94e-07	0.000239	-0.27	-0.22	Multiple sclerosis;	chr7:76346460	chr7:76968197~76969250:-
HNSC	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	4.98	8.94e-07	0.000239	0.27	0.22	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
HNSC	cis	rs1008375	0.931	rs6449309	ENSG00000249502.1	AC006160.5	-4.98	8.94e-07	0.000239	-0.25	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17571585	chr4:17587467~17614571:-
HNSC	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	4.98	8.95e-07	0.000239	0.24	0.22	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
HNSC	cis	rs11089937	0.521	rs6001221	ENSG00000211639.2	IGLV4-60	4.98	8.95e-07	0.000239	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22185176	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs12484496	ENSG00000211638.2	IGLV8-61	4.98	8.95e-07	0.000239	0.2	0.22	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22098700~22099212:+
HNSC	cis	rs79057730	0.528	rs4719313	ENSG00000225146.1	AC073957.15	4.98	8.95e-07	0.000239	0.35	0.22	Initial pursuit acceleration;	chr7:782864	chr7:1029025~1043891:+
HNSC	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	4.98	8.95e-07	0.000239	0.32	0.22	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
HNSC	cis	rs3806843	0.766	rs6848	ENSG00000202515.1	VTRNA1-3	4.98	8.96e-07	0.000239	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr5:140726158~140726246:+
HNSC	cis	rs2337406	0.538	rs10141701	ENSG00000211974.3	IGHV2-70	-4.98	8.96e-07	0.000239	-0.24	-0.22	Alzheimer's disease (late onset);	chr14:106633467	chr14:106723574~106724093:-
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000254174.1	IGHV1-12	4.98	8.97e-07	0.00024	0.19	0.22	Alzheimer's disease (late onset);	chr14:106781132	chr14:106122420~106122709:-
HNSC	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	4.98	8.97e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	4.98	8.97e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	4.98	8.97e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	4.98	8.97e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	4.98	8.97e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
HNSC	cis	rs1538970	0.781	rs11211139	ENSG00000234329.1	RP11-767N6.2	4.98	8.97e-07	0.00024	0.27	0.22	Platelet count;	chr1:45550079	chr1:45651039~45651826:-
HNSC	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	4.98	8.98e-07	0.00024	0.27	0.22	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
HNSC	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	4.98	8.98e-07	0.00024	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
HNSC	cis	rs79057730	0.599	rs112891948	ENSG00000225146.1	AC073957.15	4.98	8.98e-07	0.00024	0.35	0.22	Initial pursuit acceleration;	chr7:776422	chr7:1029025~1043891:+
HNSC	cis	rs1008375	0.864	rs4698196	ENSG00000249502.1	AC006160.5	-4.98	8.98e-07	0.00024	-0.26	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573112	chr4:17587467~17614571:-
HNSC	cis	rs763567	0.869	rs680084	ENSG00000271811.1	RP1-79C4.4	4.98	8.98e-07	0.00024	0.24	0.22	Tonsillectomy;	chr1:170659114	chr1:170667381~170669425:+
HNSC	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	4.98	8.99e-07	0.00024	0.25	0.22	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
HNSC	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-4.98	9e-07	0.00024	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
HNSC	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-4.98	9e-07	0.00024	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
HNSC	cis	rs2834288	0.535	rs13049489	ENSG00000273102.1	AP000569.9	4.98	9e-07	0.00024	0.25	0.22	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33967101~33968573:-
HNSC	cis	rs17253792	0.822	rs17683656	ENSG00000186615.9	KTN1-AS1	4.98	9.01e-07	0.000241	0.42	0.22	Putamen volume;	chr14:55586643	chr14:55499278~55580110:-
HNSC	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-4.98	9.01e-07	0.000241	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
HNSC	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-4.98	9.02e-07	0.000241	-0.42	-0.22	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
HNSC	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	4.98	9.02e-07	0.000241	0.26	0.22	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
HNSC	cis	rs1971762	0.527	rs1683151	ENSG00000270175.1	RP11-793H13.11	4.98	9.03e-07	0.000241	0.2	0.22	Height;	chr12:53552435	chr12:53500162~53500936:-
HNSC	cis	rs367615	0.68	rs816542	ENSG00000249476.1	CTD-2587M2.1	4.98	9.03e-07	0.000241	0.29	0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109646923	chr5:109237120~109326369:-
HNSC	cis	rs4218	0.681	rs4531679	ENSG00000277144.1	RP11-59H7.4	-4.98	9.04e-07	0.000241	-0.28	-0.22	Social communication problems;	chr15:59083246	chr15:59115547~59116089:-
HNSC	cis	rs6540731	0.935	rs903120	ENSG00000226251.4	RP11-15I11.3	-4.98	9.04e-07	0.000241	-0.26	-0.22	Intelligence (childhood);	chr1:212231830	chr1:212225278~212238977:-
HNSC	cis	rs6540731	1	rs2087946	ENSG00000226251.4	RP11-15I11.3	-4.98	9.04e-07	0.000241	-0.26	-0.22	Intelligence (childhood);	chr1:212232054	chr1:212225278~212238977:-
HNSC	cis	rs6540731	1	rs903121	ENSG00000226251.4	RP11-15I11.3	-4.98	9.04e-07	0.000241	-0.26	-0.22	Intelligence (childhood);	chr1:212232113	chr1:212225278~212238977:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000233609.3	RP11-62H7.2	4.98	9.04e-07	0.000242	0.22	0.22	Joint mobility (Beighton score);	chr8:9045624	chr8:8961200~8979025:+
HNSC	cis	rs144861591	1	rs144861591	ENSG00000272462.2	U91328.19	-4.98	9.05e-07	0.000242	-0.48	-0.22	Hematocrit;Mean corpuscular hemoglobin;Mean corpuscular volume;Red cell distribution width;Hemoglobin concentration;	chr6:26072764	chr6:25992662~26001775:+
HNSC	cis	rs12468226	1	rs2350809	ENSG00000226261.1	AC064836.3	4.98	9.05e-07	0.000242	0.33	0.22	Urate levels;	chr2:202464210	chr2:202336024~202336727:-
HNSC	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	4.98	9.06e-07	0.000242	0.42	0.22	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
HNSC	cis	rs9907295	0.818	rs4795093	ENSG00000270977.1	AC015849.16	-4.98	9.06e-07	0.000242	-0.3	-0.22	Fibroblast growth factor basic levels;	chr17:35853137	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.818	rs2306630	ENSG00000270977.1	AC015849.16	-4.98	9.06e-07	0.000242	-0.3	-0.22	Fibroblast growth factor basic levels;	chr17:35855337	chr17:35893707~35911023:-
HNSC	cis	rs12701220	0.542	rs6957866	ENSG00000224079.1	AC091729.7	4.98	9.06e-07	0.000242	0.36	0.22	Bronchopulmonary dysplasia;	chr7:1072038	chr7:1074450~1078036:+
HNSC	cis	rs12701220	0.689	rs6973645	ENSG00000224079.1	AC091729.7	4.98	9.06e-07	0.000242	0.36	0.22	Bronchopulmonary dysplasia;	chr7:1072610	chr7:1074450~1078036:+
HNSC	cis	rs72843506	0.586	rs74811834	ENSG00000261033.1	RP11-209D14.2	4.98	9.06e-07	0.000242	0.41	0.22	Schizophrenia;	chr17:19982271	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.52	rs78178505	ENSG00000261033.1	RP11-209D14.2	4.98	9.06e-07	0.000242	0.41	0.22	Schizophrenia;	chr17:19984410	chr17:20008051~20009234:-
HNSC	cis	rs7120173	0.693	rs12799198	ENSG00000254851.1	RP11-109L13.1	-4.98	9.06e-07	0.000242	-0.35	-0.22	Visceral adipose tissue adjusted for BMI;	chr11:116930706	chr11:117135528~117138582:+
HNSC	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	4.98	9.07e-07	0.000242	0.35	0.22	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
HNSC	cis	rs1125355	0.69	rs1515929	ENSG00000204380.3	AC005042.4	4.98	9.07e-07	0.000242	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158773125	chr2:158658337~158735002:-
HNSC	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-4.98	9.07e-07	0.000242	-0.26	-0.22	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-4.98	9.07e-07	0.000242	-0.26	-0.22	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-4.98	9.07e-07	0.000242	-0.26	-0.22	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-4.98	9.07e-07	0.000242	-0.26	-0.22	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
HNSC	cis	rs4789693	0.544	rs4789770	ENSG00000265458.1	RP13-20L14.6	4.98	9.07e-07	0.000242	0.31	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82454273~82458521:-
HNSC	cis	rs516805	0.748	rs12211888	ENSG00000279453.1	RP3-425C14.4	4.98	9.07e-07	0.000242	0.3	0.22	Lymphocyte counts;	chr6:122384621	chr6:122436789~122439223:-
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28145952	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28147378	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28147406	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28148143	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28149979	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28151096	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28152885	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28153120	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28154567	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28156691	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28158424	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28159056	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28159666	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28159843	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28159925	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28159932	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28161802	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28162053	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28162598	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28163375	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28163759	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28164580	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28164825	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28164948	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28165025	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28165528	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28168434	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28169019	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28169249	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28169676	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28169755	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28169791	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-4.98	9.07e-07	0.000242	-0.27	-0.22	Depression;	chr6:28170075	chr6:28170845~28172521:+
HNSC	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-4.98	9.07e-07	0.000242	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-4.98	9.07e-07	0.000242	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-4.98	9.07e-07	0.000242	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-4.98	9.09e-07	0.000242	-0.26	-0.22	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-4.98	9.09e-07	0.000242	-0.26	-0.22	Depression;	chr6:28138981	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-4.98	9.09e-07	0.000242	-0.26	-0.22	Depression;	chr6:28139012	chr6:28170845~28172521:+
HNSC	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	4.98	9.09e-07	0.000242	0.23	0.22	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
HNSC	cis	rs7746199	0.736	rs13193542	ENSG00000219392.1	RP1-265C24.5	-4.98	9.09e-07	0.000242	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs13193480	ENSG00000219392.1	RP1-265C24.5	-4.98	9.09e-07	0.000242	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28115628~28116551:+
HNSC	cis	rs939574	1	rs79013471	ENSG00000243910.6	TUBA4B	4.98	9.09e-07	0.000243	0.46	0.22	Platelet distribution width;	chr2:219231400	chr2:219253243~219272188:+
HNSC	cis	rs939574	1	rs3817424	ENSG00000243910.6	TUBA4B	4.98	9.09e-07	0.000243	0.46	0.22	Platelet distribution width;	chr2:219232181	chr2:219253243~219272188:+
HNSC	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-4.98	9.1e-07	0.000243	-0.2	-0.22	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000276691.1	RP5-1057I20.5	4.98	9.1e-07	0.000243	0.46	0.22	Pneumonia;	chr12:47582204	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000276691.1	RP5-1057I20.5	4.98	9.1e-07	0.000243	0.46	0.22	Pneumonia;	chr12:47582915	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000276691.1	RP5-1057I20.5	4.98	9.1e-07	0.000243	0.46	0.22	Pneumonia;	chr12:47583112	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000276691.1	RP5-1057I20.5	4.98	9.1e-07	0.000243	0.46	0.22	Pneumonia;	chr12:47583333	chr12:47788426~47788971:+
HNSC	cis	rs13434995	0.635	rs1818461	ENSG00000273257.1	RP11-177J6.1	-4.98	9.1e-07	0.000243	-0.31	-0.22	Adiponectin levels;	chr4:55379156	chr4:55387949~55388271:+
HNSC	cis	rs1218582	0.74	rs1977879	ENSG00000270361.1	RP11-307C12.13	-4.98	9.11e-07	0.000243	-0.24	-0.22	Prostate cancer;	chr1:154907267	chr1:154937370~154938059:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	4.98	9.12e-07	0.000243	0.23	0.22	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
HNSC	cis	rs7789940	1	rs17149161	ENSG00000231087.2	FDPSP7	-4.98	9.12e-07	0.000243	-0.27	-0.22	Multiple sclerosis;	chr7:76348912	chr7:76968197~76969250:-
HNSC	cis	rs7615952	0.599	rs12485717	ENSG00000248787.1	RP11-666A20.4	4.98	9.12e-07	0.000243	0.31	0.22	Blood pressure (smoking interaction);	chr3:125988232	chr3:125908005~125910272:-
HNSC	cis	rs1991651	0.578	rs11778453	ENSG00000269918.1	AF131215.9	-4.98	9.12e-07	0.000243	-0.22	-0.22	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:11104691~11106704:-
HNSC	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-4.98	9.12e-07	0.000243	-0.29	-0.22	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
HNSC	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	4.98	9.13e-07	0.000243	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	4.98	9.13e-07	0.000243	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
HNSC	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-4.98	9.13e-07	0.000243	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
HNSC	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	4.98	9.13e-07	0.000243	0.35	0.22	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	4.98	9.13e-07	0.000243	0.35	0.22	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
HNSC	cis	rs2998286	0.862	rs2993980	ENSG00000254635.4	WAC-AS1	-4.98	9.13e-07	0.000243	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506286	chr10:28522652~28532743:-
HNSC	cis	rs10791097	0.728	rs10894265	ENSG00000254842.5	RP11-890B15.2	4.98	9.13e-07	0.000244	0.19	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130844718	chr11:130844191~130865561:-
HNSC	cis	rs3733585	0.699	rs7435196	ENSG00000250413.1	RP11-448G15.1	4.98	9.15e-07	0.000244	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9965932	chr4:10006482~10009725:+
HNSC	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-4.98	9.15e-07	0.000244	-0.3	-0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
HNSC	cis	rs17428076	0.749	rs62182439	ENSG00000228389.1	AC068039.4	-4.98	9.15e-07	0.000244	-0.28	-0.22	Myopia;	chr2:171943275	chr2:171773482~171775844:+
HNSC	cis	rs3805389	0.504	rs10018932	ENSG00000273257.1	RP11-177J6.1	-4.98	9.16e-07	0.000244	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55601699	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs28756087	ENSG00000273257.1	RP11-177J6.1	-4.98	9.16e-07	0.000244	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs28713371	ENSG00000273257.1	RP11-177J6.1	-4.98	9.16e-07	0.000244	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs10011801	ENSG00000273257.1	RP11-177J6.1	-4.98	9.16e-07	0.000244	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55387949~55388271:+
HNSC	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.98	9.16e-07	0.000244	0.35	0.22	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
HNSC	cis	rs6964587	1	rs34548928	ENSG00000188693.7	CYP51A1-AS1	-4.98	9.17e-07	0.000244	-0.24	-0.22	Breast cancer;	chr7:92039051	chr7:92134604~92180725:+
HNSC	cis	rs6540731	0.967	rs4951581	ENSG00000226251.4	RP11-15I11.3	-4.98	9.17e-07	0.000244	-0.26	-0.22	Intelligence (childhood);	chr1:212228770	chr1:212225278~212238977:-
HNSC	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	4.98	9.18e-07	0.000245	0.23	0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
HNSC	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	4.97	9.19e-07	0.000245	0.25	0.22	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
HNSC	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-4.97	9.2e-07	0.000245	-0.28	-0.22	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
HNSC	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	4.97	9.2e-07	0.000245	0.28	0.22	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
HNSC	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	4.97	9.21e-07	0.000245	0.23	0.22	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	4.97	9.21e-07	0.000245	0.23	0.22	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	-4.97	9.21e-07	0.000245	-0.28	-0.22	Depression;	chr6:28206179	chr6:28161781~28169594:+
HNSC	cis	rs11976180	1	rs1919951	ENSG00000273234.1	OR2A13P	-4.97	9.22e-07	0.000246	-0.25	-0.22	Obesity-related traits;	chr7:144071798	chr7:144142009~144142938:+
HNSC	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	4.97	9.22e-07	0.000246	0.19	0.22	Breast cancer;	chr11:750849	chr11:781645~782105:+
HNSC	cis	rs12701220	0.689	rs12533004	ENSG00000224079.1	AC091729.7	4.97	9.23e-07	0.000246	0.36	0.22	Bronchopulmonary dysplasia;	chr7:1055774	chr7:1074450~1078036:+
HNSC	cis	rs9910055	0.762	rs184478	ENSG00000267080.4	ASB16-AS1	4.97	9.23e-07	0.000246	0.18	0.22	Total body bone mineral density;	chr17:44132383	chr17:44175973~44186717:-
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000254340.1	RP11-10A14.3	4.97	9.24e-07	0.000246	0.27	0.22	Mood instability;	chr8:8824682	chr8:9141424~9145435:+
HNSC	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-4.97	9.24e-07	0.000246	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
HNSC	cis	rs12935418	0.673	rs2549886	ENSG00000261061.1	RP11-303E16.2	4.97	9.25e-07	0.000246	0.25	0.22	Mean corpuscular volume;	chr16:81027627	chr16:81030770~81031485:+
HNSC	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-4.97	9.26e-07	0.000247	-0.35	-0.22	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
HNSC	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-4.97	9.26e-07	0.000247	-0.28	-0.22	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
HNSC	cis	rs67981189	0.778	rs989501	ENSG00000274818.1	RP1-292L20.3	-4.97	9.26e-07	0.000247	-0.26	-0.22	Schizophrenia;	chr14:70894697	chr14:70906657~70907111:-
HNSC	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-4.97	9.26e-07	0.000247	-0.22	-0.22	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
HNSC	cis	rs7085104	0.7	rs7096183	ENSG00000236937.2	PTGES3P4	4.97	9.27e-07	0.000247	0.28	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102845595~102845950:+
HNSC	cis	rs200972	1	rs200972	ENSG00000219392.1	RP1-265C24.5	-4.97	9.27e-07	0.000247	-0.26	-0.22	Urinary tract infection frequency;	chr6:27891059	chr6:28115628~28116551:+
HNSC	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	4.97	9.28e-07	0.000247	0.24	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
HNSC	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	4.97	9.28e-07	0.000247	0.24	0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
HNSC	cis	rs2243480	1	rs410128	ENSG00000179406.6	LINC00174	-4.97	9.29e-07	0.000247	-0.51	-0.22	Diabetic kidney disease;	chr7:66138186	chr7:66376044~66401338:-
HNSC	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	4.97	9.29e-07	0.000247	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	4.97	9.29e-07	0.000247	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000254340.1	RP11-10A14.3	4.97	9.29e-07	0.000247	0.28	0.22	Parkinson's disease;	chr8:8413361	chr8:9141424~9145435:+
HNSC	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-4.97	9.29e-07	0.000247	-0.24	-0.22	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
HNSC	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	4.97	9.3e-07	0.000248	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
HNSC	cis	rs1971762	0.545	rs10876466	ENSG00000270175.1	RP11-793H13.11	-4.97	9.3e-07	0.000248	-0.19	-0.22	Height;	chr12:53587642	chr12:53500162~53500936:-
HNSC	cis	rs763121	0.819	rs5757126	ENSG00000273076.1	RP3-508I15.22	4.97	9.32e-07	0.000248	0.24	0.22	Menopause (age at onset);	chr22:38527670	chr22:38743495~38743910:+
HNSC	cis	rs853679	0.607	rs34950484	ENSG00000219392.1	RP1-265C24.5	-4.97	9.32e-07	0.000248	-0.43	-0.22	Depression;	chr6:28310911	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-4.97	9.32e-07	0.000248	-0.27	-0.22	Depression;	chr6:28173770	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-4.97	9.32e-07	0.000248	-0.27	-0.22	Depression;	chr6:28174809	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-4.97	9.32e-07	0.000248	-0.27	-0.22	Depression;	chr6:28175233	chr6:28170845~28172521:+
HNSC	cis	rs9402743	0.671	rs2327650	ENSG00000234084.1	RP3-388E23.2	-4.97	9.33e-07	0.000248	-0.23	-0.22	Systemic lupus erythematosus;	chr6:135630279	chr6:135301568~135307158:+
HNSC	cis	rs12701220	0.59	rs1881124	ENSG00000224079.1	AC091729.7	4.97	9.33e-07	0.000248	0.36	0.22	Bronchopulmonary dysplasia;	chr7:1057130	chr7:1074450~1078036:+
HNSC	cis	rs12539814	1	rs12666210	ENSG00000204959.4	ARHGEF34P	-4.97	9.33e-07	0.000248	-0.37	-0.22	Diastolic blood pressure;	chr7:144435635	chr7:144272445~144286966:-
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-4.97	9.33e-07	0.000248	-0.26	-0.22	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
HNSC	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-4.97	9.34e-07	0.000249	-0.23	-0.22	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
HNSC	cis	rs853679	0.607	rs67998226	ENSG00000219392.1	RP1-265C24.5	-4.97	9.34e-07	0.000249	-0.43	-0.22	Depression;	chr6:28270281	chr6:28115628~28116551:+
HNSC	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-4.97	9.35e-07	0.000249	-0.29	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
HNSC	cis	rs1056107	0.866	rs10817305	ENSG00000225513.1	RP11-165N19.2	-4.97	9.35e-07	0.000249	-0.24	-0.22	Colorectal cancer;	chr9:112259120	chr9:112173522~112173971:-
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000254174.1	IGHV1-12	4.97	9.35e-07	0.000249	0.19	0.22	Alzheimer's disease (late onset);	chr14:106706726	chr14:106122420~106122709:-
HNSC	cis	rs9402743	0.666	rs1475069	ENSG00000217482.2	HMGB1P17	4.97	9.35e-07	0.000249	0.26	0.22	Systemic lupus erythematosus;	chr6:135735096	chr6:135636086~135636713:-
HNSC	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	4.97	9.36e-07	0.000249	0.25	0.22	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000254153.1	CTA-398F10.2	-4.97	9.36e-07	0.000249	-0.24	-0.22	Mood instability;	chr8:8721301	chr8:8456909~8461337:-
HNSC	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	4.97	9.37e-07	0.000249	0.28	0.22	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
HNSC	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-4.97	9.38e-07	0.000249	-0.22	-0.22	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
HNSC	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	4.97	9.39e-07	0.00025	0.24	0.22	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
HNSC	cis	rs6928977	0.896	rs2746421	ENSG00000231028.7	LINC00271	4.97	9.4e-07	0.00025	0.26	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135340491	chr6:135497801~135716055:+
HNSC	cis	rs4853525	0.62	rs6751868	ENSG00000235852.1	AC005540.3	4.97	9.4e-07	0.00025	0.29	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190877222	chr2:190880797~190882059:-
HNSC	cis	rs12893668	0.703	rs4906338	ENSG00000269940.1	RP11-73M18.7	4.97	9.41e-07	0.00025	0.22	0.22	Reticulocyte count;	chr14:103584020	chr14:103694560~103695170:+
HNSC	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-4.97	9.41e-07	0.00025	-0.33	-0.22	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
HNSC	cis	rs11098499	0.739	rs9996382	ENSG00000249244.1	RP11-548H18.2	4.97	9.42e-07	0.00025	0.26	0.22	Corneal astigmatism;	chr4:119229857	chr4:119391831~119395335:-
HNSC	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-4.97	9.42e-07	0.00025	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
HNSC	cis	rs67981189	0.896	rs221922	ENSG00000274818.1	RP1-292L20.3	-4.97	9.42e-07	0.00025	-0.26	-0.22	Schizophrenia;	chr14:71118396	chr14:70906657~70907111:-
HNSC	cis	rs7777677	0.925	rs4726544	ENSG00000244273.1	PGBD4P1	-4.97	9.42e-07	0.00025	-0.25	-0.22	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142722358~142722764:+
HNSC	cis	rs6479901	0.639	rs10995448	ENSG00000232075.1	MRPL35P2	-4.97	9.42e-07	0.000251	-0.29	-0.22	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63634317~63634827:-
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-4.97	9.43e-07	0.000251	-0.26	-0.22	Depression;	chr6:28126588	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-4.97	9.43e-07	0.000251	-0.26	-0.22	Depression;	chr6:28126953	chr6:28170845~28172521:+
HNSC	cis	rs442309	0.551	rs10995305	ENSG00000238280.1	RP11-436D10.3	-4.97	9.43e-07	0.000251	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62781150	chr10:62793562~62805887:-
HNSC	cis	rs3805389	0.504	rs1873090	ENSG00000273257.1	RP11-177J6.1	-4.97	9.43e-07	0.000251	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55605237	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	4.97	9.43e-07	0.000251	0.27	0.22	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	4.97	9.43e-07	0.000251	0.27	0.22	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	4.97	9.43e-07	0.000251	0.27	0.22	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	4.97	9.43e-07	0.000251	0.27	0.22	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000254174.1	IGHV1-12	4.97	9.44e-07	0.000251	0.18	0.22	Alzheimer's disease (late onset);	chr14:106780669	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000254174.1	IGHV1-12	4.97	9.44e-07	0.000251	0.18	0.22	Alzheimer's disease (late onset);	chr14:106781183	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000254174.1	IGHV1-12	4.97	9.44e-07	0.000251	0.18	0.22	Alzheimer's disease (late onset);	chr14:106781256	chr14:106122420~106122709:-
HNSC	cis	rs12893668	0.572	rs4906350	ENSG00000269940.1	RP11-73M18.7	4.97	9.44e-07	0.000251	0.22	0.22	Reticulocyte count;	chr14:103645457	chr14:103694560~103695170:+
HNSC	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-4.97	9.44e-07	0.000251	-0.26	-0.22	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
HNSC	cis	rs17373728	0.526	rs9298251	ENSG00000249395.2	CASC9	-4.97	9.45e-07	0.000251	-0.28	-0.22	Diabetic kidney disease;	chr8:75243181	chr8:75223404~75324741:-
HNSC	cis	rs7789940	0.904	rs12531348	ENSG00000231087.2	FDPSP7	-4.97	9.45e-07	0.000251	-0.27	-0.22	Multiple sclerosis;	chr7:76307874	chr7:76968197~76969250:-
HNSC	cis	rs7789940	0.904	rs61294900	ENSG00000231087.2	FDPSP7	-4.97	9.45e-07	0.000251	-0.27	-0.22	Multiple sclerosis;	chr7:76307895	chr7:76968197~76969250:-
HNSC	cis	rs7789940	0.904	rs56919252	ENSG00000231087.2	FDPSP7	-4.97	9.45e-07	0.000251	-0.27	-0.22	Multiple sclerosis;	chr7:76308203	chr7:76968197~76969250:-
HNSC	cis	rs9287719	0.649	rs10186984	ENSG00000243819.4	RN7SL832P	-4.97	9.45e-07	0.000251	-0.23	-0.22	Prostate cancer;	chr2:10594066	chr2:10690344~10692099:+
HNSC	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	4.97	9.45e-07	0.000251	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
HNSC	cis	rs2235642	0.582	rs2072990	ENSG00000280231.1	LA16c-380F5.3	-4.97	9.45e-07	0.000251	-0.3	-0.22	Coronary artery disease;	chr16:1517650	chr16:1553655~1554130:-
HNSC	cis	rs2235642	0.582	rs2235637	ENSG00000280231.1	LA16c-380F5.3	-4.97	9.45e-07	0.000251	-0.3	-0.22	Coronary artery disease;	chr16:1517693	chr16:1553655~1554130:-
HNSC	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-4.97	9.45e-07	0.000251	-0.23	-0.22	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-4.97	9.45e-07	0.000251	-0.23	-0.22	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
HNSC	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-4.97	9.46e-07	0.000251	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
HNSC	cis	rs4862750	0.914	rs11943333	ENSG00000250971.1	RP11-696F12.1	4.97	9.46e-07	0.000251	0.25	0.22	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:187060099~187060930:+
HNSC	cis	rs12468226	0.808	rs77251002	ENSG00000226261.1	AC064836.3	4.97	9.47e-07	0.000251	0.35	0.22	Urate levels;	chr2:202150236	chr2:202336024~202336727:-
HNSC	cis	rs2179367	0.613	rs62426122	ENSG00000216906.2	RP11-350J20.9	4.97	9.47e-07	0.000252	0.32	0.22	Dupuytren's disease;	chr6:149427449	chr6:149904243~149906418:+
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000254153.1	CTA-398F10.2	4.97	9.48e-07	0.000252	0.24	0.22	Mood instability;	chr8:8401202	chr8:8456909~8461337:-
HNSC	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-4.97	9.49e-07	0.000252	-0.25	-0.22	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
HNSC	cis	rs17428076	1	rs17428076	ENSG00000228389.1	AC068039.4	4.97	9.5e-07	0.000252	0.27	0.22	Myopia;	chr2:171987022	chr2:171773482~171775844:+
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000254153.1	CTA-398F10.2	-4.97	9.5e-07	0.000252	-0.25	-0.22	Mood instability;	chr8:8311465	chr8:8456909~8461337:-
HNSC	cis	rs9863	0.931	rs2178663	ENSG00000269938.1	RP11-214K3.20	-4.97	9.5e-07	0.000252	-0.27	-0.22	White blood cell count;	chr12:123949358	chr12:123968023~123968579:-
HNSC	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-4.97	9.5e-07	0.000252	-0.25	-0.22	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-4.97	9.5e-07	0.000252	-0.25	-0.22	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
HNSC	cis	rs1799949	0.965	rs8070179	ENSG00000236383.6	LINC00854	-4.97	9.5e-07	0.000252	-0.21	-0.22	Menopause (age at onset);	chr17:43050671	chr17:43216941~43305976:-
HNSC	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-4.97	9.52e-07	0.000253	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
HNSC	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	4.97	9.52e-07	0.000253	0.22	0.22	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
HNSC	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-4.97	9.53e-07	0.000253	-0.25	-0.22	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
HNSC	cis	rs2933343	0.729	rs813945	ENSG00000261159.1	RP11-723O4.9	4.97	9.53e-07	0.000253	0.23	0.22	IgG glycosylation;	chr3:128942094	chr3:128859716~128860526:-
HNSC	cis	rs4218	0.531	rs10431791	ENSG00000259732.1	RP11-59H7.3	-4.97	9.54e-07	0.000253	-0.28	-0.22	Social communication problems;	chr15:59055159	chr15:59121034~59133250:+
HNSC	cis	rs9650657	0.737	rs4504595	ENSG00000269918.1	AF131215.9	-4.97	9.54e-07	0.000253	-0.22	-0.22	Neuroticism;	chr8:10797995	chr8:11104691~11106704:-
HNSC	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-4.97	9.54e-07	0.000253	-0.29	-0.22	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
HNSC	cis	rs6693567	0.545	rs35705743	ENSG00000228126.1	FALEC	4.97	9.54e-07	0.000253	0.27	0.22	Migraine;	chr1:150479356	chr1:150515757~150518032:+
HNSC	cis	rs7819412	0.807	rs10105315	ENSG00000255310.2	AF131215.2	-4.97	9.55e-07	0.000253	-0.21	-0.22	Triglycerides;	chr8:11074693	chr8:11107788~11109726:-
HNSC	cis	rs1056107	0.931	rs10981332	ENSG00000225513.1	RP11-165N19.2	-4.97	9.55e-07	0.000253	-0.24	-0.22	Colorectal cancer;	chr9:112254003	chr9:112173522~112173971:-
HNSC	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.97	9.55e-07	0.000253	0.27	0.22	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.97	9.55e-07	0.000253	0.27	0.22	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
HNSC	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.97	9.55e-07	0.000253	0.27	0.22	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
HNSC	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-4.97	9.55e-07	0.000254	-0.32	-0.22	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000273009.1	RP11-352G9.1	-4.97	9.56e-07	0.000254	-0.26	-0.22	Pancreatic cancer;	chr3:196024568	chr3:195913078~195913683:-
HNSC	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	4.97	9.56e-07	0.000254	0.34	0.22	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
HNSC	cis	rs7688540	0.8	rs28531997	ENSG00000211553.1	AC253576.2	-4.97	9.56e-07	0.000254	-0.29	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:136461~136568:+
HNSC	cis	rs4761669	0.565	rs7302511	ENSG00000241556.1	RP11-490G8.1	4.97	9.56e-07	0.000254	0.23	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94795041	chr12:95467397~95467861:-
HNSC	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	4.97	9.56e-07	0.000254	0.23	0.22	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
HNSC	cis	rs12935418	0.672	rs78895138	ENSG00000261061.1	RP11-303E16.2	-4.97	9.57e-07	0.000254	-0.26	-0.22	Mean corpuscular volume;	chr16:81014820	chr16:81030770~81031485:+
HNSC	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-4.97	9.57e-07	0.000254	-0.27	-0.22	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-4.97	9.58e-07	0.000254	-0.26	-0.22	Depression;	chr6:28123153	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-4.97	9.58e-07	0.000254	-0.26	-0.22	Depression;	chr6:28124529	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-4.97	9.58e-07	0.000254	-0.26	-0.22	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-4.97	9.58e-07	0.000254	-0.26	-0.22	Depression;	chr6:28127577	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-4.97	9.58e-07	0.000254	-0.26	-0.22	Depression;	chr6:28131566	chr6:28170845~28172521:+
HNSC	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	4.97	9.58e-07	0.000254	0.22	0.22	Height;	chr5:37454091	chr5:36666214~36725195:-
HNSC	cis	rs3736485	0.808	rs28813458	ENSG00000259438.1	CTD-2650P22.1	4.97	9.59e-07	0.000254	0.23	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51654826	chr15:52010999~52019095:-
HNSC	cis	rs4873772	0.735	rs2130412	ENSG00000253330.1	RP11-697N18.3	-4.97	9.59e-07	0.000254	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47527279	chr8:47511034~47512141:-
HNSC	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-4.97	9.59e-07	0.000254	-0.22	-0.22	Height;	chr5:36789899	chr5:36666214~36725195:-
HNSC	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	4.97	9.6e-07	0.000255	0.22	0.22	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
HNSC	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-4.97	9.6e-07	0.000255	-0.23	-0.22	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
HNSC	cis	rs1971762	0.563	rs10747679	ENSG00000270175.1	RP11-793H13.11	-4.97	9.6e-07	0.000255	-0.19	-0.22	Height;	chr12:53683966	chr12:53500162~53500936:-
HNSC	cis	rs4388249	0.659	rs10078710	ENSG00000271849.1	CTC-332L22.1	4.97	9.61e-07	0.000255	0.29	0.22	Schizophrenia;	chr5:109748057	chr5:109687802~109688329:-
HNSC	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-4.97	9.62e-07	0.000255	-0.26	-0.22	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
HNSC	cis	rs12893668	0.572	rs4900591	ENSG00000269940.1	RP11-73M18.7	4.97	9.63e-07	0.000255	0.22	0.22	Reticulocyte count;	chr14:103688541	chr14:103694560~103695170:+
HNSC	cis	rs7980687	0.628	rs1609520	ENSG00000280120.1	RP11-546D6.3	-4.97	9.63e-07	0.000255	-0.19	-0.22	Head circumference (infant);Educational attainment;Height;	chr12:123251390	chr12:123152324~123153377:-
HNSC	cis	rs7615952	0.599	rs6779141	ENSG00000248787.1	RP11-666A20.4	-4.97	9.63e-07	0.000255	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:125991152	chr3:125908005~125910272:-
HNSC	cis	rs3733585	0.673	rs4235347	ENSG00000250413.1	RP11-448G15.1	4.97	9.63e-07	0.000255	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9950332	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4235348	ENSG00000250413.1	RP11-448G15.1	4.97	9.63e-07	0.000255	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9950344	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4697914	ENSG00000250413.1	RP11-448G15.1	4.97	9.63e-07	0.000255	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9950642	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.624	rs7376154	ENSG00000250413.1	RP11-448G15.1	4.97	9.63e-07	0.000255	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9950963	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.648	rs7376155	ENSG00000250413.1	RP11-448G15.1	4.97	9.63e-07	0.000255	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9950964	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000254340.1	RP11-10A14.3	-4.97	9.64e-07	0.000255	-0.28	-0.22	Mood instability;	chr8:8737594	chr8:9141424~9145435:+
HNSC	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	4.97	9.64e-07	0.000255	0.22	0.22	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	4.97	9.64e-07	0.000255	0.22	0.22	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
HNSC	cis	rs6496044	0.568	rs7166642	ENSG00000259295.5	CSPG4P12	4.97	9.64e-07	0.000256	0.26	0.22	Interstitial lung disease;	chr15:85518040	chr15:85191438~85213905:+
HNSC	cis	rs73222236	0.825	rs9833162	ENSG00000273486.1	RP11-731C17.2	4.97	9.65e-07	0.000256	0.19	0.22	Coronary artery disease;	chr3:136316895	chr3:136837338~136839021:-
HNSC	cis	rs11148252	0.532	rs9536185	ENSG00000198384.8	TPTE2P3	4.96	9.65e-07	0.000256	0.28	0.22	Lewy body disease;	chr13:52605666	chr13:52522632~52586906:+
HNSC	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-4.96	9.65e-07	0.000256	-0.25	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
HNSC	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-4.96	9.65e-07	0.000256	-0.2	-0.22	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
HNSC	cis	rs12893668	0.703	rs4906337	ENSG00000269940.1	RP11-73M18.7	4.96	9.66e-07	0.000256	0.22	0.22	Reticulocyte count;	chr14:103574077	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.703	rs7140568	ENSG00000269940.1	RP11-73M18.7	4.96	9.66e-07	0.000256	0.22	0.22	Reticulocyte count;	chr14:103575037	chr14:103694560~103695170:+
HNSC	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	4.96	9.66e-07	0.000256	0.31	0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
HNSC	cis	rs7246657	0.525	rs10410594	ENSG00000276846.1	CTD-3220F14.3	4.96	9.66e-07	0.000256	0.32	0.22	Coronary artery calcification;	chr19:36986856	chr19:37314868~37315620:-
HNSC	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-4.96	9.66e-07	0.000256	-0.28	-0.22	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
HNSC	cis	rs6693567	0.565	rs497128	ENSG00000228126.1	FALEC	-4.96	9.66e-07	0.000256	-0.27	-0.22	Migraine;	chr1:150297528	chr1:150515757~150518032:+
HNSC	cis	rs3754214	0.823	rs496203	ENSG00000228126.1	FALEC	-4.96	9.66e-07	0.000256	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr1:150297601	chr1:150515757~150518032:+
HNSC	cis	rs3754214	0.823	rs494041	ENSG00000228126.1	FALEC	-4.96	9.66e-07	0.000256	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr1:150297602	chr1:150515757~150518032:+
HNSC	cis	rs1150668	0.796	rs213236	ENSG00000219392.1	RP1-265C24.5	-4.96	9.67e-07	0.000256	-0.25	-0.22	Pubertal anthropometrics;	chr6:28356620	chr6:28115628~28116551:+
HNSC	cis	rs7535099	0.954	rs10889562	ENSG00000224570.1	RP11-430H12.2	-4.96	9.67e-07	0.000256	-0.29	-0.22	Blood protein levels;	chr1:65564762	chr1:65576129~65578380:-
HNSC	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-4.96	9.68e-07	0.000256	-0.23	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000254340.1	RP11-10A14.3	4.96	9.68e-07	0.000256	0.27	0.22	Mood instability;	chr8:8278888	chr8:9141424~9145435:+
HNSC	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.96	9.68e-07	0.000256	0.34	0.22	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
HNSC	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-4.96	9.69e-07	0.000256	-0.28	-0.22	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-4.96	9.69e-07	0.000256	-0.28	-0.22	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-4.96	9.69e-07	0.000256	-0.28	-0.22	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
HNSC	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-4.96	9.69e-07	0.000256	-0.23	-0.22	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
HNSC	cis	rs3806843	0.735	rs2563306	ENSG00000202515.1	VTRNA1-3	4.96	9.69e-07	0.000257	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.735	rs813897	ENSG00000202515.1	VTRNA1-3	4.96	9.69e-07	0.000257	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.676	rs2563304	ENSG00000202515.1	VTRNA1-3	4.96	9.69e-07	0.000257	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr5:140726158~140726246:+
HNSC	cis	rs5758659	0.819	rs134871	ENSG00000227370.1	RP4-669P10.19	-4.96	9.7e-07	0.000257	-0.21	-0.22	Cognitive function;	chr22:42256710	chr22:42132543~42132998:+
HNSC	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	4.96	9.7e-07	0.000257	0.23	0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
HNSC	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	4.96	9.7e-07	0.000257	0.23	0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
HNSC	cis	rs9300255	0.782	rs12809602	ENSG00000280120.1	RP11-546D6.3	-4.96	9.7e-07	0.000257	-0.21	-0.22	Neutrophil percentage of white cells;	chr12:123284369	chr12:123152324~123153377:-
HNSC	cis	rs10504130	0.696	rs75833886	ENSG00000253844.1	RP11-546K22.1	-4.96	9.71e-07	0.000257	-0.34	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51961458~52022974:+
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	4.96	9.71e-07	0.000257	0.21	0.22	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
HNSC	cis	rs12893668	0.603	rs12896171	ENSG00000269940.1	RP11-73M18.7	4.96	9.71e-07	0.000257	0.22	0.22	Reticulocyte count;	chr14:103669629	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.572	rs7148857	ENSG00000269940.1	RP11-73M18.7	4.96	9.71e-07	0.000257	0.22	0.22	Reticulocyte count;	chr14:103676900	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.572	rs11540512	ENSG00000269940.1	RP11-73M18.7	4.96	9.71e-07	0.000257	0.22	0.22	Reticulocyte count;	chr14:103681040	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.572	rs35011804	ENSG00000269940.1	RP11-73M18.7	4.96	9.71e-07	0.000257	0.22	0.22	Reticulocyte count;	chr14:103685063	chr14:103694560~103695170:+
HNSC	cis	rs7824557	0.836	rs1435278	ENSG00000269918.1	AF131215.9	-4.96	9.72e-07	0.000257	-0.22	-0.22	Retinal vascular caliber;	chr8:11265520	chr8:11104691~11106704:-
HNSC	cis	rs8180040	0.966	rs7628631	ENSG00000276925.1	RP11-708J19.3	4.96	9.72e-07	0.000257	0.22	0.22	Colorectal cancer;	chr3:47519373	chr3:47469777~47469987:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000179406.6	LINC00174	-4.96	9.73e-07	0.000257	-0.48	-0.22	Diabetic kidney disease;	chr7:66086239	chr7:66376044~66401338:-
HNSC	cis	rs2976388	0.692	rs1435453	ENSG00000253741.1	CTD-2292P10.4	-4.96	9.73e-07	0.000257	-0.22	-0.22	Urinary tract infection frequency;	chr8:142699357	chr8:142702252~142726973:-
HNSC	cis	rs10129255	1	rs10137758	ENSG00000224373.3	IGHV4-59	4.96	9.73e-07	0.000258	0.14	0.22	Kawasaki disease;	chr14:106697673	chr14:106627249~106627825:-
HNSC	cis	rs6693567	0.565	rs1260407	ENSG00000228126.1	FALEC	4.96	9.74e-07	0.000258	0.27	0.22	Migraine;	chr1:150333654	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs3125808	ENSG00000228126.1	FALEC	4.96	9.74e-07	0.000258	0.27	0.22	Migraine;	chr1:150341796	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.526	rs698918	ENSG00000228126.1	FALEC	4.96	9.74e-07	0.000258	0.27	0.22	Migraine;	chr1:150347286	chr1:150515757~150518032:+
HNSC	cis	rs6928977	0.863	rs2746430	ENSG00000231028.7	LINC00271	4.96	9.74e-07	0.000258	0.26	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352154	chr6:135497801~135716055:+
HNSC	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-4.96	9.74e-07	0.000258	-0.27	-0.22	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
HNSC	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	4.96	9.74e-07	0.000258	0.25	0.22	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
HNSC	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	4.96	9.75e-07	0.000258	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
HNSC	cis	rs860295	0.702	rs11264397	ENSG00000203761.5	MSTO2P	-4.96	9.75e-07	0.000258	-0.18	-0.22	Body mass index;	chr1:155641694	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.51	rs6828454	ENSG00000273257.1	RP11-177J6.1	4.96	9.76e-07	0.000258	0.26	0.22	Height;	chr4:55424329	chr4:55387949~55388271:+
HNSC	cis	rs1707322	1	rs34694458	ENSG00000234329.1	RP11-767N6.2	4.96	9.76e-07	0.000258	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45651039~45651826:-
HNSC	cis	rs72843506	0.586	rs76886618	ENSG00000261033.1	RP11-209D14.2	4.96	9.76e-07	0.000258	0.4	0.22	Schizophrenia;	chr17:19975483	chr17:20008051~20009234:-
HNSC	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	4.96	9.77e-07	0.000258	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
HNSC	cis	rs442309	0.574	rs7895364	ENSG00000238280.1	RP11-436D10.3	-4.96	9.78e-07	0.000259	-0.28	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62725053	chr10:62793562~62805887:-
HNSC	cis	rs3733585	0.673	rs7376505	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951120	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs7377578	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951151	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.624	rs76574510	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951628	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.577	rs5014939	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951629	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4560411	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951737	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.673	rs4407505	ENSG00000250413.1	RP11-448G15.1	4.96	9.78e-07	0.000259	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9951743	chr4:10006482~10009725:+
HNSC	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-4.96	9.78e-07	0.000259	-0.26	-0.22	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
HNSC	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.96	9.78e-07	0.000259	0.25	0.22	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
HNSC	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-4.96	9.78e-07	0.000259	-0.26	-0.22	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-4.96	9.79e-07	0.000259	-0.28	-0.22	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
HNSC	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-4.96	9.79e-07	0.000259	-0.28	-0.22	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
HNSC	cis	rs11247915	0.583	rs66569416	ENSG00000236782.4	RP11-96L14.7	-4.96	9.8e-07	0.000259	-0.26	-0.22	Obesity-related traits;	chr1:26333246	chr1:26169947~26171821:-
HNSC	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-4.96	9.8e-07	0.000259	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
HNSC	cis	rs2933343	0.679	rs789229	ENSG00000261159.1	RP11-723O4.9	4.96	9.8e-07	0.000259	0.22	0.22	IgG glycosylation;	chr3:128883683	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs789230	ENSG00000261159.1	RP11-723O4.9	4.96	9.8e-07	0.000259	0.22	0.22	IgG glycosylation;	chr3:128883715	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.661	rs2630259	ENSG00000261159.1	RP11-723O4.9	4.96	9.8e-07	0.000259	0.22	0.22	IgG glycosylation;	chr3:128887479	chr3:128859716~128860526:-
HNSC	cis	rs2933343	0.729	rs6790091	ENSG00000261159.1	RP11-723O4.9	4.96	9.8e-07	0.000259	0.22	0.22	IgG glycosylation;	chr3:128889908	chr3:128859716~128860526:-
HNSC	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	4.96	9.81e-07	0.000259	0.41	0.22	Depression;	chr6:28333418	chr6:28943877~28944537:+
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000254153.1	CTA-398F10.2	4.96	9.81e-07	0.000259	0.25	0.22	Systolic blood pressure;	chr8:8290748	chr8:8456909~8461337:-
HNSC	cis	rs8031584	1	rs12906054	ENSG00000260382.1	RP11-540B6.2	4.96	9.81e-07	0.000259	0.3	0.22	Huntington's disease progression;	chr15:30999820	chr15:30882267~30883231:-
HNSC	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	4.96	9.82e-07	0.00026	0.28	0.22	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
HNSC	cis	rs9329221	0.905	rs4841329	ENSG00000269918.1	AF131215.9	-4.96	9.82e-07	0.00026	-0.22	-0.22	Neuroticism;	chr8:10395588	chr8:11104691~11106704:-
HNSC	cis	rs2286503	0.901	rs10950922	ENSG00000226329.2	AC005682.6	4.96	9.82e-07	0.00026	0.27	0.22	Fibrinogen;	chr7:22814387	chr7:22863874~22881350:-
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	4.96	9.82e-07	0.00026	0.25	0.22	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
HNSC	cis	rs287982	0.611	rs75809337	ENSG00000269973.1	RP11-95D17.1	-4.96	9.83e-07	0.00026	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9837684	chr2:9936360~9939590:+
HNSC	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	4.96	9.83e-07	0.00026	0.36	0.22	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	4.96	9.83e-07	0.00026	0.36	0.22	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
HNSC	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	4.96	9.83e-07	0.00026	0.36	0.22	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
HNSC	cis	rs9329221	0.617	rs615632	ENSG00000233609.3	RP11-62H7.2	-4.96	9.83e-07	0.00026	-0.21	-0.22	Neuroticism;	chr8:9938811	chr8:8961200~8979025:+
HNSC	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-4.96	9.83e-07	0.00026	-0.23	-0.22	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
HNSC	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-4.96	9.83e-07	0.00026	-0.21	-0.22	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
HNSC	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-4.96	9.83e-07	0.00026	-0.22	-0.22	Height;	chr5:36791710	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-4.96	9.83e-07	0.00026	-0.22	-0.22	Height;	chr5:36795628	chr5:36666214~36725195:-
HNSC	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-4.96	9.85e-07	0.00026	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
HNSC	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.96	9.86e-07	0.000261	0.26	0.22	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
HNSC	cis	rs116095464	1	rs2015774	ENSG00000277812.1	AC021087.1	4.96	9.86e-07	0.000261	0.46	0.22	Breast cancer;	chr5:312843	chr5:262769~262881:+
HNSC	cis	rs73198271	0.74	rs10105920	ENSG00000173295.6	FAM86B3P	4.96	9.87e-07	0.000261	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8228595~8244865:+
HNSC	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	4.96	9.88e-07	0.000261	0.25	0.22	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
HNSC	cis	rs10504130	0.696	rs17212214	ENSG00000253844.1	RP11-546K22.1	4.96	9.88e-07	0.000261	0.32	0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51961458~52022974:+
HNSC	cis	rs656319	0.58	rs13279701	ENSG00000269918.1	AF131215.9	-4.96	9.89e-07	0.000261	-0.23	-0.22	Myopia (pathological);	chr8:10111940	chr8:11104691~11106704:-
HNSC	cis	rs9291683	0.526	rs6827785	ENSG00000250413.1	RP11-448G15.1	-4.96	9.89e-07	0.000261	-0.27	-0.22	Bone mineral density;	chr4:10016581	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-4.96	9.89e-07	0.000261	-0.3	-0.22	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000254153.1	CTA-398F10.2	-4.96	9.89e-07	0.000261	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9044411	chr8:8456909~8461337:-
HNSC	cis	rs4664293	0.647	rs10202352	ENSG00000226266.5	AC009961.3	-4.96	9.9e-07	0.000261	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159571097	chr2:159670708~159712435:-
HNSC	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	4.96	9.9e-07	0.000261	0.49	0.22	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
HNSC	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-4.96	9.9e-07	0.000261	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
HNSC	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-4.96	9.9e-07	0.000262	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
HNSC	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	4.96	9.9e-07	0.000262	0.29	0.22	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
HNSC	cis	rs9329221	0.905	rs4610752	ENSG00000269918.1	AF131215.9	-4.96	9.9e-07	0.000262	-0.22	-0.22	Neuroticism;	chr8:10391452	chr8:11104691~11106704:-
HNSC	cis	rs8068318	1	rs8068318	ENSG00000267280.4	TBX2-AS1	-4.96	9.9e-07	0.000262	-0.23	-0.22	Creatinine levels;	chr17:61406405	chr17:61393456~61411555:-
HNSC	cis	rs4664293	0.647	rs10196064	ENSG00000226266.5	AC009961.3	-4.96	9.91e-07	0.000262	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159569454	chr2:159670708~159712435:-
HNSC	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-4.96	9.91e-07	0.000262	-0.21	-0.22	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
HNSC	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-4.96	9.91e-07	0.000262	-0.21	-0.22	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
HNSC	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	4.96	9.91e-07	0.000262	0.28	0.22	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
HNSC	cis	rs9329221	0.62	rs6601427	ENSG00000269918.1	AF131215.9	-4.96	9.91e-07	0.000262	-0.21	-0.22	Neuroticism;	chr8:10298515	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	4.96	9.92e-07	0.000262	0.29	0.22	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
HNSC	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.96	9.92e-07	0.000262	-0.25	-0.22	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
HNSC	cis	rs6964587	1	rs7811564	ENSG00000188693.7	CYP51A1-AS1	-4.96	9.92e-07	0.000262	-0.24	-0.22	Breast cancer;	chr7:92034050	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs7781221	ENSG00000188693.7	CYP51A1-AS1	-4.96	9.92e-07	0.000262	-0.24	-0.22	Breast cancer;	chr7:92035331	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2285333	ENSG00000188693.7	CYP51A1-AS1	-4.96	9.92e-07	0.000262	-0.24	-0.22	Breast cancer;	chr7:92038378	chr7:92134604~92180725:+
HNSC	cis	rs7000734	0.916	rs7822998	ENSG00000245080.5	RP11-320N21.1	-4.96	9.93e-07	0.000262	-0.31	-0.22	Radiation response;	chr8:95108337	chr8:95066808~95073182:-
HNSC	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-4.96	9.93e-07	0.000262	-0.28	-0.22	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
HNSC	cis	rs2834288	0.535	rs9982605	ENSG00000273102.1	AP000569.9	4.96	9.93e-07	0.000262	0.25	0.22	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33967101~33968573:-
HNSC	cis	rs1008375	0.931	rs7672369	ENSG00000249502.1	AC006160.5	-4.96	9.93e-07	0.000262	-0.24	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17603202	chr4:17587467~17614571:-
HNSC	cis	rs853679	0.769	rs17720293	ENSG00000226314.6	ZNF192P1	-4.96	9.94e-07	0.000262	-0.37	-0.22	Depression;	chr6:28246920	chr6:28161781~28169594:+
HNSC	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-4.96	9.95e-07	0.000263	-0.2	-0.22	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
HNSC	cis	rs72949976	0.584	rs4673729	ENSG00000270659.1	RP11-105N14.1	-4.96	9.95e-07	0.000263	-0.22	-0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213159086	chr2:213152970~213153659:+
HNSC	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-4.96	9.95e-07	0.000263	-0.35	-0.22	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
HNSC	cis	rs9300255	0.566	rs1716169	ENSG00000280120.1	RP11-546D6.3	4.96	9.95e-07	0.000263	0.22	0.22	Neutrophil percentage of white cells;	chr12:123232383	chr12:123152324~123153377:-
HNSC	cis	rs7000734	0.958	rs4392868	ENSG00000245080.5	RP11-320N21.1	-4.96	9.96e-07	0.000263	-0.31	-0.22	Radiation response;	chr8:95107844	chr8:95066808~95073182:-
HNSC	cis	rs4853525	0.59	rs13414554	ENSG00000235852.1	AC005540.3	4.96	9.96e-07	0.000263	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929215	chr2:190880797~190882059:-
HNSC	cis	rs9840812	0.769	rs576771	ENSG00000239213.4	NCK1-AS1	4.96	9.97e-07	0.000263	0.2	0.22	Fibrinogen levels;	chr3:136270450	chr3:136841726~136862054:-
HNSC	cis	rs4256159	1	rs73180609	ENSG00000228956.7	SATB1-AS1	4.96	9.97e-07	0.000263	0.38	0.22	Crohn's disease;Inflammatory bowel disease;	chr3:18770480	chr3:18445024~18920401:+
HNSC	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.96	9.97e-07	0.000263	-0.25	-0.22	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
HNSC	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	4.96	9.97e-07	0.000263	0.32	0.22	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	4.96	9.97e-07	0.000263	0.32	0.22	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
HNSC	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-4.96	9.98e-07	0.000263	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
HNSC	cis	rs13113518	0.51	rs3749473	ENSG00000273257.1	RP11-177J6.1	4.96	9.98e-07	0.000263	0.26	0.22	Height;	chr4:55428461	chr4:55387949~55388271:+
HNSC	cis	rs12468226	1	rs76021735	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202511476	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs57080353	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202511824	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.81	rs3736578	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202519989	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs116439150	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202523814	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs12467409	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202529625	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.81	rs77090459	ENSG00000226261.1	AC064836.3	4.96	9.98e-07	0.000263	0.34	0.22	Urate levels;	chr2:202542132	chr2:202336024~202336727:-
HNSC	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	4.96	9.98e-07	0.000263	0.27	0.22	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
HNSC	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-4.96	9.98e-07	0.000263	-0.28	-0.22	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-4.96	9.98e-07	0.000263	-0.28	-0.22	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
HNSC	cis	rs1799949	0.929	rs799905	ENSG00000236383.6	LINC00854	-4.96	9.98e-07	0.000263	-0.21	-0.22	Menopause (age at onset);	chr17:43125170	chr17:43216941~43305976:-
HNSC	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	4.96	9.99e-07	0.000264	0.49	0.22	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
HNSC	cis	rs4819052	0.851	rs1999333	ENSG00000223768.1	LINC00205	-4.96	1e-06	0.000264	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45293285~45297354:+
HNSC	cis	rs7824557	0.778	rs3808502	ENSG00000255310.2	AF131215.2	4.96	1e-06	0.000264	0.21	0.22	Retinal vascular caliber;	chr8:11321949	chr8:11107788~11109726:-
HNSC	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-4.96	1e-06	0.000264	-0.22	-0.22	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
HNSC	cis	rs9300255	0.739	rs12824957	ENSG00000280120.1	RP11-546D6.3	-4.96	1e-06	0.000264	-0.22	-0.22	Neutrophil percentage of white cells;	chr12:123265681	chr12:123152324~123153377:-
HNSC	cis	rs9650657	0.513	rs7005884	ENSG00000269918.1	AF131215.9	-4.96	1e-06	0.000264	-0.21	-0.22	Neuroticism;	chr8:10938962	chr8:11104691~11106704:-
HNSC	cis	rs2933343	0.729	rs1680781	ENSG00000261159.1	RP11-723O4.9	4.96	1e-06	0.000264	0.22	0.22	IgG glycosylation;	chr3:128893987	chr3:128859716~128860526:-
HNSC	cis	rs3806843	0.735	rs2563333	ENSG00000202515.1	VTRNA1-3	4.96	1e-06	0.000264	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr5:140726158~140726246:+
HNSC	cis	rs11098499	0.739	rs2203039	ENSG00000249244.1	RP11-548H18.2	-4.96	1e-06	0.000265	-0.26	-0.22	Corneal astigmatism;	chr4:119211192	chr4:119391831~119395335:-
HNSC	cis	rs5758659	0.714	rs6002607	ENSG00000227370.1	RP4-669P10.19	4.96	1e-06	0.000265	0.22	0.22	Cognitive function;	chr22:42100502	chr22:42132543~42132998:+
HNSC	cis	rs6693567	0.545	rs7553647	ENSG00000228126.1	FALEC	4.96	1e-06	0.000265	0.27	0.22	Migraine;	chr1:150500190	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.507	rs9436120	ENSG00000228126.1	FALEC	4.96	1e-06	0.000265	0.27	0.22	Migraine;	chr1:150500608	chr1:150515757~150518032:+
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	4.96	1e-06	0.000265	0.18	0.22	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
HNSC	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	4.96	1.01e-06	0.000265	0.26	0.22	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
HNSC	cis	rs287982	0.611	rs80268780	ENSG00000269973.1	RP11-95D17.1	-4.96	1.01e-06	0.000265	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9840948	chr2:9936360~9939590:+
HNSC	cis	rs752590	0.806	rs874898	ENSG00000274877.1	RP11-65I12.1	-4.96	1.01e-06	0.000265	-0.3	-0.22	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113237595~113240825:+
HNSC	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-4.96	1.01e-06	0.000265	-0.27	-0.22	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000204709.4	LINC01556	-4.96	1.01e-06	0.000265	-0.31	-0.22	Depression;	chr6:28167882	chr6:28943877~28944537:+
HNSC	cis	rs860295	0.595	rs490498	ENSG00000203761.5	MSTO2P	4.96	1.01e-06	0.000265	0.17	0.22	Body mass index;	chr1:155911161	chr1:155745829~155750137:+
HNSC	cis	rs10504130	0.569	rs34213209	ENSG00000272024.1	RP11-546K22.3	-4.96	1.01e-06	0.000266	-0.32	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51950284~51950690:+
HNSC	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	4.96	1.01e-06	0.000266	0.28	0.22	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
HNSC	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	4.96	1.01e-06	0.000266	0.21	0.22	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
HNSC	cis	rs7085104	0.572	rs284860	ENSG00000236937.2	PTGES3P4	-4.96	1.01e-06	0.000266	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102845595~102845950:+
HNSC	cis	rs17345786	1	rs7641261	ENSG00000244119.1	PDCL3P4	4.96	1.01e-06	0.000266	0.25	0.22	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101712472~101713191:+
HNSC	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	4.96	1.01e-06	0.000267	0.25	0.22	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	4.96	1.01e-06	0.000267	0.25	0.22	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
HNSC	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-4.96	1.01e-06	0.000267	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
HNSC	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-4.96	1.01e-06	0.000267	-0.25	-0.22	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-4.96	1.01e-06	0.000267	-0.25	-0.22	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-4.96	1.01e-06	0.000267	-0.25	-0.22	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-4.96	1.01e-06	0.000267	-0.25	-0.22	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
HNSC	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-4.95	1.01e-06	0.000267	-0.26	-0.22	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
HNSC	cis	rs5758659	0.716	rs86669	ENSG00000227370.1	RP4-669P10.19	-4.95	1.01e-06	0.000267	-0.21	-0.22	Cognitive function;	chr22:42284794	chr22:42132543~42132998:+
HNSC	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	4.95	1.01e-06	0.000267	0.19	0.22	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
HNSC	cis	rs916888	0.773	rs199534	ENSG00000260075.1	NSFP1	-4.95	1.01e-06	0.000267	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.773	rs199533	ENSG00000260075.1	NSFP1	-4.95	1.01e-06	0.000267	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46372855~46487141:+
HNSC	cis	rs5758511	0.514	rs5758626	ENSG00000226450.2	CYP2D8P	4.95	1.01e-06	0.000267	0.22	0.22	Birth weight;	chr22:42176357	chr22:42149886~42155001:-
HNSC	cis	rs11976180	1	rs2961117	ENSG00000273234.1	OR2A13P	-4.95	1.01e-06	0.000267	-0.25	-0.22	Obesity-related traits;	chr7:144058160	chr7:144142009~144142938:+
HNSC	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-4.95	1.01e-06	0.000267	-0.25	-0.22	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
HNSC	cis	rs12893668	0.703	rs35026580	ENSG00000269940.1	RP11-73M18.7	4.95	1.02e-06	0.000267	0.22	0.22	Reticulocyte count;	chr14:103576416	chr14:103694560~103695170:+
HNSC	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	4.95	1.02e-06	0.000268	0.25	0.22	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.684	rs474892	ENSG00000173295.6	FAM86B3P	-4.95	1.02e-06	0.000268	-0.26	-0.22	Mood instability;	chr8:8739221	chr8:8228595~8244865:+
HNSC	cis	rs9990333	0.562	rs56038600	ENSG00000231464.1	AC024937.4	4.95	1.02e-06	0.000268	0.24	0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195996738~195998233:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000204709.4	LINC01556	4.95	1.02e-06	0.000268	0.3	0.22	Depression;	chr6:28079011	chr6:28943877~28944537:+
HNSC	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	4.95	1.02e-06	0.000268	0.24	0.22	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
HNSC	cis	rs4388249	1	rs12654396	ENSG00000271849.1	CTC-332L22.1	-4.95	1.02e-06	0.000268	-0.34	-0.22	Schizophrenia;	chr5:109700097	chr5:109687802~109688329:-
HNSC	cis	rs9907295	0.685	rs9909050	ENSG00000270977.1	AC015849.16	-4.95	1.02e-06	0.000268	-0.38	-0.22	Fibroblast growth factor basic levels;	chr17:35887129	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs59338510	ENSG00000270977.1	AC015849.16	-4.95	1.02e-06	0.000268	-0.38	-0.22	Fibroblast growth factor basic levels;	chr17:35888098	chr17:35893707~35911023:-
HNSC	cis	rs6951245	0.882	rs56048221	ENSG00000225146.1	AC073957.15	-4.95	1.02e-06	0.000268	-0.35	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052897	chr7:1029025~1043891:+
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Depression;	chr6:28096855	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Depression;	chr6:28099759	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Depression;	chr6:28100648	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Depression;	chr6:28104824	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.000268	-0.26	-0.22	Depression;	chr6:28107222	chr6:28170845~28172521:+
HNSC	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	4.95	1.02e-06	0.000268	0.26	0.22	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
HNSC	cis	rs11250098	0.51	rs4840525	ENSG00000269918.1	AF131215.9	-4.95	1.02e-06	0.000269	-0.22	-0.22	Morning vs. evening chronotype;	chr8:10908125	chr8:11104691~11106704:-
HNSC	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	4.95	1.02e-06	0.000269	0.25	0.22	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
HNSC	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-4.95	1.02e-06	0.000269	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
HNSC	cis	rs6693567	0.545	rs5011187	ENSG00000228126.1	FALEC	4.95	1.02e-06	0.000269	0.27	0.22	Migraine;	chr1:150450285	chr1:150515757~150518032:+
HNSC	cis	rs1707322	0.963	rs6429581	ENSG00000234329.1	RP11-767N6.2	4.95	1.02e-06	0.000269	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45651039~45651826:-
HNSC	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	4.95	1.02e-06	0.000269	0.28	0.22	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
HNSC	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	4.95	1.02e-06	0.000269	0.25	0.22	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
HNSC	cis	rs3733585	0.699	rs6449202	ENSG00000250413.1	RP11-448G15.1	4.95	1.02e-06	0.000269	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9972419	chr4:10006482~10009725:+
HNSC	cis	rs7824557	0.767	rs6985146	ENSG00000255310.2	AF131215.2	4.95	1.02e-06	0.000269	0.21	0.22	Retinal vascular caliber;	chr8:11313212	chr8:11107788~11109726:-
HNSC	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-4.95	1.02e-06	0.000269	-0.28	-0.22	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
HNSC	cis	rs916888	0.687	rs199456	ENSG00000260075.1	NSFP1	-4.95	1.02e-06	0.00027	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46372855~46487141:+
HNSC	cis	rs3806843	0.735	rs801180	ENSG00000202515.1	VTRNA1-3	4.95	1.02e-06	0.00027	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr5:140726158~140726246:+
HNSC	cis	rs6693567	0.565	rs834235	ENSG00000228126.1	FALEC	4.95	1.02e-06	0.00027	0.27	0.22	Migraine;	chr1:150389678	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs834237	ENSG00000228126.1	FALEC	4.95	1.02e-06	0.00027	0.27	0.22	Migraine;	chr1:150391454	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs2264417	ENSG00000228126.1	FALEC	4.95	1.02e-06	0.00027	0.27	0.22	Migraine;	chr1:150396025	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs1262432	ENSG00000228126.1	FALEC	4.95	1.02e-06	0.00027	0.27	0.22	Migraine;	chr1:150399363	chr1:150515757~150518032:+
HNSC	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-4.95	1.02e-06	0.00027	-0.4	-0.22	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
HNSC	cis	rs17428076	0.958	rs72890842	ENSG00000228389.1	AC068039.4	-4.95	1.03e-06	0.00027	-0.28	-0.22	Myopia;	chr2:171978369	chr2:171773482~171775844:+
HNSC	cis	rs9863	0.898	rs11057400	ENSG00000269938.1	RP11-214K3.20	-4.95	1.03e-06	0.00027	-0.27	-0.22	White blood cell count;	chr12:123940602	chr12:123968023~123968579:-
HNSC	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-4.95	1.03e-06	0.00027	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-4.95	1.03e-06	0.00027	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
HNSC	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-4.95	1.03e-06	0.00027	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-4.95	1.03e-06	0.00027	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
HNSC	cis	rs72615157	0.629	rs55839153	ENSG00000078319.8	PMS2P1	-4.95	1.03e-06	0.00027	-0.29	-0.22	Lung function (FEV1/FVC);	chr7:100154943	chr7:100320992~100341908:-
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000280411.1	IGHV1-69-2	-4.95	1.03e-06	0.00027	-0.22	-0.22	Alzheimer's disease (late onset);	chr14:106700213	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.532	rs4504231	ENSG00000249244.1	RP11-548H18.2	4.95	1.03e-06	0.00027	0.28	0.22	Corneal astigmatism;	chr4:119665736	chr4:119391831~119395335:-
HNSC	cis	rs2243480	1	rs313832	ENSG00000179406.6	LINC00174	-4.95	1.03e-06	0.000271	-0.47	-0.22	Diabetic kidney disease;	chr7:66085904	chr7:66376044~66401338:-
HNSC	cis	rs4664293	0.647	rs6711049	ENSG00000226266.5	AC009961.3	-4.95	1.03e-06	0.000271	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159584634	chr2:159670708~159712435:-
HNSC	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-4.95	1.03e-06	0.000271	-0.28	-0.22	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
HNSC	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-4.95	1.03e-06	0.000271	-0.21	-0.22	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-4.95	1.03e-06	0.000271	-0.21	-0.22	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
HNSC	cis	rs933688	1	rs12655973	ENSG00000281357.1	ARRDC3-AS1	4.95	1.03e-06	0.000271	0.32	0.22	Smoking behavior;	chr5:91440720	chr5:91380349~91439085:+
HNSC	cis	rs8177876	0.596	rs2317087	ENSG00000261061.1	RP11-303E16.2	4.95	1.03e-06	0.000271	0.39	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104753	chr16:81030770~81031485:+
HNSC	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	4.95	1.03e-06	0.000271	0.19	0.22	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
HNSC	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	4.95	1.03e-06	0.000271	0.19	0.22	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
HNSC	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-4.95	1.03e-06	0.000272	-0.28	-0.22	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
HNSC	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-4.95	1.03e-06	0.000272	-0.22	-0.22	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
HNSC	cis	rs4873772	0.735	rs12544329	ENSG00000253330.1	RP11-697N18.3	-4.95	1.04e-06	0.000272	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47511278	chr8:47511034~47512141:-
HNSC	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	4.95	1.04e-06	0.000272	0.27	0.22	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
HNSC	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-4.95	1.04e-06	0.000273	-0.34	-0.22	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
HNSC	cis	rs7512898	0.51	rs10920054	ENSG00000260088.1	RP11-92G12.3	-4.95	1.04e-06	0.000273	-0.28	-0.22	Electrocardiographic conduction measures;	chr1:200861312	chr1:200669507~200694250:+
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000224373.3	IGHV4-59	-4.95	1.04e-06	0.000273	-0.13	-0.22	Kawasaki disease;	chr14:106683806	chr14:106627249~106627825:-
HNSC	cis	rs36093844	0.8	rs75203358	ENSG00000279742.1	RP11-700A24.1	-4.95	1.04e-06	0.000273	-0.32	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856347	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.8	rs79349553	ENSG00000279742.1	RP11-700A24.1	-4.95	1.04e-06	0.000273	-0.32	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856793	chr11:85852557~85854943:-
HNSC	cis	rs3806843	0.766	rs2251860	ENSG00000202515.1	VTRNA1-3	4.95	1.04e-06	0.000273	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.766	rs702397	ENSG00000202515.1	VTRNA1-3	4.95	1.04e-06	0.000273	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.801	rs801171	ENSG00000202515.1	VTRNA1-3	4.95	1.04e-06	0.000273	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr5:140726158~140726246:+
HNSC	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-4.95	1.04e-06	0.000273	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-4.95	1.04e-06	0.000273	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
HNSC	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	4.95	1.04e-06	0.000273	0.28	0.22	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
HNSC	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-4.95	1.04e-06	0.000273	-0.18	-0.22	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000254174.1	IGHV1-12	4.95	1.04e-06	0.000273	0.19	0.22	Alzheimer's disease (late onset);	chr14:106676559	chr14:106122420~106122709:-
HNSC	cis	rs17428076	0.793	rs3770449	ENSG00000228389.1	AC068039.4	-4.95	1.04e-06	0.000273	-0.27	-0.22	Myopia;	chr2:171835538	chr2:171773482~171775844:+
HNSC	cis	rs2286503	1	rs2286498	ENSG00000226329.2	AC005682.6	-4.95	1.04e-06	0.000273	-0.27	-0.22	Fibrinogen;	chr7:22817885	chr7:22863874~22881350:-
HNSC	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	4.95	1.04e-06	0.000273	0.33	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
HNSC	cis	rs860295	0.702	rs3738590	ENSG00000203761.5	MSTO2P	-4.95	1.04e-06	0.000273	-0.17	-0.22	Body mass index;	chr1:155660961	chr1:155745829~155750137:+
HNSC	cis	rs6964833	0.935	rs34762099	ENSG00000184616.8	AC004166.6	4.95	1.04e-06	0.000273	0.28	0.22	Menarche (age at onset);	chr7:74636378	chr7:74906673~74913256:-
HNSC	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000273	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
HNSC	cis	rs9329221	0.905	rs28712068	ENSG00000255310.2	AF131215.2	-4.95	1.04e-06	0.000273	-0.21	-0.22	Neuroticism;	chr8:10393635	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-4.95	1.04e-06	0.000274	-0.26	-0.22	Depression;	chr6:28108492	chr6:28170845~28172521:+
HNSC	cis	rs3805389	0.504	rs13434995	ENSG00000273257.1	RP11-177J6.1	-4.95	1.04e-06	0.000274	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55601047	chr4:55387949~55388271:+
HNSC	cis	rs761746	0.542	rs7290856	ENSG00000236132.1	CTA-440B3.1	-4.95	1.04e-06	0.000274	-0.28	-0.22	Intelligence;	chr22:31834930	chr22:31816379~31817491:-
HNSC	cis	rs2286503	0.839	rs2270105	ENSG00000226329.2	AC005682.6	4.95	1.04e-06	0.000274	0.28	0.22	Fibrinogen;	chr7:22822848	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs2270103	ENSG00000226329.2	AC005682.6	4.95	1.04e-06	0.000274	0.28	0.22	Fibrinogen;	chr7:22823103	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs10276099	ENSG00000226329.2	AC005682.6	4.95	1.04e-06	0.000274	0.28	0.22	Fibrinogen;	chr7:22823331	chr7:22863874~22881350:-
HNSC	cis	rs8040855	0.599	rs6496800	ENSG00000259774.1	RP11-182J1.13	-4.95	1.04e-06	0.000274	-0.26	-0.22	Bulimia nervosa;	chr15:85185055	chr15:84422618~84425882:+
HNSC	cis	rs9840812	0.769	rs534944	ENSG00000273486.1	RP11-731C17.2	4.95	1.04e-06	0.000274	0.2	0.22	Fibrinogen levels;	chr3:136242189	chr3:136837338~136839021:-
HNSC	cis	rs2235642	0.533	rs9922661	ENSG00000280231.1	LA16c-380F5.3	-4.95	1.04e-06	0.000274	-0.3	-0.22	Coronary artery disease;	chr16:1555162	chr16:1553655~1554130:-
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000274576.2	IGHV2-70	-4.95	1.04e-06	0.000274	-0.25	-0.22	Alzheimer's disease (late onset);	chr14:106767918	chr14:106770577~106771020:-
HNSC	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-4.95	1.04e-06	0.000274	-0.23	-0.22	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
HNSC	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	4.95	1.04e-06	0.000274	0.28	0.22	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
HNSC	cis	rs6693567	0.565	rs578353	ENSG00000228126.1	FALEC	4.95	1.04e-06	0.000274	0.27	0.22	Migraine;	chr1:150315443	chr1:150515757~150518032:+
HNSC	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	4.95	1.04e-06	0.000274	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
HNSC	cis	rs1056107	0.898	rs940592	ENSG00000225513.1	RP11-165N19.2	-4.95	1.05e-06	0.000274	-0.24	-0.22	Colorectal cancer;	chr9:112255785	chr9:112173522~112173971:-
HNSC	cis	rs853679	0.546	rs13214023	ENSG00000219392.1	RP1-265C24.5	4.95	1.05e-06	0.000274	0.41	0.22	Depression;	chr6:28364364	chr6:28115628~28116551:+
HNSC	cis	rs9650657	0.707	rs4593498	ENSG00000269918.1	AF131215.9	-4.95	1.05e-06	0.000275	-0.22	-0.22	Neuroticism;	chr8:10797960	chr8:11104691~11106704:-
HNSC	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	4.95	1.05e-06	0.000275	0.3	0.22	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	4.95	1.05e-06	0.000275	0.27	0.22	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	4.95	1.05e-06	0.000275	0.27	0.22	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
HNSC	cis	rs853679	0.556	rs13200214	ENSG00000204709.4	LINC01556	4.95	1.05e-06	0.000275	0.47	0.22	Depression;	chr6:28049472	chr6:28943877~28944537:+
HNSC	cis	rs13126694	0.633	rs4388135	ENSG00000248429.4	RP11-597D13.9	4.95	1.05e-06	0.000275	0.26	0.22	Blood osmolality (transformed sodium);	chr4:158093301	chr4:158170752~158202877:+
HNSC	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	4.95	1.05e-06	0.000275	0.29	0.22	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
HNSC	cis	rs3805389	0.504	rs1873091	ENSG00000273257.1	RP11-177J6.1	-4.95	1.05e-06	0.000275	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55605266	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs17725110	ENSG00000273257.1	RP11-177J6.1	-4.95	1.05e-06	0.000275	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55605855	chr4:55387949~55388271:+
HNSC	cis	rs3805389	0.504	rs2412666	ENSG00000273257.1	RP11-177J6.1	-4.95	1.05e-06	0.000275	-0.35	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55607192	chr4:55387949~55388271:+
HNSC	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	4.95	1.05e-06	0.000275	0.24	0.22	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
HNSC	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	4.95	1.05e-06	0.000275	0.33	0.22	Height;	chr6:109741085	chr6:109382795~109383666:+
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000280411.1	IGHV1-69-2	-4.95	1.05e-06	0.000275	-0.23	-0.22	Alzheimer's disease (late onset);	chr14:106697724	chr14:106762092~106762588:-
HNSC	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-4.95	1.05e-06	0.000275	-0.53	-0.22	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
HNSC	cis	rs9840812	0.623	rs1145106	ENSG00000273486.1	RP11-731C17.2	4.95	1.05e-06	0.000276	0.19	0.22	Fibrinogen levels;	chr3:136393075	chr3:136837338~136839021:-
HNSC	cis	rs12701220	0.689	rs12536282	ENSG00000224079.1	AC091729.7	4.95	1.05e-06	0.000276	0.35	0.22	Bronchopulmonary dysplasia;	chr7:1076014	chr7:1074450~1078036:+
HNSC	cis	rs6540731	0.782	rs12038888	ENSG00000226251.4	RP11-15I11.3	-4.95	1.05e-06	0.000276	-0.26	-0.22	Intelligence (childhood);	chr1:212192711	chr1:212225278~212238977:-
HNSC	cis	rs13073817	0.582	rs11128893	ENSG00000228956.7	SATB1-AS1	-4.95	1.05e-06	0.000276	-0.23	-0.22	Crohn's disease;	chr3:18650089	chr3:18445024~18920401:+
HNSC	cis	rs7746199	0.736	rs13202291	ENSG00000219392.1	RP1-265C24.5	-4.95	1.05e-06	0.000276	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.736	rs17750424	ENSG00000219392.1	RP1-265C24.5	-4.95	1.05e-06	0.000276	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28115628~28116551:+
HNSC	cis	rs4873772	0.773	rs7833589	ENSG00000253330.1	RP11-697N18.3	-4.95	1.05e-06	0.000276	-0.29	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47479733	chr8:47511034~47512141:-
HNSC	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	4.95	1.05e-06	0.000276	0.32	0.22	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
HNSC	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	4.95	1.05e-06	0.000276	0.32	0.22	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
HNSC	cis	rs6540731	1	rs11119885	ENSG00000226251.4	RP11-15I11.3	-4.95	1.05e-06	0.000276	-0.26	-0.22	Intelligence (childhood);	chr1:212227656	chr1:212225278~212238977:-
HNSC	cis	rs9863	0.828	rs11057408	ENSG00000269938.1	RP11-214K3.20	-4.95	1.05e-06	0.000276	-0.26	-0.22	White blood cell count;	chr12:123980289	chr12:123968023~123968579:-
HNSC	cis	rs7615952	0.599	rs2270986	ENSG00000248787.1	RP11-666A20.4	-4.95	1.05e-06	0.000276	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:125982256	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs12496921	ENSG00000248787.1	RP11-666A20.4	-4.95	1.05e-06	0.000276	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:125983105	chr3:125908005~125910272:-
HNSC	cis	rs4763879	0.752	rs10772083	ENSG00000256673.1	RP11-599J14.2	-4.95	1.06e-06	0.000277	-0.21	-0.22	Type 1 diabetes;	chr12:9722302	chr12:9398355~9414851:-
HNSC	cis	rs6951245	0.572	rs112072378	ENSG00000225146.1	AC073957.15	-4.95	1.06e-06	0.000277	-0.47	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999764	chr7:1029025~1043891:+
HNSC	cis	rs12701220	0.689	rs12530960	ENSG00000224079.1	AC091729.7	4.95	1.06e-06	0.000277	0.36	0.22	Bronchopulmonary dysplasia;	chr7:1055835	chr7:1074450~1078036:+
HNSC	cis	rs8040855	0.599	rs6496791	ENSG00000259774.1	RP11-182J1.13	-4.95	1.06e-06	0.000277	-0.27	-0.22	Bulimia nervosa;	chr15:85182428	chr15:84422618~84425882:+
HNSC	cis	rs11756659	0.653	rs199738	ENSG00000272462.2	U91328.19	4.95	1.06e-06	0.000277	0.26	0.22	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963228	chr6:25992662~26001775:+
HNSC	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-4.95	1.06e-06	0.000277	-0.33	-0.22	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
HNSC	cis	rs9987353	0.544	rs2929470	ENSG00000254340.1	RP11-10A14.3	-4.95	1.06e-06	0.000277	-0.27	-0.22	Recombination measurement;	chr8:9204980	chr8:9141424~9145435:+
HNSC	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	4.95	1.06e-06	0.000277	0.19	0.22	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
HNSC	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	4.95	1.06e-06	0.000277	0.28	0.22	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
HNSC	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-4.95	1.06e-06	0.000277	-0.21	-0.22	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
HNSC	cis	rs1056107	0.931	rs10817304	ENSG00000225513.1	RP11-165N19.2	-4.95	1.06e-06	0.000277	-0.24	-0.22	Colorectal cancer;	chr9:112259006	chr9:112173522~112173971:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000254340.1	RP11-10A14.3	4.95	1.06e-06	0.000277	0.27	0.22	Mood instability;	chr8:8279561	chr8:9141424~9145435:+
HNSC	cis	rs36052053	0.908	rs71558360	ENSG00000219700.1	PTCHD3P3	4.95	1.06e-06	0.000277	0.36	0.22	Red cell distribution width;	chr6:109256780	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs71558361	ENSG00000219700.1	PTCHD3P3	4.95	1.06e-06	0.000277	0.36	0.22	Red cell distribution width;	chr6:109260045	chr6:109288571~109290503:-
HNSC	cis	rs4853525	0.59	rs12619017	ENSG00000235852.1	AC005540.3	4.95	1.06e-06	0.000278	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865167	chr2:190880797~190882059:-
HNSC	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	4.95	1.06e-06	0.000278	0.3	0.22	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
HNSC	cis	rs4927850	1	rs7625570	ENSG00000273009.1	RP11-352G9.1	-4.95	1.06e-06	0.000278	-0.26	-0.22	Pancreatic cancer;	chr3:196020527	chr3:195913078~195913683:-
HNSC	cis	rs9863	0.931	rs6488914	ENSG00000269938.1	RP11-214K3.20	4.95	1.06e-06	0.000278	0.27	0.22	White blood cell count;	chr12:123963294	chr12:123968023~123968579:-
HNSC	cis	rs3733585	0.673	rs7378340	ENSG00000250413.1	RP11-448G15.1	4.95	1.06e-06	0.000278	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9953574	chr4:10006482~10009725:+
HNSC	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	4.95	1.06e-06	0.000278	0.26	0.22	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	4.95	1.06e-06	0.000278	0.26	0.22	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-4.95	1.06e-06	0.000278	-0.13	-0.22	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
HNSC	cis	rs6693567	0.565	rs471657	ENSG00000228126.1	FALEC	-4.95	1.06e-06	0.000278	-0.27	-0.22	Migraine;	chr1:150304033	chr1:150515757~150518032:+
HNSC	cis	rs442309	0.687	rs10822058	ENSG00000238280.1	RP11-436D10.3	-4.95	1.06e-06	0.000278	-0.28	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62763822	chr10:62793562~62805887:-
HNSC	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-4.95	1.06e-06	0.000278	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-4.95	1.06e-06	0.000278	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
HNSC	cis	rs9929218	0.539	rs1125557	ENSG00000260459.2	FTLP14	4.95	1.06e-06	0.000278	0.29	0.22	Colorectal cancer;	chr16:68775696	chr16:68822587~68823070:+
HNSC	cis	rs9929218	0.559	rs11642362	ENSG00000260459.2	FTLP14	4.95	1.06e-06	0.000278	0.29	0.22	Colorectal cancer;	chr16:68777404	chr16:68822587~68823070:+
HNSC	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-4.95	1.06e-06	0.000278	-0.2	-0.22	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
HNSC	cis	rs950169	0.881	rs72750843	ENSG00000229212.6	RP11-561C5.4	-4.95	1.06e-06	0.000278	-0.32	-0.22	Schizophrenia;	chr15:84592552	chr15:85205440~85234795:-
HNSC	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-4.95	1.06e-06	0.000279	-0.32	-0.22	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
HNSC	cis	rs10791097	0.702	rs10894267	ENSG00000254842.5	RP11-890B15.2	4.95	1.06e-06	0.000279	0.19	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130844966	chr11:130844191~130865561:-
HNSC	cis	rs75422866	0.867	rs35044089	ENSG00000276691.1	RP5-1057I20.5	4.95	1.06e-06	0.000279	0.41	0.22	Pneumonia;	chr12:47610881	chr12:47788426~47788971:+
HNSC	cis	rs6714900	0.925	rs11680831	ENSG00000234896.1	OR7E62P	-4.95	1.06e-06	0.000279	-0.26	-0.22	Blood protein levels;	chr2:71065392	chr2:71055527~71056003:+
HNSC	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-4.95	1.06e-06	0.000279	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
HNSC	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-4.94	1.06e-06	0.000279	-0.23	-0.22	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
HNSC	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-4.94	1.06e-06	0.000279	-0.28	-0.22	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-4.94	1.07e-06	0.000279	-0.26	-0.22	Depression;	chr6:28091242	chr6:28170845~28172521:+
HNSC	cis	rs763121	0.853	rs2413546	ENSG00000273076.1	RP3-508I15.22	4.94	1.07e-06	0.000279	0.24	0.22	Menopause (age at onset);	chr22:38710996	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2413547	ENSG00000273076.1	RP3-508I15.22	4.94	1.07e-06	0.000279	0.24	0.22	Menopause (age at onset);	chr22:38711333	chr22:38743495~38743910:+
HNSC	cis	rs2243480	1	rs13247184	ENSG00000179406.6	LINC00174	-4.94	1.07e-06	0.000279	-0.48	-0.22	Diabetic kidney disease;	chr7:65893941	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs35421653	ENSG00000179406.6	LINC00174	-4.94	1.07e-06	0.000279	-0.48	-0.22	Diabetic kidney disease;	chr7:65898442	chr7:66376044~66401338:-
HNSC	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-4.94	1.07e-06	0.000279	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
HNSC	cis	rs9392556	0.6	rs611500	ENSG00000230648.1	RP3-406P24.3	4.94	1.07e-06	0.00028	0.25	0.22	Blood metabolite levels;	chr6:4126529	chr6:4018843~4021215:-
HNSC	cis	rs5758511	0.514	rs5758622	ENSG00000226450.2	CYP2D8P	4.94	1.07e-06	0.00028	0.22	0.22	Birth weight;	chr22:42167927	chr22:42149886~42155001:-
HNSC	cis	rs1065852	0.906	rs5751232	ENSG00000226450.2	CYP2D8P	4.94	1.07e-06	0.00028	0.22	0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.514	rs9607882	ENSG00000226450.2	CYP2D8P	4.94	1.07e-06	0.00028	0.22	0.22	Birth weight;	chr22:42171445	chr22:42149886~42155001:-
HNSC	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	4.94	1.07e-06	0.00028	0.22	0.22	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
HNSC	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-4.94	1.07e-06	0.00028	-0.28	-0.22	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
HNSC	cis	rs1971762	0.523	rs7135101	ENSG00000270175.1	RP11-793H13.11	-4.94	1.07e-06	0.00028	-0.19	-0.22	Height;	chr12:53686821	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.563	rs10219725	ENSG00000270175.1	RP11-793H13.11	-4.94	1.07e-06	0.00028	-0.19	-0.22	Height;	chr12:53687081	chr12:53500162~53500936:-
HNSC	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-4.94	1.07e-06	0.00028	-0.25	-0.22	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
HNSC	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	4.94	1.07e-06	0.00028	0.27	0.22	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
HNSC	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-4.94	1.07e-06	0.00028	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
HNSC	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-4.94	1.07e-06	0.00028	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
HNSC	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-4.94	1.07e-06	0.00028	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
HNSC	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	4.94	1.07e-06	0.00028	0.32	0.22	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
HNSC	cis	rs11773103	1	rs11983450	ENSG00000224046.1	AC005076.5	4.94	1.07e-06	0.00028	0.39	0.22	Bipolar disorder or major depressive disorder (combined);	chr7:87246526	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73212041	ENSG00000224046.1	AC005076.5	4.94	1.07e-06	0.00028	0.39	0.22	Bipolar disorder or major depressive disorder (combined);	chr7:87249636	chr7:87151423~87152420:-
HNSC	cis	rs12291225	0.585	rs34171876	ENSG00000251991.1	RNU7-49P	4.94	1.07e-06	0.00028	0.25	0.22	Sense of smell;	chr11:14332411	chr11:14478892~14478953:+
HNSC	cis	rs7985	0.901	rs6005133	ENSG00000244625.4	MIATNB	4.94	1.07e-06	0.00028	0.26	0.22	Electroencephalogram traits;	chr22:26681021	chr22:26672767~26780207:+
HNSC	cis	rs11633886	0.51	rs939423	ENSG00000273972.1	CTD-2306A12.1	4.94	1.07e-06	0.000281	0.26	0.22	Diisocyanate-induced asthma;	chr15:45776743	chr15:45702640~45703183:+
HNSC	cis	rs2834288	0.535	rs4816469	ENSG00000273102.1	AP000569.9	4.94	1.07e-06	0.000281	0.25	0.22	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33967101~33968573:-
HNSC	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-4.94	1.07e-06	0.000281	-0.26	-0.22	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
HNSC	cis	rs9300255	0.602	rs2851435	ENSG00000280120.1	RP11-546D6.3	4.94	1.07e-06	0.000281	0.21	0.22	Neutrophil percentage of white cells;	chr12:123227869	chr12:123152324~123153377:-
HNSC	cis	rs4657482	0.962	rs6703280	ENSG00000236364.3	RP11-525G13.2	4.94	1.07e-06	0.000281	0.22	0.22	Testicular germ cell tumor;	chr1:165871174	chr1:165890795~165900683:-
HNSC	cis	rs36052053	0.908	rs13190802	ENSG00000219700.1	PTCHD3P3	4.94	1.07e-06	0.000281	0.36	0.22	Red cell distribution width;	chr6:109260601	chr6:109288571~109290503:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000233609.3	RP11-62H7.2	-4.94	1.07e-06	0.000281	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9033292	chr8:8961200~8979025:+
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000233609.3	RP11-62H7.2	-4.94	1.07e-06	0.000281	-0.21	-0.22	Myopia (pathological);Myopia;	chr8:9033866	chr8:8961200~8979025:+
HNSC	cis	rs6693567	0.545	rs2275246	ENSG00000228126.1	FALEC	4.94	1.07e-06	0.000281	0.27	0.22	Migraine;	chr1:150487692	chr1:150515757~150518032:+
HNSC	cis	rs6674176	0.696	rs4448553	ENSG00000237950.1	RP11-7O11.3	4.94	1.07e-06	0.000281	0.26	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43945917	chr1:43944370~43946551:-
HNSC	cis	rs1056107	0.931	rs7027240	ENSG00000225513.1	RP11-165N19.2	-4.94	1.08e-06	0.000281	-0.24	-0.22	Colorectal cancer;	chr9:112258733	chr9:112173522~112173971:-
HNSC	cis	rs9880211	0.563	rs1393787	ENSG00000273486.1	RP11-731C17.2	4.94	1.08e-06	0.000281	0.2	0.22	Height;Body mass index;	chr3:136135359	chr3:136837338~136839021:-
HNSC	cis	rs1125355	0.622	rs11678112	ENSG00000204380.3	AC005042.4	4.94	1.08e-06	0.000281	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158756825	chr2:158658337~158735002:-
HNSC	cis	rs4873772	0.704	rs12675378	ENSG00000253330.1	RP11-697N18.3	-4.94	1.08e-06	0.000281	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47538132	chr8:47511034~47512141:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	4.94	1.08e-06	0.000281	0.27	0.22	Depression;	chr6:28187640	chr6:28161781~28169594:+
HNSC	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-4.94	1.08e-06	0.000281	-0.24	-0.22	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
HNSC	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-4.94	1.08e-06	0.000282	-0.23	-0.22	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
HNSC	cis	rs1799949	0.965	rs8176310	ENSG00000236383.6	LINC00854	-4.94	1.08e-06	0.000282	-0.21	-0.22	Menopause (age at onset);	chr17:43047896	chr17:43216941~43305976:-
HNSC	cis	rs12817211	0.549	rs7398567	ENSG00000272368.2	RP4-605O3.4	4.94	1.08e-06	0.000282	0.22	0.22	Colorectal or endometrial cancer;	chr12:50157375	chr12:50112197~50165618:+
HNSC	cis	rs12817211	0.549	rs10783338	ENSG00000272368.2	RP4-605O3.4	4.94	1.08e-06	0.000282	0.22	0.22	Colorectal or endometrial cancer;	chr12:50158746	chr12:50112197~50165618:+
HNSC	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	4.94	1.08e-06	0.000282	0.28	0.22	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
HNSC	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	4.94	1.08e-06	0.000282	0.22	0.22	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
HNSC	cis	rs7000734	0.958	rs7845016	ENSG00000245080.5	RP11-320N21.1	-4.94	1.08e-06	0.000282	-0.31	-0.22	Radiation response;	chr8:95108031	chr8:95066808~95073182:-
HNSC	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000282	0.32	0.22	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
HNSC	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	4.94	1.08e-06	0.000282	0.24	0.22	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
HNSC	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-4.94	1.08e-06	0.000282	-0.25	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
HNSC	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	4.94	1.08e-06	0.000282	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	4.94	1.08e-06	0.000282	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
HNSC	cis	rs4927850	1	rs10881563	ENSG00000273009.1	RP11-352G9.1	-4.94	1.08e-06	0.000282	-0.27	-0.22	Pancreatic cancer;	chr3:196023354	chr3:195913078~195913683:-
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	4.94	1.08e-06	0.000282	0.24	0.22	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
HNSC	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	4.94	1.08e-06	0.000282	0.25	0.22	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
HNSC	cis	rs4788196	1	rs4788196	ENSG00000183604.13	SMG1P5	-4.94	1.08e-06	0.000283	-0.22	-0.22	Pubertal anthropometrics;	chr16:29956113	chr16:30267553~30335374:-
HNSC	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	4.94	1.08e-06	0.000283	0.22	0.22	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
HNSC	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-4.94	1.08e-06	0.000283	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-4.94	1.08e-06	0.000283	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-4.94	1.08e-06	0.000283	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
HNSC	cis	rs7809950	0.817	rs4727678	ENSG00000238832.1	snoU109	-4.94	1.08e-06	0.000283	-0.31	-0.22	Coronary artery disease;	chr7:107443190	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.817	rs4727679	ENSG00000238832.1	snoU109	-4.94	1.08e-06	0.000283	-0.31	-0.22	Coronary artery disease;	chr7:107444573	chr7:107603363~107603507:+
HNSC	cis	rs753274	0.65	rs7257738	ENSG00000267147.2	CTC-548K16.1	-4.94	1.08e-06	0.000283	-0.28	-0.22	Tumor necrosis factor beta levels;	chr19:14308109	chr19:14333743~14343916:+
HNSC	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	4.94	1.08e-06	0.000283	0.33	0.22	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
HNSC	cis	rs71520386	0.579	rs4394299	ENSG00000221740.1	SNORD93	-4.94	1.08e-06	0.000283	-0.26	-0.22	Fibrinogen levels;	chr7:22825763	chr7:22856613~22856686:+
HNSC	cis	rs11971779	0.666	rs7786851	ENSG00000273391.1	RP11-634H22.1	-4.94	1.08e-06	0.000283	-0.26	-0.22	Diisocyanate-induced asthma;	chr7:139322274	chr7:139359032~139359566:-
HNSC	cis	rs6928977	0.5	rs6570022	ENSG00000217482.2	HMGB1P17	4.94	1.08e-06	0.000283	0.25	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135636086~135636713:-
HNSC	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-4.94	1.08e-06	0.000283	-0.26	-0.22	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
HNSC	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	4.94	1.08e-06	0.000283	0.25	0.22	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
HNSC	cis	rs72727394	0.51	rs55791667	ENSG00000259747.1	RP11-275I4.2	-4.94	1.08e-06	0.000283	-0.29	-0.22	Crohn's disease;	chr15:38628624	chr15:38671847~38689191:+
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000254174.1	IGHV1-12	4.94	1.08e-06	0.000283	0.19	0.22	Alzheimer's disease (late onset);	chr14:106680831	chr14:106122420~106122709:-
HNSC	cis	rs5758511	0.514	rs5758629	ENSG00000226450.2	CYP2D8P	4.94	1.09e-06	0.000284	0.22	0.22	Birth weight;	chr22:42178549	chr22:42149886~42155001:-
HNSC	cis	rs1056107	0.898	rs10733586	ENSG00000225513.1	RP11-165N19.2	-4.94	1.09e-06	0.000284	-0.24	-0.22	Colorectal cancer;	chr9:112229903	chr9:112173522~112173971:-
HNSC	cis	rs4141404	0.781	rs4820945	ENSG00000236132.1	CTA-440B3.1	4.94	1.09e-06	0.000284	0.27	0.22	Paclitaxel-induced neuropathy;	chr22:31153169	chr22:31816379~31817491:-
HNSC	cis	rs4141404	0.701	rs5753483	ENSG00000236132.1	CTA-440B3.1	4.94	1.09e-06	0.000284	0.27	0.22	Paclitaxel-induced neuropathy;	chr22:31153595	chr22:31816379~31817491:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-4.94	1.09e-06	0.000284	-0.27	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
HNSC	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	4.94	1.09e-06	0.000284	0.24	0.22	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
HNSC	cis	rs7824557	0.806	rs10503418	ENSG00000269918.1	AF131215.9	-4.94	1.09e-06	0.000284	-0.22	-0.22	Retinal vascular caliber;	chr8:11261474	chr8:11104691~11106704:-
HNSC	cis	rs2179367	0.568	rs9498358	ENSG00000216906.2	RP11-350J20.9	4.94	1.09e-06	0.000284	0.34	0.22	Dupuytren's disease;	chr6:149458529	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.6	rs58747890	ENSG00000216906.2	RP11-350J20.9	4.94	1.09e-06	0.000284	0.34	0.22	Dupuytren's disease;	chr6:149459369	chr6:149904243~149906418:+
HNSC	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	4.94	1.09e-06	0.000284	0.25	0.22	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
HNSC	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.94	1.09e-06	0.000284	0.25	0.22	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000254340.1	RP11-10A14.3	4.94	1.09e-06	0.000284	0.27	0.22	Mood instability;	chr8:8446992	chr8:9141424~9145435:+
HNSC	cis	rs9907295	0.901	rs28739295	ENSG00000270977.1	AC015849.16	-4.94	1.09e-06	0.000285	-0.37	-0.22	Fibroblast growth factor basic levels;	chr17:35895812	chr17:35893707~35911023:-
HNSC	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.94	1.09e-06	0.000285	0.19	0.22	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
HNSC	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	4.94	1.09e-06	0.000285	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	4.94	1.09e-06	0.000285	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
HNSC	cis	rs7809950	0.906	rs10248717	ENSG00000238832.1	snoU109	-4.94	1.09e-06	0.000285	-0.27	-0.22	Coronary artery disease;	chr7:107416350	chr7:107603363~107603507:+
HNSC	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	4.94	1.09e-06	0.000285	0.25	0.22	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
HNSC	cis	rs3733585	0.673	rs7375587	ENSG00000250413.1	RP11-448G15.1	-4.94	1.09e-06	0.000285	-0.27	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9953134	chr4:10006482~10009725:+
HNSC	cis	rs9368481	0.594	rs2636425	ENSG00000224843.5	LINC00240	-4.94	1.09e-06	0.000285	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26956992~27023924:+
HNSC	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	4.94	1.09e-06	0.000285	0.27	0.22	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
HNSC	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	4.94	1.09e-06	0.000285	0.24	0.22	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28089816	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28090857	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28091439	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28091659	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28092227	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28093966	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000285	-0.26	-0.22	Depression;	chr6:28094014	chr6:28170845~28172521:+
HNSC	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	4.94	1.09e-06	0.000285	0.19	0.22	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
HNSC	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	4.94	1.09e-06	0.000285	0.19	0.22	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
HNSC	cis	rs3806843	0.735	rs801185	ENSG00000202515.1	VTRNA1-3	4.94	1.09e-06	0.000285	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr5:140726158~140726246:+
HNSC	cis	rs10791097	0.69	rs12284487	ENSG00000254842.5	RP11-890B15.2	-4.94	1.09e-06	0.000285	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130859810	chr11:130844191~130865561:-
HNSC	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	4.94	1.09e-06	0.000286	0.29	0.22	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
HNSC	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.94	1.09e-06	0.000286	-0.22	-0.22	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
HNSC	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	4.94	1.09e-06	0.000286	0.29	0.22	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
HNSC	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-4.94	1.09e-06	0.000286	-0.25	-0.22	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
HNSC	cis	rs2836974	0.549	rs34160989	ENSG00000255568.3	BRWD1-AS2	4.94	1.09e-06	0.000286	0.26	0.22	Cognitive function;	chr21:39182192	chr21:39313935~39314962:+
HNSC	cis	rs3806843	0.735	rs3776129	ENSG00000202515.1	VTRNA1-3	4.94	1.09e-06	0.000286	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr5:140726158~140726246:+
HNSC	cis	rs11247915	0.6	rs72649360	ENSG00000236782.4	RP11-96L14.7	-4.94	1.1e-06	0.000286	-0.26	-0.22	Obesity-related traits;	chr1:26336413	chr1:26169947~26171821:-
HNSC	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-4.94	1.1e-06	0.000286	-0.28	-0.22	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
HNSC	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-4.94	1.1e-06	0.000287	-0.2	-0.22	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
HNSC	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-4.94	1.1e-06	0.000287	-0.23	-0.22	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-4.94	1.1e-06	0.000287	-0.23	-0.22	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-4.94	1.1e-06	0.000287	-0.23	-0.22	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
HNSC	cis	rs7824557	0.836	rs765731	ENSG00000269918.1	AF131215.9	-4.94	1.1e-06	0.000287	-0.22	-0.22	Retinal vascular caliber;	chr8:11263989	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000253981.4	ALG1L13P	4.94	1.1e-06	0.000287	0.25	0.22	Joint mobility (Beighton score);	chr8:9034711	chr8:8236003~8244667:-
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000254153.1	CTA-398F10.2	4.94	1.1e-06	0.000287	0.24	0.22	Neuroticism;	chr8:8866141	chr8:8456909~8461337:-
HNSC	cis	rs7402982	0.525	rs11247361	ENSG00000278022.1	RP11-35O15.2	4.94	1.1e-06	0.000287	0.26	0.22	Birth weight;	chr15:98664163	chr15:98660210~98660668:+
HNSC	cis	rs7809950	0.798	rs2701687	ENSG00000238832.1	snoU109	4.94	1.1e-06	0.000287	0.27	0.22	Coronary artery disease;	chr7:107664183	chr7:107603363~107603507:+
HNSC	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-4.94	1.1e-06	0.000287	-0.23	-0.22	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
HNSC	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-4.94	1.1e-06	0.000287	-0.22	-0.22	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
HNSC	cis	rs1479119	0.53	rs4763972	ENSG00000180861.8	LINC01559	-4.94	1.1e-06	0.000287	-0.28	-0.22	Intelligence (multi-trait analysis);	chr12:13368221	chr12:13371089~13387167:-
HNSC	cis	rs1065852	0.861	rs5758627	ENSG00000226450.2	CYP2D8P	4.94	1.1e-06	0.000287	0.22	0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42149886~42155001:-
HNSC	cis	rs10504130	0.696	rs79740712	ENSG00000253844.1	RP11-546K22.1	-4.94	1.1e-06	0.000287	-0.34	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51961458~52022974:+
HNSC	cis	rs6540731	1	rs2012917	ENSG00000226251.4	RP11-15I11.3	-4.94	1.1e-06	0.000288	-0.26	-0.22	Intelligence (childhood);	chr1:212232429	chr1:212225278~212238977:-
HNSC	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.1e-06	0.000288	-0.3	-0.22	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
HNSC	cis	rs3805389	0.504	rs59571323	ENSG00000273257.1	RP11-177J6.1	-4.94	1.1e-06	0.000288	-0.34	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.838	rs57178140	ENSG00000273257.1	RP11-177J6.1	-4.94	1.1e-06	0.000288	-0.34	-0.22	Adiponectin levels;	chr4:55611361	chr4:55387949~55388271:+
HNSC	cis	rs7829975	0.686	rs907180	ENSG00000173295.6	FAM86B3P	4.94	1.1e-06	0.000288	0.25	0.22	Mood instability;	chr8:8845317	chr8:8228595~8244865:+
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000254174.1	IGHV1-12	4.94	1.1e-06	0.000288	0.19	0.22	Alzheimer's disease (late onset);	chr14:106667442	chr14:106122420~106122709:-
HNSC	cis	rs3733585	0.699	rs6449178	ENSG00000250413.1	RP11-448G15.1	-4.94	1.1e-06	0.000288	-0.27	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9967060	chr4:10006482~10009725:+
HNSC	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	4.94	1.1e-06	0.000288	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
HNSC	cis	rs860818	1	rs858316	ENSG00000226816.2	AC005082.12	4.94	1.11e-06	0.000288	0.58	0.22	Initial pursuit acceleration;	chr7:23163511	chr7:23206013~23208045:+
HNSC	cis	rs860818	0.793	rs4722233	ENSG00000226816.2	AC005082.12	-4.94	1.11e-06	0.000288	-0.58	-0.22	Initial pursuit acceleration;	chr7:23157792	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs6960118	ENSG00000226816.2	AC005082.12	-4.94	1.11e-06	0.000288	-0.58	-0.22	Initial pursuit acceleration;	chr7:23160709	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs6964671	ENSG00000226816.2	AC005082.12	-4.94	1.11e-06	0.000288	-0.58	-0.22	Initial pursuit acceleration;	chr7:23161183	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs6461699	ENSG00000226816.2	AC005082.12	-4.94	1.11e-06	0.000288	-0.58	-0.22	Initial pursuit acceleration;	chr7:23162679	chr7:23206013~23208045:+
HNSC	cis	rs1008375	1	rs9291659	ENSG00000249502.1	AC006160.5	-4.94	1.11e-06	0.000288	-0.24	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660737	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs9991307	ENSG00000249502.1	AC006160.5	-4.94	1.11e-06	0.000288	-0.24	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660785	chr4:17587467~17614571:-
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	4.94	1.11e-06	0.000288	0.27	0.22	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
HNSC	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	4.94	1.11e-06	0.000289	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	4.94	1.11e-06	0.000289	0.27	0.22	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
HNSC	cis	rs7000734	0.563	rs62524807	ENSG00000245080.5	RP11-320N21.1	4.94	1.11e-06	0.000289	0.34	0.22	Radiation response;	chr8:95134558	chr8:95066808~95073182:-
HNSC	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	4.94	1.11e-06	0.000289	0.43	0.22	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
HNSC	cis	rs1552244	1	rs17032414	ENSG00000180385.7	EMC3-AS1	4.94	1.11e-06	0.000289	0.24	0.22	Alzheimer's disease;	chr3:10116618	chr3:9986893~10006990:+
HNSC	cis	rs1056107	0.931	rs7019056	ENSG00000225513.1	RP11-165N19.2	-4.94	1.11e-06	0.000289	-0.24	-0.22	Colorectal cancer;	chr9:112248160	chr9:112173522~112173971:-
HNSC	cis	rs950169	0.922	rs12915832	ENSG00000229212.6	RP11-561C5.4	-4.94	1.11e-06	0.000289	-0.32	-0.22	Schizophrenia;	chr15:84568226	chr15:85205440~85234795:-
HNSC	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-4.94	1.11e-06	0.000289	-0.22	-0.22	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	4.94	1.11e-06	0.000289	0.25	0.22	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
HNSC	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-4.94	1.11e-06	0.000289	-0.23	-0.22	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
HNSC	cis	rs7085104	0.572	rs284858	ENSG00000236937.2	PTGES3P4	-4.94	1.11e-06	0.00029	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102845595~102845950:+
HNSC	cis	rs9329221	0.905	rs13254263	ENSG00000255310.2	AF131215.2	-4.94	1.11e-06	0.00029	-0.21	-0.22	Neuroticism;	chr8:10397671	chr8:11107788~11109726:-
HNSC	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	4.94	1.11e-06	0.00029	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	4.94	1.11e-06	0.00029	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
HNSC	cis	rs4761669	0.565	rs34903466	ENSG00000241556.1	RP11-490G8.1	4.94	1.11e-06	0.00029	0.22	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94797573	chr12:95467397~95467861:-
HNSC	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-4.94	1.11e-06	0.00029	-0.24	-0.22	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
HNSC	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	4.94	1.11e-06	0.00029	0.25	0.22	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
HNSC	cis	rs4664293	0.669	rs357021	ENSG00000226266.5	AC009961.3	-4.94	1.11e-06	0.00029	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159632572	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs357030	ENSG00000226266.5	AC009961.3	-4.94	1.11e-06	0.00029	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159636515	chr2:159670708~159712435:-
HNSC	cis	rs7178375	1	rs1474381	ENSG00000270055.1	CTD-3092A11.2	-4.94	1.11e-06	0.00029	-0.29	-0.22	Hypertriglyceridemia;	chr15:30922788	chr15:30487963~30490313:+
HNSC	cis	rs6604026	0.922	rs58270016	ENSG00000223787.2	RP4-593M8.1	4.94	1.11e-06	0.00029	0.3	0.22	Multiple sclerosis;	chr1:92830166	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.922	rs35051335	ENSG00000223787.2	RP4-593M8.1	4.94	1.11e-06	0.00029	0.3	0.22	Multiple sclerosis;	chr1:92830273	chr1:92580476~92580821:-
HNSC	cis	rs9840812	0.773	rs61789601	ENSG00000239213.4	NCK1-AS1	-4.94	1.11e-06	0.00029	-0.23	-0.22	Fibrinogen levels;	chr3:136236137	chr3:136841726~136862054:-
HNSC	cis	rs9326248	0.559	rs476399	ENSG00000280143.1	AP000892.6	4.94	1.11e-06	0.00029	0.23	0.22	Blood protein levels;	chr11:116863012	chr11:117204967~117210292:+
HNSC	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	4.94	1.11e-06	0.00029	0.27	0.22	Height;	chr20:49215517	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	4.94	1.11e-06	0.00029	0.27	0.22	Height;	chr20:49220589	chr20:49280319~49280409:+
HNSC	cis	rs9907295	0.688	rs2376287	ENSG00000270977.1	AC015849.16	-4.94	1.11e-06	0.00029	-0.31	-0.22	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.688	rs4796133	ENSG00000270977.1	AC015849.16	-4.94	1.11e-06	0.00029	-0.31	-0.22	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.688	rs7213636	ENSG00000270977.1	AC015849.16	-4.94	1.11e-06	0.00029	-0.31	-0.22	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35893707~35911023:-
HNSC	cis	rs12935418	0.561	rs2287991	ENSG00000261061.1	RP11-303E16.2	-4.94	1.11e-06	0.00029	-0.26	-0.22	Mean corpuscular volume;	chr16:81006950	chr16:81030770~81031485:+
HNSC	cis	rs7927592	0.645	rs7936582	ENSG00000212093.1	AP000807.1	4.94	1.12e-06	0.000291	0.24	0.22	Total body bone mineral density;	chr11:68525462	chr11:68506083~68506166:-
HNSC	cis	rs2985684	1	rs17121651	ENSG00000258568.1	RHOQP1	4.94	1.12e-06	0.000291	0.23	0.22	Carotid intima media thickness;	chr14:49630454	chr14:49599994~49600572:+
HNSC	cis	rs860295	0.665	rs12079134	ENSG00000203761.5	MSTO2P	-4.94	1.12e-06	0.000291	-0.17	-0.22	Body mass index;	chr1:155496993	chr1:155745829~155750137:+
HNSC	cis	rs4664293	0.647	rs4665082	ENSG00000226266.5	AC009961.3	-4.93	1.12e-06	0.000291	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159573455	chr2:159670708~159712435:-
HNSC	cis	rs6964587	0.967	rs34863529	ENSG00000188693.7	CYP51A1-AS1	-4.93	1.12e-06	0.000291	-0.24	-0.22	Breast cancer;	chr7:92015027	chr7:92134604~92180725:+
HNSC	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	4.93	1.12e-06	0.000292	0.24	0.22	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
HNSC	cis	rs9435732	1	rs9435732	ENSG00000186715.9	MST1L	4.93	1.12e-06	0.000292	0.21	0.22	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16754910~16770237:-
HNSC	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-4.93	1.12e-06	0.000292	-0.26	-0.22	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
HNSC	cis	rs1056107	0.866	rs12351043	ENSG00000225513.1	RP11-165N19.2	-4.93	1.12e-06	0.000292	-0.24	-0.22	Colorectal cancer;	chr9:112241012	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs7864927	ENSG00000225513.1	RP11-165N19.2	-4.93	1.12e-06	0.000292	-0.24	-0.22	Colorectal cancer;	chr9:112241713	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	4.93	1.12e-06	0.000292	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	4.93	1.12e-06	0.000292	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-4.93	1.12e-06	0.000292	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
HNSC	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-4.93	1.12e-06	0.000292	-0.23	-0.22	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-4.93	1.12e-06	0.000292	-0.23	-0.22	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
HNSC	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	4.93	1.12e-06	0.000292	0.23	0.22	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
HNSC	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	4.93	1.12e-06	0.000292	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
HNSC	cis	rs6674176	0.569	rs34830883	ENSG00000237950.1	RP11-7O11.3	4.93	1.12e-06	0.000292	0.25	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939667	chr1:43944370~43946551:-
HNSC	cis	rs13113518	0.51	rs6858749	ENSG00000273257.1	RP11-177J6.1	4.93	1.12e-06	0.000292	0.26	0.22	Height;	chr4:55424270	chr4:55387949~55388271:+
HNSC	cis	rs7296418	0.961	rs4275659	ENSG00000280120.1	RP11-546D6.3	-4.93	1.12e-06	0.000292	-0.19	-0.22	Platelet count;	chr12:122963381	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	4.93	1.12e-06	0.000292	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
HNSC	cis	rs13217239	0.608	rs6930508	ENSG00000224843.5	LINC00240	4.93	1.12e-06	0.000292	0.21	0.22	Schizophrenia;	chr6:27085363	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs2142685	ENSG00000224843.5	LINC00240	4.93	1.12e-06	0.000292	0.21	0.22	Schizophrenia;	chr6:27086718	chr6:26956992~27023924:+
HNSC	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-4.93	1.12e-06	0.000292	-0.24	-0.22	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
HNSC	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-4.93	1.12e-06	0.000293	-0.24	-0.22	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000259429.4	UBE2Q2P2	-4.93	1.13e-06	0.000293	-0.21	-0.22	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82355142~82420075:+
HNSC	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-4.93	1.13e-06	0.000293	-0.26	-0.22	Height;	chr2:46614722	chr2:46668870~46670778:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000254174.1	IGHV1-12	4.93	1.13e-06	0.000293	0.19	0.22	Alzheimer's disease (late onset);	chr14:106688967	chr14:106122420~106122709:-
HNSC	cis	rs6693567	0.565	rs543179	ENSG00000228126.1	FALEC	-4.93	1.13e-06	0.000293	-0.27	-0.22	Migraine;	chr1:150302182	chr1:150515757~150518032:+
HNSC	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-4.93	1.13e-06	0.000293	-0.27	-0.22	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
HNSC	cis	rs2243480	1	rs35283677	ENSG00000179406.6	LINC00174	-4.93	1.13e-06	0.000293	-0.48	-0.22	Diabetic kidney disease;	chr7:65894246	chr7:66376044~66401338:-
HNSC	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	4.93	1.13e-06	0.000293	0.27	0.22	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
HNSC	cis	rs3806843	0.735	rs702394	ENSG00000202515.1	VTRNA1-3	4.93	1.13e-06	0.000293	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr5:140726158~140726246:+
HNSC	cis	rs7809950	0.862	rs2299421	ENSG00000238832.1	snoU109	-4.93	1.13e-06	0.000294	-0.27	-0.22	Coronary artery disease;	chr7:107305750	chr7:107603363~107603507:+
HNSC	cis	rs9329221	0.905	rs28507213	ENSG00000255310.2	AF131215.2	-4.93	1.13e-06	0.000294	-0.21	-0.22	Neuroticism;	chr8:10393339	chr8:11107788~11109726:-
HNSC	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	4.93	1.13e-06	0.000294	0.28	0.22	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
HNSC	cis	rs9863	0.896	rs76283024	ENSG00000269938.1	RP11-214K3.20	-4.93	1.13e-06	0.000294	-0.27	-0.22	White blood cell count;	chr12:123982232	chr12:123968023~123968579:-
HNSC	cis	rs728616	0.614	rs10887218	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.13e-06	0.000294	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:79663088~79826594:-
HNSC	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-4.93	1.13e-06	0.000294	-0.23	-0.22	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-4.93	1.13e-06	0.000294	-0.23	-0.22	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
HNSC	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-4.93	1.13e-06	0.000294	-0.23	-0.22	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
HNSC	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-4.93	1.13e-06	0.000294	-0.24	-0.22	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
HNSC	cis	rs6701713	0.804	rs4266886	ENSG00000274245.1	RP11-357P18.2	-4.93	1.13e-06	0.000294	-0.36	-0.22	Alzheimer's disease (late onset);	chr1:207512441	chr1:207372559~207373252:+
HNSC	cis	rs17373728	0.526	rs9886508	ENSG00000249395.2	CASC9	-4.93	1.13e-06	0.000294	-0.29	-0.22	Diabetic kidney disease;	chr8:75240756	chr8:75223404~75324741:-
HNSC	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-4.93	1.13e-06	0.000294	-0.23	-0.22	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-4.93	1.13e-06	0.000294	-0.23	-0.22	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
HNSC	cis	rs2985684	0.948	rs6572592	ENSG00000278009.1	RP11-649E7.8	4.93	1.13e-06	0.000294	0.29	0.22	Carotid intima media thickness;	chr14:49614153	chr14:49601011~49601124:-
HNSC	cis	rs7296418	0.885	rs1790104	ENSG00000280120.1	RP11-546D6.3	4.93	1.13e-06	0.000295	0.19	0.22	Platelet count;	chr12:123224862	chr12:123152324~123153377:-
HNSC	cis	rs7296418	0.816	rs1790096	ENSG00000280120.1	RP11-546D6.3	4.93	1.13e-06	0.000295	0.19	0.22	Platelet count;	chr12:123225817	chr12:123152324~123153377:-
HNSC	cis	rs66887589	0.934	rs2715016	ENSG00000245958.5	RP11-33B1.1	4.93	1.13e-06	0.000295	0.19	0.22	Diastolic blood pressure;	chr4:119531201	chr4:119454791~119552025:+
HNSC	cis	rs3736485	0.868	rs1531155	ENSG00000259438.1	CTD-2650P22.1	4.93	1.13e-06	0.000295	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51639936	chr15:52010999~52019095:-
HNSC	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-4.93	1.13e-06	0.000295	-0.25	-0.22	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
HNSC	cis	rs728616	0.558	rs723192	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.13e-06	0.000295	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79663088~79826594:-
HNSC	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	4.93	1.14e-06	0.000295	0.24	0.22	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	4.93	1.14e-06	0.000295	0.27	0.22	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	4.93	1.14e-06	0.000295	0.27	0.22	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	4.93	1.14e-06	0.000295	0.27	0.22	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	4.93	1.14e-06	0.000295	0.27	0.22	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
HNSC	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-4.93	1.14e-06	0.000296	-0.34	-0.22	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
HNSC	cis	rs2933343	0.729	rs1680780	ENSG00000261159.1	RP11-723O4.9	4.93	1.14e-06	0.000296	0.22	0.22	IgG glycosylation;	chr3:128893816	chr3:128859716~128860526:-
HNSC	cis	rs4927850	1	rs10881564	ENSG00000273009.1	RP11-352G9.1	-4.93	1.14e-06	0.000296	-0.26	-0.22	Pancreatic cancer;	chr3:196023455	chr3:195913078~195913683:-
HNSC	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-4.93	1.14e-06	0.000296	-0.23	-0.22	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
HNSC	cis	rs7662987	0.517	rs2602876	ENSG00000263923.1	RP11-571L19.7	-4.93	1.14e-06	0.000296	-0.24	-0.22	Smoking initiation;	chr4:99118384	chr4:98928897~98994994:+
HNSC	cis	rs6693567	0.545	rs2012751	ENSG00000228126.1	FALEC	4.93	1.14e-06	0.000296	0.27	0.22	Migraine;	chr1:150465790	chr1:150515757~150518032:+
HNSC	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-4.93	1.14e-06	0.000296	-0.27	-0.22	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
HNSC	cis	rs3733585	0.699	rs4473653	ENSG00000250413.1	RP11-448G15.1	4.93	1.14e-06	0.000296	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9969434	chr4:10006482~10009725:+
HNSC	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-4.93	1.14e-06	0.000296	-0.19	-0.22	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
HNSC	cis	rs7246657	0.524	rs28542490	ENSG00000276846.1	CTD-3220F14.3	4.93	1.14e-06	0.000296	0.32	0.22	Coronary artery calcification;	chr19:36965682	chr19:37314868~37315620:-
HNSC	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	4.93	1.14e-06	0.000297	0.3	0.22	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
HNSC	cis	rs3736485	0.868	rs8023455	ENSG00000259438.1	CTD-2650P22.1	4.93	1.14e-06	0.000297	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51644313	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.868	rs60060794	ENSG00000259438.1	CTD-2650P22.1	4.93	1.14e-06	0.000297	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51644984	chr15:52010999~52019095:-
HNSC	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-4.93	1.14e-06	0.000297	-0.23	-0.22	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
HNSC	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-4.93	1.14e-06	0.000297	-0.19	-0.22	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
HNSC	cis	rs7429990	0.864	rs6777081	ENSG00000228638.1	FCF1P2	4.93	1.14e-06	0.000297	0.21	0.22	Educational attainment (years of education);	chr3:48114079	chr3:48290793~48291375:-
HNSC	cis	rs8040855	0.579	rs6496797	ENSG00000259774.1	RP11-182J1.13	-4.93	1.14e-06	0.000297	-0.27	-0.22	Bulimia nervosa;	chr15:85183624	chr15:84422618~84425882:+
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000254153.1	CTA-398F10.2	4.93	1.14e-06	0.000297	0.24	0.22	Mood instability;	chr8:8410553	chr8:8456909~8461337:-
HNSC	cis	rs9329221	0.741	rs534523	ENSG00000254340.1	RP11-10A14.3	-4.93	1.14e-06	0.000297	-0.26	-0.22	Neuroticism;	chr8:10027489	chr8:9141424~9145435:+
HNSC	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	4.93	1.14e-06	0.000298	0.25	0.22	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
HNSC	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.93	1.15e-06	0.000298	-0.21	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
HNSC	cis	rs2998286	0.862	rs946594	ENSG00000254635.4	WAC-AS1	-4.93	1.15e-06	0.000298	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503318	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.862	rs1416817	ENSG00000254635.4	WAC-AS1	-4.93	1.15e-06	0.000298	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503548	chr10:28522652~28532743:-
HNSC	cis	rs11648785	0.59	rs3743827	ENSG00000222019.6	URAHP	4.93	1.15e-06	0.000298	0.21	0.22	Tanning;	chr16:90027787	chr16:90039761~90047773:-
HNSC	cis	rs2985684	1	rs7142457	ENSG00000258568.1	RHOQP1	4.93	1.15e-06	0.000298	0.23	0.22	Carotid intima media thickness;	chr14:49631144	chr14:49599994~49600572:+
HNSC	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-4.93	1.15e-06	0.000298	-0.28	-0.22	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-4.93	1.15e-06	0.000298	-0.28	-0.22	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
HNSC	cis	rs3806843	0.741	rs2563293	ENSG00000202515.1	VTRNA1-3	4.93	1.15e-06	0.000298	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr5:140726158~140726246:+
HNSC	cis	rs5758659	0.652	rs133347	ENSG00000227370.1	RP4-669P10.19	-4.93	1.15e-06	0.000298	-0.21	-0.22	Cognitive function;	chr22:42027641	chr22:42132543~42132998:+
HNSC	cis	rs3806843	0.735	rs2530240	ENSG00000202515.1	VTRNA1-3	4.93	1.15e-06	0.000298	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.735	rs801189	ENSG00000202515.1	VTRNA1-3	4.93	1.15e-06	0.000298	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.706	rs1089305	ENSG00000202515.1	VTRNA1-3	4.93	1.15e-06	0.000298	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr5:140726158~140726246:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	4.93	1.15e-06	0.000298	0.27	0.22	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
HNSC	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	4.93	1.15e-06	0.000298	0.5	0.22	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
HNSC	cis	rs1056107	0.866	rs4979093	ENSG00000225513.1	RP11-165N19.2	-4.93	1.15e-06	0.000298	-0.24	-0.22	Colorectal cancer;	chr9:112275820	chr9:112173522~112173971:-
HNSC	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	4.93	1.15e-06	0.000298	0.27	0.22	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
HNSC	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.93	1.15e-06	0.000299	-0.22	-0.22	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
HNSC	cis	rs2337406	1	rs11850709	ENSG00000254174.1	IGHV1-12	4.93	1.15e-06	0.000299	0.19	0.22	Alzheimer's disease (late onset);	chr14:106670844	chr14:106122420~106122709:-
HNSC	cis	rs13434995	0.589	rs861029	ENSG00000273257.1	RP11-177J6.1	-4.93	1.15e-06	0.000299	-0.31	-0.22	Adiponectin levels;	chr4:55379470	chr4:55387949~55388271:+
HNSC	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-4.93	1.15e-06	0.000299	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000219392.1	RP1-265C24.5	-4.93	1.15e-06	0.000299	-0.24	-0.22	Pubertal anthropometrics;	chr6:28411584	chr6:28115628~28116551:+
HNSC	cis	rs6540731	1	rs3816912	ENSG00000226251.4	RP11-15I11.3	4.93	1.15e-06	0.000299	0.26	0.22	Intelligence (childhood);	chr1:212226507	chr1:212225278~212238977:-
HNSC	cis	rs988913	0.624	rs980821	ENSG00000224984.1	RP11-524H19.2	4.93	1.15e-06	0.000299	0.26	0.22	Menarche (age at onset);	chr6:54989641	chr6:54840118~54840855:-
HNSC	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-4.93	1.15e-06	0.000299	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
HNSC	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.93	1.15e-06	0.000299	0.34	0.22	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
HNSC	cis	rs950169	0.922	rs67804993	ENSG00000229212.6	RP11-561C5.4	-4.93	1.15e-06	0.000299	-0.32	-0.22	Schizophrenia;	chr15:84560799	chr15:85205440~85234795:-
HNSC	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	4.93	1.15e-06	0.000299	0.4	0.22	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
HNSC	cis	rs7000734	0.637	rs13280952	ENSG00000245080.5	RP11-320N21.1	4.93	1.15e-06	0.000299	0.34	0.22	Radiation response;	chr8:95135339	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.637	rs13278942	ENSG00000245080.5	RP11-320N21.1	4.93	1.15e-06	0.000299	0.34	0.22	Radiation response;	chr8:95135356	chr8:95066808~95073182:-
HNSC	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-4.93	1.15e-06	3e-04	-0.28	-0.22	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
HNSC	cis	rs2361718	0.501	rs12944619	ENSG00000275479.1	RP11-334C17.6	4.93	1.15e-06	3e-04	0.25	0.22	Yeast infection;	chr17:80170310	chr17:80149627~80149798:+
HNSC	cis	rs9907295	1	rs11868244	ENSG00000270977.1	AC015849.16	-4.93	1.15e-06	3e-04	-0.32	-0.22	Fibroblast growth factor basic levels;	chr17:35916339	chr17:35893707~35911023:-
HNSC	cis	rs6723108	0.604	rs2322251	ENSG00000224043.6	CCNT2-AS1	-4.93	1.15e-06	3e-04	-0.27	-0.22	Type 2 diabetes;	chr2:134913732	chr2:134735464~134918710:-
HNSC	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.93	1.15e-06	3e-04	0.39	0.22	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-4.93	1.15e-06	3e-04	-0.26	-0.22	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
HNSC	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-4.93	1.15e-06	3e-04	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
HNSC	cis	rs7085104	0.572	rs284857	ENSG00000236937.2	PTGES3P4	-4.93	1.16e-06	3e-04	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102845595~102845950:+
HNSC	cis	rs4388249	0.861	rs34387996	ENSG00000271849.1	CTC-332L22.1	-4.93	1.16e-06	3e-04	-0.34	-0.22	Schizophrenia;	chr5:109730763	chr5:109687802~109688329:-
HNSC	cis	rs7246657	0.525	rs1667351	ENSG00000276846.1	CTD-3220F14.3	4.93	1.16e-06	3e-04	0.28	0.22	Coronary artery calcification;	chr19:36987125	chr19:37314868~37315620:-
HNSC	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-4.93	1.16e-06	3e-04	-0.28	-0.22	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
HNSC	cis	rs12893668	0.572	rs12590968	ENSG00000269940.1	RP11-73M18.7	4.93	1.16e-06	3e-04	0.22	0.22	Reticulocyte count;	chr14:103670296	chr14:103694560~103695170:+
HNSC	cis	rs5758659	0.716	rs2143138	ENSG00000227370.1	RP4-669P10.19	-4.93	1.16e-06	3e-04	-0.21	-0.22	Cognitive function;	chr22:42222334	chr22:42132543~42132998:+
HNSC	cis	rs860295	0.702	rs11264375	ENSG00000203761.5	MSTO2P	4.93	1.16e-06	3e-04	0.17	0.22	Body mass index;	chr1:155454274	chr1:155745829~155750137:+
HNSC	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	4.93	1.16e-06	3e-04	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
HNSC	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	4.93	1.16e-06	3e-04	0.23	0.22	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	4.93	1.16e-06	3e-04	0.23	0.22	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	4.93	1.16e-06	3e-04	0.23	0.22	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	4.93	1.16e-06	3e-04	0.23	0.22	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
HNSC	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	4.93	1.16e-06	0.000301	0.25	0.22	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
HNSC	cis	rs73219805	0.554	rs13266943	ENSG00000228451.3	SDAD1P1	-4.93	1.16e-06	0.000301	-0.36	-0.22	Schizophrenia;	chr8:26336629	chr8:26379259~26382953:-
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000254153.1	CTA-398F10.2	4.93	1.16e-06	0.000301	0.25	0.22	Mood instability;	chr8:8865165	chr8:8456909~8461337:-
HNSC	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	4.93	1.16e-06	0.000301	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
HNSC	cis	rs3806843	0.735	rs6849	ENSG00000202515.1	VTRNA1-3	4.93	1.16e-06	0.000301	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr5:140726158~140726246:+
HNSC	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	4.93	1.16e-06	0.000301	0.19	0.22	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	4.93	1.16e-06	0.000301	0.27	0.22	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
HNSC	cis	rs763121	0.819	rs6001205	ENSG00000273076.1	RP3-508I15.22	4.93	1.16e-06	0.000301	0.24	0.22	Menopause (age at onset);	chr22:38704259	chr22:38743495~38743910:+
HNSC	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-4.93	1.16e-06	0.000301	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-4.93	1.16e-06	0.000301	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
HNSC	cis	rs9863	0.861	rs12317176	ENSG00000269938.1	RP11-214K3.20	-4.93	1.16e-06	0.000302	-0.26	-0.22	White blood cell count;	chr12:123920171	chr12:123968023~123968579:-
HNSC	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.93	1.16e-06	0.000302	0.19	0.22	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
HNSC	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.93	1.16e-06	0.000302	0.19	0.22	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
HNSC	cis	rs4862750	0.915	rs6835681	ENSG00000250971.1	RP11-696F12.1	4.93	1.16e-06	0.000302	0.26	0.22	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:187060099~187060930:+
HNSC	cis	rs11148252	0.553	rs9536236	ENSG00000198384.8	TPTE2P3	4.93	1.16e-06	0.000302	0.28	0.22	Lewy body disease;	chr13:52680877	chr13:52522632~52586906:+
HNSC	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-4.93	1.16e-06	0.000302	-0.25	-0.22	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
HNSC	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.93	1.16e-06	0.000302	0.25	0.22	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
HNSC	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	4.93	1.16e-06	0.000302	0.2	0.22	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
HNSC	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	4.93	1.16e-06	0.000302	0.26	0.22	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
HNSC	cis	rs6928977	0.5	rs719885	ENSG00000234084.1	RP3-388E23.2	-4.93	1.16e-06	0.000302	-0.23	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135301568~135307158:+
HNSC	cis	rs7246657	0.525	rs10405238	ENSG00000276846.1	CTD-3220F14.3	4.93	1.16e-06	0.000302	0.32	0.22	Coronary artery calcification;	chr19:36997153	chr19:37314868~37315620:-
HNSC	cis	rs4787951	0.568	rs8056488	ENSG00000259940.2	CTD-3203P2.1	-4.93	1.16e-06	0.000302	-0.24	-0.22	Eosinophil percentage of white cells;	chr16:27291408	chr16:27213308~27214993:-
HNSC	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	4.93	1.17e-06	0.000302	0.43	0.22	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
HNSC	cis	rs9402743	0.671	rs7767066	ENSG00000234084.1	RP3-388E23.2	-4.93	1.17e-06	0.000302	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135623970	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.598	rs9483856	ENSG00000234084.1	RP3-388E23.2	-4.93	1.17e-06	0.000302	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135624088	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.635	rs9376118	ENSG00000234084.1	RP3-388E23.2	-4.93	1.17e-06	0.000302	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135624521	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs742738	ENSG00000234084.1	RP3-388E23.2	-4.93	1.17e-06	0.000302	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135625301	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.671	rs9402728	ENSG00000234084.1	RP3-388E23.2	-4.93	1.17e-06	0.000302	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135626450	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.86	rs3827780	ENSG00000231028.7	LINC00271	4.93	1.17e-06	0.000302	0.26	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135388622	chr6:135497801~135716055:+
HNSC	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-4.93	1.17e-06	0.000303	-0.22	-0.22	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
HNSC	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	4.93	1.17e-06	0.000303	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
HNSC	cis	rs9506514	0.722	rs4769124	ENSG00000238286.1	SLC35E1P1	4.93	1.17e-06	0.000303	0.24	0.22	Coronary artery calcification;	chr13:20652706	chr13:20607268~20608131:+
HNSC	cis	rs3806843	0.735	rs2563314	ENSG00000202515.1	VTRNA1-3	4.93	1.17e-06	0.000303	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr5:140726158~140726246:+
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000254153.1	CTA-398F10.2	-4.93	1.17e-06	0.000303	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9011767	chr8:8456909~8461337:-
HNSC	cis	rs71520386	0.632	rs10279864	ENSG00000221740.1	SNORD93	-4.93	1.17e-06	0.000303	-0.26	-0.22	Fibrinogen levels;	chr7:22824205	chr7:22856613~22856686:+
HNSC	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	4.93	1.17e-06	0.000303	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	4.93	1.17e-06	0.000303	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	4.93	1.17e-06	0.000303	0.27	0.22	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
HNSC	cis	rs603446	0.967	rs180340	ENSG00000254851.1	RP11-109L13.1	-4.93	1.17e-06	0.000303	-0.29	-0.22	Triglycerides;	chr11:116745686	chr11:117135528~117138582:+
HNSC	cis	rs6714900	0.619	rs11126315	ENSG00000234896.1	OR7E62P	4.93	1.17e-06	0.000303	0.26	0.22	Blood protein levels;	chr2:71063928	chr2:71055527~71056003:+
HNSC	cis	rs1056107	0.931	rs10759538	ENSG00000225513.1	RP11-165N19.2	-4.93	1.17e-06	0.000304	-0.24	-0.22	Colorectal cancer;	chr9:112234047	chr9:112173522~112173971:-
HNSC	cis	rs12986445	0.793	rs1515948	ENSG00000218682.1	AC010150.1	4.92	1.17e-06	0.000304	0.3	0.22	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25874738	chr2:25856461~25856966:-
HNSC	cis	rs17428076	0.872	rs55863868	ENSG00000228389.1	AC068039.4	-4.92	1.17e-06	0.000304	-0.27	-0.22	Myopia;	chr2:172023605	chr2:171773482~171775844:+
HNSC	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-4.92	1.17e-06	0.000304	-0.27	-0.22	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
HNSC	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-4.92	1.17e-06	0.000304	-0.26	-0.22	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-4.92	1.17e-06	0.000304	-0.26	-0.22	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-4.92	1.17e-06	0.000304	-0.26	-0.22	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
HNSC	cis	rs9650657	0.899	rs9650656	ENSG00000269918.1	AF131215.9	-4.92	1.17e-06	0.000304	-0.22	-0.22	Neuroticism;	chr8:10749744	chr8:11104691~11106704:-
HNSC	cis	rs9650657	1	rs9650657	ENSG00000269918.1	AF131215.9	-4.92	1.17e-06	0.000304	-0.22	-0.22	Neuroticism;	chr8:10749890	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	4.92	1.17e-06	0.000304	0.27	0.22	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
HNSC	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-4.92	1.17e-06	0.000304	-0.32	-0.22	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
HNSC	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	4.92	1.17e-06	0.000304	0.24	0.22	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
HNSC	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-4.92	1.17e-06	0.000304	-0.23	-0.22	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
HNSC	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	4.92	1.18e-06	0.000304	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	4.92	1.18e-06	0.000305	0.32	0.22	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	4.92	1.18e-06	0.000305	0.32	0.22	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	4.92	1.18e-06	0.000305	0.32	0.22	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	4.92	1.18e-06	0.000305	0.32	0.22	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
HNSC	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-4.92	1.18e-06	0.000305	-0.27	-0.22	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
HNSC	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-4.92	1.18e-06	0.000305	-0.27	-0.22	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
HNSC	cis	rs6964587	0.869	rs7812219	ENSG00000188693.7	CYP51A1-AS1	4.92	1.18e-06	0.000305	0.24	0.22	Breast cancer;	chr7:91916413	chr7:92134604~92180725:+
HNSC	cis	rs728616	0.867	rs1054054	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.18e-06	0.000305	-0.53	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61859766	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.18e-06	0.000305	-0.53	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79663088~79826594:-
HNSC	cis	rs3806843	0.771	rs801174	ENSG00000202515.1	VTRNA1-3	4.92	1.18e-06	0.000305	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr5:140726158~140726246:+
HNSC	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-4.92	1.18e-06	0.000305	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-4.92	1.18e-06	0.000305	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	4.92	1.18e-06	0.000305	0.25	0.22	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
HNSC	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	4.92	1.18e-06	0.000305	0.28	0.22	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-4.92	1.18e-06	0.000305	-0.27	-0.22	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
HNSC	cis	rs3096299	0.702	rs2086824	ENSG00000274627.1	RP11-104N10.2	-4.92	1.18e-06	0.000305	-0.22	-0.22	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89516797~89522217:+
HNSC	cis	rs2286503	0.839	rs4722189	ENSG00000226329.2	AC005682.6	4.92	1.18e-06	0.000305	0.28	0.22	Fibrinogen;	chr7:22820855	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.809	rs4719716	ENSG00000226329.2	AC005682.6	4.92	1.18e-06	0.000305	0.28	0.22	Fibrinogen;	chr7:22821750	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs2270108	ENSG00000226329.2	AC005682.6	4.92	1.18e-06	0.000305	0.28	0.22	Fibrinogen;	chr7:22822512	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.839	rs2270107	ENSG00000226329.2	AC005682.6	4.92	1.18e-06	0.000305	0.28	0.22	Fibrinogen;	chr7:22822564	chr7:22863874~22881350:-
HNSC	cis	rs10256972	0.869	rs1007766	ENSG00000225146.1	AC073957.15	4.92	1.18e-06	0.000306	0.26	0.22	Endometriosis;Longevity;	chr7:995267	chr7:1029025~1043891:+
HNSC	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	4.92	1.18e-06	0.000306	0.28	0.22	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
HNSC	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-4.92	1.18e-06	0.000306	-0.23	-0.22	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
HNSC	cis	rs7615952	0.641	rs4490307	ENSG00000248787.1	RP11-666A20.4	-4.92	1.18e-06	0.000306	-0.3	-0.22	Blood pressure (smoking interaction);	chr3:125993833	chr3:125908005~125910272:-
HNSC	cis	rs6601327	0.575	rs7001832	ENSG00000254340.1	RP11-10A14.3	-4.92	1.18e-06	0.000306	-0.27	-0.22	Multiple myeloma (hyperdiploidy);	chr8:9749725	chr8:9141424~9145435:+
HNSC	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-4.92	1.18e-06	0.000306	-0.33	-0.22	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
HNSC	cis	rs1971762	0.583	rs2365345	ENSG00000270175.1	RP11-793H13.11	-4.92	1.18e-06	0.000306	-0.19	-0.22	Height;	chr12:53693036	chr12:53500162~53500936:-
HNSC	cis	rs4218	0.531	rs6494065	ENSG00000259732.1	RP11-59H7.3	4.92	1.18e-06	0.000306	0.28	0.22	Social communication problems;	chr15:59053249	chr15:59121034~59133250:+
HNSC	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	4.92	1.18e-06	0.000306	0.23	0.22	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
HNSC	cis	rs1012068	0.81	rs5998140	ENSG00000236132.1	CTA-440B3.1	-4.92	1.18e-06	0.000306	-0.27	-0.22	Chronic hepatitis C infection;	chr22:31845961	chr22:31816379~31817491:-
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-4.92	1.18e-06	0.000307	-0.24	-0.22	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
HNSC	cis	rs10989172	0.714	rs4440728	ENSG00000175611.10	LINC00476	4.92	1.18e-06	0.000307	0.21	0.22	Common carotid intima-media thickness in HIV negative individuals;	chr9:96078350	chr9:95759231~95875977:-
HNSC	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-4.92	1.19e-06	0.000307	-0.23	-0.22	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
HNSC	cis	rs7819412	0.806	rs2409689	ENSG00000255310.2	AF131215.2	-4.92	1.19e-06	0.000307	-0.21	-0.22	Triglycerides;	chr8:11075358	chr8:11107788~11109726:-
HNSC	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	4.92	1.19e-06	0.000307	0.28	0.22	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-4.92	1.19e-06	0.000307	-0.27	-0.22	Depression;	chr6:28176973	chr6:28170845~28172521:+
HNSC	cis	rs4372836	0.93	rs7607844	ENSG00000226833.4	AC097724.3	4.92	1.19e-06	0.000307	0.29	0.22	Body mass index;	chr2:28748872	chr2:28708953~28736205:-
HNSC	cis	rs10989172	0.69	rs4562454	ENSG00000175611.10	LINC00476	4.92	1.19e-06	0.000307	0.21	0.22	Common carotid intima-media thickness in HIV negative individuals;	chr9:96078514	chr9:95759231~95875977:-
HNSC	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-4.92	1.19e-06	0.000307	-0.28	-0.22	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
HNSC	cis	rs465969	1	rs34530632	ENSG00000255389.1	C6orf3	-4.92	1.19e-06	0.000308	-0.43	-0.22	Psoriasis;	chr6:111455132	chr6:111599875~111602295:+
HNSC	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	4.92	1.19e-06	0.000308	0.22	0.22	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
HNSC	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-4.92	1.19e-06	0.000308	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
HNSC	cis	rs17428076	0.874	rs12619041	ENSG00000228389.1	AC068039.4	4.92	1.19e-06	0.000308	0.27	0.22	Myopia;	chr2:171744206	chr2:171773482~171775844:+
HNSC	cis	rs17818399	0.815	rs17819022	ENSG00000279254.1	RP11-536C12.1	-4.92	1.19e-06	0.000308	-0.26	-0.22	Height;	chr2:46623432	chr2:46668870~46670778:+
HNSC	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-4.92	1.19e-06	0.000309	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-4.92	1.19e-06	0.000309	-0.26	-0.22	Depression;	chr6:28079011	chr6:28170845~28172521:+
HNSC	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-4.92	1.19e-06	0.000309	-0.19	-0.22	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
HNSC	cis	rs10504130	0.502	rs16916968	ENSG00000272024.1	RP11-546K22.3	-4.92	1.19e-06	0.000309	-0.29	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51931851	chr8:51950284~51950690:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000233609.3	RP11-62H7.2	4.92	1.19e-06	0.000309	0.22	0.22	Joint mobility (Beighton score);	chr8:9012918	chr8:8961200~8979025:+
HNSC	cis	rs13217239	0.646	rs62401067	ENSG00000224843.5	LINC00240	-4.92	1.19e-06	0.000309	-0.22	-0.22	Schizophrenia;	chr6:27050322	chr6:26956992~27023924:+
HNSC	cis	rs1971762	0.583	rs1864448	ENSG00000270175.1	RP11-793H13.11	-4.92	1.2e-06	0.000309	-0.19	-0.22	Height;	chr12:53694072	chr12:53500162~53500936:-
HNSC	cis	rs1008375	1	rs7671752	ENSG00000249502.1	AC006160.5	-4.92	1.2e-06	0.000309	-0.24	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17659775	chr4:17587467~17614571:-
HNSC	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-4.92	1.2e-06	0.000309	-0.17	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-4.92	1.2e-06	0.000309	-0.17	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
HNSC	cis	rs656319	0.58	rs13272793	ENSG00000269918.1	AF131215.9	-4.92	1.2e-06	0.000309	-0.22	-0.22	Myopia (pathological);	chr8:10144517	chr8:11104691~11106704:-
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000273009.1	RP11-352G9.1	-4.92	1.2e-06	0.000309	-0.26	-0.22	Pancreatic cancer;	chr3:196021858	chr3:195913078~195913683:-
HNSC	cis	rs939574	1	rs45488900	ENSG00000243910.6	TUBA4B	4.92	1.2e-06	0.000309	0.45	0.22	Platelet distribution width;	chr2:219251787	chr2:219253243~219272188:+
HNSC	cis	rs67981189	0.858	rs221927	ENSG00000274818.1	RP1-292L20.3	-4.92	1.2e-06	0.000309	-0.26	-0.22	Schizophrenia;	chr14:71112024	chr14:70906657~70907111:-
HNSC	cis	rs9840812	0.645	rs13068119	ENSG00000239213.4	NCK1-AS1	-4.92	1.2e-06	0.00031	-0.22	-0.22	Fibrinogen levels;	chr3:136487527	chr3:136841726~136862054:-
HNSC	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-4.92	1.2e-06	0.00031	-0.29	-0.22	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
HNSC	cis	rs8040855	0.579	rs4843029	ENSG00000259774.1	RP11-182J1.13	-4.92	1.2e-06	0.00031	-0.26	-0.22	Bulimia nervosa;	chr15:85182164	chr15:84422618~84425882:+
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000224373.3	IGHV4-59	4.92	1.2e-06	0.00031	0.14	0.22	Kawasaki disease;	chr14:106686431	chr14:106627249~106627825:-
HNSC	cis	rs6964587	1	rs7781066	ENSG00000188693.7	CYP51A1-AS1	-4.92	1.2e-06	0.00031	-0.23	-0.22	Breast cancer;	chr7:92062632	chr7:92134604~92180725:+
HNSC	cis	rs1125355	0.622	rs10497201	ENSG00000204380.3	AC005042.4	4.92	1.2e-06	0.00031	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158757632	chr2:158658337~158735002:-
HNSC	cis	rs1125355	0.622	rs1515921	ENSG00000204380.3	AC005042.4	4.92	1.2e-06	0.00031	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158759156	chr2:158658337~158735002:-
HNSC	cis	rs1125355	0.622	rs1515920	ENSG00000204380.3	AC005042.4	4.92	1.2e-06	0.00031	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158759252	chr2:158658337~158735002:-
HNSC	cis	rs1125355	0.653	rs72937273	ENSG00000204380.3	AC005042.4	4.92	1.2e-06	0.00031	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158762204	chr2:158658337~158735002:-
HNSC	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	4.92	1.2e-06	0.00031	0.2	0.22	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
HNSC	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	4.92	1.2e-06	0.00031	0.2	0.22	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
HNSC	cis	rs6918586	0.565	rs13196986	ENSG00000272462.2	U91328.19	4.92	1.2e-06	0.000311	0.23	0.22	Schizophrenia;	chr6:26090224	chr6:25992662~26001775:+
HNSC	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	4.92	1.2e-06	0.000311	0.22	0.22	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
HNSC	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-4.92	1.2e-06	0.000311	-0.23	-0.22	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-4.92	1.2e-06	0.000311	-0.23	-0.22	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
HNSC	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-4.92	1.2e-06	0.000311	-0.23	-0.22	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
HNSC	cis	rs697003	0.672	rs701917	ENSG00000231057.3	RP11-122M14.1	-4.92	1.2e-06	0.000311	-0.23	-0.22	Red cell distribution width;	chr1:211688456	chr1:211675762~211690103:+
HNSC	cis	rs17428076	0.629	rs72892859	ENSG00000228389.1	AC068039.4	-4.92	1.2e-06	0.000311	-0.28	-0.22	Myopia;	chr2:172039980	chr2:171773482~171775844:+
HNSC	cis	rs36093844	0.752	rs80323143	ENSG00000279742.1	RP11-700A24.1	-4.92	1.2e-06	0.000311	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835053	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.651	rs55978615	ENSG00000279742.1	RP11-700A24.1	-4.92	1.2e-06	0.000311	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835348	chr11:85852557~85854943:-
HNSC	cis	rs1150668	0.699	rs1736895	ENSG00000219392.1	RP1-265C24.5	-4.92	1.2e-06	0.000311	-0.24	-0.22	Pubertal anthropometrics;	chr6:28252048	chr6:28115628~28116551:+
HNSC	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-4.92	1.2e-06	0.000311	-0.28	-0.22	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
HNSC	cis	rs13217239	0.646	rs4269366	ENSG00000224843.5	LINC00240	-4.92	1.21e-06	0.000311	-0.22	-0.22	Schizophrenia;	chr6:27048634	chr6:26956992~27023924:+
HNSC	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-4.92	1.21e-06	0.000311	-0.27	-0.22	Height;	chr4:55542948	chr4:55363971~55395847:-
HNSC	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-4.92	1.21e-06	0.000312	-0.28	-0.22	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
HNSC	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	4.92	1.21e-06	0.000312	0.32	0.22	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
HNSC	cis	rs6693567	0.565	rs7513182	ENSG00000228126.1	FALEC	-4.92	1.21e-06	0.000312	-0.27	-0.22	Migraine;	chr1:150470136	chr1:150515757~150518032:+
HNSC	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	4.92	1.21e-06	0.000312	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	4.92	1.21e-06	0.000312	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
HNSC	cis	rs1150668	0.699	rs12214383	ENSG00000219392.1	RP1-265C24.5	4.92	1.21e-06	0.000312	0.24	0.22	Pubertal anthropometrics;	chr6:28255953	chr6:28115628~28116551:+
HNSC	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	4.92	1.21e-06	0.000312	0.25	0.22	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
HNSC	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	4.92	1.21e-06	0.000312	0.21	0.22	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
HNSC	cis	rs1056107	0.7	rs10981293	ENSG00000225513.1	RP11-165N19.2	-4.92	1.21e-06	0.000312	-0.24	-0.22	Colorectal cancer;	chr9:112169467	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-4.92	1.21e-06	0.000312	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
HNSC	cis	rs11148252	0.532	rs9536190	ENSG00000198384.8	TPTE2P3	4.92	1.21e-06	0.000313	0.29	0.22	Lewy body disease;	chr13:52606909	chr13:52522632~52586906:+
HNSC	cis	rs9907295	0.901	rs28550999	ENSG00000270977.1	AC015849.16	-4.92	1.21e-06	0.000313	-0.37	-0.22	Fibroblast growth factor basic levels;	chr17:35902887	chr17:35893707~35911023:-
HNSC	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-4.92	1.21e-06	0.000313	-0.21	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
HNSC	cis	rs4761669	0.565	rs7294369	ENSG00000241556.1	RP11-490G8.1	4.92	1.21e-06	0.000313	0.23	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94800667	chr12:95467397~95467861:-
HNSC	cis	rs467650	0.5	rs13160853	ENSG00000246763.5	RGMB-AS1	-4.92	1.21e-06	0.000313	-0.26	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98585193	chr5:98769618~98773469:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	4.92	1.22e-06	0.000314	0.23	0.22	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
HNSC	cis	rs2276314	0.512	rs9949178	ENSG00000278986.1	RP11-723J4.3	4.92	1.22e-06	0.000314	0.25	0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:35870612	chr18:35972151~35973916:+
HNSC	cis	rs7688540	0.76	rs7687833	ENSG00000211553.1	AC253576.2	-4.92	1.22e-06	0.000314	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:136461~136568:+
HNSC	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-4.92	1.22e-06	0.000314	-0.23	-0.22	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
HNSC	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-4.92	1.22e-06	0.000314	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
HNSC	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-4.92	1.22e-06	0.000315	-0.27	-0.22	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-4.92	1.22e-06	0.000315	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
HNSC	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	4.92	1.22e-06	0.000315	0.22	0.22	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
HNSC	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-4.92	1.22e-06	0.000315	-0.23	-0.22	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	4.92	1.22e-06	0.000315	0.27	0.22	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.796	rs2179781	ENSG00000231028.7	LINC00271	4.92	1.22e-06	0.000315	0.25	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135398362	chr6:135497801~135716055:+
HNSC	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-4.92	1.22e-06	0.000315	-0.28	-0.22	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
HNSC	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-4.92	1.22e-06	0.000315	-0.24	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
HNSC	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.92	1.22e-06	0.000316	0.29	0.22	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
HNSC	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	4.92	1.22e-06	0.000316	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
HNSC	cis	rs71520386	0.632	rs1474349	ENSG00000221740.1	SNORD93	-4.92	1.22e-06	0.000316	-0.26	-0.22	Fibrinogen levels;	chr7:22814146	chr7:22856613~22856686:+
HNSC	cis	rs12935418	0.583	rs12446698	ENSG00000261061.1	RP11-303E16.2	-4.92	1.22e-06	0.000316	-0.29	-0.22	Mean corpuscular volume;	chr16:80930524	chr16:81030770~81031485:+
HNSC	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-4.92	1.22e-06	0.000316	-0.25	-0.22	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-4.92	1.22e-06	0.000316	-0.26	-0.22	Depression;	chr6:28136698	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-4.92	1.22e-06	0.000316	-0.26	-0.22	Depression;	chr6:28136856	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-4.92	1.22e-06	0.000316	-0.26	-0.22	Depression;	chr6:28137418	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-4.92	1.22e-06	0.000316	-0.26	-0.22	Depression;	chr6:28138363	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.607	rs13199906	ENSG00000219392.1	RP1-265C24.5	-4.92	1.23e-06	0.000316	-0.44	-0.22	Depression;	chr6:27866361	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs17763089	ENSG00000219392.1	RP1-265C24.5	-4.92	1.23e-06	0.000316	-0.44	-0.22	Depression;	chr6:27867440	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs17695758	ENSG00000219392.1	RP1-265C24.5	-4.92	1.23e-06	0.000316	-0.44	-0.22	Depression;	chr6:27869405	chr6:28115628~28116551:+
HNSC	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.92	1.23e-06	0.000316	0.29	0.22	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
HNSC	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	4.92	1.23e-06	0.000316	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	4.92	1.23e-06	0.000316	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
HNSC	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	4.92	1.23e-06	0.000316	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28074687	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28076559	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28076704	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28078391	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28080757	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-4.92	1.23e-06	0.000316	-0.26	-0.22	Depression;	chr6:28080760	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000204709.4	LINC01556	4.92	1.23e-06	0.000317	0.31	0.22	Depression;	chr6:28176973	chr6:28943877~28944537:+
HNSC	cis	rs4924935	0.669	rs9916340	ENSG00000264885.1	RP11-815I9.4	-4.92	1.23e-06	0.000317	-0.23	-0.22	Pancreatic cancer;	chr17:18849626	chr17:18667629~18669461:-
HNSC	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-4.92	1.23e-06	0.000317	-0.26	-0.22	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
HNSC	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-4.92	1.23e-06	0.000317	-0.23	-0.22	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-4.92	1.23e-06	0.000317	-0.23	-0.22	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
HNSC	cis	rs9863	0.828	rs11057409	ENSG00000269938.1	RP11-214K3.20	4.92	1.23e-06	0.000317	0.26	0.22	White blood cell count;	chr12:123994784	chr12:123968023~123968579:-
HNSC	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	4.92	1.23e-06	0.000317	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
HNSC	cis	rs3863381	0.764	rs12322631	ENSG00000277715.1	RP11-651L5.3	-4.92	1.23e-06	0.000317	-0.33	-0.22	Night sleep phenotypes;	chr12:105719542	chr12:106250759~106252786:+
HNSC	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.92	1.23e-06	0.000317	-0.21	-0.22	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000204709.4	LINC01556	4.92	1.23e-06	0.000317	0.31	0.22	Depression;	chr6:28173770	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000204709.4	LINC01556	4.92	1.23e-06	0.000317	0.31	0.22	Depression;	chr6:28174809	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000204709.4	LINC01556	4.92	1.23e-06	0.000317	0.31	0.22	Depression;	chr6:28175233	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000204709.4	LINC01556	4.92	1.23e-06	0.000317	0.3	0.22	Depression;	chr6:28071808	chr6:28943877~28944537:+
HNSC	cis	rs4218	0.543	rs35658945	ENSG00000277144.1	RP11-59H7.4	-4.92	1.23e-06	0.000317	-0.28	-0.22	Social communication problems;	chr15:59018053	chr15:59115547~59116089:-
HNSC	cis	rs4218	0.543	rs12050865	ENSG00000277144.1	RP11-59H7.4	-4.92	1.23e-06	0.000317	-0.28	-0.22	Social communication problems;	chr15:59020689	chr15:59115547~59116089:-
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-4.91	1.23e-06	0.000318	-0.27	-0.22	Depression;	chr6:28143758	chr6:28170845~28172521:+
HNSC	cis	rs7809950	0.817	rs3779495	ENSG00000238832.1	snoU109	4.91	1.23e-06	0.000318	0.32	0.22	Coronary artery disease;	chr7:107609815	chr7:107603363~107603507:+
HNSC	cis	rs10462794	1	rs6898916	ENSG00000260763.1	RP11-445O3.3	-4.91	1.23e-06	0.000318	-0.3	-0.22	DNA methylation (variation);	chr5:4481715	chr5:4436850~4440259:-
HNSC	cis	rs224278	0.51	rs1888967	ENSG00000238280.1	RP11-436D10.3	-4.91	1.23e-06	0.000318	-0.27	-0.22	Ewing sarcoma;	chr10:62819700	chr10:62793562~62805887:-
HNSC	cis	rs6928977	0.86	rs2746432	ENSG00000231028.7	LINC00271	4.91	1.23e-06	0.000318	0.26	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135375459	chr6:135497801~135716055:+
HNSC	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	4.91	1.23e-06	0.000318	0.28	0.22	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
HNSC	cis	rs9880211	0.563	rs9881400	ENSG00000273486.1	RP11-731C17.2	4.91	1.24e-06	0.000319	0.2	0.22	Height;Body mass index;	chr3:136142824	chr3:136837338~136839021:-
HNSC	cis	rs36052053	0.908	rs34599673	ENSG00000219700.1	PTCHD3P3	4.91	1.24e-06	0.000319	0.36	0.22	Red cell distribution width;	chr6:109251799	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs13209450	ENSG00000219700.1	PTCHD3P3	4.91	1.24e-06	0.000319	0.36	0.22	Red cell distribution width;	chr6:109252804	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs75793323	ENSG00000219700.1	PTCHD3P3	4.91	1.24e-06	0.000319	0.36	0.22	Red cell distribution width;	chr6:109253508	chr6:109288571~109290503:-
HNSC	cis	rs9816784	0.901	rs56253832	ENSG00000231464.1	AC024937.4	4.91	1.24e-06	0.000319	0.23	0.22	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195996738~195998233:+
HNSC	cis	rs939574	1	rs2293078	ENSG00000243910.6	TUBA4B	4.91	1.24e-06	0.000319	0.45	0.22	Platelet distribution width;	chr2:219235961	chr2:219253243~219272188:+
HNSC	cis	rs939574	1	rs56927225	ENSG00000243910.6	TUBA4B	4.91	1.24e-06	0.000319	0.45	0.22	Platelet distribution width;	chr2:219236200	chr2:219253243~219272188:+
HNSC	cis	rs6693567	0.565	rs698917	ENSG00000228126.1	FALEC	4.91	1.24e-06	0.000319	0.26	0.22	Migraine;	chr1:150347408	chr1:150515757~150518032:+
HNSC	cis	rs1125355	0.655	rs11683568	ENSG00000204380.3	AC005042.4	4.91	1.24e-06	0.000319	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158762690	chr2:158658337~158735002:-
HNSC	cis	rs2836974	0.565	rs2836939	ENSG00000255568.3	BRWD1-AS2	4.91	1.24e-06	0.000319	0.25	0.22	Cognitive function;	chr21:39206620	chr21:39313935~39314962:+
HNSC	cis	rs7048146	0.652	rs10125565	ENSG00000213539.4	YBX1P6	4.91	1.24e-06	0.000319	0.25	0.22	Vascular brain injury;	chr9:109593113	chr9:109532830~109534332:-
HNSC	cis	rs17373728	0.526	rs13275074	ENSG00000249395.2	CASC9	-4.91	1.24e-06	0.000319	-0.29	-0.22	Diabetic kidney disease;	chr8:75247125	chr8:75223404~75324741:-
HNSC	cis	rs13217239	0.646	rs10456352	ENSG00000224843.5	LINC00240	-4.91	1.24e-06	0.000319	-0.22	-0.22	Schizophrenia;	chr6:27022579	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs4583981	ENSG00000224843.5	LINC00240	-4.91	1.24e-06	0.000319	-0.22	-0.22	Schizophrenia;	chr6:27024244	chr6:26956992~27023924:+
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-4.91	1.24e-06	0.000319	-0.27	-0.22	Depression;	chr6:28180209	chr6:28170845~28172521:+
HNSC	cis	rs155076	0.666	rs4638420	ENSG00000233325.3	MIPEPP3	-4.91	1.24e-06	0.00032	-0.38	-0.22	White matter hyperintensity burden;	chr13:21298209	chr13:21298139~21306373:+
HNSC	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-4.91	1.24e-06	0.00032	-0.28	-0.22	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
HNSC	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-4.91	1.24e-06	0.00032	-0.3	-0.22	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
HNSC	cis	rs1971762	0.527	rs4019971	ENSG00000270175.1	RP11-793H13.11	-4.91	1.24e-06	0.00032	-0.19	-0.22	Height;	chr12:53584931	chr12:53500162~53500936:-
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000173295.6	FAM86B3P	-4.91	1.24e-06	0.00032	-0.25	-0.22	Joint mobility (Beighton score);	chr8:8935272	chr8:8228595~8244865:+
HNSC	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	4.91	1.24e-06	0.00032	0.28	0.22	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
HNSC	cis	rs898123	0.931	rs4852760	ENSG00000234896.1	OR7E62P	4.91	1.24e-06	0.00032	0.26	0.22	Coronary artery disease;	chr2:71111117	chr2:71055527~71056003:+
HNSC	cis	rs72843506	0.656	rs77540008	ENSG00000261033.1	RP11-209D14.2	4.91	1.24e-06	0.00032	0.38	0.22	Schizophrenia;	chr17:20069886	chr17:20008051~20009234:-
HNSC	cis	rs3806843	0.868	rs2563291	ENSG00000202515.1	VTRNA1-3	4.91	1.25e-06	0.000321	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr5:140726158~140726246:+
HNSC	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	4.91	1.25e-06	0.000321	0.29	0.22	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
HNSC	cis	rs4664293	0.647	rs2162023	ENSG00000226266.5	AC009961.3	-4.91	1.25e-06	0.000321	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159569719	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs10199805	ENSG00000226266.5	AC009961.3	-4.91	1.25e-06	0.000321	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159570880	chr2:159670708~159712435:-
HNSC	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	4.91	1.25e-06	0.000321	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
HNSC	cis	rs3806843	0.705	rs35614340	ENSG00000202515.1	VTRNA1-3	4.91	1.25e-06	0.000322	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr5:140726158~140726246:+
HNSC	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	4.91	1.25e-06	0.000322	0.26	0.22	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
HNSC	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	4.91	1.25e-06	0.000322	0.24	0.22	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
HNSC	cis	rs2998286	0.862	rs2153300	ENSG00000254635.4	WAC-AS1	-4.91	1.25e-06	0.000322	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28522652~28532743:-
HNSC	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	4.91	1.25e-06	0.000322	0.47	0.22	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
HNSC	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	4.91	1.25e-06	0.000322	0.47	0.22	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
HNSC	cis	rs6693567	0.565	rs3754217	ENSG00000228126.1	FALEC	4.91	1.25e-06	0.000322	0.27	0.22	Migraine;	chr1:150507897	chr1:150515757~150518032:+
HNSC	cis	rs4321325	0.733	rs13421996	ENSG00000236682.1	AC068282.3	-4.91	1.25e-06	0.000322	-0.36	-0.22	Protein C levels;	chr2:127177236	chr2:127389130~127400580:+
HNSC	cis	rs12935418	0.583	rs7206625	ENSG00000261061.1	RP11-303E16.2	-4.91	1.25e-06	0.000322	-0.29	-0.22	Mean corpuscular volume;	chr16:80930536	chr16:81030770~81031485:+
HNSC	cis	rs4218	0.689	rs12440692	ENSG00000277144.1	RP11-59H7.4	-4.91	1.25e-06	0.000322	-0.29	-0.22	Social communication problems;	chr15:59090671	chr15:59115547~59116089:-
HNSC	cis	rs950169	0.65	rs12902052	ENSG00000229212.6	RP11-561C5.4	-4.91	1.25e-06	0.000322	-0.32	-0.22	Schizophrenia;	chr15:84582607	chr15:85205440~85234795:-
HNSC	cis	rs2998286	0.862	rs2790460	ENSG00000254635.4	WAC-AS1	-4.91	1.25e-06	0.000322	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28502093	chr10:28522652~28532743:-
HNSC	cis	rs1125355	0.69	rs62183019	ENSG00000204380.3	AC005042.4	4.91	1.25e-06	0.000322	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158771854	chr2:158658337~158735002:-
HNSC	cis	rs4834770	0.746	rs2389747	ENSG00000249244.1	RP11-548H18.2	4.91	1.25e-06	0.000323	0.24	0.22	Blood protein levels;	chr4:119314947	chr4:119391831~119395335:-
HNSC	cis	rs4834770	0.717	rs1022146	ENSG00000249244.1	RP11-548H18.2	4.91	1.25e-06	0.000323	0.24	0.22	Blood protein levels;	chr4:119314948	chr4:119391831~119395335:-
HNSC	cis	rs9813712	0.595	rs1993217	ENSG00000228252.7	COL6A4P2	-4.91	1.25e-06	0.000323	-0.22	-0.22	Response to amphetamines;	chr3:130284832	chr3:130212823~130273806:+
HNSC	cis	rs8012947	0.916	rs12433823	ENSG00000279636.2	LINC00216	4.91	1.26e-06	0.000323	0.27	0.22	Alcohol consumption in current drinkers;	chr14:58378959	chr14:58288033~58289158:+
HNSC	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	4.91	1.26e-06	0.000323	0.24	0.22	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	4.91	1.26e-06	0.000323	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	4.91	1.26e-06	0.000323	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	4.91	1.26e-06	0.000323	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
HNSC	cis	rs10462794	0.542	rs921389	ENSG00000260763.1	RP11-445O3.3	4.91	1.26e-06	0.000323	0.29	0.22	DNA methylation (variation);	chr5:4515738	chr5:4436850~4440259:-
HNSC	cis	rs6831352	0.879	rs29001208	ENSG00000263923.1	RP11-571L19.7	4.91	1.26e-06	0.000323	0.24	0.22	Alcohol dependence;	chr4:99131388	chr4:98928897~98994994:+
HNSC	cis	rs2179367	0.6	rs9498356	ENSG00000216906.2	RP11-350J20.9	4.91	1.26e-06	0.000323	0.34	0.22	Dupuytren's disease;	chr6:149443337	chr6:149904243~149906418:+
HNSC	cis	rs3806843	0.966	rs2563263	ENSG00000202515.1	VTRNA1-3	-4.91	1.26e-06	0.000324	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr5:140726158~140726246:+
HNSC	cis	rs72843506	0.656	rs28567541	ENSG00000261033.1	RP11-209D14.2	4.91	1.26e-06	0.000324	0.36	0.22	Schizophrenia;	chr17:20051789	chr17:20008051~20009234:-
HNSC	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.91	1.26e-06	0.000324	0.19	0.22	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
HNSC	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-4.91	1.26e-06	0.000324	-0.5	-0.22	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
HNSC	cis	rs6693567	0.565	rs471738	ENSG00000228126.1	FALEC	-4.91	1.26e-06	0.000324	-0.26	-0.22	Migraine;	chr1:150304001	chr1:150515757~150518032:+
HNSC	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-4.91	1.26e-06	0.000324	-0.28	-0.22	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-4.91	1.26e-06	0.000324	-0.27	-0.22	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
HNSC	cis	rs7824557	0.778	rs3808502	ENSG00000269918.1	AF131215.9	4.91	1.26e-06	0.000324	0.22	0.22	Retinal vascular caliber;	chr8:11321949	chr8:11104691~11106704:-
HNSC	cis	rs4924935	0.624	rs9902467	ENSG00000264885.1	RP11-815I9.4	-4.91	1.26e-06	0.000325	-0.23	-0.22	Pancreatic cancer;	chr17:18851614	chr17:18667629~18669461:-
HNSC	cis	rs4761669	0.651	rs7968177	ENSG00000241556.1	RP11-490G8.1	4.91	1.26e-06	0.000325	0.22	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94795821	chr12:95467397~95467861:-
HNSC	cis	rs72772090	0.908	rs72772091	ENSG00000248734.2	CTD-2260A17.1	-4.91	1.26e-06	0.000325	-0.32	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96704418	chr5:96784777~96785999:+
HNSC	cis	rs61542988	0.532	rs10240168	ENSG00000221740.1	SNORD93	4.91	1.26e-06	0.000325	0.27	0.22	Fibrinogen levels;	chr7:22779715	chr7:22856613~22856686:+
HNSC	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	4.91	1.26e-06	0.000325	0.36	0.22	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
HNSC	cis	rs9880211	0.613	rs28535121	ENSG00000273486.1	RP11-731C17.2	4.91	1.26e-06	0.000325	0.2	0.22	Height;Body mass index;	chr3:136173956	chr3:136837338~136839021:-
HNSC	cis	rs35491132	1	rs35491132	ENSG00000219392.1	RP1-265C24.5	-4.91	1.26e-06	0.000325	-0.43	-0.22	Urinary tract infection frequency;	chr6:27559449	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	4.91	1.26e-06	0.000325	0.27	0.22	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
HNSC	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.91	1.26e-06	0.000325	0.23	0.22	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000204709.4	LINC01556	4.91	1.26e-06	0.000325	0.3	0.22	Depression;	chr6:28108492	chr6:28943877~28944537:+
HNSC	cis	rs7429990	0.901	rs9825114	ENSG00000228638.1	FCF1P2	4.91	1.27e-06	0.000325	0.21	0.22	Educational attainment (years of education);	chr3:48096592	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.932	rs6766641	ENSG00000228638.1	FCF1P2	4.91	1.27e-06	0.000325	0.21	0.22	Educational attainment (years of education);	chr3:48103734	chr3:48290793~48291375:-
HNSC	cis	rs3863381	0.764	rs74687485	ENSG00000277715.1	RP11-651L5.3	4.91	1.27e-06	0.000325	0.33	0.22	Night sleep phenotypes;	chr12:105712639	chr12:106250759~106252786:+
HNSC	cis	rs4819052	0.851	rs1999335	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000325	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45293285~45297354:+
HNSC	cis	rs5758511	0.524	rs738257	ENSG00000226450.2	CYP2D8P	4.91	1.27e-06	0.000325	0.22	0.22	Birth weight;	chr22:42173292	chr22:42149886~42155001:-
HNSC	cis	rs9863	0.896	rs7311233	ENSG00000269938.1	RP11-214K3.20	4.91	1.27e-06	0.000325	0.26	0.22	White blood cell count;	chr12:123991393	chr12:123968023~123968579:-
HNSC	cis	rs7824557	0.836	rs2736378	ENSG00000269918.1	AF131215.9	-4.91	1.27e-06	0.000326	-0.22	-0.22	Retinal vascular caliber;	chr8:11262251	chr8:11104691~11106704:-
HNSC	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-4.91	1.27e-06	0.000326	-0.25	-0.22	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
HNSC	cis	rs9840812	0.725	rs3821445	ENSG00000239213.4	NCK1-AS1	-4.91	1.27e-06	0.000326	-0.23	-0.22	Fibrinogen levels;	chr3:136283967	chr3:136841726~136862054:-
HNSC	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	4.91	1.27e-06	0.000326	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	4.91	1.27e-06	0.000326	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	4.91	1.27e-06	0.000326	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-4.91	1.27e-06	0.000326	-0.27	-0.22	Depression;	chr6:28205175	chr6:28161781~28169594:+
HNSC	cis	rs10791097	0.765	rs10894269	ENSG00000254842.5	RP11-890B15.2	-4.91	1.27e-06	0.000327	-0.2	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130852894	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.739	rs4936120	ENSG00000254842.5	RP11-890B15.2	-4.91	1.27e-06	0.000327	-0.2	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130853557	chr11:130844191~130865561:-
HNSC	cis	rs9840812	0.769	rs3755636	ENSG00000273486.1	RP11-731C17.2	4.91	1.27e-06	0.000327	0.2	0.22	Fibrinogen levels;	chr3:136249986	chr3:136837338~136839021:-
HNSC	cis	rs721917	0.525	rs10788338	ENSG00000225484.5	NUTM2B-AS1	-4.91	1.27e-06	0.000327	-0.26	-0.22	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79663088~79826594:-
HNSC	cis	rs6964587	0.732	rs12539523	ENSG00000188693.7	CYP51A1-AS1	-4.91	1.27e-06	0.000327	-0.24	-0.22	Breast cancer;	chr7:92081522	chr7:92134604~92180725:+
HNSC	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-4.91	1.27e-06	0.000327	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
HNSC	cis	rs6693567	0.565	rs834243	ENSG00000228126.1	FALEC	4.91	1.27e-06	0.000327	0.26	0.22	Migraine;	chr1:150366814	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs1313570	ENSG00000228126.1	FALEC	4.91	1.27e-06	0.000327	0.26	0.22	Migraine;	chr1:150370166	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs1260458	ENSG00000228126.1	FALEC	4.91	1.27e-06	0.000327	0.26	0.22	Migraine;	chr1:150374978	chr1:150515757~150518032:+
HNSC	cis	rs9300255	0.679	rs12817892	ENSG00000280120.1	RP11-546D6.3	-4.91	1.27e-06	0.000327	-0.22	-0.22	Neutrophil percentage of white cells;	chr12:123244155	chr12:123152324~123153377:-
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000237310.1	GS1-124K5.4	-4.91	1.27e-06	0.000327	-0.2	-0.22	Aortic root size;	chr7:66597493	chr7:66493706~66495474:+
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-4.91	1.28e-06	0.000328	-0.27	-0.22	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
HNSC	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	4.91	1.28e-06	0.000328	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	4.91	1.28e-06	0.000328	0.26	0.22	Depression;	chr6:28167882	chr6:28170845~28172521:+
HNSC	cis	rs1707322	0.963	rs12145287	ENSG00000234329.1	RP11-767N6.2	4.91	1.28e-06	0.000328	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10789479	ENSG00000234329.1	RP11-767N6.2	4.91	1.28e-06	0.000328	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45651039~45651826:-
HNSC	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	4.91	1.28e-06	0.000328	0.25	0.22	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000250412.1	KLHL2P1	4.91	1.28e-06	0.000328	0.26	0.22	Corneal astigmatism;	chr4:119230297	chr4:119334329~119378233:+
HNSC	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	4.91	1.28e-06	0.000328	0.32	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
HNSC	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	4.91	1.28e-06	0.000328	0.25	0.22	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
HNSC	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-4.91	1.28e-06	0.000328	-0.26	-0.22	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000260075.1	NSFP1	-4.91	1.28e-06	0.000328	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46372855~46487141:+
HNSC	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	4.91	1.28e-06	0.000329	0.29	0.22	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	4.91	1.28e-06	0.000329	0.29	0.22	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	4.91	1.28e-06	0.000329	0.29	0.22	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
HNSC	cis	rs8177876	0.658	rs79603321	ENSG00000261061.1	RP11-303E16.2	-4.91	1.28e-06	0.000329	-0.37	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81039139	chr16:81030770~81031485:+
HNSC	cis	rs4787951	0.56	rs2382720	ENSG00000259940.2	CTD-3203P2.1	-4.91	1.28e-06	0.000329	-0.23	-0.22	Eosinophil percentage of white cells;	chr16:27338691	chr16:27213308~27214993:-
HNSC	cis	rs7048146	0.509	rs7018564	ENSG00000213539.4	YBX1P6	4.91	1.28e-06	0.000329	0.3	0.22	Vascular brain injury;	chr9:109545674	chr9:109532830~109534332:-
HNSC	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-4.91	1.28e-06	0.000329	-0.25	-0.22	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-4.91	1.28e-06	0.000329	-0.25	-0.22	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
HNSC	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-4.91	1.28e-06	0.000329	-0.27	-0.22	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
HNSC	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-4.91	1.28e-06	0.000329	-0.27	-0.22	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
HNSC	cis	rs988913	0.533	rs980822	ENSG00000224984.1	RP11-524H19.2	4.91	1.28e-06	0.000329	0.25	0.22	Menarche (age at onset);	chr6:54989706	chr6:54840118~54840855:-
HNSC	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	4.91	1.28e-06	0.000329	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	4.91	1.28e-06	0.000329	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	4.91	1.28e-06	0.000329	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000254153.1	CTA-398F10.2	4.91	1.28e-06	0.00033	0.24	0.22	Mood instability;	chr8:8401607	chr8:8456909~8461337:-
HNSC	cis	rs13113518	0.51	rs10049561	ENSG00000273257.1	RP11-177J6.1	4.91	1.28e-06	0.00033	0.26	0.22	Height;	chr4:55426623	chr4:55387949~55388271:+
HNSC	cis	rs853679	0.607	rs34396849	ENSG00000219392.1	RP1-265C24.5	-4.91	1.29e-06	0.00033	-0.44	-0.22	Depression;	chr6:28283178	chr6:28115628~28116551:+
HNSC	cis	rs9921338	0.923	rs7186455	ENSG00000263080.1	RP11-485G7.5	4.91	1.29e-06	0.00033	0.23	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11341809~11345211:-
HNSC	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-4.91	1.29e-06	0.00033	-0.21	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
HNSC	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-4.91	1.29e-06	0.00033	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
HNSC	cis	rs7000734	0.674	rs13263827	ENSG00000245080.5	RP11-320N21.1	-4.91	1.29e-06	0.00033	-0.32	-0.22	Radiation response;	chr8:95150736	chr8:95066808~95073182:-
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	4.91	1.29e-06	0.000331	0.27	0.22	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	4.91	1.29e-06	0.000331	0.27	0.22	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	4.91	1.29e-06	0.000331	0.27	0.22	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	4.91	1.29e-06	0.000331	0.27	0.22	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
HNSC	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-4.91	1.29e-06	0.000331	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
HNSC	cis	rs9329221	0.905	rs4610752	ENSG00000255310.2	AF131215.2	-4.91	1.29e-06	0.000331	-0.21	-0.22	Neuroticism;	chr8:10391452	chr8:11107788~11109726:-
HNSC	cis	rs8054556	0.539	rs12596543	ENSG00000183604.13	SMG1P5	-4.91	1.29e-06	0.000331	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30267553~30335374:-
HNSC	cis	rs6604026	0.922	rs12728322	ENSG00000223787.2	RP4-593M8.1	4.91	1.29e-06	0.000331	0.3	0.22	Multiple sclerosis;	chr1:92829235	chr1:92580476~92580821:-
HNSC	cis	rs3806843	1	rs4451093	ENSG00000202515.1	VTRNA1-3	4.91	1.29e-06	0.000331	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr5:140726158~140726246:+
HNSC	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-4.91	1.29e-06	0.000331	-0.25	-0.22	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.713	rs200991	ENSG00000219392.1	RP1-265C24.5	4.9	1.29e-06	0.000331	0.32	0.22	Depression;	chr6:27847716	chr6:28115628~28116551:+
HNSC	cis	rs7615952	0.599	rs12486459	ENSG00000248787.1	RP11-666A20.4	-4.9	1.29e-06	0.000331	-0.32	-0.22	Blood pressure (smoking interaction);	chr3:126022622	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs67575510	ENSG00000248787.1	RP11-666A20.4	-4.9	1.29e-06	0.000331	-0.32	-0.22	Blood pressure (smoking interaction);	chr3:126023512	chr3:125908005~125910272:-
HNSC	cis	rs9329221	0.967	rs7005363	ENSG00000255310.2	AF131215.2	-4.9	1.29e-06	0.000332	-0.21	-0.22	Neuroticism;	chr8:10426238	chr8:11107788~11109726:-
HNSC	cis	rs2243480	0.666	rs1880311	ENSG00000179406.6	LINC00174	4.9	1.29e-06	0.000332	0.5	0.22	Diabetic kidney disease;	chr7:65811765	chr7:66376044~66401338:-
HNSC	cis	rs36093844	0.752	rs56036199	ENSG00000279742.1	RP11-700A24.1	-4.9	1.3e-06	0.000332	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837720	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs7931771	ENSG00000279742.1	RP11-700A24.1	-4.9	1.3e-06	0.000332	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838845	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs7931698	ENSG00000279742.1	RP11-700A24.1	-4.9	1.3e-06	0.000332	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838883	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.706	rs76407487	ENSG00000279742.1	RP11-700A24.1	-4.9	1.3e-06	0.000332	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85839589	chr11:85852557~85854943:-
HNSC	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	4.9	1.3e-06	0.000332	0.25	0.22	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
HNSC	cis	rs988913	0.671	rs4712083	ENSG00000224984.1	RP11-524H19.2	4.9	1.3e-06	0.000332	0.25	0.22	Menarche (age at onset);	chr6:54988872	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.647	rs3125263	ENSG00000224984.1	RP11-524H19.2	4.9	1.3e-06	0.000332	0.25	0.22	Menarche (age at onset);	chr6:54989172	chr6:54840118~54840855:-
HNSC	cis	rs763121	0.853	rs4820345	ENSG00000273076.1	RP3-508I15.22	4.9	1.3e-06	0.000332	0.24	0.22	Menopause (age at onset);	chr22:38695146	chr22:38743495~38743910:+
HNSC	cis	rs4873772	0.702	rs6982620	ENSG00000253330.1	RP11-697N18.3	-4.9	1.3e-06	0.000332	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47483717	chr8:47511034~47512141:-
HNSC	cis	rs2985684	1	rs8014170	ENSG00000278009.1	RP11-649E7.8	4.9	1.3e-06	0.000332	0.29	0.22	Carotid intima media thickness;	chr14:49604976	chr14:49601011~49601124:-
HNSC	cis	rs9813712	0.571	rs9836814	ENSG00000249846.5	RP11-77P16.4	4.9	1.3e-06	0.000333	0.23	0.22	Response to amphetamines;	chr3:130216054	chr3:130112550~130120579:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000204709.4	LINC01556	4.9	1.3e-06	0.000333	0.3	0.22	Depression;	chr6:28070115	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000204709.4	LINC01556	4.9	1.3e-06	0.000333	0.3	0.22	Depression;	chr6:28071237	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-4.9	1.3e-06	0.000333	-0.26	-0.22	Depression;	chr6:28071808	chr6:28170845~28172521:+
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000219392.1	RP1-265C24.5	-4.9	1.3e-06	0.000333	-0.24	-0.22	Pubertal anthropometrics;	chr6:28430174	chr6:28115628~28116551:+
HNSC	cis	rs1056107	0.931	rs7041185	ENSG00000225513.1	RP11-165N19.2	-4.9	1.3e-06	0.000333	-0.24	-0.22	Colorectal cancer;	chr9:112225084	chr9:112173522~112173971:-
HNSC	cis	rs2337406	0.85	rs75196489	ENSG00000280411.1	IGHV1-69-2	-4.9	1.3e-06	0.000333	-0.22	-0.22	Alzheimer's disease (late onset);	chr14:106699438	chr14:106762092~106762588:-
HNSC	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-4.9	1.3e-06	0.000333	-0.26	-0.22	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
HNSC	cis	rs13126694	0.778	rs10000610	ENSG00000248429.4	RP11-597D13.9	4.9	1.3e-06	0.000333	0.25	0.22	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158170752~158202877:+
HNSC	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.9	1.3e-06	0.000333	0.26	0.22	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
HNSC	cis	rs8012947	0.607	rs8004532	ENSG00000279636.2	LINC00216	4.9	1.3e-06	0.000333	0.25	0.22	Alcohol consumption in current drinkers;	chr14:58363791	chr14:58288033~58289158:+
HNSC	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	4.9	1.3e-06	0.000333	0.24	0.22	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
HNSC	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	4.9	1.3e-06	0.000333	0.24	0.22	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
HNSC	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.9	1.3e-06	0.000334	-0.27	-0.22	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
HNSC	cis	rs2998286	0.723	rs2772435	ENSG00000254635.4	WAC-AS1	-4.9	1.3e-06	0.000334	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28546534	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs2807759	ENSG00000254635.4	WAC-AS1	-4.9	1.3e-06	0.000334	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28548682	chr10:28522652~28532743:-
HNSC	cis	rs5758511	0.689	rs56906457	ENSG00000226450.2	CYP2D8P	4.9	1.3e-06	0.000334	0.22	0.22	Birth weight;	chr22:42232329	chr22:42149886~42155001:-
HNSC	cis	rs1056107	0.898	rs3736985	ENSG00000225513.1	RP11-165N19.2	-4.9	1.3e-06	0.000334	-0.24	-0.22	Colorectal cancer;	chr9:112228093	chr9:112173522~112173971:-
HNSC	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-4.9	1.3e-06	0.000334	-0.28	-0.22	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
HNSC	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-4.9	1.3e-06	0.000334	-0.28	-0.22	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
HNSC	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.9	1.3e-06	0.000334	0.35	0.22	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
HNSC	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-4.9	1.3e-06	0.000334	-0.21	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
HNSC	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-4.9	1.3e-06	0.000334	-0.21	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
HNSC	cis	rs950169	0.881	rs34117475	ENSG00000229212.6	RP11-561C5.4	-4.9	1.3e-06	0.000334	-0.32	-0.22	Schizophrenia;	chr15:84565212	chr15:85205440~85234795:-
HNSC	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	4.9	1.3e-06	0.000334	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
HNSC	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-4.9	1.31e-06	0.000334	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
HNSC	cis	rs7296418	0.961	rs1790121	ENSG00000280120.1	RP11-546D6.3	4.9	1.31e-06	0.000334	0.19	0.22	Platelet count;	chr12:123119945	chr12:123152324~123153377:-
HNSC	cis	rs12935418	0.672	rs9888895	ENSG00000261061.1	RP11-303E16.2	-4.9	1.31e-06	0.000335	-0.25	-0.22	Mean corpuscular volume;	chr16:81017496	chr16:81030770~81031485:+
HNSC	cis	rs6601327	0.573	rs13278824	ENSG00000254340.1	RP11-10A14.3	4.9	1.31e-06	0.000335	0.27	0.22	Multiple myeloma (hyperdiploidy);	chr8:9788609	chr8:9141424~9145435:+
HNSC	cis	rs6693567	0.545	rs1932934	ENSG00000228126.1	FALEC	4.9	1.31e-06	0.000335	0.27	0.22	Migraine;	chr1:150476719	chr1:150515757~150518032:+
HNSC	cis	rs71520386	0.632	rs2286500	ENSG00000221740.1	SNORD93	-4.9	1.31e-06	0.000335	-0.26	-0.22	Fibrinogen levels;	chr7:22817185	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.607	rs28617621	ENSG00000221740.1	SNORD93	-4.9	1.31e-06	0.000335	-0.26	-0.22	Fibrinogen levels;	chr7:22818063	chr7:22856613~22856686:+
HNSC	cis	rs2834288	0.535	rs7275560	ENSG00000273102.1	AP000569.9	-4.9	1.31e-06	0.000335	-0.24	-0.22	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.535	rs2834306	ENSG00000273102.1	AP000569.9	-4.9	1.31e-06	0.000335	-0.24	-0.22	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33967101~33968573:-
HNSC	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	4.9	1.31e-06	0.000335	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	4.9	1.31e-06	0.000335	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-4.9	1.31e-06	0.000335	-0.23	-0.22	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
HNSC	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-4.9	1.31e-06	0.000335	-0.23	-0.22	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-4.9	1.31e-06	0.000335	-0.23	-0.22	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-4.9	1.31e-06	0.000335	-0.23	-0.22	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
HNSC	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-4.9	1.31e-06	0.000335	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
HNSC	cis	rs9450351	0.744	rs7772723	ENSG00000203875.9	SNHG5	-4.9	1.31e-06	0.000335	-0.46	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85913980	chr6:85660950~85678736:-
HNSC	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.9	1.31e-06	0.000336	-0.25	-0.22	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
HNSC	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-4.9	1.31e-06	0.000336	-0.35	-0.22	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
HNSC	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-4.9	1.31e-06	0.000336	-0.31	-0.22	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
HNSC	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-4.9	1.31e-06	0.000336	-0.25	-0.22	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
HNSC	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-4.9	1.31e-06	0.000336	-0.26	-0.22	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	4.9	1.31e-06	0.000336	0.24	0.22	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
HNSC	cis	rs853679	0.607	rs13205211	ENSG00000219392.1	RP1-265C24.5	-4.9	1.31e-06	0.000336	-0.44	-0.22	Depression;	chr6:28235278	chr6:28115628~28116551:+
HNSC	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	4.9	1.31e-06	0.000337	0.25	0.22	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	4.9	1.31e-06	0.000337	0.24	0.22	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
HNSC	cis	rs7789940	0.904	rs73140040	ENSG00000231087.2	FDPSP7	-4.9	1.32e-06	0.000337	-0.27	-0.22	Multiple sclerosis;	chr7:76306923	chr7:76968197~76969250:-
HNSC	cis	rs2976388	0.669	rs1836633	ENSG00000253741.1	CTD-2292P10.4	-4.9	1.32e-06	0.000337	-0.21	-0.22	Urinary tract infection frequency;	chr8:142693174	chr8:142702252~142726973:-
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000254153.1	CTA-398F10.2	-4.9	1.32e-06	0.000337	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9011689	chr8:8456909~8461337:-
HNSC	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-4.9	1.32e-06	0.000337	-0.2	-0.22	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
HNSC	cis	rs8177876	0.749	rs12927828	ENSG00000261061.1	RP11-303E16.2	-4.9	1.32e-06	0.000337	-0.34	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81030770~81031485:+
HNSC	cis	rs5758511	0.514	rs2899354	ENSG00000226450.2	CYP2D8P	4.9	1.32e-06	0.000337	0.22	0.22	Birth weight;	chr22:42158403	chr22:42149886~42155001:-
HNSC	cis	rs7615952	0.641	rs12487875	ENSG00000248787.1	RP11-666A20.4	-4.9	1.32e-06	0.000337	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126068381	chr3:125908005~125910272:-
HNSC	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-4.9	1.32e-06	0.000337	-0.22	-0.22	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
HNSC	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	4.9	1.32e-06	0.000337	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
HNSC	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	4.9	1.32e-06	0.000337	0.25	0.22	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
HNSC	cis	rs9880211	0.613	rs12330335	ENSG00000273486.1	RP11-731C17.2	4.9	1.32e-06	0.000337	0.2	0.22	Height;Body mass index;	chr3:136134690	chr3:136837338~136839021:-
HNSC	cis	rs6964587	1	rs9784993	ENSG00000188693.7	CYP51A1-AS1	-4.9	1.32e-06	0.000337	-0.23	-0.22	Breast cancer;	chr7:92043089	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs36120033	ENSG00000188693.7	CYP51A1-AS1	-4.9	1.32e-06	0.000337	-0.23	-0.22	Breast cancer;	chr7:92049984	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs1859113	ENSG00000188693.7	CYP51A1-AS1	-4.9	1.32e-06	0.000337	-0.23	-0.22	Breast cancer;	chr7:92050573	chr7:92134604~92180725:+
HNSC	cis	rs13217239	0.646	rs4403259	ENSG00000224843.5	LINC00240	-4.9	1.32e-06	0.000337	-0.21	-0.22	Schizophrenia;	chr6:27029838	chr6:26956992~27023924:+
HNSC	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-4.9	1.32e-06	0.000337	-0.22	-0.22	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
HNSC	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-4.9	1.32e-06	0.000337	-0.22	-0.22	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
HNSC	cis	rs67981189	0.778	rs2189807	ENSG00000274818.1	RP1-292L20.3	4.9	1.32e-06	0.000337	0.25	0.22	Schizophrenia;	chr14:70896314	chr14:70906657~70907111:-
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000254153.1	CTA-398F10.2	-4.9	1.32e-06	0.000337	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9053494	chr8:8456909~8461337:-
HNSC	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-4.9	1.32e-06	0.000337	-0.29	-0.22	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-4.9	1.32e-06	0.000337	-0.25	-0.22	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
HNSC	cis	rs4664293	0.647	rs1549385	ENSG00000226266.5	AC009961.3	-4.9	1.32e-06	0.000338	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159582540	chr2:159670708~159712435:-
HNSC	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	4.9	1.32e-06	0.000338	0.21	0.22	Height;	chr5:37454360	chr5:36666214~36725195:-
HNSC	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-4.9	1.32e-06	0.000338	-0.29	-0.22	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	4.9	1.32e-06	0.000338	0.3	0.22	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
HNSC	cis	rs9907295	0.688	rs9890583	ENSG00000270977.1	AC015849.16	-4.9	1.32e-06	0.000338	-0.31	-0.22	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35893707~35911023:-
HNSC	cis	rs45509595	0.841	rs17751184	ENSG00000219392.1	RP1-265C24.5	-4.9	1.32e-06	0.000338	-0.43	-0.22	Breast cancer;	chr6:27807250	chr6:28115628~28116551:+
HNSC	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	4.9	1.32e-06	0.000338	0.21	0.22	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
HNSC	cis	rs3733585	0.699	rs28610447	ENSG00000250413.1	RP11-448G15.1	4.9	1.32e-06	0.000339	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9969893	chr4:10006482~10009725:+
HNSC	cis	rs9435732	0.945	rs2311528	ENSG00000186715.9	MST1L	4.9	1.32e-06	0.000339	0.22	0.22	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16983045	chr1:16754910~16770237:-
HNSC	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-4.9	1.33e-06	0.000339	-0.19	-0.22	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
HNSC	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-4.9	1.33e-06	0.000339	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-4.9	1.33e-06	0.000339	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
HNSC	cis	rs7809950	0.861	rs10264412	ENSG00000238832.1	snoU109	-4.9	1.33e-06	0.000339	-0.32	-0.22	Coronary artery disease;	chr7:107543432	chr7:107603363~107603507:+
HNSC	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-4.9	1.33e-06	0.000339	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
HNSC	cis	rs853679	0.607	rs13199772	ENSG00000219392.1	RP1-265C24.5	-4.9	1.33e-06	0.00034	-0.44	-0.22	Depression;	chr6:27866307	chr6:28115628~28116551:+
HNSC	cis	rs1665050	0.598	rs8041221	ENSG00000259732.1	RP11-59H7.3	-4.9	1.33e-06	0.00034	-0.27	-0.22	Atopic dermatitis;	chr15:59042609	chr15:59121034~59133250:+
HNSC	cis	rs12986445	0.793	rs6747116	ENSG00000218682.1	AC010150.1	4.9	1.33e-06	0.00034	0.29	0.22	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25746860	chr2:25856461~25856966:-
HNSC	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	4.9	1.33e-06	0.00034	0.24	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
HNSC	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.9	1.33e-06	0.00034	0.26	0.22	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
HNSC	cis	rs6693567	0.545	rs2133129	ENSG00000228126.1	FALEC	4.9	1.33e-06	0.00034	0.26	0.22	Migraine;	chr1:150383061	chr1:150515757~150518032:+
HNSC	cis	rs73198271	0.74	rs10100066	ENSG00000173295.6	FAM86B3P	-4.9	1.33e-06	0.00034	-0.29	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.74	rs10110711	ENSG00000173295.6	FAM86B3P	-4.9	1.33e-06	0.00034	-0.29	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8228595~8244865:+
HNSC	cis	rs1538970	0.781	rs34768551	ENSG00000234329.1	RP11-767N6.2	4.9	1.33e-06	0.00034	0.26	0.22	Platelet count;	chr1:45554736	chr1:45651039~45651826:-
HNSC	cis	rs9863	0.828	rs7135314	ENSG00000269938.1	RP11-214K3.20	-4.9	1.33e-06	0.000341	-0.26	-0.22	White blood cell count;	chr12:123994019	chr12:123968023~123968579:-
HNSC	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-4.9	1.33e-06	0.000341	-0.27	-0.22	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
HNSC	cis	rs1707322	1	rs6677777	ENSG00000234329.1	RP11-767N6.2	4.9	1.33e-06	0.000341	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45651039~45651826:-
HNSC	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-4.9	1.33e-06	0.000341	-0.22	-0.22	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
HNSC	cis	rs7535099	0.954	rs2376016	ENSG00000224570.1	RP11-430H12.2	4.9	1.33e-06	0.000341	0.28	0.22	Blood protein levels;	chr1:65568313	chr1:65576129~65578380:-
HNSC	cis	rs4853525	0.59	rs11893307	ENSG00000235852.1	AC005540.3	-4.9	1.33e-06	0.000341	-0.3	-0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863318	chr2:190880797~190882059:-
HNSC	cis	rs2762353	0.526	rs6456693	ENSG00000272462.2	U91328.19	4.9	1.33e-06	0.000341	0.21	0.22	Blood metabolite levels;	chr6:25709859	chr6:25992662~26001775:+
HNSC	cis	rs1125355	0.656	rs17809948	ENSG00000204380.3	AC005042.4	-4.9	1.33e-06	0.000341	-0.24	-0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158776903	chr2:158658337~158735002:-
HNSC	cis	rs1056107	0.763	rs10759529	ENSG00000225513.1	RP11-165N19.2	-4.9	1.34e-06	0.000341	-0.23	-0.22	Colorectal cancer;	chr9:112176651	chr9:112173522~112173971:-
HNSC	cis	rs9291683	0.62	rs4383618	ENSG00000250413.1	RP11-448G15.1	4.9	1.34e-06	0.000341	0.28	0.22	Bone mineral density;	chr4:10123527	chr4:10006482~10009725:+
HNSC	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-4.9	1.34e-06	0.000341	-0.24	-0.22	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
HNSC	cis	rs656319	0.513	rs34748716	ENSG00000269918.1	AF131215.9	-4.9	1.34e-06	0.000341	-0.23	-0.22	Myopia (pathological);	chr8:10116208	chr8:11104691~11106704:-
HNSC	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-4.9	1.34e-06	0.000342	-0.28	-0.22	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-4.9	1.34e-06	0.000342	-0.28	-0.22	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
HNSC	cis	rs9650657	0.74	rs11250077	ENSG00000269918.1	AF131215.9	-4.9	1.34e-06	0.000342	-0.22	-0.22	Neuroticism;	chr8:10798927	chr8:11104691~11106704:-
HNSC	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	4.9	1.34e-06	0.000342	0.25	0.22	Height;	chr2:46635447	chr2:46668870~46670778:+
HNSC	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-4.9	1.34e-06	0.000342	-0.23	-0.22	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-4.9	1.34e-06	0.000342	-0.23	-0.22	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
HNSC	cis	rs10466239	0.73	rs2245413	ENSG00000230555.2	RP11-517P14.2	-4.9	1.34e-06	0.000342	-0.29	-0.22	Telomere length;	chr10:43355120	chr10:43420738~43422100:+
HNSC	cis	rs9880211	0.613	rs28519617	ENSG00000273486.1	RP11-731C17.2	4.9	1.34e-06	0.000342	0.2	0.22	Height;Body mass index;	chr3:136156088	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.613	rs28669017	ENSG00000273486.1	RP11-731C17.2	4.9	1.34e-06	0.000342	0.2	0.22	Height;Body mass index;	chr3:136156090	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.613	rs10222451	ENSG00000273486.1	RP11-731C17.2	4.9	1.34e-06	0.000342	0.2	0.22	Height;Body mass index;	chr3:136158571	chr3:136837338~136839021:-
HNSC	cis	rs1707322	1	rs10158032	ENSG00000234329.1	RP11-767N6.2	4.9	1.34e-06	0.000342	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45651039~45651826:-
HNSC	cis	rs4873772	0.735	rs4873368	ENSG00000253330.1	RP11-697N18.3	-4.9	1.34e-06	0.000342	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47495279	chr8:47511034~47512141:-
HNSC	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	4.9	1.34e-06	0.000342	0.39	0.22	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
HNSC	cis	rs5758511	0.514	rs9611746	ENSG00000226450.2	CYP2D8P	4.9	1.34e-06	0.000342	0.22	0.22	Birth weight;	chr22:42165359	chr22:42149886~42155001:-
HNSC	cis	rs17253792	0.822	rs10151664	ENSG00000186615.9	KTN1-AS1	-4.9	1.34e-06	0.000342	-0.44	-0.22	Putamen volume;	chr14:55562815	chr14:55499278~55580110:-
HNSC	cis	rs10504130	0.569	rs35509250	ENSG00000272024.1	RP11-546K22.3	-4.9	1.34e-06	0.000342	-0.31	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51950284~51950690:+
HNSC	cis	rs3806843	0.733	rs801181	ENSG00000202515.1	VTRNA1-3	4.9	1.34e-06	0.000343	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr5:140726158~140726246:+
HNSC	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-4.9	1.34e-06	0.000343	-0.27	-0.22	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
HNSC	cis	rs853679	0.607	rs34878803	ENSG00000219392.1	RP1-265C24.5	-4.9	1.34e-06	0.000343	-0.44	-0.22	Depression;	chr6:28282402	chr6:28115628~28116551:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000254153.1	CTA-398F10.2	4.9	1.34e-06	0.000343	0.25	0.22	Neuroticism;	chr8:8252414	chr8:8456909~8461337:-
HNSC	cis	rs916888	0.773	rs199451	ENSG00000260075.1	NSFP1	-4.9	1.34e-06	0.000343	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46372855~46487141:+
HNSC	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-4.9	1.34e-06	0.000343	-0.2	-0.22	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
HNSC	cis	rs867371	0.929	rs1501371	ENSG00000259429.4	UBE2Q2P2	-4.9	1.34e-06	0.000343	-0.21	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82355142~82420075:+
HNSC	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-4.9	1.34e-06	0.000343	-0.21	-0.22	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
HNSC	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-4.9	1.34e-06	0.000343	-0.25	-0.22	Height;	chr2:46636416	chr2:46668870~46670778:+
HNSC	cis	rs4834770	0.718	rs4833618	ENSG00000249244.1	RP11-548H18.2	-4.9	1.34e-06	0.000343	-0.24	-0.22	Blood protein levels;	chr4:119388345	chr4:119391831~119395335:-
HNSC	cis	rs853679	0.546	rs35744819	ENSG00000219392.1	RP1-265C24.5	-4.9	1.34e-06	0.000343	-0.44	-0.22	Depression;	chr6:28350554	chr6:28115628~28116551:+
HNSC	cis	rs4853525	0.59	rs6740086	ENSG00000235852.1	AC005540.3	4.9	1.34e-06	0.000343	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190871204	chr2:190880797~190882059:-
HNSC	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.34e-06	0.000343	-0.23	-0.22	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
HNSC	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	4.9	1.34e-06	0.000343	0.28	0.22	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
HNSC	cis	rs11756659	0.505	rs16891146	ENSG00000272462.2	U91328.19	-4.9	1.34e-06	0.000343	-0.24	-0.22	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25903080	chr6:25992662~26001775:+
HNSC	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-4.9	1.35e-06	0.000344	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
HNSC	cis	rs7296418	0.754	rs1619283	ENSG00000280120.1	RP11-546D6.3	4.9	1.35e-06	0.000344	0.19	0.22	Platelet count;	chr12:123232815	chr12:123152324~123153377:-
HNSC	cis	rs988913	0.581	rs1108887	ENSG00000224984.1	RP11-524H19.2	-4.9	1.35e-06	0.000344	-0.25	-0.22	Menarche (age at onset);	chr6:54992409	chr6:54840118~54840855:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	4.9	1.35e-06	0.000344	0.23	0.22	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
HNSC	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-4.9	1.35e-06	0.000344	-0.19	-0.22	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
HNSC	cis	rs12935418	0.672	rs2602423	ENSG00000261061.1	RP11-303E16.2	4.9	1.35e-06	0.000344	0.24	0.22	Mean corpuscular volume;	chr16:81008423	chr16:81030770~81031485:+
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000204709.4	LINC01556	4.9	1.35e-06	0.000344	0.3	0.22	Depression;	chr6:28110254	chr6:28943877~28944537:+
HNSC	cis	rs9840812	0.861	rs684773	ENSG00000239213.4	NCK1-AS1	4.9	1.35e-06	0.000344	0.21	0.22	Fibrinogen levels;	chr3:136237463	chr3:136841726~136862054:-
HNSC	cis	rs6964587	1	rs28410528	ENSG00000188693.7	CYP51A1-AS1	-4.9	1.35e-06	0.000344	-0.23	-0.22	Breast cancer;	chr7:92018076	chr7:92134604~92180725:+
HNSC	cis	rs67981189	0.542	rs1012725	ENSG00000274818.1	RP1-292L20.3	-4.9	1.35e-06	0.000344	-0.28	-0.22	Schizophrenia;	chr14:71138994	chr14:70906657~70907111:-
HNSC	cis	rs11893307	0.566	rs7558832	ENSG00000228509.4	AC006460.2	4.9	1.35e-06	0.000344	0.29	0.22	Mean platelet volume;	chr2:190695863	chr2:190676944~190708716:-
HNSC	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	4.9	1.35e-06	0.000344	0.29	0.22	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
HNSC	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	4.9	1.35e-06	0.000345	0.25	0.22	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
HNSC	cis	rs67981189	0.647	rs36555	ENSG00000274818.1	RP1-292L20.3	-4.9	1.35e-06	0.000345	-0.26	-0.22	Schizophrenia;	chr14:70897844	chr14:70906657~70907111:-
HNSC	cis	rs375092	0.543	rs6461708	ENSG00000230658.1	KLHL7-AS1	-4.9	1.35e-06	0.000345	-0.36	-0.22	Personality dimensions;	chr7:23375698	chr7:23101228~23105703:-
HNSC	cis	rs36052053	0.908	rs13203987	ENSG00000219700.1	PTCHD3P3	4.9	1.35e-06	0.000345	0.35	0.22	Red cell distribution width;	chr6:109264037	chr6:109288571~109290503:-
HNSC	cis	rs10791097	0.69	rs12284540	ENSG00000254842.5	RP11-890B15.2	-4.9	1.35e-06	0.000345	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130859877	chr11:130844191~130865561:-
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000224373.3	IGHV4-59	4.9	1.35e-06	0.000345	0.14	0.22	Kawasaki disease;	chr14:106668657	chr14:106627249~106627825:-
HNSC	cis	rs2998286	0.862	rs2807763	ENSG00000254635.4	WAC-AS1	4.9	1.35e-06	0.000345	0.28	0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528702	chr10:28522652~28532743:-
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-4.9	1.35e-06	0.000346	-0.26	-0.22	Depression;	chr6:28144784	chr6:28170845~28172521:+
HNSC	cis	rs577676	0.586	rs10489231	ENSG00000271811.1	RP1-79C4.4	-4.9	1.35e-06	0.000346	-0.25	-0.22	Prevalent atrial fibrillation;	chr1:170620296	chr1:170667381~170669425:+
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28111382	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28111650	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Parkinson's disease;	chr6:28112168	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28112175	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28113851	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28114487	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28114933	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28115743	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Depression;	chr6:28116411	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Parkinson's disease;	chr6:28118700	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Parkinson's disease;	chr6:28118701	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000204709.4	LINC01556	4.9	1.36e-06	0.000346	0.3	0.22	Parkinson's disease;	chr6:28119896	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	4.9	1.36e-06	0.000346	0.27	0.22	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
HNSC	cis	rs1971762	0.563	rs11170645	ENSG00000270175.1	RP11-793H13.11	-4.9	1.36e-06	0.000346	-0.19	-0.22	Height;	chr12:53685296	chr12:53500162~53500936:-
HNSC	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-4.9	1.36e-06	0.000346	-0.19	-0.22	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
HNSC	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.9	1.36e-06	0.000346	0.22	0.22	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
HNSC	cis	rs12817211	0.502	rs7307230	ENSG00000272368.2	RP4-605O3.4	4.89	1.36e-06	0.000346	0.21	0.22	Colorectal or endometrial cancer;	chr12:50118849	chr12:50112197~50165618:+
HNSC	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	4.89	1.36e-06	0.000346	0.27	0.22	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	4.89	1.36e-06	0.000346	0.27	0.22	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
HNSC	cis	rs763512	0.504	rs11652399	ENSG00000276054.1	RP11-378E13.3	4.89	1.36e-06	0.000346	0.32	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37509679	chr17:37386886~37387926:+
HNSC	cis	rs4853525	0.59	rs1860168	ENSG00000235852.1	AC005540.3	4.89	1.36e-06	0.000346	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859774	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.59	rs9973507	ENSG00000235852.1	AC005540.3	4.89	1.36e-06	0.000346	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190860922	chr2:190880797~190882059:-
HNSC	cis	rs911555	0.57	rs752624	ENSG00000270108.1	RP11-73M18.6	4.89	1.36e-06	0.000346	0.25	0.22	Intelligence (multi-trait analysis);	chr14:103554117	chr14:103687576~103688127:+
HNSC	cis	rs7829975	0.774	rs35039922	ENSG00000254153.1	CTA-398F10.2	4.89	1.36e-06	0.000347	0.24	0.22	Mood instability;	chr8:8817815	chr8:8456909~8461337:-
HNSC	cis	rs7746199	0.736	rs34064842	ENSG00000219392.1	RP1-265C24.5	-4.89	1.36e-06	0.000347	-0.43	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28115628~28116551:+
HNSC	cis	rs7615952	0.576	rs66671308	ENSG00000248787.1	RP11-666A20.4	-4.89	1.36e-06	0.000347	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126074683	chr3:125908005~125910272:-
HNSC	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	4.89	1.36e-06	0.000347	0.3	0.22	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
HNSC	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.89	1.36e-06	0.000347	0.25	0.22	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
HNSC	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	4.89	1.36e-06	0.000347	0.21	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
HNSC	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	4.89	1.36e-06	0.000347	0.24	0.22	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
HNSC	cis	rs2933343	0.729	rs1683780	ENSG00000261159.1	RP11-723O4.9	4.89	1.36e-06	0.000347	0.22	0.22	IgG glycosylation;	chr3:128921396	chr3:128859716~128860526:-
HNSC	cis	rs17253792	0.822	rs10142497	ENSG00000186615.9	KTN1-AS1	4.89	1.36e-06	0.000347	0.4	0.22	Putamen volume;	chr14:55581230	chr14:55499278~55580110:-
HNSC	cis	rs3733585	0.624	rs58130873	ENSG00000250413.1	RP11-448G15.1	4.89	1.36e-06	0.000348	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9970457	chr4:10006482~10009725:+
HNSC	cis	rs4819052	0.851	rs2838844	ENSG00000223768.1	LINC00205	-4.89	1.36e-06	0.000348	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45293285~45297354:+
HNSC	cis	rs7104745	0.551	rs948113	ENSG00000254967.5	RP11-680F20.6	-4.89	1.36e-06	0.000348	-0.24	-0.22	Breast size;	chr11:125954842	chr11:125950116~125956319:+
HNSC	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	4.89	1.37e-06	0.000348	0.25	0.22	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
HNSC	cis	rs9329221	0.905	rs17709397	ENSG00000255310.2	AF131215.2	-4.89	1.37e-06	0.000348	-0.21	-0.22	Neuroticism;	chr8:10392351	chr8:11107788~11109726:-
HNSC	cis	rs763121	0.853	rs5757141	ENSG00000273076.1	RP3-508I15.22	4.89	1.37e-06	0.000348	0.24	0.22	Menopause (age at onset);	chr22:38561478	chr22:38743495~38743910:+
HNSC	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-4.89	1.37e-06	0.000348	-0.25	-0.22	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
HNSC	cis	rs6964587	0.967	rs6465340	ENSG00000188693.7	CYP51A1-AS1	-4.89	1.37e-06	0.000348	-0.23	-0.22	Breast cancer;	chr7:91959350	chr7:92134604~92180725:+
HNSC	cis	rs6723108	0.603	rs1374289	ENSG00000224043.6	CCNT2-AS1	4.89	1.37e-06	0.000348	0.27	0.22	Type 2 diabetes;	chr2:134936809	chr2:134735464~134918710:-
HNSC	cis	rs1056107	0.863	rs7041663	ENSG00000225513.1	RP11-165N19.2	-4.89	1.37e-06	0.000348	-0.24	-0.22	Colorectal cancer;	chr9:112240538	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.898	rs1831118	ENSG00000225513.1	RP11-165N19.2	-4.89	1.37e-06	0.000348	-0.24	-0.22	Colorectal cancer;	chr9:112240552	chr9:112173522~112173971:-
HNSC	cis	rs12935418	0.672	rs2549879	ENSG00000261061.1	RP11-303E16.2	4.89	1.37e-06	0.000348	0.24	0.22	Mean corpuscular volume;	chr16:81012496	chr16:81030770~81031485:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000254153.1	CTA-398F10.2	-4.89	1.37e-06	0.000349	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9026993	chr8:8456909~8461337:-
HNSC	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.89	1.37e-06	0.000349	0.34	0.22	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.89	1.37e-06	0.000349	0.34	0.22	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
HNSC	cis	rs67981189	0.593	rs221906	ENSG00000274818.1	RP1-292L20.3	4.89	1.37e-06	0.000349	0.24	0.22	Schizophrenia;	chr14:71130676	chr14:70906657~70907111:-
HNSC	cis	rs6723108	0.627	rs7589297	ENSG00000224043.6	CCNT2-AS1	-4.89	1.37e-06	0.000349	-0.27	-0.22	Type 2 diabetes;	chr2:134894829	chr2:134735464~134918710:-
HNSC	cis	rs72949976	0.584	rs12471432	ENSG00000270659.1	RP11-105N14.1	-4.89	1.37e-06	0.00035	-0.21	-0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213158169	chr2:213152970~213153659:+
HNSC	cis	rs72949976	0.584	rs12467619	ENSG00000270659.1	RP11-105N14.1	-4.89	1.37e-06	0.00035	-0.21	-0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213158209	chr2:213152970~213153659:+
HNSC	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	4.89	1.37e-06	0.00035	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
HNSC	cis	rs1707322	1	rs785478	ENSG00000234329.1	RP11-767N6.2	-4.89	1.37e-06	0.00035	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45651039~45651826:-
HNSC	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-4.89	1.37e-06	0.00035	-0.27	-0.22	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
HNSC	cis	rs1971762	0.563	rs3897117	ENSG00000270175.1	RP11-793H13.11	-4.89	1.37e-06	0.00035	-0.19	-0.22	Height;	chr12:53683623	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.563	rs7958775	ENSG00000270175.1	RP11-793H13.11	-4.89	1.37e-06	0.00035	-0.19	-0.22	Height;	chr12:53683772	chr12:53500162~53500936:-
HNSC	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-4.89	1.38e-06	0.000351	-0.28	-0.22	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
HNSC	cis	rs75422866	0.867	rs73113117	ENSG00000276691.1	RP5-1057I20.5	4.89	1.38e-06	0.000351	0.4	0.22	Pneumonia;	chr12:47617299	chr12:47788426~47788971:+
HNSC	cis	rs4218	0.587	rs1446237	ENSG00000277144.1	RP11-59H7.4	-4.89	1.38e-06	0.000351	-0.28	-0.22	Social communication problems;	chr15:59052603	chr15:59115547~59116089:-
HNSC	cis	rs792448	0.501	rs11119880	ENSG00000226251.4	RP11-15I11.3	-4.89	1.38e-06	0.000351	-0.25	-0.22	White blood cell count (basophil);	chr1:212205143	chr1:212225278~212238977:-
HNSC	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-4.89	1.38e-06	0.000351	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
HNSC	cis	rs6496044	0.568	rs6496039	ENSG00000259295.5	CSPG4P12	4.89	1.38e-06	0.000351	0.26	0.22	Interstitial lung disease;	chr15:85518732	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-4.89	1.38e-06	0.000351	-0.27	-0.22	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
HNSC	cis	rs1971762	0.522	rs10747680	ENSG00000270175.1	RP11-793H13.11	-4.89	1.38e-06	0.000351	-0.19	-0.22	Height;	chr12:53683992	chr12:53500162~53500936:-
HNSC	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	4.89	1.38e-06	0.000351	0.3	0.22	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
HNSC	cis	rs8012947	0.651	rs74055634	ENSG00000279636.2	LINC00216	4.89	1.38e-06	0.000351	0.25	0.22	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58288033~58289158:+
HNSC	cis	rs2904967	0.562	rs239255	ENSG00000254614.2	AP003068.23	-4.89	1.38e-06	0.000351	-0.32	-0.22	Mean corpuscular volume;	chr11:65219657	chr11:65177606~65181834:-
HNSC	cis	rs2904967	0.636	rs239256	ENSG00000254614.2	AP003068.23	-4.89	1.38e-06	0.000351	-0.32	-0.22	Mean corpuscular volume;	chr11:65219920	chr11:65177606~65181834:-
HNSC	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	4.89	1.38e-06	0.000351	0.27	0.22	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
HNSC	cis	rs7615952	0.576	rs4646748	ENSG00000241439.1	RP11-666A20.3	4.89	1.38e-06	0.000351	0.25	0.22	Blood pressure (smoking interaction);	chr3:126107486	chr3:125958556~125958817:+
HNSC	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-4.89	1.38e-06	0.000351	-0.32	-0.22	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
HNSC	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	4.89	1.38e-06	0.000351	0.21	0.22	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
HNSC	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-4.89	1.38e-06	0.000352	-0.18	-0.22	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	4.89	1.38e-06	0.000352	0.27	0.22	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	4.89	1.38e-06	0.000352	0.27	0.22	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	4.89	1.38e-06	0.000352	0.27	0.22	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	4.89	1.38e-06	0.000352	0.27	0.22	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	4.89	1.38e-06	0.000352	0.27	0.22	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
HNSC	cis	rs6928977	0.5	rs6925161	ENSG00000234084.1	RP3-388E23.2	-4.89	1.38e-06	0.000352	-0.23	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135301568~135307158:+
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-4.89	1.38e-06	0.000352	-0.26	-0.22	Depression;	chr6:28070115	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-4.89	1.38e-06	0.000352	-0.26	-0.22	Depression;	chr6:28071237	chr6:28170845~28172521:+
HNSC	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-4.89	1.38e-06	0.000352	-0.24	-0.22	Height;	chr2:46627569	chr2:46668870~46670778:+
HNSC	cis	rs3806843	1	rs11167609	ENSG00000202515.1	VTRNA1-3	-4.89	1.38e-06	0.000352	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs6885319	ENSG00000202515.1	VTRNA1-3	-4.89	1.38e-06	0.000352	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr5:140726158~140726246:+
HNSC	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	4.89	1.39e-06	0.000352	0.19	0.22	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
HNSC	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	4.89	1.39e-06	0.000353	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
HNSC	cis	rs34421088	0.576	rs2572436	ENSG00000269918.1	AF131215.9	-4.89	1.39e-06	0.000353	-0.25	-0.22	Neuroticism;	chr8:11241700	chr8:11104691~11106704:-
HNSC	cis	rs71520386	0.632	rs10269414	ENSG00000221740.1	SNORD93	-4.89	1.39e-06	0.000353	-0.26	-0.22	Fibrinogen levels;	chr7:22816674	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-4.89	1.39e-06	0.000353	-0.25	-0.22	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
HNSC	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-4.89	1.39e-06	0.000353	-0.23	-0.22	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
HNSC	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	4.89	1.39e-06	0.000353	0.25	0.22	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
HNSC	cis	rs2933343	0.679	rs1091938	ENSG00000261159.1	RP11-723O4.9	4.89	1.39e-06	0.000353	0.22	0.22	IgG glycosylation;	chr3:128918182	chr3:128859716~128860526:-
HNSC	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	4.89	1.39e-06	0.000353	0.22	0.22	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000254174.1	IGHV1-12	4.89	1.39e-06	0.000353	0.18	0.22	Alzheimer's disease (late onset);	chr14:106665764	chr14:106122420~106122709:-
HNSC	cis	rs12291225	0.585	rs4757250	ENSG00000251991.1	RNU7-49P	4.89	1.39e-06	0.000354	0.25	0.22	Sense of smell;	chr11:14354137	chr11:14478892~14478953:+
HNSC	cis	rs2439831	0.681	rs825739	ENSG00000205771.5	CATSPER2P1	-4.89	1.39e-06	0.000354	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43300230	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-4.89	1.39e-06	0.000354	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
HNSC	cis	rs8077577	0.747	rs11869582	ENSG00000273018.4	CTD-2303H24.2	-4.89	1.39e-06	0.000354	-0.34	-0.22	Obesity-related traits;	chr17:18233267	chr17:18511221~18551705:-
HNSC	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.89	1.39e-06	0.000354	0.25	0.22	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
HNSC	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-4.89	1.39e-06	0.000354	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	4.89	1.39e-06	0.000354	0.27	0.22	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
HNSC	cis	rs860295	0.702	rs12040100	ENSG00000203761.5	MSTO2P	-4.89	1.39e-06	0.000354	-0.17	-0.22	Body mass index;	chr1:155642056	chr1:155745829~155750137:+
HNSC	cis	rs860295	0.702	rs2048431	ENSG00000203761.5	MSTO2P	-4.89	1.39e-06	0.000354	-0.17	-0.22	Body mass index;	chr1:155648839	chr1:155745829~155750137:+
HNSC	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-4.89	1.39e-06	0.000355	-0.26	-0.22	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
HNSC	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-4.89	1.39e-06	0.000355	-0.24	-0.22	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
HNSC	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	4.89	1.39e-06	0.000355	0.29	0.22	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
HNSC	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-4.89	1.4e-06	0.000355	-0.23	-0.22	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-4.89	1.4e-06	0.000355	-0.23	-0.22	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
HNSC	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	4.89	1.4e-06	0.000355	0.3	0.22	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
HNSC	cis	rs9929218	0.508	rs1559366	ENSG00000260459.2	FTLP14	4.89	1.4e-06	0.000355	0.29	0.22	Colorectal cancer;	chr16:68765708	chr16:68822587~68823070:+
HNSC	cis	rs9291683	0.546	rs6820188	ENSG00000250413.1	RP11-448G15.1	-4.89	1.4e-06	0.000355	-0.27	-0.22	Bone mineral density;	chr4:10050031	chr4:10006482~10009725:+
HNSC	cis	rs9840812	0.68	rs17252498	ENSG00000273486.1	RP11-731C17.2	-4.89	1.4e-06	0.000356	-0.22	-0.22	Fibrinogen levels;	chr3:136295356	chr3:136837338~136839021:-
HNSC	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-4.89	1.4e-06	0.000356	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-4.89	1.4e-06	0.000356	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
HNSC	cis	rs1707322	0.964	rs7512395	ENSG00000234329.1	RP11-767N6.2	4.89	1.4e-06	0.000356	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45651039~45651826:-
HNSC	cis	rs1971762	0.527	rs1247957	ENSG00000270175.1	RP11-793H13.11	4.89	1.4e-06	0.000356	0.19	0.22	Height;	chr12:53567709	chr12:53500162~53500936:-
HNSC	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.89	1.4e-06	0.000356	0.23	0.22	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000254153.1	CTA-398F10.2	-4.89	1.4e-06	0.000356	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9226611	chr8:8456909~8461337:-
HNSC	cis	rs9840812	0.683	rs8045	ENSG00000273486.1	RP11-731C17.2	-4.89	1.4e-06	0.000356	-0.21	-0.22	Fibrinogen levels;	chr3:136336617	chr3:136837338~136839021:-
HNSC	cis	rs72843506	0.656	rs80250684	ENSG00000261033.1	RP11-209D14.2	4.89	1.4e-06	0.000356	0.36	0.22	Schizophrenia;	chr17:20054983	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.586	rs75048432	ENSG00000261033.1	RP11-209D14.2	4.89	1.4e-06	0.000356	0.36	0.22	Schizophrenia;	chr17:20057571	chr17:20008051~20009234:-
HNSC	cis	rs853679	0.607	rs34788973	ENSG00000219392.1	RP1-265C24.5	-4.89	1.4e-06	0.000356	-0.43	-0.22	Depression;	chr6:27911422	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs61742093	ENSG00000219392.1	RP1-265C24.5	-4.89	1.4e-06	0.000356	-0.43	-0.22	Depression;	chr6:27912204	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	4.89	1.4e-06	0.000356	0.27	0.22	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	4.89	1.4e-06	0.000356	0.27	0.22	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
HNSC	cis	rs4664293	0.647	rs357022	ENSG00000226266.5	AC009961.3	-4.89	1.4e-06	0.000356	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159632933	chr2:159670708~159712435:-
HNSC	cis	rs7615952	0.641	rs12488180	ENSG00000241439.1	RP11-666A20.3	4.89	1.4e-06	0.000357	0.24	0.22	Blood pressure (smoking interaction);	chr3:126063393	chr3:125958556~125958817:+
HNSC	cis	rs1971762	0.602	rs4759283	ENSG00000270175.1	RP11-793H13.11	-4.89	1.4e-06	0.000357	-0.19	-0.22	Height;	chr12:53685459	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.563	rs4759284	ENSG00000270175.1	RP11-793H13.11	-4.89	1.4e-06	0.000357	-0.19	-0.22	Height;	chr12:53685707	chr12:53500162~53500936:-
HNSC	cis	rs13256369	0.826	rs12678414	ENSG00000173295.6	FAM86B3P	4.89	1.4e-06	0.000357	0.28	0.22	Obesity-related traits;	chr8:8728506	chr8:8228595~8244865:+
HNSC	cis	rs8031584	1	rs11638409	ENSG00000260382.1	RP11-540B6.2	4.89	1.4e-06	0.000357	0.28	0.22	Huntington's disease progression;	chr15:30995987	chr15:30882267~30883231:-
HNSC	cis	rs8031584	1	rs11634216	ENSG00000260382.1	RP11-540B6.2	4.89	1.4e-06	0.000357	0.28	0.22	Huntington's disease progression;	chr15:30996467	chr15:30882267~30883231:-
HNSC	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-4.89	1.4e-06	0.000357	-0.26	-0.22	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
HNSC	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-4.89	1.41e-06	0.000357	-0.25	-0.22	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
HNSC	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	4.89	1.41e-06	0.000357	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	4.89	1.41e-06	0.000357	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
HNSC	cis	rs7809950	0.817	rs2807	ENSG00000238832.1	snoU109	4.89	1.41e-06	0.000357	0.32	0.22	Coronary artery disease;	chr7:107620333	chr7:107603363~107603507:+
HNSC	cis	rs79057730	0.527	rs35316052	ENSG00000225146.1	AC073957.15	4.89	1.41e-06	0.000357	0.35	0.22	Initial pursuit acceleration;	chr7:763317	chr7:1029025~1043891:+
HNSC	cis	rs4968361	0.892	rs11653976	ENSG00000266992.1	DHX40P1	-4.89	1.41e-06	0.000358	-0.39	-0.22	Schizophrenia;	chr17:59439633	chr17:59976009~60002384:-
HNSC	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-4.89	1.41e-06	0.000358	-0.27	-0.22	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
HNSC	cis	rs858239	0.676	rs3807459	ENSG00000226816.2	AC005082.12	4.89	1.41e-06	0.000358	0.26	0.22	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23206013~23208045:+
HNSC	cis	rs6723108	0.627	rs62168872	ENSG00000224043.6	CCNT2-AS1	-4.89	1.41e-06	0.000359	-0.27	-0.22	Type 2 diabetes;	chr2:134904177	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs4954196	ENSG00000224043.6	CCNT2-AS1	-4.89	1.41e-06	0.000359	-0.27	-0.22	Type 2 diabetes;	chr2:134904446	chr2:134735464~134918710:-
HNSC	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-4.89	1.41e-06	0.000359	-0.23	-0.22	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
HNSC	cis	rs6540731	1	rs6540733	ENSG00000226251.4	RP11-15I11.3	-4.89	1.41e-06	0.000359	-0.26	-0.22	Intelligence (childhood);	chr1:212219611	chr1:212225278~212238977:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000254153.1	CTA-398F10.2	-4.89	1.42e-06	0.000359	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9028444	chr8:8456909~8461337:-
HNSC	cis	rs6604026	0.922	rs1854797	ENSG00000223787.2	RP4-593M8.1	4.89	1.42e-06	0.000359	0.29	0.22	Multiple sclerosis;	chr1:92833199	chr1:92580476~92580821:-
HNSC	cis	rs67340775	0.834	rs13218875	ENSG00000219392.1	RP1-265C24.5	-4.89	1.42e-06	0.000359	-0.43	-0.22	Lung cancer in ever smokers;	chr6:27916234	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs67040724	ENSG00000219392.1	RP1-265C24.5	-4.89	1.42e-06	0.000359	-0.43	-0.22	Depression;	chr6:27937731	chr6:28115628~28116551:+
HNSC	cis	rs9990333	0.544	rs73208092	ENSG00000231464.1	AC024937.4	4.89	1.42e-06	0.00036	0.23	0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195996738~195998233:+
HNSC	cis	rs4819052	0.851	rs2838833	ENSG00000223768.1	LINC00205	-4.89	1.42e-06	0.00036	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45293285~45297354:+
HNSC	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-4.89	1.42e-06	0.00036	-0.25	-0.22	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
HNSC	cis	rs3806843	1	rs7710794	ENSG00000202515.1	VTRNA1-3	-4.89	1.42e-06	0.00036	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs10038174	ENSG00000202515.1	VTRNA1-3	-4.89	1.42e-06	0.00036	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr5:140726158~140726246:+
HNSC	cis	rs3811273	0.667	rs10152083	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22263764	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.73	rs10152089	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22263774	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs9944149	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22263875	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs9944066	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264001	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs9943971	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264098	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs9943999	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264135	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs9944001	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264193	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.504	rs9943972	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264267	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.554	rs12586764	ENSG00000211816.2	TRAV38-1	-4.89	1.42e-06	0.00036	-0.25	-0.22	Periodontal disease-related phenotypes;	chr14:22264564	chr14:22271968~22272563:+
HNSC	cis	rs6928977	0.5	rs719885	ENSG00000217482.2	HMGB1P17	4.89	1.42e-06	0.00036	0.25	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135636086~135636713:-
HNSC	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	4.89	1.42e-06	0.00036	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	4.89	1.42e-06	0.00036	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	4.89	1.42e-06	0.00036	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	4.89	1.42e-06	0.00036	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
HNSC	cis	rs17761864	0.919	rs12452089	ENSG00000262333.1	HNRNPA1P16	-4.89	1.42e-06	0.000361	-0.18	-0.22	Esophageal cancer (squamous cell);	chr17:2231708	chr17:2306761~2307715:+
HNSC	cis	rs6964587	1	rs11971885	ENSG00000188693.7	CYP51A1-AS1	-4.89	1.42e-06	0.000361	-0.23	-0.22	Breast cancer;	chr7:92045493	chr7:92134604~92180725:+
HNSC	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-4.89	1.42e-06	0.000361	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-4.89	1.42e-06	0.000361	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-4.89	1.42e-06	0.000361	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-4.89	1.42e-06	0.000361	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
HNSC	cis	rs7296418	0.961	rs1790122	ENSG00000280120.1	RP11-546D6.3	4.89	1.42e-06	0.000361	0.19	0.22	Platelet count;	chr12:123122192	chr12:123152324~123153377:-
HNSC	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000361	-0.2	-0.22	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
HNSC	cis	rs1009181	0.585	rs9379827	ENSG00000272462.2	U91328.19	-4.88	1.42e-06	0.000361	-0.25	-0.22	Childhood ear infection;	chr6:26153107	chr6:25992662~26001775:+
HNSC	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	4.88	1.43e-06	0.000361	0.27	0.22	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
HNSC	cis	rs9987353	0.519	rs2929465	ENSG00000254340.1	RP11-10A14.3	-4.88	1.43e-06	0.000361	-0.27	-0.22	Recombination measurement;	chr8:9206492	chr8:9141424~9145435:+
HNSC	cis	rs8031584	0.958	rs61997076	ENSG00000260382.1	RP11-540B6.2	4.88	1.43e-06	0.000362	0.29	0.22	Huntington's disease progression;	chr15:30924022	chr15:30882267~30883231:-
HNSC	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	4.88	1.43e-06	0.000362	0.32	0.22	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
HNSC	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-4.88	1.43e-06	0.000362	-0.22	-0.22	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
HNSC	cis	rs13217239	0.646	rs9379956	ENSG00000224843.5	LINC00240	4.88	1.43e-06	0.000362	0.21	0.22	Schizophrenia;	chr6:27065956	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs7747454	ENSG00000224843.5	LINC00240	4.88	1.43e-06	0.000362	0.21	0.22	Schizophrenia;	chr6:27066474	chr6:26956992~27023924:+
HNSC	cis	rs3806843	0.868	rs2531349	ENSG00000202515.1	VTRNA1-3	4.88	1.43e-06	0.000363	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr5:140726158~140726246:+
HNSC	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	4.88	1.43e-06	0.000363	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	4.88	1.43e-06	0.000363	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
HNSC	cis	rs1150668	0.796	rs213237	ENSG00000219392.1	RP1-265C24.5	-4.88	1.43e-06	0.000363	-0.24	-0.22	Pubertal anthropometrics;	chr6:28356161	chr6:28115628~28116551:+
HNSC	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	4.88	1.43e-06	0.000363	0.22	0.22	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
HNSC	cis	rs12935418	0.616	rs8045512	ENSG00000261061.1	RP11-303E16.2	-4.88	1.43e-06	0.000363	-0.27	-0.22	Mean corpuscular volume;	chr16:80952410	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.616	rs718954	ENSG00000261061.1	RP11-303E16.2	-4.88	1.43e-06	0.000363	-0.27	-0.22	Mean corpuscular volume;	chr16:80953219	chr16:81030770~81031485:+
HNSC	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	4.88	1.43e-06	0.000363	0.25	0.22	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
HNSC	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	4.88	1.43e-06	0.000363	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
HNSC	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	4.88	1.43e-06	0.000363	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
HNSC	cis	rs7085104	0.7	rs10883785	ENSG00000236937.2	PTGES3P4	4.88	1.44e-06	0.000364	0.27	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102845595~102845950:+
HNSC	cis	rs1125355	0.661	rs62183017	ENSG00000204380.3	AC005042.4	4.88	1.44e-06	0.000364	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158766340	chr2:158658337~158735002:-
HNSC	cis	rs1056107	0.931	rs7869523	ENSG00000225513.1	RP11-165N19.2	-4.88	1.44e-06	0.000364	-0.24	-0.22	Colorectal cancer;	chr9:112220269	chr9:112173522~112173971:-
HNSC	cis	rs8062405	0.54	rs193628	ENSG00000251417.2	RP11-1348G14.4	4.88	1.44e-06	0.000364	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28802743~28817828:+
HNSC	cis	rs2286503	0.78	rs981792	ENSG00000226329.2	AC005682.6	4.88	1.44e-06	0.000364	0.28	0.22	Fibrinogen;	chr7:22822020	chr7:22863874~22881350:-
HNSC	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-4.88	1.44e-06	0.000364	-0.25	-0.22	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000254340.1	RP11-10A14.3	-4.88	1.44e-06	0.000364	-0.27	-0.22	Mood instability;	chr8:8726362	chr8:9141424~9145435:+
HNSC	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	4.88	1.44e-06	0.000365	0.24	0.22	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
HNSC	cis	rs7615952	0.599	rs60847438	ENSG00000248787.1	RP11-666A20.4	-4.88	1.44e-06	0.000365	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126027162	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.534	rs1503072	ENSG00000248787.1	RP11-666A20.4	-4.88	1.44e-06	0.000365	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126035848	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.599	rs7631268	ENSG00000248787.1	RP11-666A20.4	-4.88	1.44e-06	0.000365	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126036821	chr3:125908005~125910272:-
HNSC	cis	rs10504130	0.518	rs6473654	ENSG00000272024.1	RP11-546K22.3	4.88	1.44e-06	0.000365	0.31	0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51950284~51950690:+
HNSC	cis	rs41298997	1	rs41298997	ENSG00000261000.1	RP11-534L20.5	-4.88	1.44e-06	0.000365	-0.25	-0.22	Psoriasis;	chr1:206481989	chr1:206503948~206504456:+
HNSC	cis	rs6723108	0.603	rs62168891	ENSG00000224043.6	CCNT2-AS1	-4.88	1.44e-06	0.000365	-0.27	-0.22	Type 2 diabetes;	chr2:134914617	chr2:134735464~134918710:-
HNSC	cis	rs1056107	0.933	rs2418201	ENSG00000225513.1	RP11-165N19.2	-4.88	1.44e-06	0.000365	-0.24	-0.22	Colorectal cancer;	chr9:112271580	chr9:112173522~112173971:-
HNSC	cis	rs9840812	0.725	rs3821445	ENSG00000273486.1	RP11-731C17.2	-4.88	1.44e-06	0.000365	-0.21	-0.22	Fibrinogen levels;	chr3:136283967	chr3:136837338~136839021:-
HNSC	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	4.88	1.44e-06	0.000365	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
HNSC	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-4.88	1.44e-06	0.000366	-0.19	-0.22	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-4.88	1.44e-06	0.000366	-0.19	-0.22	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
HNSC	cis	rs638893	1	rs583905	ENSG00000255422.1	AP002954.4	-4.88	1.45e-06	0.000366	-0.35	-0.22	Vitiligo;	chr11:118825199	chr11:118704607~118750263:+
HNSC	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.88	1.45e-06	0.000366	0.27	0.22	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
HNSC	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-4.88	1.45e-06	0.000366	-0.27	-0.22	Height;	chr20:49235382	chr20:49280319~49280409:+
HNSC	cis	rs12468226	0.689	rs17656903	ENSG00000226261.1	AC064836.3	-4.88	1.45e-06	0.000366	-0.33	-0.22	Urate levels;	chr2:202106312	chr2:202336024~202336727:-
HNSC	cis	rs4718428	0.924	rs6971897	ENSG00000273142.1	RP11-458F8.4	-4.88	1.45e-06	0.000367	-0.2	-0.22	Corneal structure;	chr7:66947787	chr7:66902857~66906297:+
HNSC	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	4.88	1.45e-06	0.000367	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.861	rs7132655	ENSG00000269938.1	RP11-214K3.20	-4.88	1.45e-06	0.000367	-0.26	-0.22	White blood cell count;	chr12:123954426	chr12:123968023~123968579:-
HNSC	cis	rs8031584	1	rs890159	ENSG00000260382.1	RP11-540B6.2	4.88	1.45e-06	0.000367	0.29	0.22	Huntington's disease progression;	chr15:30999431	chr15:30882267~30883231:-
HNSC	cis	rs36052053	0.908	rs34352435	ENSG00000219700.1	PTCHD3P3	4.88	1.45e-06	0.000367	0.35	0.22	Red cell distribution width;	chr6:109272401	chr6:109288571~109290503:-
HNSC	cis	rs72843506	0.656	rs79406817	ENSG00000261033.1	RP11-209D14.2	4.88	1.45e-06	0.000367	0.4	0.22	Schizophrenia;	chr17:20011814	chr17:20008051~20009234:-
HNSC	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	4.88	1.45e-06	0.000367	0.26	0.22	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
HNSC	cis	rs1994321	1	rs1994321	ENSG00000254991.1	RP13-631K18.3	-4.88	1.45e-06	0.000367	-0.24	-0.22	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12065766	chr11:12066929~12073014:+
HNSC	cis	rs4787484	0.593	rs12917712	ENSG00000196796.5	CTB-134H23.2	-4.88	1.45e-06	0.000368	-0.24	-0.22	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29038655~29052726:+
HNSC	cis	rs72843506	0.586	rs75721433	ENSG00000261033.1	RP11-209D14.2	4.88	1.45e-06	0.000368	0.4	0.22	Schizophrenia;	chr17:19978747	chr17:20008051~20009234:-
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28145952	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28147378	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28147406	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28148143	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28149979	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28151096	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28152885	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28153120	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28154567	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28156691	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28158424	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28159056	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28159666	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28159843	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28159925	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28159932	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28161802	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28162053	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28162598	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28163375	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28163759	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28164580	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28164825	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28164948	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28165025	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28165528	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Parkinson's disease;	chr6:28165750	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28168434	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Parkinson's disease;	chr6:28168578	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28169019	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28169249	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28169676	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28169755	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28169791	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000204709.4	LINC01556	4.88	1.45e-06	0.000368	0.31	0.22	Depression;	chr6:28170075	chr6:28943877~28944537:+
HNSC	cis	rs9813712	0.595	rs16825656	ENSG00000228252.7	COL6A4P2	-4.88	1.45e-06	0.000368	-0.22	-0.22	Response to amphetamines;	chr3:130286225	chr3:130212823~130273806:+
HNSC	cis	rs1218582	0.772	rs4845690	ENSG00000270361.1	RP11-307C12.13	4.88	1.45e-06	0.000368	0.24	0.22	Prostate cancer;	chr1:154914341	chr1:154937370~154938059:+
HNSC	cis	rs2243480	0.522	rs12698511	ENSG00000164669.11	INTS4P1	4.88	1.45e-06	0.000368	0.52	0.22	Diabetic kidney disease;	chr7:66009932	chr7:65141225~65234216:+
HNSC	cis	rs155076	1	rs261430	ENSG00000233325.3	MIPEPP3	4.88	1.45e-06	0.000368	0.38	0.22	White matter hyperintensity burden;	chr13:21291103	chr13:21298139~21306373:+
HNSC	cis	rs1971762	0.523	rs3852562	ENSG00000270175.1	RP11-793H13.11	-4.88	1.45e-06	0.000368	-0.19	-0.22	Height;	chr12:53691966	chr12:53500162~53500936:-
HNSC	cis	rs9368481	0.678	rs62402024	ENSG00000224843.5	LINC00240	-4.88	1.46e-06	0.000368	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26956992~27023924:+
HNSC	cis	rs603446	0.935	rs918143	ENSG00000254851.1	RP11-109L13.1	-4.88	1.46e-06	0.000368	-0.29	-0.22	Triglycerides;	chr11:116759884	chr11:117135528~117138582:+
HNSC	cis	rs6604026	0.848	rs2893226	ENSG00000223787.2	RP4-593M8.1	4.88	1.46e-06	0.000368	0.31	0.22	Multiple sclerosis;	chr1:92822880	chr1:92580476~92580821:-
HNSC	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-4.88	1.46e-06	0.000368	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
HNSC	cis	rs1056107	0.897	rs4979090	ENSG00000225513.1	RP11-165N19.2	-4.88	1.46e-06	0.000369	-0.24	-0.22	Colorectal cancer;	chr9:112257991	chr9:112173522~112173971:-
HNSC	cis	rs17292804	0.506	rs71417868	ENSG00000269940.1	RP11-73M18.7	4.88	1.46e-06	0.000369	0.22	0.22	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694560~103695170:+
HNSC	cis	rs453301	0.653	rs1045529	ENSG00000233609.3	RP11-62H7.2	-4.88	1.46e-06	0.000369	-0.22	-0.22	Joint mobility (Beighton score);	chr8:9032588	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs67766414	ENSG00000173295.6	FAM86B3P	-4.88	1.46e-06	0.000369	-0.29	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8228595~8244865:+
HNSC	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	4.88	1.46e-06	0.00037	0.31	0.22	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
HNSC	cis	rs11098499	0.644	rs17517414	ENSG00000249244.1	RP11-548H18.2	4.88	1.46e-06	0.00037	0.27	0.22	Corneal astigmatism;	chr4:119340946	chr4:119391831~119395335:-
HNSC	cis	rs17818399	0.926	rs1378764	ENSG00000279254.1	RP11-536C12.1	-4.88	1.46e-06	0.00037	-0.26	-0.22	Height;	chr2:46612542	chr2:46668870~46670778:+
HNSC	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	4.88	1.46e-06	0.00037	0.24	0.22	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
HNSC	cis	rs7746199	0.736	rs34965299	ENSG00000219392.1	RP1-265C24.5	-4.88	1.47e-06	0.000371	-0.43	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28115628~28116551:+
HNSC	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-4.88	1.47e-06	0.000371	-0.24	-0.22	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
HNSC	cis	rs4853525	0.651	rs62182473	ENSG00000235852.1	AC005540.3	4.88	1.47e-06	0.000371	0.28	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190876270	chr2:190880797~190882059:-
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000224373.3	IGHV4-59	4.88	1.47e-06	0.000371	0.14	0.22	Kawasaki disease;	chr14:106704386	chr14:106627249~106627825:-
HNSC	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-4.88	1.47e-06	0.000371	-0.22	-0.22	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
HNSC	cis	rs79057730	0.599	rs4333501	ENSG00000225146.1	AC073957.15	4.88	1.47e-06	0.000371	0.33	0.22	Initial pursuit acceleration;	chr7:763607	chr7:1029025~1043891:+
HNSC	cis	rs1056107	0.931	rs11792718	ENSG00000225513.1	RP11-165N19.2	-4.88	1.47e-06	0.000371	-0.24	-0.22	Colorectal cancer;	chr9:112253684	chr9:112173522~112173971:-
HNSC	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	4.88	1.47e-06	0.000371	0.29	0.22	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
HNSC	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	4.88	1.47e-06	0.000371	0.23	0.22	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
HNSC	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-4.88	1.47e-06	0.000371	-0.22	-0.22	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
HNSC	cis	rs17253792	0.822	rs17746106	ENSG00000186615.9	KTN1-AS1	-4.88	1.47e-06	0.000371	-0.4	-0.22	Putamen volume;	chr14:55602450	chr14:55499278~55580110:-
HNSC	cis	rs2835345	0.511	rs57583267	ENSG00000279365.1	KB-176G8.1	4.88	1.47e-06	0.000371	0.26	0.22	Pulmonary function;	chr21:36445230	chr21:36485867~36487760:+
HNSC	cis	rs1056107	0.933	rs7865225	ENSG00000225513.1	RP11-165N19.2	-4.88	1.47e-06	0.000372	-0.23	-0.22	Colorectal cancer;	chr9:112211969	chr9:112173522~112173971:-
HNSC	cis	rs950169	0.81	rs2879976	ENSG00000229212.6	RP11-561C5.4	-4.88	1.47e-06	0.000372	-0.31	-0.22	Schizophrenia;	chr15:84566347	chr15:85205440~85234795:-
HNSC	cis	rs453301	0.653	rs1562211	ENSG00000233609.3	RP11-62H7.2	-4.88	1.47e-06	0.000372	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9044914	chr8:8961200~8979025:+
HNSC	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	4.88	1.47e-06	0.000372	0.3	0.22	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
HNSC	cis	rs1223397	0.938	rs3817742	ENSG00000215022.6	RP1-257A7.4	-4.88	1.48e-06	0.000373	-0.27	-0.22	Blood pressure;	chr6:13279320	chr6:13264861~13295586:-
HNSC	cis	rs7615952	0.599	rs67566088	ENSG00000248787.1	RP11-666A20.4	-4.88	1.48e-06	0.000373	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126050130	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs12495947	ENSG00000248787.1	RP11-666A20.4	-4.88	1.48e-06	0.000373	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126052855	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs6805074	ENSG00000248787.1	RP11-666A20.4	-4.88	1.48e-06	0.000373	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126053431	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs4422257	ENSG00000248787.1	RP11-666A20.4	-4.88	1.48e-06	0.000373	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126055520	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs66520539	ENSG00000248787.1	RP11-666A20.4	-4.88	1.48e-06	0.000373	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126061531	chr3:125908005~125910272:-
HNSC	cis	rs6964587	0.967	rs10246036	ENSG00000188693.7	CYP51A1-AS1	4.88	1.48e-06	0.000373	0.23	0.22	Breast cancer;	chr7:91929209	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs12671991	ENSG00000188693.7	CYP51A1-AS1	4.88	1.48e-06	0.000373	0.23	0.22	Breast cancer;	chr7:91930167	chr7:92134604~92180725:+
HNSC	cis	rs5758659	0.652	rs133349	ENSG00000227370.1	RP4-669P10.19	-4.88	1.48e-06	0.000373	-0.21	-0.22	Cognitive function;	chr22:42032723	chr22:42132543~42132998:+
HNSC	cis	rs4862750	0.794	rs1030382	ENSG00000250971.1	RP11-696F12.1	4.88	1.48e-06	0.000374	0.25	0.22	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:187060099~187060930:+
HNSC	cis	rs860295	0.702	rs10796945	ENSG00000203761.5	MSTO2P	-4.88	1.48e-06	0.000374	-0.17	-0.22	Body mass index;	chr1:155457897	chr1:155745829~155750137:+
HNSC	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	4.88	1.48e-06	0.000374	0.29	0.22	Height;	chr4:55413708	chr4:55387949~55388271:+
HNSC	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-4.88	1.48e-06	0.000374	-0.22	-0.22	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
HNSC	cis	rs72772090	1	rs72772092	ENSG00000248734.2	CTD-2260A17.1	-4.88	1.48e-06	0.000374	-0.32	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96711208	chr5:96784777~96785999:+
HNSC	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	4.88	1.48e-06	0.000374	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
HNSC	cis	rs1979679	0.842	rs7138497	ENSG00000247934.4	RP11-967K21.1	-4.88	1.48e-06	0.000374	-0.24	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28163298~28190738:-
HNSC	cis	rs7746199	0.736	rs58616630	ENSG00000219392.1	RP1-265C24.5	-4.88	1.49e-06	0.000375	-0.43	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28115628~28116551:+
HNSC	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-4.88	1.49e-06	0.000375	-0.24	-0.22	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
HNSC	cis	rs9402743	0.634	rs4896156	ENSG00000234084.1	RP3-388E23.2	-4.88	1.49e-06	0.000375	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135605725	chr6:135301568~135307158:+
HNSC	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.88	1.49e-06	0.000375	0.23	0.22	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	4.88	1.49e-06	0.000375	0.25	0.22	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
HNSC	cis	rs72727394	0.51	rs16967120	ENSG00000259747.1	RP11-275I4.2	-4.88	1.49e-06	0.000375	-0.28	-0.22	Crohn's disease;	chr15:38628246	chr15:38671847~38689191:+
HNSC	cis	rs9329221	1	rs9329221	ENSG00000269918.1	AF131215.9	4.88	1.49e-06	0.000375	0.21	0.22	Neuroticism;	chr8:10382692	chr8:11104691~11106704:-
HNSC	cis	rs9650657	0.707	rs10097283	ENSG00000269918.1	AF131215.9	-4.88	1.49e-06	0.000375	-0.22	-0.22	Neuroticism;	chr8:10801896	chr8:11104691~11106704:-
HNSC	cis	rs950169	0.922	rs62029585	ENSG00000229212.6	RP11-561C5.4	-4.88	1.49e-06	0.000375	-0.32	-0.22	Schizophrenia;	chr15:84397176	chr15:85205440~85234795:-
HNSC	cis	rs12893668	0.572	rs4900590	ENSG00000269940.1	RP11-73M18.7	4.88	1.49e-06	0.000375	0.21	0.22	Reticulocyte count;	chr14:103680084	chr14:103694560~103695170:+
HNSC	cis	rs9863	0.861	rs10846579	ENSG00000269938.1	RP11-214K3.20	-4.88	1.49e-06	0.000375	-0.25	-0.22	White blood cell count;	chr12:123922856	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs11057394	ENSG00000269938.1	RP11-214K3.20	-4.88	1.49e-06	0.000375	-0.25	-0.22	White blood cell count;	chr12:123923129	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs12809125	ENSG00000269938.1	RP11-214K3.20	-4.88	1.49e-06	0.000375	-0.25	-0.22	White blood cell count;	chr12:123923444	chr12:123968023~123968579:-
HNSC	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-4.88	1.49e-06	0.000376	-0.28	-0.22	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
HNSC	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-4.88	1.49e-06	0.000376	-0.2	-0.22	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000254153.1	CTA-398F10.2	-4.88	1.49e-06	0.000376	-0.24	-0.22	Mood instability;	chr8:8936683	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000254153.1	CTA-398F10.2	-4.88	1.49e-06	0.000376	-0.24	-0.22	Mood instability;	chr8:8936944	chr8:8456909~8461337:-
HNSC	cis	rs763121	0.853	rs2072794	ENSG00000273076.1	RP3-508I15.22	4.88	1.49e-06	0.000376	0.23	0.22	Menopause (age at onset);	chr22:38754538	chr22:38743495~38743910:+
HNSC	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.88	1.49e-06	0.000376	0.27	0.22	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	4.88	1.49e-06	0.000376	0.27	0.22	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
HNSC	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-4.88	1.49e-06	0.000376	-0.23	-0.22	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
HNSC	cis	rs728616	0.614	rs1998374	ENSG00000225484.5	NUTM2B-AS1	-4.88	1.49e-06	0.000376	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:79663088~79826594:-
HNSC	cis	rs3806843	0.868	rs2531352	ENSG00000202515.1	VTRNA1-3	4.88	1.49e-06	0.000377	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr5:140726158~140726246:+
HNSC	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	4.88	1.49e-06	0.000377	0.34	0.22	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
HNSC	cis	rs6723108	0.627	rs7593370	ENSG00000224043.6	CCNT2-AS1	4.88	1.49e-06	0.000377	0.27	0.22	Type 2 diabetes;	chr2:134865947	chr2:134735464~134918710:-
HNSC	cis	rs2665103	0.589	rs2134046	ENSG00000276710.3	CSPG4P8	-4.87	1.49e-06	0.000377	-0.24	-0.22	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82459472~82477258:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-4.87	1.5e-06	0.000377	-0.26	-0.22	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000204709.4	LINC01556	4.87	1.5e-06	0.000377	0.31	0.22	Depression;	chr6:28180209	chr6:28943877~28944537:+
HNSC	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-4.87	1.5e-06	0.000377	-0.2	-0.22	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
HNSC	cis	rs6964587	0.967	rs4729015	ENSG00000188693.7	CYP51A1-AS1	4.87	1.5e-06	0.000377	0.23	0.22	Breast cancer;	chr7:91932278	chr7:92134604~92180725:+
HNSC	cis	rs9840812	0.656	rs4678437	ENSG00000273486.1	RP11-731C17.2	4.87	1.5e-06	0.000377	0.18	0.22	Fibrinogen levels;	chr3:136598823	chr3:136837338~136839021:-
HNSC	cis	rs3806843	0.741	rs4912597	ENSG00000202515.1	VTRNA1-3	4.87	1.5e-06	0.000377	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.771	rs2563334	ENSG00000202515.1	VTRNA1-3	4.87	1.5e-06	0.000377	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr5:140726158~140726246:+
HNSC	cis	rs2337406	1	rs11845269	ENSG00000254174.1	IGHV1-12	4.87	1.5e-06	0.000378	0.19	0.22	Alzheimer's disease (late onset);	chr14:106683851	chr14:106122420~106122709:-
HNSC	cis	rs3206736	0.549	rs10257774	ENSG00000197085.10	NPSR1-AS1	-4.87	1.5e-06	0.000378	-0.27	-0.22	Diastolic blood pressure;	chr7:35189996	chr7:34346512~34871582:-
HNSC	cis	rs9813712	0.571	rs9846596	ENSG00000228252.7	COL6A4P2	-4.87	1.5e-06	0.000378	-0.22	-0.22	Response to amphetamines;	chr3:130288318	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-4.87	1.5e-06	0.000378	-0.22	-0.22	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.523	rs9866942	ENSG00000228252.7	COL6A4P2	-4.87	1.5e-06	0.000378	-0.22	-0.22	Response to amphetamines;	chr3:130297796	chr3:130212823~130273806:+
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000211972.2	IGHV3-66	4.87	1.5e-06	0.000378	0.17	0.22	Kawasaki disease;	chr14:106787239	chr14:106675017~106675544:-
HNSC	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-4.87	1.5e-06	0.000378	-0.28	-0.22	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
HNSC	cis	rs1125355	0.622	rs62183014	ENSG00000204380.3	AC005042.4	4.87	1.5e-06	0.000378	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158759029	chr2:158658337~158735002:-
HNSC	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-4.87	1.5e-06	0.000378	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
HNSC	cis	rs6964587	1	rs7806157	ENSG00000188693.7	CYP51A1-AS1	-4.87	1.5e-06	0.000378	-0.23	-0.22	Breast cancer;	chr7:91972616	chr7:92134604~92180725:+
HNSC	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	4.87	1.5e-06	0.000379	0.25	0.22	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
HNSC	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-4.87	1.5e-06	0.000379	-0.26	-0.22	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
HNSC	cis	rs3733585	0.631	rs4697924	ENSG00000250413.1	RP11-448G15.1	4.87	1.5e-06	0.000379	0.29	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10122615	chr4:10006482~10009725:+
HNSC	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-4.87	1.5e-06	0.000379	-0.27	-0.22	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-4.87	1.5e-06	0.000379	-0.27	-0.22	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
HNSC	cis	rs5758659	0.652	rs5758553	ENSG00000227370.1	RP4-669P10.19	-4.87	1.5e-06	0.000379	-0.21	-0.22	Cognitive function;	chr22:42035425	chr22:42132543~42132998:+
HNSC	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	4.87	1.5e-06	0.000379	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
HNSC	cis	rs10462794	1	rs7728048	ENSG00000260763.1	RP11-445O3.3	-4.87	1.5e-06	0.000379	-0.3	-0.22	DNA methylation (variation);	chr5:4487551	chr5:4436850~4440259:-
HNSC	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	4.87	1.51e-06	0.000379	0.3	0.22	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
HNSC	cis	rs9813712	0.585	rs16824839	ENSG00000249846.5	RP11-77P16.4	-4.87	1.51e-06	0.000379	-0.3	-0.22	Response to amphetamines;	chr3:130220886	chr3:130112550~130120579:+
HNSC	cis	rs7615952	0.576	rs4646748	ENSG00000248787.1	RP11-666A20.4	-4.87	1.51e-06	0.000379	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126107486	chr3:125908005~125910272:-
HNSC	cis	rs763121	0.853	rs5757193	ENSG00000273076.1	RP3-508I15.22	-4.87	1.51e-06	0.00038	-0.24	-0.22	Menopause (age at onset);	chr22:38638862	chr22:38743495~38743910:+
HNSC	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	4.87	1.51e-06	0.00038	0.24	0.22	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
HNSC	cis	rs9880211	0.563	rs6769762	ENSG00000273486.1	RP11-731C17.2	4.87	1.51e-06	0.00038	0.2	0.22	Height;Body mass index;	chr3:136189336	chr3:136837338~136839021:-
HNSC	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	4.87	1.51e-06	0.00038	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000254153.1	CTA-398F10.2	4.87	1.51e-06	0.00038	0.24	0.22	Parkinson's disease;	chr8:8399807	chr8:8456909~8461337:-
HNSC	cis	rs1913185	0.787	rs59384952	ENSG00000240032.1	RP11-274H2.3	-4.87	1.51e-06	0.00038	-0.38	-0.22	Obesity-related traits;	chr3:146060012	chr3:146066344~146069185:-
HNSC	cis	rs9368481	0.729	rs10946881	ENSG00000224843.5	LINC00240	-4.87	1.51e-06	0.00038	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26956992~27023924:+
HNSC	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	4.87	1.51e-06	0.00038	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
HNSC	cis	rs9921338	0.887	rs7189044	ENSG00000263080.1	RP11-485G7.5	4.87	1.51e-06	0.00038	0.23	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs57579443	ENSG00000263080.1	RP11-485G7.5	4.87	1.51e-06	0.00038	0.23	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11341809~11345211:-
HNSC	cis	rs71520386	0.632	rs2286509	ENSG00000221740.1	SNORD93	-4.87	1.51e-06	0.00038	-0.25	-0.22	Fibrinogen levels;	chr7:22814832	chr7:22856613~22856686:+
HNSC	cis	rs7000734	0.958	rs6983365	ENSG00000245080.5	RP11-320N21.1	-4.87	1.51e-06	0.00038	-0.31	-0.22	Radiation response;	chr8:95114831	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.916	rs7002233	ENSG00000245080.5	RP11-320N21.1	-4.87	1.51e-06	0.00038	-0.31	-0.22	Radiation response;	chr8:95115031	chr8:95066808~95073182:-
HNSC	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.87	1.51e-06	0.00038	0.23	0.22	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
HNSC	cis	rs79349575	0.783	rs1994970	ENSG00000270781.1	RP11-501C14.9	4.87	1.51e-06	0.000381	0.23	0.22	Type 2 diabetes;	chr17:48936765	chr17:48899131~48899748:+
HNSC	cis	rs9304742	0.924	rs8111196	ENSG00000213801.4	ZNF816-ZNF321P	4.87	1.51e-06	0.000381	0.25	0.22	Psoriasis;	chr19:52953970	chr19:52927135~52942601:-
HNSC	cis	rs9304742	0.888	rs8111514	ENSG00000213801.4	ZNF816-ZNF321P	4.87	1.51e-06	0.000381	0.25	0.22	Psoriasis;	chr19:52953993	chr19:52927135~52942601:-
HNSC	cis	rs9304742	0.888	rs8112137	ENSG00000213801.4	ZNF816-ZNF321P	4.87	1.51e-06	0.000381	0.25	0.22	Psoriasis;	chr19:52954002	chr19:52927135~52942601:-
HNSC	cis	rs202072	0.872	rs445714	ENSG00000215022.6	RP1-257A7.4	-4.87	1.51e-06	0.000381	-0.28	-0.22	HIV-1 viral setpoint;	chr6:13280726	chr6:13264861~13295586:-
HNSC	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-4.87	1.51e-06	0.000381	-0.24	-0.22	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
HNSC	cis	rs11893307	0.566	rs62179714	ENSG00000235852.1	AC005540.3	4.87	1.51e-06	0.000381	0.29	0.22	Mean platelet volume;	chr2:190702815	chr2:190880797~190882059:-
HNSC	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	4.87	1.51e-06	0.000381	0.24	0.22	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
HNSC	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	4.87	1.51e-06	0.000381	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
HNSC	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-4.87	1.51e-06	0.000381	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
HNSC	cis	rs12545109	0.879	rs1975285	ENSG00000246430.5	LINC00968	-4.87	1.51e-06	0.000381	-0.28	-0.22	Obesity-related traits;	chr8:56446123	chr8:56496246~56559823:-
HNSC	cis	rs12817211	0.524	rs1554845	ENSG00000272368.2	RP4-605O3.4	-4.87	1.51e-06	0.000381	-0.22	-0.22	Colorectal or endometrial cancer;	chr12:50129721	chr12:50112197~50165618:+
HNSC	cis	rs2834288	0.535	rs881228	ENSG00000273102.1	AP000569.9	4.87	1.51e-06	0.000381	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33967101~33968573:-
HNSC	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	4.87	1.51e-06	0.000381	0.29	0.22	Pain;	chr19:21571799	chr19:21554640~21569237:-
HNSC	cis	rs71636778	0.509	rs12746810	ENSG00000260063.1	RP5-968P14.2	-4.87	1.51e-06	0.000381	-0.42	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26686642	chr1:26692132~26694131:-
HNSC	cis	rs4761669	0.565	rs7310296	ENSG00000241556.1	RP11-490G8.1	4.87	1.51e-06	0.000381	0.22	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94800647	chr12:95467397~95467861:-
HNSC	cis	rs155076	1	rs261404	ENSG00000233325.3	MIPEPP3	4.87	1.52e-06	0.000382	0.38	0.22	White matter hyperintensity burden;	chr13:21284023	chr13:21298139~21306373:+
HNSC	cis	rs516805	0.63	rs696650	ENSG00000279453.1	RP3-425C14.4	-4.87	1.52e-06	0.000382	-0.3	-0.22	Lymphocyte counts;	chr6:122261316	chr6:122436789~122439223:-
HNSC	cis	rs72843506	0.656	rs74648067	ENSG00000261033.1	RP11-209D14.2	4.87	1.52e-06	0.000382	0.41	0.22	Schizophrenia;	chr17:20022938	chr17:20008051~20009234:-
HNSC	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-4.87	1.52e-06	0.000382	-0.26	-0.22	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
HNSC	cis	rs3806843	0.868	rs2531342	ENSG00000202515.1	VTRNA1-3	4.87	1.52e-06	0.000383	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.9	rs2563279	ENSG00000202515.1	VTRNA1-3	4.87	1.52e-06	0.000383	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr5:140726158~140726246:+
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	4.87	1.52e-06	0.000383	0.27	0.22	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
HNSC	cis	rs516805	0.748	rs11154078	ENSG00000279453.1	RP3-425C14.4	4.87	1.52e-06	0.000383	0.3	0.22	Lymphocyte counts;	chr6:122387058	chr6:122436789~122439223:-
HNSC	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-4.87	1.52e-06	0.000383	-0.27	-0.22	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
HNSC	cis	rs10504130	0.696	rs111926180	ENSG00000253844.1	RP11-546K22.1	-4.87	1.52e-06	0.000383	-0.33	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51961458~52022974:+
HNSC	cis	rs3206736	0.549	rs57221424	ENSG00000197085.10	NPSR1-AS1	-4.87	1.52e-06	0.000383	-0.28	-0.22	Diastolic blood pressure;	chr7:35176058	chr7:34346512~34871582:-
HNSC	cis	rs79057730	0.599	rs9458	ENSG00000225146.1	AC073957.15	-4.87	1.52e-06	0.000383	-0.34	-0.22	Initial pursuit acceleration;	chr7:785857	chr7:1029025~1043891:+
HNSC	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-4.87	1.52e-06	0.000383	-0.27	-0.22	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
HNSC	cis	rs17818399	0.926	rs1824050	ENSG00000279254.1	RP11-536C12.1	-4.87	1.52e-06	0.000383	-0.26	-0.22	Height;	chr2:46612338	chr2:46668870~46670778:+
HNSC	cis	rs4218	0.681	rs1867757	ENSG00000259732.1	RP11-59H7.3	-4.87	1.53e-06	0.000384	-0.28	-0.22	Social communication problems;	chr15:59072315	chr15:59121034~59133250:+
HNSC	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-4.87	1.53e-06	0.000384	-0.27	-0.22	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
HNSC	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-4.87	1.53e-06	0.000384	-0.3	-0.22	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
HNSC	cis	rs4873772	0.735	rs1106607	ENSG00000253330.1	RP11-697N18.3	-4.87	1.53e-06	0.000384	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47492781	chr8:47511034~47512141:-
HNSC	cis	rs2933343	0.729	rs6767104	ENSG00000261159.1	RP11-723O4.9	-4.87	1.53e-06	0.000384	-0.22	-0.22	IgG glycosylation;	chr3:128929274	chr3:128859716~128860526:-
HNSC	cis	rs2834288	0.536	rs762357	ENSG00000273102.1	AP000569.9	4.87	1.53e-06	0.000384	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33967101~33968573:-
HNSC	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-4.87	1.53e-06	0.000384	-0.19	-0.22	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
HNSC	cis	rs4761470	0.943	rs3803069	ENSG00000258365.1	RP11-1105G2.3	-4.87	1.53e-06	0.000385	-0.28	-0.22	Estradiol plasma levels (breast cancer);	chr12:94290027	chr12:94277758~94282844:-
HNSC	cis	rs7824557	0.67	rs2736381	ENSG00000269918.1	AF131215.9	-4.87	1.53e-06	0.000385	-0.22	-0.22	Retinal vascular caliber;	chr8:11275257	chr8:11104691~11106704:-
HNSC	cis	rs7515577	0.588	rs79160953	ENSG00000223787.2	RP4-593M8.1	4.87	1.53e-06	0.000385	0.49	0.22	Cholesterol, total;	chr1:92484958	chr1:92580476~92580821:-
HNSC	cis	rs7115242	0.92	rs6589574	ENSG00000280143.1	AP000892.6	4.87	1.53e-06	0.000385	0.44	0.22	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117204967~117210292:+
HNSC	cis	rs4763879	0.593	rs2080206	ENSG00000278635.1	CTD-2318O12.1	4.87	1.53e-06	0.000385	0.17	0.22	Type 1 diabetes;	chr12:9715370	chr12:9415641~9416718:+
HNSC	cis	rs9311676	0.656	rs6445973	ENSG00000273493.1	RP11-80H18.4	-4.87	1.53e-06	0.000385	-0.25	-0.22	Systemic lupus erythematosus;	chr3:58350868	chr3:58329965~58330118:+
HNSC	cis	rs2657294	0.62	rs7903537	ENSG00000233313.2	HMGA1P5	-4.87	1.53e-06	0.000385	-0.24	-0.22	Pneumonia;	chr10:75087732	chr10:75276376~75276646:-
HNSC	cis	rs14027	0.64	rs7843304	ENSG00000279347.1	RP11-85I17.2	-4.87	1.53e-06	0.000385	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119770796	chr8:119838736~119840385:-
HNSC	cis	rs73198271	0.74	rs10103163	ENSG00000173295.6	FAM86B3P	-4.87	1.53e-06	0.000385	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.599	rs10103169	ENSG00000173295.6	FAM86B3P	-4.87	1.53e-06	0.000385	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.7	rs10103282	ENSG00000173295.6	FAM86B3P	-4.87	1.53e-06	0.000385	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8228595~8244865:+
HNSC	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-4.87	1.53e-06	0.000386	-0.29	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
HNSC	cis	rs9329221	0.905	rs13252982	ENSG00000255310.2	AF131215.2	-4.87	1.53e-06	0.000386	-0.21	-0.22	Neuroticism;	chr8:10397595	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000249244.1	RP11-548H18.2	-4.87	1.53e-06	0.000386	-0.26	-0.22	Corneal astigmatism;	chr4:119337052	chr4:119391831~119395335:-
HNSC	cis	rs7296418	0.922	rs1790134	ENSG00000280120.1	RP11-546D6.3	4.87	1.54e-06	0.000386	0.18	0.22	Platelet count;	chr12:123213351	chr12:123152324~123153377:-
HNSC	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	4.87	1.54e-06	0.000386	0.13	0.22	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
HNSC	cis	rs712039	0.652	rs736424	ENSG00000276054.1	RP11-378E13.3	4.87	1.54e-06	0.000386	0.3	0.22	Tuberculosis;	chr17:37429263	chr17:37386886~37387926:+
HNSC	cis	rs4356203	1	rs4356203	ENSG00000272034.1	SNORD14A	4.87	1.54e-06	0.000386	0.17	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17074654~17074744:-
HNSC	cis	rs36423	0.748	rs36386	ENSG00000266869.1	RP6-114E22.1	4.87	1.54e-06	0.000386	0.36	0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901187	chr14:71848606~71908430:+
HNSC	cis	rs7829975	0.667	rs1877119	ENSG00000173295.6	FAM86B3P	4.87	1.54e-06	0.000387	0.25	0.22	Mood instability;	chr8:8849687	chr8:8228595~8244865:+
HNSC	cis	rs12893668	0.603	rs61637848	ENSG00000269940.1	RP11-73M18.7	4.87	1.54e-06	0.000387	0.21	0.22	Reticulocyte count;	chr14:103629694	chr14:103694560~103695170:+
HNSC	cis	rs8054556	1	rs7190185	ENSG00000183604.13	SMG1P5	-4.87	1.54e-06	0.000387	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:30267553~30335374:-
HNSC	cis	rs17507216	0.718	rs28587782	ENSG00000276710.3	CSPG4P8	-4.87	1.54e-06	0.000387	-0.3	-0.22	Excessive daytime sleepiness;	chr15:82576881	chr15:82459472~82477258:+
HNSC	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-4.87	1.54e-06	0.000387	-0.22	-0.22	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
HNSC	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	4.87	1.54e-06	0.000387	0.22	0.22	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	4.87	1.54e-06	0.000387	0.22	0.22	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	4.87	1.54e-06	0.000387	0.22	0.22	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
HNSC	cis	rs11098499	0.644	rs3986377	ENSG00000249244.1	RP11-548H18.2	4.87	1.54e-06	0.000387	0.27	0.22	Corneal astigmatism;	chr4:119339115	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.556	rs4473640	ENSG00000249244.1	RP11-548H18.2	4.87	1.54e-06	0.000387	0.27	0.22	Educational attainment;	chr4:119339282	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs10010355	ENSG00000249244.1	RP11-548H18.2	4.87	1.54e-06	0.000387	0.27	0.22	Corneal astigmatism;	chr4:119339888	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs9307471	ENSG00000249244.1	RP11-548H18.2	4.87	1.54e-06	0.000387	0.27	0.22	Corneal astigmatism;	chr4:119340107	chr4:119391831~119395335:-
HNSC	cis	rs9650657	0.589	rs6985109	ENSG00000255310.2	AF131215.2	4.87	1.54e-06	0.000387	0.21	0.22	Neuroticism;	chr8:10904075	chr8:11107788~11109726:-
HNSC	cis	rs7829975	0.545	rs13261926	ENSG00000254340.1	RP11-10A14.3	-4.87	1.54e-06	0.000387	-0.28	-0.22	Mood instability;	chr8:8694100	chr8:9141424~9145435:+
HNSC	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.87	1.54e-06	0.000387	0.22	0.22	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.87	1.54e-06	0.000387	0.22	0.22	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
HNSC	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	4.87	1.54e-06	0.000388	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
HNSC	cis	rs6674176	0.561	rs12127226	ENSG00000237950.1	RP11-7O11.3	4.87	1.54e-06	0.000388	0.25	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43929637	chr1:43944370~43946551:-
HNSC	cis	rs9840812	0.683	rs8045	ENSG00000239213.4	NCK1-AS1	-4.87	1.54e-06	0.000388	-0.23	-0.22	Fibrinogen levels;	chr3:136336617	chr3:136841726~136862054:-
HNSC	cis	rs6964587	1	rs12333563	ENSG00000188693.7	CYP51A1-AS1	-4.87	1.54e-06	0.000388	-0.23	-0.22	Breast cancer;	chr7:92038012	chr7:92134604~92180725:+
HNSC	cis	rs7615952	0.576	rs2276729	ENSG00000241439.1	RP11-666A20.3	4.87	1.55e-06	0.000388	0.24	0.22	Blood pressure (smoking interaction);	chr3:126107371	chr3:125958556~125958817:+
HNSC	cis	rs10504130	0.696	rs76649327	ENSG00000253844.1	RP11-546K22.1	-4.87	1.55e-06	0.000389	-0.33	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51961458~52022974:+
HNSC	cis	rs1707322	1	rs7531911	ENSG00000234329.1	RP11-767N6.2	4.87	1.55e-06	0.000389	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10890359	ENSG00000234329.1	RP11-767N6.2	4.87	1.55e-06	0.000389	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45651039~45651826:-
HNSC	cis	rs3811273	0.614	rs12589726	ENSG00000211816.2	TRAV38-1	-4.87	1.55e-06	0.000389	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22262396	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs12587104	ENSG00000211816.2	TRAV38-1	-4.87	1.55e-06	0.000389	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22262556	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs7150591	ENSG00000211816.2	TRAV38-1	-4.87	1.55e-06	0.000389	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22262926	chr14:22271968~22272563:+
HNSC	cis	rs7615952	0.576	rs1127717	ENSG00000241439.1	RP11-666A20.3	4.87	1.55e-06	0.000389	0.24	0.22	Blood pressure (smoking interaction);	chr3:126107216	chr3:125958556~125958817:+
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000254174.1	IGHV1-12	4.87	1.55e-06	0.000389	0.18	0.22	Alzheimer's disease (late onset);	chr14:106662151	chr14:106122420~106122709:-
HNSC	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	4.87	1.55e-06	0.000389	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
HNSC	cis	rs2297363	0.502	rs4709395	ENSG00000213073.4	RP11-288H12.3	-4.87	1.55e-06	0.000389	-0.25	-0.22	Total cholesterol levels;Blood protein levels;	chr6:160057757	chr6:160093082~160096212:+
HNSC	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	4.87	1.55e-06	0.000389	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
HNSC	cis	rs2911132	0.66	rs754615	ENSG00000248734.2	CTD-2260A17.1	4.87	1.55e-06	0.000389	0.23	0.22	Urate levels (BMI interaction);	chr5:96750630	chr5:96784777~96785999:+
HNSC	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-4.87	1.55e-06	0.000389	-0.19	-0.22	Height;	chr11:118781100	chr11:118791254~118793137:+
HNSC	cis	rs9329221	0.683	rs688491	ENSG00000254340.1	RP11-10A14.3	-4.87	1.55e-06	0.00039	-0.26	-0.22	Neuroticism;	chr8:10027313	chr8:9141424~9145435:+
HNSC	cis	rs1555322	0.932	rs6119593	ENSG00000126005.14	MMP24-AS1	-4.87	1.55e-06	0.00039	-0.4	-0.22	Attention deficit hyperactivity disorder;	chr20:35245926	chr20:35216462~35278131:-
HNSC	cis	rs2134046	0.587	rs11854289	ENSG00000276710.3	CSPG4P8	4.87	1.55e-06	0.00039	0.23	0.22	Cognitive ability;	chr15:82266461	chr15:82459472~82477258:+
HNSC	cis	rs453301	0.624	rs330049	ENSG00000254153.1	CTA-398F10.2	4.87	1.55e-06	0.00039	0.23	0.22	Joint mobility (Beighton score);	chr8:9229789	chr8:8456909~8461337:-
HNSC	cis	rs7048146	0.531	rs7035358	ENSG00000213539.4	YBX1P6	-4.87	1.55e-06	0.00039	-0.28	-0.22	Vascular brain injury;	chr9:109534123	chr9:109532830~109534332:-
HNSC	cis	rs6693567	0.565	rs12731296	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.00039	0.26	0.22	Migraine;	chr1:150439311	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs12736375	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.00039	0.26	0.22	Migraine;	chr1:150439436	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs11205375	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.00039	0.26	0.22	Migraine;	chr1:150439998	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.516	rs3850844	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.00039	0.26	0.22	Migraine;	chr1:150441464	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs1566225	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.00039	0.26	0.22	Migraine;	chr1:150443514	chr1:150515757~150518032:+
HNSC	cis	rs1008375	0.966	rs6839660	ENSG00000249502.1	AC006160.5	-4.87	1.56e-06	0.00039	-0.23	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666364	chr4:17587467~17614571:-
HNSC	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-4.87	1.56e-06	0.000391	-0.21	-0.22	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
HNSC	cis	rs6693567	0.586	rs9661040	ENSG00000228126.1	FALEC	4.87	1.56e-06	0.000391	0.27	0.22	Migraine;	chr1:150510760	chr1:150515757~150518032:+
HNSC	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-4.87	1.56e-06	0.000391	-0.27	-0.22	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
HNSC	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-4.87	1.56e-06	0.000391	-0.26	-0.22	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
HNSC	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-4.87	1.56e-06	0.000391	-0.25	-0.22	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
HNSC	cis	rs7829975	0.577	rs940030	ENSG00000254340.1	RP11-10A14.3	-4.87	1.56e-06	0.000392	-0.28	-0.22	Mood instability;	chr8:8689418	chr8:9141424~9145435:+
HNSC	cis	rs14027	0.536	rs28827321	ENSG00000279347.1	RP11-85I17.2	-4.87	1.56e-06	0.000392	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119709534	chr8:119838736~119840385:-
HNSC	cis	rs7085104	0.514	rs284855	ENSG00000213061.2	PFN1P11	-4.87	1.56e-06	0.000392	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102838011~102845473:-
HNSC	cis	rs761746	0.582	rs7287054	ENSG00000236132.1	CTA-440B3.1	-4.87	1.56e-06	0.000392	-0.27	-0.22	Intelligence;	chr22:31844735	chr22:31816379~31817491:-
HNSC	cis	rs13073817	0.582	rs13084808	ENSG00000228956.7	SATB1-AS1	4.87	1.56e-06	0.000392	0.23	0.22	Crohn's disease;	chr3:18650601	chr3:18445024~18920401:+
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000254153.1	CTA-398F10.2	4.87	1.56e-06	0.000392	0.23	0.22	Neuroticism;	chr8:8312807	chr8:8456909~8461337:-
HNSC	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	4.87	1.56e-06	0.000392	0.25	0.22	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
HNSC	cis	rs7085104	0.7	rs6163	ENSG00000236937.2	PTGES3P4	4.87	1.56e-06	0.000392	0.27	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102845595~102845950:+
HNSC	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	4.87	1.56e-06	0.000392	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	4.87	1.56e-06	0.000392	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
HNSC	cis	rs3198697	1	rs3198697	ENSG00000263335.1	AF001548.5	-4.87	1.56e-06	0.000392	-0.29	-0.22	Triglycerides;	chr16:15036083	chr16:15726674~15732993:+
HNSC	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-4.87	1.57e-06	0.000393	-0.24	-0.22	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
HNSC	cis	rs6601327	0.571	rs7820675	ENSG00000254340.1	RP11-10A14.3	4.87	1.57e-06	0.000393	0.27	0.22	Multiple myeloma (hyperdiploidy);	chr8:9790238	chr8:9141424~9145435:+
HNSC	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-4.87	1.57e-06	0.000393	-0.24	-0.22	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-4.87	1.57e-06	0.000393	-0.24	-0.22	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-4.87	1.57e-06	0.000393	-0.24	-0.22	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
HNSC	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-4.87	1.57e-06	0.000393	-0.27	-0.22	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
HNSC	cis	rs7296418	0.961	rs949143	ENSG00000280120.1	RP11-546D6.3	4.86	1.57e-06	0.000393	0.18	0.22	Platelet count;	chr12:123110616	chr12:123152324~123153377:-
HNSC	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	4.86	1.57e-06	0.000393	0.32	0.22	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	4.86	1.57e-06	0.000393	0.32	0.22	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
HNSC	cis	rs7000734	0.874	rs1561714	ENSG00000245080.5	RP11-320N21.1	-4.86	1.57e-06	0.000394	-0.31	-0.22	Radiation response;	chr8:95107747	chr8:95066808~95073182:-
HNSC	cis	rs6928977	0.897	rs2246852	ENSG00000217482.2	HMGB1P17	-4.86	1.57e-06	0.000394	-0.25	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135636086~135636713:-
HNSC	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-4.86	1.57e-06	0.000394	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-4.86	1.57e-06	0.000394	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
HNSC	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-4.86	1.57e-06	0.000394	-0.17	-0.22	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
HNSC	cis	rs6964587	0.869	rs2023784	ENSG00000188693.7	CYP51A1-AS1	4.86	1.57e-06	0.000394	0.24	0.22	Breast cancer;	chr7:91895363	chr7:92134604~92180725:+
HNSC	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	4.86	1.57e-06	0.000394	0.24	0.22	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000254153.1	CTA-398F10.2	4.86	1.57e-06	0.000394	0.24	0.22	Mood instability;	chr8:8863963	chr8:8456909~8461337:-
HNSC	cis	rs67981189	0.821	rs8007026	ENSG00000274818.1	RP1-292L20.3	4.86	1.57e-06	0.000394	0.26	0.22	Schizophrenia;	chr14:70997667	chr14:70906657~70907111:-
HNSC	cis	rs7746199	0.673	rs72847313	ENSG00000219392.1	RP1-265C24.5	-4.86	1.57e-06	0.000394	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.611	rs17750747	ENSG00000219392.1	RP1-265C24.5	-4.86	1.57e-06	0.000394	-0.44	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28115628~28116551:+
HNSC	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	4.86	1.57e-06	0.000394	0.26	0.22	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
HNSC	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-4.86	1.57e-06	0.000395	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
HNSC	cis	rs9450351	0.744	rs9362225	ENSG00000203875.9	SNHG5	-4.86	1.57e-06	0.000395	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85500713	chr6:85660950~85678736:-
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	4.86	1.57e-06	0.000395	0.27	0.22	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	4.86	1.57e-06	0.000395	0.27	0.22	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	4.86	1.57e-06	0.000395	0.27	0.22	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
HNSC	cis	rs1012068	0.924	rs5998173	ENSG00000236132.1	CTA-440B3.1	-4.86	1.57e-06	0.000395	-0.26	-0.22	Chronic hepatitis C infection;	chr22:31909985	chr22:31816379~31817491:-
HNSC	cis	rs73222236	0.825	rs6776841	ENSG00000273486.1	RP11-731C17.2	4.86	1.57e-06	0.000395	0.18	0.22	Coronary artery disease;	chr3:136323322	chr3:136837338~136839021:-
HNSC	cis	rs17345786	0.511	rs12639028	ENSG00000244119.1	PDCL3P4	4.86	1.58e-06	0.000395	0.22	0.22	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101712472~101713191:+
HNSC	cis	rs2834288	0.535	rs4816468	ENSG00000273102.1	AP000569.9	4.86	1.58e-06	0.000395	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33967101~33968573:-
HNSC	cis	rs7809950	0.817	rs58052742	ENSG00000238832.1	snoU109	4.86	1.58e-06	0.000395	0.31	0.22	Coronary artery disease;	chr7:107569558	chr7:107603363~107603507:+
HNSC	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	4.86	1.58e-06	0.000395	0.21	0.22	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
HNSC	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-4.86	1.58e-06	0.000396	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-4.86	1.58e-06	0.000396	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-4.86	1.58e-06	0.000396	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
HNSC	cis	rs13073817	0.582	rs11921792	ENSG00000228956.7	SATB1-AS1	4.86	1.58e-06	0.000396	0.23	0.22	Crohn's disease;	chr3:18648247	chr3:18445024~18920401:+
HNSC	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	4.86	1.58e-06	0.000396	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
HNSC	cis	rs860295	0.702	rs12041534	ENSG00000203761.5	MSTO2P	4.86	1.58e-06	0.000397	0.16	0.22	Body mass index;	chr1:155437305	chr1:155745829~155750137:+
HNSC	cis	rs9840812	0.591	rs1291921	ENSG00000239213.4	NCK1-AS1	4.86	1.58e-06	0.000397	0.2	0.22	Fibrinogen levels;	chr3:136317384	chr3:136841726~136862054:-
HNSC	cis	rs3096299	0.967	rs3102341	ENSG00000261574.1	RP1-168P16.2	4.86	1.58e-06	0.000397	0.28	0.22	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89392375~89412564:-
HNSC	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.86	1.58e-06	0.000397	0.25	0.22	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
HNSC	cis	rs4699052	0.625	rs28397882	ENSG00000246560.2	RP11-10L12.4	4.86	1.58e-06	0.000397	0.25	0.22	Testicular germ cell tumor;	chr4:103361679	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.59	rs28728298	ENSG00000246560.2	RP11-10L12.4	4.86	1.58e-06	0.000397	0.25	0.22	Testicular germ cell tumor;	chr4:103361693	chr4:102828055~102844075:+
HNSC	cis	rs8091660	0.624	rs6507852	ENSG00000278983.1	RP11-426J5.3	-4.86	1.59e-06	0.000397	-0.3	-0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48548678	chr18:48564795~48568342:+
HNSC	cis	rs728616	0.614	rs10887199	ENSG00000225484.5	NUTM2B-AS1	-4.86	1.59e-06	0.000398	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79663088~79826594:-
HNSC	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.86	1.59e-06	0.000398	0.19	0.22	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
HNSC	cis	rs4873772	0.738	rs4873446	ENSG00000253330.1	RP11-697N18.3	-4.86	1.59e-06	0.000398	-0.29	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47533902	chr8:47511034~47512141:-
HNSC	cis	rs9921338	0.924	rs72773831	ENSG00000263080.1	RP11-485G7.5	4.86	1.59e-06	0.000398	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11341809~11345211:-
HNSC	cis	rs10504130	0.696	rs11785805	ENSG00000253844.1	RP11-546K22.1	-4.86	1.59e-06	0.000398	-0.32	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51961458~52022974:+
HNSC	cis	rs11148252	0.532	rs9526975	ENSG00000198384.8	TPTE2P3	4.86	1.59e-06	0.000398	0.28	0.22	Lewy body disease;	chr13:52681669	chr13:52522632~52586906:+
HNSC	cis	rs2145598	0.874	rs58231973	ENSG00000279636.2	LINC00216	-4.86	1.59e-06	0.000398	-0.24	-0.22	Coronary artery disease;	chr14:58330929	chr14:58288033~58289158:+
HNSC	cis	rs1056107	0.931	rs4979089	ENSG00000225513.1	RP11-165N19.2	-4.86	1.59e-06	0.000399	-0.23	-0.22	Colorectal cancer;	chr9:112236816	chr9:112173522~112173971:-
HNSC	cis	rs12468226	1	rs74766638	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202445168	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs76528043	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202466116	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs12468226	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202472278	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs75040639	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202486973	chr2:202336024~202336727:-
HNSC	cis	rs12468226	0.872	rs115187557	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202495351	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs74508472	ENSG00000226261.1	AC064836.3	4.86	1.59e-06	0.000399	0.32	0.22	Urate levels;	chr2:202517290	chr2:202336024~202336727:-
HNSC	cis	rs8040855	0.599	rs6496792	ENSG00000259774.1	RP11-182J1.13	-4.86	1.59e-06	0.000399	-0.26	-0.22	Bulimia nervosa;	chr15:85182514	chr15:84422618~84425882:+
HNSC	cis	rs8040855	0.599	rs6496793	ENSG00000259774.1	RP11-182J1.13	-4.86	1.59e-06	0.000399	-0.26	-0.22	Bulimia nervosa;	chr15:85182515	chr15:84422618~84425882:+
HNSC	cis	rs8040855	0.599	rs6496795	ENSG00000259774.1	RP11-182J1.13	-4.86	1.59e-06	0.000399	-0.26	-0.22	Bulimia nervosa;	chr15:85182622	chr15:84422618~84425882:+
HNSC	cis	rs8040855	0.599	rs4577058	ENSG00000259774.1	RP11-182J1.13	-4.86	1.59e-06	0.000399	-0.26	-0.22	Bulimia nervosa;	chr15:85183227	chr15:84422618~84425882:+
HNSC	cis	rs6751744	1	rs6751744	ENSG00000226266.5	AC009961.3	-4.86	1.59e-06	0.000399	-0.26	-0.22	Dysphagia;	chr2:159550974	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	4.86	1.59e-06	0.000399	0.23	0.22	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
HNSC	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	4.86	1.59e-06	0.000399	0.25	0.22	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
HNSC	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	4.86	1.6e-06	0.000399	0.25	0.22	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
HNSC	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-4.86	1.6e-06	0.000399	-0.27	-0.22	Height;	chr20:49227804	chr20:49280319~49280409:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000219392.1	RP1-265C24.5	-4.86	1.6e-06	4e-04	-0.24	-0.22	Pubertal anthropometrics;	chr6:28431347	chr6:28115628~28116551:+
HNSC	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-4.86	1.6e-06	4e-04	-0.27	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
HNSC	cis	rs763121	0.853	rs11704021	ENSG00000273076.1	RP3-508I15.22	4.86	1.6e-06	4e-04	0.23	0.22	Menopause (age at onset);	chr22:38678711	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	4.86	1.6e-06	4e-04	0.27	0.22	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	4.86	1.6e-06	4e-04	0.27	0.22	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
HNSC	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	4.86	1.6e-06	4e-04	0.28	0.22	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000254153.1	CTA-398F10.2	4.86	1.6e-06	4e-04	0.24	0.22	Parkinson's disease;	chr8:8413361	chr8:8456909~8461337:-
HNSC	cis	rs7824557	0.767	rs6985460	ENSG00000255310.2	AF131215.2	4.86	1.6e-06	4e-04	0.21	0.22	Retinal vascular caliber;	chr8:11313578	chr8:11107788~11109726:-
HNSC	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-4.86	1.6e-06	0.000401	-0.25	-0.22	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
HNSC	cis	rs7615952	0.576	rs17523380	ENSG00000241288.6	RP11-379B18.5	-4.86	1.6e-06	0.000401	-0.26	-0.22	Blood pressure (smoking interaction);	chr3:126084031	chr3:125827238~125916384:-
HNSC	cis	rs3811273	0.614	rs7156203	ENSG00000211816.2	TRAV38-1	-4.86	1.6e-06	0.000401	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22263640	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs10149605	ENSG00000211816.2	TRAV38-1	-4.86	1.6e-06	0.000401	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22263646	chr14:22271968~22272563:+
HNSC	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.86	1.6e-06	0.000401	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.86	1.6e-06	0.000401	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
HNSC	cis	rs6693567	0.545	rs4446975	ENSG00000228126.1	FALEC	4.86	1.6e-06	0.000402	0.27	0.22	Migraine;	chr1:150483693	chr1:150515757~150518032:+
HNSC	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.86	1.6e-06	0.000402	0.22	0.22	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
HNSC	cis	rs4218	0.543	rs2414618	ENSG00000277144.1	RP11-59H7.4	-4.86	1.6e-06	0.000402	-0.28	-0.22	Social communication problems;	chr15:59019684	chr15:59115547~59116089:-
HNSC	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	4.86	1.61e-06	0.000402	0.27	0.22	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
HNSC	cis	rs34421088	0.576	rs2572436	ENSG00000255310.2	AF131215.2	-4.86	1.61e-06	0.000402	-0.24	-0.22	Neuroticism;	chr8:11241700	chr8:11107788~11109726:-
HNSC	cis	rs2762353	0.779	rs9393672	ENSG00000272462.2	U91328.19	-4.86	1.61e-06	0.000402	-0.21	-0.22	Blood metabolite levels;	chr6:25842377	chr6:25992662~26001775:+
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	4.86	1.61e-06	0.000402	0.27	0.22	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	4.86	1.61e-06	0.000402	0.27	0.22	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
HNSC	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-4.86	1.61e-06	0.000402	-0.51	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
HNSC	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	4.86	1.61e-06	0.000403	0.25	0.22	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
HNSC	cis	rs3738443	0.678	rs6680707	ENSG00000259865.1	RP11-488L18.10	4.86	1.61e-06	0.000403	0.18	0.22	Alcohol dependence;	chr1:247213648	chr1:247187281~247188526:-
HNSC	cis	rs7985	0.901	rs5761679	ENSG00000244625.4	MIATNB	4.86	1.61e-06	0.000403	0.25	0.22	Electroencephalogram traits;	chr22:26681268	chr22:26672767~26780207:+
HNSC	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-4.86	1.61e-06	0.000403	-0.23	-0.22	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
HNSC	cis	rs6951245	0.572	rs11559183	ENSG00000225146.1	AC073957.15	-4.86	1.61e-06	0.000403	-0.46	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:997389	chr7:1029025~1043891:+
HNSC	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	4.86	1.61e-06	0.000403	0.24	0.22	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
HNSC	cis	rs898123	0.931	rs72837605	ENSG00000234896.1	OR7E62P	4.86	1.61e-06	0.000403	0.26	0.22	Coronary artery disease;	chr2:71112725	chr2:71055527~71056003:+
HNSC	cis	rs6479891	0.686	rs61855876	ENSG00000232075.1	MRPL35P2	4.86	1.61e-06	0.000403	0.37	0.22	Arthritis (juvenile idiopathic);	chr10:63597781	chr10:63634317~63634827:-
HNSC	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-4.86	1.61e-06	0.000403	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
HNSC	cis	rs10129255	0.53	rs11624912	ENSG00000224373.3	IGHV4-59	4.86	1.61e-06	0.000403	0.12	0.22	Kawasaki disease;	chr14:106673891	chr14:106627249~106627825:-
HNSC	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-4.86	1.61e-06	0.000403	-0.29	-0.22	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
HNSC	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	4.86	1.61e-06	0.000403	0.25	0.22	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
HNSC	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	4.86	1.62e-06	0.000404	0.23	0.22	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
HNSC	cis	rs712039	0.652	rs1616371	ENSG00000276054.1	RP11-378E13.3	4.86	1.62e-06	0.000404	0.3	0.22	Tuberculosis;	chr17:37413714	chr17:37386886~37387926:+
HNSC	cis	rs763121	0.853	rs5750668	ENSG00000273076.1	RP3-508I15.22	4.86	1.62e-06	0.000404	0.23	0.22	Menopause (age at onset);	chr22:38683959	chr22:38743495~38743910:+
HNSC	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	4.86	1.62e-06	0.000405	0.27	0.22	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
HNSC	cis	rs6600671	1	rs11249351	ENSG00000270231.3	NBPF8P	4.86	1.62e-06	0.000405	0.19	0.22	Hip geometry;	chr1:121430082	chr1:120436353~120467739:+
HNSC	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	4.86	1.62e-06	0.000405	0.31	0.22	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	4.86	1.62e-06	0.000405	0.31	0.22	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
HNSC	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-4.86	1.62e-06	0.000405	-0.28	-0.22	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-4.86	1.62e-06	0.000405	-0.28	-0.22	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-4.86	1.62e-06	0.000405	-0.26	-0.22	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
HNSC	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-4.86	1.62e-06	0.000405	-0.24	-0.22	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
HNSC	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-4.86	1.62e-06	0.000405	-0.24	-0.22	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
HNSC	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	4.86	1.62e-06	0.000405	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
HNSC	cis	rs72727394	0.51	rs17653133	ENSG00000259747.1	RP11-275I4.2	-4.86	1.62e-06	0.000405	-0.29	-0.22	Crohn's disease;	chr15:38629660	chr15:38671847~38689191:+
HNSC	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	4.86	1.62e-06	0.000405	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
HNSC	cis	rs10504130	0.696	rs113323463	ENSG00000253844.1	RP11-546K22.1	-4.86	1.62e-06	0.000405	-0.33	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.696	rs78238505	ENSG00000253844.1	RP11-546K22.1	-4.86	1.62e-06	0.000405	-0.33	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51961458~52022974:+
HNSC	cis	rs9650657	0.504	rs7813802	ENSG00000255310.2	AF131215.2	4.86	1.62e-06	0.000405	0.21	0.22	Neuroticism;	chr8:11176467	chr8:11107788~11109726:-
HNSC	cis	rs1218582	0.741	rs6656494	ENSG00000270361.1	RP11-307C12.13	-4.86	1.62e-06	0.000405	-0.24	-0.22	Prostate cancer;	chr1:154867323	chr1:154937370~154938059:+
HNSC	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-4.86	1.62e-06	0.000405	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
HNSC	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-4.86	1.62e-06	0.000406	-0.21	-0.22	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
HNSC	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-4.86	1.62e-06	0.000406	-0.21	-0.22	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
HNSC	cis	rs950169	0.686	rs12906474	ENSG00000229212.6	RP11-561C5.4	-4.86	1.62e-06	0.000406	-0.32	-0.22	Schizophrenia;	chr15:84566006	chr15:85205440~85234795:-
HNSC	cis	rs7824557	0.688	rs2572397	ENSG00000269918.1	AF131215.9	4.86	1.62e-06	0.000406	0.21	0.22	Retinal vascular caliber;	chr8:11318894	chr8:11104691~11106704:-
HNSC	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-4.86	1.63e-06	0.000406	-0.31	-0.22	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
HNSC	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	4.86	1.63e-06	0.000406	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	4.86	1.63e-06	0.000406	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
HNSC	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-4.86	1.63e-06	0.000406	-0.27	-0.22	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-4.86	1.63e-06	0.000406	-0.27	-0.22	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-4.86	1.63e-06	0.000406	-0.27	-0.22	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
HNSC	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	4.86	1.63e-06	0.000406	0.27	0.22	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
HNSC	cis	rs1125355	0.622	rs17203501	ENSG00000204380.3	AC005042.4	4.86	1.63e-06	0.000406	0.25	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158757125	chr2:158658337~158735002:-
HNSC	cis	rs763121	0.853	rs5757162	ENSG00000273076.1	RP3-508I15.22	4.86	1.63e-06	0.000407	0.24	0.22	Menopause (age at onset);	chr22:38597365	chr22:38743495~38743910:+
HNSC	cis	rs4873772	0.735	rs12549996	ENSG00000253330.1	RP11-697N18.3	-4.86	1.63e-06	0.000407	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47505644	chr8:47511034~47512141:-
HNSC	cis	rs13434995	0.513	rs2171617	ENSG00000273257.1	RP11-177J6.1	4.86	1.63e-06	0.000407	0.3	0.22	Adiponectin levels;	chr4:55591023	chr4:55387949~55388271:+
HNSC	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-4.86	1.63e-06	0.000407	-0.28	-0.22	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
HNSC	cis	rs9291683	0.554	rs7668175	ENSG00000250413.1	RP11-448G15.1	4.86	1.63e-06	0.000407	0.27	0.22	Bone mineral density;	chr4:10124158	chr4:10006482~10009725:+
HNSC	cis	rs12539814	1	rs10487628	ENSG00000204959.4	ARHGEF34P	4.86	1.63e-06	0.000407	0.39	0.22	Diastolic blood pressure;	chr7:144467232	chr7:144272445~144286966:-
HNSC	cis	rs2243480	1	rs73142162	ENSG00000179406.6	LINC00174	-4.86	1.63e-06	0.000407	-0.48	-0.22	Diabetic kidney disease;	chr7:65909309	chr7:66376044~66401338:-
HNSC	cis	rs2243480	1	rs73142166	ENSG00000179406.6	LINC00174	-4.86	1.63e-06	0.000407	-0.48	-0.22	Diabetic kidney disease;	chr7:65910845	chr7:66376044~66401338:-
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000179406.6	LINC00174	-4.86	1.63e-06	0.000407	-0.48	-0.22	Diabetic kidney disease;	chr7:65914813	chr7:66376044~66401338:-
HNSC	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-4.86	1.63e-06	0.000407	-0.26	-0.22	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-4.86	1.63e-06	0.000407	-0.26	-0.22	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
HNSC	cis	rs6657613	0.815	rs9435741	ENSG00000186715.9	MST1L	-4.86	1.63e-06	0.000407	-0.18	-0.22	Hip circumference adjusted for BMI;	chr1:17017409	chr1:16754910~16770237:-
HNSC	cis	rs4787951	0.56	rs3916997	ENSG00000259940.2	CTD-3203P2.1	-4.86	1.63e-06	0.000408	-0.23	-0.22	Eosinophil percentage of white cells;	chr16:27333793	chr16:27213308~27214993:-
HNSC	cis	rs2985684	0.901	rs2354448	ENSG00000258568.1	RHOQP1	4.86	1.63e-06	0.000408	0.22	0.22	Carotid intima media thickness;	chr14:49631578	chr14:49599994~49600572:+
HNSC	cis	rs2985684	1	rs1952012	ENSG00000258568.1	RHOQP1	4.86	1.63e-06	0.000408	0.22	0.22	Carotid intima media thickness;	chr14:49632178	chr14:49599994~49600572:+
HNSC	cis	rs2985684	1	rs2985687	ENSG00000258568.1	RHOQP1	4.86	1.63e-06	0.000408	0.22	0.22	Carotid intima media thickness;	chr14:49633668	chr14:49599994~49600572:+
HNSC	cis	rs3096299	0.933	rs2965934	ENSG00000261574.1	RP1-168P16.2	4.86	1.63e-06	0.000408	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89392375~89412564:-
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-4.86	1.63e-06	0.000408	-0.26	-0.22	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
HNSC	cis	rs603446	0.84	rs180329	ENSG00000254851.1	RP11-109L13.1	-4.86	1.63e-06	0.000408	-0.28	-0.22	Triglycerides;	chr11:116752242	chr11:117135528~117138582:+
HNSC	cis	rs6600671	0.967	rs12069545	ENSG00000270231.3	NBPF8P	4.86	1.63e-06	0.000408	0.19	0.22	Hip geometry;	chr1:121430343	chr1:120436353~120467739:+
HNSC	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	4.86	1.63e-06	0.000408	0.22	0.22	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
HNSC	cis	rs9650657	0.506	rs7823296	ENSG00000269918.1	AF131215.9	-4.86	1.63e-06	0.000408	-0.21	-0.22	Neuroticism;	chr8:10921036	chr8:11104691~11106704:-
HNSC	cis	rs11122895	0.61	rs13397902	ENSG00000236307.2	EEF1E1P1	4.86	1.63e-06	0.000408	0.23	0.22	Allergic sensitization;	chr2:111849928	chr2:111887914~111888741:+
HNSC	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	4.86	1.63e-06	0.000408	0.24	0.22	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
HNSC	cis	rs7980687	0.527	rs1727295	ENSG00000280120.1	RP11-546D6.3	4.86	1.63e-06	0.000408	0.19	0.22	Head circumference (infant);Educational attainment;Height;	chr12:123132314	chr12:123152324~123153377:-
HNSC	cis	rs17507216	0.681	rs28877110	ENSG00000276710.3	CSPG4P8	-4.86	1.63e-06	0.000408	-0.31	-0.22	Excessive daytime sleepiness;	chr15:82672111	chr15:82459472~82477258:+
HNSC	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	4.86	1.64e-06	0.000408	0.23	0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
HNSC	cis	rs4853525	0.59	rs7587672	ENSG00000235852.1	AC005540.3	4.86	1.64e-06	0.000409	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190858549	chr2:190880797~190882059:-
HNSC	cis	rs7809950	0.822	rs2712228	ENSG00000238832.1	snoU109	4.86	1.64e-06	0.000409	0.27	0.22	Coronary artery disease;	chr7:107659895	chr7:107603363~107603507:+
HNSC	cis	rs2179367	0.537	rs12192159	ENSG00000216906.2	RP11-350J20.9	4.86	1.64e-06	0.000409	0.34	0.22	Dupuytren's disease;	chr6:149445969	chr6:149904243~149906418:+
HNSC	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-4.86	1.64e-06	0.000409	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-4.86	1.64e-06	0.000409	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
HNSC	cis	rs2933343	0.7	rs1683787	ENSG00000261159.1	RP11-723O4.9	-4.86	1.64e-06	0.000409	-0.21	-0.22	IgG glycosylation;	chr3:128908178	chr3:128859716~128860526:-
HNSC	cis	rs2985684	0.901	rs57119148	ENSG00000258568.1	RHOQP1	4.86	1.64e-06	0.000409	0.22	0.22	Carotid intima media thickness;	chr14:49630508	chr14:49599994~49600572:+
HNSC	cis	rs4664293	0.609	rs357033	ENSG00000226266.5	AC009961.3	-4.86	1.64e-06	0.000409	-0.23	-0.22	Monocyte percentage of white cells;	chr2:159637962	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs6432543	ENSG00000226266.5	AC009961.3	4.86	1.64e-06	0.000409	0.23	0.22	Monocyte percentage of white cells;	chr2:159638820	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs4665099	ENSG00000226266.5	AC009961.3	4.86	1.64e-06	0.000409	0.23	0.22	Monocyte percentage of white cells;	chr2:159639027	chr2:159670708~159712435:-
HNSC	cis	rs9329221	0.621	rs522483	ENSG00000254340.1	RP11-10A14.3	-4.86	1.64e-06	0.000409	-0.26	-0.22	Neuroticism;	chr8:9955459	chr8:9141424~9145435:+
HNSC	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	4.86	1.64e-06	0.000409	0.22	0.22	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	4.86	1.64e-06	0.000409	0.22	0.22	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
HNSC	cis	rs3806843	0.966	rs10036519	ENSG00000202515.1	VTRNA1-3	4.86	1.64e-06	0.00041	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr5:140726158~140726246:+
HNSC	cis	rs1056107	0.897	rs7867328	ENSG00000225513.1	RP11-165N19.2	-4.86	1.64e-06	0.00041	-0.24	-0.22	Colorectal cancer;	chr9:112196925	chr9:112173522~112173971:-
HNSC	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	4.86	1.64e-06	0.00041	0.26	0.22	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
HNSC	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	4.86	1.64e-06	0.00041	0.19	0.22	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
HNSC	cis	rs72949976	0.606	rs11898263	ENSG00000270659.1	RP11-105N14.1	-4.86	1.64e-06	0.00041	-0.21	-0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213165925	chr2:213152970~213153659:+
HNSC	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-4.86	1.64e-06	0.00041	-0.35	-0.22	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
HNSC	cis	rs9291683	0.62	rs7699512	ENSG00000250413.1	RP11-448G15.1	4.85	1.65e-06	0.000411	0.27	0.22	Bone mineral density;	chr4:10124184	chr4:10006482~10009725:+
HNSC	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	4.85	1.65e-06	0.000411	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
HNSC	cis	rs1993293	0.569	rs62042315	ENSG00000182397.13	DNM1P46	-4.85	1.65e-06	0.000411	-0.3	-0.22	Coronary artery calcification;	chr15:99751724	chr15:99790156~99806927:-
HNSC	cis	rs4664293	0.647	rs4144512	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000411	0.23	0.22	Monocyte percentage of white cells;	chr2:159651008	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs13006088	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000411	0.23	0.22	Monocyte percentage of white cells;	chr2:159652915	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.605	rs2042774	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000411	0.23	0.22	Monocyte percentage of white cells;	chr2:159653496	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.647	rs2042775	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000411	0.23	0.22	Monocyte percentage of white cells;	chr2:159653581	chr2:159670708~159712435:-
HNSC	cis	rs6693567	0.565	rs35784258	ENSG00000228126.1	FALEC	4.85	1.65e-06	0.000411	0.26	0.22	Migraine;	chr1:150433406	chr1:150515757~150518032:+
HNSC	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	4.85	1.65e-06	0.000411	0.36	0.22	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	4.85	1.65e-06	0.000411	0.36	0.22	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
HNSC	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-4.85	1.65e-06	0.000411	-0.34	-0.22	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
HNSC	cis	rs7429990	0.932	rs6442101	ENSG00000228638.1	FCF1P2	4.85	1.65e-06	0.000411	0.21	0.22	Educational attainment (years of education);	chr3:48089403	chr3:48290793~48291375:-
HNSC	cis	rs7824557	0.815	rs958648	ENSG00000269918.1	AF131215.9	-4.85	1.65e-06	0.000411	-0.21	-0.22	Retinal vascular caliber;	chr8:11246386	chr8:11104691~11106704:-
HNSC	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	4.85	1.65e-06	0.000412	0.25	0.22	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
HNSC	cis	rs4664293	0.647	rs6724151	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000412	0.23	0.22	Monocyte percentage of white cells;	chr2:159642788	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs34573069	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000412	0.23	0.22	Monocyte percentage of white cells;	chr2:159643561	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.567	rs6711125	ENSG00000226266.5	AC009961.3	4.85	1.65e-06	0.000412	0.23	0.22	Monocyte percentage of white cells;	chr2:159645040	chr2:159670708~159712435:-
HNSC	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-4.85	1.65e-06	0.000412	-0.22	-0.22	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.607	rs66868086	ENSG00000219392.1	RP1-265C24.5	-4.85	1.65e-06	0.000412	-0.43	-0.22	Depression;	chr6:27898124	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13199649	ENSG00000219392.1	RP1-265C24.5	-4.85	1.65e-06	0.000412	-0.43	-0.22	Depression;	chr6:27901014	chr6:28115628~28116551:+
HNSC	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-4.85	1.65e-06	0.000412	-0.28	-0.22	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	4.85	1.65e-06	0.000412	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	4.85	1.65e-06	0.000412	0.24	0.22	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
HNSC	cis	rs3096299	0.967	rs2911257	ENSG00000261574.1	RP1-168P16.2	4.85	1.65e-06	0.000412	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89392375~89412564:-
HNSC	cis	rs11098499	0.722	rs17595727	ENSG00000249244.1	RP11-548H18.2	-4.85	1.65e-06	0.000412	-0.27	-0.22	Corneal astigmatism;	chr4:119340919	chr4:119391831~119395335:-
HNSC	cis	rs13126694	0.743	rs12512643	ENSG00000248429.4	RP11-597D13.9	4.85	1.65e-06	0.000412	0.25	0.22	Blood osmolality (transformed sodium);	chr4:158115588	chr4:158170752~158202877:+
HNSC	cis	rs8012947	0.607	rs1051858	ENSG00000279636.2	LINC00216	4.85	1.65e-06	0.000412	0.25	0.22	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58288033~58289158:+
HNSC	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-4.85	1.65e-06	0.000412	-0.28	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
HNSC	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-4.85	1.65e-06	0.000412	-0.28	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
HNSC	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-4.85	1.66e-06	0.000413	-0.26	-0.22	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
HNSC	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-4.85	1.66e-06	0.000413	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
HNSC	cis	rs6693567	0.545	rs11205382	ENSG00000228126.1	FALEC	-4.85	1.66e-06	0.000413	-0.26	-0.22	Migraine;	chr1:150469990	chr1:150515757~150518032:+
HNSC	cis	rs7819412	0.668	rs2409721	ENSG00000255310.2	AF131215.2	-4.85	1.66e-06	0.000413	-0.22	-0.22	Triglycerides;	chr8:11180735	chr8:11107788~11109726:-
HNSC	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	4.85	1.66e-06	0.000413	0.24	0.22	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
HNSC	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	4.85	1.66e-06	0.000413	0.27	0.22	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
HNSC	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-4.85	1.66e-06	0.000413	-0.27	-0.22	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
HNSC	cis	rs9291683	0.527	rs3822247	ENSG00000250413.1	RP11-448G15.1	4.85	1.66e-06	0.000414	0.28	0.22	Bone mineral density;	chr4:10093047	chr4:10006482~10009725:+
HNSC	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	4.85	1.66e-06	0.000414	0.29	0.22	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	4.85	1.66e-06	0.000414	0.29	0.22	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	4.85	1.66e-06	0.000414	0.29	0.22	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
HNSC	cis	rs853679	0.545	rs35949109	ENSG00000204709.4	LINC01556	4.85	1.66e-06	0.000414	0.39	0.22	Depression;	chr6:28058148	chr6:28943877~28944537:+
HNSC	cis	rs10462794	1	rs10462795	ENSG00000260763.1	RP11-445O3.3	4.85	1.66e-06	0.000414	0.28	0.22	DNA methylation (variation);	chr5:4488196	chr5:4436850~4440259:-
HNSC	cis	rs12893668	0.572	rs11846404	ENSG00000269940.1	RP11-73M18.7	4.85	1.66e-06	0.000414	0.21	0.22	Reticulocyte count;	chr14:103689771	chr14:103694560~103695170:+
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	4.85	1.66e-06	0.000414	0.24	0.22	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
HNSC	cis	rs2645424	0.602	rs3779663	ENSG00000255046.1	RP11-297N6.4	-4.85	1.67e-06	0.000415	-0.22	-0.22	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11813853	chr8:11797928~11802568:-
HNSC	cis	rs3206736	0.576	rs17205723	ENSG00000197085.10	NPSR1-AS1	4.85	1.67e-06	0.000415	0.29	0.22	Diastolic blood pressure;	chr7:35076824	chr7:34346512~34871582:-
HNSC	cis	rs6061231	0.583	rs2427313	ENSG00000275437.1	RP5-908M14.10	4.85	1.67e-06	0.000415	0.22	0.22	Colorectal cancer;	chr20:62395619	chr20:62402236~62405935:-
HNSC	cis	rs9863	0.861	rs11057393	ENSG00000269938.1	RP11-214K3.20	-4.85	1.67e-06	0.000415	-0.26	-0.22	White blood cell count;	chr12:123919222	chr12:123968023~123968579:-
HNSC	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	4.85	1.67e-06	0.000415	0.23	0.22	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
HNSC	cis	rs9840812	0.592	rs35418151	ENSG00000239213.4	NCK1-AS1	4.85	1.67e-06	0.000416	0.2	0.22	Fibrinogen levels;	chr3:136443779	chr3:136841726~136862054:-
HNSC	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	4.85	1.67e-06	0.000416	0.27	0.22	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
HNSC	cis	rs12545109	0.837	rs4738500	ENSG00000246430.5	LINC00968	-4.85	1.67e-06	0.000416	-0.28	-0.22	Obesity-related traits;	chr8:56443634	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.837	rs1437277	ENSG00000246430.5	LINC00968	-4.85	1.67e-06	0.000416	-0.28	-0.22	Obesity-related traits;	chr8:56444175	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.8	rs1437278	ENSG00000246430.5	LINC00968	-4.85	1.67e-06	0.000416	-0.28	-0.22	Obesity-related traits;	chr8:56444465	chr8:56496246~56559823:-
HNSC	cis	rs5758659	1	rs134882	ENSG00000182057.4	OGFRP1	4.85	1.67e-06	0.000416	0.22	0.22	Cognitive function;	chr22:42274959	chr22:42269753~42275196:+
HNSC	cis	rs6921919	0.562	rs13198809	ENSG00000219392.1	RP1-265C24.5	-4.85	1.67e-06	0.000416	-0.44	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28115628~28116551:+
HNSC	cis	rs73222236	0.825	rs6439638	ENSG00000273486.1	RP11-731C17.2	4.85	1.67e-06	0.000416	0.18	0.22	Coronary artery disease;	chr3:136338990	chr3:136837338~136839021:-
HNSC	cis	rs116095464	0.614	rs62344292	ENSG00000250848.1	CTD-2083E4.5	-4.85	1.67e-06	0.000416	-0.31	-0.22	Breast cancer;	chr5:244515	chr5:288833~290321:-
HNSC	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-4.85	1.67e-06	0.000416	-0.28	-0.22	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.85	1.67e-06	0.000417	0.27	0.22	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
HNSC	cis	rs9300255	0.679	rs12829456	ENSG00000280120.1	RP11-546D6.3	-4.85	1.67e-06	0.000417	-0.22	-0.22	Neutrophil percentage of white cells;	chr12:123240848	chr12:123152324~123153377:-
HNSC	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-4.85	1.67e-06	0.000417	-0.21	-0.22	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
HNSC	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-4.85	1.67e-06	0.000417	-0.24	-0.22	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
HNSC	cis	rs6964587	1	rs13231238	ENSG00000188693.7	CYP51A1-AS1	-4.85	1.67e-06	0.000417	-0.23	-0.22	Breast cancer;	chr7:92024537	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2299238	ENSG00000188693.7	CYP51A1-AS1	-4.85	1.67e-06	0.000417	-0.23	-0.22	Breast cancer;	chr7:92025203	chr7:92134604~92180725:+
HNSC	cis	rs4761669	0.565	rs7316798	ENSG00000241556.1	RP11-490G8.1	4.85	1.68e-06	0.000417	0.22	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94793404	chr12:95467397~95467861:-
HNSC	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-4.85	1.68e-06	0.000418	-0.28	-0.22	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
HNSC	cis	rs1971762	0.583	rs3852561	ENSG00000270175.1	RP11-793H13.11	-4.85	1.68e-06	0.000418	-0.19	-0.22	Height;	chr12:53692058	chr12:53500162~53500936:-
HNSC	cis	rs2834288	0.5	rs766423	ENSG00000273102.1	AP000569.9	4.85	1.68e-06	0.000418	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33967101~33968573:-
HNSC	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-4.85	1.68e-06	0.000418	-0.24	-0.22	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
HNSC	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-4.85	1.68e-06	0.000418	-0.24	-0.22	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
HNSC	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-4.85	1.68e-06	0.000418	-0.24	-0.22	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
HNSC	cis	rs795484	0.963	rs1726392	ENSG00000275409.1	RP11-131L12.4	-4.85	1.68e-06	0.000419	-0.25	-0.22	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118161120	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000254153.1	CTA-398F10.2	4.85	1.68e-06	0.000419	0.24	0.22	Mood instability;	chr8:8288087	chr8:8456909~8461337:-
HNSC	cis	rs17292804	0.527	rs12887734	ENSG00000269940.1	RP11-73M18.7	4.85	1.68e-06	0.000419	0.22	0.22	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694560~103695170:+
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	4.85	1.68e-06	0.000419	0.27	0.22	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
HNSC	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-4.85	1.68e-06	0.000419	-0.27	-0.22	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.74	rs11250119	ENSG00000269918.1	AF131215.9	-4.85	1.69e-06	0.00042	-0.22	-0.22	Triglycerides;	chr8:11179525	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.896	rs2064430	ENSG00000217482.2	HMGB1P17	4.85	1.69e-06	0.00042	0.24	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135321618	chr6:135636086~135636713:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	4.85	1.69e-06	0.00042	0.23	0.22	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	4.85	1.69e-06	0.00042	0.23	0.22	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
HNSC	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	4.85	1.69e-06	0.00042	0.23	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	4.85	1.69e-06	0.00042	0.27	0.22	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
HNSC	cis	rs5758659	0.714	rs2413668	ENSG00000227370.1	RP4-669P10.19	4.85	1.69e-06	0.00042	0.21	0.22	Cognitive function;	chr22:42109837	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.657	rs5758587	ENSG00000227370.1	RP4-669P10.19	4.85	1.69e-06	0.00042	0.21	0.22	Cognitive function;	chr22:42121632	chr22:42132543~42132998:+
HNSC	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-4.85	1.69e-06	0.00042	-0.18	-0.22	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-4.85	1.69e-06	0.00042	-0.18	-0.22	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
HNSC	cis	rs853679	0.769	rs7752608	ENSG00000219392.1	RP1-265C24.5	-4.85	1.69e-06	0.00042	-0.39	-0.22	Depression;	chr6:28333418	chr6:28115628~28116551:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000179406.6	LINC00174	-4.85	1.69e-06	0.00042	-0.29	-0.22	Aortic root size;	chr7:66708053	chr7:66376044~66401338:-
HNSC	cis	rs2976388	0.692	rs2978983	ENSG00000253741.1	CTD-2292P10.4	-4.85	1.69e-06	0.00042	-0.21	-0.22	Urinary tract infection frequency;	chr8:142684424	chr8:142702252~142726973:-
HNSC	cis	rs1218582	0.772	rs4845694	ENSG00000270361.1	RP11-307C12.13	-4.85	1.69e-06	0.000421	-0.24	-0.22	Prostate cancer;	chr1:154939175	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs11264290	ENSG00000270361.1	RP11-307C12.13	-4.85	1.69e-06	0.000421	-0.24	-0.22	Prostate cancer;	chr1:154939824	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs12095061	ENSG00000270361.1	RP11-307C12.13	-4.85	1.69e-06	0.000421	-0.24	-0.22	Prostate cancer;	chr1:154940492	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs6699043	ENSG00000270361.1	RP11-307C12.13	-4.85	1.69e-06	0.000421	-0.24	-0.22	Prostate cancer;	chr1:154940545	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.772	rs6686873	ENSG00000270361.1	RP11-307C12.13	-4.85	1.69e-06	0.000421	-0.24	-0.22	Prostate cancer;	chr1:154940928	chr1:154937370~154938059:+
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000254340.1	RP11-10A14.3	-4.85	1.69e-06	0.000421	-0.27	-0.22	Mood instability;	chr8:8723898	chr8:9141424~9145435:+
HNSC	cis	rs7324557	0.717	rs7330646	ENSG00000205861.10	C1QTNF9B-AS1	4.85	1.69e-06	0.000421	0.29	0.22	Visceral adipose tissue adjusted for BMI;	chr13:23828025	chr13:23888889~23897263:+
HNSC	cis	rs7568498	0.517	rs197261	ENSG00000227403.1	AC009299.3	4.85	1.69e-06	0.000421	0.32	0.22	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161244739~161249050:+
HNSC	cis	rs6928977	0.897	rs2614258	ENSG00000234084.1	RP3-388E23.2	4.85	1.69e-06	0.000421	0.23	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356064	chr6:135301568~135307158:+
HNSC	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-4.85	1.69e-06	0.000422	-0.27	-0.22	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
HNSC	cis	rs6674176	0.66	rs6801	ENSG00000237950.1	RP11-7O11.3	-4.85	1.7e-06	0.000422	-0.25	-0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930974	chr1:43944370~43946551:-
HNSC	cis	rs853679	0.607	rs13208096	ENSG00000219392.1	RP1-265C24.5	-4.85	1.7e-06	0.000422	-0.42	-0.22	Depression;	chr6:28257533	chr6:28115628~28116551:+
HNSC	cis	rs12468226	0.702	rs114634431	ENSG00000226261.1	AC064836.3	4.85	1.7e-06	0.000422	0.34	0.22	Urate levels;	chr2:202142530	chr2:202336024~202336727:-
HNSC	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	4.85	1.7e-06	0.000422	0.25	0.22	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
HNSC	cis	rs4657482	0.855	rs4657488	ENSG00000236364.3	RP11-525G13.2	-4.85	1.7e-06	0.000422	-0.21	-0.22	Testicular germ cell tumor;	chr1:165866154	chr1:165890795~165900683:-
HNSC	cis	rs9987353	0.544	rs2929469	ENSG00000173295.6	FAM86B3P	4.85	1.7e-06	0.000422	0.25	0.22	Recombination measurement;	chr8:9205146	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.514	rs2945873	ENSG00000254153.1	CTA-398F10.2	4.85	1.7e-06	0.000422	0.24	0.22	Mood instability;	chr8:8402935	chr8:8456909~8461337:-
HNSC	cis	rs4924935	0.669	rs7221935	ENSG00000264885.1	RP11-815I9.4	-4.85	1.7e-06	0.000422	-0.23	-0.22	Pancreatic cancer;	chr17:18857086	chr17:18667629~18669461:-
HNSC	cis	rs11672691	0.756	rs8107333	ENSG00000270164.1	LINC01480	-4.85	1.7e-06	0.000423	-0.2	-0.22	Prostate cancer;	chr19:41481965	chr19:41535183~41536904:+
HNSC	cis	rs61542988	0.57	rs62448267	ENSG00000221740.1	SNORD93	4.85	1.7e-06	0.000423	0.28	0.22	Fibrinogen levels;	chr7:22782882	chr7:22856613~22856686:+
HNSC	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-4.85	1.7e-06	0.000423	-0.21	-0.22	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000254174.1	IGHV1-12	4.85	1.7e-06	0.000423	0.19	0.22	Alzheimer's disease (late onset);	chr14:106697724	chr14:106122420~106122709:-
HNSC	cis	rs36052053	0.908	rs13220206	ENSG00000219700.1	PTCHD3P3	4.85	1.7e-06	0.000423	0.35	0.22	Red cell distribution width;	chr6:109303278	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs34780834	ENSG00000219700.1	PTCHD3P3	4.85	1.7e-06	0.000423	0.35	0.22	Red cell distribution width;	chr6:109303563	chr6:109288571~109290503:-
HNSC	cis	rs13126694	0.744	rs7657303	ENSG00000248429.4	RP11-597D13.9	-4.85	1.7e-06	0.000423	-0.24	-0.22	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158170752~158202877:+
HNSC	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	4.85	1.7e-06	0.000423	0.17	0.22	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	4.85	1.7e-06	0.000423	0.17	0.22	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
HNSC	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	4.85	1.7e-06	0.000423	0.25	0.22	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
HNSC	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	4.85	1.7e-06	0.000423	0.27	0.22	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	4.85	1.7e-06	0.000423	0.27	0.22	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
HNSC	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	4.85	1.7e-06	0.000423	0.43	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
HNSC	cis	rs9880211	0.563	rs6792630	ENSG00000273486.1	RP11-731C17.2	4.85	1.7e-06	0.000423	0.2	0.22	Height;Body mass index;	chr3:136106059	chr3:136837338~136839021:-
HNSC	cis	rs11250098	0.574	rs4240672	ENSG00000269918.1	AF131215.9	-4.85	1.7e-06	0.000424	-0.21	-0.22	Morning vs. evening chronotype;	chr8:10910407	chr8:11104691~11106704:-
HNSC	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-4.85	1.7e-06	0.000424	-0.22	-0.22	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000233609.3	RP11-62H7.2	4.85	1.71e-06	0.000424	0.21	0.22	Joint mobility (Beighton score);	chr8:8979093	chr8:8961200~8979025:+
HNSC	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	4.85	1.71e-06	0.000425	0.28	0.22	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
HNSC	cis	rs7819412	0.634	rs6987767	ENSG00000255310.2	AF131215.2	4.85	1.71e-06	0.000425	0.21	0.22	Triglycerides;	chr8:11052556	chr8:11107788~11109726:-
HNSC	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-4.85	1.71e-06	0.000425	-0.27	-0.22	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
HNSC	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	4.85	1.71e-06	0.000425	0.23	0.22	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
HNSC	cis	rs4853525	0.544	rs61187415	ENSG00000235852.1	AC005540.3	4.85	1.71e-06	0.000425	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846184	chr2:190880797~190882059:-
HNSC	cis	rs4388249	1	rs2300990	ENSG00000271849.1	CTC-332L22.1	-4.85	1.71e-06	0.000425	-0.33	-0.22	Schizophrenia;	chr5:109697692	chr5:109687802~109688329:-
HNSC	cis	rs7824557	0.724	rs2251473	ENSG00000269918.1	AF131215.9	4.85	1.71e-06	0.000425	0.21	0.22	Retinal vascular caliber;	chr8:11319617	chr8:11104691~11106704:-
HNSC	cis	rs1056107	0.933	rs7047691	ENSG00000225513.1	RP11-165N19.2	-4.85	1.71e-06	0.000425	-0.23	-0.22	Colorectal cancer;	chr9:112289887	chr9:112173522~112173971:-
HNSC	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-4.85	1.71e-06	0.000425	-0.26	-0.22	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
HNSC	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-4.85	1.71e-06	0.000426	-0.18	-0.22	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
HNSC	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	4.85	1.71e-06	0.000426	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
HNSC	cis	rs4853525	0.59	rs2355576	ENSG00000235852.1	AC005540.3	4.85	1.71e-06	0.000426	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850374	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.59	rs4513327	ENSG00000235852.1	AC005540.3	4.85	1.71e-06	0.000426	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850695	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.561	rs17746911	ENSG00000235852.1	AC005540.3	4.85	1.71e-06	0.000426	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854640	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.59	rs12614693	ENSG00000235852.1	AC005540.3	4.85	1.71e-06	0.000426	0.3	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854882	chr2:190880797~190882059:-
HNSC	cis	rs4789693	0.546	rs7220204	ENSG00000265458.1	RP13-20L14.6	4.85	1.71e-06	0.000426	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82454273~82458521:-
HNSC	cis	rs73198271	0.681	rs35457364	ENSG00000233609.3	RP11-62H7.2	-4.85	1.72e-06	0.000426	-0.24	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.681	rs11987924	ENSG00000233609.3	RP11-62H7.2	-4.85	1.72e-06	0.000426	-0.24	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8961200~8979025:+
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000204709.4	LINC01556	4.85	1.72e-06	0.000426	0.32	0.22	Depression;	chr6:28231986	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000204709.4	LINC01556	4.85	1.72e-06	0.000426	0.32	0.22	Depression;	chr6:28232159	chr6:28943877~28944537:+
HNSC	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	4.85	1.72e-06	0.000426	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	4.85	1.72e-06	0.000426	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	4.85	1.72e-06	0.000426	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
HNSC	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	4.85	1.72e-06	0.000426	0.18	0.22	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
HNSC	cis	rs853679	0.607	rs71559070	ENSG00000204709.4	LINC01556	4.85	1.72e-06	0.000427	0.46	0.22	Depression;	chr6:28071151	chr6:28943877~28944537:+
HNSC	cis	rs916888	0.821	rs70600	ENSG00000260075.1	NSFP1	-4.85	1.72e-06	0.000427	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46372855~46487141:+
HNSC	cis	rs7829975	0.577	rs79495969	ENSG00000254340.1	RP11-10A14.3	-4.85	1.72e-06	0.000427	-0.28	-0.22	Mood instability;	chr8:8687740	chr8:9141424~9145435:+
HNSC	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	4.85	1.72e-06	0.000427	0.31	0.22	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
HNSC	cis	rs7809950	0.817	rs17154091	ENSG00000238832.1	snoU109	-4.85	1.72e-06	0.000428	-0.31	-0.22	Coronary artery disease;	chr7:107444345	chr7:107603363~107603507:+
HNSC	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-4.85	1.72e-06	0.000428	-0.29	-0.22	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
HNSC	cis	rs9880211	0.562	rs13068210	ENSG00000273486.1	RP11-731C17.2	4.85	1.72e-06	0.000428	0.19	0.22	Height;Body mass index;	chr3:136186704	chr3:136837338~136839021:-
HNSC	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-4.85	1.72e-06	0.000428	-0.18	-0.22	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-4.84	1.73e-06	0.000428	-0.27	-0.22	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
HNSC	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	4.84	1.73e-06	0.000428	0.24	0.22	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
HNSC	cis	rs4819052	0.851	rs2838845	ENSG00000223768.1	LINC00205	-4.84	1.73e-06	0.000429	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45293285~45297354:+
HNSC	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	4.84	1.73e-06	0.000429	0.2	0.22	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
HNSC	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-4.84	1.73e-06	0.000429	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000204709.4	LINC01556	4.84	1.73e-06	0.000429	0.3	0.22	Depression;	chr6:28140454	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000204709.4	LINC01556	4.84	1.73e-06	0.000429	0.3	0.22	Depression;	chr6:28141189	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000204709.4	LINC01556	4.84	1.73e-06	0.000429	0.3	0.22	Depression;	chr6:28141484	chr6:28943877~28944537:+
HNSC	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-4.84	1.73e-06	0.000429	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
HNSC	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	4.84	1.73e-06	0.000429	0.33	0.22	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
HNSC	cis	rs3733585	0.648	rs67820465	ENSG00000250413.1	RP11-448G15.1	4.84	1.73e-06	0.000429	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9974249	chr4:10006482~10009725:+
HNSC	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-4.84	1.73e-06	0.000429	-0.25	-0.22	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
HNSC	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	4.84	1.73e-06	0.00043	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
HNSC	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	4.84	1.73e-06	0.00043	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
HNSC	cis	rs1056107	0.866	rs10817308	ENSG00000225513.1	RP11-165N19.2	-4.84	1.73e-06	0.00043	-0.24	-0.22	Colorectal cancer;	chr9:112273585	chr9:112173522~112173971:-
HNSC	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-4.84	1.73e-06	0.00043	-0.37	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
HNSC	cis	rs4908769	0.624	rs6678140	ENSG00000232912.4	RP5-1115A15.1	-4.84	1.73e-06	0.00043	-0.25	-0.22	Allergy;	chr1:8376742	chr1:8424645~8434838:+
HNSC	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-4.84	1.74e-06	0.000431	-0.21	-0.22	Height;	chr5:36787860	chr5:36666214~36725195:-
HNSC	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-4.84	1.74e-06	0.000431	-0.24	-0.22	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
HNSC	cis	rs9368481	0.672	rs3931463	ENSG00000224843.5	LINC00240	-4.84	1.74e-06	0.000431	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26956992~27023924:+
HNSC	cis	rs4925386	0.84	rs6143035	ENSG00000275437.1	RP5-908M14.10	-4.84	1.74e-06	0.000431	-0.23	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62402236~62405935:-
HNSC	cis	rs7535099	1	rs3790426	ENSG00000224570.1	RP11-430H12.2	-4.84	1.74e-06	0.000431	-0.29	-0.22	Blood protein levels;	chr1:65577336	chr1:65576129~65578380:-
HNSC	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-4.84	1.74e-06	0.000431	-0.36	-0.22	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	4.84	1.74e-06	0.000431	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000276691.1	RP5-1057I20.5	4.84	1.74e-06	0.000431	0.42	0.22	Pneumonia;	chr12:47706187	chr12:47788426~47788971:+
HNSC	cis	rs75422866	1	rs12423045	ENSG00000276691.1	RP5-1057I20.5	4.84	1.74e-06	0.000431	0.42	0.22	Pneumonia;	chr12:47706275	chr12:47788426~47788971:+
HNSC	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	4.84	1.74e-06	0.000431	0.24	0.22	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
HNSC	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	4.84	1.74e-06	0.000431	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	4.84	1.74e-06	0.000431	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	4.84	1.74e-06	0.000431	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	4.84	1.74e-06	0.000431	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
HNSC	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	4.84	1.74e-06	0.000431	0.25	0.22	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
HNSC	cis	rs36093844	0.752	rs17744606	ENSG00000279742.1	RP11-700A24.1	-4.84	1.74e-06	0.000431	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854407	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.752	rs74404559	ENSG00000279742.1	RP11-700A24.1	-4.84	1.74e-06	0.000431	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854626	chr11:85852557~85854943:-
HNSC	cis	rs72615157	0.634	rs2272343	ENSG00000078319.8	PMS2P1	-4.84	1.74e-06	0.000432	-0.27	-0.22	Lung function (FEV1/FVC);	chr7:100180662	chr7:100320992~100341908:-
HNSC	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-4.84	1.74e-06	0.000432	-0.25	-0.22	Height;	chr2:46641078	chr2:46668870~46670778:+
HNSC	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-4.84	1.74e-06	0.000432	-0.27	-0.22	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
HNSC	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-4.84	1.74e-06	0.000432	-0.27	-0.22	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	4.84	1.75e-06	0.000433	0.27	0.22	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
HNSC	cis	rs170183	0.934	rs13051987	ENSG00000233818.1	AP000695.4	-4.84	1.75e-06	0.000433	-0.23	-0.22	Bone mineral density;	chr21:36483676	chr21:36445731~36532408:+
HNSC	cis	rs1223397	0.938	rs3817737	ENSG00000215022.6	RP1-257A7.4	-4.84	1.75e-06	0.000433	-0.27	-0.22	Blood pressure;	chr6:13278850	chr6:13264861~13295586:-
HNSC	cis	rs6657613	0.815	rs9435672	ENSG00000186715.9	MST1L	-4.84	1.75e-06	0.000434	-0.18	-0.22	Hip circumference adjusted for BMI;	chr1:17016164	chr1:16754910~16770237:-
HNSC	cis	rs1713985	0.508	rs1277282	ENSG00000269949.1	RP11-738E22.3	4.84	1.75e-06	0.000434	0.36	0.22	Age-related macular degeneration;	chr4:56989653	chr4:56960927~56961373:-
HNSC	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	4.84	1.75e-06	0.000434	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	4.84	1.75e-06	0.000434	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
HNSC	cis	rs9368481	0.7	rs6911401	ENSG00000224843.5	LINC00240	-4.84	1.75e-06	0.000434	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26956992~27023924:+
HNSC	cis	rs3758785	0.512	rs4753597	ENSG00000255893.1	RP11-685N10.1	4.84	1.75e-06	0.000434	0.29	0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94367092	chr11:94472908~94473570:-
HNSC	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-4.84	1.75e-06	0.000434	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
HNSC	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	4.84	1.75e-06	0.000435	0.48	0.22	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
HNSC	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	4.84	1.75e-06	0.000435	0.48	0.22	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
HNSC	cis	rs6751744	0.889	rs12692553	ENSG00000226266.5	AC009961.3	-4.84	1.75e-06	0.000435	-0.26	-0.22	Dysphagia;	chr2:159534337	chr2:159670708~159712435:-
HNSC	cis	rs453301	0.653	rs11784393	ENSG00000253981.4	ALG1L13P	4.84	1.76e-06	0.000435	0.25	0.22	Joint mobility (Beighton score);	chr8:9045624	chr8:8236003~8244667:-
HNSC	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.84	1.76e-06	0.000435	0.26	0.22	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
HNSC	cis	rs62402013	1	rs62402013	ENSG00000224843.5	LINC00240	-4.84	1.76e-06	0.000435	-0.23	-0.22	Schizophrenia;	chr6:26947221	chr6:26956992~27023924:+
HNSC	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	4.84	1.76e-06	0.000435	0.22	0.22	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
HNSC	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	4.84	1.76e-06	0.000435	0.27	0.22	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
HNSC	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-4.84	1.76e-06	0.000436	-0.26	-0.22	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
HNSC	cis	rs9880211	0.613	rs6767060	ENSG00000273486.1	RP11-731C17.2	4.84	1.76e-06	0.000436	0.2	0.22	Height;Body mass index;	chr3:136148248	chr3:136837338~136839021:-
HNSC	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	4.84	1.76e-06	0.000436	0.54	0.22	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
HNSC	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.84	1.76e-06	0.000436	0.22	0.22	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.84	1.76e-06	0.000436	0.22	0.22	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
HNSC	cis	rs6693567	0.565	rs834238	ENSG00000228126.1	FALEC	4.84	1.76e-06	0.000436	0.26	0.22	Migraine;	chr1:150393993	chr1:150515757~150518032:+
HNSC	cis	rs17507216	0.718	rs7161977	ENSG00000276710.3	CSPG4P8	-4.84	1.76e-06	0.000437	-0.31	-0.22	Excessive daytime sleepiness;	chr15:82646782	chr15:82459472~82477258:+
HNSC	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-4.84	1.76e-06	0.000437	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
HNSC	cis	rs11633886	0.585	rs12915664	ENSG00000273972.1	CTD-2306A12.1	4.84	1.76e-06	0.000437	0.26	0.22	Diisocyanate-induced asthma;	chr15:45787855	chr15:45702640~45703183:+
HNSC	cis	rs72843506	0.656	rs77090106	ENSG00000261033.1	RP11-209D14.2	4.84	1.76e-06	0.000437	0.39	0.22	Schizophrenia;	chr17:20044832	chr17:20008051~20009234:-
HNSC	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-4.84	1.76e-06	0.000437	-0.28	-0.22	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
HNSC	cis	rs8012947	0.916	rs11627199	ENSG00000279636.2	LINC00216	4.84	1.76e-06	0.000437	0.26	0.22	Alcohol consumption in current drinkers;	chr14:58386288	chr14:58288033~58289158:+
HNSC	cis	rs72949976	0.584	rs12471471	ENSG00000270659.1	RP11-105N14.1	4.84	1.77e-06	0.000437	0.21	0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213158328	chr2:213152970~213153659:+
HNSC	cis	rs10989172	0.714	rs4559354	ENSG00000175611.10	LINC00476	4.84	1.77e-06	0.000437	0.21	0.22	Common carotid intima-media thickness in HIV negative individuals;	chr9:96077165	chr9:95759231~95875977:-
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-4.84	1.77e-06	0.000437	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
HNSC	cis	rs4761669	0.565	rs7314827	ENSG00000241556.1	RP11-490G8.1	4.84	1.77e-06	0.000438	0.22	0.22	Common carotid intima-media thickness in HIV infection;	chr12:94794586	chr12:95467397~95467861:-
HNSC	cis	rs14027	0.554	rs6998058	ENSG00000279347.1	RP11-85I17.2	-4.84	1.77e-06	0.000438	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119743079	chr8:119838736~119840385:-
HNSC	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.84	1.77e-06	0.000438	0.23	0.22	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	4.84	1.77e-06	0.000438	0.26	0.22	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	4.84	1.77e-06	0.000438	0.26	0.22	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
HNSC	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	4.84	1.77e-06	0.000438	0.32	0.22	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
HNSC	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	4.84	1.77e-06	0.000438	0.24	0.22	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
HNSC	cis	rs7829975	0.514	rs2976926	ENSG00000254153.1	CTA-398F10.2	4.84	1.77e-06	0.000438	0.24	0.22	Mood instability;	chr8:8404114	chr8:8456909~8461337:-
HNSC	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-4.84	1.77e-06	0.000439	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-4.84	1.77e-06	0.000439	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
HNSC	cis	rs752590	0.806	rs874898	ENSG00000189223.12	PAX8-AS1	-4.84	1.77e-06	0.000439	-0.31	-0.22	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113211522~113276581:+
HNSC	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	4.84	1.77e-06	0.000439	0.31	0.22	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
HNSC	cis	rs2998286	0.723	rs332121	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28552285	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.572	rs332124	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28553545	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332126	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28556866	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332128	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28559399	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs231202	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28560111	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332131	ENSG00000254635.4	WAC-AS1	-4.84	1.77e-06	0.000439	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28564933	chr10:28522652~28532743:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000254174.1	IGHV1-12	4.84	1.77e-06	0.000439	0.19	0.22	Alzheimer's disease (late onset);	chr14:106669877	chr14:106122420~106122709:-
HNSC	cis	rs1218582	0.772	rs6669791	ENSG00000270361.1	RP11-307C12.13	-4.84	1.77e-06	0.000439	-0.24	-0.22	Prostate cancer;	chr1:154873008	chr1:154937370~154938059:+
HNSC	cis	rs12468226	0.873	rs76552560	ENSG00000226261.1	AC064836.3	4.84	1.77e-06	0.000439	0.33	0.22	Urate levels;	chr2:202173123	chr2:202336024~202336727:-
HNSC	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-4.84	1.77e-06	0.000439	-0.27	-0.22	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
HNSC	cis	rs860818	1	rs858276	ENSG00000226816.2	AC005082.12	4.84	1.78e-06	0.000439	0.53	0.22	Initial pursuit acceleration;	chr7:23212934	chr7:23206013~23208045:+
HNSC	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-4.84	1.78e-06	0.000439	-0.41	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
HNSC	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-4.84	1.78e-06	0.000439	-0.29	-0.22	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
HNSC	cis	rs916888	0.773	rs199447	ENSG00000260075.1	NSFP1	-4.84	1.78e-06	0.00044	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46372855~46487141:+
HNSC	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-4.84	1.78e-06	0.00044	-0.26	-0.22	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	4.84	1.78e-06	0.00044	0.27	0.22	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	4.84	1.78e-06	0.00044	0.27	0.22	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
HNSC	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	4.84	1.78e-06	0.00044	0.24	0.22	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
HNSC	cis	rs763121	0.853	rs1065201	ENSG00000273076.1	RP3-508I15.22	4.84	1.78e-06	0.00044	0.23	0.22	Menopause (age at onset);	chr22:38673505	chr22:38743495~38743910:+
HNSC	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-4.84	1.78e-06	0.00044	-0.2	-0.22	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-4.84	1.78e-06	0.00044	-0.2	-0.22	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
HNSC	cis	rs763121	0.853	rs5757231	ENSG00000273076.1	RP3-508I15.22	-4.84	1.78e-06	0.00044	-0.23	-0.22	Menopause (age at onset);	chr22:38675653	chr22:38743495~38743910:+
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Depression;	chr6:28096855	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Depression;	chr6:28099759	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Parkinson's disease;	chr6:28100173	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Depression;	chr6:28100648	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Depression;	chr6:28104824	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.00044	0.3	0.22	Depression;	chr6:28107222	chr6:28943877~28944537:+
HNSC	cis	rs3733585	0.673	rs9994266	ENSG00000250413.1	RP11-448G15.1	4.84	1.78e-06	0.000441	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9952826	chr4:10006482~10009725:+
HNSC	cis	rs14027	0.559	rs9297603	ENSG00000279347.1	RP11-85I17.2	-4.84	1.78e-06	0.000441	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707078	chr8:119838736~119840385:-
HNSC	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-4.84	1.78e-06	0.000441	-0.25	-0.22	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
HNSC	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-4.84	1.78e-06	0.000441	-0.29	-0.22	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
HNSC	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-4.84	1.78e-06	0.000441	-0.29	-0.22	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
HNSC	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	4.84	1.78e-06	0.000441	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
HNSC	cis	rs7246760	0.867	rs10410379	ENSG00000267289.1	CTD-2623N2.11	4.84	1.78e-06	0.000441	0.35	0.22	Pursuit maintenance gain;	chr19:9791521	chr19:9834079~9835013:-
HNSC	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-4.84	1.78e-06	0.000441	-0.25	-0.22	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
HNSC	cis	rs860295	0.702	rs1556488	ENSG00000203761.5	MSTO2P	-4.84	1.78e-06	0.000441	-0.17	-0.22	Body mass index;	chr1:155570869	chr1:155745829~155750137:+
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000254153.1	CTA-398F10.2	-4.84	1.78e-06	0.000441	-0.24	-0.22	Mood instability;	chr8:8740878	chr8:8456909~8461337:-
HNSC	cis	rs6964587	0.967	rs2282969	ENSG00000188693.7	CYP51A1-AS1	4.84	1.79e-06	0.000442	0.23	0.22	Breast cancer;	chr7:91954458	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7785095	ENSG00000188693.7	CYP51A1-AS1	4.84	1.79e-06	0.000442	0.23	0.22	Breast cancer;	chr7:92011459	chr7:92134604~92180725:+
HNSC	cis	rs6831352	0.879	rs2851255	ENSG00000263923.1	RP11-571L19.7	-4.84	1.79e-06	0.000442	-0.23	-0.22	Alcohol dependence;	chr4:99120952	chr4:98928897~98994994:+
HNSC	cis	rs7826238	0.72	rs12546760	ENSG00000173295.6	FAM86B3P	-4.84	1.79e-06	0.000442	-0.25	-0.22	Systolic blood pressure;	chr8:8517326	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000204709.4	LINC01556	4.84	1.79e-06	0.000442	0.3	0.22	Depression;	chr6:28096845	chr6:28943877~28944537:+
HNSC	cis	rs988913	0.624	rs3105254	ENSG00000224984.1	RP11-524H19.2	4.84	1.79e-06	0.000442	0.25	0.22	Menarche (age at onset);	chr6:54981245	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.624	rs3125260	ENSG00000224984.1	RP11-524H19.2	4.84	1.79e-06	0.000442	0.25	0.22	Menarche (age at onset);	chr6:54981246	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.601	rs3125261	ENSG00000224984.1	RP11-524H19.2	4.84	1.79e-06	0.000442	0.25	0.22	Menarche (age at onset);	chr6:54981283	chr6:54840118~54840855:-
HNSC	cis	rs9929218	0.501	rs12448999	ENSG00000260459.2	FTLP14	4.84	1.79e-06	0.000443	0.28	0.22	Colorectal cancer;	chr16:68781646	chr16:68822587~68823070:+
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000280054.1	RP1-197B17.7	4.84	1.79e-06	0.000443	0.58	0.22	Pneumonia;	chr12:47577638	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000280054.1	RP1-197B17.7	4.84	1.79e-06	0.000443	0.58	0.22	Pneumonia;	chr12:47577671	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000280054.1	RP1-197B17.7	4.84	1.79e-06	0.000443	0.58	0.22	Pneumonia;	chr12:47577693	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs73111258	ENSG00000276691.1	RP5-1057I20.5	4.84	1.79e-06	0.000443	0.4	0.22	Pneumonia;	chr12:47597313	chr12:47788426~47788971:+
HNSC	cis	rs6928977	0.863	rs6918097	ENSG00000234084.1	RP3-388E23.2	4.84	1.79e-06	0.000443	0.22	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135314411	chr6:135301568~135307158:+
HNSC	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	4.84	1.79e-06	0.000443	0.24	0.22	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28111382	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28111650	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28112175	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28113851	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28114487	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28114933	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28115743	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Depression;	chr6:28116411	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-4.84	1.79e-06	0.000443	-0.26	-0.22	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
HNSC	cis	rs1979679	1	rs6487672	ENSG00000247934.4	RP11-967K21.1	-4.84	1.79e-06	0.000443	-0.24	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28163298~28190738:-
HNSC	cis	rs9921338	0.961	rs8043692	ENSG00000263080.1	RP11-485G7.5	4.84	1.8e-06	0.000444	0.23	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.923	rs6498181	ENSG00000263080.1	RP11-485G7.5	4.84	1.8e-06	0.000444	0.23	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11341809~11345211:-
HNSC	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	4.84	1.8e-06	0.000444	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
HNSC	cis	rs6964587	1	rs13231578	ENSG00000188693.7	CYP51A1-AS1	-4.84	1.8e-06	0.000444	-0.23	-0.22	Breast cancer;	chr7:92033952	chr7:92134604~92180725:+
HNSC	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	4.84	1.8e-06	0.000444	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
HNSC	cis	rs4761669	0.565	rs11835454	ENSG00000241556.1	RP11-490G8.1	-4.84	1.8e-06	0.000444	-0.22	-0.22	Common carotid intima-media thickness in HIV infection;	chr12:94801487	chr12:95467397~95467861:-
HNSC	cis	rs442309	0.687	rs10822057	ENSG00000238280.1	RP11-436D10.3	-4.84	1.8e-06	0.000444	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62760391	chr10:62793562~62805887:-
HNSC	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	4.84	1.8e-06	0.000445	0.31	0.22	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	4.84	1.8e-06	0.000445	0.31	0.22	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	4.84	1.8e-06	0.000445	0.31	0.22	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	4.84	1.8e-06	0.000445	0.31	0.22	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
HNSC	cis	rs1056107	0.763	rs60623018	ENSG00000225513.1	RP11-165N19.2	-4.84	1.8e-06	0.000445	-0.23	-0.22	Colorectal cancer;	chr9:112175922	chr9:112173522~112173971:-
HNSC	cis	rs2998286	0.862	rs1416816	ENSG00000254635.4	WAC-AS1	-4.84	1.8e-06	0.000445	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503491	chr10:28522652~28532743:-
HNSC	cis	rs6479901	0.639	rs7082200	ENSG00000232075.1	MRPL35P2	-4.84	1.8e-06	0.000445	-0.28	-0.22	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63634317~63634827:-
HNSC	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	4.84	1.8e-06	0.000445	0.28	0.22	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
HNSC	cis	rs2292864	0.764	rs2292867	ENSG00000228782.6	CTD-2026D20.3	-4.84	1.8e-06	0.000445	-0.31	-0.22	Left atrial antero-posterior diameter;	chr17:47280123	chr17:47450568~47492492:-
HNSC	cis	rs712039	0.652	rs853232	ENSG00000276054.1	RP11-378E13.3	4.84	1.8e-06	0.000445	0.29	0.22	Tuberculosis;	chr17:37481076	chr17:37386886~37387926:+
HNSC	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-4.84	1.8e-06	0.000445	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
HNSC	cis	rs116095464	0.558	rs62347677	ENSG00000250848.1	CTD-2083E4.5	-4.84	1.8e-06	0.000445	-0.3	-0.22	Breast cancer;	chr5:227338	chr5:288833~290321:-
HNSC	cis	rs13256369	0.755	rs11776987	ENSG00000173295.6	FAM86B3P	4.84	1.8e-06	0.000446	0.29	0.22	Obesity-related traits;	chr8:8701891	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-4.84	1.8e-06	0.000446	-0.23	-0.22	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
HNSC	cis	rs12468226	0.752	rs116078354	ENSG00000226261.1	AC064836.3	4.84	1.8e-06	0.000446	0.33	0.22	Urate levels;	chr2:202136356	chr2:202336024~202336727:-
HNSC	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	4.84	1.81e-06	0.000446	0.27	0.22	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
HNSC	cis	rs4789693	0.679	rs7213057	ENSG00000265458.1	RP13-20L14.6	4.84	1.81e-06	0.000446	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82421063	chr17:82454273~82458521:-
HNSC	cis	rs9921338	0.961	rs72773829	ENSG00000263080.1	RP11-485G7.5	4.84	1.81e-06	0.000446	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11341809~11345211:-
HNSC	cis	rs1713985	0.508	rs1277283	ENSG00000269949.1	RP11-738E22.3	-4.84	1.81e-06	0.000446	-0.35	-0.22	Age-related macular degeneration;	chr4:56989475	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	4.84	1.81e-06	0.000446	0.26	0.22	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	4.84	1.81e-06	0.000446	0.26	0.22	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
HNSC	cis	rs6928977	0.863	rs2614277	ENSG00000234084.1	RP3-388E23.2	4.84	1.81e-06	0.000446	0.22	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135333856	chr6:135301568~135307158:+
HNSC	cis	rs761746	0.577	rs5998136	ENSG00000236132.1	CTA-440B3.1	-4.84	1.81e-06	0.000446	-0.27	-0.22	Intelligence;	chr22:31828687	chr22:31816379~31817491:-
HNSC	cis	rs4660214	0.666	rs4617393	ENSG00000182109.6	RP11-69E11.4	-4.84	1.81e-06	0.000447	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39522280~39546187:-
HNSC	cis	rs6964587	1	rs17164275	ENSG00000188693.7	CYP51A1-AS1	-4.84	1.81e-06	0.000447	-0.23	-0.22	Breast cancer;	chr7:91961094	chr7:92134604~92180725:+
HNSC	cis	rs6586111	1	rs4934372	ENSG00000226659.1	RP11-137H2.4	4.84	1.81e-06	0.000447	0.26	0.22	Capecitabine sensitivity;	chr10:80613225	chr10:80529597~80535942:-
HNSC	cis	rs6964587	0.869	rs2374519	ENSG00000188693.7	CYP51A1-AS1	4.83	1.81e-06	0.000447	0.23	0.22	Breast cancer;	chr7:91912167	chr7:92134604~92180725:+
HNSC	cis	rs10504130	0.569	rs4418329	ENSG00000272024.1	RP11-546K22.3	-4.83	1.81e-06	0.000448	-0.31	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.569	rs4442134	ENSG00000272024.1	RP11-546K22.3	-4.83	1.81e-06	0.000448	-0.31	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51950284~51950690:+
HNSC	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	4.83	1.81e-06	0.000448	0.2	0.22	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
HNSC	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-4.83	1.81e-06	0.000448	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-4.83	1.81e-06	0.000448	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
HNSC	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-4.83	1.81e-06	0.000448	-0.35	-0.22	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
HNSC	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-4.83	1.81e-06	0.000448	-0.23	-0.22	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-4.83	1.81e-06	0.000448	-0.23	-0.22	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-4.83	1.81e-06	0.000448	-0.23	-0.22	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-4.83	1.81e-06	0.000448	-0.23	-0.22	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
HNSC	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	4.83	1.82e-06	0.000448	0.25	0.22	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
HNSC	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	4.83	1.82e-06	0.000448	0.26	0.22	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
HNSC	cis	rs4218	0.638	rs12437587	ENSG00000259732.1	RP11-59H7.3	-4.83	1.82e-06	0.000448	-0.28	-0.22	Social communication problems;	chr15:59072785	chr15:59121034~59133250:+
HNSC	cis	rs7735319	0.834	rs9687791	ENSG00000251281.1	CTD-2066L21.2	4.83	1.82e-06	0.000448	0.27	0.22	Systolic blood pressure;	chr5:33072758	chr5:33011322~33017607:-
HNSC	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-4.83	1.82e-06	0.000449	-0.27	-0.22	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
HNSC	cis	rs75583333	0.502	rs2032836	ENSG00000247699.2	CTB-127C13.1	4.83	1.82e-06	0.000449	0.26	0.22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160204355	chr5:160195744~160204826:-
HNSC	cis	rs6964587	0.967	rs10953063	ENSG00000188693.7	CYP51A1-AS1	4.83	1.82e-06	0.000449	0.23	0.22	Breast cancer;	chr7:91947644	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs17164263	ENSG00000188693.7	CYP51A1-AS1	4.83	1.82e-06	0.000449	0.23	0.22	Breast cancer;	chr7:91952252	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs10280620	ENSG00000188693.7	CYP51A1-AS1	4.83	1.82e-06	0.000449	0.23	0.22	Breast cancer;	chr7:91952869	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10280927	ENSG00000188693.7	CYP51A1-AS1	4.83	1.82e-06	0.000449	0.23	0.22	Breast cancer;	chr7:91952891	chr7:92134604~92180725:+
HNSC	cis	rs1150668	0.83	rs2859365	ENSG00000219392.1	RP1-265C24.5	4.83	1.82e-06	0.000449	0.24	0.22	Pubertal anthropometrics;	chr6:28423688	chr6:28115628~28116551:+
HNSC	cis	rs4763879	0.634	rs61915472	ENSG00000278635.1	CTD-2318O12.1	4.83	1.82e-06	0.000449	0.17	0.22	Type 1 diabetes;	chr12:9700995	chr12:9415641~9416718:+
HNSC	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	4.83	1.82e-06	0.000449	0.28	0.22	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
HNSC	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-4.83	1.82e-06	0.000449	-0.25	-0.22	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
HNSC	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	4.83	1.82e-06	0.000449	0.3	0.22	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	4.83	1.82e-06	0.000449	0.3	0.22	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
HNSC	cis	rs7789940	0.809	rs12533836	ENSG00000231087.2	FDPSP7	-4.83	1.82e-06	0.000449	-0.26	-0.22	Multiple sclerosis;	chr7:76306305	chr7:76968197~76969250:-
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000204709.4	LINC01556	4.83	1.82e-06	0.000449	0.3	0.22	Depression;	chr6:28096077	chr6:28943877~28944537:+
HNSC	cis	rs7829975	0.5	rs7841082	ENSG00000254340.1	RP11-10A14.3	-4.83	1.82e-06	0.000449	-0.27	-0.22	Mood instability;	chr8:8311465	chr8:9141424~9145435:+
HNSC	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	4.83	1.82e-06	0.000449	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-4.83	1.82e-06	0.000449	-0.26	-0.22	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
HNSC	cis	rs13126694	0.778	rs13106004	ENSG00000248429.4	RP11-597D13.9	4.83	1.82e-06	0.000449	0.25	0.22	Blood osmolality (transformed sodium);	chr4:158104532	chr4:158170752~158202877:+
HNSC	cis	rs13126694	0.744	rs13106234	ENSG00000248429.4	RP11-597D13.9	4.83	1.82e-06	0.000449	0.25	0.22	Blood osmolality (transformed sodium);	chr4:158104618	chr4:158170752~158202877:+
HNSC	cis	rs1799949	0.628	rs4474733	ENSG00000267151.3	RP11-100E5.2	4.83	1.82e-06	0.000449	0.31	0.22	Menopause (age at onset);	chr17:43356292	chr17:43444707~43451200:+
HNSC	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	4.83	1.82e-06	0.000449	0.28	0.22	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
HNSC	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	4.83	1.82e-06	0.000449	0.33	0.22	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
HNSC	cis	rs2286503	1	rs2286499	ENSG00000226329.2	AC005682.6	4.83	1.82e-06	0.000449	0.27	0.22	Fibrinogen;	chr7:22817858	chr7:22863874~22881350:-
HNSC	cis	rs57561814	0.655	rs6461660	ENSG00000179428.2	AC073072.5	-4.83	1.82e-06	0.000449	-0.38	-0.22	Tonsillectomy;	chr7:22702515	chr7:22725395~22727620:-
HNSC	cis	rs516805	0.748	rs11154077	ENSG00000279453.1	RP3-425C14.4	4.83	1.82e-06	0.000449	0.3	0.22	Lymphocyte counts;	chr6:122386994	chr6:122436789~122439223:-
HNSC	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-4.83	1.82e-06	0.000449	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000204709.4	LINC01556	4.83	1.82e-06	0.000449	0.3	0.22	Depression;	chr6:28144784	chr6:28943877~28944537:+
HNSC	cis	rs2998286	0.862	rs4237390	ENSG00000254635.4	WAC-AS1	-4.83	1.82e-06	0.000449	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504497	chr10:28522652~28532743:-
HNSC	cis	rs67981189	0.896	rs17108804	ENSG00000274818.1	RP1-292L20.3	-4.83	1.82e-06	0.00045	-0.25	-0.22	Schizophrenia;	chr14:70974807	chr14:70906657~70907111:-
HNSC	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	4.83	1.82e-06	0.00045	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	4.83	1.82e-06	0.00045	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
HNSC	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.83	1.82e-06	0.00045	0.34	0.22	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
HNSC	cis	rs9863	0.931	rs11057407	ENSG00000269938.1	RP11-214K3.20	-4.83	1.82e-06	0.00045	-0.27	-0.22	White blood cell count;	chr12:123965282	chr12:123968023~123968579:-
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-4.83	1.83e-06	0.00045	-0.27	-0.22	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
HNSC	cis	rs3811273	0.568	rs4981417	ENSG00000211816.2	TRAV38-1	-4.83	1.83e-06	0.00045	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22261486	chr14:22271968~22272563:+
HNSC	cis	rs4660214	0.639	rs6699928	ENSG00000182109.6	RP11-69E11.4	-4.83	1.83e-06	0.000451	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-4.83	1.83e-06	0.000451	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-4.83	1.83e-06	0.000451	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000254340.1	RP11-10A14.3	-4.83	1.83e-06	0.000451	-0.27	-0.22	Mood instability;	chr8:8691922	chr8:9141424~9145435:+
HNSC	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-4.83	1.83e-06	0.000451	-0.22	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
HNSC	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-4.83	1.83e-06	0.000451	-0.24	-0.22	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
HNSC	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-4.83	1.83e-06	0.000451	-0.18	-0.22	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
HNSC	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-4.83	1.83e-06	0.000451	-0.28	-0.22	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
HNSC	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-4.83	1.83e-06	0.000451	-0.18	-0.22	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
HNSC	cis	rs1913185	0.787	rs2864794	ENSG00000240032.1	RP11-274H2.3	-4.83	1.83e-06	0.000451	-0.36	-0.22	Obesity-related traits;	chr3:146148583	chr3:146066344~146069185:-
HNSC	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	4.83	1.83e-06	0.000452	0.18	0.22	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
HNSC	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-4.83	1.83e-06	0.000452	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
HNSC	cis	rs6693567	0.565	rs834234	ENSG00000228126.1	FALEC	-4.83	1.83e-06	0.000452	-0.26	-0.22	Migraine;	chr1:150380018	chr1:150515757~150518032:+
HNSC	cis	rs7085104	0.572	rs284856	ENSG00000213061.2	PFN1P11	-4.83	1.83e-06	0.000452	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102838011~102845473:-
HNSC	cis	rs4699052	0.625	rs1516740	ENSG00000246560.2	RP11-10L12.4	-4.83	1.83e-06	0.000452	-0.25	-0.22	Testicular germ cell tumor;	chr4:103374630	chr4:102828055~102844075:+
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000254153.1	CTA-398F10.2	-4.83	1.83e-06	0.000452	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9012154	chr8:8456909~8461337:-
HNSC	cis	rs2337406	1	rs17113257	ENSG00000254174.1	IGHV1-12	4.83	1.83e-06	0.000452	0.18	0.22	Alzheimer's disease (late onset);	chr14:106679574	chr14:106122420~106122709:-
HNSC	cis	rs73198271	0.7	rs10090152	ENSG00000173295.6	FAM86B3P	-4.83	1.83e-06	0.000452	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8228595~8244865:+
HNSC	cis	rs9650657	0.737	rs4551304	ENSG00000269918.1	AF131215.9	-4.83	1.83e-06	0.000452	-0.22	-0.22	Neuroticism;	chr8:10807559	chr8:11104691~11106704:-
HNSC	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-4.83	1.84e-06	0.000452	-0.23	-0.22	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-4.83	1.84e-06	0.000452	-0.23	-0.22	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-4.83	1.84e-06	0.000452	-0.23	-0.22	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
HNSC	cis	rs1056107	0.931	rs10759541	ENSG00000225513.1	RP11-165N19.2	-4.83	1.84e-06	0.000452	-0.24	-0.22	Colorectal cancer;	chr9:112243277	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs7032120	ENSG00000225513.1	RP11-165N19.2	-4.83	1.84e-06	0.000452	-0.24	-0.22	Colorectal cancer;	chr9:112243865	chr9:112173522~112173971:-
HNSC	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	4.83	1.84e-06	0.000452	0.19	0.22	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
HNSC	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	4.83	1.84e-06	0.000453	0.33	0.22	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000254153.1	CTA-398F10.2	4.83	1.84e-06	0.000453	0.24	0.22	Neuroticism;	chr8:8248986	chr8:8456909~8461337:-
HNSC	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-4.83	1.84e-06	0.000453	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-4.83	1.84e-06	0.000453	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
HNSC	cis	rs7829975	0.577	rs940032	ENSG00000254340.1	RP11-10A14.3	-4.83	1.84e-06	0.000453	-0.28	-0.22	Mood instability;	chr8:8688833	chr8:9141424~9145435:+
HNSC	cis	rs3736485	0.816	rs882386	ENSG00000259438.1	CTD-2650P22.1	4.83	1.84e-06	0.000453	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51590076	chr15:52010999~52019095:-
HNSC	cis	rs1479119	0.552	rs10744025	ENSG00000180861.8	LINC01559	4.83	1.84e-06	0.000453	0.27	0.22	Intelligence (multi-trait analysis);	chr12:13361055	chr12:13371089~13387167:-
HNSC	cis	rs7829975	0.56	rs6994131	ENSG00000254340.1	RP11-10A14.3	-4.83	1.84e-06	0.000453	-0.28	-0.22	Mood instability;	chr8:8693448	chr8:9141424~9145435:+
HNSC	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	4.83	1.84e-06	0.000453	0.26	0.22	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
HNSC	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-4.83	1.84e-06	0.000453	-0.26	-0.22	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
HNSC	cis	rs822354	1	rs266738	ENSG00000226652.2	PSMD10P2	4.83	1.84e-06	0.000453	0.24	0.22	Adiponectin levels;	chr3:186759698	chr3:186760693~186762050:+
HNSC	cis	rs2439831	0.681	rs825740	ENSG00000205771.5	CATSPER2P1	-4.83	1.84e-06	0.000454	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43300210	chr15:43726918~43747094:-
HNSC	cis	rs9300255	0.722	rs1060105	ENSG00000280120.1	RP11-546D6.3	-4.83	1.84e-06	0.000454	-0.21	-0.22	Neutrophil percentage of white cells;	chr12:123321672	chr12:123152324~123153377:-
HNSC	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-4.83	1.84e-06	0.000454	-0.28	-0.22	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
HNSC	cis	rs4664293	0.625	rs7595852	ENSG00000226266.5	AC009961.3	4.83	1.84e-06	0.000454	0.23	0.22	Monocyte percentage of white cells;	chr2:159683656	chr2:159670708~159712435:-
HNSC	cis	rs12935418	0.672	rs11866803	ENSG00000261061.1	RP11-303E16.2	-4.83	1.84e-06	0.000454	-0.25	-0.22	Mean corpuscular volume;	chr16:81017598	chr16:81030770~81031485:+
HNSC	cis	rs1479119	0.681	rs7134400	ENSG00000180861.8	LINC01559	4.83	1.84e-06	0.000454	0.28	0.22	Intelligence (multi-trait analysis);	chr12:13343636	chr12:13371089~13387167:-
HNSC	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-4.83	1.84e-06	0.000454	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
HNSC	cis	rs7824557	0.751	rs2099456	ENSG00000255310.2	AF131215.2	4.83	1.85e-06	0.000455	0.21	0.22	Retinal vascular caliber;	chr8:11269492	chr8:11107788~11109726:-
HNSC	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.83	1.85e-06	0.000455	0.24	0.22	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
HNSC	cis	rs6964587	1	rs415	ENSG00000188693.7	CYP51A1-AS1	4.83	1.85e-06	0.000456	0.23	0.22	Breast cancer;	chr7:91951176	chr7:92134604~92180725:+
HNSC	cis	rs6693567	0.545	rs7411534	ENSG00000228126.1	FALEC	4.83	1.86e-06	0.000457	0.26	0.22	Migraine;	chr1:150474793	chr1:150515757~150518032:+
HNSC	cis	rs12817211	0.502	rs12369104	ENSG00000272368.2	RP4-605O3.4	-4.83	1.86e-06	0.000457	-0.21	-0.22	Colorectal or endometrial cancer;	chr12:50141207	chr12:50112197~50165618:+
HNSC	cis	rs12468226	0.752	rs77319662	ENSG00000226261.1	AC064836.3	4.83	1.86e-06	0.000457	0.33	0.22	Urate levels;	chr2:202126928	chr2:202336024~202336727:-
HNSC	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	4.83	1.86e-06	0.000457	0.29	0.22	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	4.83	1.86e-06	0.000457	0.29	0.22	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000254340.1	RP11-10A14.3	-4.83	1.86e-06	0.000457	-0.27	-0.22	Mood instability;	chr8:8690301	chr8:9141424~9145435:+
HNSC	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	4.83	1.86e-06	0.000457	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	4.83	1.86e-06	0.000457	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	4.83	1.86e-06	0.000457	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
HNSC	cis	rs7085104	0.7	rs743572	ENSG00000236937.2	PTGES3P4	4.83	1.86e-06	0.000457	0.27	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102845595~102845950:+
HNSC	cis	rs3733585	0.699	rs60045583	ENSG00000250413.1	RP11-448G15.1	4.83	1.86e-06	0.000458	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9970326	chr4:10006482~10009725:+
HNSC	cis	rs13217239	0.646	rs10946897	ENSG00000224843.5	LINC00240	-4.83	1.86e-06	0.000458	-0.21	-0.22	Schizophrenia;	chr6:27027472	chr6:26956992~27023924:+
HNSC	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-4.83	1.86e-06	0.000458	-0.26	-0.22	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
HNSC	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-4.83	1.86e-06	0.000458	-0.23	-0.22	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
HNSC	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	4.83	1.86e-06	0.000458	0.25	0.22	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
HNSC	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-4.83	1.86e-06	0.000458	-0.28	-0.22	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
HNSC	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-4.83	1.86e-06	0.000458	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
HNSC	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-4.83	1.86e-06	0.000459	-0.27	-0.22	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
HNSC	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-4.83	1.86e-06	0.000459	-0.28	-0.22	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
HNSC	cis	rs12986445	0.793	rs9309437	ENSG00000218682.1	AC010150.1	-4.83	1.86e-06	0.000459	-0.31	-0.22	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25879728	chr2:25856461~25856966:-
HNSC	cis	rs6601327	0.634	rs12679956	ENSG00000254340.1	RP11-10A14.3	-4.83	1.87e-06	0.000459	-0.26	-0.22	Multiple myeloma (hyperdiploidy);	chr8:9727339	chr8:9141424~9145435:+
HNSC	cis	rs6964587	0.869	rs401	ENSG00000188693.7	CYP51A1-AS1	4.83	1.87e-06	0.000459	0.23	0.22	Breast cancer;	chr7:91898631	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs34791781	ENSG00000188693.7	CYP51A1-AS1	4.83	1.87e-06	0.000459	0.23	0.22	Breast cancer;	chr7:91903406	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs6946764	ENSG00000188693.7	CYP51A1-AS1	4.83	1.87e-06	0.000459	0.23	0.22	Breast cancer;	chr7:91909689	chr7:92134604~92180725:+
HNSC	cis	rs4853525	0.522	rs62179715	ENSG00000235852.1	AC005540.3	4.83	1.87e-06	0.00046	0.27	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190705346	chr2:190880797~190882059:-
HNSC	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	4.83	1.87e-06	0.00046	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000280054.1	RP1-197B17.7	4.83	1.87e-06	0.00046	0.58	0.22	Pneumonia;	chr12:47576949	chr12:47728151~47730598:-
HNSC	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	4.83	1.87e-06	0.00046	0.28	0.22	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	4.83	1.87e-06	0.00046	0.28	0.22	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	4.83	1.87e-06	0.00046	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
HNSC	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-4.83	1.87e-06	0.000461	-0.25	-0.22	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
HNSC	cis	rs9840812	0.61	rs34967300	ENSG00000239213.4	NCK1-AS1	-4.83	1.87e-06	0.000461	-0.22	-0.22	Fibrinogen levels;	chr3:136549976	chr3:136841726~136862054:-
HNSC	cis	rs6831352	0.918	rs13110176	ENSG00000263923.1	RP11-571L19.7	-4.83	1.87e-06	0.000461	-0.23	-0.22	Alcohol dependence;	chr4:99141279	chr4:98928897~98994994:+
HNSC	cis	rs12893668	0.703	rs4906336	ENSG00000269940.1	RP11-73M18.7	4.83	1.87e-06	0.000461	0.22	0.22	Reticulocyte count;	chr14:103566928	chr14:103694560~103695170:+
HNSC	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-4.83	1.87e-06	0.000461	-0.43	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
HNSC	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	4.83	1.88e-06	0.000461	0.23	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
HNSC	cis	rs1707322	1	rs7538978	ENSG00000234329.1	RP11-767N6.2	-4.83	1.88e-06	0.000462	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-4.83	1.88e-06	0.000462	-0.26	-0.22	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
HNSC	cis	rs7688540	0.76	rs4510422	ENSG00000211553.1	AC253576.2	-4.83	1.88e-06	0.000462	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:136461~136568:+
HNSC	cis	rs9863	0.794	rs7978610	ENSG00000269938.1	RP11-214K3.20	4.83	1.88e-06	0.000463	0.25	0.22	White blood cell count;	chr12:123984025	chr12:123968023~123968579:-
HNSC	cis	rs1056107	0.933	rs12376681	ENSG00000225513.1	RP11-165N19.2	-4.83	1.88e-06	0.000463	-0.23	-0.22	Colorectal cancer;	chr9:112297115	chr9:112173522~112173971:-
HNSC	cis	rs853679	0.607	rs35072899	ENSG00000219392.1	RP1-265C24.5	-4.83	1.88e-06	0.000463	-0.44	-0.22	Depression;	chr6:28313764	chr6:28115628~28116551:+
HNSC	cis	rs4356203	0.816	rs11024188	ENSG00000260196.1	RP1-239B22.5	4.83	1.88e-06	0.000463	0.25	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17195765	chr11:17380649~17383531:+
HNSC	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	4.83	1.88e-06	0.000463	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
HNSC	cis	rs763121	0.853	rs2281019	ENSG00000273076.1	RP3-508I15.22	4.83	1.88e-06	0.000463	0.23	0.22	Menopause (age at onset);	chr22:38668373	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2281020	ENSG00000273076.1	RP3-508I15.22	4.83	1.88e-06	0.000463	0.23	0.22	Menopause (age at onset);	chr22:38668401	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2281021	ENSG00000273076.1	RP3-508I15.22	4.83	1.88e-06	0.000463	0.23	0.22	Menopause (age at onset);	chr22:38668662	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5995610	ENSG00000273076.1	RP3-508I15.22	4.83	1.88e-06	0.000463	0.23	0.22	Menopause (age at onset);	chr22:38668676	chr22:38743495~38743910:+
HNSC	cis	rs1538970	0.748	rs11211137	ENSG00000234329.1	RP11-767N6.2	4.83	1.88e-06	0.000463	0.26	0.22	Platelet count;	chr1:45548220	chr1:45651039~45651826:-
HNSC	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-4.83	1.88e-06	0.000463	-0.29	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.722	rs10025925	ENSG00000249244.1	RP11-548H18.2	4.83	1.89e-06	0.000463	0.27	0.22	Corneal astigmatism;	chr4:119350589	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.731	rs10015579	ENSG00000249244.1	RP11-548H18.2	4.83	1.89e-06	0.000463	0.27	0.22	Corneal astigmatism;	chr4:119350647	chr4:119391831~119395335:-
HNSC	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	4.83	1.89e-06	0.000464	0.21	0.22	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
HNSC	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	4.83	1.89e-06	0.000464	0.25	0.22	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
HNSC	cis	rs12935418	0.672	rs2602424	ENSG00000261061.1	RP11-303E16.2	4.83	1.89e-06	0.000464	0.23	0.22	Mean corpuscular volume;	chr16:81009600	chr16:81030770~81031485:+
HNSC	cis	rs9926296	0.509	rs2159113	ENSG00000260259.1	RP11-368I7.4	-4.83	1.89e-06	0.000464	-0.27	-0.22	Vitiligo;	chr16:89765675	chr16:89682620~89686569:-
HNSC	cis	rs7773987	1	rs7773987	ENSG00000231028.7	LINC00271	4.83	1.89e-06	0.000464	0.25	0.22	Selective IgA deficiency;	chr6:135386348	chr6:135497801~135716055:+
HNSC	cis	rs4853525	0.561	rs13414648	ENSG00000235852.1	AC005540.3	4.83	1.89e-06	0.000465	0.29	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929310	chr2:190880797~190882059:-
HNSC	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-4.83	1.89e-06	0.000465	-0.3	-0.22	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
HNSC	cis	rs1991651	0.578	rs11778453	ENSG00000255310.2	AF131215.2	-4.83	1.89e-06	0.000465	-0.21	-0.22	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:11107788~11109726:-
HNSC	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-4.83	1.89e-06	0.000465	-0.26	-0.22	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
HNSC	cis	rs42490	0.625	rs39519	ENSG00000251136.7	RP11-37B2.1	4.83	1.89e-06	0.000465	0.19	0.22	Leprosy;	chr8:89833814	chr8:89609409~89757727:-
HNSC	cis	rs9992667	0.688	rs28657453	ENSG00000231160.8	KLF3-AS1	4.83	1.89e-06	0.000465	0.22	0.22	Eosinophil percentage of granulocytes;	chr4:38689377	chr4:38612701~38664883:-
HNSC	cis	rs4372836	1	rs2169748	ENSG00000226833.4	AC097724.3	-4.83	1.89e-06	0.000465	-0.28	-0.22	Body mass index;	chr2:28734887	chr2:28708953~28736205:-
HNSC	cis	rs1707322	1	rs4660905	ENSG00000234329.1	RP11-767N6.2	-4.83	1.89e-06	0.000465	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45651039~45651826:-
HNSC	cis	rs7296418	0.961	rs11608811	ENSG00000280120.1	RP11-546D6.3	4.83	1.89e-06	0.000466	0.18	0.22	Platelet count;	chr12:123044509	chr12:123152324~123153377:-
HNSC	cis	rs2985684	1	rs3007031	ENSG00000258568.1	RHOQP1	4.83	1.9e-06	0.000466	0.22	0.22	Carotid intima media thickness;	chr14:49635551	chr14:49599994~49600572:+
HNSC	cis	rs4699052	0.963	rs11733615	ENSG00000246560.2	RP11-10L12.4	4.83	1.9e-06	0.000466	0.26	0.22	Testicular germ cell tumor;	chr4:103236007	chr4:102828055~102844075:+
HNSC	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-4.82	1.9e-06	0.000467	-0.28	-0.22	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
HNSC	cis	rs11756659	0.653	rs412968	ENSG00000272462.2	U91328.19	4.82	1.9e-06	0.000467	0.25	0.22	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25953965	chr6:25992662~26001775:+
HNSC	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-4.82	1.9e-06	0.000467	-0.23	-0.22	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-4.82	1.9e-06	0.000467	-0.23	-0.22	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
HNSC	cis	rs1056107	0.933	rs10739341	ENSG00000225513.1	RP11-165N19.2	-4.82	1.9e-06	0.000467	-0.23	-0.22	Colorectal cancer;	chr9:112310497	chr9:112173522~112173971:-
HNSC	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-4.82	1.9e-06	0.000467	-0.28	-0.22	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
HNSC	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-4.82	1.9e-06	0.000467	-0.28	-0.22	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
HNSC	cis	rs8031584	1	rs35607976	ENSG00000260382.1	RP11-540B6.2	4.82	1.9e-06	0.000467	0.29	0.22	Huntington's disease progression;	chr15:30985585	chr15:30882267~30883231:-
HNSC	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-4.82	1.9e-06	0.000467	-0.18	-0.22	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
HNSC	cis	rs7085104	0.7	rs10786712	ENSG00000236937.2	PTGES3P4	-4.82	1.9e-06	0.000468	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102845595~102845950:+
HNSC	cis	rs6964587	0.934	rs7798973	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.91e-06	0.000468	-0.23	-0.22	Breast cancer;	chr7:91959046	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs28735847	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.91e-06	0.000468	-0.23	-0.22	Breast cancer;	chr7:91963441	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2188154	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.91e-06	0.000468	-0.23	-0.22	Breast cancer;	chr7:91965824	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6952671	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.91e-06	0.000468	-0.23	-0.22	Breast cancer;	chr7:91968620	chr7:92134604~92180725:+
HNSC	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-4.82	1.91e-06	0.000468	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
HNSC	cis	rs17507216	0.718	rs72751675	ENSG00000276710.3	CSPG4P8	-4.82	1.91e-06	0.000468	-0.31	-0.22	Excessive daytime sleepiness;	chr15:82630452	chr15:82459472~82477258:+
HNSC	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	4.82	1.91e-06	0.000468	0.28	0.22	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
HNSC	cis	rs4256159	1	rs34858567	ENSG00000228956.7	SATB1-AS1	4.82	1.91e-06	0.000468	0.36	0.22	Crohn's disease;Inflammatory bowel disease;	chr3:18669139	chr3:18445024~18920401:+
HNSC	cis	rs6928977	0.5	rs3734213	ENSG00000234084.1	RP3-388E23.2	-4.82	1.91e-06	0.000468	-0.23	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.5	rs6941629	ENSG00000234084.1	RP3-388E23.2	-4.82	1.91e-06	0.000468	-0.23	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135301568~135307158:+
HNSC	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	4.82	1.91e-06	0.000468	0.27	0.22	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
HNSC	cis	rs853679	0.546	rs35353359	ENSG00000219392.1	RP1-265C24.5	-4.82	1.91e-06	0.000469	-0.44	-0.22	Depression;	chr6:28356601	chr6:28115628~28116551:+
HNSC	cis	rs7674212	0.541	rs2045746	ENSG00000246560.2	RP11-10L12.4	-4.82	1.91e-06	0.000469	-0.25	-0.22	Type 2 diabetes;	chr4:103162421	chr4:102828055~102844075:+
HNSC	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-4.82	1.91e-06	0.000469	-0.28	-0.22	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-4.82	1.91e-06	0.000469	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
HNSC	cis	rs9813712	0.585	rs9855392	ENSG00000249846.5	RP11-77P16.4	-4.82	1.91e-06	0.000469	-0.28	-0.22	Response to amphetamines;	chr3:130214403	chr3:130112550~130120579:+
HNSC	cis	rs42490	0.899	rs1397308	ENSG00000251136.7	RP11-37B2.1	4.82	1.91e-06	0.000469	0.19	0.22	Leprosy;	chr8:89628493	chr8:89609409~89757727:-
HNSC	cis	rs6964587	0.869	rs10256780	ENSG00000188693.7	CYP51A1-AS1	4.82	1.91e-06	0.00047	0.23	0.22	Breast cancer;	chr7:91897862	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs10241720	ENSG00000188693.7	CYP51A1-AS1	4.82	1.91e-06	0.00047	0.23	0.22	Breast cancer;	chr7:91898053	chr7:92134604~92180725:+
HNSC	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-4.82	1.91e-06	0.00047	-0.19	-0.22	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
HNSC	cis	rs14027	0.64	rs2326378	ENSG00000279347.1	RP11-85I17.2	-4.82	1.92e-06	0.00047	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119764355	chr8:119838736~119840385:-
HNSC	cis	rs9914544	0.689	rs8073236	ENSG00000264885.1	RP11-815I9.4	-4.82	1.92e-06	0.00047	-0.22	-0.22	Educational attainment (years of education);	chr17:18883869	chr17:18667629~18669461:-
HNSC	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	4.82	1.92e-06	0.00047	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
HNSC	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-4.82	1.92e-06	0.00047	-0.19	-0.22	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-4.82	1.92e-06	0.00047	-0.19	-0.22	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-4.82	1.92e-06	0.00047	-0.19	-0.22	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
HNSC	cis	rs1056107	0.931	rs10817295	ENSG00000225513.1	RP11-165N19.2	-4.82	1.92e-06	0.00047	-0.23	-0.22	Colorectal cancer;	chr9:112235310	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs10118422	ENSG00000225513.1	RP11-165N19.2	-4.82	1.92e-06	0.00047	-0.23	-0.22	Colorectal cancer;	chr9:112236116	chr9:112173522~112173971:-
HNSC	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	4.82	1.92e-06	0.00047	0.25	0.22	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	4.82	1.92e-06	0.00047	0.14	0.22	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
HNSC	cis	rs9863	0.861	rs12298484	ENSG00000269938.1	RP11-214K3.20	-4.82	1.92e-06	0.000471	-0.26	-0.22	White blood cell count;	chr12:123934127	chr12:123968023~123968579:-
HNSC	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-4.82	1.92e-06	0.000471	-0.28	-0.22	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
HNSC	cis	rs36423	0.748	rs36377	ENSG00000266869.1	RP6-114E22.1	-4.82	1.92e-06	0.000471	-0.36	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71905994	chr14:71848606~71908430:+
HNSC	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	4.82	1.92e-06	0.000471	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	4.82	1.92e-06	0.000471	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
HNSC	cis	rs4295623	0.504	rs11250160	ENSG00000269918.1	AF131215.9	-4.82	1.92e-06	0.000471	-0.21	-0.22	Morning vs. evening chronotype;	chr8:11735208	chr8:11104691~11106704:-
HNSC	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	4.82	1.92e-06	0.000471	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
HNSC	cis	rs1913185	0.787	rs67671074	ENSG00000240032.1	RP11-274H2.3	-4.82	1.92e-06	0.000472	-0.38	-0.22	Obesity-related traits;	chr3:146085476	chr3:146066344~146069185:-
HNSC	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	4.82	1.92e-06	0.000472	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
HNSC	cis	rs6831352	0.918	rs29001211	ENSG00000263923.1	RP11-571L19.7	4.82	1.92e-06	0.000472	0.23	0.22	Alcohol dependence;	chr4:99130790	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001209	ENSG00000263923.1	RP11-571L19.7	4.82	1.92e-06	0.000472	0.23	0.22	Alcohol dependence;	chr4:99131189	chr4:98928897~98994994:+
HNSC	cis	rs2280018	0.581	rs7404524	ENSG00000263335.1	AF001548.5	-4.82	1.92e-06	0.000472	-0.29	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15726674~15732993:+
HNSC	cis	rs7115242	0.925	rs7925256	ENSG00000280143.1	AP000892.6	4.82	1.92e-06	0.000472	0.42	0.22	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117204967~117210292:+
HNSC	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	4.82	1.93e-06	0.000472	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
HNSC	cis	rs6964587	1	rs2961020	ENSG00000188693.7	CYP51A1-AS1	4.82	1.93e-06	0.000472	0.23	0.22	Breast cancer;	chr7:91943994	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10264666	ENSG00000188693.7	CYP51A1-AS1	4.82	1.93e-06	0.000472	0.23	0.22	Breast cancer;	chr7:91949325	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2282968	ENSG00000188693.7	CYP51A1-AS1	4.82	1.93e-06	0.000472	0.23	0.22	Breast cancer;	chr7:91950973	chr7:92134604~92180725:+
HNSC	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-4.82	1.93e-06	0.000472	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
HNSC	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-4.82	1.93e-06	0.000473	-0.18	-0.22	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
HNSC	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	4.82	1.93e-06	0.000473	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
HNSC	cis	rs9880211	0.679	rs9818740	ENSG00000273486.1	RP11-731C17.2	4.82	1.93e-06	0.000473	0.2	0.22	Height;Body mass index;	chr3:136220744	chr3:136837338~136839021:-
HNSC	cis	rs6928977	0.5	rs6925161	ENSG00000217482.2	HMGB1P17	4.82	1.93e-06	0.000473	0.25	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135636086~135636713:-
HNSC	cis	rs6964587	1	rs9969198	ENSG00000188693.7	CYP51A1-AS1	4.82	1.93e-06	0.000473	0.23	0.22	Breast cancer;	chr7:91938178	chr7:92134604~92180725:+
HNSC	cis	rs7590368	0.774	rs3932106	ENSG00000272275.1	RP11-791G15.2	4.82	1.93e-06	0.000473	0.29	0.22	Educational attainment (years of education);	chr2:10776282	chr2:10767875~10770058:-
HNSC	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	4.82	1.93e-06	0.000473	0.22	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
HNSC	cis	rs6878284	0.818	rs13358778	ENSG00000250682.4	LINC00491	4.82	1.93e-06	0.000473	0.3	0.22	Schizophrenia;	chr5:102410273	chr5:102609156~102671559:-
HNSC	cis	rs939574	0.512	rs908197	ENSG00000243910.6	TUBA4B	4.82	1.93e-06	0.000474	0.36	0.22	Platelet distribution width;	chr2:219279688	chr2:219253243~219272188:+
HNSC	cis	rs1218582	0.772	rs2102423	ENSG00000270361.1	RP11-307C12.13	-4.82	1.93e-06	0.000474	-0.24	-0.22	Prostate cancer;	chr1:154943592	chr1:154937370~154938059:+
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000237310.1	GS1-124K5.4	-4.82	1.93e-06	0.000474	-0.19	-0.22	Aortic root size;	chr7:66316659	chr7:66493706~66495474:+
HNSC	cis	rs6964587	0.839	rs11767135	ENSG00000188693.7	CYP51A1-AS1	4.82	1.94e-06	0.000474	0.23	0.22	Breast cancer;	chr7:91921931	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs13237856	ENSG00000188693.7	CYP51A1-AS1	4.82	1.94e-06	0.000474	0.23	0.22	Breast cancer;	chr7:91922474	chr7:92134604~92180725:+
HNSC	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	4.82	1.94e-06	0.000474	0.21	0.22	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
HNSC	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-4.82	1.94e-06	0.000474	-0.27	-0.22	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
HNSC	cis	rs12817211	0.549	rs7972465	ENSG00000272368.2	RP4-605O3.4	4.82	1.94e-06	0.000474	0.21	0.22	Colorectal or endometrial cancer;	chr12:50152342	chr12:50112197~50165618:+
HNSC	cis	rs7000734	0.674	rs10109868	ENSG00000245080.5	RP11-320N21.1	4.82	1.94e-06	0.000474	0.32	0.22	Radiation response;	chr8:95151255	chr8:95066808~95073182:-
HNSC	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-4.82	1.94e-06	0.000475	-0.24	-0.22	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
HNSC	cis	rs933688	1	rs2367526	ENSG00000281357.1	ARRDC3-AS1	4.82	1.94e-06	0.000475	0.32	0.22	Smoking behavior;	chr5:91444708	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs61612071	ENSG00000281357.1	ARRDC3-AS1	4.82	1.94e-06	0.000475	0.32	0.22	Smoking behavior;	chr5:91445653	chr5:91380349~91439085:+
HNSC	cis	rs17818399	0.926	rs35682608	ENSG00000279254.1	RP11-536C12.1	-4.82	1.94e-06	0.000475	-0.26	-0.22	Height;	chr2:46609403	chr2:46668870~46670778:+
HNSC	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	4.82	1.94e-06	0.000475	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
HNSC	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-4.82	1.94e-06	0.000476	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
HNSC	cis	rs4873772	0.773	rs4873463	ENSG00000253330.1	RP11-697N18.3	-4.82	1.94e-06	0.000476	-0.28	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47510809	chr8:47511034~47512141:-
HNSC	cis	rs6964587	0.967	rs10279943	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.94e-06	0.000476	-0.23	-0.22	Breast cancer;	chr7:91958163	chr7:92134604~92180725:+
HNSC	cis	rs17507216	0.609	rs1431716	ENSG00000276710.3	CSPG4P8	-4.82	1.94e-06	0.000476	-0.31	-0.22	Excessive daytime sleepiness;	chr15:82676180	chr15:82459472~82477258:+
HNSC	cis	rs72949976	0.606	rs1922797	ENSG00000270659.1	RP11-105N14.1	-4.82	1.94e-06	0.000476	-0.21	-0.22	Squamous cell lung carcinoma;Lung cancer;	chr2:213162918	chr2:213152970~213153659:+
HNSC	cis	rs3806843	0.932	rs2563256	ENSG00000202515.1	VTRNA1-3	4.82	1.95e-06	0.000476	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs2563255	ENSG00000202515.1	VTRNA1-3	4.82	1.95e-06	0.000476	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.9	rs2563254	ENSG00000202515.1	VTRNA1-3	4.82	1.95e-06	0.000476	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs7737424	ENSG00000202515.1	VTRNA1-3	-4.82	1.95e-06	0.000476	-0.24	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs12659129	ENSG00000202515.1	VTRNA1-3	-4.82	1.95e-06	0.000476	-0.24	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr5:140726158~140726246:+
HNSC	cis	rs9329221	0.683	rs555200	ENSG00000254340.1	RP11-10A14.3	-4.82	1.95e-06	0.000476	-0.26	-0.22	Neuroticism;	chr8:10031219	chr8:9141424~9145435:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	4.82	1.95e-06	0.000476	0.2	0.22	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
HNSC	cis	rs2337406	1	rs78631692	ENSG00000254174.1	IGHV1-12	4.82	1.95e-06	0.000476	0.19	0.22	Alzheimer's disease (late onset);	chr14:106709371	chr14:106122420~106122709:-
HNSC	cis	rs3738443	0.817	rs1115202	ENSG00000259865.1	RP11-488L18.10	4.82	1.95e-06	0.000476	0.2	0.22	Alcohol dependence;	chr1:247189878	chr1:247187281~247188526:-
HNSC	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-4.82	1.95e-06	0.000476	-0.25	-0.22	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
HNSC	cis	rs10791097	0.677	rs11222359	ENSG00000254842.5	RP11-890B15.2	-4.82	1.95e-06	0.000477	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130860753	chr11:130844191~130865561:-
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000254174.1	IGHV1-12	-4.82	1.95e-06	0.000477	-0.17	-0.22	Rheumatic heart disease;	chr14:106650770	chr14:106122420~106122709:-
HNSC	cis	rs6723108	0.627	rs55865348	ENSG00000224043.6	CCNT2-AS1	-4.82	1.95e-06	0.000477	-0.27	-0.22	Type 2 diabetes;	chr2:134892235	chr2:134735464~134918710:-
HNSC	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-4.82	1.95e-06	0.000477	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-4.82	1.95e-06	0.000477	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
HNSC	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-4.82	1.95e-06	0.000477	-0.27	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
HNSC	cis	rs2998286	0.862	rs2486637	ENSG00000254635.4	WAC-AS1	-4.82	1.95e-06	0.000477	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28505085	chr10:28522652~28532743:-
HNSC	cis	rs6831352	0.918	rs13129488	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99131874	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.84	rs35073321	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99132125	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001202	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99132631	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs29001196	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99132965	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17817359	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133046	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001195	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133093	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17217949	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133161	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs17218003	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133572	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001194	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133693	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13143133	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99133819	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs7672728	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134022	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs7689753	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134424	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218073	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134588	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218108	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134604	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13112176	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134674	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218141	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134757	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218162	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99134909	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.877	rs29001183	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99135388	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218239	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99135869	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13127153	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99136970	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13127582	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99137043	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13133633	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99137546	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13133647	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99137576	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs28987088	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99137988	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs7669636	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99138161	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs7670060	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99138417	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs7670241	ENSG00000263923.1	RP11-571L19.7	4.82	1.95e-06	0.000477	0.23	0.22	Alcohol dependence;	chr4:99138468	chr4:98928897~98994994:+
HNSC	cis	rs1707322	1	rs34444543	ENSG00000234329.1	RP11-767N6.2	4.82	1.95e-06	0.000477	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45651039~45651826:-
HNSC	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-4.82	1.95e-06	0.000478	-0.18	-0.22	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
HNSC	cis	rs72843506	0.656	rs77314146	ENSG00000261033.1	RP11-209D14.2	4.82	1.95e-06	0.000478	0.41	0.22	Schizophrenia;	chr17:20003827	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs78325601	ENSG00000261033.1	RP11-209D14.2	4.82	1.95e-06	0.000478	0.41	0.22	Schizophrenia;	chr17:20018486	chr17:20008051~20009234:-
HNSC	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-4.82	1.95e-06	0.000478	-0.23	-0.22	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-4.82	1.95e-06	0.000478	-0.23	-0.22	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
HNSC	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-4.82	1.95e-06	0.000478	-0.25	-0.22	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
HNSC	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-4.82	1.96e-06	0.000478	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
HNSC	cis	rs7475343	0.501	rs117292237	ENSG00000224034.1	RP11-445P17.8	-4.82	1.96e-06	0.000479	-0.3	-0.22	Intelligence;	chr10:5265566	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs77364195	ENSG00000224034.1	RP11-445P17.8	-4.82	1.96e-06	0.000479	-0.3	-0.22	Intelligence;	chr10:5266772	chr10:5266033~5271236:-
HNSC	cis	rs2310173	0.521	rs974950	ENSG00000281162.1	LINC01127	-4.82	1.96e-06	0.000479	-0.28	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102042732	chr2:101962056~101987167:+
HNSC	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-4.82	1.96e-06	0.000479	-0.26	-0.22	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
HNSC	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	4.82	1.96e-06	0.000479	0.3	0.22	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
HNSC	cis	rs3806843	0.966	rs7710380	ENSG00000202515.1	VTRNA1-3	-4.82	1.96e-06	0.000479	-0.24	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr5:140726158~140726246:+
HNSC	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-4.82	1.96e-06	0.000479	-0.24	-0.22	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
HNSC	cis	rs8032939	0.533	rs16967104	ENSG00000259747.1	RP11-275I4.2	4.82	1.96e-06	0.000479	0.27	0.22	Rheumatoid arthritis;	chr15:38608498	chr15:38671847~38689191:+
HNSC	cis	rs889014	0.5	rs2112676	ENSG00000253768.1	CTB-33O18.1	4.82	1.96e-06	0.000479	0.26	0.22	Height;	chr5:173564570	chr5:173562478~173573199:+
HNSC	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	4.82	1.96e-06	0.000479	0.3	0.22	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
HNSC	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-4.82	1.96e-06	0.000479	-0.22	-0.22	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-4.82	1.96e-06	0.000479	-0.22	-0.22	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-4.82	1.96e-06	0.000479	-0.22	-0.22	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-4.82	1.96e-06	0.000479	-0.22	-0.22	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
HNSC	cis	rs11672691	0.627	rs6508981	ENSG00000270164.1	LINC01480	-4.82	1.96e-06	0.000479	-0.2	-0.22	Prostate cancer;	chr19:41483668	chr19:41535183~41536904:+
HNSC	cis	rs763512	0.504	rs1045013	ENSG00000276054.1	RP11-378E13.3	4.82	1.96e-06	0.000479	0.32	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37518790	chr17:37386886~37387926:+
HNSC	cis	rs763121	0.853	rs4821808	ENSG00000273076.1	RP3-508I15.22	4.82	1.96e-06	0.000479	0.23	0.22	Menopause (age at onset);	chr22:38669734	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs4821809	ENSG00000273076.1	RP3-508I15.22	4.82	1.96e-06	0.000479	0.23	0.22	Menopause (age at onset);	chr22:38669738	chr22:38743495~38743910:+
HNSC	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	4.82	1.96e-06	0.000479	0.29	0.22	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	4.82	1.96e-06	0.000479	0.29	0.22	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	4.82	1.96e-06	0.000479	0.29	0.22	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
HNSC	cis	rs2548724	0.617	rs2123136	ENSG00000250682.4	LINC00491	4.82	1.96e-06	0.00048	0.27	0.22	Type 2 diabetes;	chr5:102372284	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.617	rs57415604	ENSG00000250682.4	LINC00491	4.82	1.96e-06	0.00048	0.27	0.22	Type 2 diabetes;	chr5:102375957	chr5:102609156~102671559:-
HNSC	cis	rs9863	0.828	rs34114498	ENSG00000269938.1	RP11-214K3.20	-4.82	1.96e-06	0.00048	-0.25	-0.22	White blood cell count;	chr12:123995826	chr12:123968023~123968579:-
HNSC	cis	rs1479119	0.552	rs7312208	ENSG00000180861.8	LINC01559	4.82	1.96e-06	0.00048	0.27	0.22	Intelligence (multi-trait analysis);	chr12:13359385	chr12:13371089~13387167:-
HNSC	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	4.82	1.97e-06	0.000481	0.24	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
HNSC	cis	rs9525927	0.625	rs9533803	ENSG00000227258.4	SMIM2-AS1	4.82	1.97e-06	0.000481	0.31	0.22	Dupuytren's disease;	chr13:44246472	chr13:44110451~44240517:+
HNSC	cis	rs761746	0.584	rs62238892	ENSG00000236132.1	CTA-440B3.1	-4.82	1.97e-06	0.000481	-0.27	-0.22	Intelligence;	chr22:31765563	chr22:31816379~31817491:-
HNSC	cis	rs11834862	0.598	rs11246996	ENSG00000256576.2	RP13-977J11.2	-4.82	1.97e-06	0.000481	-0.34	-0.22	Anti-saccade response;	chr12:132206034	chr12:132186735~132189695:-
HNSC	cis	rs3738443	0.83	rs58405512	ENSG00000259865.1	RP11-488L18.10	4.82	1.97e-06	0.000481	0.2	0.22	Alcohol dependence;	chr1:247198454	chr1:247187281~247188526:-
HNSC	cis	rs8077577	0.848	rs12600694	ENSG00000273018.4	CTD-2303H24.2	-4.82	1.97e-06	0.000481	-0.31	-0.22	Obesity-related traits;	chr17:18187705	chr17:18511221~18551705:-
HNSC	cis	rs867371	0.82	rs7164362	ENSG00000276710.3	CSPG4P8	-4.82	1.97e-06	0.000481	-0.26	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82459472~82477258:+
HNSC	cis	rs12545109	0.879	rs2576580	ENSG00000246430.5	LINC00968	-4.82	1.97e-06	0.000481	-0.28	-0.22	Obesity-related traits;	chr8:56453269	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.879	rs2609994	ENSG00000246430.5	LINC00968	-4.82	1.97e-06	0.000481	-0.28	-0.22	Obesity-related traits;	chr8:56453285	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.879	rs1513317	ENSG00000246430.5	LINC00968	-4.82	1.97e-06	0.000481	-0.28	-0.22	Obesity-related traits;	chr8:56460407	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.879	rs2670015	ENSG00000246430.5	LINC00968	-4.82	1.97e-06	0.000481	-0.28	-0.22	Obesity-related traits;	chr8:56464048	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.879	rs1581129	ENSG00000246430.5	LINC00968	-4.82	1.97e-06	0.000481	-0.28	-0.22	Obesity-related traits;	chr8:56464917	chr8:56496246~56559823:-
HNSC	cis	rs8054556	0.967	rs12918652	ENSG00000183604.13	SMG1P5	-4.82	1.97e-06	0.000481	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:30267553~30335374:-
HNSC	cis	rs10946940	0.965	rs4713112	ENSG00000219392.1	RP1-265C24.5	4.82	1.97e-06	0.000481	0.25	0.22	Systemic lupus erythematosus;	chr6:27549054	chr6:28115628~28116551:+
HNSC	cis	rs12701220	0.69	rs10243973	ENSG00000229043.2	AC091729.9	-4.82	1.97e-06	0.000481	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1025347	chr7:1160374~1165267:+
HNSC	cis	rs4664293	0.647	rs10192408	ENSG00000226266.5	AC009961.3	-4.82	1.97e-06	0.000481	-0.22	-0.22	Monocyte percentage of white cells;	chr2:159568083	chr2:159670708~159712435:-
HNSC	cis	rs9921338	0.961	rs72773825	ENSG00000263080.1	RP11-485G7.5	4.82	1.97e-06	0.000481	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11341809~11345211:-
HNSC	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
HNSC	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	4.82	1.97e-06	0.000481	0.26	0.22	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
HNSC	cis	rs79478560	0.504	rs10773046	ENSG00000269938.1	RP11-214K3.20	-4.82	1.97e-06	0.000482	-0.24	-0.22	Lymphocyte counts;	chr12:123890663	chr12:123968023~123968579:-
HNSC	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	4.82	1.97e-06	0.000482	0.36	0.22	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
HNSC	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-4.82	1.97e-06	0.000482	-0.19	-0.22	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
HNSC	cis	rs7665090	0.728	rs228632	ENSG00000246560.2	RP11-10L12.4	-4.82	1.97e-06	0.000482	-0.25	-0.22	Primary biliary cholangitis;	chr4:102652747	chr4:102828055~102844075:+
HNSC	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-4.82	1.97e-06	0.000482	-0.28	-0.22	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	4.82	1.97e-06	0.000482	0.25	0.22	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
HNSC	cis	rs240993	0.627	rs174389	ENSG00000255389.1	C6orf3	-4.82	1.97e-06	0.000482	-0.24	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111595190	chr6:111599875~111602295:+
HNSC	cis	rs577676	0.586	rs2022373	ENSG00000271811.1	RP1-79C4.4	4.82	1.98e-06	0.000483	0.25	0.22	Prevalent atrial fibrillation;	chr1:170619453	chr1:170667381~170669425:+
HNSC	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.82	1.98e-06	0.000483	0.19	0.22	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
HNSC	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	4.82	1.98e-06	0.000483	0.24	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
HNSC	cis	rs1056107	1	rs1056107	ENSG00000225513.1	RP11-165N19.2	-4.82	1.98e-06	0.000483	-0.23	-0.22	Colorectal cancer;	chr9:112324847	chr9:112173522~112173971:-
HNSC	cis	rs36052053	0.908	rs71558364	ENSG00000219700.1	PTCHD3P3	4.82	1.98e-06	0.000483	0.35	0.22	Red cell distribution width;	chr6:109295036	chr6:109288571~109290503:-
HNSC	cis	rs36052053	0.908	rs28360564	ENSG00000219700.1	PTCHD3P3	4.82	1.98e-06	0.000483	0.35	0.22	Red cell distribution width;	chr6:109297186	chr6:109288571~109290503:-
HNSC	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	4.82	1.98e-06	0.000483	0.22	0.22	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
HNSC	cis	rs3806843	0.735	rs2563335	ENSG00000202515.1	VTRNA1-3	-4.82	1.98e-06	0.000483	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr5:140726158~140726246:+
HNSC	cis	rs6964587	0.869	rs10278155	ENSG00000188693.7	CYP51A1-AS1	4.82	1.98e-06	0.000483	0.23	0.22	Breast cancer;	chr7:91903142	chr7:92134604~92180725:+
HNSC	cis	rs763121	0.853	rs3788544	ENSG00000273076.1	RP3-508I15.22	4.82	1.98e-06	0.000483	0.24	0.22	Menopause (age at onset);	chr22:38668961	chr22:38743495~38743910:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.82	1.98e-06	0.000484	0.26	0.22	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
HNSC	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	4.82	1.98e-06	0.000484	0.29	0.22	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
HNSC	cis	rs6601327	0.607	rs6992666	ENSG00000254340.1	RP11-10A14.3	-4.82	1.98e-06	0.000484	-0.26	-0.22	Multiple myeloma (hyperdiploidy);	chr8:9729194	chr8:9141424~9145435:+
HNSC	cis	rs1971762	0.545	rs11170632	ENSG00000270175.1	RP11-793H13.11	4.82	1.98e-06	0.000484	0.19	0.22	Height;	chr12:53654151	chr12:53500162~53500936:-
HNSC	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	4.82	1.98e-06	0.000484	0.3	0.22	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
HNSC	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	4.82	1.98e-06	0.000484	0.27	0.22	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
HNSC	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	4.82	1.98e-06	0.000484	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
HNSC	cis	rs3806843	1	rs10072015	ENSG00000202515.1	VTRNA1-3	4.82	1.98e-06	0.000484	0.23	0.22	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr5:140726158~140726246:+
HNSC	cis	rs12545109	0.879	rs893234	ENSG00000246430.5	LINC00968	-4.82	1.98e-06	0.000485	-0.28	-0.22	Obesity-related traits;	chr8:56451326	chr8:56496246~56559823:-
HNSC	cis	rs6964587	0.967	rs6465341	ENSG00000188693.7	CYP51A1-AS1	-4.82	1.98e-06	0.000485	-0.23	-0.22	Breast cancer;	chr7:91966807	chr7:92134604~92180725:+
HNSC	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-4.82	1.99e-06	0.000485	-0.23	-0.22	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-4.82	1.99e-06	0.000485	-0.23	-0.22	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
HNSC	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	4.82	1.99e-06	0.000485	0.2	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
HNSC	cis	rs6693567	0.565	rs1694379	ENSG00000228126.1	FALEC	4.82	1.99e-06	0.000485	0.26	0.22	Migraine;	chr1:150319969	chr1:150515757~150518032:+
HNSC	cis	rs11089937	0.626	rs9622968	ENSG00000211639.2	IGLV4-60	4.82	1.99e-06	0.000485	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22162199~22162681:+
HNSC	cis	rs2187895	0.796	rs489090	ENSG00000271811.1	RP1-79C4.4	4.82	1.99e-06	0.000485	0.32	0.22	Tonsillectomy;	chr1:170692623	chr1:170667381~170669425:+
HNSC	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-4.82	1.99e-06	0.000486	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
HNSC	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	4.81	1.99e-06	0.000486	0.19	0.22	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
HNSC	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	4.81	1.99e-06	0.000486	0.19	0.22	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
HNSC	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	4.81	1.99e-06	0.000486	0.24	0.22	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
HNSC	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	4.81	1.99e-06	0.000486	0.24	0.22	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
HNSC	cis	rs9402743	0.67	rs7769840	ENSG00000234084.1	RP3-388E23.2	4.81	1.99e-06	0.000487	0.22	0.22	Systemic lupus erythematosus;	chr6:135605412	chr6:135301568~135307158:+
HNSC	cis	rs2310173	0.521	rs2110564	ENSG00000281162.1	LINC01127	-4.81	1.99e-06	0.000487	-0.28	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102044088	chr2:101962056~101987167:+
HNSC	cis	rs2310173	0.521	rs6722640	ENSG00000281162.1	LINC01127	-4.81	1.99e-06	0.000487	-0.28	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102045151	chr2:101962056~101987167:+
HNSC	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-4.81	1.99e-06	0.000487	-0.34	-0.22	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
HNSC	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-4.81	2e-06	0.000487	-0.29	-0.22	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
HNSC	cis	rs2665103	0.715	rs16973457	ENSG00000255769.6	GOLGA2P10	-4.81	2e-06	0.000487	-0.26	-0.22	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472993~82513950:-
HNSC	cis	rs1707322	0.963	rs10789478	ENSG00000234329.1	RP11-767N6.2	4.81	2e-06	0.000487	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45651039~45651826:-
HNSC	cis	rs11722228	0.521	rs12501336	ENSG00000250413.1	RP11-448G15.1	-4.81	2e-06	0.000487	-0.32	-0.22	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10006482~10009725:+
HNSC	cis	rs14027	0.64	rs6994604	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119746463	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.64	rs7837213	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750459	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.596	rs28576821	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752777	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.64	rs16893109	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756309	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.64	rs7011974	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759623	chr8:119838736~119840385:-
HNSC	cis	rs14027	0.64	rs9693207	ENSG00000279347.1	RP11-85I17.2	-4.81	2e-06	0.000487	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759815	chr8:119838736~119840385:-
HNSC	cis	rs9921338	0.961	rs72773830	ENSG00000263080.1	RP11-485G7.5	4.81	2e-06	0.000488	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs72773832	ENSG00000263080.1	RP11-485G7.5	4.81	2e-06	0.000488	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs72773833	ENSG00000263080.1	RP11-485G7.5	4.81	2e-06	0.000488	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs72773834	ENSG00000263080.1	RP11-485G7.5	4.81	2e-06	0.000488	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11341809~11345211:-
HNSC	cis	rs73198271	0.71	rs11779561	ENSG00000253893.2	FAM85B	4.81	2e-06	0.000488	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8167819~8226614:-
HNSC	cis	rs7086627	0.515	rs4934189	ENSG00000226659.1	RP11-137H2.4	-4.81	2e-06	0.000488	-0.27	-0.22	Post bronchodilator FEV1;	chr10:80455036	chr10:80529597~80535942:-
HNSC	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-4.81	2e-06	0.000488	-0.26	-0.22	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
HNSC	cis	rs2835345	0.596	rs2409817	ENSG00000279365.1	KB-176G8.1	4.81	2e-06	0.000488	0.27	0.22	Pulmonary function;	chr21:36455410	chr21:36485867~36487760:+
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-4.81	2e-06	0.000488	-0.27	-0.22	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
HNSC	cis	rs763567	0.869	rs629234	ENSG00000271811.1	RP1-79C4.4	4.81	2e-06	0.000488	0.24	0.22	Tonsillectomy;	chr1:170662622	chr1:170667381~170669425:+
HNSC	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-4.81	2e-06	0.000488	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	4.81	2e-06	0.000488	0.3	0.22	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
HNSC	cis	rs116095464	0.558	rs10043002	ENSG00000250848.1	CTD-2083E4.5	-4.81	2e-06	0.000489	-0.3	-0.22	Breast cancer;	chr5:226638	chr5:288833~290321:-
HNSC	cis	rs9921338	0.961	rs17605444	ENSG00000263080.1	RP11-485G7.5	4.81	2e-06	0.000489	0.24	0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11341809~11345211:-
HNSC	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.81	2.01e-06	0.000489	0.22	0.22	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
HNSC	cis	rs17270561	0.779	rs12210620	ENSG00000272810.1	U91328.22	-4.81	2.01e-06	0.000489	-0.24	-0.22	Iron status biomarkers;	chr6:25884557	chr6:26013241~26013757:+
HNSC	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	4.81	2.01e-06	0.000489	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
HNSC	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	4.81	2.01e-06	0.00049	0.19	0.22	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
HNSC	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-4.81	2.01e-06	0.00049	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
HNSC	cis	rs898123	0.931	rs1024892	ENSG00000234896.1	OR7E62P	-4.81	2.01e-06	0.00049	-0.25	-0.22	Coronary artery disease;	chr2:71147142	chr2:71055527~71056003:+
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	4.81	2.01e-06	0.00049	0.25	0.22	Depression;	chr6:28109824	chr6:28170845~28172521:+
HNSC	cis	rs14027	0.64	rs16893071	ENSG00000279347.1	RP11-85I17.2	-4.81	2.01e-06	0.00049	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119738183	chr8:119838736~119840385:-
HNSC	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.01e-06	0.00049	-0.5	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
HNSC	cis	rs2058059	0.551	rs2960924	ENSG00000225648.4	SBDSP1	-4.81	2.01e-06	0.00049	-0.32	-0.22	Subcutaneous adipose tissue;	chr7:72622795	chr7:72829425~72836701:+
HNSC	cis	rs71636778	0.509	rs35917448	ENSG00000260063.1	RP5-968P14.2	-4.81	2.01e-06	0.00049	-0.43	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26690834	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71514277	ENSG00000260063.1	RP5-968P14.2	-4.81	2.01e-06	0.00049	-0.43	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26707937	chr1:26692132~26694131:-
HNSC	cis	rs1056107	0.931	rs7855745	ENSG00000225513.1	RP11-165N19.2	-4.81	2.01e-06	0.00049	-0.23	-0.22	Colorectal cancer;	chr9:112220183	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs7859107	ENSG00000225513.1	RP11-165N19.2	-4.81	2.01e-06	0.00049	-0.23	-0.22	Colorectal cancer;	chr9:112220518	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs7025680	ENSG00000225513.1	RP11-165N19.2	-4.81	2.01e-06	0.00049	-0.23	-0.22	Colorectal cancer;	chr9:112224434	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.872	rs3780514	ENSG00000225513.1	RP11-165N19.2	-4.81	2.01e-06	0.00049	-0.23	-0.22	Colorectal cancer;	chr9:112226051	chr9:112173522~112173971:-
HNSC	cis	rs4718428	1	rs4718421	ENSG00000179406.6	LINC00174	-4.81	2.01e-06	0.000491	-0.29	-0.22	Corneal structure;	chr7:66885313	chr7:66376044~66401338:-
HNSC	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-4.81	2.01e-06	0.000491	-0.25	-0.22	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
HNSC	cis	rs6831352	0.879	rs1984362	ENSG00000263923.1	RP11-571L19.7	4.81	2.01e-06	0.000491	0.24	0.22	Alcohol dependence;	chr4:99149816	chr4:98928897~98994994:+
HNSC	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	4.81	2.01e-06	0.000491	0.47	0.22	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
HNSC	cis	rs853679	0.517	rs868987	ENSG00000204709.4	LINC01556	-4.81	2.01e-06	0.000491	-0.3	-0.22	Depression;	chr6:28142370	chr6:28943877~28944537:+
HNSC	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	4.81	2.01e-06	0.000491	0.29	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
HNSC	cis	rs7621025	0.691	rs4678438	ENSG00000239213.4	NCK1-AS1	4.81	2.01e-06	0.000491	0.19	0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136841726~136862054:-
HNSC	cis	rs11089937	0.616	rs5757258	ENSG00000211638.2	IGLV8-61	-4.81	2.02e-06	0.000491	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.522	rs5757259	ENSG00000211638.2	IGLV8-61	-4.81	2.02e-06	0.000491	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs12484472	ENSG00000211638.2	IGLV8-61	-4.81	2.02e-06	0.000491	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22098700~22099212:+
HNSC	cis	rs12893668	0.703	rs34026011	ENSG00000269940.1	RP11-73M18.7	4.81	2.02e-06	0.000492	0.22	0.22	Reticulocyte count;	chr14:103584546	chr14:103694560~103695170:+
HNSC	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-4.81	2.02e-06	0.000492	-0.24	-0.22	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
HNSC	cis	rs4873772	0.703	rs2130413	ENSG00000253330.1	RP11-697N18.3	-4.81	2.02e-06	0.000492	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47569536	chr8:47511034~47512141:-
HNSC	cis	rs10462794	1	rs7709922	ENSG00000260763.1	RP11-445O3.3	-4.81	2.02e-06	0.000492	-0.3	-0.22	DNA methylation (variation);	chr5:4483320	chr5:4436850~4440259:-
HNSC	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	4.81	2.02e-06	0.000493	0.32	0.22	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
HNSC	cis	rs6928977	0.86	rs2746432	ENSG00000217482.2	HMGB1P17	-4.81	2.02e-06	0.000493	-0.24	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135375459	chr6:135636086~135636713:-
HNSC	cis	rs763121	0.853	rs5750673	ENSG00000273076.1	RP3-508I15.22	4.81	2.02e-06	0.000493	0.23	0.22	Menopause (age at onset);	chr22:38714119	chr22:38743495~38743910:+
HNSC	cis	rs6831352	0.879	rs4699716	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99144974	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs4699717	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99144986	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.84	rs34634551	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99146211	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.729	rs4699718	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99146639	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.765	rs35361391	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99148129	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs56222233	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99148475	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs7434491	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99148695	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs1984364	ENSG00000263923.1	RP11-571L19.7	4.81	2.02e-06	0.000493	0.24	0.22	Alcohol dependence;	chr4:99149626	chr4:98928897~98994994:+
HNSC	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-4.81	2.02e-06	0.000493	-0.24	-0.22	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
HNSC	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	4.81	2.02e-06	0.000493	0.35	0.22	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	4.81	2.02e-06	0.000493	0.35	0.22	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
HNSC	cis	rs10028773	0.666	rs12498657	ENSG00000249244.1	RP11-548H18.2	4.81	2.02e-06	0.000493	0.27	0.22	Educational attainment;	chr4:119341711	chr4:119391831~119395335:-
HNSC	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-4.81	2.03e-06	0.000493	-0.27	-0.22	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
HNSC	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	4.81	2.03e-06	0.000494	0.29	0.22	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
HNSC	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	4.81	2.03e-06	0.000494	0.23	0.22	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
HNSC	cis	rs6964587	1	rs36021614	ENSG00000188693.7	CYP51A1-AS1	-4.81	2.03e-06	0.000494	-0.23	-0.22	Breast cancer;	chr7:92088176	chr7:92134604~92180725:+
HNSC	cis	rs13217239	0.646	rs10946888	ENSG00000224843.5	LINC00240	-4.81	2.03e-06	0.000494	-0.21	-0.22	Schizophrenia;	chr6:26983899	chr6:26956992~27023924:+
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	4.81	2.03e-06	0.000494	0.31	0.22	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
HNSC	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.81	2.03e-06	0.000495	0.34	0.22	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
HNSC	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.81	2.03e-06	0.000495	-0.19	-0.22	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
HNSC	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-4.81	2.03e-06	0.000495	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-4.81	2.03e-06	0.000495	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
HNSC	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-4.81	2.03e-06	0.000495	-0.18	-0.22	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
HNSC	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-4.81	2.03e-06	0.000495	-0.27	-0.22	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
HNSC	cis	rs2253762	0.507	rs12264894	ENSG00000226864.1	ATE1-AS1	4.81	2.04e-06	0.000496	0.36	0.22	Breast cancer;	chr10:121992087	chr10:121928312~121951965:+
HNSC	cis	rs9880211	0.563	rs67589653	ENSG00000273486.1	RP11-731C17.2	4.81	2.04e-06	0.000496	0.2	0.22	Height;Body mass index;	chr3:136092732	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.563	rs10512990	ENSG00000273486.1	RP11-731C17.2	4.81	2.04e-06	0.000496	0.2	0.22	Height;Body mass index;	chr3:136095785	chr3:136837338~136839021:-
HNSC	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	4.81	2.04e-06	0.000496	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
HNSC	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	4.81	2.04e-06	0.000496	0.24	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
HNSC	cis	rs10083777	0.551	rs111889995	ENSG00000261061.1	RP11-303E16.2	-4.81	2.04e-06	0.000496	-0.45	-0.22	Metabolite levels (small molecules and protein measures);	chr16:81000166	chr16:81030770~81031485:+
HNSC	cis	rs1198872	0.892	rs1198864	ENSG00000272275.1	RP11-791G15.2	-4.81	2.04e-06	0.000496	-0.26	-0.22	Cardiac Troponin-T levels;	chr2:10760869	chr2:10767875~10770058:-
HNSC	cis	rs36052053	1	rs36052053	ENSG00000219700.1	PTCHD3P3	4.81	2.04e-06	0.000496	0.34	0.22	Red cell distribution width;	chr6:109262596	chr6:109288571~109290503:-
HNSC	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-4.81	2.04e-06	0.000496	-0.24	-0.22	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
HNSC	cis	rs2058059	0.551	rs2960920	ENSG00000225648.4	SBDSP1	4.81	2.04e-06	0.000496	0.32	0.22	Subcutaneous adipose tissue;	chr7:72618762	chr7:72829425~72836701:+
HNSC	cis	rs755249	0.567	rs61783378	ENSG00000228060.1	RP11-69E11.8	-4.81	2.04e-06	0.000497	-0.25	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39565160~39573203:+
HNSC	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	4.81	2.04e-06	0.000497	0.25	0.22	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
HNSC	cis	rs2985684	0.948	rs11623263	ENSG00000278009.1	RP11-649E7.8	4.81	2.04e-06	0.000497	0.28	0.22	Carotid intima media thickness;	chr14:49616577	chr14:49601011~49601124:-
HNSC	cis	rs71520386	0.607	rs28660425	ENSG00000221740.1	SNORD93	-4.81	2.04e-06	0.000497	-0.25	-0.22	Fibrinogen levels;	chr7:22818532	chr7:22856613~22856686:+
HNSC	cis	rs2337406	1	rs10459466	ENSG00000280411.1	IGHV1-69-2	-4.81	2.04e-06	0.000497	-0.23	-0.22	Alzheimer's disease (late onset);	chr14:106689255	chr14:106762092~106762588:-
HNSC	cis	rs2286503	0.533	rs1880239	ENSG00000228649.7	AC005682.5	4.81	2.04e-06	0.000497	0.27	0.22	Fibrinogen;	chr7:22832065	chr7:22854178~22861579:+
HNSC	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	4.81	2.04e-06	0.000498	0.25	0.22	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
HNSC	cis	rs763121	0.853	rs6001188	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000498	0.23	0.22	Menopause (age at onset);	chr22:38666189	chr22:38743495~38743910:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000204709.4	LINC01556	4.81	2.05e-06	0.000498	0.3	0.22	Depression;	chr6:28143758	chr6:28943877~28944537:+
HNSC	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-4.81	2.05e-06	0.000498	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
HNSC	cis	rs7475343	0.501	rs77714023	ENSG00000224034.1	RP11-445P17.8	-4.81	2.05e-06	0.000498	-0.3	-0.22	Intelligence;	chr10:5263928	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs117600605	ENSG00000224034.1	RP11-445P17.8	-4.81	2.05e-06	0.000498	-0.3	-0.22	Intelligence;	chr10:5263996	chr10:5266033~5271236:-
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	4.81	2.05e-06	0.000498	0.26	0.22	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
HNSC	cis	rs11969893	0.737	rs4098482	ENSG00000270987.1	RP3-467N11.2	4.81	2.05e-06	0.000499	0.5	0.22	Economic and political preferences (immigration/crime);	chr6:100929932	chr6:100889603~100890338:+
HNSC	cis	rs11969893	0.737	rs1854483	ENSG00000270987.1	RP3-467N11.2	4.81	2.05e-06	0.000499	0.5	0.22	Economic and political preferences (immigration/crime);	chr6:100930241	chr6:100889603~100890338:+
HNSC	cis	rs7819412	0.74	rs7844536	ENSG00000255310.2	AF131215.2	-4.81	2.05e-06	0.000499	-0.22	-0.22	Triglycerides;	chr8:11176519	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	4.81	2.05e-06	0.000499	0.3	0.22	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
HNSC	cis	rs2998286	0.643	rs332181	ENSG00000254635.4	WAC-AS1	-4.81	2.05e-06	0.000499	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621187	chr10:28522652~28532743:-
HNSC	cis	rs11098499	0.629	rs28369518	ENSG00000249244.1	RP11-548H18.2	4.81	2.05e-06	0.000499	0.26	0.22	Corneal astigmatism;	chr4:119350475	chr4:119391831~119395335:-
HNSC	cis	rs7824557	0.547	rs2409745	ENSG00000255310.2	AF131215.2	4.81	2.05e-06	0.000499	0.21	0.22	Retinal vascular caliber;	chr8:11219126	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	4.81	2.05e-06	0.000499	0.27	0.22	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
HNSC	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	4.81	2.05e-06	0.000499	0.19	0.22	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
HNSC	cis	rs763121	0.853	rs3761454	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38670815	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs3747170	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38671326	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs3747172	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38671519	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750659	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38672784	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs3747173	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38673040	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs3747174	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38673176	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757226	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38674545	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757232	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38675672	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs9306329	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38676449	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750662	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38676467	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750664	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38676764	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.626	rs5757236	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38677819	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs5757237	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38677830	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs6001191	ENSG00000273076.1	RP3-508I15.22	4.81	2.05e-06	0.000499	0.23	0.22	Menopause (age at onset);	chr22:38678447	chr22:38743495~38743910:+
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000254153.1	CTA-398F10.2	4.81	2.05e-06	0.000499	0.24	0.22	Mood instability;	chr8:8872978	chr8:8456909~8461337:-
HNSC	cis	rs1056107	0.933	rs3808879	ENSG00000225513.1	RP11-165N19.2	-4.81	2.05e-06	0.000499	-0.23	-0.22	Colorectal cancer;	chr9:112299198	chr9:112173522~112173971:-
HNSC	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.81	2.05e-06	0.000499	0.2	0.22	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
HNSC	cis	rs7085104	0.572	rs284860	ENSG00000213061.2	PFN1P11	-4.81	2.05e-06	0.000499	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102838011~102845473:-
HNSC	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	4.81	2.05e-06	5e-04	0.3	0.22	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
HNSC	cis	rs9863	0.931	rs11831913	ENSG00000269938.1	RP11-214K3.20	-4.81	2.06e-06	5e-04	-0.26	-0.22	White blood cell count;	chr12:123962351	chr12:123968023~123968579:-
HNSC	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	4.81	2.06e-06	5e-04	0.22	0.22	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
HNSC	cis	rs7000734	1	rs7000734	ENSG00000245080.5	RP11-320N21.1	-4.81	2.06e-06	5e-04	-0.3	-0.22	Radiation response;	chr8:95114802	chr8:95066808~95073182:-
HNSC	cis	rs4718428	0.96	rs6460317	ENSG00000273142.1	RP11-458F8.4	-4.81	2.06e-06	5e-04	-0.19	-0.22	Corneal structure;	chr7:66925268	chr7:66902857~66906297:+
HNSC	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-4.81	2.06e-06	5e-04	-0.25	-0.22	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
HNSC	cis	rs1056107	0.931	rs7867823	ENSG00000225513.1	RP11-165N19.2	-4.81	2.06e-06	5e-04	-0.24	-0.22	Colorectal cancer;	chr9:112245813	chr9:112173522~112173971:-
HNSC	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	4.81	2.06e-06	5e-04	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
HNSC	cis	rs13126694	0.744	rs11100148	ENSG00000248429.4	RP11-597D13.9	4.81	2.06e-06	0.000501	0.24	0.22	Blood osmolality (transformed sodium);	chr4:158074688	chr4:158170752~158202877:+
HNSC	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-4.81	2.06e-06	0.000501	-0.52	-0.22	Gout;	chr7:66723871	chr7:66654538~66669855:+
HNSC	cis	rs853679	0.607	rs56075693	ENSG00000219392.1	RP1-265C24.5	-4.81	2.06e-06	0.000501	-0.43	-0.22	Depression;	chr6:28322551	chr6:28115628~28116551:+
HNSC	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	4.81	2.06e-06	0.000501	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
HNSC	cis	rs2898290	0.617	rs13278965	ENSG00000269918.1	AF131215.9	4.81	2.06e-06	0.000501	0.22	0.22	Systolic blood pressure;	chr8:11609236	chr8:11104691~11106704:-
HNSC	cis	rs7246760	1	rs10418248	ENSG00000267289.1	CTD-2623N2.11	4.81	2.06e-06	0.000502	0.36	0.22	Pursuit maintenance gain;	chr19:9827538	chr19:9834079~9835013:-
HNSC	cis	rs9929218	0.559	rs12923775	ENSG00000260459.2	FTLP14	4.81	2.06e-06	0.000502	0.28	0.22	Colorectal cancer;	chr16:68722547	chr16:68822587~68823070:+
HNSC	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-4.81	2.06e-06	0.000502	-0.26	-0.22	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
HNSC	cis	rs721917	0.525	rs7903576	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.06e-06	0.000502	-0.26	-0.22	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79663088~79826594:-
HNSC	cis	rs6540731	0.782	rs10436962	ENSG00000226251.4	RP11-15I11.3	-4.81	2.06e-06	0.000502	-0.25	-0.22	Intelligence (childhood);	chr1:212188280	chr1:212225278~212238977:-
HNSC	cis	rs1056107	0.898	rs7037927	ENSG00000225513.1	RP11-165N19.2	-4.81	2.06e-06	0.000502	-0.23	-0.22	Colorectal cancer;	chr9:112205143	chr9:112173522~112173971:-
HNSC	cis	rs78905543	0.772	rs11135694	ENSG00000253616.4	RP11-875O11.3	4.81	2.06e-06	0.000502	0.26	0.22	Mean corpuscular volume;	chr8:23068002	chr8:23071377~23074488:-
HNSC	cis	rs9907295	0.818	rs2280789	ENSG00000270977.1	AC015849.16	-4.81	2.06e-06	0.000502	-0.29	-0.22	Fibroblast growth factor basic levels;	chr17:35879999	chr17:35893707~35911023:-
HNSC	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-4.81	2.07e-06	0.000502	-0.19	-0.22	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
HNSC	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-4.81	2.07e-06	0.000502	-0.24	-0.22	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
HNSC	cis	rs1198872	0.812	rs1198860	ENSG00000272275.1	RP11-791G15.2	-4.81	2.07e-06	0.000502	-0.26	-0.22	Cardiac Troponin-T levels;	chr2:10759727	chr2:10767875~10770058:-
HNSC	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	4.81	2.07e-06	0.000502	0.28	0.22	Pain;	chr19:21568500	chr19:21554640~21569237:-
HNSC	cis	rs3096299	0.874	rs3102342	ENSG00000261574.1	RP1-168P16.2	4.81	2.07e-06	0.000502	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89392375~89412564:-
HNSC	cis	rs7615952	0.641	rs7618515	ENSG00000248787.1	RP11-666A20.4	-4.81	2.07e-06	0.000502	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126071735	chr3:125908005~125910272:-
HNSC	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	4.81	2.07e-06	0.000503	0.2	0.22	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
HNSC	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	4.81	2.07e-06	0.000503	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
HNSC	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-4.81	2.07e-06	0.000503	-0.18	-0.22	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
HNSC	cis	rs2412819	0.571	rs514255	ENSG00000205771.5	CATSPER2P1	-4.81	2.07e-06	0.000503	-0.35	-0.22	Lung cancer;	chr15:43893134	chr15:43726918~43747094:-
HNSC	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-4.81	2.07e-06	0.000503	-0.27	-0.22	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
HNSC	cis	rs7824557	0.806	rs10503418	ENSG00000255310.2	AF131215.2	-4.81	2.07e-06	0.000503	-0.21	-0.22	Retinal vascular caliber;	chr8:11261474	chr8:11107788~11109726:-
HNSC	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	4.81	2.07e-06	0.000504	0.22	0.22	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
HNSC	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-4.81	2.07e-06	0.000504	-0.26	-0.22	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
HNSC	cis	rs5758511	0.68	rs5758651	ENSG00000226450.2	CYP2D8P	4.81	2.07e-06	0.000504	0.22	0.22	Birth weight;	chr22:42213142	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs5758652	ENSG00000226450.2	CYP2D8P	4.81	2.07e-06	0.000504	0.22	0.22	Birth weight;	chr22:42216402	chr22:42149886~42155001:-
HNSC	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.08e-06	0.000504	-0.5	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.08e-06	0.000504	-0.5	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
HNSC	cis	rs71520386	0.632	rs12532922	ENSG00000221740.1	SNORD93	-4.81	2.08e-06	0.000504	-0.25	-0.22	Fibrinogen levels;	chr7:22820796	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs12532938	ENSG00000221740.1	SNORD93	-4.81	2.08e-06	0.000504	-0.25	-0.22	Fibrinogen levels;	chr7:22820876	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs10224533	ENSG00000221740.1	SNORD93	-4.81	2.08e-06	0.000504	-0.25	-0.22	Fibrinogen levels;	chr7:22821522	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.632	rs35353454	ENSG00000221740.1	SNORD93	-4.81	2.08e-06	0.000504	-0.25	-0.22	Fibrinogen levels;	chr7:22822120	chr7:22856613~22856686:+
HNSC	cis	rs7615952	0.576	rs2276726	ENSG00000241439.1	RP11-666A20.3	4.81	2.08e-06	0.000504	0.24	0.22	Blood pressure (smoking interaction);	chr3:126107444	chr3:125958556~125958817:+
HNSC	cis	rs6723108	0.627	rs1374292	ENSG00000224043.6	CCNT2-AS1	-4.81	2.08e-06	0.000504	-0.27	-0.22	Type 2 diabetes;	chr2:134896598	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.592	rs10928523	ENSG00000224043.6	CCNT2-AS1	-4.81	2.08e-06	0.000504	-0.27	-0.22	Type 2 diabetes;	chr2:134907891	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs1374288	ENSG00000224043.6	CCNT2-AS1	-4.81	2.08e-06	0.000504	-0.27	-0.22	Type 2 diabetes;	chr2:134909483	chr2:134735464~134918710:-
HNSC	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	4.81	2.08e-06	0.000504	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000230295.1	RP11-458F8.2	-4.81	2.08e-06	0.000504	-0.29	-0.22	Diabetic kidney disease;	chr7:66078212	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000230295.1	RP11-458F8.2	-4.81	2.08e-06	0.000504	-0.29	-0.22	Diabetic kidney disease;	chr7:66078397	chr7:66880708~66882981:+
HNSC	cis	rs763121	0.853	rs4821811	ENSG00000273076.1	RP3-508I15.22	4.81	2.08e-06	0.000505	0.23	0.22	Menopause (age at onset);	chr22:38679140	chr22:38743495~38743910:+
HNSC	cis	rs712039	0.958	rs11868673	ENSG00000276054.1	RP11-378E13.3	4.81	2.08e-06	0.000505	0.27	0.22	Tuberculosis;	chr17:37517559	chr17:37386886~37387926:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	4.81	2.08e-06	0.000505	0.26	0.22	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
HNSC	cis	rs7824557	0.737	rs2293855	ENSG00000255310.2	AF131215.2	4.81	2.08e-06	0.000505	0.21	0.22	Retinal vascular caliber;	chr8:11319901	chr8:11107788~11109726:-
HNSC	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-4.81	2.08e-06	0.000505	-0.23	-0.22	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
HNSC	cis	rs1665050	0.652	rs9302206	ENSG00000259732.1	RP11-59H7.3	-4.81	2.08e-06	0.000505	-0.27	-0.22	Atopic dermatitis;	chr15:59017274	chr15:59121034~59133250:+
HNSC	cis	rs1056107	0.931	rs2027384	ENSG00000225513.1	RP11-165N19.2	-4.81	2.08e-06	0.000506	-0.23	-0.22	Colorectal cancer;	chr9:112237954	chr9:112173522~112173971:-
HNSC	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	4.81	2.08e-06	0.000506	0.21	0.22	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000259429.4	UBE2Q2P2	-4.81	2.08e-06	0.000506	-0.21	-0.22	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82355142~82420075:+
HNSC	cis	rs6928977	0.802	rs2614276	ENSG00000217482.2	HMGB1P17	-4.81	2.09e-06	0.000506	-0.25	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135360566	chr6:135636086~135636713:-
HNSC	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-4.81	2.09e-06	0.000507	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
HNSC	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	4.81	2.09e-06	0.000507	0.3	0.22	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
HNSC	cis	rs763121	0.853	rs9622833	ENSG00000273076.1	RP3-508I15.22	4.81	2.09e-06	0.000507	0.24	0.22	Menopause (age at onset);	chr22:38604392	chr22:38743495~38743910:+
HNSC	cis	rs9467773	0.511	rs11755443	ENSG00000224843.5	LINC00240	-4.81	2.09e-06	0.000507	-0.22	-0.22	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26956992~27023924:+
HNSC	cis	rs75920871	0.66	rs12271161	ENSG00000254851.1	RP11-109L13.1	4.81	2.09e-06	0.000507	0.31	0.22	Subjective well-being;	chr11:117109195	chr11:117135528~117138582:+
HNSC	cis	rs2439831	1	rs2439850	ENSG00000205771.5	CATSPER2P1	-4.8	2.09e-06	0.000507	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43492656	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2467736	ENSG00000205771.5	CATSPER2P1	-4.8	2.09e-06	0.000507	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43492719	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs2444250	ENSG00000205771.5	CATSPER2P1	-4.8	2.09e-06	0.000507	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43492853	chr15:43726918~43747094:-
HNSC	cis	rs2439831	1	rs689781	ENSG00000205771.5	CATSPER2P1	-4.8	2.09e-06	0.000507	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43499899	chr15:43726918~43747094:-
HNSC	cis	rs9393777	0.777	rs56114371	ENSG00000219392.1	RP1-265C24.5	-4.8	2.09e-06	0.000507	-0.44	-0.22	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28115628~28116551:+
HNSC	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-4.8	2.09e-06	0.000507	-0.24	-0.22	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
HNSC	cis	rs2058059	0.636	rs2960948	ENSG00000225648.4	SBDSP1	-4.8	2.09e-06	0.000507	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72685439	chr7:72829425~72836701:+
HNSC	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	4.8	2.09e-06	0.000507	0.31	0.22	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
HNSC	cis	rs1056107	0.898	rs7021564	ENSG00000225513.1	RP11-165N19.2	-4.8	2.09e-06	0.000508	-0.23	-0.22	Colorectal cancer;	chr9:112240034	chr9:112173522~112173971:-
HNSC	cis	rs757110	0.902	rs2074310	ENSG00000260196.1	RP1-239B22.5	4.8	2.09e-06	0.000508	0.26	0.22	Type 2 diabetes;	chr11:17400339	chr11:17380649~17383531:+
HNSC	cis	rs2243480	1	rs4548056	ENSG00000179406.6	LINC00174	-4.8	2.1e-06	0.000508	-0.47	-0.22	Diabetic kidney disease;	chr7:65833886	chr7:66376044~66401338:-
HNSC	cis	rs6472866	0.646	rs4735693	ENSG00000254349.4	FLJ39080	4.8	2.1e-06	0.000508	0.24	0.22	Protein quantitative trait loci;	chr8:74557189	chr8:74599775~74823313:+
HNSC	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	4.8	2.1e-06	0.000508	0.28	0.22	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000267151.3	RP11-100E5.2	4.8	2.1e-06	0.000509	0.27	0.22	Menopause (age at onset);	chr17:43078520	chr17:43444707~43451200:+
HNSC	cis	rs1056107	0.931	rs10759536	ENSG00000225513.1	RP11-165N19.2	-4.8	2.1e-06	0.000509	-0.23	-0.22	Colorectal cancer;	chr9:112229222	chr9:112173522~112173971:-
HNSC	cis	rs9291683	0.597	rs11722989	ENSG00000250413.1	RP11-448G15.1	4.8	2.1e-06	0.000509	0.27	0.22	Bone mineral density;	chr4:10124515	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	4.8	2.1e-06	0.000509	0.25	0.22	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
HNSC	cis	rs925255	0.935	rs11127150	ENSG00000270210.1	RP11-373D23.3	-4.8	2.1e-06	0.00051	-0.24	-0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28404762	chr2:28425945~28426719:+
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-4.8	2.1e-06	0.00051	-0.27	-0.22	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
HNSC	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-4.8	2.1e-06	0.00051	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
HNSC	cis	rs4140799	1	rs4140799	ENSG00000266869.1	RP6-114E22.1	4.8	2.1e-06	0.00051	0.27	0.22	Neuroticism;	chr14:71704252	chr14:71848606~71908430:+
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000254340.1	RP11-10A14.3	4.8	2.1e-06	0.00051	0.26	0.22	Mood instability;	chr8:8277287	chr8:9141424~9145435:+
HNSC	cis	rs494003	1	rs12287832	ENSG00000255120.4	OVOL1-AS1	4.8	2.1e-06	0.00051	0.29	0.22	Systemic lupus erythematosus;	chr11:65786021	chr11:65789051~65790868:-
HNSC	cis	rs1218582	0.71	rs9794000	ENSG00000270361.1	RP11-307C12.13	-4.8	2.1e-06	0.00051	-0.23	-0.22	Prostate cancer;	chr1:154906400	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.71	rs9793588	ENSG00000270361.1	RP11-307C12.13	-4.8	2.1e-06	0.00051	-0.23	-0.22	Prostate cancer;	chr1:154906402	chr1:154937370~154938059:+
HNSC	cis	rs763121	0.853	rs4821812	ENSG00000273076.1	RP3-508I15.22	4.8	2.1e-06	0.00051	0.23	0.22	Menopause (age at onset);	chr22:38679230	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs9607566	ENSG00000273076.1	RP3-508I15.22	4.8	2.1e-06	0.00051	0.23	0.22	Menopause (age at onset);	chr22:38679429	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs3827357	ENSG00000273076.1	RP3-508I15.22	4.8	2.1e-06	0.00051	0.23	0.22	Menopause (age at onset);	chr22:38683408	chr22:38743495~38743910:+
HNSC	cis	rs2911132	0.714	rs13167972	ENSG00000248734.2	CTD-2260A17.1	4.8	2.1e-06	0.00051	0.22	0.22	Urate levels (BMI interaction);	chr5:96761124	chr5:96784777~96785999:+
HNSC	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-4.8	2.1e-06	0.00051	-0.24	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
HNSC	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	4.8	2.11e-06	0.00051	0.27	0.22	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	4.8	2.11e-06	0.00051	0.27	0.22	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	4.8	2.11e-06	0.00051	0.27	0.22	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
HNSC	cis	rs12701220	0.739	rs2293523	ENSG00000224079.1	AC091729.7	4.8	2.11e-06	0.00051	0.34	0.22	Bronchopulmonary dysplasia;	chr7:1058882	chr7:1074450~1078036:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-4.8	2.11e-06	0.00051	-0.23	-0.22	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
HNSC	cis	rs116095464	0.558	rs10077076	ENSG00000250848.1	CTD-2083E4.5	-4.8	2.11e-06	0.00051	-0.3	-0.22	Breast cancer;	chr5:231825	chr5:288833~290321:-
HNSC	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	4.8	2.11e-06	0.000511	0.23	0.22	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
HNSC	cis	rs3096299	0.967	rs753853	ENSG00000261574.1	RP1-168P16.2	4.8	2.11e-06	0.000511	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89392375~89412564:-
HNSC	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-4.8	2.11e-06	0.000511	-0.23	-0.22	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-4.8	2.11e-06	0.000511	-0.23	-0.22	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
HNSC	cis	rs9450351	0.744	rs9450304	ENSG00000203875.9	SNHG5	-4.8	2.11e-06	0.000511	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85620141	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs7749600	ENSG00000203875.9	SNHG5	-4.8	2.11e-06	0.000511	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85624372	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs9344538	ENSG00000203875.9	SNHG5	-4.8	2.11e-06	0.000511	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85625243	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs9450307	ENSG00000203875.9	SNHG5	-4.8	2.11e-06	0.000511	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85634633	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs9450309	ENSG00000203875.9	SNHG5	-4.8	2.11e-06	0.000511	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85639025	chr6:85660950~85678736:-
HNSC	cis	rs10946940	0.965	rs6915266	ENSG00000219392.1	RP1-265C24.5	4.8	2.11e-06	0.000511	0.25	0.22	Systemic lupus erythematosus;	chr6:27560864	chr6:28115628~28116551:+
HNSC	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-4.8	2.11e-06	0.000511	-0.23	-0.22	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
HNSC	cis	rs1355223	0.506	rs12294339	ENSG00000271369.1	RP11-350D17.3	-4.8	2.11e-06	0.000511	-0.26	-0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34838652	chr11:34709600~34710161:+
HNSC	cis	rs1012068	0.924	rs5994449	ENSG00000236132.1	CTA-440B3.1	-4.8	2.11e-06	0.000511	-0.26	-0.22	Chronic hepatitis C infection;	chr22:31908193	chr22:31816379~31817491:-
HNSC	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	4.8	2.11e-06	0.000511	0.22	0.22	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
HNSC	cis	rs1912702	0.536	rs5009495	ENSG00000255345.1	CTD-2337I7.1	4.8	2.11e-06	0.000512	0.26	0.22	Hair greying;	chr11:79480583	chr11:79092848~79098003:+
HNSC	cis	rs3015497	0.527	rs3015473	ENSG00000269906.1	RP11-248J18.2	-4.8	2.11e-06	0.000512	-0.29	-0.22	Mean platelet volume;	chr14:50687292	chr14:50662511~50663178:-
HNSC	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-4.8	2.11e-06	0.000512	-0.28	-0.22	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
HNSC	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-4.8	2.12e-06	0.000513	-0.24	-0.22	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
HNSC	cis	rs2136613	0.728	rs10761676	ENSG00000238280.1	RP11-436D10.3	4.8	2.12e-06	0.000513	0.26	0.22	Selective IgA deficiency;	chr10:62863689	chr10:62793562~62805887:-
HNSC	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-4.8	2.12e-06	0.000513	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-4.8	2.12e-06	0.000513	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
HNSC	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-4.8	2.12e-06	0.000513	-0.19	-0.22	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
HNSC	cis	rs9353324	1	rs9450372	ENSG00000203875.9	SNHG5	-4.8	2.12e-06	0.000514	-0.48	-0.22	Interferon gamma-induced protein 10 levels;	chr6:86027230	chr6:85660950~85678736:-
HNSC	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-4.8	2.12e-06	0.000514	-0.25	-0.22	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
HNSC	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-4.8	2.12e-06	0.000514	-0.25	-0.22	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
HNSC	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-4.8	2.12e-06	0.000514	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000254174.1	IGHV1-12	4.8	2.12e-06	0.000514	0.18	0.22	Alzheimer's disease (late onset);	chr14:106704673	chr14:106122420~106122709:-
HNSC	cis	rs10995505	0.578	rs1533068	ENSG00000232075.1	MRPL35P2	-4.8	2.12e-06	0.000514	-0.28	-0.22	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63634317~63634827:-
HNSC	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-4.8	2.13e-06	0.000515	-0.28	-0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
HNSC	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	4.8	2.13e-06	0.000515	0.27	0.22	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
HNSC	cis	rs2253762	0.507	rs4752630	ENSG00000226864.1	ATE1-AS1	4.8	2.13e-06	0.000515	0.35	0.22	Breast cancer;	chr10:121991440	chr10:121928312~121951965:+
HNSC	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	4.8	2.13e-06	0.000515	0.3	0.22	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
HNSC	cis	rs712039	0.652	rs67879888	ENSG00000276054.1	RP11-378E13.3	4.8	2.13e-06	0.000515	0.3	0.22	Tuberculosis;	chr17:37435211	chr17:37386886~37387926:+
HNSC	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	4.8	2.13e-06	0.000515	0.3	0.22	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
HNSC	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	4.8	2.13e-06	0.000515	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	4.8	2.13e-06	0.000515	0.26	0.22	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
HNSC	cis	rs1707322	1	rs7547189	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs7547284	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211205	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660895	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660318	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10890360	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs6682683	ENSG00000234329.1	RP11-767N6.2	4.8	2.13e-06	0.000515	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45651039~45651826:-
HNSC	cis	rs9650657	0.645	rs9969657	ENSG00000269918.1	AF131215.9	4.8	2.13e-06	0.000515	0.21	0.22	Neuroticism;	chr8:10657768	chr8:11104691~11106704:-
HNSC	cis	rs1218582	0.772	rs2335408	ENSG00000270361.1	RP11-307C12.13	-4.8	2.13e-06	0.000515	-0.24	-0.22	Prostate cancer;	chr1:154943501	chr1:154937370~154938059:+
HNSC	cis	rs3806843	0.897	rs2531338	ENSG00000202515.1	VTRNA1-3	4.8	2.13e-06	0.000516	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr5:140726158~140726246:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-4.8	2.13e-06	0.000516	-0.29	-0.22	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
HNSC	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	4.8	2.13e-06	0.000516	0.27	0.22	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
HNSC	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-4.8	2.13e-06	0.000516	-0.24	-0.22	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
HNSC	cis	rs9402743	0.634	rs2327647	ENSG00000234084.1	RP3-388E23.2	4.8	2.13e-06	0.000517	0.22	0.22	Systemic lupus erythematosus;	chr6:135597296	chr6:135301568~135307158:+
HNSC	cis	rs12935418	0.583	rs2549841	ENSG00000261061.1	RP11-303E16.2	4.8	2.13e-06	0.000517	0.23	0.22	Mean corpuscular volume;	chr16:80989967	chr16:81030770~81031485:+
HNSC	cis	rs6723108	0.517	rs3739029	ENSG00000224043.6	CCNT2-AS1	-4.8	2.14e-06	0.000517	-0.25	-0.22	Type 2 diabetes;	chr2:134841837	chr2:134735464~134918710:-
HNSC	cis	rs2985684	1	rs56098064	ENSG00000258568.1	RHOQP1	4.8	2.14e-06	0.000517	0.22	0.22	Carotid intima media thickness;	chr14:49639131	chr14:49599994~49600572:+
HNSC	cis	rs4803480	0.872	rs10420470	ENSG00000270164.1	LINC01480	-4.8	2.14e-06	0.000517	-0.2	-0.22	Schizophrenia;	chr19:41567075	chr19:41535183~41536904:+
HNSC	cis	rs2361718	0.501	rs11869566	ENSG00000275479.1	RP11-334C17.6	4.8	2.14e-06	0.000517	0.25	0.22	Yeast infection;	chr17:80169449	chr17:80149627~80149798:+
HNSC	cis	rs9863	0.861	rs4765219	ENSG00000269938.1	RP11-214K3.20	-4.8	2.14e-06	0.000517	-0.25	-0.22	White blood cell count;	chr12:123955563	chr12:123968023~123968579:-
HNSC	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-4.8	2.14e-06	0.000517	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
HNSC	cis	rs6693567	0.526	rs3818978	ENSG00000228126.1	FALEC	-4.8	2.14e-06	0.000517	-0.26	-0.22	Migraine;	chr1:150293918	chr1:150515757~150518032:+
HNSC	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-4.8	2.14e-06	0.000517	-0.38	-0.22	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
HNSC	cis	rs11687659	0.515	rs6725611	ENSG00000235852.1	AC005540.3	4.8	2.14e-06	0.000517	0.27	0.22	Immature fraction of reticulocytes;	chr2:190714299	chr2:190880797~190882059:-
HNSC	cis	rs9650657	0.665	rs7002117	ENSG00000269918.1	AF131215.9	4.8	2.14e-06	0.000518	0.21	0.22	Neuroticism;	chr8:10758659	chr8:11104691~11106704:-
HNSC	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-4.8	2.14e-06	0.000518	-0.28	-0.22	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000254340.1	RP11-10A14.3	4.8	2.14e-06	0.000518	0.26	0.22	Mood instability;	chr8:8520592	chr8:9141424~9145435:+
HNSC	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-4.8	2.14e-06	0.000518	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	4.8	2.14e-06	0.000518	0.27	0.22	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
HNSC	cis	rs17507216	0.56	rs28493687	ENSG00000255769.6	GOLGA2P10	-4.8	2.14e-06	0.000518	-0.27	-0.22	Excessive daytime sleepiness;	chr15:82560062	chr15:82472993~82513950:-
HNSC	cis	rs3811273	0.614	rs12588618	ENSG00000211816.2	TRAV38-1	-4.8	2.14e-06	0.000518	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22264645	chr14:22271968~22272563:+
HNSC	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	4.8	2.14e-06	0.000518	0.24	0.22	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
HNSC	cis	rs7688540	0.76	rs2883229	ENSG00000211553.1	AC253576.2	-4.8	2.14e-06	0.000518	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:136461~136568:+
HNSC	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-4.8	2.14e-06	0.000518	-0.18	-0.22	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
HNSC	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-4.8	2.14e-06	0.000518	-0.24	-0.22	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-4.8	2.14e-06	0.000518	-0.24	-0.22	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
HNSC	cis	rs7429990	0.932	rs6803741	ENSG00000228638.1	FCF1P2	4.8	2.14e-06	0.000519	0.2	0.22	Educational attainment (years of education);	chr3:48082050	chr3:48290793~48291375:-
HNSC	cis	rs6928977	0.802	rs2244745	ENSG00000234084.1	RP3-388E23.2	4.8	2.14e-06	0.000519	0.22	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341683	chr6:135301568~135307158:+
HNSC	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	4.8	2.15e-06	0.000519	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
HNSC	cis	rs6693567	0.545	rs1260391	ENSG00000228126.1	FALEC	4.8	2.15e-06	0.00052	0.26	0.22	Migraine;	chr1:150400601	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.526	rs834239	ENSG00000228126.1	FALEC	4.8	2.15e-06	0.00052	0.26	0.22	Migraine;	chr1:150402982	chr1:150515757~150518032:+
HNSC	cis	rs831571	0.703	rs55714137	ENSG00000280620.1	SCAANT1	4.8	2.15e-06	0.00052	0.35	0.22	Type 2 diabetes;	chr3:64091103	chr3:63911518~63911772:-
HNSC	cis	rs1479119	0.681	rs1479113	ENSG00000180861.8	LINC01559	4.8	2.15e-06	0.00052	0.28	0.22	Intelligence (multi-trait analysis);	chr12:13345046	chr12:13371089~13387167:-
HNSC	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-4.8	2.15e-06	0.00052	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
HNSC	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	4.8	2.15e-06	0.00052	0.2	0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
HNSC	cis	rs12468226	1	rs79919139	ENSG00000226261.1	AC064836.3	4.8	2.15e-06	0.00052	0.32	0.22	Urate levels;	chr2:202382786	chr2:202336024~202336727:-
HNSC	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-4.8	2.15e-06	0.000521	-0.24	-0.22	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-4.8	2.15e-06	0.000521	-0.24	-0.22	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
HNSC	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000521	0.29	0.22	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000521	0.29	0.22	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000521	0.29	0.22	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000521	0.29	0.22	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000521	0.29	0.22	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
HNSC	cis	rs73198271	0.586	rs3789850	ENSG00000253893.2	FAM85B	4.8	2.16e-06	0.000521	0.28	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8829335	chr8:8167819~8226614:-
HNSC	cis	rs3808502	0.549	rs11991139	ENSG00000269918.1	AF131215.9	-4.8	2.16e-06	0.000521	-0.21	-0.22	Neuroticism;	chr8:11570886	chr8:11104691~11106704:-
HNSC	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	4.8	2.16e-06	0.000521	0.31	0.22	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
HNSC	cis	rs2179367	0.6	rs9498352	ENSG00000216906.2	RP11-350J20.9	4.8	2.16e-06	0.000522	0.33	0.22	Dupuytren's disease;	chr6:149439108	chr6:149904243~149906418:+
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000276691.1	RP5-1057I20.5	4.8	2.16e-06	0.000522	0.42	0.22	Pneumonia;	chr12:47715623	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000276691.1	RP5-1057I20.5	4.8	2.16e-06	0.000522	0.42	0.22	Pneumonia;	chr12:47715885	chr12:47788426~47788971:+
HNSC	cis	rs73198271	0.74	rs10092600	ENSG00000173295.6	FAM86B3P	-4.8	2.16e-06	0.000522	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8228595~8244865:+
HNSC	cis	rs2998286	0.906	rs2807742	ENSG00000254635.4	WAC-AS1	-4.8	2.16e-06	0.000522	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28492438	chr10:28522652~28532743:-
HNSC	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-4.8	2.16e-06	0.000522	-0.24	-0.22	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
HNSC	cis	rs8032939	0.533	rs72729312	ENSG00000259747.1	RP11-275I4.2	-4.8	2.16e-06	0.000522	-0.27	-0.22	Rheumatoid arthritis;	chr15:38612345	chr15:38671847~38689191:+
HNSC	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	4.8	2.16e-06	0.000522	0.28	0.22	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
HNSC	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	4.8	2.16e-06	0.000523	0.27	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
HNSC	cis	rs1707322	1	rs11211217	ENSG00000234329.1	RP11-767N6.2	4.8	2.16e-06	0.000523	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	4.8	2.16e-06	0.000523	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	4.8	2.16e-06	0.000523	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	4.8	2.16e-06	0.000523	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
HNSC	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	4.8	2.16e-06	0.000523	0.26	0.22	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
HNSC	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-4.8	2.16e-06	0.000523	-0.26	-0.22	Height;	chr2:46623011	chr2:46668870~46670778:+
HNSC	cis	rs11247915	0.622	rs36024412	ENSG00000236782.4	RP11-96L14.7	-4.8	2.17e-06	0.000523	-0.25	-0.22	Obesity-related traits;	chr1:26343953	chr1:26169947~26171821:-
HNSC	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
HNSC	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-4.8	2.17e-06	0.000523	-0.26	-0.22	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
HNSC	cis	rs9880211	0.613	rs34864445	ENSG00000273486.1	RP11-731C17.2	4.8	2.17e-06	0.000523	0.2	0.22	Height;Body mass index;	chr3:136104082	chr3:136837338~136839021:-
HNSC	cis	rs67981189	0.896	rs4048474	ENSG00000274818.1	RP1-292L20.3	4.8	2.17e-06	0.000524	0.25	0.22	Schizophrenia;	chr14:71060982	chr14:70906657~70907111:-
HNSC	cis	rs4819052	0.851	rs2838837	ENSG00000223768.1	LINC00205	-4.8	2.17e-06	0.000524	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45293285~45297354:+
HNSC	cis	rs3806843	0.932	rs2563257	ENSG00000202515.1	VTRNA1-3	4.8	2.17e-06	0.000524	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr5:140726158~140726246:+
HNSC	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-4.8	2.17e-06	0.000524	-0.24	-0.22	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
HNSC	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	4.8	2.17e-06	0.000524	0.3	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	4.8	2.17e-06	0.000524	0.3	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
HNSC	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	4.8	2.17e-06	0.000524	0.24	0.22	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
HNSC	cis	rs1707322	1	rs6675222	ENSG00000234329.1	RP11-767N6.2	4.8	2.17e-06	0.000524	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45651039~45651826:-
HNSC	cis	rs17428076	0.836	rs12622895	ENSG00000228389.1	AC068039.4	4.8	2.17e-06	0.000524	0.25	0.22	Myopia;	chr2:171829794	chr2:171773482~171775844:+
HNSC	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-4.8	2.17e-06	0.000524	-0.2	-0.22	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
HNSC	cis	rs79349575	0.716	rs595767	ENSG00000270781.1	RP11-501C14.9	-4.8	2.17e-06	0.000524	-0.23	-0.22	Type 2 diabetes;	chr17:48880625	chr17:48899131~48899748:+
HNSC	cis	rs73222236	0.825	rs9858457	ENSG00000273486.1	RP11-731C17.2	4.8	2.17e-06	0.000525	0.18	0.22	Coronary artery disease;	chr3:136530735	chr3:136837338~136839021:-
HNSC	cis	rs3096299	0.967	rs753852	ENSG00000261574.1	RP1-168P16.2	4.8	2.17e-06	0.000525	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89392375~89412564:-
HNSC	cis	rs755249	0.614	rs10888798	ENSG00000182109.6	RP11-69E11.4	-4.8	2.17e-06	0.000525	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39522280~39546187:-
HNSC	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	4.8	2.18e-06	0.000525	0.24	0.22	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
HNSC	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-4.8	2.18e-06	0.000525	-0.27	-0.22	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
HNSC	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.8	2.18e-06	0.000525	0.25	0.22	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
HNSC	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-4.8	2.18e-06	0.000525	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-4.8	2.18e-06	0.000525	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
HNSC	cis	rs1125355	0.656	rs72937298	ENSG00000204380.3	AC005042.4	4.8	2.18e-06	0.000526	0.24	0.22	Alzheimer's disease in APOE e4+ carriers;	chr2:158779536	chr2:158658337~158735002:-
HNSC	cis	rs10129255	0.719	rs7156660	ENSG00000211974.3	IGHV2-70	4.8	2.18e-06	0.000526	0.2	0.22	Kawasaki disease;	chr14:106673171	chr14:106723574~106724093:-
HNSC	cis	rs1913185	0.787	rs1449442	ENSG00000240032.1	RP11-274H2.3	-4.8	2.18e-06	0.000526	-0.39	-0.22	Obesity-related traits;	chr3:146082133	chr3:146066344~146069185:-
HNSC	cis	rs3806843	0.735	rs2530235	ENSG00000202515.1	VTRNA1-3	4.8	2.18e-06	0.000526	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr5:140726158~140726246:+
HNSC	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	4.8	2.18e-06	0.000526	0.39	0.22	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
HNSC	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	4.8	2.18e-06	0.000526	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
HNSC	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-4.8	2.18e-06	0.000527	-0.34	-0.22	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
HNSC	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-4.8	2.18e-06	0.000527	-0.34	-0.22	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
HNSC	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	4.8	2.18e-06	0.000527	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
HNSC	cis	rs6964833	0.935	rs13238996	ENSG00000184616.8	AC004166.6	4.8	2.18e-06	0.000527	0.27	0.22	Menarche (age at onset);	chr7:74655318	chr7:74906673~74913256:-
HNSC	cis	rs12893668	0.572	rs2273175	ENSG00000269940.1	RP11-73M18.7	4.8	2.18e-06	0.000527	0.21	0.22	Reticulocyte count;	chr14:103693804	chr14:103694560~103695170:+
HNSC	cis	rs7429990	0.932	rs7630685	ENSG00000228638.1	FCF1P2	4.8	2.18e-06	0.000527	0.21	0.22	Educational attainment (years of education);	chr3:48089680	chr3:48290793~48291375:-
HNSC	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	4.8	2.19e-06	0.000527	0.22	0.22	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
HNSC	cis	rs6831352	0.918	rs2851247	ENSG00000263923.1	RP11-571L19.7	4.8	2.19e-06	0.000528	0.24	0.22	Alcohol dependence;	chr4:99124940	chr4:98928897~98994994:+
HNSC	cis	rs1971762	0.545	rs876252	ENSG00000270175.1	RP11-793H13.11	-4.8	2.19e-06	0.000528	-0.19	-0.22	Height;	chr12:53677638	chr12:53500162~53500936:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	4.8	2.19e-06	0.000528	0.22	0.22	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
HNSC	cis	rs577676	0.564	rs644784	ENSG00000271811.1	RP1-79C4.4	4.79	2.19e-06	0.000529	0.24	0.22	Prevalent atrial fibrillation;	chr1:170636945	chr1:170667381~170669425:+
HNSC	cis	rs2179367	0.6	rs9498353	ENSG00000216906.2	RP11-350J20.9	4.79	2.19e-06	0.000529	0.33	0.22	Dupuytren's disease;	chr6:149439860	chr6:149904243~149906418:+
HNSC	cis	rs4862750	0.914	rs11945845	ENSG00000250971.1	RP11-696F12.1	4.79	2.19e-06	0.000529	0.25	0.22	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:187060099~187060930:+
HNSC	cis	rs933688	1	rs1035477	ENSG00000281357.1	ARRDC3-AS1	4.79	2.19e-06	0.000529	0.32	0.22	Smoking behavior;	chr5:91447508	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs1964292	ENSG00000281357.1	ARRDC3-AS1	4.79	2.19e-06	0.000529	0.32	0.22	Smoking behavior;	chr5:91447791	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs985434	ENSG00000281357.1	ARRDC3-AS1	4.79	2.19e-06	0.000529	0.32	0.22	Smoking behavior;	chr5:91448692	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs7720132	ENSG00000281357.1	ARRDC3-AS1	4.79	2.19e-06	0.000529	0.32	0.22	Smoking behavior;	chr5:91449288	chr5:91380349~91439085:+
HNSC	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	4.79	2.19e-06	0.000529	0.27	0.22	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	4.79	2.19e-06	0.000529	0.27	0.22	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
HNSC	cis	rs10435719	0.805	rs13269417	ENSG00000255495.1	AC145124.2	4.79	2.2e-06	0.00053	0.25	0.22	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:12194467~12196280:+
HNSC	cis	rs6714900	0.619	rs9636399	ENSG00000234896.1	OR7E62P	4.79	2.2e-06	0.00053	0.26	0.22	Blood protein levels;	chr2:71061782	chr2:71055527~71056003:+
HNSC	cis	rs1012068	0.547	rs5998141	ENSG00000236132.1	CTA-440B3.1	-4.79	2.2e-06	0.00053	-0.27	-0.22	Chronic hepatitis C infection;	chr22:31848254	chr22:31816379~31817491:-
HNSC	cis	rs7615952	0.599	rs2333408	ENSG00000241439.1	RP11-666A20.3	4.79	2.2e-06	0.00053	0.24	0.22	Blood pressure (smoking interaction);	chr3:126013255	chr3:125958556~125958817:+
HNSC	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	4.79	2.2e-06	0.000531	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
HNSC	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-4.79	2.2e-06	0.000531	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-4.79	2.2e-06	0.000531	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
HNSC	cis	rs6604026	0.922	rs66525381	ENSG00000223787.2	RP4-593M8.1	4.79	2.2e-06	0.000531	0.29	0.22	Multiple sclerosis;	chr1:92831207	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.922	rs34244251	ENSG00000223787.2	RP4-593M8.1	4.79	2.2e-06	0.000531	0.29	0.22	Multiple sclerosis;	chr1:92831623	chr1:92580476~92580821:-
HNSC	cis	rs2834288	0.535	rs8129694	ENSG00000273102.1	AP000569.9	-4.79	2.2e-06	0.000531	-0.24	-0.22	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33967101~33968573:-
HNSC	cis	rs67981189	0.896	rs58133478	ENSG00000274818.1	RP1-292L20.3	4.79	2.2e-06	0.000531	0.25	0.22	Schizophrenia;	chr14:71058370	chr14:70906657~70907111:-
HNSC	cis	rs116095464	0.558	rs10475136	ENSG00000250848.1	CTD-2083E4.5	-4.79	2.2e-06	0.000531	-0.3	-0.22	Breast cancer;	chr5:232681	chr5:288833~290321:-
HNSC	cis	rs73198271	0.74	rs10105690	ENSG00000173295.6	FAM86B3P	-4.79	2.2e-06	0.000531	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8228595~8244865:+
HNSC	cis	rs6586111	1	rs7097564	ENSG00000226659.1	RP11-137H2.4	-4.79	2.21e-06	0.000532	-0.26	-0.22	Capecitabine sensitivity;	chr10:80612432	chr10:80529597~80535942:-
HNSC	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	4.79	2.21e-06	0.000532	0.26	0.22	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
HNSC	cis	rs1799949	0.965	rs4793237	ENSG00000236383.6	LINC00854	-4.79	2.21e-06	0.000532	-0.21	-0.22	Menopause (age at onset);	chr17:43359227	chr17:43216941~43305976:-
HNSC	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-4.79	2.21e-06	0.000532	-0.27	-0.22	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
HNSC	cis	rs2548724	0.648	rs6893520	ENSG00000250682.4	LINC00491	-4.79	2.21e-06	0.000533	-0.27	-0.22	Type 2 diabetes;	chr5:102315157	chr5:102609156~102671559:-
HNSC	cis	rs11098499	0.691	rs28396837	ENSG00000249244.1	RP11-548H18.2	4.79	2.21e-06	0.000533	0.26	0.22	Corneal astigmatism;	chr4:119350386	chr4:119391831~119395335:-
HNSC	cis	rs3805389	0.504	rs28416150	ENSG00000273257.1	RP11-177J6.1	-4.79	2.21e-06	0.000533	-0.34	-0.22	Waist-to-hip ratio adjusted for body mass index;	chr4:55608211	chr4:55387949~55388271:+
HNSC	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	4.79	2.21e-06	0.000533	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
HNSC	cis	rs3733585	0.699	rs7686538	ENSG00000250413.1	RP11-448G15.1	4.79	2.21e-06	0.000533	0.27	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9946453	chr4:10006482~10009725:+
HNSC	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-4.79	2.21e-06	0.000533	-0.21	-0.22	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	4.79	2.21e-06	0.000533	0.26	0.22	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
HNSC	cis	rs8058578	1	rs67456513	ENSG00000279196.1	RP11-1072A3.3	4.79	2.21e-06	0.000534	0.26	0.22	Multiple myeloma;	chr16:30703507	chr16:30984630~30988270:-
HNSC	cis	rs889398	0.771	rs1566453	ENSG00000226232.7	RP11-419C5.2	-4.79	2.21e-06	0.000534	-0.19	-0.22	Body mass index;	chr16:69865884	chr16:69976388~69996188:-
HNSC	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	4.79	2.22e-06	0.000534	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
HNSC	cis	rs763121	0.853	rs3788545	ENSG00000273076.1	RP3-508I15.22	4.79	2.22e-06	0.000534	0.23	0.22	Menopause (age at onset);	chr22:38669167	chr22:38743495~38743910:+
HNSC	cis	rs13217239	0.646	rs12209886	ENSG00000224843.5	LINC00240	-4.79	2.22e-06	0.000534	-0.21	-0.22	Schizophrenia;	chr6:27016978	chr6:26956992~27023924:+
HNSC	cis	rs6940638	0.531	rs12211984	ENSG00000224843.5	LINC00240	-4.79	2.22e-06	0.000534	-0.21	-0.22	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs10456351	ENSG00000224843.5	LINC00240	-4.79	2.22e-06	0.000534	-0.21	-0.22	Schizophrenia;	chr6:27019013	chr6:26956992~27023924:+
HNSC	cis	rs9291683	0.507	rs3775940	ENSG00000250413.1	RP11-448G15.1	-4.79	2.22e-06	0.000534	-0.26	-0.22	Bone mineral density;	chr4:10023539	chr4:10006482~10009725:+
HNSC	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	4.79	2.22e-06	0.000534	0.19	0.22	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
HNSC	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	4.79	2.22e-06	0.000534	0.25	0.22	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
HNSC	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-4.79	2.22e-06	0.000534	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs12025847	ENSG00000182109.6	RP11-69E11.4	-4.79	2.22e-06	0.000534	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39522280~39546187:-
HNSC	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-4.79	2.22e-06	0.000534	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
HNSC	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-4.79	2.22e-06	0.000534	-0.26	-0.22	Height;	chr20:49283115	chr20:49280319~49280409:+
HNSC	cis	rs8032939	0.502	rs16967112	ENSG00000259747.1	RP11-275I4.2	4.79	2.22e-06	0.000534	0.27	0.22	Rheumatoid arthritis;	chr15:38611471	chr15:38671847~38689191:+
HNSC	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-4.79	2.22e-06	0.000534	-0.41	-0.22	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
HNSC	cis	rs4356203	0.735	rs12420407	ENSG00000260196.1	RP1-239B22.5	4.79	2.22e-06	0.000534	0.25	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17227409	chr11:17380649~17383531:+
HNSC	cis	rs3806843	0.898	rs3756335	ENSG00000202515.1	VTRNA1-3	-4.79	2.22e-06	0.000535	-0.24	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr5:140726158~140726246:+
HNSC	cis	rs12682352	0.602	rs6993494	ENSG00000254340.1	RP11-10A14.3	4.79	2.22e-06	0.000535	0.27	0.22	Neuroticism;	chr8:8809934	chr8:9141424~9145435:+
HNSC	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	4.79	2.22e-06	0.000535	0.25	0.22	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
HNSC	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	4.79	2.22e-06	0.000535	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	4.79	2.22e-06	0.000535	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
HNSC	cis	rs1404100	0.51	rs1038273	ENSG00000249274.1	PDLIM1P4	4.79	2.22e-06	0.000535	0.25	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067757	chr3:98782188~98783193:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-4.79	2.22e-06	0.000535	-0.29	-0.22	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
HNSC	cis	rs75422866	0.867	rs73104112	ENSG00000257433.4	RP1-197B17.3	4.79	2.22e-06	0.000535	0.47	0.22	Pneumonia;	chr12:47680969	chr12:47706085~47742294:+
HNSC	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-4.79	2.22e-06	0.000535	-0.22	-0.22	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
HNSC	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	4.79	2.22e-06	0.000536	0.24	0.22	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
HNSC	cis	rs656319	0.605	rs60278284	ENSG00000269918.1	AF131215.9	-4.79	2.23e-06	0.000536	-0.22	-0.22	Myopia (pathological);	chr8:10145700	chr8:11104691~11106704:-
HNSC	cis	rs9402743	0.631	rs9399158	ENSG00000217482.2	HMGB1P17	4.79	2.23e-06	0.000536	0.25	0.22	Systemic lupus erythematosus;	chr6:135727672	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.666	rs2038549	ENSG00000217482.2	HMGB1P17	4.79	2.23e-06	0.000536	0.25	0.22	Systemic lupus erythematosus;	chr6:135731810	chr6:135636086~135636713:-
HNSC	cis	rs9402743	0.666	rs2038550	ENSG00000217482.2	HMGB1P17	4.79	2.23e-06	0.000536	0.25	0.22	Systemic lupus erythematosus;	chr6:135731937	chr6:135636086~135636713:-
HNSC	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	4.79	2.23e-06	0.000537	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
HNSC	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-4.79	2.23e-06	0.000537	-0.24	-0.22	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-4.79	2.23e-06	0.000537	-0.24	-0.22	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
HNSC	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	4.79	2.23e-06	0.000537	0.22	0.22	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
HNSC	cis	rs988913	0.723	rs1393775	ENSG00000224984.1	RP11-524H19.2	4.79	2.23e-06	0.000537	0.25	0.22	Menarche (age at onset);	chr6:54987160	chr6:54840118~54840855:-
HNSC	cis	rs763121	0.752	rs6001190	ENSG00000273076.1	RP3-508I15.22	4.79	2.23e-06	0.000537	0.23	0.22	Menopause (age at onset);	chr22:38677806	chr22:38743495~38743910:+
HNSC	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	4.79	2.23e-06	0.000538	0.26	0.22	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
HNSC	cis	rs860295	0.702	rs3892792	ENSG00000203761.5	MSTO2P	-4.79	2.23e-06	0.000538	-0.17	-0.22	Body mass index;	chr1:155588874	chr1:155745829~155750137:+
HNSC	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	4.79	2.23e-06	0.000538	0.24	0.22	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
HNSC	cis	rs12893668	0.673	rs2296482	ENSG00000269940.1	RP11-73M18.7	4.79	2.23e-06	0.000538	0.22	0.22	Reticulocyte count;	chr14:103563482	chr14:103694560~103695170:+
HNSC	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-4.79	2.24e-06	0.000538	-0.26	-0.22	Height;	chr20:49287143	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-4.79	2.24e-06	0.000538	-0.26	-0.22	Height;	chr20:49291523	chr20:49280319~49280409:+
HNSC	cis	rs6964587	1	rs28927678	ENSG00000188693.7	CYP51A1-AS1	-4.79	2.24e-06	0.000538	-0.23	-0.22	Breast cancer;	chr7:92086348	chr7:92134604~92180725:+
HNSC	cis	rs11089937	0.522	rs2005239	ENSG00000211638.2	IGLV8-61	-4.79	2.24e-06	0.000538	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs743520	ENSG00000211638.2	IGLV8-61	-4.79	2.24e-06	0.000538	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs11705598	ENSG00000211638.2	IGLV8-61	-4.79	2.24e-06	0.000538	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22098700~22099212:+
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000254153.1	CTA-398F10.2	-4.79	2.24e-06	0.000538	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9012868	chr8:8456909~8461337:-
HNSC	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	4.79	2.24e-06	0.000538	0.25	0.22	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
HNSC	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	4.79	2.24e-06	0.000539	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	4.79	2.24e-06	0.000539	0.26	0.22	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
HNSC	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	4.79	2.24e-06	0.000539	0.26	0.22	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
HNSC	cis	rs6964587	1	rs10243241	ENSG00000188693.7	CYP51A1-AS1	-4.79	2.24e-06	0.000539	-0.23	-0.22	Breast cancer;	chr7:92076382	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs733957	ENSG00000188693.7	CYP51A1-AS1	-4.79	2.24e-06	0.000539	-0.23	-0.22	Breast cancer;	chr7:92077883	chr7:92134604~92180725:+
HNSC	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-4.79	2.24e-06	0.000539	-0.27	-0.22	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
HNSC	cis	rs13073817	0.601	rs10865753	ENSG00000228956.7	SATB1-AS1	4.79	2.24e-06	0.000539	0.23	0.22	Crohn's disease;	chr3:18643127	chr3:18445024~18920401:+
HNSC	cis	rs9650657	0.645	rs11774552	ENSG00000269918.1	AF131215.9	-4.79	2.24e-06	0.000539	-0.21	-0.22	Neuroticism;	chr8:10658169	chr8:11104691~11106704:-
HNSC	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	4.79	2.24e-06	0.00054	0.31	0.22	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	4.79	2.24e-06	0.00054	0.31	0.22	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
HNSC	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	4.79	2.25e-06	0.00054	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
HNSC	cis	rs9329221	0.507	rs12678938	ENSG00000255310.2	AF131215.2	-4.79	2.25e-06	0.00054	-0.21	-0.22	Neuroticism;	chr8:10159459	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-4.79	2.25e-06	0.00054	-0.26	-0.22	Depression;	chr6:28110254	chr6:28170845~28172521:+
HNSC	cis	rs6723108	0.603	rs6708336	ENSG00000224043.6	CCNT2-AS1	-4.79	2.25e-06	0.00054	-0.27	-0.22	Type 2 diabetes;	chr2:134961562	chr2:134735464~134918710:-
HNSC	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	4.79	2.25e-06	0.000541	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	4.79	2.25e-06	0.000541	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	4.79	2.25e-06	0.000541	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
HNSC	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	4.79	2.25e-06	0.000541	0.26	0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
HNSC	cis	rs12682352	0.602	rs6988939	ENSG00000254340.1	RP11-10A14.3	4.79	2.25e-06	0.000541	0.26	0.22	Neuroticism;	chr8:8809406	chr8:9141424~9145435:+
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000276691.1	RP5-1057I20.5	4.79	2.25e-06	0.000541	0.42	0.22	Pneumonia;	chr12:47713550	chr12:47788426~47788971:+
HNSC	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-4.79	2.25e-06	0.000541	-0.28	-0.22	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
HNSC	cis	rs9863	0.828	rs71458830	ENSG00000269938.1	RP11-214K3.20	-4.79	2.25e-06	0.000541	-0.25	-0.22	White blood cell count;	chr12:123992014	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.828	rs12809473	ENSG00000269938.1	RP11-214K3.20	-4.79	2.25e-06	0.000541	-0.25	-0.22	White blood cell count;	chr12:123992052	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.828	rs12827409	ENSG00000269938.1	RP11-214K3.20	-4.79	2.25e-06	0.000541	-0.25	-0.22	White blood cell count;	chr12:123992159	chr12:123968023~123968579:-
HNSC	cis	rs12893668	0.616	rs58033365	ENSG00000269940.1	RP11-73M18.7	4.79	2.25e-06	0.000541	0.22	0.22	Reticulocyte count;	chr14:103564564	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.645	rs12889403	ENSG00000269940.1	RP11-73M18.7	4.79	2.25e-06	0.000541	0.22	0.22	Reticulocyte count;	chr14:103568409	chr14:103694560~103695170:+
HNSC	cis	rs12893668	0.703	rs12894729	ENSG00000269940.1	RP11-73M18.7	4.79	2.25e-06	0.000541	0.22	0.22	Reticulocyte count;	chr14:103568955	chr14:103694560~103695170:+
HNSC	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	4.79	2.25e-06	0.000541	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
HNSC	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-4.79	2.25e-06	0.000541	-0.5	-0.22	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000224373.3	IGHV4-59	4.79	2.25e-06	0.000541	0.14	0.22	Kawasaki disease;	chr14:106670217	chr14:106627249~106627825:-
HNSC	cis	rs442309	0.687	rs7084016	ENSG00000238280.1	RP11-436D10.3	-4.79	2.25e-06	0.000542	-0.26	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62720681	chr10:62793562~62805887:-
HNSC	cis	rs9329221	0.87	rs11777976	ENSG00000269918.1	AF131215.9	-4.79	2.25e-06	0.000542	-0.21	-0.22	Neuroticism;	chr8:10397892	chr8:11104691~11106704:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-4.79	2.26e-06	0.000542	-0.28	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000254153.1	CTA-398F10.2	-4.79	2.26e-06	0.000542	-0.24	-0.22	Mood instability;	chr8:8939545	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000254153.1	CTA-398F10.2	-4.79	2.26e-06	0.000542	-0.24	-0.22	Mood instability;	chr8:8939563	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000254153.1	CTA-398F10.2	-4.79	2.26e-06	0.000542	-0.24	-0.22	Mood instability;	chr8:8939568	chr8:8456909~8461337:-
HNSC	cis	rs8031584	1	rs35811129	ENSG00000260382.1	RP11-540B6.2	4.79	2.26e-06	0.000543	0.29	0.22	Huntington's disease progression;	chr15:30949143	chr15:30882267~30883231:-
HNSC	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	4.79	2.26e-06	0.000543	0.19	0.22	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
HNSC	cis	rs12468226	0.935	rs75597391	ENSG00000226261.1	AC064836.3	4.79	2.26e-06	0.000543	0.32	0.22	Urate levels;	chr2:202398850	chr2:202336024~202336727:-
HNSC	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-4.79	2.26e-06	0.000543	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-4.79	2.26e-06	0.000543	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-4.79	2.26e-06	0.000543	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-4.79	2.26e-06	0.000543	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
HNSC	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-4.79	2.26e-06	0.000543	-0.24	-0.22	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
HNSC	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	4.79	2.26e-06	0.000544	0.29	0.22	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
HNSC	cis	rs11098499	0.863	rs10019674	ENSG00000250412.1	KLHL2P1	-4.79	2.26e-06	0.000544	-0.28	-0.22	Corneal astigmatism;	chr4:119522334	chr4:119334329~119378233:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	4.79	2.26e-06	0.000544	0.27	0.22	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
HNSC	cis	rs9880211	0.613	rs1393786	ENSG00000273486.1	RP11-731C17.2	4.79	2.26e-06	0.000544	0.2	0.22	Height;Body mass index;	chr3:136135193	chr3:136837338~136839021:-
HNSC	cis	rs6723108	0.603	rs62168897	ENSG00000224043.6	CCNT2-AS1	-4.79	2.26e-06	0.000544	-0.27	-0.22	Type 2 diabetes;	chr2:134960427	chr2:134735464~134918710:-
HNSC	cis	rs7246760	1	rs2081066	ENSG00000267289.1	CTD-2623N2.11	4.79	2.26e-06	0.000544	0.35	0.22	Pursuit maintenance gain;	chr19:9817368	chr19:9834079~9835013:-
HNSC	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-4.79	2.27e-06	0.000544	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-4.79	2.27e-06	0.000544	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
HNSC	cis	rs1056107	0.763	rs7024998	ENSG00000225513.1	RP11-165N19.2	-4.79	2.27e-06	0.000544	-0.23	-0.22	Colorectal cancer;	chr9:112175379	chr9:112173522~112173971:-
HNSC	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	4.79	2.27e-06	0.000544	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
HNSC	cis	rs6723108	0.627	rs3814358	ENSG00000224043.6	CCNT2-AS1	-4.79	2.27e-06	0.000544	-0.27	-0.22	Type 2 diabetes;	chr2:134866438	chr2:134735464~134918710:-
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	4.79	2.27e-06	0.000544	0.16	0.22	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
HNSC	cis	rs7746199	0.736	rs17693963	ENSG00000219392.1	RP1-265C24.5	-4.79	2.27e-06	0.000545	-0.4	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28115628~28116551:+
HNSC	cis	rs1008375	0.8	rs10008598	ENSG00000249502.1	AC006160.5	-4.79	2.27e-06	0.000545	-0.23	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17605700	chr4:17587467~17614571:-
HNSC	cis	rs12935418	0.672	rs9889194	ENSG00000261061.1	RP11-303E16.2	-4.79	2.27e-06	0.000545	-0.24	-0.22	Mean corpuscular volume;	chr16:81017212	chr16:81030770~81031485:+
HNSC	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	4.79	2.27e-06	0.000545	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
HNSC	cis	rs9402743	0.634	rs7765113	ENSG00000234084.1	RP3-388E23.2	-4.79	2.27e-06	0.000545	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135598935	chr6:135301568~135307158:+
HNSC	cis	rs2834288	0.535	rs8132681	ENSG00000273102.1	AP000569.9	4.79	2.27e-06	0.000545	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33967101~33968573:-
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	4.79	2.27e-06	0.000545	0.26	0.22	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	4.79	2.27e-06	0.000545	0.26	0.22	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	4.79	2.27e-06	0.000545	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
HNSC	cis	rs916888	0.773	rs199535	ENSG00000260075.1	NSFP1	-4.79	2.27e-06	0.000545	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46372855~46487141:+
HNSC	cis	rs6714900	0.53	rs13010446	ENSG00000234896.1	OR7E62P	-4.79	2.27e-06	0.000546	-0.26	-0.22	Blood protein levels;	chr2:71063957	chr2:71055527~71056003:+
HNSC	cis	rs7023329	0.59	rs6475566	ENSG00000244230.3	RN7SL151P	-4.79	2.27e-06	0.000546	-0.22	-0.22	Melanoma;	chr9:21733501	chr9:21699314~21699596:+
HNSC	cis	rs6723108	0.604	rs1374291	ENSG00000224043.6	CCNT2-AS1	-4.79	2.27e-06	0.000546	-0.26	-0.22	Type 2 diabetes;	chr2:134896768	chr2:134735464~134918710:-
HNSC	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	4.79	2.27e-06	0.000546	0.3	0.22	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	4.79	2.27e-06	0.000546	0.3	0.22	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	4.79	2.27e-06	0.000546	0.3	0.22	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
HNSC	cis	rs853679	0.607	rs13211507	ENSG00000219392.1	RP1-265C24.5	-4.79	2.27e-06	0.000546	-0.43	-0.22	Depression;	chr6:28289600	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs34691223	ENSG00000219392.1	RP1-265C24.5	-4.79	2.27e-06	0.000546	-0.43	-0.22	Depression;	chr6:28290431	chr6:28115628~28116551:+
HNSC	cis	rs577676	0.586	rs656539	ENSG00000271811.1	RP1-79C4.4	4.79	2.27e-06	0.000546	0.24	0.22	Prevalent atrial fibrillation;	chr1:170637213	chr1:170667381~170669425:+
HNSC	cis	rs889398	0.741	rs7192213	ENSG00000226232.7	RP11-419C5.2	-4.79	2.27e-06	0.000546	-0.19	-0.22	Body mass index;	chr16:69892377	chr16:69976388~69996188:-
HNSC	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	4.79	2.27e-06	0.000546	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
HNSC	cis	rs60822569	1	rs60822569	ENSG00000248265.1	FLJ12825	4.79	2.27e-06	0.000546	0.25	0.22	Mean platelet volume;	chr12:54323724	chr12:54058254~54122234:+
HNSC	cis	rs1008375	0.863	rs7680984	ENSG00000249502.1	AC006160.5	-4.79	2.28e-06	0.000547	-0.23	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17599261	chr4:17587467~17614571:-
HNSC	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	4.79	2.28e-06	0.000547	0.21	0.22	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
HNSC	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-4.79	2.28e-06	0.000547	-0.33	-0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
HNSC	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	4.79	2.28e-06	0.000547	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	4.79	2.28e-06	0.000547	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
HNSC	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-4.79	2.28e-06	0.000547	-0.28	-0.22	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
HNSC	cis	rs755249	0.565	rs1809697	ENSG00000182109.6	RP11-69E11.4	-4.79	2.28e-06	0.000548	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39522280~39546187:-
HNSC	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	4.79	2.28e-06	0.000548	0.24	0.22	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
HNSC	cis	rs597539	0.552	rs6591360	ENSG00000255741.1	RP11-757G1.5	-4.79	2.28e-06	0.000548	-0.3	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68941503~68942852:-
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-4.79	2.28e-06	0.000548	-0.26	-0.22	Depression;	chr6:28113616	chr6:28170845~28172521:+
HNSC	cis	rs10466239	0.803	rs10899794	ENSG00000230555.2	RP11-517P14.2	4.79	2.28e-06	0.000548	0.31	0.22	Telomere length;	chr10:43371916	chr10:43420738~43422100:+
HNSC	cis	rs3806843	0.735	rs2530242	ENSG00000202515.1	VTRNA1-3	4.79	2.28e-06	0.000548	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.735	rs2530241	ENSG00000202515.1	VTRNA1-3	4.79	2.28e-06	0.000548	0.25	0.22	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr5:140726158~140726246:+
HNSC	cis	rs11638352	1	rs2412854	ENSG00000205771.5	CATSPER2P1	4.79	2.28e-06	0.000548	0.56	0.22	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43726918~43747094:-
HNSC	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	4.79	2.28e-06	0.000548	0.27	0.22	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
HNSC	cis	rs10483853	0.579	rs10134243	ENSG00000258695.2	RP3-414A15.2	-4.79	2.29e-06	0.000549	-0.29	-0.22	Coronary artery calcification;	chr14:73478444	chr14:73522878~73530610:+
HNSC	cis	rs2337406	0.866	rs4280141	ENSG00000254174.1	IGHV1-12	-4.79	2.29e-06	0.000549	-0.18	-0.22	Alzheimer's disease (late onset);	chr14:106780476	chr14:106122420~106122709:-
HNSC	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-4.79	2.29e-06	0.00055	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
HNSC	cis	rs916888	0.773	rs169201	ENSG00000260075.1	NSFP1	-4.79	2.29e-06	0.00055	-0.32	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46372855~46487141:+
HNSC	cis	rs427691	0.625	rs370575	ENSG00000271849.1	CTC-332L22.1	-4.79	2.29e-06	0.00055	-0.33	-0.22	Autism spectrum disorder or schizophrenia;	chr5:109675587	chr5:109687802~109688329:-
HNSC	cis	rs2998286	0.723	rs332177	ENSG00000254635.4	WAC-AS1	-4.79	2.29e-06	0.00055	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28618221	chr10:28522652~28532743:-
HNSC	cis	rs2253762	0.507	rs10159582	ENSG00000226864.1	ATE1-AS1	4.79	2.29e-06	0.00055	0.36	0.22	Breast cancer;	chr10:121993110	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.507	rs10159583	ENSG00000226864.1	ATE1-AS1	4.79	2.29e-06	0.00055	0.36	0.22	Breast cancer;	chr10:121993154	chr10:121928312~121951965:+
HNSC	cis	rs1971762	0.527	rs6580958	ENSG00000270175.1	RP11-793H13.11	-4.79	2.29e-06	0.00055	-0.19	-0.22	Height;	chr12:53679699	chr12:53500162~53500936:-
HNSC	cis	rs14027	0.64	rs7009073	ENSG00000279347.1	RP11-85I17.2	-4.79	2.29e-06	0.00055	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119769677	chr8:119838736~119840385:-
HNSC	cis	rs4388249	0.651	rs253245	ENSG00000271849.1	CTC-332L22.1	-4.79	2.29e-06	0.000551	-0.35	-0.22	Schizophrenia;	chr5:109668499	chr5:109687802~109688329:-
HNSC	cis	rs14027	0.64	rs2043431	ENSG00000279347.1	RP11-85I17.2	-4.79	2.3e-06	0.000551	-0.18	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119736214	chr8:119838736~119840385:-
HNSC	cis	rs7615952	0.576	rs2276727	ENSG00000241439.1	RP11-666A20.3	4.79	2.3e-06	0.000551	0.24	0.22	Blood pressure (smoking interaction);	chr3:126107400	chr3:125958556~125958817:+
HNSC	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-4.78	2.3e-06	0.000551	-0.26	-0.22	Height;	chr20:49282523	chr20:49280319~49280409:+
HNSC	cis	rs6723108	0.603	rs56271357	ENSG00000224043.6	CCNT2-AS1	-4.78	2.3e-06	0.000551	-0.27	-0.22	Type 2 diabetes;	chr2:134963145	chr2:134735464~134918710:-
HNSC	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-4.78	2.3e-06	0.000551	-0.27	-0.22	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
HNSC	cis	rs9650657	0.645	rs56057779	ENSG00000269918.1	AF131215.9	-4.78	2.3e-06	0.000552	-0.21	-0.22	Neuroticism;	chr8:10659370	chr8:11104691~11106704:-
HNSC	cis	rs7160336	0.738	rs7161721	ENSG00000259065.1	RP5-1021I20.1	-4.78	2.3e-06	0.000552	-0.25	-0.22	Blood protein levels;	chr14:74031630	chr14:73787360~73803270:+
HNSC	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-4.78	2.3e-06	0.000552	-0.24	-0.22	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
HNSC	cis	rs116095464	0.558	rs28729548	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:228910	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9688136	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:229233	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs62347683	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:230216	chr5:288833~290321:-
HNSC	cis	rs116095464	0.51	rs55750776	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:230352	chr5:288833~290321:-
HNSC	cis	rs116095464	0.764	rs10069197	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:230707	chr5:288833~290321:-
HNSC	cis	rs116095464	0.867	rs10074958	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.3e-06	0.000552	-0.3	-0.22	Breast cancer;	chr5:230713	chr5:288833~290321:-
HNSC	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-4.78	2.3e-06	0.000552	-0.3	-0.22	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
HNSC	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-4.78	2.3e-06	0.000552	-0.28	-0.22	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
HNSC	cis	rs2834288	0.536	rs762356	ENSG00000273102.1	AP000569.9	4.78	2.3e-06	0.000552	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33967101~33968573:-
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000254340.1	RP11-10A14.3	-4.78	2.3e-06	0.000553	-0.27	-0.22	Mood instability;	chr8:8740878	chr8:9141424~9145435:+
HNSC	cis	rs4873772	0.735	rs11784823	ENSG00000253330.1	RP11-697N18.3	4.78	2.31e-06	0.000553	0.27	0.22	Lobe attachment (rater-scored or self-reported);	chr8:47498758	chr8:47511034~47512141:-
HNSC	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-4.78	2.31e-06	0.000554	-0.21	-0.22	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
HNSC	cis	rs712039	0.652	rs829163	ENSG00000276054.1	RP11-378E13.3	4.78	2.31e-06	0.000554	0.31	0.22	Tuberculosis;	chr17:37405936	chr17:37386886~37387926:+
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	-4.78	2.31e-06	0.000554	-0.27	-0.22	Depression;	chr6:28184805	chr6:28161781~28169594:+
HNSC	cis	rs6674176	0.66	rs11210936	ENSG00000237950.1	RP11-7O11.3	4.78	2.31e-06	0.000554	0.25	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43925766	chr1:43944370~43946551:-
HNSC	cis	rs11951515	0.508	rs10059993	ENSG00000249286.1	CTD-2210P15.2	4.78	2.31e-06	0.000554	0.22	0.22	Metabolite levels  (X-11787);	chr5:43598250	chr5:43586918~43588223:-
HNSC	cis	rs12291225	0.585	rs4517475	ENSG00000251991.1	RNU7-49P	4.78	2.31e-06	0.000554	0.25	0.22	Sense of smell;	chr11:14364599	chr11:14478892~14478953:+
HNSC	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	4.78	2.31e-06	0.000554	0.31	0.22	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
HNSC	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-4.78	2.31e-06	0.000554	-0.28	-0.22	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
HNSC	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-4.78	2.31e-06	0.000554	-0.25	-0.22	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
HNSC	cis	rs9863	0.828	rs75989601	ENSG00000269938.1	RP11-214K3.20	-4.78	2.31e-06	0.000554	-0.25	-0.22	White blood cell count;	chr12:123982176	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.828	rs35099862	ENSG00000269938.1	RP11-214K3.20	-4.78	2.31e-06	0.000554	-0.25	-0.22	White blood cell count;	chr12:123982657	chr12:123968023~123968579:-
HNSC	cis	rs6964587	1	rs6952389	ENSG00000188693.7	CYP51A1-AS1	-4.78	2.31e-06	0.000555	-0.23	-0.22	Breast cancer;	chr7:92028680	chr7:92134604~92180725:+
HNSC	cis	rs6723108	0.603	rs6733130	ENSG00000224043.6	CCNT2-AS1	-4.78	2.32e-06	0.000555	-0.27	-0.22	Type 2 diabetes;	chr2:134908983	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs1374287	ENSG00000224043.6	CCNT2-AS1	-4.78	2.32e-06	0.000555	-0.27	-0.22	Type 2 diabetes;	chr2:134909631	chr2:134735464~134918710:-
HNSC	cis	rs9863	0.931	rs4930721	ENSG00000269938.1	RP11-214K3.20	-4.78	2.32e-06	0.000555	-0.27	-0.22	White blood cell count;	chr12:123933342	chr12:123968023~123968579:-
HNSC	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	4.78	2.32e-06	0.000555	0.24	0.22	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
HNSC	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.78	2.32e-06	0.000555	0.19	0.22	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
HNSC	cis	rs3096299	0.935	rs3102387	ENSG00000261574.1	RP1-168P16.2	4.78	2.32e-06	0.000556	0.27	0.22	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89392375~89412564:-
HNSC	cis	rs4873772	0.735	rs923499	ENSG00000253330.1	RP11-697N18.3	-4.78	2.32e-06	0.000556	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47523060	chr8:47511034~47512141:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	4.78	2.32e-06	0.000556	0.24	0.22	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
HNSC	cis	rs1218582	0.772	rs1109815	ENSG00000270361.1	RP11-307C12.13	-4.78	2.32e-06	0.000556	-0.24	-0.22	Prostate cancer;	chr1:154936792	chr1:154937370~154938059:+
HNSC	cis	rs10462794	1	rs6882500	ENSG00000260763.1	RP11-445O3.3	4.78	2.32e-06	0.000556	0.28	0.22	DNA methylation (variation);	chr5:4485642	chr5:4436850~4440259:-
HNSC	cis	rs10462794	1	rs6555293	ENSG00000260763.1	RP11-445O3.3	4.78	2.32e-06	0.000556	0.28	0.22	DNA methylation (variation);	chr5:4486561	chr5:4436850~4440259:-
HNSC	cis	rs10462794	1	rs4479813	ENSG00000260763.1	RP11-445O3.3	4.78	2.32e-06	0.000556	0.28	0.22	DNA methylation (variation);	chr5:4486729	chr5:4436850~4440259:-
HNSC	cis	rs10462794	1	rs4409059	ENSG00000260763.1	RP11-445O3.3	4.78	2.32e-06	0.000556	0.28	0.22	DNA methylation (variation);	chr5:4486849	chr5:4436850~4440259:-
HNSC	cis	rs7829975	0.539	rs71537846	ENSG00000254340.1	RP11-10A14.3	-4.78	2.32e-06	0.000556	-0.28	-0.22	Mood instability;	chr8:8684610	chr8:9141424~9145435:+
HNSC	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	4.78	2.32e-06	0.000556	0.34	0.22	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
HNSC	cis	rs656319	0.559	rs17689289	ENSG00000269918.1	AF131215.9	4.78	2.32e-06	0.000556	0.21	0.22	Myopia (pathological);	chr8:10120470	chr8:11104691~11106704:-
HNSC	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	4.78	2.32e-06	0.000557	0.28	0.22	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
HNSC	cis	rs73222236	0.825	rs9819496	ENSG00000273486.1	RP11-731C17.2	4.78	2.32e-06	0.000557	0.18	0.22	Coronary artery disease;	chr3:136421036	chr3:136837338~136839021:-
HNSC	cis	rs4873772	0.735	rs876915	ENSG00000253330.1	RP11-697N18.3	-4.78	2.33e-06	0.000557	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47506069	chr8:47511034~47512141:-
HNSC	cis	rs9321453	1	rs9399101	ENSG00000231971.4	RP11-557H15.3	4.78	2.33e-06	0.000557	0.25	0.22	Urate levels;	chr6:134447144	chr6:134428240~134520585:-
HNSC	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	4.78	2.33e-06	0.000557	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	4.78	2.33e-06	0.000557	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
HNSC	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	4.78	2.33e-06	0.000558	0.29	0.22	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
HNSC	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-4.78	2.33e-06	0.000558	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
HNSC	cis	rs763121	0.853	rs5750626	ENSG00000273076.1	RP3-508I15.22	4.78	2.33e-06	0.000558	0.23	0.22	Menopause (age at onset);	chr22:38581885	chr22:38743495~38743910:+
HNSC	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-4.78	2.33e-06	0.000558	-0.28	-0.22	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	4.78	2.33e-06	0.000558	0.25	0.22	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
HNSC	cis	rs116095464	0.681	rs9687745	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.33e-06	0.000558	-0.3	-0.22	Breast cancer;	chr5:229194	chr5:288833~290321:-
HNSC	cis	rs2337406	1	rs1961901	ENSG00000254174.1	IGHV1-12	4.78	2.33e-06	0.000558	0.18	0.22	Alzheimer's disease (late onset);	chr14:106680856	chr14:106122420~106122709:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000254174.1	IGHV1-12	4.78	2.33e-06	0.000558	0.18	0.22	Alzheimer's disease (late onset);	chr14:106681320	chr14:106122420~106122709:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000254174.1	IGHV1-12	4.78	2.33e-06	0.000558	0.18	0.22	Alzheimer's disease (late onset);	chr14:106682029	chr14:106122420~106122709:-
HNSC	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-4.78	2.33e-06	0.000559	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
HNSC	cis	rs4906172	0.838	rs2619092	ENSG00000271780.1	RP11-1017G21.5	-4.78	2.33e-06	0.000559	-0.22	-0.22	Menopause (age at onset);	chr14:101959638	chr14:101948347~101949425:+
HNSC	cis	rs189798	0.807	rs330905	ENSG00000254153.1	CTA-398F10.2	4.78	2.33e-06	0.000559	0.25	0.22	Myopia (pathological);	chr8:9136041	chr8:8456909~8461337:-
HNSC	cis	rs9329221	0.506	rs17689674	ENSG00000254340.1	RP11-10A14.3	4.78	2.33e-06	0.000559	0.26	0.22	Neuroticism;	chr8:10124344	chr8:9141424~9145435:+
HNSC	cis	rs5758659	0.7	rs739294	ENSG00000182057.4	OGFRP1	4.78	2.34e-06	0.000559	0.23	0.22	Cognitive function;	chr22:41985722	chr22:42269753~42275196:+
HNSC	cis	rs3806843	0.966	rs2563264	ENSG00000202515.1	VTRNA1-3	4.78	2.34e-06	0.000559	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.933	rs2879087	ENSG00000202515.1	VTRNA1-3	-4.78	2.34e-06	0.00056	-0.25	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr5:140726158~140726246:+
HNSC	cis	rs2179367	0.6	rs9498355	ENSG00000216906.2	RP11-350J20.9	-4.78	2.34e-06	0.00056	-0.33	-0.22	Dupuytren's disease;	chr6:149442274	chr6:149904243~149906418:+
HNSC	cis	rs2985684	0.895	rs4900940	ENSG00000278009.1	RP11-649E7.8	4.78	2.34e-06	0.00056	0.29	0.22	Carotid intima media thickness;	chr14:49608592	chr14:49601011~49601124:-
HNSC	cis	rs10462794	0.853	rs62343516	ENSG00000260763.1	RP11-445O3.3	-4.78	2.34e-06	0.00056	-0.3	-0.22	DNA methylation (variation);	chr5:4495294	chr5:4436850~4440259:-
HNSC	cis	rs860295	0.702	rs11264387	ENSG00000203761.5	MSTO2P	-4.78	2.34e-06	0.00056	-0.17	-0.22	Body mass index;	chr1:155593361	chr1:155745829~155750137:+
HNSC	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-4.78	2.34e-06	0.00056	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
HNSC	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-4.78	2.34e-06	0.00056	-0.26	-0.22	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
HNSC	cis	rs6964587	0.934	rs12531561	ENSG00000188693.7	CYP51A1-AS1	-4.78	2.34e-06	0.00056	-0.23	-0.22	Breast cancer;	chr7:92078466	chr7:92134604~92180725:+
HNSC	cis	rs4657482	1	rs4657482	ENSG00000236364.3	RP11-525G13.2	-4.78	2.34e-06	0.000561	-0.21	-0.22	Testicular germ cell tumor;	chr1:165862412	chr1:165890795~165900683:-
HNSC	cis	rs12935418	0.616	rs2549853	ENSG00000278985.1	RP11-303E16.9	-4.78	2.34e-06	0.000561	-0.21	-0.22	Mean corpuscular volume;	chr16:80992850	chr16:80982319~80984094:-
HNSC	cis	rs853679	0.607	rs67662114	ENSG00000219392.1	RP1-265C24.5	-4.78	2.34e-06	0.000561	-0.42	-0.22	Depression;	chr6:27964523	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13216117	ENSG00000219392.1	RP1-265C24.5	-4.78	2.34e-06	0.000561	-0.42	-0.22	Depression;	chr6:27970706	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs36101351	ENSG00000219392.1	RP1-265C24.5	-4.78	2.34e-06	0.000561	-0.42	-0.22	Depression;	chr6:27975591	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs28360499	ENSG00000219392.1	RP1-265C24.5	-4.78	2.34e-06	0.000561	-0.42	-0.22	Depression;	chr6:27977618	chr6:28115628~28116551:+
HNSC	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-4.78	2.35e-06	0.000561	-0.24	-0.22	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
HNSC	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-4.78	2.35e-06	0.000562	-0.26	-0.22	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
HNSC	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	4.78	2.35e-06	0.000562	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
HNSC	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	4.78	2.35e-06	0.000562	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
HNSC	cis	rs9880211	0.613	rs9834966	ENSG00000273486.1	RP11-731C17.2	4.78	2.35e-06	0.000562	0.2	0.22	Height;Body mass index;	chr3:136089778	chr3:136837338~136839021:-
HNSC	cis	rs6964587	1	rs4727266	ENSG00000188693.7	CYP51A1-AS1	4.78	2.35e-06	0.000562	0.22	0.22	Breast cancer;	chr7:91940815	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs4727267	ENSG00000188693.7	CYP51A1-AS1	4.78	2.35e-06	0.000562	0.22	0.22	Breast cancer;	chr7:91940976	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7797369	ENSG00000188693.7	CYP51A1-AS1	4.78	2.35e-06	0.000562	0.22	0.22	Breast cancer;	chr7:91941301	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs34043009	ENSG00000188693.7	CYP51A1-AS1	4.78	2.35e-06	0.000562	0.22	0.22	Breast cancer;	chr7:91949133	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs416	ENSG00000188693.7	CYP51A1-AS1	4.78	2.35e-06	0.000562	0.22	0.22	Breast cancer;	chr7:91951257	chr7:92134604~92180725:+
HNSC	cis	rs1799949	0.965	rs6503726	ENSG00000236383.6	LINC00854	-4.78	2.35e-06	0.000562	-0.2	-0.22	Menopause (age at onset);	chr17:43132725	chr17:43216941~43305976:-
HNSC	cis	rs4664293	0.647	rs1863686	ENSG00000226266.5	AC009961.3	-4.78	2.35e-06	0.000562	-0.22	-0.22	Monocyte percentage of white cells;	chr2:159647538	chr2:159670708~159712435:-
HNSC	cis	rs7296418	0.961	rs10848428	ENSG00000280120.1	RP11-546D6.3	4.78	2.35e-06	0.000562	0.18	0.22	Platelet count;	chr12:123087948	chr12:123152324~123153377:-
HNSC	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	4.78	2.35e-06	0.000562	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	4.78	2.35e-06	0.000562	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	4.78	2.35e-06	0.000562	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
HNSC	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	4.78	2.35e-06	0.000562	0.24	0.22	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
HNSC	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.78	2.35e-06	0.000563	0.21	0.22	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
HNSC	cis	rs656319	0.513	rs1484641	ENSG00000269918.1	AF131215.9	4.78	2.35e-06	0.000563	0.22	0.22	Myopia (pathological);	chr8:10129014	chr8:11104691~11106704:-
HNSC	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	4.78	2.35e-06	0.000563	0.3	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
HNSC	cis	rs1218582	0.772	rs877343	ENSG00000270361.1	RP11-307C12.13	-4.78	2.35e-06	0.000563	-0.24	-0.22	Prostate cancer;	chr1:154937536	chr1:154937370~154938059:+
HNSC	cis	rs1971762	0.563	rs4759279	ENSG00000270175.1	RP11-793H13.11	-4.78	2.35e-06	0.000563	-0.19	-0.22	Height;	chr12:53671104	chr12:53500162~53500936:-
HNSC	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-4.78	2.36e-06	0.000564	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
HNSC	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-4.78	2.36e-06	0.000564	-0.26	-0.22	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
HNSC	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-4.78	2.36e-06	0.000564	-0.28	-0.22	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
HNSC	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-4.78	2.36e-06	0.000564	-0.18	-0.22	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000564	0.26	0.22	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000564	0.26	0.22	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000564	0.26	0.22	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000564	0.26	0.22	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
HNSC	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-4.78	2.36e-06	0.000564	-0.24	-0.22	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
HNSC	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-4.78	2.36e-06	0.000564	-0.24	-0.22	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
HNSC	cis	rs4256159	1	rs73178597	ENSG00000228956.7	SATB1-AS1	4.78	2.36e-06	0.000565	0.35	0.22	Crohn's disease;Inflammatory bowel disease;	chr3:18763329	chr3:18445024~18920401:+
HNSC	cis	rs3736485	0.844	rs28878886	ENSG00000259438.1	CTD-2650P22.1	4.78	2.36e-06	0.000565	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51468695	chr15:52010999~52019095:-
HNSC	cis	rs8058578	1	rs6565197	ENSG00000279196.1	RP11-1072A3.3	4.78	2.36e-06	0.000565	0.26	0.22	Multiple myeloma;	chr16:30695156	chr16:30984630~30988270:-
HNSC	cis	rs8058578	0.943	rs7197770	ENSG00000279196.1	RP11-1072A3.3	4.78	2.36e-06	0.000565	0.26	0.22	Multiple myeloma;	chr16:30704587	chr16:30984630~30988270:-
HNSC	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000565	0.26	0.22	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
HNSC	cis	rs988913	0.647	rs3125287	ENSG00000224984.1	RP11-524H19.2	4.78	2.36e-06	0.000565	0.25	0.22	Menarche (age at onset);	chr6:54978808	chr6:54840118~54840855:-
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	4.78	2.36e-06	0.000565	0.26	0.22	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
HNSC	cis	rs4356203	0.78	rs901942	ENSG00000260196.1	RP1-239B22.5	4.78	2.37e-06	0.000566	0.25	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234203	chr11:17380649~17383531:+
HNSC	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-4.78	2.37e-06	0.000566	-0.18	-0.22	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
HNSC	cis	rs9329221	0.618	rs73197281	ENSG00000269918.1	AF131215.9	-4.78	2.37e-06	0.000566	-0.21	-0.22	Neuroticism;	chr8:10405772	chr8:11104691~11106704:-
HNSC	cis	rs4699052	0.625	rs11734572	ENSG00000246560.2	RP11-10L12.4	4.78	2.37e-06	0.000566	0.25	0.22	Testicular germ cell tumor;	chr4:103367463	chr4:102828055~102844075:+
HNSC	cis	rs6964587	1	rs7806184	ENSG00000188693.7	CYP51A1-AS1	-4.78	2.37e-06	0.000566	-0.23	-0.22	Breast cancer;	chr7:91972664	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2237568	ENSG00000188693.7	CYP51A1-AS1	-4.78	2.37e-06	0.000566	-0.23	-0.22	Breast cancer;	chr7:91993362	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs2299235	ENSG00000188693.7	CYP51A1-AS1	-4.78	2.37e-06	0.000566	-0.23	-0.22	Breast cancer;	chr7:91998186	chr7:92134604~92180725:+
HNSC	cis	rs3733585	0.648	rs35954357	ENSG00000250413.1	RP11-448G15.1	-4.78	2.37e-06	0.000566	-0.26	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:9977134	chr4:10006482~10009725:+
HNSC	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-4.78	2.37e-06	0.000566	-0.22	-0.22	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
HNSC	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	4.78	2.37e-06	0.000567	0.29	0.22	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
HNSC	cis	rs4699052	0.662	rs6828151	ENSG00000246560.2	RP11-10L12.4	4.78	2.37e-06	0.000567	0.25	0.22	Testicular germ cell tumor;	chr4:103363599	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-4.78	2.37e-06	0.000567	-0.18	-0.22	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
HNSC	cis	rs853679	0.546	rs71537572	ENSG00000219392.1	RP1-265C24.5	-4.78	2.37e-06	0.000567	-0.42	-0.22	Depression;	chr6:28002937	chr6:28115628~28116551:+
HNSC	cis	rs7829975	0.56	rs56094035	ENSG00000173295.6	FAM86B3P	-4.78	2.37e-06	0.000567	-0.26	-0.22	Mood instability;	chr8:8694112	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.539	rs4841012	ENSG00000173295.6	FAM86B3P	-4.78	2.37e-06	0.000567	-0.26	-0.22	Mood instability;	chr8:8694200	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.56	rs4841013	ENSG00000173295.6	FAM86B3P	-4.78	2.37e-06	0.000567	-0.26	-0.22	Mood instability;	chr8:8694503	chr8:8228595~8244865:+
HNSC	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	4.78	2.37e-06	0.000567	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
HNSC	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	4.78	2.37e-06	0.000567	0.31	0.22	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
HNSC	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	4.78	2.37e-06	0.000567	0.31	0.22	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
HNSC	cis	rs13073817	0.582	rs13065348	ENSG00000228956.7	SATB1-AS1	4.78	2.37e-06	0.000567	0.23	0.22	Crohn's disease;	chr3:18639069	chr3:18445024~18920401:+
HNSC	cis	rs1056107	0.933	rs4979099	ENSG00000225513.1	RP11-165N19.2	-4.78	2.37e-06	0.000567	-0.23	-0.22	Colorectal cancer;	chr9:112319336	chr9:112173522~112173971:-
HNSC	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-4.78	2.37e-06	0.000567	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
HNSC	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	4.78	2.37e-06	0.000567	0.24	0.22	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
HNSC	cis	rs2998286	0.862	rs1339704	ENSG00000254635.4	WAC-AS1	-4.78	2.37e-06	0.000567	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28522652~28532743:-
HNSC	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	4.78	2.38e-06	0.000568	0.29	0.22	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	4.78	2.38e-06	0.000568	0.29	0.22	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	4.78	2.38e-06	0.000568	0.29	0.22	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
HNSC	cis	rs3736485	0.966	rs8040538	ENSG00000259438.1	CTD-2650P22.1	4.78	2.38e-06	0.000568	0.22	0.22	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51612387	chr15:52010999~52019095:-
HNSC	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	4.78	2.38e-06	0.000568	0.26	0.22	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	4.78	2.38e-06	0.000568	0.26	0.22	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
HNSC	cis	rs9402743	0.634	rs7767072	ENSG00000234084.1	RP3-388E23.2	-4.78	2.38e-06	0.000568	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135593899	chr6:135301568~135307158:+
HNSC	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-4.78	2.38e-06	0.000568	-0.21	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
HNSC	cis	rs116095464	0.558	rs62347678	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.38e-06	0.000568	-0.29	-0.22	Breast cancer;	chr5:227381	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs73031482	ENSG00000250848.1	CTD-2083E4.5	-4.78	2.38e-06	0.000568	-0.29	-0.22	Breast cancer;	chr5:227479	chr5:288833~290321:-
HNSC	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-4.78	2.38e-06	0.000569	-0.18	-0.22	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
HNSC	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	4.78	2.38e-06	0.000569	0.24	0.22	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
HNSC	cis	rs2548724	0.741	rs62369308	ENSG00000250682.4	LINC00491	4.78	2.38e-06	0.000569	0.29	0.22	Type 2 diabetes;	chr5:102382690	chr5:102609156~102671559:-
HNSC	cis	rs6928977	0.5	rs12211833	ENSG00000234084.1	RP3-388E23.2	-4.78	2.38e-06	0.000569	-0.23	-0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135301568~135307158:+
HNSC	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-4.78	2.38e-06	0.000569	-0.28	-0.22	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
HNSC	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-4.78	2.38e-06	0.000569	-0.26	-0.22	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
HNSC	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-4.78	2.38e-06	0.000569	-0.26	-0.22	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
HNSC	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.78	2.39e-06	0.00057	0.25	0.22	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.78	2.39e-06	0.00057	-0.23	-0.22	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
HNSC	cis	rs3806843	0.966	rs2563262	ENSG00000202515.1	VTRNA1-3	4.78	2.39e-06	0.00057	0.24	0.22	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr5:140726158~140726246:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	4.78	2.39e-06	0.00057	0.26	0.22	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
HNSC	cis	rs860295	0.678	rs1749405	ENSG00000203761.5	MSTO2P	4.78	2.39e-06	0.00057	0.16	0.22	Body mass index;	chr1:155890300	chr1:155745829~155750137:+
HNSC	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	4.78	2.39e-06	0.000571	0.21	0.22	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	4.78	2.39e-06	0.000571	0.21	0.22	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	4.78	2.39e-06	0.000571	0.26	0.22	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
HNSC	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-4.78	2.39e-06	0.000571	-0.29	-0.22	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
HNSC	cis	rs8058578	0.943	rs3747486	ENSG00000279196.1	RP11-1072A3.3	4.78	2.39e-06	0.000571	0.26	0.22	Multiple myeloma;	chr16:30775606	chr16:30984630~30988270:-
HNSC	cis	rs9914544	0.689	rs11078421	ENSG00000264885.1	RP11-815I9.4	-4.78	2.39e-06	0.000571	-0.22	-0.22	Educational attainment (years of education);	chr17:18901072	chr17:18667629~18669461:-
HNSC	cis	rs7085104	0.66	rs3781286	ENSG00000236937.2	PTGES3P4	4.78	2.39e-06	0.000571	0.27	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102845595~102845950:+
HNSC	cis	rs6499755	0.509	rs31042	ENSG00000260135.5	RP11-212I21.2	-4.78	2.39e-06	0.000572	-0.22	-0.22	Hypospadias;	chr16:55295689	chr16:55426797~55462297:-
HNSC	cis	rs7615952	0.641	rs7632497	ENSG00000241439.1	RP11-666A20.3	4.78	2.4e-06	0.000572	0.25	0.22	Blood pressure (smoking interaction);	chr3:126064243	chr3:125958556~125958817:+
HNSC	cis	rs1799949	0.965	rs9911630	ENSG00000236383.6	LINC00854	-4.78	2.4e-06	0.000572	-0.2	-0.22	Menopause (age at onset);	chr17:43036325	chr17:43216941~43305976:-
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000276691.1	RP5-1057I20.5	4.78	2.4e-06	0.000573	0.45	0.22	Pneumonia;	chr12:47584539	chr12:47788426~47788971:+
HNSC	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-4.78	2.4e-06	0.000573	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-4.78	2.4e-06	0.000573	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-4.78	2.4e-06	0.000573	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-4.78	2.4e-06	0.000573	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
HNSC	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.78	2.4e-06	0.000573	0.19	0.22	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
HNSC	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-4.78	2.4e-06	0.000573	-0.26	-0.22	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
HNSC	cis	rs7789940	1	rs7789940	ENSG00000231087.2	FDPSP7	-4.78	2.4e-06	0.000573	-0.26	-0.22	Multiple sclerosis;	chr7:76321913	chr7:76968197~76969250:-
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000259429.4	UBE2Q2P2	-4.78	2.4e-06	0.000573	-0.2	-0.22	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82355142~82420075:+
HNSC	cis	rs8032939	0.533	rs7171171	ENSG00000259747.1	RP11-275I4.2	-4.78	2.4e-06	0.000573	-0.27	-0.22	Rheumatoid arthritis;	chr15:38614840	chr15:38671847~38689191:+
HNSC	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	4.78	2.4e-06	0.000573	0.34	0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
HNSC	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	4.78	2.4e-06	0.000573	0.34	0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
HNSC	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	4.78	2.4e-06	0.000573	0.34	0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
HNSC	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-4.78	2.4e-06	0.000574	-0.26	-0.22	Height;	chr20:49306363	chr20:49280319~49280409:+
HNSC	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	4.78	2.41e-06	0.000574	0.22	0.22	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
HNSC	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	4.78	2.41e-06	0.000575	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
HNSC	cis	rs72843506	0.722	rs16942325	ENSG00000261033.1	RP11-209D14.2	4.78	2.41e-06	0.000575	0.4	0.22	Schizophrenia;	chr17:20123750	chr17:20008051~20009234:-
HNSC	cis	rs6964587	1	rs411	ENSG00000188693.7	CYP51A1-AS1	4.78	2.41e-06	0.000575	0.23	0.22	Breast cancer;	chr7:91928444	chr7:92134604~92180725:+
HNSC	cis	rs7824557	0.734	rs2293856	ENSG00000255310.2	AF131215.2	4.78	2.41e-06	0.000575	0.21	0.22	Retinal vascular caliber;	chr8:11319938	chr8:11107788~11109726:-
HNSC	cis	rs11846409	0.86	rs59055020	ENSG00000274576.2	IGHV2-70	-4.78	2.41e-06	0.000575	-0.21	-0.22	Rheumatic heart disease;	chr14:106631573	chr14:106770577~106771020:-
HNSC	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	4.77	2.41e-06	0.000575	0.22	0.22	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
HNSC	cis	rs6831352	0.879	rs29001212	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99130726	chr4:98928897~98994994:+
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000224373.3	IGHV4-59	4.77	2.41e-06	0.000575	0.15	0.22	Kawasaki disease;	chr14:106704323	chr14:106627249~106627825:-
HNSC	cis	rs116095464	0.558	rs2162870	ENSG00000250848.1	CTD-2083E4.5	-4.77	2.41e-06	0.000575	-0.3	-0.22	Breast cancer;	chr5:228014	chr5:288833~290321:-
HNSC	cis	rs6964587	0.933	rs13230837	ENSG00000188693.7	CYP51A1-AS1	-4.77	2.41e-06	0.000575	-0.23	-0.22	Breast cancer;	chr7:92149703	chr7:92134604~92180725:+
HNSC	cis	rs6831352	0.918	rs29001224	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99126222	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.84	rs29001223	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99126282	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs1126672	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99126661	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs6813415	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99127358	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs67311928	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99127848	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.877	rs28987101	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99128102	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs28987097	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99128428	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13112733	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129168	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13140423	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129249	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs13113166	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129377	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs34805407	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129635	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs35662508	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129823	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs34071486	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99129936	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs34360292	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99130152	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001216	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99130405	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs29001215	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99130571	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001214	ENSG00000263923.1	RP11-571L19.7	4.77	2.41e-06	0.000575	0.23	0.22	Alcohol dependence;	chr4:99130582	chr4:98928897~98994994:+
HNSC	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-4.77	2.41e-06	0.000575	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
HNSC	cis	rs7254192	0.506	rs2305797	ENSG00000233622.1	CYP2T1P	-4.77	2.41e-06	0.000576	-0.22	-0.22	Post bronchodilator FEV1;	chr19:40763171	chr19:40808525~40811390:-
HNSC	cis	rs1056107	0.931	rs1969946	ENSG00000225513.1	RP11-165N19.2	-4.77	2.41e-06	0.000576	-0.24	-0.22	Colorectal cancer;	chr9:112269241	chr9:112173522~112173971:-
HNSC	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.77	2.41e-06	0.000576	0.3	0.22	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
HNSC	cis	rs1479119	0.681	rs10734862	ENSG00000180861.8	LINC01559	4.77	2.41e-06	0.000576	0.28	0.22	Intelligence (multi-trait analysis);	chr12:13343403	chr12:13371089~13387167:-
HNSC	cis	rs12935418	0.552	rs2549842	ENSG00000278985.1	RP11-303E16.9	4.77	2.41e-06	0.000576	0.21	0.22	Mean corpuscular volume;	chr16:80990054	chr16:80982319~80984094:-
HNSC	cis	rs9368481	0.761	rs3931464	ENSG00000224843.5	LINC00240	-4.77	2.41e-06	0.000576	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26956992~27023924:+
HNSC	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-4.77	2.41e-06	0.000576	-0.26	-0.22	Height;	chr20:49278705	chr20:49280319~49280409:+
HNSC	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	4.77	2.42e-06	0.000576	0.21	0.22	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
HNSC	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-4.77	2.42e-06	0.000576	-0.24	-0.22	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
HNSC	cis	rs2904967	0.636	rs514076	ENSG00000254614.2	AP003068.23	-4.77	2.42e-06	0.000576	-0.32	-0.22	Mean corpuscular volume;	chr11:65222570	chr11:65177606~65181834:-
HNSC	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	4.77	2.42e-06	0.000576	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
HNSC	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	4.77	2.42e-06	0.000576	0.31	0.22	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	4.77	2.42e-06	0.000576	0.31	0.22	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
HNSC	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	4.77	2.42e-06	0.000576	0.26	0.22	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
HNSC	cis	rs9650657	0.645	rs4841407	ENSG00000269918.1	AF131215.9	-4.77	2.42e-06	0.000576	-0.21	-0.22	Neuroticism;	chr8:10658675	chr8:11104691~11106704:-
HNSC	cis	rs2985684	1	rs2985696	ENSG00000278009.1	RP11-649E7.8	4.77	2.42e-06	0.000577	0.28	0.22	Carotid intima media thickness;	chr14:49628195	chr14:49601011~49601124:-
HNSC	cis	rs6831352	0.918	rs17218288	ENSG00000263923.1	RP11-571L19.7	4.77	2.42e-06	0.000577	0.23	0.22	Alcohol dependence;	chr4:99136879	chr4:98928897~98994994:+
HNSC	cis	rs7819412	0.634	rs4841485	ENSG00000255310.2	AF131215.2	4.77	2.42e-06	0.000577	0.21	0.22	Triglycerides;	chr8:11052426	chr8:11107788~11109726:-
HNSC	cis	rs442309	0.687	rs10995283	ENSG00000238280.1	RP11-436D10.3	-4.77	2.42e-06	0.000577	-0.26	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62714628	chr10:62793562~62805887:-
HNSC	cis	rs72843506	0.656	rs79773274	ENSG00000261033.1	RP11-209D14.2	4.77	2.42e-06	0.000577	0.39	0.22	Schizophrenia;	chr17:20002618	chr17:20008051~20009234:-
HNSC	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	4.77	2.42e-06	0.000577	0.23	0.22	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-4.77	2.42e-06	0.000577	-0.23	-0.22	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-4.77	2.42e-06	0.000577	-0.23	-0.22	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
HNSC	cis	rs7824557	0.724	rs2251473	ENSG00000255310.2	AF131215.2	4.77	2.42e-06	0.000577	0.21	0.22	Retinal vascular caliber;	chr8:11319617	chr8:11107788~11109726:-
HNSC	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	4.77	2.42e-06	0.000577	0.27	0.22	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
HNSC	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-4.77	2.42e-06	0.000577	-0.21	-0.22	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	4.77	2.42e-06	0.000578	0.31	0.22	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	4.77	2.42e-06	0.000578	0.31	0.22	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
HNSC	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-4.77	2.43e-06	0.000578	-0.18	-0.22	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000224373.3	IGHV4-59	4.77	2.43e-06	0.000578	0.14	0.22	Kawasaki disease;	chr14:106705382	chr14:106627249~106627825:-
HNSC	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-4.77	2.43e-06	0.000578	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
HNSC	cis	rs4908769	0.624	rs2708633	ENSG00000232912.4	RP5-1115A15.1	-4.77	2.43e-06	0.000578	-0.24	-0.22	Allergy;	chr1:8379565	chr1:8424645~8434838:+
HNSC	cis	rs367615	0.68	rs31595	ENSG00000249476.1	CTD-2587M2.1	4.77	2.43e-06	0.000579	0.28	0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109643617	chr5:109237120~109326369:-
HNSC	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-4.77	2.43e-06	0.000579	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-4.77	2.43e-06	0.000579	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
HNSC	cis	rs7621025	0.691	rs9845762	ENSG00000239213.4	NCK1-AS1	4.77	2.43e-06	0.000579	0.19	0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136841726~136862054:-
HNSC	cis	rs9368481	0.743	rs9368480	ENSG00000224843.5	LINC00240	-4.77	2.43e-06	0.000579	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26956992~27023924:+
HNSC	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	4.77	2.43e-06	0.000579	0.25	0.22	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
HNSC	cis	rs12893668	0.572	rs34000399	ENSG00000269940.1	RP11-73M18.7	4.77	2.43e-06	0.000579	0.21	0.22	Reticulocyte count;	chr14:103635080	chr14:103694560~103695170:+
HNSC	cis	rs10462794	0.853	rs973156	ENSG00000260763.1	RP11-445O3.3	-4.77	2.43e-06	0.000579	-0.3	-0.22	DNA methylation (variation);	chr5:4505308	chr5:4436850~4440259:-
HNSC	cis	rs73222236	0.825	rs9831321	ENSG00000273486.1	RP11-731C17.2	-4.77	2.43e-06	0.000579	-0.18	-0.22	Coronary artery disease;	chr3:136423750	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.557	rs7816427	ENSG00000254340.1	RP11-10A14.3	-4.77	2.43e-06	0.000579	-0.28	-0.22	Mood instability;	chr8:8688374	chr8:9141424~9145435:+
HNSC	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-4.77	2.43e-06	0.000579	-0.53	-0.22	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
HNSC	cis	rs2998286	0.715	rs2993985	ENSG00000254635.4	WAC-AS1	-4.77	2.43e-06	0.00058	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28510311	chr10:28522652~28532743:-
HNSC	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-4.77	2.43e-06	0.00058	-0.19	-0.22	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
HNSC	cis	rs860295	0.702	rs3851912	ENSG00000203761.5	MSTO2P	-4.77	2.44e-06	0.00058	-0.17	-0.22	Body mass index;	chr1:155616653	chr1:155745829~155750137:+
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000254174.1	IGHV1-12	-4.77	2.44e-06	0.00058	-0.18	-0.22	Alzheimer's disease (late onset);	chr14:106650408	chr14:106122420~106122709:-
HNSC	cis	rs7615952	0.576	rs4646759	ENSG00000248787.1	RP11-666A20.4	-4.77	2.44e-06	0.00058	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126104103	chr3:125908005~125910272:-
HNSC	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-4.77	2.44e-06	0.000581	-0.44	-0.22	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
HNSC	cis	rs7662987	0.517	rs2602872	ENSG00000263923.1	RP11-571L19.7	-4.77	2.44e-06	0.000581	-0.23	-0.22	Smoking initiation;	chr4:99117845	chr4:98928897~98994994:+
HNSC	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	4.77	2.44e-06	0.000581	0.19	0.22	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
HNSC	cis	rs13073817	0.543	rs6802224	ENSG00000228956.7	SATB1-AS1	4.77	2.44e-06	0.000581	0.23	0.22	Crohn's disease;	chr3:18634659	chr3:18445024~18920401:+
HNSC	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-4.77	2.44e-06	0.000581	-0.23	-0.22	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
HNSC	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	4.77	2.44e-06	0.000581	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
HNSC	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	4.77	2.44e-06	0.000581	0.27	0.22	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
HNSC	cis	rs6928977	0.827	rs2614265	ENSG00000231028.7	LINC00271	4.77	2.44e-06	0.000581	0.25	0.22	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135394237	chr6:135497801~135716055:+
HNSC	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-4.77	2.44e-06	0.000582	-0.25	-0.22	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
HNSC	cis	rs1552244	1	rs9849434	ENSG00000180385.7	EMC3-AS1	-4.77	2.44e-06	0.000582	-0.24	-0.22	Alzheimer's disease;	chr3:10092026	chr3:9986893~10006990:+
HNSC	cis	rs116095464	0.558	rs7736600	ENSG00000250848.1	CTD-2083E4.5	-4.77	2.44e-06	0.000582	-0.3	-0.22	Breast cancer;	chr5:231222	chr5:288833~290321:-
HNSC	cis	rs9907295	1	rs9907295	ENSG00000270977.1	AC015849.16	-4.77	2.44e-06	0.000582	-0.39	-0.22	Fibroblast growth factor basic levels;	chr17:35930309	chr17:35893707~35911023:-
HNSC	cis	rs7819412	0.745	rs6601569	ENSG00000255310.2	AF131215.2	-4.77	2.44e-06	0.000582	-0.22	-0.22	Triglycerides;	chr8:11216069	chr8:11107788~11109726:-
HNSC	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	4.77	2.44e-06	0.000582	0.29	0.22	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
HNSC	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	4.77	2.45e-06	0.000582	0.23	0.22	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
HNSC	cis	rs7829975	0.755	rs3789849	ENSG00000254153.1	CTA-398F10.2	4.77	2.45e-06	0.000582	0.23	0.22	Mood instability;	chr8:8829544	chr8:8456909~8461337:-
HNSC	cis	rs116095464	0.558	rs10052012	ENSG00000250848.1	CTD-2083E4.5	-4.77	2.45e-06	0.000582	-0.3	-0.22	Breast cancer;	chr5:231793	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10080225	ENSG00000250848.1	CTD-2083E4.5	-4.77	2.45e-06	0.000582	-0.3	-0.22	Breast cancer;	chr5:232060	chr5:288833~290321:-
HNSC	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-4.77	2.45e-06	0.000582	-0.25	-0.22	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
HNSC	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-4.77	2.45e-06	0.000583	-0.2	-0.22	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
HNSC	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-4.77	2.45e-06	0.000583	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
HNSC	cis	rs4660261	0.561	rs11210934	ENSG00000237950.1	RP11-7O11.3	4.77	2.45e-06	0.000583	0.23	0.22	Intelligence (multi-trait analysis);	chr1:43903763	chr1:43944370~43946551:-
HNSC	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-4.77	2.45e-06	0.000583	-0.28	-0.22	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-4.77	2.45e-06	0.000583	-0.28	-0.22	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
HNSC	cis	rs10791097	0.69	rs12286234	ENSG00000254842.5	RP11-890B15.2	-4.77	2.45e-06	0.000583	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130860633	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.739	rs12279359	ENSG00000254842.5	RP11-890B15.2	-4.77	2.45e-06	0.000583	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130860649	chr11:130844191~130865561:-
HNSC	cis	rs8059260	0.541	rs12927046	ENSG00000274038.1	RP11-66H6.4	-4.77	2.45e-06	0.000583	-0.44	-0.22	Alcohol consumption over the past year;	chr16:11148334	chr16:11056556~11057034:+
HNSC	cis	rs12468226	0.752	rs79058237	ENSG00000226261.1	AC064836.3	4.77	2.45e-06	0.000583	0.34	0.22	Urate levels;	chr2:202140247	chr2:202336024~202336727:-
HNSC	cis	rs1056107	0.931	rs1359878	ENSG00000225513.1	RP11-165N19.2	-4.77	2.45e-06	0.000584	-0.23	-0.22	Colorectal cancer;	chr9:112249037	chr9:112173522~112173971:-
HNSC	cis	rs1799955	1	rs1799955	ENSG00000215515.2	IFIT1P1	-4.77	2.45e-06	0.000584	-0.29	-0.22	LDL cholesterol levels;	chr13:32355095	chr13:32384660~32386108:+
HNSC	cis	rs72772090	0.908	rs76539796	ENSG00000248734.2	CTD-2260A17.1	-4.77	2.45e-06	0.000584	-0.31	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96702971	chr5:96784777~96785999:+
HNSC	cis	rs9863	0.861	rs12301673	ENSG00000269938.1	RP11-214K3.20	-4.77	2.45e-06	0.000584	-0.25	-0.22	White blood cell count;	chr12:123971271	chr12:123968023~123968579:-
HNSC	cis	rs11969893	0.737	rs1856131	ENSG00000270987.1	RP3-467N11.2	4.77	2.45e-06	0.000584	0.52	0.22	Economic and political preferences (immigration/crime);	chr6:100959228	chr6:100889603~100890338:+
HNSC	cis	rs700651	0.789	rs6715070	ENSG00000231621.1	AC013264.2	4.77	2.45e-06	0.000584	0.2	0.22	Intracranial aneurysm;	chr2:198033541	chr2:197197991~197199273:+
HNSC	cis	rs2904524	0.588	rs12317962	ENSG00000257815.4	RP11-611E13.2	-4.77	2.45e-06	0.000584	-0.22	-0.22	Amyotrophic lateral sclerosis (age of onset);	chr12:70398802	chr12:69904033~70243360:-
HNSC	cis	rs2834288	0.536	rs8129513	ENSG00000273102.1	AP000569.9	4.77	2.45e-06	0.000584	0.24	0.22	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33967101~33968573:-
HNSC	cis	rs13217239	0.646	rs35691005	ENSG00000224843.5	LINC00240	-4.77	2.45e-06	0.000584	-0.21	-0.22	Schizophrenia;	chr6:27004291	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs10946891	ENSG00000224843.5	LINC00240	-4.77	2.45e-06	0.000584	-0.21	-0.22	Schizophrenia;	chr6:27005436	chr6:26956992~27023924:+
HNSC	cis	rs13217239	0.646	rs12201393	ENSG00000224843.5	LINC00240	-4.77	2.45e-06	0.000584	-0.21	-0.22	Schizophrenia;	chr6:27007911	chr6:26956992~27023924:+
HNSC	cis	rs1056107	0.872	rs10981315	ENSG00000225513.1	RP11-165N19.2	-4.77	2.45e-06	0.000584	-0.23	-0.22	Colorectal cancer;	chr9:112210139	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-4.77	2.45e-06	0.000584	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-4.77	2.45e-06	0.000584	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-4.77	2.46e-06	0.000584	-0.3	-0.22	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000230295.1	RP11-458F8.2	-4.77	2.46e-06	0.000585	-0.28	-0.22	Diabetic kidney disease;	chr7:66068227	chr7:66880708~66882981:+
HNSC	cis	rs2904967	0.636	rs184734	ENSG00000254614.2	AP003068.23	-4.77	2.46e-06	0.000585	-0.31	-0.22	Mean corpuscular volume;	chr11:65214732	chr11:65177606~65181834:-
HNSC	cis	rs712039	0.652	rs1829453	ENSG00000276054.1	RP11-378E13.3	4.77	2.46e-06	0.000585	0.3	0.22	Tuberculosis;	chr17:37449741	chr17:37386886~37387926:+
HNSC	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-4.77	2.46e-06	0.000585	-0.26	-0.22	Height;	chr20:49310319	chr20:49280319~49280409:+
HNSC	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	4.77	2.46e-06	0.000585	0.24	0.22	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
HNSC	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	4.77	2.46e-06	0.000586	0.22	0.22	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
HNSC	cis	rs9291683	0.575	rs3756223	ENSG00000250413.1	RP11-448G15.1	-4.77	2.46e-06	0.000586	-0.26	-0.22	Bone mineral density;	chr4:10104173	chr4:10006482~10009725:+
HNSC	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	4.77	2.46e-06	0.000586	0.24	0.22	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	4.77	2.46e-06	0.000586	0.24	0.22	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
HNSC	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	4.77	2.46e-06	0.000586	0.26	0.22	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
HNSC	cis	rs17507216	0.718	rs17158403	ENSG00000276710.3	CSPG4P8	-4.77	2.46e-06	0.000586	-0.3	-0.22	Excessive daytime sleepiness;	chr15:82572478	chr15:82459472~82477258:+
HNSC	cis	rs155076	1	rs261407	ENSG00000233325.3	MIPEPP3	4.77	2.46e-06	0.000586	0.38	0.22	White matter hyperintensity burden;	chr13:21281074	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs261406	ENSG00000233325.3	MIPEPP3	4.77	2.46e-06	0.000586	0.38	0.22	White matter hyperintensity burden;	chr13:21281715	chr13:21298139~21306373:+
HNSC	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-4.77	2.46e-06	0.000586	-0.18	-0.22	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
HNSC	cis	rs3811273	0.614	rs6572344	ENSG00000211816.2	TRAV38-1	-4.77	2.46e-06	0.000586	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22265267	chr14:22271968~22272563:+
HNSC	cis	rs763121	0.853	rs7289577	ENSG00000273076.1	RP3-508I15.22	4.77	2.46e-06	0.000586	0.23	0.22	Menopause (age at onset);	chr22:38646209	chr22:38743495~38743910:+
HNSC	cis	rs72615157	0.697	rs2056726	ENSG00000078319.8	PMS2P1	-4.77	2.46e-06	0.000586	-0.27	-0.22	Lung function (FEV1/FVC);	chr7:100182660	chr7:100320992~100341908:-
HNSC	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	4.77	2.46e-06	0.000586	0.22	0.22	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-4.77	2.47e-06	0.000586	-0.26	-0.22	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
HNSC	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-4.77	2.47e-06	0.000586	-0.17	-0.22	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
HNSC	cis	rs7665090	0.728	rs228617	ENSG00000246560.2	RP11-10L12.4	-4.77	2.47e-06	0.000586	-0.25	-0.22	Primary biliary cholangitis;	chr4:102659631	chr4:102828055~102844075:+
HNSC	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-4.77	2.47e-06	0.000586	-0.34	-0.22	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
HNSC	cis	rs6964587	1	rs10234290	ENSG00000188693.7	CYP51A1-AS1	-4.77	2.47e-06	0.000587	-0.23	-0.22	Breast cancer;	chr7:92087637	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs28584017	ENSG00000188693.7	CYP51A1-AS1	-4.77	2.47e-06	0.000587	-0.23	-0.22	Breast cancer;	chr7:92089854	chr7:92134604~92180725:+
HNSC	cis	rs2933343	0.729	rs813732	ENSG00000261159.1	RP11-723O4.9	4.77	2.47e-06	0.000587	0.22	0.22	IgG glycosylation;	chr3:128900514	chr3:128859716~128860526:-
HNSC	cis	rs10466239	0.57	rs4627023	ENSG00000230555.2	RP11-517P14.2	4.77	2.47e-06	0.000587	0.33	0.22	Telomere length;	chr10:43370437	chr10:43420738~43422100:+
HNSC	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-4.77	2.47e-06	0.000587	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-4.77	2.47e-06	0.000587	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
HNSC	cis	rs78579285	0.507	rs1061247	ENSG00000278341.1	RP5-1142A6.10	-4.77	2.47e-06	0.000587	-0.38	-0.22	Joint mobility (Beighton score);	chr16:88715383	chr16:88708956~88710437:-
HNSC	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	4.77	2.47e-06	0.000587	0.21	0.22	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.77	2.47e-06	0.000587	-0.22	-0.22	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.77	2.47e-06	0.000587	-0.22	-0.22	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.77	2.47e-06	0.000587	-0.22	-0.22	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-4.77	2.47e-06	0.000587	-0.22	-0.22	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-4.77	2.47e-06	0.000587	-0.22	-0.22	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
HNSC	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-4.77	2.47e-06	0.000587	-0.18	-0.22	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
HNSC	cis	rs860295	0.651	rs12239114	ENSG00000203761.5	MSTO2P	-4.77	2.47e-06	0.000587	-0.18	-0.22	Body mass index;	chr1:155352351	chr1:155745829~155750137:+
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000254340.1	RP11-10A14.3	4.77	2.47e-06	0.000587	0.26	0.22	Mood instability;	chr8:8288087	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	4.77	2.47e-06	0.000588	0.26	0.22	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
HNSC	cis	rs4873772	0.735	rs4608108	ENSG00000253330.1	RP11-697N18.3	-4.77	2.47e-06	0.000588	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47602961	chr8:47511034~47512141:-
HNSC	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	4.77	2.47e-06	0.000588	0.35	0.22	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
HNSC	cis	rs786425	0.538	rs786452	ENSG00000278112.1	RP11-972P1.11	-4.77	2.47e-06	0.000588	-0.21	-0.22	Pubertal anthropometrics;	chr12:123572622	chr12:123519390~123519856:-
HNSC	cis	rs1799949	0.965	rs9646413	ENSG00000236383.6	LINC00854	-4.77	2.47e-06	0.000588	-0.2	-0.22	Menopause (age at onset);	chr17:43348789	chr17:43216941~43305976:-
HNSC	cis	rs9402743	0.671	rs6934889	ENSG00000217482.2	HMGB1P17	-4.77	2.47e-06	0.000588	-0.24	-0.22	Systemic lupus erythematosus;	chr6:135629542	chr6:135636086~135636713:-
HNSC	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	4.77	2.47e-06	0.000588	0.22	0.22	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
HNSC	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	4.77	2.47e-06	0.000588	0.22	0.22	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
HNSC	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-4.77	2.47e-06	0.000588	-0.35	-0.22	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
HNSC	cis	rs4256159	1	rs73178602	ENSG00000228956.7	SATB1-AS1	4.77	2.47e-06	0.000588	0.35	0.22	Crohn's disease;Inflammatory bowel disease;	chr3:18766977	chr3:18445024~18920401:+
HNSC	cis	rs12986445	0.744	rs3845680	ENSG00000218682.1	AC010150.1	4.77	2.47e-06	0.000588	0.3	0.22	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25876144	chr2:25856461~25856966:-
HNSC	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-4.77	2.47e-06	0.000588	-0.18	-0.22	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
HNSC	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	4.77	2.48e-06	0.000588	0.25	0.22	Monocyte count;	chr11:307036	chr11:310139~311141:-
HNSC	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	4.77	2.48e-06	0.000588	0.27	0.22	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	4.77	2.48e-06	0.000588	0.27	0.22	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
HNSC	cis	rs4873772	0.704	rs4536257	ENSG00000253330.1	RP11-697N18.3	-4.77	2.48e-06	0.000588	-0.27	-0.22	Lobe attachment (rater-scored or self-reported);	chr8:47508977	chr8:47511034~47512141:-
HNSC	cis	rs9329221	0.682	rs11786677	ENSG00000269918.1	AF131215.9	4.77	2.48e-06	0.000589	0.21	0.22	Neuroticism;	chr8:10406750	chr8:11104691~11106704:-
HNSC	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4.77	2.48e-06	0.000589	-0.22	-0.22	Height;	chr5:37083971	chr5:36666214~36725195:-
HNSC	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-4.77	2.48e-06	0.000589	-0.26	-0.22	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
HNSC	cis	rs12817211	0.502	rs3741562	ENSG00000272368.2	RP4-605O3.4	-4.77	2.48e-06	0.000589	-0.21	-0.22	Colorectal or endometrial cancer;	chr12:50135953	chr12:50112197~50165618:+
HNSC	cis	rs6723108	0.627	rs1348790	ENSG00000224043.6	CCNT2-AS1	-4.77	2.48e-06	0.000589	-0.26	-0.22	Type 2 diabetes;	chr2:134882405	chr2:134735464~134918710:-
HNSC	cis	rs5758659	0.633	rs762995	ENSG00000227370.1	RP4-669P10.19	-4.77	2.48e-06	0.000589	-0.2	-0.22	Cognitive function;	chr22:42276118	chr22:42132543~42132998:+
HNSC	cis	rs12740679	1	rs12740679	ENSG00000228126.1	FALEC	-4.77	2.48e-06	0.000589	-0.3	-0.22	Headache;	chr1:150289855	chr1:150515757~150518032:+
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-4.77	2.48e-06	0.00059	-0.25	-0.22	Depression;	chr6:28135913	chr6:28170845~28172521:+
HNSC	cis	rs2253762	0.507	rs75383663	ENSG00000226864.1	ATE1-AS1	4.77	2.48e-06	0.00059	0.36	0.22	Breast cancer;	chr10:121993340	chr10:121928312~121951965:+
HNSC	cis	rs7615952	0.641	rs7632497	ENSG00000248787.1	RP11-666A20.4	-4.77	2.48e-06	0.00059	-0.3	-0.22	Blood pressure (smoking interaction);	chr3:126064243	chr3:125908005~125910272:-
HNSC	cis	rs73198271	0.74	rs10092720	ENSG00000173295.6	FAM86B3P	-4.77	2.48e-06	0.00059	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8228595~8244865:+
HNSC	cis	rs79057730	0.599	rs78347394	ENSG00000225146.1	AC073957.15	4.77	2.49e-06	0.000591	0.35	0.22	Initial pursuit acceleration;	chr7:792180	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.535	rs10005542	ENSG00000249244.1	RP11-548H18.2	4.77	2.49e-06	0.000591	0.26	0.22	Corneal astigmatism;	chr4:119347147	chr4:119391831~119395335:-
HNSC	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-4.77	2.49e-06	0.000591	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-4.77	2.49e-06	0.000591	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
HNSC	cis	rs4853525	0.522	rs62179717	ENSG00000235852.1	AC005540.3	4.77	2.49e-06	0.000591	0.27	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190726087	chr2:190880797~190882059:-
HNSC	cis	rs9329221	0.905	rs13254263	ENSG00000269918.1	AF131215.9	-4.77	2.49e-06	0.000591	-0.21	-0.22	Neuroticism;	chr8:10397671	chr8:11104691~11106704:-
HNSC	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	4.77	2.49e-06	0.000591	0.25	0.22	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
HNSC	cis	rs467650	0.534	rs27024	ENSG00000246763.5	RGMB-AS1	4.77	2.49e-06	0.000591	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98623657	chr5:98769618~98773469:-
HNSC	cis	rs9863	0.896	rs12824567	ENSG00000269938.1	RP11-214K3.20	-4.77	2.49e-06	0.000592	-0.26	-0.22	White blood cell count;	chr12:124010656	chr12:123968023~123968579:-
HNSC	cis	rs4372836	1	rs4666118	ENSG00000226833.4	AC097724.3	4.77	2.49e-06	0.000592	0.27	0.22	Body mass index;	chr2:28728832	chr2:28708953~28736205:-
HNSC	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-4.77	2.49e-06	0.000592	-0.27	-0.22	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
HNSC	cis	rs11098499	0.691	rs12510133	ENSG00000249244.1	RP11-548H18.2	4.77	2.49e-06	0.000592	0.26	0.22	Corneal astigmatism;	chr4:119350189	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.754	rs12506487	ENSG00000249244.1	RP11-548H18.2	4.77	2.49e-06	0.000592	0.26	0.22	Corneal astigmatism;	chr4:119350206	chr4:119391831~119395335:-
HNSC	cis	rs763121	0.719	rs9610995	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38661758	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs8142098	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38662752	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2413544	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38663399	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.752	rs5757222	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38664468	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs5750658	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38664912	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs8137829	ENSG00000273076.1	RP3-508I15.22	4.77	2.49e-06	0.000592	0.23	0.22	Menopause (age at onset);	chr22:38665025	chr22:38743495~38743910:+
HNSC	cis	rs4787491	0.729	rs4788212	ENSG00000183604.13	SMG1P5	4.77	2.49e-06	0.000592	0.21	0.22	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30267553~30335374:-
HNSC	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-4.77	2.49e-06	0.000592	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
HNSC	cis	rs6964587	0.869	rs2013334	ENSG00000188693.7	CYP51A1-AS1	4.77	2.49e-06	0.000592	0.23	0.22	Breast cancer;	chr7:91920343	chr7:92134604~92180725:+
HNSC	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-4.77	2.49e-06	0.000592	-0.25	-0.22	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
HNSC	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	4.77	2.5e-06	0.000592	0.27	0.22	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
HNSC	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-4.77	2.5e-06	0.000592	-0.23	-0.22	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
HNSC	cis	rs860295	0.639	rs10908469	ENSG00000203761.5	MSTO2P	-4.77	2.5e-06	0.000592	-0.17	-0.22	Body mass index;	chr1:155498941	chr1:155745829~155750137:+
HNSC	cis	rs9650657	0.504	rs10109167	ENSG00000255310.2	AF131215.2	-4.77	2.5e-06	0.000593	-0.21	-0.22	Neuroticism;	chr8:11176016	chr8:11107788~11109726:-
HNSC	cis	rs73222236	0.825	rs9834631	ENSG00000273486.1	RP11-731C17.2	4.77	2.5e-06	0.000593	0.18	0.22	Coronary artery disease;	chr3:136577757	chr3:136837338~136839021:-
HNSC	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	4.77	2.5e-06	0.000593	0.24	0.22	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
HNSC	cis	rs13073817	0.582	rs34661921	ENSG00000228956.7	SATB1-AS1	4.77	2.5e-06	0.000593	0.22	0.22	Crohn's disease;	chr3:18647223	chr3:18445024~18920401:+
HNSC	cis	rs587080	0.654	rs595366	ENSG00000245532.5	NEAT1	-4.77	2.5e-06	0.000593	-0.19	-0.22	Plateletcrit;	chr11:65429460	chr11:65422774~65445540:+
HNSC	cis	rs587080	0.624	rs674485	ENSG00000245532.5	NEAT1	-4.77	2.5e-06	0.000593	-0.19	-0.22	Plateletcrit;	chr11:65429922	chr11:65422774~65445540:+
HNSC	cis	rs763121	0.853	rs2413545	ENSG00000273076.1	RP3-508I15.22	4.77	2.5e-06	0.000593	0.23	0.22	Menopause (age at onset);	chr22:38696519	chr22:38743495~38743910:+
HNSC	cis	rs5758511	0.508	rs2854827	ENSG00000205702.9	CYP2D7	4.77	2.5e-06	0.000593	0.19	0.22	Birth weight;	chr22:42065914	chr22:42140203~42144577:-
HNSC	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-4.77	2.5e-06	0.000594	-0.24	-0.22	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
HNSC	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-4.77	2.5e-06	0.000594	-0.21	-0.22	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
HNSC	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	4.77	2.5e-06	0.000594	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	4.77	2.5e-06	0.000594	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	4.77	2.5e-06	0.000594	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
HNSC	cis	rs577676	0.586	rs666419	ENSG00000271811.1	RP1-79C4.4	4.77	2.5e-06	0.000594	0.24	0.22	Prevalent atrial fibrillation;	chr1:170645103	chr1:170667381~170669425:+
HNSC	cis	rs2058059	0.513	rs2960965	ENSG00000225648.4	SBDSP1	-4.77	2.5e-06	0.000594	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72701360	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.639	rs2960966	ENSG00000225648.4	SBDSP1	-4.77	2.5e-06	0.000594	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72701555	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.553	rs2960967	ENSG00000225648.4	SBDSP1	-4.77	2.5e-06	0.000594	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72701793	chr7:72829425~72836701:+
HNSC	cis	rs2058059	0.595	rs3015844	ENSG00000225648.4	SBDSP1	-4.77	2.5e-06	0.000594	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72708751	chr7:72829425~72836701:+
HNSC	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	4.77	2.51e-06	0.000594	0.28	0.22	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
HNSC	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-4.77	2.51e-06	0.000595	-0.25	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-4.77	2.51e-06	0.000595	-0.25	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-4.77	2.51e-06	0.000595	-0.25	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-4.77	2.51e-06	0.000595	-0.25	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
HNSC	cis	rs10791097	0.739	rs11222358	ENSG00000254842.5	RP11-890B15.2	-4.77	2.51e-06	0.000595	-0.19	-0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130860602	chr11:130844191~130865561:-
HNSC	cis	rs13073817	0.582	rs34887125	ENSG00000228956.7	SATB1-AS1	4.77	2.51e-06	0.000595	0.22	0.22	Crohn's disease;	chr3:18647303	chr3:18445024~18920401:+
HNSC	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	4.77	2.51e-06	0.000596	0.36	0.22	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
HNSC	cis	rs656319	0.513	rs34990153	ENSG00000255310.2	AF131215.2	-4.77	2.51e-06	0.000596	-0.22	-0.22	Myopia (pathological);	chr8:10138879	chr8:11107788~11109726:-
HNSC	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-4.77	2.51e-06	0.000596	-0.33	-0.22	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
HNSC	cis	rs3811273	0.614	rs4982592	ENSG00000211816.2	TRAV38-1	-4.77	2.51e-06	0.000596	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22264791	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs4981418	ENSG00000211816.2	TRAV38-1	-4.77	2.51e-06	0.000596	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22265131	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs4982593	ENSG00000211816.2	TRAV38-1	-4.77	2.51e-06	0.000596	-0.24	-0.22	Periodontal disease-related phenotypes;	chr14:22265205	chr14:22271968~22272563:+
HNSC	cis	rs9863	0.828	rs12833624	ENSG00000269938.1	RP11-214K3.20	-4.77	2.51e-06	0.000596	-0.24	-0.22	White blood cell count;	chr12:123992326	chr12:123968023~123968579:-
HNSC	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	4.77	2.51e-06	0.000596	0.26	0.22	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
HNSC	cis	rs8007643	0.915	rs11849372	ENSG00000211778.2	TRAV4	4.77	2.52e-06	0.000596	0.3	0.22	Nose morphology;	chr14:20893225	chr14:21736152~21736982:+
HNSC	cis	rs6964587	0.869	rs406	ENSG00000188693.7	CYP51A1-AS1	4.77	2.52e-06	0.000597	0.23	0.22	Breast cancer;	chr7:91917212	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.904	rs2023785	ENSG00000188693.7	CYP51A1-AS1	4.77	2.52e-06	0.000597	0.23	0.22	Breast cancer;	chr7:91918055	chr7:92134604~92180725:+
HNSC	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-4.77	2.52e-06	0.000597	-0.28	-0.22	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
HNSC	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	4.77	2.52e-06	0.000597	0.17	0.22	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
HNSC	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-4.77	2.52e-06	0.000597	-0.27	-0.22	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
HNSC	cis	rs73222236	0.787	rs6806795	ENSG00000273486.1	RP11-731C17.2	4.77	2.52e-06	0.000597	0.18	0.22	Coronary artery disease;	chr3:136587297	chr3:136837338~136839021:-
HNSC	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	4.77	2.52e-06	0.000597	0.35	0.22	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	4.77	2.52e-06	0.000597	0.35	0.22	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
HNSC	cis	rs6723108	0.603	rs6430555	ENSG00000224043.6	CCNT2-AS1	-4.77	2.52e-06	0.000597	-0.26	-0.22	Type 2 diabetes;	chr2:134890089	chr2:134735464~134918710:-
HNSC	cis	rs795484	0.683	rs572869	ENSG00000275409.1	RP11-131L12.4	-4.77	2.52e-06	0.000598	-0.24	-0.22	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118370362	chr12:118430147~118430699:+
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	4.77	2.52e-06	0.000598	0.26	0.22	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
HNSC	cis	rs1056107	0.931	rs3908938	ENSG00000225513.1	RP11-165N19.2	-4.77	2.52e-06	0.000598	-0.23	-0.22	Colorectal cancer;	chr9:112228940	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.931	rs3908939	ENSG00000225513.1	RP11-165N19.2	-4.77	2.52e-06	0.000598	-0.23	-0.22	Colorectal cancer;	chr9:112229058	chr9:112173522~112173971:-
HNSC	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-4.77	2.52e-06	0.000598	-0.2	-0.22	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
HNSC	cis	rs1218582	0.741	rs883718	ENSG00000270361.1	RP11-307C12.13	-4.77	2.52e-06	0.000598	-0.23	-0.22	Prostate cancer;	chr1:154873798	chr1:154937370~154938059:+
HNSC	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-4.77	2.53e-06	0.000598	-0.24	-0.22	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
HNSC	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	4.77	2.53e-06	0.000599	0.28	0.22	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	4.77	2.53e-06	0.000599	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
HNSC	cis	rs2058059	0.636	rs2960968	ENSG00000225648.4	SBDSP1	-4.76	2.53e-06	0.000599	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72702378	chr7:72829425~72836701:+
HNSC	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-4.76	2.53e-06	0.000599	-0.24	-0.22	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
HNSC	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-4.76	2.53e-06	0.000599	-0.25	-0.22	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
HNSC	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-4.76	2.53e-06	0.000599	-0.25	-0.22	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
HNSC	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	4.76	2.53e-06	0.000599	0.38	0.22	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
HNSC	cis	rs12893668	0.542	rs12884809	ENSG00000269940.1	RP11-73M18.7	4.76	2.53e-06	0.000599	0.2	0.22	Reticulocyte count;	chr14:103628983	chr14:103694560~103695170:+
HNSC	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-4.76	2.53e-06	0.000599	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-4.76	2.53e-06	0.000599	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
HNSC	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-4.76	2.53e-06	0.000599	-0.28	-0.22	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
HNSC	cis	rs6951245	0.572	rs60918895	ENSG00000225146.1	AC073957.15	-4.76	2.53e-06	0.000599	-0.43	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999400	chr7:1029025~1043891:+
HNSC	cis	rs950776	0.745	rs36045869	ENSG00000261762.1	RP11-650L12.2	4.76	2.53e-06	6e-04	0.26	0.22	Sudden cardiac arrest;	chr15:78637156	chr15:78589123~78591276:-
HNSC	cis	rs67981189	0.806	rs2810107	ENSG00000274818.1	RP1-292L20.3	-4.76	2.53e-06	6e-04	-0.25	-0.22	Schizophrenia;	chr14:70954340	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs2526846	ENSG00000274818.1	RP1-292L20.3	-4.76	2.53e-06	6e-04	-0.25	-0.22	Schizophrenia;	chr14:70957538	chr14:70906657~70907111:-
HNSC	cis	rs7475343	0.501	rs4339945	ENSG00000224034.1	RP11-445P17.8	-4.76	2.53e-06	6e-04	-0.3	-0.22	Intelligence;	chr10:5264435	chr10:5266033~5271236:-
HNSC	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-4.76	2.53e-06	6e-04	-0.28	-0.22	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
HNSC	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-4.76	2.53e-06	6e-04	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
HNSC	cis	rs853679	0.607	rs34662244	ENSG00000219392.1	RP1-265C24.5	-4.76	2.53e-06	6e-04	-0.45	-0.22	Depression;	chr6:28106103	chr6:28115628~28116551:+
HNSC	cis	rs35952432	1	rs35952432	ENSG00000219392.1	RP1-265C24.5	-4.76	2.53e-06	6e-04	-0.45	-0.22	Lung cancer;	chr6:28107123	chr6:28115628~28116551:+
HNSC	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	4.76	2.54e-06	0.000601	0.22	0.22	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
HNSC	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	4.76	2.54e-06	0.000601	0.26	0.22	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
HNSC	cis	rs7246760	1	rs10421336	ENSG00000267289.1	CTD-2623N2.11	4.76	2.54e-06	0.000601	0.36	0.22	Pursuit maintenance gain;	chr19:9829155	chr19:9834079~9835013:-
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	4.76	2.54e-06	0.000601	0.26	0.22	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
HNSC	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	4.76	2.54e-06	0.000601	0.25	0.22	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
HNSC	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	4.76	2.54e-06	0.000601	0.22	0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
HNSC	cis	rs656319	0.513	rs6985941	ENSG00000269918.1	AF131215.9	-4.76	2.54e-06	0.000602	-0.22	-0.22	Myopia (pathological);	chr8:10125669	chr8:11104691~11106704:-
HNSC	cis	rs36052053	0.908	rs13205489	ENSG00000219700.1	PTCHD3P3	-4.76	2.54e-06	0.000602	-0.34	-0.22	Red cell distribution width;	chr6:109282207	chr6:109288571~109290503:-
HNSC	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-4.76	2.54e-06	0.000602	-0.24	-0.22	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
HNSC	cis	rs9880211	0.644	rs6799320	ENSG00000273486.1	RP11-731C17.2	4.76	2.54e-06	0.000602	0.2	0.22	Height;Body mass index;	chr3:136083597	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.613	rs9653930	ENSG00000273486.1	RP11-731C17.2	4.76	2.54e-06	0.000602	0.2	0.22	Height;Body mass index;	chr3:136091472	chr3:136837338~136839021:-
HNSC	cis	rs6831352	0.879	rs35146617	ENSG00000263923.1	RP11-571L19.7	4.76	2.54e-06	0.000602	0.24	0.22	Alcohol dependence;	chr4:99145535	chr4:98928897~98994994:+
HNSC	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-4.76	2.54e-06	0.000602	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-4.76	2.54e-06	0.000602	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
HNSC	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-4.76	2.54e-06	0.000603	-0.24	-0.22	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
HNSC	cis	rs72615157	0.634	rs74742883	ENSG00000078319.8	PMS2P1	-4.76	2.55e-06	0.000603	-0.26	-0.22	Lung function (FEV1/FVC);	chr7:100188142	chr7:100320992~100341908:-
HNSC	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	4.76	2.55e-06	0.000603	0.24	0.22	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
HNSC	cis	rs9650657	0.571	rs4240673	ENSG00000269918.1	AF131215.9	-4.76	2.55e-06	0.000603	-0.21	-0.22	Neuroticism;	chr8:10930102	chr8:11104691~11106704:-
HNSC	cis	rs697003	1	rs697003	ENSG00000231057.3	RP11-122M14.1	-4.76	2.55e-06	0.000603	-0.21	-0.22	Red cell distribution width;	chr1:211669734	chr1:211675762~211690103:+
HNSC	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-4.76	2.55e-06	0.000604	-0.29	-0.22	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
HNSC	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	4.76	2.55e-06	0.000604	0.24	0.22	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
HNSC	cis	rs2058059	0.512	rs3015937	ENSG00000225648.4	SBDSP1	-4.76	2.55e-06	0.000604	-0.3	-0.22	Subcutaneous adipose tissue;	chr7:72698883	chr7:72829425~72836701:+
HNSC	cis	rs9402743	0.666	rs2038551	ENSG00000217482.2	HMGB1P17	4.76	2.55e-06	0.000604	0.25	0.22	Systemic lupus erythematosus;	chr6:135738039	chr6:135636086~135636713:-
HNSC	cis	rs9329221	0.683	rs525726	ENSG00000254340.1	RP11-10A14.3	-4.76	2.55e-06	0.000604	-0.26	-0.22	Neuroticism;	chr8:10030287	chr8:9141424~9145435:+
HNSC	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	4.76	2.55e-06	0.000604	0.35	0.22	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
HNSC	cis	rs13073817	0.582	rs4432662	ENSG00000228956.7	SATB1-AS1	4.76	2.55e-06	0.000604	0.23	0.22	Crohn's disease;	chr3:18643848	chr3:18445024~18920401:+
HNSC	cis	rs7809950	0.678	rs62482507	ENSG00000238832.1	snoU109	-4.76	2.55e-06	0.000604	-0.31	-0.22	Coronary artery disease;	chr7:107384043	chr7:107603363~107603507:+
HNSC	cis	rs7746199	0.673	rs35501037	ENSG00000219392.1	RP1-265C24.5	-4.76	2.55e-06	0.000604	-0.42	-0.22	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28115628~28116551:+
HNSC	cis	rs4699052	0.625	rs6828829	ENSG00000246560.2	RP11-10L12.4	4.76	2.55e-06	0.000604	0.25	0.22	Testicular germ cell tumor;	chr4:103414510	chr4:102828055~102844075:+
HNSC	cis	rs656319	0.674	rs1484639	ENSG00000254340.1	RP11-10A14.3	4.76	2.55e-06	0.000604	0.26	0.22	Myopia (pathological);	chr8:10125714	chr8:9141424~9145435:+
HNSC	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	4.76	2.55e-06	0.000605	0.24	0.22	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
HNSC	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	4.76	2.55e-06	0.000605	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	4.76	2.55e-06	0.000605	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	4.76	2.55e-06	0.000605	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
HNSC	cis	rs6964587	1	rs2299239	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.56e-06	0.000605	-0.23	-0.22	Breast cancer;	chr7:92025303	chr7:92134604~92180725:+
HNSC	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-4.76	2.56e-06	0.000605	-0.22	-0.22	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
HNSC	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	4.76	2.56e-06	0.000605	0.22	0.22	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
HNSC	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	4.76	2.56e-06	0.000605	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
HNSC	cis	rs9880211	0.898	rs73230099	ENSG00000273486.1	RP11-731C17.2	4.76	2.56e-06	0.000605	0.2	0.22	Height;Body mass index;	chr3:136833785	chr3:136837338~136839021:-
HNSC	cis	rs3811273	0.614	rs61974560	ENSG00000211816.2	TRAV38-1	-4.76	2.56e-06	0.000605	-0.26	-0.22	Periodontal disease-related phenotypes;	chr14:22267406	chr14:22271968~22272563:+
HNSC	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	4.76	2.56e-06	0.000606	0.19	0.22	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
HNSC	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-4.76	2.56e-06	0.000606	-0.35	-0.22	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
HNSC	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-4.76	2.56e-06	0.000606	-0.27	-0.22	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-4.76	2.56e-06	0.000606	-0.28	-0.22	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
HNSC	cis	rs7662987	0.517	rs1311615	ENSG00000263923.1	RP11-571L19.7	-4.76	2.56e-06	0.000606	-0.23	-0.22	Smoking initiation;	chr4:99091110	chr4:98928897~98994994:+
HNSC	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	4.76	2.56e-06	0.000606	0.28	0.22	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
HNSC	cis	rs12817211	0.549	rs6580728	ENSG00000272368.2	RP4-605O3.4	-4.76	2.56e-06	0.000606	-0.21	-0.22	Colorectal or endometrial cancer;	chr12:50147344	chr12:50112197~50165618:+
HNSC	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-4.76	2.56e-06	0.000606	-0.18	-0.22	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
HNSC	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	4.76	2.56e-06	0.000607	0.35	0.22	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
HNSC	cis	rs7085104	0.572	rs284858	ENSG00000213061.2	PFN1P11	-4.76	2.56e-06	0.000607	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102838011~102845473:-
HNSC	cis	rs11951515	0.508	rs10065689	ENSG00000249286.1	CTD-2210P15.2	4.76	2.57e-06	0.000607	0.22	0.22	Metabolite levels  (X-11787);	chr5:43604156	chr5:43586918~43588223:-
HNSC	cis	rs6964587	1	rs58965837	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.57e-06	0.000607	-0.22	-0.22	Breast cancer;	chr7:91955944	chr7:92134604~92180725:+
HNSC	cis	rs889398	0.741	rs10852461	ENSG00000226232.7	RP11-419C5.2	-4.76	2.57e-06	0.000607	-0.19	-0.22	Body mass index;	chr16:69894943	chr16:69976388~69996188:-
HNSC	cis	rs67981189	0.788	rs34093157	ENSG00000274818.1	RP1-292L20.3	4.76	2.57e-06	0.000608	0.25	0.22	Schizophrenia;	chr14:71101966	chr14:70906657~70907111:-
HNSC	cis	rs4819052	0.885	rs9980676	ENSG00000223768.1	LINC00205	-4.76	2.57e-06	0.000608	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs2838836	ENSG00000223768.1	LINC00205	-4.76	2.57e-06	0.000608	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45293285~45297354:+
HNSC	cis	rs7535099	1	rs1938489	ENSG00000224570.1	RP11-430H12.2	-4.76	2.57e-06	0.000608	-0.29	-0.22	Blood protein levels;	chr1:65582939	chr1:65576129~65578380:-
HNSC	cis	rs728616	0.867	rs12414877	ENSG00000225484.5	NUTM2B-AS1	-4.76	2.57e-06	0.000608	-0.52	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79663088~79826594:-
HNSC	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-4.76	2.57e-06	0.000608	-0.25	-0.22	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
HNSC	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-4.76	2.57e-06	0.000608	-0.2	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
HNSC	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-4.76	2.57e-06	0.000608	-0.38	-0.22	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	4.76	2.57e-06	0.000608	0.38	0.22	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
HNSC	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-4.76	2.57e-06	0.000609	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	4.76	2.58e-06	0.000609	0.26	0.22	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
HNSC	cis	rs763121	0.853	rs6519119	ENSG00000273076.1	RP3-508I15.22	4.76	2.58e-06	0.000609	0.23	0.22	Menopause (age at onset);	chr22:38593002	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	4.76	2.58e-06	0.000609	0.26	0.22	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
HNSC	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	4.76	2.58e-06	0.000609	0.3	0.22	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	4.76	2.58e-06	0.000609	0.3	0.22	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
HNSC	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-4.76	2.58e-06	0.000609	-0.27	-0.22	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
HNSC	cis	rs9527	1	rs12416687	ENSG00000236937.2	PTGES3P4	4.76	2.58e-06	0.000609	0.32	0.22	Arsenic metabolism;	chr10:102869254	chr10:102845595~102845950:+
HNSC	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-4.76	2.58e-06	0.00061	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-4.76	2.58e-06	0.00061	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-4.76	2.58e-06	0.00061	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	4.76	2.58e-06	0.00061	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	4.76	2.58e-06	0.00061	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	4.76	2.58e-06	0.00061	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
HNSC	cis	rs7824557	0.872	rs6601577	ENSG00000269918.1	AF131215.9	4.76	2.58e-06	0.00061	0.21	0.22	Retinal vascular caliber;	chr8:11245173	chr8:11104691~11106704:-
HNSC	cis	rs6723108	0.517	rs1530555	ENSG00000224043.6	CCNT2-AS1	-4.76	2.58e-06	0.00061	-0.25	-0.22	Type 2 diabetes;	chr2:134842169	chr2:134735464~134918710:-
HNSC	cis	rs9987353	0.519	rs2929465	ENSG00000173295.6	FAM86B3P	-4.76	2.58e-06	0.000611	-0.25	-0.22	Recombination measurement;	chr8:9206492	chr8:8228595~8244865:+
HNSC	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	4.76	2.58e-06	0.000611	0.24	0.22	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
HNSC	cis	rs11089937	0.616	rs4991802	ENSG00000211638.2	IGLV8-61	-4.76	2.58e-06	0.000611	-0.19	-0.22	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22098700~22099212:+
HNSC	cis	rs6964587	1	rs13224513	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.58e-06	0.000611	-0.23	-0.22	Breast cancer;	chr7:91972151	chr7:92134604~92180725:+
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000254153.1	CTA-398F10.2	4.76	2.59e-06	0.000611	0.24	0.22	Joint mobility (Beighton score);	chr8:8967994	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000254153.1	CTA-398F10.2	4.76	2.59e-06	0.000611	0.24	0.22	Mood instability;	chr8:8968365	chr8:8456909~8461337:-
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000254153.1	CTA-398F10.2	4.76	2.59e-06	0.000611	0.23	0.22	Mood instability;	chr8:8816091	chr8:8456909~8461337:-
HNSC	cis	rs6693567	0.565	rs1776273	ENSG00000228126.1	FALEC	4.76	2.59e-06	0.000611	0.25	0.22	Migraine;	chr1:150297785	chr1:150515757~150518032:+
HNSC	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-4.76	2.59e-06	0.000611	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
HNSC	cis	rs440932	0.798	rs330942	ENSG00000254153.1	CTA-398F10.2	4.76	2.59e-06	0.000611	0.23	0.22	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8456909~8461337:-
HNSC	cis	rs2179367	0.6	rs11155654	ENSG00000216906.2	RP11-350J20.9	4.76	2.59e-06	0.000611	0.33	0.22	Dupuytren's disease;	chr6:149442001	chr6:149904243~149906418:+
HNSC	cis	rs6964587	1	rs7455444	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.59e-06	0.000611	-0.23	-0.22	Breast cancer;	chr7:92009999	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10263309	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.59e-06	0.000611	-0.23	-0.22	Breast cancer;	chr7:92015951	chr7:92134604~92180725:+
HNSC	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-4.76	2.59e-06	0.000611	-0.3	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
HNSC	cis	rs9813712	0.595	rs1993217	ENSG00000249846.5	RP11-77P16.4	-4.76	2.59e-06	0.000612	-0.24	-0.22	Response to amphetamines;	chr3:130284832	chr3:130112550~130120579:+
HNSC	cis	rs7829975	0.514	rs2979139	ENSG00000254153.1	CTA-398F10.2	4.76	2.59e-06	0.000612	0.24	0.22	Mood instability;	chr8:8410803	chr8:8456909~8461337:-
HNSC	cis	rs1552244	0.832	rs61056817	ENSG00000180385.7	EMC3-AS1	4.76	2.59e-06	0.000612	0.25	0.22	Alzheimer's disease;	chr3:9985957	chr3:9986893~10006990:+
HNSC	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-4.76	2.59e-06	0.000612	-0.19	-0.22	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-4.76	2.59e-06	0.000612	-0.19	-0.22	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
HNSC	cis	rs13073817	0.582	rs13064342	ENSG00000228956.7	SATB1-AS1	4.76	2.59e-06	0.000612	0.22	0.22	Crohn's disease;	chr3:18645526	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.582	rs13064527	ENSG00000228956.7	SATB1-AS1	4.76	2.59e-06	0.000612	0.22	0.22	Crohn's disease;	chr3:18645678	chr3:18445024~18920401:+
HNSC	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-4.76	2.59e-06	0.000613	-0.22	-0.22	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-4.76	2.59e-06	0.000613	-0.22	-0.22	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
HNSC	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	4.76	2.59e-06	0.000613	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	4.76	2.59e-06	0.000613	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
HNSC	cis	rs9402743	0.634	rs9494289	ENSG00000234084.1	RP3-388E23.2	-4.76	2.59e-06	0.000613	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135594751	chr6:135301568~135307158:+
HNSC	cis	rs17270561	0.887	rs12201170	ENSG00000272810.1	U91328.22	-4.76	2.6e-06	0.000613	-0.25	-0.22	Iron status biomarkers;	chr6:25866019	chr6:26013241~26013757:+
HNSC	cis	rs3738443	0.768	rs6668154	ENSG00000259865.1	RP11-488L18.10	4.76	2.6e-06	0.000613	0.19	0.22	Alcohol dependence;	chr1:247187981	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.768	rs6665647	ENSG00000259865.1	RP11-488L18.10	4.76	2.6e-06	0.000613	0.19	0.22	Alcohol dependence;	chr1:247188127	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.868	rs61839994	ENSG00000259865.1	RP11-488L18.10	4.76	2.6e-06	0.000613	0.19	0.22	Alcohol dependence;	chr1:247195479	chr1:247187281~247188526:-
HNSC	cis	rs1799949	1	rs12951869	ENSG00000236383.6	LINC00854	-4.76	2.6e-06	0.000614	-0.2	-0.22	Menopause (age at onset);	chr17:43035550	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11654452	ENSG00000236383.6	LINC00854	-4.76	2.6e-06	0.000614	-0.2	-0.22	Menopause (age at onset);	chr17:43037366	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4793189	ENSG00000236383.6	LINC00854	-4.76	2.6e-06	0.000614	-0.2	-0.22	Menopause (age at onset);	chr17:43038698	chr17:43216941~43305976:-
HNSC	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.76	2.6e-06	0.000614	-0.23	-0.22	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
HNSC	cis	rs6657613	0.815	rs2871775	ENSG00000186715.9	MST1L	-4.76	2.6e-06	0.000614	-0.18	-0.22	Hip circumference adjusted for BMI;	chr1:17019410	chr1:16754910~16770237:-
HNSC	cis	rs6701713	0.919	rs6661489	ENSG00000274245.1	RP11-357P18.2	-4.76	2.6e-06	0.000614	-0.35	-0.22	Alzheimer's disease (late onset);	chr1:207524699	chr1:207372559~207373252:+
HNSC	cis	rs10109025	0.701	rs10101292	ENSG00000269918.1	AF131215.9	-4.76	2.6e-06	0.000614	-0.22	-0.22	Joint mobility (Beighton score);	chr8:10998964	chr8:11104691~11106704:-
HNSC	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-4.76	2.6e-06	0.000614	-0.24	-0.22	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
HNSC	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-4.76	2.6e-06	0.000614	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-4.76	2.6e-06	0.000614	-0.25	-0.22	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
HNSC	cis	rs7617773	0.963	rs6800730	ENSG00000228638.1	FCF1P2	-4.76	2.6e-06	0.000614	-0.2	-0.22	Coronary artery disease;	chr3:48132720	chr3:48290793~48291375:-
HNSC	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	4.76	2.6e-06	0.000614	0.28	0.22	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
HNSC	cis	rs2243480	0.522	rs431168	ENSG00000164669.11	INTS4P1	4.76	2.6e-06	0.000615	0.53	0.22	Diabetic kidney disease;	chr7:66046617	chr7:65141225~65234216:+
HNSC	cis	rs7085104	0.572	rs284857	ENSG00000213061.2	PFN1P11	-4.76	2.6e-06	0.000615	-0.27	-0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102838011~102845473:-
HNSC	cis	rs1971762	0.545	rs7485472	ENSG00000270175.1	RP11-793H13.11	-4.76	2.6e-06	0.000615	-0.19	-0.22	Height;	chr12:53650654	chr12:53500162~53500936:-
HNSC	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	4.76	2.61e-06	0.000615	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	4.76	2.61e-06	0.000615	0.29	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
HNSC	cis	rs7824557	0.815	rs958648	ENSG00000255310.2	AF131215.2	-4.76	2.61e-06	0.000615	-0.2	-0.22	Retinal vascular caliber;	chr8:11246386	chr8:11107788~11109726:-
HNSC	cis	rs2280018	0.538	rs7404526	ENSG00000263335.1	AF001548.5	-4.76	2.61e-06	0.000615	-0.28	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15726674~15732993:+
HNSC	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-4.76	2.61e-06	0.000615	-0.28	-0.22	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-4.76	2.61e-06	0.000615	-0.28	-0.22	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-4.76	2.61e-06	0.000615	-0.28	-0.22	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs35030260	ENSG00000219392.1	RP1-265C24.5	-4.76	2.61e-06	0.000616	-0.43	-0.22	Depression;	chr6:28337731	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13217619	ENSG00000219392.1	RP1-265C24.5	-4.76	2.61e-06	0.000616	-0.43	-0.22	Depression;	chr6:28338894	chr6:28115628~28116551:+
HNSC	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	4.76	2.61e-06	0.000616	0.25	0.22	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
HNSC	cis	rs2286503	1	rs2286503	ENSG00000226329.2	AC005682.6	4.76	2.61e-06	0.000616	0.26	0.22	Fibrinogen;	chr7:22816987	chr7:22863874~22881350:-
HNSC	cis	rs2286503	1	rs2286501	ENSG00000226329.2	AC005682.6	4.76	2.61e-06	0.000616	0.26	0.22	Fibrinogen;	chr7:22817166	chr7:22863874~22881350:-
HNSC	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	4.76	2.61e-06	0.000616	0.21	0.22	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
HNSC	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	4.76	2.61e-06	0.000616	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
HNSC	cis	rs3806843	1	rs10053586	ENSG00000202515.1	VTRNA1-3	-4.76	2.61e-06	0.000616	-0.24	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr5:140726158~140726246:+
HNSC	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	4.76	2.61e-06	0.000616	0.24	0.22	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
HNSC	cis	rs7824557	0.767	rs2164273	ENSG00000255310.2	AF131215.2	4.76	2.61e-06	0.000616	0.21	0.22	Retinal vascular caliber;	chr8:11310990	chr8:11107788~11109726:-
HNSC	cis	rs898123	0.897	rs72837607	ENSG00000234896.1	OR7E62P	4.76	2.61e-06	0.000617	0.26	0.22	Coronary artery disease;	chr2:71119819	chr2:71055527~71056003:+
HNSC	cis	rs6964587	0.967	rs7786031	ENSG00000188693.7	CYP51A1-AS1	-4.76	2.61e-06	0.000617	-0.23	-0.22	Breast cancer;	chr7:92019687	chr7:92134604~92180725:+
HNSC	cis	rs9402743	0.634	rs9483853	ENSG00000234084.1	RP3-388E23.2	-4.76	2.61e-06	0.000617	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135595767	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.634	rs4394233	ENSG00000234084.1	RP3-388E23.2	-4.76	2.61e-06	0.000617	-0.22	-0.22	Systemic lupus erythematosus;	chr6:135596752	chr6:135301568~135307158:+
HNSC	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	4.76	2.62e-06	0.000617	0.21	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
HNSC	cis	rs4908769	0.624	rs2708630	ENSG00000232912.4	RP5-1115A15.1	-4.76	2.62e-06	0.000617	-0.24	-0.22	Allergy;	chr1:8387344	chr1:8424645~8434838:+
HNSC	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	4.76	2.62e-06	0.000617	0.27	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
HNSC	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	4.76	2.62e-06	0.000618	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
HNSC	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	4.76	2.62e-06	0.000618	0.25	0.21	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
HNSC	cis	rs12935418	0.672	rs3784814	ENSG00000278985.1	RP11-303E16.9	4.76	2.62e-06	0.000618	0.21	0.21	Mean corpuscular volume;	chr16:81007652	chr16:80982319~80984094:-
HNSC	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	4.76	2.62e-06	0.000618	0.25	0.21	Height;	chr14:75064757	chr14:75011269~75012851:-
HNSC	cis	rs9300255	0.679	rs58809476	ENSG00000280120.1	RP11-546D6.3	-4.76	2.62e-06	0.000618	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123240333	chr12:123152324~123153377:-
HNSC	cis	rs889398	0.741	rs8049373	ENSG00000226232.7	RP11-419C5.2	-4.76	2.62e-06	0.000619	-0.19	-0.21	Body mass index;	chr16:69905802	chr16:69976388~69996188:-
HNSC	cis	rs73222236	0.783	rs67214626	ENSG00000273486.1	RP11-731C17.2	4.76	2.62e-06	0.000619	0.18	0.21	Coronary artery disease;	chr3:136270534	chr3:136837338~136839021:-
HNSC	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-4.76	2.62e-06	0.000619	-0.27	-0.21	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
HNSC	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-4.76	2.63e-06	0.000619	-0.17	-0.21	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
HNSC	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.76	2.63e-06	0.000619	0.22	0.21	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.76	2.63e-06	0.000619	0.22	0.21	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.76	2.63e-06	0.000619	0.22	0.21	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
HNSC	cis	rs4787491	0.729	rs7191849	ENSG00000183604.13	SMG1P5	-4.76	2.63e-06	0.00062	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30267553~30335374:-
HNSC	cis	rs988913	0.581	rs2174115	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54992981	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.581	rs3125267	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54993123	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.581	rs2134537	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54993208	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.513	rs2134538	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54993359	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.581	rs3125269	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54993651	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.581	rs1580891	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54994294	chr6:54840118~54840855:-
HNSC	cis	rs651907	0.557	rs11710533	ENSG00000244119.1	PDCL3P4	4.76	2.63e-06	0.00062	0.21	0.21	Colorectal cancer;	chr3:101632628	chr3:101712472~101713191:+
HNSC	cis	rs9863	0.861	rs4405410	ENSG00000269938.1	RP11-214K3.20	-4.76	2.63e-06	0.00062	-0.25	-0.21	White blood cell count;	chr12:123951241	chr12:123968023~123968579:-
HNSC	cis	rs11893307	0.566	rs7558832	ENSG00000235852.1	AC005540.3	4.76	2.63e-06	0.00062	0.28	0.21	Mean platelet volume;	chr2:190695863	chr2:190880797~190882059:-
HNSC	cis	rs988913	0.581	rs1354288	ENSG00000224984.1	RP11-524H19.2	4.76	2.63e-06	0.00062	0.25	0.21	Menarche (age at onset);	chr6:54991825	chr6:54840118~54840855:-
HNSC	cis	rs4718428	0.924	rs6971897	ENSG00000179406.6	LINC00174	-4.76	2.64e-06	0.000621	-0.29	-0.21	Corneal structure;	chr7:66947787	chr7:66376044~66401338:-
HNSC	cis	rs12468226	1	rs12472408	ENSG00000226261.1	AC064836.3	4.76	2.64e-06	0.000621	0.31	0.21	Urate levels;	chr2:202413973	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs115170232	ENSG00000226261.1	AC064836.3	4.76	2.64e-06	0.000621	0.31	0.21	Urate levels;	chr2:202416790	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs76284304	ENSG00000226261.1	AC064836.3	4.76	2.64e-06	0.000621	0.31	0.21	Urate levels;	chr2:202427116	chr2:202336024~202336727:-
HNSC	cis	rs12468226	1	rs16839149	ENSG00000226261.1	AC064836.3	4.76	2.64e-06	0.000621	0.31	0.21	Urate levels;	chr2:202427621	chr2:202336024~202336727:-
HNSC	cis	rs6964587	0.934	rs2961019	ENSG00000188693.7	CYP51A1-AS1	4.76	2.64e-06	0.000622	0.23	0.21	Breast cancer;	chr7:91943435	chr7:92134604~92180725:+
HNSC	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	4.76	2.64e-06	0.000622	0.22	0.21	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
HNSC	cis	rs2058059	0.636	rs2022928	ENSG00000225648.4	SBDSP1	-4.76	2.64e-06	0.000622	-0.3	-0.21	Subcutaneous adipose tissue;	chr7:72707432	chr7:72829425~72836701:+
HNSC	cis	rs1552244	0.882	rs17050699	ENSG00000180385.7	EMC3-AS1	4.76	2.64e-06	0.000622	0.24	0.21	Alzheimer's disease;	chr3:9995483	chr3:9986893~10006990:+
HNSC	cis	rs72843506	0.722	rs9908418	ENSG00000261033.1	RP11-209D14.2	4.76	2.64e-06	0.000622	0.35	0.21	Schizophrenia;	chr17:20311252	chr17:20008051~20009234:-
HNSC	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-4.76	2.64e-06	0.000622	-0.28	-0.21	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
HNSC	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	4.76	2.64e-06	0.000622	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	4.76	2.64e-06	0.000622	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	4.76	2.64e-06	0.000622	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	4.76	2.64e-06	0.000622	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	4.76	2.64e-06	0.000622	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
HNSC	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.76	2.64e-06	0.000622	0.22	0.21	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
HNSC	cis	rs889398	0.741	rs6499270	ENSG00000226232.7	RP11-419C5.2	4.76	2.64e-06	0.000622	0.19	0.21	Body mass index;	chr16:69883837	chr16:69976388~69996188:-
HNSC	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	4.76	2.64e-06	0.000622	0.24	0.21	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
HNSC	cis	rs1008375	0.966	rs6449313	ENSG00000249502.1	AC006160.5	-4.76	2.64e-06	0.000623	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586697	chr4:17587467~17614571:-
HNSC	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-4.76	2.64e-06	0.000623	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
HNSC	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	4.76	2.64e-06	0.000623	0.37	0.21	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.691	rs12502524	ENSG00000249244.1	RP11-548H18.2	4.76	2.65e-06	0.000623	0.26	0.21	Corneal astigmatism;	chr4:119350259	chr4:119391831~119395335:-
HNSC	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	4.76	2.65e-06	0.000624	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
HNSC	cis	rs6693567	0.565	rs11205370	ENSG00000228126.1	FALEC	4.75	2.65e-06	0.000624	0.26	0.21	Migraine;	chr1:150425091	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs11205371	ENSG00000228126.1	FALEC	4.75	2.65e-06	0.000624	0.26	0.21	Migraine;	chr1:150426034	chr1:150515757~150518032:+
HNSC	cis	rs9650657	0.771	rs4240670	ENSG00000269918.1	AF131215.9	-4.75	2.65e-06	0.000624	-0.22	-0.21	Neuroticism;	chr8:10808338	chr8:11104691~11106704:-
HNSC	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	4.75	2.65e-06	0.000624	0.21	0.21	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
HNSC	cis	rs4699052	0.507	rs7662107	ENSG00000246560.2	RP11-10L12.4	4.75	2.65e-06	0.000625	0.27	0.21	Testicular germ cell tumor;	chr4:103337239	chr4:102828055~102844075:+
HNSC	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-4.75	2.65e-06	0.000625	-0.28	-0.21	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
HNSC	cis	rs6723108	0.581	rs1446525	ENSG00000224043.6	CCNT2-AS1	-4.75	2.66e-06	0.000626	-0.26	-0.21	Type 2 diabetes;	chr2:134880277	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs6430554	ENSG00000224043.6	CCNT2-AS1	-4.75	2.66e-06	0.000626	-0.26	-0.21	Type 2 diabetes;	chr2:134880891	chr2:134735464~134918710:-
HNSC	cis	rs4699052	0.625	rs28498687	ENSG00000246560.2	RP11-10L12.4	4.75	2.66e-06	0.000626	0.25	0.21	Testicular germ cell tumor;	chr4:103412574	chr4:102828055~102844075:+
HNSC	cis	rs2333021	0.727	rs1986616	ENSG00000258376.2	RP4-647C14.2	4.75	2.66e-06	0.000626	0.25	0.21	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73074228	chr14:73242651~73245979:-
HNSC	cis	rs988913	0.723	rs9464197	ENSG00000224984.1	RP11-524H19.2	4.75	2.66e-06	0.000626	0.24	0.21	Menarche (age at onset);	chr6:55133940	chr6:54840118~54840855:-
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000254340.1	RP11-10A14.3	-4.75	2.66e-06	0.000626	-0.27	-0.21	Mood instability;	chr8:8691510	chr8:9141424~9145435:+
HNSC	cis	rs9816784	0.576	rs12631246	ENSG00000231464.1	AC024937.4	4.75	2.66e-06	0.000627	0.23	0.21	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195996738~195998233:+
HNSC	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-4.75	2.66e-06	0.000627	-0.18	-0.21	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-4.75	2.66e-06	0.000627	-0.29	-0.21	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-4.75	2.66e-06	0.000627	-0.29	-0.21	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
HNSC	cis	rs11023332	0.706	rs10766197	ENSG00000251991.1	RNU7-49P	4.75	2.66e-06	0.000627	0.24	0.21	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr11:14478892~14478953:+
HNSC	cis	rs12893668	0.703	rs55751606	ENSG00000269940.1	RP11-73M18.7	4.75	2.66e-06	0.000627	0.22	0.21	Reticulocyte count;	chr14:103562469	chr14:103694560~103695170:+
HNSC	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	4.75	2.66e-06	0.000627	0.37	0.21	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
HNSC	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-4.75	2.67e-06	0.000628	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
HNSC	cis	rs12291225	0.585	rs10832246	ENSG00000251991.1	RNU7-49P	4.75	2.67e-06	0.000628	0.25	0.21	Sense of smell;	chr11:14359282	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.585	rs11023197	ENSG00000251991.1	RNU7-49P	4.75	2.67e-06	0.000628	0.25	0.21	Sense of smell;	chr11:14359452	chr11:14478892~14478953:+
HNSC	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-4.75	2.67e-06	0.000628	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-4.75	2.67e-06	0.000628	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-4.75	2.67e-06	0.000628	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000254340.1	RP11-10A14.3	4.75	2.67e-06	0.000628	0.26	0.21	Mood instability;	chr8:8283379	chr8:9141424~9145435:+
HNSC	cis	rs763121	0.853	rs35565791	ENSG00000273076.1	RP3-508I15.22	4.75	2.67e-06	0.000628	0.23	0.21	Menopause (age at onset);	chr22:38667006	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs35522482	ENSG00000273076.1	RP3-508I15.22	4.75	2.67e-06	0.000628	0.23	0.21	Menopause (age at onset);	chr22:38667010	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2072796	ENSG00000273076.1	RP3-508I15.22	4.75	2.67e-06	0.000628	0.23	0.21	Menopause (age at onset);	chr22:38668225	chr22:38743495~38743910:+
HNSC	cis	rs4819052	0.807	rs4819047	ENSG00000223768.1	LINC00205	-4.75	2.67e-06	0.000629	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45293285~45297354:+
HNSC	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	4.75	2.67e-06	0.000629	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	4.75	2.67e-06	0.000629	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.828	rs4765562	ENSG00000269938.1	RP11-214K3.20	-4.75	2.67e-06	0.000629	-0.24	-0.21	White blood cell count;	chr12:123988024	chr12:123968023~123968579:-
HNSC	cis	rs6964587	1	rs6968870	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.67e-06	0.000629	-0.23	-0.21	Breast cancer;	chr7:92031797	chr7:92134604~92180725:+
HNSC	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-4.75	2.68e-06	0.00063	-0.27	-0.21	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
HNSC	cis	rs3806843	0.766	rs2530239	ENSG00000202515.1	VTRNA1-3	4.75	2.68e-06	0.00063	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr5:140726158~140726246:+
HNSC	cis	rs6787172	0.748	rs7630443	ENSG00000272087.1	RP11-379F4.7	-4.75	2.68e-06	0.00063	-0.22	-0.21	Subjective well-being;	chr3:158406115	chr3:158693120~158693768:-
HNSC	cis	rs116095464	0.558	rs2288459	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.68e-06	0.00063	-0.29	-0.21	Breast cancer;	chr5:231028	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs2288458	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.68e-06	0.00063	-0.29	-0.21	Breast cancer;	chr5:231145	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs2288457	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.68e-06	0.00063	-0.29	-0.21	Breast cancer;	chr5:231155	chr5:288833~290321:-
HNSC	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	4.75	2.68e-06	0.00063	0.26	0.21	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
HNSC	cis	rs728616	0.867	rs56000427	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.68e-06	0.00063	-0.52	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:79663088~79826594:-
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.75	2.68e-06	0.00063	0.25	0.21	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
HNSC	cis	rs4218	0.635	rs10431792	ENSG00000277144.1	RP11-59H7.4	-4.75	2.68e-06	0.00063	-0.28	-0.21	Social communication problems;	chr15:59066181	chr15:59115547~59116089:-
HNSC	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.75	2.68e-06	0.000631	-0.23	-0.21	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000250412.1	KLHL2P1	4.75	2.68e-06	0.000631	0.28	0.21	Corneal astigmatism;	chr4:119502574	chr4:119334329~119378233:+
HNSC	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	4.75	2.68e-06	0.000631	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	4.75	2.68e-06	0.000631	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	4.75	2.68e-06	0.000631	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
HNSC	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	4.75	2.68e-06	0.000631	0.38	0.21	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
HNSC	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	4.75	2.68e-06	0.000631	0.38	0.21	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-4.75	2.68e-06	0.000631	-0.23	-0.21	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
HNSC	cis	rs6723108	0.603	rs1947112	ENSG00000224043.6	CCNT2-AS1	-4.75	2.68e-06	0.000631	-0.26	-0.21	Type 2 diabetes;	chr2:134958387	chr2:134735464~134918710:-
HNSC	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-4.75	2.69e-06	0.000632	-0.22	-0.21	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-4.75	2.69e-06	0.000632	-0.22	-0.21	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
HNSC	cis	rs10435719	0.746	rs58007588	ENSG00000255495.1	AC145124.2	4.75	2.69e-06	0.000632	0.25	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:12194467~12196280:+
HNSC	cis	rs7296418	0.961	rs10773921	ENSG00000280120.1	RP11-546D6.3	4.75	2.69e-06	0.000632	0.18	0.21	Platelet count;	chr12:123057059	chr12:123152324~123153377:-
HNSC	cis	rs7829975	0.684	rs488904	ENSG00000254153.1	CTA-398F10.2	-4.75	2.69e-06	0.000632	-0.24	-0.21	Mood instability;	chr8:8730061	chr8:8456909~8461337:-
HNSC	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-4.75	2.69e-06	0.000632	-0.24	-0.21	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
HNSC	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-4.75	2.69e-06	0.000632	-0.24	-0.21	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
HNSC	cis	rs9393777	0.841	rs13207082	ENSG00000219392.1	RP1-265C24.5	-4.75	2.69e-06	0.000632	-0.39	-0.21	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-4.75	2.69e-06	0.000632	-0.22	-0.21	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
HNSC	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	4.75	2.69e-06	0.000633	0.29	0.21	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
HNSC	cis	rs12682352	0.602	rs28399241	ENSG00000254340.1	RP11-10A14.3	4.75	2.69e-06	0.000633	0.27	0.21	Neuroticism;	chr8:8805705	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	4.75	2.69e-06	0.000633	0.26	0.21	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
HNSC	cis	rs1557765	0.527	rs4756887	ENSG00000260196.1	RP1-239B22.5	4.75	2.69e-06	0.000633	0.23	0.21	Body mass index;Social communication problems;	chr11:17373050	chr11:17380649~17383531:+
HNSC	cis	rs42490	0.576	rs376962	ENSG00000251136.7	RP11-37B2.1	-4.75	2.69e-06	0.000633	-0.2	-0.21	Leprosy;	chr8:89862004	chr8:89609409~89757727:-
HNSC	cis	rs1799949	1	rs11657053	ENSG00000236383.6	LINC00854	-4.75	2.69e-06	0.000634	-0.2	-0.21	Menopause (age at onset);	chr17:43039112	chr17:43216941~43305976:-
HNSC	cis	rs6693567	0.565	rs698921	ENSG00000228126.1	FALEC	4.75	2.7e-06	0.000634	0.26	0.21	Migraine;	chr1:150407041	chr1:150515757~150518032:+
HNSC	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-4.75	2.7e-06	0.000634	-0.31	-0.21	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
HNSC	cis	rs11976180	1	rs2961118	ENSG00000273234.1	OR2A13P	-4.75	2.7e-06	0.000634	-0.24	-0.21	Obesity-related traits;	chr7:144058350	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2371244	ENSG00000273234.1	OR2A13P	-4.75	2.7e-06	0.000634	-0.24	-0.21	Obesity-related traits;	chr7:144060518	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs4726669	ENSG00000273234.1	OR2A13P	-4.75	2.7e-06	0.000634	-0.24	-0.21	Obesity-related traits;	chr7:144061098	chr7:144142009~144142938:+
HNSC	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	4.75	2.7e-06	0.000634	0.25	0.21	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
HNSC	cis	rs6928977	1	rs6928977	ENSG00000217482.2	HMGB1P17	-4.75	2.7e-06	0.000634	-0.24	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135636086~135636713:-
HNSC	cis	rs6964587	1	rs12539231	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.7e-06	0.000634	-0.23	-0.21	Breast cancer;	chr7:92005649	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs28399886	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.7e-06	0.000634	-0.23	-0.21	Breast cancer;	chr7:92009137	chr7:92134604~92180725:+
HNSC	cis	rs697003	0.966	rs701929	ENSG00000231057.3	RP11-122M14.1	4.75	2.7e-06	0.000634	0.21	0.21	Red cell distribution width;	chr1:211673534	chr1:211675762~211690103:+
HNSC	cis	rs79478560	0.504	rs1317386	ENSG00000269938.1	RP11-214K3.20	4.75	2.7e-06	0.000634	0.23	0.21	Lymphocyte counts;	chr12:123889131	chr12:123968023~123968579:-
HNSC	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	4.75	2.7e-06	0.000634	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
HNSC	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	4.75	2.7e-06	0.000634	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
HNSC	cis	rs7662987	0.517	rs2851265	ENSG00000263923.1	RP11-571L19.7	-4.75	2.7e-06	0.000634	-0.23	-0.21	Smoking initiation;	chr4:99108533	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602877	ENSG00000263923.1	RP11-571L19.7	-4.75	2.7e-06	0.000634	-0.23	-0.21	Smoking initiation;	chr4:99118696	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602878	ENSG00000263923.1	RP11-571L19.7	-4.75	2.7e-06	0.000634	-0.23	-0.21	Smoking initiation;	chr4:99118802	chr4:98928897~98994994:+
HNSC	cis	rs7121616	0.576	rs7111598	ENSG00000200879.1	SNORD14E	4.75	2.7e-06	0.000635	0.29	0.21	Breast cancer;	chr11:123055438	chr11:123058077~123058161:-
HNSC	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-4.75	2.7e-06	0.000635	-0.26	-0.21	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
HNSC	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	4.75	2.7e-06	0.000635	0.22	0.21	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
HNSC	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	4.75	2.7e-06	0.000635	0.29	0.21	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000254340.1	RP11-10A14.3	4.75	2.71e-06	0.000636	0.26	0.21	Mood instability;	chr8:8522961	chr8:9141424~9145435:+
HNSC	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	4.75	2.71e-06	0.000636	0.21	0.21	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
HNSC	cis	rs6723108	0.603	rs3769023	ENSG00000224043.6	CCNT2-AS1	-4.75	2.71e-06	0.000637	-0.26	-0.21	Type 2 diabetes;	chr2:134956133	chr2:134735464~134918710:-
HNSC	cis	rs6964587	1	rs10235941	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.71e-06	0.000637	-0.22	-0.21	Breast cancer;	chr7:91957736	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs2188153	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.71e-06	0.000637	-0.22	-0.21	Breast cancer;	chr7:91965803	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs10429103	ENSG00000188693.7	CYP51A1-AS1	-4.75	2.71e-06	0.000637	-0.22	-0.21	Breast cancer;	chr7:91969129	chr7:92134604~92180725:+
HNSC	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
HNSC	cis	rs155076	1	rs564685	ENSG00000233325.3	MIPEPP3	4.75	2.71e-06	0.000637	0.38	0.21	White matter hyperintensity burden;	chr13:21272740	chr13:21298139~21306373:+
HNSC	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000637	0.29	0.21	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
HNSC	cis	rs10462794	1	rs4296773	ENSG00000260763.1	RP11-445O3.3	4.75	2.71e-06	0.000637	0.28	0.21	DNA methylation (variation);	chr5:4486857	chr5:4436850~4440259:-
HNSC	cis	rs3806843	0.966	rs10060640	ENSG00000202515.1	VTRNA1-3	-4.75	2.71e-06	0.000637	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr5:140726158~140726246:+
HNSC	cis	rs1555322	0.872	rs2425033	ENSG00000126005.14	MMP24-AS1	-4.75	2.72e-06	0.000638	-0.37	-0.21	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35216462~35278131:-
HNSC	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-4.75	2.72e-06	0.000638	-0.5	-0.21	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
HNSC	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	4.75	2.72e-06	0.000638	0.23	0.21	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
HNSC	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.75	2.72e-06	0.000638	-0.21	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
HNSC	cis	rs1964356	0.967	rs17701675	ENSG00000233609.3	RP11-62H7.2	-4.75	2.72e-06	0.000638	-0.21	-0.21	Mean corpuscular volume;	chr8:8993123	chr8:8961200~8979025:+
HNSC	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-4.75	2.72e-06	0.000638	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
HNSC	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.75	2.72e-06	0.000639	-0.23	-0.21	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
HNSC	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	4.75	2.72e-06	0.000639	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	4.75	2.72e-06	0.000639	0.26	0.21	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	4.75	2.72e-06	0.000639	0.26	0.21	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
HNSC	cis	rs5758659	0.716	rs5758661	ENSG00000273366.1	CTA-989H11.1	-4.75	2.72e-06	0.000639	-0.25	-0.21	Cognitive function;	chr22:42228439	chr22:42278188~42278846:+
HNSC	cis	rs116095464	0.558	rs6878087	ENSG00000250848.1	CTD-2083E4.5	4.75	2.72e-06	0.000639	0.29	0.21	Breast cancer;	chr5:223002	chr5:288833~290321:-
HNSC	cis	rs11893307	0.509	rs17465200	ENSG00000228509.4	AC006460.2	4.75	2.72e-06	0.000639	0.27	0.21	Mean platelet volume;	chr2:190684910	chr2:190676944~190708716:-
HNSC	cis	rs6723108	0.627	rs2053727	ENSG00000224043.6	CCNT2-AS1	-4.75	2.72e-06	0.000639	-0.26	-0.21	Type 2 diabetes;	chr2:134885728	chr2:134735464~134918710:-
HNSC	cis	rs3863381	1	rs3863381	ENSG00000277715.1	RP11-651L5.3	4.75	2.72e-06	0.00064	0.28	0.21	Night sleep phenotypes;	chr12:105709790	chr12:106250759~106252786:+
HNSC	cis	rs11098499	0.569	rs10023641	ENSG00000249244.1	RP11-548H18.2	4.75	2.73e-06	0.00064	0.26	0.21	Corneal astigmatism;	chr4:119337255	chr4:119391831~119395335:-
HNSC	cis	rs3736485	0.932	rs28795073	ENSG00000259438.1	CTD-2650P22.1	4.75	2.73e-06	0.00064	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51635365	chr15:52010999~52019095:-
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000254340.1	RP11-10A14.3	-4.75	2.73e-06	0.00064	-0.27	-0.21	Mood instability;	chr8:8689600	chr8:9141424~9145435:+
HNSC	cis	rs1355223	0.583	rs2941044	ENSG00000271369.1	RP11-350D17.3	4.75	2.73e-06	0.00064	0.25	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34845897	chr11:34709600~34710161:+
HNSC	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-4.75	2.73e-06	0.000641	-0.25	-0.21	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
HNSC	cis	rs116095464	1	rs6555160	ENSG00000250848.1	CTD-2083E4.5	4.75	2.73e-06	0.000641	0.35	0.21	Breast cancer;	chr5:311554	chr5:288833~290321:-
HNSC	cis	rs9300255	0.543	rs520088	ENSG00000280120.1	RP11-546D6.3	4.75	2.73e-06	0.000641	0.2	0.21	Neutrophil percentage of white cells;	chr12:123037603	chr12:123152324~123153377:-
HNSC	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	4.75	2.73e-06	0.000641	0.24	0.21	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	4.75	2.73e-06	0.000641	0.24	0.21	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000226314.6	ZNF192P1	-4.75	2.73e-06	0.000641	-0.26	-0.21	Parkinson's disease;	chr6:27997725	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000226314.6	ZNF192P1	-4.75	2.73e-06	0.000641	-0.26	-0.21	Parkinson's disease;	chr6:27999813	chr6:28161781~28169594:+
HNSC	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.75	2.73e-06	0.000641	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.75	2.73e-06	0.000641	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.75	2.73e-06	0.000641	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
HNSC	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.75	2.73e-06	0.000642	0.24	0.21	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
HNSC	cis	rs170183	1	rs170183	ENSG00000233818.1	AP000695.4	4.75	2.73e-06	0.000642	0.22	0.21	Bone mineral density;	chr21:36476036	chr21:36445731~36532408:+
HNSC	cis	rs12817211	0.524	rs7967979	ENSG00000272368.2	RP4-605O3.4	-4.75	2.74e-06	0.000642	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50126893	chr12:50112197~50165618:+
HNSC	cis	rs12817211	0.548	rs2204684	ENSG00000272368.2	RP4-605O3.4	-4.75	2.74e-06	0.000642	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50128689	chr12:50112197~50165618:+
HNSC	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	4.75	2.74e-06	0.000642	0.26	0.21	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
HNSC	cis	rs597539	0.552	rs6591361	ENSG00000255741.1	RP11-757G1.5	-4.75	2.74e-06	0.000642	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68941503~68942852:-
HNSC	cis	rs11756659	0.653	rs199729	ENSG00000272462.2	U91328.19	4.75	2.74e-06	0.000642	0.25	0.21	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:25992662~26001775:+
HNSC	cis	rs1150668	0.768	rs1233713	ENSG00000219392.1	RP1-265C24.5	-4.75	2.74e-06	0.000642	-0.24	-0.21	Pubertal anthropometrics;	chr6:28230503	chr6:28115628~28116551:+
HNSC	cis	rs10083777	0.551	rs79378252	ENSG00000261061.1	RP11-303E16.2	-4.75	2.74e-06	0.000643	-0.44	-0.21	Metabolite levels (small molecules and protein measures);	chr16:81014554	chr16:81030770~81031485:+
HNSC	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-4.75	2.74e-06	0.000643	-0.22	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
HNSC	cis	rs4763879	0.593	rs7960328	ENSG00000278635.1	CTD-2318O12.1	4.75	2.74e-06	0.000643	0.16	0.21	Type 1 diabetes;	chr12:9699584	chr12:9415641~9416718:+
HNSC	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-4.75	2.74e-06	0.000643	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
HNSC	cis	rs3736485	0.932	rs8037167	ENSG00000259438.1	CTD-2650P22.1	4.75	2.74e-06	0.000643	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51625929	chr15:52010999~52019095:-
HNSC	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	4.75	2.74e-06	0.000643	0.22	0.21	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
HNSC	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-4.75	2.75e-06	0.000644	-0.18	-0.21	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
HNSC	cis	rs7590368	0.924	rs72779464	ENSG00000272275.1	RP11-791G15.2	4.75	2.75e-06	0.000644	0.28	0.21	Educational attainment (years of education);	chr2:10823033	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs17456225	ENSG00000272275.1	RP11-791G15.2	4.75	2.75e-06	0.000644	0.28	0.21	Educational attainment (years of education);	chr2:10823112	chr2:10767875~10770058:-
HNSC	cis	rs9650657	0.644	rs4395858	ENSG00000269918.1	AF131215.9	4.75	2.75e-06	0.000644	0.21	0.21	Neuroticism;	chr8:10663511	chr8:11104691~11106704:-
HNSC	cis	rs4718428	0.96	rs6460317	ENSG00000179406.6	LINC00174	-4.75	2.75e-06	0.000644	-0.29	-0.21	Corneal structure;	chr7:66925268	chr7:66376044~66401338:-
HNSC	cis	rs10462794	1	rs6860429	ENSG00000260763.1	RP11-445O3.3	-4.75	2.75e-06	0.000645	-0.28	-0.21	DNA methylation (variation);	chr5:4482122	chr5:4436850~4440259:-
HNSC	cis	rs1971762	0.545	rs9788134	ENSG00000270175.1	RP11-793H13.11	-4.75	2.75e-06	0.000645	-0.19	-0.21	Height;	chr12:53652283	chr12:53500162~53500936:-
HNSC	cis	rs67981189	0.896	rs2526890	ENSG00000274818.1	RP1-292L20.3	-4.75	2.75e-06	0.000645	-0.25	-0.21	Schizophrenia;	chr14:70963410	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs2810100	ENSG00000274818.1	RP1-292L20.3	-4.75	2.75e-06	0.000645	-0.25	-0.21	Schizophrenia;	chr14:70965455	chr14:70906657~70907111:-
HNSC	cis	rs116095464	0.718	rs62331563	ENSG00000277812.1	AC021087.1	4.75	2.75e-06	0.000645	0.53	0.21	Breast cancer;	chr5:355171	chr5:262769~262881:+
HNSC	cis	rs10466239	0.73	rs2946992	ENSG00000230555.2	RP11-517P14.2	-4.75	2.75e-06	0.000645	-0.3	-0.21	Telomere length;	chr10:43358831	chr10:43420738~43422100:+
HNSC	cis	rs116095464	0.558	rs10057299	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:242020	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs13354585	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:242148	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs13356367	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:242280	chr5:288833~290321:-
HNSC	cis	rs116095464	0.85	rs10055295	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:243634	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10055354	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:243679	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs60251075	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:245177	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs62344300	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:246221	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10462754	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:246554	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10462755	ENSG00000250848.1	CTD-2083E4.5	-4.75	2.75e-06	0.000645	-0.3	-0.21	Breast cancer;	chr5:246633	chr5:288833~290321:-
HNSC	cis	rs3806843	0.735	rs801188	ENSG00000202515.1	VTRNA1-3	4.75	2.75e-06	0.000645	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr5:140726158~140726246:+
HNSC	cis	rs988913	0.624	rs1580892	ENSG00000224984.1	RP11-524H19.2	4.75	2.75e-06	0.000646	0.24	0.21	Menarche (age at onset);	chr6:54994415	chr6:54840118~54840855:-
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	4.75	2.75e-06	0.000646	0.24	0.21	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
HNSC	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-4.75	2.76e-06	0.000646	-0.28	-0.21	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
HNSC	cis	rs2058059	0.593	rs2960944	ENSG00000225648.4	SBDSP1	-4.75	2.76e-06	0.000646	-0.3	-0.21	Subcutaneous adipose tissue;	chr7:72680285	chr7:72829425~72836701:+
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000254153.1	CTA-398F10.2	4.75	2.76e-06	0.000646	0.24	0.21	Mood instability;	chr8:8444284	chr8:8456909~8461337:-
HNSC	cis	rs728616	0.717	rs116884206	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.76e-06	0.000646	-0.51	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:79663088~79826594:-
HNSC	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	4.75	2.76e-06	0.000646	0.24	0.21	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-4.75	2.76e-06	0.000646	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
HNSC	cis	rs9926296	0.744	rs164746	ENSG00000274627.1	RP11-104N10.2	4.75	2.76e-06	0.000647	0.21	0.21	Vitiligo;	chr16:89642611	chr16:89516797~89522217:+
HNSC	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	4.75	2.76e-06	0.000647	0.29	0.21	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
HNSC	cis	rs35963943	0.625	rs11921933	ENSG00000228956.7	SATB1-AS1	4.75	2.76e-06	0.000647	0.26	0.21	Lymphocyte counts;	chr3:18674802	chr3:18445024~18920401:+
HNSC	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	4.75	2.76e-06	0.000647	0.24	0.21	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
HNSC	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-4.75	2.76e-06	0.000647	-0.27	-0.21	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	4.75	2.76e-06	0.000647	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
HNSC	cis	rs1056107	0.933	rs10116045	ENSG00000225513.1	RP11-165N19.2	-4.75	2.76e-06	0.000647	-0.23	-0.21	Colorectal cancer;	chr9:112285580	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs6477908	ENSG00000225513.1	RP11-165N19.2	-4.75	2.76e-06	0.000647	-0.23	-0.21	Colorectal cancer;	chr9:112285627	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs4979095	ENSG00000225513.1	RP11-165N19.2	-4.75	2.76e-06	0.000647	-0.23	-0.21	Colorectal cancer;	chr9:112286527	chr9:112173522~112173971:-
HNSC	cis	rs2286503	0.966	rs6949233	ENSG00000226329.2	AC005682.6	4.75	2.76e-06	0.000647	0.26	0.21	Fibrinogen;	chr7:22818572	chr7:22863874~22881350:-
HNSC	cis	rs2243480	1	rs160643	ENSG00000229886.1	RP5-1132H15.3	4.75	2.77e-06	0.000648	0.32	0.21	Diabetic kidney disease;	chr7:66093235	chr7:66025126~66031544:-
HNSC	cis	rs6723108	0.627	rs4954193	ENSG00000224043.6	CCNT2-AS1	-4.75	2.77e-06	0.000648	-0.26	-0.21	Type 2 diabetes;	chr2:134884610	chr2:134735464~134918710:-
HNSC	cis	rs9329221	0.905	rs13252982	ENSG00000269918.1	AF131215.9	-4.75	2.77e-06	0.000648	-0.21	-0.21	Neuroticism;	chr8:10397595	chr8:11104691~11106704:-
HNSC	cis	rs6163	0.727	rs284854	ENSG00000236937.2	PTGES3P4	-4.75	2.77e-06	0.000648	-0.26	-0.21	Waist circumference;Hip circumference;	chr10:102814805	chr10:102845595~102845950:+
HNSC	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.75	2.77e-06	0.000648	0.21	0.21	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
HNSC	cis	rs301801	0.803	rs2661863	ENSG00000232912.4	RP5-1115A15.1	-4.75	2.77e-06	0.000649	-0.24	-0.21	Optic cup area;Vertical cup-disc ratio;	chr1:8392665	chr1:8424645~8434838:+
HNSC	cis	rs1056107	0.931	rs2274519	ENSG00000225513.1	RP11-165N19.2	-4.75	2.77e-06	0.000649	-0.23	-0.21	Colorectal cancer;	chr9:112235008	chr9:112173522~112173971:-
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	4.75	2.77e-06	0.000649	0.26	0.21	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
HNSC	cis	rs2236295	0.618	rs224285	ENSG00000238280.1	RP11-436D10.3	4.75	2.77e-06	0.000649	0.27	0.21	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62825050	chr10:62793562~62805887:-
HNSC	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-4.75	2.77e-06	0.000649	-0.24	-0.21	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
HNSC	cis	rs6831352	0.918	rs13110764	ENSG00000263923.1	RP11-571L19.7	4.75	2.78e-06	0.00065	0.23	0.21	Alcohol dependence;	chr4:99141315	chr4:98928897~98994994:+
HNSC	cis	rs3806843	0.705	rs2530230	ENSG00000202515.1	VTRNA1-3	4.74	2.78e-06	0.00065	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr5:140726158~140726246:+
HNSC	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	4.74	2.78e-06	0.00065	0.24	0.21	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
HNSC	cis	rs7572733	0.935	rs938929	ENSG00000222017.1	AC011997.1	-4.74	2.78e-06	0.000651	-0.26	-0.21	Dermatomyositis;	chr2:197916136	chr2:197693106~197774823:+
HNSC	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	4.74	2.78e-06	0.000651	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	4.74	2.78e-06	0.000651	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	4.74	2.78e-06	0.000651	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-4.74	2.78e-06	0.000651	-0.25	-0.21	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
HNSC	cis	rs2921036	0.545	rs4840975	ENSG00000254153.1	CTA-398F10.2	-4.74	2.78e-06	0.000651	-0.24	-0.21	Neuroticism;	chr8:8505748	chr8:8456909~8461337:-
HNSC	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	4.74	2.78e-06	0.000652	0.25	0.21	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
HNSC	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-4.74	2.78e-06	0.000652	-0.28	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
HNSC	cis	rs9863	0.828	rs56041971	ENSG00000269938.1	RP11-214K3.20	-4.74	2.78e-06	0.000652	-0.25	-0.21	White blood cell count;	chr12:123996319	chr12:123968023~123968579:-
HNSC	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-4.74	2.78e-06	0.000652	-0.24	-0.21	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
HNSC	cis	rs453301	0.624	rs330049	ENSG00000233609.3	RP11-62H7.2	4.74	2.79e-06	0.000652	0.2	0.21	Joint mobility (Beighton score);	chr8:9229789	chr8:8961200~8979025:+
HNSC	cis	rs1056107	0.931	rs7033486	ENSG00000225513.1	RP11-165N19.2	4.74	2.79e-06	0.000652	0.23	0.21	Colorectal cancer;	chr9:112248027	chr9:112173522~112173971:-
HNSC	cis	rs9863	0.828	rs7307277	ENSG00000269938.1	RP11-214K3.20	-4.74	2.79e-06	0.000652	-0.25	-0.21	White blood cell count;	chr12:123990609	chr12:123968023~123968579:-
HNSC	cis	rs9392556	0.734	rs648900	ENSG00000230648.1	RP3-406P24.3	4.74	2.79e-06	0.000653	0.24	0.21	Blood metabolite levels;	chr6:4109188	chr6:4018843~4021215:-
HNSC	cis	rs453301	0.506	rs686189	ENSG00000173295.6	FAM86B3P	-4.74	2.79e-06	0.000653	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8766127	chr8:8228595~8244865:+
HNSC	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-4.74	2.79e-06	0.000653	-0.26	-0.21	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
HNSC	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-4.74	2.79e-06	0.000653	-0.28	-0.21	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
HNSC	cis	rs13113518	1	rs7660980	ENSG00000273257.1	RP11-177J6.1	-4.74	2.79e-06	0.000653	-0.26	-0.21	Height;	chr4:55542948	chr4:55387949~55388271:+
HNSC	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	4.74	2.8e-06	0.000654	0.24	0.21	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	4.74	2.8e-06	0.000654	0.24	0.21	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	4.74	2.8e-06	0.000654	0.26	0.21	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
HNSC	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	4.74	2.8e-06	0.000655	0.28	0.21	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	4.74	2.8e-06	0.000655	0.28	0.21	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
HNSC	cis	rs60617249	0.826	rs4947968	ENSG00000228204.2	RP4-724E13.2	4.74	2.8e-06	0.000655	0.23	0.21	Major depression and alcohol dependence;	chr7:50874232	chr7:50866747~51022990:+
HNSC	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	4.74	2.8e-06	0.000655	0.24	0.21	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
HNSC	cis	rs6601327	0.543	rs11249948	ENSG00000254340.1	RP11-10A14.3	4.74	2.8e-06	0.000655	0.27	0.21	Multiple myeloma (hyperdiploidy);	chr8:9791176	chr8:9141424~9145435:+
HNSC	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-4.74	2.8e-06	0.000655	-0.23	-0.21	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
HNSC	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	4.74	2.8e-06	0.000655	0.26	0.21	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
HNSC	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-4.74	2.8e-06	0.000655	-0.17	-0.21	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
HNSC	cis	rs754133	0.964	rs894737	ENSG00000248265.1	FLJ12825	4.74	2.8e-06	0.000655	0.26	0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54024359	chr12:54058254~54122234:+
HNSC	cis	rs6496044	0.568	rs11636764	ENSG00000259295.5	CSPG4P12	4.74	2.8e-06	0.000656	0.25	0.21	Interstitial lung disease;	chr15:85536520	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.591	rs979825	ENSG00000259295.5	CSPG4P12	4.74	2.8e-06	0.000656	0.25	0.21	Interstitial lung disease;	chr15:85537394	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.547	rs8039929	ENSG00000259295.5	CSPG4P12	4.74	2.8e-06	0.000656	0.25	0.21	Interstitial lung disease;	chr15:85537731	chr15:85191438~85213905:+
HNSC	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-4.74	2.8e-06	0.000656	-0.49	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
HNSC	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	4.74	2.8e-06	0.000656	0.24	0.21	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
HNSC	cis	rs67981189	1	rs67981189	ENSG00000274818.1	RP1-292L20.3	4.74	2.81e-06	0.000656	0.25	0.21	Schizophrenia;	chr14:71005509	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs7145484	ENSG00000274818.1	RP1-292L20.3	4.74	2.81e-06	0.000656	0.25	0.21	Schizophrenia;	chr14:71006820	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.858	rs17108877	ENSG00000274818.1	RP1-292L20.3	4.74	2.81e-06	0.000656	0.25	0.21	Schizophrenia;	chr14:71007092	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs7146932	ENSG00000274818.1	RP1-292L20.3	4.74	2.81e-06	0.000656	0.25	0.21	Schizophrenia;	chr14:71010328	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs7153237	ENSG00000274818.1	RP1-292L20.3	4.74	2.81e-06	0.000656	0.25	0.21	Schizophrenia;	chr14:71021937	chr14:70906657~70907111:-
HNSC	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	4.74	2.81e-06	0.000657	0.26	0.21	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
HNSC	cis	rs2562456	1	rs2359155	ENSG00000268081.1	RP11-678G14.2	-4.74	2.81e-06	0.000657	-0.28	-0.21	Pain;	chr19:21489067	chr19:21554640~21569237:-
HNSC	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	4.74	2.81e-06	0.000657	0.27	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
HNSC	cis	rs6964587	1	rs10225892	ENSG00000188693.7	CYP51A1-AS1	-4.74	2.81e-06	0.000657	-0.23	-0.21	Breast cancer;	chr7:92041706	chr7:92134604~92180725:+
HNSC	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	4.74	2.81e-06	0.000657	0.34	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
HNSC	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	4.74	2.81e-06	0.000657	0.17	0.21	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
HNSC	cis	rs4819052	0.851	rs875621	ENSG00000223768.1	LINC00205	-4.74	2.81e-06	0.000658	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45293285~45297354:+
HNSC	cis	rs2998286	0.862	rs2993981	ENSG00000254635.4	WAC-AS1	-4.74	2.81e-06	0.000658	-0.27	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.862	rs2993982	ENSG00000254635.4	WAC-AS1	-4.74	2.81e-06	0.000658	-0.27	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28522652~28532743:-
HNSC	cis	rs1552244	0.882	rs13084194	ENSG00000180385.7	EMC3-AS1	4.74	2.81e-06	0.000658	0.25	0.21	Alzheimer's disease;	chr3:9989808	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs13099507	ENSG00000180385.7	EMC3-AS1	4.74	2.81e-06	0.000658	0.25	0.21	Alzheimer's disease;	chr3:9989919	chr3:9986893~10006990:+
HNSC	cis	rs7615952	0.576	rs4646763	ENSG00000248787.1	RP11-666A20.4	-4.74	2.82e-06	0.000658	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126103286	chr3:125908005~125910272:-
HNSC	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-4.74	2.82e-06	0.000658	-0.28	-0.21	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
HNSC	cis	rs6928977	0.897	rs6570001	ENSG00000234084.1	RP3-388E23.2	4.74	2.82e-06	0.000658	0.23	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135330583	chr6:135301568~135307158:+
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-4.74	2.82e-06	0.000658	-0.34	-0.21	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
HNSC	cis	rs4947019	0.609	rs2275649	ENSG00000260273.1	RP11-425D10.10	4.74	2.82e-06	0.000658	0.6	0.21	Hematological parameters;	chr6:109370125	chr6:109382795~109383666:+
HNSC	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	4.74	2.82e-06	0.000659	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
HNSC	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	4.74	2.82e-06	0.000659	0.27	0.21	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	4.74	2.82e-06	0.000659	0.27	0.21	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
HNSC	cis	rs56804039	1	rs67180327	ENSG00000173295.6	FAM86B3P	-4.74	2.82e-06	0.000659	-0.28	-0.21	Cervical cancer;	chr8:8523244	chr8:8228595~8244865:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000204709.4	LINC01556	4.74	2.82e-06	0.000659	0.29	0.21	Depression;	chr6:28140307	chr6:28943877~28944537:+
HNSC	cis	rs13438327	1	rs13308002	ENSG00000183444.10	OR7E38P	4.74	2.82e-06	0.000659	0.43	0.21	Sudden cardiac arrest;	chr7:97990935	chr7:97966090~97967074:-
HNSC	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	4.74	2.82e-06	0.000659	0.2	0.21	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
HNSC	cis	rs6751744	0.924	rs13386318	ENSG00000226266.5	AC009961.3	-4.74	2.82e-06	0.000659	-0.26	-0.21	Dysphagia;	chr2:159541846	chr2:159670708~159712435:-
HNSC	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.74	2.82e-06	0.00066	-0.22	-0.21	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
HNSC	cis	rs9840812	0.773	rs61789601	ENSG00000273486.1	RP11-731C17.2	-4.74	2.82e-06	0.00066	-0.21	-0.21	Fibrinogen levels;	chr3:136236137	chr3:136837338~136839021:-
HNSC	cis	rs755249	0.53	rs4660475	ENSG00000228060.1	RP11-69E11.8	-4.74	2.82e-06	0.00066	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.53	rs66848709	ENSG00000228060.1	RP11-69E11.8	-4.74	2.82e-06	0.00066	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39565160~39573203:+
HNSC	cis	rs72634501	0.716	rs67062906	ENSG00000228060.1	RP11-69E11.8	-4.74	2.82e-06	0.00066	-0.24	-0.21	HDL cholesterol;	chr1:39151018	chr1:39565160~39573203:+
HNSC	cis	rs8058578	0.945	rs885107	ENSG00000279196.1	RP11-1072A3.3	4.74	2.83e-06	0.00066	0.26	0.21	Multiple myeloma;	chr16:30661398	chr16:30984630~30988270:-
HNSC	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	4.74	2.83e-06	0.00066	0.22	0.21	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
HNSC	cis	rs459482	0.504	rs469288	ENSG00000228318.3	AP001610.5	4.74	2.83e-06	0.00066	0.22	0.21	IgG glycosylation;	chr21:41445655	chr21:41441056~41445708:-
HNSC	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-4.74	2.83e-06	0.00066	-0.18	-0.21	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	4.74	2.83e-06	0.00066	0.26	0.21	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
HNSC	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-4.74	2.83e-06	0.00066	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
HNSC	cis	rs3806843	0.518	rs2569191	ENSG00000202515.1	VTRNA1-3	4.74	2.83e-06	0.000661	0.25	0.21	Depressive symptoms (multi-trait analysis);	chr5:140634318	chr5:140726158~140726246:+
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000217862.2	HIST1H4PS1	-4.74	2.83e-06	0.000661	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28200255	chr6:27807075~27807339:+
HNSC	cis	rs712039	0.652	rs17137970	ENSG00000276054.1	RP11-378E13.3	4.74	2.83e-06	0.000661	0.29	0.21	Tuberculosis;	chr17:37411739	chr17:37386886~37387926:+
HNSC	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	4.74	2.83e-06	0.000661	0.24	0.21	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
HNSC	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-4.74	2.83e-06	0.000661	-0.18	-0.21	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
HNSC	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	4.74	2.83e-06	0.000661	0.26	0.21	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
HNSC	cis	rs73198271	0.74	rs1039911	ENSG00000173295.6	FAM86B3P	-4.74	2.83e-06	0.000661	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8228595~8244865:+
HNSC	cis	rs4873772	0.837	rs56092229	ENSG00000253330.1	RP11-697N18.3	-4.74	2.83e-06	0.000662	-0.27	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47562955	chr8:47511034~47512141:-
HNSC	cis	rs42490	0.664	rs39767	ENSG00000251136.7	RP11-37B2.1	-4.74	2.83e-06	0.000662	-0.18	-0.21	Leprosy;	chr8:89807770	chr8:89609409~89757727:-
HNSC	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-4.74	2.83e-06	0.000662	-0.2	-0.21	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
HNSC	cis	rs3738443	0.868	rs4351686	ENSG00000259865.1	RP11-488L18.10	4.74	2.83e-06	0.000662	0.19	0.21	Alcohol dependence;	chr1:247190028	chr1:247187281~247188526:-
HNSC	cis	rs1665050	0.895	rs8028752	ENSG00000259732.1	RP11-59H7.3	-4.74	2.83e-06	0.000662	-0.31	-0.21	Atopic dermatitis;	chr15:59003803	chr15:59121034~59133250:+
HNSC	cis	rs2665103	0.715	rs7403041	ENSG00000255769.6	GOLGA2P10	4.74	2.83e-06	0.000662	0.25	0.21	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472993~82513950:-
HNSC	cis	rs3806843	0.966	rs4141841	ENSG00000202515.1	VTRNA1-3	-4.74	2.83e-06	0.000662	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs10050455	ENSG00000202515.1	VTRNA1-3	-4.74	2.83e-06	0.000662	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr5:140726158~140726246:+
HNSC	cis	rs4819052	0.851	rs2255774	ENSG00000223768.1	LINC00205	-4.74	2.84e-06	0.000662	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45293285~45297354:+
HNSC	cis	rs9840812	0.645	rs9883916	ENSG00000239213.4	NCK1-AS1	4.74	2.84e-06	0.000662	0.21	0.21	Fibrinogen levels;	chr3:136489946	chr3:136841726~136862054:-
HNSC	cis	rs9840812	0.769	rs4678428	ENSG00000239213.4	NCK1-AS1	4.74	2.84e-06	0.000663	0.19	0.21	Fibrinogen levels;	chr3:136269570	chr3:136841726~136862054:-
HNSC	cis	rs6964587	1	rs55745934	ENSG00000188693.7	CYP51A1-AS1	-4.74	2.84e-06	0.000663	-0.23	-0.21	Breast cancer;	chr7:92041684	chr7:92134604~92180725:+
HNSC	cis	rs9739070	1	rs9739070	ENSG00000280120.1	RP11-546D6.3	4.74	2.84e-06	0.000663	0.2	0.21	Allergy;	chr12:123286485	chr12:123152324~123153377:-
HNSC	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.74	2.84e-06	0.000663	-0.22	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
HNSC	cis	rs6723108	0.603	rs10187990	ENSG00000224043.6	CCNT2-AS1	-4.74	2.84e-06	0.000663	-0.26	-0.21	Type 2 diabetes;	chr2:134939987	chr2:134735464~134918710:-
HNSC	cis	rs6964587	1	rs12530646	ENSG00000188693.7	CYP51A1-AS1	4.74	2.84e-06	0.000663	0.23	0.21	Breast cancer;	chr7:91958722	chr7:92134604~92180725:+
HNSC	cis	rs721917	0.565	rs7476563	ENSG00000225484.5	NUTM2B-AS1	-4.74	2.84e-06	0.000663	-0.26	-0.21	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79663088~79826594:-
HNSC	cis	rs1479119	0.681	rs10772654	ENSG00000180861.8	LINC01559	4.74	2.84e-06	0.000664	0.28	0.21	Intelligence (multi-trait analysis);	chr12:13343124	chr12:13371089~13387167:-
HNSC	cis	rs3733585	0.699	rs4408959	ENSG00000250413.1	RP11-448G15.1	4.74	2.84e-06	0.000664	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9947244	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4276278	ENSG00000250413.1	RP11-448G15.1	4.74	2.84e-06	0.000664	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9947246	chr4:10006482~10009725:+
HNSC	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	4.74	2.84e-06	0.000664	0.31	0.21	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
HNSC	cis	rs9863	0.861	rs7961449	ENSG00000269938.1	RP11-214K3.20	4.74	2.84e-06	0.000664	0.25	0.21	White blood cell count;	chr12:123952668	chr12:123968023~123968579:-
HNSC	cis	rs6921919	0.673	rs13201681	ENSG00000219392.1	RP1-265C24.5	-4.74	2.84e-06	0.000664	-0.44	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28115628~28116551:+
HNSC	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-4.74	2.85e-06	0.000664	-0.19	-0.21	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
HNSC	cis	rs7735319	0.774	rs13168871	ENSG00000251281.1	CTD-2066L21.2	4.74	2.85e-06	0.000665	0.26	0.21	Systolic blood pressure;	chr5:33066773	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.834	rs7707864	ENSG00000251281.1	CTD-2066L21.2	4.74	2.85e-06	0.000665	0.26	0.21	Systolic blood pressure;	chr5:33067611	chr5:33011322~33017607:-
HNSC	cis	rs2548724	0.796	rs7734060	ENSG00000250682.4	LINC00491	4.74	2.85e-06	0.000665	0.3	0.21	Type 2 diabetes;	chr5:102444775	chr5:102609156~102671559:-
HNSC	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-4.74	2.85e-06	0.000665	-0.27	-0.21	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
HNSC	cis	rs7735319	0.834	rs13166521	ENSG00000251281.1	CTD-2066L21.2	4.74	2.85e-06	0.000665	0.26	0.21	Systolic blood pressure;	chr5:33062086	chr5:33011322~33017607:-
HNSC	cis	rs656319	0.559	rs55683917	ENSG00000269918.1	AF131215.9	-4.74	2.85e-06	0.000665	-0.21	-0.21	Myopia (pathological);	chr8:10118969	chr8:11104691~11106704:-
HNSC	cis	rs72843506	0.586	rs75836592	ENSG00000261033.1	RP11-209D14.2	4.74	2.85e-06	0.000665	0.38	0.21	Schizophrenia;	chr17:19935039	chr17:20008051~20009234:-
HNSC	cis	rs1713985	0.508	rs1277286	ENSG00000269949.1	RP11-738E22.3	-4.74	2.85e-06	0.000666	-0.35	-0.21	Age-related macular degeneration;	chr4:56988132	chr4:56960927~56961373:-
HNSC	cis	rs763121	0.853	rs9610986	ENSG00000273076.1	RP3-508I15.22	4.74	2.85e-06	0.000666	0.23	0.21	Menopause (age at onset);	chr22:38629272	chr22:38743495~38743910:+
HNSC	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	4.74	2.85e-06	0.000666	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
HNSC	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.74	2.86e-06	0.000666	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
HNSC	cis	rs9393777	0.92	rs35716472	ENSG00000219392.1	RP1-265C24.5	-4.74	2.86e-06	0.000667	-0.41	-0.21	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28115628~28116551:+
HNSC	cis	rs494003	1	rs11227284	ENSG00000255120.4	OVOL1-AS1	4.74	2.86e-06	0.000667	0.28	0.21	Systemic lupus erythematosus;	chr11:65735753	chr11:65789051~65790868:-
HNSC	cis	rs494003	1	rs72922733	ENSG00000255120.4	OVOL1-AS1	4.74	2.86e-06	0.000667	0.28	0.21	Systemic lupus erythematosus;	chr11:65753275	chr11:65789051~65790868:-
HNSC	cis	rs1707322	0.964	rs1768802	ENSG00000234329.1	RP11-767N6.2	-4.74	2.86e-06	0.000667	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1588663	ENSG00000234329.1	RP11-767N6.2	-4.74	2.86e-06	0.000667	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1768801	ENSG00000234329.1	RP11-767N6.2	-4.74	2.86e-06	0.000667	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1768800	ENSG00000234329.1	RP11-767N6.2	-4.74	2.86e-06	0.000667	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-4.74	2.86e-06	0.000667	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
HNSC	cis	rs9300255	0.664	rs28636834	ENSG00000280120.1	RP11-546D6.3	-4.74	2.86e-06	0.000668	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123386523	chr12:123152324~123153377:-
HNSC	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-4.74	2.86e-06	0.000668	-0.27	-0.21	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-4.74	2.86e-06	0.000668	-0.27	-0.21	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
HNSC	cis	rs2179367	0.632	rs2143075	ENSG00000216906.2	RP11-350J20.9	4.74	2.86e-06	0.000668	0.31	0.21	Dupuytren's disease;	chr6:149425507	chr6:149904243~149906418:+
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000204709.4	LINC01556	4.74	2.86e-06	0.000668	0.29	0.21	Depression;	chr6:28139876	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000204709.4	LINC01556	4.74	2.86e-06	0.000668	0.29	0.21	Depression;	chr6:28139998	chr6:28943877~28944537:+
HNSC	cis	rs11976180	1	rs2961119	ENSG00000273234.1	OR2A13P	-4.74	2.86e-06	0.000668	-0.24	-0.21	Obesity-related traits;	chr7:144058759	chr7:144142009~144142938:+
HNSC	cis	rs6831352	0.801	rs2602897	ENSG00000263923.1	RP11-571L19.7	-4.74	2.87e-06	0.000668	-0.23	-0.21	Alcohol dependence;	chr4:99125142	chr4:98928897~98994994:+
HNSC	cis	rs35963943	0.571	rs4494952	ENSG00000228956.7	SATB1-AS1	4.74	2.87e-06	0.000668	0.26	0.21	Lymphocyte counts;	chr3:18675290	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4128129	ENSG00000228956.7	SATB1-AS1	4.74	2.87e-06	0.000668	0.26	0.21	Lymphocyte counts;	chr3:18675364	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4560321	ENSG00000228956.7	SATB1-AS1	4.74	2.87e-06	0.000668	0.26	0.21	Lymphocyte counts;	chr3:18676316	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13071063	ENSG00000228956.7	SATB1-AS1	4.74	2.87e-06	0.000668	0.26	0.21	Lymphocyte counts;	chr3:18677286	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.52	rs11925163	ENSG00000228956.7	SATB1-AS1	4.74	2.87e-06	0.000668	0.26	0.21	Lymphocyte counts;	chr3:18677680	chr3:18445024~18920401:+
HNSC	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	4.74	2.87e-06	0.000668	0.19	0.21	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
HNSC	cis	rs7824557	0.767	rs2164273	ENSG00000269918.1	AF131215.9	4.74	2.87e-06	0.000669	0.21	0.21	Retinal vascular caliber;	chr8:11310990	chr8:11104691~11106704:-
HNSC	cis	rs14027	0.64	rs16893104	ENSG00000279347.1	RP11-85I17.2	-4.74	2.87e-06	0.000669	-0.18	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119754778	chr8:119838736~119840385:-
HNSC	cis	rs6600671	1	rs4844616	ENSG00000270231.3	NBPF8P	4.74	2.87e-06	0.000669	0.19	0.21	Hip geometry;	chr1:121429348	chr1:120436353~120467739:+
HNSC	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	4.74	2.87e-06	0.000669	0.22	0.21	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
HNSC	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	4.74	2.87e-06	0.000669	0.24	0.21	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	4.74	2.87e-06	0.000669	0.24	0.21	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	4.74	2.87e-06	0.000669	0.24	0.21	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
HNSC	cis	rs9402743	0.671	rs6934889	ENSG00000234084.1	RP3-388E23.2	4.74	2.87e-06	0.000669	0.22	0.21	Systemic lupus erythematosus;	chr6:135629542	chr6:135301568~135307158:+
HNSC	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-4.74	2.87e-06	0.00067	-0.3	-0.21	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
HNSC	cis	rs6928977	0.896	rs9321501	ENSG00000217482.2	HMGB1P17	-4.74	2.87e-06	0.00067	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135636086~135636713:-
HNSC	cis	rs2439831	1	rs689754	ENSG00000205771.5	CATSPER2P1	-4.74	2.87e-06	0.00067	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43483697	chr15:43726918~43747094:-
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	4.74	2.87e-06	0.00067	0.26	0.21	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
HNSC	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-4.74	2.88e-06	0.00067	-0.22	-0.21	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
HNSC	cis	rs9907295	1	rs11080361	ENSG00000270977.1	AC015849.16	-4.74	2.88e-06	0.00067	-0.35	-0.21	Fibroblast growth factor basic levels;	chr17:35916184	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs11080362	ENSG00000270977.1	AC015849.16	-4.74	2.88e-06	0.00067	-0.35	-0.21	Fibroblast growth factor basic levels;	chr17:35916224	chr17:35893707~35911023:-
HNSC	cis	rs3096299	0.933	rs3114848	ENSG00000261574.1	RP1-168P16.2	4.74	2.88e-06	0.00067	0.27	0.21	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89392375~89412564:-
HNSC	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-4.74	2.88e-06	0.000671	-0.26	-0.21	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
HNSC	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	4.74	2.88e-06	0.000671	0.33	0.21	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
HNSC	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-4.74	2.88e-06	0.000671	-0.18	-0.21	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-4.74	2.88e-06	0.000671	-0.18	-0.21	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
HNSC	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.74	2.88e-06	0.000671	0.31	0.21	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
HNSC	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-4.74	2.88e-06	0.000671	-0.27	-0.21	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
HNSC	cis	rs2657294	0.62	rs2395136	ENSG00000233313.2	HMGA1P5	-4.74	2.88e-06	0.000672	-0.23	-0.21	Pneumonia;	chr10:75088213	chr10:75276376~75276646:-
HNSC	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-4.74	2.89e-06	0.000672	-0.37	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-4.74	2.89e-06	0.000672	-0.37	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
HNSC	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-4.74	2.89e-06	0.000672	-0.22	-0.21	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
HNSC	cis	rs13073817	0.543	rs10865755	ENSG00000228956.7	SATB1-AS1	4.74	2.89e-06	0.000673	0.22	0.21	Crohn's disease;	chr3:18644714	chr3:18445024~18920401:+
HNSC	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	4.74	2.89e-06	0.000673	0.24	0.21	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
HNSC	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	4.74	2.89e-06	0.000673	0.35	0.21	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000254340.1	RP11-10A14.3	-4.74	2.89e-06	0.000673	-0.26	-0.21	Mood instability;	chr8:8721301	chr8:9141424~9145435:+
HNSC	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	4.74	2.89e-06	0.000674	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
HNSC	cis	rs916888	0.773	rs199448	ENSG00000260075.1	NSFP1	-4.74	2.89e-06	0.000674	-0.3	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46372855~46487141:+
HNSC	cis	rs6668534	0.679	rs10753610	ENSG00000225217.1	HSPA7	-4.74	2.89e-06	0.000674	-0.29	-0.21	Blood protein levels;	chr1:161694033	chr1:161606291~161608217:+
HNSC	cis	rs6674176	0.66	rs3791112	ENSG00000237950.1	RP11-7O11.3	4.74	2.9e-06	0.000675	0.25	0.21	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43913576	chr1:43944370~43946551:-
HNSC	cis	rs13073817	0.582	rs13079342	ENSG00000228956.7	SATB1-AS1	4.74	2.9e-06	0.000675	0.23	0.21	Crohn's disease;	chr3:18635956	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.582	rs6763215	ENSG00000228956.7	SATB1-AS1	4.74	2.9e-06	0.000675	0.23	0.21	Crohn's disease;	chr3:18637009	chr3:18445024~18920401:+
HNSC	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	4.74	2.9e-06	0.000675	0.2	0.21	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
HNSC	cis	rs12893668	0.703	rs2274267	ENSG00000269940.1	RP11-73M18.7	4.74	2.9e-06	0.000675	0.22	0.21	Reticulocyte count;	chr14:103563112	chr14:103694560~103695170:+
HNSC	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-4.74	2.9e-06	0.000675	-0.37	-0.21	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
HNSC	cis	rs17428076	0.681	rs62182424	ENSG00000228389.1	AC068039.4	-4.74	2.9e-06	0.000675	-0.29	-0.21	Myopia;	chr2:171895213	chr2:171773482~171775844:+
HNSC	cis	rs7662987	0.517	rs1154406	ENSG00000263923.1	RP11-571L19.7	-4.74	2.9e-06	0.000675	-0.23	-0.21	Smoking initiation;	chr4:99087343	chr4:98928897~98994994:+
HNSC	cis	rs9880211	0.613	rs13079205	ENSG00000273486.1	RP11-731C17.2	4.74	2.9e-06	0.000675	0.2	0.21	Height;Body mass index;	chr3:136081851	chr3:136837338~136839021:-
HNSC	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-4.74	2.9e-06	0.000676	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
HNSC	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-4.74	2.9e-06	0.000676	-0.25	-0.21	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-4.74	2.9e-06	0.000676	-0.25	-0.21	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
HNSC	cis	rs1056107	0.933	rs10981354	ENSG00000225513.1	RP11-165N19.2	-4.74	2.9e-06	0.000676	-0.23	-0.21	Colorectal cancer;	chr9:112308436	chr9:112173522~112173971:-
HNSC	cis	rs6928977	0.863	rs9389286	ENSG00000217482.2	HMGB1P17	-4.74	2.9e-06	0.000676	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135319827	chr6:135636086~135636713:-
HNSC	cis	rs6723108	0.603	rs12469411	ENSG00000224043.6	CCNT2-AS1	-4.74	2.9e-06	0.000676	-0.26	-0.21	Type 2 diabetes;	chr2:134906986	chr2:134735464~134918710:-
HNSC	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-4.74	2.91e-06	0.000676	-0.33	-0.21	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
HNSC	cis	rs6964587	0.967	rs10231350	ENSG00000188693.7	CYP51A1-AS1	-4.74	2.91e-06	0.000676	-0.23	-0.21	Breast cancer;	chr7:92179185	chr7:92134604~92180725:+
HNSC	cis	rs1056107	0.897	rs7026917	ENSG00000225513.1	RP11-165N19.2	-4.74	2.91e-06	0.000676	-0.23	-0.21	Colorectal cancer;	chr9:112228592	chr9:112173522~112173971:-
HNSC	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	4.74	2.91e-06	0.000677	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
HNSC	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-4.74	2.91e-06	0.000677	-0.46	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
HNSC	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-4.74	2.91e-06	0.000677	-0.18	-0.21	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
HNSC	cis	rs17253792	0.822	rs10136155	ENSG00000186615.9	KTN1-AS1	-4.73	2.91e-06	0.000678	-0.39	-0.21	Putamen volume;	chr14:55582411	chr14:55499278~55580110:-
HNSC	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	4.73	2.91e-06	0.000678	0.31	0.21	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
HNSC	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	4.73	2.91e-06	0.000678	0.31	0.21	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
HNSC	cis	rs763121	0.853	rs5757204	ENSG00000273076.1	RP3-508I15.22	4.73	2.91e-06	0.000678	0.23	0.21	Menopause (age at onset);	chr22:38650695	chr22:38743495~38743910:+
HNSC	cis	rs10462794	0.542	rs62343552	ENSG00000260763.1	RP11-445O3.3	-4.73	2.91e-06	0.000678	-0.29	-0.21	DNA methylation (variation);	chr5:4516633	chr5:4436850~4440259:-
HNSC	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	4.73	2.92e-06	0.000678	0.24	0.21	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
HNSC	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-4.73	2.92e-06	0.000678	-0.18	-0.21	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-4.73	2.92e-06	0.000678	-0.18	-0.21	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
HNSC	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-4.73	2.92e-06	0.000678	-0.18	-0.21	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
HNSC	cis	rs4144743	0.528	rs12940207	ENSG00000228782.6	CTD-2026D20.3	-4.73	2.92e-06	0.000679	-0.31	-0.21	Body mass index;	chr17:47274828	chr17:47450568~47492492:-
HNSC	cis	rs4787491	0.729	rs4788215	ENSG00000183604.13	SMG1P5	-4.73	2.92e-06	0.000679	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30267553~30335374:-
HNSC	cis	rs4787491	0.765	rs4788216	ENSG00000183604.13	SMG1P5	-4.73	2.92e-06	0.000679	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036756	chr16:30267553~30335374:-
HNSC	cis	rs4787491	0.704	rs67218159	ENSG00000183604.13	SMG1P5	-4.73	2.92e-06	0.000679	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039184	chr16:30267553~30335374:-
HNSC	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	4.73	2.92e-06	0.000679	0.21	0.21	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
HNSC	cis	rs11633886	0.585	rs17636535	ENSG00000273972.1	CTD-2306A12.1	4.73	2.92e-06	0.000679	0.25	0.21	Diisocyanate-induced asthma;	chr15:45786680	chr15:45702640~45703183:+
HNSC	cis	rs6964587	1	rs6969536	ENSG00000188693.7	CYP51A1-AS1	-4.73	2.92e-06	0.000679	-0.23	-0.21	Breast cancer;	chr7:92060037	chr7:92134604~92180725:+
HNSC	cis	rs763121	0.853	rs5757196	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38643850	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.785	rs5757199	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38644612	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs9610993	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38646813	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757200	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38647486	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757203	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38648147	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2205802	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38650322	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs8138996	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38651430	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs6001182	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38651438	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757208	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38653225	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs6001184	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38656111	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs6001185	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38656150	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2294296	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38657044	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs2064088	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38657377	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5757213	ENSG00000273076.1	RP3-508I15.22	4.73	2.92e-06	0.00068	0.23	0.21	Menopause (age at onset);	chr22:38657883	chr22:38743495~38743910:+
HNSC	cis	rs2253762	0.507	rs11200310	ENSG00000226864.1	ATE1-AS1	4.73	2.92e-06	0.00068	0.37	0.21	Breast cancer;	chr10:121989944	chr10:121928312~121951965:+
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000173295.6	FAM86B3P	-4.73	2.92e-06	0.00068	-0.24	-0.21	Joint mobility (Beighton score);	chr8:8936144	chr8:8228595~8244865:+
HNSC	cis	rs9300255	0.663	rs7953929	ENSG00000280120.1	RP11-546D6.3	4.73	2.93e-06	0.00068	0.21	0.21	Neutrophil percentage of white cells;	chr12:123273688	chr12:123152324~123153377:-
HNSC	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	4.73	2.93e-06	0.000681	0.2	0.21	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
HNSC	cis	rs6061231	0.631	rs2427317	ENSG00000275437.1	RP5-908M14.10	4.73	2.93e-06	0.000681	0.21	0.21	Colorectal cancer;	chr20:62400669	chr20:62402236~62405935:-
HNSC	cis	rs11089937	0.667	rs5757081	ENSG00000211639.2	IGLV4-60	4.73	2.93e-06	0.000681	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22162199~22162681:+
HNSC	cis	rs7824557	0.724	rs2572398	ENSG00000255310.2	AF131215.2	4.73	2.93e-06	0.000681	0.2	0.21	Retinal vascular caliber;	chr8:11320584	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	4.73	2.93e-06	0.000681	0.25	0.21	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	4.73	2.93e-06	0.000681	0.25	0.21	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
HNSC	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-4.73	2.93e-06	0.000681	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
HNSC	cis	rs17428076	0.71	rs56049564	ENSG00000228389.1	AC068039.4	-4.73	2.93e-06	0.000682	-0.29	-0.21	Myopia;	chr2:171792170	chr2:171773482~171775844:+
HNSC	cis	rs10266483	0.562	rs10949887	ENSG00000228653.2	HNRNPCP7	-4.73	2.93e-06	0.000682	-0.25	-0.21	Response to statin therapy;	chr7:64291702	chr7:64500825~64501729:+
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000254153.1	CTA-398F10.2	-4.73	2.93e-06	0.000682	-0.24	-0.21	Mood instability;	chr8:8687298	chr8:8456909~8461337:-
HNSC	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-4.73	2.94e-06	0.000682	-0.26	-0.21	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000224373.3	IGHV4-59	4.73	2.94e-06	0.000682	0.14	0.21	Kawasaki disease;	chr14:106711377	chr14:106627249~106627825:-
HNSC	cis	rs2337406	1	rs17113276	ENSG00000254174.1	IGHV1-12	-4.73	2.94e-06	0.000683	-0.18	-0.21	Alzheimer's disease (late onset);	chr14:106683485	chr14:106122420~106122709:-
HNSC	cis	rs6964587	0.967	rs17164315	ENSG00000188693.7	CYP51A1-AS1	-4.73	2.94e-06	0.000683	-0.22	-0.21	Breast cancer;	chr7:92029836	chr7:92134604~92180725:+
HNSC	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	4.73	2.94e-06	0.000683	0.32	0.21	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
HNSC	cis	rs853679	0.607	rs34243448	ENSG00000219392.1	RP1-265C24.5	-4.73	2.94e-06	0.000683	-0.43	-0.21	Depression;	chr6:28225324	chr6:28115628~28116551:+
HNSC	cis	rs4787491	0.704	rs35605010	ENSG00000183604.13	SMG1P5	-4.73	2.94e-06	0.000683	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30267553~30335374:-
HNSC	cis	rs4787491	0.729	rs4788213	ENSG00000183604.13	SMG1P5	-4.73	2.94e-06	0.000683	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30267553~30335374:-
HNSC	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	4.73	2.94e-06	0.000683	0.29	0.21	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	4.73	2.94e-06	0.000683	0.29	0.21	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	4.73	2.94e-06	0.000683	0.29	0.21	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
HNSC	cis	rs6831352	0.918	rs29001232	ENSG00000263923.1	RP11-571L19.7	4.73	2.94e-06	0.000683	0.23	0.21	Alcohol dependence;	chr4:99125503	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs29001231	ENSG00000263923.1	RP11-571L19.7	4.73	2.94e-06	0.000683	0.23	0.21	Alcohol dependence;	chr4:99125529	chr4:98928897~98994994:+
HNSC	cis	rs9291683	0.546	rs13146686	ENSG00000250413.1	RP11-448G15.1	-4.73	2.94e-06	0.000684	-0.27	-0.21	Bone mineral density;	chr4:10033309	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000254153.1	CTA-398F10.2	-4.73	2.94e-06	0.000684	-0.24	-0.21	Mood instability;	chr8:8720610	chr8:8456909~8461337:-
HNSC	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	4.73	2.94e-06	0.000684	0.19	0.21	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
HNSC	cis	rs75422866	0.85	rs73111212	ENSG00000276691.1	RP5-1057I20.5	4.73	2.94e-06	0.000684	0.43	0.21	Pneumonia;	chr12:47577638	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.85	rs73111216	ENSG00000276691.1	RP5-1057I20.5	4.73	2.94e-06	0.000684	0.43	0.21	Pneumonia;	chr12:47577671	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.85	rs73111217	ENSG00000276691.1	RP5-1057I20.5	4.73	2.94e-06	0.000684	0.43	0.21	Pneumonia;	chr12:47577693	chr12:47788426~47788971:+
HNSC	cis	rs14027	0.64	rs28421406	ENSG00000279347.1	RP11-85I17.2	-4.73	2.94e-06	0.000684	-0.18	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752249	chr8:119838736~119840385:-
HNSC	cis	rs9863	0.828	rs4765541	ENSG00000269938.1	RP11-214K3.20	-4.73	2.95e-06	0.000684	-0.24	-0.21	White blood cell count;	chr12:123981448	chr12:123968023~123968579:-
HNSC	cis	rs1056107	0.933	rs10981311	ENSG00000225513.1	RP11-165N19.2	-4.73	2.95e-06	0.000684	-0.23	-0.21	Colorectal cancer;	chr9:112203076	chr9:112173522~112173971:-
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000254153.1	CTA-398F10.2	-4.73	2.95e-06	0.000685	-0.23	-0.21	Mood instability;	chr8:8937520	chr8:8456909~8461337:-
HNSC	cis	rs7688540	0.515	rs28415975	ENSG00000211553.1	AC253576.2	-4.73	2.95e-06	0.000685	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:136461~136568:+
HNSC	cis	rs4853525	0.59	rs13399044	ENSG00000235852.1	AC005540.3	4.73	2.95e-06	0.000685	0.29	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944844	chr2:190880797~190882059:-
HNSC	cis	rs2235642	0.507	rs2235643	ENSG00000280231.1	LA16c-380F5.3	4.73	2.95e-06	0.000686	0.28	0.21	Coronary artery disease;	chr16:1535114	chr16:1553655~1554130:-
HNSC	cis	rs6674176	0.597	rs6671164	ENSG00000237950.1	RP11-7O11.3	4.73	2.95e-06	0.000686	0.25	0.21	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43937817	chr1:43944370~43946551:-
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000204709.4	LINC01556	4.73	2.96e-06	0.000687	0.29	0.21	Depression;	chr6:28113616	chr6:28943877~28944537:+
HNSC	cis	rs1555322	0.872	rs2425046	ENSG00000279253.1	RP4-614O4.13	-4.73	2.96e-06	0.000687	-0.34	-0.21	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35262727~35264187:-
HNSC	cis	rs6928977	0.896	rs2064431	ENSG00000217482.2	HMGB1P17	-4.73	2.96e-06	0.000687	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135636086~135636713:-
HNSC	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-4.73	2.96e-06	0.000687	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
HNSC	cis	rs9863	0.861	rs4765305	ENSG00000269938.1	RP11-214K3.20	-4.73	2.96e-06	0.000687	-0.24	-0.21	White blood cell count;	chr12:123946065	chr12:123968023~123968579:-
HNSC	cis	rs6586111	1	rs7067994	ENSG00000226659.1	RP11-137H2.4	-4.73	2.96e-06	0.000687	-0.26	-0.21	Capecitabine sensitivity;	chr10:80613703	chr10:80529597~80535942:-
HNSC	cis	rs6586111	1	rs6586109	ENSG00000226659.1	RP11-137H2.4	-4.73	2.96e-06	0.000687	-0.26	-0.21	Capecitabine sensitivity;	chr10:80615758	chr10:80529597~80535942:-
HNSC	cis	rs73198271	0.74	rs10100066	ENSG00000233609.3	RP11-62H7.2	-4.73	2.96e-06	0.000688	-0.24	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs10110711	ENSG00000233609.3	RP11-62H7.2	-4.73	2.96e-06	0.000688	-0.24	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8961200~8979025:+
HNSC	cis	rs638893	0.947	rs515707	ENSG00000255422.1	AP002954.4	-4.73	2.96e-06	0.000688	-0.33	-0.21	Vitiligo;	chr11:118814772	chr11:118704607~118750263:+
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-4.73	2.96e-06	0.000688	-0.23	-0.21	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
HNSC	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-4.73	2.96e-06	0.000688	-0.27	-0.21	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-4.73	2.96e-06	0.000688	-0.27	-0.21	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-4.73	2.96e-06	0.000688	-0.27	-0.21	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
HNSC	cis	rs755249	0.567	rs67408364	ENSG00000228060.1	RP11-69E11.8	-4.73	2.96e-06	0.000688	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39565160~39573203:+
HNSC	cis	rs7824557	0.736	rs10107010	ENSG00000269918.1	AF131215.9	-4.73	2.97e-06	0.000689	-0.21	-0.21	Retinal vascular caliber;	chr8:11275203	chr8:11104691~11106704:-
HNSC	cis	rs9402743	0.634	rs66513771	ENSG00000234084.1	RP3-388E23.2	-4.73	2.97e-06	0.000689	-0.22	-0.21	Systemic lupus erythematosus;	chr6:135603885	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.634	rs7774974	ENSG00000234084.1	RP3-388E23.2	-4.73	2.97e-06	0.000689	-0.22	-0.21	Systemic lupus erythematosus;	chr6:135604248	chr6:135301568~135307158:+
HNSC	cis	rs6928977	0.538	rs6570019	ENSG00000234084.1	RP3-388E23.2	-4.73	2.97e-06	0.000689	-0.22	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.564	rs6570020	ENSG00000234084.1	RP3-388E23.2	-4.73	2.97e-06	0.000689	-0.22	-0.21	Systemic lupus erythematosus;	chr6:135604607	chr6:135301568~135307158:+
HNSC	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-4.73	2.97e-06	0.000689	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-4.73	2.97e-06	0.000689	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-4.73	2.97e-06	0.000689	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
HNSC	cis	rs933688	1	rs9293568	ENSG00000281357.1	ARRDC3-AS1	4.73	2.97e-06	0.000689	0.31	0.21	Smoking behavior;	chr5:91442028	chr5:91380349~91439085:+
HNSC	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-4.73	2.97e-06	0.00069	-0.27	-0.21	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
HNSC	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	4.73	2.97e-06	0.00069	0.26	0.21	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	-4.73	2.97e-06	0.00069	-0.27	-0.21	Depression;	chr6:28192182	chr6:28161781~28169594:+
HNSC	cis	rs2286503	0.966	rs2286507	ENSG00000226329.2	AC005682.6	4.73	2.98e-06	0.000691	0.26	0.21	Fibrinogen;	chr7:22815141	chr7:22863874~22881350:-
HNSC	cis	rs763121	0.853	rs5750630	ENSG00000273076.1	RP3-508I15.22	4.73	2.98e-06	0.000691	0.23	0.21	Menopause (age at onset);	chr22:38589813	chr22:38743495~38743910:+
HNSC	cis	rs2276314	0.512	rs7227264	ENSG00000278986.1	RP11-723J4.3	-4.73	2.98e-06	0.000691	-0.24	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:35874668	chr18:35972151~35973916:+
HNSC	cis	rs3806843	0.801	rs2531358	ENSG00000202515.1	VTRNA1-3	4.73	2.98e-06	0.000691	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr5:140726158~140726246:+
HNSC	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	4.73	2.98e-06	0.000691	0.28	0.21	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	4.73	2.98e-06	0.000692	0.25	0.21	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
HNSC	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	4.73	2.98e-06	0.000692	0.25	0.21	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
HNSC	cis	rs5758659	0.652	rs133358	ENSG00000227370.1	RP4-669P10.19	-4.73	2.98e-06	0.000692	-0.2	-0.21	Cognitive function;	chr22:42046535	chr22:42132543~42132998:+
HNSC	cis	rs6723108	0.603	rs4953938	ENSG00000224043.6	CCNT2-AS1	4.73	2.98e-06	0.000692	0.27	0.21	Type 2 diabetes;	chr2:134937278	chr2:134735464~134918710:-
HNSC	cis	rs5769707	0.681	rs916360	ENSG00000235111.1	RP1-29C18.8	-4.73	2.98e-06	0.000692	-0.28	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49612657~49615716:-
HNSC	cis	rs67981189	0.858	rs2526862	ENSG00000274818.1	RP1-292L20.3	-4.73	2.99e-06	0.000693	-0.25	-0.21	Schizophrenia;	chr14:70942897	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.788	rs2526860	ENSG00000274818.1	RP1-292L20.3	-4.73	2.99e-06	0.000693	-0.25	-0.21	Schizophrenia;	chr14:70945161	chr14:70906657~70907111:-
HNSC	cis	rs9921338	0.961	rs56136462	ENSG00000263080.1	RP11-485G7.5	4.73	2.99e-06	0.000693	0.24	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11341809~11345211:-
HNSC	cis	rs6723108	0.604	rs6430551	ENSG00000224043.6	CCNT2-AS1	-4.73	2.99e-06	0.000693	-0.26	-0.21	Type 2 diabetes;	chr2:134863986	chr2:134735464~134918710:-
HNSC	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	4.73	2.99e-06	0.000693	0.22	0.21	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	4.73	2.99e-06	0.000693	0.22	0.21	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.698	rs4422403	ENSG00000249244.1	RP11-548H18.2	4.73	2.99e-06	0.000693	0.26	0.21	Corneal astigmatism;	chr4:119337039	chr4:119391831~119395335:-
HNSC	cis	rs8058578	1	rs7187359	ENSG00000279196.1	RP11-1072A3.3	4.73	2.99e-06	0.000693	0.26	0.21	Multiple myeloma;	chr16:30691834	chr16:30984630~30988270:-
HNSC	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	4.73	2.99e-06	0.000693	0.36	0.21	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
HNSC	cis	rs1008375	1	rs917665	ENSG00000249502.1	AC006160.5	4.73	2.99e-06	0.000693	0.23	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666881	chr4:17587467~17614571:-
HNSC	cis	rs172166	0.538	rs149956	ENSG00000219392.1	RP1-265C24.5	-4.73	2.99e-06	0.000693	-0.25	-0.21	Cardiac Troponin-T levels;	chr6:28068473	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.747	rs1534400	ENSG00000243819.4	RN7SL832P	4.73	2.99e-06	0.000694	0.21	0.21	Prostate cancer;	chr2:10556707	chr2:10690344~10692099:+
HNSC	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-4.73	2.99e-06	0.000694	-0.17	-0.21	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-4.73	2.99e-06	0.000694	-0.25	-0.21	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
HNSC	cis	rs853679	0.607	rs13204012	ENSG00000219392.1	RP1-265C24.5	-4.73	2.99e-06	0.000694	-0.44	-0.21	Depression;	chr6:28233753	chr6:28115628~28116551:+
HNSC	cis	rs4787491	0.765	rs8054507	ENSG00000183604.13	SMG1P5	-4.73	2.99e-06	0.000695	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30267553~30335374:-
HNSC	cis	rs4218	0.543	rs8025246	ENSG00000277144.1	RP11-59H7.4	-4.73	3e-06	0.000695	-0.25	-0.21	Social communication problems;	chr15:59025814	chr15:59115547~59116089:-
HNSC	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-4.73	3e-06	0.000695	-0.19	-0.21	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-4.73	3e-06	0.000695	-0.19	-0.21	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
HNSC	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-4.73	3e-06	0.000695	-0.18	-0.21	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
HNSC	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-4.73	3e-06	0.000695	-0.18	-0.21	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
HNSC	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	4.73	3e-06	0.000695	0.25	0.21	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000204709.4	LINC01556	4.73	3e-06	0.000695	0.29	0.21	Depression;	chr6:28139049	chr6:28943877~28944537:+
HNSC	cis	rs79057730	0.599	rs6951032	ENSG00000225146.1	AC073957.15	4.73	3e-06	0.000695	0.34	0.21	Initial pursuit acceleration;	chr7:754455	chr7:1029025~1043891:+
HNSC	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-4.73	3e-06	0.000695	-0.26	-0.21	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
HNSC	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	4.73	3e-06	0.000696	0.25	0.21	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
HNSC	cis	rs2602836	0.6	rs6858148	ENSG00000263923.1	RP11-571L19.7	4.73	3e-06	0.000696	0.21	0.21	HDL cholesterol;HDL cholesterol levels;	chr4:99144766	chr4:98928897~98994994:+
HNSC	cis	rs9907295	0.786	rs9901418	ENSG00000270977.1	AC015849.16	-4.73	3e-06	0.000696	-0.35	-0.21	Fibroblast growth factor basic levels;	chr17:35915699	chr17:35893707~35911023:-
HNSC	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	4.73	3e-06	0.000697	0.26	0.21	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
HNSC	cis	rs9329221	0.678	rs560638	ENSG00000254340.1	RP11-10A14.3	-4.73	3.01e-06	0.000697	-0.26	-0.21	Neuroticism;	chr8:10025257	chr8:9141424~9145435:+
HNSC	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-4.73	3.01e-06	0.000697	-0.28	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
HNSC	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-4.73	3.01e-06	0.000697	-0.28	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
HNSC	cis	rs7000734	0.958	rs2044034	ENSG00000245080.5	RP11-320N21.1	-4.73	3.01e-06	0.000697	-0.3	-0.21	Radiation response;	chr8:95112163	chr8:95066808~95073182:-
HNSC	cis	rs7000734	0.958	rs4735350	ENSG00000245080.5	RP11-320N21.1	-4.73	3.01e-06	0.000697	-0.3	-0.21	Radiation response;	chr8:95113806	chr8:95066808~95073182:-
HNSC	cis	rs12745968	0.653	rs11164810	ENSG00000223787.2	RP4-593M8.1	-4.73	3.01e-06	0.000697	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr1:92779423	chr1:92580476~92580821:-
HNSC	cis	rs35963943	0.625	rs13067530	ENSG00000228956.7	SATB1-AS1	4.73	3.01e-06	0.000697	0.26	0.21	Lymphocyte counts;	chr3:18685306	chr3:18445024~18920401:+
HNSC	cis	rs9863	0.861	rs7973683	ENSG00000269938.1	RP11-214K3.20	-4.73	3.01e-06	0.000697	-0.24	-0.21	White blood cell count;	chr12:123964676	chr12:123968023~123968579:-
HNSC	cis	rs75583333	0.502	rs2032836	ENSG00000247699.2	CTB-127C13.1	-4.73	3.01e-06	0.000697	-0.27	-0.21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160204355	chr5:160195744~160204826:-
HNSC	cis	rs7662987	0.54	rs2851278	ENSG00000263923.1	RP11-571L19.7	-4.73	3.01e-06	0.000698	-0.23	-0.21	Smoking initiation;	chr4:99100102	chr4:98928897~98994994:+
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000254153.1	CTA-398F10.2	4.73	3.01e-06	0.000698	0.23	0.21	Joint mobility (Beighton score);	chr8:8970227	chr8:8456909~8461337:-
HNSC	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	4.73	3.01e-06	0.000698	0.22	0.21	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
HNSC	cis	rs5758511	0.68	rs5758686	ENSG00000226450.2	CYP2D8P	4.73	3.02e-06	0.000699	0.21	0.21	Birth weight;	chr22:42259371	chr22:42149886~42155001:-
HNSC	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	4.73	3.02e-06	0.000699	0.19	0.21	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
HNSC	cis	rs2179367	0.553	rs7762222	ENSG00000216906.2	RP11-350J20.9	4.73	3.02e-06	0.000699	0.32	0.21	Dupuytren's disease;	chr6:149444846	chr6:149904243~149906418:+
HNSC	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-4.73	3.02e-06	7e-04	-0.34	-0.21	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
HNSC	cis	rs6586111	1	rs7071672	ENSG00000226659.1	RP11-137H2.4	-4.73	3.02e-06	7e-04	-0.26	-0.21	Capecitabine sensitivity;	chr10:80616209	chr10:80529597~80535942:-
HNSC	cis	rs1125355	0.557	rs4362514	ENSG00000204380.3	AC005042.4	4.73	3.02e-06	7e-04	0.24	0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158750464	chr2:158658337~158735002:-
HNSC	cis	rs4787951	0.568	rs12933581	ENSG00000259940.2	CTD-3203P2.1	-4.73	3.02e-06	0.000701	-0.24	-0.21	Eosinophil percentage of white cells;	chr16:27293527	chr16:27213308~27214993:-
HNSC	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	4.73	3.03e-06	0.000701	0.24	0.21	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	4.73	3.03e-06	0.000701	0.24	0.21	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
HNSC	cis	rs67981189	0.896	rs34049963	ENSG00000274818.1	RP1-292L20.3	4.73	3.03e-06	0.000701	0.25	0.21	Schizophrenia;	chr14:70974029	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs3814871	ENSG00000274818.1	RP1-292L20.3	4.73	3.03e-06	0.000701	0.25	0.21	Schizophrenia;	chr14:70978071	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs17108822	ENSG00000274818.1	RP1-292L20.3	4.73	3.03e-06	0.000701	0.25	0.21	Schizophrenia;	chr14:70979189	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs8012728	ENSG00000274818.1	RP1-292L20.3	4.73	3.03e-06	0.000701	0.25	0.21	Schizophrenia;	chr14:70981231	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs34731365	ENSG00000274818.1	RP1-292L20.3	4.73	3.03e-06	0.000701	0.25	0.21	Schizophrenia;	chr14:70982877	chr14:70906657~70907111:-
HNSC	cis	rs898123	0.897	rs11541017	ENSG00000234896.1	OR7E62P	4.73	3.03e-06	0.000701	0.25	0.21	Coronary artery disease;	chr2:71124357	chr2:71055527~71056003:+
HNSC	cis	rs9329221	0.905	rs10283145	ENSG00000269918.1	AF131215.9	-4.73	3.03e-06	0.000701	-0.21	-0.21	Neuroticism;	chr8:10383901	chr8:11104691~11106704:-
HNSC	cis	rs202072	0.585	rs536208	ENSG00000215022.6	RP1-257A7.4	-4.73	3.03e-06	0.000702	-0.32	-0.21	HIV-1 viral setpoint;	chr6:13256715	chr6:13264861~13295586:-
HNSC	cis	rs1799955	1	rs11571725	ENSG00000215515.2	IFIT1P1	4.73	3.03e-06	0.000702	0.28	0.21	LDL cholesterol levels;	chr13:32364744	chr13:32384660~32386108:+
HNSC	cis	rs896655	0.622	rs7848524	ENSG00000244230.3	RN7SL151P	-4.73	3.03e-06	0.000702	-0.21	-0.21	Coronary artery disease;	chr9:21701433	chr9:21699314~21699596:+
HNSC	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-4.73	3.03e-06	0.000702	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-4.73	3.03e-06	0.000702	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-4.73	3.03e-06	0.000702	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-4.73	3.03e-06	0.000702	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-4.73	3.03e-06	0.000702	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
HNSC	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	4.73	3.03e-06	0.000702	0.23	0.21	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
HNSC	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	4.73	3.03e-06	0.000702	0.23	0.21	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
HNSC	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	4.73	3.03e-06	0.000702	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
HNSC	cis	rs8031584	0.918	rs35396566	ENSG00000260382.1	RP11-540B6.2	4.73	3.03e-06	0.000702	0.28	0.21	Huntington's disease progression;	chr15:30970854	chr15:30882267~30883231:-
HNSC	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	4.73	3.03e-06	0.000702	0.29	0.21	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
HNSC	cis	rs6964587	0.935	rs28412174	ENSG00000188693.7	CYP51A1-AS1	4.73	3.03e-06	0.000703	0.22	0.21	Breast cancer;	chr7:91947931	chr7:92134604~92180725:+
HNSC	cis	rs1008375	0.932	rs12500912	ENSG00000249502.1	AC006160.5	-4.73	3.03e-06	0.000703	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601695	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs12500947	ENSG00000249502.1	AC006160.5	-4.73	3.03e-06	0.000703	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601801	chr4:17587467~17614571:-
HNSC	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	4.73	3.04e-06	0.000703	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
HNSC	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	4.73	3.04e-06	0.000703	0.21	0.21	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
HNSC	cis	rs17270561	0.723	rs12192635	ENSG00000272810.1	U91328.22	-4.73	3.04e-06	0.000703	-0.22	-0.21	Iron status biomarkers;	chr6:25880679	chr6:26013241~26013757:+
HNSC	cis	rs10462794	0.756	rs13167384	ENSG00000260763.1	RP11-445O3.3	4.73	3.04e-06	0.000703	0.26	0.21	DNA methylation (variation);	chr5:4489995	chr5:4436850~4440259:-
HNSC	cis	rs7819412	0.74	rs11250119	ENSG00000255310.2	AF131215.2	-4.73	3.04e-06	0.000703	-0.21	-0.21	Triglycerides;	chr8:11179525	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000224373.3	IGHV4-59	4.73	3.04e-06	0.000704	0.12	0.21	Kawasaki disease;	chr14:106676185	chr14:106627249~106627825:-
HNSC	cis	rs7688540	0.771	rs11730202	ENSG00000211553.1	AC253576.2	-4.73	3.04e-06	0.000704	-0.31	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:136461~136568:+
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000260075.1	NSFP1	-4.73	3.04e-06	0.000704	-0.31	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46372855~46487141:+
HNSC	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-4.73	3.05e-06	0.000705	-0.25	-0.21	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
HNSC	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-4.73	3.05e-06	0.000705	-0.25	-0.21	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
HNSC	cis	rs9368481	0.729	rs9379948	ENSG00000224843.5	LINC00240	-4.73	3.05e-06	0.000706	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26956992~27023924:+
HNSC	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	4.73	3.05e-06	0.000706	0.35	0.21	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
HNSC	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	4.72	3.05e-06	0.000706	0.24	0.21	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
HNSC	cis	rs1008375	0.932	rs4698626	ENSG00000249502.1	AC006160.5	-4.72	3.05e-06	0.000706	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604198	chr4:17587467~17614571:-
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	4.72	3.05e-06	0.000706	0.26	0.21	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
HNSC	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-4.72	3.05e-06	0.000706	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-4.72	3.05e-06	0.000706	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
HNSC	cis	rs1056107	0.902	rs2182810	ENSG00000225513.1	RP11-165N19.2	-4.72	3.05e-06	0.000706	-0.23	-0.21	Colorectal cancer;	chr9:112204169	chr9:112173522~112173971:-
HNSC	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	4.72	3.05e-06	0.000706	0.47	0.21	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
HNSC	cis	rs9326248	0.559	rs484646	ENSG00000280143.1	AP000892.6	4.72	3.05e-06	0.000707	0.22	0.21	Blood protein levels;	chr11:116862140	chr11:117204967~117210292:+
HNSC	cis	rs4787491	0.729	rs8043883	ENSG00000183604.13	SMG1P5	-4.72	3.05e-06	0.000707	-0.21	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30267553~30335374:-
HNSC	cis	rs6928977	0.796	rs2179781	ENSG00000217482.2	HMGB1P17	-4.72	3.05e-06	0.000707	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135398362	chr6:135636086~135636713:-
HNSC	cis	rs2337406	0.778	rs58113768	ENSG00000254174.1	IGHV1-12	4.72	3.06e-06	0.000707	0.19	0.21	Alzheimer's disease (late onset);	chr14:106700213	chr14:106122420~106122709:-
HNSC	cis	rs12935418	0.552	rs2123626	ENSG00000261061.1	RP11-303E16.2	4.72	3.06e-06	0.000707	0.23	0.21	Mean corpuscular volume;	chr16:80988205	chr16:81030770~81031485:+
HNSC	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	4.72	3.06e-06	0.000707	0.29	0.21	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	4.72	3.06e-06	0.000707	0.29	0.21	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	4.72	3.06e-06	0.000707	0.29	0.21	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	4.72	3.06e-06	0.000707	0.29	0.21	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
HNSC	cis	rs2058059	0.636	rs3015935	ENSG00000225648.4	SBDSP1	-4.72	3.06e-06	0.000707	-0.3	-0.21	Subcutaneous adipose tissue;	chr7:72697290	chr7:72829425~72836701:+
HNSC	cis	rs853679	0.556	rs13197633	ENSG00000204709.4	LINC01556	4.72	3.06e-06	0.000707	0.48	0.21	Depression;	chr6:28206979	chr6:28943877~28944537:+
HNSC	cis	rs36563	0.631	rs2526866	ENSG00000274818.1	RP1-292L20.3	-4.72	3.06e-06	0.000707	-0.36	-0.21	Alcohol dependence;	chr14:70930090	chr14:70906657~70907111:-
HNSC	cis	rs9863	0.828	rs952632	ENSG00000269938.1	RP11-214K3.20	-4.72	3.06e-06	0.000707	-0.25	-0.21	White blood cell count;	chr12:123985191	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.694	rs11837287	ENSG00000269938.1	RP11-214K3.20	-4.72	3.06e-06	0.000707	-0.25	-0.21	White blood cell count;	chr12:123985512	chr12:123968023~123968579:-
HNSC	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-4.72	3.06e-06	0.000707	-0.23	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
HNSC	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	4.72	3.06e-06	0.000708	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	4.72	3.06e-06	0.000708	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	4.72	3.06e-06	0.000708	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
HNSC	cis	rs67981189	0.896	rs2526874	ENSG00000274818.1	RP1-292L20.3	-4.72	3.06e-06	0.000708	-0.25	-0.21	Schizophrenia;	chr14:70914502	chr14:70906657~70907111:-
HNSC	cis	rs9880211	0.898	rs73231903	ENSG00000273486.1	RP11-731C17.2	4.72	3.06e-06	0.000708	0.2	0.21	Height;Body mass index;	chr3:136842783	chr3:136837338~136839021:-
HNSC	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-4.72	3.06e-06	0.000708	-0.26	-0.21	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
HNSC	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	4.72	3.06e-06	0.000709	0.25	0.21	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
HNSC	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-4.72	3.06e-06	0.000709	-0.27	-0.21	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
HNSC	cis	rs3096299	0.967	rs2911253	ENSG00000261574.1	RP1-168P16.2	4.72	3.06e-06	0.000709	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89392375~89412564:-
HNSC	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-4.72	3.06e-06	0.000709	-0.23	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
HNSC	cis	rs9650657	0.59	rs10096777	ENSG00000269918.1	AF131215.9	-4.72	3.07e-06	0.000709	-0.21	-0.21	Neuroticism;	chr8:10660990	chr8:11104691~11106704:-
HNSC	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-4.72	3.07e-06	0.000709	-0.26	-0.21	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
HNSC	cis	rs6964587	1	rs6950470	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.07e-06	0.000709	-0.23	-0.21	Breast cancer;	chr7:92051327	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7791138	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.07e-06	0.000709	-0.23	-0.21	Breast cancer;	chr7:92057475	chr7:92134604~92180725:+
HNSC	cis	rs1056107	0.83	rs10739340	ENSG00000225513.1	RP11-165N19.2	-4.72	3.07e-06	0.000709	-0.23	-0.21	Colorectal cancer;	chr9:112295272	chr9:112173522~112173971:-
HNSC	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	4.72	3.07e-06	0.000709	0.17	0.21	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
HNSC	cis	rs7809950	0.817	rs2222845	ENSG00000238832.1	snoU109	4.72	3.07e-06	0.000709	0.31	0.21	Coronary artery disease;	chr7:107641384	chr7:107603363~107603507:+
HNSC	cis	rs1056107	0.763	rs10115594	ENSG00000225513.1	RP11-165N19.2	-4.72	3.07e-06	0.00071	-0.23	-0.21	Colorectal cancer;	chr9:112174198	chr9:112173522~112173971:-
HNSC	cis	rs9880211	0.644	rs35352346	ENSG00000273486.1	RP11-731C17.2	4.72	3.07e-06	0.00071	0.19	0.21	Height;Body mass index;	chr3:136162646	chr3:136837338~136839021:-
HNSC	cis	rs6964587	0.967	rs7783414	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.07e-06	0.00071	-0.23	-0.21	Breast cancer;	chr7:92156643	chr7:92134604~92180725:+
HNSC	cis	rs7572733	0.935	rs771016	ENSG00000222017.1	AC011997.1	4.72	3.07e-06	0.00071	0.26	0.21	Dermatomyositis;	chr2:197800796	chr2:197693106~197774823:+
HNSC	cis	rs7735319	0.834	rs13166521	ENSG00000250697.1	CTD-2066L21.3	4.72	3.07e-06	0.000711	0.26	0.21	Systolic blood pressure;	chr5:33062086	chr5:32925639~33297910:-
HNSC	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	4.72	3.08e-06	0.000711	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	4.72	3.08e-06	0.000711	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	4.72	3.08e-06	0.000711	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
HNSC	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	4.72	3.08e-06	0.000711	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
HNSC	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	4.72	3.08e-06	0.000712	0.28	0.21	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
HNSC	cis	rs4834770	1	rs878374	ENSG00000250412.1	KLHL2P1	4.72	3.08e-06	0.000712	0.25	0.21	Blood protein levels;	chr4:119316409	chr4:119334329~119378233:+
HNSC	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	4.72	3.08e-06	0.000712	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
HNSC	cis	rs2998286	0.723	rs332161	ENSG00000254635.4	WAC-AS1	4.72	3.08e-06	0.000712	0.29	0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28522652~28532743:-
HNSC	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-4.72	3.08e-06	0.000712	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
HNSC	cis	rs35306767	0.855	rs72778229	ENSG00000229869.1	RP11-363N22.2	-4.72	3.08e-06	0.000712	-0.33	-0.21	Eosinophil percentage of granulocytes;	chr10:906051	chr10:933026~942743:+
HNSC	cis	rs11083475	0.714	rs1471432	ENSG00000269486.2	CTC-360G5.9	4.72	3.08e-06	0.000712	0.23	0.21	Heart rate;	chr19:38769642	chr19:38935297~38938632:-
HNSC	cis	rs5758659	0.935	rs134879	ENSG00000182057.4	OGFRP1	4.72	3.08e-06	0.000712	0.22	0.21	Cognitive function;	chr22:42268195	chr22:42269753~42275196:+
HNSC	cis	rs4761669	0.565	rs11835590	ENSG00000241556.1	RP11-490G8.1	-4.72	3.08e-06	0.000712	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94801919	chr12:95467397~95467861:-
HNSC	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-4.72	3.08e-06	0.000712	-0.17	-0.21	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-4.72	3.08e-06	0.000712	-0.17	-0.21	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-4.72	3.08e-06	0.000712	-0.17	-0.21	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
HNSC	cis	rs950169	0.922	rs11633534	ENSG00000229212.6	RP11-561C5.4	-4.72	3.09e-06	0.000713	-0.3	-0.21	Schizophrenia;	chr15:84581411	chr15:85205440~85234795:-
HNSC	cis	rs6601327	0.613	rs33994795	ENSG00000254340.1	RP11-10A14.3	-4.72	3.09e-06	0.000713	-0.25	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9615919	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	4.72	3.09e-06	0.000713	0.28	0.21	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
HNSC	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	4.72	3.09e-06	0.000713	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
HNSC	cis	rs73222236	0.825	rs7644471	ENSG00000273486.1	RP11-731C17.2	4.72	3.09e-06	0.000713	0.18	0.21	Coronary artery disease;	chr3:136565719	chr3:136837338~136839021:-
HNSC	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	4.72	3.09e-06	0.000713	0.3	0.21	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
HNSC	cis	rs9311676	0.656	rs4681679	ENSG00000273493.1	RP11-80H18.4	-4.72	3.09e-06	0.000713	-0.24	-0.21	Systemic lupus erythematosus;	chr3:58346341	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.681	rs4681846	ENSG00000273493.1	RP11-80H18.4	-4.72	3.09e-06	0.000713	-0.24	-0.21	Systemic lupus erythematosus;	chr3:58346816	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs9881869	ENSG00000273493.1	RP11-80H18.4	-4.72	3.09e-06	0.000713	-0.24	-0.21	Systemic lupus erythematosus;	chr3:58347528	chr3:58329965~58330118:+
HNSC	cis	rs9863	0.896	rs12829951	ENSG00000269938.1	RP11-214K3.20	-4.72	3.09e-06	0.000713	-0.25	-0.21	White blood cell count;	chr12:123941294	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs7131882	ENSG00000269938.1	RP11-214K3.20	-4.72	3.09e-06	0.000713	-0.25	-0.21	White blood cell count;	chr12:123942189	chr12:123968023~123968579:-
HNSC	cis	rs6601327	0.571	rs7838571	ENSG00000254340.1	RP11-10A14.3	4.72	3.09e-06	0.000713	0.26	0.21	Multiple myeloma (hyperdiploidy);	chr8:9790286	chr8:9141424~9145435:+
HNSC	cis	rs754133	0.964	rs894738	ENSG00000248265.1	FLJ12825	4.72	3.09e-06	0.000714	0.25	0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54023741	chr12:54058254~54122234:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000254153.1	CTA-398F10.2	-4.72	3.09e-06	0.000714	-0.23	-0.21	Mood instability;	chr8:8939009	chr8:8456909~8461337:-
HNSC	cis	rs72843506	0.722	rs78041331	ENSG00000261033.1	RP11-209D14.2	4.72	3.09e-06	0.000715	0.39	0.21	Schizophrenia;	chr17:20305533	chr17:20008051~20009234:-
HNSC	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-4.72	3.1e-06	0.000715	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
HNSC	cis	rs6558530	0.932	rs9022	ENSG00000253982.1	CTD-2336O2.1	4.72	3.1e-06	0.000715	0.25	0.21	Systolic blood pressure;	chr8:1762811	chr8:1761990~1764502:-
HNSC	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	4.72	3.1e-06	0.000716	0.22	0.21	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
HNSC	cis	rs6964587	0.904	rs6465339	ENSG00000188693.7	CYP51A1-AS1	4.72	3.1e-06	0.000716	0.22	0.21	Breast cancer;	chr7:91941476	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs12666179	ENSG00000188693.7	CYP51A1-AS1	4.72	3.1e-06	0.000716	0.22	0.21	Breast cancer;	chr7:91944796	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs417	ENSG00000188693.7	CYP51A1-AS1	4.72	3.1e-06	0.000716	0.22	0.21	Breast cancer;	chr7:91951807	chr7:92134604~92180725:+
HNSC	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	4.72	3.1e-06	0.000716	0.18	0.21	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
HNSC	cis	rs11976180	1	rs1533266	ENSG00000273234.1	OR2A13P	-4.72	3.1e-06	0.000716	-0.24	-0.21	Obesity-related traits;	chr7:144069621	chr7:144142009~144142938:+
HNSC	cis	rs539096	0.5	rs2906457	ENSG00000237950.1	RP11-7O11.3	4.72	3.1e-06	0.000716	0.23	0.21	Intelligence (multi-trait analysis);	chr1:43872903	chr1:43944370~43946551:-
HNSC	cis	rs6693567	0.565	rs696617	ENSG00000228126.1	FALEC	4.72	3.1e-06	0.000716	0.26	0.21	Migraine;	chr1:150403835	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.545	rs1694386	ENSG00000228126.1	FALEC	4.72	3.1e-06	0.000716	0.26	0.21	Migraine;	chr1:150405489	chr1:150515757~150518032:+
HNSC	cis	rs4218	0.531	rs12101733	ENSG00000259732.1	RP11-59H7.3	-4.72	3.1e-06	0.000716	-0.26	-0.21	Social communication problems;	chr15:59047566	chr15:59121034~59133250:+
HNSC	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	4.72	3.1e-06	0.000716	0.25	0.21	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
HNSC	cis	rs6928977	0.5	rs9494308	ENSG00000234084.1	RP3-388E23.2	4.72	3.1e-06	0.000716	0.22	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135301568~135307158:+
HNSC	cis	rs5758659	0.652	rs1063392	ENSG00000227370.1	RP4-669P10.19	4.72	3.11e-06	0.000717	0.2	0.21	Cognitive function;	chr22:42058946	chr22:42132543~42132998:+
HNSC	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	4.72	3.11e-06	0.000717	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
HNSC	cis	rs7829975	0.846	rs1879957	ENSG00000254340.1	RP11-10A14.3	-4.72	3.11e-06	0.000717	-0.26	-0.21	Mood instability;	chr8:8687298	chr8:9141424~9145435:+
HNSC	cis	rs2548724	0.588	rs62371034	ENSG00000250682.4	LINC00491	4.72	3.11e-06	0.000717	0.28	0.21	Type 2 diabetes;	chr5:102489780	chr5:102609156~102671559:-
HNSC	cis	rs6964587	1	rs6979085	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.11e-06	0.000717	-0.22	-0.21	Breast cancer;	chr7:92044309	chr7:92134604~92180725:+
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000254174.1	IGHV1-12	4.72	3.11e-06	0.000717	0.18	0.21	Alzheimer's disease (late onset);	chr14:106656649	chr14:106122420~106122709:-
HNSC	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-4.72	3.11e-06	0.000717	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	4.72	3.11e-06	0.000718	0.26	0.21	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
HNSC	cis	rs3733585	0.699	rs7694997	ENSG00000250413.1	RP11-448G15.1	4.72	3.11e-06	0.000718	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9946187	chr4:10006482~10009725:+
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-4.72	3.11e-06	0.000718	-0.26	-0.21	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
HNSC	cis	rs9863	0.828	rs4765127	ENSG00000269938.1	RP11-214K3.20	-4.72	3.11e-06	0.000718	-0.25	-0.21	White blood cell count;	chr12:123975620	chr12:123968023~123968579:-
HNSC	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-4.72	3.11e-06	0.000718	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-4.72	3.11e-06	0.000718	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
HNSC	cis	rs8054556	0.647	rs4077410	ENSG00000183604.13	SMG1P5	-4.72	3.11e-06	0.000719	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:30267553~30335374:-
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	4.72	3.12e-06	0.000719	0.2	0.21	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
HNSC	cis	rs11834862	0.663	rs11246993	ENSG00000256576.2	RP13-977J11.2	-4.72	3.12e-06	0.000719	-0.32	-0.21	Anti-saccade response;	chr12:132204507	chr12:132186735~132189695:-
HNSC	cis	rs17507216	0.56	rs2871011	ENSG00000255769.6	GOLGA2P10	-4.72	3.12e-06	0.000719	-0.27	-0.21	Excessive daytime sleepiness;	chr15:82560792	chr15:82472993~82513950:-
HNSC	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-4.72	3.12e-06	0.000719	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
HNSC	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	4.72	3.12e-06	0.000719	0.23	0.21	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
HNSC	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	4.72	3.12e-06	0.000719	0.23	0.21	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
HNSC	cis	rs12935418	0.616	rs2549858	ENSG00000278985.1	RP11-303E16.9	-4.72	3.12e-06	0.000719	-0.21	-0.21	Mean corpuscular volume;	chr16:80993389	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.616	rs2549859	ENSG00000278985.1	RP11-303E16.9	-4.72	3.12e-06	0.000719	-0.21	-0.21	Mean corpuscular volume;	chr16:80993398	chr16:80982319~80984094:-
HNSC	cis	rs7296418	0.961	rs1790094	ENSG00000280120.1	RP11-546D6.3	4.72	3.12e-06	0.000719	0.18	0.21	Platelet count;	chr12:123102141	chr12:123152324~123153377:-
HNSC	cis	rs721917	0.525	rs11201011	ENSG00000225484.5	NUTM2B-AS1	-4.72	3.12e-06	0.00072	-0.26	-0.21	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.525	rs4281433	ENSG00000225484.5	NUTM2B-AS1	-4.72	3.12e-06	0.00072	-0.26	-0.21	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79663088~79826594:-
HNSC	cis	rs11098499	0.661	rs10015965	ENSG00000249244.1	RP11-548H18.2	4.72	3.12e-06	0.00072	0.26	0.21	Corneal astigmatism;	chr4:119347082	chr4:119391831~119395335:-
HNSC	cis	rs4356203	0.905	rs7478986	ENSG00000260196.1	RP1-239B22.5	-4.72	3.12e-06	0.00072	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17109702	chr11:17380649~17383531:+
HNSC	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-4.72	3.12e-06	0.00072	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
HNSC	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	4.72	3.12e-06	0.00072	0.37	0.21	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
HNSC	cis	rs72843506	0.586	rs79246843	ENSG00000261033.1	RP11-209D14.2	4.72	3.12e-06	0.00072	0.37	0.21	Schizophrenia;	chr17:19938749	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.586	rs74429763	ENSG00000261033.1	RP11-209D14.2	4.72	3.12e-06	0.00072	0.37	0.21	Schizophrenia;	chr17:19960206	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.586	rs16960554	ENSG00000261033.1	RP11-209D14.2	4.72	3.12e-06	0.00072	0.37	0.21	Schizophrenia;	chr17:19966485	chr17:20008051~20009234:-
HNSC	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-4.72	3.12e-06	0.000721	-0.5	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
HNSC	cis	rs7735319	0.834	rs34666210	ENSG00000251281.1	CTD-2066L21.2	4.72	3.12e-06	0.000721	0.26	0.21	Systolic blood pressure;	chr5:33069978	chr5:33011322~33017607:-
HNSC	cis	rs9353324	1	rs7771366	ENSG00000203875.9	SNHG5	-4.72	3.13e-06	0.000721	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85582193	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs6902638	ENSG00000203875.9	SNHG5	-4.72	3.13e-06	0.000721	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85608881	chr6:85660950~85678736:-
HNSC	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	4.72	3.13e-06	0.000721	0.33	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
HNSC	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	4.72	3.13e-06	0.000721	0.19	0.21	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
HNSC	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	4.72	3.13e-06	0.000721	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
HNSC	cis	rs853679	1	rs735765	ENSG00000219392.1	RP1-265C24.5	-4.72	3.13e-06	0.000721	-0.34	-0.21	Depression;	chr6:28202519	chr6:28115628~28116551:+
HNSC	cis	rs988913	0.581	rs1108888	ENSG00000224984.1	RP11-524H19.2	-4.72	3.13e-06	0.000721	-0.24	-0.21	Menarche (age at onset);	chr6:54992490	chr6:54840118~54840855:-
HNSC	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	4.72	3.13e-06	0.000721	0.23	0.21	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
HNSC	cis	rs3806843	0.735	rs778597	ENSG00000202515.1	VTRNA1-3	-4.72	3.13e-06	0.000722	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr5:140726158~140726246:+
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000254153.1	CTA-398F10.2	-4.72	3.13e-06	0.000722	-0.23	-0.21	Mood instability;	chr8:8939092	chr8:8456909~8461337:-
HNSC	cis	rs3806843	1	rs4151682	ENSG00000202515.1	VTRNA1-3	-4.72	3.13e-06	0.000722	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr5:140726158~140726246:+
HNSC	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-4.72	3.13e-06	0.000722	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
HNSC	cis	rs7824557	0.836	rs765731	ENSG00000255310.2	AF131215.2	-4.72	3.13e-06	0.000722	-0.21	-0.21	Retinal vascular caliber;	chr8:11263989	chr8:11107788~11109726:-
HNSC	cis	rs13073817	0.582	rs13059713	ENSG00000228956.7	SATB1-AS1	4.72	3.14e-06	0.000723	0.22	0.21	Crohn's disease;	chr3:18645428	chr3:18445024~18920401:+
HNSC	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-4.72	3.14e-06	0.000723	-0.3	-0.21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
HNSC	cis	rs6964833	1	rs36044436	ENSG00000184616.8	AC004166.6	4.72	3.14e-06	0.000723	0.27	0.21	Menarche (age at onset);	chr7:74675495	chr7:74906673~74913256:-
HNSC	cis	rs5753618	1	rs5753618	ENSG00000236132.1	CTA-440B3.1	-4.72	3.14e-06	0.000723	-0.28	-0.21	Colorectal cancer;	chr22:31442532	chr22:31816379~31817491:-
HNSC	cis	rs12285276	0.576	rs2593756	ENSG00000205106.4	DKFZp779M0652	4.72	3.14e-06	0.000723	0.26	0.21	Visceral fat;	chr11:45746850	chr11:45771432~45772358:+
HNSC	cis	rs853679	0.607	rs71559070	ENSG00000219392.1	RP1-265C24.5	-4.72	3.14e-06	0.000723	-0.43	-0.21	Depression;	chr6:28071151	chr6:28115628~28116551:+
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-4.72	3.14e-06	0.000724	-0.25	-0.21	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
HNSC	cis	rs6964587	0.933	rs10271174	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.14e-06	0.000724	-0.23	-0.21	Breast cancer;	chr7:92156656	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs11772102	ENSG00000188693.7	CYP51A1-AS1	4.72	3.14e-06	0.000724	0.22	0.21	Breast cancer;	chr7:91929012	chr7:92134604~92180725:+
HNSC	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	4.72	3.14e-06	0.000724	0.29	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
HNSC	cis	rs57561814	0.655	rs75443424	ENSG00000179428.2	AC073072.5	-4.72	3.14e-06	0.000724	-0.38	-0.21	Tonsillectomy;	chr7:22702900	chr7:22725395~22727620:-
HNSC	cis	rs57561814	0.655	rs113221056	ENSG00000179428.2	AC073072.5	-4.72	3.14e-06	0.000724	-0.38	-0.21	Tonsillectomy;	chr7:22703977	chr7:22725395~22727620:-
HNSC	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-4.72	3.14e-06	0.000724	-0.27	-0.21	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000254174.1	IGHV1-12	4.72	3.14e-06	0.000725	0.17	0.21	Alzheimer's disease (late onset);	chr14:106665591	chr14:106122420~106122709:-
HNSC	cis	rs6688613	1	rs11578336	ENSG00000215834.7	FMO9P	4.72	3.15e-06	0.000725	0.26	0.21	Refractive astigmatism;	chr1:166989473	chr1:166603675~166631400:+
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000204709.4	LINC01556	4.72	3.15e-06	0.000725	0.29	0.21	Parkinson's disease;	chr6:28138569	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000204709.4	LINC01556	4.72	3.15e-06	0.000725	0.29	0.21	Depression;	chr6:28138981	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000204709.4	LINC01556	4.72	3.15e-06	0.000725	0.29	0.21	Depression;	chr6:28139012	chr6:28943877~28944537:+
HNSC	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	4.72	3.15e-06	0.000725	0.22	0.21	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
HNSC	cis	rs17818399	0.926	rs13032670	ENSG00000279254.1	RP11-536C12.1	-4.72	3.15e-06	0.000726	-0.26	-0.21	Height;	chr2:46603655	chr2:46668870~46670778:+
HNSC	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-4.72	3.15e-06	0.000726	-0.26	-0.21	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
HNSC	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-4.72	3.15e-06	0.000727	-0.3	-0.21	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	4.72	3.16e-06	0.000727	0.25	0.21	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
HNSC	cis	rs72843506	1	rs7223910	ENSG00000261033.1	RP11-209D14.2	4.72	3.16e-06	0.000727	0.3	0.21	Schizophrenia;	chr17:20079455	chr17:20008051~20009234:-
HNSC	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.72	3.16e-06	0.000727	0.23	0.21	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
HNSC	cis	rs3733585	0.673	rs4580649	ENSG00000250413.1	RP11-448G15.1	4.72	3.16e-06	0.000727	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9946837	chr4:10006482~10009725:+
HNSC	cis	rs11834862	0.765	rs10902511	ENSG00000256576.2	RP13-977J11.2	-4.72	3.16e-06	0.000728	-0.32	-0.21	Anti-saccade response;	chr12:132204891	chr12:132186735~132189695:-
HNSC	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.72	3.16e-06	0.000728	-0.24	-0.21	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
HNSC	cis	rs17428076	0.756	rs62181743	ENSG00000228389.1	AC068039.4	-4.72	3.16e-06	0.000728	-0.29	-0.21	Myopia;	chr2:171695491	chr2:171773482~171775844:+
HNSC	cis	rs73198271	0.74	rs10109886	ENSG00000253893.2	FAM85B	4.72	3.16e-06	0.000728	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8167819~8226614:-
HNSC	cis	rs61160187	0.788	rs12519587	ENSG00000215032.2	GNL3LP1	4.72	3.16e-06	0.000728	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:60891935~60893577:-
HNSC	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.72	3.16e-06	0.000728	0.31	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
HNSC	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	4.72	3.16e-06	0.000728	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	4.72	3.16e-06	0.000728	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
HNSC	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-4.72	3.17e-06	0.000729	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
HNSC	cis	rs7590368	1	rs7576898	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10818830	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs2884289	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10819598	chr2:10767875~10770058:-
HNSC	cis	rs7590368	0.961	rs2357815	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10819643	chr2:10767875~10770058:-
HNSC	cis	rs7590368	0.962	rs13431633	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10820099	chr2:10767875~10770058:-
HNSC	cis	rs7590368	0.961	rs13431852	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10820284	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs13429247	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10820403	chr2:10767875~10770058:-
HNSC	cis	rs7590368	0.961	rs13432104	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10820535	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs7590368	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10821348	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs55968911	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10821714	chr2:10767875~10770058:-
HNSC	cis	rs7590368	1	rs55771723	ENSG00000272275.1	RP11-791G15.2	4.72	3.17e-06	0.000729	0.28	0.21	Educational attainment (years of education);	chr2:10821776	chr2:10767875~10770058:-
HNSC	cis	rs853679	0.607	rs34218844	ENSG00000219392.1	RP1-265C24.5	-4.72	3.17e-06	0.000729	-0.42	-0.21	Depression;	chr6:28322870	chr6:28115628~28116551:+
HNSC	cis	rs3806843	0.966	rs3806844	ENSG00000202515.1	VTRNA1-3	-4.72	3.17e-06	0.000729	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr5:140726158~140726246:+
HNSC	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	4.72	3.17e-06	0.000729	0.28	0.21	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	4.72	3.17e-06	0.000729	0.24	0.21	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
HNSC	cis	rs9329221	0.65	rs657913	ENSG00000254340.1	RP11-10A14.3	-4.72	3.17e-06	0.000729	-0.26	-0.21	Neuroticism;	chr8:10025065	chr8:9141424~9145435:+
HNSC	cis	rs13126694	0.659	rs28514324	ENSG00000248429.4	RP11-597D13.9	4.72	3.17e-06	0.00073	0.24	0.21	Blood osmolality (transformed sodium);	chr4:158092778	chr4:158170752~158202877:+
HNSC	cis	rs6918586	1	rs198811	ENSG00000272462.2	U91328.19	4.72	3.17e-06	0.00073	0.2	0.21	Schizophrenia;	chr6:26128218	chr6:25992662~26001775:+
HNSC	cis	rs9402743	0.634	rs2327646	ENSG00000234084.1	RP3-388E23.2	-4.72	3.17e-06	0.00073	-0.21	-0.21	Systemic lupus erythematosus;	chr6:135597186	chr6:135301568~135307158:+
HNSC	cis	rs4908769	0.66	rs301801	ENSG00000232912.4	RP5-1115A15.1	4.72	3.17e-06	0.00073	0.23	0.21	Allergy;	chr1:8435885	chr1:8424645~8434838:+
HNSC	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	4.72	3.17e-06	0.00073	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
HNSC	cis	rs6964587	1	rs6953515	ENSG00000188693.7	CYP51A1-AS1	-4.72	3.17e-06	0.000731	-0.23	-0.21	Breast cancer;	chr7:92029306	chr7:92134604~92180725:+
HNSC	cis	rs3736485	0.966	rs17609917	ENSG00000259438.1	CTD-2650P22.1	4.72	3.18e-06	0.000731	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51619290	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs17609924	ENSG00000259438.1	CTD-2650P22.1	4.72	3.18e-06	0.000731	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51619395	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs8028017	ENSG00000259438.1	CTD-2650P22.1	4.72	3.18e-06	0.000731	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620511	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs10519312	ENSG00000259438.1	CTD-2650P22.1	4.72	3.18e-06	0.000731	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620774	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs28428679	ENSG00000259438.1	CTD-2650P22.1	4.72	3.18e-06	0.000731	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620843	chr15:52010999~52019095:-
HNSC	cis	rs7746199	0.736	rs34573979	ENSG00000219392.1	RP1-265C24.5	-4.72	3.18e-06	0.000731	-0.42	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28115628~28116551:+
HNSC	cis	rs36563	0.631	rs17108910	ENSG00000274818.1	RP1-292L20.3	4.72	3.18e-06	0.000731	0.33	0.21	Alcohol dependence;	chr14:71030982	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-4.72	3.18e-06	0.000731	-0.25	-0.21	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
HNSC	cis	rs5770917	1	rs5770917	ENSG00000272821.1	CTA-384D8.36	-4.72	3.18e-06	0.000731	-0.36	-0.21	Narcolepsy;	chr22:50578924	chr22:50523926~50524780:+
HNSC	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-4.72	3.18e-06	0.000731	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-4.72	3.18e-06	0.000731	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-4.72	3.18e-06	0.000731	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
HNSC	cis	rs17270561	1	rs12211184	ENSG00000272810.1	U91328.22	-4.72	3.18e-06	0.000731	-0.25	-0.21	Iron status biomarkers;	chr6:25823546	chr6:26013241~26013757:+
HNSC	cis	rs1799949	1	rs12944597	ENSG00000236383.6	LINC00854	-4.72	3.18e-06	0.000732	-0.21	-0.21	Menopause (age at onset);	chr17:43035667	chr17:43216941~43305976:-
HNSC	cis	rs9392556	0.6	rs664299	ENSG00000230648.1	RP3-406P24.3	4.72	3.18e-06	0.000732	0.24	0.21	Blood metabolite levels;	chr6:4112007	chr6:4018843~4021215:-
HNSC	cis	rs1799949	1	rs8176126	ENSG00000236383.6	LINC00854	4.72	3.18e-06	0.000733	0.2	0.21	Menopause (age at onset);	chr17:43107032	chr17:43216941~43305976:-
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	4.72	3.19e-06	0.000733	0.25	0.21	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
HNSC	cis	rs11089937	0.616	rs1076851	ENSG00000211638.2	IGLV8-61	-4.72	3.19e-06	0.000733	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22177442	chr22:22098700~22099212:+
HNSC	cis	rs7662987	0.517	rs3018047	ENSG00000263923.1	RP11-571L19.7	4.72	3.19e-06	0.000733	0.23	0.21	Smoking initiation;	chr4:99093359	chr4:98928897~98994994:+
HNSC	cis	rs4218	0.531	rs6494065	ENSG00000277144.1	RP11-59H7.4	4.72	3.19e-06	0.000733	0.25	0.21	Social communication problems;	chr15:59053249	chr15:59115547~59116089:-
HNSC	cis	rs1355223	0.506	rs6484738	ENSG00000271369.1	RP11-350D17.3	-4.72	3.19e-06	0.000733	-0.25	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34839311	chr11:34709600~34710161:+
HNSC	cis	rs7572733	0.84	rs770667	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197748584	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs1065953	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197749888	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs700648	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197757912	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs700649	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197758028	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs700650	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197759561	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.811	rs771013	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197760513	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs1065949	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000733	0.26	0.21	Dermatomyositis;	chr2:197762331	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs700653	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000734	0.26	0.21	Dermatomyositis;	chr2:197772709	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs700654	ENSG00000222017.1	AC011997.1	4.72	3.19e-06	0.000734	0.26	0.21	Dermatomyositis;	chr2:197778697	chr2:197693106~197774823:+
HNSC	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-4.72	3.19e-06	0.000734	-0.23	-0.21	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
HNSC	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	4.72	3.19e-06	0.000734	0.22	0.21	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
HNSC	cis	rs2033711	0.936	rs7257999	ENSG00000269473.1	CTD-2619J13.19	4.72	3.19e-06	0.000734	0.27	0.21	Uric acid clearance;	chr19:58453493	chr19:58440448~58445849:+
HNSC	cis	rs4372836	1	rs7562170	ENSG00000226833.4	AC097724.3	-4.72	3.19e-06	0.000734	-0.27	-0.21	Body mass index;	chr2:28720650	chr2:28708953~28736205:-
HNSC	cis	rs17057718	1	rs747089	ENSG00000272146.4	RP11-755B10.4	-4.72	3.19e-06	0.000734	-0.33	-0.21	Cerebrospinal fluid biomarker levels;	chr3:57119841	chr3:57597715~57600927:+
HNSC	cis	rs11638352	0.661	rs2706462	ENSG00000259479.5	SORD2P	-4.72	3.19e-06	0.000734	-0.4	-0.21	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44183130	chr15:44826371~44884694:-
HNSC	cis	rs8059260	0.866	rs12922318	ENSG00000274038.1	RP11-66H6.4	-4.72	3.2e-06	0.000735	-0.31	-0.21	Alcohol consumption over the past year;	chr16:10946769	chr16:11056556~11057034:+
HNSC	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	4.71	3.2e-06	0.000735	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
HNSC	cis	rs9929218	0.529	rs17715450	ENSG00000260459.2	FTLP14	4.71	3.2e-06	0.000735	0.28	0.21	Colorectal cancer;	chr16:68695882	chr16:68822587~68823070:+
HNSC	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.71	3.2e-06	0.000736	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.71	3.2e-06	0.000736	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
HNSC	cis	rs1150688	1	rs1150688	ENSG00000219392.1	RP1-265C24.5	-4.71	3.2e-06	0.000736	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28115628~28116551:+
HNSC	cis	rs3758785	0.562	rs79850307	ENSG00000255893.1	RP11-685N10.1	-4.71	3.2e-06	0.000736	-0.31	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94411859	chr11:94472908~94473570:-
HNSC	cis	rs11951515	0.508	rs6860493	ENSG00000249286.1	CTD-2210P15.2	4.71	3.2e-06	0.000737	0.22	0.21	Metabolite levels  (X-11787);	chr5:43602611	chr5:43586918~43588223:-
HNSC	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.71	3.21e-06	0.000737	0.28	0.21	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000224373.3	IGHV4-59	4.71	3.21e-06	0.000737	0.14	0.21	Kawasaki disease;	chr14:106705271	chr14:106627249~106627825:-
HNSC	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-4.71	3.21e-06	0.000737	-0.21	-0.21	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
HNSC	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	4.71	3.21e-06	0.000737	0.29	0.21	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
HNSC	cis	rs7296418	0.961	rs4148863	ENSG00000280120.1	RP11-546D6.3	4.71	3.21e-06	0.000737	0.18	0.21	Platelet count;	chr12:123084828	chr12:123152324~123153377:-
HNSC	cis	rs4819052	0.851	rs13050359	ENSG00000223768.1	LINC00205	-4.71	3.21e-06	0.000737	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45293285~45297354:+
HNSC	cis	rs7829975	0.577	rs17684466	ENSG00000254340.1	RP11-10A14.3	-4.71	3.21e-06	0.000738	-0.27	-0.21	Mood instability;	chr8:8687723	chr8:9141424~9145435:+
HNSC	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	4.71	3.21e-06	0.000738	0.17	0.21	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
HNSC	cis	rs7590368	1	rs72779469	ENSG00000272275.1	RP11-791G15.2	4.71	3.21e-06	0.000738	0.28	0.21	Educational attainment (years of education);	chr2:10823638	chr2:10767875~10770058:-
HNSC	cis	rs889398	0.741	rs4146819	ENSG00000226232.7	RP11-419C5.2	-4.71	3.21e-06	0.000738	-0.19	-0.21	Body mass index;	chr16:69889660	chr16:69976388~69996188:-
HNSC	cis	rs889398	0.741	rs7193038	ENSG00000226232.7	RP11-419C5.2	-4.71	3.21e-06	0.000738	-0.19	-0.21	Body mass index;	chr16:69892231	chr16:69976388~69996188:-
HNSC	cis	rs7615952	0.512	rs1077621	ENSG00000248787.1	RP11-666A20.4	-4.71	3.21e-06	0.000738	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126100956	chr3:125908005~125910272:-
HNSC	cis	rs1056107	0.898	rs1417111	ENSG00000225513.1	RP11-165N19.2	-4.71	3.21e-06	0.000738	-0.23	-0.21	Colorectal cancer;	chr9:112229033	chr9:112173522~112173971:-
HNSC	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	4.71	3.21e-06	0.000738	0.3	0.21	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
HNSC	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	4.71	3.22e-06	0.000739	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
HNSC	cis	rs7824557	0.767	rs17797443	ENSG00000255310.2	AF131215.2	4.71	3.22e-06	0.000739	0.21	0.21	Retinal vascular caliber;	chr8:11306503	chr8:11107788~11109726:-
HNSC	cis	rs3736485	0.932	rs2278990	ENSG00000259438.1	CTD-2650P22.1	4.71	3.22e-06	0.000739	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51622465	chr15:52010999~52019095:-
HNSC	cis	rs9813712	0.595	rs1453240	ENSG00000249846.5	RP11-77P16.4	-4.71	3.22e-06	0.00074	-0.23	-0.21	Response to amphetamines;	chr3:130282849	chr3:130112550~130120579:+
HNSC	cis	rs3206736	0.548	rs6971363	ENSG00000197085.10	NPSR1-AS1	-4.71	3.22e-06	0.00074	-0.26	-0.21	Diastolic blood pressure;	chr7:34914069	chr7:34346512~34871582:-
HNSC	cis	rs4372836	1	rs4640348	ENSG00000226833.4	AC097724.3	4.71	3.22e-06	0.00074	0.27	0.21	Body mass index;	chr2:28742613	chr2:28708953~28736205:-
HNSC	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	4.71	3.22e-06	0.000741	0.17	0.21	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
HNSC	cis	rs7590368	0.779	rs3856465	ENSG00000272275.1	RP11-791G15.2	4.71	3.23e-06	0.000741	0.28	0.21	Educational attainment (years of education);	chr2:10776544	chr2:10767875~10770058:-
HNSC	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	4.71	3.23e-06	0.000741	0.23	0.21	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.71	3.23e-06	0.000741	0.23	0.21	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
HNSC	cis	rs4218	0.531	rs12101733	ENSG00000277144.1	RP11-59H7.4	-4.71	3.23e-06	0.000742	-0.25	-0.21	Social communication problems;	chr15:59047566	chr15:59115547~59116089:-
HNSC	cis	rs4664293	0.625	rs35241460	ENSG00000226266.5	AC009961.3	4.71	3.23e-06	0.000742	0.22	0.21	Monocyte percentage of white cells;	chr2:159651689	chr2:159670708~159712435:-
HNSC	cis	rs1056107	0.574	rs9886804	ENSG00000225513.1	RP11-165N19.2	4.71	3.23e-06	0.000742	0.23	0.21	Colorectal cancer;	chr9:112159787	chr9:112173522~112173971:-
HNSC	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	4.71	3.23e-06	0.000742	0.35	0.21	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	4.71	3.23e-06	0.000742	0.35	0.21	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
HNSC	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
HNSC	cis	rs11722228	0.522	rs62286604	ENSG00000250413.1	RP11-448G15.1	-4.71	3.23e-06	0.000742	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10129537	chr4:10006482~10009725:+
HNSC	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	4.71	3.23e-06	0.000742	0.26	0.21	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
HNSC	cis	rs9329221	0.512	rs7843924	ENSG00000254340.1	RP11-10A14.3	4.71	3.23e-06	0.000742	0.26	0.21	Neuroticism;	chr8:10119030	chr8:9141424~9145435:+
HNSC	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	4.71	3.23e-06	0.000742	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
HNSC	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-4.71	3.23e-06	0.000742	-0.24	-0.21	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
HNSC	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	4.71	3.23e-06	0.000742	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
HNSC	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-4.71	3.24e-06	0.000743	-0.24	-0.21	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	4.71	3.24e-06	0.000743	0.25	0.21	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
HNSC	cis	rs7819412	0.66	rs7462931	ENSG00000255310.2	AF131215.2	-4.71	3.24e-06	0.000743	-0.21	-0.21	Triglycerides;	chr8:11052833	chr8:11107788~11109726:-
HNSC	cis	rs11893307	0.507	rs1465305	ENSG00000235852.1	AC005540.3	4.71	3.24e-06	0.000743	0.27	0.21	Mean platelet volume;	chr2:190720666	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.507	rs1465303	ENSG00000235852.1	AC005540.3	4.71	3.24e-06	0.000743	0.27	0.21	Mean platelet volume;	chr2:190720714	chr2:190880797~190882059:-
HNSC	cis	rs11969893	0.737	rs6930051	ENSG00000270987.1	RP3-467N11.2	4.71	3.24e-06	0.000743	0.52	0.21	Economic and political preferences (immigration/crime);	chr6:100958232	chr6:100889603~100890338:+
HNSC	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-4.71	3.24e-06	0.000744	-0.27	-0.21	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
HNSC	cis	rs116095464	0.558	rs55776650	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:273711	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs59113266	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:279850	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs11959126	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:283765	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7356696	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:284136	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7356561	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:284266	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs59284383	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:284410	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7731089	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.24e-06	0.000744	-0.3	-0.21	Breast cancer;	chr5:290307	chr5:288833~290321:-
HNSC	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-4.71	3.24e-06	0.000744	-0.27	-0.21	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-4.71	3.24e-06	0.000744	-0.27	-0.21	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
HNSC	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	4.71	3.24e-06	0.000744	0.23	0.21	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
HNSC	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-4.71	3.24e-06	0.000744	-0.26	-0.21	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
HNSC	cis	rs3806843	0.966	rs2240693	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs2240692	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs6579987	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs1030163	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs1030164	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs4151680	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs3822346	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.933	rs2337987	ENSG00000202515.1	VTRNA1-3	-4.71	3.24e-06	0.000744	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr5:140726158~140726246:+
HNSC	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.71	3.24e-06	0.000744	0.24	0.21	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
HNSC	cis	rs11247915	0.54	rs11582416	ENSG00000236782.4	RP11-96L14.7	4.71	3.24e-06	0.000744	0.24	0.21	Obesity-related traits;	chr1:26351230	chr1:26169947~26171821:-
HNSC	cis	rs2904524	1	rs4761189	ENSG00000257815.4	RP11-611E13.2	-4.71	3.25e-06	0.000745	-0.27	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70247078	chr12:69904033~70243360:-
HNSC	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	4.71	3.25e-06	0.000746	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	4.71	3.25e-06	0.000746	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
HNSC	cis	rs1008375	0.863	rs10003291	ENSG00000249502.1	AC006160.5	-4.71	3.25e-06	0.000746	-0.24	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17599105	chr4:17587467~17614571:-
HNSC	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-4.71	3.25e-06	0.000746	-0.27	-0.21	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
HNSC	cis	rs10462794	0.789	rs10043704	ENSG00000260763.1	RP11-445O3.3	4.71	3.25e-06	0.000746	0.26	0.21	DNA methylation (variation);	chr5:4491020	chr5:4436850~4440259:-
HNSC	cis	rs442309	0.687	rs10995294	ENSG00000238280.1	RP11-436D10.3	-4.71	3.25e-06	0.000746	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62723157	chr10:62793562~62805887:-
HNSC	cis	rs9863	0.931	rs4765335	ENSG00000269938.1	RP11-214K3.20	-4.71	3.25e-06	0.000746	-0.25	-0.21	White blood cell count;	chr12:123946265	chr12:123968023~123968579:-
HNSC	cis	rs8035957	0.697	rs72727394	ENSG00000259747.1	RP11-275I4.2	-4.71	3.25e-06	0.000746	-0.29	-0.21	Type 1 diabetes;	chr15:38554821	chr15:38671847~38689191:+
HNSC	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-4.71	3.25e-06	0.000746	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
HNSC	cis	rs889398	0.835	rs62050037	ENSG00000226232.7	RP11-419C5.2	4.71	3.26e-06	0.000747	0.19	0.21	Body mass index;	chr16:69750767	chr16:69976388~69996188:-
HNSC	cis	rs10435719	0.867	rs6999030	ENSG00000255495.1	AC145124.2	4.71	3.26e-06	0.000747	0.24	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.834	rs6985792	ENSG00000255495.1	AC145124.2	4.71	3.26e-06	0.000747	0.24	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12194467~12196280:+
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	4.71	3.26e-06	0.000747	0.26	0.21	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
HNSC	cis	rs6831352	0.918	rs2213035	ENSG00000263923.1	RP11-571L19.7	4.71	3.26e-06	0.000748	0.23	0.21	Alcohol dependence;	chr4:99143082	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs3919370	ENSG00000263923.1	RP11-571L19.7	4.71	3.26e-06	0.000748	0.23	0.21	Alcohol dependence;	chr4:99143175	chr4:98928897~98994994:+
HNSC	cis	rs7085104	0.513	rs192569	ENSG00000236937.2	PTGES3P4	-4.71	3.26e-06	0.000748	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102845595~102845950:+
HNSC	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	4.71	3.26e-06	0.000748	0.29	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
HNSC	cis	rs933688	1	rs12656350	ENSG00000281357.1	ARRDC3-AS1	4.71	3.26e-06	0.000748	0.32	0.21	Smoking behavior;	chr5:91455526	chr5:91380349~91439085:+
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	4.71	3.27e-06	0.000749	0.26	0.21	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
HNSC	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	4.71	3.27e-06	0.00075	0.34	0.21	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
HNSC	cis	rs9650657	0.538	rs11250093	ENSG00000269918.1	AF131215.9	4.71	3.27e-06	0.00075	0.21	0.21	Neuroticism;	chr8:10941318	chr8:11104691~11106704:-
HNSC	cis	rs7665090	0.87	rs228613	ENSG00000246560.2	RP11-10L12.4	-4.71	3.27e-06	0.00075	-0.24	-0.21	Primary biliary cholangitis;	chr4:102656308	chr4:102828055~102844075:+
HNSC	cis	rs9863	0.828	rs7311969	ENSG00000269938.1	RP11-214K3.20	4.71	3.27e-06	0.00075	0.24	0.21	White blood cell count;	chr12:123985786	chr12:123968023~123968579:-
HNSC	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	4.71	3.27e-06	0.00075	0.27	0.21	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
HNSC	cis	rs6964587	1	rs7789492	ENSG00000188693.7	CYP51A1-AS1	-4.71	3.28e-06	0.000751	-0.22	-0.21	Breast cancer;	chr7:92039540	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs926192	ENSG00000188693.7	CYP51A1-AS1	-4.71	3.28e-06	0.000751	-0.22	-0.21	Breast cancer;	chr7:92042539	chr7:92134604~92180725:+
HNSC	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-4.71	3.28e-06	0.000751	-0.33	-0.21	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
HNSC	cis	rs8040855	0.599	rs4643289	ENSG00000259774.1	RP11-182J1.13	-4.71	3.28e-06	0.000752	-0.26	-0.21	Bulimia nervosa;	chr15:85183483	chr15:84422618~84425882:+
HNSC	cis	rs6496044	0.568	rs12708554	ENSG00000259295.5	CSPG4P12	4.71	3.28e-06	0.000752	0.25	0.21	Interstitial lung disease;	chr15:85531066	chr15:85191438~85213905:+
HNSC	cis	rs7572733	0.875	rs771018	ENSG00000222017.1	AC011997.1	4.71	3.28e-06	0.000752	0.26	0.21	Dermatomyositis;	chr2:197785535	chr2:197693106~197774823:+
HNSC	cis	rs67981189	0.896	rs12883437	ENSG00000274818.1	RP1-292L20.3	4.71	3.28e-06	0.000752	0.25	0.21	Schizophrenia;	chr14:70998064	chr14:70906657~70907111:-
HNSC	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-4.71	3.28e-06	0.000752	-0.27	-0.21	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	4.71	3.28e-06	0.000752	0.25	0.21	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
HNSC	cis	rs35963943	0.625	rs13075184	ENSG00000228956.7	SATB1-AS1	4.71	3.29e-06	0.000753	0.26	0.21	Lymphocyte counts;	chr3:18683182	chr3:18445024~18920401:+
HNSC	cis	rs6964587	0.81	rs408	ENSG00000188693.7	CYP51A1-AS1	4.71	3.29e-06	0.000753	0.23	0.21	Breast cancer;	chr7:91926970	chr7:92134604~92180725:+
HNSC	cis	rs8028182	0.636	rs7166737	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.29e-06	0.000753	-0.27	-0.21	Sudden cardiac arrest;	chr15:75390172	chr15:75527150~75601205:-
HNSC	cis	rs9402743	0.671	rs4896158	ENSG00000234084.1	RP3-388E23.2	-4.71	3.29e-06	0.000754	-0.22	-0.21	Systemic lupus erythematosus;	chr6:135630087	chr6:135301568~135307158:+
HNSC	cis	rs1056107	0.933	rs7038215	ENSG00000225513.1	RP11-165N19.2	-4.71	3.29e-06	0.000754	-0.23	-0.21	Colorectal cancer;	chr9:112208523	chr9:112173522~112173971:-
HNSC	cis	rs9287719	0.967	rs4669596	ENSG00000243819.4	RN7SL832P	4.71	3.29e-06	0.000754	0.2	0.21	Prostate cancer;	chr2:10580446	chr2:10690344~10692099:+
HNSC	cis	rs6964587	1	rs7802668	ENSG00000188693.7	CYP51A1-AS1	-4.71	3.29e-06	0.000754	-0.23	-0.21	Breast cancer;	chr7:92019625	chr7:92134604~92180725:+
HNSC	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
HNSC	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-4.71	3.3e-06	0.000755	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
HNSC	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	4.71	3.3e-06	0.000755	0.33	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
HNSC	cis	rs11976180	1	rs1919949	ENSG00000273234.1	OR2A13P	-4.71	3.3e-06	0.000755	-0.24	-0.21	Obesity-related traits;	chr7:144070630	chr7:144142009~144142938:+
HNSC	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	4.71	3.3e-06	0.000755	0.28	0.21	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
HNSC	cis	rs9329221	0.51	rs6995837	ENSG00000254340.1	RP11-10A14.3	4.71	3.3e-06	0.000755	0.25	0.21	Neuroticism;	chr8:10118165	chr8:9141424~9145435:+
HNSC	cis	rs9329221	0.537	rs6995859	ENSG00000254340.1	RP11-10A14.3	4.71	3.3e-06	0.000755	0.25	0.21	Neuroticism;	chr8:10118199	chr8:9141424~9145435:+
HNSC	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	4.71	3.3e-06	0.000755	0.22	0.21	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
HNSC	cis	rs116095464	0.558	rs7725227	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.3e-06	0.000755	-0.29	-0.21	Breast cancer;	chr5:233402	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7710005	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.3e-06	0.000755	-0.29	-0.21	Breast cancer;	chr5:233457	chr5:288833~290321:-
HNSC	cis	rs1056107	0.931	rs10759540	ENSG00000225513.1	RP11-165N19.2	-4.71	3.3e-06	0.000756	-0.23	-0.21	Colorectal cancer;	chr9:112239394	chr9:112173522~112173971:-
HNSC	cis	rs9903692	0.909	rs1468270	ENSG00000263412.1	RP5-890E16.2	-4.71	3.3e-06	0.000756	-0.2	-0.21	Pulse pressure;	chr17:48047829	chr17:48045141~48048073:-
HNSC	cis	rs7615952	0.576	rs6780025	ENSG00000248787.1	RP11-666A20.4	-4.71	3.3e-06	0.000756	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126096781	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.576	rs6804482	ENSG00000248787.1	RP11-666A20.4	-4.71	3.3e-06	0.000756	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126096919	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.576	rs12497295	ENSG00000248787.1	RP11-666A20.4	-4.71	3.3e-06	0.000756	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126099807	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.512	rs4646765	ENSG00000248787.1	RP11-666A20.4	-4.71	3.3e-06	0.000756	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126101864	chr3:125908005~125910272:-
HNSC	cis	rs10109025	0.701	rs10101292	ENSG00000255310.2	AF131215.2	-4.71	3.31e-06	0.000756	-0.21	-0.21	Joint mobility (Beighton score);	chr8:10998964	chr8:11107788~11109726:-
HNSC	cis	rs10462794	0.853	rs4701907	ENSG00000260763.1	RP11-445O3.3	-4.71	3.31e-06	0.000757	-0.3	-0.21	DNA methylation (variation);	chr5:4503625	chr5:4436850~4440259:-
HNSC	cis	rs5758511	0.68	rs1033460	ENSG00000226450.2	CYP2D8P	4.71	3.31e-06	0.000757	0.21	0.21	Birth weight;	chr22:42223302	chr22:42149886~42155001:-
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000226314.6	ZNF192P1	-4.71	3.31e-06	0.000757	-0.26	-0.21	Parkinson's disease;	chr6:28002926	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000226314.6	ZNF192P1	-4.71	3.31e-06	0.000757	-0.26	-0.21	Parkinson's disease;	chr6:28002927	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000226314.6	ZNF192P1	-4.71	3.31e-06	0.000757	-0.26	-0.21	Parkinson's disease;	chr6:28007039	chr6:28161781~28169594:+
HNSC	cis	rs867371	0.82	rs7164362	ENSG00000259429.4	UBE2Q2P2	-4.71	3.31e-06	0.000757	-0.21	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82355142~82420075:+
HNSC	cis	rs2253762	0.507	rs10159998	ENSG00000226864.1	ATE1-AS1	4.71	3.31e-06	0.000758	0.35	0.21	Breast cancer;	chr10:121994550	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs11200311	ENSG00000226864.1	ATE1-AS1	4.71	3.31e-06	0.000758	0.35	0.21	Breast cancer;	chr10:121995094	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs79069897	ENSG00000226864.1	ATE1-AS1	4.71	3.31e-06	0.000758	0.35	0.21	Breast cancer;	chr10:121995680	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs77032313	ENSG00000226864.1	ATE1-AS1	4.71	3.31e-06	0.000758	0.35	0.21	Breast cancer;	chr10:121995687	chr10:121928312~121951965:+
HNSC	cis	rs10462794	1	rs6863111	ENSG00000260763.1	RP11-445O3.3	4.71	3.31e-06	0.000758	0.28	0.21	DNA methylation (variation);	chr5:4485695	chr5:4436850~4440259:-
HNSC	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-4.71	3.31e-06	0.000758	-0.17	-0.21	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
HNSC	cis	rs3806843	0.966	rs11953833	ENSG00000202515.1	VTRNA1-3	-4.71	3.31e-06	0.000758	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr5:140726158~140726246:+
HNSC	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	4.71	3.31e-06	0.000758	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
HNSC	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	4.71	3.31e-06	0.000758	0.29	0.21	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
HNSC	cis	rs6964587	0.967	rs13233496	ENSG00000188693.7	CYP51A1-AS1	-4.71	3.32e-06	0.000759	-0.23	-0.21	Breast cancer;	chr7:92183721	chr7:92134604~92180725:+
HNSC	cis	rs13126694	0.744	rs13121497	ENSG00000248429.4	RP11-597D13.9	4.71	3.32e-06	0.000759	0.24	0.21	Blood osmolality (transformed sodium);	chr4:158076724	chr4:158170752~158202877:+
HNSC	cis	rs67981189	0.896	rs7146591	ENSG00000274818.1	RP1-292L20.3	-4.71	3.32e-06	0.000759	-0.25	-0.21	Schizophrenia;	chr14:70971511	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs4391999	ENSG00000274818.1	RP1-292L20.3	4.71	3.32e-06	0.000759	0.25	0.21	Schizophrenia;	chr14:70978696	chr14:70906657~70907111:-
HNSC	cis	rs79057730	0.599	rs4720893	ENSG00000225146.1	AC073957.15	4.71	3.32e-06	0.000759	0.34	0.21	Initial pursuit acceleration;	chr7:764797	chr7:1029025~1043891:+
HNSC	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-4.71	3.32e-06	0.00076	-0.25	-0.21	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
HNSC	cis	rs6928977	0.863	rs2746419	ENSG00000234084.1	RP3-388E23.2	4.71	3.33e-06	0.000761	0.21	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135332717	chr6:135301568~135307158:+
HNSC	cis	rs12893668	0.703	rs4906337	ENSG00000269910.1	RP11-73M18.10	4.71	3.33e-06	0.000761	0.21	0.21	Reticulocyte count;	chr14:103574077	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.703	rs7140568	ENSG00000269910.1	RP11-73M18.10	4.71	3.33e-06	0.000761	0.21	0.21	Reticulocyte count;	chr14:103575037	chr14:103694516~103695050:-
HNSC	cis	rs61542988	1	rs61542988	ENSG00000221740.1	SNORD93	4.71	3.33e-06	0.000761	0.24	0.21	Fibrinogen levels;	chr7:22842672	chr7:22856613~22856686:+
HNSC	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	4.71	3.33e-06	0.000761	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
HNSC	cis	rs6430585	0.528	rs6711493	ENSG00000231890.6	DARS-AS1	-4.71	3.33e-06	0.000761	-0.35	-0.21	Corneal structure;	chr2:135934983	chr2:135985176~136022593:+
HNSC	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	4.71	3.33e-06	0.000761	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
HNSC	cis	rs853679	0.607	rs13201308	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28162311	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs34505829	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28165461	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs35098436	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28166443	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs72846794	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28169721	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13217984	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28171932	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.505	rs35781323	ENSG00000204709.4	LINC01556	4.71	3.33e-06	0.000761	0.47	0.21	Depression;	chr6:28177054	chr6:28943877~28944537:+
HNSC	cis	rs3806843	0.966	rs3806842	ENSG00000202515.1	VTRNA1-3	-4.71	3.33e-06	0.000762	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr5:140726158~140726246:+
HNSC	cis	rs656319	0.564	rs11776035	ENSG00000269918.1	AF131215.9	-4.71	3.33e-06	0.000762	-0.22	-0.21	Myopia (pathological);	chr8:10214017	chr8:11104691~11106704:-
HNSC	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	4.71	3.33e-06	0.000762	0.31	0.21	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
HNSC	cis	rs6723108	0.627	rs1446524	ENSG00000224043.6	CCNT2-AS1	-4.71	3.33e-06	0.000762	-0.26	-0.21	Type 2 diabetes;	chr2:134873761	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs10928522	ENSG00000224043.6	CCNT2-AS1	-4.71	3.33e-06	0.000762	-0.26	-0.21	Type 2 diabetes;	chr2:134875292	chr2:134735464~134918710:-
HNSC	cis	rs7674212	0.541	rs2045746	ENSG00000251288.2	RP11-10L12.2	4.71	3.33e-06	0.000762	0.25	0.21	Type 2 diabetes;	chr4:103162421	chr4:102751401~102752641:+
HNSC	cis	rs11673344	0.542	rs826328	ENSG00000276846.1	CTD-3220F14.3	4.71	3.34e-06	0.000762	0.23	0.21	Obesity-related traits;	chr19:37004479	chr19:37314868~37315620:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	4.71	3.34e-06	0.000762	0.26	0.21	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
HNSC	cis	rs5758511	0.514	rs4453786	ENSG00000226450.2	CYP2D8P	4.71	3.34e-06	0.000763	0.21	0.21	Birth weight;	chr22:42167302	chr22:42149886~42155001:-
HNSC	cis	rs116095464	0.614	rs28736753	ENSG00000250848.1	CTD-2083E4.5	-4.71	3.34e-06	0.000763	-0.3	-0.21	Breast cancer;	chr5:273966	chr5:288833~290321:-
HNSC	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-4.71	3.34e-06	0.000763	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-4.71	3.34e-06	0.000763	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
HNSC	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	4.71	3.34e-06	0.000763	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000254340.1	RP11-10A14.3	4.71	3.34e-06	0.000764	0.25	0.21	Systolic blood pressure;	chr8:8462453	chr8:9141424~9145435:+
HNSC	cis	rs4699052	0.625	rs10212959	ENSG00000246560.2	RP11-10L12.4	-4.71	3.34e-06	0.000764	-0.24	-0.21	Testicular germ cell tumor;	chr4:103379778	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	4.71	3.35e-06	0.000764	0.25	0.21	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
HNSC	cis	rs42490	0.576	rs381456	ENSG00000251136.7	RP11-37B2.1	-4.71	3.35e-06	0.000764	-0.2	-0.21	Leprosy;	chr8:89865176	chr8:89609409~89757727:-
HNSC	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	4.7	3.35e-06	0.000765	0.23	0.21	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.7	3.35e-06	0.000765	0.23	0.21	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
HNSC	cis	rs11951515	0.508	rs67261887	ENSG00000249286.1	CTD-2210P15.2	4.7	3.35e-06	0.000765	0.22	0.21	Metabolite levels  (X-11787);	chr5:43612339	chr5:43586918~43588223:-
HNSC	cis	rs7868228	1	rs7868228	ENSG00000240498.5	CDKN2B-AS1	4.7	3.35e-06	0.000766	0.29	0.21	Gut microbiome composition (winter);	chr9:21667763	chr9:21994778~22121097:+
HNSC	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	4.7	3.35e-06	0.000766	0.25	0.21	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
HNSC	cis	rs6964587	1	rs2188155	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:91970511	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs28615927	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:91971334	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs10228800	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:91980797	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6976122	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:91981648	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs13230588	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:91986113	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs3753109	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:92000687	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6964587	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:92001306	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7805077	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.36e-06	0.000766	-0.22	-0.21	Breast cancer;	chr7:92015239	chr7:92134604~92180725:+
HNSC	cis	rs1056107	0.931	rs2418199	ENSG00000225513.1	RP11-165N19.2	-4.7	3.36e-06	0.000766	-0.23	-0.21	Colorectal cancer;	chr9:112242888	chr9:112173522~112173971:-
HNSC	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-4.7	3.36e-06	0.000767	-0.26	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
HNSC	cis	rs17428076	0.837	rs72889848	ENSG00000228389.1	AC068039.4	-4.7	3.36e-06	0.000767	-0.27	-0.21	Myopia;	chr2:171670728	chr2:171773482~171775844:+
HNSC	cis	rs6496044	0.568	rs6496040	ENSG00000259295.5	CSPG4P12	4.7	3.36e-06	0.000767	0.25	0.21	Interstitial lung disease;	chr15:85520898	chr15:85191438~85213905:+
HNSC	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	4.7	3.36e-06	0.000767	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	4.7	3.36e-06	0.000767	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	4.7	3.36e-06	0.000767	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	4.7	3.36e-06	0.000767	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
HNSC	cis	rs8028182	0.636	rs8028277	ENSG00000260269.4	CTD-2323K18.1	-4.7	3.36e-06	0.000767	-0.27	-0.21	Sudden cardiac arrest;	chr15:75391744	chr15:75527150~75601205:-
HNSC	cis	rs9910055	0.573	rs228768	ENSG00000267080.4	ASB16-AS1	-4.7	3.36e-06	0.000768	-0.17	-0.21	Total body bone mineral density;	chr17:44114525	chr17:44175973~44186717:-
HNSC	cis	rs656319	0.513	rs17746227	ENSG00000269918.1	AF131215.9	-4.7	3.37e-06	0.000769	-0.22	-0.21	Myopia (pathological);	chr8:10124144	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	4.7	3.37e-06	0.000769	0.25	0.21	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
HNSC	cis	rs7735319	0.8	rs58843681	ENSG00000251281.1	CTD-2066L21.2	4.7	3.37e-06	0.000769	0.26	0.21	Systolic blood pressure;	chr5:33064046	chr5:33011322~33017607:-
HNSC	cis	rs11673344	0.542	rs826331	ENSG00000276846.1	CTD-3220F14.3	4.7	3.37e-06	0.000769	0.23	0.21	Obesity-related traits;	chr19:37007360	chr19:37314868~37315620:-
HNSC	cis	rs9393777	0.92	rs13207689	ENSG00000219392.1	RP1-265C24.5	-4.7	3.37e-06	0.00077	-0.44	-0.21	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28115628~28116551:+
HNSC	cis	rs1008375	1	rs10939742	ENSG00000249502.1	AC006160.5	-4.7	3.37e-06	0.00077	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658313	chr4:17587467~17614571:-
HNSC	cis	rs1056107	0.731	rs10114892	ENSG00000225513.1	RP11-165N19.2	-4.7	3.37e-06	0.00077	-0.23	-0.21	Colorectal cancer;	chr9:112173696	chr9:112173522~112173971:-
HNSC	cis	rs11098499	0.722	rs10006192	ENSG00000249244.1	RP11-548H18.2	4.7	3.38e-06	0.00077	0.26	0.21	Corneal astigmatism;	chr4:119341867	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.615	rs28551750	ENSG00000249244.1	RP11-548H18.2	4.7	3.38e-06	0.00077	0.26	0.21	Corneal astigmatism;	chr4:119343746	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs9995716	ENSG00000249244.1	RP11-548H18.2	4.7	3.38e-06	0.00077	0.26	0.21	Corneal astigmatism;	chr4:119343841	chr4:119391831~119395335:-
HNSC	cis	rs1056107	0.931	rs7852473	ENSG00000225513.1	RP11-165N19.2	-4.7	3.38e-06	0.00077	-0.23	-0.21	Colorectal cancer;	chr9:112245751	chr9:112173522~112173971:-
HNSC	cis	rs754133	0.963	rs12319419	ENSG00000248265.1	FLJ12825	4.7	3.38e-06	0.000771	0.26	0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026992	chr12:54058254~54122234:+
HNSC	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	4.7	3.38e-06	0.000771	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
HNSC	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.7	3.38e-06	0.000771	0.2	0.21	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
HNSC	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-4.7	3.38e-06	0.000771	-0.28	-0.21	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
HNSC	cis	rs898123	0.931	rs4852763	ENSG00000234896.1	OR7E62P	4.7	3.38e-06	0.000772	0.25	0.21	Coronary artery disease;	chr2:71149679	chr2:71055527~71056003:+
HNSC	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-4.7	3.38e-06	0.000772	-0.27	-0.21	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	4.7	3.38e-06	0.000772	0.26	0.21	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
HNSC	cis	rs4908769	0.66	rs172531	ENSG00000232912.4	RP5-1115A15.1	-4.7	3.38e-06	0.000772	-0.23	-0.21	Allergy;	chr1:8435530	chr1:8424645~8434838:+
HNSC	cis	rs35963943	0.571	rs11914305	ENSG00000228956.7	SATB1-AS1	4.7	3.38e-06	0.000772	0.26	0.21	Lymphocyte counts;	chr3:18675073	chr3:18445024~18920401:+
HNSC	cis	rs7176527	0.579	rs366717	ENSG00000259570.1	RP11-671M22.4	-4.7	3.39e-06	0.000772	-0.29	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84394512~84395514:+
HNSC	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-4.7	3.39e-06	0.000772	-0.27	-0.21	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
HNSC	cis	rs7615952	0.576	rs2276727	ENSG00000248787.1	RP11-666A20.4	-4.7	3.39e-06	0.000772	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126107400	chr3:125908005~125910272:-
HNSC	cis	rs9329221	0.655	rs656319	ENSG00000254340.1	RP11-10A14.3	-4.7	3.39e-06	0.000772	-0.25	-0.21	Neuroticism;	chr8:9956901	chr8:9141424~9145435:+
HNSC	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-4.7	3.39e-06	0.000772	-0.17	-0.21	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
HNSC	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-4.7	3.39e-06	0.000773	-0.24	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-4.7	3.39e-06	0.000773	-0.24	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-4.7	3.39e-06	0.000773	-0.24	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-4.7	3.39e-06	0.000773	-0.24	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
HNSC	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	4.7	3.39e-06	0.000773	0.41	0.21	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
HNSC	cis	rs2985684	1	rs3007030	ENSG00000278009.1	RP11-649E7.8	4.7	3.39e-06	0.000773	0.28	0.21	Carotid intima media thickness;	chr14:49619845	chr14:49601011~49601124:-
HNSC	cis	rs2427308	0.643	rs477859	ENSG00000275437.1	RP5-908M14.10	-4.7	3.39e-06	0.000773	-0.23	-0.21	Colorectal cancer;	chr20:62362541	chr20:62402236~62405935:-
HNSC	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	4.7	3.39e-06	0.000773	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	4.7	3.39e-06	0.000773	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	4.7	3.39e-06	0.000773	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	4.7	3.39e-06	0.000773	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
HNSC	cis	rs12893668	0.703	rs8017993	ENSG00000269940.1	RP11-73M18.7	4.7	3.39e-06	0.000773	0.21	0.21	Reticulocyte count;	chr14:103581397	chr14:103694560~103695170:+
HNSC	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-4.7	3.4e-06	0.000774	-0.33	-0.21	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
HNSC	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-4.7	3.4e-06	0.000774	-0.33	-0.21	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
HNSC	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-4.7	3.4e-06	0.000774	-0.33	-0.21	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
HNSC	cis	rs3738443	0.868	rs7536883	ENSG00000259865.1	RP11-488L18.10	4.7	3.4e-06	0.000774	0.19	0.21	Alcohol dependence;	chr1:247196266	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.817	rs61839996	ENSG00000259865.1	RP11-488L18.10	4.7	3.4e-06	0.000774	0.19	0.21	Alcohol dependence;	chr1:247197571	chr1:247187281~247188526:-
HNSC	cis	rs1552244	0.935	rs11926481	ENSG00000180385.7	EMC3-AS1	4.7	3.4e-06	0.000775	0.24	0.21	Alzheimer's disease;	chr3:10100418	chr3:9986893~10006990:+
HNSC	cis	rs2058059	0.636	rs3132428	ENSG00000225648.4	SBDSP1	-4.7	3.4e-06	0.000775	-0.29	-0.21	Subcutaneous adipose tissue;	chr7:72717018	chr7:72829425~72836701:+
HNSC	cis	rs7824557	0.843	rs2572418	ENSG00000269918.1	AF131215.9	-4.7	3.4e-06	0.000775	-0.21	-0.21	Retinal vascular caliber;	chr8:11255580	chr8:11104691~11106704:-
HNSC	cis	rs10462794	0.853	rs17678610	ENSG00000260763.1	RP11-445O3.3	-4.7	3.4e-06	0.000775	-0.29	-0.21	DNA methylation (variation);	chr5:4508975	chr5:4436850~4440259:-
HNSC	cis	rs1552244	0.882	rs6443276	ENSG00000180385.7	EMC3-AS1	4.7	3.4e-06	0.000775	0.23	0.21	Alzheimer's disease;	chr3:9967221	chr3:9986893~10006990:+
HNSC	cis	rs4763879	0.634	rs12424826	ENSG00000278635.1	CTD-2318O12.1	4.7	3.4e-06	0.000775	0.16	0.21	Type 1 diabetes;	chr12:9701981	chr12:9415641~9416718:+
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-4.7	3.4e-06	0.000775	-0.25	-0.21	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
HNSC	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	4.7	3.4e-06	0.000775	0.34	0.21	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
HNSC	cis	rs9527	0.615	rs11191401	ENSG00000236937.2	PTGES3P4	4.7	3.4e-06	0.000776	0.29	0.21	Arsenic metabolism;	chr10:102813646	chr10:102845595~102845950:+
HNSC	cis	rs933688	1	rs4382199	ENSG00000281357.1	ARRDC3-AS1	4.7	3.4e-06	0.000776	0.31	0.21	Smoking behavior;	chr5:91448411	chr5:91380349~91439085:+
HNSC	cis	rs1223397	0.938	rs17700321	ENSG00000215022.6	RP1-257A7.4	-4.7	3.4e-06	0.000776	-0.26	-0.21	Blood pressure;	chr6:13280434	chr6:13264861~13295586:-
HNSC	cis	rs5758659	0.679	rs134870	ENSG00000273366.1	CTA-989H11.1	-4.7	3.41e-06	0.000776	-0.25	-0.21	Cognitive function;	chr22:42256311	chr22:42278188~42278846:+
HNSC	cis	rs1056107	0.933	rs7861788	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000776	-0.23	-0.21	Colorectal cancer;	chr9:112207709	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs4644329	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000776	-0.23	-0.21	Colorectal cancer;	chr9:112207713	chr9:112173522~112173971:-
HNSC	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	4.7	3.41e-06	0.000777	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
HNSC	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	4.7	3.41e-06	0.000777	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	4.7	3.41e-06	0.000777	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
HNSC	cis	rs1056107	0.933	rs6477896	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000777	-0.23	-0.21	Colorectal cancer;	chr9:112205498	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs6477897	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000777	-0.23	-0.21	Colorectal cancer;	chr9:112205658	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs7861162	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000777	-0.23	-0.21	Colorectal cancer;	chr9:112207436	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs7861447	ENSG00000225513.1	RP11-165N19.2	-4.7	3.41e-06	0.000777	-0.23	-0.21	Colorectal cancer;	chr9:112207493	chr9:112173522~112173971:-
HNSC	cis	rs3806843	0.966	rs11958868	ENSG00000202515.1	VTRNA1-3	-4.7	3.41e-06	0.000777	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr5:140726158~140726246:+
HNSC	cis	rs116095464	0.51	rs73016876	ENSG00000250848.1	CTD-2083E4.5	-4.7	3.41e-06	0.000778	-0.3	-0.21	Breast cancer;	chr5:244360	chr5:288833~290321:-
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	4.7	3.42e-06	0.000779	0.2	0.21	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
HNSC	cis	rs11250098	0.503	rs13270870	ENSG00000269918.1	AF131215.9	-4.7	3.42e-06	0.000779	-0.21	-0.21	Morning vs. evening chronotype;	chr8:10913272	chr8:11104691~11106704:-
HNSC	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-4.7	3.42e-06	0.00078	-0.29	-0.21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
HNSC	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	4.7	3.42e-06	0.00078	0.23	0.21	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
HNSC	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	4.7	3.42e-06	0.00078	0.36	0.21	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
HNSC	cis	rs6831352	0.918	rs2602896	ENSG00000263923.1	RP11-571L19.7	4.7	3.43e-06	0.00078	0.23	0.21	Alcohol dependence;	chr4:99125056	chr4:98928897~98994994:+
HNSC	cis	rs6964587	0.9	rs7783674	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.43e-06	0.00078	-0.22	-0.21	Breast cancer;	chr7:92154898	chr7:92134604~92180725:+
HNSC	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-4.7	3.43e-06	0.00078	-0.26	-0.21	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
HNSC	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-4.7	3.43e-06	0.00078	-0.26	-0.21	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
HNSC	cis	rs8074700	0.954	rs4793599	ENSG00000239552.2	HOXB-AS2	4.7	3.43e-06	0.000781	0.23	0.21	Body mass index in non-asthmatics;	chr17:48669013	chr17:48557262~48560333:+
HNSC	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	4.7	3.43e-06	0.000781	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	4.7	3.43e-06	0.000781	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
HNSC	cis	rs13073817	0.582	rs10865754	ENSG00000228956.7	SATB1-AS1	4.7	3.43e-06	0.000781	0.22	0.21	Crohn's disease;	chr3:18644675	chr3:18445024~18920401:+
HNSC	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-4.7	3.43e-06	0.000782	-0.33	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
HNSC	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	4.7	3.43e-06	0.000782	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
HNSC	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-4.7	3.43e-06	0.000782	-0.19	-0.21	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
HNSC	cis	rs67981189	0.896	rs2526877	ENSG00000274818.1	RP1-292L20.3	-4.7	3.44e-06	0.000782	-0.24	-0.21	Schizophrenia;	chr14:70966605	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs7157250	ENSG00000274818.1	RP1-292L20.3	4.7	3.44e-06	0.000782	0.24	0.21	Schizophrenia;	chr14:70991112	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs4132849	ENSG00000274818.1	RP1-292L20.3	4.7	3.44e-06	0.000782	0.24	0.21	Schizophrenia;	chr14:70992806	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.821	rs56021283	ENSG00000274818.1	RP1-292L20.3	4.7	3.44e-06	0.000782	0.24	0.21	Schizophrenia;	chr14:70996042	chr14:70906657~70907111:-
HNSC	cis	rs73607972	0.935	rs6499628	ENSG00000275191.1	RP11-36I17.2	-4.7	3.44e-06	0.000783	-0.3	-0.21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53570265	chr16:53628256~53628816:-
HNSC	cis	rs1150668	0.799	rs1736891	ENSG00000219392.1	RP1-265C24.5	-4.7	3.44e-06	0.000783	-0.24	-0.21	Pubertal anthropometrics;	chr6:28219323	chr6:28115628~28116551:+
HNSC	cis	rs4819052	0.851	rs4819049	ENSG00000223768.1	LINC00205	-4.7	3.44e-06	0.000783	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45293285~45297354:+
HNSC	cis	rs4834770	1	rs4336213	ENSG00000250412.1	KLHL2P1	4.7	3.44e-06	0.000784	0.24	0.21	Blood protein levels;	chr4:119315314	chr4:119334329~119378233:+
HNSC	cis	rs853679	0.607	rs66886492	ENSG00000219392.1	RP1-265C24.5	-4.7	3.44e-06	0.000784	-0.43	-0.21	Depression;	chr6:28121953	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs35345226	ENSG00000219392.1	RP1-265C24.5	-4.7	3.44e-06	0.000784	-0.43	-0.21	Depression;	chr6:28123802	chr6:28115628~28116551:+
HNSC	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	4.7	3.44e-06	0.000784	0.24	0.21	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	4.7	3.44e-06	0.000784	0.24	0.21	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	4.7	3.44e-06	0.000784	0.24	0.21	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	4.7	3.44e-06	0.000784	0.24	0.21	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
HNSC	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-4.7	3.44e-06	0.000784	-0.35	-0.21	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
HNSC	cis	rs3096299	1	rs3096299	ENSG00000261574.1	RP1-168P16.2	4.7	3.45e-06	0.000785	0.27	0.21	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89392375~89412564:-
HNSC	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	4.7	3.45e-06	0.000785	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
HNSC	cis	rs6601327	0.678	rs10106040	ENSG00000254340.1	RP11-10A14.3	4.7	3.45e-06	0.000785	0.26	0.21	Multiple myeloma (hyperdiploidy);	chr8:9754903	chr8:9141424~9145435:+
HNSC	cis	rs964611	0.882	rs6493315	ENSG00000259488.2	RP11-154J22.1	-4.7	3.45e-06	0.000785	-0.19	-0.21	Metabolite levels (Pyroglutamine);	chr15:48274817	chr15:48312353~48331856:-
HNSC	cis	rs4218	0.531	rs1374156	ENSG00000277144.1	RP11-59H7.4	-4.7	3.45e-06	0.000785	-0.25	-0.21	Social communication problems;	chr15:59046746	chr15:59115547~59116089:-
HNSC	cis	rs1056107	0.843	rs10981312	ENSG00000225513.1	RP11-165N19.2	-4.7	3.45e-06	0.000785	-0.23	-0.21	Colorectal cancer;	chr9:112203105	chr9:112173522~112173971:-
HNSC	cis	rs1056107	0.933	rs7021460	ENSG00000225513.1	RP11-165N19.2	-4.7	3.45e-06	0.000785	-0.23	-0.21	Colorectal cancer;	chr9:112205095	chr9:112173522~112173971:-
HNSC	cis	rs67981189	0.865	rs2526876	ENSG00000274818.1	RP1-292L20.3	-4.7	3.45e-06	0.000785	-0.25	-0.21	Schizophrenia;	chr14:70911471	chr14:70906657~70907111:-
HNSC	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-4.7	3.46e-06	0.000786	-0.28	-0.21	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-4.7	3.46e-06	0.000786	-0.28	-0.21	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
HNSC	cis	rs72843506	0.656	rs16960678	ENSG00000261033.1	RP11-209D14.2	4.7	3.46e-06	0.000787	0.35	0.21	Schizophrenia;	chr17:20080378	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs73984571	ENSG00000261033.1	RP11-209D14.2	4.7	3.46e-06	0.000787	0.35	0.21	Schizophrenia;	chr17:20080746	chr17:20008051~20009234:-
HNSC	cis	rs6723108	0.627	rs6706537	ENSG00000224043.6	CCNT2-AS1	-4.7	3.46e-06	0.000787	-0.26	-0.21	Type 2 diabetes;	chr2:134861412	chr2:134735464~134918710:-
HNSC	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	4.7	3.46e-06	0.000788	0.21	0.21	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
HNSC	cis	rs4218	0.588	rs9788719	ENSG00000277144.1	RP11-59H7.4	-4.7	3.47e-06	0.000788	-0.26	-0.21	Social communication problems;	chr15:59028920	chr15:59115547~59116089:-
HNSC	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	4.7	3.47e-06	0.000788	0.27	0.21	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
HNSC	cis	rs8077577	0.945	rs62073649	ENSG00000273018.4	CTD-2303H24.2	-4.7	3.47e-06	0.000788	-0.32	-0.21	Obesity-related traits;	chr17:18177208	chr17:18511221~18551705:-
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	4.7	3.47e-06	0.000789	0.26	0.21	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
HNSC	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	4.7	3.47e-06	0.000789	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	4.7	3.47e-06	0.000789	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
HNSC	cis	rs638893	0.898	rs587816	ENSG00000255422.1	AP002954.4	-4.7	3.47e-06	0.000789	-0.33	-0.21	Vitiligo;	chr11:118819162	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.898	rs577121	ENSG00000255422.1	AP002954.4	-4.7	3.47e-06	0.000789	-0.33	-0.21	Vitiligo;	chr11:118819841	chr11:118704607~118750263:+
HNSC	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	4.7	3.47e-06	0.000789	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	4.7	3.47e-06	0.000789	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
HNSC	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-4.7	3.47e-06	0.000789	-0.2	-0.21	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	4.7	3.47e-06	0.000789	0.26	0.21	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-4.7	3.47e-06	0.00079	-0.18	-0.21	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
HNSC	cis	rs13217239	0.646	rs7768407	ENSG00000224843.5	LINC00240	-4.7	3.47e-06	0.00079	-0.21	-0.21	Schizophrenia;	chr6:27049016	chr6:26956992~27023924:+
HNSC	cis	rs7535099	0.954	rs6678948	ENSG00000224570.1	RP11-430H12.2	-4.7	3.47e-06	0.00079	-0.28	-0.21	Blood protein levels;	chr1:65571906	chr1:65576129~65578380:-
HNSC	cis	rs2835345	0.511	rs57583267	ENSG00000230479.1	AP000695.6	4.7	3.47e-06	0.00079	0.23	0.21	Pulmonary function;	chr21:36445230	chr21:36430360~36481070:+
HNSC	cis	rs35963943	0.625	rs4411904	ENSG00000228956.7	SATB1-AS1	4.7	3.48e-06	0.000791	0.26	0.21	Lymphocyte counts;	chr3:18679003	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4413336	ENSG00000228956.7	SATB1-AS1	4.7	3.48e-06	0.000791	0.26	0.21	Lymphocyte counts;	chr3:18679188	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs7611052	ENSG00000228956.7	SATB1-AS1	4.7	3.48e-06	0.000791	0.26	0.21	Lymphocyte counts;	chr3:18680012	chr3:18445024~18920401:+
HNSC	cis	rs795484	0.963	rs795483	ENSG00000275409.1	RP11-131L12.4	-4.7	3.48e-06	0.000791	-0.24	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118152774	chr12:118430147~118430699:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.7	3.48e-06	0.000791	0.22	0.21	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	4.7	3.48e-06	0.000791	0.22	0.21	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
HNSC	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	4.7	3.48e-06	0.000791	0.27	0.21	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
HNSC	cis	rs116095464	0.558	rs6555055	ENSG00000250848.1	CTD-2083E4.5	-4.7	3.48e-06	0.000792	-0.29	-0.21	Breast cancer;	chr5:226045	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6555056	ENSG00000250848.1	CTD-2083E4.5	-4.7	3.48e-06	0.000792	-0.29	-0.21	Breast cancer;	chr5:226107	chr5:288833~290321:-
HNSC	cis	rs643955	0.609	rs13259465	ENSG00000269918.1	AF131215.9	-4.7	3.48e-06	0.000792	-0.22	-0.21	Systemic lupus erythematosus;	chr8:10125443	chr8:11104691~11106704:-
HNSC	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	4.7	3.48e-06	0.000792	0.23	0.21	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28089816	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28090857	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28091439	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28091659	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28092227	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28093966	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000204709.4	LINC01556	4.7	3.49e-06	0.000793	0.29	0.21	Depression;	chr6:28094014	chr6:28943877~28944537:+
HNSC	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	4.7	3.49e-06	0.000793	0.23	0.21	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	4.7	3.49e-06	0.000793	0.23	0.21	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	4.7	3.49e-06	0.000793	0.23	0.21	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
HNSC	cis	rs35963943	0.625	rs13073040	ENSG00000228956.7	SATB1-AS1	4.7	3.49e-06	0.000793	0.26	0.21	Lymphocyte counts;	chr3:18678812	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4575922	ENSG00000228956.7	SATB1-AS1	4.7	3.49e-06	0.000793	0.26	0.21	Lymphocyte counts;	chr3:18678893	chr3:18445024~18920401:+
HNSC	cis	rs9880211	0.898	rs73230099	ENSG00000239213.4	NCK1-AS1	4.7	3.49e-06	0.000793	0.21	0.21	Height;Body mass index;	chr3:136833785	chr3:136841726~136862054:-
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-4.7	3.49e-06	0.000793	-0.26	-0.21	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
HNSC	cis	rs8091660	0.624	rs907546	ENSG00000278983.1	RP11-426J5.3	4.7	3.49e-06	0.000793	0.3	0.21	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549919	chr18:48564795~48568342:+
HNSC	cis	rs3736485	0.966	rs6493513	ENSG00000259438.1	CTD-2650P22.1	4.7	3.5e-06	0.000795	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51617977	chr15:52010999~52019095:-
HNSC	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-4.7	3.5e-06	0.000795	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
HNSC	cis	rs6964587	0.872	rs57969083	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.5e-06	0.000795	-0.22	-0.21	Breast cancer;	chr7:92036313	chr7:92134604~92180725:+
HNSC	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	4.7	3.5e-06	0.000795	0.24	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
HNSC	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	4.7	3.5e-06	0.000795	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	4.7	3.5e-06	0.000795	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	4.7	3.5e-06	0.000795	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	4.7	3.5e-06	0.000795	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
HNSC	cis	rs36052053	0.521	rs13219774	ENSG00000203799.9	CCDC162P	4.7	3.5e-06	0.000795	0.39	0.21	Red cell distribution width;	chr6:109243023	chr6:109285485~109355063:+
HNSC	cis	rs7868228	1	rs7868151	ENSG00000240498.5	CDKN2B-AS1	-4.7	3.5e-06	0.000795	-0.29	-0.21	Gut microbiome composition (winter);	chr9:21667865	chr9:21994778~22121097:+
HNSC	cis	rs3736485	0.966	rs2305708	ENSG00000259438.1	CTD-2650P22.1	4.7	3.5e-06	0.000796	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51617763	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs4774596	ENSG00000259438.1	CTD-2650P22.1	4.7	3.5e-06	0.000796	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51618778	chr15:52010999~52019095:-
HNSC	cis	rs11773103	0.748	rs73194619	ENSG00000224046.1	AC005076.5	4.7	3.5e-06	0.000796	0.39	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87294804	chr7:87151423~87152420:-
HNSC	cis	rs6964587	1	rs12540565	ENSG00000188693.7	CYP51A1-AS1	-4.7	3.5e-06	0.000796	-0.22	-0.21	Breast cancer;	chr7:92003899	chr7:92134604~92180725:+
HNSC	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	4.7	3.51e-06	0.000796	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
HNSC	cis	rs12468579	0.74	rs12693588	ENSG00000235852.1	AC005540.3	4.7	3.51e-06	0.000797	0.25	0.21	JT interval (sulfonylurea treatment interaction);	chr2:190967766	chr2:190880797~190882059:-
HNSC	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-4.7	3.51e-06	0.000797	-0.23	-0.21	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
HNSC	cis	rs3736485	0.966	rs11633713	ENSG00000259438.1	CTD-2650P22.1	4.7	3.51e-06	0.000797	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51615855	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs4775965	ENSG00000259438.1	CTD-2650P22.1	4.7	3.51e-06	0.000797	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616054	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs9920124	ENSG00000259438.1	CTD-2650P22.1	4.7	3.51e-06	0.000797	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616745	chr15:52010999~52019095:-
HNSC	cis	rs2236295	0.597	rs7477765	ENSG00000238280.1	RP11-436D10.3	-4.7	3.51e-06	0.000797	-0.26	-0.21	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62831984	chr10:62793562~62805887:-
HNSC	cis	rs1056107	0.737	rs7041381	ENSG00000225513.1	RP11-165N19.2	-4.7	3.51e-06	0.000797	-0.22	-0.21	Colorectal cancer;	chr9:112309799	chr9:112173522~112173971:-
HNSC	cis	rs9880211	0.718	rs28631273	ENSG00000273486.1	RP11-731C17.2	4.69	3.51e-06	0.000797	0.19	0.21	Height;Body mass index;	chr3:136215869	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	4.69	3.51e-06	0.000797	0.26	0.21	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
HNSC	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	4.69	3.51e-06	0.000797	0.26	0.21	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
HNSC	cis	rs1355223	0.506	rs7131272	ENSG00000271369.1	RP11-350D17.3	4.69	3.51e-06	0.000798	0.26	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848001	chr11:34709600~34710161:+
HNSC	cis	rs7809950	1	rs2178497	ENSG00000238832.1	snoU109	4.69	3.51e-06	0.000798	0.28	0.21	Coronary artery disease;	chr7:107638456	chr7:107603363~107603507:+
HNSC	cis	rs3736485	0.966	rs2124877	ENSG00000259438.1	CTD-2650P22.1	4.69	3.52e-06	0.000798	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614078	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs2124878	ENSG00000259438.1	CTD-2650P22.1	4.69	3.52e-06	0.000798	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614140	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.903	rs750162	ENSG00000259438.1	CTD-2650P22.1	4.69	3.52e-06	0.000798	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614956	chr15:52010999~52019095:-
HNSC	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	4.69	3.52e-06	0.000798	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
HNSC	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.69	3.52e-06	0.000799	-0.2	-0.21	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
HNSC	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	4.69	3.52e-06	0.000799	0.24	0.21	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	4.69	3.52e-06	0.000799	0.24	0.21	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
HNSC	cis	rs9907295	1	rs11653016	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9889977	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9894799	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9903590	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9897665	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9912049	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9911016	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9912894	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9303693	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9914468	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9893004	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9899215	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9907145	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9901195	ENSG00000270977.1	AC015849.16	-4.69	3.52e-06	0.000799	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35893707~35911023:-
HNSC	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-4.69	3.52e-06	0.000799	-0.28	-0.21	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
HNSC	cis	rs2286503	0.901	rs2286505	ENSG00000226329.2	AC005682.6	4.69	3.52e-06	0.000799	0.26	0.21	Fibrinogen;	chr7:22815221	chr7:22863874~22881350:-
HNSC	cis	rs3736485	0.966	rs8040080	ENSG00000259438.1	CTD-2650P22.1	4.69	3.52e-06	8e-04	0.22	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51612262	chr15:52010999~52019095:-
HNSC	cis	rs116095464	0.867	rs7726582	ENSG00000250848.1	CTD-2083E4.5	-4.69	3.52e-06	8e-04	-0.29	-0.21	Breast cancer;	chr5:215234	chr5:288833~290321:-
HNSC	cis	rs9880211	1	rs9828976	ENSG00000273486.1	RP11-731C17.2	4.69	3.52e-06	8e-04	0.2	0.21	Height;Body mass index;	chr3:136817993	chr3:136837338~136839021:-
HNSC	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	4.69	3.52e-06	8e-04	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
HNSC	cis	rs9990333	0.562	rs12632706	ENSG00000231464.1	AC024937.4	4.69	3.52e-06	8e-04	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195996738~195998233:+
HNSC	cis	rs155076	0.938	rs536209	ENSG00000233325.3	MIPEPP3	4.69	3.52e-06	8e-04	0.37	0.21	White matter hyperintensity burden;	chr13:21273575	chr13:21298139~21306373:+
HNSC	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.69	3.53e-06	8e-04	0.24	0.21	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
HNSC	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-4.69	3.53e-06	8e-04	-0.35	-0.21	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
HNSC	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	4.69	3.53e-06	8e-04	0.23	0.21	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
HNSC	cis	rs5758659	0.692	rs5751251	ENSG00000227370.1	RP4-669P10.19	-4.69	3.53e-06	0.000801	-0.2	-0.21	Cognitive function;	chr22:42244600	chr22:42132543~42132998:+
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	4.69	3.53e-06	0.000801	0.26	0.21	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
HNSC	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	4.69	3.53e-06	0.000801	0.2	0.21	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
HNSC	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	4.69	3.53e-06	0.000801	0.29	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
HNSC	cis	rs1823913	0.538	rs6732537	ENSG00000280083.1	RP11-317J9.1	-4.69	3.53e-06	0.000801	-0.25	-0.21	Obesity-related traits;	chr2:191346755	chr2:191154118~191156070:-
HNSC	cis	rs1555322	0.872	rs2425048	ENSG00000279253.1	RP4-614O4.13	-4.69	3.53e-06	0.000802	-0.34	-0.21	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35262727~35264187:-
HNSC	cis	rs9402743	0.597	rs9385729	ENSG00000234084.1	RP3-388E23.2	-4.69	3.53e-06	0.000802	-0.21	-0.21	Systemic lupus erythematosus;	chr6:135600001	chr6:135301568~135307158:+
HNSC	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-4.69	3.54e-06	0.000802	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000233609.3	RP11-62H7.2	-4.69	3.54e-06	0.000802	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9009151	chr8:8961200~8979025:+
HNSC	cis	rs858267	0.661	rs1178515	ENSG00000230658.1	KLHL7-AS1	-4.69	3.54e-06	0.000802	-0.55	-0.21	Blood protein levels;	chr7:23141617	chr7:23101228~23105703:-
HNSC	cis	rs3806843	0.735	rs801168	ENSG00000202515.1	VTRNA1-3	4.69	3.54e-06	0.000802	0.23	0.21	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr5:140726158~140726246:+
HNSC	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	4.69	3.54e-06	0.000803	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	4.69	3.54e-06	0.000803	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	4.69	3.54e-06	0.000803	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	4.69	3.54e-06	0.000803	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
HNSC	cis	rs7746199	0.736	rs35037868	ENSG00000219392.1	RP1-265C24.5	-4.69	3.54e-06	0.000803	-0.43	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28115628~28116551:+
HNSC	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	4.69	3.54e-06	0.000804	0.19	0.21	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
HNSC	cis	rs7809950	0.593	rs62482503	ENSG00000238832.1	snoU109	-4.69	3.54e-06	0.000804	-0.3	-0.21	Coronary artery disease;	chr7:107347543	chr7:107603363~107603507:+
HNSC	cis	rs4660214	0.666	rs683135	ENSG00000182109.6	RP11-69E11.4	4.69	3.55e-06	0.000804	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39522280~39546187:-
HNSC	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	4.69	3.55e-06	0.000804	0.23	0.21	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
HNSC	cis	rs73198271	0.813	rs17697237	ENSG00000253893.2	FAM85B	-4.69	3.55e-06	0.000805	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.74	rs10105920	ENSG00000233609.3	RP11-62H7.2	4.69	3.55e-06	0.000805	0.23	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8961200~8979025:+
HNSC	cis	rs867371	0.656	rs2665103	ENSG00000276710.3	CSPG4P8	4.69	3.55e-06	0.000805	0.22	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82459472~82477258:+
HNSC	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	4.69	3.55e-06	0.000805	0.25	0.21	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
HNSC	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	4.69	3.55e-06	0.000805	0.27	0.21	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
HNSC	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-4.69	3.55e-06	0.000806	-0.27	-0.21	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
HNSC	cis	rs9304742	0.962	rs12461778	ENSG00000213801.4	ZNF816-ZNF321P	4.69	3.56e-06	0.000806	0.24	0.21	Psoriasis;	chr19:52951710	chr19:52927135~52942601:-
HNSC	cis	rs9304742	0.962	rs12461796	ENSG00000213801.4	ZNF816-ZNF321P	4.69	3.56e-06	0.000806	0.24	0.21	Psoriasis;	chr19:52951835	chr19:52927135~52942601:-
HNSC	cis	rs9304742	0.962	rs12150933	ENSG00000213801.4	ZNF816-ZNF321P	4.69	3.56e-06	0.000806	0.24	0.21	Psoriasis;	chr19:52951968	chr19:52927135~52942601:-
HNSC	cis	rs6668534	0.904	rs1340976	ENSG00000225217.1	HSPA7	-4.69	3.56e-06	0.000807	-0.28	-0.21	Blood protein levels;	chr1:161691699	chr1:161606291~161608217:+
HNSC	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	4.69	3.56e-06	0.000807	0.26	0.21	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
HNSC	cis	rs5758511	0.68	rs5758657	ENSG00000226450.2	CYP2D8P	4.69	3.56e-06	0.000807	0.21	0.21	Birth weight;	chr22:42222663	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs1033459	ENSG00000226450.2	CYP2D8P	4.69	3.56e-06	0.000807	0.21	0.21	Birth weight;	chr22:42223061	chr22:42149886~42155001:-
HNSC	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-4.69	3.57e-06	0.000808	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
HNSC	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-4.69	3.57e-06	0.000809	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
HNSC	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	4.69	3.57e-06	0.000809	0.25	0.21	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
HNSC	cis	rs12893668	0.703	rs35026580	ENSG00000269910.1	RP11-73M18.10	4.69	3.57e-06	0.000809	0.21	0.21	Reticulocyte count;	chr14:103576416	chr14:103694516~103695050:-
HNSC	cis	rs4256159	1	rs73178598	ENSG00000228956.7	SATB1-AS1	4.69	3.57e-06	0.000809	0.36	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18763719	chr3:18445024~18920401:+
HNSC	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	4.69	3.57e-06	0.000809	0.33	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
HNSC	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-4.69	3.57e-06	0.000809	-0.24	-0.21	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
HNSC	cis	rs7923609	0.818	rs10761716	ENSG00000232075.1	MRPL35P2	-4.69	3.58e-06	0.00081	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63122540	chr10:63634317~63634827:-
HNSC	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-4.69	3.58e-06	0.00081	-0.27	-0.21	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
HNSC	cis	rs1223397	0.938	rs3817738	ENSG00000215022.6	RP1-257A7.4	-4.69	3.58e-06	0.00081	-0.27	-0.21	Blood pressure;	chr6:13279156	chr6:13264861~13295586:-
HNSC	cis	rs1971762	0.527	rs1247956	ENSG00000270175.1	RP11-793H13.11	4.69	3.58e-06	0.000811	0.19	0.21	Height;	chr12:53570030	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.509	rs1247955	ENSG00000270175.1	RP11-793H13.11	4.69	3.58e-06	0.000811	0.19	0.21	Height;	chr12:53570349	chr12:53500162~53500936:-
HNSC	cis	rs853679	0.607	rs34243448	ENSG00000204709.4	LINC01556	4.69	3.58e-06	0.000811	0.44	0.21	Depression;	chr6:28225324	chr6:28943877~28944537:+
HNSC	cis	rs712039	0.958	rs1016679	ENSG00000276054.1	RP11-378E13.3	-4.69	3.58e-06	0.000811	-0.26	-0.21	Tuberculosis;	chr17:37514228	chr17:37386886~37387926:+
HNSC	cis	rs9393777	0.92	rs13196692	ENSG00000219392.1	RP1-265C24.5	-4.69	3.58e-06	0.000811	-0.43	-0.21	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000226314.6	ZNF192P1	-4.69	3.58e-06	0.000812	-0.32	-0.21	Depression;	chr6:28129415	chr6:28161781~28169594:+
HNSC	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	4.69	3.59e-06	0.000812	0.23	0.21	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
HNSC	cis	rs3096299	0.935	rs3114890	ENSG00000261574.1	RP1-168P16.2	4.69	3.59e-06	0.000812	0.27	0.21	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89392375~89412564:-
HNSC	cis	rs7829975	0.846	rs11779061	ENSG00000254153.1	CTA-398F10.2	-4.69	3.59e-06	0.000812	-0.24	-0.21	Mood instability;	chr8:8691922	chr8:8456909~8461337:-
HNSC	cis	rs11146838	1	rs11146838	ENSG00000099251.13	HSD17B7P2	4.69	3.59e-06	0.000812	0.21	0.21	Breast cancer;	chr10:38856846	chr10:38356380~38378505:+
HNSC	cis	rs4218	0.531	rs8026611	ENSG00000277144.1	RP11-59H7.4	-4.69	3.59e-06	0.000812	-0.25	-0.21	Social communication problems;	chr15:59048927	chr15:59115547~59116089:-
HNSC	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	4.69	3.59e-06	0.000812	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
HNSC	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-4.69	3.59e-06	0.000813	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
HNSC	cis	rs2253762	0.54	rs4752631	ENSG00000226864.1	ATE1-AS1	4.69	3.59e-06	0.000813	0.35	0.21	Breast cancer;	chr10:121996442	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs11200313	ENSG00000226864.1	ATE1-AS1	4.69	3.59e-06	0.000813	0.35	0.21	Breast cancer;	chr10:121996523	chr10:121928312~121951965:+
HNSC	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-4.69	3.59e-06	0.000813	-0.2	-0.21	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
HNSC	cis	rs73198271	0.74	rs67766414	ENSG00000233609.3	RP11-62H7.2	-4.69	3.59e-06	0.000813	-0.24	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8961200~8979025:+
HNSC	cis	rs4660214	0.59	rs11205885	ENSG00000182109.6	RP11-69E11.4	-4.69	3.59e-06	0.000814	-0.22	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39522280~39546187:-
HNSC	cis	rs13438327	0.901	rs112830011	ENSG00000183444.10	OR7E38P	4.69	3.6e-06	0.000814	0.45	0.21	Sudden cardiac arrest;	chr7:97988216	chr7:97966090~97967074:-
HNSC	cis	rs6831352	0.918	rs35784540	ENSG00000263923.1	RP11-571L19.7	4.69	3.6e-06	0.000814	0.23	0.21	Alcohol dependence;	chr4:99140541	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs34876213	ENSG00000263923.1	RP11-571L19.7	4.69	3.6e-06	0.000814	0.23	0.21	Alcohol dependence;	chr4:99141065	chr4:98928897~98994994:+
HNSC	cis	rs11846409	0.932	rs74091728	ENSG00000254174.1	IGHV1-12	4.69	3.6e-06	0.000815	0.17	0.21	Rheumatic heart disease;	chr14:106638762	chr14:106122420~106122709:-
HNSC	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	4.69	3.6e-06	0.000815	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
HNSC	cis	rs116095464	0.542	rs28650039	ENSG00000250848.1	CTD-2083E4.5	-4.69	3.61e-06	0.000816	-0.3	-0.21	Breast cancer;	chr5:273839	chr5:288833~290321:-
HNSC	cis	rs6964587	1	rs10225885	ENSG00000188693.7	CYP51A1-AS1	-4.69	3.61e-06	0.000816	-0.23	-0.21	Breast cancer;	chr7:92041693	chr7:92134604~92180725:+
HNSC	cis	rs17507216	0.671	rs4779035	ENSG00000276710.3	CSPG4P8	-4.69	3.61e-06	0.000817	-0.3	-0.21	Excessive daytime sleepiness;	chr15:82591686	chr15:82459472~82477258:+
HNSC	cis	rs1008375	0.618	rs13129002	ENSG00000249502.1	AC006160.5	-4.69	3.61e-06	0.000817	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565890	chr4:17587467~17614571:-
HNSC	cis	rs4218	0.689	rs35066133	ENSG00000259732.1	RP11-59H7.3	-4.69	3.61e-06	0.000817	-0.27	-0.21	Social communication problems;	chr15:59081917	chr15:59121034~59133250:+
HNSC	cis	rs73198271	0.641	rs34473848	ENSG00000233609.3	RP11-62H7.2	-4.69	3.62e-06	0.000818	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.601	rs11997731	ENSG00000233609.3	RP11-62H7.2	-4.69	3.62e-06	0.000818	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8961200~8979025:+
HNSC	cis	rs9863	0.861	rs11057399	ENSG00000269938.1	RP11-214K3.20	-4.69	3.62e-06	0.000818	-0.25	-0.21	White blood cell count;	chr12:123940531	chr12:123968023~123968579:-
HNSC	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-4.69	3.62e-06	0.000818	-0.23	-0.21	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
HNSC	cis	rs7809950	0.678	rs4730235	ENSG00000238832.1	snoU109	-4.69	3.62e-06	0.000818	-0.3	-0.21	Coronary artery disease;	chr7:107382061	chr7:107603363~107603507:+
HNSC	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	4.69	3.62e-06	0.000819	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
HNSC	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	4.69	3.62e-06	0.000819	0.25	0.21	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
HNSC	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-4.69	3.62e-06	0.000819	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
HNSC	cis	rs9650657	0.707	rs2005309	ENSG00000269918.1	AF131215.9	-4.69	3.62e-06	0.000819	-0.21	-0.21	Neuroticism;	chr8:10794660	chr8:11104691~11106704:-
HNSC	cis	rs7809950	0.637	rs2701685	ENSG00000238832.1	snoU109	4.69	3.62e-06	0.00082	0.28	0.21	Coronary artery disease;	chr7:107659139	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.817	rs34325395	ENSG00000238832.1	snoU109	-4.69	3.62e-06	0.00082	-0.31	-0.21	Coronary artery disease;	chr7:107473363	chr7:107603363~107603507:+
HNSC	cis	rs11089937	0.616	rs4991801	ENSG00000211638.2	IGLV8-61	-4.69	3.63e-06	0.00082	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22098700~22099212:+
HNSC	cis	rs4853525	0.59	rs3771308	ENSG00000235852.1	AC005540.3	4.69	3.63e-06	0.00082	0.29	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190936179	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.561	rs10931476	ENSG00000235852.1	AC005540.3	4.69	3.63e-06	0.00082	0.29	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190938082	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.504	rs2883582	ENSG00000235852.1	AC005540.3	4.69	3.63e-06	0.00082	0.29	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190939306	chr2:190880797~190882059:-
HNSC	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-4.69	3.63e-06	0.000821	-0.22	-0.21	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-4.69	3.63e-06	0.000821	-0.22	-0.21	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-4.69	3.63e-06	0.000821	-0.22	-0.21	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
HNSC	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-4.69	3.63e-06	0.000821	-0.23	-0.21	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
HNSC	cis	rs7824557	0.872	rs2572417	ENSG00000269918.1	AF131215.9	-4.69	3.63e-06	0.000821	-0.2	-0.21	Retinal vascular caliber;	chr8:11253953	chr8:11104691~11106704:-
HNSC	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-4.69	3.63e-06	0.000821	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
HNSC	cis	rs202072	0.652	rs453695	ENSG00000215022.6	RP1-257A7.4	4.69	3.63e-06	0.000821	0.34	0.21	HIV-1 viral setpoint;	chr6:13262274	chr6:13264861~13295586:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000280411.1	IGHV1-69-2	-4.69	3.63e-06	0.000821	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106697010	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000280411.1	IGHV1-69-2	-4.69	3.63e-06	0.000821	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106697140	chr14:106762092~106762588:-
HNSC	cis	rs6142102	0.812	rs6059578	ENSG00000275784.1	RP5-1125A11.6	-4.69	3.63e-06	0.000821	-0.28	-0.21	Skin pigmentation;	chr20:33939900	chr20:33989480~33991818:-
HNSC	cis	rs11976180	1	rs1919950	ENSG00000273234.1	OR2A13P	-4.69	3.63e-06	0.000822	-0.24	-0.21	Obesity-related traits;	chr7:144070805	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2961132	ENSG00000273234.1	OR2A13P	-4.69	3.63e-06	0.000822	-0.24	-0.21	Obesity-related traits;	chr7:144071035	chr7:144142009~144142938:+
HNSC	cis	rs933688	1	rs2059207	ENSG00000281357.1	ARRDC3-AS1	4.69	3.63e-06	0.000822	0.3	0.21	Smoking behavior;	chr5:91436114	chr5:91380349~91439085:+
HNSC	cis	rs1223397	1	rs1223402	ENSG00000215022.6	RP1-257A7.4	-4.69	3.63e-06	0.000822	-0.27	-0.21	Blood pressure;	chr6:13271408	chr6:13264861~13295586:-
HNSC	cis	rs9300255	0.722	rs28592876	ENSG00000280120.1	RP11-546D6.3	-4.69	3.63e-06	0.000822	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123381882	chr12:123152324~123153377:-
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-4.69	3.64e-06	0.000822	-0.28	-0.21	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-4.69	3.64e-06	0.000822	-0.28	-0.21	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-4.69	3.64e-06	0.000822	-0.28	-0.21	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
HNSC	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-4.69	3.64e-06	0.000822	-0.24	-0.21	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
HNSC	cis	rs56804039	1	rs67611618	ENSG00000173295.6	FAM86B3P	-4.69	3.64e-06	0.000822	-0.28	-0.21	Cervical cancer;	chr8:8523429	chr8:8228595~8244865:+
HNSC	cis	rs56804039	1	rs58361948	ENSG00000173295.6	FAM86B3P	-4.69	3.64e-06	0.000822	-0.28	-0.21	Cervical cancer;	chr8:8523485	chr8:8228595~8244865:+
HNSC	cis	rs56804039	1	rs56804039	ENSG00000173295.6	FAM86B3P	-4.69	3.64e-06	0.000822	-0.28	-0.21	Cervical cancer;	chr8:8523519	chr8:8228595~8244865:+
HNSC	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-4.69	3.64e-06	0.000822	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
HNSC	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	4.69	3.64e-06	0.000822	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	4.69	3.64e-06	0.000822	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
HNSC	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	4.69	3.64e-06	0.000823	0.26	0.21	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
HNSC	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	4.69	3.64e-06	0.000823	0.24	0.21	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
HNSC	cis	rs11089937	0.616	rs5757247	ENSG00000211638.2	IGLV8-61	-4.69	3.64e-06	0.000823	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22098700~22099212:+
HNSC	cis	rs9611565	0.921	rs3927	ENSG00000235513.1	RP4-756G23.5	4.69	3.64e-06	0.000823	0.24	0.21	Vitiligo;	chr22:41326860	chr22:41209122~41217627:-
HNSC	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000824	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
HNSC	cis	rs3733829	0.925	rs7245595	ENSG00000233622.1	CYP2T1P	-4.69	3.65e-06	0.000824	-0.22	-0.21	Smoking behavior;	chr19:40789954	chr19:40808525~40811390:-
HNSC	cis	rs7824557	0.767	rs6985146	ENSG00000269918.1	AF131215.9	4.69	3.65e-06	0.000824	0.21	0.21	Retinal vascular caliber;	chr8:11313212	chr8:11104691~11106704:-
HNSC	cis	rs9329221	0.537	rs6983332	ENSG00000254340.1	RP11-10A14.3	-4.69	3.65e-06	0.000825	-0.25	-0.21	Neuroticism;	chr8:10120408	chr8:9141424~9145435:+
HNSC	cis	rs6964587	1	rs13245393	ENSG00000188693.7	CYP51A1-AS1	-4.69	3.65e-06	0.000825	-0.22	-0.21	Breast cancer;	chr7:92012614	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6944591	ENSG00000188693.7	CYP51A1-AS1	-4.69	3.65e-06	0.000825	-0.22	-0.21	Breast cancer;	chr7:92013400	chr7:92134604~92180725:+
HNSC	cis	rs763121	0.853	rs4821798	ENSG00000273076.1	RP3-508I15.22	4.69	3.65e-06	0.000825	0.21	0.21	Menopause (age at onset);	chr22:38625160	chr22:38743495~38743910:+
HNSC	cis	rs3733585	0.699	rs1122142	ENSG00000250413.1	RP11-448G15.1	4.69	3.65e-06	0.000825	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9945924	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.699	rs4339211	ENSG00000250413.1	RP11-448G15.1	4.69	3.65e-06	0.000825	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9946034	chr4:10006482~10009725:+
HNSC	cis	rs13256369	0.708	rs11783670	ENSG00000173295.6	FAM86B3P	4.69	3.65e-06	0.000825	0.28	0.21	Obesity-related traits;	chr8:8701884	chr8:8228595~8244865:+
HNSC	cis	rs9467773	0.511	rs17278688	ENSG00000224843.5	LINC00240	-4.69	3.65e-06	0.000825	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26956992~27023924:+
HNSC	cis	rs6723108	0.604	rs1893396	ENSG00000224043.6	CCNT2-AS1	-4.69	3.65e-06	0.000825	-0.26	-0.21	Type 2 diabetes;	chr2:134841439	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.603	rs3739030	ENSG00000224043.6	CCNT2-AS1	-4.69	3.65e-06	0.000825	-0.26	-0.21	Type 2 diabetes;	chr2:134841811	chr2:134735464~134918710:-
HNSC	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	4.69	3.65e-06	0.000826	0.2	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
HNSC	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-4.69	3.65e-06	0.000826	-0.2	-0.21	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-4.69	3.65e-06	0.000826	-0.2	-0.21	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-4.69	3.65e-06	0.000826	-0.2	-0.21	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-4.69	3.65e-06	0.000826	-0.2	-0.21	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-4.69	3.65e-06	0.000826	-0.2	-0.21	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
HNSC	cis	rs1355223	0.583	rs1553757	ENSG00000271369.1	RP11-350D17.3	4.69	3.65e-06	0.000826	0.24	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34845542	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.583	rs1549789	ENSG00000271369.1	RP11-350D17.3	4.69	3.65e-06	0.000826	0.24	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34846400	chr11:34709600~34710161:+
HNSC	cis	rs1799949	0.683	rs55737636	ENSG00000236383.6	LINC00854	-4.69	3.66e-06	0.000826	-0.2	-0.21	Menopause (age at onset);	chr17:43112722	chr17:43216941~43305976:-
HNSC	cis	rs3743266	0.634	rs7165874	ENSG00000245534.5	RORA-AS1	-4.69	3.66e-06	0.000827	-0.27	-0.21	Menarche (age at onset);	chr15:60492410	chr15:60479178~60630637:+
HNSC	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	4.69	3.66e-06	0.000827	0.29	0.21	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
HNSC	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	4.69	3.66e-06	0.000827	0.22	0.21	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	4.69	3.66e-06	0.000827	0.22	0.21	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
HNSC	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-4.69	3.66e-06	0.000827	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
HNSC	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-4.69	3.66e-06	0.000828	-0.18	-0.21	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
HNSC	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	4.69	3.66e-06	0.000828	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	4.69	3.66e-06	0.000828	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
HNSC	cis	rs35963943	0.625	rs11708645	ENSG00000228956.7	SATB1-AS1	4.69	3.66e-06	0.000828	0.26	0.21	Lymphocyte counts;	chr3:18673748	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs11712368	ENSG00000228956.7	SATB1-AS1	4.69	3.66e-06	0.000828	0.26	0.21	Lymphocyte counts;	chr3:18674100	chr3:18445024~18920401:+
HNSC	cis	rs763121	0.853	rs8140617	ENSG00000273076.1	RP3-508I15.22	-4.69	3.67e-06	0.000828	-0.23	-0.21	Menopause (age at onset);	chr22:38574434	chr22:38743495~38743910:+
HNSC	cis	rs67981189	0.727	rs221903	ENSG00000274818.1	RP1-292L20.3	-4.69	3.67e-06	0.000828	-0.25	-0.21	Schizophrenia;	chr14:71133491	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	4.69	3.67e-06	0.000828	0.26	0.21	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	4.69	3.67e-06	0.000828	0.26	0.21	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	4.69	3.67e-06	0.000828	0.26	0.21	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
HNSC	cis	rs3811273	0.614	rs8003694	ENSG00000211816.2	TRAV38-1	-4.69	3.67e-06	0.000829	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22264736	chr14:22271968~22272563:+
HNSC	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-4.69	3.67e-06	0.000829	-0.27	-0.21	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
HNSC	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-4.69	3.67e-06	0.000829	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	4.69	3.67e-06	0.000829	0.24	0.21	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
HNSC	cis	rs4873772	0.837	rs11782572	ENSG00000253330.1	RP11-697N18.3	4.69	3.67e-06	0.000829	0.26	0.21	Lobe attachment (rater-scored or self-reported);	chr8:47558483	chr8:47511034~47512141:-
HNSC	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	4.69	3.67e-06	0.000829	0.34	0.21	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
HNSC	cis	rs35963943	0.625	rs12636814	ENSG00000228956.7	SATB1-AS1	4.69	3.67e-06	0.000829	0.26	0.21	Lymphocyte counts;	chr3:18686686	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13099122	ENSG00000228956.7	SATB1-AS1	4.69	3.67e-06	0.000829	0.26	0.21	Lymphocyte counts;	chr3:18687066	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13079505	ENSG00000228956.7	SATB1-AS1	4.69	3.67e-06	0.000829	0.26	0.21	Lymphocyte counts;	chr3:18687285	chr3:18445024~18920401:+
HNSC	cis	rs9329221	0.537	rs1484640	ENSG00000254340.1	RP11-10A14.3	4.69	3.67e-06	0.000829	0.26	0.21	Neuroticism;	chr8:10125733	chr8:9141424~9145435:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000281831.1	HCP5B	4.69	3.67e-06	0.000829	0.29	0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29871895~29873783:-
HNSC	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	4.68	3.68e-06	0.000831	0.26	0.21	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	4.68	3.68e-06	0.000831	0.26	0.21	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
HNSC	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	4.68	3.68e-06	0.000831	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
HNSC	cis	rs4761669	0.675	rs12579933	ENSG00000241556.1	RP11-490G8.1	4.68	3.68e-06	0.000831	0.21	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94809386	chr12:95467397~95467861:-
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.68	3.68e-06	0.000831	-0.22	-0.21	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-4.68	3.68e-06	0.000831	-0.22	-0.21	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	4.68	3.68e-06	0.000831	0.26	0.21	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	4.68	3.68e-06	0.000831	0.26	0.21	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
HNSC	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.68	3.68e-06	0.000831	0.22	0.21	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
HNSC	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-4.68	3.68e-06	0.000831	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-4.68	3.68e-06	0.000831	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-4.68	3.68e-06	0.000831	-0.25	-0.21	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.68	3.68e-06	0.000832	0.22	0.21	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	4.68	3.68e-06	0.000832	0.22	0.21	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
HNSC	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	4.68	3.69e-06	0.000832	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	4.68	3.69e-06	0.000832	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
HNSC	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-4.68	3.69e-06	0.000832	-0.17	-0.21	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-4.68	3.69e-06	0.000832	-0.17	-0.21	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-4.68	3.69e-06	0.000832	-0.25	-0.21	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-4.68	3.69e-06	0.000832	-0.22	-0.21	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-4.68	3.69e-06	0.000832	-0.22	-0.21	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-4.68	3.69e-06	0.000832	-0.22	-0.21	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
HNSC	cis	rs6928977	0.827	rs2614265	ENSG00000217482.2	HMGB1P17	-4.68	3.69e-06	0.000832	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135394237	chr6:135636086~135636713:-
HNSC	cis	rs12817211	0.502	rs11169282	ENSG00000272368.2	RP4-605O3.4	4.68	3.69e-06	0.000832	0.21	0.21	Colorectal or endometrial cancer;	chr12:50136188	chr12:50112197~50165618:+
HNSC	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-4.68	3.69e-06	0.000832	-0.22	-0.21	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
HNSC	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	4.68	3.69e-06	0.000833	0.18	0.21	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	4.68	3.69e-06	0.000833	0.25	0.21	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
HNSC	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	4.68	3.69e-06	0.000833	0.27	0.21	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
HNSC	cis	rs79057730	0.599	rs35928068	ENSG00000225146.1	AC073957.15	4.68	3.7e-06	0.000834	0.34	0.21	Initial pursuit acceleration;	chr7:765726	chr7:1029025~1043891:+
HNSC	cis	rs116095464	0.558	rs28558836	ENSG00000250848.1	CTD-2083E4.5	-4.68	3.7e-06	0.000834	-0.29	-0.21	Breast cancer;	chr5:285633	chr5:288833~290321:-
HNSC	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-4.68	3.7e-06	0.000834	-0.26	-0.21	Height;	chr20:49254902	chr20:49280319~49280409:+
HNSC	cis	rs1009181	0.56	rs9379829	ENSG00000272462.2	U91328.19	-4.68	3.7e-06	0.000834	-0.24	-0.21	Childhood ear infection;	chr6:26171991	chr6:25992662~26001775:+
HNSC	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	4.68	3.7e-06	0.000834	0.24	0.21	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	4.68	3.7e-06	0.000834	0.24	0.21	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	4.68	3.7e-06	0.000834	0.24	0.21	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	4.68	3.7e-06	0.000834	0.25	0.21	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
HNSC	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-4.68	3.7e-06	0.000834	-0.24	-0.21	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
HNSC	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	4.68	3.7e-06	0.000834	0.24	0.21	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
HNSC	cis	rs1008375	1	rs2159583	ENSG00000249502.1	AC006160.5	-4.68	3.7e-06	0.000835	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657215	chr4:17587467~17614571:-
HNSC	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	4.68	3.7e-06	0.000835	0.18	0.21	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
HNSC	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	4.68	3.7e-06	0.000835	0.18	0.21	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
HNSC	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-4.68	3.7e-06	0.000835	-0.24	-0.21	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
HNSC	cis	rs73198271	0.71	rs3827808	ENSG00000253893.2	FAM85B	4.68	3.71e-06	0.000836	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8167819~8226614:-
HNSC	cis	rs1799949	1	rs8176109	ENSG00000236383.6	LINC00854	-4.68	3.71e-06	0.000837	-0.2	-0.21	Menopause (age at onset);	chr17:43113759	chr17:43216941~43305976:-
HNSC	cis	rs12817211	0.549	rs7138945	ENSG00000272368.2	RP4-605O3.4	-4.68	3.71e-06	0.000837	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50145636	chr12:50112197~50165618:+
HNSC	cis	rs9929218	0.529	rs11640736	ENSG00000260459.2	FTLP14	4.68	3.71e-06	0.000837	0.27	0.21	Colorectal cancer;	chr16:68704421	chr16:68822587~68823070:+
HNSC	cis	rs9291683	0.597	rs11723016	ENSG00000250413.1	RP11-448G15.1	4.68	3.71e-06	0.000837	0.26	0.21	Bone mineral density;	chr4:10124565	chr4:10006482~10009725:+
HNSC	cis	rs1799949	1	rs12944458	ENSG00000236383.6	LINC00854	-4.68	3.72e-06	0.000838	-0.2	-0.21	Menopause (age at onset);	chr17:43028755	chr17:43216941~43305976:-
HNSC	cis	rs1008375	0.897	rs2315554	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000839	-0.24	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658784	chr4:17587467~17614571:-
HNSC	cis	rs7432375	0.566	rs835636	ENSG00000239213.4	NCK1-AS1	4.68	3.72e-06	0.000839	0.18	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136841726~136862054:-
HNSC	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	4.68	3.72e-06	0.000839	0.22	0.21	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
HNSC	cis	rs67981189	0.574	rs221916	ENSG00000274818.1	RP1-292L20.3	-4.68	3.72e-06	0.000839	-0.23	-0.21	Schizophrenia;	chr14:71125361	chr14:70906657~70907111:-
HNSC	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	4.68	3.72e-06	0.000839	0.34	0.21	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
HNSC	cis	rs9921338	0.961	rs9936328	ENSG00000263080.1	RP11-485G7.5	4.68	3.72e-06	0.000839	0.23	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11341809~11345211:-
HNSC	cis	rs577676	0.586	rs12031871	ENSG00000271811.1	RP1-79C4.4	4.68	3.73e-06	0.00084	0.23	0.21	Prevalent atrial fibrillation;	chr1:170621426	chr1:170667381~170669425:+
HNSC	cis	rs651386	0.505	rs10753817	ENSG00000271811.1	RP1-79C4.4	4.68	3.73e-06	0.00084	0.23	0.21	Atrial fibrillation;	chr1:170622667	chr1:170667381~170669425:+
HNSC	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-4.68	3.73e-06	0.00084	-0.22	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
HNSC	cis	rs4787491	0.729	rs4238960	ENSG00000183604.13	SMG1P5	-4.68	3.73e-06	0.000841	-0.2	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30267553~30335374:-
HNSC	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	4.68	3.73e-06	0.000841	0.2	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
HNSC	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	4.68	3.73e-06	0.000841	0.23	0.21	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
HNSC	cis	rs1056107	0.933	rs6477891	ENSG00000225513.1	RP11-165N19.2	-4.68	3.73e-06	0.000841	-0.23	-0.21	Colorectal cancer;	chr9:112200029	chr9:112173522~112173971:-
HNSC	cis	rs853679	0.76	rs9468317	ENSG00000204709.4	LINC01556	4.68	3.73e-06	0.000841	0.3	0.21	Depression;	chr6:28230678	chr6:28943877~28944537:+
HNSC	cis	rs4819052	0.851	rs2838833	ENSG00000215447.6	BX322557.10	-4.68	3.73e-06	0.000841	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-4.68	3.73e-06	0.000841	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
HNSC	cis	rs7665090	0.87	rs228623	ENSG00000246560.2	RP11-10L12.4	-4.68	3.74e-06	0.000842	-0.24	-0.21	Primary biliary cholangitis;	chr4:102651163	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.837	rs228624	ENSG00000246560.2	RP11-10L12.4	-4.68	3.74e-06	0.000842	-0.24	-0.21	Primary biliary cholangitis;	chr4:102651283	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	4.68	3.74e-06	0.000842	0.26	0.21	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
HNSC	cis	rs6723108	0.603	rs3814355	ENSG00000224043.6	CCNT2-AS1	-4.68	3.74e-06	0.000843	-0.26	-0.21	Type 2 diabetes;	chr2:134953946	chr2:134735464~134918710:-
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-4.68	3.74e-06	0.000843	-0.25	-0.21	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
HNSC	cis	rs3811273	0.614	rs4982597	ENSG00000211816.2	TRAV38-1	-4.68	3.74e-06	0.000843	-0.25	-0.21	Periodontal disease-related phenotypes;	chr14:22267065	chr14:22271968~22272563:+
HNSC	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.68	3.74e-06	0.000843	0.19	0.21	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
HNSC	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	4.68	3.75e-06	0.000844	0.17	0.21	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
HNSC	cis	rs1056107	0.966	rs7043856	ENSG00000225513.1	RP11-165N19.2	-4.68	3.75e-06	0.000844	-0.23	-0.21	Colorectal cancer;	chr9:112325876	chr9:112173522~112173971:-
HNSC	cis	rs1056107	1	rs4363271	ENSG00000225513.1	RP11-165N19.2	-4.68	3.75e-06	0.000844	-0.23	-0.21	Colorectal cancer;	chr9:112326251	chr9:112173522~112173971:-
HNSC	cis	rs7980687	0.55	rs1727324	ENSG00000280120.1	RP11-546D6.3	4.68	3.75e-06	0.000844	0.21	0.21	Head circumference (infant);Educational attainment;Height;	chr12:123214056	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.51	rs1727322	ENSG00000280120.1	RP11-546D6.3	4.68	3.75e-06	0.000844	0.21	0.21	Neutrophil percentage of white cells;	chr12:123214973	chr12:123152324~123153377:-
HNSC	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-4.68	3.75e-06	0.000845	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
HNSC	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.68	3.75e-06	0.000845	0.21	0.21	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
HNSC	cis	rs12935418	0.523	rs2549840	ENSG00000261061.1	RP11-303E16.2	4.68	3.75e-06	0.000845	0.22	0.21	Mean corpuscular volume;	chr16:80989817	chr16:81030770~81031485:+
HNSC	cis	rs13108904	0.901	rs4974594	ENSG00000272588.1	RP11-440L14.4	-4.68	3.76e-06	0.000846	-0.22	-0.21	Obesity-related traits;	chr4:1306692	chr4:757022~757740:-
HNSC	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-4.68	3.76e-06	0.000846	-0.28	-0.21	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
HNSC	cis	rs9863	0.896	rs7307053	ENSG00000269938.1	RP11-214K3.20	4.68	3.76e-06	0.000846	0.25	0.21	White blood cell count;	chr12:124009993	chr12:123968023~123968579:-
HNSC	cis	rs7296418	0.961	rs11613937	ENSG00000280120.1	RP11-546D6.3	4.68	3.76e-06	0.000846	0.18	0.21	Platelet count;	chr12:123035524	chr12:123152324~123153377:-
HNSC	cis	rs11846409	0.655	rs79296226	ENSG00000254174.1	IGHV1-12	-4.68	3.76e-06	0.000846	-0.17	-0.21	Rheumatic heart disease;	chr14:106650436	chr14:106122420~106122709:-
HNSC	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	4.68	3.76e-06	0.000847	0.26	0.21	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
HNSC	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	4.68	3.76e-06	0.000847	0.23	0.21	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
HNSC	cis	rs494453	0.538	rs2789544	ENSG00000227811.2	FAM212B-AS1	4.68	3.76e-06	0.000847	0.31	0.21	Osteoporosis-related phenotypes;	chr1:111639341	chr1:111739841~111747798:+
HNSC	cis	rs2361718	0.501	rs12944619	ENSG00000279259.1	RP11-334C17.3	4.68	3.77e-06	0.000847	0.27	0.21	Yeast infection;	chr17:80170310	chr17:80147250~80148596:+
HNSC	cis	rs4862750	0.872	rs7658314	ENSG00000250971.1	RP11-696F12.1	4.68	3.77e-06	0.000848	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.832	rs6419953	ENSG00000250971.1	RP11-696F12.1	4.68	3.77e-06	0.000848	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:187060099~187060930:+
HNSC	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	4.68	3.77e-06	0.000848	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
HNSC	cis	rs6928977	0.538	rs9494290	ENSG00000234084.1	RP3-388E23.2	-4.68	3.77e-06	0.000848	-0.22	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135301568~135307158:+
HNSC	cis	rs56804039	1	rs11777086	ENSG00000173295.6	FAM86B3P	-4.68	3.77e-06	0.000848	-0.28	-0.21	Cervical cancer;	chr8:8526969	chr8:8228595~8244865:+
HNSC	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-4.68	3.77e-06	0.000848	-0.2	-0.21	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
HNSC	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-4.68	3.77e-06	0.000848	-0.24	-0.21	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000233609.3	RP11-62H7.2	-4.68	3.77e-06	0.000849	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9225906	chr8:8961200~8979025:+
HNSC	cis	rs2682471	1	rs2682471	ENSG00000245648.1	RP11-277P12.20	-4.68	3.77e-06	0.000849	-0.26	-0.21	Macrophage inflammatory protein 1a levels;	chr12:10446748	chr12:10363769~10398506:+
HNSC	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
HNSC	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
HNSC	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-4.68	3.77e-06	0.000849	-0.35	-0.21	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
HNSC	cis	rs7535099	0.954	rs12067730	ENSG00000224570.1	RP11-430H12.2	-4.68	3.77e-06	0.000849	-0.28	-0.21	Blood protein levels;	chr1:65583339	chr1:65576129~65578380:-
HNSC	cis	rs6964587	1	rs10228334	ENSG00000188693.7	CYP51A1-AS1	-4.68	3.77e-06	0.000849	-0.22	-0.21	Breast cancer;	chr7:92084658	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs13239875	ENSG00000188693.7	CYP51A1-AS1	-4.68	3.77e-06	0.000849	-0.22	-0.21	Breast cancer;	chr7:92086790	chr7:92134604~92180725:+
HNSC	cis	rs9990333	0.521	rs3862281	ENSG00000231464.1	AC024937.4	4.68	3.77e-06	0.000849	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195996738~195998233:+
HNSC	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-4.68	3.77e-06	0.000849	-0.27	-0.21	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
HNSC	cis	rs9907295	0.901	rs9907121	ENSG00000270977.1	AC015849.16	-4.68	3.77e-06	0.000849	-0.32	-0.21	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4796118	ENSG00000270977.1	AC015849.16	-4.68	3.77e-06	0.000849	-0.32	-0.21	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35893707~35911023:-
HNSC	cis	rs6918586	1	rs198806	ENSG00000272462.2	U91328.19	-4.68	3.78e-06	0.000849	-0.2	-0.21	Schizophrenia;	chr6:26133388	chr6:25992662~26001775:+
HNSC	cis	rs6601327	0.775	rs12156017	ENSG00000254340.1	RP11-10A14.3	-4.68	3.78e-06	0.000849	-0.25	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9549327	chr8:9141424~9145435:+
HNSC	cis	rs9304742	0.962	rs12459008	ENSG00000213801.4	ZNF816-ZNF321P	-4.68	3.78e-06	0.000849	-0.24	-0.21	Psoriasis;	chr19:52951536	chr19:52927135~52942601:-
HNSC	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-4.68	3.78e-06	0.000849	-0.29	-0.21	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
HNSC	cis	rs1799949	0.896	rs8176098	ENSG00000236383.6	LINC00854	-4.68	3.78e-06	0.00085	-0.2	-0.21	Menopause (age at onset);	chr17:43116189	chr17:43216941~43305976:-
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000254153.1	CTA-398F10.2	4.68	3.78e-06	0.00085	0.23	0.21	Mood instability;	chr8:8795379	chr8:8456909~8461337:-
HNSC	cis	rs5752326	0.764	rs5997093	ENSG00000261188.1	CTA-445C9.14	-4.68	3.78e-06	0.00085	-0.3	-0.21	Ischemic stroke;	chr22:26455862	chr22:26512537~26514568:+
HNSC	cis	rs12935418	0.523	rs2549846	ENSG00000278985.1	RP11-303E16.9	-4.68	3.78e-06	0.00085	-0.2	-0.21	Mean corpuscular volume;	chr16:80990522	chr16:80982319~80984094:-
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000224373.3	IGHV4-59	4.68	3.78e-06	0.000851	0.12	0.21	Kawasaki disease;	chr14:106681273	chr14:106627249~106627825:-
HNSC	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	4.68	3.78e-06	0.000851	0.26	0.21	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
HNSC	cis	rs6723108	0.627	rs6430549	ENSG00000224043.6	CCNT2-AS1	-4.68	3.78e-06	0.000851	-0.26	-0.21	Type 2 diabetes;	chr2:134858776	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs1446523	ENSG00000224043.6	CCNT2-AS1	-4.68	3.78e-06	0.000851	-0.26	-0.21	Type 2 diabetes;	chr2:134859051	chr2:134735464~134918710:-
HNSC	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	4.68	3.79e-06	0.000851	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	4.68	3.79e-06	0.000851	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
HNSC	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	4.68	3.79e-06	0.000852	0.26	0.21	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	4.68	3.79e-06	0.000852	0.26	0.21	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	4.68	3.79e-06	0.000852	0.26	0.21	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	4.68	3.79e-06	0.000852	0.26	0.21	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
HNSC	cis	rs75422866	0.867	rs73113143	ENSG00000276691.1	RP5-1057I20.5	4.68	3.79e-06	0.000852	0.39	0.21	Pneumonia;	chr12:47623060	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs75568526	ENSG00000276691.1	RP5-1057I20.5	4.68	3.79e-06	0.000852	0.39	0.21	Pneumonia;	chr12:47649718	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs116302411	ENSG00000276691.1	RP5-1057I20.5	4.68	3.79e-06	0.000852	0.39	0.21	Pneumonia;	chr12:47649788	chr12:47788426~47788971:+
HNSC	cis	rs67981189	0.896	rs2526878	ENSG00000274818.1	RP1-292L20.3	-4.68	3.79e-06	0.000852	-0.25	-0.21	Schizophrenia;	chr14:70910578	chr14:70906657~70907111:-
HNSC	cis	rs56804039	1	rs11780966	ENSG00000173295.6	FAM86B3P	-4.68	3.79e-06	0.000852	-0.28	-0.21	Cervical cancer;	chr8:8525886	chr8:8228595~8244865:+
HNSC	cis	rs1971762	0.509	rs10783592	ENSG00000270175.1	RP11-793H13.11	-4.68	3.79e-06	0.000852	-0.19	-0.21	Height;	chr12:53643646	chr12:53500162~53500936:-
HNSC	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-4.68	3.79e-06	0.000853	-0.2	-0.21	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
HNSC	cis	rs12935418	0.583	rs2244452	ENSG00000278985.1	RP11-303E16.9	-4.68	3.8e-06	0.000854	-0.2	-0.21	Mean corpuscular volume;	chr16:80991767	chr16:80982319~80984094:-
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	4.68	3.8e-06	0.000854	0.26	0.21	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
HNSC	cis	rs7824557	0.767	rs2164272	ENSG00000255310.2	AF131215.2	4.68	3.8e-06	0.000854	0.2	0.21	Retinal vascular caliber;	chr8:11304987	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.701	rs2060465	ENSG00000255310.2	AF131215.2	4.68	3.8e-06	0.000854	0.2	0.21	Retinal vascular caliber;	chr8:11305100	chr8:11107788~11109726:-
HNSC	cis	rs60617249	0.795	rs11531636	ENSG00000228204.2	RP4-724E13.2	-4.68	3.8e-06	0.000855	-0.22	-0.21	Major depression and alcohol dependence;	chr7:50871251	chr7:50866747~51022990:+
HNSC	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	4.68	3.8e-06	0.000855	0.24	0.21	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
HNSC	cis	rs9910055	1	rs9895423	ENSG00000267080.4	ASB16-AS1	-4.68	3.8e-06	0.000855	-0.17	-0.21	Total body bone mineral density;	chr17:44208372	chr17:44175973~44186717:-
HNSC	cis	rs10504130	0.569	rs6473653	ENSG00000272024.1	RP11-546K22.3	4.68	3.81e-06	0.000855	0.31	0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51950284~51950690:+
HNSC	cis	rs1823913	0.503	rs6706578	ENSG00000280083.1	RP11-317J9.1	-4.68	3.81e-06	0.000855	-0.25	-0.21	Obesity-related traits;	chr2:191346992	chr2:191154118~191156070:-
HNSC	cis	rs2276314	0.512	rs9951125	ENSG00000278986.1	RP11-723J4.3	-4.68	3.81e-06	0.000855	-0.24	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:35872841	chr18:35972151~35973916:+
HNSC	cis	rs2486288	0.656	rs8037583	ENSG00000259479.5	SORD2P	-4.68	3.81e-06	0.000855	-0.24	-0.21	Glomerular filtration rate;	chr15:45254180	chr15:44826371~44884694:-
HNSC	cis	rs4218	0.531	rs1374156	ENSG00000259732.1	RP11-59H7.3	-4.68	3.81e-06	0.000856	-0.26	-0.21	Social communication problems;	chr15:59046746	chr15:59121034~59133250:+
HNSC	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	4.68	3.81e-06	0.000856	0.54	0.21	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
HNSC	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	4.68	3.81e-06	0.000856	0.54	0.21	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
HNSC	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-4.68	3.81e-06	0.000856	-0.26	-0.21	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-4.68	3.81e-06	0.000856	-0.26	-0.21	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
HNSC	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	4.68	3.81e-06	0.000856	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
HNSC	cis	rs2665103	0.687	rs11633000	ENSG00000255769.6	GOLGA2P10	-4.68	3.81e-06	0.000856	-0.25	-0.21	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472993~82513950:-
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	4.68	3.81e-06	0.000857	0.26	0.21	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
HNSC	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	4.68	3.81e-06	0.000857	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-4.68	3.81e-06	0.000857	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
HNSC	cis	rs9291683	0.527	rs11727087	ENSG00000250413.1	RP11-448G15.1	-4.68	3.81e-06	0.000857	-0.26	-0.21	Bone mineral density;	chr4:10094396	chr4:10006482~10009725:+
HNSC	cis	rs7824557	0.767	rs17797443	ENSG00000269918.1	AF131215.9	4.68	3.82e-06	0.000858	0.21	0.21	Retinal vascular caliber;	chr8:11306503	chr8:11104691~11106704:-
HNSC	cis	rs6601327	0.641	rs12155819	ENSG00000233609.3	RP11-62H7.2	-4.68	3.82e-06	0.000858	-0.2	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8961200~8979025:+
HNSC	cis	rs6601327	0.7	rs12114661	ENSG00000233609.3	RP11-62H7.2	-4.68	3.82e-06	0.000858	-0.2	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8961200~8979025:+
HNSC	cis	rs6601327	0.641	rs4129360	ENSG00000233609.3	RP11-62H7.2	-4.68	3.82e-06	0.000858	-0.2	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8961200~8979025:+
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	4.68	3.82e-06	0.000858	0.22	0.21	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-4.68	3.82e-06	0.000858	-0.22	-0.21	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-4.68	3.82e-06	0.000858	-0.22	-0.21	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-4.68	3.82e-06	0.000858	-0.22	-0.21	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-4.68	3.82e-06	0.000858	-0.22	-0.21	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-4.68	3.82e-06	0.000858	-0.22	-0.21	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
HNSC	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-4.68	3.82e-06	0.000858	-0.25	-0.21	Height;	chr2:46596853	chr2:46668870~46670778:+
HNSC	cis	rs1799949	0.965	rs8176161	ENSG00000236383.6	LINC00854	-4.68	3.82e-06	0.000859	-0.2	-0.21	Menopause (age at onset);	chr17:43089373	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.894	rs8176160	ENSG00000236383.6	LINC00854	-4.68	3.82e-06	0.000859	-0.2	-0.21	Menopause (age at onset);	chr17:43089486	chr17:43216941~43305976:-
HNSC	cis	rs7296418	0.922	rs1727293	ENSG00000280120.1	RP11-546D6.3	4.68	3.82e-06	0.000859	0.18	0.21	Platelet count;	chr12:123163485	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	4.68	3.82e-06	0.000859	0.26	0.21	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	4.68	3.82e-06	0.000859	0.26	0.21	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
HNSC	cis	rs6940638	0.513	rs4424065	ENSG00000224843.5	LINC00240	4.68	3.83e-06	0.000859	0.2	0.21	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26956992~27023924:+
HNSC	cis	rs12893668	0.608	rs12889721	ENSG00000269940.1	RP11-73M18.7	4.68	3.83e-06	0.00086	0.21	0.21	Reticulocyte count;	chr14:103568526	chr14:103694560~103695170:+
HNSC	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-4.68	3.83e-06	0.00086	-0.19	-0.21	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
HNSC	cis	rs4372836	1	rs55835850	ENSG00000226833.4	AC097724.3	-4.68	3.83e-06	0.00086	-0.27	-0.21	Body mass index;	chr2:28726430	chr2:28708953~28736205:-
HNSC	cis	rs240768	0.511	rs61289570	ENSG00000270987.1	RP3-467N11.2	4.68	3.83e-06	0.000861	0.51	0.21	Economic and political preferences (immigration/crime);	chr6:100955222	chr6:100889603~100890338:+
HNSC	cis	rs11969893	0.737	rs9498439	ENSG00000270987.1	RP3-467N11.2	4.68	3.83e-06	0.000861	0.51	0.21	Economic and political preferences (immigration/crime);	chr6:100956892	chr6:100889603~100890338:+
HNSC	cis	rs7688540	0.8	rs9328737	ENSG00000211553.1	AC253576.2	-4.68	3.83e-06	0.000861	-0.27	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:136461~136568:+
HNSC	cis	rs4925386	0.84	rs6143036	ENSG00000275437.1	RP5-908M14.10	4.68	3.83e-06	0.000861	0.23	0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62402236~62405935:-
HNSC	cis	rs66887589	0.87	rs10518336	ENSG00000249244.1	RP11-548H18.2	4.68	3.83e-06	0.000861	0.24	0.21	Diastolic blood pressure;	chr4:119601779	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	4.68	3.83e-06	0.000861	0.25	0.21	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
HNSC	cis	rs73252553	0.615	rs1973604	ENSG00000281501.1	SEPSECS-AS1	-4.68	3.84e-06	0.000861	-0.33	-0.21	Cannabis dependence symptom count;	chr4:25252741	chr4:25160641~25201440:+
HNSC	cis	rs9402743	0.634	rs6570018	ENSG00000234084.1	RP3-388E23.2	-4.68	3.84e-06	0.000861	-0.21	-0.21	Systemic lupus erythematosus;	chr6:135602218	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.634	rs9494294	ENSG00000234084.1	RP3-388E23.2	-4.68	3.84e-06	0.000861	-0.21	-0.21	Systemic lupus erythematosus;	chr6:135603460	chr6:135301568~135307158:+
HNSC	cis	rs4372836	0.93	rs7589860	ENSG00000226833.4	AC097724.3	4.68	3.84e-06	0.000861	0.27	0.21	Body mass index;	chr2:28744782	chr2:28708953~28736205:-
HNSC	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-4.68	3.84e-06	0.000861	-0.24	-0.21	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
HNSC	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	4.68	3.84e-06	0.000862	0.2	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
HNSC	cis	rs6831352	0.918	rs7694646	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99138581	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs7670638	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99138656	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs4699712	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99139339	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs4699713	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99139362	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs4699714	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99139387	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.84	rs17817868	ENSG00000263923.1	RP11-571L19.7	4.68	3.84e-06	0.000862	0.23	0.21	Alcohol dependence;	chr4:99139472	chr4:98928897~98994994:+
HNSC	cis	rs2985684	1	rs2224949	ENSG00000278009.1	RP11-649E7.8	-4.68	3.84e-06	0.000862	-0.27	-0.21	Carotid intima media thickness;	chr14:49629842	chr14:49601011~49601124:-
HNSC	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	4.68	3.84e-06	0.000862	0.22	0.21	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
HNSC	cis	rs9921338	0.923	rs4563054	ENSG00000263080.1	RP11-485G7.5	4.68	3.84e-06	0.000862	0.24	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11341809~11345211:-
HNSC	cis	rs9907295	1	rs11653282	ENSG00000270977.1	AC015849.16	-4.68	3.84e-06	0.000862	-0.29	-0.21	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35893707~35911023:-
HNSC	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	4.68	3.84e-06	0.000863	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
HNSC	cis	rs11722228	0.508	rs2241472	ENSG00000250413.1	RP11-448G15.1	-4.68	3.85e-06	0.000863	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10006482~10009725:+
HNSC	cis	rs6964587	1	rs12536529	ENSG00000188693.7	CYP51A1-AS1	4.68	3.85e-06	0.000863	0.22	0.21	Breast cancer;	chr7:92054772	chr7:92134604~92180725:+
HNSC	cis	rs8028182	0.549	rs4886696	ENSG00000260269.4	CTD-2323K18.1	4.68	3.85e-06	0.000864	0.27	0.21	Sudden cardiac arrest;	chr15:75372229	chr15:75527150~75601205:-
HNSC	cis	rs870825	0.616	rs7667409	ENSG00000254233.1	RP11-242J7.1	-4.68	3.85e-06	0.000864	-0.31	-0.21	Blood protein levels;	chr4:184729787	chr4:184584093~184625030:-
HNSC	cis	rs853679	0.607	rs68188794	ENSG00000219392.1	RP1-265C24.5	-4.68	3.85e-06	0.000864	-0.44	-0.21	Depression;	chr6:28112999	chr6:28115628~28116551:+
HNSC	cis	rs6964587	0.9	rs4279	ENSG00000188693.7	CYP51A1-AS1	-4.68	3.85e-06	0.000864	-0.22	-0.21	Breast cancer;	chr7:92134814	chr7:92134604~92180725:+
HNSC	cis	rs12893668	0.645	rs35229468	ENSG00000269940.1	RP11-73M18.7	4.68	3.85e-06	0.000864	0.21	0.21	Reticulocyte count;	chr14:103585720	chr14:103694560~103695170:+
HNSC	cis	rs7824557	0.767	rs3808509	ENSG00000269918.1	AF131215.9	4.67	3.85e-06	0.000864	0.21	0.21	Retinal vascular caliber;	chr8:11305747	chr8:11104691~11106704:-
HNSC	cis	rs4218	0.541	rs1374155	ENSG00000277144.1	RP11-59H7.4	-4.67	3.85e-06	0.000864	-0.26	-0.21	Social communication problems;	chr15:59030630	chr15:59115547~59116089:-
HNSC	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	4.67	3.86e-06	0.000865	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
HNSC	cis	rs4061073	0.924	rs67060003	ENSG00000198711.5	SSBP3-AS1	-4.67	3.86e-06	0.000865	-0.2	-0.21	Body mass index;	chr1:54232568	chr1:54236440~54239063:+
HNSC	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	4.67	3.86e-06	0.000865	0.26	0.21	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
HNSC	cis	rs14027	0.512	rs7012791	ENSG00000279347.1	RP11-85I17.2	4.67	3.86e-06	0.000865	0.18	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707451	chr8:119838736~119840385:-
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	-4.67	3.86e-06	0.000866	-0.27	-0.21	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	-4.67	3.86e-06	0.000866	-0.27	-0.21	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	-4.67	3.86e-06	0.000866	-0.27	-0.21	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
HNSC	cis	rs1355223	0.867	rs2281908	ENSG00000271369.1	RP11-350D17.3	-4.67	3.86e-06	0.000866	-0.24	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34662031	chr11:34709600~34710161:+
HNSC	cis	rs4965006	1	rs4965006	ENSG00000273568.1	RP11-417L19.6	4.67	3.86e-06	0.000866	0.35	0.21	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934988	chr12:131934642~131934928:+
HNSC	cis	rs6964587	1	rs1859114	ENSG00000188693.7	CYP51A1-AS1	-4.67	3.86e-06	0.000866	-0.22	-0.21	Breast cancer;	chr7:92053534	chr7:92134604~92180725:+
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000249244.1	RP11-548H18.2	-4.67	3.86e-06	0.000867	-0.25	-0.21	Corneal astigmatism;	chr4:119633836	chr4:119391831~119395335:-
HNSC	cis	rs1555322	0.818	rs2425022	ENSG00000126005.14	MMP24-AS1	-4.67	3.87e-06	0.000867	-0.35	-0.21	Attention deficit hyperactivity disorder;	chr20:35243384	chr20:35216462~35278131:-
HNSC	cis	rs964611	0.882	rs6493317	ENSG00000259488.2	RP11-154J22.1	-4.67	3.87e-06	0.000867	-0.19	-0.21	Metabolite levels (Pyroglutamine);	chr15:48275959	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs6493318	ENSG00000259488.2	RP11-154J22.1	-4.67	3.87e-06	0.000867	-0.19	-0.21	Metabolite levels (Pyroglutamine);	chr15:48276062	chr15:48312353~48331856:-
HNSC	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-4.67	3.87e-06	0.000867	-0.28	-0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
HNSC	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-4.67	3.87e-06	0.000868	-0.22	-0.21	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-4.67	3.87e-06	0.000868	-0.22	-0.21	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-4.67	3.87e-06	0.000868	-0.22	-0.21	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
HNSC	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-4.67	3.87e-06	0.000868	-0.22	-0.21	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
HNSC	cis	rs9487051	0.597	rs351732	ENSG00000243587.6	C6orf183	-4.67	3.87e-06	0.000868	-0.22	-0.21	Reticulocyte fraction of red cells;	chr6:109186488	chr6:109165833~109271014:+
HNSC	cis	rs9525927	0.67	rs2246478	ENSG00000227258.4	SMIM2-AS1	-4.67	3.87e-06	0.000868	-0.29	-0.21	Dupuytren's disease;	chr13:44255164	chr13:44110451~44240517:+
HNSC	cis	rs9487051	0.621	rs566164	ENSG00000243587.6	C6orf183	-4.67	3.87e-06	0.000868	-0.21	-0.21	Reticulocyte fraction of red cells;	chr6:109185258	chr6:109165833~109271014:+
HNSC	cis	rs7824557	0.767	rs3808509	ENSG00000255310.2	AF131215.2	4.67	3.88e-06	0.000869	0.2	0.21	Retinal vascular caliber;	chr8:11305747	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000204709.4	LINC01556	4.67	3.88e-06	0.000869	0.29	0.21	Parkinson's disease;	chr6:28069254	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.935	rs10803723	ENSG00000243819.4	RN7SL832P	4.67	3.88e-06	0.000869	0.2	0.21	Prostate cancer;	chr2:10582751	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.935	rs6751075	ENSG00000243819.4	RN7SL832P	4.67	3.88e-06	0.000869	0.2	0.21	Prostate cancer;	chr2:10583420	chr2:10690344~10692099:+
HNSC	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	4.67	3.88e-06	0.00087	0.33	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
HNSC	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	4.67	3.88e-06	0.00087	0.2	0.21	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
HNSC	cis	rs11976180	1	rs1540894	ENSG00000273234.1	OR2A13P	-4.67	3.88e-06	0.00087	-0.24	-0.21	Obesity-related traits;	chr7:144070583	chr7:144142009~144142938:+
HNSC	cis	rs7809950	0.678	rs2395868	ENSG00000238832.1	snoU109	4.67	3.88e-06	0.00087	0.3	0.21	Coronary artery disease;	chr7:107257055	chr7:107603363~107603507:+
HNSC	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	4.67	3.89e-06	0.000871	0.25	0.21	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
HNSC	cis	rs2835345	0.563	rs12482435	ENSG00000279365.1	KB-176G8.1	4.67	3.89e-06	0.000871	0.25	0.21	Pulmonary function;	chr21:36448658	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12482423	ENSG00000279365.1	KB-176G8.1	4.67	3.89e-06	0.000871	0.25	0.21	Pulmonary function;	chr21:36448662	chr21:36485867~36487760:+
HNSC	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-4.67	3.89e-06	0.000871	-0.23	-0.21	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
HNSC	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-4.67	3.89e-06	0.000872	-0.28	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
HNSC	cis	rs10773046	0.74	rs9669530	ENSG00000269938.1	RP11-214K3.20	-4.67	3.89e-06	0.000872	-0.24	-0.21	Osteoarthritis (hip);	chr12:123885264	chr12:123968023~123968579:-
HNSC	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	4.67	3.89e-06	0.000872	0.19	0.21	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	4.67	3.89e-06	0.000872	0.19	0.21	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	4.67	3.89e-06	0.000872	0.19	0.21	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
HNSC	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	4.67	3.89e-06	0.000872	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	4.67	3.89e-06	0.000872	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	4.67	3.89e-06	0.000872	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	4.67	3.89e-06	0.000872	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	4.67	3.89e-06	0.000872	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
HNSC	cis	rs73198271	0.603	rs777705	ENSG00000253893.2	FAM85B	4.67	3.9e-06	0.000873	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8729358	chr8:8167819~8226614:-
HNSC	cis	rs4853525	0.522	rs6744420	ENSG00000235852.1	AC005540.3	-4.67	3.9e-06	0.000873	-0.26	-0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190724356	chr2:190880797~190882059:-
HNSC	cis	rs712039	0.652	rs853206	ENSG00000276054.1	RP11-378E13.3	4.67	3.9e-06	0.000873	0.29	0.21	Tuberculosis;	chr17:37464692	chr17:37386886~37387926:+
HNSC	cis	rs9300255	0.679	rs10846507	ENSG00000280120.1	RP11-546D6.3	4.67	3.9e-06	0.000873	0.19	0.21	Neutrophil percentage of white cells;	chr12:123301945	chr12:123152324~123153377:-
HNSC	cis	rs4252134	0.687	rs45475797	ENSG00000231863.1	RP3-428L16.1	4.67	3.9e-06	0.000873	0.28	0.21	Giant cell arteritis;	chr6:160816859	chr6:160931080~160969771:+
HNSC	cis	rs3096299	0.509	rs4785691	ENSG00000261118.1	RP11-104N10.1	4.67	3.9e-06	0.000873	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89492017~89504460:-
HNSC	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	4.67	3.9e-06	0.000873	0.2	0.21	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
HNSC	cis	rs4218	0.681	rs10518996	ENSG00000259732.1	RP11-59H7.3	-4.67	3.9e-06	0.000873	-0.27	-0.21	Social communication problems;	chr15:59085247	chr15:59121034~59133250:+
HNSC	cis	rs1476670	0.565	rs2108201	ENSG00000230615.5	RP5-1198O20.4	-4.67	3.9e-06	0.000873	-0.24	-0.21	Eotaxin levels;	chr1:44049211	chr1:44030443~44115913:+
HNSC	cis	rs7824557	0.767	rs2060463	ENSG00000255310.2	AF131215.2	4.67	3.9e-06	0.000874	0.2	0.21	Retinal vascular caliber;	chr8:11304101	chr8:11107788~11109726:-
HNSC	cis	rs5758659	0.819	rs134871	ENSG00000273366.1	CTA-989H11.1	-4.67	3.9e-06	0.000874	-0.24	-0.21	Cognitive function;	chr22:42256710	chr22:42278188~42278846:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000204709.4	LINC01556	-4.67	3.9e-06	0.000874	-0.29	-0.21	Parkinson's disease;	chr6:28065396	chr6:28943877~28944537:+
HNSC	cis	rs6723108	0.627	rs6430545	ENSG00000224043.6	CCNT2-AS1	4.67	3.9e-06	0.000874	0.26	0.21	Type 2 diabetes;	chr2:134845031	chr2:134735464~134918710:-
HNSC	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	4.67	3.9e-06	0.000874	0.31	0.21	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
HNSC	cis	rs7735319	0.834	rs9687791	ENSG00000250697.1	CTD-2066L21.3	4.67	3.9e-06	0.000874	0.26	0.21	Systolic blood pressure;	chr5:33072758	chr5:32925639~33297910:-
HNSC	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-4.67	3.9e-06	0.000874	-0.27	-0.21	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
HNSC	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	4.67	3.9e-06	0.000874	0.26	0.21	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
HNSC	cis	rs6928977	0.896	rs2614285	ENSG00000217482.2	HMGB1P17	-4.67	3.9e-06	0.000874	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371480	chr6:135636086~135636713:-
HNSC	cis	rs7824557	0.734	rs2293856	ENSG00000269918.1	AF131215.9	4.67	3.9e-06	0.000874	0.21	0.21	Retinal vascular caliber;	chr8:11319938	chr8:11104691~11106704:-
HNSC	cis	rs10791097	0.703	rs11222360	ENSG00000254842.5	RP11-890B15.2	-4.67	3.9e-06	0.000875	-0.19	-0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130860976	chr11:130844191~130865561:-
HNSC	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	4.67	3.91e-06	0.000875	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	4.67	3.91e-06	0.000875	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	4.67	3.91e-06	0.000875	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	4.67	3.91e-06	0.000875	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	4.67	3.91e-06	0.000875	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	4.67	3.91e-06	0.000875	0.31	0.21	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	4.67	3.91e-06	0.000875	0.31	0.21	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
HNSC	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-4.67	3.91e-06	0.000876	-0.23	-0.21	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
HNSC	cis	rs73222236	0.794	rs60614489	ENSG00000273486.1	RP11-731C17.2	4.67	3.91e-06	0.000876	0.18	0.21	Coronary artery disease;	chr3:136268136	chr3:136837338~136839021:-
HNSC	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-4.67	3.91e-06	0.000876	-0.18	-0.21	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
HNSC	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-4.67	3.91e-06	0.000876	-0.35	-0.21	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
HNSC	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	4.67	3.91e-06	0.000876	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
HNSC	cis	rs9650657	0.504	rs10108347	ENSG00000255310.2	AF131215.2	-4.67	3.91e-06	0.000877	-0.2	-0.21	Neuroticism;	chr8:11176008	chr8:11107788~11109726:-
HNSC	cis	rs79057730	0.599	rs79272827	ENSG00000225146.1	AC073957.15	4.67	3.92e-06	0.000877	0.34	0.21	Initial pursuit acceleration;	chr7:767378	chr7:1029025~1043891:+
HNSC	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-4.67	3.92e-06	0.000877	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
HNSC	cis	rs853679	0.607	rs34166054	ENSG00000204709.4	LINC01556	4.67	3.92e-06	0.000877	0.45	0.21	Depression;	chr6:28098023	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13203816	ENSG00000204709.4	LINC01556	4.67	3.92e-06	0.000877	0.45	0.21	Depression;	chr6:28111820	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.556	rs34588114	ENSG00000204709.4	LINC01556	4.67	3.92e-06	0.000877	0.45	0.21	Depression;	chr6:28112850	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs34371502	ENSG00000204709.4	LINC01556	4.67	3.92e-06	0.000877	0.45	0.21	Depression;	chr6:28113980	chr6:28943877~28944537:+
HNSC	cis	rs1125355	0.589	rs62183013	ENSG00000204380.3	AC005042.4	4.67	3.92e-06	0.000877	0.24	0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158751362	chr2:158658337~158735002:-
HNSC	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	4.67	3.92e-06	0.000877	0.24	0.21	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
HNSC	cis	rs330048	0.51	rs11784654	ENSG00000173295.6	FAM86B3P	-4.67	3.92e-06	0.000877	-0.24	-0.21	Systemic lupus erythematosus;	chr8:9112101	chr8:8228595~8244865:+
HNSC	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	4.67	3.92e-06	0.000878	0.29	0.21	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
HNSC	cis	rs11098499	0.615	rs59867181	ENSG00000249244.1	RP11-548H18.2	-4.67	3.92e-06	0.000878	-0.25	-0.21	Corneal astigmatism;	chr4:119635312	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.562	rs2389879	ENSG00000249244.1	RP11-548H18.2	-4.67	3.92e-06	0.000878	-0.25	-0.21	Corneal astigmatism;	chr4:119636529	chr4:119391831~119395335:-
HNSC	cis	rs6964587	1	rs35317449	ENSG00000188693.7	CYP51A1-AS1	-4.67	3.92e-06	0.000878	-0.22	-0.21	Breast cancer;	chr7:92007696	chr7:92134604~92180725:+
HNSC	cis	rs11756659	0.653	rs412968	ENSG00000217159.2	LARP1P1	4.67	3.92e-06	0.000878	0.3	0.21	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25953965	chr6:26164072~26164363:+
HNSC	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-4.67	3.92e-06	0.000878	-0.24	-0.21	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
HNSC	cis	rs35963943	0.625	rs13087376	ENSG00000228956.7	SATB1-AS1	4.67	3.92e-06	0.000878	0.26	0.21	Lymphocyte counts;	chr3:18685223	chr3:18445024~18920401:+
HNSC	cis	rs4388249	1	rs1866372	ENSG00000271849.1	CTC-332L22.1	-4.67	3.92e-06	0.000878	-0.33	-0.21	Schizophrenia;	chr5:109704265	chr5:109687802~109688329:-
HNSC	cis	rs6723108	0.627	rs6430550	ENSG00000224043.6	CCNT2-AS1	-4.67	3.92e-06	0.000878	-0.26	-0.21	Type 2 diabetes;	chr2:134858815	chr2:134735464~134918710:-
HNSC	cis	rs615632	0.57	rs17734541	ENSG00000254340.1	RP11-10A14.3	4.67	3.93e-06	0.000879	0.25	0.21	Neuroticism;	chr8:9850923	chr8:9141424~9145435:+
HNSC	cis	rs79220007	1	rs79220007	ENSG00000272462.2	U91328.19	-4.67	3.93e-06	0.000879	-0.46	-0.21	Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr6:26098246	chr6:25992662~26001775:+
HNSC	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	4.67	3.93e-06	0.000879	0.28	0.21	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
HNSC	cis	rs9287719	0.967	rs10929682	ENSG00000243819.4	RN7SL832P	4.67	3.93e-06	0.000879	0.2	0.21	Prostate cancer;	chr2:10592063	chr2:10690344~10692099:+
HNSC	cis	rs1150668	0.835	rs1233696	ENSG00000219392.1	RP1-265C24.5	-4.67	3.93e-06	0.000879	-0.24	-0.21	Pubertal anthropometrics;	chr6:28175232	chr6:28115628~28116551:+
HNSC	cis	rs17270561	1	rs79867288	ENSG00000272810.1	U91328.22	-4.67	3.93e-06	0.000879	-0.25	-0.21	Iron status biomarkers;	chr6:25828188	chr6:26013241~26013757:+
HNSC	cis	rs17270561	1	rs12200962	ENSG00000272810.1	U91328.22	-4.67	3.93e-06	0.000879	-0.25	-0.21	Iron status biomarkers;	chr6:25828758	chr6:26013241~26013757:+
HNSC	cis	rs1555322	0.505	rs2254207	ENSG00000279253.1	RP4-614O4.13	-4.67	3.93e-06	0.000879	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35262727~35264187:-
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	4.67	3.93e-06	0.000879	0.26	0.21	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
HNSC	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-4.67	3.93e-06	0.00088	-0.2	-0.21	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
HNSC	cis	rs7809950	1	rs2237677	ENSG00000238832.1	snoU109	-4.67	3.93e-06	0.00088	-0.26	-0.21	Coronary artery disease;	chr7:107562057	chr7:107603363~107603507:+
HNSC	cis	rs3806843	1	rs7732179	ENSG00000202515.1	VTRNA1-3	-4.67	3.93e-06	0.00088	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr5:140726158~140726246:+
HNSC	cis	rs6964587	1	rs6961928	ENSG00000188693.7	CYP51A1-AS1	-4.67	3.93e-06	0.00088	-0.22	-0.21	Breast cancer;	chr7:92040494	chr7:92134604~92180725:+
HNSC	cis	rs189798	1	rs189798	ENSG00000254153.1	CTA-398F10.2	-4.67	3.93e-06	0.00088	-0.24	-0.21	Myopia (pathological);	chr8:9133067	chr8:8456909~8461337:-
HNSC	cis	rs6831352	0.918	rs13138294	ENSG00000263923.1	RP11-571L19.7	4.67	3.94e-06	0.000881	0.23	0.21	Alcohol dependence;	chr4:99141524	chr4:98928897~98994994:+
HNSC	cis	rs10462794	0.853	rs10063884	ENSG00000260763.1	RP11-445O3.3	4.67	3.94e-06	0.000881	0.28	0.21	DNA methylation (variation);	chr5:4505369	chr5:4436850~4440259:-
HNSC	cis	rs6163	0.727	rs284862	ENSG00000236937.2	PTGES3P4	-4.67	3.94e-06	0.000881	-0.26	-0.21	Waist circumference;Hip circumference;	chr10:102812324	chr10:102845595~102845950:+
HNSC	cis	rs62432291	0.681	rs385438	ENSG00000235086.1	FNDC1-IT1	-4.67	3.94e-06	0.000881	-0.28	-0.21	Joint mobility (Beighton score);	chr6:159235181	chr6:159240786~159243329:+
HNSC	cis	rs4947019	0.609	rs9487082	ENSG00000260273.1	RP11-425D10.10	4.67	3.94e-06	0.000882	0.59	0.21	Hematological parameters;	chr6:109388333	chr6:109382795~109383666:+
HNSC	cis	rs5758511	0.68	rs5758684	ENSG00000226450.2	CYP2D8P	4.67	3.94e-06	0.000882	0.21	0.21	Birth weight;	chr22:42253503	chr22:42149886~42155001:-
HNSC	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-4.67	3.94e-06	0.000882	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
HNSC	cis	rs889398	0.683	rs8047682	ENSG00000226232.7	RP11-419C5.2	-4.67	3.94e-06	0.000882	-0.19	-0.21	Body mass index;	chr16:69879543	chr16:69976388~69996188:-
HNSC	cis	rs9402743	0.671	rs9373138	ENSG00000234084.1	RP3-388E23.2	-4.67	3.94e-06	0.000882	-0.22	-0.21	Systemic lupus erythematosus;	chr6:135630343	chr6:135301568~135307158:+
HNSC	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	4.67	3.94e-06	0.000882	0.25	0.21	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
HNSC	cis	rs6586111	0.967	rs6586110	ENSG00000226659.1	RP11-137H2.4	-4.67	3.94e-06	0.000882	-0.25	-0.21	Capecitabine sensitivity;	chr10:80616736	chr10:80529597~80535942:-
HNSC	cis	rs17270561	0.887	rs717551	ENSG00000272810.1	U91328.22	-4.67	3.94e-06	0.000882	-0.25	-0.21	Iron status biomarkers;	chr6:25855396	chr6:26013241~26013757:+
HNSC	cis	rs9921338	0.961	rs7202814	ENSG00000263080.1	RP11-485G7.5	4.67	3.94e-06	0.000882	0.24	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11341809~11345211:-
HNSC	cis	rs155076	1	rs261427	ENSG00000233325.3	MIPEPP3	4.67	3.95e-06	0.000882	0.37	0.21	White matter hyperintensity burden;	chr13:21286859	chr13:21298139~21306373:+
HNSC	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.67	3.95e-06	0.000883	0.24	0.21	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	4.67	3.95e-06	0.000883	0.26	0.21	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
HNSC	cis	rs6831352	0.879	rs29001229	ENSG00000263923.1	RP11-571L19.7	4.67	3.95e-06	0.000883	0.23	0.21	Alcohol dependence;	chr4:99125672	chr4:98928897~98994994:+
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-4.67	3.95e-06	0.000883	-0.22	-0.21	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
HNSC	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	4.67	3.95e-06	0.000883	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
HNSC	cis	rs4787491	0.729	rs12446378	ENSG00000183604.13	SMG1P5	-4.67	3.95e-06	0.000884	-0.2	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30267553~30335374:-
HNSC	cis	rs1056107	0.933	rs10981350	ENSG00000225513.1	RP11-165N19.2	-4.67	3.95e-06	0.000884	-0.22	-0.21	Colorectal cancer;	chr9:112304611	chr9:112173522~112173971:-
HNSC	cis	rs4862750	0.794	rs7692427	ENSG00000250971.1	RP11-696F12.1	4.67	3.96e-06	0.000884	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.832	rs9995958	ENSG00000250971.1	RP11-696F12.1	4.67	3.96e-06	0.000884	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:187060099~187060930:+
HNSC	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	4.67	3.96e-06	0.000885	0.24	0.21	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
HNSC	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	4.67	3.96e-06	0.000885	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	4.67	3.96e-06	0.000885	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	4.67	3.96e-06	0.000885	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	4.67	3.96e-06	0.000885	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	4.67	3.96e-06	0.000885	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
HNSC	cis	rs13073817	0.582	rs11916371	ENSG00000228956.7	SATB1-AS1	4.67	3.96e-06	0.000885	0.22	0.21	Crohn's disease;	chr3:18643456	chr3:18445024~18920401:+
HNSC	cis	rs13073817	0.582	rs4380426	ENSG00000228956.7	SATB1-AS1	4.67	3.96e-06	0.000885	0.22	0.21	Crohn's disease;	chr3:18644016	chr3:18445024~18920401:+
HNSC	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	4.67	3.96e-06	0.000886	0.21	0.21	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
HNSC	cis	rs7824557	0.767	rs2060463	ENSG00000269918.1	AF131215.9	4.67	3.96e-06	0.000886	0.21	0.21	Retinal vascular caliber;	chr8:11304101	chr8:11104691~11106704:-
HNSC	cis	rs4061073	1	rs4061073	ENSG00000198711.5	SSBP3-AS1	4.67	3.96e-06	0.000886	0.2	0.21	Body mass index;	chr1:54231070	chr1:54236440~54239063:+
HNSC	cis	rs9287719	0.967	rs12622765	ENSG00000243819.4	RN7SL832P	4.67	3.96e-06	0.000886	0.2	0.21	Prostate cancer;	chr2:10588205	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs759402	ENSG00000243819.4	RN7SL832P	4.67	3.96e-06	0.000886	0.2	0.21	Prostate cancer;	chr2:10589428	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs759403	ENSG00000243819.4	RN7SL832P	4.67	3.96e-06	0.000886	0.2	0.21	Prostate cancer;	chr2:10589771	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs11674433	ENSG00000243819.4	RN7SL832P	4.67	3.96e-06	0.000886	0.2	0.21	Prostate cancer;	chr2:10590713	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2024431	ENSG00000243819.4	RN7SL832P	4.67	3.96e-06	0.000886	0.2	0.21	Prostate cancer;	chr2:10591201	chr2:10690344~10692099:+
HNSC	cis	rs763121	0.853	rs1013338	ENSG00000273076.1	RP3-508I15.22	4.67	3.96e-06	0.000886	0.21	0.21	Menopause (age at onset);	chr22:38578149	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	4.67	3.96e-06	0.000886	0.21	0.21	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
HNSC	cis	rs73198271	0.694	rs73201840	ENSG00000173295.6	FAM86B3P	-4.67	3.96e-06	0.000886	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.694	rs113694763	ENSG00000173295.6	FAM86B3P	-4.67	3.96e-06	0.000886	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.694	rs115037021	ENSG00000173295.6	FAM86B3P	-4.67	3.96e-06	0.000886	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.694	rs114184516	ENSG00000173295.6	FAM86B3P	-4.67	3.96e-06	0.000886	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8228595~8244865:+
HNSC	cis	rs116095464	0.681	rs10060016	ENSG00000250848.1	CTD-2083E4.5	-4.67	3.96e-06	0.000886	-0.29	-0.21	Breast cancer;	chr5:240985	chr5:288833~290321:-
HNSC	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	4.67	3.96e-06	0.000886	0.23	0.21	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	4.67	3.96e-06	0.000886	0.23	0.21	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	4.67	3.96e-06	0.000886	0.23	0.21	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
HNSC	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-4.67	3.97e-06	0.000886	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-4.67	3.97e-06	0.000886	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-4.67	3.97e-06	0.000886	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-4.67	3.97e-06	0.000886	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
HNSC	cis	rs2337406	1	rs75651733	ENSG00000280411.1	IGHV1-69-2	-4.67	3.97e-06	0.000886	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106701309	chr14:106762092~106762588:-
HNSC	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-4.67	3.97e-06	0.000887	-0.17	-0.21	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
HNSC	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	4.67	3.97e-06	0.000887	0.26	0.21	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
HNSC	cis	rs1125355	0.589	rs62183012	ENSG00000204380.3	AC005042.4	4.67	3.97e-06	0.000887	0.24	0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158751248	chr2:158658337~158735002:-
HNSC	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-4.67	3.97e-06	0.000887	-0.25	-0.21	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
HNSC	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	4.67	3.97e-06	0.000887	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	4.67	3.97e-06	0.000887	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
HNSC	cis	rs7937890	0.706	rs7115393	ENSG00000254418.1	RP11-21L19.1	-4.67	3.97e-06	0.000887	-0.25	-0.21	Mitochondrial DNA levels;	chr11:14246832	chr11:14262846~14273691:-
HNSC	cis	rs11098499	0.562	rs13101722	ENSG00000249244.1	RP11-548H18.2	-4.67	3.97e-06	0.000887	-0.25	-0.21	Corneal astigmatism;	chr4:119634820	chr4:119391831~119395335:-
HNSC	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	4.67	3.97e-06	0.000887	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
HNSC	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	4.67	3.97e-06	0.000888	0.24	0.21	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
HNSC	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	4.67	3.97e-06	0.000888	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
HNSC	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-4.67	3.97e-06	0.000888	-0.2	-0.21	Longevity;	chr3:48393626	chr3:48256350~48256938:-
HNSC	cis	rs2255336	0.671	rs7301582	ENSG00000245648.1	RP11-277P12.20	-4.67	3.97e-06	0.000888	-0.32	-0.21	Blood protein levels;	chr12:10449091	chr12:10363769~10398506:+
HNSC	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.67	3.98e-06	0.000888	0.31	0.21	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
HNSC	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	4.67	3.98e-06	0.000888	0.19	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
HNSC	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	4.67	3.98e-06	0.000889	0.2	0.21	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
HNSC	cis	rs3806843	1	rs1030165	ENSG00000202515.1	VTRNA1-3	-4.67	3.98e-06	0.000889	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs1030166	ENSG00000202515.1	VTRNA1-3	-4.67	3.98e-06	0.000889	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr5:140726158~140726246:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-4.67	3.98e-06	0.000889	-0.24	-0.21	Depression;	chr6:28198669	chr6:28170845~28172521:+
HNSC	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	4.67	3.98e-06	0.000889	0.23	0.21	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
HNSC	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-4.67	3.98e-06	0.00089	-0.49	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-4.67	3.98e-06	0.00089	-0.49	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
HNSC	cis	rs1056107	0.897	rs7851034	ENSG00000225513.1	RP11-165N19.2	-4.67	3.98e-06	0.00089	-0.23	-0.21	Colorectal cancer;	chr9:112193100	chr9:112173522~112173971:-
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000224373.3	IGHV4-59	4.67	3.99e-06	0.00089	0.14	0.21	Kawasaki disease;	chr14:106705441	chr14:106627249~106627825:-
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000204709.4	LINC01556	4.67	3.99e-06	0.00089	0.29	0.21	Depression;	chr6:28136698	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000204709.4	LINC01556	4.67	3.99e-06	0.00089	0.29	0.21	Depression;	chr6:28136856	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000204709.4	LINC01556	4.67	3.99e-06	0.00089	0.29	0.21	Depression;	chr6:28137418	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000204709.4	LINC01556	4.67	3.99e-06	0.00089	0.29	0.21	Depression;	chr6:28138363	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-4.67	3.99e-06	0.000891	-0.25	-0.21	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
HNSC	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	4.67	3.99e-06	0.000892	0.32	0.21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
HNSC	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	4.67	3.99e-06	0.000892	0.34	0.21	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
HNSC	cis	rs6496044	0.634	rs4843066	ENSG00000259295.5	CSPG4P12	4.67	4e-06	0.000892	0.25	0.21	Interstitial lung disease;	chr15:85519680	chr15:85191438~85213905:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-4.67	4e-06	0.000893	-0.24	-0.21	Depression;	chr6:28197321	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-4.67	4e-06	0.000893	-0.24	-0.21	Depression;	chr6:28197412	chr6:28170845~28172521:+
HNSC	cis	rs9990333	0.562	rs55970879	ENSG00000231464.1	AC024937.4	4.67	4e-06	0.000893	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195996738~195998233:+
HNSC	cis	rs11893307	0.566	rs10203824	ENSG00000235852.1	AC005540.3	4.67	4e-06	0.000893	0.28	0.21	Mean platelet volume;	chr2:190731124	chr2:190880797~190882059:-
HNSC	cis	rs35963943	0.625	rs13099740	ENSG00000228956.7	SATB1-AS1	4.67	4e-06	0.000893	0.26	0.21	Lymphocyte counts;	chr3:18678178	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs11709227	ENSG00000228956.7	SATB1-AS1	4.67	4e-06	0.000893	0.26	0.21	Lymphocyte counts;	chr3:18678475	chr3:18445024~18920401:+
HNSC	cis	rs2427308	0.607	rs1741635	ENSG00000275437.1	RP5-908M14.10	-4.67	4e-06	0.000893	-0.23	-0.21	Colorectal cancer;	chr20:62363141	chr20:62402236~62405935:-
HNSC	cis	rs67981189	0.896	rs8003227	ENSG00000274818.1	RP1-292L20.3	4.67	4e-06	0.000893	0.25	0.21	Schizophrenia;	chr14:71093635	chr14:70906657~70907111:-
HNSC	cis	rs9880211	0.528	rs75685279	ENSG00000273486.1	RP11-731C17.2	4.67	4e-06	0.000894	0.2	0.21	Height;Body mass index;	chr3:136715991	chr3:136837338~136839021:-
HNSC	cis	rs2835345	0.63	rs55681268	ENSG00000279365.1	KB-176G8.1	4.67	4e-06	0.000894	0.25	0.21	Pulmonary function;	chr21:36449419	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12627161	ENSG00000279365.1	KB-176G8.1	4.67	4e-06	0.000894	0.25	0.21	Pulmonary function;	chr21:36449649	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12627241	ENSG00000279365.1	KB-176G8.1	4.67	4e-06	0.000894	0.25	0.21	Pulmonary function;	chr21:36449689	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12627173	ENSG00000279365.1	KB-176G8.1	4.67	4e-06	0.000894	0.25	0.21	Pulmonary function;	chr21:36449715	chr21:36485867~36487760:+
HNSC	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	4.67	4.01e-06	0.000894	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
HNSC	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	4.67	4.01e-06	0.000894	0.2	0.21	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
HNSC	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	4.67	4.01e-06	0.000894	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
HNSC	cis	rs3736485	0.932	rs2278989	ENSG00000259438.1	CTD-2650P22.1	4.67	4.01e-06	0.000895	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51622519	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.932	rs10519313	ENSG00000259438.1	CTD-2650P22.1	4.67	4.01e-06	0.000895	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51623615	chr15:52010999~52019095:-
HNSC	cis	rs853679	0.546	rs35016036	ENSG00000219392.1	RP1-265C24.5	-4.67	4.01e-06	0.000895	-0.42	-0.21	Depression;	chr6:28347103	chr6:28115628~28116551:+
HNSC	cis	rs1799949	0.896	rs35908185	ENSG00000236383.6	LINC00854	-4.67	4.01e-06	0.000895	-0.2	-0.21	Menopause (age at onset);	chr17:43103094	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs8176130	ENSG00000236383.6	LINC00854	-4.67	4.01e-06	0.000895	-0.2	-0.21	Menopause (age at onset);	chr17:43106026	chr17:43216941~43305976:-
HNSC	cis	rs4372836	1	rs6710959	ENSG00000226833.4	AC097724.3	4.67	4.01e-06	0.000895	0.27	0.21	Body mass index;	chr2:28735737	chr2:28708953~28736205:-
HNSC	cis	rs4372836	1	rs2169751	ENSG00000226833.4	AC097724.3	4.67	4.01e-06	0.000895	0.27	0.21	Body mass index;	chr2:28743892	chr2:28708953~28736205:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	4.67	4.01e-06	0.000895	0.26	0.21	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	4.67	4.01e-06	0.000895	0.26	0.21	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
HNSC	cis	rs4372836	1	rs11690423	ENSG00000226833.4	AC097724.3	-4.67	4.01e-06	0.000895	-0.26	-0.21	Body mass index;	chr2:28728671	chr2:28708953~28736205:-
HNSC	cis	rs75422866	0.764	rs73104177	ENSG00000280054.1	RP1-197B17.7	4.67	4.01e-06	0.000895	0.53	0.21	Pneumonia;	chr12:47713550	chr12:47728151~47730598:-
HNSC	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	4.67	4.01e-06	0.000895	0.21	0.21	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
HNSC	cis	rs1799949	1	rs8176120	ENSG00000236383.6	LINC00854	-4.67	4.02e-06	0.000896	-0.2	-0.21	Menopause (age at onset);	chr17:43109216	chr17:43216941~43305976:-
HNSC	cis	rs12935418	0.523	rs2549845	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80990520	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.552	rs2549847	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80990617	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2602449	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80990668	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549848	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80990693	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2316923	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80991216	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2098726	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80991670	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.552	rs2113196	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80991885	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2113197	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80991901	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549852	ENSG00000278985.1	RP11-303E16.9	-4.67	4.02e-06	0.000896	-0.2	-0.21	Mean corpuscular volume;	chr16:80992410	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.616	rs2549855	ENSG00000261061.1	RP11-303E16.2	-4.67	4.02e-06	0.000896	-0.22	-0.21	Mean corpuscular volume;	chr16:80993247	chr16:81030770~81031485:+
HNSC	cis	rs9329221	0.935	rs3750310	ENSG00000255310.2	AF131215.2	-4.67	4.02e-06	0.000896	-0.2	-0.21	Neuroticism;	chr8:10425916	chr8:11107788~11109726:-
HNSC	cis	rs11577354	0.527	rs1134890	ENSG00000207181.1	SNORA14B	-4.67	4.02e-06	0.000896	-0.28	-0.21	Obesity-related traits;	chr1:235108743	chr1:235127803~235127937:-
HNSC	cis	rs3015497	0.583	rs3783408	ENSG00000269906.1	RP11-248J18.2	4.67	4.02e-06	0.000896	0.29	0.21	Mean platelet volume;	chr14:50533475	chr14:50662511~50663178:-
HNSC	cis	rs7809950	0.678	rs13230144	ENSG00000238832.1	snoU109	-4.67	4.02e-06	0.000896	-0.3	-0.21	Coronary artery disease;	chr7:107268727	chr7:107603363~107603507:+
HNSC	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-4.67	4.02e-06	0.000897	-0.26	-0.21	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	4.67	4.02e-06	0.000897	0.26	0.21	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	4.67	4.02e-06	0.000897	0.26	0.21	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
HNSC	cis	rs6928977	0.896	rs2614259	ENSG00000217482.2	HMGB1P17	-4.67	4.02e-06	0.000897	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356114	chr6:135636086~135636713:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000224373.3	IGHV4-59	4.67	4.02e-06	0.000898	0.14	0.21	Kawasaki disease;	chr14:106708947	chr14:106627249~106627825:-
HNSC	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	4.67	4.03e-06	0.000898	0.24	0.21	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	4.67	4.03e-06	0.000898	0.24	0.21	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
HNSC	cis	rs6831352	0.879	rs36034266	ENSG00000263923.1	RP11-571L19.7	4.67	4.03e-06	0.000898	0.23	0.21	Alcohol dependence;	chr4:99140237	chr4:98928897~98994994:+
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000224373.3	IGHV4-59	4.67	4.03e-06	0.000898	0.12	0.21	Kawasaki disease;	chr14:106682022	chr14:106627249~106627825:-
HNSC	cis	rs539096	0.5	rs2527776	ENSG00000237950.1	RP11-7O11.3	4.67	4.03e-06	0.000898	0.23	0.21	Intelligence (multi-trait analysis);	chr1:43879620	chr1:43944370~43946551:-
HNSC	cis	rs539096	0.5	rs803678	ENSG00000237950.1	RP11-7O11.3	4.67	4.03e-06	0.000898	0.23	0.21	Intelligence (multi-trait analysis);	chr1:43885226	chr1:43944370~43946551:-
HNSC	cis	rs933688	1	rs10474353	ENSG00000281357.1	ARRDC3-AS1	4.67	4.03e-06	0.000899	0.3	0.21	Smoking behavior;	chr5:91436468	chr5:91380349~91439085:+
HNSC	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	4.67	4.03e-06	0.000899	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.682	rs7013471	ENSG00000173295.6	FAM86B3P	-4.67	4.03e-06	0.000899	-0.24	-0.21	Mood instability;	chr8:8829815	chr8:8228595~8244865:+
HNSC	cis	rs933688	1	rs6867091	ENSG00000281357.1	ARRDC3-AS1	4.67	4.03e-06	0.000899	0.3	0.21	Smoking behavior;	chr5:91438516	chr5:91380349~91439085:+
HNSC	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-4.67	4.04e-06	9e-04	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
HNSC	cis	rs7824557	0.767	rs2164272	ENSG00000269918.1	AF131215.9	4.67	4.04e-06	9e-04	0.21	0.21	Retinal vascular caliber;	chr8:11304987	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.701	rs2060465	ENSG00000269918.1	AF131215.9	4.67	4.04e-06	9e-04	0.21	0.21	Retinal vascular caliber;	chr8:11305100	chr8:11104691~11106704:-
HNSC	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-4.67	4.04e-06	9e-04	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-4.67	4.04e-06	9e-04	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
HNSC	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-4.67	4.04e-06	9e-04	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
HNSC	cis	rs9368481	0.761	rs4713062	ENSG00000224843.5	LINC00240	4.67	4.04e-06	9e-04	0.21	0.21	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26956992~27023924:+
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	4.66	4.04e-06	9e-04	0.26	0.21	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
HNSC	cis	rs7819412	0.745	rs6601569	ENSG00000255495.1	AC145124.2	-4.66	4.04e-06	9e-04	-0.25	-0.21	Triglycerides;	chr8:11216069	chr8:12194467~12196280:+
HNSC	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.66	4.04e-06	9e-04	-0.22	-0.21	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.66	4.04e-06	9e-04	-0.22	-0.21	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
HNSC	cis	rs6964587	0.933	rs6465350	ENSG00000188693.7	CYP51A1-AS1	-4.66	4.04e-06	9e-04	-0.22	-0.21	Breast cancer;	chr7:92139301	chr7:92134604~92180725:+
HNSC	cis	rs11846409	0.629	rs76295389	ENSG00000254174.1	IGHV1-12	-4.66	4.04e-06	9e-04	-0.17	-0.21	Rheumatic heart disease;	chr14:106650437	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.698	rs71419854	ENSG00000254174.1	IGHV1-12	-4.66	4.04e-06	9e-04	-0.17	-0.21	Rheumatic heart disease;	chr14:106650440	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.5	rs71419855	ENSG00000254174.1	IGHV1-12	-4.66	4.04e-06	9e-04	-0.17	-0.21	Alzheimer's disease (late onset);	chr14:106650444	chr14:106122420~106122709:-
HNSC	cis	rs172166	0.516	rs1150670	ENSG00000219392.1	RP1-265C24.5	-4.66	4.04e-06	0.000901	-0.24	-0.21	Cardiac Troponin-T levels;	chr6:28162781	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.516	rs2021826	ENSG00000219392.1	RP1-265C24.5	-4.66	4.04e-06	0.000901	-0.24	-0.21	Cardiac Troponin-T levels;	chr6:28164978	chr6:28115628~28116551:+
HNSC	cis	rs10510102	0.516	rs12244921	ENSG00000226864.1	ATE1-AS1	4.66	4.04e-06	0.000901	0.36	0.21	Breast cancer;	chr10:121990342	chr10:121928312~121951965:+
HNSC	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	4.66	4.05e-06	0.000901	0.24	0.21	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
HNSC	cis	rs9921338	0.961	rs8048768	ENSG00000263080.1	RP11-485G7.5	4.66	4.05e-06	0.000901	0.23	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs11074958	ENSG00000263080.1	RP11-485G7.5	4.66	4.05e-06	0.000901	0.23	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11341809~11345211:-
HNSC	cis	rs72615157	0.634	rs7789890	ENSG00000078319.8	PMS2P1	-4.66	4.05e-06	0.000901	-0.26	-0.21	Lung function (FEV1/FVC);	chr7:100202936	chr7:100320992~100341908:-
HNSC	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	4.66	4.05e-06	0.000902	0.26	0.21	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
HNSC	cis	rs72843506	0.586	rs75128113	ENSG00000261033.1	RP11-209D14.2	4.66	4.05e-06	0.000902	0.37	0.21	Schizophrenia;	chr17:20000172	chr17:20008051~20009234:-
HNSC	cis	rs172166	0.538	rs1150686	ENSG00000219392.1	RP1-265C24.5	-4.66	4.05e-06	0.000902	-0.24	-0.21	Cardiac Troponin-T levels;	chr6:28193493	chr6:28115628~28116551:+
HNSC	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	4.66	4.05e-06	0.000902	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
HNSC	cis	rs67311347	0.594	rs12629111	ENSG00000223797.4	ENTPD3-AS1	4.66	4.05e-06	0.000902	0.2	0.21	Renal cell carcinoma;	chr3:40243860	chr3:40313802~40453329:-
HNSC	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	4.66	4.05e-06	0.000903	0.26	0.21	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
HNSC	cis	rs7267979	0.546	rs8115804	ENSG00000231081.1	RP4-760C5.3	4.66	4.06e-06	0.000903	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:26008791~26010531:-
HNSC	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	4.66	4.06e-06	0.000903	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000224373.3	IGHV4-59	4.66	4.06e-06	0.000904	0.13	0.21	Kawasaki disease;	chr14:106690981	chr14:106627249~106627825:-
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-4.66	4.06e-06	0.000904	-0.26	-0.21	Depression;	chr6:28201380	chr6:28161781~28169594:+
HNSC	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	4.66	4.06e-06	0.000904	0.25	0.21	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
HNSC	cis	rs301901	0.531	rs34555613	ENSG00000250155.1	CTD-2353F22.1	-4.66	4.06e-06	0.000904	-0.23	-0.21	Height;	chr5:37456193	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.575	rs12516683	ENSG00000250155.1	CTD-2353F22.1	-4.66	4.06e-06	0.000904	-0.23	-0.21	Telomere length;	chr5:37456710	chr5:36666214~36725195:-
HNSC	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	4.66	4.06e-06	0.000904	0.31	0.21	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
HNSC	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-4.66	4.06e-06	0.000904	-0.22	-0.21	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
HNSC	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	4.66	4.06e-06	0.000904	0.2	0.21	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
HNSC	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-4.66	4.07e-06	0.000905	-0.31	-0.21	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000219891.2	ZSCAN12P1	4.66	4.07e-06	0.000905	0.3	0.21	Parkinson's disease;	chr6:28043807	chr6:28091154~28093664:+
HNSC	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	4.66	4.07e-06	0.000905	0.22	0.21	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
HNSC	cis	rs5758659	0.845	rs5758645	ENSG00000227370.1	RP4-669P10.19	-4.66	4.07e-06	0.000906	-0.2	-0.21	Cognitive function;	chr22:42202945	chr22:42132543~42132998:+
HNSC	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-4.66	4.07e-06	0.000906	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
HNSC	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-4.66	4.07e-06	0.000906	-0.2	-0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
HNSC	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-4.66	4.07e-06	0.000906	-0.25	-0.21	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
HNSC	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.66	4.08e-06	0.000907	0.24	0.21	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.66	4.08e-06	0.000907	0.24	0.21	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
HNSC	cis	rs8054556	0.669	rs9972866	ENSG00000183604.13	SMG1P5	-4.66	4.08e-06	0.000907	-0.2	-0.21	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30267553~30335374:-
HNSC	cis	rs11893307	0.507	rs1465304	ENSG00000235852.1	AC005540.3	4.66	4.08e-06	0.000907	0.26	0.21	Mean platelet volume;	chr2:190720672	chr2:190880797~190882059:-
HNSC	cis	rs67981189	0.896	rs17108967	ENSG00000274818.1	RP1-292L20.3	4.66	4.08e-06	0.000908	0.24	0.21	Schizophrenia;	chr14:71075451	chr14:70906657~70907111:-
HNSC	cis	rs17818399	0.51	rs1451153	ENSG00000279254.1	RP11-536C12.1	-4.66	4.08e-06	0.000908	-0.23	-0.21	Height;	chr2:46572713	chr2:46668870~46670778:+
HNSC	cis	rs11098499	1	rs6849889	ENSG00000250412.1	KLHL2P1	4.66	4.08e-06	0.000908	0.27	0.21	Corneal astigmatism;	chr4:119265193	chr4:119334329~119378233:+
HNSC	cis	rs516805	0.748	rs55863504	ENSG00000279453.1	RP3-425C14.4	4.66	4.08e-06	0.000908	0.28	0.21	Lymphocyte counts;	chr6:122376339	chr6:122436789~122439223:-
HNSC	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-4.66	4.08e-06	0.000909	-0.18	-0.21	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
HNSC	cis	rs17292804	0.506	rs71417868	ENSG00000269910.1	RP11-73M18.10	4.66	4.09e-06	0.000909	0.2	0.21	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694516~103695050:-
HNSC	cis	rs10514928	1	rs10514928	ENSG00000228782.6	CTD-2026D20.3	-4.66	4.09e-06	0.000909	-0.45	-0.21	Left atrial antero-posterior diameter;	chr17:47426173	chr17:47450568~47492492:-
HNSC	cis	rs155076	1	rs261423	ENSG00000233325.3	MIPEPP3	4.66	4.09e-06	0.00091	0.37	0.21	White matter hyperintensity burden;	chr13:21278192	chr13:21298139~21306373:+
HNSC	cis	rs12893668	0.703	rs4906338	ENSG00000269910.1	RP11-73M18.10	4.66	4.09e-06	0.00091	0.21	0.21	Reticulocyte count;	chr14:103584020	chr14:103694516~103695050:-
HNSC	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-4.66	4.09e-06	0.000911	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
HNSC	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-4.66	4.1e-06	0.000911	-0.34	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
HNSC	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-4.66	4.1e-06	0.000911	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
HNSC	cis	rs1275468	0.798	rs2366987	ENSG00000257497.2	RP11-585P4.5	-4.66	4.1e-06	0.000911	-0.31	-0.21	Polycystic ovary syndrome;	chr12:75536346	chr12:75483454~75489820:-
HNSC	cis	rs7296418	0.885	rs1051434	ENSG00000280120.1	RP11-546D6.3	4.66	4.1e-06	0.000912	0.18	0.21	Platelet count;	chr12:123156653	chr12:123152324~123153377:-
HNSC	cis	rs3806843	1	rs10037757	ENSG00000202515.1	VTRNA1-3	-4.66	4.1e-06	0.000912	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr5:140726158~140726246:+
HNSC	cis	rs10791097	0.678	rs10894272	ENSG00000254842.5	RP11-890B15.2	-4.66	4.1e-06	0.000912	-0.18	-0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130861186	chr11:130844191~130865561:-
HNSC	cis	rs6601327	0.641	rs4840437	ENSG00000254340.1	RP11-10A14.3	-4.66	4.1e-06	0.000912	-0.25	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9748754	chr8:9141424~9145435:+
HNSC	cis	rs1008375	0.966	rs4698636	ENSG00000249502.1	AC006160.5	-4.66	4.1e-06	0.000912	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631211	chr4:17587467~17614571:-
HNSC	cis	rs73198271	0.751	rs55816468	ENSG00000173295.6	FAM86B3P	-4.66	4.1e-06	0.000912	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8228595~8244865:+
HNSC	cis	rs1125355	0.69	rs72937289	ENSG00000204380.3	AC005042.4	4.66	4.1e-06	0.000912	0.24	0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158771000	chr2:158658337~158735002:-
HNSC	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-4.66	4.1e-06	0.000913	-0.21	-0.21	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
HNSC	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-4.66	4.1e-06	0.000913	-0.27	-0.21	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-4.66	4.1e-06	0.000913	-0.27	-0.21	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-4.66	4.1e-06	0.000913	-0.27	-0.21	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
HNSC	cis	rs10829156	0.732	rs10828834	ENSG00000240291.1	RP11-499P20.2	4.66	4.11e-06	0.000913	0.22	0.21	Sudden cardiac arrest;	chr10:18523505	chr10:18513115~18545651:-
HNSC	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	4.66	4.11e-06	0.000913	0.27	0.21	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
HNSC	cis	rs8028182	0.549	rs3809547	ENSG00000260269.4	CTD-2323K18.1	4.66	4.11e-06	0.000913	0.27	0.21	Sudden cardiac arrest;	chr15:75336500	chr15:75527150~75601205:-
HNSC	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.11e-06	0.000913	-0.44	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
HNSC	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	4.66	4.11e-06	0.000913	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	4.66	4.11e-06	0.000913	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
HNSC	cis	rs155076	1	rs567166	ENSG00000233325.3	MIPEPP3	4.66	4.11e-06	0.000913	0.37	0.21	White matter hyperintensity burden;	chr13:21263380	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs2783107	ENSG00000233325.3	MIPEPP3	4.66	4.11e-06	0.000913	0.37	0.21	White matter hyperintensity burden;	chr13:21263393	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs566364	ENSG00000233325.3	MIPEPP3	4.66	4.11e-06	0.000913	0.37	0.21	White matter hyperintensity burden;	chr13:21263444	chr13:21298139~21306373:+
HNSC	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-4.66	4.11e-06	0.000914	-0.2	-0.21	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-4.66	4.11e-06	0.000914	-0.2	-0.21	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-4.66	4.11e-06	0.000914	-0.2	-0.21	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
HNSC	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	4.66	4.11e-06	0.000914	0.2	0.21	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
HNSC	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	4.66	4.11e-06	0.000914	0.4	0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
HNSC	cis	rs6928977	0.896	rs2746429	ENSG00000217482.2	HMGB1P17	-4.66	4.11e-06	0.000914	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352146	chr6:135636086~135636713:-
HNSC	cis	rs9300255	0.77	rs12299125	ENSG00000280120.1	RP11-546D6.3	-4.66	4.11e-06	0.000914	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123377900	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.722	rs28458312	ENSG00000280120.1	RP11-546D6.3	-4.66	4.11e-06	0.000914	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123378718	chr12:123152324~123153377:-
HNSC	cis	rs1971762	0.545	rs10747675	ENSG00000270175.1	RP11-793H13.11	4.66	4.11e-06	0.000914	0.18	0.21	Height;	chr12:53606247	chr12:53500162~53500936:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	4.66	4.12e-06	0.000915	0.22	0.21	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
HNSC	cis	rs4256159	1	rs73178563	ENSG00000228956.7	SATB1-AS1	4.66	4.12e-06	0.000915	0.35	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18755071	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs11919315	ENSG00000228956.7	SATB1-AS1	4.66	4.12e-06	0.000915	0.35	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18755332	chr3:18445024~18920401:+
HNSC	cis	rs11722228	0.508	rs2241473	ENSG00000250413.1	RP11-448G15.1	-4.66	4.12e-06	0.000915	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10084325	chr4:10006482~10009725:+
HNSC	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	4.66	4.12e-06	0.000915	0.25	0.21	Height;	chr14:75066238	chr14:75011269~75012851:-
HNSC	cis	rs3096299	0.967	rs7205785	ENSG00000261574.1	RP1-168P16.2	4.66	4.12e-06	0.000915	0.27	0.21	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89392375~89412564:-
HNSC	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-4.66	4.12e-06	0.000916	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
HNSC	cis	rs795484	0.963	rs795475	ENSG00000275409.1	RP11-131L12.4	-4.66	4.12e-06	0.000916	-0.24	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118159851	chr12:118430147~118430699:+
HNSC	cis	rs4761669	0.565	rs7308671	ENSG00000241556.1	RP11-490G8.1	4.66	4.12e-06	0.000916	0.21	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94805350	chr12:95467397~95467861:-
HNSC	cis	rs3806843	0.735	rs778596	ENSG00000202515.1	VTRNA1-3	4.66	4.12e-06	0.000916	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr5:140726158~140726246:+
HNSC	cis	rs860295	0.529	rs1475766	ENSG00000229953.1	RP11-284F21.7	4.66	4.12e-06	0.000916	0.25	0.21	Body mass index;	chr1:156011698	chr1:156646507~156661424:-
HNSC	cis	rs9329221	0.935	rs3750311	ENSG00000255310.2	AF131215.2	-4.66	4.12e-06	0.000916	-0.2	-0.21	Neuroticism;	chr8:10426092	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	-4.66	4.12e-06	0.000916	-0.26	-0.21	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
HNSC	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	4.66	4.13e-06	0.000917	0.19	0.21	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
HNSC	cis	rs1355223	0.583	rs2956074	ENSG00000271369.1	RP11-350D17.3	4.66	4.13e-06	0.000917	0.24	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843333	chr11:34709600~34710161:+
HNSC	cis	rs6964587	0.869	rs11769294	ENSG00000188693.7	CYP51A1-AS1	-4.66	4.13e-06	0.000917	-0.22	-0.21	Breast cancer;	chr7:91920623	chr7:92134604~92180725:+
HNSC	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	4.66	4.13e-06	0.000917	0.24	0.21	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
HNSC	cis	rs9840812	0.953	rs34330586	ENSG00000239213.4	NCK1-AS1	-4.66	4.13e-06	0.000917	-0.2	-0.21	Fibrinogen levels;	chr3:136081567	chr3:136841726~136862054:-
HNSC	cis	rs721917	0.506	rs927452	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.13e-06	0.000917	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79663088~79826594:-
HNSC	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-4.66	4.13e-06	0.000917	-0.28	-0.21	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	4.66	4.13e-06	0.000918	0.26	0.21	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	4.66	4.13e-06	0.000918	0.26	0.21	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-4.66	4.13e-06	0.000918	-0.25	-0.21	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
HNSC	cis	rs4660214	0.666	rs10493087	ENSG00000182109.6	RP11-69E11.4	-4.66	4.13e-06	0.000918	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs11205828	ENSG00000182109.6	RP11-69E11.4	-4.66	4.13e-06	0.000918	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39522280~39546187:-
HNSC	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-4.66	4.13e-06	0.000918	-0.28	-0.21	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
HNSC	cis	rs7086627	0.515	rs4933390	ENSG00000226659.1	RP11-137H2.4	-4.66	4.13e-06	0.000918	-0.26	-0.21	Post bronchodilator FEV1;	chr10:80453325	chr10:80529597~80535942:-
HNSC	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	4.66	4.14e-06	0.000919	0.25	0.21	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
HNSC	cis	rs442309	0.841	rs224044	ENSG00000238280.1	RP11-436D10.3	-4.66	4.14e-06	0.000919	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62765310	chr10:62793562~62805887:-
HNSC	cis	rs4388249	1	rs3819904	ENSG00000271849.1	CTC-332L22.1	-4.66	4.14e-06	0.00092	-0.32	-0.21	Schizophrenia;	chr5:109699795	chr5:109687802~109688329:-
HNSC	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	4.66	4.14e-06	0.00092	0.17	0.21	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
HNSC	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	4.66	4.14e-06	0.00092	0.17	0.21	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
HNSC	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-4.66	4.14e-06	0.00092	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-4.66	4.14e-06	0.00092	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-4.66	4.14e-06	0.00092	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-4.66	4.14e-06	0.00092	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
HNSC	cis	rs6496044	0.507	rs410522	ENSG00000259295.5	CSPG4P12	-4.66	4.15e-06	0.00092	-0.25	-0.21	Interstitial lung disease;	chr15:85663813	chr15:85191438~85213905:+
HNSC	cis	rs9329221	0.683	rs814359	ENSG00000254340.1	RP11-10A14.3	-4.66	4.15e-06	0.000921	-0.25	-0.21	Neuroticism;	chr8:10025622	chr8:9141424~9145435:+
HNSC	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	4.66	4.15e-06	0.000921	0.21	0.21	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
HNSC	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-4.66	4.15e-06	0.000921	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
HNSC	cis	rs2898290	0.617	rs13273172	ENSG00000269918.1	AF131215.9	-4.66	4.15e-06	0.000921	-0.21	-0.21	Systolic blood pressure;	chr8:11603602	chr8:11104691~11106704:-
HNSC	cis	rs3764021	0.933	rs2268146	ENSG00000256673.1	RP11-599J14.2	-4.66	4.15e-06	0.000921	-0.2	-0.21	Type 1 diabetes;	chr12:9716675	chr12:9398355~9414851:-
HNSC	cis	rs2985684	0.948	rs12886130	ENSG00000278009.1	RP11-649E7.8	4.66	4.15e-06	0.000922	0.28	0.21	Carotid intima media thickness;	chr14:49616035	chr14:49601011~49601124:-
HNSC	cis	rs12935418	0.616	rs2549857	ENSG00000261061.1	RP11-303E16.2	-4.66	4.15e-06	0.000922	-0.22	-0.21	Mean corpuscular volume;	chr16:80993353	chr16:81030770~81031485:+
HNSC	cis	rs9650657	0.783	rs28570522	ENSG00000269918.1	AF131215.9	-4.66	4.15e-06	0.000922	-0.22	-0.21	Neuroticism;	chr8:10773058	chr8:11104691~11106704:-
HNSC	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-4.66	4.15e-06	0.000922	-0.2	-0.21	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
HNSC	cis	rs7824557	0.767	rs10104728	ENSG00000255310.2	AF131215.2	4.66	4.15e-06	0.000922	0.2	0.21	Retinal vascular caliber;	chr8:11313791	chr8:11107788~11109726:-
HNSC	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-4.66	4.16e-06	0.000922	-0.23	-0.21	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
HNSC	cis	rs7824557	0.836	rs2736378	ENSG00000255310.2	AF131215.2	-4.66	4.16e-06	0.000923	-0.21	-0.21	Retinal vascular caliber;	chr8:11262251	chr8:11107788~11109726:-
HNSC	cis	rs761746	0.577	rs5994431	ENSG00000236132.1	CTA-440B3.1	4.66	4.16e-06	0.000923	0.26	0.21	Intelligence;	chr22:31814314	chr22:31816379~31817491:-
HNSC	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	4.66	4.16e-06	0.000923	0.29	0.21	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
HNSC	cis	rs7824557	0.836	rs1435278	ENSG00000255310.2	AF131215.2	-4.66	4.16e-06	0.000923	-0.2	-0.21	Retinal vascular caliber;	chr8:11265520	chr8:11107788~11109726:-
HNSC	cis	rs6964587	0.647	rs38801	ENSG00000188693.7	CYP51A1-AS1	4.66	4.16e-06	0.000923	0.22	0.21	Breast cancer;	chr7:92417013	chr7:92134604~92180725:+
HNSC	cis	rs7475343	0.501	rs1889459	ENSG00000224034.1	RP11-445P17.8	-4.66	4.16e-06	0.000924	-0.29	-0.21	Intelligence;	chr10:5272080	chr10:5266033~5271236:-
HNSC	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	4.66	4.16e-06	0.000924	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
HNSC	cis	rs950776	0.72	rs11637890	ENSG00000261762.1	RP11-650L12.2	-4.66	4.16e-06	0.000924	-0.26	-0.21	Sudden cardiac arrest;	chr15:78643077	chr15:78589123~78591276:-
HNSC	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-4.66	4.17e-06	0.000924	-0.19	-0.21	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
HNSC	cis	rs67981189	0.835	rs2526855	ENSG00000274818.1	RP1-292L20.3	-4.66	4.17e-06	0.000925	-0.25	-0.21	Schizophrenia;	chr14:70946629	chr14:70906657~70907111:-
HNSC	cis	rs1008375	1	rs10939738	ENSG00000249502.1	AC006160.5	-4.66	4.17e-06	0.000925	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17602672	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs4698627	ENSG00000249502.1	AC006160.5	-4.66	4.17e-06	0.000925	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604336	chr4:17587467~17614571:-
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	4.66	4.17e-06	0.000925	0.26	0.21	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
HNSC	cis	rs4372836	0.828	rs6728459	ENSG00000226833.4	AC097724.3	4.66	4.17e-06	0.000926	0.27	0.21	Body mass index;	chr2:28776470	chr2:28708953~28736205:-
HNSC	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	4.66	4.17e-06	0.000926	0.23	0.21	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
HNSC	cis	rs6928977	0.826	rs9321502	ENSG00000231028.7	LINC00271	4.66	4.17e-06	0.000926	0.25	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135335114	chr6:135497801~135716055:+
HNSC	cis	rs1799949	1	rs35070007	ENSG00000236383.6	LINC00854	4.66	4.17e-06	0.000926	0.19	0.21	Menopause (age at onset);	chr17:43164730	chr17:43216941~43305976:-
HNSC	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	4.66	4.17e-06	0.000926	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	4.66	4.17e-06	0.000926	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
HNSC	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	4.66	4.17e-06	0.000926	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
HNSC	cis	rs4873772	0.837	rs2129617	ENSG00000253330.1	RP11-697N18.3	-4.66	4.17e-06	0.000926	-0.26	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47643268	chr8:47511034~47512141:-
HNSC	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-4.66	4.18e-06	0.000926	-0.24	-0.21	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
HNSC	cis	rs7829975	0.714	rs7823757	ENSG00000254153.1	CTA-398F10.2	4.66	4.18e-06	0.000926	0.23	0.21	Mood instability;	chr8:8812667	chr8:8456909~8461337:-
HNSC	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-4.66	4.18e-06	0.000926	-0.38	-0.21	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
HNSC	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.66	4.18e-06	0.000927	-0.22	-0.21	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
HNSC	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	4.66	4.18e-06	0.000927	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
HNSC	cis	rs3806843	0.832	rs2531360	ENSG00000202515.1	VTRNA1-3	4.66	4.18e-06	0.000927	0.23	0.21	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr5:140726158~140726246:+
HNSC	cis	rs1552244	1	rs6807846	ENSG00000180385.7	EMC3-AS1	4.66	4.18e-06	0.000928	0.23	0.21	Alzheimer's disease;	chr3:10092807	chr3:9986893~10006990:+
HNSC	cis	rs4862750	0.872	rs56389997	ENSG00000250971.1	RP11-696F12.1	4.66	4.18e-06	0.000928	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186973642	chr4:187060099~187060930:+
HNSC	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	4.66	4.18e-06	0.000928	0.2	0.21	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	4.66	4.18e-06	0.000928	0.2	0.21	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
HNSC	cis	rs6964833	0.554	rs112506907	ENSG00000184616.8	AC004166.6	4.66	4.18e-06	0.000928	0.24	0.21	Menarche (age at onset);	chr7:74654407	chr7:74906673~74913256:-
HNSC	cis	rs6928977	0.675	rs12206850	ENSG00000231028.7	LINC00271	-4.66	4.19e-06	0.000928	-0.25	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135497801~135716055:+
HNSC	cis	rs11451044	1	rs11451044	ENSG00000248265.1	FLJ12825	4.66	4.19e-06	0.000929	0.24	0.21	Red blood cell count;	chr12:54322000	chr12:54058254~54122234:+
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	4.66	4.19e-06	0.000929	0.25	0.21	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
HNSC	cis	rs4326844	0.903	rs10876550	ENSG00000248265.1	FLJ12825	4.66	4.19e-06	0.000929	0.24	0.21	Platelet count;	chr12:54318524	chr12:54058254~54122234:+
HNSC	cis	rs11893307	0.537	rs7571572	ENSG00000228509.4	AC006460.2	4.66	4.19e-06	0.000929	0.27	0.21	Mean platelet volume;	chr2:190688911	chr2:190676944~190708716:-
HNSC	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-4.66	4.19e-06	0.000929	-0.39	-0.21	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
HNSC	cis	rs754133	0.964	rs4759318	ENSG00000248265.1	FLJ12825	4.66	4.19e-06	0.000929	0.26	0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026314	chr12:54058254~54122234:+
HNSC	cis	rs761746	0.579	rs5998121	ENSG00000236132.1	CTA-440B3.1	-4.66	4.19e-06	0.000929	-0.26	-0.21	Intelligence;	chr22:31776381	chr22:31816379~31817491:-
HNSC	cis	rs761746	0.579	rs5998126	ENSG00000236132.1	CTA-440B3.1	-4.66	4.19e-06	0.000929	-0.26	-0.21	Intelligence;	chr22:31782416	chr22:31816379~31817491:-
HNSC	cis	rs4372836	1	rs72782294	ENSG00000226833.4	AC097724.3	-4.66	4.19e-06	0.000929	-0.26	-0.21	Body mass index;	chr2:28730524	chr2:28708953~28736205:-
HNSC	cis	rs7829975	0.577	rs7816329	ENSG00000254340.1	RP11-10A14.3	-4.66	4.19e-06	0.00093	-0.27	-0.21	Mood instability;	chr8:8686333	chr8:9141424~9145435:+
HNSC	cis	rs3806843	1	rs6898939	ENSG00000202515.1	VTRNA1-3	-4.66	4.19e-06	0.00093	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr5:140726158~140726246:+
HNSC	cis	rs9863	0.828	rs12303933	ENSG00000269938.1	RP11-214K3.20	-4.66	4.2e-06	0.00093	-0.25	-0.21	White blood cell count;	chr12:123997709	chr12:123968023~123968579:-
HNSC	cis	rs763121	0.706	rs3827356	ENSG00000273076.1	RP3-508I15.22	-4.66	4.2e-06	0.00093	-0.22	-0.21	Menopause (age at onset);	chr22:38668801	chr22:38743495~38743910:+
HNSC	cis	rs6964587	0.967	rs34344935	ENSG00000188693.7	CYP51A1-AS1	-4.66	4.2e-06	0.00093	-0.23	-0.21	Breast cancer;	chr7:92206122	chr7:92134604~92180725:+
HNSC	cis	rs2904524	1	rs1983437	ENSG00000257815.4	RP11-611E13.2	-4.66	4.2e-06	0.000931	-0.25	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70329989	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs2272180	ENSG00000257815.4	RP11-611E13.2	-4.66	4.2e-06	0.000931	-0.25	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70330227	chr12:69904033~70243360:-
HNSC	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-4.66	4.2e-06	0.000931	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-4.66	4.2e-06	0.000931	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
HNSC	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	4.66	4.2e-06	0.000931	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-4.66	4.2e-06	0.000931	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
HNSC	cis	rs12935418	0.672	rs11150334	ENSG00000261061.1	RP11-303E16.2	-4.66	4.2e-06	0.000932	-0.23	-0.21	Mean corpuscular volume;	chr16:81008937	chr16:81030770~81031485:+
HNSC	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	4.66	4.2e-06	0.000932	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
HNSC	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.66	4.2e-06	0.000932	0.24	0.21	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000280411.1	IGHV1-69-2	-4.66	4.21e-06	0.000933	-0.22	-0.21	Alzheimer's disease (late onset);	chr14:106670302	chr14:106762092~106762588:-
HNSC	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	4.66	4.21e-06	0.000933	0.24	0.21	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
HNSC	cis	rs5758511	0.68	rs5758682	ENSG00000226450.2	CYP2D8P	4.66	4.21e-06	0.000933	0.21	0.21	Birth weight;	chr22:42249196	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs34107327	ENSG00000226450.2	CYP2D8P	4.66	4.21e-06	0.000933	0.21	0.21	Birth weight;	chr22:42252347	chr22:42149886~42155001:-
HNSC	cis	rs1056107	0.933	rs7037658	ENSG00000225513.1	RP11-165N19.2	-4.66	4.21e-06	0.000933	-0.22	-0.21	Colorectal cancer;	chr9:112309244	chr9:112173522~112173971:-
HNSC	cis	rs67981189	0.896	rs34763296	ENSG00000274818.1	RP1-292L20.3	4.66	4.21e-06	0.000934	0.24	0.21	Schizophrenia;	chr14:71083458	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.789	rs12101246	ENSG00000274818.1	RP1-292L20.3	4.66	4.21e-06	0.000934	0.24	0.21	Schizophrenia;	chr14:71084618	chr14:70906657~70907111:-
HNSC	cis	rs7824557	0.534	rs10092549	ENSG00000255310.2	AF131215.2	-4.66	4.21e-06	0.000934	-0.21	-0.21	Retinal vascular caliber;	chr8:11231570	chr8:11107788~11109726:-
HNSC	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	4.66	4.22e-06	0.000934	0.22	0.21	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
HNSC	cis	rs4763879	0.54	rs741200	ENSG00000278635.1	CTD-2318O12.1	4.66	4.22e-06	0.000935	0.16	0.21	Type 1 diabetes;	chr12:9717819	chr12:9415641~9416718:+
HNSC	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	4.66	4.22e-06	0.000935	0.26	0.21	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
HNSC	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	4.66	4.22e-06	0.000935	0.27	0.21	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
HNSC	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-4.66	4.22e-06	0.000935	-0.26	-0.21	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
HNSC	cis	rs7615952	0.599	rs2279821	ENSG00000248787.1	RP11-666A20.4	-4.66	4.22e-06	0.000935	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126015465	chr3:125908005~125910272:-
HNSC	cis	rs9392556	0.533	rs619439	ENSG00000230648.1	RP3-406P24.3	4.66	4.22e-06	0.000935	0.24	0.21	Blood metabolite levels;	chr6:4113695	chr6:4018843~4021215:-
HNSC	cis	rs12682352	0.602	rs11783966	ENSG00000254340.1	RP11-10A14.3	-4.66	4.22e-06	0.000935	-0.26	-0.21	Neuroticism;	chr8:8807637	chr8:9141424~9145435:+
HNSC	cis	rs1387259	0.698	rs4579969	ENSG00000257763.1	OR5BK1P	-4.66	4.22e-06	0.000935	-0.2	-0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48355792~48356614:-
HNSC	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-4.66	4.22e-06	0.000936	-0.24	-0.21	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
HNSC	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	4.66	4.23e-06	0.000936	0.28	0.21	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
HNSC	cis	rs9402743	0.634	rs9321512	ENSG00000234084.1	RP3-388E23.2	4.66	4.23e-06	0.000936	0.21	0.21	Systemic lupus erythematosus;	chr6:135603299	chr6:135301568~135307158:+
HNSC	cis	rs17739794	0.905	rs10088235	ENSG00000254207.1	RP11-43A14.1	-4.66	4.23e-06	0.000936	-0.24	-0.21	Clozapine-induced cytotoxicity;	chr8:859090	chr8:725188~725877:-
HNSC	cis	rs4356203	0.905	rs11821773	ENSG00000260196.1	RP1-239B22.5	-4.65	4.23e-06	0.000937	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17380649~17383531:+
HNSC	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.65	4.23e-06	0.000937	0.19	0.21	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.65	4.23e-06	0.000937	0.19	0.21	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
HNSC	cis	rs55661361	0.708	rs7113041	ENSG00000245498.5	RP11-677M14.7	-4.65	4.24e-06	0.000938	-0.22	-0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742695	chr11:124800450~124834487:+
HNSC	cis	rs4787484	1	rs7189550	ENSG00000196796.5	CTB-134H23.2	-4.65	4.24e-06	0.000939	-0.23	-0.21	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29038655~29052726:+
HNSC	cis	rs7296418	0.961	rs12425850	ENSG00000280120.1	RP11-546D6.3	4.65	4.24e-06	0.000939	0.18	0.21	Platelet count;	chr12:123017425	chr12:123152324~123153377:-
HNSC	cis	rs7296418	0.922	rs12425009	ENSG00000280120.1	RP11-546D6.3	4.65	4.24e-06	0.000939	0.18	0.21	Platelet count;	chr12:123017497	chr12:123152324~123153377:-
HNSC	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	4.65	4.24e-06	0.000939	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
HNSC	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	4.65	4.24e-06	0.000939	0.2	0.21	Height;	chr5:37468413	chr5:36666214~36725195:-
HNSC	cis	rs4908769	0.66	rs159961	ENSG00000232912.4	RP5-1115A15.1	4.65	4.24e-06	0.000939	0.23	0.21	Allergy;	chr1:8424168	chr1:8424645~8434838:+
HNSC	cis	rs4908769	0.66	rs301797	ENSG00000232912.4	RP5-1115A15.1	4.65	4.24e-06	0.000939	0.23	0.21	Allergy;	chr1:8427263	chr1:8424645~8434838:+
HNSC	cis	rs12935418	0.524	rs9933697	ENSG00000261061.1	RP11-303E16.2	-4.65	4.24e-06	0.00094	-0.23	-0.21	Mean corpuscular volume;	chr16:80939637	chr16:81030770~81031485:+
HNSC	cis	rs442309	0.64	rs11597299	ENSG00000238280.1	RP11-436D10.3	-4.65	4.25e-06	0.00094	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62706515	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.687	rs11599754	ENSG00000238280.1	RP11-436D10.3	-4.65	4.25e-06	0.00094	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62706891	chr10:62793562~62805887:-
HNSC	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-4.65	4.25e-06	0.00094	-0.27	-0.21	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
HNSC	cis	rs14027	0.64	rs9297604	ENSG00000279347.1	RP11-85I17.2	4.65	4.25e-06	0.00094	0.18	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119738772	chr8:119838736~119840385:-
HNSC	cis	rs3812049	1	rs3812049	ENSG00000245937.6	LINC01184	4.65	4.25e-06	0.00094	0.28	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128083158	chr5:127940426~128083172:-
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	-4.65	4.25e-06	0.000941	-0.26	-0.21	Depression;	chr6:28206812	chr6:28161781~28169594:+
HNSC	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-4.65	4.25e-06	0.000941	-0.22	-0.21	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
HNSC	cis	rs853679	0.607	rs34166054	ENSG00000219392.1	RP1-265C24.5	-4.65	4.25e-06	0.000941	-0.43	-0.21	Depression;	chr6:28098023	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13203816	ENSG00000219392.1	RP1-265C24.5	-4.65	4.25e-06	0.000941	-0.43	-0.21	Depression;	chr6:28111820	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.556	rs34588114	ENSG00000219392.1	RP1-265C24.5	-4.65	4.25e-06	0.000941	-0.43	-0.21	Depression;	chr6:28112850	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs34371502	ENSG00000219392.1	RP1-265C24.5	-4.65	4.25e-06	0.000941	-0.43	-0.21	Depression;	chr6:28113980	chr6:28115628~28116551:+
HNSC	cis	rs73222236	0.825	rs55797013	ENSG00000273486.1	RP11-731C17.2	4.65	4.25e-06	0.000941	0.18	0.21	Coronary artery disease;	chr3:136300362	chr3:136837338~136839021:-
HNSC	cis	rs929354	0.629	rs6950739	ENSG00000224629.1	RP5-1142J19.2	-4.65	4.25e-06	0.000941	-0.21	-0.21	Body mass index;	chr7:157189756	chr7:157263022~157263229:-
HNSC	cis	rs17428076	0.71	rs17499593	ENSG00000228389.1	AC068039.4	-4.65	4.25e-06	0.000941	-0.28	-0.21	Myopia;	chr2:171793245	chr2:171773482~171775844:+
HNSC	cis	rs1971762	0.583	rs3844370	ENSG00000270175.1	RP11-793H13.11	-4.65	4.25e-06	0.000941	-0.18	-0.21	Height;	chr12:53692353	chr12:53500162~53500936:-
HNSC	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-4.65	4.25e-06	0.000941	-0.27	-0.21	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
HNSC	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	4.65	4.25e-06	0.000941	0.21	0.21	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
HNSC	cis	rs4853525	0.522	rs7574840	ENSG00000235852.1	AC005540.3	4.65	4.25e-06	0.000942	0.26	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190719510	chr2:190880797~190882059:-
HNSC	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-4.65	4.25e-06	0.000942	-0.28	-0.21	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
HNSC	cis	rs9813712	0.595	rs16825656	ENSG00000249846.5	RP11-77P16.4	-4.65	4.26e-06	0.000942	-0.23	-0.21	Response to amphetamines;	chr3:130286225	chr3:130112550~130120579:+
HNSC	cis	rs73198271	0.74	rs10092600	ENSG00000233609.3	RP11-62H7.2	-4.65	4.26e-06	0.000942	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8961200~8979025:+
HNSC	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-4.65	4.26e-06	0.000943	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
HNSC	cis	rs11154801	0.589	rs6924066	ENSG00000234084.1	RP3-388E23.2	-4.65	4.26e-06	0.000943	-0.22	-0.21	Multiple sclerosis;	chr6:135598006	chr6:135301568~135307158:+
HNSC	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	4.65	4.26e-06	0.000943	0.25	0.21	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
HNSC	cis	rs2985684	1	rs2985697	ENSG00000278009.1	RP11-649E7.8	4.65	4.26e-06	0.000943	0.28	0.21	Carotid intima media thickness;	chr14:49626184	chr14:49601011~49601124:-
HNSC	cis	rs9880211	0.613	rs6439629	ENSG00000273486.1	RP11-731C17.2	4.65	4.26e-06	0.000944	0.18	0.21	Height;Body mass index;	chr3:136182428	chr3:136837338~136839021:-
HNSC	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	4.65	4.26e-06	0.000944	0.18	0.21	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
HNSC	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000945	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	4.65	4.27e-06	0.000945	0.25	0.21	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
HNSC	cis	rs11976180	1	rs1533268	ENSG00000273234.1	OR2A13P	-4.65	4.27e-06	0.000945	-0.23	-0.21	Obesity-related traits;	chr7:144069265	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs1533267	ENSG00000273234.1	OR2A13P	-4.65	4.27e-06	0.000945	-0.23	-0.21	Obesity-related traits;	chr7:144069347	chr7:144142009~144142938:+
HNSC	cis	rs7726839	0.578	rs10080150	ENSG00000271781.1	CTD-2589H19.6	4.65	4.27e-06	0.000945	0.26	0.21	Obesity-related traits;	chr5:593045	chr5:675826~676616:+
HNSC	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-4.65	4.27e-06	0.000945	-0.25	-0.21	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
HNSC	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	4.65	4.27e-06	0.000945	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
HNSC	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-4.65	4.27e-06	0.000945	-0.27	-0.21	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
HNSC	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	4.65	4.27e-06	0.000945	0.23	0.21	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
HNSC	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	4.65	4.27e-06	0.000945	0.26	0.21	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
HNSC	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	4.65	4.27e-06	0.000946	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	4.65	4.27e-06	0.000946	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	4.65	4.27e-06	0.000946	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	4.65	4.27e-06	0.000946	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	4.65	4.27e-06	0.000946	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
HNSC	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-4.65	4.28e-06	0.000946	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
HNSC	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-4.65	4.28e-06	0.000946	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-4.65	4.28e-06	0.000946	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-4.65	4.28e-06	0.000946	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
HNSC	cis	rs950776	0.667	rs57728226	ENSG00000261762.1	RP11-650L12.2	4.65	4.28e-06	0.000946	0.26	0.21	Sudden cardiac arrest;	chr15:78637008	chr15:78589123~78591276:-
HNSC	cis	rs9311676	0.656	rs11130632	ENSG00000273493.1	RP11-80H18.4	4.65	4.28e-06	0.000946	0.23	0.21	Systemic lupus erythematosus;	chr3:58383597	chr3:58329965~58330118:+
HNSC	cis	rs7819412	0.715	rs35223712	ENSG00000255310.2	AF131215.2	-4.65	4.28e-06	0.000946	-0.21	-0.21	Triglycerides;	chr8:11186417	chr8:11107788~11109726:-
HNSC	cis	rs71636778	0.57	rs12728091	ENSG00000260063.1	RP5-968P14.2	-4.65	4.28e-06	0.000946	-0.41	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26817022	chr1:26692132~26694131:-
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	4.65	4.28e-06	0.000947	0.25	0.21	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
HNSC	cis	rs860295	0.812	rs11264363	ENSG00000203761.5	MSTO2P	-4.65	4.28e-06	0.000947	-0.16	-0.21	Body mass index;	chr1:155348517	chr1:155745829~155750137:+
HNSC	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-4.65	4.28e-06	0.000947	-0.26	-0.21	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
HNSC	cis	rs9450351	0.744	rs111533912	ENSG00000203875.9	SNHG5	-4.65	4.28e-06	0.000947	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85622231	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs9450308	ENSG00000203875.9	SNHG5	-4.65	4.28e-06	0.000947	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85638820	chr6:85660950~85678736:-
HNSC	cis	rs13256369	1	rs12550458	ENSG00000173295.6	FAM86B3P	4.65	4.28e-06	0.000948	0.28	0.21	Obesity-related traits;	chr8:8710322	chr8:8228595~8244865:+
HNSC	cis	rs13256369	1	rs12545771	ENSG00000173295.6	FAM86B3P	4.65	4.28e-06	0.000948	0.28	0.21	Obesity-related traits;	chr8:8710467	chr8:8228595~8244865:+
HNSC	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	4.65	4.29e-06	0.000948	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
HNSC	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-4.65	4.29e-06	0.000948	-0.28	-0.21	Pain;	chr19:21475141	chr19:21554640~21569237:-
HNSC	cis	rs7592578	0.537	rs62180982	ENSG00000228509.4	AC006460.2	4.65	4.29e-06	0.000948	0.33	0.21	Diastolic blood pressure;	chr2:190399759	chr2:190676944~190708716:-
HNSC	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-4.65	4.29e-06	0.000949	-0.22	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	4.65	4.29e-06	0.000949	0.25	0.21	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	4.65	4.29e-06	0.000949	0.25	0.21	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
HNSC	cis	rs17818399	0.926	rs35350086	ENSG00000279254.1	RP11-536C12.1	-4.65	4.29e-06	0.000949	-0.25	-0.21	Height;	chr2:46606897	chr2:46668870~46670778:+
HNSC	cis	rs9910055	0.96	rs9911991	ENSG00000267080.4	ASB16-AS1	-4.65	4.29e-06	0.000949	-0.18	-0.21	Total body bone mineral density;	chr17:44201548	chr17:44175973~44186717:-
HNSC	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	4.65	4.3e-06	0.00095	0.21	0.21	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
HNSC	cis	rs10504130	0.666	rs7833668	ENSG00000253844.1	RP11-546K22.1	4.65	4.3e-06	0.00095	0.29	0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:51941326	chr8:51961458~52022974:+
HNSC	cis	rs3096299	0.967	rs16965692	ENSG00000261574.1	RP1-168P16.2	4.65	4.3e-06	0.00095	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89392375~89412564:-
HNSC	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.65	4.3e-06	0.00095	-0.24	-0.21	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-4.65	4.3e-06	0.00095	-0.28	-0.21	Gout;	chr7:66715944	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-4.65	4.3e-06	0.00095	-0.28	-0.21	Gout;	chr7:66721259	chr7:66880708~66882981:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-4.65	4.3e-06	0.00095	-0.28	-0.21	Gout;	chr7:66732812	chr7:66880708~66882981:+
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	4.65	4.3e-06	0.00095	0.25	0.21	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
HNSC	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	4.65	4.3e-06	0.00095	0.24	0.21	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
HNSC	cis	rs950776	0.518	rs28438420	ENSG00000261762.1	RP11-650L12.2	-4.65	4.3e-06	0.00095	-0.24	-0.21	Sudden cardiac arrest;	chr15:78543946	chr15:78589123~78591276:-
HNSC	cis	rs73198271	0.855	rs57301822	ENSG00000253893.2	FAM85B	4.65	4.3e-06	0.000951	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8167819~8226614:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	4.65	4.3e-06	0.000951	0.25	0.21	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
HNSC	cis	rs656319	0.674	rs1484639	ENSG00000269918.1	AF131215.9	4.65	4.3e-06	0.000951	0.21	0.21	Myopia (pathological);	chr8:10125714	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.701	rs4568582	ENSG00000255310.2	AF131215.2	4.65	4.31e-06	0.000951	0.2	0.21	Retinal vascular caliber;	chr8:11302986	chr8:11107788~11109726:-
HNSC	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	4.65	4.31e-06	0.000952	0.27	0.21	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	4.65	4.31e-06	0.000952	0.27	0.21	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
HNSC	cis	rs9311676	0.656	rs4681682	ENSG00000273493.1	RP11-80H18.4	-4.65	4.31e-06	0.000952	-0.24	-0.21	Systemic lupus erythematosus;	chr3:58352106	chr3:58329965~58330118:+
HNSC	cis	rs6964587	1	rs2282970	ENSG00000188693.7	CYP51A1-AS1	-4.65	4.31e-06	0.000953	-0.22	-0.21	Breast cancer;	chr7:91954967	chr7:92134604~92180725:+
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	4.65	4.31e-06	0.000953	0.25	0.21	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
HNSC	cis	rs9880211	0.898	rs73231903	ENSG00000239213.4	NCK1-AS1	4.65	4.31e-06	0.000953	0.21	0.21	Height;Body mass index;	chr3:136842783	chr3:136841726~136862054:-
HNSC	cis	rs4660214	0.666	rs1180383	ENSG00000182109.6	RP11-69E11.4	4.65	4.31e-06	0.000953	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39522280~39546187:-
HNSC	cis	rs3096299	0.967	rs2965830	ENSG00000261574.1	RP1-168P16.2	4.65	4.31e-06	0.000953	0.27	0.21	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89392375~89412564:-
HNSC	cis	rs7000734	0.958	rs11781181	ENSG00000245080.5	RP11-320N21.1	-4.65	4.31e-06	0.000953	-0.29	-0.21	Radiation response;	chr8:95110769	chr8:95066808~95073182:-
HNSC	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-4.65	4.31e-06	0.000953	-0.24	-0.21	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
HNSC	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-4.65	4.31e-06	0.000953	-0.24	-0.21	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
HNSC	cis	rs1355223	0.506	rs1509660	ENSG00000271369.1	RP11-350D17.3	-4.65	4.31e-06	0.000953	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843470	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.506	rs1509659	ENSG00000271369.1	RP11-350D17.3	-4.65	4.31e-06	0.000953	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843586	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.506	rs11032894	ENSG00000271369.1	RP11-350D17.3	-4.65	4.31e-06	0.000953	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843997	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.506	rs7947848	ENSG00000271369.1	RP11-350D17.3	-4.65	4.31e-06	0.000953	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34844673	chr11:34709600~34710161:+
HNSC	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	4.65	4.31e-06	0.000953	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
HNSC	cis	rs7515577	0.533	rs12757307	ENSG00000223787.2	RP4-593M8.1	4.65	4.32e-06	0.000953	0.49	0.21	Cholesterol, total;	chr1:92934792	chr1:92580476~92580821:-
HNSC	cis	rs988913	0.706	rs10948870	ENSG00000224984.1	RP11-524H19.2	4.65	4.32e-06	0.000953	0.25	0.21	Menarche (age at onset);	chr6:54880300	chr6:54840118~54840855:-
HNSC	cis	rs4713118	0.525	rs9357042	ENSG00000219392.1	RP1-265C24.5	-4.65	4.32e-06	0.000954	-0.24	-0.21	Parkinson's disease;	chr6:27615016	chr6:28115628~28116551:+
HNSC	cis	rs79349575	0.783	rs903567	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48902956	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62075818	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48904965	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs9912829	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48905387	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62075820	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48905809	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4294857	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48906029	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs61576918	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48908231	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.729	rs62075824	ENSG00000270781.1	RP11-501C14.9	-4.65	4.32e-06	0.000954	-0.22	-0.21	Type 2 diabetes;	chr17:48909317	chr17:48899131~48899748:+
HNSC	cis	rs8031584	1	rs8031584	ENSG00000260382.1	RP11-540B6.2	4.65	4.32e-06	0.000955	0.27	0.21	Huntington's disease progression;	chr15:30995140	chr15:30882267~30883231:-
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-4.65	4.33e-06	0.000955	-0.23	-0.21	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
HNSC	cis	rs4372836	0.964	rs4665432	ENSG00000226833.4	AC097724.3	-4.65	4.33e-06	0.000955	-0.26	-0.21	Body mass index;	chr2:28729160	chr2:28708953~28736205:-
HNSC	cis	rs4372836	1	rs11688129	ENSG00000226833.4	AC097724.3	-4.65	4.33e-06	0.000955	-0.26	-0.21	Body mass index;	chr2:28729715	chr2:28708953~28736205:-
HNSC	cis	rs4372836	1	rs4549034	ENSG00000226833.4	AC097724.3	4.65	4.33e-06	0.000955	0.26	0.21	Body mass index;	chr2:28749713	chr2:28708953~28736205:-
HNSC	cis	rs4372836	1	rs4372836	ENSG00000226833.4	AC097724.3	4.65	4.33e-06	0.000955	0.26	0.21	Body mass index;	chr2:28751017	chr2:28708953~28736205:-
HNSC	cis	rs597539	0.652	rs667989	ENSG00000255741.1	RP11-757G1.5	-4.65	4.33e-06	0.000956	-0.3	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68941503~68942852:-
HNSC	cis	rs7746199	0.736	rs13195636	ENSG00000219392.1	RP1-265C24.5	-4.65	4.33e-06	0.000956	-0.42	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28115628~28116551:+
HNSC	cis	rs12935418	0.616	rs56299740	ENSG00000261061.1	RP11-303E16.2	-4.65	4.33e-06	0.000957	-0.28	-0.21	Mean corpuscular volume;	chr16:80930272	chr16:81030770~81031485:+
HNSC	cis	rs5758659	1	rs5751255	ENSG00000182057.4	OGFRP1	4.65	4.33e-06	0.000957	0.21	0.21	Cognitive function;	chr22:42252402	chr22:42269753~42275196:+
HNSC	cis	rs1971762	0.583	rs12319789	ENSG00000270175.1	RP11-793H13.11	-4.65	4.34e-06	0.000957	-0.18	-0.21	Height;	chr12:53696666	chr12:53500162~53500936:-
HNSC	cis	rs10266483	0.545	rs12540100	ENSG00000228653.2	HNRNPCP7	-4.65	4.34e-06	0.000957	-0.26	-0.21	Response to statin therapy;	chr7:64289924	chr7:64500825~64501729:+
HNSC	cis	rs116095464	0.558	rs7708182	ENSG00000250848.1	CTD-2083E4.5	-4.65	4.34e-06	0.000957	-0.29	-0.21	Breast cancer;	chr5:234673	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10058428	ENSG00000250848.1	CTD-2083E4.5	-4.65	4.34e-06	0.000957	-0.29	-0.21	Breast cancer;	chr5:235493	chr5:288833~290321:-
HNSC	cis	rs6693567	0.565	rs11205373	ENSG00000228126.1	FALEC	4.65	4.34e-06	0.000957	0.25	0.21	Migraine;	chr1:150432232	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.565	rs4926395	ENSG00000228126.1	FALEC	4.65	4.34e-06	0.000957	0.25	0.21	Migraine;	chr1:150432822	chr1:150515757~150518032:+
HNSC	cis	rs7621025	0.586	rs12330725	ENSG00000239213.4	NCK1-AS1	-4.65	4.34e-06	0.000957	-0.19	-0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136841726~136862054:-
HNSC	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	4.65	4.34e-06	0.000957	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
HNSC	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-4.65	4.34e-06	0.000957	-0.37	-0.21	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
HNSC	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	4.65	4.34e-06	0.000958	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
HNSC	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-4.65	4.34e-06	0.000958	-0.28	-0.21	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
HNSC	cis	rs4853525	0.522	rs10490538	ENSG00000235852.1	AC005540.3	-4.65	4.35e-06	0.000959	-0.26	-0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190725340	chr2:190880797~190882059:-
HNSC	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-4.65	4.35e-06	0.000959	-0.28	-0.21	Pain;	chr19:21568988	chr19:21554640~21569237:-
HNSC	cis	rs1479119	0.621	rs1479115	ENSG00000180861.8	LINC01559	4.65	4.35e-06	0.000959	0.27	0.21	Intelligence (multi-trait analysis);	chr12:13347541	chr12:13371089~13387167:-
HNSC	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	4.65	4.35e-06	0.000959	0.24	0.21	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
HNSC	cis	rs1355223	0.583	rs2116085	ENSG00000271369.1	RP11-350D17.3	4.65	4.35e-06	0.00096	0.25	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34862454	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.583	rs2915238	ENSG00000271369.1	RP11-350D17.3	4.65	4.35e-06	0.00096	0.25	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34862858	chr11:34709600~34710161:+
HNSC	cis	rs1185460	1	rs1185460	ENSG00000272186.1	RP11-110I1.13	4.65	4.35e-06	0.00096	0.24	0.21	Coronary artery disease;	chr11:119072723	chr11:119067374~119067698:-
HNSC	cis	rs11976180	1	rs2371247	ENSG00000273234.1	OR2A13P	-4.65	4.35e-06	0.00096	-0.23	-0.21	Obesity-related traits;	chr7:144067086	chr7:144142009~144142938:+
HNSC	cis	rs9311676	0.656	rs6800514	ENSG00000273493.1	RP11-80H18.4	4.65	4.36e-06	0.00096	0.23	0.21	Systemic lupus erythematosus;	chr3:58372990	chr3:58329965~58330118:+
HNSC	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	4.65	4.36e-06	0.00096	0.24	0.21	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
HNSC	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-4.65	4.36e-06	0.000961	-0.24	-0.21	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
HNSC	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-4.65	4.36e-06	0.000961	-0.21	-0.21	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
HNSC	cis	rs9863	0.896	rs2130382	ENSG00000269938.1	RP11-214K3.20	-4.65	4.36e-06	0.000961	-0.26	-0.21	White blood cell count;	chr12:124000096	chr12:123968023~123968579:-
HNSC	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-4.65	4.36e-06	0.000961	-0.3	-0.21	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-4.65	4.36e-06	0.000961	-0.3	-0.21	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
HNSC	cis	rs4372836	1	rs34409160	ENSG00000226833.4	AC097724.3	-4.65	4.36e-06	0.000961	-0.27	-0.21	Body mass index;	chr2:28720999	chr2:28708953~28736205:-
HNSC	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	4.65	4.36e-06	0.000961	0.33	0.21	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
HNSC	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-4.65	4.36e-06	0.000962	-0.26	-0.21	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
HNSC	cis	rs11673344	0.503	rs703531	ENSG00000276846.1	CTD-3220F14.3	4.65	4.36e-06	0.000962	0.23	0.21	Obesity-related traits;	chr19:37010050	chr19:37314868~37315620:-
HNSC	cis	rs4718428	1	rs4718421	ENSG00000273142.1	RP11-458F8.4	-4.65	4.36e-06	0.000962	-0.19	-0.21	Corneal structure;	chr7:66885313	chr7:66902857~66906297:+
HNSC	cis	rs11893307	0.537	rs57780226	ENSG00000228509.4	AC006460.2	4.65	4.36e-06	0.000962	0.27	0.21	Mean platelet volume;	chr2:190683139	chr2:190676944~190708716:-
HNSC	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	4.65	4.36e-06	0.000962	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
HNSC	cis	rs1008375	0.646	rs13145480	ENSG00000249502.1	AC006160.5	4.65	4.36e-06	0.000962	0.23	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17563520	chr4:17587467~17614571:-
HNSC	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	4.65	4.37e-06	0.000963	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	4.65	4.37e-06	0.000963	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
HNSC	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	4.65	4.37e-06	0.000964	0.27	0.21	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
HNSC	cis	rs4256159	1	rs11711121	ENSG00000228956.7	SATB1-AS1	4.65	4.37e-06	0.000964	0.36	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18737557	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs57630709	ENSG00000228956.7	SATB1-AS1	4.65	4.37e-06	0.000964	0.36	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18739046	chr3:18445024~18920401:+
HNSC	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-4.65	4.38e-06	0.000965	-0.28	-0.21	Pain;	chr19:21528400	chr19:21554640~21569237:-
HNSC	cis	rs10435719	0.647	rs10092605	ENSG00000255495.1	AC145124.2	4.65	4.38e-06	0.000965	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:12194467~12196280:+
HNSC	cis	rs913655	0.545	rs2493619	ENSG00000225527.1	RP11-383B4.4	-4.65	4.38e-06	0.000965	-0.26	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18777926	chr10:18531849~18533336:-
HNSC	cis	rs6831352	0.918	rs1042364	ENSG00000263923.1	RP11-571L19.7	-4.65	4.38e-06	0.000965	-0.23	-0.21	Alcohol dependence;	chr4:99124423	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs2602894	ENSG00000263923.1	RP11-571L19.7	-4.65	4.38e-06	0.000965	-0.23	-0.21	Alcohol dependence;	chr4:99124496	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs2602895	ENSG00000263923.1	RP11-571L19.7	-4.65	4.38e-06	0.000965	-0.23	-0.21	Alcohol dependence;	chr4:99124689	chr4:98928897~98994994:+
HNSC	cis	rs4664293	0.625	rs10460300	ENSG00000226266.5	AC009961.3	4.65	4.38e-06	0.000965	0.22	0.21	Monocyte percentage of white cells;	chr2:159778210	chr2:159670708~159712435:-
HNSC	cis	rs75422866	0.85	rs73111226	ENSG00000280054.1	RP1-197B17.7	4.65	4.38e-06	0.000966	0.57	0.21	Pneumonia;	chr12:47582204	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.702	rs12426387	ENSG00000280054.1	RP1-197B17.7	4.65	4.38e-06	0.000966	0.57	0.21	Pneumonia;	chr12:47582915	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.85	rs12423789	ENSG00000280054.1	RP1-197B17.7	4.65	4.38e-06	0.000966	0.57	0.21	Pneumonia;	chr12:47583112	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.702	rs73111229	ENSG00000280054.1	RP1-197B17.7	4.65	4.38e-06	0.000966	0.57	0.21	Pneumonia;	chr12:47583333	chr12:47728151~47730598:-
HNSC	cis	rs7824557	0.843	rs2736375	ENSG00000269918.1	AF131215.9	-4.65	4.39e-06	0.000966	-0.21	-0.21	Retinal vascular caliber;	chr8:11258240	chr8:11104691~11106704:-
HNSC	cis	rs2276314	0.512	rs4393644	ENSG00000278986.1	RP11-723J4.3	-4.65	4.39e-06	0.000967	-0.24	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:35878684	chr18:35972151~35973916:+
HNSC	cis	rs17818399	0.749	rs4142759	ENSG00000279254.1	RP11-536C12.1	-4.65	4.39e-06	0.000967	-0.26	-0.21	Height;	chr2:46556751	chr2:46668870~46670778:+
HNSC	cis	rs3736485	0.966	rs8042840	ENSG00000259438.1	CTD-2650P22.1	4.65	4.39e-06	0.000967	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616301	chr15:52010999~52019095:-
HNSC	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	4.65	4.39e-06	0.000968	0.25	0.21	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
HNSC	cis	rs11976180	1	rs2951353	ENSG00000273234.1	OR2A13P	-4.65	4.39e-06	0.000968	-0.23	-0.21	Obesity-related traits;	chr7:144064023	chr7:144142009~144142938:+
HNSC	cis	rs950169	0.58	rs11634320	ENSG00000229212.6	RP11-561C5.4	4.65	4.39e-06	0.000968	0.3	0.21	Schizophrenia;	chr15:84628952	chr15:85205440~85234795:-
HNSC	cis	rs933688	1	rs2052553	ENSG00000281357.1	ARRDC3-AS1	4.65	4.39e-06	0.000968	0.3	0.21	Smoking behavior;	chr5:91434089	chr5:91380349~91439085:+
HNSC	cis	rs7735319	0.834	rs9687791	ENSG00000249102.1	CTD-2066L21.1	4.65	4.39e-06	0.000968	0.25	0.21	Systolic blood pressure;	chr5:33072758	chr5:33008994~33025724:+
HNSC	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.65	4.4e-06	0.000969	0.23	0.21	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
HNSC	cis	rs2998286	0.723	rs332152	ENSG00000254635.4	WAC-AS1	-4.65	4.4e-06	0.000969	-0.29	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28522652~28532743:-
HNSC	cis	rs3736485	0.932	rs11633395	ENSG00000259438.1	CTD-2650P22.1	4.65	4.41e-06	0.00097	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51625760	chr15:52010999~52019095:-
HNSC	cis	rs4908769	0.588	rs2784737	ENSG00000232912.4	RP5-1115A15.1	-4.65	4.41e-06	0.00097	-0.24	-0.21	Allergy;	chr1:8403116	chr1:8424645~8434838:+
HNSC	cis	rs853679	0.556	rs13200214	ENSG00000219392.1	RP1-265C24.5	-4.65	4.41e-06	0.00097	-0.43	-0.21	Depression;	chr6:28049472	chr6:28115628~28116551:+
HNSC	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	4.65	4.41e-06	0.00097	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
HNSC	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-4.65	4.41e-06	0.00097	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
HNSC	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	4.65	4.41e-06	0.000971	0.25	0.21	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
HNSC	cis	rs2998286	0.815	rs332132	ENSG00000254635.4	WAC-AS1	-4.65	4.41e-06	0.000971	-0.29	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28565185	chr10:28522652~28532743:-
HNSC	cis	rs1642645	0.872	rs642112	ENSG00000228452.1	RP5-994D16.9	-4.65	4.41e-06	0.000971	-0.29	-0.21	Left ventricular obstructive tract defect (maternal effect);	chr1:41987646	chr1:42775813~42776790:-
HNSC	cis	rs597539	0.652	rs516425	ENSG00000255741.1	RP11-757G1.5	-4.65	4.41e-06	0.000971	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68941503~68942852:-
HNSC	cis	rs11673344	0.542	rs826324	ENSG00000276846.1	CTD-3220F14.3	4.65	4.41e-06	0.000971	0.23	0.21	Obesity-related traits;	chr19:37014343	chr19:37314868~37315620:-
HNSC	cis	rs3736485	0.868	rs2124592	ENSG00000259438.1	CTD-2650P22.1	4.65	4.41e-06	0.000971	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51630782	chr15:52010999~52019095:-
HNSC	cis	rs925255	0.901	rs906805	ENSG00000270210.1	RP11-373D23.3	4.65	4.41e-06	0.000972	0.23	0.21	Inflammatory bowel disease;Crohn's disease;	chr2:28382012	chr2:28425945~28426719:+
HNSC	cis	rs3015497	0.624	rs2934700	ENSG00000269906.1	RP11-248J18.2	-4.65	4.41e-06	0.000972	-0.28	-0.21	Mean platelet volume;	chr14:50668459	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.624	rs3015486	ENSG00000269906.1	RP11-248J18.2	-4.65	4.41e-06	0.000972	-0.28	-0.21	Mean platelet volume;	chr14:50668612	chr14:50662511~50663178:-
HNSC	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	4.65	4.41e-06	0.000972	0.31	0.21	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
HNSC	cis	rs3738443	0.599	rs6693807	ENSG00000259865.1	RP11-488L18.10	-4.65	4.41e-06	0.000972	-0.17	-0.21	Alcohol dependence;	chr1:247230353	chr1:247187281~247188526:-
HNSC	cis	rs10504130	1	rs16916961	ENSG00000272024.1	RP11-546K22.3	-4.65	4.42e-06	0.000972	-0.35	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:51918618	chr8:51950284~51950690:+
HNSC	cis	rs3096299	0.9	rs4785663	ENSG00000261574.1	RP1-168P16.2	4.65	4.42e-06	0.000973	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89392375~89412564:-
HNSC	cis	rs17253792	0.822	rs11546	ENSG00000186615.9	KTN1-AS1	-4.65	4.42e-06	0.000973	-0.39	-0.21	Putamen volume;	chr14:55679639	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10148122	ENSG00000186615.9	KTN1-AS1	-4.65	4.42e-06	0.000973	-0.39	-0.21	Putamen volume;	chr14:55679976	chr14:55499278~55580110:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	4.65	4.42e-06	0.000973	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	4.65	4.42e-06	0.000973	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
HNSC	cis	rs7735319	0.834	rs13184103	ENSG00000251281.1	CTD-2066L21.2	4.65	4.42e-06	0.000973	0.26	0.21	Systolic blood pressure;	chr5:33061918	chr5:33011322~33017607:-
HNSC	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-4.65	4.42e-06	0.000974	-0.24	-0.21	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	4.65	4.42e-06	0.000974	0.24	0.21	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	4.65	4.42e-06	0.000974	0.24	0.21	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	4.65	4.42e-06	0.000974	0.24	0.21	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
HNSC	cis	rs638893	1	rs649338	ENSG00000255422.1	AP002954.4	-4.65	4.42e-06	0.000974	-0.34	-0.21	Vitiligo;	chr11:118834945	chr11:118704607~118750263:+
HNSC	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	4.65	4.43e-06	0.000974	0.17	0.21	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
HNSC	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	4.65	4.43e-06	0.000974	0.17	0.21	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
HNSC	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	4.65	4.43e-06	0.000974	0.17	0.21	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
HNSC	cis	rs860295	0.665	rs11264393	ENSG00000203761.5	MSTO2P	-4.65	4.43e-06	0.000974	-0.16	-0.21	Body mass index;	chr1:155604680	chr1:155745829~155750137:+
HNSC	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-4.64	4.43e-06	0.000975	-0.26	-0.21	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
HNSC	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	4.64	4.43e-06	0.000975	0.2	0.21	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
HNSC	cis	rs4841134	0.729	rs4840406	ENSG00000233609.3	RP11-62H7.2	-4.64	4.43e-06	0.000975	-0.2	-0.21	Age-related disease endophenotypes;	chr8:9357041	chr8:8961200~8979025:+
HNSC	cis	rs1223397	1	rs1223399	ENSG00000215022.6	RP1-257A7.4	-4.64	4.43e-06	0.000975	-0.26	-0.21	Blood pressure;	chr6:13270988	chr6:13264861~13295586:-
HNSC	cis	rs7586673	0.725	rs6715870	ENSG00000227403.1	AC009299.3	-4.64	4.43e-06	0.000975	-0.3	-0.21	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161244739~161249050:+
HNSC	cis	rs1971762	0.545	rs4759280	ENSG00000270175.1	RP11-793H13.11	-4.64	4.43e-06	0.000975	-0.19	-0.21	Height;	chr12:53671174	chr12:53500162~53500936:-
HNSC	cis	rs1913185	0.891	rs67325724	ENSG00000240032.1	RP11-274H2.3	-4.64	4.43e-06	0.000975	-0.39	-0.21	Obesity-related traits;	chr3:146156940	chr3:146066344~146069185:-
HNSC	cis	rs3743266	0.593	rs4775276	ENSG00000245534.5	RORA-AS1	-4.64	4.44e-06	0.000976	-0.27	-0.21	Menarche (age at onset);	chr15:60513986	chr15:60479178~60630637:+
HNSC	cis	rs4326844	0.845	rs11559982	ENSG00000248265.1	FLJ12825	4.64	4.44e-06	0.000976	0.24	0.21	Platelet count;	chr12:54317790	chr12:54058254~54122234:+
HNSC	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	4.64	4.44e-06	0.000976	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000254340.1	RP11-10A14.3	-4.64	4.44e-06	0.000976	-0.26	-0.21	Mood instability;	chr8:8687362	chr8:9141424~9145435:+
HNSC	cis	rs4253772	0.53	rs9627387	ENSG00000277232.2	GTSE1-AS1	-4.64	4.44e-06	0.000976	-0.26	-0.21	Cholesterol, total;LDL cholesterol;	chr22:46288781	chr22:46295143~46296660:-
HNSC	cis	rs2439831	1	rs2253708	ENSG00000205771.5	CATSPER2P1	-4.64	4.44e-06	0.000977	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43505075	chr15:43726918~43747094:-
HNSC	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	4.64	4.44e-06	0.000977	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	4.64	4.44e-06	0.000977	0.25	0.21	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	4.64	4.44e-06	0.000977	0.25	0.21	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
HNSC	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	4.64	4.44e-06	0.000977	0.32	0.21	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
HNSC	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	4.64	4.45e-06	0.000978	0.21	0.21	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
HNSC	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-4.64	4.45e-06	0.000979	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
HNSC	cis	rs172166	0.585	rs149963	ENSG00000219392.1	RP1-265C24.5	-4.64	4.45e-06	0.000979	-0.24	-0.21	Cardiac Troponin-T levels;	chr6:28049354	chr6:28115628~28116551:+
HNSC	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-4.64	4.45e-06	0.00098	-0.27	-0.21	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
HNSC	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	4.64	4.45e-06	0.00098	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
HNSC	cis	rs13256369	0.901	rs12679831	ENSG00000173295.6	FAM86B3P	4.64	4.46e-06	0.00098	0.28	0.21	Obesity-related traits;	chr8:8708901	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.901	rs12681327	ENSG00000173295.6	FAM86B3P	4.64	4.46e-06	0.00098	0.28	0.21	Obesity-related traits;	chr8:8708904	chr8:8228595~8244865:+
HNSC	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	4.64	4.46e-06	0.00098	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
HNSC	cis	rs3015497	0.646	rs871643	ENSG00000269906.1	RP11-248J18.2	-4.64	4.46e-06	0.00098	-0.28	-0.21	Mean platelet volume;	chr14:50640734	chr14:50662511~50663178:-
HNSC	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-4.64	4.46e-06	0.00098	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
HNSC	cis	rs2929451	0.566	rs17658270	ENSG00000254340.1	RP11-10A14.3	4.64	4.46e-06	0.000981	0.27	0.21	Nose size;	chr8:9296109	chr8:9141424~9145435:+
HNSC	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	4.64	4.46e-06	0.000981	0.27	0.21	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
HNSC	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	4.64	4.46e-06	0.000981	0.22	0.21	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-4.64	4.46e-06	0.000981	-0.22	-0.21	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
HNSC	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	4.64	4.47e-06	0.000982	0.28	0.21	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	4.64	4.47e-06	0.000982	0.28	0.21	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
HNSC	cis	rs898123	0.931	rs12476801	ENSG00000234896.1	OR7E62P	4.64	4.47e-06	0.000982	0.25	0.21	Coronary artery disease;	chr2:71143092	chr2:71055527~71056003:+
HNSC	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-4.64	4.47e-06	0.000983	-0.28	-0.21	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
HNSC	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-4.64	4.48e-06	0.000984	-0.18	-0.21	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
HNSC	cis	rs7973683	0.541	rs7976319	ENSG00000269938.1	RP11-214K3.20	-4.64	4.48e-06	0.000984	-0.24	-0.21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123903964	chr12:123968023~123968579:-
HNSC	cis	rs9393777	0.844	rs72839477	ENSG00000219392.1	RP1-265C24.5	-4.64	4.48e-06	0.000984	-0.43	-0.21	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28115628~28116551:+
HNSC	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-4.64	4.48e-06	0.000985	-0.27	-0.21	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
HNSC	cis	rs9311676	0.632	rs7624283	ENSG00000273493.1	RP11-80H18.4	4.64	4.48e-06	0.000985	0.23	0.21	Systemic lupus erythematosus;	chr3:58384170	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs7647078	ENSG00000273493.1	RP11-80H18.4	4.64	4.48e-06	0.000985	0.23	0.21	Systemic lupus erythematosus;	chr3:58384185	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs7647184	ENSG00000273493.1	RP11-80H18.4	4.64	4.48e-06	0.000985	0.23	0.21	Systemic lupus erythematosus;	chr3:58384319	chr3:58329965~58330118:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	4.64	4.48e-06	0.000985	0.25	0.21	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
HNSC	cis	rs5758511	0.679	rs55867855	ENSG00000226450.2	CYP2D8P	4.64	4.48e-06	0.000985	0.21	0.21	Birth weight;	chr22:42227252	chr22:42149886~42155001:-
HNSC	cis	rs6928977	0.896	rs2614284	ENSG00000217482.2	HMGB1P17	-4.64	4.48e-06	0.000985	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135636086~135636713:-
HNSC	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-4.64	4.48e-06	0.000985	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
HNSC	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	4.64	4.49e-06	0.000986	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	4.64	4.49e-06	0.000986	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
HNSC	cis	rs7735319	0.834	rs34976989	ENSG00000251281.1	CTD-2066L21.2	4.64	4.49e-06	0.000987	0.26	0.21	Systolic blood pressure;	chr5:33070636	chr5:33011322~33017607:-
HNSC	cis	rs8035957	0.963	rs11631591	ENSG00000259747.1	RP11-275I4.2	-4.64	4.49e-06	0.000987	-0.23	-0.21	Type 1 diabetes;	chr15:38558061	chr15:38671847~38689191:+
HNSC	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	4.64	4.5e-06	0.000988	0.23	0.21	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
HNSC	cis	rs4218	0.569	rs73418864	ENSG00000277144.1	RP11-59H7.4	-4.64	4.5e-06	0.000989	-0.28	-0.21	Social communication problems;	chr15:59098996	chr15:59115547~59116089:-
HNSC	cis	rs6964587	1	rs756647	ENSG00000188693.7	CYP51A1-AS1	-4.64	4.5e-06	0.000989	-0.22	-0.21	Breast cancer;	chr7:91957075	chr7:92134604~92180725:+
HNSC	cis	rs62246343	0.605	rs17050395	ENSG00000206573.7	THUMPD3-AS1	-4.64	4.5e-06	0.000989	-0.17	-0.21	Fibrinogen levels;	chr3:9492290	chr3:9349689~9398579:-
HNSC	cis	rs17818399	0.926	rs13033177	ENSG00000279254.1	RP11-536C12.1	-4.64	4.51e-06	0.000989	-0.25	-0.21	Height;	chr2:46603923	chr2:46668870~46670778:+
HNSC	cis	rs73201462	1	rs2955083	ENSG00000231305.3	RP11-723O4.2	4.64	4.51e-06	0.00099	0.31	0.21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242335	chr3:128861313~128871540:-
HNSC	cis	rs73222236	0.825	rs34962604	ENSG00000273486.1	RP11-731C17.2	4.64	4.51e-06	0.00099	0.17	0.21	Coronary artery disease;	chr3:136511148	chr3:136837338~136839021:-
HNSC	cis	rs4218	0.701	rs56375269	ENSG00000277144.1	RP11-59H7.4	-4.64	4.51e-06	0.00099	-0.27	-0.21	Social communication problems;	chr15:59137741	chr15:59115547~59116089:-
HNSC	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	4.64	4.51e-06	0.00099	0.24	0.21	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	4.64	4.51e-06	0.00099	0.24	0.21	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	4.64	4.51e-06	0.00099	0.24	0.21	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
HNSC	cis	rs1557765	0.527	rs2018218	ENSG00000260196.1	RP1-239B22.5	4.64	4.51e-06	0.00099	0.22	0.21	Body mass index;Social communication problems;	chr11:17369308	chr11:17380649~17383531:+
HNSC	cis	rs9813712	0.571	rs9866568	ENSG00000228252.7	COL6A4P2	-4.64	4.51e-06	0.000991	-0.21	-0.21	Response to amphetamines;	chr3:130297539	chr3:130212823~130273806:+
HNSC	cis	rs4295623	0.556	rs10903343	ENSG00000269918.1	AF131215.9	4.64	4.51e-06	0.000991	0.21	0.21	Morning vs. evening chronotype;	chr8:11838363	chr8:11104691~11106704:-
HNSC	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	4.64	4.51e-06	0.000991	0.31	0.21	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
HNSC	cis	rs7809950	0.678	rs17154040	ENSG00000238832.1	snoU109	4.64	4.51e-06	0.000991	0.29	0.21	Coronary artery disease;	chr7:107364801	chr7:107603363~107603507:+
HNSC	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	4.64	4.51e-06	0.000991	0.3	0.21	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
HNSC	cis	rs6601327	0.641	rs7461939	ENSG00000233609.3	RP11-62H7.2	-4.64	4.52e-06	0.000991	-0.2	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:8961200~8979025:+
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000267151.3	RP11-100E5.2	4.64	4.52e-06	0.000992	0.3	0.21	Menopause (age at onset);	chr17:43064188	chr17:43444707~43451200:+
HNSC	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	4.64	4.52e-06	0.000992	0.2	0.21	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
HNSC	cis	rs964611	0.882	rs6493319	ENSG00000259488.2	RP11-154J22.1	-4.64	4.52e-06	0.000992	-0.18	-0.21	Metabolite levels (Pyroglutamine);	chr15:48276071	chr15:48312353~48331856:-
HNSC	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-4.64	4.52e-06	0.000992	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
HNSC	cis	rs9880211	0.718	rs35320690	ENSG00000273486.1	RP11-731C17.2	-4.64	4.52e-06	0.000992	-0.18	-0.21	Height;Body mass index;	chr3:136213652	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000254153.1	CTA-398F10.2	4.64	4.52e-06	0.000992	0.23	0.21	Mood instability;	chr8:8846820	chr8:8456909~8461337:-
HNSC	cis	rs9611565	0.921	rs4822021	ENSG00000235513.1	RP4-756G23.5	4.64	4.52e-06	0.000993	0.23	0.21	Vitiligo;	chr22:41330049	chr22:41209122~41217627:-
HNSC	cis	rs12935418	0.552	rs2549838	ENSG00000261061.1	RP11-303E16.2	4.64	4.52e-06	0.000993	0.22	0.21	Mean corpuscular volume;	chr16:80989605	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549839	ENSG00000261061.1	RP11-303E16.2	4.64	4.52e-06	0.000993	0.22	0.21	Mean corpuscular volume;	chr16:80989630	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549843	ENSG00000261061.1	RP11-303E16.2	4.64	4.52e-06	0.000993	0.22	0.21	Mean corpuscular volume;	chr16:80990140	chr16:81030770~81031485:+
HNSC	cis	rs73198271	0.92	rs11781542	ENSG00000253893.2	FAM85B	4.64	4.53e-06	0.000993	0.3	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8759671	chr8:8167819~8226614:-
HNSC	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	4.64	4.53e-06	0.000994	0.21	0.21	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
HNSC	cis	rs6964587	0.967	rs7801058	ENSG00000188693.7	CYP51A1-AS1	-4.64	4.53e-06	0.000994	-0.22	-0.21	Breast cancer;	chr7:92155067	chr7:92134604~92180725:+
HNSC	cis	rs1050631	1	rs1050631	ENSG00000278986.1	RP11-723J4.3	-4.64	4.53e-06	0.000994	-0.24	-0.21	Esophageal squamous cell cancer (length of survival);	chr18:36114157	chr18:35972151~35973916:+
HNSC	cis	rs939574	1	rs1024131	ENSG00000243910.6	TUBA4B	4.64	4.53e-06	0.000994	0.43	0.21	Platelet distribution width;	chr2:219252736	chr2:219253243~219272188:+
HNSC	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	4.64	4.53e-06	0.000994	0.26	0.21	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
HNSC	cis	rs889398	0.741	rs3790075	ENSG00000226232.7	RP11-419C5.2	-4.64	4.53e-06	0.000995	-0.19	-0.21	Body mass index;	chr16:69873908	chr16:69976388~69996188:-
HNSC	cis	rs889398	0.741	rs7190013	ENSG00000226232.7	RP11-419C5.2	-4.64	4.53e-06	0.000995	-0.19	-0.21	Body mass index;	chr16:69874345	chr16:69976388~69996188:-
HNSC	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	4.64	4.53e-06	0.000995	0.29	0.21	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
HNSC	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	4.64	4.54e-06	0.000996	0.22	0.21	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
HNSC	cis	rs1479119	0.681	rs11055378	ENSG00000180861.8	LINC01559	4.64	4.54e-06	0.000996	0.27	0.21	Intelligence (multi-trait analysis);	chr12:13348295	chr12:13371089~13387167:-
HNSC	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-4.64	4.54e-06	0.000996	-0.19	-0.21	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
HNSC	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	4.64	4.54e-06	0.000996	0.43	0.21	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000254340.1	RP11-10A14.3	-4.64	4.54e-06	0.000996	-0.26	-0.21	Mood instability;	chr8:8523020	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	4.64	4.54e-06	0.000996	0.26	0.21	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
HNSC	cis	rs1008375	1	rs2872958	ENSG00000249502.1	AC006160.5	-4.64	4.54e-06	0.000996	-0.23	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663409	chr4:17587467~17614571:-
HNSC	cis	rs6928977	0.863	rs2179780	ENSG00000217482.2	HMGB1P17	-4.64	4.54e-06	0.000996	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135329128	chr6:135636086~135636713:-
HNSC	cis	rs41307935	0.818	rs71636779	ENSG00000260063.1	RP5-968P14.2	-4.64	4.54e-06	0.000996	-0.41	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26787521	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.915	rs57189461	ENSG00000260063.1	RP5-968P14.2	-4.64	4.54e-06	0.000996	-0.41	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26798054	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12748152	ENSG00000260063.1	RP5-968P14.2	-4.64	4.54e-06	0.000996	-0.41	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26811902	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71636783	ENSG00000260063.1	RP5-968P14.2	-4.64	4.54e-06	0.000996	-0.41	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813370	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.73	rs34716450	ENSG00000260063.1	RP5-968P14.2	-4.64	4.54e-06	0.000996	-0.41	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26817084	chr1:26692132~26694131:-
HNSC	cis	rs1913185	0.837	rs67154251	ENSG00000240032.1	RP11-274H2.3	-4.64	4.54e-06	0.000997	-0.39	-0.21	Obesity-related traits;	chr3:146157193	chr3:146066344~146069185:-
HNSC	cis	rs12935418	0.616	rs2549857	ENSG00000278985.1	RP11-303E16.9	4.64	4.54e-06	0.000997	0.2	0.21	Mean corpuscular volume;	chr16:80993353	chr16:80982319~80984094:-
HNSC	cis	rs2292864	0.764	rs35265764	ENSG00000228782.6	CTD-2026D20.3	-4.64	4.54e-06	0.000997	-0.32	-0.21	Left atrial antero-posterior diameter;	chr17:47286180	chr17:47450568~47492492:-
HNSC	cis	rs933688	1	rs6866191	ENSG00000281357.1	ARRDC3-AS1	4.64	4.55e-06	0.000997	0.31	0.21	Smoking behavior;	chr5:91451035	chr5:91380349~91439085:+
HNSC	cis	rs4873772	0.802	rs4873619	ENSG00000253330.1	RP11-697N18.3	-4.64	4.55e-06	0.000997	-0.27	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47718125	chr8:47511034~47512141:-
HNSC	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-4.64	4.55e-06	0.000998	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
HNSC	cis	rs9291683	1	rs9291683	ENSG00000250413.1	RP11-448G15.1	-4.64	4.55e-06	0.000998	-0.26	-0.21	Bone mineral density;	chr4:10322536	chr4:10006482~10009725:+
HNSC	cis	rs1150668	0.83	rs2531831	ENSG00000219392.1	RP1-265C24.5	-4.64	4.55e-06	0.000998	-0.23	-0.21	Pubertal anthropometrics;	chr6:28420988	chr6:28115628~28116551:+
HNSC	cis	rs17373728	0.526	rs7017326	ENSG00000249395.2	CASC9	-4.64	4.55e-06	0.000998	-0.28	-0.21	Diabetic kidney disease;	chr8:75234339	chr8:75223404~75324741:-
HNSC	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-4.64	4.55e-06	0.000998	-0.23	-0.21	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-4.64	4.55e-06	0.000998	-0.23	-0.21	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
HNSC	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	4.64	4.55e-06	0.000998	0.25	0.21	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
HNSC	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	4.64	4.55e-06	0.000998	0.24	0.21	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
HNSC	cis	rs3806843	0.966	rs10053945	ENSG00000202515.1	VTRNA1-3	-4.64	4.55e-06	0.000998	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs1548700	ENSG00000202515.1	VTRNA1-3	-4.64	4.55e-06	0.000998	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs1548699	ENSG00000202515.1	VTRNA1-3	-4.64	4.55e-06	0.000998	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs12055222	ENSG00000202515.1	VTRNA1-3	-4.64	4.55e-06	0.000998	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr5:140726158~140726246:+
HNSC	cis	rs73222236	0.787	rs6783337	ENSG00000273486.1	RP11-731C17.2	4.64	4.55e-06	0.000999	0.17	0.21	Coronary artery disease;	chr3:136333895	chr3:136837338~136839021:-
HNSC	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	4.64	4.55e-06	0.000999	0.21	0.21	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
HNSC	cis	rs1008375	0.931	rs3796814	ENSG00000249502.1	AC006160.5	-4.64	4.55e-06	0.000999	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17600410	chr4:17587467~17614571:-
HNSC	cis	rs9300255	0.679	rs4759420	ENSG00000280120.1	RP11-546D6.3	4.64	4.55e-06	0.000999	0.19	0.21	Neutrophil percentage of white cells;	chr12:123310324	chr12:123152324~123153377:-
HNSC	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-4.64	4.55e-06	0.000999	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
HNSC	cis	rs763121	0.853	rs5750627	ENSG00000273076.1	RP3-508I15.22	4.64	4.56e-06	0.000999	0.22	0.21	Menopause (age at onset);	chr22:38586316	chr22:38743495~38743910:+
HNSC	cis	rs656319	0.607	rs35437983	ENSG00000255310.2	AF131215.2	-4.64	4.56e-06	0.000999	-0.21	-0.21	Myopia (pathological);	chr8:10147543	chr8:11107788~11109726:-
HNSC	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.001	0.25	0.21	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
HNSC	cis	rs7819412	0.715	rs2409727	ENSG00000255310.2	AF131215.2	-4.64	4.56e-06	0.001	-0.21	-0.21	Triglycerides;	chr8:11185727	chr8:11107788~11109726:-
HNSC	cis	rs763121	0.853	rs2072795	ENSG00000273076.1	RP3-508I15.22	-4.64	4.56e-06	0.001	-0.22	-0.21	Menopause (age at onset);	chr22:38668204	chr22:38743495~38743910:+
HNSC	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-4.64	4.56e-06	0.001	-0.25	-0.21	Height;	chr14:75062916	chr14:75011269~75012851:-
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000224373.3	IGHV4-59	4.64	4.56e-06	0.001	0.13	0.21	Kawasaki disease;	chr14:106690675	chr14:106627249~106627825:-
HNSC	cis	rs6921919	0.778	rs67381177	ENSG00000219392.1	RP1-265C24.5	-4.64	4.57e-06	0.001	-0.44	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28115628~28116551:+
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000280411.1	IGHV1-69-2	-4.64	4.57e-06	0.001	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106696601	chr14:106762092~106762588:-
HNSC	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	4.64	4.57e-06	0.001	0.25	0.21	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
HNSC	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	4.64	4.57e-06	0.001	0.3	0.21	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
HNSC	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	4.64	4.57e-06	0.001	0.21	0.21	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
HNSC	cis	rs79349575	0.749	rs46521	ENSG00000270781.1	RP11-501C14.9	-4.64	4.57e-06	0.001	-0.22	-0.21	Type 2 diabetes;	chr17:48911167	chr17:48899131~48899748:+
HNSC	cis	rs4763879	0.634	rs11052582	ENSG00000278635.1	CTD-2318O12.1	4.64	4.57e-06	0.001	0.16	0.21	Type 1 diabetes;	chr12:9706714	chr12:9415641~9416718:+
HNSC	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-4.64	4.57e-06	0.001	-0.26	-0.21	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
HNSC	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-4.64	4.57e-06	0.001	-0.19	-0.21	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
HNSC	cis	rs4853525	0.59	rs2203715	ENSG00000235852.1	AC005540.3	4.64	4.58e-06	0.001	0.28	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944157	chr2:190880797~190882059:-
HNSC	cis	rs9863	0.861	rs10846580	ENSG00000269938.1	RP11-214K3.20	-4.64	4.58e-06	0.001	-0.24	-0.21	White blood cell count;	chr12:123930906	chr12:123968023~123968579:-
HNSC	cis	rs4873772	0.837	rs55941013	ENSG00000253330.1	RP11-697N18.3	-4.64	4.58e-06	0.001	-0.26	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47567514	chr8:47511034~47512141:-
HNSC	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	4.64	4.58e-06	0.001	0.34	0.21	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	4.64	4.58e-06	0.001	0.34	0.21	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	4.64	4.58e-06	0.001	0.34	0.21	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	4.64	4.58e-06	0.001	0.34	0.21	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
HNSC	cis	rs1799949	1	rs35668327	ENSG00000236383.6	LINC00854	-4.64	4.58e-06	0.001	-0.19	-0.21	Menopause (age at onset);	chr17:43121078	chr17:43216941~43305976:-
HNSC	cis	rs4761669	0.701	rs9668373	ENSG00000241556.1	RP11-490G8.1	4.64	4.58e-06	0.001	0.21	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94785933	chr12:95467397~95467861:-
HNSC	cis	rs17507216	0.518	rs1877240	ENSG00000255769.6	GOLGA2P10	-4.64	4.58e-06	0.001	-0.37	-0.21	Excessive daytime sleepiness;	chr15:82770126	chr15:82472993~82513950:-
HNSC	cis	rs2835345	0.511	rs2835356	ENSG00000279365.1	KB-176G8.1	4.64	4.58e-06	0.001	0.25	0.21	Pulmonary function;	chr21:36444900	chr21:36485867~36487760:+
HNSC	cis	rs116095464	0.558	rs12173244	ENSG00000250848.1	CTD-2083E4.5	-4.64	4.58e-06	0.001	-0.29	-0.21	Breast cancer;	chr5:269409	chr5:288833~290321:-
HNSC	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	4.64	4.58e-06	0.001	0.28	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
HNSC	cis	rs3806843	0.676	rs2569159	ENSG00000202515.1	VTRNA1-3	4.64	4.59e-06	0.001	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.676	rs778593	ENSG00000202515.1	VTRNA1-3	4.64	4.59e-06	0.001	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.676	rs778594	ENSG00000202515.1	VTRNA1-3	4.64	4.59e-06	0.001	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr5:140726158~140726246:+
HNSC	cis	rs9880211	1	rs9809988	ENSG00000273486.1	RP11-731C17.2	4.64	4.59e-06	0.001	0.2	0.21	Height;Body mass index;	chr3:136803379	chr3:136837338~136839021:-
HNSC	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-4.64	4.59e-06	0.00101	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-4.64	4.59e-06	0.00101	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	4.64	4.59e-06	0.00101	0.25	0.21	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
HNSC	cis	rs6142102	1	rs6059673	ENSG00000275784.1	RP5-1125A11.6	-4.64	4.59e-06	0.00101	-0.28	-0.21	Skin pigmentation;	chr20:34117755	chr20:33989480~33991818:-
HNSC	cis	rs4218	0.731	rs11539756	ENSG00000277144.1	RP11-59H7.4	-4.64	4.59e-06	0.00101	-0.29	-0.21	Social communication problems;	chr15:59136912	chr15:59115547~59116089:-
HNSC	cis	rs75422866	0.764	rs73104184	ENSG00000280054.1	RP1-197B17.7	4.64	4.59e-06	0.00101	0.53	0.21	Pneumonia;	chr12:47715623	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.764	rs73104188	ENSG00000280054.1	RP1-197B17.7	4.64	4.59e-06	0.00101	0.53	0.21	Pneumonia;	chr12:47715885	chr12:47728151~47730598:-
HNSC	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-4.64	4.6e-06	0.00101	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
HNSC	cis	rs4853525	0.651	rs1921908	ENSG00000235852.1	AC005540.3	4.64	4.6e-06	0.00101	0.27	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190870481	chr2:190880797~190882059:-
HNSC	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-4.64	4.6e-06	0.00101	-0.25	-0.21	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
HNSC	cis	rs56804039	1	rs7017341	ENSG00000173295.6	FAM86B3P	-4.64	4.6e-06	0.00101	-0.28	-0.21	Cervical cancer;	chr8:8524154	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	4.64	4.6e-06	0.00101	0.25	0.21	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
HNSC	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	4.64	4.6e-06	0.00101	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
HNSC	cis	rs3806843	1	rs991918	ENSG00000202515.1	VTRNA1-3	-4.64	4.6e-06	0.00101	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr5:140726158~140726246:+
HNSC	cis	rs75422866	0.85	rs73111231	ENSG00000280054.1	RP1-197B17.7	4.64	4.6e-06	0.00101	0.57	0.21	Pneumonia;	chr12:47584539	chr12:47728151~47730598:-
HNSC	cis	rs3806843	1	rs3756340	ENSG00000202515.1	VTRNA1-3	-4.64	4.61e-06	0.00101	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs7701755	ENSG00000202515.1	VTRNA1-3	-4.64	4.61e-06	0.00101	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr5:140726158~140726246:+
HNSC	cis	rs7246760	1	rs10419915	ENSG00000267289.1	CTD-2623N2.11	4.64	4.61e-06	0.00101	0.34	0.21	Pursuit maintenance gain;	chr19:9780281	chr19:9834079~9835013:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	4.64	4.61e-06	0.00101	0.26	0.21	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
HNSC	cis	rs72615157	0.561	rs113401658	ENSG00000078319.8	PMS2P1	-4.64	4.61e-06	0.00101	-0.28	-0.21	Lung function (FEV1/FVC);	chr7:100260882	chr7:100320992~100341908:-
HNSC	cis	rs763121	0.889	rs1043402	ENSG00000273076.1	RP3-508I15.22	4.64	4.61e-06	0.00101	0.23	0.21	Menopause (age at onset);	chr22:38483683	chr22:38743495~38743910:+
HNSC	cis	rs6993244	1	rs6993244	ENSG00000233609.3	RP11-62H7.2	4.64	4.61e-06	0.00101	0.21	0.21	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8961200~8979025:+
HNSC	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	4.64	4.61e-06	0.00101	0.26	0.21	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
HNSC	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	4.64	4.61e-06	0.00101	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
HNSC	cis	rs11976180	0.953	rs2951355	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144063469	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2951354	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144063908	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2961125	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144064677	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2961126	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144065643	chr7:144142009~144142938:+
HNSC	cis	rs11976180	0.953	rs2961127	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144065644	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs1919948	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144065750	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2961128	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144066390	chr7:144142009~144142938:+
HNSC	cis	rs11976180	1	rs2371248	ENSG00000273234.1	OR2A13P	-4.64	4.61e-06	0.00101	-0.23	-0.21	Obesity-related traits;	chr7:144067096	chr7:144142009~144142938:+
HNSC	cis	rs8058578	1	rs7198250	ENSG00000279196.1	RP11-1072A3.3	4.64	4.61e-06	0.00101	0.25	0.21	Multiple myeloma;	chr16:30735501	chr16:30984630~30988270:-
HNSC	cis	rs3806843	0.518	rs2563310	ENSG00000202515.1	VTRNA1-3	4.64	4.61e-06	0.00101	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr5:140726158~140726246:+
HNSC	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	4.64	4.61e-06	0.00101	0.17	0.21	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
HNSC	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	4.64	4.61e-06	0.00101	0.17	0.21	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
HNSC	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	4.64	4.61e-06	0.00101	0.3	0.21	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	4.64	4.61e-06	0.00101	0.3	0.21	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	4.64	4.61e-06	0.00101	0.3	0.21	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	4.64	4.61e-06	0.00101	0.3	0.21	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	4.64	4.61e-06	0.00101	0.3	0.21	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
HNSC	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	4.64	4.61e-06	0.00101	0.27	0.21	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
HNSC	cis	rs5758511	0.68	rs5758651	ENSG00000205702.9	CYP2D7	4.64	4.62e-06	0.00101	0.19	0.21	Birth weight;	chr22:42213142	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs5758652	ENSG00000205702.9	CYP2D7	4.64	4.62e-06	0.00101	0.19	0.21	Birth weight;	chr22:42216402	chr22:42140203~42144577:-
HNSC	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-4.64	4.62e-06	0.00101	-0.26	-0.21	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
HNSC	cis	rs253959	0.672	rs1133186	ENSG00000271918.1	CTD-2287O16.5	4.64	4.62e-06	0.00101	0.17	0.21	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116083807~116085416:-
HNSC	cis	rs757081	0.667	rs17561348	ENSG00000260196.1	RP1-239B22.5	4.64	4.62e-06	0.00101	0.26	0.21	Systolic blood pressure;	chr11:17140068	chr11:17380649~17383531:+
HNSC	cis	rs6831352	0.918	rs29001203	ENSG00000263923.1	RP11-571L19.7	4.64	4.62e-06	0.00101	0.22	0.21	Alcohol dependence;	chr4:99131940	chr4:98928897~98994994:+
HNSC	cis	rs453301	0.653	rs7005133	ENSG00000253981.4	ALG1L13P	4.64	4.62e-06	0.00101	0.24	0.21	Joint mobility (Beighton score);	chr8:9043712	chr8:8236003~8244667:-
HNSC	cis	rs7296418	0.961	rs7957096	ENSG00000280120.1	RP11-546D6.3	4.64	4.62e-06	0.00101	0.17	0.21	Platelet count;	chr12:123060331	chr12:123152324~123153377:-
HNSC	cis	rs516805	0.748	rs11968579	ENSG00000279453.1	RP3-425C14.4	4.64	4.63e-06	0.00101	0.3	0.21	Lymphocyte counts;	chr6:122575950	chr6:122436789~122439223:-
HNSC	cis	rs4862750	0.957	rs1030381	ENSG00000250971.1	RP11-696F12.1	4.64	4.63e-06	0.00101	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:187060099~187060930:+
HNSC	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	4.64	4.63e-06	0.00101	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.828	rs12303671	ENSG00000269938.1	RP11-214K3.20	-4.64	4.63e-06	0.00101	-0.24	-0.21	White blood cell count;	chr12:124008063	chr12:123968023~123968579:-
HNSC	cis	rs41307935	0.818	rs35161452	ENSG00000260063.1	RP5-968P14.2	-4.64	4.64e-06	0.00101	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26691718	chr1:26692132~26694131:-
HNSC	cis	rs12893668	0.543	rs12147645	ENSG00000269940.1	RP11-73M18.7	4.64	4.64e-06	0.00101	0.2	0.21	Reticulocyte count;	chr14:103633871	chr14:103694560~103695170:+
HNSC	cis	rs11083475	0.686	rs73040728	ENSG00000269486.2	CTC-360G5.9	4.63	4.64e-06	0.00101	0.23	0.21	Heart rate;	chr19:38766961	chr19:38935297~38938632:-
HNSC	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	4.63	4.64e-06	0.00102	0.21	0.21	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
HNSC	cis	rs6723108	0.627	rs2053726	ENSG00000224043.6	CCNT2-AS1	-4.63	4.64e-06	0.00102	-0.26	-0.21	Type 2 diabetes;	chr2:134852584	chr2:134735464~134918710:-
HNSC	cis	rs9907295	1	rs16971670	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35916548	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9896658	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35916758	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9894314	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35916822	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9897095	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35916928	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9896265	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35916930	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9900236	ENSG00000270977.1	AC015849.16	-4.63	4.64e-06	0.00102	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35917049	chr17:35893707~35911023:-
HNSC	cis	rs5758511	0.68	rs17002902	ENSG00000226450.2	CYP2D8P	4.63	4.65e-06	0.00102	0.21	0.21	Birth weight;	chr22:42229503	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs5758662	ENSG00000226450.2	CYP2D8P	4.63	4.65e-06	0.00102	0.21	0.21	Birth weight;	chr22:42232082	chr22:42149886~42155001:-
HNSC	cis	rs804280	0.509	rs9886639	ENSG00000255495.1	AC145124.2	4.63	4.65e-06	0.00102	0.23	0.21	Myopia (pathological);	chr8:11927020	chr8:12194467~12196280:+
HNSC	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-4.63	4.65e-06	0.00102	-0.26	-0.21	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
HNSC	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	4.63	4.65e-06	0.00102	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
HNSC	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	4.63	4.65e-06	0.00102	0.21	0.21	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
HNSC	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-4.63	4.66e-06	0.00102	-0.29	-0.21	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	4.63	4.66e-06	0.00102	0.25	0.21	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
HNSC	cis	rs6951245	0.744	rs10265758	ENSG00000225146.1	AC073957.15	-4.63	4.66e-06	0.00102	-0.32	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1029025~1043891:+
HNSC	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-4.63	4.66e-06	0.00102	-0.27	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
HNSC	cis	rs4372836	0.964	rs2045884	ENSG00000226833.4	AC097724.3	4.63	4.66e-06	0.00102	0.27	0.21	Body mass index;	chr2:28741489	chr2:28708953~28736205:-
HNSC	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.63	4.66e-06	0.00102	-0.2	-0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.63	4.66e-06	0.00102	-0.2	-0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
HNSC	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	4.63	4.67e-06	0.00102	0.28	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
HNSC	cis	rs1707322	0.963	rs1768815	ENSG00000234329.1	RP11-767N6.2	-4.63	4.67e-06	0.00102	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	4.63	4.67e-06	0.00102	0.26	0.21	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
HNSC	cis	rs35522438	1	rs35522438	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.67e-06	0.00102	-0.22	-0.21	Breast cancer;	chr7:92243558	chr7:92134604~92180725:+
HNSC	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	4.63	4.67e-06	0.00102	0.29	0.21	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
HNSC	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.67e-06	0.00102	-0.24	-0.21	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.00102	0.29	0.21	Depression;	chr6:28123153	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.00102	0.29	0.21	Depression;	chr6:28124529	chr6:28943877~28944537:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.00102	0.29	0.21	Parkinson's disease;	chr6:28127394	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.00102	0.29	0.21	Depression;	chr6:28127577	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.00102	0.29	0.21	Depression;	chr6:28131566	chr6:28943877~28944537:+
HNSC	cis	rs6600671	1	rs7532615	ENSG00000270231.3	NBPF8P	-4.63	4.68e-06	0.00102	-0.18	-0.21	Hip geometry;	chr1:121430980	chr1:120436353~120467739:+
HNSC	cis	rs6928977	0.86	rs2614264	ENSG00000231028.7	LINC00271	-4.63	4.68e-06	0.00102	-0.24	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135497801~135716055:+
HNSC	cis	rs13256369	0.802	rs34762800	ENSG00000173295.6	FAM86B3P	4.63	4.68e-06	0.00102	0.28	0.21	Obesity-related traits;	chr8:8701784	chr8:8228595~8244865:+
HNSC	cis	rs6964587	1	rs6960867	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.68e-06	0.00102	-0.23	-0.21	Breast cancer;	chr7:92083384	chr7:92134604~92180725:+
HNSC	cis	rs860295	0.702	rs34124416	ENSG00000203761.5	MSTO2P	-4.63	4.68e-06	0.00102	-0.16	-0.21	Body mass index;	chr1:155608258	chr1:155745829~155750137:+
HNSC	cis	rs516805	0.667	rs7752093	ENSG00000279453.1	RP3-425C14.4	4.63	4.68e-06	0.00102	0.29	0.21	Lymphocyte counts;	chr6:122301265	chr6:122436789~122439223:-
HNSC	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-4.63	4.68e-06	0.00102	-0.24	-0.21	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
HNSC	cis	rs2835345	0.511	rs2835356	ENSG00000230479.1	AP000695.6	4.63	4.69e-06	0.00102	0.23	0.21	Pulmonary function;	chr21:36444900	chr21:36430360~36481070:+
HNSC	cis	rs3811273	0.614	rs7154715	ENSG00000211816.2	TRAV38-1	-4.63	4.69e-06	0.00102	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22263528	chr14:22271968~22272563:+
HNSC	cis	rs72843506	0.656	rs73984564	ENSG00000261033.1	RP11-209D14.2	4.63	4.69e-06	0.00102	0.34	0.21	Schizophrenia;	chr17:20068535	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs13339684	ENSG00000261033.1	RP11-209D14.2	4.63	4.69e-06	0.00102	0.34	0.21	Schizophrenia;	chr17:20073898	chr17:20008051~20009234:-
HNSC	cis	rs9393777	0.764	rs35565446	ENSG00000219392.1	RP1-265C24.5	-4.63	4.69e-06	0.00102	-0.44	-0.21	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28115628~28116551:+
HNSC	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	4.63	4.69e-06	0.00102	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	4.63	4.69e-06	0.00102	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
HNSC	cis	rs73198271	0.74	rs10105690	ENSG00000233609.3	RP11-62H7.2	-4.63	4.69e-06	0.00102	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8961200~8979025:+
HNSC	cis	rs7590368	0.961	rs12474895	ENSG00000272275.1	RP11-791G15.2	4.63	4.69e-06	0.00103	0.27	0.21	Educational attainment (years of education);	chr2:10817722	chr2:10767875~10770058:-
HNSC	cis	rs9329221	0.537	rs6986911	ENSG00000254340.1	RP11-10A14.3	4.63	4.7e-06	0.00103	0.24	0.21	Neuroticism;	chr8:10121013	chr8:9141424~9145435:+
HNSC	cis	rs1594829	0.553	rs1564577	ENSG00000228451.3	SDAD1P1	4.63	4.7e-06	0.00103	0.24	0.21	Height;	chr8:26307207	chr8:26379259~26382953:-
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	4.63	4.7e-06	0.00103	0.25	0.21	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000255495.1	AC145124.2	4.63	4.7e-06	0.00103	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12194467~12196280:+
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000254153.1	CTA-398F10.2	4.63	4.7e-06	0.00103	0.23	0.21	Mood instability;	chr8:8445843	chr8:8456909~8461337:-
HNSC	cis	rs8028182	0.636	rs7175852	ENSG00000260269.4	CTD-2323K18.1	-4.63	4.7e-06	0.00103	-0.27	-0.21	Sudden cardiac arrest;	chr15:75402194	chr15:75527150~75601205:-
HNSC	cis	rs6964587	0.967	rs12531966	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.7e-06	0.00103	-0.22	-0.21	Breast cancer;	chr7:92136526	chr7:92134604~92180725:+
HNSC	cis	rs4787951	0.56	rs3024548	ENSG00000259940.2	CTD-3203P2.1	-4.63	4.7e-06	0.00103	-0.22	-0.21	Eosinophil percentage of white cells;	chr16:27343210	chr16:27213308~27214993:-
HNSC	cis	rs60617249	0.831	rs2107693	ENSG00000228204.2	RP4-724E13.2	4.63	4.7e-06	0.00103	0.22	0.21	Major depression and alcohol dependence;	chr7:50894656	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.831	rs13244204	ENSG00000228204.2	RP4-724E13.2	4.63	4.7e-06	0.00103	0.22	0.21	Major depression and alcohol dependence;	chr7:50897509	chr7:50866747~51022990:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-4.63	4.7e-06	0.00103	-0.28	-0.21	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
HNSC	cis	rs651907	0.557	rs12629954	ENSG00000244119.1	PDCL3P4	4.63	4.7e-06	0.00103	0.2	0.21	Colorectal cancer;	chr3:101641779	chr3:101712472~101713191:+
HNSC	cis	rs1555322	0.872	rs6579227	ENSG00000279253.1	RP4-614O4.13	-4.63	4.7e-06	0.00103	-0.34	-0.21	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35262727~35264187:-
HNSC	cis	rs3806843	1	rs2879089	ENSG00000202515.1	VTRNA1-3	-4.63	4.7e-06	0.00103	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr5:140726158~140726246:+
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000204709.4	LINC01556	4.63	4.71e-06	0.00103	0.31	0.21	Parkinson's disease;	chr6:28134687	chr6:28943877~28944537:+
HNSC	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	4.63	4.71e-06	0.00103	0.3	0.21	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	4.63	4.71e-06	0.00103	0.3	0.21	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
HNSC	cis	rs1056107	0.933	rs10759546	ENSG00000225513.1	RP11-165N19.2	-4.63	4.71e-06	0.00103	-0.22	-0.21	Colorectal cancer;	chr9:112260664	chr9:112173522~112173971:-
HNSC	cis	rs4925386	0.84	rs6143034	ENSG00000275437.1	RP5-908M14.10	4.63	4.71e-06	0.00103	0.22	0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62402236~62405935:-
HNSC	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	4.63	4.71e-06	0.00103	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
HNSC	cis	rs6964587	1	rs6942649	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.71e-06	0.00103	-0.2	-0.21	Breast cancer;	chr7:91965196	chr7:92134604~92180725:+
HNSC	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-4.63	4.71e-06	0.00103	-0.22	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
HNSC	cis	rs116095464	0.558	rs1541822	ENSG00000250848.1	CTD-2083E4.5	4.63	4.71e-06	0.00103	0.29	0.21	Breast cancer;	chr5:269119	chr5:288833~290321:-
HNSC	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-4.63	4.71e-06	0.00103	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
HNSC	cis	rs73198271	0.7	rs10090152	ENSG00000233609.3	RP11-62H7.2	-4.63	4.71e-06	0.00103	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8961200~8979025:+
HNSC	cis	rs1056107	0.931	rs7048773	ENSG00000225513.1	RP11-165N19.2	-4.63	4.72e-06	0.00103	-0.22	-0.21	Colorectal cancer;	chr9:112226388	chr9:112173522~112173971:-
HNSC	cis	rs804280	0.509	rs10109241	ENSG00000255495.1	AC145124.2	4.63	4.72e-06	0.00103	0.23	0.21	Myopia (pathological);	chr8:11927476	chr8:12194467~12196280:+
HNSC	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-4.63	4.73e-06	0.00103	-0.23	-0.21	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
HNSC	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	4.63	4.73e-06	0.00103	0.32	0.21	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
HNSC	cis	rs7826238	0.509	rs2948288	ENSG00000254153.1	CTA-398F10.2	4.63	4.73e-06	0.00103	0.24	0.21	Systolic blood pressure;	chr8:8257782	chr8:8456909~8461337:-
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-4.63	4.73e-06	0.00103	-0.25	-0.21	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
HNSC	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-4.63	4.73e-06	0.00103	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
HNSC	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-4.63	4.73e-06	0.00103	-0.26	-0.21	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
HNSC	cis	rs9450351	0.744	rs9450295	ENSG00000203875.9	SNHG5	-4.63	4.73e-06	0.00103	-0.48	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85548156	chr6:85660950~85678736:-
HNSC	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-4.63	4.73e-06	0.00103	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
HNSC	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	4.63	4.73e-06	0.00103	0.24	0.21	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-4.63	4.73e-06	0.00103	-0.25	-0.21	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
HNSC	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	4.63	4.73e-06	0.00103	0.24	0.21	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	4.63	4.73e-06	0.00103	0.24	0.21	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	4.63	4.73e-06	0.00103	0.22	0.21	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
HNSC	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	4.63	4.74e-06	0.00103	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
HNSC	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	4.63	4.74e-06	0.00103	0.27	0.21	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-4.63	4.74e-06	0.00103	-0.29	-0.21	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-4.63	4.74e-06	0.00103	-0.29	-0.21	Gout;	chr7:66642037	chr7:66880708~66882981:+
HNSC	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-4.63	4.74e-06	0.00103	-0.24	-0.21	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
HNSC	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	4.63	4.74e-06	0.00103	0.27	0.21	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
HNSC	cis	rs710913	0.604	rs1180343	ENSG00000182109.6	RP11-69E11.4	-4.63	4.74e-06	0.00103	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39522280~39546187:-
HNSC	cis	rs6964587	0.773	rs2097810	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.74e-06	0.00103	-0.22	-0.21	Breast cancer;	chr7:92347912	chr7:92134604~92180725:+
HNSC	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-4.63	4.75e-06	0.00104	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
HNSC	cis	rs6964587	0.869	rs7810391	ENSG00000188693.7	CYP51A1-AS1	4.63	4.75e-06	0.00104	0.22	0.21	Breast cancer;	chr7:91890913	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs7778667	ENSG00000188693.7	CYP51A1-AS1	4.63	4.75e-06	0.00104	0.22	0.21	Breast cancer;	chr7:91891502	chr7:92134604~92180725:+
HNSC	cis	rs10829156	0.732	rs7100884	ENSG00000240291.1	RP11-499P20.2	4.63	4.75e-06	0.00104	0.22	0.21	Sudden cardiac arrest;	chr10:18523768	chr10:18513115~18545651:-
HNSC	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	4.63	4.75e-06	0.00104	0.24	0.21	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
HNSC	cis	rs7848679	0.935	rs13283838	ENSG00000230013.1	RP11-217B7.3	4.63	4.75e-06	0.00104	0.36	0.21	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr9:105007946	chr9:104990796~104991781:-
HNSC	cis	rs1557765	0.527	rs11024272	ENSG00000260196.1	RP1-239B22.5	4.63	4.75e-06	0.00104	0.22	0.21	Body mass index;Social communication problems;	chr11:17374213	chr11:17380649~17383531:+
HNSC	cis	rs1557765	0.527	rs10832782	ENSG00000260196.1	RP1-239B22.5	4.63	4.75e-06	0.00104	0.22	0.21	Body mass index;Social communication problems;	chr11:17375726	chr11:17380649~17383531:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.63	4.75e-06	0.00104	0.25	0.21	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.789	rs2810073	ENSG00000274818.1	RP1-292L20.3	-4.63	4.76e-06	0.00104	-0.25	-0.21	Schizophrenia;	chr14:70917131	chr14:70906657~70907111:-
HNSC	cis	rs3806843	0.648	rs702399	ENSG00000202515.1	VTRNA1-3	4.63	4.76e-06	0.00104	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr5:140726158~140726246:+
HNSC	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	4.63	4.76e-06	0.00104	0.25	0.21	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
HNSC	cis	rs2665103	0.61	rs56398167	ENSG00000276710.3	CSPG4P8	-4.63	4.76e-06	0.00104	-0.22	-0.21	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82459472~82477258:+
HNSC	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-4.63	4.76e-06	0.00104	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-4.63	4.76e-06	0.00104	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-4.63	4.76e-06	0.00104	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-4.63	4.76e-06	0.00104	-0.25	-0.21	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
HNSC	cis	rs2253762	0.54	rs10887036	ENSG00000226864.1	ATE1-AS1	4.63	4.76e-06	0.00104	0.35	0.21	Breast cancer;	chr10:121997570	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs10887037	ENSG00000226864.1	ATE1-AS1	4.63	4.76e-06	0.00104	0.35	0.21	Breast cancer;	chr10:121997572	chr10:121928312~121951965:+
HNSC	cis	rs3808502	0.574	rs4841559	ENSG00000269918.1	AF131215.9	-4.63	4.76e-06	0.00104	-0.2	-0.21	Neuroticism;	chr8:11559376	chr8:11104691~11106704:-
HNSC	cis	rs10185424	0.521	rs4851531	ENSG00000281162.1	LINC01127	-4.63	4.77e-06	0.00104	-0.27	-0.21	Crohn's disease;Ulcerative colitis;	chr2:102032147	chr2:101962056~101987167:+
HNSC	cis	rs7824557	0.527	rs2572376	ENSG00000269918.1	AF131215.9	-4.63	4.77e-06	0.00104	-0.2	-0.21	Retinal vascular caliber;	chr8:11380247	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.588	rs6534149	ENSG00000249244.1	RP11-548H18.2	-4.63	4.77e-06	0.00104	-0.26	-0.21	Corneal astigmatism;	chr4:119638137	chr4:119391831~119395335:-
HNSC	cis	rs8058578	0.832	rs3812999	ENSG00000279196.1	RP11-1072A3.3	4.63	4.77e-06	0.00104	0.25	0.21	Multiple myeloma;	chr16:30762284	chr16:30984630~30988270:-
HNSC	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	4.63	4.77e-06	0.00104	0.19	0.21	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	4.63	4.77e-06	0.00104	0.19	0.21	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	4.63	4.77e-06	0.00104	0.19	0.21	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
HNSC	cis	rs12893668	0.703	rs2403197	ENSG00000269940.1	RP11-73M18.7	4.63	4.77e-06	0.00104	0.21	0.21	Reticulocyte count;	chr14:103587427	chr14:103694560~103695170:+
HNSC	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	4.63	4.77e-06	0.00104	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
HNSC	cis	rs1971762	0.545	rs3864905	ENSG00000270175.1	RP11-793H13.11	-4.63	4.77e-06	0.00104	-0.19	-0.21	Height;	chr12:53664540	chr12:53500162~53500936:-
HNSC	cis	rs41307935	0.908	rs4579782	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26700496	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs57217461	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701425	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.57	rs12737407	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26709671	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.778	rs78533482	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26715851	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34576193	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26728289	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs41303629	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26731130	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.73	rs34951175	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778568	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs60798877	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781648	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.915	rs12685	ENSG00000260063.1	RP5-968P14.2	-4.63	4.77e-06	0.00104	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781754	chr1:26692132~26694131:-
HNSC	cis	rs73198271	0.653	rs10099808	ENSG00000233609.3	RP11-62H7.2	4.63	4.77e-06	0.00104	0.23	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8961200~8979025:+
HNSC	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	4.63	4.78e-06	0.00104	0.21	0.21	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
HNSC	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-4.63	4.78e-06	0.00104	-0.29	-0.21	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
HNSC	cis	rs6831352	0.918	rs29001199	ENSG00000263923.1	RP11-571L19.7	4.63	4.78e-06	0.00104	0.23	0.21	Alcohol dependence;	chr4:99132740	chr4:98928897~98994994:+
HNSC	cis	rs42490	0.664	rs394108	ENSG00000251136.7	RP11-37B2.1	-4.63	4.78e-06	0.00104	-0.18	-0.21	Leprosy;	chr8:89812991	chr8:89609409~89757727:-
HNSC	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	4.63	4.78e-06	0.00104	0.24	0.21	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	4.63	4.78e-06	0.00104	0.24	0.21	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	4.63	4.78e-06	0.00104	0.24	0.21	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
HNSC	cis	rs11089937	0.626	rs4821784	ENSG00000211639.2	IGLV4-60	4.63	4.78e-06	0.00104	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22162199~22162681:+
HNSC	cis	rs67981189	0.896	rs2810098	ENSG00000274818.1	RP1-292L20.3	-4.63	4.78e-06	0.00104	-0.24	-0.21	Schizophrenia;	chr14:70967194	chr14:70906657~70907111:-
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000224373.3	IGHV4-59	4.63	4.78e-06	0.00104	0.12	0.21	Kawasaki disease;	chr14:106685105	chr14:106627249~106627825:-
HNSC	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-4.63	4.78e-06	0.00104	-0.19	-0.21	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
HNSC	cis	rs6723108	0.559	rs1942051	ENSG00000224043.6	CCNT2-AS1	-4.63	4.78e-06	0.00104	-0.26	-0.21	Type 2 diabetes;	chr2:134846120	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.627	rs10928519	ENSG00000224043.6	CCNT2-AS1	-4.63	4.78e-06	0.00104	-0.26	-0.21	Type 2 diabetes;	chr2:134846389	chr2:134735464~134918710:-
HNSC	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	4.63	4.78e-06	0.00104	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
HNSC	cis	rs1008375	0.931	rs2315558	ENSG00000249502.1	AC006160.5	-4.63	4.78e-06	0.00104	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17672935	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs2215450	ENSG00000249502.1	AC006160.5	-4.63	4.78e-06	0.00104	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673771	chr4:17587467~17614571:-
HNSC	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-4.63	4.78e-06	0.00104	-0.17	-0.21	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
HNSC	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.63	4.78e-06	0.00104	-0.22	-0.21	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
HNSC	cis	rs36052053	0.908	rs13190802	ENSG00000203799.9	CCDC162P	4.63	4.78e-06	0.00104	0.31	0.21	Red cell distribution width;	chr6:109260601	chr6:109285485~109355063:+
HNSC	cis	rs3736485	0.932	rs4774598	ENSG00000259438.1	CTD-2650P22.1	4.63	4.78e-06	0.00104	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51627470	chr15:52010999~52019095:-
HNSC	cis	rs6964587	0.869	rs6975243	ENSG00000188693.7	CYP51A1-AS1	4.63	4.78e-06	0.00104	0.23	0.21	Breast cancer;	chr7:91885358	chr7:92134604~92180725:+
HNSC	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	4.63	4.79e-06	0.00104	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
HNSC	cis	rs72949976	0.646	rs1441170	ENSG00000270659.1	RP11-105N14.1	4.63	4.79e-06	0.00104	0.21	0.21	Squamous cell lung carcinoma;Lung cancer;	chr2:213168839	chr2:213152970~213153659:+
HNSC	cis	rs10504130	0.569	rs12678646	ENSG00000272024.1	RP11-546K22.3	-4.63	4.79e-06	0.00104	-0.29	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51950284~51950690:+
HNSC	cis	rs577676	0.586	rs533603	ENSG00000271811.1	RP1-79C4.4	4.63	4.79e-06	0.00104	0.24	0.21	Prevalent atrial fibrillation;	chr1:170639527	chr1:170667381~170669425:+
HNSC	cis	rs577676	0.586	rs578928	ENSG00000271811.1	RP1-79C4.4	4.63	4.79e-06	0.00104	0.24	0.21	Prevalent atrial fibrillation;	chr1:170640602	chr1:170667381~170669425:+
HNSC	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	4.63	4.79e-06	0.00104	0.22	0.21	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
HNSC	cis	rs7621025	0.755	rs1017881	ENSG00000239213.4	NCK1-AS1	4.63	4.8e-06	0.00104	0.19	0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136841726~136862054:-
HNSC	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-4.63	4.8e-06	0.00104	-0.31	-0.21	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
HNSC	cis	rs12701220	0.541	rs12535516	ENSG00000224079.1	AC091729.7	4.63	4.8e-06	0.00104	0.32	0.21	Bronchopulmonary dysplasia;	chr7:1074804	chr7:1074450~1078036:+
HNSC	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-4.63	4.8e-06	0.00104	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
HNSC	cis	rs1056107	0.731	rs7047547	ENSG00000225513.1	RP11-165N19.2	-4.63	4.8e-06	0.00104	-0.23	-0.21	Colorectal cancer;	chr9:112173568	chr9:112173522~112173971:-
HNSC	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-4.63	4.8e-06	0.00105	-0.2	-0.21	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
HNSC	cis	rs939574	1	rs11552796	ENSG00000243910.6	TUBA4B	4.63	4.8e-06	0.00105	0.41	0.21	Platelet distribution width;	chr2:219243578	chr2:219253243~219272188:+
HNSC	cis	rs4819052	0.851	rs4819046	ENSG00000223768.1	LINC00205	-4.63	4.8e-06	0.00105	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45293285~45297354:+
HNSC	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-4.63	4.8e-06	0.00105	-0.26	-0.21	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
HNSC	cis	rs4763879	0.865	rs4763840	ENSG00000256673.1	RP11-599J14.2	4.63	4.81e-06	0.00105	0.2	0.21	Type 1 diabetes;	chr12:9731814	chr12:9398355~9414851:-
HNSC	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	4.63	4.81e-06	0.00105	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
HNSC	cis	rs6964587	1	rs2282974	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.81e-06	0.00105	-0.22	-0.21	Breast cancer;	chr7:92132303	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs55801687	ENSG00000188693.7	CYP51A1-AS1	-4.63	4.81e-06	0.00105	-0.22	-0.21	Breast cancer;	chr7:92133315	chr7:92134604~92180725:+
HNSC	cis	rs1994321	0.779	rs7481690	ENSG00000254991.1	RP13-631K18.3	-4.63	4.81e-06	0.00105	-0.23	-0.21	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12062143	chr11:12066929~12073014:+
HNSC	cis	rs9840812	0.68	rs17252498	ENSG00000239213.4	NCK1-AS1	-4.63	4.81e-06	0.00105	-0.22	-0.21	Fibrinogen levels;	chr3:136295356	chr3:136841726~136862054:-
HNSC	cis	rs9990333	0.562	rs73210005	ENSG00000231464.1	AC024937.4	4.63	4.81e-06	0.00105	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195996738~195998233:+
HNSC	cis	rs721917	0.525	rs2758545	ENSG00000225484.5	NUTM2B-AS1	-4.63	4.81e-06	0.00105	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79663088~79826594:-
HNSC	cis	rs11722228	0.522	rs881641	ENSG00000250413.1	RP11-448G15.1	-4.63	4.82e-06	0.00105	-0.31	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10132123	chr4:10006482~10009725:+
HNSC	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-4.63	4.82e-06	0.00105	-0.29	-0.21	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
HNSC	cis	rs7809950	0.815	rs62482495	ENSG00000238832.1	snoU109	-4.63	4.82e-06	0.00105	-0.3	-0.21	Coronary artery disease;	chr7:107324564	chr7:107603363~107603507:+
HNSC	cis	rs763121	0.853	rs5757181	ENSG00000273076.1	RP3-508I15.22	4.63	4.82e-06	0.00105	0.23	0.21	Menopause (age at onset);	chr22:38617517	chr22:38743495~38743910:+
HNSC	cis	rs3806843	1	rs10477034	ENSG00000202515.1	VTRNA1-3	-4.63	4.82e-06	0.00105	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr5:140726158~140726246:+
HNSC	cis	rs12701220	0.817	rs59471534	ENSG00000229043.2	AC091729.9	-4.63	4.83e-06	0.00105	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1160374~1165267:+
HNSC	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	4.63	4.83e-06	0.00105	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
HNSC	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	4.63	4.83e-06	0.00105	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	4.63	4.83e-06	0.00105	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	4.63	4.83e-06	0.00105	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	4.63	4.83e-06	0.00105	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
HNSC	cis	rs7824557	0.737	rs2293855	ENSG00000269918.1	AF131215.9	4.63	4.83e-06	0.00105	0.21	0.21	Retinal vascular caliber;	chr8:11319901	chr8:11104691~11106704:-
HNSC	cis	rs367615	0.68	rs1103198	ENSG00000249476.1	CTD-2587M2.1	4.63	4.84e-06	0.00105	0.28	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109637882	chr5:109237120~109326369:-
HNSC	cis	rs42490	0.664	rs389848	ENSG00000251136.7	RP11-37B2.1	-4.63	4.84e-06	0.00105	-0.18	-0.21	Leprosy;	chr8:89784739	chr8:89609409~89757727:-
HNSC	cis	rs67981189	0.865	rs34488204	ENSG00000274818.1	RP1-292L20.3	4.63	4.84e-06	0.00105	0.24	0.21	Schizophrenia;	chr14:71028571	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs3814869	ENSG00000274818.1	RP1-292L20.3	4.63	4.84e-06	0.00105	0.24	0.21	Schizophrenia;	chr14:71028982	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs17108925	ENSG00000274818.1	RP1-292L20.3	4.63	4.84e-06	0.00105	0.24	0.21	Schizophrenia;	chr14:71033010	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs28374308	ENSG00000274818.1	RP1-292L20.3	4.63	4.84e-06	0.00105	0.24	0.21	Schizophrenia;	chr14:71035040	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs8016506	ENSG00000274818.1	RP1-292L20.3	4.63	4.84e-06	0.00105	0.24	0.21	Schizophrenia;	chr14:71039600	chr14:70906657~70907111:-
HNSC	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-4.63	4.84e-06	0.00105	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
HNSC	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	4.63	4.85e-06	0.00105	0.2	0.21	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
HNSC	cis	rs17270561	0.779	rs17271767	ENSG00000272810.1	U91328.22	-4.63	4.85e-06	0.00105	-0.23	-0.21	Iron status biomarkers;	chr6:25886693	chr6:26013241~26013757:+
HNSC	cis	rs56804039	1	rs6986470	ENSG00000173295.6	FAM86B3P	-4.63	4.85e-06	0.00105	-0.28	-0.21	Cervical cancer;	chr8:8523920	chr8:8228595~8244865:+
HNSC	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	4.63	4.85e-06	0.00105	0.19	0.21	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
HNSC	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	4.63	4.85e-06	0.00105	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	4.63	4.85e-06	0.00105	0.25	0.21	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
HNSC	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	4.63	4.85e-06	0.00105	0.24	0.21	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
HNSC	cis	rs17373728	0.507	rs13248105	ENSG00000249395.2	CASC9	-4.63	4.85e-06	0.00105	-0.27	-0.21	Diabetic kidney disease;	chr8:75254634	chr8:75223404~75324741:-
HNSC	cis	rs2307394	0.964	rs35370215	ENSG00000281469.1	RP11-567F11.1	4.63	4.85e-06	0.00106	0.24	0.21	Urate levels;	chr2:147777063	chr2:148044380~148044894:+
HNSC	cis	rs36052053	0.521	rs13200680	ENSG00000203799.9	CCDC162P	4.63	4.85e-06	0.00106	0.38	0.21	Red cell distribution width;	chr6:109192842	chr6:109285485~109355063:+
HNSC	cis	rs6928977	0.896	rs1012645	ENSG00000217482.2	HMGB1P17	-4.63	4.85e-06	0.00106	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135636086~135636713:-
HNSC	cis	rs1707322	0.963	rs34907901	ENSG00000234329.1	RP11-767N6.2	4.63	4.86e-06	0.00106	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45651039~45651826:-
HNSC	cis	rs3806843	0.966	rs3756338	ENSG00000202515.1	VTRNA1-3	-4.63	4.86e-06	0.00106	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr5:140726158~140726246:+
HNSC	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	4.62	4.86e-06	0.00106	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
HNSC	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-4.62	4.86e-06	0.00106	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
HNSC	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	4.62	4.86e-06	0.00106	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
HNSC	cis	rs3096299	0.809	rs2911264	ENSG00000261574.1	RP1-168P16.2	4.62	4.86e-06	0.00106	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89392375~89412564:-
HNSC	cis	rs1008375	0.932	rs2302391	ENSG00000249502.1	AC006160.5	-4.62	4.86e-06	0.00106	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658614	chr4:17587467~17614571:-
HNSC	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	4.62	4.86e-06	0.00106	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
HNSC	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-4.62	4.86e-06	0.00106	-0.2	-0.21	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
HNSC	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	4.62	4.87e-06	0.00106	0.2	0.21	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	4.62	4.87e-06	0.00106	0.2	0.21	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
HNSC	cis	rs5758511	0.68	rs1033460	ENSG00000205702.9	CYP2D7	4.62	4.87e-06	0.00106	0.19	0.21	Birth weight;	chr22:42223302	chr22:42140203~42144577:-
HNSC	cis	rs4862750	0.837	rs1863404	ENSG00000250971.1	RP11-696F12.1	4.62	4.87e-06	0.00106	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:187060099~187060930:+
HNSC	cis	rs13438327	0.708	rs13246032	ENSG00000183444.10	OR7E38P	4.62	4.87e-06	0.00106	0.44	0.21	Sudden cardiac arrest;	chr7:97996332	chr7:97966090~97967074:-
HNSC	cis	rs763121	0.853	rs6001175	ENSG00000273076.1	RP3-508I15.22	4.62	4.87e-06	0.00106	0.21	0.21	Menopause (age at onset);	chr22:38622329	chr22:38743495~38743910:+
HNSC	cis	rs879620	0.89	rs2601781	ENSG00000262888.1	RP11-462G12.2	-4.62	4.87e-06	0.00106	-0.26	-0.21	Hip circumference;Body mass index;	chr16:3967391	chr16:3931217~3946305:-
HNSC	cis	rs7615952	0.599	rs6438955	ENSG00000241439.1	RP11-666A20.3	4.62	4.87e-06	0.00106	0.23	0.21	Blood pressure (smoking interaction);	chr3:126011490	chr3:125958556~125958817:+
HNSC	cis	rs1125355	0.589	rs11681670	ENSG00000204380.3	AC005042.4	4.62	4.87e-06	0.00106	0.24	0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158753780	chr2:158658337~158735002:-
HNSC	cis	rs9840812	0.769	rs489398	ENSG00000239213.4	NCK1-AS1	4.62	4.88e-06	0.00106	0.21	0.21	Fibrinogen levels;	chr3:136276656	chr3:136841726~136862054:-
HNSC	cis	rs12682352	0.579	rs7006589	ENSG00000254340.1	RP11-10A14.3	4.62	4.88e-06	0.00106	0.25	0.21	Neuroticism;	chr8:8810976	chr8:9141424~9145435:+
HNSC	cis	rs72843506	0.586	rs113833946	ENSG00000261033.1	RP11-209D14.2	4.62	4.88e-06	0.00106	0.37	0.21	Schizophrenia;	chr17:19955593	chr17:20008051~20009234:-
HNSC	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	4.62	4.89e-06	0.00106	0.25	0.21	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
HNSC	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-4.62	4.89e-06	0.00106	-0.17	-0.21	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
HNSC	cis	rs3806843	0.735	rs778595	ENSG00000202515.1	VTRNA1-3	4.62	4.89e-06	0.00106	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr5:140726158~140726246:+
HNSC	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-4.62	4.89e-06	0.00106	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
HNSC	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	4.62	4.89e-06	0.00106	0.25	0.21	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
HNSC	cis	rs721917	0.506	rs2475756	ENSG00000225484.5	NUTM2B-AS1	-4.62	4.89e-06	0.00106	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79663088~79826594:-
HNSC	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	4.62	4.9e-06	0.00106	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
HNSC	cis	rs6496044	0.568	rs11632326	ENSG00000259295.5	CSPG4P12	4.62	4.9e-06	0.00106	0.25	0.21	Interstitial lung disease;	chr15:85536603	chr15:85191438~85213905:+
HNSC	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-4.62	4.9e-06	0.00106	-0.28	-0.21	Pain;	chr19:21543535	chr19:21554640~21569237:-
HNSC	cis	rs9863	0.896	rs77112003	ENSG00000269938.1	RP11-214K3.20	-4.62	4.9e-06	0.00106	-0.25	-0.21	White blood cell count;	chr12:124002996	chr12:123968023~123968579:-
HNSC	cis	rs9880211	0.8	rs13314357	ENSG00000273486.1	RP11-731C17.2	4.62	4.9e-06	0.00106	0.2	0.21	Height;Body mass index;	chr3:136768717	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.741	rs9650622	ENSG00000233609.3	RP11-62H7.2	-4.62	4.9e-06	0.00106	-0.2	-0.21	Neuroticism;	chr8:9946782	chr8:8961200~8979025:+
HNSC	cis	rs1971762	0.527	rs7952858	ENSG00000270175.1	RP11-793H13.11	-4.62	4.9e-06	0.00106	-0.18	-0.21	Height;	chr12:53645908	chr12:53500162~53500936:-
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000254153.1	CTA-398F10.2	4.62	4.9e-06	0.00106	0.23	0.21	Mood instability;	chr8:8797017	chr8:8456909~8461337:-
HNSC	cis	rs36052053	0.908	rs71558360	ENSG00000203799.9	CCDC162P	4.62	4.9e-06	0.00106	0.31	0.21	Red cell distribution width;	chr6:109256780	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs71558361	ENSG00000203799.9	CCDC162P	4.62	4.9e-06	0.00106	0.31	0.21	Red cell distribution width;	chr6:109260045	chr6:109285485~109355063:+
HNSC	cis	rs7809950	0.768	rs2701678	ENSG00000238832.1	snoU109	4.62	4.9e-06	0.00106	0.28	0.21	Coronary artery disease;	chr7:107643266	chr7:107603363~107603507:+
HNSC	cis	rs7296418	0.738	rs10846489	ENSG00000280120.1	RP11-546D6.3	-4.62	4.9e-06	0.00106	-0.17	-0.21	Platelet count;	chr12:123259380	chr12:123152324~123153377:-
HNSC	cis	rs6831352	0.918	rs17218560	ENSG00000263923.1	RP11-571L19.7	-4.62	4.9e-06	0.00106	-0.23	-0.21	Alcohol dependence;	chr4:99139643	chr4:98928897~98994994:+
HNSC	cis	rs1008375	1	rs1008374	ENSG00000249502.1	AC006160.5	-4.62	4.91e-06	0.00107	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17681596	chr4:17587467~17614571:-
HNSC	cis	rs7824557	0.688	rs2572397	ENSG00000255310.2	AF131215.2	4.62	4.91e-06	0.00107	0.2	0.21	Retinal vascular caliber;	chr8:11318894	chr8:11107788~11109726:-
HNSC	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	4.62	4.91e-06	0.00107	0.26	0.21	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
HNSC	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-4.62	4.91e-06	0.00107	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
HNSC	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	4.62	4.91e-06	0.00107	0.26	0.21	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	4.62	4.91e-06	0.00107	0.26	0.21	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
HNSC	cis	rs4761669	0.675	rs6538539	ENSG00000241556.1	RP11-490G8.1	-4.62	4.91e-06	0.00107	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94801517	chr12:95467397~95467861:-
HNSC	cis	rs7086627	0.515	rs7078254	ENSG00000226659.1	RP11-137H2.4	-4.62	4.91e-06	0.00107	-0.26	-0.21	Post bronchodilator FEV1;	chr10:80452437	chr10:80529597~80535942:-
HNSC	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-4.62	4.91e-06	0.00107	-0.21	-0.21	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
HNSC	cis	rs7824557	0.767	rs6991606	ENSG00000255310.2	AF131215.2	4.62	4.91e-06	0.00107	0.2	0.21	Retinal vascular caliber;	chr8:11318650	chr8:11107788~11109726:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	4.62	4.91e-06	0.00107	0.26	0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	4.62	4.91e-06	0.00107	0.13	0.21	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
HNSC	cis	rs3863381	0.764	rs79880109	ENSG00000277715.1	RP11-651L5.3	4.62	4.92e-06	0.00107	0.33	0.21	Night sleep phenotypes;	chr12:105712061	chr12:106250759~106252786:+
HNSC	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	4.62	4.92e-06	0.00107	0.24	0.21	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	4.62	4.92e-06	0.00107	0.24	0.21	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	4.62	4.92e-06	0.00107	0.24	0.21	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	4.62	4.92e-06	0.00107	0.24	0.21	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
HNSC	cis	rs6601327	0.613	rs12682175	ENSG00000254340.1	RP11-10A14.3	-4.62	4.92e-06	0.00107	-0.25	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9621651	chr8:9141424~9145435:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.62	4.92e-06	0.00107	-0.22	-0.21	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
HNSC	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	4.62	4.92e-06	0.00107	0.22	0.21	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
HNSC	cis	rs9863	0.861	rs7958691	ENSG00000269938.1	RP11-214K3.20	-4.62	4.92e-06	0.00107	-0.24	-0.21	White blood cell count;	chr12:123956196	chr12:123968023~123968579:-
HNSC	cis	rs7662987	0.517	rs2851286	ENSG00000263923.1	RP11-571L19.7	4.62	4.93e-06	0.00107	0.23	0.21	Smoking initiation;	chr4:99093825	chr4:98928897~98994994:+
HNSC	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-4.62	4.93e-06	0.00107	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
HNSC	cis	rs7809950	0.817	rs11535285	ENSG00000238832.1	snoU109	-4.62	4.93e-06	0.00107	-0.3	-0.21	Coronary artery disease;	chr7:107503421	chr7:107603363~107603507:+
HNSC	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-4.62	4.94e-06	0.00107	-0.21	-0.21	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
HNSC	cis	rs597539	0.518	rs35093305	ENSG00000261625.1	RP11-554A11.4	-4.62	4.94e-06	0.00107	-0.23	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:69000765~69002048:-
HNSC	cis	rs4787491	0.679	rs7204852	ENSG00000183604.13	SMG1P5	-4.62	4.94e-06	0.00107	-0.2	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30267553~30335374:-
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	4.62	4.94e-06	0.00107	0.25	0.21	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
HNSC	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-4.62	4.95e-06	0.00107	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
HNSC	cis	rs4873772	0.808	rs6987043	ENSG00000253330.1	RP11-697N18.3	-4.62	4.95e-06	0.00107	-0.27	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47679023	chr8:47511034~47512141:-
HNSC	cis	rs5769707	0.681	rs4622843	ENSG00000235111.1	RP1-29C18.8	-4.62	4.95e-06	0.00107	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49612657~49615716:-
HNSC	cis	rs5758511	0.68	rs5758688	ENSG00000205702.9	CYP2D7	4.62	4.95e-06	0.00107	0.19	0.21	Birth weight;	chr22:42266495	chr22:42140203~42144577:-
HNSC	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-4.62	4.95e-06	0.00107	-0.27	-0.21	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
HNSC	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	4.62	4.95e-06	0.00107	0.29	0.21	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
HNSC	cis	rs9990333	0.562	rs58079878	ENSG00000231464.1	AC024937.4	4.62	4.95e-06	0.00107	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195996738~195998233:+
HNSC	cis	rs7615952	0.576	rs4646763	ENSG00000241439.1	RP11-666A20.3	4.62	4.95e-06	0.00107	0.24	0.21	Blood pressure (smoking interaction);	chr3:126103286	chr3:125958556~125958817:+
HNSC	cis	rs7937890	0.668	rs12361851	ENSG00000254418.1	RP11-21L19.1	-4.62	4.95e-06	0.00107	-0.25	-0.21	Mitochondrial DNA levels;	chr11:14246122	chr11:14262846~14273691:-
HNSC	cis	rs9329221	0.741	rs13264066	ENSG00000233609.3	RP11-62H7.2	-4.62	4.96e-06	0.00107	-0.2	-0.21	Neuroticism;	chr8:9946565	chr8:8961200~8979025:+
HNSC	cis	rs860295	0.702	rs12043132	ENSG00000203761.5	MSTO2P	-4.62	4.96e-06	0.00107	-0.16	-0.21	Body mass index;	chr1:155592576	chr1:155745829~155750137:+
HNSC	cis	rs9863	0.861	rs9971695	ENSG00000269938.1	RP11-214K3.20	-4.62	4.96e-06	0.00107	-0.24	-0.21	White blood cell count;	chr12:123928944	chr12:123968023~123968579:-
HNSC	cis	rs7552167	1	rs7552167	ENSG00000230023.2	RP11-10N16.2	4.62	4.96e-06	0.00108	0.33	0.21	Psoriasis vulgaris;	chr1:24192153	chr1:24200240~24211693:+
HNSC	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-4.62	4.96e-06	0.00108	-0.38	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
HNSC	cis	rs4787484	1	rs11344	ENSG00000196796.5	CTB-134H23.2	4.62	4.96e-06	0.00108	0.23	0.21	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29038655~29052726:+
HNSC	cis	rs17345786	1	rs17345528	ENSG00000244119.1	PDCL3P4	-4.62	4.96e-06	0.00108	-0.22	-0.21	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101712472~101713191:+
HNSC	cis	rs116095464	0.558	rs13357299	ENSG00000250848.1	CTD-2083E4.5	-4.62	4.96e-06	0.00108	-0.29	-0.21	Breast cancer;	chr5:242096	chr5:288833~290321:-
HNSC	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	4.62	4.97e-06	0.00108	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
HNSC	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	4.62	4.97e-06	0.00108	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	4.62	4.97e-06	0.00108	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
HNSC	cis	rs3864639	1	rs3864639	ENSG00000233448.2	PMS2P9	4.62	4.97e-06	0.00108	0.24	0.21	Obesity-related traits;	chr7:77109274	chr7:77039944~77043776:+
HNSC	cis	rs9650657	0.537	rs4841457	ENSG00000255310.2	AF131215.2	-4.62	4.97e-06	0.00108	-0.2	-0.21	Neuroticism;	chr8:10916001	chr8:11107788~11109726:-
HNSC	cis	rs5758659	0.623	rs133328	ENSG00000227370.1	RP4-669P10.19	-4.62	4.98e-06	0.00108	-0.2	-0.21	Cognitive function;	chr22:42012075	chr22:42132543~42132998:+
HNSC	cis	rs6723108	0.627	rs4954189	ENSG00000224043.6	CCNT2-AS1	-4.62	4.98e-06	0.00108	-0.26	-0.21	Type 2 diabetes;	chr2:134849763	chr2:134735464~134918710:-
HNSC	cis	rs651386	0.506	rs10919448	ENSG00000271811.1	RP1-79C4.4	4.62	4.98e-06	0.00108	0.23	0.21	Atrial fibrillation;	chr1:170630432	chr1:170667381~170669425:+
HNSC	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	4.62	4.98e-06	0.00108	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	4.62	4.98e-06	0.00108	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	4.62	4.98e-06	0.00108	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	4.62	4.98e-06	0.00108	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	4.62	4.98e-06	0.00108	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
HNSC	cis	rs4356203	0.905	rs7107283	ENSG00000272034.1	SNORD14A	4.62	4.98e-06	0.00108	0.16	0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17074654~17074744:-
HNSC	cis	rs9863	0.861	rs77020228	ENSG00000269938.1	RP11-214K3.20	-4.62	4.98e-06	0.00108	-0.25	-0.21	White blood cell count;	chr12:123933925	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs11057396	ENSG00000269938.1	RP11-214K3.20	-4.62	4.98e-06	0.00108	-0.25	-0.21	White blood cell count;	chr12:123934515	chr12:123968023~123968579:-
HNSC	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	4.62	4.98e-06	0.00108	0.24	0.21	Height;	chr14:75040822	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	4.62	4.98e-06	0.00108	0.24	0.21	Height;	chr14:75045806	chr14:75011269~75012851:-
HNSC	cis	rs4664293	0.625	rs7590617	ENSG00000226266.5	AC009961.3	4.62	4.98e-06	0.00108	0.22	0.21	Monocyte percentage of white cells;	chr2:159775437	chr2:159670708~159712435:-
HNSC	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	4.62	4.98e-06	0.00108	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	4.62	4.98e-06	0.00108	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
HNSC	cis	rs4947019	0.686	rs9487083	ENSG00000260273.1	RP11-425D10.10	4.62	4.98e-06	0.00108	0.54	0.21	Hematological parameters;	chr6:109394399	chr6:109382795~109383666:+
HNSC	cis	rs7824557	0.527	rs4634600	ENSG00000269918.1	AF131215.9	-4.62	4.98e-06	0.00108	-0.2	-0.21	Retinal vascular caliber;	chr8:11381508	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.527	rs4631425	ENSG00000269918.1	AF131215.9	-4.62	4.98e-06	0.00108	-0.2	-0.21	Retinal vascular caliber;	chr8:11381545	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.585	rs4549730	ENSG00000269918.1	AF131215.9	-4.62	4.98e-06	0.00108	-0.2	-0.21	Neuroticism;	chr8:11381569	chr8:11104691~11106704:-
HNSC	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-4.62	4.98e-06	0.00108	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
HNSC	cis	rs11846409	0.932	rs10151046	ENSG00000254174.1	IGHV1-12	4.62	4.98e-06	0.00108	0.16	0.21	Rheumatic heart disease;	chr14:106633095	chr14:106122420~106122709:-
HNSC	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-4.62	4.98e-06	0.00108	-0.28	-0.21	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
HNSC	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	4.62	4.99e-06	0.00108	0.19	0.21	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
HNSC	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	4.62	4.99e-06	0.00108	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	4.62	4.99e-06	0.00108	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
HNSC	cis	rs12935418	0.616	rs9921448	ENSG00000278985.1	RP11-303E16.9	4.62	4.99e-06	0.00108	0.2	0.21	Mean corpuscular volume;	chr16:80975593	chr16:80982319~80984094:-
HNSC	cis	rs9921338	0.961	rs8056282	ENSG00000263080.1	RP11-485G7.5	4.62	4.99e-06	0.00108	0.23	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11313379	chr16:11341809~11345211:-
HNSC	cis	rs3806843	1	rs6870764	ENSG00000202515.1	VTRNA1-3	-4.62	5e-06	0.00108	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs6891995	ENSG00000202515.1	VTRNA1-3	-4.62	5e-06	0.00108	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs13184940	ENSG00000202515.1	VTRNA1-3	-4.62	5e-06	0.00108	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs1476768	ENSG00000202515.1	VTRNA1-3	-4.62	5e-06	0.00108	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs9686540	ENSG00000202515.1	VTRNA1-3	-4.62	5e-06	0.00108	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr5:140726158~140726246:+
HNSC	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-4.62	5e-06	0.00108	-0.18	-0.21	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
HNSC	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-4.62	5e-06	0.00108	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
HNSC	cis	rs1713985	1	rs1713985	ENSG00000269949.1	RP11-738E22.3	-4.62	5e-06	0.00108	-0.38	-0.21	Age-related macular degeneration;	chr4:56920284	chr4:56960927~56961373:-
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-4.62	5e-06	0.00108	-0.27	-0.21	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000254340.1	RP11-10A14.3	4.62	5e-06	0.00108	0.26	0.21	Mood instability;	chr8:8444284	chr8:9141424~9145435:+
HNSC	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-4.62	5e-06	0.00108	-0.3	-0.21	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
HNSC	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-4.62	5e-06	0.00108	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-4.62	5e-06	0.00108	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
HNSC	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	4.62	5.01e-06	0.00108	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
HNSC	cis	rs4664293	0.647	rs357028	ENSG00000226266.5	AC009961.3	-4.62	5.01e-06	0.00108	-0.21	-0.21	Monocyte percentage of white cells;	chr2:159635331	chr2:159670708~159712435:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000254174.1	IGHV1-12	4.62	5.01e-06	0.00108	0.18	0.21	Alzheimer's disease (late onset);	chr14:106701309	chr14:106122420~106122709:-
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	4.62	5.01e-06	0.00109	0.25	0.21	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
HNSC	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	4.62	5.01e-06	0.00109	0.23	0.21	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
HNSC	cis	rs73222236	0.825	rs7622833	ENSG00000273486.1	RP11-731C17.2	4.62	5.01e-06	0.00109	0.17	0.21	Coronary artery disease;	chr3:136323079	chr3:136837338~136839021:-
HNSC	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-4.62	5.01e-06	0.00109	-0.22	-0.21	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
HNSC	cis	rs1223397	0.938	rs17767967	ENSG00000215022.6	RP1-257A7.4	-4.62	5.01e-06	0.00109	-0.27	-0.21	Blood pressure;	chr6:13281835	chr6:13264861~13295586:-
HNSC	cis	rs7824557	0.527	rs2572449	ENSG00000269918.1	AF131215.9	4.62	5.01e-06	0.00109	0.2	0.21	Retinal vascular caliber;	chr8:11381628	chr8:11104691~11106704:-
HNSC	cis	rs933688	0.759	rs1423593	ENSG00000281357.1	ARRDC3-AS1	4.62	5.02e-06	0.00109	0.31	0.21	Smoking behavior;	chr5:91456534	chr5:91380349~91439085:+
HNSC	cis	rs9990333	0.562	rs75681503	ENSG00000231464.1	AC024937.4	4.62	5.02e-06	0.00109	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195996738~195998233:+
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	4.62	5.02e-06	0.00109	0.25	0.21	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
HNSC	cis	rs57960857	1	rs57960857	ENSG00000251022.5	THAP9-AS1	4.62	5.02e-06	0.00109	0.2	0.21	Neutrophil percentage of white cells;	chr4:82886057	chr4:82893009~82900960:-
HNSC	cis	rs1223397	1	rs1223403	ENSG00000215022.6	RP1-257A7.4	-4.62	5.02e-06	0.00109	-0.27	-0.21	Blood pressure;	chr6:13271580	chr6:13264861~13295586:-
HNSC	cis	rs3015497	0.646	rs2934698	ENSG00000269906.1	RP11-248J18.2	-4.62	5.02e-06	0.00109	-0.29	-0.21	Mean platelet volume;	chr14:50671165	chr14:50662511~50663178:-
HNSC	cis	rs4664293	0.625	rs7564585	ENSG00000226266.5	AC009961.3	4.62	5.02e-06	0.00109	0.22	0.21	Monocyte percentage of white cells;	chr2:159775582	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.546	rs7564399	ENSG00000226266.5	AC009961.3	4.62	5.02e-06	0.00109	0.22	0.21	Monocyte percentage of white cells;	chr2:159775608	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.625	rs35481084	ENSG00000226266.5	AC009961.3	4.62	5.02e-06	0.00109	0.22	0.21	Monocyte percentage of white cells;	chr2:159777729	chr2:159670708~159712435:-
HNSC	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-4.62	5.03e-06	0.00109	-0.27	-0.21	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
HNSC	cis	rs1355223	0.583	rs2941060	ENSG00000271369.1	RP11-350D17.3	4.62	5.03e-06	0.00109	0.24	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857607	chr11:34709600~34710161:+
HNSC	cis	rs6964587	0.869	rs7793946	ENSG00000188693.7	CYP51A1-AS1	4.62	5.03e-06	0.00109	0.23	0.21	Breast cancer;	chr7:91891314	chr7:92134604~92180725:+
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000224373.3	IGHV4-59	-4.62	5.03e-06	0.00109	-0.13	-0.21	Kawasaki disease;	chr14:106684476	chr14:106627249~106627825:-
HNSC	cis	rs2243480	1	rs1618893	ENSG00000106610.13	STAG3L4	-4.62	5.03e-06	0.00109	-0.39	-0.21	Diabetic kidney disease;	chr7:66631132	chr7:67302621~67321526:+
HNSC	cis	rs1908814	0.504	rs7830734	ENSG00000255495.1	AC145124.2	4.62	5.04e-06	0.00109	0.23	0.21	Neuroticism;	chr8:11938130	chr8:12194467~12196280:+
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	4.62	5.04e-06	0.00109	0.27	0.21	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
HNSC	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	4.62	5.04e-06	0.00109	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
HNSC	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	4.62	5.04e-06	0.00109	0.25	0.21	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
HNSC	cis	rs3736485	0.966	rs28376817	ENSG00000259438.1	CTD-2650P22.1	4.62	5.04e-06	0.00109	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51597083	chr15:52010999~52019095:-
HNSC	cis	rs3806843	0.676	rs2245643	ENSG00000202515.1	VTRNA1-3	4.62	5.04e-06	0.00109	0.23	0.21	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr5:140726158~140726246:+
HNSC	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	4.62	5.04e-06	0.00109	0.2	0.21	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
HNSC	cis	rs7572733	0.935	rs6753450	ENSG00000222017.1	AC011997.1	4.62	5.04e-06	0.00109	0.25	0.21	Dermatomyositis;	chr2:197870307	chr2:197693106~197774823:+
HNSC	cis	rs12935418	0.583	rs2549856	ENSG00000261061.1	RP11-303E16.2	4.62	5.04e-06	0.00109	0.22	0.21	Mean corpuscular volume;	chr16:80993322	chr16:81030770~81031485:+
HNSC	cis	rs988913	0.706	rs7761336	ENSG00000224984.1	RP11-524H19.2	4.62	5.04e-06	0.00109	0.24	0.21	Menarche (age at onset);	chr6:54869804	chr6:54840118~54840855:-
HNSC	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	4.62	5.04e-06	0.00109	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
HNSC	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	4.62	5.04e-06	0.00109	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
HNSC	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	4.62	5.05e-06	0.00109	0.29	0.21	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
HNSC	cis	rs7086627	0.515	rs10887903	ENSG00000226659.1	RP11-137H2.4	-4.62	5.05e-06	0.00109	-0.25	-0.21	Post bronchodilator FEV1;	chr10:80450885	chr10:80529597~80535942:-
HNSC	cis	rs11673344	0.523	rs2562594	ENSG00000276846.1	CTD-3220F14.3	4.62	5.05e-06	0.00109	0.23	0.21	Obesity-related traits;	chr19:37023783	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs8101392	ENSG00000276846.1	CTD-3220F14.3	4.62	5.05e-06	0.00109	0.23	0.21	Obesity-related traits;	chr19:37024416	chr19:37314868~37315620:-
HNSC	cis	rs5758511	0.68	rs5758682	ENSG00000205702.9	CYP2D7	4.62	5.05e-06	0.00109	0.19	0.21	Birth weight;	chr22:42249196	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs34107327	ENSG00000205702.9	CYP2D7	4.62	5.05e-06	0.00109	0.19	0.21	Birth weight;	chr22:42252347	chr22:42140203~42144577:-
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000204709.4	LINC01556	4.62	5.05e-06	0.00109	0.29	0.21	Depression;	chr6:28091242	chr6:28943877~28944537:+
HNSC	cis	rs3806843	0.966	rs3756341	ENSG00000202515.1	VTRNA1-3	-4.62	5.06e-06	0.00109	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr5:140726158~140726246:+
HNSC	cis	rs6723108	0.627	rs10432371	ENSG00000224043.6	CCNT2-AS1	-4.62	5.06e-06	0.00109	-0.26	-0.21	Type 2 diabetes;	chr2:134852176	chr2:134735464~134918710:-
HNSC	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	4.62	5.06e-06	0.00109	0.26	0.21	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
HNSC	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-4.62	5.06e-06	0.0011	-0.22	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
HNSC	cis	rs948562	0.569	rs74810062	ENSG00000280010.1	AP001350.4	4.62	5.07e-06	0.0011	0.36	0.21	Lymphoma;	chr11:58446218	chr11:58627435~58628528:+
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000224373.3	IGHV4-59	4.62	5.07e-06	0.0011	0.14	0.21	Kawasaki disease;	chr14:106716897	chr14:106627249~106627825:-
HNSC	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-4.62	5.07e-06	0.0011	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
HNSC	cis	rs4862750	0.872	rs6553030	ENSG00000250971.1	RP11-696F12.1	4.62	5.07e-06	0.0011	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.832	rs6836076	ENSG00000250971.1	RP11-696F12.1	4.62	5.07e-06	0.0011	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs6836781	ENSG00000250971.1	RP11-696F12.1	4.62	5.07e-06	0.0011	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs11947595	ENSG00000250971.1	RP11-696F12.1	4.62	5.07e-06	0.0011	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:187060099~187060930:+
HNSC	cis	rs17428076	0.872	rs17428174	ENSG00000228389.1	AC068039.4	-4.62	5.07e-06	0.0011	-0.25	-0.21	Myopia;	chr2:172021244	chr2:171773482~171775844:+
HNSC	cis	rs4699052	0.963	rs4699057	ENSG00000246560.2	RP11-10L12.4	-4.62	5.07e-06	0.0011	-0.25	-0.21	Testicular germ cell tumor;	chr4:103249966	chr4:102828055~102844075:+
HNSC	cis	rs6496044	0.611	rs6496055	ENSG00000259295.5	CSPG4P12	4.62	5.07e-06	0.0011	0.25	0.21	Interstitial lung disease;	chr15:85527457	chr15:85191438~85213905:+
HNSC	cis	rs494003	1	rs578056	ENSG00000255120.4	OVOL1-AS1	4.62	5.08e-06	0.0011	0.26	0.21	Systemic lupus erythematosus;	chr11:65747403	chr11:65789051~65790868:-
HNSC	cis	rs6723108	0.627	rs4954191	ENSG00000224043.6	CCNT2-AS1	-4.62	5.08e-06	0.0011	-0.26	-0.21	Type 2 diabetes;	chr2:134854878	chr2:134735464~134918710:-
HNSC	cis	rs11673344	0.542	rs2562585	ENSG00000276846.1	CTD-3220F14.3	4.62	5.08e-06	0.0011	0.23	0.21	Obesity-related traits;	chr19:37018321	chr19:37314868~37315620:-
HNSC	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	4.62	5.08e-06	0.0011	0.25	0.21	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-4.62	5.08e-06	0.0011	-0.28	-0.21	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-4.62	5.08e-06	0.0011	-0.25	-0.21	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
HNSC	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-4.62	5.08e-06	0.0011	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
HNSC	cis	rs2898290	0.617	rs13278965	ENSG00000255310.2	AF131215.2	4.62	5.08e-06	0.0011	0.2	0.21	Systolic blood pressure;	chr8:11609236	chr8:11107788~11109726:-
HNSC	cis	rs9640161	0.83	rs1051760	ENSG00000261305.1	RP4-584D14.7	4.62	5.08e-06	0.0011	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150373541	chr7:150341771~150342607:+
HNSC	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	4.62	5.08e-06	0.0011	0.22	0.21	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
HNSC	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-4.62	5.09e-06	0.0011	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
HNSC	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-4.61	5.09e-06	0.0011	-0.25	-0.21	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
HNSC	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-4.61	5.09e-06	0.0011	-0.23	-0.21	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
HNSC	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	4.61	5.09e-06	0.0011	0.26	0.21	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
HNSC	cis	rs4295623	0.553	rs11250163	ENSG00000255310.2	AF131215.2	4.61	5.1e-06	0.0011	0.2	0.21	Morning vs. evening chronotype;	chr8:11738928	chr8:11107788~11109726:-
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	4.61	5.1e-06	0.0011	0.31	0.21	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
HNSC	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.61	5.1e-06	0.0011	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
HNSC	cis	rs916888	0.773	rs199445	ENSG00000260075.1	NSFP1	-4.61	5.1e-06	0.0011	-0.3	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.773	rs199443	ENSG00000260075.1	NSFP1	-4.61	5.1e-06	0.0011	-0.3	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46372855~46487141:+
HNSC	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	4.61	5.11e-06	0.0011	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	4.61	5.11e-06	0.0011	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
HNSC	cis	rs1056107	0.897	rs1887518	ENSG00000225513.1	RP11-165N19.2	4.61	5.11e-06	0.0011	0.22	0.21	Colorectal cancer;	chr9:112195177	chr9:112173522~112173971:-
HNSC	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	4.61	5.11e-06	0.0011	0.25	0.21	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
HNSC	cis	rs9287719	0.967	rs4284804	ENSG00000243819.4	RN7SL832P	4.61	5.11e-06	0.0011	0.2	0.21	Prostate cancer;	chr2:10581998	chr2:10690344~10692099:+
HNSC	cis	rs853679	0.546	rs13213152	ENSG00000219392.1	RP1-265C24.5	-4.61	5.12e-06	0.0011	-0.43	-0.21	Depression;	chr6:28381921	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs13213986	ENSG00000219392.1	RP1-265C24.5	-4.61	5.12e-06	0.0011	-0.43	-0.21	Depression;	chr6:28390232	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs34546986	ENSG00000219392.1	RP1-265C24.5	-4.61	5.12e-06	0.0011	-0.43	-0.21	Depression;	chr6:28394532	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs34871267	ENSG00000219392.1	RP1-265C24.5	-4.61	5.12e-06	0.0011	-0.43	-0.21	Depression;	chr6:28396455	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs35883476	ENSG00000219392.1	RP1-265C24.5	-4.61	5.12e-06	0.0011	-0.43	-0.21	Depression;	chr6:28400731	chr6:28115628~28116551:+
HNSC	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	4.61	5.12e-06	0.00111	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
HNSC	cis	rs3733585	0.673	rs9993410	ENSG00000250413.1	RP11-448G15.1	4.61	5.12e-06	0.00111	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9949640	chr4:10006482~10009725:+
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	4.61	5.13e-06	0.00111	0.22	0.21	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
HNSC	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	4.61	5.13e-06	0.00111	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	4.61	5.13e-06	0.00111	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
HNSC	cis	rs8067545	0.641	rs860335	ENSG00000266126.1	RP11-209D14.4	4.61	5.13e-06	0.00111	0.24	0.21	Schizophrenia;	chr17:19934366	chr17:19929372~19929737:-
HNSC	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	4.61	5.13e-06	0.00111	0.2	0.21	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
HNSC	cis	rs9650657	0.537	rs7016385	ENSG00000269918.1	AF131215.9	4.61	5.13e-06	0.00111	0.2	0.21	Neuroticism;	chr8:10921962	chr8:11104691~11106704:-
HNSC	cis	rs2904524	1	rs7309116	ENSG00000257815.4	RP11-611E13.2	-4.61	5.13e-06	0.00111	-0.25	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70341314	chr12:69904033~70243360:-
HNSC	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-4.61	5.13e-06	0.00111	-0.28	-0.21	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
HNSC	cis	rs72615157	0.561	rs113844570	ENSG00000078319.8	PMS2P1	-4.61	5.13e-06	0.00111	-0.28	-0.21	Lung function (FEV1/FVC);	chr7:100276155	chr7:100320992~100341908:-
HNSC	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-4.61	5.13e-06	0.00111	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
HNSC	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-4.61	5.13e-06	0.00111	-0.35	-0.21	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
HNSC	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	4.61	5.14e-06	0.00111	0.37	0.21	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
HNSC	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-4.61	5.14e-06	0.00111	-0.26	-0.21	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
HNSC	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	4.61	5.14e-06	0.00111	0.2	0.21	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	4.61	5.14e-06	0.00111	0.25	0.21	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
HNSC	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-4.61	5.14e-06	0.00111	-0.23	-0.21	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
HNSC	cis	rs4853525	0.522	rs1860167	ENSG00000235852.1	AC005540.3	4.61	5.14e-06	0.00111	0.26	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190717661	chr2:190880797~190882059:-
HNSC	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	4.61	5.14e-06	0.00111	0.24	0.21	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	4.61	5.14e-06	0.00111	0.24	0.21	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	4.61	5.14e-06	0.00111	0.25	0.21	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
HNSC	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	4.61	5.15e-06	0.00111	0.28	0.21	Gout;	chr7:66682070	chr7:66880708~66882981:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	4.61	5.15e-06	0.00111	0.28	0.21	Gout;	chr7:66682162	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66679692	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66692349	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66693433	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66694214	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66701371	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66702658	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66706390	chr7:66880708~66882981:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-4.61	5.15e-06	0.00111	-0.28	-0.21	Gout;	chr7:66710076	chr7:66880708~66882981:+
HNSC	cis	rs2933343	0.63	rs75824035	ENSG00000261159.1	RP11-723O4.9	4.61	5.15e-06	0.00111	0.21	0.21	IgG glycosylation;	chr3:128934142	chr3:128859716~128860526:-
HNSC	cis	rs7735319	0.8	rs58843681	ENSG00000250697.1	CTD-2066L21.3	4.61	5.15e-06	0.00111	0.26	0.21	Systolic blood pressure;	chr5:33064046	chr5:32925639~33297910:-
HNSC	cis	rs10462794	0.853	rs10061389	ENSG00000260763.1	RP11-445O3.3	-4.61	5.15e-06	0.00111	-0.28	-0.21	DNA methylation (variation);	chr5:4509839	chr5:4436850~4440259:-
HNSC	cis	rs853679	0.546	rs35017208	ENSG00000219392.1	RP1-265C24.5	-4.61	5.15e-06	0.00111	-0.42	-0.21	Depression;	chr6:28377505	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs36092177	ENSG00000219392.1	RP1-265C24.5	-4.61	5.15e-06	0.00111	-0.42	-0.21	Depression;	chr6:28390030	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs2232429	ENSG00000219392.1	RP1-265C24.5	-4.61	5.15e-06	0.00111	-0.42	-0.21	Depression;	chr6:28391855	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs2232426	ENSG00000219392.1	RP1-265C24.5	-4.61	5.15e-06	0.00111	-0.42	-0.21	Depression;	chr6:28392882	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs2232423	ENSG00000219392.1	RP1-265C24.5	-4.61	5.15e-06	0.00111	-0.42	-0.21	Depression;	chr6:28398374	chr6:28115628~28116551:+
HNSC	cis	rs7615952	0.641	rs61048217	ENSG00000248787.1	RP11-666A20.4	-4.61	5.15e-06	0.00111	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126089062	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs60839048	ENSG00000248787.1	RP11-666A20.4	-4.61	5.15e-06	0.00111	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126089095	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs7640158	ENSG00000248787.1	RP11-666A20.4	-4.61	5.15e-06	0.00111	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126089168	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.641	rs2365019	ENSG00000248787.1	RP11-666A20.4	-4.61	5.15e-06	0.00111	-0.3	-0.21	Blood pressure (smoking interaction);	chr3:126089292	chr3:125908005~125910272:-
HNSC	cis	rs4978813	0.519	rs6477707	ENSG00000213539.4	YBX1P6	4.61	5.15e-06	0.00111	0.25	0.21	Plantar warts;	chr9:109498479	chr9:109532830~109534332:-
HNSC	cis	rs4978813	0.519	rs10979891	ENSG00000213539.4	YBX1P6	4.61	5.15e-06	0.00111	0.25	0.21	Plantar warts;	chr9:109499064	chr9:109532830~109534332:-
HNSC	cis	rs4253772	0.55	rs6007761	ENSG00000277232.2	GTSE1-AS1	4.61	5.15e-06	0.00111	0.26	0.21	Cholesterol, total;LDL cholesterol;	chr22:46274497	chr22:46295143~46296660:-
HNSC	cis	rs9880211	0.528	rs75685279	ENSG00000239213.4	NCK1-AS1	4.61	5.15e-06	0.00111	0.21	0.21	Height;Body mass index;	chr3:136715991	chr3:136841726~136862054:-
HNSC	cis	rs7809950	0.678	rs6949634	ENSG00000238832.1	snoU109	-4.61	5.15e-06	0.00111	-0.3	-0.21	Coronary artery disease;	chr7:107344239	chr7:107603363~107603507:+
HNSC	cis	rs11893307	0.509	rs12618075	ENSG00000228509.4	AC006460.2	4.61	5.15e-06	0.00111	0.27	0.21	Mean platelet volume;	chr2:190681095	chr2:190676944~190708716:-
HNSC	cis	rs67981189	0.896	rs2526882	ENSG00000274818.1	RP1-292L20.3	-4.61	5.16e-06	0.00111	-0.24	-0.21	Schizophrenia;	chr14:70907985	chr14:70906657~70907111:-
HNSC	cis	rs12935418	0.672	rs3784814	ENSG00000261061.1	RP11-303E16.2	-4.61	5.16e-06	0.00111	-0.22	-0.21	Mean corpuscular volume;	chr16:81007652	chr16:81030770~81031485:+
HNSC	cis	rs73198271	0.74	rs1039912	ENSG00000173295.6	FAM86B3P	-4.61	5.16e-06	0.00111	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8228595~8244865:+
HNSC	cis	rs9392556	0.6	rs661404	ENSG00000230648.1	RP3-406P24.3	4.61	5.16e-06	0.00111	0.24	0.21	Blood metabolite levels;	chr6:4125863	chr6:4018843~4021215:-
HNSC	cis	rs2518049	0.563	rs17134724	ENSG00000224034.1	RP11-445P17.8	-4.61	5.16e-06	0.00111	-0.29	-0.21	Metabolic traits;	chr10:5276549	chr10:5266033~5271236:-
HNSC	cis	rs7985	0.901	rs736690	ENSG00000244625.4	MIATNB	4.61	5.16e-06	0.00111	0.24	0.21	Electroencephalogram traits;	chr22:26678805	chr22:26672767~26780207:+
HNSC	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.61	5.16e-06	0.00111	0.19	0.21	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
HNSC	cis	rs13256369	0.851	rs11249890	ENSG00000173295.6	FAM86B3P	4.61	5.16e-06	0.00111	0.28	0.21	Obesity-related traits;	chr8:8707735	chr8:8228595~8244865:+
HNSC	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-4.61	5.16e-06	0.00111	-0.24	-0.21	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
HNSC	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	4.61	5.16e-06	0.00111	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
HNSC	cis	rs721917	0.525	rs2250473	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.17e-06	0.00112	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2758561	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.17e-06	0.00112	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79663088~79826594:-
HNSC	cis	rs9813712	0.571	rs9866568	ENSG00000249846.5	RP11-77P16.4	-4.61	5.17e-06	0.00112	-0.23	-0.21	Response to amphetamines;	chr3:130297539	chr3:130112550~130120579:+
HNSC	cis	rs12682352	0.602	rs4841044	ENSG00000254340.1	RP11-10A14.3	-4.61	5.17e-06	0.00112	-0.26	-0.21	Neuroticism;	chr8:8807430	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	4.61	5.17e-06	0.00112	0.25	0.21	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	4.61	5.17e-06	0.00112	0.25	0.21	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	4.61	5.17e-06	0.00112	0.25	0.21	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs383402	ENSG00000230295.1	RP11-458F8.2	4.61	5.18e-06	0.00112	0.27	0.21	Diabetic kidney disease;	chr7:66121666	chr7:66880708~66882981:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	4.61	5.18e-06	0.00112	0.25	0.21	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
HNSC	cis	rs116095464	0.558	rs56127718	ENSG00000250848.1	CTD-2083E4.5	-4.61	5.18e-06	0.00112	-0.29	-0.21	Breast cancer;	chr5:270158	chr5:288833~290321:-
HNSC	cis	rs116095464	0.614	rs10061564	ENSG00000250848.1	CTD-2083E4.5	-4.61	5.18e-06	0.00112	-0.29	-0.21	Breast cancer;	chr5:271214	chr5:288833~290321:-
HNSC	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	4.61	5.19e-06	0.00112	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
HNSC	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-4.61	5.19e-06	0.00112	-0.27	-0.21	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
HNSC	cis	rs853679	0.546	rs13195291	ENSG00000204709.4	LINC01556	4.61	5.19e-06	0.00112	0.46	0.21	Depression;	chr6:28201463	chr6:28943877~28944537:+
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000255495.1	AC145124.2	4.61	5.19e-06	0.00112	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12194467~12196280:+
HNSC	cis	rs12935418	0.583	rs2244452	ENSG00000261061.1	RP11-303E16.2	4.61	5.19e-06	0.00112	0.22	0.21	Mean corpuscular volume;	chr16:80991767	chr16:81030770~81031485:+
HNSC	cis	rs1799949	0.965	rs9897425	ENSG00000236383.6	LINC00854	-4.61	5.2e-06	0.00112	-0.2	-0.21	Menopause (age at onset);	chr17:43352811	chr17:43216941~43305976:-
HNSC	cis	rs11722228	0.549	rs2241488	ENSG00000250413.1	RP11-448G15.1	-4.61	5.2e-06	0.00112	-0.33	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10099507	chr4:10006482~10009725:+
HNSC	cis	rs6928977	0.863	rs2223803	ENSG00000217482.2	HMGB1P17	-4.61	5.2e-06	0.00112	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135636086~135636713:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-4.61	5.2e-06	0.00112	-0.21	-0.21	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
HNSC	cis	rs6688613	1	rs6688613	ENSG00000215834.7	FMO9P	-4.61	5.2e-06	0.00112	-0.25	-0.21	Refractive astigmatism;	chr1:166982632	chr1:166603675~166631400:+
HNSC	cis	rs9329221	0.527	rs4841352	ENSG00000269918.1	AF131215.9	4.61	5.2e-06	0.00112	0.21	0.21	Neuroticism;	chr8:10470080	chr8:11104691~11106704:-
HNSC	cis	rs9321453	0.962	rs6910954	ENSG00000231971.4	RP11-557H15.3	4.61	5.21e-06	0.00112	0.25	0.21	Urate levels;	chr6:134445337	chr6:134428240~134520585:-
HNSC	cis	rs17270561	0.779	rs12209218	ENSG00000272810.1	U91328.22	-4.61	5.21e-06	0.00112	-0.23	-0.21	Iron status biomarkers;	chr6:25887548	chr6:26013241~26013757:+
HNSC	cis	rs9863	0.794	rs7133378	ENSG00000269938.1	RP11-214K3.20	-4.61	5.21e-06	0.00112	-0.24	-0.21	White blood cell count;	chr12:123924955	chr12:123968023~123968579:-
HNSC	cis	rs3015497	0.543	rs3015493	ENSG00000269906.1	RP11-248J18.2	-4.61	5.21e-06	0.00112	-0.29	-0.21	Mean platelet volume;	chr14:50657635	chr14:50662511~50663178:-
HNSC	cis	rs9907295	0.892	rs4795100	ENSG00000270977.1	AC015849.16	-4.61	5.22e-06	0.00112	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35917470	chr17:35893707~35911023:-
HNSC	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	4.61	5.22e-06	0.00112	0.34	0.21	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	4.61	5.22e-06	0.00112	0.26	0.21	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
HNSC	cis	rs9287719	1	rs9287719	ENSG00000243819.4	RN7SL832P	4.61	5.22e-06	0.00112	0.2	0.21	Prostate cancer;	chr2:10570604	chr2:10690344~10692099:+
HNSC	cis	rs853679	0.527	rs9461443	ENSG00000219891.2	ZSCAN12P1	4.61	5.22e-06	0.00112	0.29	0.21	Depression;	chr6:28226851	chr6:28091154~28093664:+
HNSC	cis	rs577676	0.586	rs12068805	ENSG00000271811.1	RP1-79C4.4	4.61	5.22e-06	0.00113	0.24	0.21	Prevalent atrial fibrillation;	chr1:170632172	chr1:170667381~170669425:+
HNSC	cis	rs577676	0.586	rs12566725	ENSG00000271811.1	RP1-79C4.4	4.61	5.22e-06	0.00113	0.24	0.21	Prevalent atrial fibrillation;	chr1:170632794	chr1:170667381~170669425:+
HNSC	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	4.61	5.23e-06	0.00113	0.23	0.21	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-4.61	5.23e-06	0.00113	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
HNSC	cis	rs757081	0.667	rs12577388	ENSG00000260196.1	RP1-239B22.5	-4.61	5.23e-06	0.00113	-0.26	-0.21	Systolic blood pressure;	chr11:17079608	chr11:17380649~17383531:+
HNSC	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-4.61	5.23e-06	0.00113	-0.28	-0.21	Gout;	chr7:66693028	chr7:66880708~66882981:+
HNSC	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-4.61	5.23e-06	0.00113	-0.24	-0.21	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
HNSC	cis	rs12935418	0.583	rs2549856	ENSG00000278985.1	RP11-303E16.9	-4.61	5.23e-06	0.00113	-0.2	-0.21	Mean corpuscular volume;	chr16:80993322	chr16:80982319~80984094:-
HNSC	cis	rs1971762	0.563	rs4759285	ENSG00000270175.1	RP11-793H13.11	-4.61	5.23e-06	0.00113	-0.18	-0.21	Height;	chr12:53685729	chr12:53500162~53500936:-
HNSC	cis	rs9368481	0.761	rs9357030	ENSG00000224843.5	LINC00240	4.61	5.24e-06	0.00113	0.21	0.21	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26956992~27023924:+
HNSC	cis	rs13256369	0.802	rs11995449	ENSG00000173295.6	FAM86B3P	4.61	5.24e-06	0.00113	0.28	0.21	Obesity-related traits;	chr8:8702388	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	4.61	5.24e-06	0.00113	0.26	0.21	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
HNSC	cis	rs6964587	1	rs12533199	ENSG00000188693.7	CYP51A1-AS1	-4.61	5.24e-06	0.00113	-0.22	-0.21	Breast cancer;	chr7:92128079	chr7:92134604~92180725:+
HNSC	cis	rs9450351	0.744	rs9353319	ENSG00000203875.9	SNHG5	-4.61	5.24e-06	0.00113	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85522825	chr6:85660950~85678736:-
HNSC	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	4.61	5.24e-06	0.00113	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
HNSC	cis	rs73222236	0.75	rs35375192	ENSG00000273486.1	RP11-731C17.2	4.61	5.24e-06	0.00113	0.17	0.21	Coronary artery disease;	chr3:136456683	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.755	rs3789849	ENSG00000173295.6	FAM86B3P	4.61	5.25e-06	0.00113	0.23	0.21	Mood instability;	chr8:8829544	chr8:8228595~8244865:+
HNSC	cis	rs1008375	1	rs10939744	ENSG00000249502.1	AC006160.5	-4.61	5.25e-06	0.00113	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17662850	chr4:17587467~17614571:-
HNSC	cis	rs916888	0.821	rs199513	ENSG00000260075.1	NSFP1	4.61	5.25e-06	0.00113	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46372855~46487141:+
HNSC	cis	rs4218	0.619	rs10851643	ENSG00000277144.1	RP11-59H7.4	-4.61	5.25e-06	0.00113	-0.26	-0.21	Social communication problems;	chr15:59102985	chr15:59115547~59116089:-
HNSC	cis	rs7015630	0.657	rs2338882	ENSG00000251136.7	RP11-37B2.1	-4.61	5.25e-06	0.00113	-0.24	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89809970	chr8:89609409~89757727:-
HNSC	cis	rs916888	0.773	rs199439	ENSG00000260075.1	NSFP1	-4.61	5.25e-06	0.00113	-0.3	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46372855~46487141:+
HNSC	cis	rs9907295	0.71	rs28912068	ENSG00000270977.1	AC015849.16	-4.61	5.26e-06	0.00113	-0.32	-0.21	Fibroblast growth factor basic levels;	chr17:35881967	chr17:35893707~35911023:-
HNSC	cis	rs597539	0.652	rs569777	ENSG00000255741.1	RP11-757G1.5	-4.61	5.26e-06	0.00113	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68941503~68942852:-
HNSC	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-4.61	5.26e-06	0.00113	-0.28	-0.21	Pain;	chr19:21543479	chr19:21554640~21569237:-
HNSC	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	4.61	5.26e-06	0.00113	0.21	0.21	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
HNSC	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-4.61	5.26e-06	0.00113	-0.27	-0.21	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
HNSC	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-4.61	5.26e-06	0.00113	-0.27	-0.21	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
HNSC	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-4.61	5.26e-06	0.00113	-0.28	-0.21	Pain;	chr19:21540147	chr19:21554640~21569237:-
HNSC	cis	rs5758511	0.679	rs55867855	ENSG00000205702.9	CYP2D7	4.61	5.26e-06	0.00113	0.19	0.21	Birth weight;	chr22:42227252	chr22:42140203~42144577:-
HNSC	cis	rs2253762	0.527	rs11200323	ENSG00000226864.1	ATE1-AS1	-4.61	5.27e-06	0.00113	-0.3	-0.21	Breast cancer;	chr10:122008869	chr10:121928312~121951965:+
HNSC	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	4.61	5.27e-06	0.00113	0.23	0.21	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
HNSC	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	4.61	5.27e-06	0.00113	0.2	0.21	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	4.61	5.27e-06	0.00113	0.2	0.21	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
HNSC	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	4.61	5.27e-06	0.00113	0.22	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
HNSC	cis	rs442309	0.687	rs10822053	ENSG00000238280.1	RP11-436D10.3	4.61	5.27e-06	0.00113	0.25	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62701075	chr10:62793562~62805887:-
HNSC	cis	rs34421088	0.576	rs2572432	ENSG00000269918.1	AF131215.9	-4.61	5.27e-06	0.00113	-0.23	-0.21	Neuroticism;	chr8:11244214	chr8:11104691~11106704:-
HNSC	cis	rs4853525	0.651	rs12623559	ENSG00000235852.1	AC005540.3	4.61	5.27e-06	0.00113	0.27	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868617	chr2:190880797~190882059:-
HNSC	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-4.61	5.27e-06	0.00113	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-4.61	5.27e-06	0.00113	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
HNSC	cis	rs9863	0.828	rs1187415	ENSG00000269938.1	RP11-214K3.20	4.61	5.27e-06	0.00113	0.24	0.21	White blood cell count;	chr12:124006982	chr12:123968023~123968579:-
HNSC	cis	rs6142102	1	rs6059672	ENSG00000275784.1	RP5-1125A11.6	-4.61	5.27e-06	0.00113	-0.28	-0.21	Skin pigmentation;	chr20:34117662	chr20:33989480~33991818:-
HNSC	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	4.61	5.27e-06	0.00113	0.23	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
HNSC	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-4.61	5.27e-06	0.00113	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
HNSC	cis	rs73222236	0.825	rs6804194	ENSG00000273486.1	RP11-731C17.2	4.61	5.27e-06	0.00113	0.17	0.21	Coronary artery disease;	chr3:136441890	chr3:136837338~136839021:-
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000224373.3	IGHV4-59	4.61	5.27e-06	0.00113	0.12	0.21	Kawasaki disease;	chr14:106687277	chr14:106627249~106627825:-
HNSC	cis	rs721917	0.646	rs2819096	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.28e-06	0.00114	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79947857	chr10:79663088~79826594:-
HNSC	cis	rs73222236	0.787	rs34379561	ENSG00000273486.1	RP11-731C17.2	4.61	5.28e-06	0.00114	0.17	0.21	Coronary artery disease;	chr3:136464374	chr3:136837338~136839021:-
HNSC	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	4.61	5.28e-06	0.00114	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
HNSC	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	4.61	5.28e-06	0.00114	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
HNSC	cis	rs3806843	0.9	rs3756334	ENSG00000202515.1	VTRNA1-3	-4.61	5.29e-06	0.00114	-0.24	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr5:140726158~140726246:+
HNSC	cis	rs2933343	0.818	rs6764681	ENSG00000261159.1	RP11-723O4.9	-4.61	5.29e-06	0.00114	-0.24	-0.21	IgG glycosylation;	chr3:128849537	chr3:128859716~128860526:-
HNSC	cis	rs7809950	0.773	rs2237668	ENSG00000238832.1	snoU109	-4.61	5.29e-06	0.00114	-0.3	-0.21	Coronary artery disease;	chr7:107409764	chr7:107603363~107603507:+
HNSC	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	4.61	5.3e-06	0.00114	0.21	0.21	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
HNSC	cis	rs1707322	1	rs4524994	ENSG00000234329.1	RP11-767N6.2	4.61	5.3e-06	0.00114	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45651039~45651826:-
HNSC	cis	rs7809950	0.678	rs982447	ENSG00000238832.1	snoU109	-4.61	5.3e-06	0.00114	-0.29	-0.21	Coronary artery disease;	chr7:107333089	chr7:107603363~107603507:+
HNSC	cis	rs9329221	0.502	rs11777364	ENSG00000255310.2	AF131215.2	4.61	5.3e-06	0.00114	0.2	0.21	Neuroticism;	chr8:10431036	chr8:11107788~11109726:-
HNSC	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-4.61	5.3e-06	0.00114	-0.21	-0.21	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	4.61	5.3e-06	0.00114	0.25	0.21	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
HNSC	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	4.61	5.3e-06	0.00114	0.25	0.21	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs160643	ENSG00000179406.6	LINC00174	-4.61	5.31e-06	0.00114	-0.39	-0.21	Diabetic kidney disease;	chr7:66093235	chr7:66376044~66401338:-
HNSC	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-4.61	5.31e-06	0.00114	-0.27	-0.21	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
HNSC	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	4.61	5.31e-06	0.00114	0.33	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
HNSC	cis	rs6968419	0.585	rs9692117	ENSG00000237870.5	AC073130.1	4.61	5.31e-06	0.00114	0.23	0.21	Intraocular pressure;	chr7:116287905	chr7:116275606~116286734:-
HNSC	cis	rs2361718	0.5	rs12451697	ENSG00000275479.1	RP11-334C17.6	4.61	5.31e-06	0.00114	0.24	0.21	Yeast infection;	chr17:80126891	chr17:80149627~80149798:+
HNSC	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	4.61	5.31e-06	0.00114	0.18	0.21	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
HNSC	cis	rs911555	0.57	rs942862	ENSG00000270108.1	RP11-73M18.6	4.61	5.31e-06	0.00114	0.24	0.21	Intelligence (multi-trait analysis);	chr14:103555787	chr14:103687576~103688127:+
HNSC	cis	rs12935418	0.583	rs2167889	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80987867	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.552	rs2911148	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80988289	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.552	rs2549833	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80988627	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.552	rs2602448	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80989067	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549836	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80989476	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549837	ENSG00000261061.1	RP11-303E16.2	4.61	5.31e-06	0.00114	0.22	0.21	Mean corpuscular volume;	chr16:80989510	chr16:81030770~81031485:+
HNSC	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	4.61	5.31e-06	0.00114	0.21	0.21	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
HNSC	cis	rs7824557	0.767	rs11250127	ENSG00000255310.2	AF131215.2	4.61	5.31e-06	0.00114	0.2	0.21	Retinal vascular caliber;	chr8:11312700	chr8:11107788~11109726:-
HNSC	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	4.61	5.31e-06	0.00114	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
HNSC	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	4.61	5.31e-06	0.00114	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
HNSC	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.61	5.32e-06	0.00114	0.2	0.21	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
HNSC	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	4.61	5.32e-06	0.00114	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
HNSC	cis	rs1799949	1	rs35330014	ENSG00000236383.6	LINC00854	-4.6	5.33e-06	0.00114	-0.2	-0.21	Menopause (age at onset);	chr17:43060530	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs3092994	ENSG00000236383.6	LINC00854	-4.6	5.33e-06	0.00114	-0.2	-0.21	Menopause (age at onset);	chr17:43063808	chr17:43216941~43305976:-
HNSC	cis	rs4218	0.532	rs17236369	ENSG00000277144.1	RP11-59H7.4	-4.6	5.33e-06	0.00114	-0.24	-0.21	Social communication problems;	chr15:59021656	chr15:59115547~59116089:-
HNSC	cis	rs3806843	1	rs3756339	ENSG00000202515.1	VTRNA1-3	-4.6	5.33e-06	0.00114	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs3733708	ENSG00000202515.1	VTRNA1-3	-4.6	5.33e-06	0.00114	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs2240694	ENSG00000202515.1	VTRNA1-3	-4.6	5.33e-06	0.00114	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr5:140726158~140726246:+
HNSC	cis	rs9863	0.828	rs12833624	ENSG00000270028.1	RP11-380L11.4	4.6	5.33e-06	0.00114	0.24	0.21	White blood cell count;	chr12:123992326	chr12:123925461~123926083:-
HNSC	cis	rs60617249	0.795	rs34174508	ENSG00000228204.2	RP4-724E13.2	4.6	5.33e-06	0.00114	0.22	0.21	Major depression and alcohol dependence;	chr7:50874048	chr7:50866747~51022990:+
HNSC	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-4.6	5.33e-06	0.00114	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-4.6	5.33e-06	0.00114	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
HNSC	cis	rs8067545	0.616	rs203470	ENSG00000266126.1	RP11-209D14.4	4.6	5.33e-06	0.00114	0.24	0.21	Schizophrenia;	chr17:19955313	chr17:19929372~19929737:-
HNSC	cis	rs116095464	0.558	rs10036253	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:238404	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10075018	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:239060	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10076655	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:239349	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs28418643	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:240744	chr5:288833~290321:-
HNSC	cis	rs116095464	0.614	rs62344339	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:252880	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9687898	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:253837	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9688045	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:253920	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs112343653	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:257059	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs73024831	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:257077	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs62344345	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:257305	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs57335027	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:262792	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6869925	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:263921	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6875291	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:264077	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6866776	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:264380	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6874745	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:264412	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7715108	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:264546	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7730700	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.33e-06	0.00114	-0.29	-0.21	Breast cancer;	chr5:264598	chr5:288833~290321:-
HNSC	cis	rs3733585	0.699	rs12498150	ENSG00000250413.1	RP11-448G15.1	4.6	5.33e-06	0.00114	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9948913	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000254153.1	CTA-398F10.2	-4.6	5.33e-06	0.00115	-0.23	-0.21	Mood instability;	chr8:8937291	chr8:8456909~8461337:-
HNSC	cis	rs728616	0.51	rs61860860	ENSG00000225484.5	NUTM2B-AS1	-4.6	5.33e-06	0.00115	-0.37	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79663088~79826594:-
HNSC	cis	rs9813712	0.571	rs9846596	ENSG00000249846.5	RP11-77P16.4	-4.6	5.34e-06	0.00115	-0.23	-0.21	Response to amphetamines;	chr3:130288318	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.595	rs1453239	ENSG00000249846.5	RP11-77P16.4	-4.6	5.34e-06	0.00115	-0.23	-0.21	Response to amphetamines;	chr3:130288915	chr3:130112550~130120579:+
HNSC	cis	rs9813712	0.523	rs9866942	ENSG00000249846.5	RP11-77P16.4	-4.6	5.34e-06	0.00115	-0.23	-0.21	Response to amphetamines;	chr3:130297796	chr3:130112550~130120579:+
HNSC	cis	rs11971779	0.729	rs10464730	ENSG00000273391.1	RP11-634H22.1	4.6	5.34e-06	0.00115	0.26	0.21	Diisocyanate-induced asthma;	chr7:139317481	chr7:139359032~139359566:-
HNSC	cis	rs9300255	0.722	rs10773008	ENSG00000280120.1	RP11-546D6.3	4.6	5.34e-06	0.00115	0.19	0.21	Neutrophil percentage of white cells;	chr12:123316273	chr12:123152324~123153377:-
HNSC	cis	rs4761669	0.565	rs12099898	ENSG00000241556.1	RP11-490G8.1	4.6	5.34e-06	0.00115	0.21	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94805011	chr12:95467397~95467861:-
HNSC	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	4.6	5.34e-06	0.00115	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
HNSC	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-4.6	5.35e-06	0.00115	-0.28	-0.21	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
HNSC	cis	rs2439831	0.85	rs12441127	ENSG00000201136.1	RNU6-353P	-4.6	5.35e-06	0.00115	-0.33	-0.21	Lung cancer in ever smokers;	chr15:43728977	chr15:43702363~43702470:+
HNSC	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	4.6	5.35e-06	0.00115	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
HNSC	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	4.6	5.35e-06	0.00115	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
HNSC	cis	rs17739794	0.677	rs17739674	ENSG00000254207.1	RP11-43A14.1	4.6	5.35e-06	0.00115	0.23	0.21	Clozapine-induced cytotoxicity;	chr8:851584	chr8:725188~725877:-
HNSC	cis	rs9450351	0.744	rs6902904	ENSG00000203875.9	SNHG5	-4.6	5.35e-06	0.00115	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85660950~85678736:-
HNSC	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	4.6	5.35e-06	0.00115	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
HNSC	cis	rs12935418	0.672	rs2549883	ENSG00000261061.1	RP11-303E16.2	4.6	5.35e-06	0.00115	0.22	0.21	Mean corpuscular volume;	chr16:81022273	chr16:81030770~81031485:+
HNSC	cis	rs757081	0.667	rs17641418	ENSG00000260196.1	RP1-239B22.5	-4.6	5.35e-06	0.00115	-0.26	-0.21	Systolic blood pressure;	chr11:17139794	chr11:17380649~17383531:+
HNSC	cis	rs1594829	0.553	rs2046226	ENSG00000228451.3	SDAD1P1	4.6	5.35e-06	0.00115	0.24	0.21	Height;	chr8:26294534	chr8:26379259~26382953:-
HNSC	cis	rs1594829	0.535	rs1434022	ENSG00000228451.3	SDAD1P1	4.6	5.35e-06	0.00115	0.24	0.21	Height;	chr8:26295706	chr8:26379259~26382953:-
HNSC	cis	rs1594829	0.553	rs6996531	ENSG00000228451.3	SDAD1P1	4.6	5.35e-06	0.00115	0.24	0.21	Height;	chr8:26295939	chr8:26379259~26382953:-
HNSC	cis	rs1594829	0.553	rs17055108	ENSG00000228451.3	SDAD1P1	4.6	5.35e-06	0.00115	0.24	0.21	Height;	chr8:26303223	chr8:26379259~26382953:-
HNSC	cis	rs1594829	0.553	rs11135933	ENSG00000228451.3	SDAD1P1	4.6	5.35e-06	0.00115	0.24	0.21	Height;	chr8:26304848	chr8:26379259~26382953:-
HNSC	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-4.6	5.36e-06	0.00115	-0.26	-0.21	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
HNSC	cis	rs7615952	0.599	rs6766327	ENSG00000241439.1	RP11-666A20.3	4.6	5.36e-06	0.00115	0.24	0.21	Blood pressure (smoking interaction);	chr3:126004834	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs12491577	ENSG00000241439.1	RP11-666A20.3	4.6	5.36e-06	0.00115	0.24	0.21	Blood pressure (smoking interaction);	chr3:126012288	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.599	rs1875683	ENSG00000241439.1	RP11-666A20.3	4.6	5.36e-06	0.00115	0.24	0.21	Blood pressure (smoking interaction);	chr3:126013638	chr3:125958556~125958817:+
HNSC	cis	rs12539814	1	rs12539814	ENSG00000204959.4	ARHGEF34P	4.6	5.36e-06	0.00115	0.36	0.21	Diastolic blood pressure;	chr7:144433417	chr7:144272445~144286966:-
HNSC	cis	rs7085104	0.7	rs3740397	ENSG00000236937.2	PTGES3P4	4.6	5.36e-06	0.00115	0.26	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102845595~102845950:+
HNSC	cis	rs7829975	0.509	rs2945269	ENSG00000254153.1	CTA-398F10.2	4.6	5.36e-06	0.00115	0.24	0.21	Mood instability;	chr8:8258056	chr8:8456909~8461337:-
HNSC	cis	rs10845170	1	rs10845170	ENSG00000256667.5	KLRAP1	-4.6	5.37e-06	0.00115	-0.17	-0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:10571818	chr12:10588063~10599669:-
HNSC	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-4.6	5.37e-06	0.00115	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
HNSC	cis	rs11722228	0.522	rs77691548	ENSG00000250413.1	RP11-448G15.1	-4.6	5.37e-06	0.00115	-0.31	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10006482~10009725:+
HNSC	cis	rs12935418	0.616	rs2602453	ENSG00000261061.1	RP11-303E16.2	4.6	5.37e-06	0.00115	0.22	0.21	Mean corpuscular volume;	chr16:80994358	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2970086	ENSG00000261061.1	RP11-303E16.2	4.6	5.37e-06	0.00115	0.22	0.21	Mean corpuscular volume;	chr16:80994835	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2970085	ENSG00000261061.1	RP11-303E16.2	4.6	5.37e-06	0.00115	0.22	0.21	Mean corpuscular volume;	chr16:80994842	chr16:81030770~81031485:+
HNSC	cis	rs72843506	0.722	rs74255387	ENSG00000261033.1	RP11-209D14.2	4.6	5.37e-06	0.00115	0.38	0.21	Schizophrenia;	chr17:20198070	chr17:20008051~20009234:-
HNSC	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-4.6	5.37e-06	0.00115	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-4.6	5.37e-06	0.00115	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-4.6	5.37e-06	0.00115	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
HNSC	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	4.6	5.37e-06	0.00115	0.26	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
HNSC	cis	rs9959145	1	rs9946557	ENSG00000267249.1	RP11-973H7.3	-4.6	5.37e-06	0.00115	-0.32	-0.21	Immune response to smallpox vaccine (IL-6);	chr18:12563862	chr18:12670426~12671145:-
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000255495.1	AC145124.2	4.6	5.37e-06	0.00115	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12194467~12196280:+
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	4.6	5.38e-06	0.00115	0.22	0.21	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
HNSC	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4.6	5.38e-06	0.00115	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
HNSC	cis	rs4873772	0.773	rs10109113	ENSG00000253330.1	RP11-697N18.3	-4.6	5.38e-06	0.00115	-0.27	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47475519	chr8:47511034~47512141:-
HNSC	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-4.6	5.38e-06	0.00115	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
HNSC	cis	rs13126694	0.744	rs7673290	ENSG00000248429.4	RP11-597D13.9	4.6	5.38e-06	0.00115	0.24	0.21	Blood osmolality (transformed sodium);	chr4:157998335	chr4:158170752~158202877:+
HNSC	cis	rs5758511	0.68	rs58654759	ENSG00000205702.9	CYP2D7	4.6	5.39e-06	0.00115	0.19	0.21	Birth weight;	chr22:42246570	chr22:42140203~42144577:-
HNSC	cis	rs2548724	0.561	rs1584713	ENSG00000250682.4	LINC00491	4.6	5.39e-06	0.00115	0.26	0.21	Type 2 diabetes;	chr5:102431585	chr5:102609156~102671559:-
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000254153.1	CTA-398F10.2	-4.6	5.39e-06	0.00115	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8936097	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000211974.3	IGHV2-70	4.6	5.39e-06	0.00116	0.2	0.21	Kawasaki disease;	chr14:106803901	chr14:106723574~106724093:-
HNSC	cis	rs6163	0.588	rs10786706	ENSG00000213061.2	PFN1P11	4.6	5.39e-06	0.00116	0.25	0.21	Waist circumference;Hip circumference;	chr10:102740902	chr10:102838011~102845473:-
HNSC	cis	rs752590	0.65	rs6751201	ENSG00000189223.12	PAX8-AS1	4.6	5.39e-06	0.00116	0.3	0.21	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113211522~113276581:+
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-4.6	5.39e-06	0.00116	-0.19	-0.21	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
HNSC	cis	rs4388249	1	rs2300991	ENSG00000271849.1	CTC-332L22.1	-4.6	5.39e-06	0.00116	-0.32	-0.21	Schizophrenia;	chr5:109702737	chr5:109687802~109688329:-
HNSC	cis	rs761746	0.705	rs10154390	ENSG00000236132.1	CTA-440B3.1	-4.6	5.39e-06	0.00116	-0.27	-0.21	Intelligence;	chr22:31655103	chr22:31816379~31817491:-
HNSC	cis	rs73222236	0.75	rs7648591	ENSG00000273486.1	RP11-731C17.2	4.6	5.39e-06	0.00116	0.18	0.21	Coronary artery disease;	chr3:136507541	chr3:136837338~136839021:-
HNSC	cis	rs6601327	0.613	rs10094989	ENSG00000254340.1	RP11-10A14.3	4.6	5.39e-06	0.00116	0.25	0.21	Multiple myeloma (hyperdiploidy);	chr8:9754499	chr8:9141424~9145435:+
HNSC	cis	rs2286503	0.78	rs1304431	ENSG00000226329.2	AC005682.6	4.6	5.39e-06	0.00116	0.26	0.21	Fibrinogen;	chr7:22825793	chr7:22863874~22881350:-
HNSC	cis	rs1185460	0.967	rs1786141	ENSG00000272186.1	RP11-110I1.13	-4.6	5.39e-06	0.00116	-0.23	-0.21	Coronary artery disease;	chr11:119067604	chr11:119067374~119067698:-
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000255495.1	AC145124.2	4.6	5.39e-06	0.00116	0.23	0.21	Neuroticism;	chr8:11936935	chr8:12194467~12196280:+
HNSC	cis	rs9863	0.861	rs7312404	ENSG00000269938.1	RP11-214K3.20	-4.6	5.39e-06	0.00116	-0.24	-0.21	White blood cell count;	chr12:123962181	chr12:123968023~123968579:-
HNSC	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	4.6	5.4e-06	0.00116	0.27	0.21	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
HNSC	cis	rs9531006	0.752	rs12585712	ENSG00000227676.3	LINC01068	4.6	5.4e-06	0.00116	0.31	0.21	Sleep duration;	chr13:79998784	chr13:79566727~79571436:+
HNSC	cis	rs394563	0.601	rs432582	ENSG00000231760.4	RP11-350J20.5	4.6	5.4e-06	0.00116	0.28	0.21	Dupuytren's disease;	chr6:149473007	chr6:149796151~149826294:-
HNSC	cis	rs189798	0.738	rs330911	ENSG00000254153.1	CTA-398F10.2	4.6	5.4e-06	0.00116	0.25	0.21	Myopia (pathological);	chr8:9138763	chr8:8456909~8461337:-
HNSC	cis	rs11871801	0.756	rs34762299	ENSG00000267151.3	RP11-100E5.2	4.6	5.4e-06	0.00116	0.34	0.21	Crohn's disease;	chr17:42453081	chr17:43444707~43451200:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000233609.3	RP11-62H7.2	-4.6	5.4e-06	0.00116	-0.19	-0.21	Joint mobility (Beighton score);	chr8:9226344	chr8:8961200~8979025:+
HNSC	cis	rs9329221	0.527	rs4841352	ENSG00000255020.1	AF131216.5	4.6	5.41e-06	0.00116	0.23	0.21	Neuroticism;	chr8:10470080	chr8:11345748~11347502:-
HNSC	cis	rs1799949	1	rs11659028	ENSG00000236383.6	LINC00854	-4.6	5.41e-06	0.00116	-0.2	-0.21	Menopause (age at onset);	chr17:43043008	chr17:43216941~43305976:-
HNSC	cis	rs7809950	0.861	rs2701682	ENSG00000238832.1	snoU109	4.6	5.41e-06	0.00116	0.3	0.21	Coronary artery disease;	chr7:107655390	chr7:107603363~107603507:+
HNSC	cis	rs36052053	0.908	rs34599673	ENSG00000203799.9	CCDC162P	4.6	5.41e-06	0.00116	0.31	0.21	Red cell distribution width;	chr6:109251799	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs13209450	ENSG00000203799.9	CCDC162P	4.6	5.41e-06	0.00116	0.31	0.21	Red cell distribution width;	chr6:109252804	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs75793323	ENSG00000203799.9	CCDC162P	4.6	5.41e-06	0.00116	0.31	0.21	Red cell distribution width;	chr6:109253508	chr6:109285485~109355063:+
HNSC	cis	rs916888	0.697	rs199516	ENSG00000260075.1	NSFP1	4.6	5.41e-06	0.00116	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46372855~46487141:+
HNSC	cis	rs3096299	0.967	rs2911256	ENSG00000261574.1	RP1-168P16.2	4.6	5.41e-06	0.00116	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89392375~89412564:-
HNSC	cis	rs11893307	0.509	rs2356126	ENSG00000228509.4	AC006460.2	4.6	5.41e-06	0.00116	0.27	0.21	Mean platelet volume;	chr2:190677788	chr2:190676944~190708716:-
HNSC	cis	rs913655	0.545	rs2451512	ENSG00000225527.1	RP11-383B4.4	-4.6	5.41e-06	0.00116	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18778181	chr10:18531849~18533336:-
HNSC	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-4.6	5.42e-06	0.00116	-0.18	-0.21	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
HNSC	cis	rs11633886	0.528	rs3914852	ENSG00000273972.1	CTD-2306A12.1	4.6	5.42e-06	0.00116	0.24	0.21	Diisocyanate-induced asthma;	chr15:45808853	chr15:45702640~45703183:+
HNSC	cis	rs17507216	0.518	rs1877240	ENSG00000276710.3	CSPG4P8	-4.6	5.42e-06	0.00116	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82770126	chr15:82459472~82477258:+
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	4.6	5.42e-06	0.00116	0.25	0.21	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.6	5.42e-06	0.00116	0.22	0.21	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.6	5.42e-06	0.00116	0.22	0.21	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	4.6	5.42e-06	0.00116	0.22	0.21	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	4.6	5.42e-06	0.00116	0.22	0.21	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
HNSC	cis	rs116095464	0.614	rs10067482	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.42e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:219213	chr5:288833~290321:-
HNSC	cis	rs67981189	0.865	rs2810115	ENSG00000274818.1	RP1-292L20.3	-4.6	5.42e-06	0.00116	-0.24	-0.21	Schizophrenia;	chr14:70928070	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs917065	ENSG00000274818.1	RP1-292L20.3	-4.6	5.42e-06	0.00116	-0.24	-0.21	Schizophrenia;	chr14:70931129	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs1018977	ENSG00000274818.1	RP1-292L20.3	-4.6	5.42e-06	0.00116	-0.24	-0.21	Schizophrenia;	chr14:70933936	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.752	rs2332477	ENSG00000274818.1	RP1-292L20.3	-4.6	5.42e-06	0.00116	-0.24	-0.21	Schizophrenia;	chr14:70936594	chr14:70906657~70907111:-
HNSC	cis	rs3758785	0.623	rs13447720	ENSG00000255893.1	RP11-685N10.1	-4.6	5.42e-06	0.00116	-0.31	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94432160	chr11:94472908~94473570:-
HNSC	cis	rs9450351	0.744	rs73751283	ENSG00000203875.9	SNHG5	-4.6	5.43e-06	0.00116	-0.45	-0.21	Interferon gamma-induced protein 10 levels;	chr6:86072398	chr6:85660950~85678736:-
HNSC	cis	rs3806843	1	rs12717860	ENSG00000202515.1	VTRNA1-3	-4.6	5.43e-06	0.00116	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr5:140726158~140726246:+
HNSC	cis	rs9640161	0.83	rs1051764	ENSG00000261305.1	RP4-584D14.7	4.6	5.43e-06	0.00116	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150373574	chr7:150341771~150342607:+
HNSC	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-4.6	5.43e-06	0.00116	-0.24	-0.21	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
HNSC	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-4.6	5.43e-06	0.00116	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
HNSC	cis	rs8028182	0.636	rs4886703	ENSG00000260269.4	CTD-2323K18.1	-4.6	5.43e-06	0.00116	-0.26	-0.21	Sudden cardiac arrest;	chr15:75438025	chr15:75527150~75601205:-
HNSC	cis	rs12935418	0.523	rs2549845	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80990520	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.552	rs2549847	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80990617	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2602449	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80990668	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549848	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80990693	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2316923	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80991216	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2098726	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80991670	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.552	rs2113196	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80991885	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2113197	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80991901	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs2549852	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80992410	chr16:81030770~81031485:+
HNSC	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-4.6	5.44e-06	0.00116	-0.16	-0.21	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
HNSC	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	4.6	5.44e-06	0.00116	0.24	0.21	Height;	chr14:75053362	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	4.6	5.44e-06	0.00116	0.24	0.21	Height;	chr14:75059147	chr14:75011269~75012851:-
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	4.6	5.44e-06	0.00116	0.25	0.21	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-4.6	5.44e-06	0.00116	-0.22	-0.21	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
HNSC	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-4.6	5.44e-06	0.00116	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
HNSC	cis	rs12935418	0.616	rs2549853	ENSG00000261061.1	RP11-303E16.2	4.6	5.44e-06	0.00116	0.22	0.21	Mean corpuscular volume;	chr16:80992850	chr16:81030770~81031485:+
HNSC	cis	rs116095464	0.558	rs3213838	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.44e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:223775	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6555052	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.44e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:224153	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs61689490	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.44e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:224789	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs61492827	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.44e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:225659	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs56342538	ENSG00000250848.1	CTD-2083E4.5	-4.6	5.44e-06	0.00116	-0.29	-0.21	Breast cancer;	chr5:225681	chr5:288833~290321:-
HNSC	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-4.6	5.45e-06	0.00117	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
HNSC	cis	rs73198271	0.74	rs1039910	ENSG00000173295.6	FAM86B3P	-4.6	5.45e-06	0.00117	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8228595~8244865:+
HNSC	cis	rs6831352	0.589	rs2602836	ENSG00000263923.1	RP11-571L19.7	4.6	5.45e-06	0.00117	0.2	0.21	Alcohol dependence;	chr4:99093654	chr4:98928897~98994994:+
HNSC	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	4.6	5.46e-06	0.00117	0.2	0.21	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-4.6	5.46e-06	0.00117	-0.25	-0.21	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
HNSC	cis	rs7429990	1	rs1665982	ENSG00000228638.1	FCF1P2	4.6	5.46e-06	0.00117	0.22	0.21	Educational attainment (years of education);	chr3:47863589	chr3:48290793~48291375:-
HNSC	cis	rs4256159	1	rs76447456	ENSG00000228956.7	SATB1-AS1	4.6	5.46e-06	0.00117	0.35	0.21	Crohn's disease;Inflammatory bowel disease;	chr3:18768310	chr3:18445024~18920401:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	4.6	5.46e-06	0.00117	0.17	0.21	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
HNSC	cis	rs2280018	0.609	rs2941253	ENSG00000263335.1	AF001548.5	-4.6	5.46e-06	0.00117	-0.28	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15726674~15732993:+
HNSC	cis	rs913655	0.545	rs2495836	ENSG00000225527.1	RP11-383B4.4	-4.6	5.47e-06	0.00117	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18780052	chr10:18531849~18533336:-
HNSC	cis	rs9840812	0.769	rs4678428	ENSG00000273486.1	RP11-731C17.2	4.6	5.47e-06	0.00117	0.17	0.21	Fibrinogen levels;	chr3:136269570	chr3:136837338~136839021:-
HNSC	cis	rs11893307	0.566	rs62179714	ENSG00000228509.4	AC006460.2	4.6	5.47e-06	0.00117	0.28	0.21	Mean platelet volume;	chr2:190702815	chr2:190676944~190708716:-
HNSC	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-4.6	5.47e-06	0.00117	-0.24	-0.21	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
HNSC	cis	rs12935418	0.583	rs2549861	ENSG00000261061.1	RP11-303E16.2	4.6	5.47e-06	0.00117	0.22	0.21	Mean corpuscular volume;	chr16:80994699	chr16:81030770~81031485:+
HNSC	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-4.6	5.47e-06	0.00117	-0.27	-0.21	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
HNSC	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-4.6	5.47e-06	0.00117	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000254153.1	CTA-398F10.2	-4.6	5.47e-06	0.00117	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8935355	chr8:8456909~8461337:-
HNSC	cis	rs4388249	1	rs1866373	ENSG00000271849.1	CTC-332L22.1	-4.6	5.47e-06	0.00117	-0.32	-0.21	Schizophrenia;	chr5:109704541	chr5:109687802~109688329:-
HNSC	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	4.6	5.47e-06	0.00117	0.21	0.21	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
HNSC	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	4.6	5.47e-06	0.00117	0.29	0.21	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
HNSC	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-4.6	5.47e-06	0.00117	-0.27	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
HNSC	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	4.6	5.48e-06	0.00117	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
HNSC	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-4.6	5.48e-06	0.00117	-0.23	-0.21	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
HNSC	cis	rs7973683	0.541	rs6488910	ENSG00000269938.1	RP11-214K3.20	-4.6	5.49e-06	0.00117	-0.24	-0.21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123968023~123968579:-
HNSC	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	4.6	5.49e-06	0.00117	0.22	0.21	Myopia;	chr2:171827893	chr2:171773482~171775844:+
HNSC	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	4.6	5.49e-06	0.00117	0.3	0.21	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
HNSC	cis	rs853679	0.546	rs35656932	ENSG00000204709.4	LINC01556	4.6	5.49e-06	0.00117	0.45	0.21	Depression;	chr6:28223510	chr6:28943877~28944537:+
HNSC	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	4.6	5.49e-06	0.00117	0.24	0.21	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
HNSC	cis	rs7819412	0.668	rs2409721	ENSG00000269918.1	AF131215.9	-4.6	5.49e-06	0.00117	-0.21	-0.21	Triglycerides;	chr8:11180735	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.767	rs1897950	ENSG00000255310.2	AF131215.2	4.6	5.49e-06	0.00117	0.2	0.21	Retinal vascular caliber;	chr8:11312042	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.767	rs1897951	ENSG00000255310.2	AF131215.2	4.6	5.49e-06	0.00117	0.2	0.21	Retinal vascular caliber;	chr8:11312345	chr8:11107788~11109726:-
HNSC	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	4.6	5.49e-06	0.00117	0.24	0.21	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
HNSC	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	4.6	5.49e-06	0.00117	0.24	0.21	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-4.6	5.49e-06	0.00117	-0.33	-0.21	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
HNSC	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-4.6	5.5e-06	0.00117	-0.27	-0.21	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
HNSC	cis	rs2253762	0.54	rs10159634	ENSG00000226864.1	ATE1-AS1	-4.6	5.5e-06	0.00117	-0.33	-0.21	Breast cancer;	chr10:121994520	chr10:121928312~121951965:+
HNSC	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	4.6	5.5e-06	0.00117	0.23	0.21	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
HNSC	cis	rs3808502	0.549	rs1382563	ENSG00000269918.1	AF131215.9	4.6	5.5e-06	0.00117	0.2	0.21	Neuroticism;	chr8:11569281	chr8:11104691~11106704:-
HNSC	cis	rs1594829	0.553	rs2046224	ENSG00000228451.3	SDAD1P1	4.6	5.5e-06	0.00117	0.24	0.21	Height;	chr8:26294088	chr8:26379259~26382953:-
HNSC	cis	rs13438327	1	rs10251155	ENSG00000183444.10	OR7E38P	4.6	5.5e-06	0.00118	0.44	0.21	Sudden cardiac arrest;	chr7:97989224	chr7:97966090~97967074:-
HNSC	cis	rs11250098	0.547	rs2409764	ENSG00000255310.2	AF131215.2	4.6	5.5e-06	0.00118	0.2	0.21	Morning vs. evening chronotype;	chr8:11423764	chr8:11107788~11109726:-
HNSC	cis	rs7615952	0.641	rs7618515	ENSG00000241439.1	RP11-666A20.3	4.6	5.5e-06	0.00118	0.24	0.21	Blood pressure (smoking interaction);	chr3:126071735	chr3:125958556~125958817:+
HNSC	cis	rs2933343	0.716	rs9872706	ENSG00000261159.1	RP11-723O4.9	-4.6	5.5e-06	0.00118	-0.24	-0.21	IgG glycosylation;	chr3:128848262	chr3:128859716~128860526:-
HNSC	cis	rs11098499	1	rs12506395	ENSG00000250412.1	KLHL2P1	4.6	5.5e-06	0.00118	0.27	0.21	Corneal astigmatism;	chr4:119263939	chr4:119334329~119378233:+
HNSC	cis	rs2835345	0.563	rs12627167	ENSG00000279365.1	KB-176G8.1	4.6	5.5e-06	0.00118	0.25	0.21	Pulmonary function;	chr21:36449855	chr21:36485867~36487760:+
HNSC	cis	rs2548724	0.513	rs1452058	ENSG00000250682.4	LINC00491	4.6	5.51e-06	0.00118	0.28	0.21	Type 2 diabetes;	chr5:102307199	chr5:102609156~102671559:-
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000204709.4	LINC01556	-4.6	5.51e-06	0.00118	-0.28	-0.21	Depression;	chr6:28109824	chr6:28943877~28944537:+
HNSC	cis	rs13256369	0.802	rs12681925	ENSG00000173295.6	FAM86B3P	4.6	5.51e-06	0.00118	0.28	0.21	Obesity-related traits;	chr8:8704139	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs12680019	ENSG00000173295.6	FAM86B3P	4.6	5.51e-06	0.00118	0.28	0.21	Obesity-related traits;	chr8:8704188	chr8:8228595~8244865:+
HNSC	cis	rs933688	0.877	rs10474352	ENSG00000281357.1	ARRDC3-AS1	4.6	5.51e-06	0.00118	0.3	0.21	Smoking behavior;	chr5:91436408	chr5:91380349~91439085:+
HNSC	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.6	5.51e-06	0.00118	0.34	0.21	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.6	5.51e-06	0.00118	0.34	0.21	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
HNSC	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-4.6	5.51e-06	0.00118	-0.27	-0.21	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
HNSC	cis	rs8077577	1	rs2015336	ENSG00000273018.4	CTD-2303H24.2	-4.6	5.51e-06	0.00118	-0.31	-0.21	Obesity-related traits;	chr17:18170296	chr17:18511221~18551705:-
HNSC	cis	rs9329221	0.51	rs4841282	ENSG00000254340.1	RP11-10A14.3	4.6	5.51e-06	0.00118	0.25	0.21	Neuroticism;	chr8:10118094	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000254340.1	RP11-10A14.3	-4.6	5.51e-06	0.00118	-0.26	-0.21	Mood instability;	chr8:8685814	chr8:9141424~9145435:+
HNSC	cis	rs11673344	0.523	rs10420330	ENSG00000276846.1	CTD-3220F14.3	4.6	5.51e-06	0.00118	0.23	0.21	Obesity-related traits;	chr19:37111269	chr19:37314868~37315620:-
HNSC	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-4.6	5.51e-06	0.00118	-0.18	-0.21	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
HNSC	cis	rs7615952	0.599	rs66532274	ENSG00000241439.1	RP11-666A20.3	4.6	5.51e-06	0.00118	0.23	0.21	Blood pressure (smoking interaction);	chr3:126013002	chr3:125958556~125958817:+
HNSC	cis	rs3015497	0.505	rs17791470	ENSG00000269906.1	RP11-248J18.2	4.6	5.52e-06	0.00118	0.3	0.21	Mean platelet volume;	chr14:50473181	chr14:50662511~50663178:-
HNSC	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-4.6	5.52e-06	0.00118	-0.28	-0.21	Pain;	chr19:21527079	chr19:21554640~21569237:-
HNSC	cis	rs7572733	0.84	rs770666	ENSG00000222017.1	AC011997.1	4.6	5.52e-06	0.00118	0.25	0.21	Dermatomyositis;	chr2:197747173	chr2:197693106~197774823:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000280411.1	IGHV1-69-2	-4.6	5.52e-06	0.00118	-0.2	-0.21	Alzheimer's disease (late onset);	chr14:106700837	chr14:106762092~106762588:-
HNSC	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	4.6	5.52e-06	0.00118	0.24	0.21	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
HNSC	cis	rs7824557	0.767	rs28507159	ENSG00000269918.1	AF131215.9	4.6	5.52e-06	0.00118	0.21	0.21	Retinal vascular caliber;	chr8:11308567	chr8:11104691~11106704:-
HNSC	cis	rs6061231	0.631	rs2427318	ENSG00000275437.1	RP5-908M14.10	4.6	5.53e-06	0.00118	0.21	0.21	Colorectal cancer;	chr20:62400671	chr20:62402236~62405935:-
HNSC	cis	rs913655	0.508	rs2480313	ENSG00000225527.1	RP11-383B4.4	-4.6	5.53e-06	0.00118	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18774868	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.508	rs2493622	ENSG00000225527.1	RP11-383B4.4	-4.6	5.53e-06	0.00118	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18776152	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.545	rs2480309	ENSG00000225527.1	RP11-383B4.4	-4.6	5.53e-06	0.00118	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18776350	chr10:18531849~18533336:-
HNSC	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-4.6	5.53e-06	0.00118	-0.26	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
HNSC	cis	rs17428076	0.872	rs17500114	ENSG00000228389.1	AC068039.4	-4.6	5.53e-06	0.00118	-0.25	-0.21	Myopia;	chr2:172031684	chr2:171773482~171775844:+
HNSC	cis	rs9311676	0.656	rs11915480	ENSG00000273493.1	RP11-80H18.4	4.6	5.53e-06	0.00118	0.22	0.21	Systemic lupus erythematosus;	chr3:58391432	chr3:58329965~58330118:+
HNSC	cis	rs651386	0.529	rs10919446	ENSG00000271811.1	RP1-79C4.4	-4.6	5.53e-06	0.00118	-0.23	-0.21	Atrial fibrillation;	chr1:170624975	chr1:170667381~170669425:+
HNSC	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	4.6	5.53e-06	0.00118	0.23	0.21	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
HNSC	cis	rs1799949	1	rs12942277	ENSG00000236383.6	LINC00854	-4.6	5.53e-06	0.00118	-0.2	-0.21	Menopause (age at onset);	chr17:43035957	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs34616041	ENSG00000236383.6	LINC00854	-4.6	5.53e-06	0.00118	-0.2	-0.21	Menopause (age at onset);	chr17:43036769	chr17:43216941~43305976:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	4.6	5.53e-06	0.00118	0.13	0.21	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
HNSC	cis	rs36423	1	rs36423	ENSG00000266869.1	RP6-114E22.1	-4.6	5.53e-06	0.00118	-0.38	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71886485	chr14:71848606~71908430:+
HNSC	cis	rs700651	0.789	rs10184395	ENSG00000231621.1	AC013264.2	-4.6	5.53e-06	0.00118	-0.2	-0.21	Intracranial aneurysm;	chr2:198029561	chr2:197197991~197199273:+
HNSC	cis	rs58873874	0.522	rs6875379	ENSG00000248544.2	CTB-47B11.3	4.6	5.53e-06	0.00118	0.36	0.21	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157375741~157384950:-
HNSC	cis	rs7296418	0.885	rs1716184	ENSG00000280120.1	RP11-546D6.3	4.6	5.54e-06	0.00118	0.18	0.21	Platelet count;	chr12:123152962	chr12:123152324~123153377:-
HNSC	cis	rs9487051	0.621	rs353052	ENSG00000243587.6	C6orf183	-4.6	5.54e-06	0.00118	-0.22	-0.21	Reticulocyte fraction of red cells;	chr6:109186104	chr6:109165833~109271014:+
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	4.6	5.54e-06	0.00118	0.2	0.21	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
HNSC	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-4.6	5.54e-06	0.00118	-0.2	-0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
HNSC	cis	rs1223397	0.702	rs1223400	ENSG00000215022.6	RP1-257A7.4	-4.6	5.54e-06	0.00118	-0.26	-0.21	Blood pressure;	chr6:13271010	chr6:13264861~13295586:-
HNSC	cis	rs6951245	0.572	rs73264028	ENSG00000225146.1	AC073957.15	-4.6	5.54e-06	0.00118	-0.41	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005819	chr7:1029025~1043891:+
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000219392.1	RP1-265C24.5	-4.6	5.54e-06	0.00118	-0.23	-0.21	Pubertal anthropometrics;	chr6:28399578	chr6:28115628~28116551:+
HNSC	cis	rs13438327	1	rs35481514	ENSG00000183444.10	OR7E38P	4.6	5.55e-06	0.00118	0.44	0.21	Sudden cardiac arrest;	chr7:97990785	chr7:97966090~97967074:-
HNSC	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	4.6	5.55e-06	0.00118	0.3	0.21	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
HNSC	cis	rs1008375	1	rs1860597	ENSG00000249502.1	AC006160.5	-4.6	5.55e-06	0.00118	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656027	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs11737138	ENSG00000249502.1	AC006160.5	-4.6	5.55e-06	0.00118	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656363	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs2109522	ENSG00000249502.1	AC006160.5	-4.6	5.55e-06	0.00118	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657022	chr4:17587467~17614571:-
HNSC	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	4.6	5.55e-06	0.00119	0.31	0.21	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
HNSC	cis	rs4819052	0.851	rs2255774	ENSG00000215447.6	BX322557.10	-4.6	5.56e-06	0.00119	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45288052~45291738:+
HNSC	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	4.6	5.56e-06	0.00119	0.27	0.21	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
HNSC	cis	rs2008905	1	rs2008905	ENSG00000272034.1	SNORD14A	4.6	5.56e-06	0.00119	0.16	0.21	Schizophrenia;	chr11:17163076	chr11:17074654~17074744:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000224373.3	IGHV4-59	4.6	5.56e-06	0.00119	0.14	0.21	Kawasaki disease;	chr14:106805607	chr14:106627249~106627825:-
HNSC	cis	rs4388249	0.651	rs31599	ENSG00000271849.1	CTC-332L22.1	-4.6	5.56e-06	0.00119	-0.34	-0.21	Schizophrenia;	chr5:109671554	chr5:109687802~109688329:-
HNSC	cis	rs7824557	0.767	rs7003241	ENSG00000255310.2	AF131215.2	4.6	5.56e-06	0.00119	0.2	0.21	Retinal vascular caliber;	chr8:11311566	chr8:11107788~11109726:-
HNSC	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-4.6	5.56e-06	0.00119	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
HNSC	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	4.6	5.56e-06	0.00119	0.21	0.21	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
HNSC	cis	rs7809950	0.773	rs9791733	ENSG00000238832.1	snoU109	-4.6	5.56e-06	0.00119	-0.3	-0.21	Coronary artery disease;	chr7:107401285	chr7:107603363~107603507:+
HNSC	cis	rs746265	0.527	rs16968739	ENSG00000259450.1	RP11-265N7.1	4.6	5.57e-06	0.00119	0.34	0.21	PR interval;	chr15:39311939	chr15:39188438~39194309:-
HNSC	cis	rs9527	1	rs9527	ENSG00000236937.2	PTGES3P4	4.6	5.57e-06	0.00119	0.3	0.21	Arsenic metabolism;	chr10:102863821	chr10:102845595~102845950:+
HNSC	cis	rs11846409	0.932	rs28617526	ENSG00000254174.1	IGHV1-12	4.6	5.58e-06	0.00119	0.16	0.21	Rheumatic heart disease;	chr14:106637322	chr14:106122420~106122709:-
HNSC	cis	rs804280	0.56	rs10503426	ENSG00000269918.1	AF131215.9	4.59	5.58e-06	0.00119	0.21	0.21	Myopia (pathological);	chr8:11731874	chr8:11104691~11106704:-
HNSC	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	4.59	5.58e-06	0.00119	0.27	0.21	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
HNSC	cis	rs889398	0.802	rs12925700	ENSG00000226232.7	RP11-419C5.2	4.59	5.58e-06	0.00119	0.19	0.21	Body mass index;	chr16:69759560	chr16:69976388~69996188:-
HNSC	cis	rs5758659	0.652	rs133322	ENSG00000227370.1	RP4-669P10.19	-4.59	5.58e-06	0.00119	-0.2	-0.21	Cognitive function;	chr22:42009655	chr22:42132543~42132998:+
HNSC	cis	rs61270009	0.955	rs10514300	ENSG00000247828.6	TMEM161B-AS1	4.59	5.58e-06	0.00119	0.22	0.21	Depressive symptoms;	chr5:88409465	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs3733809	ENSG00000247828.6	TMEM161B-AS1	4.59	5.58e-06	0.00119	0.22	0.21	Depressive symptoms;	chr5:88410112	chr5:88268895~88436685:+
HNSC	cis	rs3015497	0.646	rs2934687	ENSG00000269906.1	RP11-248J18.2	-4.59	5.58e-06	0.00119	-0.28	-0.21	Mean platelet volume;	chr14:50645171	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.608	rs3015499	ENSG00000269906.1	RP11-248J18.2	-4.59	5.58e-06	0.00119	-0.28	-0.21	Mean platelet volume;	chr14:50645742	chr14:50662511~50663178:-
HNSC	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	4.59	5.58e-06	0.00119	0.35	0.21	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
HNSC	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-4.59	5.58e-06	0.00119	-0.17	-0.21	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
HNSC	cis	rs638893	0.842	rs480791	ENSG00000255422.1	AP002954.4	-4.59	5.58e-06	0.00119	-0.35	-0.21	Vitiligo;	chr11:118833546	chr11:118704607~118750263:+
HNSC	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	4.59	5.58e-06	0.00119	0.2	0.21	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	4.59	5.58e-06	0.00119	0.2	0.21	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
HNSC	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	4.59	5.58e-06	0.00119	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
HNSC	cis	rs8028182	0.636	rs4486847	ENSG00000260269.4	CTD-2323K18.1	-4.59	5.58e-06	0.00119	-0.26	-0.21	Sudden cardiac arrest;	chr15:75436190	chr15:75527150~75601205:-
HNSC	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.59	5.58e-06	0.00119	-0.23	-0.21	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
HNSC	cis	rs6490294	0.898	rs57646770	ENSG00000226469.1	ADAM1B	4.59	5.59e-06	0.00119	0.24	0.21	Mean platelet volume;	chr12:111993408	chr12:111927018~111929017:+
HNSC	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	4.59	5.59e-06	0.00119	0.23	0.21	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
HNSC	cis	rs4218	0.541	rs8030323	ENSG00000277144.1	RP11-59H7.4	-4.59	5.59e-06	0.00119	-0.27	-0.21	Social communication problems;	chr15:59048048	chr15:59115547~59116089:-
HNSC	cis	rs6964587	0.967	rs12538325	ENSG00000188693.7	CYP51A1-AS1	-4.59	5.59e-06	0.00119	-0.23	-0.21	Breast cancer;	chr7:92128165	chr7:92134604~92180725:+
HNSC	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-4.59	5.59e-06	0.00119	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	4.59	5.59e-06	0.00119	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	4.59	5.59e-06	0.00119	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
HNSC	cis	rs7296418	0.885	rs1727305	ENSG00000280120.1	RP11-546D6.3	4.59	5.59e-06	0.00119	0.18	0.21	Platelet count;	chr12:123148835	chr12:123152324~123153377:-
HNSC	cis	rs72843506	1	rs10459969	ENSG00000261033.1	RP11-209D14.2	4.59	5.59e-06	0.00119	0.3	0.21	Schizophrenia;	chr17:20032588	chr17:20008051~20009234:-
HNSC	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	4.59	5.59e-06	0.00119	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	4.59	5.59e-06	0.00119	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
HNSC	cis	rs1056107	0.897	rs10817298	ENSG00000225513.1	RP11-165N19.2	-4.59	5.59e-06	0.00119	-0.22	-0.21	Colorectal cancer;	chr9:112244396	chr9:112173522~112173971:-
HNSC	cis	rs6964587	1	rs12537846	ENSG00000188693.7	CYP51A1-AS1	4.59	5.6e-06	0.00119	0.22	0.21	Breast cancer;	chr7:92092267	chr7:92134604~92180725:+
HNSC	cis	rs42490	0.664	rs372981	ENSG00000251136.7	RP11-37B2.1	-4.59	5.6e-06	0.00119	-0.18	-0.21	Leprosy;	chr8:89784740	chr8:89609409~89757727:-
HNSC	cis	rs9907295	1	rs11657908	ENSG00000270977.1	AC015849.16	-4.59	5.6e-06	0.00119	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35908993	chr17:35893707~35911023:-
HNSC	cis	rs7824557	0.872	rs2572417	ENSG00000255310.2	AF131215.2	-4.59	5.6e-06	0.00119	-0.19	-0.21	Retinal vascular caliber;	chr8:11253953	chr8:11107788~11109726:-
HNSC	cis	rs4873772	0.735	rs10958058	ENSG00000253330.1	RP11-697N18.3	-4.59	5.6e-06	0.00119	-0.26	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47592067	chr8:47511034~47512141:-
HNSC	cis	rs11633886	0.528	rs2248207	ENSG00000273972.1	CTD-2306A12.1	4.59	5.6e-06	0.00119	0.24	0.21	Diisocyanate-induced asthma;	chr15:45809215	chr15:45702640~45703183:+
HNSC	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-4.59	5.6e-06	0.00119	-0.29	-0.21	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
HNSC	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-4.59	5.61e-06	0.0012	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-4.59	5.61e-06	0.0012	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-4.59	5.61e-06	0.0012	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-4.59	5.61e-06	0.0012	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-4.59	5.61e-06	0.0012	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
HNSC	cis	rs6601327	0.518	rs13264850	ENSG00000233609.3	RP11-62H7.2	-4.59	5.61e-06	0.0012	-0.2	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8961200~8979025:+
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-4.59	5.61e-06	0.0012	-0.28	-0.21	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
HNSC	cis	rs4761669	0.816	rs10859755	ENSG00000241556.1	RP11-490G8.1	-4.59	5.61e-06	0.0012	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94799076	chr12:95467397~95467861:-
HNSC	cis	rs2548724	0.561	rs12658397	ENSG00000250682.4	LINC00491	4.59	5.61e-06	0.0012	0.26	0.21	Type 2 diabetes;	chr5:102415949	chr5:102609156~102671559:-
HNSC	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	4.59	5.61e-06	0.0012	0.26	0.21	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	4.59	5.61e-06	0.0012	0.26	0.21	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
HNSC	cis	rs9300255	0.543	rs655293	ENSG00000280120.1	RP11-546D6.3	4.59	5.61e-06	0.0012	0.2	0.21	Neutrophil percentage of white cells;	chr12:123043858	chr12:123152324~123153377:-
HNSC	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	4.59	5.61e-06	0.0012	0.25	0.21	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
HNSC	cis	rs2337406	0.925	rs873534	ENSG00000280411.1	IGHV1-69-2	-4.59	5.62e-06	0.0012	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106667423	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	4.59	5.62e-06	0.0012	0.26	0.21	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	4.59	5.62e-06	0.0012	0.26	0.21	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
HNSC	cis	rs6831352	0.879	rs56272995	ENSG00000263923.1	RP11-571L19.7	4.59	5.62e-06	0.0012	0.23	0.21	Alcohol dependence;	chr4:99139731	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.879	rs56295995	ENSG00000263923.1	RP11-571L19.7	4.59	5.62e-06	0.0012	0.23	0.21	Alcohol dependence;	chr4:99139748	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs17218602	ENSG00000263923.1	RP11-571L19.7	4.59	5.62e-06	0.0012	0.23	0.21	Alcohol dependence;	chr4:99139922	chr4:98928897~98994994:+
HNSC	cis	rs2835345	0.563	rs73204244	ENSG00000279365.1	KB-176G8.1	4.59	5.62e-06	0.0012	0.25	0.21	Pulmonary function;	chr21:36452373	chr21:36485867~36487760:+
HNSC	cis	rs442309	1	rs224071	ENSG00000238280.1	RP11-436D10.3	4.59	5.63e-06	0.0012	0.25	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62748715	chr10:62793562~62805887:-
HNSC	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	4.59	5.63e-06	0.0012	0.26	0.21	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
HNSC	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-4.59	5.64e-06	0.0012	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
HNSC	cis	rs727563	0.565	rs132774	ENSG00000233903.2	Z83851.4	-4.59	5.64e-06	0.0012	-0.29	-0.21	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr22:42276355~42277052:+
HNSC	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	4.59	5.64e-06	0.0012	0.2	0.21	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
HNSC	cis	rs4853525	0.522	rs6434412	ENSG00000235852.1	AC005540.3	4.59	5.64e-06	0.0012	0.26	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190720549	chr2:190880797~190882059:-
HNSC	cis	rs7824557	0.701	rs4568582	ENSG00000269918.1	AF131215.9	4.59	5.65e-06	0.0012	0.21	0.21	Retinal vascular caliber;	chr8:11302986	chr8:11104691~11106704:-
HNSC	cis	rs4218	0.531	rs8026611	ENSG00000259732.1	RP11-59H7.3	-4.59	5.65e-06	0.0012	-0.26	-0.21	Social communication problems;	chr15:59048927	chr15:59121034~59133250:+
HNSC	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	4.59	5.65e-06	0.0012	0.25	0.21	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
HNSC	cis	rs11893307	0.537	rs3771319	ENSG00000235852.1	AC005540.3	4.59	5.65e-06	0.0012	0.28	0.21	Mean platelet volume;	chr2:190660507	chr2:190880797~190882059:-
HNSC	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-4.59	5.66e-06	0.0012	-0.33	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
HNSC	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	4.59	5.66e-06	0.00121	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	4.59	5.66e-06	0.00121	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
HNSC	cis	rs1971762	0.527	rs7976398	ENSG00000270175.1	RP11-793H13.11	-4.59	5.66e-06	0.00121	-0.18	-0.21	Height;	chr12:53635078	chr12:53500162~53500936:-
HNSC	cis	rs1971762	0.527	rs7300936	ENSG00000270175.1	RP11-793H13.11	-4.59	5.66e-06	0.00121	-0.18	-0.21	Height;	chr12:53636802	chr12:53500162~53500936:-
HNSC	cis	rs9300255	0.664	rs28372579	ENSG00000280120.1	RP11-546D6.3	-4.59	5.66e-06	0.00121	-0.2	-0.21	Neutrophil percentage of white cells;	chr12:123396629	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	4.59	5.66e-06	0.00121	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	4.59	5.66e-06	0.00121	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	4.59	5.66e-06	0.00121	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
HNSC	cis	rs1009181	0.585	rs72834696	ENSG00000272462.2	U91328.19	-4.59	5.66e-06	0.00121	-0.24	-0.21	Childhood ear infection;	chr6:26161171	chr6:25992662~26001775:+
HNSC	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-4.59	5.67e-06	0.00121	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-4.59	5.67e-06	0.00121	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
HNSC	cis	rs11157436	0.602	rs2075492	ENSG00000211812.1	TRAV26-2	-4.59	5.67e-06	0.00121	-0.19	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163321	chr14:22202583~22203368:+
HNSC	cis	rs2548724	0.561	rs953280	ENSG00000250682.4	LINC00491	-4.59	5.67e-06	0.00121	-0.26	-0.21	Type 2 diabetes;	chr5:102508055	chr5:102609156~102671559:-
HNSC	cis	rs394563	0.601	rs431978	ENSG00000231760.4	RP11-350J20.5	-4.59	5.67e-06	0.00121	-0.27	-0.21	Dupuytren's disease;	chr6:149471864	chr6:149796151~149826294:-
HNSC	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	4.59	5.67e-06	0.00121	0.24	0.21	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-4.59	5.67e-06	0.00121	-0.25	-0.21	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
HNSC	cis	rs2058059	0.681	rs2844177	ENSG00000225648.4	SBDSP1	-4.59	5.67e-06	0.00121	-0.29	-0.21	Subcutaneous adipose tissue;	chr7:72657954	chr7:72829425~72836701:+
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-4.59	5.68e-06	0.00121	-0.25	-0.21	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
HNSC	cis	rs453301	0.506	rs476845	ENSG00000173295.6	FAM86B3P	-4.59	5.68e-06	0.00121	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8765367	chr8:8228595~8244865:+
HNSC	cis	rs9300255	0.543	rs1260294	ENSG00000280120.1	RP11-546D6.3	-4.59	5.68e-06	0.00121	-0.21	-0.21	Neutrophil percentage of white cells;	chr12:123075742	chr12:123152324~123153377:-
HNSC	cis	rs6951245	0.572	rs80133931	ENSG00000225146.1	AC073957.15	-4.59	5.68e-06	0.00121	-0.45	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:987650	chr7:1029025~1043891:+
HNSC	cis	rs72843506	0.722	rs117096120	ENSG00000261033.1	RP11-209D14.2	4.59	5.68e-06	0.00121	0.38	0.21	Schizophrenia;	chr17:20264380	chr17:20008051~20009234:-
HNSC	cis	rs367615	0.591	rs4530812	ENSG00000249476.1	CTD-2587M2.1	-4.59	5.68e-06	0.00121	-0.24	-0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109522886	chr5:109237120~109326369:-
HNSC	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	4.59	5.69e-06	0.00121	0.2	0.21	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
HNSC	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-4.59	5.69e-06	0.00121	-0.2	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
HNSC	cis	rs721917	0.506	rs2758555	ENSG00000225484.5	NUTM2B-AS1	-4.59	5.69e-06	0.00121	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79663088~79826594:-
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000256975.1	RP11-525E9.1	-4.59	5.69e-06	0.00121	-0.28	-0.21	IgG glycosylation;	chr12:9426513	chr12:9506347~9508440:-
HNSC	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	4.59	5.69e-06	0.00121	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
HNSC	cis	rs7296418	0.63	rs11057238	ENSG00000280120.1	RP11-546D6.3	4.59	5.7e-06	0.00121	0.18	0.21	Platelet count;	chr12:123283424	chr12:123152324~123153377:-
HNSC	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.59	5.7e-06	0.00121	0.21	0.21	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
HNSC	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-4.59	5.7e-06	0.00121	-0.26	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
HNSC	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	4.59	5.7e-06	0.00121	0.28	0.21	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000254340.1	RP11-10A14.3	4.59	5.7e-06	0.00121	0.26	0.21	Mood instability;	chr8:8445843	chr8:9141424~9145435:+
HNSC	cis	rs116095464	0.614	rs56299325	ENSG00000250848.1	CTD-2083E4.5	-4.59	5.7e-06	0.00121	-0.28	-0.21	Breast cancer;	chr5:220479	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs62346526	ENSG00000250848.1	CTD-2083E4.5	-4.59	5.7e-06	0.00121	-0.28	-0.21	Breast cancer;	chr5:220499	chr5:288833~290321:-
HNSC	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	4.59	5.7e-06	0.00121	0.24	0.21	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
HNSC	cis	rs4761669	0.509	rs10859756	ENSG00000241556.1	RP11-490G8.1	4.59	5.7e-06	0.00121	0.2	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94807530	chr12:95467397~95467861:-
HNSC	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	4.59	5.7e-06	0.00121	0.24	0.21	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	4.59	5.7e-06	0.00121	0.25	0.21	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
HNSC	cis	rs3806843	1	rs11167600	ENSG00000202515.1	VTRNA1-3	-4.59	5.71e-06	0.00121	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr5:140726158~140726246:+
HNSC	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	4.59	5.71e-06	0.00121	0.24	0.21	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
HNSC	cis	rs761746	0.614	rs131250	ENSG00000236132.1	CTA-440B3.1	-4.59	5.71e-06	0.00121	-0.26	-0.21	Intelligence;	chr22:31733617	chr22:31816379~31817491:-
HNSC	cis	rs761746	0.579	rs131253	ENSG00000236132.1	CTA-440B3.1	-4.59	5.71e-06	0.00121	-0.26	-0.21	Intelligence;	chr22:31734696	chr22:31816379~31817491:-
HNSC	cis	rs761746	0.614	rs5994427	ENSG00000236132.1	CTA-440B3.1	-4.59	5.71e-06	0.00121	-0.26	-0.21	Intelligence;	chr22:31736590	chr22:31816379~31817491:-
HNSC	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-4.59	5.71e-06	0.00122	-0.17	-0.21	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-4.59	5.71e-06	0.00122	-0.17	-0.21	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
HNSC	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-4.59	5.71e-06	0.00122	-0.17	-0.21	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-4.59	5.71e-06	0.00122	-0.17	-0.21	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
HNSC	cis	rs4763879	0.634	rs61915473	ENSG00000278635.1	CTD-2318O12.1	4.59	5.71e-06	0.00122	0.16	0.21	Type 1 diabetes;	chr12:9705282	chr12:9415641~9416718:+
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000254153.1	CTA-398F10.2	4.59	5.71e-06	0.00122	0.23	0.21	Joint mobility (Beighton score);	chr8:9003920	chr8:8456909~8461337:-
HNSC	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-4.59	5.71e-06	0.00122	-0.24	-0.21	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
HNSC	cis	rs8028182	0.636	rs4886699	ENSG00000260269.4	CTD-2323K18.1	-4.59	5.71e-06	0.00122	-0.26	-0.21	Sudden cardiac arrest;	chr15:75399962	chr15:75527150~75601205:-
HNSC	cis	rs9650657	0.74	rs10481451	ENSG00000255310.2	AF131215.2	-4.59	5.72e-06	0.00122	-0.2	-0.21	Neuroticism;	chr8:10791818	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.767	rs11250127	ENSG00000269918.1	AF131215.9	4.59	5.72e-06	0.00122	0.21	0.21	Retinal vascular caliber;	chr8:11312700	chr8:11104691~11106704:-
HNSC	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	4.59	5.72e-06	0.00122	0.21	0.21	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
HNSC	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-4.59	5.72e-06	0.00122	-0.22	-0.21	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
HNSC	cis	rs12893668	0.667	rs8017628	ENSG00000269940.1	RP11-73M18.7	4.59	5.72e-06	0.00122	0.2	0.21	Reticulocyte count;	chr14:103581091	chr14:103694560~103695170:+
HNSC	cis	rs7824557	0.527	rs2572447	ENSG00000269918.1	AF131215.9	-4.59	5.72e-06	0.00122	-0.2	-0.21	Retinal vascular caliber;	chr8:11382001	chr8:11104691~11106704:-
HNSC	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-4.59	5.72e-06	0.00122	-0.24	-0.21	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
HNSC	cis	rs11976180	1	rs2951308	ENSG00000273234.1	OR2A13P	4.59	5.73e-06	0.00122	0.23	0.21	Obesity-related traits;	chr7:144070056	chr7:144142009~144142938:+
HNSC	cis	rs13256369	0.951	rs10503394	ENSG00000173295.6	FAM86B3P	4.59	5.73e-06	0.00122	0.27	0.21	Obesity-related traits;	chr8:8708265	chr8:8228595~8244865:+
HNSC	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	4.59	5.73e-06	0.00122	0.25	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
HNSC	cis	rs2187895	1	rs2187895	ENSG00000271811.1	RP1-79C4.4	4.59	5.73e-06	0.00122	0.29	0.21	Tonsillectomy;	chr1:170715290	chr1:170667381~170669425:+
HNSC	cis	rs9300255	0.722	rs10846515	ENSG00000280120.1	RP11-546D6.3	4.59	5.73e-06	0.00122	0.19	0.21	Neutrophil percentage of white cells;	chr12:123317125	chr12:123152324~123153377:-
HNSC	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	4.59	5.74e-06	0.00122	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	4.59	5.74e-06	0.00122	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	4.59	5.74e-06	0.00122	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
HNSC	cis	rs5758511	0.68	rs5758686	ENSG00000205702.9	CYP2D7	4.59	5.74e-06	0.00122	0.19	0.21	Birth weight;	chr22:42259371	chr22:42140203~42144577:-
HNSC	cis	rs577676	0.586	rs549449	ENSG00000271811.1	RP1-79C4.4	4.59	5.74e-06	0.00122	0.23	0.21	Prevalent atrial fibrillation;	chr1:170641569	chr1:170667381~170669425:+
HNSC	cis	rs577676	0.586	rs639720	ENSG00000271811.1	RP1-79C4.4	4.59	5.74e-06	0.00122	0.23	0.21	Prevalent atrial fibrillation;	chr1:170643785	chr1:170667381~170669425:+
HNSC	cis	rs577676	0.586	rs593173	ENSG00000271811.1	RP1-79C4.4	4.59	5.74e-06	0.00122	0.23	0.21	Prevalent atrial fibrillation;	chr1:170646719	chr1:170667381~170669425:+
HNSC	cis	rs4908769	0.624	rs2120461	ENSG00000232912.4	RP5-1115A15.1	-4.59	5.74e-06	0.00122	-0.23	-0.21	Allergy;	chr1:8387662	chr1:8424645~8434838:+
HNSC	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	4.59	5.74e-06	0.00122	0.23	0.21	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
HNSC	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-4.59	5.74e-06	0.00122	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
HNSC	cis	rs1538970	0.504	rs3790585	ENSG00000234329.1	RP11-767N6.2	4.59	5.74e-06	0.00122	0.28	0.21	Platelet count;	chr1:45557684	chr1:45651039~45651826:-
HNSC	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	4.59	5.74e-06	0.00122	0.43	0.21	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-4.59	5.74e-06	0.00122	-0.21	-0.21	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
HNSC	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	4.59	5.75e-06	0.00122	0.24	0.21	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
HNSC	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	4.59	5.75e-06	0.00122	0.24	0.21	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
HNSC	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-4.59	5.75e-06	0.00122	-0.23	-0.21	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
HNSC	cis	rs2980436	1	rs2980436	ENSG00000254340.1	RP11-10A14.3	-4.59	5.75e-06	0.00122	-0.26	-0.21	Schizophrenia;	chr8:8234503	chr8:9141424~9145435:+
HNSC	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	4.59	5.75e-06	0.00122	0.28	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
HNSC	cis	rs9959145	1	rs9989546	ENSG00000267249.1	RP11-973H7.3	-4.59	5.75e-06	0.00122	-0.32	-0.21	Immune response to smallpox vaccine (IL-6);	chr18:12562538	chr18:12670426~12671145:-
HNSC	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	4.59	5.75e-06	0.00122	0.3	0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
HNSC	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-4.59	5.75e-06	0.00122	-0.29	-0.21	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
HNSC	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	4.59	5.75e-06	0.00122	0.2	0.21	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
HNSC	cis	rs12935418	0.616	rs12444054	ENSG00000261061.1	RP11-303E16.2	-4.59	5.75e-06	0.00122	-0.28	-0.21	Mean corpuscular volume;	chr16:80930320	chr16:81030770~81031485:+
HNSC	cis	rs1799949	1	rs72829113	ENSG00000236383.6	LINC00854	-4.59	5.75e-06	0.00122	-0.2	-0.21	Menopause (age at onset);	chr17:43029818	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11653253	ENSG00000236383.6	LINC00854	-4.59	5.75e-06	0.00122	-0.2	-0.21	Menopause (age at onset);	chr17:43030645	chr17:43216941~43305976:-
HNSC	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	4.59	5.75e-06	0.00122	0.23	0.21	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
HNSC	cis	rs73222236	0.825	rs35644083	ENSG00000273486.1	RP11-731C17.2	4.59	5.76e-06	0.00122	0.17	0.21	Coronary artery disease;	chr3:136503626	chr3:136837338~136839021:-
HNSC	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-4.59	5.76e-06	0.00122	-0.24	-0.21	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
HNSC	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-4.59	5.76e-06	0.00122	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
HNSC	cis	rs9650657	0.737	rs2409669	ENSG00000269918.1	AF131215.9	-4.59	5.76e-06	0.00122	-0.21	-0.21	Neuroticism;	chr8:10766459	chr8:11104691~11106704:-
HNSC	cis	rs7535099	1	rs12059300	ENSG00000224570.1	RP11-430H12.2	-4.59	5.76e-06	0.00122	-0.28	-0.21	Blood protein levels;	chr1:65581389	chr1:65576129~65578380:-
HNSC	cis	rs4862750	0.624	rs34414639	ENSG00000250971.1	RP11-696F12.1	4.59	5.76e-06	0.00122	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186952263	chr4:187060099~187060930:+
HNSC	cis	rs1971762	0.527	rs6580953	ENSG00000270175.1	RP11-793H13.11	-4.59	5.76e-06	0.00122	-0.18	-0.21	Height;	chr12:53627354	chr12:53500162~53500936:-
HNSC	cis	rs7535099	0.909	rs3790432	ENSG00000224570.1	RP11-430H12.2	-4.59	5.76e-06	0.00122	-0.27	-0.21	Blood protein levels;	chr1:65570056	chr1:65576129~65578380:-
HNSC	cis	rs73222236	0.825	rs9812513	ENSG00000273486.1	RP11-731C17.2	4.59	5.76e-06	0.00122	0.17	0.21	Coronary artery disease;	chr3:136335316	chr3:136837338~136839021:-
HNSC	cis	rs7735319	0.774	rs13168871	ENSG00000250697.1	CTD-2066L21.3	4.59	5.77e-06	0.00123	0.26	0.21	Systolic blood pressure;	chr5:33066773	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.834	rs7707864	ENSG00000250697.1	CTD-2066L21.3	4.59	5.77e-06	0.00123	0.26	0.21	Systolic blood pressure;	chr5:33067611	chr5:32925639~33297910:-
HNSC	cis	rs12701220	0.894	rs12701348	ENSG00000229043.2	AC091729.9	-4.59	5.77e-06	0.00123	-0.3	-0.21	Bronchopulmonary dysplasia;	chr7:999821	chr7:1160374~1165267:+
HNSC	cis	rs9650657	0.645	rs4841408	ENSG00000269918.1	AF131215.9	-4.59	5.77e-06	0.00123	-0.2	-0.21	Neuroticism;	chr8:10658826	chr8:11104691~11106704:-
HNSC	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.59	5.77e-06	0.00123	0.24	0.21	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
HNSC	cis	rs7615952	0.576	rs4646759	ENSG00000241439.1	RP11-666A20.3	4.59	5.77e-06	0.00123	0.24	0.21	Blood pressure (smoking interaction);	chr3:126104103	chr3:125958556~125958817:+
HNSC	cis	rs60617249	0.831	rs13232494	ENSG00000228204.2	RP4-724E13.2	4.59	5.77e-06	0.00123	0.22	0.21	Major depression and alcohol dependence;	chr7:50883432	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.831	rs11765438	ENSG00000228204.2	RP4-724E13.2	4.59	5.77e-06	0.00123	0.22	0.21	Major depression and alcohol dependence;	chr7:50884288	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.725	rs2018824	ENSG00000228204.2	RP4-724E13.2	4.59	5.77e-06	0.00123	0.22	0.21	Major depression and alcohol dependence;	chr7:50887018	chr7:50866747~51022990:+
HNSC	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	4.59	5.78e-06	0.00123	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
HNSC	cis	rs6964587	0.967	rs410	ENSG00000188693.7	CYP51A1-AS1	4.59	5.79e-06	0.00123	0.22	0.21	Breast cancer;	chr7:91928111	chr7:92134604~92180725:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	4.59	5.79e-06	0.00123	0.24	0.21	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
HNSC	cis	rs9650657	0.537	rs11250092	ENSG00000269918.1	AF131215.9	4.59	5.79e-06	0.00123	0.2	0.21	Neuroticism;	chr8:10929033	chr8:11104691~11106704:-
HNSC	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-4.59	5.79e-06	0.00123	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-4.59	5.79e-06	0.00123	-0.22	-0.21	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
HNSC	cis	rs5758511	0.633	rs5751258	ENSG00000205702.9	CYP2D7	4.59	5.79e-06	0.00123	0.19	0.21	Birth weight;	chr22:42267865	chr22:42140203~42144577:-
HNSC	cis	rs12935418	0.634	rs9934940	ENSG00000261061.1	RP11-303E16.2	-4.59	5.8e-06	0.00123	-0.24	-0.21	Mean corpuscular volume;	chr16:81016021	chr16:81030770~81031485:+
HNSC	cis	rs867371	0.614	rs1814739	ENSG00000276710.3	CSPG4P8	-4.59	5.8e-06	0.00123	-0.26	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82459472~82477258:+
HNSC	cis	rs964611	0.882	rs2291342	ENSG00000259488.2	RP11-154J22.1	-4.59	5.8e-06	0.00123	-0.19	-0.21	Metabolite levels (Pyroglutamine);	chr15:48291886	chr15:48312353~48331856:-
HNSC	cis	rs13256369	0.851	rs13258283	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706120	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13249700	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706127	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13254997	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706243	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13255061	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706324	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs12541477	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706385	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13266562	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706555	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13256611	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8706831	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs11786125	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8707060	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs11249888	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8707424	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs11249889	ENSG00000173295.6	FAM86B3P	4.59	5.8e-06	0.00123	0.27	0.21	Obesity-related traits;	chr8:8707482	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.641	rs12487875	ENSG00000241439.1	RP11-666A20.3	4.59	5.8e-06	0.00123	0.24	0.21	Blood pressure (smoking interaction);	chr3:126068381	chr3:125958556~125958817:+
HNSC	cis	rs17428076	0.756	rs62182432	ENSG00000228389.1	AC068039.4	-4.59	5.8e-06	0.00123	-0.28	-0.21	Myopia;	chr2:171918221	chr2:171773482~171775844:+
HNSC	cis	rs442309	1	rs224148	ENSG00000238280.1	RP11-436D10.3	-4.59	5.81e-06	0.00123	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62726879	chr10:62793562~62805887:-
HNSC	cis	rs442309	1	rs224149	ENSG00000238280.1	RP11-436D10.3	-4.59	5.81e-06	0.00123	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62727313	chr10:62793562~62805887:-
HNSC	cis	rs442309	1	rs224150	ENSG00000238280.1	RP11-436D10.3	-4.59	5.81e-06	0.00123	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62728327	chr10:62793562~62805887:-
HNSC	cis	rs442309	1	rs190113	ENSG00000238280.1	RP11-436D10.3	-4.59	5.81e-06	0.00123	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62728463	chr10:62793562~62805887:-
HNSC	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-4.59	5.81e-06	0.00123	-0.23	-0.21	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
HNSC	cis	rs712039	0.617	rs36081240	ENSG00000276054.1	RP11-378E13.3	4.59	5.81e-06	0.00123	0.3	0.21	Tuberculosis;	chr17:37424955	chr17:37386886~37387926:+
HNSC	cis	rs988913	0.697	rs9475159	ENSG00000224984.1	RP11-524H19.2	-4.59	5.81e-06	0.00123	-0.24	-0.21	Menarche (age at onset);	chr6:55130719	chr6:54840118~54840855:-
HNSC	cis	rs6964587	0.967	rs58673519	ENSG00000188693.7	CYP51A1-AS1	-4.59	5.81e-06	0.00123	-0.22	-0.21	Breast cancer;	chr7:92194573	chr7:92134604~92180725:+
HNSC	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	4.59	5.81e-06	0.00123	0.21	0.21	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
HNSC	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	4.59	5.81e-06	0.00123	0.24	0.21	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
HNSC	cis	rs9329221	0.868	rs7831557	ENSG00000269918.1	AF131215.9	-4.59	5.81e-06	0.00123	-0.2	-0.21	Neuroticism;	chr8:10422718	chr8:11104691~11106704:-
HNSC	cis	rs9640161	0.83	rs1051823	ENSG00000261305.1	RP4-584D14.7	4.59	5.82e-06	0.00123	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150373725	chr7:150341771~150342607:+
HNSC	cis	rs3206736	0.541	rs6964650	ENSG00000197085.10	NPSR1-AS1	-4.59	5.82e-06	0.00123	-0.26	-0.21	Diastolic blood pressure;	chr7:34925335	chr7:34346512~34871582:-
HNSC	cis	rs8054556	0.647	rs4787488	ENSG00000183604.13	SMG1P5	4.59	5.82e-06	0.00123	0.2	0.21	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:30267553~30335374:-
HNSC	cis	rs4699052	0.625	rs1400365	ENSG00000246560.2	RP11-10L12.4	4.59	5.82e-06	0.00124	0.24	0.21	Testicular germ cell tumor;	chr4:103368239	chr4:102828055~102844075:+
HNSC	cis	rs116095464	0.558	rs9654452	ENSG00000250848.1	CTD-2083E4.5	-4.59	5.82e-06	0.00124	-0.29	-0.21	Breast cancer;	chr5:299446	chr5:288833~290321:-
HNSC	cis	rs4978813	0.519	rs10979888	ENSG00000213539.4	YBX1P6	4.59	5.82e-06	0.00124	0.25	0.21	Plantar warts;	chr9:109490670	chr9:109532830~109534332:-
HNSC	cis	rs5758659	0.622	rs6519298	ENSG00000182057.4	OGFRP1	4.59	5.82e-06	0.00124	0.21	0.21	Cognitive function;	chr22:41968993	chr22:42269753~42275196:+
HNSC	cis	rs728616	0.764	rs79529820	ENSG00000225484.5	NUTM2B-AS1	-4.59	5.82e-06	0.00124	-0.4	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060773	chr10:79663088~79826594:-
HNSC	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	4.59	5.83e-06	0.00124	0.19	0.21	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	4.59	5.83e-06	0.00124	0.19	0.21	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
HNSC	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	4.59	5.83e-06	0.00124	0.25	0.21	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
HNSC	cis	rs8058578	1	rs6565201	ENSG00000279196.1	RP11-1072A3.3	4.59	5.83e-06	0.00124	0.25	0.21	Multiple myeloma;	chr16:30735870	chr16:30984630~30988270:-
HNSC	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.59	5.83e-06	0.00124	-0.22	-0.21	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
HNSC	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-4.59	5.83e-06	0.00124	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
HNSC	cis	rs73198271	0.74	rs10113326	ENSG00000173295.6	FAM86B3P	-4.59	5.84e-06	0.00124	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8228595~8244865:+
HNSC	cis	rs10773046	0.74	rs10773044	ENSG00000269938.1	RP11-214K3.20	-4.59	5.84e-06	0.00124	-0.23	-0.21	Osteoarthritis (hip);	chr12:123867118	chr12:123968023~123968579:-
HNSC	cis	rs10946940	0.965	rs6910838	ENSG00000219392.1	RP1-265C24.5	4.58	5.84e-06	0.00124	0.24	0.21	Systemic lupus erythematosus;	chr6:27547740	chr6:28115628~28116551:+
HNSC	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-4.58	5.84e-06	0.00124	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
HNSC	cis	rs4834770	1	rs878375	ENSG00000250412.1	KLHL2P1	4.58	5.84e-06	0.00124	0.24	0.21	Blood protein levels;	chr4:119316419	chr4:119334329~119378233:+
HNSC	cis	rs7824557	0.767	rs1897950	ENSG00000269918.1	AF131215.9	4.58	5.84e-06	0.00124	0.21	0.21	Retinal vascular caliber;	chr8:11312042	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.767	rs1897951	ENSG00000269918.1	AF131215.9	4.58	5.84e-06	0.00124	0.21	0.21	Retinal vascular caliber;	chr8:11312345	chr8:11104691~11106704:-
HNSC	cis	rs12935418	0.672	rs11150334	ENSG00000278985.1	RP11-303E16.9	4.58	5.84e-06	0.00124	0.2	0.21	Mean corpuscular volume;	chr16:81008937	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.616	rs2549863	ENSG00000261061.1	RP11-303E16.2	4.58	5.84e-06	0.00124	0.22	0.21	Mean corpuscular volume;	chr16:80995762	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.616	rs1469123	ENSG00000261061.1	RP11-303E16.2	4.58	5.84e-06	0.00124	0.22	0.21	Mean corpuscular volume;	chr16:80995944	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs1469124	ENSG00000261061.1	RP11-303E16.2	4.58	5.84e-06	0.00124	0.22	0.21	Mean corpuscular volume;	chr16:80996049	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.583	rs1469125	ENSG00000261061.1	RP11-303E16.2	4.58	5.84e-06	0.00124	0.22	0.21	Mean corpuscular volume;	chr16:80996163	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.523	rs1469126	ENSG00000261061.1	RP11-303E16.2	4.58	5.84e-06	0.00124	0.22	0.21	Mean corpuscular volume;	chr16:80996284	chr16:81030770~81031485:+
HNSC	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-4.58	5.85e-06	0.00124	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
HNSC	cis	rs4853525	0.561	rs12693589	ENSG00000235852.1	AC005540.3	4.58	5.85e-06	0.00124	0.28	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190967936	chr2:190880797~190882059:-
HNSC	cis	rs4862750	0.872	rs13101408	ENSG00000250971.1	RP11-696F12.1	4.58	5.85e-06	0.00124	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186973623	chr4:187060099~187060930:+
HNSC	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.58	5.85e-06	0.00124	0.24	0.21	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
HNSC	cis	rs7868228	1	rs12685591	ENSG00000240498.5	CDKN2B-AS1	-4.58	5.86e-06	0.00124	-0.28	-0.21	Gut microbiome composition (winter);	chr9:21669887	chr9:21994778~22121097:+
HNSC	cis	rs896655	0.747	rs10811585	ENSG00000244230.3	RN7SL151P	4.58	5.86e-06	0.00124	0.21	0.21	Coronary artery disease;	chr9:21701535	chr9:21699314~21699596:+
HNSC	cis	rs721917	0.526	rs2256574	ENSG00000225484.5	NUTM2B-AS1	-4.58	5.86e-06	0.00124	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79663088~79826594:-
HNSC	cis	rs2058059	0.636	rs3015897	ENSG00000225648.4	SBDSP1	-4.58	5.86e-06	0.00124	-0.29	-0.21	Subcutaneous adipose tissue;	chr7:72658854	chr7:72829425~72836701:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-4.58	5.86e-06	0.00124	-0.21	-0.21	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
HNSC	cis	rs2998286	0.723	rs332191	ENSG00000254635.4	WAC-AS1	-4.58	5.87e-06	0.00124	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28632196	chr10:28522652~28532743:-
HNSC	cis	rs9880211	0.898	rs1052620	ENSG00000273486.1	RP11-731C17.2	4.58	5.87e-06	0.00124	0.2	0.21	Height;Body mass index;	chr3:136855679	chr3:136837338~136839021:-
HNSC	cis	rs7615952	0.576	rs66671308	ENSG00000241439.1	RP11-666A20.3	4.58	5.87e-06	0.00124	0.24	0.21	Blood pressure (smoking interaction);	chr3:126074683	chr3:125958556~125958817:+
HNSC	cis	rs7035284	1	rs7028950	ENSG00000265194.1	RP11-70L8.4	-4.58	5.87e-06	0.00124	-0.26	-0.21	Pediatric bone mineral content (radius);	chr9:21682261	chr9:21858910~21861926:-
HNSC	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	4.58	5.87e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	4.58	5.87e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	4.58	5.87e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
HNSC	cis	rs1198872	0.892	rs1198862	ENSG00000272275.1	RP11-791G15.2	-4.58	5.87e-06	0.00125	-0.24	-0.21	Cardiac Troponin-T levels;	chr2:10760201	chr2:10767875~10770058:-
HNSC	cis	rs1198872	0.892	rs1198863	ENSG00000272275.1	RP11-791G15.2	-4.58	5.87e-06	0.00125	-0.24	-0.21	Cardiac Troponin-T levels;	chr2:10760349	chr2:10767875~10770058:-
HNSC	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	4.58	5.87e-06	0.00125	0.21	0.21	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000250412.1	KLHL2P1	4.58	5.88e-06	0.00125	0.27	0.21	Corneal astigmatism;	chr4:119346947	chr4:119334329~119378233:+
HNSC	cis	rs4908769	0.624	rs301791	ENSG00000232912.4	RP5-1115A15.1	-4.58	5.88e-06	0.00125	-0.23	-0.21	Allergy;	chr1:8408312	chr1:8424645~8434838:+
HNSC	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-4.58	5.88e-06	0.00125	-0.27	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
HNSC	cis	rs72615157	0.634	rs79986079	ENSG00000078319.8	PMS2P1	-4.58	5.88e-06	0.00125	-0.26	-0.21	Lung function (FEV1/FVC);	chr7:100204421	chr7:100320992~100341908:-
HNSC	cis	rs7937890	0.874	rs2303972	ENSG00000254418.1	RP11-21L19.1	-4.58	5.88e-06	0.00125	-0.24	-0.21	Mitochondrial DNA levels;	chr11:14281736	chr11:14262846~14273691:-
HNSC	cis	rs4252134	0.687	rs62436736	ENSG00000231863.1	RP3-428L16.1	4.58	5.88e-06	0.00125	0.28	0.21	Giant cell arteritis;	chr6:160823806	chr6:160931080~160969771:+
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000230295.1	RP11-458F8.2	-4.58	5.88e-06	0.00125	-0.28	-0.21	Diabetic kidney disease;	chr7:66474549	chr7:66880708~66882981:+
HNSC	cis	rs4356203	0.519	rs214097	ENSG00000272034.1	SNORD14A	-4.58	5.88e-06	0.00125	-0.16	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17074654~17074744:-
HNSC	cis	rs7296418	0.738	rs1568428	ENSG00000280120.1	RP11-546D6.3	-4.58	5.88e-06	0.00125	-0.17	-0.21	Platelet count;	chr12:123254329	chr12:123152324~123153377:-
HNSC	cis	rs2548724	0.561	rs6596486	ENSG00000250682.4	LINC00491	4.58	5.88e-06	0.00125	0.26	0.21	Type 2 diabetes;	chr5:102420358	chr5:102609156~102671559:-
HNSC	cis	rs5758511	0.68	rs1107553	ENSG00000205702.9	CYP2D7	4.58	5.88e-06	0.00125	0.18	0.21	Birth weight;	chr22:42271467	chr22:42140203~42144577:-
HNSC	cis	rs11773103	1	rs73204819	ENSG00000224046.1	AC005076.5	4.58	5.89e-06	0.00125	0.37	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87141009	chr7:87151423~87152420:-
HNSC	cis	rs7572733	0.935	rs771015	ENSG00000222017.1	AC011997.1	4.58	5.89e-06	0.00125	0.25	0.21	Dermatomyositis;	chr2:197803570	chr2:197693106~197774823:+
HNSC	cis	rs2179367	0.568	rs6932778	ENSG00000216906.2	RP11-350J20.9	4.58	5.89e-06	0.00125	0.32	0.21	Dupuytren's disease;	chr6:149328293	chr6:149904243~149906418:+
HNSC	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	4.58	5.89e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	4.58	5.89e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	4.58	5.89e-06	0.00125	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
HNSC	cis	rs2665103	0.715	rs11639440	ENSG00000255769.6	GOLGA2P10	-4.58	5.89e-06	0.00125	-0.25	-0.21	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472993~82513950:-
HNSC	cis	rs155076	0.711	rs4769158	ENSG00000233325.3	MIPEPP3	-4.58	5.89e-06	0.00125	-0.34	-0.21	White matter hyperintensity burden;	chr13:21307836	chr13:21298139~21306373:+
HNSC	cis	rs155076	0.625	rs4769159	ENSG00000233325.3	MIPEPP3	-4.58	5.89e-06	0.00125	-0.34	-0.21	White matter hyperintensity burden;	chr13:21307839	chr13:21298139~21306373:+
HNSC	cis	rs155076	0.711	rs4770129	ENSG00000233325.3	MIPEPP3	-4.58	5.89e-06	0.00125	-0.34	-0.21	White matter hyperintensity burden;	chr13:21307920	chr13:21298139~21306373:+
HNSC	cis	rs17345786	1	rs3762729	ENSG00000244119.1	PDCL3P4	4.58	5.9e-06	0.00125	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101712472~101713191:+
HNSC	cis	rs17345786	1	rs997739	ENSG00000244119.1	PDCL3P4	4.58	5.9e-06	0.00125	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101712472~101713191:+
HNSC	cis	rs17345786	1	rs73863360	ENSG00000244119.1	PDCL3P4	4.58	5.9e-06	0.00125	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101712472~101713191:+
HNSC	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	4.58	5.9e-06	0.00125	0.27	0.21	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
HNSC	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-4.58	5.9e-06	0.00125	-0.27	-0.21	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-4.58	5.9e-06	0.00125	-0.27	-0.21	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-4.58	5.9e-06	0.00125	-0.27	-0.21	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
HNSC	cis	rs17428076	0.681	rs62183776	ENSG00000228389.1	AC068039.4	-4.58	5.9e-06	0.00125	-0.28	-0.21	Myopia;	chr2:171993206	chr2:171773482~171775844:+
HNSC	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-4.58	5.91e-06	0.00125	-0.27	-0.21	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
HNSC	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-4.58	5.91e-06	0.00125	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
HNSC	cis	rs7267979	0.546	rs8115804	ENSG00000204556.4	CTD-2514C3.1	4.58	5.91e-06	0.00125	0.28	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:26018832~26020684:+
HNSC	cis	rs9863	0.828	rs34114498	ENSG00000270028.1	RP11-380L11.4	4.58	5.91e-06	0.00125	0.24	0.21	White blood cell count;	chr12:123995826	chr12:123925461~123926083:-
HNSC	cis	rs6490294	0.851	rs1016079	ENSG00000226469.1	ADAM1B	-4.58	5.91e-06	0.00125	-0.24	-0.21	Mean platelet volume;	chr12:111972382	chr12:111927018~111929017:+
HNSC	cis	rs3736485	0.673	rs7171884	ENSG00000259438.1	CTD-2650P22.1	4.58	5.91e-06	0.00125	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51663536	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.673	rs7170980	ENSG00000259438.1	CTD-2650P22.1	4.58	5.91e-06	0.00125	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51663859	chr15:52010999~52019095:-
HNSC	cis	rs10644111	1	rs10644111	ENSG00000188693.7	CYP51A1-AS1	-4.58	5.91e-06	0.00125	-0.22	-0.21	Breast cancer;	chr7:92022864	chr7:92134604~92180725:+
HNSC	cis	rs7572733	0.935	rs700659	ENSG00000222017.1	AC011997.1	4.58	5.92e-06	0.00125	0.25	0.21	Dermatomyositis;	chr2:197795199	chr2:197693106~197774823:+
HNSC	cis	rs11951515	0.508	rs1366410	ENSG00000249286.1	CTD-2210P15.2	4.58	5.92e-06	0.00125	0.21	0.21	Metabolite levels  (X-11787);	chr5:43601508	chr5:43586918~43588223:-
HNSC	cis	rs763121	0.853	rs5750672	ENSG00000273076.1	RP3-508I15.22	-4.58	5.92e-06	0.00125	-0.22	-0.21	Menopause (age at onset);	chr22:38708163	chr22:38743495~38743910:+
HNSC	cis	rs889398	0.771	rs1500337	ENSG00000226232.7	RP11-419C5.2	4.58	5.92e-06	0.00125	0.18	0.21	Body mass index;	chr16:69867981	chr16:69976388~69996188:-
HNSC	cis	rs73222236	0.825	rs56040643	ENSG00000273486.1	RP11-731C17.2	4.58	5.92e-06	0.00125	0.17	0.21	Coronary artery disease;	chr3:136538621	chr3:136837338~136839021:-
HNSC	cis	rs4763879	0.634	rs7974396	ENSG00000278635.1	CTD-2318O12.1	4.58	5.92e-06	0.00125	0.16	0.21	Type 1 diabetes;	chr12:9708101	chr12:9415641~9416718:+
HNSC	cis	rs10946940	0.93	rs12215012	ENSG00000219392.1	RP1-265C24.5	4.58	5.92e-06	0.00125	0.24	0.21	Systemic lupus erythematosus;	chr6:27539715	chr6:28115628~28116551:+
HNSC	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.58	5.93e-06	0.00126	0.23	0.21	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
HNSC	cis	rs3733585	0.673	rs10000983	ENSG00000250413.1	RP11-448G15.1	4.58	5.93e-06	0.00126	0.25	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9949982	chr4:10006482~10009725:+
HNSC	cis	rs12893668	0.697	rs67899457	ENSG00000269940.1	RP11-73M18.7	4.58	5.93e-06	0.00126	0.2	0.21	Reticulocyte count;	chr14:103593729	chr14:103694560~103695170:+
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	4.58	5.93e-06	0.00126	0.22	0.21	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
HNSC	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	4.58	5.93e-06	0.00126	0.3	0.21	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	4.58	5.93e-06	0.00126	0.3	0.21	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	4.58	5.93e-06	0.00126	0.3	0.21	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
HNSC	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-4.58	5.93e-06	0.00126	-0.24	-0.21	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
HNSC	cis	rs2835345	0.507	rs7280011	ENSG00000279365.1	KB-176G8.1	4.58	5.93e-06	0.00126	0.26	0.21	Pulmonary function;	chr21:36455256	chr21:36485867~36487760:+
HNSC	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-4.58	5.94e-06	0.00126	-0.26	-0.21	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
HNSC	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-4.58	5.94e-06	0.00126	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
HNSC	cis	rs116095464	0.558	rs1971229	ENSG00000250848.1	CTD-2083E4.5	-4.58	5.94e-06	0.00126	-0.29	-0.21	Breast cancer;	chr5:268072	chr5:288833~290321:-
HNSC	cis	rs11893307	0.537	rs7571572	ENSG00000235852.1	AC005540.3	4.58	5.95e-06	0.00126	0.27	0.21	Mean platelet volume;	chr2:190688911	chr2:190880797~190882059:-
HNSC	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	4.58	5.95e-06	0.00126	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	4.58	5.95e-06	0.00126	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
HNSC	cis	rs889398	0.537	rs3790086	ENSG00000226232.7	RP11-419C5.2	-4.58	5.95e-06	0.00126	-0.18	-0.21	Body mass index;	chr16:69853804	chr16:69976388~69996188:-
HNSC	cis	rs4356203	0.933	rs12801545	ENSG00000272034.1	SNORD14A	4.58	5.95e-06	0.00126	0.16	0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17074654~17074744:-
HNSC	cis	rs761746	0.614	rs8141214	ENSG00000236132.1	CTA-440B3.1	-4.58	5.95e-06	0.00126	-0.26	-0.21	Intelligence;	chr22:31800195	chr22:31816379~31817491:-
HNSC	cis	rs6964587	0.967	rs6980247	ENSG00000188693.7	CYP51A1-AS1	-4.58	5.95e-06	0.00126	-0.22	-0.21	Breast cancer;	chr7:91964914	chr7:92134604~92180725:+
HNSC	cis	rs116095464	0.558	rs55664502	ENSG00000250848.1	CTD-2083E4.5	-4.58	5.96e-06	0.00126	-0.29	-0.21	Breast cancer;	chr5:270370	chr5:288833~290321:-
HNSC	cis	rs116095464	0.51	rs7723883	ENSG00000250848.1	CTD-2083E4.5	-4.58	5.96e-06	0.00126	-0.29	-0.21	Breast cancer;	chr5:270683	chr5:288833~290321:-
HNSC	cis	rs6430585	0.528	rs309142	ENSG00000231890.6	DARS-AS1	-4.58	5.96e-06	0.00126	-0.34	-0.21	Corneal structure;	chr2:135957754	chr2:135985176~136022593:+
HNSC	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	4.58	5.96e-06	0.00126	0.25	0.21	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
HNSC	cis	rs7829975	0.56	rs17154599	ENSG00000254340.1	RP11-10A14.3	-4.58	5.96e-06	0.00126	-0.26	-0.21	Mood instability;	chr8:8693908	chr8:9141424~9145435:+
HNSC	cis	rs7171171	0.706	rs7173588	ENSG00000259747.1	RP11-275I4.2	4.58	5.96e-06	0.00126	0.25	0.21	Type 1 diabetes;	chr15:38618343	chr15:38671847~38689191:+
HNSC	cis	rs7824557	0.614	rs2293858	ENSG00000255310.2	AF131215.2	4.58	5.96e-06	0.00126	0.19	0.21	Retinal vascular caliber;	chr8:11356372	chr8:11107788~11109726:-
HNSC	cis	rs10510102	0.516	rs10219133	ENSG00000226864.1	ATE1-AS1	4.58	5.96e-06	0.00126	0.39	0.21	Breast cancer;	chr10:121987898	chr10:121928312~121951965:+
HNSC	cis	rs9880211	0.948	rs6806123	ENSG00000273486.1	RP11-731C17.2	4.58	5.96e-06	0.00126	0.19	0.21	Height;Body mass index;	chr3:136586634	chr3:136837338~136839021:-
HNSC	cis	rs988913	0.723	rs6936015	ENSG00000224984.1	RP11-524H19.2	4.58	5.96e-06	0.00126	0.24	0.21	Menarche (age at onset);	chr6:55127011	chr6:54840118~54840855:-
HNSC	cis	rs9650657	0.562	rs10090444	ENSG00000255310.2	AF131215.2	4.58	5.97e-06	0.00126	0.2	0.21	Neuroticism;	chr8:10887959	chr8:11107788~11109726:-
HNSC	cis	rs4862750	0.914	rs10027250	ENSG00000250971.1	RP11-696F12.1	4.58	5.97e-06	0.00126	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186952306	chr4:187060099~187060930:+
HNSC	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	4.58	5.97e-06	0.00126	0.22	0.21	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000254340.1	RP11-10A14.3	-4.58	5.97e-06	0.00126	-0.25	-0.21	Mood instability;	chr8:8827443	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000224373.3	IGHV4-59	4.58	5.97e-06	0.00126	0.13	0.21	Kawasaki disease;	chr14:106697402	chr14:106627249~106627825:-
HNSC	cis	rs7535099	0.909	rs72681384	ENSG00000224570.1	RP11-430H12.2	-4.58	5.97e-06	0.00126	-0.27	-0.21	Blood protein levels;	chr1:65566256	chr1:65576129~65578380:-
HNSC	cis	rs7572733	0.515	rs1836234	ENSG00000231621.1	AC013264.2	-4.58	5.97e-06	0.00126	-0.2	-0.21	Dermatomyositis;	chr2:198018149	chr2:197197991~197199273:+
HNSC	cis	rs700651	0.789	rs116165148	ENSG00000231621.1	AC013264.2	-4.58	5.97e-06	0.00126	-0.2	-0.21	Intracranial aneurysm;	chr2:198023623	chr2:197197991~197199273:+
HNSC	cis	rs700651	0.789	rs1978889	ENSG00000231621.1	AC013264.2	-4.58	5.97e-06	0.00126	-0.2	-0.21	Intracranial aneurysm;	chr2:198024642	chr2:197197991~197199273:+
HNSC	cis	rs11893307	0.509	rs12618075	ENSG00000235852.1	AC005540.3	4.58	5.98e-06	0.00126	0.26	0.21	Mean platelet volume;	chr2:190681095	chr2:190880797~190882059:-
HNSC	cis	rs11722228	0.522	rs7681250	ENSG00000250413.1	RP11-448G15.1	-4.58	5.98e-06	0.00126	-0.31	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10131389	chr4:10006482~10009725:+
HNSC	cis	rs11722228	0.522	rs7662229	ENSG00000250413.1	RP11-448G15.1	-4.58	5.98e-06	0.00126	-0.31	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10131390	chr4:10006482~10009725:+
HNSC	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-4.58	5.98e-06	0.00126	-0.17	-0.21	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000254340.1	RP11-10A14.3	4.58	5.98e-06	0.00126	0.25	0.21	Neuroticism;	chr8:8240557	chr8:9141424~9145435:+
HNSC	cis	rs7809950	0.731	rs4730238	ENSG00000238832.1	snoU109	-4.58	5.98e-06	0.00126	-0.3	-0.21	Coronary artery disease;	chr7:107414342	chr7:107603363~107603507:+
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000255495.1	AC145124.2	-4.58	5.98e-06	0.00127	-0.23	-0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12194467~12196280:+
HNSC	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-4.58	5.98e-06	0.00127	-0.28	-0.21	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
HNSC	cis	rs3808502	0.549	rs4841564	ENSG00000269918.1	AF131215.9	-4.58	5.98e-06	0.00127	-0.2	-0.21	Neuroticism;	chr8:11568300	chr8:11104691~11106704:-
HNSC	cis	rs116095464	0.558	rs10057674	ENSG00000250848.1	CTD-2083E4.5	-4.58	5.98e-06	0.00127	-0.29	-0.21	Breast cancer;	chr5:266698	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs1812843	ENSG00000250848.1	CTD-2083E4.5	-4.58	5.98e-06	0.00127	-0.29	-0.21	Breast cancer;	chr5:267543	chr5:288833~290321:-
HNSC	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	4.58	5.98e-06	0.00127	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
HNSC	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	4.58	5.98e-06	0.00127	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
HNSC	cis	rs172166	0.56	rs203878	ENSG00000219392.1	RP1-265C24.5	-4.58	5.98e-06	0.00127	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28081218	chr6:28115628~28116551:+
HNSC	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	4.58	5.98e-06	0.00127	0.23	0.21	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
HNSC	cis	rs12468579	1	rs12468579	ENSG00000235852.1	AC005540.3	4.58	5.99e-06	0.00127	0.24	0.21	JT interval (sulfonylurea treatment interaction);	chr2:190967538	chr2:190880797~190882059:-
HNSC	cis	rs757081	0.637	rs34941502	ENSG00000260196.1	RP1-239B22.5	-4.58	6e-06	0.00127	-0.25	-0.21	Systolic blood pressure;	chr11:17133885	chr11:17380649~17383531:+
HNSC	cis	rs17428076	0.71	rs62181740	ENSG00000228389.1	AC068039.4	-4.58	6e-06	0.00127	-0.28	-0.21	Myopia;	chr2:171683891	chr2:171773482~171775844:+
HNSC	cis	rs17428076	0.749	rs62181741	ENSG00000228389.1	AC068039.4	-4.58	6e-06	0.00127	-0.28	-0.21	Myopia;	chr2:171684565	chr2:171773482~171775844:+
HNSC	cis	rs4862750	0.872	rs6811837	ENSG00000250971.1	RP11-696F12.1	4.58	6e-06	0.00127	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186977008	chr4:187060099~187060930:+
HNSC	cis	rs9840812	1	rs9840812	ENSG00000239213.4	NCK1-AS1	4.58	6e-06	0.00127	0.19	0.21	Fibrinogen levels;	chr3:136124320	chr3:136841726~136862054:-
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	4.58	6e-06	0.00127	0.22	0.21	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000254340.1	RP11-10A14.3	4.58	6e-06	0.00127	0.25	0.21	Mood instability;	chr8:8721284	chr8:9141424~9145435:+
HNSC	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	4.58	6.01e-06	0.00127	0.32	0.21	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
HNSC	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-4.58	6.01e-06	0.00127	-0.27	-0.21	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
HNSC	cis	rs9863	0.827	rs12823740	ENSG00000269938.1	RP11-214K3.20	-4.58	6.01e-06	0.00127	-0.24	-0.21	White blood cell count;	chr12:123973455	chr12:123968023~123968579:-
HNSC	cis	rs1223397	1	rs1232392	ENSG00000215022.6	RP1-257A7.4	-4.58	6.01e-06	0.00127	-0.27	-0.21	Blood pressure;	chr6:13272439	chr6:13264861~13295586:-
HNSC	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	4.58	6.01e-06	0.00127	0.17	0.21	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
HNSC	cis	rs7980687	0.678	rs7132277	ENSG00000280120.1	RP11-546D6.3	-4.58	6.01e-06	0.00127	-0.21	-0.21	Head circumference (infant);Educational attainment;Height;	chr12:123108835	chr12:123152324~123153377:-
HNSC	cis	rs3096299	0.933	rs747485	ENSG00000261574.1	RP1-168P16.2	4.58	6.02e-06	0.00127	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89392375~89412564:-
HNSC	cis	rs10791097	0.642	rs7107568	ENSG00000254842.5	RP11-890B15.2	-4.58	6.02e-06	0.00127	-0.18	-0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130909773	chr11:130844191~130865561:-
HNSC	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	4.58	6.02e-06	0.00127	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
HNSC	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-4.58	6.02e-06	0.00127	-0.24	-0.21	Height;	chr14:75069666	chr14:75011269~75012851:-
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	4.58	6.02e-06	0.00127	0.25	0.21	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	4.58	6.02e-06	0.00127	0.25	0.21	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
HNSC	cis	rs11098499	1	rs58601355	ENSG00000250412.1	KLHL2P1	4.58	6.02e-06	0.00127	0.27	0.21	Corneal astigmatism;	chr4:119265212	chr4:119334329~119378233:+
HNSC	cis	rs2998286	0.723	rs332186	ENSG00000254635.4	WAC-AS1	-4.58	6.03e-06	0.00127	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624674	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332187	ENSG00000254635.4	WAC-AS1	-4.58	6.03e-06	0.00127	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624887	chr10:28522652~28532743:-
HNSC	cis	rs9907295	0.901	rs9914401	ENSG00000270977.1	AC015849.16	-4.58	6.03e-06	0.00127	-0.31	-0.21	Fibroblast growth factor basic levels;	chr17:35861810	chr17:35893707~35911023:-
HNSC	cis	rs11871801	0.756	rs12948911	ENSG00000267151.3	RP11-100E5.2	4.58	6.03e-06	0.00127	0.34	0.21	Crohn's disease;	chr17:42446588	chr17:43444707~43451200:+
HNSC	cis	rs7735319	0.834	rs13166521	ENSG00000249102.1	CTD-2066L21.1	4.58	6.03e-06	0.00128	0.25	0.21	Systolic blood pressure;	chr5:33062086	chr5:33008994~33025724:+
HNSC	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	4.58	6.03e-06	0.00128	0.24	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
HNSC	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	4.58	6.03e-06	0.00128	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
HNSC	cis	rs9527	0.615	rs10883781	ENSG00000236937.2	PTGES3P4	4.58	6.03e-06	0.00128	0.28	0.21	Arsenic metabolism;	chr10:102821373	chr10:102845595~102845950:+
HNSC	cis	rs6430585	0.528	rs614193	ENSG00000231890.6	DARS-AS1	-4.58	6.04e-06	0.00128	-0.35	-0.21	Corneal structure;	chr2:135896355	chr2:135985176~136022593:+
HNSC	cis	rs6928977	0.863	rs2614255	ENSG00000217482.2	HMGB1P17	-4.58	6.04e-06	0.00128	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135342443	chr6:135636086~135636713:-
HNSC	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-4.58	6.04e-06	0.00128	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
HNSC	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-4.58	6.04e-06	0.00128	-0.26	-0.21	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
HNSC	cis	rs700651	0.789	rs1813106	ENSG00000231621.1	AC013264.2	-4.58	6.04e-06	0.00128	-0.2	-0.21	Intracranial aneurysm;	chr2:198015865	chr2:197197991~197199273:+
HNSC	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	4.58	6.04e-06	0.00128	0.21	0.21	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	4.58	6.04e-06	0.00128	0.25	0.21	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
HNSC	cis	rs7615952	0.599	rs12485717	ENSG00000241439.1	RP11-666A20.3	-4.58	6.04e-06	0.00128	-0.23	-0.21	Blood pressure (smoking interaction);	chr3:125988232	chr3:125958556~125958817:+
HNSC	cis	rs4723738	0.729	rs10226230	ENSG00000227191.5	TRGC2	4.58	6.05e-06	0.00128	0.15	0.21	Treatment response for severe sepsis;	chr7:38229691	chr7:38239580~38368091:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000224373.3	IGHV4-59	4.58	6.05e-06	0.00128	0.13	0.21	Kawasaki disease;	chr14:106689997	chr14:106627249~106627825:-
HNSC	cis	rs9987353	0.519	rs13276350	ENSG00000173295.6	FAM86B3P	-4.58	6.05e-06	0.00128	-0.25	-0.21	Recombination measurement;	chr8:9205647	chr8:8228595~8244865:+
HNSC	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	4.58	6.06e-06	0.00128	0.23	0.21	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
HNSC	cis	rs1799949	0.894	rs36062488	ENSG00000236383.6	LINC00854	4.58	6.07e-06	0.00128	0.19	0.21	Menopause (age at onset);	chr17:43185455	chr17:43216941~43305976:-
HNSC	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	4.58	6.07e-06	0.00128	0.2	0.21	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	4.58	6.07e-06	0.00128	0.2	0.21	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
HNSC	cis	rs12701220	0.595	rs12532837	ENSG00000229043.2	AC091729.9	-4.58	6.07e-06	0.00128	-0.31	-0.21	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1160374~1165267:+
HNSC	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	4.58	6.07e-06	0.00128	0.21	0.21	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
HNSC	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-4.58	6.07e-06	0.00128	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-4.58	6.07e-06	0.00128	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
HNSC	cis	rs11673344	0.542	rs826325	ENSG00000276846.1	CTD-3220F14.3	4.58	6.07e-06	0.00128	0.23	0.21	Obesity-related traits;	chr19:37003580	chr19:37314868~37315620:-
HNSC	cis	rs2098713	0.575	rs10461981	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Telomere length;	chr5:37470124	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.544	rs13181312	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Telomere length;	chr5:37470861	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.575	rs11739453	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Telomere length;	chr5:37471040	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.507	rs12516086	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Height;	chr5:37473085	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.54	rs13188782	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Height;	chr5:37476142	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.575	rs11745000	ENSG00000250155.1	CTD-2353F22.1	-4.58	6.08e-06	0.00128	-0.22	-0.21	Telomere length;	chr5:37476980	chr5:36666214~36725195:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-4.58	6.08e-06	0.00128	-0.25	-0.21	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
HNSC	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	4.58	6.08e-06	0.00128	0.22	0.21	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
HNSC	cis	rs17270561	0.779	rs78589800	ENSG00000272810.1	U91328.22	-4.58	6.08e-06	0.00128	-0.23	-0.21	Iron status biomarkers;	chr6:25883272	chr6:26013241~26013757:+
HNSC	cis	rs603446	0.934	rs180351	ENSG00000254851.1	RP11-109L13.1	-4.58	6.08e-06	0.00128	-0.27	-0.21	Triglycerides;	chr11:116736925	chr11:117135528~117138582:+
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	4.58	6.08e-06	0.00128	0.25	0.21	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	4.58	6.08e-06	0.00128	0.25	0.21	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-4.58	6.08e-06	0.00128	-0.25	-0.21	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
HNSC	cis	rs7572733	0.935	rs12995110	ENSG00000222017.1	AC011997.1	-4.58	6.08e-06	0.00128	-0.25	-0.21	Dermatomyositis;	chr2:197924289	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs4850816	ENSG00000222017.1	AC011997.1	-4.58	6.08e-06	0.00128	-0.25	-0.21	Dermatomyositis;	chr2:197925041	chr2:197693106~197774823:+
HNSC	cis	rs6430585	0.528	rs660002	ENSG00000231890.6	DARS-AS1	-4.58	6.08e-06	0.00128	-0.33	-0.21	Corneal structure;	chr2:135965934	chr2:135985176~136022593:+
HNSC	cis	rs1799949	1	rs36036395	ENSG00000236383.6	LINC00854	-4.58	6.08e-06	0.00128	-0.2	-0.21	Menopause (age at onset);	chr17:43029280	chr17:43216941~43305976:-
HNSC	cis	rs3736485	0.966	rs1031664	ENSG00000259438.1	CTD-2650P22.1	4.58	6.09e-06	0.00129	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51462700	chr15:52010999~52019095:-
HNSC	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-4.58	6.09e-06	0.00129	-0.24	-0.21	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
HNSC	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-4.58	6.09e-06	0.00129	-0.17	-0.21	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
HNSC	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-4.58	6.1e-06	0.00129	-0.2	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000204709.4	LINC01556	4.58	6.1e-06	0.00129	0.28	0.21	Depression;	chr6:28133900	chr6:28943877~28944537:+
HNSC	cis	rs13256369	0.802	rs2280560	ENSG00000173295.6	FAM86B3P	4.58	6.1e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8703092	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs12153	ENSG00000173295.6	FAM86B3P	4.58	6.1e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8703399	chr8:8228595~8244865:+
HNSC	cis	rs757110	0.526	rs757081	ENSG00000260196.1	RP1-239B22.5	-4.58	6.1e-06	0.00129	-0.24	-0.21	Type 2 diabetes;	chr11:17330136	chr11:17380649~17383531:+
HNSC	cis	rs1479119	0.681	rs10744022	ENSG00000180861.8	LINC01559	4.58	6.1e-06	0.00129	0.26	0.21	Intelligence (multi-trait analysis);	chr12:13349659	chr12:13371089~13387167:-
HNSC	cis	rs7572733	0.901	rs13011918	ENSG00000222017.1	AC011997.1	-4.58	6.11e-06	0.00129	-0.25	-0.21	Dermatomyositis;	chr2:197914359	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs1401093	ENSG00000222017.1	AC011997.1	-4.58	6.11e-06	0.00129	-0.25	-0.21	Dermatomyositis;	chr2:197915115	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs1401094	ENSG00000222017.1	AC011997.1	-4.58	6.11e-06	0.00129	-0.25	-0.21	Dermatomyositis;	chr2:197915125	chr2:197693106~197774823:+
HNSC	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	4.58	6.11e-06	0.00129	0.31	0.21	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
HNSC	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	4.58	6.11e-06	0.00129	0.31	0.21	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
HNSC	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	4.58	6.11e-06	0.00129	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	4.58	6.11e-06	0.00129	0.25	0.21	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
HNSC	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	4.57	6.11e-06	0.00129	0.2	0.21	Height;	chr5:37474023	chr5:36666214~36725195:-
HNSC	cis	rs4763879	0.634	rs2098298	ENSG00000278635.1	CTD-2318O12.1	4.57	6.11e-06	0.00129	0.16	0.21	Type 1 diabetes;	chr12:9707473	chr12:9415641~9416718:+
HNSC	cis	rs4763879	0.594	rs12427310	ENSG00000278635.1	CTD-2318O12.1	4.57	6.11e-06	0.00129	0.16	0.21	Type 1 diabetes;	chr12:9707539	chr12:9415641~9416718:+
HNSC	cis	rs13256369	0.95	rs12548792	ENSG00000173295.6	FAM86B3P	4.57	6.12e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8710521	chr8:8228595~8244865:+
HNSC	cis	rs3806843	0.676	rs1583005	ENSG00000202515.1	VTRNA1-3	4.57	6.12e-06	0.00129	0.23	0.21	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr5:140726158~140726246:+
HNSC	cis	rs3015497	0.624	rs3015488	ENSG00000269906.1	RP11-248J18.2	-4.57	6.13e-06	0.00129	-0.28	-0.21	Mean platelet volume;	chr14:50668591	chr14:50662511~50663178:-
HNSC	cis	rs13256369	0.802	rs1060107	ENSG00000173295.6	FAM86B3P	4.57	6.13e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8703889	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs4840350	ENSG00000173295.6	FAM86B3P	4.57	6.13e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8703932	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs1060106	ENSG00000173295.6	FAM86B3P	4.57	6.13e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8703942	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs11249883	ENSG00000173295.6	FAM86B3P	4.57	6.13e-06	0.00129	0.27	0.21	Obesity-related traits;	chr8:8704027	chr8:8228595~8244865:+
HNSC	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	4.57	6.13e-06	0.00129	0.29	0.21	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.5	rs6570022	ENSG00000234084.1	RP3-388E23.2	-4.57	6.13e-06	0.00129	-0.21	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135301568~135307158:+
HNSC	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-4.57	6.13e-06	0.00129	-0.27	-0.21	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
HNSC	cis	rs4761669	0.701	rs9667991	ENSG00000241556.1	RP11-490G8.1	-4.57	6.13e-06	0.00129	-0.2	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94786086	chr12:95467397~95467861:-
HNSC	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-4.57	6.14e-06	0.0013	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
HNSC	cis	rs597539	0.652	rs559032	ENSG00000255741.1	RP11-757G1.5	-4.57	6.14e-06	0.0013	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68941503~68942852:-
HNSC	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	4.57	6.14e-06	0.0013	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
HNSC	cis	rs55661361	0.532	rs3802902	ENSG00000254941.1	RP11-677M14.5	-4.57	6.14e-06	0.0013	-0.23	-0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124807822~124808269:-
HNSC	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	4.57	6.14e-06	0.0013	0.19	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
HNSC	cis	rs3811273	0.614	rs4982594	ENSG00000211816.2	TRAV38-1	-4.57	6.14e-06	0.0013	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22266671	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs4982595	ENSG00000211816.2	TRAV38-1	-4.57	6.14e-06	0.0013	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22266915	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs10150341	ENSG00000211816.2	TRAV38-1	-4.57	6.14e-06	0.0013	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22267213	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs10150343	ENSG00000211816.2	TRAV38-1	-4.57	6.14e-06	0.0013	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22267219	chr14:22271968~22272563:+
HNSC	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-4.57	6.14e-06	0.0013	-0.23	-0.21	Height;	chr2:46572204	chr2:46668870~46670778:+
HNSC	cis	rs7535099	0.954	rs11208680	ENSG00000224570.1	RP11-430H12.2	-4.57	6.14e-06	0.0013	-0.28	-0.21	Blood protein levels;	chr1:65587380	chr1:65576129~65578380:-
HNSC	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	4.57	6.15e-06	0.0013	0.23	0.21	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
HNSC	cis	rs7243790	0.807	rs13380938	ENSG00000277324.1	RP11-850A17.1	-4.57	6.15e-06	0.0013	-0.23	-0.21	Diastolic blood pressure;	chr18:54369177	chr18:54268346~54270028:-
HNSC	cis	rs9840812	0.769	rs489398	ENSG00000273486.1	RP11-731C17.2	4.57	6.15e-06	0.0013	0.2	0.21	Fibrinogen levels;	chr3:136276656	chr3:136837338~136839021:-
HNSC	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-4.57	6.15e-06	0.0013	-0.18	-0.21	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
HNSC	cis	rs7809950	0.954	rs2712229	ENSG00000238832.1	snoU109	4.57	6.16e-06	0.0013	0.26	0.21	Coronary artery disease;	chr7:107654881	chr7:107603363~107603507:+
HNSC	cis	rs9863	0.827	rs4930706	ENSG00000269938.1	RP11-214K3.20	-4.57	6.16e-06	0.0013	-0.24	-0.21	White blood cell count;	chr12:123932791	chr12:123968023~123968579:-
HNSC	cis	rs757081	0.667	rs17473243	ENSG00000260196.1	RP1-239B22.5	-4.57	6.16e-06	0.0013	-0.25	-0.21	Systolic blood pressure;	chr11:17244712	chr11:17380649~17383531:+
HNSC	cis	rs3736485	0.903	rs11070863	ENSG00000259438.1	CTD-2650P22.1	4.57	6.16e-06	0.0013	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51612393	chr15:52010999~52019095:-
HNSC	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	4.57	6.16e-06	0.0013	0.22	0.21	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
HNSC	cis	rs9863	0.861	rs4930723	ENSG00000269938.1	RP11-214K3.20	-4.57	6.16e-06	0.0013	-0.25	-0.21	White blood cell count;	chr12:123939053	chr12:123968023~123968579:-
HNSC	cis	rs12701220	0.817	rs1058729	ENSG00000229043.2	AC091729.9	-4.57	6.17e-06	0.0013	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1160374~1165267:+
HNSC	cis	rs10462794	0.853	rs6886143	ENSG00000260763.1	RP11-445O3.3	4.57	6.17e-06	0.0013	0.27	0.21	DNA methylation (variation);	chr5:4506635	chr5:4436850~4440259:-
HNSC	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	4.57	6.17e-06	0.0013	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
HNSC	cis	rs9907295	1	rs9904675	ENSG00000270977.1	AC015849.16	-4.57	6.17e-06	0.0013	-0.36	-0.21	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35893707~35911023:-
HNSC	cis	rs17428076	0.749	rs62182404	ENSG00000228389.1	AC068039.4	-4.57	6.17e-06	0.0013	-0.28	-0.21	Myopia;	chr2:171891652	chr2:171773482~171775844:+
HNSC	cis	rs4660214	0.666	rs3116398	ENSG00000182109.6	RP11-69E11.4	-4.57	6.18e-06	0.0013	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-4.57	6.18e-06	0.0013	-0.25	-0.21	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
HNSC	cis	rs9450351	0.744	rs12528808	ENSG00000203875.9	SNHG5	-4.57	6.18e-06	0.0013	-0.47	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85495926	chr6:85660950~85678736:-
HNSC	cis	rs2286503	0.839	rs4722188	ENSG00000226329.2	AC005682.6	4.57	6.18e-06	0.0013	0.26	0.21	Fibrinogen;	chr7:22820592	chr7:22863874~22881350:-
HNSC	cis	rs2237234	1	rs2237234	ENSG00000241549.7	GUSBP2	4.57	6.18e-06	0.0013	0.22	0.21	Autism spectrum disorder or schizophrenia;	chr6:26391166	chr6:26871484~26956554:-
HNSC	cis	rs17292804	0.527	rs12887734	ENSG00000269910.1	RP11-73M18.10	4.57	6.19e-06	0.0013	0.2	0.21	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694516~103695050:-
HNSC	cis	rs116095464	0.558	rs6872854	ENSG00000250848.1	CTD-2083E4.5	-4.57	6.19e-06	0.0013	-0.28	-0.21	Breast cancer;	chr5:208923	chr5:288833~290321:-
HNSC	cis	rs60617249	0.794	rs2113476	ENSG00000228204.2	RP4-724E13.2	4.57	6.19e-06	0.0013	0.21	0.21	Major depression and alcohol dependence;	chr7:50876147	chr7:50866747~51022990:+
HNSC	cis	rs6964587	0.708	rs38800	ENSG00000188693.7	CYP51A1-AS1	4.57	6.19e-06	0.00131	0.21	0.21	Breast cancer;	chr7:92416877	chr7:92134604~92180725:+
HNSC	cis	rs9992667	0.725	rs1466414	ENSG00000231160.8	KLF3-AS1	4.57	6.19e-06	0.00131	0.21	0.21	Eosinophil percentage of granulocytes;	chr4:38662703	chr4:38612701~38664883:-
HNSC	cis	rs73222236	0.825	rs9853387	ENSG00000273486.1	RP11-731C17.2	4.57	6.19e-06	0.00131	0.17	0.21	Coronary artery disease;	chr3:136320146	chr3:136837338~136839021:-
HNSC	cis	rs7086627	0.515	rs1870147	ENSG00000226659.1	RP11-137H2.4	-4.57	6.2e-06	0.00131	-0.26	-0.21	Post bronchodilator FEV1;	chr10:80452785	chr10:80529597~80535942:-
HNSC	cis	rs9329221	0.905	rs6601451	ENSG00000269918.1	AF131215.9	-4.57	6.2e-06	0.00131	-0.2	-0.21	Neuroticism;	chr8:10386171	chr8:11104691~11106704:-
HNSC	cis	rs1056107	0.931	rs10481637	ENSG00000225513.1	RP11-165N19.2	-4.57	6.2e-06	0.00131	-0.22	-0.21	Colorectal cancer;	chr9:112334457	chr9:112173522~112173971:-
HNSC	cis	rs853679	0.607	rs13205211	ENSG00000204709.4	LINC01556	4.57	6.2e-06	0.00131	0.43	0.21	Depression;	chr6:28235278	chr6:28943877~28944537:+
HNSC	cis	rs11951515	0.663	rs1564198	ENSG00000249286.1	CTD-2210P15.2	-4.57	6.2e-06	0.00131	-0.22	-0.21	Metabolite levels  (X-11787);	chr5:43338820	chr5:43586918~43588223:-
HNSC	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	4.57	6.2e-06	0.00131	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
HNSC	cis	rs712039	0.652	rs853224	ENSG00000276054.1	RP11-378E13.3	4.57	6.2e-06	0.00131	0.29	0.21	Tuberculosis;	chr17:37431229	chr17:37386886~37387926:+
HNSC	cis	rs7824557	0.767	rs7003241	ENSG00000269918.1	AF131215.9	4.57	6.2e-06	0.00131	0.21	0.21	Retinal vascular caliber;	chr8:11311566	chr8:11104691~11106704:-
HNSC	cis	rs4908768	0.52	rs4908507	ENSG00000232912.4	RP5-1115A15.1	4.57	6.2e-06	0.00131	0.22	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678878	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.52	rs11121216	ENSG00000232912.4	RP5-1115A15.1	4.57	6.2e-06	0.00131	0.22	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678885	chr1:8424645~8434838:+
HNSC	cis	rs17594362	0.887	rs34485273	ENSG00000229473.2	RGS17P1	-4.57	6.2e-06	0.00131	-0.33	-0.21	Multiple sclerosis;	chr13:41575556	chr13:40992779~40993331:-
HNSC	cis	rs6586111	1	rs7073089	ENSG00000226659.1	RP11-137H2.4	-4.57	6.2e-06	0.00131	-0.25	-0.21	Capecitabine sensitivity;	chr10:80611289	chr10:80529597~80535942:-
HNSC	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-4.57	6.21e-06	0.00131	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-4.57	6.21e-06	0.00131	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
HNSC	cis	rs10515750	0.643	rs10054755	ENSG00000248544.2	CTB-47B11.3	4.57	6.21e-06	0.00131	0.35	0.21	Lung function (FEV1/FVC);	chr5:157384037	chr5:157375741~157384950:-
HNSC	cis	rs10515750	0.643	rs10063539	ENSG00000248544.2	CTB-47B11.3	4.57	6.21e-06	0.00131	0.35	0.21	Lung function (FEV1/FVC);	chr5:157384666	chr5:157375741~157384950:-
HNSC	cis	rs9611565	0.659	rs9611610	ENSG00000235513.1	RP4-756G23.5	4.57	6.21e-06	0.00131	0.24	0.21	Vitiligo;	chr22:41553255	chr22:41209122~41217627:-
HNSC	cis	rs3811273	0.614	rs7157477	ENSG00000211816.2	TRAV38-1	-4.57	6.22e-06	0.00131	-0.23	-0.21	Periodontal disease-related phenotypes;	chr14:22266229	chr14:22271968~22272563:+
HNSC	cis	rs9450351	0.744	rs6923017	ENSG00000203875.9	SNHG5	-4.57	6.22e-06	0.00131	-0.45	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85592619	chr6:85660950~85678736:-
HNSC	cis	rs9353324	1	rs7775788	ENSG00000203875.9	SNHG5	-4.57	6.22e-06	0.00131	-0.45	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85595761	chr6:85660950~85678736:-
HNSC	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	4.57	6.22e-06	0.00131	0.25	0.21	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
HNSC	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	4.57	6.22e-06	0.00131	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
HNSC	cis	rs889398	0.771	rs1566454	ENSG00000226232.7	RP11-419C5.2	-4.57	6.22e-06	0.00131	-0.18	-0.21	Body mass index;	chr16:69866180	chr16:69976388~69996188:-
HNSC	cis	rs889398	0.651	rs1566455	ENSG00000226232.7	RP11-419C5.2	-4.57	6.22e-06	0.00131	-0.18	-0.21	Body mass index;	chr16:69866261	chr16:69976388~69996188:-
HNSC	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	4.57	6.22e-06	0.00131	0.2	0.21	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
HNSC	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	4.57	6.22e-06	0.00131	0.25	0.21	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
HNSC	cis	rs1799949	0.965	rs799916	ENSG00000236383.6	LINC00854	4.57	6.22e-06	0.00131	0.19	0.21	Menopause (age at onset);	chr17:43091173	chr17:43216941~43305976:-
HNSC	cis	rs889398	0.771	rs4985448	ENSG00000226232.7	RP11-419C5.2	-4.57	6.22e-06	0.00131	-0.18	-0.21	Body mass index;	chr16:69865492	chr16:69976388~69996188:-
HNSC	cis	rs10773046	0.702	rs11057379	ENSG00000269938.1	RP11-214K3.20	-4.57	6.23e-06	0.00131	-0.23	-0.21	Osteoarthritis (hip);	chr12:123871110	chr12:123968023~123968579:-
HNSC	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.23e-06	0.00131	-0.46	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
HNSC	cis	rs6601327	0.641	rs10102170	ENSG00000254340.1	RP11-10A14.3	4.57	6.23e-06	0.00131	0.25	0.21	Multiple myeloma (hyperdiploidy);	chr8:9753960	chr8:9141424~9145435:+
HNSC	cis	rs13256369	0.951	rs13270852	ENSG00000173295.6	FAM86B3P	4.57	6.23e-06	0.00131	0.27	0.21	Obesity-related traits;	chr8:8709343	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.851	rs13271698	ENSG00000173295.6	FAM86B3P	4.57	6.23e-06	0.00131	0.27	0.21	Obesity-related traits;	chr8:8710029	chr8:8228595~8244865:+
HNSC	cis	rs9329221	0.538	rs9650651	ENSG00000269918.1	AF131215.9	4.57	6.23e-06	0.00131	0.2	0.21	Neuroticism;	chr8:10410030	chr8:11104691~11106704:-
HNSC	cis	rs79057730	0.599	rs4721086	ENSG00000225146.1	AC073957.15	4.57	6.23e-06	0.00131	0.31	0.21	Initial pursuit acceleration;	chr7:781486	chr7:1029025~1043891:+
HNSC	cis	rs2911132	0.621	rs17480169	ENSG00000248734.2	CTD-2260A17.1	4.57	6.23e-06	0.00131	0.23	0.21	Urate levels (BMI interaction);	chr5:96753363	chr5:96784777~96785999:+
HNSC	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-4.57	6.23e-06	0.00131	-0.21	-0.21	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
HNSC	cis	rs5758511	0.68	rs5758667	ENSG00000205702.9	CYP2D7	4.57	6.23e-06	0.00131	0.19	0.21	Birth weight;	chr22:42237198	chr22:42140203~42144577:-
HNSC	cis	rs56804039	1	rs59620654	ENSG00000173295.6	FAM86B3P	-4.57	6.24e-06	0.00131	-0.27	-0.21	Cervical cancer;	chr8:8525122	chr8:8228595~8244865:+
HNSC	cis	rs56804039	1	rs34154295	ENSG00000173295.6	FAM86B3P	-4.57	6.24e-06	0.00131	-0.27	-0.21	Cervical cancer;	chr8:8525967	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000254153.1	CTA-398F10.2	-4.57	6.24e-06	0.00131	-0.23	-0.21	Mood instability;	chr8:8937937	chr8:8456909~8461337:-
HNSC	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	4.57	6.24e-06	0.00131	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
HNSC	cis	rs2985684	0.779	rs12160	ENSG00000278009.1	RP11-649E7.8	4.57	6.24e-06	0.00131	0.27	0.21	Carotid intima media thickness;	chr14:49625214	chr14:49601011~49601124:-
HNSC	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	4.57	6.24e-06	0.00131	0.25	0.21	Depression;	chr6:28110525	chr6:28170845~28172521:+
HNSC	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	4.57	6.24e-06	0.00131	0.24	0.21	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
HNSC	cis	rs11250098	0.574	rs4554431	ENSG00000269918.1	AF131215.9	-4.57	6.25e-06	0.00132	-0.2	-0.21	Morning vs. evening chronotype;	chr8:10914128	chr8:11104691~11106704:-
HNSC	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	4.57	6.25e-06	0.00132	0.34	0.21	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
HNSC	cis	rs757081	0.648	rs10832750	ENSG00000260196.1	RP1-239B22.5	4.57	6.25e-06	0.00132	0.22	0.21	Systolic blood pressure;	chr11:17239371	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs12420958	ENSG00000260196.1	RP1-239B22.5	-4.57	6.25e-06	0.00132	-0.26	-0.21	Systolic blood pressure;	chr11:17078885	chr11:17380649~17383531:+
HNSC	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	4.57	6.25e-06	0.00132	0.29	0.21	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
HNSC	cis	rs9867325	1	rs9867325	ENSG00000273486.1	RP11-731C17.2	4.57	6.25e-06	0.00132	0.2	0.21	Body mass index;	chr3:136900067	chr3:136837338~136839021:-
HNSC	cis	rs9867325	1	rs9840500	ENSG00000273486.1	RP11-731C17.2	4.57	6.25e-06	0.00132	0.2	0.21	Body mass index;	chr3:136902496	chr3:136837338~136839021:-
HNSC	cis	rs1971762	0.545	rs7297461	ENSG00000270175.1	RP11-793H13.11	-4.57	6.26e-06	0.00132	-0.18	-0.21	Height;	chr12:53653394	chr12:53500162~53500936:-
HNSC	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-4.57	6.26e-06	0.00132	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
HNSC	cis	rs853679	0.607	rs56189111	ENSG00000219392.1	RP1-265C24.5	-4.57	6.26e-06	0.00132	-0.42	-0.21	Depression;	chr6:28304196	chr6:28115628~28116551:+
HNSC	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-4.57	6.26e-06	0.00132	-0.24	-0.21	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
HNSC	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-4.57	6.26e-06	0.00132	-0.21	-0.21	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	4.57	6.26e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	4.57	6.26e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	4.57	6.26e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	4.57	6.26e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	4.57	6.26e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
HNSC	cis	rs7535099	0.954	rs6588152	ENSG00000224570.1	RP11-430H12.2	-4.57	6.27e-06	0.00132	-0.27	-0.21	Blood protein levels;	chr1:65573315	chr1:65576129~65578380:-
HNSC	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-4.57	6.27e-06	0.00132	-0.24	-0.21	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
HNSC	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	4.57	6.27e-06	0.00132	0.26	0.21	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	4.57	6.27e-06	0.00132	0.25	0.21	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
HNSC	cis	rs7598759	1	rs7598759	ENSG00000181798.2	LINC00471	-4.57	6.27e-06	0.00132	-0.2	-0.21	Noise-induced hearing loss;	chr2:231457245	chr2:231508426~231514339:-
HNSC	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	4.57	6.28e-06	0.00132	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
HNSC	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-4.57	6.28e-06	0.00132	-0.19	-0.21	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
HNSC	cis	rs853679	0.607	rs13207345	ENSG00000219392.1	RP1-265C24.5	-4.57	6.29e-06	0.00132	-0.42	-0.21	Depression;	chr6:28297795	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs72854513	ENSG00000219392.1	RP1-265C24.5	-4.57	6.29e-06	0.00132	-0.42	-0.21	Depression;	chr6:28298177	chr6:28115628~28116551:+
HNSC	cis	rs2985684	1	rs7142457	ENSG00000278009.1	RP11-649E7.8	4.57	6.29e-06	0.00132	0.27	0.21	Carotid intima media thickness;	chr14:49631144	chr14:49601011~49601124:-
HNSC	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.57	6.29e-06	0.00132	0.19	0.21	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
HNSC	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	4.57	6.29e-06	0.00132	0.31	0.21	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
HNSC	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	4.57	6.29e-06	0.00132	0.21	0.21	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
HNSC	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-4.57	6.29e-06	0.00132	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	4.57	6.29e-06	0.00132	0.24	0.21	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	4.57	6.3e-06	0.00132	0.25	0.21	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	4.57	6.3e-06	0.00132	0.25	0.21	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000254153.1	CTA-398F10.2	-4.57	6.3e-06	0.00133	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9017276	chr8:8456909~8461337:-
HNSC	cis	rs6964587	0.773	rs38793	ENSG00000188693.7	CYP51A1-AS1	4.57	6.31e-06	0.00133	0.22	0.21	Breast cancer;	chr7:92397873	chr7:92134604~92180725:+
HNSC	cis	rs7071275	0.564	rs10788191	ENSG00000223432.1	RP11-62L18.3	4.57	6.31e-06	0.00133	0.26	0.21	Dupuytren's disease;	chr10:121627812	chr10:121615425~121615839:-
HNSC	cis	rs879620	0.929	rs2238435	ENSG00000262888.1	RP11-462G12.2	-4.57	6.31e-06	0.00133	-0.25	-0.21	Hip circumference;Body mass index;	chr16:3964281	chr16:3931217~3946305:-
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-4.57	6.31e-06	0.00133	-0.27	-0.21	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
HNSC	cis	rs7809950	0.954	rs11977187	ENSG00000238832.1	snoU109	4.57	6.31e-06	0.00133	0.27	0.21	Coronary artery disease;	chr7:107569938	chr7:107603363~107603507:+
HNSC	cis	rs2998286	0.768	rs332137	ENSG00000254635.4	WAC-AS1	-4.57	6.32e-06	0.00133	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.768	rs332140	ENSG00000254635.4	WAC-AS1	-4.57	6.32e-06	0.00133	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332142	ENSG00000254635.4	WAC-AS1	-4.57	6.32e-06	0.00133	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332143	ENSG00000254635.4	WAC-AS1	-4.57	6.32e-06	0.00133	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28522652~28532743:-
HNSC	cis	rs4388249	1	rs2300992	ENSG00000271849.1	CTC-332L22.1	-4.57	6.32e-06	0.00133	-0.32	-0.21	Schizophrenia;	chr5:109702815	chr5:109687802~109688329:-
HNSC	cis	rs12034383	0.902	rs2274566	ENSG00000274245.1	RP11-357P18.2	4.57	6.32e-06	0.00133	0.27	0.21	Erythrocyte sedimentation rate;	chr1:207580000	chr1:207372559~207373252:+
HNSC	cis	rs61935443	0.501	rs4761667	ENSG00000241556.1	RP11-490G8.1	-4.57	6.32e-06	0.00133	-0.21	-0.21	Schizophrenia;	chr12:94790459	chr12:95467397~95467861:-
HNSC	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	4.57	6.32e-06	0.00133	0.38	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
HNSC	cis	rs721917	0.506	rs2244451	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2265961	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs7088752	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs7078242	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.525	rs2244001	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs1811886	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2819113	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs4320898	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs4322333	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.33e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79663088~79826594:-
HNSC	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	4.57	6.33e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
HNSC	cis	rs12682352	0.535	rs12677550	ENSG00000254340.1	RP11-10A14.3	-4.57	6.33e-06	0.00133	-0.26	-0.21	Neuroticism;	chr8:8786812	chr8:9141424~9145435:+
HNSC	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-4.57	6.33e-06	0.00133	-0.17	-0.21	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
HNSC	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-4.57	6.33e-06	0.00133	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
HNSC	cis	rs13256369	0.851	rs13267036	ENSG00000173295.6	FAM86B3P	4.57	6.33e-06	0.00133	0.27	0.21	Obesity-related traits;	chr8:8709175	chr8:8228595~8244865:+
HNSC	cis	rs10027350	0.714	rs3796791	ENSG00000281501.1	SEPSECS-AS1	4.57	6.34e-06	0.00133	0.26	0.21	Childhood ear infection;	chr4:25132423	chr4:25160641~25201440:+
HNSC	cis	rs7615952	0.515	rs4441610	ENSG00000248787.1	RP11-666A20.4	-4.57	6.34e-06	0.00133	-0.28	-0.21	Blood pressure (smoking interaction);	chr3:125962464	chr3:125908005~125910272:-
HNSC	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-4.57	6.34e-06	0.00133	-0.26	-0.21	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
HNSC	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	4.57	6.34e-06	0.00133	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
HNSC	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-4.57	6.34e-06	0.00133	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
HNSC	cis	rs4908769	0.627	rs301798	ENSG00000232912.4	RP5-1115A15.1	4.57	6.34e-06	0.00133	0.23	0.21	Allergy;	chr1:8428505	chr1:8424645~8434838:+
HNSC	cis	rs4862750	0.914	rs1991256	ENSG00000250971.1	RP11-696F12.1	4.57	6.34e-06	0.00133	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.914	rs1991255	ENSG00000250971.1	RP11-696F12.1	4.57	6.34e-06	0.00133	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:187060099~187060930:+
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-4.57	6.34e-06	0.00133	-0.24	-0.21	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
HNSC	cis	rs9650657	0.746	rs4841441	ENSG00000269918.1	AF131215.9	-4.57	6.34e-06	0.00133	-0.21	-0.21	Neuroticism;	chr8:10773388	chr8:11104691~11106704:-
HNSC	cis	rs10028773	0.515	rs9994488	ENSG00000249244.1	RP11-548H18.2	4.57	6.34e-06	0.00133	0.25	0.21	Educational attainment;	chr4:119666626	chr4:119391831~119395335:-
HNSC	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	4.57	6.35e-06	0.00133	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
HNSC	cis	rs9321453	1	rs4266506	ENSG00000231971.4	RP11-557H15.3	4.57	6.35e-06	0.00133	0.25	0.21	Urate levels;	chr6:134453083	chr6:134428240~134520585:-
HNSC	cis	rs9321453	1	rs4467792	ENSG00000231971.4	RP11-557H15.3	4.57	6.35e-06	0.00133	0.25	0.21	Urate levels;	chr6:134453085	chr6:134428240~134520585:-
HNSC	cis	rs721917	0.525	rs2758541	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.35e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2758539	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.35e-06	0.00133	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79663088~79826594:-
HNSC	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-4.57	6.35e-06	0.00133	-0.25	-0.21	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
HNSC	cis	rs11773103	1	rs11773164	ENSG00000224046.1	AC005076.5	4.57	6.35e-06	0.00133	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87280623	chr7:87151423~87152420:-
HNSC	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	4.57	6.35e-06	0.00133	0.23	0.21	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
HNSC	cis	rs6964587	0.869	rs405	ENSG00000188693.7	CYP51A1-AS1	4.57	6.35e-06	0.00133	0.22	0.21	Breast cancer;	chr7:91917013	chr7:92134604~92180725:+
HNSC	cis	rs440932	0.565	rs19334	ENSG00000254153.1	CTA-398F10.2	4.57	6.35e-06	0.00133	0.22	0.21	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8456909~8461337:-
HNSC	cis	rs1056107	0.933	rs7866603	ENSG00000225513.1	RP11-165N19.2	-4.57	6.36e-06	0.00134	-0.22	-0.21	Colorectal cancer;	chr9:112202052	chr9:112173522~112173971:-
HNSC	cis	rs36093844	0.706	rs75217143	ENSG00000279742.1	RP11-700A24.1	-4.57	6.37e-06	0.00134	-0.3	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85851227	chr11:85852557~85854943:-
HNSC	cis	rs1150668	0.745	rs213238	ENSG00000219392.1	RP1-265C24.5	-4.57	6.37e-06	0.00134	-0.23	-0.21	Pubertal anthropometrics;	chr6:28354216	chr6:28115628~28116551:+
HNSC	cis	rs9907295	1	rs11080360	ENSG00000270977.1	AC015849.16	-4.57	6.37e-06	0.00134	-0.38	-0.21	Fibroblast growth factor basic levels;	chr17:35916086	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs11869976	ENSG00000270977.1	AC015849.16	-4.57	6.37e-06	0.00134	-0.38	-0.21	Fibroblast growth factor basic levels;	chr17:35916492	chr17:35893707~35911023:-
HNSC	cis	rs763121	0.853	rs6519120	ENSG00000273076.1	RP3-508I15.22	-4.57	6.37e-06	0.00134	-0.23	-0.21	Menopause (age at onset);	chr22:38595388	chr22:38743495~38743910:+
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	4.57	6.37e-06	0.00134	0.25	0.21	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	4.57	6.37e-06	0.00134	0.25	0.21	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	4.57	6.37e-06	0.00134	0.25	0.21	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	4.57	6.37e-06	0.00134	0.25	0.21	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	4.57	6.37e-06	0.00134	0.25	0.21	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
HNSC	cis	rs1355223	0.583	rs1396880	ENSG00000271369.1	RP11-350D17.3	-4.57	6.37e-06	0.00134	-0.23	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34849005	chr11:34709600~34710161:+
HNSC	cis	rs7824557	0.767	rs28507159	ENSG00000255310.2	AF131215.2	4.57	6.38e-06	0.00134	0.2	0.21	Retinal vascular caliber;	chr8:11308567	chr8:11107788~11109726:-
HNSC	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	4.57	6.39e-06	0.00134	0.28	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
HNSC	cis	rs6831352	0.76	rs1311616	ENSG00000263923.1	RP11-571L19.7	-4.57	6.39e-06	0.00134	-0.22	-0.21	Alcohol dependence;	chr4:99091152	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs1311617	ENSG00000263923.1	RP11-571L19.7	-4.57	6.39e-06	0.00134	-0.22	-0.21	Smoking initiation;	chr4:99091274	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs1311618	ENSG00000263923.1	RP11-571L19.7	-4.57	6.39e-06	0.00134	-0.22	-0.21	Smoking initiation;	chr4:99091461	chr4:98928897~98994994:+
HNSC	cis	rs12935418	0.672	rs2549879	ENSG00000278985.1	RP11-303E16.9	-4.57	6.39e-06	0.00134	-0.2	-0.21	Mean corpuscular volume;	chr16:81012496	chr16:80982319~80984094:-
HNSC	cis	rs4862750	0.872	rs9998172	ENSG00000250971.1	RP11-696F12.1	4.57	6.39e-06	0.00134	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186977619	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs9998173	ENSG00000250971.1	RP11-696F12.1	4.57	6.39e-06	0.00134	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186977624	chr4:187060099~187060930:+
HNSC	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	4.57	6.39e-06	0.00134	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
HNSC	cis	rs7665090	0.967	rs228611	ENSG00000246560.2	RP11-10L12.4	-4.57	6.4e-06	0.00134	-0.24	-0.21	Primary biliary cholangitis;	chr4:102640552	chr4:102828055~102844075:+
HNSC	cis	rs7178375	1	rs11070678	ENSG00000270055.1	CTD-3092A11.2	-4.56	6.4e-06	0.00134	-0.27	-0.21	Hypertriglyceridemia;	chr15:30927561	chr15:30487963~30490313:+
HNSC	cis	rs11154801	0.732	rs13202115	ENSG00000234084.1	RP3-388E23.2	-4.56	6.4e-06	0.00134	-0.21	-0.21	Multiple sclerosis;	chr6:135604386	chr6:135301568~135307158:+
HNSC	cis	rs3733585	0.699	rs12498956	ENSG00000250413.1	RP11-448G15.1	4.56	6.4e-06	0.00134	0.25	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9949081	chr4:10006482~10009725:+
HNSC	cis	rs72843506	0.656	rs56138907	ENSG00000261033.1	RP11-209D14.2	4.56	6.4e-06	0.00134	0.34	0.21	Schizophrenia;	chr17:20085732	chr17:20008051~20009234:-
HNSC	cis	rs516805	0.748	rs1267941	ENSG00000279453.1	RP3-425C14.4	-4.56	6.41e-06	0.00135	-0.29	-0.21	Lymphocyte counts;	chr6:122471888	chr6:122436789~122439223:-
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	4.56	6.41e-06	0.00135	0.19	0.21	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
HNSC	cis	rs9921338	0.54	rs2868409	ENSG00000263080.1	RP11-485G7.5	4.56	6.41e-06	0.00135	0.2	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11323512	chr16:11341809~11345211:-
HNSC	cis	rs9987353	0.544	rs2929470	ENSG00000173295.6	FAM86B3P	-4.56	6.42e-06	0.00135	-0.23	-0.21	Recombination measurement;	chr8:9204980	chr8:8228595~8244865:+
HNSC	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-4.56	6.42e-06	0.00135	-0.32	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
HNSC	cis	rs2361718	0.501	rs8065486	ENSG00000275479.1	RP11-334C17.6	-4.56	6.42e-06	0.00135	-0.23	-0.21	Yeast infection;	chr17:80164397	chr17:80149627~80149798:+
HNSC	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	4.56	6.42e-06	0.00135	0.2	0.21	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
HNSC	cis	rs763121	0.853	rs7289855	ENSG00000273076.1	RP3-508I15.22	4.56	6.42e-06	0.00135	0.22	0.21	Menopause (age at onset);	chr22:38646216	chr22:38743495~38743910:+
HNSC	cis	rs7824557	0.736	rs35392635	ENSG00000269918.1	AF131215.9	4.56	6.42e-06	0.00135	0.21	0.21	Retinal vascular caliber;	chr8:11306840	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.767	rs11775635	ENSG00000269918.1	AF131215.9	4.56	6.42e-06	0.00135	0.21	0.21	Retinal vascular caliber;	chr8:11307356	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.863	rs3822192	ENSG00000250412.1	KLHL2P1	4.56	6.42e-06	0.00135	0.27	0.21	Corneal astigmatism;	chr4:119524565	chr4:119334329~119378233:+
HNSC	cis	rs7809950	0.724	rs1858888	ENSG00000238832.1	snoU109	-4.56	6.42e-06	0.00135	-0.3	-0.21	Coronary artery disease;	chr7:107405617	chr7:107603363~107603507:+
HNSC	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.56	6.42e-06	0.00135	0.2	0.21	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
HNSC	cis	rs4660214	0.666	rs7553009	ENSG00000182109.6	RP11-69E11.4	-4.56	6.43e-06	0.00135	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39522280~39546187:-
HNSC	cis	rs79349575	0.721	rs9904645	ENSG00000270781.1	RP11-501C14.9	-4.56	6.43e-06	0.00135	-0.22	-0.21	Type 2 diabetes;	chr17:48892303	chr17:48899131~48899748:+
HNSC	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-4.56	6.43e-06	0.00135	-0.21	-0.21	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-4.56	6.43e-06	0.00135	-0.21	-0.21	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-4.56	6.43e-06	0.00135	-0.21	-0.21	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
HNSC	cis	rs73198271	0.74	rs11781430	ENSG00000233609.3	RP11-62H7.2	-4.56	6.43e-06	0.00135	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8961200~8979025:+
HNSC	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	4.56	6.44e-06	0.00135	0.29	0.21	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
HNSC	cis	rs10946940	0.965	rs62401383	ENSG00000219392.1	RP1-265C24.5	4.56	6.44e-06	0.00135	0.24	0.21	Systemic lupus erythematosus;	chr6:27596768	chr6:28115628~28116551:+
HNSC	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-4.56	6.44e-06	0.00135	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
HNSC	cis	rs5758659	0.716	rs2143138	ENSG00000273366.1	CTA-989H11.1	-4.56	6.44e-06	0.00135	-0.24	-0.21	Cognitive function;	chr22:42222334	chr22:42278188~42278846:+
HNSC	cis	rs7615952	0.605	rs11708269	ENSG00000241288.6	RP11-379B18.5	-4.56	6.45e-06	0.00135	-0.37	-0.21	Blood pressure (smoking interaction);	chr3:125613306	chr3:125827238~125916384:-
HNSC	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-4.56	6.45e-06	0.00135	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-4.56	6.45e-06	0.00135	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
HNSC	cis	rs6928977	0.86	rs2757649	ENSG00000217482.2	HMGB1P17	4.56	6.45e-06	0.00135	0.23	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135636086~135636713:-
HNSC	cis	rs11773103	0.881	rs73202993	ENSG00000224046.1	AC005076.5	4.56	6.45e-06	0.00135	0.41	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87127277	chr7:87151423~87152420:-
HNSC	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	4.56	6.45e-06	0.00135	0.24	0.21	Height;	chr14:75045909	chr14:75011269~75012851:-
HNSC	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-4.56	6.45e-06	0.00135	-0.21	-0.21	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
HNSC	cis	rs79349575	0.594	rs1985785	ENSG00000270781.1	RP11-501C14.9	-4.56	6.46e-06	0.00135	-0.22	-0.21	Type 2 diabetes;	chr17:48890426	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.685	rs1124829	ENSG00000270781.1	RP11-501C14.9	-4.56	6.46e-06	0.00135	-0.22	-0.21	Type 2 diabetes;	chr17:48890435	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.721	rs1008834	ENSG00000270781.1	RP11-501C14.9	-4.56	6.46e-06	0.00135	-0.22	-0.21	Type 2 diabetes;	chr17:48890646	chr17:48899131~48899748:+
HNSC	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-4.56	6.46e-06	0.00135	-0.24	-0.21	Height;	chr14:75066976	chr14:75011269~75012851:-
HNSC	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	4.56	6.46e-06	0.00135	0.18	0.21	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
HNSC	cis	rs763121	0.853	rs5757211	ENSG00000273076.1	RP3-508I15.22	4.56	6.46e-06	0.00135	0.22	0.21	Menopause (age at onset);	chr22:38655700	chr22:38743495~38743910:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000254340.1	RP11-10A14.3	4.56	6.46e-06	0.00135	0.25	0.21	Mood instability;	chr8:8521596	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000254340.1	RP11-10A14.3	4.56	6.46e-06	0.00135	0.25	0.21	Mood instability;	chr8:8521597	chr8:9141424~9145435:+
HNSC	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-4.56	6.47e-06	0.00135	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
HNSC	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	4.56	6.47e-06	0.00135	0.17	0.21	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
HNSC	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-4.56	6.47e-06	0.00135	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-4.56	6.47e-06	0.00135	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-4.56	6.47e-06	0.00135	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000254153.1	CTA-398F10.2	-4.56	6.47e-06	0.00135	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9016136	chr8:8456909~8461337:-
HNSC	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-4.56	6.47e-06	0.00135	-0.21	-0.21	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
HNSC	cis	rs1008375	0.872	rs6831115	ENSG00000249502.1	AC006160.5	-4.56	6.47e-06	0.00136	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638840	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs6811887	ENSG00000249502.1	AC006160.5	-4.56	6.47e-06	0.00136	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17639235	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs28501187	ENSG00000249502.1	AC006160.5	-4.56	6.47e-06	0.00136	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641997	chr4:17587467~17614571:-
HNSC	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-4.56	6.47e-06	0.00136	-0.17	-0.21	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
HNSC	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-4.56	6.47e-06	0.00136	-0.26	-0.21	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
HNSC	cis	rs7615952	0.576	rs6780025	ENSG00000241439.1	RP11-666A20.3	4.56	6.47e-06	0.00136	0.24	0.21	Blood pressure (smoking interaction);	chr3:126096781	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.576	rs6804482	ENSG00000241439.1	RP11-666A20.3	4.56	6.47e-06	0.00136	0.24	0.21	Blood pressure (smoking interaction);	chr3:126096919	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.576	rs12497295	ENSG00000241439.1	RP11-666A20.3	4.56	6.47e-06	0.00136	0.24	0.21	Blood pressure (smoking interaction);	chr3:126099807	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.512	rs4646765	ENSG00000241439.1	RP11-666A20.3	4.56	6.47e-06	0.00136	0.24	0.21	Blood pressure (smoking interaction);	chr3:126101864	chr3:125958556~125958817:+
HNSC	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	4.56	6.47e-06	0.00136	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
HNSC	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-4.56	6.48e-06	0.00136	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
HNSC	cis	rs11722228	0.508	rs3756227	ENSG00000250413.1	RP11-448G15.1	-4.56	6.48e-06	0.00136	-0.31	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10086371	chr4:10006482~10009725:+
HNSC	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-4.56	6.48e-06	0.00136	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
HNSC	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-4.56	6.49e-06	0.00136	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
HNSC	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	4.56	6.49e-06	0.00136	0.23	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
HNSC	cis	rs73222236	0.825	rs9866535	ENSG00000273486.1	RP11-731C17.2	4.56	6.49e-06	0.00136	0.17	0.21	Coronary artery disease;	chr3:136465513	chr3:136837338~136839021:-
HNSC	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-4.56	6.49e-06	0.00136	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	4.56	6.49e-06	0.00136	0.25	0.21	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
HNSC	cis	rs916888	0.821	rs199505	ENSG00000260075.1	NSFP1	4.56	6.49e-06	0.00136	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.821	rs70602	ENSG00000260075.1	NSFP1	4.56	6.49e-06	0.00136	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46372855~46487141:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	4.56	6.49e-06	0.00136	0.24	0.21	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
HNSC	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	4.56	6.49e-06	0.00136	0.2	0.21	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
HNSC	cis	rs11098499	0.687	rs71610270	ENSG00000249244.1	RP11-548H18.2	4.56	6.49e-06	0.00136	0.25	0.21	Corneal astigmatism;	chr4:119366281	chr4:119391831~119395335:-
HNSC	cis	rs9867325	0.895	rs9879531	ENSG00000273486.1	RP11-731C17.2	4.56	6.49e-06	0.00136	0.2	0.21	Body mass index;	chr3:136920133	chr3:136837338~136839021:-
HNSC	cis	rs651907	0.557	rs11917569	ENSG00000244119.1	PDCL3P4	4.56	6.49e-06	0.00136	0.2	0.21	Colorectal cancer;	chr3:101636219	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	4.56	6.49e-06	0.00136	0.2	0.21	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
HNSC	cis	rs6142102	0.812	rs6059558	ENSG00000275784.1	RP5-1125A11.6	-4.56	6.5e-06	0.00136	-0.27	-0.21	Skin pigmentation;	chr20:33929024	chr20:33989480~33991818:-
HNSC	cis	rs6601327	0.613	rs4612345	ENSG00000254340.1	RP11-10A14.3	-4.56	6.5e-06	0.00136	-0.25	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:9141424~9145435:+
HNSC	cis	rs13434995	0.513	rs13134079	ENSG00000273257.1	RP11-177J6.1	4.56	6.5e-06	0.00136	0.28	0.21	Adiponectin levels;	chr4:55542021	chr4:55387949~55388271:+
HNSC	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	4.56	6.5e-06	0.00136	0.19	0.21	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
HNSC	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	4.56	6.5e-06	0.00136	0.19	0.21	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	4.56	6.5e-06	0.00136	0.23	0.21	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	4.56	6.5e-06	0.00136	0.22	0.21	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
HNSC	cis	rs516805	0.706	rs1034060	ENSG00000279453.1	RP3-425C14.4	4.56	6.5e-06	0.00136	0.27	0.21	Lymphocyte counts;	chr6:122319181	chr6:122436789~122439223:-
HNSC	cis	rs1008375	0.966	rs2302393	ENSG00000249502.1	AC006160.5	-4.56	6.5e-06	0.00136	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17652718	chr4:17587467~17614571:-
HNSC	cis	rs73222236	0.825	rs9812319	ENSG00000273486.1	RP11-731C17.2	4.56	6.5e-06	0.00136	0.17	0.21	Coronary artery disease;	chr3:136520018	chr3:136837338~136839021:-
HNSC	cis	rs8028182	0.636	rs4451914	ENSG00000260269.4	CTD-2323K18.1	-4.56	6.51e-06	0.00136	-0.26	-0.21	Sudden cardiac arrest;	chr15:75447483	chr15:75527150~75601205:-
HNSC	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	4.56	6.51e-06	0.00136	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-4.56	6.51e-06	0.00136	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-4.56	6.51e-06	0.00136	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
HNSC	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.56	6.51e-06	0.00136	0.24	0.21	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
HNSC	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	4.56	6.51e-06	0.00136	0.19	0.21	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
HNSC	cis	rs6496044	0.568	rs12899946	ENSG00000259295.5	CSPG4P12	4.56	6.51e-06	0.00136	0.24	0.21	Interstitial lung disease;	chr15:85522851	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs12898783	ENSG00000259295.5	CSPG4P12	4.56	6.51e-06	0.00136	0.24	0.21	Interstitial lung disease;	chr15:85522869	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs11855789	ENSG00000259295.5	CSPG4P12	4.56	6.51e-06	0.00136	0.24	0.21	Interstitial lung disease;	chr15:85523172	chr15:85191438~85213905:+
HNSC	cis	rs6500395	0.962	rs11647046	ENSG00000261267.1	RP11-44I10.3	-4.56	6.51e-06	0.00136	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48589306	chr16:48559661~48587403:+
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000219392.1	RP1-265C24.5	-4.56	6.51e-06	0.00136	-0.23	-0.21	Pubertal anthropometrics;	chr6:28412544	chr6:28115628~28116551:+
HNSC	cis	rs6496044	0.568	rs7176291	ENSG00000259295.5	CSPG4P12	4.56	6.51e-06	0.00136	0.24	0.21	Interstitial lung disease;	chr15:85524167	chr15:85191438~85213905:+
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-4.56	6.51e-06	0.00136	-0.19	-0.21	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
HNSC	cis	rs6964587	0.967	rs34574955	ENSG00000188693.7	CYP51A1-AS1	-4.56	6.51e-06	0.00136	-0.22	-0.21	Breast cancer;	chr7:92218236	chr7:92134604~92180725:+
HNSC	cis	rs2911132	0.564	rs28580505	ENSG00000248734.2	CTD-2260A17.1	4.56	6.51e-06	0.00136	0.23	0.21	Urate levels (BMI interaction);	chr5:96765516	chr5:96784777~96785999:+
HNSC	cis	rs2911132	0.621	rs28432918	ENSG00000248734.2	CTD-2260A17.1	4.56	6.51e-06	0.00136	0.23	0.21	Urate levels (BMI interaction);	chr5:96765522	chr5:96784777~96785999:+
HNSC	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	4.56	6.52e-06	0.00136	0.18	0.21	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	4.56	6.52e-06	0.00136	0.18	0.21	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
HNSC	cis	rs442309	0.551	rs7083045	ENSG00000238280.1	RP11-436D10.3	-4.56	6.52e-06	0.00136	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62780204	chr10:62793562~62805887:-
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-4.56	6.52e-06	0.00136	-0.24	-0.21	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
HNSC	cis	rs1552244	0.882	rs68080705	ENSG00000180385.7	EMC3-AS1	4.56	6.52e-06	0.00136	0.23	0.21	Alzheimer's disease;	chr3:9984059	chr3:9986893~10006990:+
HNSC	cis	rs9880211	0.8	rs13433683	ENSG00000273486.1	RP11-731C17.2	-4.56	6.53e-06	0.00137	-0.2	-0.21	Height;Body mass index;	chr3:136799828	chr3:136837338~136839021:-
HNSC	cis	rs6964587	1	rs10488510	ENSG00000188693.7	CYP51A1-AS1	-4.56	6.53e-06	0.00137	-0.22	-0.21	Breast cancer;	chr7:92030911	chr7:92134604~92180725:+
HNSC	cis	rs6430585	0.528	rs3098102	ENSG00000231890.6	DARS-AS1	-4.56	6.53e-06	0.00137	-0.35	-0.21	Corneal structure;	chr2:135897263	chr2:135985176~136022593:+
HNSC	cis	rs7824557	0.767	rs6991606	ENSG00000269918.1	AF131215.9	4.56	6.54e-06	0.00137	0.2	0.21	Retinal vascular caliber;	chr8:11318650	chr8:11104691~11106704:-
HNSC	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-4.56	6.54e-06	0.00137	-0.3	-0.21	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
HNSC	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-4.56	6.54e-06	0.00137	-0.3	-0.21	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
HNSC	cis	rs7107174	0.901	rs10899496	ENSG00000251323.2	RP11-452H21.4	4.56	6.54e-06	0.00137	0.29	0.21	Testicular germ cell tumor;	chr11:78412785	chr11:78423982~78429836:-
HNSC	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-4.56	6.54e-06	0.00137	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000173295.6	FAM86B3P	4.56	6.54e-06	0.00137	0.24	0.21	Recombination measurement;	chr8:9205517	chr8:8228595~8244865:+
HNSC	cis	rs1316952	0.831	rs112703259	ENSG00000269938.1	RP11-214K3.20	-4.56	6.54e-06	0.00137	-0.43	-0.21	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123906042	chr12:123968023~123968579:-
HNSC	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	4.56	6.54e-06	0.00137	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
HNSC	cis	rs1908814	0.516	rs10113062	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11935740	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs10113145	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11935786	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs4367597	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11936020	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.899	rs9329251	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.773	rs7842810	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs7812563	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11936979	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs13281077	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11937305	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs13281315	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11937346	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs4840597	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Neuroticism;	chr8:11938559	chr8:12194467~12196280:+
HNSC	cis	rs804280	0.509	rs4841639	ENSG00000255495.1	AC145124.2	4.56	6.55e-06	0.00137	0.23	0.21	Myopia (pathological);	chr8:11938584	chr8:12194467~12196280:+
HNSC	cis	rs757081	0.667	rs34724588	ENSG00000260196.1	RP1-239B22.5	-4.56	6.55e-06	0.00137	-0.25	-0.21	Systolic blood pressure;	chr11:17116034	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs3950680	ENSG00000260196.1	RP1-239B22.5	-4.56	6.55e-06	0.00137	-0.25	-0.21	Systolic blood pressure;	chr11:17117119	chr11:17380649~17383531:+
HNSC	cis	rs2286503	0.78	rs2240727	ENSG00000226329.2	AC005682.6	4.56	6.55e-06	0.00137	0.26	0.21	Fibrinogen;	chr7:22812893	chr7:22863874~22881350:-
HNSC	cis	rs3738443	0.678	rs57861883	ENSG00000259865.1	RP11-488L18.10	4.56	6.55e-06	0.00137	0.17	0.21	Alcohol dependence;	chr1:247214089	chr1:247187281~247188526:-
HNSC	cis	rs4819052	0.851	rs8130285	ENSG00000223768.1	LINC00205	-4.56	6.55e-06	0.00137	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45293285~45297354:+
HNSC	cis	rs6601327	0.607	rs35316422	ENSG00000233609.3	RP11-62H7.2	-4.56	6.55e-06	0.00137	-0.19	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9717619	chr8:8961200~8979025:+
HNSC	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	4.56	6.56e-06	0.00137	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
HNSC	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-4.56	6.56e-06	0.00137	-0.22	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
HNSC	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-4.56	6.56e-06	0.00137	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
HNSC	cis	rs4908769	0.624	rs301796	ENSG00000232912.4	RP5-1115A15.1	4.56	6.57e-06	0.00137	0.23	0.21	Allergy;	chr1:8406670	chr1:8424645~8434838:+
HNSC	cis	rs4908769	0.587	rs301795	ENSG00000232912.4	RP5-1115A15.1	4.56	6.57e-06	0.00137	0.23	0.21	Allergy;	chr1:8407293	chr1:8424645~8434838:+
HNSC	cis	rs1799955	1	rs9567600	ENSG00000215515.2	IFIT1P1	-4.56	6.57e-06	0.00137	-0.28	-0.21	LDL cholesterol levels;	chr13:32359789	chr13:32384660~32386108:+
HNSC	cis	rs1799955	1	rs11571717	ENSG00000215515.2	IFIT1P1	-4.56	6.57e-06	0.00137	-0.28	-0.21	LDL cholesterol levels;	chr13:32360774	chr13:32384660~32386108:+
HNSC	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	4.56	6.57e-06	0.00137	0.21	0.21	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
HNSC	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	4.56	6.57e-06	0.00137	0.2	0.21	Height;	chr5:37475788	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	4.56	6.57e-06	0.00137	0.2	0.21	Height;	chr5:37475789	chr5:36666214~36725195:-
HNSC	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	4.56	6.57e-06	0.00137	0.21	0.21	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
HNSC	cis	rs4356203	0.519	rs214092	ENSG00000272034.1	SNORD14A	-4.56	6.57e-06	0.00137	-0.16	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17074654~17074744:-
HNSC	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	4.56	6.57e-06	0.00137	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
HNSC	cis	rs9863	0.794	rs12310367	ENSG00000269938.1	RP11-214K3.20	-4.56	6.57e-06	0.00137	-0.24	-0.21	White blood cell count;	chr12:124002131	chr12:123968023~123968579:-
HNSC	cis	rs394563	0.601	rs439495	ENSG00000231760.4	RP11-350J20.5	-4.56	6.57e-06	0.00137	-0.29	-0.21	Dupuytren's disease;	chr6:149472088	chr6:149796151~149826294:-
HNSC	cis	rs7735319	0.834	rs13184103	ENSG00000250697.1	CTD-2066L21.3	4.56	6.58e-06	0.00137	0.26	0.21	Systolic blood pressure;	chr5:33061918	chr5:32925639~33297910:-
HNSC	cis	rs651386	0.529	rs12072276	ENSG00000271811.1	RP1-79C4.4	4.56	6.58e-06	0.00138	0.23	0.21	Atrial fibrillation;	chr1:170624928	chr1:170667381~170669425:+
HNSC	cis	rs11773103	1	rs17161329	ENSG00000224046.1	AC005076.5	4.56	6.59e-06	0.00138	0.35	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87140790	chr7:87151423~87152420:-
HNSC	cis	rs6951245	0.638	rs74976697	ENSG00000225146.1	AC073957.15	-4.56	6.59e-06	0.00138	-0.32	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1029025~1043891:+
HNSC	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	4.56	6.59e-06	0.00138	0.25	0.21	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
HNSC	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	4.56	6.59e-06	0.00138	0.18	0.21	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
HNSC	cis	rs11673344	0.542	rs2562598	ENSG00000276846.1	CTD-3220F14.3	4.56	6.59e-06	0.00138	0.22	0.21	Obesity-related traits;	chr19:37025318	chr19:37314868~37315620:-
HNSC	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-4.56	6.6e-06	0.00138	-0.23	-0.21	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
HNSC	cis	rs10435719	0.902	rs7459983	ENSG00000255495.1	AC145124.2	4.56	6.6e-06	0.00138	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:12194467~12196280:+
HNSC	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-4.56	6.6e-06	0.00138	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
HNSC	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-4.56	6.6e-06	0.00138	-0.32	-0.21	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
HNSC	cis	rs11098499	1	rs3749591	ENSG00000250412.1	KLHL2P1	4.56	6.6e-06	0.00138	0.27	0.21	Corneal astigmatism;	chr4:119292875	chr4:119334329~119378233:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000233609.3	RP11-62H7.2	4.56	6.61e-06	0.00138	0.2	0.21	Mood instability;	chr8:8283379	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	4.56	6.61e-06	0.00138	0.25	0.21	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
HNSC	cis	rs1799949	0.965	rs7223952	ENSG00000236383.6	LINC00854	-4.56	6.61e-06	0.00138	-0.19	-0.21	Menopause (age at onset);	chr17:43042868	chr17:43216941~43305976:-
HNSC	cis	rs9321453	1	rs9321453	ENSG00000231971.4	RP11-557H15.3	4.56	6.62e-06	0.00138	0.24	0.21	Urate levels;	chr6:134452416	chr6:134428240~134520585:-
HNSC	cis	rs73198271	0.74	rs10103163	ENSG00000233609.3	RP11-62H7.2	-4.56	6.62e-06	0.00138	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.599	rs10103169	ENSG00000233609.3	RP11-62H7.2	-4.56	6.62e-06	0.00138	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.7	rs10103282	ENSG00000233609.3	RP11-62H7.2	-4.56	6.62e-06	0.00138	-0.23	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8961200~8979025:+
HNSC	cis	rs62432291	0.614	rs452112	ENSG00000235086.1	FNDC1-IT1	-4.56	6.62e-06	0.00138	-0.28	-0.21	Joint mobility (Beighton score);	chr6:159236996	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs417719	ENSG00000235086.1	FNDC1-IT1	-4.56	6.62e-06	0.00138	-0.28	-0.21	Joint mobility (Beighton score);	chr6:159237010	chr6:159240786~159243329:+
HNSC	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	4.56	6.62e-06	0.00138	0.18	0.21	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
HNSC	cis	rs2055729	0.645	rs7828229	ENSG00000254340.1	RP11-10A14.3	-4.56	6.62e-06	0.00138	-0.29	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9885331	chr8:9141424~9145435:+
HNSC	cis	rs7662987	0.517	rs2851263	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99109203	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602858	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99109310	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.76	rs2602859	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Alcohol dependence;	chr4:99109432	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2851260	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99112423	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602865	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99113690	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602866	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99113846	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602873	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99117881	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2851256	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99118398	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs4235436	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99118469	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602881	ENSG00000263923.1	RP11-571L19.7	-4.56	6.62e-06	0.00138	-0.22	-0.21	Smoking initiation;	chr4:99119544	chr4:98928897~98994994:+
HNSC	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-4.56	6.62e-06	0.00138	-0.26	-0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
HNSC	cis	rs8177876	0.686	rs804897	ENSG00000261838.4	RP11-303E16.6	-4.56	6.62e-06	0.00138	-0.39	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81069854~81076598:+
HNSC	cis	rs116095464	0.51	rs10057501	ENSG00000250848.1	CTD-2083E4.5	-4.56	6.62e-06	0.00138	-0.29	-0.21	Breast cancer;	chr5:239430	chr5:288833~290321:-
HNSC	cis	rs1971762	0.527	rs2365343	ENSG00000270175.1	RP11-793H13.11	4.56	6.62e-06	0.00138	0.18	0.21	Height;	chr12:53644365	chr12:53500162~53500936:-
HNSC	cis	rs1008375	0.863	rs2058336	ENSG00000249502.1	AC006160.5	-4.56	6.62e-06	0.00138	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606676	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs4698628	ENSG00000249502.1	AC006160.5	-4.56	6.62e-06	0.00138	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606997	chr4:17587467~17614571:-
HNSC	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-4.56	6.64e-06	0.00138	-0.3	-0.21	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
HNSC	cis	rs9311676	0.656	rs11712139	ENSG00000273493.1	RP11-80H18.4	4.56	6.64e-06	0.00139	0.22	0.21	Systemic lupus erythematosus;	chr3:58399048	chr3:58329965~58330118:+
HNSC	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	4.56	6.64e-06	0.00139	0.29	0.21	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	4.56	6.64e-06	0.00139	0.29	0.21	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	4.56	6.64e-06	0.00139	0.29	0.21	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
HNSC	cis	rs757081	0.636	rs214934	ENSG00000260196.1	RP1-239B22.5	-4.56	6.64e-06	0.00139	-0.25	-0.21	Systolic blood pressure;	chr11:17171928	chr11:17380649~17383531:+
HNSC	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-4.56	6.65e-06	0.00139	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
HNSC	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	4.56	6.65e-06	0.00139	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	4.56	6.65e-06	0.00139	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	4.56	6.65e-06	0.00139	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	4.56	6.65e-06	0.00139	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
HNSC	cis	rs6701713	0.919	rs2296160	ENSG00000274245.1	RP11-357P18.2	-4.56	6.65e-06	0.00139	-0.34	-0.21	Alzheimer's disease (late onset);	chr1:207621975	chr1:207372559~207373252:+
HNSC	cis	rs6701713	0.959	rs10863420	ENSG00000274245.1	RP11-357P18.2	-4.56	6.65e-06	0.00139	-0.34	-0.21	Alzheimer's disease (late onset);	chr1:207626529	chr1:207372559~207373252:+
HNSC	cis	rs853679	0.607	rs35749575	ENSG00000219392.1	RP1-265C24.5	-4.56	6.65e-06	0.00139	-0.43	-0.21	Depression;	chr6:28147040	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13205911	ENSG00000219392.1	RP1-265C24.5	-4.56	6.65e-06	0.00139	-0.43	-0.21	Depression;	chr6:28156336	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13197176	ENSG00000219392.1	RP1-265C24.5	-4.56	6.65e-06	0.00139	-0.43	-0.21	Depression;	chr6:28161454	chr6:28115628~28116551:+
HNSC	cis	rs4862750	0.914	rs9998558	ENSG00000250971.1	RP11-696F12.1	4.56	6.65e-06	0.00139	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:187060099~187060930:+
HNSC	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	4.56	6.65e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
HNSC	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-4.56	6.66e-06	0.00139	-0.21	-0.21	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
HNSC	cis	rs3733829	0.657	rs12151282	ENSG00000233622.1	CYP2T1P	-4.56	6.66e-06	0.00139	-0.22	-0.21	Smoking behavior;	chr19:40792514	chr19:40808525~40811390:-
HNSC	cis	rs5758659	0.652	rs4822084	ENSG00000227370.1	RP4-669P10.19	4.56	6.66e-06	0.00139	0.2	0.21	Cognitive function;	chr22:42039864	chr22:42132543~42132998:+
HNSC	cis	rs11098499	0.722	rs1814814	ENSG00000249244.1	RP11-548H18.2	4.56	6.66e-06	0.00139	0.24	0.21	Corneal astigmatism;	chr4:119336969	chr4:119391831~119395335:-
HNSC	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-4.56	6.66e-06	0.00139	-0.26	-0.21	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-4.56	6.66e-06	0.00139	-0.26	-0.21	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
HNSC	cis	rs4388249	0.687	rs2301017	ENSG00000271849.1	CTC-332L22.1	-4.56	6.66e-06	0.00139	-0.28	-0.21	Schizophrenia;	chr5:109863696	chr5:109687802~109688329:-
HNSC	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	4.56	6.67e-06	0.00139	0.26	0.21	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	4.56	6.67e-06	0.00139	0.26	0.21	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	4.56	6.67e-06	0.00139	0.26	0.21	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
HNSC	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	4.56	6.67e-06	0.00139	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-4.56	6.67e-06	0.00139	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-4.56	6.67e-06	0.00139	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
HNSC	cis	rs2985684	0.947	rs1952013	ENSG00000278009.1	RP11-649E7.8	4.56	6.67e-06	0.00139	0.28	0.21	Carotid intima media thickness;	chr14:49620639	chr14:49601011~49601124:-
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	4.56	6.67e-06	0.00139	0.24	0.21	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
HNSC	cis	rs913655	0.508	rs2493624	ENSG00000225527.1	RP11-383B4.4	-4.56	6.67e-06	0.00139	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18773327	chr10:18531849~18533336:-
HNSC	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	4.56	6.67e-06	0.00139	0.23	0.21	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
HNSC	cis	rs597539	0.652	rs674654	ENSG00000255741.1	RP11-757G1.5	-4.56	6.68e-06	0.00139	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.616	rs513476	ENSG00000255741.1	RP11-757G1.5	-4.56	6.68e-06	0.00139	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68941503~68942852:-
HNSC	cis	rs8074700	1	rs7215276	ENSG00000239552.2	HOXB-AS2	4.56	6.68e-06	0.00139	0.22	0.21	Body mass index in non-asthmatics;	chr17:48671873	chr17:48557262~48560333:+
HNSC	cis	rs7735319	0.8	rs58843681	ENSG00000249102.1	CTD-2066L21.1	4.56	6.68e-06	0.00139	0.25	0.21	Systolic blood pressure;	chr5:33064046	chr5:33008994~33025724:+
HNSC	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	4.56	6.68e-06	0.00139	0.21	0.21	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
HNSC	cis	rs3808502	0.563	rs12549150	ENSG00000255495.1	AC145124.2	4.56	6.69e-06	0.00139	0.23	0.21	Neuroticism;	chr8:11565427	chr8:12194467~12196280:+
HNSC	cis	rs73222236	0.825	rs9826146	ENSG00000273486.1	RP11-731C17.2	4.56	6.69e-06	0.00139	0.17	0.21	Coronary artery disease;	chr3:136264247	chr3:136837338~136839021:-
HNSC	cis	rs763121	0.819	rs4560233	ENSG00000273076.1	RP3-508I15.22	4.55	6.7e-06	0.0014	0.22	0.21	Menopause (age at onset);	chr22:38586437	chr22:38743495~38743910:+
HNSC	cis	rs4787491	0.729	rs11544328	ENSG00000183604.13	SMG1P5	-4.55	6.7e-06	0.0014	-0.2	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30267553~30335374:-
HNSC	cis	rs9863	0.828	rs11057412	ENSG00000270028.1	RP11-380L11.4	4.55	6.7e-06	0.0014	0.24	0.21	White blood cell count;	chr12:124004595	chr12:123925461~123926083:-
HNSC	cis	rs4761669	0.785	rs4761505	ENSG00000241556.1	RP11-490G8.1	4.55	6.7e-06	0.0014	0.21	0.21	Common carotid intima-media thickness in HIV infection;	chr12:94806945	chr12:95467397~95467861:-
HNSC	cis	rs3096299	0.967	rs2965935	ENSG00000261574.1	RP1-168P16.2	-4.55	6.7e-06	0.0014	-0.26	-0.21	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89392375~89412564:-
HNSC	cis	rs9329221	0.537	rs6601415	ENSG00000254340.1	RP11-10A14.3	4.55	6.7e-06	0.0014	0.25	0.21	Neuroticism;	chr8:10119295	chr8:9141424~9145435:+
HNSC	cis	rs4761669	0.816	rs4296095	ENSG00000241556.1	RP11-490G8.1	-4.55	6.7e-06	0.0014	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94796670	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.771	rs4296094	ENSG00000241556.1	RP11-490G8.1	-4.55	6.7e-06	0.0014	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94796695	chr12:95467397~95467861:-
HNSC	cis	rs853679	0.556	rs45509595	ENSG00000219392.1	RP1-265C24.5	-4.55	6.7e-06	0.0014	-0.42	-0.21	Depression;	chr6:27873148	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs35656932	ENSG00000219392.1	RP1-265C24.5	-4.55	6.7e-06	0.0014	-0.43	-0.21	Depression;	chr6:28223510	chr6:28115628~28116551:+
HNSC	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	4.55	6.71e-06	0.0014	0.24	0.21	Height;	chr14:75038305	chr14:75011269~75012851:-
HNSC	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-4.55	6.71e-06	0.0014	-0.27	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
HNSC	cis	rs73222236	0.787	rs7621970	ENSG00000273486.1	RP11-731C17.2	4.55	6.71e-06	0.0014	0.17	0.21	Coronary artery disease;	chr3:136645500	chr3:136837338~136839021:-
HNSC	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-4.55	6.71e-06	0.0014	-0.26	-0.21	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
HNSC	cis	rs9840812	0.639	rs610860	ENSG00000239213.4	NCK1-AS1	4.55	6.71e-06	0.0014	0.22	0.21	Fibrinogen levels;	chr3:136333974	chr3:136841726~136862054:-
HNSC	cis	rs728616	0.717	rs12412999	ENSG00000225484.5	NUTM2B-AS1	-4.55	6.71e-06	0.0014	-0.49	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79663088~79826594:-
HNSC	cis	rs916888	0.738	rs199515	ENSG00000260075.1	NSFP1	4.55	6.72e-06	0.0014	0.29	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46372855~46487141:+
HNSC	cis	rs4763879	0.634	rs917913	ENSG00000278635.1	CTD-2318O12.1	4.55	6.72e-06	0.0014	0.16	0.21	Type 1 diabetes;	chr12:9707040	chr12:9415641~9416718:+
HNSC	cis	rs13256369	0.802	rs12681326	ENSG00000173295.6	FAM86B3P	4.55	6.72e-06	0.0014	0.27	0.21	Obesity-related traits;	chr8:8708879	chr8:8228595~8244865:+
HNSC	cis	rs2395909	1	rs2395909	ENSG00000238832.1	snoU109	4.55	6.72e-06	0.0014	0.25	0.21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr7:107652218	chr7:107603363~107603507:+
HNSC	cis	rs9880211	0.8	rs1872239	ENSG00000273486.1	RP11-731C17.2	4.55	6.72e-06	0.0014	0.19	0.21	Height;Body mass index;	chr3:136785069	chr3:136837338~136839021:-
HNSC	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	4.55	6.72e-06	0.0014	0.24	0.21	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
HNSC	cis	rs1913185	0.787	rs58874363	ENSG00000240032.1	RP11-274H2.3	-4.55	6.72e-06	0.0014	-0.35	-0.21	Obesity-related traits;	chr3:146126725	chr3:146066344~146069185:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-4.55	6.72e-06	0.0014	-0.27	-0.21	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
HNSC	cis	rs2548724	0.617	rs7728630	ENSG00000250682.4	LINC00491	4.55	6.73e-06	0.0014	0.27	0.21	Type 2 diabetes;	chr5:102389775	chr5:102609156~102671559:-
HNSC	cis	rs2933343	0.716	rs9867404	ENSG00000261159.1	RP11-723O4.9	-4.55	6.74e-06	0.0014	-0.24	-0.21	IgG glycosylation;	chr3:128847295	chr3:128859716~128860526:-
HNSC	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	4.55	6.74e-06	0.0014	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
HNSC	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-4.55	6.74e-06	0.0014	-0.25	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
HNSC	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-4.55	6.75e-06	0.0014	-0.21	-0.21	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
HNSC	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs68153882	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9971426	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs35056669	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9972487	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs3732967	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9973753	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs3732966	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9974056	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs13062917	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9975348	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.816	rs13076197	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9978089	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.688	rs7645137	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9978865	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs34779351	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9980117	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs13077641	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9981251	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs13074282	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9983015	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs67895180	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9984395	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.882	rs3755782	ENSG00000180385.7	EMC3-AS1	4.55	6.75e-06	0.0014	0.23	0.21	Alzheimer's disease;	chr3:9987621	chr3:9986893~10006990:+
HNSC	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-4.55	6.75e-06	0.00141	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
HNSC	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	4.55	6.75e-06	0.00141	0.25	0.21	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
HNSC	cis	rs4699052	0.625	rs6822783	ENSG00000246560.2	RP11-10L12.4	4.55	6.75e-06	0.00141	0.23	0.21	Testicular germ cell tumor;	chr4:103363767	chr4:102828055~102844075:+
HNSC	cis	rs9467711	0.56	rs6900665	ENSG00000241549.7	GUSBP2	4.55	6.75e-06	0.00141	0.31	0.21	Autism spectrum disorder or schizophrenia;	chr6:26486941	chr6:26871484~26956554:-
HNSC	cis	rs964611	0.882	rs68004907	ENSG00000259488.2	RP11-154J22.1	-4.55	6.75e-06	0.00141	-0.18	-0.21	Metabolite levels (Pyroglutamine);	chr15:48293162	chr15:48312353~48331856:-
HNSC	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	4.55	6.75e-06	0.00141	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	4.55	6.75e-06	0.00141	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	4.55	6.75e-06	0.00141	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
HNSC	cis	rs3733585	0.654	rs4447863	ENSG00000250413.1	RP11-448G15.1	4.55	6.75e-06	0.00141	0.26	0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:9937345	chr4:10006482~10009725:+
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000254153.1	CTA-398F10.2	-4.55	6.75e-06	0.00141	-0.23	-0.21	Mood instability;	chr8:8812572	chr8:8456909~8461337:-
HNSC	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-4.55	6.76e-06	0.00141	-0.29	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
HNSC	cis	rs6496044	0.611	rs8026938	ENSG00000259295.5	CSPG4P12	-4.55	6.76e-06	0.00141	-0.24	-0.21	Interstitial lung disease;	chr15:85525887	chr15:85191438~85213905:+
HNSC	cis	rs17407555	0.52	rs4292327	ENSG00000250413.1	RP11-448G15.1	4.55	6.76e-06	0.00141	0.31	0.21	Schizophrenia (age at onset);	chr4:9942076	chr4:10006482~10009725:+
HNSC	cis	rs911555	0.57	rs11625397	ENSG00000269958.1	RP11-73M18.8	-4.55	6.76e-06	0.00141	-0.19	-0.21	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103696353~103697163:+
HNSC	cis	rs9840812	0.725	rs696517	ENSG00000239213.4	NCK1-AS1	4.55	6.76e-06	0.00141	0.22	0.21	Fibrinogen levels;	chr3:136348813	chr3:136841726~136862054:-
HNSC	cis	rs6964587	1	rs7784248	ENSG00000188693.7	CYP51A1-AS1	-4.55	6.76e-06	0.00141	-0.22	-0.21	Breast cancer;	chr7:92128797	chr7:92134604~92180725:+
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000233609.3	RP11-62H7.2	4.55	6.76e-06	0.00141	0.2	0.21	Mood instability;	chr8:8445843	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000254153.1	CTA-398F10.2	4.55	6.77e-06	0.00141	0.22	0.21	Neuroticism;	chr8:8866747	chr8:8456909~8461337:-
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000254153.1	CTA-398F10.2	4.55	6.77e-06	0.00141	0.22	0.21	Neuroticism;	chr8:8866766	chr8:8456909~8461337:-
HNSC	cis	rs7121616	0.576	rs60405069	ENSG00000200879.1	SNORD14E	4.55	6.77e-06	0.00141	0.29	0.21	Breast cancer;	chr11:123043616	chr11:123058077~123058161:-
HNSC	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	4.55	6.77e-06	0.00141	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000204709.4	LINC01556	4.55	6.77e-06	0.00141	0.28	0.21	Depression;	chr6:28126588	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000204709.4	LINC01556	4.55	6.77e-06	0.00141	0.28	0.21	Depression;	chr6:28126953	chr6:28943877~28944537:+
HNSC	cis	rs10946940	0.93	rs10807029	ENSG00000219392.1	RP1-265C24.5	4.55	6.77e-06	0.00141	0.24	0.21	Systemic lupus erythematosus;	chr6:27605684	chr6:28115628~28116551:+
HNSC	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-4.55	6.78e-06	0.00141	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-4.55	6.78e-06	0.00141	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
HNSC	cis	rs1799949	1	rs8077486	ENSG00000236383.6	LINC00854	-4.55	6.78e-06	0.00141	-0.19	-0.21	Menopause (age at onset);	chr17:43060788	chr17:43216941~43305976:-
HNSC	cis	rs6964587	0.74	rs2020360	ENSG00000188693.7	CYP51A1-AS1	-4.55	6.78e-06	0.00141	-0.22	-0.21	Breast cancer;	chr7:91810192	chr7:92134604~92180725:+
HNSC	cis	rs7572733	0.84	rs12472359	ENSG00000222017.1	AC011997.1	-4.55	6.78e-06	0.00141	-0.25	-0.21	Dermatomyositis;	chr2:197723141	chr2:197693106~197774823:+
HNSC	cis	rs1056107	0.902	rs10124118	ENSG00000225513.1	RP11-165N19.2	-4.55	6.78e-06	0.00141	-0.22	-0.21	Colorectal cancer;	chr9:112240354	chr9:112173522~112173971:-
HNSC	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	4.55	6.79e-06	0.00141	0.26	0.21	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
HNSC	cis	rs42490	0.536	rs365871	ENSG00000251136.7	RP11-37B2.1	-4.55	6.79e-06	0.00141	-0.19	-0.21	Leprosy;	chr8:89861458	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.536	rs386857	ENSG00000251136.7	RP11-37B2.1	-4.55	6.79e-06	0.00141	-0.19	-0.21	Leprosy;	chr8:89862824	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.536	rs400571	ENSG00000251136.7	RP11-37B2.1	-4.55	6.79e-06	0.00141	-0.19	-0.21	Leprosy;	chr8:89863336	chr8:89609409~89757727:-
HNSC	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-4.55	6.79e-06	0.00141	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
HNSC	cis	rs889398	0.769	rs12927052	ENSG00000226232.7	RP11-419C5.2	4.55	6.79e-06	0.00141	0.18	0.21	Body mass index;	chr16:69823140	chr16:69976388~69996188:-
HNSC	cis	rs9326246	0.643	rs2072560	ENSG00000280143.1	AP000892.6	4.55	6.8e-06	0.00141	0.45	0.21	Coronary artery disease;	chr11:116791110	chr11:117204967~117210292:+
HNSC	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-4.55	6.8e-06	0.00141	-0.26	-0.21	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
HNSC	cis	rs4787951	0.605	rs4360944	ENSG00000259940.2	CTD-3203P2.1	-4.55	6.8e-06	0.00141	-0.23	-0.21	Eosinophil percentage of white cells;	chr16:27296366	chr16:27213308~27214993:-
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000254153.1	CTA-398F10.2	-4.55	6.8e-06	0.00141	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8935833	chr8:8456909~8461337:-
HNSC	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	4.55	6.8e-06	0.00141	0.23	0.21	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
HNSC	cis	rs4873772	0.735	rs1872840	ENSG00000253330.1	RP11-697N18.3	-4.55	6.8e-06	0.00142	-0.26	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47719868	chr8:47511034~47512141:-
HNSC	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	4.55	6.81e-06	0.00142	0.29	0.21	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
HNSC	cis	rs7824557	0.872	rs1347410	ENSG00000269918.1	AF131215.9	-4.55	6.81e-06	0.00142	-0.2	-0.21	Retinal vascular caliber;	chr8:11253733	chr8:11104691~11106704:-
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000219392.1	RP1-265C24.5	-4.55	6.81e-06	0.00142	-0.23	-0.21	Pubertal anthropometrics;	chr6:28381487	chr6:28115628~28116551:+
HNSC	cis	rs761746	0.543	rs5998122	ENSG00000236132.1	CTA-440B3.1	-4.55	6.81e-06	0.00142	-0.26	-0.21	Intelligence;	chr22:31777067	chr22:31816379~31817491:-
HNSC	cis	rs761746	0.614	rs2108108	ENSG00000236132.1	CTA-440B3.1	-4.55	6.81e-06	0.00142	-0.26	-0.21	Intelligence;	chr22:31785951	chr22:31816379~31817491:-
HNSC	cis	rs12935418	0.523	rs2549846	ENSG00000261061.1	RP11-303E16.2	4.55	6.81e-06	0.00142	0.22	0.21	Mean corpuscular volume;	chr16:80990522	chr16:81030770~81031485:+
HNSC	cis	rs17253792	0.822	rs76557162	ENSG00000186615.9	KTN1-AS1	-4.55	6.82e-06	0.00142	-0.38	-0.21	Putamen volume;	chr14:55597983	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.908	rs74354306	ENSG00000186615.9	KTN1-AS1	-4.55	6.82e-06	0.00142	-0.38	-0.21	Putamen volume;	chr14:55599060	chr14:55499278~55580110:-
HNSC	cis	rs11673344	0.542	rs1667380	ENSG00000276846.1	CTD-3220F14.3	4.55	6.82e-06	0.00142	0.22	0.21	Obesity-related traits;	chr19:37001848	chr19:37314868~37315620:-
HNSC	cis	rs10654220	1	rs10654220	ENSG00000280120.1	RP11-546D6.3	4.55	6.82e-06	0.00142	0.2	0.21	Platelet count;	chr12:123218875	chr12:123152324~123153377:-
HNSC	cis	rs4787491	0.729	rs11642399	ENSG00000183604.13	SMG1P5	-4.55	6.82e-06	0.00142	-0.2	-0.21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30267553~30335374:-
HNSC	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	4.55	6.82e-06	0.00142	0.22	0.21	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
HNSC	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	4.55	6.82e-06	0.00142	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.828	rs7975482	ENSG00000269938.1	RP11-214K3.20	-4.55	6.83e-06	0.00142	-0.24	-0.21	White blood cell count;	chr12:123997143	chr12:123968023~123968579:-
HNSC	cis	rs1799949	0.965	rs8176193	ENSG00000236383.6	LINC00854	-4.55	6.84e-06	0.00142	-0.19	-0.21	Menopause (age at onset);	chr17:43079499	chr17:43216941~43305976:-
HNSC	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	4.55	6.84e-06	0.00142	0.28	0.21	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
HNSC	cis	rs442309	0.687	rs10822052	ENSG00000238280.1	RP11-436D10.3	4.55	6.84e-06	0.00142	0.25	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62696010	chr10:62793562~62805887:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	4.55	6.84e-06	0.00142	0.25	0.21	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
HNSC	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	4.55	6.84e-06	0.00142	0.32	0.21	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
HNSC	cis	rs1799949	0.896	rs8176086	ENSG00000236383.6	LINC00854	-4.55	6.85e-06	0.00142	-0.19	-0.21	Menopause (age at onset);	chr17:43122761	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.93	rs3765640	ENSG00000236383.6	LINC00854	-4.55	6.85e-06	0.00142	-0.19	-0.21	Menopause (age at onset);	chr17:43124230	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176077	ENSG00000236383.6	LINC00854	-4.55	6.85e-06	0.00142	-0.19	-0.21	Menopause (age at onset);	chr17:43124331	chr17:43216941~43305976:-
HNSC	cis	rs9329221	0.537	rs13254175	ENSG00000254340.1	RP11-10A14.3	4.55	6.85e-06	0.00142	0.24	0.21	Neuroticism;	chr8:10121262	chr8:9141424~9145435:+
HNSC	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	4.55	6.85e-06	0.00142	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
HNSC	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	4.55	6.85e-06	0.00142	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
HNSC	cis	rs853679	0.607	rs35902873	ENSG00000219392.1	RP1-265C24.5	-4.55	6.85e-06	0.00142	-0.43	-0.21	Depression;	chr6:28091171	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13197574	ENSG00000219392.1	RP1-265C24.5	-4.55	6.85e-06	0.00142	-0.43	-0.21	Depression;	chr6:28092461	chr6:28115628~28116551:+
HNSC	cis	rs13256369	0.95	rs1522839	ENSG00000173295.6	FAM86B3P	4.55	6.85e-06	0.00142	0.27	0.21	Obesity-related traits;	chr8:8722943	chr8:8228595~8244865:+
HNSC	cis	rs442309	0.967	rs224031	ENSG00000238280.1	RP11-436D10.3	-4.55	6.85e-06	0.00142	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62761596	chr10:62793562~62805887:-
HNSC	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	4.55	6.85e-06	0.00142	0.29	0.21	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
HNSC	cis	rs6714900	0.925	rs11680831	ENSG00000205847.5	OR7E91P	-4.55	6.86e-06	0.00142	-0.25	-0.21	Blood protein levels;	chr2:71065392	chr2:71029028~71029893:+
HNSC	cis	rs1552244	0.882	rs13100734	ENSG00000180385.7	EMC3-AS1	4.55	6.86e-06	0.00142	0.23	0.21	Alzheimer's disease;	chr3:9981194	chr3:9986893~10006990:+
HNSC	cis	rs467650	0.529	rs1508791	ENSG00000246763.5	RGMB-AS1	-4.55	6.86e-06	0.00143	-0.23	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98660173	chr5:98769618~98773469:-
HNSC	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	4.55	6.86e-06	0.00143	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
HNSC	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	4.55	6.86e-06	0.00143	0.24	0.21	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
HNSC	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-4.55	6.86e-06	0.00143	-0.27	-0.21	Pain;	chr19:21499260	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-4.55	6.86e-06	0.00143	-0.27	-0.21	Pain;	chr19:21510513	chr19:21554640~21569237:-
HNSC	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-4.55	6.86e-06	0.00143	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
HNSC	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-4.55	6.87e-06	0.00143	-0.21	-0.21	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
HNSC	cis	rs6964587	1	rs61244255	ENSG00000188693.7	CYP51A1-AS1	-4.55	6.87e-06	0.00143	-0.22	-0.21	Breast cancer;	chr7:92122348	chr7:92134604~92180725:+
HNSC	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-4.55	6.87e-06	0.00143	-0.25	-0.21	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
HNSC	cis	rs853679	0.607	rs34765154	ENSG00000204709.4	LINC01556	4.55	6.88e-06	0.00143	0.45	0.21	Depression;	chr6:28162672	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.556	rs67297533	ENSG00000204709.4	LINC01556	4.55	6.88e-06	0.00143	0.45	0.21	Depression;	chr6:28173475	chr6:28943877~28944537:+
HNSC	cis	rs3738443	0.678	rs61636449	ENSG00000259865.1	RP11-488L18.10	4.55	6.88e-06	0.00143	0.17	0.21	Alcohol dependence;	chr1:247213758	chr1:247187281~247188526:-
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	4.55	6.88e-06	0.00143	0.25	0.21	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
HNSC	cis	rs155076	0.702	rs482731	ENSG00000233325.3	MIPEPP3	4.55	6.88e-06	0.00143	0.36	0.21	White matter hyperintensity burden;	chr13:21271936	chr13:21298139~21306373:+
HNSC	cis	rs9329221	0.537	rs2062331	ENSG00000254340.1	RP11-10A14.3	-4.55	6.88e-06	0.00143	-0.24	-0.21	Neuroticism;	chr8:10122482	chr8:9141424~9145435:+
HNSC	cis	rs73198271	0.751	rs55816468	ENSG00000253893.2	FAM85B	4.55	6.88e-06	0.00143	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8167819~8226614:-
HNSC	cis	rs6504950	0.783	rs7211787	ENSG00000275710.1	RP11-257O5.4	4.55	6.88e-06	0.00143	0.26	0.21	Breast cancer;	chr17:55157551	chr17:54964474~54964679:+
HNSC	cis	rs73222236	0.963	rs9837224	ENSG00000273486.1	RP11-731C17.2	4.55	6.89e-06	0.00143	0.17	0.21	Coronary artery disease;	chr3:136111385	chr3:136837338~136839021:-
HNSC	cis	rs7824557	0.736	rs10107010	ENSG00000255310.2	AF131215.2	-4.55	6.89e-06	0.00143	-0.19	-0.21	Retinal vascular caliber;	chr8:11275203	chr8:11107788~11109726:-
HNSC	cis	rs11723261	0.582	rs11735742	ENSG00000211553.1	AC253576.2	4.55	6.89e-06	0.00143	0.29	0.21	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:136461~136568:+
HNSC	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-4.55	6.89e-06	0.00143	-0.17	-0.21	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
HNSC	cis	rs4761669	0.848	rs4761666	ENSG00000241556.1	RP11-490G8.1	-4.55	6.89e-06	0.00143	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94790381	chr12:95467397~95467861:-
HNSC	cis	rs73198271	0.855	rs57301822	ENSG00000173295.6	FAM86B3P	-4.55	6.9e-06	0.00143	-0.27	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8228595~8244865:+
HNSC	cis	rs6500395	0.926	rs2883643	ENSG00000261267.1	RP11-44I10.3	-4.55	6.9e-06	0.00143	-0.26	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48659107	chr16:48559661~48587403:+
HNSC	cis	rs896655	0.58	rs6475552	ENSG00000244230.3	RN7SL151P	4.55	6.9e-06	0.00143	0.21	0.21	Coronary artery disease;	chr9:21701675	chr9:21699314~21699596:+
HNSC	cis	rs11773103	1	rs55737734	ENSG00000224046.1	AC005076.5	4.55	6.9e-06	0.00143	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87255021	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73212049	ENSG00000224046.1	AC005076.5	4.55	6.9e-06	0.00143	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87256162	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs56367205	ENSG00000224046.1	AC005076.5	4.55	6.9e-06	0.00143	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87263835	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.609	rs73212056	ENSG00000224046.1	AC005076.5	4.55	6.9e-06	0.00143	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87269766	chr7:87151423~87152420:-
HNSC	cis	rs964611	0.882	rs12442530	ENSG00000259488.2	RP11-154J22.1	-4.55	6.9e-06	0.00143	-0.19	-0.21	Metabolite levels (Pyroglutamine);	chr15:48288376	chr15:48312353~48331856:-
HNSC	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-4.55	6.9e-06	0.00143	-0.19	-0.21	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
HNSC	cis	rs11673344	0.598	rs826326	ENSG00000276846.1	CTD-3220F14.3	4.55	6.9e-06	0.00143	0.22	0.21	Obesity-related traits;	chr19:37003863	chr19:37314868~37315620:-
HNSC	cis	rs9840812	0.817	rs61789561	ENSG00000273486.1	RP11-731C17.2	-4.55	6.9e-06	0.00143	-0.2	-0.21	Fibrinogen levels;	chr3:136198785	chr3:136837338~136839021:-
HNSC	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	4.55	6.91e-06	0.00143	0.21	0.21	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
HNSC	cis	rs7809950	0.678	rs7788271	ENSG00000238832.1	snoU109	-4.55	6.91e-06	0.00143	-0.29	-0.21	Coronary artery disease;	chr7:107345428	chr7:107603363~107603507:+
HNSC	cis	rs6831352	0.918	rs29001201	ENSG00000263923.1	RP11-571L19.7	4.55	6.92e-06	0.00144	0.22	0.21	Alcohol dependence;	chr4:99132710	chr4:98928897~98994994:+
HNSC	cis	rs6693567	0.565	rs832621	ENSG00000228126.1	FALEC	4.55	6.92e-06	0.00144	0.25	0.21	Migraine;	chr1:150420433	chr1:150515757~150518032:+
HNSC	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	4.55	6.92e-06	0.00144	0.21	0.21	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
HNSC	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	4.55	6.92e-06	0.00144	0.19	0.21	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
HNSC	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-4.55	6.92e-06	0.00144	-0.22	-0.21	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000211974.3	IGHV2-70	4.55	6.92e-06	0.00144	0.19	0.21	Kawasaki disease;	chr14:106697673	chr14:106723574~106724093:-
HNSC	cis	rs7000734	0.916	rs6987741	ENSG00000245080.5	RP11-320N21.1	-4.55	6.93e-06	0.00144	-0.28	-0.21	Radiation response;	chr8:95115024	chr8:95066808~95073182:-
HNSC	cis	rs10462794	0.853	rs1450827	ENSG00000260763.1	RP11-445O3.3	4.55	6.93e-06	0.00144	0.26	0.21	DNA methylation (variation);	chr5:4510974	chr5:4436850~4440259:-
HNSC	cis	rs36052053	0.521	rs71558350	ENSG00000203799.9	CCDC162P	4.55	6.93e-06	0.00144	0.38	0.21	Red cell distribution width;	chr6:109193340	chr6:109285485~109355063:+
HNSC	cis	rs9840812	0.953	rs61791721	ENSG00000239213.4	NCK1-AS1	-4.55	6.93e-06	0.00144	-0.19	-0.21	Fibrinogen levels;	chr3:136085708	chr3:136841726~136862054:-
HNSC	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.55	6.93e-06	0.00144	-0.23	-0.21	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.55	6.93e-06	0.00144	-0.23	-0.21	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.55	6.93e-06	0.00144	-0.23	-0.21	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
HNSC	cis	rs5758511	0.68	rs5758657	ENSG00000205702.9	CYP2D7	4.55	6.94e-06	0.00144	0.19	0.21	Birth weight;	chr22:42222663	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs1033459	ENSG00000205702.9	CYP2D7	4.55	6.94e-06	0.00144	0.19	0.21	Birth weight;	chr22:42223061	chr22:42140203~42144577:-
HNSC	cis	rs79349575	0.777	rs28517720	ENSG00000270781.1	RP11-501C14.9	-4.55	6.94e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48899394	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.756	rs2643361	ENSG00000270781.1	RP11-501C14.9	-4.55	6.94e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48900100	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs2546491	ENSG00000270781.1	RP11-501C14.9	-4.55	6.94e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48900554	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs962272	ENSG00000270781.1	RP11-501C14.9	-4.55	6.94e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48900921	chr17:48899131~48899748:+
HNSC	cis	rs73222236	0.825	rs9860801	ENSG00000273486.1	RP11-731C17.2	4.55	6.94e-06	0.00144	0.17	0.21	Coronary artery disease;	chr3:136369196	chr3:136837338~136839021:-
HNSC	cis	rs853679	0.607	rs68188794	ENSG00000204709.4	LINC01556	4.55	6.94e-06	0.00144	0.44	0.21	Depression;	chr6:28112999	chr6:28943877~28944537:+
HNSC	cis	rs2835345	0.563	rs12482435	ENSG00000230479.1	AP000695.6	4.55	6.94e-06	0.00144	0.22	0.21	Pulmonary function;	chr21:36448658	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12482423	ENSG00000230479.1	AP000695.6	4.55	6.94e-06	0.00144	0.22	0.21	Pulmonary function;	chr21:36448662	chr21:36430360~36481070:+
HNSC	cis	rs1485395	0.891	rs11170624	ENSG00000257379.1	RP11-793H13.8	4.55	6.94e-06	0.00144	0.29	0.21	Migraine without aura;	chr12:53636454	chr12:53441741~53467528:+
HNSC	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	4.55	6.95e-06	0.00144	0.25	0.21	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
HNSC	cis	rs9450351	0.744	rs6906618	ENSG00000203875.9	SNHG5	-4.55	6.95e-06	0.00144	-0.44	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85660950~85678736:-
HNSC	cis	rs61935443	0.501	rs10745697	ENSG00000241556.1	RP11-490G8.1	-4.55	6.95e-06	0.00144	-0.21	-0.21	Schizophrenia;	chr12:94800091	chr12:95467397~95467861:-
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000259429.4	UBE2Q2P2	-4.55	6.95e-06	0.00144	-0.19	-0.21	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82355142~82420075:+
HNSC	cis	rs7809950	0.678	rs2237665	ENSG00000238832.1	snoU109	-4.55	6.95e-06	0.00144	-0.29	-0.21	Coronary artery disease;	chr7:107266553	chr7:107603363~107603507:+
HNSC	cis	rs79349575	0.783	rs318095	ENSG00000270781.1	RP11-501C14.9	-4.55	6.95e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48897372	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs318096	ENSG00000270781.1	RP11-501C14.9	-4.55	6.95e-06	0.00144	-0.22	-0.21	Type 2 diabetes;	chr17:48898008	chr17:48899131~48899748:+
HNSC	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-4.55	6.95e-06	0.00144	-0.27	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000254340.1	RP11-10A14.3	4.55	6.96e-06	0.00144	0.25	0.21	Mood instability;	chr8:8521482	chr8:9141424~9145435:+
HNSC	cis	rs4218	0.681	rs12913177	ENSG00000277144.1	RP11-59H7.4	4.55	6.96e-06	0.00144	0.28	0.21	Social communication problems;	chr15:59066273	chr15:59115547~59116089:-
HNSC	cis	rs8077577	0.943	rs62072467	ENSG00000273018.4	CTD-2303H24.2	-4.55	6.96e-06	0.00144	-0.33	-0.21	Obesity-related traits;	chr17:18213141	chr17:18511221~18551705:-
HNSC	cis	rs442309	0.687	rs10822054	ENSG00000238280.1	RP11-436D10.3	-4.55	6.96e-06	0.00144	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62720492	chr10:62793562~62805887:-
HNSC	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	4.55	6.96e-06	0.00144	0.21	0.21	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	4.55	6.96e-06	0.00144	0.21	0.21	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	4.55	6.96e-06	0.00144	0.21	0.21	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
HNSC	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	4.55	6.96e-06	0.00144	0.21	0.21	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
HNSC	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.55	6.96e-06	0.00144	0.2	0.21	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.55	6.96e-06	0.00144	0.2	0.21	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.55	6.96e-06	0.00144	0.2	0.21	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
HNSC	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.55	6.96e-06	0.00144	0.24	0.21	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
HNSC	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.55	6.96e-06	0.00144	0.24	0.21	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
HNSC	cis	rs6500395	0.962	rs1386042	ENSG00000261267.1	RP11-44I10.3	-4.55	6.96e-06	0.00144	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48566421	chr16:48559661~48587403:+
HNSC	cis	rs6723108	0.627	rs4954187	ENSG00000224043.6	CCNT2-AS1	-4.55	6.97e-06	0.00144	-0.25	-0.21	Type 2 diabetes;	chr2:134842848	chr2:134735464~134918710:-
HNSC	cis	rs761746	0.577	rs131244	ENSG00000236132.1	CTA-440B3.1	-4.55	6.97e-06	0.00144	-0.25	-0.21	Intelligence;	chr22:31730577	chr22:31816379~31817491:-
HNSC	cis	rs950776	0.642	rs7178007	ENSG00000261762.1	RP11-650L12.2	4.55	6.97e-06	0.00144	0.25	0.21	Sudden cardiac arrest;	chr15:78672912	chr15:78589123~78591276:-
HNSC	cis	rs3736485	0.932	rs4775966	ENSG00000259438.1	CTD-2650P22.1	4.55	6.97e-06	0.00144	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51621591	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.932	rs2278988	ENSG00000259438.1	CTD-2650P22.1	4.55	6.97e-06	0.00144	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51623037	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.932	rs2124879	ENSG00000259438.1	CTD-2650P22.1	4.55	6.97e-06	0.00144	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51624636	chr15:52010999~52019095:-
HNSC	cis	rs2985684	1	rs17121651	ENSG00000278009.1	RP11-649E7.8	4.55	6.97e-06	0.00144	0.27	0.21	Carotid intima media thickness;	chr14:49630454	chr14:49601011~49601124:-
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000230295.1	RP11-458F8.2	-4.55	6.97e-06	0.00144	-0.19	-0.21	Corneal structure;	chr7:66968576	chr7:66880708~66882981:+
HNSC	cis	rs6928977	0.675	rs7750586	ENSG00000231028.7	LINC00271	4.55	6.97e-06	0.00144	0.24	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135497801~135716055:+
HNSC	cis	rs116095464	0.619	rs2303741	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:218241	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs56043030	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:220802	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10067021	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:221375	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9312977	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:221801	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6881920	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:222296	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6878061	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:222957	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs6882584	ENSG00000250848.1	CTD-2083E4.5	-4.55	6.97e-06	0.00145	-0.28	-0.21	Breast cancer;	chr5:223296	chr5:288833~290321:-
HNSC	cis	rs853679	0.76	rs9468317	ENSG00000219891.2	ZSCAN12P1	4.55	6.98e-06	0.00145	0.3	0.21	Depression;	chr6:28230678	chr6:28091154~28093664:+
HNSC	cis	rs10129255	0.5	rs2105989	ENSG00000224373.3	IGHV4-59	4.55	6.98e-06	0.00145	0.12	0.21	Kawasaki disease;	chr14:106682199	chr14:106627249~106627825:-
HNSC	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	4.55	6.98e-06	0.00145	0.2	0.21	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
HNSC	cis	rs11250097	0.535	rs11250086	ENSG00000269918.1	AF131215.9	-4.55	6.98e-06	0.00145	-0.2	-0.21	Neuroticism;	chr8:10912273	chr8:11104691~11106704:-
HNSC	cis	rs3736485	0.868	rs8034197	ENSG00000259438.1	CTD-2650P22.1	4.55	6.98e-06	0.00145	0.21	0.21	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51630309	chr15:52010999~52019095:-
HNSC	cis	rs9393777	0.841	rs13191474	ENSG00000219392.1	RP1-265C24.5	-4.55	6.98e-06	0.00145	-0.41	-0.21	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28115628~28116551:+
HNSC	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-4.55	6.98e-06	0.00145	-0.23	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
HNSC	cis	rs5758511	0.68	rs58654759	ENSG00000226450.2	CYP2D8P	4.55	6.99e-06	0.00145	0.21	0.21	Birth weight;	chr22:42246570	chr22:42149886~42155001:-
HNSC	cis	rs9863	0.828	rs11057413	ENSG00000269938.1	RP11-214K3.20	-4.55	6.99e-06	0.00145	-0.24	-0.21	White blood cell count;	chr12:124004615	chr12:123968023~123968579:-
HNSC	cis	rs7829975	0.658	rs907181	ENSG00000254153.1	CTA-398F10.2	4.55	6.99e-06	0.00145	0.22	0.21	Mood instability;	chr8:8845365	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.607	rs66886492	ENSG00000204709.4	LINC01556	4.55	6.99e-06	0.00145	0.43	0.21	Depression;	chr6:28121953	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs35345226	ENSG00000204709.4	LINC01556	4.55	6.99e-06	0.00145	0.43	0.21	Depression;	chr6:28123802	chr6:28943877~28944537:+
HNSC	cis	rs6500395	0.89	rs9936445	ENSG00000261267.1	RP11-44I10.3	-4.55	6.99e-06	0.00145	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48583843	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.89	rs3843724	ENSG00000261267.1	RP11-44I10.3	-4.55	6.99e-06	0.00145	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48584662	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11647048	ENSG00000261267.1	RP11-44I10.3	-4.55	6.99e-06	0.00145	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48589316	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.926	rs11076572	ENSG00000261267.1	RP11-44I10.3	-4.55	6.99e-06	0.00145	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48589710	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs2101372	ENSG00000261267.1	RP11-44I10.3	-4.55	6.99e-06	0.00145	-0.25	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr16:48593395	chr16:48559661~48587403:+
HNSC	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-4.55	6.99e-06	0.00145	-0.2	-0.21	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
HNSC	cis	rs467650	0.509	rs2545678	ENSG00000246763.5	RGMB-AS1	-4.55	7e-06	0.00145	-0.23	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98664664	chr5:98769618~98773469:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	4.55	7e-06	0.00145	0.27	0.21	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
HNSC	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-4.55	7e-06	0.00145	-0.31	-0.21	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
HNSC	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	4.55	7e-06	0.00145	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
HNSC	cis	rs8014204	0.544	rs2286913	ENSG00000279594.1	RP11-950C14.10	4.55	7e-06	0.00145	0.26	0.21	Caffeine consumption;	chr14:74919873	chr14:75011269~75012851:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	4.55	7e-06	0.00145	0.24	0.21	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
HNSC	cis	rs6951245	0.572	rs73264010	ENSG00000225146.1	AC073957.15	-4.54	7.01e-06	0.00145	-0.41	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1000841	chr7:1029025~1043891:+
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-4.54	7.01e-06	0.00145	-0.24	-0.21	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000254340.1	RP11-10A14.3	4.54	7.01e-06	0.00145	0.25	0.21	Neuroticism;	chr8:8237204	chr8:9141424~9145435:+
HNSC	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-4.54	7.01e-06	0.00145	-0.24	-0.21	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
HNSC	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	4.54	7.01e-06	0.00145	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
HNSC	cis	rs6693567	0.565	rs834242	ENSG00000228126.1	FALEC	4.54	7.01e-06	0.00145	0.25	0.21	Migraine;	chr1:150407382	chr1:150515757~150518032:+
HNSC	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	4.54	7.01e-06	0.00145	0.18	0.21	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	4.54	7.01e-06	0.00145	0.18	0.21	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
HNSC	cis	rs3863381	0.536	rs74805761	ENSG00000277715.1	RP11-651L5.3	4.54	7.01e-06	0.00145	0.32	0.21	Night sleep phenotypes;	chr12:105719665	chr12:106250759~106252786:+
HNSC	cis	rs10129255	1	rs8010605	ENSG00000224373.3	IGHV4-59	4.54	7.02e-06	0.00145	0.13	0.21	Kawasaki disease;	chr14:106678742	chr14:106627249~106627825:-
HNSC	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
HNSC	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-4.54	7.02e-06	0.00145	-0.26	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
HNSC	cis	rs11846409	0.932	rs61233250	ENSG00000254174.1	IGHV1-12	4.54	7.02e-06	0.00145	0.16	0.21	Rheumatic heart disease;	chr14:106634072	chr14:106122420~106122709:-
HNSC	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	4.54	7.02e-06	0.00145	0.29	0.21	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
HNSC	cis	rs721917	0.506	rs1923540	ENSG00000225484.5	NUTM2B-AS1	-4.54	7.02e-06	0.00145	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79663088~79826594:-
HNSC	cis	rs651907	0.557	rs12629658	ENSG00000244119.1	PDCL3P4	4.54	7.02e-06	0.00145	0.2	0.21	Colorectal cancer;	chr3:101637691	chr3:101712472~101713191:+
HNSC	cis	rs72843506	0.656	rs73984568	ENSG00000261033.1	RP11-209D14.2	4.54	7.02e-06	0.00145	0.34	0.21	Schizophrenia;	chr17:20074301	chr17:20008051~20009234:-
HNSC	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-4.54	7.02e-06	0.00145	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-4.54	7.02e-06	0.00145	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-4.54	7.02e-06	0.00145	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	4.54	7.02e-06	0.00145	0.13	0.21	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
HNSC	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	4.54	7.03e-06	0.00145	0.21	0.21	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	4.54	7.03e-06	0.00145	0.25	0.21	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
HNSC	cis	rs721917	0.525	rs2246111	ENSG00000225484.5	NUTM2B-AS1	-4.54	7.03e-06	0.00145	-0.25	-0.21	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79663088~79826594:-
HNSC	cis	rs7829975	0.846	rs7005216	ENSG00000254153.1	CTA-398F10.2	-4.54	7.03e-06	0.00146	-0.23	-0.21	Mood instability;	chr8:8689600	chr8:8456909~8461337:-
HNSC	cis	rs1050631	0.96	rs1789503	ENSG00000278986.1	RP11-723J4.3	4.54	7.03e-06	0.00146	0.23	0.21	Esophageal squamous cell cancer (length of survival);	chr18:36116902	chr18:35972151~35973916:+
HNSC	cis	rs739496	0.579	rs7975437	ENSG00000226469.1	ADAM1B	4.54	7.03e-06	0.00146	0.24	0.21	Platelet count;	chr12:111939145	chr12:111927018~111929017:+
HNSC	cis	rs7296418	0.699	rs11057219	ENSG00000280120.1	RP11-546D6.3	4.54	7.03e-06	0.00146	0.17	0.21	Platelet count;	chr12:123265526	chr12:123152324~123153377:-
HNSC	cis	rs7296418	0.663	rs4553407	ENSG00000280120.1	RP11-546D6.3	4.54	7.03e-06	0.00146	0.17	0.21	Platelet count;	chr12:123266201	chr12:123152324~123153377:-
HNSC	cis	rs11756659	0.697	rs7746105	ENSG00000272462.2	U91328.19	-4.54	7.03e-06	0.00146	-0.25	-0.21	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25944050	chr6:25992662~26001775:+
HNSC	cis	rs9311676	0.632	rs11714389	ENSG00000273493.1	RP11-80H18.4	4.54	7.03e-06	0.00146	0.22	0.21	Systemic lupus erythematosus;	chr3:58461572	chr3:58329965~58330118:+
HNSC	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.54	7.04e-06	0.00146	-0.23	-0.21	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
HNSC	cis	rs4372836	1	rs7598876	ENSG00000226833.4	AC097724.3	4.54	7.04e-06	0.00146	0.26	0.21	Body mass index;	chr2:28751600	chr2:28708953~28736205:-
HNSC	cis	rs11250098	0.503	rs7821826	ENSG00000269918.1	AF131215.9	-4.54	7.05e-06	0.00146	-0.2	-0.21	Morning vs. evening chronotype;	chr8:10911929	chr8:11104691~11106704:-
HNSC	cis	rs4853525	0.59	rs3771310	ENSG00000235852.1	AC005540.3	4.54	7.05e-06	0.00146	0.28	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190908462	chr2:190880797~190882059:-
HNSC	cis	rs2279440	0.759	rs17050392	ENSG00000206573.7	THUMPD3-AS1	-4.54	7.05e-06	0.00146	-0.19	-0.21	Glucose homeostasis traits;	chr3:9481610	chr3:9349689~9398579:-
HNSC	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	4.54	7.05e-06	0.00146	0.2	0.21	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
HNSC	cis	rs1799949	1	rs8176103	ENSG00000236383.6	LINC00854	-4.54	7.05e-06	0.00146	-0.19	-0.21	Menopause (age at onset);	chr17:43115033	chr17:43216941~43305976:-
HNSC	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-4.54	7.06e-06	0.00146	-0.36	-0.21	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
HNSC	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-4.54	7.06e-06	0.00146	-0.24	-0.21	Height;	chr14:75105716	chr14:75011269~75012851:-
HNSC	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-4.54	7.06e-06	0.00146	-0.18	-0.21	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000219392.1	RP1-265C24.5	-4.54	7.06e-06	0.00146	-0.23	-0.21	Pubertal anthropometrics;	chr6:28421445	chr6:28115628~28116551:+
HNSC	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-4.54	7.06e-06	0.00146	-0.33	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
HNSC	cis	rs7824557	0.933	rs6601576	ENSG00000269918.1	AF131215.9	-4.54	7.06e-06	0.00146	-0.2	-0.21	Retinal vascular caliber;	chr8:11242766	chr8:11104691~11106704:-
HNSC	cis	rs4388249	1	rs11241032	ENSG00000271849.1	CTC-332L22.1	-4.54	7.06e-06	0.00146	-0.32	-0.21	Schizophrenia;	chr5:109723507	chr5:109687802~109688329:-
HNSC	cis	rs11098499	0.866	rs12501602	ENSG00000249244.1	RP11-548H18.2	4.54	7.06e-06	0.00146	0.25	0.21	Corneal astigmatism;	chr4:119366780	chr4:119391831~119395335:-
HNSC	cis	rs6601327	0.641	rs6601350	ENSG00000233609.3	RP11-62H7.2	-4.54	7.07e-06	0.00146	-0.19	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8961200~8979025:+
HNSC	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	4.54	7.07e-06	0.00146	0.26	0.21	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
HNSC	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	4.54	7.07e-06	0.00146	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
HNSC	cis	rs78579285	0.583	rs1061238	ENSG00000278341.1	RP5-1142A6.10	4.54	7.07e-06	0.00146	0.38	0.21	Joint mobility (Beighton score);	chr16:88715442	chr16:88708956~88710437:-
HNSC	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-4.54	7.08e-06	0.00147	-0.24	-0.21	Height;	chr14:75038783	chr14:75011269~75012851:-
HNSC	cis	rs7824557	0.713	rs6601575	ENSG00000255310.2	AF131215.2	4.54	7.08e-06	0.00147	0.2	0.21	Retinal vascular caliber;	chr8:11240295	chr8:11107788~11109726:-
HNSC	cis	rs7662987	0.517	rs1154405	ENSG00000263923.1	RP11-571L19.7	-4.54	7.08e-06	0.00147	-0.22	-0.21	Smoking initiation;	chr4:99087599	chr4:98928897~98994994:+
HNSC	cis	rs2098713	0.569	rs10941340	ENSG00000250155.1	CTD-2353F22.1	-4.54	7.09e-06	0.00147	-0.22	-0.21	Telomere length;	chr5:37502569	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs35187630	ENSG00000250155.1	CTD-2353F22.1	-4.54	7.09e-06	0.00147	-0.22	-0.21	Telomere length;	chr5:37503660	chr5:36666214~36725195:-
HNSC	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	4.54	7.09e-06	0.00147	0.22	0.21	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
HNSC	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	4.54	7.09e-06	0.00147	0.28	0.21	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
HNSC	cis	rs10027350	0.927	rs1035091	ENSG00000281501.1	SEPSECS-AS1	4.54	7.09e-06	0.00147	0.25	0.21	Childhood ear infection;	chr4:25150252	chr4:25160641~25201440:+
HNSC	cis	rs4925386	0.802	rs6142735	ENSG00000275437.1	RP5-908M14.10	4.54	7.09e-06	0.00147	0.22	0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62402236~62405935:-
HNSC	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	4.54	7.09e-06	0.00147	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
HNSC	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	4.54	7.09e-06	0.00147	0.26	0.21	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
HNSC	cis	rs67981189	0.892	rs221899	ENSG00000274818.1	RP1-292L20.3	4.54	7.09e-06	0.00147	0.24	0.21	Schizophrenia;	chr14:71138551	chr14:70906657~70907111:-
HNSC	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-4.54	7.1e-06	0.00147	-0.27	-0.21	Pain;	chr19:21505137	chr19:21554640~21569237:-
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-4.54	7.1e-06	0.00147	-0.24	-0.21	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-4.54	7.1e-06	0.00147	-0.24	-0.21	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
HNSC	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	4.54	7.1e-06	0.00147	0.21	0.21	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
HNSC	cis	rs1125355	0.655	rs1515924	ENSG00000204380.3	AC005042.4	-4.54	7.1e-06	0.00147	-0.23	-0.21	Alzheimer's disease in APOE e4+ carriers;	chr2:158792828	chr2:158658337~158735002:-
HNSC	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	4.54	7.1e-06	0.00147	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.827	rs7134121	ENSG00000269938.1	RP11-214K3.20	-4.54	7.1e-06	0.00147	-0.24	-0.21	White blood cell count;	chr12:123962799	chr12:123968023~123968579:-
HNSC	cis	rs2998286	0.723	rs332172	ENSG00000254635.4	WAC-AS1	-4.54	7.11e-06	0.00147	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28522652~28532743:-
HNSC	cis	rs7296418	0.63	rs7974099	ENSG00000280120.1	RP11-546D6.3	4.54	7.11e-06	0.00147	0.17	0.21	Platelet count;	chr12:123286928	chr12:123152324~123153377:-
HNSC	cis	rs11089937	0.616	rs5757244	ENSG00000211638.2	IGLV8-61	-4.54	7.11e-06	0.00147	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22098700~22099212:+
HNSC	cis	rs1799949	1	rs12516	ENSG00000236383.6	LINC00854	-4.54	7.11e-06	0.00147	-0.19	-0.21	Menopause (age at onset);	chr17:43044391	chr17:43216941~43305976:-
HNSC	cis	rs9287719	0.967	rs6748036	ENSG00000243819.4	RN7SL832P	4.54	7.11e-06	0.00147	0.2	0.21	Prostate cancer;	chr2:10577363	chr2:10690344~10692099:+
HNSC	cis	rs62025270	0.688	rs55957626	ENSG00000259762.1	RP11-158M2.4	-4.54	7.11e-06	0.00147	-0.29	-0.21	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85750336~85752901:-
HNSC	cis	rs7829975	0.782	rs6990746	ENSG00000254153.1	CTA-398F10.2	-4.54	7.11e-06	0.00147	-0.23	-0.21	Mood instability;	chr8:8690301	chr8:8456909~8461337:-
HNSC	cis	rs9311676	0.609	rs62258077	ENSG00000273493.1	RP11-80H18.4	4.54	7.11e-06	0.00147	0.22	0.21	Systemic lupus erythematosus;	chr3:58377644	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62258078	ENSG00000273493.1	RP11-80H18.4	4.54	7.11e-06	0.00147	0.22	0.21	Systemic lupus erythematosus;	chr3:58377705	chr3:58329965~58330118:+
HNSC	cis	rs73222236	0.963	rs6774226	ENSG00000273486.1	RP11-731C17.2	4.54	7.11e-06	0.00147	0.17	0.21	Coronary artery disease;	chr3:136083314	chr3:136837338~136839021:-
HNSC	cis	rs3733829	0.889	rs35858034	ENSG00000233622.1	CYP2T1P	-4.54	7.11e-06	0.00147	-0.22	-0.21	Smoking behavior;	chr19:40793959	chr19:40808525~40811390:-
HNSC	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	4.54	7.12e-06	0.00147	0.29	0.21	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	4.54	7.12e-06	0.00147	0.29	0.21	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	4.54	7.12e-06	0.00147	0.29	0.21	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
HNSC	cis	rs9287719	0.967	rs12464817	ENSG00000243819.4	RN7SL832P	4.54	7.12e-06	0.00147	0.2	0.21	Prostate cancer;	chr2:10567086	chr2:10690344~10692099:+
HNSC	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-4.54	7.13e-06	0.00147	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
HNSC	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	4.54	7.13e-06	0.00147	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
HNSC	cis	rs1008375	1	rs6849704	ENSG00000249502.1	AC006160.5	-4.54	7.13e-06	0.00147	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650408	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs10805357	ENSG00000249502.1	AC006160.5	-4.54	7.13e-06	0.00147	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650729	chr4:17587467~17614571:-
HNSC	cis	rs804280	0.517	rs7815179	ENSG00000255495.1	AC145124.2	4.54	7.13e-06	0.00147	0.23	0.21	Myopia (pathological);	chr8:11934539	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.871	rs7815186	ENSG00000255495.1	AC145124.2	4.54	7.13e-06	0.00147	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs7833079	ENSG00000255495.1	AC145124.2	4.54	7.13e-06	0.00147	0.23	0.21	Neuroticism;	chr8:11934620	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.899	rs7815595	ENSG00000255495.1	AC145124.2	4.54	7.13e-06	0.00147	0.23	0.21	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12194467~12196280:+
HNSC	cis	rs11773103	1	rs73212060	ENSG00000224046.1	AC005076.5	4.54	7.13e-06	0.00147	0.38	0.21	Bipolar disorder or major depressive disorder (combined);	chr7:87277197	chr7:87151423~87152420:-
HNSC	cis	rs4908769	0.66	rs301803	ENSG00000232912.4	RP5-1115A15.1	4.54	7.13e-06	0.00147	0.23	0.21	Allergy;	chr1:8438620	chr1:8424645~8434838:+
HNSC	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-4.54	7.13e-06	0.00147	-0.28	-0.21	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
HNSC	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-4.54	7.13e-06	0.00147	-0.21	-0.21	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
HNSC	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-4.54	7.13e-06	0.00147	-0.25	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
HNSC	cis	rs853679	0.607	rs35001169	ENSG00000219392.1	RP1-265C24.5	-4.54	7.13e-06	0.00147	-0.43	-0.21	Depression;	chr6:28219854	chr6:28115628~28116551:+
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	4.54	7.14e-06	0.00147	0.25	0.21	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
HNSC	cis	rs3738443	0.868	rs60698393	ENSG00000259865.1	RP11-488L18.10	4.54	7.14e-06	0.00147	0.18	0.21	Alcohol dependence;	chr1:247198135	chr1:247187281~247188526:-
HNSC	cis	rs2762353	0.639	rs566530	ENSG00000272462.2	U91328.19	-4.54	7.14e-06	0.00147	-0.2	-0.21	Blood metabolite levels;	chr6:25878133	chr6:25992662~26001775:+
HNSC	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	4.54	7.15e-06	0.00148	0.23	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
HNSC	cis	rs12539814	0.929	rs12671701	ENSG00000204959.4	ARHGEF34P	4.54	7.15e-06	0.00148	0.41	0.21	Diastolic blood pressure;	chr7:144459893	chr7:144272445~144286966:-
HNSC	cis	rs1823874	0.653	rs12902823	ENSG00000182397.13	DNM1P46	-4.54	7.15e-06	0.00148	-0.21	-0.21	IgG glycosylation;	chr15:99812013	chr15:99790156~99806927:-
HNSC	cis	rs9287719	0.967	rs4669593	ENSG00000243819.4	RN7SL832P	4.54	7.15e-06	0.00148	0.2	0.21	Prostate cancer;	chr2:10561782	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs3814388	ENSG00000243819.4	RN7SL832P	4.54	7.15e-06	0.00148	0.2	0.21	Prostate cancer;	chr2:10561973	chr2:10690344~10692099:+
HNSC	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	4.54	7.15e-06	0.00148	0.25	0.21	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
HNSC	cis	rs929354	0.713	rs3802129	ENSG00000224629.1	RP5-1142J19.2	-4.54	7.16e-06	0.00148	-0.2	-0.21	Body mass index;	chr7:157172603	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs1002389	ENSG00000224629.1	RP5-1142J19.2	-4.54	7.16e-06	0.00148	-0.2	-0.21	Body mass index;	chr7:157175629	chr7:157263022~157263229:-
HNSC	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.54	7.16e-06	0.00148	0.22	0.21	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
HNSC	cis	rs71636778	0.509	rs35989952	ENSG00000260063.1	RP5-968P14.2	-4.54	7.16e-06	0.00148	-0.39	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26678663	chr1:26692132~26694131:-
HNSC	cis	rs42490	0.689	rs43228	ENSG00000251136.7	RP11-37B2.1	-4.54	7.16e-06	0.00148	-0.18	-0.21	Leprosy;	chr8:89816790	chr8:89609409~89757727:-
HNSC	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	4.54	7.17e-06	0.00148	0.23	0.21	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
HNSC	cis	rs5758511	0.68	rs5758667	ENSG00000226450.2	CYP2D8P	4.54	7.17e-06	0.00148	0.2	0.21	Birth weight;	chr22:42237198	chr22:42149886~42155001:-
HNSC	cis	rs7296418	0.619	rs7139321	ENSG00000280120.1	RP11-546D6.3	4.54	7.17e-06	0.00148	0.17	0.21	Platelet count;	chr12:123234981	chr12:123152324~123153377:-
HNSC	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	4.54	7.17e-06	0.00148	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
HNSC	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	4.54	7.18e-06	0.00148	0.24	0.21	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
HNSC	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	4.54	7.18e-06	0.00148	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
HNSC	cis	rs710913	0.557	rs1180320	ENSG00000182109.6	RP11-69E11.4	4.54	7.18e-06	0.00148	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39616330	chr1:39522280~39546187:-
HNSC	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	4.54	7.18e-06	0.00148	0.25	0.21	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
HNSC	cis	rs964611	0.882	rs10152424	ENSG00000259488.2	RP11-154J22.1	-4.54	7.18e-06	0.00148	-0.18	-0.21	Metabolite levels (Pyroglutamine);	chr15:48299790	chr15:48312353~48331856:-
HNSC	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-4.54	7.18e-06	0.00148	-0.22	-0.21	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
HNSC	cis	rs4978813	0.519	rs10979887	ENSG00000213539.4	YBX1P6	4.54	7.19e-06	0.00148	0.24	0.21	Plantar warts;	chr9:109489537	chr9:109532830~109534332:-
HNSC	cis	rs1799949	0.93	rs2298861	ENSG00000236383.6	LINC00854	-4.54	7.19e-06	0.00148	-0.2	-0.21	Menopause (age at onset);	chr17:43024814	chr17:43216941~43305976:-
HNSC	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-4.54	7.2e-06	0.00149	-0.25	-0.21	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
HNSC	cis	rs72772090	0.71	rs11750400	ENSG00000248734.2	CTD-2260A17.1	-4.54	7.2e-06	0.00149	-0.32	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.71	rs10515244	ENSG00000248734.2	CTD-2260A17.1	-4.54	7.2e-06	0.00149	-0.32	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.71	rs1559085	ENSG00000248734.2	CTD-2260A17.1	-4.54	7.2e-06	0.00149	-0.32	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96784777~96785999:+
HNSC	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	4.54	7.2e-06	0.00149	0.17	0.21	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
HNSC	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	4.54	7.2e-06	0.00149	0.29	0.21	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
HNSC	cis	rs3015497	0.57	rs2934679	ENSG00000269906.1	RP11-248J18.2	4.54	7.2e-06	0.00149	0.27	0.21	Mean platelet volume;	chr14:50627027	chr14:50662511~50663178:-
HNSC	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-4.54	7.2e-06	0.00149	-0.3	-0.21	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
HNSC	cis	rs7015630	0.657	rs34126178	ENSG00000251136.7	RP11-37B2.1	-4.54	7.2e-06	0.00149	-0.25	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89807953	chr8:89609409~89757727:-
HNSC	cis	rs5758511	0.68	rs5758684	ENSG00000205702.9	CYP2D7	4.54	7.2e-06	0.00149	0.19	0.21	Birth weight;	chr22:42253503	chr22:42140203~42144577:-
HNSC	cis	rs73222236	0.679	rs66810260	ENSG00000273486.1	RP11-731C17.2	4.54	7.21e-06	0.00149	0.17	0.21	Coronary artery disease;	chr3:136574215	chr3:136837338~136839021:-
HNSC	cis	rs9863	0.861	rs3789967	ENSG00000269938.1	RP11-214K3.20	-4.54	7.21e-06	0.00149	-0.24	-0.21	White blood cell count;	chr12:123962792	chr12:123968023~123968579:-
HNSC	cis	rs9880211	0.718	rs56398805	ENSG00000273486.1	RP11-731C17.2	4.54	7.21e-06	0.00149	0.18	0.21	Height;Body mass index;	chr3:136213558	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.527	rs6989657	ENSG00000255020.1	AF131216.5	4.54	7.21e-06	0.00149	0.23	0.21	Neuroticism;	chr8:10473363	chr8:11345748~11347502:-
HNSC	cis	rs1015362	0.54	rs2050209	ENSG00000276073.1	RP5-1125A11.7	4.54	7.21e-06	0.00149	0.27	0.21	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33985617~33988989:-
HNSC	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	4.54	7.21e-06	0.00149	0.23	0.21	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
HNSC	cis	rs17428076	0.681	rs62182401	ENSG00000228389.1	AC068039.4	-4.54	7.21e-06	0.00149	-0.28	-0.21	Myopia;	chr2:171876838	chr2:171773482~171775844:+
HNSC	cis	rs4840086	1	rs2894891	ENSG00000219755.1	RP1-199J3.5	4.54	7.21e-06	0.00149	0.26	0.21	Menarche (age at onset);	chr6:99762031	chr6:99575712~99576456:+
HNSC	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	4.54	7.21e-06	0.00149	0.2	0.21	Height;	chr5:37474739	chr5:36666214~36725195:-
HNSC	cis	rs4761669	0.848	rs10777617	ENSG00000241556.1	RP11-490G8.1	-4.54	7.22e-06	0.00149	-0.21	-0.21	Common carotid intima-media thickness in HIV infection;	chr12:94783625	chr12:95467397~95467861:-
HNSC	cis	rs116095464	0.51	rs60844864	ENSG00000250848.1	CTD-2083E4.5	-4.54	7.22e-06	0.00149	-0.28	-0.21	Breast cancer;	chr5:266885	chr5:288833~290321:-
HNSC	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	4.54	7.22e-06	0.00149	0.21	0.21	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
HNSC	cis	rs11722228	0.549	rs62288521	ENSG00000250413.1	RP11-448G15.1	-4.54	7.22e-06	0.00149	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10006482~10009725:+
HNSC	cis	rs7735319	0.834	rs34666210	ENSG00000250697.1	CTD-2066L21.3	4.54	7.22e-06	0.00149	0.26	0.21	Systolic blood pressure;	chr5:33069978	chr5:32925639~33297910:-
HNSC	cis	rs7948661	1	rs9332846	ENSG00000278376.1	RP11-158I9.8	4.54	7.23e-06	0.00149	0.38	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118506808	chr11:118791254~118793137:+
HNSC	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-4.54	7.23e-06	0.00149	-0.27	-0.21	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
HNSC	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-4.54	7.23e-06	0.00149	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
HNSC	cis	rs7688540	0.771	rs61792116	ENSG00000211553.1	AC253576.2	-4.54	7.23e-06	0.00149	-0.32	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:136461~136568:+
HNSC	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-4.54	7.23e-06	0.00149	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
HNSC	cis	rs9880211	0.563	rs6793835	ENSG00000273486.1	RP11-731C17.2	-4.54	7.24e-06	0.00149	-0.19	-0.21	Height;Body mass index;	chr3:136101092	chr3:136837338~136839021:-
HNSC	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-4.54	7.24e-06	0.00149	-0.25	-0.21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
HNSC	cis	rs1008375	1	rs10939743	ENSG00000249502.1	AC006160.5	-4.54	7.24e-06	0.00149	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661108	chr4:17587467~17614571:-
HNSC	cis	rs13256369	0.951	rs13260947	ENSG00000173295.6	FAM86B3P	4.54	7.24e-06	0.00149	0.27	0.21	Obesity-related traits;	chr8:8708373	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.951	rs13259955	ENSG00000173295.6	FAM86B3P	4.54	7.24e-06	0.00149	0.27	0.21	Obesity-related traits;	chr8:8708375	chr8:8228595~8244865:+
HNSC	cis	rs6601327	0.585	rs11249934	ENSG00000254340.1	RP11-10A14.3	4.54	7.24e-06	0.00149	0.24	0.21	Multiple myeloma (hyperdiploidy);	chr8:9653320	chr8:9141424~9145435:+
HNSC	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-4.54	7.24e-06	0.00149	-0.2	-0.21	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	4.54	7.25e-06	0.0015	0.24	0.21	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
HNSC	cis	rs36052053	1	rs36052053	ENSG00000203799.9	CCDC162P	4.54	7.25e-06	0.0015	0.3	0.21	Red cell distribution width;	chr6:109262596	chr6:109285485~109355063:+
HNSC	cis	rs1538970	0.781	rs12049503	ENSG00000234329.1	RP11-767N6.2	4.54	7.26e-06	0.0015	0.24	0.21	Platelet count;	chr1:45555884	chr1:45651039~45651826:-
HNSC	cis	rs9287719	0.967	rs7570118	ENSG00000243819.4	RN7SL832P	4.54	7.26e-06	0.0015	0.2	0.21	Prostate cancer;	chr2:10577881	chr2:10690344~10692099:+
HNSC	cis	rs6964587	1	rs2282975	ENSG00000188693.7	CYP51A1-AS1	-4.54	7.26e-06	0.0015	-0.22	-0.21	Breast cancer;	chr7:92132324	chr7:92134604~92180725:+
HNSC	cis	rs3758785	0.697	rs3758789	ENSG00000255893.1	RP11-685N10.1	-4.54	7.26e-06	0.0015	-0.31	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399958	chr11:94472908~94473570:-
HNSC	cis	rs913655	0.508	rs2480336	ENSG00000225527.1	RP11-383B4.4	-4.54	7.26e-06	0.0015	-0.25	-0.21	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18775807	chr10:18531849~18533336:-
HNSC	cis	rs964611	0.882	rs59324936	ENSG00000259488.2	RP11-154J22.1	-4.54	7.26e-06	0.0015	-0.21	-0.21	Metabolite levels (Pyroglutamine);	chr15:48354061	chr15:48312353~48331856:-
HNSC	cis	rs11089937	0.616	rs713644	ENSG00000211638.2	IGLV8-61	-4.54	7.26e-06	0.0015	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs713624	ENSG00000211638.2	IGLV8-61	-4.54	7.26e-06	0.0015	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22098700~22099212:+
HNSC	cis	rs2292864	0.764	rs72825627	ENSG00000228782.6	CTD-2026D20.3	-4.54	7.27e-06	0.0015	-0.33	-0.21	Left atrial antero-posterior diameter;	chr17:47308923	chr17:47450568~47492492:-
HNSC	cis	rs1150668	0.799	rs9301	ENSG00000219392.1	RP1-265C24.5	-4.54	7.27e-06	0.0015	-0.23	-0.21	Pubertal anthropometrics;	chr6:28324929	chr6:28115628~28116551:+
HNSC	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-4.54	7.27e-06	0.0015	-0.23	-0.21	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
HNSC	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	4.54	7.27e-06	0.0015	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	4.54	7.27e-06	0.0015	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
HNSC	cis	rs6964587	0.9	rs6972027	ENSG00000188693.7	CYP51A1-AS1	-4.54	7.27e-06	0.0015	-0.22	-0.21	Breast cancer;	chr7:92152066	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.935	rs9770444	ENSG00000188693.7	CYP51A1-AS1	-4.54	7.27e-06	0.0015	-0.22	-0.21	Breast cancer;	chr7:92153848	chr7:92134604~92180725:+
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	4.54	7.27e-06	0.0015	0.24	0.21	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
HNSC	cis	rs8077577	0.945	rs34474249	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.27e-06	0.0015	-0.31	-0.21	Obesity-related traits;	chr17:18171211	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.945	rs11654146	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.27e-06	0.0015	-0.31	-0.21	Obesity-related traits;	chr17:18172827	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs10048161	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.27e-06	0.0015	-0.31	-0.21	Obesity-related traits;	chr17:18179482	chr17:18511221~18551705:-
HNSC	cis	rs597539	0.652	rs622082	ENSG00000255741.1	RP11-757G1.5	-4.54	7.27e-06	0.0015	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs546382	ENSG00000255741.1	RP11-757G1.5	-4.54	7.27e-06	0.0015	-0.29	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68941503~68942852:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000254340.1	RP11-10A14.3	4.54	7.28e-06	0.0015	0.25	0.21	Mood instability;	chr8:8522714	chr8:9141424~9145435:+
HNSC	cis	rs4388249	0.651	rs577391	ENSG00000271849.1	CTC-332L22.1	-4.54	7.28e-06	0.0015	-0.34	-0.21	Schizophrenia;	chr5:109680504	chr5:109687802~109688329:-
HNSC	cis	rs13434995	0.513	rs7660668	ENSG00000273257.1	RP11-177J6.1	4.54	7.28e-06	0.0015	0.28	0.21	Adiponectin levels;	chr4:55535530	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs7698022	ENSG00000273257.1	RP11-177J6.1	4.54	7.28e-06	0.0015	0.28	0.21	Adiponectin levels;	chr4:55541180	chr4:55387949~55388271:+
HNSC	cis	rs6601327	0.586	rs6601340	ENSG00000254340.1	RP11-10A14.3	-4.54	7.28e-06	0.0015	-0.24	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9603805	chr8:9141424~9145435:+
HNSC	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	4.54	7.28e-06	0.0015	0.23	0.21	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
HNSC	cis	rs10462794	0.756	rs13156459	ENSG00000260763.1	RP11-445O3.3	4.54	7.28e-06	0.0015	0.25	0.21	DNA methylation (variation);	chr5:4487216	chr5:4436850~4440259:-
HNSC	cis	rs10462794	0.789	rs13161966	ENSG00000260763.1	RP11-445O3.3	4.54	7.28e-06	0.0015	0.25	0.21	DNA methylation (variation);	chr5:4488249	chr5:4436850~4440259:-
HNSC	cis	rs4372836	0.796	rs7580078	ENSG00000226833.4	AC097724.3	4.54	7.28e-06	0.0015	0.26	0.21	Body mass index;	chr2:28774135	chr2:28708953~28736205:-
HNSC	cis	rs755249	0.567	rs112672438	ENSG00000228060.1	RP11-69E11.8	-4.54	7.29e-06	0.0015	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16825921	ENSG00000228060.1	RP11-69E11.8	-4.54	7.29e-06	0.0015	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-4.54	7.29e-06	0.0015	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-4.54	7.29e-06	0.0015	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
HNSC	cis	rs8054556	0.669	rs12931955	ENSG00000183604.13	SMG1P5	-4.54	7.29e-06	0.0015	-0.2	-0.21	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:30267553~30335374:-
HNSC	cis	rs4713118	0.715	rs200480	ENSG00000219392.1	RP1-265C24.5	-4.54	7.29e-06	0.0015	-0.24	-0.21	Parkinson's disease;	chr6:27805886	chr6:28115628~28116551:+
HNSC	cis	rs7085104	0.513	rs619824	ENSG00000236937.2	PTGES3P4	4.54	7.29e-06	0.0015	0.25	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102845595~102845950:+
HNSC	cis	rs7824557	0.843	rs2736375	ENSG00000255310.2	AF131215.2	-4.54	7.29e-06	0.0015	-0.2	-0.21	Retinal vascular caliber;	chr8:11258240	chr8:11107788~11109726:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-4.54	7.29e-06	0.0015	-0.28	-0.21	Gout;	chr7:66654674	chr7:66880708~66882981:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-4.54	7.29e-06	0.0015	-0.28	-0.21	Gout;	chr7:66661502	chr7:66880708~66882981:+
HNSC	cis	rs916888	0.773	rs538628	ENSG00000260075.1	NSFP1	-4.54	7.29e-06	0.0015	-0.29	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46372855~46487141:+
HNSC	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	4.54	7.29e-06	0.0015	0.25	0.21	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
HNSC	cis	rs853679	0.599	rs13193295	ENSG00000219392.1	RP1-265C24.5	-4.54	7.29e-06	0.0015	-0.4	-0.21	Depression;	chr6:28035450	chr6:28115628~28116551:+
HNSC	cis	rs1799949	0.894	rs71367985	ENSG00000236383.6	LINC00854	-4.54	7.29e-06	0.0015	-0.19	-0.21	Menopause (age at onset);	chr17:43222443	chr17:43216941~43305976:-
HNSC	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	4.54	7.3e-06	0.0015	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
HNSC	cis	rs7107174	0.748	rs4415799	ENSG00000251323.2	RP11-452H21.4	-4.54	7.3e-06	0.0015	-0.26	-0.21	Testicular germ cell tumor;	chr11:78265429	chr11:78423982~78429836:-
HNSC	cis	rs1908814	0.51	rs57655799	ENSG00000255495.1	AC145124.2	4.54	7.3e-06	0.0015	0.23	0.21	Neuroticism;	chr8:11924908	chr8:12194467~12196280:+
HNSC	cis	rs3806843	0.619	rs2569160	ENSG00000202515.1	VTRNA1-3	4.54	7.3e-06	0.0015	0.24	0.21	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr5:140726158~140726246:+
HNSC	cis	rs5758511	0.514	rs1989375	ENSG00000226450.2	CYP2D8P	4.54	7.3e-06	0.0015	0.2	0.21	Birth weight;	chr22:42177133	chr22:42149886~42155001:-
HNSC	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	4.54	7.3e-06	0.0015	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
HNSC	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	4.54	7.3e-06	0.0015	0.21	0.21	Height;	chr5:37439326	chr5:36666214~36725195:-
HNSC	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	4.54	7.31e-06	0.00151	0.23	0.21	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
HNSC	cis	rs9959145	1	rs28821540	ENSG00000267249.1	RP11-973H7.3	-4.54	7.31e-06	0.00151	-0.31	-0.21	Immune response to smallpox vaccine (IL-6);	chr18:12558309	chr18:12670426~12671145:-
HNSC	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	4.54	7.31e-06	0.00151	0.32	0.21	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
HNSC	cis	rs2337406	1	rs78631692	ENSG00000280411.1	IGHV1-69-2	-4.54	7.31e-06	0.00151	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106709371	chr14:106762092~106762588:-
HNSC	cis	rs155076	1	rs658244	ENSG00000233325.3	MIPEPP3	4.54	7.31e-06	0.00151	0.36	0.21	White matter hyperintensity burden;	chr13:21276837	chr13:21298139~21306373:+
HNSC	cis	rs1479119	0.573	rs10845752	ENSG00000180861.8	LINC01559	4.54	7.32e-06	0.00151	0.26	0.21	Intelligence (multi-trait analysis);	chr12:13353530	chr12:13371089~13387167:-
HNSC	cis	rs1150668	0.83	rs213240	ENSG00000219392.1	RP1-265C24.5	-4.54	7.32e-06	0.00151	-0.23	-0.21	Pubertal anthropometrics;	chr6:28348098	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-4.54	7.32e-06	0.00151	-0.26	-0.21	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
HNSC	cis	rs9329221	0.527	rs7833781	ENSG00000269918.1	AF131215.9	4.54	7.32e-06	0.00151	0.21	0.21	Neuroticism;	chr8:10475967	chr8:11104691~11106704:-
HNSC	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-4.54	7.32e-06	0.00151	-0.27	-0.21	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-4.54	7.32e-06	0.00151	-0.27	-0.21	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-4.54	7.32e-06	0.00151	-0.27	-0.21	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
HNSC	cis	rs7829975	0.846	rs6601724	ENSG00000254153.1	CTA-398F10.2	-4.54	7.32e-06	0.00151	-0.23	-0.21	Mood instability;	chr8:8687362	chr8:8456909~8461337:-
HNSC	cis	rs757081	0.667	rs1987694	ENSG00000260196.1	RP1-239B22.5	-4.54	7.32e-06	0.00151	-0.25	-0.21	Systolic blood pressure;	chr11:17086101	chr11:17380649~17383531:+
HNSC	cis	rs4253772	0.591	rs6008361	ENSG00000277232.2	GTSE1-AS1	4.54	7.32e-06	0.00151	0.25	0.21	Cholesterol, total;LDL cholesterol;	chr22:46256475	chr22:46295143~46296660:-
HNSC	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	4.54	7.32e-06	0.00151	0.25	0.21	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
HNSC	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	4.54	7.32e-06	0.00151	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
HNSC	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-4.54	7.33e-06	0.00151	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-4.54	7.33e-06	0.00151	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-4.54	7.33e-06	0.00151	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
HNSC	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	4.54	7.33e-06	0.00151	0.28	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
HNSC	cis	rs9300255	0.722	rs12322888	ENSG00000280120.1	RP11-546D6.3	4.54	7.33e-06	0.00151	0.18	0.21	Neutrophil percentage of white cells;	chr12:123341012	chr12:123152324~123153377:-
HNSC	cis	rs73222236	0.825	rs7621017	ENSG00000273486.1	RP11-731C17.2	4.53	7.33e-06	0.00151	0.17	0.21	Coronary artery disease;	chr3:136553387	chr3:136837338~136839021:-
HNSC	cis	rs11633886	0.565	rs1356881	ENSG00000273972.1	CTD-2306A12.1	4.53	7.34e-06	0.00151	0.24	0.21	Diisocyanate-induced asthma;	chr15:45781261	chr15:45702640~45703183:+
HNSC	cis	rs7819412	0.561	rs2001328	ENSG00000255310.2	AF131215.2	-4.53	7.34e-06	0.00151	-0.2	-0.21	Triglycerides;	chr8:11129689	chr8:11107788~11109726:-
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000280054.1	RP1-197B17.7	4.53	7.35e-06	0.00151	0.57	0.21	Pneumonia;	chr12:47578764	chr12:47728151~47730598:-
HNSC	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-4.53	7.35e-06	0.00151	-0.24	-0.21	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
HNSC	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-4.53	7.35e-06	0.00151	-0.24	-0.21	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
HNSC	cis	rs7662987	0.517	rs1133485	ENSG00000263923.1	RP11-571L19.7	-4.53	7.35e-06	0.00151	-0.22	-0.21	Smoking initiation;	chr4:99102660	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602845	ENSG00000263923.1	RP11-571L19.7	-4.53	7.35e-06	0.00151	-0.22	-0.21	Smoking initiation;	chr4:99102793	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2034696	ENSG00000263923.1	RP11-571L19.7	-4.53	7.35e-06	0.00151	-0.22	-0.21	Smoking initiation;	chr4:99103171	chr4:98928897~98994994:+
HNSC	cis	rs10185424	0.521	rs4851529	ENSG00000281162.1	LINC01127	-4.53	7.35e-06	0.00151	-0.26	-0.21	Crohn's disease;Ulcerative colitis;	chr2:102030838	chr2:101962056~101987167:+
HNSC	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	4.53	7.36e-06	0.00151	0.22	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
HNSC	cis	rs6601327	0.602	rs7820917	ENSG00000254340.1	RP11-10A14.3	4.53	7.36e-06	0.00151	0.25	0.21	Multiple myeloma (hyperdiploidy);	chr8:9790358	chr8:9141424~9145435:+
HNSC	cis	rs761746	0.577	rs2012150	ENSG00000236132.1	CTA-440B3.1	-4.53	7.36e-06	0.00151	-0.25	-0.21	Intelligence;	chr22:31820153	chr22:31816379~31817491:-
HNSC	cis	rs155076	1	rs2478824	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21270005	chr13:21298139~21306373:+
HNSC	cis	rs155076	0.938	rs9509630	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21270175	chr13:21298139~21306373:+
HNSC	cis	rs155076	0.938	rs9509633	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21270343	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs58519241	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21270867	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs598754	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21270871	chr13:21298139~21306373:+
HNSC	cis	rs155076	0.938	rs485361	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21271687	chr13:21298139~21306373:+
HNSC	cis	rs155076	1	rs484365	ENSG00000233325.3	MIPEPP3	4.53	7.36e-06	0.00152	0.36	0.21	White matter hyperintensity burden;	chr13:21271805	chr13:21298139~21306373:+
HNSC	cis	rs7587476	0.599	rs61073893	ENSG00000229267.2	AC072062.1	-4.53	7.36e-06	0.00152	-0.31	-0.21	Neuroblastoma;	chr2:214880090	chr2:214810229~214963274:+
HNSC	cis	rs3806843	0.933	rs10069930	ENSG00000202515.1	VTRNA1-3	-4.53	7.36e-06	0.00152	-0.23	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr5:140726158~140726246:+
HNSC	cis	rs988913	0.768	rs9396003	ENSG00000224984.1	RP11-524H19.2	4.53	7.36e-06	0.00152	0.24	0.21	Menarche (age at onset);	chr6:54877055	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.706	rs6910384	ENSG00000224984.1	RP11-524H19.2	4.53	7.36e-06	0.00152	0.24	0.21	Menarche (age at onset);	chr6:54879200	chr6:54840118~54840855:-
HNSC	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-4.53	7.37e-06	0.00152	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
HNSC	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-4.53	7.37e-06	0.00152	-0.31	-0.21	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
HNSC	cis	rs9287719	0.967	rs6721739	ENSG00000243819.4	RN7SL832P	-4.53	7.37e-06	0.00152	-0.2	-0.21	Prostate cancer;	chr2:10611120	chr2:10690344~10692099:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	4.53	7.37e-06	0.00152	0.27	0.21	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
HNSC	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	4.53	7.37e-06	0.00152	0.25	0.21	Height;	chr20:49286482	chr20:49280319~49280409:+
HNSC	cis	rs11098499	0.738	rs28687057	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119359657	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.775	rs67281037	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119360002	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.506	rs12374346	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Educational attainment;	chr4:119360550	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.775	rs10021601	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119361408	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs6857892	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119361541	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.909	rs28581362	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119362393	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.82	rs12503082	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119363162	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs12499602	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119363232	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.774	rs11098505	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119363472	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs13105020	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119364533	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs6824111	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119364813	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.775	rs10029303	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119365600	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs9995136	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119365690	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs13125526	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119366864	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs12513310	ENSG00000249244.1	RP11-548H18.2	4.53	7.38e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119366884	chr4:119391831~119395335:-
HNSC	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.53	7.38e-06	0.00152	0.34	0.21	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000254153.1	CTA-398F10.2	-4.53	7.38e-06	0.00152	-0.22	-0.21	Joint mobility (Beighton score);	chr8:9225923	chr8:8456909~8461337:-
HNSC	cis	rs1799949	1	rs4793194	ENSG00000236383.6	LINC00854	-4.53	7.38e-06	0.00152	-0.19	-0.21	Menopause (age at onset);	chr17:43066316	chr17:43216941~43305976:-
HNSC	cis	rs1008375	1	rs1860596	ENSG00000249502.1	AC006160.5	-4.53	7.38e-06	0.00152	-0.21	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658459	chr4:17587467~17614571:-
HNSC	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-4.53	7.38e-06	0.00152	-0.27	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
HNSC	cis	rs1008375	1	rs6854733	ENSG00000249502.1	AC006160.5	-4.53	7.39e-06	0.00152	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638903	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs55939327	ENSG00000249502.1	AC006160.5	-4.53	7.39e-06	0.00152	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641314	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs2286771	ENSG00000249502.1	AC006160.5	-4.53	7.39e-06	0.00152	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17642225	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs28545485	ENSG00000249502.1	AC006160.5	-4.53	7.39e-06	0.00152	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17643753	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs10011865	ENSG00000249502.1	AC006160.5	-4.53	7.39e-06	0.00152	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17644087	chr4:17587467~17614571:-
HNSC	cis	rs7824557	0.614	rs17741537	ENSG00000255310.2	AF131215.2	4.53	7.39e-06	0.00152	0.19	0.21	Retinal vascular caliber;	chr8:11355583	chr8:11107788~11109726:-
HNSC	cis	rs7610312	0.681	rs2363687	ENSG00000273493.1	RP11-80H18.4	-4.53	7.39e-06	0.00152	-0.24	-0.21	Red blood cell count;	chr3:58281676	chr3:58329965~58330118:+
HNSC	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	4.53	7.39e-06	0.00152	0.26	0.21	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	4.53	7.39e-06	0.00152	0.26	0.21	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
HNSC	cis	rs9311676	0.656	rs62258093	ENSG00000273493.1	RP11-80H18.4	4.53	7.39e-06	0.00152	0.22	0.21	Systemic lupus erythematosus;	chr3:58386018	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62258094	ENSG00000273493.1	RP11-80H18.4	4.53	7.39e-06	0.00152	0.22	0.21	Systemic lupus erythematosus;	chr3:58386043	chr3:58329965~58330118:+
HNSC	cis	rs1485395	0.891	rs10161319	ENSG00000257379.1	RP11-793H13.8	4.53	7.4e-06	0.00152	0.29	0.21	Migraine without aura;	chr12:53642530	chr12:53441741~53467528:+
HNSC	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-4.53	7.4e-06	0.00152	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	4.53	7.4e-06	0.00152	0.25	0.21	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
HNSC	cis	rs11722228	0.549	rs3796818	ENSG00000250413.1	RP11-448G15.1	-4.53	7.4e-06	0.00152	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10006482~10009725:+
HNSC	cis	rs11722228	0.549	rs41268389	ENSG00000250413.1	RP11-448G15.1	-4.53	7.4e-06	0.00152	-0.32	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10006482~10009725:+
HNSC	cis	rs6964587	0.967	rs10279210	ENSG00000188693.7	CYP51A1-AS1	-4.53	7.41e-06	0.00152	-0.22	-0.21	Breast cancer;	chr7:91987577	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs3753108	ENSG00000188693.7	CYP51A1-AS1	-4.53	7.41e-06	0.00152	-0.22	-0.21	Breast cancer;	chr7:92000670	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.934	rs6465344	ENSG00000188693.7	CYP51A1-AS1	-4.53	7.41e-06	0.00152	-0.22	-0.21	Breast cancer;	chr7:92010959	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs7788092	ENSG00000188693.7	CYP51A1-AS1	-4.53	7.41e-06	0.00152	-0.22	-0.21	Breast cancer;	chr7:92016884	chr7:92134604~92180725:+
HNSC	cis	rs12986445	0.652	rs11897652	ENSG00000218682.1	AC010150.1	4.53	7.41e-06	0.00152	0.27	0.21	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25767112	chr2:25856461~25856966:-
HNSC	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-4.53	7.41e-06	0.00152	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
HNSC	cis	rs1056107	0.933	rs943621	ENSG00000225513.1	RP11-165N19.2	-4.53	7.41e-06	0.00152	-0.22	-0.21	Colorectal cancer;	chr9:112231510	chr9:112173522~112173971:-
HNSC	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-4.53	7.41e-06	0.00152	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
HNSC	cis	rs442309	1	rs442309	ENSG00000238280.1	RP11-436D10.3	-4.53	7.42e-06	0.00153	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62730735	chr10:62793562~62805887:-
HNSC	cis	rs442309	1	rs224048	ENSG00000238280.1	RP11-436D10.3	-4.53	7.42e-06	0.00153	-0.24	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62731789	chr10:62793562~62805887:-
HNSC	cis	rs1479119	0.65	rs10772653	ENSG00000180861.8	LINC01559	4.53	7.42e-06	0.00153	0.26	0.21	Intelligence (multi-trait analysis);	chr12:13342709	chr12:13371089~13387167:-
HNSC	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	4.53	7.42e-06	0.00153	0.43	0.21	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
HNSC	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-4.53	7.42e-06	0.00153	-0.24	-0.21	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
HNSC	cis	rs9311676	0.632	rs62258075	ENSG00000273493.1	RP11-80H18.4	4.53	7.43e-06	0.00153	0.22	0.21	Systemic lupus erythematosus;	chr3:58374124	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs57700771	ENSG00000273493.1	RP11-80H18.4	4.53	7.43e-06	0.00153	0.22	0.21	Systemic lupus erythematosus;	chr3:58374600	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11130630	ENSG00000273493.1	RP11-80H18.4	4.53	7.43e-06	0.00153	0.22	0.21	Systemic lupus erythematosus;	chr3:58375073	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs6774357	ENSG00000273493.1	RP11-80H18.4	4.53	7.43e-06	0.00153	0.22	0.21	Systemic lupus erythematosus;	chr3:58375803	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs6777066	ENSG00000273493.1	RP11-80H18.4	4.53	7.43e-06	0.00153	0.22	0.21	Systemic lupus erythematosus;	chr3:58375876	chr3:58329965~58330118:+
HNSC	cis	rs9840812	0.953	rs4678322	ENSG00000239213.4	NCK1-AS1	-4.53	7.43e-06	0.00153	-0.19	-0.21	Fibrinogen levels;	chr3:136093681	chr3:136841726~136862054:-
HNSC	cis	rs853679	0.599	rs13193295	ENSG00000204709.4	LINC01556	4.53	7.43e-06	0.00153	0.41	0.21	Depression;	chr6:28035450	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs72846780	ENSG00000219392.1	RP1-265C24.5	-4.53	7.43e-06	0.00153	-0.42	-0.21	Depression;	chr6:28151277	chr6:28115628~28116551:+
HNSC	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-4.53	7.44e-06	0.00153	-0.27	-0.21	Pain;	chr19:21531402	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-4.53	7.44e-06	0.00153	-0.27	-0.21	Pain;	chr19:21532048	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-4.53	7.44e-06	0.00153	-0.27	-0.21	Pain;	chr19:21533017	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-4.53	7.44e-06	0.00153	-0.27	-0.21	Pain;	chr19:21533718	chr19:21554640~21569237:-
HNSC	cis	rs78579285	0.51	rs78759106	ENSG00000278341.1	RP5-1142A6.10	-4.53	7.44e-06	0.00153	-0.37	-0.21	Joint mobility (Beighton score);	chr16:88722127	chr16:88708956~88710437:-
HNSC	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	4.53	7.44e-06	0.00153	0.21	0.21	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
HNSC	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	4.53	7.44e-06	0.00153	0.2	0.21	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
HNSC	cis	rs4862750	0.874	rs6822062	ENSG00000250971.1	RP11-696F12.1	4.53	7.44e-06	0.00153	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr4:186974399	chr4:187060099~187060930:+
HNSC	cis	rs71520386	0.561	rs10274260	ENSG00000221740.1	SNORD93	-4.53	7.45e-06	0.00153	-0.23	-0.21	Fibrinogen levels;	chr7:22805227	chr7:22856613~22856686:+
HNSC	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-4.53	7.45e-06	0.00153	-0.33	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.874	rs28452522	ENSG00000249244.1	RP11-548H18.2	4.53	7.45e-06	0.00153	0.25	0.21	Corneal astigmatism;	chr4:119189629	chr4:119391831~119395335:-
HNSC	cis	rs1056107	0.931	rs7871559	ENSG00000225513.1	RP11-165N19.2	-4.53	7.45e-06	0.00153	-0.22	-0.21	Colorectal cancer;	chr9:112225574	chr9:112173522~112173971:-
HNSC	cis	rs9300255	0.543	rs1617156	ENSG00000280120.1	RP11-546D6.3	4.53	7.45e-06	0.00153	0.19	0.21	Neutrophil percentage of white cells;	chr12:123105618	chr12:123152324~123153377:-
HNSC	cis	rs13434995	0.513	rs6554285	ENSG00000273257.1	RP11-177J6.1	4.53	7.45e-06	0.00153	0.28	0.21	Adiponectin levels;	chr4:55533953	chr4:55387949~55388271:+
HNSC	cis	rs116095464	0.614	rs4371799	ENSG00000250848.1	CTD-2083E4.5	-4.53	7.45e-06	0.00153	-0.28	-0.21	Breast cancer;	chr5:268077	chr5:288833~290321:-
HNSC	cis	rs6928977	0.897	rs2746431	ENSG00000217482.2	HMGB1P17	-4.53	7.45e-06	0.00153	-0.23	-0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366063	chr6:135636086~135636713:-
HNSC	cis	rs6964587	1	rs2106171	ENSG00000188693.7	CYP51A1-AS1	-4.53	7.46e-06	0.00153	-0.22	-0.21	Breast cancer;	chr7:92121136	chr7:92134604~92180725:+
HNSC	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	4.53	7.46e-06	0.00153	0.19	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
HNSC	cis	rs6928977	0.802	rs2614276	ENSG00000231028.7	LINC00271	4.53	7.46e-06	0.00153	0.25	0.21	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135360566	chr6:135497801~135716055:+
HNSC	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-4.53	7.46e-06	0.00153	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
HNSC	cis	rs2048656	0.598	rs7846399	ENSG00000254340.1	RP11-10A14.3	-4.53	7.46e-06	0.00153	-0.24	-0.21	Schizophrenia;	chr8:9635619	chr8:9141424~9145435:+
HNSC	cis	rs7662987	0.517	rs1377689	ENSG00000263923.1	RP11-571L19.7	-4.53	7.47e-06	0.00153	-0.22	-0.21	Smoking initiation;	chr4:99100636	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs1453873	ENSG00000263923.1	RP11-571L19.7	-4.53	7.47e-06	0.00153	-0.22	-0.21	Smoking initiation;	chr4:99101420	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs1453874	ENSG00000263923.1	RP11-571L19.7	-4.53	7.47e-06	0.00153	-0.22	-0.21	Smoking initiation;	chr4:99101573	chr4:98928897~98994994:+
HNSC	cis	rs7789940	0.857	rs12532935	ENSG00000231087.2	FDPSP7	-4.53	7.47e-06	0.00153	-0.25	-0.21	Multiple sclerosis;	chr7:76310381	chr7:76968197~76969250:-
HNSC	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-4.53	7.47e-06	0.00153	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
HNSC	cis	rs11893307	0.509	rs2109958	ENSG00000228509.4	AC006460.2	4.53	7.47e-06	0.00153	0.27	0.21	Mean platelet volume;	chr2:190668388	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.509	rs11895262	ENSG00000228509.4	AC006460.2	4.53	7.47e-06	0.00153	0.27	0.21	Mean platelet volume;	chr2:190669136	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.509	rs12612904	ENSG00000228509.4	AC006460.2	4.53	7.47e-06	0.00153	0.27	0.21	Mean platelet volume;	chr2:190670121	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.509	rs2109957	ENSG00000228509.4	AC006460.2	4.53	7.47e-06	0.00153	0.27	0.21	Mean platelet volume;	chr2:190670585	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.509	rs12611764	ENSG00000228509.4	AC006460.2	4.53	7.47e-06	0.00153	0.27	0.21	Mean platelet volume;	chr2:190672417	chr2:190676944~190708716:-
HNSC	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	4.53	7.47e-06	0.00153	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	4.53	7.47e-06	0.00153	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
HNSC	cis	rs1479119	0.681	rs1382680	ENSG00000180861.8	LINC01559	4.53	7.48e-06	0.00154	0.26	0.21	Intelligence (multi-trait analysis);	chr12:13346641	chr12:13371089~13387167:-
HNSC	cis	rs1479119	0.681	rs1382682	ENSG00000180861.8	LINC01559	4.53	7.48e-06	0.00154	0.26	0.21	Intelligence (multi-trait analysis);	chr12:13346797	chr12:13371089~13387167:-
HNSC	cis	rs2209875	0.797	rs17080844	ENSG00000224945.1	RP11-82L18.2	-4.53	7.48e-06	0.00154	-0.27	-0.21	Pelvic organ prolapse (moderate/severe);	chr9:89172241	chr9:89088604~89109934:-
HNSC	cis	rs6693567	0.586	rs4970979	ENSG00000228126.1	FALEC	4.53	7.48e-06	0.00154	0.25	0.21	Migraine;	chr1:150511364	chr1:150515757~150518032:+
HNSC	cis	rs6693567	0.586	rs875514	ENSG00000228126.1	FALEC	4.53	7.48e-06	0.00154	0.25	0.21	Migraine;	chr1:150512079	chr1:150515757~150518032:+
HNSC	cis	rs3808502	0.516	rs6983727	ENSG00000269918.1	AF131215.9	4.53	7.48e-06	0.00154	0.2	0.21	Neuroticism;	chr8:11558303	chr8:11104691~11106704:-
HNSC	cis	rs4660261	0.545	rs803682	ENSG00000237950.1	RP11-7O11.3	4.53	7.49e-06	0.00154	0.22	0.21	Intelligence (multi-trait analysis);	chr1:43896951	chr1:43944370~43946551:-
HNSC	cis	rs2548724	0.738	rs1982418	ENSG00000250682.4	LINC00491	4.53	7.49e-06	0.00154	0.27	0.21	Type 2 diabetes;	chr5:102302677	chr5:102609156~102671559:-
HNSC	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	4.53	7.49e-06	0.00154	0.22	0.21	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	4.53	7.49e-06	0.00154	0.22	0.21	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
HNSC	cis	rs17345786	0.906	rs11708616	ENSG00000244119.1	PDCL3P4	4.53	7.49e-06	0.00154	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101712472~101713191:+
HNSC	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	4.53	7.49e-06	0.00154	0.26	0.21	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
HNSC	cis	rs9926296	0.585	rs6500441	ENSG00000260259.1	RP11-368I7.4	-4.53	7.49e-06	0.00154	-0.23	-0.21	Vitiligo;	chr16:89762261	chr16:89682620~89686569:-
HNSC	cis	rs9311676	0.656	rs6775710	ENSG00000273493.1	RP11-80H18.4	-4.53	7.49e-06	0.00154	-0.24	-0.21	Systemic lupus erythematosus;	chr3:58350474	chr3:58329965~58330118:+
HNSC	cis	rs7789940	0.904	rs7459185	ENSG00000231087.2	FDPSP7	4.53	7.5e-06	0.00154	0.24	0.21	Multiple sclerosis;	chr7:76305323	chr7:76968197~76969250:-
HNSC	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.53	7.5e-06	0.00154	0.33	0.21	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	4.53	7.51e-06	0.00154	0.25	0.21	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
HNSC	cis	rs9863	0.861	rs4930725	ENSG00000269938.1	RP11-214K3.20	-4.53	7.51e-06	0.00154	-0.24	-0.21	White blood cell count;	chr12:123943615	chr12:123968023~123968579:-
HNSC	cis	rs9311676	0.656	rs11721168	ENSG00000273493.1	RP11-80H18.4	4.53	7.51e-06	0.00154	0.22	0.21	Systemic lupus erythematosus;	chr3:58422952	chr3:58329965~58330118:+
HNSC	cis	rs5758511	0.68	rs5758688	ENSG00000226450.2	CYP2D8P	4.53	7.51e-06	0.00154	0.2	0.21	Birth weight;	chr22:42266495	chr22:42149886~42155001:-
HNSC	cis	rs1707322	0.929	rs785513	ENSG00000234329.1	RP11-767N6.2	-4.53	7.52e-06	0.00154	-0.22	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45651039~45651826:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-4.53	7.52e-06	0.00154	-0.28	-0.21	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
HNSC	cis	rs712039	0.652	rs853197	ENSG00000276054.1	RP11-378E13.3	4.53	7.52e-06	0.00154	0.29	0.21	Tuberculosis;	chr17:37488610	chr17:37386886~37387926:+
HNSC	cis	rs62025270	0.688	rs62025297	ENSG00000259762.1	RP11-158M2.4	-4.53	7.52e-06	0.00154	-0.28	-0.21	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85750336~85752901:-
HNSC	cis	rs7746199	0.736	rs35848276	ENSG00000219392.1	RP1-265C24.5	-4.53	7.52e-06	0.00154	-0.42	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28115628~28116551:+
HNSC	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-4.53	7.52e-06	0.00154	-0.25	-0.21	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
HNSC	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	4.53	7.52e-06	0.00154	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
HNSC	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-4.53	7.53e-06	0.00155	-0.19	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
HNSC	cis	rs6088580	0.567	rs6088520	ENSG00000276073.1	RP5-1125A11.7	4.53	7.53e-06	0.00155	0.22	0.21	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:33985617~33988989:-
HNSC	cis	rs13126694	0.678	rs4691452	ENSG00000248429.4	RP11-597D13.9	4.53	7.54e-06	0.00155	0.23	0.21	Blood osmolality (transformed sodium);	chr4:158080652	chr4:158170752~158202877:+
HNSC	cis	rs13126694	0.744	rs11942932	ENSG00000248429.4	RP11-597D13.9	4.53	7.54e-06	0.00155	0.23	0.21	Blood osmolality (transformed sodium);	chr4:158081929	chr4:158170752~158202877:+
HNSC	cis	rs17345786	0.817	rs11720560	ENSG00000244119.1	PDCL3P4	4.53	7.54e-06	0.00155	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101712472~101713191:+
HNSC	cis	rs3096299	0.967	rs2911255	ENSG00000261574.1	RP1-168P16.2	4.53	7.54e-06	0.00155	0.25	0.21	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89392375~89412564:-
HNSC	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	4.53	7.54e-06	0.00155	0.27	0.21	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
HNSC	cis	rs7572733	0.935	rs700665	ENSG00000222017.1	AC011997.1	4.53	7.55e-06	0.00155	0.25	0.21	Dermatomyositis;	chr2:197808655	chr2:197693106~197774823:+
HNSC	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-4.53	7.55e-06	0.00155	-0.22	-0.21	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
HNSC	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-4.53	7.55e-06	0.00155	-0.23	-0.21	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-4.53	7.55e-06	0.00155	-0.23	-0.21	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
HNSC	cis	rs3096299	0.967	rs11648663	ENSG00000261574.1	RP1-168P16.2	4.53	7.55e-06	0.00155	0.26	0.21	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89392375~89412564:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-4.53	7.55e-06	0.00155	-0.19	-0.21	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
HNSC	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	4.53	7.55e-06	0.00155	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	4.53	7.55e-06	0.00155	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	4.53	7.55e-06	0.00155	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	4.53	7.55e-06	0.00155	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
HNSC	cis	rs8032939	0.533	rs60924694	ENSG00000259747.1	RP11-275I4.2	-4.53	7.55e-06	0.00155	-0.26	-0.21	Rheumatoid arthritis;	chr15:38614327	chr15:38671847~38689191:+
HNSC	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	4.53	7.56e-06	0.00155	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	4.53	7.56e-06	0.00155	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	4.53	7.56e-06	0.00155	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	4.53	7.56e-06	0.00155	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
HNSC	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	4.53	7.56e-06	0.00155	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
HNSC	cis	rs73222236	0.75	rs6439642	ENSG00000273486.1	RP11-731C17.2	4.53	7.56e-06	0.00155	0.17	0.21	Coronary artery disease;	chr3:136473965	chr3:136837338~136839021:-
HNSC	cis	rs4660214	0.666	rs61783383	ENSG00000182109.6	RP11-69E11.4	-4.53	7.56e-06	0.00155	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs6704246	ENSG00000182109.6	RP11-69E11.4	-4.53	7.56e-06	0.00155	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs597311	ENSG00000182109.6	RP11-69E11.4	4.53	7.56e-06	0.00155	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.615	rs597708	ENSG00000182109.6	RP11-69E11.4	4.53	7.56e-06	0.00155	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs636156	ENSG00000182109.6	RP11-69E11.4	4.53	7.56e-06	0.00155	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39522280~39546187:-
HNSC	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-4.53	7.56e-06	0.00155	-0.27	-0.21	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-4.53	7.56e-06	0.00155	-0.27	-0.21	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-4.53	7.56e-06	0.00155	-0.27	-0.21	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
HNSC	cis	rs2337406	1	rs17112416	ENSG00000280411.1	IGHV1-69-2	4.53	7.56e-06	0.00155	0.2	0.21	Alzheimer's disease (late onset);	chr14:106686773	chr14:106762092~106762588:-
HNSC	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	4.53	7.57e-06	0.00155	0.24	0.21	Height;	chr2:46636110	chr2:46668870~46670778:+
HNSC	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-4.53	7.57e-06	0.00155	-0.17	-0.21	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
HNSC	cis	rs1555322	0.818	rs2425021	ENSG00000126005.14	MMP24-AS1	-4.53	7.57e-06	0.00155	-0.36	-0.21	Attention deficit hyperactivity disorder;	chr20:35241975	chr20:35216462~35278131:-
HNSC	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	4.53	7.57e-06	0.00155	0.19	0.21	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
HNSC	cis	rs763121	0.853	rs2179142	ENSG00000273076.1	RP3-508I15.22	4.53	7.57e-06	0.00155	0.21	0.21	Menopause (age at onset);	chr22:38641949	chr22:38743495~38743910:+
HNSC	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-4.53	7.57e-06	0.00155	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
HNSC	cis	rs7662987	0.54	rs2851257	ENSG00000263923.1	RP11-571L19.7	-4.53	7.58e-06	0.00155	-0.22	-0.21	Smoking initiation;	chr4:99118348	chr4:98928897~98994994:+
HNSC	cis	rs3808502	0.549	rs7831039	ENSG00000269918.1	AF131215.9	-4.53	7.58e-06	0.00155	-0.2	-0.21	Neuroticism;	chr8:11570128	chr8:11104691~11106704:-
HNSC	cis	rs9611565	0.921	rs2143695	ENSG00000235513.1	RP4-756G23.5	4.53	7.58e-06	0.00155	0.22	0.21	Vitiligo;	chr22:41332616	chr22:41209122~41217627:-
HNSC	cis	rs7809950	0.678	rs7803151	ENSG00000238832.1	snoU109	-4.53	7.58e-06	0.00155	-0.3	-0.21	Coronary artery disease;	chr7:107293801	chr7:107603363~107603507:+
HNSC	cis	rs3811273	0.614	rs8020929	ENSG00000211816.2	TRAV38-1	-4.53	7.58e-06	0.00155	-0.22	-0.21	Periodontal disease-related phenotypes;	chr14:22267444	chr14:22271968~22272563:+
HNSC	cis	rs7429990	0.965	rs4858887	ENSG00000228638.1	FCF1P2	4.53	7.58e-06	0.00155	0.2	0.21	Educational attainment (years of education);	chr3:48050527	chr3:48290793~48291375:-
HNSC	cis	rs964611	0.938	rs7174051	ENSG00000259488.2	RP11-154J22.1	-4.53	7.59e-06	0.00156	-0.18	-0.21	Metabolite levels (Pyroglutamine);	chr15:48292131	chr15:48312353~48331856:-
HNSC	cis	rs1971762	0.527	rs7311902	ENSG00000270175.1	RP11-793H13.11	-4.53	7.59e-06	0.00156	-0.18	-0.21	Height;	chr12:53621452	chr12:53500162~53500936:-
HNSC	cis	rs1008375	0.966	rs4698638	ENSG00000249502.1	AC006160.5	-4.53	7.59e-06	0.00156	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631365	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs6818639	ENSG00000249502.1	AC006160.5	-4.53	7.59e-06	0.00156	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631426	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs3846357	ENSG00000249502.1	AC006160.5	-4.53	7.59e-06	0.00156	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17634264	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs1860599	ENSG00000249502.1	AC006160.5	-4.53	7.59e-06	0.00156	-0.22	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17637277	chr4:17587467~17614571:-
HNSC	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-4.53	7.6e-06	0.00156	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-4.53	7.6e-06	0.00156	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
HNSC	cis	rs7868228	1	rs7861868	ENSG00000240498.5	CDKN2B-AS1	-4.53	7.6e-06	0.00156	-0.27	-0.21	Gut microbiome composition (winter);	chr9:21671192	chr9:21994778~22121097:+
HNSC	cis	rs9840812	0.725	rs696517	ENSG00000273486.1	RP11-731C17.2	4.53	7.6e-06	0.00156	0.2	0.21	Fibrinogen levels;	chr3:136348813	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	4.53	7.6e-06	0.00156	0.24	0.21	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
HNSC	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	4.53	7.6e-06	0.00156	0.28	0.21	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
HNSC	cis	rs75422866	0.51	rs73105845	ENSG00000274902.1	RP1-197B17.4	4.53	7.6e-06	0.00156	0.47	0.21	Pneumonia;	chr12:47741824	chr12:47731908~47732351:+
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000250412.1	KLHL2P1	4.53	7.61e-06	0.00156	0.26	0.21	Corneal astigmatism;	chr4:119502780	chr4:119334329~119378233:+
HNSC	cis	rs36093844	0.54	rs7116742	ENSG00000279742.1	RP11-700A24.1	-4.53	7.61e-06	0.00156	-0.29	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85720712	chr11:85852557~85854943:-
HNSC	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-4.53	7.61e-06	0.00156	-0.31	-0.21	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
HNSC	cis	rs73198271	0.74	rs964771	ENSG00000233609.3	RP11-62H7.2	4.53	7.62e-06	0.00156	0.22	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8961200~8979025:+
HNSC	cis	rs761746	0.577	rs131245	ENSG00000236132.1	CTA-440B3.1	-4.53	7.62e-06	0.00156	-0.25	-0.21	Intelligence;	chr22:31730777	chr22:31816379~31817491:-
HNSC	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-4.53	7.62e-06	0.00156	-0.25	-0.21	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
HNSC	cis	rs2098713	0.569	rs13189481	ENSG00000250155.1	CTD-2353F22.1	-4.53	7.62e-06	0.00156	-0.22	-0.21	Telomere length;	chr5:37499415	chr5:36666214~36725195:-
HNSC	cis	rs4908769	0.624	rs2708632	ENSG00000232912.4	RP5-1115A15.1	-4.53	7.62e-06	0.00156	-0.23	-0.21	Allergy;	chr1:8404449	chr1:8424645~8434838:+
HNSC	cis	rs17407555	0.789	rs12648610	ENSG00000250413.1	RP11-448G15.1	4.53	7.62e-06	0.00156	0.28	0.21	Schizophrenia (age at onset);	chr4:10113188	chr4:10006482~10009725:+
HNSC	cis	rs1008375	1	rs3815414	ENSG00000249502.1	AC006160.5	4.53	7.62e-06	0.00156	0.22	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17605036	chr4:17587467~17614571:-
HNSC	cis	rs36052053	0.521	rs71558353	ENSG00000203799.9	CCDC162P	4.53	7.63e-06	0.00156	0.37	0.21	Red cell distribution width;	chr6:109201315	chr6:109285485~109355063:+
HNSC	cis	rs9650657	0.617	rs7814795	ENSG00000255310.2	AF131215.2	-4.53	7.63e-06	0.00156	-0.19	-0.21	Neuroticism;	chr8:10661775	chr8:11107788~11109726:-
HNSC	cis	rs9311676	0.656	rs11917529	ENSG00000273493.1	RP11-80H18.4	4.53	7.63e-06	0.00156	0.22	0.21	Systemic lupus erythematosus;	chr3:58396431	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs3191903	ENSG00000273493.1	RP11-80H18.4	4.53	7.63e-06	0.00156	0.22	0.21	Systemic lupus erythematosus;	chr3:58397119	chr3:58329965~58330118:+
HNSC	cis	rs7015630	0.618	rs28405481	ENSG00000251136.7	RP11-37B2.1	-4.53	7.63e-06	0.00156	-0.23	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89807501	chr8:89609409~89757727:-
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000254153.1	CTA-398F10.2	-4.53	7.63e-06	0.00156	-0.23	-0.21	Mood instability;	chr8:8938391	chr8:8456909~8461337:-
HNSC	cis	rs9863	0.861	rs75321546	ENSG00000269938.1	RP11-214K3.20	-4.53	7.63e-06	0.00156	-0.24	-0.2	White blood cell count;	chr12:123962918	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs55990776	ENSG00000269938.1	RP11-214K3.20	-4.53	7.63e-06	0.00156	-0.24	-0.2	White blood cell count;	chr12:123962919	chr12:123968023~123968579:-
HNSC	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-4.53	7.63e-06	0.00156	-0.2	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000255495.1	AC145124.2	4.53	7.64e-06	0.00156	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12194467~12196280:+
HNSC	cis	rs11098499	0.954	rs6820115	ENSG00000249244.1	RP11-548H18.2	4.53	7.64e-06	0.00157	0.24	0.2	Corneal astigmatism;	chr4:119477027	chr4:119391831~119395335:-
HNSC	cis	rs2548724	0.593	rs1597768	ENSG00000250682.4	LINC00491	4.53	7.64e-06	0.00157	0.26	0.2	Type 2 diabetes;	chr5:102321151	chr5:102609156~102671559:-
HNSC	cis	rs4218	0.734	rs12912071	ENSG00000277144.1	RP11-59H7.4	-4.53	7.65e-06	0.00157	-0.25	-0.2	Social communication problems;	chr15:59150951	chr15:59115547~59116089:-
HNSC	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-4.53	7.65e-06	0.00157	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	4.53	7.65e-06	0.00157	0.17	0.2	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
HNSC	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-4.53	7.65e-06	0.00157	-0.48	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
HNSC	cis	rs2337406	1	rs17095456	ENSG00000280411.1	IGHV1-69-2	-4.53	7.65e-06	0.00157	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106676559	chr14:106762092~106762588:-
HNSC	cis	rs4660214	0.666	rs950805	ENSG00000182109.6	RP11-69E11.4	-4.53	7.66e-06	0.00157	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-4.53	7.66e-06	0.00157	-0.25	-0.2	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
HNSC	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	4.53	7.66e-06	0.00157	0.22	0.2	Myopia;	chr2:171827496	chr2:171773482~171775844:+
HNSC	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	4.53	7.67e-06	0.00157	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	4.53	7.67e-06	0.00157	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
HNSC	cis	rs3096299	0.933	rs3096297	ENSG00000261574.1	RP1-168P16.2	4.53	7.67e-06	0.00157	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89392375~89412564:-
HNSC	cis	rs73222236	0.825	rs9843801	ENSG00000273486.1	RP11-731C17.2	4.53	7.67e-06	0.00157	0.17	0.2	Coronary artery disease;	chr3:136281904	chr3:136837338~136839021:-
HNSC	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	4.53	7.67e-06	0.00157	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	4.53	7.67e-06	0.00157	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
HNSC	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	4.52	7.67e-06	0.00157	0.29	0.2	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
HNSC	cis	rs6586111	1	rs7071690	ENSG00000226659.1	RP11-137H2.4	-4.52	7.67e-06	0.00157	-0.24	-0.2	Capecitabine sensitivity;	chr10:80616261	chr10:80529597~80535942:-
HNSC	cis	rs12745968	0.623	rs6680578	ENSG00000223787.2	RP4-593M8.1	-4.52	7.67e-06	0.00157	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92711321	chr1:92580476~92580821:-
HNSC	cis	rs442309	1	rs224052	ENSG00000238280.1	RP11-436D10.3	-4.52	7.68e-06	0.00157	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62734414	chr10:62793562~62805887:-
HNSC	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	4.52	7.68e-06	0.00157	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
HNSC	cis	rs17253792	0.822	rs75509578	ENSG00000186615.9	KTN1-AS1	-4.52	7.68e-06	0.00157	-0.38	-0.2	Putamen volume;	chr14:55666775	chr14:55499278~55580110:-
HNSC	cis	rs4388249	1	rs17162341	ENSG00000271849.1	CTC-332L22.1	-4.52	7.68e-06	0.00157	-0.32	-0.2	Schizophrenia;	chr5:109845686	chr5:109687802~109688329:-
HNSC	cis	rs3811273	0.614	rs4982598	ENSG00000211816.2	TRAV38-1	-4.52	7.68e-06	0.00157	-0.22	-0.2	Periodontal disease-related phenotypes;	chr14:22267740	chr14:22271968~22272563:+
HNSC	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-4.52	7.69e-06	0.00157	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
HNSC	cis	rs7121616	0.576	rs7948948	ENSG00000200879.1	SNORD14E	4.52	7.69e-06	0.00157	0.29	0.2	Breast cancer;	chr11:123057467	chr11:123058077~123058161:-
HNSC	cis	rs7824557	0.767	rs10104728	ENSG00000269918.1	AF131215.9	4.52	7.7e-06	0.00158	0.2	0.2	Retinal vascular caliber;	chr8:11313791	chr8:11104691~11106704:-
HNSC	cis	rs7615952	0.512	rs1077621	ENSG00000241439.1	RP11-666A20.3	4.52	7.7e-06	0.00158	0.24	0.2	Blood pressure (smoking interaction);	chr3:126100956	chr3:125958556~125958817:+
HNSC	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	4.52	7.7e-06	0.00158	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
HNSC	cis	rs933688	1	rs35712350	ENSG00000281357.1	ARRDC3-AS1	4.52	7.7e-06	0.00158	0.3	0.2	Smoking behavior;	chr5:91383702	chr5:91380349~91439085:+
HNSC	cis	rs6601327	0.54	rs12542912	ENSG00000254340.1	RP11-10A14.3	-4.52	7.7e-06	0.00158	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9727686	chr8:9141424~9145435:+
HNSC	cis	rs6601327	0.641	rs7014663	ENSG00000254340.1	RP11-10A14.3	-4.52	7.7e-06	0.00158	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9729765	chr8:9141424~9145435:+
HNSC	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	4.52	7.7e-06	0.00158	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	4.52	7.7e-06	0.00158	0.25	0.2	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-4.52	7.71e-06	0.00158	-0.27	-0.2	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	4.52	7.71e-06	0.00158	0.27	0.2	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
HNSC	cis	rs755249	0.53	rs1472662	ENSG00000228060.1	RP11-69E11.8	-4.52	7.71e-06	0.00158	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39565160~39573203:+
HNSC	cis	rs442309	1	rs224057	ENSG00000238280.1	RP11-436D10.3	-4.52	7.71e-06	0.00158	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62738008	chr10:62793562~62805887:-
HNSC	cis	rs36052053	0.521	rs71558357	ENSG00000203799.9	CCDC162P	4.52	7.71e-06	0.00158	0.38	0.2	Red cell distribution width;	chr6:109238166	chr6:109285485~109355063:+
HNSC	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-4.52	7.71e-06	0.00158	-0.24	-0.2	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
HNSC	cis	rs4819052	0.851	rs10470246	ENSG00000223768.1	LINC00205	-4.52	7.72e-06	0.00158	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs10470247	ENSG00000223768.1	LINC00205	-4.52	7.72e-06	0.00158	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4819043	ENSG00000223768.1	LINC00205	-4.52	7.72e-06	0.00158	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs4819044	ENSG00000223768.1	LINC00205	-4.52	7.72e-06	0.00158	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45293285~45297354:+
HNSC	cis	rs172166	0.516	rs2622322	ENSG00000219392.1	RP1-265C24.5	-4.52	7.72e-06	0.00158	-0.23	-0.2	Cardiac Troponin-T levels;	chr6:28149665	chr6:28115628~28116551:+
HNSC	cis	rs6928977	0.863	rs6918097	ENSG00000231028.7	LINC00271	4.52	7.72e-06	0.00158	0.24	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135314411	chr6:135497801~135716055:+
HNSC	cis	rs7615952	0.515	rs7637246	ENSG00000241288.6	RP11-379B18.5	-4.52	7.73e-06	0.00158	-0.28	-0.2	Blood pressure (smoking interaction);	chr3:125959863	chr3:125827238~125916384:-
HNSC	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-4.52	7.73e-06	0.00158	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
HNSC	cis	rs8054556	0.647	rs4788211	ENSG00000183604.13	SMG1P5	-4.52	7.73e-06	0.00158	-0.2	-0.2	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:30267553~30335374:-
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000254153.1	CTA-398F10.2	-4.52	7.73e-06	0.00158	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9018719	chr8:8456909~8461337:-
HNSC	cis	rs67311347	1	rs11129876	ENSG00000280739.1	EIF1B-AS1	-4.52	7.74e-06	0.00158	-0.22	-0.2	Renal cell carcinoma;	chr3:40360145	chr3:40173145~40309698:-
HNSC	cis	rs12682352	0.652	rs1567398	ENSG00000254153.1	CTA-398F10.2	-4.52	7.74e-06	0.00158	-0.22	-0.2	Neuroticism;	chr8:8869294	chr8:8456909~8461337:-
HNSC	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	4.52	7.75e-06	0.00158	0.23	0.2	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	4.52	7.75e-06	0.00158	0.23	0.2	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
HNSC	cis	rs4787491	0.729	rs11150584	ENSG00000183604.13	SMG1P5	-4.52	7.75e-06	0.00158	-0.2	-0.2	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30267553~30335374:-
HNSC	cis	rs5758511	0.633	rs5758689	ENSG00000205702.9	CYP2D7	4.52	7.75e-06	0.00158	0.19	0.2	Birth weight;	chr22:42268966	chr22:42140203~42144577:-
HNSC	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-4.52	7.75e-06	0.00158	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
HNSC	cis	rs6558530	0.666	rs6558520	ENSG00000253982.1	CTD-2336O2.1	4.52	7.75e-06	0.00159	0.26	0.2	Systolic blood pressure;	chr8:1749407	chr8:1761990~1764502:-
HNSC	cis	rs875971	0.651	rs313829	ENSG00000272831.1	RP11-792A8.4	-4.52	7.76e-06	0.00159	-0.2	-0.2	Aortic root size;	chr7:66087510	chr7:66739829~66740385:-
HNSC	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-4.52	7.76e-06	0.00159	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
HNSC	cis	rs12893668	0.644	rs12890820	ENSG00000269940.1	RP11-73M18.7	4.52	7.77e-06	0.00159	0.2	0.2	Reticulocyte count;	chr14:103568512	chr14:103694560~103695170:+
HNSC	cis	rs72843506	0.656	rs73984573	ENSG00000261033.1	RP11-209D14.2	4.52	7.77e-06	0.00159	0.33	0.2	Schizophrenia;	chr17:20082027	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs78408002	ENSG00000261033.1	RP11-209D14.2	4.52	7.77e-06	0.00159	0.33	0.2	Schizophrenia;	chr17:20082601	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs7210439	ENSG00000261033.1	RP11-209D14.2	4.52	7.77e-06	0.00159	0.33	0.2	Schizophrenia;	chr17:20082728	chr17:20008051~20009234:-
HNSC	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-4.52	7.77e-06	0.00159	-0.3	-0.2	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
HNSC	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	4.52	7.77e-06	0.00159	0.24	0.2	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	4.52	7.77e-06	0.00159	0.24	0.2	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000254153.1	CTA-398F10.2	-4.52	7.77e-06	0.00159	-0.22	-0.2	Joint mobility (Beighton score);	chr8:9226261	chr8:8456909~8461337:-
HNSC	cis	rs2548724	0.796	rs62369303	ENSG00000250682.4	LINC00491	4.52	7.78e-06	0.00159	0.27	0.2	Type 2 diabetes;	chr5:102375604	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.796	rs7733501	ENSG00000250682.4	LINC00491	4.52	7.78e-06	0.00159	0.27	0.2	Type 2 diabetes;	chr5:102376295	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.736	rs35392635	ENSG00000255310.2	AF131215.2	4.52	7.78e-06	0.00159	0.2	0.2	Retinal vascular caliber;	chr8:11306840	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.767	rs11775635	ENSG00000255310.2	AF131215.2	4.52	7.78e-06	0.00159	0.2	0.2	Retinal vascular caliber;	chr8:11307356	chr8:11107788~11109726:-
HNSC	cis	rs9863	0.861	rs4930726	ENSG00000269938.1	RP11-214K3.20	-4.52	7.78e-06	0.00159	-0.23	-0.2	White blood cell count;	chr12:123943784	chr12:123968023~123968579:-
HNSC	cis	rs1185460	0.967	rs1784460	ENSG00000272186.1	RP11-110I1.13	4.52	7.78e-06	0.00159	0.23	0.2	Coronary artery disease;	chr11:119067660	chr11:119067374~119067698:-
HNSC	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	4.52	7.79e-06	0.00159	0.18	0.2	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
HNSC	cis	rs4144743	0.528	rs16941802	ENSG00000228782.6	CTD-2026D20.3	4.52	7.79e-06	0.00159	0.3	0.2	Body mass index;	chr17:47277987	chr17:47450568~47492492:-
HNSC	cis	rs11722228	0.521	rs62288520	ENSG00000250413.1	RP11-448G15.1	-4.52	7.8e-06	0.00159	-0.32	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10006482~10009725:+
HNSC	cis	rs6964587	1	rs6465343	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.8e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:91988894	chr7:92134604~92180725:+
HNSC	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-4.52	7.8e-06	0.00159	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
HNSC	cis	rs9300255	0.722	rs12304248	ENSG00000280120.1	RP11-546D6.3	-4.52	7.8e-06	0.00159	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123325878	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.664	rs12316131	ENSG00000280120.1	RP11-546D6.3	-4.52	7.8e-06	0.00159	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123333249	chr12:123152324~123153377:-
HNSC	cis	rs12935418	0.672	rs2602423	ENSG00000278985.1	RP11-303E16.9	-4.52	7.8e-06	0.00159	-0.2	-0.2	Mean corpuscular volume;	chr16:81008423	chr16:80982319~80984094:-
HNSC	cis	rs11893307	0.509	rs2356126	ENSG00000235852.1	AC005540.3	4.52	7.8e-06	0.00159	0.26	0.2	Mean platelet volume;	chr2:190677788	chr2:190880797~190882059:-
HNSC	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-4.52	7.8e-06	0.00159	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
HNSC	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	4.52	7.8e-06	0.00159	0.19	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
HNSC	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	4.52	7.81e-06	0.00159	0.22	0.2	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
HNSC	cis	rs3808502	0.525	rs9650661	ENSG00000269918.1	AF131215.9	-4.52	7.81e-06	0.00159	-0.2	-0.2	Neuroticism;	chr8:11569624	chr8:11104691~11106704:-
HNSC	cis	rs35417517	1	rs35417517	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.81e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:92143417	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs6974827	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.81e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:92143631	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.9	rs6465352	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.81e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:92145803	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs6973896	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.81e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:92149151	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs1978061	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.81e-06	0.00159	-0.22	-0.2	Breast cancer;	chr7:92149928	chr7:92134604~92180725:+
HNSC	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-4.52	7.81e-06	0.0016	-0.24	-0.2	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
HNSC	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-4.52	7.81e-06	0.0016	-0.27	-0.2	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
HNSC	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-4.52	7.81e-06	0.0016	-0.26	-0.2	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	4.52	7.81e-06	0.0016	0.12	0.2	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
HNSC	cis	rs67981189	0.766	rs2526852	ENSG00000274818.1	RP1-292L20.3	-4.52	7.81e-06	0.0016	-0.24	-0.2	Schizophrenia;	chr14:70949450	chr14:70906657~70907111:-
HNSC	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	4.52	7.81e-06	0.0016	0.2	0.2	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000241278.1	ENPP7P4	-4.52	7.82e-06	0.0016	-0.3	-0.2	Blood pressure (smoking interaction);	chr3:125880231	chr3:125848223~125909372:+
HNSC	cis	rs11098499	0.913	rs11098496	ENSG00000250412.1	KLHL2P1	4.52	7.82e-06	0.0016	0.26	0.2	Corneal astigmatism;	chr4:119246311	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs35197422	ENSG00000250412.1	KLHL2P1	4.52	7.82e-06	0.0016	0.26	0.2	Corneal astigmatism;	chr4:119248159	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs1511015	ENSG00000250412.1	KLHL2P1	4.52	7.82e-06	0.0016	0.26	0.2	Corneal astigmatism;	chr4:119249318	chr4:119334329~119378233:+
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000254340.1	RP11-10A14.3	4.52	7.82e-06	0.0016	0.25	0.2	Mood instability;	chr8:8527137	chr8:9141424~9145435:+
HNSC	cis	rs79057730	0.527	rs34519158	ENSG00000225146.1	AC073957.15	4.52	7.82e-06	0.0016	0.33	0.2	Initial pursuit acceleration;	chr7:771477	chr7:1029025~1043891:+
HNSC	cis	rs79057730	0.599	rs34411410	ENSG00000225146.1	AC073957.15	4.52	7.82e-06	0.0016	0.33	0.2	Initial pursuit acceleration;	chr7:772084	chr7:1029025~1043891:+
HNSC	cis	rs17253792	0.822	rs76918910	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55592044	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77599953	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55592187	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10137364	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55593269	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs17683728	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55593671	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76264681	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55593729	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs17746033	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55595119	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs8009608	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55595872	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76201070	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55596886	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10150498	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55597406	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10133962	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55599370	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10083499	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55599872	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75437558	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55600080	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75232282	ENSG00000186615.9	KTN1-AS1	-4.52	7.82e-06	0.0016	-0.38	-0.2	Putamen volume;	chr14:55600572	chr14:55499278~55580110:-
HNSC	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-4.52	7.82e-06	0.0016	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-4.52	7.82e-06	0.0016	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-4.52	7.82e-06	0.0016	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	4.52	7.82e-06	0.0016	0.25	0.2	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000255495.1	AC145124.2	4.52	7.83e-06	0.0016	0.23	0.2	Myopia (pathological);	chr8:11929423	chr8:12194467~12196280:+
HNSC	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-4.52	7.83e-06	0.0016	-0.17	-0.2	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-4.52	7.83e-06	0.0016	-0.17	-0.2	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
HNSC	cis	rs9311676	0.656	rs56028017	ENSG00000273493.1	RP11-80H18.4	4.52	7.84e-06	0.0016	0.22	0.2	Systemic lupus erythematosus;	chr3:58386781	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs12495490	ENSG00000273493.1	RP11-80H18.4	4.52	7.84e-06	0.0016	0.22	0.2	Systemic lupus erythematosus;	chr3:58387524	chr3:58329965~58330118:+
HNSC	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-4.52	7.84e-06	0.0016	-0.28	-0.2	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
HNSC	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-4.52	7.84e-06	0.0016	-0.27	-0.2	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
HNSC	cis	rs4713118	0.619	rs200486	ENSG00000219392.1	RP1-265C24.5	-4.52	7.84e-06	0.0016	-0.28	-0.2	Parkinson's disease;	chr6:27811728	chr6:28115628~28116551:+
HNSC	cis	rs2548724	0.588	rs62369341	ENSG00000250682.4	LINC00491	4.52	7.84e-06	0.0016	0.26	0.2	Type 2 diabetes;	chr5:102402034	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.588	rs62369342	ENSG00000250682.4	LINC00491	4.52	7.84e-06	0.0016	0.26	0.2	Type 2 diabetes;	chr5:102402190	chr5:102609156~102671559:-
HNSC	cis	rs853679	0.607	rs34765154	ENSG00000219392.1	RP1-265C24.5	-4.52	7.84e-06	0.0016	-0.44	-0.2	Depression;	chr6:28162672	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.556	rs67297533	ENSG00000219392.1	RP1-265C24.5	-4.52	7.84e-06	0.0016	-0.44	-0.2	Depression;	chr6:28173475	chr6:28115628~28116551:+
HNSC	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-4.52	7.85e-06	0.0016	-0.27	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
HNSC	cis	rs79349575	0.716	rs46522	ENSG00000270781.1	RP11-501C14.9	-4.52	7.85e-06	0.0016	-0.22	-0.2	Type 2 diabetes;	chr17:48911235	chr17:48899131~48899748:+
HNSC	cis	rs11893307	0.509	rs17465200	ENSG00000235852.1	AC005540.3	4.52	7.85e-06	0.0016	0.26	0.2	Mean platelet volume;	chr2:190684910	chr2:190880797~190882059:-
HNSC	cis	rs12745968	0.589	rs12025792	ENSG00000223787.2	RP4-593M8.1	-4.52	7.85e-06	0.0016	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92641851	chr1:92580476~92580821:-
HNSC	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-4.52	7.85e-06	0.0016	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
HNSC	cis	rs6493858	0.839	rs2460650	ENSG00000277245.1	RP11-48G14.3	-4.52	7.85e-06	0.0016	-0.24	-0.2	Relative hand skill in reading disability;	chr15:56255278	chr15:56447120~56447697:+
HNSC	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	4.52	7.85e-06	0.0016	0.29	0.2	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
HNSC	cis	rs9914988	0.613	rs7214938	ENSG00000264577.1	AC010761.8	4.52	7.85e-06	0.0016	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28953208	chr17:28721487~28722877:-
HNSC	cis	rs9914988	0.613	rs7214943	ENSG00000264577.1	AC010761.8	4.52	7.85e-06	0.0016	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28953210	chr17:28721487~28722877:-
HNSC	cis	rs9311676	0.656	rs11918201	ENSG00000273493.1	RP11-80H18.4	4.52	7.86e-06	0.0016	0.22	0.2	Systemic lupus erythematosus;	chr3:58402050	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs55913214	ENSG00000273493.1	RP11-80H18.4	4.52	7.86e-06	0.0016	0.22	0.2	Systemic lupus erythematosus;	chr3:58402299	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs55668308	ENSG00000273493.1	RP11-80H18.4	4.52	7.86e-06	0.0016	0.22	0.2	Systemic lupus erythematosus;	chr3:58402726	chr3:58329965~58330118:+
HNSC	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
HNSC	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-4.52	7.86e-06	0.0016	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
HNSC	cis	rs73198271	0.813	rs17697237	ENSG00000173295.6	FAM86B3P	4.52	7.86e-06	0.0016	0.26	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8228595~8244865:+
HNSC	cis	rs16858210	0.874	rs10937153	ENSG00000234371.6	RPSAP31	-4.52	7.86e-06	0.0016	-0.24	-0.2	Menopause (age at onset);	chr3:183845137	chr3:183884924~183888449:+
HNSC	cis	rs4356203	0.543	rs214093	ENSG00000272034.1	SNORD14A	-4.52	7.86e-06	0.0016	-0.16	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17074654~17074744:-
HNSC	cis	rs1198872	0.892	rs1198865	ENSG00000272275.1	RP11-791G15.2	-4.52	7.86e-06	0.0016	-0.24	-0.2	Cardiac Troponin-T levels;	chr2:10760936	chr2:10767875~10770058:-
HNSC	cis	rs72843506	1	rs72843506	ENSG00000261033.1	RP11-209D14.2	4.52	7.87e-06	0.0016	0.3	0.2	Schizophrenia;	chr17:20042974	chr17:20008051~20009234:-
HNSC	cis	rs853679	0.607	rs34662244	ENSG00000204709.4	LINC01556	4.52	7.87e-06	0.00161	0.44	0.2	Depression;	chr6:28106103	chr6:28943877~28944537:+
HNSC	cis	rs35952432	1	rs35952432	ENSG00000204709.4	LINC01556	4.52	7.87e-06	0.00161	0.44	0.2	Lung cancer;	chr6:28107123	chr6:28943877~28944537:+
HNSC	cis	rs9393777	0.92	rs35768595	ENSG00000219392.1	RP1-265C24.5	-4.52	7.88e-06	0.00161	-0.43	-0.2	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28115628~28116551:+
HNSC	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	4.52	7.88e-06	0.00161	0.26	0.2	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
HNSC	cis	rs7819412	0.595	rs4841500	ENSG00000255310.2	AF131215.2	-4.52	7.88e-06	0.00161	-0.2	-0.2	Triglycerides;	chr8:11130765	chr8:11107788~11109726:-
HNSC	cis	rs4523957	0.855	rs7217226	ENSG00000262333.1	HNRNPA1P16	4.52	7.88e-06	0.00161	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2232771	chr17:2306761~2307715:+
HNSC	cis	rs8077577	0.895	rs62073615	ENSG00000273018.4	CTD-2303H24.2	-4.52	7.89e-06	0.00161	-0.31	-0.2	Obesity-related traits;	chr17:18177015	chr17:18511221~18551705:-
HNSC	cis	rs5758511	0.68	rs5758692	ENSG00000226450.2	CYP2D8P	4.52	7.89e-06	0.00161	0.2	0.2	Birth weight;	chr22:42273023	chr22:42149886~42155001:-
HNSC	cis	rs155076	1	rs9509638	ENSG00000233325.3	MIPEPP3	4.52	7.89e-06	0.00161	0.36	0.2	White matter hyperintensity burden;	chr13:21286054	chr13:21298139~21306373:+
HNSC	cis	rs11098499	0.866	rs11098506	ENSG00000249244.1	RP11-548H18.2	4.52	7.89e-06	0.00161	0.25	0.2	Corneal astigmatism;	chr4:119363816	chr4:119391831~119395335:-
HNSC	cis	rs5758511	0.689	rs5758691	ENSG00000226450.2	CYP2D8P	4.52	7.89e-06	0.00161	0.2	0.2	Birth weight;	chr22:42272498	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs1001586	ENSG00000226450.2	CYP2D8P	4.52	7.89e-06	0.00161	0.2	0.2	Birth weight;	chr22:42274287	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.68	rs739147	ENSG00000226450.2	CYP2D8P	4.52	7.89e-06	0.00161	0.2	0.2	Birth weight;	chr22:42275060	chr22:42149886~42155001:-
HNSC	cis	rs9990333	0.544	rs112577972	ENSG00000231464.1	AC024937.4	4.52	7.89e-06	0.00161	0.22	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195996738~195998233:+
HNSC	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-4.52	7.89e-06	0.00161	-0.24	-0.2	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
HNSC	cis	rs9788333	0.962	rs34853044	ENSG00000236953.1	ZDHHC20-IT1	-4.52	7.9e-06	0.00161	-0.23	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21309645	chr13:21376977~21377874:-
HNSC	cis	rs1008375	0.902	rs12503164	ENSG00000249502.1	AC006160.5	-4.52	7.9e-06	0.00161	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654484	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698198	ENSG00000249502.1	AC006160.5	-4.52	7.9e-06	0.00161	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654913	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698199	ENSG00000249502.1	AC006160.5	-4.52	7.9e-06	0.00161	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17655115	chr4:17587467~17614571:-
HNSC	cis	rs10791097	0.694	rs4936123	ENSG00000254842.5	RP11-890B15.2	-4.52	7.9e-06	0.00161	-0.18	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130871072	chr11:130844191~130865561:-
HNSC	cis	rs3736485	0.966	rs12440990	ENSG00000259438.1	CTD-2650P22.1	4.52	7.9e-06	0.00161	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51610062	chr15:52010999~52019095:-
HNSC	cis	rs721917	0.586	rs2758550	ENSG00000225484.5	NUTM2B-AS1	-4.52	7.9e-06	0.00161	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79663088~79826594:-
HNSC	cis	rs5758659	0.594	rs739292	ENSG00000227370.1	RP4-669P10.19	-4.52	7.91e-06	0.00161	-0.2	-0.2	Cognitive function;	chr22:41972853	chr22:42132543~42132998:+
HNSC	cis	rs73222236	0.857	rs16843991	ENSG00000273486.1	RP11-731C17.2	4.52	7.91e-06	0.00161	0.17	0.2	Coronary artery disease;	chr3:136477186	chr3:136837338~136839021:-
HNSC	cis	rs3758785	0.623	rs77241189	ENSG00000255893.1	RP11-685N10.1	-4.52	7.91e-06	0.00161	-0.29	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410151	chr11:94472908~94473570:-
HNSC	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-4.52	7.91e-06	0.00161	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
HNSC	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	4.52	7.91e-06	0.00161	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	4.52	7.91e-06	0.00161	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
HNSC	cis	rs7809950	0.723	rs62483634	ENSG00000238832.1	snoU109	-4.52	7.91e-06	0.00161	-0.28	-0.2	Coronary artery disease;	chr7:107238071	chr7:107603363~107603507:+
HNSC	cis	rs6964587	0.773	rs10488514	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.91e-06	0.00161	-0.22	-0.2	Breast cancer;	chr7:92322528	chr7:92134604~92180725:+
HNSC	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	4.52	7.91e-06	0.00161	0.29	0.2	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	4.52	7.91e-06	0.00161	0.29	0.2	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
HNSC	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.52	7.91e-06	0.00161	0.19	0.2	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.52	7.91e-06	0.00161	0.19	0.2	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.52	7.91e-06	0.00161	0.19	0.2	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.52	7.91e-06	0.00161	0.19	0.2	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.52	7.91e-06	0.00161	0.19	0.2	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
HNSC	cis	rs9311676	0.632	rs4130877	ENSG00000273493.1	RP11-80H18.4	4.52	7.92e-06	0.00161	0.22	0.2	Systemic lupus erythematosus;	chr3:58389166	chr3:58329965~58330118:+
HNSC	cis	rs2286503	0.752	rs6461669	ENSG00000226329.2	AC005682.6	4.52	7.92e-06	0.00161	0.26	0.2	Fibrinogen;	chr7:22818447	chr7:22863874~22881350:-
HNSC	cis	rs4356203	0.875	rs11024136	ENSG00000272034.1	SNORD14A	-4.52	7.92e-06	0.00161	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17074654~17074744:-
HNSC	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	4.52	7.92e-06	0.00161	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
HNSC	cis	rs7121616	0.576	rs1064585	ENSG00000200879.1	SNORD14E	4.52	7.92e-06	0.00161	0.28	0.2	Breast cancer;	chr11:123058699	chr11:123058077~123058161:-
HNSC	cis	rs1799949	0.896	rs33933393	ENSG00000236383.6	LINC00854	-4.52	7.92e-06	0.00161	-0.19	-0.2	Menopause (age at onset);	chr17:43165415	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs33946455	ENSG00000236383.6	LINC00854	-4.52	7.92e-06	0.00161	-0.19	-0.2	Menopause (age at onset);	chr17:43169829	chr17:43216941~43305976:-
HNSC	cis	rs9914266	1	rs9914266	ENSG00000262333.1	HNRNPA1P16	4.52	7.92e-06	0.00161	0.16	0.2	Myocardial infarction;	chr17:2229956	chr17:2306761~2307715:+
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	4.52	7.93e-06	0.00162	0.33	0.2	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000273009.1	RP11-352G9.1	4.52	7.93e-06	0.00162	0.24	0.2	Pancreatic cancer;	chr3:196024759	chr3:195913078~195913683:-
HNSC	cis	rs3811273	0.614	rs7152167	ENSG00000211816.2	TRAV38-1	-4.52	7.93e-06	0.00162	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22266254	chr14:22271968~22272563:+
HNSC	cis	rs3808502	0.563	rs12549144	ENSG00000269918.1	AF131215.9	4.52	7.93e-06	0.00162	0.2	0.2	Neuroticism;	chr8:11565352	chr8:11104691~11106704:-
HNSC	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	4.52	7.93e-06	0.00162	0.27	0.2	Pain;	chr19:21560061	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	4.52	7.93e-06	0.00162	0.27	0.2	Pain;	chr19:21563578	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	4.52	7.93e-06	0.00162	0.27	0.2	Pain;	chr19:21567257	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	4.52	7.93e-06	0.00162	0.27	0.2	Pain;	chr19:21567449	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	4.52	7.93e-06	0.00162	0.27	0.2	Pain;	chr19:21567846	chr19:21554640~21569237:-
HNSC	cis	rs7824557	0.767	rs7837036	ENSG00000255310.2	AF131215.2	4.52	7.93e-06	0.00162	0.19	0.2	Retinal vascular caliber;	chr8:11317980	chr8:11107788~11109726:-
HNSC	cis	rs9880211	1	rs9883189	ENSG00000273486.1	RP11-731C17.2	4.52	7.93e-06	0.00162	0.19	0.2	Height;Body mass index;	chr3:136570624	chr3:136837338~136839021:-
HNSC	cis	rs9880211	1	rs28641809	ENSG00000273486.1	RP11-731C17.2	4.52	7.93e-06	0.00162	0.19	0.2	Height;Body mass index;	chr3:136571647	chr3:136837338~136839021:-
HNSC	cis	rs853679	0.546	rs13214023	ENSG00000204709.4	LINC01556	-4.52	7.94e-06	0.00162	-0.39	-0.2	Depression;	chr6:28364364	chr6:28943877~28944537:+
HNSC	cis	rs9880211	0.613	rs6799056	ENSG00000273486.1	RP11-731C17.2	4.52	7.94e-06	0.00162	0.18	0.2	Height;Body mass index;	chr3:136083508	chr3:136837338~136839021:-
HNSC	cis	rs1355223	0.583	rs1828298	ENSG00000271369.1	RP11-350D17.3	4.52	7.94e-06	0.00162	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848892	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.583	rs1396881	ENSG00000271369.1	RP11-350D17.3	4.52	7.94e-06	0.00162	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848959	chr11:34709600~34710161:+
HNSC	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	4.52	7.94e-06	0.00162	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000254174.1	IGHV1-12	4.52	7.95e-06	0.00162	0.16	0.2	Rheumatic heart disease;	chr14:106631568	chr14:106122420~106122709:-
HNSC	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	4.52	7.95e-06	0.00162	0.32	0.2	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
HNSC	cis	rs61542988	0.57	rs62448268	ENSG00000221740.1	SNORD93	4.52	7.95e-06	0.00162	0.27	0.2	Fibrinogen levels;	chr7:22789845	chr7:22856613~22856686:+
HNSC	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	4.52	7.95e-06	0.00162	0.26	0.2	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	4.52	7.95e-06	0.00162	0.26	0.2	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
HNSC	cis	rs2835345	0.563	rs73204246	ENSG00000279365.1	KB-176G8.1	4.52	7.95e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452402	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs73204248	ENSG00000279365.1	KB-176G8.1	4.52	7.95e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452411	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs4481073	ENSG00000279365.1	KB-176G8.1	4.52	7.95e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452657	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs2835361	ENSG00000279365.1	KB-176G8.1	4.52	7.95e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452699	chr21:36485867~36487760:+
HNSC	cis	rs929354	0.742	rs7801905	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157147417	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.713	rs7798816	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157147880	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs3808317	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157151766	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.713	rs6946660	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157155954	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.713	rs6946947	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157156093	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.651	rs6951298	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157156455	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs62491945	ENSG00000224629.1	RP5-1142J19.2	-4.52	7.96e-06	0.00162	-0.2	-0.2	Body mass index;	chr7:157162886	chr7:157263022~157263229:-
HNSC	cis	rs4862750	0.872	rs10027252	ENSG00000250971.1	RP11-696F12.1	4.52	7.96e-06	0.00162	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186952308	chr4:187060099~187060930:+
HNSC	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-4.52	7.96e-06	0.00162	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
HNSC	cis	rs6964587	1	rs6967256	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.96e-06	0.00162	-0.21	-0.2	Breast cancer;	chr7:92013905	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.967	rs28594877	ENSG00000188693.7	CYP51A1-AS1	-4.52	7.96e-06	0.00162	-0.21	-0.2	Breast cancer;	chr7:92014756	chr7:92134604~92180725:+
HNSC	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-4.52	7.96e-06	0.00162	-0.32	-0.2	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
HNSC	cis	rs5758511	0.68	rs1107554	ENSG00000205702.9	CYP2D7	4.52	7.96e-06	0.00162	0.18	0.2	Birth weight;	chr22:42271588	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.564	rs11098507	ENSG00000249244.1	RP11-548H18.2	4.52	7.96e-06	0.00162	0.25	0.2	Corneal astigmatism;	chr4:119367131	chr4:119391831~119395335:-
HNSC	cis	rs12935418	0.672	rs2602424	ENSG00000278985.1	RP11-303E16.9	-4.52	7.96e-06	0.00162	-0.2	-0.2	Mean corpuscular volume;	chr16:81009600	chr16:80982319~80984094:-
HNSC	cis	rs7829975	0.577	rs79495969	ENSG00000173295.6	FAM86B3P	-4.52	7.97e-06	0.00162	-0.24	-0.2	Mood instability;	chr8:8687740	chr8:8228595~8244865:+
HNSC	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-4.52	7.97e-06	0.00162	-0.28	-0.2	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
HNSC	cis	rs2835345	0.563	rs74439245	ENSG00000279365.1	KB-176G8.1	4.52	7.97e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452322	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs76422022	ENSG00000279365.1	KB-176G8.1	4.52	7.97e-06	0.00162	0.24	0.2	Pulmonary function;	chr21:36452328	chr21:36485867~36487760:+
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000249244.1	RP11-548H18.2	4.52	7.97e-06	0.00162	0.25	0.2	Corneal astigmatism;	chr4:119359886	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000249244.1	RP11-548H18.2	4.52	7.97e-06	0.00162	0.25	0.2	Corneal astigmatism;	chr4:119359887	chr4:119391831~119395335:-
HNSC	cis	rs12600394	1	rs62059972	ENSG00000236088.8	COX10-AS1	4.52	7.97e-06	0.00162	0.3	0.2	Response to platinum-based chemotherapy (cisplatin);	chr17:14616319	chr17:13756478~14069495:-
HNSC	cis	rs1355223	0.583	rs2941057	ENSG00000271369.1	RP11-350D17.3	4.52	7.97e-06	0.00162	0.24	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34860673	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.552	rs2421743	ENSG00000271369.1	RP11-350D17.3	4.52	7.97e-06	0.00162	0.24	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34861293	chr11:34709600~34710161:+
HNSC	cis	rs6831352	0.918	rs2602893	ENSG00000263923.1	RP11-571L19.7	-4.52	7.98e-06	0.00162	-0.22	-0.2	Alcohol dependence;	chr4:99122944	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs2851251	ENSG00000263923.1	RP11-571L19.7	-4.52	7.98e-06	0.00162	-0.22	-0.2	Alcohol dependence;	chr4:99122960	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.838	rs2851250	ENSG00000263923.1	RP11-571L19.7	-4.52	7.98e-06	0.00162	-0.22	-0.2	Alcohol dependence;	chr4:99122962	chr4:98928897~98994994:+
HNSC	cis	rs3808502	0.503	rs34190028	ENSG00000269918.1	AF131215.9	-4.52	7.98e-06	0.00162	-0.2	-0.2	Neuroticism;	chr8:11559641	chr8:11104691~11106704:-
HNSC	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	4.52	7.98e-06	0.00163	0.18	0.2	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
HNSC	cis	rs3758785	0.512	rs7950328	ENSG00000255893.1	RP11-685N10.1	-4.52	7.99e-06	0.00163	-0.28	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94366449	chr11:94472908~94473570:-
HNSC	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	4.52	7.99e-06	0.00163	0.44	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	4.52	7.99e-06	0.00163	0.44	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000254153.1	CTA-398F10.2	-4.52	7.99e-06	0.00163	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9015783	chr8:8456909~8461337:-
HNSC	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-4.52	8e-06	0.00163	-0.22	-0.2	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
HNSC	cis	rs11098499	0.71	rs4145952	ENSG00000249244.1	RP11-548H18.2	4.52	8e-06	0.00163	0.24	0.2	Corneal astigmatism;	chr4:119234651	chr4:119391831~119395335:-
HNSC	cis	rs2548724	0.796	rs75119073	ENSG00000250682.4	LINC00491	4.52	8e-06	0.00163	0.27	0.2	Type 2 diabetes;	chr5:102377603	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.527	rs2572448	ENSG00000269918.1	AF131215.9	-4.52	8e-06	0.00163	-0.2	-0.2	Retinal vascular caliber;	chr8:11381843	chr8:11104691~11106704:-
HNSC	cis	rs4699052	0.826	rs17033498	ENSG00000246560.2	RP11-10L12.4	4.52	8e-06	0.00163	0.25	0.2	Testicular germ cell tumor;	chr4:103258804	chr4:102828055~102844075:+
HNSC	cis	rs10242455	0.702	rs17161700	ENSG00000078319.8	PMS2P1	-4.52	8e-06	0.00163	-0.43	-0.2	Blood metabolite levels;	chr7:99379444	chr7:100320992~100341908:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000211974.3	IGHV2-70	4.52	8e-06	0.00163	0.2	0.2	Kawasaki disease;	chr14:106805607	chr14:106723574~106724093:-
HNSC	cis	rs7621025	0.675	rs34602896	ENSG00000273486.1	RP11-731C17.2	-4.52	8.01e-06	0.00163	-0.19	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136837338~136839021:-
HNSC	cis	rs11250098	0.541	rs6997997	ENSG00000269918.1	AF131215.9	-4.52	8.01e-06	0.00163	-0.2	-0.2	Morning vs. evening chronotype;	chr8:10908572	chr8:11104691~11106704:-
HNSC	cis	rs7296418	0.883	rs1727312	ENSG00000280120.1	RP11-546D6.3	4.52	8.01e-06	0.00163	0.17	0.2	Platelet count;	chr12:123157673	chr12:123152324~123153377:-
HNSC	cis	rs2835345	0.563	rs12482257	ENSG00000279365.1	KB-176G8.1	4.52	8.02e-06	0.00163	0.24	0.2	Pulmonary function;	chr21:36451660	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12482140	ENSG00000279365.1	KB-176G8.1	4.52	8.02e-06	0.00163	0.24	0.2	Pulmonary function;	chr21:36451735	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.528	rs73204243	ENSG00000279365.1	KB-176G8.1	4.52	8.02e-06	0.00163	0.24	0.2	Pulmonary function;	chr21:36451776	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.595	rs78237434	ENSG00000279365.1	KB-176G8.1	4.52	8.02e-06	0.00163	0.24	0.2	Pulmonary function;	chr21:36451826	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs78113480	ENSG00000279365.1	KB-176G8.1	4.52	8.02e-06	0.00163	0.24	0.2	Pulmonary function;	chr21:36452022	chr21:36485867~36487760:+
HNSC	cis	rs7735319	0.834	rs34976989	ENSG00000250697.1	CTD-2066L21.3	4.52	8.02e-06	0.00163	0.26	0.2	Systolic blood pressure;	chr5:33070636	chr5:32925639~33297910:-
HNSC	cis	rs36052053	0.908	rs13199388	ENSG00000203799.9	CCDC162P	4.52	8.02e-06	0.00163	0.31	0.2	Red cell distribution width;	chr6:109262897	chr6:109285485~109355063:+
HNSC	cis	rs9321453	1	rs6937846	ENSG00000231971.4	RP11-557H15.3	4.52	8.02e-06	0.00163	0.25	0.2	Urate levels;	chr6:134454494	chr6:134428240~134520585:-
HNSC	cis	rs253959	0.629	rs10054121	ENSG00000271918.1	CTD-2287O16.5	4.52	8.02e-06	0.00163	0.17	0.2	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116083807~116085416:-
HNSC	cis	rs17253792	0.822	rs10083431	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55601630	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10083303	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55601803	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78820104	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55602136	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76055105	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55602409	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78386830	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55602506	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75115817	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55602819	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77990307	ENSG00000186615.9	KTN1-AS1	-4.52	8.02e-06	0.00163	-0.38	-0.2	Putamen volume;	chr14:55603331	chr14:55499278~55580110:-
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000267151.3	RP11-100E5.2	4.51	8.03e-06	0.00163	0.29	0.2	Menopause (age at onset);	chr17:43067543	chr17:43444707~43451200:+
HNSC	cis	rs6601327	0.641	rs11780399	ENSG00000254340.1	RP11-10A14.3	-4.51	8.03e-06	0.00163	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9731657	chr8:9141424~9145435:+
HNSC	cis	rs964184	1	rs964184	ENSG00000254851.1	RP11-109L13.1	-4.51	8.03e-06	0.00163	-0.37	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116778201	chr11:117135528~117138582:+
HNSC	cis	rs11846409	0.932	rs2583329	ENSG00000254174.1	IGHV1-12	-4.51	8.03e-06	0.00163	-0.16	-0.2	Rheumatic heart disease;	chr14:106632971	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.86	rs10150951	ENSG00000254174.1	IGHV1-12	4.51	8.03e-06	0.00163	0.16	0.2	Rheumatic heart disease;	chr14:106632988	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.86	rs17112419	ENSG00000254174.1	IGHV1-12	4.51	8.03e-06	0.00163	0.16	0.2	Rheumatic heart disease;	chr14:106633260	chr14:106122420~106122709:-
HNSC	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	4.51	8.04e-06	0.00163	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
HNSC	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	4.51	8.04e-06	0.00163	0.24	0.2	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
HNSC	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	4.51	8.04e-06	0.00163	0.24	0.2	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	4.51	8.04e-06	0.00163	0.24	0.2	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	4.51	8.04e-06	0.00163	0.24	0.2	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
HNSC	cis	rs8077577	0.895	rs16960990	ENSG00000273018.4	CTD-2303H24.2	-4.51	8.04e-06	0.00163	-0.3	-0.2	Obesity-related traits;	chr17:18205287	chr17:18511221~18551705:-
HNSC	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-4.51	8.04e-06	0.00163	-0.25	-0.2	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-4.51	8.04e-06	0.00163	-0.25	-0.2	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
HNSC	cis	rs9880211	0.948	rs9813691	ENSG00000273486.1	RP11-731C17.2	4.51	8.04e-06	0.00163	0.19	0.2	Height;Body mass index;	chr3:136541880	chr3:136837338~136839021:-
HNSC	cis	rs4938303	0.549	rs12291024	ENSG00000254851.1	RP11-109L13.1	4.51	8.04e-06	0.00163	0.31	0.2	Triglycerides;	chr11:116689951	chr11:117135528~117138582:+
HNSC	cis	rs11673344	0.523	rs2562599	ENSG00000276846.1	CTD-3220F14.3	-4.51	8.04e-06	0.00164	-0.22	-0.2	Obesity-related traits;	chr19:37025472	chr19:37314868~37315620:-
HNSC	cis	rs11722228	0.549	rs73212863	ENSG00000250413.1	RP11-448G15.1	-4.51	8.05e-06	0.00164	-0.32	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10006482~10009725:+
HNSC	cis	rs11722228	0.508	rs73212864	ENSG00000250413.1	RP11-448G15.1	-4.51	8.05e-06	0.00164	-0.32	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10006482~10009725:+
HNSC	cis	rs9368481	0.761	rs4358615	ENSG00000224843.5	LINC00240	-4.51	8.05e-06	0.00164	-0.2	-0.2	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26956992~27023924:+
HNSC	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	4.51	8.05e-06	0.00164	0.26	0.2	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	4.51	8.05e-06	0.00164	0.26	0.2	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
HNSC	cis	rs442309	0.967	rs224032	ENSG00000238280.1	RP11-436D10.3	-4.51	8.05e-06	0.00164	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62762069	chr10:62793562~62805887:-
HNSC	cis	rs4372836	0.897	rs6707130	ENSG00000226833.4	AC097724.3	4.51	8.06e-06	0.00164	0.25	0.2	Body mass index;	chr2:28750410	chr2:28708953~28736205:-
HNSC	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-4.51	8.06e-06	0.00164	-0.18	-0.2	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
HNSC	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	4.51	8.07e-06	0.00164	0.27	0.2	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
HNSC	cis	rs2337406	0.538	rs10141701	ENSG00000254174.1	IGHV1-12	4.51	8.07e-06	0.00164	0.15	0.2	Alzheimer's disease (late onset);	chr14:106633467	chr14:106122420~106122709:-
HNSC	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-4.51	8.07e-06	0.00164	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
HNSC	cis	rs116095464	0.558	rs10057492	ENSG00000250848.1	CTD-2083E4.5	-4.51	8.07e-06	0.00164	-0.29	-0.2	Breast cancer;	chr5:239388	chr5:288833~290321:-
HNSC	cis	rs6928977	0.66	rs12203875	ENSG00000217482.2	HMGB1P17	-4.51	8.07e-06	0.00164	-0.24	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135539276	chr6:135636086~135636713:-
HNSC	cis	rs1799949	1	rs3950989	ENSG00000236383.6	LINC00854	-4.51	8.07e-06	0.00164	-0.19	-0.2	Menopause (age at onset);	chr17:43085936	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs2070834	ENSG00000236383.6	LINC00854	-4.51	8.07e-06	0.00164	-0.19	-0.2	Menopause (age at onset);	chr17:43090268	chr17:43216941~43305976:-
HNSC	cis	rs7735319	0.834	rs13184103	ENSG00000249102.1	CTD-2066L21.1	4.51	8.08e-06	0.00164	0.25	0.2	Systolic blood pressure;	chr5:33061918	chr5:33008994~33025724:+
HNSC	cis	rs7824557	0.527	rs10109537	ENSG00000269918.1	AF131215.9	-4.51	8.08e-06	0.00164	-0.2	-0.2	Retinal vascular caliber;	chr8:11382131	chr8:11104691~11106704:-
HNSC	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-4.51	8.08e-06	0.00164	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
HNSC	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-4.51	8.08e-06	0.00164	-0.25	-0.2	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
HNSC	cis	rs202072	0.725	rs445590	ENSG00000215022.6	RP1-257A7.4	-4.51	8.09e-06	0.00164	-0.26	-0.2	HIV-1 viral setpoint;	chr6:13280632	chr6:13264861~13295586:-
HNSC	cis	rs202072	0.769	rs445591	ENSG00000215022.6	RP1-257A7.4	-4.51	8.09e-06	0.00164	-0.26	-0.2	HIV-1 viral setpoint;	chr6:13280634	chr6:13264861~13295586:-
HNSC	cis	rs3736485	0.966	rs11070854	ENSG00000259438.1	CTD-2650P22.1	4.51	8.09e-06	0.00164	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51516168	chr15:52010999~52019095:-
HNSC	cis	rs597539	0.652	rs553875	ENSG00000255741.1	RP11-757G1.5	-4.51	8.09e-06	0.00164	-0.29	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs627731	ENSG00000255741.1	RP11-757G1.5	-4.51	8.09e-06	0.00164	-0.29	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68941503~68942852:-
HNSC	cis	rs4761669	0.545	rs7136948	ENSG00000241556.1	RP11-490G8.1	-4.51	8.09e-06	0.00164	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94812100	chr12:95467397~95467861:-
HNSC	cis	rs4841134	0.679	rs958374	ENSG00000233609.3	RP11-62H7.2	4.51	8.09e-06	0.00164	0.2	0.2	Age-related disease endophenotypes;	chr8:9340151	chr8:8961200~8979025:+
HNSC	cis	rs3733585	0.699	rs1079128	ENSG00000250413.1	RP11-448G15.1	4.51	8.1e-06	0.00165	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9949597	chr4:10006482~10009725:+
HNSC	cis	rs12935418	0.672	rs9934957	ENSG00000261061.1	RP11-303E16.2	4.51	8.1e-06	0.00165	0.23	0.2	Mean corpuscular volume;	chr16:81016078	chr16:81030770~81031485:+
HNSC	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	4.51	8.1e-06	0.00165	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
HNSC	cis	rs453301	0.624	rs330060	ENSG00000233609.3	RP11-62H7.2	-4.51	8.11e-06	0.00165	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9233392	chr8:8961200~8979025:+
HNSC	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	4.51	8.11e-06	0.00165	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	4.51	8.11e-06	0.00165	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	4.51	8.11e-06	0.00165	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
HNSC	cis	rs67981189	0.865	rs2189806	ENSG00000274818.1	RP1-292L20.3	-4.51	8.11e-06	0.00165	-0.24	-0.2	Schizophrenia;	chr14:70921681	chr14:70906657~70907111:-
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000233609.3	RP11-62H7.2	4.51	8.12e-06	0.00165	0.2	0.2	Recombination measurement;	chr8:9228513	chr8:8961200~8979025:+
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	4.51	8.12e-06	0.00165	0.23	0.2	Depression;	chr6:28187640	chr6:28170845~28172521:+
HNSC	cis	rs1994321	0.657	rs1814174	ENSG00000254991.1	RP13-631K18.3	4.51	8.12e-06	0.00165	0.23	0.2	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12061821	chr11:12066929~12073014:+
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-4.51	8.12e-06	0.00165	-0.24	-0.2	Depression;	chr6:28184805	chr6:28170845~28172521:+
HNSC	cis	rs67981189	0.858	rs35631530	ENSG00000274818.1	RP1-292L20.3	4.51	8.12e-06	0.00165	0.24	0.2	Schizophrenia;	chr14:71041312	chr14:70906657~70907111:-
HNSC	cis	rs17270561	0.723	rs12213243	ENSG00000272810.1	U91328.22	-4.51	8.12e-06	0.00165	-0.22	-0.2	Iron status biomarkers;	chr6:25889880	chr6:26013241~26013757:+
HNSC	cis	rs9487051	0.597	rs351731	ENSG00000243587.6	C6orf183	-4.51	8.12e-06	0.00165	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109186639	chr6:109165833~109271014:+
HNSC	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	4.51	8.12e-06	0.00165	0.25	0.2	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000254340.1	RP11-10A14.3	4.51	8.13e-06	0.00165	0.25	0.2	Mood instability;	chr8:8465578	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-4.51	8.13e-06	0.00165	-0.26	-0.2	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
HNSC	cis	rs4660214	0.666	rs2275187	ENSG00000182109.6	RP11-69E11.4	-4.51	8.13e-06	0.00165	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.657	rs10434028	ENSG00000249244.1	RP11-548H18.2	4.51	8.13e-06	0.00165	0.24	0.2	Corneal astigmatism;	chr4:119373309	chr4:119391831~119395335:-
HNSC	cis	rs75422866	0.85	rs73111210	ENSG00000276691.1	RP5-1057I20.5	4.51	8.13e-06	0.00165	0.42	0.2	Pneumonia;	chr12:47576949	chr12:47788426~47788971:+
HNSC	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-4.51	8.13e-06	0.00165	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
HNSC	cis	rs8028182	0.636	rs4564532	ENSG00000260269.4	CTD-2323K18.1	-4.51	8.14e-06	0.00165	-0.26	-0.2	Sudden cardiac arrest;	chr15:75413955	chr15:75527150~75601205:-
HNSC	cis	rs9907295	1	rs9889274	ENSG00000270977.1	AC015849.16	-4.51	8.14e-06	0.00165	-0.37	-0.2	Fibroblast growth factor basic levels;	chr17:35910397	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9891064	ENSG00000270977.1	AC015849.16	-4.51	8.14e-06	0.00165	-0.37	-0.2	Fibroblast growth factor basic levels;	chr17:35913045	chr17:35893707~35911023:-
HNSC	cis	rs9907295	1	rs9899870	ENSG00000270977.1	AC015849.16	-4.51	8.14e-06	0.00165	-0.37	-0.2	Fibroblast growth factor basic levels;	chr17:35914438	chr17:35893707~35911023:-
HNSC	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	4.51	8.14e-06	0.00165	0.24	0.2	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
HNSC	cis	rs453301	0.624	rs330056	ENSG00000233609.3	RP11-62H7.2	-4.51	8.14e-06	0.00165	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9232185	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.624	rs330058	ENSG00000233609.3	RP11-62H7.2	-4.51	8.14e-06	0.00165	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9232299	chr8:8961200~8979025:+
HNSC	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-4.51	8.14e-06	0.00165	-0.31	-0.2	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
HNSC	cis	rs11250098	0.541	rs6997839	ENSG00000269918.1	AF131215.9	-4.51	8.14e-06	0.00165	-0.2	-0.2	Morning vs. evening chronotype;	chr8:10908518	chr8:11104691~11106704:-
HNSC	cis	rs1991651	0.578	rs13259086	ENSG00000269918.1	AF131215.9	4.51	8.14e-06	0.00165	0.2	0.2	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:11104691~11106704:-
HNSC	cis	rs6964587	1	rs1063243	ENSG00000188693.7	CYP51A1-AS1	-4.51	8.15e-06	0.00165	-0.21	-0.2	Breast cancer;	chr7:92097613	chr7:92134604~92180725:+
HNSC	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	4.51	8.15e-06	0.00165	0.24	0.2	Height;	chr14:75127759	chr14:75011269~75012851:-
HNSC	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-4.51	8.15e-06	0.00166	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
HNSC	cis	rs250677	0.524	rs250665	ENSG00000250072.4	CTC-529P8.1	-4.51	8.15e-06	0.00166	-0.25	-0.2	Breast cancer;	chr5:149074831	chr5:149063317~149109787:+
HNSC	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	4.51	8.15e-06	0.00166	0.24	0.2	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
HNSC	cis	rs1799949	0.965	rs7212284	ENSG00000236383.6	LINC00854	-4.51	8.16e-06	0.00166	-0.19	-0.2	Menopause (age at onset);	chr17:43053924	chr17:43216941~43305976:-
HNSC	cis	rs3015497	0.603	rs1060197	ENSG00000269906.1	RP11-248J18.2	4.51	8.16e-06	0.00166	0.27	0.2	Mean platelet volume;	chr14:50591009	chr14:50662511~50663178:-
HNSC	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-4.51	8.16e-06	0.00166	-0.26	-0.2	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
HNSC	cis	rs6500395	0.788	rs12446280	ENSG00000261267.1	RP11-44I10.3	-4.51	8.16e-06	0.00166	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48617260	chr16:48559661~48587403:+
HNSC	cis	rs8177876	0.658	rs2316730	ENSG00000261061.1	RP11-303E16.2	-4.51	8.16e-06	0.00166	-0.38	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81030770~81031485:+
HNSC	cis	rs2247572	0.564	rs1387316	ENSG00000250295.5	RP11-434I12.2	-4.51	8.17e-06	0.00166	-0.28	-0.2	Cognitive performance;	chr8:72610157	chr8:73297711~73356461:-
HNSC	cis	rs6601327	0.54	rs6982148	ENSG00000254340.1	RP11-10A14.3	-4.51	8.17e-06	0.00166	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9723560	chr8:9141424~9145435:+
HNSC	cis	rs9880211	0.948	rs34282798	ENSG00000273486.1	RP11-731C17.2	4.51	8.17e-06	0.00166	0.19	0.2	Height;Body mass index;	chr3:136424515	chr3:136837338~136839021:-
HNSC	cis	rs9880211	1	rs34757183	ENSG00000273486.1	RP11-731C17.2	4.51	8.17e-06	0.00166	0.19	0.2	Height;Body mass index;	chr3:136424826	chr3:136837338~136839021:-
HNSC	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	4.51	8.17e-06	0.00166	0.25	0.2	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
HNSC	cis	rs9959145	0.778	rs2186906	ENSG00000267249.1	RP11-973H7.3	-4.51	8.17e-06	0.00166	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12572196	chr18:12670426~12671145:-
HNSC	cis	rs6601327	0.641	rs11778555	ENSG00000254340.1	RP11-10A14.3	-4.51	8.17e-06	0.00166	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9730064	chr8:9141424~9145435:+
HNSC	cis	rs6601327	0.641	rs11785923	ENSG00000254340.1	RP11-10A14.3	-4.51	8.17e-06	0.00166	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9730164	chr8:9141424~9145435:+
HNSC	cis	rs7937890	0.572	rs2597202	ENSG00000251991.1	RNU7-49P	4.51	8.17e-06	0.00166	0.24	0.2	Mitochondrial DNA levels;	chr11:14463099	chr11:14478892~14478953:+
HNSC	cis	rs73198271	0.74	rs28402110	ENSG00000173295.6	FAM86B3P	-4.51	8.17e-06	0.00166	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.74	rs10112989	ENSG00000173295.6	FAM86B3P	-4.51	8.17e-06	0.00166	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8228595~8244865:+
HNSC	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-4.51	8.17e-06	0.00166	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
HNSC	cis	rs9611565	0.921	rs6002333	ENSG00000235513.1	RP4-756G23.5	4.51	8.17e-06	0.00166	0.23	0.2	Vitiligo;	chr22:41323465	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.913	rs10010696	ENSG00000250412.1	KLHL2P1	4.51	8.18e-06	0.00166	0.26	0.2	Corneal astigmatism;	chr4:119243148	chr4:119334329~119378233:+
HNSC	cis	rs4295623	0.789	rs12541318	ENSG00000269918.1	AF131215.9	-4.51	8.18e-06	0.00166	-0.21	-0.2	Morning vs. evening chronotype;	chr8:11737461	chr8:11104691~11106704:-
HNSC	cis	rs17666538	0.585	rs336444	ENSG00000254207.1	RP11-43A14.1	-4.51	8.18e-06	0.00166	-0.39	-0.2	IgG glycosylation;	chr8:683123	chr8:725188~725877:-
HNSC	cis	rs4356203	0.905	rs7938820	ENSG00000272034.1	SNORD14A	4.51	8.18e-06	0.00166	0.15	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17074654~17074744:-
HNSC	cis	rs11673344	0.542	rs826327	ENSG00000276846.1	CTD-3220F14.3	4.51	8.18e-06	0.00166	0.22	0.2	Obesity-related traits;	chr19:37004397	chr19:37314868~37315620:-
HNSC	cis	rs3736485	0.966	rs62016017	ENSG00000259438.1	CTD-2650P22.1	4.51	8.19e-06	0.00166	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51605205	chr15:52010999~52019095:-
HNSC	cis	rs7809950	0.678	rs75617662	ENSG00000238832.1	snoU109	-4.51	8.19e-06	0.00166	-0.29	-0.2	Coronary artery disease;	chr7:107389994	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.678	rs7790080	ENSG00000238832.1	snoU109	-4.51	8.19e-06	0.00166	-0.29	-0.2	Coronary artery disease;	chr7:107390877	chr7:107603363~107603507:+
HNSC	cis	rs721917	0.525	rs2819106	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.19e-06	0.00166	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79663088~79826594:-
HNSC	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-4.51	8.19e-06	0.00166	-0.24	-0.2	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-4.51	8.19e-06	0.00166	-0.24	-0.2	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
HNSC	cis	rs4873772	0.735	rs4873565	ENSG00000253330.1	RP11-697N18.3	-4.51	8.19e-06	0.00166	-0.26	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47689290	chr8:47511034~47512141:-
HNSC	cis	rs9863	0.828	rs11057412	ENSG00000269938.1	RP11-214K3.20	-4.51	8.2e-06	0.00166	-0.23	-0.2	White blood cell count;	chr12:124004595	chr12:123968023~123968579:-
HNSC	cis	rs9813712	0.595	rs12490957	ENSG00000228252.7	COL6A4P2	4.51	8.2e-06	0.00166	0.2	0.2	Response to amphetamines;	chr3:130287851	chr3:130212823~130273806:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	4.51	8.21e-06	0.00166	0.19	0.2	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000219891.2	ZSCAN12P1	4.51	8.21e-06	0.00167	0.36	0.2	Depression;	chr6:28111963	chr6:28091154~28093664:+
HNSC	cis	rs6500395	1	rs12933948	ENSG00000261267.1	RP11-44I10.3	4.51	8.21e-06	0.00167	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48671914	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs2041921	ENSG00000261267.1	RP11-44I10.3	4.51	8.21e-06	0.00167	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48680091	chr16:48559661~48587403:+
HNSC	cis	rs9611565	0.921	rs8137373	ENSG00000235513.1	RP4-756G23.5	-4.51	8.21e-06	0.00167	-0.22	-0.2	Vitiligo;	chr22:41333212	chr22:41209122~41217627:-
HNSC	cis	rs11834862	0.77	rs10444603	ENSG00000256576.2	RP13-977J11.2	-4.51	8.21e-06	0.00167	-0.31	-0.2	Anti-saccade response;	chr12:132210365	chr12:132186735~132189695:-
HNSC	cis	rs12893668	0.703	rs34186780	ENSG00000269940.1	RP11-73M18.7	4.51	8.21e-06	0.00167	0.21	0.2	Reticulocyte count;	chr14:103561258	chr14:103694560~103695170:+
HNSC	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-4.51	8.21e-06	0.00167	-0.21	-0.2	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
HNSC	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	4.51	8.21e-06	0.00167	0.21	0.2	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
HNSC	cis	rs189798	0.807	rs330912	ENSG00000254153.1	CTA-398F10.2	4.51	8.21e-06	0.00167	0.25	0.2	Myopia (pathological);	chr8:9138784	chr8:8456909~8461337:-
HNSC	cis	rs721917	0.506	rs1923538	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.22e-06	0.00167	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.507	rs2819101	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.22e-06	0.00167	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2819100	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.22e-06	0.00167	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2758547	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.22e-06	0.00167	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79663088~79826594:-
HNSC	cis	rs4908769	0.624	rs301789	ENSG00000232912.4	RP5-1115A15.1	4.51	8.22e-06	0.00167	0.23	0.2	Allergy;	chr1:8409277	chr1:8424645~8434838:+
HNSC	cis	rs721917	0.506	rs7073842	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.22e-06	0.00167	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79663088~79826594:-
HNSC	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-4.51	8.23e-06	0.00167	-0.22	-0.2	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
HNSC	cis	rs9287719	0.901	rs10210859	ENSG00000243819.4	RN7SL832P	4.51	8.23e-06	0.00167	0.2	0.2	Prostate cancer;	chr2:10593803	chr2:10690344~10692099:+
HNSC	cis	rs12545109	0.837	rs6474063	ENSG00000246430.5	LINC00968	-4.51	8.24e-06	0.00167	-0.25	-0.2	Obesity-related traits;	chr8:56442986	chr8:56496246~56559823:-
HNSC	cis	rs3733585	0.699	rs2018643	ENSG00000250413.1	RP11-448G15.1	-4.51	8.24e-06	0.00167	-0.25	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9945497	chr4:10006482~10009725:+
HNSC	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	4.51	8.24e-06	0.00167	0.23	0.2	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
HNSC	cis	rs6601327	0.606	rs9644707	ENSG00000254340.1	RP11-10A14.3	-4.51	8.24e-06	0.00167	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9732606	chr8:9141424~9145435:+
HNSC	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-4.51	8.24e-06	0.00167	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000254340.1	RP11-10A14.3	4.51	8.25e-06	0.00167	0.25	0.2	Neuroticism;	chr8:8241055	chr8:9141424~9145435:+
HNSC	cis	rs9910055	0.615	rs189049	ENSG00000267080.4	ASB16-AS1	4.51	8.25e-06	0.00167	0.17	0.2	Total body bone mineral density;	chr17:44119845	chr17:44175973~44186717:-
HNSC	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	4.51	8.25e-06	0.00167	0.25	0.2	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
HNSC	cis	rs2364403	1	rs12091361	ENSG00000225855.5	RUSC1-AS1	4.51	8.25e-06	0.00167	0.16	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:155959882	chr1:155316863~155324176:-
HNSC	cis	rs2364403	1	rs12080846	ENSG00000225855.5	RUSC1-AS1	4.51	8.25e-06	0.00167	0.16	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:155959910	chr1:155316863~155324176:-
HNSC	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	4.51	8.26e-06	0.00167	0.23	0.2	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000224373.3	IGHV4-59	-4.51	8.26e-06	0.00167	-0.13	-0.2	Kawasaki disease;	chr14:106779223	chr14:106627249~106627825:-
HNSC	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	4.51	8.26e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	4.51	8.26e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
HNSC	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	4.51	8.26e-06	0.00167	0.22	0.2	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
HNSC	cis	rs4388249	1	rs2300993	ENSG00000271849.1	CTC-332L22.1	-4.51	8.26e-06	0.00167	-0.32	-0.2	Schizophrenia;	chr5:109702928	chr5:109687802~109688329:-
HNSC	cis	rs7829975	0.582	rs448231	ENSG00000254153.1	CTA-398F10.2	-4.51	8.26e-06	0.00167	-0.22	-0.2	Mood instability;	chr8:8932549	chr8:8456909~8461337:-
HNSC	cis	rs5758511	0.68	rs17002902	ENSG00000205702.9	CYP2D7	4.51	8.27e-06	0.00167	0.18	0.2	Birth weight;	chr22:42229503	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.68	rs5758662	ENSG00000205702.9	CYP2D7	4.51	8.27e-06	0.00167	0.18	0.2	Birth weight;	chr22:42232082	chr22:42140203~42144577:-
HNSC	cis	rs11893307	0.537	rs57780226	ENSG00000235852.1	AC005540.3	4.51	8.27e-06	0.00168	0.26	0.2	Mean platelet volume;	chr2:190683139	chr2:190880797~190882059:-
HNSC	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-4.51	8.27e-06	0.00168	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
HNSC	cis	rs1555322	0.872	rs2425033	ENSG00000279253.1	RP4-614O4.13	-4.51	8.27e-06	0.00168	-0.28	-0.2	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35262727~35264187:-
HNSC	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	4.51	8.27e-06	0.00168	0.2	0.2	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
HNSC	cis	rs9959145	1	rs79998152	ENSG00000267249.1	RP11-973H7.3	-4.51	8.27e-06	0.00168	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12567413	chr18:12670426~12671145:-
HNSC	cis	rs9959145	0.778	rs77764901	ENSG00000267249.1	RP11-973H7.3	-4.51	8.27e-06	0.00168	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12567459	chr18:12670426~12671145:-
HNSC	cis	rs9926296	0.585	rs4785595	ENSG00000260259.1	RP11-368I7.4	4.51	8.27e-06	0.00168	0.23	0.2	Vitiligo;	chr16:89769113	chr16:89682620~89686569:-
HNSC	cis	rs8028182	0.636	rs10152155	ENSG00000260269.4	CTD-2323K18.1	-4.51	8.28e-06	0.00168	-0.26	-0.2	Sudden cardiac arrest;	chr15:75409213	chr15:75527150~75601205:-
HNSC	cis	rs11148252	0.532	rs9536262	ENSG00000198384.8	TPTE2P3	-4.51	8.28e-06	0.00168	-0.25	-0.2	Lewy body disease;	chr13:52728939	chr13:52522632~52586906:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	4.51	8.28e-06	0.00168	0.27	0.2	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	4.51	8.28e-06	0.00168	0.27	0.2	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	4.51	8.28e-06	0.00168	0.27	0.2	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	4.51	8.28e-06	0.00168	0.27	0.2	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
HNSC	cis	rs988913	0.723	rs4715515	ENSG00000224984.1	RP11-524H19.2	4.51	8.28e-06	0.00168	0.23	0.2	Menarche (age at onset);	chr6:55103646	chr6:54840118~54840855:-
HNSC	cis	rs61935443	0.501	rs10859754	ENSG00000241556.1	RP11-490G8.1	-4.51	8.29e-06	0.00168	-0.21	-0.2	Schizophrenia;	chr12:94798953	chr12:95467397~95467861:-
HNSC	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	4.51	8.29e-06	0.00168	0.27	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
HNSC	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	4.51	8.3e-06	0.00168	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.828	rs7311969	ENSG00000270028.1	RP11-380L11.4	-4.51	8.3e-06	0.00168	-0.23	-0.2	White blood cell count;	chr12:123985786	chr12:123925461~123926083:-
HNSC	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	4.51	8.3e-06	0.00168	0.24	0.2	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
HNSC	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-4.51	8.3e-06	0.00168	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
HNSC	cis	rs12893668	0.703	rs34026011	ENSG00000269910.1	RP11-73M18.10	4.51	8.3e-06	0.00168	0.2	0.2	Reticulocyte count;	chr14:103584546	chr14:103694516~103695050:-
HNSC	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	4.51	8.3e-06	0.00168	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
HNSC	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	4.51	8.31e-06	0.00168	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	4.51	8.31e-06	0.00168	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	4.51	8.31e-06	0.00168	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
HNSC	cis	rs1355223	0.583	rs2915177	ENSG00000271369.1	RP11-350D17.3	4.51	8.31e-06	0.00168	0.24	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34858719	chr11:34709600~34710161:+
HNSC	cis	rs4873772	0.735	rs16928696	ENSG00000253330.1	RP11-697N18.3	-4.51	8.31e-06	0.00168	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47612438	chr8:47511034~47512141:-
HNSC	cis	rs4873772	0.735	rs6989917	ENSG00000253330.1	RP11-697N18.3	-4.51	8.31e-06	0.00168	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47614197	chr8:47511034~47512141:-
HNSC	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-4.51	8.31e-06	0.00168	-0.25	-0.2	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
HNSC	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-4.51	8.31e-06	0.00168	-0.19	-0.2	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
HNSC	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00168	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
HNSC	cis	rs755249	0.53	rs4660443	ENSG00000228060.1	RP11-69E11.8	-4.51	8.32e-06	0.00168	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39565160~39573203:+
HNSC	cis	rs2361718	0.522	rs11867921	ENSG00000275479.1	RP11-334C17.6	4.51	8.32e-06	0.00168	0.24	0.2	Yeast infection;	chr17:80147371	chr17:80149627~80149798:+
HNSC	cis	rs11148252	0.557	rs9536223	ENSG00000198384.8	TPTE2P3	4.51	8.32e-06	0.00168	0.25	0.2	Lewy body disease;	chr13:52659059	chr13:52522632~52586906:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000254153.1	CTA-398F10.2	4.51	8.32e-06	0.00168	0.23	0.2	Mood instability;	chr8:8821020	chr8:8456909~8461337:-
HNSC	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	4.51	8.32e-06	0.00168	0.29	0.2	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
HNSC	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-4.51	8.32e-06	0.00168	-0.26	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
HNSC	cis	rs9311676	0.656	rs11712213	ENSG00000273493.1	RP11-80H18.4	4.51	8.32e-06	0.00168	0.22	0.2	Systemic lupus erythematosus;	chr3:58399268	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs6773193	ENSG00000273493.1	RP11-80H18.4	4.51	8.32e-06	0.00168	0.22	0.2	Systemic lupus erythematosus;	chr3:58400233	chr3:58329965~58330118:+
HNSC	cis	rs2279168	0.867	rs60803479	ENSG00000259295.5	CSPG4P12	-4.51	8.32e-06	0.00168	-0.38	-0.2	Response to platinum-based chemotherapy (carboplatin);	chr15:85498031	chr15:85191438~85213905:+
HNSC	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	4.51	8.33e-06	0.00169	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
HNSC	cis	rs3096299	0.967	rs28644774	ENSG00000261574.1	RP1-168P16.2	4.51	8.33e-06	0.00169	0.26	0.2	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89392375~89412564:-
HNSC	cis	rs34787248	1	rs34787248	ENSG00000219891.2	ZSCAN12P1	4.51	8.33e-06	0.00169	0.3	0.2	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28091154~28093664:+
HNSC	cis	rs12935418	0.616	rs1127390	ENSG00000278985.1	RP11-303E16.9	4.51	8.33e-06	0.00169	0.2	0.2	Mean corpuscular volume;	chr16:80976176	chr16:80982319~80984094:-
HNSC	cis	rs9487051	0.597	rs9400265	ENSG00000243587.6	C6orf183	-4.51	8.33e-06	0.00169	-0.22	-0.2	Reticulocyte fraction of red cells;	chr6:109273729	chr6:109165833~109271014:+
HNSC	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-4.51	8.33e-06	0.00169	-0.19	-0.2	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
HNSC	cis	rs4356203	0.905	rs7930058	ENSG00000272034.1	SNORD14A	-4.51	8.33e-06	0.00169	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17074654~17074744:-
HNSC	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	4.51	8.33e-06	0.00169	0.24	0.2	Height;	chr14:75107384	chr14:75011269~75012851:-
HNSC	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-4.51	8.33e-06	0.00169	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
HNSC	cis	rs964611	0.882	rs4325499	ENSG00000259488.2	RP11-154J22.1	-4.51	8.33e-06	0.00169	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48289551	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.872	rs6493320	ENSG00000259488.2	RP11-154J22.1	-4.51	8.33e-06	0.00169	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48290070	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs6493321	ENSG00000259488.2	RP11-154J22.1	-4.51	8.33e-06	0.00169	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48290117	chr15:48312353~48331856:-
HNSC	cis	rs72772090	1	rs72772090	ENSG00000248734.2	CTD-2260A17.1	-4.51	8.34e-06	0.00169	-0.3	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96700607	chr5:96784777~96785999:+
HNSC	cis	rs6951245	0.678	rs28600085	ENSG00000225146.1	AC073957.15	-4.51	8.34e-06	0.00169	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1029025~1043891:+
HNSC	cis	rs7552167	1	rs59960858	ENSG00000230023.2	RP11-10N16.2	-4.51	8.34e-06	0.00169	-0.34	-0.2	Psoriasis vulgaris;	chr1:24192947	chr1:24200240~24211693:+
HNSC	cis	rs12908161	0.959	rs11637728	ENSG00000275120.1	RP11-182J1.17	4.51	8.34e-06	0.00169	0.28	0.2	Schizophrenia;	chr15:84660161	chr15:84599434~84606463:-
HNSC	cis	rs72843166	0.592	rs112829995	ENSG00000265282.1	RP11-269G24.4	4.51	8.35e-06	0.00169	0.3	0.2	Intelligence (multi-trait analysis);	chr17:63451000	chr17:63430468~63432211:-
HNSC	cis	rs72843506	0.656	rs9911879	ENSG00000261033.1	RP11-209D14.2	4.51	8.35e-06	0.00169	0.34	0.2	Schizophrenia;	chr17:20086829	chr17:20008051~20009234:-
HNSC	cis	rs6964587	1	rs2299240	ENSG00000188693.7	CYP51A1-AS1	-4.51	8.35e-06	0.00169	-0.22	-0.2	Breast cancer;	chr7:92025304	chr7:92134604~92180725:+
HNSC	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-4.51	8.35e-06	0.00169	-0.26	-0.2	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
HNSC	cis	rs4523957	0.855	rs9896535	ENSG00000262333.1	HNRNPA1P16	4.51	8.35e-06	0.00169	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2229911	chr17:2306761~2307715:+
HNSC	cis	rs17253792	0.732	rs8017891	ENSG00000186615.9	KTN1-AS1	4.51	8.35e-06	0.00169	0.35	0.2	Putamen volume;	chr14:55706249	chr14:55499278~55580110:-
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	4.51	8.35e-06	0.00169	0.22	0.2	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
HNSC	cis	rs4789693	0.746	rs4789775	ENSG00000265458.1	RP13-20L14.6	4.51	8.35e-06	0.00169	0.29	0.2	Glucocorticoid-induced osteonecrosis;	chr17:82434029	chr17:82454273~82458521:-
HNSC	cis	rs4787951	0.517	rs3024585	ENSG00000259940.2	CTD-3203P2.1	-4.51	8.35e-06	0.00169	-0.21	-0.2	Eosinophil percentage of white cells;	chr16:27348523	chr16:27213308~27214993:-
HNSC	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-4.51	8.35e-06	0.00169	-0.27	-0.2	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
HNSC	cis	rs1008375	1	rs11727312	ENSG00000249502.1	AC006160.5	-4.51	8.36e-06	0.00169	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17667562	chr4:17587467~17614571:-
HNSC	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	4.51	8.36e-06	0.00169	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
HNSC	cis	rs7819412	0.502	rs4841499	ENSG00000255310.2	AF131215.2	-4.51	8.36e-06	0.00169	-0.21	-0.2	Triglycerides;	chr8:11130628	chr8:11107788~11109726:-
HNSC	cis	rs800888	0.548	rs2721938	ENSG00000249917.2	LINC00536	4.51	8.36e-06	0.00169	0.24	0.2	Monocyte percentage of white cells;	chr8:115623384	chr8:115950511~116325059:-
HNSC	cis	rs804280	0.543	rs13261205	ENSG00000255495.1	AC145124.2	4.51	8.37e-06	0.00169	0.23	0.2	Myopia (pathological);	chr8:11933707	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.867	rs34465618	ENSG00000255495.1	AC145124.2	4.51	8.37e-06	0.00169	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.867	rs34583868	ENSG00000255495.1	AC145124.2	4.51	8.37e-06	0.00169	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:12194467~12196280:+
HNSC	cis	rs804280	0.518	rs34266352	ENSG00000255495.1	AC145124.2	4.51	8.37e-06	0.00169	0.23	0.2	Myopia (pathological);	chr8:11933953	chr8:12194467~12196280:+
HNSC	cis	rs804280	0.542	rs36100659	ENSG00000255495.1	AC145124.2	4.51	8.37e-06	0.00169	0.23	0.2	Myopia (pathological);	chr8:11934144	chr8:12194467~12196280:+
HNSC	cis	rs9467773	0.526	rs3734536	ENSG00000241549.7	GUSBP2	4.51	8.37e-06	0.00169	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26365118	chr6:26871484~26956554:-
HNSC	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	4.51	8.37e-06	0.00169	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
HNSC	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	4.51	8.37e-06	0.00169	0.23	0.2	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	4.51	8.37e-06	0.00169	0.23	0.2	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	4.51	8.37e-06	0.00169	0.23	0.2	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
HNSC	cis	rs721917	0.506	rs2254016	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.38e-06	0.00169	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79663088~79826594:-
HNSC	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	4.51	8.38e-06	0.00169	0.29	0.2	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
HNSC	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	4.51	8.38e-06	0.00169	0.26	0.2	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
HNSC	cis	rs561341	0.941	rs72825746	ENSG00000278867.1	RP11-640N20.4	-4.51	8.38e-06	0.00169	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:32037591	chr17:32051030~32053208:+
HNSC	cis	rs3096299	0.967	rs2965937	ENSG00000261574.1	RP1-168P16.2	4.51	8.38e-06	0.00169	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89392375~89412564:-
HNSC	cis	rs4256159	0.569	rs13076846	ENSG00000228956.7	SATB1-AS1	4.51	8.38e-06	0.0017	0.27	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18678145	chr3:18445024~18920401:+
HNSC	cis	rs2904524	1	rs7311497	ENSG00000257815.4	RP11-611E13.2	-4.51	8.38e-06	0.0017	-0.24	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70343818	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs11178195	ENSG00000257815.4	RP11-611E13.2	-4.51	8.38e-06	0.0017	-0.24	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70345715	chr12:69904033~70243360:-
HNSC	cis	rs10462794	0.802	rs1562826	ENSG00000260763.1	RP11-445O3.3	4.51	8.39e-06	0.0017	0.27	0.2	DNA methylation (variation);	chr5:4510659	chr5:4436850~4440259:-
HNSC	cis	rs6095360	1	rs1569750	ENSG00000222365.1	SNORD12B	-4.51	8.39e-06	0.0017	-0.22	-0.2	Intelligence (multi-trait analysis);	chr20:48986704	chr20:49280319~49280409:+
HNSC	cis	rs7824557	0.578	rs2060458	ENSG00000255310.2	AF131215.2	4.51	8.39e-06	0.0017	0.19	0.2	Retinal vascular caliber;	chr8:11355302	chr8:11107788~11109726:-
HNSC	cis	rs8010715	0.636	rs2277482	ENSG00000259321.1	RP11-468E2.5	4.51	8.4e-06	0.0017	0.18	0.2	IgG glycosylation;	chr14:24118586	chr14:24139445~24140444:+
HNSC	cis	rs6500395	0.926	rs11076570	ENSG00000261267.1	RP11-44I10.3	-4.5	8.4e-06	0.0017	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48564004	chr16:48559661~48587403:+
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000254174.1	IGHV1-12	-4.5	8.4e-06	0.0017	-0.16	-0.2	Alzheimer's disease (late onset);	chr14:106647269	chr14:106122420~106122709:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-4.5	8.4e-06	0.0017	-0.15	-0.2	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
HNSC	cis	rs12935418	0.583	rs2167889	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80987867	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.552	rs2911148	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80988289	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.552	rs2549833	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80988627	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.552	rs2602448	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80989067	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549836	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80989476	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549837	ENSG00000278985.1	RP11-303E16.9	-4.5	8.4e-06	0.0017	-0.19	-0.2	Mean corpuscular volume;	chr16:80989510	chr16:80982319~80984094:-
HNSC	cis	rs561341	0.882	rs72825748	ENSG00000278867.1	RP11-640N20.4	-4.5	8.4e-06	0.0017	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:32040377	chr17:32051030~32053208:+
HNSC	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-4.5	8.4e-06	0.0017	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
HNSC	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	4.5	8.41e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
HNSC	cis	rs9914988	0.613	rs34120713	ENSG00000264577.1	AC010761.8	4.5	8.41e-06	0.0017	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28945857	chr17:28721487~28722877:-
HNSC	cis	rs6496044	0.568	rs1351196	ENSG00000259295.5	CSPG4P12	4.5	8.41e-06	0.0017	0.24	0.2	Interstitial lung disease;	chr15:85534173	chr15:85191438~85213905:+
HNSC	cis	rs11633886	0.585	rs2244179	ENSG00000273972.1	CTD-2306A12.1	4.5	8.41e-06	0.0017	0.24	0.2	Diisocyanate-induced asthma;	chr15:45797924	chr15:45702640~45703183:+
HNSC	cis	rs4853525	0.59	rs2355570	ENSG00000235852.1	AC005540.3	4.5	8.41e-06	0.0017	0.27	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190916443	chr2:190880797~190882059:-
HNSC	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	4.5	8.41e-06	0.0017	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
HNSC	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	4.5	8.41e-06	0.0017	0.26	0.2	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
HNSC	cis	rs9402743	0.709	rs9373136	ENSG00000234084.1	RP3-388E23.2	-4.5	8.41e-06	0.0017	-0.21	-0.2	Systemic lupus erythematosus;	chr6:135617531	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.678	rs965191	ENSG00000234084.1	RP3-388E23.2	-4.5	8.41e-06	0.0017	-0.21	-0.2	Systemic lupus erythematosus;	chr6:135618363	chr6:135301568~135307158:+
HNSC	cis	rs13256369	0.802	rs11249884	ENSG00000173295.6	FAM86B3P	-4.5	8.42e-06	0.0017	-0.27	-0.2	Obesity-related traits;	chr8:8704042	chr8:8228595~8244865:+
HNSC	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	4.5	8.42e-06	0.0017	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
HNSC	cis	rs2483058	0.531	rs17433769	ENSG00000261000.1	RP11-534L20.5	-4.5	8.42e-06	0.0017	-0.2	-0.2	Cholesterol and Triglycerides;	chr1:206464459	chr1:206503948~206504456:+
HNSC	cis	rs4873772	0.837	rs2129618	ENSG00000253330.1	RP11-697N18.3	-4.5	8.42e-06	0.0017	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47643557	chr8:47511034~47512141:-
HNSC	cis	rs72772090	0.71	rs11750399	ENSG00000248734.2	CTD-2260A17.1	-4.5	8.42e-06	0.0017	-0.32	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96784777~96785999:+
HNSC	cis	rs467650	0.549	rs2547958	ENSG00000246763.5	RGMB-AS1	-4.5	8.42e-06	0.0017	-0.23	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98658249	chr5:98769618~98773469:-
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000224373.3	IGHV4-59	4.5	8.42e-06	0.0017	0.13	0.2	Kawasaki disease;	chr14:106775695	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000224373.3	IGHV4-59	4.5	8.42e-06	0.0017	0.13	0.2	Kawasaki disease;	chr14:106775735	chr14:106627249~106627825:-
HNSC	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	4.5	8.42e-06	0.0017	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
HNSC	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-4.5	8.43e-06	0.0017	-0.25	-0.2	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
HNSC	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	4.5	8.43e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	4.5	8.43e-06	0.0017	0.29	0.2	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	4.5	8.43e-06	0.0017	0.24	0.2	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
HNSC	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	4.5	8.43e-06	0.0017	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
HNSC	cis	rs4761669	0.958	rs7134873	ENSG00000241556.1	RP11-490G8.1	-4.5	8.44e-06	0.0017	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94799613	chr12:95467397~95467861:-
HNSC	cis	rs61935443	0.501	rs10777621	ENSG00000241556.1	RP11-490G8.1	-4.5	8.44e-06	0.0017	-0.21	-0.2	Schizophrenia;	chr12:94800344	chr12:95467397~95467861:-
HNSC	cis	rs13256369	0.708	rs10903310	ENSG00000173295.6	FAM86B3P	-4.5	8.44e-06	0.0017	-0.28	-0.2	Obesity-related traits;	chr8:8732177	chr8:8228595~8244865:+
HNSC	cis	rs6693567	0.586	rs12031973	ENSG00000228126.1	FALEC	4.5	8.44e-06	0.00171	0.25	0.2	Migraine;	chr1:150513090	chr1:150515757~150518032:+
HNSC	cis	rs8028182	0.609	rs8038760	ENSG00000260269.4	CTD-2323K18.1	-4.5	8.45e-06	0.00171	-0.26	-0.2	Sudden cardiac arrest;	chr15:75449754	chr15:75527150~75601205:-
HNSC	cis	rs9840812	0.769	rs632016	ENSG00000273486.1	RP11-731C17.2	4.5	8.45e-06	0.00171	0.17	0.2	Fibrinogen levels;	chr3:136258198	chr3:136837338~136839021:-
HNSC	cis	rs9987353	0.518	rs4841110	ENSG00000254153.1	CTA-398F10.2	4.5	8.45e-06	0.00171	0.23	0.2	Recombination measurement;	chr8:9228513	chr8:8456909~8461337:-
HNSC	cis	rs9959145	0.929	rs113231666	ENSG00000267249.1	RP11-973H7.3	-4.5	8.46e-06	0.00171	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12574011	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs79692970	ENSG00000267249.1	RP11-973H7.3	-4.5	8.46e-06	0.00171	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12580218	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs11660232	ENSG00000267249.1	RP11-973H7.3	-4.5	8.46e-06	0.00171	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12585546	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs28575715	ENSG00000267249.1	RP11-973H7.3	-4.5	8.46e-06	0.00171	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12586349	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs28527375	ENSG00000267249.1	RP11-973H7.3	-4.5	8.46e-06	0.00171	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12593394	chr18:12670426~12671145:-
HNSC	cis	rs1799949	1	rs16942	ENSG00000236383.6	LINC00854	-4.5	8.46e-06	0.00171	-0.19	-0.2	Menopause (age at onset);	chr17:43091983	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176145	ENSG00000236383.6	LINC00854	-4.5	8.46e-06	0.00171	-0.19	-0.2	Menopause (age at onset);	chr17:43097077	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs8176140	ENSG00000236383.6	LINC00854	-4.5	8.46e-06	0.00171	-0.19	-0.2	Menopause (age at onset);	chr17:43099629	chr17:43216941~43305976:-
HNSC	cis	rs3736485	0.844	rs7162412	ENSG00000259438.1	CTD-2650P22.1	4.5	8.46e-06	0.00171	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51461797	chr15:52010999~52019095:-
HNSC	cis	rs4061073	1	rs2297026	ENSG00000198711.5	SSBP3-AS1	-4.5	8.47e-06	0.00171	-0.2	-0.2	Body mass index;	chr1:54228541	chr1:54236440~54239063:+
HNSC	cis	rs11846409	1	rs11846409	ENSG00000254174.1	IGHV1-12	4.5	8.47e-06	0.00171	0.16	0.2	Rheumatic heart disease;	chr14:106645692	chr14:106122420~106122709:-
HNSC	cis	rs3808502	0.526	rs36048422	ENSG00000269918.1	AF131215.9	-4.5	8.47e-06	0.00171	-0.2	-0.2	Neuroticism;	chr8:11559635	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.526	rs11783065	ENSG00000269918.1	AF131215.9	-4.5	8.47e-06	0.00171	-0.2	-0.2	Neuroticism;	chr8:11559748	chr8:11104691~11106704:-
HNSC	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-4.5	8.47e-06	0.00171	-0.21	-0.2	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
HNSC	cis	rs4761669	0.848	rs10777618	ENSG00000241556.1	RP11-490G8.1	-4.5	8.47e-06	0.00171	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94784261	chr12:95467397~95467861:-
HNSC	cis	rs8028182	0.549	rs11072542	ENSG00000260269.4	CTD-2323K18.1	4.5	8.47e-06	0.00171	0.26	0.2	Sudden cardiac arrest;	chr15:75342258	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.549	rs10775209	ENSG00000260269.4	CTD-2323K18.1	4.5	8.47e-06	0.00171	0.26	0.2	Sudden cardiac arrest;	chr15:75342418	chr15:75527150~75601205:-
HNSC	cis	rs12655019	0.92	rs3756586	ENSG00000271828.1	CTD-2310F14.1	4.5	8.47e-06	0.00171	0.42	0.2	Breast cancer (early onset);	chr5:56921369	chr5:56927874~56929573:+
HNSC	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-4.5	8.47e-06	0.00171	-0.16	-0.2	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
HNSC	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-4.5	8.47e-06	0.00171	-0.16	-0.2	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
HNSC	cis	rs9329221	0.683	rs3105738	ENSG00000254340.1	RP11-10A14.3	-4.5	8.48e-06	0.00171	-0.24	-0.2	Neuroticism;	chr8:10032404	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.615	rs9295747	ENSG00000219392.1	RP1-265C24.5	4.5	8.48e-06	0.00171	0.24	0.2	Parkinson's disease;	chr6:27769214	chr6:28115628~28116551:+
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000211974.3	IGHV2-70	-4.5	8.48e-06	0.00171	-0.19	-0.2	Kawasaki disease;	chr14:106779223	chr14:106723574~106724093:-
HNSC	cis	rs36052053	0.521	rs13219774	ENSG00000219700.1	PTCHD3P3	4.5	8.48e-06	0.00171	0.4	0.2	Red cell distribution width;	chr6:109243023	chr6:109288571~109290503:-
HNSC	cis	rs35306767	0.903	rs17159950	ENSG00000229869.1	RP11-363N22.2	-4.5	8.48e-06	0.00171	-0.3	-0.2	Eosinophil percentage of granulocytes;	chr10:829347	chr10:933026~942743:+
HNSC	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-4.5	8.48e-06	0.00171	-0.25	-0.2	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
HNSC	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-4.5	8.5e-06	0.00171	-0.4	-0.2	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
HNSC	cis	rs11089937	0.626	rs11089933	ENSG00000211639.2	IGLV4-60	4.5	8.5e-06	0.00172	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22162199~22162681:+
HNSC	cis	rs36563	0.631	rs45483794	ENSG00000274818.1	RP1-292L20.3	4.5	8.5e-06	0.00172	0.33	0.2	Alcohol dependence;	chr14:71012236	chr14:70906657~70907111:-
HNSC	cis	rs763121	0.849	rs12004	ENSG00000273076.1	RP3-508I15.22	4.5	8.51e-06	0.00172	0.22	0.2	Menopause (age at onset);	chr22:38481456	chr22:38743495~38743910:+
HNSC	cis	rs17594362	0.697	rs7322968	ENSG00000229473.2	RGS17P1	4.5	8.51e-06	0.00172	0.28	0.2	Multiple sclerosis;	chr13:41576362	chr13:40992779~40993331:-
HNSC	cis	rs11098499	0.863	rs3736115	ENSG00000250412.1	KLHL2P1	-4.5	8.51e-06	0.00172	-0.27	-0.2	Corneal astigmatism;	chr4:119567548	chr4:119334329~119378233:+
HNSC	cis	rs9368481	0.547	rs2093303	ENSG00000224843.5	LINC00240	-4.5	8.51e-06	0.00172	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26956992~27023924:+
HNSC	cis	rs6964587	0.839	rs17731846	ENSG00000188693.7	CYP51A1-AS1	-4.5	8.52e-06	0.00172	-0.22	-0.2	Breast cancer;	chr7:91811028	chr7:92134604~92180725:+
HNSC	cis	rs6928977	0.86	rs3827780	ENSG00000217482.2	HMGB1P17	-4.5	8.52e-06	0.00172	-0.22	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135388622	chr6:135636086~135636713:-
HNSC	cis	rs13434995	0.513	rs41324951	ENSG00000273257.1	RP11-177J6.1	4.5	8.52e-06	0.00172	0.28	0.2	Adiponectin levels;	chr4:55422576	chr4:55387949~55388271:+
HNSC	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	4.5	8.52e-06	0.00172	0.2	0.2	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
HNSC	cis	rs7615952	0.641	rs61048217	ENSG00000241439.1	RP11-666A20.3	4.5	8.52e-06	0.00172	0.24	0.2	Blood pressure (smoking interaction);	chr3:126089062	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs60839048	ENSG00000241439.1	RP11-666A20.3	4.5	8.52e-06	0.00172	0.24	0.2	Blood pressure (smoking interaction);	chr3:126089095	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs7640158	ENSG00000241439.1	RP11-666A20.3	4.5	8.52e-06	0.00172	0.24	0.2	Blood pressure (smoking interaction);	chr3:126089168	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs2365019	ENSG00000241439.1	RP11-666A20.3	4.5	8.52e-06	0.00172	0.24	0.2	Blood pressure (smoking interaction);	chr3:126089292	chr3:125958556~125958817:+
HNSC	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	4.5	8.52e-06	0.00172	0.18	0.2	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
HNSC	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	4.5	8.52e-06	0.00172	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
HNSC	cis	rs4660214	0.666	rs6698791	ENSG00000182109.6	RP11-69E11.4	-4.5	8.53e-06	0.00172	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39522280~39546187:-
HNSC	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	4.5	8.53e-06	0.00172	0.46	0.2	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
HNSC	cis	rs929354	0.557	rs62491947	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157168119	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs2107863	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157171037	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.713	rs3802130	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157172543	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs4716460	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157177360	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs3802126	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157177587	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs3802124	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.53e-06	0.00172	-0.2	-0.2	Body mass index;	chr7:157177915	chr7:157263022~157263229:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000106610.13	STAG3L4	-4.5	8.53e-06	0.00172	-0.41	-0.2	Gout;	chr7:66693028	chr7:67302621~67321526:+
HNSC	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-4.5	8.53e-06	0.00172	-0.21	-0.2	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
HNSC	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	4.5	8.54e-06	0.00172	0.29	0.2	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
HNSC	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.5	8.54e-06	0.00172	0.34	0.2	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.866	rs12374244	ENSG00000249244.1	RP11-548H18.2	4.5	8.54e-06	0.00172	0.25	0.2	Corneal astigmatism;	chr4:119360817	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs12374352	ENSG00000249244.1	RP11-548H18.2	4.5	8.54e-06	0.00172	0.25	0.2	Corneal astigmatism;	chr4:119360822	chr4:119391831~119395335:-
HNSC	cis	rs721917	0.506	rs2758543	ENSG00000225484.5	NUTM2B-AS1	-4.5	8.54e-06	0.00172	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79663088~79826594:-
HNSC	cis	rs7824557	0.591	rs2060457	ENSG00000255310.2	AF131215.2	4.5	8.54e-06	0.00172	0.19	0.2	Retinal vascular caliber;	chr8:11355741	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.614	rs2060456	ENSG00000255310.2	AF131215.2	4.5	8.54e-06	0.00172	0.19	0.2	Retinal vascular caliber;	chr8:11355854	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.614	rs5029571	ENSG00000255310.2	AF131215.2	4.5	8.54e-06	0.00172	0.19	0.2	Retinal vascular caliber;	chr8:11355880	chr8:11107788~11109726:-
HNSC	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-4.5	8.54e-06	0.00172	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000254153.1	CTA-398F10.2	4.5	8.55e-06	0.00172	0.22	0.2	Mood instability;	chr8:8821666	chr8:8456909~8461337:-
HNSC	cis	rs6831352	0.734	rs2602857	ENSG00000263923.1	RP11-571L19.7	-4.5	8.55e-06	0.00172	-0.21	-0.2	Alcohol dependence;	chr4:99109167	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.734	rs3018046	ENSG00000263923.1	RP11-571L19.7	-4.5	8.55e-06	0.00172	-0.21	-0.2	Alcohol dependence;	chr4:99109237	chr4:98928897~98994994:+
HNSC	cis	rs17594362	1	rs35516249	ENSG00000229473.2	RGS17P1	-4.5	8.55e-06	0.00172	-0.32	-0.2	Multiple sclerosis;	chr13:41572081	chr13:40992779~40993331:-
HNSC	cis	rs7973683	0.513	rs57316347	ENSG00000269938.1	RP11-214K3.20	-4.5	8.55e-06	0.00172	-0.24	-0.2	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904506	chr12:123968023~123968579:-
HNSC	cis	rs1218582	0.772	rs4845693	ENSG00000270361.1	RP11-307C12.13	4.5	8.56e-06	0.00172	0.22	0.2	Prostate cancer;	chr1:154938781	chr1:154937370~154938059:+
HNSC	cis	rs11893307	0.566	rs13412750	ENSG00000228509.4	AC006460.2	4.5	8.56e-06	0.00173	0.27	0.2	Mean platelet volume;	chr2:190770232	chr2:190676944~190708716:-
HNSC	cis	rs9329221	0.62	rs6601427	ENSG00000255310.2	AF131215.2	-4.5	8.56e-06	0.00173	-0.19	-0.2	Neuroticism;	chr8:10298515	chr8:11107788~11109726:-
HNSC	cis	rs8028182	0.636	rs4462560	ENSG00000260269.4	CTD-2323K18.1	4.5	8.56e-06	0.00173	0.26	0.2	Sudden cardiac arrest;	chr15:75355623	chr15:75527150~75601205:-
HNSC	cis	rs73198271	0.74	rs10098636	ENSG00000173295.6	FAM86B3P	-4.5	8.56e-06	0.00173	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8228595~8244865:+
HNSC	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	4.5	8.56e-06	0.00173	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
HNSC	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	4.5	8.56e-06	0.00173	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
HNSC	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	4.5	8.57e-06	0.00173	0.29	0.2	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
HNSC	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-4.5	8.57e-06	0.00173	-0.27	-0.2	Pain;	chr19:21505800	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-4.5	8.57e-06	0.00173	-0.27	-0.2	Pain;	chr19:21509773	chr19:21554640~21569237:-
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-4.5	8.57e-06	0.00173	-0.12	-0.2	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
HNSC	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-4.5	8.58e-06	0.00173	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
HNSC	cis	rs7121616	0.576	rs73608699	ENSG00000200879.1	SNORD14E	4.5	8.58e-06	0.00173	0.29	0.2	Breast cancer;	chr11:123044718	chr11:123058077~123058161:-
HNSC	cis	rs6831352	1	rs10017466	ENSG00000263923.1	RP11-571L19.7	-4.5	8.58e-06	0.00173	-0.2	-0.2	Alcohol dependence;	chr4:99134649	chr4:98928897~98994994:+
HNSC	cis	rs7615952	0.599	rs60847438	ENSG00000241439.1	RP11-666A20.3	4.5	8.58e-06	0.00173	0.24	0.2	Blood pressure (smoking interaction);	chr3:126027162	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.534	rs1503072	ENSG00000241439.1	RP11-666A20.3	4.5	8.58e-06	0.00173	0.24	0.2	Blood pressure (smoking interaction);	chr3:126035848	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.599	rs7631268	ENSG00000241439.1	RP11-666A20.3	4.5	8.58e-06	0.00173	0.24	0.2	Blood pressure (smoking interaction);	chr3:126036821	chr3:125958556~125958817:+
HNSC	cis	rs7662987	0.517	rs2924580	ENSG00000263923.1	RP11-571L19.7	-4.5	8.58e-06	0.00173	-0.22	-0.2	Smoking initiation;	chr4:99111017	chr4:98928897~98994994:+
HNSC	cis	rs12893668	0.645	rs35229468	ENSG00000269910.1	RP11-73M18.10	4.5	8.58e-06	0.00173	0.2	0.2	Reticulocyte count;	chr14:103585720	chr14:103694516~103695050:-
HNSC	cis	rs6964587	1	rs7811873	ENSG00000188693.7	CYP51A1-AS1	-4.5	8.59e-06	0.00173	-0.22	-0.2	Breast cancer;	chr7:92121806	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2269727	ENSG00000188693.7	CYP51A1-AS1	-4.5	8.59e-06	0.00173	-0.22	-0.2	Breast cancer;	chr7:92123376	chr7:92134604~92180725:+
HNSC	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	4.5	8.59e-06	0.00173	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	4.5	8.59e-06	0.00173	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
HNSC	cis	rs7824557	0.767	rs6985460	ENSG00000269918.1	AF131215.9	4.5	8.59e-06	0.00173	0.2	0.2	Retinal vascular caliber;	chr8:11313578	chr8:11104691~11106704:-
HNSC	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	4.5	8.59e-06	0.00173	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
HNSC	cis	rs2835345	0.561	rs5026478	ENSG00000279365.1	KB-176G8.1	4.5	8.59e-06	0.00173	0.24	0.2	Pulmonary function;	chr21:36453531	chr21:36485867~36487760:+
HNSC	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	4.5	8.59e-06	0.00173	0.17	0.2	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
HNSC	cis	rs860295	0.651	rs6692183	ENSG00000203761.5	MSTO2P	-4.5	8.59e-06	0.00173	-0.16	-0.2	Body mass index;	chr1:155334536	chr1:155745829~155750137:+
HNSC	cis	rs9910055	0.607	rs13726	ENSG00000267080.4	ASB16-AS1	-4.5	8.59e-06	0.00173	-0.16	-0.2	Total body bone mineral density;	chr17:44162193	chr17:44175973~44186717:-
HNSC	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	4.5	8.6e-06	0.00173	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
HNSC	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-4.5	8.6e-06	0.00173	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
HNSC	cis	rs73198271	0.751	rs55816468	ENSG00000233609.3	RP11-62H7.2	-4.5	8.61e-06	0.00173	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8961200~8979025:+
HNSC	cis	rs61542988	0.535	rs10807813	ENSG00000221740.1	SNORD93	4.5	8.61e-06	0.00173	0.27	0.2	Fibrinogen levels;	chr7:22790342	chr7:22856613~22856686:+
HNSC	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-4.5	8.61e-06	0.00173	-0.23	-0.2	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
HNSC	cis	rs6964587	1	rs12531366	ENSG00000188693.7	CYP51A1-AS1	-4.5	8.61e-06	0.00173	-0.21	-0.2	Breast cancer;	chr7:92054535	chr7:92134604~92180725:+
HNSC	cis	rs2439831	0.85	rs3862142	ENSG00000201136.1	RNU6-353P	-4.5	8.61e-06	0.00173	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43772608	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.702	rs2788	ENSG00000201136.1	RNU6-353P	-4.5	8.61e-06	0.00173	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43772688	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs28891769	ENSG00000201136.1	RNU6-353P	-4.5	8.61e-06	0.00173	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43780662	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs28578398	ENSG00000201136.1	RNU6-353P	-4.5	8.61e-06	0.00173	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43782848	chr15:43702363~43702470:+
HNSC	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-4.5	8.62e-06	0.00174	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
HNSC	cis	rs4295623	0.585	rs13259242	ENSG00000255310.2	AF131215.2	-4.5	8.62e-06	0.00174	-0.2	-0.2	Morning vs. evening chronotype;	chr8:11735524	chr8:11107788~11109726:-
HNSC	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-4.5	8.63e-06	0.00174	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
HNSC	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-4.5	8.63e-06	0.00174	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
HNSC	cis	rs9329221	0.527	rs10903328	ENSG00000255020.1	AF131216.5	4.5	8.63e-06	0.00174	0.23	0.2	Neuroticism;	chr8:10474657	chr8:11345748~11347502:-
HNSC	cis	rs17345786	1	rs58907984	ENSG00000244119.1	PDCL3P4	4.5	8.64e-06	0.00174	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101712472~101713191:+
HNSC	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	4.5	8.64e-06	0.00174	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
HNSC	cis	rs6500395	0.962	rs989070	ENSG00000261267.1	RP11-44I10.3	-4.5	8.64e-06	0.00174	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48568332	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9934626	ENSG00000261267.1	RP11-44I10.3	-4.5	8.64e-06	0.00174	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48568850	chr16:48559661~48587403:+
HNSC	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	4.5	8.64e-06	0.00174	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
HNSC	cis	rs11098499	0.866	rs6847778	ENSG00000249244.1	RP11-548H18.2	4.5	8.64e-06	0.00174	0.25	0.2	Corneal astigmatism;	chr4:119372427	chr4:119391831~119395335:-
HNSC	cis	rs80256351	0.517	rs7561771	ENSG00000271615.1	CTD-2026C7.1	4.5	8.64e-06	0.00174	0.25	0.2	Schizophrenia;	chr2:58233129	chr2:57755428~57766052:+
HNSC	cis	rs2985684	0.901	rs2354448	ENSG00000278009.1	RP11-649E7.8	4.5	8.64e-06	0.00174	0.26	0.2	Carotid intima media thickness;	chr14:49631578	chr14:49601011~49601124:-
HNSC	cis	rs2985684	1	rs1952012	ENSG00000278009.1	RP11-649E7.8	4.5	8.64e-06	0.00174	0.26	0.2	Carotid intima media thickness;	chr14:49632178	chr14:49601011~49601124:-
HNSC	cis	rs2985684	1	rs2985687	ENSG00000278009.1	RP11-649E7.8	4.5	8.64e-06	0.00174	0.26	0.2	Carotid intima media thickness;	chr14:49633668	chr14:49601011~49601124:-
HNSC	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	4.5	8.64e-06	0.00174	0.26	0.2	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	4.5	8.64e-06	0.00174	0.26	0.2	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	4.5	8.64e-06	0.00174	0.26	0.2	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	4.5	8.64e-06	0.00174	0.26	0.2	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
HNSC	cis	rs12986445	0.843	rs9309427	ENSG00000218682.1	AC010150.1	4.5	8.64e-06	0.00174	0.28	0.2	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25795865	chr2:25856461~25856966:-
HNSC	cis	rs61776719	0.738	rs7555461	ENSG00000212541.1	RNU6-510P	4.5	8.65e-06	0.00174	0.23	0.2	Coronary artery disease;	chr1:37979077	chr1:37991462~37991569:+
HNSC	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	4.5	8.65e-06	0.00174	0.24	0.2	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
HNSC	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	4.5	8.65e-06	0.00174	0.23	0.2	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
HNSC	cis	rs17594362	0.697	rs9562317	ENSG00000229473.2	RGS17P1	-4.5	8.65e-06	0.00174	-0.28	-0.2	Multiple sclerosis;	chr13:41562923	chr13:40992779~40993331:-
HNSC	cis	rs1713985	0.508	rs4865171	ENSG00000269949.1	RP11-738E22.3	4.5	8.66e-06	0.00174	0.34	0.2	Age-related macular degeneration;	chr4:57026477	chr4:56960927~56961373:-
HNSC	cis	rs911555	0.57	rs11625397	ENSG00000270108.1	RP11-73M18.6	-4.5	8.66e-06	0.00174	-0.22	-0.2	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103687576~103688127:+
HNSC	cis	rs2337406	1	rs74090714	ENSG00000280411.1	IGHV1-69-2	-4.5	8.66e-06	0.00174	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106691225	chr14:106762092~106762588:-
HNSC	cis	rs7937890	0.598	rs10734225	ENSG00000251991.1	RNU7-49P	4.5	8.66e-06	0.00174	0.24	0.2	Mitochondrial DNA levels;	chr11:14421448	chr11:14478892~14478953:+
HNSC	cis	rs853679	0.607	rs13204012	ENSG00000204709.4	LINC01556	4.5	8.66e-06	0.00174	0.43	0.2	Depression;	chr6:28233753	chr6:28943877~28944537:+
HNSC	cis	rs6831352	0.879	rs2602879	ENSG00000263923.1	RP11-571L19.7	-4.5	8.67e-06	0.00174	-0.22	-0.2	Alcohol dependence;	chr4:99119501	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602880	ENSG00000263923.1	RP11-571L19.7	-4.5	8.67e-06	0.00174	-0.22	-0.2	Smoking initiation;	chr4:99119502	chr4:98928897~98994994:+
HNSC	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	4.5	8.67e-06	0.00174	0.27	0.2	Pain;	chr19:21546020	chr19:21554640~21569237:-
HNSC	cis	rs4862750	0.872	rs7672831	ENSG00000250971.1	RP11-696F12.1	4.5	8.67e-06	0.00174	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186977728	chr4:187060099~187060930:+
HNSC	cis	rs7178909	0.835	rs2174292	ENSG00000259677.1	RP11-493E3.1	4.5	8.67e-06	0.00175	0.23	0.2	Common traits (Other);	chr15:89872349	chr15:89876540~89877285:+
HNSC	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	4.5	8.67e-06	0.00175	0.26	0.2	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	4.5	8.67e-06	0.00175	0.26	0.2	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	4.5	8.67e-06	0.00175	0.26	0.2	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	4.5	8.67e-06	0.00175	0.26	0.2	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	4.5	8.67e-06	0.00175	0.26	0.2	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
HNSC	cis	rs7824557	0.767	rs7837036	ENSG00000269918.1	AF131215.9	4.5	8.67e-06	0.00175	0.2	0.2	Retinal vascular caliber;	chr8:11317980	chr8:11104691~11106704:-
HNSC	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-4.5	8.68e-06	0.00175	-0.27	-0.2	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-4.5	8.68e-06	0.00175	-0.27	-0.2	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
HNSC	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	4.5	8.68e-06	0.00175	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
HNSC	cis	rs939574	1	rs9989854	ENSG00000243910.6	TUBA4B	-4.5	8.69e-06	0.00175	-0.38	-0.2	Platelet distribution width;	chr2:219221558	chr2:219253243~219272188:+
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	4.5	8.69e-06	0.00175	0.25	0.2	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	4.5	8.69e-06	0.00175	0.25	0.2	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
HNSC	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	4.5	8.7e-06	0.00175	0.22	0.2	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
HNSC	cis	rs1799949	0.965	rs8176323	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43043694	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4793190	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43048092	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176297	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43051308	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176296	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43051574	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4793191	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43052360	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4793192	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43052373	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176289	ENSG00000236383.6	LINC00854	-4.5	8.7e-06	0.00175	-0.19	-0.2	Menopause (age at onset);	chr17:43054039	chr17:43216941~43305976:-
HNSC	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	4.5	8.7e-06	0.00175	0.22	0.2	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
HNSC	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-4.5	8.7e-06	0.00175	-0.22	-0.2	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
HNSC	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	4.5	8.7e-06	0.00175	0.23	0.2	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
HNSC	cis	rs853679	0.607	rs72846780	ENSG00000204709.4	LINC01556	4.5	8.7e-06	0.00175	0.44	0.2	Depression;	chr6:28151277	chr6:28943877~28944537:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000106610.13	STAG3L4	4.5	8.7e-06	0.00175	0.41	0.2	Diabetic kidney disease;	chr7:66324467	chr7:67302621~67321526:+
HNSC	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	4.5	8.71e-06	0.00175	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
HNSC	cis	rs1479119	0.681	rs10772655	ENSG00000180861.8	LINC01559	4.5	8.71e-06	0.00175	0.26	0.2	Intelligence (multi-trait analysis);	chr12:13345447	chr12:13371089~13387167:-
HNSC	cis	rs6964587	0.9	rs11984136	ENSG00000188693.7	CYP51A1-AS1	-4.5	8.71e-06	0.00175	-0.21	-0.2	Breast cancer;	chr7:92137639	chr7:92134604~92180725:+
HNSC	cis	rs3736485	0.966	rs2124876	ENSG00000259438.1	CTD-2650P22.1	4.5	8.71e-06	0.00175	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51613965	chr15:52010999~52019095:-
HNSC	cis	rs3096299	0.933	rs2930219	ENSG00000261574.1	RP1-168P16.2	4.5	8.71e-06	0.00175	0.26	0.2	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89392375~89412564:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-4.5	8.71e-06	0.00175	-0.19	-0.2	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
HNSC	cis	rs9311676	0.656	rs4399910	ENSG00000273493.1	RP11-80H18.4	4.5	8.71e-06	0.00175	0.22	0.2	Systemic lupus erythematosus;	chr3:58404082	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs59643048	ENSG00000273493.1	RP11-80H18.4	4.5	8.71e-06	0.00175	0.22	0.2	Systemic lupus erythematosus;	chr3:58404521	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs12496906	ENSG00000273493.1	RP11-80H18.4	4.5	8.71e-06	0.00175	0.22	0.2	Systemic lupus erythematosus;	chr3:58404763	chr3:58329965~58330118:+
HNSC	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-4.5	8.72e-06	0.00175	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-4.5	8.72e-06	0.00175	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
HNSC	cis	rs4925386	0.84	rs6142738	ENSG00000275437.1	RP5-908M14.10	-4.5	8.72e-06	0.00175	-0.22	-0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62402236~62405935:-
HNSC	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	4.5	8.72e-06	0.00175	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
HNSC	cis	rs9880211	0.583	rs9870122	ENSG00000273486.1	RP11-731C17.2	4.5	8.72e-06	0.00175	0.18	0.2	Height;Body mass index;	chr3:136101423	chr3:136837338~136839021:-
HNSC	cis	rs597539	0.616	rs10896386	ENSG00000255741.1	RP11-757G1.5	-4.5	8.72e-06	0.00175	-0.28	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68941503~68942852:-
HNSC	cis	rs763121	0.889	rs2267390	ENSG00000273076.1	RP3-508I15.22	4.5	8.72e-06	0.00175	0.22	0.2	Menopause (age at onset);	chr22:38493652	chr22:38743495~38743910:+
HNSC	cis	rs7735319	0.774	rs13168871	ENSG00000249102.1	CTD-2066L21.1	4.5	8.72e-06	0.00175	0.25	0.2	Systolic blood pressure;	chr5:33066773	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.834	rs7707864	ENSG00000249102.1	CTD-2066L21.1	4.5	8.72e-06	0.00175	0.25	0.2	Systolic blood pressure;	chr5:33067611	chr5:33008994~33025724:+
HNSC	cis	rs1979679	0.842	rs36097532	ENSG00000247934.4	RP11-967K21.1	-4.5	8.72e-06	0.00175	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28163298~28190738:-
HNSC	cis	rs2998286	0.723	rs332154	ENSG00000254635.4	WAC-AS1	-4.5	8.72e-06	0.00175	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.723	rs332156	ENSG00000254635.4	WAC-AS1	-4.5	8.72e-06	0.00175	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28522652~28532743:-
HNSC	cis	rs2998286	0.54	rs332158	ENSG00000254635.4	WAC-AS1	-4.5	8.72e-06	0.00175	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28595433	chr10:28522652~28532743:-
HNSC	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	4.5	8.73e-06	0.00175	0.28	0.2	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	4.5	8.73e-06	0.00175	0.28	0.2	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	4.5	8.74e-06	0.00176	0.24	0.2	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
HNSC	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	4.5	8.74e-06	0.00176	0.16	0.2	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
HNSC	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-4.5	8.74e-06	0.00176	-0.27	-0.2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
HNSC	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.5	8.75e-06	0.00176	-0.18	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
HNSC	cis	rs10773046	0.74	rs1882489	ENSG00000269938.1	RP11-214K3.20	-4.5	8.75e-06	0.00176	-0.22	-0.2	Osteoarthritis (hip);	chr12:123879894	chr12:123968023~123968579:-
HNSC	cis	rs8077577	0.945	rs997315	ENSG00000273018.4	CTD-2303H24.2	-4.5	8.75e-06	0.00176	-0.31	-0.2	Obesity-related traits;	chr17:18181972	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.945	rs11656035	ENSG00000273018.4	CTD-2303H24.2	-4.5	8.75e-06	0.00176	-0.31	-0.2	Obesity-related traits;	chr17:18182711	chr17:18511221~18551705:-
HNSC	cis	rs4862750	0.914	rs6553026	ENSG00000250971.1	RP11-696F12.1	4.5	8.75e-06	0.00176	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:187060099~187060930:+
HNSC	cis	rs7662987	0.517	rs3018048	ENSG00000263923.1	RP11-571L19.7	-4.5	8.75e-06	0.00176	-0.22	-0.2	Smoking initiation;	chr4:99084387	chr4:98928897~98994994:+
HNSC	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	4.5	8.75e-06	0.00176	0.28	0.2	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
HNSC	cis	rs2333021	1	rs2333021	ENSG00000258376.2	RP4-647C14.2	-4.5	8.75e-06	0.00176	-0.24	-0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:73242651~73245979:-
HNSC	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	4.5	8.75e-06	0.00176	0.28	0.2	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
HNSC	cis	rs36052053	0.908	rs36094641	ENSG00000203799.9	CCDC162P	4.5	8.76e-06	0.00176	0.31	0.2	Red cell distribution width;	chr6:109282652	chr6:109285485~109355063:+
HNSC	cis	rs739496	0.579	rs3741998	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111902039	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs12319165	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111902930	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs73426310	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111904606	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs12427012	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111905570	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12316525	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111906315	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs73426314	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111907252	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12582302	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111907830	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs11066077	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111908857	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs10849984	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111909924	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs10849985	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111909950	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs7136469	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111910387	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.799	rs11066082	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111913544	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs61612992	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111920260	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs7300320	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111922364	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs11066089	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111925463	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs3752630	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111938186	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs3752631	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111938353	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7959619	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111938793	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs11066095	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111939733	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7133881	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111940964	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.748	rs7295665	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111941467	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.614	rs7137889	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111941783	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7973309	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Platelet count;	chr12:111944447	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs12579298	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111956218	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs12306814	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111966009	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs12423061	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111967091	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs112426410	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111969634	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs9971871	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111970572	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs60217649	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00176	0.23	0.2	Mean platelet volume;	chr12:111973116	chr12:111927018~111929017:+
HNSC	cis	rs9329221	0.537	rs13264586	ENSG00000254340.1	RP11-10A14.3	4.5	8.76e-06	0.00176	0.24	0.2	Neuroticism;	chr8:10121875	chr8:9141424~9145435:+
HNSC	cis	rs3015497	0.646	rs3015494	ENSG00000269906.1	RP11-248J18.2	-4.5	8.76e-06	0.00176	-0.27	-0.2	Mean platelet volume;	chr14:50648439	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.646	rs2172673	ENSG00000269906.1	RP11-248J18.2	-4.5	8.76e-06	0.00176	-0.27	-0.2	Mean platelet volume;	chr14:50649089	chr14:50662511~50663178:-
HNSC	cis	rs2098713	0.537	rs13163168	ENSG00000250155.1	CTD-2353F22.1	-4.5	8.76e-06	0.00176	-0.22	-0.2	Telomere length;	chr5:37487015	chr5:36666214~36725195:-
HNSC	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-4.5	8.77e-06	0.00176	-0.26	-0.2	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
HNSC	cis	rs597539	0.652	rs513615	ENSG00000255741.1	RP11-757G1.5	-4.5	8.78e-06	0.00176	-0.29	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68941503~68942852:-
HNSC	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	4.5	8.78e-06	0.00176	0.25	0.2	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
HNSC	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	4.5	8.78e-06	0.00176	0.25	0.2	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
HNSC	cis	rs1799949	1	rs2298862	ENSG00000236383.6	LINC00854	-4.5	8.78e-06	0.00176	-0.2	-0.2	Menopause (age at onset);	chr17:43024671	chr17:43216941~43305976:-
HNSC	cis	rs2835345	0.563	rs12627167	ENSG00000230479.1	AP000695.6	4.5	8.78e-06	0.00176	0.22	0.2	Pulmonary function;	chr21:36449855	chr21:36430360~36481070:+
HNSC	cis	rs9880211	1	rs17200216	ENSG00000273486.1	RP11-731C17.2	4.5	8.78e-06	0.00176	0.19	0.2	Height;Body mass index;	chr3:136348390	chr3:136837338~136839021:-
HNSC	cis	rs929354	0.772	rs6459737	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157182442	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs3802120	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157185100	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6971896	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157185718	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6957939	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157185791	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6954050	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157185860	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs11980541	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157196082	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs2366214	ENSG00000224629.1	RP5-1142J19.2	-4.5	8.78e-06	0.00176	-0.2	-0.2	Body mass index;	chr7:157199767	chr7:157263022~157263229:-
HNSC	cis	rs7937890	0.572	rs2597218	ENSG00000251991.1	RNU7-49P	4.5	8.78e-06	0.00176	0.24	0.2	Mitochondrial DNA levels;	chr11:14510792	chr11:14478892~14478953:+
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000224373.3	IGHV4-59	4.5	8.78e-06	0.00176	0.13	0.2	Kawasaki disease;	chr14:106691290	chr14:106627249~106627825:-
HNSC	cis	rs11247915	0.644	rs11588739	ENSG00000236782.4	RP11-96L14.7	-4.5	8.78e-06	0.00176	-0.24	-0.2	Obesity-related traits;	chr1:26326828	chr1:26169947~26171821:-
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000211974.3	IGHV2-70	4.49	8.79e-06	0.00176	0.19	0.2	Kawasaki disease;	chr14:106775695	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000211974.3	IGHV2-70	4.49	8.79e-06	0.00176	0.19	0.2	Kawasaki disease;	chr14:106775735	chr14:106723574~106724093:-
HNSC	cis	rs6723108	0.581	rs10176573	ENSG00000224043.6	CCNT2-AS1	-4.49	8.79e-06	0.00176	-0.25	-0.2	Type 2 diabetes;	chr2:134899901	chr2:134735464~134918710:-
HNSC	cis	rs12935418	0.616	rs2602453	ENSG00000278985.1	RP11-303E16.9	-4.49	8.79e-06	0.00177	-0.2	-0.2	Mean corpuscular volume;	chr16:80994358	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2970086	ENSG00000278985.1	RP11-303E16.9	-4.49	8.79e-06	0.00177	-0.2	-0.2	Mean corpuscular volume;	chr16:80994835	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2970085	ENSG00000278985.1	RP11-303E16.9	-4.49	8.79e-06	0.00177	-0.2	-0.2	Mean corpuscular volume;	chr16:80994842	chr16:80982319~80984094:-
HNSC	cis	rs4763879	0.634	rs2012643	ENSG00000278635.1	CTD-2318O12.1	4.49	8.79e-06	0.00177	0.16	0.2	Type 1 diabetes;	chr12:9707128	chr12:9415641~9416718:+
HNSC	cis	rs721917	0.506	rs2819098	ENSG00000225484.5	NUTM2B-AS1	-4.49	8.79e-06	0.00177	-0.25	-0.2	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79663088~79826594:-
HNSC	cis	rs1355223	0.583	rs2941041	ENSG00000271369.1	RP11-350D17.3	4.49	8.8e-06	0.00177	0.24	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853187	chr11:34709600~34710161:+
HNSC	cis	rs1908814	0.541	rs7824267	ENSG00000255495.1	AC145124.2	4.49	8.8e-06	0.00177	0.23	0.2	Neuroticism;	chr8:11936770	chr8:12194467~12196280:+
HNSC	cis	rs889398	0.771	rs8048550	ENSG00000226232.7	RP11-419C5.2	-4.49	8.81e-06	0.00177	-0.18	-0.2	Body mass index;	chr16:69857856	chr16:69976388~69996188:-
HNSC	cis	rs73222236	0.963	rs9875207	ENSG00000273486.1	RP11-731C17.2	4.49	8.81e-06	0.00177	0.17	0.2	Coronary artery disease;	chr3:136111296	chr3:136837338~136839021:-
HNSC	cis	rs2835345	0.528	rs12483650	ENSG00000279365.1	KB-176G8.1	4.49	8.81e-06	0.00177	0.24	0.2	Pulmonary function;	chr21:36450778	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.563	rs12483621	ENSG00000279365.1	KB-176G8.1	4.49	8.81e-06	0.00177	0.24	0.2	Pulmonary function;	chr21:36450798	chr21:36485867~36487760:+
HNSC	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	4.49	8.81e-06	0.00177	0.27	0.2	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
HNSC	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	4.49	8.81e-06	0.00177	0.29	0.2	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	4.49	8.81e-06	0.00177	0.29	0.2	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
HNSC	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	4.49	8.82e-06	0.00177	0.25	0.2	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
HNSC	cis	rs3738443	0.868	rs6660351	ENSG00000259865.1	RP11-488L18.10	4.49	8.82e-06	0.00177	0.19	0.2	Alcohol dependence;	chr1:247184526	chr1:247187281~247188526:-
HNSC	cis	rs7085104	0.66	rs7902804	ENSG00000236937.2	PTGES3P4	4.49	8.82e-06	0.00177	0.25	0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102845595~102845950:+
HNSC	cis	rs739496	0.579	rs3177647	ENSG00000226469.1	ADAM1B	4.49	8.83e-06	0.00177	0.23	0.2	Platelet count;	chr12:111839772	chr12:111927018~111929017:+
HNSC	cis	rs1218582	0.741	rs11264291	ENSG00000270361.1	RP11-307C12.13	-4.49	8.83e-06	0.00177	-0.22	-0.2	Prostate cancer;	chr1:154942321	chr1:154937370~154938059:+
HNSC	cis	rs3736485	0.844	rs62014659	ENSG00000259438.1	CTD-2650P22.1	4.49	8.83e-06	0.00177	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51526394	chr15:52010999~52019095:-
HNSC	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-4.49	8.84e-06	0.00177	-0.22	-0.2	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
HNSC	cis	rs9311676	0.656	rs4339119	ENSG00000273493.1	RP11-80H18.4	4.49	8.84e-06	0.00177	0.22	0.2	Systemic lupus erythematosus;	chr3:58403735	chr3:58329965~58330118:+
HNSC	cis	rs4356203	0.875	rs7939614	ENSG00000272034.1	SNORD14A	-4.49	8.84e-06	0.00177	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs9919540	ENSG00000272034.1	SNORD14A	-4.49	8.84e-06	0.00177	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17074654~17074744:-
HNSC	cis	rs860295	0.651	rs6677385	ENSG00000203761.5	MSTO2P	-4.49	8.85e-06	0.00177	-0.16	-0.2	Body mass index;	chr1:155334790	chr1:155745829~155750137:+
HNSC	cis	rs6430585	0.528	rs309152	ENSG00000231890.6	DARS-AS1	4.49	8.85e-06	0.00178	0.33	0.2	Corneal structure;	chr2:135899682	chr2:135985176~136022593:+
HNSC	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-4.49	8.85e-06	0.00178	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
HNSC	cis	rs3096299	0.933	rs28608022	ENSG00000261574.1	RP1-168P16.2	4.49	8.85e-06	0.00178	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89392375~89412564:-
HNSC	cis	rs2985684	1	rs2147712	ENSG00000278009.1	RP11-649E7.8	4.49	8.85e-06	0.00178	0.27	0.2	Carotid intima media thickness;	chr14:49624966	chr14:49601011~49601124:-
HNSC	cis	rs61542988	0.57	rs7781074	ENSG00000221740.1	SNORD93	-4.49	8.86e-06	0.00178	-0.27	-0.2	Fibrinogen levels;	chr7:22786741	chr7:22856613~22856686:+
HNSC	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	4.49	8.86e-06	0.00178	0.19	0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
HNSC	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-4.49	8.86e-06	0.00178	-0.27	-0.2	Pain;	chr19:21513185	chr19:21554640~21569237:-
HNSC	cis	rs7923609	0.841	rs10822186	ENSG00000232075.1	MRPL35P2	-4.49	8.87e-06	0.00178	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63590623	chr10:63634317~63634827:-
HNSC	cis	rs4761669	0.651	rs4761504	ENSG00000241556.1	RP11-490G8.1	4.49	8.87e-06	0.00178	0.2	0.2	Common carotid intima-media thickness in HIV infection;	chr12:94805491	chr12:95467397~95467861:-
HNSC	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-4.49	8.87e-06	0.00178	-0.17	-0.2	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
HNSC	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	4.49	8.87e-06	0.00178	0.23	0.2	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
HNSC	cis	rs6928977	0.832	rs2614286	ENSG00000217482.2	HMGB1P17	4.49	8.87e-06	0.00178	0.22	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371533	chr6:135636086~135636713:-
HNSC	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	4.49	8.87e-06	0.00178	0.24	0.2	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
HNSC	cis	rs757081	0.667	rs17560341	ENSG00000260196.1	RP1-239B22.5	-4.49	8.87e-06	0.00178	-0.25	-0.2	Systolic blood pressure;	chr11:17085616	chr11:17380649~17383531:+
HNSC	cis	rs2280018	0.526	rs2966128	ENSG00000263335.1	AF001548.5	-4.49	8.87e-06	0.00178	-0.28	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15726674~15732993:+
HNSC	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	4.49	8.88e-06	0.00178	0.13	0.2	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	4.49	8.88e-06	0.00178	0.13	0.2	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	4.49	8.88e-06	0.00178	0.13	0.2	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	4.49	8.88e-06	0.00178	0.13	0.2	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
HNSC	cis	rs929354	0.713	rs10085650	ENSG00000224629.1	RP5-1142J19.2	-4.49	8.88e-06	0.00178	-0.2	-0.2	Body mass index;	chr7:157200719	chr7:157263022~157263229:-
HNSC	cis	rs62246343	0.564	rs58000154	ENSG00000206573.7	THUMPD3-AS1	-4.49	8.88e-06	0.00178	-0.22	-0.2	Fibrinogen levels;	chr3:9479602	chr3:9349689~9398579:-
HNSC	cis	rs3736485	0.966	rs2414111	ENSG00000259438.1	CTD-2650P22.1	-4.49	8.88e-06	0.00178	-0.21	-0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51609160	chr15:52010999~52019095:-
HNSC	cis	rs6964587	0.967	rs12535601	ENSG00000188693.7	CYP51A1-AS1	-4.49	8.88e-06	0.00178	-0.21	-0.2	Breast cancer;	chr7:92089032	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6946356	ENSG00000188693.7	CYP51A1-AS1	-4.49	8.88e-06	0.00178	-0.21	-0.2	Breast cancer;	chr7:92098071	chr7:92134604~92180725:+
HNSC	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-4.49	8.88e-06	0.00178	-0.22	-0.2	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
HNSC	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	4.49	8.88e-06	0.00178	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
HNSC	cis	rs1799949	1	rs2292595	ENSG00000236383.6	LINC00854	-4.49	8.89e-06	0.00178	-0.19	-0.2	Menopause (age at onset);	chr17:43138657	chr17:43216941~43305976:-
HNSC	cis	rs4761669	0.771	rs4269983	ENSG00000241556.1	RP11-490G8.1	-4.49	8.89e-06	0.00178	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797089	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.804	rs4486690	ENSG00000241556.1	RP11-490G8.1	-4.49	8.89e-06	0.00178	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797106	chr12:95467397~95467861:-
HNSC	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-4.49	8.89e-06	0.00178	-0.25	-0.2	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
HNSC	cis	rs2361718	0.5	rs4889970	ENSG00000275479.1	RP11-334C17.6	-4.49	8.9e-06	0.00178	-0.23	-0.2	Yeast infection;	chr17:80122287	chr17:80149627~80149798:+
HNSC	cis	rs7178375	1	rs7176351	ENSG00000270055.1	CTD-3092A11.2	-4.49	8.9e-06	0.00178	-0.26	-0.2	Hypertriglyceridemia;	chr15:30916524	chr15:30487963~30490313:+
HNSC	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-4.49	8.9e-06	0.00178	-0.26	-0.2	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
HNSC	cis	rs860295	0.529	rs1475766	ENSG00000272405.1	RP11-284F21.10	4.49	8.9e-06	0.00178	0.25	0.2	Body mass index;	chr1:156011698	chr1:156641666~156644887:-
HNSC	cis	rs4873772	0.738	rs62539116	ENSG00000253330.1	RP11-697N18.3	-4.49	8.9e-06	0.00178	-0.26	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47585965	chr8:47511034~47512141:-
HNSC	cis	rs2732480	0.577	rs2634693	ENSG00000257763.1	OR5BK1P	4.49	8.9e-06	0.00179	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48355792~48356614:-
HNSC	cis	rs6163	0.588	rs3818708	ENSG00000213061.2	PFN1P11	4.49	8.9e-06	0.00179	0.24	0.2	Waist circumference;Hip circumference;	chr10:102743827	chr10:102838011~102845473:-
HNSC	cis	rs71636778	0.509	rs12743862	ENSG00000260063.1	RP5-968P14.2	-4.49	8.91e-06	0.00179	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701730	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs35041418	ENSG00000260063.1	RP5-968P14.2	-4.49	8.91e-06	0.00179	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26722492	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs12739212	ENSG00000260063.1	RP5-968P14.2	-4.49	8.91e-06	0.00179	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26724087	chr1:26692132~26694131:-
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000224373.3	IGHV4-59	4.49	8.91e-06	0.00179	0.13	0.2	Kawasaki disease;	chr14:106780451	chr14:106627249~106627825:-
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	4.49	8.91e-06	0.00179	0.25	0.2	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	4.49	8.91e-06	0.00179	0.25	0.2	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	4.49	8.91e-06	0.00179	0.25	0.2	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
HNSC	cis	rs4356203	0.905	rs9919600	ENSG00000272034.1	SNORD14A	-4.49	8.92e-06	0.00179	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs7939750	ENSG00000272034.1	SNORD14A	-4.49	8.92e-06	0.00179	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17074654~17074744:-
HNSC	cis	rs4761669	0.816	rs10745696	ENSG00000241556.1	RP11-490G8.1	-4.49	8.92e-06	0.00179	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94798355	chr12:95467397~95467861:-
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000233609.3	RP11-62H7.2	4.49	8.92e-06	0.00179	0.19	0.2	Systolic blood pressure;	chr8:8273016	chr8:8961200~8979025:+
HNSC	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	4.49	8.92e-06	0.00179	0.26	0.2	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
HNSC	cis	rs11098499	1	rs10029750	ENSG00000250412.1	KLHL2P1	4.49	8.93e-06	0.00179	0.26	0.2	Corneal astigmatism;	chr4:119251388	chr4:119334329~119378233:+
HNSC	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	4.49	8.93e-06	0.00179	0.23	0.2	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	4.49	8.93e-06	0.00179	0.23	0.2	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
HNSC	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	4.49	8.93e-06	0.00179	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	4.49	8.93e-06	0.00179	0.13	0.2	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
HNSC	cis	rs929354	0.772	rs6969244	ENSG00000224629.1	RP5-1142J19.2	-4.49	8.93e-06	0.00179	-0.2	-0.2	Body mass index;	chr7:157211318	chr7:157263022~157263229:-
HNSC	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	4.49	8.93e-06	0.00179	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
HNSC	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	4.49	8.94e-06	0.00179	0.27	0.2	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
HNSC	cis	rs9650657	0.589	rs12542037	ENSG00000255310.2	AF131215.2	4.49	8.95e-06	0.00179	0.2	0.2	Neuroticism;	chr8:10900986	chr8:11107788~11109726:-
HNSC	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-4.49	8.95e-06	0.00179	-0.21	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
HNSC	cis	rs442309	1	rs224058	ENSG00000238280.1	RP11-436D10.3	4.49	8.95e-06	0.00179	0.24	0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62739105	chr10:62793562~62805887:-
HNSC	cis	rs9650657	0.571	rs11783247	ENSG00000269918.1	AF131215.9	-4.49	8.95e-06	0.00179	-0.2	-0.2	Neuroticism;	chr8:10931365	chr8:11104691~11106704:-
HNSC	cis	rs9926296	0.687	rs258317	ENSG00000274627.1	RP11-104N10.2	4.49	8.95e-06	0.00179	0.2	0.2	Vitiligo;	chr16:89665830	chr16:89516797~89522217:+
HNSC	cis	rs4761669	0.816	rs892496	ENSG00000241556.1	RP11-490G8.1	-4.49	8.96e-06	0.00179	-0.21	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797841	chr12:95467397~95467861:-
HNSC	cis	rs4713118	0.581	rs200504	ENSG00000219392.1	RP1-265C24.5	-4.49	8.96e-06	0.00179	-0.28	-0.2	Parkinson's disease;	chr6:27818042	chr6:28115628~28116551:+
HNSC	cis	rs9863	0.861	rs3789967	ENSG00000270028.1	RP11-380L11.4	4.49	8.97e-06	0.0018	0.24	0.2	White blood cell count;	chr12:123962792	chr12:123925461~123926083:-
HNSC	cis	rs172166	0.516	rs2791333	ENSG00000219392.1	RP1-265C24.5	-4.49	8.97e-06	0.0018	-0.23	-0.2	Cardiac Troponin-T levels;	chr6:28143336	chr6:28115628~28116551:+
HNSC	cis	rs9880211	1	rs28811905	ENSG00000273486.1	RP11-731C17.2	4.49	8.98e-06	0.0018	0.19	0.2	Height;Body mass index;	chr3:136533210	chr3:136837338~136839021:-
HNSC	cis	rs116095464	1	rs6555160	ENSG00000277812.1	AC021087.1	-4.49	8.98e-06	0.0018	-0.4	-0.2	Breast cancer;	chr5:311554	chr5:262769~262881:+
HNSC	cis	rs9311676	0.656	rs7642652	ENSG00000273493.1	RP11-80H18.4	4.49	8.98e-06	0.0018	0.22	0.2	Systemic lupus erythematosus;	chr3:58387940	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs7620012	ENSG00000273493.1	RP11-80H18.4	4.49	8.98e-06	0.0018	0.22	0.2	Systemic lupus erythematosus;	chr3:58387989	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs7643057	ENSG00000273493.1	RP11-80H18.4	4.49	8.98e-06	0.0018	0.22	0.2	Systemic lupus erythematosus;	chr3:58388288	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs7610312	ENSG00000273493.1	RP11-80H18.4	4.49	8.98e-06	0.0018	0.22	0.2	Systemic lupus erythematosus;	chr3:58388302	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs56288363	ENSG00000273493.1	RP11-80H18.4	4.49	8.98e-06	0.0018	0.22	0.2	Systemic lupus erythematosus;	chr3:58388806	chr3:58329965~58330118:+
HNSC	cis	rs6809854	0.545	rs336611	ENSG00000228956.7	SATB1-AS1	-4.49	8.99e-06	0.0018	-0.22	-0.2	Psoriasis;Itch intensity from mosquito bite;	chr3:18609015	chr3:18445024~18920401:+
HNSC	cis	rs11893307	0.509	rs6726273	ENSG00000235852.1	AC005540.3	4.49	8.99e-06	0.0018	0.27	0.2	Mean platelet volume;	chr2:190664970	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.509	rs62179690	ENSG00000235852.1	AC005540.3	4.49	8.99e-06	0.0018	0.27	0.2	Mean platelet volume;	chr2:190665147	chr2:190880797~190882059:-
HNSC	cis	rs913655	0.574	rs2495837	ENSG00000225527.1	RP11-383B4.4	-4.49	8.99e-06	0.0018	-0.24	-0.2	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18780001	chr10:18531849~18533336:-
HNSC	cis	rs11722228	0.508	rs61335146	ENSG00000250413.1	RP11-448G15.1	-4.49	8.99e-06	0.0018	-0.3	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10129169	chr4:10006482~10009725:+
HNSC	cis	rs4356203	0.905	rs11024158	ENSG00000272034.1	SNORD14A	4.49	8.99e-06	0.0018	0.15	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17074654~17074744:-
HNSC	cis	rs4873772	0.837	rs12678110	ENSG00000253330.1	RP11-697N18.3	-4.49	8.99e-06	0.0018	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47649528	chr8:47511034~47512141:-
HNSC	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	4.49	9e-06	0.0018	0.34	0.2	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
HNSC	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-4.49	9e-06	0.0018	-0.25	-0.2	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
HNSC	cis	rs9300255	0.722	rs67624109	ENSG00000280120.1	RP11-546D6.3	-4.49	9e-06	0.0018	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123340088	chr12:123152324~123153377:-
HNSC	cis	rs721917	0.506	rs2819102	ENSG00000225484.5	NUTM2B-AS1	-4.49	9e-06	0.0018	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79663088~79826594:-
HNSC	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-4.49	9.01e-06	0.0018	-0.32	-0.2	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
HNSC	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	4.49	9.02e-06	0.00181	0.39	0.2	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
HNSC	cis	rs6831352	0.734	rs3100630	ENSG00000263923.1	RP11-571L19.7	-4.49	9.03e-06	0.00181	-0.21	-0.2	Alcohol dependence;	chr4:99110564	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.703	rs3133152	ENSG00000263923.1	RP11-571L19.7	-4.49	9.03e-06	0.00181	-0.21	-0.2	Alcohol dependence;	chr4:99110570	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.703	rs2602862	ENSG00000263923.1	RP11-571L19.7	-4.49	9.03e-06	0.00181	-0.21	-0.2	Alcohol dependence;	chr4:99112070	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.734	rs2851259	ENSG00000263923.1	RP11-571L19.7	-4.49	9.03e-06	0.00181	-0.21	-0.2	Alcohol dependence;	chr4:99112835	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.703	rs4235435	ENSG00000263923.1	RP11-571L19.7	-4.49	9.03e-06	0.00181	-0.21	-0.2	Alcohol dependence;	chr4:99118427	chr4:98928897~98994994:+
HNSC	cis	rs9304742	0.854	rs11084211	ENSG00000213801.4	ZNF816-ZNF321P	4.49	9.03e-06	0.00181	0.23	0.2	Psoriasis;	chr19:52957608	chr19:52927135~52942601:-
HNSC	cis	rs9393777	0.92	rs35120058	ENSG00000219392.1	RP1-265C24.5	-4.49	9.03e-06	0.00181	-0.4	-0.2	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28115628~28116551:+
HNSC	cis	rs2985684	1	rs1957977	ENSG00000278009.1	RP11-649E7.8	4.49	9.03e-06	0.00181	0.27	0.2	Carotid intima media thickness;	chr14:49623885	chr14:49601011~49601124:-
HNSC	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	4.49	9.03e-06	0.00181	0.18	0.2	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	4.49	9.03e-06	0.00181	0.18	0.2	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
HNSC	cis	rs6964587	0.934	rs6973792	ENSG00000188693.7	CYP51A1-AS1	-4.49	9.04e-06	0.00181	-0.22	-0.2	Breast cancer;	chr7:92120484	chr7:92134604~92180725:+
HNSC	cis	rs4713118	0.629	rs203887	ENSG00000204709.4	LINC01556	4.49	9.04e-06	0.00181	0.3	0.2	Parkinson's disease;	chr6:28053491	chr6:28943877~28944537:+
HNSC	cis	rs9329221	0.537	rs2062332	ENSG00000254340.1	RP11-10A14.3	4.49	9.04e-06	0.00181	0.24	0.2	Neuroticism;	chr8:10122514	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-4.49	9.04e-06	0.00181	-0.25	-0.2	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
HNSC	cis	rs755249	1	rs76841360	ENSG00000182109.6	RP11-69E11.4	4.49	9.04e-06	0.00181	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39522280~39546187:-
HNSC	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	4.49	9.05e-06	0.00181	0.23	0.2	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
HNSC	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-4.49	9.05e-06	0.00181	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
HNSC	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	4.49	9.06e-06	0.00181	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	4.49	9.06e-06	0.00181	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
HNSC	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-4.49	9.06e-06	0.00181	-0.25	-0.2	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-4.49	9.07e-06	0.00181	-0.24	-0.2	Depression;	chr6:28193021	chr6:28170845~28172521:+
HNSC	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	4.49	9.07e-06	0.00181	0.2	0.2	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
HNSC	cis	rs13434995	0.513	rs60097207	ENSG00000273257.1	RP11-177J6.1	-4.49	9.07e-06	0.00181	-0.28	-0.2	Adiponectin levels;	chr4:55406696	chr4:55387949~55388271:+
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-4.49	9.07e-06	0.00181	-0.18	-0.2	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
HNSC	cis	rs7015630	0.542	rs13280951	ENSG00000251136.7	RP11-37B2.1	-4.49	9.08e-06	0.00182	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89809746	chr8:89609409~89757727:-
HNSC	cis	rs7824557	0.767	rs4559208	ENSG00000269918.1	AF131215.9	4.49	9.08e-06	0.00182	0.2	0.2	Retinal vascular caliber;	chr8:11296416	chr8:11104691~11106704:-
HNSC	cis	rs7296418	0.699	rs1109559	ENSG00000280120.1	RP11-546D6.3	4.49	9.08e-06	0.00182	0.17	0.2	Platelet count;	chr12:123273314	chr12:123152324~123153377:-
HNSC	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	4.49	9.08e-06	0.00182	0.2	0.2	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
HNSC	cis	rs72615157	0.634	rs11762932	ENSG00000078319.8	PMS2P1	4.49	9.08e-06	0.00182	0.25	0.2	Lung function (FEV1/FVC);	chr7:100195043	chr7:100320992~100341908:-
HNSC	cis	rs6601327	0.585	rs1394	ENSG00000254340.1	RP11-10A14.3	-4.49	9.09e-06	0.00182	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9654144	chr8:9141424~9145435:+
HNSC	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-4.49	9.09e-06	0.00182	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
HNSC	cis	rs5758511	0.633	rs5751258	ENSG00000226450.2	CYP2D8P	4.49	9.09e-06	0.00182	0.2	0.2	Birth weight;	chr22:42267865	chr22:42149886~42155001:-
HNSC	cis	rs6601327	0.613	rs11785458	ENSG00000254340.1	RP11-10A14.3	-4.49	9.09e-06	0.00182	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9649300	chr8:9141424~9145435:+
HNSC	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-4.49	9.09e-06	0.00182	-0.23	-0.2	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
HNSC	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-4.49	9.09e-06	0.00182	-0.23	-0.2	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
HNSC	cis	rs1113500	0.787	rs2336126	ENSG00000226822.1	RP11-356N1.2	4.49	9.1e-06	0.00182	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108098283	chr1:108071482~108074519:+
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	4.49	9.11e-06	0.00182	0.25	0.2	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
HNSC	cis	rs656319	0.559	rs17689007	ENSG00000269918.1	AF131215.9	-4.49	9.11e-06	0.00182	-0.2	-0.2	Myopia (pathological);	chr8:10117314	chr8:11104691~11106704:-
HNSC	cis	rs4253772	0.55	rs739164	ENSG00000277232.2	GTSE1-AS1	4.49	9.11e-06	0.00182	0.25	0.2	Cholesterol, total;LDL cholesterol;	chr22:46288661	chr22:46295143~46296660:-
HNSC	cis	rs7296418	0.518	rs28825193	ENSG00000280120.1	RP11-546D6.3	4.49	9.11e-06	0.00182	0.17	0.2	Platelet count;	chr12:123393715	chr12:123152324~123153377:-
HNSC	cis	rs6951245	0.505	rs56117635	ENSG00000225146.1	AC073957.15	-4.49	9.11e-06	0.00182	-0.4	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:990398	chr7:1029025~1043891:+
HNSC	cis	rs17154702	0.524	rs2664041	ENSG00000253893.2	FAM85B	4.49	9.11e-06	0.00182	0.27	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8735634	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.603	rs570364	ENSG00000253893.2	FAM85B	4.49	9.11e-06	0.00182	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736128	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.632	rs570396	ENSG00000253893.2	FAM85B	4.49	9.11e-06	0.00182	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736142	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.603	rs571130	ENSG00000253893.2	FAM85B	4.49	9.11e-06	0.00182	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736181	chr8:8167819~8226614:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-4.49	9.11e-06	0.00182	-0.28	-0.2	Gout;	chr7:66645053	chr7:66880708~66882981:+
HNSC	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	4.49	9.12e-06	0.00182	0.27	0.2	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
HNSC	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-4.49	9.13e-06	0.00182	-0.23	-0.2	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
HNSC	cis	rs9329221	0.537	rs13282106	ENSG00000269918.1	AF131215.9	4.49	9.13e-06	0.00182	0.2	0.2	Neuroticism;	chr8:10124390	chr8:11104691~11106704:-
HNSC	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	4.49	9.13e-06	0.00182	0.21	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
HNSC	cis	rs6142102	0.659	rs6057945	ENSG00000275784.1	RP5-1125A11.6	-4.49	9.13e-06	0.00182	-0.26	-0.2	Skin pigmentation;	chr20:33929374	chr20:33989480~33991818:-
HNSC	cis	rs4356203	0.875	rs7125607	ENSG00000272034.1	SNORD14A	-4.49	9.13e-06	0.00183	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17074654~17074744:-
HNSC	cis	rs6787172	0.748	rs11710570	ENSG00000272087.1	RP11-379F4.7	4.49	9.13e-06	0.00183	0.21	0.2	Subjective well-being;	chr3:158338865	chr3:158693120~158693768:-
HNSC	cis	rs651386	0.506	rs11577602	ENSG00000271811.1	RP1-79C4.4	4.49	9.14e-06	0.00183	0.22	0.2	Atrial fibrillation;	chr1:170627404	chr1:170667381~170669425:+
HNSC	cis	rs577676	0.586	rs10800530	ENSG00000271811.1	RP1-79C4.4	4.49	9.14e-06	0.00183	0.22	0.2	Prevalent atrial fibrillation;	chr1:170627431	chr1:170667381~170669425:+
HNSC	cis	rs4787484	1	rs7189750	ENSG00000196796.5	CTB-134H23.2	4.49	9.14e-06	0.00183	0.22	0.2	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29038655~29052726:+
HNSC	cis	rs4873772	0.837	rs4489323	ENSG00000253330.1	RP11-697N18.3	-4.49	9.14e-06	0.00183	-0.26	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47679430	chr8:47511034~47512141:-
HNSC	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	4.49	9.14e-06	0.00183	0.2	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
HNSC	cis	rs4356203	0.905	rs11024159	ENSG00000272034.1	SNORD14A	-4.49	9.14e-06	0.00183	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17074654~17074744:-
HNSC	cis	rs1864400	0.641	rs61845681	ENSG00000273008.1	RP11-351D16.3	4.49	9.14e-06	0.00183	0.3	0.2	Hirschsprung disease;	chr10:43237732	chr10:43136824~43138334:-
HNSC	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	4.49	9.14e-06	0.00183	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
HNSC	cis	rs6500395	0.925	rs12920170	ENSG00000261267.1	RP11-44I10.3	4.49	9.15e-06	0.00183	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48667619	chr16:48559661~48587403:+
HNSC	cis	rs763567	0.539	rs593479	ENSG00000271811.1	RP1-79C4.4	4.49	9.15e-06	0.00183	0.23	0.2	Tonsillectomy;	chr1:170673758	chr1:170667381~170669425:+
HNSC	cis	rs16858210	0.874	rs55666767	ENSG00000234371.6	RPSAP31	4.49	9.15e-06	0.00183	0.25	0.2	Menopause (age at onset);	chr3:183855447	chr3:183884924~183888449:+
HNSC	cis	rs9959145	0.925	rs78425322	ENSG00000267249.1	RP11-973H7.3	-4.49	9.15e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12670426~12671145:-
HNSC	cis	rs4908769	0.66	rs159962	ENSG00000232912.4	RP5-1115A15.1	4.49	9.15e-06	0.00183	0.22	0.2	Allergy;	chr1:8430923	chr1:8424645~8434838:+
HNSC	cis	rs721917	0.506	rs2819097	ENSG00000225484.5	NUTM2B-AS1	-4.49	9.16e-06	0.00183	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79663088~79826594:-
HNSC	cis	rs1056107	0.933	rs12554866	ENSG00000225513.1	RP11-165N19.2	4.49	9.16e-06	0.00183	0.23	0.2	Colorectal cancer;	chr9:112201066	chr9:112173522~112173971:-
HNSC	cis	rs6586111	1	rs6586111	ENSG00000226659.1	RP11-137H2.4	-4.49	9.16e-06	0.00183	-0.24	-0.2	Capecitabine sensitivity;	chr10:80617834	chr10:80529597~80535942:-
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	4.49	9.16e-06	0.00183	0.25	0.2	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
HNSC	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	4.49	9.16e-06	0.00183	0.23	0.2	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
HNSC	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	4.49	9.16e-06	0.00183	0.23	0.2	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
HNSC	cis	rs4862750	0.872	rs6811569	ENSG00000250971.1	RP11-696F12.1	-4.49	9.16e-06	0.00183	-0.24	-0.2	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:187060099~187060930:+
HNSC	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	4.49	9.16e-06	0.00183	0.22	0.2	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
HNSC	cis	rs6496044	0.507	rs7175731	ENSG00000259295.5	CSPG4P12	-4.49	9.16e-06	0.00183	-0.24	-0.2	Interstitial lung disease;	chr15:85611115	chr15:85191438~85213905:+
HNSC	cis	rs6701713	0.959	rs1408077	ENSG00000274245.1	RP11-357P18.2	-4.49	9.17e-06	0.00183	-0.34	-0.2	Alzheimer's disease (late onset);	chr1:207630796	chr1:207372559~207373252:+
HNSC	cis	rs12935418	0.616	rs9931292	ENSG00000278985.1	RP11-303E16.9	4.49	9.17e-06	0.00183	0.2	0.2	Mean corpuscular volume;	chr16:80975671	chr16:80982319~80984094:-
HNSC	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	4.49	9.17e-06	0.00183	0.24	0.2	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	4.49	9.17e-06	0.00183	0.24	0.2	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
HNSC	cis	rs860295	0.58	rs7528441	ENSG00000225855.5	RUSC1-AS1	4.49	9.17e-06	0.00183	0.14	0.2	Body mass index;	chr1:155873465	chr1:155316863~155324176:-
HNSC	cis	rs6500395	0.584	rs1345433	ENSG00000261267.1	RP11-44I10.3	-4.49	9.17e-06	0.00183	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48704311	chr16:48559661~48587403:+
HNSC	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	4.49	9.17e-06	0.00183	0.18	0.2	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
HNSC	cis	rs9880211	0.948	rs34913797	ENSG00000273486.1	RP11-731C17.2	4.49	9.17e-06	0.00183	0.19	0.2	Height;Body mass index;	chr3:136408728	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-4.49	9.18e-06	0.00183	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
HNSC	cis	rs10946940	0.965	rs6921256	ENSG00000219392.1	RP1-265C24.5	-4.49	9.18e-06	0.00183	-0.23	-0.2	Systemic lupus erythematosus;	chr6:27619739	chr6:28115628~28116551:+
HNSC	cis	rs55665837	0.524	rs61884009	ENSG00000251991.1	RNU7-49P	4.49	9.18e-06	0.00183	0.25	0.2	Vitamin D levels;	chr11:14404916	chr11:14478892~14478953:+
HNSC	cis	rs1799949	1	rs11656097	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43138596	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11658754	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43140722	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.93	rs33968979	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43145975	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs12952790	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43147590	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs12950607	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43147911	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11079056	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43148782	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs12936816	ENSG00000236383.6	LINC00854	-4.49	9.18e-06	0.00183	-0.19	-0.2	Menopause (age at onset);	chr17:43149692	chr17:43216941~43305976:-
HNSC	cis	rs9959145	1	rs111268621	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12546290	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs9966118	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12548859	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs77079191	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12549379	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs1940973	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12550748	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs79785672	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12552110	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs77321492	ENSG00000267249.1	RP11-973H7.3	-4.49	9.19e-06	0.00183	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12552124	chr18:12670426~12671145:-
HNSC	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-4.48	9.19e-06	0.00184	-0.22	-0.2	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
HNSC	cis	rs1150668	0.799	rs1150707	ENSG00000219392.1	RP1-265C24.5	-4.48	9.19e-06	0.00184	-0.23	-0.2	Pubertal anthropometrics;	chr6:28229827	chr6:28115628~28116551:+
HNSC	cis	rs9311676	0.656	rs62258081	ENSG00000273493.1	RP11-80H18.4	4.48	9.19e-06	0.00184	0.22	0.2	Systemic lupus erythematosus;	chr3:58381978	chr3:58329965~58330118:+
HNSC	cis	rs17345786	0.861	rs79181492	ENSG00000244119.1	PDCL3P4	4.48	9.2e-06	0.00184	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101712472~101713191:+
HNSC	cis	rs67981189	0.593	rs221915	ENSG00000274818.1	RP1-292L20.3	-4.48	9.2e-06	0.00184	-0.23	-0.2	Schizophrenia;	chr14:71125425	chr14:70906657~70907111:-
HNSC	cis	rs2835345	0.563	rs58602880	ENSG00000279365.1	KB-176G8.1	4.48	9.2e-06	0.00184	0.25	0.2	Pulmonary function;	chr21:36454610	chr21:36485867~36487760:+
HNSC	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	4.48	9.2e-06	0.00184	0.13	0.2	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
HNSC	cis	rs8010715	0.636	rs2277480	ENSG00000259321.1	RP11-468E2.5	4.48	9.21e-06	0.00184	0.18	0.2	IgG glycosylation;	chr14:24118306	chr14:24139445~24140444:+
HNSC	cis	rs10129255	0.872	rs1858683	ENSG00000211974.3	IGHV2-70	4.48	9.21e-06	0.00184	0.19	0.2	Kawasaki disease;	chr14:106670217	chr14:106723574~106724093:-
HNSC	cis	rs1594829	0.553	rs7003030	ENSG00000228451.3	SDAD1P1	4.48	9.21e-06	0.00184	0.23	0.2	Height;	chr8:26315183	chr8:26379259~26382953:-
HNSC	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-4.48	9.21e-06	0.00184	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
HNSC	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	4.48	9.21e-06	0.00184	0.2	0.2	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
HNSC	cis	rs1479119	0.681	rs1382679	ENSG00000180861.8	LINC01559	4.48	9.21e-06	0.00184	0.26	0.2	Intelligence (multi-trait analysis);	chr12:13346347	chr12:13371089~13387167:-
HNSC	cis	rs6601327	0.613	rs12547642	ENSG00000254340.1	RP11-10A14.3	-4.48	9.21e-06	0.00184	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9636417	chr8:9141424~9145435:+
HNSC	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-4.48	9.21e-06	0.00184	-0.25	-0.2	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
HNSC	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-4.48	9.21e-06	0.00184	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	4.48	9.22e-06	0.00184	0.24	0.2	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
HNSC	cis	rs9863	0.861	rs3802999	ENSG00000269938.1	RP11-214K3.20	-4.48	9.22e-06	0.00184	-0.24	-0.2	White blood cell count;	chr12:123929551	chr12:123968023~123968579:-
HNSC	cis	rs35963943	0.625	rs11714576	ENSG00000228956.7	SATB1-AS1	4.48	9.22e-06	0.00184	0.25	0.2	Lymphocyte counts;	chr3:18668639	chr3:18445024~18920401:+
HNSC	cis	rs1799949	0.929	rs799906	ENSG00000236383.6	LINC00854	-4.48	9.22e-06	0.00184	-0.19	-0.2	Menopause (age at onset);	chr17:43126099	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs799908	ENSG00000236383.6	LINC00854	-4.48	9.22e-06	0.00184	-0.19	-0.2	Menopause (age at onset);	chr17:43126899	chr17:43216941~43305976:-
HNSC	cis	rs889398	0.616	rs35808754	ENSG00000226232.7	RP11-419C5.2	4.48	9.23e-06	0.00184	0.18	0.2	Body mass index;	chr16:69737807	chr16:69976388~69996188:-
HNSC	cis	rs7296418	0.599	rs2277343	ENSG00000280120.1	RP11-546D6.3	4.48	9.23e-06	0.00184	0.17	0.2	Platelet count;	chr12:123309903	chr12:123152324~123153377:-
HNSC	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-4.48	9.23e-06	0.00184	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
HNSC	cis	rs61160187	0.582	rs13359074	ENSG00000215032.2	GNL3LP1	4.48	9.23e-06	0.00184	0.23	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906758	chr5:60891935~60893577:-
HNSC	cis	rs9311676	0.618	rs12152336	ENSG00000273493.1	RP11-80H18.4	4.48	9.23e-06	0.00184	0.22	0.2	Systemic lupus erythematosus;	chr3:58379419	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs67904096	ENSG00000273493.1	RP11-80H18.4	4.48	9.23e-06	0.00184	0.22	0.2	Systemic lupus erythematosus;	chr3:58379781	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11130631	ENSG00000273493.1	RP11-80H18.4	4.48	9.23e-06	0.00184	0.22	0.2	Systemic lupus erythematosus;	chr3:58380401	chr3:58329965~58330118:+
HNSC	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-4.48	9.24e-06	0.00184	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
HNSC	cis	rs6964587	1	rs10245095	ENSG00000188693.7	CYP51A1-AS1	-4.48	9.24e-06	0.00184	-0.21	-0.2	Breast cancer;	chr7:92081531	chr7:92134604~92180725:+
HNSC	cis	rs9329221	0.527	rs34308302	ENSG00000255020.1	AF131216.5	-4.48	9.24e-06	0.00184	-0.23	-0.2	Neuroticism;	chr8:10474512	chr8:11345748~11347502:-
HNSC	cis	rs8077577	0.945	rs8069094	ENSG00000273018.4	CTD-2303H24.2	-4.48	9.24e-06	0.00184	-0.3	-0.2	Obesity-related traits;	chr17:18193214	chr17:18511221~18551705:-
HNSC	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-4.48	9.24e-06	0.00184	-0.25	-0.2	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
HNSC	cis	rs3758785	0.623	rs75164831	ENSG00000255893.1	RP11-685N10.1	-4.48	9.24e-06	0.00184	-0.31	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410667	chr11:94472908~94473570:-
HNSC	cis	rs10462794	0.713	rs896134	ENSG00000260763.1	RP11-445O3.3	4.48	9.24e-06	0.00184	0.27	0.2	DNA methylation (variation);	chr5:4511429	chr5:4436850~4440259:-
HNSC	cis	rs1355223	0.545	rs7106831	ENSG00000271369.1	RP11-350D17.3	-4.48	9.24e-06	0.00184	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr11:34709600~34710161:+
HNSC	cis	rs11673344	0.523	rs6510584	ENSG00000276846.1	CTD-3220F14.3	4.48	9.24e-06	0.00184	0.22	0.2	Obesity-related traits;	chr19:37058699	chr19:37314868~37315620:-
HNSC	cis	rs13434995	0.588	rs114571142	ENSG00000273257.1	RP11-177J6.1	-4.48	9.24e-06	0.00184	-0.28	-0.2	Adiponectin levels;	chr4:55412991	chr4:55387949~55388271:+
HNSC	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-4.48	9.25e-06	0.00184	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
HNSC	cis	rs700641	1	rs700641	ENSG00000222017.1	AC011997.1	4.48	9.25e-06	0.00185	0.25	0.2	Morning vs. evening chronotype;	chr2:197734509	chr2:197693106~197774823:+
HNSC	cis	rs12666612	0.584	rs115946365	ENSG00000237773.4	AC003075.4	4.48	9.25e-06	0.00185	0.47	0.2	Obesity-related traits;	chr7:18189308	chr7:17279834~17299357:-
HNSC	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	4.48	9.25e-06	0.00185	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
HNSC	cis	rs9863	0.804	rs80270210	ENSG00000269938.1	RP11-214K3.20	-4.48	9.25e-06	0.00185	-0.26	-0.2	White blood cell count;	chr12:123962850	chr12:123968023~123968579:-
HNSC	cis	rs2337406	0.641	rs10133227	ENSG00000254174.1	IGHV1-12	-4.48	9.25e-06	0.00185	-0.16	-0.2	Alzheimer's disease (late onset);	chr14:106814260	chr14:106122420~106122709:-
HNSC	cis	rs4660214	0.666	rs663892	ENSG00000182109.6	RP11-69E11.4	4.48	9.25e-06	0.00185	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39522280~39546187:-
HNSC	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-4.48	9.25e-06	0.00185	-0.23	-0.2	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
HNSC	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	4.48	9.25e-06	0.00185	0.26	0.2	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
HNSC	cis	rs9368481	0.594	rs7768643	ENSG00000224843.5	LINC00240	-4.48	9.25e-06	0.00185	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.594	rs7768814	ENSG00000224843.5	LINC00240	-4.48	9.25e-06	0.00185	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26956992~27023924:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000226155.1	AC124944.3	-4.48	9.26e-06	0.00185	-0.24	-0.2	Pancreatic cancer;	chr3:196026895	chr3:195912049~195913986:+
HNSC	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-4.48	9.27e-06	0.00185	-0.25	-0.2	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
HNSC	cis	rs4660214	0.666	rs588326	ENSG00000182109.6	RP11-69E11.4	4.48	9.27e-06	0.00185	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39522280~39546187:-
HNSC	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.48	9.28e-06	0.00185	-0.22	-0.2	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
HNSC	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	4.48	9.28e-06	0.00185	0.28	0.2	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
HNSC	cis	rs440932	0.887	rs398801	ENSG00000254153.1	CTA-398F10.2	-4.48	9.29e-06	0.00185	-0.24	-0.2	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8456909~8461337:-
HNSC	cis	rs3096299	0.933	rs2965823	ENSG00000261574.1	RP1-168P16.2	4.48	9.3e-06	0.00185	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89392375~89412564:-
HNSC	cis	rs896655	0.631	rs1335510	ENSG00000244230.3	RN7SL151P	4.48	9.3e-06	0.00185	0.22	0.2	Coronary artery disease;	chr9:21757804	chr9:21699314~21699596:+
HNSC	cis	rs8396	1	rs9410	ENSG00000271817.2	U3	4.48	9.3e-06	0.00185	0.21	0.2	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158710839	chr4:158700691~158700909:+
HNSC	cis	rs7735319	0.834	rs34666210	ENSG00000249102.1	CTD-2066L21.1	4.48	9.3e-06	0.00185	0.24	0.2	Systolic blood pressure;	chr5:33069978	chr5:33008994~33025724:+
HNSC	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	4.48	9.3e-06	0.00185	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
HNSC	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	4.48	9.3e-06	0.00185	0.24	0.2	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000211974.3	IGHV2-70	4.48	9.31e-06	0.00186	0.19	0.2	Kawasaki disease;	chr14:106705271	chr14:106723574~106724093:-
HNSC	cis	rs929354	0.685	rs1808217	ENSG00000224629.1	RP5-1142J19.2	-4.48	9.31e-06	0.00186	-0.2	-0.2	Body mass index;	chr7:157210047	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs2006844	ENSG00000224629.1	RP5-1142J19.2	-4.48	9.31e-06	0.00186	-0.2	-0.2	Body mass index;	chr7:157210157	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs886677	ENSG00000224629.1	RP5-1142J19.2	-4.48	9.31e-06	0.00186	-0.2	-0.2	Body mass index;	chr7:157211088	chr7:157263022~157263229:-
HNSC	cis	rs55661361	0.679	rs12287365	ENSG00000245498.5	RP11-677M14.7	4.48	9.31e-06	0.00186	0.21	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742814	chr11:124800450~124834487:+
HNSC	cis	rs55661361	0.651	rs12293624	ENSG00000245498.5	RP11-677M14.7	4.48	9.31e-06	0.00186	0.21	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742937	chr11:124800450~124834487:+
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-4.48	9.31e-06	0.00186	-0.25	-0.2	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs67340775	ENSG00000204709.4	LINC01556	4.48	9.32e-06	0.00186	0.41	0.2	Depression;	chr6:28336607	chr6:28943877~28944537:+
HNSC	cis	rs4326844	0.583	rs10506328	ENSG00000248265.1	FLJ12825	4.48	9.32e-06	0.00186	0.24	0.2	Platelet count;	chr12:54293448	chr12:54058254~54122234:+
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000254153.1	CTA-398F10.2	4.48	9.32e-06	0.00186	0.22	0.2	Mood instability;	chr8:8813089	chr8:8456909~8461337:-
HNSC	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	4.48	9.32e-06	0.00186	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.644	rs4395858	ENSG00000255310.2	AF131215.2	4.48	9.32e-06	0.00186	0.19	0.2	Neuroticism;	chr8:10663511	chr8:11107788~11109726:-
HNSC	cis	rs4660214	0.614	rs11205802	ENSG00000182109.6	RP11-69E11.4	-4.48	9.32e-06	0.00186	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.614	rs10888715	ENSG00000182109.6	RP11-69E11.4	-4.48	9.32e-06	0.00186	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39522280~39546187:-
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000233609.3	RP11-62H7.2	-4.48	9.32e-06	0.00186	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9226611	chr8:8961200~8979025:+
HNSC	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	4.48	9.32e-06	0.00186	0.26	0.2	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
HNSC	cis	rs728616	0.867	rs61859763	ENSG00000225484.5	NUTM2B-AS1	-4.48	9.32e-06	0.00186	-0.48	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79663088~79826594:-
HNSC	cis	rs61270009	0.955	rs17548339	ENSG00000247828.6	TMEM161B-AS1	4.48	9.33e-06	0.00186	0.22	0.2	Depressive symptoms;	chr5:88391761	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs16903122	ENSG00000247828.6	TMEM161B-AS1	4.48	9.33e-06	0.00186	0.22	0.2	Depressive symptoms;	chr5:88397744	chr5:88268895~88436685:+
HNSC	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	4.48	9.33e-06	0.00186	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
HNSC	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-4.48	9.33e-06	0.00186	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-4.48	9.33e-06	0.00186	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-4.48	9.33e-06	0.00186	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-4.48	9.33e-06	0.00186	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
HNSC	cis	rs7746199	0.736	rs13202295	ENSG00000219392.1	RP1-265C24.5	-4.48	9.33e-06	0.00186	-0.41	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28115628~28116551:+
HNSC	cis	rs6500395	1	rs1558817	ENSG00000261267.1	RP11-44I10.3	-4.48	9.35e-06	0.00186	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48696811	chr16:48559661~48587403:+
HNSC	cis	rs4787491	0.704	rs66467443	ENSG00000183604.13	SMG1P5	-4.48	9.35e-06	0.00186	-0.2	-0.2	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30267553~30335374:-
HNSC	cis	rs988913	0.706	rs4521592	ENSG00000224984.1	RP11-524H19.2	4.48	9.35e-06	0.00186	0.23	0.2	Menarche (age at onset);	chr6:55090481	chr6:54840118~54840855:-
HNSC	cis	rs17507216	0.718	rs72751657	ENSG00000276710.3	CSPG4P8	-4.48	9.35e-06	0.00186	-0.29	-0.2	Excessive daytime sleepiness;	chr15:82581259	chr15:82459472~82477258:+
HNSC	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	4.48	9.35e-06	0.00186	0.24	0.2	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
HNSC	cis	rs638893	1	rs636736	ENSG00000255422.1	AP002954.4	-4.48	9.35e-06	0.00186	-0.33	-0.2	Vitiligo;	chr11:118834436	chr11:118704607~118750263:+
HNSC	cis	rs11951515	0.7	rs4443426	ENSG00000249286.1	CTD-2210P15.2	4.48	9.36e-06	0.00186	0.21	0.2	Metabolite levels  (X-11787);	chr5:43279470	chr5:43586918~43588223:-
HNSC	cis	rs2361718	0.564	rs2304844	ENSG00000275479.1	RP11-334C17.6	4.48	9.36e-06	0.00186	0.23	0.2	Yeast infection;	chr17:80110708	chr17:80149627~80149798:+
HNSC	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-4.48	9.36e-06	0.00186	-0.34	-0.2	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
HNSC	cis	rs924712	0.572	rs9367594	ENSG00000224984.1	RP11-524H19.2	-4.48	9.36e-06	0.00186	-0.23	-0.2	Breast cancer;	chr6:54838072	chr6:54840118~54840855:-
HNSC	cis	rs11722228	0.522	rs73212817	ENSG00000250413.1	RP11-448G15.1	-4.48	9.36e-06	0.00186	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10062387	chr4:10006482~10009725:+
HNSC	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	4.48	9.36e-06	0.00186	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
HNSC	cis	rs155076	0.666	rs9509640	ENSG00000233325.3	MIPEPP3	-4.48	9.36e-06	0.00187	-0.35	-0.2	White matter hyperintensity burden;	chr13:21298741	chr13:21298139~21306373:+
HNSC	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-4.48	9.36e-06	0.00187	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
HNSC	cis	rs11089937	0.584	rs5757245	ENSG00000211638.2	IGLV8-61	-4.48	9.37e-06	0.00187	-0.19	-0.2	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22098700~22099212:+
HNSC	cis	rs3738443	0.868	rs35229190	ENSG00000259865.1	RP11-488L18.10	4.48	9.37e-06	0.00187	0.18	0.2	Alcohol dependence;	chr1:247202339	chr1:247187281~247188526:-
HNSC	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	4.48	9.37e-06	0.00187	0.2	0.2	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
HNSC	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-4.48	9.37e-06	0.00187	-0.27	-0.2	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
HNSC	cis	rs4321325	0.536	rs10198483	ENSG00000236682.1	AC068282.3	-4.48	9.37e-06	0.00187	-0.29	-0.2	Protein C levels;	chr2:127176526	chr2:127389130~127400580:+
HNSC	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	4.48	9.37e-06	0.00187	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
HNSC	cis	rs6723108	0.517	rs4954192	ENSG00000224043.6	CCNT2-AS1	-4.48	9.38e-06	0.00187	-0.24	-0.2	Type 2 diabetes;	chr2:134875411	chr2:134735464~134918710:-
HNSC	cis	rs10028773	0.6	rs4001390	ENSG00000249244.1	RP11-548H18.2	4.48	9.38e-06	0.00187	0.25	0.2	Educational attainment;	chr4:119344628	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.691	rs2136911	ENSG00000249244.1	RP11-548H18.2	4.48	9.38e-06	0.00187	0.25	0.2	Corneal astigmatism;	chr4:119344704	chr4:119391831~119395335:-
HNSC	cis	rs10028773	0.568	rs6838457	ENSG00000249244.1	RP11-548H18.2	4.48	9.38e-06	0.00187	0.25	0.2	Educational attainment;	chr4:119346212	chr4:119391831~119395335:-
HNSC	cis	rs6964587	1	rs12540055	ENSG00000188693.7	CYP51A1-AS1	-4.48	9.38e-06	0.00187	-0.21	-0.2	Breast cancer;	chr7:92078607	chr7:92134604~92180725:+
HNSC	cis	rs10435719	0.867	rs62493601	ENSG00000255495.1	AC145124.2	4.48	9.38e-06	0.00187	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.753	rs9694940	ENSG00000255495.1	AC145124.2	4.48	9.38e-06	0.00187	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.78	rs9692662	ENSG00000255495.1	AC145124.2	4.48	9.38e-06	0.00187	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:12194467~12196280:+
HNSC	cis	rs10435719	0.899	rs9693925	ENSG00000255495.1	AC145124.2	4.48	9.38e-06	0.00187	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:12194467~12196280:+
HNSC	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	4.48	9.38e-06	0.00187	0.22	0.2	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
HNSC	cis	rs35963943	0.625	rs12635064	ENSG00000228956.7	SATB1-AS1	4.48	9.39e-06	0.00187	0.25	0.2	Lymphocyte counts;	chr3:18698827	chr3:18445024~18920401:+
HNSC	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	4.48	9.39e-06	0.00187	0.29	0.2	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
HNSC	cis	rs7662987	0.517	rs2851277	ENSG00000263923.1	RP11-571L19.7	-4.48	9.39e-06	0.00187	-0.22	-0.2	Smoking initiation;	chr4:99101759	chr4:98928897~98994994:+
HNSC	cis	rs757081	0.608	rs214938	ENSG00000260196.1	RP1-239B22.5	-4.48	9.4e-06	0.00187	-0.25	-0.2	Systolic blood pressure;	chr11:17166969	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs7108067	ENSG00000260196.1	RP1-239B22.5	-4.48	9.4e-06	0.00187	-0.25	-0.2	Systolic blood pressure;	chr11:17178673	chr11:17380649~17383531:+
HNSC	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	4.48	9.4e-06	0.00187	0.24	0.2	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
HNSC	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	4.48	9.41e-06	0.00187	0.2	0.2	Height;	chr5:37488095	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.779	rs6815934	ENSG00000249244.1	RP11-548H18.2	4.48	9.41e-06	0.00187	0.25	0.2	Corneal astigmatism;	chr4:119346155	chr4:119391831~119395335:-
HNSC	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	4.48	9.42e-06	0.00187	0.21	0.2	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
HNSC	cis	rs6831352	0.734	rs1154400	ENSG00000263923.1	RP11-571L19.7	-4.48	9.42e-06	0.00187	-0.21	-0.2	Alcohol dependence;	chr4:99088859	chr4:98928897~98994994:+
HNSC	cis	rs7829975	0.56	rs6994131	ENSG00000173295.6	FAM86B3P	-4.48	9.42e-06	0.00187	-0.24	-0.2	Mood instability;	chr8:8693448	chr8:8228595~8244865:+
HNSC	cis	rs12935418	0.672	rs1453328	ENSG00000261061.1	RP11-303E16.2	-4.48	9.42e-06	0.00188	-0.22	-0.2	Mean corpuscular volume;	chr16:81019240	chr16:81030770~81031485:+
HNSC	cis	rs6500395	0.962	rs11648101	ENSG00000261267.1	RP11-44I10.3	-4.48	9.42e-06	0.00188	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48680267	chr16:48559661~48587403:+
HNSC	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-4.48	9.42e-06	0.00188	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-4.48	9.42e-06	0.00188	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
HNSC	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	4.48	9.42e-06	0.00188	0.3	0.2	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
HNSC	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-4.48	9.42e-06	0.00188	-0.2	-0.2	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
HNSC	cis	rs4660214	0.568	rs6692769	ENSG00000182109.6	RP11-69E11.4	-4.48	9.43e-06	0.00188	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39522280~39546187:-
HNSC	cis	rs73222236	0.825	rs9872326	ENSG00000273486.1	RP11-731C17.2	4.48	9.43e-06	0.00188	0.17	0.2	Coronary artery disease;	chr3:136267702	chr3:136837338~136839021:-
HNSC	cis	rs36563	0.631	rs1859915	ENSG00000274818.1	RP1-292L20.3	4.48	9.43e-06	0.00188	0.32	0.2	Alcohol dependence;	chr14:71018861	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.896	rs1859468	ENSG00000274818.1	RP1-292L20.3	-4.48	9.43e-06	0.00188	-0.24	-0.2	Schizophrenia;	chr14:70935573	chr14:70906657~70907111:-
HNSC	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-4.48	9.44e-06	0.00188	-0.37	-0.2	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
HNSC	cis	rs2439831	0.85	rs16950562	ENSG00000201136.1	RNU6-353P	-4.48	9.44e-06	0.00188	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43744166	chr15:43702363~43702470:+
HNSC	cis	rs1050631	1	rs719147	ENSG00000278986.1	RP11-723J4.3	4.48	9.44e-06	0.00188	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36118229	chr18:35972151~35973916:+
HNSC	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	4.48	9.44e-06	0.00188	0.29	0.2	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
HNSC	cis	rs4908769	0.66	rs302714	ENSG00000232912.4	RP5-1115A15.1	4.48	9.45e-06	0.00188	0.23	0.2	Allergy;	chr1:8426071	chr1:8424645~8434838:+
HNSC	cis	rs3736485	0.966	rs11070862	ENSG00000259438.1	CTD-2650P22.1	4.48	9.45e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51610030	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs2899476	ENSG00000259438.1	CTD-2650P22.1	4.48	9.45e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51611677	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs2414113	ENSG00000259438.1	CTD-2650P22.1	4.48	9.45e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51611699	chr15:52010999~52019095:-
HNSC	cis	rs1050631	1	rs1539822	ENSG00000278986.1	RP11-723J4.3	4.48	9.45e-06	0.00188	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36115980	chr18:35972151~35973916:+
HNSC	cis	rs1050631	1	rs1785916	ENSG00000278986.1	RP11-723J4.3	4.48	9.45e-06	0.00188	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36116193	chr18:35972151~35973916:+
HNSC	cis	rs1050631	1	rs1789504	ENSG00000278986.1	RP11-723J4.3	4.48	9.45e-06	0.00188	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36116809	chr18:35972151~35973916:+
HNSC	cis	rs853679	0.607	rs35749575	ENSG00000204709.4	LINC01556	4.48	9.46e-06	0.00188	0.43	0.2	Depression;	chr6:28147040	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13205911	ENSG00000204709.4	LINC01556	4.48	9.46e-06	0.00188	0.43	0.2	Depression;	chr6:28156336	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13197176	ENSG00000204709.4	LINC01556	4.48	9.46e-06	0.00188	0.43	0.2	Depression;	chr6:28161454	chr6:28943877~28944537:+
HNSC	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	4.48	9.46e-06	0.00188	0.26	0.2	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
HNSC	cis	rs1659258	0.568	rs1713941	ENSG00000232508.1	MRPL45P1	4.48	9.46e-06	0.00188	0.34	0.2	Visceral fat;	chr2:88329841	chr2:88364695~88365608:-
HNSC	cis	rs8074700	1	rs8074700	ENSG00000239552.2	HOXB-AS2	4.48	9.46e-06	0.00188	0.22	0.2	Body mass index in non-asthmatics;	chr17:48672429	chr17:48557262~48560333:+
HNSC	cis	rs929354	0.713	rs1034785	ENSG00000224629.1	RP5-1142J19.2	-4.48	9.46e-06	0.00188	-0.2	-0.2	Body mass index;	chr7:157209689	chr7:157263022~157263229:-
HNSC	cis	rs3736485	0.966	rs7177720	ENSG00000259438.1	CTD-2650P22.1	4.48	9.46e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598085	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs7170444	ENSG00000259438.1	CTD-2650P22.1	4.48	9.46e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598303	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs7170217	ENSG00000259438.1	CTD-2650P22.1	4.48	9.46e-06	0.00188	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598481	chr15:52010999~52019095:-
HNSC	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	4.48	9.46e-06	0.00188	0.27	0.2	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
HNSC	cis	rs4256159	1	rs73172355	ENSG00000228956.7	SATB1-AS1	4.48	9.47e-06	0.00188	0.34	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18736399	chr3:18445024~18920401:+
HNSC	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-4.48	9.47e-06	0.00188	-0.26	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	4.48	9.48e-06	0.00189	0.24	0.2	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
HNSC	cis	rs11722228	0.522	rs12504600	ENSG00000250413.1	RP11-448G15.1	-4.48	9.48e-06	0.00189	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10065514	chr4:10006482~10009725:+
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-4.48	9.49e-06	0.00189	-0.19	-0.2	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
HNSC	cis	rs4853525	0.62	rs1914408	ENSG00000235852.1	AC005540.3	-4.48	9.49e-06	0.00189	-0.28	-0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190975250	chr2:190880797~190882059:-
HNSC	cis	rs7665090	0.84	rs228618	ENSG00000246560.2	RP11-10L12.4	-4.48	9.49e-06	0.00189	-0.23	-0.2	Primary biliary cholangitis;	chr4:102646191	chr4:102828055~102844075:+
HNSC	cis	rs9813712	0.595	rs1453238	ENSG00000249846.5	RP11-77P16.4	4.48	9.5e-06	0.00189	0.22	0.2	Response to amphetamines;	chr3:130290494	chr3:130112550~130120579:+
HNSC	cis	rs6964587	0.773	rs12536421	ENSG00000188693.7	CYP51A1-AS1	-4.48	9.5e-06	0.00189	-0.21	-0.2	Breast cancer;	chr7:92378906	chr7:92134604~92180725:+
HNSC	cis	rs597539	0.652	rs478647	ENSG00000255741.1	RP11-757G1.5	-4.48	9.5e-06	0.00189	-0.29	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68941503~68942852:-
HNSC	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	4.48	9.51e-06	0.00189	0.26	0.2	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
HNSC	cis	rs4787484	0.964	rs7498372	ENSG00000196796.5	CTB-134H23.2	4.48	9.51e-06	0.00189	0.22	0.2	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29038655~29052726:+
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000280411.1	IGHV1-69-2	-4.48	9.51e-06	0.00189	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106767918	chr14:106762092~106762588:-
HNSC	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-4.48	9.51e-06	0.00189	-0.22	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
HNSC	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	4.48	9.51e-06	0.00189	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
HNSC	cis	rs2243480	1	rs160634	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.51e-06	0.00189	-0.34	-0.2	Diabetic kidney disease;	chr7:66063677	chr7:66025126~66031544:-
HNSC	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	4.48	9.52e-06	0.00189	0.25	0.2	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
HNSC	cis	rs2439831	0.85	rs2277531	ENSG00000201136.1	RNU6-353P	-4.48	9.52e-06	0.00189	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43776871	chr15:43702363~43702470:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-4.48	9.52e-06	0.00189	-0.27	-0.2	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
HNSC	cis	rs9311676	0.656	rs10866016	ENSG00000273493.1	RP11-80H18.4	4.48	9.52e-06	0.00189	0.22	0.2	Systemic lupus erythematosus;	chr3:58405117	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs62258120	ENSG00000273493.1	RP11-80H18.4	4.48	9.52e-06	0.00189	0.22	0.2	Systemic lupus erythematosus;	chr3:58405401	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs66793022	ENSG00000273493.1	RP11-80H18.4	4.48	9.52e-06	0.00189	0.22	0.2	Systemic lupus erythematosus;	chr3:58405838	chr3:58329965~58330118:+
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000219891.2	ZSCAN12P1	-4.48	9.53e-06	0.00189	-0.28	-0.2	Parkinson's disease;	chr6:28002253	chr6:28091154~28093664:+
HNSC	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	4.48	9.53e-06	0.00189	0.27	0.2	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	4.48	9.53e-06	0.00189	0.27	0.2	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
HNSC	cis	rs9880211	0.948	rs9820621	ENSG00000273486.1	RP11-731C17.2	4.48	9.53e-06	0.00189	0.19	0.2	Height;Body mass index;	chr3:136391671	chr3:136837338~136839021:-
HNSC	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-4.48	9.53e-06	0.00189	-0.35	-0.2	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
HNSC	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.48	9.53e-06	0.00189	-0.28	-0.2	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
HNSC	cis	rs67340775	0.541	rs200973	ENSG00000219392.1	RP1-265C24.5	-4.48	9.53e-06	0.00189	-0.3	-0.2	Lung cancer in ever smokers;	chr6:27890643	chr6:28115628~28116551:+
HNSC	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	4.48	9.53e-06	0.00189	0.17	0.2	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
HNSC	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-4.48	9.53e-06	0.00189	-0.26	-0.2	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
HNSC	cis	rs9287719	0.967	rs6432113	ENSG00000243819.4	RN7SL832P	-4.48	9.53e-06	0.00189	-0.19	-0.2	Prostate cancer;	chr2:10604763	chr2:10690344~10692099:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	4.48	9.53e-06	0.00189	0.24	0.2	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
HNSC	cis	rs3096299	0.9	rs744327	ENSG00000261574.1	RP1-168P16.2	4.48	9.54e-06	0.00189	0.26	0.2	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89392375~89412564:-
HNSC	cis	rs6500395	0.962	rs9921737	ENSG00000261267.1	RP11-44I10.3	-4.48	9.54e-06	0.0019	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48555962	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9921741	ENSG00000261267.1	RP11-44I10.3	-4.48	9.54e-06	0.0019	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48555985	chr16:48559661~48587403:+
HNSC	cis	rs7809950	0.817	rs2701679	ENSG00000238832.1	snoU109	4.48	9.54e-06	0.0019	0.27	0.2	Coronary artery disease;	chr7:107643463	chr7:107603363~107603507:+
HNSC	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	4.48	9.54e-06	0.0019	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	4.48	9.54e-06	0.0019	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
HNSC	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	4.48	9.54e-06	0.0019	0.2	0.2	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
HNSC	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-4.48	9.54e-06	0.0019	-0.22	-0.2	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
HNSC	cis	rs7809950	0.678	rs62483641	ENSG00000238832.1	snoU109	-4.48	9.55e-06	0.0019	-0.29	-0.2	Coronary artery disease;	chr7:107261296	chr7:107603363~107603507:+
HNSC	cis	rs950776	0.72	rs11633223	ENSG00000261762.1	RP11-650L12.2	4.48	9.55e-06	0.0019	0.25	0.2	Sudden cardiac arrest;	chr15:78643134	chr15:78589123~78591276:-
HNSC	cis	rs9903692	0.865	rs7220520	ENSG00000263412.1	RP5-890E16.2	-4.48	9.55e-06	0.0019	-0.19	-0.2	Pulse pressure;	chr17:48090580	chr17:48045141~48048073:-
HNSC	cis	rs4388249	1	rs4388249	ENSG00000271849.1	CTC-332L22.1	4.48	9.55e-06	0.0019	0.3	0.2	Schizophrenia;	chr5:109700365	chr5:109687802~109688329:-
HNSC	cis	rs494003	0.951	rs11227283	ENSG00000255120.4	OVOL1-AS1	4.48	9.55e-06	0.0019	0.26	0.2	Systemic lupus erythematosus;	chr11:65731551	chr11:65789051~65790868:-
HNSC	cis	rs494003	1	rs11227288	ENSG00000255120.4	OVOL1-AS1	4.48	9.55e-06	0.0019	0.26	0.2	Systemic lupus erythematosus;	chr11:65749117	chr11:65789051~65790868:-
HNSC	cis	rs494003	1	rs10896043	ENSG00000255120.4	OVOL1-AS1	-4.48	9.55e-06	0.0019	-0.26	-0.2	Systemic lupus erythematosus;	chr11:65776356	chr11:65789051~65790868:-
HNSC	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	4.48	9.55e-06	0.0019	0.24	0.2	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
HNSC	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	4.48	9.55e-06	0.0019	0.24	0.2	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
HNSC	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-4.48	9.55e-06	0.0019	-0.23	-0.2	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
HNSC	cis	rs9329221	0.537	rs13282106	ENSG00000254340.1	RP11-10A14.3	4.48	9.56e-06	0.0019	0.24	0.2	Neuroticism;	chr8:10124390	chr8:9141424~9145435:+
HNSC	cis	rs10435719	0.867	rs35778860	ENSG00000255495.1	AC145124.2	4.48	9.56e-06	0.0019	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:12194467~12196280:+
HNSC	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-4.48	9.56e-06	0.0019	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
HNSC	cis	rs3811273	0.614	rs7146368	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265436	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs7151848	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265503	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.667	rs7147374	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265607	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs7145658	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265772	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs7152255	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265774	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.614	rs7147116	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265811	chr14:22271968~22272563:+
HNSC	cis	rs3811273	0.505	rs7145836	ENSG00000211816.2	TRAV38-1	-4.48	9.56e-06	0.0019	-0.23	-0.2	Periodontal disease-related phenotypes;	chr14:22265875	chr14:22271968~22272563:+
HNSC	cis	rs2985684	0.901	rs57119148	ENSG00000278009.1	RP11-649E7.8	4.48	9.56e-06	0.0019	0.26	0.2	Carotid intima media thickness;	chr14:49630508	chr14:49601011~49601124:-
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000211974.3	IGHV2-70	4.48	9.56e-06	0.0019	0.2	0.2	Kawasaki disease;	chr14:106704323	chr14:106723574~106724093:-
HNSC	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	4.48	9.57e-06	0.0019	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
HNSC	cis	rs4523957	0.855	rs12602764	ENSG00000262333.1	HNRNPA1P16	4.48	9.57e-06	0.0019	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2219906	chr17:2306761~2307715:+
HNSC	cis	rs3736485	0.966	rs7176044	ENSG00000259438.1	CTD-2650P22.1	4.48	9.57e-06	0.0019	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51603146	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs11634039	ENSG00000259438.1	CTD-2650P22.1	4.48	9.57e-06	0.0019	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51603378	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs11634180	ENSG00000259438.1	CTD-2650P22.1	4.48	9.57e-06	0.0019	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51603560	chr15:52010999~52019095:-
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000224373.3	IGHV4-59	4.48	9.58e-06	0.0019	0.13	0.2	Kawasaki disease;	chr14:106783079	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000224373.3	IGHV4-59	4.48	9.58e-06	0.0019	0.13	0.2	Kawasaki disease;	chr14:106783685	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000224373.3	IGHV4-59	4.48	9.58e-06	0.0019	0.13	0.2	Kawasaki disease;	chr14:106784199	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000224373.3	IGHV4-59	4.48	9.58e-06	0.0019	0.13	0.2	Kawasaki disease;	chr14:106784709	chr14:106627249~106627825:-
HNSC	cis	rs763121	0.853	rs5757187	ENSG00000273076.1	RP3-508I15.22	-4.48	9.58e-06	0.0019	-0.22	-0.2	Menopause (age at onset);	chr22:38625517	chr22:38743495~38743910:+
HNSC	cis	rs13126694	0.744	rs10003459	ENSG00000248429.4	RP11-597D13.9	-4.48	9.58e-06	0.0019	-0.23	-0.2	Blood osmolality (transformed sodium);	chr4:158095602	chr4:158170752~158202877:+
HNSC	cis	rs9393777	0.841	rs34332556	ENSG00000219392.1	RP1-265C24.5	-4.48	9.58e-06	0.0019	-0.4	-0.2	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28115628~28116551:+
HNSC	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	4.48	9.59e-06	0.0019	0.18	0.2	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000255495.1	AC145124.2	4.48	9.59e-06	0.0019	0.23	0.2	Neuroticism;	chr8:11939219	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000255495.1	AC145124.2	4.48	9.59e-06	0.0019	0.23	0.2	Neuroticism;	chr8:11939586	chr8:12194467~12196280:+
HNSC	cis	rs7100689	0.56	rs10887891	ENSG00000226659.1	RP11-137H2.4	-4.48	9.59e-06	0.0019	-0.27	-0.2	Post bronchodilator FEV1;	chr10:80447961	chr10:80529597~80535942:-
HNSC	cis	rs739496	0.579	rs12423041	ENSG00000226469.1	ADAM1B	4.48	9.59e-06	0.0019	0.24	0.2	Platelet count;	chr12:111887042	chr12:111927018~111929017:+
HNSC	cis	rs8024893	0.764	rs7182721	ENSG00000270055.1	CTD-3092A11.2	4.48	9.59e-06	0.0019	0.28	0.2	Red cell distribution width;	chr15:31239730	chr15:30487963~30490313:+
HNSC	cis	rs3733585	0.699	rs6449177	ENSG00000250413.1	RP11-448G15.1	4.48	9.59e-06	0.0019	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9966426	chr4:10006482~10009725:+
HNSC	cis	rs12935418	0.552	rs2549835	ENSG00000278985.1	RP11-303E16.9	-4.48	9.6e-06	0.00191	-0.19	-0.2	Mean corpuscular volume;	chr16:80989005	chr16:80982319~80984094:-
HNSC	cis	rs739496	0.527	rs2269801	ENSG00000226469.1	ADAM1B	4.48	9.6e-06	0.00191	0.23	0.2	Platelet count;	chr12:111888319	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.748	rs2269802	ENSG00000226469.1	ADAM1B	4.48	9.6e-06	0.00191	0.23	0.2	Mean platelet volume;	chr12:111888334	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7974772	ENSG00000226469.1	ADAM1B	4.48	9.6e-06	0.00191	0.23	0.2	Platelet count;	chr12:111894479	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs10849981	ENSG00000226469.1	ADAM1B	4.48	9.6e-06	0.00191	0.23	0.2	Platelet count;	chr12:111897413	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs10849982	ENSG00000226469.1	ADAM1B	4.48	9.6e-06	0.00191	0.23	0.2	Platelet count;	chr12:111897735	chr12:111927018~111929017:+
HNSC	cis	rs4144743	0.528	rs2292866	ENSG00000228782.6	CTD-2026D20.3	-4.48	9.6e-06	0.00191	-0.29	-0.2	Body mass index;	chr17:47279416	chr17:47450568~47492492:-
HNSC	cis	rs71636778	0.509	rs12738345	ENSG00000260063.1	RP5-968P14.2	-4.48	9.6e-06	0.00191	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26693253	chr1:26692132~26694131:-
HNSC	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	4.48	9.6e-06	0.00191	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
HNSC	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	4.48	9.6e-06	0.00191	0.27	0.2	Pain;	chr19:21548822	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	4.48	9.6e-06	0.00191	0.27	0.2	Pain;	chr19:21549451	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	4.48	9.6e-06	0.00191	0.27	0.2	Pain;	chr19:21554036	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	4.48	9.6e-06	0.00191	0.27	0.2	Pain;	chr19:21554618	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	4.48	9.6e-06	0.00191	0.27	0.2	Pain;	chr19:21555338	chr19:21554640~21569237:-
HNSC	cis	rs7615952	0.515	rs4267608	ENSG00000241288.6	RP11-379B18.5	-4.47	9.61e-06	0.00191	-0.27	-0.2	Blood pressure (smoking interaction);	chr3:125961657	chr3:125827238~125916384:-
HNSC	cis	rs853679	0.607	rs35902873	ENSG00000204709.4	LINC01556	4.47	9.61e-06	0.00191	0.43	0.2	Depression;	chr6:28091171	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13197574	ENSG00000204709.4	LINC01556	4.47	9.61e-06	0.00191	0.43	0.2	Depression;	chr6:28092461	chr6:28943877~28944537:+
HNSC	cis	rs35963943	0.625	rs13064712	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18689742	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.681	rs66715408	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18694359	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs11128902	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18695070	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs11709459	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18696294	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs7649278	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18696525	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs7647689	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18697138	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs7610722	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18697169	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs6783241	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18699338	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4600838	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18699701	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4600837	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18699987	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs6803335	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18702551	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4515070	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18703405	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13058750	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18705174	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs9917685	ENSG00000228956.7	SATB1-AS1	4.47	9.62e-06	0.00191	0.25	0.2	Lymphocyte counts;	chr3:18705452	chr3:18445024~18920401:+
HNSC	cis	rs1223397	0.938	rs35511719	ENSG00000215022.6	RP1-257A7.4	-4.47	9.62e-06	0.00191	-0.26	-0.2	Blood pressure;	chr6:13282210	chr6:13264861~13295586:-
HNSC	cis	rs4908768	0.52	rs6695867	ENSG00000232912.4	RP5-1115A15.1	4.47	9.63e-06	0.00191	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8424645~8434838:+
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000241439.1	RP11-666A20.3	4.47	9.63e-06	0.00191	0.22	0.2	Blood pressure (smoking interaction);	chr3:126006108	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000241439.1	RP11-666A20.3	4.47	9.63e-06	0.00191	0.22	0.2	Blood pressure (smoking interaction);	chr3:126006716	chr3:125958556~125958817:+
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-4.47	9.63e-06	0.00191	-0.24	-0.2	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
HNSC	cis	rs9287719	0.967	rs7355649	ENSG00000243819.4	RN7SL832P	4.47	9.63e-06	0.00191	0.19	0.2	Prostate cancer;	chr2:10607968	chr2:10690344~10692099:+
HNSC	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-4.47	9.63e-06	0.00191	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
HNSC	cis	rs5769707	0.632	rs5770601	ENSG00000235111.1	RP1-29C18.8	-4.47	9.64e-06	0.00191	-0.27	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49612657~49615716:-
HNSC	cis	rs71636778	0.509	rs12730386	ENSG00000260063.1	RP5-968P14.2	-4.47	9.64e-06	0.00191	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711498	chr1:26692132~26694131:-
HNSC	cis	rs12935418	0.552	rs2549835	ENSG00000261061.1	RP11-303E16.2	4.47	9.64e-06	0.00191	0.22	0.2	Mean corpuscular volume;	chr16:80989005	chr16:81030770~81031485:+
HNSC	cis	rs9329221	0.905	rs10283145	ENSG00000255310.2	AF131215.2	-4.47	9.65e-06	0.00191	-0.19	-0.2	Neuroticism;	chr8:10383901	chr8:11107788~11109726:-
HNSC	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-4.47	9.65e-06	0.00191	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
HNSC	cis	rs1799949	0.965	rs35521261	ENSG00000236383.6	LINC00854	-4.47	9.65e-06	0.00191	-0.19	-0.2	Menopause (age at onset);	chr17:43161595	chr17:43216941~43305976:-
HNSC	cis	rs6951245	0.744	rs10265736	ENSG00000225146.1	AC073957.15	-4.47	9.65e-06	0.00191	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1029025~1043891:+
HNSC	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-4.47	9.66e-06	0.00192	-0.25	-0.2	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
HNSC	cis	rs4761702	0.614	rs4761704	ENSG00000257252.4	RP11-486A14.2	-4.47	9.66e-06	0.00192	-0.26	-0.2	Immature fraction of reticulocytes;	chr12:93328951	chr12:93317135~93377736:-
HNSC	cis	rs3015497	0.646	rs2934693	ENSG00000269906.1	RP11-248J18.2	-4.47	9.66e-06	0.00192	-0.28	-0.2	Mean platelet volume;	chr14:50634923	chr14:50662511~50663178:-
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	-4.47	9.66e-06	0.00192	-0.29	-0.2	Depression;	chr6:28103220	chr6:28161781~28169594:+
HNSC	cis	rs11633886	0.528	rs2248216	ENSG00000273972.1	CTD-2306A12.1	4.47	9.66e-06	0.00192	0.24	0.2	Diisocyanate-induced asthma;	chr15:45809383	chr15:45702640~45703183:+
HNSC	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	4.47	9.66e-06	0.00192	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
HNSC	cis	rs929354	0.742	rs6956046	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.66e-06	0.00192	-0.2	-0.2	Body mass index;	chr7:157170180	chr7:157263022~157263229:-
HNSC	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-4.47	9.67e-06	0.00192	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
HNSC	cis	rs4256159	1	rs79524629	ENSG00000228956.7	SATB1-AS1	4.47	9.67e-06	0.00192	0.34	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18783123	chr3:18445024~18920401:+
HNSC	cis	rs10462794	1	rs13358031	ENSG00000260763.1	RP11-445O3.3	-4.47	9.67e-06	0.00192	-0.27	-0.2	DNA methylation (variation);	chr5:4477152	chr5:4436850~4440259:-
HNSC	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-4.47	9.67e-06	0.00192	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
HNSC	cis	rs67981189	0.865	rs2810117	ENSG00000274818.1	RP1-292L20.3	-4.47	9.68e-06	0.00192	-0.24	-0.2	Schizophrenia;	chr14:70924308	chr14:70906657~70907111:-
HNSC	cis	rs6142102	0.812	rs761236	ENSG00000275784.1	RP5-1125A11.6	-4.47	9.68e-06	0.00192	-0.26	-0.2	Skin pigmentation;	chr20:33932245	chr20:33989480~33991818:-
HNSC	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	4.47	9.68e-06	0.00192	0.21	0.2	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
HNSC	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-4.47	9.68e-06	0.00192	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000224373.3	IGHV4-59	4.47	9.68e-06	0.00192	0.13	0.2	Kawasaki disease;	chr14:106781682	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000224373.3	IGHV4-59	4.47	9.68e-06	0.00192	0.13	0.2	Kawasaki disease;	chr14:106781820	chr14:106627249~106627825:-
HNSC	cis	rs889398	0.771	rs12927431	ENSG00000226232.7	RP11-419C5.2	4.47	9.68e-06	0.00192	0.18	0.2	Body mass index;	chr16:69823144	chr16:69976388~69996188:-
HNSC	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-4.47	9.69e-06	0.00192	-0.23	-0.2	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
HNSC	cis	rs853679	0.517	rs6932109	ENSG00000204709.4	LINC01556	-4.47	9.69e-06	0.00192	-0.28	-0.2	Depression;	chr6:28110525	chr6:28943877~28944537:+
HNSC	cis	rs5752326	0.867	rs1894704	ENSG00000261188.1	CTA-445C9.14	4.47	9.69e-06	0.00192	0.29	0.2	Ischemic stroke;	chr22:26457939	chr22:26512537~26514568:+
HNSC	cis	rs11722228	0.549	rs73212853	ENSG00000250413.1	RP11-448G15.1	-4.47	9.69e-06	0.00192	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10094606	chr4:10006482~10009725:+
HNSC	cis	rs2292864	1	rs2292864	ENSG00000228782.6	CTD-2026D20.3	-4.47	9.69e-06	0.00192	-0.32	-0.2	Left atrial antero-posterior diameter;	chr17:47290315	chr17:47450568~47492492:-
HNSC	cis	rs7824557	0.707	rs3808518	ENSG00000255310.2	AF131215.2	-4.47	9.69e-06	0.00192	-0.19	-0.2	Retinal vascular caliber;	chr8:11285763	chr8:11107788~11109726:-
HNSC	cis	rs12935418	0.672	rs7197370	ENSG00000261061.1	RP11-303E16.2	-4.47	9.69e-06	0.00192	-0.22	-0.2	Mean corpuscular volume;	chr16:81017520	chr16:81030770~81031485:+
HNSC	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-4.47	9.69e-06	0.00192	-0.36	-0.2	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-4.47	9.69e-06	0.00192	-0.21	-0.2	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
HNSC	cis	rs12935418	0.523	rs2549840	ENSG00000278985.1	RP11-303E16.9	-4.47	9.7e-06	0.00192	-0.19	-0.2	Mean corpuscular volume;	chr16:80989817	chr16:80982319~80984094:-
HNSC	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-4.47	9.7e-06	0.00192	-0.25	-0.2	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
HNSC	cis	rs9880211	0.613	rs12695644	ENSG00000273486.1	RP11-731C17.2	4.47	9.7e-06	0.00192	0.18	0.2	Height;Body mass index;	chr3:136126096	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.963	rs10512987	ENSG00000273486.1	RP11-731C17.2	-4.47	9.71e-06	0.00192	-0.17	-0.2	Coronary artery disease;	chr3:136104235	chr3:136837338~136839021:-
HNSC	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	4.47	9.71e-06	0.00192	0.17	0.2	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
HNSC	cis	rs9880211	1	rs28634226	ENSG00000273486.1	RP11-731C17.2	4.47	9.71e-06	0.00192	0.19	0.2	Height;Body mass index;	chr3:136411040	chr3:136837338~136839021:-
HNSC	cis	rs3736485	0.903	rs9944241	ENSG00000259438.1	CTD-2650P22.1	4.47	9.71e-06	0.00192	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51605861	chr15:52010999~52019095:-
HNSC	cis	rs9311676	0.618	rs12152337	ENSG00000273493.1	RP11-80H18.4	4.47	9.71e-06	0.00193	0.22	0.2	Systemic lupus erythematosus;	chr3:58379544	chr3:58329965~58330118:+
HNSC	cis	rs4660214	0.666	rs1180384	ENSG00000182109.6	RP11-69E11.4	4.47	9.71e-06	0.00193	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39522280~39546187:-
HNSC	cis	rs6500395	0.962	rs1115759	ENSG00000261267.1	RP11-44I10.3	-4.47	9.71e-06	0.00193	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48565619	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7197732	ENSG00000261267.1	RP11-44I10.3	-4.47	9.71e-06	0.00193	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48541967	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.926	rs1039344	ENSG00000261267.1	RP11-44I10.3	-4.47	9.71e-06	0.00193	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48543658	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9937134	ENSG00000261267.1	RP11-44I10.3	-4.47	9.71e-06	0.00193	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48543772	chr16:48559661~48587403:+
HNSC	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.47	9.72e-06	0.00193	0.21	0.2	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
HNSC	cis	rs55661361	0.651	rs12293621	ENSG00000245498.5	RP11-677M14.7	4.47	9.72e-06	0.00193	0.21	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742932	chr11:124800450~124834487:+
HNSC	cis	rs10829156	0.732	rs1917823	ENSG00000240291.1	RP11-499P20.2	4.47	9.72e-06	0.00193	0.22	0.2	Sudden cardiac arrest;	chr10:18528184	chr10:18513115~18545651:-
HNSC	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	4.47	9.73e-06	0.00193	0.21	0.2	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
HNSC	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	4.47	9.73e-06	0.00193	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000254153.1	CTA-398F10.2	4.47	9.74e-06	0.00193	0.22	0.2	Parkinson's disease;	chr8:8397365	chr8:8456909~8461337:-
HNSC	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	4.47	9.74e-06	0.00193	0.24	0.2	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
HNSC	cis	rs72949976	0.934	rs13406406	ENSG00000270659.1	RP11-105N14.1	4.47	9.74e-06	0.00193	0.2	0.2	Squamous cell lung carcinoma;Lung cancer;	chr2:213170102	chr2:213152970~213153659:+
HNSC	cis	rs7824557	0.843	rs2572418	ENSG00000255310.2	AF131215.2	-4.47	9.74e-06	0.00193	-0.19	-0.2	Retinal vascular caliber;	chr8:11255580	chr8:11107788~11109726:-
HNSC	cis	rs4523957	0.713	rs9906500	ENSG00000262333.1	HNRNPA1P16	4.47	9.74e-06	0.00193	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2225916	chr17:2306761~2307715:+
HNSC	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	4.47	9.74e-06	0.00193	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	4.47	9.74e-06	0.00193	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
HNSC	cis	rs9650657	0.803	rs13276026	ENSG00000269918.1	AF131215.9	-4.47	9.75e-06	0.00193	-0.2	-0.2	Neuroticism;	chr8:10752445	chr8:11104691~11106704:-
HNSC	cis	rs11773103	1	rs11760687	ENSG00000224046.1	AC005076.5	4.47	9.75e-06	0.00193	0.37	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87333425	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs11771466	ENSG00000224046.1	AC005076.5	4.47	9.75e-06	0.00193	0.37	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87333487	chr7:87151423~87152420:-
HNSC	cis	rs79349575	0.87	rs12941262	ENSG00000270781.1	RP11-501C14.9	-4.47	9.75e-06	0.00193	-0.21	-0.2	Type 2 diabetes;	chr17:48889675	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.778	rs12950328	ENSG00000270781.1	RP11-501C14.9	-4.47	9.75e-06	0.00193	-0.21	-0.2	Type 2 diabetes;	chr17:48889699	chr17:48899131~48899748:+
HNSC	cis	rs3758785	0.737	rs3758786	ENSG00000255893.1	RP11-685N10.1	-4.47	9.75e-06	0.00193	-0.31	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399118	chr11:94472908~94473570:-
HNSC	cis	rs10504130	0.666	rs7819892	ENSG00000253844.1	RP11-546K22.1	4.47	9.75e-06	0.00193	0.3	0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:51932916	chr8:51961458~52022974:+
HNSC	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	4.47	9.75e-06	0.00193	0.23	0.2	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
HNSC	cis	rs11722228	0.549	rs73212830	ENSG00000250413.1	RP11-448G15.1	-4.47	9.75e-06	0.00193	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10006482~10009725:+
HNSC	cis	rs13434995	0.513	rs12509047	ENSG00000273257.1	RP11-177J6.1	4.47	9.76e-06	0.00193	0.27	0.2	Adiponectin levels;	chr4:55545245	chr4:55387949~55388271:+
HNSC	cis	rs10773046	0.74	rs7314963	ENSG00000269938.1	RP11-214K3.20	-4.47	9.76e-06	0.00193	-0.22	-0.2	Osteoarthritis (hip);	chr12:123865897	chr12:123968023~123968579:-
HNSC	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.47	9.76e-06	0.00193	0.33	0.2	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
HNSC	cis	rs11893307	0.509	rs4368360	ENSG00000228509.4	AC006460.2	4.47	9.76e-06	0.00193	0.27	0.2	Mean platelet volume;	chr2:190671327	chr2:190676944~190708716:-
HNSC	cis	rs9300255	0.602	rs2695478	ENSG00000280120.1	RP11-546D6.3	4.47	9.76e-06	0.00193	0.2	0.2	Neutrophil percentage of white cells;	chr12:123204974	chr12:123152324~123153377:-
HNSC	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-4.47	9.76e-06	0.00193	-0.17	-0.2	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000219392.1	RP1-265C24.5	-4.47	9.77e-06	0.00193	-0.23	-0.2	Pubertal anthropometrics;	chr6:28294921	chr6:28115628~28116551:+
HNSC	cis	rs739496	0.579	rs12296574	ENSG00000226469.1	ADAM1B	4.47	9.77e-06	0.00193	0.23	0.2	Platelet count;	chr12:111884973	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs1981517	ENSG00000226469.1	ADAM1B	4.47	9.77e-06	0.00193	0.23	0.2	Platelet count;	chr12:111885778	chr12:111927018~111929017:+
HNSC	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-4.47	9.77e-06	0.00193	-0.25	-0.2	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
HNSC	cis	rs853679	0.585	rs201001	ENSG00000219392.1	RP1-265C24.5	-4.47	9.77e-06	0.00193	-0.28	-0.2	Depression;	chr6:27841121	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.585	rs201000	ENSG00000219392.1	RP1-265C24.5	-4.47	9.77e-06	0.00193	-0.28	-0.2	Depression;	chr6:27841381	chr6:28115628~28116551:+
HNSC	cis	rs36052053	0.521	rs35370422	ENSG00000203799.9	CCDC162P	4.47	9.77e-06	0.00193	0.36	0.2	Red cell distribution width;	chr6:109210537	chr6:109285485~109355063:+
HNSC	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-4.47	9.77e-06	0.00193	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-4.47	9.77e-06	0.00193	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
HNSC	cis	rs2548724	0.561	rs10463981	ENSG00000250682.4	LINC00491	4.47	9.77e-06	0.00194	0.26	0.2	Type 2 diabetes;	chr5:102451358	chr5:102609156~102671559:-
HNSC	cis	rs9393777	0.92	rs13195040	ENSG00000219392.1	RP1-265C24.5	4.47	9.78e-06	0.00194	0.4	0.2	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28115628~28116551:+
HNSC	cis	rs9650657	0.524	rs2163379	ENSG00000269918.1	AF131215.9	4.47	9.78e-06	0.00194	0.22	0.2	Neuroticism;	chr8:10874540	chr8:11104691~11106704:-
HNSC	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-4.47	9.78e-06	0.00194	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
HNSC	cis	rs3015497	0.603	rs2934684	ENSG00000269906.1	RP11-248J18.2	-4.47	9.78e-06	0.00194	-0.27	-0.2	Mean platelet volume;	chr14:50591516	chr14:50662511~50663178:-
HNSC	cis	rs9880211	0.8	rs9871184	ENSG00000273486.1	RP11-731C17.2	4.47	9.78e-06	0.00194	0.19	0.2	Height;Body mass index;	chr3:136795468	chr3:136837338~136839021:-
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000233609.3	RP11-62H7.2	4.47	9.78e-06	0.00194	0.19	0.2	Systolic blood pressure;	chr8:8462519	chr8:8961200~8979025:+
HNSC	cis	rs11756659	0.653	rs185635	ENSG00000217159.2	LARP1P1	4.47	9.79e-06	0.00194	0.28	0.2	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:26164072~26164363:+
HNSC	cis	rs1355223	0.506	rs11032898	ENSG00000271369.1	RP11-350D17.3	-4.47	9.79e-06	0.00194	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848564	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.506	rs11032899	ENSG00000271369.1	RP11-350D17.3	-4.47	9.79e-06	0.00194	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848687	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.506	rs1828299	ENSG00000271369.1	RP11-350D17.3	-4.47	9.79e-06	0.00194	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848871	chr11:34709600~34710161:+
HNSC	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-4.47	9.79e-06	0.00194	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-4.47	9.79e-06	0.00194	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-4.47	9.79e-06	0.00194	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-4.47	9.79e-06	0.00194	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
HNSC	cis	rs13434995	0.513	rs1021307	ENSG00000273257.1	RP11-177J6.1	4.47	9.79e-06	0.00194	0.27	0.2	Adiponectin levels;	chr4:55529547	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs1021306	ENSG00000273257.1	RP11-177J6.1	4.47	9.79e-06	0.00194	0.27	0.2	Adiponectin levels;	chr4:55529777	chr4:55387949~55388271:+
HNSC	cis	rs7819412	0.654	rs34741518	ENSG00000255310.2	AF131215.2	-4.47	9.79e-06	0.00194	-0.19	-0.2	Triglycerides;	chr8:10919350	chr8:11107788~11109726:-
HNSC	cis	rs804292	0.695	rs804279	ENSG00000255046.1	RP11-297N6.4	4.47	9.79e-06	0.00194	0.25	0.2	Nicotine use;Alcohol dependence;	chr8:11766380	chr8:11797928~11802568:-
HNSC	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-4.47	9.8e-06	0.00194	-0.25	-0.2	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
HNSC	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-4.47	9.8e-06	0.00194	-0.25	-0.2	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
HNSC	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-4.47	9.8e-06	0.00194	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
HNSC	cis	rs17253792	0.822	rs75763956	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55604458	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78522049	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55604485	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs79022053	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55605003	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76555508	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55605150	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.908	rs9972177	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55606488	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs9972178	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55606762	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs9972180	ENSG00000186615.9	KTN1-AS1	-4.47	9.81e-06	0.00194	-0.37	-0.2	Putamen volume;	chr14:55607014	chr14:55499278~55580110:-
HNSC	cis	rs6558530	0.666	rs28376731	ENSG00000253982.1	CTD-2336O2.1	4.47	9.81e-06	0.00194	0.26	0.2	Systolic blood pressure;	chr8:1748086	chr8:1761990~1764502:-
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	4.47	9.81e-06	0.00194	0.21	0.2	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
HNSC	cis	rs6964587	0.743	rs33993294	ENSG00000188693.7	CYP51A1-AS1	-4.47	9.81e-06	0.00194	-0.22	-0.2	Breast cancer;	chr7:92369341	chr7:92134604~92180725:+
HNSC	cis	rs12935418	0.616	rs2549854	ENSG00000261061.1	RP11-303E16.2	-4.47	9.81e-06	0.00194	-0.22	-0.2	Mean corpuscular volume;	chr16:80993034	chr16:81030770~81031485:+
HNSC	cis	rs67981189	0.752	rs221902	ENSG00000274818.1	RP1-292L20.3	-4.47	9.81e-06	0.00194	-0.24	-0.2	Schizophrenia;	chr14:71134362	chr14:70906657~70907111:-
HNSC	cis	rs10773046	0.74	rs10773043	ENSG00000269938.1	RP11-214K3.20	-4.47	9.82e-06	0.00194	-0.22	-0.2	Osteoarthritis (hip);	chr12:123866157	chr12:123968023~123968579:-
HNSC	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-4.47	9.82e-06	0.00194	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-4.47	9.82e-06	0.00194	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	4.47	9.82e-06	0.00194	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
HNSC	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	4.47	9.82e-06	0.00194	0.23	0.2	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
HNSC	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-4.47	9.82e-06	0.00194	-0.23	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-4.47	9.82e-06	0.00194	-0.23	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-4.47	9.82e-06	0.00194	-0.23	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
HNSC	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	4.47	9.82e-06	0.00194	0.23	0.2	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
HNSC	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	4.47	9.83e-06	0.00194	0.25	0.2	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
HNSC	cis	rs8028182	0.549	rs7402844	ENSG00000260269.4	CTD-2323K18.1	4.47	9.83e-06	0.00195	0.26	0.2	Sudden cardiac arrest;	chr15:75345055	chr15:75527150~75601205:-
HNSC	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-4.47	9.84e-06	0.00195	-0.23	-0.2	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
HNSC	cis	rs1642645	0.872	rs661428	ENSG00000228452.1	RP5-994D16.9	-4.47	9.84e-06	0.00195	-0.29	-0.2	Left ventricular obstructive tract defect (maternal effect);	chr1:41985847	chr1:42775813~42776790:-
HNSC	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-4.47	9.84e-06	0.00195	-0.27	-0.2	Pain;	chr19:21499472	chr19:21554640~21569237:-
HNSC	cis	rs73198271	0.74	rs10094270	ENSG00000173295.6	FAM86B3P	-4.47	9.84e-06	0.00195	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.74	rs28521727	ENSG00000173295.6	FAM86B3P	-4.47	9.84e-06	0.00195	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8228595~8244865:+
HNSC	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	4.47	9.84e-06	0.00195	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	4.47	9.84e-06	0.00195	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	4.47	9.84e-06	0.00195	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
HNSC	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-4.47	9.84e-06	0.00195	-0.23	-0.2	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
HNSC	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	4.47	9.85e-06	0.00195	0.28	0.2	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
HNSC	cis	rs10266483	0.545	rs73132069	ENSG00000228653.2	HNRNPCP7	4.47	9.85e-06	0.00195	0.25	0.2	Response to statin therapy;	chr7:64258440	chr7:64500825~64501729:+
HNSC	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	4.47	9.85e-06	0.00195	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
HNSC	cis	rs6496044	0.568	rs2880765	ENSG00000259295.5	CSPG4P12	-4.47	9.85e-06	0.00195	-0.23	-0.2	Interstitial lung disease;	chr15:85513231	chr15:85191438~85213905:+
HNSC	cis	rs35306767	0.903	rs12249634	ENSG00000229869.1	RP11-363N22.2	-4.47	9.85e-06	0.00195	-0.3	-0.2	Eosinophil percentage of granulocytes;	chr10:826804	chr10:933026~942743:+
HNSC	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	4.47	9.85e-06	0.00195	0.25	0.2	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
HNSC	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	4.47	9.86e-06	0.00195	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
HNSC	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-4.47	9.86e-06	0.00195	-0.21	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
HNSC	cis	rs6928977	0.5	rs11154810	ENSG00000234084.1	RP3-388E23.2	4.47	9.87e-06	0.00195	0.21	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135301568~135307158:+
HNSC	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.47	9.87e-06	0.00195	0.19	0.2	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
HNSC	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.47	9.87e-06	0.00195	0.19	0.2	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
HNSC	cis	rs9840812	0.953	rs4678361	ENSG00000239213.4	NCK1-AS1	4.47	9.87e-06	0.00195	0.19	0.2	Fibrinogen levels;	chr3:136114163	chr3:136841726~136862054:-
HNSC	cis	rs11673344	0.583	rs7254411	ENSG00000276846.1	CTD-3220F14.3	4.47	9.87e-06	0.00195	0.22	0.2	Obesity-related traits;	chr19:37034969	chr19:37314868~37315620:-
HNSC	cis	rs7121616	0.576	rs1841580	ENSG00000200879.1	SNORD14E	4.47	9.88e-06	0.00195	0.28	0.2	Breast cancer;	chr11:123055956	chr11:123058077~123058161:-
HNSC	cis	rs739496	0.579	rs9971746	ENSG00000226469.1	ADAM1B	-4.47	9.88e-06	0.00195	-0.23	-0.2	Platelet count;	chr12:111899558	chr12:111927018~111929017:+
HNSC	cis	rs11089937	0.616	rs12484482	ENSG00000211638.2	IGLV8-61	-4.47	9.88e-06	0.00195	-0.19	-0.2	Periodontitis (PAL4Q3);	chr22:22180158	chr22:22098700~22099212:+
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000280411.1	IGHV1-69-2	-4.47	9.88e-06	0.00195	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106706790	chr14:106762092~106762588:-
HNSC	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-4.47	9.88e-06	0.00195	-0.21	-0.2	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
HNSC	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	4.47	9.88e-06	0.00195	0.18	0.2	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
HNSC	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	4.47	9.88e-06	0.00195	0.23	0.2	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
HNSC	cis	rs2548724	0.587	rs59399361	ENSG00000250682.4	LINC00491	4.47	9.88e-06	0.00195	0.26	0.2	Type 2 diabetes;	chr5:102413414	chr5:102609156~102671559:-
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	4.47	9.88e-06	0.00195	0.25	0.2	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
HNSC	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	4.47	9.89e-06	0.00196	0.31	0.2	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	4.47	9.9e-06	0.00196	0.34	0.2	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
HNSC	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-4.47	9.9e-06	0.00196	-0.17	-0.2	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
HNSC	cis	rs1218582	0.682	rs12046459	ENSG00000270361.1	RP11-307C12.13	-4.47	9.9e-06	0.00196	-0.22	-0.2	Prostate cancer;	chr1:154939541	chr1:154937370~154938059:+
HNSC	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-4.47	9.9e-06	0.00196	-0.23	-0.2	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
HNSC	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-4.47	9.9e-06	0.00196	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
HNSC	cis	rs2911132	0.564	rs13181579	ENSG00000248734.2	CTD-2260A17.1	4.47	9.91e-06	0.00196	0.22	0.2	Urate levels (BMI interaction);	chr5:96755234	chr5:96784777~96785999:+
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-4.47	9.91e-06	0.00196	-0.18	-0.2	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
HNSC	cis	rs795484	0.963	rs1277441	ENSG00000275409.1	RP11-131L12.4	-4.47	9.92e-06	0.00196	-0.23	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118168184	chr12:118430147~118430699:+
HNSC	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-4.47	9.92e-06	0.00196	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-4.47	9.92e-06	0.00196	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
HNSC	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	4.47	9.92e-06	0.00196	0.23	0.2	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
HNSC	cis	rs9300255	0.722	rs11830103	ENSG00000280120.1	RP11-546D6.3	-4.47	9.92e-06	0.00196	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123338999	chr12:123152324~123153377:-
HNSC	cis	rs1062753	0.527	rs6002560	ENSG00000227370.1	RP4-669P10.19	-4.47	9.92e-06	0.00196	-0.2	-0.2	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41960882	chr22:42132543~42132998:+
HNSC	cis	rs9450351	0.744	rs9362250	ENSG00000203875.9	SNHG5	-4.47	9.93e-06	0.00196	-0.43	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85867970	chr6:85660950~85678736:-
HNSC	cis	rs11089937	0.616	rs66651705	ENSG00000211638.2	IGLV8-61	-4.47	9.93e-06	0.00196	-0.19	-0.2	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22098700~22099212:+
HNSC	cis	rs4256159	1	rs11919236	ENSG00000228956.7	SATB1-AS1	4.47	9.93e-06	0.00196	0.34	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18755292	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs73178580	ENSG00000228956.7	SATB1-AS1	4.47	9.93e-06	0.00196	0.34	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18758386	chr3:18445024~18920401:+
HNSC	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	4.47	9.94e-06	0.00196	0.17	0.2	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
HNSC	cis	rs9880211	1	rs9880211	ENSG00000273486.1	RP11-731C17.2	4.47	9.94e-06	0.00196	0.19	0.2	Height;Body mass index;	chr3:136388707	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	4.47	9.94e-06	0.00196	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
HNSC	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-4.47	9.95e-06	0.00197	-0.27	-0.2	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
HNSC	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	4.47	9.95e-06	0.00197	0.29	0.2	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	4.47	9.95e-06	0.00197	0.29	0.2	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	4.47	9.95e-06	0.00197	0.29	0.2	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
HNSC	cis	rs3733585	0.631	rs4697925	ENSG00000250413.1	RP11-448G15.1	4.47	9.95e-06	0.00197	0.26	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10122706	chr4:10006482~10009725:+
HNSC	cis	rs6968419	0.585	rs10953816	ENSG00000237870.5	AC073130.1	4.47	9.96e-06	0.00197	0.22	0.2	Intraocular pressure;	chr7:116278473	chr7:116275606~116286734:-
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000254153.1	CTA-398F10.2	4.47	9.97e-06	0.00197	0.22	0.2	Mood instability;	chr8:8277287	chr8:8456909~8461337:-
HNSC	cis	rs6964587	1	rs2282971	ENSG00000188693.7	CYP51A1-AS1	-4.47	9.97e-06	0.00197	-0.22	-0.2	Breast cancer;	chr7:91955042	chr7:92134604~92180725:+
HNSC	cis	rs13325613	0.834	rs34870159	ENSG00000223552.1	RP11-24F11.2	-4.47	9.97e-06	0.00197	-0.32	-0.2	Monocyte count;	chr3:46147998	chr3:46364955~46407059:-
HNSC	cis	rs2028414	0.512	rs2247712	ENSG00000258701.1	LINC00638	4.47	9.97e-06	0.00197	0.27	0.2	IgG glycosylation;	chr14:104893490	chr14:104821201~104823718:+
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000250412.1	KLHL2P1	-4.47	9.98e-06	0.00197	-0.26	-0.2	Corneal astigmatism;	chr4:119328344	chr4:119334329~119378233:+
HNSC	cis	rs3806843	0.933	rs2240696	ENSG00000202515.1	VTRNA1-3	-4.47	9.98e-06	0.00197	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs2240695	ENSG00000202515.1	VTRNA1-3	-4.47	9.98e-06	0.00197	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr5:140726158~140726246:+
HNSC	cis	rs3806843	0.966	rs6579965	ENSG00000202515.1	VTRNA1-3	-4.47	9.98e-06	0.00197	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs6898906	ENSG00000202515.1	VTRNA1-3	-4.47	9.98e-06	0.00197	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr5:140726158~140726246:+
HNSC	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	4.47	9.98e-06	0.00197	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
HNSC	cis	rs929354	0.772	rs3802118	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157194120	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs3802117	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157194306	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6967764	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157202270	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs2023977	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157203328	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6459738	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157205838	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs6459739	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157206169	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs7785227	ENSG00000224629.1	RP5-1142J19.2	-4.47	9.98e-06	0.00197	-0.2	-0.2	Body mass index;	chr7:157206603	chr7:157263022~157263229:-
HNSC	cis	rs2098713	0.614	rs13155645	ENSG00000250155.1	CTD-2353F22.1	-4.47	9.98e-06	0.00197	-0.22	-0.2	Telomere length;	chr5:37476899	chr5:36666214~36725195:-
HNSC	cis	rs1008375	0.897	rs1006723	ENSG00000249502.1	AC006160.5	-4.47	9.98e-06	0.00197	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616901	chr4:17587467~17614571:-
HNSC	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-4.47	9.98e-06	0.00197	-0.25	-0.2	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
HNSC	cis	rs6601327	0.606	rs4841204	ENSG00000254340.1	RP11-10A14.3	-4.47	9.99e-06	0.00197	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9725897	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.965	rs8176322	ENSG00000236383.6	LINC00854	-4.47	9.99e-06	0.00197	-0.19	-0.2	Menopause (age at onset);	chr17:43043756	chr17:43216941~43305976:-
HNSC	cis	rs516805	0.667	rs2816165	ENSG00000279453.1	RP3-425C14.4	-4.47	1e-05	0.00197	-0.29	-0.2	Lymphocyte counts;	chr6:122114717	chr6:122436789~122439223:-
HNSC	cis	rs755249	0.761	rs3768321	ENSG00000228060.1	RP11-69E11.8	-4.47	1e-05	0.00197	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39565160~39573203:+
HNSC	cis	rs11846409	0.932	rs74091721	ENSG00000254174.1	IGHV1-12	4.47	1e-05	0.00197	0.16	0.2	Rheumatic heart disease;	chr14:106638262	chr14:106122420~106122709:-
HNSC	cis	rs7121616	0.562	rs7131452	ENSG00000200879.1	SNORD14E	4.47	1e-05	0.00197	0.26	0.2	Breast cancer;	chr11:123065314	chr11:123058077~123058161:-
HNSC	cis	rs1008375	0.966	rs2286773	ENSG00000249502.1	AC006160.5	-4.47	1e-05	0.00197	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614591	chr4:17587467~17614571:-
HNSC	cis	rs9903692	0.954	rs7217496	ENSG00000263412.1	RP5-890E16.2	-4.47	1e-05	0.00197	-0.19	-0.2	Pulse pressure;	chr17:48076840	chr17:48045141~48048073:-
HNSC	cis	rs6831352	0.693	rs2602875	ENSG00000263923.1	RP11-571L19.7	-4.47	1e-05	0.00198	-0.21	-0.2	Alcohol dependence;	chr4:99118344	chr4:98928897~98994994:+
HNSC	cis	rs6430585	0.528	rs309165	ENSG00000231890.6	DARS-AS1	-4.47	1e-05	0.00198	-0.33	-0.2	Corneal structure;	chr2:135909731	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs309158	ENSG00000231890.6	DARS-AS1	-4.47	1e-05	0.00198	-0.33	-0.2	Corneal structure;	chr2:135922964	chr2:135985176~136022593:+
HNSC	cis	rs11761441	0.669	rs13241486	ENSG00000242611.1	AC093627.8	-4.47	1e-05	0.00198	-0.25	-0.2	Alzheimer's disease in APOE e4- carriers;	chr7:79536	chr7:77038~80418:+
HNSC	cis	rs9921338	0.961	rs7198849	ENSG00000263080.1	RP11-485G7.5	4.47	1e-05	0.00198	0.22	0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11341809~11345211:-
HNSC	cis	rs4356203	0.905	rs11821773	ENSG00000272034.1	SNORD14A	-4.47	1e-05	0.00198	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17074654~17074744:-
HNSC	cis	rs11098499	0.779	rs10857066	ENSG00000249244.1	RP11-548H18.2	4.47	1e-05	0.00198	0.25	0.2	Corneal astigmatism;	chr4:119365441	chr4:119391831~119395335:-
HNSC	cis	rs6490294	0.571	rs11066119	ENSG00000226469.1	ADAM1B	4.47	1e-05	0.00198	0.28	0.2	Mean platelet volume;	chr12:111996700	chr12:111927018~111929017:+
HNSC	cis	rs2243480	1	rs316315	ENSG00000229886.1	RP5-1132H15.3	-4.47	1e-05	0.00198	-0.28	-0.2	Diabetic kidney disease;	chr7:66126218	chr7:66025126~66031544:-
HNSC	cis	rs2492286	0.569	rs9848287	ENSG00000242551.2	POU5F1P6	-4.47	1e-05	0.00198	-0.22	-0.2	Eosinophil counts;	chr3:128628799	chr3:128674735~128677005:-
HNSC	cis	rs7819412	0.595	rs4841500	ENSG00000269918.1	AF131215.9	-4.47	1e-05	0.00198	-0.2	-0.2	Triglycerides;	chr8:11130765	chr8:11104691~11106704:-
HNSC	cis	rs79349575	0.756	rs4793605	ENSG00000270781.1	RP11-501C14.9	-4.47	1e-05	0.00198	-0.22	-0.2	Type 2 diabetes;	chr17:48958507	chr17:48899131~48899748:+
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	4.47	1e-05	0.00198	0.22	0.2	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
HNSC	cis	rs9329221	0.537	rs12678800	ENSG00000254340.1	RP11-10A14.3	4.47	1e-05	0.00198	0.24	0.2	Neuroticism;	chr8:10121430	chr8:9141424~9145435:+
HNSC	cis	rs9880211	1	rs9837158	ENSG00000273486.1	RP11-731C17.2	4.47	1e-05	0.00198	0.19	0.2	Height;Body mass index;	chr3:136354321	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-4.47	1e-05	0.00198	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
HNSC	cis	rs6601327	0.6	rs10103925	ENSG00000254340.1	RP11-10A14.3	-4.47	1e-05	0.00198	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9794701	chr8:9141424~9145435:+
HNSC	cis	rs3758785	0.596	rs2096762	ENSG00000255893.1	RP11-685N10.1	4.46	1.01e-05	0.00198	0.24	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94381507	chr11:94472908~94473570:-
HNSC	cis	rs3758785	0.619	rs2096763	ENSG00000255893.1	RP11-685N10.1	4.46	1.01e-05	0.00198	0.24	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94381528	chr11:94472908~94473570:-
HNSC	cis	rs7824557	0.527	rs2572369	ENSG00000269918.1	AF131215.9	-4.46	1.01e-05	0.00198	-0.2	-0.2	Retinal vascular caliber;	chr8:11381088	chr8:11104691~11106704:-
HNSC	cis	rs4523957	0.786	rs216213	ENSG00000262333.1	HNRNPA1P16	-4.46	1.01e-05	0.00198	-0.16	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2230931	chr17:2306761~2307715:+
HNSC	cis	rs13126694	0.744	rs6843728	ENSG00000248429.4	RP11-597D13.9	-4.46	1.01e-05	0.00198	-0.24	-0.2	Blood osmolality (transformed sodium);	chr4:158093947	chr4:158170752~158202877:+
HNSC	cis	rs4947019	0.609	rs2177092	ENSG00000260273.1	RP11-425D10.10	4.46	1.01e-05	0.00198	0.54	0.2	Hematological parameters;	chr6:109365466	chr6:109382795~109383666:+
HNSC	cis	rs2835345	0.563	rs60511692	ENSG00000279365.1	KB-176G8.1	4.46	1.01e-05	0.00198	0.24	0.2	Pulmonary function;	chr21:36454091	chr21:36485867~36487760:+
HNSC	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-4.46	1.01e-05	0.00199	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
HNSC	cis	rs916888	0.821	rs199506	ENSG00000260075.1	NSFP1	4.46	1.01e-05	0.00199	0.29	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46372855~46487141:+
HNSC	cis	rs35963943	0.625	rs7645073	ENSG00000228956.7	SATB1-AS1	4.46	1.01e-05	0.00199	0.25	0.2	Lymphocyte counts;	chr3:18700278	chr3:18445024~18920401:+
HNSC	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-4.46	1.01e-05	0.00199	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
HNSC	cis	rs4761669	0.796	rs4415833	ENSG00000241556.1	RP11-490G8.1	-4.46	1.01e-05	0.00199	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797072	chr12:95467397~95467861:-
HNSC	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	4.46	1.01e-05	0.00199	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
HNSC	cis	rs9311676	0.656	rs62258127	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58411375	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs62258128	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58411415	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62258129	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58411460	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs55711525	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58412048	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.586	rs11707019	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58412309	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.609	rs62258133	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58412591	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs62258134	ENSG00000273493.1	RP11-80H18.4	4.46	1.01e-05	0.00199	0.22	0.2	Systemic lupus erythematosus;	chr3:58412720	chr3:58329965~58330118:+
HNSC	cis	rs17507216	0.718	rs72751662	ENSG00000276710.3	CSPG4P8	-4.46	1.01e-05	0.00199	-0.29	-0.2	Excessive daytime sleepiness;	chr15:82594705	chr15:82459472~82477258:+
HNSC	cis	rs2364403	1	rs12091273	ENSG00000225855.5	RUSC1-AS1	4.46	1.01e-05	0.00199	0.15	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:155959771	chr1:155316863~155324176:-
HNSC	cis	rs7735319	0.966	rs6895701	ENSG00000251281.1	CTD-2066L21.2	4.46	1.01e-05	0.00199	0.24	0.2	Systolic blood pressure;	chr5:33130367	chr5:33011322~33017607:-
HNSC	cis	rs6600671	1	rs1832558	ENSG00000270231.3	NBPF8P	4.46	1.01e-05	0.00199	0.18	0.2	Hip geometry;	chr1:121435521	chr1:120436353~120467739:+
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000211974.3	IGHV2-70	4.46	1.01e-05	0.00199	0.19	0.2	Kawasaki disease;	chr14:106787630	chr14:106723574~106724093:-
HNSC	cis	rs9863	0.861	rs34878139	ENSG00000269938.1	RP11-214K3.20	-4.46	1.01e-05	0.00199	-0.23	-0.2	White blood cell count;	chr12:123961706	chr12:123968023~123968579:-
HNSC	cis	rs9863	0.861	rs11833002	ENSG00000269938.1	RP11-214K3.20	-4.46	1.01e-05	0.00199	-0.23	-0.2	White blood cell count;	chr12:123962069	chr12:123968023~123968579:-
HNSC	cis	rs4523957	0.748	rs12603592	ENSG00000262333.1	HNRNPA1P16	4.46	1.01e-05	0.00199	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2216524	chr17:2306761~2307715:+
HNSC	cis	rs4841097	0.876	rs6601288	ENSG00000253981.4	ALG1L13P	4.46	1.01e-05	0.00199	0.23	0.2	Platelet distribution width;	chr8:9085920	chr8:8236003~8244667:-
HNSC	cis	rs6496044	0.507	rs2467096	ENSG00000259295.5	CSPG4P12	-4.46	1.01e-05	0.00199	-0.24	-0.2	Interstitial lung disease;	chr15:85667447	chr15:85191438~85213905:+
HNSC	cis	rs9287719	0.967	rs12467642	ENSG00000243819.4	RN7SL832P	4.46	1.01e-05	0.00199	0.19	0.2	Prostate cancer;	chr2:10621358	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs12464908	ENSG00000243819.4	RN7SL832P	4.46	1.01e-05	0.00199	0.19	0.2	Prostate cancer;	chr2:10621370	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7563816	ENSG00000243819.4	RN7SL832P	4.46	1.01e-05	0.00199	0.19	0.2	Prostate cancer;	chr2:10623274	chr2:10690344~10692099:+
HNSC	cis	rs4321325	0.733	rs13389505	ENSG00000236682.1	AC068282.3	-4.46	1.01e-05	0.00199	-0.32	-0.2	Protein C levels;	chr2:127177312	chr2:127389130~127400580:+
HNSC	cis	rs7572733	0.935	rs10192466	ENSG00000222017.1	AC011997.1	4.46	1.01e-05	0.00199	0.24	0.2	Dermatomyositis;	chr2:197873295	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs700691	ENSG00000222017.1	AC011997.1	4.46	1.01e-05	0.00199	0.24	0.2	Dermatomyositis;	chr2:197863128	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.905	rs700693	ENSG00000222017.1	AC011997.1	4.46	1.01e-05	0.00199	0.24	0.2	Dermatomyositis;	chr2:197865291	chr2:197693106~197774823:+
HNSC	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.46	1.01e-05	0.00199	0.19	0.2	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
HNSC	cis	rs10462794	0.851	rs12517452	ENSG00000260763.1	RP11-445O3.3	-4.46	1.01e-05	0.00199	-0.28	-0.2	DNA methylation (variation);	chr5:4492459	chr5:4436850~4440259:-
HNSC	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
HNSC	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	4.46	1.01e-05	0.00199	0.23	0.2	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
HNSC	cis	rs3096299	0.933	rs2965939	ENSG00000261574.1	RP1-168P16.2	4.46	1.01e-05	0.00199	0.26	0.2	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89392375~89412564:-
HNSC	cis	rs9300255	0.722	rs12298826	ENSG00000280120.1	RP11-546D6.3	-4.46	1.01e-05	0.00199	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123344481	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.722	rs34997336	ENSG00000280120.1	RP11-546D6.3	-4.46	1.01e-05	0.00199	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123344569	chr12:123152324~123153377:-
HNSC	cis	rs4372836	1	rs4666119	ENSG00000226833.4	AC097724.3	4.46	1.01e-05	0.00199	0.25	0.2	Body mass index;	chr2:28752824	chr2:28708953~28736205:-
HNSC	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	4.46	1.01e-05	0.00199	0.25	0.2	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
HNSC	cis	rs11250098	0.6	rs4240671	ENSG00000255310.2	AF131215.2	4.46	1.01e-05	0.00199	0.19	0.2	Morning vs. evening chronotype;	chr8:10910238	chr8:11107788~11109726:-
HNSC	cis	rs6430585	0.528	rs2278682	ENSG00000231890.6	DARS-AS1	-4.46	1.01e-05	0.00199	-0.34	-0.2	Corneal structure;	chr2:135985573	chr2:135985176~136022593:+
HNSC	cis	rs9880211	0.898	rs9870825	ENSG00000273486.1	RP11-731C17.2	4.46	1.01e-05	0.00199	0.19	0.2	Height;Body mass index;	chr3:136346878	chr3:136837338~136839021:-
HNSC	cis	rs9959145	0.925	rs11664431	ENSG00000267249.1	RP11-973H7.3	-4.46	1.01e-05	0.00199	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12635886	chr18:12670426~12671145:-
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	4.46	1.01e-05	0.002	0.28	0.2	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
HNSC	cis	rs12935418	0.579	rs1477381	ENSG00000278985.1	RP11-303E16.9	-4.46	1.01e-05	0.002	-0.19	-0.2	Mean corpuscular volume;	chr16:80981095	chr16:80982319~80984094:-
HNSC	cis	rs17507216	0.628	rs17158396	ENSG00000255769.6	GOLGA2P10	-4.46	1.01e-05	0.002	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82615688	chr15:82472993~82513950:-
HNSC	cis	rs4761702	0.614	rs11106976	ENSG00000257252.4	RP11-486A14.2	-4.46	1.01e-05	0.002	-0.26	-0.2	Immature fraction of reticulocytes;	chr12:93327763	chr12:93317135~93377736:-
HNSC	cis	rs9959145	0.85	rs76780647	ENSG00000267249.1	RP11-973H7.3	-4.46	1.01e-05	0.002	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12710821	chr18:12670426~12671145:-
HNSC	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	4.46	1.01e-05	0.002	0.44	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
HNSC	cis	rs10129255	1	rs10129255	ENSG00000224373.3	IGHV4-59	-4.46	1.01e-05	0.002	-0.13	-0.2	Kawasaki disease;	chr14:106767970	chr14:106627249~106627825:-
HNSC	cis	rs73222236	0.857	rs28396702	ENSG00000273486.1	RP11-731C17.2	4.46	1.01e-05	0.002	0.17	0.2	Coronary artery disease;	chr3:136448539	chr3:136837338~136839021:-
HNSC	cis	rs172166	0.561	rs149971	ENSG00000219392.1	RP1-265C24.5	-4.46	1.01e-05	0.002	-0.23	-0.2	Cardiac Troponin-T levels;	chr6:28014374	chr6:28115628~28116551:+
HNSC	cis	rs8054556	0.633	rs12928610	ENSG00000183604.13	SMG1P5	-4.46	1.01e-05	0.002	-0.2	-0.2	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:30267553~30335374:-
HNSC	cis	rs948562	0.535	rs11229439	ENSG00000280010.1	AP001350.4	4.46	1.01e-05	0.002	0.34	0.2	Lymphoma;	chr11:58425138	chr11:58627435~58628528:+
HNSC	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	4.46	1.01e-05	0.002	0.43	0.2	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000254153.1	CTA-398F10.2	-4.46	1.02e-05	0.002	-0.22	-0.2	Joint mobility (Beighton score);	chr8:9009151	chr8:8456909~8461337:-
HNSC	cis	rs17428076	0.794	rs56133507	ENSG00000228389.1	AC068039.4	-4.46	1.02e-05	0.002	-0.27	-0.2	Myopia;	chr2:171961945	chr2:171773482~171775844:+
HNSC	cis	rs710913	0.527	rs2004330	ENSG00000182109.6	RP11-69E11.4	-4.46	1.02e-05	0.002	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39498201	chr1:39522280~39546187:-
HNSC	cis	rs11722228	0.549	rs73212828	ENSG00000250413.1	RP11-448G15.1	-4.46	1.02e-05	0.002	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10006482~10009725:+
HNSC	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	4.46	1.02e-05	0.002	0.27	0.2	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
HNSC	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-4.46	1.02e-05	0.002	-0.25	-0.2	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
HNSC	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.02e-05	0.002	-0.33	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
HNSC	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.02e-05	0.002	-0.33	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
HNSC	cis	rs2732480	0.577	rs2634691	ENSG00000257763.1	OR5BK1P	4.46	1.02e-05	0.002	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48355792~48356614:-
HNSC	cis	rs61935443	0.501	rs10777622	ENSG00000241556.1	RP11-490G8.1	-4.46	1.02e-05	0.002	-0.21	-0.2	Schizophrenia;	chr12:94801407	chr12:95467397~95467861:-
HNSC	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-4.46	1.02e-05	0.002	-0.2	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
HNSC	cis	rs1799949	1	rs8176234	ENSG00000236383.6	LINC00854	-4.46	1.02e-05	0.002	-0.19	-0.2	Menopause (age at onset);	chr17:43067763	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176233	ENSG00000236383.6	LINC00854	-4.46	1.02e-05	0.002	-0.19	-0.2	Menopause (age at onset);	chr17:43067787	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176220	ENSG00000236383.6	LINC00854	-4.46	1.02e-05	0.002	-0.19	-0.2	Menopause (age at onset);	chr17:43070445	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1799966	ENSG00000236383.6	LINC00854	-4.46	1.02e-05	0.002	-0.19	-0.2	Menopause (age at onset);	chr17:43071077	chr17:43216941~43305976:-
HNSC	cis	rs7824557	0.614	rs2736277	ENSG00000255310.2	AF131215.2	-4.46	1.02e-05	0.002	-0.18	-0.2	Retinal vascular caliber;	chr8:11361384	chr8:11107788~11109726:-
HNSC	cis	rs755249	0.53	rs112205225	ENSG00000228060.1	RP11-69E11.8	-4.46	1.02e-05	0.002	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39565160~39573203:+
HNSC	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	4.46	1.02e-05	0.002	0.26	0.2	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
HNSC	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	4.46	1.02e-05	0.002	0.24	0.2	Height;	chr14:75112713	chr14:75011269~75012851:-
HNSC	cis	rs9438901	0.592	rs1293259	ENSG00000224183.1	SDHDP6	4.46	1.02e-05	0.002	0.32	0.2	Red cell distribution width;	chr1:25369344	chr1:25294164~25294643:-
HNSC	cis	rs4761669	0.816	rs1434243	ENSG00000241556.1	RP11-490G8.1	-4.46	1.02e-05	0.002	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797558	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.816	rs1434244	ENSG00000241556.1	RP11-490G8.1	-4.46	1.02e-05	0.002	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797590	chr12:95467397~95467861:-
HNSC	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-4.46	1.02e-05	0.00201	-0.22	-0.2	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
HNSC	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-4.46	1.02e-05	0.00201	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-4.46	1.02e-05	0.00201	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
HNSC	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	4.46	1.02e-05	0.00201	0.23	0.2	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
HNSC	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	4.46	1.02e-05	0.00201	0.23	0.2	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	4.46	1.02e-05	0.00201	0.28	0.2	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	4.46	1.02e-05	0.00201	0.28	0.2	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
HNSC	cis	rs73219805	0.554	rs3808569	ENSG00000228451.3	SDAD1P1	-4.46	1.02e-05	0.00201	-0.36	-0.2	Schizophrenia;	chr8:26356252	chr8:26379259~26382953:-
HNSC	cis	rs56114371	0.53	rs9348774	ENSG00000219392.1	RP1-265C24.5	-4.46	1.02e-05	0.00201	-0.27	-0.2	Breast cancer;	chr6:27721151	chr6:28115628~28116551:+
HNSC	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-4.46	1.02e-05	0.00201	-0.24	-0.2	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
HNSC	cis	rs870825	0.858	rs2014964	ENSG00000254233.1	RP11-242J7.1	4.46	1.02e-05	0.00201	0.38	0.2	Blood protein levels;	chr4:184667682	chr4:184584093~184625030:-
HNSC	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	4.46	1.02e-05	0.00201	0.29	0.2	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
HNSC	cis	rs9300255	0.679	rs28583837	ENSG00000280120.1	RP11-546D6.3	-4.46	1.02e-05	0.00201	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123379073	chr12:123152324~123153377:-
HNSC	cis	rs12701220	0.894	rs2141274	ENSG00000224079.1	AC091729.7	4.46	1.02e-05	0.00201	0.29	0.2	Bronchopulmonary dysplasia;	chr7:995081	chr7:1074450~1078036:+
HNSC	cis	rs1198872	0.892	rs1198866	ENSG00000272275.1	RP11-791G15.2	-4.46	1.02e-05	0.00201	-0.24	-0.2	Cardiac Troponin-T levels;	chr2:10761664	chr2:10767875~10770058:-
HNSC	cis	rs3806843	1	rs13157397	ENSG00000202515.1	VTRNA1-3	-4.46	1.02e-05	0.00201	-0.23	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr5:140726158~140726246:+
HNSC	cis	rs929354	0.742	rs2051877	ENSG00000224629.1	RP5-1142J19.2	-4.46	1.02e-05	0.00201	-0.2	-0.2	Body mass index;	chr7:157216119	chr7:157263022~157263229:-
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000254153.1	CTA-398F10.2	4.46	1.02e-05	0.00201	0.22	0.2	Mood instability;	chr8:8816226	chr8:8456909~8461337:-
HNSC	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	4.46	1.02e-05	0.00201	0.22	0.2	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
HNSC	cis	rs988913	0.723	rs4715520	ENSG00000224984.1	RP11-524H19.2	-4.46	1.02e-05	0.00201	-0.24	-0.2	Menarche (age at onset);	chr6:55131197	chr6:54840118~54840855:-
HNSC	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	4.46	1.02e-05	0.00201	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
HNSC	cis	rs3736485	0.966	rs11636170	ENSG00000259438.1	CTD-2650P22.1	4.46	1.02e-05	0.00201	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51474890	chr15:52010999~52019095:-
HNSC	cis	rs3015497	0.527	rs3015473	ENSG00000277050.1	RP11-102G14.1	-4.46	1.02e-05	0.00201	-0.21	-0.2	Mean platelet volume;	chr14:50687292	chr14:51637348~51637947:-
HNSC	cis	rs2492286	0.597	rs1126828	ENSG00000242551.2	POU5F1P6	-4.46	1.02e-05	0.00201	-0.22	-0.2	Eosinophil counts;	chr3:128625943	chr3:128674735~128677005:-
HNSC	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	4.46	1.02e-05	0.00201	0.24	0.2	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
HNSC	cis	rs913655	0.545	rs2495835	ENSG00000225527.1	RP11-383B4.4	-4.46	1.02e-05	0.00201	-0.24	-0.2	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18780119	chr10:18531849~18533336:-
HNSC	cis	rs4908769	0.624	rs3765971	ENSG00000232912.4	RP5-1115A15.1	-4.46	1.02e-05	0.00201	-0.22	-0.2	Allergy;	chr1:8385300	chr1:8424645~8434838:+
HNSC	cis	rs10791097	0.609	rs3751039	ENSG00000254842.5	RP11-890B15.2	4.46	1.02e-05	0.00201	0.17	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130903181	chr11:130844191~130865561:-
HNSC	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-4.46	1.02e-05	0.00201	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
HNSC	cis	rs3015497	0.624	rs2934700	ENSG00000277050.1	RP11-102G14.1	-4.46	1.02e-05	0.00202	-0.21	-0.2	Mean platelet volume;	chr14:50668459	chr14:51637348~51637947:-
HNSC	cis	rs3015497	0.624	rs3015486	ENSG00000277050.1	RP11-102G14.1	-4.46	1.02e-05	0.00202	-0.21	-0.2	Mean platelet volume;	chr14:50668612	chr14:51637348~51637947:-
HNSC	cis	rs4356203	0.905	rs7946165	ENSG00000272034.1	SNORD14A	-4.46	1.02e-05	0.00202	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17074654~17074744:-
HNSC	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-4.46	1.02e-05	0.00202	-0.23	-0.2	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
HNSC	cis	rs3738443	0.868	rs12569042	ENSG00000259865.1	RP11-488L18.10	4.46	1.02e-05	0.00202	0.18	0.2	Alcohol dependence;	chr1:247203078	chr1:247187281~247188526:-
HNSC	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	4.46	1.02e-05	0.00202	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
HNSC	cis	rs12935418	0.616	rs2602446	ENSG00000278985.1	RP11-303E16.9	-4.46	1.03e-05	0.00202	-0.19	-0.2	Mean corpuscular volume;	chr16:80984310	chr16:80982319~80984094:-
HNSC	cis	rs964611	0.882	rs1905612	ENSG00000259488.2	RP11-154J22.1	4.46	1.03e-05	0.00202	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48363720	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs971952	ENSG00000259488.2	RP11-154J22.1	4.46	1.03e-05	0.00202	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48363743	chr15:48312353~48331856:-
HNSC	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-4.46	1.03e-05	0.00202	-0.18	-0.2	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
HNSC	cis	rs4862750	0.914	rs7658351	ENSG00000250971.1	RP11-696F12.1	4.46	1.03e-05	0.00202	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186954526	chr4:187060099~187060930:+
HNSC	cis	rs2835345	0.63	rs55681268	ENSG00000230479.1	AP000695.6	4.46	1.03e-05	0.00202	0.22	0.2	Pulmonary function;	chr21:36449419	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12627161	ENSG00000230479.1	AP000695.6	4.46	1.03e-05	0.00202	0.22	0.2	Pulmonary function;	chr21:36449649	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12627241	ENSG00000230479.1	AP000695.6	4.46	1.03e-05	0.00202	0.22	0.2	Pulmonary function;	chr21:36449689	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12627173	ENSG00000230479.1	AP000695.6	4.46	1.03e-05	0.00202	0.22	0.2	Pulmonary function;	chr21:36449715	chr21:36430360~36481070:+
HNSC	cis	rs459482	0.508	rs467558	ENSG00000228318.3	AP001610.5	4.46	1.03e-05	0.00202	0.22	0.2	IgG glycosylation;	chr21:41439468	chr21:41441056~41445708:-
HNSC	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	4.46	1.03e-05	0.00202	0.24	0.2	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000219891.2	ZSCAN12P1	4.46	1.03e-05	0.00202	0.28	0.2	Parkinson's disease;	chr6:27999496	chr6:28091154~28093664:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000224373.3	IGHV4-59	4.46	1.03e-05	0.00202	0.14	0.2	Kawasaki disease;	chr14:106695603	chr14:106627249~106627825:-
HNSC	cis	rs2492286	0.518	rs2712418	ENSG00000242551.2	POU5F1P6	-4.46	1.03e-05	0.00202	-0.22	-0.2	Eosinophil counts;	chr3:128624793	chr3:128674735~128677005:-
HNSC	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	4.46	1.03e-05	0.00202	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	4.46	1.03e-05	0.00202	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
HNSC	cis	rs41307935	0.818	rs35738294	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26693642	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71636769	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694100	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71636770	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694624	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34585496	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26699449	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.57	rs12744003	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701808	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs77408691	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26707898	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.73	rs12724159	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26709637	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12729444	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26710663	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12726081	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711084	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs79568175	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711725	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12726287	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26712737	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs12756154	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26714018	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs35407375	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26714727	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.818	rs80036989	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26721033	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12756074	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26721402	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs71636773	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724828	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs60401377	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26725756	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.818	rs35145624	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26726121	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs35256560	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26727525	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs56932185	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26730152	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs34014719	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26746275	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs59715866	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26752685	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12737946	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753403	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12742115	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753440	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.57	rs71636776	ENSG00000260063.1	RP5-968P14.2	-4.46	1.03e-05	0.00202	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756557	chr1:26692132~26694131:-
HNSC	cis	rs6125961	0.629	rs6125971	ENSG00000224397.4	LINC01272	4.46	1.03e-05	0.00202	0.28	0.2	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50299229	chr20:50267486~50279795:+
HNSC	cis	rs800888	0.518	rs2721946	ENSG00000249917.2	LINC00536	-4.46	1.03e-05	0.00202	-0.26	-0.2	Monocyte percentage of white cells;	chr8:115629733	chr8:115950511~116325059:-
HNSC	cis	rs12468579	0.74	rs11894425	ENSG00000235852.1	AC005540.3	4.46	1.03e-05	0.00202	0.23	0.2	JT interval (sulfonylurea treatment interaction);	chr2:190973115	chr2:190880797~190882059:-
HNSC	cis	rs9311676	0.656	rs55692656	ENSG00000273493.1	RP11-80H18.4	4.46	1.03e-05	0.00203	0.22	0.2	Systemic lupus erythematosus;	chr3:58397447	chr3:58329965~58330118:+
HNSC	cis	rs7296418	0.663	rs28450974	ENSG00000280120.1	RP11-546D6.3	4.46	1.03e-05	0.00203	0.17	0.2	Platelet count;	chr12:123376873	chr12:123152324~123153377:-
HNSC	cis	rs6831352	0.734	rs1453872	ENSG00000263923.1	RP11-571L19.7	-4.46	1.03e-05	0.00203	-0.21	-0.2	Alcohol dependence;	chr4:99101331	chr4:98928897~98994994:+
HNSC	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	4.46	1.03e-05	0.00203	0.18	0.2	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
HNSC	cis	rs1008375	1	rs17507481	ENSG00000249502.1	AC006160.5	-4.46	1.03e-05	0.00203	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618443	chr4:17587467~17614571:-
HNSC	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00203	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00203	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00203	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
HNSC	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-4.46	1.03e-05	0.00203	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.684	rs546603	ENSG00000254153.1	CTA-398F10.2	-4.46	1.03e-05	0.00203	-0.23	-0.2	Mood instability;	chr8:8738328	chr8:8456909~8461337:-
HNSC	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	4.46	1.03e-05	0.00203	0.24	0.2	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
HNSC	cis	rs6490294	0.571	rs12312538	ENSG00000226469.1	ADAM1B	4.46	1.03e-05	0.00203	0.29	0.2	Mean platelet volume;	chr12:112051717	chr12:111927018~111929017:+
HNSC	cis	rs10773046	0.74	rs10846566	ENSG00000269938.1	RP11-214K3.20	-4.46	1.03e-05	0.00203	-0.22	-0.2	Osteoarthritis (hip);	chr12:123868823	chr12:123968023~123968579:-
HNSC	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	4.46	1.03e-05	0.00203	0.23	0.2	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
HNSC	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-4.46	1.03e-05	0.00203	-0.43	-0.2	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
HNSC	cis	rs9914988	0.613	rs12451190	ENSG00000264577.1	AC010761.8	4.46	1.03e-05	0.00203	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28954859	chr17:28721487~28722877:-
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	4.46	1.03e-05	0.00203	0.34	0.2	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
HNSC	cis	rs11846409	0.932	rs60659763	ENSG00000254174.1	IGHV1-12	4.46	1.03e-05	0.00203	0.16	0.2	Rheumatic heart disease;	chr14:106634172	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs57080270	ENSG00000254174.1	IGHV1-12	4.46	1.03e-05	0.00203	0.16	0.2	Rheumatic heart disease;	chr14:106634215	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs60917084	ENSG00000254174.1	IGHV1-12	4.46	1.03e-05	0.00203	0.16	0.2	Rheumatic heart disease;	chr14:106634621	chr14:106122420~106122709:-
HNSC	cis	rs1555322	0.932	rs2425018	ENSG00000126005.14	MMP24-AS1	-4.46	1.04e-05	0.00203	-0.37	-0.2	Attention deficit hyperactivity disorder;	chr20:35230963	chr20:35216462~35278131:-
HNSC	cis	rs2243480	1	rs316315	ENSG00000230295.1	RP11-458F8.2	4.46	1.04e-05	0.00203	0.22	0.2	Diabetic kidney disease;	chr7:66126218	chr7:66880708~66882981:+
HNSC	cis	rs10946940	1	rs10946940	ENSG00000219392.1	RP1-265C24.5	4.46	1.04e-05	0.00203	0.23	0.2	Systemic lupus erythematosus;	chr6:27592808	chr6:28115628~28116551:+
HNSC	cis	rs9531006	0.719	rs2118798	ENSG00000227676.3	LINC01068	4.46	1.04e-05	0.00204	0.3	0.2	Sleep duration;	chr13:79974171	chr13:79566727~79571436:+
HNSC	cis	rs9531006	0.752	rs12867413	ENSG00000227676.3	LINC01068	4.46	1.04e-05	0.00204	0.3	0.2	Sleep duration;	chr13:79975184	chr13:79566727~79571436:+
HNSC	cis	rs12935418	0.552	rs2549838	ENSG00000278985.1	RP11-303E16.9	-4.46	1.04e-05	0.00204	-0.19	-0.2	Mean corpuscular volume;	chr16:80989605	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549839	ENSG00000278985.1	RP11-303E16.9	-4.46	1.04e-05	0.00204	-0.19	-0.2	Mean corpuscular volume;	chr16:80989630	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs2549843	ENSG00000278985.1	RP11-303E16.9	-4.46	1.04e-05	0.00204	-0.19	-0.2	Mean corpuscular volume;	chr16:80990140	chr16:80982319~80984094:-
HNSC	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-4.46	1.04e-05	0.00204	-0.21	-0.2	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	4.46	1.04e-05	0.00204	0.23	0.2	Depression;	chr6:28199145	chr6:28170845~28172521:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-4.46	1.04e-05	0.00204	-0.27	-0.2	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
HNSC	cis	rs6964587	0.839	rs10808086	ENSG00000188693.7	CYP51A1-AS1	-4.46	1.04e-05	0.00204	-0.22	-0.2	Breast cancer;	chr7:91818201	chr7:92134604~92180725:+
HNSC	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-4.46	1.04e-05	0.00204	-0.22	-0.2	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
HNSC	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-4.46	1.04e-05	0.00204	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
HNSC	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	4.46	1.04e-05	0.00204	0.22	0.2	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000255495.1	AC145124.2	4.46	1.04e-05	0.00204	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12194467~12196280:+
HNSC	cis	rs4834770	1	rs4834770	ENSG00000250412.1	KLHL2P1	4.46	1.04e-05	0.00204	0.23	0.2	Blood protein levels;	chr4:119320694	chr4:119334329~119378233:+
HNSC	cis	rs4834770	1	rs6823963	ENSG00000250412.1	KLHL2P1	4.46	1.04e-05	0.00204	0.23	0.2	Blood protein levels;	chr4:119321009	chr4:119334329~119378233:+
HNSC	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-4.46	1.04e-05	0.00204	-0.34	-0.2	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-4.46	1.04e-05	0.00204	-0.27	-0.2	Gout;	chr7:66671562	chr7:66880708~66882981:+
HNSC	cis	rs240993	0.812	rs7766610	ENSG00000230177.1	RP5-1112D6.4	-4.46	1.04e-05	0.00204	-0.26	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111277932~111278742:+
HNSC	cis	rs6500395	0.926	rs11076571	ENSG00000261267.1	RP11-44I10.3	-4.46	1.04e-05	0.00204	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48564153	chr16:48559661~48587403:+
HNSC	cis	rs9300255	0.506	rs11057251	ENSG00000280120.1	RP11-546D6.3	-4.46	1.04e-05	0.00204	-0.17	-0.2	Neutrophil percentage of white cells;	chr12:123306680	chr12:123152324~123153377:-
HNSC	cis	rs710913	0.618	rs11206437	ENSG00000182109.6	RP11-69E11.4	4.46	1.04e-05	0.00204	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	4.46	1.04e-05	0.00204	0.26	0.2	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
HNSC	cis	rs597539	0.58	rs7935851	ENSG00000261625.1	RP11-554A11.4	-4.46	1.04e-05	0.00204	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:69000765~69002048:-
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-4.46	1.04e-05	0.00204	-0.18	-0.2	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
HNSC	cis	rs5758511	0.514	rs5758622	ENSG00000205702.9	CYP2D7	4.46	1.04e-05	0.00204	0.18	0.2	Birth weight;	chr22:42167927	chr22:42140203~42144577:-
HNSC	cis	rs1065852	0.906	rs5751232	ENSG00000205702.9	CYP2D7	4.46	1.04e-05	0.00204	0.18	0.2	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.514	rs9607882	ENSG00000205702.9	CYP2D7	4.46	1.04e-05	0.00204	0.18	0.2	Birth weight;	chr22:42171445	chr22:42140203~42144577:-
HNSC	cis	rs6688613	1	rs7528849	ENSG00000215834.7	FMO9P	4.46	1.04e-05	0.00204	0.24	0.2	Refractive astigmatism;	chr1:166985633	chr1:166603675~166631400:+
HNSC	cis	rs9450351	0.744	rs6910543	ENSG00000203875.9	SNHG5	-4.46	1.04e-05	0.00204	-0.46	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85519023	chr6:85660950~85678736:-
HNSC	cis	rs10027350	0.964	rs3756208	ENSG00000281501.1	SEPSECS-AS1	4.46	1.04e-05	0.00204	0.25	0.2	Childhood ear infection;	chr4:25132047	chr4:25160641~25201440:+
HNSC	cis	rs6496044	0.568	rs1982742	ENSG00000259295.5	CSPG4P12	4.46	1.04e-05	0.00204	0.24	0.2	Interstitial lung disease;	chr15:85525519	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs1982743	ENSG00000259295.5	CSPG4P12	4.46	1.04e-05	0.00204	0.24	0.2	Interstitial lung disease;	chr15:85525528	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs6496049	ENSG00000259295.5	CSPG4P12	4.46	1.04e-05	0.00204	0.24	0.2	Interstitial lung disease;	chr15:85525974	chr15:85191438~85213905:+
HNSC	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-4.46	1.04e-05	0.00204	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000204709.4	LINC01556	4.46	1.04e-05	0.00204	0.28	0.2	Depression;	chr6:28135913	chr6:28943877~28944537:+
HNSC	cis	rs467650	0.509	rs152989	ENSG00000246763.5	RGMB-AS1	4.46	1.04e-05	0.00204	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98654131	chr5:98769618~98773469:-
HNSC	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	4.46	1.04e-05	0.00204	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
HNSC	cis	rs7824557	0.547	rs2736287	ENSG00000255495.1	AC145124.2	-4.46	1.04e-05	0.00204	-0.22	-0.2	Retinal vascular caliber;	chr8:11370497	chr8:12194467~12196280:+
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000259429.4	UBE2Q2P2	-4.46	1.04e-05	0.00204	-0.19	-0.2	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82355142~82420075:+
HNSC	cis	rs597539	0.652	rs11603827	ENSG00000255741.1	RP11-757G1.5	-4.46	1.04e-05	0.00204	-0.28	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68941503~68942852:-
HNSC	cis	rs5758511	0.514	rs2899354	ENSG00000205702.9	CYP2D7	4.46	1.04e-05	0.00204	0.18	0.2	Birth weight;	chr22:42158403	chr22:42140203~42144577:-
HNSC	cis	rs1799949	1	rs915945	ENSG00000236383.6	LINC00854	-4.46	1.04e-05	0.00204	-0.2	-0.2	Menopause (age at onset);	chr17:43027847	chr17:43216941~43305976:-
HNSC	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	4.46	1.04e-05	0.00204	0.25	0.2	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	4.46	1.04e-05	0.00204	0.25	0.2	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	4.46	1.04e-05	0.00204	0.25	0.2	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	4.46	1.04e-05	0.00204	0.25	0.2	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	4.46	1.04e-05	0.00204	0.25	0.2	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
HNSC	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-4.46	1.04e-05	0.00204	-0.23	-0.2	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
HNSC	cis	rs9311676	0.656	rs56097407	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58392352	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs62258102	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393057	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11130634	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393396	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11130635	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393416	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.609	rs6770113	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393570	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs6445977	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393833	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs6445978	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58393859	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11130636	ENSG00000273493.1	RP11-80H18.4	4.46	1.04e-05	0.00204	0.22	0.2	Systemic lupus erythematosus;	chr3:58394371	chr3:58329965~58330118:+
HNSC	cis	rs73201462	1	rs2999090	ENSG00000231305.3	RP11-723O4.2	-4.46	1.04e-05	0.00204	-0.3	-0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128212497	chr3:128861313~128871540:-
HNSC	cis	rs72772090	0.71	rs11739280	ENSG00000248734.2	CTD-2260A17.1	4.46	1.04e-05	0.00204	0.31	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96784777~96785999:+
HNSC	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-4.46	1.04e-05	0.00205	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
HNSC	cis	rs6601327	0.635	rs7821575	ENSG00000254340.1	RP11-10A14.3	-4.46	1.04e-05	0.00205	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9808445	chr8:9141424~9145435:+
HNSC	cis	rs10466239	0.803	rs60739384	ENSG00000230555.2	RP11-517P14.2	4.46	1.04e-05	0.00205	0.29	0.2	Telomere length;	chr10:43372581	chr10:43420738~43422100:+
HNSC	cis	rs7023329	0.59	rs2184551	ENSG00000244230.3	RN7SL151P	-4.46	1.04e-05	0.00205	-0.21	-0.2	Melanoma;	chr9:21773223	chr9:21699314~21699596:+
HNSC	cis	rs11157436	0.602	rs2075493	ENSG00000211812.1	TRAV26-2	-4.46	1.04e-05	0.00205	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22202583~22203368:+
HNSC	cis	rs35963943	0.625	rs13070928	ENSG00000228956.7	SATB1-AS1	4.46	1.04e-05	0.00205	0.24	0.2	Lymphocyte counts;	chr3:18669908	chr3:18445024~18920401:+
HNSC	cis	rs638893	0.947	rs12808822	ENSG00000255422.1	AP002954.4	-4.46	1.04e-05	0.00205	-0.33	-0.2	Vitiligo;	chr11:118831560	chr11:118704607~118750263:+
HNSC	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-4.46	1.04e-05	0.00205	-0.25	-0.2	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
HNSC	cis	rs916888	0.821	rs199509	ENSG00000260075.1	NSFP1	4.46	1.04e-05	0.00205	0.29	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.821	rs199507	ENSG00000260075.1	NSFP1	4.46	1.04e-05	0.00205	0.29	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46372855~46487141:+
HNSC	cis	rs853679	0.607	rs67998226	ENSG00000226314.6	ZNF192P1	-4.46	1.04e-05	0.00205	-0.37	-0.2	Depression;	chr6:28270281	chr6:28161781~28169594:+
HNSC	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-4.46	1.04e-05	0.00205	-0.37	-0.2	Gout;	chr7:66723871	chr7:66902857~66906297:+
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000219891.2	ZSCAN12P1	4.46	1.05e-05	0.00205	0.28	0.2	Parkinson's disease;	chr6:28012442	chr6:28091154~28093664:+
HNSC	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	4.46	1.05e-05	0.00205	0.2	0.2	Height;	chr5:37505544	chr5:36666214~36725195:-
HNSC	cis	rs60617249	0.862	rs11238407	ENSG00000228204.2	RP4-724E13.2	-4.46	1.05e-05	0.00205	-0.21	-0.2	Major depression and alcohol dependence;	chr7:50942784	chr7:50866747~51022990:+
HNSC	cis	rs9840812	0.953	rs61791721	ENSG00000273486.1	RP11-731C17.2	-4.46	1.05e-05	0.00205	-0.18	-0.2	Fibrinogen levels;	chr3:136085708	chr3:136837338~136839021:-
HNSC	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-4.46	1.05e-05	0.00205	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
HNSC	cis	rs10946940	0.897	rs6456801	ENSG00000219392.1	RP1-265C24.5	-4.46	1.05e-05	0.00205	-0.23	-0.2	Systemic lupus erythematosus;	chr6:27657753	chr6:28115628~28116551:+
HNSC	cis	rs721917	0.525	rs2258874	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.05e-05	0.00205	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79663088~79826594:-
HNSC	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	4.46	1.05e-05	0.00205	0.21	0.2	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
HNSC	cis	rs494003	1	rs494003	ENSG00000255120.4	OVOL1-AS1	4.46	1.05e-05	0.00205	0.25	0.2	Systemic lupus erythematosus;	chr11:65774827	chr11:65789051~65790868:-
HNSC	cis	rs9914988	0.613	rs4795475	ENSG00000264577.1	AC010761.8	4.46	1.05e-05	0.00205	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28912358	chr17:28721487~28722877:-
HNSC	cis	rs755249	0.567	rs16825887	ENSG00000228060.1	RP11-69E11.8	4.46	1.05e-05	0.00205	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39565160~39573203:+
HNSC	cis	rs6964587	0.839	rs6949881	ENSG00000188693.7	CYP51A1-AS1	-4.46	1.05e-05	0.00205	-0.21	-0.2	Breast cancer;	chr7:91804513	chr7:92134604~92180725:+
HNSC	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	4.46	1.05e-05	0.00205	0.27	0.2	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
HNSC	cis	rs9840812	1	rs9840812	ENSG00000273486.1	RP11-731C17.2	4.46	1.05e-05	0.00205	0.18	0.2	Fibrinogen levels;	chr3:136124320	chr3:136837338~136839021:-
HNSC	cis	rs75920871	0.502	rs10790166	ENSG00000254851.1	RP11-109L13.1	4.46	1.05e-05	0.00205	0.28	0.2	Subjective well-being;	chr11:116908783	chr11:117135528~117138582:+
HNSC	cis	rs6490294	0.571	rs7970397	ENSG00000226469.1	ADAM1B	4.46	1.05e-05	0.00206	0.29	0.2	Mean platelet volume;	chr12:112142267	chr12:111927018~111929017:+
HNSC	cis	rs62432291	0.681	rs365045	ENSG00000235086.1	FNDC1-IT1	4.46	1.05e-05	0.00206	0.27	0.2	Joint mobility (Beighton score);	chr6:159211218	chr6:159240786~159243329:+
HNSC	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	4.46	1.05e-05	0.00206	0.17	0.2	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
HNSC	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-4.46	1.05e-05	0.00206	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
HNSC	cis	rs6500395	1	rs1362636	ENSG00000261267.1	RP11-44I10.3	4.46	1.05e-05	0.00206	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48678868	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs4785536	ENSG00000261267.1	RP11-44I10.3	4.46	1.05e-05	0.00206	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48679069	chr16:48559661~48587403:+
HNSC	cis	rs1908814	0.516	rs11250178	ENSG00000255495.1	AC145124.2	4.46	1.05e-05	0.00206	0.23	0.2	Neuroticism;	chr8:11942725	chr8:12194467~12196280:+
HNSC	cis	rs71636778	0.509	rs34216334	ENSG00000260063.1	RP5-968P14.2	-4.46	1.05e-05	0.00206	-0.38	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26736928	chr1:26692132~26694131:-
HNSC	cis	rs12935418	0.616	rs2549828	ENSG00000278985.1	RP11-303E16.9	-4.46	1.05e-05	0.00206	-0.19	-0.2	Mean corpuscular volume;	chr16:80985378	chr16:80982319~80984094:-
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-4.46	1.05e-05	0.00206	-0.15	-0.2	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
HNSC	cis	rs116095464	0.51	rs7714944	ENSG00000250848.1	CTD-2083E4.5	-4.46	1.05e-05	0.00206	-0.27	-0.2	Breast cancer;	chr5:231650	chr5:288833~290321:-
HNSC	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-4.45	1.05e-05	0.00206	-0.26	-0.2	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
HNSC	cis	rs9393777	0.92	rs34150729	ENSG00000219392.1	RP1-265C24.5	-4.45	1.05e-05	0.00206	-0.42	-0.2	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28115628~28116551:+
HNSC	cis	rs9393777	0.92	rs13191227	ENSG00000219392.1	RP1-265C24.5	-4.45	1.05e-05	0.00206	-0.42	-0.2	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28115628~28116551:+
HNSC	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-4.45	1.05e-05	0.00206	-0.19	-0.2	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
HNSC	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	4.45	1.05e-05	0.00206	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
HNSC	cis	rs1799949	1	rs11655505	ENSG00000236383.6	LINC00854	-4.45	1.05e-05	0.00206	-0.19	-0.2	Menopause (age at onset);	chr17:43126360	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs4793204	ENSG00000236383.6	LINC00854	-4.45	1.05e-05	0.00206	-0.19	-0.2	Menopause (age at onset);	chr17:43127281	chr17:43216941~43305976:-
HNSC	cis	rs889398	0.967	rs35967356	ENSG00000226232.7	RP11-419C5.2	4.45	1.05e-05	0.00206	0.18	0.2	Body mass index;	chr16:69547451	chr16:69976388~69996188:-
HNSC	cis	rs62432291	0.681	rs1699442	ENSG00000235086.1	FNDC1-IT1	4.45	1.05e-05	0.00206	0.27	0.2	Joint mobility (Beighton score);	chr6:159234886	chr6:159240786~159243329:+
HNSC	cis	rs13256369	0.708	rs11249886	ENSG00000173295.6	FAM86B3P	4.45	1.05e-05	0.00206	0.26	0.2	Obesity-related traits;	chr8:8704511	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs11249887	ENSG00000173295.6	FAM86B3P	4.45	1.05e-05	0.00206	0.26	0.2	Obesity-related traits;	chr8:8704674	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.755	rs12550057	ENSG00000173295.6	FAM86B3P	4.45	1.05e-05	0.00206	0.26	0.2	Obesity-related traits;	chr8:8704758	chr8:8228595~8244865:+
HNSC	cis	rs116095464	0.558	rs6866632	ENSG00000250848.1	CTD-2083E4.5	-4.45	1.05e-05	0.00206	-0.28	-0.2	Breast cancer;	chr5:264314	chr5:288833~290321:-
HNSC	cis	rs763121	0.813	rs4821807	ENSG00000273076.1	RP3-508I15.22	4.45	1.05e-05	0.00206	0.22	0.2	Menopause (age at onset);	chr22:38669577	chr22:38743495~38743910:+
HNSC	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	4.45	1.05e-05	0.00206	0.28	0.2	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
HNSC	cis	rs9910055	0.659	rs186603	ENSG00000267080.4	ASB16-AS1	4.45	1.05e-05	0.00206	0.16	0.2	Total body bone mineral density;	chr17:44130516	chr17:44175973~44186717:-
HNSC	cis	rs11951515	0.508	rs7706431	ENSG00000249286.1	CTD-2210P15.2	4.45	1.05e-05	0.00206	0.21	0.2	Metabolite levels  (X-11787);	chr5:43582321	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.508	rs6898866	ENSG00000249286.1	CTD-2210P15.2	4.45	1.05e-05	0.00206	0.21	0.2	Metabolite levels  (X-11787);	chr5:43586273	chr5:43586918~43588223:-
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-4.45	1.05e-05	0.00206	-0.25	-0.2	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
HNSC	cis	rs7824557	0.527	rs2572446	ENSG00000269918.1	AF131215.9	-4.45	1.05e-05	0.00206	-0.2	-0.2	Retinal vascular caliber;	chr8:11382056	chr8:11104691~11106704:-
HNSC	cis	rs61270009	0.955	rs34148755	ENSG00000247828.6	TMEM161B-AS1	4.45	1.05e-05	0.00207	0.21	0.2	Depressive symptoms;	chr5:88394130	chr5:88268895~88436685:+
HNSC	cis	rs71520386	1	rs71520386	ENSG00000230658.1	KLHL7-AS1	4.45	1.05e-05	0.00207	0.32	0.2	Fibrinogen levels;	chr7:22813902	chr7:23101228~23105703:-
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	4.45	1.05e-05	0.00207	0.27	0.2	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
HNSC	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-4.45	1.05e-05	0.00207	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
HNSC	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	4.45	1.05e-05	0.00207	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
HNSC	cis	rs2098713	0.569	rs13155335	ENSG00000250155.1	CTD-2353F22.1	-4.45	1.06e-05	0.00207	-0.22	-0.2	Telomere length;	chr5:37506809	chr5:36666214~36725195:-
HNSC	cis	rs4834770	1	rs2282688	ENSG00000250412.1	KLHL2P1	4.45	1.06e-05	0.00207	0.23	0.2	Blood protein levels;	chr4:119322567	chr4:119334329~119378233:+
HNSC	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-4.45	1.06e-05	0.00207	-0.29	-0.2	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	4.45	1.06e-05	0.00207	0.24	0.2	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	4.45	1.06e-05	0.00207	0.24	0.2	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	4.45	1.06e-05	0.00207	0.24	0.2	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
HNSC	cis	rs6601327	0.518	rs13264850	ENSG00000254340.1	RP11-10A14.3	-4.45	1.06e-05	0.00207	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:9141424~9145435:+
HNSC	cis	rs3758785	0.737	rs79512686	ENSG00000255893.1	RP11-685N10.1	-4.45	1.06e-05	0.00207	-0.3	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94398331	chr11:94472908~94473570:-
HNSC	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-4.45	1.06e-05	0.00207	-0.16	-0.2	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
HNSC	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-4.45	1.06e-05	0.00207	-0.16	-0.2	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
HNSC	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	4.45	1.06e-05	0.00207	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
HNSC	cis	rs7621025	0.662	rs3856637	ENSG00000239213.4	NCK1-AS1	4.45	1.06e-05	0.00207	0.17	0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136672353	chr3:136841726~136862054:-
HNSC	cis	rs11846409	0.872	rs74091715	ENSG00000254174.1	IGHV1-12	4.45	1.06e-05	0.00207	0.16	0.2	Rheumatic heart disease;	chr14:106637731	chr14:106122420~106122709:-
HNSC	cis	rs6601327	0.641	rs11782886	ENSG00000254340.1	RP11-10A14.3	-4.45	1.06e-05	0.00207	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9730381	chr8:9141424~9145435:+
HNSC	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.45	1.06e-05	0.00207	-0.34	-0.2	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
HNSC	cis	rs929354	0.772	rs10230895	ENSG00000224629.1	RP5-1142J19.2	-4.45	1.06e-05	0.00207	-0.2	-0.2	Body mass index;	chr7:157214344	chr7:157263022~157263229:-
HNSC	cis	rs116095464	1	rs2015774	ENSG00000250848.1	CTD-2083E4.5	-4.45	1.06e-05	0.00207	-0.34	-0.2	Breast cancer;	chr5:312843	chr5:288833~290321:-
HNSC	cis	rs1799949	0.93	rs8176194	ENSG00000236383.6	LINC00854	-4.45	1.06e-05	0.00207	-0.19	-0.2	Menopause (age at onset);	chr17:43079204	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1060915	ENSG00000236383.6	LINC00854	-4.45	1.06e-05	0.00207	-0.19	-0.2	Menopause (age at onset);	chr17:43082453	chr17:43216941~43305976:-
HNSC	cis	rs6951245	0.706	rs28483034	ENSG00000225146.1	AC073957.15	-4.45	1.06e-05	0.00207	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1029025~1043891:+
HNSC	cis	rs9300255	0.77	rs28683528	ENSG00000280120.1	RP11-546D6.3	-4.45	1.06e-05	0.00207	-0.19	-0.2	Neutrophil percentage of white cells;	chr12:123360804	chr12:123152324~123153377:-
HNSC	cis	rs7824557	0.527	rs2572449	ENSG00000255310.2	AF131215.2	4.45	1.06e-05	0.00207	0.19	0.2	Retinal vascular caliber;	chr8:11381628	chr8:11107788~11109726:-
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-4.45	1.06e-05	0.00207	-0.18	-0.2	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
HNSC	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	4.45	1.06e-05	0.00207	0.26	0.2	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
HNSC	cis	rs10266483	0.515	rs6949304	ENSG00000228653.2	HNRNPCP7	4.45	1.06e-05	0.00207	0.25	0.2	Response to statin therapy;	chr7:64257903	chr7:64500825~64501729:+
HNSC	cis	rs2337406	1	rs11850600	ENSG00000280411.1	IGHV1-69-2	-4.45	1.06e-05	0.00207	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106670765	chr14:106762092~106762588:-
HNSC	cis	rs6601327	0.606	rs4841203	ENSG00000254340.1	RP11-10A14.3	-4.45	1.06e-05	0.00208	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:9141424~9145435:+
HNSC	cis	rs2732480	0.577	rs2634684	ENSG00000257763.1	OR5BK1P	-4.45	1.06e-05	0.00208	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48355792~48356614:-
HNSC	cis	rs3806843	0.966	rs2337986	ENSG00000202515.1	VTRNA1-3	-4.45	1.06e-05	0.00208	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs1548701	ENSG00000202515.1	VTRNA1-3	-4.45	1.06e-05	0.00208	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs10073974	ENSG00000202515.1	VTRNA1-3	-4.45	1.06e-05	0.00208	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs3756342	ENSG00000202515.1	VTRNA1-3	-4.45	1.06e-05	0.00208	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs3733710	ENSG00000202515.1	VTRNA1-3	-4.45	1.06e-05	0.00208	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr5:140726158~140726246:+
HNSC	cis	rs2286503	0.533	rs1880239	ENSG00000221740.1	SNORD93	4.45	1.06e-05	0.00208	0.25	0.2	Fibrinogen;	chr7:22832065	chr7:22856613~22856686:+
HNSC	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-4.45	1.06e-05	0.00208	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
HNSC	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-4.45	1.06e-05	0.00208	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
HNSC	cis	rs9880211	0.613	rs67109185	ENSG00000273486.1	RP11-731C17.2	4.45	1.06e-05	0.00208	0.18	0.2	Height;Body mass index;	chr3:136108550	chr3:136837338~136839021:-
HNSC	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-4.45	1.06e-05	0.00208	-0.21	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
HNSC	cis	rs459482	0.504	rs469483	ENSG00000228318.3	AP001610.5	4.45	1.06e-05	0.00208	0.21	0.2	IgG glycosylation;	chr21:41446588	chr21:41441056~41445708:-
HNSC	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-4.45	1.06e-05	0.00208	-0.23	-0.2	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
HNSC	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-4.45	1.06e-05	0.00208	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
HNSC	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-4.45	1.06e-05	0.00208	-0.27	-0.2	Pain;	chr19:21521677	chr19:21554640~21569237:-
HNSC	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-4.45	1.06e-05	0.00208	-0.31	-0.2	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
HNSC	cis	rs9527	0.641	rs4919684	ENSG00000236937.2	PTGES3P4	4.45	1.06e-05	0.00208	0.27	0.2	Arsenic metabolism;	chr10:102827267	chr10:102845595~102845950:+
HNSC	cis	rs11098499	0.866	rs12510451	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119367988	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.774	rs73842616	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119369528	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.645	rs72676059	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119369673	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.569	rs55845118	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119369758	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs7677068	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119370549	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.866	rs9991221	ENSG00000249244.1	RP11-548H18.2	4.45	1.06e-05	0.00208	0.24	0.2	Corneal astigmatism;	chr4:119370952	chr4:119391831~119395335:-
HNSC	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	4.45	1.06e-05	0.00208	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	4.45	1.06e-05	0.00208	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	4.45	1.06e-05	0.00208	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	4.45	1.06e-05	0.00208	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	4.45	1.06e-05	0.00208	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
HNSC	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	4.45	1.06e-05	0.00208	0.2	0.2	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
HNSC	cis	rs4713118	0.628	rs9295740	ENSG00000219392.1	RP1-265C24.5	-4.45	1.06e-05	0.00208	-0.27	-0.2	Parkinson's disease;	chr6:27721723	chr6:28115628~28116551:+
HNSC	cis	rs8058578	1	rs7204278	ENSG00000279196.1	RP11-1072A3.3	4.45	1.06e-05	0.00208	0.24	0.2	Multiple myeloma;	chr16:30718953	chr16:30984630~30988270:-
HNSC	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-4.45	1.06e-05	0.00208	-0.26	-0.2	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
HNSC	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-4.45	1.06e-05	0.00208	-0.23	-0.2	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
HNSC	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	4.45	1.06e-05	0.00208	0.31	0.2	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
HNSC	cis	rs9840812	0.639	rs610860	ENSG00000273486.1	RP11-731C17.2	4.45	1.06e-05	0.00208	0.2	0.2	Fibrinogen levels;	chr3:136333974	chr3:136837338~136839021:-
HNSC	cis	rs11168936	1	rs11168936	ENSG00000258017.1	RP11-386G11.10	-4.45	1.06e-05	0.00208	-0.23	-0.2	Cancer (pleiotropy);	chr12:49251457	chr12:49127782~49147869:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-4.45	1.06e-05	0.00208	-0.25	-0.2	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-4.45	1.06e-05	0.00208	-0.25	-0.2	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
HNSC	cis	rs5758511	0.68	rs5758698	ENSG00000226450.2	CYP2D8P	4.45	1.06e-05	0.00208	0.2	0.2	Birth weight;	chr22:42288812	chr22:42149886~42155001:-
HNSC	cis	rs7829975	0.502	rs7820738	ENSG00000173295.6	FAM86B3P	-4.45	1.07e-05	0.00208	-0.23	-0.2	Mood instability;	chr8:8845097	chr8:8228595~8244865:+
HNSC	cis	rs6701713	0.959	rs1830763	ENSG00000274245.1	RP11-357P18.2	-4.45	1.07e-05	0.00208	-0.34	-0.2	Alzheimer's disease (late onset);	chr1:207627044	chr1:207372559~207373252:+
HNSC	cis	rs6701713	0.959	rs1408078	ENSG00000274245.1	RP11-357P18.2	-4.45	1.07e-05	0.00208	-0.34	-0.2	Alzheimer's disease (late onset);	chr1:207627210	chr1:207372559~207373252:+
HNSC	cis	rs7735319	0.899	rs13168108	ENSG00000251281.1	CTD-2066L21.2	4.45	1.07e-05	0.00208	0.24	0.2	Systolic blood pressure;	chr5:33119232	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs13169007	ENSG00000251281.1	CTD-2066L21.2	4.45	1.07e-05	0.00208	0.24	0.2	Systolic blood pressure;	chr5:33119553	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs13182741	ENSG00000251281.1	CTD-2066L21.2	4.45	1.07e-05	0.00208	0.24	0.2	Systolic blood pressure;	chr5:33134293	chr5:33011322~33017607:-
HNSC	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-4.45	1.07e-05	0.00208	-0.29	-0.2	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
HNSC	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-4.45	1.07e-05	0.00208	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
HNSC	cis	rs728616	0.614	rs35193855	ENSG00000225484.5	NUTM2B-AS1	-4.45	1.07e-05	0.00208	-0.38	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79663088~79826594:-
HNSC	cis	rs9300255	0.602	rs2695479	ENSG00000280120.1	RP11-546D6.3	4.45	1.07e-05	0.00209	0.19	0.2	Neutrophil percentage of white cells;	chr12:123204839	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.602	rs2695476	ENSG00000280120.1	RP11-546D6.3	4.45	1.07e-05	0.00209	0.19	0.2	Neutrophil percentage of white cells;	chr12:123209659	chr12:123152324~123153377:-
HNSC	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-4.45	1.07e-05	0.00209	-0.22	-0.2	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
HNSC	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-4.45	1.07e-05	0.00209	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-4.45	1.07e-05	0.00209	-0.18	-0.2	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
HNSC	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	4.45	1.07e-05	0.00209	0.22	0.2	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
HNSC	cis	rs73198271	0.565	rs575895	ENSG00000253893.2	FAM85B	4.45	1.07e-05	0.00209	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736737	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.565	rs575920	ENSG00000253893.2	FAM85B	4.45	1.07e-05	0.00209	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736744	chr8:8167819~8226614:-
HNSC	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	4.45	1.07e-05	0.00209	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
HNSC	cis	rs2243480	0.522	rs1638736	ENSG00000230295.1	RP11-458F8.2	-4.45	1.07e-05	0.00209	-0.33	-0.2	Diabetic kidney disease;	chr7:66627321	chr7:66880708~66882981:+
HNSC	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-4.45	1.07e-05	0.00209	-0.33	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
HNSC	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	4.45	1.07e-05	0.00209	0.18	0.2	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
HNSC	cis	rs7568498	0.517	rs11678856	ENSG00000227403.1	AC009299.3	4.45	1.07e-05	0.00209	0.3	0.2	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161244739~161249050:+
HNSC	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	4.45	1.07e-05	0.00209	0.23	0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
HNSC	cis	rs6500395	0.926	rs1039342	ENSG00000261267.1	RP11-44I10.3	-4.45	1.07e-05	0.00209	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48543587	chr16:48559661~48587403:+
HNSC	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-4.45	1.07e-05	0.00209	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
HNSC	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-4.45	1.07e-05	0.00209	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
HNSC	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-4.45	1.07e-05	0.00209	-0.22	-0.2	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
HNSC	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-4.45	1.07e-05	0.00209	-0.21	-0.2	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
HNSC	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-4.45	1.07e-05	0.00209	-0.17	-0.2	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
HNSC	cis	rs6831352	0.725	rs2602846	ENSG00000263923.1	RP11-571L19.7	-4.45	1.07e-05	0.00209	-0.22	-0.2	Alcohol dependence;	chr4:99104000	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.744	rs2602847	ENSG00000263923.1	RP11-571L19.7	-4.45	1.07e-05	0.00209	-0.22	-0.2	Alcohol dependence;	chr4:99104812	chr4:98928897~98994994:+
HNSC	cis	rs10791097	0.694	rs7942621	ENSG00000254842.5	RP11-890B15.2	-4.45	1.07e-05	0.00209	-0.17	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130881413	chr11:130844191~130865561:-
HNSC	cis	rs9650657	0.737	rs2116095	ENSG00000269918.1	AF131215.9	-4.45	1.07e-05	0.00209	-0.2	-0.2	Neuroticism;	chr8:10777787	chr8:11104691~11106704:-
HNSC	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	4.45	1.07e-05	0.00209	0.21	0.2	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-4.45	1.07e-05	0.00209	-0.25	-0.2	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
HNSC	cis	rs11722228	0.549	rs56146302	ENSG00000250413.1	RP11-448G15.1	-4.45	1.07e-05	0.0021	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10006482~10009725:+
HNSC	cis	rs11722228	0.549	rs55848383	ENSG00000250413.1	RP11-448G15.1	-4.45	1.07e-05	0.0021	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10006482~10009725:+
HNSC	cis	rs2280018	0.526	rs2966129	ENSG00000263335.1	AF001548.5	4.45	1.07e-05	0.0021	0.27	0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15726674~15732993:+
HNSC	cis	rs9863	0.862	rs6488912	ENSG00000269938.1	RP11-214K3.20	-4.45	1.07e-05	0.0021	-0.23	-0.2	White blood cell count;	chr12:123958205	chr12:123968023~123968579:-
HNSC	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-4.45	1.07e-05	0.0021	-0.17	-0.2	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
HNSC	cis	rs9921338	0.961	rs4390613	ENSG00000263080.1	RP11-485G7.5	-4.45	1.07e-05	0.0021	-0.22	-0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11341809~11345211:-
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000211974.3	IGHV2-70	4.45	1.07e-05	0.0021	0.19	0.2	Kawasaki disease;	chr14:106777528	chr14:106723574~106724093:-
HNSC	cis	rs739496	0.579	rs73422318	ENSG00000226469.1	ADAM1B	4.45	1.07e-05	0.0021	0.23	0.2	Platelet count;	chr12:111838169	chr12:111927018~111929017:+
HNSC	cis	rs889398	0.771	rs3790080	ENSG00000226232.7	RP11-419C5.2	-4.45	1.07e-05	0.0021	-0.18	-0.2	Body mass index;	chr16:69868236	chr16:69976388~69996188:-
HNSC	cis	rs6928977	0.896	rs2246943	ENSG00000217482.2	HMGB1P17	-4.45	1.07e-05	0.0021	-0.22	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135636086~135636713:-
HNSC	cis	rs11633886	0.51	rs12594473	ENSG00000273972.1	CTD-2306A12.1	4.45	1.07e-05	0.0021	0.24	0.2	Diisocyanate-induced asthma;	chr15:45750399	chr15:45702640~45703183:+
HNSC	cis	rs6964587	1	rs10234071	ENSG00000188693.7	CYP51A1-AS1	4.45	1.08e-05	0.0021	0.21	0.2	Breast cancer;	chr7:92015838	chr7:92134604~92180725:+
HNSC	cis	rs4834770	1	rs10034579	ENSG00000250412.1	KLHL2P1	4.45	1.08e-05	0.0021	0.23	0.2	Blood protein levels;	chr4:119322874	chr4:119334329~119378233:+
HNSC	cis	rs6973609	0.524	rs343709	ENSG00000271122.1	RP11-379H18.1	4.45	1.08e-05	0.0021	0.18	0.2	Obesity-related traits;	chr7:35595704	chr7:35695214~35699413:+
HNSC	cis	rs2333021	0.78	rs2806042	ENSG00000258376.2	RP4-647C14.2	4.45	1.08e-05	0.0021	0.24	0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72947939	chr14:73242651~73245979:-
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-4.45	1.08e-05	0.0021	-0.23	-0.2	Depression;	chr6:28201380	chr6:28170845~28172521:+
HNSC	cis	rs804280	0.509	rs13268030	ENSG00000255495.1	AC145124.2	4.45	1.08e-05	0.0021	0.22	0.2	Myopia (pathological);	chr8:11925564	chr8:12194467~12196280:+
HNSC	cis	rs11098499	0.955	rs11931312	ENSG00000250412.1	KLHL2P1	4.45	1.08e-05	0.0021	0.25	0.2	Corneal astigmatism;	chr4:119237868	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs1397608	ENSG00000250412.1	KLHL2P1	4.45	1.08e-05	0.0021	0.25	0.2	Corneal astigmatism;	chr4:119240589	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs7685268	ENSG00000250412.1	KLHL2P1	4.45	1.08e-05	0.0021	0.25	0.2	Corneal astigmatism;	chr4:119241033	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs7684942	ENSG00000250412.1	KLHL2P1	4.45	1.08e-05	0.0021	0.25	0.2	Corneal astigmatism;	chr4:119241046	chr4:119334329~119378233:+
HNSC	cis	rs2762353	0.779	rs1408273	ENSG00000272462.2	U91328.19	4.45	1.08e-05	0.0021	0.19	0.2	Blood metabolite levels;	chr6:25840718	chr6:25992662~26001775:+
HNSC	cis	rs7324557	0.717	rs9553071	ENSG00000205861.10	C1QTNF9B-AS1	-4.45	1.08e-05	0.0021	-0.28	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23807240	chr13:23888889~23897263:+
HNSC	cis	rs7735319	0.834	rs34976989	ENSG00000249102.1	CTD-2066L21.1	4.45	1.08e-05	0.0021	0.24	0.2	Systolic blood pressure;	chr5:33070636	chr5:33008994~33025724:+
HNSC	cis	rs11170631	0.504	rs12817180	ENSG00000270175.1	RP11-793H13.11	-4.45	1.08e-05	0.00211	-0.18	-0.2	Height;	chr12:53641664	chr12:53500162~53500936:-
HNSC	cis	rs1912702	0.632	rs12275436	ENSG00000255345.1	CTD-2337I7.1	4.45	1.08e-05	0.00211	0.24	0.2	Hair greying;	chr11:79481756	chr11:79092848~79098003:+
HNSC	cis	rs116095464	0.558	rs28635197	ENSG00000250848.1	CTD-2083E4.5	-4.45	1.08e-05	0.00211	-0.28	-0.2	Breast cancer;	chr5:278956	chr5:288833~290321:-
HNSC	cis	rs6490294	0.571	rs7965087	ENSG00000226469.1	ADAM1B	4.45	1.08e-05	0.00211	0.29	0.2	Mean platelet volume;	chr12:112110758	chr12:111927018~111929017:+
HNSC	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	4.45	1.08e-05	0.00211	0.38	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
HNSC	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-4.45	1.08e-05	0.00211	-0.17	-0.2	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
HNSC	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-4.45	1.08e-05	0.00211	-0.17	-0.2	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
HNSC	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-4.45	1.08e-05	0.00211	-0.26	-0.2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
HNSC	cis	rs9959145	1	rs17595746	ENSG00000267249.1	RP11-973H7.3	-4.45	1.08e-05	0.00211	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12707859	chr18:12670426~12671145:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000211974.3	IGHV2-70	-4.45	1.08e-05	0.00211	-0.18	-0.2	Kawasaki disease;	chr14:106767970	chr14:106723574~106724093:-
HNSC	cis	rs9393777	0.92	rs34071253	ENSG00000219392.1	RP1-265C24.5	-4.45	1.08e-05	0.00211	-0.4	-0.2	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28115628~28116551:+
HNSC	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	4.45	1.08e-05	0.00211	0.22	0.2	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
HNSC	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	4.45	1.08e-05	0.00211	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
HNSC	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-4.45	1.08e-05	0.00211	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
HNSC	cis	rs853679	0.607	rs35001169	ENSG00000204709.4	LINC01556	4.45	1.08e-05	0.00211	0.44	0.2	Depression;	chr6:28219854	chr6:28943877~28944537:+
HNSC	cis	rs4834770	0.792	rs7676969	ENSG00000249244.1	RP11-548H18.2	4.45	1.08e-05	0.00211	0.23	0.2	Blood protein levels;	chr4:119252569	chr4:119391831~119395335:-
HNSC	cis	rs4834770	0.685	rs4496567	ENSG00000249244.1	RP11-548H18.2	4.45	1.08e-05	0.00211	0.23	0.2	Blood protein levels;	chr4:119254470	chr4:119391831~119395335:-
HNSC	cis	rs739496	0.579	rs2879603	ENSG00000226469.1	ADAM1B	4.45	1.08e-05	0.00211	0.23	0.2	Platelet count;	chr12:111840221	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs3213628	ENSG00000226469.1	ADAM1B	4.45	1.08e-05	0.00211	0.23	0.2	Platelet count;	chr12:111842969	chr12:111927018~111929017:+
HNSC	cis	rs929354	0.742	rs3808316	ENSG00000224629.1	RP5-1142J19.2	-4.45	1.08e-05	0.00211	-0.2	-0.2	Body mass index;	chr7:157152093	chr7:157263022~157263229:-
HNSC	cis	rs61542988	0.532	rs12673996	ENSG00000221740.1	SNORD93	4.45	1.08e-05	0.00211	0.25	0.2	Fibrinogen levels;	chr7:22793781	chr7:22856613~22856686:+
HNSC	cis	rs1930961	0.558	rs5996951	ENSG00000272977.1	CTA-390C10.10	-4.45	1.08e-05	0.00211	-0.33	-0.2	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25476218~25479971:+
HNSC	cis	rs7824557	0.707	rs3808519	ENSG00000255310.2	AF131215.2	4.45	1.08e-05	0.00211	0.19	0.2	Retinal vascular caliber;	chr8:11285461	chr8:11107788~11109726:-
HNSC	cis	rs1316952	0.831	rs79810037	ENSG00000269938.1	RP11-214K3.20	-4.45	1.08e-05	0.00212	-0.41	-0.2	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123908296	chr12:123968023~123968579:-
HNSC	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-4.45	1.08e-05	0.00212	-0.34	-0.2	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-4.45	1.08e-05	0.00212	-0.34	-0.2	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-4.45	1.08e-05	0.00212	-0.34	-0.2	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
HNSC	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	4.45	1.08e-05	0.00212	0.18	0.2	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000211974.3	IGHV2-70	4.45	1.08e-05	0.00212	0.19	0.2	Kawasaki disease;	chr14:106716993	chr14:106723574~106724093:-
HNSC	cis	rs17428076	0.681	rs72881959	ENSG00000228389.1	AC068039.4	-4.45	1.09e-05	0.00212	-0.28	-0.2	Myopia;	chr2:171787327	chr2:171773482~171775844:+
HNSC	cis	rs9611565	0.921	rs2235846	ENSG00000235513.1	RP4-756G23.5	4.45	1.09e-05	0.00212	0.21	0.2	Vitiligo;	chr22:41345038	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.921	rs5751081	ENSG00000235513.1	RP4-756G23.5	4.45	1.09e-05	0.00212	0.21	0.2	Vitiligo;	chr22:41346784	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.921	rs2281332	ENSG00000235513.1	RP4-756G23.5	4.45	1.09e-05	0.00212	0.21	0.2	Vitiligo;	chr22:41350208	chr22:41209122~41217627:-
HNSC	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-4.45	1.09e-05	0.00212	-0.23	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
HNSC	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-4.45	1.09e-05	0.00212	-0.25	-0.2	Height;	chr3:52819385	chr3:53064283~53065091:-
HNSC	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-4.45	1.09e-05	0.00212	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
HNSC	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	4.45	1.09e-05	0.00212	0.29	0.2	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
HNSC	cis	rs911555	0.57	rs942862	ENSG00000269958.1	RP11-73M18.8	4.45	1.09e-05	0.00212	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103555787	chr14:103696353~103697163:+
HNSC	cis	rs1355223	0.583	rs2915178	ENSG00000271369.1	RP11-350D17.3	4.45	1.09e-05	0.00212	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34856504	chr11:34709600~34710161:+
HNSC	cis	rs516805	0.667	rs225074	ENSG00000279453.1	RP3-425C14.4	-4.45	1.09e-05	0.00212	-0.28	-0.2	Lymphocyte counts;	chr6:122265102	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.665	rs225077	ENSG00000279453.1	RP3-425C14.4	-4.45	1.09e-05	0.00212	-0.28	-0.2	Lymphocyte counts;	chr6:122269794	chr6:122436789~122439223:-
HNSC	cis	rs10872587	0.555	rs9497426	ENSG00000235652.6	RP11-545I5.3	-4.45	1.09e-05	0.00212	-0.24	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145913508	chr6:145799409~145886585:+
HNSC	cis	rs8077577	0.789	rs11078411	ENSG00000273018.4	CTD-2303H24.2	-4.45	1.09e-05	0.00212	-0.29	-0.2	Obesity-related traits;	chr17:18184780	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.945	rs11653988	ENSG00000273018.4	CTD-2303H24.2	-4.45	1.09e-05	0.00212	-0.29	-0.2	Obesity-related traits;	chr17:18185519	chr17:18511221~18551705:-
HNSC	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-4.45	1.09e-05	0.00212	-0.2	-0.2	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
HNSC	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-4.45	1.09e-05	0.00212	-0.17	-0.2	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
HNSC	cis	rs964611	0.882	rs11630744	ENSG00000259488.2	RP11-154J22.1	4.45	1.09e-05	0.00212	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48355310	chr15:48312353~48331856:-
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000219891.2	ZSCAN12P1	4.45	1.09e-05	0.00213	0.28	0.2	Parkinson's disease;	chr6:27997725	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000219891.2	ZSCAN12P1	4.45	1.09e-05	0.00213	0.28	0.2	Parkinson's disease;	chr6:27999813	chr6:28091154~28093664:+
HNSC	cis	rs7615952	0.599	rs67566088	ENSG00000241439.1	RP11-666A20.3	4.45	1.09e-05	0.00213	0.23	0.2	Blood pressure (smoking interaction);	chr3:126050130	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs12495947	ENSG00000241439.1	RP11-666A20.3	4.45	1.09e-05	0.00213	0.23	0.2	Blood pressure (smoking interaction);	chr3:126052855	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs6805074	ENSG00000241439.1	RP11-666A20.3	4.45	1.09e-05	0.00213	0.23	0.2	Blood pressure (smoking interaction);	chr3:126053431	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs4422257	ENSG00000241439.1	RP11-666A20.3	4.45	1.09e-05	0.00213	0.23	0.2	Blood pressure (smoking interaction);	chr3:126055520	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.641	rs66520539	ENSG00000241439.1	RP11-666A20.3	4.45	1.09e-05	0.00213	0.23	0.2	Blood pressure (smoking interaction);	chr3:126061531	chr3:125958556~125958817:+
HNSC	cis	rs10946940	0.864	rs13201411	ENSG00000219392.1	RP1-265C24.5	4.45	1.09e-05	0.00213	0.23	0.2	Systemic lupus erythematosus;	chr6:27530438	chr6:28115628~28116551:+
HNSC	cis	rs10946940	0.896	rs12208078	ENSG00000219392.1	RP1-265C24.5	4.45	1.09e-05	0.00213	0.23	0.2	Systemic lupus erythematosus;	chr6:27530802	chr6:28115628~28116551:+
HNSC	cis	rs10946940	0.965	rs10946935	ENSG00000219392.1	RP1-265C24.5	4.45	1.09e-05	0.00213	0.23	0.2	Systemic lupus erythematosus;	chr6:27533566	chr6:28115628~28116551:+
HNSC	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	4.45	1.09e-05	0.00213	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
HNSC	cis	rs7829975	0.714	rs4841040	ENSG00000233609.3	RP11-62H7.2	4.45	1.09e-05	0.00213	0.19	0.2	Mood instability;	chr8:8797017	chr8:8961200~8979025:+
HNSC	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-4.45	1.09e-05	0.00213	-0.27	-0.2	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
HNSC	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	4.45	1.09e-05	0.00213	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
HNSC	cis	rs12893668	0.703	rs34896432	ENSG00000269940.1	RP11-73M18.7	4.45	1.09e-05	0.00213	0.21	0.2	Reticulocyte count;	chr14:103561658	chr14:103694560~103695170:+
HNSC	cis	rs3806843	1	rs10223116	ENSG00000202515.1	VTRNA1-3	-4.45	1.09e-05	0.00213	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr5:140726158~140726246:+
HNSC	cis	rs12893668	0.667	rs8017628	ENSG00000269910.1	RP11-73M18.10	4.45	1.09e-05	0.00213	0.2	0.2	Reticulocyte count;	chr14:103581091	chr14:103694516~103695050:-
HNSC	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-4.45	1.09e-05	0.00213	-0.17	-0.2	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
HNSC	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-4.45	1.09e-05	0.00213	-0.21	-0.2	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
HNSC	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	4.45	1.09e-05	0.00213	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
HNSC	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-4.45	1.09e-05	0.00213	-0.23	-0.2	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
HNSC	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-4.45	1.09e-05	0.00213	-0.16	-0.2	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
HNSC	cis	rs6601327	0.578	rs4075359	ENSG00000254340.1	RP11-10A14.3	-4.45	1.09e-05	0.00213	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9630303	chr8:9141424~9145435:+
HNSC	cis	rs367615	0.68	rs253246	ENSG00000249476.1	CTD-2587M2.1	4.45	1.09e-05	0.00213	0.26	0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109648317	chr5:109237120~109326369:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000233609.3	RP11-62H7.2	4.45	1.1e-05	0.00213	0.19	0.2	Mood instability;	chr8:8279561	chr8:8961200~8979025:+
HNSC	cis	rs1555322	0.932	rs6060321	ENSG00000126005.14	MMP24-AS1	-4.45	1.1e-05	0.00213	-0.36	-0.2	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35216462~35278131:-
HNSC	cis	rs13204927	1	rs13204927	ENSG00000203799.9	CCDC162P	4.45	1.1e-05	0.00214	0.23	0.2	Mean corpuscular hemoglobin;	chr6:109281587	chr6:109285485~109355063:+
HNSC	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	4.45	1.1e-05	0.00214	0.2	0.2	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
HNSC	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	4.45	1.1e-05	0.00214	0.18	0.2	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	4.45	1.1e-05	0.00214	0.18	0.2	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	4.45	1.1e-05	0.00214	0.18	0.2	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	4.45	1.1e-05	0.00214	0.18	0.2	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	4.45	1.1e-05	0.00214	0.18	0.2	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
HNSC	cis	rs4908769	0.624	rs894875	ENSG00000232912.4	RP5-1115A15.1	-4.45	1.1e-05	0.00214	-0.23	-0.2	Allergy;	chr1:8372076	chr1:8424645~8434838:+
HNSC	cis	rs11098499	0.955	rs6815725	ENSG00000250412.1	KLHL2P1	4.45	1.1e-05	0.00214	0.25	0.2	Corneal astigmatism;	chr4:119237255	chr4:119334329~119378233:+
HNSC	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-4.45	1.1e-05	0.00214	-0.16	-0.2	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
HNSC	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	4.45	1.1e-05	0.00214	0.25	0.2	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
HNSC	cis	rs9880211	0.948	rs13326151	ENSG00000273486.1	RP11-731C17.2	4.45	1.1e-05	0.00214	0.19	0.2	Height;Body mass index;	chr3:136542902	chr3:136837338~136839021:-
HNSC	cis	rs8068318	0.883	rs11079429	ENSG00000267280.4	TBX2-AS1	4.45	1.1e-05	0.00214	0.21	0.2	Creatinine levels;	chr17:61395042	chr17:61393456~61411555:-
HNSC	cis	rs9929218	0.581	rs7203337	ENSG00000260459.2	FTLP14	4.45	1.1e-05	0.00214	0.26	0.2	Colorectal cancer;	chr16:68740897	chr16:68822587~68823070:+
HNSC	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-4.45	1.1e-05	0.00214	-0.25	-0.2	Height;	chr20:49262572	chr20:49280319~49280409:+
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-4.44	1.1e-05	0.00214	-0.18	-0.2	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
HNSC	cis	rs62229266	0.626	rs2835268	ENSG00000230212.5	AP000688.14	-4.44	1.1e-05	0.00214	-0.22	-0.2	Mitral valve prolapse;	chr21:36076838	chr21:36069642~36126640:-
HNSC	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-4.44	1.1e-05	0.00214	-0.2	-0.2	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
HNSC	cis	rs13256369	0.901	rs4841015	ENSG00000173295.6	FAM86B3P	4.44	1.1e-05	0.00214	0.26	0.2	Obesity-related traits;	chr8:8709630	chr8:8228595~8244865:+
HNSC	cis	rs6496044	0.568	rs3743321	ENSG00000259295.5	CSPG4P12	4.44	1.1e-05	0.00214	0.23	0.2	Interstitial lung disease;	chr15:85521737	chr15:85191438~85213905:+
HNSC	cis	rs6964587	0.773	rs17757926	ENSG00000188693.7	CYP51A1-AS1	-4.44	1.1e-05	0.00214	-0.22	-0.2	Breast cancer;	chr7:92358388	chr7:92134604~92180725:+
HNSC	cis	rs4834770	1	rs4834771	ENSG00000250412.1	KLHL2P1	4.44	1.1e-05	0.00214	0.23	0.2	Blood protein levels;	chr4:119321617	chr4:119334329~119378233:+
HNSC	cis	rs4834770	1	rs1397613	ENSG00000250412.1	KLHL2P1	4.44	1.1e-05	0.00214	0.23	0.2	Blood protein levels;	chr4:119321774	chr4:119334329~119378233:+
HNSC	cis	rs10462794	0.853	rs4702793	ENSG00000260763.1	RP11-445O3.3	-4.44	1.1e-05	0.00214	-0.27	-0.2	DNA methylation (variation);	chr5:4507262	chr5:4436850~4440259:-
HNSC	cis	rs10462794	0.853	rs4702795	ENSG00000260763.1	RP11-445O3.3	-4.44	1.1e-05	0.00214	-0.27	-0.2	DNA methylation (variation);	chr5:4507889	chr5:4436850~4440259:-
HNSC	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	4.44	1.1e-05	0.00214	0.21	0.2	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
HNSC	cis	rs3096299	0.933	rs2965824	ENSG00000261574.1	RP1-168P16.2	4.44	1.1e-05	0.00215	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89392375~89412564:-
HNSC	cis	rs71636778	0.509	rs35617712	ENSG00000260063.1	RP5-968P14.2	-4.44	1.1e-05	0.00215	-0.38	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724732	chr1:26692132~26694131:-
HNSC	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.44	1.1e-05	0.00215	-0.21	-0.2	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
HNSC	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	4.44	1.1e-05	0.00215	0.27	0.2	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
HNSC	cis	rs427691	0.625	rs845739	ENSG00000271849.1	CTC-332L22.1	-4.44	1.1e-05	0.00215	-0.32	-0.2	Autism spectrum disorder or schizophrenia;	chr5:109682839	chr5:109687802~109688329:-
HNSC	cis	rs73198271	0.71	rs7837843	ENSG00000233609.3	RP11-62H7.2	-4.44	1.1e-05	0.00215	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.64	rs7838012	ENSG00000233609.3	RP11-62H7.2	-4.44	1.1e-05	0.00215	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8961200~8979025:+
HNSC	cis	rs757110	0.933	rs7124355	ENSG00000260196.1	RP1-239B22.5	-4.44	1.1e-05	0.00215	-0.24	-0.2	Type 2 diabetes;	chr11:17391413	chr11:17380649~17383531:+
HNSC	cis	rs17428076	0.794	rs62183763	ENSG00000228389.1	AC068039.4	-4.44	1.1e-05	0.00215	-0.27	-0.2	Myopia;	chr2:171973172	chr2:171773482~171775844:+
HNSC	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-4.44	1.1e-05	0.00215	-0.25	-0.2	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
HNSC	cis	rs8012947	0.565	rs7151036	ENSG00000279636.2	LINC00216	4.44	1.11e-05	0.00215	0.23	0.2	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58288033~58289158:+
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000219891.2	ZSCAN12P1	4.44	1.11e-05	0.00215	0.28	0.2	Parkinson's disease;	chr6:28009959	chr6:28091154~28093664:+
HNSC	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	4.44	1.11e-05	0.00215	0.23	0.2	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
HNSC	cis	rs7121616	0.576	rs7949127	ENSG00000200879.1	SNORD14E	4.44	1.11e-05	0.00215	0.28	0.2	Breast cancer;	chr11:123057408	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.576	rs7949220	ENSG00000200879.1	SNORD14E	4.44	1.11e-05	0.00215	0.28	0.2	Breast cancer;	chr11:123057418	chr11:123058077~123058161:-
HNSC	cis	rs889014	0.5	rs11747139	ENSG00000253768.1	CTB-33O18.1	-4.44	1.11e-05	0.00215	-0.24	-0.2	Height;	chr5:173567741	chr5:173562478~173573199:+
HNSC	cis	rs3748022	1	rs3748022	ENSG00000261000.1	RP11-534L20.5	-4.44	1.11e-05	0.00215	-0.23	-0.2	Lymphocyte counts;	chr1:206496132	chr1:206503948~206504456:+
HNSC	cis	rs804280	0.542	rs34117651	ENSG00000255495.1	AC145124.2	4.44	1.11e-05	0.00216	0.23	0.2	Myopia (pathological);	chr8:11934108	chr8:12194467~12196280:+
HNSC	cis	rs11098499	0.955	rs1511019	ENSG00000250412.1	KLHL2P1	4.44	1.11e-05	0.00216	0.26	0.2	Corneal astigmatism;	chr4:119244852	chr4:119334329~119378233:+
HNSC	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-4.44	1.11e-05	0.00216	-0.17	-0.2	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
HNSC	cis	rs1008375	1	rs2315556	ENSG00000249502.1	AC006160.5	-4.44	1.11e-05	0.00216	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17669238	chr4:17587467~17614571:-
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-4.44	1.11e-05	0.00216	-0.18	-0.2	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
HNSC	cis	rs2548724	0.617	rs2167585	ENSG00000250682.4	LINC00491	4.44	1.11e-05	0.00216	0.26	0.2	Type 2 diabetes;	chr5:102378598	chr5:102609156~102671559:-
HNSC	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	4.44	1.11e-05	0.00216	0.23	0.2	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
HNSC	cis	rs12935418	0.583	rs2549861	ENSG00000278985.1	RP11-303E16.9	-4.44	1.11e-05	0.00216	-0.19	-0.2	Mean corpuscular volume;	chr16:80994699	chr16:80982319~80984094:-
HNSC	cis	rs11157436	0.602	rs928954	ENSG00000211812.1	TRAV26-2	-4.44	1.11e-05	0.00216	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22202583~22203368:+
HNSC	cis	rs6601327	0.632	rs6980595	ENSG00000254340.1	RP11-10A14.3	-4.44	1.11e-05	0.00216	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9793652	chr8:9141424~9145435:+
HNSC	cis	rs6831352	0.918	rs2851253	ENSG00000263923.1	RP11-571L19.7	4.44	1.11e-05	0.00216	0.22	0.2	Alcohol dependence;	chr4:99122354	chr4:98928897~98994994:+
HNSC	cis	rs11089937	0.616	rs5750675	ENSG00000211638.2	IGLV8-61	-4.44	1.11e-05	0.00216	-0.18	-0.2	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22098700~22099212:+
HNSC	cis	rs3015497	0.505	rs3920549	ENSG00000269906.1	RP11-248J18.2	4.44	1.11e-05	0.00216	0.29	0.2	Mean platelet volume;	chr14:50516471	chr14:50662511~50663178:-
HNSC	cis	rs13256369	0.755	rs12680167	ENSG00000173295.6	FAM86B3P	4.44	1.11e-05	0.00216	0.26	0.2	Obesity-related traits;	chr8:8704957	chr8:8228595~8244865:+
HNSC	cis	rs78579285	0.545	rs79311053	ENSG00000278341.1	RP5-1142A6.10	-4.44	1.11e-05	0.00216	-0.36	-0.2	Joint mobility (Beighton score);	chr16:88718798	chr16:88708956~88710437:-
HNSC	cis	rs78579285	0.545	rs113385327	ENSG00000278341.1	RP5-1142A6.10	-4.44	1.11e-05	0.00216	-0.36	-0.2	Joint mobility (Beighton score);	chr16:88718834	chr16:88708956~88710437:-
HNSC	cis	rs1799949	0.965	rs12947782	ENSG00000236383.6	LINC00854	-4.44	1.11e-05	0.00216	-0.19	-0.2	Menopause (age at onset);	chr17:43127865	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs33945274	ENSG00000236383.6	LINC00854	-4.44	1.11e-05	0.00216	-0.19	-0.2	Menopause (age at onset);	chr17:43128056	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs33925201	ENSG00000236383.6	LINC00854	-4.44	1.11e-05	0.00216	-0.19	-0.2	Menopause (age at onset);	chr17:43128665	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11653069	ENSG00000236383.6	LINC00854	-4.44	1.11e-05	0.00216	-0.19	-0.2	Menopause (age at onset);	chr17:43131360	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs33988650	ENSG00000236383.6	LINC00854	-4.44	1.11e-05	0.00216	-0.19	-0.2	Menopause (age at onset);	chr17:43135863	chr17:43216941~43305976:-
HNSC	cis	rs8180040	0.726	rs7610636	ENSG00000276925.1	RP11-708J19.3	4.44	1.11e-05	0.00216	0.19	0.2	Colorectal cancer;	chr3:47022946	chr3:47469777~47469987:+
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000254153.1	CTA-398F10.2	-4.44	1.11e-05	0.00216	-0.24	-0.2	Neuroticism;	chr8:8504313	chr8:8456909~8461337:-
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	4.44	1.11e-05	0.00217	0.34	0.2	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-4.44	1.11e-05	0.00217	-0.18	-0.2	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
HNSC	cis	rs2439831	0.85	rs12441861	ENSG00000201136.1	RNU6-353P	-4.44	1.11e-05	0.00217	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43768685	chr15:43702363~43702470:+
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000233609.3	RP11-62H7.2	4.44	1.11e-05	0.00217	0.19	0.2	Mood instability;	chr8:8465578	chr8:8961200~8979025:+
HNSC	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.44	1.11e-05	0.00217	0.19	0.2	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
HNSC	cis	rs9921338	0.887	rs13330151	ENSG00000263080.1	RP11-485G7.5	4.44	1.11e-05	0.00217	0.23	0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11341809~11345211:-
HNSC	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	4.44	1.11e-05	0.00217	0.27	0.2	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
HNSC	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-4.44	1.11e-05	0.00217	-0.25	-0.2	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
HNSC	cis	rs9402743	0.634	rs9494306	ENSG00000234084.1	RP3-388E23.2	-4.44	1.11e-05	0.00217	-0.21	-0.2	Systemic lupus erythematosus;	chr6:135622823	chr6:135301568~135307158:+
HNSC	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	4.44	1.11e-05	0.00217	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
HNSC	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-4.44	1.11e-05	0.00217	-0.19	-0.2	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
HNSC	cis	rs7980687	0.506	rs1611973	ENSG00000280120.1	RP11-546D6.3	4.44	1.12e-05	0.00217	0.17	0.2	Head circumference (infant);Educational attainment;Height;	chr12:123138184	chr12:123152324~123153377:-
HNSC	cis	rs12468226	1	rs3731696	ENSG00000226261.1	AC064836.3	4.44	1.12e-05	0.00217	0.32	0.2	Urate levels;	chr2:202567081	chr2:202336024~202336727:-
HNSC	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	4.44	1.12e-05	0.00217	0.23	0.2	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
HNSC	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-4.44	1.12e-05	0.00217	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
HNSC	cis	rs7824557	0.872	rs6601577	ENSG00000255310.2	AF131215.2	4.44	1.12e-05	0.00217	0.19	0.2	Retinal vascular caliber;	chr8:11245173	chr8:11107788~11109726:-
HNSC	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-4.44	1.12e-05	0.00217	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
HNSC	cis	rs11247915	0.6	rs3795686	ENSG00000236782.4	RP11-96L14.7	-4.44	1.12e-05	0.00217	-0.23	-0.2	Obesity-related traits;	chr1:26255600	chr1:26169947~26171821:-
HNSC	cis	rs57339844	1	rs57339844	ENSG00000273080.1	RP11-301O19.1	-4.44	1.12e-05	0.00217	-0.21	-0.2	Mean platelet volume;	chr2:85891155	chr2:86195590~86196049:+
HNSC	cis	rs3805389	0.924	rs10029142	ENSG00000273257.1	RP11-177J6.1	-4.44	1.12e-05	0.00217	-0.27	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55612967	chr4:55387949~55388271:+
HNSC	cis	rs11846409	0.86	rs74091720	ENSG00000254174.1	IGHV1-12	4.44	1.12e-05	0.00217	0.16	0.2	Rheumatic heart disease;	chr14:106638192	chr14:106122420~106122709:-
HNSC	cis	rs7171171	0.667	rs883625	ENSG00000259747.1	RP11-275I4.2	-4.44	1.12e-05	0.00217	-0.25	-0.2	Type 1 diabetes;	chr15:38625831	chr15:38671847~38689191:+
HNSC	cis	rs2337406	1	rs74090714	ENSG00000254174.1	IGHV1-12	4.44	1.12e-05	0.00217	0.17	0.2	Alzheimer's disease (late onset);	chr14:106691225	chr14:106122420~106122709:-
HNSC	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	4.44	1.12e-05	0.00217	0.23	0.2	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
HNSC	cis	rs1799949	1	rs16941	ENSG00000236383.6	LINC00854	-4.44	1.12e-05	0.00217	-0.19	-0.2	Menopause (age at onset);	chr17:43092418	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs67060599	ENSG00000236383.6	LINC00854	-4.44	1.12e-05	0.00217	-0.19	-0.2	Menopause (age at onset);	chr17:43103085	chr17:43216941~43305976:-
HNSC	cis	rs1008375	1	rs62295634	ENSG00000249502.1	AC006160.5	-4.44	1.12e-05	0.00217	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683723	chr4:17587467~17614571:-
HNSC	cis	rs4834770	1	rs6857641	ENSG00000250412.1	KLHL2P1	4.44	1.12e-05	0.00218	0.23	0.2	Blood protein levels;	chr4:119322356	chr4:119334329~119378233:+
HNSC	cis	rs6600671	1	rs10794671	ENSG00000270231.3	NBPF8P	4.44	1.12e-05	0.00218	0.17	0.2	Hip geometry;	chr1:121426382	chr1:120436353~120467739:+
HNSC	cis	rs6600671	1	rs1856572	ENSG00000270231.3	NBPF8P	4.44	1.12e-05	0.00218	0.17	0.2	Hip geometry;	chr1:121427719	chr1:120436353~120467739:+
HNSC	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	4.44	1.12e-05	0.00218	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	4.44	1.12e-05	0.00218	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
HNSC	cis	rs9813712	0.595	rs1901787	ENSG00000249846.5	RP11-77P16.4	4.44	1.12e-05	0.00218	0.22	0.2	Response to amphetamines;	chr3:130288678	chr3:130112550~130120579:+
HNSC	cis	rs1865760	0.623	rs12216125	ENSG00000272810.1	U91328.22	-4.44	1.12e-05	0.00218	-0.19	-0.2	Height;	chr6:25997230	chr6:26013241~26013757:+
HNSC	cis	rs8077577	0.895	rs62073607	ENSG00000273018.4	CTD-2303H24.2	-4.44	1.12e-05	0.00218	-0.3	-0.2	Obesity-related traits;	chr17:18168024	chr17:18511221~18551705:-
HNSC	cis	rs2055729	0.645	rs12543685	ENSG00000254340.1	RP11-10A14.3	4.44	1.12e-05	0.00218	0.29	0.2	Multiple myeloma (hyperdiploidy);	chr8:9889546	chr8:9141424~9145435:+
HNSC	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	4.44	1.12e-05	0.00218	0.27	0.2	Pain;	chr19:21577269	chr19:21554640~21569237:-
HNSC	cis	rs7246760	1	rs28802413	ENSG00000267289.1	CTD-2623N2.11	4.44	1.12e-05	0.00218	0.33	0.2	Pursuit maintenance gain;	chr19:9790941	chr19:9834079~9835013:-
HNSC	cis	rs7246760	1	rs7246760	ENSG00000267289.1	CTD-2623N2.11	4.44	1.12e-05	0.00218	0.33	0.2	Pursuit maintenance gain;	chr19:9807553	chr19:9834079~9835013:-
HNSC	cis	rs7246760	1	rs112124298	ENSG00000267289.1	CTD-2623N2.11	4.44	1.12e-05	0.00218	0.33	0.2	Pursuit maintenance gain;	chr19:9812478	chr19:9834079~9835013:-
HNSC	cis	rs4523957	0.855	rs1231209	ENSG00000262333.1	HNRNPA1P16	4.44	1.12e-05	0.00218	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2221678	chr17:2306761~2307715:+
HNSC	cis	rs9287719	0.967	rs6735074	ENSG00000243819.4	RN7SL832P	-4.44	1.12e-05	0.00218	-0.19	-0.2	Prostate cancer;	chr2:10594640	chr2:10690344~10692099:+
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	4.44	1.12e-05	0.00218	0.23	0.2	Depression;	chr6:28200948	chr6:28170845~28172521:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-4.44	1.12e-05	0.00218	-0.18	-0.2	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
HNSC	cis	rs728616	0.867	rs17886286	ENSG00000225484.5	NUTM2B-AS1	-4.44	1.12e-05	0.00218	-0.48	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:79663088~79826594:-
HNSC	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	4.44	1.12e-05	0.00218	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
HNSC	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
HNSC	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00218	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
HNSC	cis	rs7121616	0.531	rs1461497	ENSG00000200879.1	SNORD14E	4.44	1.12e-05	0.00218	0.28	0.2	Breast cancer;	chr11:123060505	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.531	rs41361350	ENSG00000200879.1	SNORD14E	4.44	1.12e-05	0.00218	0.28	0.2	Breast cancer;	chr11:123060917	chr11:123058077~123058161:-
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000219891.2	ZSCAN12P1	4.44	1.12e-05	0.00218	0.3	0.2	Depression;	chr6:28231986	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000219891.2	ZSCAN12P1	4.44	1.12e-05	0.00218	0.3	0.2	Depression;	chr6:28232159	chr6:28091154~28093664:+
HNSC	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	4.44	1.12e-05	0.00218	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
HNSC	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-4.44	1.12e-05	0.00218	-0.25	-0.2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
HNSC	cis	rs4787951	0.583	rs3024577	ENSG00000259940.2	CTD-3203P2.1	-4.44	1.12e-05	0.00218	-0.21	-0.2	Eosinophil percentage of white cells;	chr16:27346882	chr16:27213308~27214993:-
HNSC	cis	rs4925386	0.84	rs6143024	ENSG00000275437.1	RP5-908M14.10	4.44	1.12e-05	0.00219	0.22	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62402236~62405935:-
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000254340.1	RP11-10A14.3	4.44	1.12e-05	0.00219	0.24	0.2	Mood instability;	chr8:8462594	chr8:9141424~9145435:+
HNSC	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.44	1.12e-05	0.00219	0.22	0.2	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	4.44	1.12e-05	0.00219	0.2	0.2	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
HNSC	cis	rs12935418	0.616	rs2549863	ENSG00000278985.1	RP11-303E16.9	-4.44	1.13e-05	0.00219	-0.19	-0.2	Mean corpuscular volume;	chr16:80995762	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.616	rs1469123	ENSG00000278985.1	RP11-303E16.9	-4.44	1.13e-05	0.00219	-0.19	-0.2	Mean corpuscular volume;	chr16:80995944	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs1469124	ENSG00000278985.1	RP11-303E16.9	-4.44	1.13e-05	0.00219	-0.19	-0.2	Mean corpuscular volume;	chr16:80996049	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.583	rs1469125	ENSG00000278985.1	RP11-303E16.9	-4.44	1.13e-05	0.00219	-0.19	-0.2	Mean corpuscular volume;	chr16:80996163	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.523	rs1469126	ENSG00000278985.1	RP11-303E16.9	-4.44	1.13e-05	0.00219	-0.19	-0.2	Mean corpuscular volume;	chr16:80996284	chr16:80982319~80984094:-
HNSC	cis	rs3736485	0.738	rs930920	ENSG00000259438.1	CTD-2650P22.1	4.44	1.13e-05	0.00219	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51457529	chr15:52010999~52019095:-
HNSC	cis	rs9311676	0.656	rs11917591	ENSG00000273493.1	RP11-80H18.4	-4.44	1.13e-05	0.00219	-0.22	-0.2	Systemic lupus erythematosus;	chr3:58382722	chr3:58329965~58330118:+
HNSC	cis	rs2833693	0.519	rs2833699	ENSG00000261610.1	AP000265.1	4.44	1.13e-05	0.00219	0.22	0.2	Temperament;	chr21:32184240	chr21:32259804~32261585:-
HNSC	cis	rs6604026	1	rs6604026	ENSG00000223787.2	RP4-593M8.1	4.44	1.13e-05	0.00219	0.27	0.2	Multiple sclerosis;	chr1:92838046	chr1:92580476~92580821:-
HNSC	cis	rs3863381	0.656	rs76167100	ENSG00000277715.1	RP11-651L5.3	4.44	1.13e-05	0.00219	0.34	0.2	Night sleep phenotypes;	chr12:105722537	chr12:106250759~106252786:+
HNSC	cis	rs7824557	0.51	rs1435274	ENSG00000269918.1	AF131215.9	-4.44	1.13e-05	0.00219	-0.2	-0.2	Retinal vascular caliber;	chr8:11378401	chr8:11104691~11106704:-
HNSC	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-4.44	1.13e-05	0.00219	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
HNSC	cis	rs9300255	0.506	rs61388686	ENSG00000280120.1	RP11-546D6.3	4.44	1.13e-05	0.00219	0.17	0.2	Neutrophil percentage of white cells;	chr12:123326326	chr12:123152324~123153377:-
HNSC	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	4.44	1.13e-05	0.00219	0.22	0.2	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	4.44	1.13e-05	0.00219	0.22	0.2	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
HNSC	cis	rs6500395	1	rs1558816	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48670957	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1558815	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48670958	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12919520	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48671849	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12934126	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48672040	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1477134	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48673062	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs4785535	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48673748	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs2111242	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48674389	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7206647	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48675309	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7195684	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48676839	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12599028	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48679171	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7185899	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48680190	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12597928	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48680455	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11076578	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48680609	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs3919552	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48682417	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs961951	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48682809	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12599744	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48682818	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1420704	ENSG00000261267.1	RP11-44I10.3	4.44	1.13e-05	0.00219	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48682991	chr16:48559661~48587403:+
HNSC	cis	rs9880211	0.8	rs9865995	ENSG00000273486.1	RP11-731C17.2	4.44	1.13e-05	0.00219	0.19	0.2	Height;Body mass index;	chr3:136794508	chr3:136837338~136839021:-
HNSC	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	4.44	1.13e-05	0.00219	0.23	0.2	Shingles;	chr7:38346957	chr7:38358512~38359162:-
HNSC	cis	rs12893668	0.703	rs2403197	ENSG00000269910.1	RP11-73M18.10	4.44	1.13e-05	0.00219	0.2	0.2	Reticulocyte count;	chr14:103587427	chr14:103694516~103695050:-
HNSC	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	4.44	1.13e-05	0.00219	0.19	0.2	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
HNSC	cis	rs1008375	0.966	rs12509962	ENSG00000249502.1	AC006160.5	-4.44	1.13e-05	0.00219	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678669	chr4:17587467~17614571:-
HNSC	cis	rs4356203	0.905	rs10832733	ENSG00000260196.1	RP1-239B22.5	-4.44	1.13e-05	0.00219	-0.21	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17380649~17383531:+
HNSC	cis	rs964611	0.882	rs10163162	ENSG00000259488.2	RP11-154J22.1	-4.44	1.13e-05	0.00219	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48266334	chr15:48312353~48331856:-
HNSC	cis	rs853679	0.607	rs33932084	ENSG00000219392.1	RP1-265C24.5	-4.44	1.13e-05	0.0022	-0.4	-0.2	Depression;	chr6:28301047	chr6:28115628~28116551:+
HNSC	cis	rs17253792	0.822	rs77315200	ENSG00000186615.9	KTN1-AS1	-4.44	1.13e-05	0.0022	-0.38	-0.2	Putamen volume;	chr14:55605925	chr14:55499278~55580110:-
HNSC	cis	rs9467773	0.587	rs12214031	ENSG00000241549.7	GUSBP2	4.44	1.13e-05	0.0022	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26376400	chr6:26871484~26956554:-
HNSC	cis	rs6710503	1	rs11892043	ENSG00000271936.1	RP11-443B20.1	-4.44	1.13e-05	0.0022	-0.22	-0.2	Lung cancer in ever smokers;Breast cancer;	chr2:24767213	chr2:24825610~24826717:+
HNSC	cis	rs3736485	0.966	rs10220909	ENSG00000259438.1	CTD-2650P22.1	4.44	1.13e-05	0.0022	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51470215	chr15:52010999~52019095:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-4.44	1.13e-05	0.0022	-0.27	-0.2	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
HNSC	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	4.44	1.13e-05	0.0022	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-4.44	1.13e-05	0.0022	-0.15	-0.2	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
HNSC	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	4.44	1.13e-05	0.0022	0.23	0.2	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000224373.3	IGHV4-59	-4.44	1.13e-05	0.0022	-0.13	-0.2	Kawasaki disease;	chr14:106769752	chr14:106627249~106627825:-
HNSC	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	4.44	1.13e-05	0.0022	0.33	0.2	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.691	rs10028773	ENSG00000249244.1	RP11-548H18.2	-4.44	1.13e-05	0.0022	-0.24	-0.2	Corneal astigmatism;	chr4:119344104	chr4:119391831~119395335:-
HNSC	cis	rs6668534	1	rs6668534	ENSG00000225217.1	HSPA7	-4.44	1.13e-05	0.0022	-0.26	-0.2	Blood protein levels;	chr1:161702205	chr1:161606291~161608217:+
HNSC	cis	rs11846409	0.521	rs10143547	ENSG00000254174.1	IGHV1-12	4.44	1.13e-05	0.0022	0.16	0.2	Rheumatic heart disease;	chr14:106644638	chr14:106122420~106122709:-
HNSC	cis	rs4862750	0.914	rs1863405	ENSG00000250971.1	RP11-696F12.1	-4.44	1.13e-05	0.0022	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:187060099~187060930:+
HNSC	cis	rs795484	1	rs795484	ENSG00000275409.1	RP11-131L12.4	-4.44	1.13e-05	0.0022	-0.23	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118152057	chr12:118430147~118430699:+
HNSC	cis	rs7973683	0.541	rs57078519	ENSG00000269938.1	RP11-214K3.20	-4.44	1.13e-05	0.0022	-0.23	-0.2	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904237	chr12:123968023~123968579:-
HNSC	cis	rs1198872	0.892	rs10427170	ENSG00000272275.1	RP11-791G15.2	4.44	1.13e-05	0.0022	0.23	0.2	Cardiac Troponin-T levels;	chr2:10762044	chr2:10767875~10770058:-
HNSC	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	4.44	1.14e-05	0.0022	0.23	0.2	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
HNSC	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-4.44	1.14e-05	0.0022	-0.26	-0.2	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
HNSC	cis	rs9813712	0.595	rs6439226	ENSG00000249846.5	RP11-77P16.4	4.44	1.14e-05	0.0022	0.22	0.2	Response to amphetamines;	chr3:130283686	chr3:130112550~130120579:+
HNSC	cis	rs4372836	0.964	rs56240884	ENSG00000226833.4	AC097724.3	-4.44	1.14e-05	0.0022	-0.26	-0.2	Body mass index;	chr2:28717288	chr2:28708953~28736205:-
HNSC	cis	rs9990333	0.562	rs56224853	ENSG00000231464.1	AC024937.4	4.44	1.14e-05	0.0022	0.22	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195996738~195998233:+
HNSC	cis	rs9990333	0.544	rs73210008	ENSG00000231464.1	AC024937.4	4.44	1.14e-05	0.0022	0.22	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195996738~195998233:+
HNSC	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-4.44	1.14e-05	0.0022	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
HNSC	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	4.44	1.14e-05	0.00221	0.22	0.2	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
HNSC	cis	rs6601327	0.641	rs12155819	ENSG00000254340.1	RP11-10A14.3	-4.44	1.14e-05	0.00221	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:9141424~9145435:+
HNSC	cis	rs6601327	0.7	rs12114661	ENSG00000254340.1	RP11-10A14.3	-4.44	1.14e-05	0.00221	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:9141424~9145435:+
HNSC	cis	rs6601327	0.641	rs4129360	ENSG00000254340.1	RP11-10A14.3	-4.44	1.14e-05	0.00221	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:9141424~9145435:+
HNSC	cis	rs7615952	0.641	rs12488180	ENSG00000248787.1	RP11-666A20.4	-4.44	1.14e-05	0.00221	-0.27	-0.2	Blood pressure (smoking interaction);	chr3:126063393	chr3:125908005~125910272:-
HNSC	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	4.44	1.14e-05	0.00221	0.26	0.2	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
HNSC	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	4.44	1.14e-05	0.00221	0.26	0.2	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
HNSC	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	4.44	1.14e-05	0.00221	0.19	0.2	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
HNSC	cis	rs1185460	0.967	rs4454730	ENSG00000272186.1	RP11-110I1.13	-4.44	1.14e-05	0.00221	-0.22	-0.2	Coronary artery disease;	chr11:119066733	chr11:119067374~119067698:-
HNSC	cis	rs1185460	0.967	rs4545564	ENSG00000272186.1	RP11-110I1.13	-4.44	1.14e-05	0.00221	-0.22	-0.2	Coronary artery disease;	chr11:119066807	chr11:119067374~119067698:-
HNSC	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-4.44	1.14e-05	0.00221	-0.29	-0.2	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
HNSC	cis	rs6601450	0.54	rs7824225	ENSG00000269918.1	AF131215.9	-4.44	1.14e-05	0.00221	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10415736	chr8:11104691~11106704:-
HNSC	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	4.44	1.14e-05	0.00221	0.21	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
HNSC	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-4.44	1.14e-05	0.00221	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
HNSC	cis	rs10773046	0.74	rs1317312	ENSG00000269938.1	RP11-214K3.20	-4.44	1.14e-05	0.00221	-0.22	-0.2	Osteoarthritis (hip);	chr12:123879584	chr12:123968023~123968579:-
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000254340.1	RP11-10A14.3	-4.44	1.14e-05	0.00221	-0.25	-0.2	Mood instability;	chr8:8720610	chr8:9141424~9145435:+
HNSC	cis	rs6479891	0.591	rs72824934	ENSG00000232075.1	MRPL35P2	4.44	1.14e-05	0.00221	0.32	0.2	Arthritis (juvenile idiopathic);	chr10:63106041	chr10:63634317~63634827:-
HNSC	cis	rs9287719	0.967	rs6759714	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10607081	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6744854	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10607120	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6759740	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10607145	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6709466	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608131	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6719701	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608157	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs6432115	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608217	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432116	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608489	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2110776	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608684	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2110778	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10608844	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432117	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10609233	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432118	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10609315	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.935	rs728283	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10609964	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs728282	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10610177	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs728281	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10610229	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs6721510	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10610920	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6721514	ENSG00000243819.4	RN7SL832P	4.44	1.14e-05	0.00221	0.19	0.2	Prostate cancer;	chr2:10610936	chr2:10690344~10692099:+
HNSC	cis	rs929354	0.772	rs2301916	ENSG00000224629.1	RP5-1142J19.2	-4.44	1.14e-05	0.00221	-0.2	-0.2	Body mass index;	chr7:157181433	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.806	rs28446734	ENSG00000224629.1	RP5-1142J19.2	-4.44	1.14e-05	0.00221	-0.2	-0.2	Body mass index;	chr7:157204081	chr7:157263022~157263229:-
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000219891.2	ZSCAN12P1	4.44	1.14e-05	0.00221	0.28	0.2	Parkinson's disease;	chr6:28004655	chr6:28091154~28093664:+
HNSC	cis	rs9487051	0.872	rs4601178	ENSG00000219700.1	PTCHD3P3	4.44	1.14e-05	0.00221	0.2	0.2	Reticulocyte fraction of red cells;	chr6:109290043	chr6:109288571~109290503:-
HNSC	cis	rs9531006	0.752	rs11840618	ENSG00000227676.3	LINC01068	4.44	1.14e-05	0.00221	0.3	0.2	Sleep duration;	chr13:79981626	chr13:79566727~79571436:+
HNSC	cis	rs2835345	0.563	rs12483690	ENSG00000279365.1	KB-176G8.1	4.44	1.14e-05	0.00221	0.24	0.2	Pulmonary function;	chr21:36451265	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.596	rs12482097	ENSG00000279365.1	KB-176G8.1	4.44	1.14e-05	0.00221	0.24	0.2	Pulmonary function;	chr21:36451592	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.596	rs12482138	ENSG00000279365.1	KB-176G8.1	4.44	1.14e-05	0.00221	0.24	0.2	Pulmonary function;	chr21:36451608	chr21:36485867~36487760:+
HNSC	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	4.44	1.14e-05	0.00221	0.41	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000219891.2	ZSCAN12P1	4.44	1.14e-05	0.00221	0.3	0.2	Depression;	chr6:28237724	chr6:28091154~28093664:+
HNSC	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	4.44	1.14e-05	0.00221	0.18	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
HNSC	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	4.44	1.14e-05	0.00221	0.18	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
HNSC	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	4.44	1.14e-05	0.00221	0.23	0.2	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
HNSC	cis	rs7294478	1	rs7294478	ENSG00000256967.1	RP11-273B20.1	4.44	1.14e-05	0.00221	0.19	0.2	Neuritic plaque;	chr12:7114209	chr12:7129079~7131198:-
HNSC	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-4.44	1.14e-05	0.00221	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
HNSC	cis	rs11673344	0.503	rs7246720	ENSG00000276846.1	CTD-3220F14.3	4.44	1.14e-05	0.00221	0.22	0.2	Obesity-related traits;	chr19:37073726	chr19:37314868~37315620:-
HNSC	cis	rs889398	0.802	rs12925700	ENSG00000196696.11	PDXDC2P	4.44	1.14e-05	0.00221	0.14	0.2	Body mass index;	chr16:69759560	chr16:69976297~70065948:-
HNSC	cis	rs6964587	1	rs7797834	ENSG00000188693.7	CYP51A1-AS1	4.44	1.14e-05	0.00221	0.21	0.2	Breast cancer;	chr7:92113836	chr7:92134604~92180725:+
HNSC	cis	rs8058578	1	rs8048448	ENSG00000279196.1	RP11-1072A3.3	4.44	1.14e-05	0.00221	0.24	0.2	Multiple myeloma;	chr16:30680887	chr16:30984630~30988270:-
HNSC	cis	rs9959145	0.929	rs113240057	ENSG00000267249.1	RP11-973H7.3	-4.44	1.14e-05	0.00221	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12693707	chr18:12670426~12671145:-
HNSC	cis	rs8028182	0.636	rs4075522	ENSG00000260269.4	CTD-2323K18.1	-4.44	1.14e-05	0.00222	-0.26	-0.2	Sudden cardiac arrest;	chr15:75571994	chr15:75527150~75601205:-
HNSC	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	4.44	1.14e-05	0.00222	0.19	0.2	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	4.44	1.14e-05	0.00222	0.24	0.2	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	4.44	1.14e-05	0.00222	0.24	0.2	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	4.44	1.14e-05	0.00222	0.24	0.2	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
HNSC	cis	rs9450351	0.744	rs56344601	ENSG00000203875.9	SNHG5	-4.44	1.14e-05	0.00222	-0.43	-0.2	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs6901489	ENSG00000203875.9	SNHG5	-4.44	1.14e-05	0.00222	-0.43	-0.2	Interferon gamma-induced protein 10 levels;	chr6:86066343	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs6913399	ENSG00000203875.9	SNHG5	-4.44	1.14e-05	0.00222	-0.43	-0.2	Interferon gamma-induced protein 10 levels;	chr6:86068202	chr6:85660950~85678736:-
HNSC	cis	rs2562456	1	rs2562456	ENSG00000268081.1	RP11-678G14.2	4.44	1.14e-05	0.00222	0.26	0.2	Pain;	chr19:21483408	chr19:21554640~21569237:-
HNSC	cis	rs3811273	0.614	rs6572348	ENSG00000211816.2	TRAV38-1	-4.44	1.14e-05	0.00222	-0.22	-0.2	Periodontal disease-related phenotypes;	chr14:22268353	chr14:22271968~22272563:+
HNSC	cis	rs6500395	1	rs7190106	ENSG00000261267.1	RP11-44I10.3	-4.44	1.14e-05	0.00222	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48671631	chr16:48559661~48587403:+
HNSC	cis	rs9863	0.861	rs7973683	ENSG00000270028.1	RP11-380L11.4	4.44	1.14e-05	0.00222	0.23	0.2	White blood cell count;	chr12:123964676	chr12:123925461~123926083:-
HNSC	cis	rs2286503	0.78	rs12113458	ENSG00000226329.2	AC005682.6	4.44	1.14e-05	0.00222	0.26	0.2	Fibrinogen;	chr7:22816009	chr7:22863874~22881350:-
HNSC	cis	rs1941023	0.677	rs4939372	ENSG00000279632.1	RP11-286N22.6	4.44	1.14e-05	0.00222	0.22	0.2	Congenital heart disease (maternal effect);	chr11:60490328	chr11:61426448~61427325:-
HNSC	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	4.44	1.14e-05	0.00222	0.25	0.2	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	4.44	1.14e-05	0.00222	0.25	0.2	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-4.44	1.14e-05	0.00222	-0.12	-0.2	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000233609.3	RP11-62H7.2	4.44	1.14e-05	0.00222	0.19	0.2	Systolic blood pressure;	chr8:8461832	chr8:8961200~8979025:+
HNSC	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	4.44	1.14e-05	0.00222	0.23	0.2	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
HNSC	cis	rs79057730	0.528	rs6965219	ENSG00000225146.1	AC073957.15	4.44	1.14e-05	0.00222	0.3	0.2	Initial pursuit acceleration;	chr7:782170	chr7:1029025~1043891:+
HNSC	cis	rs12935418	0.672	rs1453327	ENSG00000278985.1	RP11-303E16.9	-4.44	1.14e-05	0.00222	-0.19	-0.2	Mean corpuscular volume;	chr16:81014959	chr16:80982319~80984094:-
HNSC	cis	rs6928977	0.675	rs11154803	ENSG00000231028.7	LINC00271	-4.44	1.15e-05	0.00222	-0.24	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135497801~135716055:+
HNSC	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-4.44	1.15e-05	0.00222	-0.24	-0.2	Height;	chr14:75056679	chr14:75011269~75012851:-
HNSC	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-4.44	1.15e-05	0.00222	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-4.44	1.15e-05	0.00222	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-4.44	1.15e-05	0.00222	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-4.44	1.15e-05	0.00222	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
HNSC	cis	rs73222236	0.825	rs7612160	ENSG00000273486.1	RP11-731C17.2	4.44	1.15e-05	0.00222	0.17	0.2	Coronary artery disease;	chr3:136553963	chr3:136837338~136839021:-
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	4.44	1.15e-05	0.00222	0.24	0.2	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
HNSC	cis	rs9880211	1	rs12695649	ENSG00000273486.1	RP11-731C17.2	4.44	1.15e-05	0.00222	0.19	0.2	Height;Body mass index;	chr3:136553074	chr3:136837338~136839021:-
HNSC	cis	rs2904524	1	rs17107933	ENSG00000257815.4	RP11-611E13.2	4.44	1.15e-05	0.00222	0.26	0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70283707	chr12:69904033~70243360:-
HNSC	cis	rs4925386	0.681	rs2427295	ENSG00000275437.1	RP5-908M14.10	4.44	1.15e-05	0.00222	0.22	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62402236~62405935:-
HNSC	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-4.44	1.15e-05	0.00222	-0.34	-0.2	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
HNSC	cis	rs3736485	0.966	rs12443007	ENSG00000259438.1	CTD-2650P22.1	4.44	1.15e-05	0.00222	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51599995	chr15:52010999~52019095:-
HNSC	cis	rs11992186	0.597	rs11781841	ENSG00000254340.1	RP11-10A14.3	-4.44	1.15e-05	0.00222	-0.26	-0.2	Neuroticism;	chr8:8737753	chr8:9141424~9145435:+
HNSC	cis	rs7674212	0.54	rs2711897	ENSG00000251288.2	RP11-10L12.2	-4.44	1.15e-05	0.00223	-0.23	-0.2	Type 2 diabetes;	chr4:103102410	chr4:102751401~102752641:+
HNSC	cis	rs3015497	0.646	rs3015492	ENSG00000269906.1	RP11-248J18.2	-4.44	1.15e-05	0.00223	-0.26	-0.2	Mean platelet volume;	chr14:50658025	chr14:50662511~50663178:-
HNSC	cis	rs924712	0.522	rs4715486	ENSG00000224984.1	RP11-524H19.2	-4.44	1.15e-05	0.00223	-0.23	-0.2	Breast cancer;	chr6:54848105	chr6:54840118~54840855:-
HNSC	cis	rs13434995	0.513	rs62303681	ENSG00000273257.1	RP11-177J6.1	-4.44	1.15e-05	0.00223	-0.28	-0.2	Adiponectin levels;	chr4:55403812	chr4:55387949~55388271:+
HNSC	cis	rs9287719	0.87	rs728135	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605006	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs963831	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605058	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs728134	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605061	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2884233	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605177	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.839	rs12692415	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605348	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs12692416	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605501	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs12692417	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605592	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs12692418	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10605744	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6755548	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10606000	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6761678	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10606215	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6759100	ENSG00000243819.4	RN7SL832P	4.44	1.15e-05	0.00223	0.19	0.2	Prostate cancer;	chr2:10606584	chr2:10690344~10692099:+
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000224373.3	IGHV4-59	4.43	1.15e-05	0.00223	0.13	0.2	Kawasaki disease;	chr14:106777528	chr14:106627249~106627825:-
HNSC	cis	rs4356203	0.905	rs11024148	ENSG00000272034.1	SNORD14A	-4.43	1.15e-05	0.00223	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17074654~17074744:-
HNSC	cis	rs467650	0.509	rs152985	ENSG00000246763.5	RGMB-AS1	4.43	1.15e-05	0.00223	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98653103	chr5:98769618~98773469:-
HNSC	cis	rs889398	0.774	rs6499263	ENSG00000226232.7	RP11-419C5.2	-4.43	1.15e-05	0.00223	-0.18	-0.2	Body mass index;	chr16:69856246	chr16:69976388~69996188:-
HNSC	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-4.43	1.15e-05	0.00223	-0.31	-0.2	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
HNSC	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-4.43	1.15e-05	0.00223	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
HNSC	cis	rs11773103	1	rs11768281	ENSG00000224046.1	AC005076.5	4.43	1.15e-05	0.00223	0.37	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87326790	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73194650	ENSG00000224046.1	AC005076.5	4.43	1.15e-05	0.00223	0.37	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87328655	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs11760719	ENSG00000224046.1	AC005076.5	4.43	1.15e-05	0.00223	0.37	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87329513	chr7:87151423~87152420:-
HNSC	cis	rs7178375	1	rs28881289	ENSG00000270055.1	CTD-3092A11.2	-4.43	1.15e-05	0.00223	-0.27	-0.2	Hypertriglyceridemia;	chr15:30931752	chr15:30487963~30490313:+
HNSC	cis	rs7178375	0.941	rs35497908	ENSG00000270055.1	CTD-3092A11.2	-4.43	1.15e-05	0.00223	-0.27	-0.2	Hypertriglyceridemia;	chr15:30931868	chr15:30487963~30490313:+
HNSC	cis	rs1594829	0.535	rs11784209	ENSG00000228451.3	SDAD1P1	4.43	1.15e-05	0.00223	0.23	0.2	Height;	chr8:26312730	chr8:26379259~26382953:-
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000255495.1	AC145124.2	4.43	1.15e-05	0.00223	0.22	0.2	Neuroticism;	chr8:11939165	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000255495.1	AC145124.2	4.43	1.15e-05	0.00223	0.22	0.2	Neuroticism;	chr8:11939166	chr8:12194467~12196280:+
HNSC	cis	rs11122895	0.509	rs55937046	ENSG00000236307.2	EEF1E1P1	4.43	1.15e-05	0.00223	0.19	0.2	Allergic sensitization;	chr2:111689719	chr2:111887914~111888741:+
HNSC	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-4.43	1.15e-05	0.00223	-0.17	-0.2	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
HNSC	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-4.43	1.15e-05	0.00223	-0.17	-0.2	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00223	0.24	0.2	Corneal astigmatism;	chr4:119480680	chr4:119391831~119395335:-
HNSC	cis	rs3736485	0.609	rs11637716	ENSG00000259438.1	CTD-2650P22.1	4.43	1.15e-05	0.00223	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51672989	chr15:52010999~52019095:-
HNSC	cis	rs9880211	0.8	rs115050567	ENSG00000273486.1	RP11-731C17.2	4.43	1.15e-05	0.00223	0.19	0.2	Height;Body mass index;	chr3:136796817	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs9858560	ENSG00000273486.1	RP11-731C17.2	4.43	1.15e-05	0.00223	0.19	0.2	Height;Body mass index;	chr3:136798312	chr3:136837338~136839021:-
HNSC	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	4.43	1.15e-05	0.00223	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
HNSC	cis	rs4061073	0.961	rs9012	ENSG00000198711.5	SSBP3-AS1	-4.43	1.15e-05	0.00223	-0.2	-0.2	Body mass index;	chr1:54225792	chr1:54236440~54239063:+
HNSC	cis	rs7829975	0.511	rs2980512	ENSG00000254153.1	CTA-398F10.2	4.43	1.15e-05	0.00223	0.22	0.2	Mood instability;	chr8:8283379	chr8:8456909~8461337:-
HNSC	cis	rs911555	0.504	rs4906340	ENSG00000269958.1	RP11-73M18.8	-4.43	1.15e-05	0.00224	-0.2	-0.2	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103696353~103697163:+
HNSC	cis	rs6787172	0.811	rs12637678	ENSG00000272087.1	RP11-379F4.7	4.43	1.15e-05	0.00224	0.21	0.2	Subjective well-being;	chr3:158530833	chr3:158693120~158693768:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000233609.3	RP11-62H7.2	4.43	1.16e-05	0.00224	0.19	0.2	Mood instability;	chr8:8272638	chr8:8961200~8979025:+
HNSC	cis	rs11098499	1	rs13435802	ENSG00000250412.1	KLHL2P1	-4.43	1.16e-05	0.00224	-0.25	-0.2	Corneal astigmatism;	chr4:119256805	chr4:119334329~119378233:+
HNSC	cis	rs9650657	0.617	rs28680211	ENSG00000255310.2	AF131215.2	-4.43	1.16e-05	0.00224	-0.19	-0.2	Neuroticism;	chr8:10661935	chr8:11107788~11109726:-
HNSC	cis	rs4862750	0.794	rs7672272	ENSG00000250971.1	RP11-696F12.1	4.43	1.16e-05	0.00224	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186975620	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs6852907	ENSG00000250971.1	RP11-696F12.1	4.43	1.16e-05	0.00224	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186975940	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs6830426	ENSG00000250971.1	RP11-696F12.1	4.43	1.16e-05	0.00224	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186976116	chr4:187060099~187060930:+
HNSC	cis	rs4862750	0.872	rs6830828	ENSG00000250971.1	RP11-696F12.1	4.43	1.16e-05	0.00224	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186976318	chr4:187060099~187060930:+
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-4.43	1.16e-05	0.00224	-0.18	-0.2	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
HNSC	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	4.43	1.16e-05	0.00224	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	4.43	1.16e-05	0.00224	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
HNSC	cis	rs12745968	0.589	rs10874725	ENSG00000223787.2	RP4-593M8.1	-4.43	1.16e-05	0.00224	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92625293	chr1:92580476~92580821:-
HNSC	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-4.43	1.16e-05	0.00224	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
HNSC	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-4.43	1.16e-05	0.00224	-0.36	-0.2	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
HNSC	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-4.43	1.16e-05	0.00224	-0.36	-0.2	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
HNSC	cis	rs2439831	0.85	rs60883262	ENSG00000201136.1	RNU6-353P	-4.43	1.16e-05	0.00224	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43784305	chr15:43702363~43702470:+
HNSC	cis	rs7520050	0.966	rs6429582	ENSG00000280836.1	AL355480.1	-4.43	1.16e-05	0.00224	-0.21	-0.2	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45581219~45581321:-
HNSC	cis	rs13256369	0.802	rs11781257	ENSG00000173295.6	FAM86B3P	4.43	1.16e-05	0.00224	0.26	0.2	Obesity-related traits;	chr8:8702153	chr8:8228595~8244865:+
HNSC	cis	rs10773046	0.74	rs11057383	ENSG00000269938.1	RP11-214K3.20	-4.43	1.16e-05	0.00224	-0.22	-0.2	Osteoarthritis (hip);	chr12:123884874	chr12:123968023~123968579:-
HNSC	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-4.43	1.16e-05	0.00224	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
HNSC	cis	rs11846409	0.799	rs10467899	ENSG00000254174.1	IGHV1-12	4.43	1.16e-05	0.00224	0.16	0.2	Rheumatic heart disease;	chr14:106644012	chr14:106122420~106122709:-
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000280411.1	IGHV1-69-2	-4.43	1.16e-05	0.00224	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106686309	chr14:106762092~106762588:-
HNSC	cis	rs9311676	0.656	rs56232415	ENSG00000273493.1	RP11-80H18.4	4.43	1.16e-05	0.00224	0.22	0.2	Systemic lupus erythematosus;	chr3:58409123	chr3:58329965~58330118:+
HNSC	cis	rs3764021	1	rs3764021	ENSG00000256673.1	RP11-599J14.2	-4.43	1.16e-05	0.00224	-0.19	-0.2	Type 1 diabetes;	chr12:9681032	chr12:9398355~9414851:-
HNSC	cis	rs4761669	0.848	rs10859752	ENSG00000241556.1	RP11-490G8.1	-4.43	1.16e-05	0.00224	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94785403	chr12:95467397~95467861:-
HNSC	cis	rs62458065	0.85	rs6462362	ENSG00000226468.2	AC018641.7	4.43	1.16e-05	0.00224	0.33	0.2	Metabolite levels (HVA/MHPG ratio);	chr7:32425121	chr7:32456963~32457758:-
HNSC	cis	rs8067545	0.641	rs203482	ENSG00000266126.1	RP11-209D14.4	4.43	1.16e-05	0.00224	0.23	0.2	Schizophrenia;	chr17:19923897	chr17:19929372~19929737:-
HNSC	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	4.43	1.16e-05	0.00224	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
HNSC	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	4.43	1.16e-05	0.00225	0.23	0.2	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
HNSC	cis	rs763567	0.605	rs577676	ENSG00000271811.1	RP1-79C4.4	4.43	1.16e-05	0.00225	0.21	0.2	Tonsillectomy;	chr1:170618199	chr1:170667381~170669425:+
HNSC	cis	rs7809950	0.723	rs62483633	ENSG00000238832.1	snoU109	-4.43	1.16e-05	0.00225	-0.29	-0.2	Coronary artery disease;	chr7:107236199	chr7:107603363~107603507:+
HNSC	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	4.43	1.16e-05	0.00225	0.28	0.2	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	4.43	1.16e-05	0.00225	0.28	0.2	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	4.43	1.16e-05	0.00225	0.28	0.2	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	4.43	1.16e-05	0.00225	0.28	0.2	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
HNSC	cis	rs4660214	0.789	rs1180375	ENSG00000182109.6	RP11-69E11.4	4.43	1.16e-05	0.00225	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39522280~39546187:-
HNSC	cis	rs6964587	0.934	rs7793861	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.16e-05	0.00225	-0.21	-0.2	Breast cancer;	chr7:92113414	chr7:92134604~92180725:+
HNSC	cis	rs721917	0.506	rs2493722	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.545	rs2758542	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs7914360	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2493725	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2254025	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.525	rs2254017	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2254013	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2253875	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.544	rs9325567	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.525	rs2250652	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.16e-05	0.00225	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79663088~79826594:-
HNSC	cis	rs2933343	0.621	rs883843	ENSG00000261159.1	RP11-723O4.9	-4.43	1.16e-05	0.00225	-0.2	-0.2	IgG glycosylation;	chr3:128848540	chr3:128859716~128860526:-
HNSC	cis	rs9527	0.662	rs10883783	ENSG00000236937.2	PTGES3P4	4.43	1.16e-05	0.00225	0.27	0.2	Arsenic metabolism;	chr10:102831395	chr10:102845595~102845950:+
HNSC	cis	rs79349575	0.749	rs318093	ENSG00000270781.1	RP11-501C14.9	-4.43	1.16e-05	0.00225	-0.21	-0.2	Type 2 diabetes;	chr17:48911992	chr17:48899131~48899748:+
HNSC	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-4.43	1.16e-05	0.00225	-0.17	-0.2	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
HNSC	cis	rs7586673	0.725	rs6757645	ENSG00000227403.1	AC009299.3	-4.43	1.16e-05	0.00225	-0.28	-0.2	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161244739~161249050:+
HNSC	cis	rs1113500	0.633	rs1777451	ENSG00000226822.1	RP11-356N1.2	-4.43	1.16e-05	0.00225	-0.23	-0.2	Growth-regulated protein alpha levels;	chr1:108035560	chr1:108071482~108074519:+
HNSC	cis	rs12935418	0.579	rs1477381	ENSG00000261061.1	RP11-303E16.2	4.43	1.16e-05	0.00225	0.21	0.2	Mean corpuscular volume;	chr16:80981095	chr16:81030770~81031485:+
HNSC	cis	rs6688613	1	rs6695162	ENSG00000215834.7	FMO9P	4.43	1.17e-05	0.00225	0.24	0.2	Refractive astigmatism;	chr1:166984218	chr1:166603675~166631400:+
HNSC	cis	rs7121616	0.576	rs7111590	ENSG00000200879.1	SNORD14E	4.43	1.17e-05	0.00225	0.28	0.2	Breast cancer;	chr11:123055419	chr11:123058077~123058161:-
HNSC	cis	rs198389	0.568	rs12406667	ENSG00000242349.4	NPPA-AS1	4.43	1.17e-05	0.00225	0.19	0.2	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813794	chr1:11841017~11848079:+
HNSC	cis	rs7324557	0.684	rs9507165	ENSG00000205861.10	C1QTNF9B-AS1	-4.43	1.17e-05	0.00225	-0.28	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23810291	chr13:23888889~23897263:+
HNSC	cis	rs7819412	0.561	rs2001328	ENSG00000269918.1	AF131215.9	-4.43	1.17e-05	0.00225	-0.2	-0.2	Triglycerides;	chr8:11129689	chr8:11104691~11106704:-
HNSC	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-4.43	1.17e-05	0.00226	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
HNSC	cis	rs8067545	0.641	rs203450	ENSG00000266126.1	RP11-209D14.4	4.43	1.17e-05	0.00226	0.23	0.2	Schizophrenia;	chr17:19919757	chr17:19929372~19929737:-
HNSC	cis	rs853679	0.546	rs13195291	ENSG00000219392.1	RP1-265C24.5	-4.43	1.17e-05	0.00226	-0.43	-0.2	Depression;	chr6:28201463	chr6:28115628~28116551:+
HNSC	cis	rs9527	0.571	rs12765337	ENSG00000236937.2	PTGES3P4	4.43	1.17e-05	0.00226	0.25	0.2	Arsenic metabolism;	chr10:102875587	chr10:102845595~102845950:+
HNSC	cis	rs9527	0.525	rs12770034	ENSG00000236937.2	PTGES3P4	4.43	1.17e-05	0.00226	0.25	0.2	Arsenic metabolism;	chr10:102875838	chr10:102845595~102845950:+
HNSC	cis	rs6496044	0.507	rs62022863	ENSG00000259295.5	CSPG4P12	-4.43	1.17e-05	0.00226	-0.24	-0.2	Interstitial lung disease;	chr15:85618822	chr15:85191438~85213905:+
HNSC	cis	rs9300255	0.544	rs1727310	ENSG00000280120.1	RP11-546D6.3	4.43	1.17e-05	0.00226	0.2	0.2	Neutrophil percentage of white cells;	chr12:123175963	chr12:123152324~123153377:-
HNSC	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-4.43	1.17e-05	0.00226	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
HNSC	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	4.43	1.17e-05	0.00226	0.23	0.2	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
HNSC	cis	rs2237234	0.813	rs34565965	ENSG00000241549.7	GUSBP2	4.43	1.17e-05	0.00226	0.24	0.2	Autism spectrum disorder or schizophrenia;	chr6:26350582	chr6:26871484~26956554:-
HNSC	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-4.43	1.17e-05	0.00226	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
HNSC	cis	rs1008375	1	rs10019856	ENSG00000249502.1	AC006160.5	-4.43	1.17e-05	0.00226	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614119	chr4:17587467~17614571:-
HNSC	cis	rs7121616	0.576	rs1461495	ENSG00000200879.1	SNORD14E	-4.43	1.17e-05	0.00226	-0.28	-0.2	Breast cancer;	chr11:123056136	chr11:123058077~123058161:-
HNSC	cis	rs6430585	0.528	rs309119	ENSG00000231890.6	DARS-AS1	-4.43	1.17e-05	0.00226	-0.34	-0.2	Corneal structure;	chr2:135952802	chr2:135985176~136022593:+
HNSC	cis	rs9450351	0.744	rs7744309	ENSG00000203875.9	SNHG5	-4.43	1.17e-05	0.00227	-0.46	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85556764	chr6:85660950~85678736:-
HNSC	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	4.43	1.17e-05	0.00227	0.25	0.2	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	4.43	1.17e-05	0.00227	0.25	0.2	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
HNSC	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-4.43	1.17e-05	0.00227	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
HNSC	cis	rs6500602	0.653	rs3747579	ENSG00000280063.1	RP11-295D4.3	-4.43	1.17e-05	0.00227	-0.15	-0.2	Schizophrenia;	chr16:4395326	chr16:4346694~4348648:-
HNSC	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	4.43	1.17e-05	0.00227	0.27	0.2	Pain;	chr19:21568976	chr19:21554640~21569237:-
HNSC	cis	rs7396835	0.551	rs10750098	ENSG00000280143.1	AP000892.6	4.43	1.17e-05	0.00227	0.32	0.2	Quantitative traits;	chr11:116834852	chr11:117204967~117210292:+
HNSC	cis	rs6142102	0.778	rs6059555	ENSG00000275784.1	RP5-1125A11.6	-4.43	1.17e-05	0.00227	-0.26	-0.2	Skin pigmentation;	chr20:33926518	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.778	rs4911374	ENSG00000275784.1	RP5-1125A11.6	-4.43	1.17e-05	0.00227	-0.26	-0.2	Skin pigmentation;	chr20:33928195	chr20:33989480~33991818:-
HNSC	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-4.43	1.17e-05	0.00227	-0.2	-0.2	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
HNSC	cis	rs9311676	0.609	rs55646457	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58429536	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.609	rs1126551	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58430808	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62259772	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58431689	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.609	rs11925862	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58432200	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs34086582	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58434217	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11130642	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58434315	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11924677	ENSG00000273493.1	RP11-80H18.4	4.43	1.18e-05	0.00227	0.22	0.2	Systemic lupus erythematosus;	chr3:58434815	chr3:58329965~58330118:+
HNSC	cis	rs11846409	0.932	rs28378201	ENSG00000254174.1	IGHV1-12	4.43	1.18e-05	0.00227	0.16	0.2	Rheumatic heart disease;	chr14:106637262	chr14:106122420~106122709:-
HNSC	cis	rs7005380	1	rs7005380	ENSG00000279347.1	RP11-85I17.2	4.43	1.18e-05	0.00227	0.17	0.2	Interstitial lung disease;	chr8:119941633	chr8:119838736~119840385:-
HNSC	cis	rs6787172	0.811	rs7620927	ENSG00000272087.1	RP11-379F4.7	4.43	1.18e-05	0.00227	0.21	0.2	Subjective well-being;	chr3:158528094	chr3:158693120~158693768:-
HNSC	cis	rs9368481	0.569	rs6907403	ENSG00000224843.5	LINC00240	-4.43	1.18e-05	0.00227	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.502	rs3933232	ENSG00000224843.5	LINC00240	-4.43	1.18e-05	0.00227	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.524	rs12530345	ENSG00000224843.5	LINC00240	-4.43	1.18e-05	0.00227	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26956992~27023924:+
HNSC	cis	rs9368481	0.546	rs12664610	ENSG00000224843.5	LINC00240	-4.43	1.18e-05	0.00227	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26956992~27023924:+
HNSC	cis	rs2492286	0.597	rs7647337	ENSG00000242551.2	POU5F1P6	-4.43	1.18e-05	0.00227	-0.22	-0.2	Eosinophil counts;	chr3:128628353	chr3:128674735~128677005:-
HNSC	cis	rs7674212	0.512	rs2720462	ENSG00000251288.2	RP11-10L12.2	-4.43	1.18e-05	0.00227	-0.23	-0.2	Type 2 diabetes;	chr4:103135053	chr4:102751401~102752641:+
HNSC	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-4.43	1.18e-05	0.00227	-0.26	-0.2	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-4.43	1.18e-05	0.00227	-0.26	-0.2	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
HNSC	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-4.43	1.18e-05	0.00227	-0.28	-0.2	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
HNSC	cis	rs9880211	0.613	rs13081671	ENSG00000273486.1	RP11-731C17.2	4.43	1.18e-05	0.00227	0.17	0.2	Height;Body mass index;	chr3:136157707	chr3:136837338~136839021:-
HNSC	cis	rs9287719	0.837	rs4233883	ENSG00000243819.4	RN7SL832P	4.43	1.18e-05	0.00227	0.19	0.2	Prostate cancer;	chr2:10615470	chr2:10690344~10692099:+
HNSC	cis	rs6500395	0.926	rs11645193	ENSG00000261267.1	RP11-44I10.3	-4.43	1.18e-05	0.00227	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48560318	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.926	rs1120275	ENSG00000261267.1	RP11-44I10.3	-4.43	1.18e-05	0.00227	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48564826	chr16:48559661~48587403:+
HNSC	cis	rs9329221	0.905	rs6601451	ENSG00000255310.2	AF131215.2	-4.43	1.18e-05	0.00227	-0.19	-0.2	Neuroticism;	chr8:10386171	chr8:11107788~11109726:-
HNSC	cis	rs792448	0.59	rs36010081	ENSG00000226251.4	RP11-15I11.3	-4.43	1.18e-05	0.00227	-0.31	-0.2	White blood cell count (basophil);	chr1:212250440	chr1:212225278~212238977:-
HNSC	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	4.43	1.18e-05	0.00227	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
HNSC	cis	rs17345786	0.906	rs58835747	ENSG00000244119.1	PDCL3P4	4.43	1.18e-05	0.00227	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101712472~101713191:+
HNSC	cis	rs3805389	1	rs10026676	ENSG00000273257.1	RP11-177J6.1	-4.43	1.18e-05	0.00227	-0.27	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55612585	chr4:55387949~55388271:+
HNSC	cis	rs79349575	0.783	rs832410	ENSG00000270781.1	RP11-501C14.9	-4.43	1.18e-05	0.00227	-0.21	-0.2	Type 2 diabetes;	chr17:48895503	chr17:48899131~48899748:+
HNSC	cis	rs9959145	1	rs78543731	ENSG00000267249.1	RP11-973H7.3	-4.43	1.18e-05	0.00227	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12665565	chr18:12670426~12671145:-
HNSC	cis	rs9959145	0.706	rs117416781	ENSG00000267249.1	RP11-973H7.3	-4.43	1.18e-05	0.00227	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12684925	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs78908311	ENSG00000267249.1	RP11-973H7.3	-4.43	1.18e-05	0.00227	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12688279	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs78421903	ENSG00000267249.1	RP11-973H7.3	-4.43	1.18e-05	0.00227	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12688701	chr18:12670426~12671145:-
HNSC	cis	rs79349575	0.749	rs519537	ENSG00000270781.1	RP11-501C14.9	-4.43	1.18e-05	0.00228	-0.21	-0.2	Type 2 diabetes;	chr17:48893778	chr17:48899131~48899748:+
HNSC	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-4.43	1.18e-05	0.00228	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
HNSC	cis	rs9910055	1	rs2071167	ENSG00000267080.4	ASB16-AS1	4.43	1.18e-05	0.00228	0.16	0.2	Total body bone mineral density;	chr17:44210151	chr17:44175973~44186717:-
HNSC	cis	rs11722228	0.508	rs3822246	ENSG00000250413.1	RP11-448G15.1	-4.43	1.18e-05	0.00228	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10006482~10009725:+
HNSC	cis	rs1580019	1	rs1580019	ENSG00000226468.2	AC018641.7	4.43	1.18e-05	0.00228	0.27	0.2	Cognitive ability;	chr7:32453557	chr7:32456963~32457758:-
HNSC	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-4.43	1.18e-05	0.00228	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
HNSC	cis	rs924712	0.572	rs6922968	ENSG00000224984.1	RP11-524H19.2	-4.43	1.18e-05	0.00228	-0.23	-0.2	Breast cancer;	chr6:54842466	chr6:54840118~54840855:-
HNSC	cis	rs9907295	0.818	rs9889874	ENSG00000270977.1	AC015849.16	-4.43	1.18e-05	0.00228	-0.27	-0.2	Fibroblast growth factor basic levels;	chr17:35875293	chr17:35893707~35911023:-
HNSC	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-4.43	1.18e-05	0.00228	-0.16	-0.2	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
HNSC	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	4.43	1.18e-05	0.00228	0.23	0.2	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
HNSC	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-4.43	1.18e-05	0.00228	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-4.43	1.18e-05	0.00228	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
HNSC	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	4.43	1.18e-05	0.00228	0.23	0.2	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
HNSC	cis	rs9527	0.662	rs4919687	ENSG00000236937.2	PTGES3P4	4.43	1.18e-05	0.00228	0.27	0.2	Arsenic metabolism;	chr10:102835491	chr10:102845595~102845950:+
HNSC	cis	rs889398	0.738	rs7196842	ENSG00000226232.7	RP11-419C5.2	-4.43	1.18e-05	0.00228	-0.18	-0.2	Body mass index;	chr16:69889430	chr16:69976388~69996188:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000211974.3	IGHV2-70	4.43	1.18e-05	0.00228	0.19	0.2	Kawasaki disease;	chr14:106705382	chr14:106723574~106724093:-
HNSC	cis	rs4372836	1	rs2276547	ENSG00000226833.4	AC097724.3	4.43	1.18e-05	0.00228	0.25	0.2	Body mass index;	chr2:28752241	chr2:28708953~28736205:-
HNSC	cis	rs7121616	0.545	rs7109348	ENSG00000200879.1	SNORD14E	4.43	1.18e-05	0.00228	0.28	0.2	Breast cancer;	chr11:123056555	chr11:123058077~123058161:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	4.43	1.18e-05	0.00228	0.24	0.2	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	4.43	1.18e-05	0.00228	0.24	0.2	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	4.43	1.18e-05	0.00228	0.17	0.2	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
HNSC	cis	rs72634501	0.716	rs72660086	ENSG00000228060.1	RP11-69E11.8	-4.43	1.18e-05	0.00228	-0.24	-0.2	HDL cholesterol;	chr1:39106320	chr1:39565160~39573203:+
HNSC	cis	rs4660214	0.724	rs10788933	ENSG00000182109.6	RP11-69E11.4	-4.43	1.18e-05	0.00228	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39522280~39546187:-
HNSC	cis	rs7662987	0.517	rs2851268	ENSG00000263923.1	RP11-571L19.7	-4.43	1.18e-05	0.00228	-0.21	-0.2	Smoking initiation;	chr4:99106727	chr4:98928897~98994994:+
HNSC	cis	rs12545109	0.876	rs1992120	ENSG00000246430.5	LINC00968	-4.43	1.18e-05	0.00228	-0.26	-0.2	Obesity-related traits;	chr8:56424553	chr8:56496246~56559823:-
HNSC	cis	rs9840812	0.953	rs4678322	ENSG00000273486.1	RP11-731C17.2	-4.43	1.18e-05	0.00228	-0.18	-0.2	Fibrinogen levels;	chr3:136093681	chr3:136837338~136839021:-
HNSC	cis	rs73198271	0.653	rs10087742	ENSG00000233609.3	RP11-62H7.2	-4.43	1.18e-05	0.00228	-0.21	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8961200~8979025:+
HNSC	cis	rs3806843	0.676	rs2245640	ENSG00000202515.1	VTRNA1-3	4.43	1.18e-05	0.00228	0.23	0.2	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr5:140726158~140726246:+
HNSC	cis	rs6601327	0.67	rs7004937	ENSG00000254340.1	RP11-10A14.3	4.43	1.18e-05	0.00228	0.24	0.2	Multiple myeloma (hyperdiploidy);	chr8:9563451	chr8:9141424~9145435:+
HNSC	cis	rs2665103	0.589	rs3858953	ENSG00000276710.3	CSPG4P8	-4.43	1.18e-05	0.00229	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82459472~82477258:+
HNSC	cis	rs853679	0.585	rs201004	ENSG00000219392.1	RP1-265C24.5	-4.43	1.19e-05	0.00229	-0.28	-0.2	Depression;	chr6:27837156	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs67340775	ENSG00000226314.6	ZNF192P1	-4.43	1.19e-05	0.00229	-0.37	-0.2	Depression;	chr6:28336607	chr6:28161781~28169594:+
HNSC	cis	rs4356203	0.905	rs7927240	ENSG00000272034.1	SNORD14A	-4.43	1.19e-05	0.00229	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17074654~17074744:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	4.43	1.19e-05	0.00229	0.27	0.2	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
HNSC	cis	rs721917	0.506	rs2244451	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2265961	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs7088752	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs7078242	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.525	rs2244001	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs1811886	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2819113	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs4320898	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs4322333	ENSG00000244733.5	RP11-506M13.3	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79660891~79677996:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000254153.1	CTA-398F10.2	4.43	1.19e-05	0.00229	0.22	0.2	Mood instability;	chr8:8822104	chr8:8456909~8461337:-
HNSC	cis	rs10435719	0.764	rs10103485	ENSG00000255495.1	AC145124.2	4.43	1.19e-05	0.00229	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:12194467~12196280:+
HNSC	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	4.43	1.19e-05	0.00229	0.27	0.2	Pain;	chr19:21569041	chr19:21554640~21569237:-
HNSC	cis	rs9402743	0.632	rs9389330	ENSG00000217482.2	HMGB1P17	-4.43	1.19e-05	0.00229	-0.21	-0.2	Systemic lupus erythematosus;	chr6:135787865	chr6:135636086~135636713:-
HNSC	cis	rs1150668	0.799	rs7206	ENSG00000219392.1	RP1-265C24.5	-4.43	1.19e-05	0.00229	-0.22	-0.2	Pubertal anthropometrics;	chr6:28233360	chr6:28115628~28116551:+
HNSC	cis	rs6831352	0.877	rs2602890	ENSG00000263923.1	RP11-571L19.7	-4.43	1.19e-05	0.00229	-0.22	-0.2	Alcohol dependence;	chr4:99122028	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs2602891	ENSG00000263923.1	RP11-571L19.7	-4.43	1.19e-05	0.00229	-0.22	-0.2	Alcohol dependence;	chr4:99122133	chr4:98928897~98994994:+
HNSC	cis	rs721917	0.525	rs1054053	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79663088~79826594:-
HNSC	cis	rs721917	0.506	rs2758558	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.19e-05	0.00229	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79663088~79826594:-
HNSC	cis	rs7121616	0.545	rs7109336	ENSG00000200879.1	SNORD14E	4.43	1.19e-05	0.00229	0.28	0.2	Breast cancer;	chr11:123056530	chr11:123058077~123058161:-
HNSC	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	4.43	1.19e-05	0.00229	0.21	0.2	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000254153.1	CTA-398F10.2	4.43	1.19e-05	0.00229	0.22	0.2	Mood instability;	chr8:8822967	chr8:8456909~8461337:-
HNSC	cis	rs7267979	0.702	rs449801	ENSG00000231081.1	RP4-760C5.3	-4.43	1.19e-05	0.00229	-0.2	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26008791~26010531:-
HNSC	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-4.43	1.19e-05	0.0023	-0.27	-0.2	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
HNSC	cis	rs10266483	0.576	rs2863327	ENSG00000228653.2	HNRNPCP7	4.43	1.19e-05	0.0023	0.25	0.2	Response to statin therapy;	chr7:64268698	chr7:64500825~64501729:+
HNSC	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	4.43	1.19e-05	0.0023	0.23	0.2	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
HNSC	cis	rs6688613	1	rs6699520	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166986168	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs10918605	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166986401	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs7554962	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166987060	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs6427049	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166987356	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs10918606	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166988012	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs17551703	ENSG00000215834.7	FMO9P	4.43	1.19e-05	0.0023	0.24	0.2	Refractive astigmatism;	chr1:166988642	chr1:166603675~166631400:+
HNSC	cis	rs6890684	0.542	rs62366215	ENSG00000215032.2	GNL3LP1	4.43	1.19e-05	0.0023	0.22	0.2	Intelligence (multi-trait analysis);	chr5:61253693	chr5:60891935~60893577:-
HNSC	cis	rs9584850	0.834	rs9584854	ENSG00000231194.1	FARP1-AS1	4.43	1.19e-05	0.0023	0.25	0.2	Neuroticism;	chr13:98466336	chr13:98435405~98435840:-
HNSC	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	4.43	1.19e-05	0.0023	0.21	0.2	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
HNSC	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	4.43	1.19e-05	0.0023	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	4.43	1.19e-05	0.0023	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
HNSC	cis	rs5758511	0.633	rs5758689	ENSG00000226450.2	CYP2D8P	4.43	1.19e-05	0.0023	0.2	0.2	Birth weight;	chr22:42268966	chr22:42149886~42155001:-
HNSC	cis	rs9311676	0.632	rs1126722	ENSG00000273493.1	RP11-80H18.4	4.43	1.19e-05	0.0023	0.22	0.2	Systemic lupus erythematosus;	chr3:58427791	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs4228	ENSG00000273493.1	RP11-80H18.4	4.43	1.19e-05	0.0023	0.22	0.2	Systemic lupus erythematosus;	chr3:58427942	chr3:58329965~58330118:+
HNSC	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-4.43	1.19e-05	0.0023	-0.23	-0.2	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
HNSC	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-4.43	1.19e-05	0.0023	-0.36	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
HNSC	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-4.43	1.19e-05	0.0023	-0.21	-0.2	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-4.43	1.19e-05	0.0023	-0.21	-0.2	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-4.43	1.19e-05	0.0023	-0.21	-0.2	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
HNSC	cis	rs13434995	0.513	rs62303726	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55490415	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs55729020	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55491681	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs3805156	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55497925	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62303731	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55499667	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62303732	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55499868	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs56196624	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55500340	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62305264	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55502968	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62305265	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55503474	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62305268	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55506991	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62305270	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55507842	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs7681414	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55508890	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs62305271	ENSG00000273257.1	RP11-177J6.1	-4.43	1.2e-05	0.0023	-0.27	-0.2	Adiponectin levels;	chr4:55509715	chr4:55387949~55388271:+
HNSC	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-4.43	1.2e-05	0.0023	-0.26	-0.2	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
HNSC	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-4.43	1.2e-05	0.0023	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
HNSC	cis	rs17507216	0.718	rs72753931	ENSG00000276710.3	CSPG4P8	-4.43	1.2e-05	0.0023	-0.29	-0.2	Excessive daytime sleepiness;	chr15:82721485	chr15:82459472~82477258:+
HNSC	cis	rs9527	0.662	rs743575	ENSG00000236937.2	PTGES3P4	4.43	1.2e-05	0.0023	0.27	0.2	Arsenic metabolism;	chr10:102835149	chr10:102845595~102845950:+
HNSC	cis	rs4660214	0.694	rs16866216	ENSG00000182109.6	RP11-69E11.4	-4.43	1.2e-05	0.0023	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39522280~39546187:-
HNSC	cis	rs6964587	1	rs6956596	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.2e-05	0.0023	-0.22	-0.2	Breast cancer;	chr7:92120793	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs6974607	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.2e-05	0.0023	-0.22	-0.2	Breast cancer;	chr7:92120802	chr7:92134604~92180725:+
HNSC	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-4.43	1.2e-05	0.00231	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
HNSC	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-4.43	1.2e-05	0.00231	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
HNSC	cis	rs721917	0.506	rs2758556	ENSG00000225484.5	NUTM2B-AS1	4.43	1.2e-05	0.00231	0.24	0.2	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79663088~79826594:-
HNSC	cis	rs1008375	0.932	rs9291660	ENSG00000249502.1	AC006160.5	-4.43	1.2e-05	0.00231	-0.23	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661791	chr4:17587467~17614571:-
HNSC	cis	rs6964587	1	rs2299232	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.2e-05	0.00231	-0.22	-0.2	Breast cancer;	chr7:91997385	chr7:92134604~92180725:+
HNSC	cis	rs9329221	0.537	rs1484640	ENSG00000269918.1	AF131215.9	4.43	1.2e-05	0.00231	0.2	0.2	Neuroticism;	chr8:10125733	chr8:11104691~11106704:-
HNSC	cis	rs911555	0.511	rs2296483	ENSG00000270108.1	RP11-73M18.6	4.43	1.2e-05	0.00231	0.22	0.2	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103687576~103688127:+
HNSC	cis	rs494003	0.951	rs11227302	ENSG00000255120.4	OVOL1-AS1	4.43	1.2e-05	0.00231	0.26	0.2	Systemic lupus erythematosus;	chr11:65787031	chr11:65789051~65790868:-
HNSC	cis	rs17345786	0.954	rs17508319	ENSG00000244119.1	PDCL3P4	4.43	1.2e-05	0.00231	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101712472~101713191:+
HNSC	cis	rs12701220	0.894	rs10263252	ENSG00000224079.1	AC091729.7	4.43	1.2e-05	0.00231	0.29	0.2	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1074450~1078036:+
HNSC	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-4.43	1.2e-05	0.00231	-0.23	-0.2	Height;	chr14:75119585	chr14:75011269~75012851:-
HNSC	cis	rs9298506	1	rs4455806	ENSG00000254142.2	RP11-53M11.3	4.43	1.2e-05	0.00231	0.3	0.2	Intracranial aneurysm;	chr8:54545313	chr8:54554361~54561927:+
HNSC	cis	rs9298506	1	rs10097401	ENSG00000254142.2	RP11-53M11.3	4.43	1.2e-05	0.00231	0.3	0.2	Intracranial aneurysm;	chr8:54548255	chr8:54554361~54561927:+
HNSC	cis	rs3736485	0.966	rs2414110	ENSG00000259438.1	CTD-2650P22.1	4.43	1.2e-05	0.00231	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51609105	chr15:52010999~52019095:-
HNSC	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-4.43	1.2e-05	0.00231	-0.25	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
HNSC	cis	rs12047808	0.544	rs3902993	ENSG00000227141.2	RP11-545A16.3	-4.42	1.2e-05	0.00231	-0.25	-0.2	Multiple sclerosis (age of onset);	chr1:179584291	chr1:179586705~179589175:+
HNSC	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	4.42	1.2e-05	0.00231	0.19	0.2	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000280411.1	IGHV1-69-2	-4.42	1.2e-05	0.00231	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106667442	chr14:106762092~106762588:-
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000280107.1	AL022393.9	-4.42	1.2e-05	0.00231	-0.25	-0.2	Parkinson's disease;	chr6:28134687	chr6:28170845~28172521:+
HNSC	cis	rs71520386	0.583	rs28799344	ENSG00000221740.1	SNORD93	-4.42	1.2e-05	0.00232	-0.22	-0.2	Fibrinogen levels;	chr7:22805647	chr7:22856613~22856686:+
HNSC	cis	rs71520386	0.583	rs35322907	ENSG00000221740.1	SNORD93	-4.42	1.2e-05	0.00232	-0.22	-0.2	Fibrinogen levels;	chr7:22806592	chr7:22856613~22856686:+
HNSC	cis	rs2286503	0.78	rs2286506	ENSG00000226329.2	AC005682.6	4.42	1.2e-05	0.00232	0.26	0.2	Fibrinogen;	chr7:22815196	chr7:22863874~22881350:-
HNSC	cis	rs2286503	0.752	rs2286504	ENSG00000226329.2	AC005682.6	4.42	1.2e-05	0.00232	0.26	0.2	Fibrinogen;	chr7:22815228	chr7:22863874~22881350:-
HNSC	cis	rs3736485	0.868	rs4774597	ENSG00000259438.1	CTD-2650P22.1	4.42	1.2e-05	0.00232	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51627459	chr15:52010999~52019095:-
HNSC	cis	rs9329221	0.527	rs34259385	ENSG00000269918.1	AF131215.9	-4.42	1.2e-05	0.00232	-0.21	-0.2	Neuroticism;	chr8:10467946	chr8:11104691~11106704:-
HNSC	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	4.42	1.21e-05	0.00232	0.25	0.2	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
HNSC	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	4.42	1.21e-05	0.00232	0.27	0.2	Pain;	chr19:21569087	chr19:21554640~21569237:-
HNSC	cis	rs5758511	0.524	rs738257	ENSG00000205702.9	CYP2D7	4.42	1.21e-05	0.00232	0.18	0.2	Birth weight;	chr22:42173292	chr22:42140203~42144577:-
HNSC	cis	rs9863	0.862	rs6488912	ENSG00000270028.1	RP11-380L11.4	4.42	1.21e-05	0.00232	0.23	0.2	White blood cell count;	chr12:123958205	chr12:123925461~123926083:-
HNSC	cis	rs6500395	1	rs2080508	ENSG00000261267.1	RP11-44I10.3	4.42	1.21e-05	0.00232	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48656754	chr16:48559661~48587403:+
HNSC	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	4.42	1.21e-05	0.00232	0.25	0.2	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
HNSC	cis	rs2243480	1	rs10807702	ENSG00000229886.1	RP5-1132H15.3	4.42	1.21e-05	0.00232	0.34	0.2	Diabetic kidney disease;	chr7:66302856	chr7:66025126~66031544:-
HNSC	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	4.42	1.21e-05	0.00232	0.26	0.2	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	4.42	1.21e-05	0.00232	0.26	0.2	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000219891.2	ZSCAN12P1	4.42	1.21e-05	0.00232	0.28	0.2	Parkinson's disease;	chr6:27891675	chr6:28091154~28093664:+
HNSC	cis	rs9959145	1	rs9959145	ENSG00000267249.1	RP11-973H7.3	-4.42	1.21e-05	0.00232	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12606464	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs111384103	ENSG00000267249.1	RP11-973H7.3	-4.42	1.21e-05	0.00232	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12606483	chr18:12670426~12671145:-
HNSC	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	4.42	1.21e-05	0.00232	0.2	0.2	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
HNSC	cis	rs4523957	0.855	rs216212	ENSG00000262333.1	HNRNPA1P16	-4.42	1.21e-05	0.00232	-0.16	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2230920	chr17:2306761~2307715:+
HNSC	cis	rs1125355	0.69	rs1356173	ENSG00000204380.3	AC005042.4	4.42	1.21e-05	0.00232	0.23	0.2	Alzheimer's disease in APOE e4+ carriers;	chr2:158795461	chr2:158658337~158735002:-
HNSC	cis	rs9368481	0.569	rs10946868	ENSG00000224843.5	LINC00240	-4.42	1.21e-05	0.00232	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26956992~27023924:+
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000219891.2	ZSCAN12P1	4.42	1.21e-05	0.00232	0.28	0.2	Parkinson's disease;	chr6:28002926	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000219891.2	ZSCAN12P1	4.42	1.21e-05	0.00232	0.28	0.2	Parkinson's disease;	chr6:28002927	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000219891.2	ZSCAN12P1	4.42	1.21e-05	0.00232	0.28	0.2	Parkinson's disease;	chr6:28007039	chr6:28091154~28093664:+
HNSC	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	4.42	1.21e-05	0.00232	0.27	0.2	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
HNSC	cis	rs3863381	0.656	rs73395348	ENSG00000277715.1	RP11-651L5.3	4.42	1.21e-05	0.00232	0.33	0.2	Night sleep phenotypes;	chr12:105722676	chr12:106250759~106252786:+
HNSC	cis	rs17253792	0.822	rs76267907	ENSG00000186615.9	KTN1-AS1	-4.42	1.21e-05	0.00232	-0.37	-0.2	Putamen volume;	chr14:55600251	chr14:55499278~55580110:-
HNSC	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	4.42	1.21e-05	0.00232	0.25	0.2	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
HNSC	cis	rs72843506	0.656	rs74333705	ENSG00000261033.1	RP11-209D14.2	4.42	1.21e-05	0.00232	0.37	0.2	Schizophrenia;	chr17:20097448	chr17:20008051~20009234:-
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	4.42	1.21e-05	0.00233	0.28	0.2	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	4.42	1.21e-05	0.00233	0.28	0.2	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
HNSC	cis	rs9304742	0.646	rs10408610	ENSG00000213801.4	ZNF816-ZNF321P	4.42	1.21e-05	0.00233	0.22	0.2	Psoriasis;	chr19:52960660	chr19:52927135~52942601:-
HNSC	cis	rs4356203	0.87	rs7936310	ENSG00000272034.1	SNORD14A	4.42	1.21e-05	0.00233	0.15	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17074654~17074744:-
HNSC	cis	rs11992162	1	rs7460395	ENSG00000269918.1	AF131215.9	4.42	1.21e-05	0.00233	0.2	0.2	Monocyte count;	chr8:11977866	chr8:11104691~11106704:-
HNSC	cis	rs721917	0.565	rs2255601	ENSG00000225484.5	NUTM2B-AS1	-4.42	1.21e-05	0.00233	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79663088~79826594:-
HNSC	cis	rs9487051	0.621	rs351737	ENSG00000243587.6	C6orf183	-4.42	1.21e-05	0.00233	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109184537	chr6:109165833~109271014:+
HNSC	cis	rs4862750	0.872	rs6821507	ENSG00000250971.1	RP11-696F12.1	-4.42	1.21e-05	0.00233	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:187060099~187060930:+
HNSC	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	4.42	1.21e-05	0.00233	0.28	0.2	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	4.42	1.21e-05	0.00233	0.28	0.2	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	4.42	1.21e-05	0.00233	0.28	0.2	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
HNSC	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	4.42	1.21e-05	0.00233	0.19	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
HNSC	cis	rs8054556	0.647	rs11863174	ENSG00000183604.13	SMG1P5	-4.42	1.21e-05	0.00233	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30267553~30335374:-
HNSC	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-4.42	1.21e-05	0.00233	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-4.42	1.21e-05	0.00233	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-4.42	1.21e-05	0.00233	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-4.42	1.21e-05	0.00233	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
HNSC	cis	rs4356203	0.678	rs1125737	ENSG00000272034.1	SNORD14A	-4.42	1.21e-05	0.00233	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17074654~17074744:-
HNSC	cis	rs1799949	0.929	rs12937015	ENSG00000236383.6	LINC00854	-4.42	1.21e-05	0.00233	-0.19	-0.2	Menopause (age at onset);	chr17:43155456	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4340367	ENSG00000236383.6	LINC00854	-4.42	1.21e-05	0.00233	-0.19	-0.2	Menopause (age at onset);	chr17:43155755	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4792981	ENSG00000236383.6	LINC00854	-4.42	1.21e-05	0.00233	-0.19	-0.2	Menopause (age at onset);	chr17:43156257	chr17:43216941~43305976:-
HNSC	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-4.42	1.21e-05	0.00233	-0.26	-0.2	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
HNSC	cis	rs7824557	0.527	rs2736305	ENSG00000269918.1	AF131215.9	-4.42	1.21e-05	0.00233	-0.2	-0.2	Retinal vascular caliber;	chr8:11380264	chr8:11104691~11106704:-
HNSC	cis	rs5758511	0.68	rs5751243	ENSG00000226450.2	CYP2D8P	4.42	1.21e-05	0.00233	0.19	0.2	Birth weight;	chr22:42221171	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.637	rs5751244	ENSG00000226450.2	CYP2D8P	4.42	1.21e-05	0.00233	0.19	0.2	Birth weight;	chr22:42221405	chr22:42149886~42155001:-
HNSC	cis	rs7171171	0.706	rs7164418	ENSG00000259747.1	RP11-275I4.2	-4.42	1.21e-05	0.00233	-0.25	-0.2	Type 1 diabetes;	chr15:38620621	chr15:38671847~38689191:+
HNSC	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	4.42	1.21e-05	0.00233	0.27	0.2	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
HNSC	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-4.42	1.21e-05	0.00233	-0.2	-0.2	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
HNSC	cis	rs8046011	0.537	rs55801751	ENSG00000280153.1	RP11-876N24.3	4.42	1.21e-05	0.00233	0.2	0.2	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11225472	chr16:10933903~10936280:+
HNSC	cis	rs11951515	0.508	rs7705166	ENSG00000249286.1	CTD-2210P15.2	4.42	1.21e-05	0.00233	0.2	0.2	Metabolite levels  (X-11787);	chr5:43587346	chr5:43586918~43588223:-
HNSC	cis	rs79349575	0.721	rs2291725	ENSG00000270781.1	RP11-501C14.9	-4.42	1.21e-05	0.00233	-0.21	-0.2	Type 2 diabetes;	chr17:48961770	chr17:48899131~48899748:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-4.42	1.21e-05	0.00233	-0.12	-0.2	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
HNSC	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.42	1.21e-05	0.00233	-0.22	-0.2	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
HNSC	cis	rs9321453	1	rs4896048	ENSG00000231971.4	RP11-557H15.3	4.42	1.21e-05	0.00233	0.24	0.2	Urate levels;	chr6:134449334	chr6:134428240~134520585:-
HNSC	cis	rs763512	0.504	rs853216	ENSG00000276054.1	RP11-378E13.3	4.42	1.22e-05	0.00234	0.28	0.2	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37502902	chr17:37386886~37387926:+
HNSC	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-4.42	1.22e-05	0.00234	-0.26	-0.2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
HNSC	cis	rs11722228	0.521	rs56403947	ENSG00000250413.1	RP11-448G15.1	-4.42	1.22e-05	0.00234	-0.31	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10110905	chr4:10006482~10009725:+
HNSC	cis	rs72843506	0.656	rs7225605	ENSG00000261033.1	RP11-209D14.2	4.42	1.22e-05	0.00234	0.33	0.2	Schizophrenia;	chr17:20083136	chr17:20008051~20009234:-
HNSC	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-4.42	1.22e-05	0.00234	-0.25	-0.2	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
HNSC	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-4.42	1.22e-05	0.00234	-0.25	-0.2	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
HNSC	cis	rs8028182	0.609	rs10220738	ENSG00000260269.4	CTD-2323K18.1	4.42	1.22e-05	0.00234	0.26	0.2	Sudden cardiac arrest;	chr15:75374205	chr15:75527150~75601205:-
HNSC	cis	rs253959	0.672	rs4920903	ENSG00000271918.1	CTD-2287O16.5	4.42	1.22e-05	0.00234	0.17	0.2	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116083807~116085416:-
HNSC	cis	rs7429990	0.965	rs7642590	ENSG00000228638.1	FCF1P2	4.42	1.22e-05	0.00234	0.19	0.2	Educational attainment (years of education);	chr3:48058260	chr3:48290793~48291375:-
HNSC	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-4.42	1.22e-05	0.00234	-0.23	-0.2	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
HNSC	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	4.42	1.22e-05	0.00234	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
HNSC	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	4.42	1.22e-05	0.00234	0.25	0.2	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
HNSC	cis	rs2337406	0.866	rs8016203	ENSG00000280411.1	IGHV1-69-2	-4.42	1.22e-05	0.00234	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106780575	chr14:106762092~106762588:-
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	4.42	1.22e-05	0.00234	0.24	0.2	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
HNSC	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	4.42	1.22e-05	0.00234	0.42	0.2	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
HNSC	cis	rs11673344	0.523	rs2562605	ENSG00000276846.1	CTD-3220F14.3	4.42	1.22e-05	0.00234	0.22	0.2	Obesity-related traits;	chr19:37029302	chr19:37314868~37315620:-
HNSC	cis	rs1008375	0.966	rs2315553	ENSG00000249502.1	AC006160.5	-4.42	1.22e-05	0.00234	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17625709	chr4:17587467~17614571:-
HNSC	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-4.42	1.22e-05	0.00234	-0.23	-0.2	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
HNSC	cis	rs6601327	0.551	rs13272424	ENSG00000254340.1	RP11-10A14.3	-4.42	1.22e-05	0.00235	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:9141424~9145435:+
HNSC	cis	rs11148252	0.574	rs73186430	ENSG00000198384.8	TPTE2P3	4.42	1.22e-05	0.00235	0.24	0.2	Lewy body disease;	chr13:52658756	chr13:52522632~52586906:+
HNSC	cis	rs1015213	1	rs16917014	ENSG00000272024.1	RP11-546K22.3	-4.42	1.22e-05	0.00235	-0.36	-0.2	Glaucoma (primary angle closure);	chr8:51978562	chr8:51950284~51950690:+
HNSC	cis	rs6601327	0.607	rs35316422	ENSG00000254340.1	RP11-10A14.3	-4.42	1.22e-05	0.00235	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9717619	chr8:9141424~9145435:+
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-4.42	1.22e-05	0.00235	-0.18	-0.2	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
HNSC	cis	rs36350	0.5	rs4569194	ENSG00000266869.1	RP6-114E22.1	-4.42	1.22e-05	0.00235	-0.25	-0.2	Autism spectrum disorder or schizophrenia;	chr14:71986673	chr14:71848606~71908430:+
HNSC	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	4.42	1.22e-05	0.00235	0.24	0.2	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
HNSC	cis	rs6964587	1	rs35653487	ENSG00000188693.7	CYP51A1-AS1	-4.42	1.22e-05	0.00235	-0.21	-0.2	Breast cancer;	chr7:92116127	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs2301559	ENSG00000188693.7	CYP51A1-AS1	-4.42	1.22e-05	0.00235	-0.21	-0.2	Breast cancer;	chr7:92117413	chr7:92134604~92180725:+
HNSC	cis	rs10435719	0.834	rs11250176	ENSG00000255495.1	AC145124.2	4.42	1.22e-05	0.00235	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12194467~12196280:+
HNSC	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-4.42	1.22e-05	0.00235	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
HNSC	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00235	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00235	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
HNSC	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	4.42	1.23e-05	0.00235	0.27	0.2	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
HNSC	cis	rs6163	0.588	rs67506723	ENSG00000213061.2	PFN1P11	4.42	1.23e-05	0.00235	0.24	0.2	Waist circumference;Hip circumference;	chr10:102749307	chr10:102838011~102845473:-
HNSC	cis	rs911555	0.57	rs752624	ENSG00000269958.1	RP11-73M18.8	4.42	1.23e-05	0.00235	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103554117	chr14:103696353~103697163:+
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-4.42	1.23e-05	0.00235	-0.23	-0.2	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
HNSC	cis	rs2439831	0.702	rs7171750	ENSG00000201136.1	RNU6-353P	-4.42	1.23e-05	0.00235	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43733660	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs11070408	ENSG00000201136.1	RNU6-353P	-4.42	1.23e-05	0.00235	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43742590	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs28718261	ENSG00000201136.1	RNU6-353P	-4.42	1.23e-05	0.00235	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43751595	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs28595038	ENSG00000201136.1	RNU6-353P	-4.42	1.23e-05	0.00235	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43752661	chr15:43702363~43702470:+
HNSC	cis	rs71520386	0.898	rs12536091	ENSG00000221740.1	SNORD93	-4.42	1.23e-05	0.00236	-0.26	-0.2	Fibrinogen levels;	chr7:22788581	chr7:22856613~22856686:+
HNSC	cis	rs763567	0.845	rs539045	ENSG00000271811.1	RP1-79C4.4	4.42	1.23e-05	0.00236	0.21	0.2	Tonsillectomy;	chr1:170638940	chr1:170667381~170669425:+
HNSC	cis	rs4938303	0.549	rs11216096	ENSG00000254851.1	RP11-109L13.1	4.42	1.23e-05	0.00236	0.3	0.2	Triglycerides;	chr11:116691864	chr11:117135528~117138582:+
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000255495.1	AC145124.2	4.42	1.23e-05	0.00236	0.22	0.2	Neuroticism;	chr8:11939481	chr8:12194467~12196280:+
HNSC	cis	rs2732480	0.557	rs2732441	ENSG00000257763.1	OR5BK1P	4.42	1.23e-05	0.00236	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.577	rs2732448	ENSG00000257763.1	OR5BK1P	4.42	1.23e-05	0.00236	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.577	rs2732466	ENSG00000257763.1	OR5BK1P	4.42	1.23e-05	0.00236	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.557	rs2634682	ENSG00000257763.1	OR5BK1P	4.42	1.23e-05	0.00236	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48355792~48356614:-
HNSC	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-4.42	1.23e-05	0.00236	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-4.42	1.23e-05	0.00236	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-4.42	1.23e-05	0.00236	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-4.42	1.23e-05	0.00236	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
HNSC	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-4.42	1.23e-05	0.00236	-0.24	-0.2	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
HNSC	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	4.42	1.23e-05	0.00236	0.2	0.2	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000219891.2	ZSCAN12P1	4.42	1.23e-05	0.00236	0.28	0.2	Parkinson's disease;	chr6:28053811	chr6:28091154~28093664:+
HNSC	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-4.42	1.23e-05	0.00236	-0.28	-0.2	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
HNSC	cis	rs7809950	0.678	rs2107317	ENSG00000238832.1	snoU109	-4.42	1.23e-05	0.00236	-0.29	-0.2	Coronary artery disease;	chr7:107259240	chr7:107603363~107603507:+
HNSC	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00236	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00236	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00236	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00236	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
HNSC	cis	rs4660214	0.724	rs11205695	ENSG00000182109.6	RP11-69E11.4	-4.42	1.23e-05	0.00236	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39522280~39546187:-
HNSC	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	4.42	1.23e-05	0.00236	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
HNSC	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-4.42	1.23e-05	0.00236	-0.23	-0.2	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
HNSC	cis	rs3736485	0.844	rs28680710	ENSG00000259438.1	CTD-2650P22.1	4.42	1.23e-05	0.00236	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51496794	chr15:52010999~52019095:-
HNSC	cis	rs2732480	0.967	rs2732469	ENSG00000257763.1	OR5BK1P	4.42	1.23e-05	0.00236	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48355792~48356614:-
HNSC	cis	rs1355223	0.506	rs7130774	ENSG00000271369.1	RP11-350D17.3	-4.42	1.23e-05	0.00236	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847720	chr11:34709600~34710161:+
HNSC	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-4.42	1.23e-05	0.00236	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
HNSC	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	4.42	1.23e-05	0.00236	0.13	0.2	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
HNSC	cis	rs3015497	0.527	rs2934672	ENSG00000277050.1	RP11-102G14.1	-4.42	1.23e-05	0.00236	-0.21	-0.2	Mean platelet volume;	chr14:50685754	chr14:51637348~51637947:-
HNSC	cis	rs7121616	0.576	rs4802	ENSG00000200879.1	SNORD14E	4.42	1.23e-05	0.00237	0.26	0.2	Breast cancer;	chr11:123057914	chr11:123058077~123058161:-
HNSC	cis	rs1823913	0.538	rs13432697	ENSG00000280083.1	RP11-317J9.1	-4.42	1.23e-05	0.00237	-0.23	-0.2	Obesity-related traits;	chr2:191345944	chr2:191154118~191156070:-
HNSC	cis	rs6601327	0.965	rs7016732	ENSG00000254340.1	RP11-10A14.3	-4.42	1.23e-05	0.00237	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9539717	chr8:9141424~9145435:+
HNSC	cis	rs7267979	0.657	rs6107073	ENSG00000204556.4	CTD-2514C3.1	-4.42	1.23e-05	0.00237	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26018832~26020684:+
HNSC	cis	rs3736485	0.844	rs28415556	ENSG00000259438.1	CTD-2650P22.1	4.42	1.24e-05	0.00237	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51468277	chr15:52010999~52019095:-
HNSC	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	4.42	1.24e-05	0.00237	0.2	0.2	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
HNSC	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	4.42	1.24e-05	0.00237	0.22	0.2	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	4.42	1.24e-05	0.00237	0.21	0.2	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
HNSC	cis	rs9393777	0.92	rs41269265	ENSG00000219392.1	RP1-265C24.5	-4.42	1.24e-05	0.00237	-0.4	-0.2	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28115628~28116551:+
HNSC	cis	rs3736485	0.844	rs8024506	ENSG00000259438.1	CTD-2650P22.1	4.42	1.24e-05	0.00237	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51500737	chr15:52010999~52019095:-
HNSC	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-4.42	1.24e-05	0.00237	-0.2	-0.2	Height;	chr5:37276224	chr5:36666214~36725195:-
HNSC	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	4.42	1.24e-05	0.00237	0.24	0.2	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
HNSC	cis	rs9880211	1	rs9841529	ENSG00000273486.1	RP11-731C17.2	4.42	1.24e-05	0.00237	0.19	0.2	Height;Body mass index;	chr3:136418441	chr3:136837338~136839021:-
HNSC	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	4.42	1.24e-05	0.00237	0.24	0.2	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
HNSC	cis	rs755249	0.508	rs10888688	ENSG00000182109.6	RP11-69E11.4	-4.42	1.24e-05	0.00237	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39522280~39546187:-
HNSC	cis	rs9287719	0.967	rs4470306	ENSG00000243819.4	RN7SL832P	4.42	1.24e-05	0.00237	0.19	0.2	Prostate cancer;	chr2:10603872	chr2:10690344~10692099:+
HNSC	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	4.42	1.24e-05	0.00237	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
HNSC	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-4.42	1.24e-05	0.00237	-0.27	-0.2	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	-4.42	1.24e-05	0.00237	-0.26	-0.2	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
HNSC	cis	rs9329221	0.537	rs6983332	ENSG00000269918.1	AF131215.9	-4.42	1.24e-05	0.00237	-0.2	-0.2	Neuroticism;	chr8:10120408	chr8:11104691~11106704:-
HNSC	cis	rs1065852	0.861	rs5758627	ENSG00000205702.9	CYP2D7	4.42	1.24e-05	0.00237	0.18	0.2	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42140203~42144577:-
HNSC	cis	rs964611	0.882	rs73406442	ENSG00000259488.2	RP11-154J22.1	-4.42	1.24e-05	0.00237	-0.2	-0.2	Metabolite levels (Pyroglutamine);	chr15:48354146	chr15:48312353~48331856:-
HNSC	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	4.42	1.24e-05	0.00237	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
HNSC	cis	rs12745968	0.589	rs3936944	ENSG00000223787.2	RP4-593M8.1	-4.42	1.24e-05	0.00237	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92641401	chr1:92580476~92580821:-
HNSC	cis	rs2055729	0.645	rs12543996	ENSG00000254340.1	RP11-10A14.3	-4.42	1.24e-05	0.00237	-0.28	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9885156	chr8:9141424~9145435:+
HNSC	cis	rs795484	0.926	rs556081	ENSG00000275409.1	RP11-131L12.4	4.42	1.24e-05	0.00237	0.23	0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118294870	chr12:118430147~118430699:+
HNSC	cis	rs6831352	1	rs1126670	ENSG00000263923.1	RP11-571L19.7	-4.42	1.24e-05	0.00237	-0.2	-0.2	Alcohol dependence;	chr4:99131582	chr4:98928897~98994994:+
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000254153.1	CTA-398F10.2	4.42	1.24e-05	0.00237	0.22	0.2	Mood instability;	chr8:8278888	chr8:8456909~8461337:-
HNSC	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	4.42	1.24e-05	0.00237	0.23	0.2	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
HNSC	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	4.42	1.24e-05	0.00237	0.2	0.2	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
HNSC	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-4.42	1.24e-05	0.00238	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
HNSC	cis	rs36052053	0.908	rs71558363	ENSG00000203799.9	CCDC162P	4.42	1.24e-05	0.00238	0.3	0.2	Red cell distribution width;	chr6:109283778	chr6:109285485~109355063:+
HNSC	cis	rs10504130	1	rs60304457	ENSG00000272024.1	RP11-546K22.3	-4.42	1.24e-05	0.00238	-0.34	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:51923541	chr8:51950284~51950690:+
HNSC	cis	rs9527	0.662	rs10786714	ENSG00000236937.2	PTGES3P4	4.42	1.24e-05	0.00238	0.27	0.2	Arsenic metabolism;	chr10:102838849	chr10:102845595~102845950:+
HNSC	cis	rs4523957	0.82	rs7212249	ENSG00000262333.1	HNRNPA1P16	4.42	1.24e-05	0.00238	0.16	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2232686	chr17:2306761~2307715:+
HNSC	cis	rs12935418	0.616	rs2549828	ENSG00000261061.1	RP11-303E16.2	4.42	1.24e-05	0.00238	0.21	0.2	Mean corpuscular volume;	chr16:80985378	chr16:81030770~81031485:+
HNSC	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	4.42	1.24e-05	0.00238	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
HNSC	cis	rs11633886	0.585	rs2460630	ENSG00000273972.1	CTD-2306A12.1	4.42	1.24e-05	0.00238	0.23	0.2	Diisocyanate-induced asthma;	chr15:45799596	chr15:45702640~45703183:+
HNSC	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	4.42	1.24e-05	0.00238	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
HNSC	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-4.42	1.24e-05	0.00238	-0.19	-0.2	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
HNSC	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	4.42	1.24e-05	0.00238	0.24	0.2	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
HNSC	cis	rs10927875	0.631	rs945418	ENSG00000226029.1	RP4-798A10.2	-4.42	1.24e-05	0.00238	-0.2	-0.2	Dilated cardiomyopathy;	chr1:16018235	chr1:16460948~16468481:+
HNSC	cis	rs3096299	0.967	rs28575874	ENSG00000261574.1	RP1-168P16.2	4.42	1.24e-05	0.00238	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89392375~89412564:-
HNSC	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-4.42	1.24e-05	0.00238	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-4.42	1.24e-05	0.00238	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-4.42	1.24e-05	0.00238	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
HNSC	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	4.42	1.24e-05	0.00238	0.22	0.2	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
HNSC	cis	rs9959145	0.925	rs75813125	ENSG00000267249.1	RP11-973H7.3	-4.42	1.24e-05	0.00238	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12612326	chr18:12670426~12671145:-
HNSC	cis	rs9959145	0.706	rs28663159	ENSG00000267249.1	RP11-973H7.3	-4.42	1.24e-05	0.00238	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12612441	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs28565322	ENSG00000267249.1	RP11-973H7.3	-4.42	1.24e-05	0.00238	-0.31	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12614184	chr18:12670426~12671145:-
HNSC	cis	rs394563	0.601	rs376269	ENSG00000231760.4	RP11-350J20.5	4.42	1.24e-05	0.00238	0.27	0.2	Dupuytren's disease;	chr6:149474018	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	4.42	1.25e-05	0.00238	0.24	0.2	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
HNSC	cis	rs9368481	0.524	rs9393768	ENSG00000224843.5	LINC00240	-4.42	1.25e-05	0.00238	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26956992~27023924:+
HNSC	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	4.42	1.25e-05	0.00238	0.19	0.2	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
HNSC	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-4.42	1.25e-05	0.00238	-0.22	-0.2	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
HNSC	cis	rs1008375	1	rs4642241	ENSG00000249502.1	AC006160.5	-4.42	1.25e-05	0.00239	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17615488	chr4:17587467~17614571:-
HNSC	cis	rs13434995	0.513	rs10462033	ENSG00000273257.1	RP11-177J6.1	-4.42	1.25e-05	0.00239	-0.27	-0.2	Adiponectin levels;	chr4:55511552	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs1915905	ENSG00000273257.1	RP11-177J6.1	-4.42	1.25e-05	0.00239	-0.27	-0.2	Adiponectin levels;	chr4:55512381	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs1522109	ENSG00000273257.1	RP11-177J6.1	-4.42	1.25e-05	0.00239	-0.27	-0.2	Adiponectin levels;	chr4:55514403	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs6554282	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55519812	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs6554283	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55521053	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs1546004	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55521612	chr4:55387949~55388271:+
HNSC	cis	rs12935418	0.616	rs2549855	ENSG00000278985.1	RP11-303E16.9	4.42	1.25e-05	0.00239	0.19	0.2	Mean corpuscular volume;	chr16:80993247	chr16:80982319~80984094:-
HNSC	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-4.42	1.25e-05	0.00239	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
HNSC	cis	rs5758511	0.514	rs5758626	ENSG00000205702.9	CYP2D7	4.42	1.25e-05	0.00239	0.18	0.2	Birth weight;	chr22:42176357	chr22:42140203~42144577:-
HNSC	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	4.42	1.25e-05	0.00239	0.23	0.2	Height;	chr14:75125780	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	4.42	1.25e-05	0.00239	0.23	0.2	Height;	chr14:75128451	chr14:75011269~75012851:-
HNSC	cis	rs36052053	0.521	rs71558353	ENSG00000219700.1	PTCHD3P3	4.42	1.25e-05	0.00239	0.39	0.2	Red cell distribution width;	chr6:109201315	chr6:109288571~109290503:-
HNSC	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	4.42	1.25e-05	0.00239	0.21	0.2	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
HNSC	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	4.42	1.25e-05	0.00239	0.27	0.2	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
HNSC	cis	rs7086627	0.515	rs2125040	ENSG00000226659.1	RP11-137H2.4	-4.42	1.25e-05	0.00239	-0.25	-0.2	Post bronchodilator FEV1;	chr10:80448666	chr10:80529597~80535942:-
HNSC	cis	rs929354	0.553	rs34498858	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157138643	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs10274687	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157140487	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.685	rs7807856	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157141804	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs6459734	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157142760	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.605	rs7806314	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157154209	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.742	rs7806775	ENSG00000224629.1	RP5-1142J19.2	-4.42	1.25e-05	0.00239	-0.2	-0.2	Body mass index;	chr7:157154505	chr7:157263022~157263229:-
HNSC	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-4.42	1.25e-05	0.00239	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
HNSC	cis	rs7512552	0.966	rs10788873	ENSG00000228126.1	FALEC	-4.42	1.25e-05	0.00239	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150278123	chr1:150515757~150518032:+
HNSC	cis	rs964611	0.882	rs3784616	ENSG00000259488.2	RP11-154J22.1	-4.42	1.25e-05	0.00239	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48278381	chr15:48312353~48331856:-
HNSC	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	4.42	1.25e-05	0.00239	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
HNSC	cis	rs7324557	1	rs7324557	ENSG00000205861.10	C1QTNF9B-AS1	4.42	1.25e-05	0.00239	0.26	0.2	Visceral adipose tissue adjusted for BMI;	chr13:23722723	chr13:23888889~23897263:+
HNSC	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	4.42	1.25e-05	0.00239	0.22	0.2	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
HNSC	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	4.42	1.25e-05	0.00239	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
HNSC	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	4.42	1.25e-05	0.00239	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
HNSC	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	4.42	1.25e-05	0.00239	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
HNSC	cis	rs7572733	0.935	rs771010	ENSG00000222017.1	AC011997.1	-4.42	1.25e-05	0.00239	-0.24	-0.2	Dermatomyositis;	chr2:197826282	chr2:197693106~197774823:+
HNSC	cis	rs13434995	0.537	rs4865012	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55554619	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs6846764	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55557322	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs6853506	ENSG00000273257.1	RP11-177J6.1	4.42	1.25e-05	0.00239	0.27	0.2	Adiponectin levels;	chr4:55558207	chr4:55387949~55388271:+
HNSC	cis	rs1602565	0.925	rs7931008	ENSG00000255450.1	CTD-2063L20.1	-4.42	1.25e-05	0.00239	-0.31	-0.2	Schizophrenia;	chr11:29138819	chr11:29275655~29276565:+
HNSC	cis	rs2548724	0.509	rs1580038	ENSG00000250682.4	LINC00491	4.42	1.25e-05	0.0024	0.26	0.2	Type 2 diabetes;	chr5:102382180	chr5:102609156~102671559:-
HNSC	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-4.42	1.25e-05	0.0024	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
HNSC	cis	rs4834770	0.792	rs6823331	ENSG00000249244.1	RP11-548H18.2	4.42	1.25e-05	0.0024	0.23	0.2	Blood protein levels;	chr4:119259635	chr4:119391831~119395335:-
HNSC	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-4.42	1.25e-05	0.0024	-0.23	-0.2	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
HNSC	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-4.42	1.25e-05	0.0024	-0.26	-0.2	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	4.42	1.25e-05	0.0024	0.28	0.2	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
HNSC	cis	rs2998286	0.723	rs332162	ENSG00000254635.4	WAC-AS1	-4.42	1.25e-05	0.0024	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599960	chr10:28522652~28532743:-
HNSC	cis	rs9329221	0.506	rs17689674	ENSG00000269918.1	AF131215.9	4.42	1.25e-05	0.0024	0.2	0.2	Neuroticism;	chr8:10124344	chr8:11104691~11106704:-
HNSC	cis	rs4253772	0.614	rs11090859	ENSG00000277232.2	GTSE1-AS1	-4.42	1.25e-05	0.0024	-0.25	-0.2	Cholesterol, total;LDL cholesterol;	chr22:46291563	chr22:46295143~46296660:-
HNSC	cis	rs7085104	0.66	rs7902804	ENSG00000213061.2	PFN1P11	4.42	1.26e-05	0.0024	0.25	0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102838011~102845473:-
HNSC	cis	rs42490	0.664	rs453266	ENSG00000251136.7	RP11-37B2.1	-4.42	1.26e-05	0.0024	-0.17	-0.2	Leprosy;	chr8:89823789	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.638	rs369771	ENSG00000251136.7	RP11-37B2.1	-4.42	1.26e-05	0.0024	-0.17	-0.2	Leprosy;	chr8:89823884	chr8:89609409~89757727:-
HNSC	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-4.42	1.26e-05	0.0024	-0.25	-0.2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
HNSC	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-4.42	1.26e-05	0.0024	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
HNSC	cis	rs6964587	1	rs10281556	ENSG00000188693.7	CYP51A1-AS1	4.41	1.26e-05	0.0024	0.21	0.2	Breast cancer;	chr7:92030739	chr7:92134604~92180725:+
HNSC	cis	rs467650	0.529	rs2549200	ENSG00000246763.5	RGMB-AS1	-4.41	1.26e-05	0.0024	-0.23	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98660644	chr5:98769618~98773469:-
HNSC	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-4.41	1.26e-05	0.0024	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
HNSC	cis	rs10462794	0.789	rs4458551	ENSG00000260763.1	RP11-445O3.3	4.41	1.26e-05	0.0024	0.25	0.2	DNA methylation (variation);	chr5:4486738	chr5:4436850~4440259:-
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-4.41	1.26e-05	0.0024	-0.23	-0.2	Depression;	chr6:28206179	chr6:28170845~28172521:+
HNSC	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	4.41	1.26e-05	0.0024	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
HNSC	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	4.41	1.26e-05	0.00241	0.19	0.2	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
HNSC	cis	rs17594362	0.943	rs12430833	ENSG00000229473.2	RGS17P1	-4.41	1.26e-05	0.00241	-0.31	-0.2	Multiple sclerosis;	chr13:41572911	chr13:40992779~40993331:-
HNSC	cis	rs1015213	1	rs16917012	ENSG00000272024.1	RP11-546K22.3	-4.41	1.26e-05	0.00241	-0.33	-0.2	Glaucoma (primary angle closure);	chr8:51978515	chr8:51950284~51950690:+
HNSC	cis	rs11673344	0.504	rs1667378	ENSG00000276846.1	CTD-3220F14.3	4.41	1.26e-05	0.00241	0.22	0.2	Obesity-related traits;	chr19:37001171	chr19:37314868~37315620:-
HNSC	cis	rs2136613	0.703	rs10761675	ENSG00000238280.1	RP11-436D10.3	-4.41	1.26e-05	0.00241	-0.24	-0.2	Selective IgA deficiency;	chr10:62863436	chr10:62793562~62805887:-
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000248280.1	RP11-33B1.2	4.41	1.26e-05	0.00241	0.24	0.2	Corneal astigmatism;	chr4:119401102	chr4:119440561~119450157:-
HNSC	cis	rs72843506	0.656	rs10459970	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20034028	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs2385960	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20034904	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs8073875	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20035746	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs57040439	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20036522	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs58313980	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20036737	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.656	rs73984559	ENSG00000261033.1	RP11-209D14.2	4.41	1.26e-05	0.00241	0.33	0.2	Schizophrenia;	chr17:20043203	chr17:20008051~20009234:-
HNSC	cis	rs757081	0.606	rs679201	ENSG00000260196.1	RP1-239B22.5	-4.41	1.26e-05	0.00241	-0.24	-0.2	Systolic blood pressure;	chr11:17179344	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.702	rs522619	ENSG00000260196.1	RP1-239B22.5	-4.41	1.26e-05	0.00241	-0.24	-0.2	Systolic blood pressure;	chr11:17182901	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.643	rs665311	ENSG00000260196.1	RP1-239B22.5	-4.41	1.26e-05	0.00241	-0.24	-0.2	Systolic blood pressure;	chr11:17185193	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs569780	ENSG00000260196.1	RP1-239B22.5	-4.41	1.26e-05	0.00241	-0.24	-0.2	Systolic blood pressure;	chr11:17185198	chr11:17380649~17383531:+
HNSC	cis	rs6964587	0.967	rs41371748	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.26e-05	0.00241	-0.22	-0.2	Breast cancer;	chr7:92078905	chr7:92134604~92180725:+
HNSC	cis	rs36052053	0.521	rs71558350	ENSG00000219700.1	PTCHD3P3	4.41	1.26e-05	0.00241	0.39	0.2	Red cell distribution width;	chr6:109193340	chr6:109288571~109290503:-
HNSC	cis	rs1008375	0.932	rs9283698	ENSG00000249502.1	AC006160.5	-4.41	1.26e-05	0.00241	-0.23	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660848	chr4:17587467~17614571:-
HNSC	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	4.41	1.26e-05	0.00241	0.23	0.2	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
HNSC	cis	rs1979679	0.918	rs11049513	ENSG00000247934.4	RP11-967K21.1	-4.41	1.26e-05	0.00241	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28163298~28190738:-
HNSC	cis	rs9527	0.571	rs3740400	ENSG00000236937.2	PTGES3P4	4.41	1.26e-05	0.00241	0.25	0.2	Arsenic metabolism;	chr10:102869708	chr10:102845595~102845950:+
HNSC	cis	rs9527	0.571	rs7904113	ENSG00000236937.2	PTGES3P4	4.41	1.26e-05	0.00241	0.25	0.2	Arsenic metabolism;	chr10:102873357	chr10:102845595~102845950:+
HNSC	cis	rs9287719	0.967	rs715247	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10596165	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs715246	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10596229	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2010073	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10596352	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2010080	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10596426	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.901	rs6432109	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10596695	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7592691	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10597300	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs6432110	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10597892	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7605461	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598008	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7593496	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598050	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7608498	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598302	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7582775	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598323	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6750891	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598437	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6733416	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598558	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6751398	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10598846	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.901	rs13034017	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599466	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs13034061	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599525	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.935	rs7600495	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599674	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7600587	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599725	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.839	rs7600695	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599819	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7587114	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599837	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7600728	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599873	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7600820	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599918	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7587231	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10599967	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4668691	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10600368	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs10181806	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10601015	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs11687023	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10601286	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs10454738	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10601923	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6706542	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10602365	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2287061	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10603027	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs2287062	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10603065	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.935	rs1309	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10603420	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs3815521	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10603528	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs10929686	ENSG00000243819.4	RN7SL832P	4.41	1.26e-05	0.00241	0.19	0.2	Prostate cancer;	chr2:10603579	chr2:10690344~10692099:+
HNSC	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	4.41	1.26e-05	0.00241	0.23	0.2	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
HNSC	cis	rs8177876	0.658	rs12456	ENSG00000261061.1	RP11-303E16.2	-4.41	1.26e-05	0.00241	-0.34	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81030770~81031485:+
HNSC	cis	rs7475343	0.501	rs80079690	ENSG00000224034.1	RP11-445P17.8	-4.41	1.26e-05	0.00241	-0.28	-0.2	Intelligence;	chr10:5258474	chr10:5266033~5271236:-
HNSC	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	4.41	1.26e-05	0.00241	0.21	0.2	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
HNSC	cis	rs2439831	0.85	rs7169988	ENSG00000201136.1	RNU6-353P	-4.41	1.26e-05	0.00241	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43768237	chr15:43702363~43702470:+
HNSC	cis	rs9914988	0.613	rs4794842	ENSG00000264577.1	AC010761.8	4.41	1.26e-05	0.00241	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28963733	chr17:28721487~28722877:-
HNSC	cis	rs10266483	0.545	rs116760071	ENSG00000228653.2	HNRNPCP7	4.41	1.26e-05	0.00241	0.24	0.2	Response to statin therapy;	chr7:64289082	chr7:64500825~64501729:+
HNSC	cis	rs9903692	0.909	rs11079806	ENSG00000263412.1	RP5-890E16.2	-4.41	1.26e-05	0.00241	-0.19	-0.2	Pulse pressure;	chr17:48065318	chr17:48045141~48048073:-
HNSC	cis	rs516805	0.665	rs517427	ENSG00000279453.1	RP3-425C14.4	-4.41	1.26e-05	0.00241	-0.27	-0.2	Lymphocyte counts;	chr6:122291180	chr6:122436789~122439223:-
HNSC	cis	rs12893668	0.673	rs2296482	ENSG00000269910.1	RP11-73M18.10	4.41	1.27e-05	0.00241	0.2	0.2	Reticulocyte count;	chr14:103563482	chr14:103694516~103695050:-
HNSC	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	4.41	1.27e-05	0.00242	0.25	0.2	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
HNSC	cis	rs12893668	0.638	rs11851616	ENSG00000269940.1	RP11-73M18.7	4.41	1.27e-05	0.00242	0.2	0.2	Reticulocyte count;	chr14:103599263	chr14:103694560~103695170:+
HNSC	cis	rs7121616	1	rs7113273	ENSG00000200879.1	SNORD14E	-4.41	1.27e-05	0.00242	-0.24	-0.2	Breast cancer;	chr11:123092192	chr11:123058077~123058161:-
HNSC	cis	rs6490294	0.799	rs73424286	ENSG00000226469.1	ADAM1B	4.41	1.27e-05	0.00242	0.23	0.2	Mean platelet volume;	chr12:111889338	chr12:111927018~111929017:+
HNSC	cis	rs2974760	0.606	rs6600143	ENSG00000268836.1	LA16c-OS12.2	-4.41	1.27e-05	0.00242	-0.22	-0.2	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:185748~186294:-
HNSC	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	4.41	1.27e-05	0.00242	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
HNSC	cis	rs853679	0.546	rs71537572	ENSG00000204709.4	LINC01556	4.41	1.27e-05	0.00242	0.41	0.2	Depression;	chr6:28002937	chr6:28943877~28944537:+
HNSC	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-4.41	1.27e-05	0.00242	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-4.41	1.27e-05	0.00242	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
HNSC	cis	rs4356203	0.783	rs7113964	ENSG00000272034.1	SNORD14A	-4.41	1.27e-05	0.00242	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17074654~17074744:-
HNSC	cis	rs9863	0.827	rs6488913	ENSG00000270028.1	RP11-380L11.4	-4.41	1.27e-05	0.00242	-0.23	-0.2	White blood cell count;	chr12:123961022	chr12:123925461~123926083:-
HNSC	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-4.41	1.27e-05	0.00242	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-4.41	1.27e-05	0.00242	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
HNSC	cis	rs9907295	0.579	rs9899866	ENSG00000270977.1	AC015849.16	4.41	1.27e-05	0.00242	0.34	0.2	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35893707~35911023:-
HNSC	cis	rs7773987	1	rs7773987	ENSG00000217482.2	HMGB1P17	-4.41	1.27e-05	0.00242	-0.22	-0.2	Selective IgA deficiency;	chr6:135386348	chr6:135636086~135636713:-
HNSC	cis	rs4256159	0.866	rs9834151	ENSG00000228956.7	SATB1-AS1	4.41	1.27e-05	0.00242	0.32	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18773126	chr3:18445024~18920401:+
HNSC	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-4.41	1.27e-05	0.00242	-0.23	-0.2	Height;	chr14:75071514	chr14:75011269~75012851:-
HNSC	cis	rs4699052	0.59	rs1356293	ENSG00000246560.2	RP11-10L12.4	4.41	1.27e-05	0.00242	0.23	0.2	Testicular germ cell tumor;	chr4:103367043	chr4:102828055~102844075:+
HNSC	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-4.41	1.27e-05	0.00242	-0.16	-0.2	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
HNSC	cis	rs73222236	0.825	rs9850383	ENSG00000273486.1	RP11-731C17.2	4.41	1.27e-05	0.00242	0.17	0.2	Coronary artery disease;	chr3:136462601	chr3:136837338~136839021:-
HNSC	cis	rs17345786	1	rs3804778	ENSG00000244119.1	PDCL3P4	4.41	1.27e-05	0.00242	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101712472~101713191:+
HNSC	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-4.41	1.27e-05	0.00242	-0.23	-0.2	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
HNSC	cis	rs42490	0.664	rs376110	ENSG00000251136.7	RP11-37B2.1	-4.41	1.27e-05	0.00243	-0.17	-0.2	Leprosy;	chr8:89819362	chr8:89609409~89757727:-
HNSC	cis	rs4578769	0.531	rs9951973	ENSG00000265943.1	RP11-739L10.1	-4.41	1.27e-05	0.00243	-0.24	-0.2	Eosinophil percentage of white cells;	chr18:22974353	chr18:22699481~22933764:-
HNSC	cis	rs9311676	0.632	rs6785572	ENSG00000273493.1	RP11-80H18.4	-4.41	1.27e-05	0.00243	-0.22	-0.2	Systemic lupus erythematosus;	chr3:58375790	chr3:58329965~58330118:+
HNSC	cis	rs757081	0.637	rs586785	ENSG00000260196.1	RP1-239B22.5	-4.41	1.27e-05	0.00243	-0.24	-0.2	Systolic blood pressure;	chr11:17187167	chr11:17380649~17383531:+
HNSC	cis	rs11633886	0.528	rs2899383	ENSG00000273972.1	CTD-2306A12.1	4.41	1.27e-05	0.00243	0.23	0.2	Diisocyanate-induced asthma;	chr15:45804853	chr15:45702640~45703183:+
HNSC	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	4.41	1.27e-05	0.00243	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
HNSC	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-4.41	1.27e-05	0.00243	-0.25	-0.2	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
HNSC	cis	rs4787951	0.698	rs12933283	ENSG00000259940.2	CTD-3203P2.1	-4.41	1.27e-05	0.00243	-0.23	-0.2	Eosinophil percentage of white cells;	chr16:27308057	chr16:27213308~27214993:-
HNSC	cis	rs17412738	0.607	rs10512843	ENSG00000248724.5	NPHP3-AS1	-4.41	1.27e-05	0.00243	-0.33	-0.2	Blood protein levels;	chr3:132448983	chr3:132721750~132874223:+
HNSC	cis	rs11673344	0.504	rs2595555	ENSG00000276846.1	CTD-3220F14.3	4.41	1.27e-05	0.00243	0.22	0.2	Obesity-related traits;	chr19:37000219	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs1667377	ENSG00000276846.1	CTD-3220F14.3	4.41	1.27e-05	0.00243	0.22	0.2	Obesity-related traits;	chr19:37000966	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs1667379	ENSG00000276846.1	CTD-3220F14.3	4.41	1.27e-05	0.00243	0.22	0.2	Obesity-related traits;	chr19:37001192	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.701	rs2005643	ENSG00000211974.3	IGHV2-70	4.41	1.27e-05	0.00243	0.18	0.2	Kawasaki disease;	chr14:106676288	chr14:106723574~106724093:-
HNSC	cis	rs12935418	0.616	rs2602446	ENSG00000261061.1	RP11-303E16.2	4.41	1.27e-05	0.00243	0.21	0.2	Mean corpuscular volume;	chr16:80984310	chr16:81030770~81031485:+
HNSC	cis	rs72843506	0.656	rs9901357	ENSG00000261033.1	RP11-209D14.2	4.41	1.27e-05	0.00243	0.34	0.2	Schizophrenia;	chr17:20105729	chr17:20008051~20009234:-
HNSC	cis	rs2998286	0.723	rs332139	ENSG00000254635.4	WAC-AS1	-4.41	1.27e-05	0.00243	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28522652~28532743:-
HNSC	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	4.41	1.27e-05	0.00243	0.27	0.2	Pain;	chr19:21516423	chr19:21554640~21569237:-
HNSC	cis	rs56804039	0.895	rs11776995	ENSG00000173295.6	FAM86B3P	-4.41	1.27e-05	0.00243	-0.26	-0.2	Cervical cancer;	chr8:8528037	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs13281933	ENSG00000173295.6	FAM86B3P	4.41	1.28e-05	0.00243	0.26	0.2	Obesity-related traits;	chr8:8705155	chr8:8228595~8244865:+
HNSC	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.28e-05	0.00243	-0.2	-0.2	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
HNSC	cis	rs4699052	0.59	rs1156669	ENSG00000246560.2	RP11-10L12.4	4.41	1.28e-05	0.00243	0.23	0.2	Testicular germ cell tumor;	chr4:103367047	chr4:102828055~102844075:+
HNSC	cis	rs3015497	0.549	rs10133807	ENSG00000277050.1	RP11-102G14.1	-4.41	1.28e-05	0.00243	-0.21	-0.2	Mean platelet volume;	chr14:50684804	chr14:51637348~51637947:-
HNSC	cis	rs116095464	0.558	rs7703803	ENSG00000250848.1	CTD-2083E4.5	-4.41	1.28e-05	0.00243	-0.28	-0.2	Breast cancer;	chr5:292196	chr5:288833~290321:-
HNSC	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-4.41	1.28e-05	0.00243	-0.19	-0.2	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
HNSC	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-4.41	1.28e-05	0.00244	-0.17	-0.2	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
HNSC	cis	rs42490	0.664	rs39515	ENSG00000251136.7	RP11-37B2.1	-4.41	1.28e-05	0.00244	-0.17	-0.2	Leprosy;	chr8:89816761	chr8:89609409~89757727:-
HNSC	cis	rs916888	0.821	rs199512	ENSG00000260075.1	NSFP1	4.41	1.28e-05	0.00244	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46372855~46487141:+
HNSC	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.41	1.28e-05	0.00244	0.23	0.2	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
HNSC	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	4.41	1.28e-05	0.00244	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
HNSC	cis	rs516805	0.667	rs7771090	ENSG00000279453.1	RP3-425C14.4	-4.41	1.28e-05	0.00244	-0.27	-0.2	Lymphocyte counts;	chr6:122339732	chr6:122436789~122439223:-
HNSC	cis	rs889398	0.741	rs6499269	ENSG00000226232.7	RP11-419C5.2	-4.41	1.28e-05	0.00244	-0.18	-0.2	Body mass index;	chr16:69875015	chr16:69976388~69996188:-
HNSC	cis	rs2253762	0.54	rs12249581	ENSG00000226864.1	ATE1-AS1	4.41	1.28e-05	0.00244	0.35	0.2	Breast cancer;	chr10:122013486	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs79586669	ENSG00000226864.1	ATE1-AS1	4.41	1.28e-05	0.00244	0.35	0.2	Breast cancer;	chr10:122015153	chr10:121928312~121951965:+
HNSC	cis	rs2548724	0.716	rs6884141	ENSG00000250682.4	LINC00491	4.41	1.28e-05	0.00244	0.28	0.2	Type 2 diabetes;	chr5:102480400	chr5:102609156~102671559:-
HNSC	cis	rs6500395	0.926	rs8057777	ENSG00000261267.1	RP11-44I10.3	-4.41	1.28e-05	0.00244	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48531732	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9938126	ENSG00000261267.1	RP11-44I10.3	-4.41	1.28e-05	0.00244	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48538210	chr16:48559661~48587403:+
HNSC	cis	rs1552244	0.935	rs2272124	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10096505	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs55882090	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10097398	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7622963	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10098141	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs34179822	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10098333	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.938	rs7647987	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10099012	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs3826	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10099381	chr3:9986893~10006990:+
HNSC	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	4.41	1.28e-05	0.00244	0.34	0.2	QT interval;	chr4:75125224	chr4:75081702~75084717:-
HNSC	cis	rs9300255	0.544	rs1790123	ENSG00000280120.1	RP11-546D6.3	4.41	1.28e-05	0.00244	0.19	0.2	Neutrophil percentage of white cells;	chr12:123174995	chr12:123152324~123153377:-
HNSC	cis	rs7572733	0.935	rs6742782	ENSG00000222017.1	AC011997.1	4.41	1.28e-05	0.00244	0.24	0.2	Dermatomyositis;	chr2:197890297	chr2:197693106~197774823:+
HNSC	cis	rs3736485	0.578	rs11638106	ENSG00000259438.1	CTD-2650P22.1	4.41	1.28e-05	0.00244	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677098	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.609	rs11631725	ENSG00000259438.1	CTD-2650P22.1	4.41	1.28e-05	0.00244	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677277	chr15:52010999~52019095:-
HNSC	cis	rs9880211	1	rs9828088	ENSG00000273486.1	RP11-731C17.2	4.41	1.28e-05	0.00244	0.19	0.2	Height;Body mass index;	chr3:136528948	chr3:136837338~136839021:-
HNSC	cis	rs8074700	1	rs11654007	ENSG00000239552.2	HOXB-AS2	-4.41	1.28e-05	0.00244	-0.21	-0.2	Body mass index in non-asthmatics;	chr17:48671375	chr17:48557262~48560333:+
HNSC	cis	rs6964587	0.967	rs6970743	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.28e-05	0.00244	-0.21	-0.2	Breast cancer;	chr7:92114997	chr7:92134604~92180725:+
HNSC	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	4.41	1.28e-05	0.00244	0.24	0.2	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	4.41	1.28e-05	0.00244	0.24	0.2	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
HNSC	cis	rs6964587	0.773	rs13223564	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.28e-05	0.00244	-0.22	-0.2	Breast cancer;	chr7:92303352	chr7:92134604~92180725:+
HNSC	cis	rs7086627	0.515	rs7088877	ENSG00000226659.1	RP11-137H2.4	-4.41	1.28e-05	0.00244	-0.25	-0.2	Post bronchodilator FEV1;	chr10:80449104	chr10:80529597~80535942:-
HNSC	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	4.41	1.28e-05	0.00244	0.2	0.2	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
HNSC	cis	rs1552244	1	rs12152512	ENSG00000180385.7	EMC3-AS1	4.41	1.28e-05	0.00244	0.22	0.2	Alzheimer's disease;	chr3:10102086	chr3:9986893~10006990:+
HNSC	cis	rs5758659	0.622	rs6519298	ENSG00000227370.1	RP4-669P10.19	-4.41	1.28e-05	0.00244	-0.19	-0.2	Cognitive function;	chr22:41968993	chr22:42132543~42132998:+
HNSC	cis	rs79349575	0.783	rs4255820	ENSG00000270781.1	RP11-501C14.9	-4.41	1.28e-05	0.00244	-0.21	-0.2	Type 2 diabetes;	chr17:48919221	chr17:48899131~48899748:+
HNSC	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-4.41	1.28e-05	0.00244	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
HNSC	cis	rs11846409	0.932	rs2015469	ENSG00000254174.1	IGHV1-12	4.41	1.28e-05	0.00244	0.15	0.2	Rheumatic heart disease;	chr14:106631857	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs56167903	ENSG00000254174.1	IGHV1-12	4.41	1.28e-05	0.00244	0.15	0.2	Rheumatic heart disease;	chr14:106632070	chr14:106122420~106122709:-
HNSC	cis	rs9584850	0.834	rs745638	ENSG00000231194.1	FARP1-AS1	-4.41	1.28e-05	0.00244	-0.25	-0.2	Neuroticism;	chr13:98467053	chr13:98435405~98435840:-
HNSC	cis	rs12935418	0.616	rs1127390	ENSG00000261061.1	RP11-303E16.2	-4.41	1.28e-05	0.00244	-0.21	-0.2	Mean corpuscular volume;	chr16:80976176	chr16:81030770~81031485:+
HNSC	cis	rs9287719	0.967	rs4519489	ENSG00000243819.4	RN7SL832P	4.41	1.28e-05	0.00244	0.19	0.2	Prostate cancer;	chr2:10598961	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4453662	ENSG00000243819.4	RN7SL832P	4.41	1.28e-05	0.00244	0.19	0.2	Prostate cancer;	chr2:10599002	chr2:10690344~10692099:+
HNSC	cis	rs12701220	0.689	rs12701824	ENSG00000229043.2	AC091729.9	-4.41	1.28e-05	0.00244	-0.3	-0.2	Bronchopulmonary dysplasia;	chr7:1062728	chr7:1160374~1165267:+
HNSC	cis	rs9329221	0.521	rs17693945	ENSG00000269918.1	AF131215.9	-4.41	1.28e-05	0.00244	-0.21	-0.2	Neuroticism;	chr8:10248500	chr8:11104691~11106704:-
HNSC	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	4.41	1.28e-05	0.00244	0.29	0.2	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
HNSC	cis	rs9311676	0.609	rs55797456	ENSG00000273493.1	RP11-80H18.4	4.41	1.28e-05	0.00245	0.22	0.2	Systemic lupus erythematosus;	chr3:58392479	chr3:58329965~58330118:+
HNSC	cis	rs9287719	0.967	rs6744599	ENSG00000243819.4	RN7SL832P	-4.41	1.28e-05	0.00245	-0.19	-0.2	Prostate cancer;	chr2:10606887	chr2:10690344~10692099:+
HNSC	cis	rs728616	0.867	rs28365998	ENSG00000225484.5	NUTM2B-AS1	-4.41	1.28e-05	0.00245	-0.49	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:79663088~79826594:-
HNSC	cis	rs739496	0.579	rs7980569	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111843580	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7970847	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111843689	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs3782885	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111844779	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs11066046	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111846077	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs2158030	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111847787	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.799	rs7315642	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Mean platelet volume;	chr12:111848992	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12302040	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111850375	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12322899	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111850398	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12307192	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111852542	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12307365	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111852847	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs6489817	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111853438	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7296199	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111854040	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs12313385	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111854343	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7310605	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111854666	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs57427612	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111856192	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7976557	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111862976	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs11066054	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111868361	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7297760	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111875884	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.799	rs12426566	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Mean platelet volume;	chr12:111877368	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs2097701	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111878970	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7294623	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111879292	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs16941703	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111880930	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.527	rs61440627	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00245	0.23	0.2	Platelet count;	chr12:111881193	chr12:111927018~111929017:+
HNSC	cis	rs757081	0.667	rs476890	ENSG00000260196.1	RP1-239B22.5	-4.41	1.29e-05	0.00245	-0.24	-0.2	Systolic blood pressure;	chr11:17188415	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs615424	ENSG00000260196.1	RP1-239B22.5	-4.41	1.29e-05	0.00245	-0.24	-0.2	Systolic blood pressure;	chr11:17188934	chr11:17380649~17383531:+
HNSC	cis	rs1218582	0.774	rs4845681	ENSG00000270361.1	RP11-307C12.13	-4.41	1.29e-05	0.00245	-0.22	-0.2	Prostate cancer;	chr1:154895579	chr1:154937370~154938059:+
HNSC	cis	rs3806843	1	rs10057161	ENSG00000202515.1	VTRNA1-3	-4.41	1.29e-05	0.00245	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr5:140726158~140726246:+
HNSC	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-4.41	1.29e-05	0.00245	-0.17	-0.2	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
HNSC	cis	rs9880211	1	rs6805316	ENSG00000273486.1	RP11-731C17.2	4.41	1.29e-05	0.00245	0.19	0.2	Height;Body mass index;	chr3:136233270	chr3:136837338~136839021:-
HNSC	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	4.41	1.29e-05	0.00245	0.2	0.2	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
HNSC	cis	rs1150668	0.835	rs203869	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00245	-0.23	-0.2	Pubertal anthropometrics;	chr6:28073041	chr6:28115628~28116551:+
HNSC	cis	rs9287719	0.967	rs4613248	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10603925	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs10191883	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604010	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs4629131	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604033	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.901	rs4555317	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604121	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4555318	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604169	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs4622695	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604201	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs6432111	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604494	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432114	ENSG00000243819.4	RN7SL832P	4.41	1.29e-05	0.00245	0.19	0.2	Prostate cancer;	chr2:10604804	chr2:10690344~10692099:+
HNSC	cis	rs7615952	0.641	rs4490307	ENSG00000241439.1	RP11-666A20.3	4.41	1.29e-05	0.00245	0.22	0.2	Blood pressure (smoking interaction);	chr3:125993833	chr3:125958556~125958817:+
HNSC	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-4.41	1.29e-05	0.00245	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
HNSC	cis	rs3738443	0.817	rs61840052	ENSG00000259865.1	RP11-488L18.10	4.41	1.29e-05	0.00245	0.18	0.2	Alcohol dependence;	chr1:247204036	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.817	rs61840053	ENSG00000259865.1	RP11-488L18.10	4.41	1.29e-05	0.00245	0.18	0.2	Alcohol dependence;	chr1:247204038	chr1:247187281~247188526:-
HNSC	cis	rs6601327	0.607	rs13276086	ENSG00000254340.1	RP11-10A14.3	-4.41	1.29e-05	0.00245	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:9141424~9145435:+
HNSC	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	4.41	1.29e-05	0.00245	0.2	0.2	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
HNSC	cis	rs6964587	0.633	rs13231620	ENSG00000188693.7	CYP51A1-AS1	4.41	1.29e-05	0.00246	0.22	0.2	Breast cancer;	chr7:91878545	chr7:92134604~92180725:+
HNSC	cis	rs73201462	0.708	rs2811477	ENSG00000231305.3	RP11-723O4.2	-4.41	1.29e-05	0.00246	-0.35	-0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128179940	chr3:128861313~128871540:-
HNSC	cis	rs3015497	0.527	rs2934668	ENSG00000277050.1	RP11-102G14.1	-4.41	1.29e-05	0.00246	-0.21	-0.2	Mean platelet volume;	chr14:50686807	chr14:51637348~51637947:-
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	4.41	1.29e-05	0.00246	0.25	0.2	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
HNSC	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-4.41	1.29e-05	0.00246	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
HNSC	cis	rs6490294	0.571	rs7309841	ENSG00000226469.1	ADAM1B	4.41	1.29e-05	0.00246	0.28	0.2	Mean platelet volume;	chr12:112127249	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7294753	ENSG00000226469.1	ADAM1B	4.41	1.29e-05	0.00246	0.28	0.2	Mean platelet volume;	chr12:112129646	chr12:111927018~111929017:+
HNSC	cis	rs4253772	0.513	rs9615345	ENSG00000277232.2	GTSE1-AS1	-4.41	1.29e-05	0.00246	-0.26	-0.2	Cholesterol, total;LDL cholesterol;	chr22:46317734	chr22:46295143~46296660:-
HNSC	cis	rs394563	0.625	rs394526	ENSG00000231760.4	RP11-350J20.5	4.41	1.29e-05	0.00246	0.26	0.2	Dupuytren's disease;	chr6:149475839	chr6:149796151~149826294:-
HNSC	cis	rs12034383	1	rs11803956	ENSG00000274245.1	RP11-357P18.2	4.41	1.29e-05	0.00246	0.25	0.2	Erythrocyte sedimentation rate;	chr1:207629676	chr1:207372559~207373252:+
HNSC	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	4.41	1.29e-05	0.00246	0.27	0.2	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	4.41	1.29e-05	0.00246	0.27	0.2	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
HNSC	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	4.41	1.29e-05	0.00246	0.27	0.2	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
HNSC	cis	rs853679	0.607	rs13201308	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28162311	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs34505829	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28165461	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs35098436	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28166443	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs72846794	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28169721	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.607	rs13217984	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28171932	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.505	rs35781323	ENSG00000219392.1	RP1-265C24.5	-4.41	1.29e-05	0.00246	-0.42	-0.2	Depression;	chr6:28177054	chr6:28115628~28116551:+
HNSC	cis	rs2439831	0.681	rs484029	ENSG00000205771.5	CATSPER2P1	-4.41	1.29e-05	0.00246	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43327362	chr15:43726918~43747094:-
HNSC	cis	rs6831352	0.837	rs2924583	ENSG00000263923.1	RP11-571L19.7	-4.41	1.29e-05	0.00246	-0.22	-0.2	Alcohol dependence;	chr4:99123489	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.918	rs2851249	ENSG00000263923.1	RP11-571L19.7	-4.41	1.29e-05	0.00246	-0.22	-0.2	Alcohol dependence;	chr4:99123671	chr4:98928897~98994994:+
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	4.41	1.29e-05	0.00246	0.24	0.2	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
HNSC	cis	rs4906332	1	rs4900574	ENSG00000244691.1	RPL10AP1	4.41	1.29e-05	0.00246	0.23	0.2	Coronary artery disease;	chr14:103412687	chr14:103412119~103412761:-
HNSC	cis	rs36350	0.5	rs12590831	ENSG00000266869.1	RP6-114E22.1	-4.41	1.3e-05	0.00246	-0.25	-0.2	Autism spectrum disorder or schizophrenia;	chr14:71988105	chr14:71848606~71908430:+
HNSC	cis	rs6604026	0.922	rs11164825	ENSG00000223787.2	RP4-593M8.1	4.41	1.3e-05	0.00246	0.27	0.2	Multiple sclerosis;	chr1:92846150	chr1:92580476~92580821:-
HNSC	cis	rs853679	0.607	rs67662114	ENSG00000204709.4	LINC01556	4.41	1.3e-05	0.00246	0.41	0.2	Depression;	chr6:27964523	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13216117	ENSG00000204709.4	LINC01556	4.41	1.3e-05	0.00246	0.41	0.2	Depression;	chr6:27970706	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs36101351	ENSG00000204709.4	LINC01556	4.41	1.3e-05	0.00246	0.41	0.2	Depression;	chr6:27975591	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs28360499	ENSG00000204709.4	LINC01556	4.41	1.3e-05	0.00246	0.41	0.2	Depression;	chr6:27977618	chr6:28943877~28944537:+
HNSC	cis	rs1008375	1	rs10440301	ENSG00000249502.1	AC006160.5	-4.41	1.3e-05	0.00246	-0.22	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661576	chr4:17587467~17614571:-
HNSC	cis	rs6601327	0.606	rs13268319	ENSG00000254340.1	RP11-10A14.3	-4.41	1.3e-05	0.00246	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:9141424~9145435:+
HNSC	cis	rs7296418	0.63	rs11608305	ENSG00000280120.1	RP11-546D6.3	4.41	1.3e-05	0.00246	0.17	0.2	Platelet count;	chr12:123306618	chr12:123152324~123153377:-
HNSC	cis	rs34421088	0.576	rs2736369	ENSG00000269918.1	AF131215.9	-4.41	1.3e-05	0.00246	-0.22	-0.2	Neuroticism;	chr8:11243889	chr8:11104691~11106704:-
HNSC	cis	rs9926296	0.744	rs460879	ENSG00000274627.1	RP11-104N10.2	4.41	1.3e-05	0.00247	0.2	0.2	Vitiligo;	chr16:89646481	chr16:89516797~89522217:+
HNSC	cis	rs929354	0.772	rs2301914	ENSG00000224629.1	RP5-1142J19.2	-4.41	1.3e-05	0.00247	-0.2	-0.2	Body mass index;	chr7:157207482	chr7:157263022~157263229:-
HNSC	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	4.41	1.3e-05	0.00247	0.31	0.2	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
HNSC	cis	rs9840812	0.953	rs4678361	ENSG00000273486.1	RP11-731C17.2	4.41	1.3e-05	0.00247	0.18	0.2	Fibrinogen levels;	chr3:136114163	chr3:136837338~136839021:-
HNSC	cis	rs36052053	0.521	rs36085386	ENSG00000203799.9	CCDC162P	4.41	1.3e-05	0.00247	0.36	0.2	Red cell distribution width;	chr6:109223182	chr6:109285485~109355063:+
HNSC	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-4.41	1.3e-05	0.00247	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
HNSC	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-4.41	1.3e-05	0.00247	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-4.41	1.3e-05	0.00247	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
HNSC	cis	rs1602565	0.858	rs7941881	ENSG00000255450.1	CTD-2063L20.1	-4.41	1.3e-05	0.00247	-0.31	-0.2	Schizophrenia;	chr11:29167805	chr11:29275655~29276565:+
HNSC	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	4.41	1.3e-05	0.00247	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
HNSC	cis	rs1198872	0.812	rs1198867	ENSG00000272275.1	RP11-791G15.2	-4.41	1.3e-05	0.00247	-0.23	-0.2	Cardiac Troponin-T levels;	chr2:10762281	chr2:10767875~10770058:-
HNSC	cis	rs1198872	0.892	rs1198869	ENSG00000272275.1	RP11-791G15.2	-4.41	1.3e-05	0.00247	-0.23	-0.2	Cardiac Troponin-T levels;	chr2:10762319	chr2:10767875~10770058:-
HNSC	cis	rs10773046	0.74	rs10773045	ENSG00000269938.1	RP11-214K3.20	-4.41	1.3e-05	0.00247	-0.22	-0.2	Osteoarthritis (hip);	chr12:123867119	chr12:123968023~123968579:-
HNSC	cis	rs9311676	0.656	rs12497250	ENSG00000273493.1	RP11-80H18.4	4.41	1.3e-05	0.00247	0.21	0.2	Systemic lupus erythematosus;	chr3:58413672	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs12487420	ENSG00000273493.1	RP11-80H18.4	4.41	1.3e-05	0.00247	0.21	0.2	Systemic lupus erythematosus;	chr3:58413784	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11705721	ENSG00000273493.1	RP11-80H18.4	4.41	1.3e-05	0.00247	0.21	0.2	Systemic lupus erythematosus;	chr3:58414687	chr3:58329965~58330118:+
HNSC	cis	rs9650657	0.707	rs6984744	ENSG00000269918.1	AF131215.9	-4.41	1.3e-05	0.00248	-0.2	-0.2	Neuroticism;	chr8:10758755	chr8:11104691~11106704:-
HNSC	cis	rs964611	0.938	rs7174204	ENSG00000259488.2	RP11-154J22.1	-4.41	1.3e-05	0.00248	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48286949	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.938	rs8026751	ENSG00000259488.2	RP11-154J22.1	-4.41	1.3e-05	0.00248	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48290648	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.872	rs72623972	ENSG00000259488.2	RP11-154J22.1	-4.41	1.3e-05	0.00248	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48294797	chr15:48312353~48331856:-
HNSC	cis	rs7829975	0.511	rs1543238	ENSG00000233609.3	RP11-62H7.2	4.41	1.3e-05	0.00248	0.19	0.2	Mood instability;	chr8:8277287	chr8:8961200~8979025:+
HNSC	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	4.41	1.3e-05	0.00248	0.19	0.2	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
HNSC	cis	rs1665050	0.652	rs62002516	ENSG00000259732.1	RP11-59H7.3	-4.41	1.3e-05	0.00248	-0.26	-0.2	Atopic dermatitis;	chr15:59009703	chr15:59121034~59133250:+
HNSC	cis	rs35306767	0.903	rs17159970	ENSG00000229869.1	RP11-363N22.2	-4.41	1.3e-05	0.00248	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:889661	chr10:933026~942743:+
HNSC	cis	rs7701440	0.512	rs12513581	ENSG00000215032.2	GNL3LP1	4.41	1.3e-05	0.00248	0.22	0.2	Educational attainment;	chr5:61237380	chr5:60891935~60893577:-
HNSC	cis	rs1552244	0.935	rs66493421	ENSG00000180385.7	EMC3-AS1	4.41	1.3e-05	0.00248	0.24	0.2	Alzheimer's disease;	chr3:10050885	chr3:9986893~10006990:+
HNSC	cis	rs9880211	0.948	rs9857966	ENSG00000273486.1	RP11-731C17.2	4.41	1.3e-05	0.00248	0.19	0.2	Height;Body mass index;	chr3:136560548	chr3:136837338~136839021:-
HNSC	cis	rs7121616	0.576	rs73610509	ENSG00000200879.1	SNORD14E	4.41	1.31e-05	0.00248	0.28	0.2	Breast cancer;	chr11:123048564	chr11:123058077~123058161:-
HNSC	cis	rs9914988	0.613	rs66701171	ENSG00000264577.1	AC010761.8	4.41	1.31e-05	0.00248	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28949403	chr17:28721487~28722877:-
HNSC	cis	rs73198271	0.74	rs10092720	ENSG00000233609.3	RP11-62H7.2	-4.41	1.31e-05	0.00248	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8961200~8979025:+
HNSC	cis	rs1275468	0.731	rs3912214	ENSG00000257497.2	RP11-585P4.5	-4.41	1.31e-05	0.00248	-0.31	-0.2	Polycystic ovary syndrome;	chr12:75550245	chr12:75483454~75489820:-
HNSC	cis	rs6964587	0.934	rs7811328	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.31e-05	0.00248	-0.21	-0.2	Breast cancer;	chr7:92091617	chr7:92134604~92180725:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000233609.3	RP11-62H7.2	4.41	1.31e-05	0.00248	0.18	0.2	Neuroticism;	chr8:8461672	chr8:8961200~8979025:+
HNSC	cis	rs1799949	0.965	rs8176087	ENSG00000236383.6	LINC00854	-4.41	1.31e-05	0.00248	-0.19	-0.2	Menopause (age at onset);	chr17:43118649	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs34942571	ENSG00000236383.6	LINC00854	-4.41	1.31e-05	0.00248	-0.19	-0.2	Menopause (age at onset);	chr17:43121362	chr17:43216941~43305976:-
HNSC	cis	rs11673344	0.523	rs2562607	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37031358	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs2385415	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37035291	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs7246739	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37040829	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.562	rs7257320	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37080933	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs10403975	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37082172	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs2385375	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37087620	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs35162188	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37088908	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs10403728	ENSG00000276846.1	CTD-3220F14.3	4.41	1.31e-05	0.00248	0.22	0.2	Obesity-related traits;	chr19:37091569	chr19:37314868~37315620:-
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-4.41	1.31e-05	0.00248	-0.15	-0.2	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
HNSC	cis	rs712039	0.652	rs853196	ENSG00000276054.1	RP11-378E13.3	4.41	1.31e-05	0.00248	0.28	0.2	Tuberculosis;	chr17:37488553	chr17:37386886~37387926:+
HNSC	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-4.41	1.31e-05	0.00248	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000106610.13	STAG3L4	4.41	1.31e-05	0.00248	0.4	0.2	Diabetic kidney disease;	chr7:66307771	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000106610.13	STAG3L4	4.41	1.31e-05	0.00248	0.4	0.2	Diabetic kidney disease;	chr7:66308442	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000106610.13	STAG3L4	4.41	1.31e-05	0.00248	0.4	0.2	Diabetic kidney disease;	chr7:66315709	chr7:67302621~67321526:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000106610.13	STAG3L4	4.41	1.31e-05	0.00248	0.4	0.2	Diabetic kidney disease;	chr7:66333815	chr7:67302621~67321526:+
HNSC	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-4.41	1.31e-05	0.00248	-0.23	-0.2	Height;	chr20:49316942	chr20:49280319~49280409:+
HNSC	cis	rs638893	0.853	rs4938549	ENSG00000255422.1	AP002954.4	-4.41	1.31e-05	0.00248	-0.33	-0.2	Vitiligo;	chr11:118830888	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.898	rs530646	ENSG00000255422.1	AP002954.4	-4.41	1.31e-05	0.00248	-0.33	-0.2	Vitiligo;	chr11:118830959	chr11:118704607~118750263:+
HNSC	cis	rs9813712	0.547	rs6807290	ENSG00000249846.5	RP11-77P16.4	4.41	1.31e-05	0.00248	0.22	0.2	Response to amphetamines;	chr3:130297952	chr3:130112550~130120579:+
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-4.41	1.31e-05	0.00248	-0.24	-0.2	Depression;	chr6:28192182	chr6:28170845~28172521:+
HNSC	cis	rs12468226	0.81	rs115255999	ENSG00000226261.1	AC064836.3	4.41	1.31e-05	0.00249	0.31	0.2	Urate levels;	chr2:202572326	chr2:202336024~202336727:-
HNSC	cis	rs459482	0.501	rs148214	ENSG00000228318.3	AP001610.5	4.41	1.31e-05	0.00249	0.21	0.2	IgG glycosylation;	chr21:41442291	chr21:41441056~41445708:-
HNSC	cis	rs9863	0.861	rs11835839	ENSG00000269938.1	RP11-214K3.20	-4.41	1.31e-05	0.00249	-0.23	-0.2	White blood cell count;	chr12:123946502	chr12:123968023~123968579:-
HNSC	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	4.41	1.31e-05	0.00249	0.19	0.2	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
HNSC	cis	rs9863	0.828	rs12303671	ENSG00000270028.1	RP11-380L11.4	4.41	1.31e-05	0.00249	0.23	0.2	White blood cell count;	chr12:124008063	chr12:123925461~123926083:-
HNSC	cis	rs889398	0.741	rs11075744	ENSG00000226232.7	RP11-419C5.2	-4.41	1.31e-05	0.00249	-0.17	-0.2	Body mass index;	chr16:69875212	chr16:69976388~69996188:-
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	4.41	1.31e-05	0.00249	0.24	0.2	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
HNSC	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	4.41	1.31e-05	0.00249	0.17	0.2	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
HNSC	cis	rs67981189	0.593	rs221919	ENSG00000274818.1	RP1-292L20.3	-4.41	1.31e-05	0.00249	-0.22	-0.2	Schizophrenia;	chr14:71121512	chr14:70906657~70907111:-
HNSC	cis	rs3096299	0.967	rs2965827	ENSG00000261574.1	RP1-168P16.2	-4.41	1.31e-05	0.00249	-0.25	-0.2	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89392375~89412564:-
HNSC	cis	rs4862750	0.874	rs6553027	ENSG00000250971.1	RP11-696F12.1	4.41	1.31e-05	0.00249	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:187060099~187060930:+
HNSC	cis	rs3736485	0.844	rs56189052	ENSG00000259438.1	CTD-2650P22.1	4.41	1.31e-05	0.00249	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51530181	chr15:52010999~52019095:-
HNSC	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	4.41	1.31e-05	0.00249	0.19	0.2	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	4.41	1.31e-05	0.00249	0.19	0.2	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
HNSC	cis	rs459482	0.504	rs469390	ENSG00000228318.3	AP001610.5	-4.41	1.31e-05	0.00249	-0.2	-0.2	IgG glycosylation;	chr21:41446003	chr21:41441056~41445708:-
HNSC	cis	rs516805	0.748	rs197685	ENSG00000279453.1	RP3-425C14.4	-4.41	1.31e-05	0.00249	-0.28	-0.2	Lymphocyte counts;	chr6:122554622	chr6:122436789~122439223:-
HNSC	cis	rs61935443	0.501	rs9668170	ENSG00000241556.1	RP11-490G8.1	-4.4	1.31e-05	0.00249	-0.21	-0.2	Schizophrenia;	chr12:94782036	chr12:95467397~95467861:-
HNSC	cis	rs804280	0.542	rs35647515	ENSG00000255495.1	AC145124.2	4.4	1.31e-05	0.00249	0.23	0.2	Myopia (pathological);	chr8:11934120	chr8:12194467~12196280:+
HNSC	cis	rs12935418	0.583	rs2911150	ENSG00000261061.1	RP11-303E16.2	-4.4	1.31e-05	0.00249	-0.21	-0.2	Mean corpuscular volume;	chr16:80995194	chr16:81030770~81031485:+
HNSC	cis	rs67981189	0.593	rs221918	ENSG00000274818.1	RP1-292L20.3	-4.4	1.31e-05	0.00249	-0.22	-0.2	Schizophrenia;	chr14:71121698	chr14:70906657~70907111:-
HNSC	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-4.4	1.31e-05	0.0025	-0.25	-0.2	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-4.4	1.31e-05	0.0025	-0.25	-0.2	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-4.4	1.31e-05	0.0025	-0.25	-0.2	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
HNSC	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	4.4	1.31e-05	0.0025	0.2	0.2	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
HNSC	cis	rs1056107	0.897	rs1972322	ENSG00000225513.1	RP11-165N19.2	-4.4	1.32e-05	0.0025	-0.21	-0.2	Colorectal cancer;	chr9:112197447	chr9:112173522~112173971:-
HNSC	cis	rs2286503	0.533	rs1880239	ENSG00000226329.2	AC005682.6	4.4	1.32e-05	0.0025	0.29	0.2	Fibrinogen;	chr7:22832065	chr7:22863874~22881350:-
HNSC	cis	rs516805	0.634	rs2816159	ENSG00000279453.1	RP3-425C14.4	-4.4	1.32e-05	0.0025	-0.28	-0.2	Lymphocyte counts;	chr6:122121982	chr6:122436789~122439223:-
HNSC	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	4.4	1.32e-05	0.0025	0.23	0.2	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	4.4	1.32e-05	0.0025	0.21	0.2	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	4.4	1.32e-05	0.0025	0.21	0.2	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
HNSC	cis	rs9914988	0.613	rs12941884	ENSG00000264577.1	AC010761.8	4.4	1.32e-05	0.0025	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28957425	chr17:28721487~28722877:-
HNSC	cis	rs6500395	0.962	rs9922356	ENSG00000261267.1	RP11-44I10.3	-4.4	1.32e-05	0.0025	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48606114	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs13331902	ENSG00000261267.1	RP11-44I10.3	-4.4	1.32e-05	0.0025	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48611078	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.926	rs9936446	ENSG00000261267.1	RP11-44I10.3	-4.4	1.32e-05	0.0025	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48611896	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9924483	ENSG00000261267.1	RP11-44I10.3	-4.4	1.32e-05	0.0025	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48612347	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs1564979	ENSG00000261267.1	RP11-44I10.3	-4.4	1.32e-05	0.0025	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48613106	chr16:48559661~48587403:+
HNSC	cis	rs763121	0.524	rs760645	ENSG00000273076.1	RP3-508I15.22	4.4	1.32e-05	0.0025	0.2	0.2	Menopause (age at onset);	chr22:38636265	chr22:38743495~38743910:+
HNSC	cis	rs1056107	0.933	rs11542205	ENSG00000225513.1	RP11-165N19.2	-4.4	1.32e-05	0.0025	-0.21	-0.2	Colorectal cancer;	chr9:112221986	chr9:112173522~112173971:-
HNSC	cis	rs2297363	0.502	rs4709393	ENSG00000213073.4	RP11-288H12.3	-4.4	1.32e-05	0.0025	-0.22	-0.2	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:160093082~160096212:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	4.4	1.32e-05	0.0025	0.21	0.2	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
HNSC	cis	rs11633886	0.565	rs1402164	ENSG00000273972.1	CTD-2306A12.1	4.4	1.32e-05	0.0025	0.24	0.2	Diisocyanate-induced asthma;	chr15:45779974	chr15:45702640~45703183:+
HNSC	cis	rs6430585	0.528	rs309161	ENSG00000231890.6	DARS-AS1	4.4	1.32e-05	0.0025	0.33	0.2	Corneal structure;	chr2:135931179	chr2:135985176~136022593:+
HNSC	cis	rs7121616	0.545	rs11600517	ENSG00000200879.1	SNORD14E	4.4	1.32e-05	0.0025	0.28	0.2	Breast cancer;	chr11:123047247	chr11:123058077~123058161:-
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-4.4	1.32e-05	0.0025	-0.15	-0.2	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
HNSC	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-4.4	1.32e-05	0.0025	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-4.4	1.32e-05	0.0025	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
HNSC	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	4.4	1.32e-05	0.0025	0.2	0.2	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
HNSC	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-4.4	1.32e-05	0.0025	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
HNSC	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-4.4	1.32e-05	0.0025	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
HNSC	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-4.4	1.32e-05	0.0025	-0.16	-0.2	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
HNSC	cis	rs6831352	0.959	rs6532796	ENSG00000263923.1	RP11-571L19.7	4.4	1.32e-05	0.0025	0.2	0.2	Alcohol dependence;	chr4:99121091	chr4:98928897~98994994:+
HNSC	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-4.4	1.32e-05	0.0025	-0.27	-0.2	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
HNSC	cis	rs7824557	0.564	rs2736304	ENSG00000269918.1	AF131215.9	-4.4	1.32e-05	0.0025	-0.19	-0.2	Retinal vascular caliber;	chr8:11379455	chr8:11104691~11106704:-
HNSC	cis	rs9311676	0.632	rs6774577	ENSG00000273493.1	RP11-80H18.4	4.4	1.32e-05	0.0025	0.22	0.2	Systemic lupus erythematosus;	chr3:58375989	chr3:58329965~58330118:+
HNSC	cis	rs453301	0.597	rs7001187	ENSG00000254153.1	CTA-398F10.2	-4.4	1.32e-05	0.00251	-0.22	-0.2	Joint mobility (Beighton score);	chr8:8935272	chr8:8456909~8461337:-
HNSC	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-4.4	1.32e-05	0.00251	-0.35	-0.2	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
HNSC	cis	rs5758659	0.569	rs133294	ENSG00000182057.4	OGFRP1	4.4	1.32e-05	0.00251	0.21	0.2	Cognitive function;	chr22:41986801	chr22:42269753~42275196:+
HNSC	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	4.4	1.32e-05	0.00251	0.41	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
HNSC	cis	rs4761669	0.545	rs1347317	ENSG00000241556.1	RP11-490G8.1	-4.4	1.32e-05	0.00251	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94814183	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.545	rs1347316	ENSG00000241556.1	RP11-490G8.1	-4.4	1.32e-05	0.00251	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94814234	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.545	rs1347315	ENSG00000241556.1	RP11-490G8.1	-4.4	1.32e-05	0.00251	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94814325	chr12:95467397~95467861:-
HNSC	cis	rs13434995	0.513	rs1048004	ENSG00000273257.1	RP11-177J6.1	-4.4	1.32e-05	0.00251	-0.27	-0.2	Adiponectin levels;	chr4:55434042	chr4:55387949~55388271:+
HNSC	cis	rs1485395	0.836	rs10876471	ENSG00000257379.1	RP11-793H13.8	4.4	1.32e-05	0.00251	0.28	0.2	Migraine without aura;	chr12:53630760	chr12:53441741~53467528:+
HNSC	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-4.4	1.32e-05	0.00251	-0.29	-0.2	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
HNSC	cis	rs72634501	0.531	rs67758468	ENSG00000182109.6	RP11-69E11.4	4.4	1.32e-05	0.00251	0.22	0.2	HDL cholesterol;	chr1:39156916	chr1:39522280~39546187:-
HNSC	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	4.4	1.32e-05	0.00251	0.2	0.2	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
HNSC	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	4.4	1.32e-05	0.00251	0.22	0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
HNSC	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	4.4	1.32e-05	0.00251	0.25	0.2	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
HNSC	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-4.4	1.32e-05	0.00251	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
HNSC	cis	rs7572733	0.84	rs700640	ENSG00000222017.1	AC011997.1	4.4	1.32e-05	0.00251	0.24	0.2	Dermatomyositis;	chr2:197726162	chr2:197693106~197774823:+
HNSC	cis	rs3736485	0.966	rs4775958	ENSG00000259438.1	CTD-2650P22.1	4.4	1.32e-05	0.00251	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51599365	chr15:52010999~52019095:-
HNSC	cis	rs4660214	0.666	rs7538300	ENSG00000182109.6	RP11-69E11.4	-4.4	1.32e-05	0.00251	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs11205739	ENSG00000182109.6	RP11-69E11.4	-4.4	1.32e-05	0.00251	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39522280~39546187:-
HNSC	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-4.4	1.32e-05	0.00251	-0.29	-0.2	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
HNSC	cis	rs11098499	1	rs28374891	ENSG00000250412.1	KLHL2P1	4.4	1.33e-05	0.00251	0.25	0.2	Corneal astigmatism;	chr4:119262395	chr4:119334329~119378233:+
HNSC	cis	rs615632	0.53	rs10092464	ENSG00000254340.1	RP11-10A14.3	-4.4	1.33e-05	0.00251	-0.25	-0.2	Neuroticism;	chr8:9946675	chr8:9141424~9145435:+
HNSC	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	4.4	1.33e-05	0.00251	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
HNSC	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-4.4	1.33e-05	0.00251	-0.46	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
HNSC	cis	rs755249	0.727	rs12028034	ENSG00000182109.6	RP11-69E11.4	-4.4	1.33e-05	0.00251	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39522280~39546187:-
HNSC	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	4.4	1.33e-05	0.00251	0.18	0.2	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
HNSC	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	4.4	1.33e-05	0.00252	0.28	0.2	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
HNSC	cis	rs7824557	0.614	rs4394351	ENSG00000255310.2	AF131215.2	4.4	1.33e-05	0.00252	0.19	0.2	Retinal vascular caliber;	chr8:11355366	chr8:11107788~11109726:-
HNSC	cis	rs9321453	1	rs9376037	ENSG00000231971.4	RP11-557H15.3	4.4	1.33e-05	0.00252	0.24	0.2	Urate levels;	chr6:134453899	chr6:134428240~134520585:-
HNSC	cis	rs9291683	0.527	rs3822241	ENSG00000250413.1	RP11-448G15.1	4.4	1.33e-05	0.00252	0.25	0.2	Bone mineral density;	chr4:10093307	chr4:10006482~10009725:+
HNSC	cis	rs7735319	0.966	rs35958302	ENSG00000251281.1	CTD-2066L21.2	4.4	1.33e-05	0.00252	0.23	0.2	Systolic blood pressure;	chr5:33157849	chr5:33011322~33017607:-
HNSC	cis	rs3736485	0.966	rs2414114	ENSG00000259438.1	CTD-2650P22.1	4.4	1.33e-05	0.00252	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51613584	chr15:52010999~52019095:-
HNSC	cis	rs6601327	0.602	rs12678014	ENSG00000254340.1	RP11-10A14.3	4.4	1.33e-05	0.00252	0.25	0.2	Multiple myeloma (hyperdiploidy);	chr8:9791655	chr8:9141424~9145435:+
HNSC	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	4.4	1.33e-05	0.00252	0.22	0.2	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	4.4	1.33e-05	0.00252	0.22	0.2	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
HNSC	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-4.4	1.33e-05	0.00252	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
HNSC	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-4.4	1.33e-05	0.00252	-0.22	-0.2	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
HNSC	cis	rs7005380	0.581	rs13265513	ENSG00000279347.1	RP11-85I17.2	4.4	1.33e-05	0.00252	0.18	0.2	Interstitial lung disease;	chr8:119907686	chr8:119838736~119840385:-
HNSC	cis	rs17428076	0.794	rs62182446	ENSG00000228389.1	AC068039.4	-4.4	1.33e-05	0.00252	-0.27	-0.2	Myopia;	chr2:171964701	chr2:171773482~171775844:+
HNSC	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	4.4	1.33e-05	0.00252	0.17	0.2	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
HNSC	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-4.4	1.33e-05	0.00252	-0.25	-0.2	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
HNSC	cis	rs2071303	1	rs2071303	ENSG00000272462.2	U91328.19	-4.4	1.33e-05	0.00252	-0.2	-0.2	Intelligence (multi-trait analysis);	chr6:26091108	chr6:25992662~26001775:+
HNSC	cis	rs516805	0.63	rs225087	ENSG00000279453.1	RP3-425C14.4	-4.4	1.33e-05	0.00252	-0.28	-0.2	Lymphocyte counts;	chr6:122277884	chr6:122436789~122439223:-
HNSC	cis	rs7819412	0.522	rs10088853	ENSG00000255310.2	AF131215.2	-4.4	1.33e-05	0.00252	-0.2	-0.2	Triglycerides;	chr8:11130457	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.703	rs2409713	ENSG00000269918.1	AF131215.9	-4.4	1.33e-05	0.00253	-0.2	-0.2	Triglycerides;	chr8:11152287	chr8:11104691~11106704:-
HNSC	cis	rs6500395	0.928	rs4785532	ENSG00000261267.1	RP11-44I10.3	4.4	1.34e-05	0.00253	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48661589	chr16:48559661~48587403:+
HNSC	cis	rs4873772	0.743	rs4873529	ENSG00000253330.1	RP11-697N18.3	-4.4	1.34e-05	0.00253	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47653224	chr8:47511034~47512141:-
HNSC	cis	rs889398	0.594	rs3790085	ENSG00000226232.7	RP11-419C5.2	-4.4	1.34e-05	0.00253	-0.17	-0.2	Body mass index;	chr16:69853817	chr16:69976388~69996188:-
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000211974.3	IGHV2-70	4.4	1.34e-05	0.00253	0.19	0.2	Kawasaki disease;	chr14:106704386	chr14:106723574~106724093:-
HNSC	cis	rs4523957	0.671	rs4790070	ENSG00000262333.1	HNRNPA1P16	-4.4	1.34e-05	0.00253	-0.18	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2254800	chr17:2306761~2307715:+
HNSC	cis	rs9880211	0.8	rs34324561	ENSG00000273486.1	RP11-731C17.2	4.4	1.34e-05	0.00253	0.19	0.2	Height;Body mass index;	chr3:136382400	chr3:136837338~136839021:-
HNSC	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	4.4	1.34e-05	0.00253	0.17	0.2	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
HNSC	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	4.4	1.34e-05	0.00253	0.23	0.2	Height;	chr14:75044372	chr14:75011269~75012851:-
HNSC	cis	rs9813712	0.595	rs12490957	ENSG00000249846.5	RP11-77P16.4	4.4	1.34e-05	0.00253	0.21	0.2	Response to amphetamines;	chr3:130287851	chr3:130112550~130120579:+
HNSC	cis	rs2732480	0.538	rs2732462	ENSG00000257763.1	OR5BK1P	4.4	1.34e-05	0.00254	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48355792~48356614:-
HNSC	cis	rs964611	0.882	rs7175172	ENSG00000259488.2	RP11-154J22.1	-4.4	1.34e-05	0.00254	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48280021	chr15:48312353~48331856:-
HNSC	cis	rs721917	0.525	rs11201011	ENSG00000244733.5	RP11-506M13.3	-4.4	1.34e-05	0.00254	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.525	rs4281433	ENSG00000244733.5	RP11-506M13.3	-4.4	1.34e-05	0.00254	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79660891~79677996:+
HNSC	cis	rs116139393	0.536	rs13247186	ENSG00000187953.9	PMS2CL	-4.4	1.34e-05	0.00254	-0.25	-0.2	Alzheimer's disease (APOE e4 interaction);	chr7:6729524	chr7:6710128~6753862:+
HNSC	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	4.4	1.34e-05	0.00254	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
HNSC	cis	rs9921338	0.961	rs9302459	ENSG00000263080.1	RP11-485G7.5	-4.4	1.34e-05	0.00254	-0.22	-0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11341809~11345211:-
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000253893.2	FAM85B	4.4	1.34e-05	0.00254	0.23	0.2	Mean corpuscular volume;	chr8:8996725	chr8:8167819~8226614:-
HNSC	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.22	0.2	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
HNSC	cis	rs9291683	0.527	rs73212848	ENSG00000250413.1	RP11-448G15.1	4.4	1.34e-05	0.00254	0.25	0.2	Bone mineral density;	chr4:10091675	chr4:10006482~10009725:+
HNSC	cis	rs7267979	0.738	rs2892409	ENSG00000204556.4	CTD-2514C3.1	-4.4	1.34e-05	0.00254	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26018832~26020684:+
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000255495.1	AC145124.2	4.4	1.34e-05	0.00254	0.23	0.2	Neuroticism;	chr8:11935465	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000255495.1	AC145124.2	4.4	1.34e-05	0.00254	0.23	0.2	Neuroticism;	chr8:11935469	chr8:12194467~12196280:+
HNSC	cis	rs3805389	1	rs3805389	ENSG00000273257.1	RP11-177J6.1	-4.4	1.34e-05	0.00254	-0.27	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55387949~55388271:+
HNSC	cis	rs9650657	0.538	rs6984496	ENSG00000269918.1	AF131215.9	-4.4	1.34e-05	0.00254	-0.19	-0.2	Neuroticism;	chr8:10938583	chr8:11104691~11106704:-
HNSC	cis	rs9393777	0.92	rs66462181	ENSG00000219392.1	RP1-265C24.5	-4.4	1.34e-05	0.00254	-0.42	-0.2	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28115628~28116551:+
HNSC	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	4.4	1.34e-05	0.00254	0.22	0.2	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
HNSC	cis	rs7829975	0.511	rs2955578	ENSG00000254153.1	CTA-398F10.2	4.4	1.34e-05	0.00254	0.22	0.2	Mood instability;	chr8:8279561	chr8:8456909~8461337:-
HNSC	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-4.4	1.34e-05	0.00254	-0.27	-0.2	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
HNSC	cis	rs9311676	0.656	rs11718352	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58415753	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.618	rs62258135	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58417603	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs55783924	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58417883	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs6799077	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58418369	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs56398717	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58418628	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs55727087	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58418820	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11714807	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58419704	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs11130637	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58419846	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11130638	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58420220	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.618	rs11130639	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58420277	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62258139	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58421109	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs62258140	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58421356	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs11915190	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58423973	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.656	rs34579268	ENSG00000273493.1	RP11-80H18.4	4.4	1.34e-05	0.00254	0.21	0.2	Systemic lupus erythematosus;	chr3:58424827	chr3:58329965~58330118:+
HNSC	cis	rs3806843	1	rs3806845	ENSG00000202515.1	VTRNA1-3	-4.4	1.34e-05	0.00254	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr5:140726158~140726246:+
HNSC	cis	rs3806843	1	rs3733707	ENSG00000202515.1	VTRNA1-3	-4.4	1.34e-05	0.00254	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr5:140726158~140726246:+
HNSC	cis	rs1125355	0.69	rs62183660	ENSG00000204380.3	AC005042.4	4.4	1.34e-05	0.00254	0.22	0.2	Alzheimer's disease in APOE e4+ carriers;	chr2:158782804	chr2:158658337~158735002:-
HNSC	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-4.4	1.34e-05	0.00254	-0.22	-0.2	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
HNSC	cis	rs459482	0.504	rs469073	ENSG00000228318.3	AP001610.5	4.4	1.34e-05	0.00254	0.21	0.2	IgG glycosylation;	chr21:41444274	chr21:41441056~41445708:-
HNSC	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-4.4	1.34e-05	0.00254	-0.23	-0.2	Height;	chr14:75095168	chr14:75011269~75012851:-
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	4.4	1.34e-05	0.00254	0.24	0.2	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
HNSC	cis	rs3808502	0.525	rs13280813	ENSG00000269918.1	AF131215.9	-4.4	1.34e-05	0.00254	-0.19	-0.2	Neuroticism;	chr8:11567596	chr8:11104691~11106704:-
HNSC	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-4.4	1.34e-05	0.00254	-0.22	-0.2	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
HNSC	cis	rs7819412	0.505	rs67849263	ENSG00000269918.1	AF131215.9	-4.4	1.34e-05	0.00254	-0.21	-0.2	Triglycerides;	chr8:11150034	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000211974.3	IGHV2-70	4.4	1.34e-05	0.00254	0.19	0.2	Kawasaki disease;	chr14:106708947	chr14:106723574~106724093:-
HNSC	cis	rs3096299	0.802	rs3102336	ENSG00000261574.1	RP1-168P16.2	4.4	1.34e-05	0.00254	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89392375~89412564:-
HNSC	cis	rs1008375	0.686	rs34338142	ENSG00000249502.1	AC006160.5	-4.4	1.34e-05	0.00254	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624551	chr4:17587467~17614571:-
HNSC	cis	rs6490294	0.808	rs7137270	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Mean platelet volume;	chr12:111825598	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.652	rs10849974	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Platelet count;	chr12:111826354	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.615	rs57303367	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Platelet count;	chr12:111827279	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.563	rs61547643	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Platelet count;	chr12:111828820	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.512	rs73422315	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Platelet count;	chr12:111830495	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs7488629	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Platelet count;	chr12:111835696	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.748	rs73422316	ENSG00000226469.1	ADAM1B	4.4	1.35e-05	0.00255	0.23	0.2	Mean platelet volume;	chr12:111835870	chr12:111927018~111929017:+
HNSC	cis	rs116095464	0.558	rs28636067	ENSG00000250848.1	CTD-2083E4.5	-4.4	1.35e-05	0.00255	-0.29	-0.2	Breast cancer;	chr5:199300	chr5:288833~290321:-
HNSC	cis	rs7809950	0.678	rs7788330	ENSG00000238832.1	snoU109	-4.4	1.35e-05	0.00255	-0.28	-0.2	Coronary artery disease;	chr7:107345203	chr7:107603363~107603507:+
HNSC	cis	rs7809950	0.678	rs77395658	ENSG00000238832.1	snoU109	-4.4	1.35e-05	0.00255	-0.28	-0.2	Coronary artery disease;	chr7:107360206	chr7:107603363~107603507:+
HNSC	cis	rs9287719	0.774	rs4997811	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10615412	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.745	rs4997810	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10615414	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.745	rs4997809	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10615416	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.837	rs4233882	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10615438	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.837	rs4331474	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10615457	chr2:10690344~10692099:+
HNSC	cis	rs9487051	0.621	rs9374076	ENSG00000243587.6	C6orf183	-4.4	1.35e-05	0.00255	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109276623	chr6:109165833~109271014:+
HNSC	cis	rs1799949	0.965	rs2236762	ENSG00000236383.6	LINC00854	-4.4	1.35e-05	0.00255	-0.18	-0.2	Menopause (age at onset);	chr17:43074658	chr17:43216941~43305976:-
HNSC	cis	rs9287719	0.967	rs10929688	ENSG00000243819.4	RN7SL832P	4.4	1.35e-05	0.00255	0.19	0.2	Prostate cancer;	chr2:10616524	chr2:10690344~10692099:+
HNSC	cis	rs11673344	0.523	rs7260488	ENSG00000276846.1	CTD-3220F14.3	4.4	1.35e-05	0.00255	0.22	0.2	Obesity-related traits;	chr19:37058883	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs8110158	ENSG00000276846.1	CTD-3220F14.3	4.4	1.35e-05	0.00255	0.22	0.2	Obesity-related traits;	chr19:37063491	chr19:37314868~37315620:-
HNSC	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	4.4	1.35e-05	0.00255	0.17	0.2	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
HNSC	cis	rs17150703	0.63	rs12545481	ENSG00000254340.1	RP11-10A14.3	4.4	1.35e-05	0.00255	0.29	0.2	Obesity (early onset extreme);	chr8:9889867	chr8:9141424~9145435:+
HNSC	cis	rs11893307	0.566	rs10170782	ENSG00000235852.1	AC005540.3	4.4	1.35e-05	0.00255	0.27	0.2	Mean platelet volume;	chr2:190758510	chr2:190880797~190882059:-
HNSC	cis	rs116095464	0.614	rs78905930	ENSG00000250848.1	CTD-2083E4.5	-4.4	1.35e-05	0.00255	-0.28	-0.2	Breast cancer;	chr5:246445	chr5:288833~290321:-
HNSC	cis	rs7735319	0.966	rs35317495	ENSG00000251281.1	CTD-2066L21.2	4.4	1.35e-05	0.00256	0.23	0.2	Systolic blood pressure;	chr5:33155097	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.901	rs7731489	ENSG00000251281.1	CTD-2066L21.2	4.4	1.35e-05	0.00256	0.23	0.2	Systolic blood pressure;	chr5:33156621	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.87	rs7735427	ENSG00000251281.1	CTD-2066L21.2	4.4	1.35e-05	0.00256	0.23	0.2	Systolic blood pressure;	chr5:33156782	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs62368014	ENSG00000251281.1	CTD-2066L21.2	4.4	1.35e-05	0.00256	0.23	0.2	Systolic blood pressure;	chr5:33157378	chr5:33011322~33017607:-
HNSC	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	4.4	1.35e-05	0.00256	0.24	0.2	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	4.4	1.35e-05	0.00256	0.24	0.2	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
HNSC	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	4.4	1.35e-05	0.00256	0.24	0.2	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
HNSC	cis	rs9329221	0.716	rs11989640	ENSG00000269918.1	AF131215.9	-4.4	1.35e-05	0.00256	-0.21	-0.2	Neuroticism;	chr8:10398544	chr8:11104691~11106704:-
HNSC	cis	rs2098713	0.569	rs533889	ENSG00000250155.1	CTD-2353F22.1	4.4	1.35e-05	0.00256	0.22	0.2	Telomere length;	chr5:37533613	chr5:36666214~36725195:-
HNSC	cis	rs11098499	0.78	rs10013652	ENSG00000249244.1	RP11-548H18.2	4.4	1.35e-05	0.00256	0.24	0.2	Corneal astigmatism;	chr4:119371101	chr4:119391831~119395335:-
HNSC	cis	rs6928977	0.897	rs2246852	ENSG00000231028.7	LINC00271	4.4	1.35e-05	0.00256	0.24	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135497801~135716055:+
HNSC	cis	rs13256369	0.802	rs35382339	ENSG00000173295.6	FAM86B3P	4.4	1.35e-05	0.00256	0.26	0.2	Obesity-related traits;	chr8:8701745	chr8:8228595~8244865:+
HNSC	cis	rs4256159	1	rs57898039	ENSG00000228956.7	SATB1-AS1	4.4	1.35e-05	0.00256	0.33	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18750216	chr3:18445024~18920401:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	4.4	1.35e-05	0.00256	0.24	0.2	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
HNSC	cis	rs6496044	0.548	rs7163032	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00256	0.23	0.2	Interstitial lung disease;	chr15:85529188	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.527	rs7163068	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00256	0.23	0.2	Interstitial lung disease;	chr15:85529235	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs10468112	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00256	0.23	0.2	Interstitial lung disease;	chr15:85530193	chr15:85191438~85213905:+
HNSC	cis	rs4356203	0.905	rs35933265	ENSG00000272034.1	SNORD14A	-4.4	1.35e-05	0.00256	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17074654~17074744:-
HNSC	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	4.4	1.35e-05	0.00256	0.17	0.2	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
HNSC	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	4.4	1.35e-05	0.00256	0.27	0.2	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
HNSC	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-4.4	1.35e-05	0.00256	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
HNSC	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	4.4	1.35e-05	0.00256	0.24	0.2	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
HNSC	cis	rs2732480	0.577	rs2732479	ENSG00000257763.1	OR5BK1P	4.4	1.35e-05	0.00256	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.537	rs1061986	ENSG00000257763.1	OR5BK1P	4.4	1.35e-05	0.00256	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.577	rs2732481	ENSG00000257763.1	OR5BK1P	4.4	1.35e-05	0.00256	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.557	rs2732484	ENSG00000257763.1	OR5BK1P	4.4	1.35e-05	0.00256	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48355792~48356614:-
HNSC	cis	rs7819412	0.595	rs10106914	ENSG00000255310.2	AF131215.2	-4.4	1.35e-05	0.00256	-0.19	-0.2	Triglycerides;	chr8:11130141	chr8:11107788~11109726:-
HNSC	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-4.4	1.35e-05	0.00256	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
HNSC	cis	rs964611	0.882	rs8027003	ENSG00000259488.2	RP11-154J22.1	-4.4	1.35e-05	0.00256	-0.2	-0.2	Metabolite levels (Pyroglutamine);	chr15:48355229	chr15:48312353~48331856:-
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	4.4	1.35e-05	0.00256	0.24	0.2	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000211974.3	IGHV2-70	4.4	1.35e-05	0.00256	0.19	0.2	Kawasaki disease;	chr14:106705441	chr14:106723574~106724093:-
HNSC	cis	rs13434995	0.513	rs17779627	ENSG00000273257.1	RP11-177J6.1	-4.4	1.36e-05	0.00256	-0.27	-0.2	Adiponectin levels;	chr4:55483775	chr4:55387949~55388271:+
HNSC	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	4.4	1.36e-05	0.00256	0.32	0.2	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	4.4	1.36e-05	0.00256	0.32	0.2	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
HNSC	cis	rs1008375	1	rs28497813	ENSG00000249502.1	AC006160.5	-4.4	1.36e-05	0.00256	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683880	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs28480159	ENSG00000249502.1	AC006160.5	-4.4	1.36e-05	0.00256	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684084	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs28750296	ENSG00000249502.1	AC006160.5	-4.4	1.36e-05	0.00256	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684203	chr4:17587467~17614571:-
HNSC	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-4.4	1.36e-05	0.00256	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
HNSC	cis	rs4908769	0.624	rs1763839	ENSG00000232912.4	RP5-1115A15.1	4.4	1.36e-05	0.00256	0.22	0.2	Allergy;	chr1:8413276	chr1:8424645~8434838:+
HNSC	cis	rs889398	0.77	rs8052225	ENSG00000226232.7	RP11-419C5.2	-4.4	1.36e-05	0.00256	-0.18	-0.2	Body mass index;	chr16:69849750	chr16:69976388~69996188:-
HNSC	cis	rs9650657	0.836	rs4841438	ENSG00000269918.1	AF131215.9	-4.4	1.36e-05	0.00256	-0.2	-0.2	Neuroticism;	chr8:10749246	chr8:11104691~11106704:-
HNSC	cis	rs9650657	0.836	rs11250067	ENSG00000269918.1	AF131215.9	-4.4	1.36e-05	0.00256	-0.2	-0.2	Neuroticism;	chr8:10749444	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs11777746	ENSG00000255310.2	AF131215.2	4.4	1.36e-05	0.00257	0.19	0.2	Retinal vascular caliber;	chr8:11347246	chr8:11107788~11109726:-
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000254340.1	RP11-10A14.3	4.4	1.36e-05	0.00257	0.23	0.2	Neuroticism;	chr8:8460377	chr8:9141424~9145435:+
HNSC	cis	rs2307394	0.964	rs12997065	ENSG00000281469.1	RP11-567F11.1	4.4	1.36e-05	0.00257	0.23	0.2	Urate levels;	chr2:147777249	chr2:148044380~148044894:+
HNSC	cis	rs3738443	1	rs3738443	ENSG00000259865.1	RP11-488L18.10	-4.4	1.36e-05	0.00257	-0.19	-0.2	Alcohol dependence;	chr1:247184887	chr1:247187281~247188526:-
HNSC	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-4.4	1.36e-05	0.00257	-0.22	-0.2	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
HNSC	cis	rs35963943	0.625	rs13082395	ENSG00000228956.7	SATB1-AS1	4.4	1.36e-05	0.00257	0.23	0.2	Lymphocyte counts;	chr3:18671647	chr3:18445024~18920401:+
HNSC	cis	rs6500395	0.962	rs1039341	ENSG00000261267.1	RP11-44I10.3	-4.4	1.36e-05	0.00257	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48540958	chr16:48559661~48587403:+
HNSC	cis	rs459482	0.504	rs467773	ENSG00000228318.3	AP001610.5	4.4	1.36e-05	0.00257	0.2	0.2	IgG glycosylation;	chr21:41446179	chr21:41441056~41445708:-
HNSC	cis	rs459482	0.504	rs363882	ENSG00000228318.3	AP001610.5	4.4	1.36e-05	0.00257	0.2	0.2	IgG glycosylation;	chr21:41446346	chr21:41441056~41445708:-
HNSC	cis	rs1979679	0.918	rs2169755	ENSG00000247934.4	RP11-967K21.1	-4.4	1.36e-05	0.00257	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28163298~28190738:-
HNSC	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-4.4	1.36e-05	0.00257	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
HNSC	cis	rs72843506	0.586	rs61749865	ENSG00000261033.1	RP11-209D14.2	4.4	1.36e-05	0.00258	0.35	0.2	Schizophrenia;	chr17:19931799	chr17:20008051~20009234:-
HNSC	cis	rs6496044	0.568	rs2344436	ENSG00000259295.5	CSPG4P12	4.4	1.37e-05	0.00258	0.23	0.2	Interstitial lung disease;	chr15:85531675	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs6496065	ENSG00000259295.5	CSPG4P12	4.4	1.37e-05	0.00258	0.23	0.2	Interstitial lung disease;	chr15:85532141	chr15:85191438~85213905:+
HNSC	cis	rs6496044	0.568	rs6496066	ENSG00000259295.5	CSPG4P12	4.4	1.37e-05	0.00258	0.23	0.2	Interstitial lung disease;	chr15:85532231	chr15:85191438~85213905:+
HNSC	cis	rs6928977	0.86	rs2614266	ENSG00000217482.2	HMGB1P17	-4.4	1.37e-05	0.00258	-0.22	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135636086~135636713:-
HNSC	cis	rs9880211	1	rs9812579	ENSG00000273486.1	RP11-731C17.2	4.4	1.37e-05	0.00258	0.19	0.2	Height;Body mass index;	chr3:136432408	chr3:136837338~136839021:-
HNSC	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
HNSC	cis	rs1979679	1	rs1979679	ENSG00000247934.4	RP11-967K21.1	-4.4	1.37e-05	0.00258	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28163298~28190738:-
HNSC	cis	rs1979679	1	rs11049487	ENSG00000247934.4	RP11-967K21.1	-4.4	1.37e-05	0.00258	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28163298~28190738:-
HNSC	cis	rs523522	0.962	rs4767903	ENSG00000278344.1	RP11-18C24.8	4.4	1.37e-05	0.00258	0.26	0.2	High light scatter reticulocyte count;	chr12:120492243	chr12:120500735~120501090:-
HNSC	cis	rs6964587	1	rs10488512	ENSG00000188693.7	CYP51A1-AS1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Breast cancer;	chr7:92124265	chr7:92134604~92180725:+
HNSC	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	4.4	1.37e-05	0.00258	0.2	0.2	Height;	chr5:37498809	chr5:36666214~36725195:-
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000233609.3	RP11-62H7.2	4.4	1.37e-05	0.00258	0.18	0.2	Neuroticism;	chr8:8461340	chr8:8961200~8979025:+
HNSC	cis	rs11638352	1	rs4924729	ENSG00000205771.5	CATSPER2P1	4.4	1.37e-05	0.00258	0.48	0.2	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43999046	chr15:43726918~43747094:-
HNSC	cis	rs10266483	0.545	rs114664455	ENSG00000228653.2	HNRNPCP7	4.4	1.37e-05	0.00258	0.25	0.2	Response to statin therapy;	chr7:64263634	chr7:64500825~64501729:+
HNSC	cis	rs1799949	1	rs33926631	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00258	-0.18	-0.2	Menopause (age at onset);	chr17:43152446	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1960605	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00258	-0.18	-0.2	Menopause (age at onset);	chr17:43153380	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs2037076	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00258	-0.18	-0.2	Menopause (age at onset);	chr17:43153866	chr17:43216941~43305976:-
HNSC	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-4.4	1.37e-05	0.00258	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-4.4	1.37e-05	0.00258	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
HNSC	cis	rs638893	1	rs28827279	ENSG00000255422.1	AP002954.4	-4.4	1.37e-05	0.00258	-0.32	-0.2	Vitiligo;	chr11:118830054	chr11:118704607~118750263:+
HNSC	cis	rs6964587	1	rs2157747	ENSG00000188693.7	CYP51A1-AS1	-4.4	1.37e-05	0.00258	-0.21	-0.2	Breast cancer;	chr7:92121264	chr7:92134604~92180725:+
HNSC	cis	rs5758659	0.692	rs5751251	ENSG00000273366.1	CTA-989H11.1	-4.4	1.37e-05	0.00259	-0.23	-0.2	Cognitive function;	chr22:42244600	chr22:42278188~42278846:+
HNSC	cis	rs11638352	1	rs4924737	ENSG00000205771.5	CATSPER2P1	4.4	1.37e-05	0.00259	0.54	0.2	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44072703	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.562	rs58583086	ENSG00000249244.1	RP11-548H18.2	-4.4	1.37e-05	0.00259	-0.24	-0.2	Corneal astigmatism;	chr4:119635207	chr4:119391831~119395335:-
HNSC	cis	rs1799949	1	rs8176273	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43059636	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176269	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43061609	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8176265	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43061979	chr17:43216941~43305976:-
HNSC	cis	rs1185460	0.967	rs1786684	ENSG00000272186.1	RP11-110I1.13	-4.4	1.37e-05	0.00259	-0.22	-0.2	Coronary artery disease;	chr11:119067724	chr11:119067374~119067698:-
HNSC	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	4.4	1.37e-05	0.00259	0.42	0.2	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
HNSC	cis	rs1799949	1	rs2271574	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43175631	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs33994002	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43176801	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs33920795	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43176993	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs33918839	ENSG00000236383.6	LINC00854	-4.4	1.37e-05	0.00259	-0.19	-0.2	Menopause (age at onset);	chr17:43177155	chr17:43216941~43305976:-
HNSC	cis	rs11673344	0.503	rs1667370	ENSG00000276846.1	CTD-3220F14.3	4.4	1.37e-05	0.00259	0.21	0.2	Obesity-related traits;	chr19:36999318	chr19:37314868~37315620:-
HNSC	cis	rs6723108	0.627	rs12469941	ENSG00000224043.6	CCNT2-AS1	4.4	1.37e-05	0.00259	0.24	0.2	Type 2 diabetes;	chr2:134872357	chr2:134735464~134918710:-
HNSC	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-4.4	1.37e-05	0.00259	-0.16	-0.2	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
HNSC	cis	rs79349575	0.783	rs12603969	ENSG00000270781.1	RP11-501C14.9	-4.4	1.37e-05	0.00259	-0.21	-0.2	Type 2 diabetes;	chr17:48957057	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12601955	ENSG00000270781.1	RP11-501C14.9	-4.4	1.37e-05	0.00259	-0.21	-0.2	Type 2 diabetes;	chr17:48957058	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.594	rs62078375	ENSG00000270781.1	RP11-501C14.9	-4.4	1.37e-05	0.00259	-0.21	-0.2	Type 2 diabetes;	chr17:48957612	chr17:48899131~48899748:+
HNSC	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	4.4	1.37e-05	0.00259	0.19	0.2	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
HNSC	cis	rs7296418	0.517	rs73231928	ENSG00000280120.1	RP11-546D6.3	4.39	1.37e-05	0.00259	0.17	0.2	Platelet count;	chr12:123239778	chr12:123152324~123153377:-
HNSC	cis	rs7296418	0.675	rs1879379	ENSG00000280120.1	RP11-546D6.3	4.39	1.37e-05	0.00259	0.17	0.2	Platelet count;	chr12:123242896	chr12:123152324~123153377:-
HNSC	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-4.39	1.37e-05	0.00259	-0.16	-0.2	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
HNSC	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.39	1.37e-05	0.00259	-0.23	-0.2	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
HNSC	cis	rs73222236	0.75	rs3932048	ENSG00000273486.1	RP11-731C17.2	4.39	1.37e-05	0.00259	0.17	0.2	Coronary artery disease;	chr3:136540082	chr3:136837338~136839021:-
HNSC	cis	rs6500395	1	rs7202551	ENSG00000261267.1	RP11-44I10.3	4.39	1.37e-05	0.00259	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48695073	chr16:48559661~48587403:+
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000280411.1	IGHV1-69-2	-4.39	1.37e-05	0.00259	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106680831	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.954	rs12502423	ENSG00000250412.1	KLHL2P1	4.39	1.37e-05	0.00259	0.26	0.2	Corneal astigmatism;	chr4:119503017	chr4:119334329~119378233:+
HNSC	cis	rs7868228	1	rs7864407	ENSG00000240498.5	CDKN2B-AS1	-4.39	1.37e-05	0.00259	-0.26	-0.2	Gut microbiome composition (winter);	chr9:21666949	chr9:21994778~22121097:+
HNSC	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	4.39	1.37e-05	0.00259	0.2	0.2	Height;	chr5:37504063	chr5:36666214~36725195:-
HNSC	cis	rs12745968	0.589	rs6603989	ENSG00000223787.2	RP4-593M8.1	-4.39	1.38e-05	0.00259	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92561371	chr1:92580476~92580821:-
HNSC	cis	rs11673344	0.504	rs7245882	ENSG00000276846.1	CTD-3220F14.3	-4.39	1.38e-05	0.00259	-0.22	-0.2	Obesity-related traits;	chr19:37089513	chr19:37314868~37315620:-
HNSC	cis	rs7296418	0.63	rs28419092	ENSG00000280120.1	RP11-546D6.3	4.39	1.38e-05	0.00259	0.17	0.2	Platelet count;	chr12:123328082	chr12:123152324~123153377:-
HNSC	cis	rs12478296	1	rs55758933	ENSG00000261186.2	RP11-341N2.1	-4.39	1.38e-05	0.00259	-0.33	-0.2	Obesity-related traits;	chr2:242098138	chr2:242087351~242088457:-
HNSC	cis	rs1125355	0.69	rs11691004	ENSG00000204380.3	AC005042.4	-4.39	1.38e-05	0.0026	-0.22	-0.2	Alzheimer's disease in APOE e4+ carriers;	chr2:158787663	chr2:158658337~158735002:-
HNSC	cis	rs4761669	0.628	rs10745700	ENSG00000241556.1	RP11-490G8.1	-4.39	1.38e-05	0.0026	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94812851	chr12:95467397~95467861:-
HNSC	cis	rs889398	0.802	rs12598642	ENSG00000226232.7	RP11-419C5.2	4.39	1.38e-05	0.0026	0.18	0.2	Body mass index;	chr16:69814869	chr16:69976388~69996188:-
HNSC	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	4.39	1.38e-05	0.0026	0.33	0.2	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
HNSC	cis	rs3806843	0.583	rs408652	ENSG00000276545.1	PCDHGB9P	4.39	1.38e-05	0.0026	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140950428	chr5:141439853~141442449:+
HNSC	cis	rs394563	0.601	rs367133	ENSG00000231760.4	RP11-350J20.5	4.39	1.38e-05	0.0026	0.26	0.2	Dupuytren's disease;	chr6:149476584	chr6:149796151~149826294:-
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000255495.1	AC145124.2	4.39	1.38e-05	0.0026	0.23	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000255495.1	AC145124.2	4.39	1.38e-05	0.0026	0.23	0.2	Neuroticism;	chr8:11935587	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000255495.1	AC145124.2	4.39	1.38e-05	0.0026	0.23	0.2	Neuroticism;	chr8:11935631	chr8:12194467~12196280:+
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000255495.1	AC145124.2	4.39	1.38e-05	0.0026	0.23	0.2	Neuroticism;	chr8:11935669	chr8:12194467~12196280:+
HNSC	cis	rs6964587	0.839	rs6952459	ENSG00000188693.7	CYP51A1-AS1	-4.39	1.38e-05	0.0026	-0.21	-0.2	Breast cancer;	chr7:91806506	chr7:92134604~92180725:+
HNSC	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	4.39	1.38e-05	0.0026	0.27	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
HNSC	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	4.39	1.38e-05	0.0026	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.771	rs6601513	ENSG00000269918.1	AF131215.9	-4.39	1.38e-05	0.0026	-0.2	-0.2	Neuroticism;	chr8:10737333	chr8:11104691~11106704:-
HNSC	cis	rs2834288	0.959	rs2834294	ENSG00000273102.1	AP000569.9	-4.39	1.38e-05	0.0026	-0.21	-0.2	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33967101~33968573:-
HNSC	cis	rs755249	0.917	rs61779331	ENSG00000182109.6	RP11-69E11.4	4.39	1.38e-05	0.0026	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39522280~39546187:-
HNSC	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-4.39	1.38e-05	0.0026	-0.27	-0.2	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
HNSC	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	4.39	1.38e-05	0.0026	0.19	0.2	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
HNSC	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	4.39	1.38e-05	0.0026	0.19	0.2	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.898	rs28877020	ENSG00000273486.1	RP11-731C17.2	4.39	1.38e-05	0.0026	0.19	0.2	Height;Body mass index;	chr3:136676874	chr3:136837338~136839021:-
HNSC	cis	rs6831352	0.734	rs1311620	ENSG00000263923.1	RP11-571L19.7	-4.39	1.38e-05	0.0026	-0.21	-0.2	Alcohol dependence;	chr4:99091940	chr4:98928897~98994994:+
HNSC	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-4.39	1.38e-05	0.00261	-0.21	-0.2	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
HNSC	cis	rs9329221	0.527	rs10903328	ENSG00000269918.1	AF131215.9	4.39	1.38e-05	0.00261	0.2	0.2	Neuroticism;	chr8:10474657	chr8:11104691~11106704:-
HNSC	cis	rs5758511	0.68	rs1107554	ENSG00000226450.2	CYP2D8P	4.39	1.38e-05	0.00261	0.19	0.2	Birth weight;	chr22:42271588	chr22:42149886~42155001:-
HNSC	cis	rs1355223	0.525	rs7129533	ENSG00000271369.1	RP11-350D17.3	-4.39	1.38e-05	0.00261	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850745	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.525	rs55796371	ENSG00000271369.1	RP11-350D17.3	-4.39	1.38e-05	0.00261	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851222	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.525	rs12280958	ENSG00000271369.1	RP11-350D17.3	-4.39	1.38e-05	0.00261	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851252	chr11:34709600~34710161:+
HNSC	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	4.39	1.38e-05	0.00261	0.29	0.2	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
HNSC	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	4.39	1.38e-05	0.00261	0.29	0.2	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
HNSC	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-4.39	1.38e-05	0.00261	-0.17	-0.2	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	4.39	1.38e-05	0.00261	0.24	0.2	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
HNSC	cis	rs17345786	0.911	rs10936707	ENSG00000244119.1	PDCL3P4	4.39	1.38e-05	0.00261	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101712472~101713191:+
HNSC	cis	rs11673344	0.523	rs2562609	ENSG00000276846.1	CTD-3220F14.3	4.39	1.38e-05	0.00261	0.22	0.2	Obesity-related traits;	chr19:37036255	chr19:37314868~37315620:-
HNSC	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-4.39	1.39e-05	0.00261	-0.31	-0.2	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
HNSC	cis	rs2834288	0.7	rs2409502	ENSG00000273102.1	AP000569.9	-4.39	1.39e-05	0.00261	-0.23	-0.2	Gut microbiota (bacterial taxa);	chr21:33902431	chr21:33967101~33968573:-
HNSC	cis	rs60617249	0.895	rs17725609	ENSG00000228204.2	RP4-724E13.2	4.39	1.39e-05	0.00261	0.21	0.2	Major depression and alcohol dependence;	chr7:50920019	chr7:50866747~51022990:+
HNSC	cis	rs7735319	0.966	rs1842248	ENSG00000251281.1	CTD-2066L21.2	4.39	1.39e-05	0.00261	0.23	0.2	Systolic blood pressure;	chr5:33165734	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs2101014	ENSG00000251281.1	CTD-2066L21.2	4.39	1.39e-05	0.00261	0.23	0.2	Systolic blood pressure;	chr5:33166307	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs62368018	ENSG00000251281.1	CTD-2066L21.2	4.39	1.39e-05	0.00261	0.23	0.2	Systolic blood pressure;	chr5:33167320	chr5:33011322~33017607:-
HNSC	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-4.39	1.39e-05	0.00261	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
HNSC	cis	rs3736485	0.844	rs17603116	ENSG00000259438.1	CTD-2650P22.1	4.39	1.39e-05	0.00261	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51494680	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.844	rs17524813	ENSG00000259438.1	CTD-2650P22.1	4.39	1.39e-05	0.00261	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51501336	chr15:52010999~52019095:-
HNSC	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-4.39	1.39e-05	0.00261	-0.22	-0.2	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
HNSC	cis	rs16858210	0.874	rs34113436	ENSG00000234371.6	RPSAP31	4.39	1.39e-05	0.00261	0.24	0.2	Menopause (age at onset);	chr3:183856048	chr3:183884924~183888449:+
HNSC	cis	rs7809950	1	rs10276604	ENSG00000238832.1	snoU109	4.39	1.39e-05	0.00261	0.26	0.2	Coronary artery disease;	chr7:107576293	chr7:107603363~107603507:+
HNSC	cis	rs638893	1	rs638893	ENSG00000255422.1	AP002954.4	-4.39	1.39e-05	0.00261	-0.32	-0.2	Vitiligo;	chr11:118827828	chr11:118704607~118750263:+
HNSC	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-4.39	1.39e-05	0.00261	-0.23	-0.2	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
HNSC	cis	rs3015469	0.584	rs1950730	ENSG00000269906.1	RP11-248J18.2	-4.39	1.39e-05	0.00261	-0.27	-0.2	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50409110	chr14:50662511~50663178:-
HNSC	cis	rs12935418	0.672	rs9921914	ENSG00000261061.1	RP11-303E16.2	-4.39	1.39e-05	0.00261	-0.21	-0.2	Mean corpuscular volume;	chr16:81022506	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.672	rs3826048	ENSG00000261061.1	RP11-303E16.2	-4.39	1.39e-05	0.00261	-0.21	-0.2	Mean corpuscular volume;	chr16:81023230	chr16:81030770~81031485:+
HNSC	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-4.39	1.39e-05	0.00262	-0.26	-0.2	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
HNSC	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-4.39	1.39e-05	0.00262	-0.25	-0.2	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
HNSC	cis	rs1642645	0.793	rs642579	ENSG00000228452.1	RP5-994D16.9	-4.39	1.39e-05	0.00262	-0.28	-0.2	Left ventricular obstructive tract defect (maternal effect);	chr1:41965726	chr1:42775813~42776790:-
HNSC	cis	rs12701220	0.803	rs12701432	ENSG00000224079.1	AC091729.7	4.39	1.39e-05	0.00262	0.28	0.2	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1074450~1078036:+
HNSC	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-4.39	1.39e-05	0.00262	-0.16	-0.2	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
HNSC	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	4.39	1.39e-05	0.00262	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
HNSC	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	4.39	1.39e-05	0.00262	0.17	0.2	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
HNSC	cis	rs9437689	0.789	rs2797616	ENSG00000237416.5	RP11-465K1.2	4.39	1.39e-05	0.00262	0.24	0.2	Phospholipid levels (plasma);	chr1:94964359	chr1:94836748~94855426:-
HNSC	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-4.39	1.39e-05	0.00262	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-4.39	1.39e-05	0.00262	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-4.39	1.39e-05	0.00262	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
HNSC	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-4.39	1.39e-05	0.00262	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
HNSC	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-4.39	1.39e-05	0.00262	-0.15	-0.2	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
HNSC	cis	rs1707322	1	rs12077974	ENSG00000234329.1	RP11-767N6.2	4.39	1.39e-05	0.00262	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45651039~45651826:-
HNSC	cis	rs7937890	0.56	rs2597194	ENSG00000251991.1	RNU7-49P	4.39	1.39e-05	0.00262	0.23	0.2	Mitochondrial DNA levels;	chr11:14475723	chr11:14478892~14478953:+
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	4.39	1.39e-05	0.00263	0.24	0.2	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
HNSC	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-4.39	1.4e-05	0.00263	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
HNSC	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-4.39	1.4e-05	0.00263	-0.21	-0.2	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
HNSC	cis	rs7937890	0.593	rs2597189	ENSG00000251991.1	RNU7-49P	4.39	1.4e-05	0.00263	0.23	0.2	Mitochondrial DNA levels;	chr11:14490514	chr11:14478892~14478953:+
HNSC	cis	rs2361710	1	rs2361710	ENSG00000279259.1	RP11-334C17.3	-4.39	1.4e-05	0.00263	-0.22	-0.2	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80138078	chr17:80147250~80148596:+
HNSC	cis	rs72627509	0.723	rs67043033	ENSG00000269949.1	RP11-738E22.3	4.39	1.4e-05	0.00263	0.32	0.2	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56873067	chr4:56960927~56961373:-
HNSC	cis	rs72627509	0.68	rs73165962	ENSG00000269949.1	RP11-738E22.3	4.39	1.4e-05	0.00263	0.32	0.2	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874367	chr4:56960927~56961373:-
HNSC	cis	rs72627509	0.638	rs73165963	ENSG00000269949.1	RP11-738E22.3	4.39	1.4e-05	0.00263	0.32	0.2	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874370	chr4:56960927~56961373:-
HNSC	cis	rs4787951	0.698	rs4238955	ENSG00000259940.2	CTD-3203P2.1	-4.39	1.4e-05	0.00263	-0.23	-0.2	Eosinophil percentage of white cells;	chr16:27305255	chr16:27213308~27214993:-
HNSC	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-4.39	1.4e-05	0.00263	-0.31	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
HNSC	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	4.39	1.4e-05	0.00263	0.17	0.2	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
HNSC	cis	rs6500395	1	rs8059819	ENSG00000261267.1	RP11-44I10.3	4.39	1.4e-05	0.00263	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48648923	chr16:48559661~48587403:+
HNSC	cis	rs4862750	0.872	rs13101380	ENSG00000250971.1	RP11-696F12.1	4.39	1.4e-05	0.00263	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186973590	chr4:187060099~187060930:+
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000224373.3	IGHV4-59	4.39	1.4e-05	0.00263	0.13	0.2	Kawasaki disease;	chr14:106782206	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000224373.3	IGHV4-59	4.39	1.4e-05	0.00263	0.13	0.2	Kawasaki disease;	chr14:106782238	chr14:106627249~106627825:-
HNSC	cis	rs3806843	1	rs4404730	ENSG00000202515.1	VTRNA1-3	-4.39	1.4e-05	0.00263	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr5:140726158~140726246:+
HNSC	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-4.39	1.4e-05	0.00263	-0.24	-0.2	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
HNSC	cis	rs6840258	1	rs17701999	ENSG00000251411.1	RP11-397E7.4	-4.39	1.4e-05	0.00263	-0.25	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034392	chr4:86913266~86914817:-
HNSC	cis	rs11098499	0.955	rs1551	ENSG00000250412.1	KLHL2P1	4.39	1.4e-05	0.00263	0.25	0.2	Corneal astigmatism;	chr4:119237345	chr4:119334329~119378233:+
HNSC	cis	rs67981189	0.865	rs2810071	ENSG00000274818.1	RP1-292L20.3	-4.39	1.4e-05	0.00263	-0.23	-0.2	Schizophrenia;	chr14:70920931	chr14:70906657~70907111:-
HNSC	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-4.39	1.4e-05	0.00263	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
HNSC	cis	rs4356203	0.87	rs10832748	ENSG00000272034.1	SNORD14A	-4.39	1.4e-05	0.00263	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17074654~17074744:-
HNSC	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	4.39	1.4e-05	0.00263	0.24	0.2	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-4.39	1.4e-05	0.00263	-0.22	-0.2	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-4.39	1.4e-05	0.00263	-0.22	-0.2	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
HNSC	cis	rs9840812	0.769	rs632016	ENSG00000239213.4	NCK1-AS1	4.39	1.4e-05	0.00264	0.18	0.2	Fibrinogen levels;	chr3:136258198	chr3:136841726~136862054:-
HNSC	cis	rs9863	0.828	rs4765562	ENSG00000270028.1	RP11-380L11.4	4.39	1.4e-05	0.00264	0.23	0.2	White blood cell count;	chr12:123988024	chr12:123925461~123926083:-
HNSC	cis	rs1555322	1	rs1555322	ENSG00000279253.1	RP4-614O4.13	-4.39	1.4e-05	0.00264	-0.29	-0.2	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35262727~35264187:-
HNSC	cis	rs13434995	0.513	rs1979604	ENSG00000273257.1	RP11-177J6.1	4.39	1.4e-05	0.00264	0.27	0.2	Adiponectin levels;	chr4:55552588	chr4:55387949~55388271:+
HNSC	cis	rs35963943	0.625	rs11715656	ENSG00000228956.7	SATB1-AS1	4.39	1.4e-05	0.00264	0.24	0.2	Lymphocyte counts;	chr3:18677008	chr3:18445024~18920401:+
HNSC	cis	rs6688613	1	rs1327866	ENSG00000215834.7	FMO9P	-4.39	1.4e-05	0.00264	-0.24	-0.2	Refractive astigmatism;	chr1:166983673	chr1:166603675~166631400:+
HNSC	cis	rs8028182	0.636	rs11636199	ENSG00000260269.4	CTD-2323K18.1	-4.39	1.4e-05	0.00264	-0.25	-0.2	Sudden cardiac arrest;	chr15:75532996	chr15:75527150~75601205:-
HNSC	cis	rs7176527	0.519	rs12148368	ENSG00000259570.1	RP11-671M22.4	-4.39	1.4e-05	0.00264	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84394512~84395514:+
HNSC	cis	rs12893668	0.637	rs12892038	ENSG00000269940.1	RP11-73M18.7	4.39	1.4e-05	0.00264	0.2	0.2	Reticulocyte count;	chr14:103602292	chr14:103694560~103695170:+
HNSC	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	4.39	1.4e-05	0.00264	0.19	0.2	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
HNSC	cis	rs67340775	0.541	rs200968	ENSG00000219392.1	RP1-265C24.5	-4.39	1.4e-05	0.00264	-0.3	-0.2	Lung cancer in ever smokers;	chr6:27891790	chr6:28115628~28116551:+
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000255495.1	AC145124.2	-4.39	1.4e-05	0.00264	-0.22	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:12194467~12196280:+
HNSC	cis	rs4356203	0.87	rs214900	ENSG00000260196.1	RP1-239B22.5	4.39	1.4e-05	0.00264	0.2	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17380649~17383531:+
HNSC	cis	rs1799949	1	rs8176133	ENSG00000236383.6	LINC00854	-4.39	1.4e-05	0.00264	-0.19	-0.2	Menopause (age at onset);	chr17:43105441	chr17:43216941~43305976:-
HNSC	cis	rs12893668	0.663	rs12889731	ENSG00000269940.1	RP11-73M18.7	4.39	1.41e-05	0.00264	0.2	0.2	Reticulocyte count;	chr14:103621145	chr14:103694560~103695170:+
HNSC	cis	rs72772090	1	rs11738135	ENSG00000248734.2	CTD-2260A17.1	-4.39	1.41e-05	0.00264	-0.29	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712632	chr5:96784777~96785999:+
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-4.39	1.41e-05	0.00264	-0.18	-0.2	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
HNSC	cis	rs739496	0.579	rs80017658	ENSG00000226469.1	ADAM1B	4.39	1.41e-05	0.00264	0.23	0.2	Platelet count;	chr12:111942568	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs73426362	ENSG00000226469.1	ADAM1B	4.39	1.41e-05	0.00264	0.23	0.2	Platelet count;	chr12:111942666	chr12:111927018~111929017:+
HNSC	cis	rs11992162	1	rs11784499	ENSG00000269918.1	AF131215.9	4.39	1.41e-05	0.00264	0.2	0.2	Monocyte count;	chr8:11977030	chr8:11104691~11106704:-
HNSC	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	4.39	1.41e-05	0.00264	0.2	0.2	Height;	chr5:37533964	chr5:36666214~36725195:-
HNSC	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-4.39	1.41e-05	0.00265	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
HNSC	cis	rs13434995	0.513	rs4865006	ENSG00000273257.1	RP11-177J6.1	4.39	1.41e-05	0.00265	0.27	0.2	Adiponectin levels;	chr4:55526112	chr4:55387949~55388271:+
HNSC	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-4.39	1.41e-05	0.00265	-0.29	-0.2	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
HNSC	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-4.39	1.41e-05	0.00265	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-4.39	1.41e-05	0.00265	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-4.39	1.41e-05	0.00265	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-4.39	1.41e-05	0.00265	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
HNSC	cis	rs9914988	0.613	rs12948391	ENSG00000264577.1	AC010761.8	4.39	1.41e-05	0.00265	0.2	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28948603	chr17:28721487~28722877:-
HNSC	cis	rs3015497	0.646	rs3015492	ENSG00000277050.1	RP11-102G14.1	-4.39	1.41e-05	0.00265	-0.2	-0.2	Mean platelet volume;	chr14:50658025	chr14:51637348~51637947:-
HNSC	cis	rs1050631	0.96	rs1789516	ENSG00000278986.1	RP11-723J4.3	4.39	1.41e-05	0.00265	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36111725	chr18:35972151~35973916:+
HNSC	cis	rs1050631	1	rs1785919	ENSG00000278986.1	RP11-723J4.3	4.39	1.41e-05	0.00265	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36112001	chr18:35972151~35973916:+
HNSC	cis	rs1050631	0.924	rs1785918	ENSG00000278986.1	RP11-723J4.3	4.39	1.41e-05	0.00265	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36113235	chr18:35972151~35973916:+
HNSC	cis	rs9650657	0.769	rs1968400	ENSG00000269918.1	AF131215.9	-4.39	1.41e-05	0.00265	-0.2	-0.2	Neuroticism;	chr8:10757921	chr8:11104691~11106704:-
HNSC	cis	rs7475343	0.543	rs17134601	ENSG00000224034.1	RP11-445P17.8	4.39	1.41e-05	0.00265	0.27	0.2	Intelligence;	chr10:5219212	chr10:5266033~5271236:-
HNSC	cis	rs4356203	0.905	rs2052188	ENSG00000260196.1	RP1-239B22.5	4.39	1.41e-05	0.00265	0.2	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17380649~17383531:+
HNSC	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-4.39	1.41e-05	0.00265	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
HNSC	cis	rs10773046	0.74	rs11057382	ENSG00000269938.1	RP11-214K3.20	-4.39	1.41e-05	0.00265	-0.22	-0.2	Osteoarthritis (hip);	chr12:123878342	chr12:123968023~123968579:-
HNSC	cis	rs5758511	0.68	rs5758687	ENSG00000226450.2	CYP2D8P	4.39	1.41e-05	0.00265	0.19	0.2	Birth weight;	chr22:42260582	chr22:42149886~42155001:-
HNSC	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	4.39	1.41e-05	0.00265	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	4.39	1.41e-05	0.00265	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	4.39	1.41e-05	0.00265	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
HNSC	cis	rs4356203	0.87	rs214922	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.811	rs214920	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs214918	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs214915	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs214914	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.84	rs214911	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs214910	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs214909	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs618331	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs7949699	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs11024204	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs10741724	ENSG00000272034.1	SNORD14A	-4.39	1.41e-05	0.00265	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17074654~17074744:-
HNSC	cis	rs453301	0.571	rs330048	ENSG00000233609.3	RP11-62H7.2	-4.39	1.41e-05	0.00265	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9229768	chr8:8961200~8979025:+
HNSC	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-4.39	1.41e-05	0.00265	-0.23	-0.2	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
HNSC	cis	rs274567	0.711	rs404771	ENSG00000233006.5	AC034220.3	4.39	1.41e-05	0.00265	0.23	0.2	Blood metabolite levels;	chr5:132299399	chr5:132311285~132369916:-
HNSC	cis	rs7824557	0.767	rs4559208	ENSG00000255310.2	AF131215.2	4.39	1.41e-05	0.00265	0.19	0.2	Retinal vascular caliber;	chr8:11296416	chr8:11107788~11109726:-
HNSC	cis	rs6951245	0.572	rs73259905	ENSG00000225146.1	AC073957.15	-4.39	1.41e-05	0.00265	-0.4	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:983728	chr7:1029025~1043891:+
HNSC	cis	rs2998286	0.723	rs332146	ENSG00000254635.4	WAC-AS1	-4.39	1.41e-05	0.00265	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28522652~28532743:-
HNSC	cis	rs3736485	0.844	rs11070853	ENSG00000259438.1	CTD-2650P22.1	4.39	1.41e-05	0.00265	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51492006	chr15:52010999~52019095:-
HNSC	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-4.39	1.41e-05	0.00265	-0.26	-0.2	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
HNSC	cis	rs9903692	0.954	rs12941295	ENSG00000263412.1	RP5-890E16.2	4.39	1.41e-05	0.00265	0.19	0.2	Pulse pressure;	chr17:48110825	chr17:48045141~48048073:-
HNSC	cis	rs11098499	1	rs13116504	ENSG00000250412.1	KLHL2P1	4.39	1.41e-05	0.00265	0.25	0.2	Corneal astigmatism;	chr4:119288257	chr4:119334329~119378233:+
HNSC	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.39	1.41e-05	0.00265	0.22	0.2	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
HNSC	cis	rs13256369	0.802	rs13280101	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.26	0.2	Obesity-related traits;	chr8:8705263	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs13255789	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.26	0.2	Obesity-related traits;	chr8:8705281	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.756	rs13282580	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.26	0.2	Obesity-related traits;	chr8:8705393	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.802	rs13256404	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.26	0.2	Obesity-related traits;	chr8:8705464	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.756	rs13280759	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.26	0.2	Obesity-related traits;	chr8:8705485	chr8:8228595~8244865:+
HNSC	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	4.39	1.41e-05	0.00266	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
HNSC	cis	rs3736485	0.844	rs11638240	ENSG00000259438.1	CTD-2650P22.1	4.39	1.41e-05	0.00266	0.21	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51552132	chr15:52010999~52019095:-
HNSC	cis	rs9487051	0.872	rs9386790	ENSG00000219700.1	PTCHD3P3	-4.39	1.41e-05	0.00266	-0.19	-0.2	Reticulocyte fraction of red cells;	chr6:109287257	chr6:109288571~109290503:-
HNSC	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-4.39	1.41e-05	0.00266	-0.22	-0.2	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
HNSC	cis	rs36563	0.561	rs17108824	ENSG00000274818.1	RP1-292L20.3	4.39	1.42e-05	0.00266	0.32	0.2	Alcohol dependence;	chr14:70980185	chr14:70906657~70907111:-
HNSC	cis	rs467650	0.509	rs2591443	ENSG00000246763.5	RGMB-AS1	-4.39	1.42e-05	0.00266	-0.23	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98769618~98773469:-
HNSC	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	4.39	1.42e-05	0.00266	0.21	0.2	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
HNSC	cis	rs7809950	0.817	rs2204833	ENSG00000238832.1	snoU109	4.39	1.42e-05	0.00266	0.28	0.2	Coronary artery disease;	chr7:107642624	chr7:107603363~107603507:+
HNSC	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-4.39	1.42e-05	0.00266	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
HNSC	cis	rs763121	0.889	rs6001209	ENSG00000273076.1	RP3-508I15.22	-4.39	1.42e-05	0.00266	-0.2	-0.2	Menopause (age at onset);	chr22:38725247	chr22:38743495~38743910:+
HNSC	cis	rs10927875	0.722	rs6660685	ENSG00000226029.1	RP4-798A10.2	-4.39	1.42e-05	0.00266	-0.2	-0.2	Dilated cardiomyopathy;	chr1:16020493	chr1:16460948~16468481:+
HNSC	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	4.39	1.42e-05	0.00266	0.23	0.2	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
HNSC	cis	rs7324557	0.684	rs58663560	ENSG00000205861.10	C1QTNF9B-AS1	-4.39	1.42e-05	0.00266	-0.28	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23830800	chr13:23888889~23897263:+
HNSC	cis	rs10927875	0.631	rs28579893	ENSG00000226029.1	RP4-798A10.2	-4.39	1.42e-05	0.00266	-0.2	-0.2	Dilated cardiomyopathy;	chr1:16021039	chr1:16460948~16468481:+
HNSC	cis	rs6490294	0.571	rs11066120	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:111998391	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7312472	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112000966	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs57439171	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112001483	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7316650	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112001860	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7313773	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112003884	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7295294	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112027089	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs6489824	ENSG00000226469.1	ADAM1B	4.39	1.42e-05	0.00266	0.28	0.2	Mean platelet volume;	chr12:112030613	chr12:111927018~111929017:+
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-4.39	1.42e-05	0.00266	-0.25	-0.2	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-4.39	1.42e-05	0.00266	-0.26	-0.2	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
HNSC	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-4.39	1.42e-05	0.00267	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
HNSC	cis	rs7688540	0.771	rs61794996	ENSG00000211553.1	AC253576.2	-4.39	1.42e-05	0.00267	-0.3	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:136461~136568:+
HNSC	cis	rs9527	0.614	rs4919691	ENSG00000236937.2	PTGES3P4	4.39	1.42e-05	0.00267	0.25	0.2	Arsenic metabolism;	chr10:102864718	chr10:102845595~102845950:+
HNSC	cis	rs988913	0.723	rs4490666	ENSG00000224984.1	RP11-524H19.2	-4.39	1.42e-05	0.00267	-0.23	-0.2	Menarche (age at onset);	chr6:55135853	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.723	rs7761785	ENSG00000224984.1	RP11-524H19.2	-4.39	1.42e-05	0.00267	-0.23	-0.2	Menarche (age at onset);	chr6:55137239	chr6:54840118~54840855:-
HNSC	cis	rs12935418	0.616	rs9937731	ENSG00000261061.1	RP11-303E16.2	-4.39	1.42e-05	0.00267	-0.22	-0.2	Mean corpuscular volume;	chr16:80978406	chr16:81030770~81031485:+
HNSC	cis	rs6787172	0.748	rs7650256	ENSG00000272087.1	RP11-379F4.7	4.39	1.42e-05	0.00267	0.21	0.2	Subjective well-being;	chr3:158392698	chr3:158693120~158693768:-
HNSC	cis	rs831571	0.668	rs17069879	ENSG00000280620.1	SCAANT1	-4.39	1.42e-05	0.00267	-0.3	-0.2	Type 2 diabetes;	chr3:64097741	chr3:63911518~63911772:-
HNSC	cis	rs9863	0.827	rs6488913	ENSG00000269938.1	RP11-214K3.20	4.39	1.42e-05	0.00267	0.23	0.2	White blood cell count;	chr12:123961022	chr12:123968023~123968579:-
HNSC	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	4.39	1.42e-05	0.00267	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	4.39	1.42e-05	0.00267	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	4.39	1.42e-05	0.00267	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	4.39	1.42e-05	0.00267	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	4.39	1.42e-05	0.00267	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
HNSC	cis	rs8067545	0.641	rs1638525	ENSG00000266126.1	RP11-209D14.4	4.39	1.42e-05	0.00267	0.23	0.2	Schizophrenia;	chr17:19945281	chr17:19929372~19929737:-
HNSC	cis	rs79349575	0.783	rs28409394	ENSG00000270781.1	RP11-501C14.9	-4.39	1.42e-05	0.00267	-0.21	-0.2	Type 2 diabetes;	chr17:48920756	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4793991	ENSG00000270781.1	RP11-501C14.9	-4.39	1.42e-05	0.00267	-0.21	-0.2	Type 2 diabetes;	chr17:48924439	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.715	rs62075844	ENSG00000270781.1	RP11-501C14.9	-4.39	1.42e-05	0.00267	-0.21	-0.2	Type 2 diabetes;	chr17:48925027	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs957557	ENSG00000270781.1	RP11-501C14.9	-4.39	1.42e-05	0.00267	-0.21	-0.2	Type 2 diabetes;	chr17:48925859	chr17:48899131~48899748:+
HNSC	cis	rs1008375	1	rs60178264	ENSG00000249502.1	AC006160.5	-4.39	1.42e-05	0.00267	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683685	chr4:17587467~17614571:-
HNSC	cis	rs10266483	0.515	rs17689514	ENSG00000228653.2	HNRNPCP7	4.39	1.42e-05	0.00267	0.25	0.2	Response to statin therapy;	chr7:64279269	chr7:64500825~64501729:+
HNSC	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	4.39	1.42e-05	0.00267	0.28	0.2	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
HNSC	cis	rs6500395	0.963	rs6500404	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48656172	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs6500405	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48656575	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.928	rs723807	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48657532	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs8052196	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48657733	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.832	rs8052733	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48658067	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs12919278	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48658626	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12597569	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48659431	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs12447645	ENSG00000261267.1	RP11-44I10.3	4.39	1.42e-05	0.00267	0.25	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48660529	chr16:48559661~48587403:+
HNSC	cis	rs1823874	0.886	rs2123933	ENSG00000182397.13	DNM1P46	-4.39	1.42e-05	0.00267	-0.2	-0.2	IgG glycosylation;	chr15:99824131	chr15:99790156~99806927:-
HNSC	cis	rs12478296	1	rs4973685	ENSG00000261186.2	RP11-341N2.1	-4.39	1.42e-05	0.00267	-0.34	-0.2	Obesity-related traits;	chr2:242076938	chr2:242087351~242088457:-
HNSC	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-4.39	1.42e-05	0.00267	-0.23	-0.2	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
HNSC	cis	rs1008375	0.966	rs2191504	ENSG00000249502.1	AC006160.5	-4.39	1.43e-05	0.00267	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673969	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs1121091	ENSG00000249502.1	AC006160.5	-4.39	1.43e-05	0.00267	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674763	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs1121090	ENSG00000249502.1	AC006160.5	-4.39	1.43e-05	0.00267	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674814	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs2315560	ENSG00000249502.1	AC006160.5	-4.39	1.43e-05	0.00267	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675682	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	4.39	1.43e-05	0.00267	0.24	0.2	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
HNSC	cis	rs17666538	0.642	rs7821983	ENSG00000254207.1	RP11-43A14.1	4.39	1.43e-05	0.00267	0.41	0.2	IgG glycosylation;	chr8:693696	chr8:725188~725877:-
HNSC	cis	rs9880211	0.948	rs34135127	ENSG00000273486.1	RP11-731C17.2	4.39	1.43e-05	0.00267	0.19	0.2	Height;Body mass index;	chr3:136507656	chr3:136837338~136839021:-
HNSC	cis	rs6928977	0.863	rs7772681	ENSG00000217482.2	HMGB1P17	4.39	1.43e-05	0.00268	0.22	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135327875	chr6:135636086~135636713:-
HNSC	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-4.39	1.43e-05	0.00268	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
HNSC	cis	rs4356203	0.87	rs214926	ENSG00000272034.1	SNORD14A	-4.39	1.43e-05	0.00268	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17074654~17074744:-
HNSC	cis	rs1050631	1	rs11081934	ENSG00000278986.1	RP11-723J4.3	4.39	1.43e-05	0.00268	0.22	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36125341	chr18:35972151~35973916:+
HNSC	cis	rs72843166	0.562	rs3760257	ENSG00000265282.1	RP11-269G24.4	4.39	1.43e-05	0.00268	0.29	0.2	Intelligence (multi-trait analysis);	chr17:63419110	chr17:63430468~63432211:-
HNSC	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-4.39	1.43e-05	0.00268	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
HNSC	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-4.39	1.43e-05	0.00268	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
HNSC	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	4.39	1.43e-05	0.00268	0.2	0.2	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
HNSC	cis	rs12893668	0.703	rs34896432	ENSG00000269910.1	RP11-73M18.10	4.39	1.43e-05	0.00268	0.2	0.2	Reticulocyte count;	chr14:103561658	chr14:103694516~103695050:-
HNSC	cis	rs4761669	0.816	rs4761506	ENSG00000241556.1	RP11-490G8.1	-4.39	1.43e-05	0.00268	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94807044	chr12:95467397~95467861:-
HNSC	cis	rs2337406	0.866	rs78462736	ENSG00000280411.1	IGHV1-69-2	-4.39	1.43e-05	0.00268	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106779942	chr14:106762092~106762588:-
HNSC	cis	rs12893668	0.514	rs3212090	ENSG00000269910.1	RP11-73M18.10	4.39	1.43e-05	0.00268	0.19	0.2	Reticulocyte count;	chr14:103702526	chr14:103694516~103695050:-
HNSC	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00268	0.23	0.2	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00268	0.23	0.2	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
HNSC	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-4.39	1.43e-05	0.00268	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
HNSC	cis	rs9450351	0.744	rs6937582	ENSG00000203875.9	SNHG5	-4.39	1.43e-05	0.00268	-0.43	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85855880	chr6:85660950~85678736:-
HNSC	cis	rs1008375	0.932	rs4698629	ENSG00000249502.1	AC006160.5	-4.39	1.43e-05	0.00268	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17607261	chr4:17587467~17614571:-
HNSC	cis	rs11098499	0.955	rs35434465	ENSG00000250412.1	KLHL2P1	4.39	1.43e-05	0.00268	0.25	0.2	Corneal astigmatism;	chr4:119248223	chr4:119334329~119378233:+
HNSC	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-4.39	1.43e-05	0.00268	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
HNSC	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	4.39	1.43e-05	0.00269	0.22	0.2	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
HNSC	cis	rs4523957	0.818	rs4790887	ENSG00000262333.1	HNRNPA1P16	-4.39	1.43e-05	0.00269	-0.16	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2227298	chr17:2306761~2307715:+
HNSC	cis	rs1799949	1	rs2175957	ENSG00000236383.6	LINC00854	-4.39	1.43e-05	0.00269	-0.19	-0.2	Menopause (age at onset);	chr17:43134805	chr17:43216941~43305976:-
HNSC	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	4.39	1.43e-05	0.00269	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
HNSC	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-4.39	1.43e-05	0.00269	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
HNSC	cis	rs9487051	0.621	rs6925339	ENSG00000243587.6	C6orf183	-4.39	1.43e-05	0.00269	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109238213	chr6:109165833~109271014:+
HNSC	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	4.38	1.43e-05	0.00269	0.23	0.2	Height;	chr14:75068316	chr14:75011269~75012851:-
HNSC	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	4.38	1.43e-05	0.00269	0.26	0.2	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
HNSC	cis	rs79349575	0.811	rs60708039	ENSG00000270781.1	RP11-501C14.9	-4.38	1.43e-05	0.00269	-0.21	-0.2	Type 2 diabetes;	chr17:48922011	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs55771415	ENSG00000270781.1	RP11-501C14.9	-4.38	1.43e-05	0.00269	-0.21	-0.2	Type 2 diabetes;	chr17:48922575	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs2088139	ENSG00000270781.1	RP11-501C14.9	-4.38	1.43e-05	0.00269	-0.21	-0.2	Type 2 diabetes;	chr17:48922748	chr17:48899131~48899748:+
HNSC	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	4.38	1.44e-05	0.00269	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	4.38	1.44e-05	0.00269	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
HNSC	cis	rs9500256	0.655	rs12209098	ENSG00000225096.1	XXbac-BPG55C20.7	4.38	1.44e-05	0.00269	0.23	0.2	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57965630~57972218:+
HNSC	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	4.38	1.44e-05	0.00269	0.22	0.2	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
HNSC	cis	rs6490294	0.748	rs111752063	ENSG00000226469.1	ADAM1B	4.38	1.44e-05	0.00269	0.23	0.2	Mean platelet volume;	chr12:111859646	chr12:111927018~111929017:+
HNSC	cis	rs12701220	0.817	rs1058727	ENSG00000229043.2	AC091729.9	-4.38	1.44e-05	0.00269	-0.26	-0.2	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1160374~1165267:+
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000224373.3	IGHV4-59	4.38	1.44e-05	0.00269	0.13	0.2	Kawasaki disease;	chr14:106716993	chr14:106627249~106627825:-
HNSC	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-4.38	1.44e-05	0.00269	-0.22	-0.2	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
HNSC	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-4.38	1.44e-05	0.00269	-0.22	-0.2	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
HNSC	cis	rs12935418	0.616	rs2549858	ENSG00000261061.1	RP11-303E16.2	4.38	1.44e-05	0.0027	0.21	0.2	Mean corpuscular volume;	chr16:80993389	chr16:81030770~81031485:+
HNSC	cis	rs12935418	0.616	rs2549859	ENSG00000261061.1	RP11-303E16.2	4.38	1.44e-05	0.0027	0.21	0.2	Mean corpuscular volume;	chr16:80993398	chr16:81030770~81031485:+
HNSC	cis	rs5769707	0.642	rs4824070	ENSG00000235111.1	RP1-29C18.8	-4.38	1.44e-05	0.0027	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49612657~49615716:-
HNSC	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	4.38	1.44e-05	0.0027	0.22	0.2	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
HNSC	cis	rs1355223	0.525	rs10836316	ENSG00000271369.1	RP11-350D17.3	-4.38	1.44e-05	0.0027	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852748	chr11:34709600~34710161:+
HNSC	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	4.38	1.44e-05	0.0027	0.16	0.2	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
HNSC	cis	rs2439831	0.702	rs7175032	ENSG00000201136.1	RNU6-353P	-4.38	1.44e-05	0.0027	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43768038	chr15:43702363~43702470:+
HNSC	cis	rs67311347	0.911	rs58282210	ENSG00000280739.1	EIF1B-AS1	4.38	1.44e-05	0.0027	0.22	0.2	Renal cell carcinoma;	chr3:40376452	chr3:40173145~40309698:-
HNSC	cis	rs9880211	0.898	rs34031772	ENSG00000273486.1	RP11-731C17.2	4.38	1.44e-05	0.0027	0.19	0.2	Height;Body mass index;	chr3:136299299	chr3:136837338~136839021:-
HNSC	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-4.38	1.44e-05	0.0027	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
HNSC	cis	rs1979679	0.719	rs11049489	ENSG00000247934.4	RP11-967K21.1	-4.38	1.44e-05	0.0027	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28163298~28190738:-
HNSC	cis	rs4925386	0.765	rs6142737	ENSG00000275437.1	RP5-908M14.10	4.38	1.44e-05	0.0027	0.21	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62402236~62405935:-
HNSC	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	4.38	1.44e-05	0.0027	0.21	0.2	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
HNSC	cis	rs9840812	0.773	rs1154988	ENSG00000273486.1	RP11-731C17.2	-4.38	1.44e-05	0.0027	-0.18	-0.2	Fibrinogen levels;	chr3:136206349	chr3:136837338~136839021:-
HNSC	cis	rs9650657	0.513	rs4841459	ENSG00000255310.2	AF131215.2	-4.38	1.44e-05	0.0027	-0.19	-0.2	Neuroticism;	chr8:10924932	chr8:11107788~11109726:-
HNSC	cis	rs4761470	1	rs4761470	ENSG00000258365.1	RP11-1105G2.3	-4.38	1.44e-05	0.0027	-0.25	-0.2	Estradiol plasma levels (breast cancer);	chr12:94289428	chr12:94277758~94282844:-
HNSC	cis	rs6504950	0.783	rs12936639	ENSG00000275710.1	RP11-257O5.4	4.38	1.44e-05	0.0027	0.25	0.2	Breast cancer;	chr17:55158621	chr17:54964474~54964679:+
HNSC	cis	rs9863	0.861	rs11057397	ENSG00000269938.1	RP11-214K3.20	-4.38	1.44e-05	0.0027	-0.24	-0.2	White blood cell count;	chr12:123935181	chr12:123968023~123968579:-
HNSC	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-4.38	1.44e-05	0.0027	-0.25	-0.2	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
HNSC	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	4.38	1.44e-05	0.0027	0.21	0.2	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-4.38	1.44e-05	0.0027	-0.25	-0.2	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-4.38	1.44e-05	0.0027	-0.25	-0.2	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-4.38	1.44e-05	0.0027	-0.25	-0.2	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
HNSC	cis	rs13434995	0.513	rs62309729	ENSG00000273257.1	RP11-177J6.1	-4.38	1.44e-05	0.0027	-0.27	-0.2	Adiponectin levels;	chr4:55536679	chr4:55387949~55388271:+
HNSC	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	4.38	1.44e-05	0.0027	0.29	0.2	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
HNSC	cis	rs12682352	0.602	rs11783966	ENSG00000173295.6	FAM86B3P	-4.38	1.44e-05	0.0027	-0.23	-0.2	Neuroticism;	chr8:8807637	chr8:8228595~8244865:+
HNSC	cis	rs4713118	0.615	rs9348772	ENSG00000219392.1	RP1-265C24.5	-4.38	1.44e-05	0.0027	-0.23	-0.2	Parkinson's disease;	chr6:27688311	chr6:28115628~28116551:+
HNSC	cis	rs6601327	0.641	rs7462070	ENSG00000233609.3	RP11-62H7.2	-4.38	1.44e-05	0.0027	-0.19	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:8961200~8979025:+
HNSC	cis	rs6500395	1	rs9936004	ENSG00000261267.1	RP11-44I10.3	-4.38	1.44e-05	0.0027	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48532177	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9941275	ENSG00000261267.1	RP11-44I10.3	-4.38	1.44e-05	0.0027	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48539517	chr16:48559661~48587403:+
HNSC	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-4.38	1.44e-05	0.00271	-0.25	-0.2	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
HNSC	cis	rs3805389	1	rs28564902	ENSG00000273257.1	RP11-177J6.1	-4.38	1.44e-05	0.00271	-0.27	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55613324	chr4:55387949~55388271:+
HNSC	cis	rs964611	0.786	rs10519169	ENSG00000259488.2	RP11-154J22.1	-4.38	1.44e-05	0.00271	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48372829	chr15:48312353~48331856:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	4.38	1.45e-05	0.00271	0.18	0.2	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
HNSC	cis	rs6601327	0.551	rs13272424	ENSG00000233609.3	RP11-62H7.2	-4.38	1.45e-05	0.00271	-0.19	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8961200~8979025:+
HNSC	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-4.38	1.45e-05	0.00271	-0.27	-0.2	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-4.38	1.45e-05	0.00271	-0.27	-0.2	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
HNSC	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	4.38	1.45e-05	0.00271	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	4.38	1.45e-05	0.00271	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	4.38	1.45e-05	0.00271	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	4.38	1.45e-05	0.00271	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
HNSC	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	4.38	1.45e-05	0.00271	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
HNSC	cis	rs1008375	1	rs10805359	ENSG00000249502.1	AC006160.5	-4.38	1.45e-05	0.00271	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683263	chr4:17587467~17614571:-
HNSC	cis	rs795484	0.856	rs1151900	ENSG00000275409.1	RP11-131L12.4	-4.38	1.45e-05	0.00271	-0.23	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118248477	chr12:118430147~118430699:+
HNSC	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	4.38	1.45e-05	0.00271	0.32	0.2	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
HNSC	cis	rs11893307	0.566	rs10203824	ENSG00000228509.4	AC006460.2	4.38	1.45e-05	0.00271	0.27	0.2	Mean platelet volume;	chr2:190731124	chr2:190676944~190708716:-
HNSC	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	4.38	1.45e-05	0.00271	0.2	0.2	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
HNSC	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	4.38	1.45e-05	0.00271	0.2	0.2	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
HNSC	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-4.38	1.45e-05	0.00271	-0.23	-0.2	Depression;	chr6:28205175	chr6:28170845~28172521:+
HNSC	cis	rs4908769	0.624	rs1763838	ENSG00000232912.4	RP5-1115A15.1	4.38	1.45e-05	0.00271	0.22	0.2	Allergy;	chr1:8413271	chr1:8424645~8434838:+
HNSC	cis	rs916888	0.821	rs415430	ENSG00000260075.1	NSFP1	4.38	1.45e-05	0.00271	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46372855~46487141:+
HNSC	cis	rs916888	0.779	rs430685	ENSG00000260075.1	NSFP1	4.38	1.45e-05	0.00271	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46372855~46487141:+
HNSC	cis	rs1594829	0.535	rs17055121	ENSG00000228451.3	SDAD1P1	4.38	1.45e-05	0.00272	0.23	0.2	Height;	chr8:26313459	chr8:26379259~26382953:-
HNSC	cis	rs36563	0.631	rs2051864	ENSG00000274818.1	RP1-292L20.3	-4.38	1.45e-05	0.00272	-0.32	-0.2	Alcohol dependence;	chr14:70955876	chr14:70906657~70907111:-
HNSC	cis	rs72843506	0.586	rs74433421	ENSG00000261033.1	RP11-209D14.2	4.38	1.45e-05	0.00272	0.35	0.2	Schizophrenia;	chr17:19914774	chr17:20008051~20009234:-
HNSC	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	4.38	1.45e-05	0.00272	0.24	0.2	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
HNSC	cis	rs2255336	0.81	rs7959328	ENSG00000245648.1	RP11-277P12.20	4.38	1.45e-05	0.00272	0.35	0.2	Blood protein levels;	chr12:10361467	chr12:10363769~10398506:+
HNSC	cis	rs12893668	0.616	rs58033365	ENSG00000269910.1	RP11-73M18.10	4.38	1.45e-05	0.00272	0.2	0.2	Reticulocyte count;	chr14:103564564	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.645	rs12889403	ENSG00000269910.1	RP11-73M18.10	4.38	1.45e-05	0.00272	0.2	0.2	Reticulocyte count;	chr14:103568409	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.703	rs12894729	ENSG00000269910.1	RP11-73M18.10	4.38	1.45e-05	0.00272	0.2	0.2	Reticulocyte count;	chr14:103568955	chr14:103694516~103695050:-
HNSC	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	4.38	1.45e-05	0.00272	0.19	0.2	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	4.38	1.45e-05	0.00272	0.19	0.2	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
HNSC	cis	rs6964587	1	rs9691325	ENSG00000188693.7	CYP51A1-AS1	-4.38	1.45e-05	0.00272	-0.21	-0.2	Breast cancer;	chr7:92101733	chr7:92134604~92180725:+
HNSC	cis	rs3736485	0.966	rs6493510	ENSG00000259438.1	CTD-2650P22.1	4.38	1.45e-05	0.00272	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51608454	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs2414109	ENSG00000259438.1	CTD-2650P22.1	4.38	1.45e-05	0.00272	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51608818	chr15:52010999~52019095:-
HNSC	cis	rs9531006	0.711	rs3850064	ENSG00000227676.3	LINC01068	4.38	1.45e-05	0.00272	0.3	0.2	Sleep duration;	chr13:79949727	chr13:79566727~79571436:+
HNSC	cis	rs5769707	0.681	rs6009803	ENSG00000235111.1	RP1-29C18.8	-4.38	1.45e-05	0.00272	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49612657~49615716:-
HNSC	cis	rs12745968	0.532	rs10874724	ENSG00000223787.2	RP4-593M8.1	-4.38	1.46e-05	0.00272	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr1:92622626	chr1:92580476~92580821:-
HNSC	cis	rs763567	0.935	rs580487	ENSG00000271811.1	RP1-79C4.4	4.38	1.46e-05	0.00272	0.21	0.2	Tonsillectomy;	chr1:170640484	chr1:170667381~170669425:+
HNSC	cis	rs35963943	0.625	rs4128130	ENSG00000228956.7	SATB1-AS1	4.38	1.46e-05	0.00272	0.24	0.2	Lymphocyte counts;	chr3:18675361	chr3:18445024~18920401:+
HNSC	cis	rs889398	0.741	rs6499268	ENSG00000226232.7	RP11-419C5.2	-4.38	1.46e-05	0.00272	-0.18	-0.2	Body mass index;	chr16:69872626	chr16:69976388~69996188:-
HNSC	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	4.38	1.46e-05	0.00272	0.24	0.2	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
HNSC	cis	rs72843506	0.722	rs78477504	ENSG00000261033.1	RP11-209D14.2	4.38	1.46e-05	0.00273	0.34	0.2	Schizophrenia;	chr17:20235034	chr17:20008051~20009234:-
HNSC	cis	rs12893668	0.572	rs1606	ENSG00000269910.1	RP11-73M18.10	4.38	1.46e-05	0.00273	0.19	0.2	Reticulocyte count;	chr14:103694944	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.543	rs1799796	ENSG00000269910.1	RP11-73M18.10	4.38	1.46e-05	0.00273	0.19	0.2	Reticulocyte count;	chr14:103699590	chr14:103694516~103695050:-
HNSC	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-4.38	1.46e-05	0.00273	-0.24	-0.2	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
HNSC	cis	rs10791097	0.629	rs11222361	ENSG00000254842.5	RP11-890B15.2	-4.38	1.46e-05	0.00273	-0.18	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130861529	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.653	rs11222362	ENSG00000254842.5	RP11-890B15.2	-4.38	1.46e-05	0.00273	-0.18	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130861530	chr11:130844191~130865561:-
HNSC	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	4.38	1.46e-05	0.00273	0.19	0.2	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
HNSC	cis	rs721917	0.506	rs927452	ENSG00000244733.5	RP11-506M13.3	-4.38	1.46e-05	0.00273	-0.23	-0.2	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79660891~79677996:+
HNSC	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-4.38	1.46e-05	0.00273	-0.27	-0.2	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
HNSC	cis	rs189798	0.738	rs330908	ENSG00000254153.1	CTA-398F10.2	4.38	1.46e-05	0.00273	0.22	0.2	Myopia (pathological);	chr8:9137656	chr8:8456909~8461337:-
HNSC	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-4.38	1.46e-05	0.00273	-0.23	-0.2	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
HNSC	cis	rs11098499	0.954	rs12508504	ENSG00000250412.1	KLHL2P1	4.38	1.46e-05	0.00273	0.26	0.2	Corneal astigmatism;	chr4:119489452	chr4:119334329~119378233:+
HNSC	cis	rs948562	0.585	rs11229477	ENSG00000280010.1	AP001350.4	4.38	1.46e-05	0.00273	0.34	0.2	Lymphoma;	chr11:58461125	chr11:58627435~58628528:+
HNSC	cis	rs910316	0.819	rs175461	ENSG00000279594.1	RP11-950C14.10	-4.38	1.46e-05	0.00273	-0.24	-0.2	Height;	chr14:75115113	chr14:75011269~75012851:-
HNSC	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
HNSC	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-4.38	1.46e-05	0.00273	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
HNSC	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	4.38	1.46e-05	0.00273	0.17	0.2	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
HNSC	cis	rs13073817	0.74	rs7638294	ENSG00000228956.7	SATB1-AS1	4.38	1.46e-05	0.00273	0.21	0.2	Crohn's disease;	chr3:18633926	chr3:18445024~18920401:+
HNSC	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	4.38	1.46e-05	0.00273	0.33	0.2	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
HNSC	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	4.38	1.46e-05	0.00273	0.42	0.2	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
HNSC	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	4.38	1.46e-05	0.00273	0.42	0.2	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
HNSC	cis	rs761746	0.739	rs131233	ENSG00000236132.1	CTA-440B3.1	-4.38	1.46e-05	0.00273	-0.25	-0.2	Intelligence;	chr22:31721114	chr22:31816379~31817491:-
HNSC	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
HNSC	cis	rs4908760	0.792	rs11121215	ENSG00000232912.4	RP5-1115A15.1	4.38	1.46e-05	0.00273	0.21	0.2	Vitiligo;	chr1:8673069	chr1:8424645~8434838:+
HNSC	cis	rs8068318	1	rs7215775	ENSG00000267280.4	TBX2-AS1	-4.38	1.46e-05	0.00274	-0.21	-0.2	Creatinine levels;	chr17:61406955	chr17:61393456~61411555:-
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000233609.3	RP11-62H7.2	4.38	1.46e-05	0.00274	0.19	0.2	Mood instability;	chr8:8237348	chr8:8961200~8979025:+
HNSC	cis	rs10773046	0.74	rs7313897	ENSG00000269938.1	RP11-214K3.20	-4.38	1.46e-05	0.00274	-0.22	-0.2	Osteoarthritis (hip);	chr12:123865813	chr12:123968023~123968579:-
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	4.38	1.47e-05	0.00274	0.24	0.2	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
HNSC	cis	rs79349575	0.745	rs170319	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48914169	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs318090	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48914390	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.721	rs3744608	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48915871	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.651	rs4378658	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48916008	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12453374	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48917484	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12453394	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48917608	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.811	rs12601072	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48920636	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs58838744	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48921540	chr17:48899131~48899748:+
HNSC	cis	rs5758659	0.845	rs5758645	ENSG00000182057.4	OGFRP1	4.38	1.47e-05	0.00274	0.2	0.2	Cognitive function;	chr22:42202945	chr22:42269753~42275196:+
HNSC	cis	rs79349575	0.783	rs62075838	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48919070	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62075839	ENSG00000270781.1	RP11-501C14.9	-4.38	1.47e-05	0.00274	-0.21	-0.2	Type 2 diabetes;	chr17:48919072	chr17:48899131~48899748:+
HNSC	cis	rs2070074	0.591	rs3763614	ENSG00000230074.1	RP11-195F19.9	-4.38	1.47e-05	0.00274	-0.54	-0.2	CTACK levels;	chr9:34584137	chr9:34665665~34681298:+
HNSC	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	4.38	1.47e-05	0.00274	0.23	0.2	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
HNSC	cis	rs4925386	0.819	rs2890083	ENSG00000273619.1	RP5-908M14.9	4.38	1.47e-05	0.00274	0.17	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62336902	chr20:62386303~62386970:-
HNSC	cis	rs9611565	0.918	rs4820438	ENSG00000235513.1	RP4-756G23.5	4.38	1.47e-05	0.00274	0.22	0.2	Vitiligo;	chr22:41371131	chr22:41209122~41217627:-
HNSC	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-4.38	1.47e-05	0.00274	-0.2	-0.2	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
HNSC	cis	rs7113211	0.812	rs7113406	ENSG00000176343.5	RPL37AP8	4.38	1.47e-05	0.00274	0.21	0.2	Expressive vocabulary in infants;	chr11:112772253	chr11:111889199~111889474:-
HNSC	cis	rs2467099	0.732	rs2168855	ENSG00000267801.1	RP11-552F3.9	4.38	1.47e-05	0.00274	0.26	0.2	Systolic blood pressure;	chr17:75947269	chr17:75876372~75879546:+
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000233609.3	RP11-62H7.2	4.38	1.47e-05	0.00274	0.18	0.2	Mood instability;	chr8:8462781	chr8:8961200~8979025:+
HNSC	cis	rs6490294	0.571	rs6489830	ENSG00000226469.1	ADAM1B	4.38	1.47e-05	0.00274	0.29	0.2	Mean platelet volume;	chr12:112144736	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs12422864	ENSG00000226469.1	ADAM1B	4.38	1.47e-05	0.00274	0.29	0.2	Mean platelet volume;	chr12:112146397	chr12:111927018~111929017:+
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000211974.3	IGHV2-70	4.38	1.47e-05	0.00274	0.19	0.2	Kawasaki disease;	chr14:106711838	chr14:106723574~106724093:-
HNSC	cis	rs853679	0.824	rs34712084	ENSG00000219891.2	ZSCAN12P1	4.38	1.47e-05	0.00274	0.36	0.2	Depression;	chr6:28076050	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.824	rs1321505	ENSG00000219891.2	ZSCAN12P1	4.38	1.47e-05	0.00274	0.36	0.2	Depression;	chr6:28085045	chr6:28091154~28093664:+
HNSC	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-4.38	1.47e-05	0.00274	-0.25	-0.2	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
HNSC	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	4.38	1.47e-05	0.00275	0.25	0.2	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
HNSC	cis	rs72843166	0.562	rs2286572	ENSG00000265282.1	RP11-269G24.4	4.38	1.47e-05	0.00275	0.29	0.2	Intelligence (multi-trait analysis);	chr17:63440881	chr17:63430468~63432211:-
HNSC	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	4.38	1.47e-05	0.00275	0.24	0.2	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
HNSC	cis	rs17345786	0.861	rs11711808	ENSG00000244119.1	PDCL3P4	4.38	1.47e-05	0.00275	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101712472~101713191:+
HNSC	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	4.38	1.47e-05	0.00275	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
HNSC	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-4.38	1.47e-05	0.00275	-0.23	-0.2	Height;	chr14:75123026	chr14:75011269~75012851:-
HNSC	cis	rs9393777	0.92	rs67859638	ENSG00000219392.1	RP1-265C24.5	-4.38	1.47e-05	0.00275	-0.41	-0.2	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28115628~28116551:+
HNSC	cis	rs6490294	0.571	rs11066117	ENSG00000226469.1	ADAM1B	4.38	1.47e-05	0.00275	0.28	0.2	Mean platelet volume;	chr12:111994905	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs11066118	ENSG00000226469.1	ADAM1B	4.38	1.47e-05	0.00275	0.28	0.2	Mean platelet volume;	chr12:111996348	chr12:111927018~111929017:+
HNSC	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	4.38	1.47e-05	0.00275	0.24	0.2	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
HNSC	cis	rs12893668	0.703	rs4906336	ENSG00000269910.1	RP11-73M18.10	4.38	1.47e-05	0.00275	0.2	0.2	Reticulocyte count;	chr14:103566928	chr14:103694516~103695050:-
HNSC	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-4.38	1.47e-05	0.00275	-0.23	-0.2	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
HNSC	cis	rs3758785	0.512	rs11020758	ENSG00000255893.1	RP11-685N10.1	-4.38	1.47e-05	0.00275	-0.31	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94377118	chr11:94472908~94473570:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-4.38	1.47e-05	0.00275	-0.15	-0.2	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
HNSC	cis	rs754133	1	rs754133	ENSG00000248265.1	FLJ12825	4.38	1.48e-05	0.00275	0.24	0.2	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54025136	chr12:54058254~54122234:+
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	4.38	1.48e-05	0.00275	0.23	0.2	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
HNSC	cis	rs889398	0.741	rs2362642	ENSG00000226232.7	RP11-419C5.2	-4.38	1.48e-05	0.00276	-0.18	-0.2	Body mass index;	chr16:69897555	chr16:69976388~69996188:-
HNSC	cis	rs11673344	0.562	rs6510580	ENSG00000276846.1	CTD-3220F14.3	4.38	1.48e-05	0.00276	0.22	0.2	Obesity-related traits;	chr19:37038452	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs2082009	ENSG00000276846.1	CTD-3220F14.3	4.38	1.48e-05	0.00276	0.22	0.2	Obesity-related traits;	chr19:37039834	chr19:37314868~37315620:-
HNSC	cis	rs7121616	0.595	rs7941144	ENSG00000200879.1	SNORD14E	4.38	1.48e-05	0.00276	0.25	0.2	Breast cancer;	chr11:123079805	chr11:123058077~123058161:-
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000224373.3	IGHV4-59	-4.38	1.48e-05	0.00276	-0.13	-0.2	Kawasaki disease;	chr14:106775945	chr14:106627249~106627825:-
HNSC	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	4.38	1.48e-05	0.00276	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
HNSC	cis	rs1009181	0.585	rs9379830	ENSG00000272462.2	U91328.19	-4.38	1.48e-05	0.00276	-0.23	-0.2	Childhood ear infection;	chr6:26173539	chr6:25992662~26001775:+
HNSC	cis	rs7121616	0.576	rs7942164	ENSG00000200879.1	SNORD14E	4.38	1.48e-05	0.00276	0.27	0.2	Breast cancer;	chr11:123050459	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.576	rs56131320	ENSG00000200879.1	SNORD14E	4.38	1.48e-05	0.00276	0.27	0.2	Breast cancer;	chr11:123053058	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.576	rs7929869	ENSG00000200879.1	SNORD14E	4.38	1.48e-05	0.00276	0.27	0.2	Breast cancer;	chr11:123054435	chr11:123058077~123058161:-
HNSC	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	4.38	1.48e-05	0.00276	0.19	0.2	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
HNSC	cis	rs10773046	0.74	rs7297429	ENSG00000269938.1	RP11-214K3.20	-4.38	1.48e-05	0.00276	-0.22	-0.2	Osteoarthritis (hip);	chr12:123883031	chr12:123968023~123968579:-
HNSC	cis	rs1799949	0.965	rs12950779	ENSG00000236383.6	LINC00854	-4.38	1.48e-05	0.00276	-0.18	-0.2	Menopause (age at onset);	chr17:43154506	chr17:43216941~43305976:-
HNSC	cis	rs9847710	1	rs2564956	ENSG00000242142.1	SERBP1P3	4.38	1.48e-05	0.00276	0.22	0.2	Ulcerative colitis;	chr3:53036446	chr3:53064283~53065091:-
HNSC	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	4.38	1.48e-05	0.00276	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
HNSC	cis	rs10773046	0.74	rs1922258	ENSG00000269938.1	RP11-214K3.20	-4.38	1.48e-05	0.00276	-0.22	-0.2	Osteoarthritis (hip);	chr12:123869110	chr12:123968023~123968579:-
HNSC	cis	rs56804039	0.524	rs6988990	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8510890	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs7011761	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8511045	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs7016788	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8511226	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs7012227	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8511280	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs6995198	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8512445	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs6985671	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00276	-0.34	-0.2	Cervical cancer;	chr8:8512494	chr8:8228595~8244865:+
HNSC	cis	rs7819412	0.715	rs35223712	ENSG00000269918.1	AF131215.9	-4.38	1.48e-05	0.00276	-0.2	-0.2	Triglycerides;	chr8:11186417	chr8:11104691~11106704:-
HNSC	cis	rs12887734	0.546	rs66676135	ENSG00000269940.1	RP11-73M18.7	4.38	1.48e-05	0.00276	0.19	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694560~103695170:+
HNSC	cis	rs11893307	0.509	rs4368360	ENSG00000235852.1	AC005540.3	4.38	1.48e-05	0.00276	0.26	0.2	Mean platelet volume;	chr2:190671327	chr2:190880797~190882059:-
HNSC	cis	rs6490294	0.528	rs60690688	ENSG00000226469.1	ADAM1B	4.38	1.48e-05	0.00276	0.28	0.2	Mean platelet volume;	chr12:112104179	chr12:111927018~111929017:+
HNSC	cis	rs5752326	0.867	rs929131	ENSG00000261188.1	CTA-445C9.14	-4.38	1.48e-05	0.00276	-0.28	-0.2	Ischemic stroke;	chr22:26448803	chr22:26512537~26514568:+
HNSC	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	4.38	1.48e-05	0.00276	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
HNSC	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	4.38	1.48e-05	0.00276	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
HNSC	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	4.38	1.48e-05	0.00276	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
HNSC	cis	rs7824557	0.872	rs1347410	ENSG00000255310.2	AF131215.2	-4.38	1.48e-05	0.00276	-0.19	-0.2	Retinal vascular caliber;	chr8:11253733	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.599	rs149990	ENSG00000204709.4	LINC01556	4.38	1.48e-05	0.00277	0.34	0.2	Depression;	chr6:28030480	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.599	rs149943	ENSG00000204709.4	LINC01556	4.38	1.48e-05	0.00277	0.34	0.2	Depression;	chr6:28034610	chr6:28943877~28944537:+
HNSC	cis	rs3015497	0.967	rs3015483	ENSG00000277050.1	RP11-102G14.1	-4.38	1.48e-05	0.00277	-0.19	-0.2	Mean platelet volume;	chr14:50670756	chr14:51637348~51637947:-
HNSC	cis	rs853679	0.517	rs16893666	ENSG00000219891.2	ZSCAN12P1	-4.38	1.48e-05	0.00277	-0.27	-0.2	Depression;	chr6:28086929	chr6:28091154~28093664:+
HNSC	cis	rs9880211	1	rs35899944	ENSG00000273486.1	RP11-731C17.2	4.38	1.48e-05	0.00277	0.19	0.2	Height;Body mass index;	chr3:136510215	chr3:136837338~136839021:-
HNSC	cis	rs56804039	0.524	rs6993658	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00277	-0.34	-0.2	Cervical cancer;	chr8:8512842	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs6998450	ENSG00000173295.6	FAM86B3P	-4.38	1.48e-05	0.00277	-0.34	-0.2	Cervical cancer;	chr8:8512843	chr8:8228595~8244865:+
HNSC	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-4.38	1.48e-05	0.00277	-0.2	-0.2	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
HNSC	cis	rs9311676	0.632	rs62258126	ENSG00000273493.1	RP11-80H18.4	4.38	1.48e-05	0.00277	0.21	0.2	Systemic lupus erythematosus;	chr3:58410387	chr3:58329965~58330118:+
HNSC	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-4.38	1.48e-05	0.00277	-0.2	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
HNSC	cis	rs10510102	0.872	rs12248004	ENSG00000226864.1	ATE1-AS1	4.38	1.48e-05	0.00277	0.37	0.2	Breast cancer;	chr10:121972215	chr10:121928312~121951965:+
HNSC	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-4.38	1.48e-05	0.00277	-0.29	-0.2	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
HNSC	cis	rs7819412	0.659	rs4073948	ENSG00000255310.2	AF131215.2	-4.38	1.49e-05	0.00277	-0.19	-0.2	Triglycerides;	chr8:10915134	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.607	rs34218844	ENSG00000204709.4	LINC01556	4.38	1.49e-05	0.00277	0.41	0.2	Depression;	chr6:28322870	chr6:28943877~28944537:+
HNSC	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	4.38	1.49e-05	0.00277	0.22	0.2	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
HNSC	cis	rs9907295	0.901	rs9898152	ENSG00000270977.1	AC015849.16	-4.38	1.49e-05	0.00277	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35869211	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs78023535	ENSG00000270977.1	AC015849.16	-4.38	1.49e-05	0.00277	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35869598	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs4795095	ENSG00000270977.1	AC015849.16	-4.38	1.49e-05	0.00277	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35870296	chr17:35893707~35911023:-
HNSC	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	4.38	1.49e-05	0.00277	0.22	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
HNSC	cis	rs9321453	1	rs9321449	ENSG00000231971.4	RP11-557H15.3	4.38	1.49e-05	0.00277	0.24	0.2	Urate levels;	chr6:134444615	chr6:134428240~134520585:-
HNSC	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	4.38	1.49e-05	0.00277	0.22	0.2	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
HNSC	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-4.38	1.49e-05	0.00277	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
HNSC	cis	rs7615952	0.599	rs2279821	ENSG00000241439.1	RP11-666A20.3	4.38	1.49e-05	0.00277	0.23	0.2	Blood pressure (smoking interaction);	chr3:126015465	chr3:125958556~125958817:+
HNSC	cis	rs7278690	1	rs7278690	ENSG00000281903.1	AF127936.7	4.38	1.49e-05	0.00277	0.48	0.2	Breast cancer;	chr21:14855305	chr21:14819699~14918552:-
HNSC	cis	rs9910055	0.53	rs2269908	ENSG00000267080.4	ASB16-AS1	-4.38	1.49e-05	0.00278	-0.16	-0.2	Total body bone mineral density;	chr17:44216830	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.53	rs2269907	ENSG00000267080.4	ASB16-AS1	-4.38	1.49e-05	0.00278	-0.16	-0.2	Total body bone mineral density;	chr17:44216847	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.53	rs8072954	ENSG00000267080.4	ASB16-AS1	-4.38	1.49e-05	0.00278	-0.16	-0.2	Total body bone mineral density;	chr17:44217354	chr17:44175973~44186717:-
HNSC	cis	rs1009181	0.585	rs2183947	ENSG00000272462.2	U91328.19	-4.38	1.49e-05	0.00278	-0.22	-0.2	Childhood ear infection;	chr6:26159128	chr6:25992662~26001775:+
HNSC	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	4.38	1.49e-05	0.00278	0.19	0.2	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
HNSC	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	4.38	1.49e-05	0.00278	0.19	0.2	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	4.38	1.49e-05	0.00278	0.19	0.2	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
HNSC	cis	rs9611565	0.694	rs79008	ENSG00000235513.1	RP4-756G23.5	4.38	1.49e-05	0.00278	0.23	0.2	Vitiligo;	chr22:41454496	chr22:41209122~41217627:-
HNSC	cis	rs911555	0.511	rs8007489	ENSG00000270108.1	RP11-73M18.6	-4.38	1.49e-05	0.00278	-0.22	-0.2	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103687576~103688127:+
HNSC	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	4.38	1.49e-05	0.00278	0.27	0.2	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
HNSC	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-4.38	1.49e-05	0.00278	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
HNSC	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-4.38	1.49e-05	0.00278	-0.27	-0.2	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
HNSC	cis	rs72843506	0.722	rs74658636	ENSG00000261033.1	RP11-209D14.2	4.38	1.49e-05	0.00278	0.34	0.2	Schizophrenia;	chr17:20294669	chr17:20008051~20009234:-
HNSC	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	4.38	1.49e-05	0.00278	0.23	0.2	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
HNSC	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	4.38	1.49e-05	0.00278	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
HNSC	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	4.38	1.49e-05	0.00278	0.27	0.2	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
HNSC	cis	rs2070074	0.591	rs72737109	ENSG00000230074.1	RP11-195F19.9	-4.38	1.49e-05	0.00278	-0.54	-0.2	CTACK levels;	chr9:34586464	chr9:34665665~34681298:+
HNSC	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	4.38	1.49e-05	0.00278	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
HNSC	cis	rs9840812	0.577	rs503973	ENSG00000273486.1	RP11-731C17.2	-4.38	1.49e-05	0.00279	-0.18	-0.2	Fibrinogen levels;	chr3:136340695	chr3:136837338~136839021:-
HNSC	cis	rs28489187	0.505	rs7525786	ENSG00000223653.4	RP11-131L23.1	-4.38	1.49e-05	0.00279	-0.25	-0.2	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85418393	chr1:85276715~85448124:+
HNSC	cis	rs11638352	1	rs2899103	ENSG00000205771.5	CATSPER2P1	4.38	1.49e-05	0.00279	0.51	0.2	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44048357	chr15:43726918~43747094:-
HNSC	cis	rs754133	0.964	rs736825	ENSG00000248265.1	FLJ12825	4.38	1.49e-05	0.00279	0.24	0.2	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54023792	chr12:54058254~54122234:+
HNSC	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	4.38	1.49e-05	0.00279	0.22	0.2	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
HNSC	cis	rs13325613	0.834	rs13084057	ENSG00000223552.1	RP11-24F11.2	4.38	1.49e-05	0.00279	0.3	0.2	Monocyte count;	chr3:46143233	chr3:46364955~46407059:-
HNSC	cis	rs9287719	0.934	rs6706763	ENSG00000243819.4	RN7SL832P	4.38	1.49e-05	0.00279	0.19	0.2	Prostate cancer;	chr2:10611281	chr2:10690344~10692099:+
HNSC	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	4.38	1.49e-05	0.00279	0.25	0.2	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
HNSC	cis	rs6430585	0.528	rs309120	ENSG00000231890.6	DARS-AS1	-4.38	1.5e-05	0.00279	-0.33	-0.2	Corneal structure;	chr2:135951217	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs3112496	ENSG00000231890.6	DARS-AS1	-4.38	1.5e-05	0.00279	-0.33	-0.2	Corneal structure;	chr2:135953494	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs309113	ENSG00000231890.6	DARS-AS1	-4.38	1.5e-05	0.00279	-0.33	-0.2	Corneal structure;	chr2:135979890	chr2:135985176~136022593:+
HNSC	cis	rs13073817	0.615	rs336639	ENSG00000228956.7	SATB1-AS1	4.38	1.5e-05	0.00279	0.23	0.2	Crohn's disease;	chr3:18574620	chr3:18445024~18920401:+
HNSC	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-4.38	1.5e-05	0.00279	-0.29	-0.2	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
HNSC	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-4.38	1.5e-05	0.00279	-0.2	-0.2	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
HNSC	cis	rs795484	0.926	rs1726390	ENSG00000275409.1	RP11-131L12.4	-4.38	1.5e-05	0.00279	-0.23	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118207579	chr12:118430147~118430699:+
HNSC	cis	rs3096299	0.748	rs3102339	ENSG00000261574.1	RP1-168P16.2	4.38	1.5e-05	0.00279	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89392375~89412564:-
HNSC	cis	rs9650657	0.589	rs10107145	ENSG00000255310.2	AF131215.2	-4.37	1.5e-05	0.00279	-0.19	-0.2	Neuroticism;	chr8:10900703	chr8:11107788~11109726:-
HNSC	cis	rs1316952	0.667	rs76411891	ENSG00000269938.1	RP11-214K3.20	-4.37	1.5e-05	0.00279	-0.38	-0.2	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123903689	chr12:123968023~123968579:-
HNSC	cis	rs1799949	0.536	rs4793227	ENSG00000236383.6	LINC00854	-4.37	1.5e-05	0.0028	-0.19	-0.2	Menopause (age at onset);	chr17:43334882	chr17:43216941~43305976:-
HNSC	cis	rs6928977	0.86	rs2746438	ENSG00000217482.2	HMGB1P17	-4.37	1.5e-05	0.0028	-0.22	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135636086~135636713:-
HNSC	cis	rs10462794	1	rs9313085	ENSG00000260763.1	RP11-445O3.3	4.37	1.5e-05	0.0028	0.26	0.2	DNA methylation (variation);	chr5:4488908	chr5:4436850~4440259:-
HNSC	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	4.37	1.5e-05	0.0028	0.23	0.2	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
HNSC	cis	rs8177376	0.581	rs512577	ENSG00000254905.1	RP11-712L6.7	-4.37	1.5e-05	0.0028	-0.23	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126222046	chr11:126292922~126294254:-
HNSC	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-4.37	1.5e-05	0.0028	-0.23	-0.2	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
HNSC	cis	rs11673344	0.523	rs8108509	ENSG00000276846.1	CTD-3220F14.3	4.37	1.5e-05	0.0028	0.22	0.2	Obesity-related traits;	chr19:37060370	chr19:37314868~37315620:-
HNSC	cis	rs7824557	0.527	rs2736298	ENSG00000269918.1	AF131215.9	-4.37	1.5e-05	0.0028	-0.19	-0.2	Retinal vascular caliber;	chr8:11377627	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	4.37	1.5e-05	0.0028	0.13	0.2	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
HNSC	cis	rs3738443	0.678	rs4314914	ENSG00000259865.1	RP11-488L18.10	4.37	1.5e-05	0.0028	0.16	0.2	Alcohol dependence;	chr1:247210326	chr1:247187281~247188526:-
HNSC	cis	rs516805	0.633	rs9490414	ENSG00000279453.1	RP3-425C14.4	4.37	1.5e-05	0.0028	0.27	0.2	Lymphocyte counts;	chr6:122245612	chr6:122436789~122439223:-
HNSC	cis	rs853679	0.607	rs34661125	ENSG00000204709.4	LINC01556	4.37	1.5e-05	0.0028	0.4	0.2	Depression;	chr6:28314117	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13190888	ENSG00000204709.4	LINC01556	4.37	1.5e-05	0.0028	0.4	0.2	Depression;	chr6:28318208	chr6:28943877~28944537:+
HNSC	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-4.37	1.5e-05	0.0028	-0.21	-0.2	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-4.37	1.5e-05	0.0028	-0.24	-0.2	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
HNSC	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-4.37	1.5e-05	0.0028	-0.28	-0.2	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
HNSC	cis	rs13434995	0.796	rs34299771	ENSG00000273257.1	RP11-177J6.1	-4.37	1.51e-05	0.0028	-0.31	-0.2	Adiponectin levels;	chr4:55591936	chr4:55387949~55388271:+
HNSC	cis	rs889398	0.802	rs8050414	ENSG00000226232.7	RP11-419C5.2	-4.37	1.51e-05	0.0028	-0.18	-0.2	Body mass index;	chr16:69852910	chr16:69976388~69996188:-
HNSC	cis	rs889398	0.802	rs8051168	ENSG00000226232.7	RP11-419C5.2	-4.37	1.51e-05	0.0028	-0.18	-0.2	Body mass index;	chr16:69853371	chr16:69976388~69996188:-
HNSC	cis	rs12545109	0.8	rs2609979	ENSG00000246430.5	LINC00968	-4.37	1.51e-05	0.0028	-0.25	-0.2	Obesity-related traits;	chr8:56477507	chr8:56496246~56559823:-
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000211974.3	IGHV2-70	4.37	1.51e-05	0.00281	0.19	0.2	Kawasaki disease;	chr14:106777570	chr14:106723574~106724093:-
HNSC	cis	rs9788721	0.868	rs17486278	ENSG00000261762.1	RP11-650L12.2	-4.37	1.51e-05	0.00281	-0.23	-0.2	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78575140	chr15:78589123~78591276:-
HNSC	cis	rs2904524	1	rs12309104	ENSG00000257815.4	RP11-611E13.2	-4.37	1.51e-05	0.00281	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70318084	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.881	rs940429	ENSG00000257815.4	RP11-611E13.2	-4.37	1.51e-05	0.00281	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70319028	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs12313398	ENSG00000257815.4	RP11-611E13.2	-4.37	1.51e-05	0.00281	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70320891	chr12:69904033~70243360:-
HNSC	cis	rs4819052	0.851	rs7279011	ENSG00000223768.1	LINC00205	-4.37	1.51e-05	0.00281	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs7279182	ENSG00000223768.1	LINC00205	-4.37	1.51e-05	0.00281	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.765	rs2838827	ENSG00000223768.1	LINC00205	-4.37	1.51e-05	0.00281	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45293285~45297354:+
HNSC	cis	rs75920871	0.589	rs73008568	ENSG00000254851.1	RP11-109L13.1	-4.37	1.51e-05	0.00281	-0.39	-0.2	Subjective well-being;	chr11:117194291	chr11:117135528~117138582:+
HNSC	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-4.37	1.51e-05	0.00281	-0.16	-0.2	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
HNSC	cis	rs12893668	0.637	rs4525427	ENSG00000269940.1	RP11-73M18.7	4.37	1.51e-05	0.00281	0.2	0.2	Reticulocyte count;	chr14:103606456	chr14:103694560~103695170:+
HNSC	cis	rs3736485	0.844	rs12593979	ENSG00000259438.1	CTD-2650P22.1	-4.37	1.51e-05	0.00281	-0.2	-0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51449382	chr15:52010999~52019095:-
HNSC	cis	rs516805	0.667	rs9482234	ENSG00000279453.1	RP3-425C14.4	4.37	1.51e-05	0.00281	0.27	0.2	Lymphocyte counts;	chr6:122313998	chr6:122436789~122439223:-
HNSC	cis	rs7610312	0.681	rs6924	ENSG00000273493.1	RP11-80H18.4	-4.37	1.51e-05	0.00281	-0.24	-0.2	Red blood cell count;	chr3:58294334	chr3:58329965~58330118:+
HNSC	cis	rs12893668	0.581	rs34843146	ENSG00000269940.1	RP11-73M18.7	4.37	1.51e-05	0.00281	0.2	0.2	Reticulocyte count;	chr14:103613527	chr14:103694560~103695170:+
HNSC	cis	rs3015497	0.646	rs3015494	ENSG00000277050.1	RP11-102G14.1	-4.37	1.51e-05	0.00281	-0.2	-0.2	Mean platelet volume;	chr14:50648439	chr14:51637348~51637947:-
HNSC	cis	rs3015497	0.646	rs2172673	ENSG00000277050.1	RP11-102G14.1	-4.37	1.51e-05	0.00281	-0.2	-0.2	Mean platelet volume;	chr14:50649089	chr14:51637348~51637947:-
HNSC	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-4.37	1.51e-05	0.00281	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
HNSC	cis	rs13434995	0.513	rs67963898	ENSG00000273257.1	RP11-177J6.1	-4.37	1.51e-05	0.00281	-0.27	-0.2	Adiponectin levels;	chr4:55475520	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.955	rs13114751	ENSG00000250412.1	KLHL2P1	4.37	1.51e-05	0.00281	0.25	0.2	Corneal astigmatism;	chr4:119235462	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.913	rs35271032	ENSG00000250412.1	KLHL2P1	4.37	1.51e-05	0.00281	0.25	0.2	Corneal astigmatism;	chr4:119235504	chr4:119334329~119378233:+
HNSC	cis	rs442309	0.875	rs224146	ENSG00000238280.1	RP11-436D10.3	-4.37	1.51e-05	0.00282	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62723179	chr10:62793562~62805887:-
HNSC	cis	rs6490294	0.528	rs7980579	ENSG00000226469.1	ADAM1B	4.37	1.51e-05	0.00282	0.28	0.2	Mean platelet volume;	chr12:112009556	chr12:111927018~111929017:+
HNSC	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	4.37	1.51e-05	0.00282	0.23	0.2	Height;	chr14:75094449	chr14:75011269~75012851:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000280411.1	IGHV1-69-2	-4.37	1.51e-05	0.00282	-0.19	-0.2	Alzheimer's disease (late onset);	chr14:106669877	chr14:106762092~106762588:-
HNSC	cis	rs61776719	0.747	rs28428561	ENSG00000212541.1	RNU6-510P	4.37	1.51e-05	0.00282	0.22	0.2	Coronary artery disease;	chr1:37968634	chr1:37991462~37991569:+
HNSC	cis	rs9907295	0.584	rs9913559	ENSG00000270977.1	AC015849.16	-4.37	1.51e-05	0.00282	-0.31	-0.2	Fibroblast growth factor basic levels;	chr17:35930065	chr17:35893707~35911023:-
HNSC	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	4.37	1.51e-05	0.00282	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
HNSC	cis	rs6831352	0.879	rs2602888	ENSG00000263923.1	RP11-571L19.7	-4.37	1.51e-05	0.00282	-0.21	-0.2	Alcohol dependence;	chr4:99120555	chr4:98928897~98994994:+
HNSC	cis	rs3731896	0.848	rs4485556	ENSG00000243910.6	TUBA4B	4.37	1.51e-05	0.00282	0.32	0.2	Educational attainment;	chr2:219292696	chr2:219253243~219272188:+
HNSC	cis	rs17345786	0.953	rs78645744	ENSG00000244119.1	PDCL3P4	4.37	1.52e-05	0.00282	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101712472~101713191:+
HNSC	cis	rs7429990	0.828	rs11712152	ENSG00000228638.1	FCF1P2	-4.37	1.52e-05	0.00282	-0.19	-0.2	Educational attainment (years of education);	chr3:47655314	chr3:48290793~48291375:-
HNSC	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	4.37	1.52e-05	0.00282	0.19	0.2	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
HNSC	cis	rs3198697	0.663	rs12928099	ENSG00000263335.1	AF001548.5	-4.37	1.52e-05	0.00282	-0.3	-0.2	Triglycerides;	chr16:15056648	chr16:15726674~15732993:+
HNSC	cis	rs988913	0.723	rs7761568	ENSG00000224984.1	RP11-524H19.2	-4.37	1.52e-05	0.00282	-0.23	-0.2	Menarche (age at onset);	chr6:55140628	chr6:54840118~54840855:-
HNSC	cis	rs2904524	1	rs7980085	ENSG00000257815.4	RP11-611E13.2	4.37	1.52e-05	0.00282	0.24	0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70293850	chr12:69904033~70243360:-
HNSC	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-4.37	1.52e-05	0.00282	-0.17	-0.2	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
HNSC	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-4.37	1.52e-05	0.00282	-0.17	-0.2	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
HNSC	cis	rs7980687	0.638	rs7299943	ENSG00000280120.1	RP11-546D6.3	4.37	1.52e-05	0.00282	0.18	0.2	Head circumference (infant);Educational attainment;Height;	chr12:123108938	chr12:123152324~123153377:-
HNSC	cis	rs394563	0.601	rs391875	ENSG00000231760.4	RP11-350J20.5	4.37	1.52e-05	0.00282	0.27	0.2	Dupuytren's disease;	chr6:149474000	chr6:149796151~149826294:-
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	4.37	1.52e-05	0.00282	0.24	0.2	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
HNSC	cis	rs9320282	0.587	rs1546721	ENSG00000243587.6	C6orf183	-4.37	1.52e-05	0.00283	-0.2	-0.2	Basophil percentage of white cells;White blood cell count (basophil);	chr6:109304593	chr6:109165833~109271014:+
HNSC	cis	rs6500395	0.554	rs2355302	ENSG00000261267.1	RP11-44I10.3	-4.37	1.52e-05	0.00283	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48704517	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.584	rs9922553	ENSG00000261267.1	RP11-44I10.3	-4.37	1.52e-05	0.00283	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48705148	chr16:48559661~48587403:+
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	4.37	1.52e-05	0.00283	0.25	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
HNSC	cis	rs4873772	0.8	rs4594029	ENSG00000253330.1	RP11-697N18.3	-4.37	1.52e-05	0.00283	-0.26	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47545661	chr8:47511034~47512141:-
HNSC	cis	rs4853525	0.561	rs7597768	ENSG00000235852.1	AC005540.3	4.37	1.52e-05	0.00283	0.27	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977153	chr2:190880797~190882059:-
HNSC	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-4.37	1.52e-05	0.00283	-0.26	-0.2	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
HNSC	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	4.37	1.52e-05	0.00283	0.2	0.2	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	4.37	1.52e-05	0.00283	0.2	0.2	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	4.37	1.52e-05	0.00283	0.2	0.2	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
HNSC	cis	rs73201462	1	rs2999089	ENSG00000231305.3	RP11-723O4.2	4.37	1.52e-05	0.00283	0.3	0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128216316	chr3:128861313~128871540:-
HNSC	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-4.37	1.52e-05	0.00283	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000260075.1	NSFP1	4.37	1.52e-05	0.00283	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46372855~46487141:+
HNSC	cis	rs6831352	0.959	rs6848050	ENSG00000263923.1	RP11-571L19.7	-4.37	1.52e-05	0.00283	-0.2	-0.2	Alcohol dependence;	chr4:99132582	chr4:98928897~98994994:+
HNSC	cis	rs6831352	1	rs6532798	ENSG00000263923.1	RP11-571L19.7	-4.37	1.52e-05	0.00283	-0.2	-0.2	Alcohol dependence;	chr4:99133676	chr4:98928897~98994994:+
HNSC	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-4.37	1.52e-05	0.00283	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
HNSC	cis	rs6688613	1	rs12130629	ENSG00000215834.7	FMO9P	4.37	1.52e-05	0.00283	0.24	0.2	Refractive astigmatism;	chr1:166984047	chr1:166603675~166631400:+
HNSC	cis	rs4819052	0.807	rs7283915	ENSG00000223768.1	LINC00205	-4.37	1.52e-05	0.00283	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45293285~45297354:+
HNSC	cis	rs4819052	0.851	rs2838850	ENSG00000223768.1	LINC00205	-4.37	1.52e-05	0.00283	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45293285~45297354:+
HNSC	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	4.37	1.52e-05	0.00283	0.25	0.2	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
HNSC	cis	rs6490294	0.571	rs10849992	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112005213	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7310545	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112006156	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7296841	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112006305	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs11066127	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112008551	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7952986	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112010358	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7132863	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112011079	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs12300496	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112012629	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs11066128	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112012950	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.571	rs7316563	ENSG00000226469.1	ADAM1B	4.37	1.52e-05	0.00283	0.28	0.2	Mean platelet volume;	chr12:112015831	chr12:111927018~111929017:+
HNSC	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	4.37	1.52e-05	0.00283	0.2	0.2	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
HNSC	cis	rs4965006	0.915	rs7969545	ENSG00000273568.1	RP11-417L19.6	4.37	1.52e-05	0.00283	0.33	0.2	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131934642~131934928:+
HNSC	cis	rs9311676	0.586	rs73085867	ENSG00000273493.1	RP11-80H18.4	4.37	1.52e-05	0.00283	0.21	0.2	Systemic lupus erythematosus;	chr3:58449064	chr3:58329965~58330118:+
HNSC	cis	rs12893668	0.703	rs35498576	ENSG00000269940.1	RP11-73M18.7	4.37	1.52e-05	0.00283	0.2	0.2	Reticulocyte count;	chr14:103559556	chr14:103694560~103695170:+
HNSC	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	4.37	1.53e-05	0.00284	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	4.37	1.53e-05	0.00284	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
HNSC	cis	rs8180040	0.726	rs2305634	ENSG00000276925.1	RP11-708J19.3	4.37	1.53e-05	0.00284	0.19	0.2	Colorectal cancer;	chr3:47002048	chr3:47469777~47469987:+
HNSC	cis	rs35306767	0.951	rs11253530	ENSG00000229869.1	RP11-363N22.2	-4.37	1.53e-05	0.00284	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:947789	chr10:933026~942743:+
HNSC	cis	rs6500395	0.962	rs7199625	ENSG00000261267.1	RP11-44I10.3	-4.37	1.53e-05	0.00284	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48616306	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9941336	ENSG00000261267.1	RP11-44I10.3	-4.37	1.53e-05	0.00284	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48618858	chr16:48559661~48587403:+
HNSC	cis	rs9311676	0.632	rs11719192	ENSG00000273493.1	RP11-80H18.4	4.37	1.53e-05	0.00284	0.21	0.2	Systemic lupus erythematosus;	chr3:58446090	chr3:58329965~58330118:+
HNSC	cis	rs11756659	0.653	rs199729	ENSG00000217159.2	LARP1P1	4.37	1.53e-05	0.00284	0.28	0.2	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:26164072~26164363:+
HNSC	cis	rs35306767	0.855	rs11253499	ENSG00000229869.1	RP11-363N22.2	-4.37	1.53e-05	0.00284	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:898150	chr10:933026~942743:+
HNSC	cis	rs6831352	0.703	rs2602854	ENSG00000263923.1	RP11-571L19.7	-4.37	1.53e-05	0.00284	-0.21	-0.2	Alcohol dependence;	chr4:99107500	chr4:98928897~98994994:+
HNSC	cis	rs9910055	0.53	rs7222349	ENSG00000267080.4	ASB16-AS1	-4.37	1.53e-05	0.00284	-0.16	-0.2	Total body bone mineral density;	chr17:44227276	chr17:44175973~44186717:-
HNSC	cis	rs4819052	0.851	rs4819041	ENSG00000223768.1	LINC00205	-4.37	1.53e-05	0.00284	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45293285~45297354:+
HNSC	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	4.37	1.53e-05	0.00284	0.19	0.2	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
HNSC	cis	rs12545109	0.8	rs2576599	ENSG00000246430.5	LINC00968	-4.37	1.53e-05	0.00284	-0.25	-0.2	Obesity-related traits;	chr8:56475851	chr8:56496246~56559823:-
HNSC	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.37	1.53e-05	0.00284	0.23	0.2	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
HNSC	cis	rs10927875	0.691	rs1048302	ENSG00000226029.1	RP4-798A10.2	-4.37	1.53e-05	0.00284	-0.2	-0.2	Dilated cardiomyopathy;	chr1:16014384	chr1:16460948~16468481:+
HNSC	cis	rs3736485	0.609	rs744039	ENSG00000259438.1	CTD-2650P22.1	4.37	1.53e-05	0.00284	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51681176	chr15:52010999~52019095:-
HNSC	cis	rs11992162	0.551	rs59191504	ENSG00000227888.4	FAM66A	-4.37	1.53e-05	0.00284	-0.2	-0.2	Monocyte count;	chr8:11927572	chr8:12362019~12388296:+
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000254153.1	CTA-398F10.2	-4.37	1.53e-05	0.00284	-0.21	-0.2	Myopia (pathological);	chr8:9111923	chr8:8456909~8461337:-
HNSC	cis	rs2732480	0.557	rs923397	ENSG00000257763.1	OR5BK1P	4.37	1.53e-05	0.00285	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.557	rs2409004	ENSG00000257763.1	OR5BK1P	4.37	1.53e-05	0.00285	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48355792~48356614:-
HNSC	cis	rs9813712	0.855	rs6806152	ENSG00000228252.7	COL6A4P2	-4.37	1.53e-05	0.00285	-0.21	-0.2	Response to amphetamines;	chr3:130245358	chr3:130212823~130273806:+
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000219392.1	RP1-265C24.5	-4.37	1.53e-05	0.00285	-0.23	-0.2	Parkinson's disease;	chr6:27992657	chr6:28115628~28116551:+
HNSC	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-4.37	1.53e-05	0.00285	-0.2	-0.2	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
HNSC	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	4.37	1.53e-05	0.00285	0.23	0.2	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
HNSC	cis	rs1355223	0.583	rs2941058	ENSG00000271369.1	RP11-350D17.3	4.37	1.53e-05	0.00285	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34858698	chr11:34709600~34710161:+
HNSC	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-4.37	1.53e-05	0.00285	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-4.37	1.53e-05	0.00285	-0.11	-0.2	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
HNSC	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.37	1.53e-05	0.00285	-0.22	-0.2	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
HNSC	cis	rs4356203	0.87	rs214925	ENSG00000260196.1	RP1-239B22.5	-4.37	1.53e-05	0.00285	-0.21	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17380649~17383531:+
HNSC	cis	rs6601327	0.613	rs11785458	ENSG00000233609.3	RP11-62H7.2	-4.37	1.53e-05	0.00285	-0.18	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9649300	chr8:8961200~8979025:+
HNSC	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-4.37	1.53e-05	0.00285	-0.34	-0.2	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
HNSC	cis	rs1538970	0.81	rs12067642	ENSG00000234329.1	RP11-767N6.2	4.37	1.53e-05	0.00285	0.23	0.2	Platelet count;	chr1:45461845	chr1:45651039~45651826:-
HNSC	cis	rs7829975	0.577	rs940032	ENSG00000173295.6	FAM86B3P	-4.37	1.53e-05	0.00285	-0.23	-0.2	Mood instability;	chr8:8688833	chr8:8228595~8244865:+
HNSC	cis	rs7829975	0.714	rs11784052	ENSG00000254153.1	CTA-398F10.2	4.37	1.53e-05	0.00285	0.21	0.2	Mood instability;	chr8:8814452	chr8:8456909~8461337:-
HNSC	cis	rs3806843	1	rs2337985	ENSG00000202515.1	VTRNA1-3	-4.37	1.54e-05	0.00285	-0.22	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr5:140726158~140726246:+
HNSC	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	4.37	1.54e-05	0.00285	0.21	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
HNSC	cis	rs4523957	0.855	rs143499	ENSG00000262333.1	HNRNPA1P16	-4.37	1.54e-05	0.00286	-0.16	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2229030	chr17:2306761~2307715:+
HNSC	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-4.37	1.54e-05	0.00286	-0.2	-0.2	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
HNSC	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	4.37	1.54e-05	0.00286	0.24	0.2	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
HNSC	cis	rs710913	0.587	rs6690413	ENSG00000182109.6	RP11-69E11.4	4.37	1.54e-05	0.00286	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39522280~39546187:-
HNSC	cis	rs6081541	1	rs6081547	ENSG00000179447.2	RP5-1027G4.3	-4.37	1.54e-05	0.00286	-0.27	-0.2	Psychosis (atypical);	chr20:19243943	chr20:19242302~19284596:-
HNSC	cis	rs36052053	0.908	rs34739891	ENSG00000203799.9	CCDC162P	4.37	1.54e-05	0.00286	0.3	0.2	Red cell distribution width;	chr6:109290264	chr6:109285485~109355063:+
HNSC	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	4.37	1.54e-05	0.00286	0.24	0.2	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
HNSC	cis	rs6701713	0.959	rs4844610	ENSG00000274245.1	RP11-357P18.2	-4.37	1.54e-05	0.00286	-0.34	-0.2	Alzheimer's disease (late onset);	chr1:207629207	chr1:207372559~207373252:+
HNSC	cis	rs6500395	0.962	rs1477135	ENSG00000261267.1	RP11-44I10.3	-4.37	1.54e-05	0.00286	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48692912	chr16:48559661~48587403:+
HNSC	cis	rs62027291	0.95	rs11072638	ENSG00000259422.1	RP11-593F23.1	-4.37	1.54e-05	0.00286	-0.31	-0.2	Plateletcrit;	chr15:76978007	chr15:76174891~76181486:-
HNSC	cis	rs6964587	0.9	rs62467794	ENSG00000188693.7	CYP51A1-AS1	-4.37	1.54e-05	0.00286	-0.22	-0.2	Breast cancer;	chr7:92221264	chr7:92134604~92180725:+
HNSC	cis	rs2492286	0.569	rs2712383	ENSG00000242551.2	POU5F1P6	-4.37	1.54e-05	0.00286	-0.22	-0.2	Eosinophil counts;	chr3:128629033	chr3:128674735~128677005:-
HNSC	cis	rs6081541	1	rs62201127	ENSG00000179447.2	RP5-1027G4.3	-4.37	1.54e-05	0.00286	-0.27	-0.2	Psychosis (atypical);	chr20:19245192	chr20:19242302~19284596:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-4.37	1.54e-05	0.00286	-0.11	-0.2	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
HNSC	cis	rs916888	0.821	rs199514	ENSG00000260075.1	NSFP1	4.37	1.54e-05	0.00286	0.28	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46372855~46487141:+
HNSC	cis	rs13434995	0.513	rs62303718	ENSG00000273257.1	RP11-177J6.1	-4.37	1.54e-05	0.00286	-0.27	-0.2	Adiponectin levels;	chr4:55476770	chr4:55387949~55388271:+
HNSC	cis	rs3736485	0.844	rs8039073	ENSG00000259438.1	CTD-2650P22.1	4.37	1.54e-05	0.00287	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51467709	chr15:52010999~52019095:-
HNSC	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	4.37	1.54e-05	0.00287	0.34	0.2	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
HNSC	cis	rs7324557	0.683	rs9510868	ENSG00000205861.10	C1QTNF9B-AS1	-4.37	1.54e-05	0.00287	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23809555	chr13:23888889~23897263:+
HNSC	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-4.37	1.54e-05	0.00287	-0.2	-0.2	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
HNSC	cis	rs12893668	0.572	rs12590968	ENSG00000269910.1	RP11-73M18.10	4.37	1.55e-05	0.00287	0.19	0.2	Reticulocyte count;	chr14:103670296	chr14:103694516~103695050:-
HNSC	cis	rs9450351	0.744	rs6912150	ENSG00000203875.9	SNHG5	-4.37	1.55e-05	0.00287	-0.41	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85660950~85678736:-
HNSC	cis	rs72843166	0.509	rs75195552	ENSG00000265282.1	RP11-269G24.4	4.37	1.55e-05	0.00287	0.29	0.2	Intelligence (multi-trait analysis);	chr17:63446864	chr17:63430468~63432211:-
HNSC	cis	rs4843747	0.671	rs9921236	ENSG00000260750.4	RP11-482M8.1	4.37	1.55e-05	0.00287	0.24	0.2	Menopause (age at onset);	chr16:88083409	chr16:87492555~87515635:+
HNSC	cis	rs10504130	1	rs12678639	ENSG00000272024.1	RP11-546K22.3	-4.37	1.55e-05	0.00287	-0.34	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:51918088	chr8:51950284~51950690:+
HNSC	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.37	1.55e-05	0.00287	-0.22	-0.2	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
HNSC	cis	rs9880211	0.898	rs13434116	ENSG00000273486.1	RP11-731C17.2	4.37	1.55e-05	0.00287	0.19	0.2	Height;Body mass index;	chr3:136634232	chr3:136837338~136839021:-
HNSC	cis	rs9487051	0.621	rs448496	ENSG00000243587.6	C6orf183	-4.37	1.55e-05	0.00287	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109218954	chr6:109165833~109271014:+
HNSC	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	4.37	1.55e-05	0.00287	0.19	0.2	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
HNSC	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-4.37	1.55e-05	0.00287	-0.24	-0.2	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
HNSC	cis	rs7937890	0.599	rs2597204	ENSG00000251991.1	RNU7-49P	4.37	1.55e-05	0.00287	0.23	0.2	Mitochondrial DNA levels;	chr11:14459471	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.686	rs907180	ENSG00000254153.1	CTA-398F10.2	4.37	1.55e-05	0.00287	0.21	0.2	Mood instability;	chr8:8845317	chr8:8456909~8461337:-
HNSC	cis	rs3015497	0.789	rs11621971	ENSG00000277050.1	RP11-102G14.1	4.37	1.55e-05	0.00287	0.18	0.2	Mean platelet volume;	chr14:50657809	chr14:51637348~51637947:-
HNSC	cis	rs7824557	0.707	rs3808519	ENSG00000269918.1	AF131215.9	4.37	1.55e-05	0.00287	0.19	0.2	Retinal vascular caliber;	chr8:11285461	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.86	rs2746433	ENSG00000217482.2	HMGB1P17	-4.37	1.55e-05	0.00288	-0.22	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135636086~135636713:-
HNSC	cis	rs656319	0.607	rs12156030	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.21	-0.2	Myopia (pathological);	chr8:10240012	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2572389	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11378883	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2736301	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11378904	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2736302	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11378910	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs7821459	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11379172	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs7834572	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11379176	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs4631424	ENSG00000269918.1	AF131215.9	-4.37	1.55e-05	0.00288	-0.19	-0.2	Retinal vascular caliber;	chr8:11379300	chr8:11104691~11106704:-
HNSC	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-4.37	1.55e-05	0.00288	-0.25	-0.2	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
HNSC	cis	rs72843506	0.528	rs73981803	ENSG00000261033.1	RP11-209D14.2	4.37	1.55e-05	0.00288	0.32	0.2	Schizophrenia;	chr17:20088952	chr17:20008051~20009234:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000250412.1	KLHL2P1	-4.37	1.55e-05	0.00288	-0.25	-0.2	Corneal astigmatism;	chr4:119339630	chr4:119334329~119378233:+
HNSC	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-4.37	1.55e-05	0.00288	-0.24	-0.2	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
HNSC	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00288	-0.3	-0.2	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
HNSC	cis	rs453301	0.624	rs2979265	ENSG00000253981.4	ALG1L13P	4.37	1.55e-05	0.00288	0.22	0.2	Joint mobility (Beighton score);	chr8:9001207	chr8:8236003~8244667:-
HNSC	cis	rs61935443	0.55	rs7311367	ENSG00000241556.1	RP11-490G8.1	-4.37	1.55e-05	0.00288	-0.2	-0.2	Schizophrenia;	chr12:94797254	chr12:95467397~95467861:-
HNSC	cis	rs6831352	0.589	rs1133483	ENSG00000263923.1	RP11-571L19.7	-4.37	1.55e-05	0.00288	-0.19	-0.2	Alcohol dependence;	chr4:99102772	chr4:98928897~98994994:+
HNSC	cis	rs853679	0.546	rs35016036	ENSG00000204709.4	LINC01556	4.37	1.55e-05	0.00288	0.41	0.2	Depression;	chr6:28347103	chr6:28943877~28944537:+
HNSC	cis	rs10129255	1	rs10134517	ENSG00000211974.3	IGHV2-70	4.37	1.56e-05	0.00289	0.19	0.2	Kawasaki disease;	chr14:106718498	chr14:106723574~106724093:-
HNSC	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	4.37	1.56e-05	0.00289	0.29	0.2	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
HNSC	cis	rs3015497	0.752	rs6572682	ENSG00000277050.1	RP11-102G14.1	-4.37	1.56e-05	0.00289	-0.19	-0.2	Mean platelet volume;	chr14:50678082	chr14:51637348~51637947:-
HNSC	cis	rs6500395	1	rs1486411	ENSG00000261267.1	RP11-44I10.3	-4.37	1.56e-05	0.00289	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48553172	chr16:48559661~48587403:+
HNSC	cis	rs2548724	0.645	rs841922	ENSG00000250682.4	LINC00491	-4.37	1.56e-05	0.00289	-0.26	-0.2	Type 2 diabetes;	chr5:102294992	chr5:102609156~102671559:-
HNSC	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-4.37	1.56e-05	0.00289	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
HNSC	cis	rs924712	0.522	rs1910356	ENSG00000224984.1	RP11-524H19.2	-4.37	1.56e-05	0.00289	-0.23	-0.2	Breast cancer;	chr6:54841345	chr6:54840118~54840855:-
HNSC	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	4.37	1.56e-05	0.00289	0.19	0.2	Height;	chr5:37535278	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	4.37	1.56e-05	0.00289	0.19	0.2	Height;	chr5:37540355	chr5:36666214~36725195:-
HNSC	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-4.37	1.56e-05	0.00289	-0.25	-0.2	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	4.37	1.56e-05	0.00289	0.24	0.2	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	4.37	1.56e-05	0.00289	0.24	0.2	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	4.37	1.56e-05	0.00289	0.24	0.2	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
HNSC	cis	rs7819412	0.595	rs10106914	ENSG00000269918.1	AF131215.9	-4.37	1.56e-05	0.00289	-0.2	-0.2	Triglycerides;	chr8:11130141	chr8:11104691~11106704:-
HNSC	cis	rs73198271	0.653	rs3827811	ENSG00000253893.2	FAM85B	4.37	1.56e-05	0.00289	0.26	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8167819~8226614:-
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000106610.13	STAG3L4	-4.37	1.56e-05	0.00289	-0.4	-0.2	Diabetic kidney disease;	chr7:66433290	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000106610.13	STAG3L4	-4.37	1.56e-05	0.00289	-0.4	-0.2	Diabetic kidney disease;	chr7:66482930	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000106610.13	STAG3L4	-4.37	1.56e-05	0.00289	-0.4	-0.2	Diabetic kidney disease;	chr7:66486966	chr7:67302621~67321526:+
HNSC	cis	rs2948294	0.566	rs13274039	ENSG00000253981.4	ALG1L13P	4.37	1.56e-05	0.00289	0.23	0.2	Red cell distribution width;	chr8:8254137	chr8:8236003~8244667:-
HNSC	cis	rs9311676	0.632	rs56026131	ENSG00000273493.1	RP11-80H18.4	4.37	1.56e-05	0.00289	0.22	0.2	Systemic lupus erythematosus;	chr3:58436756	chr3:58329965~58330118:+
HNSC	cis	rs36052053	0.908	rs932222	ENSG00000203799.9	CCDC162P	-4.37	1.56e-05	0.00289	-0.29	-0.2	Red cell distribution width;	chr6:109265475	chr6:109285485~109355063:+
HNSC	cis	rs8077577	0.895	rs11655588	ENSG00000273018.4	CTD-2303H24.2	4.37	1.56e-05	0.00289	0.3	0.2	Obesity-related traits;	chr17:18204137	chr17:18511221~18551705:-
HNSC	cis	rs9527	0.615	rs4919685	ENSG00000236937.2	PTGES3P4	4.37	1.56e-05	0.00289	0.27	0.2	Arsenic metabolism;	chr10:102827605	chr10:102845595~102845950:+
HNSC	cis	rs12935418	0.672	rs2549883	ENSG00000278985.1	RP11-303E16.9	-4.37	1.56e-05	0.00289	-0.19	-0.2	Mean corpuscular volume;	chr16:81022273	chr16:80982319~80984094:-
HNSC	cis	rs7512552	1	rs7512552	ENSG00000228126.1	FALEC	-4.37	1.56e-05	0.0029	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150293284	chr1:150515757~150518032:+
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000224373.3	IGHV4-59	4.37	1.56e-05	0.0029	0.13	0.2	Kawasaki disease;	chr14:106799309	chr14:106627249~106627825:-
HNSC	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	4.37	1.56e-05	0.0029	0.24	0.2	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
HNSC	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	4.37	1.56e-05	0.0029	0.23	0.2	Height;	chr14:75077398	chr14:75011269~75012851:-
HNSC	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-4.37	1.56e-05	0.0029	-0.21	-0.2	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-4.37	1.56e-05	0.0029	-0.21	-0.2	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
HNSC	cis	rs73222236	0.817	rs7629905	ENSG00000273486.1	RP11-731C17.2	4.37	1.56e-05	0.0029	0.17	0.2	Coronary artery disease;	chr3:136620847	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.817	rs9828068	ENSG00000273486.1	RP11-731C17.2	4.37	1.56e-05	0.0029	0.17	0.2	Coronary artery disease;	chr3:136623860	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.782	rs9820513	ENSG00000273486.1	RP11-731C17.2	4.37	1.56e-05	0.0029	0.17	0.2	Coronary artery disease;	chr3:136627450	chr3:136837338~136839021:-
HNSC	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	4.37	1.56e-05	0.0029	0.25	0.2	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
HNSC	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-4.37	1.56e-05	0.0029	-0.18	-0.2	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
HNSC	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-4.37	1.57e-05	0.0029	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
HNSC	cis	rs6496044	0.507	rs1471455	ENSG00000259295.5	CSPG4P12	-4.37	1.57e-05	0.0029	-0.24	-0.2	Interstitial lung disease;	chr15:85611496	chr15:85191438~85213905:+
HNSC	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	4.36	1.57e-05	0.0029	0.23	0.2	Height;	chr14:75112940	chr14:75011269~75012851:-
HNSC	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-4.36	1.57e-05	0.0029	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
HNSC	cis	rs7829975	0.511	rs2948286	ENSG00000254153.1	CTA-398F10.2	4.36	1.57e-05	0.00291	0.22	0.2	Mood instability;	chr8:8272638	chr8:8456909~8461337:-
HNSC	cis	rs4908768	0.539	rs1381928	ENSG00000232912.4	RP5-1115A15.1	4.36	1.57e-05	0.00291	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8424645~8434838:+
HNSC	cis	rs12745968	0.525	rs6603997	ENSG00000223787.2	RP4-593M8.1	-4.36	1.57e-05	0.00291	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92597054	chr1:92580476~92580821:-
HNSC	cis	rs2732480	0.577	rs2450994	ENSG00000257763.1	OR5BK1P	4.36	1.57e-05	0.00291	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48355792~48356614:-
HNSC	cis	rs9311676	0.632	rs11923181	ENSG00000273493.1	RP11-80H18.4	4.36	1.57e-05	0.00291	0.21	0.2	Systemic lupus erythematosus;	chr3:58394842	chr3:58329965~58330118:+
HNSC	cis	rs4356203	0.905	rs214940	ENSG00000260196.1	RP1-239B22.5	-4.36	1.57e-05	0.00291	-0.21	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17380649~17383531:+
HNSC	cis	rs10256972	0.706	rs7784559	ENSG00000229043.2	AC091729.9	-4.36	1.57e-05	0.00291	-0.25	-0.2	Endometriosis;Longevity;	chr7:963337	chr7:1160374~1165267:+
HNSC	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	4.36	1.57e-05	0.00291	0.23	0.2	Height;	chr14:75189542	chr14:75011269~75012851:-
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000254340.1	RP11-10A14.3	4.36	1.57e-05	0.00291	0.24	0.2	Mood instability;	chr8:8525195	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	4.36	1.57e-05	0.00291	0.24	0.2	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
HNSC	cis	rs9527	0.571	rs12219246	ENSG00000236937.2	PTGES3P4	4.36	1.57e-05	0.00291	0.24	0.2	Arsenic metabolism;	chr10:102853598	chr10:102845595~102845950:+
HNSC	cis	rs61841072	0.961	rs1985630	ENSG00000253326.2	RP11-261C10.7	-4.36	1.57e-05	0.00291	-0.26	-0.2	Schizophrenia;	chr1:242971392	chr1:243054861~243056394:-
HNSC	cis	rs12893668	0.572	rs4906356	ENSG00000269910.1	RP11-73M18.10	4.36	1.57e-05	0.00291	0.19	0.2	Reticulocyte count;	chr14:103672364	chr14:103694516~103695050:-
HNSC	cis	rs13434995	0.513	rs17722870	ENSG00000273257.1	RP11-177J6.1	-4.36	1.57e-05	0.00291	-0.27	-0.2	Adiponectin levels;	chr4:55478519	chr4:55387949~55388271:+
HNSC	cis	rs7572733	0.935	rs700669	ENSG00000222017.1	AC011997.1	4.36	1.57e-05	0.00291	0.24	0.2	Dermatomyositis;	chr2:197819743	chr2:197693106~197774823:+
HNSC	cis	rs75422866	0.85	rs73111220	ENSG00000276691.1	RP5-1057I20.5	4.36	1.57e-05	0.00291	0.42	0.2	Pneumonia;	chr12:47578764	chr12:47788426~47788971:+
HNSC	cis	rs7735319	0.966	rs35408434	ENSG00000251281.1	CTD-2066L21.2	4.36	1.57e-05	0.00291	0.23	0.2	Systolic blood pressure;	chr5:33163321	chr5:33011322~33017607:-
HNSC	cis	rs11673344	0.504	rs4806408	ENSG00000276846.1	CTD-3220F14.3	4.36	1.57e-05	0.00291	0.22	0.2	Obesity-related traits;	chr19:37097875	chr19:37314868~37315620:-
HNSC	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	4.36	1.57e-05	0.00291	0.3	0.2	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
HNSC	cis	rs8010715	0.52	rs12435994	ENSG00000259321.1	RP11-468E2.5	4.36	1.57e-05	0.00292	0.17	0.2	IgG glycosylation;	chr14:24120252	chr14:24139445~24140444:+
HNSC	cis	rs8010715	0.596	rs12435995	ENSG00000259321.1	RP11-468E2.5	4.36	1.57e-05	0.00292	0.17	0.2	IgG glycosylation;	chr14:24120255	chr14:24139445~24140444:+
HNSC	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	4.36	1.57e-05	0.00292	0.3	0.2	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
HNSC	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	4.36	1.58e-05	0.00292	0.28	0.2	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
HNSC	cis	rs35306767	0.903	rs12764024	ENSG00000229869.1	RP11-363N22.2	-4.36	1.58e-05	0.00292	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:876921	chr10:933026~942743:+
HNSC	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.36	1.58e-05	0.00292	0.22	0.2	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
HNSC	cis	rs3015497	0.527	rs2934671	ENSG00000277050.1	RP11-102G14.1	-4.36	1.58e-05	0.00292	-0.21	-0.2	Mean platelet volume;	chr14:50686363	chr14:51637348~51637947:-
HNSC	cis	rs3015497	0.527	rs2934670	ENSG00000277050.1	RP11-102G14.1	-4.36	1.58e-05	0.00292	-0.21	-0.2	Mean platelet volume;	chr14:50686691	chr14:51637348~51637947:-
HNSC	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-4.36	1.58e-05	0.00292	-0.15	-0.2	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
HNSC	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	4.36	1.58e-05	0.00292	0.2	0.2	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
HNSC	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-4.36	1.58e-05	0.00292	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-4.36	1.58e-05	0.00292	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
HNSC	cis	rs6500395	1	rs9936454	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00292	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48583871	chr16:48559661~48587403:+
HNSC	cis	rs3015497	0.603	rs2291672	ENSG00000269906.1	RP11-248J18.2	-4.36	1.58e-05	0.00292	-0.27	-0.2	Mean platelet volume;	chr14:50593734	chr14:50662511~50663178:-
HNSC	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-4.36	1.58e-05	0.00292	-0.22	-0.2	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
HNSC	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	4.36	1.58e-05	0.00292	0.22	0.2	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	4.36	1.58e-05	0.00292	0.22	0.2	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	4.36	1.58e-05	0.00292	0.22	0.2	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
HNSC	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	4.36	1.58e-05	0.00292	0.22	0.2	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	4.36	1.58e-05	0.00292	0.22	0.2	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
HNSC	cis	rs12893668	0.667	rs71417869	ENSG00000269940.1	RP11-73M18.7	4.36	1.58e-05	0.00292	0.19	0.2	Reticulocyte count;	chr14:103611097	chr14:103694560~103695170:+
HNSC	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	4.36	1.58e-05	0.00292	0.24	0.2	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
HNSC	cis	rs4252134	0.764	rs62436704	ENSG00000231863.1	RP3-428L16.1	4.36	1.58e-05	0.00292	0.26	0.2	Giant cell arteritis;	chr6:160778704	chr6:160931080~160969771:+
HNSC	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	4.36	1.58e-05	0.00292	0.25	0.2	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
HNSC	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	4.36	1.58e-05	0.00292	0.19	0.2	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
HNSC	cis	rs13434995	0.513	rs1801260	ENSG00000273257.1	RP11-177J6.1	-4.36	1.58e-05	0.00293	-0.27	-0.2	Adiponectin levels;	chr4:55435202	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs17721215	ENSG00000273257.1	RP11-177J6.1	-4.36	1.58e-05	0.00293	-0.27	-0.2	Adiponectin levels;	chr4:55437620	chr4:55387949~55388271:+
HNSC	cis	rs5758511	0.514	rs9611746	ENSG00000205702.9	CYP2D7	4.36	1.58e-05	0.00293	0.18	0.2	Birth weight;	chr22:42165359	chr22:42140203~42144577:-
HNSC	cis	rs11673344	0.523	rs7245520	ENSG00000276846.1	CTD-3220F14.3	4.36	1.58e-05	0.00293	0.22	0.2	Obesity-related traits;	chr19:37036416	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs7256380	ENSG00000276846.1	CTD-3220F14.3	4.36	1.58e-05	0.00293	0.22	0.2	Obesity-related traits;	chr19:37041178	chr19:37314868~37315620:-
HNSC	cis	rs9650657	0.836	rs2898252	ENSG00000269918.1	AF131215.9	-4.36	1.58e-05	0.00293	-0.2	-0.2	Neuroticism;	chr8:10746654	chr8:11104691~11106704:-
HNSC	cis	rs3096299	0.679	rs3102338	ENSG00000261574.1	RP1-168P16.2	4.36	1.58e-05	0.00293	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89392375~89412564:-
HNSC	cis	rs34421088	0.576	rs2572432	ENSG00000255310.2	AF131215.2	-4.36	1.58e-05	0.00293	-0.21	-0.2	Neuroticism;	chr8:11244214	chr8:11107788~11109726:-
HNSC	cis	rs2279168	0.749	rs56725751	ENSG00000259295.5	CSPG4P12	-4.36	1.58e-05	0.00293	-0.37	-0.2	Response to platinum-based chemotherapy (carboplatin);	chr15:85501061	chr15:85191438~85213905:+
HNSC	cis	rs2279168	0.867	rs73450329	ENSG00000259295.5	CSPG4P12	-4.36	1.58e-05	0.00293	-0.37	-0.2	Response to platinum-based chemotherapy (carboplatin);	chr15:85502007	chr15:85191438~85213905:+
HNSC	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	4.36	1.58e-05	0.00293	0.23	0.2	Height;	chr14:75077486	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	4.36	1.58e-05	0.00293	0.23	0.2	Height;	chr14:75103590	chr14:75011269~75012851:-
HNSC	cis	rs6500395	1	rs3848319	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48577022	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9931123	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48580382	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7196823	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48582367	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11644518	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48582878	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs3848321	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48586869	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs6500395	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48587491	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs904818	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48588671	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs904819	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48588672	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9931737	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48589628	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.925	rs6500396	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48591547	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9923371	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48594104	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs55671623	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48597243	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1386040	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48597296	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11649236	ENSG00000261267.1	RP11-44I10.3	-4.36	1.58e-05	0.00293	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48598567	chr16:48559661~48587403:+
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000211974.3	IGHV2-70	4.36	1.58e-05	0.00293	0.18	0.2	Kawasaki disease;	chr14:106686431	chr14:106723574~106724093:-
HNSC	cis	rs3811273	0.764	rs60839960	ENSG00000211816.2	TRAV38-1	-4.36	1.58e-05	0.00293	-0.25	-0.2	Periodontal disease-related phenotypes;	chr14:22256540	chr14:22271968~22272563:+
HNSC	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	4.36	1.58e-05	0.00293	0.25	0.2	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
HNSC	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	4.36	1.58e-05	0.00293	0.2	0.2	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
HNSC	cis	rs7662987	0.517	rs2602882	ENSG00000263923.1	RP11-571L19.7	-4.36	1.58e-05	0.00293	-0.21	-0.2	Smoking initiation;	chr4:99119614	chr4:98928897~98994994:+
HNSC	cis	rs7662987	0.517	rs2602883	ENSG00000263923.1	RP11-571L19.7	-4.36	1.58e-05	0.00293	-0.21	-0.2	Smoking initiation;	chr4:99119763	chr4:98928897~98994994:+
HNSC	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	4.36	1.58e-05	0.00293	0.21	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	4.36	1.58e-05	0.00293	0.21	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
HNSC	cis	rs11148252	0.595	rs4885117	ENSG00000198384.8	TPTE2P3	4.36	1.59e-05	0.00293	0.24	0.2	Lewy body disease;	chr13:52578892	chr13:52522632~52586906:+
HNSC	cis	rs853679	0.607	rs35030260	ENSG00000204709.4	LINC01556	4.36	1.59e-05	0.00293	0.41	0.2	Depression;	chr6:28337731	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs13217619	ENSG00000204709.4	LINC01556	4.36	1.59e-05	0.00293	0.41	0.2	Depression;	chr6:28338894	chr6:28943877~28944537:+
HNSC	cis	rs6840258	0.941	rs7665282	ENSG00000251411.1	RP11-397E7.4	-4.36	1.59e-05	0.00293	-0.26	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86979698	chr4:86913266~86914817:-
HNSC	cis	rs3015497	0.603	rs3015449	ENSG00000269906.1	RP11-248J18.2	-4.36	1.59e-05	0.00293	-0.27	-0.2	Mean platelet volume;	chr14:50611358	chr14:50662511~50663178:-
HNSC	cis	rs12893668	0.667	rs11844466	ENSG00000269940.1	RP11-73M18.7	4.36	1.59e-05	0.00293	0.2	0.2	Reticulocyte count;	chr14:103600085	chr14:103694560~103695170:+
HNSC	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00293	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00293	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00293	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00293	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00293	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
HNSC	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-4.36	1.59e-05	0.00293	-0.25	-0.2	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
HNSC	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-4.36	1.59e-05	0.00294	-0.25	-0.2	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
HNSC	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-4.36	1.59e-05	0.00294	-0.28	-0.2	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
HNSC	cis	rs7824557	0.638	rs4413734	ENSG00000255310.2	AF131215.2	4.36	1.59e-05	0.00294	0.19	0.2	Retinal vascular caliber;	chr8:11355269	chr8:11107788~11109726:-
HNSC	cis	rs73222236	0.787	rs35681043	ENSG00000273486.1	RP11-731C17.2	4.36	1.59e-05	0.00294	0.16	0.2	Coronary artery disease;	chr3:136261583	chr3:136837338~136839021:-
HNSC	cis	rs6163	0.508	rs11191381	ENSG00000236937.2	PTGES3P4	4.36	1.59e-05	0.00294	0.27	0.2	Waist circumference;Hip circumference;	chr10:102733687	chr10:102845595~102845950:+
HNSC	cis	rs6163	0.54	rs11191385	ENSG00000236937.2	PTGES3P4	4.36	1.59e-05	0.00294	0.27	0.2	Waist circumference;Hip circumference;	chr10:102753292	chr10:102845595~102845950:+
HNSC	cis	rs3736485	0.609	rs11638154	ENSG00000259438.1	CTD-2650P22.1	4.36	1.59e-05	0.00294	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677219	chr15:52010999~52019095:-
HNSC	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-4.36	1.59e-05	0.00294	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
HNSC	cis	rs9329221	0.572	rs4841295	ENSG00000269918.1	AF131215.9	4.36	1.59e-05	0.00294	0.2	0.2	Neuroticism;	chr8:10247605	chr8:11104691~11106704:-
HNSC	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-4.36	1.59e-05	0.00294	-0.24	-0.2	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
HNSC	cis	rs1062753	0.527	rs62240998	ENSG00000227370.1	RP4-669P10.19	4.36	1.59e-05	0.00294	0.2	0.2	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41958697	chr22:42132543~42132998:+
HNSC	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00294	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-4.36	1.59e-05	0.00294	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
HNSC	cis	rs1799949	1	rs8176202	ENSG00000236383.6	LINC00854	-4.36	1.59e-05	0.00295	-0.19	-0.2	Menopause (age at onset);	chr17:43078211	chr17:43216941~43305976:-
HNSC	cis	rs755249	0.508	rs12023553	ENSG00000182109.6	RP11-69E11.4	-4.36	1.59e-05	0.00295	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39522280~39546187:-
HNSC	cis	rs2732480	0.577	rs2732486	ENSG00000257763.1	OR5BK1P	4.36	1.59e-05	0.00295	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.517	rs2634676	ENSG00000257763.1	OR5BK1P	4.36	1.59e-05	0.00295	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48355792~48356614:-
HNSC	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-4.36	1.59e-05	0.00295	-0.24	-0.2	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
HNSC	cis	rs9368481	0.761	rs7775041	ENSG00000224843.5	LINC00240	4.36	1.59e-05	0.00295	0.2	0.2	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26956992~27023924:+
HNSC	cis	rs4927850	1	rs7627706	ENSG00000226155.1	AC124944.3	-4.36	1.59e-05	0.00295	-0.24	-0.2	Pancreatic cancer;	chr3:196026482	chr3:195912049~195913986:+
HNSC	cis	rs4927850	0.881	rs7630489	ENSG00000226155.1	AC124944.3	-4.36	1.59e-05	0.00295	-0.24	-0.2	Pancreatic cancer;	chr3:196026530	chr3:195912049~195913986:+
HNSC	cis	rs9311676	0.632	rs62259780	ENSG00000273493.1	RP11-80H18.4	4.36	1.59e-05	0.00295	0.21	0.2	Systemic lupus erythematosus;	chr3:58442351	chr3:58329965~58330118:+
HNSC	cis	rs6964587	0.755	rs13229505	ENSG00000188693.7	CYP51A1-AS1	-4.36	1.59e-05	0.00295	-0.22	-0.2	Breast cancer;	chr7:91815365	chr7:92134604~92180725:+
HNSC	cis	rs11083475	0.681	rs62121377	ENSG00000269486.2	CTC-360G5.9	4.36	1.6e-05	0.00295	0.21	0.2	Heart rate;	chr19:38766656	chr19:38935297~38938632:-
HNSC	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-4.36	1.6e-05	0.00295	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
HNSC	cis	rs2255336	0.81	rs7139147	ENSG00000245648.1	RP11-277P12.20	4.36	1.6e-05	0.00295	0.35	0.2	Blood protein levels;	chr12:10361956	chr12:10363769~10398506:+
HNSC	cis	rs9287719	0.967	rs10203664	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10612251	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs10203785	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10612382	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs9287720	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10612538	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.87	rs10167676	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613014	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs12995159	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613197	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs12995602	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613416	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432119	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613561	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432120	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613645	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432121	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613678	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6432122	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10613718	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6712406	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10614294	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs4371336	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10615597	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4405729	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10615653	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.839	rs11683335	ENSG00000243819.4	RN7SL832P	4.36	1.6e-05	0.00295	0.19	0.2	Prostate cancer;	chr2:10616539	chr2:10690344~10692099:+
HNSC	cis	rs3738443	0.868	rs61840048	ENSG00000259865.1	RP11-488L18.10	4.36	1.6e-05	0.00295	0.18	0.2	Alcohol dependence;	chr1:247199829	chr1:247187281~247188526:-
HNSC	cis	rs4965359	0.537	rs8023514	ENSG00000270127.2	RP11-526I2.5	-4.36	1.6e-05	0.00295	-0.19	-0.2	Central corneal thickness;	chr15:101034231	chr15:100547765~100550153:-
HNSC	cis	rs6831352	0.918	rs1042365	ENSG00000263923.1	RP11-571L19.7	4.36	1.6e-05	0.00295	0.21	0.2	Alcohol dependence;	chr4:99124349	chr4:98928897~98994994:+
HNSC	cis	rs467650	0.553	rs29771	ENSG00000246763.5	RGMB-AS1	4.36	1.6e-05	0.00295	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98640442	chr5:98769618~98773469:-
HNSC	cis	rs3736485	0.903	rs11630743	ENSG00000259438.1	CTD-2650P22.1	4.36	1.6e-05	0.00295	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51458412	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.903	rs11630842	ENSG00000259438.1	CTD-2650P22.1	4.36	1.6e-05	0.00295	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51458455	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.903	rs7165887	ENSG00000259438.1	CTD-2650P22.1	4.36	1.6e-05	0.00295	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51458649	chr15:52010999~52019095:-
HNSC	cis	rs9329221	0.527	rs4841351	ENSG00000255020.1	AF131216.5	-4.36	1.6e-05	0.00296	-0.22	-0.2	Neuroticism;	chr8:10469857	chr8:11345748~11347502:-
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000254153.1	CTA-398F10.2	-4.36	1.6e-05	0.00296	-0.23	-0.2	Recombination measurement;	chr8:9208000	chr8:8456909~8461337:-
HNSC	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	4.36	1.6e-05	0.00296	0.19	0.2	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
HNSC	cis	rs9568867	1	rs12429545	ENSG00000273784.3	RP11-78J21.7	4.36	1.6e-05	0.00296	0.29	0.2	Obesity;Body mass index;	chr13:53528071	chr13:52600042~52642542:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000211974.3	IGHV2-70	4.36	1.6e-05	0.00296	0.18	0.2	Kawasaki disease;	chr14:106781682	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000211974.3	IGHV2-70	4.36	1.6e-05	0.00296	0.18	0.2	Kawasaki disease;	chr14:106781820	chr14:106723574~106724093:-
HNSC	cis	rs12935418	0.672	rs6564814	ENSG00000278985.1	RP11-303E16.9	4.36	1.6e-05	0.00296	0.19	0.2	Mean corpuscular volume;	chr16:81016567	chr16:80982319~80984094:-
HNSC	cis	rs7615952	0.599	rs2270986	ENSG00000241439.1	RP11-666A20.3	4.36	1.6e-05	0.00296	0.22	0.2	Blood pressure (smoking interaction);	chr3:125982256	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.599	rs12496921	ENSG00000241439.1	RP11-666A20.3	4.36	1.6e-05	0.00296	0.22	0.2	Blood pressure (smoking interaction);	chr3:125983105	chr3:125958556~125958817:+
HNSC	cis	rs6500395	0.926	rs9929569	ENSG00000261267.1	RP11-44I10.3	-4.36	1.6e-05	0.00296	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48643673	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs7499213	ENSG00000261267.1	RP11-44I10.3	-4.36	1.6e-05	0.00296	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48646686	chr16:48559661~48587403:+
HNSC	cis	rs9583531	0.714	rs79483970	ENSG00000259831.1	LINC00567	-4.36	1.6e-05	0.00296	-0.36	-0.2	Coronary artery disease;	chr13:110689951	chr13:110809676~110813084:-
HNSC	cis	rs35306767	0.953	rs12357633	ENSG00000229869.1	RP11-363N22.2	-4.36	1.6e-05	0.00296	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:911306	chr10:933026~942743:+
HNSC	cis	rs61270009	1	rs61270009	ENSG00000247828.6	TMEM161B-AS1	4.36	1.6e-05	0.00296	0.21	0.2	Depressive symptoms;	chr5:88280322	chr5:88268895~88436685:+
HNSC	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-4.36	1.6e-05	0.00296	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
HNSC	cis	rs11756659	0.505	rs16891142	ENSG00000272462.2	U91328.19	4.36	1.6e-05	0.00296	0.22	0.2	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25898911	chr6:25992662~26001775:+
HNSC	cis	rs4924935	1	rs4924935	ENSG00000264885.1	RP11-815I9.4	-4.36	1.6e-05	0.00296	-0.23	-0.2	Pancreatic cancer;	chr17:18850557	chr17:18667629~18669461:-
HNSC	cis	rs1050631	1	rs1789514	ENSG00000278986.1	RP11-723J4.3	4.36	1.6e-05	0.00296	0.22	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36112691	chr18:35972151~35973916:+
HNSC	cis	rs59072263	0.85	rs55916403	ENSG00000233264.2	AC006042.8	4.36	1.6e-05	0.00296	0.31	0.2	Intraocular pressure;	chr7:8104421	chr7:7980312~7982228:+
HNSC	cis	rs12600394	1	rs4239129	ENSG00000236088.8	COX10-AS1	4.36	1.6e-05	0.00296	0.3	0.2	Response to platinum-based chemotherapy (cisplatin);	chr17:14609344	chr17:13756478~14069495:-
HNSC	cis	rs4862750	0.872	rs13143414	ENSG00000250971.1	RP11-696F12.1	4.36	1.6e-05	0.00296	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:187060099~187060930:+
HNSC	cis	rs13256369	0.901	rs13251887	ENSG00000173295.6	FAM86B3P	4.36	1.6e-05	0.00296	0.26	0.2	Obesity-related traits;	chr8:8711168	chr8:8228595~8244865:+
HNSC	cis	rs13256369	1	rs885000	ENSG00000173295.6	FAM86B3P	4.36	1.6e-05	0.00296	0.26	0.2	Obesity-related traits;	chr8:8711365	chr8:8228595~8244865:+
HNSC	cis	rs13256369	1	rs883648	ENSG00000173295.6	FAM86B3P	4.36	1.6e-05	0.00296	0.26	0.2	Obesity-related traits;	chr8:8712011	chr8:8228595~8244865:+
HNSC	cis	rs1008375	0.966	rs11733730	ENSG00000249502.1	AC006160.5	-4.36	1.6e-05	0.00296	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17623586	chr4:17587467~17614571:-
HNSC	cis	rs5758511	0.689	rs62240864	ENSG00000205702.9	CYP2D7	4.36	1.6e-05	0.00296	0.19	0.2	Birth weight;	chr22:42167883	chr22:42140203~42144577:-
HNSC	cis	rs9807989	0.801	rs4851566	ENSG00000234389.1	AC007278.3	4.36	1.6e-05	0.00296	0.2	0.2	Asthma;	chr2:102356339	chr2:102438713~102440475:+
HNSC	cis	rs73198271	0.773	rs66618176	ENSG00000173295.6	FAM86B3P	-4.36	1.6e-05	0.00296	-0.26	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8228595~8244865:+
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000254340.1	RP11-10A14.3	4.36	1.6e-05	0.00296	0.24	0.2	Systolic blood pressure;	chr8:8290748	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.872	rs8015406	ENSG00000211974.3	IGHV2-70	4.36	1.6e-05	0.00296	0.18	0.2	Kawasaki disease;	chr14:106670611	chr14:106723574~106724093:-
HNSC	cis	rs56804039	0.524	rs11785096	ENSG00000173295.6	FAM86B3P	-4.36	1.6e-05	0.00296	-0.33	-0.2	Cervical cancer;	chr8:8515304	chr8:8228595~8244865:+
HNSC	cis	rs4862750	0.914	rs9995391	ENSG00000250971.1	RP11-696F12.1	-4.36	1.6e-05	0.00296	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:187060099~187060930:+
HNSC	cis	rs13434995	0.513	rs880358	ENSG00000273257.1	RP11-177J6.1	-4.36	1.61e-05	0.00296	-0.27	-0.2	Adiponectin levels;	chr4:55410311	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs17776975	ENSG00000273257.1	RP11-177J6.1	-4.36	1.61e-05	0.00296	-0.27	-0.2	Adiponectin levels;	chr4:55410728	chr4:55387949~55388271:+
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000255495.1	AC145124.2	4.36	1.61e-05	0.00296	0.22	0.2	Neuroticism;	chr8:11942522	chr8:12194467~12196280:+
HNSC	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-4.36	1.61e-05	0.00296	-0.26	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
HNSC	cis	rs1050631	0.96	rs4799848	ENSG00000278986.1	RP11-723J4.3	4.36	1.61e-05	0.00297	0.23	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36106329	chr18:35972151~35973916:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	4.36	1.61e-05	0.00297	0.23	0.2	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
HNSC	cis	rs933688	1	rs1035476	ENSG00000281357.1	ARRDC3-AS1	4.36	1.61e-05	0.00297	0.29	0.2	Smoking behavior;	chr5:91450159	chr5:91380349~91439085:+
HNSC	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-4.36	1.61e-05	0.00297	-0.24	-0.2	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
HNSC	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-4.36	1.61e-05	0.00297	-0.21	-0.2	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
HNSC	cis	rs11711311	0.712	rs6764048	ENSG00000241529.3	RN7SL767P	4.36	1.61e-05	0.00297	0.26	0.2	IgG glycosylation;	chr3:113614012	chr3:113632704~113632998:+
HNSC	cis	rs3096299	0.933	rs2965938	ENSG00000261574.1	RP1-168P16.2	4.36	1.61e-05	0.00297	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89392375~89412564:-
HNSC	cis	rs11122895	0.509	rs10174353	ENSG00000236307.2	EEF1E1P1	4.36	1.61e-05	0.00297	0.19	0.2	Allergic sensitization;	chr2:111690311	chr2:111887914~111888741:+
HNSC	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	4.36	1.61e-05	0.00297	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
HNSC	cis	rs11673344	0.523	rs6510585	ENSG00000276846.1	CTD-3220F14.3	4.36	1.61e-05	0.00297	0.22	0.2	Obesity-related traits;	chr19:37063081	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs17206540	ENSG00000276846.1	CTD-3220F14.3	4.36	1.61e-05	0.00297	0.22	0.2	Obesity-related traits;	chr19:37069009	chr19:37314868~37315620:-
HNSC	cis	rs12478296	0.892	rs60042638	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242096556	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs12474070	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242097587	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs56102931	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242097785	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs55732177	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242097855	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs55717005	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242098920	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs55814222	ENSG00000261186.2	RP11-341N2.1	-4.36	1.61e-05	0.00297	-0.32	-0.2	Obesity-related traits;	chr2:242099015	chr2:242087351~242088457:-
HNSC	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	4.36	1.61e-05	0.00297	0.23	0.2	Height;	chr14:75077767	chr14:75011269~75012851:-
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	4.36	1.61e-05	0.00297	0.24	0.2	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
HNSC	cis	rs1008375	1	rs11722037	ENSG00000249502.1	AC006160.5	-4.36	1.61e-05	0.00297	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682188	chr4:17587467~17614571:-
HNSC	cis	rs453301	0.631	rs17700611	ENSG00000254153.1	CTA-398F10.2	-4.36	1.61e-05	0.00297	-0.22	-0.2	Joint mobility (Beighton score);	chr8:8936144	chr8:8456909~8461337:-
HNSC	cis	rs7048146	0.509	rs34877230	ENSG00000213539.4	YBX1P6	4.36	1.61e-05	0.00298	0.26	0.2	Vascular brain injury;	chr9:109552369	chr9:109532830~109534332:-
HNSC	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-4.36	1.61e-05	0.00298	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
HNSC	cis	rs7819412	0.539	rs11250131	ENSG00000255495.1	AC145124.2	-4.36	1.61e-05	0.00298	-0.22	-0.2	Triglycerides;	chr8:11393666	chr8:12194467~12196280:+
HNSC	cis	rs4295623	0.531	rs2898295	ENSG00000255310.2	AF131215.2	-4.36	1.61e-05	0.00298	-0.18	-0.2	Morning vs. evening chronotype;	chr8:11738460	chr8:11107788~11109726:-
HNSC	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	4.36	1.61e-05	0.00298	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
HNSC	cis	rs9313772	0.722	rs6556345	ENSG00000254350.1	RP11-542A14.1	-4.36	1.62e-05	0.00298	-0.21	-0.2	Blood pressure;	chr5:158430418	chr5:158424585~158452758:+
HNSC	cis	rs35306767	0.903	rs11253504	ENSG00000229869.1	RP11-363N22.2	-4.36	1.62e-05	0.00298	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:910106	chr10:933026~942743:+
HNSC	cis	rs964611	0.938	rs8039653	ENSG00000259488.2	RP11-154J22.1	-4.36	1.62e-05	0.00298	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48280438	chr15:48312353~48331856:-
HNSC	cis	rs3738443	0.644	rs2799177	ENSG00000259865.1	RP11-488L18.10	-4.36	1.62e-05	0.00298	-0.18	-0.2	Alcohol dependence;	chr1:247235898	chr1:247187281~247188526:-
HNSC	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-4.36	1.62e-05	0.00298	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-4.36	1.62e-05	0.00298	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
HNSC	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-4.36	1.62e-05	0.00298	-0.26	-0.2	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
HNSC	cis	rs7829975	0.545	rs13261926	ENSG00000173295.6	FAM86B3P	-4.36	1.62e-05	0.00298	-0.24	-0.2	Mood instability;	chr8:8694100	chr8:8228595~8244865:+
HNSC	cis	rs6601327	0.641	rs7461939	ENSG00000254340.1	RP11-10A14.3	-4.36	1.62e-05	0.00298	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:9141424~9145435:+
HNSC	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-4.36	1.62e-05	0.00298	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
HNSC	cis	rs9287719	0.967	rs10195802	ENSG00000243819.4	RN7SL832P	4.36	1.62e-05	0.00299	0.19	0.2	Prostate cancer;	chr2:10614406	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7563894	ENSG00000243819.4	RN7SL832P	4.36	1.62e-05	0.00299	0.19	0.2	Prostate cancer;	chr2:10614523	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7566767	ENSG00000243819.4	RN7SL832P	4.36	1.62e-05	0.00299	0.19	0.2	Prostate cancer;	chr2:10614537	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs7566875	ENSG00000243819.4	RN7SL832P	4.36	1.62e-05	0.00299	0.19	0.2	Prostate cancer;	chr2:10614666	chr2:10690344~10692099:+
HNSC	cis	rs2284553	0.505	rs7282876	ENSG00000272659.1	AP000295.10	4.36	1.62e-05	0.00299	0.26	0.2	Inflammatory bowel disease;Crohn's disease;	chr21:33378032	chr21:33309491~33310181:+
HNSC	cis	rs2136613	0.533	rs1509956	ENSG00000238280.1	RP11-436D10.3	-4.36	1.62e-05	0.00299	-0.23	-0.2	Selective IgA deficiency;	chr10:62843574	chr10:62793562~62805887:-
HNSC	cis	rs10256972	0.758	rs7789093	ENSG00000229043.2	AC091729.9	-4.36	1.62e-05	0.00299	-0.25	-0.2	Endometriosis;Longevity;	chr7:963345	chr7:1160374~1165267:+
HNSC	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	4.36	1.62e-05	0.00299	0.23	0.2	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
HNSC	cis	rs62458065	0.85	rs28693551	ENSG00000226468.2	AC018641.7	4.36	1.62e-05	0.00299	0.33	0.2	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32456963~32457758:-
HNSC	cis	rs62458065	0.85	rs28677012	ENSG00000226468.2	AC018641.7	4.36	1.62e-05	0.00299	0.33	0.2	Metabolite levels (HVA/MHPG ratio);	chr7:32430199	chr7:32456963~32457758:-
HNSC	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	4.36	1.62e-05	0.00299	0.28	0.2	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
HNSC	cis	rs7829975	0.511	rs1401390	ENSG00000233609.3	RP11-62H7.2	4.36	1.62e-05	0.00299	0.19	0.2	Mood instability;	chr8:8278888	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-4.36	1.62e-05	0.00299	-0.22	-0.2	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	4.36	1.62e-05	0.00299	0.24	0.2	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	4.36	1.62e-05	0.00299	0.24	0.2	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
HNSC	cis	rs9450351	0.744	rs7752222	ENSG00000203875.9	SNHG5	-4.36	1.62e-05	0.00299	-0.41	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs7738777	ENSG00000203875.9	SNHG5	-4.36	1.62e-05	0.00299	-0.41	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85660950~85678736:-
HNSC	cis	rs9788333	0.888	rs35880230	ENSG00000236953.1	ZDHHC20-IT1	-4.36	1.62e-05	0.00299	-0.23	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21311833	chr13:21376977~21377874:-
HNSC	cis	rs4803480	0.72	rs4141218	ENSG00000270164.1	LINC01480	-4.36	1.62e-05	0.00299	-0.18	-0.2	Schizophrenia;	chr19:41575555	chr19:41535183~41536904:+
HNSC	cis	rs5769707	0.681	rs739236	ENSG00000235111.1	RP1-29C18.8	-4.36	1.62e-05	0.00299	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.681	rs1107514	ENSG00000235111.1	RP1-29C18.8	-4.36	1.62e-05	0.00299	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49612657~49615716:-
HNSC	cis	rs5752326	1	rs5761530	ENSG00000261188.1	CTA-445C9.14	4.36	1.62e-05	0.003	0.28	0.2	Ischemic stroke;	chr22:26447950	chr22:26512537~26514568:+
HNSC	cis	rs5752326	0.867	rs5761531	ENSG00000261188.1	CTA-445C9.14	4.36	1.62e-05	0.003	0.28	0.2	Ischemic stroke;	chr22:26448180	chr22:26512537~26514568:+
HNSC	cis	rs5752326	0.558	rs5752329	ENSG00000261188.1	CTA-445C9.14	4.36	1.62e-05	0.003	0.28	0.2	Ischemic stroke;	chr22:26450724	chr22:26512537~26514568:+
HNSC	cis	rs5752326	0.867	rs1894706	ENSG00000261188.1	CTA-445C9.14	4.36	1.62e-05	0.003	0.28	0.2	Ischemic stroke;	chr22:26458475	chr22:26512537~26514568:+
HNSC	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	4.36	1.62e-05	0.003	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000254153.1	CTA-398F10.2	-4.36	1.62e-05	0.003	-0.21	-0.2	Mood instability;	chr8:8872251	chr8:8456909~8461337:-
HNSC	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-4.36	1.62e-05	0.003	-0.24	-0.2	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
HNSC	cis	rs1355223	0.583	rs2956076	ENSG00000271369.1	RP11-350D17.3	4.36	1.62e-05	0.003	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852577	chr11:34709600~34710161:+
HNSC	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-4.36	1.63e-05	0.003	-0.27	-0.2	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
HNSC	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	4.36	1.63e-05	0.003	0.22	0.2	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
HNSC	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	4.36	1.63e-05	0.003	0.22	0.2	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
HNSC	cis	rs35963943	0.625	rs4640590	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18681571	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13069627	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18682423	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs4395422	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18682439	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13066974	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18685010	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs12638640	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18686395	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13062958	ENSG00000228956.7	SATB1-AS1	4.36	1.63e-05	0.003	0.24	0.2	Lymphocyte counts;	chr3:18688357	chr3:18445024~18920401:+
HNSC	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-4.36	1.63e-05	0.003	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-4.36	1.63e-05	0.003	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-4.36	1.63e-05	0.003	-0.23	-0.2	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-4.36	1.63e-05	0.003	-0.27	-0.2	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	4.36	1.63e-05	0.003	0.21	0.2	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
HNSC	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-4.36	1.63e-05	0.003	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
HNSC	cis	rs7572733	0.534	rs700662	ENSG00000231621.1	AC013264.2	-4.36	1.63e-05	0.003	-0.19	-0.2	Dermatomyositis;	chr2:197804027	chr2:197197991~197199273:+
HNSC	cis	rs795484	0.963	rs1277442	ENSG00000275409.1	RP11-131L12.4	4.36	1.63e-05	0.003	0.23	0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118167766	chr12:118430147~118430699:+
HNSC	cis	rs4295623	0.504	rs11250160	ENSG00000255310.2	AF131215.2	-4.36	1.63e-05	0.003	-0.19	-0.2	Morning vs. evening chronotype;	chr8:11735208	chr8:11107788~11109726:-
HNSC	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	4.36	1.63e-05	0.003	0.32	0.2	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
HNSC	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-4.36	1.63e-05	0.00301	-0.27	-0.2	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
HNSC	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-4.36	1.63e-05	0.00301	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
HNSC	cis	rs67478160	0.643	rs6576005	ENSG00000259515.1	RP11-365N19.2	4.36	1.63e-05	0.00301	0.18	0.2	Schizophrenia;	chr14:103826032	chr14:102933574~102937177:+
HNSC	cis	rs11969893	0.85	rs9498414	ENSG00000270987.1	RP3-467N11.2	4.36	1.63e-05	0.00301	0.46	0.2	Economic and political preferences (immigration/crime);	chr6:100875100	chr6:100889603~100890338:+
HNSC	cis	rs6928977	0.932	rs6935146	ENSG00000217482.2	HMGB1P17	4.36	1.63e-05	0.00301	0.21	0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135636086~135636713:-
HNSC	cis	rs4356203	0.87	rs7342262	ENSG00000272034.1	SNORD14A	-4.36	1.63e-05	0.00301	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17074654~17074744:-
HNSC	cis	rs6490294	0.904	rs12423126	ENSG00000226469.1	ADAM1B	4.36	1.63e-05	0.00301	0.23	0.2	Mean platelet volume;	chr12:111991665	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs11066111	ENSG00000226469.1	ADAM1B	4.36	1.63e-05	0.00301	0.23	0.2	Mean platelet volume;	chr12:111977375	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs11066112	ENSG00000226469.1	ADAM1B	4.36	1.63e-05	0.00301	0.23	0.2	Mean platelet volume;	chr12:111978782	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs2339908	ENSG00000226469.1	ADAM1B	4.36	1.63e-05	0.00301	0.23	0.2	Mean platelet volume;	chr12:111980692	chr12:111927018~111929017:+
HNSC	cis	rs4252134	0.687	rs3846778	ENSG00000231863.1	RP3-428L16.1	4.36	1.63e-05	0.00301	0.26	0.2	Giant cell arteritis;	chr6:160809769	chr6:160931080~160969771:+
HNSC	cis	rs11098499	0.731	rs6846966	ENSG00000249244.1	RP11-548H18.2	4.36	1.63e-05	0.00301	0.24	0.2	Corneal astigmatism;	chr4:119372053	chr4:119391831~119395335:-
HNSC	cis	rs12701220	0.541	rs12535516	ENSG00000229043.2	AC091729.9	-4.36	1.63e-05	0.00301	-0.29	-0.2	Bronchopulmonary dysplasia;	chr7:1074804	chr7:1160374~1165267:+
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000211974.3	IGHV2-70	4.36	1.64e-05	0.00301	0.18	0.2	Kawasaki disease;	chr14:106780451	chr14:106723574~106724093:-
HNSC	cis	rs11098499	0.739	rs9996382	ENSG00000250412.1	KLHL2P1	4.36	1.64e-05	0.00301	0.24	0.2	Corneal astigmatism;	chr4:119229857	chr4:119334329~119378233:+
HNSC	cis	rs61935443	0.501	rs4761668	ENSG00000241556.1	RP11-490G8.1	-4.36	1.64e-05	0.00301	-0.21	-0.2	Schizophrenia;	chr12:94790600	chr12:95467397~95467861:-
HNSC	cis	rs9910055	0.53	rs2269905	ENSG00000267080.4	ASB16-AS1	-4.36	1.64e-05	0.00301	-0.16	-0.2	Total body bone mineral density;	chr17:44217094	chr17:44175973~44186717:-
HNSC	cis	rs7674212	0.51	rs2720468	ENSG00000251288.2	RP11-10L12.2	-4.36	1.64e-05	0.00301	-0.23	-0.2	Type 2 diabetes;	chr4:103163996	chr4:102751401~102752641:+
HNSC	cis	rs4862750	0.832	rs6836426	ENSG00000250971.1	RP11-696F12.1	4.36	1.64e-05	0.00301	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186976683	chr4:187060099~187060930:+
HNSC	cis	rs9880211	1	rs9878078	ENSG00000273486.1	RP11-731C17.2	4.36	1.64e-05	0.00301	0.19	0.2	Height;Body mass index;	chr3:136518731	chr3:136837338~136839021:-
HNSC	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-4.36	1.64e-05	0.00301	-0.22	-0.2	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
HNSC	cis	rs10028773	0.515	rs9994651	ENSG00000249244.1	RP11-548H18.2	4.36	1.64e-05	0.00301	0.24	0.2	Educational attainment;	chr4:119666648	chr4:119391831~119395335:-
HNSC	cis	rs12893668	0.608	rs12889721	ENSG00000269910.1	RP11-73M18.10	4.36	1.64e-05	0.00302	0.19	0.2	Reticulocyte count;	chr14:103568526	chr14:103694516~103695050:-
HNSC	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-4.35	1.64e-05	0.00302	-0.27	-0.2	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
HNSC	cis	rs2732480	0.557	rs2732454	ENSG00000257763.1	OR5BK1P	4.35	1.64e-05	0.00302	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48355792~48356614:-
HNSC	cis	rs36052053	0.521	rs71558357	ENSG00000219700.1	PTCHD3P3	4.35	1.64e-05	0.00302	0.39	0.2	Red cell distribution width;	chr6:109238166	chr6:109288571~109290503:-
HNSC	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-4.35	1.64e-05	0.00302	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
HNSC	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	4.35	1.64e-05	0.00302	0.21	0.2	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
HNSC	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-4.35	1.64e-05	0.00302	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
HNSC	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-4.35	1.64e-05	0.00302	-0.21	-0.2	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
HNSC	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-4.35	1.64e-05	0.00302	-0.17	-0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
HNSC	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	4.35	1.64e-05	0.00302	0.3	0.2	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	4.35	1.64e-05	0.00302	0.3	0.2	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
HNSC	cis	rs72843506	0.722	rs3764436	ENSG00000261033.1	RP11-209D14.2	4.35	1.64e-05	0.00302	0.36	0.2	Schizophrenia;	chr17:20110489	chr17:20008051~20009234:-
HNSC	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-4.35	1.64e-05	0.00302	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-4.35	1.64e-05	0.00302	-0.27	-0.2	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-4.35	1.64e-05	0.00302	-0.27	-0.2	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-4.35	1.64e-05	0.00302	-0.27	-0.2	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-4.35	1.64e-05	0.00302	-0.27	-0.2	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
HNSC	cis	rs3805389	0.961	rs62308665	ENSG00000273257.1	RP11-177J6.1	-4.35	1.64e-05	0.00302	-0.27	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55611630	chr4:55387949~55388271:+
HNSC	cis	rs4908760	0.827	rs10864360	ENSG00000232912.4	RP5-1115A15.1	4.35	1.64e-05	0.00302	0.21	0.2	Vitiligo;	chr1:8664463	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs11121212	ENSG00000232912.4	RP5-1115A15.1	4.35	1.64e-05	0.00302	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8424645~8434838:+
HNSC	cis	rs9300255	0.77	rs7980687	ENSG00000280120.1	RP11-546D6.3	-4.35	1.64e-05	0.00302	-0.18	-0.2	Neutrophil percentage of white cells;	chr12:123338164	chr12:123152324~123153377:-
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	4.35	1.64e-05	0.00302	0.23	0.2	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
HNSC	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-4.35	1.64e-05	0.00302	-0.25	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
HNSC	cis	rs3015497	0.608	rs2934665	ENSG00000269906.1	RP11-248J18.2	-4.35	1.64e-05	0.00302	-0.27	-0.2	Mean platelet volume;	chr14:50688001	chr14:50662511~50663178:-
HNSC	cis	rs4862750	0.914	rs1346126	ENSG00000250971.1	RP11-696F12.1	4.35	1.64e-05	0.00302	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186955250	chr4:187060099~187060930:+
HNSC	cis	rs9788333	0.962	rs61951450	ENSG00000236953.1	ZDHHC20-IT1	-4.35	1.64e-05	0.00302	-0.23	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312215	chr13:21376977~21377874:-
HNSC	cis	rs9788333	0.962	rs12584792	ENSG00000236953.1	ZDHHC20-IT1	-4.35	1.64e-05	0.00302	-0.23	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21313069	chr13:21376977~21377874:-
HNSC	cis	rs929354	0.772	rs7778193	ENSG00000224629.1	RP5-1142J19.2	-4.35	1.64e-05	0.00302	-0.2	-0.2	Body mass index;	chr7:157187393	chr7:157263022~157263229:-
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	4.35	1.64e-05	0.00303	0.18	0.2	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	4.35	1.64e-05	0.00303	0.18	0.2	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	4.35	1.64e-05	0.00303	0.18	0.2	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	4.35	1.64e-05	0.00303	0.18	0.2	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
HNSC	cis	rs7086627	0.515	rs10887905	ENSG00000226659.1	RP11-137H2.4	-4.35	1.64e-05	0.00303	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80451099	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs7077373	ENSG00000226659.1	RP11-137H2.4	-4.35	1.64e-05	0.00303	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80451859	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs12245180	ENSG00000226659.1	RP11-137H2.4	-4.35	1.64e-05	0.00303	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80452141	chr10:80529597~80535942:-
HNSC	cis	rs9287719	0.967	rs6432126	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10616975	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.904	rs55738250	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10617006	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs6727768	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10617353	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.934	rs6710033	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10617551	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4669598	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10617712	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs4669599	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10617903	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs10167129	ENSG00000243819.4	RN7SL832P	4.35	1.65e-05	0.00303	0.19	0.2	Prostate cancer;	chr2:10618449	chr2:10690344~10692099:+
HNSC	cis	rs7615952	0.599	rs12486459	ENSG00000241439.1	RP11-666A20.3	4.35	1.65e-05	0.00303	0.23	0.2	Blood pressure (smoking interaction);	chr3:126022622	chr3:125958556~125958817:+
HNSC	cis	rs7615952	0.599	rs67575510	ENSG00000241439.1	RP11-666A20.3	4.35	1.65e-05	0.00303	0.23	0.2	Blood pressure (smoking interaction);	chr3:126023512	chr3:125958556~125958817:+
HNSC	cis	rs1125355	0.69	rs72939206	ENSG00000204380.3	AC005042.4	4.35	1.65e-05	0.00303	0.22	0.2	Alzheimer's disease in APOE e4+ carriers;	chr2:158785799	chr2:158658337~158735002:-
HNSC	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-4.35	1.65e-05	0.00303	-0.2	-0.2	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
HNSC	cis	rs911555	0.546	rs28798508	ENSG00000270108.1	RP11-73M18.6	4.35	1.65e-05	0.00303	0.22	0.2	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103687576~103688127:+
HNSC	cis	rs7071275	0.527	rs10788190	ENSG00000223432.1	RP11-62L18.3	4.35	1.65e-05	0.00303	0.25	0.2	Dupuytren's disease;	chr10:121627515	chr10:121615425~121615839:-
HNSC	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-4.35	1.65e-05	0.00304	-0.22	-0.2	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
HNSC	cis	rs72727394	0.51	rs72729321	ENSG00000259747.1	RP11-275I4.2	-4.35	1.65e-05	0.00304	-0.26	-0.2	Crohn's disease;	chr15:38625810	chr15:38671847~38689191:+
HNSC	cis	rs2243480	1	rs316315	ENSG00000232546.1	RP11-458F8.1	4.35	1.65e-05	0.00304	0.23	0.2	Diabetic kidney disease;	chr7:66126218	chr7:66848496~66858136:+
HNSC	cis	rs7572733	0.935	rs9288281	ENSG00000222017.1	AC011997.1	4.35	1.65e-05	0.00304	0.24	0.2	Dermatomyositis;	chr2:197879642	chr2:197693106~197774823:+
HNSC	cis	rs6500395	1	rs1909765	ENSG00000261267.1	RP11-44I10.3	-4.35	1.65e-05	0.00304	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48563447	chr16:48559661~48587403:+
HNSC	cis	rs10129255	0.5	rs1974468	ENSG00000224373.3	IGHV4-59	4.35	1.65e-05	0.00304	0.11	0.2	Kawasaki disease;	chr14:106686149	chr14:106627249~106627825:-
HNSC	cis	rs42490	0.664	rs39516	ENSG00000251136.7	RP11-37B2.1	-4.35	1.65e-05	0.00304	-0.17	-0.2	Leprosy;	chr8:89822157	chr8:89609409~89757727:-
HNSC	cis	rs6490294	0.571	rs7959011	ENSG00000226469.1	ADAM1B	4.35	1.65e-05	0.00304	0.28	0.2	Mean platelet volume;	chr12:112063433	chr12:111927018~111929017:+
HNSC	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	4.35	1.66e-05	0.00304	0.18	0.2	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
HNSC	cis	rs1167832	1	rs1167832	ENSG00000127957.15	PMS2P3	4.35	1.66e-05	0.00305	0.24	0.2	Ankle injury;	chr7:75537904	chr7:75502930~75528148:-
HNSC	cis	rs4862750	1	rs4862750	ENSG00000250971.1	RP11-696F12.1	4.35	1.66e-05	0.00305	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:187060099~187060930:+
HNSC	cis	rs4862750	1	rs4862751	ENSG00000250971.1	RP11-696F12.1	4.35	1.66e-05	0.00305	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:187060099~187060930:+
HNSC	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	4.35	1.66e-05	0.00305	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
HNSC	cis	rs638893	0.636	rs7119702	ENSG00000255422.1	AP002954.4	-4.35	1.66e-05	0.00305	-0.33	-0.2	Vitiligo;	chr11:118736985	chr11:118704607~118750263:+
HNSC	cis	rs7572733	0.935	rs1369511	ENSG00000222017.1	AC011997.1	4.35	1.66e-05	0.00305	0.24	0.2	Dermatomyositis;	chr2:197881391	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs2217837	ENSG00000222017.1	AC011997.1	4.35	1.66e-05	0.00305	0.24	0.2	Dermatomyositis;	chr2:197881535	chr2:197693106~197774823:+
HNSC	cis	rs924712	0.522	rs7750012	ENSG00000224984.1	RP11-524H19.2	4.35	1.66e-05	0.00305	0.23	0.2	Breast cancer;	chr6:54837845	chr6:54840118~54840855:-
HNSC	cis	rs9926296	0.712	rs258332	ENSG00000274627.1	RP11-104N10.2	4.35	1.66e-05	0.00305	0.2	0.2	Vitiligo;	chr16:89661275	chr16:89516797~89522217:+
HNSC	cis	rs6964587	1	rs6956431	ENSG00000188693.7	CYP51A1-AS1	-4.35	1.66e-05	0.00305	-0.21	-0.2	Breast cancer;	chr7:92120702	chr7:92134604~92180725:+
HNSC	cis	rs12893668	0.703	rs34186780	ENSG00000269910.1	RP11-73M18.10	4.35	1.66e-05	0.00305	0.2	0.2	Reticulocyte count;	chr14:103561258	chr14:103694516~103695050:-
HNSC	cis	rs7948661	1	rs2071702	ENSG00000278376.1	RP11-158I9.8	4.35	1.66e-05	0.00305	0.34	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118503146	chr11:118791254~118793137:+
HNSC	cis	rs2985684	0.748	rs2985686	ENSG00000278009.1	RP11-649E7.8	4.35	1.66e-05	0.00305	0.26	0.2	Carotid intima media thickness;	chr14:49633965	chr14:49601011~49601124:-
HNSC	cis	rs4862750	0.914	rs6553028	ENSG00000250971.1	RP11-696F12.1	4.35	1.66e-05	0.00305	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:187060099~187060930:+
HNSC	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-4.35	1.66e-05	0.00305	-0.23	-0.2	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
HNSC	cis	rs9733	0.744	rs4970976	ENSG00000236713.1	RP11-363I22.3	4.35	1.66e-05	0.00305	0.21	0.2	Tonsillectomy;	chr1:150807048	chr1:150780272~150780644:+
HNSC	cis	rs7572733	0.901	rs6734096	ENSG00000222017.1	AC011997.1	4.35	1.66e-05	0.00305	0.24	0.2	Dermatomyositis;	chr2:197891735	chr2:197693106~197774823:+
HNSC	cis	rs4660214	0.666	rs2256614	ENSG00000182109.6	RP11-69E11.4	4.35	1.66e-05	0.00305	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs596062	ENSG00000182109.6	RP11-69E11.4	4.35	1.66e-05	0.00305	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39522280~39546187:-
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-4.35	1.66e-05	0.00305	-0.27	-0.2	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
HNSC	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	4.35	1.66e-05	0.00305	0.25	0.2	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
HNSC	cis	rs7520050	0.807	rs5021934	ENSG00000280836.1	AL355480.1	4.35	1.66e-05	0.00305	0.19	0.2	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45581219~45581321:-
HNSC	cis	rs189798	0.807	rs330909	ENSG00000254153.1	CTA-398F10.2	4.35	1.66e-05	0.00305	0.23	0.2	Myopia (pathological);	chr8:9137877	chr8:8456909~8461337:-
HNSC	cis	rs2732480	0.577	rs1489109	ENSG00000257763.1	OR5BK1P	4.35	1.66e-05	0.00305	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.577	rs1489108	ENSG00000257763.1	OR5BK1P	4.35	1.66e-05	0.00305	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48355792~48356614:-
HNSC	cis	rs1050631	1	rs2236718	ENSG00000278986.1	RP11-723J4.3	4.35	1.66e-05	0.00305	0.22	0.2	Esophageal squamous cell cancer (length of survival);	chr18:36125172	chr18:35972151~35973916:+
HNSC	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	4.35	1.66e-05	0.00306	0.29	0.2	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
HNSC	cis	rs7716219	0.638	rs1559213	ENSG00000251307.1	RP11-506H20.1	4.35	1.66e-05	0.00306	0.22	0.2	Height;	chr5:55574362	chr5:55233934~55295201:+
HNSC	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	4.35	1.66e-05	0.00306	0.23	0.2	Height;	chr14:75093260	chr14:75011269~75012851:-
HNSC	cis	rs9880211	0.948	rs13316214	ENSG00000273486.1	RP11-731C17.2	4.35	1.66e-05	0.00306	0.19	0.2	Height;Body mass index;	chr3:136439379	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.954	rs11734241	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119495717	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs28685688	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119499179	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs7687843	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119500056	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs2306455	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119500814	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10031483	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119501481	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10031665	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119501697	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs3733523	ENSG00000250412.1	KLHL2P1	4.35	1.66e-05	0.00306	0.25	0.2	Corneal astigmatism;	chr4:119502564	chr4:119334329~119378233:+
HNSC	cis	rs3863381	0.656	rs17037498	ENSG00000277715.1	RP11-651L5.3	4.35	1.66e-05	0.00306	0.32	0.2	Night sleep phenotypes;	chr12:105721422	chr12:106250759~106252786:+
HNSC	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	4.35	1.66e-05	0.00306	0.24	0.2	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
HNSC	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	4.35	1.66e-05	0.00306	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
HNSC	cis	rs7572733	0.84	rs4850808	ENSG00000222017.1	AC011997.1	4.35	1.67e-05	0.00306	0.23	0.2	Dermatomyositis;	chr2:197711418	chr2:197693106~197774823:+
HNSC	cis	rs6500395	1	rs9922734	ENSG00000261267.1	RP11-44I10.3	4.35	1.67e-05	0.00306	0.24	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48569281	chr16:48559661~48587403:+
HNSC	cis	rs2439831	0.85	rs10163054	ENSG00000201136.1	RNU6-353P	-4.35	1.67e-05	0.00306	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43755440	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs7168158	ENSG00000201136.1	RNU6-353P	-4.35	1.67e-05	0.00306	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43758178	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs7174208	ENSG00000201136.1	RNU6-353P	-4.35	1.67e-05	0.00306	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43760484	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs12101756	ENSG00000201136.1	RNU6-353P	-4.35	1.67e-05	0.00306	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43761689	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs12442129	ENSG00000201136.1	RNU6-353P	-4.35	1.67e-05	0.00306	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43763658	chr15:43702363~43702470:+
HNSC	cis	rs4294134	0.608	rs35229763	ENSG00000223718.3	AC093107.7	4.35	1.67e-05	0.00306	0.31	0.2	Paget's disease;	chr7:135561557	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11767012	ENSG00000223718.3	AC093107.7	4.35	1.67e-05	0.00306	0.31	0.2	Paget's disease;	chr7:135561999	chr7:135660039~135660647:+
HNSC	cis	rs4761669	0.804	rs10777626	ENSG00000241556.1	RP11-490G8.1	-4.35	1.67e-05	0.00306	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94810881	chr12:95467397~95467861:-
HNSC	cis	rs4761669	0.848	rs10745699	ENSG00000241556.1	RP11-490G8.1	-4.35	1.67e-05	0.00306	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94811687	chr12:95467397~95467861:-
HNSC	cis	rs4372836	0.675	rs72782280	ENSG00000226833.4	AC097724.3	-4.35	1.67e-05	0.00306	-0.27	-0.2	Body mass index;	chr2:28688483	chr2:28708953~28736205:-
HNSC	cis	rs7121616	0.576	rs7123232	ENSG00000200879.1	SNORD14E	4.35	1.67e-05	0.00306	0.27	0.2	Breast cancer;	chr11:123056237	chr11:123058077~123058161:-
HNSC	cis	rs453301	0.624	rs2979256	ENSG00000253981.4	ALG1L13P	4.35	1.67e-05	0.00307	0.22	0.2	Joint mobility (Beighton score);	chr8:9014200	chr8:8236003~8244667:-
HNSC	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	4.35	1.67e-05	0.00307	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
HNSC	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-4.35	1.67e-05	0.00307	-0.23	-0.2	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
HNSC	cis	rs4761669	0.545	rs6538540	ENSG00000241556.1	RP11-490G8.1	-4.35	1.67e-05	0.00307	-0.19	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94814845	chr12:95467397~95467861:-
HNSC	cis	rs7429990	0.864	rs883662	ENSG00000228638.1	FCF1P2	-4.35	1.67e-05	0.00307	-0.18	-0.2	Educational attainment (years of education);	chr3:47619342	chr3:48290793~48291375:-
HNSC	cis	rs11722228	0.508	rs9732	ENSG00000250413.1	RP11-448G15.1	-4.35	1.67e-05	0.00307	-0.3	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10006482~10009725:+
HNSC	cis	rs853679	0.607	rs56075693	ENSG00000204709.4	LINC01556	4.35	1.67e-05	0.00307	0.41	0.2	Depression;	chr6:28322551	chr6:28943877~28944537:+
HNSC	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-4.35	1.67e-05	0.00307	-0.2	-0.2	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000254340.1	RP11-10A14.3	4.35	1.67e-05	0.00307	0.24	0.2	Mood instability;	chr8:8483595	chr8:9141424~9145435:+
HNSC	cis	rs2904524	1	rs7300901	ENSG00000257815.4	RP11-611E13.2	-4.35	1.67e-05	0.00307	-0.24	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70323451	chr12:69904033~70243360:-
HNSC	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-4.35	1.67e-05	0.00307	-0.27	-0.2	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-4.35	1.67e-05	0.00307	-0.27	-0.2	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
HNSC	cis	rs2732480	0.577	rs2634680	ENSG00000257763.1	OR5BK1P	4.35	1.67e-05	0.00307	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.577	rs2634678	ENSG00000257763.1	OR5BK1P	4.35	1.67e-05	0.00307	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48355792~48356614:-
HNSC	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	4.35	1.67e-05	0.00307	0.23	0.2	Depression;	chr6:28205232	chr6:28170845~28172521:+
HNSC	cis	rs198813	0.611	rs198823	ENSG00000272462.2	U91328.19	-4.35	1.67e-05	0.00307	-0.19	-0.2	Intelligence (multi-trait analysis);	chr6:26122705	chr6:25992662~26001775:+
HNSC	cis	rs4356203	0.87	rs10832746	ENSG00000272034.1	SNORD14A	-4.35	1.67e-05	0.00307	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17074654~17074744:-
HNSC	cis	rs3015497	0.603	rs2356453	ENSG00000269906.1	RP11-248J18.2	-4.35	1.67e-05	0.00307	-0.27	-0.2	Mean platelet volume;	chr14:50582930	chr14:50662511~50663178:-
HNSC	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-4.35	1.67e-05	0.00308	-0.26	-0.2	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
HNSC	cis	rs728616	0.614	rs55720611	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.68e-05	0.00308	-0.37	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:79663088~79826594:-
HNSC	cis	rs3738443	0.868	rs56029850	ENSG00000259865.1	RP11-488L18.10	4.35	1.68e-05	0.00308	0.17	0.2	Alcohol dependence;	chr1:247201027	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.868	rs55643126	ENSG00000259865.1	RP11-488L18.10	4.35	1.68e-05	0.00308	0.17	0.2	Alcohol dependence;	chr1:247201042	chr1:247187281~247188526:-
HNSC	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	4.35	1.68e-05	0.00308	0.2	0.2	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
HNSC	cis	rs250677	0.524	rs417413	ENSG00000250072.4	CTC-529P8.1	-4.35	1.68e-05	0.00308	-0.24	-0.2	Breast cancer;	chr5:149073163	chr5:149063317~149109787:+
HNSC	cis	rs7621025	0.664	rs6439657	ENSG00000273486.1	RP11-731C17.2	-4.35	1.68e-05	0.00308	-0.18	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136837338~136839021:-
HNSC	cis	rs11722228	0.508	rs3796826	ENSG00000250413.1	RP11-448G15.1	-4.35	1.68e-05	0.00308	-0.3	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10006482~10009725:+
HNSC	cis	rs11722228	0.508	rs3796825	ENSG00000250413.1	RP11-448G15.1	-4.35	1.68e-05	0.00308	-0.3	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10006482~10009725:+
HNSC	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-4.35	1.68e-05	0.00308	-0.25	-0.2	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
HNSC	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	4.35	1.68e-05	0.00308	0.22	0.2	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
HNSC	cis	rs2253762	0.54	rs79547192	ENSG00000226864.1	ATE1-AS1	4.35	1.68e-05	0.00308	0.33	0.2	Breast cancer;	chr10:121998664	chr10:121928312~121951965:+
HNSC	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	4.35	1.68e-05	0.00308	0.17	0.2	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
HNSC	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-4.35	1.68e-05	0.00308	-0.26	-0.2	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
HNSC	cis	rs11893307	0.509	rs2109958	ENSG00000235852.1	AC005540.3	4.35	1.68e-05	0.00308	0.26	0.2	Mean platelet volume;	chr2:190668388	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.509	rs11895262	ENSG00000235852.1	AC005540.3	4.35	1.68e-05	0.00308	0.26	0.2	Mean platelet volume;	chr2:190669136	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.509	rs12612904	ENSG00000235852.1	AC005540.3	4.35	1.68e-05	0.00308	0.26	0.2	Mean platelet volume;	chr2:190670121	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.509	rs2109957	ENSG00000235852.1	AC005540.3	4.35	1.68e-05	0.00308	0.26	0.2	Mean platelet volume;	chr2:190670585	chr2:190880797~190882059:-
HNSC	cis	rs11893307	0.509	rs12611764	ENSG00000235852.1	AC005540.3	4.35	1.68e-05	0.00308	0.26	0.2	Mean platelet volume;	chr2:190672417	chr2:190880797~190882059:-
HNSC	cis	rs72843506	0.656	rs16960660	ENSG00000261033.1	RP11-209D14.2	4.35	1.68e-05	0.00308	0.32	0.2	Schizophrenia;	chr17:20062274	chr17:20008051~20009234:-
HNSC	cis	rs13434995	0.513	rs73236142	ENSG00000273257.1	RP11-177J6.1	-4.35	1.68e-05	0.00308	-0.27	-0.2	Adiponectin levels;	chr4:55446143	chr4:55387949~55388271:+
HNSC	cis	rs7621025	0.599	rs13063987	ENSG00000273486.1	RP11-731C17.2	-4.35	1.68e-05	0.00308	-0.18	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136837338~136839021:-
HNSC	cis	rs5758511	0.514	rs4453786	ENSG00000227370.1	RP4-669P10.19	4.35	1.68e-05	0.00309	0.23	0.2	Birth weight;	chr22:42167302	chr22:42132543~42132998:+
HNSC	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-4.35	1.68e-05	0.00309	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
HNSC	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-4.35	1.68e-05	0.00309	-0.17	-0.2	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
HNSC	cis	rs561341	0.825	rs2008368	ENSG00000278867.1	RP11-640N20.4	-4.35	1.68e-05	0.00309	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32020378	chr17:32051030~32053208:+
HNSC	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	4.35	1.68e-05	0.00309	0.27	0.2	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
HNSC	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-4.35	1.68e-05	0.00309	-0.21	-0.2	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
HNSC	cis	rs7121616	0.563	rs4936770	ENSG00000200879.1	SNORD14E	4.35	1.68e-05	0.00309	0.25	0.2	Breast cancer;	chr11:123058167	chr11:123058077~123058161:-
HNSC	cis	rs4356203	0.905	rs35933265	ENSG00000260196.1	RP1-239B22.5	-4.35	1.68e-05	0.00309	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17380649~17383531:+
HNSC	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	4.35	1.68e-05	0.00309	0.23	0.2	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
HNSC	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-4.35	1.68e-05	0.00309	-0.27	-0.2	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
HNSC	cis	rs7735319	0.966	rs6895701	ENSG00000249102.1	CTD-2066L21.1	4.35	1.68e-05	0.00309	0.23	0.2	Systolic blood pressure;	chr5:33130367	chr5:33008994~33025724:+
HNSC	cis	rs6081541	1	rs6106043	ENSG00000179447.2	RP5-1027G4.3	-4.35	1.69e-05	0.00309	-0.26	-0.2	Psychosis (atypical);	chr20:19241607	chr20:19242302~19284596:-
HNSC	cis	rs6081541	1	rs6081548	ENSG00000179447.2	RP5-1027G4.3	-4.35	1.69e-05	0.00309	-0.26	-0.2	Psychosis (atypical);	chr20:19249683	chr20:19242302~19284596:-
HNSC	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-4.35	1.69e-05	0.00309	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
HNSC	cis	rs3863381	0.656	rs73395343	ENSG00000277715.1	RP11-651L5.3	4.35	1.69e-05	0.00309	0.33	0.2	Night sleep phenotypes;	chr12:105721728	chr12:106250759~106252786:+
HNSC	cis	rs3863381	0.656	rs73395345	ENSG00000277715.1	RP11-651L5.3	4.35	1.69e-05	0.00309	0.33	0.2	Night sleep phenotypes;	chr12:105721958	chr12:106250759~106252786:+
HNSC	cis	rs13242809	1	rs13242809	ENSG00000179428.2	AC073072.5	-4.35	1.69e-05	0.00309	-0.25	-0.2	Lymphocyte counts;	chr7:22706945	chr7:22725395~22727620:-
HNSC	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	4.35	1.69e-05	0.0031	0.24	0.2	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
HNSC	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	4.35	1.69e-05	0.0031	0.24	0.2	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
HNSC	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-4.35	1.69e-05	0.0031	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
HNSC	cis	rs9650657	0.645	rs4841409	ENSG00000269918.1	AF131215.9	4.35	1.69e-05	0.0031	0.19	0.2	Neuroticism;	chr8:10658864	chr8:11104691~11106704:-
HNSC	cis	rs721917	0.544	rs2243639	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.69e-05	0.0031	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79941966	chr10:79663088~79826594:-
HNSC	cis	rs10266483	0.545	rs7777148	ENSG00000228653.2	HNRNPCP7	4.35	1.69e-05	0.0031	0.24	0.2	Response to statin therapy;	chr7:64285795	chr7:64500825~64501729:+
HNSC	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	4.35	1.69e-05	0.0031	0.27	0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
HNSC	cis	rs9583531	0.714	rs76166228	ENSG00000259831.1	LINC00567	-4.35	1.69e-05	0.0031	-0.36	-0.2	Coronary artery disease;	chr13:110691427	chr13:110809676~110813084:-
HNSC	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	4.35	1.69e-05	0.0031	0.23	0.2	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
HNSC	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-4.35	1.69e-05	0.0031	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
HNSC	cis	rs56804039	1	rs17616779	ENSG00000173295.6	FAM86B3P	4.35	1.69e-05	0.0031	0.25	0.2	Cervical cancer;	chr8:8524864	chr8:8228595~8244865:+
HNSC	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	4.35	1.69e-05	0.00311	0.27	0.2	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
HNSC	cis	rs9863	0.861	rs34878139	ENSG00000270028.1	RP11-380L11.4	4.35	1.69e-05	0.00311	0.23	0.2	White blood cell count;	chr12:123961706	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs11833002	ENSG00000270028.1	RP11-380L11.4	4.35	1.69e-05	0.00311	0.23	0.2	White blood cell count;	chr12:123962069	chr12:123925461~123926083:-
HNSC	cis	rs11098499	0.954	rs11940028	ENSG00000250412.1	KLHL2P1	4.35	1.69e-05	0.00311	0.25	0.2	Corneal astigmatism;	chr4:119490752	chr4:119334329~119378233:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000224373.3	IGHV4-59	4.35	1.69e-05	0.00311	0.13	0.2	Kawasaki disease;	chr14:106777570	chr14:106627249~106627825:-
HNSC	cis	rs5758511	0.689	rs45441993	ENSG00000205702.9	CYP2D7	4.35	1.69e-05	0.00311	0.19	0.2	Birth weight;	chr22:42075734	chr22:42140203~42144577:-
HNSC	cis	rs1713985	0.698	rs1277281	ENSG00000269949.1	RP11-738E22.3	-4.35	1.69e-05	0.00311	-0.35	-0.2	Age-related macular degeneration;	chr4:56989926	chr4:56960927~56961373:-
HNSC	cis	rs9287719	0.699	rs4669602	ENSG00000234818.1	AC092687.5	4.35	1.69e-05	0.00311	0.22	0.2	Prostate cancer;	chr2:10647841	chr2:10589166~10604830:+
HNSC	cis	rs6500395	1	rs1120276	ENSG00000261267.1	RP11-44I10.3	-4.35	1.69e-05	0.00311	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48564606	chr16:48559661~48587403:+
HNSC	cis	rs12545912	0.821	rs1055328	ENSG00000254340.1	RP11-10A14.3	-4.35	1.7e-05	0.00311	-0.27	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9781806	chr8:9141424~9145435:+
HNSC	cis	rs427691	0.625	rs845735	ENSG00000271849.1	CTC-332L22.1	4.35	1.7e-05	0.00311	0.31	0.2	Autism spectrum disorder or schizophrenia;	chr5:109688170	chr5:109687802~109688329:-
HNSC	cis	rs9863	0.827	rs12823740	ENSG00000270028.1	RP11-380L11.4	4.35	1.7e-05	0.00311	0.23	0.2	White blood cell count;	chr12:123973455	chr12:123925461~123926083:-
HNSC	cis	rs10504130	0.518	rs6473654	ENSG00000253844.1	RP11-546K22.1	4.35	1.7e-05	0.00311	0.29	0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51961458~52022974:+
HNSC	cis	rs11644601	1	rs11644601	ENSG00000263335.1	AF001548.5	-4.35	1.7e-05	0.00311	-0.3	-0.2	Metabolite levels (lipid measures);	chr16:15078261	chr16:15726674~15732993:+
HNSC	cis	rs2279168	0.867	rs74024831	ENSG00000259295.5	CSPG4P12	-4.35	1.7e-05	0.00311	-0.4	-0.2	Response to platinum-based chemotherapy (carboplatin);	chr15:85404133	chr15:85191438~85213905:+
HNSC	cis	rs9311676	0.656	rs11917567	ENSG00000273493.1	RP11-80H18.4	4.35	1.7e-05	0.00311	0.22	0.2	Systemic lupus erythematosus;	chr3:58396527	chr3:58329965~58330118:+
HNSC	cis	rs8054556	0.647	rs11649149	ENSG00000183604.13	SMG1P5	-4.35	1.7e-05	0.00311	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:30267553~30335374:-
HNSC	cis	rs7246760	1	rs7250487	ENSG00000267289.1	CTD-2623N2.11	4.35	1.7e-05	0.00311	0.32	0.2	Pursuit maintenance gain;	chr19:9775682	chr19:9834079~9835013:-
HNSC	cis	rs11633886	0.528	rs2247958	ENSG00000273972.1	CTD-2306A12.1	4.35	1.7e-05	0.00311	0.23	0.2	Diisocyanate-induced asthma;	chr15:45807336	chr15:45702640~45703183:+
HNSC	cis	rs1008375	1	rs10805358	ENSG00000249502.1	AC006160.5	-4.35	1.7e-05	0.00312	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650827	chr4:17587467~17614571:-
HNSC	cis	rs2548724	0.617	rs62369307	ENSG00000250682.4	LINC00491	4.35	1.7e-05	0.00312	0.25	0.2	Type 2 diabetes;	chr5:102380755	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.617	rs1376905	ENSG00000250682.4	LINC00491	4.35	1.7e-05	0.00312	0.25	0.2	Type 2 diabetes;	chr5:102389132	chr5:102609156~102671559:-
HNSC	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-4.35	1.7e-05	0.00312	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-4.35	1.7e-05	0.00312	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
HNSC	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-4.35	1.7e-05	0.00312	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
HNSC	cis	rs2307394	0.929	rs13022319	ENSG00000281469.1	RP11-567F11.1	4.35	1.7e-05	0.00312	0.23	0.2	Urate levels;	chr2:147776805	chr2:148044380~148044894:+
HNSC	cis	rs755249	0.529	rs604316	ENSG00000182109.6	RP11-69E11.4	4.35	1.7e-05	0.00312	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39522280~39546187:-
HNSC	cis	rs9531006	0.752	rs3850061	ENSG00000227676.3	LINC01068	4.35	1.7e-05	0.00312	0.3	0.2	Sleep duration;	chr13:79944751	chr13:79566727~79571436:+
HNSC	cis	rs9531006	0.752	rs3850062	ENSG00000227676.3	LINC01068	4.35	1.7e-05	0.00312	0.3	0.2	Sleep duration;	chr13:79945171	chr13:79566727~79571436:+
HNSC	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	4.35	1.7e-05	0.00312	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	4.35	1.7e-05	0.00312	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
HNSC	cis	rs1799949	1	rs8176242	ENSG00000236383.6	LINC00854	-4.35	1.7e-05	0.00312	-0.19	-0.2	Menopause (age at onset);	chr17:43065857	chr17:43216941~43305976:-
HNSC	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	4.35	1.7e-05	0.00312	0.23	0.2	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
HNSC	cis	rs13434995	0.513	rs11240	ENSG00000273257.1	RP11-177J6.1	-4.35	1.7e-05	0.00312	-0.27	-0.2	Adiponectin levels;	chr4:55453183	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs7676245	ENSG00000273257.1	RP11-177J6.1	-4.35	1.7e-05	0.00312	-0.27	-0.2	Adiponectin levels;	chr4:55455150	chr4:55387949~55388271:+
HNSC	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-4.35	1.7e-05	0.00312	-0.25	-0.2	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
HNSC	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-4.35	1.7e-05	0.00312	-0.22	-0.2	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
HNSC	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	4.35	1.71e-05	0.00312	0.22	0.2	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
HNSC	cis	rs1799949	1	rs11652332	ENSG00000236383.6	LINC00854	-4.35	1.71e-05	0.00312	-0.19	-0.2	Menopause (age at onset);	chr17:43143472	chr17:43216941~43305976:-
HNSC	cis	rs9329221	1	rs9329221	ENSG00000255310.2	AF131215.2	4.35	1.71e-05	0.00312	0.19	0.2	Neuroticism;	chr8:10382692	chr8:11107788~11109726:-
HNSC	cis	rs4660214	0.666	rs636083	ENSG00000182109.6	RP11-69E11.4	4.35	1.71e-05	0.00313	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39522280~39546187:-
HNSC	cis	rs6601327	0.67	rs6990418	ENSG00000254340.1	RP11-10A14.3	4.35	1.71e-05	0.00313	0.23	0.2	Multiple myeloma (hyperdiploidy);	chr8:9564496	chr8:9141424~9145435:+
HNSC	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-4.35	1.71e-05	0.00313	-0.22	-0.2	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
HNSC	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	4.35	1.71e-05	0.00313	0.2	0.2	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
HNSC	cis	rs6601327	0.641	rs6601350	ENSG00000254340.1	RP11-10A14.3	-4.35	1.71e-05	0.00313	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:9141424~9145435:+
HNSC	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-4.34	1.71e-05	0.00313	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
HNSC	cis	rs889398	0.769	rs12927052	ENSG00000196696.11	PDXDC2P	4.34	1.71e-05	0.00313	0.14	0.2	Body mass index;	chr16:69823140	chr16:69976297~70065948:-
HNSC	cis	rs6601327	0.67	rs12545250	ENSG00000254340.1	RP11-10A14.3	4.34	1.71e-05	0.00313	0.23	0.2	Multiple myeloma (hyperdiploidy);	chr8:9563056	chr8:9141424~9145435:+
HNSC	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	4.34	1.71e-05	0.00313	0.18	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
HNSC	cis	rs4660214	0.724	rs10888683	ENSG00000182109.6	RP11-69E11.4	4.34	1.71e-05	0.00314	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39522280~39546187:-
HNSC	cis	rs728616	0.867	rs56008106	ENSG00000225484.5	NUTM2B-AS1	-4.34	1.71e-05	0.00314	-0.48	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79663088~79826594:-
HNSC	cis	rs3096299	0.748	rs2965822	ENSG00000261574.1	RP1-168P16.2	4.34	1.71e-05	0.00314	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89392375~89412564:-
HNSC	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	4.34	1.71e-05	0.00314	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
HNSC	cis	rs7829975	0.536	rs2980439	ENSG00000254340.1	RP11-10A14.3	4.34	1.71e-05	0.00314	0.24	0.2	Mood instability;	chr8:8237348	chr8:9141424~9145435:+
HNSC	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	4.34	1.71e-05	0.00314	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
HNSC	cis	rs4356203	0.87	rs11024208	ENSG00000272034.1	SNORD14A	-4.34	1.72e-05	0.00314	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17074654~17074744:-
HNSC	cis	rs11673344	0.543	rs8108429	ENSG00000276846.1	CTD-3220F14.3	4.34	1.72e-05	0.00314	0.22	0.2	Obesity-related traits;	chr19:37145874	chr19:37314868~37315620:-
HNSC	cis	rs804280	0.509	rs12719915	ENSG00000227888.4	FAM66A	-4.34	1.72e-05	0.00314	-0.2	-0.2	Myopia (pathological);	chr8:11928746	chr8:12362019~12388296:+
HNSC	cis	rs7948661	1	rs9332809	ENSG00000278376.1	RP11-158I9.8	4.34	1.72e-05	0.00314	0.37	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118490757	chr11:118791254~118793137:+
HNSC	cis	rs7948661	1	rs2276045	ENSG00000278376.1	RP11-158I9.8	4.34	1.72e-05	0.00314	0.37	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494453	chr11:118791254~118793137:+
HNSC	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	4.34	1.72e-05	0.00314	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
HNSC	cis	rs7520050	0.966	rs7524495	ENSG00000280836.1	AL355480.1	4.34	1.72e-05	0.00314	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs12411269	ENSG00000280836.1	AL355480.1	4.34	1.72e-05	0.00314	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs11211198	ENSG00000280836.1	AL355480.1	4.34	1.72e-05	0.00314	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs10890352	ENSG00000280836.1	AL355480.1	4.34	1.72e-05	0.00314	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6700597	ENSG00000280836.1	AL355480.1	4.34	1.72e-05	0.00314	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45581219~45581321:-
HNSC	cis	rs9807989	0.839	rs6749114	ENSG00000234389.1	AC007278.3	4.34	1.72e-05	0.00314	0.2	0.2	Asthma;	chr2:102351127	chr2:102438713~102440475:+
HNSC	cis	rs55704346	0.664	rs62411611	ENSG00000281501.1	SEPSECS-AS1	-4.34	1.72e-05	0.00314	-0.24	-0.2	Tonsillectomy;	chr4:25279707	chr4:25160641~25201440:+
HNSC	cis	rs763512	0.504	rs58201617	ENSG00000276054.1	RP11-378E13.3	4.34	1.72e-05	0.00314	0.27	0.2	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37505345	chr17:37386886~37387926:+
HNSC	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-4.34	1.72e-05	0.00314	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-4.34	1.72e-05	0.00314	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-4.34	1.72e-05	0.00314	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
HNSC	cis	rs4761669	0.804	rs9669686	ENSG00000241556.1	RP11-490G8.1	-4.34	1.72e-05	0.00314	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94785727	chr12:95467397~95467861:-
HNSC	cis	rs283610	0.735	rs10050833	ENSG00000182383.8	RPL27AP5	-4.34	1.72e-05	0.00314	-0.18	-0.2	Obesity-related traits;	chr5:73991295	chr5:74990189~74990637:-
HNSC	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	4.34	1.72e-05	0.00314	0.23	0.2	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000211974.3	IGHV2-70	4.34	1.72e-05	0.00314	0.18	0.2	Kawasaki disease;	chr14:106776528	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000211974.3	IGHV2-70	4.34	1.72e-05	0.00314	0.18	0.2	Kawasaki disease;	chr14:106776695	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000211974.3	IGHV2-70	4.34	1.72e-05	0.00314	0.18	0.2	Kawasaki disease;	chr14:106778202	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000211974.3	IGHV2-70	4.34	1.72e-05	0.00314	0.18	0.2	Kawasaki disease;	chr14:106778401	chr14:106723574~106724093:-
HNSC	cis	rs6831352	0.734	rs12502237	ENSG00000263923.1	RP11-571L19.7	-4.34	1.72e-05	0.00314	-0.21	-0.2	Alcohol dependence;	chr4:99094524	chr4:98928897~98994994:+
HNSC	cis	rs4938303	0.549	rs12420888	ENSG00000254851.1	RP11-109L13.1	4.34	1.72e-05	0.00314	0.29	0.2	Triglycerides;	chr11:116693106	chr11:117135528~117138582:+
HNSC	cis	rs72634501	0.622	rs4660416	ENSG00000228060.1	RP11-69E11.8	-4.34	1.72e-05	0.00315	-0.23	-0.2	HDL cholesterol;	chr1:39113314	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	4.34	1.72e-05	0.00315	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
HNSC	cis	rs7824557	0.767	rs3808513	ENSG00000255310.2	AF131215.2	-4.34	1.72e-05	0.00315	-0.19	-0.2	Retinal vascular caliber;	chr8:11299951	chr8:11107788~11109726:-
HNSC	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	4.34	1.72e-05	0.00315	0.23	0.2	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
HNSC	cis	rs67981189	0.572	rs2810077	ENSG00000274818.1	RP1-292L20.3	-4.34	1.72e-05	0.00315	-0.22	-0.2	Schizophrenia;	chr14:70897097	chr14:70906657~70907111:-
HNSC	cis	rs6163	0.727	rs284854	ENSG00000213061.2	PFN1P11	-4.34	1.72e-05	0.00315	-0.24	-0.2	Waist circumference;Hip circumference;	chr10:102814805	chr10:102838011~102845473:-
HNSC	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-4.34	1.72e-05	0.00315	-0.22	-0.2	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
HNSC	cis	rs7255436	0.965	rs7254882	ENSG00000269386.4	RAB11B-AS1	4.34	1.72e-05	0.00315	0.18	0.2	HDL cholesterol;	chr19:8388938	chr19:8374373~8390685:-
HNSC	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-4.34	1.72e-05	0.00315	-0.25	-0.2	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000211974.3	IGHV2-70	4.34	1.72e-05	0.00315	0.18	0.2	Kawasaki disease;	chr14:106689997	chr14:106723574~106724093:-
HNSC	cis	rs9393777	0.841	rs13207082	ENSG00000226314.6	ZNF192P1	-4.34	1.72e-05	0.00315	-0.34	-0.2	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28161781~28169594:+
HNSC	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-4.34	1.72e-05	0.00315	-0.18	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
HNSC	cis	rs234043	1	rs234055	ENSG00000223387.5	RP11-408H1.3	4.34	1.73e-05	0.00316	0.26	0.2	Renal cell carcinoma;	chr3:172593030	chr3:172560888~172595607:-
HNSC	cis	rs3808502	0.526	rs7822958	ENSG00000269918.1	AF131215.9	-4.34	1.73e-05	0.00316	-0.19	-0.2	Neuroticism;	chr8:11564933	chr8:11104691~11106704:-
HNSC	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-4.34	1.73e-05	0.00316	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	4.34	1.73e-05	0.00316	0.23	0.2	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
HNSC	cis	rs4140799	0.746	rs7350725	ENSG00000266869.1	RP6-114E22.1	-4.34	1.73e-05	0.00316	-0.23	-0.2	Neuroticism;	chr14:71749958	chr14:71848606~71908430:+
HNSC	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	4.34	1.73e-05	0.00316	0.22	0.2	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
HNSC	cis	rs3015497	1	rs3015495	ENSG00000277050.1	RP11-102G14.1	-4.34	1.73e-05	0.00316	-0.19	-0.2	Mean platelet volume;	chr14:50647985	chr14:51637348~51637947:-
HNSC	cis	rs6493858	0.839	rs2713924	ENSG00000277245.1	RP11-48G14.3	-4.34	1.73e-05	0.00316	-0.23	-0.2	Relative hand skill in reading disability;	chr15:56230612	chr15:56447120~56447697:+
HNSC	cis	rs853679	0.76	rs2299029	ENSG00000219891.2	ZSCAN12P1	4.34	1.73e-05	0.00316	0.29	0.2	Depression;	chr6:28231053	chr6:28091154~28093664:+
HNSC	cis	rs116139393	0.656	rs10244591	ENSG00000187953.9	PMS2CL	-4.34	1.73e-05	0.00316	-0.25	-0.2	Alzheimer's disease (APOE e4 interaction);	chr7:6731467	chr7:6710128~6753862:+
HNSC	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-4.34	1.73e-05	0.00316	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
HNSC	cis	rs72843506	0.586	rs59890010	ENSG00000261033.1	RP11-209D14.2	4.34	1.73e-05	0.00316	0.32	0.2	Schizophrenia;	chr17:19960360	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.586	rs73980762	ENSG00000261033.1	RP11-209D14.2	4.34	1.73e-05	0.00316	0.32	0.2	Schizophrenia;	chr17:19966113	chr17:20008051~20009234:-
HNSC	cis	rs11893307	0.537	rs61345672	ENSG00000235852.1	AC005540.3	4.34	1.73e-05	0.00316	0.26	0.2	Mean platelet volume;	chr2:190642288	chr2:190880797~190882059:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000233609.3	RP11-62H7.2	-4.34	1.73e-05	0.00316	-0.18	-0.2	Neuroticism;	chr8:8237241	chr8:8961200~8979025:+
HNSC	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	4.34	1.73e-05	0.00316	0.23	0.2	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
HNSC	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-4.34	1.73e-05	0.00316	-0.28	-0.2	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
HNSC	cis	rs1008375	0.966	rs2098152	ENSG00000249502.1	AC006160.5	-4.34	1.73e-05	0.00316	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682769	chr4:17587467~17614571:-
HNSC	cis	rs7819412	0.522	rs3021495	ENSG00000255310.2	AF131215.2	-4.34	1.73e-05	0.00316	-0.2	-0.2	Triglycerides;	chr8:11137233	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	4.34	1.73e-05	0.00317	0.26	0.2	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
HNSC	cis	rs6583331	0.5	rs1684456	ENSG00000232065.1	LINC01063	4.34	1.73e-05	0.00317	0.17	0.2	Vitiligo;	chr3:196624792	chr3:196631498~196632587:-
HNSC	cis	rs17428076	0.718	rs17499544	ENSG00000228389.1	AC068039.4	4.34	1.73e-05	0.00317	0.26	0.2	Myopia;	chr2:171784224	chr2:171773482~171775844:+
HNSC	cis	rs73198271	0.603	rs546606	ENSG00000253893.2	FAM85B	4.34	1.73e-05	0.00317	0.26	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738333	chr8:8167819~8226614:-
HNSC	cis	rs36563	0.568	rs55685004	ENSG00000274818.1	RP1-292L20.3	4.34	1.73e-05	0.00317	0.33	0.2	Alcohol dependence;	chr14:71084242	chr14:70906657~70907111:-
HNSC	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	4.34	1.73e-05	0.00317	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
HNSC	cis	rs73198271	0.694	rs73201840	ENSG00000233609.3	RP11-62H7.2	-4.34	1.73e-05	0.00317	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.694	rs113694763	ENSG00000233609.3	RP11-62H7.2	-4.34	1.73e-05	0.00317	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.694	rs115037021	ENSG00000233609.3	RP11-62H7.2	-4.34	1.73e-05	0.00317	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.694	rs114184516	ENSG00000233609.3	RP11-62H7.2	-4.34	1.73e-05	0.00317	-0.22	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8961200~8979025:+
HNSC	cis	rs79349575	0.783	rs4793992	ENSG00000270781.1	RP11-501C14.9	-4.34	1.73e-05	0.00317	-0.21	-0.2	Type 2 diabetes;	chr17:48930845	chr17:48899131~48899748:+
HNSC	cis	rs6964587	1	rs10274756	ENSG00000188693.7	CYP51A1-AS1	-4.34	1.73e-05	0.00317	-0.21	-0.2	Breast cancer;	chr7:92111482	chr7:92134604~92180725:+
HNSC	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-4.34	1.74e-05	0.00317	-0.22	-0.2	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
HNSC	cis	rs3198697	0.617	rs11075253	ENSG00000263335.1	AF001548.5	-4.34	1.74e-05	0.00317	-0.3	-0.2	Triglycerides;	chr16:15054789	chr16:15726674~15732993:+
HNSC	cis	rs700651	0.753	rs10207232	ENSG00000231621.1	AC013264.2	-4.34	1.74e-05	0.00317	-0.19	-0.2	Intracranial aneurysm;	chr2:198029089	chr2:197197991~197199273:+
HNSC	cis	rs9611565	0.685	rs169363	ENSG00000235513.1	RP4-756G23.5	-4.34	1.74e-05	0.00317	-0.23	-0.2	Vitiligo;	chr22:41457113	chr22:41209122~41217627:-
HNSC	cis	rs17761864	0.881	rs17834563	ENSG00000262333.1	HNRNPA1P16	4.34	1.74e-05	0.00317	0.17	0.2	Esophageal cancer (squamous cell);	chr17:2269416	chr17:2306761~2307715:+
HNSC	cis	rs35306767	0.951	rs12777021	ENSG00000229869.1	RP11-363N22.2	-4.34	1.74e-05	0.00317	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:921330	chr10:933026~942743:+
HNSC	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	4.34	1.74e-05	0.00317	0.21	0.2	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
HNSC	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-4.34	1.74e-05	0.00318	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
HNSC	cis	rs9880211	1	rs6771002	ENSG00000273486.1	RP11-731C17.2	4.34	1.74e-05	0.00318	0.19	0.2	Height;Body mass index;	chr3:136522186	chr3:136837338~136839021:-
HNSC	cis	rs889398	0.802	rs12919094	ENSG00000226232.7	RP11-419C5.2	4.34	1.74e-05	0.00318	0.17	0.2	Body mass index;	chr16:69809454	chr16:69976388~69996188:-
HNSC	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-4.34	1.74e-05	0.00318	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
HNSC	cis	rs6500395	1	rs2354579	ENSG00000261267.1	RP11-44I10.3	-4.34	1.74e-05	0.00318	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48567610	chr16:48559661~48587403:+
HNSC	cis	rs17076726	0.519	rs6885371	ENSG00000253785.1	CTC-308K20.3	-4.34	1.74e-05	0.00318	-0.21	-0.2	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173910177	chr5:172975511~172976374:+
HNSC	cis	rs17076726	0.519	rs6885516	ENSG00000253785.1	CTC-308K20.3	-4.34	1.74e-05	0.00318	-0.21	-0.2	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173910178	chr5:172975511~172976374:+
HNSC	cis	rs7572733	0.534	rs7557203	ENSG00000231621.1	AC013264.2	-4.34	1.74e-05	0.00318	-0.19	-0.2	Dermatomyositis;	chr2:197930926	chr2:197197991~197199273:+
HNSC	cis	rs71636778	0.509	rs60659886	ENSG00000260063.1	RP5-968P14.2	-4.34	1.74e-05	0.00318	-0.34	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26667754	chr1:26692132~26694131:-
HNSC	cis	rs61935443	0.501	rs10777627	ENSG00000241556.1	RP11-490G8.1	-4.34	1.74e-05	0.00318	-0.2	-0.2	Schizophrenia;	chr12:94817844	chr12:95467397~95467861:-
HNSC	cis	rs2739330	0.734	rs2000467	ENSG00000235689.1	AP000351.13	-4.34	1.74e-05	0.00318	-0.2	-0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:24006305~24008258:-
HNSC	cis	rs9450351	0.744	rs1447157	ENSG00000203875.9	SNHG5	-4.34	1.74e-05	0.00318	-0.42	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85879434	chr6:85660950~85678736:-
HNSC	cis	rs250677	0.524	rs40521	ENSG00000250072.4	CTC-529P8.1	4.34	1.74e-05	0.00318	0.23	0.2	Breast cancer;	chr5:149060076	chr5:149063317~149109787:+
HNSC	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-4.34	1.74e-05	0.00319	-0.2	-0.2	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
HNSC	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	4.34	1.74e-05	0.00319	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
HNSC	cis	rs3863381	0.764	rs11837061	ENSG00000277715.1	RP11-651L5.3	4.34	1.75e-05	0.00319	0.29	0.2	Night sleep phenotypes;	chr12:105712373	chr12:106250759~106252786:+
HNSC	cis	rs10800309	0.71	rs4656308	ENSG00000225217.1	HSPA7	-4.34	1.75e-05	0.00319	-0.28	-0.2	Inflammatory bowel disease;Ulcerative colitis;	chr1:161508961	chr1:161606291~161608217:+
HNSC	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-4.34	1.75e-05	0.00319	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
HNSC	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-4.34	1.75e-05	0.00319	-0.27	-0.2	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
HNSC	cis	rs9329221	0.537	rs6601414	ENSG00000254340.1	RP11-10A14.3	4.34	1.75e-05	0.00319	0.24	0.2	Neuroticism;	chr8:10119238	chr8:9141424~9145435:+
HNSC	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	4.34	1.75e-05	0.00319	0.19	0.2	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-4.34	1.75e-05	0.00319	-0.15	-0.2	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
HNSC	cis	rs11893307	0.509	rs6726273	ENSG00000228509.4	AC006460.2	4.34	1.75e-05	0.00319	0.26	0.2	Mean platelet volume;	chr2:190664970	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.509	rs62179690	ENSG00000228509.4	AC006460.2	4.34	1.75e-05	0.00319	0.26	0.2	Mean platelet volume;	chr2:190665147	chr2:190676944~190708716:-
HNSC	cis	rs10256972	0.694	rs7784701	ENSG00000229043.2	AC091729.9	-4.34	1.75e-05	0.00319	-0.25	-0.2	Endometriosis;Longevity;	chr7:963405	chr7:1160374~1165267:+
HNSC	cis	rs9903692	0.779	rs2285863	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48048616	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs12936731	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48050997	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.909	rs9899275	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48051953	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs12450620	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48052892	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs7212202	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48055361	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs34750858	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48055575	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs875065	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48062207	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs875066	ENSG00000263412.1	RP5-890E16.2	-4.34	1.75e-05	0.00319	-0.18	-0.2	Pulse pressure;	chr17:48062370	chr17:48045141~48048073:-
HNSC	cis	rs3736485	0.966	rs8042289	ENSG00000259438.1	CTD-2650P22.1	4.34	1.75e-05	0.00319	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51607687	chr15:52010999~52019095:-
HNSC	cis	rs11098499	0.71	rs6851130	ENSG00000250412.1	KLHL2P1	-4.34	1.75e-05	0.00319	-0.24	-0.2	Corneal astigmatism;	chr4:119212557	chr4:119334329~119378233:+
HNSC	cis	rs1008375	1	rs2058339	ENSG00000249502.1	AC006160.5	-4.34	1.75e-05	0.0032	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676833	chr4:17587467~17614571:-
HNSC	cis	rs13434995	0.513	rs2130040	ENSG00000273257.1	RP11-177J6.1	4.34	1.75e-05	0.0032	0.27	0.2	Adiponectin levels;	chr4:55564036	chr4:55387949~55388271:+
HNSC	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-4.34	1.75e-05	0.0032	-0.22	-0.2	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
HNSC	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	4.34	1.75e-05	0.0032	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	4.34	1.75e-05	0.0032	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
HNSC	cis	rs9813712	0.717	rs9835466	ENSG00000249846.5	RP11-77P16.4	4.34	1.75e-05	0.0032	0.27	0.2	Response to amphetamines;	chr3:130258530	chr3:130112550~130120579:+
HNSC	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	4.34	1.75e-05	0.0032	0.19	0.2	Height;	chr5:37510578	chr5:36666214~36725195:-
HNSC	cis	rs739496	0.579	rs12321677	ENSG00000226469.1	ADAM1B	-4.34	1.75e-05	0.0032	-0.23	-0.2	Platelet count;	chr12:111901211	chr12:111927018~111929017:+
HNSC	cis	rs3736485	0.966	rs11070859	ENSG00000259438.1	CTD-2650P22.1	4.34	1.75e-05	0.0032	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598605	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs4775959	ENSG00000259438.1	CTD-2650P22.1	4.34	1.75e-05	0.0032	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51599439	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs11070860	ENSG00000259438.1	CTD-2650P22.1	4.34	1.75e-05	0.0032	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51600457	chr15:52010999~52019095:-
HNSC	cis	rs739496	0.579	rs7956495	ENSG00000226469.1	ADAM1B	4.34	1.75e-05	0.0032	0.23	0.2	Platelet count;	chr12:111857889	chr12:111927018~111929017:+
HNSC	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-4.34	1.75e-05	0.0032	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
HNSC	cis	rs1056107	0.831	rs10981305	ENSG00000225513.1	RP11-165N19.2	-4.34	1.75e-05	0.0032	-0.21	-0.2	Colorectal cancer;	chr9:112197858	chr9:112173522~112173971:-
HNSC	cis	rs2548724	1	rs841932	ENSG00000250682.4	LINC00491	-4.34	1.75e-05	0.0032	-0.27	-0.2	Type 2 diabetes;	chr5:102287324	chr5:102609156~102671559:-
HNSC	cis	rs9914544	0.762	rs4322727	ENSG00000264885.1	RP11-815I9.4	4.34	1.75e-05	0.0032	0.2	0.2	Educational attainment (years of education);	chr17:18895260	chr17:18667629~18669461:-
HNSC	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-4.34	1.76e-05	0.0032	-0.26	-0.2	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
HNSC	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	4.34	1.76e-05	0.0032	0.43	0.2	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
HNSC	cis	rs35306767	0.951	rs55742421	ENSG00000229869.1	RP11-363N22.2	-4.34	1.76e-05	0.0032	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:915097	chr10:933026~942743:+
HNSC	cis	rs58873874	0.579	rs11551374	ENSG00000251405.2	CTB-109A12.1	4.34	1.76e-05	0.0032	0.36	0.2	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157362615~157460078:-
HNSC	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	4.34	1.76e-05	0.0032	0.25	0.2	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
HNSC	cis	rs144861591	1	rs144861591	ENSG00000272810.1	U91328.22	-4.34	1.76e-05	0.0032	-0.39	-0.2	Hematocrit;Mean corpuscular hemoglobin;Mean corpuscular volume;Red cell distribution width;Hemoglobin concentration;	chr6:26072764	chr6:26013241~26013757:+
HNSC	cis	rs26528	0.584	rs153103	ENSG00000251417.2	RP11-1348G14.4	4.34	1.76e-05	0.0032	0.24	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28802743~28817828:+
HNSC	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-4.34	1.76e-05	0.00321	-0.26	-0.2	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
HNSC	cis	rs2279440	0.85	rs3872707	ENSG00000206573.7	THUMPD3-AS1	-4.34	1.76e-05	0.00321	-0.19	-0.2	Glucose homeostasis traits;	chr3:9472332	chr3:9349689~9398579:-
HNSC	cis	rs4356203	0.87	rs214921	ENSG00000272034.1	SNORD14A	-4.34	1.76e-05	0.00321	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17074654~17074744:-
HNSC	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.34	1.76e-05	0.00321	0.23	0.2	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
HNSC	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.34	1.76e-05	0.00321	0.23	0.2	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
HNSC	cis	rs2865126	0.818	rs8088701	ENSG00000264714.1	RP11-21G15.1	-4.34	1.76e-05	0.00321	-0.24	-0.2	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10764367	chr18:10724619~10728539:+
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000219891.2	ZSCAN12P1	4.34	1.76e-05	0.00321	0.29	0.2	Depression;	chr6:28240414	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000219891.2	ZSCAN12P1	4.34	1.76e-05	0.00321	0.29	0.2	Depression;	chr6:28240780	chr6:28091154~28093664:+
HNSC	cis	rs7085104	0.591	rs4919683	ENSG00000236937.2	PTGES3P4	4.34	1.76e-05	0.00321	0.24	0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102845595~102845950:+
HNSC	cis	rs3096299	0.9	rs2911258	ENSG00000261574.1	RP1-168P16.2	4.34	1.76e-05	0.00321	0.25	0.2	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89392375~89412564:-
HNSC	cis	rs6964587	1	rs11982213	ENSG00000188693.7	CYP51A1-AS1	-4.34	1.76e-05	0.00321	-0.21	-0.2	Breast cancer;	chr7:92093652	chr7:92134604~92180725:+
HNSC	cis	rs1729407	0.647	rs2727791	ENSG00000280143.1	AP000892.6	4.34	1.76e-05	0.00321	0.2	0.2	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117204967~117210292:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-4.34	1.76e-05	0.00321	-0.18	-0.2	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
HNSC	cis	rs5758659	0.652	rs133300	ENSG00000227370.1	RP4-669P10.19	-4.34	1.76e-05	0.00321	-0.19	-0.2	Cognitive function;	chr22:41993835	chr22:42132543~42132998:+
HNSC	cis	rs61841072	0.961	rs7517403	ENSG00000253326.2	RP11-261C10.7	-4.34	1.76e-05	0.00321	-0.26	-0.2	Schizophrenia;	chr1:242972590	chr1:243054861~243056394:-
HNSC	cis	rs7296418	0.699	rs11057254	ENSG00000280120.1	RP11-546D6.3	4.34	1.76e-05	0.00321	0.17	0.2	Platelet count;	chr12:123310034	chr12:123152324~123153377:-
HNSC	cis	rs35851103	0.507	rs6601649	ENSG00000254507.2	RP11-481A20.10	4.34	1.76e-05	0.00321	0.2	0.2	Neuroticism;	chr8:11999808	chr8:12003400~12004082:-
HNSC	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-4.34	1.76e-05	0.00321	-0.2	-0.2	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
HNSC	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.34	1.76e-05	0.00321	0.28	0.2	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
HNSC	cis	rs12935418	0.552	rs2123626	ENSG00000278985.1	RP11-303E16.9	-4.34	1.76e-05	0.00321	-0.19	-0.2	Mean corpuscular volume;	chr16:80988205	chr16:80982319~80984094:-
HNSC	cis	rs4761669	0.816	rs4761672	ENSG00000241556.1	RP11-490G8.1	-4.34	1.76e-05	0.00321	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94807078	chr12:95467397~95467861:-
HNSC	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-4.34	1.76e-05	0.00321	-0.24	-0.2	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
HNSC	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-4.34	1.76e-05	0.00321	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
HNSC	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	4.34	1.76e-05	0.00321	0.19	0.2	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	4.34	1.76e-05	0.00321	0.13	0.2	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
HNSC	cis	rs10504130	0.666	rs7813414	ENSG00000253844.1	RP11-546K22.1	-4.34	1.76e-05	0.00321	-0.3	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:51947645	chr8:51961458~52022974:+
HNSC	cis	rs721917	0.565	rs7476563	ENSG00000244733.5	RP11-506M13.3	-4.34	1.76e-05	0.00322	-0.23	-0.2	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79660891~79677996:+
HNSC	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-4.34	1.76e-05	0.00322	-0.21	-0.2	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-4.34	1.76e-05	0.00322	-0.21	-0.2	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-4.34	1.76e-05	0.00322	-0.21	-0.2	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
HNSC	cis	rs3736485	0.873	rs12442725	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51582215	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs17609791	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51582627	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs28695624	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51582731	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs28410165	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51582822	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.903	rs4545756	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51585593	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs17609812	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51587063	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs1077361	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51588722	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs1902592	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51589783	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs1902593	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51589883	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs882385	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51590172	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs4775956	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51590441	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs2899475	ENSG00000259438.1	CTD-2650P22.1	4.34	1.76e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51590854	chr15:52010999~52019095:-
HNSC	cis	rs467650	0.553	rs149508	ENSG00000248489.1	CTD-2007H13.3	4.34	1.76e-05	0.00322	0.25	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98642741	chr5:98929171~98995013:+
HNSC	cis	rs467650	0.553	rs40807	ENSG00000248489.1	CTD-2007H13.3	4.34	1.76e-05	0.00322	0.25	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98646095	chr5:98929171~98995013:+
HNSC	cis	rs467650	0.553	rs40173	ENSG00000248489.1	CTD-2007H13.3	4.34	1.76e-05	0.00322	0.25	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98647713	chr5:98929171~98995013:+
HNSC	cis	rs467650	0.553	rs27020	ENSG00000248489.1	CTD-2007H13.3	4.34	1.76e-05	0.00322	0.25	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98647962	chr5:98929171~98995013:+
HNSC	cis	rs9880211	0.898	rs9866840	ENSG00000273486.1	RP11-731C17.2	4.34	1.76e-05	0.00322	0.19	0.2	Height;Body mass index;	chr3:136310416	chr3:136837338~136839021:-
HNSC	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-4.34	1.76e-05	0.00322	-0.2	-0.2	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
HNSC	cis	rs1665050	0.749	rs8037569	ENSG00000259732.1	RP11-59H7.3	-4.34	1.77e-05	0.00322	-0.25	-0.2	Atopic dermatitis;	chr15:59010263	chr15:59121034~59133250:+
HNSC	cis	rs9487051	0.597	rs422113	ENSG00000243587.6	C6orf183	4.34	1.77e-05	0.00322	0.2	0.2	Reticulocyte fraction of red cells;	chr6:109203214	chr6:109165833~109271014:+
HNSC	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-4.34	1.77e-05	0.00322	-0.21	-0.2	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	4.34	1.77e-05	0.00322	0.23	0.2	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
HNSC	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	4.34	1.77e-05	0.00322	0.19	0.2	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
HNSC	cis	rs6674176	0.597	rs4031031	ENSG00000237950.1	RP11-7O11.3	4.34	1.77e-05	0.00322	0.22	0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927861	chr1:43944370~43946551:-
HNSC	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	4.34	1.77e-05	0.00322	0.42	0.2	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
HNSC	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-4.34	1.77e-05	0.00322	-0.45	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
HNSC	cis	rs11098499	0.955	rs1511018	ENSG00000250412.1	KLHL2P1	4.34	1.77e-05	0.00322	0.25	0.2	Corneal astigmatism;	chr4:119240425	chr4:119334329~119378233:+
HNSC	cis	rs7809950	0.678	rs7777950	ENSG00000238832.1	snoU109	-4.34	1.77e-05	0.00322	-0.28	-0.2	Coronary artery disease;	chr7:107364227	chr7:107603363~107603507:+
HNSC	cis	rs8058578	1	rs56656810	ENSG00000279196.1	RP11-1072A3.3	4.34	1.77e-05	0.00322	0.24	0.2	Multiple myeloma;	chr16:30777438	chr16:30984630~30988270:-
HNSC	cis	rs73198271	0.96	rs73198290	ENSG00000253893.2	FAM85B	4.34	1.77e-05	0.00322	0.29	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758499	chr8:8167819~8226614:-
HNSC	cis	rs2548724	0.645	rs62372171	ENSG00000250682.4	LINC00491	4.34	1.77e-05	0.00322	0.26	0.2	Type 2 diabetes;	chr5:102298873	chr5:102609156~102671559:-
HNSC	cis	rs4761669	0.724	rs4297523	ENSG00000241556.1	RP11-490G8.1	-4.34	1.77e-05	0.00322	-0.2	-0.2	Common carotid intima-media thickness in HIV infection;	chr12:94797070	chr12:95467397~95467861:-
HNSC	cis	rs3736485	0.966	rs4775961	ENSG00000259438.1	CTD-2650P22.1	4.34	1.77e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51600762	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs4774595	ENSG00000259438.1	CTD-2650P22.1	4.34	1.77e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51600964	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs7174435	ENSG00000259438.1	CTD-2650P22.1	4.34	1.77e-05	0.00322	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51602868	chr15:52010999~52019095:-
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-4.34	1.77e-05	0.00322	-0.25	-0.2	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
HNSC	cis	rs9287719	0.967	rs1541573	ENSG00000243819.4	RN7SL832P	4.34	1.77e-05	0.00322	0.19	0.2	Prostate cancer;	chr2:10633259	chr2:10690344~10692099:+
HNSC	cis	rs9287719	0.967	rs1541574	ENSG00000243819.4	RN7SL832P	4.34	1.77e-05	0.00322	0.19	0.2	Prostate cancer;	chr2:10633382	chr2:10690344~10692099:+
HNSC	cis	rs1602565	0.858	rs7936198	ENSG00000255450.1	CTD-2063L20.1	-4.34	1.77e-05	0.00322	-0.31	-0.2	Schizophrenia;	chr11:29165065	chr11:29275655~29276565:+
HNSC	cis	rs3736485	0.934	rs4775955	ENSG00000259438.1	CTD-2650P22.1	-4.34	1.77e-05	0.00322	-0.2	-0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51581252	chr15:52010999~52019095:-
HNSC	cis	rs6674176	0.561	rs7161	ENSG00000237950.1	RP11-7O11.3	-4.34	1.77e-05	0.00322	-0.22	-0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43973302	chr1:43944370~43946551:-
HNSC	cis	rs860295	0.676	rs5020058	ENSG00000203761.5	MSTO2P	-4.34	1.77e-05	0.00322	-0.16	-0.2	Body mass index;	chr1:155537752	chr1:155745829~155750137:+
HNSC	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-4.34	1.77e-05	0.00322	-0.24	-0.2	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
HNSC	cis	rs227275	0.53	rs3960788	ENSG00000230069.3	LRRC37A15P	-4.34	1.77e-05	0.00323	-0.2	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102727274~102730721:-
HNSC	cis	rs4295623	0.553	rs34962960	ENSG00000255310.2	AF131215.2	-4.34	1.77e-05	0.00323	-0.19	-0.2	Morning vs. evening chronotype;	chr8:11737088	chr8:11107788~11109726:-
HNSC	cis	rs795484	0.89	rs811247	ENSG00000275409.1	RP11-131L12.4	-4.34	1.77e-05	0.00323	-0.22	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118185031	chr12:118430147~118430699:+
HNSC	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-4.34	1.77e-05	0.00323	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
HNSC	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	4.34	1.77e-05	0.00323	0.22	0.2	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	4.34	1.77e-05	0.00323	0.22	0.2	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	4.34	1.77e-05	0.00323	0.22	0.2	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
HNSC	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	4.34	1.77e-05	0.00323	0.19	0.2	Height;	chr5:37499677	chr5:36666214~36725195:-
HNSC	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-4.34	1.77e-05	0.00323	-0.33	-0.2	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
HNSC	cis	rs11577354	0.548	rs7554276	ENSG00000207181.1	SNORA14B	-4.34	1.77e-05	0.00323	-0.24	-0.2	Obesity-related traits;	chr1:235104702	chr1:235127803~235127937:-
HNSC	cis	rs9863	0.861	rs11835839	ENSG00000270028.1	RP11-380L11.4	4.34	1.77e-05	0.00323	0.23	0.2	White blood cell count;	chr12:123946502	chr12:123925461~123926083:-
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-4.34	1.77e-05	0.00323	-0.18	-0.2	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
HNSC	cis	rs7829975	0.557	rs7816427	ENSG00000173295.6	FAM86B3P	-4.34	1.77e-05	0.00323	-0.23	-0.2	Mood instability;	chr8:8688374	chr8:8228595~8244865:+
HNSC	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	4.34	1.77e-05	0.00323	0.45	0.2	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
HNSC	cis	rs6142618	1	rs6142618	ENSG00000275576.1	RP5-836N17.4	4.34	1.77e-05	0.00323	0.2	0.2	Inflammatory bowel disease;	chr20:32137845	chr20:32116171~32116629:+
HNSC	cis	rs7324557	0.717	rs9510869	ENSG00000205861.10	C1QTNF9B-AS1	-4.34	1.78e-05	0.00323	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23809990	chr13:23888889~23897263:+
HNSC	cis	rs7324557	0.717	rs9510870	ENSG00000205861.10	C1QTNF9B-AS1	-4.34	1.78e-05	0.00323	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23810346	chr13:23888889~23897263:+
HNSC	cis	rs2412819	0.571	rs66903736	ENSG00000166763.7	STRCP1	4.34	1.78e-05	0.00323	0.29	0.2	Lung cancer;	chr15:43619435	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs66749753	ENSG00000166763.7	STRCP1	4.34	1.78e-05	0.00323	0.29	0.2	Lung cancer;	chr15:43619601	chr15:43699488~43718184:-
HNSC	cis	rs4372836	1	rs11127188	ENSG00000226833.4	AC097724.3	4.34	1.78e-05	0.00323	0.24	0.2	Body mass index;	chr2:28749986	chr2:28708953~28736205:-
HNSC	cis	rs12216125	0.801	rs56107510	ENSG00000272810.1	U91328.22	-4.34	1.78e-05	0.00324	-0.19	-0.2	Iron status biomarkers;	chr6:25987208	chr6:26013241~26013757:+
HNSC	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	4.34	1.78e-05	0.00324	0.24	0.2	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
HNSC	cis	rs7610312	0.612	rs2176083	ENSG00000273493.1	RP11-80H18.4	-4.34	1.78e-05	0.00324	-0.24	-0.2	Red blood cell count;	chr3:58294044	chr3:58329965~58330118:+
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	4.34	1.78e-05	0.00324	0.24	0.2	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
HNSC	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	4.34	1.78e-05	0.00324	0.3	0.2	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
HNSC	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	4.34	1.78e-05	0.00324	0.3	0.2	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
HNSC	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	4.34	1.78e-05	0.00324	0.3	0.2	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
HNSC	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	4.34	1.78e-05	0.00324	0.3	0.2	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
HNSC	cis	rs12745968	0.589	rs10747446	ENSG00000223787.2	RP4-593M8.1	-4.34	1.78e-05	0.00324	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr1:92642845	chr1:92580476~92580821:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000229886.1	RP5-1132H15.3	-4.34	1.78e-05	0.00324	-0.34	-0.2	Diabetic kidney disease;	chr7:66219914	chr7:66025126~66031544:-
HNSC	cis	rs7735319	0.899	rs13168108	ENSG00000249102.1	CTD-2066L21.1	4.34	1.78e-05	0.00324	0.23	0.2	Systolic blood pressure;	chr5:33119232	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs13169007	ENSG00000249102.1	CTD-2066L21.1	4.34	1.78e-05	0.00324	0.23	0.2	Systolic blood pressure;	chr5:33119553	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs13182741	ENSG00000249102.1	CTD-2066L21.1	4.34	1.78e-05	0.00324	0.23	0.2	Systolic blood pressure;	chr5:33134293	chr5:33008994~33025724:+
HNSC	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.34	1.78e-05	0.00324	-0.2	-0.2	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
HNSC	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-4.34	1.78e-05	0.00324	-0.17	-0.2	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
HNSC	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	4.34	1.78e-05	0.00324	0.18	0.2	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	4.34	1.78e-05	0.00324	0.18	0.2	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	4.34	1.78e-05	0.00324	0.18	0.2	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
HNSC	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-4.34	1.78e-05	0.00324	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-4.34	1.78e-05	0.00324	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-4.34	1.78e-05	0.00324	-0.19	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000259429.4	UBE2Q2P2	-4.34	1.78e-05	0.00324	-0.19	-0.2	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82355142~82420075:+
HNSC	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	4.34	1.78e-05	0.00324	0.18	0.2	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
HNSC	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-4.34	1.78e-05	0.00324	-0.41	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
HNSC	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-4.34	1.78e-05	0.00325	-0.2	-0.2	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
HNSC	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	4.34	1.78e-05	0.00325	0.17	0.2	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
HNSC	cis	rs72634501	0.642	rs67452844	ENSG00000228060.1	RP11-69E11.8	-4.34	1.79e-05	0.00325	-0.22	-0.2	HDL cholesterol;	chr1:39150610	chr1:39565160~39573203:+
HNSC	cis	rs11673344	0.523	rs2082010	ENSG00000276846.1	CTD-3220F14.3	4.34	1.79e-05	0.00325	0.21	0.2	Obesity-related traits;	chr19:37039874	chr19:37314868~37315620:-
HNSC	cis	rs7662987	0.517	rs1154410	ENSG00000263923.1	RP11-571L19.7	-4.34	1.79e-05	0.00325	-0.21	-0.2	Smoking initiation;	chr4:99085494	chr4:98928897~98994994:+
HNSC	cis	rs754133	0.891	rs12426399	ENSG00000248265.1	FLJ12825	4.33	1.79e-05	0.00325	0.24	0.2	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026126	chr12:54058254~54122234:+
HNSC	cis	rs3808502	0.526	rs1042701	ENSG00000269918.1	AF131215.9	-4.33	1.79e-05	0.00325	-0.19	-0.2	Neuroticism;	chr8:11564536	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.526	rs7843987	ENSG00000269918.1	AF131215.9	-4.33	1.79e-05	0.00325	-0.19	-0.2	Neuroticism;	chr8:11564621	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.526	rs7823100	ENSG00000269918.1	AF131215.9	-4.33	1.79e-05	0.00325	-0.19	-0.2	Neuroticism;	chr8:11564982	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.526	rs7823101	ENSG00000269918.1	AF131215.9	-4.33	1.79e-05	0.00325	-0.19	-0.2	Neuroticism;	chr8:11564983	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.602	rs928955	ENSG00000211812.1	TRAV26-2	-4.33	1.79e-05	0.00325	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.602	rs12587826	ENSG00000211812.1	TRAV26-2	-4.33	1.79e-05	0.00325	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22202583~22203368:+
HNSC	cis	rs11098499	0.955	rs56386062	ENSG00000250412.1	KLHL2P1	4.33	1.79e-05	0.00325	0.25	0.2	Corneal astigmatism;	chr4:119233980	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs4145951	ENSG00000250412.1	KLHL2P1	4.33	1.79e-05	0.00325	0.25	0.2	Corneal astigmatism;	chr4:119234662	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.955	rs35916640	ENSG00000250412.1	KLHL2P1	4.33	1.79e-05	0.00325	0.25	0.2	Corneal astigmatism;	chr4:119234697	chr4:119334329~119378233:+
HNSC	cis	rs7829975	0.684	rs546603	ENSG00000254340.1	RP11-10A14.3	-4.33	1.79e-05	0.00325	-0.24	-0.2	Mood instability;	chr8:8738328	chr8:9141424~9145435:+
HNSC	cis	rs12468579	0.77	rs13395505	ENSG00000235852.1	AC005540.3	-4.33	1.79e-05	0.00325	-0.23	-0.2	JT interval (sulfonylurea treatment interaction);	chr2:190973788	chr2:190880797~190882059:-
HNSC	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	4.33	1.79e-05	0.00326	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
HNSC	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-4.33	1.79e-05	0.00326	-0.24	-0.2	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
HNSC	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-4.33	1.79e-05	0.00326	-0.18	-0.2	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
HNSC	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	4.33	1.79e-05	0.00326	0.19	0.2	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
HNSC	cis	rs6968802	1	rs6968802	ENSG00000233264.2	AC006042.8	4.33	1.79e-05	0.00326	0.29	0.2	Granulocyte percentage of myeloid white cells;	chr7:8016446	chr7:7980312~7982228:+
HNSC	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	4.33	1.79e-05	0.00326	0.23	0.2	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
HNSC	cis	rs5758511	0.634	rs1001587	ENSG00000226450.2	CYP2D8P	4.33	1.79e-05	0.00326	0.19	0.2	Birth weight;	chr22:42274105	chr22:42149886~42155001:-
HNSC	cis	rs2145598	0.868	rs2348075	ENSG00000279636.2	LINC00216	-4.33	1.79e-05	0.00326	-0.21	-0.2	Coronary artery disease;	chr14:58386422	chr14:58288033~58289158:+
HNSC	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-4.33	1.79e-05	0.00326	-0.37	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
HNSC	cis	rs6831352	0.918	rs34936974	ENSG00000263923.1	RP11-571L19.7	-4.33	1.8e-05	0.00327	-0.21	-0.2	Alcohol dependence;	chr4:99131233	chr4:98928897~98994994:+
HNSC	cis	rs7829975	0.66	rs10093926	ENSG00000254153.1	CTA-398F10.2	-4.33	1.8e-05	0.00327	-0.22	-0.2	Mood instability;	chr8:8691510	chr8:8456909~8461337:-
HNSC	cis	rs13434995	0.513	rs6554291	ENSG00000273257.1	RP11-177J6.1	-4.33	1.8e-05	0.00327	-0.26	-0.2	Adiponectin levels;	chr4:55571204	chr4:55387949~55388271:+
HNSC	cis	rs11992162	0.636	rs4841642	ENSG00000227888.4	FAM66A	4.33	1.8e-05	0.00327	0.2	0.2	Monocyte count;	chr8:11940825	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.636	rs4841646	ENSG00000227888.4	FAM66A	4.33	1.8e-05	0.00327	0.2	0.2	Monocyte count;	chr8:11941198	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.613	rs6998690	ENSG00000227888.4	FAM66A	4.33	1.8e-05	0.00327	0.2	0.2	Monocyte count;	chr8:11941287	chr8:12362019~12388296:+
HNSC	cis	rs9311676	0.656	rs55964615	ENSG00000273493.1	RP11-80H18.4	4.33	1.8e-05	0.00327	0.22	0.2	Systemic lupus erythematosus;	chr3:58403393	chr3:58329965~58330118:+
HNSC	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-4.33	1.8e-05	0.00327	-0.23	-0.2	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
HNSC	cis	rs73607972	0.866	rs17803830	ENSG00000275191.1	RP11-36I17.2	4.33	1.8e-05	0.00327	0.29	0.2	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53608948	chr16:53628256~53628816:-
HNSC	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-4.33	1.8e-05	0.00327	-0.22	-0.2	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
HNSC	cis	rs2548724	0.536	rs55912935	ENSG00000250682.4	LINC00491	4.33	1.8e-05	0.00327	0.26	0.2	Type 2 diabetes;	chr5:102475250	chr5:102609156~102671559:-
HNSC	cis	rs11098499	0.954	rs11729521	ENSG00000250412.1	KLHL2P1	4.33	1.8e-05	0.00327	0.25	0.2	Corneal astigmatism;	chr4:119495633	chr4:119334329~119378233:+
HNSC	cis	rs721917	0.525	rs7903576	ENSG00000244733.5	RP11-506M13.3	-4.33	1.8e-05	0.00327	-0.23	-0.2	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79660891~79677996:+
HNSC	cis	rs2016266	0.859	rs10783575	ENSG00000270175.1	RP11-793H13.11	4.33	1.8e-05	0.00327	0.19	0.2	Bone mineral density;Bone mineral density (spine);	chr12:53349101	chr12:53500162~53500936:-
HNSC	cis	rs467650	0.509	rs183628	ENSG00000246763.5	RGMB-AS1	4.33	1.8e-05	0.00328	0.22	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98643787	chr5:98769618~98773469:-
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000219891.2	ZSCAN12P1	4.33	1.8e-05	0.00328	0.27	0.2	Depression;	chr6:28229408	chr6:28091154~28093664:+
HNSC	cis	rs5758659	0.729	rs134866	ENSG00000273366.1	CTA-989H11.1	-4.33	1.8e-05	0.00328	-0.23	-0.2	Cognitive function;	chr22:42254657	chr22:42278188~42278846:+
HNSC	cis	rs924712	0.522	rs1503133	ENSG00000224984.1	RP11-524H19.2	-4.33	1.8e-05	0.00328	-0.23	-0.2	Breast cancer;	chr6:54845113	chr6:54840118~54840855:-
HNSC	cis	rs656319	0.58	rs13252589	ENSG00000269918.1	AF131215.9	-4.33	1.8e-05	0.00328	-0.2	-0.2	Myopia (pathological);	chr8:10148016	chr8:11104691~11106704:-
HNSC	cis	rs1799949	1	rs4793229	ENSG00000236383.6	LINC00854	4.33	1.8e-05	0.00328	0.18	0.2	Menopause (age at onset);	chr17:43340966	chr17:43216941~43305976:-
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00328	0.24	0.2	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
HNSC	cis	rs3015497	0.904	rs3015501	ENSG00000277050.1	RP11-102G14.1	-4.33	1.8e-05	0.00328	-0.18	-0.2	Mean platelet volume;	chr14:50641806	chr14:51637348~51637947:-
HNSC	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	4.33	1.8e-05	0.00328	0.24	0.2	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
HNSC	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	4.33	1.8e-05	0.00328	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
HNSC	cis	rs12745968	0.62	rs4847267	ENSG00000223787.2	RP4-593M8.1	4.33	1.81e-05	0.00328	0.23	0.2	Bipolar disorder and schizophrenia;	chr1:92689790	chr1:92580476~92580821:-
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000211974.3	IGHV2-70	-4.33	1.81e-05	0.00328	-0.18	-0.2	Kawasaki disease;	chr14:106769752	chr14:106723574~106724093:-
HNSC	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.33	1.81e-05	0.00328	0.2	0.2	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000106610.13	STAG3L4	4.33	1.81e-05	0.00329	0.4	0.2	Gout;	chr7:66682070	chr7:67302621~67321526:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000106610.13	STAG3L4	4.33	1.81e-05	0.00329	0.4	0.2	Gout;	chr7:66682162	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs2707844	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Diabetic kidney disease;	chr7:66594522	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Diabetic kidney disease;	chr7:66597113	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Diabetic kidney disease;	chr7:66597524	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66679692	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66692349	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66693433	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66694214	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66701371	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66702658	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66706390	chr7:67302621~67321526:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000106610.13	STAG3L4	-4.33	1.81e-05	0.00329	-0.4	-0.2	Gout;	chr7:66710076	chr7:67302621~67321526:+
HNSC	cis	rs2835345	0.596	rs62229441	ENSG00000279365.1	KB-176G8.1	4.33	1.81e-05	0.00329	0.24	0.2	Pulmonary function;	chr21:36447559	chr21:36485867~36487760:+
HNSC	cis	rs9788721	1	rs9788721	ENSG00000261762.1	RP11-650L12.2	4.33	1.81e-05	0.00329	0.23	0.2	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78510527	chr15:78589123~78591276:-
HNSC	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-4.33	1.81e-05	0.00329	-0.2	-0.2	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
HNSC	cis	rs12478296	1	rs6739247	ENSG00000261186.2	RP11-341N2.1	-4.33	1.81e-05	0.00329	-0.32	-0.2	Obesity-related traits;	chr2:242097038	chr2:242087351~242088457:-
HNSC	cis	rs2486288	0.656	rs8039354	ENSG00000259479.5	SORD2P	4.33	1.81e-05	0.00329	0.23	0.2	Glomerular filtration rate;	chr15:45259558	chr15:44826371~44884694:-
HNSC	cis	rs35306767	0.903	rs11253488	ENSG00000229869.1	RP11-363N22.2	-4.33	1.81e-05	0.00329	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:876542	chr10:933026~942743:+
HNSC	cis	rs3738443	0.817	rs6698690	ENSG00000259865.1	RP11-488L18.10	4.33	1.81e-05	0.00329	0.17	0.2	Alcohol dependence;	chr1:247199176	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.868	rs7551871	ENSG00000259865.1	RP11-488L18.10	4.33	1.81e-05	0.00329	0.17	0.2	Alcohol dependence;	chr1:247199888	chr1:247187281~247188526:-
HNSC	cis	rs4841134	0.684	rs878336	ENSG00000233609.3	RP11-62H7.2	-4.33	1.81e-05	0.00329	-0.19	-0.2	Age-related disease endophenotypes;	chr8:9368119	chr8:8961200~8979025:+
HNSC	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-4.33	1.81e-05	0.0033	-0.21	-0.2	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
HNSC	cis	rs9910055	0.659	rs227580	ENSG00000267080.4	ASB16-AS1	4.33	1.81e-05	0.0033	0.15	0.2	Total body bone mineral density;	chr17:44145700	chr17:44175973~44186717:-
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	4.33	1.81e-05	0.0033	0.23	0.2	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
HNSC	cis	rs6500395	1	rs6500402	ENSG00000261267.1	RP11-44I10.3	-4.33	1.81e-05	0.0033	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48653443	chr16:48559661~48587403:+
HNSC	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-4.33	1.81e-05	0.0033	-0.19	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
HNSC	cis	rs7572733	0.935	rs10198606	ENSG00000222017.1	AC011997.1	-4.33	1.82e-05	0.0033	-0.23	-0.2	Dermatomyositis;	chr2:197905015	chr2:197693106~197774823:+
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000254153.1	CTA-398F10.2	4.33	1.82e-05	0.0033	0.22	0.2	Mood instability;	chr8:8803028	chr8:8456909~8461337:-
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	4.33	1.82e-05	0.0033	0.13	0.2	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
HNSC	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	4.33	1.82e-05	0.0033	0.2	0.2	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-4.33	1.82e-05	0.0033	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
HNSC	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	4.33	1.82e-05	0.0033	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
HNSC	cis	rs9311676	0.632	rs11925533	ENSG00000273493.1	RP11-80H18.4	4.33	1.82e-05	0.0033	0.21	0.2	Systemic lupus erythematosus;	chr3:58444181	chr3:58329965~58330118:+
HNSC	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.33	1.82e-05	0.0033	0.3	0.2	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
HNSC	cis	rs7255436	0.928	rs7250870	ENSG00000269386.4	RAB11B-AS1	4.33	1.82e-05	0.0033	0.18	0.2	HDL cholesterol;	chr19:8388798	chr19:8374373~8390685:-
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	4.33	1.82e-05	0.0033	0.2	0.2	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	4.33	1.82e-05	0.0033	0.2	0.2	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
HNSC	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-4.33	1.82e-05	0.0033	-0.34	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
HNSC	cis	rs9959145	1	rs76195993	ENSG00000267249.1	RP11-973H7.3	-4.33	1.82e-05	0.0033	-0.3	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12651888	chr18:12670426~12671145:-
HNSC	cis	rs9959145	1	rs74732619	ENSG00000267249.1	RP11-973H7.3	-4.33	1.82e-05	0.0033	-0.3	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12652017	chr18:12670426~12671145:-
HNSC	cis	rs7868228	1	rs7868333	ENSG00000240498.5	CDKN2B-AS1	-4.33	1.82e-05	0.0033	-0.27	-0.2	Gut microbiome composition (winter);	chr9:21667826	chr9:21994778~22121097:+
HNSC	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-4.33	1.82e-05	0.0033	-0.22	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
HNSC	cis	rs13434995	0.513	rs972446	ENSG00000273257.1	RP11-177J6.1	4.33	1.82e-05	0.0033	0.27	0.2	Adiponectin levels;	chr4:55569581	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs11732481	ENSG00000273257.1	RP11-177J6.1	4.33	1.82e-05	0.0033	0.27	0.2	Adiponectin levels;	chr4:55570212	chr4:55387949~55388271:+
HNSC	cis	rs11678825	0.639	rs77134676	ENSG00000272663.1	RP11-191L17.1	-4.33	1.82e-05	0.0033	-0.31	-0.2	Reticulocyte fraction of red cells;	chr2:48440510	chr2:48440043~48440597:-
HNSC	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	4.33	1.82e-05	0.00331	0.28	0.2	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
HNSC	cis	rs6601327	0.585	rs11249934	ENSG00000233609.3	RP11-62H7.2	4.33	1.82e-05	0.00331	0.18	0.2	Multiple myeloma (hyperdiploidy);	chr8:9653320	chr8:8961200~8979025:+
HNSC	cis	rs2548724	0.716	rs6881112	ENSG00000250682.4	LINC00491	4.33	1.82e-05	0.00331	0.26	0.2	Type 2 diabetes;	chr5:102440038	chr5:102609156~102671559:-
HNSC	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	4.33	1.82e-05	0.00331	0.2	0.2	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
HNSC	cis	rs2055729	0.528	rs11987861	ENSG00000254340.1	RP11-10A14.3	-4.33	1.82e-05	0.00331	-0.28	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9884696	chr8:9141424~9145435:+
HNSC	cis	rs5758659	0.692	rs5751251	ENSG00000182057.4	OGFRP1	4.33	1.82e-05	0.00331	0.2	0.2	Cognitive function;	chr22:42244600	chr22:42269753~42275196:+
HNSC	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-4.33	1.82e-05	0.00331	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
HNSC	cis	rs9840812	0.953	rs34330586	ENSG00000273486.1	RP11-731C17.2	-4.33	1.82e-05	0.00331	-0.18	-0.2	Fibrinogen levels;	chr3:136081567	chr3:136837338~136839021:-
HNSC	cis	rs2985684	1	rs3007031	ENSG00000278009.1	RP11-649E7.8	4.33	1.82e-05	0.00331	0.26	0.2	Carotid intima media thickness;	chr14:49635551	chr14:49601011~49601124:-
HNSC	cis	rs7255436	0.965	rs62117510	ENSG00000269386.4	RAB11B-AS1	4.33	1.82e-05	0.00331	0.18	0.2	HDL cholesterol;	chr19:8387729	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.965	rs28729307	ENSG00000269386.4	RAB11B-AS1	4.33	1.82e-05	0.00331	0.18	0.2	HDL cholesterol;	chr19:8387858	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.894	rs10413136	ENSG00000269386.4	RAB11B-AS1	4.33	1.82e-05	0.00331	0.18	0.2	HDL cholesterol;	chr19:8387995	chr19:8374373~8390685:-
HNSC	cis	rs7196129	0.966	rs12598978	ENSG00000183604.13	SMG1P5	4.33	1.82e-05	0.00331	0.19	0.2	Monocyte count;	chr16:30471219	chr16:30267553~30335374:-
HNSC	cis	rs7085104	0.513	rs192569	ENSG00000213061.2	PFN1P11	-4.33	1.82e-05	0.00331	-0.24	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102838011~102845473:-
HNSC	cis	rs11722228	1	rs6823877	ENSG00000250413.1	RP11-448G15.1	4.33	1.82e-05	0.00331	0.26	0.2	Urate levels;Serum uric acid levels;Gout;	chr4:9920307	chr4:10006482~10009725:+
HNSC	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-4.33	1.83e-05	0.00332	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
HNSC	cis	rs889398	0.616	rs35808754	ENSG00000196696.11	PDXDC2P	4.33	1.83e-05	0.00332	0.14	0.2	Body mass index;	chr16:69737807	chr16:69976297~70065948:-
HNSC	cis	rs1056107	0.897	rs7867278	ENSG00000225513.1	RP11-165N19.2	-4.33	1.83e-05	0.00332	-0.21	-0.2	Colorectal cancer;	chr9:112196676	chr9:112173522~112173971:-
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000254153.1	CTA-398F10.2	4.33	1.83e-05	0.00332	0.21	0.2	Mood instability;	chr8:8814919	chr8:8456909~8461337:-
HNSC	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	4.33	1.83e-05	0.00332	0.39	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	4.33	1.83e-05	0.00332	0.39	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	4.33	1.83e-05	0.00332	0.39	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
HNSC	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	4.33	1.83e-05	0.00332	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
HNSC	cis	rs1799949	1	rs11653231	ENSG00000236383.6	LINC00854	-4.33	1.83e-05	0.00332	-0.18	-0.2	Menopause (age at onset);	chr17:43179443	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1399323	ENSG00000236383.6	LINC00854	-4.33	1.83e-05	0.00332	-0.18	-0.2	Menopause (age at onset);	chr17:43180313	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs35954893	ENSG00000236383.6	LINC00854	-4.33	1.83e-05	0.00332	-0.18	-0.2	Menopause (age at onset);	chr17:43181769	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.93	rs4445938	ENSG00000236383.6	LINC00854	-4.33	1.83e-05	0.00332	-0.18	-0.2	Menopause (age at onset);	chr17:43185883	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs8074136	ENSG00000236383.6	LINC00854	-4.33	1.83e-05	0.00332	-0.18	-0.2	Menopause (age at onset);	chr17:43190296	chr17:43216941~43305976:-
HNSC	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-4.33	1.83e-05	0.00332	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
HNSC	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-4.33	1.83e-05	0.00332	-0.21	-0.2	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
HNSC	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	4.33	1.83e-05	0.00332	0.19	0.2	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
HNSC	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-4.33	1.83e-05	0.00332	-0.24	-0.2	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000219891.2	ZSCAN12P1	4.33	1.83e-05	0.00332	0.29	0.2	Depression;	chr6:28241324	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000219891.2	ZSCAN12P1	4.33	1.83e-05	0.00332	0.29	0.2	Depression;	chr6:28241753	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000219891.2	ZSCAN12P1	4.33	1.83e-05	0.00332	0.29	0.2	Depression;	chr6:28242515	chr6:28091154~28093664:+
HNSC	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-4.33	1.83e-05	0.00333	-0.21	-0.2	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
HNSC	cis	rs73222236	0.787	rs6782151	ENSG00000273486.1	RP11-731C17.2	4.33	1.83e-05	0.00333	0.16	0.2	Coronary artery disease;	chr3:136616953	chr3:136837338~136839021:-
HNSC	cis	rs55823223	0.68	rs57287238	ENSG00000267801.1	RP11-552F3.9	4.33	1.83e-05	0.00333	0.24	0.2	Psoriasis;	chr17:75854859	chr17:75876372~75879546:+
HNSC	cis	rs9487051	0.621	rs446974	ENSG00000243587.6	C6orf183	-4.33	1.83e-05	0.00333	-0.2	-0.2	Reticulocyte fraction of red cells;	chr6:109204386	chr6:109165833~109271014:+
HNSC	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	4.33	1.83e-05	0.00333	0.41	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
HNSC	cis	rs12893668	0.603	rs12896171	ENSG00000269910.1	RP11-73M18.10	4.33	1.83e-05	0.00333	0.19	0.2	Reticulocyte count;	chr14:103669629	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.572	rs7148857	ENSG00000269910.1	RP11-73M18.10	4.33	1.83e-05	0.00333	0.19	0.2	Reticulocyte count;	chr14:103676900	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.572	rs11540512	ENSG00000269910.1	RP11-73M18.10	4.33	1.83e-05	0.00333	0.19	0.2	Reticulocyte count;	chr14:103681040	chr14:103694516~103695050:-
HNSC	cis	rs12893668	0.572	rs35011804	ENSG00000269910.1	RP11-73M18.10	4.33	1.83e-05	0.00333	0.19	0.2	Reticulocyte count;	chr14:103685063	chr14:103694516~103695050:-
HNSC	cis	rs7980687	0.662	rs585522	ENSG00000280120.1	RP11-546D6.3	4.33	1.83e-05	0.00333	0.18	0.2	Head circumference (infant);Educational attainment;Height;	chr12:123066266	chr12:123152324~123153377:-
HNSC	cis	rs516805	0.683	rs115988443	ENSG00000279453.1	RP3-425C14.4	4.33	1.83e-05	0.00333	0.28	0.2	Lymphocyte counts;	chr6:122383201	chr6:122436789~122439223:-
HNSC	cis	rs4294134	0.608	rs11532803	ENSG00000223718.3	AC093107.7	4.33	1.84e-05	0.00333	0.31	0.2	Paget's disease;	chr7:135560986	chr7:135660039~135660647:+
HNSC	cis	rs12887734	0.566	rs8548	ENSG00000269940.1	RP11-73M18.7	4.33	1.84e-05	0.00333	0.19	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694560~103695170:+
HNSC	cis	rs1355223	0.583	rs2915179	ENSG00000271369.1	RP11-350D17.3	4.33	1.84e-05	0.00333	0.22	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850396	chr11:34709600~34710161:+
HNSC	cis	rs1223397	0.702	rs13191897	ENSG00000215022.6	RP1-257A7.4	-4.33	1.84e-05	0.00333	-0.26	-0.2	Blood pressure;	chr6:13288196	chr6:13264861~13295586:-
HNSC	cis	rs1223397	0.938	rs3734878	ENSG00000215022.6	RP1-257A7.4	-4.33	1.84e-05	0.00333	-0.26	-0.2	Blood pressure;	chr6:13288618	chr6:13264861~13295586:-
HNSC	cis	rs853679	0.599	rs149949	ENSG00000204709.4	LINC01556	4.33	1.84e-05	0.00333	0.33	0.2	Depression;	chr6:28043738	chr6:28943877~28944537:+
HNSC	cis	rs9304742	0.683	rs10402714	ENSG00000213801.4	ZNF816-ZNF321P	4.33	1.84e-05	0.00333	0.22	0.2	Psoriasis;	chr19:52960427	chr19:52927135~52942601:-
HNSC	cis	rs1015213	1	rs1015213	ENSG00000272024.1	RP11-546K22.3	4.33	1.84e-05	0.00333	0.35	0.2	Glaucoma (primary angle closure);	chr8:51974981	chr8:51950284~51950690:+
HNSC	cis	rs9863	0.828	rs12311848	ENSG00000269938.1	RP11-214K3.20	-4.33	1.84e-05	0.00334	-0.23	-0.2	White blood cell count;	chr12:124002304	chr12:123968023~123968579:-
HNSC	cis	rs12893668	0.572	rs4900591	ENSG00000269910.1	RP11-73M18.10	4.33	1.84e-05	0.00334	0.19	0.2	Reticulocyte count;	chr14:103688541	chr14:103694516~103695050:-
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000254340.1	RP11-10A14.3	4.33	1.84e-05	0.00334	0.23	0.2	Systolic blood pressure;	chr8:8297953	chr8:9141424~9145435:+
HNSC	cis	rs9487051	0.872	rs9372211	ENSG00000219700.1	PTCHD3P3	4.33	1.84e-05	0.00334	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109288445	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.844	rs9386792	ENSG00000219700.1	PTCHD3P3	4.33	1.84e-05	0.00334	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109288772	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.872	rs9398197	ENSG00000219700.1	PTCHD3P3	4.33	1.84e-05	0.00334	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109288785	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.872	rs9487038	ENSG00000219700.1	PTCHD3P3	4.33	1.84e-05	0.00334	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109288949	chr6:109288571~109290503:-
HNSC	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-4.33	1.84e-05	0.00334	-0.21	-0.2	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
HNSC	cis	rs4294134	0.608	rs35956223	ENSG00000223718.3	AC093107.7	4.33	1.84e-05	0.00334	0.31	0.2	Paget's disease;	chr7:135560306	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs35357843	ENSG00000223718.3	AC093107.7	4.33	1.84e-05	0.00334	0.31	0.2	Paget's disease;	chr7:135560320	chr7:135660039~135660647:+
HNSC	cis	rs6500395	1	rs12598514	ENSG00000261267.1	RP11-44I10.3	4.33	1.84e-05	0.00334	0.24	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48655408	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.928	rs2080509	ENSG00000261267.1	RP11-44I10.3	4.33	1.84e-05	0.00334	0.24	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48657004	chr16:48559661~48587403:+
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000211974.3	IGHV2-70	4.33	1.84e-05	0.00334	0.18	0.2	Kawasaki disease;	chr14:106711377	chr14:106723574~106724093:-
HNSC	cis	rs3806843	1	rs10477033	ENSG00000202515.1	VTRNA1-3	-4.33	1.84e-05	0.00334	-0.21	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr5:140726158~140726246:+
HNSC	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.33	1.84e-05	0.00334	-0.3	-0.2	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
HNSC	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.33	1.84e-05	0.00334	-0.3	-0.2	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
HNSC	cis	rs933688	1	rs12651840	ENSG00000281357.1	ARRDC3-AS1	4.33	1.84e-05	0.00334	0.29	0.2	Smoking behavior;	chr5:91433775	chr5:91380349~91439085:+
HNSC	cis	rs10742752	0.58	rs12271560	ENSG00000255267.3	RP11-430H10.2	4.33	1.84e-05	0.00334	0.26	0.2	Body mass index;	chr11:45393595	chr11:45371397~45388508:+
HNSC	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	4.33	1.84e-05	0.00334	0.4	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
HNSC	cis	rs1479119	0.681	rs7961936	ENSG00000180861.8	LINC01559	4.33	1.84e-05	0.00334	0.25	0.2	Intelligence (multi-trait analysis);	chr12:13347907	chr12:13371089~13387167:-
HNSC	cis	rs1479119	0.681	rs10772656	ENSG00000180861.8	LINC01559	4.33	1.84e-05	0.00334	0.25	0.2	Intelligence (multi-trait analysis);	chr12:13348720	chr12:13371089~13387167:-
HNSC	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-4.33	1.84e-05	0.00334	-0.25	-0.2	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
HNSC	cis	rs3015497	0.753	rs12881776	ENSG00000277050.1	RP11-102G14.1	-4.33	1.84e-05	0.00334	-0.19	-0.2	Mean platelet volume;	chr14:50669612	chr14:51637348~51637947:-
HNSC	cis	rs755249	0.567	rs61779275	ENSG00000228060.1	RP11-69E11.8	-4.33	1.84e-05	0.00334	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39565160~39573203:+
HNSC	cis	rs6601327	0.578	rs4075359	ENSG00000233609.3	RP11-62H7.2	-4.33	1.84e-05	0.00334	-0.18	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9630303	chr8:8961200~8979025:+
HNSC	cis	rs3096299	0.9	rs3114867	ENSG00000261574.1	RP1-168P16.2	4.33	1.84e-05	0.00334	0.24	0.2	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89392375~89412564:-
HNSC	cis	rs6500395	1	rs1224	ENSG00000261267.1	RP11-44I10.3	-4.33	1.84e-05	0.00334	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48538906	chr16:48559661~48587403:+
HNSC	cis	rs4925386	0.759	rs2427293	ENSG00000275437.1	RP5-908M14.10	-4.33	1.84e-05	0.00334	-0.22	-0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62402236~62405935:-
HNSC	cis	rs4873772	0.837	rs11778548	ENSG00000253330.1	RP11-697N18.3	-4.33	1.84e-05	0.00334	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47717645	chr8:47511034~47512141:-
HNSC	cis	rs7824557	0.628	rs7820301	ENSG00000255495.1	AC145124.2	4.33	1.84e-05	0.00334	0.22	0.2	Retinal vascular caliber;	chr8:11371163	chr8:12194467~12196280:+
HNSC	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-4.33	1.84e-05	0.00334	-0.27	-0.2	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
HNSC	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-4.33	1.85e-05	0.00335	-0.25	-0.2	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
HNSC	cis	rs73222236	0.817	rs6772759	ENSG00000273486.1	RP11-731C17.2	4.33	1.85e-05	0.00335	0.16	0.2	Coronary artery disease;	chr3:136652645	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.817	rs9869361	ENSG00000273486.1	RP11-731C17.2	4.33	1.85e-05	0.00335	0.16	0.2	Coronary artery disease;	chr3:136654174	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.586	rs6763239	ENSG00000273486.1	RP11-731C17.2	4.33	1.85e-05	0.00335	0.16	0.2	Coronary artery disease;	chr3:136660909	chr3:136837338~136839021:-
HNSC	cis	rs1008375	0.8	rs28754811	ENSG00000249502.1	AC006160.5	-4.33	1.85e-05	0.00335	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17610689	chr4:17587467~17614571:-
HNSC	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	4.33	1.85e-05	0.00335	0.23	0.2	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
HNSC	cis	rs67981189	0.593	rs221904	ENSG00000274818.1	RP1-292L20.3	-4.33	1.85e-05	0.00335	-0.22	-0.2	Schizophrenia;	chr14:71132771	chr14:70906657~70907111:-
HNSC	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-4.33	1.85e-05	0.00335	-0.26	-0.2	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
HNSC	cis	rs5758659	0.716	rs86669	ENSG00000273366.1	CTA-989H11.1	-4.33	1.85e-05	0.00335	-0.23	-0.2	Cognitive function;	chr22:42284794	chr22:42278188~42278846:+
HNSC	cis	rs9487051	0.872	rs1320612	ENSG00000219700.1	PTCHD3P3	4.33	1.85e-05	0.00335	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109290787	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.872	rs6924815	ENSG00000219700.1	PTCHD3P3	4.33	1.85e-05	0.00335	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109291141	chr6:109288571~109290503:-
HNSC	cis	rs7701440	0.512	rs40506	ENSG00000215032.2	GNL3LP1	4.33	1.85e-05	0.00335	0.22	0.2	Educational attainment;	chr5:61229383	chr5:60891935~60893577:-
HNSC	cis	rs4938330	0.629	rs12269901	ENSG00000254851.1	RP11-109L13.1	4.33	1.85e-05	0.00335	0.27	0.2	Blood protein levels;	chr11:117103213	chr11:117135528~117138582:+
HNSC	cis	rs13434995	0.513	rs55885973	ENSG00000273257.1	RP11-177J6.1	-4.33	1.85e-05	0.00335	-0.26	-0.2	Adiponectin levels;	chr4:55480054	chr4:55387949~55388271:+
HNSC	cis	rs11673344	0.523	rs1402468	ENSG00000276846.1	CTD-3220F14.3	4.33	1.85e-05	0.00335	0.21	0.2	Obesity-related traits;	chr19:37129346	chr19:37314868~37315620:-
HNSC	cis	rs9914988	0.509	rs17721557	ENSG00000264577.1	AC010761.8	-4.33	1.85e-05	0.00335	-0.19	-0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28932999	chr17:28721487~28722877:-
HNSC	cis	rs4925386	0.681	rs2427296	ENSG00000275437.1	RP5-908M14.10	4.33	1.85e-05	0.00335	0.22	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62402236~62405935:-
HNSC	cis	rs7701440	0.512	rs34631	ENSG00000215032.2	GNL3LP1	4.33	1.85e-05	0.00335	0.22	0.2	Educational attainment;	chr5:61230499	chr5:60891935~60893577:-
HNSC	cis	rs12893668	0.703	rs35498576	ENSG00000269910.1	RP11-73M18.10	4.33	1.85e-05	0.00335	0.2	0.2	Reticulocyte count;	chr14:103559556	chr14:103694516~103695050:-
HNSC	cis	rs12600394	1	rs4239130	ENSG00000236088.8	COX10-AS1	4.33	1.85e-05	0.00336	0.28	0.2	Response to platinum-based chemotherapy (cisplatin);	chr17:14609441	chr17:13756478~14069495:-
HNSC	cis	rs9287719	0.967	rs9679581	ENSG00000243819.4	RN7SL832P	4.33	1.85e-05	0.00336	0.19	0.2	Prostate cancer;	chr2:10611610	chr2:10690344~10692099:+
HNSC	cis	rs11098499	0.605	rs6833140	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00336	0.24	0.2	Corneal astigmatism;	chr4:119345667	chr4:119391831~119395335:-
HNSC	cis	rs7824557	0.564	rs2572379	ENSG00000269918.1	AF131215.9	-4.33	1.85e-05	0.00336	-0.19	-0.2	Retinal vascular caliber;	chr8:11379971	chr8:11104691~11106704:-
HNSC	cis	rs12935418	0.583	rs2911150	ENSG00000278985.1	RP11-303E16.9	4.33	1.85e-05	0.00336	0.19	0.2	Mean corpuscular volume;	chr16:80995194	chr16:80982319~80984094:-
HNSC	cis	rs7688540	0.656	rs79657896	ENSG00000211553.1	AC253576.2	-4.33	1.85e-05	0.00336	-0.31	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:136461~136568:+
HNSC	cis	rs4256159	1	rs11707468	ENSG00000228956.7	SATB1-AS1	4.33	1.85e-05	0.00336	0.34	0.2	Crohn's disease;Inflammatory bowel disease;	chr3:18746611	chr3:18445024~18920401:+
HNSC	cis	rs1056107	0.831	rs11787835	ENSG00000225513.1	RP11-165N19.2	-4.33	1.85e-05	0.00336	-0.21	-0.2	Colorectal cancer;	chr9:112188318	chr9:112173522~112173971:-
HNSC	cis	rs9487051	0.837	rs4403290	ENSG00000219700.1	PTCHD3P3	4.33	1.85e-05	0.00336	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109290380	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.735	rs882074	ENSG00000219700.1	PTCHD3P3	4.33	1.85e-05	0.00336	0.19	0.2	Reticulocyte fraction of red cells;	chr6:109290517	chr6:109288571~109290503:-
HNSC	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	4.33	1.85e-05	0.00336	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
HNSC	cis	rs8067545	0.641	rs397969	ENSG00000266126.1	RP11-209D14.4	4.33	1.85e-05	0.00336	0.22	0.2	Schizophrenia;	chr17:19900934	chr17:19929372~19929737:-
HNSC	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	4.33	1.85e-05	0.00336	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
HNSC	cis	rs6890684	0.569	rs34627	ENSG00000215032.2	GNL3LP1	4.33	1.86e-05	0.00336	0.22	0.2	Intelligence (multi-trait analysis);	chr5:61232979	chr5:60891935~60893577:-
HNSC	cis	rs6890684	0.569	rs159360	ENSG00000215032.2	GNL3LP1	4.33	1.86e-05	0.00336	0.22	0.2	Intelligence (multi-trait analysis);	chr5:61233623	chr5:60891935~60893577:-
HNSC	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-4.33	1.86e-05	0.00336	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
HNSC	cis	rs8063160	0.688	rs35415928	ENSG00000260259.1	RP11-368I7.4	-4.33	1.86e-05	0.00336	-0.44	-0.2	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89657860	chr16:89682620~89686569:-
HNSC	cis	rs1971762	0.521	rs5009146	ENSG00000270175.1	RP11-793H13.11	-4.33	1.86e-05	0.00336	-0.17	-0.2	Height;	chr12:53695513	chr12:53500162~53500936:-
HNSC	cis	rs4925386	0.625	rs3810550	ENSG00000275437.1	RP5-908M14.10	4.33	1.86e-05	0.00336	0.22	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62402236~62405935:-
HNSC	cis	rs2980439	0.818	rs2948300	ENSG00000254340.1	RP11-10A14.3	4.33	1.86e-05	0.00337	0.24	0.2	Neuroticism;	chr8:8248986	chr8:9141424~9145435:+
HNSC	cis	rs67311347	0.544	rs2123998	ENSG00000280739.1	EIF1B-AS1	-4.33	1.86e-05	0.00337	-0.2	-0.2	Renal cell carcinoma;	chr3:40317514	chr3:40173145~40309698:-
HNSC	cis	rs11098499	0.78	rs7692994	ENSG00000249244.1	RP11-548H18.2	4.33	1.86e-05	0.00337	0.23	0.2	Corneal astigmatism;	chr4:119506334	chr4:119391831~119395335:-
HNSC	cis	rs6490294	0.571	rs12423960	ENSG00000226469.1	ADAM1B	4.33	1.86e-05	0.00337	0.28	0.2	Mean platelet volume;	chr12:112004612	chr12:111927018~111929017:+
HNSC	cis	rs3736485	0.789	rs11070857	ENSG00000259438.1	CTD-2650P22.1	4.33	1.86e-05	0.00337	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51565023	chr15:52010999~52019095:-
HNSC	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	4.33	1.86e-05	0.00337	0.17	0.2	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
HNSC	cis	rs11098499	1	rs6837898	ENSG00000250412.1	KLHL2P1	4.33	1.86e-05	0.00337	0.25	0.2	Corneal astigmatism;	chr4:119257999	chr4:119334329~119378233:+
HNSC	cis	rs1113500	0.73	rs1618693	ENSG00000226822.1	RP11-356N1.2	-4.33	1.86e-05	0.00337	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108048961	chr1:108071482~108074519:+
HNSC	cis	rs1113500	0.698	rs1781078	ENSG00000226822.1	RP11-356N1.2	-4.33	1.86e-05	0.00337	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108049020	chr1:108071482~108074519:+
HNSC	cis	rs1552244	1	rs7622966	ENSG00000180385.7	EMC3-AS1	4.33	1.86e-05	0.00337	0.21	0.2	Alzheimer's disease;	chr3:10098149	chr3:9986893~10006990:+
HNSC	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-4.33	1.86e-05	0.00337	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
HNSC	cis	rs7572733	0.935	rs6734561	ENSG00000222017.1	AC011997.1	4.33	1.86e-05	0.00337	0.24	0.2	Dermatomyositis;	chr2:197860352	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.901	rs700689	ENSG00000222017.1	AC011997.1	4.33	1.86e-05	0.00337	0.24	0.2	Dermatomyositis;	chr2:197861925	chr2:197693106~197774823:+
HNSC	cis	rs7824557	0.707	rs3808518	ENSG00000269918.1	AF131215.9	-4.33	1.86e-05	0.00337	-0.19	-0.2	Retinal vascular caliber;	chr8:11285763	chr8:11104691~11106704:-
HNSC	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	4.33	1.86e-05	0.00338	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
HNSC	cis	rs7829975	0.523	rs9644774	ENSG00000254340.1	RP11-10A14.3	-4.33	1.86e-05	0.00338	-0.26	-0.2	Mood instability;	chr8:8702322	chr8:9141424~9145435:+
HNSC	cis	rs1799949	0.86	rs8176279	ENSG00000236383.6	LINC00854	-4.33	1.86e-05	0.00338	-0.18	-0.2	Menopause (age at onset);	chr17:43058379	chr17:43216941~43305976:-
HNSC	cis	rs116095464	0.558	rs113796397	ENSG00000250848.1	CTD-2083E4.5	-4.33	1.87e-05	0.00338	-0.27	-0.2	Breast cancer;	chr5:246388	chr5:288833~290321:-
HNSC	cis	rs9907295	1	rs11653051	ENSG00000270977.1	AC015849.16	-4.32	1.87e-05	0.00338	-0.32	-0.2	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35893707~35911023:-
HNSC	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	4.32	1.87e-05	0.00338	0.22	0.2	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
HNSC	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-4.32	1.87e-05	0.00338	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-4.32	1.87e-05	0.00338	-0.23	-0.2	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
HNSC	cis	rs700651	0.752	rs7592556	ENSG00000231621.1	AC013264.2	-4.32	1.87e-05	0.00339	-0.19	-0.2	Intracranial aneurysm;	chr2:198026297	chr2:197197991~197199273:+
HNSC	cis	rs67311347	0.955	rs12487955	ENSG00000280739.1	EIF1B-AS1	4.32	1.87e-05	0.00339	0.22	0.2	Renal cell carcinoma;	chr3:40371362	chr3:40173145~40309698:-
HNSC	cis	rs9287719	0.967	rs6432112	ENSG00000243819.4	RN7SL832P	-4.32	1.87e-05	0.00339	-0.19	-0.2	Prostate cancer;	chr2:10604748	chr2:10690344~10692099:+
HNSC	cis	rs763121	0.889	rs1837988	ENSG00000273076.1	RP3-508I15.22	4.32	1.87e-05	0.00339	0.21	0.2	Menopause (age at onset);	chr22:38505089	chr22:38743495~38743910:+
HNSC	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00339	0.22	0.2	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00339	0.22	0.2	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00339	0.22	0.2	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00339	0.22	0.2	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
HNSC	cis	rs1713985	0.508	rs2687239	ENSG00000269949.1	RP11-738E22.3	-4.32	1.87e-05	0.00339	-0.33	-0.2	Age-related macular degeneration;	chr4:57012468	chr4:56960927~56961373:-
HNSC	cis	rs1713985	0.508	rs1718866	ENSG00000269949.1	RP11-738E22.3	-4.32	1.87e-05	0.00339	-0.33	-0.2	Age-related macular degeneration;	chr4:57017009	chr4:56960927~56961373:-
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000254174.1	IGHV1-12	4.32	1.87e-05	0.00339	0.16	0.2	Rheumatic heart disease;	chr14:106637687	chr14:106122420~106122709:-
HNSC	cis	rs9329221	0.597	rs17751178	ENSG00000269918.1	AF131215.9	4.32	1.87e-05	0.00339	0.19	0.2	Neuroticism;	chr8:10259220	chr8:11104691~11106704:-
HNSC	cis	rs913655	0.508	rs2495839	ENSG00000225527.1	RP11-383B4.4	-4.32	1.87e-05	0.00339	-0.24	-0.2	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18765647	chr10:18531849~18533336:-
HNSC	cis	rs28489187	0.617	rs2840319	ENSG00000223653.4	RP11-131L23.1	-4.32	1.88e-05	0.00339	-0.26	-0.2	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85420541	chr1:85276715~85448124:+
HNSC	cis	rs516805	0.748	rs197682	ENSG00000279453.1	RP3-425C14.4	-4.32	1.88e-05	0.0034	-0.28	-0.2	Lymphocyte counts;	chr6:122551848	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs197683	ENSG00000279453.1	RP3-425C14.4	-4.32	1.88e-05	0.0034	-0.28	-0.2	Lymphocyte counts;	chr6:122552277	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs197684	ENSG00000279453.1	RP3-425C14.4	-4.32	1.88e-05	0.0034	-0.28	-0.2	Lymphocyte counts;	chr6:122553697	chr6:122436789~122439223:-
HNSC	cis	rs12745968	0.587	rs1034218	ENSG00000223787.2	RP4-593M8.1	-4.32	1.88e-05	0.0034	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr1:92583574	chr1:92580476~92580821:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000211974.3	IGHV2-70	4.32	1.88e-05	0.0034	0.18	0.2	Kawasaki disease;	chr14:106779068	chr14:106723574~106724093:-
HNSC	cis	rs964611	0.882	rs4775746	ENSG00000259488.2	RP11-154J22.1	4.32	1.88e-05	0.0034	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48346050	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs4775748	ENSG00000259488.2	RP11-154J22.1	4.32	1.88e-05	0.0034	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48346598	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs12917438	ENSG00000259488.2	RP11-154J22.1	4.32	1.88e-05	0.0034	0.2	0.2	Metabolite levels (Pyroglutamine);	chr15:48347540	chr15:48312353~48331856:-
HNSC	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	4.32	1.88e-05	0.0034	0.24	0.2	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
HNSC	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-4.32	1.88e-05	0.0034	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
HNSC	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-4.32	1.88e-05	0.0034	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
HNSC	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	4.32	1.88e-05	0.0034	0.23	0.2	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
HNSC	cis	rs138024639	1	rs138024639	ENSG00000219392.1	RP1-265C24.5	-4.32	1.88e-05	0.0034	-0.42	-0.2	Breast cancer;	chr6:28468244	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs55690788	ENSG00000219392.1	RP1-265C24.5	-4.32	1.88e-05	0.0034	-0.42	-0.2	Depression;	chr6:28468368	chr6:28115628~28116551:+
HNSC	cis	rs739496	0.579	rs16941759	ENSG00000226469.1	ADAM1B	-4.32	1.88e-05	0.0034	-0.23	-0.2	Platelet count;	chr12:111930117	chr12:111927018~111929017:+
HNSC	cis	rs7572733	0.84	rs6743671	ENSG00000222017.1	AC011997.1	-4.32	1.88e-05	0.0034	-0.24	-0.2	Dermatomyositis;	chr2:197698918	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs13034353	ENSG00000222017.1	AC011997.1	-4.32	1.88e-05	0.0034	-0.24	-0.2	Dermatomyositis;	chr2:197701039	chr2:197693106~197774823:+
HNSC	cis	rs17772222	0.597	rs17700296	ENSG00000258789.1	RP11-507K2.3	-4.32	1.88e-05	0.0034	-0.24	-0.2	Coronary artery calcification;	chr14:88840976	chr14:88551597~88552493:+
HNSC	cis	rs1552244	0.882	rs3846168	ENSG00000180385.7	EMC3-AS1	4.32	1.88e-05	0.0034	0.21	0.2	Alzheimer's disease;	chr3:9955241	chr3:9986893~10006990:+
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000211974.3	IGHV2-70	4.32	1.88e-05	0.0034	0.18	0.2	Kawasaki disease;	chr14:106697402	chr14:106723574~106724093:-
HNSC	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	4.32	1.88e-05	0.0034	0.26	0.2	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	4.32	1.88e-05	0.0034	0.26	0.2	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-4.32	1.88e-05	0.0034	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
HNSC	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-4.32	1.88e-05	0.0034	-0.26	-0.2	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
HNSC	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.32	1.88e-05	0.0034	-0.3	-0.2	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
HNSC	cis	rs561341	0.941	rs736678	ENSG00000278867.1	RP11-640N20.4	-4.32	1.88e-05	0.0034	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32020404	chr17:32051030~32053208:+
HNSC	cis	rs1056107	0.831	rs7856158	ENSG00000225513.1	RP11-165N19.2	4.32	1.88e-05	0.0034	0.21	0.2	Colorectal cancer;	chr9:112188892	chr9:112173522~112173971:-
HNSC	cis	rs11992162	0.56	rs13276386	ENSG00000227888.4	FAM66A	4.32	1.88e-05	0.0034	0.2	0.2	Monocyte count;	chr8:11939912	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.621	rs13268810	ENSG00000227888.4	FAM66A	4.32	1.88e-05	0.0034	0.2	0.2	Monocyte count;	chr8:11939921	chr8:12362019~12388296:+
HNSC	cis	rs17407555	0.518	rs16891234	ENSG00000250413.1	RP11-448G15.1	4.32	1.88e-05	0.00341	0.29	0.2	Schizophrenia (age at onset);	chr4:9944539	chr4:10006482~10009725:+
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-4.32	1.88e-05	0.00341	-0.23	-0.2	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-4.32	1.88e-05	0.00341	-0.23	-0.2	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-4.32	1.88e-05	0.00341	-0.23	-0.2	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
HNSC	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-4.32	1.88e-05	0.00341	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	4.32	1.89e-05	0.00341	0.24	0.2	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	4.32	1.89e-05	0.00341	0.24	0.2	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
HNSC	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-4.32	1.89e-05	0.00341	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-4.32	1.89e-05	0.00341	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
HNSC	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	4.32	1.89e-05	0.00341	0.23	0.2	Height;	chr14:75122492	chr14:75011269~75012851:-
HNSC	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-4.32	1.89e-05	0.00341	-0.35	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
HNSC	cis	rs561341	1	rs55736640	ENSG00000278867.1	RP11-640N20.4	-4.32	1.89e-05	0.00341	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32006829	chr17:32051030~32053208:+
HNSC	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	4.32	1.89e-05	0.00341	0.34	0.2	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
HNSC	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-4.32	1.89e-05	0.00342	-0.26	-0.2	Pain;	chr19:21495996	chr19:21554640~21569237:-
HNSC	cis	rs5770917	1	rs2269382	ENSG00000272821.1	CTA-384D8.36	-4.32	1.89e-05	0.00342	-0.36	-0.2	Narcolepsy;	chr22:50580482	chr22:50523926~50524780:+
HNSC	cis	rs5770917	1	rs2269381	ENSG00000272821.1	CTA-384D8.36	-4.32	1.89e-05	0.00342	-0.36	-0.2	Narcolepsy;	chr22:50581640	chr22:50523926~50524780:+
HNSC	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-4.32	1.89e-05	0.00342	-0.22	-0.2	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
HNSC	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	4.32	1.89e-05	0.00342	0.18	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
HNSC	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.89e-05	0.00342	-0.26	-0.2	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
HNSC	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.32	1.89e-05	0.00342	-0.3	-0.2	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
HNSC	cis	rs11648785	0.59	rs4324129	ENSG00000221819.5	GAS8-AS1	4.32	1.89e-05	0.00342	0.2	0.2	Tanning;	chr16:90032653	chr16:90028908~90029367:-
HNSC	cis	rs4660261	0.526	rs810680	ENSG00000237950.1	RP11-7O11.3	4.32	1.89e-05	0.00342	0.22	0.2	Intelligence (multi-trait analysis);	chr1:43882184	chr1:43944370~43946551:-
HNSC	cis	rs859767	0.501	rs6745983	ENSG00000224043.6	CCNT2-AS1	4.32	1.89e-05	0.00342	0.23	0.2	Neuroticism;	chr2:134673139	chr2:134735464~134918710:-
HNSC	cis	rs911555	0.511	rs2296483	ENSG00000269958.1	RP11-73M18.8	4.32	1.89e-05	0.00342	0.18	0.2	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103696353~103697163:+
HNSC	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.89e-05	0.00342	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
HNSC	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-4.32	1.89e-05	0.00342	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
HNSC	cis	rs467650	0.509	rs27391	ENSG00000246763.5	RGMB-AS1	4.32	1.89e-05	0.00342	0.22	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98644719	chr5:98769618~98773469:-
HNSC	cis	rs728616	0.867	rs7893241	ENSG00000225484.5	NUTM2B-AS1	-4.32	1.89e-05	0.00342	-0.45	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79663088~79826594:-
HNSC	cis	rs58873874	0.579	rs11738062	ENSG00000251405.2	CTB-109A12.1	4.32	1.89e-05	0.00342	0.35	0.2	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157362615~157460078:-
HNSC	cis	rs72772090	0.708	rs17082200	ENSG00000248734.2	CTD-2260A17.1	-4.32	1.9e-05	0.00343	-0.29	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712900	chr5:96784777~96785999:+
HNSC	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	4.32	1.9e-05	0.00343	0.23	0.2	Height;	chr14:75116565	chr14:75011269~75012851:-
HNSC	cis	rs2904524	1	rs76608560	ENSG00000257815.4	RP11-611E13.2	-4.32	1.9e-05	0.00343	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70259132	chr12:69904033~70243360:-
HNSC	cis	rs237743	0.786	rs34078534	ENSG00000222365.1	SNORD12B	-4.32	1.9e-05	0.00343	-0.25	-0.2	Height;	chr20:49208367	chr20:49280319~49280409:+
HNSC	cis	rs6500395	0.926	rs1039343	ENSG00000261267.1	RP11-44I10.3	-4.32	1.9e-05	0.00343	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48543596	chr16:48559661~48587403:+
HNSC	cis	rs7868228	1	rs10119803	ENSG00000240498.5	CDKN2B-AS1	-4.32	1.9e-05	0.00343	-0.25	-0.2	Gut microbiome composition (winter);	chr9:21666067	chr9:21994778~22121097:+
HNSC	cis	rs12893668	0.703	rs55751606	ENSG00000269910.1	RP11-73M18.10	4.32	1.9e-05	0.00343	0.2	0.2	Reticulocyte count;	chr14:103562469	chr14:103694516~103695050:-
HNSC	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	4.32	1.9e-05	0.00343	0.23	0.2	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	4.32	1.9e-05	0.00343	0.23	0.2	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
HNSC	cis	rs62027291	0.95	rs17465482	ENSG00000259422.1	RP11-593F23.1	-4.32	1.9e-05	0.00343	-0.31	-0.2	Plateletcrit;	chr15:76970148	chr15:76174891~76181486:-
HNSC	cis	rs4372836	0.929	rs11675572	ENSG00000226833.4	AC097724.3	-4.32	1.9e-05	0.00343	-0.25	-0.2	Body mass index;	chr2:28708510	chr2:28708953~28736205:-
HNSC	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.9e-05	0.00343	-0.26	-0.2	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.9e-05	0.00343	-0.26	-0.2	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
HNSC	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.9e-05	0.00343	-0.26	-0.2	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
HNSC	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.9e-05	0.00343	-0.26	-0.2	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
HNSC	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	4.32	1.9e-05	0.00343	0.23	0.2	Height;	chr14:75139089	chr14:75011269~75012851:-
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000224373.3	IGHV4-59	4.32	1.9e-05	0.00343	0.13	0.2	Kawasaki disease;	chr14:106776528	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000224373.3	IGHV4-59	4.32	1.9e-05	0.00343	0.13	0.2	Kawasaki disease;	chr14:106776695	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000224373.3	IGHV4-59	4.32	1.9e-05	0.00343	0.13	0.2	Kawasaki disease;	chr14:106778202	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000224373.3	IGHV4-59	4.32	1.9e-05	0.00343	0.13	0.2	Kawasaki disease;	chr14:106778401	chr14:106627249~106627825:-
HNSC	cis	rs2732480	0.538	rs1387259	ENSG00000257763.1	OR5BK1P	-4.32	1.9e-05	0.00343	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48355792~48356614:-
HNSC	cis	rs2337406	1	rs17113257	ENSG00000280411.1	IGHV1-69-2	-4.32	1.9e-05	0.00343	-0.19	-0.2	Alzheimer's disease (late onset);	chr14:106679574	chr14:106762092~106762588:-
HNSC	cis	rs6543140	0.964	rs10169192	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102455751	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs11886793	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102455760	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs2310301	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102456475	chr2:102438713~102440475:+
HNSC	cis	rs6543140	1	rs6543140	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102457814	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs13390895	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102459039	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.865	rs6760275	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102463147	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs6734203	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102463606	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs6543142	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102465546	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.929	rs6742530	ENSG00000234389.1	AC007278.3	4.32	1.9e-05	0.00343	0.2	0.2	Blood protein levels;	chr2:102465820	chr2:102438713~102440475:+
HNSC	cis	rs9313772	0.775	rs6556344	ENSG00000254350.1	RP11-542A14.1	-4.32	1.9e-05	0.00344	-0.21	-0.2	Blood pressure;	chr5:158376326	chr5:158424585~158452758:+
HNSC	cis	rs3738443	0.868	rs2892054	ENSG00000259865.1	RP11-488L18.10	4.32	1.9e-05	0.00344	0.17	0.2	Alcohol dependence;	chr1:247203803	chr1:247187281~247188526:-
HNSC	cis	rs763121	0.889	rs9610971	ENSG00000273076.1	RP3-508I15.22	4.32	1.9e-05	0.00344	0.21	0.2	Menopause (age at onset);	chr22:38514805	chr22:38743495~38743910:+
HNSC	cis	rs7674212	0.541	rs2720464	ENSG00000251288.2	RP11-10L12.2	-4.32	1.9e-05	0.00344	-0.22	-0.2	Type 2 diabetes;	chr4:103152044	chr4:102751401~102752641:+
HNSC	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	4.32	1.9e-05	0.00344	0.2	0.2	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
HNSC	cis	rs4819052	0.808	rs2838825	ENSG00000223768.1	LINC00205	-4.32	1.9e-05	0.00344	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45293285~45297354:+
HNSC	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	4.32	1.9e-05	0.00344	0.26	0.2	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
HNSC	cis	rs2286503	1	rs1029740	ENSG00000226329.2	AC005682.6	4.32	1.9e-05	0.00344	0.24	0.2	Fibrinogen;	chr7:22833967	chr7:22863874~22881350:-
HNSC	cis	rs6973609	0.524	rs343711	ENSG00000271122.1	RP11-379H18.1	4.32	1.9e-05	0.00344	0.18	0.2	Obesity-related traits;	chr7:35594740	chr7:35695214~35699413:+
HNSC	cis	rs7568498	0.564	rs10490563	ENSG00000227403.1	AC009299.3	4.32	1.9e-05	0.00344	0.29	0.2	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161244739~161249050:+
HNSC	cis	rs7568498	0.564	rs9287807	ENSG00000227403.1	AC009299.3	4.32	1.9e-05	0.00344	0.29	0.2	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161244739~161249050:+
HNSC	cis	rs7824557	0.614	rs2736277	ENSG00000269918.1	AF131215.9	-4.32	1.91e-05	0.00344	-0.18	-0.2	Retinal vascular caliber;	chr8:11361384	chr8:11104691~11106704:-
HNSC	cis	rs4919687	0.679	rs12762176	ENSG00000236937.2	PTGES3P4	4.32	1.91e-05	0.00344	0.26	0.2	Colorectal cancer;	chr10:102739475	chr10:102845595~102845950:+
HNSC	cis	rs9487051	0.597	rs351746	ENSG00000243587.6	C6orf183	-4.32	1.91e-05	0.00344	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109208118	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs351747	ENSG00000243587.6	C6orf183	-4.32	1.91e-05	0.00344	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109210652	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs351750	ENSG00000243587.6	C6orf183	-4.32	1.91e-05	0.00344	-0.21	-0.2	Reticulocyte fraction of red cells;	chr6:109212182	chr6:109165833~109271014:+
HNSC	cis	rs2136613	0.728	rs10822062	ENSG00000238280.1	RP11-436D10.3	-4.32	1.91e-05	0.00344	-0.23	-0.2	Selective IgA deficiency;	chr10:62837761	chr10:62793562~62805887:-
HNSC	cis	rs12546962	0.654	rs9329191	ENSG00000233609.3	RP11-62H7.2	-4.32	1.91e-05	0.00344	-0.21	-0.2	Body mass index;	chr8:9359074	chr8:8961200~8979025:+
HNSC	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	4.32	1.91e-05	0.00344	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
HNSC	cis	rs4930561	0.765	rs7931502	ENSG00000184795.9	UNC93B5	4.32	1.91e-05	0.00344	0.22	0.2	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr11:67711702~67716005:-
HNSC	cis	rs11773103	0.708	rs55825235	ENSG00000224046.1	AC005076.5	4.32	1.91e-05	0.00344	0.24	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87151423~87152420:-
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	4.32	1.91e-05	0.00344	0.21	0.2	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
HNSC	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	4.32	1.91e-05	0.00345	0.27	0.2	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
HNSC	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-4.32	1.91e-05	0.00345	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
HNSC	cis	rs72634501	0.531	rs67758468	ENSG00000228060.1	RP11-69E11.8	-4.32	1.91e-05	0.00345	-0.21	-0.2	HDL cholesterol;	chr1:39156916	chr1:39565160~39573203:+
HNSC	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	4.32	1.91e-05	0.00345	0.26	0.2	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
HNSC	cis	rs913655	0.508	rs11006727	ENSG00000225527.1	RP11-383B4.4	-4.32	1.91e-05	0.00345	-0.23	-0.2	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18743425	chr10:18531849~18533336:-
HNSC	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.91e-05	0.00345	-0.24	-0.2	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
HNSC	cis	rs12745968	0.589	rs7541942	ENSG00000223787.2	RP4-593M8.1	-4.32	1.91e-05	0.00345	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92555807	chr1:92580476~92580821:-
HNSC	cis	rs1713985	0.92	rs1002285	ENSG00000269949.1	RP11-738E22.3	-4.32	1.91e-05	0.00345	-0.35	-0.2	Age-related macular degeneration;	chr4:56906546	chr4:56960927~56961373:-
HNSC	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	4.32	1.91e-05	0.00345	0.24	0.2	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
HNSC	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	4.32	1.91e-05	0.00345	0.23	0.2	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
HNSC	cis	rs11098499	0.779	rs7699346	ENSG00000250412.1	KLHL2P1	4.32	1.91e-05	0.00345	0.25	0.2	Corneal astigmatism;	chr4:119389387	chr4:119334329~119378233:+
HNSC	cis	rs11250098	0.567	rs4326350	ENSG00000269918.1	AF131215.9	4.32	1.91e-05	0.00345	0.19	0.2	Morning vs. evening chronotype;	chr8:10906145	chr8:11104691~11106704:-
HNSC	cis	rs9313772	0.655	rs13160158	ENSG00000254350.1	RP11-542A14.1	-4.32	1.91e-05	0.00345	-0.21	-0.2	Blood pressure;	chr5:158446080	chr5:158424585~158452758:+
HNSC	cis	rs7324557	0.717	rs9507164	ENSG00000205861.10	C1QTNF9B-AS1	-4.32	1.92e-05	0.00346	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23806400	chr13:23888889~23897263:+
HNSC	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-4.32	1.92e-05	0.00346	-0.21	-0.2	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
HNSC	cis	rs6831352	1	rs1126671	ENSG00000263923.1	RP11-571L19.7	-4.32	1.92e-05	0.00346	-0.2	-0.2	Alcohol dependence;	chr4:99127263	chr4:98928897~98994994:+
HNSC	cis	rs6831352	1	rs6837685	ENSG00000263923.1	RP11-571L19.7	-4.32	1.92e-05	0.00346	-0.2	-0.2	Alcohol dependence;	chr4:99127994	chr4:98928897~98994994:+
HNSC	cis	rs6831352	0.959	rs4699710	ENSG00000263923.1	RP11-571L19.7	-4.32	1.92e-05	0.00346	-0.2	-0.2	Alcohol dependence;	chr4:99130668	chr4:98928897~98994994:+
HNSC	cis	rs4388249	0.687	rs3797672	ENSG00000271849.1	CTC-332L22.1	4.32	1.92e-05	0.00346	0.27	0.2	Schizophrenia;	chr5:109866122	chr5:109687802~109688329:-
HNSC	cis	rs4862750	0.872	rs4862748	ENSG00000250971.1	RP11-696F12.1	-4.32	1.92e-05	0.00346	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr4:186956234	chr4:187060099~187060930:+
HNSC	cis	rs72772090	1	rs56116814	ENSG00000248734.2	CTD-2260A17.1	-4.32	1.92e-05	0.00346	-0.3	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96713010	chr5:96784777~96785999:+
HNSC	cis	rs9910055	0.659	rs112114764	ENSG00000267080.4	ASB16-AS1	4.32	1.92e-05	0.00346	0.16	0.2	Total body bone mineral density;	chr17:44123673	chr17:44175973~44186717:-
HNSC	cis	rs694739	0.536	rs11231740	ENSG00000236935.1	AP003774.1	-4.32	1.92e-05	0.00346	-0.19	-0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64279169	chr11:64325050~64329504:-
HNSC	cis	rs9393777	0.92	rs72839445	ENSG00000219392.1	RP1-265C24.5	-4.32	1.92e-05	0.00346	-0.41	-0.2	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28115628~28116551:+
HNSC	cis	rs8014204	0.604	rs11159109	ENSG00000279594.1	RP11-950C14.10	4.32	1.92e-05	0.00346	0.24	0.2	Caffeine consumption;	chr14:74922371	chr14:75011269~75012851:-
HNSC	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.32	1.92e-05	0.00346	0.22	0.2	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
HNSC	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.32	1.92e-05	0.00346	0.22	0.2	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
HNSC	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.32	1.92e-05	0.00346	0.22	0.2	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
HNSC	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-4.32	1.92e-05	0.00346	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
HNSC	cis	rs5758511	0.514	rs5758629	ENSG00000205702.9	CYP2D7	4.32	1.92e-05	0.00346	0.18	0.2	Birth weight;	chr22:42178549	chr22:42140203~42144577:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000106610.13	STAG3L4	-4.32	1.92e-05	0.00347	-0.39	-0.2	Diabetic kidney disease;	chr7:66358338	chr7:67302621~67321526:+
HNSC	cis	rs7829975	0.539	rs940031	ENSG00000254340.1	RP11-10A14.3	-4.32	1.92e-05	0.00347	-0.25	-0.2	Mood instability;	chr8:8689338	chr8:9141424~9145435:+
HNSC	cis	rs755249	1	rs4660303	ENSG00000182109.6	RP11-69E11.4	4.32	1.92e-05	0.00347	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39522280~39546187:-
HNSC	cis	rs6964587	0.773	rs62467797	ENSG00000188693.7	CYP51A1-AS1	-4.32	1.92e-05	0.00347	-0.21	-0.2	Breast cancer;	chr7:92260408	chr7:92134604~92180725:+
HNSC	cis	rs12893668	0.703	rs8017993	ENSG00000269910.1	RP11-73M18.10	4.32	1.92e-05	0.00347	0.19	0.2	Reticulocyte count;	chr14:103581397	chr14:103694516~103695050:-
HNSC	cis	rs2074409	0.53	rs7224979	ENSG00000276054.1	RP11-378E13.3	-4.32	1.92e-05	0.00347	-0.27	-0.2	Response to angiotensin II receptor blocker therapy;	chr17:37593525	chr17:37386886~37387926:+
HNSC	cis	rs7429990	0.864	rs12635438	ENSG00000228638.1	FCF1P2	-4.32	1.92e-05	0.00347	-0.18	-0.2	Educational attainment (years of education);	chr3:47693210	chr3:48290793~48291375:-
HNSC	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-4.32	1.92e-05	0.00347	-0.14	-0.2	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
HNSC	cis	rs1479119	0.552	rs7314181	ENSG00000180861.8	LINC01559	4.32	1.92e-05	0.00347	0.25	0.2	Intelligence (multi-trait analysis);	chr12:13368242	chr12:13371089~13387167:-
HNSC	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	4.32	1.92e-05	0.00347	0.22	0.2	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
HNSC	cis	rs8177876	0.822	rs4889225	ENSG00000261838.4	RP11-303E16.6	-4.32	1.92e-05	0.00347	-0.35	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81069854~81076598:+
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	4.32	1.92e-05	0.00347	0.33	0.2	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
HNSC	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-4.32	1.92e-05	0.00347	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-4.32	1.92e-05	0.00347	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
HNSC	cis	rs9531006	0.752	rs66994466	ENSG00000227676.3	LINC01068	4.32	1.92e-05	0.00347	0.29	0.2	Sleep duration;	chr13:79993977	chr13:79566727~79571436:+
HNSC	cis	rs9313772	0.722	rs2901006	ENSG00000254350.1	RP11-542A14.1	-4.32	1.93e-05	0.00347	-0.21	-0.2	Blood pressure;	chr5:158433805	chr5:158424585~158452758:+
HNSC	cis	rs9611565	0.694	rs106860	ENSG00000235513.1	RP4-756G23.5	4.32	1.93e-05	0.00347	0.24	0.2	Vitiligo;	chr22:41444403	chr22:41209122~41217627:-
HNSC	cis	rs2286503	0.78	rs929464	ENSG00000226329.2	AC005682.6	4.32	1.93e-05	0.00347	0.25	0.2	Fibrinogen;	chr7:22835151	chr7:22863874~22881350:-
HNSC	cis	rs8077577	0.895	rs1563373	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.93e-05	0.00348	-0.3	-0.2	Obesity-related traits;	chr17:18210914	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs62072465	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.93e-05	0.00348	-0.3	-0.2	Obesity-related traits;	chr17:18211180	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs62072468	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.93e-05	0.00348	-0.3	-0.2	Obesity-related traits;	chr17:18214865	chr17:18511221~18551705:-
HNSC	cis	rs72717009	0.825	rs6671753	ENSG00000225217.1	HSPA7	-4.32	1.93e-05	0.00348	-0.34	-0.2	Rheumatoid arthritis;	chr1:161508918	chr1:161606291~161608217:+
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000224373.3	IGHV4-59	4.32	1.93e-05	0.00348	0.13	0.2	Kawasaki disease;	chr14:106779713	chr14:106627249~106627825:-
HNSC	cis	rs1585471	0.895	rs2613727	ENSG00000249532.3	RP11-148B6.1	4.32	1.93e-05	0.00348	0.24	0.2	Myopia (pathological);	chr4:111679316	chr4:112646476~112650051:-
HNSC	cis	rs9903692	0.954	rs9747001	ENSG00000263412.1	RP5-890E16.2	-4.32	1.93e-05	0.00348	-0.18	-0.2	Pulse pressure;	chr17:48077307	chr17:48045141~48048073:-
HNSC	cis	rs1355223	0.583	rs2941043	ENSG00000271369.1	RP11-350D17.3	-4.32	1.93e-05	0.00348	-0.22	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34849447	chr11:34709600~34710161:+
HNSC	cis	rs7829975	0.684	rs488904	ENSG00000254340.1	RP11-10A14.3	-4.32	1.93e-05	0.00348	-0.24	-0.2	Mood instability;	chr8:8730061	chr8:9141424~9145435:+
HNSC	cis	rs1008375	0.843	rs59112113	ENSG00000249502.1	AC006160.5	-4.32	1.93e-05	0.00348	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683713	chr4:17587467~17614571:-
HNSC	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-4.32	1.93e-05	0.00348	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
HNSC	cis	rs11722228	1	rs4697695	ENSG00000250413.1	RP11-448G15.1	-4.32	1.93e-05	0.00348	-0.26	-0.2	Urate levels;Serum uric acid levels;Gout;	chr4:9914226	chr4:10006482~10009725:+
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	4.32	1.93e-05	0.00348	0.24	0.2	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
HNSC	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-4.32	1.93e-05	0.00348	-0.22	-0.2	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
HNSC	cis	rs12655019	0.92	rs12654125	ENSG00000271828.1	CTD-2310F14.1	4.32	1.93e-05	0.00348	0.43	0.2	Breast cancer (early onset);	chr5:56919926	chr5:56927874~56929573:+
HNSC	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	4.32	1.93e-05	0.00348	0.3	0.2	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
HNSC	cis	rs597539	0.652	rs478647	ENSG00000261625.1	RP11-554A11.4	-4.32	1.93e-05	0.00348	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:69000765~69002048:-
HNSC	cis	rs2834288	0.608	rs2017190	ENSG00000273102.1	AP000569.9	4.32	1.93e-05	0.00348	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33938609	chr21:33967101~33968573:-
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000211974.3	IGHV2-70	4.32	1.93e-05	0.00348	0.18	0.2	Kawasaki disease;	chr14:106782206	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000211974.3	IGHV2-70	4.32	1.93e-05	0.00348	0.18	0.2	Kawasaki disease;	chr14:106782238	chr14:106723574~106724093:-
HNSC	cis	rs4372836	0.964	rs2293553	ENSG00000226833.4	AC097724.3	-4.32	1.93e-05	0.00349	-0.25	-0.2	Body mass index;	chr2:28709418	chr2:28708953~28736205:-
HNSC	cis	rs1665050	0.546	rs7175490	ENSG00000259732.1	RP11-59H7.3	-4.32	1.93e-05	0.00349	-0.25	-0.2	Atopic dermatitis;	chr15:59041735	chr15:59121034~59133250:+
HNSC	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.32	1.93e-05	0.00349	-0.21	-0.2	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
HNSC	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	4.32	1.93e-05	0.00349	0.21	0.2	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
HNSC	cis	rs7107174	1	rs2510043	ENSG00000251323.2	RP11-452H21.4	4.32	1.93e-05	0.00349	0.28	0.2	Testicular germ cell tumor;	chr11:78266435	chr11:78423982~78429836:-
HNSC	cis	rs4356203	0.905	rs11024158	ENSG00000260196.1	RP1-239B22.5	4.32	1.93e-05	0.00349	0.2	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17380649~17383531:+
HNSC	cis	rs9914988	0.56	rs8066347	ENSG00000264577.1	AC010761.8	4.32	1.93e-05	0.00349	0.18	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28917455	chr17:28721487~28722877:-
HNSC	cis	rs10462794	0.618	rs4235603	ENSG00000260763.1	RP11-445O3.3	4.32	1.94e-05	0.00349	0.27	0.2	DNA methylation (variation);	chr5:4520384	chr5:4436850~4440259:-
HNSC	cis	rs6500395	1	rs7184144	ENSG00000261267.1	RP11-44I10.3	-4.32	1.94e-05	0.00349	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48572166	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7198773	ENSG00000261267.1	RP11-44I10.3	-4.32	1.94e-05	0.00349	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48572180	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9938308	ENSG00000261267.1	RP11-44I10.3	-4.32	1.94e-05	0.00349	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48573318	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7188741	ENSG00000261267.1	RP11-44I10.3	-4.32	1.94e-05	0.00349	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48574055	chr16:48559661~48587403:+
HNSC	cis	rs9910055	0.53	rs11656758	ENSG00000267080.4	ASB16-AS1	-4.32	1.94e-05	0.00349	-0.16	-0.2	Total body bone mineral density;	chr17:44224173	chr17:44175973~44186717:-
HNSC	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	4.32	1.94e-05	0.00349	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
HNSC	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-4.32	1.94e-05	0.00349	-0.25	-0.2	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
HNSC	cis	rs8077577	0.895	rs11871491	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.94e-05	0.00349	-0.29	-0.2	Obesity-related traits;	chr17:18202342	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.836	rs58441148	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.94e-05	0.00349	-0.29	-0.2	Obesity-related traits;	chr17:18203184	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs11655797	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.94e-05	0.00349	-0.29	-0.2	Obesity-related traits;	chr17:18204536	chr17:18511221~18551705:-
HNSC	cis	rs9650657	0.836	rs891556	ENSG00000269918.1	AF131215.9	-4.32	1.94e-05	0.00349	-0.2	-0.2	Neuroticism;	chr8:10766123	chr8:11104691~11106704:-
HNSC	cis	rs4356203	0.87	rs603618	ENSG00000272034.1	SNORD14A	-4.32	1.94e-05	0.00349	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs10832745	ENSG00000272034.1	SNORD14A	-4.32	1.94e-05	0.00349	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs10832747	ENSG00000272034.1	SNORD14A	-4.32	1.94e-05	0.00349	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17074654~17074744:-
HNSC	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.32	1.94e-05	0.0035	0.18	0.2	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
HNSC	cis	rs964611	0.882	rs7179027	ENSG00000259488.2	RP11-154J22.1	-4.32	1.94e-05	0.0035	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48287279	chr15:48312353~48331856:-
HNSC	cis	rs11089937	0.616	rs5757247	ENSG00000211639.2	IGLV4-60	4.32	1.94e-05	0.0035	0.18	0.2	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22162199~22162681:+
HNSC	cis	rs62025270	0.688	rs55738258	ENSG00000259762.1	RP11-158M2.4	-4.32	1.94e-05	0.0035	-0.27	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85750336~85752901:-
HNSC	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	4.32	1.94e-05	0.0035	0.23	0.2	Height;	chr14:75097956	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	4.32	1.94e-05	0.0035	0.23	0.2	Height;	chr14:75099506	chr14:75011269~75012851:-
HNSC	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	4.32	1.94e-05	0.0035	0.21	0.2	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
HNSC	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	4.32	1.94e-05	0.0035	0.21	0.2	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
HNSC	cis	rs10129255	1	rs10129319	ENSG00000211974.3	IGHV2-70	4.32	1.94e-05	0.0035	0.18	0.2	Kawasaki disease;	chr14:106767996	chr14:106723574~106724093:-
HNSC	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-4.32	1.94e-05	0.0035	-0.28	-0.2	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000254153.1	CTA-398F10.2	4.32	1.94e-05	0.0035	0.21	0.2	Mood instability;	chr8:8804171	chr8:8456909~8461337:-
HNSC	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-4.32	1.94e-05	0.0035	-0.21	-0.2	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
HNSC	cis	rs16858210	0.647	rs12107414	ENSG00000234371.6	RPSAP31	4.32	1.94e-05	0.0035	0.26	0.2	Menopause (age at onset);	chr3:183856760	chr3:183884924~183888449:+
HNSC	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	4.32	1.94e-05	0.0035	0.19	0.2	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
HNSC	cis	rs6490294	0.851	rs56814171	ENSG00000226469.1	ADAM1B	4.32	1.94e-05	0.0035	0.23	0.2	Mean platelet volume;	chr12:111965146	chr12:111927018~111929017:+
HNSC	cis	rs870825	0.655	rs7675046	ENSG00000254233.1	RP11-242J7.1	-4.32	1.94e-05	0.0035	-0.28	-0.2	Blood protein levels;	chr4:184731047	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.581	rs7675106	ENSG00000254233.1	RP11-242J7.1	-4.32	1.94e-05	0.0035	-0.28	-0.2	Blood protein levels;	chr4:184731234	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7680779	ENSG00000254233.1	RP11-242J7.1	-4.32	1.94e-05	0.0035	-0.28	-0.2	Blood protein levels;	chr4:184731676	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7680639	ENSG00000254233.1	RP11-242J7.1	-4.32	1.94e-05	0.0035	-0.28	-0.2	Blood protein levels;	chr4:184731761	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7680835	ENSG00000254233.1	RP11-242J7.1	-4.32	1.94e-05	0.0035	-0.28	-0.2	Blood protein levels;	chr4:184731838	chr4:184584093~184625030:-
HNSC	cis	rs9914544	0.564	rs1859083	ENSG00000264885.1	RP11-815I9.4	4.32	1.94e-05	0.0035	0.2	0.2	Educational attainment (years of education);	chr17:18939993	chr17:18667629~18669461:-
HNSC	cis	rs7824557	0.591	rs2736283	ENSG00000255495.1	AC145124.2	-4.32	1.94e-05	0.0035	-0.22	-0.2	Retinal vascular caliber;	chr8:11368401	chr8:12194467~12196280:+
HNSC	cis	rs2835345	0.563	rs60727080	ENSG00000279365.1	KB-176G8.1	4.32	1.94e-05	0.0035	0.24	0.2	Pulmonary function;	chr21:36454876	chr21:36485867~36487760:+
HNSC	cis	rs1125355	0.69	rs72939209	ENSG00000204380.3	AC005042.4	4.32	1.94e-05	0.0035	0.21	0.2	Alzheimer's disease in APOE e4+ carriers;	chr2:158786291	chr2:158658337~158735002:-
HNSC	cis	rs2115630	0.846	rs8024538	ENSG00000259295.5	CSPG4P12	-4.32	1.94e-05	0.0035	-0.23	-0.2	P wave terminal force;	chr15:84825188	chr15:85191438~85213905:+
HNSC	cis	rs9329221	0.621	rs12156350	ENSG00000269918.1	AF131215.9	-4.32	1.95e-05	0.0035	-0.19	-0.2	Neuroticism;	chr8:10411006	chr8:11104691~11106704:-
HNSC	cis	rs690037	0.78	rs690437	ENSG00000272529.1	RP11-415F23.4	4.32	1.95e-05	0.0035	0.17	0.2	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr3:16345126~16346440:+
HNSC	cis	rs9611565	0.838	rs4239894	ENSG00000235513.1	RP4-756G23.5	4.32	1.95e-05	0.0035	0.22	0.2	Vitiligo;	chr22:41349544	chr22:41209122~41217627:-
HNSC	cis	rs561341	1	rs72825740	ENSG00000278867.1	RP11-640N20.4	-4.32	1.95e-05	0.0035	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32011337	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.941	rs17780080	ENSG00000278867.1	RP11-640N20.4	-4.32	1.95e-05	0.0035	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32016127	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.941	rs17780086	ENSG00000278867.1	RP11-640N20.4	-4.32	1.95e-05	0.0035	-0.27	-0.2	Hip circumference adjusted for BMI;	chr17:32016263	chr17:32051030~32053208:+
HNSC	cis	rs11992162	0.636	rs13265816	ENSG00000227888.4	FAM66A	4.32	1.95e-05	0.00351	0.2	0.2	Monocyte count;	chr8:11939976	chr8:12362019~12388296:+
HNSC	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	4.32	1.95e-05	0.00351	0.23	0.2	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
HNSC	cis	rs287982	0.611	rs111493633	ENSG00000269973.1	RP11-95D17.1	-4.32	1.95e-05	0.00351	-0.28	-0.2	Nonsyndromic cleft lip with cleft palate;	chr2:9840033	chr2:9936360~9939590:+
HNSC	cis	rs9584850	0.834	rs7339274	ENSG00000231194.1	FARP1-AS1	-4.32	1.95e-05	0.00351	-0.24	-0.2	Neuroticism;	chr13:98468018	chr13:98435405~98435840:-
HNSC	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	4.32	1.95e-05	0.00351	0.23	0.2	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
HNSC	cis	rs9329221	0.527	rs7833781	ENSG00000255020.1	AF131216.5	4.32	1.95e-05	0.00351	0.22	0.2	Neuroticism;	chr8:10475967	chr8:11345748~11347502:-
HNSC	cis	rs9880211	0.752	rs67145204	ENSG00000273486.1	RP11-731C17.2	4.32	1.95e-05	0.00351	0.19	0.2	Height;Body mass index;	chr3:136609823	chr3:136837338~136839021:-
HNSC	cis	rs35306767	0.903	rs7077278	ENSG00000229869.1	RP11-363N22.2	4.31	1.95e-05	0.00351	0.29	0.2	Eosinophil percentage of granulocytes;	chr10:865351	chr10:933026~942743:+
HNSC	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	4.31	1.95e-05	0.00351	0.23	0.2	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
HNSC	cis	rs4927850	0.957	rs4927851	ENSG00000226155.1	AC124944.3	-4.31	1.95e-05	0.00351	-0.24	-0.2	Pancreatic cancer;	chr3:196024982	chr3:195912049~195913986:+
HNSC	cis	rs4927850	0.918	rs4361313	ENSG00000226155.1	AC124944.3	-4.31	1.95e-05	0.00351	-0.24	-0.2	Pancreatic cancer;	chr3:196025389	chr3:195912049~195913986:+
HNSC	cis	rs11089937	0.651	rs2877023	ENSG00000211639.2	IGLV4-60	4.31	1.95e-05	0.00351	0.19	0.2	Periodontitis (PAL4Q3);	chr22:22182414	chr22:22162199~22162681:+
HNSC	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-4.31	1.95e-05	0.00351	-0.26	-0.2	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
HNSC	cis	rs3736485	0.873	rs10851502	ENSG00000259438.1	CTD-2650P22.1	4.31	1.95e-05	0.00352	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598739	chr15:52010999~52019095:-
HNSC	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	4.31	1.95e-05	0.00352	0.22	0.2	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000254153.1	CTA-398F10.2	4.31	1.95e-05	0.00352	0.22	0.2	Mood instability;	chr8:8824682	chr8:8456909~8461337:-
HNSC	cis	rs988913	0.706	rs4296891	ENSG00000224984.1	RP11-524H19.2	4.31	1.95e-05	0.00352	0.22	0.2	Menarche (age at onset);	chr6:55073395	chr6:54840118~54840855:-
HNSC	cis	rs11846409	0.932	rs73378155	ENSG00000254174.1	IGHV1-12	4.31	1.95e-05	0.00352	0.15	0.2	Rheumatic heart disease;	chr14:106637840	chr14:106122420~106122709:-
HNSC	cis	rs453301	0.507	rs2929306	ENSG00000233609.3	RP11-62H7.2	-4.31	1.96e-05	0.00352	-0.18	-0.2	Joint mobility (Beighton score);	chr8:9227399	chr8:8961200~8979025:+
HNSC	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	4.31	1.96e-05	0.00352	0.19	0.2	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
HNSC	cis	rs9926296	0.712	rs258330	ENSG00000274627.1	RP11-104N10.2	4.31	1.96e-05	0.00352	0.19	0.2	Vitiligo;	chr16:89663166	chr16:89516797~89522217:+
HNSC	cis	rs6504108	0.624	rs3805363	ENSG00000278765.1	RP5-890E16.5	-4.31	1.96e-05	0.00352	-0.25	-0.2	Body mass index;	chr17:48164260	chr17:48066704~48067293:-
HNSC	cis	rs73222236	0.825	rs9868120	ENSG00000273486.1	RP11-731C17.2	4.31	1.96e-05	0.00352	0.16	0.2	Coronary artery disease;	chr3:136446234	chr3:136837338~136839021:-
HNSC	cis	rs6500395	0.962	rs9937568	ENSG00000261267.1	RP11-44I10.3	4.31	1.96e-05	0.00352	0.24	0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48578450	chr16:48559661~48587403:+
HNSC	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	4.31	1.96e-05	0.00352	0.22	0.2	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000241439.1	RP11-666A20.3	4.31	1.96e-05	0.00352	0.22	0.2	Blood pressure (smoking interaction);	chr3:125987203	chr3:125958556~125958817:+
HNSC	cis	rs12468226	0.689	rs73989733	ENSG00000226261.1	AC064836.3	4.31	1.96e-05	0.00352	0.29	0.2	Urate levels;	chr2:202115241	chr2:202336024~202336727:-
HNSC	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	4.31	1.96e-05	0.00352	0.23	0.2	Height;	chr14:75135034	chr14:75011269~75012851:-
HNSC	cis	rs843532	0.588	rs6806616	ENSG00000236833.1	AC024560.2	-4.31	1.96e-05	0.00352	-0.25	-0.2	Glucose homeostasis traits;	chr3:196790760	chr3:197660565~197665757:-
HNSC	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-4.31	1.96e-05	0.00352	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
HNSC	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	4.31	1.96e-05	0.00353	0.4	0.2	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
HNSC	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	4.31	1.96e-05	0.00353	0.4	0.2	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
HNSC	cis	rs4927850	0.501	rs9881504	ENSG00000239122.1	RNU2-11P	-4.31	1.96e-05	0.00353	-0.17	-0.2	Pancreatic cancer;	chr3:195929743	chr3:195928589~195928775:-
HNSC	cis	rs62025270	0.688	rs62025298	ENSG00000259762.1	RP11-158M2.4	-4.31	1.96e-05	0.00353	-0.27	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85750336~85752901:-
HNSC	cis	rs4862750	0.758	rs2375915	ENSG00000250971.1	RP11-696F12.1	4.31	1.96e-05	0.00353	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186975101	chr4:187060099~187060930:+
HNSC	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-4.31	1.96e-05	0.00353	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
HNSC	cis	rs728616	0.558	rs35698456	ENSG00000225484.5	NUTM2B-AS1	-4.31	1.96e-05	0.00353	-0.35	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80381806	chr10:79663088~79826594:-
HNSC	cis	rs3733829	1	rs3733829	ENSG00000233622.1	CYP2T1P	4.31	1.96e-05	0.00353	0.2	0.2	Smoking behavior;	chr19:40804666	chr19:40808525~40811390:-
HNSC	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	4.31	1.96e-05	0.00353	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
HNSC	cis	rs656319	0.605	rs17747335	ENSG00000269918.1	AF131215.9	-4.31	1.96e-05	0.00353	-0.19	-0.2	Myopia (pathological);	chr8:10145676	chr8:11104691~11106704:-
HNSC	cis	rs73607972	0.935	rs16952396	ENSG00000275191.1	RP11-36I17.2	-4.31	1.96e-05	0.00353	-0.28	-0.2	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53616751	chr16:53628256~53628816:-
HNSC	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-4.31	1.96e-05	0.00353	-0.21	-0.2	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
HNSC	cis	rs4873772	0.772	rs62539150	ENSG00000253330.1	RP11-697N18.3	-4.31	1.96e-05	0.00353	-0.25	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47698420	chr8:47511034~47512141:-
HNSC	cis	rs3808502	0.516	rs6983727	ENSG00000255310.2	AF131215.2	4.31	1.96e-05	0.00353	0.18	0.2	Neuroticism;	chr8:11558303	chr8:11107788~11109726:-
HNSC	cis	rs12745968	0.629	rs2145824	ENSG00000223787.2	RP4-593M8.1	-4.31	1.96e-05	0.00353	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92734844	chr1:92580476~92580821:-
HNSC	cis	rs9393777	0.844	rs28360634	ENSG00000219392.1	RP1-265C24.5	-4.31	1.96e-05	0.00353	-0.39	-0.2	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	4.31	1.96e-05	0.00353	0.23	0.2	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
HNSC	cis	rs7224668	0.647	rs2271090	ENSG00000280407.2	RP13-516M14.8	4.31	1.96e-05	0.00353	0.16	0.2	IgG glycosylation;	chr17:81272805	chr17:82249067~82251844:+
HNSC	cis	rs9807989	0.839	rs7603730	ENSG00000234389.1	AC007278.3	4.31	1.96e-05	0.00353	0.19	0.2	Asthma;	chr2:102357911	chr2:102438713~102440475:+
HNSC	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.31	1.96e-05	0.00353	0.33	0.2	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
HNSC	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-4.31	1.97e-05	0.00353	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
HNSC	cis	rs9287719	0.934	rs10201077	ENSG00000243819.4	RN7SL832P	4.31	1.97e-05	0.00354	0.19	0.2	Prostate cancer;	chr2:10612300	chr2:10690344~10692099:+
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000250412.1	KLHL2P1	4.31	1.97e-05	0.00354	0.25	0.2	Corneal astigmatism;	chr4:119301143	chr4:119334329~119378233:+
HNSC	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	4.31	1.97e-05	0.00354	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.861	rs4930726	ENSG00000270028.1	RP11-380L11.4	4.31	1.97e-05	0.00354	0.22	0.2	White blood cell count;	chr12:123943784	chr12:123925461~123926083:-
HNSC	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-4.31	1.97e-05	0.00354	-0.21	-0.2	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
HNSC	cis	rs6964587	1	rs4265	ENSG00000188693.7	CYP51A1-AS1	4.31	1.97e-05	0.00354	0.21	0.2	Breast cancer;	chr7:92090294	chr7:92134604~92180725:+
HNSC	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00354	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
HNSC	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	4.31	1.97e-05	0.00354	0.27	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
HNSC	cis	rs11098499	0.863	rs6835635	ENSG00000250412.1	KLHL2P1	4.31	1.97e-05	0.00354	0.25	0.2	Corneal astigmatism;	chr4:119537712	chr4:119334329~119378233:+
HNSC	cis	rs12034383	1	rs12041437	ENSG00000274245.1	RP11-357P18.2	-4.31	1.97e-05	0.00354	-0.25	-0.2	Erythrocyte sedimentation rate;	chr1:207629919	chr1:207372559~207373252:+
HNSC	cis	rs12034383	1	rs12034383	ENSG00000274245.1	RP11-357P18.2	-4.31	1.97e-05	0.00354	-0.25	-0.2	Erythrocyte sedimentation rate;	chr1:207630250	chr1:207372559~207373252:+
HNSC	cis	rs172166	0.516	rs1225618	ENSG00000219392.1	RP1-265C24.5	-4.31	1.97e-05	0.00354	-0.22	-0.2	Cardiac Troponin-T levels;	chr6:28161935	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs2306457	ENSG00000250412.1	KLHL2P1	4.31	1.97e-05	0.00355	0.25	0.2	Corneal astigmatism;	chr4:119551684	chr4:119334329~119378233:+
HNSC	cis	rs4295623	0.585	rs34421088	ENSG00000255310.2	AF131215.2	-4.31	1.97e-05	0.00355	-0.19	-0.2	Morning vs. evening chronotype;	chr8:11731533	chr8:11107788~11109726:-
HNSC	cis	rs494453	0.583	rs564807	ENSG00000227811.2	FAM212B-AS1	-4.31	1.97e-05	0.00355	-0.28	-0.2	Osteoporosis-related phenotypes;	chr1:111669679	chr1:111739841~111747798:+
HNSC	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-4.31	1.97e-05	0.00355	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
HNSC	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	4.31	1.97e-05	0.00355	0.23	0.2	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	4.31	1.97e-05	0.00355	0.23	0.2	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
HNSC	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-4.31	1.97e-05	0.00355	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
HNSC	cis	rs2412819	0.571	rs8030536	ENSG00000166763.7	STRCP1	4.31	1.98e-05	0.00355	0.29	0.2	Lung cancer;	chr15:43627365	chr15:43699488~43718184:-
HNSC	cis	rs6125961	0.598	rs6067395	ENSG00000224397.4	LINC01272	-4.31	1.98e-05	0.00355	-0.27	-0.2	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50297049	chr20:50267486~50279795:+
HNSC	cis	rs17818399	0.645	rs35870739	ENSG00000279254.1	RP11-536C12.1	-4.31	1.98e-05	0.00355	-0.24	-0.2	Height;	chr2:46557092	chr2:46668870~46670778:+
HNSC	cis	rs17818399	0.749	rs13000560	ENSG00000279254.1	RP11-536C12.1	-4.31	1.98e-05	0.00355	-0.24	-0.2	Height;	chr2:46563858	chr2:46668870~46670778:+
HNSC	cis	rs2904524	1	rs79903423	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70308032	chr12:69904033~70243360:-
HNSC	cis	rs6543140	0.855	rs4851591	ENSG00000234389.1	AC007278.3	4.31	1.98e-05	0.00355	0.2	0.2	Blood protein levels;	chr2:102460963	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs7561351	ENSG00000234389.1	AC007278.3	4.31	1.98e-05	0.00355	0.2	0.2	Blood protein levels;	chr2:102461320	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs13393175	ENSG00000234389.1	AC007278.3	4.31	1.98e-05	0.00355	0.2	0.2	Blood protein levels;	chr2:102462389	chr2:102438713~102440475:+
HNSC	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-4.31	1.98e-05	0.00355	-0.22	-0.2	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
HNSC	cis	rs9527	0.571	rs7096249	ENSG00000236937.2	PTGES3P4	4.31	1.98e-05	0.00355	0.24	0.2	Arsenic metabolism;	chr10:102858767	chr10:102845595~102845950:+
HNSC	cis	rs9527	0.571	rs10786715	ENSG00000236937.2	PTGES3P4	4.31	1.98e-05	0.00355	0.24	0.2	Arsenic metabolism;	chr10:102860978	chr10:102845595~102845950:+
HNSC	cis	rs3736485	0.966	rs7177471	ENSG00000259438.1	CTD-2650P22.1	4.31	1.98e-05	0.00355	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51619035	chr15:52010999~52019095:-
HNSC	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	4.31	1.98e-05	0.00355	0.22	0.2	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
HNSC	cis	rs11951515	0.7	rs11740128	ENSG00000249286.1	CTD-2210P15.2	-4.31	1.98e-05	0.00355	-0.2	-0.2	Metabolite levels  (X-11787);	chr5:43283918	chr5:43586918~43588223:-
HNSC	cis	rs9400271	0.632	rs9384703	ENSG00000243587.6	C6orf183	-4.31	1.98e-05	0.00355	-0.19	-0.2	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109265600	chr6:109165833~109271014:+
HNSC	cis	rs2904524	1	rs79224766	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70292399	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs2091131	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70294834	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs17107947	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70295689	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs75796761	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70298071	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs74809484	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70299136	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs75846246	ENSG00000257815.4	RP11-611E13.2	-4.31	1.98e-05	0.00355	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70305146	chr12:69904033~70243360:-
HNSC	cis	rs763567	0.935	rs639652	ENSG00000271811.1	RP1-79C4.4	4.31	1.98e-05	0.00355	0.21	0.2	Tonsillectomy;	chr1:170643732	chr1:170667381~170669425:+
HNSC	cis	rs9287719	1	rs9679122	ENSG00000243819.4	RN7SL832P	4.31	1.98e-05	0.00355	0.19	0.2	Prostate cancer;	chr2:10611584	chr2:10690344~10692099:+
HNSC	cis	rs2048656	0.6	rs1976671	ENSG00000254340.1	RP11-10A14.3	4.31	1.98e-05	0.00355	0.24	0.2	Schizophrenia;	chr8:9822124	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000250412.1	KLHL2P1	4.31	1.98e-05	0.00356	0.26	0.2	Corneal astigmatism;	chr4:119645578	chr4:119334329~119378233:+
HNSC	cis	rs17345786	0.906	rs55710435	ENSG00000244119.1	PDCL3P4	4.31	1.98e-05	0.00356	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101712472~101713191:+
HNSC	cis	rs9467773	0.626	rs9379860	ENSG00000241549.7	GUSBP2	4.31	1.98e-05	0.00356	0.18	0.2	Intelligence (multi-trait analysis);	chr6:26370377	chr6:26871484~26956554:-
HNSC	cis	rs853679	1	rs1778508	ENSG00000204709.4	LINC01556	-4.31	1.98e-05	0.00356	-0.3	-0.2	Depression;	chr6:28262103	chr6:28943877~28944537:+
HNSC	cis	rs7809950	0.798	rs2701684	ENSG00000238832.1	snoU109	4.31	1.98e-05	0.00356	0.23	0.2	Coronary artery disease;	chr7:107659082	chr7:107603363~107603507:+
HNSC	cis	rs2486288	0.656	rs11629807	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45254839	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.587	rs12899942	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45255082	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs12899058	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45255126	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs12904150	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45255407	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs9920290	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45255837	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11854325	ENSG00000259479.5	SORD2P	-4.31	1.98e-05	0.00356	-0.23	-0.2	Glomerular filtration rate;	chr15:45256761	chr15:44826371~44884694:-
HNSC	cis	rs9880211	1	rs13071220	ENSG00000273486.1	RP11-731C17.2	4.31	1.98e-05	0.00356	0.19	0.2	Height;Body mass index;	chr3:136595277	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.618	rs73197281	ENSG00000255310.2	AF131215.2	-4.31	1.98e-05	0.00356	-0.19	-0.2	Neuroticism;	chr8:10405772	chr8:11107788~11109726:-
HNSC	cis	rs2898681	0.519	rs76606067	ENSG00000248375.1	RP11-177B4.1	-4.31	1.98e-05	0.00356	-0.32	-0.2	Optic nerve measurement (cup area);	chr4:52862054	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.521	rs115874483	ENSG00000248375.1	RP11-177B4.1	-4.31	1.98e-05	0.00356	-0.32	-0.2	Optic nerve measurement (cup area);	chr4:52862105	chr4:52720081~52720831:-
HNSC	cis	rs4218	0.541	rs8030246	ENSG00000277144.1	RP11-59H7.4	-4.31	1.98e-05	0.00356	-0.25	-0.2	Social communication problems;	chr15:59049447	chr15:59115547~59116089:-
HNSC	cis	rs6500395	1	rs3848322	ENSG00000261267.1	RP11-44I10.3	-4.31	1.99e-05	0.00357	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48587053	chr16:48559661~48587403:+
HNSC	cis	rs35963943	0.625	rs11709148	ENSG00000228956.7	SATB1-AS1	4.31	1.99e-05	0.00357	0.23	0.2	Lymphocyte counts;	chr3:18678209	chr3:18445024~18920401:+
HNSC	cis	rs72843506	0.591	rs75925580	ENSG00000261033.1	RP11-209D14.2	4.31	1.99e-05	0.00357	0.33	0.2	Schizophrenia;	chr17:20211700	chr17:20008051~20009234:-
HNSC	cis	rs11098499	1	rs11098499	ENSG00000250412.1	KLHL2P1	4.31	1.99e-05	0.00357	0.25	0.2	Corneal astigmatism;	chr4:119266456	chr4:119334329~119378233:+
HNSC	cis	rs1799949	1	rs8176083	ENSG00000236383.6	LINC00854	-4.31	1.99e-05	0.00357	-0.19	-0.2	Menopause (age at onset);	chr17:43123134	chr17:43216941~43305976:-
HNSC	cis	rs2933343	0.621	rs4927921	ENSG00000261159.1	RP11-723O4.9	-4.31	1.99e-05	0.00357	-0.2	-0.2	IgG glycosylation;	chr3:128850025	chr3:128859716~128860526:-
HNSC	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-4.31	1.99e-05	0.00357	-0.24	-0.2	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
HNSC	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	4.31	1.99e-05	0.00357	0.37	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
HNSC	cis	rs7824557	0.527	rs4634600	ENSG00000255310.2	AF131215.2	-4.31	1.99e-05	0.00357	-0.18	-0.2	Retinal vascular caliber;	chr8:11381508	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.527	rs4631425	ENSG00000255310.2	AF131215.2	-4.31	1.99e-05	0.00357	-0.18	-0.2	Retinal vascular caliber;	chr8:11381545	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.585	rs4549730	ENSG00000255310.2	AF131215.2	-4.31	1.99e-05	0.00357	-0.18	-0.2	Neuroticism;	chr8:11381569	chr8:11107788~11109726:-
HNSC	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.31	1.99e-05	0.00357	0.22	0.2	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
HNSC	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-4.31	1.99e-05	0.00357	-0.3	-0.2	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
HNSC	cis	rs853679	0.556	rs13197633	ENSG00000219392.1	RP1-265C24.5	-4.31	1.99e-05	0.00357	-0.42	-0.2	Depression;	chr6:28206979	chr6:28115628~28116551:+
HNSC	cis	rs10462794	0.756	rs896133	ENSG00000260763.1	RP11-445O3.3	4.31	1.99e-05	0.00357	0.25	0.2	DNA methylation (variation);	chr5:4511476	chr5:4436850~4440259:-
HNSC	cis	rs60617249	0.772	rs11536638	ENSG00000228204.2	RP4-724E13.2	4.31	1.99e-05	0.00357	0.21	0.2	Major depression and alcohol dependence;	chr7:50893606	chr7:50866747~51022990:+
HNSC	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	4.31	1.99e-05	0.00357	0.23	0.2	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
HNSC	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	4.31	1.99e-05	0.00358	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
HNSC	cis	rs2467099	0.786	rs1463486	ENSG00000267801.1	RP11-552F3.9	4.31	1.99e-05	0.00358	0.25	0.2	Systolic blood pressure;	chr17:75947861	chr17:75876372~75879546:+
HNSC	cis	rs11992162	0.56	rs7846248	ENSG00000227888.4	FAM66A	4.31	1.99e-05	0.00358	0.2	0.2	Monocyte count;	chr8:11936540	chr8:12362019~12388296:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000241278.1	ENPP7P4	-4.31	1.99e-05	0.00358	-0.29	-0.2	Blood pressure (smoking interaction);	chr3:125913841	chr3:125848223~125909372:+
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000219891.2	ZSCAN12P1	4.31	1.99e-05	0.00358	0.32	0.2	Depression;	chr6:28235522	chr6:28091154~28093664:+
HNSC	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-4.31	1.99e-05	0.00358	-0.26	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
HNSC	cis	rs911555	0.504	rs8006526	ENSG00000270108.1	RP11-73M18.6	4.31	1.99e-05	0.00358	0.22	0.2	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103687576~103688127:+
HNSC	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-4.31	1.99e-05	0.00358	-0.21	-0.2	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
HNSC	cis	rs17345786	0.906	rs72944107	ENSG00000244119.1	PDCL3P4	4.31	2e-05	0.00358	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101712472~101713191:+
HNSC	cis	rs467650	0.509	rs29768	ENSG00000246763.5	RGMB-AS1	4.31	2e-05	0.00358	0.22	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98645743	chr5:98769618~98773469:-
HNSC	cis	rs858239	0.511	rs10256996	ENSG00000226816.2	AC005082.12	-4.31	2e-05	0.00358	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23206013~23208045:+
HNSC	cis	rs795484	0.856	rs1699160	ENSG00000275409.1	RP11-131L12.4	-4.31	2e-05	0.00358	-0.23	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118318531	chr12:118430147~118430699:+
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000219891.2	ZSCAN12P1	4.31	2e-05	0.00358	0.28	0.2	Parkinson's disease;	chr6:28053997	chr6:28091154~28093664:+
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	4.31	2e-05	0.00358	0.22	0.2	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
HNSC	cis	rs10129255	1	rs9324091	ENSG00000211974.3	IGHV2-70	4.31	2e-05	0.00359	0.18	0.2	Kawasaki disease;	chr14:106676625	chr14:106723574~106724093:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000211974.3	IGHV2-70	4.31	2e-05	0.00359	0.18	0.2	Kawasaki disease;	chr14:106678368	chr14:106723574~106724093:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000211974.3	IGHV2-70	4.31	2e-05	0.00359	0.18	0.2	Kawasaki disease;	chr14:106678854	chr14:106723574~106724093:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000211974.3	IGHV2-70	4.31	2e-05	0.00359	0.18	0.2	Kawasaki disease;	chr14:106678896	chr14:106723574~106724093:-
HNSC	cis	rs6095360	1	rs1538482	ENSG00000222365.1	SNORD12B	-4.31	2e-05	0.00359	-0.21	-0.2	Intelligence (multi-trait analysis);	chr20:49088959	chr20:49280319~49280409:+
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	4.31	2e-05	0.00359	0.18	0.2	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
HNSC	cis	rs4789693	0.679	rs7217570	ENSG00000265458.1	RP13-20L14.6	-4.31	2e-05	0.00359	-0.26	-0.2	Glucocorticoid-induced osteonecrosis;	chr17:82421456	chr17:82454273~82458521:-
HNSC	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	4.31	2e-05	0.00359	0.18	0.2	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
HNSC	cis	rs721917	0.569	rs2247820	ENSG00000244733.5	RP11-506M13.3	-4.31	2e-05	0.00359	-0.23	-0.2	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79660891~79677996:+
HNSC	cis	rs964611	0.882	rs60899194	ENSG00000259488.2	RP11-154J22.1	-4.31	2e-05	0.00359	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48290763	chr15:48312353~48331856:-
HNSC	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-4.31	2e-05	0.00359	-0.19	-0.2	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
HNSC	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	4.31	2e-05	0.00359	0.23	0.2	Height;	chr14:75124119	chr14:75011269~75012851:-
HNSC	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-4.31	2e-05	0.00359	-0.2	-0.2	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
HNSC	cis	rs354225	0.532	rs354211	ENSG00000237887.1	AC092839.1	-4.31	2e-05	0.00359	-0.23	-0.2	Schizophrenia;	chr2:54705379	chr2:54529343~54529801:+
HNSC	cis	rs1185460	0.967	rs1784461	ENSG00000272186.1	RP11-110I1.13	-4.31	2e-05	0.00359	-0.22	-0.2	Coronary artery disease;	chr11:119067274	chr11:119067374~119067698:-
HNSC	cis	rs60617249	0.735	rs6976357	ENSG00000228204.2	RP4-724E13.2	4.31	2e-05	0.00359	0.21	0.2	Major depression and alcohol dependence;	chr7:50898140	chr7:50866747~51022990:+
HNSC	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-4.31	2e-05	0.00359	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
HNSC	cis	rs9880211	0.948	rs1604793	ENSG00000273486.1	RP11-731C17.2	4.31	2e-05	0.00359	0.19	0.2	Height;Body mass index;	chr3:136462228	chr3:136837338~136839021:-
HNSC	cis	rs10791097	0.72	rs6590518	ENSG00000254842.5	RP11-890B15.2	-4.31	2e-05	0.00359	-0.17	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863635	chr11:130844191~130865561:-
HNSC	cis	rs2412819	0.545	rs35333173	ENSG00000166763.7	STRCP1	4.31	2e-05	0.00359	0.28	0.2	Lung cancer;	chr15:43640818	chr15:43699488~43718184:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000255495.1	AC145124.2	4.31	2e-05	0.00359	0.22	0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:12194467~12196280:+
HNSC	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	4.31	2e-05	0.00359	0.24	0.2	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
HNSC	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-4.31	2e-05	0.0036	-0.29	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
HNSC	cis	rs7829975	0.742	rs1533059	ENSG00000254153.1	CTA-398F10.2	-4.31	2.01e-05	0.0036	-0.21	-0.2	Mood instability;	chr8:8827443	chr8:8456909~8461337:-
HNSC	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	4.31	2.01e-05	0.0036	0.19	0.2	Height;	chr5:37490184	chr5:36666214~36725195:-
HNSC	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	4.31	2.01e-05	0.0036	0.26	0.2	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
HNSC	cis	rs7100689	0.58	rs7083519	ENSG00000226659.1	RP11-137H2.4	-4.31	2.01e-05	0.0036	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80447768	chr10:80529597~80535942:-
HNSC	cis	rs7100689	0.58	rs10736366	ENSG00000226659.1	RP11-137H2.4	-4.31	2.01e-05	0.0036	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80448165	chr10:80529597~80535942:-
HNSC	cis	rs7100689	0.58	rs2168721	ENSG00000226659.1	RP11-137H2.4	-4.31	2.01e-05	0.0036	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80448436	chr10:80529597~80535942:-
HNSC	cis	rs9880211	1	rs17364492	ENSG00000273486.1	RP11-731C17.2	-4.31	2.01e-05	0.0036	-0.18	-0.2	Height;Body mass index;	chr3:136485595	chr3:136837338~136839021:-
HNSC	cis	rs2602836	0.83	rs2602874	ENSG00000263923.1	RP11-571L19.7	-4.31	2.01e-05	0.0036	-0.19	-0.2	HDL cholesterol;HDL cholesterol levels;	chr4:99118245	chr4:98928897~98994994:+
HNSC	cis	rs10495285	0.929	rs6675090	ENSG00000213028.3	RP11-108F13.2	-4.31	2.01e-05	0.0036	-0.23	-0.2	Response to cytadine analogues (cytosine arabinoside);	chr1:229671284	chr1:229688999~229689904:-
HNSC	cis	rs3811273	1	rs10872997	ENSG00000211816.2	TRAV38-1	-4.31	2.01e-05	0.0036	-0.28	-0.2	Periodontal disease-related phenotypes;	chr14:22255085	chr14:22271968~22272563:+
HNSC	cis	rs3758785	0.597	rs615465	ENSG00000255893.1	RP11-685N10.1	4.31	2.01e-05	0.0036	0.23	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94353088	chr11:94472908~94473570:-
HNSC	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	4.31	2.01e-05	0.0036	0.26	0.2	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
HNSC	cis	rs9329221	0.506	rs6993610	ENSG00000255020.1	AF131216.5	-4.31	2.01e-05	0.0036	-0.22	-0.2	Neuroticism;	chr8:10473484	chr8:11345748~11347502:-
HNSC	cis	rs3733585	0.605	rs4697926	ENSG00000250413.1	RP11-448G15.1	-4.31	2.01e-05	0.0036	-0.25	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10122943	chr4:10006482~10009725:+
HNSC	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	4.31	2.01e-05	0.0036	0.27	0.2	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
HNSC	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.0036	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
HNSC	cis	rs3808502	0.526	rs11985709	ENSG00000269918.1	AF131215.9	-4.31	2.01e-05	0.0036	-0.19	-0.2	Neuroticism;	chr8:11565574	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.31	2.01e-05	0.00361	0.2	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
HNSC	cis	rs4947019	0.609	rs9487074	ENSG00000260273.1	RP11-425D10.10	4.31	2.01e-05	0.00361	0.53	0.2	Hematological parameters;	chr6:109368478	chr6:109382795~109383666:+
HNSC	cis	rs2439831	0.85	rs16965120	ENSG00000275601.1	AC011330.13	-4.31	2.01e-05	0.00361	-0.32	-0.2	Lung cancer in ever smokers;	chr15:43808144	chr15:43642389~43643023:-
HNSC	cis	rs7429990	0.965	rs62260764	ENSG00000228638.1	FCF1P2	-4.31	2.01e-05	0.00361	-0.21	-0.2	Educational attainment (years of education);	chr3:47949010	chr3:48290793~48291375:-
HNSC	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-4.31	2.01e-05	0.00361	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
HNSC	cis	rs5758511	0.514	rs1989375	ENSG00000205702.9	CYP2D7	4.31	2.01e-05	0.00361	0.17	0.2	Birth weight;	chr22:42177133	chr22:42140203~42144577:-
HNSC	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	4.31	2.01e-05	0.00361	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	4.31	2.01e-05	0.00361	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
HNSC	cis	rs964611	0.882	rs67904691	ENSG00000259488.2	RP11-154J22.1	-4.31	2.01e-05	0.00361	-0.18	-0.2	Metabolite levels (Pyroglutamine);	chr15:48295386	chr15:48312353~48331856:-
HNSC	cis	rs739496	0.579	rs12319315	ENSG00000226469.1	ADAM1B	4.31	2.01e-05	0.00361	0.23	0.2	Platelet count;	chr12:111903215	chr12:111927018~111929017:+
HNSC	cis	rs35306767	0.951	rs61833265	ENSG00000229869.1	RP11-363N22.2	-4.31	2.01e-05	0.00361	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:944203	chr10:933026~942743:+
HNSC	cis	rs780096	0.56	rs4665972	ENSG00000234072.1	AC074117.10	-4.31	2.02e-05	0.00361	-0.17	-0.2	Total body bone mineral density;	chr2:27375230	chr2:27356246~27367622:+
HNSC	cis	rs1930961	0.558	rs12160908	ENSG00000272977.1	CTA-390C10.10	-4.31	2.02e-05	0.00361	-0.32	-0.2	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25476218~25479971:+
HNSC	cis	rs35306767	0.903	rs11253495	ENSG00000229869.1	RP11-363N22.2	-4.31	2.02e-05	0.00361	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:891124	chr10:933026~942743:+
HNSC	cis	rs13043901	0.904	rs2766667	ENSG00000197670.6	RP4-724E16.2	-4.31	2.02e-05	0.00361	-0.19	-0.2	Type 2 diabetes (age of onset);	chr20:53555865	chr20:53552770~53575863:+
HNSC	cis	rs8028182	0.636	rs11634863	ENSG00000260269.4	CTD-2323K18.1	-4.31	2.02e-05	0.00361	-0.25	-0.2	Sudden cardiac arrest;	chr15:75474331	chr15:75527150~75601205:-
HNSC	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-4.31	2.02e-05	0.00361	-0.21	-0.2	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
HNSC	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-4.31	2.02e-05	0.00361	-0.27	-0.2	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
HNSC	cis	rs72627509	0.68	rs56162812	ENSG00000269949.1	RP11-738E22.3	4.31	2.02e-05	0.00361	0.31	0.2	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874501	chr4:56960927~56961373:-
HNSC	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	4.31	2.02e-05	0.00361	0.28	0.2	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
HNSC	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	4.31	2.02e-05	0.00362	0.34	0.2	QT interval;	chr4:75134108	chr4:75081702~75084717:-
HNSC	cis	rs638893	0.636	rs2186781	ENSG00000255422.1	AP002954.4	-4.31	2.02e-05	0.00362	-0.33	-0.2	Vitiligo;	chr11:118734738	chr11:118704607~118750263:+
HNSC	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	4.31	2.02e-05	0.00362	0.26	0.2	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
HNSC	cis	rs35306767	0.903	rs12264711	ENSG00000229869.1	RP11-363N22.2	-4.31	2.02e-05	0.00362	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:883585	chr10:933026~942743:+
HNSC	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-4.31	2.02e-05	0.00362	-0.23	-0.2	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
HNSC	cis	rs1008375	0.835	rs9760627	ENSG00000249502.1	AC006160.5	-4.31	2.02e-05	0.00362	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649885	chr4:17587467~17614571:-
HNSC	cis	rs11098499	0.863	rs3775841	ENSG00000250412.1	KLHL2P1	4.31	2.02e-05	0.00362	0.25	0.2	Corneal astigmatism;	chr4:119504622	chr4:119334329~119378233:+
HNSC	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-4.31	2.02e-05	0.00362	-0.21	-0.2	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
HNSC	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	4.31	2.02e-05	0.00362	0.27	0.2	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
HNSC	cis	rs2548724	1	rs2548724	ENSG00000250682.4	LINC00491	-4.31	2.02e-05	0.00362	-0.28	-0.2	Type 2 diabetes;	chr5:102284470	chr5:102609156~102671559:-
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000280107.1	AL022393.9	-4.31	2.02e-05	0.00362	-0.23	-0.2	Depression;	chr6:28206812	chr6:28170845~28172521:+
HNSC	cis	rs427691	0.536	rs25916	ENSG00000271849.1	CTC-332L22.1	-4.31	2.02e-05	0.00362	-0.29	-0.2	Autism spectrum disorder or schizophrenia;	chr5:109656764	chr5:109687802~109688329:-
HNSC	cis	rs9903692	0.954	rs9899461	ENSG00000263412.1	RP5-890E16.2	4.31	2.02e-05	0.00362	0.19	0.2	Pulse pressure;	chr17:48051991	chr17:48045141~48048073:-
HNSC	cis	rs7615952	0.515	rs7630575	ENSG00000248787.1	RP11-666A20.4	-4.31	2.02e-05	0.00362	-0.27	-0.2	Blood pressure (smoking interaction);	chr3:125963487	chr3:125908005~125910272:-
HNSC	cis	rs12745968	0.589	rs7417452	ENSG00000223787.2	RP4-593M8.1	-4.31	2.02e-05	0.00362	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr1:92566496	chr1:92580476~92580821:-
HNSC	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-4.31	2.02e-05	0.00362	-0.2	-0.2	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
HNSC	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	4.31	2.02e-05	0.00363	0.19	0.2	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
HNSC	cis	rs35963943	0.625	rs4414873	ENSG00000228956.7	SATB1-AS1	4.31	2.02e-05	0.00363	0.23	0.2	Lymphocyte counts;	chr3:18708283	chr3:18445024~18920401:+
HNSC	cis	rs4862750	0.872	rs1991254	ENSG00000250971.1	RP11-696F12.1	4.31	2.03e-05	0.00363	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186954221	chr4:187060099~187060930:+
HNSC	cis	rs7735319	0.966	rs1842248	ENSG00000249102.1	CTD-2066L21.1	4.31	2.03e-05	0.00363	0.22	0.2	Systolic blood pressure;	chr5:33165734	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs2101014	ENSG00000249102.1	CTD-2066L21.1	4.31	2.03e-05	0.00363	0.22	0.2	Systolic blood pressure;	chr5:33166307	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs62368018	ENSG00000249102.1	CTD-2066L21.1	4.31	2.03e-05	0.00363	0.22	0.2	Systolic blood pressure;	chr5:33167320	chr5:33008994~33025724:+
HNSC	cis	rs11157436	0.602	rs1894369	ENSG00000211812.1	TRAV26-2	4.31	2.03e-05	0.00363	0.18	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22202583~22203368:+
HNSC	cis	rs6490294	0.904	rs1016078	ENSG00000226469.1	ADAM1B	4.31	2.03e-05	0.00363	0.22	0.2	Mean platelet volume;	chr12:111972273	chr12:111927018~111929017:+
HNSC	cis	rs4787484	1	rs12930239	ENSG00000196796.5	CTB-134H23.2	4.31	2.03e-05	0.00363	0.22	0.2	Response to taxane treatment (placlitaxel);	chr16:29897456	chr16:29038655~29052726:+
HNSC	cis	rs78579285	0.589	rs113010486	ENSG00000278341.1	RP5-1142A6.10	-4.31	2.03e-05	0.00363	-0.35	-0.2	Joint mobility (Beighton score);	chr16:88731990	chr16:88708956~88710437:-
HNSC	cis	rs7572733	0.935	rs10048735	ENSG00000222017.1	AC011997.1	4.31	2.03e-05	0.00363	0.23	0.2	Dermatomyositis;	chr2:197877801	chr2:197693106~197774823:+
HNSC	cis	rs6500395	0.962	rs17826468	ENSG00000261267.1	RP11-44I10.3	-4.31	2.03e-05	0.00363	-0.25	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48534360	chr16:48559661~48587403:+
HNSC	cis	rs1218582	0.711	rs4845677	ENSG00000270361.1	RP11-307C12.13	-4.31	2.03e-05	0.00363	-0.22	-0.2	Prostate cancer;	chr1:154865574	chr1:154937370~154938059:+
HNSC	cis	rs7829975	0.811	rs7011229	ENSG00000254153.1	CTA-398F10.2	-4.31	2.03e-05	0.00363	-0.22	-0.2	Mood instability;	chr8:8685814	chr8:8456909~8461337:-
HNSC	cis	rs4356203	0.87	rs7937176	ENSG00000272034.1	SNORD14A	-4.31	2.03e-05	0.00363	-0.15	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17074654~17074744:-
HNSC	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	4.31	2.03e-05	0.00364	0.22	0.2	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
HNSC	cis	rs7572733	0.84	rs2341510	ENSG00000222017.1	AC011997.1	-4.31	2.03e-05	0.00364	-0.24	-0.2	Dermatomyositis;	chr2:197693955	chr2:197693106~197774823:+
HNSC	cis	rs11773103	0.881	rs56404754	ENSG00000224046.1	AC005076.5	4.31	2.03e-05	0.00364	0.29	0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87137693	chr7:87151423~87152420:-
HNSC	cis	rs4843747	0.671	rs9933794	ENSG00000260750.4	RP11-482M8.1	4.31	2.03e-05	0.00364	0.24	0.2	Menopause (age at onset);	chr16:88083375	chr16:87492555~87515635:+
HNSC	cis	rs2136613	0.728	rs10822065	ENSG00000238280.1	RP11-436D10.3	-4.31	2.03e-05	0.00364	-0.23	-0.2	Selective IgA deficiency;	chr10:62851172	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.728	rs4141618	ENSG00000238280.1	RP11-436D10.3	-4.31	2.03e-05	0.00364	-0.23	-0.2	Selective IgA deficiency;	chr10:62854449	chr10:62793562~62805887:-
HNSC	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-4.31	2.03e-05	0.00364	-0.23	-0.2	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
HNSC	cis	rs9926296	0.682	rs258328	ENSG00000274627.1	RP11-104N10.2	4.31	2.03e-05	0.00364	0.19	0.2	Vitiligo;	chr16:89663906	chr16:89516797~89522217:+
HNSC	cis	rs2657294	0.62	rs7475340	ENSG00000233313.2	HMGA1P5	-4.31	2.03e-05	0.00364	-0.21	-0.2	Pneumonia;	chr10:75079597	chr10:75276376~75276646:-
HNSC	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	4.31	2.03e-05	0.00364	0.21	0.2	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
HNSC	cis	rs2904524	1	rs77397439	ENSG00000257815.4	RP11-611E13.2	-4.31	2.03e-05	0.00364	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70313566	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs58828627	ENSG00000257815.4	RP11-611E13.2	-4.31	2.03e-05	0.00364	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70317513	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs1404124	ENSG00000257815.4	RP11-611E13.2	-4.31	2.03e-05	0.00364	-0.25	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70319519	chr12:69904033~70243360:-
HNSC	cis	rs4927850	1	rs7627868	ENSG00000226155.1	AC124944.3	-4.31	2.03e-05	0.00364	-0.24	-0.2	Pancreatic cancer;	chr3:196026602	chr3:195912049~195913986:+
HNSC	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-4.31	2.03e-05	0.00364	-0.21	-0.2	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-4.31	2.03e-05	0.00364	-0.21	-0.2	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-4.31	2.03e-05	0.00364	-0.21	-0.2	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
HNSC	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	4.31	2.03e-05	0.00364	0.19	0.2	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
HNSC	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	4.31	2.03e-05	0.00364	0.25	0.2	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
HNSC	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	4.31	2.03e-05	0.00364	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
HNSC	cis	rs6504108	0.577	rs2109982	ENSG00000278765.1	RP5-890E16.5	-4.31	2.03e-05	0.00364	-0.24	-0.2	Body mass index;	chr17:48167407	chr17:48066704~48067293:-
HNSC	cis	rs7615952	0.599	rs6779141	ENSG00000241439.1	RP11-666A20.3	4.31	2.03e-05	0.00364	0.22	0.2	Blood pressure (smoking interaction);	chr3:125991152	chr3:125958556~125958817:+
HNSC	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	4.31	2.03e-05	0.00364	0.23	0.2	Height;	chr14:75087658	chr14:75011269~75012851:-
HNSC	cis	rs7824557	0.67	rs2736381	ENSG00000255310.2	AF131215.2	-4.31	2.04e-05	0.00364	-0.19	-0.2	Retinal vascular caliber;	chr8:11275257	chr8:11107788~11109726:-
HNSC	cis	rs4356203	0.905	rs2052188	ENSG00000272034.1	SNORD14A	4.31	2.04e-05	0.00364	0.15	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17074654~17074744:-
HNSC	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	4.31	2.04e-05	0.00364	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
HNSC	cis	rs9880211	0.948	rs9844666	ENSG00000273486.1	RP11-731C17.2	4.3	2.04e-05	0.00364	0.19	0.2	Height;Body mass index;	chr3:136255374	chr3:136837338~136839021:-
HNSC	cis	rs12655019	0.92	rs7731829	ENSG00000271828.1	CTD-2310F14.1	4.3	2.04e-05	0.00365	0.42	0.2	Breast cancer (early onset);	chr5:56911884	chr5:56927874~56929573:+
HNSC	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	4.3	2.04e-05	0.00365	0.42	0.2	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
HNSC	cis	rs7005380	0.556	rs6996081	ENSG00000279347.1	RP11-85I17.2	-4.3	2.04e-05	0.00365	-0.19	-0.2	Interstitial lung disease;	chr8:119934865	chr8:119838736~119840385:-
HNSC	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.3	2.04e-05	0.00365	-0.21	-0.2	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
HNSC	cis	rs172166	0.561	rs149976	ENSG00000219392.1	RP1-265C24.5	4.3	2.04e-05	0.00365	0.22	0.2	Cardiac Troponin-T levels;	chr6:28019998	chr6:28115628~28116551:+
HNSC	cis	rs2980439	0.783	rs2955587	ENSG00000233609.3	RP11-62H7.2	4.3	2.04e-05	0.00365	0.19	0.2	Neuroticism;	chr8:8240557	chr8:8961200~8979025:+
HNSC	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-4.3	2.04e-05	0.00365	-0.22	-0.2	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
HNSC	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-4.3	2.04e-05	0.00365	-0.22	-0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
HNSC	cis	rs8044868	0.53	rs12918956	ENSG00000259209.3	RP5-991G20.2	-4.3	2.04e-05	0.00365	-0.2	-0.2	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72190436	chr16:72805998~72809872:+
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000254340.1	RP11-10A14.3	4.3	2.04e-05	0.00365	0.24	0.2	Mood instability;	chr8:8482967	chr8:9141424~9145435:+
HNSC	cis	rs4787491	0.729	rs3814878	ENSG00000183604.13	SMG1P5	-4.3	2.04e-05	0.00365	-0.19	-0.2	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30267553~30335374:-
HNSC	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	4.3	2.04e-05	0.00365	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
HNSC	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	4.3	2.04e-05	0.00365	0.19	0.2	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
HNSC	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-4.3	2.04e-05	0.00365	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
HNSC	cis	rs62027291	0.95	rs62027293	ENSG00000259422.1	RP11-593F23.1	-4.3	2.04e-05	0.00365	-0.3	-0.2	Plateletcrit;	chr15:76977577	chr15:76174891~76181486:-
HNSC	cis	rs16858210	0.874	rs73177525	ENSG00000234371.6	RPSAP31	4.3	2.04e-05	0.00365	0.23	0.2	Menopause (age at onset);	chr3:183852498	chr3:183884924~183888449:+
HNSC	cis	rs6479901	0.548	rs10995441	ENSG00000232075.1	MRPL35P2	-4.3	2.04e-05	0.00366	-0.28	-0.2	Intelligence (multi-trait analysis);	chr10:63109479	chr10:63634317~63634827:-
HNSC	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-4.3	2.04e-05	0.00366	-0.21	-0.2	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
HNSC	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-4.3	2.04e-05	0.00366	-0.24	-0.2	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000211976.2	IGHV3-73	-4.3	2.05e-05	0.00366	-0.14	-0.2	Kawasaki disease;	chr14:106768275	chr14:106802694~106803233:-
HNSC	cis	rs3015497	0.631	rs17718908	ENSG00000269906.1	RP11-248J18.2	4.3	2.05e-05	0.00366	0.26	0.2	Mean platelet volume;	chr14:50538495	chr14:50662511~50663178:-
HNSC	cis	rs2361718	0.521	rs2361724	ENSG00000275479.1	RP11-334C17.6	4.3	2.05e-05	0.00366	0.22	0.2	Yeast infection;	chr17:80125315	chr17:80149627~80149798:+
HNSC	cis	rs6500395	1	rs7191028	ENSG00000261267.1	RP11-44I10.3	-4.3	2.05e-05	0.00366	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48592112	chr16:48559661~48587403:+
HNSC	cis	rs3764021	1	rs3764021	ENSG00000256975.1	RP11-525E9.1	4.3	2.05e-05	0.00366	0.24	0.2	Type 1 diabetes;	chr12:9681032	chr12:9506347~9508440:-
HNSC	cis	rs2518049	1	rs2518047	ENSG00000224034.1	RP11-445P17.8	4.3	2.05e-05	0.00367	0.26	0.2	Metabolic traits;	chr10:5094168	chr10:5266033~5271236:-
HNSC	cis	rs4930561	0.714	rs7950451	ENSG00000184795.9	UNC93B5	-4.3	2.05e-05	0.00367	-0.22	-0.2	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr11:67711702~67716005:-
HNSC	cis	rs4930561	0.714	rs7950452	ENSG00000184795.9	UNC93B5	-4.3	2.05e-05	0.00367	-0.22	-0.2	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr11:67711702~67716005:-
HNSC	cis	rs35963943	0.625	rs12107647	ENSG00000228956.7	SATB1-AS1	4.3	2.05e-05	0.00367	0.23	0.2	Lymphocyte counts;	chr3:18670285	chr3:18445024~18920401:+
HNSC	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-4.3	2.05e-05	0.00367	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
HNSC	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	4.3	2.05e-05	0.00367	0.21	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
HNSC	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	4.3	2.05e-05	0.00367	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
HNSC	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	4.3	2.05e-05	0.00367	0.22	0.2	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
HNSC	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-4.3	2.05e-05	0.00367	-0.25	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
HNSC	cis	rs9311676	0.632	rs11130646	ENSG00000273493.1	RP11-80H18.4	4.3	2.05e-05	0.00367	0.21	0.2	Systemic lupus erythematosus;	chr3:58461286	chr3:58329965~58330118:+
HNSC	cis	rs1223397	0.938	rs13205692	ENSG00000215022.6	RP1-257A7.4	-4.3	2.05e-05	0.00367	-0.26	-0.2	Blood pressure;	chr6:13291328	chr6:13264861~13295586:-
HNSC	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.3	2.05e-05	0.00367	-0.21	-0.2	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.3	2.05e-05	0.00367	-0.21	-0.2	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
HNSC	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	4.3	2.05e-05	0.00367	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	4.3	2.05e-05	0.00367	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-4.3	2.05e-05	0.00367	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-4.3	2.05e-05	0.00367	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
HNSC	cis	rs35306767	0.903	rs4522091	ENSG00000229869.1	RP11-363N22.2	-4.3	2.05e-05	0.00367	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:828176	chr10:933026~942743:+
HNSC	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.3	2.05e-05	0.00367	-0.21	-0.2	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.3	2.05e-05	0.00367	-0.21	-0.2	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
HNSC	cis	rs9467773	0.566	rs66972160	ENSG00000241549.7	GUSBP2	4.3	2.05e-05	0.00367	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26359078	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.526	rs9348710	ENSG00000241549.7	GUSBP2	4.3	2.05e-05	0.00367	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26360258	chr6:26871484~26956554:-
HNSC	cis	rs35306767	1	rs35306767	ENSG00000229869.1	RP11-363N22.2	-4.3	2.05e-05	0.00367	-0.29	-0.2	Eosinophil percentage of granulocytes;	chr10:943497	chr10:933026~942743:+
HNSC	cis	rs73198271	0.603	rs557892	ENSG00000253893.2	FAM85B	4.3	2.05e-05	0.00367	0.26	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738538	chr8:8167819~8226614:-
HNSC	cis	rs7005380	0.531	rs7018038	ENSG00000279347.1	RP11-85I17.2	4.3	2.05e-05	0.00367	0.18	0.2	Interstitial lung disease;	chr8:119922664	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs6469876	ENSG00000279347.1	RP11-85I17.2	4.3	2.05e-05	0.00367	0.18	0.2	Interstitial lung disease;	chr8:119923011	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs4871786	ENSG00000279347.1	RP11-85I17.2	4.3	2.05e-05	0.00367	0.18	0.2	Interstitial lung disease;	chr8:119924171	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs9987142	ENSG00000279347.1	RP11-85I17.2	4.3	2.05e-05	0.00367	0.18	0.2	Interstitial lung disease;	chr8:119924781	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs9297607	ENSG00000279347.1	RP11-85I17.2	4.3	2.05e-05	0.00367	0.18	0.2	Interstitial lung disease;	chr8:119924831	chr8:119838736~119840385:-
HNSC	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-4.3	2.06e-05	0.00367	-0.16	-0.2	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
HNSC	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-4.3	2.06e-05	0.00367	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
HNSC	cis	rs4853525	0.859	rs1882396	ENSG00000228509.4	AC006460.2	4.3	2.06e-05	0.00368	0.24	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851286	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.859	rs1894775	ENSG00000228509.4	AC006460.2	4.3	2.06e-05	0.00368	0.24	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851980	chr2:190676944~190708716:-
HNSC	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-4.3	2.06e-05	0.00368	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
HNSC	cis	rs2361718	0.5	rs8068856	ENSG00000275479.1	RP11-334C17.6	4.3	2.06e-05	0.00368	0.22	0.2	Yeast infection;	chr17:80126932	chr17:80149627~80149798:+
HNSC	cis	rs7701440	0.512	rs7443733	ENSG00000215032.2	GNL3LP1	4.3	2.06e-05	0.00368	0.22	0.2	Educational attainment;	chr5:61238155	chr5:60891935~60893577:-
HNSC	cis	rs442309	0.871	rs224043	ENSG00000238280.1	RP11-436D10.3	-4.3	2.06e-05	0.00368	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62765232	chr10:62793562~62805887:-
HNSC	cis	rs3736485	0.844	rs4774591	ENSG00000259438.1	CTD-2650P22.1	4.3	2.06e-05	0.00368	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51477988	chr15:52010999~52019095:-
HNSC	cis	rs1799949	0.93	rs3092987	ENSG00000236383.6	LINC00854	-4.3	2.06e-05	0.00368	-0.18	-0.2	Menopause (age at onset);	chr17:43070706	chr17:43216941~43305976:-
HNSC	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	4.3	2.06e-05	0.00368	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
HNSC	cis	rs1642645	0.872	rs238675	ENSG00000228452.1	RP5-994D16.9	-4.3	2.06e-05	0.00368	-0.27	-0.2	Left ventricular obstructive tract defect (maternal effect);	chr1:42004603	chr1:42775813~42776790:-
HNSC	cis	rs12478296	1	rs57603292	ENSG00000261186.2	RP11-341N2.1	-4.3	2.06e-05	0.00368	-0.34	-0.2	Obesity-related traits;	chr2:242086386	chr2:242087351~242088457:-
HNSC	cis	rs3015497	0.603	rs3015455	ENSG00000269906.1	RP11-248J18.2	-4.3	2.06e-05	0.00368	-0.27	-0.2	Mean platelet volume;	chr14:50595444	chr14:50662511~50663178:-
HNSC	cis	rs6601327	0.585	rs1394	ENSG00000233609.3	RP11-62H7.2	-4.3	2.06e-05	0.00369	-0.18	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9654144	chr8:8961200~8979025:+
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000254174.1	IGHV1-12	-4.3	2.06e-05	0.00369	-0.16	-0.2	Rheumatic heart disease;	chr14:106630317	chr14:106122420~106122709:-
HNSC	cis	rs6601327	0.575	rs6994574	ENSG00000254340.1	RP11-10A14.3	-4.3	2.06e-05	0.00369	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9720745	chr8:9141424~9145435:+
HNSC	cis	rs2412819	0.571	rs8038068	ENSG00000166763.7	STRCP1	4.3	2.06e-05	0.00369	0.29	0.2	Lung cancer;	chr15:43622175	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs56246169	ENSG00000166763.7	STRCP1	4.3	2.06e-05	0.00369	0.29	0.2	Lung cancer;	chr15:43628358	chr15:43699488~43718184:-
HNSC	cis	rs9807989	0.839	rs1362348	ENSG00000234389.1	AC007278.3	4.3	2.06e-05	0.00369	0.19	0.2	Asthma;	chr2:102368164	chr2:102438713~102440475:+
HNSC	cis	rs8077577	1	rs8077577	ENSG00000273018.4	CTD-2303H24.2	-4.3	2.06e-05	0.00369	-0.29	-0.2	Obesity-related traits;	chr17:18161416	chr17:18511221~18551705:-
HNSC	cis	rs13434995	0.513	rs6802	ENSG00000273257.1	RP11-177J6.1	-4.3	2.07e-05	0.00369	-0.27	-0.2	Adiponectin levels;	chr4:55425934	chr4:55387949~55388271:+
HNSC	cis	rs929354	0.742	rs10251112	ENSG00000224629.1	RP5-1142J19.2	-4.3	2.07e-05	0.00369	-0.2	-0.2	Body mass index;	chr7:157170830	chr7:157263022~157263229:-
HNSC	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	4.3	2.07e-05	0.00369	0.23	0.2	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
HNSC	cis	rs1075232	0.522	rs57924788	ENSG00000270055.1	CTD-3092A11.2	-4.3	2.07e-05	0.00369	-0.3	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31457519	chr15:30487963~30490313:+
HNSC	cis	rs970821	0.667	rs2891799	ENSG00000253106.1	RP11-158K1.3	4.3	2.07e-05	0.0037	0.17	0.2	Breast cancer;	chr8:123732420	chr8:124488510~124491643:+
HNSC	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-4.3	2.07e-05	0.0037	-0.39	-0.2	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
HNSC	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	4.3	2.07e-05	0.0037	0.16	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
HNSC	cis	rs7824557	0.602	rs7820895	ENSG00000255495.1	AC145124.2	4.3	2.07e-05	0.0037	0.22	0.2	Retinal vascular caliber;	chr8:11348753	chr8:12194467~12196280:+
HNSC	cis	rs57561814	0.51	rs1524107	ENSG00000179428.2	AC073072.5	-4.3	2.07e-05	0.0037	-0.4	-0.2	Tonsillectomy;	chr7:22728600	chr7:22725395~22727620:-
HNSC	cis	rs17767294	0.611	rs66487884	ENSG00000204709.4	LINC01556	4.3	2.07e-05	0.0037	0.35	0.2	Parkinson's disease;	chr6:28235134	chr6:28943877~28944537:+
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000254340.1	RP11-10A14.3	4.3	2.07e-05	0.0037	0.23	0.2	Neuroticism;	chr8:8461340	chr8:9141424~9145435:+
HNSC	cis	rs7829975	0.593	rs2921051	ENSG00000233609.3	RP11-62H7.2	4.3	2.07e-05	0.0037	0.18	0.2	Mood instability;	chr8:8462594	chr8:8961200~8979025:+
HNSC	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	4.3	2.07e-05	0.0037	0.23	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
HNSC	cis	rs4862750	0.872	rs13110072	ENSG00000250971.1	RP11-696F12.1	4.3	2.07e-05	0.0037	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:187060099~187060930:+
HNSC	cis	rs13434995	0.513	rs62303728	ENSG00000273257.1	RP11-177J6.1	-4.3	2.07e-05	0.0037	-0.27	-0.2	Adiponectin levels;	chr4:55495762	chr4:55387949~55388271:+
HNSC	cis	rs7829975	0.742	rs7832968	ENSG00000233609.3	RP11-62H7.2	4.3	2.07e-05	0.0037	0.19	0.2	Mood instability;	chr8:8795379	chr8:8961200~8979025:+
HNSC	cis	rs6964587	0.839	rs13246743	ENSG00000188693.7	CYP51A1-AS1	-4.3	2.07e-05	0.0037	-0.21	-0.2	Breast cancer;	chr7:91824631	chr7:92134604~92180725:+
HNSC	cis	rs11098499	0.554	rs2175381	ENSG00000249244.1	RP11-548H18.2	4.3	2.07e-05	0.0037	0.24	0.2	Corneal astigmatism;	chr4:119344812	chr4:119391831~119395335:-
HNSC	cis	rs11098499	0.599	rs3864142	ENSG00000249244.1	RP11-548H18.2	4.3	2.07e-05	0.0037	0.24	0.2	Corneal astigmatism;	chr4:119345036	chr4:119391831~119395335:-
HNSC	cis	rs6095360	1	rs2426125	ENSG00000222365.1	SNORD12B	-4.3	2.07e-05	0.0037	-0.21	-0.2	Intelligence (multi-trait analysis);	chr20:49084445	chr20:49280319~49280409:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000211974.3	IGHV2-70	4.3	2.07e-05	0.0037	0.18	0.2	Kawasaki disease;	chr14:106767956	chr14:106723574~106724093:-
HNSC	cis	rs7086627	0.515	rs11202957	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80449836	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs11202959	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80449916	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs11202960	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80450051	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs10887894	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80450196	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs10887895	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80450255	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs11202963	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80450636	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs10887901	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.0037	-0.24	-0.2	Post bronchodilator FEV1;	chr10:80450825	chr10:80529597~80535942:-
HNSC	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-4.3	2.07e-05	0.0037	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
HNSC	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	4.3	2.07e-05	0.0037	0.24	0.2	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000224373.3	IGHV4-59	4.3	2.07e-05	0.0037	0.11	0.2	Kawasaki disease;	chr14:106785926	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000224373.3	IGHV4-59	4.3	2.07e-05	0.0037	0.11	0.2	Kawasaki disease;	chr14:106787090	chr14:106627249~106627825:-
HNSC	cis	rs6500395	1	rs1115758	ENSG00000261267.1	RP11-44I10.3	-4.3	2.07e-05	0.0037	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr16:48565698	chr16:48559661~48587403:+
HNSC	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-4.3	2.07e-05	0.0037	-0.27	-0.2	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
HNSC	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	4.3	2.07e-05	0.0037	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
HNSC	cis	rs36052053	0.808	rs78799897	ENSG00000203799.9	CCDC162P	4.3	2.07e-05	0.0037	0.29	0.2	Red cell distribution width;	chr6:109285941	chr6:109285485~109355063:+
HNSC	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.08e-05	0.00371	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
HNSC	cis	rs6493858	0.839	rs2718915	ENSG00000277245.1	RP11-48G14.3	-4.3	2.08e-05	0.00371	-0.22	-0.2	Relative hand skill in reading disability;	chr15:56236242	chr15:56447120~56447697:+
HNSC	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	4.3	2.08e-05	0.00371	0.23	0.2	Height;	chr14:75079853	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	4.3	2.08e-05	0.00371	0.23	0.2	Height;	chr14:75079880	chr14:75011269~75012851:-
HNSC	cis	rs9650657	0.538	rs11250093	ENSG00000255310.2	AF131215.2	4.3	2.08e-05	0.00371	0.19	0.2	Neuroticism;	chr8:10941318	chr8:11107788~11109726:-
HNSC	cis	rs755249	0.567	rs6668369	ENSG00000182109.6	RP11-69E11.4	4.3	2.08e-05	0.00371	0.22	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.954	rs17006190	ENSG00000250412.1	KLHL2P1	4.3	2.08e-05	0.00371	0.25	0.2	Corneal astigmatism;	chr4:119497683	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs3733519	ENSG00000250412.1	KLHL2P1	4.3	2.08e-05	0.00371	0.25	0.2	Corneal astigmatism;	chr4:119502293	chr4:119334329~119378233:+
HNSC	cis	rs12935418	0.579	rs7197606	ENSG00000278985.1	RP11-303E16.9	4.3	2.08e-05	0.00371	0.19	0.2	Mean corpuscular volume;	chr16:81019914	chr16:80982319~80984094:-
HNSC	cis	rs3758785	0.512	rs75719210	ENSG00000255893.1	RP11-685N10.1	-4.3	2.08e-05	0.00371	-0.3	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368599	chr11:94472908~94473570:-
HNSC	cis	rs12935418	0.672	rs6564814	ENSG00000261061.1	RP11-303E16.2	-4.3	2.08e-05	0.00371	-0.21	-0.2	Mean corpuscular volume;	chr16:81016567	chr16:81030770~81031485:+
HNSC	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	4.3	2.08e-05	0.00371	0.23	0.2	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
HNSC	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	4.3	2.08e-05	0.00372	0.22	0.2	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
HNSC	cis	rs721917	0.607	rs4319455	ENSG00000244733.5	RP11-506M13.3	-4.3	2.08e-05	0.00372	-0.23	-0.2	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79660891~79677996:+
HNSC	cis	rs6001482	0.778	rs1012819	ENSG00000253818.1	IGLV1-41	-4.3	2.08e-05	0.00372	-0.16	-0.2	Diastolic blood pressure;	chr22:22238997	chr22:22404207~22404721:+
HNSC	cis	rs526231	0.543	rs246905	ENSG00000250682.4	LINC00491	4.3	2.08e-05	0.00372	0.25	0.2	Primary biliary cholangitis;	chr5:103255242	chr5:102609156~102671559:-
HNSC	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	4.3	2.09e-05	0.00372	0.17	0.2	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	4.3	2.09e-05	0.00372	0.17	0.2	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
HNSC	cis	rs950169	0.58	rs17532346	ENSG00000229212.6	RP11-561C5.4	-4.3	2.09e-05	0.00372	-0.28	-0.2	Schizophrenia;	chr15:84628264	chr15:85205440~85234795:-
HNSC	cis	rs28489187	0.617	rs7547571	ENSG00000223653.4	RP11-131L23.1	-4.3	2.09e-05	0.00372	-0.26	-0.2	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85418408	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.577	rs6697083	ENSG00000223653.4	RP11-131L23.1	-4.3	2.09e-05	0.00372	-0.26	-0.2	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85422092	chr1:85276715~85448124:+
HNSC	cis	rs889398	0.742	rs12446197	ENSG00000226232.7	RP11-419C5.2	4.3	2.09e-05	0.00372	0.17	0.2	Body mass index;	chr16:69820966	chr16:69976388~69996188:-
HNSC	cis	rs929354	0.772	rs2051876	ENSG00000224629.1	RP5-1142J19.2	4.3	2.09e-05	0.00372	0.19	0.2	Body mass index;	chr7:157216343	chr7:157263022~157263229:-
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000219891.2	ZSCAN12P1	4.3	2.09e-05	0.00372	0.28	0.2	Parkinson's disease;	chr6:28056708	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000219891.2	ZSCAN12P1	4.3	2.09e-05	0.00372	0.28	0.2	Parkinson's disease;	chr6:28056792	chr6:28091154~28093664:+
HNSC	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	4.3	2.09e-05	0.00372	0.16	0.2	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
HNSC	cis	rs116095464	0.558	rs10079760	ENSG00000250848.1	CTD-2083E4.5	-4.3	2.09e-05	0.00372	-0.26	-0.2	Breast cancer;	chr5:230663	chr5:288833~290321:-
HNSC	cis	rs656319	0.629	rs11774276	ENSG00000269918.1	AF131215.9	-4.3	2.09e-05	0.00373	-0.2	-0.2	Myopia (pathological);	chr8:10212799	chr8:11104691~11106704:-
HNSC	cis	rs9863	0.861	rs4765305	ENSG00000270028.1	RP11-380L11.4	4.3	2.09e-05	0.00373	0.22	0.2	White blood cell count;	chr12:123946065	chr12:123925461~123926083:-
HNSC	cis	rs2492286	0.529	rs11918394	ENSG00000242551.2	POU5F1P6	-4.3	2.09e-05	0.00373	-0.22	-0.2	Eosinophil counts;	chr3:128649868	chr3:128674735~128677005:-
HNSC	cis	rs1799949	1	rs8176318	ENSG00000236383.6	LINC00854	-4.3	2.09e-05	0.00373	-0.18	-0.2	Menopause (age at onset);	chr17:43045257	chr17:43216941~43305976:-
HNSC	cis	rs2361718	0.522	rs11867921	ENSG00000279259.1	RP11-334C17.3	4.3	2.09e-05	0.00373	0.26	0.2	Yeast infection;	chr17:80147371	chr17:80147250~80148596:+
HNSC	cis	rs11098499	1	rs11098500	ENSG00000250412.1	KLHL2P1	4.3	2.09e-05	0.00373	0.25	0.2	Corneal astigmatism;	chr4:119298084	chr4:119334329~119378233:+
HNSC	cis	rs875971	0.502	rs2946580	ENSG00000164669.11	INTS4P1	4.3	2.09e-05	0.00373	0.28	0.2	Aortic root size;	chr7:66066855	chr7:65141225~65234216:+
HNSC	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-4.3	2.09e-05	0.00373	-0.24	-0.2	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
HNSC	cis	rs1008375	1	rs11724495	ENSG00000249502.1	AC006160.5	-4.3	2.09e-05	0.00373	-0.21	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17619687	chr4:17587467~17614571:-
HNSC	cis	rs9863	0.828	rs4765541	ENSG00000270028.1	RP11-380L11.4	4.3	2.09e-05	0.00373	0.22	0.2	White blood cell count;	chr12:123981448	chr12:123925461~123926083:-
HNSC	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	4.3	2.09e-05	0.00373	0.19	0.2	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
HNSC	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-4.3	2.09e-05	0.00373	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
HNSC	cis	rs3015497	0.603	rs12891820	ENSG00000269906.1	RP11-248J18.2	4.3	2.09e-05	0.00373	0.26	0.2	Mean platelet volume;	chr14:50550056	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.583	rs12881560	ENSG00000269906.1	RP11-248J18.2	4.3	2.09e-05	0.00373	0.26	0.2	Mean platelet volume;	chr14:50551535	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.603	rs12882292	ENSG00000269906.1	RP11-248J18.2	4.3	2.09e-05	0.00373	0.26	0.2	Mean platelet volume;	chr14:50551644	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.603	rs2934686	ENSG00000269906.1	RP11-248J18.2	4.3	2.09e-05	0.00373	0.26	0.2	Mean platelet volume;	chr14:50562995	chr14:50662511~50663178:-
HNSC	cis	rs13178541	0.683	rs4036630	ENSG00000250378.1	RP11-119J18.1	-4.3	2.09e-05	0.00373	-0.26	-0.2	IgG glycosylation;	chr5:135752980	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.748	rs7379672	ENSG00000250378.1	RP11-119J18.1	-4.3	2.09e-05	0.00373	-0.26	-0.2	IgG glycosylation;	chr5:135754136	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs11950793	ENSG00000250378.1	RP11-119J18.1	-4.3	2.09e-05	0.00373	-0.26	-0.2	IgG glycosylation;	chr5:135754394	chr5:135812667~135826582:+
HNSC	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	4.3	2.09e-05	0.00373	0.34	0.2	QT interval;	chr4:75139193	chr4:75081702~75084717:-
HNSC	cis	rs9311676	0.632	rs11130643	ENSG00000273493.1	RP11-80H18.4	4.3	2.09e-05	0.00373	0.21	0.2	Systemic lupus erythematosus;	chr3:58437561	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.609	rs55845662	ENSG00000273493.1	RP11-80H18.4	4.3	2.09e-05	0.00373	0.21	0.2	Systemic lupus erythematosus;	chr3:58439172	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs56281646	ENSG00000273493.1	RP11-80H18.4	4.3	2.09e-05	0.00373	0.21	0.2	Systemic lupus erythematosus;	chr3:58439190	chr3:58329965~58330118:+
HNSC	cis	rs9311676	0.632	rs62259779	ENSG00000273493.1	RP11-80H18.4	4.3	2.09e-05	0.00373	0.21	0.2	Systemic lupus erythematosus;	chr3:58439965	chr3:58329965~58330118:+
HNSC	cis	rs61270009	0.955	rs450202	ENSG00000247828.6	TMEM161B-AS1	-4.3	2.09e-05	0.00373	-0.2	-0.2	Depressive symptoms;	chr5:88222635	chr5:88268895~88436685:+
HNSC	cis	rs7819412	0.715	rs2409727	ENSG00000269918.1	AF131215.9	-4.3	2.09e-05	0.00373	-0.2	-0.2	Triglycerides;	chr8:11185727	chr8:11104691~11106704:-
HNSC	cis	rs3808502	0.549	rs11991139	ENSG00000255310.2	AF131215.2	-4.3	2.09e-05	0.00373	-0.18	-0.2	Neuroticism;	chr8:11570886	chr8:11107788~11109726:-
HNSC	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	4.3	2.09e-05	0.00373	0.2	0.2	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000224373.3	IGHV4-59	4.3	2.1e-05	0.00374	0.13	0.2	Kawasaki disease;	chr14:106777611	chr14:106627249~106627825:-
HNSC	cis	rs2732480	0.577	rs2732457	ENSG00000257763.1	OR5BK1P	-4.3	2.1e-05	0.00374	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48355792~48356614:-
HNSC	cis	rs2492286	0.569	rs9289331	ENSG00000242551.2	POU5F1P6	-4.3	2.1e-05	0.00374	-0.22	-0.2	Eosinophil counts;	chr3:128635173	chr3:128674735~128677005:-
HNSC	cis	rs61935443	0.501	rs7311211	ENSG00000241556.1	RP11-490G8.1	-4.3	2.1e-05	0.00374	-0.2	-0.2	Schizophrenia;	chr12:94797413	chr12:95467397~95467861:-
HNSC	cis	rs7121616	0.576	rs11600486	ENSG00000200879.1	SNORD14E	4.3	2.1e-05	0.00374	0.27	0.2	Breast cancer;	chr11:123047060	chr11:123058077~123058161:-
HNSC	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-4.3	2.1e-05	0.00374	-0.22	-0.2	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
HNSC	cis	rs6558530	0.666	rs4242538	ENSG00000253982.1	CTD-2336O2.1	4.3	2.1e-05	0.00374	0.24	0.2	Systolic blood pressure;	chr8:1745844	chr8:1761990~1764502:-
HNSC	cis	rs6088580	0.609	rs6059844	ENSG00000276073.1	RP5-1125A11.7	-4.3	2.1e-05	0.00374	-0.2	-0.2	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:33985617~33988989:-
HNSC	cis	rs1799949	1	rs4793215	ENSG00000236383.6	LINC00854	-4.3	2.1e-05	0.00374	-0.18	-0.2	Menopause (age at onset);	chr17:43166915	chr17:43216941~43305976:-
HNSC	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	4.3	2.1e-05	0.00374	0.21	0.2	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
HNSC	cis	rs7701440	0.512	rs2055375	ENSG00000215032.2	GNL3LP1	-4.3	2.1e-05	0.00374	-0.22	-0.2	Educational attainment;	chr5:61235393	chr5:60891935~60893577:-
HNSC	cis	rs8067545	0.641	rs169412	ENSG00000266126.1	RP11-209D14.4	4.3	2.1e-05	0.00374	0.22	0.2	Schizophrenia;	chr17:19948562	chr17:19929372~19929737:-
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000254340.1	RP11-10A14.3	4.3	2.1e-05	0.00374	0.23	0.2	Neuroticism;	chr8:8461672	chr8:9141424~9145435:+
HNSC	cis	rs7580658	0.588	rs2069920	ENSG00000236682.1	AC068282.3	-4.3	2.1e-05	0.00375	-0.23	-0.2	Protein C levels;	chr2:127422070	chr2:127389130~127400580:+
HNSC	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-4.3	2.1e-05	0.00375	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-4.3	2.1e-05	0.00375	-0.21	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
HNSC	cis	rs4853525	0.62	rs2066804	ENSG00000235852.1	AC005540.3	4.3	2.1e-05	0.00375	0.27	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977033	chr2:190880797~190882059:-
HNSC	cis	rs1713985	0.508	rs1718862	ENSG00000269949.1	RP11-738E22.3	-4.3	2.1e-05	0.00375	-0.33	-0.2	Age-related macular degeneration;	chr4:57023166	chr4:56960927~56961373:-
HNSC	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	4.3	2.1e-05	0.00375	0.19	0.2	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	4.3	2.1e-05	0.00375	0.19	0.2	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	4.3	2.1e-05	0.00375	0.19	0.2	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
HNSC	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-4.3	2.1e-05	0.00375	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-4.3	2.1e-05	0.00375	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
HNSC	cis	rs78579285	0.544	rs11549835	ENSG00000278341.1	RP5-1142A6.10	-4.3	2.1e-05	0.00375	-0.36	-0.2	Joint mobility (Beighton score);	chr16:88714665	chr16:88708956~88710437:-
HNSC	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-4.3	2.11e-05	0.00375	-0.24	-0.2	Height;	chr20:49219081	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-4.3	2.11e-05	0.00375	-0.24	-0.2	Height;	chr20:49220669	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-4.3	2.11e-05	0.00375	-0.24	-0.2	Height;	chr20:49223054	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-4.3	2.11e-05	0.00375	-0.24	-0.2	Height;	chr20:49225123	chr20:49280319~49280409:+
HNSC	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	4.3	2.11e-05	0.00375	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.714	rs6994038	ENSG00000233609.3	RP11-62H7.2	4.3	2.11e-05	0.00375	0.19	0.2	Mood instability;	chr8:8803028	chr8:8961200~8979025:+
HNSC	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	4.3	2.11e-05	0.00375	0.3	0.2	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	4.3	2.11e-05	0.00375	0.3	0.2	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
HNSC	cis	rs58873874	0.737	rs10476050	ENSG00000248544.2	CTB-47B11.3	4.3	2.11e-05	0.00375	0.46	0.2	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs10476052	ENSG00000248544.2	CTB-47B11.3	4.3	2.11e-05	0.00375	0.46	0.2	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs78832945	ENSG00000248544.2	CTB-47B11.3	4.3	2.11e-05	0.00375	0.46	0.2	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157375741~157384950:-
HNSC	cis	rs72843506	0.656	rs9913018	ENSG00000261033.1	RP11-209D14.2	4.3	2.11e-05	0.00375	0.34	0.2	Schizophrenia;	chr17:20160759	chr17:20008051~20009234:-
HNSC	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.3	2.11e-05	0.00375	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.3	2.11e-05	0.00375	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
HNSC	cis	rs6928289	0.84	rs7739823	ENSG00000234956.4	RP11-356I2.1	4.3	2.11e-05	0.00375	0.21	0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137329932	chr6:137730170~137738983:-
HNSC	cis	rs2732480	0.538	rs2468943	ENSG00000257763.1	OR5BK1P	-4.3	2.11e-05	0.00376	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48355792~48356614:-
HNSC	cis	rs7824557	0.545	rs2572450	ENSG00000255495.1	AC145124.2	-4.3	2.11e-05	0.00376	-0.22	-0.2	Retinal vascular caliber;	chr8:11372129	chr8:12194467~12196280:+
HNSC	cis	rs9527	0.662	rs4919686	ENSG00000236937.2	PTGES3P4	4.3	2.11e-05	0.00376	0.27	0.2	Arsenic metabolism;	chr10:102832492	chr10:102845595~102845950:+
HNSC	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	4.3	2.11e-05	0.00376	0.2	0.2	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000106610.13	STAG3L4	-4.3	2.11e-05	0.00376	-0.4	-0.2	Gout;	chr7:66654674	chr7:67302621~67321526:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000106610.13	STAG3L4	-4.3	2.11e-05	0.00376	-0.4	-0.2	Gout;	chr7:66661502	chr7:67302621~67321526:+
HNSC	cis	rs11098499	1	rs35643470	ENSG00000250412.1	KLHL2P1	4.3	2.11e-05	0.00376	0.25	0.2	Corneal astigmatism;	chr4:119263793	chr4:119334329~119378233:+
HNSC	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-4.3	2.11e-05	0.00376	-0.2	-0.2	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
HNSC	cis	rs853679	0.607	rs34661125	ENSG00000226314.6	ZNF192P1	-4.3	2.11e-05	0.00376	-0.36	-0.2	Depression;	chr6:28314117	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs13190888	ENSG00000226314.6	ZNF192P1	-4.3	2.11e-05	0.00376	-0.36	-0.2	Depression;	chr6:28318208	chr6:28161781~28169594:+
HNSC	cis	rs3015497	0.543	rs1565834	ENSG00000269906.1	RP11-248J18.2	4.3	2.11e-05	0.00376	0.26	0.2	Mean platelet volume;	chr14:50544810	chr14:50662511~50663178:-
HNSC	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	4.3	2.11e-05	0.00376	0.34	0.2	QT interval;	chr4:75124631	chr4:75081702~75084717:-
HNSC	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	4.3	2.11e-05	0.00376	0.34	0.2	QT interval;	chr4:75125677	chr4:75081702~75084717:-
HNSC	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	4.3	2.11e-05	0.00376	0.34	0.2	QT interval;	chr4:75125682	chr4:75081702~75084717:-
HNSC	cis	rs9914988	0.667	rs11652544	ENSG00000264577.1	AC010761.8	4.3	2.11e-05	0.00376	0.18	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28925971	chr17:28721487~28722877:-
HNSC	cis	rs656319	0.638	rs670044	ENSG00000254340.1	RP11-10A14.3	4.3	2.11e-05	0.00376	0.24	0.2	Myopia (pathological);	chr8:10035019	chr8:9141424~9145435:+
HNSC	cis	rs4862750	0.872	rs6825289	ENSG00000250971.1	RP11-696F12.1	4.3	2.11e-05	0.00376	0.23	0.2	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:187060099~187060930:+
HNSC	cis	rs3736485	0.609	rs1456299	ENSG00000259438.1	CTD-2650P22.1	4.3	2.11e-05	0.00376	0.2	0.2	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689868	chr15:52010999~52019095:-
HNSC	cis	rs8077577	0.895	rs16960996	ENSG00000273018.4	CTD-2303H24.2	-4.3	2.11e-05	0.00376	-0.3	-0.2	Obesity-related traits;	chr17:18207245	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs1563371	ENSG00000273018.4	CTD-2303H24.2	-4.3	2.11e-05	0.00376	-0.3	-0.2	Obesity-related traits;	chr17:18208479	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs13284	ENSG00000273018.4	CTD-2303H24.2	-4.3	2.11e-05	0.00376	-0.3	-0.2	Obesity-related traits;	chr17:18208816	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.895	rs3088233	ENSG00000273018.4	CTD-2303H24.2	-4.3	2.11e-05	0.00376	-0.3	-0.2	Obesity-related traits;	chr17:18209361	chr17:18511221~18551705:-
HNSC	cis	rs9527	0.545	rs35756290	ENSG00000236937.2	PTGES3P4	4.3	2.11e-05	0.00376	0.27	0.2	Arsenic metabolism;	chr10:102825815	chr10:102845595~102845950:+
HNSC	cis	rs3758785	0.641	rs7949222	ENSG00000255893.1	RP11-685N10.1	4.3	2.11e-05	0.00376	0.23	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94365335	chr11:94472908~94473570:-
HNSC	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-4.3	2.11e-05	0.00376	-0.2	-0.2	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
HNSC	cis	rs1925953	0.683	rs3125915	ENSG00000233589.1	RP4-694A7.2	-4.3	2.11e-05	0.00376	-0.24	-0.19	Vertical cup-disc ratio;	chr1:68378727	chr1:68479129~68483539:+
HNSC	cis	rs728616	0.867	rs55690691	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.11e-05	0.00376	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs1983775	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.11e-05	0.00376	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs1983776	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.11e-05	0.00376	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79663088~79826594:-
HNSC	cis	rs12935418	0.616	rs9931292	ENSG00000261061.1	RP11-303E16.2	-4.3	2.11e-05	0.00376	-0.21	-0.19	Mean corpuscular volume;	chr16:80975671	chr16:81030770~81031485:+
HNSC	cis	rs7615952	0.641	rs6438951	ENSG00000241439.1	RP11-666A20.3	4.3	2.11e-05	0.00376	0.22	0.19	Blood pressure (smoking interaction);	chr3:125978156	chr3:125958556~125958817:+
HNSC	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	4.3	2.12e-05	0.00377	0.2	0.19	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	4.3	2.12e-05	0.00377	0.2	0.19	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
HNSC	cis	rs7572733	0.935	rs700679	ENSG00000222017.1	AC011997.1	4.3	2.12e-05	0.00377	0.23	0.19	Dermatomyositis;	chr2:197842192	chr2:197693106~197774823:+
HNSC	cis	rs8054556	0.669	rs4787491	ENSG00000183604.13	SMG1P5	-4.3	2.12e-05	0.00377	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr16:30004016	chr16:30267553~30335374:-
HNSC	cis	rs9650657	0.585	rs4841401	ENSG00000269918.1	AF131215.9	-4.3	2.12e-05	0.00377	-0.19	-0.19	Neuroticism;	chr8:10632082	chr8:11104691~11106704:-
HNSC	cis	rs5760092	0.755	rs915589	ENSG00000235689.1	AP000351.13	-4.3	2.12e-05	0.00377	-0.24	-0.19	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:24006305~24008258:-
HNSC	cis	rs1125355	0.69	rs17810428	ENSG00000204380.3	AC005042.4	4.3	2.12e-05	0.00377	0.22	0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158804939	chr2:158658337~158735002:-
HNSC	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	4.3	2.12e-05	0.00377	0.21	0.19	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
HNSC	cis	rs13178541	0.81	rs11242264	ENSG00000250378.1	RP11-119J18.1	-4.3	2.12e-05	0.00377	-0.26	-0.19	IgG glycosylation;	chr5:135762546	chr5:135812667~135826582:+
HNSC	cis	rs12935418	0.672	rs9921914	ENSG00000278985.1	RP11-303E16.9	4.3	2.12e-05	0.00377	0.19	0.19	Mean corpuscular volume;	chr16:81022506	chr16:80982319~80984094:-
HNSC	cis	rs12935418	0.672	rs3826048	ENSG00000278985.1	RP11-303E16.9	4.3	2.12e-05	0.00377	0.19	0.19	Mean corpuscular volume;	chr16:81023230	chr16:80982319~80984094:-
HNSC	cis	rs1198872	0.892	rs1198868	ENSG00000272275.1	RP11-791G15.2	-4.3	2.12e-05	0.00377	-0.23	-0.19	Cardiac Troponin-T levels;	chr2:10762287	chr2:10767875~10770058:-
HNSC	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	4.3	2.12e-05	0.00378	0.23	0.19	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000254340.1	RP11-10A14.3	4.3	2.12e-05	0.00378	0.24	0.19	Systolic blood pressure;	chr8:8488264	chr8:9141424~9145435:+
HNSC	cis	rs755249	0.917	rs61779330	ENSG00000182109.6	RP11-69E11.4	4.3	2.12e-05	0.00378	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.876	rs72662001	ENSG00000182109.6	RP11-69E11.4	4.3	2.12e-05	0.00378	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.917	rs72663503	ENSG00000182109.6	RP11-69E11.4	4.3	2.12e-05	0.00378	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39522280~39546187:-
HNSC	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-4.3	2.13e-05	0.00378	-0.18	-0.19	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
HNSC	cis	rs283610	0.735	rs10058435	ENSG00000182383.8	RPL27AP5	-4.3	2.13e-05	0.00378	-0.17	-0.19	Obesity-related traits;	chr5:73990920	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.735	rs10058557	ENSG00000182383.8	RPL27AP5	-4.3	2.13e-05	0.00378	-0.17	-0.19	Obesity-related traits;	chr5:73991255	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.651	rs10942689	ENSG00000182383.8	RPL27AP5	-4.3	2.13e-05	0.00378	-0.17	-0.19	Obesity-related traits;	chr5:73991337	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.735	rs10942691	ENSG00000182383.8	RPL27AP5	-4.3	2.13e-05	0.00378	-0.17	-0.19	Obesity-related traits;	chr5:73991387	chr5:74990189~74990637:-
HNSC	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-4.3	2.13e-05	0.00378	-0.22	-0.19	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
HNSC	cis	rs427691	0.625	rs845733	ENSG00000271849.1	CTC-332L22.1	-4.29	2.13e-05	0.00378	-0.3	-0.19	Autism spectrum disorder or schizophrenia;	chr5:109687700	chr5:109687802~109688329:-
HNSC	cis	rs7701440	0.512	rs10939886	ENSG00000215032.2	GNL3LP1	4.29	2.13e-05	0.00378	0.21	0.19	Educational attainment;	chr5:61235738	chr5:60891935~60893577:-
HNSC	cis	rs10761256	0.621	rs12551601	ENSG00000227603.1	RP11-165J3.6	-4.29	2.13e-05	0.00379	-0.2	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr9:93719002	chr9:93435332~93437121:-
HNSC	cis	rs9926296	0.744	rs460984	ENSG00000274627.1	RP11-104N10.2	4.29	2.13e-05	0.00379	0.2	0.19	Vitiligo;	chr16:89646766	chr16:89516797~89522217:+
HNSC	cis	rs6723108	0.738	rs6430538	ENSG00000224043.6	CCNT2-AS1	4.29	2.13e-05	0.00379	0.23	0.19	Type 2 diabetes;	chr2:134782397	chr2:134735464~134918710:-
HNSC	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-4.29	2.13e-05	0.00379	-0.26	-0.19	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
HNSC	cis	rs2486288	0.656	rs9921025	ENSG00000259479.5	SORD2P	-4.29	2.13e-05	0.00379	-0.22	-0.19	Glomerular filtration rate;	chr15:45254404	chr15:44826371~44884694:-
HNSC	cis	rs2361718	0.5	rs4889818	ENSG00000275479.1	RP11-334C17.6	4.29	2.13e-05	0.00379	0.23	0.19	Yeast infection;	chr17:80111429	chr17:80149627~80149798:+
HNSC	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	4.29	2.13e-05	0.00379	0.27	0.19	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
HNSC	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	4.29	2.13e-05	0.00379	0.27	0.19	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
HNSC	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	4.29	2.13e-05	0.00379	0.27	0.19	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
HNSC	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	4.29	2.13e-05	0.00379	0.27	0.19	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
HNSC	cis	rs2098713	0.537	rs12109722	ENSG00000250155.1	CTD-2353F22.1	-4.29	2.13e-05	0.00379	-0.21	-0.19	Telomere length;	chr5:37489522	chr5:36666214~36725195:-
HNSC	cis	rs8067545	0.641	rs4925060	ENSG00000266126.1	RP11-209D14.4	4.29	2.13e-05	0.00379	0.22	0.19	Schizophrenia;	chr17:19959945	chr17:19929372~19929737:-
HNSC	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-4.29	2.13e-05	0.00379	-0.26	-0.19	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
HNSC	cis	rs2904524	1	rs74993103	ENSG00000257815.4	RP11-611E13.2	-4.29	2.13e-05	0.00379	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70259786	chr12:69904033~70243360:-
HNSC	cis	rs763567	0.935	rs2988392	ENSG00000271811.1	RP1-79C4.4	4.29	2.13e-05	0.0038	0.21	0.19	Tonsillectomy;	chr1:170647214	chr1:170667381~170669425:+
HNSC	cis	rs72843506	0.586	rs80289275	ENSG00000261033.1	RP11-209D14.2	4.29	2.13e-05	0.0038	0.34	0.19	Schizophrenia;	chr17:19914367	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.586	rs79634508	ENSG00000261033.1	RP11-209D14.2	4.29	2.13e-05	0.0038	0.34	0.19	Schizophrenia;	chr17:19933734	chr17:20008051~20009234:-
HNSC	cis	rs2412819	0.571	rs17727853	ENSG00000166763.7	STRCP1	4.29	2.13e-05	0.0038	0.28	0.19	Lung cancer;	chr15:43630299	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs62018900	ENSG00000166763.7	STRCP1	4.29	2.13e-05	0.0038	0.28	0.19	Lung cancer;	chr15:43633252	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs112667279	ENSG00000166763.7	STRCP1	4.29	2.13e-05	0.0038	0.28	0.19	Lung cancer;	chr15:43649258	chr15:43699488~43718184:-
HNSC	cis	rs755249	0.529	rs4660732	ENSG00000182109.6	RP11-69E11.4	4.29	2.13e-05	0.0038	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61779285	ENSG00000182109.6	RP11-69E11.4	4.29	2.13e-05	0.0038	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39522280~39546187:-
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000211974.3	IGHV2-70	4.29	2.13e-05	0.0038	0.18	0.19	Kawasaki disease;	chr14:106680324	chr14:106723574~106724093:-
HNSC	cis	rs11773103	0.867	rs73194657	ENSG00000224046.1	AC005076.5	4.29	2.14e-05	0.0038	0.33	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87334365	chr7:87151423~87152420:-
HNSC	cis	rs2136613	0.728	rs10761664	ENSG00000238280.1	RP11-436D10.3	4.29	2.14e-05	0.0038	0.23	0.19	Selective IgA deficiency;	chr10:62847301	chr10:62793562~62805887:-
HNSC	cis	rs3015497	0.967	rs8018308	ENSG00000277050.1	RP11-102G14.1	-4.29	2.14e-05	0.0038	-0.18	-0.19	Mean platelet volume;	chr14:50655915	chr14:51637348~51637947:-
HNSC	cis	rs6543140	0.964	rs1523206	ENSG00000234389.1	AC007278.3	4.29	2.14e-05	0.0038	0.2	0.19	Blood protein levels;	chr2:102453715	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs1523205	ENSG00000234389.1	AC007278.3	4.29	2.14e-05	0.0038	0.2	0.19	Blood protein levels;	chr2:102453716	chr2:102438713~102440475:+
HNSC	cis	rs79349575	0.783	rs58591767	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48948714	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs59270107	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48948823	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62078370	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48949474	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs11079844	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48950972	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62078372	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48951627	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12602933	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48951918	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4794003	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48952542	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12602746	ENSG00000270781.1	RP11-501C14.9	-4.29	2.14e-05	0.0038	-0.21	-0.19	Type 2 diabetes;	chr17:48954379	chr17:48899131~48899748:+
HNSC	cis	rs6430585	0.591	rs309170	ENSG00000231890.6	DARS-AS1	-4.29	2.14e-05	0.0038	-0.33	-0.19	Corneal structure;	chr2:135915205	chr2:135985176~136022593:+
HNSC	cis	rs4523957	0.671	rs7223161	ENSG00000262333.1	HNRNPA1P16	4.29	2.14e-05	0.0038	0.18	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2272887	chr17:2306761~2307715:+
HNSC	cis	rs11893307	0.509	rs62182902	ENSG00000235852.1	AC005540.3	4.29	2.14e-05	0.0038	0.26	0.19	Mean platelet volume;	chr2:190638041	chr2:190880797~190882059:-
HNSC	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-4.29	2.14e-05	0.0038	-0.2	-0.19	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
HNSC	cis	rs1023500	1	rs1047997	ENSG00000205702.9	CYP2D7	-4.29	2.14e-05	0.0038	-0.16	-0.19	Schizophrenia;	chr22:41938949	chr22:42140203~42144577:-
HNSC	cis	rs763121	0.819	rs5757133	ENSG00000273076.1	RP3-508I15.22	-4.29	2.14e-05	0.0038	-0.21	-0.19	Menopause (age at onset);	chr22:38551830	chr22:38743495~38743910:+
HNSC	cis	rs4372836	0.93	rs4233727	ENSG00000226833.4	AC097724.3	4.29	2.14e-05	0.0038	0.24	0.19	Body mass index;	chr2:28754378	chr2:28708953~28736205:-
HNSC	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-4.29	2.14e-05	0.0038	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
HNSC	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-4.29	2.14e-05	0.0038	-0.24	-0.19	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
HNSC	cis	rs6809854	0.545	rs336609	ENSG00000228956.7	SATB1-AS1	4.29	2.14e-05	0.0038	0.22	0.19	Psoriasis;Itch intensity from mosquito bite;	chr3:18607959	chr3:18445024~18920401:+
HNSC	cis	rs17345786	1	rs17345786	ENSG00000244119.1	PDCL3P4	-4.29	2.14e-05	0.00381	-0.22	-0.19	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101712472~101713191:+
HNSC	cis	rs436483	0.967	rs391234	ENSG00000213385.3	RP11-577H5.1	4.29	2.14e-05	0.00381	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr7:102050995	chr7:102755146~102755939:+
HNSC	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	4.29	2.14e-05	0.00381	0.23	0.19	Height;	chr14:75077276	chr14:75011269~75012851:-
HNSC	cis	rs6600671	0.967	rs4844613	ENSG00000270231.3	NBPF8P	4.29	2.14e-05	0.00381	0.17	0.19	Hip geometry;	chr1:121431913	chr1:120436353~120467739:+
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000233609.3	RP11-62H7.2	4.29	2.14e-05	0.00381	0.18	0.19	Mood instability;	chr8:8461157	chr8:8961200~8979025:+
HNSC	cis	rs13126694	0.744	rs9968557	ENSG00000248429.4	RP11-597D13.9	4.29	2.14e-05	0.00381	0.22	0.19	Blood osmolality (transformed sodium);	chr4:158098673	chr4:158170752~158202877:+
HNSC	cis	rs2337406	1	rs17113331	ENSG00000280411.1	IGHV1-69-2	-4.29	2.14e-05	0.00381	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106703843	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000211974.3	IGHV2-70	4.29	2.15e-05	0.00381	0.19	0.19	Kawasaki disease;	chr14:106799304	chr14:106723574~106724093:-
HNSC	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-4.29	2.15e-05	0.00381	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
HNSC	cis	rs10149470	0.549	rs9652403	ENSG00000269958.1	RP11-73M18.8	4.29	2.15e-05	0.00381	0.18	0.19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103696353~103697163:+
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000219891.2	ZSCAN12P1	4.29	2.15e-05	0.00381	0.28	0.19	Parkinson's disease;	chr6:28054470	chr6:28091154~28093664:+
HNSC	cis	rs9298506	0.948	rs72648770	ENSG00000254142.2	RP11-53M11.3	4.29	2.15e-05	0.00381	0.31	0.19	Intracranial aneurysm;	chr8:54542004	chr8:54554361~54561927:+
HNSC	cis	rs5752326	0.702	rs3752589	ENSG00000261188.1	CTA-445C9.14	4.29	2.15e-05	0.00381	0.31	0.19	Ischemic stroke;	chr22:26451620	chr22:26512537~26514568:+
HNSC	cis	rs4873772	0.735	rs4873395	ENSG00000253330.1	RP11-697N18.3	4.29	2.15e-05	0.00381	0.24	0.19	Lobe attachment (rater-scored or self-reported);	chr8:47594066	chr8:47511034~47512141:-
HNSC	cis	rs9903692	0.954	rs7224014	ENSG00000263412.1	RP5-890E16.2	-4.29	2.15e-05	0.00381	-0.18	-0.19	Pulse pressure;	chr17:48073499	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs2240122	ENSG00000263412.1	RP5-890E16.2	-4.29	2.15e-05	0.00381	-0.18	-0.19	Pulse pressure;	chr17:48075197	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.738	rs35202025	ENSG00000263412.1	RP5-890E16.2	-4.29	2.15e-05	0.00381	-0.18	-0.19	Pulse pressure;	chr17:48075355	chr17:48045141~48048073:-
HNSC	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	4.29	2.15e-05	0.00382	0.22	0.19	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
HNSC	cis	rs4834770	0.746	rs2389747	ENSG00000250412.1	KLHL2P1	4.29	2.15e-05	0.00382	0.22	0.19	Blood protein levels;	chr4:119314947	chr4:119334329~119378233:+
HNSC	cis	rs4834770	0.717	rs1022146	ENSG00000250412.1	KLHL2P1	4.29	2.15e-05	0.00382	0.22	0.19	Blood protein levels;	chr4:119314948	chr4:119334329~119378233:+
HNSC	cis	rs1008375	1	rs7694020	ENSG00000249502.1	AC006160.5	-4.29	2.15e-05	0.00382	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680974	chr4:17587467~17614571:-
HNSC	cis	rs12545109	0.643	rs1119707	ENSG00000246430.5	LINC00968	-4.29	2.15e-05	0.00382	-0.25	-0.19	Obesity-related traits;	chr8:56498989	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.8	rs1996105	ENSG00000246430.5	LINC00968	-4.29	2.15e-05	0.00382	-0.25	-0.19	Obesity-related traits;	chr8:56500564	chr8:56496246~56559823:-
HNSC	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	4.29	2.15e-05	0.00382	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
HNSC	cis	rs3015497	0.603	rs2983420	ENSG00000269906.1	RP11-248J18.2	4.29	2.15e-05	0.00382	0.26	0.19	Mean platelet volume;	chr14:50570232	chr14:50662511~50663178:-
HNSC	cis	rs847649	0.732	rs6465876	ENSG00000239969.4	RP11-163E9.2	-4.29	2.15e-05	0.00382	-0.22	-0.19	Morning vs. evening chronotype;	chr7:102857122	chr7:102364162~102380633:+
HNSC	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-4.29	2.15e-05	0.00382	-0.26	-0.19	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
HNSC	cis	rs9531006	0.79	rs9601294	ENSG00000227676.3	LINC01068	4.29	2.15e-05	0.00382	0.26	0.19	Sleep duration;	chr13:79934952	chr13:79566727~79571436:+
HNSC	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-4.29	2.15e-05	0.00382	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
HNSC	cis	rs755249	1	rs12037222	ENSG00000182109.6	RP11-69E11.4	4.29	2.15e-05	0.00382	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39522280~39546187:-
HNSC	cis	rs9840812	0.656	rs4678437	ENSG00000239213.4	NCK1-AS1	4.29	2.15e-05	0.00382	0.17	0.19	Fibrinogen levels;	chr3:136598823	chr3:136841726~136862054:-
HNSC	cis	rs11098499	0.739	rs6534130	ENSG00000250412.1	KLHL2P1	-4.29	2.15e-05	0.00382	-0.23	-0.19	Corneal astigmatism;	chr4:119210184	chr4:119334329~119378233:+
HNSC	cis	rs6964587	0.934	rs35968894	ENSG00000188693.7	CYP51A1-AS1	-4.29	2.15e-05	0.00383	-0.22	-0.19	Breast cancer;	chr7:92132831	chr7:92134604~92180725:+
HNSC	cis	rs2548724	0.588	rs17333350	ENSG00000250682.4	LINC00491	-4.29	2.15e-05	0.00383	-0.25	-0.19	Type 2 diabetes;	chr5:102478905	chr5:102609156~102671559:-
HNSC	cis	rs2342371	0.641	rs4916427	ENSG00000243339.3	RN7SL738P	-4.29	2.15e-05	0.00383	-0.27	-0.19	Fat distribution (HIV);	chr3:196367342	chr3:196399911~196400207:+
HNSC	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-4.29	2.15e-05	0.00383	-0.22	-0.19	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
HNSC	cis	rs72843506	0.722	rs75226250	ENSG00000261033.1	RP11-209D14.2	4.29	2.15e-05	0.00383	0.34	0.19	Schizophrenia;	chr17:20229004	chr17:20008051~20009234:-
HNSC	cis	rs4862750	0.957	rs2375916	ENSG00000250971.1	RP11-696F12.1	4.29	2.15e-05	0.00383	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:187060099~187060930:+
HNSC	cis	rs42490	0.57	rs454561	ENSG00000251136.7	RP11-37B2.1	-4.29	2.16e-05	0.00383	-0.17	-0.19	Leprosy;	chr8:89824387	chr8:89609409~89757727:-
HNSC	cis	rs4862750	0.872	rs7679956	ENSG00000250971.1	RP11-696F12.1	4.29	2.16e-05	0.00383	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186979075	chr4:187060099~187060930:+
HNSC	cis	rs7688540	0.713	rs4624608	ENSG00000211553.1	AC253576.2	-4.29	2.16e-05	0.00383	-0.27	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:136461~136568:+
HNSC	cis	rs8077577	0.945	rs11871039	ENSG00000273018.4	CTD-2303H24.2	-4.29	2.16e-05	0.00383	-0.3	-0.19	Obesity-related traits;	chr17:18175590	chr17:18511221~18551705:-
HNSC	cis	rs73198271	0.729	rs66564323	ENSG00000253893.2	FAM85B	4.29	2.16e-05	0.00383	0.29	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747486	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.729	rs67653033	ENSG00000253893.2	FAM85B	4.29	2.16e-05	0.00383	0.29	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747534	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.729	rs67000451	ENSG00000253893.2	FAM85B	4.29	2.16e-05	0.00383	0.29	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747573	chr8:8167819~8226614:-
HNSC	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-4.29	2.16e-05	0.00383	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
HNSC	cis	rs2985684	1	rs56098064	ENSG00000278009.1	RP11-649E7.8	4.29	2.16e-05	0.00383	0.25	0.19	Carotid intima media thickness;	chr14:49639131	chr14:49601011~49601124:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-4.29	2.16e-05	0.00383	-0.26	-0.19	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
HNSC	cis	rs72634501	0.716	rs67637163	ENSG00000228060.1	RP11-69E11.8	-4.29	2.16e-05	0.00384	-0.23	-0.19	HDL cholesterol;	chr1:39110949	chr1:39565160~39573203:+
HNSC	cis	rs1832007	0.554	rs34179396	ENSG00000224034.1	RP11-445P17.8	-4.29	2.16e-05	0.00384	-0.22	-0.19	Triglyceride levels;Triglycerides;	chr10:5278817	chr10:5266033~5271236:-
HNSC	cis	rs10129255	1	rs11627342	ENSG00000211974.3	IGHV2-70	4.29	2.16e-05	0.00384	0.18	0.19	Kawasaki disease;	chr14:106675823	chr14:106723574~106724093:-
HNSC	cis	rs929354	0.772	rs1182360	ENSG00000224629.1	RP5-1142J19.2	-4.29	2.16e-05	0.00384	-0.2	-0.19	Body mass index;	chr7:157227856	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs1182432	ENSG00000224629.1	RP5-1142J19.2	-4.29	2.16e-05	0.00384	-0.2	-0.19	Body mass index;	chr7:157236482	chr7:157263022~157263229:-
HNSC	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	4.29	2.16e-05	0.00384	0.17	0.19	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
HNSC	cis	rs73198271	0.773	rs66618176	ENSG00000233609.3	RP11-62H7.2	-4.29	2.16e-05	0.00384	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8961200~8979025:+
HNSC	cis	rs11673344	0.542	rs826327	ENSG00000267698.1	AC002116.7	4.29	2.16e-05	0.00384	0.17	0.19	Obesity-related traits;	chr19:37004397	chr19:36014508~36045972:+
HNSC	cis	rs2834288	0.666	rs762188	ENSG00000273102.1	AP000569.9	-4.29	2.16e-05	0.00384	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33902206	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.7	rs731059	ENSG00000273102.1	AP000569.9	-4.29	2.16e-05	0.00384	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33902813	chr21:33967101~33968573:-
HNSC	cis	rs13434995	0.513	rs550144	ENSG00000273257.1	RP11-177J6.1	4.29	2.16e-05	0.00384	0.26	0.19	Adiponectin levels;	chr4:55415317	chr4:55387949~55388271:+
HNSC	cis	rs8044868	0.53	rs4788464	ENSG00000259209.3	RP5-991G20.2	4.29	2.16e-05	0.00384	0.2	0.19	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72190000	chr16:72805998~72809872:+
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	4.29	2.16e-05	0.00384	0.23	0.19	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	4.29	2.16e-05	0.00384	0.23	0.19	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
HNSC	cis	rs3736485	0.966	rs12102203	ENSG00000259438.1	CTD-2650P22.1	4.29	2.17e-05	0.00384	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51499362	chr15:52010999~52019095:-
HNSC	cis	rs933688	0.938	rs12110065	ENSG00000281357.1	ARRDC3-AS1	4.29	2.17e-05	0.00384	0.29	0.19	Smoking behavior;	chr5:91422657	chr5:91380349~91439085:+
HNSC	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-4.29	2.17e-05	0.00385	-0.21	-0.19	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
HNSC	cis	rs1008375	0.932	rs6841784	ENSG00000249502.1	AC006160.5	-4.29	2.17e-05	0.00385	-0.22	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624795	chr4:17587467~17614571:-
HNSC	cis	rs7005380	0.581	rs2176750	ENSG00000279347.1	RP11-85I17.2	4.29	2.17e-05	0.00385	0.18	0.19	Interstitial lung disease;	chr8:119925460	chr8:119838736~119840385:-
HNSC	cis	rs9910055	0.529	rs183462	ENSG00000267080.4	ASB16-AS1	4.29	2.17e-05	0.00385	0.16	0.19	Total body bone mineral density;	chr17:44106008	chr17:44175973~44186717:-
HNSC	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-4.29	2.17e-05	0.00385	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
HNSC	cis	rs67981189	0.593	rs221926	ENSG00000274818.1	RP1-292L20.3	-4.29	2.17e-05	0.00385	-0.21	-0.19	Schizophrenia;	chr14:71112418	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs221925	ENSG00000274818.1	RP1-292L20.3	-4.29	2.17e-05	0.00385	-0.21	-0.19	Schizophrenia;	chr14:71112912	chr14:70906657~70907111:-
HNSC	cis	rs5758511	0.68	rs5758681	ENSG00000226450.2	CYP2D8P	4.29	2.17e-05	0.00385	0.19	0.19	Birth weight;	chr22:42249085	chr22:42149886~42155001:-
HNSC	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-4.29	2.17e-05	0.00385	-0.4	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
HNSC	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	4.29	2.17e-05	0.00385	0.29	0.19	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
HNSC	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	4.29	2.17e-05	0.00385	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
HNSC	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-4.29	2.17e-05	0.00385	-0.22	-0.19	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
HNSC	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-4.29	2.17e-05	0.00385	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-4.29	2.17e-05	0.00385	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-4.29	2.17e-05	0.00385	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
HNSC	cis	rs7610312	0.681	rs9822734	ENSG00000273493.1	RP11-80H18.4	-4.29	2.17e-05	0.00385	-0.23	-0.19	Red blood cell count;	chr3:58285851	chr3:58329965~58330118:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000254153.1	CTA-398F10.2	4.29	2.17e-05	0.00385	0.21	0.19	Mood instability;	chr8:8813226	chr8:8456909~8461337:-
HNSC	cis	rs67981189	0.656	rs2810113	ENSG00000274818.1	RP1-292L20.3	-4.29	2.17e-05	0.00385	-0.21	-0.19	Schizophrenia;	chr14:70929053	chr14:70906657~70907111:-
HNSC	cis	rs10504130	0.932	rs11787229	ENSG00000272024.1	RP11-546K22.3	-4.29	2.17e-05	0.00385	-0.35	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51935311	chr8:51950284~51950690:+
HNSC	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	4.29	2.17e-05	0.00385	0.24	0.19	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
HNSC	cis	rs1185460	0.967	rs1784459	ENSG00000272186.1	RP11-110I1.13	-4.29	2.17e-05	0.00385	-0.22	-0.19	Coronary artery disease;	chr11:119067677	chr11:119067374~119067698:-
HNSC	cis	rs11098499	0.954	rs7681544	ENSG00000250412.1	KLHL2P1	4.29	2.17e-05	0.00385	0.25	0.19	Corneal astigmatism;	chr4:119490100	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs11935596	ENSG00000250412.1	KLHL2P1	4.29	2.17e-05	0.00385	0.25	0.19	Corneal astigmatism;	chr4:119491302	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs12507964	ENSG00000250412.1	KLHL2P1	4.29	2.17e-05	0.00385	0.25	0.19	Corneal astigmatism;	chr4:119491906	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs11098530	ENSG00000250412.1	KLHL2P1	4.29	2.17e-05	0.00385	0.25	0.19	Corneal astigmatism;	chr4:119491999	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs6834796	ENSG00000250412.1	KLHL2P1	4.29	2.17e-05	0.00385	0.25	0.19	Corneal astigmatism;	chr4:119493538	chr4:119334329~119378233:+
HNSC	cis	rs2904524	1	rs76044745	ENSG00000257815.4	RP11-611E13.2	-4.29	2.17e-05	0.00386	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70345310	chr12:69904033~70243360:-
HNSC	cis	rs853679	0.882	rs9393908	ENSG00000219891.2	ZSCAN12P1	4.29	2.17e-05	0.00386	0.35	0.19	Depression;	chr6:28223052	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.882	rs9366717	ENSG00000219891.2	ZSCAN12P1	4.29	2.17e-05	0.00386	0.35	0.19	Depression;	chr6:28223279	chr6:28091154~28093664:+
HNSC	cis	rs9880211	1	rs6768743	ENSG00000273486.1	RP11-731C17.2	-4.29	2.17e-05	0.00386	-0.18	-0.19	Height;Body mass index;	chr3:136486165	chr3:136837338~136839021:-
HNSC	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	4.29	2.17e-05	0.00386	0.2	0.19	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
HNSC	cis	rs7985	0.935	rs4280	ENSG00000244625.4	MIATNB	4.29	2.17e-05	0.00386	0.22	0.19	Electroencephalogram traits;	chr22:26671082	chr22:26672767~26780207:+
HNSC	cis	rs7630852	0.965	rs4256169	ENSG00000236833.1	AC024560.2	4.29	2.18e-05	0.00386	0.21	0.19	Eosinophil counts;	chr3:196785852	chr3:197660565~197665757:-
HNSC	cis	rs4372836	0.894	rs55877710	ENSG00000226833.4	AC097724.3	-4.29	2.18e-05	0.00386	-0.25	-0.19	Body mass index;	chr2:28706442	chr2:28708953~28736205:-
HNSC	cis	rs4372836	0.929	rs55883854	ENSG00000226833.4	AC097724.3	-4.29	2.18e-05	0.00386	-0.25	-0.19	Body mass index;	chr2:28706675	chr2:28708953~28736205:-
HNSC	cis	rs4740619	0.556	rs2987011	ENSG00000232000.2	CLCN3P1	-4.29	2.18e-05	0.00386	-0.22	-0.19	Body mass index;	chr9:15966438	chr9:14987302~15146401:-
HNSC	cis	rs7121616	1	rs7123187	ENSG00000200879.1	SNORD14E	4.29	2.18e-05	0.00386	0.24	0.19	Breast cancer;	chr11:123090915	chr11:123058077~123058161:-
HNSC	cis	rs12682352	0.535	rs12677550	ENSG00000253893.2	FAM85B	4.29	2.18e-05	0.00386	0.24	0.19	Neuroticism;	chr8:8786812	chr8:8167819~8226614:-
HNSC	cis	rs11722228	0.522	rs73212880	ENSG00000250413.1	RP11-448G15.1	-4.29	2.18e-05	0.00386	-0.3	-0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10006482~10009725:+
HNSC	cis	rs11992186	0.597	rs77717027	ENSG00000254340.1	RP11-10A14.3	-4.29	2.18e-05	0.00386	-0.25	-0.19	Neuroticism;	chr8:8734122	chr8:9141424~9145435:+
HNSC	cis	rs2055729	0.645	rs12544019	ENSG00000254340.1	RP11-10A14.3	4.29	2.18e-05	0.00386	0.28	0.19	Multiple myeloma (hyperdiploidy);	chr8:9885068	chr8:9141424~9145435:+
HNSC	cis	rs7819412	0.502	rs4840548	ENSG00000255310.2	AF131215.2	-4.29	2.18e-05	0.00386	-0.2	-0.19	Triglycerides;	chr8:11135373	chr8:11107788~11109726:-
HNSC	cis	rs4761669	0.959	rs10777625	ENSG00000241556.1	RP11-490G8.1	-4.29	2.18e-05	0.00386	-0.2	-0.19	Common carotid intima-media thickness in HIV infection;	chr12:94810676	chr12:95467397~95467861:-
HNSC	cis	rs67072384	0.901	rs58076660	ENSG00000213365.3	AP000593.6	4.29	2.18e-05	0.00386	0.31	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72730450	chr11:72280151~72281178:+
HNSC	cis	rs9650657	0.65	rs2898248	ENSG00000269918.1	AF131215.9	4.29	2.18e-05	0.00387	0.19	0.19	Neuroticism;	chr8:10779240	chr8:11104691~11106704:-
HNSC	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	4.29	2.18e-05	0.00387	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-4.29	2.18e-05	0.00387	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.866	rs7665125	ENSG00000249244.1	RP11-548H18.2	4.29	2.18e-05	0.00387	0.23	0.19	Corneal astigmatism;	chr4:119480924	chr4:119391831~119395335:-
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000233609.3	RP11-62H7.2	-4.29	2.18e-05	0.00387	-0.18	-0.19	Joint mobility (Beighton score);	chr8:9226955	chr8:8961200~8979025:+
HNSC	cis	rs7626444	0.51	rs7649045	ENSG00000272359.1	U4	-4.29	2.18e-05	0.00387	-0.22	-0.19	Monocyte count;	chr3:196793007	chr3:196747192~196747324:-
HNSC	cis	rs13434995	0.513	rs62303711	ENSG00000273257.1	RP11-177J6.1	-4.29	2.18e-05	0.00387	-0.26	-0.19	Adiponectin levels;	chr4:55458325	chr4:55387949~55388271:+
HNSC	cis	rs62025270	0.688	rs17577869	ENSG00000259762.1	RP11-158M2.4	-4.29	2.18e-05	0.00387	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85750336~85752901:-
HNSC	cis	rs10435719	0.746	rs58007588	ENSG00000227888.4	FAM66A	4.29	2.19e-05	0.00388	0.2	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:12362019~12388296:+
HNSC	cis	rs7735319	0.966	rs35958302	ENSG00000249102.1	CTD-2066L21.1	4.29	2.19e-05	0.00388	0.22	0.19	Systolic blood pressure;	chr5:33157849	chr5:33008994~33025724:+
HNSC	cis	rs9329221	0.537	rs6986911	ENSG00000269918.1	AF131215.9	4.29	2.19e-05	0.00388	0.19	0.19	Neuroticism;	chr8:10121013	chr8:11104691~11106704:-
HNSC	cis	rs1476670	0.71	rs2485993	ENSG00000230615.5	RP5-1198O20.4	4.29	2.19e-05	0.00388	0.24	0.19	Eotaxin levels;	chr1:44037368	chr1:44030443~44115913:+
HNSC	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.29	2.19e-05	0.00388	0.22	0.19	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
HNSC	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	4.29	2.19e-05	0.00388	0.2	0.19	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
HNSC	cis	rs10791097	0.694	rs876641	ENSG00000254842.5	RP11-890B15.2	-4.29	2.19e-05	0.00388	-0.17	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130882145	chr11:130844191~130865561:-
HNSC	cis	rs12655019	0.92	rs6450410	ENSG00000271828.1	CTD-2310F14.1	4.29	2.19e-05	0.00388	0.42	0.19	Breast cancer (early onset);	chr5:56910874	chr5:56927874~56929573:+
HNSC	cis	rs1799949	0.773	rs2137990	ENSG00000236383.6	LINC00854	4.29	2.19e-05	0.00388	0.18	0.19	Menopause (age at onset);	chr17:43165879	chr17:43216941~43305976:-
HNSC	cis	rs2136613	0.728	rs7078554	ENSG00000238280.1	RP11-436D10.3	-4.29	2.19e-05	0.00388	-0.23	-0.19	Selective IgA deficiency;	chr10:62835274	chr10:62793562~62805887:-
HNSC	cis	rs6831352	0.918	rs2851246	ENSG00000263923.1	RP11-571L19.7	-4.29	2.19e-05	0.00388	-0.21	-0.19	Alcohol dependence;	chr4:99124953	chr4:98928897~98994994:+
HNSC	cis	rs17345786	0.906	rs12638137	ENSG00000244119.1	PDCL3P4	4.29	2.19e-05	0.00389	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101712472~101713191:+
HNSC	cis	rs3758785	0.641	rs10831207	ENSG00000255893.1	RP11-685N10.1	4.29	2.19e-05	0.00389	0.23	0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94356197	chr11:94472908~94473570:-
HNSC	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-4.29	2.19e-05	0.00389	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
HNSC	cis	rs11951515	1	rs11951515	ENSG00000249286.1	CTD-2210P15.2	4.29	2.19e-05	0.00389	0.21	0.19	Metabolite levels  (X-11787);	chr5:43382756	chr5:43586918~43588223:-
HNSC	cis	rs6568686	0.53	rs72938270	ENSG00000255389.1	C6orf3	4.29	2.19e-05	0.00389	0.28	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111630009	chr6:111599875~111602295:+
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	4.29	2.2e-05	0.00389	0.33	0.19	Gout;	chr7:66654674	chr7:66025126~66031544:-
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	4.29	2.2e-05	0.00389	0.33	0.19	Gout;	chr7:66661502	chr7:66025126~66031544:-
HNSC	cis	rs1008375	1	rs1974624	ENSG00000249502.1	AC006160.5	-4.29	2.2e-05	0.00389	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648658	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.902	rs6844984	ENSG00000249502.1	AC006160.5	-4.29	2.2e-05	0.00389	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649681	chr4:17587467~17614571:-
HNSC	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-4.29	2.2e-05	0.00389	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
HNSC	cis	rs964611	0.882	rs3784619	ENSG00000259488.2	RP11-154J22.1	4.29	2.2e-05	0.00389	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48333741	chr15:48312353~48331856:-
HNSC	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	4.29	2.2e-05	0.00389	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
HNSC	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	4.29	2.2e-05	0.00389	0.21	0.19	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
HNSC	cis	rs73222236	0.75	rs9811261	ENSG00000273486.1	RP11-731C17.2	4.29	2.2e-05	0.00389	0.16	0.19	Coronary artery disease;	chr3:136379717	chr3:136837338~136839021:-
HNSC	cis	rs755249	0.567	rs16825887	ENSG00000182109.6	RP11-69E11.4	-4.29	2.2e-05	0.00389	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39522280~39546187:-
HNSC	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	4.29	2.2e-05	0.0039	0.18	0.19	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	4.29	2.2e-05	0.0039	0.18	0.19	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
HNSC	cis	rs13126694	0.71	rs9995402	ENSG00000248429.4	RP11-597D13.9	4.29	2.2e-05	0.0039	0.22	0.19	Blood osmolality (transformed sodium);	chr4:158105262	chr4:158170752~158202877:+
HNSC	cis	rs13126694	0.71	rs34237515	ENSG00000248429.4	RP11-597D13.9	4.29	2.2e-05	0.0039	0.22	0.19	Blood osmolality (transformed sodium);	chr4:158105607	chr4:158170752~158202877:+
HNSC	cis	rs8077577	1	rs7207276	ENSG00000273018.4	CTD-2303H24.2	-4.29	2.2e-05	0.0039	-0.29	-0.19	Obesity-related traits;	chr17:18162423	chr17:18511221~18551705:-
HNSC	cis	rs9487051	0.621	rs830554	ENSG00000243587.6	C6orf183	4.29	2.2e-05	0.0039	0.2	0.19	Reticulocyte fraction of red cells;	chr6:109222023	chr6:109165833~109271014:+
HNSC	cis	rs4938303	0.549	rs12785772	ENSG00000254851.1	RP11-109L13.1	4.29	2.2e-05	0.0039	0.29	0.19	Triglycerides;	chr11:116692892	chr11:117135528~117138582:+
HNSC	cis	rs9487051	0.872	rs1111866	ENSG00000219700.1	PTCHD3P3	-4.29	2.2e-05	0.0039	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109289643	chr6:109288571~109290503:-
HNSC	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	4.29	2.2e-05	0.0039	0.21	0.19	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
HNSC	cis	rs792448	0.743	rs1774249	ENSG00000226251.4	RP11-15I11.3	-4.29	2.2e-05	0.00391	-0.24	-0.19	White blood cell count (basophil);	chr1:212342271	chr1:212225278~212238977:-
HNSC	cis	rs467650	0.549	rs720859	ENSG00000246763.5	RGMB-AS1	-4.29	2.21e-05	0.00391	-0.22	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98659713	chr5:98769618~98773469:-
HNSC	cis	rs2361710	0.704	rs4889979	ENSG00000279259.1	RP11-334C17.3	4.29	2.21e-05	0.00391	0.23	0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80147908	chr17:80147250~80148596:+
HNSC	cis	rs35306767	0.903	rs35637113	ENSG00000229869.1	RP11-363N22.2	-4.29	2.21e-05	0.00391	-0.29	-0.19	Eosinophil percentage of granulocytes;	chr10:828209	chr10:933026~942743:+
HNSC	cis	rs9959145	1	rs78874284	ENSG00000267249.1	RP11-973H7.3	-4.29	2.21e-05	0.00391	-0.3	-0.19	Immune response to smallpox vaccine (IL-6);	chr18:12630717	chr18:12670426~12671145:-
HNSC	cis	rs757081	0.634	rs17472942	ENSG00000260196.1	RP1-239B22.5	-4.29	2.21e-05	0.00391	-0.24	-0.19	Systolic blood pressure;	chr11:17073155	chr11:17380649~17383531:+
HNSC	cis	rs3736485	0.652	rs2054166	ENSG00000259438.1	CTD-2650P22.1	4.29	2.21e-05	0.00391	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51682713	chr15:52010999~52019095:-
HNSC	cis	rs7086627	0.515	rs10887900	ENSG00000226659.1	RP11-137H2.4	-4.29	2.21e-05	0.00391	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80450509	chr10:80529597~80535942:-
HNSC	cis	rs7520050	0.966	rs11211199	ENSG00000280836.1	AL355480.1	4.29	2.21e-05	0.00391	0.2	0.19	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45581219~45581321:-
HNSC	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	4.29	2.21e-05	0.00391	0.22	0.19	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
HNSC	cis	rs10773046	0.566	rs1922257	ENSG00000269938.1	RP11-214K3.20	-4.29	2.21e-05	0.00391	-0.22	-0.19	Osteoarthritis (hip);	chr12:123869583	chr12:123968023~123968579:-
HNSC	cis	rs11148252	0.595	rs4884522	ENSG00000198384.8	TPTE2P3	4.29	2.21e-05	0.00392	0.24	0.19	Lewy body disease;	chr13:52479633	chr13:52522632~52586906:+
HNSC	cis	rs9287719	0.901	rs55861579	ENSG00000243819.4	RN7SL832P	4.29	2.21e-05	0.00392	0.19	0.19	Prostate cancer;	chr2:10623214	chr2:10690344~10692099:+
HNSC	cis	rs6095360	1	rs1885163	ENSG00000222365.1	SNORD12B	-4.29	2.21e-05	0.00392	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49085228	chr20:49280319~49280409:+
HNSC	cis	rs4819052	0.851	rs35560973	ENSG00000223768.1	LINC00205	-4.29	2.21e-05	0.00392	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45293285~45297354:+
HNSC	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	4.29	2.21e-05	0.00392	0.16	0.19	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
HNSC	cis	rs7819412	0.522	rs10088853	ENSG00000269918.1	AF131215.9	-4.29	2.21e-05	0.00392	-0.2	-0.19	Triglycerides;	chr8:11130457	chr8:11104691~11106704:-
HNSC	cis	rs7512552	0.966	rs1122967	ENSG00000228126.1	FALEC	-4.29	2.21e-05	0.00392	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150286426	chr1:150515757~150518032:+
HNSC	cis	rs73222236	0.75	rs9832572	ENSG00000273486.1	RP11-731C17.2	4.29	2.21e-05	0.00392	0.16	0.19	Coronary artery disease;	chr3:136615386	chr3:136837338~136839021:-
HNSC	cis	rs10462794	0.853	rs1562825	ENSG00000260763.1	RP11-445O3.3	-4.29	2.21e-05	0.00392	-0.26	-0.19	DNA methylation (variation);	chr5:4510870	chr5:4436850~4440259:-
HNSC	cis	rs9304742	0.611	rs10415443	ENSG00000213801.4	ZNF816-ZNF321P	4.29	2.21e-05	0.00392	0.22	0.19	Psoriasis;	chr19:52961611	chr19:52927135~52942601:-
HNSC	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	4.29	2.21e-05	0.00392	0.2	0.19	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
HNSC	cis	rs3015497	0.603	rs3015462	ENSG00000269906.1	RP11-248J18.2	4.29	2.21e-05	0.00392	0.26	0.19	Mean platelet volume;	chr14:50567899	chr14:50662511~50663178:-
HNSC	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-4.29	2.21e-05	0.00392	-0.32	-0.19	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00392	-0.18	-0.19	Kawasaki disease;	chr14:106775945	chr14:106723574~106724093:-
HNSC	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-4.29	2.22e-05	0.00392	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
HNSC	cis	rs9400271	0.632	rs949881	ENSG00000243587.6	C6orf183	-4.29	2.22e-05	0.00392	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109265037	chr6:109165833~109271014:+
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000233609.3	RP11-62H7.2	-4.29	2.22e-05	0.00392	-0.18	-0.19	Joint mobility (Beighton score);	chr8:9227707	chr8:8961200~8979025:+
HNSC	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-4.29	2.22e-05	0.00393	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-4.29	2.22e-05	0.00393	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-4.29	2.22e-05	0.00393	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
HNSC	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-4.29	2.22e-05	0.00393	-0.23	-0.19	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
HNSC	cis	rs7824557	0.564	rs7839307	ENSG00000255310.2	AF131215.2	4.28	2.22e-05	0.00393	0.19	0.19	Retinal vascular caliber;	chr8:11341283	chr8:11107788~11109726:-
HNSC	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-4.28	2.22e-05	0.00393	-0.24	-0.19	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
HNSC	cis	rs3015497	0.626	rs7150204	ENSG00000277050.1	RP11-102G14.1	-4.28	2.22e-05	0.00393	-0.19	-0.19	Mean platelet volume;	chr14:50670637	chr14:51637348~51637947:-
HNSC	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	4.28	2.22e-05	0.00393	0.33	0.19	QT interval;	chr4:75100963	chr4:75081702~75084717:-
HNSC	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	4.28	2.22e-05	0.00393	0.33	0.19	QT interval;	chr4:75101024	chr4:75081702~75084717:-
HNSC	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	4.28	2.22e-05	0.00393	0.33	0.19	QT interval;	chr4:75103663	chr4:75081702~75084717:-
HNSC	cis	rs933688	1	rs11948075	ENSG00000281357.1	ARRDC3-AS1	4.28	2.22e-05	0.00393	0.29	0.19	Smoking behavior;	chr5:91384762	chr5:91380349~91439085:+
HNSC	cis	rs933688	0.938	rs7705465	ENSG00000281357.1	ARRDC3-AS1	4.28	2.22e-05	0.00393	0.29	0.19	Smoking behavior;	chr5:91385132	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs889213	ENSG00000281357.1	ARRDC3-AS1	4.28	2.22e-05	0.00393	0.29	0.19	Smoking behavior;	chr5:91386334	chr5:91380349~91439085:+
HNSC	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	4.28	2.22e-05	0.00393	0.19	0.19	Asthma;	chr2:102364083	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	4.28	2.22e-05	0.00393	0.19	0.19	Asthma;	chr2:102364846	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	4.28	2.22e-05	0.00393	0.19	0.19	Asthma;	chr2:102365634	chr2:102438713~102440475:+
HNSC	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-4.28	2.22e-05	0.00393	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
HNSC	cis	rs61270009	0.913	rs357512	ENSG00000247828.6	TMEM161B-AS1	-4.28	2.22e-05	0.00393	-0.2	-0.19	Depressive symptoms;	chr5:88222061	chr5:88268895~88436685:+
HNSC	cis	rs2055729	0.524	rs111479670	ENSG00000254340.1	RP11-10A14.3	-4.28	2.22e-05	0.00393	-0.31	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9938044	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-4.28	2.22e-05	0.00393	-0.23	-0.19	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
HNSC	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-4.28	2.22e-05	0.00393	-0.27	-0.19	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-4.28	2.22e-05	0.00393	-0.27	-0.19	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
HNSC	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	4.28	2.22e-05	0.00393	0.22	0.19	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
HNSC	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	4.28	2.22e-05	0.00393	0.23	0.19	Height;	chr14:75101435	chr14:75011269~75012851:-
HNSC	cis	rs72634501	0.716	rs4660165	ENSG00000228060.1	RP11-69E11.8	4.28	2.22e-05	0.00393	0.22	0.19	HDL cholesterol;	chr1:39112860	chr1:39565160~39573203:+
HNSC	cis	rs67981189	0.896	rs2010061	ENSG00000274818.1	RP1-292L20.3	-4.28	2.22e-05	0.00393	-0.22	-0.19	Schizophrenia;	chr14:70899479	chr14:70906657~70907111:-
HNSC	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	4.28	2.22e-05	0.00394	0.19	0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
HNSC	cis	rs394563	0.517	rs385303	ENSG00000231760.4	RP11-350J20.5	4.28	2.23e-05	0.00394	0.27	0.19	Dupuytren's disease;	chr6:149457928	chr6:149796151~149826294:-
HNSC	cis	rs4256159	0.935	rs13078720	ENSG00000228956.7	SATB1-AS1	4.28	2.23e-05	0.00394	0.32	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18688760	chr3:18445024~18920401:+
HNSC	cis	rs651907	0.737	rs9844218	ENSG00000244119.1	PDCL3P4	-4.28	2.23e-05	0.00394	-0.2	-0.19	Colorectal cancer;	chr3:101866139	chr3:101712472~101713191:+
HNSC	cis	rs9880211	0.563	rs9848926	ENSG00000239213.4	NCK1-AS1	4.28	2.23e-05	0.00394	0.18	0.19	Height;Body mass index;	chr3:136097460	chr3:136841726~136862054:-
HNSC	cis	rs3015497	0.603	rs3015447	ENSG00000269906.1	RP11-248J18.2	-4.28	2.23e-05	0.00394	-0.26	-0.19	Mean platelet volume;	chr14:50615868	chr14:50662511~50663178:-
HNSC	cis	rs57561814	0.655	rs58879058	ENSG00000179428.2	AC073072.5	-4.28	2.23e-05	0.00394	-0.36	-0.19	Tonsillectomy;	chr7:22702203	chr7:22725395~22727620:-
HNSC	cis	rs9880211	0.752	rs9838884	ENSG00000273486.1	RP11-731C17.2	4.28	2.23e-05	0.00394	0.2	0.19	Height;Body mass index;	chr3:136736862	chr3:136837338~136839021:-
HNSC	cis	rs12291225	0.839	rs4757244	ENSG00000254418.1	RP11-21L19.1	-4.28	2.23e-05	0.00394	-0.24	-0.19	Sense of smell;	chr11:14237109	chr11:14262846~14273691:-
HNSC	cis	rs9951026	0.735	rs2276269	ENSG00000264464.1	RP11-110H1.8	-4.28	2.23e-05	0.00394	-0.23	-0.19	Testicular germ cell tumor;	chr18:49575632	chr18:49499390~49501860:+
HNSC	cis	rs7169223	0.653	rs3743057	ENSG00000261762.1	RP11-650L12.2	-4.28	2.23e-05	0.00394	-0.26	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78796665	chr15:78589123~78591276:-
HNSC	cis	rs9584850	0.718	rs6491427	ENSG00000231194.1	FARP1-AS1	4.28	2.23e-05	0.00394	0.24	0.19	Neuroticism;	chr13:98460912	chr13:98435405~98435840:-
HNSC	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-4.28	2.23e-05	0.00394	-0.26	-0.19	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
HNSC	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-4.28	2.23e-05	0.00394	-0.23	-0.19	Height;	chr14:75124143	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-4.28	2.23e-05	0.00394	-0.23	-0.19	Height;	chr14:75124368	chr14:75011269~75012851:-
HNSC	cis	rs7829975	0.807	rs519019	ENSG00000233609.3	RP11-62H7.2	-4.28	2.23e-05	0.00394	-0.19	-0.19	Mood instability;	chr8:8737594	chr8:8961200~8979025:+
HNSC	cis	rs9880211	0.752	rs9847427	ENSG00000273486.1	RP11-731C17.2	4.28	2.23e-05	0.00394	0.19	0.19	Height;Body mass index;	chr3:136632708	chr3:136837338~136839021:-
HNSC	cis	rs453301	0.624	rs2915251	ENSG00000253981.4	ALG1L13P	4.28	2.23e-05	0.00395	0.22	0.19	Joint mobility (Beighton score);	chr8:9009901	chr8:8236003~8244667:-
HNSC	cis	rs7005380	0.581	rs2326432	ENSG00000279347.1	RP11-85I17.2	-4.28	2.23e-05	0.00395	-0.18	-0.19	Interstitial lung disease;	chr8:119920672	chr8:119838736~119840385:-
HNSC	cis	rs2492286	0.518	rs2811506	ENSG00000242551.2	POU5F1P6	-4.28	2.23e-05	0.00395	-0.21	-0.19	Eosinophil counts;	chr3:128610801	chr3:128674735~128677005:-
HNSC	cis	rs4372836	0.964	rs34627117	ENSG00000226833.4	AC097724.3	-4.28	2.23e-05	0.00395	-0.25	-0.19	Body mass index;	chr2:28707610	chr2:28708953~28736205:-
HNSC	cis	rs2333021	0.745	rs12323848	ENSG00000258376.2	RP4-647C14.2	-4.28	2.23e-05	0.00395	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72986502	chr14:73242651~73245979:-
HNSC	cis	rs202072	0.652	rs202064	ENSG00000215022.6	RP1-257A7.4	4.28	2.23e-05	0.00395	0.3	0.19	HIV-1 viral setpoint;	chr6:13263794	chr6:13264861~13295586:-
HNSC	cis	rs7107174	1	rs58235466	ENSG00000251323.2	RP11-452H21.4	4.28	2.23e-05	0.00395	0.28	0.19	Testicular germ cell tumor;	chr11:78319840	chr11:78423982~78429836:-
HNSC	cis	rs9467773	0.587	rs9467722	ENSG00000241549.7	GUSBP2	4.28	2.24e-05	0.00395	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26352338	chr6:26871484~26956554:-
HNSC	cis	rs9880211	1	rs13092193	ENSG00000273486.1	RP11-731C17.2	4.28	2.24e-05	0.00395	0.18	0.19	Height;Body mass index;	chr3:136521524	chr3:136837338~136839021:-
HNSC	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-4.28	2.24e-05	0.00395	-0.25	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
HNSC	cis	rs6061231	0.561	rs67072353	ENSG00000275437.1	RP5-908M14.10	4.28	2.24e-05	0.00395	0.23	0.19	Colorectal cancer;	chr20:62365646	chr20:62402236~62405935:-
HNSC	cis	rs964611	0.938	rs12050648	ENSG00000259488.2	RP11-154J22.1	-4.28	2.24e-05	0.00395	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48297544	chr15:48312353~48331856:-
HNSC	cis	rs853679	0.882	rs4713139	ENSG00000226314.6	ZNF192P1	-4.28	2.24e-05	0.00395	-0.31	-0.19	Depression;	chr6:28124907	chr6:28161781~28169594:+
HNSC	cis	rs913655	0.545	rs2480338	ENSG00000225527.1	RP11-383B4.4	-4.28	2.24e-05	0.00396	-0.23	-0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18782322	chr10:18531849~18533336:-
HNSC	cis	rs7324557	0.717	rs6490826	ENSG00000205861.10	C1QTNF9B-AS1	-4.28	2.24e-05	0.00396	-0.27	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23804999	chr13:23888889~23897263:+
HNSC	cis	rs9487051	0.597	rs59673	ENSG00000243587.6	C6orf183	-4.28	2.24e-05	0.00396	-0.21	-0.19	Reticulocyte fraction of red cells;	chr6:109227510	chr6:109165833~109271014:+
HNSC	cis	rs12745968	0.653	rs6604013	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92726577	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.653	rs4847301	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92735367	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.595	rs6604014	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92750161	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.561	rs4847306	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92751415	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.59	rs2391195	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92753126	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.59	rs1337107	ENSG00000223787.2	RP4-593M8.1	-4.28	2.24e-05	0.00396	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92753219	chr1:92580476~92580821:-
HNSC	cis	rs1355223	0.506	rs7131229	ENSG00000271369.1	RP11-350D17.3	4.28	2.24e-05	0.00396	0.24	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847781	chr11:34709600~34710161:+
HNSC	cis	rs9910055	0.762	rs4239142	ENSG00000267080.4	ASB16-AS1	4.28	2.24e-05	0.00396	0.15	0.19	Total body bone mineral density;	chr17:44128508	chr17:44175973~44186717:-
HNSC	cis	rs1008375	0.932	rs3846356	ENSG00000249502.1	AC006160.5	-4.28	2.24e-05	0.00396	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612553	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.863	rs4590022	ENSG00000249502.1	AC006160.5	-4.28	2.24e-05	0.00396	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612811	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs4698630	ENSG00000249502.1	AC006160.5	-4.28	2.24e-05	0.00396	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613069	chr4:17587467~17614571:-
HNSC	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	4.28	2.24e-05	0.00396	0.26	0.19	Pain;	chr19:21497382	chr19:21554640~21569237:-
HNSC	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	4.28	2.24e-05	0.00396	0.21	0.19	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
HNSC	cis	rs5769707	0.605	rs2071900	ENSG00000235111.1	RP1-29C18.8	-4.28	2.24e-05	0.00396	-0.25	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49658527	chr22:49612657~49615716:-
HNSC	cis	rs3805389	1	rs3805383	ENSG00000273257.1	RP11-177J6.1	-4.28	2.24e-05	0.00396	-0.26	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55609171	chr4:55387949~55388271:+
HNSC	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	4.28	2.24e-05	0.00396	0.23	0.19	Height;	chr14:75133994	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	4.28	2.24e-05	0.00396	0.23	0.19	Height;	chr14:75136131	chr14:75011269~75012851:-
HNSC	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-4.28	2.24e-05	0.00396	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
HNSC	cis	rs2733201	1	rs11070419	ENSG00000205771.5	CATSPER2P1	4.28	2.24e-05	0.00396	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44034981	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs4924734	ENSG00000205771.5	CATSPER2P1	4.28	2.24e-05	0.00396	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44035872	chr15:43726918~43747094:-
HNSC	cis	rs2733201	1	rs4923972	ENSG00000205771.5	CATSPER2P1	4.28	2.24e-05	0.00396	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44037058	chr15:43726918~43747094:-
HNSC	cis	rs6964587	0.782	rs13221571	ENSG00000188693.7	CYP51A1-AS1	4.28	2.24e-05	0.00396	0.21	0.19	Breast cancer;	chr7:91870922	chr7:92134604~92180725:+
HNSC	cis	rs42490	0.716	rs42346	ENSG00000251136.7	RP11-37B2.1	4.28	2.24e-05	0.00396	0.17	0.19	Leprosy;	chr8:89816829	chr8:89609409~89757727:-
HNSC	cis	rs721917	0.525	rs10788338	ENSG00000244733.5	RP11-506M13.3	-4.28	2.24e-05	0.00396	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79660891~79677996:+
HNSC	cis	rs11157436	0.602	rs1894370	ENSG00000211812.1	TRAV26-2	-4.28	2.24e-05	0.00397	-0.18	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22202583~22203368:+
HNSC	cis	rs55823223	0.648	rs936394	ENSG00000267801.1	RP11-552F3.9	4.28	2.25e-05	0.00397	0.24	0.19	Psoriasis;	chr17:75855927	chr17:75876372~75879546:+
HNSC	cis	rs12478296	0.786	rs28802397	ENSG00000261186.2	RP11-341N2.1	-4.28	2.25e-05	0.00397	-0.32	-0.19	Obesity-related traits;	chr2:242107579	chr2:242087351~242088457:-
HNSC	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-4.28	2.25e-05	0.00397	-0.19	-0.19	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
HNSC	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-4.28	2.25e-05	0.00397	-0.25	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
HNSC	cis	rs2243480	1	rs1404147	ENSG00000229886.1	RP5-1132H15.3	4.28	2.25e-05	0.00397	0.3	0.19	Diabetic kidney disease;	chr7:65799537	chr7:66025126~66031544:-
HNSC	cis	rs2333021	0.78	rs2243596	ENSG00000258376.2	RP4-647C14.2	4.28	2.25e-05	0.00397	0.23	0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:73242651~73245979:-
HNSC	cis	rs7324557	0.93	rs7324545	ENSG00000205861.10	C1QTNF9B-AS1	4.28	2.25e-05	0.00397	0.26	0.19	Visceral adipose tissue adjusted for BMI;	chr13:23722702	chr13:23888889~23897263:+
HNSC	cis	rs1594829	0.553	rs2046225	ENSG00000228451.3	SDAD1P1	-4.28	2.25e-05	0.00397	-0.22	-0.19	Height;	chr8:26294286	chr8:26379259~26382953:-
HNSC	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	4.28	2.25e-05	0.00397	0.23	0.19	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
HNSC	cis	rs8077577	0.945	rs62073608	ENSG00000273018.4	CTD-2303H24.2	-4.28	2.25e-05	0.00397	-0.3	-0.19	Obesity-related traits;	chr17:18168134	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.945	rs62073609	ENSG00000273018.4	CTD-2303H24.2	-4.28	2.25e-05	0.00397	-0.3	-0.19	Obesity-related traits;	chr17:18168529	chr17:18511221~18551705:-
HNSC	cis	rs1799949	1	rs3092988	ENSG00000236383.6	LINC00854	-4.28	2.25e-05	0.00398	-0.18	-0.19	Menopause (age at onset);	chr17:43049685	chr17:43216941~43305976:-
HNSC	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-4.28	2.25e-05	0.00398	-0.21	-0.19	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
HNSC	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-4.28	2.25e-05	0.00398	-0.32	-0.19	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
HNSC	cis	rs7809950	0.817	rs2712230	ENSG00000238832.1	snoU109	4.28	2.25e-05	0.00398	0.27	0.19	Coronary artery disease;	chr7:107653706	chr7:107603363~107603507:+
HNSC	cis	rs7824557	0.628	rs11777746	ENSG00000269918.1	AF131215.9	4.28	2.25e-05	0.00398	0.19	0.19	Retinal vascular caliber;	chr8:11347246	chr8:11104691~11106704:-
HNSC	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	4.28	2.25e-05	0.00398	0.26	0.19	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000106610.13	STAG3L4	-4.28	2.26e-05	0.00398	-0.39	-0.19	Gout;	chr7:66715944	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000106610.13	STAG3L4	-4.28	2.26e-05	0.00398	-0.39	-0.19	Gout;	chr7:66721259	chr7:67302621~67321526:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000106610.13	STAG3L4	-4.28	2.26e-05	0.00398	-0.39	-0.19	Gout;	chr7:66732812	chr7:67302621~67321526:+
HNSC	cis	rs7568498	0.517	rs197261	ENSG00000235724.7	AC009299.2	4.28	2.26e-05	0.00398	0.26	0.19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161222785~161308303:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000229886.1	RP5-1132H15.3	4.28	2.26e-05	0.00398	0.33	0.19	Gout;	chr7:66645053	chr7:66025126~66031544:-
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000211974.3	IGHV2-70	4.28	2.26e-05	0.00399	0.18	0.19	Kawasaki disease;	chr14:106779713	chr14:106723574~106724093:-
HNSC	cis	rs7610312	0.681	rs9864859	ENSG00000273493.1	RP11-80H18.4	-4.28	2.26e-05	0.00399	-0.23	-0.19	Red blood cell count;	chr3:58286444	chr3:58329965~58330118:+
HNSC	cis	rs1799949	0.931	rs34410138	ENSG00000236383.6	LINC00854	-4.28	2.26e-05	0.00399	-0.18	-0.19	Menopause (age at onset);	chr17:43127753	chr17:43216941~43305976:-
HNSC	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-4.28	2.26e-05	0.00399	-0.18	-0.19	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
HNSC	cis	rs7824557	0.606	rs1435277	ENSG00000269918.1	AF131215.9	4.28	2.26e-05	0.00399	0.19	0.19	Retinal vascular caliber;	chr8:11339461	chr8:11104691~11106704:-
HNSC	cis	rs116095464	0.558	rs7708515	ENSG00000250848.1	CTD-2083E4.5	-4.28	2.26e-05	0.00399	-0.26	-0.19	Breast cancer;	chr5:234874	chr5:288833~290321:-
HNSC	cis	rs7572733	0.534	rs700688	ENSG00000231621.1	AC013264.2	4.28	2.26e-05	0.00399	0.19	0.19	Dermatomyositis;	chr2:197859109	chr2:197197991~197199273:+
HNSC	cis	rs9880211	0.948	rs13321721	ENSG00000273486.1	RP11-731C17.2	4.28	2.26e-05	0.00399	0.19	0.19	Height;Body mass index;	chr3:136490708	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-4.28	2.26e-05	0.00399	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
HNSC	cis	rs7121616	0.576	rs4936767	ENSG00000200879.1	SNORD14E	4.28	2.26e-05	0.004	0.25	0.19	Breast cancer;	chr11:123047451	chr11:123058077~123058161:-
HNSC	cis	rs9300255	0.544	rs1727309	ENSG00000280120.1	RP11-546D6.3	4.28	2.26e-05	0.004	0.19	0.19	Neutrophil percentage of white cells;	chr12:123173711	chr12:123152324~123153377:-
HNSC	cis	rs8077577	0.895	rs6502640	ENSG00000273018.4	CTD-2303H24.2	-4.28	2.26e-05	0.004	-0.29	-0.19	Obesity-related traits;	chr17:18219171	chr17:18511221~18551705:-
HNSC	cis	rs7826238	0.564	rs2921053	ENSG00000233609.3	RP11-62H7.2	4.28	2.27e-05	0.004	0.18	0.19	Systolic blood pressure;	chr8:8462453	chr8:8961200~8979025:+
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000239122.1	RNU2-11P	-4.28	2.27e-05	0.004	-0.2	-0.19	Pancreatic cancer;	chr3:195925837	chr3:195928589~195928775:-
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000239122.1	RNU2-11P	-4.28	2.27e-05	0.004	-0.2	-0.19	Pancreatic cancer;	chr3:195925980	chr3:195928589~195928775:-
HNSC	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	4.28	2.27e-05	0.004	0.23	0.19	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
HNSC	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-4.28	2.27e-05	0.004	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
HNSC	cis	rs2834288	0.7	rs731060	ENSG00000273102.1	AP000569.9	-4.28	2.27e-05	0.004	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33902624	chr21:33967101~33968573:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000235689.1	AP000351.13	4.28	2.27e-05	0.004	0.2	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:24006305~24008258:-
HNSC	cis	rs494453	0.583	rs559981	ENSG00000227811.2	FAM212B-AS1	-4.28	2.27e-05	0.004	-0.28	-0.19	Osteoporosis-related phenotypes;	chr1:111676716	chr1:111739841~111747798:+
HNSC	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	4.28	2.27e-05	0.004	0.23	0.19	Height;	chr14:75127136	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	4.28	2.27e-05	0.004	0.23	0.19	Height;	chr14:75127199	chr14:75011269~75012851:-
HNSC	cis	rs795484	0.926	rs708865	ENSG00000275409.1	RP11-131L12.4	-4.28	2.27e-05	0.004	-0.23	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118245728	chr12:118430147~118430699:+
HNSC	cis	rs2865126	0.818	rs8087370	ENSG00000264714.1	RP11-21G15.1	-4.28	2.27e-05	0.004	-0.24	-0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10764176	chr18:10724619~10728539:+
HNSC	cis	rs1355223	0.545	rs7123029	ENSG00000271369.1	RP11-350D17.3	-4.28	2.27e-05	0.00401	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853268	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.545	rs7111695	ENSG00000271369.1	RP11-350D17.3	-4.28	2.27e-05	0.00401	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853359	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.507	rs11032903	ENSG00000271369.1	RP11-350D17.3	-4.28	2.27e-05	0.00401	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854629	chr11:34709600~34710161:+
HNSC	cis	rs1355223	0.545	rs12278318	ENSG00000271369.1	RP11-350D17.3	-4.28	2.27e-05	0.00401	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854960	chr11:34709600~34710161:+
HNSC	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-4.28	2.27e-05	0.00401	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
HNSC	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-4.28	2.27e-05	0.00401	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
HNSC	cis	rs1602565	1	rs11030598	ENSG00000255450.1	CTD-2063L20.1	-4.28	2.27e-05	0.00401	-0.33	-0.19	Schizophrenia;	chr11:29170376	chr11:29275655~29276565:+
HNSC	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	4.28	2.27e-05	0.00401	0.2	0.19	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
HNSC	cis	rs9287719	0.934	rs6727884	ENSG00000243819.4	RN7SL832P	-4.28	2.27e-05	0.00401	-0.19	-0.19	Prostate cancer;	chr2:10617431	chr2:10690344~10692099:+
HNSC	cis	rs4938303	0.549	rs12785990	ENSG00000254851.1	RP11-109L13.1	4.28	2.27e-05	0.00401	0.29	0.19	Triglycerides;	chr11:116692990	chr11:117135528~117138582:+
HNSC	cis	rs6496044	0.963	rs11853972	ENSG00000259295.5	CSPG4P12	4.28	2.27e-05	0.00401	0.24	0.19	Interstitial lung disease;	chr15:85519209	chr15:85191438~85213905:+
HNSC	cis	rs2337406	1	rs3858878	ENSG00000280411.1	IGHV1-69-2	-4.28	2.28e-05	0.00401	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106688061	chr14:106762092~106762588:-
HNSC	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	4.28	2.28e-05	0.00401	0.25	0.19	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
HNSC	cis	rs58873874	0.579	rs77042939	ENSG00000248544.2	CTB-47B11.3	4.28	2.28e-05	0.00402	0.39	0.19	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157375741~157384950:-
HNSC	cis	rs1800562	1	rs1800562	ENSG00000272810.1	U91328.22	-4.28	2.28e-05	0.00402	-0.34	-0.19	Hematology traits;Iron status biomarkers (transferrin levels);Iron status biomarkers;Red blood cell count;Red blood cell traits;Mean corpuscular volume;Iron status biomarkers (ferritin levels);Iron status biomarkers (transferrin saturation);Diastolic blood pressure;Cholesterol, total;Cardiovascular disease risk factors;Hematocrit;Alcohol consumption (transferrin glycosylation);Hemoglobin;Iron status biomarkers (iron levels);Hematological parameters;LDL cholesterol;Mean corpuscular hemoglobin;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hepcidin levels;	chr6:26092913	chr6:26013241~26013757:+
HNSC	cis	rs2904524	1	rs17107935	ENSG00000257815.4	RP11-611E13.2	-4.28	2.28e-05	0.00402	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70286084	chr12:69904033~70243360:-
HNSC	cis	rs12545912	0.569	rs615171	ENSG00000254340.1	RP11-10A14.3	-4.28	2.28e-05	0.00402	-0.31	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9938679	chr8:9141424~9145435:+
HNSC	cis	rs9311676	0.609	rs62258080	ENSG00000273493.1	RP11-80H18.4	4.28	2.28e-05	0.00402	0.22	0.19	Systemic lupus erythematosus;	chr3:58381766	chr3:58329965~58330118:+
HNSC	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-4.28	2.28e-05	0.00402	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
HNSC	cis	rs3096299	0.869	rs748941	ENSG00000261574.1	RP1-168P16.2	4.28	2.28e-05	0.00402	0.24	0.19	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89392375~89412564:-
HNSC	cis	rs116095464	0.558	rs6555058	ENSG00000250848.1	CTD-2083E4.5	4.28	2.28e-05	0.00402	0.27	0.19	Breast cancer;	chr5:226261	chr5:288833~290321:-
HNSC	cis	rs7824557	0.564	rs2572394	ENSG00000269918.1	AF131215.9	-4.28	2.28e-05	0.00402	-0.19	-0.19	Retinal vascular caliber;	chr8:11377884	chr8:11104691~11106704:-
HNSC	cis	rs6964587	0.692	rs10227225	ENSG00000188693.7	CYP51A1-AS1	4.28	2.28e-05	0.00402	0.2	0.19	Breast cancer;	chr7:91941760	chr7:92134604~92180725:+
HNSC	cis	rs34421088	0.576	rs2736369	ENSG00000255310.2	AF131215.2	-4.28	2.28e-05	0.00402	-0.21	-0.19	Neuroticism;	chr8:11243889	chr8:11107788~11109726:-
HNSC	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	4.28	2.28e-05	0.00402	0.18	0.19	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
HNSC	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	4.28	2.28e-05	0.00402	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
HNSC	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-4.28	2.28e-05	0.00402	-0.32	-0.19	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
HNSC	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-4.28	2.28e-05	0.00402	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-4.28	2.28e-05	0.00402	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
HNSC	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	4.28	2.28e-05	0.00402	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	4.28	2.28e-05	0.00402	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	4.28	2.28e-05	0.00402	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
HNSC	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-4.28	2.28e-05	0.00402	-0.25	-0.19	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
HNSC	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	4.28	2.28e-05	0.00402	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
HNSC	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-4.28	2.28e-05	0.00403	-0.16	-0.19	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
HNSC	cis	rs1008375	1	rs3933453	ENSG00000249502.1	AC006160.5	-4.28	2.28e-05	0.00403	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17634696	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698641	ENSG00000249502.1	AC006160.5	-4.28	2.28e-05	0.00403	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641007	chr4:17587467~17614571:-
HNSC	cis	rs4356203	0.87	rs214900	ENSG00000272034.1	SNORD14A	4.28	2.28e-05	0.00403	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17074654~17074744:-
HNSC	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	4.28	2.28e-05	0.00403	0.19	0.19	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
HNSC	cis	rs11157436	0.918	rs1076546	ENSG00000211812.1	TRAV26-2	-4.28	2.28e-05	0.00403	-0.2	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22202583~22203368:+
HNSC	cis	rs3015497	0.789	rs10133849	ENSG00000277050.1	RP11-102G14.1	-4.28	2.28e-05	0.00403	-0.19	-0.19	Mean platelet volume;	chr14:50654982	chr14:51637348~51637947:-
HNSC	cis	rs7610312	0.681	rs4681674	ENSG00000273493.1	RP11-80H18.4	-4.28	2.29e-05	0.00403	-0.23	-0.19	Red blood cell count;	chr3:58288088	chr3:58329965~58330118:+
HNSC	cis	rs4295623	0.816	rs35558975	ENSG00000269918.1	AF131215.9	-4.28	2.29e-05	0.00403	-0.2	-0.19	Morning vs. evening chronotype;	chr8:11726967	chr8:11104691~11106704:-
HNSC	cis	rs2518049	1	rs2518049	ENSG00000224034.1	RP11-445P17.8	-4.28	2.29e-05	0.00403	-0.26	-0.19	Metabolic traits;	chr10:5095844	chr10:5266033~5271236:-
HNSC	cis	rs73198271	0.855	rs57301822	ENSG00000233609.3	RP11-62H7.2	-4.28	2.29e-05	0.00403	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8961200~8979025:+
HNSC	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	4.28	2.29e-05	0.00403	0.27	0.19	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
HNSC	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-4.28	2.29e-05	0.00403	-0.27	-0.19	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
HNSC	cis	rs11098499	0.909	rs28555550	ENSG00000250412.1	KLHL2P1	4.28	2.29e-05	0.00403	0.25	0.19	Corneal astigmatism;	chr4:119289885	chr4:119334329~119378233:+
HNSC	cis	rs11098499	1	rs28419773	ENSG00000250412.1	KLHL2P1	4.28	2.29e-05	0.00403	0.25	0.19	Corneal astigmatism;	chr4:119289906	chr4:119334329~119378233:+
HNSC	cis	rs12682352	0.602	rs28399241	ENSG00000173295.6	FAM86B3P	4.28	2.29e-05	0.00403	0.22	0.19	Neuroticism;	chr8:8805705	chr8:8228595~8244865:+
HNSC	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-4.28	2.29e-05	0.00404	-0.25	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
HNSC	cis	rs6604026	0.922	rs11586570	ENSG00000223787.2	RP4-593M8.1	4.28	2.29e-05	0.00404	0.27	0.19	Multiple sclerosis;	chr1:92839814	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.922	rs12750269	ENSG00000223787.2	RP4-593M8.1	4.28	2.29e-05	0.00404	0.27	0.19	Multiple sclerosis;	chr1:92846104	chr1:92580476~92580821:-
HNSC	cis	rs6604026	0.922	rs12746956	ENSG00000223787.2	RP4-593M8.1	4.28	2.29e-05	0.00404	0.27	0.19	Multiple sclerosis;	chr1:92846585	chr1:92580476~92580821:-
HNSC	cis	rs6500395	1	rs8059905	ENSG00000261267.1	RP11-44I10.3	-4.28	2.29e-05	0.00404	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48596023	chr16:48559661~48587403:+
HNSC	cis	rs7824557	0.564	rs7839307	ENSG00000269918.1	AF131215.9	4.28	2.29e-05	0.00404	0.19	0.19	Retinal vascular caliber;	chr8:11341283	chr8:11104691~11106704:-
HNSC	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-4.28	2.29e-05	0.00404	-0.28	-0.19	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
HNSC	cis	rs7176527	0.784	rs62021162	ENSG00000259570.1	RP11-671M22.4	-4.28	2.29e-05	0.00404	-0.28	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84394512~84395514:+
HNSC	cis	rs8028182	0.666	rs4886708	ENSG00000260269.4	CTD-2323K18.1	-4.28	2.29e-05	0.00404	-0.25	-0.19	Sudden cardiac arrest;	chr15:75470267	chr15:75527150~75601205:-
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	4.28	2.29e-05	0.00404	0.18	0.19	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
HNSC	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-4.28	2.29e-05	0.00404	-0.21	-0.19	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
HNSC	cis	rs2337406	1	rs11850709	ENSG00000280411.1	IGHV1-69-2	-4.28	2.29e-05	0.00404	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106670844	chr14:106762092~106762588:-
HNSC	cis	rs73198271	0.96	rs73198287	ENSG00000253893.2	FAM85B	4.28	2.29e-05	0.00404	0.29	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr8:8167819~8226614:-
HNSC	cis	rs1602565	0.858	rs1552717	ENSG00000255450.1	CTD-2063L20.1	-4.28	2.3e-05	0.00404	-0.29	-0.19	Schizophrenia;	chr11:29136948	chr11:29275655~29276565:+
HNSC	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	4.28	2.3e-05	0.00404	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
HNSC	cis	rs2486288	0.656	rs11639420	ENSG00000259479.5	SORD2P	-4.28	2.3e-05	0.00404	-0.22	-0.19	Glomerular filtration rate;	chr15:45267070	chr15:44826371~44884694:-
HNSC	cis	rs393155	0.517	rs330050	ENSG00000233609.3	RP11-62H7.2	-4.28	2.3e-05	0.00405	-0.18	-0.19	Neuroticism;	chr8:9230169	chr8:8961200~8979025:+
HNSC	cis	rs453301	0.571	rs330054	ENSG00000233609.3	RP11-62H7.2	-4.28	2.3e-05	0.00405	-0.18	-0.19	Joint mobility (Beighton score);	chr8:9230781	chr8:8961200~8979025:+
HNSC	cis	rs3736485	0.844	rs7181470	ENSG00000259438.1	CTD-2650P22.1	4.28	2.3e-05	0.00405	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51508685	chr15:52010999~52019095:-
HNSC	cis	rs6831352	1	rs1126673	ENSG00000263923.1	RP11-571L19.7	-4.28	2.3e-05	0.00405	-0.2	-0.19	Alcohol dependence;	chr4:99124465	chr4:98928897~98994994:+
HNSC	cis	rs6558530	0.666	rs6558518	ENSG00000253982.1	CTD-2336O2.1	4.28	2.3e-05	0.00405	0.25	0.19	Systolic blood pressure;	chr8:1749143	chr8:1761990~1764502:-
HNSC	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	4.28	2.3e-05	0.00405	0.21	0.19	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
HNSC	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	4.28	2.3e-05	0.00405	0.2	0.19	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs6874182	ENSG00000247828.6	TMEM161B-AS1	4.28	2.3e-05	0.00405	0.2	0.19	Depressive symptoms;	chr5:88407268	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	4.28	2.3e-05	0.00405	0.2	0.19	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	4.28	2.3e-05	0.00405	0.2	0.19	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
HNSC	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	4.28	2.3e-05	0.00405	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	4.28	2.3e-05	0.00405	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	4.28	2.3e-05	0.00405	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	4.28	2.3e-05	0.00405	0.23	0.19	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
HNSC	cis	rs755249	0.508	rs6703800	ENSG00000182109.6	RP11-69E11.4	-4.28	2.3e-05	0.00405	-0.2	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39522280~39546187:-
HNSC	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-4.28	2.3e-05	0.00405	-0.26	-0.19	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
HNSC	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	4.28	2.3e-05	0.00405	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
HNSC	cis	rs11951515	0.508	rs11958046	ENSG00000249286.1	CTD-2210P15.2	4.28	2.3e-05	0.00405	0.2	0.19	Metabolite levels  (X-11787);	chr5:43583287	chr5:43586918~43588223:-
HNSC	cis	rs7572733	0.84	rs7340470	ENSG00000222017.1	AC011997.1	-4.28	2.3e-05	0.00405	-0.24	-0.19	Dermatomyositis;	chr2:197680738	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.84	rs12622674	ENSG00000222017.1	AC011997.1	-4.28	2.3e-05	0.00405	-0.24	-0.19	Dermatomyositis;	chr2:197687088	chr2:197693106~197774823:+
HNSC	cis	rs2439831	0.85	rs8023458	ENSG00000201136.1	RNU6-353P	-4.28	2.3e-05	0.00405	-0.31	-0.19	Lung cancer in ever smokers;	chr15:43788741	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.85	rs16963953	ENSG00000201136.1	RNU6-353P	-4.28	2.3e-05	0.00405	-0.31	-0.19	Lung cancer in ever smokers;	chr15:43789521	chr15:43702363~43702470:+
HNSC	cis	rs79349575	0.783	rs4399576	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48932473	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.687	rs12602179	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48932672	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs17708633	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48934258	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs9747646	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48939520	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs62075852	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48939814	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs12601858	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48940115	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs8182364	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48940663	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.681	rs56080003	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48941687	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4793995	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48942037	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4793996	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48942235	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.715	rs4793997	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48942310	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4793998	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48942537	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs2270574	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48944908	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs4794000	ENSG00000270781.1	RP11-501C14.9	-4.28	2.3e-05	0.00405	-0.2	-0.19	Type 2 diabetes;	chr17:48945393	chr17:48899131~48899748:+
HNSC	cis	rs9311676	0.609	rs11921259	ENSG00000273493.1	RP11-80H18.4	4.28	2.3e-05	0.00405	0.21	0.19	Systemic lupus erythematosus;	chr3:58382919	chr3:58329965~58330118:+
HNSC	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102359712	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102360736	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102361051	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102361270	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102361999	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	4.28	2.3e-05	0.00405	0.19	0.19	Asthma;	chr2:102363164	chr2:102438713~102440475:+
HNSC	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	4.28	2.3e-05	0.00405	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	4.28	2.3e-05	0.00405	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
HNSC	cis	rs9311676	0.656	rs56198078	ENSG00000273493.1	RP11-80H18.4	4.28	2.3e-05	0.00406	0.21	0.19	Systemic lupus erythematosus;	chr3:58406497	chr3:58329965~58330118:+
HNSC	cis	rs7243790	0.967	rs62091589	ENSG00000277324.1	RP11-850A17.1	-4.28	2.3e-05	0.00406	-0.22	-0.19	Diastolic blood pressure;	chr18:54425327	chr18:54268346~54270028:-
HNSC	cis	rs7071275	0.525	rs1649184	ENSG00000223432.1	RP11-62L18.3	-4.28	2.31e-05	0.00406	-0.25	-0.19	Dupuytren's disease;	chr10:121617734	chr10:121615425~121615839:-
HNSC	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00406	0.22	0.19	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
HNSC	cis	rs454422	0.556	rs6053817	ENSG00000275632.1	RP5-967N21.11	4.28	2.31e-05	0.00406	0.21	0.19	HIV-1 viral setpoint;	chr20:6000052	chr20:6000418~6000941:+
HNSC	cis	rs7121616	0.595	rs7949414	ENSG00000200879.1	SNORD14E	4.28	2.31e-05	0.00406	0.25	0.19	Breast cancer;	chr11:123072787	chr11:123058077~123058161:-
HNSC	cis	rs1602565	0.858	rs10160490	ENSG00000255450.1	CTD-2063L20.1	-4.28	2.31e-05	0.00406	-0.3	-0.19	Schizophrenia;	chr11:29134283	chr11:29275655~29276565:+
HNSC	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00406	0.18	0.19	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00406	0.18	0.19	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00406	0.18	0.19	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00406	0.18	0.19	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
HNSC	cis	rs6500395	1	rs9933976	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48556234	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs3826174	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48557101	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7187513	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48557727	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9939103	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48558465	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1106386	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48559154	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs2354578	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48559387	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs871903	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48559732	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs36077931	ENSG00000261267.1	RP11-44I10.3	-4.28	2.31e-05	0.00406	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48560310	chr16:48559661~48587403:+
HNSC	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-4.28	2.31e-05	0.00407	-0.25	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
HNSC	cis	rs11846409	0.932	rs731012	ENSG00000254174.1	IGHV1-12	4.28	2.31e-05	0.00407	0.16	0.19	Rheumatic heart disease;	chr14:106632578	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs731011	ENSG00000254174.1	IGHV1-12	4.28	2.31e-05	0.00407	0.16	0.19	Rheumatic heart disease;	chr14:106632619	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs10138537	ENSG00000254174.1	IGHV1-12	4.28	2.31e-05	0.00407	0.16	0.19	Rheumatic heart disease;	chr14:106632778	chr14:106122420~106122709:-
HNSC	cis	rs9291683	0.507	rs6827754	ENSG00000250413.1	RP11-448G15.1	4.28	2.31e-05	0.00407	0.24	0.19	Bone mineral density;	chr4:10016529	chr4:10006482~10009725:+
HNSC	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	4.28	2.31e-05	0.00407	0.19	0.19	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
HNSC	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	4.28	2.31e-05	0.00407	0.2	0.19	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	4.28	2.31e-05	0.00407	0.2	0.19	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	4.28	2.31e-05	0.00407	0.2	0.19	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
HNSC	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	4.28	2.31e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
HNSC	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	4.28	2.31e-05	0.00407	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
HNSC	cis	rs12545912	0.525	rs544515	ENSG00000254340.1	RP11-10A14.3	-4.28	2.31e-05	0.00407	-0.31	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9938105	chr8:9141424~9145435:+
HNSC	cis	rs879620	1	rs2531995	ENSG00000262185.1	RP11-462G12.1	-4.28	2.31e-05	0.00407	-0.24	-0.19	Hip circumference;Body mass index;	chr16:3963466	chr16:3947609~3950444:-
HNSC	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-4.28	2.31e-05	0.00407	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-4.28	2.31e-05	0.00407	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
HNSC	cis	rs9450351	0.744	rs9444353	ENSG00000203875.9	SNHG5	-4.28	2.31e-05	0.00407	-0.45	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85566986	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs9351063	ENSG00000203875.9	SNHG5	-4.28	2.31e-05	0.00407	-0.45	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85567123	chr6:85660950~85678736:-
HNSC	cis	rs7246760	0.609	rs12459250	ENSG00000267289.1	CTD-2623N2.11	4.28	2.31e-05	0.00407	0.33	0.19	Pursuit maintenance gain;	chr19:9798867	chr19:9834079~9835013:-
HNSC	cis	rs7246760	1	rs10425775	ENSG00000267289.1	CTD-2623N2.11	4.28	2.31e-05	0.00407	0.33	0.19	Pursuit maintenance gain;	chr19:9802241	chr19:9834079~9835013:-
HNSC	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	4.28	2.31e-05	0.00407	0.2	0.19	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
HNSC	cis	rs9513627	0.573	rs4771336	ENSG00000280710.1	RP11-214F16.8	4.28	2.31e-05	0.00407	0.25	0.19	Obesity-related traits;	chr13:99558356	chr13:99498524~99501315:+
HNSC	cis	rs2562456	0.917	rs2681376	ENSG00000268081.1	RP11-678G14.2	-4.28	2.32e-05	0.00408	-0.26	-0.19	Pain;	chr19:21532723	chr19:21554640~21569237:-
HNSC	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	4.28	2.32e-05	0.00408	0.23	0.19	Height;	chr14:75058746	chr14:75011269~75012851:-
HNSC	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-4.28	2.32e-05	0.00408	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-4.28	2.32e-05	0.00408	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-4.28	2.32e-05	0.00408	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000233609.3	RP11-62H7.2	4.28	2.32e-05	0.00408	0.19	0.19	Neuroticism;	chr8:8866905	chr8:8961200~8979025:+
HNSC	cis	rs1009077	0.716	rs62319657	ENSG00000245958.5	RP11-33B1.1	4.28	2.32e-05	0.00408	0.22	0.19	Endometriosis;	chr4:119621367	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs13136296	ENSG00000245958.5	RP11-33B1.1	4.28	2.32e-05	0.00408	0.22	0.19	Endometriosis;	chr4:119622000	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs62319658	ENSG00000245958.5	RP11-33B1.1	4.28	2.32e-05	0.00408	0.22	0.19	Endometriosis;	chr4:119623849	chr4:119454791~119552025:+
HNSC	cis	rs9611565	0.729	rs505533	ENSG00000235513.1	RP4-756G23.5	-4.27	2.32e-05	0.00408	-0.22	-0.19	Vitiligo;	chr22:41468212	chr22:41209122~41217627:-
HNSC	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-4.27	2.32e-05	0.00408	-0.26	-0.19	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
HNSC	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.27	2.32e-05	0.00408	0.28	0.19	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
HNSC	cis	rs889398	0.835	rs62050037	ENSG00000196696.11	PDXDC2P	4.27	2.32e-05	0.00408	0.14	0.19	Body mass index;	chr16:69750767	chr16:69976297~70065948:-
HNSC	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	4.27	2.32e-05	0.00408	0.22	0.19	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
HNSC	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	4.27	2.32e-05	0.00408	0.19	0.19	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
HNSC	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-4.27	2.32e-05	0.00408	-0.2	-0.19	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
HNSC	cis	rs6163	0.727	rs284862	ENSG00000213061.2	PFN1P11	-4.27	2.32e-05	0.00408	-0.24	-0.19	Waist circumference;Hip circumference;	chr10:102812324	chr10:102838011~102845473:-
HNSC	cis	rs11673344	0.503	rs1667370	ENSG00000267698.1	AC002116.7	4.27	2.32e-05	0.00408	0.17	0.19	Obesity-related traits;	chr19:36999318	chr19:36014508~36045972:+
HNSC	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-4.27	2.32e-05	0.00408	-0.23	-0.19	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
HNSC	cis	rs10495285	1	rs10495285	ENSG00000213028.3	RP11-108F13.2	4.27	2.32e-05	0.00408	0.23	0.19	Response to cytadine analogues (cytosine arabinoside);	chr1:229669248	chr1:229688999~229689904:-
HNSC	cis	rs1355223	0.525	rs7129517	ENSG00000271369.1	RP11-350D17.3	-4.27	2.32e-05	0.00408	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850689	chr11:34709600~34710161:+
HNSC	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	4.27	2.32e-05	0.00409	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
HNSC	cis	rs1056107	0.897	rs10817282	ENSG00000225513.1	RP11-165N19.2	-4.27	2.32e-05	0.00409	-0.21	-0.19	Colorectal cancer;	chr9:112194636	chr9:112173522~112173971:-
HNSC	cis	rs12893668	0.703	rs2274267	ENSG00000269910.1	RP11-73M18.10	4.27	2.33e-05	0.00409	0.19	0.19	Reticulocyte count;	chr14:103563112	chr14:103694516~103695050:-
HNSC	cis	rs13434995	0.562	rs10529258	ENSG00000273257.1	RP11-177J6.1	-4.27	2.33e-05	0.00409	-0.27	-0.19	Adiponectin levels;	chr4:55546702	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.512	rs115635692	ENSG00000273257.1	RP11-177J6.1	-4.27	2.33e-05	0.00409	-0.27	-0.19	Adiponectin levels;	chr4:55546706	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.626	rs116135676	ENSG00000273257.1	RP11-177J6.1	-4.27	2.33e-05	0.00409	-0.27	-0.19	Adiponectin levels;	chr4:55546707	chr4:55387949~55388271:+
HNSC	cis	rs8077577	0.945	rs62073604	ENSG00000273018.4	CTD-2303H24.2	-4.27	2.33e-05	0.00409	-0.29	-0.19	Obesity-related traits;	chr17:18162574	chr17:18511221~18551705:-
HNSC	cis	rs10462794	0.789	rs12659657	ENSG00000260763.1	RP11-445O3.3	-4.27	2.33e-05	0.00409	-0.23	-0.19	DNA methylation (variation);	chr5:4475977	chr5:4436850~4440259:-
HNSC	cis	rs72717009	0.825	rs7515174	ENSG00000225217.1	HSPA7	-4.27	2.33e-05	0.00409	-0.34	-0.19	Rheumatoid arthritis;	chr1:161507159	chr1:161606291~161608217:+
HNSC	cis	rs72717009	0.825	rs7539468	ENSG00000225217.1	HSPA7	-4.27	2.33e-05	0.00409	-0.34	-0.19	Rheumatoid arthritis;	chr1:161507276	chr1:161606291~161608217:+
HNSC	cis	rs72717009	0.778	rs9427400	ENSG00000225217.1	HSPA7	-4.27	2.33e-05	0.00409	-0.34	-0.19	Rheumatoid arthritis;	chr1:161507414	chr1:161606291~161608217:+
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	4.27	2.33e-05	0.00409	0.21	0.19	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
HNSC	cis	rs2998286	0.723	rs332189	ENSG00000254635.4	WAC-AS1	-4.27	2.33e-05	0.00409	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28628292	chr10:28522652~28532743:-
HNSC	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	4.27	2.33e-05	0.00409	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	4.27	2.33e-05	0.00409	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	4.27	2.33e-05	0.00409	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
HNSC	cis	rs755249	0.501	rs4660669	ENSG00000182109.6	RP11-69E11.4	-4.27	2.33e-05	0.00409	-0.2	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39522280~39546187:-
HNSC	cis	rs13434995	0.513	rs62303730	ENSG00000273257.1	RP11-177J6.1	-4.27	2.33e-05	0.0041	-0.27	-0.19	Adiponectin levels;	chr4:55498948	chr4:55387949~55388271:+
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	4.27	2.33e-05	0.0041	0.23	0.19	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
HNSC	cis	rs9880211	0.948	rs17298525	ENSG00000273486.1	RP11-731C17.2	4.27	2.33e-05	0.0041	0.19	0.19	Height;Body mass index;	chr3:136474183	chr3:136837338~136839021:-
HNSC	cis	rs7868228	1	rs55884419	ENSG00000240498.5	CDKN2B-AS1	-4.27	2.33e-05	0.0041	-0.25	-0.19	Gut microbiome composition (winter);	chr9:21673227	chr9:21994778~22121097:+
HNSC	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-4.27	2.33e-05	0.0041	-0.22	-0.19	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
HNSC	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-4.27	2.33e-05	0.0041	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
HNSC	cis	rs5770917	1	rs5770924	ENSG00000272821.1	CTA-384D8.36	-4.27	2.33e-05	0.0041	-0.36	-0.19	Narcolepsy;	chr22:50586113	chr22:50523926~50524780:+
HNSC	cis	rs347412	1	rs347416	ENSG00000237263.1	MAPK6PS3	4.27	2.33e-05	0.0041	0.24	0.19	Pulmonary function in asthmatics;	chr13:42213726	chr13:42068932~42071093:-
HNSC	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-4.27	2.33e-05	0.0041	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
HNSC	cis	rs2361718	0.5	rs8064429	ENSG00000279259.1	RP11-334C17.3	4.27	2.33e-05	0.0041	0.25	0.19	Yeast infection;	chr17:80122388	chr17:80147250~80148596:+
HNSC	cis	rs1799949	1	rs11657835	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.0041	-0.18	-0.19	Menopause (age at onset);	chr17:43139936	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1135214	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.0041	-0.18	-0.19	Menopause (age at onset);	chr17:43140306	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4793212	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.0041	-0.18	-0.19	Menopause (age at onset);	chr17:43150733	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs34534709	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.0041	-0.18	-0.19	Menopause (age at onset);	chr17:43150923	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs34059614	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.0041	-0.18	-0.19	Menopause (age at onset);	chr17:43151054	chr17:43216941~43305976:-
HNSC	cis	rs7937890	0.904	rs67623158	ENSG00000254418.1	RP11-21L19.1	-4.27	2.33e-05	0.0041	-0.22	-0.19	Mitochondrial DNA levels;	chr11:14273650	chr11:14262846~14273691:-
HNSC	cis	rs28489187	0.617	rs233112	ENSG00000223653.4	RP11-131L23.1	-4.27	2.33e-05	0.0041	-0.26	-0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85320068	chr1:85276715~85448124:+
HNSC	cis	rs11239930	1	rs11239930	ENSG00000230832.3	RP11-325P15.2	-4.27	2.33e-05	0.0041	-0.21	-0.19	AIDS progression;	chr1:147089017	chr1:147082338~147083578:-
HNSC	cis	rs2548724	0.617	rs62372237	ENSG00000250682.4	LINC00491	4.27	2.33e-05	0.0041	0.25	0.19	Type 2 diabetes;	chr5:102332390	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.648	rs12655961	ENSG00000250682.4	LINC00491	4.27	2.33e-05	0.0041	0.25	0.19	Type 2 diabetes;	chr5:102333311	chr5:102609156~102671559:-
HNSC	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-4.27	2.33e-05	0.0041	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
HNSC	cis	rs72627123	0.881	rs28548133	ENSG00000259065.1	RP5-1021I20.1	4.27	2.33e-05	0.0041	0.34	0.19	Morning vs. evening chronotype;	chr14:73842451	chr14:73787360~73803270:+
HNSC	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-4.27	2.34e-05	0.00411	-0.22	-0.19	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
HNSC	cis	rs4356203	0.905	rs7946010	ENSG00000260196.1	RP1-239B22.5	4.27	2.34e-05	0.00411	0.2	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17380649~17383531:+
HNSC	cis	rs1799949	1	rs16940	ENSG00000236383.6	LINC00854	-4.27	2.34e-05	0.00411	-0.18	-0.19	Menopause (age at onset);	chr17:43093220	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.93	rs66499067	ENSG00000236383.6	LINC00854	-4.27	2.34e-05	0.00411	-0.18	-0.19	Menopause (age at onset);	chr17:43096467	chr17:43216941~43305976:-
HNSC	cis	rs6964587	0.836	rs757040	ENSG00000188693.7	CYP51A1-AS1	4.27	2.34e-05	0.00411	0.21	0.19	Breast cancer;	chr7:91922702	chr7:92134604~92180725:+
HNSC	cis	rs11723261	0.582	rs6599293	ENSG00000211553.1	AC253576.2	-4.27	2.34e-05	0.00411	-0.28	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:136461~136568:+
HNSC	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	4.27	2.34e-05	0.00411	0.2	0.19	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
HNSC	cis	rs42490	0.716	rs40638	ENSG00000251136.7	RP11-37B2.1	-4.27	2.34e-05	0.00411	-0.17	-0.19	Leprosy;	chr8:89815824	chr8:89609409~89757727:-
HNSC	cis	rs42490	0.716	rs370282	ENSG00000251136.7	RP11-37B2.1	-4.27	2.34e-05	0.00411	-0.17	-0.19	Leprosy;	chr8:89816117	chr8:89609409~89757727:-
HNSC	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-4.27	2.34e-05	0.00411	-0.16	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
HNSC	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-4.27	2.34e-05	0.00411	-0.24	-0.19	Height;	chr20:49241753	chr20:49280319~49280409:+
HNSC	cis	rs800888	0.518	rs2737225	ENSG00000249917.2	LINC00536	-4.27	2.34e-05	0.00411	-0.26	-0.19	Monocyte percentage of white cells;	chr8:115627235	chr8:115950511~116325059:-
HNSC	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	4.27	2.34e-05	0.00412	0.19	0.19	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	4.27	2.34e-05	0.00412	0.19	0.19	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	4.27	2.34e-05	0.00412	0.19	0.19	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
HNSC	cis	rs4713118	0.869	rs2056925	ENSG00000216901.1	AL022393.7	4.27	2.34e-05	0.00412	0.24	0.19	Parkinson's disease;	chr6:27723126	chr6:28176188~28176674:+
HNSC	cis	rs763567	0.817	rs598993	ENSG00000271811.1	RP1-79C4.4	4.27	2.34e-05	0.00412	0.21	0.19	Tonsillectomy;	chr1:170634981	chr1:170667381~170669425:+
HNSC	cis	rs763567	0.935	rs541557	ENSG00000271811.1	RP1-79C4.4	4.27	2.34e-05	0.00412	0.21	0.19	Tonsillectomy;	chr1:170635797	chr1:170667381~170669425:+
HNSC	cis	rs2998286	0.637	rs332113	ENSG00000254635.4	WAC-AS1	-4.27	2.35e-05	0.00412	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28634806	chr10:28522652~28532743:-
HNSC	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	4.27	2.35e-05	0.00412	0.19	0.19	Height;	chr5:37508981	chr5:36666214~36725195:-
HNSC	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	4.27	2.35e-05	0.00412	0.23	0.19	Height;	chr14:75142025	chr14:75011269~75012851:-
HNSC	cis	rs3015497	0.603	rs955879	ENSG00000269906.1	RP11-248J18.2	-4.27	2.35e-05	0.00412	-0.26	-0.19	Mean platelet volume;	chr14:50615256	chr14:50662511~50663178:-
HNSC	cis	rs58873874	0.737	rs10515750	ENSG00000251405.2	CTB-109A12.1	4.27	2.35e-05	0.00412	0.4	0.19	Bipolar disorder (body mass index interaction);	chr5:157383064	chr5:157362615~157460078:-
HNSC	cis	rs1602565	0.698	rs10835489	ENSG00000255450.1	CTD-2063L20.1	-4.27	2.35e-05	0.00412	-0.3	-0.19	Schizophrenia;	chr11:29138393	chr11:29275655~29276565:+
HNSC	cis	rs4660214	0.724	rs12117785	ENSG00000182109.6	RP11-69E11.4	-4.27	2.35e-05	0.00412	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39522280~39546187:-
HNSC	cis	rs948562	0.535	rs11229369	ENSG00000280010.1	AP001350.4	4.27	2.35e-05	0.00412	0.33	0.19	Lymphoma;	chr11:58341039	chr11:58627435~58628528:+
HNSC	cis	rs295490	0.748	rs10513063	ENSG00000272656.1	RP11-219D15.3	4.27	2.35e-05	0.00412	0.45	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341586	chr3:139349024~139349371:-
HNSC	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.27	2.35e-05	0.00413	0.18	0.19	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
HNSC	cis	rs2657294	0.62	rs2395132	ENSG00000233313.2	HMGA1P5	-4.27	2.35e-05	0.00413	-0.21	-0.19	Pneumonia;	chr10:75080840	chr10:75276376~75276646:-
HNSC	cis	rs6496044	0.507	rs8034676	ENSG00000259295.5	CSPG4P12	4.27	2.35e-05	0.00413	0.23	0.19	Interstitial lung disease;	chr15:85616031	chr15:85191438~85213905:+
HNSC	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-4.27	2.35e-05	0.00413	-0.2	-0.19	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
HNSC	cis	rs7688540	0.771	rs11248013	ENSG00000211553.1	AC253576.2	-4.27	2.35e-05	0.00413	-0.31	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:136461~136568:+
HNSC	cis	rs7178375	1	rs4779797	ENSG00000270015.1	RP11-540B6.6	-4.27	2.35e-05	0.00413	-0.24	-0.19	Hypertriglyceridemia;	chr15:30916222	chr15:30926514~30928407:+
HNSC	cis	rs9880211	1	rs67949818	ENSG00000273486.1	RP11-731C17.2	4.27	2.35e-05	0.00413	0.18	0.19	Height;Body mass index;	chr3:136494136	chr3:136837338~136839021:-
HNSC	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-4.27	2.35e-05	0.00413	-0.2	-0.19	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
HNSC	cis	rs7107174	1	rs2512542	ENSG00000251323.2	RP11-452H21.4	4.27	2.35e-05	0.00413	0.28	0.19	Testicular germ cell tumor;	chr11:78270734	chr11:78423982~78429836:-
HNSC	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	-4.27	2.35e-05	0.00413	-0.31	-0.19	Depression;	chr6:28139579	chr6:28161781~28169594:+
HNSC	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	4.27	2.35e-05	0.00413	0.27	0.19	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
HNSC	cis	rs1009181	0.585	rs4486004	ENSG00000272462.2	U91328.19	-4.27	2.35e-05	0.00413	-0.21	-0.19	Childhood ear infection;	chr6:26167482	chr6:25992662~26001775:+
HNSC	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-4.27	2.35e-05	0.00413	-0.2	-0.19	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
HNSC	cis	rs748404	0.666	rs8027748	ENSG00000166763.7	STRCP1	4.27	2.35e-05	0.00413	0.28	0.19	Lung cancer;	chr15:43447622	chr15:43699488~43718184:-
HNSC	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-4.27	2.35e-05	0.00413	-0.32	-0.19	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
HNSC	cis	rs6831352	0.918	rs2851248	ENSG00000263923.1	RP11-571L19.7	-4.27	2.36e-05	0.00413	-0.21	-0.19	Alcohol dependence;	chr4:99124823	chr4:98928897~98994994:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000250412.1	KLHL2P1	4.27	2.36e-05	0.00413	0.25	0.19	Corneal astigmatism;	chr4:119326939	chr4:119334329~119378233:+
HNSC	cis	rs964611	0.882	rs12594698	ENSG00000259488.2	RP11-154J22.1	-4.27	2.36e-05	0.00413	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48282759	chr15:48312353~48331856:-
HNSC	cis	rs3096299	0.967	rs28689480	ENSG00000261574.1	RP1-168P16.2	4.27	2.36e-05	0.00414	0.24	0.19	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89392375~89412564:-
HNSC	cis	rs1659258	0.614	rs1258399	ENSG00000232508.1	MRPL45P1	4.27	2.36e-05	0.00414	0.34	0.19	Visceral fat;	chr2:88322904	chr2:88364695~88365608:-
HNSC	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	4.27	2.36e-05	0.00414	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
HNSC	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-4.27	2.36e-05	0.00414	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
HNSC	cis	rs721917	0.506	rs2758538	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.36e-05	0.00414	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79663088~79826594:-
HNSC	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	4.27	2.36e-05	0.00414	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
HNSC	cis	rs17772222	0.636	rs3850390	ENSG00000258789.1	RP11-507K2.3	-4.27	2.36e-05	0.00414	-0.24	-0.19	Coronary artery calcification;	chr14:88829185	chr14:88551597~88552493:+
HNSC	cis	rs2274273	0.745	rs8005399	ENSG00000233924.1	AL160471.6	-4.27	2.36e-05	0.00414	-0.22	-0.19	Protein biomarker;	chr14:55076127	chr14:55004813~55005687:-
HNSC	cis	rs2998286	0.723	rs332151	ENSG00000254635.4	WAC-AS1	-4.27	2.36e-05	0.00414	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585331	chr10:28522652~28532743:-
HNSC	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-4.27	2.36e-05	0.00414	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
HNSC	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	4.27	2.36e-05	0.00414	0.22	0.19	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000211974.3	IGHV2-70	4.27	2.36e-05	0.00414	0.18	0.19	Kawasaki disease;	chr14:106776558	chr14:106723574~106724093:-
HNSC	cis	rs10829156	0.947	rs10764661	ENSG00000240291.1	RP11-499P20.2	4.27	2.36e-05	0.00414	0.2	0.19	Sudden cardiac arrest;	chr10:18659018	chr10:18513115~18545651:-
HNSC	cis	rs795484	0.89	rs61945179	ENSG00000275409.1	RP11-131L12.4	-4.27	2.36e-05	0.00414	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118215171	chr12:118430147~118430699:+
HNSC	cis	rs1050631	1	rs1107840	ENSG00000278986.1	RP11-723J4.3	4.27	2.36e-05	0.00414	0.22	0.19	Esophageal squamous cell cancer (length of survival);	chr18:36127201	chr18:35972151~35973916:+
HNSC	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-4.27	2.36e-05	0.00414	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
HNSC	cis	rs71520386	0.846	rs13243243	ENSG00000221740.1	SNORD93	4.27	2.36e-05	0.00415	0.25	0.19	Fibrinogen levels;	chr7:22781400	chr7:22856613~22856686:+
HNSC	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	4.27	2.36e-05	0.00415	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
HNSC	cis	rs13256369	0.95	rs13255655	ENSG00000173295.6	FAM86B3P	4.27	2.37e-05	0.00415	0.26	0.19	Obesity-related traits;	chr8:8720226	chr8:8228595~8244865:+
HNSC	cis	rs6964587	0.843	rs56075286	ENSG00000188693.7	CYP51A1-AS1	-4.27	2.37e-05	0.00415	-0.21	-0.19	Breast cancer;	chr7:92102204	chr7:92134604~92180725:+
HNSC	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
HNSC	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	4.27	2.37e-05	0.00415	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
HNSC	cis	rs7243790	0.905	rs1523871	ENSG00000277324.1	RP11-850A17.1	-4.27	2.37e-05	0.00415	-0.22	-0.19	Diastolic blood pressure;	chr18:54424507	chr18:54268346~54270028:-
HNSC	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	4.27	2.37e-05	0.00416	0.19	0.19	Asthma;	chr2:102358590	chr2:102438713~102440475:+
HNSC	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-4.27	2.37e-05	0.00416	-0.32	-0.19	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
HNSC	cis	rs10510102	0.516	rs10437506	ENSG00000226864.1	ATE1-AS1	4.27	2.37e-05	0.00416	0.36	0.19	Breast cancer;	chr10:121984011	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.516	rs74461504	ENSG00000226864.1	ATE1-AS1	4.27	2.37e-05	0.00416	0.36	0.19	Breast cancer;	chr10:121986077	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.516	rs61071865	ENSG00000226864.1	ATE1-AS1	4.27	2.37e-05	0.00416	0.36	0.19	Breast cancer;	chr10:121986236	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.516	rs10159589	ENSG00000226864.1	ATE1-AS1	4.27	2.37e-05	0.00416	0.36	0.19	Breast cancer;	chr10:121986659	chr10:121928312~121951965:+
HNSC	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-4.27	2.37e-05	0.00416	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-4.27	2.37e-05	0.00416	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
HNSC	cis	rs11098499	1	rs11726229	ENSG00000250412.1	KLHL2P1	4.27	2.37e-05	0.00416	0.25	0.19	Corneal astigmatism;	chr4:119290425	chr4:119334329~119378233:+
HNSC	cis	rs11098499	1	rs7659194	ENSG00000250412.1	KLHL2P1	4.27	2.37e-05	0.00416	0.25	0.19	Corneal astigmatism;	chr4:119285992	chr4:119334329~119378233:+
HNSC	cis	rs10791097	0.72	rs7119425	ENSG00000254842.5	RP11-890B15.2	-4.27	2.38e-05	0.00417	-0.17	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863290	chr11:130844191~130865561:-
HNSC	cis	rs1223397	0.938	rs34505804	ENSG00000215022.6	RP1-257A7.4	-4.27	2.38e-05	0.00417	-0.25	-0.19	Blood pressure;	chr6:13292282	chr6:13264861~13295586:-
HNSC	cis	rs6674176	1	rs11210937	ENSG00000237950.1	RP11-7O11.3	4.27	2.38e-05	0.00417	0.25	0.19	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939891	chr1:43944370~43946551:-
HNSC	cis	rs13082711	0.52	rs2643825	ENSG00000272282.1	RP11-222K16.2	-4.27	2.38e-05	0.00417	-0.23	-0.19	Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr3:27521122	chr3:27712910~27714005:+
HNSC	cis	rs11250098	0.547	rs2409764	ENSG00000269918.1	AF131215.9	4.27	2.38e-05	0.00417	0.19	0.19	Morning vs. evening chronotype;	chr8:11423764	chr8:11104691~11106704:-
HNSC	cis	rs2548724	0.648	rs12654151	ENSG00000250682.4	LINC00491	4.27	2.38e-05	0.00417	0.25	0.19	Type 2 diabetes;	chr5:102333505	chr5:102609156~102671559:-
HNSC	cis	rs2486288	0.656	rs10519018	ENSG00000259479.5	SORD2P	-4.27	2.38e-05	0.00417	-0.22	-0.19	Glomerular filtration rate;	chr15:45257067	chr15:44826371~44884694:-
HNSC	cis	rs988913	0.781	rs1963697	ENSG00000224984.1	RP11-524H19.2	4.27	2.38e-05	0.00417	0.22	0.19	Menarche (age at onset);	chr6:54908016	chr6:54840118~54840855:-
HNSC	cis	rs853679	0.546	rs200949	ENSG00000219392.1	RP1-265C24.5	-4.27	2.38e-05	0.00417	-0.31	-0.19	Depression;	chr6:27867657	chr6:28115628~28116551:+
HNSC	cis	rs4862750	0.957	rs4861733	ENSG00000250971.1	RP11-696F12.1	4.27	2.38e-05	0.00417	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:187060099~187060930:+
HNSC	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	4.27	2.38e-05	0.00417	0.21	0.19	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
HNSC	cis	rs6928977	0.675	rs58761508	ENSG00000231028.7	LINC00271	4.27	2.38e-05	0.00417	0.23	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135497801~135716055:+
HNSC	cis	rs6928977	0.631	rs9385726	ENSG00000231028.7	LINC00271	4.27	2.38e-05	0.00417	0.23	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135497801~135716055:+
HNSC	cis	rs6928977	0.637	rs9647635	ENSG00000231028.7	LINC00271	4.27	2.38e-05	0.00417	0.23	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135497801~135716055:+
HNSC	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	4.27	2.38e-05	0.00418	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
HNSC	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	4.27	2.38e-05	0.00418	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	4.27	2.38e-05	0.00418	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
HNSC	cis	rs2486288	0.656	rs2413768	ENSG00000259479.5	SORD2P	-4.27	2.38e-05	0.00418	-0.22	-0.19	Glomerular filtration rate;	chr15:45269786	chr15:44826371~44884694:-
HNSC	cis	rs9990343	0.748	rs11130087	ENSG00000223552.1	RP11-24F11.2	-4.27	2.38e-05	0.00418	-0.17	-0.19	Brain structure;	chr3:46293138	chr3:46364955~46407059:-
HNSC	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	4.27	2.38e-05	0.00418	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	4.27	2.38e-05	0.00418	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	4.27	2.38e-05	0.00418	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
HNSC	cis	rs3015497	0.603	rs61476576	ENSG00000269906.1	RP11-248J18.2	4.27	2.38e-05	0.00418	0.26	0.19	Mean platelet volume;	chr14:50555047	chr14:50662511~50663178:-
HNSC	cis	rs9813712	0.595	rs1901787	ENSG00000228252.7	COL6A4P2	4.27	2.39e-05	0.00418	0.19	0.19	Response to amphetamines;	chr3:130288678	chr3:130212823~130273806:+
HNSC	cis	rs1008375	1	rs10012335	ENSG00000249502.1	AC006160.5	-4.27	2.39e-05	0.00418	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17627007	chr4:17587467~17614571:-
HNSC	cis	rs2548724	0.617	rs7714927	ENSG00000250682.4	LINC00491	4.27	2.39e-05	0.00418	0.25	0.19	Type 2 diabetes;	chr5:102341173	chr5:102609156~102671559:-
HNSC	cis	rs1479119	0.681	rs1382681	ENSG00000180861.8	LINC01559	4.27	2.39e-05	0.00418	0.25	0.19	Intelligence (multi-trait analysis);	chr12:13346737	chr12:13371089~13387167:-
HNSC	cis	rs964611	0.882	rs16960737	ENSG00000259488.2	RP11-154J22.1	-4.27	2.39e-05	0.00418	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48299863	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs66823218	ENSG00000259488.2	RP11-154J22.1	-4.27	2.39e-05	0.00418	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48299886	chr15:48312353~48331856:-
HNSC	cis	rs6504108	0.624	rs17681336	ENSG00000278765.1	RP5-890E16.5	-4.27	2.39e-05	0.00418	-0.24	-0.19	Body mass index;	chr17:48172430	chr17:48066704~48067293:-
HNSC	cis	rs11098499	0.82	rs11737395	ENSG00000250412.1	KLHL2P1	4.27	2.39e-05	0.00418	0.26	0.19	Corneal astigmatism;	chr4:119599549	chr4:119334329~119378233:+
HNSC	cis	rs7324557	0.717	rs9510866	ENSG00000205861.10	C1QTNF9B-AS1	-4.27	2.39e-05	0.00418	-0.27	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23806708	chr13:23888889~23897263:+
HNSC	cis	rs12701220	0.553	rs34062359	ENSG00000224079.1	AC091729.7	4.27	2.39e-05	0.00419	0.3	0.19	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1074450~1078036:+
HNSC	cis	rs7572733	0.935	rs10931796	ENSG00000222017.1	AC011997.1	4.27	2.39e-05	0.00419	0.23	0.19	Dermatomyositis;	chr2:197975937	chr2:197693106~197774823:+
HNSC	cis	rs73198271	0.813	rs56007835	ENSG00000173295.6	FAM86B3P	-4.27	2.39e-05	0.00419	-0.26	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8228595~8244865:+
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000224373.3	IGHV4-59	4.27	2.39e-05	0.00419	0.11	0.19	Kawasaki disease;	chr14:106802182	chr14:106627249~106627825:-
HNSC	cis	rs7121616	1	rs79401687	ENSG00000200879.1	SNORD14E	4.27	2.39e-05	0.00419	0.25	0.19	Breast cancer;	chr11:123096264	chr11:123058077~123058161:-
HNSC	cis	rs950776	0.642	rs922691	ENSG00000261762.1	RP11-650L12.2	4.27	2.39e-05	0.00419	0.24	0.19	Sudden cardiac arrest;	chr15:78671652	chr15:78589123~78591276:-
HNSC	cis	rs1799949	0.93	rs1554063	ENSG00000236383.6	LINC00854	-4.27	2.39e-05	0.00419	-0.18	-0.19	Menopause (age at onset);	chr17:43135128	chr17:43216941~43305976:-
HNSC	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-4.27	2.39e-05	0.00419	-0.25	-0.19	Pain;	chr19:21483795	chr19:21554640~21569237:-
HNSC	cis	rs4873772	0.558	rs7825148	ENSG00000253330.1	RP11-697N18.3	-4.27	2.39e-05	0.00419	-0.25	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47465991	chr8:47511034~47512141:-
HNSC	cis	rs116095464	0.558	rs34629844	ENSG00000250848.1	CTD-2083E4.5	-4.27	2.39e-05	0.00419	-0.27	-0.19	Breast cancer;	chr5:200714	chr5:288833~290321:-
HNSC	cis	rs780096	0.526	rs11682621	ENSG00000234072.1	AC074117.10	-4.27	2.39e-05	0.00419	-0.16	-0.19	Total body bone mineral density;	chr2:27526802	chr2:27356246~27367622:+
HNSC	cis	rs875971	0.825	rs59466412	ENSG00000232559.3	GS1-124K5.12	-4.27	2.39e-05	0.00419	-0.23	-0.19	Aortic root size;	chr7:66100371	chr7:66554588~66576923:-
HNSC	cis	rs75422866	0.541	rs61918136	ENSG00000276691.1	RP5-1057I20.5	4.27	2.39e-05	0.0042	0.32	0.19	Pneumonia;	chr12:47566798	chr12:47788426~47788971:+
HNSC	cis	rs1881744	0.588	rs78808618	ENSG00000276691.1	RP5-1057I20.5	4.27	2.39e-05	0.0042	0.32	0.19	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47788426~47788971:+
HNSC	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	4.27	2.4e-05	0.0042	0.17	0.19	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
HNSC	cis	rs6710503	1	rs6761875	ENSG00000271936.1	RP11-443B20.1	4.27	2.4e-05	0.0042	0.21	0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24749348	chr2:24825610~24826717:+
HNSC	cis	rs9880211	0.948	rs9872178	ENSG00000273486.1	RP11-731C17.2	4.27	2.4e-05	0.0042	0.18	0.19	Height;Body mass index;	chr3:136267596	chr3:136837338~136839021:-
HNSC	cis	rs1008375	1	rs12507142	ENSG00000249502.1	AC006160.5	-4.27	2.4e-05	0.0042	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654480	chr4:17587467~17614571:-
HNSC	cis	rs4930561	0.765	rs34493482	ENSG00000184795.9	UNC93B5	-4.27	2.4e-05	0.0042	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr11:67711702~67716005:-
HNSC	cis	rs4356203	0.678	rs1125737	ENSG00000260196.1	RP1-239B22.5	-4.27	2.4e-05	0.0042	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17380649~17383531:+
HNSC	cis	rs3736485	0.844	rs7174495	ENSG00000259438.1	CTD-2650P22.1	4.27	2.4e-05	0.0042	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51603094	chr15:52010999~52019095:-
HNSC	cis	rs7113211	0.729	rs12806454	ENSG00000176343.5	RPL37AP8	-4.27	2.4e-05	0.0042	-0.2	-0.19	Expressive vocabulary in infants;	chr11:112772730	chr11:111889199~111889474:-
HNSC	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-4.27	2.4e-05	0.0042	-0.29	-0.19	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
HNSC	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-4.27	2.4e-05	0.0042	-0.25	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
HNSC	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-4.27	2.4e-05	0.0042	-0.17	-0.19	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
HNSC	cis	rs7829975	0.577	rs940030	ENSG00000173295.6	FAM86B3P	-4.27	2.4e-05	0.00421	-0.23	-0.19	Mood instability;	chr8:8689418	chr8:8228595~8244865:+
HNSC	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	4.27	2.4e-05	0.00421	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	4.27	2.4e-05	0.00421	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
HNSC	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	4.27	2.4e-05	0.00421	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
HNSC	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	4.27	2.4e-05	0.00421	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.644	rs28787668	ENSG00000250412.1	KLHL2P1	4.27	2.4e-05	0.00421	0.25	0.19	Corneal astigmatism;	chr4:119633532	chr4:119334329~119378233:+
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	4.27	2.4e-05	0.00421	0.27	0.19	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
HNSC	cis	rs13325613	0.834	rs34401473	ENSG00000223552.1	RP11-24F11.2	-4.27	2.4e-05	0.00421	-0.32	-0.19	Monocyte count;	chr3:46148280	chr3:46364955~46407059:-
HNSC	cis	rs12893668	0.703	rs7148456	ENSG00000269940.1	RP11-73M18.7	-4.27	2.41e-05	0.00421	-0.19	-0.19	Reticulocyte count;	chr14:103561933	chr14:103694560~103695170:+
HNSC	cis	rs8067545	0.641	rs1479129	ENSG00000266126.1	RP11-209D14.4	4.27	2.41e-05	0.00421	0.22	0.19	Schizophrenia;	chr17:19942456	chr17:19929372~19929737:-
HNSC	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-4.27	2.41e-05	0.00421	-0.22	-0.19	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
HNSC	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	4.27	2.41e-05	0.00421	0.27	0.19	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
HNSC	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	4.27	2.41e-05	0.00421	0.19	0.19	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
HNSC	cis	rs11146838	1	rs11146838	ENSG00000120555.12	SEPT7P9	4.27	2.41e-05	0.00422	0.19	0.19	Breast cancer;	chr10:38856846	chr10:38383069~38402916:-
HNSC	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-4.27	2.41e-05	0.00422	-0.19	-0.19	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
HNSC	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-4.27	2.41e-05	0.00422	-0.2	-0.19	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
HNSC	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	4.27	2.41e-05	0.00422	0.2	0.19	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
HNSC	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-4.27	2.41e-05	0.00422	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
HNSC	cis	rs7121616	0.774	rs74693612	ENSG00000200879.1	SNORD14E	4.27	2.41e-05	0.00422	0.23	0.19	Breast cancer;	chr11:123092310	chr11:123058077~123058161:-
HNSC	cis	rs11638352	1	rs2412848	ENSG00000205771.5	CATSPER2P1	-4.27	2.41e-05	0.00422	-0.5	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43977409	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs2930528	ENSG00000205771.5	CATSPER2P1	-4.27	2.41e-05	0.00422	-0.5	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43978333	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs11632901	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43988055	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs6493092	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43997220	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs11638352	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44000939	chr15:43726918~43747094:-
HNSC	cis	rs2733201	1	rs12913809	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44001013	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs2412853	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44003059	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs4924731	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44004526	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs6493093	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44013297	chr15:43726918~43747094:-
HNSC	cis	rs2733201	1	rs4923969	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44016338	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs8037441	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44019718	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs12324261	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44026273	chr15:43726918~43747094:-
HNSC	cis	rs2733201	1	rs8036541	ENSG00000205771.5	CATSPER2P1	4.27	2.41e-05	0.00422	0.5	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44027179	chr15:43726918~43747094:-
HNSC	cis	rs16858210	0.648	rs79478990	ENSG00000234371.6	RPSAP31	4.27	2.41e-05	0.00422	0.23	0.19	Menopause (age at onset);	chr3:183869306	chr3:183884924~183888449:+
HNSC	cis	rs189798	0.807	rs12785	ENSG00000254153.1	CTA-398F10.2	4.27	2.41e-05	0.00422	0.23	0.19	Myopia (pathological);	chr8:9137426	chr8:8456909~8461337:-
HNSC	cis	rs2998286	0.678	rs2807758	ENSG00000254635.4	WAC-AS1	-4.27	2.41e-05	0.00422	-0.3	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28549643	chr10:28522652~28532743:-
HNSC	cis	rs71520386	0.846	rs35247857	ENSG00000221740.1	SNORD93	-4.27	2.41e-05	0.00422	-0.25	-0.19	Fibrinogen levels;	chr7:22780901	chr7:22856613~22856686:+
HNSC	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-4.27	2.41e-05	0.00422	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
HNSC	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-4.27	2.41e-05	0.00422	-0.25	-0.19	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
HNSC	cis	rs9990343	0.783	rs4267678	ENSG00000223552.1	RP11-24F11.2	-4.27	2.41e-05	0.00422	-0.17	-0.19	Brain structure;	chr3:46294694	chr3:46364955~46407059:-
HNSC	cis	rs6163	0.508	rs12776506	ENSG00000236937.2	PTGES3P4	4.27	2.41e-05	0.00422	0.26	0.19	Waist circumference;Hip circumference;	chr10:102773071	chr10:102845595~102845950:+
HNSC	cis	rs10819861	0.645	rs7045648	ENSG00000271384.1	RP11-435O5.7	4.27	2.41e-05	0.00422	0.19	0.19	Electrocardiographic traits;	chr9:96092757	chr9:95406990~95407662:-
HNSC	cis	rs11098499	0.739	rs7441137	ENSG00000250412.1	KLHL2P1	-4.27	2.41e-05	0.00422	-0.23	-0.19	Corneal astigmatism;	chr4:119212066	chr4:119334329~119378233:+
HNSC	cis	rs12545109	0.765	rs1960727	ENSG00000246430.5	LINC00968	-4.27	2.42e-05	0.00423	-0.24	-0.19	Obesity-related traits;	chr8:56498809	chr8:56496246~56559823:-
HNSC	cis	rs2548724	0.66	rs10434749	ENSG00000250682.4	LINC00491	4.27	2.42e-05	0.00423	0.25	0.19	Type 2 diabetes;	chr5:102456271	chr5:102609156~102671559:-
HNSC	cis	rs9903692	0.954	rs2051821	ENSG00000263412.1	RP5-890E16.2	-4.27	2.42e-05	0.00423	-0.18	-0.19	Pulse pressure;	chr17:48066153	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.909	rs8078125	ENSG00000263412.1	RP5-890E16.2	-4.27	2.42e-05	0.00423	-0.18	-0.19	Pulse pressure;	chr17:48068347	chr17:48045141~48048073:-
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000211974.3	IGHV2-70	4.27	2.42e-05	0.00423	0.18	0.19	Kawasaki disease;	chr14:106668657	chr14:106723574~106724093:-
HNSC	cis	rs4927850	1	rs7625570	ENSG00000226155.1	AC124944.3	-4.27	2.42e-05	0.00423	-0.23	-0.19	Pancreatic cancer;	chr3:196020527	chr3:195912049~195913986:+
HNSC	cis	rs17214007	0.518	rs56374730	ENSG00000263065.1	AF001548.6	-4.27	2.42e-05	0.00423	-0.25	-0.19	Cognitive function;	chr16:15773795	chr16:15741151~15741791:+
HNSC	cis	rs7824557	0.606	rs2736273	ENSG00000255310.2	AF131215.2	4.27	2.42e-05	0.00423	0.18	0.19	Retinal vascular caliber;	chr8:11342429	chr8:11107788~11109726:-
HNSC	cis	rs9813712	0.595	rs1453238	ENSG00000228252.7	COL6A4P2	4.26	2.42e-05	0.00424	0.19	0.19	Response to amphetamines;	chr3:130290494	chr3:130212823~130273806:+
HNSC	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-4.26	2.42e-05	0.00424	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
HNSC	cis	rs3736485	0.764	rs55805232	ENSG00000259438.1	CTD-2650P22.1	4.26	2.42e-05	0.00424	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51604401	chr15:52010999~52019095:-
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000219891.2	ZSCAN12P1	4.26	2.42e-05	0.00424	0.27	0.19	Parkinson's disease;	chr6:27885390	chr6:28091154~28093664:+
HNSC	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-4.26	2.42e-05	0.00424	-0.25	-0.19	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
HNSC	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-4.26	2.42e-05	0.00424	-0.26	-0.19	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
HNSC	cis	rs1862618	0.641	rs2591954	ENSG00000271828.1	CTD-2310F14.1	-4.26	2.42e-05	0.00424	-0.24	-0.19	Initial pursuit acceleration;	chr5:56949217	chr5:56927874~56929573:+
HNSC	cis	rs11673344	0.503	rs10414520	ENSG00000276846.1	CTD-3220F14.3	4.26	2.42e-05	0.00424	0.21	0.19	Obesity-related traits;	chr19:37057279	chr19:37314868~37315620:-
HNSC	cis	rs17772222	0.636	rs10484010	ENSG00000258789.1	RP11-507K2.3	-4.26	2.42e-05	0.00424	-0.23	-0.19	Coronary artery calcification;	chr14:88831944	chr14:88551597~88552493:+
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000224373.3	IGHV4-59	4.26	2.43e-05	0.00424	0.12	0.19	Kawasaki disease;	chr14:106808609	chr14:106627249~106627825:-
HNSC	cis	rs9487051	0.872	rs9487034	ENSG00000219700.1	PTCHD3P3	4.26	2.43e-05	0.00424	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109284696	chr6:109288571~109290503:-
HNSC	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	4.26	2.43e-05	0.00424	0.19	0.19	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
HNSC	cis	rs4815191	0.755	rs6036352	ENSG00000279164.1	RP4-737E23.5	4.26	2.43e-05	0.00424	0.28	0.19	Obesity-related traits;	chr20:23267353	chr20:23148086~23149939:+
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000219891.2	ZSCAN12P1	4.26	2.43e-05	0.00424	0.27	0.19	Parkinson's disease;	chr6:27881898	chr6:28091154~28093664:+
HNSC	cis	rs6504108	0.602	rs2938483	ENSG00000278765.1	RP5-890E16.5	-4.26	2.43e-05	0.00425	-0.24	-0.19	Body mass index;	chr17:48240642	chr17:48066704~48067293:-
HNSC	cis	rs7824557	0.527	rs2572376	ENSG00000255310.2	AF131215.2	-4.26	2.43e-05	0.00425	-0.18	-0.19	Retinal vascular caliber;	chr8:11380247	chr8:11107788~11109726:-
HNSC	cis	rs7610312	0.681	rs1554128	ENSG00000273493.1	RP11-80H18.4	4.26	2.43e-05	0.00425	0.23	0.19	Red blood cell count;	chr3:58291994	chr3:58329965~58330118:+
HNSC	cis	rs9450351	0.744	rs9342047	ENSG00000203875.9	SNHG5	-4.26	2.43e-05	0.00425	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85869115	chr6:85660950~85678736:-
HNSC	cis	rs11157436	0.581	rs17255433	ENSG00000211812.1	TRAV26-2	-4.26	2.43e-05	0.00425	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.602	rs17255440	ENSG00000211812.1	TRAV26-2	-4.26	2.43e-05	0.00425	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22202583~22203368:+
HNSC	cis	rs12439619	0.921	rs56042848	ENSG00000276710.3	CSPG4P8	-4.26	2.43e-05	0.00425	-0.23	-0.19	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82459472~82477258:+
HNSC	cis	rs9650657	0.771	rs4840516	ENSG00000269918.1	AF131215.9	4.26	2.43e-05	0.00425	0.19	0.19	Neuroticism;	chr8:10809825	chr8:11104691~11106704:-
HNSC	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	4.26	2.43e-05	0.00425	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
HNSC	cis	rs12893668	0.644	rs12890820	ENSG00000269910.1	RP11-73M18.10	4.26	2.43e-05	0.00425	0.19	0.19	Reticulocyte count;	chr14:103568512	chr14:103694516~103695050:-
HNSC	cis	rs2904524	1	rs17107926	ENSG00000257815.4	RP11-611E13.2	-4.26	2.43e-05	0.00425	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70282250	chr12:69904033~70243360:-
HNSC	cis	rs9990343	0.783	rs6441955	ENSG00000223552.1	RP11-24F11.2	-4.26	2.43e-05	0.00425	-0.16	-0.19	Brain structure;	chr3:46294844	chr3:46364955~46407059:-
HNSC	cis	rs9990343	0.783	rs6441956	ENSG00000223552.1	RP11-24F11.2	-4.26	2.43e-05	0.00425	-0.16	-0.19	Brain structure;	chr3:46294910	chr3:46364955~46407059:-
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000236529.1	RP13-254B10.1	4.26	2.43e-05	0.00425	0.21	0.19	Aortic root size;	chr7:66517181	chr7:65840212~65840596:+
HNSC	cis	rs4356203	0.87	rs214925	ENSG00000272034.1	SNORD14A	-4.26	2.43e-05	0.00425	-0.15	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17074654~17074744:-
HNSC	cis	rs3736485	0.816	rs12443362	ENSG00000259438.1	CTD-2650P22.1	4.26	2.43e-05	0.00425	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51582345	chr15:52010999~52019095:-
HNSC	cis	rs1008375	1	rs6846238	ENSG00000249502.1	AC006160.5	-4.26	2.44e-05	0.00426	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628316	chr4:17587467~17614571:-
HNSC	cis	rs6860540	0.796	rs868988	ENSG00000251405.2	CTB-109A12.1	-4.26	2.44e-05	0.00426	-0.22	-0.19	Inflammatory skin disease;	chr5:157507379	chr5:157362615~157460078:-
HNSC	cis	rs7824557	0.614	rs2060459	ENSG00000255310.2	AF131215.2	4.26	2.44e-05	0.00426	0.18	0.19	Retinal vascular caliber;	chr8:11355090	chr8:11107788~11109726:-
HNSC	cis	rs897984	0.683	rs12926237	ENSG00000279196.1	RP11-1072A3.3	-4.26	2.44e-05	0.00426	-0.21	-0.19	Dementia with Lewy bodies;	chr16:30826275	chr16:30984630~30988270:-
HNSC	cis	rs330048	0.525	rs10112237	ENSG00000173295.6	FAM86B3P	-4.26	2.44e-05	0.00426	-0.22	-0.19	Systemic lupus erythematosus;	chr8:9215219	chr8:8228595~8244865:+
HNSC	cis	rs9467711	0.606	rs16891727	ENSG00000241549.7	GUSBP2	4.26	2.44e-05	0.00426	0.3	0.19	Autism spectrum disorder or schizophrenia;	chr6:26488632	chr6:26871484~26956554:-
HNSC	cis	rs7674212	0.541	rs2720448	ENSG00000251288.2	RP11-10L12.2	-4.26	2.44e-05	0.00426	-0.22	-0.19	Type 2 diabetes;	chr4:103109432	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.541	rs2623064	ENSG00000251288.2	RP11-10L12.2	-4.26	2.44e-05	0.00426	-0.22	-0.19	Type 2 diabetes;	chr4:103109635	chr4:102751401~102752641:+
HNSC	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	4.26	2.44e-05	0.00426	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
HNSC	cis	rs5758511	0.514	rs9607885	ENSG00000226450.2	CYP2D8P	4.26	2.44e-05	0.00426	0.18	0.19	Birth weight;	chr22:42182590	chr22:42149886~42155001:-
HNSC	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	4.26	2.44e-05	0.00426	0.23	0.19	Height;	chr5:128012123	chr5:127940426~128083172:-
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.26	2.44e-05	0.00426	-0.21	-0.19	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
HNSC	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	4.26	2.44e-05	0.00426	0.23	0.19	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
HNSC	cis	rs11089937	0.554	rs5995628	ENSG00000211638.2	IGLV8-61	-4.26	2.44e-05	0.00427	-0.18	-0.19	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22098700~22099212:+
HNSC	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-4.26	2.44e-05	0.00427	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
HNSC	cis	rs2145598	0.802	rs2147610	ENSG00000279636.2	LINC00216	-4.26	2.44e-05	0.00427	-0.21	-0.19	Coronary artery disease;	chr14:58380269	chr14:58288033~58289158:+
HNSC	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-4.26	2.44e-05	0.00427	-0.18	-0.19	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
HNSC	cis	rs11756659	0.505	rs62392761	ENSG00000272462.2	U91328.19	4.26	2.44e-05	0.00427	0.22	0.19	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25920511	chr6:25992662~26001775:+
HNSC	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	4.26	2.44e-05	0.00427	0.23	0.19	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
HNSC	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	4.26	2.44e-05	0.00427	0.23	0.19	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
HNSC	cis	rs62344088	1	rs56315075	ENSG00000277812.1	AC021087.1	4.26	2.44e-05	0.00427	0.48	0.19	Asthma (childhood onset);	chr5:103789	chr5:262769~262881:+
HNSC	cis	rs1113500	0.814	rs1592282	ENSG00000226822.1	RP11-356N1.2	4.26	2.44e-05	0.00427	0.22	0.19	Growth-regulated protein alpha levels;	chr1:108058743	chr1:108071482~108074519:+
HNSC	cis	rs11089937	0.616	rs4991798	ENSG00000211638.2	IGLV8-61	-4.26	2.44e-05	0.00427	-0.18	-0.19	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs4991799	ENSG00000211638.2	IGLV8-61	-4.26	2.44e-05	0.00427	-0.18	-0.19	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs4991800	ENSG00000211638.2	IGLV8-61	-4.26	2.44e-05	0.00427	-0.18	-0.19	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22098700~22099212:+
HNSC	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-4.26	2.44e-05	0.00427	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
HNSC	cis	rs9921338	0.961	rs7206749	ENSG00000263080.1	RP11-485G7.5	4.26	2.45e-05	0.00427	0.22	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs55707838	ENSG00000263080.1	RP11-485G7.5	4.26	2.45e-05	0.00427	0.22	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11341809~11345211:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000254340.1	RP11-10A14.3	4.26	2.45e-05	0.00428	0.24	0.19	Neuroticism;	chr8:8287918	chr8:9141424~9145435:+
HNSC	cis	rs3015497	0.624	rs3015488	ENSG00000277050.1	RP11-102G14.1	-4.26	2.45e-05	0.00428	-0.2	-0.19	Mean platelet volume;	chr14:50668591	chr14:51637348~51637947:-
HNSC	cis	rs56804039	0.524	rs6982112	ENSG00000173295.6	FAM86B3P	4.26	2.45e-05	0.00428	0.31	0.19	Cervical cancer;	chr8:8514866	chr8:8228595~8244865:+
HNSC	cis	rs2732480	0.577	rs2634681	ENSG00000257763.1	OR5BK1P	-4.26	2.45e-05	0.00428	-0.19	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48355792~48356614:-
HNSC	cis	rs4660261	0.526	rs2485996	ENSG00000237950.1	RP11-7O11.3	4.26	2.45e-05	0.00428	0.21	0.19	Intelligence (multi-trait analysis);	chr1:43888989	chr1:43944370~43946551:-
HNSC	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	4.26	2.45e-05	0.00428	0.23	0.19	Height;	chr14:75118164	chr14:75011269~75012851:-
HNSC	cis	rs11951515	0.899	rs6883936	ENSG00000249286.1	CTD-2210P15.2	4.26	2.45e-05	0.00428	0.22	0.19	Metabolite levels  (X-11787);	chr5:43399062	chr5:43586918~43588223:-
HNSC	cis	rs9914988	0.667	rs17794574	ENSG00000264577.1	AC010761.8	4.26	2.45e-05	0.00428	0.19	0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28927161	chr17:28721487~28722877:-
HNSC	cis	rs73198271	0.96	rs73198288	ENSG00000253893.2	FAM85B	4.26	2.45e-05	0.00428	0.28	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr8:8167819~8226614:-
HNSC	cis	rs6831352	0.918	rs17817958	ENSG00000263923.1	RP11-571L19.7	-4.26	2.45e-05	0.00428	-0.23	-0.19	Alcohol dependence;	chr4:99140094	chr4:98928897~98994994:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	4.26	2.45e-05	0.00428	0.33	0.19	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
HNSC	cis	rs9926296	0.715	rs2115401	ENSG00000274627.1	RP11-104N10.2	-4.26	2.45e-05	0.00429	-0.19	-0.19	Vitiligo;	chr16:89674201	chr16:89516797~89522217:+
HNSC	cis	rs71520386	0.846	rs17778126	ENSG00000221740.1	SNORD93	-4.26	2.45e-05	0.00429	-0.26	-0.19	Fibrinogen levels;	chr7:22779340	chr7:22856613~22856686:+
HNSC	cis	rs1050631	1	rs1785914	ENSG00000278986.1	RP11-723J4.3	-4.26	2.46e-05	0.00429	-0.22	-0.19	Esophageal squamous cell cancer (length of survival);	chr18:36120833	chr18:35972151~35973916:+
HNSC	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	4.26	2.46e-05	0.00429	0.22	0.19	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
HNSC	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	4.26	2.46e-05	0.00429	0.25	0.19	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
HNSC	cis	rs988913	0.813	rs1566723	ENSG00000224984.1	RP11-524H19.2	4.26	2.46e-05	0.00429	0.22	0.19	Menarche (age at onset);	chr6:54913035	chr6:54840118~54840855:-
HNSC	cis	rs11098499	0.913	rs67073020	ENSG00000250412.1	KLHL2P1	4.26	2.46e-05	0.00429	0.26	0.19	Corneal astigmatism;	chr4:119231402	chr4:119334329~119378233:+
HNSC	cis	rs73198271	0.96	rs73198286	ENSG00000253893.2	FAM85B	4.26	2.46e-05	0.00429	0.29	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr8:8167819~8226614:-
HNSC	cis	rs6964587	0.655	rs6965864	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.46e-05	0.00429	-0.2	-0.19	Breast cancer;	chr7:91966282	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.62	rs7808587	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.46e-05	0.00429	-0.2	-0.19	Breast cancer;	chr7:91990782	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.62	rs6967588	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.46e-05	0.00429	-0.2	-0.19	Breast cancer;	chr7:92014088	chr7:92134604~92180725:+
HNSC	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	4.26	2.46e-05	0.00429	0.26	0.19	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
HNSC	cis	rs1125355	0.69	rs62183662	ENSG00000204380.3	AC005042.4	4.26	2.46e-05	0.00429	0.21	0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158785067	chr2:158658337~158735002:-
HNSC	cis	rs1799949	0.93	rs35292991	ENSG00000236383.6	LINC00854	-4.26	2.46e-05	0.00429	-0.18	-0.19	Menopause (age at onset);	chr17:43181999	chr17:43216941~43305976:-
HNSC	cis	rs9611565	0.84	rs4822025	ENSG00000235513.1	RP4-756G23.5	4.26	2.46e-05	0.00429	0.23	0.19	Vitiligo;	chr22:41380642	chr22:41209122~41217627:-
HNSC	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	4.26	2.46e-05	0.0043	0.21	0.19	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.954	rs10008392	ENSG00000250412.1	KLHL2P1	4.26	2.46e-05	0.0043	0.25	0.19	Corneal astigmatism;	chr4:119397684	chr4:119334329~119378233:+
HNSC	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-4.26	2.46e-05	0.0043	-0.2	-0.19	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
HNSC	cis	rs728616	0.571	rs113030473	ENSG00000225484.5	NUTM2B-AS1	-4.26	2.46e-05	0.0043	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79663088~79826594:-
HNSC	cis	rs7809950	0.871	rs11771278	ENSG00000238832.1	snoU109	4.26	2.46e-05	0.0043	0.23	0.19	Coronary artery disease;	chr7:107645480	chr7:107603363~107603507:+
HNSC	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	4.26	2.46e-05	0.0043	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
HNSC	cis	rs7610312	0.646	rs4681673	ENSG00000273493.1	RP11-80H18.4	-4.26	2.46e-05	0.0043	-0.23	-0.19	Red blood cell count;	chr3:58288016	chr3:58329965~58330118:+
HNSC	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	4.26	2.46e-05	0.0043	0.18	0.19	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
HNSC	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-4.26	2.46e-05	0.0043	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
HNSC	cis	rs10819861	0.645	rs7862829	ENSG00000271384.1	RP11-435O5.7	4.26	2.47e-05	0.0043	0.19	0.19	Electrocardiographic traits;	chr9:96094462	chr9:95406990~95407662:-
HNSC	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	4.26	2.47e-05	0.0043	0.19	0.19	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
HNSC	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-4.26	2.47e-05	0.0043	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
HNSC	cis	rs7824557	0.527	rs2572448	ENSG00000255310.2	AF131215.2	-4.26	2.47e-05	0.0043	-0.18	-0.19	Retinal vascular caliber;	chr8:11381843	chr8:11107788~11109726:-
HNSC	cis	rs12986445	0.843	rs11894773	ENSG00000218682.1	AC010150.1	-4.26	2.47e-05	0.0043	-0.26	-0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25852344	chr2:25856461~25856966:-
HNSC	cis	rs3015497	0.789	rs2356457	ENSG00000277050.1	RP11-102G14.1	-4.26	2.47e-05	0.0043	-0.18	-0.19	Mean platelet volume;	chr14:50650145	chr14:51637348~51637947:-
HNSC	cis	rs1620921	0.564	rs28594774	ENSG00000231863.1	RP3-428L16.1	-4.26	2.47e-05	0.00431	-0.23	-0.19	Lipoprotein (a) - cholesterol levels;	chr6:160850634	chr6:160931080~160969771:+
HNSC	cis	rs755249	0.958	rs17264866	ENSG00000182109.6	RP11-69E11.4	4.26	2.47e-05	0.00431	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39522280~39546187:-
HNSC	cis	rs3733585	0.683	rs6449140	ENSG00000250413.1	RP11-448G15.1	4.26	2.47e-05	0.00431	0.24	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9934813	chr4:10006482~10009725:+
HNSC	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-4.26	2.47e-05	0.00431	-0.27	-0.19	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
HNSC	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-4.26	2.47e-05	0.00431	-0.26	-0.19	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
HNSC	cis	rs11577354	0.509	rs7522498	ENSG00000207181.1	SNORA14B	-4.26	2.47e-05	0.00431	-0.24	-0.19	Obesity-related traits;	chr1:235104719	chr1:235127803~235127937:-
HNSC	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-4.26	2.47e-05	0.00431	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
HNSC	cis	rs9910055	0.53	rs2269906	ENSG00000267080.4	ASB16-AS1	4.26	2.47e-05	0.00431	0.15	0.19	Total body bone mineral density;	chr17:44216969	chr17:44175973~44186717:-
HNSC	cis	rs5758511	0.68	rs739146	ENSG00000226450.2	CYP2D8P	4.26	2.47e-05	0.00432	0.19	0.19	Birth weight;	chr22:42264408	chr22:42149886~42155001:-
HNSC	cis	rs9450351	0.744	rs7775016	ENSG00000203875.9	SNHG5	-4.26	2.47e-05	0.00432	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85780196	chr6:85660950~85678736:-
HNSC	cis	rs240993	0.812	rs9387013	ENSG00000230177.1	RP5-1112D6.4	4.26	2.47e-05	0.00432	0.24	0.19	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111277932~111278742:+
HNSC	cis	rs11723261	0.582	rs4634177	ENSG00000211553.1	AC253576.2	-4.26	2.47e-05	0.00432	-0.28	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:136461~136568:+
HNSC	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-4.26	2.47e-05	0.00432	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
HNSC	cis	rs9650657	0.836	rs6601523	ENSG00000255310.2	AF131215.2	-4.26	2.48e-05	0.00432	-0.19	-0.19	Neuroticism;	chr8:10777631	chr8:11107788~11109726:-
HNSC	cis	rs58873874	0.737	rs11739062	ENSG00000248544.2	CTB-47B11.3	4.26	2.48e-05	0.00432	0.46	0.19	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157375741~157384950:-
HNSC	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	4.26	2.48e-05	0.00432	0.23	0.19	Height;	chr14:75123410	chr14:75011269~75012851:-
HNSC	cis	rs7688540	0.771	rs12505835	ENSG00000211553.1	AC253576.2	-4.26	2.48e-05	0.00432	-0.31	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:136461~136568:+
HNSC	cis	rs911555	0.504	rs745079	ENSG00000270108.1	RP11-73M18.6	4.26	2.48e-05	0.00432	0.22	0.19	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103687576~103688127:+
HNSC	cis	rs911555	0.504	rs61995761	ENSG00000270108.1	RP11-73M18.6	4.26	2.48e-05	0.00432	0.22	0.19	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103687576~103688127:+
HNSC	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-4.26	2.48e-05	0.00432	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-4.26	2.48e-05	0.00432	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
HNSC	cis	rs8077577	0.943	rs62073603	ENSG00000273018.4	CTD-2303H24.2	-4.26	2.48e-05	0.00432	-0.29	-0.19	Obesity-related traits;	chr17:18161002	chr17:18511221~18551705:-
HNSC	cis	rs9914988	0.667	rs11655019	ENSG00000264577.1	AC010761.8	4.26	2.48e-05	0.00432	0.18	0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28928173	chr17:28721487~28722877:-
HNSC	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	4.26	2.48e-05	0.00432	0.39	0.19	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
HNSC	cis	rs17666538	0.535	rs168062	ENSG00000254207.1	RP11-43A14.1	4.26	2.48e-05	0.00432	0.41	0.19	IgG glycosylation;	chr8:682444	chr8:725188~725877:-
HNSC	cis	rs2281727	0.5	rs2169356	ENSG00000262333.1	HNRNPA1P16	4.26	2.48e-05	0.00432	0.16	0.19	Body mass index;Coronary artery disease;	chr17:2234722	chr17:2306761~2307715:+
HNSC	cis	rs131805	1	rs3091397	ENSG00000205559.3	CHKB-AS1	-4.26	2.48e-05	0.00433	-0.24	-0.19	Granulocyte percentage of myeloid white cells;	chr22:50519091	chr22:50583026~50583877:+
HNSC	cis	rs3808502	0.574	rs4841559	ENSG00000255310.2	AF131215.2	-4.26	2.48e-05	0.00433	-0.18	-0.19	Neuroticism;	chr8:11559376	chr8:11107788~11109726:-
HNSC	cis	rs5758511	0.68	rs1107553	ENSG00000226450.2	CYP2D8P	4.26	2.48e-05	0.00433	0.19	0.19	Birth weight;	chr22:42271467	chr22:42149886~42155001:-
HNSC	cis	rs7005380	0.581	rs9987165	ENSG00000279347.1	RP11-85I17.2	4.26	2.48e-05	0.00433	0.18	0.19	Interstitial lung disease;	chr8:119921633	chr8:119838736~119840385:-
HNSC	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	4.26	2.48e-05	0.00433	0.2	0.19	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
HNSC	cis	rs62458065	0.85	rs7785999	ENSG00000226468.2	AC018641.7	4.26	2.48e-05	0.00433	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32456963~32457758:-
HNSC	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-4.26	2.48e-05	0.00433	-0.21	-0.19	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
HNSC	cis	rs10927875	0.691	rs1048261	ENSG00000226029.1	RP4-798A10.2	-4.26	2.48e-05	0.00433	-0.2	-0.19	Dilated cardiomyopathy;	chr1:16014456	chr1:16460948~16468481:+
HNSC	cis	rs74024059	0.661	rs2460801	ENSG00000260269.4	CTD-2323K18.1	4.26	2.48e-05	0.00433	0.48	0.19	Red blood cell count;Hematocrit;	chr15:75872007	chr15:75527150~75601205:-
HNSC	cis	rs74024059	1	rs2655137	ENSG00000260269.4	CTD-2323K18.1	-4.26	2.48e-05	0.00433	-0.48	-0.19	Red blood cell count;Hematocrit;	chr15:75869557	chr15:75527150~75601205:-
HNSC	cis	rs74024059	1	rs2604405	ENSG00000260269.4	CTD-2323K18.1	-4.26	2.48e-05	0.00433	-0.48	-0.19	Red blood cell count;Hematocrit;	chr15:75869788	chr15:75527150~75601205:-
HNSC	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-4.26	2.48e-05	0.00433	-0.21	-0.19	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
HNSC	cis	rs9467711	0.559	rs9348721	ENSG00000241549.7	GUSBP2	4.26	2.49e-05	0.00434	0.3	0.19	Autism spectrum disorder or schizophrenia;	chr6:26485345	chr6:26871484~26956554:-
HNSC	cis	rs3805389	0.961	rs9996936	ENSG00000273257.1	RP11-177J6.1	-4.26	2.49e-05	0.00434	-0.26	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55601472	chr4:55387949~55388271:+
HNSC	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	4.26	2.49e-05	0.00434	0.23	0.19	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
HNSC	cis	rs6026584	1	rs6026584	ENSG00000270951.1	RP1-309F20.4	4.26	2.49e-05	0.00434	0.21	0.19	Renal function-related traits (BUN);	chr20:58894018	chr20:58876592~58876981:-
HNSC	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-4.26	2.49e-05	0.00434	-0.19	-0.19	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
HNSC	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	4.26	2.49e-05	0.00434	0.24	0.19	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000219891.2	ZSCAN12P1	4.26	2.49e-05	0.00434	0.28	0.19	Parkinson's disease;	chr6:28047791	chr6:28091154~28093664:+
HNSC	cis	rs7196129	0.932	rs11574938	ENSG00000183604.13	SMG1P5	4.26	2.49e-05	0.00434	0.19	0.19	Monocyte count;	chr16:30474072	chr16:30267553~30335374:-
HNSC	cis	rs757081	0.667	rs644419	ENSG00000260196.1	RP1-239B22.5	4.26	2.49e-05	0.00434	0.24	0.19	Systolic blood pressure;	chr11:17190828	chr11:17380649~17383531:+
HNSC	cis	rs7178909	0.732	rs57163265	ENSG00000259677.1	RP11-493E3.1	4.26	2.49e-05	0.00434	0.22	0.19	Common traits (Other);	chr15:89857418	chr15:89876540~89877285:+
HNSC	cis	rs1538970	0.816	rs9727262	ENSG00000234329.1	RP11-767N6.2	4.26	2.49e-05	0.00434	0.23	0.19	Platelet count;	chr1:45532907	chr1:45651039~45651826:-
HNSC	cis	rs61542988	0.57	rs10950919	ENSG00000221740.1	SNORD93	4.26	2.49e-05	0.00434	0.25	0.19	Fibrinogen levels;	chr7:22794202	chr7:22856613~22856686:+
HNSC	cis	rs79349575	0.783	rs56046215	ENSG00000270781.1	RP11-501C14.9	-4.26	2.49e-05	0.00434	-0.2	-0.19	Type 2 diabetes;	chr17:48931395	chr17:48899131~48899748:+
HNSC	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-4.26	2.49e-05	0.00434	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
HNSC	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-4.26	2.49e-05	0.00435	-0.28	-0.19	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
HNSC	cis	rs12745968	0.589	rs6682801	ENSG00000223787.2	RP4-593M8.1	-4.26	2.49e-05	0.00435	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92608984	chr1:92580476~92580821:-
HNSC	cis	rs4388249	1	rs11241041	ENSG00000271849.1	CTC-332L22.1	-4.26	2.49e-05	0.00435	-0.31	-0.19	Schizophrenia;	chr5:109847640	chr5:109687802~109688329:-
HNSC	cis	rs1008375	1	rs555	ENSG00000249502.1	AC006160.5	-4.26	2.49e-05	0.00435	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624035	chr4:17587467~17614571:-
HNSC	cis	rs2911132	0.564	rs17401719	ENSG00000248734.2	CTD-2260A17.1	-4.26	2.49e-05	0.00435	-0.21	-0.19	Urate levels (BMI interaction);	chr5:96753342	chr5:96784777~96785999:+
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000250412.1	KLHL2P1	4.26	2.5e-05	0.00435	0.25	0.19	Corneal astigmatism;	chr4:119316298	chr4:119334329~119378233:+
HNSC	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-4.26	2.5e-05	0.00435	-0.21	-0.19	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
HNSC	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-4.26	2.5e-05	0.00435	-0.25	-0.19	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
HNSC	cis	rs60617249	0.772	rs9692034	ENSG00000228204.2	RP4-724E13.2	4.26	2.5e-05	0.00435	0.21	0.19	Major depression and alcohol dependence;	chr7:50889592	chr7:50866747~51022990:+
HNSC	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	4.26	2.5e-05	0.00435	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	4.26	2.5e-05	0.00435	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
HNSC	cis	rs6714900	0.887	rs2287327	ENSG00000234896.1	OR7E62P	-4.26	2.5e-05	0.00435	-0.23	-0.19	Blood protein levels;	chr2:71070852	chr2:71055527~71056003:+
HNSC	cis	rs2834288	0.7	rs731061	ENSG00000273102.1	AP000569.9	-4.26	2.5e-05	0.00435	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33902937	chr21:33967101~33968573:-
HNSC	cis	rs6500395	1	rs1420701	ENSG00000261267.1	RP11-44I10.3	4.26	2.5e-05	0.00435	0.24	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48696962	chr16:48559661~48587403:+
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	4.26	2.5e-05	0.00435	0.27	0.19	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
HNSC	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	4.26	2.5e-05	0.00435	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
HNSC	cis	rs3096299	0.781	rs3102381	ENSG00000261574.1	RP1-168P16.2	4.26	2.5e-05	0.00436	0.24	0.19	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89392375~89412564:-
HNSC	cis	rs4841134	0.625	rs12235038	ENSG00000233609.3	RP11-62H7.2	-4.26	2.5e-05	0.00436	-0.18	-0.19	Age-related disease endophenotypes;	chr8:9379893	chr8:8961200~8979025:+
HNSC	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	4.26	2.5e-05	0.00436	0.22	0.19	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
HNSC	cis	rs9880211	0.8	rs9873536	ENSG00000273486.1	RP11-731C17.2	4.26	2.5e-05	0.00436	0.19	0.19	Height;Body mass index;	chr3:136755425	chr3:136837338~136839021:-
HNSC	cis	rs7781557	0.64	rs17135916	ENSG00000239969.4	RP11-163E9.2	-4.26	2.5e-05	0.00436	-0.29	-0.19	Colorectal adenoma (advanced);	chr7:102912550	chr7:102364162~102380633:+
HNSC	cis	rs67478160	0.608	rs11628787	ENSG00000259515.1	RP11-365N19.2	-4.26	2.5e-05	0.00436	-0.17	-0.19	Schizophrenia;	chr14:103857647	chr14:102933574~102937177:+
HNSC	cis	rs6964587	0.839	rs6950538	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.5e-05	0.00436	-0.2	-0.19	Breast cancer;	chr7:91788501	chr7:92134604~92180725:+
HNSC	cis	rs447735	0.587	rs11647958	ENSG00000274627.1	RP11-104N10.2	4.26	2.5e-05	0.00436	0.19	0.19	Hemoglobin concentration;	chr16:89654501	chr16:89516797~89522217:+
HNSC	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-4.26	2.5e-05	0.00436	-0.22	-0.19	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
HNSC	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-4.26	2.5e-05	0.00436	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
HNSC	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-4.26	2.5e-05	0.00436	-0.23	-0.19	Height;	chr14:75193543	chr14:75011269~75012851:-
HNSC	cis	rs6500395	1	rs9928051	ENSG00000261267.1	RP11-44I10.3	-4.26	2.51e-05	0.00436	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48523405	chr16:48559661~48587403:+
HNSC	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	4.26	2.51e-05	0.00437	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
HNSC	cis	rs704795	0.651	rs11693959	ENSG00000234072.1	AC074117.10	-4.26	2.51e-05	0.00437	-0.19	-0.19	Menopause (age at onset);	chr2:27351292	chr2:27356246~27367622:+
HNSC	cis	rs9329221	0.506	rs6993610	ENSG00000269918.1	AF131215.9	-4.26	2.51e-05	0.00437	-0.2	-0.19	Neuroticism;	chr8:10473484	chr8:11104691~11106704:-
HNSC	cis	rs4660261	0.526	rs2906458	ENSG00000237950.1	RP11-7O11.3	-4.26	2.51e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr1:43870717	chr1:43944370~43946551:-
HNSC	cis	rs7572733	0.905	rs6718039	ENSG00000222017.1	AC011997.1	4.26	2.51e-05	0.00437	0.23	0.19	Dermatomyositis;	chr2:197896918	chr2:197693106~197774823:+
HNSC	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	4.26	2.51e-05	0.00437	0.17	0.19	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
HNSC	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	4.26	2.51e-05	0.00437	0.17	0.19	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
HNSC	cis	rs4578769	0.531	rs768793	ENSG00000265943.1	RP11-739L10.1	4.26	2.51e-05	0.00437	0.23	0.19	Eosinophil percentage of white cells;	chr18:22976640	chr18:22699481~22933764:-
HNSC	cis	rs2333021	1	rs4899453	ENSG00000258376.2	RP4-647C14.2	4.26	2.51e-05	0.00437	0.23	0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:73242651~73245979:-
HNSC	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-4.26	2.51e-05	0.00437	-0.21	-0.19	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
HNSC	cis	rs9611565	0.605	rs202638	ENSG00000235513.1	RP4-756G23.5	-4.26	2.51e-05	0.00437	-0.22	-0.19	Vitiligo;	chr22:41459454	chr22:41209122~41217627:-
HNSC	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	4.26	2.51e-05	0.00437	0.26	0.19	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
HNSC	cis	rs7015630	0.648	rs62530862	ENSG00000251136.7	RP11-37B2.1	-4.26	2.51e-05	0.00437	-0.23	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89822659	chr8:89609409~89757727:-
HNSC	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	4.26	2.51e-05	0.00437	0.43	0.19	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
HNSC	cis	rs73198271	0.74	rs10094270	ENSG00000233609.3	RP11-62H7.2	-4.26	2.51e-05	0.00437	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs28521727	ENSG00000233609.3	RP11-62H7.2	-4.26	2.51e-05	0.00437	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8961200~8979025:+
HNSC	cis	rs6604026	0.883	rs10874745	ENSG00000223787.2	RP4-593M8.1	4.26	2.51e-05	0.00437	0.26	0.19	Multiple sclerosis;	chr1:92855984	chr1:92580476~92580821:-
HNSC	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	4.26	2.51e-05	0.00437	0.19	0.19	Height;	chr5:37427041	chr5:36666214~36725195:-
HNSC	cis	rs9650657	0.836	rs6601523	ENSG00000269918.1	AF131215.9	-4.26	2.51e-05	0.00437	-0.2	-0.19	Neuroticism;	chr8:10777631	chr8:11104691~11106704:-
HNSC	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	4.26	2.51e-05	0.00437	0.18	0.19	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
HNSC	cis	rs755249	0.701	rs4660823	ENSG00000182109.6	RP11-69E11.4	4.26	2.51e-05	0.00438	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39532851	chr1:39522280~39546187:-
HNSC	cis	rs1862618	0.671	rs2591956	ENSG00000271828.1	CTD-2310F14.1	-4.26	2.51e-05	0.00438	-0.24	-0.19	Initial pursuit acceleration;	chr5:56948777	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.671	rs2591955	ENSG00000271828.1	CTD-2310F14.1	-4.26	2.51e-05	0.00438	-0.24	-0.19	Initial pursuit acceleration;	chr5:56949121	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.671	rs906631	ENSG00000271828.1	CTD-2310F14.1	-4.26	2.51e-05	0.00438	-0.24	-0.19	Initial pursuit acceleration;	chr5:56949976	chr5:56927874~56929573:+
HNSC	cis	rs6500395	1	rs9930199	ENSG00000261267.1	RP11-44I10.3	-4.26	2.52e-05	0.00438	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48537352	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs3743779	ENSG00000261267.1	RP11-44I10.3	-4.26	2.52e-05	0.00438	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48540129	chr16:48559661~48587403:+
HNSC	cis	rs7824557	0.591	rs2293859	ENSG00000255310.2	AF131215.2	4.26	2.52e-05	0.00438	0.18	0.19	Retinal vascular caliber;	chr8:11359252	chr8:11107788~11109726:-
HNSC	cis	rs72627123	0.867	rs17094076	ENSG00000259065.1	RP5-1021I20.1	-4.26	2.52e-05	0.00438	-0.34	-0.19	Morning vs. evening chronotype;	chr14:73933789	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627138	ENSG00000259065.1	RP5-1021I20.1	-4.26	2.52e-05	0.00438	-0.34	-0.19	Morning vs. evening chronotype;	chr14:73935197	chr14:73787360~73803270:+
HNSC	cis	rs7610312	0.681	rs7626140	ENSG00000273493.1	RP11-80H18.4	-4.26	2.52e-05	0.00438	-0.23	-0.19	Red blood cell count;	chr3:58292517	chr3:58329965~58330118:+
HNSC	cis	rs17264034	1	rs17263917	ENSG00000250786.1	SNHG18	4.26	2.52e-05	0.00438	0.33	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552226	chr5:9546200~9550609:+
HNSC	cis	rs6688613	0.679	rs12116418	ENSG00000215834.7	FMO9P	4.26	2.52e-05	0.00438	0.24	0.19	Refractive astigmatism;	chr1:166975036	chr1:166603675~166631400:+
HNSC	cis	rs7243790	0.805	rs3809947	ENSG00000277324.1	RP11-850A17.1	-4.26	2.52e-05	0.00438	-0.22	-0.19	Diastolic blood pressure;	chr18:54380396	chr18:54268346~54270028:-
HNSC	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	4.26	2.52e-05	0.00438	0.21	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
HNSC	cis	rs13126694	0.71	rs4574459	ENSG00000248429.4	RP11-597D13.9	4.26	2.52e-05	0.00438	0.22	0.19	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158170752~158202877:+
HNSC	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-4.26	2.52e-05	0.00438	-0.22	-0.19	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
HNSC	cis	rs597480	0.637	rs678376	ENSG00000279742.1	RP11-700A24.1	-4.26	2.52e-05	0.00438	-0.22	-0.19	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85719354	chr11:85852557~85854943:-
HNSC	cis	rs875971	0.862	rs2460432	ENSG00000232559.3	GS1-124K5.12	-4.26	2.52e-05	0.00439	-0.23	-0.19	Aortic root size;	chr7:66089398	chr7:66554588~66576923:-
HNSC	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	4.26	2.52e-05	0.00439	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
HNSC	cis	rs7824557	0.527	rs57629785	ENSG00000269918.1	AF131215.9	-4.26	2.52e-05	0.00439	-0.19	-0.19	Retinal vascular caliber;	chr8:11377641	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2572395	ENSG00000269918.1	AF131215.9	-4.26	2.52e-05	0.00439	-0.19	-0.19	Retinal vascular caliber;	chr8:11377851	chr8:11104691~11106704:-
HNSC	cis	rs2858942	0.575	rs2858011	ENSG00000268836.1	LA16c-OS12.2	4.26	2.52e-05	0.00439	0.2	0.19	Mean corpuscular hemoglobin;	chr16:197939	chr16:185748~186294:-
HNSC	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.26	2.52e-05	0.00439	-0.21	-0.19	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
HNSC	cis	rs9527	0.615	rs4919682	ENSG00000236937.2	PTGES3P4	4.26	2.52e-05	0.00439	0.27	0.19	Arsenic metabolism;	chr10:102824573	chr10:102845595~102845950:+
HNSC	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-4.26	2.52e-05	0.00439	-0.2	-0.19	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
HNSC	cis	rs9329221	0.537	rs12678797	ENSG00000254340.1	RP11-10A14.3	-4.26	2.52e-05	0.00439	-0.23	-0.19	Neuroticism;	chr8:10121409	chr8:9141424~9145435:+
HNSC	cis	rs9910055	0.529	rs170637	ENSG00000267080.4	ASB16-AS1	4.26	2.52e-05	0.00439	0.16	0.19	Total body bone mineral density;	chr17:44109500	chr17:44175973~44186717:-
HNSC	cis	rs7735319	0.966	rs35317495	ENSG00000249102.1	CTD-2066L21.1	4.26	2.52e-05	0.00439	0.22	0.19	Systolic blood pressure;	chr5:33155097	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.901	rs7731489	ENSG00000249102.1	CTD-2066L21.1	4.26	2.52e-05	0.00439	0.22	0.19	Systolic blood pressure;	chr5:33156621	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.87	rs7735427	ENSG00000249102.1	CTD-2066L21.1	4.26	2.52e-05	0.00439	0.22	0.19	Systolic blood pressure;	chr5:33156782	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs62368014	ENSG00000249102.1	CTD-2066L21.1	4.26	2.52e-05	0.00439	0.22	0.19	Systolic blood pressure;	chr5:33157378	chr5:33008994~33025724:+
HNSC	cis	rs9313772	0.722	rs3981335	ENSG00000254350.1	RP11-542A14.1	-4.26	2.53e-05	0.00439	-0.21	-0.19	Blood pressure;	chr5:158432272	chr5:158424585~158452758:+
HNSC	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	4.26	2.53e-05	0.00439	0.27	0.19	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
HNSC	cis	rs2145598	0.835	rs2147609	ENSG00000279636.2	LINC00216	-4.26	2.53e-05	0.00439	-0.21	-0.19	Coronary artery disease;	chr14:58380261	chr14:58288033~58289158:+
HNSC	cis	rs73198271	0.96	rs12155530	ENSG00000253893.2	FAM85B	4.26	2.53e-05	0.00439	0.28	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8753454	chr8:8167819~8226614:-
HNSC	cis	rs7824557	0.564	rs2572392	ENSG00000269918.1	AF131215.9	-4.26	2.53e-05	0.00439	-0.19	-0.19	Retinal vascular caliber;	chr8:11378096	chr8:11104691~11106704:-
HNSC	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	4.26	2.53e-05	0.00439	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
HNSC	cis	rs11846409	0.86	rs55745256	ENSG00000254174.1	IGHV1-12	4.26	2.53e-05	0.00439	0.16	0.19	Rheumatic heart disease;	chr14:106632365	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs731013	ENSG00000254174.1	IGHV1-12	4.26	2.53e-05	0.00439	0.16	0.19	Rheumatic heart disease;	chr14:106632481	chr14:106122420~106122709:-
HNSC	cis	rs11846409	0.932	rs756588	ENSG00000254174.1	IGHV1-12	-4.26	2.53e-05	0.00439	-0.16	-0.19	Rheumatic heart disease;	chr14:106632316	chr14:106122420~106122709:-
HNSC	cis	rs9910055	0.53	rs11652651	ENSG00000267080.4	ASB16-AS1	4.26	2.53e-05	0.00439	0.15	0.19	Total body bone mineral density;	chr17:44225539	chr17:44175973~44186717:-
HNSC	cis	rs60617249	0.862	rs12533749	ENSG00000228204.2	RP4-724E13.2	4.25	2.53e-05	0.00439	0.2	0.19	Major depression and alcohol dependence;	chr7:50942193	chr7:50866747~51022990:+
HNSC	cis	rs1009077	0.716	rs2892870	ENSG00000245958.5	RP11-33B1.1	4.25	2.53e-05	0.0044	0.23	0.19	Endometriosis;	chr4:119642218	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.863	rs7699064	ENSG00000250412.1	KLHL2P1	-4.25	2.53e-05	0.0044	-0.25	-0.19	Corneal astigmatism;	chr4:119507154	chr4:119334329~119378233:+
HNSC	cis	rs9650657	0.812	rs11250074	ENSG00000269918.1	AF131215.9	-4.25	2.53e-05	0.0044	-0.2	-0.19	Neuroticism;	chr8:10774749	chr8:11104691~11106704:-
HNSC	cis	rs4523957	0.855	rs9893573	ENSG00000262333.1	HNRNPA1P16	4.25	2.53e-05	0.0044	0.16	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2222709	chr17:2306761~2307715:+
HNSC	cis	rs6964587	0.692	rs2158138	ENSG00000188693.7	CYP51A1-AS1	-4.25	2.53e-05	0.0044	-0.2	-0.19	Breast cancer;	chr7:92071565	chr7:92134604~92180725:+
HNSC	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	4.25	2.53e-05	0.0044	0.24	0.19	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
HNSC	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-4.25	2.53e-05	0.0044	-0.23	-0.19	Height;	chr14:75178824	chr14:75011269~75012851:-
HNSC	cis	rs6831352	0.959	rs1139490	ENSG00000263923.1	RP11-571L19.7	-4.25	2.53e-05	0.0044	-0.19	-0.19	Alcohol dependence;	chr4:99123990	chr4:98928897~98994994:+
HNSC	cis	rs42490	0.716	rs43135	ENSG00000251136.7	RP11-37B2.1	-4.25	2.53e-05	0.0044	-0.17	-0.19	Leprosy;	chr8:89823722	chr8:89609409~89757727:-
HNSC	cis	rs9329221	0.682	rs11786677	ENSG00000255310.2	AF131215.2	4.25	2.53e-05	0.0044	0.18	0.19	Neuroticism;	chr8:10406750	chr8:11107788~11109726:-
HNSC	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	4.25	2.53e-05	0.0044	0.24	0.19	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
HNSC	cis	rs3015497	0.763	rs2934689	ENSG00000277050.1	RP11-102G14.1	-4.25	2.54e-05	0.00441	-0.18	-0.19	Mean platelet volume;	chr14:50651609	chr14:51637348~51637947:-
HNSC	cis	rs7824557	0.564	rs2437152	ENSG00000269918.1	AF131215.9	-4.25	2.54e-05	0.00441	-0.19	-0.19	Retinal vascular caliber;	chr8:11377988	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2736300	ENSG00000269918.1	AF131215.9	-4.25	2.54e-05	0.00441	-0.19	-0.19	Retinal vascular caliber;	chr8:11378070	chr8:11104691~11106704:-
HNSC	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	4.25	2.54e-05	0.00441	0.19	0.19	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
HNSC	cis	rs11247915	0.561	rs11583258	ENSG00000236782.4	RP11-96L14.7	-4.25	2.54e-05	0.00441	-0.23	-0.19	Obesity-related traits;	chr1:26297779	chr1:26169947~26171821:-
HNSC	cis	rs6095360	0.934	rs6095395	ENSG00000222365.1	SNORD12B	-4.25	2.54e-05	0.00441	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49010558	chr20:49280319~49280409:+
HNSC	cis	rs2136613	0.728	rs10995325	ENSG00000238280.1	RP11-436D10.3	-4.25	2.54e-05	0.00441	-0.23	-0.19	Selective IgA deficiency;	chr10:62842577	chr10:62793562~62805887:-
HNSC	cis	rs3015497	0.608	rs2934665	ENSG00000277050.1	RP11-102G14.1	-4.25	2.54e-05	0.00441	-0.2	-0.19	Mean platelet volume;	chr14:50688001	chr14:51637348~51637947:-
HNSC	cis	rs9880211	0.752	rs9820717	ENSG00000273486.1	RP11-731C17.2	4.25	2.54e-05	0.00441	0.19	0.19	Height;Body mass index;	chr3:136627771	chr3:136837338~136839021:-
HNSC	cis	rs17761864	0.959	rs16952025	ENSG00000262333.1	HNRNPA1P16	4.25	2.54e-05	0.00441	0.16	0.19	Esophageal cancer (squamous cell);	chr17:2213504	chr17:2306761~2307715:+
HNSC	cis	rs227275	0.525	rs4596243	ENSG00000230069.3	LRRC37A15P	-4.25	2.54e-05	0.00441	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102727274~102730721:-
HNSC	cis	rs13434995	0.513	rs58476959	ENSG00000273257.1	RP11-177J6.1	-4.25	2.54e-05	0.00441	-0.25	-0.19	Adiponectin levels;	chr4:55496234	chr4:55387949~55388271:+
HNSC	cis	rs12893668	0.572	rs4906350	ENSG00000269910.1	RP11-73M18.10	4.25	2.54e-05	0.00441	0.18	0.19	Reticulocyte count;	chr14:103645457	chr14:103694516~103695050:-
HNSC	cis	rs9880211	0.706	rs9289513	ENSG00000273486.1	RP11-731C17.2	4.25	2.54e-05	0.00441	0.19	0.19	Height;Body mass index;	chr3:136732904	chr3:136837338~136839021:-
HNSC	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	4.25	2.54e-05	0.00442	0.25	0.19	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	4.25	2.54e-05	0.00442	0.25	0.19	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
HNSC	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-4.25	2.54e-05	0.00442	-0.3	-0.19	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
HNSC	cis	rs4372836	0.964	rs4408686	ENSG00000226833.4	AC097724.3	-4.25	2.54e-05	0.00442	-0.24	-0.19	Body mass index;	chr2:28717660	chr2:28708953~28736205:-
HNSC	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	4.25	2.54e-05	0.00442	0.16	0.19	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
HNSC	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	4.25	2.54e-05	0.00442	0.16	0.19	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
HNSC	cis	rs3736485	0.844	rs12101858	ENSG00000259438.1	CTD-2650P22.1	4.25	2.54e-05	0.00442	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51491784	chr15:52010999~52019095:-
HNSC	cis	rs13073817	0.615	rs336641	ENSG00000228956.7	SATB1-AS1	4.25	2.54e-05	0.00442	0.23	0.19	Crohn's disease;	chr3:18575784	chr3:18445024~18920401:+
HNSC	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-4.25	2.54e-05	0.00442	-0.19	-0.19	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
HNSC	cis	rs4763879	0.778	rs9332411	ENSG00000278635.1	CTD-2318O12.1	4.25	2.54e-05	0.00442	0.15	0.19	Type 1 diabetes;	chr12:9681749	chr12:9415641~9416718:+
HNSC	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	4.25	2.55e-05	0.00443	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	4.25	2.55e-05	0.00443	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	4.25	2.55e-05	0.00443	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	4.25	2.55e-05	0.00443	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
HNSC	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.25	2.55e-05	0.00443	0.22	0.19	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
HNSC	cis	rs6688613	1	rs7518155	ENSG00000215834.7	FMO9P	-4.25	2.55e-05	0.00443	-0.23	-0.19	Refractive astigmatism;	chr1:166985659	chr1:166603675~166631400:+
HNSC	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	4.25	2.55e-05	0.00443	0.23	0.19	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
HNSC	cis	rs3805389	0.924	rs2412665	ENSG00000273257.1	RP11-177J6.1	-4.25	2.55e-05	0.00443	-0.26	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55606812	chr4:55387949~55388271:+
HNSC	cis	rs9652601	0.959	rs2041670	ENSG00000274038.1	RP11-66H6.4	-4.25	2.55e-05	0.00443	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11080795	chr16:11056556~11057034:+
HNSC	cis	rs7246760	1	rs28441975	ENSG00000267289.1	CTD-2623N2.11	4.25	2.55e-05	0.00443	0.31	0.19	Pursuit maintenance gain;	chr19:9786955	chr19:9834079~9835013:-
HNSC	cis	rs4266144	0.558	rs4680339	ENSG00000241770.1	RP11-555M1.3	4.25	2.55e-05	0.00443	0.21	0.19	Coronary artery disease;	chr3:157117630	chr3:157163452~157169133:+
HNSC	cis	rs8010715	0.636	rs3825584	ENSG00000259321.1	RP11-468E2.5	4.25	2.55e-05	0.00443	0.17	0.19	IgG glycosylation;	chr14:24118430	chr14:24139445~24140444:+
HNSC	cis	rs16846053	0.515	rs4001644	ENSG00000227403.1	AC009299.3	-4.25	2.55e-05	0.00443	-0.34	-0.19	Blood osmolality (transformed sodium);	chr2:161542357	chr2:161244739~161249050:+
HNSC	cis	rs2835345	0.563	rs58602880	ENSG00000230479.1	AP000695.6	4.25	2.55e-05	0.00443	0.21	0.19	Pulmonary function;	chr21:36454610	chr21:36430360~36481070:+
HNSC	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	4.25	2.55e-05	0.00443	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
HNSC	cis	rs8028182	0.636	rs8034317	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.55e-05	0.00443	-0.25	-0.19	Sudden cardiac arrest;	chr15:75472002	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs28737338	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.55e-05	0.00443	-0.25	-0.19	Sudden cardiac arrest;	chr15:75476338	chr15:75527150~75601205:-
HNSC	cis	rs2486288	0.656	rs11632419	ENSG00000259479.5	SORD2P	-4.25	2.55e-05	0.00443	-0.22	-0.19	Glomerular filtration rate;	chr15:45265258	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs2271438	ENSG00000259479.5	SORD2P	-4.25	2.55e-05	0.00443	-0.22	-0.19	Glomerular filtration rate;	chr15:45265270	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11854365	ENSG00000259479.5	SORD2P	-4.25	2.55e-05	0.00443	-0.22	-0.19	Glomerular filtration rate;	chr15:45265885	chr15:44826371~44884694:-
HNSC	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-4.25	2.55e-05	0.00443	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-4.25	2.55e-05	0.00443	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
HNSC	cis	rs801193	1	rs10252765	ENSG00000272831.1	RP11-792A8.4	4.25	2.55e-05	0.00443	0.16	0.19	Aortic root size;	chr7:66763745	chr7:66739829~66740385:-
HNSC	cis	rs58873874	0.737	rs10061544	ENSG00000248544.2	CTB-47B11.3	4.25	2.55e-05	0.00443	0.39	0.19	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs10078836	ENSG00000248544.2	CTB-47B11.3	4.25	2.55e-05	0.00443	0.39	0.19	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157375741~157384950:-
HNSC	cis	rs6095360	0.727	rs35393280	ENSG00000222365.1	SNORD12B	-4.25	2.55e-05	0.00443	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:48927097	chr20:49280319~49280409:+
HNSC	cis	rs9650657	0.737	rs4504595	ENSG00000255310.2	AF131215.2	-4.25	2.55e-05	0.00444	-0.19	-0.19	Neuroticism;	chr8:10797995	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	4.25	2.56e-05	0.00444	0.11	0.19	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
HNSC	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	4.25	2.56e-05	0.00444	0.23	0.19	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
HNSC	cis	rs11157436	0.509	rs12589104	ENSG00000211812.1	TRAV26-2	-4.25	2.56e-05	0.00444	-0.18	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22202583~22203368:+
HNSC	cis	rs9921338	0.924	rs7193645	ENSG00000263080.1	RP11-485G7.5	4.25	2.56e-05	0.00444	0.22	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11341809~11345211:-
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	4.25	2.56e-05	0.00444	0.23	0.19	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000106610.13	STAG3L4	-4.25	2.56e-05	0.00444	-0.39	-0.19	Diabetic kidney disease;	chr7:66474549	chr7:67302621~67321526:+
HNSC	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	4.25	2.56e-05	0.00444	0.19	0.19	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
HNSC	cis	rs4660214	0.666	rs10888682	ENSG00000182109.6	RP11-69E11.4	-4.25	2.56e-05	0.00444	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39522280~39546187:-
HNSC	cis	rs4660214	0.666	rs11205698	ENSG00000182109.6	RP11-69E11.4	-4.25	2.56e-05	0.00444	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39522280~39546187:-
HNSC	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-4.25	2.56e-05	0.00444	-0.26	-0.19	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
HNSC	cis	rs1602565	0.778	rs10835480	ENSG00000255450.1	CTD-2063L20.1	-4.25	2.56e-05	0.00444	-0.3	-0.19	Schizophrenia;	chr11:29093511	chr11:29275655~29276565:+
HNSC	cis	rs7824557	0.591	rs2736282	ENSG00000255495.1	AC145124.2	4.25	2.56e-05	0.00444	0.21	0.19	Retinal vascular caliber;	chr8:11367971	chr8:12194467~12196280:+
HNSC	cis	rs78579285	0.622	rs4782322	ENSG00000278341.1	RP5-1142A6.10	-4.25	2.56e-05	0.00445	-0.35	-0.19	Joint mobility (Beighton score);	chr16:88731261	chr16:88708956~88710437:-
HNSC	cis	rs12237653	1	rs12237653	ENSG00000236404.7	VLDLR-AS1	4.25	2.56e-05	0.00445	0.31	0.19	Gambling;	chr9:2551654	chr9:2422702~2643359:-
HNSC	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-4.25	2.56e-05	0.00445	-0.26	-0.19	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
HNSC	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	4.25	2.56e-05	0.00445	0.26	0.19	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
HNSC	cis	rs73222236	0.825	rs59931907	ENSG00000273486.1	RP11-731C17.2	4.25	2.56e-05	0.00445	0.16	0.19	Coronary artery disease;	chr3:136646255	chr3:136837338~136839021:-
HNSC	cis	rs62292953	1	rs10512861	ENSG00000248724.5	NPHP3-AS1	-4.25	2.56e-05	0.00445	-0.34	-0.19	Red cell distribution width;	chr3:132539117	chr3:132721750~132874223:+
HNSC	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-4.25	2.56e-05	0.00445	-0.2	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
HNSC	cis	rs9921338	0.961	rs56010295	ENSG00000263080.1	RP11-485G7.5	4.25	2.56e-05	0.00445	0.22	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11285050	chr16:11341809~11345211:-
HNSC	cis	rs5167	0.504	rs3760629	ENSG00000269148.1	AC092301.3	4.25	2.56e-05	0.00445	0.17	0.19	Blood protein levels;	chr19:44954889	chr19:45830164~45831108:+
HNSC	cis	rs9313772	0.722	rs1320237	ENSG00000254350.1	RP11-542A14.1	-4.25	2.56e-05	0.00445	-0.21	-0.19	Blood pressure;	chr5:158427884	chr5:158424585~158452758:+
HNSC	cis	rs11673344	0.504	rs4806407	ENSG00000276846.1	CTD-3220F14.3	-4.25	2.57e-05	0.00445	-0.21	-0.19	Obesity-related traits;	chr19:37097849	chr19:37314868~37315620:-
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000226155.1	AC124944.3	-4.25	2.57e-05	0.00446	-0.25	-0.19	Pancreatic cancer;	chr3:195925837	chr3:195912049~195913986:+
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000226155.1	AC124944.3	-4.25	2.57e-05	0.00446	-0.25	-0.19	Pancreatic cancer;	chr3:195925980	chr3:195912049~195913986:+
HNSC	cis	rs1008375	1	rs1121089	ENSG00000249502.1	AC006160.5	-4.25	2.57e-05	0.00446	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674853	chr4:17587467~17614571:-
HNSC	cis	rs5758511	0.573	rs4501042	ENSG00000235513.1	RP4-756G23.5	4.25	2.57e-05	0.00446	0.2	0.19	Birth weight;	chr22:41849759	chr22:41209122~41217627:-
HNSC	cis	rs7781557	0.64	rs17135913	ENSG00000239969.4	RP11-163E9.2	-4.25	2.57e-05	0.00446	-0.29	-0.19	Colorectal adenoma (advanced);	chr7:102898068	chr7:102364162~102380633:+
HNSC	cis	rs2098713	0.502	rs596585	ENSG00000250155.1	CTD-2353F22.1	4.25	2.57e-05	0.00446	0.21	0.19	Telomere length;	chr5:37530563	chr5:36666214~36725195:-
HNSC	cis	rs11648785	0.506	rs7191175	ENSG00000221819.5	GAS8-AS1	-4.25	2.57e-05	0.00446	-0.19	-0.19	Tanning;	chr16:90028869	chr16:90028908~90029367:-
HNSC	cis	rs1821002	1	rs1821002	ENSG00000269918.1	AF131215.9	-4.25	2.57e-05	0.00446	-0.19	-0.19	Systolic blood pressure;	chr8:10782555	chr8:11104691~11106704:-
HNSC	cis	rs1008375	0.966	rs4698642	ENSG00000249502.1	AC006160.5	-4.25	2.57e-05	0.00446	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17677551	chr4:17587467~17614571:-
HNSC	cis	rs988913	0.813	rs4712082	ENSG00000224984.1	RP11-524H19.2	4.25	2.57e-05	0.00446	0.21	0.19	Menarche (age at onset);	chr6:54906221	chr6:54840118~54840855:-
HNSC	cis	rs12935418	0.579	rs7197606	ENSG00000261061.1	RP11-303E16.2	-4.25	2.57e-05	0.00446	-0.21	-0.19	Mean corpuscular volume;	chr16:81019914	chr16:81030770~81031485:+
HNSC	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-4.25	2.57e-05	0.00446	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
HNSC	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-4.25	2.57e-05	0.00446	-0.14	-0.19	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-4.25	2.57e-05	0.00446	-0.14	-0.19	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
HNSC	cis	rs7243790	0.774	rs7240534	ENSG00000277324.1	RP11-850A17.1	-4.25	2.57e-05	0.00446	-0.22	-0.19	Diastolic blood pressure;	chr18:54359527	chr18:54268346~54270028:-
HNSC	cis	rs7121616	1	rs75228513	ENSG00000200879.1	SNORD14E	4.25	2.57e-05	0.00446	0.25	0.19	Breast cancer;	chr11:123096160	chr11:123058077~123058161:-
HNSC	cis	rs8077577	0.895	rs62072500	ENSG00000273018.4	CTD-2303H24.2	-4.25	2.57e-05	0.00446	-0.29	-0.19	Obesity-related traits;	chr17:18223604	chr17:18511221~18551705:-
HNSC	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	4.25	2.57e-05	0.00446	0.22	0.19	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
HNSC	cis	rs4523957	0.533	rs216216	ENSG00000262333.1	HNRNPA1P16	-4.25	2.57e-05	0.00446	-0.18	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2241752	chr17:2306761~2307715:+
HNSC	cis	rs13178541	0.683	rs9800300	ENSG00000250378.1	RP11-119J18.1	-4.25	2.57e-05	0.00446	-0.26	-0.19	IgG glycosylation;	chr5:135760622	chr5:135812667~135826582:+
HNSC	cis	rs3015497	0.646	rs2934687	ENSG00000277050.1	RP11-102G14.1	-4.25	2.57e-05	0.00446	-0.2	-0.19	Mean platelet volume;	chr14:50645171	chr14:51637348~51637947:-
HNSC	cis	rs3015497	0.608	rs3015499	ENSG00000277050.1	RP11-102G14.1	-4.25	2.57e-05	0.00446	-0.2	-0.19	Mean platelet volume;	chr14:50645742	chr14:51637348~51637947:-
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000233609.3	RP11-62H7.2	-4.25	2.58e-05	0.00447	-0.18	-0.19	Myopia (pathological);	chr8:9111923	chr8:8961200~8979025:+
HNSC	cis	rs6723108	0.738	rs6751833	ENSG00000224043.6	CCNT2-AS1	-4.25	2.58e-05	0.00447	-0.24	-0.19	Type 2 diabetes;	chr2:134780328	chr2:134735464~134918710:-
HNSC	cis	rs6973609	0.524	rs2392375	ENSG00000271122.1	RP11-379H18.1	-4.25	2.58e-05	0.00447	-0.18	-0.19	Obesity-related traits;	chr7:35599704	chr7:35695214~35699413:+
HNSC	cis	rs597539	0.552	rs10792006	ENSG00000255741.1	RP11-757G1.5	4.25	2.58e-05	0.00447	0.24	0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68954837	chr11:68941503~68942852:-
HNSC	cis	rs7243790	0.805	rs12604412	ENSG00000277324.1	RP11-850A17.1	-4.25	2.58e-05	0.00447	-0.22	-0.19	Diastolic blood pressure;	chr18:54372922	chr18:54268346~54270028:-
HNSC	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-4.25	2.58e-05	0.00447	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
HNSC	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	4.25	2.58e-05	0.00448	0.19	0.19	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
HNSC	cis	rs2905347	0.964	rs2961270	ENSG00000179428.2	AC073072.5	4.25	2.58e-05	0.00448	0.23	0.19	Major depression and alcohol dependence;	chr7:22582519	chr7:22725395~22727620:-
HNSC	cis	rs1538970	0.816	rs868351	ENSG00000234329.1	RP11-767N6.2	4.25	2.58e-05	0.00448	0.22	0.19	Platelet count;	chr1:45544146	chr1:45651039~45651826:-
HNSC	cis	rs6887276	0.504	rs34145453	ENSG00000245937.6	LINC01184	-4.25	2.58e-05	0.00448	-0.23	-0.19	Height;	chr5:128011321	chr5:127940426~128083172:-
HNSC	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	4.25	2.58e-05	0.00448	0.17	0.19	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
HNSC	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	4.25	2.58e-05	0.00448	0.23	0.19	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
HNSC	cis	rs11098499	0.863	rs9884402	ENSG00000250412.1	KLHL2P1	4.25	2.58e-05	0.00448	0.25	0.19	Corneal astigmatism;	chr4:119568827	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.731	rs9995026	ENSG00000250412.1	KLHL2P1	4.25	2.58e-05	0.00448	0.25	0.19	Corneal astigmatism;	chr4:119569344	chr4:119334329~119378233:+
HNSC	cis	rs7809950	0.678	rs62482499	ENSG00000238832.1	snoU109	-4.25	2.58e-05	0.00448	-0.26	-0.19	Coronary artery disease;	chr7:107334614	chr7:107603363~107603507:+
HNSC	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	4.25	2.59e-05	0.00448	0.18	0.19	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
HNSC	cis	rs2361718	0.501	rs11869566	ENSG00000279259.1	RP11-334C17.3	4.25	2.59e-05	0.00448	0.25	0.19	Yeast infection;	chr17:80169449	chr17:80147250~80148596:+
HNSC	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	4.25	2.59e-05	0.00449	0.23	0.19	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
HNSC	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-4.25	2.59e-05	0.00449	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
HNSC	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-4.25	2.59e-05	0.00449	-0.25	-0.19	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-4.25	2.59e-05	0.00449	-0.25	-0.19	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
HNSC	cis	rs3015497	0.753	rs4643225	ENSG00000277050.1	RP11-102G14.1	-4.25	2.59e-05	0.00449	-0.18	-0.19	Mean platelet volume;	chr14:50655487	chr14:51637348~51637947:-
HNSC	cis	rs9300255	0.62	rs1727311	ENSG00000280120.1	RP11-546D6.3	4.25	2.59e-05	0.00449	0.19	0.19	Neutrophil percentage of white cells;	chr12:123176169	chr12:123152324~123153377:-
HNSC	cis	rs9300255	0.544	rs1716174	ENSG00000280120.1	RP11-546D6.3	4.25	2.59e-05	0.00449	0.19	0.19	Neutrophil percentage of white cells;	chr12:123176170	chr12:123152324~123153377:-
HNSC	cis	rs11633886	0.585	rs2460629	ENSG00000273972.1	CTD-2306A12.1	4.25	2.59e-05	0.00449	0.23	0.19	Diisocyanate-induced asthma;	chr15:45798785	chr15:45702640~45703183:+
HNSC	cis	rs11673344	0.562	rs7250507	ENSG00000276846.1	CTD-3220F14.3	4.25	2.59e-05	0.00449	0.21	0.19	Obesity-related traits;	chr19:37095772	chr19:37314868~37315620:-
HNSC	cis	rs67478160	0.575	rs8014294	ENSG00000259515.1	RP11-365N19.2	4.25	2.59e-05	0.00449	0.17	0.19	Schizophrenia;	chr14:103856646	chr14:102933574~102937177:+
HNSC	cis	rs7113211	0.812	rs11214361	ENSG00000176343.5	RPL37AP8	4.25	2.59e-05	0.00449	0.21	0.19	Expressive vocabulary in infants;	chr11:112772652	chr11:111889199~111889474:-
HNSC	cis	rs6964587	0.839	rs2049314	ENSG00000188693.7	CYP51A1-AS1	-4.25	2.59e-05	0.00449	-0.21	-0.19	Breast cancer;	chr7:91834820	chr7:92134604~92180725:+
HNSC	cis	rs561341	1	rs564714	ENSG00000278867.1	RP11-640N20.4	-4.25	2.59e-05	0.00449	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31991385	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs510264	ENSG00000278867.1	RP11-640N20.4	-4.25	2.59e-05	0.00449	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31996395	chr17:32051030~32053208:+
HNSC	cis	rs7804306	0.522	rs2882015	ENSG00000233264.2	AC006042.8	4.25	2.59e-05	0.00449	0.28	0.19	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8029247	chr7:7980312~7982228:+
HNSC	cis	rs4660214	0.666	rs11205696	ENSG00000182109.6	RP11-69E11.4	-4.25	2.59e-05	0.00449	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39522280~39546187:-
HNSC	cis	rs2898681	0.561	rs58577680	ENSG00000248375.1	RP11-177B4.1	-4.25	2.59e-05	0.00449	-0.32	-0.19	Optic nerve measurement (cup area);	chr4:52868127	chr4:52720081~52720831:-
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000254174.1	IGHV1-12	4.25	2.59e-05	0.00449	0.15	0.19	Rheumatic heart disease;	chr14:106638433	chr14:106122420~106122709:-
HNSC	cis	rs62344088	0.59	rs62345236	ENSG00000250848.1	CTD-2083E4.5	-4.25	2.59e-05	0.0045	-0.36	-0.19	Asthma (childhood onset);	chr5:283404	chr5:288833~290321:-
HNSC	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-4.25	2.59e-05	0.0045	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-4.25	2.59e-05	0.0045	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-4.25	2.59e-05	0.0045	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-4.25	2.59e-05	0.0045	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
HNSC	cis	rs4388249	0.95	rs3797693	ENSG00000271849.1	CTC-332L22.1	-4.25	2.6e-05	0.0045	-0.29	-0.19	Schizophrenia;	chr5:109750314	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs2301000	ENSG00000271849.1	CTC-332L22.1	-4.25	2.6e-05	0.0045	-0.29	-0.19	Schizophrenia;	chr5:109751735	chr5:109687802~109688329:-
HNSC	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	4.25	2.6e-05	0.0045	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.954	rs6848389	ENSG00000250412.1	KLHL2P1	4.25	2.6e-05	0.0045	0.25	0.19	Corneal astigmatism;	chr4:119481467	chr4:119334329~119378233:+
HNSC	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-4.25	2.6e-05	0.0045	-0.19	-0.19	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
HNSC	cis	rs2239557	0.539	rs7161037	ENSG00000259065.1	RP5-1021I20.1	-4.25	2.6e-05	0.0045	-0.28	-0.19	Common traits (Other);	chr14:73966426	chr14:73787360~73803270:+
HNSC	cis	rs9925964	0.687	rs12917722	ENSG00000232748.3	RP11-196G11.6	4.25	2.6e-05	0.0045	0.26	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:31056460~31062803:+
HNSC	cis	rs1008375	0.933	rs4698637	ENSG00000249502.1	AC006160.5	-4.25	2.6e-05	0.0045	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631220	chr4:17587467~17614571:-
HNSC	cis	rs728616	1	rs728616	ENSG00000225484.5	NUTM2B-AS1	-4.25	2.6e-05	0.0045	-0.4	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79663088~79826594:-
HNSC	cis	rs728616	1	rs728615	ENSG00000225484.5	NUTM2B-AS1	-4.25	2.6e-05	0.0045	-0.4	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79663088~79826594:-
HNSC	cis	rs4927850	0.881	rs7624638	ENSG00000226155.1	AC124944.3	-4.25	2.6e-05	0.0045	-0.23	-0.19	Pancreatic cancer;	chr3:196021858	chr3:195912049~195913986:+
HNSC	cis	rs6840258	1	rs56395939	ENSG00000251411.1	RP11-397E7.4	-4.25	2.6e-05	0.00451	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87042481	chr4:86913266~86914817:-
HNSC	cis	rs11633886	0.546	rs1033167	ENSG00000273972.1	CTD-2306A12.1	-4.25	2.6e-05	0.00451	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45747340	chr15:45702640~45703183:+
HNSC	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-4.25	2.6e-05	0.00451	-0.25	-0.19	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
HNSC	cis	rs7243790	0.805	rs12458588	ENSG00000277324.1	RP11-850A17.1	-4.25	2.6e-05	0.00451	-0.22	-0.19	Diastolic blood pressure;	chr18:54377323	chr18:54268346~54270028:-
HNSC	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	4.25	2.6e-05	0.00451	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
HNSC	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	4.25	2.6e-05	0.00451	0.24	0.19	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
HNSC	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	4.25	2.61e-05	0.00451	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
HNSC	cis	rs638893	0.636	rs493720	ENSG00000255422.1	AP002954.4	-4.25	2.61e-05	0.00451	-0.32	-0.19	Vitiligo;	chr11:118733969	chr11:118704607~118750263:+
HNSC	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-4.25	2.61e-05	0.00451	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-4.25	2.61e-05	0.00451	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
HNSC	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-4.25	2.61e-05	0.00451	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
HNSC	cis	rs761746	0.739	rs5994420	ENSG00000236132.1	CTA-440B3.1	-4.25	2.61e-05	0.00451	-0.25	-0.19	Intelligence;	chr22:31674765	chr22:31816379~31817491:-
HNSC	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-4.25	2.61e-05	0.00451	-0.25	-0.19	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
HNSC	cis	rs283610	0.741	rs1155627	ENSG00000182383.8	RPL27AP5	-4.25	2.61e-05	0.00451	-0.17	-0.19	Obesity-related traits;	chr5:73992415	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.741	rs1155628	ENSG00000182383.8	RPL27AP5	-4.25	2.61e-05	0.00451	-0.17	-0.19	Obesity-related traits;	chr5:73992421	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.705	rs5007747	ENSG00000182383.8	RPL27AP5	-4.25	2.61e-05	0.00451	-0.17	-0.19	Obesity-related traits;	chr5:73992497	chr5:74990189~74990637:-
HNSC	cis	rs283610	0.735	rs10474412	ENSG00000182383.8	RPL27AP5	-4.25	2.61e-05	0.00451	-0.17	-0.19	Obesity-related traits;	chr5:73992758	chr5:74990189~74990637:-
HNSC	cis	rs4664293	0.667	rs3815876	ENSG00000226266.5	AC009961.3	-4.25	2.61e-05	0.00451	-0.21	-0.19	Monocyte percentage of white cells;	chr2:159783640	chr2:159670708~159712435:-
HNSC	cis	rs7005380	0.581	rs9987139	ENSG00000279347.1	RP11-85I17.2	4.25	2.61e-05	0.00451	0.18	0.19	Interstitial lung disease;	chr8:119924619	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs9987135	ENSG00000279347.1	RP11-85I17.2	4.25	2.61e-05	0.00451	0.18	0.19	Interstitial lung disease;	chr8:119924655	chr8:119838736~119840385:-
HNSC	cis	rs9467773	0.506	rs9393709	ENSG00000241549.7	GUSBP2	4.25	2.61e-05	0.00452	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26364919	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.526	rs12199613	ENSG00000241549.7	GUSBP2	4.25	2.61e-05	0.00452	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26366990	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.526	rs9688946	ENSG00000241549.7	GUSBP2	4.25	2.61e-05	0.00452	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26367217	chr6:26871484~26956554:-
HNSC	cis	rs2933343	0.553	rs789212	ENSG00000261159.1	RP11-723O4.9	4.25	2.61e-05	0.00452	0.2	0.19	IgG glycosylation;	chr3:128968069	chr3:128859716~128860526:-
HNSC	cis	rs7735319	0.966	rs35408434	ENSG00000249102.1	CTD-2066L21.1	4.25	2.61e-05	0.00452	0.22	0.19	Systolic blood pressure;	chr5:33163321	chr5:33008994~33025724:+
HNSC	cis	rs9880211	0.8	rs9813376	ENSG00000273486.1	RP11-731C17.2	4.25	2.61e-05	0.00452	0.19	0.19	Height;Body mass index;	chr3:136756584	chr3:136837338~136839021:-
HNSC	cis	rs2255336	0.81	rs7976624	ENSG00000245648.1	RP11-277P12.20	4.25	2.61e-05	0.00452	0.34	0.19	Blood protein levels;	chr12:10359392	chr12:10363769~10398506:+
HNSC	cis	rs4321325	0.733	rs74707659	ENSG00000236682.1	AC068282.3	-4.25	2.61e-05	0.00452	-0.34	-0.19	Protein C levels;	chr2:127187893	chr2:127389130~127400580:+
HNSC	cis	rs2253762	0.54	rs7358186	ENSG00000226864.1	ATE1-AS1	4.25	2.61e-05	0.00452	0.33	0.19	Breast cancer;	chr10:122000816	chr10:121928312~121951965:+
HNSC	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-4.25	2.61e-05	0.00452	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
HNSC	cis	rs4713118	0.866	rs2179094	ENSG00000216901.1	AL022393.7	4.25	2.61e-05	0.00452	0.25	0.19	Parkinson's disease;	chr6:27774046	chr6:28176188~28176674:+
HNSC	cis	rs6964587	0.839	rs13229273	ENSG00000188693.7	CYP51A1-AS1	-4.25	2.61e-05	0.00452	-0.21	-0.19	Breast cancer;	chr7:91815158	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.839	rs62466159	ENSG00000188693.7	CYP51A1-AS1	-4.25	2.61e-05	0.00452	-0.21	-0.19	Breast cancer;	chr7:91821193	chr7:92134604~92180725:+
HNSC	cis	rs75422866	0.51	rs73104197	ENSG00000280054.1	RP1-197B17.7	4.25	2.61e-05	0.00452	0.45	0.19	Pneumonia;	chr12:47717273	chr12:47728151~47730598:-
HNSC	cis	rs67340775	0.541	rs200966	ENSG00000219392.1	RP1-265C24.5	-4.25	2.61e-05	0.00452	-0.29	-0.19	Lung cancer in ever smokers;	chr6:27894374	chr6:28115628~28116551:+
HNSC	cis	rs9467773	0.526	rs10946817	ENSG00000241549.7	GUSBP2	4.25	2.61e-05	0.00452	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26363828	chr6:26871484~26956554:-
HNSC	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-4.25	2.61e-05	0.00452	-0.32	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
HNSC	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	4.25	2.61e-05	0.00452	0.52	0.19	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
HNSC	cis	rs6964587	0.773	rs59242586	ENSG00000188693.7	CYP51A1-AS1	-4.25	2.61e-05	0.00453	-0.21	-0.19	Breast cancer;	chr7:92288831	chr7:92134604~92180725:+
HNSC	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-4.25	2.62e-05	0.00453	-0.22	-0.19	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
HNSC	cis	rs10791097	0.694	rs2155749	ENSG00000254842.5	RP11-890B15.2	-4.25	2.62e-05	0.00453	-0.17	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130881199	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs2155750	ENSG00000254842.5	RP11-890B15.2	-4.25	2.62e-05	0.00453	-0.17	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130881366	chr11:130844191~130865561:-
HNSC	cis	rs6457807	0.722	rs9394278	ENSG00000272374.1	RP3-329A5.8	4.25	2.62e-05	0.00453	0.22	0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr6:35167930	chr6:35220370~35224630:-
HNSC	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	4.25	2.62e-05	0.00453	0.17	0.19	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
HNSC	cis	rs10149470	0.549	rs9652403	ENSG00000270108.1	RP11-73M18.6	4.25	2.62e-05	0.00453	0.22	0.19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103687576~103688127:+
HNSC	cis	rs1602565	0.858	rs10835483	ENSG00000255450.1	CTD-2063L20.1	-4.25	2.62e-05	0.00453	-0.29	-0.19	Schizophrenia;	chr11:29109058	chr11:29275655~29276565:+
HNSC	cis	rs12546962	0.654	rs10089120	ENSG00000233609.3	RP11-62H7.2	-4.25	2.62e-05	0.00454	-0.2	-0.19	Body mass index;	chr8:9351551	chr8:8961200~8979025:+
HNSC	cis	rs4761669	0.816	rs4761670	ENSG00000241556.1	RP11-490G8.1	-4.25	2.62e-05	0.00454	-0.19	-0.19	Common carotid intima-media thickness in HIV infection;	chr12:94806067	chr12:95467397~95467861:-
HNSC	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.25	2.62e-05	0.00454	0.3	0.19	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
HNSC	cis	rs11638352	1	rs2615294	ENSG00000205771.5	CATSPER2P1	4.25	2.63e-05	0.00454	0.53	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120422	chr15:43726918~43747094:-
HNSC	cis	rs11638352	1	rs2555380	ENSG00000205771.5	CATSPER2P1	4.25	2.63e-05	0.00454	0.53	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120437	chr15:43726918~43747094:-
HNSC	cis	rs795484	0.926	rs353888	ENSG00000275409.1	RP11-131L12.4	-4.25	2.63e-05	0.00454	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118212556	chr12:118430147~118430699:+
HNSC	cis	rs9910055	0.821	rs4473241	ENSG00000267080.4	ASB16-AS1	-4.25	2.63e-05	0.00454	-0.15	-0.19	Total body bone mineral density;	chr17:44203914	chr17:44175973~44186717:-
HNSC	cis	rs7005380	0.581	rs13265734	ENSG00000279347.1	RP11-85I17.2	-4.25	2.63e-05	0.00454	-0.18	-0.19	Interstitial lung disease;	chr8:119907708	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.525	rs7000068	ENSG00000279347.1	RP11-85I17.2	-4.25	2.63e-05	0.00454	-0.18	-0.19	Interstitial lung disease;	chr8:119910723	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.538	rs7000488	ENSG00000279347.1	RP11-85I17.2	-4.25	2.63e-05	0.00454	-0.18	-0.19	Interstitial lung disease;	chr8:119911059	chr8:119838736~119840385:-
HNSC	cis	rs57502260	0.79	rs7129320	ENSG00000212093.1	AP000807.1	4.25	2.63e-05	0.00454	0.27	0.19	Total body bone mineral density (age 45-60);	chr11:68620752	chr11:68506083~68506166:-
HNSC	cis	rs7819412	0.502	rs4841499	ENSG00000269918.1	AF131215.9	-4.25	2.63e-05	0.00454	-0.2	-0.19	Triglycerides;	chr8:11130628	chr8:11104691~11106704:-
HNSC	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-4.25	2.63e-05	0.00455	-0.2	-0.19	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
HNSC	cis	rs11083475	0.714	rs7248584	ENSG00000269486.2	CTC-360G5.9	4.25	2.63e-05	0.00455	0.21	0.19	Heart rate;	chr19:38767470	chr19:38935297~38938632:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000219891.2	ZSCAN12P1	4.25	2.63e-05	0.00455	0.29	0.19	Depression;	chr6:28242910	chr6:28091154~28093664:+
HNSC	cis	rs2548724	1	rs841934	ENSG00000250682.4	LINC00491	-4.25	2.63e-05	0.00455	-0.27	-0.19	Type 2 diabetes;	chr5:102286496	chr5:102609156~102671559:-
HNSC	cis	rs2361710	0.704	rs12937349	ENSG00000279259.1	RP11-334C17.3	4.25	2.63e-05	0.00455	0.22	0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80146521	chr17:80147250~80148596:+
HNSC	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	4.25	2.63e-05	0.00455	0.22	0.19	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
HNSC	cis	rs7824557	0.527	rs2572447	ENSG00000255310.2	AF131215.2	-4.25	2.63e-05	0.00455	-0.18	-0.19	Retinal vascular caliber;	chr8:11382001	chr8:11107788~11109726:-
HNSC	cis	rs712039	0.652	rs34711199	ENSG00000276054.1	RP11-378E13.3	4.25	2.63e-05	0.00455	0.26	0.19	Tuberculosis;	chr17:37497933	chr17:37386886~37387926:+
HNSC	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	4.25	2.64e-05	0.00456	0.27	0.19	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
HNSC	cis	rs7572733	0.534	rs58374969	ENSG00000231621.1	AC013264.2	-4.25	2.64e-05	0.00456	-0.19	-0.19	Dermatomyositis;	chr2:197899639	chr2:197197991~197199273:+
HNSC	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	4.25	2.64e-05	0.00456	0.23	0.19	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
HNSC	cis	rs57561814	0.51	rs2066992	ENSG00000179428.2	AC073072.5	-4.25	2.64e-05	0.00456	-0.39	-0.19	Tonsillectomy;	chr7:22728630	chr7:22725395~22727620:-
HNSC	cis	rs60617249	0.831	rs1119943	ENSG00000228204.2	RP4-724E13.2	4.24	2.64e-05	0.00456	0.2	0.19	Major depression and alcohol dependence;	chr7:50896921	chr7:50866747~51022990:+
HNSC	cis	rs12745968	0.62	rs6666831	ENSG00000223787.2	RP4-593M8.1	-4.24	2.64e-05	0.00456	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92757240	chr1:92580476~92580821:-
HNSC	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	4.24	2.64e-05	0.00456	0.27	0.19	Pain;	chr19:21304368	chr19:21554640~21569237:-
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-4.24	2.64e-05	0.00457	-0.19	-0.19	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
HNSC	cis	rs12745968	0.653	rs2107519	ENSG00000223787.2	RP4-593M8.1	-4.24	2.64e-05	0.00457	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92727313	chr1:92580476~92580821:-
HNSC	cis	rs6964587	1	rs9785013	ENSG00000188693.7	CYP51A1-AS1	-4.24	2.64e-05	0.00457	-0.2	-0.19	Breast cancer;	chr7:92044988	chr7:92134604~92180725:+
HNSC	cis	rs1008375	0.931	rs6813374	ENSG00000249502.1	AC006160.5	-4.24	2.64e-05	0.00457	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647871	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs6813375	ENSG00000249502.1	AC006160.5	-4.24	2.64e-05	0.00457	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647876	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs1558378	ENSG00000249502.1	AC006160.5	-4.24	2.64e-05	0.00457	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648728	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs1558377	ENSG00000249502.1	AC006160.5	-4.24	2.64e-05	0.00457	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649135	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs2872957	ENSG00000249502.1	AC006160.5	-4.24	2.64e-05	0.00457	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650134	chr4:17587467~17614571:-
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-4.24	2.65e-05	0.00457	-0.14	-0.19	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
HNSC	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-4.24	2.65e-05	0.00457	-0.22	-0.19	Height;	chr14:75135159	chr14:75011269~75012851:-
HNSC	cis	rs12893668	0.572	rs4900590	ENSG00000269910.1	RP11-73M18.10	4.24	2.65e-05	0.00457	0.18	0.19	Reticulocyte count;	chr14:103680084	chr14:103694516~103695050:-
HNSC	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-4.24	2.65e-05	0.00457	-0.2	-0.19	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
HNSC	cis	rs950776	0.714	rs3743074	ENSG00000261762.1	RP11-650L12.2	-4.24	2.65e-05	0.00457	-0.23	-0.19	Sudden cardiac arrest;	chr15:78617138	chr15:78589123~78591276:-
HNSC	cis	rs7735319	0.533	rs2331146	ENSG00000249572.1	CTD-2203K17.1	-4.24	2.65e-05	0.00457	-0.21	-0.19	Systolic blood pressure;	chr5:33052415	chr5:33424025~33440619:-
HNSC	cis	rs2307394	0.896	rs13016083	ENSG00000281469.1	RP11-567F11.1	4.24	2.65e-05	0.00457	0.22	0.19	Urate levels;	chr2:147813376	chr2:148044380~148044894:+
HNSC	cis	rs7178375	0.678	rs34678577	ENSG00000270015.1	RP11-540B6.6	4.24	2.65e-05	0.00457	0.24	0.19	Hypertriglyceridemia;	chr15:30885262	chr15:30926514~30928407:+
HNSC	cis	rs6163	0.588	rs11191392	ENSG00000236937.2	PTGES3P4	4.24	2.65e-05	0.00457	0.23	0.19	Waist circumference;Hip circumference;	chr10:102767194	chr10:102845595~102845950:+
HNSC	cis	rs116095464	1	rs55671190	ENSG00000250848.1	CTD-2083E4.5	-4.24	2.65e-05	0.00457	-0.36	-0.19	Breast cancer;	chr5:287307	chr5:288833~290321:-
HNSC	cis	rs3736485	0.873	rs7162563	ENSG00000259438.1	CTD-2650P22.1	4.24	2.65e-05	0.00458	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51482870	chr15:52010999~52019095:-
HNSC	cis	rs12545109	0.8	rs1467125	ENSG00000246430.5	LINC00968	-4.24	2.65e-05	0.00458	-0.25	-0.19	Obesity-related traits;	chr8:56506079	chr8:56496246~56559823:-
HNSC	cis	rs9291683	0.605	rs73224439	ENSG00000250413.1	RP11-448G15.1	4.24	2.65e-05	0.00458	0.24	0.19	Bone mineral density;	chr4:10330194	chr4:10006482~10009725:+
HNSC	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-4.24	2.65e-05	0.00458	-0.21	-0.19	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
HNSC	cis	rs115344852	0.575	rs1015811	ENSG00000216901.1	AL022393.7	4.24	2.65e-05	0.00458	0.24	0.19	Epithelial ovarian cancer;	chr6:28480309	chr6:28176188~28176674:+
HNSC	cis	rs2548724	0.741	rs11948335	ENSG00000250682.4	LINC00491	4.24	2.65e-05	0.00458	0.26	0.19	Type 2 diabetes;	chr5:102368475	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.796	rs58644688	ENSG00000250682.4	LINC00491	4.24	2.65e-05	0.00458	0.26	0.19	Type 2 diabetes;	chr5:102375793	chr5:102609156~102671559:-
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000224373.3	IGHV4-59	4.24	2.65e-05	0.00458	0.11	0.19	Kawasaki disease;	chr14:106792798	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000224373.3	IGHV4-59	4.24	2.65e-05	0.00458	0.11	0.19	Kawasaki disease;	chr14:106800208	chr14:106627249~106627825:-
HNSC	cis	rs42490	0.716	rs40547	ENSG00000251136.7	RP11-37B2.1	-4.24	2.65e-05	0.00458	-0.17	-0.19	Leprosy;	chr8:89817685	chr8:89609409~89757727:-
HNSC	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-4.24	2.65e-05	0.00458	-0.33	-0.19	QT interval;	chr4:75105647	chr4:75081702~75084717:-
HNSC	cis	rs11250098	0.51	rs4840525	ENSG00000255310.2	AF131215.2	-4.24	2.65e-05	0.00458	-0.18	-0.19	Morning vs. evening chronotype;	chr8:10908125	chr8:11107788~11109726:-
HNSC	cis	rs6601327	0.634	rs12679956	ENSG00000233609.3	RP11-62H7.2	-4.24	2.65e-05	0.00458	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9727339	chr8:8961200~8979025:+
HNSC	cis	rs9990343	0.715	rs11922338	ENSG00000223552.1	RP11-24F11.2	-4.24	2.65e-05	0.00458	-0.16	-0.19	Brain structure;	chr3:46292869	chr3:46364955~46407059:-
HNSC	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	4.24	2.65e-05	0.00458	0.3	0.19	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
HNSC	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.24	2.65e-05	0.00458	-0.22	-0.19	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
HNSC	cis	rs6500395	0.89	rs11861666	ENSG00000261267.1	RP11-44I10.3	-4.24	2.65e-05	0.00458	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48646003	chr16:48559661~48587403:+
HNSC	cis	rs516805	0.561	rs9490497	ENSG00000279453.1	RP3-425C14.4	-4.24	2.65e-05	0.00458	-0.3	-0.19	Lymphocyte counts;	chr6:122615904	chr6:122436789~122439223:-
HNSC	cis	rs9487051	0.597	rs412754	ENSG00000243587.6	C6orf183	-4.24	2.65e-05	0.00458	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109200854	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs429534	ENSG00000243587.6	C6orf183	-4.24	2.65e-05	0.00458	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109202053	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs396635	ENSG00000243587.6	C6orf183	-4.24	2.65e-05	0.00458	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109202305	chr6:109165833~109271014:+
HNSC	cis	rs9929218	0.529	rs35854485	ENSG00000260459.2	FTLP14	4.24	2.65e-05	0.00458	0.25	0.19	Colorectal cancer;	chr16:68696952	chr16:68822587~68823070:+
HNSC	cis	rs4947019	0.534	rs75527655	ENSG00000260273.1	RP11-425D10.10	4.24	2.65e-05	0.00458	0.53	0.19	Hematological parameters;	chr6:109392693	chr6:109382795~109383666:+
HNSC	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	4.24	2.65e-05	0.00459	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	4.24	2.65e-05	0.00459	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs60323161	ENSG00000182109.6	RP11-69E11.4	4.24	2.65e-05	0.00459	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	4.24	2.65e-05	0.00459	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000219891.2	ZSCAN12P1	4.24	2.66e-05	0.00459	0.28	0.19	Parkinson's disease;	chr6:28046819	chr6:28091154~28093664:+
HNSC	cis	rs6460942	0.597	rs62449509	ENSG00000226690.5	AC005281.1	4.24	2.66e-05	0.00459	0.31	0.19	Coronary artery disease;	chr7:12475387	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.659	rs6969309	ENSG00000226690.5	AC005281.1	4.24	2.66e-05	0.00459	0.31	0.19	Coronary artery disease;	chr7:12476221	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs7811374	ENSG00000226690.5	AC005281.1	4.24	2.66e-05	0.00459	0.31	0.19	Coronary artery disease;	chr7:12477811	chr7:12496429~12541910:+
HNSC	cis	rs75422866	0.558	rs73104190	ENSG00000280054.1	RP1-197B17.7	4.24	2.66e-05	0.00459	0.45	0.19	Pneumonia;	chr12:47716040	chr12:47728151~47730598:-
HNSC	cis	rs1538970	0.816	rs61788356	ENSG00000234329.1	RP11-767N6.2	4.24	2.66e-05	0.00459	0.23	0.19	Platelet count;	chr1:45541003	chr1:45651039~45651826:-
HNSC	cis	rs6500395	1	rs1039340	ENSG00000261267.1	RP11-44I10.3	-4.24	2.66e-05	0.00459	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48540726	chr16:48559661~48587403:+
HNSC	cis	rs11756659	0.653	rs199738	ENSG00000217159.2	LARP1P1	4.24	2.66e-05	0.00459	0.27	0.19	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963228	chr6:26164072~26164363:+
HNSC	cis	rs3758785	0.512	rs11600240	ENSG00000255893.1	RP11-685N10.1	-4.24	2.66e-05	0.00459	-0.29	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94365167	chr11:94472908~94473570:-
HNSC	cis	rs12682352	0.602	rs635594	ENSG00000173295.6	FAM86B3P	-4.24	2.66e-05	0.00459	-0.22	-0.19	Neuroticism;	chr8:8755877	chr8:8228595~8244865:+
HNSC	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	4.24	2.66e-05	0.00459	0.2	0.19	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
HNSC	cis	rs7071275	0.564	rs10437462	ENSG00000223432.1	RP11-62L18.3	4.24	2.66e-05	0.00459	0.25	0.19	Dupuytren's disease;	chr10:121629368	chr10:121615425~121615839:-
HNSC	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-4.24	2.66e-05	0.00459	-0.22	-0.19	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000224373.3	IGHV4-59	4.24	2.66e-05	0.00459	0.12	0.19	Kawasaki disease;	chr14:106779068	chr14:106627249~106627825:-
HNSC	cis	rs4853525	0.561	rs11898764	ENSG00000228509.4	AC006460.2	-4.24	2.66e-05	0.00459	-0.27	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190847844	chr2:190676944~190708716:-
HNSC	cis	rs9903692	0.789	rs12601675	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48113566	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.908	rs8066391	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48117934	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.908	rs11079809	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48120859	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs3744346	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48121514	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.908	rs7222136	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48122230	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs1010228	ENSG00000263412.1	RP5-890E16.2	4.24	2.66e-05	0.00459	0.18	0.19	Pulse pressure;	chr17:48122986	chr17:48045141~48048073:-
HNSC	cis	rs4873772	0.834	rs7842068	ENSG00000253330.1	RP11-697N18.3	-4.24	2.66e-05	0.00459	-0.25	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47670402	chr8:47511034~47512141:-
HNSC	cis	rs9903692	0.954	rs11651097	ENSG00000263412.1	RP5-890E16.2	-4.24	2.66e-05	0.0046	-0.18	-0.19	Pulse pressure;	chr17:48069677	chr17:48045141~48048073:-
HNSC	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	4.24	2.66e-05	0.0046	0.26	0.19	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	4.24	2.66e-05	0.0046	0.26	0.19	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	4.24	2.66e-05	0.0046	0.26	0.19	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	4.24	2.66e-05	0.0046	0.26	0.19	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
HNSC	cis	rs7267979	0.789	rs2260197	ENSG00000204556.4	CTD-2514C3.1	-4.24	2.66e-05	0.0046	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26018832~26020684:+
HNSC	cis	rs6887276	0.504	rs28540272	ENSG00000245937.6	LINC01184	-4.24	2.66e-05	0.0046	-0.23	-0.19	Height;	chr5:128013207	chr5:127940426~128083172:-
HNSC	cis	rs6831352	0.819	rs1154401	ENSG00000263923.1	RP11-571L19.7	-4.24	2.66e-05	0.0046	-0.2	-0.19	Alcohol dependence;	chr4:99088587	chr4:98928897~98994994:+
HNSC	cis	rs11638352	1	rs1365456	ENSG00000205771.5	CATSPER2P1	4.24	2.66e-05	0.0046	0.53	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44086645	chr15:43726918~43747094:-
HNSC	cis	rs4853525	0.62	rs6718902	ENSG00000235852.1	AC005540.3	-4.24	2.67e-05	0.0046	-0.26	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190973478	chr2:190880797~190882059:-
HNSC	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-4.24	2.67e-05	0.0046	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
HNSC	cis	rs6095360	1	rs6512554	ENSG00000222365.1	SNORD12B	-4.24	2.67e-05	0.0046	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:48916213	chr20:49280319~49280409:+
HNSC	cis	rs9880211	0.752	rs9881831	ENSG00000273486.1	RP11-731C17.2	4.24	2.67e-05	0.0046	0.19	0.19	Height;Body mass index;	chr3:136670876	chr3:136837338~136839021:-
HNSC	cis	rs7824557	0.505	rs2572440	ENSG00000255495.1	AC145124.2	4.24	2.67e-05	0.0046	0.21	0.19	Retinal vascular caliber;	chr8:11391501	chr8:12194467~12196280:+
HNSC	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-4.24	2.67e-05	0.0046	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
HNSC	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	4.24	2.67e-05	0.00461	0.19	0.19	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	4.24	2.67e-05	0.00461	0.19	0.19	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	4.24	2.67e-05	0.00461	0.19	0.19	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
HNSC	cis	rs9531006	0.636	rs12583645	ENSG00000227676.3	LINC01068	4.24	2.67e-05	0.00461	0.29	0.19	Sleep duration;	chr13:79929175	chr13:79566727~79571436:+
HNSC	cis	rs79349575	0.811	rs1057897	ENSG00000270781.1	RP11-501C14.9	-4.24	2.67e-05	0.00461	-0.2	-0.19	Type 2 diabetes;	chr17:48928147	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.749	rs12601672	ENSG00000270781.1	RP11-501C14.9	-4.24	2.67e-05	0.00461	-0.2	-0.19	Type 2 diabetes;	chr17:48929131	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.783	rs17635252	ENSG00000270781.1	RP11-501C14.9	-4.24	2.67e-05	0.00461	-0.2	-0.19	Type 2 diabetes;	chr17:48929588	chr17:48899131~48899748:+
HNSC	cis	rs4266144	0.569	rs729257	ENSG00000241770.1	RP11-555M1.3	-4.24	2.67e-05	0.00461	-0.23	-0.19	Coronary artery disease;	chr3:157111034	chr3:157163452~157169133:+
HNSC	cis	rs1555322	0.745	rs2425017	ENSG00000126005.14	MMP24-AS1	-4.24	2.67e-05	0.00461	-0.35	-0.19	Attention deficit hyperactivity disorder;	chr20:35229835	chr20:35216462~35278131:-
HNSC	cis	rs2333194	0.707	rs10134224	ENSG00000258695.2	RP3-414A15.2	-4.24	2.67e-05	0.00461	-0.2	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73315235	chr14:73522878~73530610:+
HNSC	cis	rs6973609	0.524	rs12673985	ENSG00000271122.1	RP11-379H18.1	-4.24	2.67e-05	0.00461	-0.17	-0.19	Obesity-related traits;	chr7:35607298	chr7:35695214~35699413:+
HNSC	cis	rs3811273	0.614	rs6572346	ENSG00000211816.2	TRAV38-1	-4.24	2.67e-05	0.00461	-0.22	-0.19	Periodontal disease-related phenotypes;	chr14:22266389	chr14:22271968~22272563:+
HNSC	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-4.24	2.68e-05	0.00462	-0.22	-0.19	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-4.24	2.68e-05	0.00462	-0.22	-0.19	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
HNSC	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-4.24	2.68e-05	0.00462	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
HNSC	cis	rs36052053	0.908	rs13220206	ENSG00000203799.9	CCDC162P	4.24	2.68e-05	0.00462	0.29	0.19	Red cell distribution width;	chr6:109303278	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs34780834	ENSG00000203799.9	CCDC162P	4.24	2.68e-05	0.00462	0.29	0.19	Red cell distribution width;	chr6:109303563	chr6:109285485~109355063:+
HNSC	cis	rs7572733	0.935	rs1850633	ENSG00000222017.1	AC011997.1	4.24	2.68e-05	0.00462	0.23	0.19	Dermatomyositis;	chr2:197964858	chr2:197693106~197774823:+
HNSC	cis	rs7475343	0.501	rs76669111	ENSG00000224034.1	RP11-445P17.8	-4.24	2.68e-05	0.00462	-0.28	-0.19	Intelligence;	chr10:5203817	chr10:5266033~5271236:-
HNSC	cis	rs10510102	0.516	rs10159759	ENSG00000226864.1	ATE1-AS1	4.24	2.68e-05	0.00462	0.36	0.19	Breast cancer;	chr10:121986533	chr10:121928312~121951965:+
HNSC	cis	rs5758659	0.652	rs4822084	ENSG00000270083.1	RP1-257I20.14	-4.24	2.68e-05	0.00462	-0.18	-0.19	Cognitive function;	chr22:42039864	chr22:42089630~42090028:-
HNSC	cis	rs2098713	0.544	rs13188741	ENSG00000250155.1	CTD-2353F22.1	-4.24	2.68e-05	0.00462	-0.21	-0.19	Telomere length;	chr5:37432269	chr5:36666214~36725195:-
HNSC	cis	rs10129255	1	rs4612959	ENSG00000211974.3	IGHV2-70	4.24	2.68e-05	0.00462	0.18	0.19	Kawasaki disease;	chr14:106767055	chr14:106723574~106724093:-
HNSC	cis	rs8067545	0.641	rs175922	ENSG00000266126.1	RP11-209D14.4	4.24	2.68e-05	0.00462	0.22	0.19	Schizophrenia;	chr17:19922266	chr17:19929372~19929737:-
HNSC	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-4.24	2.68e-05	0.00462	-0.22	-0.19	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
HNSC	cis	rs1602565	0.858	rs769045	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29128152	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2958635	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29128299	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2958631	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29131880	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2933174	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29132098	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs10160488	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29133910	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs1844903	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29135188	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs1552715	ENSG00000255450.1	CTD-2063L20.1	-4.24	2.68e-05	0.00462	-0.29	-0.19	Schizophrenia;	chr11:29136208	chr11:29275655~29276565:+
HNSC	cis	rs61542988	0.606	rs4722185	ENSG00000221740.1	SNORD93	4.24	2.68e-05	0.00462	0.25	0.19	Fibrinogen levels;	chr7:22793092	chr7:22856613~22856686:+
HNSC	cis	rs8014204	0.604	rs11625594	ENSG00000279594.1	RP11-950C14.10	4.24	2.68e-05	0.00463	0.24	0.19	Caffeine consumption;	chr14:74923130	chr14:75011269~75012851:-
HNSC	cis	rs9611565	0.729	rs202654	ENSG00000235513.1	RP4-756G23.5	-4.24	2.68e-05	0.00463	-0.22	-0.19	Vitiligo;	chr22:41445030	chr22:41209122~41217627:-
HNSC	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-4.24	2.69e-05	0.00463	-0.2	-0.19	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	4.24	2.69e-05	0.00463	0.23	0.19	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
HNSC	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	4.24	2.69e-05	0.00463	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
HNSC	cis	rs1862618	0.671	rs252897	ENSG00000271828.1	CTD-2310F14.1	4.24	2.69e-05	0.00463	0.24	0.19	Initial pursuit acceleration;	chr5:56927173	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-4.24	2.69e-05	0.00463	-0.24	-0.19	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs316331	ENSG00000229886.1	RP5-1132H15.3	-4.24	2.69e-05	0.00463	-0.32	-0.19	Diabetic kidney disease;	chr7:66139635	chr7:66025126~66031544:-
HNSC	cis	rs67340775	0.541	rs200975	ENSG00000219392.1	RP1-265C24.5	-4.24	2.69e-05	0.00463	-0.29	-0.19	Lung cancer in ever smokers;	chr6:27887847	chr6:28115628~28116551:+
HNSC	cis	rs67340775	0.541	rs200974	ENSG00000219392.1	RP1-265C24.5	-4.24	2.69e-05	0.00463	-0.29	-0.19	Lung cancer in ever smokers;	chr6:27888067	chr6:28115628~28116551:+
HNSC	cis	rs3736485	0.816	rs11070851	ENSG00000259438.1	CTD-2650P22.1	-4.24	2.69e-05	0.00464	-0.19	-0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51471052	chr15:52010999~52019095:-
HNSC	cis	rs9863	0.828	rs1187415	ENSG00000270028.1	RP11-380L11.4	-4.24	2.69e-05	0.00464	-0.22	-0.19	White blood cell count;	chr12:124006982	chr12:123925461~123926083:-
HNSC	cis	rs911555	0.539	rs4374097	ENSG00000270108.1	RP11-73M18.6	4.24	2.69e-05	0.00464	0.22	0.19	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103687576~103688127:+
HNSC	cis	rs8177876	0.822	rs7206814	ENSG00000261838.4	RP11-303E16.6	-4.24	2.69e-05	0.00464	-0.34	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81069854~81076598:+
HNSC	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-4.24	2.69e-05	0.00464	-0.19	-0.19	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
HNSC	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-4.24	2.69e-05	0.00464	-0.15	-0.19	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
HNSC	cis	rs11673344	0.504	rs1667378	ENSG00000267698.1	AC002116.7	4.24	2.69e-05	0.00464	0.17	0.19	Obesity-related traits;	chr19:37001171	chr19:36014508~36045972:+
HNSC	cis	rs8054556	0.692	rs4788199	ENSG00000183604.13	SMG1P5	-4.24	2.69e-05	0.00464	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:30267553~30335374:-
HNSC	cis	rs17594362	0.697	rs9566789	ENSG00000229473.2	RGS17P1	-4.24	2.69e-05	0.00464	-0.26	-0.19	Multiple sclerosis;	chr13:41562164	chr13:40992779~40993331:-
HNSC	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	4.24	2.69e-05	0.00464	0.3	0.19	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
HNSC	cis	rs7005380	0.581	rs9987297	ENSG00000279347.1	RP11-85I17.2	4.24	2.7e-05	0.00464	0.18	0.19	Interstitial lung disease;	chr8:119921449	chr8:119838736~119840385:-
HNSC	cis	rs6499755	0.841	rs31082	ENSG00000260135.5	RP11-212I21.2	-4.24	2.7e-05	0.00464	-0.21	-0.19	Hypospadias;	chr16:55327581	chr16:55426797~55462297:-
HNSC	cis	rs6496932	0.563	rs2344083	ENSG00000259774.1	RP11-182J1.13	-4.24	2.7e-05	0.00465	-0.24	-0.19	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:84422618~84425882:+
HNSC	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	4.24	2.7e-05	0.00465	0.25	0.19	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
HNSC	cis	rs7338174	0.655	rs9316535	ENSG00000237152.3	DLEU7-AS1	4.24	2.7e-05	0.00465	0.49	0.19	Mitochondrial DNA levels;	chr13:51329329	chr13:50807856~50849905:+
HNSC	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	4.24	2.7e-05	0.00466	0.22	0.19	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	4.24	2.7e-05	0.00466	0.22	0.19	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
HNSC	cis	rs929354	0.772	rs1182441	ENSG00000224629.1	RP5-1142J19.2	4.24	2.7e-05	0.00466	0.19	0.19	Body mass index;	chr7:157233956	chr7:157263022~157263229:-
HNSC	cis	rs1008375	1	rs56308330	ENSG00000249502.1	AC006160.5	-4.24	2.71e-05	0.00466	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641427	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs28693609	ENSG00000249502.1	AC006160.5	-4.24	2.71e-05	0.00466	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17643610	chr4:17587467~17614571:-
HNSC	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-4.24	2.71e-05	0.00466	-0.22	-0.19	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
HNSC	cis	rs4699052	0.625	rs2138592	ENSG00000246560.2	RP11-10L12.4	4.24	2.71e-05	0.00466	0.22	0.19	Testicular germ cell tumor;	chr4:103334561	chr4:102828055~102844075:+
HNSC	cis	rs7824557	0.603	rs11250130	ENSG00000269918.1	AF131215.9	-4.24	2.71e-05	0.00466	-0.19	-0.19	Retinal vascular caliber;	chr8:11356946	chr8:11104691~11106704:-
HNSC	cis	rs4294134	0.608	rs13237671	ENSG00000223718.3	AC093107.7	4.24	2.71e-05	0.00466	0.3	0.19	Paget's disease;	chr7:135559856	chr7:135660039~135660647:+
HNSC	cis	rs950776	0.642	rs61630816	ENSG00000261762.1	RP11-650L12.2	4.24	2.71e-05	0.00466	0.23	0.19	Sudden cardiac arrest;	chr15:78673524	chr15:78589123~78591276:-
HNSC	cis	rs950776	0.642	rs34694149	ENSG00000261762.1	RP11-650L12.2	4.24	2.71e-05	0.00466	0.23	0.19	Sudden cardiac arrest;	chr15:78673575	chr15:78589123~78591276:-
HNSC	cis	rs2333021	0.78	rs12887074	ENSG00000258376.2	RP4-647C14.2	-4.24	2.71e-05	0.00466	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72981132	chr14:73242651~73245979:-
HNSC	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-4.24	2.71e-05	0.00467	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
HNSC	cis	rs7121616	0.576	rs73610510	ENSG00000200879.1	SNORD14E	4.24	2.71e-05	0.00467	0.27	0.19	Breast cancer;	chr11:123049365	chr11:123058077~123058161:-
HNSC	cis	rs9487051	0.597	rs351718	ENSG00000243587.6	C6orf183	-4.24	2.71e-05	0.00467	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109231715	chr6:109165833~109271014:+
HNSC	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	4.24	2.71e-05	0.00467	0.24	0.19	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
HNSC	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-4.24	2.71e-05	0.00467	-0.21	-0.19	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
HNSC	cis	rs16858210	0.607	rs60244260	ENSG00000234371.6	RPSAP31	4.24	2.71e-05	0.00467	0.26	0.19	Menopause (age at onset);	chr3:183852946	chr3:183884924~183888449:+
HNSC	cis	rs16858210	0.607	rs59321941	ENSG00000234371.6	RPSAP31	4.24	2.71e-05	0.00467	0.26	0.19	Menopause (age at onset);	chr3:183853236	chr3:183884924~183888449:+
HNSC	cis	rs3808502	0.549	rs4841564	ENSG00000255310.2	AF131215.2	-4.24	2.71e-05	0.00467	-0.18	-0.19	Neuroticism;	chr8:11568300	chr8:11107788~11109726:-
HNSC	cis	rs11168351	1	rs11168351	ENSG00000257763.1	OR5BK1P	4.24	2.72e-05	0.00467	0.18	0.19	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48355792~48356614:-
HNSC	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-4.24	2.72e-05	0.00467	-0.12	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
HNSC	cis	rs7826238	0.594	rs2948285	ENSG00000254153.1	CTA-398F10.2	4.24	2.72e-05	0.00468	0.21	0.19	Systolic blood pressure;	chr8:8273016	chr8:8456909~8461337:-
HNSC	cis	rs7824557	0.767	rs3808513	ENSG00000269918.1	AF131215.9	-4.24	2.72e-05	0.00468	-0.19	-0.19	Retinal vascular caliber;	chr8:11299951	chr8:11104691~11106704:-
HNSC	cis	rs71537559	1	rs71537559	ENSG00000219392.1	RP1-265C24.5	-4.24	2.72e-05	0.00468	-0.38	-0.19	Squamous cell lung carcinoma;	chr6:27342000	chr6:28115628~28116551:+
HNSC	cis	rs889398	0.835	rs12925429	ENSG00000226232.7	RP11-419C5.2	4.24	2.72e-05	0.00468	0.17	0.19	Body mass index;	chr16:69767636	chr16:69976388~69996188:-
HNSC	cis	rs7512552	0.966	rs2274127	ENSG00000228126.1	FALEC	-4.24	2.72e-05	0.00468	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150280573	chr1:150515757~150518032:+
HNSC	cis	rs3733585	0.683	rs13112015	ENSG00000250413.1	RP11-448G15.1	4.24	2.72e-05	0.00468	0.24	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9932172	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	4.24	2.72e-05	0.00468	0.24	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
HNSC	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.24	2.72e-05	0.00468	0.22	0.19	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
HNSC	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-4.24	2.72e-05	0.00468	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
HNSC	cis	rs804280	1	rs804280	ENSG00000269918.1	AF131215.9	4.24	2.72e-05	0.00469	0.19	0.19	Myopia (pathological);	chr8:11755189	chr8:11104691~11106704:-
HNSC	cis	rs4908769	0.553	rs301792	ENSG00000232912.4	RP5-1115A15.1	4.24	2.72e-05	0.00469	0.21	0.19	Allergy;	chr1:8408218	chr1:8424645~8434838:+
HNSC	cis	rs4908769	0.624	rs301790	ENSG00000232912.4	RP5-1115A15.1	4.24	2.72e-05	0.00469	0.21	0.19	Allergy;	chr1:8409224	chr1:8424645~8434838:+
HNSC	cis	rs9903692	0.909	rs12952163	ENSG00000263412.1	RP5-890E16.2	-4.24	2.72e-05	0.00469	-0.18	-0.19	Pulse pressure;	chr17:48082029	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.648	rs35361214	ENSG00000263412.1	RP5-890E16.2	-4.24	2.72e-05	0.00469	-0.18	-0.19	Pulse pressure;	chr17:48087729	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.697	rs6504024	ENSG00000263412.1	RP5-890E16.2	-4.24	2.72e-05	0.00469	-0.18	-0.19	Pulse pressure;	chr17:48088224	chr17:48045141~48048073:-
HNSC	cis	rs4388249	1	rs2300997	ENSG00000271849.1	CTC-332L22.1	-4.24	2.72e-05	0.00469	-0.29	-0.19	Schizophrenia;	chr5:109746893	chr5:109687802~109688329:-
HNSC	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-4.24	2.72e-05	0.00469	-0.17	-0.19	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-4.24	2.72e-05	0.00469	-0.17	-0.19	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
HNSC	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-4.24	2.72e-05	0.00469	-0.17	-0.19	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
HNSC	cis	rs853679	0.607	rs56189111	ENSG00000204709.4	LINC01556	4.24	2.72e-05	0.00469	0.4	0.19	Depression;	chr6:28304196	chr6:28943877~28944537:+
HNSC	cis	rs7826238	0.72	rs12546760	ENSG00000254340.1	RP11-10A14.3	-4.24	2.73e-05	0.00469	-0.24	-0.19	Systolic blood pressure;	chr8:8517326	chr8:9141424~9145435:+
HNSC	cis	rs615632	0.57	rs17734541	ENSG00000233609.3	RP11-62H7.2	4.24	2.73e-05	0.00469	0.18	0.19	Neuroticism;	chr8:9850923	chr8:8961200~8979025:+
HNSC	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-4.24	2.73e-05	0.00469	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
HNSC	cis	rs929354	0.739	rs1182439	ENSG00000224629.1	RP5-1142J19.2	4.24	2.73e-05	0.00469	0.19	0.19	Body mass index;	chr7:157234673	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs1182438	ENSG00000224629.1	RP5-1142J19.2	4.24	2.73e-05	0.00469	0.19	0.19	Body mass index;	chr7:157234744	chr7:157263022~157263229:-
HNSC	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-4.24	2.73e-05	0.00469	-0.2	-0.19	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-4.24	2.73e-05	0.00469	-0.2	-0.19	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
HNSC	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	4.24	2.73e-05	0.00469	0.19	0.19	Height;	chr5:37430113	chr5:36666214~36725195:-
HNSC	cis	rs11756659	0.505	rs62394320	ENSG00000272462.2	U91328.19	4.24	2.73e-05	0.00469	0.21	0.19	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25891952	chr6:25992662~26001775:+
HNSC	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	4.24	2.73e-05	0.00469	0.24	0.19	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
HNSC	cis	rs10129255	1	rs8010605	ENSG00000211974.3	IGHV2-70	4.24	2.73e-05	0.0047	0.18	0.19	Kawasaki disease;	chr14:106678742	chr14:106723574~106724093:-
HNSC	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	4.24	2.73e-05	0.0047	0.19	0.19	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
HNSC	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	4.24	2.73e-05	0.0047	0.25	0.19	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs10014719	ENSG00000250412.1	KLHL2P1	4.24	2.73e-05	0.0047	0.25	0.19	Corneal astigmatism;	chr4:119399560	chr4:119334329~119378233:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000280411.1	IGHV1-69-2	-4.24	2.73e-05	0.0047	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106688967	chr14:106762092~106762588:-
HNSC	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-4.24	2.73e-05	0.0047	-0.23	-0.19	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
HNSC	cis	rs10129255	1	rs11621409	ENSG00000211974.3	IGHV2-70	4.24	2.73e-05	0.0047	0.19	0.19	Kawasaki disease;	chr14:106695603	chr14:106723574~106724093:-
HNSC	cis	rs7324557	0.683	rs9510884	ENSG00000205861.10	C1QTNF9B-AS1	4.24	2.73e-05	0.0047	0.26	0.19	Visceral adipose tissue adjusted for BMI;	chr13:23830873	chr13:23888889~23897263:+
HNSC	cis	rs67072384	1	rs7120605	ENSG00000213365.3	AP000593.6	4.24	2.73e-05	0.0047	0.32	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733570	chr11:72280151~72281178:+
HNSC	cis	rs67072384	1	rs56693670	ENSG00000213365.3	AP000593.6	4.24	2.73e-05	0.0047	0.32	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734098	chr11:72280151~72281178:+
HNSC	cis	rs67072384	1	rs55957377	ENSG00000213365.3	AP000593.6	4.24	2.73e-05	0.0047	0.32	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734431	chr11:72280151~72281178:+
HNSC	cis	rs67072384	1	rs12289259	ENSG00000213365.3	AP000593.6	4.24	2.73e-05	0.0047	0.32	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72735686	chr11:72280151~72281178:+
HNSC	cis	rs10484434	0.901	rs1800758	ENSG00000272810.1	U91328.22	4.24	2.73e-05	0.0047	0.25	0.19	HIV-1 viral setpoint;	chr6:26093008	chr6:26013241~26013757:+
HNSC	cis	rs2239557	0.539	rs2302118	ENSG00000259065.1	RP5-1021I20.1	-4.24	2.73e-05	0.0047	-0.28	-0.19	Common traits (Other);	chr14:73955626	chr14:73787360~73803270:+
HNSC	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-4.24	2.73e-05	0.0047	-0.25	-0.19	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
HNSC	cis	rs9313772	0.722	rs10476247	ENSG00000254350.1	RP11-542A14.1	-4.24	2.73e-05	0.0047	-0.2	-0.19	Blood pressure;	chr5:158429561	chr5:158424585~158452758:+
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000226314.6	ZNF192P1	-4.24	2.74e-05	0.0047	-0.3	-0.19	Depression;	chr6:28111963	chr6:28161781~28169594:+
HNSC	cis	rs7809950	0.678	rs62483640	ENSG00000238832.1	snoU109	-4.24	2.74e-05	0.0047	-0.28	-0.19	Coronary artery disease;	chr7:107259769	chr7:107603363~107603507:+
HNSC	cis	rs61270009	0.955	rs4269995	ENSG00000247828.6	TMEM161B-AS1	4.24	2.74e-05	0.00471	0.2	0.19	Depressive symptoms;	chr5:88405406	chr5:88268895~88436685:+
HNSC	cis	rs9584850	0.915	rs7983438	ENSG00000231194.1	FARP1-AS1	4.24	2.74e-05	0.00471	0.24	0.19	Neuroticism;	chr13:98451063	chr13:98435405~98435840:-
HNSC	cis	rs12935418	0.616	rs9937731	ENSG00000278985.1	RP11-303E16.9	4.24	2.74e-05	0.00471	0.19	0.19	Mean corpuscular volume;	chr16:80978406	chr16:80982319~80984094:-
HNSC	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-4.24	2.74e-05	0.00471	-0.22	-0.19	Height;	chr14:75170656	chr14:75011269~75012851:-
HNSC	cis	rs7674212	0.541	rs2623070	ENSG00000251288.2	RP11-10L12.2	4.24	2.74e-05	0.00471	0.22	0.19	Type 2 diabetes;	chr4:103116231	chr4:102751401~102752641:+
HNSC	cis	rs10504130	1	rs74953260	ENSG00000272024.1	RP11-546K22.3	-4.24	2.74e-05	0.00471	-0.32	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51863087	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75826750	ENSG00000272024.1	RP11-546K22.3	-4.24	2.74e-05	0.00471	-0.32	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51863133	chr8:51950284~51950690:+
HNSC	cis	rs4947019	0.686	rs3757229	ENSG00000260273.1	RP11-425D10.10	4.24	2.74e-05	0.00471	0.53	0.19	Hematological parameters;	chr6:109382935	chr6:109382795~109383666:+
HNSC	cis	rs4947019	0.686	rs17070554	ENSG00000260273.1	RP11-425D10.10	4.24	2.74e-05	0.00471	0.53	0.19	Hematological parameters;	chr6:109383183	chr6:109382795~109383666:+
HNSC	cis	rs7735319	0.966	rs3860754	ENSG00000251281.1	CTD-2066L21.2	-4.24	2.74e-05	0.00471	-0.22	-0.19	Systolic blood pressure;	chr5:33149343	chr5:33011322~33017607:-
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000219891.2	ZSCAN12P1	4.24	2.74e-05	0.00471	0.27	0.19	Parkinson's disease;	chr6:28055973	chr6:28091154~28093664:+
HNSC	cis	rs2486288	0.656	rs11632920	ENSG00000259479.5	SORD2P	-4.24	2.74e-05	0.00471	-0.22	-0.19	Glomerular filtration rate;	chr15:45259066	chr15:44826371~44884694:-
HNSC	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	4.24	2.74e-05	0.00471	0.19	0.19	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
HNSC	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.24	2.74e-05	0.00471	0.19	0.19	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
HNSC	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	4.24	2.74e-05	0.00471	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
HNSC	cis	rs1799949	0.965	rs11650132	ENSG00000236383.6	LINC00854	-4.24	2.74e-05	0.00471	-0.18	-0.19	Menopause (age at onset);	chr17:43174070	chr17:43216941~43305976:-
HNSC	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-4.24	2.74e-05	0.00471	-0.2	-0.19	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-4.24	2.74e-05	0.00471	-0.2	-0.19	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-4.24	2.74e-05	0.00471	-0.2	-0.19	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
HNSC	cis	rs516805	0.667	rs9632500	ENSG00000279453.1	RP3-425C14.4	4.24	2.74e-05	0.00471	0.26	0.19	Lymphocyte counts;	chr6:122251472	chr6:122436789~122439223:-
HNSC	cis	rs9531006	0.636	rs36063327	ENSG00000227676.3	LINC01068	4.24	2.74e-05	0.00471	0.29	0.19	Sleep duration;	chr13:79934233	chr13:79566727~79571436:+
HNSC	cis	rs9531006	0.636	rs9601293	ENSG00000227676.3	LINC01068	4.24	2.74e-05	0.00471	0.29	0.19	Sleep duration;	chr13:79934759	chr13:79566727~79571436:+
HNSC	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	4.24	2.74e-05	0.00471	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000211974.3	IGHV2-70	4.24	2.74e-05	0.00472	0.18	0.19	Kawasaki disease;	chr14:106690675	chr14:106723574~106724093:-
HNSC	cis	rs7023329	0.561	rs1414242	ENSG00000244230.3	RN7SL151P	4.24	2.74e-05	0.00472	0.19	0.19	Melanoma;	chr9:21748240	chr9:21699314~21699596:+
HNSC	cis	rs9990343	0.967	rs6803980	ENSG00000223552.1	RP11-24F11.2	-4.24	2.75e-05	0.00472	-0.16	-0.19	Brain structure;	chr3:46301144	chr3:46364955~46407059:-
HNSC	cis	rs12745968	0.653	rs10874736	ENSG00000223787.2	RP4-593M8.1	-4.24	2.75e-05	0.00472	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92714639	chr1:92580476~92580821:-
HNSC	cis	rs240993	0.812	rs6942129	ENSG00000230177.1	RP5-1112D6.4	-4.24	2.75e-05	0.00472	-0.25	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111442417	chr6:111277932~111278742:+
HNSC	cis	rs3758785	0.512	rs534137	ENSG00000255893.1	RP11-685N10.1	4.24	2.75e-05	0.00472	0.23	0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94339820	chr11:94472908~94473570:-
HNSC	cis	rs3015497	1	rs3015497	ENSG00000277050.1	RP11-102G14.1	-4.24	2.75e-05	0.00472	-0.18	-0.19	Mean platelet volume;	chr14:50646680	chr14:51637348~51637947:-
HNSC	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	4.24	2.75e-05	0.00472	0.18	0.19	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
HNSC	cis	rs11098499	0.739	rs9884728	ENSG00000250412.1	KLHL2P1	-4.24	2.75e-05	0.00472	-0.23	-0.19	Corneal astigmatism;	chr4:119205924	chr4:119334329~119378233:+
HNSC	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-4.24	2.75e-05	0.00472	-0.26	-0.19	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
HNSC	cis	rs853679	1	rs9986596	ENSG00000204709.4	LINC01556	4.24	2.75e-05	0.00472	0.3	0.19	Depression;	chr6:28251883	chr6:28943877~28944537:+
HNSC	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	4.24	2.75e-05	0.00472	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
HNSC	cis	rs9450351	0.744	rs9450294	ENSG00000203875.9	SNHG5	-4.24	2.75e-05	0.00472	-0.42	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85540712	chr6:85660950~85678736:-
HNSC	cis	rs9929218	0.529	rs11075694	ENSG00000260459.2	FTLP14	4.24	2.75e-05	0.00473	0.25	0.19	Colorectal cancer;	chr16:68696463	chr16:68822587~68823070:+
HNSC	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-4.24	2.75e-05	0.00473	-0.23	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
HNSC	cis	rs9880211	0.613	rs6786582	ENSG00000239213.4	NCK1-AS1	-4.24	2.75e-05	0.00473	-0.17	-0.19	Height;Body mass index;	chr3:136180142	chr3:136841726~136862054:-
HNSC	cis	rs73198271	0.613	rs11249892	ENSG00000253893.2	FAM85B	4.24	2.75e-05	0.00473	0.26	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8167819~8226614:-
HNSC	cis	rs6081541	1	rs6081544	ENSG00000179447.2	RP5-1027G4.3	-4.24	2.75e-05	0.00473	-0.26	-0.19	Psychosis (atypical);	chr20:19236132	chr20:19242302~19284596:-
HNSC	cis	rs11976180	1	rs6464574	ENSG00000244479.5	OR2A1-AS1	4.24	2.75e-05	0.00473	0.22	0.19	Obesity-related traits;	chr7:144051164	chr7:144251264~144356181:-
HNSC	cis	rs1008375	0.933	rs6847966	ENSG00000249502.1	AC006160.5	-4.23	2.76e-05	0.00473	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632632	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs6848360	ENSG00000249502.1	AC006160.5	-4.23	2.76e-05	0.00473	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632819	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs7659718	ENSG00000249502.1	AC006160.5	-4.23	2.76e-05	0.00473	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17636397	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs6449319	ENSG00000249502.1	AC006160.5	-4.23	2.76e-05	0.00473	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638660	chr4:17587467~17614571:-
HNSC	cis	rs1009077	0.627	rs3775846	ENSG00000245958.5	RP11-33B1.1	4.23	2.76e-05	0.00474	0.23	0.19	Endometriosis;	chr4:119511372	chr4:119454791~119552025:+
HNSC	cis	rs6500395	0.962	rs9972682	ENSG00000261267.1	RP11-44I10.3	-4.23	2.76e-05	0.00474	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48652733	chr16:48559661~48587403:+
HNSC	cis	rs7429990	0.828	rs55823596	ENSG00000228638.1	FCF1P2	-4.23	2.76e-05	0.00474	-0.18	-0.19	Educational attainment (years of education);	chr3:47758541	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs4858853	ENSG00000228638.1	FCF1P2	-4.23	2.76e-05	0.00474	-0.18	-0.19	Educational attainment (years of education);	chr3:47760605	chr3:48290793~48291375:-
HNSC	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-4.23	2.76e-05	0.00474	-0.21	-0.19	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
HNSC	cis	rs12478296	0.681	rs55802421	ENSG00000261186.2	RP11-341N2.1	-4.23	2.76e-05	0.00474	-0.32	-0.19	Obesity-related traits;	chr2:242091811	chr2:242087351~242088457:-
HNSC	cis	rs12478296	0.681	rs56357900	ENSG00000261186.2	RP11-341N2.1	-4.23	2.76e-05	0.00474	-0.32	-0.19	Obesity-related traits;	chr2:242091815	chr2:242087351~242088457:-
HNSC	cis	rs3811273	1	rs10139994	ENSG00000211816.2	TRAV38-1	-4.23	2.76e-05	0.00475	-0.23	-0.19	Periodontal disease-related phenotypes;	chr14:22254607	chr14:22271968~22272563:+
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000219392.1	RP1-265C24.5	4.23	2.76e-05	0.00475	0.21	0.19	Pubertal anthropometrics;	chr6:28377433	chr6:28115628~28116551:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000219392.1	RP1-265C24.5	4.23	2.76e-05	0.00475	0.21	0.19	Pubertal anthropometrics;	chr6:28380381	chr6:28115628~28116551:+
HNSC	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	4.23	2.76e-05	0.00475	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	4.23	2.76e-05	0.00475	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
HNSC	cis	rs4699052	0.625	rs11097808	ENSG00000246560.2	RP11-10L12.4	4.23	2.77e-05	0.00475	0.22	0.19	Testicular germ cell tumor;	chr4:103341973	chr4:102828055~102844075:+
HNSC	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	4.23	2.77e-05	0.00475	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
HNSC	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	4.23	2.77e-05	0.00475	0.3	0.19	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
HNSC	cis	rs7296418	0.58	rs78455769	ENSG00000280120.1	RP11-546D6.3	4.23	2.77e-05	0.00475	0.16	0.19	Platelet count;	chr12:123371896	chr12:123152324~123153377:-
HNSC	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	4.23	2.77e-05	0.00475	0.19	0.19	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
HNSC	cis	rs3736485	0.873	rs12441759	ENSG00000259438.1	CTD-2650P22.1	4.23	2.77e-05	0.00475	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51462836	chr15:52010999~52019095:-
HNSC	cis	rs6840258	0.825	rs79998318	ENSG00000251411.1	RP11-397E7.4	-4.23	2.77e-05	0.00475	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87033014	chr4:86913266~86914817:-
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000211974.3	IGHV2-70	4.23	2.77e-05	0.00475	0.18	0.19	Kawasaki disease;	chr14:106690981	chr14:106723574~106724093:-
HNSC	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-4.23	2.77e-05	0.00476	-0.19	-0.19	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
HNSC	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	4.23	2.77e-05	0.00476	0.23	0.19	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
HNSC	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	4.23	2.77e-05	0.00476	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	4.23	2.77e-05	0.00476	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
HNSC	cis	rs9650657	0.59	rs10096777	ENSG00000255310.2	AF131215.2	-4.23	2.77e-05	0.00476	-0.18	-0.19	Neuroticism;	chr8:10660990	chr8:11107788~11109726:-
HNSC	cis	rs6928977	0.675	rs6908428	ENSG00000231028.7	LINC00271	-4.23	2.78e-05	0.00476	-0.23	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135497801~135716055:+
HNSC	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-4.23	2.78e-05	0.00476	-0.19	-0.19	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
HNSC	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	4.23	2.78e-05	0.00476	0.21	0.19	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
HNSC	cis	rs12935418	0.616	rs13332890	ENSG00000261061.1	RP11-303E16.2	-4.23	2.78e-05	0.00476	-0.22	-0.19	Mean corpuscular volume;	chr16:80971836	chr16:81030770~81031485:+
HNSC	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	4.23	2.78e-05	0.00476	0.17	0.19	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
HNSC	cis	rs9807989	0.773	rs72823661	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102352256	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.801	rs72823663	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102352278	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs67088699	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102352291	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.773	rs5010059	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102352366	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs11695627	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102353645	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.801	rs7558339	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102353783	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs7608638	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102353829	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs4485584	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102354290	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs4485585	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102354299	chr2:102438713~102440475:+
HNSC	cis	rs9807989	1	rs9807989	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102354740	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs9808453	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102354846	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs4851565	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102355021	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.765	rs9807962	ENSG00000234389.1	AC007278.3	4.23	2.78e-05	0.00477	0.19	0.19	Asthma;	chr2:102355204	chr2:102438713~102440475:+
HNSC	cis	rs1008375	1	rs56974987	ENSG00000249502.1	AC006160.5	-4.23	2.78e-05	0.00477	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17626233	chr4:17587467~17614571:-
HNSC	cis	rs6787172	0.811	rs9883657	ENSG00000272087.1	RP11-379F4.7	-4.23	2.78e-05	0.00477	-0.2	-0.19	Subjective well-being;	chr3:158508210	chr3:158693120~158693768:-
HNSC	cis	rs638893	0.947	rs1170396	ENSG00000255422.1	AP002954.4	-4.23	2.78e-05	0.00477	-0.32	-0.19	Vitiligo;	chr11:118833108	chr11:118704607~118750263:+
HNSC	cis	rs10462794	0.756	rs10073674	ENSG00000260763.1	RP11-445O3.3	4.23	2.78e-05	0.00477	0.24	0.19	DNA methylation (variation);	chr5:4478504	chr5:4436850~4440259:-
HNSC	cis	rs62246343	0.564	rs17050383	ENSG00000206573.7	THUMPD3-AS1	-4.23	2.78e-05	0.00477	-0.18	-0.19	Fibrinogen levels;	chr3:9472896	chr3:9349689~9398579:-
HNSC	cis	rs2933343	0.621	rs6764682	ENSG00000261159.1	RP11-723O4.9	-4.23	2.78e-05	0.00477	-0.19	-0.19	IgG glycosylation;	chr3:128849540	chr3:128859716~128860526:-
HNSC	cis	rs1713985	0.508	rs1713951	ENSG00000269949.1	RP11-738E22.3	-4.23	2.78e-05	0.00477	-0.33	-0.19	Age-related macular degeneration;	chr4:56994951	chr4:56960927~56961373:-
HNSC	cis	rs795484	0.926	rs708867	ENSG00000275409.1	RP11-131L12.4	-4.23	2.78e-05	0.00477	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191894	chr12:118430147~118430699:+
HNSC	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	4.23	2.78e-05	0.00477	0.24	0.19	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
HNSC	cis	rs12478296	0.792	rs57482298	ENSG00000261186.2	RP11-341N2.1	-4.23	2.78e-05	0.00477	-0.33	-0.19	Obesity-related traits;	chr2:242068997	chr2:242087351~242088457:-
HNSC	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-4.23	2.78e-05	0.00477	-0.24	-0.19	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
HNSC	cis	rs11638815	0.603	rs7171180	ENSG00000259429.4	UBE2Q2P2	4.23	2.78e-05	0.00477	0.18	0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:82355142~82420075:+
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000254174.1	IGHV1-12	-4.23	2.78e-05	0.00477	-0.15	-0.19	Alzheimer's disease (late onset);	chr14:106650277	chr14:106122420~106122709:-
HNSC	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	4.23	2.78e-05	0.00477	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
HNSC	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	4.23	2.78e-05	0.00477	0.25	0.19	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
HNSC	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-4.23	2.78e-05	0.00477	-0.22	-0.19	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
HNSC	cis	rs6973609	0.524	rs10239070	ENSG00000271122.1	RP11-379H18.1	-4.23	2.78e-05	0.00478	-0.17	-0.19	Obesity-related traits;	chr7:35606934	chr7:35695214~35699413:+
HNSC	cis	rs5758659	0.652	rs133336	ENSG00000227370.1	RP4-669P10.19	-4.23	2.78e-05	0.00478	-0.18	-0.19	Cognitive function;	chr22:42020299	chr22:42132543~42132998:+
HNSC	cis	rs72843166	0.562	rs17687691	ENSG00000265282.1	RP11-269G24.4	4.23	2.78e-05	0.00478	0.29	0.19	Intelligence (multi-trait analysis);	chr17:63404133	chr17:63430468~63432211:-
HNSC	cis	rs6964587	0.692	rs418	ENSG00000188693.7	CYP51A1-AS1	4.23	2.78e-05	0.00478	0.2	0.19	Breast cancer;	chr7:91954020	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.621	rs39744	ENSG00000188693.7	CYP51A1-AS1	-4.23	2.78e-05	0.00478	-0.19	-0.19	Breast cancer;	chr7:92413702	chr7:92134604~92180725:+
HNSC	cis	rs7615952	0.599	rs6803160	ENSG00000241439.1	RP11-666A20.3	4.23	2.79e-05	0.00478	0.21	0.19	Blood pressure (smoking interaction);	chr3:125990711	chr3:125958556~125958817:+
HNSC	cis	rs9880211	0.706	rs67382287	ENSG00000273486.1	RP11-731C17.2	4.23	2.79e-05	0.00478	0.19	0.19	Height;Body mass index;	chr3:136661617	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.23	2.79e-05	0.00478	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	4.23	2.79e-05	0.00478	0.22	0.19	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
HNSC	cis	rs889398	0.802	rs9940315	ENSG00000226232.7	RP11-419C5.2	-4.23	2.79e-05	0.00478	-0.17	-0.19	Body mass index;	chr16:69842261	chr16:69976388~69996188:-
HNSC	cis	rs2739330	0.652	rs2000469	ENSG00000235689.1	AP000351.13	4.23	2.79e-05	0.00478	0.2	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:24006305~24008258:-
HNSC	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	4.23	2.79e-05	0.00478	0.23	0.19	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
HNSC	cis	rs9880211	1	rs9826454	ENSG00000273486.1	RP11-731C17.2	4.23	2.79e-05	0.00478	0.18	0.19	Height;Body mass index;	chr3:136234378	chr3:136837338~136839021:-
HNSC	cis	rs61861422	0.516	rs12412216	ENSG00000273980.1	RP13-49I15.6	-4.23	2.79e-05	0.00478	-0.31	-0.19	Primary sclerosing cholangitis;	chr10:132579834	chr10:133257144~133257551:-
HNSC	cis	rs79220007	1	rs79220007	ENSG00000272810.1	U91328.22	-4.23	2.79e-05	0.00478	-0.39	-0.19	Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr6:26098246	chr6:26013241~26013757:+
HNSC	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-4.23	2.79e-05	0.00479	-0.22	-0.19	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
HNSC	cis	rs11157436	0.602	rs2331594	ENSG00000211812.1	TRAV26-2	-4.23	2.79e-05	0.00479	-0.18	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.602	rs12588757	ENSG00000211812.1	TRAV26-2	-4.23	2.79e-05	0.00479	-0.18	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22202583~22203368:+
HNSC	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	4.23	2.79e-05	0.00479	0.23	0.19	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
HNSC	cis	rs7581030	0.537	rs12476972	ENSG00000281195.1	ZNF638-IT1	4.23	2.79e-05	0.00479	0.16	0.19	Testicular germ cell tumor;	chr2:71259120	chr2:71373938~71376320:+
HNSC	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-4.23	2.79e-05	0.00479	-0.22	-0.19	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-4.23	2.79e-05	0.00479	-0.22	-0.19	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
HNSC	cis	rs4713118	0.824	rs9468225	ENSG00000224843.5	LINC00240	4.23	2.79e-05	0.00479	0.22	0.19	Parkinson's disease;	chr6:27777940	chr6:26956992~27023924:+
HNSC	cis	rs6081541	1	rs3790167	ENSG00000179447.2	RP5-1027G4.3	-4.23	2.79e-05	0.00479	-0.25	-0.19	Psychosis (atypical);	chr20:19240267	chr20:19242302~19284596:-
HNSC	cis	rs436483	0.967	rs421168	ENSG00000213385.3	RP11-577H5.1	-4.23	2.79e-05	0.00479	-0.2	-0.19	Lobe attachment (rater-scored or self-reported);	chr7:102050604	chr7:102755146~102755939:+
HNSC	cis	rs7178909	0.902	rs3784386	ENSG00000259677.1	RP11-493E3.1	4.23	2.79e-05	0.00479	0.22	0.19	Common traits (Other);	chr15:89894194	chr15:89876540~89877285:+
HNSC	cis	rs67311347	0.544	rs6769627	ENSG00000280739.1	EIF1B-AS1	4.23	2.79e-05	0.00479	0.21	0.19	Renal cell carcinoma;	chr3:40286354	chr3:40173145~40309698:-
HNSC	cis	rs7520050	0.966	rs6695809	ENSG00000280836.1	AL355480.1	4.23	2.79e-05	0.00479	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45581219~45581321:-
HNSC	cis	rs6543140	0.964	rs4851592	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.2	0.19	Blood protein levels;	chr2:102471181	chr2:102438713~102440475:+
HNSC	cis	rs35963943	0.625	rs6550603	ENSG00000228956.7	SATB1-AS1	4.23	2.79e-05	0.00479	0.23	0.19	Lymphocyte counts;	chr3:18702069	chr3:18445024~18920401:+
HNSC	cis	rs9393777	0.92	rs34953377	ENSG00000219392.1	RP1-265C24.5	-4.23	2.79e-05	0.00479	-0.38	-0.19	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28115628~28116551:+
HNSC	cis	rs9393777	0.778	rs66841633	ENSG00000219392.1	RP1-265C24.5	-4.23	2.79e-05	0.00479	-0.38	-0.19	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28115628~28116551:+
HNSC	cis	rs1642645	0.872	rs4660586	ENSG00000228452.1	RP5-994D16.9	-4.23	2.79e-05	0.00479	-0.27	-0.19	Left ventricular obstructive tract defect (maternal effect);	chr1:41941558	chr1:42775813~42776790:-
HNSC	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-4.23	2.79e-05	0.00479	-0.23	-0.19	Height;	chr14:75135260	chr14:75011269~75012851:-
HNSC	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102350776	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.765	rs6751967	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102350953	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.765	rs6751977	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102350970	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.801	rs6734742	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351397	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.801	rs6752482	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351398	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351547	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351751	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351752	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351825	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351896	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	4.23	2.79e-05	0.00479	0.19	0.19	Asthma;	chr2:102351902	chr2:102438713~102440475:+
HNSC	cis	rs6840258	1	rs17012234	ENSG00000251411.1	RP11-397E7.4	4.23	2.8e-05	0.00479	0.25	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86990539	chr4:86913266~86914817:-
HNSC	cis	rs9910055	0.659	rs2251165	ENSG00000267080.4	ASB16-AS1	-4.23	2.8e-05	0.00479	-0.15	-0.19	Total body bone mineral density;	chr17:44157380	chr17:44175973~44186717:-
HNSC	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	4.23	2.8e-05	0.00479	0.22	0.19	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
HNSC	cis	rs1979679	0.842	rs981494	ENSG00000247934.4	RP11-967K21.1	4.23	2.8e-05	0.00479	0.2	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28163298~28190738:-
HNSC	cis	rs4843747	0.671	rs72818577	ENSG00000260750.4	RP11-482M8.1	4.23	2.8e-05	0.0048	0.24	0.19	Menopause (age at onset);	chr16:88077575	chr16:87492555~87515635:+
HNSC	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-4.23	2.8e-05	0.0048	-0.14	-0.19	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
HNSC	cis	rs4660214	0.724	rs7554301	ENSG00000182109.6	RP11-69E11.4	-4.23	2.8e-05	0.0048	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39522280~39546187:-
HNSC	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	4.23	2.8e-05	0.0048	0.27	0.19	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
HNSC	cis	rs1620921	0.657	rs7383363	ENSG00000231863.1	RP3-428L16.1	-4.23	2.8e-05	0.0048	-0.23	-0.19	Lipoprotein (a) - cholesterol levels;	chr6:160853930	chr6:160931080~160969771:+
HNSC	cis	rs9733	0.715	rs7534124	ENSG00000236713.1	RP11-363I22.3	4.23	2.8e-05	0.0048	0.21	0.19	Tonsillectomy;	chr1:150766597	chr1:150780272~150780644:+
HNSC	cis	rs7520050	0.966	rs11211208	ENSG00000280836.1	AL355480.1	4.23	2.8e-05	0.0048	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000280411.1	IGHV1-69-2	-4.23	2.8e-05	0.0048	-0.14	-0.19	Kawasaki disease;	chr14:106716897	chr14:106762092~106762588:-
HNSC	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-4.23	2.8e-05	0.0048	-0.22	-0.19	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
HNSC	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	4.23	2.8e-05	0.0048	0.24	0.19	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
HNSC	cis	rs9611565	0.694	rs5758365	ENSG00000235513.1	RP4-756G23.5	-4.23	2.8e-05	0.0048	-0.24	-0.19	Vitiligo;	chr22:41462653	chr22:41209122~41217627:-
HNSC	cis	rs12530134	0.523	rs7762088	ENSG00000225532.1	XX-C2158C6.3	4.23	2.8e-05	0.0048	0.34	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr6:170485482	chr6:170736173~170737777:-
HNSC	cis	rs12986445	0.947	rs6738270	ENSG00000218682.1	AC010150.1	4.23	2.8e-05	0.0048	0.24	0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25927720	chr2:25856461~25856966:-
HNSC	cis	rs11672691	0.67	rs758643	ENSG00000270164.1	LINC01480	4.23	2.8e-05	0.0048	0.18	0.19	Prostate cancer;	chr19:41485616	chr19:41535183~41536904:+
HNSC	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-4.23	2.8e-05	0.0048	-0.16	-0.19	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
HNSC	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-4.23	2.8e-05	0.0048	-0.24	-0.19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
HNSC	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-4.23	2.8e-05	0.0048	-0.25	-0.19	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
HNSC	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	4.23	2.8e-05	0.00481	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	4.23	2.8e-05	0.00481	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	4.23	2.8e-05	0.00481	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
HNSC	cis	rs17253792	0.822	rs74051609	ENSG00000186615.9	KTN1-AS1	-4.23	2.8e-05	0.00481	-0.34	-0.19	Putamen volume;	chr14:55704414	chr14:55499278~55580110:-
HNSC	cis	rs9907295	0.748	rs4795091	ENSG00000270977.1	AC015849.16	-4.23	2.8e-05	0.00481	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35814874	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.71	rs4795092	ENSG00000270977.1	AC015849.16	-4.23	2.8e-05	0.00481	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35814967	chr17:35893707~35911023:-
HNSC	cis	rs7121616	0.563	rs1461494	ENSG00000200879.1	SNORD14E	4.23	2.81e-05	0.00481	0.25	0.19	Breast cancer;	chr11:123055777	chr11:123058077~123058161:-
HNSC	cis	rs7005380	0.581	rs869340	ENSG00000279347.1	RP11-85I17.2	4.23	2.81e-05	0.00481	0.18	0.19	Interstitial lung disease;	chr8:119920372	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs869341	ENSG00000279347.1	RP11-85I17.2	4.23	2.81e-05	0.00481	0.18	0.19	Interstitial lung disease;	chr8:119920565	chr8:119838736~119840385:-
HNSC	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	4.23	2.81e-05	0.00481	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	4.23	2.81e-05	0.00481	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
HNSC	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	4.23	2.81e-05	0.00481	0.22	0.19	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
HNSC	cis	rs9650657	0.737	rs4841436	ENSG00000269918.1	AF131215.9	4.23	2.81e-05	0.00481	0.19	0.19	Neuroticism;	chr8:10736964	chr8:11104691~11106704:-
HNSC	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	4.23	2.81e-05	0.00482	0.24	0.19	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
HNSC	cis	rs860295	0.676	rs5020058	ENSG00000225855.5	RUSC1-AS1	4.23	2.81e-05	0.00482	0.14	0.19	Body mass index;	chr1:155537752	chr1:155316863~155324176:-
HNSC	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	4.23	2.81e-05	0.00482	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
HNSC	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	4.23	2.81e-05	0.00482	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
HNSC	cis	rs9611565	0.879	rs2235845	ENSG00000235513.1	RP4-756G23.5	4.23	2.81e-05	0.00482	0.2	0.19	Vitiligo;	chr22:41333290	chr22:41209122~41217627:-
HNSC	cis	rs17772222	0.511	rs7155535	ENSG00000258789.1	RP11-507K2.3	-4.23	2.81e-05	0.00482	-0.21	-0.19	Coronary artery calcification;	chr14:88844002	chr14:88551597~88552493:+
HNSC	cis	rs933688	1	rs6862125	ENSG00000281357.1	ARRDC3-AS1	4.23	2.82e-05	0.00482	0.28	0.19	Smoking behavior;	chr5:91428781	chr5:91380349~91439085:+
HNSC	cis	rs700651	0.685	rs976180	ENSG00000231621.1	AC013264.2	4.23	2.82e-05	0.00482	0.18	0.19	Intracranial aneurysm;	chr2:198015719	chr2:197197991~197199273:+
HNSC	cis	rs1799949	1	rs8070085	ENSG00000236383.6	LINC00854	4.23	2.82e-05	0.00482	0.19	0.19	Menopause (age at onset);	chr17:43189967	chr17:43216941~43305976:-
HNSC	cis	rs4308124	1	rs57874285	ENSG00000227992.1	AC108463.2	-4.23	2.82e-05	0.00482	-0.19	-0.19	Vitiligo;	chr2:111255095	chr2:111203964~111206215:-
HNSC	cis	rs4308124	1	rs57707030	ENSG00000227992.1	AC108463.2	-4.23	2.82e-05	0.00482	-0.19	-0.19	Vitiligo;	chr2:111255105	chr2:111203964~111206215:-
HNSC	cis	rs3096299	0.933	rs889576	ENSG00000261574.1	RP1-168P16.2	-4.23	2.82e-05	0.00482	-0.24	-0.19	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89392375~89412564:-
HNSC	cis	rs4489787	1	rs12298871	ENSG00000257763.1	OR5BK1P	4.23	2.82e-05	0.00483	0.33	0.19	Prostate cancer (SNP x SNP interaction);	chr12:48395194	chr12:48355792~48356614:-
HNSC	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.23	2.82e-05	0.00483	0.33	0.19	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
HNSC	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.23	2.82e-05	0.00483	0.33	0.19	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
HNSC	cis	rs4294134	0.608	rs11763242	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135558225	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11766433	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135558308	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11767351	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135559089	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11764262	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135559184	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11760746	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135559267	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.58	rs11760731	ENSG00000223718.3	AC093107.7	4.23	2.82e-05	0.00483	0.3	0.19	Paget's disease;	chr7:135559431	chr7:135660039~135660647:+
HNSC	cis	rs2904524	1	rs17108018	ENSG00000257815.4	RP11-611E13.2	-4.23	2.82e-05	0.00483	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70343166	chr12:69904033~70243360:-
HNSC	cis	rs36052053	0.521	rs36085386	ENSG00000219700.1	PTCHD3P3	4.23	2.82e-05	0.00483	0.37	0.19	Red cell distribution width;	chr6:109223182	chr6:109288571~109290503:-
HNSC	cis	rs10461617	0.541	rs832575	ENSG00000271828.1	CTD-2310F14.1	4.23	2.82e-05	0.00483	0.3	0.19	Type 2 diabetes;	chr5:56865960	chr5:56927874~56929573:+
HNSC	cis	rs7824557	0.564	rs1435275	ENSG00000269918.1	AF131215.9	-4.23	2.82e-05	0.00483	-0.18	-0.19	Retinal vascular caliber;	chr8:11378226	chr8:11104691~11106704:-
HNSC	cis	rs10519937	0.935	rs12233927	ENSG00000230929.5	RP11-395C3.1	-4.23	2.82e-05	0.00483	-0.27	-0.19	IgG glycosylation;	chr5:127401752	chr5:126628019~126628319:-
HNSC	cis	rs9487051	0.837	rs9480920	ENSG00000219700.1	PTCHD3P3	4.23	2.82e-05	0.00483	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109284119	chr6:109288571~109290503:-
HNSC	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-4.23	2.82e-05	0.00483	-0.19	-0.19	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
HNSC	cis	rs6601327	0.606	rs9644707	ENSG00000233609.3	RP11-62H7.2	-4.23	2.82e-05	0.00484	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9732606	chr8:8961200~8979025:+
HNSC	cis	rs79057730	0.599	rs6944167	ENSG00000225146.1	AC073957.15	4.23	2.82e-05	0.00484	0.28	0.19	Initial pursuit acceleration;	chr7:786637	chr7:1029025~1043891:+
HNSC	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-4.23	2.83e-05	0.00484	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
HNSC	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	4.23	2.83e-05	0.00484	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	4.23	2.83e-05	0.00484	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
HNSC	cis	rs2243480	1	rs778729	ENSG00000106610.13	STAG3L4	-4.23	2.83e-05	0.00484	-0.39	-0.19	Diabetic kidney disease;	chr7:66359432	chr7:67302621~67321526:+
HNSC	cis	rs1642645	0.831	rs348128	ENSG00000228452.1	RP5-994D16.9	-4.23	2.83e-05	0.00484	-0.27	-0.19	Left ventricular obstructive tract defect (maternal effect);	chr1:42022690	chr1:42775813~42776790:-
HNSC	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	4.23	2.83e-05	0.00484	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
HNSC	cis	rs12478296	1	rs59036157	ENSG00000261186.2	RP11-341N2.1	-4.23	2.83e-05	0.00484	-0.33	-0.19	Obesity-related traits;	chr2:242098077	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs56323081	ENSG00000261186.2	RP11-341N2.1	-4.23	2.83e-05	0.00484	-0.33	-0.19	Obesity-related traits;	chr2:242098656	chr2:242087351~242088457:-
HNSC	cis	rs9650657	0.645	rs9969657	ENSG00000255310.2	AF131215.2	4.23	2.83e-05	0.00484	0.18	0.19	Neuroticism;	chr8:10657768	chr8:11107788~11109726:-
HNSC	cis	rs7027203	0.576	rs7874836	ENSG00000227603.1	RP11-165J3.6	-4.23	2.83e-05	0.00484	-0.17	-0.19	DNA methylation (variation);	chr9:93797088	chr9:93435332~93437121:-
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28057501	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28057708	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28058299	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28058358	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28059910	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28060612	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28060704	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28062059	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000219891.2	ZSCAN12P1	4.23	2.83e-05	0.00484	0.27	0.19	Parkinson's disease;	chr6:28062721	chr6:28091154~28093664:+
HNSC	cis	rs6558530	0.666	rs11136422	ENSG00000253982.1	CTD-2336O2.1	4.23	2.83e-05	0.00484	0.25	0.19	Systolic blood pressure;	chr8:1747743	chr8:1761990~1764502:-
HNSC	cis	rs12349081	0.614	rs9657608	ENSG00000224854.3	CDKN2A-AS1	-4.23	2.83e-05	0.00484	-0.31	-0.19	Cancer;	chr9:21956231	chr9:21966929~21967751:+
HNSC	cis	rs9531006	0.636	rs1811362	ENSG00000227676.3	LINC01068	4.23	2.83e-05	0.00484	0.28	0.19	Sleep duration;	chr13:79901570	chr13:79566727~79571436:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	4.23	2.83e-05	0.00484	0.33	0.19	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	4.23	2.83e-05	0.00484	0.33	0.19	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	4.23	2.83e-05	0.00484	0.33	0.19	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	4.23	2.83e-05	0.00484	0.33	0.19	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
HNSC	cis	rs9880211	0.8	rs9819856	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136773307	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs36109616	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136773561	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs35198484	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136773795	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.66	rs9289514	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136774361	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs79876804	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136775308	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs75901823	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136775309	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.706	rs35716521	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136775828	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs35210994	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136777294	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs17365792	ENSG00000273486.1	RP11-731C17.2	4.23	2.83e-05	0.00484	0.19	0.19	Height;Body mass index;	chr3:136778550	chr3:136837338~136839021:-
HNSC	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	4.23	2.83e-05	0.00485	0.26	0.19	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
HNSC	cis	rs1799949	0.965	rs33961729	ENSG00000236383.6	LINC00854	-4.23	2.83e-05	0.00485	-0.18	-0.19	Menopause (age at onset);	chr17:43135907	chr17:43216941~43305976:-
HNSC	cis	rs3808502	0.647	rs7821302	ENSG00000269918.1	AF131215.9	-4.23	2.83e-05	0.00485	-0.19	-0.19	Neuroticism;	chr8:11379063	chr8:11104691~11106704:-
HNSC	cis	rs1799949	1	rs11654731	ENSG00000236383.6	LINC00854	-4.23	2.83e-05	0.00485	-0.18	-0.19	Menopause (age at onset);	chr17:43174923	chr17:43216941~43305976:-
HNSC	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	4.23	2.83e-05	0.00485	0.25	0.19	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
HNSC	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-4.23	2.83e-05	0.00485	-0.22	-0.19	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00485	0.22	0.19	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00485	0.22	0.19	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00485	0.22	0.19	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00485	0.22	0.19	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00485	0.22	0.19	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
HNSC	cis	rs12893668	0.628	rs57072546	ENSG00000269940.1	RP11-73M18.7	4.23	2.84e-05	0.00485	0.19	0.19	Reticulocyte count;	chr14:103597386	chr14:103694560~103695170:+
HNSC	cis	rs7178909	0.835	rs17241302	ENSG00000259677.1	RP11-493E3.1	4.23	2.84e-05	0.00485	0.22	0.19	Common traits (Other);	chr15:89863305	chr15:89876540~89877285:+
HNSC	cis	rs3015497	0.603	rs3015451	ENSG00000269906.1	RP11-248J18.2	-4.23	2.84e-05	0.00485	-0.26	-0.19	Mean platelet volume;	chr14:50604373	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.603	rs1845416	ENSG00000269906.1	RP11-248J18.2	-4.23	2.84e-05	0.00485	-0.26	-0.19	Mean platelet volume;	chr14:50604882	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.603	rs1494178	ENSG00000269906.1	RP11-248J18.2	-4.23	2.84e-05	0.00485	-0.26	-0.19	Mean platelet volume;	chr14:50605492	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.603	rs3015450	ENSG00000269906.1	RP11-248J18.2	-4.23	2.84e-05	0.00485	-0.26	-0.19	Mean platelet volume;	chr14:50605995	chr14:50662511~50663178:-
HNSC	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	4.23	2.84e-05	0.00486	0.24	0.19	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
HNSC	cis	rs7552167	0.636	rs4090311	ENSG00000230023.2	RP11-10N16.2	4.23	2.84e-05	0.00486	0.3	0.19	Psoriasis vulgaris;	chr1:24187278	chr1:24200240~24211693:+
HNSC	cis	rs516805	0.715	rs11154087	ENSG00000279453.1	RP3-425C14.4	4.23	2.84e-05	0.00486	0.27	0.19	Lymphocyte counts;	chr6:122575484	chr6:122436789~122439223:-
HNSC	cis	rs17253792	0.822	rs10139905	ENSG00000186615.9	KTN1-AS1	-4.23	2.84e-05	0.00486	-0.34	-0.19	Putamen volume;	chr14:55703313	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs8013714	ENSG00000186615.9	KTN1-AS1	-4.23	2.84e-05	0.00486	-0.34	-0.19	Putamen volume;	chr14:55705568	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs8013831	ENSG00000186615.9	KTN1-AS1	-4.23	2.84e-05	0.00486	-0.34	-0.19	Putamen volume;	chr14:55706180	chr14:55499278~55580110:-
HNSC	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	4.23	2.84e-05	0.00486	0.22	0.19	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
HNSC	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	4.23	2.84e-05	0.00486	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
HNSC	cis	rs17345786	0.906	rs72946021	ENSG00000244119.1	PDCL3P4	4.23	2.84e-05	0.00486	0.21	0.19	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101712472~101713191:+
HNSC	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-4.23	2.84e-05	0.00486	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000254174.1	IGHV1-12	4.23	2.84e-05	0.00486	0.16	0.19	Rheumatic heart disease;	chr14:106618321	chr14:106122420~106122709:-
HNSC	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	4.23	2.84e-05	0.00486	0.24	0.19	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
HNSC	cis	rs9807989	0.765	rs6704565	ENSG00000234389.1	AC007278.3	4.23	2.84e-05	0.00486	0.19	0.19	Asthma;	chr2:102350971	chr2:102438713~102440475:+
HNSC	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	4.23	2.84e-05	0.00486	0.21	0.19	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	4.23	2.84e-05	0.00486	0.21	0.19	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	4.23	2.84e-05	0.00486	0.21	0.19	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
HNSC	cis	rs7027203	0.576	rs7862149	ENSG00000227603.1	RP11-165J3.6	4.23	2.84e-05	0.00486	0.17	0.19	DNA methylation (variation);	chr9:93784496	chr9:93435332~93437121:-
HNSC	cis	rs36052053	0.908	rs71558364	ENSG00000203799.9	CCDC162P	4.23	2.84e-05	0.00486	0.29	0.19	Red cell distribution width;	chr6:109295036	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs28360564	ENSG00000203799.9	CCDC162P	4.23	2.84e-05	0.00486	0.29	0.19	Red cell distribution width;	chr6:109297186	chr6:109285485~109355063:+
HNSC	cis	rs12478296	1	rs7603984	ENSG00000261186.2	RP11-341N2.1	-4.23	2.84e-05	0.00486	-0.33	-0.19	Obesity-related traits;	chr2:242105143	chr2:242087351~242088457:-
HNSC	cis	rs7580658	0.929	rs13029237	ENSG00000236682.1	AC068282.3	-4.23	2.84e-05	0.00486	-0.22	-0.19	Protein C levels;	chr2:127390278	chr2:127389130~127400580:+
HNSC	cis	rs964611	0.882	rs9635331	ENSG00000259488.2	RP11-154J22.1	-4.23	2.84e-05	0.00486	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48277940	chr15:48312353~48331856:-
HNSC	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-4.23	2.85e-05	0.00487	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
HNSC	cis	rs6710503	0.723	rs2076885	ENSG00000271936.1	RP11-443B20.1	-4.23	2.85e-05	0.00487	-0.23	-0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24778032	chr2:24825610~24826717:+
HNSC	cis	rs131805	1	rs131805	ENSG00000205559.3	CHKB-AS1	-4.23	2.85e-05	0.00487	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr22:50525724	chr22:50583026~50583877:+
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000226314.6	ZNF192P1	-4.23	2.85e-05	0.00487	-0.28	-0.19	Depression;	chr6:28235522	chr6:28161781~28169594:+
HNSC	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-4.23	2.85e-05	0.00487	-0.33	-0.19	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-4.23	2.85e-05	0.00487	-0.33	-0.19	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
HNSC	cis	rs7824557	0.51	rs2736297	ENSG00000269918.1	AF131215.9	-4.23	2.85e-05	0.00487	-0.18	-0.19	Retinal vascular caliber;	chr8:11377376	chr8:11104691~11106704:-
HNSC	cis	rs9487051	0.872	rs9386791	ENSG00000219700.1	PTCHD3P3	4.23	2.85e-05	0.00487	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109287294	chr6:109288571~109290503:-
HNSC	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-4.23	2.85e-05	0.00487	-0.25	-0.19	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
HNSC	cis	rs7735319	0.966	rs3860752	ENSG00000251281.1	CTD-2066L21.2	4.23	2.85e-05	0.00487	0.23	0.19	Systolic blood pressure;	chr5:33114871	chr5:33011322~33017607:-
HNSC	cis	rs55661361	0.708	rs12278912	ENSG00000245498.5	RP11-677M14.7	4.23	2.85e-05	0.00487	0.21	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742263	chr11:124800450~124834487:+
HNSC	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.23	2.85e-05	0.00487	0.19	0.19	Height;	chr5:37481330	chr5:36666214~36725195:-
HNSC	cis	rs12439619	0.921	rs4778672	ENSG00000276710.3	CSPG4P8	4.23	2.85e-05	0.00487	0.23	0.19	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82459472~82477258:+
HNSC	cis	rs9929218	0.551	rs3785135	ENSG00000260459.2	FTLP14	-4.23	2.85e-05	0.00488	-0.25	-0.19	Colorectal cancer;	chr16:68695073	chr16:68822587~68823070:+
HNSC	cis	rs453301	0.624	rs4841083	ENSG00000253981.4	ALG1L13P	4.23	2.85e-05	0.00488	0.22	0.19	Joint mobility (Beighton score);	chr8:9012918	chr8:8236003~8244667:-
HNSC	cis	rs853679	0.517	rs868987	ENSG00000219891.2	ZSCAN12P1	-4.23	2.85e-05	0.00488	-0.27	-0.19	Depression;	chr6:28142370	chr6:28091154~28093664:+
HNSC	cis	rs2492286	0.597	rs6802078	ENSG00000242551.2	POU5F1P6	-4.23	2.85e-05	0.00488	-0.22	-0.19	Eosinophil counts;	chr3:128639910	chr3:128674735~128677005:-
HNSC	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-4.23	2.85e-05	0.00488	-0.25	-0.19	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
HNSC	cis	rs2032447	0.53	rs9356996	ENSG00000272462.2	U91328.19	-4.23	2.85e-05	0.00488	-0.19	-0.19	Intelligence (multi-trait analysis);	chr6:26008259	chr6:25992662~26001775:+
HNSC	cis	rs9650657	0.655	rs10093774	ENSG00000269918.1	AF131215.9	4.23	2.86e-05	0.00488	0.19	0.19	Neuroticism;	chr8:10845783	chr8:11104691~11106704:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000233609.3	RP11-62H7.2	-4.23	2.86e-05	0.00488	-0.19	-0.19	Recombination measurement;	chr8:9213523	chr8:8961200~8979025:+
HNSC	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	4.23	2.86e-05	0.00488	0.27	0.19	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	4.23	2.86e-05	0.00488	0.26	0.19	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
HNSC	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-4.23	2.86e-05	0.00488	-0.2	-0.19	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
HNSC	cis	rs79349575	0.756	rs3848460	ENSG00000270781.1	RP11-501C14.9	4.23	2.86e-05	0.00488	0.2	0.19	Type 2 diabetes;	chr17:48969752	chr17:48899131~48899748:+
HNSC	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	4.23	2.86e-05	0.00488	0.29	0.19	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	4.23	2.86e-05	0.00488	0.29	0.19	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
HNSC	cis	rs3736485	0.966	rs12592889	ENSG00000259438.1	CTD-2650P22.1	4.23	2.86e-05	0.00489	0.2	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51502975	chr15:52010999~52019095:-
HNSC	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-4.23	2.86e-05	0.00489	-0.2	-0.19	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
HNSC	cis	rs6840258	1	rs55787557	ENSG00000251411.1	RP11-397E7.4	-4.23	2.86e-05	0.00489	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87029673	chr4:86913266~86914817:-
HNSC	cis	rs2221433	0.889	rs1394564	ENSG00000260310.1	RP11-27M24.2	4.23	2.86e-05	0.00489	0.24	0.19	Eating disorders;	chr16:10583324	chr16:10576499~10578183:-
HNSC	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-4.23	2.86e-05	0.00489	-0.23	-0.19	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
HNSC	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	4.23	2.86e-05	0.00489	0.25	0.19	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
HNSC	cis	rs11250098	0.548	rs7837038	ENSG00000269918.1	AF131215.9	-4.23	2.86e-05	0.00489	-0.19	-0.19	Morning vs. evening chronotype;	chr8:10925564	chr8:11104691~11106704:-
HNSC	cis	rs36093844	0.626	rs17817919	ENSG00000279742.1	RP11-700A24.1	4.23	2.86e-05	0.00489	0.26	0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86043679	chr11:85852557~85854943:-
HNSC	cis	rs12545912	0.569	rs583484	ENSG00000254340.1	RP11-10A14.3	-4.23	2.86e-05	0.00489	-0.3	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9936859	chr8:9141424~9145435:+
HNSC	cis	rs7246657	0.551	rs28462002	ENSG00000276846.1	CTD-3220F14.3	4.23	2.86e-05	0.00489	0.3	0.19	Coronary artery calcification;	chr19:37143560	chr19:37314868~37315620:-
HNSC	cis	rs7027203	0.576	rs4509402	ENSG00000227603.1	RP11-165J3.6	4.23	2.86e-05	0.00489	0.17	0.19	DNA methylation (variation);	chr9:93781095	chr9:93435332~93437121:-
HNSC	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-4.23	2.86e-05	0.00489	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-4.23	2.86e-05	0.00489	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
HNSC	cis	rs6601327	0.607	rs6992666	ENSG00000233609.3	RP11-62H7.2	-4.23	2.86e-05	0.00489	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9729194	chr8:8961200~8979025:+
HNSC	cis	rs9329221	0.537	rs6983332	ENSG00000255310.2	AF131215.2	-4.23	2.86e-05	0.00489	-0.18	-0.19	Neuroticism;	chr8:10120408	chr8:11107788~11109726:-
HNSC	cis	rs1538138	0.609	rs7753505	ENSG00000226453.1	RP11-379B8.1	-4.23	2.86e-05	0.00489	-0.22	-0.19	Corneal structure;	chr6:82109730	chr6:81845185~81933480:-
HNSC	cis	rs2548724	0.645	rs2600824	ENSG00000250682.4	LINC00491	-4.23	2.86e-05	0.00489	-0.25	-0.19	Type 2 diabetes;	chr5:102291707	chr5:102609156~102671559:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000229886.1	RP5-1132H15.3	4.23	2.86e-05	0.00489	0.32	0.19	Diabetic kidney disease;	chr7:65953889	chr7:66025126~66031544:-
HNSC	cis	rs10504130	0.502	rs12674620	ENSG00000272024.1	RP11-546K22.3	4.23	2.86e-05	0.00489	0.27	0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51755043	chr8:51950284~51950690:+
HNSC	cis	rs1602565	0.858	rs11030589	ENSG00000255450.1	CTD-2063L20.1	-4.23	2.86e-05	0.00489	-0.29	-0.19	Schizophrenia;	chr11:29124896	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs11030590	ENSG00000255450.1	CTD-2063L20.1	-4.23	2.86e-05	0.00489	-0.29	-0.19	Schizophrenia;	chr11:29124961	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs6484426	ENSG00000255450.1	CTD-2063L20.1	-4.23	2.86e-05	0.00489	-0.29	-0.19	Schizophrenia;	chr11:29125554	chr11:29275655~29276565:+
HNSC	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	4.23	2.86e-05	0.00489	0.27	0.19	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
HNSC	cis	rs9807989	0.811	rs11688559	ENSG00000234389.1	AC007278.3	4.23	2.86e-05	0.00489	0.19	0.19	Asthma;	chr2:102353453	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs11688568	ENSG00000234389.1	AC007278.3	4.23	2.86e-05	0.00489	0.19	0.19	Asthma;	chr2:102353489	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs11688573	ENSG00000234389.1	AC007278.3	4.23	2.86e-05	0.00489	0.19	0.19	Asthma;	chr2:102353511	chr2:102438713~102440475:+
HNSC	cis	rs9807989	0.811	rs11689730	ENSG00000234389.1	AC007278.3	4.23	2.86e-05	0.00489	0.19	0.19	Asthma;	chr2:102353524	chr2:102438713~102440475:+
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	4.23	2.87e-05	0.00489	0.21	0.19	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
HNSC	cis	rs2904524	1	rs2870881	ENSG00000257815.4	RP11-611E13.2	-4.23	2.87e-05	0.0049	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70257881	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs75401536	ENSG00000257815.4	RP11-611E13.2	-4.23	2.87e-05	0.0049	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70264369	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs1524245	ENSG00000257815.4	RP11-611E13.2	-4.23	2.87e-05	0.0049	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70265048	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs4761191	ENSG00000257815.4	RP11-611E13.2	-4.23	2.87e-05	0.0049	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70268594	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs56970859	ENSG00000257815.4	RP11-611E13.2	-4.23	2.87e-05	0.0049	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70270576	chr12:69904033~70243360:-
HNSC	cis	rs11773103	0.881	rs11971310	ENSG00000224046.1	AC005076.5	4.23	2.87e-05	0.0049	0.28	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87136326	chr7:87151423~87152420:-
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66370832	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66375924	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66398480	chr7:67302621~67321526:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66407358	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66408105	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66418618	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000106610.13	STAG3L4	-4.23	2.87e-05	0.0049	-0.38	-0.19	Diabetic kidney disease;	chr7:66422670	chr7:67302621~67321526:+
HNSC	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	4.23	2.87e-05	0.0049	0.27	0.19	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
HNSC	cis	rs7809950	0.768	rs62482493	ENSG00000238832.1	snoU109	-4.23	2.87e-05	0.0049	-0.29	-0.19	Coronary artery disease;	chr7:107311134	chr7:107603363~107603507:+
HNSC	cis	rs16846053	0.515	rs6432688	ENSG00000227403.1	AC009299.3	-4.23	2.87e-05	0.0049	-0.34	-0.19	Blood osmolality (transformed sodium);	chr2:161522146	chr2:161244739~161249050:+
HNSC	cis	rs35963943	0.625	rs12108075	ENSG00000228956.7	SATB1-AS1	4.23	2.87e-05	0.0049	0.23	0.19	Lymphocyte counts;	chr3:18670258	chr3:18445024~18920401:+
HNSC	cis	rs7475343	0.501	rs7897822	ENSG00000224034.1	RP11-445P17.8	-4.23	2.87e-05	0.0049	-0.27	-0.19	Intelligence;	chr10:5242594	chr10:5266033~5271236:-
HNSC	cis	rs16858210	0.607	rs35205152	ENSG00000234371.6	RPSAP31	4.23	2.87e-05	0.00491	0.26	0.19	Menopause (age at onset);	chr3:183845541	chr3:183884924~183888449:+
HNSC	cis	rs5758511	0.514	rs5751240	ENSG00000226450.2	CYP2D8P	4.23	2.87e-05	0.00491	0.19	0.19	Birth weight;	chr22:42199252	chr22:42149886~42155001:-
HNSC	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-4.22	2.87e-05	0.00491	-0.22	-0.19	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
HNSC	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	4.22	2.87e-05	0.00491	0.19	0.19	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
HNSC	cis	rs1050631	1	rs1789550	ENSG00000278986.1	RP11-723J4.3	-4.22	2.88e-05	0.00491	-0.22	-0.19	Esophageal squamous cell cancer (length of survival);	chr18:36119590	chr18:35972151~35973916:+
HNSC	cis	rs4787951	0.56	rs3024530	ENSG00000259940.2	CTD-3203P2.1	4.22	2.88e-05	0.00491	0.2	0.19	Eosinophil percentage of white cells;	chr16:27339366	chr16:27213308~27214993:-
HNSC	cis	rs2239557	0.508	rs10483857	ENSG00000259065.1	RP5-1021I20.1	4.22	2.88e-05	0.00491	0.28	0.19	Common traits (Other);	chr14:73899508	chr14:73787360~73803270:+
HNSC	cis	rs1971762	0.545	rs10747676	ENSG00000270175.1	RP11-793H13.11	-4.22	2.88e-05	0.00491	-0.17	-0.19	Height;	chr12:53656146	chr12:53500162~53500936:-
HNSC	cis	rs2492286	0.597	rs2712372	ENSG00000242551.2	POU5F1P6	-4.22	2.88e-05	0.00492	-0.21	-0.19	Eosinophil counts;	chr3:128604994	chr3:128674735~128677005:-
HNSC	cis	rs6504108	0.624	rs7225865	ENSG00000278765.1	RP5-890E16.5	-4.22	2.88e-05	0.00492	-0.24	-0.19	Body mass index;	chr17:48132602	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs34949267	ENSG00000278765.1	RP5-890E16.5	-4.22	2.88e-05	0.00492	-0.24	-0.19	Body mass index;	chr17:48134690	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs12941830	ENSG00000278765.1	RP5-890E16.5	-4.22	2.88e-05	0.00492	-0.24	-0.19	Body mass index;	chr17:48141769	chr17:48066704~48067293:-
HNSC	cis	rs4356203	0.543	rs214088	ENSG00000272034.1	SNORD14A	-4.22	2.88e-05	0.00492	-0.15	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17074654~17074744:-
HNSC	cis	rs1008375	1	rs3815413	ENSG00000249502.1	AC006160.5	-4.22	2.88e-05	0.00492	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653025	chr4:17587467~17614571:-
HNSC	cis	rs970821	0.667	rs13276451	ENSG00000253106.1	RP11-158K1.3	4.22	2.88e-05	0.00492	0.17	0.19	Breast cancer;	chr8:123734452	chr8:124488510~124491643:+
HNSC	cis	rs56080343	0.748	rs56190986	ENSG00000275409.1	RP11-131L12.4	-4.22	2.88e-05	0.00492	-0.4	-0.19	Neuroticism;	chr12:118408458	chr12:118430147~118430699:+
HNSC	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	4.22	2.88e-05	0.00492	0.23	0.19	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
HNSC	cis	rs9329221	0.527	rs6989657	ENSG00000269918.1	AF131215.9	4.22	2.88e-05	0.00492	0.2	0.19	Neuroticism;	chr8:10473363	chr8:11104691~11106704:-
HNSC	cis	rs6973609	0.524	rs11772625	ENSG00000271122.1	RP11-379H18.1	-4.22	2.88e-05	0.00492	-0.17	-0.19	Obesity-related traits;	chr7:35601941	chr7:35695214~35699413:+
HNSC	cis	rs7772486	0.558	rs2142980	ENSG00000235652.6	RP11-545I5.3	-4.22	2.88e-05	0.00492	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145759543	chr6:145799409~145886585:+
HNSC	cis	rs7255436	0.931	rs7249520	ENSG00000269386.4	RAB11B-AS1	4.22	2.88e-05	0.00492	0.18	0.19	HDL cholesterol;	chr19:8381172	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.965	rs7249624	ENSG00000269386.4	RAB11B-AS1	4.22	2.88e-05	0.00492	0.18	0.19	HDL cholesterol;	chr19:8381251	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.83	rs4350678	ENSG00000269386.4	RAB11B-AS1	4.22	2.88e-05	0.00492	0.18	0.19	HDL cholesterol;	chr19:8382482	chr19:8374373~8390685:-
HNSC	cis	rs539096	0.566	rs3011220	ENSG00000237950.1	RP11-7O11.3	4.22	2.88e-05	0.00492	0.21	0.19	Intelligence (multi-trait analysis);	chr1:43843195	chr1:43944370~43946551:-
HNSC	cis	rs9650657	0.513	rs7005884	ENSG00000255310.2	AF131215.2	-4.22	2.89e-05	0.00492	-0.18	-0.19	Neuroticism;	chr8:10938962	chr8:11107788~11109726:-
HNSC	cis	rs7630852	1	rs9852432	ENSG00000236833.1	AC024560.2	4.22	2.89e-05	0.00492	0.2	0.19	Eosinophil counts;	chr3:196780210	chr3:197660565~197665757:-
HNSC	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	4.22	2.89e-05	0.00492	0.2	0.19	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
HNSC	cis	rs870825	0.616	rs4519834	ENSG00000254233.1	RP11-242J7.1	-4.22	2.89e-05	0.00492	-0.28	-0.19	Blood protein levels;	chr4:184712711	chr4:184584093~184625030:-
HNSC	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	4.22	2.89e-05	0.00493	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	4.22	2.89e-05	0.00493	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	4.22	2.89e-05	0.00493	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	4.22	2.89e-05	0.00493	0.2	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
HNSC	cis	rs1218582	0.71	rs7553195	ENSG00000270361.1	RP11-307C12.13	-4.22	2.89e-05	0.00493	-0.21	-0.19	Prostate cancer;	chr1:154865320	chr1:154937370~154938059:+
HNSC	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	4.22	2.89e-05	0.00493	0.32	0.19	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
HNSC	cis	rs17772222	0.511	rs3850392	ENSG00000258789.1	RP11-507K2.3	-4.22	2.89e-05	0.00493	-0.21	-0.19	Coronary artery calcification;	chr14:88833286	chr14:88551597~88552493:+
HNSC	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-4.22	2.89e-05	0.00493	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000241439.1	RP11-666A20.3	4.22	2.89e-05	0.00493	0.21	0.19	Blood pressure (smoking interaction);	chr3:125989134	chr3:125958556~125958817:+
HNSC	cis	rs2361710	0.668	rs4889830	ENSG00000279259.1	RP11-334C17.3	4.22	2.89e-05	0.00493	0.22	0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80140729	chr17:80147250~80148596:+
HNSC	cis	rs7005380	0.581	rs7007672	ENSG00000279347.1	RP11-85I17.2	-4.22	2.89e-05	0.00493	-0.18	-0.19	Interstitial lung disease;	chr8:119906981	chr8:119838736~119840385:-
HNSC	cis	rs2361718	0.5	rs12451697	ENSG00000279259.1	RP11-334C17.3	4.22	2.89e-05	0.00493	0.25	0.19	Yeast infection;	chr17:80126891	chr17:80147250~80148596:+
HNSC	cis	rs6504108	0.624	rs1860863	ENSG00000278765.1	RP5-890E16.5	-4.22	2.89e-05	0.00493	-0.24	-0.19	Body mass index;	chr17:48127316	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs1860862	ENSG00000278765.1	RP5-890E16.5	-4.22	2.89e-05	0.00493	-0.24	-0.19	Body mass index;	chr17:48127474	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.602	rs3944039	ENSG00000278765.1	RP5-890E16.5	-4.22	2.89e-05	0.00493	-0.24	-0.19	Body mass index;	chr17:48127708	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs2041572	ENSG00000278765.1	RP5-890E16.5	-4.22	2.89e-05	0.00493	-0.24	-0.19	Body mass index;	chr17:48127911	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs758999	ENSG00000278765.1	RP5-890E16.5	-4.22	2.89e-05	0.00493	-0.24	-0.19	Body mass index;	chr17:48128653	chr17:48066704~48067293:-
HNSC	cis	rs1113500	0.73	rs1777457	ENSG00000226822.1	RP11-356N1.2	-4.22	2.89e-05	0.00493	-0.22	-0.19	Growth-regulated protein alpha levels;	chr1:108045573	chr1:108071482~108074519:+
HNSC	cis	rs7716219	0.751	rs4865956	ENSG00000251307.1	RP11-506H20.1	4.22	2.89e-05	0.00493	0.21	0.19	Height;	chr5:55586677	chr5:55233934~55295201:+
HNSC	cis	rs9329221	0.537	rs13254175	ENSG00000269918.1	AF131215.9	4.22	2.89e-05	0.00493	0.19	0.19	Neuroticism;	chr8:10121262	chr8:11104691~11106704:-
HNSC	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	4.22	2.89e-05	0.00493	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-4.22	2.89e-05	0.00493	-0.14	-0.19	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
HNSC	cis	rs1113500	0.73	rs1777456	ENSG00000226822.1	RP11-356N1.2	-4.22	2.89e-05	0.00493	-0.22	-0.19	Growth-regulated protein alpha levels;	chr1:108045850	chr1:108071482~108074519:+
HNSC	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-4.22	2.89e-05	0.00493	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
HNSC	cis	rs6500395	0.962	rs55782524	ENSG00000261267.1	RP11-44I10.3	-4.22	2.89e-05	0.00493	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48523582	chr16:48559661~48587403:+
HNSC	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	4.22	2.89e-05	0.00493	0.23	0.19	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
HNSC	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-4.22	2.89e-05	0.00493	-0.19	-0.19	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
HNSC	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	4.22	2.89e-05	0.00494	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	4.22	2.89e-05	0.00494	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
HNSC	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-4.22	2.89e-05	0.00494	-0.25	-0.19	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
HNSC	cis	rs896655	0.622	rs1889680	ENSG00000244230.3	RN7SL151P	-4.22	2.89e-05	0.00494	-0.19	-0.19	Coronary artery disease;	chr9:21695461	chr9:21699314~21699596:+
HNSC	cis	rs3758785	0.512	rs79702466	ENSG00000255893.1	RP11-685N10.1	-4.22	2.89e-05	0.00494	-0.29	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368030	chr11:94472908~94473570:-
HNSC	cis	rs8077577	0.895	rs62072498	ENSG00000273018.4	CTD-2303H24.2	-4.22	2.89e-05	0.00494	-0.29	-0.19	Obesity-related traits;	chr17:18222637	chr17:18511221~18551705:-
HNSC	cis	rs67981189	0.593	rs2240341	ENSG00000274818.1	RP1-292L20.3	-4.22	2.89e-05	0.00494	-0.21	-0.19	Schizophrenia;	chr14:70906863	chr14:70906657~70907111:-
HNSC	cis	rs2834288	0.666	rs2834293	ENSG00000273102.1	AP000569.9	-4.22	2.9e-05	0.00494	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33903905	chr21:33967101~33968573:-
HNSC	cis	rs13434995	0.513	rs7665846	ENSG00000273257.1	RP11-177J6.1	4.22	2.9e-05	0.00494	0.26	0.19	Adiponectin levels;	chr4:55573078	chr4:55387949~55388271:+
HNSC	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	4.22	2.9e-05	0.00494	0.27	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
HNSC	cis	rs1538138	0.609	rs9449420	ENSG00000226453.1	RP11-379B8.1	-4.22	2.9e-05	0.00494	-0.22	-0.19	Corneal structure;	chr6:82110702	chr6:81845185~81933480:-
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-4.22	2.9e-05	0.00494	-0.23	-0.19	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
HNSC	cis	rs2645424	0.671	rs2294138	ENSG00000255046.1	RP11-297N6.4	4.22	2.9e-05	0.00494	0.21	0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr8:11797928~11802568:-
HNSC	cis	rs10242455	0.702	rs28753399	ENSG00000078319.8	PMS2P1	-4.22	2.9e-05	0.00494	-0.4	-0.19	Blood metabolite levels;	chr7:99399636	chr7:100320992~100341908:-
HNSC	cis	rs10242455	0.702	rs28668326	ENSG00000078319.8	PMS2P1	-4.22	2.9e-05	0.00494	-0.4	-0.19	Blood metabolite levels;	chr7:99400530	chr7:100320992~100341908:-
HNSC	cis	rs3822625	0.541	rs76679228	ENSG00000271828.1	CTD-2310F14.1	4.22	2.9e-05	0.00494	0.42	0.19	Breast cancer (early onset);	chr5:56903684	chr5:56927874~56929573:+
HNSC	cis	rs7621025	0.664	rs6439657	ENSG00000239213.4	NCK1-AS1	-4.22	2.9e-05	0.00494	-0.18	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136841726~136862054:-
HNSC	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	4.22	2.9e-05	0.00494	0.16	0.19	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
HNSC	cis	rs6504108	0.624	rs7220768	ENSG00000278765.1	RP5-890E16.5	-4.22	2.9e-05	0.00494	-0.24	-0.19	Body mass index;	chr17:48147467	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs7220922	ENSG00000278765.1	RP5-890E16.5	-4.22	2.9e-05	0.00494	-0.24	-0.19	Body mass index;	chr17:48147546	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs7225550	ENSG00000278765.1	RP5-890E16.5	-4.22	2.9e-05	0.00494	-0.24	-0.19	Body mass index;	chr17:48147881	chr17:48066704~48067293:-
HNSC	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	4.22	2.9e-05	0.00494	0.25	0.19	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
HNSC	cis	rs56804039	0.524	rs55669645	ENSG00000173295.6	FAM86B3P	-4.22	2.9e-05	0.00495	-0.33	-0.19	Cervical cancer;	chr8:8509849	chr8:8228595~8244865:+
HNSC	cis	rs9311676	1	rs9311676	ENSG00000273493.1	RP11-80H18.4	-4.22	2.9e-05	0.00495	-0.21	-0.19	Systemic lupus erythematosus;	chr3:58484624	chr3:58329965~58330118:+
HNSC	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	4.22	2.9e-05	0.00495	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
HNSC	cis	rs910316	0.523	rs4026175	ENSG00000279594.1	RP11-950C14.10	4.22	2.9e-05	0.00495	0.24	0.19	Height;	chr14:75035537	chr14:75011269~75012851:-
HNSC	cis	rs9951026	0.735	rs6507931	ENSG00000264464.1	RP11-110H1.8	-4.22	2.9e-05	0.00495	-0.22	-0.19	Testicular germ cell tumor;	chr18:49586638	chr18:49499390~49501860:+
HNSC	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	4.22	2.9e-05	0.00495	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
HNSC	cis	rs12545109	0.842	rs10958482	ENSG00000246430.5	LINC00968	-4.22	2.9e-05	0.00495	-0.24	-0.19	Obesity-related traits;	chr8:56476772	chr8:56496246~56559823:-
HNSC	cis	rs964611	0.808	rs35405890	ENSG00000259488.2	RP11-154J22.1	-4.22	2.9e-05	0.00495	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48299070	chr15:48312353~48331856:-
HNSC	cis	rs11673344	0.503	rs703531	ENSG00000267698.1	AC002116.7	4.22	2.9e-05	0.00495	0.17	0.19	Obesity-related traits;	chr19:37010050	chr19:36014508~36045972:+
HNSC	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	4.22	2.9e-05	0.00495	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
HNSC	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-4.22	2.91e-05	0.00495	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
HNSC	cis	rs9907295	0.901	rs4251729	ENSG00000270977.1	AC015849.16	-4.22	2.91e-05	0.00495	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35893707~35911023:-
HNSC	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-4.22	2.91e-05	0.00495	-0.4	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
HNSC	cis	rs9353324	1	rs58334368	ENSG00000203875.9	SNHG5	-4.22	2.91e-05	0.00495	-0.4	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85660950~85678736:-
HNSC	cis	rs7267979	0.789	rs2260197	ENSG00000231081.1	RP4-760C5.3	-4.22	2.91e-05	0.00495	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26008791~26010531:-
HNSC	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-4.22	2.91e-05	0.00496	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
HNSC	cis	rs9929218	0.551	rs3785134	ENSG00000260459.2	FTLP14	4.22	2.91e-05	0.00496	0.25	0.19	Colorectal cancer;	chr16:68695035	chr16:68822587~68823070:+
HNSC	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	4.22	2.91e-05	0.00496	0.44	0.19	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
HNSC	cis	rs7520050	0.931	rs11211189	ENSG00000280836.1	AL355480.1	4.22	2.91e-05	0.00496	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45581219~45581321:-
HNSC	cis	rs6964587	0.934	rs4512319	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.91e-05	0.00496	-0.21	-0.19	Breast cancer;	chr7:92104515	chr7:92134604~92180725:+
HNSC	cis	rs7512552	0.966	rs2147324	ENSG00000228126.1	FALEC	-4.22	2.91e-05	0.00496	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150283177	chr1:150515757~150518032:+
HNSC	cis	rs755249	0.501	rs2490945	ENSG00000182109.6	RP11-69E11.4	4.22	2.91e-05	0.00496	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.501	rs621807	ENSG00000182109.6	RP11-69E11.4	4.22	2.91e-05	0.00496	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39522280~39546187:-
HNSC	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-4.22	2.91e-05	0.00496	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-4.22	2.91e-05	0.00496	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
HNSC	cis	rs7178375	0.843	rs3794596	ENSG00000270055.1	CTD-3092A11.2	-4.22	2.91e-05	0.00496	-0.25	-0.19	Hypertriglyceridemia;	chr15:30930823	chr15:30487963~30490313:+
HNSC	cis	rs6504108	0.647	rs7210149	ENSG00000278765.1	RP5-890E16.5	-4.22	2.91e-05	0.00496	-0.24	-0.19	Body mass index;	chr17:48220260	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.602	rs1452667	ENSG00000278765.1	RP5-890E16.5	-4.22	2.91e-05	0.00496	-0.24	-0.19	Body mass index;	chr17:48225053	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs4793779	ENSG00000278765.1	RP5-890E16.5	-4.22	2.91e-05	0.00496	-0.24	-0.19	Body mass index;	chr17:48229235	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs1452666	ENSG00000278765.1	RP5-890E16.5	-4.22	2.91e-05	0.00496	-0.24	-0.19	Body mass index;	chr17:48230388	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs1377201	ENSG00000278765.1	RP5-890E16.5	-4.22	2.91e-05	0.00496	-0.24	-0.19	Body mass index;	chr17:48234766	chr17:48066704~48067293:-
HNSC	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-4.22	2.91e-05	0.00496	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
HNSC	cis	rs9859260	0.744	rs557527	ENSG00000242086.7	LINC00969	-4.22	2.91e-05	0.00496	-0.16	-0.19	Mean corpuscular volume;	chr3:196053838	chr3:195658062~195739964:+
HNSC	cis	rs11122895	0.527	rs10186692	ENSG00000236307.2	EEF1E1P1	4.22	2.91e-05	0.00496	0.18	0.19	Allergic sensitization;	chr2:111686719	chr2:111887914~111888741:+
HNSC	cis	rs6701713	1	rs2093761	ENSG00000274245.1	RP11-357P18.2	-4.22	2.91e-05	0.00496	-0.32	-0.19	Alzheimer's disease (late onset);	chr1:207613197	chr1:207372559~207373252:+
HNSC	cis	rs467650	0.553	rs27706	ENSG00000248489.1	CTD-2007H13.3	4.22	2.91e-05	0.00496	0.25	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98646475	chr5:98929171~98995013:+
HNSC	cis	rs72843506	0.722	rs5025290	ENSG00000261033.1	RP11-209D14.2	4.22	2.91e-05	0.00496	0.33	0.19	Schizophrenia;	chr17:20302504	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.722	rs9895177	ENSG00000261033.1	RP11-209D14.2	4.22	2.91e-05	0.00496	0.33	0.19	Schizophrenia;	chr17:20304281	chr17:20008051~20009234:-
HNSC	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	4.22	2.91e-05	0.00496	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	4.22	2.91e-05	0.00496	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	4.22	2.91e-05	0.00496	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
HNSC	cis	rs7868228	1	rs4512473	ENSG00000240498.5	CDKN2B-AS1	-4.22	2.91e-05	0.00496	-0.25	-0.19	Gut microbiome composition (winter);	chr9:21663041	chr9:21994778~22121097:+
HNSC	cis	rs896655	1	rs10811586	ENSG00000244230.3	RN7SL151P	-4.22	2.91e-05	0.00496	-0.19	-0.19	Coronary artery disease;	chr9:21701943	chr9:21699314~21699596:+
HNSC	cis	rs2492286	0.597	rs2712407	ENSG00000242551.2	POU5F1P6	-4.22	2.91e-05	0.00496	-0.21	-0.19	Eosinophil counts;	chr3:128607964	chr3:128674735~128677005:-
HNSC	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-4.22	2.91e-05	0.00496	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
HNSC	cis	rs870825	0.616	rs7692104	ENSG00000254233.1	RP11-242J7.1	4.22	2.92e-05	0.00496	0.28	0.19	Blood protein levels;	chr4:184729741	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7692367	ENSG00000254233.1	RP11-242J7.1	4.22	2.92e-05	0.00496	0.28	0.19	Blood protein levels;	chr4:184729902	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28607131	ENSG00000254233.1	RP11-242J7.1	4.22	2.92e-05	0.00496	0.28	0.19	Blood protein levels;	chr4:184730463	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28490461	ENSG00000254233.1	RP11-242J7.1	4.22	2.92e-05	0.00496	0.28	0.19	Blood protein levels;	chr4:184730484	chr4:184584093~184625030:-
HNSC	cis	rs7255436	0.965	rs11668346	ENSG00000269386.4	RAB11B-AS1	4.22	2.92e-05	0.00496	0.18	0.19	HDL cholesterol;	chr19:8385970	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.965	rs12981318	ENSG00000269386.4	RAB11B-AS1	4.22	2.92e-05	0.00496	0.18	0.19	HDL cholesterol;	chr19:8386546	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.965	rs7351098	ENSG00000269386.4	RAB11B-AS1	4.22	2.92e-05	0.00496	0.18	0.19	HDL cholesterol;	chr19:8386787	chr19:8374373~8390685:-
HNSC	cis	rs7255436	0.965	rs11666003	ENSG00000269386.4	RAB11B-AS1	4.22	2.92e-05	0.00496	0.18	0.19	HDL cholesterol;	chr19:8387218	chr19:8374373~8390685:-
HNSC	cis	rs1665050	0.534	rs56402153	ENSG00000277144.1	RP11-59H7.4	-4.22	2.92e-05	0.00496	-0.24	-0.19	Atopic dermatitis;	chr15:58941113	chr15:59115547~59116089:-
HNSC	cis	rs2243480	1	rs4718334	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.92e-05	0.00496	-0.32	-0.19	Diabetic kidney disease;	chr7:66324467	chr7:66025126~66031544:-
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000219891.2	ZSCAN12P1	4.22	2.92e-05	0.00496	0.27	0.19	Parkinson's disease;	chr6:28052201	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000219891.2	ZSCAN12P1	4.22	2.92e-05	0.00496	0.27	0.19	Parkinson's disease;	chr6:28053036	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000219891.2	ZSCAN12P1	4.22	2.92e-05	0.00496	0.27	0.19	Parkinson's disease;	chr6:28053042	chr6:28091154~28093664:+
HNSC	cis	rs11168618	0.846	rs11168599	ENSG00000240399.1	RP1-228P16.1	4.22	2.92e-05	0.00496	0.16	0.19	Adiponectin levels;	chr12:48486168	chr12:48054813~48055591:-
HNSC	cis	rs7572733	0.515	rs6726506	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00496	-0.18	-0.19	Dermatomyositis;	chr2:197981762	chr2:197197991~197199273:+
HNSC	cis	rs6964587	0.773	rs13236026	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.92e-05	0.00496	-0.21	-0.19	Breast cancer;	chr7:92256559	chr7:92134604~92180725:+
HNSC	cis	rs1799949	0.501	rs2343819	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43332285	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.501	rs35399157	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43334234	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.602	rs4600503	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43336956	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.501	rs9675035	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43337648	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs11649954	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43342667	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1824889	ENSG00000236383.6	LINC00854	-4.22	2.92e-05	0.00496	-0.18	-0.19	Menopause (age at onset);	chr17:43344508	chr17:43216941~43305976:-
HNSC	cis	rs7085104	0.632	rs7097872	ENSG00000236937.2	PTGES3P4	4.22	2.92e-05	0.00496	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102845595~102845950:+
HNSC	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.92e-05	0.00496	-0.32	-0.19	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
HNSC	cis	rs4853525	0.859	rs6434424	ENSG00000228509.4	AC006460.2	4.22	2.92e-05	0.00496	0.23	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190857400	chr2:190676944~190708716:-
HNSC	cis	rs9650657	0.812	rs6993841	ENSG00000269918.1	AF131215.9	-4.22	2.92e-05	0.00497	-0.19	-0.19	Neuroticism;	chr8:10775174	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-4.22	2.92e-05	0.00497	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
HNSC	cis	rs1113500	0.805	rs11185244	ENSG00000226822.1	RP11-356N1.2	4.22	2.92e-05	0.00497	0.21	0.19	Growth-regulated protein alpha levels;	chr1:108058525	chr1:108071482~108074519:+
HNSC	cis	rs9921338	0.961	rs4780358	ENSG00000263080.1	RP11-485G7.5	4.22	2.92e-05	0.00497	0.21	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11341809~11345211:-
HNSC	cis	rs8024893	0.764	rs8035110	ENSG00000270055.1	CTD-3092A11.2	4.22	2.93e-05	0.00497	0.27	0.19	Red cell distribution width;	chr15:31241884	chr15:30487963~30490313:+
HNSC	cis	rs12935418	0.672	rs1453328	ENSG00000278985.1	RP11-303E16.9	4.22	2.93e-05	0.00498	0.19	0.19	Mean corpuscular volume;	chr16:81019240	chr16:80982319~80984094:-
HNSC	cis	rs8077577	0.895	rs62072464	ENSG00000273018.4	CTD-2303H24.2	-4.22	2.93e-05	0.00498	-0.29	-0.19	Obesity-related traits;	chr17:18205000	chr17:18511221~18551705:-
HNSC	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-4.22	2.93e-05	0.00498	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
HNSC	cis	rs7296418	0.663	rs11057284	ENSG00000280120.1	RP11-546D6.3	4.22	2.93e-05	0.00498	0.16	0.19	Platelet count;	chr12:123346145	chr12:123152324~123153377:-
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000254340.1	RP11-10A14.3	4.22	2.93e-05	0.00498	0.23	0.19	Neuroticism;	chr8:8312807	chr8:9141424~9145435:+
HNSC	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	4.22	2.93e-05	0.00498	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	4.22	2.93e-05	0.00498	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
HNSC	cis	rs12034383	0.967	rs7519119	ENSG00000274245.1	RP11-357P18.2	-4.22	2.93e-05	0.00498	-0.24	-0.19	Erythrocyte sedimentation rate;	chr1:207612807	chr1:207372559~207373252:+
HNSC	cis	rs4819052	0.807	rs1075788	ENSG00000223768.1	LINC00205	-4.22	2.93e-05	0.00498	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45293285~45297354:+
HNSC	cis	rs516805	0.748	rs572261	ENSG00000279453.1	RP3-425C14.4	-4.22	2.93e-05	0.00498	-0.27	-0.19	Lymphocyte counts;	chr6:122408877	chr6:122436789~122439223:-
HNSC	cis	rs11673344	0.504	rs4805205	ENSG00000276846.1	CTD-3220F14.3	4.22	2.93e-05	0.00498	0.21	0.19	Obesity-related traits;	chr19:37136693	chr19:37314868~37315620:-
HNSC	cis	rs8031584	0.679	rs34017474	ENSG00000215302.7	CTD-3092A11.1	-4.22	2.93e-05	0.00498	-0.22	-0.19	Huntington's disease progression;	chr15:30938408	chr15:30470779~30507623:+
HNSC	cis	rs2274273	0.712	rs17832311	ENSG00000233924.1	AL160471.6	-4.22	2.93e-05	0.00498	-0.21	-0.19	Protein biomarker;	chr14:55067748	chr14:55004813~55005687:-
HNSC	cis	rs330048	0.561	rs330088	ENSG00000254153.1	CTA-398F10.2	4.22	2.93e-05	0.00498	0.21	0.19	Systemic lupus erythematosus;	chr8:9292236	chr8:8456909~8461337:-
HNSC	cis	rs755249	0.567	rs16826069	ENSG00000228060.1	RP11-69E11.8	-4.22	2.93e-05	0.00498	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	4.22	2.94e-05	0.00499	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
HNSC	cis	rs11951515	0.663	rs35231094	ENSG00000249286.1	CTD-2210P15.2	4.22	2.94e-05	0.00499	0.2	0.19	Metabolite levels  (X-11787);	chr5:43281983	chr5:43586918~43588223:-
HNSC	cis	rs17264034	0.861	rs55891419	ENSG00000250786.1	SNHG18	4.22	2.94e-05	0.00499	0.33	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553468	chr5:9546200~9550609:+
HNSC	cis	rs1113500	0.787	rs473704	ENSG00000226822.1	RP11-356N1.2	-4.22	2.94e-05	0.00499	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108094688	chr1:108071482~108074519:+
HNSC	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	4.22	2.94e-05	0.00499	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
HNSC	cis	rs72843506	0.722	rs79590067	ENSG00000261033.1	RP11-209D14.2	4.22	2.94e-05	0.00499	0.33	0.19	Schizophrenia;	chr17:20204101	chr17:20008051~20009234:-
HNSC	cis	rs6504108	0.624	rs4794525	ENSG00000278765.1	RP5-890E16.5	-4.22	2.94e-05	0.00499	-0.24	-0.19	Body mass index;	chr17:48220996	chr17:48066704~48067293:-
HNSC	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	4.22	2.94e-05	0.00499	0.2	0.19	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	4.22	2.94e-05	0.00499	0.2	0.19	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	4.22	2.94e-05	0.00499	0.2	0.19	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
HNSC	cis	rs4660214	0.666	rs6600290	ENSG00000182109.6	RP11-69E11.4	-4.22	2.94e-05	0.00499	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	4.22	2.94e-05	0.005	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	4.22	2.94e-05	0.005	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
HNSC	cis	rs933688	0.877	rs1477349	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91411956	chr5:91380349~91439085:+
HNSC	cis	rs933688	0.938	rs1477348	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91412006	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs12654787	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91417442	chr5:91380349~91439085:+
HNSC	cis	rs933688	0.938	rs10063683	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91418778	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs6867219	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91422191	chr5:91380349~91439085:+
HNSC	cis	rs933688	0.938	rs7708782	ENSG00000281357.1	ARRDC3-AS1	4.22	2.94e-05	0.005	0.29	0.19	Smoking behavior;	chr5:91422700	chr5:91380349~91439085:+
HNSC	cis	rs2904524	0.867	rs17107870	ENSG00000257815.4	RP11-611E13.2	-4.22	2.94e-05	0.005	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70251669	chr12:69904033~70243360:-
HNSC	cis	rs6601327	0.54	rs12542912	ENSG00000233609.3	RP11-62H7.2	-4.22	2.94e-05	0.005	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9727686	chr8:8961200~8979025:+
HNSC	cis	rs6601327	0.641	rs7014663	ENSG00000233609.3	RP11-62H7.2	-4.22	2.94e-05	0.005	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9729765	chr8:8961200~8979025:+
HNSC	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	4.22	2.94e-05	0.005	0.25	0.19	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	4.22	2.94e-05	0.005	0.33	0.19	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
HNSC	cis	rs755249	0.567	rs2018212	ENSG00000182109.6	RP11-69E11.4	4.22	2.94e-05	0.005	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs4660751	ENSG00000182109.6	RP11-69E11.4	4.22	2.94e-05	0.005	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39522280~39546187:-
HNSC	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.22	2.95e-05	0.005	0.33	0.19	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
HNSC	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.22	2.95e-05	0.005	0.33	0.19	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
HNSC	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	4.22	2.95e-05	0.005	0.23	0.19	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
HNSC	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-4.22	2.95e-05	0.005	-0.2	-0.19	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
HNSC	cis	rs4803480	0.572	rs8111065	ENSG00000270164.1	LINC01480	-4.22	2.95e-05	0.005	-0.25	-0.19	Schizophrenia;	chr19:41606201	chr19:41535183~41536904:+
HNSC	cis	rs4356203	0.905	rs7396382	ENSG00000260196.1	RP1-239B22.5	4.22	2.95e-05	0.00501	0.2	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17380649~17383531:+
HNSC	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-4.22	2.95e-05	0.00501	-0.26	-0.19	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
HNSC	cis	rs9329221	0.513	rs4841296	ENSG00000269918.1	AF131215.9	-4.22	2.95e-05	0.00501	-0.19	-0.19	Neuroticism;	chr8:10247937	chr8:11104691~11106704:-
HNSC	cis	rs2548724	0.66	rs62369343	ENSG00000250682.4	LINC00491	4.22	2.95e-05	0.00501	0.25	0.19	Type 2 diabetes;	chr5:102405249	chr5:102609156~102671559:-
HNSC	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-4.22	2.95e-05	0.00501	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-4.22	2.95e-05	0.00501	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-4.22	2.95e-05	0.00501	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
HNSC	cis	rs9329221	0.538	rs9650651	ENSG00000255310.2	AF131215.2	4.22	2.95e-05	0.00501	0.18	0.19	Neuroticism;	chr8:10410030	chr8:11107788~11109726:-
HNSC	cis	rs755249	0.567	rs67408364	ENSG00000182109.6	RP11-69E11.4	4.22	2.95e-05	0.00501	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39522280~39546187:-
HNSC	cis	rs1008375	0.966	rs6833808	ENSG00000249502.1	AC006160.5	-4.22	2.95e-05	0.00501	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650903	chr4:17587467~17614571:-
HNSC	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-4.22	2.95e-05	0.00501	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
HNSC	cis	rs17818399	0.547	rs7607308	ENSG00000279254.1	RP11-536C12.1	-4.22	2.95e-05	0.00501	-0.23	-0.19	Height;	chr2:46531965	chr2:46668870~46670778:+
HNSC	cis	rs9650657	0.737	rs2116095	ENSG00000255310.2	AF131215.2	-4.22	2.95e-05	0.00501	-0.18	-0.19	Neuroticism;	chr8:10777787	chr8:11107788~11109726:-
HNSC	cis	rs11673344	0.523	rs7258438	ENSG00000276846.1	CTD-3220F14.3	4.22	2.95e-05	0.00501	0.21	0.19	Obesity-related traits;	chr19:37032534	chr19:37314868~37315620:-
HNSC	cis	rs795484	0.889	rs708868	ENSG00000275409.1	RP11-131L12.4	-4.22	2.95e-05	0.00501	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191964	chr12:118430147~118430699:+
HNSC	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	4.22	2.95e-05	0.00501	0.22	0.19	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
HNSC	cis	rs116095464	0.558	rs6962	ENSG00000277812.1	AC021087.1	4.22	2.96e-05	0.00502	0.35	0.19	Breast cancer;	chr5:256394	chr5:262769~262881:+
HNSC	cis	rs7809950	0.678	rs2237659	ENSG00000238832.1	snoU109	4.22	2.96e-05	0.00502	0.28	0.19	Coronary artery disease;	chr7:107207047	chr7:107603363~107603507:+
HNSC	cis	rs6500395	1	rs1872654	ENSG00000261267.1	RP11-44I10.3	-4.22	2.96e-05	0.00502	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48637139	chr16:48559661~48587403:+
HNSC	cis	rs8028182	0.636	rs4545784	ENSG00000260269.4	CTD-2323K18.1	-4.22	2.96e-05	0.00502	-0.25	-0.19	Sudden cardiac arrest;	chr15:75463310	chr15:75527150~75601205:-
HNSC	cis	rs6430585	0.528	rs309133	ENSG00000231890.6	DARS-AS1	-4.22	2.96e-05	0.00502	-0.32	-0.19	Corneal structure;	chr2:135994272	chr2:135985176~136022593:+
HNSC	cis	rs950776	0.642	rs12905641	ENSG00000261762.1	RP11-650L12.2	-4.22	2.96e-05	0.00502	-0.23	-0.19	Sudden cardiac arrest;	chr15:78672020	chr15:78589123~78591276:-
HNSC	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	4.22	2.96e-05	0.00502	0.19	0.19	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
HNSC	cis	rs1218582	0.741	rs2335407	ENSG00000270361.1	RP11-307C12.13	4.22	2.96e-05	0.00502	0.21	0.19	Prostate cancer;	chr1:154870871	chr1:154937370~154938059:+
HNSC	cis	rs910316	0.967	rs4899549	ENSG00000279594.1	RP11-950C14.10	-4.22	2.96e-05	0.00502	-0.23	-0.19	Height;	chr14:75180791	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.967	rs4899550	ENSG00000279594.1	RP11-950C14.10	-4.22	2.96e-05	0.00502	-0.23	-0.19	Height;	chr14:75180963	chr14:75011269~75012851:-
HNSC	cis	rs7824557	0.778	rs6601572	ENSG00000269918.1	AF131215.9	-4.22	2.96e-05	0.00502	-0.19	-0.19	Retinal vascular caliber;	chr8:11235828	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.602	rs17255447	ENSG00000211812.1	TRAV26-2	4.22	2.96e-05	0.00502	0.17	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22202583~22203368:+
HNSC	cis	rs1316952	0.831	rs77732168	ENSG00000269938.1	RP11-214K3.20	-4.22	2.96e-05	0.00502	-0.36	-0.19	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123907573	chr12:123968023~123968579:-
HNSC	cis	rs913655	0.508	rs12413511	ENSG00000225527.1	RP11-383B4.4	-4.22	2.96e-05	0.00503	-0.23	-0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18723961	chr10:18531849~18533336:-
HNSC	cis	rs721917	0.506	rs2758539	ENSG00000244733.5	RP11-506M13.3	-4.22	2.96e-05	0.00503	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79660891~79677996:+
HNSC	cis	rs867371	0.614	rs1814739	ENSG00000259429.4	UBE2Q2P2	-4.22	2.96e-05	0.00503	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82355142~82420075:+
HNSC	cis	rs17428076	0.681	rs62183851	ENSG00000228389.1	AC068039.4	-4.22	2.96e-05	0.00503	-0.27	-0.19	Myopia;	chr2:172060524	chr2:171773482~171775844:+
HNSC	cis	rs17772222	0.917	rs2004329	ENSG00000258789.1	RP11-507K2.3	-4.22	2.97e-05	0.00503	-0.23	-0.19	Coronary artery calcification;	chr14:88532965	chr14:88551597~88552493:+
HNSC	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	4.22	2.97e-05	0.00503	0.19	0.19	Height;	chr5:37428489	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.561	rs62359058	ENSG00000250155.1	CTD-2353F22.1	4.22	2.97e-05	0.00503	0.19	0.19	Telomere length;	chr5:37592593	chr5:36666214~36725195:-
HNSC	cis	rs7829975	0.774	rs1703982	ENSG00000233609.3	RP11-62H7.2	-4.22	2.97e-05	0.00503	-0.19	-0.19	Mood instability;	chr8:8740878	chr8:8961200~8979025:+
HNSC	cis	rs7520050	0.966	rs4376778	ENSG00000280836.1	AL355480.1	4.22	2.97e-05	0.00503	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45581219~45581321:-
HNSC	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-4.22	2.97e-05	0.00504	-0.21	-0.19	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
HNSC	cis	rs9650657	0.655	rs1991651	ENSG00000269918.1	AF131215.9	4.22	2.97e-05	0.00504	0.19	0.19	Neuroticism;	chr8:10848901	chr8:11104691~11106704:-
HNSC	cis	rs9880211	1	rs12695645	ENSG00000273486.1	RP11-731C17.2	4.22	2.97e-05	0.00504	0.18	0.19	Height;Body mass index;	chr3:136272039	chr3:136837338~136839021:-
HNSC	cis	rs1008375	1	rs2058338	ENSG00000249502.1	AC006160.5	4.22	2.97e-05	0.00504	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676977	chr4:17587467~17614571:-
HNSC	cis	rs4787951	0.58	rs1805010	ENSG00000259940.2	CTD-3203P2.1	-4.22	2.97e-05	0.00504	-0.21	-0.19	Eosinophil percentage of white cells;	chr16:27344882	chr16:27213308~27214993:-
HNSC	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-4.22	2.97e-05	0.00504	-0.26	-0.19	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
HNSC	cis	rs9650657	0.775	rs10100265	ENSG00000269918.1	AF131215.9	-4.22	2.97e-05	0.00504	-0.19	-0.19	Neuroticism;	chr8:10775649	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.955	rs13113112	ENSG00000250412.1	KLHL2P1	4.22	2.97e-05	0.00504	0.25	0.19	Corneal astigmatism;	chr4:119234885	chr4:119334329~119378233:+
HNSC	cis	rs795484	0.926	rs353894	ENSG00000275409.1	RP11-131L12.4	-4.22	2.97e-05	0.00504	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118195702	chr12:118430147~118430699:+
HNSC	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	4.22	2.97e-05	0.00504	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	4.22	2.97e-05	0.00504	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
HNSC	cis	rs7475343	0.501	rs77697233	ENSG00000224034.1	RP11-445P17.8	-4.22	2.97e-05	0.00504	-0.27	-0.19	Intelligence;	chr10:5204162	chr10:5266033~5271236:-
HNSC	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.22	2.97e-05	0.00504	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
HNSC	cis	rs2236295	0.503	rs10822064	ENSG00000238280.1	RP11-436D10.3	4.22	2.97e-05	0.00504	0.23	0.19	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62849964	chr10:62793562~62805887:-
HNSC	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	4.22	2.97e-05	0.00505	0.4	0.19	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
HNSC	cis	rs9400271	0.632	rs9398191	ENSG00000243587.6	C6orf183	-4.22	2.98e-05	0.00505	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109265358	chr6:109165833~109271014:+
HNSC	cis	rs17407555	0.741	rs12509713	ENSG00000250413.1	RP11-448G15.1	4.22	2.98e-05	0.00505	0.26	0.19	Schizophrenia (age at onset);	chr4:10105445	chr4:10006482~10009725:+
HNSC	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	4.22	2.98e-05	0.00505	0.19	0.19	Asthma;	chr2:102370999	chr2:102438713~102440475:+
HNSC	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-4.22	2.98e-05	0.00505	-0.24	-0.19	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
HNSC	cis	rs4388249	0.904	rs71575306	ENSG00000271849.1	CTC-332L22.1	-4.22	2.98e-05	0.00505	-0.31	-0.19	Schizophrenia;	chr5:109710509	chr5:109687802~109688329:-
HNSC	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-4.22	2.98e-05	0.00506	-0.14	-0.19	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
HNSC	cis	rs11673344	0.542	rs826324	ENSG00000267698.1	AC002116.7	4.22	2.98e-05	0.00506	0.17	0.19	Obesity-related traits;	chr19:37014343	chr19:36014508~36045972:+
HNSC	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	4.22	2.98e-05	0.00506	0.21	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
HNSC	cis	rs9329221	0.527	rs4841351	ENSG00000269918.1	AF131215.9	-4.22	2.98e-05	0.00506	-0.2	-0.19	Neuroticism;	chr8:10469857	chr8:11104691~11106704:-
HNSC	cis	rs2337406	1	rs17113276	ENSG00000280411.1	IGHV1-69-2	4.22	2.98e-05	0.00506	0.18	0.19	Alzheimer's disease (late onset);	chr14:106683485	chr14:106762092~106762588:-
HNSC	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-4.22	2.98e-05	0.00506	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-4.22	2.98e-05	0.00506	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.539	rs940031	ENSG00000173295.6	FAM86B3P	-4.22	2.98e-05	0.00506	-0.22	-0.19	Mood instability;	chr8:8689338	chr8:8228595~8244865:+
HNSC	cis	rs7824557	0.564	rs2572386	ENSG00000269918.1	AF131215.9	-4.22	2.98e-05	0.00506	-0.18	-0.19	Retinal vascular caliber;	chr8:11379466	chr8:11104691~11106704:-
HNSC	cis	rs1008375	1	rs4698200	ENSG00000249502.1	AC006160.5	-4.22	2.98e-05	0.00506	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17655428	chr4:17587467~17614571:-
HNSC	cis	rs36093844	0.654	rs79753303	ENSG00000279742.1	RP11-700A24.1	-4.22	2.98e-05	0.00506	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85809537	chr11:85852557~85854943:-
HNSC	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-4.22	2.99e-05	0.00506	-0.19	-0.19	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
HNSC	cis	rs2486288	0.656	rs11637838	ENSG00000259479.5	SORD2P	-4.22	2.99e-05	0.00506	-0.22	-0.19	Glomerular filtration rate;	chr15:45258459	chr15:44826371~44884694:-
HNSC	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	4.22	2.99e-05	0.00506	0.29	0.19	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	4.22	2.99e-05	0.00506	0.29	0.19	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
HNSC	cis	rs1056107	0.863	rs1320460	ENSG00000225513.1	RP11-165N19.2	-4.22	2.99e-05	0.00506	-0.2	-0.19	Colorectal cancer;	chr9:112194345	chr9:112173522~112173971:-
HNSC	cis	rs9393777	0.546	rs9366673	ENSG00000241549.7	GUSBP2	4.22	2.99e-05	0.00506	0.23	0.19	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26871484~26956554:-
HNSC	cis	rs6601327	1	rs6601327	ENSG00000254340.1	RP11-10A14.3	-4.22	2.99e-05	0.00506	-0.23	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:9141424~9145435:+
HNSC	cis	rs62027291	1	rs62027291	ENSG00000259422.1	RP11-593F23.1	-4.22	2.99e-05	0.00506	-0.3	-0.19	Plateletcrit;	chr15:76973710	chr15:76174891~76181486:-
HNSC	cis	rs137699	1	rs2413588	ENSG00000261202.1	RP3-496C20.1	-4.22	2.99e-05	0.00507	-0.22	-0.19	IgG glycosylation;	chr22:39359170	chr22:40043068~40044530:-
HNSC	cis	rs137699	1	rs760742	ENSG00000261202.1	RP3-496C20.1	-4.22	2.99e-05	0.00507	-0.22	-0.19	IgG glycosylation;	chr22:39359185	chr22:40043068~40044530:-
HNSC	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-4.22	2.99e-05	0.00507	-0.24	-0.19	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-4.22	2.99e-05	0.00507	-0.24	-0.19	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
HNSC	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-4.22	2.99e-05	0.00507	-0.19	-0.19	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
HNSC	cis	rs9487051	0.872	rs1111865	ENSG00000219700.1	PTCHD3P3	-4.22	2.99e-05	0.00507	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109289660	chr6:109288571~109290503:-
HNSC	cis	rs17739794	0.967	rs3860880	ENSG00000254207.1	RP11-43A14.1	-4.22	2.99e-05	0.00507	-0.22	-0.19	Clozapine-induced cytotoxicity;	chr8:859497	chr8:725188~725877:-
HNSC	cis	rs13434995	0.513	rs4336288	ENSG00000273257.1	RP11-177J6.1	4.22	2.99e-05	0.00507	0.26	0.19	Adiponectin levels;	chr4:55584088	chr4:55387949~55388271:+
HNSC	cis	rs9847710	1	rs2581817	ENSG00000242142.1	SERBP1P3	4.22	2.99e-05	0.00507	0.21	0.19	Ulcerative colitis;	chr3:53037781	chr3:53064283~53065091:-
HNSC	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-4.22	2.99e-05	0.00507	-0.33	-0.19	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
HNSC	cis	rs638893	0.717	rs622690	ENSG00000255422.1	AP002954.4	-4.22	2.99e-05	0.00507	-0.31	-0.19	Vitiligo;	chr11:118833556	chr11:118704607~118750263:+
HNSC	cis	rs7829975	0.684	rs474892	ENSG00000254340.1	RP11-10A14.3	-4.22	2.99e-05	0.00507	-0.24	-0.19	Mood instability;	chr8:8739221	chr8:9141424~9145435:+
HNSC	cis	rs61160187	0.51	rs10077663	ENSG00000272308.1	RP11-231G3.1	-4.22	3e-05	0.00508	-0.19	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60866457~60866935:-
HNSC	cis	rs3806843	0.576	rs246063	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140944907	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246062	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140944995	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.521	rs246061	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945071	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.607	rs246060	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945164	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246059	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945425	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.548	rs246058	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945549	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.548	rs246057	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945998	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.548	rs246055	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140946077	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.547	rs246054	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140946574	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.548	rs246052	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140946828	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.52	rs246051	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140946879	chr5:141439853~141442449:+
HNSC	cis	rs31872	0.521	rs246050	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Visceral adipose tissue adjusted for BMI;	chr5:140947275	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246049	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140948005	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246047	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140948752	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246046	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140949679	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246045	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140950299	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246043	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140951339	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.608	rs246042	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140951382	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246041	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140951543	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.548	rs246038	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952114	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246037	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952261	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246036	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952301	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246034	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952479	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.547	rs246033	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952530	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246032	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140952962	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.517	rs246031	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140953522	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246030	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140953569	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246029	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140953641	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246028	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140953928	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246027	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140954016	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246021	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140954919	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246020	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140955186	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.551	rs246018	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140955458	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.518	rs173471	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140955641	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.549	rs246012	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140956692	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246011	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140956820	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.547	rs246010	ENSG00000276545.1	PCDHGB9P	4.22	3e-05	0.00508	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140957050	chr5:141439853~141442449:+
HNSC	cis	rs7674212	0.541	rs2720458	ENSG00000251288.2	RP11-10L12.2	-4.22	3e-05	0.00508	-0.22	-0.19	Type 2 diabetes;	chr4:103131806	chr4:102751401~102752641:+
HNSC	cis	rs2657294	0.62	rs4746259	ENSG00000233313.2	HMGA1P5	-4.22	3e-05	0.00508	-0.21	-0.19	Pneumonia;	chr10:75082310	chr10:75276376~75276646:-
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000224373.3	IGHV4-59	4.22	3e-05	0.00508	0.11	0.19	Kawasaki disease;	chr14:106807047	chr14:106627249~106627825:-
HNSC	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	4.22	3e-05	0.00508	0.31	0.19	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
HNSC	cis	rs7015630	0.657	rs34525502	ENSG00000251136.7	RP11-37B2.1	-4.22	3e-05	0.00508	-0.23	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89840352	chr8:89609409~89757727:-
HNSC	cis	rs6500395	1	rs11859909	ENSG00000261267.1	RP11-44I10.3	-4.21	3e-05	0.00508	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48634530	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs8044519	ENSG00000261267.1	RP11-44I10.3	-4.21	3e-05	0.00508	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48635170	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.926	rs7192297	ENSG00000261267.1	RP11-44I10.3	-4.21	3e-05	0.00508	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48636510	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11641458	ENSG00000261267.1	RP11-44I10.3	-4.21	3e-05	0.00508	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48636934	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1872655	ENSG00000261267.1	RP11-44I10.3	-4.21	3e-05	0.00508	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48636972	chr16:48559661~48587403:+
HNSC	cis	rs7085104	0.632	rs6162	ENSG00000236937.2	PTGES3P4	4.21	3e-05	0.00508	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102845595~102845950:+
HNSC	cis	rs2518049	0.95	rs1937847	ENSG00000224034.1	RP11-445P17.8	-4.21	3e-05	0.00508	-0.25	-0.19	Metabolic traits;	chr10:5092319	chr10:5266033~5271236:-
HNSC	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	4.21	3e-05	0.00508	0.31	0.19	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
HNSC	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	4.21	3e-05	0.00508	0.17	0.19	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
HNSC	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-4.21	3e-05	0.00508	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
HNSC	cis	rs2384207	0.584	rs2232515	ENSG00000201208.1	Y_RNA	-4.21	3e-05	0.00508	-0.29	-0.19	Response to fenofibrate (adiponectin levels);	chr12:113296608	chr12:113178423~113178519:-
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000259429.4	UBE2Q2P2	-4.21	3e-05	0.00509	-0.18	-0.19	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82355142~82420075:+
HNSC	cis	rs2518049	0.904	rs7901781	ENSG00000224034.1	RP11-445P17.8	-4.21	3e-05	0.00509	-0.25	-0.19	Metabolic traits;	chr10:5077352	chr10:5266033~5271236:-
HNSC	cis	rs2337406	1	rs11845269	ENSG00000280411.1	IGHV1-69-2	-4.21	3.01e-05	0.00509	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106683851	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-4.21	3.01e-05	0.00509	-0.14	-0.19	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
HNSC	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-4.21	3.01e-05	0.00509	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-4.21	3.01e-05	0.00509	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
HNSC	cis	rs12600394	0.887	rs2109176	ENSG00000236088.8	COX10-AS1	4.21	3.01e-05	0.00509	0.27	0.19	Response to platinum-based chemotherapy (cisplatin);	chr17:14610010	chr17:13756478~14069495:-
HNSC	cis	rs12600394	1	rs2109177	ENSG00000236088.8	COX10-AS1	4.21	3.01e-05	0.00509	0.27	0.19	Response to platinum-based chemotherapy (cisplatin);	chr17:14610204	chr17:13756478~14069495:-
HNSC	cis	rs6500395	1	rs9925406	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.00509	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48637525	chr16:48559661~48587403:+
HNSC	cis	rs1714507	0.533	rs1620229	ENSG00000272087.1	RP11-379F4.7	4.21	3.01e-05	0.00509	0.21	0.19	Subjective well-being;	chr3:158575469	chr3:158693120~158693768:-
HNSC	cis	rs656319	0.58	rs13272793	ENSG00000255310.2	AF131215.2	-4.21	3.01e-05	0.00509	-0.18	-0.19	Myopia (pathological);	chr8:10144517	chr8:11107788~11109726:-
HNSC	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	4.21	3.01e-05	0.00509	0.23	0.19	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
HNSC	cis	rs9531006	0.636	rs7332417	ENSG00000227676.3	LINC01068	4.21	3.01e-05	0.0051	0.29	0.19	Sleep duration;	chr13:79920719	chr13:79566727~79571436:+
HNSC	cis	rs6500395	0.926	rs11643272	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48605812	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs868792	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48606721	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs11640463	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48610523	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs8058362	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48611405	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9933329	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48612661	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs3743780	ENSG00000261267.1	RP11-44I10.3	-4.21	3.01e-05	0.0051	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48613569	chr16:48559661~48587403:+
HNSC	cis	rs11098499	0.739	rs4833612	ENSG00000250412.1	KLHL2P1	-4.21	3.01e-05	0.0051	-0.23	-0.19	Corneal astigmatism;	chr4:119226441	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.739	rs10013032	ENSG00000250412.1	KLHL2P1	-4.21	3.01e-05	0.0051	-0.23	-0.19	Corneal astigmatism;	chr4:119228264	chr4:119334329~119378233:+
HNSC	cis	rs7324557	0.717	rs7325423	ENSG00000205861.10	C1QTNF9B-AS1	-4.21	3.01e-05	0.0051	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23827670	chr13:23888889~23897263:+
HNSC	cis	rs283610	0.735	rs1155626	ENSG00000182383.8	RPL27AP5	-4.21	3.01e-05	0.0051	-0.17	-0.19	Obesity-related traits;	chr5:73992339	chr5:74990189~74990637:-
HNSC	cis	rs7674212	0.541	rs11727498	ENSG00000251288.2	RP11-10L12.2	-4.21	3.01e-05	0.0051	-0.22	-0.19	Type 2 diabetes;	chr4:103179830	chr4:102751401~102752641:+
HNSC	cis	rs757081	0.648	rs7108315	ENSG00000260196.1	RP1-239B22.5	-4.21	3.01e-05	0.0051	-0.2	-0.19	Systolic blood pressure;	chr11:17245617	chr11:17380649~17383531:+
HNSC	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	4.21	3.01e-05	0.0051	0.22	0.19	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
HNSC	cis	rs2865126	0.818	rs7227167	ENSG00000264714.1	RP11-21G15.1	-4.21	3.02e-05	0.00511	-0.24	-0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10763009	chr18:10724619~10728539:+
HNSC	cis	rs11673344	0.503	rs1829603	ENSG00000276846.1	CTD-3220F14.3	4.21	3.02e-05	0.00511	0.21	0.19	Obesity-related traits;	chr19:37065396	chr19:37314868~37315620:-
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-4.21	3.02e-05	0.00511	-0.26	-0.19	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
HNSC	cis	rs61270009	0.818	rs6452786	ENSG00000247828.6	TMEM161B-AS1	4.21	3.02e-05	0.00511	0.2	0.19	Depressive symptoms;	chr5:88409022	chr5:88268895~88436685:+
HNSC	cis	rs4356203	0.87	rs10832748	ENSG00000260196.1	RP1-239B22.5	-4.21	3.02e-05	0.00511	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17380649~17383531:+
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000224373.3	IGHV4-59	4.21	3.02e-05	0.00511	0.12	0.19	Kawasaki disease;	chr14:106813798	chr14:106627249~106627825:-
HNSC	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.21	3.02e-05	0.00511	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.21	3.02e-05	0.00511	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
HNSC	cis	rs2333194	0.846	rs7159794	ENSG00000258695.2	RP3-414A15.2	-4.21	3.02e-05	0.00511	-0.2	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73337735	chr14:73522878~73530610:+
HNSC	cis	rs71520386	0.861	rs35841035	ENSG00000221740.1	SNORD93	-4.21	3.02e-05	0.00511	-0.26	-0.19	Fibrinogen levels;	chr7:22822987	chr7:22856613~22856686:+
HNSC	cis	rs11673344	0.504	rs4254428	ENSG00000276846.1	CTD-3220F14.3	4.21	3.02e-05	0.00511	0.21	0.19	Obesity-related traits;	chr19:37093748	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs11084874	ENSG00000276846.1	CTD-3220F14.3	4.21	3.02e-05	0.00511	0.21	0.19	Obesity-related traits;	chr19:37096667	chr19:37314868~37315620:-
HNSC	cis	rs12478296	0.786	rs55876934	ENSG00000261186.2	RP11-341N2.1	-4.21	3.02e-05	0.00511	-0.32	-0.19	Obesity-related traits;	chr2:242091665	chr2:242087351~242088457:-
HNSC	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-4.21	3.02e-05	0.00511	-0.23	-0.19	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
HNSC	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.21	3.02e-05	0.00511	-0.2	-0.19	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
HNSC	cis	rs7826238	0.539	rs2945891	ENSG00000233609.3	RP11-62H7.2	4.21	3.02e-05	0.00511	0.18	0.19	Systolic blood pressure;	chr8:8297953	chr8:8961200~8979025:+
HNSC	cis	rs240993	0.812	rs9487644	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.00512	-0.24	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.761	rs9487645	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.00512	-0.24	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111277932~111278742:+
HNSC	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-4.21	3.02e-05	0.00512	-0.2	-0.19	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
HNSC	cis	rs4218	0.681	rs4531679	ENSG00000259732.1	RP11-59H7.3	-4.21	3.02e-05	0.00512	-0.25	-0.19	Social communication problems;	chr15:59083246	chr15:59121034~59133250:+
HNSC	cis	rs17373728	0.526	rs1351226	ENSG00000249395.2	CASC9	-4.21	3.02e-05	0.00512	-0.25	-0.19	Diabetic kidney disease;	chr8:75214150	chr8:75223404~75324741:-
HNSC	cis	rs7475343	0.501	rs117310669	ENSG00000224034.1	RP11-445P17.8	-4.21	3.02e-05	0.00512	-0.27	-0.19	Intelligence;	chr10:5210050	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs4424574	ENSG00000224034.1	RP11-445P17.8	-4.21	3.02e-05	0.00512	-0.27	-0.19	Intelligence;	chr10:5210114	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs1831977	ENSG00000224034.1	RP11-445P17.8	-4.21	3.02e-05	0.00512	-0.27	-0.19	Intelligence;	chr10:5212858	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs17134588	ENSG00000224034.1	RP11-445P17.8	-4.21	3.02e-05	0.00512	-0.27	-0.19	Intelligence;	chr10:5214534	chr10:5266033~5271236:-
HNSC	cis	rs964611	0.882	rs8040405	ENSG00000259488.2	RP11-154J22.1	-4.21	3.02e-05	0.00512	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48280640	chr15:48312353~48331856:-
HNSC	cis	rs61935443	0.501	rs7961115	ENSG00000241556.1	RP11-490G8.1	4.21	3.02e-05	0.00512	0.2	0.19	Schizophrenia;	chr12:94809363	chr12:95467397~95467861:-
HNSC	cis	rs7610312	0.681	rs6774235	ENSG00000273493.1	RP11-80H18.4	-4.21	3.03e-05	0.00512	-0.23	-0.19	Red blood cell count;	chr3:58285236	chr3:58329965~58330118:+
HNSC	cis	rs8028182	0.636	rs28610581	ENSG00000260269.4	CTD-2323K18.1	-4.21	3.03e-05	0.00512	-0.25	-0.19	Sudden cardiac arrest;	chr15:75520133	chr15:75527150~75601205:-
HNSC	cis	rs72843506	0.722	rs9908032	ENSG00000261033.1	RP11-209D14.2	4.21	3.03e-05	0.00512	0.32	0.19	Schizophrenia;	chr17:20204871	chr17:20008051~20009234:-
HNSC	cis	rs3811273	0.614	rs12589879	ENSG00000211816.2	TRAV38-1	-4.21	3.03e-05	0.00512	-0.22	-0.19	Periodontal disease-related phenotypes;	chr14:22266010	chr14:22271968~22272563:+
HNSC	cis	rs879620	1	rs879620	ENSG00000262888.1	RP11-462G12.2	4.21	3.03e-05	0.00512	0.23	0.19	Hip circumference;Body mass index;	chr16:3965728	chr16:3931217~3946305:-
HNSC	cis	rs7085104	0.632	rs7096475	ENSG00000236937.2	PTGES3P4	4.21	3.03e-05	0.00512	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102845595~102845950:+
HNSC	cis	rs9583531	0.66	rs61971610	ENSG00000259831.1	LINC00567	-4.21	3.03e-05	0.00512	-0.35	-0.19	Coronary artery disease;	chr13:110678129	chr13:110809676~110813084:-
HNSC	cis	rs6840258	1	rs56201818	ENSG00000251411.1	RP11-397E7.4	-4.21	3.03e-05	0.00512	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031481	chr4:86913266~86914817:-
HNSC	cis	rs3015497	0.646	rs871643	ENSG00000277050.1	RP11-102G14.1	-4.21	3.03e-05	0.00512	-0.2	-0.19	Mean platelet volume;	chr14:50640734	chr14:51637348~51637947:-
HNSC	cis	rs72627123	1	rs58204112	ENSG00000259065.1	RP5-1021I20.1	-4.21	3.03e-05	0.00512	-0.34	-0.19	Morning vs. evening chronotype;	chr14:73892714	chr14:73787360~73803270:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000280411.1	IGHV1-69-2	-4.21	3.03e-05	0.00513	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106680856	chr14:106762092~106762588:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000280411.1	IGHV1-69-2	-4.21	3.03e-05	0.00513	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106681320	chr14:106762092~106762588:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000280411.1	IGHV1-69-2	-4.21	3.03e-05	0.00513	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106682029	chr14:106762092~106762588:-
HNSC	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-4.21	3.03e-05	0.00513	-0.24	-0.19	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
HNSC	cis	rs4927850	0.529	rs6800500	ENSG00000231464.1	AC024937.4	4.21	3.03e-05	0.00513	0.21	0.19	Pancreatic cancer;	chr3:196106636	chr3:195996738~195998233:+
HNSC	cis	rs2686555	0.576	rs2686553	ENSG00000200795.1	RNU4-1	4.21	3.03e-05	0.00513	0.26	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr12:120639586	chr12:120293097~120293237:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	4.21	3.03e-05	0.00513	0.21	0.19	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
HNSC	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-4.21	3.03e-05	0.00513	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
HNSC	cis	rs1790761	0.505	rs17593068	ENSG00000184224.3	C11orf72	-4.21	3.03e-05	0.00513	-0.24	-0.19	Mean corpuscular volume;	chr11:67583461	chr11:67602880~67606706:-
HNSC	cis	rs7267979	0.844	rs6050477	ENSG00000204556.4	CTD-2514C3.1	4.21	3.03e-05	0.00513	0.24	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26018832~26020684:+
HNSC	cis	rs7948661	0.661	rs7116876	ENSG00000278376.1	RP11-158I9.8	4.21	3.03e-05	0.00513	0.36	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118500310	chr11:118791254~118793137:+
HNSC	cis	rs9287719	0.935	rs61424402	ENSG00000243819.4	RN7SL832P	4.21	3.03e-05	0.00513	0.18	0.19	Prostate cancer;	chr2:10618245	chr2:10690344~10692099:+
HNSC	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-4.21	3.03e-05	0.00513	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
HNSC	cis	rs9287719	0.967	rs6712304	ENSG00000243819.4	RN7SL832P	4.21	3.03e-05	0.00513	0.18	0.19	Prostate cancer;	chr2:10614249	chr2:10690344~10692099:+
HNSC	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	4.21	3.04e-05	0.00513	0.27	0.19	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
HNSC	cis	rs9910055	1	rs9910055	ENSG00000267080.4	ASB16-AS1	-4.21	3.04e-05	0.00514	-0.16	-0.19	Total body bone mineral density;	chr17:44205669	chr17:44175973~44186717:-
HNSC	cis	rs6601327	0.613	rs10094989	ENSG00000233609.3	RP11-62H7.2	4.21	3.04e-05	0.00514	0.18	0.19	Multiple myeloma (hyperdiploidy);	chr8:9754499	chr8:8961200~8979025:+
HNSC	cis	rs9487051	0.872	rs9386794	ENSG00000219700.1	PTCHD3P3	4.21	3.04e-05	0.00514	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109290318	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.898	rs882072	ENSG00000219700.1	PTCHD3P3	4.21	3.04e-05	0.00514	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109290603	chr6:109288571~109290503:-
HNSC	cis	rs7246657	0.551	rs4806414	ENSG00000276846.1	CTD-3220F14.3	4.21	3.04e-05	0.00514	0.3	0.19	Coronary artery calcification;	chr19:37147886	chr19:37314868~37315620:-
HNSC	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-4.21	3.04e-05	0.00514	-0.21	-0.19	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
HNSC	cis	rs3806843	0.551	rs184996	ENSG00000276545.1	PCDHGB9P	4.21	3.04e-05	0.00514	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140944188	chr5:141439853~141442449:+
HNSC	cis	rs853679	0.607	rs13208096	ENSG00000204709.4	LINC01556	4.21	3.04e-05	0.00514	0.38	0.19	Depression;	chr6:28257533	chr6:28943877~28944537:+
HNSC	cis	rs9487051	0.872	rs6924776	ENSG00000219700.1	PTCHD3P3	4.21	3.04e-05	0.00514	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109291073	chr6:109288571~109290503:-
HNSC	cis	rs9298506	1	rs4552882	ENSG00000254142.2	RP11-53M11.3	4.21	3.04e-05	0.00514	0.29	0.19	Intracranial aneurysm;	chr8:54549764	chr8:54554361~54561927:+
HNSC	cis	rs9880211	0.8	rs28390205	ENSG00000273486.1	RP11-731C17.2	4.21	3.04e-05	0.00514	0.19	0.19	Height;Body mass index;	chr3:136646008	chr3:136837338~136839021:-
HNSC	cis	rs9329221	0.537	rs2062331	ENSG00000269918.1	AF131215.9	-4.21	3.04e-05	0.00514	-0.18	-0.19	Neuroticism;	chr8:10122482	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	4.21	3.04e-05	0.00514	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
HNSC	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-4.21	3.04e-05	0.00514	-0.19	-0.19	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
HNSC	cis	rs1862618	0.671	rs2591957	ENSG00000271828.1	CTD-2310F14.1	-4.21	3.04e-05	0.00514	-0.24	-0.19	Initial pursuit acceleration;	chr5:56947319	chr5:56927874~56929573:+
HNSC	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	4.21	3.05e-05	0.00515	0.2	0.19	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
HNSC	cis	rs10129255	0.957	rs10140904	ENSG00000224373.3	IGHV4-59	4.21	3.05e-05	0.00515	0.12	0.19	Kawasaki disease;	chr14:106776558	chr14:106627249~106627825:-
HNSC	cis	rs56114371	0.568	rs200468	ENSG00000216901.1	AL022393.7	4.21	3.05e-05	0.00515	0.26	0.19	Breast cancer;	chr6:27790076	chr6:28176188~28176674:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-4.21	3.05e-05	0.00515	-0.24	-0.19	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
HNSC	cis	rs6651255	0.738	rs1989396	ENSG00000224110.3	MTRF1LP2	4.21	3.05e-05	0.00515	0.22	0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129744285	chr8:129728744~129730445:+
HNSC	cis	rs4356203	0.519	rs214084	ENSG00000272034.1	SNORD14A	-4.21	3.05e-05	0.00515	-0.15	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.519	rs214083	ENSG00000272034.1	SNORD14A	-4.21	3.05e-05	0.00515	-0.15	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17074654~17074744:-
HNSC	cis	rs2904524	0.588	rs968122	ENSG00000257815.4	RP11-611E13.2	4.21	3.05e-05	0.00515	0.19	0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70397835	chr12:69904033~70243360:-
HNSC	cis	rs17666538	0.585	rs1037393	ENSG00000254207.1	RP11-43A14.1	4.21	3.05e-05	0.00515	0.41	0.19	IgG glycosylation;	chr8:672634	chr8:725188~725877:-
HNSC	cis	rs11976180	1	rs2951308	ENSG00000244479.5	OR2A1-AS1	-4.21	3.05e-05	0.00515	-0.22	-0.19	Obesity-related traits;	chr7:144070056	chr7:144251264~144356181:-
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-4.21	3.05e-05	0.00516	-0.25	-0.19	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
HNSC	cis	rs889398	0.904	rs6499244	ENSG00000196696.11	PDXDC2P	-4.21	3.05e-05	0.00516	-0.13	-0.19	Body mass index;	chr16:69701368	chr16:69976297~70065948:-
HNSC	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	4.21	3.05e-05	0.00516	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
HNSC	cis	rs73198271	0.562	rs17154743	ENSG00000173295.6	FAM86B3P	-4.21	3.05e-05	0.00516	-0.26	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793277	chr8:8228595~8244865:+
HNSC	cis	rs9400271	0.632	rs9384706	ENSG00000243587.6	C6orf183	-4.21	3.05e-05	0.00516	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109280301	chr6:109165833~109271014:+
HNSC	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	4.21	3.05e-05	0.00516	0.22	0.19	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
HNSC	cis	rs35306767	0.903	rs12778891	ENSG00000229869.1	RP11-363N22.2	-4.21	3.05e-05	0.00516	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:904190	chr10:933026~942743:+
HNSC	cis	rs2905347	0.895	rs2961281	ENSG00000179428.2	AC073072.5	4.21	3.05e-05	0.00516	0.22	0.19	Major depression and alcohol dependence;	chr7:22600673	chr7:22725395~22727620:-
HNSC	cis	rs9326246	0.643	rs651821	ENSG00000280143.1	AP000892.6	4.21	3.05e-05	0.00516	0.35	0.19	Coronary artery disease;	chr11:116791863	chr11:117204967~117210292:+
HNSC	cis	rs10242455	0.702	rs10251282	ENSG00000078319.8	PMS2P1	-4.21	3.06e-05	0.00516	-0.4	-0.19	Blood metabolite levels;	chr7:99392613	chr7:100320992~100341908:-
HNSC	cis	rs10242455	0.702	rs28460612	ENSG00000078319.8	PMS2P1	-4.21	3.06e-05	0.00516	-0.4	-0.19	Blood metabolite levels;	chr7:99395582	chr7:100320992~100341908:-
HNSC	cis	rs2919917	0.628	rs2717544	ENSG00000260398.1	RP11-594N15.3	-4.21	3.06e-05	0.00516	-0.25	-0.19	Lymphocyte counts;	chr8:78724307	chr8:78605952~78609705:+
HNSC	cis	rs597539	0.652	rs673821	ENSG00000255741.1	RP11-757G1.5	-4.21	3.06e-05	0.00516	-0.26	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68941503~68942852:-
HNSC	cis	rs11722779	0.933	rs7695096	ENSG00000230069.3	LRRC37A15P	-4.21	3.06e-05	0.00516	-0.19	-0.19	Schizophrenia;	chr4:103011399	chr4:102727274~102730721:-
HNSC	cis	rs9400271	0.632	rs9487020	ENSG00000243587.6	C6orf183	-4.21	3.06e-05	0.00517	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109266469	chr6:109165833~109271014:+
HNSC	cis	rs4372836	1	rs7579277	ENSG00000226833.4	AC097724.3	4.21	3.06e-05	0.00517	0.24	0.19	Body mass index;	chr2:28773429	chr2:28708953~28736205:-
HNSC	cis	rs4819052	0.851	rs2838826	ENSG00000223768.1	LINC00205	-4.21	3.06e-05	0.00517	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45293285~45297354:+
HNSC	cis	rs853679	0.517	rs1904840	ENSG00000219891.2	ZSCAN12P1	4.21	3.06e-05	0.00517	0.27	0.19	Depression;	chr6:28140454	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368555	ENSG00000219891.2	ZSCAN12P1	4.21	3.06e-05	0.00517	0.27	0.19	Depression;	chr6:28141189	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393893	ENSG00000219891.2	ZSCAN12P1	4.21	3.06e-05	0.00517	0.27	0.19	Depression;	chr6:28141484	chr6:28091154~28093664:+
HNSC	cis	rs9311676	0.656	rs68021431	ENSG00000273493.1	RP11-80H18.4	4.21	3.06e-05	0.00517	0.21	0.19	Systemic lupus erythematosus;	chr3:58417409	chr3:58329965~58330118:+
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	4.21	3.06e-05	0.00517	0.23	0.19	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	4.21	3.06e-05	0.00517	0.25	0.19	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
HNSC	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-4.21	3.06e-05	0.00517	-0.2	-0.19	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-4.21	3.06e-05	0.00517	-0.22	-0.19	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
HNSC	cis	rs561341	1	rs72825712	ENSG00000278867.1	RP11-640N20.4	-4.21	3.06e-05	0.00517	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31989100	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs560132	ENSG00000278867.1	RP11-640N20.4	-4.21	3.06e-05	0.00517	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31993000	chr17:32051030~32053208:+
HNSC	cis	rs73198271	1	rs55971558	ENSG00000253893.2	FAM85B	4.21	3.06e-05	0.00517	0.28	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr8:8167819~8226614:-
HNSC	cis	rs8028182	0.636	rs11637068	ENSG00000260269.4	CTD-2323K18.1	-4.21	3.06e-05	0.00517	-0.25	-0.19	Sudden cardiac arrest;	chr15:75450661	chr15:75527150~75601205:-
HNSC	cis	rs6787172	0.783	rs12489496	ENSG00000272087.1	RP11-379F4.7	4.21	3.06e-05	0.00517	0.2	0.19	Subjective well-being;	chr3:158518455	chr3:158693120~158693768:-
HNSC	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-4.21	3.06e-05	0.00517	-0.22	-0.19	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
HNSC	cis	rs12478296	0.792	rs6738361	ENSG00000261186.2	RP11-341N2.1	-4.21	3.06e-05	0.00517	-0.32	-0.19	Obesity-related traits;	chr2:242072106	chr2:242087351~242088457:-
HNSC	cis	rs137699	0.959	rs5757633	ENSG00000261202.1	RP3-496C20.1	-4.21	3.06e-05	0.00517	-0.22	-0.19	IgG glycosylation;	chr22:39360265	chr22:40043068~40044530:-
HNSC	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-4.21	3.06e-05	0.00518	-0.23	-0.19	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-4.21	3.06e-05	0.00518	-0.23	-0.19	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-4.21	3.06e-05	0.00518	-0.23	-0.19	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-4.21	3.06e-05	0.00518	-0.23	-0.19	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-4.21	3.06e-05	0.00518	-0.23	-0.19	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
HNSC	cis	rs467650	0.509	rs27575	ENSG00000246763.5	RGMB-AS1	4.21	3.06e-05	0.00518	0.21	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98649207	chr5:98769618~98773469:-
HNSC	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	4.21	3.06e-05	0.00518	0.3	0.19	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
HNSC	cis	rs7868228	1	rs7853884	ENSG00000240498.5	CDKN2B-AS1	4.21	3.06e-05	0.00518	0.25	0.19	Gut microbiome composition (winter);	chr9:21667374	chr9:21994778~22121097:+
HNSC	cis	rs9923283	1	rs9888858	ENSG00000183604.13	SMG1P5	4.21	3.06e-05	0.00518	0.28	0.19	Plateletcrit;	chr16:29645556	chr16:30267553~30335374:-
HNSC	cis	rs2098713	0.544	rs2056870	ENSG00000250155.1	CTD-2353F22.1	-4.21	3.07e-05	0.00518	-0.21	-0.19	Telomere length;	chr5:37424947	chr5:36666214~36725195:-
HNSC	cis	rs2985684	1	rs11157696	ENSG00000278009.1	RP11-649E7.8	-4.21	3.07e-05	0.00518	-0.25	-0.19	Carotid intima media thickness;	chr14:49639028	chr14:49601011~49601124:-
HNSC	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	4.21	3.07e-05	0.00518	0.23	0.19	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
HNSC	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-4.21	3.07e-05	0.00518	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
HNSC	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-4.21	3.07e-05	0.00518	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
HNSC	cis	rs4321325	0.733	rs111245735	ENSG00000236682.1	AC068282.3	-4.21	3.07e-05	0.00518	-0.34	-0.19	Protein C levels;	chr2:127184946	chr2:127389130~127400580:+
HNSC	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	4.21	3.07e-05	0.00518	0.27	0.19	Pain;	chr19:21300986	chr19:21554640~21569237:-
HNSC	cis	rs1659258	0.527	rs1258391	ENSG00000232508.1	MRPL45P1	-4.21	3.07e-05	0.00518	-0.33	-0.19	Visceral fat;	chr2:88315705	chr2:88364695~88365608:-
HNSC	cis	rs6951245	0.572	rs73265911	ENSG00000225146.1	AC073957.15	-4.21	3.07e-05	0.00518	-0.34	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1015727	chr7:1029025~1043891:+
HNSC	cis	rs11098499	0.754	rs878376	ENSG00000250412.1	KLHL2P1	4.21	3.07e-05	0.00519	0.25	0.19	Corneal astigmatism;	chr4:119316547	chr4:119334329~119378233:+
HNSC	cis	rs7475343	0.501	rs3750571	ENSG00000224034.1	RP11-445P17.8	4.21	3.07e-05	0.00519	0.27	0.19	Intelligence;	chr10:5205471	chr10:5266033~5271236:-
HNSC	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-4.21	3.07e-05	0.00519	-0.21	-0.19	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
HNSC	cis	rs2905347	0.965	rs2961272	ENSG00000179428.2	AC073072.5	4.21	3.07e-05	0.00519	0.23	0.19	Major depression and alcohol dependence;	chr7:22585117	chr7:22725395~22727620:-
HNSC	cis	rs9903692	0.954	rs8065670	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48096478	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.866	rs11079807	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48098685	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs10853094	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48098700	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs4794441	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48099094	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.908	rs12950402	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48102752	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs4794448	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48103445	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs68175794	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48103742	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.862	rs12943543	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48104003	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs4794451	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48107419	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.862	rs4794453	ENSG00000263412.1	RP5-890E16.2	4.21	3.07e-05	0.00519	0.18	0.19	Pulse pressure;	chr17:48107564	chr17:48045141~48048073:-
HNSC	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	4.21	3.08e-05	0.00519	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	4.21	3.08e-05	0.00519	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
HNSC	cis	rs6601327	0.641	rs11780399	ENSG00000233609.3	RP11-62H7.2	-4.21	3.08e-05	0.00519	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9731657	chr8:8961200~8979025:+
HNSC	cis	rs454217	0.875	rs7958204	ENSG00000277851.1	RP11-756G20.1	4.21	3.08e-05	0.00519	0.2	0.19	Smoking quantity;	chr12:92323167	chr12:92247756~92363832:-
HNSC	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	4.21	3.08e-05	0.00519	0.18	0.19	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
HNSC	cis	rs889398	0.802	rs2937121	ENSG00000226232.7	RP11-419C5.2	4.21	3.08e-05	0.00519	0.17	0.19	Body mass index;	chr16:69836506	chr16:69976388~69996188:-
HNSC	cis	rs11098499	0.863	rs11098532	ENSG00000250412.1	KLHL2P1	4.21	3.08e-05	0.0052	0.25	0.19	Corneal astigmatism;	chr4:119569571	chr4:119334329~119378233:+
HNSC	cis	rs853679	0.824	rs34712084	ENSG00000226314.6	ZNF192P1	-4.21	3.08e-05	0.0052	-0.3	-0.19	Depression;	chr6:28076050	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.824	rs1321505	ENSG00000226314.6	ZNF192P1	-4.21	3.08e-05	0.0052	-0.3	-0.19	Depression;	chr6:28085045	chr6:28161781~28169594:+
HNSC	cis	rs516805	0.667	rs2606600	ENSG00000279453.1	RP3-425C14.4	4.21	3.08e-05	0.0052	0.27	0.19	Lymphocyte counts;	chr6:122204398	chr6:122436789~122439223:-
HNSC	cis	rs11893307	0.599	rs12617417	ENSG00000235852.1	AC005540.3	4.21	3.08e-05	0.0052	0.27	0.19	Mean platelet volume;	chr2:190798845	chr2:190880797~190882059:-
HNSC	cis	rs9768139	0.733	rs12698208	ENSG00000223872.1	AC006372.5	-4.21	3.08e-05	0.0052	-0.2	-0.19	Calcium levels;	chr7:158324883	chr7:157501322~157503577:+
HNSC	cis	rs2333021	0.78	rs28619241	ENSG00000258376.2	RP4-647C14.2	-4.21	3.08e-05	0.0052	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72972902	chr14:73242651~73245979:-
HNSC	cis	rs2333021	0.78	rs12931	ENSG00000258376.2	RP4-647C14.2	-4.21	3.08e-05	0.0052	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72974156	chr14:73242651~73245979:-
HNSC	cis	rs2980439	0.783	rs2948305	ENSG00000233609.3	RP11-62H7.2	4.21	3.08e-05	0.0052	0.19	0.19	Neuroticism;	chr8:8241055	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.579	rs7006589	ENSG00000173295.6	FAM86B3P	4.21	3.08e-05	0.0052	0.22	0.19	Neuroticism;	chr8:8810976	chr8:8228595~8244865:+
HNSC	cis	rs3018712	0.59	rs2156464	ENSG00000255031.4	RP11-802E16.3	-4.21	3.08e-05	0.0052	-0.2	-0.19	Total body bone mineral density;	chr11:68659776	chr11:68050740~68053762:+
HNSC	cis	rs9650657	0.645	rs56057779	ENSG00000255310.2	AF131215.2	-4.21	3.08e-05	0.0052	-0.18	-0.19	Neuroticism;	chr8:10659370	chr8:11107788~11109726:-
HNSC	cis	rs11083475	0.557	rs2368519	ENSG00000207296.1	RNU6-140P	-4.21	3.08e-05	0.0052	-0.19	-0.19	Heart rate;	chr19:38768601	chr19:38797002~38797109:-
HNSC	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	4.21	3.08e-05	0.0052	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
HNSC	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	4.21	3.08e-05	0.0052	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
HNSC	cis	rs7429990	0.864	rs13085978	ENSG00000228638.1	FCF1P2	-4.21	3.09e-05	0.00521	-0.18	-0.19	Educational attainment (years of education);	chr3:47608585	chr3:48290793~48291375:-
HNSC	cis	rs62458065	0.85	rs7804998	ENSG00000226468.2	AC018641.7	4.21	3.09e-05	0.00521	0.31	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32421585	chr7:32456963~32457758:-
HNSC	cis	rs7630852	0.965	rs6774504	ENSG00000236833.1	AC024560.2	-4.21	3.09e-05	0.00521	-0.2	-0.19	Eosinophil counts;	chr3:196784021	chr3:197660565~197665757:-
HNSC	cis	rs73198271	0.74	rs10113326	ENSG00000233609.3	RP11-62H7.2	-4.21	3.09e-05	0.00521	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8961200~8979025:+
HNSC	cis	rs5758511	0.68	rs56111723	ENSG00000226450.2	CYP2D8P	4.21	3.09e-05	0.00521	0.18	0.19	Birth weight;	chr22:42268877	chr22:42149886~42155001:-
HNSC	cis	rs1008375	1	rs4698634	ENSG00000249502.1	AC006160.5	4.21	3.09e-05	0.00521	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628569	chr4:17587467~17614571:-
HNSC	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-4.21	3.09e-05	0.00521	-0.24	-0.19	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
HNSC	cis	rs73186030	0.748	rs16832956	ENSG00000272758.4	RP11-299J3.8	4.21	3.09e-05	0.00522	0.21	0.19	Serum parathyroid hormone levels;	chr3:122298661	chr3:122416207~122443180:+
HNSC	cis	rs3096299	0.679	rs3096322	ENSG00000261574.1	RP1-168P16.2	-4.21	3.09e-05	0.00522	-0.24	-0.19	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89392375~89412564:-
HNSC	cis	rs7824557	0.583	rs4448232	ENSG00000255495.1	AC145124.2	4.21	3.09e-05	0.00522	0.22	0.19	Retinal vascular caliber;	chr8:11373845	chr8:12194467~12196280:+
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000211974.3	IGHV2-70	4.21	3.09e-05	0.00522	0.18	0.19	Kawasaki disease;	chr14:106787730	chr14:106723574~106724093:-
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-4.21	3.09e-05	0.00522	-0.23	-0.19	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
HNSC	cis	rs9487051	0.872	rs9386789	ENSG00000219700.1	PTCHD3P3	4.21	3.1e-05	0.00522	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109282015	chr6:109288571~109290503:-
HNSC	cis	rs17655565	0.537	rs67353063	ENSG00000257500.1	RP11-1020M18.10	-4.21	3.1e-05	0.00522	-0.32	-0.19	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52408561	chr12:52407580~52428494:+
HNSC	cis	rs9650657	0.707	rs4593498	ENSG00000255310.2	AF131215.2	-4.21	3.1e-05	0.00522	-0.18	-0.19	Neuroticism;	chr8:10797960	chr8:11107788~11109726:-
HNSC	cis	rs3806843	0.576	rs246064	ENSG00000276545.1	PCDHGB9P	4.21	3.1e-05	0.00522	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140944724	chr5:141439853~141442449:+
HNSC	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	4.21	3.1e-05	0.00522	0.24	0.19	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	4.21	3.1e-05	0.00522	0.24	0.19	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	4.21	3.1e-05	0.00522	0.24	0.19	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
HNSC	cis	rs9907295	0.688	rs4572457	ENSG00000270977.1	AC015849.16	-4.21	3.1e-05	0.00522	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35813645	chr17:35893707~35911023:-
HNSC	cis	rs58785573	0.624	rs2126526	ENSG00000231160.8	KLF3-AS1	-4.21	3.1e-05	0.00523	-0.18	-0.19	Lymphocyte percentage of white cells;	chr4:38617068	chr4:38612701~38664883:-
HNSC	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.3	0.19	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.3	0.19	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
HNSC	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	4.21	3.1e-05	0.00523	0.15	0.19	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
HNSC	cis	rs2492286	0.518	rs2712412	ENSG00000242551.2	POU5F1P6	-4.21	3.1e-05	0.00523	-0.2	-0.19	Eosinophil counts;	chr3:128647208	chr3:128674735~128677005:-
HNSC	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	4.21	3.1e-05	0.00523	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
HNSC	cis	rs9650657	0.871	rs7814142	ENSG00000269918.1	AF131215.9	-4.21	3.1e-05	0.00523	-0.19	-0.19	Neuroticism;	chr8:10780042	chr8:11104691~11106704:-
HNSC	cis	rs847649	0.842	rs4729860	ENSG00000239969.4	RP11-163E9.2	4.21	3.1e-05	0.00523	0.23	0.19	Morning vs. evening chronotype;	chr7:102985120	chr7:102364162~102380633:+
HNSC	cis	rs67072384	1	rs72964198	ENSG00000213365.3	AP000593.6	4.21	3.1e-05	0.00523	0.33	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72735419	chr11:72280151~72281178:+
HNSC	cis	rs11673344	0.504	rs8099987	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.21	0.19	Obesity-related traits;	chr19:37132570	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs8110796	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.21	0.19	Obesity-related traits;	chr19:37132682	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs8111285	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.21	0.19	Obesity-related traits;	chr19:37132747	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs6510591	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.21	0.19	Obesity-related traits;	chr19:37133186	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs6510592	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00523	0.21	0.19	Obesity-related traits;	chr19:37133430	chr19:37314868~37315620:-
HNSC	cis	rs12701220	0.689	rs12536282	ENSG00000229043.2	AC091729.9	-4.21	3.1e-05	0.00523	-0.29	-0.19	Bronchopulmonary dysplasia;	chr7:1076014	chr7:1160374~1165267:+
HNSC	cis	rs4761669	0.816	rs4761671	ENSG00000241556.1	RP11-490G8.1	-4.21	3.1e-05	0.00523	-0.19	-0.19	Common carotid intima-media thickness in HIV infection;	chr12:94807038	chr12:95467397~95467861:-
HNSC	cis	rs67072384	1	rs12292781	ENSG00000213365.3	AP000593.6	4.21	3.1e-05	0.00523	0.32	0.19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737340	chr11:72280151~72281178:+
HNSC	cis	rs757081	0.648	rs214907	ENSG00000260196.1	RP1-239B22.5	-4.21	3.1e-05	0.00523	-0.2	-0.19	Systolic blood pressure;	chr11:17223232	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.543	rs214088	ENSG00000260196.1	RP1-239B22.5	-4.21	3.1e-05	0.00523	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17380649~17383531:+
HNSC	cis	rs10510102	0.507	rs12244092	ENSG00000226864.1	ATE1-AS1	4.21	3.1e-05	0.00523	0.33	0.19	Breast cancer;	chr10:122005769	chr10:121928312~121951965:+
HNSC	cis	rs7071275	0.525	rs1649187	ENSG00000223432.1	RP11-62L18.3	-4.21	3.1e-05	0.00523	-0.25	-0.19	Dupuytren's disease;	chr10:121620879	chr10:121615425~121615839:-
HNSC	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-4.21	3.11e-05	0.00524	-0.22	-0.19	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-4.21	3.11e-05	0.00524	-0.22	-0.19	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
HNSC	cis	rs2904524	1	rs74768022	ENSG00000257815.4	RP11-611E13.2	-4.21	3.11e-05	0.00524	-0.24	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70333874	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs17107996	ENSG00000257815.4	RP11-611E13.2	-4.21	3.11e-05	0.00524	-0.24	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70334297	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs74823021	ENSG00000257815.4	RP11-611E13.2	-4.21	3.11e-05	0.00524	-0.24	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70334627	chr12:69904033~70243360:-
HNSC	cis	rs4660261	0.526	rs803680	ENSG00000237950.1	RP11-7O11.3	4.21	3.11e-05	0.00524	0.21	0.19	Intelligence (multi-trait analysis);	chr1:43898698	chr1:43944370~43946551:-
HNSC	cis	rs3011225	0.691	rs3791102	ENSG00000237950.1	RP11-7O11.3	4.21	3.11e-05	0.00524	0.21	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43900945	chr1:43944370~43946551:-
HNSC	cis	rs3736485	0.844	rs4775943	ENSG00000259438.1	CTD-2650P22.1	4.21	3.11e-05	0.00524	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51477908	chr15:52010999~52019095:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66046610	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66049744	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66051386	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66052736	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000230295.1	RP11-458F8.2	-4.21	3.11e-05	0.00524	-0.26	-0.19	Diabetic kidney disease;	chr7:66055492	chr7:66880708~66882981:+
HNSC	cis	rs35306767	0.855	rs61830932	ENSG00000229869.1	RP11-363N22.2	-4.21	3.11e-05	0.00524	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:888243	chr10:933026~942743:+
HNSC	cis	rs9487051	0.597	rs351730	ENSG00000243587.6	C6orf183	-4.21	3.11e-05	0.00524	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109189563	chr6:109165833~109271014:+
HNSC	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	4.21	3.11e-05	0.00524	0.26	0.19	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
HNSC	cis	rs4321325	0.733	rs78593261	ENSG00000236682.1	AC068282.3	-4.21	3.11e-05	0.00524	-0.33	-0.19	Protein C levels;	chr2:127189468	chr2:127389130~127400580:+
HNSC	cis	rs4321325	0.733	rs75834205	ENSG00000236682.1	AC068282.3	-4.21	3.11e-05	0.00524	-0.33	-0.19	Protein C levels;	chr2:127189661	chr2:127389130~127400580:+
HNSC	cis	rs1009077	0.716	rs13147817	ENSG00000245958.5	RP11-33B1.1	4.21	3.11e-05	0.00525	0.22	0.19	Endometriosis;	chr4:119634500	chr4:119454791~119552025:+
HNSC	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	4.21	3.11e-05	0.00525	0.21	0.19	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
HNSC	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-4.21	3.11e-05	0.00525	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
HNSC	cis	rs6026584	1	rs2057291	ENSG00000270951.1	RP1-309F20.4	-4.21	3.11e-05	0.00525	-0.21	-0.19	Renal function-related traits (BUN);	chr20:58896988	chr20:58876592~58876981:-
HNSC	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-4.21	3.11e-05	0.00525	-0.25	-0.19	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
HNSC	cis	rs9859260	0.701	rs9872347	ENSG00000231464.1	AC024937.4	4.21	3.11e-05	0.00525	0.21	0.19	Mean corpuscular volume;	chr3:196104366	chr3:195996738~195998233:+
HNSC	cis	rs72627123	1	rs45559033	ENSG00000259065.1	RP5-1021I20.1	-4.21	3.12e-05	0.00525	-0.34	-0.19	Morning vs. evening chronotype;	chr14:73874421	chr14:73787360~73803270:+
HNSC	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	4.21	3.12e-05	0.00525	0.3	0.19	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
HNSC	cis	rs9926296	0.712	rs2437957	ENSG00000274627.1	RP11-104N10.2	4.21	3.12e-05	0.00525	0.19	0.19	Vitiligo;	chr16:89649240	chr16:89516797~89522217:+
HNSC	cis	rs2247572	0.564	rs1595875	ENSG00000250295.5	RP11-434I12.2	4.21	3.12e-05	0.00525	0.25	0.19	Cognitive performance;	chr8:72658921	chr8:73297711~73356461:-
HNSC	cis	rs6500395	1	rs3817029	ENSG00000261267.1	RP11-44I10.3	-4.21	3.12e-05	0.00525	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48551031	chr16:48559661~48587403:+
HNSC	cis	rs10129255	0.957	rs8009638	ENSG00000280411.1	IGHV1-69-2	-4.21	3.12e-05	0.00526	-0.14	-0.19	Kawasaki disease;	chr14:106777570	chr14:106762092~106762588:-
HNSC	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-4.21	3.12e-05	0.00526	-0.18	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
HNSC	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-4.21	3.12e-05	0.00526	-0.18	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
HNSC	cis	rs62458065	0.85	rs10273165	ENSG00000226468.2	AC018641.7	4.21	3.12e-05	0.00526	0.31	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32421228	chr7:32456963~32457758:-
HNSC	cis	rs62458065	0.85	rs7785659	ENSG00000226468.2	AC018641.7	4.21	3.12e-05	0.00526	0.31	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32421403	chr7:32456963~32457758:-
HNSC	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	4.21	3.12e-05	0.00526	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
HNSC	cis	rs9329221	0.537	rs12678800	ENSG00000269918.1	AF131215.9	4.21	3.12e-05	0.00526	0.18	0.19	Neuroticism;	chr8:10121430	chr8:11104691~11106704:-
HNSC	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-4.21	3.12e-05	0.00526	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
HNSC	cis	rs17594362	0.573	rs79859984	ENSG00000229473.2	RGS17P1	-4.21	3.12e-05	0.00526	-0.3	-0.19	Multiple sclerosis;	chr13:41573291	chr13:40992779~40993331:-
HNSC	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	4.21	3.12e-05	0.00526	0.27	0.19	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
HNSC	cis	rs440932	1	rs378974	ENSG00000254153.1	CTA-398F10.2	4.21	3.13e-05	0.00526	0.22	0.19	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8456909~8461337:-
HNSC	cis	rs4713118	0.505	rs156740	ENSG00000217862.2	HIST1H4PS1	-4.21	3.13e-05	0.00527	-0.2	-0.19	Parkinson's disease;	chr6:27992657	chr6:27807075~27807339:+
HNSC	cis	rs9650657	0.571	rs4240673	ENSG00000255310.2	AF131215.2	-4.21	3.13e-05	0.00527	-0.18	-0.19	Neuroticism;	chr8:10930102	chr8:11107788~11109726:-
HNSC	cis	rs7005380	0.965	rs9918815	ENSG00000279347.1	RP11-85I17.2	4.21	3.13e-05	0.00527	0.16	0.19	Interstitial lung disease;	chr8:119939370	chr8:119838736~119840385:-
HNSC	cis	rs7771547	0.573	rs546353	ENSG00000219023.1	RP3-340B19.2	4.21	3.13e-05	0.00527	0.17	0.19	Platelet distribution width;	chr6:36430820	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs547026	ENSG00000219023.1	RP3-340B19.2	4.21	3.13e-05	0.00527	0.17	0.19	Platelet distribution width;	chr6:36430839	chr6:35555873~35556264:+
HNSC	cis	rs9813712	0.953	rs6782280	ENSG00000228252.7	COL6A4P2	4.21	3.13e-05	0.00527	0.2	0.19	Response to amphetamines;	chr3:130245370	chr3:130212823~130273806:+
HNSC	cis	rs12701220	0.503	rs12702047	ENSG00000224079.1	AC091729.7	4.21	3.13e-05	0.00527	0.3	0.19	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1074450~1078036:+
HNSC	cis	rs9311676	0.656	rs11923253	ENSG00000273493.1	RP11-80H18.4	4.21	3.13e-05	0.00527	0.21	0.19	Systemic lupus erythematosus;	chr3:58391265	chr3:58329965~58330118:+
HNSC	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs9998585	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119475647	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs6842762	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119477081	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs11098527	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119478751	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs6822679	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119481547	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs4577559	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119482888	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs7656252	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119483113	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs28845498	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119484031	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs28753180	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119484212	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs56270433	ENSG00000250412.1	KLHL2P1	4.21	3.13e-05	0.00527	0.25	0.19	Corneal astigmatism;	chr4:119484875	chr4:119334329~119378233:+
HNSC	cis	rs9531006	0.571	rs6563150	ENSG00000227676.3	LINC01068	4.2	3.13e-05	0.00527	0.29	0.19	Sleep duration;	chr13:79926969	chr13:79566727~79571436:+
HNSC	cis	rs12745968	0.653	rs7418336	ENSG00000223787.2	RP4-593M8.1	-4.2	3.13e-05	0.00527	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92697828	chr1:92580476~92580821:-
HNSC	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	4.2	3.13e-05	0.00527	0.29	0.19	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	4.2	3.13e-05	0.00527	0.29	0.19	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	4.2	3.13e-05	0.00527	0.29	0.19	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	4.2	3.13e-05	0.00527	0.29	0.19	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	4.2	3.13e-05	0.00527	0.29	0.19	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
HNSC	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-4.2	3.13e-05	0.00528	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
HNSC	cis	rs889398	0.933	rs6499240	ENSG00000226232.7	RP11-419C5.2	-4.2	3.13e-05	0.00528	-0.17	-0.19	Body mass index;	chr16:69653009	chr16:69976388~69996188:-
HNSC	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-4.2	3.13e-05	0.00528	-0.21	-0.19	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
HNSC	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	4.2	3.13e-05	0.00528	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
HNSC	cis	rs71520386	1	rs71520386	ENSG00000221740.1	SNORD93	-4.2	3.14e-05	0.00528	-0.26	-0.19	Fibrinogen levels;	chr7:22813902	chr7:22856613~22856686:+
HNSC	cis	rs4253772	0.637	rs9627350	ENSG00000277232.2	GTSE1-AS1	-4.2	3.14e-05	0.00528	-0.24	-0.19	Cholesterol, total;LDL cholesterol;	chr22:46267120	chr22:46295143~46296660:-
HNSC	cis	rs763121	0.719	rs138699	ENSG00000273076.1	RP3-508I15.22	4.2	3.14e-05	0.00528	0.21	0.19	Menopause (age at onset);	chr22:38733703	chr22:38743495~38743910:+
HNSC	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	4.2	3.14e-05	0.00529	0.23	0.19	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
HNSC	cis	rs74024059	1	rs2593281	ENSG00000260269.4	CTD-2323K18.1	-4.2	3.14e-05	0.00529	-0.47	-0.19	Red blood cell count;Hematocrit;	chr15:75860847	chr15:75527150~75601205:-
HNSC	cis	rs74024059	0.661	rs2604403	ENSG00000260269.4	CTD-2323K18.1	-4.2	3.14e-05	0.00529	-0.47	-0.19	Red blood cell count;Hematocrit;	chr15:75861341	chr15:75527150~75601205:-
HNSC	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	4.2	3.14e-05	0.00529	0.24	0.19	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
HNSC	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-4.2	3.14e-05	0.00529	-0.25	-0.19	Pain;	chr19:21491155	chr19:21554640~21569237:-
HNSC	cis	rs516805	0.748	rs12211993	ENSG00000279453.1	RP3-425C14.4	4.2	3.14e-05	0.00529	0.27	0.19	Lymphocyte counts;	chr6:122570216	chr6:122436789~122439223:-
HNSC	cis	rs6500395	1	rs28577888	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48639370	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs7201196	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48640119	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.962	rs9936883	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48642532	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9933237	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48642651	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9933314	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48642697	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs4517800	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48643493	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9936467	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48644072	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9938633	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48648182	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs9930365	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48648243	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs8052073	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48648785	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs4493038	ENSG00000261267.1	RP11-44I10.3	-4.2	3.14e-05	0.00529	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48650009	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs2883642	ENSG00000261267.1	RP11-44I10.3	4.2	3.14e-05	0.00529	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48651235	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs2355297	ENSG00000261267.1	RP11-44I10.3	4.2	3.14e-05	0.00529	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48651427	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs4785247	ENSG00000261267.1	RP11-44I10.3	4.2	3.14e-05	0.00529	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48653821	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs4785248	ENSG00000261267.1	RP11-44I10.3	4.2	3.14e-05	0.00529	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48654036	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.889	rs2080507	ENSG00000261267.1	RP11-44I10.3	4.2	3.14e-05	0.00529	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48654723	chr16:48559661~48587403:+
HNSC	cis	rs6928977	0.869	rs6912933	ENSG00000217482.2	HMGB1P17	-4.2	3.14e-05	0.00529	-0.21	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306396	chr6:135636086~135636713:-
HNSC	cis	rs9467773	0.626	rs6935803	ENSG00000241549.7	GUSBP2	4.2	3.15e-05	0.00529	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26350267	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.626	rs6936006	ENSG00000241549.7	GUSBP2	4.2	3.15e-05	0.00529	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26350337	chr6:26871484~26956554:-
HNSC	cis	rs8014204	0.604	rs2159906	ENSG00000279594.1	RP11-950C14.10	4.2	3.15e-05	0.0053	0.23	0.19	Caffeine consumption;	chr14:74924209	chr14:75011269~75012851:-
HNSC	cis	rs1008375	0.932	rs10029173	ENSG00000249502.1	AC006160.5	4.2	3.15e-05	0.0053	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657975	chr4:17587467~17614571:-
HNSC	cis	rs6688613	1	rs6682062	ENSG00000215834.7	FMO9P	-4.2	3.15e-05	0.0053	-0.23	-0.19	Refractive astigmatism;	chr1:166980742	chr1:166603675~166631400:+
HNSC	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	4.2	3.15e-05	0.0053	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.501	rs2980769	ENSG00000254340.1	RP11-10A14.3	4.2	3.15e-05	0.0053	0.22	0.19	Mood instability;	chr8:8462781	chr8:9141424~9145435:+
HNSC	cis	rs3808502	0.527	rs2736389	ENSG00000269918.1	AF131215.9	4.2	3.15e-05	0.0053	0.21	0.19	Neuroticism;	chr8:11303801	chr8:11104691~11106704:-
HNSC	cis	rs4908760	0.566	rs7532459	ENSG00000232912.4	RP5-1115A15.1	4.2	3.15e-05	0.0053	0.21	0.19	Vitiligo;	chr1:8617714	chr1:8424645~8434838:+
HNSC	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	4.2	3.15e-05	0.0053	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
HNSC	cis	rs4853525	0.818	rs4853520	ENSG00000228509.4	AC006460.2	4.2	3.15e-05	0.0053	0.23	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854772	chr2:190676944~190708716:-
HNSC	cis	rs7580658	0.963	rs12991768	ENSG00000236682.1	AC068282.3	-4.2	3.15e-05	0.0053	-0.22	-0.19	Protein C levels;	chr2:127388669	chr2:127389130~127400580:+
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000233609.3	RP11-62H7.2	-4.2	3.15e-05	0.0053	-0.19	-0.19	Recombination measurement;	chr8:9202567	chr8:8961200~8979025:+
HNSC	cis	rs7630852	1	rs7626440	ENSG00000236833.1	AC024560.2	4.2	3.15e-05	0.00531	0.19	0.19	Eosinophil counts;	chr3:196778019	chr3:197660565~197665757:-
HNSC	cis	rs6928977	0.714	rs11154801	ENSG00000231028.7	LINC00271	-4.2	3.15e-05	0.00531	-0.23	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135497801~135716055:+
HNSC	cis	rs12745968	0.62	rs7535490	ENSG00000223787.2	RP4-593M8.1	-4.2	3.16e-05	0.00531	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92596292	chr1:92580476~92580821:-
HNSC	cis	rs9531006	0.636	rs4885683	ENSG00000227676.3	LINC01068	4.2	3.16e-05	0.00531	0.29	0.19	Sleep duration;	chr13:79923049	chr13:79566727~79571436:+
HNSC	cis	rs6840258	1	rs72667752	ENSG00000251411.1	RP11-397E7.4	-4.2	3.16e-05	0.00531	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87018379	chr4:86913266~86914817:-
HNSC	cis	rs6840258	1	rs72667754	ENSG00000251411.1	RP11-397E7.4	-4.2	3.16e-05	0.00531	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87020909	chr4:86913266~86914817:-
HNSC	cis	rs9487051	0.872	rs1111864	ENSG00000219700.1	PTCHD3P3	4.2	3.16e-05	0.00531	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109289935	chr6:109288571~109290503:-
HNSC	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	4.2	3.16e-05	0.00531	0.23	0.19	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
HNSC	cis	rs12285276	0.636	rs7114337	ENSG00000205106.4	DKFZp779M0652	4.2	3.16e-05	0.00531	0.29	0.19	Visceral fat;	chr11:45779608	chr11:45771432~45772358:+
HNSC	cis	rs7772486	0.777	rs1546966	ENSG00000235652.6	RP11-545I5.3	4.2	3.16e-05	0.00531	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145799409~145886585:+
HNSC	cis	rs9863	0.827	rs4930706	ENSG00000270028.1	RP11-380L11.4	4.2	3.16e-05	0.00531	0.22	0.19	White blood cell count;	chr12:123932791	chr12:123925461~123926083:-
HNSC	cis	rs757081	0.667	rs12577418	ENSG00000260196.1	RP1-239B22.5	-4.2	3.16e-05	0.00531	-0.24	-0.19	Systolic blood pressure;	chr11:17080007	chr11:17380649~17383531:+
HNSC	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	4.2	3.16e-05	0.00531	0.21	0.19	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
HNSC	cis	rs72843166	0.562	rs17687323	ENSG00000265282.1	RP11-269G24.4	4.2	3.16e-05	0.00531	0.29	0.19	Intelligence (multi-trait analysis);	chr17:63355505	chr17:63430468~63432211:-
HNSC	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-4.2	3.16e-05	0.00531	-0.25	-0.19	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
HNSC	cis	rs3736485	0.789	rs6493499	ENSG00000259438.1	CTD-2650P22.1	4.2	3.16e-05	0.00532	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51520645	chr15:52010999~52019095:-
HNSC	cis	rs13434995	0.513	rs62303722	ENSG00000273257.1	RP11-177J6.1	-4.2	3.16e-05	0.00532	-0.26	-0.19	Adiponectin levels;	chr4:55482076	chr4:55387949~55388271:+
HNSC	cis	rs4834770	0.765	rs1511016	ENSG00000249244.1	RP11-548H18.2	4.2	3.16e-05	0.00532	0.22	0.19	Blood protein levels;	chr4:119249200	chr4:119391831~119395335:-
HNSC	cis	rs761746	0.739	rs5998086	ENSG00000236132.1	CTA-440B3.1	-4.2	3.16e-05	0.00532	-0.24	-0.19	Intelligence;	chr22:31684258	chr22:31816379~31817491:-
HNSC	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	4.2	3.16e-05	0.00532	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	4.2	3.16e-05	0.00532	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	4.2	3.16e-05	0.00532	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	4.2	3.16e-05	0.00532	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
HNSC	cis	rs9368481	0.645	rs10456350	ENSG00000224843.5	LINC00240	-4.2	3.16e-05	0.00532	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26956992~27023924:+
HNSC	cis	rs1485395	0.891	rs7976278	ENSG00000257379.1	RP11-793H13.8	4.2	3.16e-05	0.00532	0.28	0.19	Migraine without aura;	chr12:53651337	chr12:53441741~53467528:+
HNSC	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	4.2	3.16e-05	0.00532	0.22	0.19	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
HNSC	cis	rs3806843	0.569	rs753279	ENSG00000202515.1	VTRNA1-3	4.2	3.16e-05	0.00532	0.21	0.19	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr5:140726158~140726246:+
HNSC	cis	rs9611565	0.918	rs2281333	ENSG00000235513.1	RP4-756G23.5	4.2	3.16e-05	0.00532	0.21	0.19	Vitiligo;	chr22:41353626	chr22:41209122~41217627:-
HNSC	cis	rs755249	0.567	rs61783378	ENSG00000182109.6	RP11-69E11.4	4.2	3.16e-05	0.00532	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39522280~39546187:-
HNSC	cis	rs1602565	0.925	rs7930981	ENSG00000255450.1	CTD-2063L20.1	-4.2	3.16e-05	0.00532	-0.31	-0.19	Schizophrenia;	chr11:29138752	chr11:29275655~29276565:+
HNSC	cis	rs7005380	0.581	rs10099088	ENSG00000279347.1	RP11-85I17.2	-4.2	3.17e-05	0.00532	-0.17	-0.19	Interstitial lung disease;	chr8:119927418	chr8:119838736~119840385:-
HNSC	cis	rs9611565	0.765	rs767593	ENSG00000235513.1	RP4-756G23.5	4.2	3.17e-05	0.00532	0.23	0.19	Vitiligo;	chr22:41383967	chr22:41209122~41217627:-
HNSC	cis	rs4356203	0.905	rs11024159	ENSG00000260196.1	RP1-239B22.5	-4.2	3.17e-05	0.00532	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.648	rs7108316	ENSG00000260196.1	RP1-239B22.5	-4.2	3.17e-05	0.00533	-0.2	-0.19	Systolic blood pressure;	chr11:17253488	chr11:17380649~17383531:+
HNSC	cis	rs7267979	0.753	rs404148	ENSG00000231081.1	RP4-760C5.3	-4.2	3.17e-05	0.00533	-0.19	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26008791~26010531:-
HNSC	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	4.2	3.17e-05	0.00533	0.25	0.19	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	4.2	3.17e-05	0.00533	0.25	0.19	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
HNSC	cis	rs1799949	1	rs1973646	ENSG00000236383.6	LINC00854	-4.2	3.17e-05	0.00533	-0.18	-0.19	Menopause (age at onset);	chr17:43158478	chr17:43216941~43305976:-
HNSC	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-4.2	3.17e-05	0.00533	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-4.2	3.17e-05	0.00533	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
HNSC	cis	rs9733	0.744	rs11204725	ENSG00000236713.1	RP11-363I22.3	4.2	3.17e-05	0.00533	0.2	0.19	Tonsillectomy;	chr1:150770224	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.744	rs12125650	ENSG00000236713.1	RP11-363I22.3	4.2	3.17e-05	0.00533	0.2	0.19	Tonsillectomy;	chr1:150787698	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.688	rs12725667	ENSG00000236713.1	RP11-363I22.3	4.2	3.17e-05	0.00533	0.2	0.19	Tonsillectomy;	chr1:150793594	chr1:150780272~150780644:+
HNSC	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	4.2	3.17e-05	0.00533	0.22	0.19	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	4.2	3.17e-05	0.00533	0.22	0.19	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	4.2	3.17e-05	0.00533	0.22	0.19	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	4.2	3.17e-05	0.00533	0.22	0.19	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
HNSC	cis	rs11098499	0.863	rs7669520	ENSG00000250412.1	KLHL2P1	4.2	3.17e-05	0.00533	0.25	0.19	Corneal astigmatism;	chr4:119594123	chr4:119334329~119378233:+
HNSC	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-4.2	3.17e-05	0.00533	-0.16	-0.19	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
HNSC	cis	rs9584850	0.834	rs4294654	ENSG00000231194.1	FARP1-AS1	4.2	3.17e-05	0.00533	0.24	0.19	Neuroticism;	chr13:98467353	chr13:98435405~98435840:-
HNSC	cis	rs8067545	0.641	rs2108978	ENSG00000266126.1	RP11-209D14.4	4.2	3.17e-05	0.00533	0.22	0.19	Schizophrenia;	chr17:19958145	chr17:19929372~19929737:-
HNSC	cis	rs9329221	0.527	rs34259385	ENSG00000255310.2	AF131215.2	-4.2	3.18e-05	0.00534	-0.19	-0.19	Neuroticism;	chr8:10467946	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.51	rs1435274	ENSG00000255310.2	AF131215.2	-4.2	3.18e-05	0.00534	-0.18	-0.19	Retinal vascular caliber;	chr8:11378401	chr8:11107788~11109726:-
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000233609.3	RP11-62H7.2	4.2	3.18e-05	0.00534	0.18	0.19	Neuroticism;	chr8:8460377	chr8:8961200~8979025:+
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	4.2	3.18e-05	0.00534	0.27	0.19	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
HNSC	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-4.2	3.18e-05	0.00534	-0.23	-0.19	Height;	chr14:75185155	chr14:75011269~75012851:-
HNSC	cis	rs843532	0.588	rs7646247	ENSG00000236833.1	AC024560.2	-4.2	3.18e-05	0.00534	-0.24	-0.19	Glucose homeostasis traits;	chr3:196792338	chr3:197660565~197665757:-
HNSC	cis	rs516805	0.568	rs56290570	ENSG00000279453.1	RP3-425C14.4	4.2	3.18e-05	0.00534	0.26	0.19	Lymphocyte counts;	chr6:122240177	chr6:122436789~122439223:-
HNSC	cis	rs6973609	0.524	rs10279330	ENSG00000271122.1	RP11-379H18.1	-4.2	3.18e-05	0.00534	-0.17	-0.19	Obesity-related traits;	chr7:35607370	chr7:35695214~35699413:+
HNSC	cis	rs4294134	0.545	rs11534080	ENSG00000223718.3	AC093107.7	4.2	3.18e-05	0.00534	0.29	0.19	Paget's disease;	chr7:135562780	chr7:135660039~135660647:+
HNSC	cis	rs4294134	0.608	rs11535258	ENSG00000223718.3	AC093107.7	4.2	3.18e-05	0.00534	0.29	0.19	Paget's disease;	chr7:135562799	chr7:135660039~135660647:+
HNSC	cis	rs10791097	0.72	rs6590516	ENSG00000254842.5	RP11-890B15.2	-4.2	3.18e-05	0.00534	-0.17	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863498	chr11:130844191~130865561:-
HNSC	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	4.2	3.18e-05	0.00534	0.25	0.19	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
HNSC	cis	rs6026584	1	rs1407040	ENSG00000270951.1	RP1-309F20.4	-4.2	3.18e-05	0.00534	-0.21	-0.19	Renal function-related traits (BUN);	chr20:58897119	chr20:58876592~58876981:-
HNSC	cis	rs13434995	0.562	rs73236140	ENSG00000273257.1	RP11-177J6.1	-4.2	3.18e-05	0.00534	-0.26	-0.19	Adiponectin levels;	chr4:55440049	chr4:55387949~55388271:+
HNSC	cis	rs11893307	0.509	rs62182902	ENSG00000228509.4	AC006460.2	4.2	3.18e-05	0.00535	0.26	0.19	Mean platelet volume;	chr2:190638041	chr2:190676944~190708716:-
HNSC	cis	rs35306767	0.714	rs12777800	ENSG00000229869.1	RP11-363N22.2	-4.2	3.18e-05	0.00535	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:1024421	chr10:933026~942743:+
HNSC	cis	rs3811273	1	rs10151596	ENSG00000211816.2	TRAV38-1	-4.2	3.18e-05	0.00535	-0.24	-0.19	Periodontal disease-related phenotypes;	chr14:22255314	chr14:22271968~22272563:+
HNSC	cis	rs597539	0.615	rs583182	ENSG00000255741.1	RP11-757G1.5	-4.2	3.18e-05	0.00535	-0.25	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68941503~68942852:-
HNSC	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-4.2	3.19e-05	0.00535	-0.27	-0.19	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000280411.1	IGHV1-69-2	-4.2	3.19e-05	0.00535	-0.14	-0.19	Kawasaki disease;	chr14:106711838	chr14:106762092~106762588:-
HNSC	cis	rs6601327	0.641	rs11778555	ENSG00000233609.3	RP11-62H7.2	-4.2	3.19e-05	0.00535	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9730064	chr8:8961200~8979025:+
HNSC	cis	rs6601327	0.641	rs11785923	ENSG00000233609.3	RP11-62H7.2	-4.2	3.19e-05	0.00535	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9730164	chr8:8961200~8979025:+
HNSC	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-4.2	3.19e-05	0.00536	-0.28	-0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
HNSC	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-4.2	3.19e-05	0.00536	-0.23	-0.19	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	4.2	3.19e-05	0.00536	0.23	0.19	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
HNSC	cis	rs13178541	0.748	rs4360035	ENSG00000250378.1	RP11-119J18.1	-4.2	3.19e-05	0.00536	-0.25	-0.19	IgG glycosylation;	chr5:135760843	chr5:135812667~135826582:+
HNSC	cis	rs12745968	0.589	rs6697491	ENSG00000223787.2	RP4-593M8.1	-4.2	3.19e-05	0.00536	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92567157	chr1:92580476~92580821:-
HNSC	cis	rs4853525	0.859	rs1882397	ENSG00000228509.4	AC006460.2	4.2	3.19e-05	0.00536	0.23	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855406	chr2:190676944~190708716:-
HNSC	cis	rs11148252	0.574	rs3742297	ENSG00000198384.8	TPTE2P3	4.2	3.19e-05	0.00536	0.23	0.19	Lewy body disease;	chr13:52703932	chr13:52522632~52586906:+
HNSC	cis	rs11148252	0.574	rs9536247	ENSG00000198384.8	TPTE2P3	4.2	3.19e-05	0.00536	0.23	0.19	Lewy body disease;	chr13:52705407	chr13:52522632~52586906:+
HNSC	cis	rs11098499	0.754	rs9991959	ENSG00000250412.1	KLHL2P1	-4.2	3.19e-05	0.00536	-0.24	-0.19	Corneal astigmatism;	chr4:119332618	chr4:119334329~119378233:+
HNSC	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4.2	3.19e-05	0.00536	0.38	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	4.2	3.19e-05	0.00536	0.38	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
HNSC	cis	rs1223397	0.938	rs35549743	ENSG00000215022.6	RP1-257A7.4	-4.2	3.19e-05	0.00536	-0.25	-0.19	Blood pressure;	chr6:13294122	chr6:13264861~13295586:-
HNSC	cis	rs78579285	0.583	rs77376965	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.19e-05	0.00536	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88734069	chr16:88708956~88710437:-
HNSC	cis	rs7085104	0.632	rs3781287	ENSG00000236937.2	PTGES3P4	4.2	3.19e-05	0.00536	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102845595~102845950:+
HNSC	cis	rs6490294	0.904	rs11066098	ENSG00000226469.1	ADAM1B	4.2	3.19e-05	0.00536	0.22	0.19	Mean platelet volume;	chr12:111950324	chr12:111927018~111929017:+
HNSC	cis	rs1552244	0.882	rs113268531	ENSG00000180385.7	EMC3-AS1	4.2	3.2e-05	0.00537	0.21	0.19	Alzheimer's disease;	chr3:10125385	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.938	rs67667957	ENSG00000180385.7	EMC3-AS1	4.2	3.2e-05	0.00537	0.21	0.19	Alzheimer's disease;	chr3:10125580	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.938	rs56274701	ENSG00000180385.7	EMC3-AS1	4.2	3.2e-05	0.00537	0.21	0.19	Alzheimer's disease;	chr3:10126106	chr3:9986893~10006990:+
HNSC	cis	rs7948661	1	rs9332793	ENSG00000278376.1	RP11-158I9.8	4.2	3.2e-05	0.00537	0.36	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118483743	chr11:118791254~118793137:+
HNSC	cis	rs78579285	0.584	rs9922996	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.2e-05	0.00537	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88734262	chr16:88708956~88710437:-
HNSC	cis	rs78579285	0.584	rs9930994	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.2e-05	0.00537	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88734285	chr16:88708956~88710437:-
HNSC	cis	rs78579285	0.584	rs35265318	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.2e-05	0.00537	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88734377	chr16:88708956~88710437:-
HNSC	cis	rs78579285	0.584	rs35353288	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.2e-05	0.00537	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88734406	chr16:88708956~88710437:-
HNSC	cis	rs35963943	0.625	rs13070384	ENSG00000228956.7	SATB1-AS1	4.2	3.2e-05	0.00537	0.23	0.19	Lymphocyte counts;	chr3:18669718	chr3:18445024~18920401:+
HNSC	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	4.2	3.2e-05	0.00537	0.25	0.19	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
HNSC	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-4.2	3.2e-05	0.00537	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
HNSC	cis	rs1008375	0.932	rs964012	ENSG00000249502.1	AC006160.5	-4.2	3.2e-05	0.00537	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17617561	chr4:17587467~17614571:-
HNSC	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-4.2	3.2e-05	0.00537	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
HNSC	cis	rs10129255	0.957	rs56134540	ENSG00000211974.3	IGHV2-70	4.2	3.2e-05	0.00537	0.18	0.19	Kawasaki disease;	chr14:106691290	chr14:106723574~106724093:-
HNSC	cis	rs516805	0.634	rs2816142	ENSG00000279453.1	RP3-425C14.4	4.2	3.2e-05	0.00537	0.27	0.19	Lymphocyte counts;	chr6:122177653	chr6:122436789~122439223:-
HNSC	cis	rs1580019	0.883	rs6945294	ENSG00000226468.2	AC018641.7	-4.2	3.2e-05	0.00537	-0.26	-0.19	Cognitive ability;	chr7:32432487	chr7:32456963~32457758:-
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000250412.1	KLHL2P1	4.2	3.2e-05	0.00537	0.25	0.19	Corneal astigmatism;	chr4:119315475	chr4:119334329~119378233:+
HNSC	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.2	3.2e-05	0.00537	0.22	0.19	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
HNSC	cis	rs853679	0.607	rs13207345	ENSG00000204709.4	LINC01556	4.2	3.2e-05	0.00537	0.4	0.19	Depression;	chr6:28297795	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs72854513	ENSG00000204709.4	LINC01556	4.2	3.2e-05	0.00537	0.4	0.19	Depression;	chr6:28298177	chr6:28943877~28944537:+
HNSC	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-4.2	3.2e-05	0.00538	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
HNSC	cis	rs3811273	1	rs10148895	ENSG00000211816.2	TRAV38-1	4.2	3.2e-05	0.00538	0.24	0.19	Periodontal disease-related phenotypes;	chr14:22254840	chr14:22271968~22272563:+
HNSC	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-4.2	3.2e-05	0.00538	-0.25	-0.19	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
HNSC	cis	rs3736485	0.844	rs55981933	ENSG00000259438.1	CTD-2650P22.1	4.2	3.21e-05	0.00538	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51493239	chr15:52010999~52019095:-
HNSC	cis	rs728616	0.867	rs61858980	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.21e-05	0.00538	-0.38	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79663088~79826594:-
HNSC	cis	rs11893307	0.566	rs10170782	ENSG00000228509.4	AC006460.2	4.2	3.21e-05	0.00538	0.26	0.19	Mean platelet volume;	chr2:190758510	chr2:190676944~190708716:-
HNSC	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	4.2	3.21e-05	0.00538	0.25	0.19	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
HNSC	cis	rs36093924	0.646	rs4822069	ENSG00000227370.1	RP4-669P10.19	4.2	3.21e-05	0.00538	0.18	0.19	Intelligence;	chr22:41955477	chr22:42132543~42132998:+
HNSC	cis	rs6500395	0.928	rs7199206	ENSG00000261267.1	RP11-44I10.3	4.2	3.21e-05	0.00538	0.24	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48668627	chr16:48559661~48587403:+
HNSC	cis	rs11638815	0.581	rs2870965	ENSG00000259429.4	UBE2Q2P2	-4.2	3.21e-05	0.00539	-0.19	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:82355142~82420075:+
HNSC	cis	rs7829975	0.533	rs13274028	ENSG00000254340.1	RP11-10A14.3	4.2	3.21e-05	0.00539	0.24	0.19	Mood instability;	chr8:8871683	chr8:9141424~9145435:+
HNSC	cis	rs9880211	0.699	rs9809269	ENSG00000273486.1	RP11-731C17.2	4.2	3.21e-05	0.00539	0.19	0.19	Height;Body mass index;	chr3:136711064	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-4.2	3.21e-05	0.00539	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
HNSC	cis	rs116095464	0.558	rs9312957	ENSG00000250848.1	CTD-2083E4.5	-4.2	3.21e-05	0.00539	-0.27	-0.19	Breast cancer;	chr5:202079	chr5:288833~290321:-
HNSC	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	4.2	3.21e-05	0.00539	0.2	0.19	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	4.2	3.21e-05	0.00539	0.2	0.19	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
HNSC	cis	rs2337406	0.81	rs7161739	ENSG00000280411.1	IGHV1-69-2	-4.2	3.21e-05	0.00539	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106776118	chr14:106762092~106762588:-
HNSC	cis	rs2898681	0.561	rs7699960	ENSG00000248375.1	RP11-177B4.1	-4.2	3.21e-05	0.00539	-0.31	-0.19	Optic nerve measurement (cup area);	chr4:52869494	chr4:52720081~52720831:-
HNSC	cis	rs10927875	0.722	rs1763605	ENSG00000226029.1	RP4-798A10.2	-4.2	3.21e-05	0.00539	-0.19	-0.19	Dilated cardiomyopathy;	chr1:16012430	chr1:16460948~16468481:+
HNSC	cis	rs4281086	0.587	rs56225449	ENSG00000269918.1	AF131215.9	4.2	3.21e-05	0.00539	0.2	0.19	Obesity-related traits;	chr8:10507671	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.527	rs10109537	ENSG00000255310.2	AF131215.2	-4.2	3.21e-05	0.00539	-0.18	-0.19	Retinal vascular caliber;	chr8:11382131	chr8:11107788~11109726:-
HNSC	cis	rs11893307	0.537	rs3771319	ENSG00000228509.4	AC006460.2	4.2	3.21e-05	0.00539	0.26	0.19	Mean platelet volume;	chr2:190660507	chr2:190676944~190708716:-
HNSC	cis	rs10256972	0.706	rs7784559	ENSG00000225146.1	AC073957.15	4.2	3.21e-05	0.00539	0.25	0.19	Endometriosis;Longevity;	chr7:963337	chr7:1029025~1043891:+
HNSC	cis	rs4699052	0.662	rs1516732	ENSG00000246560.2	RP11-10L12.4	4.2	3.21e-05	0.00539	0.22	0.19	Testicular germ cell tumor;	chr4:103329997	chr4:102828055~102844075:+
HNSC	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-4.2	3.21e-05	0.00539	-0.22	-0.19	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
HNSC	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-4.2	3.21e-05	0.00539	-0.22	-0.19	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
HNSC	cis	rs9910055	0.531	rs6503490	ENSG00000267080.4	ASB16-AS1	-4.2	3.22e-05	0.0054	-0.15	-0.19	Total body bone mineral density;	chr17:44169288	chr17:44175973~44186717:-
HNSC	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-4.2	3.22e-05	0.0054	-0.28	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
HNSC	cis	rs8028182	0.636	rs7495610	ENSG00000260269.4	CTD-2323K18.1	-4.2	3.22e-05	0.0054	-0.24	-0.19	Sudden cardiac arrest;	chr15:75492100	chr15:75527150~75601205:-
HNSC	cis	rs5758511	0.633	rs5758690	ENSG00000226450.2	CYP2D8P	4.2	3.22e-05	0.0054	0.18	0.19	Birth weight;	chr22:42272289	chr22:42149886~42155001:-
HNSC	cis	rs10742752	0.58	rs12271560	ENSG00000254651.1	RP11-430H10.3	4.2	3.22e-05	0.0054	0.23	0.19	Body mass index;	chr11:45393595	chr11:45399448~45400528:+
HNSC	cis	rs1008375	1	rs7697889	ENSG00000249502.1	AC006160.5	-4.2	3.22e-05	0.0054	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616338	chr4:17587467~17614571:-
HNSC	cis	rs3806843	0.576	rs155363	ENSG00000276545.1	PCDHGB9P	4.2	3.22e-05	0.0054	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140921958	chr5:141439853~141442449:+
HNSC	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-4.2	3.22e-05	0.0054	-0.19	-0.19	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
HNSC	cis	rs2467099	1	rs2467099	ENSG00000267801.1	RP11-552F3.9	4.2	3.22e-05	0.0054	0.24	0.19	Systolic blood pressure;	chr17:75952964	chr17:75876372~75879546:+
HNSC	cis	rs79349575	0.783	rs2112617	ENSG00000270781.1	RP11-501C14.9	-4.2	3.22e-05	0.0054	-0.2	-0.19	Type 2 diabetes;	chr17:48899763	chr17:48899131~48899748:+
HNSC	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-4.2	3.22e-05	0.0054	-0.19	-0.19	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
HNSC	cis	rs1555322	1	rs1555322	ENSG00000126005.14	MMP24-AS1	-4.2	3.22e-05	0.0054	-0.35	-0.19	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35216462~35278131:-
HNSC	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	4.2	3.22e-05	0.0054	0.25	0.19	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
HNSC	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	4.2	3.22e-05	0.0054	0.23	0.19	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs1267820	ENSG00000106610.13	STAG3L4	-4.2	3.22e-05	0.0054	-0.39	-0.19	Diabetic kidney disease;	chr7:66585308	chr7:67302621~67321526:+
HNSC	cis	rs17761864	0.959	rs17761837	ENSG00000262333.1	HNRNPA1P16	-4.2	3.22e-05	0.00541	-0.17	-0.19	Esophageal cancer (squamous cell);	chr17:2251031	chr17:2306761~2307715:+
HNSC	cis	rs7819412	0.668	rs2409715	ENSG00000269918.1	AF131215.9	-4.2	3.22e-05	0.00541	-0.19	-0.19	Triglycerides;	chr8:11152626	chr8:11104691~11106704:-
HNSC	cis	rs7005380	0.58	rs10110216	ENSG00000279347.1	RP11-85I17.2	-4.2	3.22e-05	0.00541	-0.16	-0.19	Interstitial lung disease;	chr8:119875307	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.58	rs10110223	ENSG00000279347.1	RP11-85I17.2	-4.2	3.22e-05	0.00541	-0.16	-0.19	Interstitial lung disease;	chr8:119875326	chr8:119838736~119840385:-
HNSC	cis	rs10504130	1	rs16916865	ENSG00000272024.1	RP11-546K22.3	-4.2	3.22e-05	0.00541	-0.3	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51833290	chr8:51950284~51950690:+
HNSC	cis	rs9329221	0.537	rs1351876	ENSG00000269918.1	AF131215.9	-4.2	3.22e-05	0.00541	-0.18	-0.19	Neuroticism;	chr8:10127267	chr8:11104691~11106704:-
HNSC	cis	rs867371	0.614	rs7183805	ENSG00000276710.3	CSPG4P8	-4.2	3.22e-05	0.00541	-0.24	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82459472~82477258:+
HNSC	cis	rs1198872	0.503	rs1627163	ENSG00000272275.1	RP11-791G15.2	-4.2	3.22e-05	0.00541	-0.24	-0.19	Cardiac Troponin-T levels;	chr2:10814718	chr2:10767875~10770058:-
HNSC	cis	rs9929218	0.529	rs2296404	ENSG00000260459.2	FTLP14	4.2	3.22e-05	0.00541	0.25	0.19	Colorectal cancer;	chr16:68695622	chr16:68822587~68823070:+
HNSC	cis	rs804280	0.509	rs13276433	ENSG00000255495.1	AC145124.2	4.2	3.22e-05	0.00541	0.21	0.19	Myopia (pathological);	chr8:11925527	chr8:12194467~12196280:+
HNSC	cis	rs9450351	0.744	rs9362247	ENSG00000203875.9	SNHG5	-4.2	3.22e-05	0.00541	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs6913958	ENSG00000203875.9	SNHG5	-4.2	3.22e-05	0.00541	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85825481	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.546	rs9344550	ENSG00000203875.9	SNHG5	-4.2	3.22e-05	0.00541	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85829000	chr6:85660950~85678736:-
HNSC	cis	rs75422866	0.867	rs7304743	ENSG00000276691.1	RP5-1057I20.5	-4.2	3.23e-05	0.00541	-0.32	-0.19	Pneumonia;	chr12:47683658	chr12:47788426~47788971:+
HNSC	cis	rs964611	0.882	rs16960809	ENSG00000259488.2	RP11-154J22.1	4.2	3.23e-05	0.00541	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48354318	chr15:48312353~48331856:-
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	4.2	3.23e-05	0.00541	0.23	0.19	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
HNSC	cis	rs2048656	0.598	rs7846399	ENSG00000233609.3	RP11-62H7.2	-4.2	3.23e-05	0.00541	-0.18	-0.19	Schizophrenia;	chr8:9635619	chr8:8961200~8979025:+
HNSC	cis	rs6964587	0.869	rs6979024	ENSG00000188693.7	CYP51A1-AS1	4.2	3.23e-05	0.00541	0.21	0.19	Breast cancer;	chr7:91852198	chr7:92134604~92180725:+
HNSC	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	4.2	3.23e-05	0.00541	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
HNSC	cis	rs73198271	0.74	rs28402110	ENSG00000233609.3	RP11-62H7.2	-4.2	3.23e-05	0.00541	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs10112989	ENSG00000233609.3	RP11-62H7.2	-4.2	3.23e-05	0.00541	-0.22	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8961200~8979025:+
HNSC	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	4.2	3.23e-05	0.00542	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
HNSC	cis	rs2361718	0.5	rs8064429	ENSG00000275479.1	RP11-334C17.6	4.2	3.23e-05	0.00542	0.22	0.19	Yeast infection;	chr17:80122388	chr17:80149627~80149798:+
HNSC	cis	rs11157436	0.602	rs11157439	ENSG00000211812.1	TRAV26-2	-4.2	3.23e-05	0.00542	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.602	rs10872984	ENSG00000211812.1	TRAV26-2	-4.2	3.23e-05	0.00542	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22202583~22203368:+
HNSC	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	4.2	3.23e-05	0.00542	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
HNSC	cis	rs2361718	0.564	rs2304844	ENSG00000279259.1	RP11-334C17.3	4.2	3.23e-05	0.00542	0.25	0.19	Yeast infection;	chr17:80110708	chr17:80147250~80148596:+
HNSC	cis	rs9611565	0.649	rs79009	ENSG00000235513.1	RP4-756G23.5	-4.2	3.23e-05	0.00542	-0.23	-0.19	Vitiligo;	chr22:41464860	chr22:41209122~41217627:-
HNSC	cis	rs11773103	0.881	rs73204813	ENSG00000224046.1	AC005076.5	4.2	3.24e-05	0.00542	0.28	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87137427	chr7:87151423~87152420:-
HNSC	cis	rs4252134	0.615	rs73029749	ENSG00000233342.1	RP11-235G24.3	-4.2	3.24e-05	0.00542	-0.25	-0.19	Giant cell arteritis;	chr6:160847379	chr6:160926369~160927162:+
HNSC	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	4.2	3.24e-05	0.00542	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
HNSC	cis	rs853679	1	rs10456362	ENSG00000204709.4	LINC01556	-4.2	3.24e-05	0.00542	-0.29	-0.19	Depression;	chr6:28254038	chr6:28943877~28944537:+
HNSC	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-4.2	3.24e-05	0.00543	-0.24	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
HNSC	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-4.2	3.24e-05	0.00543	-0.22	-0.19	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
HNSC	cis	rs17594362	1	rs12866839	ENSG00000229473.2	RGS17P1	4.2	3.24e-05	0.00543	0.3	0.19	Multiple sclerosis;	chr13:41578118	chr13:40992779~40993331:-
HNSC	cis	rs16846053	0.515	rs7588198	ENSG00000227403.1	AC009299.3	-4.2	3.24e-05	0.00543	-0.34	-0.19	Blood osmolality (transformed sodium);	chr2:161508691	chr2:161244739~161249050:+
HNSC	cis	rs16846053	0.515	rs10202267	ENSG00000227403.1	AC009299.3	-4.2	3.24e-05	0.00543	-0.34	-0.19	Blood osmolality (transformed sodium);	chr2:161509616	chr2:161244739~161249050:+
HNSC	cis	rs16846053	0.515	rs7595197	ENSG00000227403.1	AC009299.3	-4.2	3.24e-05	0.00543	-0.34	-0.19	Blood osmolality (transformed sodium);	chr2:161510325	chr2:161244739~161249050:+
HNSC	cis	rs6088580	0.634	rs4277599	ENSG00000276073.1	RP5-1125A11.7	4.2	3.24e-05	0.00543	0.2	0.19	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33985617~33988989:-
HNSC	cis	rs72843506	0.722	rs16964352	ENSG00000261033.1	RP11-209D14.2	4.2	3.24e-05	0.00543	0.32	0.19	Schizophrenia;	chr17:20245095	chr17:20008051~20009234:-
HNSC	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-4.2	3.24e-05	0.00543	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
HNSC	cis	rs1008375	0.897	rs3733577	ENSG00000249502.1	AC006160.5	-4.2	3.24e-05	0.00543	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647610	chr4:17587467~17614571:-
HNSC	cis	rs12745968	0.624	rs1059268	ENSG00000223787.2	RP4-593M8.1	-4.2	3.24e-05	0.00543	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92509687	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.589	rs1059267	ENSG00000223787.2	RP4-593M8.1	-4.2	3.24e-05	0.00543	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92509705	chr1:92580476~92580821:-
HNSC	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-4.2	3.24e-05	0.00543	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
HNSC	cis	rs12478296	1	rs55777943	ENSG00000261186.2	RP11-341N2.1	-4.2	3.24e-05	0.00543	-0.33	-0.19	Obesity-related traits;	chr2:242098535	chr2:242087351~242088457:-
HNSC	cis	rs12478296	0.901	rs7603560	ENSG00000261186.2	RP11-341N2.1	-4.2	3.24e-05	0.00543	-0.33	-0.19	Obesity-related traits;	chr2:242101105	chr2:242087351~242088457:-
HNSC	cis	rs62246343	0.541	rs17050396	ENSG00000254485.4	RP11-380O24.1	4.2	3.24e-05	0.00543	0.24	0.19	Fibrinogen levels;	chr3:9492652	chr3:9292588~9363303:-
HNSC	cis	rs13434995	0.536	rs62303712	ENSG00000273257.1	RP11-177J6.1	-4.2	3.24e-05	0.00543	-0.26	-0.19	Adiponectin levels;	chr4:55460484	chr4:55387949~55388271:+
HNSC	cis	rs12682352	0.602	rs6993494	ENSG00000173295.6	FAM86B3P	4.2	3.24e-05	0.00544	0.22	0.19	Neuroticism;	chr8:8809934	chr8:8228595~8244865:+
HNSC	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	4.2	3.24e-05	0.00544	0.17	0.19	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
HNSC	cis	rs79349575	0.715	rs55724082	ENSG00000270781.1	RP11-501C14.9	-4.2	3.25e-05	0.00544	-0.2	-0.19	Type 2 diabetes;	chr17:48940517	chr17:48899131~48899748:+
HNSC	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	4.2	3.25e-05	0.00544	0.19	0.19	Asthma;	chr2:102369915	chr2:102438713~102440475:+
HNSC	cis	rs442309	0.846	rs224130	ENSG00000238280.1	RP11-436D10.3	-4.2	3.25e-05	0.00544	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62705211	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.846	rs224131	ENSG00000238280.1	RP11-436D10.3	-4.2	3.25e-05	0.00544	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62705334	chr10:62793562~62805887:-
HNSC	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-4.2	3.25e-05	0.00544	-0.14	-0.19	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-4.2	3.25e-05	0.00544	-0.14	-0.19	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-4.2	3.25e-05	0.00544	-0.14	-0.19	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-4.2	3.25e-05	0.00544	-0.14	-0.19	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
HNSC	cis	rs7610312	0.681	rs9848070	ENSG00000273493.1	RP11-80H18.4	-4.2	3.25e-05	0.00544	-0.23	-0.19	Red blood cell count;	chr3:58286908	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs9848072	ENSG00000273493.1	RP11-80H18.4	-4.2	3.25e-05	0.00544	-0.23	-0.19	Red blood cell count;	chr3:58286912	chr3:58329965~58330118:+
HNSC	cis	rs6674176	0.628	rs4660758	ENSG00000237950.1	RP11-7O11.3	4.2	3.25e-05	0.00544	0.21	0.19	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43959207	chr1:43944370~43946551:-
HNSC	cis	rs9611565	0.84	rs3788584	ENSG00000235513.1	RP4-756G23.5	4.2	3.25e-05	0.00544	0.22	0.19	Vitiligo;	chr22:41383069	chr22:41209122~41217627:-
HNSC	cis	rs4356203	0.87	rs214901	ENSG00000272034.1	SNORD14A	4.2	3.25e-05	0.00544	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17074654~17074744:-
HNSC	cis	rs6831352	0.734	rs2602856	ENSG00000263923.1	RP11-571L19.7	-4.2	3.25e-05	0.00544	-0.19	-0.19	Alcohol dependence;	chr4:99107994	chr4:98928897~98994994:+
HNSC	cis	rs7824557	0.606	rs1435277	ENSG00000255310.2	AF131215.2	4.2	3.25e-05	0.00545	0.18	0.19	Retinal vascular caliber;	chr8:11339461	chr8:11107788~11109726:-
HNSC	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	4.2	3.25e-05	0.00545	0.25	0.19	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
HNSC	cis	rs7829975	0.577	rs17684466	ENSG00000173295.6	FAM86B3P	-4.2	3.25e-05	0.00545	-0.23	-0.19	Mood instability;	chr8:8687723	chr8:8228595~8244865:+
HNSC	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-4.2	3.25e-05	0.00545	-0.23	-0.19	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
HNSC	cis	rs7688540	0.771	rs74984113	ENSG00000211553.1	AC253576.2	-4.2	3.26e-05	0.00545	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:136461~136568:+
HNSC	cis	rs9487051	0.621	rs351719	ENSG00000243587.6	C6orf183	4.2	3.26e-05	0.00545	0.2	0.19	Reticulocyte fraction of red cells;	chr6:109231231	chr6:109165833~109271014:+
HNSC	cis	rs2243480	1	rs6958420	ENSG00000229886.1	RP5-1132H15.3	-4.2	3.26e-05	0.00545	-0.32	-0.19	Diabetic kidney disease;	chr7:66286184	chr7:66025126~66031544:-
HNSC	cis	rs7914558	0.752	rs7896519	ENSG00000236937.2	PTGES3P4	4.2	3.26e-05	0.00545	0.23	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102845595~102845950:+
HNSC	cis	rs55823223	0.503	rs9906971	ENSG00000267801.1	RP11-552F3.9	4.2	3.26e-05	0.00545	0.22	0.19	Psoriasis;	chr17:75852396	chr17:75876372~75879546:+
HNSC	cis	rs9907295	0.818	rs3785764	ENSG00000270977.1	AC015849.16	-4.2	3.26e-05	0.00546	-0.32	-0.19	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.748	rs78672421	ENSG00000270977.1	AC015849.16	-4.2	3.26e-05	0.00546	-0.32	-0.19	Fibroblast growth factor basic levels;	chr17:35837325	chr17:35893707~35911023:-
HNSC	cis	rs1355223	0.752	rs286893	ENSG00000271369.1	RP11-350D17.3	4.2	3.26e-05	0.00546	0.22	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34653335	chr11:34709600~34710161:+
HNSC	cis	rs9313772	0.748	rs4704940	ENSG00000254350.1	RP11-542A14.1	-4.2	3.26e-05	0.00546	-0.2	-0.19	Blood pressure;	chr5:158435419	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs4704941	ENSG00000254350.1	RP11-542A14.1	-4.2	3.26e-05	0.00546	-0.2	-0.19	Blood pressure;	chr5:158435607	chr5:158424585~158452758:+
HNSC	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	4.2	3.26e-05	0.00546	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	4.2	3.26e-05	0.00546	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	4.2	3.26e-05	0.00546	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
HNSC	cis	rs7829975	0.682	rs7013471	ENSG00000254153.1	CTA-398F10.2	-4.2	3.26e-05	0.00546	-0.21	-0.19	Mood instability;	chr8:8829815	chr8:8456909~8461337:-
HNSC	cis	rs4294134	0.608	rs13233394	ENSG00000223718.3	AC093107.7	4.2	3.26e-05	0.00546	0.3	0.19	Paget's disease;	chr7:135558492	chr7:135660039~135660647:+
HNSC	cis	rs12545109	0.8	rs2576591	ENSG00000246430.5	LINC00968	-4.2	3.26e-05	0.00546	-0.25	-0.19	Obesity-related traits;	chr8:56511047	chr8:56496246~56559823:-
HNSC	cis	rs4924935	0.646	rs8070707	ENSG00000264885.1	RP11-815I9.4	4.2	3.26e-05	0.00546	0.2	0.19	Pancreatic cancer;	chr17:18917144	chr17:18667629~18669461:-
HNSC	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	4.2	3.26e-05	0.00546	0.29	0.19	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000211974.3	IGHV2-70	4.2	3.27e-05	0.00547	0.18	0.19	Kawasaki disease;	chr14:106718572	chr14:106723574~106724093:-
HNSC	cis	rs61935443	0.501	rs10745693	ENSG00000241556.1	RP11-490G8.1	-4.2	3.27e-05	0.00547	-0.2	-0.19	Schizophrenia;	chr12:94784758	chr12:95467397~95467861:-
HNSC	cis	rs224278	0.604	rs1040875	ENSG00000238280.1	RP11-436D10.3	-4.19	3.27e-05	0.00547	-0.23	-0.19	Ewing sarcoma;	chr10:62828449	chr10:62793562~62805887:-
HNSC	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	4.19	3.27e-05	0.00547	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	4.19	3.27e-05	0.00547	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.19	3.27e-05	0.00547	0.2	0.19	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
HNSC	cis	rs860295	0.665	rs11264393	ENSG00000225855.5	RUSC1-AS1	4.19	3.27e-05	0.00547	0.13	0.19	Body mass index;	chr1:155604680	chr1:155316863~155324176:-
HNSC	cis	rs6840258	1	rs72667759	ENSG00000251411.1	RP11-397E7.4	-4.19	3.27e-05	0.00547	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031047	chr4:86913266~86914817:-
HNSC	cis	rs2467099	0.786	rs1135889	ENSG00000267801.1	RP11-552F3.9	4.19	3.27e-05	0.00547	0.25	0.19	Systolic blood pressure;	chr17:75930040	chr17:75876372~75879546:+
HNSC	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.19	3.27e-05	0.00547	0.26	0.19	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
HNSC	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.19	3.27e-05	0.00547	0.26	0.19	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
HNSC	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	4.19	3.27e-05	0.00547	0.16	0.19	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
HNSC	cis	rs12545109	0.765	rs2576594	ENSG00000246430.5	LINC00968	-4.19	3.27e-05	0.00548	-0.24	-0.19	Obesity-related traits;	chr8:56499567	chr8:56496246~56559823:-
HNSC	cis	rs1008375	1	rs2159584	ENSG00000249502.1	AC006160.5	-4.19	3.27e-05	0.00548	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618945	chr4:17587467~17614571:-
HNSC	cis	rs9650657	0.74	rs11250077	ENSG00000255310.2	AF131215.2	-4.19	3.27e-05	0.00548	-0.18	-0.19	Neuroticism;	chr8:10798927	chr8:11107788~11109726:-
HNSC	cis	rs9859260	0.71	rs41298097	ENSG00000242086.7	LINC00969	-4.19	3.27e-05	0.00548	-0.16	-0.19	Mean corpuscular volume;	chr3:196052284	chr3:195658062~195739964:+
HNSC	cis	rs9859260	0.71	rs34906439	ENSG00000242086.7	LINC00969	-4.19	3.27e-05	0.00548	-0.16	-0.19	Mean corpuscular volume;	chr3:196052835	chr3:195658062~195739964:+
HNSC	cis	rs11122895	0.509	rs3860380	ENSG00000236307.2	EEF1E1P1	-4.19	3.27e-05	0.00548	-0.18	-0.19	Allergic sensitization;	chr2:111693810	chr2:111887914~111888741:+
HNSC	cis	rs683257	0.636	rs55942214	ENSG00000234147.1	RP3-460G2.2	-4.19	3.27e-05	0.00548	-0.33	-0.19	Facial emotion recognition (angry faces);	chr6:140827313	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.636	rs56266921	ENSG00000234147.1	RP3-460G2.2	-4.19	3.27e-05	0.00548	-0.33	-0.19	Facial emotion recognition (angry faces);	chr6:140827339	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.636	rs72988142	ENSG00000234147.1	RP3-460G2.2	-4.19	3.27e-05	0.00548	-0.33	-0.19	Facial emotion recognition (angry faces);	chr6:140827387	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.563	rs9495842	ENSG00000234147.1	RP3-460G2.2	-4.19	3.27e-05	0.00548	-0.33	-0.19	Facial emotion recognition (angry faces);	chr6:140828411	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.636	rs9495843	ENSG00000234147.1	RP3-460G2.2	-4.19	3.27e-05	0.00548	-0.33	-0.19	Facial emotion recognition (angry faces);	chr6:140829354	chr6:140845958~140852924:-
HNSC	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	4.19	3.28e-05	0.00548	0.15	0.19	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
HNSC	cis	rs9733	0.744	rs2089081	ENSG00000236713.1	RP11-363I22.3	4.19	3.28e-05	0.00548	0.2	0.19	Tonsillectomy;	chr1:150827641	chr1:150780272~150780644:+
HNSC	cis	rs7572733	0.84	rs10497807	ENSG00000222017.1	AC011997.1	-4.19	3.28e-05	0.00548	-0.23	-0.19	Dermatomyositis;	chr2:197720363	chr2:197693106~197774823:+
HNSC	cis	rs739496	0.615	rs56884502	ENSG00000226469.1	ADAM1B	4.19	3.28e-05	0.00548	0.22	0.19	Platelet count;	chr12:111769496	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.642	rs74849450	ENSG00000226469.1	ADAM1B	4.19	3.28e-05	0.00548	0.22	0.19	Platelet count;	chr12:111771034	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.579	rs2238152	ENSG00000226469.1	ADAM1B	4.19	3.28e-05	0.00548	0.22	0.19	Platelet count;	chr12:111776655	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.501	rs441	ENSG00000226469.1	ADAM1B	4.19	3.28e-05	0.00548	0.22	0.19	Platelet count;	chr12:111791045	chr12:111927018~111929017:+
HNSC	cis	rs73198271	0.74	rs1039911	ENSG00000233609.3	RP11-62H7.2	-4.19	3.28e-05	0.00548	-0.21	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8961200~8979025:+
HNSC	cis	rs12439619	0.883	rs62012045	ENSG00000276710.3	CSPG4P8	-4.19	3.28e-05	0.00548	-0.23	-0.19	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82459472~82477258:+
HNSC	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	4.19	3.28e-05	0.00548	0.24	0.19	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
HNSC	cis	rs7178909	0.902	rs8034116	ENSG00000259677.1	RP11-493E3.1	4.19	3.28e-05	0.00548	0.21	0.19	Common traits (Other);	chr15:89898336	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.902	rs8033554	ENSG00000259677.1	RP11-493E3.1	4.19	3.28e-05	0.00548	0.21	0.19	Common traits (Other);	chr15:89898337	chr15:89876540~89877285:+
HNSC	cis	rs7829975	0.871	rs572307	ENSG00000233609.3	RP11-62H7.2	-4.19	3.28e-05	0.00549	-0.18	-0.19	Mood instability;	chr8:8721301	chr8:8961200~8979025:+
HNSC	cis	rs2274273	0.743	rs7161656	ENSG00000233924.1	AL160471.6	-4.19	3.28e-05	0.00549	-0.21	-0.19	Protein biomarker;	chr14:55057812	chr14:55004813~55005687:-
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000254340.1	RP11-10A14.3	4.19	3.28e-05	0.00549	0.23	0.19	Neuroticism;	chr8:8237439	chr8:9141424~9145435:+
HNSC	cis	rs9926296	0.712	rs258319	ENSG00000274627.1	RP11-104N10.2	4.19	3.28e-05	0.00549	0.19	0.19	Vitiligo;	chr16:89665616	chr16:89516797~89522217:+
HNSC	cis	rs9393777	0.623	rs3734544	ENSG00000241549.7	GUSBP2	4.19	3.28e-05	0.00549	0.24	0.19	Intelligence (multi-trait analysis);	chr6:26468432	chr6:26871484~26956554:-
HNSC	cis	rs17594362	1	rs34756176	ENSG00000229473.2	RGS17P1	-4.19	3.28e-05	0.00549	-0.3	-0.19	Multiple sclerosis;	chr13:41578409	chr13:40992779~40993331:-
HNSC	cis	rs11673344	0.523	rs10406110	ENSG00000276846.1	CTD-3220F14.3	4.19	3.28e-05	0.00549	0.21	0.19	Obesity-related traits;	chr19:37160027	chr19:37314868~37315620:-
HNSC	cis	rs9527	0.501	rs12244388	ENSG00000236937.2	PTGES3P4	4.19	3.28e-05	0.00549	0.24	0.19	Arsenic metabolism;	chr10:102880295	chr10:102845595~102845950:+
HNSC	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	4.19	3.28e-05	0.00549	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
HNSC	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	4.19	3.28e-05	0.00549	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	4.19	3.28e-05	0.00549	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	4.19	3.28e-05	0.00549	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
HNSC	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	4.19	3.28e-05	0.00549	0.27	0.19	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
HNSC	cis	rs757081	0.648	rs1488933	ENSG00000260196.1	RP1-239B22.5	-4.19	3.28e-05	0.00549	-0.2	-0.19	Systolic blood pressure;	chr11:17245482	chr11:17380649~17383531:+
HNSC	cis	rs11969893	0.737	rs1358758	ENSG00000270987.1	RP3-467N11.2	4.19	3.28e-05	0.00549	0.44	0.19	Economic and political preferences (immigration/crime);	chr6:100964015	chr6:100889603~100890338:+
HNSC	cis	rs7005380	0.581	rs12677306	ENSG00000279347.1	RP11-85I17.2	-4.19	3.28e-05	0.00549	-0.17	-0.19	Interstitial lung disease;	chr8:119903842	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs12679478	ENSG00000279347.1	RP11-85I17.2	-4.19	3.28e-05	0.00549	-0.17	-0.19	Interstitial lung disease;	chr8:119903994	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.538	rs7461170	ENSG00000279347.1	RP11-85I17.2	-4.19	3.28e-05	0.00549	-0.17	-0.19	Interstitial lung disease;	chr8:119904014	chr8:119838736~119840385:-
HNSC	cis	rs911555	0.576	rs8015723	ENSG00000244691.1	RPL10AP1	4.19	3.29e-05	0.0055	0.24	0.19	Intelligence (multi-trait analysis);	chr14:103429572	chr14:103412119~103412761:-
HNSC	cis	rs4372836	1	rs6707848	ENSG00000226833.4	AC097724.3	4.19	3.29e-05	0.0055	0.24	0.19	Body mass index;	chr2:28765217	chr2:28708953~28736205:-
HNSC	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	4.19	3.29e-05	0.0055	0.2	0.19	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
HNSC	cis	rs2255336	0.81	rs7956385	ENSG00000245648.1	RP11-277P12.20	4.19	3.29e-05	0.0055	0.34	0.19	Blood protein levels;	chr12:10361398	chr12:10363769~10398506:+
HNSC	cis	rs761746	0.739	rs140081	ENSG00000236132.1	CTA-440B3.1	-4.19	3.29e-05	0.0055	-0.24	-0.19	Intelligence;	chr22:31716475	chr22:31816379~31817491:-
HNSC	cis	rs7005380	0.58	rs13263296	ENSG00000279347.1	RP11-85I17.2	-4.19	3.29e-05	0.0055	-0.16	-0.19	Interstitial lung disease;	chr8:119874305	chr8:119838736~119840385:-
HNSC	cis	rs79057730	0.639	rs6463933	ENSG00000225146.1	AC073957.15	4.19	3.29e-05	0.0055	0.29	0.19	Initial pursuit acceleration;	chr7:754317	chr7:1029025~1043891:+
HNSC	cis	rs12745968	0.685	rs11164807	ENSG00000223787.2	RP4-593M8.1	-4.19	3.29e-05	0.0055	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92768538	chr1:92580476~92580821:-
HNSC	cis	rs2518049	0.563	rs75811842	ENSG00000224034.1	RP11-445P17.8	-4.19	3.29e-05	0.0055	-0.26	-0.19	Metabolic traits;	chr10:5219138	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs76494948	ENSG00000224034.1	RP11-445P17.8	-4.19	3.29e-05	0.0055	-0.26	-0.19	Intelligence;	chr10:5219148	chr10:5266033~5271236:-
HNSC	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	4.19	3.29e-05	0.0055	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
HNSC	cis	rs860818	1	rs1637224	ENSG00000226816.2	AC005082.12	4.19	3.29e-05	0.00551	0.52	0.19	Initial pursuit acceleration;	chr7:23188781	chr7:23206013~23208045:+
HNSC	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	4.19	3.29e-05	0.00551	0.16	0.19	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	4.19	3.29e-05	0.00551	0.32	0.19	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
HNSC	cis	rs58873874	0.579	rs11738062	ENSG00000248544.2	CTB-47B11.3	4.19	3.3e-05	0.00551	0.33	0.19	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157375741~157384950:-
HNSC	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	4.19	3.3e-05	0.00551	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	4.19	3.3e-05	0.00551	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
HNSC	cis	rs12478296	0.901	rs59477854	ENSG00000261186.2	RP11-341N2.1	-4.19	3.3e-05	0.00551	-0.29	-0.19	Obesity-related traits;	chr2:242073339	chr2:242087351~242088457:-
HNSC	cis	rs7771547	0.573	rs10440841	ENSG00000219023.1	RP3-340B19.2	-4.19	3.3e-05	0.00551	-0.17	-0.19	Platelet distribution width;	chr6:36431309	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs9470278	ENSG00000219023.1	RP3-340B19.2	-4.19	3.3e-05	0.00551	-0.17	-0.19	Platelet distribution width;	chr6:36431462	chr6:35555873~35556264:+
HNSC	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	4.19	3.3e-05	0.00551	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
HNSC	cis	rs9450351	0.744	rs9362248	ENSG00000203875.9	SNHG5	-4.19	3.3e-05	0.00551	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85847249	chr6:85660950~85678736:-
HNSC	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-4.19	3.3e-05	0.00551	-0.23	-0.19	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
HNSC	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-4.19	3.3e-05	0.00551	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
HNSC	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	4.19	3.3e-05	0.00551	0.23	0.19	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
HNSC	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	4.19	3.3e-05	0.00551	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
HNSC	cis	rs853679	0.607	rs34950484	ENSG00000204709.4	LINC01556	4.19	3.3e-05	0.00552	0.38	0.19	Depression;	chr6:28310911	chr6:28943877~28944537:+
HNSC	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-4.19	3.3e-05	0.00552	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
HNSC	cis	rs12887734	0.524	rs12888002	ENSG00000269940.1	RP11-73M18.7	4.19	3.3e-05	0.00552	0.19	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694560~103695170:+
HNSC	cis	rs820077	0.551	rs9469953	ENSG00000272374.1	RP3-329A5.8	4.19	3.3e-05	0.00552	0.21	0.19	Systemic lupus erythematosus;	chr6:35162039	chr6:35220370~35224630:-
HNSC	cis	rs4927850	0.723	rs7630825	ENSG00000273009.1	RP11-352G9.1	-4.19	3.3e-05	0.00552	-0.22	-0.19	Pancreatic cancer;	chr3:196026869	chr3:195913078~195913683:-
HNSC	cis	rs116095464	0.558	rs62346506	ENSG00000250848.1	CTD-2083E4.5	-4.19	3.31e-05	0.00553	-0.27	-0.19	Breast cancer;	chr5:201479	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9312956	ENSG00000250848.1	CTD-2083E4.5	-4.19	3.31e-05	0.00553	-0.27	-0.19	Breast cancer;	chr5:201697	chr5:288833~290321:-
HNSC	cis	rs2070419	0.756	rs11088181	ENSG00000261610.1	AP000265.1	4.19	3.31e-05	0.00553	0.23	0.19	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31568428	chr21:32259804~32261585:-
HNSC	cis	rs7937890	0.598	rs10734225	ENSG00000254418.1	RP11-21L19.1	4.19	3.31e-05	0.00553	0.24	0.19	Mitochondrial DNA levels;	chr11:14421448	chr11:14262846~14273691:-
HNSC	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	4.19	3.31e-05	0.00553	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
HNSC	cis	rs9329221	0.525	rs4394398	ENSG00000269918.1	AF131215.9	-4.19	3.31e-05	0.00553	-0.2	-0.19	Neuroticism;	chr8:10226884	chr8:11104691~11106704:-
HNSC	cis	rs7572733	0.935	rs13394871	ENSG00000222017.1	AC011997.1	4.19	3.31e-05	0.00553	0.23	0.19	Dermatomyositis;	chr2:197981613	chr2:197693106~197774823:+
HNSC	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-4.19	3.31e-05	0.00553	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
HNSC	cis	rs8010715	0.848	rs2277483	ENSG00000259321.1	RP11-468E2.5	4.19	3.31e-05	0.00553	0.17	0.19	IgG glycosylation;	chr14:24122683	chr14:24139445~24140444:+
HNSC	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-4.19	3.31e-05	0.00554	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-4.19	3.31e-05	0.00554	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
HNSC	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	4.19	3.31e-05	0.00554	0.2	0.19	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
HNSC	cis	rs6988985	0.791	rs13257680	ENSG00000247317.3	RP11-273G15.2	4.19	3.31e-05	0.00554	0.22	0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142915893	chr8:142981738~143018437:-
HNSC	cis	rs913655	0.508	rs1817765	ENSG00000225527.1	RP11-383B4.4	-4.19	3.32e-05	0.00554	-0.23	-0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18722276	chr10:18531849~18533336:-
HNSC	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	4.19	3.32e-05	0.00554	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	4.19	3.32e-05	0.00554	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	4.19	3.32e-05	0.00554	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	4.19	3.32e-05	0.00554	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
HNSC	cis	rs4252134	0.801	rs62436702	ENSG00000231863.1	RP3-428L16.1	4.19	3.32e-05	0.00554	0.25	0.19	Giant cell arteritis;	chr6:160775530	chr6:160931080~160969771:+
HNSC	cis	rs4356203	0.905	rs6486352	ENSG00000272034.1	SNORD14A	4.19	3.32e-05	0.00554	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17074654~17074744:-
HNSC	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-4.19	3.32e-05	0.00554	-0.26	-0.19	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
HNSC	cis	rs4388249	1	rs17162347	ENSG00000271849.1	CTC-332L22.1	-4.19	3.32e-05	0.00554	-0.3	-0.19	Schizophrenia;	chr5:109847218	chr5:109687802~109688329:-
HNSC	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	4.19	3.32e-05	0.00554	0.19	0.19	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
HNSC	cis	rs11148252	0.553	rs7999849	ENSG00000198384.8	TPTE2P3	4.19	3.32e-05	0.00554	0.23	0.19	Lewy body disease;	chr13:52675279	chr13:52522632~52586906:+
HNSC	cis	rs2048656	0.54	rs55868514	ENSG00000254340.1	RP11-10A14.3	-4.19	3.32e-05	0.00554	-0.24	-0.19	Schizophrenia;	chr8:9822890	chr8:9141424~9145435:+
HNSC	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	4.19	3.32e-05	0.00555	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	4.19	3.32e-05	0.00555	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
HNSC	cis	rs4356203	0.519	rs214084	ENSG00000260196.1	RP1-239B22.5	-4.19	3.32e-05	0.00555	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.519	rs214083	ENSG00000260196.1	RP1-239B22.5	-4.19	3.32e-05	0.00555	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17380649~17383531:+
HNSC	cis	rs2412819	0.571	rs56226333	ENSG00000166763.7	STRCP1	4.19	3.32e-05	0.00555	0.27	0.19	Lung cancer;	chr15:43632410	chr15:43699488~43718184:-
HNSC	cis	rs2835345	0.528	rs12483650	ENSG00000230479.1	AP000695.6	4.19	3.32e-05	0.00555	0.2	0.19	Pulmonary function;	chr21:36450778	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12483621	ENSG00000230479.1	AP000695.6	4.19	3.32e-05	0.00555	0.2	0.19	Pulmonary function;	chr21:36450798	chr21:36430360~36481070:+
HNSC	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	4.19	3.32e-05	0.00555	0.25	0.19	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
HNSC	cis	rs72843506	0.722	rs12051550	ENSG00000261033.1	RP11-209D14.2	4.19	3.32e-05	0.00555	0.32	0.19	Schizophrenia;	chr17:20226233	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.722	rs9901484	ENSG00000261033.1	RP11-209D14.2	4.19	3.32e-05	0.00555	0.32	0.19	Schizophrenia;	chr17:20229581	chr17:20008051~20009234:-
HNSC	cis	rs853679	0.546	rs35744819	ENSG00000204709.4	LINC01556	4.19	3.32e-05	0.00555	0.39	0.19	Depression;	chr6:28350554	chr6:28943877~28944537:+
HNSC	cis	rs11773103	0.881	rs11978231	ENSG00000224046.1	AC005076.5	4.19	3.32e-05	0.00555	0.27	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87136444	chr7:87151423~87152420:-
HNSC	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-4.19	3.32e-05	0.00555	-0.24	-0.19	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
HNSC	cis	rs1113500	0.814	rs893983	ENSG00000226822.1	RP11-356N1.2	-4.19	3.33e-05	0.00555	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108087716	chr1:108071482~108074519:+
HNSC	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	4.19	3.33e-05	0.00555	0.19	0.19	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
HNSC	cis	rs795484	0.926	rs353897	ENSG00000275409.1	RP11-131L12.4	-4.19	3.33e-05	0.00556	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118202036	chr12:118430147~118430699:+
HNSC	cis	rs831571	0.653	rs73120967	ENSG00000280620.1	SCAANT1	4.19	3.33e-05	0.00556	0.31	0.19	Type 2 diabetes;	chr3:64084696	chr3:63911518~63911772:-
HNSC	cis	rs2333021	0.77	rs12892806	ENSG00000258376.2	RP4-647C14.2	-4.19	3.33e-05	0.00556	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72936225	chr14:73242651~73245979:-
HNSC	cis	rs12745968	0.624	rs6675753	ENSG00000223787.2	RP4-593M8.1	-4.19	3.33e-05	0.00556	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92750039	chr1:92580476~92580821:-
HNSC	cis	rs721917	0.506	rs2758543	ENSG00000244733.5	RP11-506M13.3	-4.19	3.33e-05	0.00556	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79660891~79677996:+
HNSC	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.19	3.33e-05	0.00556	0.2	0.19	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
HNSC	cis	rs2384207	0.584	rs7953252	ENSG00000201208.1	Y_RNA	-4.19	3.33e-05	0.00556	-0.28	-0.19	Response to fenofibrate (adiponectin levels);	chr12:113302637	chr12:113178423~113178519:-
HNSC	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	4.19	3.33e-05	0.00556	0.23	0.19	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
HNSC	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-4.19	3.33e-05	0.00556	-0.18	-0.19	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
HNSC	cis	rs12887734	0.566	rs3742366	ENSG00000269940.1	RP11-73M18.7	4.19	3.33e-05	0.00556	0.19	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694560~103695170:+
HNSC	cis	rs9992667	0.577	rs10021686	ENSG00000231160.8	KLF3-AS1	4.19	3.33e-05	0.00556	0.25	0.19	Eosinophil percentage of granulocytes;	chr4:38703636	chr4:38612701~38664883:-
HNSC	cis	rs4256159	1	rs11706265	ENSG00000228956.7	SATB1-AS1	4.19	3.33e-05	0.00556	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18781130	chr3:18445024~18920401:+
HNSC	cis	rs11893307	0.599	rs13423600	ENSG00000235852.1	AC005540.3	4.19	3.33e-05	0.00556	0.27	0.19	Mean platelet volume;	chr2:190803575	chr2:190880797~190882059:-
HNSC	cis	rs9329221	0.527	rs34308302	ENSG00000269918.1	AF131215.9	-4.19	3.33e-05	0.00556	-0.2	-0.19	Neuroticism;	chr8:10474512	chr8:11104691~11106704:-
HNSC	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	4.19	3.33e-05	0.00556	0.22	0.19	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	4.19	3.33e-05	0.00556	0.22	0.19	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	4.19	3.33e-05	0.00556	0.22	0.19	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
HNSC	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	4.19	3.33e-05	0.00556	0.22	0.19	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
HNSC	cis	rs2243480	1	rs59794892	ENSG00000229886.1	RP5-1132H15.3	4.19	3.33e-05	0.00557	0.33	0.19	Diabetic kidney disease;	chr7:65950886	chr7:66025126~66031544:-
HNSC	cis	rs11098499	0.955	rs13129661	ENSG00000250412.1	KLHL2P1	4.19	3.33e-05	0.00557	0.24	0.19	Corneal astigmatism;	chr4:119231754	chr4:119334329~119378233:+
HNSC	cis	rs3015497	0.603	rs3015443	ENSG00000269906.1	RP11-248J18.2	-4.19	3.34e-05	0.00557	-0.26	-0.19	Mean platelet volume;	chr14:50618490	chr14:50662511~50663178:-
HNSC	cis	rs6601327	0.641	rs10102170	ENSG00000233609.3	RP11-62H7.2	4.19	3.34e-05	0.00557	0.18	0.19	Multiple myeloma (hyperdiploidy);	chr8:9753960	chr8:8961200~8979025:+
HNSC	cis	rs7701440	0.508	rs476099	ENSG00000215032.2	GNL3LP1	4.19	3.34e-05	0.00557	0.21	0.19	Educational attainment;	chr5:61237147	chr5:60891935~60893577:-
HNSC	cis	rs11722228	0.522	rs2241468	ENSG00000250413.1	RP11-448G15.1	-4.19	3.34e-05	0.00557	-0.3	-0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10112281	chr4:10006482~10009725:+
HNSC	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-4.19	3.34e-05	0.00557	-0.19	-0.19	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
HNSC	cis	rs9313772	0.783	rs7726308	ENSG00000254350.1	RP11-542A14.1	-4.19	3.34e-05	0.00557	-0.2	-0.19	Blood pressure;	chr5:158446519	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs11959225	ENSG00000254350.1	RP11-542A14.1	-4.19	3.34e-05	0.00557	-0.2	-0.19	Blood pressure;	chr5:158449466	chr5:158424585~158452758:+
HNSC	cis	rs7829975	0.577	rs7816329	ENSG00000173295.6	FAM86B3P	-4.19	3.34e-05	0.00557	-0.23	-0.19	Mood instability;	chr8:8686333	chr8:8228595~8244865:+
HNSC	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	4.19	3.34e-05	0.00557	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
HNSC	cis	rs4356203	0.905	rs214906	ENSG00000272034.1	SNORD14A	4.19	3.34e-05	0.00557	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17074654~17074744:-
HNSC	cis	rs10129255	0.957	rs61997760	ENSG00000280411.1	IGHV1-69-2	-4.19	3.34e-05	0.00558	-0.14	-0.19	Kawasaki disease;	chr14:106716993	chr14:106762092~106762588:-
HNSC	cis	rs656319	0.513	rs3885723	ENSG00000255310.2	AF131215.2	-4.19	3.34e-05	0.00558	-0.19	-0.19	Myopia (pathological);	chr8:10134151	chr8:11107788~11109726:-
HNSC	cis	rs1878047	0.702	rs12975233	ENSG00000131401.10	NAPSB	4.19	3.34e-05	0.00558	0.14	0.19	Body mass index;	chr19:51275698	chr19:50333796~50344767:-
HNSC	cis	rs10090774	0.786	rs11776239	ENSG00000279766.1	RP11-642A1.2	-4.19	3.34e-05	0.00558	-0.19	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708602	chr8:140572142~140572812:-
HNSC	cis	rs4356203	0.875	rs7125607	ENSG00000260196.1	RP1-239B22.5	-4.19	3.35e-05	0.00558	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17380649~17383531:+
HNSC	cis	rs36052053	0.908	rs34352435	ENSG00000203799.9	CCDC162P	4.19	3.35e-05	0.00559	0.28	0.19	Red cell distribution width;	chr6:109272401	chr6:109285485~109355063:+
HNSC	cis	rs71520386	0.861	rs35841035	ENSG00000230658.1	KLHL7-AS1	4.19	3.35e-05	0.00559	0.3	0.19	Fibrinogen levels;	chr7:22822987	chr7:23101228~23105703:-
HNSC	cis	rs1659258	0.527	rs1258404	ENSG00000232508.1	MRPL45P1	4.19	3.35e-05	0.00559	0.33	0.19	Visceral fat;	chr2:88320697	chr2:88364695~88365608:-
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000106610.13	STAG3L4	-4.19	3.35e-05	0.00559	-0.25	-0.19	Aortic root size;	chr7:66762495	chr7:67302621~67321526:+
HNSC	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	4.19	3.35e-05	0.00559	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
HNSC	cis	rs3736485	0.844	rs67524810	ENSG00000259438.1	CTD-2650P22.1	4.19	3.35e-05	0.00559	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51513094	chr15:52010999~52019095:-
HNSC	cis	rs9450351	1	rs7774219	ENSG00000203875.9	SNHG5	-4.19	3.35e-05	0.00559	-0.41	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85908837	chr6:85660950~85678736:-
HNSC	cis	rs950169	0.544	rs2036949	ENSG00000229212.6	RP11-561C5.4	-4.19	3.35e-05	0.00559	-0.28	-0.19	Schizophrenia;	chr15:84620374	chr15:85205440~85234795:-
HNSC	cis	rs11098499	0.82	rs6829903	ENSG00000250412.1	KLHL2P1	4.19	3.35e-05	0.00559	0.25	0.19	Corneal astigmatism;	chr4:119585729	chr4:119334329~119378233:+
HNSC	cis	rs7688540	0.771	rs10027325	ENSG00000250892.1	RP11-1365D11.1	-4.19	3.35e-05	0.00559	-0.33	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:201409~205009:-
HNSC	cis	rs7688540	0.771	rs1986557	ENSG00000250892.1	RP11-1365D11.1	-4.19	3.35e-05	0.00559	-0.33	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:201409~205009:-
HNSC	cis	rs9926296	0.712	rs459920	ENSG00000274627.1	RP11-104N10.2	4.19	3.35e-05	0.00559	0.19	0.19	Vitiligo;	chr16:89664419	chr16:89516797~89522217:+
HNSC	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	4.19	3.35e-05	0.00559	0.28	0.19	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
HNSC	cis	rs638893	0.636	rs526850	ENSG00000255422.1	AP002954.4	-4.19	3.35e-05	0.00559	-0.31	-0.19	Vitiligo;	chr11:118734418	chr11:118704607~118750263:+
HNSC	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	4.19	3.35e-05	0.00559	0.26	0.19	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
HNSC	cis	rs9859260	0.71	rs419068	ENSG00000242086.7	LINC00969	-4.19	3.35e-05	0.00559	-0.16	-0.19	Mean corpuscular volume;	chr3:196055305	chr3:195658062~195739964:+
HNSC	cis	rs9859260	0.71	rs366268	ENSG00000242086.7	LINC00969	-4.19	3.35e-05	0.00559	-0.16	-0.19	Mean corpuscular volume;	chr3:196055306	chr3:195658062~195739964:+
HNSC	cis	rs9859260	0.744	rs419059	ENSG00000242086.7	LINC00969	-4.19	3.35e-05	0.00559	-0.16	-0.19	Mean corpuscular volume;	chr3:196055313	chr3:195658062~195739964:+
HNSC	cis	rs913655	0.574	rs2480343	ENSG00000225527.1	RP11-383B4.4	-4.19	3.35e-05	0.00559	-0.23	-0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18783334	chr10:18531849~18533336:-
HNSC	cis	rs9910055	0.529	rs228746	ENSG00000267080.4	ASB16-AS1	4.19	3.36e-05	0.0056	0.15	0.19	Total body bone mineral density;	chr17:44096384	chr17:44175973~44186717:-
HNSC	cis	rs61935443	0.501	rs10859753	ENSG00000241556.1	RP11-490G8.1	4.19	3.36e-05	0.0056	0.19	0.19	Schizophrenia;	chr12:94798671	chr12:95467397~95467861:-
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119333282	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119334135	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119335037	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119335609	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119335868	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119336073	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000250412.1	KLHL2P1	4.19	3.36e-05	0.0056	0.24	0.19	Corneal astigmatism;	chr4:119336262	chr4:119334329~119378233:+
HNSC	cis	rs4699052	0.625	rs7695593	ENSG00000246560.2	RP11-10L12.4	4.19	3.36e-05	0.0056	0.22	0.19	Testicular germ cell tumor;	chr4:103342626	chr4:102828055~102844075:+
HNSC	cis	rs4873772	0.837	rs62539144	ENSG00000253330.1	RP11-697N18.3	-4.19	3.36e-05	0.0056	-0.24	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47650686	chr8:47511034~47512141:-
HNSC	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-4.19	3.36e-05	0.0056	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
HNSC	cis	rs2638953	0.893	rs7969086	ENSG00000257176.2	RP11-996F15.2	-4.19	3.36e-05	0.0056	-0.21	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507273	chr12:29280418~29317848:-
HNSC	cis	rs757081	0.667	rs60173525	ENSG00000260196.1	RP1-239B22.5	-4.19	3.36e-05	0.0056	-0.23	-0.19	Systolic blood pressure;	chr11:17238420	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.667	rs12577525	ENSG00000260196.1	RP1-239B22.5	-4.19	3.36e-05	0.0056	-0.23	-0.19	Systolic blood pressure;	chr11:17238569	chr11:17380649~17383531:+
HNSC	cis	rs7826238	0.535	rs2979179	ENSG00000254340.1	RP11-10A14.3	4.19	3.36e-05	0.00561	0.22	0.19	Systolic blood pressure;	chr8:8462519	chr8:9141424~9145435:+
HNSC	cis	rs11157436	0.602	rs11157438	ENSG00000211812.1	TRAV26-2	-4.19	3.36e-05	0.00561	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22202583~22203368:+
HNSC	cis	rs2243480	1	rs1638734	ENSG00000106610.13	STAG3L4	-4.19	3.36e-05	0.00561	-0.39	-0.19	Diabetic kidney disease;	chr7:66632552	chr7:67302621~67321526:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000106610.13	STAG3L4	-4.19	3.36e-05	0.00561	-0.39	-0.19	Gout;	chr7:66642037	chr7:67302621~67321526:+
HNSC	cis	rs2486288	0.656	rs2413773	ENSG00000259479.5	SORD2P	-4.19	3.36e-05	0.00561	-0.22	-0.19	Glomerular filtration rate;	chr15:45257244	chr15:44826371~44884694:-
HNSC	cis	rs853679	0.607	rs34396849	ENSG00000204709.4	LINC01556	4.19	3.37e-05	0.00561	0.39	0.19	Depression;	chr6:28283178	chr6:28943877~28944537:+
HNSC	cis	rs7824557	0.545	rs2572380	ENSG00000269918.1	AF131215.9	-4.19	3.37e-05	0.00561	-0.18	-0.19	Retinal vascular caliber;	chr8:11379968	chr8:11104691~11106704:-
HNSC	cis	rs683257	0.929	rs72990194	ENSG00000234147.1	RP3-460G2.2	-4.19	3.37e-05	0.00561	-0.41	-0.19	Facial emotion recognition (angry faces);	chr6:140901871	chr6:140845958~140852924:-
HNSC	cis	rs4256159	1	rs11708026	ENSG00000228956.7	SATB1-AS1	4.19	3.37e-05	0.00561	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18700310	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs73170234	ENSG00000228956.7	SATB1-AS1	4.19	3.37e-05	0.00561	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18703972	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs58559219	ENSG00000228956.7	SATB1-AS1	4.19	3.37e-05	0.00561	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18708849	chr3:18445024~18920401:+
HNSC	cis	rs7508	0.619	rs483159	ENSG00000253671.1	RP11-806O11.1	-4.19	3.37e-05	0.00561	-0.23	-0.19	Atrial fibrillation;	chr8:18054329	chr8:17808941~17820868:+
HNSC	cis	rs13434995	0.513	rs13133077	ENSG00000273257.1	RP11-177J6.1	4.19	3.37e-05	0.00561	0.26	0.19	Adiponectin levels;	chr4:55577642	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs7665286	ENSG00000273257.1	RP11-177J6.1	4.19	3.37e-05	0.00561	0.26	0.19	Adiponectin levels;	chr4:55578765	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.513	rs7683997	ENSG00000273257.1	RP11-177J6.1	4.19	3.37e-05	0.00561	0.26	0.19	Adiponectin levels;	chr4:55581272	chr4:55387949~55388271:+
HNSC	cis	rs950776	0.642	rs58946838	ENSG00000261762.1	RP11-650L12.2	4.19	3.37e-05	0.00561	0.24	0.19	Sudden cardiac arrest;	chr15:78669107	chr15:78589123~78591276:-
HNSC	cis	rs911555	0.504	rs4444269	ENSG00000270108.1	RP11-73M18.6	4.19	3.37e-05	0.00561	0.21	0.19	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103687576~103688127:+
HNSC	cis	rs911555	0.504	rs8021368	ENSG00000270108.1	RP11-73M18.6	4.19	3.37e-05	0.00561	0.21	0.19	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103687576~103688127:+
HNSC	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	4.19	3.37e-05	0.00561	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
HNSC	cis	rs7429990	0.864	rs11712464	ENSG00000228638.1	FCF1P2	-4.19	3.37e-05	0.00561	-0.18	-0.19	Educational attainment (years of education);	chr3:47724057	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs56376646	ENSG00000228638.1	FCF1P2	-4.19	3.37e-05	0.00561	-0.18	-0.19	Educational attainment (years of education);	chr3:47732588	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs11927129	ENSG00000228638.1	FCF1P2	-4.19	3.37e-05	0.00561	-0.18	-0.19	Educational attainment (years of education);	chr3:47745413	chr3:48290793~48291375:-
HNSC	cis	rs2524005	1	rs2524005	ENSG00000204709.4	LINC01556	4.19	3.37e-05	0.00561	0.27	0.19	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:28943877~28944537:+
HNSC	cis	rs4862750	0.872	rs4862747	ENSG00000250971.1	RP11-696F12.1	-4.19	3.37e-05	0.00561	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:187060099~187060930:+
HNSC	cis	rs17345786	0.906	rs72940399	ENSG00000244119.1	PDCL3P4	4.19	3.37e-05	0.00561	0.21	0.19	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101712472~101713191:+
HNSC	cis	rs60617249	0.801	rs2216815	ENSG00000228204.2	RP4-724E13.2	4.19	3.37e-05	0.00562	0.2	0.19	Major depression and alcohol dependence;	chr7:50875749	chr7:50866747~51022990:+
HNSC	cis	rs8077577	0.671	rs4500798	ENSG00000273018.4	CTD-2303H24.2	-4.19	3.37e-05	0.00562	-0.26	-0.19	Obesity-related traits;	chr17:18351765	chr17:18511221~18551705:-
HNSC	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.674	rs7269912	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49039661	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs13042443	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49047217	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs2227946	ENSG00000222365.1	SNORD12B	-4.19	3.37e-05	0.00562	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49068783	chr20:49280319~49280409:+
HNSC	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	4.19	3.37e-05	0.00562	0.22	0.19	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
HNSC	cis	rs1790761	0.505	rs7927657	ENSG00000184224.3	C11orf72	-4.19	3.37e-05	0.00562	-0.23	-0.19	Mean corpuscular volume;	chr11:67579517	chr11:67602880~67606706:-
HNSC	cis	rs1790761	0.505	rs7941395	ENSG00000184224.3	C11orf72	-4.19	3.37e-05	0.00562	-0.23	-0.19	Mean corpuscular volume;	chr11:67579946	chr11:67602880~67606706:-
HNSC	cis	rs1790761	0.505	rs7941648	ENSG00000184224.3	C11orf72	-4.19	3.37e-05	0.00562	-0.23	-0.19	Mean corpuscular volume;	chr11:67580124	chr11:67602880~67606706:-
HNSC	cis	rs1790761	0.505	rs7945035	ENSG00000184224.3	C11orf72	-4.19	3.37e-05	0.00562	-0.23	-0.19	Mean corpuscular volume;	chr11:67580691	chr11:67602880~67606706:-
HNSC	cis	rs1790761	0.505	rs2370141	ENSG00000184224.3	C11orf72	-4.19	3.37e-05	0.00562	-0.23	-0.19	Mean corpuscular volume;	chr11:67581058	chr11:67602880~67606706:-
HNSC	cis	rs1714507	0.533	rs2731122	ENSG00000272087.1	RP11-379F4.7	4.19	3.37e-05	0.00562	0.21	0.19	Subjective well-being;	chr3:158577491	chr3:158693120~158693768:-
HNSC	cis	rs1714507	0.533	rs2731120	ENSG00000272087.1	RP11-379F4.7	-4.19	3.37e-05	0.00562	-0.21	-0.19	Subjective well-being;	chr3:158579844	chr3:158693120~158693768:-
HNSC	cis	rs1714507	0.533	rs2731118	ENSG00000272087.1	RP11-379F4.7	-4.19	3.37e-05	0.00562	-0.21	-0.19	Subjective well-being;	chr3:158589942	chr3:158693120~158693768:-
HNSC	cis	rs1714507	0.533	rs2573179	ENSG00000272087.1	RP11-379F4.7	-4.19	3.37e-05	0.00562	-0.21	-0.19	Subjective well-being;	chr3:158590018	chr3:158693120~158693768:-
HNSC	cis	rs453301	0.598	rs1025395	ENSG00000253981.4	ALG1L13P	4.19	3.37e-05	0.00562	0.21	0.19	Joint mobility (Beighton score);	chr8:8979093	chr8:8236003~8244667:-
HNSC	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-4.19	3.37e-05	0.00562	-0.23	-0.19	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
HNSC	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-4.19	3.38e-05	0.00562	-0.19	-0.19	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
HNSC	cis	rs9329221	0.527	rs7833781	ENSG00000255310.2	AF131215.2	4.19	3.38e-05	0.00563	0.19	0.19	Neuroticism;	chr8:10475967	chr8:11107788~11109726:-
HNSC	cis	rs9611565	0.527	rs2234053	ENSG00000235513.1	RP4-756G23.5	4.19	3.38e-05	0.00563	0.22	0.19	Vitiligo;	chr22:41381311	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.802	rs2234058	ENSG00000235513.1	RP4-756G23.5	4.19	3.38e-05	0.00563	0.22	0.19	Vitiligo;	chr22:41381879	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.84	rs2234059	ENSG00000235513.1	RP4-756G23.5	4.19	3.38e-05	0.00563	0.22	0.19	Vitiligo;	chr22:41381909	chr22:41209122~41217627:-
HNSC	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	4.19	3.38e-05	0.00563	0.28	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000254174.1	IGHV1-12	4.19	3.38e-05	0.00563	0.14	0.19	Alzheimer's disease (late onset);	chr14:106631885	chr14:106122420~106122709:-
HNSC	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	4.19	3.38e-05	0.00563	0.21	0.19	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
HNSC	cis	rs4388249	0.95	rs724214	ENSG00000271849.1	CTC-332L22.1	-4.19	3.38e-05	0.00563	-0.29	-0.19	Schizophrenia;	chr5:109752655	chr5:109687802~109688329:-
HNSC	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	4.19	3.38e-05	0.00563	0.27	0.19	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
HNSC	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	4.19	3.38e-05	0.00563	0.23	0.19	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
HNSC	cis	rs7824557	0.564	rs2736293	ENSG00000269918.1	AF131215.9	-4.19	3.38e-05	0.00563	-0.18	-0.19	Retinal vascular caliber;	chr8:11377104	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs2736294	ENSG00000269918.1	AF131215.9	-4.19	3.38e-05	0.00563	-0.18	-0.19	Retinal vascular caliber;	chr8:11377117	chr8:11104691~11106704:-
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	4.19	3.38e-05	0.00564	0.33	0.19	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
HNSC	cis	rs67311347	0.713	rs9861194	ENSG00000280739.1	EIF1B-AS1	4.19	3.38e-05	0.00564	0.21	0.19	Renal cell carcinoma;	chr3:40267734	chr3:40173145~40309698:-
HNSC	cis	rs10927875	0.722	rs1763606	ENSG00000226029.1	RP4-798A10.2	-4.19	3.38e-05	0.00564	-0.19	-0.19	Dilated cardiomyopathy;	chr1:16011787	chr1:16460948~16468481:+
HNSC	cis	rs11098499	0.909	rs28571712	ENSG00000250412.1	KLHL2P1	4.19	3.39e-05	0.00564	0.25	0.19	Corneal astigmatism;	chr4:119454825	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs9994730	ENSG00000250412.1	KLHL2P1	4.19	3.39e-05	0.00564	0.25	0.19	Corneal astigmatism;	chr4:119460409	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs11098526	ENSG00000250412.1	KLHL2P1	4.19	3.39e-05	0.00564	0.25	0.19	Corneal astigmatism;	chr4:119469204	chr4:119334329~119378233:+
HNSC	cis	rs482329	0.623	rs2770366	ENSG00000224939.1	LINC00184	4.19	3.39e-05	0.00564	0.24	0.19	Life threatening arrhythmia;	chr1:234665153	chr1:234629311~234634780:+
HNSC	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-4.19	3.39e-05	0.00564	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
HNSC	cis	rs2839186	0.709	rs2839176	ENSG00000239415.1	AP001469.9	4.19	3.39e-05	0.00564	0.17	0.19	Testicular germ cell tumor;	chr21:46258259	chr21:46251549~46254133:-
HNSC	cis	rs35963943	0.625	rs4133217	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18694729	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs11128903	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18695152	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs7638551	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18696668	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs6810331	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18701910	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs9917638	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18705617	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs9917639	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18705875	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs9917695	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18705917	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13065200	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18706250	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.6	rs4320078	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18706534	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.571	rs4461441	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18706814	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.571	rs4596169	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18706825	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs9917662	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18707386	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13072369	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18708574	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13072692	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18708755	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13094139	ENSG00000228956.7	SATB1-AS1	4.19	3.39e-05	0.00564	0.23	0.19	Lymphocyte counts;	chr3:18709230	chr3:18445024~18920401:+
HNSC	cis	rs2013441	0.866	rs2703813	ENSG00000261033.1	RP11-209D14.2	4.19	3.39e-05	0.00564	0.22	0.19	Obesity-related traits;	chr17:20212002	chr17:20008051~20009234:-
HNSC	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	4.19	3.39e-05	0.00564	0.17	0.19	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
HNSC	cis	rs9880211	0.8	rs35100027	ENSG00000273486.1	RP11-731C17.2	4.19	3.39e-05	0.00565	0.19	0.19	Height;Body mass index;	chr3:136748719	chr3:136837338~136839021:-
HNSC	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-4.19	3.39e-05	0.00565	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
HNSC	cis	rs4252134	0.551	rs6926947	ENSG00000233342.1	RP11-235G24.3	-4.19	3.39e-05	0.00565	-0.24	-0.19	Giant cell arteritis;	chr6:160851644	chr6:160926369~160927162:+
HNSC	cis	rs755249	0.567	rs6668369	ENSG00000228060.1	RP11-69E11.8	-4.19	3.39e-05	0.00565	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39565160~39573203:+
HNSC	cis	rs1008375	0.932	rs6449321	ENSG00000249502.1	AC006160.5	-4.19	3.4e-05	0.00565	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17642849	chr4:17587467~17614571:-
HNSC	cis	rs7824557	0.606	rs1047950	ENSG00000269918.1	AF131215.9	4.19	3.4e-05	0.00565	0.19	0.19	Retinal vascular caliber;	chr8:11327587	chr8:11104691~11106704:-
HNSC	cis	rs2098713	0.561	rs55960353	ENSG00000250155.1	CTD-2353F22.1	4.19	3.4e-05	0.00565	0.19	0.19	Telomere length;	chr5:37599484	chr5:36666214~36725195:-
HNSC	cis	rs13325613	0.834	rs35754688	ENSG00000223552.1	RP11-24F11.2	-4.19	3.4e-05	0.00565	-0.3	-0.19	Monocyte count;	chr3:46146214	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34191675	ENSG00000223552.1	RP11-24F11.2	-4.19	3.4e-05	0.00565	-0.3	-0.19	Monocyte count;	chr3:46147956	chr3:46364955~46407059:-
HNSC	cis	rs2904524	1	rs58612372	ENSG00000257815.4	RP11-611E13.2	-4.19	3.4e-05	0.00565	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70276566	chr12:69904033~70243360:-
HNSC	cis	rs7824557	0.527	rs2736296	ENSG00000269918.1	AF131215.9	-4.19	3.4e-05	0.00565	-0.18	-0.19	Retinal vascular caliber;	chr8:11377335	chr8:11104691~11106704:-
HNSC	cis	rs6964587	0.692	rs17672805	ENSG00000188693.7	CYP51A1-AS1	4.19	3.4e-05	0.00565	0.2	0.19	Breast cancer;	chr7:91944152	chr7:92134604~92180725:+
HNSC	cis	rs13256369	1	rs1109619	ENSG00000173295.6	FAM86B3P	4.19	3.4e-05	0.00565	0.25	0.19	Obesity-related traits;	chr8:8714106	chr8:8228595~8244865:+
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000106610.13	STAG3L4	-4.19	3.4e-05	0.00566	-0.38	-0.19	Diabetic kidney disease;	chr7:66500834	chr7:67302621~67321526:+
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	-4.19	3.4e-05	0.00566	-0.24	-0.19	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
HNSC	cis	rs12745968	0.62	rs7514156	ENSG00000223787.2	RP4-593M8.1	-4.19	3.4e-05	0.00566	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92504652	chr1:92580476~92580821:-
HNSC	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-4.19	3.4e-05	0.00566	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-4.19	3.4e-05	0.00566	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
HNSC	cis	rs6504108	0.602	rs7219967	ENSG00000278765.1	RP5-890E16.5	-4.19	3.4e-05	0.00566	-0.24	-0.19	Body mass index;	chr17:48216712	chr17:48066704~48067293:-
HNSC	cis	rs2760061	0.583	rs708124	ENSG00000270110.1	RP5-1139B12.4	-4.19	3.4e-05	0.00566	-0.2	-0.19	Diastolic blood pressure;	chr1:228033070	chr1:228295911~228302998:-
HNSC	cis	rs4253772	0.591	rs12167567	ENSG00000277232.2	GTSE1-AS1	-4.19	3.4e-05	0.00566	-0.24	-0.19	Cholesterol, total;LDL cholesterol;	chr22:46264045	chr22:46295143~46296660:-
HNSC	cis	rs9859260	0.744	rs406271	ENSG00000242086.7	LINC00969	-4.19	3.4e-05	0.00566	-0.16	-0.19	Mean corpuscular volume;	chr3:196050105	chr3:195658062~195739964:+
HNSC	cis	rs13073817	0.543	rs336614	ENSG00000228956.7	SATB1-AS1	-4.19	3.4e-05	0.00566	-0.2	-0.19	Crohn's disease;	chr3:18590414	chr3:18445024~18920401:+
HNSC	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	4.19	3.4e-05	0.00566	0.16	0.19	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
HNSC	cis	rs1602565	0.858	rs11030592	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29148960	chr11:29275655~29276565:+
HNSC	cis	rs1602565	1	rs11030593	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29149691	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs10835490	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29150097	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs12293421	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29151199	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs7952432	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29152651	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs10835492	ENSG00000255450.1	CTD-2063L20.1	-4.19	3.41e-05	0.00567	-0.29	-0.19	Schizophrenia;	chr11:29153076	chr11:29275655~29276565:+
HNSC	cis	rs9650657	0.801	rs4841437	ENSG00000269918.1	AF131215.9	-4.19	3.41e-05	0.00567	-0.19	-0.19	Neuroticism;	chr8:10739285	chr8:11104691~11106704:-
HNSC	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	4.19	3.41e-05	0.00567	0.39	0.19	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000106610.13	STAG3L4	-4.19	3.41e-05	0.00567	-0.39	-0.19	Diabetic kidney disease;	chr7:66302856	chr7:67302621~67321526:+
HNSC	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	4.19	3.41e-05	0.00567	0.26	0.19	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
HNSC	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	4.19	3.41e-05	0.00567	0.29	0.19	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
HNSC	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	4.19	3.41e-05	0.00567	0.29	0.19	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
HNSC	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	4.19	3.41e-05	0.00567	0.29	0.19	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
HNSC	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-4.18	3.41e-05	0.00567	-0.22	-0.19	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
HNSC	cis	rs728616	0.867	rs2152550	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.41e-05	0.00567	-0.38	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79663088~79826594:-
HNSC	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-4.18	3.41e-05	0.00567	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
HNSC	cis	rs929354	0.742	rs1182396	ENSG00000224629.1	RP5-1142J19.2	4.18	3.41e-05	0.00567	0.19	0.19	Body mass index;	chr7:157239137	chr7:157263022~157263229:-
HNSC	cis	rs1713985	1	rs802920	ENSG00000269949.1	RP11-738E22.3	-4.18	3.41e-05	0.00567	-0.38	-0.19	Age-related macular degeneration;	chr4:56907332	chr4:56960927~56961373:-
HNSC	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-4.18	3.41e-05	0.00567	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs8118101	ENSG00000222365.1	SNORD12B	-4.18	3.41e-05	0.00567	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49073301	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs7271812	ENSG00000222365.1	SNORD12B	-4.18	3.41e-05	0.00567	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49076496	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs11908024	ENSG00000222365.1	SNORD12B	-4.18	3.41e-05	0.00567	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49081649	chr20:49280319~49280409:+
HNSC	cis	rs11098499	0.954	rs6847248	ENSG00000250412.1	KLHL2P1	4.18	3.41e-05	0.00567	0.25	0.19	Corneal astigmatism;	chr4:119304800	chr4:119334329~119378233:+
HNSC	cis	rs3806843	0.576	rs405192	ENSG00000276545.1	PCDHGB9P	4.18	3.41e-05	0.00568	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140945125	chr5:141439853~141442449:+
HNSC	cis	rs9650657	0.707	rs10097283	ENSG00000255310.2	AF131215.2	-4.18	3.41e-05	0.00568	-0.18	-0.19	Neuroticism;	chr8:10801896	chr8:11107788~11109726:-
HNSC	cis	rs13178541	0.683	rs7378856	ENSG00000250378.1	RP11-119J18.1	-4.18	3.41e-05	0.00568	-0.25	-0.19	IgG glycosylation;	chr5:135751404	chr5:135812667~135826582:+
HNSC	cis	rs394563	0.517	rs377454	ENSG00000231760.4	RP11-350J20.5	4.18	3.41e-05	0.00568	0.26	0.19	Dupuytren's disease;	chr6:149469957	chr6:149796151~149826294:-
HNSC	cis	rs7580658	0.963	rs62160261	ENSG00000236682.1	AC068282.3	-4.18	3.41e-05	0.00568	-0.22	-0.19	Protein C levels;	chr2:127395085	chr2:127389130~127400580:+
HNSC	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	4.18	3.42e-05	0.00568	0.17	0.19	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
HNSC	cis	rs6840258	1	rs7695426	ENSG00000251411.1	RP11-397E7.4	-4.18	3.42e-05	0.00568	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000125	chr4:86913266~86914817:-
HNSC	cis	rs9611565	0.643	rs202634	ENSG00000235513.1	RP4-756G23.5	-4.18	3.42e-05	0.00568	-0.23	-0.19	Vitiligo;	chr22:41413619	chr22:41209122~41217627:-
HNSC	cis	rs7937890	0.9	rs7118682	ENSG00000254418.1	RP11-21L19.1	-4.18	3.42e-05	0.00568	-0.21	-0.19	Mitochondrial DNA levels;	chr11:14253004	chr11:14262846~14273691:-
HNSC	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-4.18	3.42e-05	0.00568	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
HNSC	cis	rs4840086	1	rs4840086	ENSG00000219755.1	RP1-199J3.5	4.18	3.42e-05	0.00568	0.24	0.19	Menarche (age at onset);	chr6:99760562	chr6:99575712~99576456:+
HNSC	cis	rs7824557	0.933	rs6601576	ENSG00000255310.2	AF131215.2	-4.18	3.42e-05	0.00568	-0.18	-0.19	Retinal vascular caliber;	chr8:11242766	chr8:11107788~11109726:-
HNSC	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	4.18	3.42e-05	0.00568	0.27	0.19	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	4.18	3.42e-05	0.00568	0.24	0.19	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	4.18	3.42e-05	0.00568	0.24	0.19	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
HNSC	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	4.18	3.42e-05	0.00568	0.17	0.19	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
HNSC	cis	rs9584850	0.834	rs3803253	ENSG00000231194.1	FARP1-AS1	4.18	3.42e-05	0.00568	0.24	0.19	Neuroticism;	chr13:98464895	chr13:98435405~98435840:-
HNSC	cis	rs13434995	0.513	rs17721497	ENSG00000273257.1	RP11-177J6.1	4.18	3.42e-05	0.00569	0.26	0.19	Adiponectin levels;	chr4:55445081	chr4:55387949~55388271:+
HNSC	cis	rs17253792	0.822	rs10083493	ENSG00000186615.9	KTN1-AS1	-4.18	3.42e-05	0.00569	-0.36	-0.19	Putamen volume;	chr14:55578693	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.732	rs10146604	ENSG00000186615.9	KTN1-AS1	-4.18	3.42e-05	0.00569	-0.36	-0.19	Putamen volume;	chr14:55579052	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10149408	ENSG00000186615.9	KTN1-AS1	-4.18	3.42e-05	0.00569	-0.36	-0.19	Putamen volume;	chr14:55579357	chr14:55499278~55580110:-
HNSC	cis	rs9859260	0.555	rs9877493	ENSG00000231464.1	AC024937.4	4.18	3.42e-05	0.00569	0.21	0.19	Mean corpuscular volume;	chr3:196105276	chr3:195996738~195998233:+
HNSC	cis	rs11673344	0.563	rs4805199	ENSG00000276846.1	CTD-3220F14.3	4.18	3.42e-05	0.00569	0.2	0.19	Obesity-related traits;	chr19:37115527	chr19:37314868~37315620:-
HNSC	cis	rs3808502	0.549	rs1382563	ENSG00000255310.2	AF131215.2	4.18	3.42e-05	0.00569	0.18	0.19	Neuroticism;	chr8:11569281	chr8:11107788~11109726:-
HNSC	cis	rs7809950	0.723	rs2237662	ENSG00000238832.1	snoU109	-4.18	3.42e-05	0.00569	-0.27	-0.19	Coronary artery disease;	chr7:107233620	chr7:107603363~107603507:+
HNSC	cis	rs889398	0.741	rs6499270	ENSG00000196696.11	PDXDC2P	4.18	3.42e-05	0.00569	0.13	0.19	Body mass index;	chr16:69883837	chr16:69976297~70065948:-
HNSC	cis	rs12478296	1	rs66612947	ENSG00000261186.2	RP11-341N2.1	-4.18	3.42e-05	0.00569	-0.32	-0.19	Obesity-related traits;	chr2:242093811	chr2:242087351~242088457:-
HNSC	cis	rs9487051	0.621	rs449736	ENSG00000243587.6	C6orf183	-4.18	3.42e-05	0.00569	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109203139	chr6:109165833~109271014:+
HNSC	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-4.18	3.43e-05	0.00569	-0.44	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
HNSC	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	4.18	3.43e-05	0.0057	0.27	0.19	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
HNSC	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-4.18	3.43e-05	0.0057	-0.18	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
HNSC	cis	rs4908768	0.501	rs6577513	ENSG00000232912.4	RP5-1115A15.1	4.18	3.43e-05	0.0057	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8424645~8434838:+
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000280411.1	IGHV1-69-2	-4.18	3.43e-05	0.0057	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106706726	chr14:106762092~106762588:-
HNSC	cis	rs7824557	0.569	rs35418978	ENSG00000255020.1	AF131216.5	4.18	3.43e-05	0.0057	0.2	0.19	Retinal vascular caliber;	chr8:11328944	chr8:11345748~11347502:-
HNSC	cis	rs7824557	0.606	rs2736264	ENSG00000255020.1	AF131216.5	4.18	3.43e-05	0.0057	0.2	0.19	Retinal vascular caliber;	chr8:11329130	chr8:11345748~11347502:-
HNSC	cis	rs17373728	0.526	rs10957753	ENSG00000249395.2	CASC9	-4.18	3.43e-05	0.0057	-0.25	-0.19	Diabetic kidney disease;	chr8:75221193	chr8:75223404~75324741:-
HNSC	cis	rs11673344	0.504	rs10402907	ENSG00000276846.1	CTD-3220F14.3	4.18	3.43e-05	0.0057	0.2	0.19	Obesity-related traits;	chr19:37112874	chr19:37314868~37315620:-
HNSC	cis	rs9487051	0.582	rs351723	ENSG00000243587.6	C6orf183	-4.18	3.43e-05	0.0057	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109224344	chr6:109165833~109271014:+
HNSC	cis	rs5758511	0.596	rs55644935	ENSG00000226450.2	CYP2D8P	4.18	3.43e-05	0.0057	0.18	0.19	Birth weight;	chr22:42270063	chr22:42149886~42155001:-
HNSC	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	4.18	3.43e-05	0.0057	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	4.18	3.43e-05	0.0057	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	4.18	3.43e-05	0.0057	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
HNSC	cis	rs988913	0.813	rs7741915	ENSG00000224984.1	RP11-524H19.2	4.18	3.43e-05	0.0057	0.21	0.19	Menarche (age at onset);	chr6:54891073	chr6:54840118~54840855:-
HNSC	cis	rs4356203	0.87	rs7936310	ENSG00000260196.1	RP1-239B22.5	4.18	3.43e-05	0.0057	0.2	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17380649~17383531:+
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	4.18	3.43e-05	0.0057	0.11	0.19	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
HNSC	cis	rs35306767	0.903	rs61833260	ENSG00000229869.1	RP11-363N22.2	-4.18	3.43e-05	0.00571	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:929208	chr10:933026~942743:+
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000254174.1	IGHV1-12	4.18	3.43e-05	0.00571	0.15	0.19	Rheumatic heart disease;	chr14:106644643	chr14:106122420~106122709:-
HNSC	cis	rs7475343	0.501	rs3829125	ENSG00000224034.1	RP11-445P17.8	-4.18	3.43e-05	0.00571	-0.27	-0.19	Intelligence;	chr10:5205821	chr10:5266033~5271236:-
HNSC	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	4.18	3.43e-05	0.00571	0.27	0.19	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
HNSC	cis	rs35963943	0.625	rs9917661	ENSG00000228956.7	SATB1-AS1	4.18	3.44e-05	0.00571	0.23	0.19	Lymphocyte counts;	chr3:18707339	chr3:18445024~18920401:+
HNSC	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00571	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
HNSC	cis	rs2486288	0.656	rs1060896	ENSG00000259479.5	SORD2P	-4.18	3.44e-05	0.00571	-0.22	-0.19	Glomerular filtration rate;	chr15:45262069	chr15:44826371~44884694:-
HNSC	cis	rs8028182	0.636	rs7171507	ENSG00000260269.4	CTD-2323K18.1	-4.18	3.44e-05	0.00571	-0.24	-0.19	Sudden cardiac arrest;	chr15:75444946	chr15:75527150~75601205:-
HNSC	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	4.18	3.44e-05	0.00571	0.33	0.19	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
HNSC	cis	rs4356203	0.87	rs12286505	ENSG00000260196.1	RP1-239B22.5	4.18	3.44e-05	0.00571	0.2	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17380649~17383531:+
HNSC	cis	rs1862618	0.671	rs832531	ENSG00000271828.1	CTD-2310F14.1	4.18	3.44e-05	0.00571	0.23	0.19	Initial pursuit acceleration;	chr5:56932574	chr5:56927874~56929573:+
HNSC	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	4.18	3.44e-05	0.00571	0.42	0.19	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
HNSC	cis	rs9450351	0.744	rs9344559	ENSG00000203875.9	SNHG5	-4.18	3.44e-05	0.00571	-0.39	-0.19	Interferon gamma-induced protein 10 levels;	chr6:86012192	chr6:85660950~85678736:-
HNSC	cis	rs6840258	1	rs72667753	ENSG00000251411.1	RP11-397E7.4	-4.18	3.44e-05	0.00571	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019860	chr4:86913266~86914817:-
HNSC	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.18	3.44e-05	0.00571	0.18	0.19	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
HNSC	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00571	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
HNSC	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	4.18	3.44e-05	0.00572	0.21	0.19	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
HNSC	cis	rs9903692	0.954	rs9889470	ENSG00000263412.1	RP5-890E16.2	-4.18	3.44e-05	0.00572	-0.18	-0.19	Pulse pressure;	chr17:48233713	chr17:48045141~48048073:-
HNSC	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	4.18	3.44e-05	0.00572	0.22	0.19	Height;	chr14:75128243	chr14:75011269~75012851:-
HNSC	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	4.18	3.44e-05	0.00572	0.21	0.19	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
HNSC	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	4.18	3.44e-05	0.00572	0.28	0.19	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
HNSC	cis	rs853679	1	rs7740487	ENSG00000204709.4	LINC01556	4.18	3.44e-05	0.00572	0.29	0.19	Depression;	chr6:28248708	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs68141011	ENSG00000204709.4	LINC01556	4.18	3.44e-05	0.00572	0.29	0.19	Depression;	chr6:28250019	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs13200462	ENSG00000204709.4	LINC01556	4.18	3.44e-05	0.00572	0.29	0.19	Depression;	chr6:28250421	chr6:28943877~28944537:+
HNSC	cis	rs9313772	0.722	rs10476245	ENSG00000254350.1	RP11-542A14.1	-4.18	3.44e-05	0.00572	-0.2	-0.19	Blood pressure;	chr5:158413562	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs2419914	ENSG00000254350.1	RP11-542A14.1	-4.18	3.44e-05	0.00572	-0.2	-0.19	Blood pressure;	chr5:158417878	chr5:158424585~158452758:+
HNSC	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.44e-05	0.00572	-0.44	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
HNSC	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00572	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00572	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00572	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	4.18	3.44e-05	0.00572	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
HNSC	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-4.18	3.45e-05	0.00572	-0.31	-0.19	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
HNSC	cis	rs721917	0.629	rs1304463	ENSG00000244733.5	RP11-506M13.3	-4.18	3.45e-05	0.00572	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79660891~79677996:+
HNSC	cis	rs67478160	0.609	rs6576003	ENSG00000259515.1	RP11-365N19.2	4.18	3.45e-05	0.00572	0.17	0.19	Schizophrenia;	chr14:103824993	chr14:102933574~102937177:+
HNSC	cis	rs933688	1	rs11950530	ENSG00000281357.1	ARRDC3-AS1	4.18	3.45e-05	0.00572	0.28	0.19	Smoking behavior;	chr5:91392923	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs10058025	ENSG00000281357.1	ARRDC3-AS1	4.18	3.45e-05	0.00572	0.28	0.19	Smoking behavior;	chr5:91393235	chr5:91380349~91439085:+
HNSC	cis	rs933688	1	rs6869717	ENSG00000281357.1	ARRDC3-AS1	4.18	3.45e-05	0.00572	0.28	0.19	Smoking behavior;	chr5:91398980	chr5:91380349~91439085:+
HNSC	cis	rs9487051	0.872	rs9487032	ENSG00000219700.1	PTCHD3P3	4.18	3.45e-05	0.00572	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109284120	chr6:109288571~109290503:-
HNSC	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-4.18	3.45e-05	0.00572	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
HNSC	cis	rs2136613	0.533	rs10761673	ENSG00000238280.1	RP11-436D10.3	-4.18	3.45e-05	0.00572	-0.22	-0.19	Selective IgA deficiency;	chr10:62855691	chr10:62793562~62805887:-
HNSC	cis	rs7085104	0.552	rs11191414	ENSG00000236937.2	PTGES3P4	4.18	3.45e-05	0.00572	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102845595~102845950:+
HNSC	cis	rs755249	0.567	rs72661961	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.532	rs61779277	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.532	rs61779278	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs2296172	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61779279	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs76111861	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs72661965	ENSG00000228060.1	RP11-69E11.8	-4.18	3.45e-05	0.00572	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39565160~39573203:+
HNSC	cis	rs2486288	0.656	rs2413774	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45257225	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs2413772	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45257664	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11632724	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258593	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11632651	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258640	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11637920	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258707	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11632777	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258847	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11632778	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258858	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11632752	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45258942	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs12911186	ENSG00000259479.5	SORD2P	-4.18	3.45e-05	0.00572	-0.22	-0.19	Glomerular filtration rate;	chr15:45259225	chr15:44826371~44884694:-
HNSC	cis	rs757081	0.648	rs10766382	ENSG00000260196.1	RP1-239B22.5	-4.18	3.45e-05	0.00572	-0.2	-0.19	Systolic blood pressure;	chr11:17252894	chr11:17380649~17383531:+
HNSC	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	4.18	3.45e-05	0.00572	0.21	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
HNSC	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	4.18	3.45e-05	0.00572	0.38	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
HNSC	cis	rs1908814	0.516	rs4841641	ENSG00000255495.1	AC145124.2	4.18	3.45e-05	0.00573	0.21	0.19	Neuroticism;	chr8:11940718	chr8:12194467~12196280:+
HNSC	cis	rs2742234	0.91	rs2505505	ENSG00000273008.1	RP11-351D16.3	-4.18	3.45e-05	0.00573	-0.23	-0.19	Hirschsprung disease;	chr10:43152773	chr10:43136824~43138334:-
HNSC	cis	rs9611565	0.84	rs2234052	ENSG00000235513.1	RP4-756G23.5	4.18	3.45e-05	0.00573	0.22	0.19	Vitiligo;	chr22:41381237	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.84	rs9607799	ENSG00000235513.1	RP4-756G23.5	4.18	3.45e-05	0.00573	0.22	0.19	Vitiligo;	chr22:41381554	chr22:41209122~41217627:-
HNSC	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-4.18	3.45e-05	0.00573	-0.2	-0.19	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
HNSC	cis	rs2243480	0.708	rs35825036	ENSG00000106610.13	STAG3L4	-4.18	3.45e-05	0.00573	-0.39	-0.19	Diabetic kidney disease;	chr7:66521515	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs13237037	ENSG00000106610.13	STAG3L4	-4.18	3.45e-05	0.00573	-0.39	-0.19	Diabetic kidney disease;	chr7:66532895	chr7:67302621~67321526:+
HNSC	cis	rs2243480	0.901	rs13237344	ENSG00000106610.13	STAG3L4	-4.18	3.45e-05	0.00573	-0.39	-0.19	Diabetic kidney disease;	chr7:66557269	chr7:67302621~67321526:+
HNSC	cis	rs2243480	1	rs1796228	ENSG00000106610.13	STAG3L4	-4.18	3.45e-05	0.00573	-0.39	-0.19	Diabetic kidney disease;	chr7:66568097	chr7:67302621~67321526:+
HNSC	cis	rs73198271	0.653	rs10087633	ENSG00000233609.3	RP11-62H7.2	-4.18	3.45e-05	0.00573	-0.2	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8961200~8979025:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	4.18	3.45e-05	0.00573	0.33	0.19	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
HNSC	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	4.18	3.45e-05	0.00573	0.19	0.19	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
HNSC	cis	rs12545109	0.8	rs2576602	ENSG00000246430.5	LINC00968	-4.18	3.46e-05	0.00574	-0.23	-0.19	Obesity-related traits;	chr8:56481936	chr8:56496246~56559823:-
HNSC	cis	rs4930561	0.714	rs6591335	ENSG00000184795.9	UNC93B5	-4.18	3.46e-05	0.00574	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68209345	chr11:67711702~67716005:-
HNSC	cis	rs4713118	0.513	rs149972	ENSG00000219891.2	ZSCAN12P1	4.18	3.46e-05	0.00574	0.25	0.19	Parkinson's disease;	chr6:28015449	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.513	rs149975	ENSG00000219891.2	ZSCAN12P1	4.18	3.46e-05	0.00574	0.25	0.19	Parkinson's disease;	chr6:28018562	chr6:28091154~28093664:+
HNSC	cis	rs1799949	1	rs35956818	ENSG00000236383.6	LINC00854	-4.18	3.46e-05	0.00574	-0.18	-0.19	Menopause (age at onset);	chr17:43345617	chr17:43216941~43305976:-
HNSC	cis	rs6095360	1	rs3092427	ENSG00000222365.1	SNORD12B	-4.18	3.46e-05	0.00574	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49158244	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.933	rs348267	ENSG00000222365.1	SNORD12B	-4.18	3.46e-05	0.00574	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49159384	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs2426139	ENSG00000222365.1	SNORD12B	-4.18	3.46e-05	0.00574	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49163568	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs348276	ENSG00000222365.1	SNORD12B	-4.18	3.46e-05	0.00574	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49169653	chr20:49280319~49280409:+
HNSC	cis	rs6493858	0.839	rs2460647	ENSG00000277245.1	RP11-48G14.3	-4.18	3.46e-05	0.00574	-0.22	-0.19	Relative hand skill in reading disability;	chr15:56217710	chr15:56447120~56447697:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000106610.13	STAG3L4	-4.18	3.46e-05	0.00574	-0.39	-0.19	Diabetic kidney disease;	chr7:66591724	chr7:67302621~67321526:+
HNSC	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	4.18	3.46e-05	0.00574	0.23	0.19	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
HNSC	cis	rs13434995	0.513	rs62303691	ENSG00000273257.1	RP11-177J6.1	-4.18	3.46e-05	0.00574	-0.26	-0.19	Adiponectin levels;	chr4:55442085	chr4:55387949~55388271:+
HNSC	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	4.18	3.46e-05	0.00574	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	4.18	3.46e-05	0.00574	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	4.18	3.46e-05	0.00574	0.36	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
HNSC	cis	rs3096299	0.591	rs748940	ENSG00000261574.1	RP1-168P16.2	4.18	3.46e-05	0.00575	0.24	0.19	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89392375~89412564:-
HNSC	cis	rs721917	0.525	rs2250473	ENSG00000244733.5	RP11-506M13.3	-4.18	3.46e-05	0.00575	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2758561	ENSG00000244733.5	RP11-506M13.3	-4.18	3.46e-05	0.00575	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79660891~79677996:+
HNSC	cis	rs9290663	0.504	rs7427925	ENSG00000271131.1	RP11-33A14.3	4.18	3.46e-05	0.00575	0.22	0.19	Acute lymphoblastic leukemia (childhood);	chr3:178711915	chr3:178493327~178493810:-
HNSC	cis	rs6928977	0.66	rs12203875	ENSG00000234084.1	RP3-388E23.2	4.18	3.46e-05	0.00575	0.2	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135539276	chr6:135301568~135307158:+
HNSC	cis	rs6500395	1	rs6500398	ENSG00000261267.1	RP11-44I10.3	-4.18	3.46e-05	0.00575	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48616421	chr16:48559661~48587403:+
HNSC	cis	rs6500395	1	rs1486412	ENSG00000261267.1	RP11-44I10.3	-4.18	3.46e-05	0.00575	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48617839	chr16:48559661~48587403:+
HNSC	cis	rs597539	0.652	rs1249474	ENSG00000255741.1	RP11-757G1.5	-4.18	3.46e-05	0.00575	-0.25	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68941503~68942852:-
HNSC	cis	rs858239	0.601	rs28673077	ENSG00000226816.2	AC005082.12	4.18	3.46e-05	0.00575	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23206013~23208045:+
HNSC	cis	rs3736485	0.966	rs12441167	ENSG00000259438.1	CTD-2650P22.1	4.18	3.47e-05	0.00575	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51558455	chr15:52010999~52019095:-
HNSC	cis	rs7824557	0.65	rs2572406	ENSG00000269918.1	AF131215.9	4.18	3.47e-05	0.00575	0.18	0.19	Retinal vascular caliber;	chr8:11234743	chr8:11104691~11106704:-
HNSC	cis	rs9400271	0.632	rs9384705	ENSG00000243587.6	C6orf183	-4.18	3.47e-05	0.00575	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109267041	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs9372205	ENSG00000243587.6	C6orf183	-4.18	3.47e-05	0.00575	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109267198	chr6:109165833~109271014:+
HNSC	cis	rs867371	0.82	rs12443224	ENSG00000259429.4	UBE2Q2P2	-4.18	3.47e-05	0.00575	-0.18	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82355142~82420075:+
HNSC	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-4.18	3.47e-05	0.00575	-0.22	-0.19	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
HNSC	cis	rs12289961	0.634	rs11229378	ENSG00000280010.1	AP001350.4	4.18	3.47e-05	0.00576	0.33	0.19	Lymphoma;	chr11:58364344	chr11:58627435~58628528:+
HNSC	cis	rs12289961	0.634	rs77183714	ENSG00000280010.1	AP001350.4	4.18	3.47e-05	0.00576	0.33	0.19	Lymphoma;	chr11:58364460	chr11:58627435~58628528:+
HNSC	cis	rs71520386	0.846	rs76474740	ENSG00000221740.1	SNORD93	-4.18	3.47e-05	0.00576	-0.25	-0.19	Fibrinogen levels;	chr7:22775741	chr7:22856613~22856686:+
HNSC	cis	rs561341	1	rs117979353	ENSG00000278867.1	RP11-640N20.4	-4.18	3.47e-05	0.00576	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31945847	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs55978022	ENSG00000278867.1	RP11-640N20.4	-4.18	3.47e-05	0.00576	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31948918	chr17:32051030~32053208:+
HNSC	cis	rs4372836	0.893	rs745645	ENSG00000226833.4	AC097724.3	-4.18	3.47e-05	0.00576	-0.24	-0.19	Body mass index;	chr2:28708705	chr2:28708953~28736205:-
HNSC	cis	rs9813712	0.547	rs6807290	ENSG00000228252.7	COL6A4P2	4.18	3.47e-05	0.00576	0.19	0.19	Response to amphetamines;	chr3:130297952	chr3:130212823~130273806:+
HNSC	cis	rs7735319	0.966	rs7709083	ENSG00000251281.1	CTD-2066L21.2	4.18	3.47e-05	0.00576	0.22	0.19	Systolic blood pressure;	chr5:33159470	chr5:33011322~33017607:-
HNSC	cis	rs11098499	0.909	rs10026736	ENSG00000250412.1	KLHL2P1	4.18	3.47e-05	0.00576	0.25	0.19	Corneal astigmatism;	chr4:119463167	chr4:119334329~119378233:+
HNSC	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	4.18	3.47e-05	0.00576	0.19	0.19	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
HNSC	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	4.18	3.47e-05	0.00576	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
HNSC	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-4.18	3.47e-05	0.00576	-0.31	-0.19	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
HNSC	cis	rs9313772	0.722	rs11960291	ENSG00000254350.1	RP11-542A14.1	-4.18	3.47e-05	0.00576	-0.2	-0.19	Blood pressure;	chr5:158436000	chr5:158424585~158452758:+
HNSC	cis	rs853679	0.517	rs4713145	ENSG00000219891.2	ZSCAN12P1	4.18	3.47e-05	0.00576	0.27	0.19	Depression;	chr6:28139049	chr6:28091154~28093664:+
HNSC	cis	rs13256369	1	rs13282915	ENSG00000173295.6	FAM86B3P	4.18	3.48e-05	0.00577	0.25	0.19	Obesity-related traits;	chr8:8713381	chr8:8228595~8244865:+
HNSC	cis	rs116095464	0.558	rs62346508	ENSG00000250848.1	CTD-2083E4.5	-4.18	3.48e-05	0.00577	-0.26	-0.19	Breast cancer;	chr5:203553	chr5:288833~290321:-
HNSC	cis	rs17761864	1	rs56043407	ENSG00000262333.1	HNRNPA1P16	-4.18	3.48e-05	0.00577	-0.17	-0.19	Esophageal cancer (squamous cell);	chr17:2262784	chr17:2306761~2307715:+
HNSC	cis	rs916888	0.773	rs9896243	ENSG00000260075.1	NSFP1	-4.18	3.48e-05	0.00577	-0.27	-0.19	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46372855~46487141:+
HNSC	cis	rs4388249	0.904	rs62376382	ENSG00000271849.1	CTC-332L22.1	-4.18	3.48e-05	0.00577	-0.3	-0.19	Schizophrenia;	chr5:109853939	chr5:109687802~109688329:-
HNSC	cis	rs2098713	0.507	rs13175953	ENSG00000250155.1	CTD-2353F22.1	-4.18	3.48e-05	0.00577	-0.21	-0.19	Telomere length;	chr5:37509131	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs2886667	ENSG00000250155.1	CTD-2353F22.1	-4.18	3.48e-05	0.00577	-0.21	-0.19	Telomere length;	chr5:37510849	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs57898883	ENSG00000250155.1	CTD-2353F22.1	-4.18	3.48e-05	0.00577	-0.21	-0.19	Telomere length;	chr5:37517831	chr5:36666214~36725195:-
HNSC	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-4.18	3.48e-05	0.00577	-0.25	-0.19	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
HNSC	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-4.18	3.48e-05	0.00577	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
HNSC	cis	rs4356203	0.905	rs17472886	ENSG00000272034.1	SNORD14A	-4.18	3.48e-05	0.00577	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17074654~17074744:-
HNSC	cis	rs67981189	0.593	rs2810101	ENSG00000274818.1	RP1-292L20.3	-4.18	3.48e-05	0.00577	-0.21	-0.19	Schizophrenia;	chr14:70963110	chr14:70906657~70907111:-
HNSC	cis	rs10773046	0.786	rs1882488	ENSG00000269938.1	RP11-214K3.20	-4.18	3.48e-05	0.00577	-0.22	-0.19	Osteoarthritis (hip);	chr12:123888909	chr12:123968023~123968579:-
HNSC	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	4.18	3.48e-05	0.00577	0.22	0.19	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
HNSC	cis	rs2904524	1	rs9804870	ENSG00000257815.4	RP11-611E13.2	-4.18	3.48e-05	0.00577	-0.23	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70346955	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.881	rs12316184	ENSG00000257815.4	RP11-611E13.2	-4.18	3.48e-05	0.00577	-0.23	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70348121	chr12:69904033~70243360:-
HNSC	cis	rs6163	0.588	rs11191392	ENSG00000213061.2	PFN1P11	4.18	3.48e-05	0.00577	0.23	0.19	Waist circumference;Hip circumference;	chr10:102767194	chr10:102838011~102845473:-
HNSC	cis	rs2055729	0.645	rs62489486	ENSG00000254340.1	RP11-10A14.3	4.18	3.48e-05	0.00577	0.28	0.19	Multiple myeloma (hyperdiploidy);	chr8:9884415	chr8:9141424~9145435:+
HNSC	cis	rs67981189	0.574	rs2526884	ENSG00000274818.1	RP1-292L20.3	-4.18	3.48e-05	0.00578	-0.21	-0.19	Schizophrenia;	chr14:70901250	chr14:70906657~70907111:-
HNSC	cis	rs7630852	1	rs7630852	ENSG00000236833.1	AC024560.2	4.18	3.48e-05	0.00578	0.2	0.19	Eosinophil counts;	chr3:196781680	chr3:197660565~197665757:-
HNSC	cis	rs7688540	0.665	rs11731933	ENSG00000211553.1	AC253576.2	-4.18	3.49e-05	0.00578	-0.28	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:136461~136568:+
HNSC	cis	rs6095360	1	rs6019547	ENSG00000222365.1	SNORD12B	-4.18	3.49e-05	0.00578	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:48944554	chr20:49280319~49280409:+
HNSC	cis	rs60617249	0.772	rs28633916	ENSG00000228204.2	RP4-724E13.2	4.18	3.49e-05	0.00578	0.2	0.19	Major depression and alcohol dependence;	chr7:50880967	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.772	rs6964785	ENSG00000228204.2	RP4-724E13.2	4.18	3.49e-05	0.00578	0.2	0.19	Major depression and alcohol dependence;	chr7:50881375	chr7:50866747~51022990:+
HNSC	cis	rs12745968	0.619	rs10874738	ENSG00000223787.2	RP4-593M8.1	-4.18	3.49e-05	0.00578	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92758662	chr1:92580476~92580821:-
HNSC	cis	rs62432291	0.681	rs400477	ENSG00000235086.1	FNDC1-IT1	4.18	3.49e-05	0.00578	0.26	0.19	Joint mobility (Beighton score);	chr6:159214911	chr6:159240786~159243329:+
HNSC	cis	rs137699	1	rs5757630	ENSG00000261202.1	RP3-496C20.1	-4.18	3.49e-05	0.00578	-0.22	-0.19	IgG glycosylation;	chr22:39358428	chr22:40043068~40044530:-
HNSC	cis	rs6890684	0.569	rs6864489	ENSG00000215032.2	GNL3LP1	4.18	3.49e-05	0.00578	0.21	0.19	Intelligence (multi-trait analysis);	chr5:61250143	chr5:60891935~60893577:-
HNSC	cis	rs7674212	0.541	rs4699050	ENSG00000251288.2	RP11-10L12.2	-4.18	3.49e-05	0.00578	-0.22	-0.19	Type 2 diabetes;	chr4:103193140	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.541	rs17217473	ENSG00000251288.2	RP11-10L12.2	-4.18	3.49e-05	0.00578	-0.22	-0.19	Type 2 diabetes;	chr4:103193585	chr4:102751401~102752641:+
HNSC	cis	rs10129255	0.957	rs8009464	ENSG00000211974.3	IGHV2-70	4.18	3.49e-05	0.00578	0.18	0.19	Kawasaki disease;	chr14:106777611	chr14:106723574~106724093:-
HNSC	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-4.18	3.49e-05	0.00578	-0.27	-0.19	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
HNSC	cis	rs9321453	1	rs9321451	ENSG00000231971.4	RP11-557H15.3	4.18	3.49e-05	0.00578	0.24	0.19	Urate levels;	chr6:134449485	chr6:134428240~134520585:-
HNSC	cis	rs7246657	0.551	rs12972146	ENSG00000276846.1	CTD-3220F14.3	4.18	3.49e-05	0.00578	0.3	0.19	Coronary artery calcification;	chr19:37135193	chr19:37314868~37315620:-
HNSC	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-4.18	3.49e-05	0.00578	-0.34	-0.19	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
HNSC	cis	rs4081724	0.565	rs56317325	ENSG00000267296.2	CEBPA-AS1	4.18	3.49e-05	0.00578	0.36	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33310031	chr19:33302857~33305054:+
HNSC	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-4.18	3.49e-05	0.00579	-0.28	-0.19	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
HNSC	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	4.18	3.49e-05	0.00579	0.2	0.19	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
HNSC	cis	rs227275	0.556	rs6842179	ENSG00000230069.3	LRRC37A15P	-4.18	3.49e-05	0.00579	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102727274~102730721:-
HNSC	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-4.18	3.49e-05	0.00579	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
HNSC	cis	rs240993	0.68	rs2075966	ENSG00000255389.1	C6orf3	4.18	3.49e-05	0.00579	0.24	0.19	Inflammatory skin disease;Psoriasis;	chr6:111563565	chr6:111599875~111602295:+
HNSC	cis	rs9903692	0.779	rs6504025	ENSG00000263412.1	RP5-890E16.2	-4.18	3.49e-05	0.00579	-0.18	-0.19	Pulse pressure;	chr17:48088711	chr17:48045141~48048073:-
HNSC	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-4.18	3.5e-05	0.00579	-0.18	-0.19	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
HNSC	cis	rs4713118	0.824	rs2179095	ENSG00000224843.5	LINC00240	-4.18	3.5e-05	0.00579	-0.22	-0.19	Parkinson's disease;	chr6:27783079	chr6:26956992~27023924:+
HNSC	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	4.18	3.5e-05	0.00579	0.22	0.19	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
HNSC	cis	rs561341	1	rs72821971	ENSG00000278867.1	RP11-640N20.4	-4.18	3.5e-05	0.00579	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:31942324	chr17:32051030~32053208:+
HNSC	cis	rs2834288	0.7	rs6517196	ENSG00000273102.1	AP000569.9	-4.18	3.5e-05	0.00579	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33905116	chr21:33967101~33968573:-
HNSC	cis	rs2998286	0.774	rs2790442	ENSG00000254635.4	WAC-AS1	-4.18	3.5e-05	0.00579	-0.29	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28539597	chr10:28522652~28532743:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000229886.1	RP5-1132H15.3	4.18	3.5e-05	0.0058	0.32	0.19	Diabetic kidney disease;	chr7:65916269	chr7:66025126~66031544:-
HNSC	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	4.18	3.5e-05	0.0058	0.2	0.19	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
HNSC	cis	rs6500395	0.928	rs12934788	ENSG00000261267.1	RP11-44I10.3	4.18	3.5e-05	0.0058	0.24	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48672432	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.928	rs4553627	ENSG00000261267.1	RP11-44I10.3	4.18	3.5e-05	0.0058	0.24	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48674890	chr16:48559661~48587403:+
HNSC	cis	rs9987353	0.522	rs2929466	ENSG00000254153.1	CTA-398F10.2	-4.18	3.5e-05	0.0058	-0.21	-0.19	Recombination measurement;	chr8:9206389	chr8:8456909~8461337:-
HNSC	cis	rs11673344	0.504	rs2118208	ENSG00000276846.1	CTD-3220F14.3	4.18	3.5e-05	0.0058	0.21	0.19	Obesity-related traits;	chr19:37135573	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs2118209	ENSG00000276846.1	CTD-3220F14.3	4.18	3.5e-05	0.0058	0.21	0.19	Obesity-related traits;	chr19:37135618	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs4805204	ENSG00000276846.1	CTD-3220F14.3	4.18	3.5e-05	0.0058	0.21	0.19	Obesity-related traits;	chr19:37136666	chr19:37314868~37315620:-
HNSC	cis	rs2274273	0.682	rs10145268	ENSG00000233924.1	AL160471.6	-4.18	3.5e-05	0.0058	-0.21	-0.19	Protein biomarker;	chr14:55037796	chr14:55004813~55005687:-
HNSC	cis	rs11577354	0.613	rs10925533	ENSG00000207181.1	SNORA14B	-4.18	3.5e-05	0.0058	-0.24	-0.19	Obesity-related traits;	chr1:235106706	chr1:235127803~235127937:-
HNSC	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	4.18	3.5e-05	0.0058	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
HNSC	cis	rs7572733	0.905	rs6735214	ENSG00000222017.1	AC011997.1	4.18	3.5e-05	0.0058	0.23	0.19	Dermatomyositis;	chr2:197895783	chr2:197693106~197774823:+
HNSC	cis	rs7429990	0.965	rs4858881	ENSG00000228638.1	FCF1P2	4.18	3.5e-05	0.0058	0.17	0.19	Educational attainment (years of education);	chr3:48082306	chr3:48290793~48291375:-
HNSC	cis	rs5758511	0.514	rs5758637	ENSG00000227370.1	RP4-669P10.19	4.18	3.5e-05	0.0058	0.22	0.19	Birth weight;	chr22:42184927	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs9607885	ENSG00000205702.9	CYP2D7	4.18	3.5e-05	0.0058	0.17	0.19	Birth weight;	chr22:42182590	chr22:42140203~42144577:-
HNSC	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	4.18	3.5e-05	0.0058	0.19	0.19	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
HNSC	cis	rs7829975	0.902	rs485107	ENSG00000233609.3	RP11-62H7.2	-4.18	3.5e-05	0.0058	-0.18	-0.19	Mood instability;	chr8:8723898	chr8:8961200~8979025:+
HNSC	cis	rs853679	0.607	rs34950484	ENSG00000226314.6	ZNF192P1	-4.18	3.5e-05	0.00581	-0.35	-0.19	Depression;	chr6:28310911	chr6:28161781~28169594:+
HNSC	cis	rs11098499	0.954	rs10518328	ENSG00000250412.1	KLHL2P1	4.18	3.51e-05	0.00581	0.24	0.19	Corneal astigmatism;	chr4:119480624	chr4:119334329~119378233:+
HNSC	cis	rs3808502	0.525	rs13280813	ENSG00000255310.2	AF131215.2	-4.18	3.51e-05	0.00581	-0.18	-0.19	Neuroticism;	chr8:11567596	chr8:11107788~11109726:-
HNSC	cis	rs9929218	0.507	rs62057805	ENSG00000260459.2	FTLP14	4.18	3.51e-05	0.00581	0.25	0.19	Colorectal cancer;	chr16:68708487	chr16:68822587~68823070:+
HNSC	cis	rs9929218	0.508	rs6499194	ENSG00000260459.2	FTLP14	4.18	3.51e-05	0.00581	0.25	0.19	Colorectal cancer;	chr16:68710197	chr16:68822587~68823070:+
HNSC	cis	rs9868809	0.764	rs2633958	ENSG00000229759.1	MRPS18AP1	4.18	3.51e-05	0.00581	0.33	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48597999	chr3:48256350~48256938:-
HNSC	cis	rs10791097	0.72	rs6590515	ENSG00000254842.5	RP11-890B15.2	4.18	3.51e-05	0.00581	0.16	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863470	chr11:130844191~130865561:-
HNSC	cis	rs1714507	0.515	rs2731112	ENSG00000272087.1	RP11-379F4.7	4.18	3.51e-05	0.00581	0.21	0.19	Subjective well-being;	chr3:158572439	chr3:158693120~158693768:-
HNSC	cis	rs9650657	0.899	rs9650656	ENSG00000255310.2	AF131215.2	-4.18	3.51e-05	0.00581	-0.18	-0.19	Neuroticism;	chr8:10749744	chr8:11107788~11109726:-
HNSC	cis	rs9650657	1	rs9650657	ENSG00000255310.2	AF131215.2	-4.18	3.51e-05	0.00581	-0.18	-0.19	Neuroticism;	chr8:10749890	chr8:11107788~11109726:-
HNSC	cis	rs35000415	0.688	rs13241591	ENSG00000275106.1	RP11-309L24.10	-4.18	3.51e-05	0.00581	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129074692	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.688	rs13229034	ENSG00000275106.1	RP11-309L24.10	-4.18	3.51e-05	0.00581	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129074789	chr7:128952527~128953316:-
HNSC	cis	rs1799949	1	rs4793197	ENSG00000236383.6	LINC00854	-4.18	3.51e-05	0.00581	-0.18	-0.19	Menopause (age at onset);	chr17:43079885	chr17:43216941~43305976:-
HNSC	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	4.18	3.51e-05	0.00581	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
HNSC	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-4.18	3.51e-05	0.00581	-0.25	-0.19	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
HNSC	cis	rs7429990	0.965	rs35689209	ENSG00000228638.1	FCF1P2	4.18	3.51e-05	0.00582	0.17	0.19	Educational attainment (years of education);	chr3:48078273	chr3:48290793~48291375:-
HNSC	cis	rs700651	0.789	rs6434949	ENSG00000231621.1	AC013264.2	-4.18	3.51e-05	0.00582	-0.18	-0.19	Intracranial aneurysm;	chr2:197990786	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs6724526	ENSG00000231621.1	AC013264.2	-4.18	3.51e-05	0.00582	-0.18	-0.19	Dermatomyositis;	chr2:197993677	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs893808	ENSG00000231621.1	AC013264.2	-4.18	3.51e-05	0.00582	-0.18	-0.19	Dermatomyositis;	chr2:197996113	chr2:197197991~197199273:+
HNSC	cis	rs1602565	0.858	rs2452146	ENSG00000255450.1	CTD-2063L20.1	-4.18	3.51e-05	0.00582	-0.3	-0.19	Schizophrenia;	chr11:29170443	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2467587	ENSG00000255450.1	CTD-2063L20.1	-4.18	3.51e-05	0.00582	-0.3	-0.19	Schizophrenia;	chr11:29170445	chr11:29275655~29276565:+
HNSC	cis	rs12762955	0.677	rs11250267	ENSG00000229869.1	RP11-363N22.2	-4.18	3.51e-05	0.00582	-0.27	-0.19	Response to angiotensin II receptor blocker therapy;	chr10:1110547	chr10:933026~942743:+
HNSC	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	4.18	3.51e-05	0.00582	0.32	0.19	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
HNSC	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	4.18	3.51e-05	0.00582	0.22	0.19	Height;	chr14:75100475	chr14:75011269~75012851:-
HNSC	cis	rs6928977	0.896	rs2614257	ENSG00000217482.2	HMGB1P17	-4.18	3.51e-05	0.00582	-0.21	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135636086~135636713:-
HNSC	cis	rs2337406	1	rs1858677	ENSG00000280411.1	IGHV1-69-2	-4.18	3.51e-05	0.00582	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106706828	chr14:106762092~106762588:-
HNSC	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	4.18	3.51e-05	0.00582	0.19	0.19	Asthma;	chr2:102369762	chr2:102438713~102440475:+
HNSC	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	4.18	3.52e-05	0.00582	0.25	0.19	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
HNSC	cis	rs4843747	0.671	rs72818576	ENSG00000260750.4	RP11-482M8.1	4.18	3.52e-05	0.00582	0.24	0.19	Menopause (age at onset);	chr16:88077413	chr16:87492555~87515635:+
HNSC	cis	rs72843506	0.722	rs9902683	ENSG00000261033.1	RP11-209D14.2	4.18	3.52e-05	0.00582	0.34	0.19	Schizophrenia;	chr17:20112115	chr17:20008051~20009234:-
HNSC	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	4.18	3.52e-05	0.00582	0.16	0.19	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
HNSC	cis	rs8058578	0.775	rs8046391	ENSG00000279196.1	RP11-1072A3.3	4.18	3.52e-05	0.00582	0.22	0.19	Multiple myeloma;	chr16:30825327	chr16:30984630~30988270:-
HNSC	cis	rs7621025	0.675	rs34602896	ENSG00000239213.4	NCK1-AS1	-4.18	3.52e-05	0.00582	-0.18	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136841726~136862054:-
HNSC	cis	rs755249	0.959	rs72663520	ENSG00000182109.6	RP11-69E11.4	4.18	3.52e-05	0.00582	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39522280~39546187:-
HNSC	cis	rs913672	0.637	rs2274950	ENSG00000224397.4	LINC01272	-4.18	3.52e-05	0.00583	-0.25	-0.19	Monocyte count;	chr20:50277887	chr20:50267486~50279795:+
HNSC	cis	rs2980439	0.607	rs2980419	ENSG00000254153.1	CTA-398F10.2	4.18	3.52e-05	0.00583	0.22	0.19	Neuroticism;	chr8:8256619	chr8:8456909~8461337:-
HNSC	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	4.18	3.52e-05	0.00583	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
HNSC	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-4.18	3.52e-05	0.00583	-0.35	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
HNSC	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	4.18	3.52e-05	0.00583	0.23	0.19	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
HNSC	cis	rs4218	0.505	rs6494064	ENSG00000259732.1	RP11-59H7.3	4.18	3.52e-05	0.00583	0.23	0.19	Social communication problems;	chr15:59053192	chr15:59121034~59133250:+
HNSC	cis	rs1008375	0.932	rs9884565	ENSG00000249502.1	AC006160.5	-4.18	3.53e-05	0.00583	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653473	chr4:17587467~17614571:-
HNSC	cis	rs9311676	0.656	rs56384862	ENSG00000273493.1	RP11-80H18.4	4.18	3.53e-05	0.00584	0.21	0.19	Systemic lupus erythematosus;	chr3:58410136	chr3:58329965~58330118:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-4.18	3.53e-05	0.00584	-0.26	-0.19	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
HNSC	cis	rs964611	0.882	rs6493316	ENSG00000259488.2	RP11-154J22.1	-4.18	3.53e-05	0.00584	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48275280	chr15:48312353~48331856:-
HNSC	cis	rs4256159	1	rs34933630	ENSG00000228956.7	SATB1-AS1	4.18	3.53e-05	0.00584	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18695825	chr3:18445024~18920401:+
HNSC	cis	rs7121616	0.531	rs10892958	ENSG00000200879.1	SNORD14E	4.18	3.53e-05	0.00584	0.26	0.19	Breast cancer;	chr11:123061415	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.531	rs11218941	ENSG00000200879.1	SNORD14E	4.18	3.53e-05	0.00584	0.26	0.19	Breast cancer;	chr11:123061701	chr11:123058077~123058161:-
HNSC	cis	rs7520050	0.966	rs4660317	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs10749860	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs6688365	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6656992	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs61783220	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs7540325	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45581219~45581321:-
HNSC	cis	rs7520050	1	rs7540699	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs4660319	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs11211213	ENSG00000280836.1	AL355480.1	4.18	3.53e-05	0.00584	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45581219~45581321:-
HNSC	cis	rs7819412	0.505	rs17782536	ENSG00000255310.2	AF131215.2	-4.18	3.53e-05	0.00584	-0.19	-0.19	Triglycerides;	chr8:11164172	chr8:11107788~11109726:-
HNSC	cis	rs9611565	0.802	rs73176694	ENSG00000235513.1	RP4-756G23.5	4.18	3.53e-05	0.00584	0.23	0.19	Vitiligo;	chr22:41390784	chr22:41209122~41217627:-
HNSC	cis	rs7121616	0.576	rs7102045	ENSG00000200879.1	SNORD14E	4.18	3.53e-05	0.00584	0.26	0.19	Breast cancer;	chr11:123052713	chr11:123058077~123058161:-
HNSC	cis	rs860295	0.702	rs34124416	ENSG00000225855.5	RUSC1-AS1	4.18	3.53e-05	0.00584	0.13	0.19	Body mass index;	chr1:155608258	chr1:155316863~155324176:-
HNSC	cis	rs4713118	0.824	rs9468225	ENSG00000216901.1	AL022393.7	4.18	3.53e-05	0.00584	0.25	0.19	Parkinson's disease;	chr6:27777940	chr6:28176188~28176674:+
HNSC	cis	rs12745968	0.589	rs912796	ENSG00000223787.2	RP4-593M8.1	-4.18	3.53e-05	0.00585	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92495853	chr1:92580476~92580821:-
HNSC	cis	rs9487051	0.872	rs9400269	ENSG00000219700.1	PTCHD3P3	4.18	3.54e-05	0.00585	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109284862	chr6:109288571~109290503:-
HNSC	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	4.18	3.54e-05	0.00585	0.26	0.19	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
HNSC	cis	rs12986445	0.843	rs10209507	ENSG00000218682.1	AC010150.1	4.18	3.54e-05	0.00585	0.26	0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25781549	chr2:25856461~25856966:-
HNSC	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.18	3.54e-05	0.00585	0.21	0.19	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
HNSC	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-4.18	3.54e-05	0.00585	-0.18	-0.19	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
HNSC	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-4.18	3.54e-05	0.00586	-0.2	-0.19	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
HNSC	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	4.18	3.54e-05	0.00586	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
HNSC	cis	rs6500395	0.925	rs9933148	ENSG00000261267.1	RP11-44I10.3	-4.18	3.54e-05	0.00586	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48638188	chr16:48559661~48587403:+
HNSC	cis	rs11122895	0.509	rs6708131	ENSG00000236307.2	EEF1E1P1	4.18	3.54e-05	0.00586	0.18	0.19	Allergic sensitization;	chr2:111688082	chr2:111887914~111888741:+
HNSC	cis	rs9313772	0.775	rs7725627	ENSG00000254350.1	RP11-542A14.1	-4.18	3.54e-05	0.00586	-0.2	-0.19	Blood pressure;	chr5:158399114	chr5:158424585~158452758:+
HNSC	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	4.18	3.54e-05	0.00586	0.25	0.19	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	4.18	3.54e-05	0.00586	0.25	0.19	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	4.18	3.54e-05	0.00586	0.25	0.19	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
HNSC	cis	rs1008375	1	rs28552744	ENSG00000249502.1	AC006160.5	-4.18	3.54e-05	0.00586	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618542	chr4:17587467~17614571:-
HNSC	cis	rs7209700	0.547	rs55845779	ENSG00000262879.4	RP11-156P1.3	4.18	3.55e-05	0.00587	0.27	0.19	IgG glycosylation;	chr17:47277385	chr17:46984045~47100323:-
HNSC	cis	rs7209700	0.547	rs11649785	ENSG00000262879.4	RP11-156P1.3	4.18	3.55e-05	0.00587	0.27	0.19	IgG glycosylation;	chr17:47278354	chr17:46984045~47100323:-
HNSC	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	4.18	3.55e-05	0.00587	0.27	0.19	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
HNSC	cis	rs755249	0.567	rs112672438	ENSG00000182109.6	RP11-69E11.4	4.18	3.55e-05	0.00587	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	4.18	3.55e-05	0.00587	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	4.18	3.55e-05	0.00587	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	4.18	3.55e-05	0.00587	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
HNSC	cis	rs72717009	0.825	rs7529225	ENSG00000225217.1	HSPA7	-4.18	3.55e-05	0.00587	-0.33	-0.19	Rheumatoid arthritis;	chr1:161509562	chr1:161606291~161608217:+
HNSC	cis	rs10791097	0.694	rs4264159	ENSG00000254842.5	RP11-890B15.2	-4.18	3.55e-05	0.00587	-0.16	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885889	chr11:130844191~130865561:-
HNSC	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-4.18	3.55e-05	0.00587	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
HNSC	cis	rs7824557	0.583	rs2263512	ENSG00000255495.1	AC145124.2	-4.18	3.55e-05	0.00587	-0.21	-0.19	Retinal vascular caliber;	chr8:11375910	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.583	rs6601585	ENSG00000255495.1	AC145124.2	-4.18	3.55e-05	0.00587	-0.21	-0.19	Retinal vascular caliber;	chr8:11376150	chr8:12194467~12196280:+
HNSC	cis	rs17761864	0.922	rs72819571	ENSG00000262333.1	HNRNPA1P16	-4.18	3.55e-05	0.00587	-0.17	-0.19	Esophageal cancer (squamous cell);	chr17:2267207	chr17:2306761~2307715:+
HNSC	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	4.18	3.55e-05	0.00587	0.28	0.19	Depression;	chr6:28239422	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.863	rs6853998	ENSG00000250412.1	KLHL2P1	4.18	3.55e-05	0.00587	0.25	0.19	Corneal astigmatism;	chr4:119554705	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs6858777	ENSG00000250412.1	KLHL2P1	4.18	3.55e-05	0.00587	0.25	0.19	Corneal astigmatism;	chr4:119554811	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs11731756	ENSG00000250412.1	KLHL2P1	4.18	3.55e-05	0.00587	0.25	0.19	Corneal astigmatism;	chr4:119557541	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs34308924	ENSG00000250412.1	KLHL2P1	4.18	3.55e-05	0.00587	0.25	0.19	Corneal astigmatism;	chr4:119560276	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs2170276	ENSG00000250412.1	KLHL2P1	4.18	3.55e-05	0.00587	0.25	0.19	Corneal astigmatism;	chr4:119564669	chr4:119334329~119378233:+
HNSC	cis	rs1602565	0.778	rs1491814	ENSG00000255450.1	CTD-2063L20.1	-4.18	3.55e-05	0.00587	-0.29	-0.19	Schizophrenia;	chr11:29127626	chr11:29275655~29276565:+
HNSC	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	4.18	3.55e-05	0.00587	0.2	0.19	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.18	3.55e-05	0.00588	-0.21	-0.19	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
HNSC	cis	rs3015497	0.789	rs2934688	ENSG00000277050.1	RP11-102G14.1	-4.17	3.56e-05	0.00588	-0.18	-0.19	Mean platelet volume;	chr14:50645642	chr14:51637348~51637947:-
HNSC	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-4.17	3.56e-05	0.00588	-0.23	-0.19	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
HNSC	cis	rs57502260	0.704	rs2186937	ENSG00000212093.1	AP000807.1	4.17	3.56e-05	0.00588	0.28	0.19	Total body bone mineral density (age 45-60);	chr11:68489379	chr11:68506083~68506166:-
HNSC	cis	rs7005380	0.538	rs1879149	ENSG00000279347.1	RP11-85I17.2	4.17	3.56e-05	0.00588	0.17	0.19	Interstitial lung disease;	chr8:119919585	chr8:119838736~119840385:-
HNSC	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	4.17	3.56e-05	0.00589	0.26	0.19	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
HNSC	cis	rs9910055	0.593	rs2905983	ENSG00000267080.4	ASB16-AS1	4.17	3.56e-05	0.00589	0.15	0.19	Total body bone mineral density;	chr17:44135061	chr17:44175973~44186717:-
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000228039.3	KB-1125A3.10	4.17	3.56e-05	0.00589	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23963780~23964374:+
HNSC	cis	rs9329221	0.537	rs13264586	ENSG00000269918.1	AF131215.9	4.17	3.56e-05	0.00589	0.18	0.19	Neuroticism;	chr8:10121875	chr8:11104691~11106704:-
HNSC	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-4.17	3.56e-05	0.00589	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-4.17	3.56e-05	0.00589	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
HNSC	cis	rs9611565	0.765	rs132907	ENSG00000235513.1	RP4-756G23.5	-4.17	3.56e-05	0.00589	-0.23	-0.19	Vitiligo;	chr22:41405264	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.681	rs6002372	ENSG00000235513.1	RP4-756G23.5	-4.17	3.56e-05	0.00589	-0.23	-0.19	Vitiligo;	chr22:41405295	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs132908	ENSG00000235513.1	RP4-756G23.5	-4.17	3.56e-05	0.00589	-0.23	-0.19	Vitiligo;	chr22:41405791	chr22:41209122~41217627:-
HNSC	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	4.17	3.56e-05	0.00589	0.18	0.19	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
HNSC	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	4.17	3.56e-05	0.00589	0.29	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
HNSC	cis	rs10129255	1	rs4612959	ENSG00000224373.3	IGHV4-59	4.17	3.56e-05	0.00589	0.12	0.19	Kawasaki disease;	chr14:106767055	chr14:106627249~106627825:-
HNSC	cis	rs7824557	0.583	rs2263511	ENSG00000255495.1	AC145124.2	-4.17	3.56e-05	0.00589	-0.21	-0.19	Retinal vascular caliber;	chr8:11375809	chr8:12194467~12196280:+
HNSC	cis	rs1790761	0.505	rs6591256	ENSG00000184224.3	C11orf72	-4.17	3.56e-05	0.00589	-0.23	-0.19	Mean corpuscular volume;	chr11:67582428	chr11:67602880~67606706:-
HNSC	cis	rs73173548	0.502	rs4423262	ENSG00000247828.6	TMEM161B-AS1	4.17	3.56e-05	0.00589	0.2	0.19	Macular telangiectasia type 2;	chr5:88438609	chr5:88268895~88436685:+
HNSC	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	4.17	3.57e-05	0.0059	0.17	0.19	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	4.17	3.57e-05	0.0059	0.17	0.19	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	4.17	3.57e-05	0.0059	0.17	0.19	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	4.17	3.57e-05	0.0059	0.17	0.19	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
HNSC	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	4.17	3.57e-05	0.0059	0.27	0.19	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
HNSC	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	4.17	3.57e-05	0.0059	0.28	0.19	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
HNSC	cis	rs7015630	0.563	rs28461337	ENSG00000251136.7	RP11-37B2.1	-4.17	3.57e-05	0.0059	-0.22	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89812907	chr8:89609409~89757727:-
HNSC	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-4.17	3.57e-05	0.0059	-0.26	-0.19	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
HNSC	cis	rs11098499	0.863	rs13140391	ENSG00000250412.1	KLHL2P1	4.17	3.57e-05	0.0059	0.25	0.19	Corneal astigmatism;	chr4:119582282	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs13140409	ENSG00000250412.1	KLHL2P1	4.17	3.57e-05	0.0059	0.25	0.19	Corneal astigmatism;	chr4:119582305	chr4:119334329~119378233:+
HNSC	cis	rs8058578	0.887	rs28421305	ENSG00000279196.1	RP11-1072A3.3	4.17	3.57e-05	0.0059	0.22	0.19	Multiple myeloma;	chr16:30826807	chr16:30984630~30988270:-
HNSC	cis	rs60617249	0.772	rs4947981	ENSG00000228204.2	RP4-724E13.2	4.17	3.57e-05	0.0059	0.2	0.19	Major depression and alcohol dependence;	chr7:50880612	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.772	rs10249897	ENSG00000228204.2	RP4-724E13.2	4.17	3.57e-05	0.0059	0.2	0.19	Major depression and alcohol dependence;	chr7:50881158	chr7:50866747~51022990:+
HNSC	cis	rs7071275	0.564	rs17102363	ENSG00000223432.1	RP11-62L18.3	4.17	3.57e-05	0.0059	0.25	0.19	Dupuytren's disease;	chr10:121628725	chr10:121615425~121615839:-
HNSC	cis	rs6831352	0.918	rs13107558	ENSG00000263923.1	RP11-571L19.7	4.17	3.57e-05	0.0059	0.2	0.19	Alcohol dependence;	chr4:99129049	chr4:98928897~98994994:+
HNSC	cis	rs7296418	0.636	rs11057261	ENSG00000280120.1	RP11-546D6.3	4.17	3.57e-05	0.0059	0.16	0.19	Platelet count;	chr12:123313020	chr12:123152324~123153377:-
HNSC	cis	rs2243480	1	rs383402	ENSG00000229886.1	RP5-1132H15.3	-4.17	3.57e-05	0.0059	-0.31	-0.19	Diabetic kidney disease;	chr7:66121666	chr7:66025126~66031544:-
HNSC	cis	rs6723108	0.702	rs55920206	ENSG00000224043.6	CCNT2-AS1	4.17	3.57e-05	0.0059	0.22	0.19	Type 2 diabetes;	chr2:134674496	chr2:134735464~134918710:-
HNSC	cis	rs12545109	0.8	rs2609978	ENSG00000246430.5	LINC00968	-4.17	3.57e-05	0.0059	-0.24	-0.19	Obesity-related traits;	chr8:56481908	chr8:56496246~56559823:-
HNSC	cis	rs11951515	1	rs3756416	ENSG00000249286.1	CTD-2210P15.2	4.17	3.57e-05	0.00591	0.2	0.19	Metabolite levels  (X-11787);	chr5:43383400	chr5:43586918~43588223:-
HNSC	cis	rs1642645	0.872	rs1408948	ENSG00000228452.1	RP5-994D16.9	4.17	3.57e-05	0.00591	0.26	0.19	Left ventricular obstructive tract defect (maternal effect);	chr1:41952035	chr1:42775813~42776790:-
HNSC	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	4.17	3.58e-05	0.00591	0.22	0.19	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
HNSC	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-4.17	3.58e-05	0.00591	-0.2	-0.19	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
HNSC	cis	rs6840360	0.606	rs2709814	ENSG00000251611.1	RP11-610P16.1	-4.17	3.58e-05	0.00591	-0.18	-0.19	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151407551~151408835:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	4.17	3.58e-05	0.00591	0.25	0.19	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
HNSC	cis	rs9959145	1	rs1592641	ENSG00000267249.1	RP11-973H7.3	4.17	3.58e-05	0.00591	0.27	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12647241	chr18:12670426~12671145:-
HNSC	cis	rs10791097	0.72	rs6590517	ENSG00000254842.5	RP11-890B15.2	-4.17	3.58e-05	0.00591	-0.16	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863610	chr11:130844191~130865561:-
HNSC	cis	rs597539	0.518	rs35093305	ENSG00000255741.1	RP11-757G1.5	-4.17	3.58e-05	0.00591	-0.26	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68941503~68942852:-
HNSC	cis	rs2243480	0.803	rs13224048	ENSG00000106610.13	STAG3L4	-4.17	3.58e-05	0.00591	-0.39	-0.19	Diabetic kidney disease;	chr7:66528779	chr7:67302621~67321526:+
HNSC	cis	rs6601327	0.641	rs11782886	ENSG00000233609.3	RP11-62H7.2	-4.17	3.58e-05	0.00592	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9730381	chr8:8961200~8979025:+
HNSC	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	4.17	3.58e-05	0.00592	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
HNSC	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	4.17	3.58e-05	0.00592	0.22	0.19	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
HNSC	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	4.17	3.58e-05	0.00592	0.2	0.19	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000229886.1	RP5-1132H15.3	4.17	3.58e-05	0.00592	0.32	0.19	Diabetic kidney disease;	chr7:65951319	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000229886.1	RP5-1132H15.3	4.17	3.58e-05	0.00592	0.32	0.19	Diabetic kidney disease;	chr7:65951525	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000229886.1	RP5-1132H15.3	4.17	3.58e-05	0.00592	0.32	0.19	Diabetic kidney disease;	chr7:65951549	chr7:66025126~66031544:-
HNSC	cis	rs7278690	0.777	rs6517070	ENSG00000281903.1	AF127936.7	4.17	3.58e-05	0.00592	0.41	0.19	Breast cancer;	chr21:14866227	chr21:14819699~14918552:-
HNSC	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-4.17	3.58e-05	0.00592	-0.23	-0.19	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
HNSC	cis	rs9487051	0.872	rs7772602	ENSG00000219700.1	PTCHD3P3	-4.17	3.58e-05	0.00592	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109287458	chr6:109288571~109290503:-
HNSC	cis	rs2657294	0.603	rs11543	ENSG00000226051.5	ZNF503-AS1	-4.17	3.58e-05	0.00592	-0.25	-0.19	Pneumonia;	chr10:75210855	chr10:75269819~75373500:+
HNSC	cis	rs7572733	0.773	rs6748788	ENSG00000222017.1	AC011997.1	-4.17	3.58e-05	0.00592	-0.23	-0.19	Dermatomyositis;	chr2:197668882	chr2:197693106~197774823:+
HNSC	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	4.17	3.59e-05	0.00592	0.33	0.19	QT interval;	chr4:75144808	chr4:75081702~75084717:-
HNSC	cis	rs853679	0.517	rs3757187	ENSG00000219891.2	ZSCAN12P1	4.17	3.59e-05	0.00592	0.27	0.19	Depression;	chr6:28139876	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs3757185	ENSG00000219891.2	ZSCAN12P1	4.17	3.59e-05	0.00592	0.27	0.19	Depression;	chr6:28139998	chr6:28091154~28093664:+
HNSC	cis	rs9611565	0.918	rs9611566	ENSG00000235513.1	RP4-756G23.5	-4.17	3.59e-05	0.00592	-0.22	-0.19	Vitiligo;	chr22:41372621	chr22:41209122~41217627:-
HNSC	cis	rs7178909	0.8	rs3825866	ENSG00000259677.1	RP11-493E3.1	4.17	3.59e-05	0.00592	0.21	0.19	Common traits (Other);	chr15:89894406	chr15:89876540~89877285:+
HNSC	cis	rs6430585	0.528	rs309166	ENSG00000231890.6	DARS-AS1	-4.17	3.59e-05	0.00592	-0.32	-0.19	Corneal structure;	chr2:135909917	chr2:135985176~136022593:+
HNSC	cis	rs6095360	1	rs6019573	ENSG00000222365.1	SNORD12B	-4.17	3.59e-05	0.00592	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48986295	chr20:49280319~49280409:+
HNSC	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	4.17	3.59e-05	0.00592	0.19	0.19	Asthma;	chr2:102358304	chr2:102438713~102440475:+
HNSC	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-4.17	3.59e-05	0.00593	-0.22	-0.19	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
HNSC	cis	rs516805	0.748	rs72962455	ENSG00000279453.1	RP3-425C14.4	4.17	3.59e-05	0.00593	0.27	0.19	Lymphocyte counts;	chr6:122563378	chr6:122436789~122439223:-
HNSC	cis	rs9650657	0.737	rs2409669	ENSG00000255310.2	AF131215.2	-4.17	3.59e-05	0.00593	-0.18	-0.19	Neuroticism;	chr8:10766459	chr8:11107788~11109726:-
HNSC	cis	rs889398	0.741	rs3790076	ENSG00000226232.7	RP11-419C5.2	4.17	3.59e-05	0.00593	0.17	0.19	Body mass index;	chr16:69873542	chr16:69976388~69996188:-
HNSC	cis	rs72717009	0.825	rs9427399	ENSG00000225217.1	HSPA7	-4.17	3.59e-05	0.00593	-0.33	-0.19	Rheumatoid arthritis;	chr1:161506743	chr1:161606291~161608217:+
HNSC	cis	rs58873874	0.737	rs10515750	ENSG00000248544.2	CTB-47B11.3	4.17	3.59e-05	0.00593	0.38	0.19	Bipolar disorder (body mass index interaction);	chr5:157383064	chr5:157375741~157384950:-
HNSC	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	4.17	3.59e-05	0.00593	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
HNSC	cis	rs5758659	0.633	rs762995	ENSG00000273366.1	CTA-989H11.1	-4.17	3.59e-05	0.00593	-0.22	-0.19	Cognitive function;	chr22:42276118	chr22:42278188~42278846:+
HNSC	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-4.17	3.6e-05	0.00593	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000233609.3	RP11-62H7.2	4.17	3.6e-05	0.00594	0.18	0.19	Mood instability;	chr8:8783635	chr8:8961200~8979025:+
HNSC	cis	rs9990333	0.622	rs57783901	ENSG00000273009.1	RP11-352G9.1	-4.17	3.6e-05	0.00594	-0.21	-0.19	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195913078~195913683:-
HNSC	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-4.17	3.6e-05	0.00594	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
HNSC	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-4.17	3.6e-05	0.00594	-0.25	-0.19	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
HNSC	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-4.17	3.6e-05	0.00594	-0.25	-0.19	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
HNSC	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-4.17	3.6e-05	0.00594	-0.25	-0.19	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
HNSC	cis	rs73607972	0.935	rs17214955	ENSG00000275191.1	RP11-36I17.2	-4.17	3.6e-05	0.00594	-0.28	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612064	chr16:53628256~53628816:-
HNSC	cis	rs3738443	0.599	rs1934986	ENSG00000259865.1	RP11-488L18.10	4.17	3.6e-05	0.00594	0.17	0.19	Alcohol dependence;	chr1:247235696	chr1:247187281~247188526:-
HNSC	cis	rs755249	0.567	rs4660546	ENSG00000182109.6	RP11-69E11.4	4.17	3.6e-05	0.00594	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs2036463	ENSG00000182109.6	RP11-69E11.4	4.17	3.6e-05	0.00594	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs2036464	ENSG00000182109.6	RP11-69E11.4	4.17	3.6e-05	0.00594	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.567	rs905381	ENSG00000182109.6	RP11-69E11.4	4.17	3.6e-05	0.00594	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39522280~39546187:-
HNSC	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	4.17	3.6e-05	0.00594	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000254340.1	RP11-10A14.3	4.17	3.6e-05	0.00594	0.23	0.19	Mood instability;	chr8:8484905	chr8:9141424~9145435:+
HNSC	cis	rs10504130	0.932	rs79067987	ENSG00000272024.1	RP11-546K22.3	-4.17	3.6e-05	0.00594	-0.34	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51935697	chr8:51950284~51950690:+
HNSC	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	4.17	3.6e-05	0.00594	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
HNSC	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	4.17	3.6e-05	0.00594	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
HNSC	cis	rs9487051	0.872	rs7773331	ENSG00000219700.1	PTCHD3P3	4.17	3.6e-05	0.00594	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109288005	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.872	rs9374079	ENSG00000219700.1	PTCHD3P3	4.17	3.6e-05	0.00594	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109288416	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.802	rs9487039	ENSG00000219700.1	PTCHD3P3	4.17	3.6e-05	0.00594	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109288960	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.872	rs9487042	ENSG00000219700.1	PTCHD3P3	4.17	3.6e-05	0.00594	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109289240	chr6:109288571~109290503:-
HNSC	cis	rs1665050	0.625	rs8028764	ENSG00000259732.1	RP11-59H7.3	-4.17	3.6e-05	0.00594	-0.24	-0.19	Atopic dermatitis;	chr15:59012436	chr15:59121034~59133250:+
HNSC	cis	rs7520050	0.831	rs61783170	ENSG00000280836.1	AL355480.1	4.17	3.6e-05	0.00594	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45581219~45581321:-
HNSC	cis	rs2898290	0.617	rs13273172	ENSG00000255310.2	AF131215.2	-4.17	3.6e-05	0.00595	-0.18	-0.19	Systolic blood pressure;	chr8:11603602	chr8:11107788~11109726:-
HNSC	cis	rs78579285	0.544	rs4782321	ENSG00000278341.1	RP5-1142A6.10	-4.17	3.6e-05	0.00595	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88713767	chr16:88708956~88710437:-
HNSC	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	4.17	3.6e-05	0.00595	0.16	0.19	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
HNSC	cis	rs9926296	0.744	rs6860	ENSG00000274627.1	RP11-104N10.2	4.17	3.6e-05	0.00595	0.19	0.19	Vitiligo;	chr16:89644712	chr16:89516797~89522217:+
HNSC	cis	rs4356203	0.87	rs12286505	ENSG00000272034.1	SNORD14A	4.17	3.61e-05	0.00595	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17074654~17074744:-
HNSC	cis	rs9467773	0.587	rs10946813	ENSG00000241549.7	GUSBP2	-4.17	3.61e-05	0.00595	-0.18	-0.19	Intelligence (multi-trait analysis);	chr6:26344913	chr6:26871484~26956554:-
HNSC	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-4.17	3.61e-05	0.00595	-0.17	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
HNSC	cis	rs6601450	0.579	rs11775625	ENSG00000269918.1	AF131215.9	4.17	3.61e-05	0.00595	0.18	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10414929	chr8:11104691~11106704:-
HNSC	cis	rs12030196	0.743	rs71646019	ENSG00000230812.4	LINC01358	4.17	3.61e-05	0.00595	0.21	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967682	chr1:59020387~59044614:+
HNSC	cis	rs686320	0.748	rs550894	ENSG00000245532.5	NEAT1	4.17	3.61e-05	0.00596	0.24	0.19	Hip circumference adjusted for BMI;	chr11:65444469	chr11:65422774~65445540:+
HNSC	cis	rs7178909	0.866	rs3784388	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89894069	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.872	rs3784387	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89894138	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.902	rs28372736	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89894626	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.902	rs10459674	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89895063	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.902	rs2043882	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89896521	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.902	rs2043881	ENSG00000259677.1	RP11-493E3.1	4.17	3.61e-05	0.00596	0.21	0.19	Common traits (Other);	chr15:89896728	chr15:89876540~89877285:+
HNSC	cis	rs2055729	0.645	rs612689	ENSG00000254340.1	RP11-10A14.3	4.17	3.61e-05	0.00596	0.29	0.19	Multiple myeloma (hyperdiploidy);	chr8:9895455	chr8:9141424~9145435:+
HNSC	cis	rs911119	0.954	rs2424582	ENSG00000270001.1	RP11-218C14.8	-4.17	3.61e-05	0.00596	-0.27	-0.19	Chronic kidney disease;	chr20:23641913	chr20:23631826~23632316:-
HNSC	cis	rs761746	0.695	rs3804087	ENSG00000236132.1	CTA-440B3.1	4.17	3.61e-05	0.00596	0.24	0.19	Intelligence;	chr22:31683317	chr22:31816379~31817491:-
HNSC	cis	rs9880211	0.752	rs35428413	ENSG00000273486.1	RP11-731C17.2	4.17	3.62e-05	0.00596	0.19	0.19	Height;Body mass index;	chr3:136661856	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.699	rs13433688	ENSG00000273486.1	RP11-731C17.2	4.17	3.62e-05	0.00596	0.19	0.19	Height;Body mass index;	chr3:136690329	chr3:136837338~136839021:-
HNSC	cis	rs11673344	0.504	rs7258360	ENSG00000276846.1	CTD-3220F14.3	4.17	3.62e-05	0.00596	0.2	0.19	Obesity-related traits;	chr19:37115015	chr19:37314868~37315620:-
HNSC	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	4.17	3.62e-05	0.00596	0.25	0.19	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
HNSC	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-4.17	3.62e-05	0.00596	-0.22	-0.19	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
HNSC	cis	rs10466239	0.892	rs17153534	ENSG00000230555.2	RP11-517P14.2	4.17	3.62e-05	0.00597	0.34	0.19	Telomere length;	chr10:43353203	chr10:43420738~43422100:+
HNSC	cis	rs10466239	1	rs10466239	ENSG00000230555.2	RP11-517P14.2	4.17	3.62e-05	0.00597	0.34	0.19	Telomere length;	chr10:43354379	chr10:43420738~43422100:+
HNSC	cis	rs9650657	0.77	rs9969626	ENSG00000269918.1	AF131215.9	-4.17	3.62e-05	0.00597	-0.19	-0.19	Neuroticism;	chr8:10813291	chr8:11104691~11106704:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000272831.1	RP11-792A8.4	4.17	3.62e-05	0.00597	0.16	0.19	Aortic root size;	chr7:66631041	chr7:66739829~66740385:-
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000254174.1	IGHV1-12	4.17	3.62e-05	0.00597	0.15	0.19	Rheumatic heart disease;	chr14:106619987	chr14:106122420~106122709:-
HNSC	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-4.17	3.62e-05	0.00597	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
HNSC	cis	rs8028182	0.636	rs6495182	ENSG00000260269.4	CTD-2323K18.1	-4.17	3.62e-05	0.00597	-0.25	-0.19	Sudden cardiac arrest;	chr15:75522047	chr15:75527150~75601205:-
HNSC	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-4.17	3.62e-05	0.00598	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-4.17	3.62e-05	0.00598	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
HNSC	cis	rs5758511	0.573	rs1883205	ENSG00000235513.1	RP4-756G23.5	4.17	3.62e-05	0.00598	0.2	0.19	Birth weight;	chr22:41847016	chr22:41209122~41217627:-
HNSC	cis	rs6964587	0.692	rs6953256	ENSG00000188693.7	CYP51A1-AS1	4.17	3.63e-05	0.00598	0.2	0.19	Breast cancer;	chr7:91946103	chr7:92134604~92180725:+
HNSC	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.17	3.63e-05	0.00598	0.21	0.19	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
HNSC	cis	rs9903692	0.954	rs2109984	ENSG00000263412.1	RP5-890E16.2	-4.17	3.63e-05	0.00598	-0.18	-0.19	Pulse pressure;	chr17:48093737	chr17:48045141~48048073:-
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	4.17	3.63e-05	0.00598	0.23	0.19	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
HNSC	cis	rs73198271	0.71	rs7837843	ENSG00000173295.6	FAM86B3P	-4.17	3.63e-05	0.00598	-0.24	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.64	rs7838012	ENSG00000173295.6	FAM86B3P	-4.17	3.63e-05	0.00598	-0.24	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8228595~8244865:+
HNSC	cis	rs9313772	0.775	rs10214268	ENSG00000254350.1	RP11-542A14.1	-4.17	3.63e-05	0.00598	-0.2	-0.19	Blood pressure;	chr5:158380787	chr5:158424585~158452758:+
HNSC	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-4.17	3.63e-05	0.00598	-0.22	-0.19	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
HNSC	cis	rs1028883	0.682	rs4885108	ENSG00000228295.1	LINC00392	4.17	3.63e-05	0.00598	0.2	0.19	Lean body mass;	chr13:73571912	chr13:73564244~73588070:+
HNSC	cis	rs72627123	1	rs72627117	ENSG00000259065.1	RP5-1021I20.1	-4.17	3.63e-05	0.00598	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73888530	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627119	ENSG00000259065.1	RP5-1021I20.1	-4.17	3.63e-05	0.00598	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73889571	chr14:73787360~73803270:+
HNSC	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	4.17	3.63e-05	0.00598	0.29	0.19	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
HNSC	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	4.17	3.63e-05	0.00598	0.29	0.19	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
HNSC	cis	rs9925964	0.748	rs4889603	ENSG00000232748.3	RP11-196G11.6	-4.17	3.63e-05	0.00598	-0.25	-0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31056460~31062803:+
HNSC	cis	rs7267979	0.844	rs6050477	ENSG00000231081.1	RP4-760C5.3	4.17	3.63e-05	0.00598	0.19	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26008791~26010531:-
HNSC	cis	rs12545109	0.8	rs1837620	ENSG00000246430.5	LINC00968	-4.17	3.63e-05	0.00599	-0.23	-0.19	Obesity-related traits;	chr8:56486914	chr8:56496246~56559823:-
HNSC	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-4.17	3.63e-05	0.00599	-0.25	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
HNSC	cis	rs2333194	0.869	rs177368	ENSG00000258695.2	RP3-414A15.2	-4.17	3.63e-05	0.00599	-0.2	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73294539	chr14:73522878~73530610:+
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-4.17	3.63e-05	0.00599	-0.18	-0.19	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
HNSC	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-4.17	3.63e-05	0.00599	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
HNSC	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-4.17	3.63e-05	0.00599	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
HNSC	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-4.17	3.63e-05	0.00599	-0.22	-0.19	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
HNSC	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	4.17	3.63e-05	0.00599	0.16	0.19	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
HNSC	cis	rs9863	0.861	rs10846579	ENSG00000270028.1	RP11-380L11.4	4.17	3.64e-05	0.00599	0.22	0.19	White blood cell count;	chr12:123922856	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs11057394	ENSG00000270028.1	RP11-380L11.4	4.17	3.64e-05	0.00599	0.22	0.19	White blood cell count;	chr12:123923129	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs12809125	ENSG00000270028.1	RP11-380L11.4	4.17	3.64e-05	0.00599	0.22	0.19	White blood cell count;	chr12:123923444	chr12:123925461~123926083:-
HNSC	cis	rs12034383	0.967	rs12028134	ENSG00000274245.1	RP11-357P18.2	-4.17	3.64e-05	0.006	-0.24	-0.19	Erythrocyte sedimentation rate;	chr1:207627064	chr1:207372559~207373252:+
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000224373.3	IGHV4-59	4.17	3.64e-05	0.006	0.12	0.19	Kawasaki disease;	chr14:106692376	chr14:106627249~106627825:-
HNSC	cis	rs6964587	0.967	rs9656003	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.64e-05	0.006	-0.2	-0.19	Breast cancer;	chr7:92137008	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.933	rs28671255	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.64e-05	0.006	-0.2	-0.19	Breast cancer;	chr7:92141391	chr7:92134604~92180725:+
HNSC	cis	rs7615952	0.673	rs115942855	ENSG00000241439.1	RP11-666A20.3	4.17	3.64e-05	0.006	0.28	0.19	Blood pressure (smoking interaction);	chr3:125883117	chr3:125958556~125958817:+
HNSC	cis	rs9300255	0.509	rs641760	ENSG00000280120.1	RP11-546D6.3	4.17	3.64e-05	0.006	0.18	0.19	Neutrophil percentage of white cells;	chr12:123034319	chr12:123152324~123153377:-
HNSC	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	4.17	3.64e-05	0.006	0.27	0.19	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	4.17	3.64e-05	0.006	0.27	0.19	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
HNSC	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	4.17	3.64e-05	0.006	0.29	0.19	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	4.17	3.64e-05	0.006	0.29	0.19	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
HNSC	cis	rs7005380	0.581	rs7813430	ENSG00000279347.1	RP11-85I17.2	4.17	3.64e-05	0.006	0.17	0.19	Interstitial lung disease;	chr8:119926834	chr8:119838736~119840385:-
HNSC	cis	rs7196129	0.966	rs11150589	ENSG00000183604.13	SMG1P5	4.17	3.64e-05	0.006	0.19	0.19	Monocyte count;	chr16:30471173	chr16:30267553~30335374:-
HNSC	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	4.17	3.64e-05	0.006	0.25	0.19	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	4.17	3.64e-05	0.006	0.25	0.19	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	4.17	3.64e-05	0.006	0.25	0.19	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
HNSC	cis	rs11098499	0.644	rs10050092	ENSG00000250412.1	KLHL2P1	4.17	3.64e-05	0.006	0.24	0.19	Corneal astigmatism;	chr4:119610930	chr4:119334329~119378233:+
HNSC	cis	rs7005380	1	rs10955943	ENSG00000279347.1	RP11-85I17.2	4.17	3.64e-05	0.006	0.16	0.19	Interstitial lung disease;	chr8:119931903	chr8:119838736~119840385:-
HNSC	cis	rs6688613	0.729	rs41269702	ENSG00000215834.7	FMO9P	4.17	3.65e-05	0.00601	0.25	0.19	Refractive astigmatism;	chr1:166989700	chr1:166603675~166631400:+
HNSC	cis	rs12716977	1	rs12716977	ENSG00000183604.13	SMG1P5	4.17	3.65e-05	0.00601	0.19	0.19	Lymphocyte percentage of white cells;Lymphocyte counts;	chr16:30471482	chr16:30267553~30335374:-
HNSC	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	4.17	3.65e-05	0.00601	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
HNSC	cis	rs7475343	0.501	rs17134531	ENSG00000224034.1	RP11-445P17.8	-4.17	3.65e-05	0.00601	-0.27	-0.19	Intelligence;	chr10:5204122	chr10:5266033~5271236:-
HNSC	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	4.17	3.65e-05	0.00601	0.21	0.19	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
HNSC	cis	rs12545109	0.8	rs2118260	ENSG00000246430.5	LINC00968	-4.17	3.65e-05	0.00601	-0.24	-0.19	Obesity-related traits;	chr8:56480922	chr8:56496246~56559823:-
HNSC	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	4.17	3.65e-05	0.00601	0.26	0.19	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
HNSC	cis	rs367615	0.642	rs439182	ENSG00000249476.1	CTD-2587M2.1	-4.17	3.65e-05	0.00601	-0.26	-0.19	Colorectal cancer (SNP x SNP interaction);	chr5:109616666	chr5:109237120~109326369:-
HNSC	cis	rs3015497	0.934	rs2934691	ENSG00000277050.1	RP11-102G14.1	-4.17	3.65e-05	0.00601	-0.18	-0.19	Mean platelet volume;	chr14:50654615	chr14:51637348~51637947:-
HNSC	cis	rs9313772	0.722	rs7736044	ENSG00000254350.1	RP11-542A14.1	-4.17	3.65e-05	0.00602	-0.2	-0.19	Blood pressure;	chr5:158448578	chr5:158424585~158452758:+
HNSC	cis	rs523522	0.923	rs1048830	ENSG00000278344.1	RP11-18C24.8	4.17	3.65e-05	0.00602	0.25	0.19	High light scatter reticulocyte count;	chr12:120444414	chr12:120500735~120501090:-
HNSC	cis	rs62560775	0.541	rs12352425	ENSG00000240498.5	CDKN2B-AS1	4.17	3.65e-05	0.00602	0.32	0.19	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21994778~22121097:+
HNSC	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	4.17	3.65e-05	0.00602	0.16	0.19	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
HNSC	cis	rs4947019	0.609	rs4946972	ENSG00000260273.1	RP11-425D10.10	4.17	3.66e-05	0.00602	0.5	0.19	Hematological parameters;	chr6:109400025	chr6:109382795~109383666:+
HNSC	cis	rs1008375	0.897	rs6820164	ENSG00000249502.1	AC006160.5	-4.17	3.66e-05	0.00602	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628492	chr4:17587467~17614571:-
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000233609.3	RP11-62H7.2	4.17	3.66e-05	0.00602	0.19	0.19	Mood instability;	chr8:8828344	chr8:8961200~8979025:+
HNSC	cis	rs1065852	0.906	rs5751230	ENSG00000226450.2	CYP2D8P	4.17	3.66e-05	0.00602	0.18	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42157347	chr22:42149886~42155001:-
HNSC	cis	rs6964587	1	rs9690778	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.66e-05	0.00602	-0.2	-0.19	Breast cancer;	chr7:92105985	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs57816416	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.66e-05	0.00602	-0.2	-0.19	Breast cancer;	chr7:92106764	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs12704635	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.66e-05	0.00602	-0.2	-0.19	Breast cancer;	chr7:92108010	chr7:92134604~92180725:+
HNSC	cis	rs4862750	0.832	rs10007858	ENSG00000250971.1	RP11-696F12.1	4.17	3.66e-05	0.00602	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186956338	chr4:187060099~187060930:+
HNSC	cis	rs7520050	0.966	rs12409773	ENSG00000280836.1	AL355480.1	4.17	3.66e-05	0.00602	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45581219~45581321:-
HNSC	cis	rs7520050	1	rs12410070	ENSG00000280836.1	AL355480.1	4.17	3.66e-05	0.00602	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs12410071	ENSG00000280836.1	AL355480.1	4.17	3.66e-05	0.00602	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45581219~45581321:-
HNSC	cis	rs11247915	0.561	rs12750420	ENSG00000236782.4	RP11-96L14.7	-4.17	3.66e-05	0.00602	-0.22	-0.19	Obesity-related traits;	chr1:26282158	chr1:26169947~26171821:-
HNSC	cis	rs72627123	0.749	rs72627104	ENSG00000259065.1	RP5-1021I20.1	-4.17	3.66e-05	0.00602	-0.35	-0.19	Morning vs. evening chronotype;	chr14:73839245	chr14:73787360~73803270:+
HNSC	cis	rs2361710	0.668	rs2304855	ENSG00000279259.1	RP11-334C17.3	4.17	3.66e-05	0.00602	0.22	0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80144467	chr17:80147250~80148596:+
HNSC	cis	rs9880211	0.8	rs1872239	ENSG00000239213.4	NCK1-AS1	4.17	3.66e-05	0.00603	0.19	0.19	Height;Body mass index;	chr3:136785069	chr3:136841726~136862054:-
HNSC	cis	rs17345786	0.906	rs11710016	ENSG00000244119.1	PDCL3P4	-4.17	3.66e-05	0.00603	-0.21	-0.19	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101712472~101713191:+
HNSC	cis	rs10735851	1	rs10735851	ENSG00000270175.1	RP11-793H13.11	-4.17	3.66e-05	0.00603	-0.19	-0.19	Total body bone mineral density;	chr12:53349280	chr12:53500162~53500936:-
HNSC	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	4.17	3.66e-05	0.00603	0.16	0.19	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	4.17	3.66e-05	0.00603	0.16	0.19	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	4.17	3.66e-05	0.00603	0.23	0.19	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	4.17	3.66e-05	0.00603	0.23	0.19	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
HNSC	cis	rs1799949	1	rs11653460	ENSG00000236383.6	LINC00854	-4.17	3.66e-05	0.00603	-0.18	-0.19	Menopause (age at onset);	chr17:43179289	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs11650913	ENSG00000236383.6	LINC00854	-4.17	3.66e-05	0.00603	-0.18	-0.19	Menopause (age at onset);	chr17:43179580	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs12936831	ENSG00000236383.6	LINC00854	-4.17	3.66e-05	0.00603	-0.18	-0.19	Menopause (age at onset);	chr17:43179799	chr17:43216941~43305976:-
HNSC	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	4.17	3.66e-05	0.00603	0.23	0.19	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000106610.13	STAG3L4	-4.17	3.67e-05	0.00603	-0.38	-0.19	Diabetic kidney disease;	chr7:66500146	chr7:67302621~67321526:+
HNSC	cis	rs9880211	0.752	rs13062352	ENSG00000273486.1	RP11-731C17.2	4.17	3.67e-05	0.00603	0.19	0.19	Height;Body mass index;	chr3:136745920	chr3:136837338~136839021:-
HNSC	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.17	3.67e-05	0.00603	0.32	0.19	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	4.17	3.67e-05	0.00603	0.25	0.19	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
HNSC	cis	rs10502219	0.597	rs4936357	ENSG00000235910.1	APOA1-AS	4.17	3.67e-05	0.00604	0.27	0.19	Mitochondrial DNA levels;	chr11:116569446	chr11:116836117~116855729:+
HNSC	cis	rs10554589	1	rs10554589	ENSG00000274627.1	RP11-104N10.2	4.17	3.67e-05	0.00604	0.24	0.19	Lymphocyte counts;	chr16:89295874	chr16:89516797~89522217:+
HNSC	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-4.17	3.67e-05	0.00604	-0.19	-0.19	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
HNSC	cis	rs6095360	1	rs6095360	ENSG00000222365.1	SNORD12B	-4.17	3.67e-05	0.00604	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:48915999	chr20:49280319~49280409:+
HNSC	cis	rs1713985	0.698	rs1277307	ENSG00000269949.1	RP11-738E22.3	-4.17	3.67e-05	0.00604	-0.33	-0.19	Age-related macular degeneration;	chr4:57030533	chr4:56960927~56961373:-
HNSC	cis	rs9880211	0.699	rs34804893	ENSG00000273486.1	RP11-731C17.2	4.17	3.67e-05	0.00604	0.19	0.19	Height;Body mass index;	chr3:136621128	chr3:136837338~136839021:-
HNSC	cis	rs3015497	1	rs4075253	ENSG00000277050.1	RP11-102G14.1	-4.17	3.67e-05	0.00604	-0.18	-0.19	Mean platelet volume;	chr14:50641019	chr14:51637348~51637947:-
HNSC	cis	rs5758659	0.594	rs739292	ENSG00000182057.4	OGFRP1	4.17	3.67e-05	0.00604	0.19	0.19	Cognitive function;	chr22:41972853	chr22:42269753~42275196:+
HNSC	cis	rs10462794	0.686	rs12516470	ENSG00000260763.1	RP11-445O3.3	-4.17	3.67e-05	0.00604	-0.24	-0.19	DNA methylation (variation);	chr5:4493831	chr5:4436850~4440259:-
HNSC	cis	rs10462794	0.686	rs4702789	ENSG00000260763.1	RP11-445O3.3	-4.17	3.67e-05	0.00604	-0.24	-0.19	DNA methylation (variation);	chr5:4494688	chr5:4436850~4440259:-
HNSC	cis	rs1799949	0.965	rs11651623	ENSG00000236383.6	LINC00854	-4.17	3.67e-05	0.00604	-0.18	-0.19	Menopause (age at onset);	chr17:43177830	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs11657883	ENSG00000236383.6	LINC00854	-4.17	3.67e-05	0.00604	-0.18	-0.19	Menopause (age at onset);	chr17:43178007	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs11656945	ENSG00000236383.6	LINC00854	-4.17	3.67e-05	0.00604	-0.18	-0.19	Menopause (age at onset);	chr17:43178248	chr17:43216941~43305976:-
HNSC	cis	rs2486288	0.656	rs12915314	ENSG00000259479.5	SORD2P	-4.17	3.67e-05	0.00604	-0.22	-0.19	Glomerular filtration rate;	chr15:45259293	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs8039138	ENSG00000259479.5	SORD2P	-4.17	3.67e-05	0.00604	-0.22	-0.19	Glomerular filtration rate;	chr15:45259394	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs8039540	ENSG00000259479.5	SORD2P	-4.17	3.67e-05	0.00604	-0.22	-0.19	Glomerular filtration rate;	chr15:45259644	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs8040185	ENSG00000259479.5	SORD2P	-4.17	3.67e-05	0.00604	-0.22	-0.19	Glomerular filtration rate;	chr15:45259883	chr15:44826371~44884694:-
HNSC	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-4.17	3.68e-05	0.00605	-0.2	-0.19	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
HNSC	cis	rs10504130	0.932	rs11777016	ENSG00000272024.1	RP11-546K22.3	-4.17	3.68e-05	0.00605	-0.33	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51874258	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs76649221	ENSG00000272024.1	RP11-546K22.3	-4.17	3.68e-05	0.00605	-0.33	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51884175	chr8:51950284~51950690:+
HNSC	cis	rs3758785	0.641	rs4753600	ENSG00000255893.1	RP11-685N10.1	4.17	3.68e-05	0.00605	0.22	0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368179	chr11:94472908~94473570:-
HNSC	cis	rs1862618	0.671	rs2255726	ENSG00000271828.1	CTD-2310F14.1	-4.17	3.68e-05	0.00605	-0.23	-0.19	Initial pursuit acceleration;	chr5:56947301	chr5:56927874~56929573:+
HNSC	cis	rs2274273	0.712	rs6572999	ENSG00000233924.1	AL160471.6	-4.17	3.68e-05	0.00605	-0.21	-0.19	Protein biomarker;	chr14:55060656	chr14:55004813~55005687:-
HNSC	cis	rs4819052	0.851	rs2838866	ENSG00000215447.6	BX322557.10	-4.17	3.68e-05	0.00605	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45288052~45291738:+
HNSC	cis	rs12745968	0.589	rs10874727	ENSG00000223787.2	RP4-593M8.1	-4.17	3.68e-05	0.00605	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92637595	chr1:92580476~92580821:-
HNSC	cis	rs72843166	0.562	rs17760469	ENSG00000265282.1	RP11-269G24.4	4.17	3.68e-05	0.00605	0.28	0.19	Intelligence (multi-trait analysis);	chr17:63351596	chr17:63430468~63432211:-
HNSC	cis	rs36093924	0.586	rs6002561	ENSG00000227370.1	RP4-669P10.19	4.17	3.68e-05	0.00605	0.18	0.19	Intelligence;	chr22:41963200	chr22:42132543~42132998:+
HNSC	cis	rs12701220	0.572	rs7792825	ENSG00000224079.1	AC091729.7	4.17	3.68e-05	0.00605	0.27	0.19	Bronchopulmonary dysplasia;	chr7:966937	chr7:1074450~1078036:+
HNSC	cis	rs6500395	0.584	rs1592570	ENSG00000261267.1	RP11-44I10.3	-4.17	3.68e-05	0.00606	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48708555	chr16:48559661~48587403:+
HNSC	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-4.17	3.68e-05	0.00606	-0.18	-0.19	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-4.17	3.68e-05	0.00606	-0.18	-0.19	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
HNSC	cis	rs1008375	1	rs4698635	ENSG00000249502.1	AC006160.5	-4.17	3.68e-05	0.00606	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628619	chr4:17587467~17614571:-
HNSC	cis	rs9650657	0.707	rs4841452	ENSG00000269918.1	AF131215.9	-4.17	3.68e-05	0.00606	-0.19	-0.19	Neuroticism;	chr8:10829611	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	4.17	3.68e-05	0.00606	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
HNSC	cis	rs1665050	0.749	rs8037569	ENSG00000277144.1	RP11-59H7.4	-4.17	3.68e-05	0.00606	-0.23	-0.19	Atopic dermatitis;	chr15:59010263	chr15:59115547~59116089:-
HNSC	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	4.17	3.68e-05	0.00606	0.29	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
HNSC	cis	rs9353324	1	rs9351066	ENSG00000203875.9	SNHG5	-4.17	3.69e-05	0.00606	-0.44	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85689099	chr6:85660950~85678736:-
HNSC	cis	rs78579285	0.704	rs78905828	ENSG00000278341.1	RP5-1142A6.10	-4.17	3.69e-05	0.00606	-0.35	-0.19	Joint mobility (Beighton score);	chr16:88736165	chr16:88708956~88710437:-
HNSC	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-4.17	3.69e-05	0.00606	-0.21	-0.19	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
HNSC	cis	rs12893668	0.697	rs67899457	ENSG00000269910.1	RP11-73M18.10	4.17	3.69e-05	0.00606	0.18	0.19	Reticulocyte count;	chr14:103593729	chr14:103694516~103695050:-
HNSC	cis	rs9525927	0.67	rs2246499	ENSG00000227258.4	SMIM2-AS1	-4.17	3.69e-05	0.00606	-0.26	-0.19	Dupuytren's disease;	chr13:44255900	chr13:44110451~44240517:+
HNSC	cis	rs13201294	1	rs13201294	ENSG00000219392.1	RP1-265C24.5	-4.17	3.69e-05	0.00606	-0.33	-0.19	Squamous cell lung carcinoma;	chr6:27588362	chr6:28115628~28116551:+
HNSC	cis	rs7826238	0.524	rs2921055	ENSG00000254340.1	RP11-10A14.3	4.17	3.69e-05	0.00607	0.22	0.19	Systolic blood pressure;	chr8:8461832	chr8:9141424~9145435:+
HNSC	cis	rs1056107	0.897	rs7851129	ENSG00000225513.1	RP11-165N19.2	-4.17	3.69e-05	0.00607	-0.2	-0.19	Colorectal cancer;	chr9:112193127	chr9:112173522~112173971:-
HNSC	cis	rs4947019	0.688	rs9480937	ENSG00000260273.1	RP11-425D10.10	-4.17	3.69e-05	0.00607	-0.52	-0.19	Hematological parameters;	chr6:109358629	chr6:109382795~109383666:+
HNSC	cis	rs9992667	0.829	rs337628	ENSG00000231160.8	KLF3-AS1	4.17	3.69e-05	0.00607	0.2	0.19	Eosinophil percentage of granulocytes;	chr4:38633523	chr4:38612701~38664883:-
HNSC	cis	rs9650657	0.675	rs2409658	ENSG00000269918.1	AF131215.9	-4.17	3.69e-05	0.00607	-0.19	-0.19	Neuroticism;	chr8:10811455	chr8:11104691~11106704:-
HNSC	cis	rs4372836	0.964	rs17007191	ENSG00000226833.4	AC097724.3	-4.17	3.69e-05	0.00607	-0.24	-0.19	Body mass index;	chr2:28709636	chr2:28708953~28736205:-
HNSC	cis	rs13256369	1	rs10103769	ENSG00000173295.6	FAM86B3P	4.17	3.69e-05	0.00607	0.25	0.19	Obesity-related traits;	chr8:8715526	chr8:8228595~8244865:+
HNSC	cis	rs1555322	1	rs2425037	ENSG00000126005.14	MMP24-AS1	4.17	3.69e-05	0.00607	0.35	0.19	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35216462~35278131:-
HNSC	cis	rs3015497	0.789	rs923908	ENSG00000277050.1	RP11-102G14.1	-4.17	3.69e-05	0.00607	-0.18	-0.19	Mean platelet volume;	chr14:50656877	chr14:51637348~51637947:-
HNSC	cis	rs2361718	0.501	rs8065486	ENSG00000279259.1	RP11-334C17.3	-4.17	3.69e-05	0.00607	-0.24	-0.19	Yeast infection;	chr17:80164397	chr17:80147250~80148596:+
HNSC	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	4.17	3.7e-05	0.00607	0.22	0.19	Height;	chr14:75088921	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	4.17	3.7e-05	0.00607	0.22	0.19	Height;	chr14:75088933	chr14:75011269~75012851:-
HNSC	cis	rs6568686	0.577	rs383515	ENSG00000255389.1	C6orf3	4.17	3.7e-05	0.00607	0.26	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111595465	chr6:111599875~111602295:+
HNSC	cis	rs10466239	0.892	rs74701654	ENSG00000230555.2	RP11-517P14.2	4.17	3.7e-05	0.00608	0.34	0.19	Telomere length;	chr10:43350863	chr10:43420738~43422100:+
HNSC	cis	rs929354	0.772	rs3802125	ENSG00000224629.1	RP5-1142J19.2	-4.17	3.7e-05	0.00608	-0.19	-0.19	Body mass index;	chr7:157177869	chr7:157263022~157263229:-
HNSC	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-4.17	3.7e-05	0.00608	-0.22	-0.19	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-4.17	3.7e-05	0.00608	-0.25	-0.19	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
HNSC	cis	rs9926296	0.744	rs154656	ENSG00000274627.1	RP11-104N10.2	4.17	3.7e-05	0.00608	0.19	0.19	Vitiligo;	chr16:89641595	chr16:89516797~89522217:+
HNSC	cis	rs17761864	0.96	rs72819572	ENSG00000262333.1	HNRNPA1P16	-4.17	3.7e-05	0.00608	-0.17	-0.19	Esophageal cancer (squamous cell);	chr17:2277477	chr17:2306761~2307715:+
HNSC	cis	rs436483	0.838	rs392438	ENSG00000213385.3	RP11-577H5.1	-4.17	3.7e-05	0.00608	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr7:102045552	chr7:102755146~102755939:+
HNSC	cis	rs17594362	0.697	rs1887743	ENSG00000229473.2	RGS17P1	-4.17	3.7e-05	0.00608	-0.26	-0.19	Multiple sclerosis;	chr13:41564073	chr13:40992779~40993331:-
HNSC	cis	rs67981189	0.513	rs221893	ENSG00000274818.1	RP1-292L20.3	-4.17	3.7e-05	0.00609	-0.21	-0.19	Schizophrenia;	chr14:71144697	chr14:70906657~70907111:-
HNSC	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-4.17	3.7e-05	0.00609	-0.2	-0.19	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
HNSC	cis	rs6601327	0.641	rs9644704	ENSG00000254340.1	RP11-10A14.3	-4.17	3.71e-05	0.00609	-0.23	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9702659	chr8:9141424~9145435:+
HNSC	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	4.17	3.71e-05	0.00609	0.16	0.19	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
HNSC	cis	rs34097030	1	rs34097030	ENSG00000207217.1	SNORA42	-4.17	3.71e-05	0.00609	-0.25	-0.19	Reticulocyte fraction of red cells;	chr7:6014758	chr7:6016877~6017011:+
HNSC	cis	rs3736485	0.934	rs8038203	ENSG00000259438.1	CTD-2650P22.1	4.17	3.71e-05	0.00609	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51578486	chr15:52010999~52019095:-
HNSC	cis	rs10742752	0.603	rs11038428	ENSG00000255267.3	RP11-430H10.2	4.16	3.71e-05	0.00609	0.25	0.19	Body mass index;	chr11:45382767	chr11:45371397~45388508:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	4.16	3.71e-05	0.00609	0.27	0.19	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	4.16	3.71e-05	0.00609	0.27	0.19	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	4.16	3.71e-05	0.00609	0.27	0.19	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	4.16	3.71e-05	0.00609	0.27	0.19	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
HNSC	cis	rs71520386	0.796	rs71530697	ENSG00000230658.1	KLHL7-AS1	4.16	3.71e-05	0.00609	0.29	0.19	Fibrinogen levels;	chr7:22799134	chr7:23101228~23105703:-
HNSC	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-4.16	3.71e-05	0.00609	-0.33	-0.19	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
HNSC	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-4.16	3.71e-05	0.00609	-0.33	-0.19	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
HNSC	cis	rs7005380	0.538	rs6469875	ENSG00000279347.1	RP11-85I17.2	-4.16	3.71e-05	0.0061	-0.17	-0.19	Interstitial lung disease;	chr8:119914393	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.538	rs2056305	ENSG00000279347.1	RP11-85I17.2	-4.16	3.71e-05	0.0061	-0.17	-0.19	Interstitial lung disease;	chr8:119916865	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.581	rs28546392	ENSG00000279347.1	RP11-85I17.2	4.16	3.71e-05	0.0061	0.17	0.19	Interstitial lung disease;	chr8:119919067	chr8:119838736~119840385:-
HNSC	cis	rs9329221	0.527	rs4841352	ENSG00000255310.2	AF131215.2	4.16	3.71e-05	0.0061	0.19	0.19	Neuroticism;	chr8:10470080	chr8:11107788~11109726:-
HNSC	cis	rs13434995	0.513	rs17722979	ENSG00000273257.1	RP11-177J6.1	-4.16	3.71e-05	0.0061	-0.25	-0.19	Adiponectin levels;	chr4:55480244	chr4:55387949~55388271:+
HNSC	cis	rs17404153	0.599	rs17244458	ENSG00000248724.5	NPHP3-AS1	-4.16	3.71e-05	0.0061	-0.33	-0.19	LDL cholesterol;HDL cholesterol;	chr3:132410660	chr3:132721750~132874223:+
HNSC	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	4.16	3.72e-05	0.0061	0.25	0.19	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
HNSC	cis	rs62432291	0.681	rs397476	ENSG00000235086.1	FNDC1-IT1	-4.16	3.72e-05	0.0061	-0.25	-0.19	Joint mobility (Beighton score);	chr6:159218252	chr6:159240786~159243329:+
HNSC	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	4.16	3.72e-05	0.0061	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
HNSC	cis	rs60617249	0.772	rs10250209	ENSG00000228204.2	RP4-724E13.2	4.16	3.72e-05	0.0061	0.2	0.19	Major depression and alcohol dependence;	chr7:50915187	chr7:50866747~51022990:+
HNSC	cis	rs9650657	0.593	rs1968401	ENSG00000269918.1	AF131215.9	-4.16	3.72e-05	0.00611	-0.18	-0.19	Neuroticism;	chr8:10757873	chr8:11104691~11106704:-
HNSC	cis	rs6496044	0.507	rs2467096	ENSG00000259407.1	RP11-158M2.3	4.16	3.72e-05	0.00611	0.2	0.19	Interstitial lung disease;	chr15:85667447	chr15:85744109~85750281:-
HNSC	cis	rs9926296	0.744	rs164748	ENSG00000274627.1	RP11-104N10.2	4.16	3.72e-05	0.00611	0.19	0.19	Vitiligo;	chr16:89641884	chr16:89516797~89522217:+
HNSC	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	4.16	3.72e-05	0.00611	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	4.16	3.72e-05	0.00611	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
HNSC	cis	rs7824557	0.614	rs2293858	ENSG00000269918.1	AF131215.9	4.16	3.72e-05	0.00611	0.18	0.19	Retinal vascular caliber;	chr8:11356372	chr8:11104691~11106704:-
HNSC	cis	rs4295623	0.559	rs2409836	ENSG00000269918.1	AF131215.9	4.16	3.73e-05	0.00612	0.19	0.19	Morning vs. evening chronotype;	chr8:11831719	chr8:11104691~11106704:-
HNSC	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	4.16	3.73e-05	0.00612	0.21	0.19	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
HNSC	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	4.16	3.73e-05	0.00612	0.21	0.19	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
HNSC	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	4.16	3.73e-05	0.00612	0.18	0.19	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
HNSC	cis	rs9487051	0.872	rs9400271	ENSG00000219700.1	PTCHD3P3	4.16	3.73e-05	0.00612	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109286353	chr6:109288571~109290503:-
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000250412.1	KLHL2P1	4.16	3.73e-05	0.00612	0.24	0.19	Corneal astigmatism;	chr4:119332755	chr4:119334329~119378233:+
HNSC	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	4.16	3.73e-05	0.00612	0.21	0.19	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
HNSC	cis	rs73607972	0.877	rs4290466	ENSG00000275191.1	RP11-36I17.2	4.16	3.73e-05	0.00613	0.28	0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53658122	chr16:53628256~53628816:-
HNSC	cis	rs2243480	1	rs316315	ENSG00000179406.6	LINC00174	4.16	3.73e-05	0.00613	0.33	0.19	Diabetic kidney disease;	chr7:66126218	chr7:66376044~66401338:-
HNSC	cis	rs6558174	0.965	rs4072394	ENSG00000253986.1	CTC-756D1.3	-4.16	3.73e-05	0.00613	-0.21	-0.19	Breast cancer;	chr8:22633287	chr8:23493009~23494198:-
HNSC	cis	rs7552167	0.925	rs11249021	ENSG00000230023.2	RP11-10N16.2	4.16	3.73e-05	0.00613	0.3	0.19	Psoriasis vulgaris;	chr1:24186391	chr1:24200240~24211693:+
HNSC	cis	rs116095464	0.558	rs10065239	ENSG00000250848.1	CTD-2083E4.5	-4.16	3.74e-05	0.00613	-0.27	-0.19	Breast cancer;	chr5:275173	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs56298907	ENSG00000250848.1	CTD-2083E4.5	-4.16	3.74e-05	0.00613	-0.27	-0.19	Breast cancer;	chr5:283165	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs7356535	ENSG00000250848.1	CTD-2083E4.5	-4.16	3.74e-05	0.00613	-0.27	-0.19	Breast cancer;	chr5:284002	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs55833259	ENSG00000250848.1	CTD-2083E4.5	-4.16	3.74e-05	0.00613	-0.27	-0.19	Breast cancer;	chr5:286613	chr5:288833~290321:-
HNSC	cis	rs2492286	0.597	rs2811487	ENSG00000242551.2	POU5F1P6	-4.16	3.74e-05	0.00613	-0.21	-0.19	Eosinophil counts;	chr3:128613036	chr3:128674735~128677005:-
HNSC	cis	rs2905347	0.895	rs2905308	ENSG00000179428.2	AC073072.5	4.16	3.74e-05	0.00614	0.22	0.19	Major depression and alcohol dependence;	chr7:22608575	chr7:22725395~22727620:-
HNSC	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	4.16	3.74e-05	0.00614	0.25	0.19	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
HNSC	cis	rs4081724	0.565	rs73024301	ENSG00000267296.2	CEBPA-AS1	4.16	3.74e-05	0.00614	0.35	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33312285	chr19:33302857~33305054:+
HNSC	cis	rs7674212	0.57	rs2069274	ENSG00000251288.2	RP11-10L12.2	-4.16	3.74e-05	0.00614	-0.21	-0.19	Type 2 diabetes;	chr4:103099624	chr4:102751401~102752641:+
HNSC	cis	rs442309	0.846	rs224070	ENSG00000238280.1	RP11-436D10.3	-4.16	3.74e-05	0.00614	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62748658	chr10:62793562~62805887:-
HNSC	cis	rs12545109	0.8	rs1595940	ENSG00000246430.5	LINC00968	-4.16	3.74e-05	0.00614	-0.24	-0.19	Obesity-related traits;	chr8:56485750	chr8:56496246~56559823:-
HNSC	cis	rs1479119	0.681	rs10744021	ENSG00000180861.8	LINC01559	4.16	3.75e-05	0.00615	0.24	0.19	Intelligence (multi-trait analysis);	chr12:13345958	chr12:13371089~13387167:-
HNSC	cis	rs6012564	0.963	rs2075679	ENSG00000227431.4	CSE1L-AS1	4.16	3.75e-05	0.00615	0.22	0.19	Anger;	chr20:49085052	chr20:49040463~49046044:-
HNSC	cis	rs9313772	0.722	rs13180995	ENSG00000254350.1	RP11-542A14.1	-4.16	3.75e-05	0.00615	-0.2	-0.19	Blood pressure;	chr5:158425798	chr5:158424585~158452758:+
HNSC	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-4.16	3.75e-05	0.00615	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-4.16	3.75e-05	0.00615	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
HNSC	cis	rs6500395	0.962	rs1564980	ENSG00000261267.1	RP11-44I10.3	-4.16	3.75e-05	0.00615	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48617466	chr16:48559661~48587403:+
HNSC	cis	rs1113500	0.805	rs11185248	ENSG00000226822.1	RP11-356N1.2	-4.16	3.75e-05	0.00615	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108068379	chr1:108071482~108074519:+
HNSC	cis	rs6951245	0.706	rs1133116	ENSG00000225146.1	AC073957.15	-4.16	3.75e-05	0.00615	-0.31	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1029025~1043891:+
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	-4.16	3.75e-05	0.00615	-0.24	-0.19	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
HNSC	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	4.16	3.75e-05	0.00615	0.27	0.19	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
HNSC	cis	rs12034383	0.967	rs7542544	ENSG00000274245.1	RP11-357P18.2	-4.16	3.75e-05	0.00615	-0.24	-0.19	Erythrocyte sedimentation rate;	chr1:207612878	chr1:207372559~207373252:+
HNSC	cis	rs6964587	0.773	rs12740	ENSG00000188693.7	CYP51A1-AS1	-4.16	3.75e-05	0.00615	-0.2	-0.19	Breast cancer;	chr7:92399988	chr7:92134604~92180725:+
HNSC	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-4.16	3.75e-05	0.00615	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
HNSC	cis	rs79349575	0.783	rs15563	ENSG00000270781.1	RP11-501C14.9	-4.16	3.75e-05	0.00616	-0.2	-0.19	Type 2 diabetes;	chr17:48927831	chr17:48899131~48899748:+
HNSC	cis	rs61160187	0.51	rs4700393	ENSG00000272308.1	RP11-231G3.1	-4.16	3.75e-05	0.00616	-0.19	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60866457~60866935:-
HNSC	cis	rs6500395	0.962	rs1872652	ENSG00000261267.1	RP11-44I10.3	-4.16	3.75e-05	0.00616	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48609017	chr16:48559661~48587403:+
HNSC	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	4.16	3.75e-05	0.00616	0.19	0.19	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
HNSC	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	4.16	3.75e-05	0.00616	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000272831.1	RP11-792A8.4	4.16	3.76e-05	0.00616	0.16	0.19	Aortic root size;	chr7:66711400	chr7:66739829~66740385:-
HNSC	cis	rs2055729	0.645	rs62489489	ENSG00000254340.1	RP11-10A14.3	4.16	3.76e-05	0.00616	0.29	0.19	Multiple myeloma (hyperdiploidy);	chr8:9895563	chr8:9141424~9145435:+
HNSC	cis	rs7781557	0.64	rs6968036	ENSG00000239969.4	RP11-163E9.2	-4.16	3.76e-05	0.00616	-0.29	-0.19	Colorectal adenoma (advanced);	chr7:102915473	chr7:102364162~102380633:+
HNSC	cis	rs755249	1	rs17513135	ENSG00000182109.6	RP11-69E11.4	4.16	3.76e-05	0.00616	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39522280~39546187:-
HNSC	cis	rs7824557	0.544	rs1865521	ENSG00000255495.1	AC145124.2	4.16	3.76e-05	0.00616	0.21	0.19	Retinal vascular caliber;	chr8:11373740	chr8:12194467~12196280:+
HNSC	cis	rs73201462	0.803	rs2955084	ENSG00000231305.3	RP11-723O4.2	4.16	3.76e-05	0.00616	0.33	0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242462	chr3:128861313~128871540:-
HNSC	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	4.16	3.76e-05	0.00617	0.2	0.19	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
HNSC	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	4.16	3.76e-05	0.00617	0.28	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
HNSC	cis	rs2865126	0.818	rs7241380	ENSG00000264714.1	RP11-21G15.1	4.16	3.76e-05	0.00617	0.22	0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10762964	chr18:10724619~10728539:+
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000226329.2	AC005682.6	4.16	3.76e-05	0.00617	0.24	0.19	Fibrinogen;	chr7:22851123	chr7:22863874~22881350:-
HNSC	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-4.16	3.76e-05	0.00617	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
HNSC	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	4.16	3.76e-05	0.00617	0.16	0.19	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
HNSC	cis	rs6493858	0.809	rs2414464	ENSG00000277245.1	RP11-48G14.3	-4.16	3.76e-05	0.00617	-0.22	-0.19	Relative hand skill in reading disability;	chr15:56209907	chr15:56447120~56447697:+
HNSC	cis	rs1799949	1	rs12944430	ENSG00000236383.6	LINC00854	-4.16	3.76e-05	0.00617	-0.18	-0.19	Menopause (age at onset);	chr17:43178803	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs11658499	ENSG00000236383.6	LINC00854	-4.16	3.76e-05	0.00617	-0.18	-0.19	Menopause (age at onset);	chr17:43182732	chr17:43216941~43305976:-
HNSC	cis	rs189798	0.738	rs330911	ENSG00000253981.4	ALG1L13P	4.16	3.76e-05	0.00617	0.23	0.19	Myopia (pathological);	chr8:9138763	chr8:8236003~8244667:-
HNSC	cis	rs6973609	0.524	rs11762428	ENSG00000271122.1	RP11-379H18.1	-4.16	3.76e-05	0.00617	-0.17	-0.19	Obesity-related traits;	chr7:35610953	chr7:35695214~35699413:+
HNSC	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	4.16	3.76e-05	0.00617	0.25	0.19	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	4.16	3.76e-05	0.00617	0.25	0.19	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	4.16	3.76e-05	0.00617	0.25	0.19	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	4.16	3.76e-05	0.00617	0.25	0.19	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
HNSC	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-4.16	3.76e-05	0.00617	-0.41	-0.19	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
HNSC	cis	rs11846409	0.86	rs59055020	ENSG00000254174.1	IGHV1-12	4.16	3.76e-05	0.00617	0.14	0.19	Rheumatic heart disease;	chr14:106631573	chr14:106122420~106122709:-
HNSC	cis	rs6831352	0.819	rs896992	ENSG00000263923.1	RP11-571L19.7	-4.16	3.77e-05	0.00617	-0.2	-0.19	Alcohol dependence;	chr4:99081221	chr4:98928897~98994994:+
HNSC	cis	rs9611565	0.918	rs4822024	ENSG00000235513.1	RP4-756G23.5	4.16	3.77e-05	0.00617	0.22	0.19	Vitiligo;	chr22:41361643	chr22:41209122~41217627:-
HNSC	cis	rs72627123	1	rs17093474	ENSG00000259065.1	RP5-1021I20.1	-4.16	3.77e-05	0.00617	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73875710	chr14:73787360~73803270:+
HNSC	cis	rs7520050	0.966	rs6672898	ENSG00000280836.1	AL355480.1	4.16	3.77e-05	0.00617	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45581219~45581321:-
HNSC	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-4.16	3.77e-05	0.00618	-0.24	-0.19	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000254174.1	IGHV1-12	-4.16	3.77e-05	0.00618	-0.15	-0.19	Rheumatic heart disease;	chr14:106629835	chr14:106122420~106122709:-
HNSC	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-4.16	3.77e-05	0.00618	-0.33	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
HNSC	cis	rs2333021	0.78	rs12886469	ENSG00000258376.2	RP4-647C14.2	-4.16	3.77e-05	0.00618	-0.22	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72985979	chr14:73242651~73245979:-
HNSC	cis	rs13438327	1	rs13438327	ENSG00000183444.10	OR7E38P	4.16	3.77e-05	0.00618	0.37	0.19	Sudden cardiac arrest;	chr7:97991379	chr7:97966090~97967074:-
HNSC	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	4.16	3.77e-05	0.00618	0.32	0.19	Gout;	chr7:66715944	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	4.16	3.77e-05	0.00618	0.32	0.19	Gout;	chr7:66721259	chr7:66025126~66031544:-
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	4.16	3.77e-05	0.00618	0.32	0.19	Gout;	chr7:66732812	chr7:66025126~66031544:-
HNSC	cis	rs757081	0.648	rs11024223	ENSG00000260196.1	RP1-239B22.5	4.16	3.77e-05	0.00618	0.2	0.19	Systolic blood pressure;	chr11:17256146	chr11:17380649~17383531:+
HNSC	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-4.16	3.77e-05	0.00618	-0.18	-0.19	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
HNSC	cis	rs6964587	0.621	rs38798	ENSG00000188693.7	CYP51A1-AS1	4.16	3.77e-05	0.00618	0.19	0.19	Breast cancer;	chr7:92415225	chr7:92134604~92180725:+
HNSC	cis	rs6723108	0.738	rs7599054	ENSG00000224043.6	CCNT2-AS1	-4.16	3.77e-05	0.00618	-0.23	-0.19	Type 2 diabetes;	chr2:134782976	chr2:134735464~134918710:-
HNSC	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-4.16	3.77e-05	0.00618	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
HNSC	cis	rs9329221	0.537	rs2062332	ENSG00000269918.1	AF131215.9	4.16	3.77e-05	0.00618	0.18	0.19	Neuroticism;	chr8:10122514	chr8:11104691~11106704:-
HNSC	cis	rs7735319	0.966	rs35958302	ENSG00000250697.1	CTD-2066L21.3	4.16	3.77e-05	0.00618	0.22	0.19	Systolic blood pressure;	chr5:33157849	chr5:32925639~33297910:-
HNSC	cis	rs7429990	0.727	rs61675361	ENSG00000228638.1	FCF1P2	-4.16	3.77e-05	0.00618	-0.18	-0.19	Educational attainment (years of education);	chr3:47610630	chr3:48290793~48291375:-
HNSC	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	4.16	3.77e-05	0.00619	0.22	0.19	Height;	chr14:75142565	chr14:75011269~75012851:-
HNSC	cis	rs1714507	0.533	rs1714516	ENSG00000272087.1	RP11-379F4.7	4.16	3.78e-05	0.00619	0.21	0.19	Subjective well-being;	chr3:158575835	chr3:158693120~158693768:-
HNSC	cis	rs853679	0.882	rs9393908	ENSG00000226314.6	ZNF192P1	-4.16	3.78e-05	0.00619	-0.3	-0.19	Depression;	chr6:28223052	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.882	rs9366717	ENSG00000226314.6	ZNF192P1	-4.16	3.78e-05	0.00619	-0.3	-0.19	Depression;	chr6:28223279	chr6:28161781~28169594:+
HNSC	cis	rs35963943	0.625	rs13098953	ENSG00000228956.7	SATB1-AS1	4.16	3.78e-05	0.00619	0.23	0.19	Lymphocyte counts;	chr3:18709581	chr3:18445024~18920401:+
HNSC	cis	rs853679	0.607	rs34878803	ENSG00000204709.4	LINC01556	4.16	3.78e-05	0.00619	0.39	0.19	Depression;	chr6:28282402	chr6:28943877~28944537:+
HNSC	cis	rs2274273	0.774	rs9323278	ENSG00000233924.1	AL160471.6	-4.16	3.78e-05	0.00619	-0.21	-0.19	Protein biomarker;	chr14:55074856	chr14:55004813~55005687:-
HNSC	cis	rs8024893	1	rs8024893	ENSG00000270055.1	CTD-3092A11.2	4.16	3.78e-05	0.00619	0.26	0.19	Red cell distribution width;	chr15:31248786	chr15:30487963~30490313:+
HNSC	cis	rs7809950	0.678	rs2301801	ENSG00000238832.1	snoU109	-4.16	3.78e-05	0.00619	-0.27	-0.19	Coronary artery disease;	chr7:107230301	chr7:107603363~107603507:+
HNSC	cis	rs442309	0.901	rs224033	ENSG00000238280.1	RP11-436D10.3	-4.16	3.78e-05	0.0062	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62762354	chr10:62793562~62805887:-
HNSC	cis	rs55823223	0.564	rs9894009	ENSG00000267801.1	RP11-552F3.9	4.16	3.78e-05	0.0062	0.22	0.19	Psoriasis;	chr17:75854333	chr17:75876372~75879546:+
HNSC	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-4.16	3.78e-05	0.0062	-0.2	-0.19	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
HNSC	cis	rs17594362	0.573	rs79034467	ENSG00000229473.2	RGS17P1	-4.16	3.78e-05	0.0062	-0.3	-0.19	Multiple sclerosis;	chr13:41573399	chr13:40992779~40993331:-
HNSC	cis	rs853679	0.607	rs13211507	ENSG00000204709.4	LINC01556	4.16	3.78e-05	0.0062	0.39	0.19	Depression;	chr6:28289600	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.607	rs34691223	ENSG00000204709.4	LINC01556	4.16	3.78e-05	0.0062	0.39	0.19	Depression;	chr6:28290431	chr6:28943877~28944537:+
HNSC	cis	rs2408955	0.715	rs1793957	ENSG00000257763.1	OR5BK1P	4.16	3.79e-05	0.0062	0.18	0.19	Glycated hemoglobin levels;	chr12:47999041	chr12:48355792~48356614:-
HNSC	cis	rs11992162	0.636	rs4841644	ENSG00000227888.4	FAM66A	4.16	3.79e-05	0.0062	0.19	0.19	Monocyte count;	chr8:11940924	chr8:12362019~12388296:+
HNSC	cis	rs7824557	0.544	rs1865521	ENSG00000269918.1	AF131215.9	4.16	3.79e-05	0.0062	0.19	0.19	Retinal vascular caliber;	chr8:11373740	chr8:11104691~11106704:-
HNSC	cis	rs12478296	1	rs11899408	ENSG00000261186.2	RP11-341N2.1	-4.16	3.79e-05	0.0062	-0.3	-0.19	Obesity-related traits;	chr2:242072479	chr2:242087351~242088457:-
HNSC	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.16	3.79e-05	0.0062	0.32	0.19	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.642	rs11624918	ENSG00000211972.2	IGHV3-66	4.16	3.79e-05	0.00621	0.15	0.19	Kawasaki disease;	chr14:106664672	chr14:106675017~106675544:-
HNSC	cis	rs74781061	0.932	rs7497342	ENSG00000260103.2	RP11-10O17.1	-4.16	3.79e-05	0.00621	-0.22	-0.19	Endometriosis;	chr15:74655722	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs11072497	ENSG00000260103.2	RP11-10O17.1	-4.16	3.79e-05	0.00621	-0.22	-0.19	Endometriosis;	chr15:74659016	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs11072498	ENSG00000260103.2	RP11-10O17.1	-4.16	3.79e-05	0.00621	-0.22	-0.19	Endometriosis;	chr15:74661846	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs2415245	ENSG00000260103.2	RP11-10O17.1	-4.16	3.79e-05	0.00621	-0.22	-0.19	Endometriosis;	chr15:74678091	chr15:74478070~74490286:-
HNSC	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-4.16	3.79e-05	0.00621	-0.21	-0.19	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
HNSC	cis	rs4927850	0.958	rs1975582	ENSG00000226155.1	AC124944.3	-4.16	3.79e-05	0.00621	-0.23	-0.19	Pancreatic cancer;	chr3:196024568	chr3:195912049~195913986:+
HNSC	cis	rs853679	0.607	rs34878803	ENSG00000226314.6	ZNF192P1	-4.16	3.79e-05	0.00621	-0.36	-0.19	Depression;	chr6:28282402	chr6:28161781~28169594:+
HNSC	cis	rs516805	0.561	rs7754101	ENSG00000279453.1	RP3-425C14.4	4.16	3.79e-05	0.00621	0.29	0.19	Lymphocyte counts;	chr6:122607828	chr6:122436789~122439223:-
HNSC	cis	rs1185460	0.967	rs1786685	ENSG00000272186.1	RP11-110I1.13	-4.16	3.8e-05	0.00622	-0.21	-0.19	Coronary artery disease;	chr11:119068246	chr11:119067374~119067698:-
HNSC	cis	rs3015497	0.789	rs1389652	ENSG00000277050.1	RP11-102G14.1	-4.16	3.8e-05	0.00622	-0.18	-0.19	Mean platelet volume;	chr14:50658522	chr14:51637348~51637947:-
HNSC	cis	rs1218582	0.774	rs11264284	ENSG00000270361.1	RP11-307C12.13	-4.16	3.8e-05	0.00622	-0.21	-0.19	Prostate cancer;	chr1:154903317	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.774	rs4845683	ENSG00000270361.1	RP11-307C12.13	-4.16	3.8e-05	0.00622	-0.21	-0.19	Prostate cancer;	chr1:154904931	chr1:154937370~154938059:+
HNSC	cis	rs1218582	0.774	rs1007170	ENSG00000270361.1	RP11-307C12.13	-4.16	3.8e-05	0.00622	-0.21	-0.19	Prostate cancer;	chr1:154908985	chr1:154937370~154938059:+
HNSC	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	4.16	3.8e-05	0.00622	0.22	0.19	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
HNSC	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.16	3.8e-05	0.00622	-0.21	-0.19	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
HNSC	cis	rs1552244	1	rs17032283	ENSG00000180385.7	EMC3-AS1	4.16	3.8e-05	0.00622	0.21	0.19	Alzheimer's disease;	chr3:10039861	chr3:9986893~10006990:+
HNSC	cis	rs11148252	0.553	rs2147692	ENSG00000198384.8	TPTE2P3	4.16	3.8e-05	0.00622	0.23	0.19	Lewy body disease;	chr13:52712888	chr13:52522632~52586906:+
HNSC	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-4.16	3.8e-05	0.00622	-0.28	-0.19	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
HNSC	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00622	-0.24	-0.19	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
HNSC	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00622	-0.24	-0.19	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
HNSC	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00622	-0.24	-0.19	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00622	-0.24	-0.19	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
HNSC	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00622	-0.24	-0.19	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
HNSC	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	4.16	3.8e-05	0.00622	0.46	0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
HNSC	cis	rs172166	0.561	rs149973	ENSG00000219392.1	RP1-265C24.5	-4.16	3.8e-05	0.00622	-0.21	-0.19	Cardiac Troponin-T levels;	chr6:28015835	chr6:28115628~28116551:+
HNSC	cis	rs172166	0.561	rs149974	ENSG00000219392.1	RP1-265C24.5	-4.16	3.8e-05	0.00622	-0.21	-0.19	Cardiac Troponin-T levels;	chr6:28017318	chr6:28115628~28116551:+
HNSC	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	4.16	3.8e-05	0.00622	0.23	0.19	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
HNSC	cis	rs11893307	0.599	rs11900857	ENSG00000235852.1	AC005540.3	4.16	3.8e-05	0.00622	0.26	0.19	Mean platelet volume;	chr2:190794285	chr2:190880797~190882059:-
HNSC	cis	rs6809854	0.526	rs6792314	ENSG00000228956.7	SATB1-AS1	4.16	3.8e-05	0.00622	0.21	0.19	Psoriasis;Itch intensity from mosquito bite;	chr3:18632501	chr3:18445024~18920401:+
HNSC	cis	rs7829975	0.902	rs777707	ENSG00000233609.3	RP11-62H7.2	4.16	3.8e-05	0.00622	0.18	0.19	Mood instability;	chr8:8726834	chr8:8961200~8979025:+
HNSC	cis	rs6500395	1	rs2111243	ENSG00000261267.1	RP11-44I10.3	4.16	3.8e-05	0.00622	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48690986	chr16:48559661~48587403:+
HNSC	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	4.16	3.8e-05	0.00623	0.24	0.19	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
HNSC	cis	rs3808502	0.526	rs7822958	ENSG00000255310.2	AF131215.2	-4.16	3.8e-05	0.00623	-0.18	-0.19	Neuroticism;	chr8:11564933	chr8:11107788~11109726:-
HNSC	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	4.16	3.8e-05	0.00623	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
HNSC	cis	rs7209700	0.547	rs7217214	ENSG00000262879.4	RP11-156P1.3	4.16	3.8e-05	0.00623	0.27	0.19	IgG glycosylation;	chr17:47277861	chr17:46984045~47100323:-
HNSC	cis	rs6688613	1	rs2296837	ENSG00000215834.7	FMO9P	4.16	3.8e-05	0.00623	0.23	0.19	Refractive astigmatism;	chr1:166989364	chr1:166603675~166631400:+
HNSC	cis	rs9859260	0.744	rs3933	ENSG00000242086.7	LINC00969	-4.16	3.8e-05	0.00623	-0.16	-0.19	Mean corpuscular volume;	chr3:196058126	chr3:195658062~195739964:+
HNSC	cis	rs9863	0.861	rs10846580	ENSG00000270028.1	RP11-380L11.4	4.16	3.8e-05	0.00623	0.22	0.19	White blood cell count;	chr12:123930906	chr12:123925461~123926083:-
HNSC	cis	rs9650657	0.648	rs6601512	ENSG00000269918.1	AF131215.9	-4.16	3.81e-05	0.00623	-0.19	-0.19	Neuroticism;	chr8:10728086	chr8:11104691~11106704:-
HNSC	cis	rs9531006	0.636	rs2329003	ENSG00000227676.3	LINC01068	4.16	3.81e-05	0.00623	0.28	0.19	Sleep duration;	chr13:79927065	chr13:79566727~79571436:+
HNSC	cis	rs7985	1	rs5761672	ENSG00000244625.4	MIATNB	4.16	3.81e-05	0.00623	0.22	0.19	Electroencephalogram traits;	chr22:26673476	chr22:26672767~26780207:+
HNSC	cis	rs9400271	0.632	rs9398192	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109266033	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.609	rs9386782	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109267440	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.609	rs9386783	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109267441	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs9374071	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109267478	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs6930844	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109269083	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs6930698	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109269101	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs34981677	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109269717	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs9386784	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109270005	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs9400262	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109270230	chr6:109165833~109271014:+
HNSC	cis	rs9400271	0.632	rs9374072	ENSG00000243587.6	C6orf183	-4.16	3.81e-05	0.00623	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109270383	chr6:109165833~109271014:+
HNSC	cis	rs35000415	0.938	rs12531054	ENSG00000244556.1	ODCP	-4.16	3.81e-05	0.00623	-0.37	-0.19	Systemic lupus erythematosus;	chr7:129004197	chr7:129028889~129030527:+
HNSC	cis	rs1853665	1	rs9383993	ENSG00000231760.4	RP11-350J20.5	-4.16	3.81e-05	0.00623	-0.31	-0.19	Radiation response;	chr6:149978163	chr6:149796151~149826294:-
HNSC	cis	rs3811273	0.614	rs7153774	ENSG00000211816.2	TRAV38-1	4.16	3.81e-05	0.00623	0.21	0.19	Periodontal disease-related phenotypes;	chr14:22263044	chr14:22271968~22272563:+
HNSC	cis	rs865483	0.895	rs853191	ENSG00000276054.1	RP11-378E13.3	4.16	3.81e-05	0.00623	0.23	0.19	Monocyte count;	chr17:37461654	chr17:37386886~37387926:+
HNSC	cis	rs3736485	0.844	rs12438892	ENSG00000259438.1	CTD-2650P22.1	4.16	3.81e-05	0.00623	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51463043	chr15:52010999~52019095:-
HNSC	cis	rs72843506	0.722	rs76309839	ENSG00000261033.1	RP11-209D14.2	4.16	3.81e-05	0.00623	0.33	0.19	Schizophrenia;	chr17:20272147	chr17:20008051~20009234:-
HNSC	cis	rs2980439	0.818	rs2948294	ENSG00000233609.3	RP11-62H7.2	4.16	3.81e-05	0.00623	0.18	0.19	Neuroticism;	chr8:8237439	chr8:8961200~8979025:+
HNSC	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-4.16	3.81e-05	0.00624	-0.23	-0.19	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
HNSC	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	4.16	3.81e-05	0.00624	0.17	0.19	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
HNSC	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	4.16	3.81e-05	0.00624	0.18	0.19	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
HNSC	cis	rs8177876	0.822	rs804902	ENSG00000261838.4	RP11-303E16.6	4.16	3.81e-05	0.00624	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81069854~81076598:+
HNSC	cis	rs9910055	0.708	rs2631298	ENSG00000267080.4	ASB16-AS1	-4.16	3.81e-05	0.00624	-0.15	-0.19	Total body bone mineral density;	chr17:44142464	chr17:44175973~44186717:-
HNSC	cis	rs7552167	0.925	rs3932664	ENSG00000230023.2	RP11-10N16.2	4.16	3.81e-05	0.00624	0.3	0.19	Psoriasis vulgaris;	chr1:24185173	chr1:24200240~24211693:+
HNSC	cis	rs4713118	0.513	rs149941	ENSG00000219891.2	ZSCAN12P1	4.16	3.81e-05	0.00624	0.25	0.19	Parkinson's disease;	chr6:28033255	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.513	rs149942	ENSG00000219891.2	ZSCAN12P1	4.16	3.81e-05	0.00624	0.25	0.19	Parkinson's disease;	chr6:28033832	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.513	rs149944	ENSG00000219891.2	ZSCAN12P1	4.16	3.81e-05	0.00624	0.25	0.19	Parkinson's disease;	chr6:28035040	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.513	rs149945	ENSG00000219891.2	ZSCAN12P1	4.16	3.81e-05	0.00624	0.25	0.19	Parkinson's disease;	chr6:28035075	chr6:28091154~28093664:+
HNSC	cis	rs1316952	0.831	rs74624536	ENSG00000269938.1	RP11-214K3.20	-4.16	3.81e-05	0.00624	-0.35	-0.19	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123908529	chr12:123968023~123968579:-
HNSC	cis	rs11098499	0.863	rs59732491	ENSG00000250412.1	KLHL2P1	4.16	3.81e-05	0.00624	0.25	0.19	Corneal astigmatism;	chr4:119568433	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs11723090	ENSG00000250412.1	KLHL2P1	4.16	3.81e-05	0.00624	0.25	0.19	Corneal astigmatism;	chr4:119569437	chr4:119334329~119378233:+
HNSC	cis	rs2115630	0.905	rs1975277	ENSG00000259295.5	CSPG4P12	-4.16	3.81e-05	0.00624	-0.21	-0.19	P wave terminal force;	chr15:84786327	chr15:85191438~85213905:+
HNSC	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-4.16	3.81e-05	0.00624	-0.22	-0.19	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
HNSC	cis	rs3738443	1	rs61839991	ENSG00000259865.1	RP11-488L18.10	4.16	3.82e-05	0.00624	0.18	0.19	Alcohol dependence;	chr1:247186284	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.953	rs56065612	ENSG00000259865.1	RP11-488L18.10	4.16	3.82e-05	0.00624	0.18	0.19	Alcohol dependence;	chr1:247194812	chr1:247187281~247188526:-
HNSC	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-4.16	3.82e-05	0.00624	-0.22	-0.19	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
HNSC	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	4.16	3.82e-05	0.00624	0.23	0.19	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
HNSC	cis	rs7824557	1	rs7824557	ENSG00000269918.1	AF131215.9	-4.16	3.82e-05	0.00625	-0.18	-0.19	Retinal vascular caliber;	chr8:11246602	chr8:11104691~11106704:-
HNSC	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-4.16	3.82e-05	0.00625	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
HNSC	cis	rs2361710	0.669	rs12940486	ENSG00000279259.1	RP11-334C17.3	4.16	3.82e-05	0.00625	0.22	0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80144770	chr17:80147250~80148596:+
HNSC	cis	rs9907295	0.581	rs4251751	ENSG00000270977.1	AC015849.16	-4.16	3.82e-05	0.00625	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35823733	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.748	rs4251752	ENSG00000270977.1	AC015849.16	-4.16	3.82e-05	0.00625	-0.31	-0.19	Fibroblast growth factor basic levels;	chr17:35823900	chr17:35893707~35911023:-
HNSC	cis	rs9910055	0.659	rs2246287	ENSG00000267080.4	ASB16-AS1	-4.16	3.82e-05	0.00625	-0.15	-0.19	Total body bone mineral density;	chr17:44155074	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.659	rs6503488	ENSG00000267080.4	ASB16-AS1	-4.16	3.82e-05	0.00625	-0.15	-0.19	Total body bone mineral density;	chr17:44168790	chr17:44175973~44186717:-
HNSC	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	4.16	3.82e-05	0.00625	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
HNSC	cis	rs7429990	0.932	rs7620736	ENSG00000228638.1	FCF1P2	4.16	3.82e-05	0.00625	0.17	0.19	Educational attainment (years of education);	chr3:48068479	chr3:48290793~48291375:-
HNSC	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	4.16	3.82e-05	0.00625	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
HNSC	cis	rs2247572	0.667	rs2264036	ENSG00000250295.5	RP11-434I12.2	-4.16	3.82e-05	0.00625	-0.25	-0.19	Cognitive performance;	chr8:72647920	chr8:73297711~73356461:-
HNSC	cis	rs2247572	0.667	rs2449099	ENSG00000250295.5	RP11-434I12.2	4.16	3.82e-05	0.00625	0.25	0.19	Cognitive performance;	chr8:72649352	chr8:73297711~73356461:-
HNSC	cis	rs9611565	0.659	rs12483786	ENSG00000235513.1	RP4-756G23.5	4.16	3.82e-05	0.00625	0.22	0.19	Vitiligo;	chr22:41542532	chr22:41209122~41217627:-
HNSC	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	4.16	3.82e-05	0.00625	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
HNSC	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-4.16	3.82e-05	0.00625	-0.19	-0.19	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
HNSC	cis	rs7610312	0.646	rs6764635	ENSG00000273493.1	RP11-80H18.4	-4.16	3.82e-05	0.00626	-0.23	-0.19	Red blood cell count;	chr3:58291802	chr3:58329965~58330118:+
HNSC	cis	rs7610312	0.681	rs1554127	ENSG00000273493.1	RP11-80H18.4	-4.16	3.82e-05	0.00626	-0.23	-0.19	Red blood cell count;	chr3:58291819	chr3:58329965~58330118:+
HNSC	cis	rs7475343	0.501	rs17134533	ENSG00000224034.1	RP11-445P17.8	-4.16	3.83e-05	0.00626	-0.27	-0.19	Intelligence;	chr10:5205135	chr10:5266033~5271236:-
HNSC	cis	rs6710503	0.632	rs17737058	ENSG00000271936.1	RP11-443B20.1	-4.16	3.83e-05	0.00626	-0.23	-0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24768700	chr2:24825610~24826717:+
HNSC	cis	rs9298506	1	rs28457828	ENSG00000254142.2	RP11-53M11.3	4.16	3.83e-05	0.00626	0.28	0.19	Intracranial aneurysm;	chr8:54538582	chr8:54554361~54561927:+
HNSC	cis	rs3736485	0.966	rs12101730	ENSG00000259438.1	CTD-2650P22.1	4.16	3.83e-05	0.00626	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51508536	chr15:52010999~52019095:-
HNSC	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	4.16	3.83e-05	0.00626	0.25	0.19	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
HNSC	cis	rs6504108	0.624	rs2021752	ENSG00000278765.1	RP5-890E16.5	4.16	3.83e-05	0.00626	0.24	0.19	Body mass index;	chr17:48162901	chr17:48066704~48067293:-
HNSC	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	4.16	3.83e-05	0.00626	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
HNSC	cis	rs792448	0.926	rs701905	ENSG00000226251.4	RP11-15I11.3	-4.16	3.83e-05	0.00626	-0.24	-0.19	White blood cell count (basophil);	chr1:212379769	chr1:212225278~212238977:-
HNSC	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-4.16	3.83e-05	0.00627	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-4.16	3.83e-05	0.00627	-0.25	-0.19	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
HNSC	cis	rs12545109	0.8	rs1440763	ENSG00000246430.5	LINC00968	-4.16	3.83e-05	0.00627	-0.24	-0.19	Obesity-related traits;	chr8:56497922	chr8:56496246~56559823:-
HNSC	cis	rs11633886	0.528	rs2460632	ENSG00000273972.1	CTD-2306A12.1	4.16	3.83e-05	0.00627	0.22	0.19	Diisocyanate-induced asthma;	chr15:45803763	chr15:45702640~45703183:+
HNSC	cis	rs2333021	0.934	rs7155380	ENSG00000258376.2	RP4-647C14.2	-4.16	3.83e-05	0.00627	-0.23	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73014626	chr14:73242651~73245979:-
HNSC	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	4.16	3.83e-05	0.00627	0.28	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
HNSC	cis	rs2274273	0.682	rs8008134	ENSG00000233924.1	AL160471.6	-4.16	3.84e-05	0.00627	-0.21	-0.19	Protein biomarker;	chr14:55040802	chr14:55004813~55005687:-
HNSC	cis	rs9921338	0.961	rs8060767	ENSG00000263080.1	RP11-485G7.5	4.16	3.84e-05	0.00627	0.21	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11341809~11345211:-
HNSC	cis	rs17818399	0.533	rs13420857	ENSG00000279254.1	RP11-536C12.1	4.16	3.84e-05	0.00627	0.21	0.19	Height;	chr2:46570866	chr2:46668870~46670778:+
HNSC	cis	rs7712401	0.569	rs7709836	ENSG00000260686.1	CTB-36H16.2	-4.16	3.84e-05	0.00627	-0.17	-0.19	Mean platelet volume;	chr5:123017138	chr5:122832356~122834533:+
HNSC	cis	rs8046011	0.537	rs1640922	ENSG00000280153.1	RP11-876N24.3	4.16	3.84e-05	0.00627	0.18	0.19	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11225985	chr16:10933903~10936280:+
HNSC	cis	rs6840258	1	rs72667765	ENSG00000251411.1	RP11-397E7.4	-4.16	3.84e-05	0.00628	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87044790	chr4:86913266~86914817:-
HNSC	cis	rs860295	0.702	rs1556488	ENSG00000225855.5	RUSC1-AS1	4.16	3.84e-05	0.00628	0.13	0.19	Body mass index;	chr1:155570869	chr1:155316863~155324176:-
HNSC	cis	rs7267979	0.702	rs449801	ENSG00000204556.4	CTD-2514C3.1	-4.16	3.84e-05	0.00628	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26018832~26020684:+
HNSC	cis	rs1707322	1	rs1613296	ENSG00000234329.1	RP11-767N6.2	-4.16	3.84e-05	0.00628	-0.21	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45651039~45651826:-
HNSC	cis	rs7027203	0.576	rs7848045	ENSG00000227603.1	RP11-165J3.6	4.16	3.84e-05	0.00628	0.17	0.19	DNA methylation (variation);	chr9:93789542	chr9:93435332~93437121:-
HNSC	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	4.16	3.84e-05	0.00628	0.22	0.19	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
HNSC	cis	rs10462794	0.686	rs7445894	ENSG00000260763.1	RP11-445O3.3	-4.16	3.84e-05	0.00628	-0.24	-0.19	DNA methylation (variation);	chr5:4502397	chr5:4436850~4440259:-
HNSC	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	4.16	3.84e-05	0.00628	0.25	0.19	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
HNSC	cis	rs9329221	0.716	rs11989640	ENSG00000255310.2	AF131215.2	-4.16	3.84e-05	0.00628	-0.2	-0.19	Neuroticism;	chr8:10398544	chr8:11107788~11109726:-
HNSC	cis	rs67311347	0.544	rs6599088	ENSG00000280739.1	EIF1B-AS1	4.16	3.84e-05	0.00628	0.2	0.19	Renal cell carcinoma;	chr3:40287797	chr3:40173145~40309698:-
HNSC	cis	rs804280	0.56	rs10503426	ENSG00000255310.2	AF131215.2	4.16	3.85e-05	0.00629	0.18	0.19	Myopia (pathological);	chr8:11731874	chr8:11107788~11109726:-
HNSC	cis	rs700651	0.789	rs10497812	ENSG00000231621.1	AC013264.2	4.16	3.85e-05	0.00629	0.18	0.19	Intracranial aneurysm;	chr2:198046521	chr2:197197991~197199273:+
HNSC	cis	rs2732480	0.5	rs12829841	ENSG00000257763.1	OR5BK1P	4.16	3.85e-05	0.00629	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.523	rs34286639	ENSG00000257763.1	OR5BK1P	4.16	3.85e-05	0.00629	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48355792~48356614:-
HNSC	cis	rs1387259	0.929	rs11168484	ENSG00000257763.1	OR5BK1P	4.16	3.85e-05	0.00629	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48355792~48356614:-
HNSC	cis	rs58873874	0.579	rs10037386	ENSG00000251405.2	CTB-109A12.1	4.16	3.85e-05	0.00629	0.33	0.19	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157362615~157460078:-
HNSC	cis	rs442309	0.841	rs224042	ENSG00000238280.1	RP11-436D10.3	-4.16	3.85e-05	0.00629	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62764530	chr10:62793562~62805887:-
HNSC	cis	rs2865126	0.818	rs2865130	ENSG00000264714.1	RP11-21G15.1	-4.16	3.85e-05	0.00629	-0.23	-0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10763815	chr18:10724619~10728539:+
HNSC	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-4.16	3.85e-05	0.00629	-0.22	-0.19	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
HNSC	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-4.16	3.85e-05	0.00629	-0.15	-0.19	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
HNSC	cis	rs240993	0.812	rs9481160	ENSG00000230177.1	RP5-1112D6.4	4.16	3.85e-05	0.00629	0.24	0.19	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111277932~111278742:+
HNSC	cis	rs11638815	0.603	rs10162807	ENSG00000259429.4	UBE2Q2P2	-4.16	3.85e-05	0.00629	-0.19	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:82355142~82420075:+
HNSC	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	4.16	3.85e-05	0.00629	0.26	0.19	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
HNSC	cis	rs1865760	0.534	rs2032444	ENSG00000272810.1	U91328.22	-4.16	3.85e-05	0.00629	-0.18	-0.19	Height;	chr6:26046516	chr6:26013241~26013757:+
HNSC	cis	rs67311347	1	rs11914297	ENSG00000280739.1	EIF1B-AS1	4.16	3.85e-05	0.00629	0.21	0.19	Renal cell carcinoma;	chr3:40368579	chr3:40173145~40309698:-
HNSC	cis	rs4356203	0.905	rs7123301	ENSG00000272034.1	SNORD14A	-4.16	3.85e-05	0.0063	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17074654~17074744:-
HNSC	cis	rs6490294	0.571	rs73421065	ENSG00000226469.1	ADAM1B	4.16	3.85e-05	0.0063	0.27	0.19	Mean platelet volume;	chr12:112121575	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.528	rs58047810	ENSG00000226469.1	ADAM1B	4.16	3.85e-05	0.0063	0.27	0.19	Mean platelet volume;	chr12:112124682	chr12:111927018~111929017:+
HNSC	cis	rs9313772	0.775	rs6863563	ENSG00000254350.1	RP11-542A14.1	4.16	3.86e-05	0.0063	0.2	0.19	Blood pressure;	chr5:158380193	chr5:158424585~158452758:+
HNSC	cis	rs6490294	0.571	rs58368428	ENSG00000226469.1	ADAM1B	4.16	3.86e-05	0.0063	0.27	0.19	Mean platelet volume;	chr12:112024471	chr12:111927018~111929017:+
HNSC	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-4.16	3.86e-05	0.0063	-0.14	-0.19	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
HNSC	cis	rs929354	0.772	rs3802123	ENSG00000224629.1	RP5-1142J19.2	-4.16	3.86e-05	0.0063	-0.19	-0.19	Body mass index;	chr7:157177947	chr7:157263022~157263229:-
HNSC	cis	rs9652601	0.959	rs9652582	ENSG00000274038.1	RP11-66H6.4	-4.16	3.86e-05	0.0063	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11080707	chr16:11056556~11057034:+
HNSC	cis	rs929354	0.707	rs1182445	ENSG00000224629.1	RP5-1142J19.2	4.16	3.86e-05	0.0063	0.19	0.19	Body mass index;	chr7:157231734	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs1182444	ENSG00000224629.1	RP5-1142J19.2	4.16	3.86e-05	0.0063	0.19	0.19	Body mass index;	chr7:157231816	chr7:157263022~157263229:-
HNSC	cis	rs939574	0.858	rs2891733	ENSG00000243910.6	TUBA4B	4.16	3.86e-05	0.0063	0.33	0.19	Platelet distribution width;	chr2:219270486	chr2:219253243~219272188:+
HNSC	cis	rs7475343	0.501	rs7908297	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5209739	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7909379	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5209851	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7909380	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5209852	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7475279	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5210903	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7475281	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5210939	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7078211	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5211675	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs6601927	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5212183	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7897431	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5212225	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs1832007	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5212884	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs17134585	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5214309	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs77503049	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5214795	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs76551580	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5214871	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs78585347	ENSG00000224034.1	RP11-445P17.8	-4.16	3.86e-05	0.0063	-0.27	-0.19	Intelligence;	chr10:5215134	chr10:5266033~5271236:-
HNSC	cis	rs11673344	0.504	rs4239587	ENSG00000276846.1	CTD-3220F14.3	4.16	3.86e-05	0.0063	0.21	0.19	Obesity-related traits;	chr19:37136211	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs4805202	ENSG00000276846.1	CTD-3220F14.3	4.16	3.86e-05	0.0063	0.21	0.19	Obesity-related traits;	chr19:37136499	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs4805203	ENSG00000276846.1	CTD-3220F14.3	4.16	3.86e-05	0.0063	0.21	0.19	Obesity-related traits;	chr19:37136586	chr19:37314868~37315620:-
HNSC	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-4.16	3.86e-05	0.00631	-0.22	-0.19	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
HNSC	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-4.16	3.86e-05	0.00631	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-4.16	3.86e-05	0.00631	-0.18	-0.19	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-4.16	3.86e-05	0.00631	-0.18	-0.19	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-4.16	3.86e-05	0.00631	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-4.16	3.86e-05	0.00631	-0.18	-0.19	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
HNSC	cis	rs36052053	0.908	rs13205489	ENSG00000203799.9	CCDC162P	-4.16	3.86e-05	0.00631	-0.28	-0.19	Red cell distribution width;	chr6:109282207	chr6:109285485~109355063:+
HNSC	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-4.16	3.86e-05	0.00631	-0.22	-0.19	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
HNSC	cis	rs7035284	1	rs7028950	ENSG00000229835.2	KHSRPP1	-4.16	3.86e-05	0.00631	-0.23	-0.19	Pediatric bone mineral content (radius);	chr9:21682261	chr9:21695176~21696943:+
HNSC	cis	rs7701440	0.512	rs7444594	ENSG00000215032.2	GNL3LP1	4.16	3.86e-05	0.00631	0.21	0.19	Educational attainment;	chr5:61238832	chr5:60891935~60893577:-
HNSC	cis	rs988913	0.793	rs9382390	ENSG00000224984.1	RP11-524H19.2	4.16	3.87e-05	0.00631	0.23	0.19	Menarche (age at onset);	chr6:54876225	chr6:54840118~54840855:-
HNSC	cis	rs2274273	0.554	rs3742564	ENSG00000233924.1	AL160471.6	4.16	3.87e-05	0.00631	0.21	0.19	Protein biomarker;	chr14:55063402	chr14:55004813~55005687:-
HNSC	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	4.16	3.87e-05	0.00631	0.17	0.19	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
HNSC	cis	rs860818	1	rs858293	ENSG00000226816.2	AC005082.12	4.15	3.87e-05	0.00632	0.48	0.19	Initial pursuit acceleration;	chr7:23206705	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.665	rs1897207	ENSG00000269918.1	AF131215.9	-4.15	3.87e-05	0.00632	-0.18	-0.19	Neuroticism;	chr8:10757725	chr8:11104691~11106704:-
HNSC	cis	rs7027203	0.576	rs4415381	ENSG00000227603.1	RP11-165J3.6	4.15	3.87e-05	0.00632	0.17	0.19	DNA methylation (variation);	chr9:93792321	chr9:93435332~93437121:-
HNSC	cis	rs11638815	0.626	rs11635624	ENSG00000259429.4	UBE2Q2P2	-4.15	3.87e-05	0.00632	-0.18	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:82355142~82420075:+
HNSC	cis	rs721917	0.506	rs7073842	ENSG00000244733.5	RP11-506M13.3	-4.15	3.87e-05	0.00632	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79660891~79677996:+
HNSC	cis	rs1050631	1	rs11873168	ENSG00000278986.1	RP11-723J4.3	4.15	3.87e-05	0.00632	0.21	0.19	Esophageal squamous cell cancer (length of survival);	chr18:36127618	chr18:35972151~35973916:+
HNSC	cis	rs440932	1	rs440932	ENSG00000254153.1	CTA-398F10.2	4.15	3.87e-05	0.00632	0.22	0.19	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8456909~8461337:-
HNSC	cis	rs7809950	0.678	rs2237660	ENSG00000238832.1	snoU109	-4.15	3.87e-05	0.00632	-0.28	-0.19	Coronary artery disease;	chr7:107222518	chr7:107603363~107603507:+
HNSC	cis	rs6601327	0.607	rs13276086	ENSG00000233609.3	RP11-62H7.2	-4.15	3.87e-05	0.00632	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:8961200~8979025:+
HNSC	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-4.15	3.87e-05	0.00632	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
HNSC	cis	rs919433	0.857	rs36071109	ENSG00000231621.1	AC013264.2	4.15	3.88e-05	0.00633	0.17	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197197991~197199273:+
HNSC	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	4.15	3.88e-05	0.00633	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
HNSC	cis	rs16858210	0.837	rs11716104	ENSG00000234371.6	RPSAP31	4.15	3.88e-05	0.00633	0.23	0.19	Menopause (age at onset);	chr3:183864211	chr3:183884924~183888449:+
HNSC	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-4.15	3.88e-05	0.00633	-0.25	-0.19	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	4.15	3.88e-05	0.00633	0.25	0.19	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
HNSC	cis	rs2911132	0.506	rs1862609	ENSG00000248734.2	CTD-2260A17.1	4.15	3.88e-05	0.00633	0.21	0.19	Urate levels (BMI interaction);	chr5:96750986	chr5:96784777~96785999:+
HNSC	cis	rs1113500	0.73	rs1343203	ENSG00000226822.1	RP11-356N1.2	4.15	3.88e-05	0.00633	0.22	0.19	Growth-regulated protein alpha levels;	chr1:108048560	chr1:108071482~108074519:+
HNSC	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-4.15	3.88e-05	0.00633	-0.18	-0.19	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-4.15	3.88e-05	0.00633	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	4.15	3.88e-05	0.00633	0.27	0.19	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000241278.1	ENPP7P4	-4.15	3.88e-05	0.00633	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125912928	chr3:125848223~125909372:+
HNSC	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-4.15	3.88e-05	0.00633	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
HNSC	cis	rs375092	0.689	rs187985	ENSG00000234286.1	AC006026.13	-4.15	3.88e-05	0.00633	-0.24	-0.19	Personality dimensions;	chr7:23386613	chr7:23680195~23680786:-
HNSC	cis	rs35963943	0.625	rs13099246	ENSG00000228956.7	SATB1-AS1	4.15	3.88e-05	0.00633	0.22	0.19	Lymphocyte counts;	chr3:18670689	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13077024	ENSG00000228956.7	SATB1-AS1	4.15	3.88e-05	0.00633	0.22	0.19	Lymphocyte counts;	chr3:18670740	chr3:18445024~18920401:+
HNSC	cis	rs35963943	0.625	rs13076720	ENSG00000228956.7	SATB1-AS1	4.15	3.88e-05	0.00633	0.22	0.19	Lymphocyte counts;	chr3:18670831	chr3:18445024~18920401:+
HNSC	cis	rs17507216	0.667	rs13379724	ENSG00000255769.6	GOLGA2P10	-4.15	3.88e-05	0.00633	-0.28	-0.19	Excessive daytime sleepiness;	chr15:82619892	chr15:82472993~82513950:-
HNSC	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-4.15	3.88e-05	0.00634	-0.23	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
HNSC	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-4.15	3.88e-05	0.00634	-0.22	-0.19	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
HNSC	cis	rs10742752	0.557	rs7928480	ENSG00000255267.3	RP11-430H10.2	4.15	3.88e-05	0.00634	0.25	0.19	Body mass index;	chr11:45385943	chr11:45371397~45388508:+
HNSC	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-4.15	3.89e-05	0.00634	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
HNSC	cis	rs656319	0.58	rs17690549	ENSG00000255310.2	AF131215.2	-4.15	3.89e-05	0.00634	-0.18	-0.19	Myopia (pathological);	chr8:10141028	chr8:11107788~11109726:-
HNSC	cis	rs9313772	0.722	rs2901005	ENSG00000254350.1	RP11-542A14.1	-4.15	3.89e-05	0.00634	-0.2	-0.19	Blood pressure;	chr5:158433631	chr5:158424585~158452758:+
HNSC	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-4.15	3.89e-05	0.00634	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
HNSC	cis	rs61160187	0.51	rs6893642	ENSG00000272308.1	RP11-231G3.1	-4.15	3.89e-05	0.00634	-0.19	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.51	rs3936423	ENSG00000272308.1	RP11-231G3.1	-4.15	3.89e-05	0.00634	-0.19	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.51	rs1445293	ENSG00000272308.1	RP11-231G3.1	-4.15	3.89e-05	0.00634	-0.19	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60866457~60866935:-
HNSC	cis	rs929354	0.772	rs1182448	ENSG00000224629.1	RP5-1142J19.2	4.15	3.89e-05	0.00634	0.19	0.19	Body mass index;	chr7:157228721	chr7:157263022~157263229:-
HNSC	cis	rs7765004	0.851	rs6940434	ENSG00000228624.6	RP3-399L15.3	4.15	3.89e-05	0.00634	0.19	0.19	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113755682	chr6:113969701~114471705:+
HNSC	cis	rs7765004	0.887	rs6918103	ENSG00000228624.6	RP3-399L15.3	4.15	3.89e-05	0.00634	0.19	0.19	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113755888	chr6:113969701~114471705:+
HNSC	cis	rs7765004	0.887	rs9384882	ENSG00000228624.6	RP3-399L15.3	4.15	3.89e-05	0.00634	0.19	0.19	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113756130	chr6:113969701~114471705:+
HNSC	cis	rs889398	0.771	rs12927431	ENSG00000196696.11	PDXDC2P	4.15	3.89e-05	0.00634	0.13	0.19	Body mass index;	chr16:69823144	chr16:69976297~70065948:-
HNSC	cis	rs240993	0.812	rs240990	ENSG00000230177.1	RP5-1112D6.4	-4.15	3.89e-05	0.00634	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111343820	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs460594	ENSG00000230177.1	RP5-1112D6.4	-4.15	3.89e-05	0.00634	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111348602	chr6:111277932~111278742:+
HNSC	cis	rs67311347	0.713	rs4974018	ENSG00000280739.1	EIF1B-AS1	4.15	3.89e-05	0.00635	0.21	0.19	Renal cell carcinoma;	chr3:40265928	chr3:40173145~40309698:-
HNSC	cis	rs792448	1	rs1086893	ENSG00000226251.4	RP11-15I11.3	-4.15	3.89e-05	0.00635	-0.24	-0.19	White blood cell count (basophil);	chr1:212389772	chr1:212225278~212238977:-
HNSC	cis	rs6964587	0.692	rs4729018	ENSG00000188693.7	CYP51A1-AS1	-4.15	3.89e-05	0.00635	-0.2	-0.19	Breast cancer;	chr7:92015299	chr7:92134604~92180725:+
HNSC	cis	rs4704187	0.687	rs1422698	ENSG00000272040.1	CTC-366B18.4	-4.15	3.89e-05	0.00635	-0.17	-0.19	Response to amphetamines;	chr5:75147307	chr5:75608817~75609983:+
HNSC	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-4.15	3.89e-05	0.00635	-0.22	-0.19	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-4.15	3.89e-05	0.00635	-0.22	-0.19	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-4.15	3.89e-05	0.00635	-0.22	-0.19	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-4.15	3.89e-05	0.00635	-0.22	-0.19	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-4.15	3.89e-05	0.00635	-0.22	-0.19	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
HNSC	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.15	3.89e-05	0.00635	0.19	0.19	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
HNSC	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-4.15	3.89e-05	0.00635	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
HNSC	cis	rs2243480	0.522	rs73150635	ENSG00000230295.1	RP11-458F8.2	-4.15	3.89e-05	0.00635	-0.32	-0.19	Diabetic kidney disease;	chr7:66507503	chr7:66880708~66882981:+
HNSC	cis	rs10186458	0.545	rs62124612	ENSG00000234378.1	AC098828.2	4.15	3.89e-05	0.00635	0.22	0.19	Kidney disease (early stage) in type 1 diabetes;	chr2:20385516	chr2:20063856~20106829:-
HNSC	cis	rs12478296	0.892	rs11897561	ENSG00000261186.2	RP11-341N2.1	-4.15	3.9e-05	0.00635	-0.29	-0.19	Obesity-related traits;	chr2:242072825	chr2:242087351~242088457:-
HNSC	cis	rs4523957	0.89	rs9895551	ENSG00000262333.1	HNRNPA1P16	-4.15	3.9e-05	0.00635	-0.15	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2212628	chr17:2306761~2307715:+
HNSC	cis	rs7121616	0.562	rs2061602	ENSG00000200879.1	SNORD14E	4.15	3.9e-05	0.00635	0.24	0.19	Breast cancer;	chr11:123065079	chr11:123058077~123058161:-
HNSC	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	4.15	3.9e-05	0.00635	0.16	0.19	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
HNSC	cis	rs283610	0.603	rs11744221	ENSG00000182383.8	RPL27AP5	-4.15	3.9e-05	0.00636	-0.17	-0.19	Obesity-related traits;	chr5:73996342	chr5:74990189~74990637:-
HNSC	cis	rs6504108	0.624	rs2278868	ENSG00000278765.1	RP5-890E16.5	-4.15	3.9e-05	0.00636	-0.24	-0.19	Body mass index;	chr17:48184809	chr17:48066704~48067293:-
HNSC	cis	rs3015497	0.789	rs7147956	ENSG00000277050.1	RP11-102G14.1	-4.15	3.9e-05	0.00636	-0.18	-0.19	Mean platelet volume;	chr14:50675887	chr14:51637348~51637947:-
HNSC	cis	rs4372836	0.964	rs4531886	ENSG00000226833.4	AC097724.3	-4.15	3.9e-05	0.00636	-0.25	-0.19	Body mass index;	chr2:28695098	chr2:28708953~28736205:-
HNSC	cis	rs17666538	0.585	rs6559064	ENSG00000254207.1	RP11-43A14.1	4.15	3.9e-05	0.00636	0.4	0.19	IgG glycosylation;	chr8:673061	chr8:725188~725877:-
HNSC	cis	rs17666538	0.585	rs6559065	ENSG00000254207.1	RP11-43A14.1	4.15	3.9e-05	0.00636	0.4	0.19	IgG glycosylation;	chr8:673156	chr8:725188~725877:-
HNSC	cis	rs1580019	0.922	rs1466147	ENSG00000226468.2	AC018641.7	-4.15	3.9e-05	0.00636	-0.26	-0.19	Cognitive ability;	chr7:32446650	chr7:32456963~32457758:-
HNSC	cis	rs2098713	0.561	rs12655908	ENSG00000250155.1	CTD-2353F22.1	4.15	3.9e-05	0.00636	0.19	0.19	Telomere length;	chr5:37595793	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.561	rs4869530	ENSG00000250155.1	CTD-2353F22.1	4.15	3.9e-05	0.00636	0.19	0.19	Telomere length;	chr5:37598468	chr5:36666214~36725195:-
HNSC	cis	rs1799949	0.93	rs4584865	ENSG00000236383.6	LINC00854	-4.15	3.9e-05	0.00636	-0.18	-0.19	Menopause (age at onset);	chr17:43347551	chr17:43216941~43305976:-
HNSC	cis	rs62025270	0.547	rs338520	ENSG00000259295.5	CSPG4P12	4.15	3.9e-05	0.00636	0.24	0.19	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85191438~85213905:+
HNSC	cis	rs1008375	0.932	rs6449317	ENSG00000249502.1	AC006160.5	-4.15	3.91e-05	0.00637	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629630	chr4:17587467~17614571:-
HNSC	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-4.15	3.91e-05	0.00637	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
HNSC	cis	rs2835345	0.63	rs73204235	ENSG00000279365.1	KB-176G8.1	4.15	3.91e-05	0.00637	0.23	0.19	Pulmonary function;	chr21:36446920	chr21:36485867~36487760:+
HNSC	cis	rs2835345	0.63	rs73204236	ENSG00000279365.1	KB-176G8.1	4.15	3.91e-05	0.00637	0.23	0.19	Pulmonary function;	chr21:36446921	chr21:36485867~36487760:+
HNSC	cis	rs10129255	1	rs10137758	ENSG00000280411.1	IGHV1-69-2	-4.15	3.91e-05	0.00637	-0.14	-0.19	Kawasaki disease;	chr14:106697673	chr14:106762092~106762588:-
HNSC	cis	rs516805	0.63	rs699405	ENSG00000279453.1	RP3-425C14.4	-4.15	3.91e-05	0.00637	-0.25	-0.19	Lymphocyte counts;	chr6:122274145	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.596	rs225088	ENSG00000279453.1	RP3-425C14.4	-4.15	3.91e-05	0.00637	-0.25	-0.19	Lymphocyte counts;	chr6:122277898	chr6:122436789~122439223:-
HNSC	cis	rs9304742	0.962	rs1044467	ENSG00000242779.5	ZNF702P	4.15	3.91e-05	0.00637	0.22	0.19	Psoriasis;	chr19:52949516	chr19:52968251~53037898:-
HNSC	cis	rs7824557	0.628	rs2572387	ENSG00000255310.2	AF131215.2	4.15	3.91e-05	0.00637	0.18	0.19	Retinal vascular caliber;	chr8:11346656	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	4.15	3.91e-05	0.00637	0.24	0.19	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
HNSC	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	4.15	3.91e-05	0.00637	0.21	0.19	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
HNSC	cis	rs6964587	1	rs3753107	ENSG00000188693.7	CYP51A1-AS1	4.15	3.91e-05	0.00637	0.2	0.19	Breast cancer;	chr7:91999837	chr7:92134604~92180725:+
HNSC	cis	rs35306767	0.714	rs28512382	ENSG00000229869.1	RP11-363N22.2	-4.15	3.91e-05	0.00637	-0.27	-0.19	Eosinophil percentage of granulocytes;	chr10:1046255	chr10:933026~942743:+
HNSC	cis	rs10791097	0.694	rs4457753	ENSG00000254842.5	RP11-890B15.2	-4.15	3.91e-05	0.00637	-0.16	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885680	chr11:130844191~130865561:-
HNSC	cis	rs1994321	0.657	rs11022143	ENSG00000254991.1	RP13-631K18.3	-4.15	3.91e-05	0.00637	-0.21	-0.19	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12062817	chr11:12066929~12073014:+
HNSC	cis	rs4388249	0.95	rs12656712	ENSG00000271849.1	CTC-332L22.1	-4.15	3.91e-05	0.00638	-0.29	-0.19	Schizophrenia;	chr5:109849713	chr5:109687802~109688329:-
HNSC	cis	rs61935443	0.501	rs10745698	ENSG00000241556.1	RP11-490G8.1	-4.15	3.91e-05	0.00638	-0.19	-0.19	Schizophrenia;	chr12:94810296	chr12:95467397~95467861:-
HNSC	cis	rs4321325	0.733	rs78516281	ENSG00000236682.1	AC068282.3	-4.15	3.91e-05	0.00638	-0.32	-0.19	Protein C levels;	chr2:127186988	chr2:127389130~127400580:+
HNSC	cis	rs2274273	0.682	rs7151224	ENSG00000233924.1	AL160471.6	-4.15	3.92e-05	0.00638	-0.21	-0.19	Protein biomarker;	chr14:55050544	chr14:55004813~55005687:-
HNSC	cis	rs73198271	0.74	rs1039910	ENSG00000233609.3	RP11-62H7.2	-4.15	3.92e-05	0.00638	-0.21	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.602	rs1473029	ENSG00000173295.6	FAM86B3P	4.15	3.92e-05	0.00638	0.22	0.19	Neuroticism;	chr8:8811407	chr8:8228595~8244865:+
HNSC	cis	rs11098499	0.863	rs13134665	ENSG00000250412.1	KLHL2P1	4.15	3.92e-05	0.00638	0.24	0.19	Corneal astigmatism;	chr4:119505275	chr4:119334329~119378233:+
HNSC	cis	rs2518049	0.95	rs10904411	ENSG00000224034.1	RP11-445P17.8	4.15	3.92e-05	0.00638	0.25	0.19	Metabolic traits;	chr10:5082563	chr10:5266033~5271236:-
HNSC	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	4.15	3.92e-05	0.00638	0.21	0.19	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	4.15	3.92e-05	0.00638	0.21	0.19	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
HNSC	cis	rs6601327	0.606	rs13268319	ENSG00000233609.3	RP11-62H7.2	-4.15	3.92e-05	0.00639	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:8961200~8979025:+
HNSC	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	4.15	3.92e-05	0.00639	0.21	0.19	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
HNSC	cis	rs757081	0.648	rs10832752	ENSG00000260196.1	RP1-239B22.5	-4.15	3.92e-05	0.00639	-0.2	-0.19	Systolic blood pressure;	chr11:17263940	chr11:17380649~17383531:+
HNSC	cis	rs12701220	0.503	rs12702024	ENSG00000224079.1	AC091729.7	4.15	3.92e-05	0.00639	0.3	0.19	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1074450~1078036:+
HNSC	cis	rs516805	0.667	rs928011	ENSG00000279453.1	RP3-425C14.4	4.15	3.92e-05	0.00639	0.25	0.19	Lymphocyte counts;	chr6:122248991	chr6:122436789~122439223:-
HNSC	cis	rs8028182	0.501	rs11072553	ENSG00000260269.4	CTD-2323K18.1	-4.15	3.92e-05	0.00639	-0.24	-0.19	Sudden cardiac arrest;	chr15:75640436	chr15:75527150~75601205:-
HNSC	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	4.15	3.92e-05	0.00639	0.3	0.19	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
HNSC	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-4.15	3.93e-05	0.00639	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
HNSC	cis	rs73201462	1	rs57699322	ENSG00000231305.3	RP11-723O4.2	-4.15	3.93e-05	0.0064	-0.27	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346470	chr3:128861313~128871540:-
HNSC	cis	rs10129255	0.912	rs61996059	ENSG00000211974.3	IGHV2-70	4.15	3.93e-05	0.0064	0.18	0.19	Kawasaki disease;	chr14:106716897	chr14:106723574~106724093:-
HNSC	cis	rs74024059	1	rs2454212	ENSG00000260269.4	CTD-2323K18.1	4.15	3.93e-05	0.0064	0.47	0.19	Red blood cell count;Hematocrit;	chr15:76022201	chr15:75527150~75601205:-
HNSC	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	4.15	3.93e-05	0.0064	0.24	0.19	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
HNSC	cis	rs6928977	0.675	rs7759971	ENSG00000231028.7	LINC00271	-4.15	3.93e-05	0.0064	-0.23	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135497801~135716055:+
HNSC	cis	rs9926296	0.682	rs467357	ENSG00000274627.1	RP11-104N10.2	4.15	3.93e-05	0.0064	0.19	0.19	Vitiligo;	chr16:89650989	chr16:89516797~89522217:+
HNSC	cis	rs1538970	0.884	rs781232	ENSG00000234329.1	RP11-767N6.2	-4.15	3.93e-05	0.0064	-0.21	-0.19	Platelet count;	chr1:45424727	chr1:45651039~45651826:-
HNSC	cis	rs11098499	0.909	rs79026312	ENSG00000250412.1	KLHL2P1	4.15	3.93e-05	0.0064	0.24	0.19	Corneal astigmatism;	chr4:119519522	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs35111518	ENSG00000250412.1	KLHL2P1	4.15	3.93e-05	0.0064	0.24	0.19	Corneal astigmatism;	chr4:119519527	chr4:119334329~119378233:+
HNSC	cis	rs795484	0.856	rs431038	ENSG00000275409.1	RP11-131L12.4	-4.15	3.93e-05	0.0064	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118220002	chr12:118430147~118430699:+
HNSC	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	4.15	3.93e-05	0.0064	0.21	0.19	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
HNSC	cis	rs7475343	0.543	rs77355283	ENSG00000224034.1	RP11-445P17.8	-4.15	3.93e-05	0.0064	-0.26	-0.19	Intelligence;	chr10:5220173	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs17134616	ENSG00000224034.1	RP11-445P17.8	-4.15	3.93e-05	0.0064	-0.26	-0.19	Intelligence;	chr10:5221498	chr10:5266033~5271236:-
HNSC	cis	rs12030196	0.827	rs932772	ENSG00000230812.4	LINC01358	4.15	3.93e-05	0.0064	0.21	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58968221	chr1:59020387~59044614:+
HNSC	cis	rs4948102	0.732	rs6951810	ENSG00000213650.3	RP11-760D2.7	4.15	3.93e-05	0.00641	0.21	0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56008905	chr7:56567906~56568858:-
HNSC	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	4.15	3.93e-05	0.00641	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
HNSC	cis	rs62025270	0.632	rs7181796	ENSG00000259762.1	RP11-158M2.4	-4.15	3.94e-05	0.00641	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85750336~85752901:-
HNSC	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	4.15	3.94e-05	0.00641	0.26	0.19	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	4.15	3.94e-05	0.00641	0.26	0.19	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
HNSC	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-4.15	3.94e-05	0.00641	-0.24	-0.19	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
HNSC	cis	rs78579285	0.544	rs4782320	ENSG00000278341.1	RP5-1142A6.10	-4.15	3.94e-05	0.00641	-0.34	-0.19	Joint mobility (Beighton score);	chr16:88713457	chr16:88708956~88710437:-
HNSC	cis	rs11834862	0.653	rs11246997	ENSG00000256576.2	RP13-977J11.2	-4.15	3.94e-05	0.00641	-0.29	-0.19	Anti-saccade response;	chr12:132206139	chr12:132186735~132189695:-
HNSC	cis	rs757081	0.578	rs7109536	ENSG00000260196.1	RP1-239B22.5	-4.15	3.94e-05	0.00641	-0.2	-0.19	Systolic blood pressure;	chr11:17233965	chr11:17380649~17383531:+
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000254340.1	RP11-10A14.3	4.15	3.94e-05	0.00642	0.23	0.19	Neuroticism;	chr8:8312614	chr8:9141424~9145435:+
HNSC	cis	rs17407555	0.657	rs1558488	ENSG00000250413.1	RP11-448G15.1	-4.15	3.94e-05	0.00642	-0.25	-0.19	Schizophrenia (age at onset);	chr4:10325790	chr4:10006482~10009725:+
HNSC	cis	rs6500395	1	rs9937610	ENSG00000261267.1	RP11-44I10.3	-4.15	3.94e-05	0.00642	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48637363	chr16:48559661~48587403:+
HNSC	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-4.15	3.94e-05	0.00642	-0.22	-0.19	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-4.15	3.94e-05	0.00642	-0.22	-0.19	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
HNSC	cis	rs913672	0.609	rs8116154	ENSG00000224397.4	LINC01272	4.15	3.94e-05	0.00642	0.25	0.19	Monocyte count;	chr20:50276198	chr20:50267486~50279795:+
HNSC	cis	rs11098499	0.908	rs7695996	ENSG00000250412.1	KLHL2P1	4.15	3.94e-05	0.00642	0.24	0.19	Corneal astigmatism;	chr4:119400878	chr4:119334329~119378233:+
HNSC	cis	rs950169	0.58	rs11634322	ENSG00000229212.6	RP11-561C5.4	-4.15	3.94e-05	0.00642	-0.27	-0.19	Schizophrenia;	chr15:84628978	chr15:85205440~85234795:-
HNSC	cis	rs7572733	0.84	rs4286272	ENSG00000222017.1	AC011997.1	-4.15	3.94e-05	0.00642	-0.23	-0.19	Dermatomyositis;	chr2:197670954	chr2:197693106~197774823:+
HNSC	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	4.15	3.94e-05	0.00642	0.25	0.19	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
HNSC	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-4.15	3.94e-05	0.00642	-0.18	-0.19	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
HNSC	cis	rs11098499	0.954	rs3890049	ENSG00000250412.1	KLHL2P1	4.15	3.95e-05	0.00642	0.24	0.19	Corneal astigmatism;	chr4:119405128	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs71629403	ENSG00000250412.1	KLHL2P1	4.15	3.95e-05	0.00642	0.24	0.19	Corneal astigmatism;	chr4:119451412	chr4:119334329~119378233:+
HNSC	cis	rs1355223	0.506	rs7130678	ENSG00000271369.1	RP11-350D17.3	-4.15	3.95e-05	0.00642	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847634	chr11:34709600~34710161:+
HNSC	cis	rs12478296	0.792	rs6755390	ENSG00000261186.2	RP11-341N2.1	-4.15	3.95e-05	0.00642	-0.31	-0.19	Obesity-related traits;	chr2:242070847	chr2:242087351~242088457:-
HNSC	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-4.15	3.95e-05	0.00642	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
HNSC	cis	rs67981189	0.537	rs917067	ENSG00000274818.1	RP1-292L20.3	-4.15	3.95e-05	0.00643	-0.2	-0.19	Schizophrenia;	chr14:70905187	chr14:70906657~70907111:-
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000224373.3	IGHV4-59	4.15	3.95e-05	0.00643	0.11	0.19	Kawasaki disease;	chr14:106782337	chr14:106627249~106627825:-
HNSC	cis	rs7937890	0.572	rs2597202	ENSG00000254418.1	RP11-21L19.1	4.15	3.95e-05	0.00643	0.24	0.19	Mitochondrial DNA levels;	chr11:14463099	chr11:14262846~14273691:-
HNSC	cis	rs9650657	0.506	rs7823296	ENSG00000255310.2	AF131215.2	-4.15	3.95e-05	0.00643	-0.18	-0.19	Neuroticism;	chr8:10921036	chr8:11107788~11109726:-
HNSC	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-4.15	3.95e-05	0.00643	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
HNSC	cis	rs7973683	0.541	rs12309481	ENSG00000269938.1	RP11-214K3.20	-4.15	3.95e-05	0.00643	-0.22	-0.19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904603	chr12:123968023~123968579:-
HNSC	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	4.15	3.95e-05	0.00643	0.24	0.19	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
HNSC	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-4.15	3.95e-05	0.00643	-0.14	-0.19	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
HNSC	cis	rs7824557	0.815	rs2736372	ENSG00000269918.1	AF131215.9	-4.15	3.96e-05	0.00644	-0.18	-0.19	Retinal vascular caliber;	chr8:11248532	chr8:11104691~11106704:-
HNSC	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	4.15	3.96e-05	0.00644	0.21	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
HNSC	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-4.15	3.96e-05	0.00644	-0.29	-0.19	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
HNSC	cis	rs7221109	0.711	rs1358174	ENSG00000278834.1	RP11-458J1.1	4.15	3.96e-05	0.00644	0.18	0.19	Type 1 diabetes;	chr17:40601507	chr17:40648300~40649718:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-4.15	3.96e-05	0.00644	-0.25	-0.19	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
HNSC	cis	rs35264875	0.808	rs2305498	ENSG00000259799.1	RP11-554A11.9	4.15	3.96e-05	0.00644	0.26	0.19	Blond vs. brown hair color;	chr11:69099446	chr11:69155910~69159752:+
HNSC	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-4.15	3.96e-05	0.00644	-0.24	-0.19	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
HNSC	cis	rs757081	0.547	rs11024220	ENSG00000260196.1	RP1-239B22.5	-4.15	3.96e-05	0.00644	-0.2	-0.19	Systolic blood pressure;	chr11:17252987	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.579	rs11024221	ENSG00000260196.1	RP1-239B22.5	-4.15	3.96e-05	0.00644	-0.2	-0.19	Systolic blood pressure;	chr11:17253003	chr11:17380649~17383531:+
HNSC	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-4.15	3.96e-05	0.00644	-0.25	-0.19	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
HNSC	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-4.15	3.96e-05	0.00645	-0.24	-0.19	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
HNSC	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	4.15	3.96e-05	0.00645	0.25	0.19	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
HNSC	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	4.15	3.96e-05	0.00645	0.25	0.19	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
HNSC	cis	rs8030379	0.667	rs4842921	ENSG00000230373.7	GOLGA6L5P	-4.15	3.96e-05	0.00645	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84507885~84516814:-
HNSC	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-4.15	3.96e-05	0.00645	-0.25	-0.19	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
HNSC	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	4.15	3.96e-05	0.00645	0.25	0.19	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
HNSC	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	4.15	3.96e-05	0.00645	0.28	0.19	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
HNSC	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	4.15	3.97e-05	0.00645	0.24	0.19	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
HNSC	cis	rs1991651	0.578	rs13259086	ENSG00000255310.2	AF131215.2	4.15	3.97e-05	0.00645	0.18	0.19	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.503	rs34190028	ENSG00000255310.2	AF131215.2	-4.15	3.97e-05	0.00645	-0.18	-0.19	Neuroticism;	chr8:11559641	chr8:11107788~11109726:-
HNSC	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	4.15	3.97e-05	0.00645	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
HNSC	cis	rs17739794	0.557	rs7816977	ENSG00000254207.1	RP11-43A14.1	-4.15	3.97e-05	0.00645	-0.23	-0.19	Clozapine-induced cytotoxicity;	chr8:864612	chr8:725188~725877:-
HNSC	cis	rs11951515	0.7	rs66585077	ENSG00000249286.1	CTD-2210P15.2	4.15	3.97e-05	0.00645	0.2	0.19	Metabolite levels  (X-11787);	chr5:43281754	chr5:43586918~43588223:-
HNSC	cis	rs3806843	0.576	rs246008	ENSG00000276545.1	PCDHGB9P	4.15	3.97e-05	0.00646	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140958900	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246007	ENSG00000276545.1	PCDHGB9P	4.15	3.97e-05	0.00646	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140959163	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246006	ENSG00000276545.1	PCDHGB9P	4.15	3.97e-05	0.00646	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140959643	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246005	ENSG00000276545.1	PCDHGB9P	4.15	3.97e-05	0.00646	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140960299	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.576	rs246003	ENSG00000276545.1	PCDHGB9P	4.15	3.97e-05	0.00646	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140961280	chr5:141439853~141442449:+
HNSC	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	4.15	3.97e-05	0.00646	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	4.15	3.97e-05	0.00646	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
HNSC	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	4.15	3.97e-05	0.00646	0.22	0.19	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
HNSC	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-4.15	3.97e-05	0.00646	-0.16	-0.19	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
HNSC	cis	rs721917	0.525	rs2758541	ENSG00000244733.5	RP11-506M13.3	-4.15	3.97e-05	0.00646	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79660891~79677996:+
HNSC	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	4.15	3.97e-05	0.00646	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
HNSC	cis	rs7829975	0.742	rs882462	ENSG00000233609.3	RP11-62H7.2	4.15	3.97e-05	0.00646	0.18	0.19	Mood instability;	chr8:8821020	chr8:8961200~8979025:+
HNSC	cis	rs6988985	0.791	rs11781816	ENSG00000247317.3	RP11-273G15.2	4.15	3.97e-05	0.00646	0.22	0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142916379	chr8:142981738~143018437:-
HNSC	cis	rs9910055	0.659	rs721769	ENSG00000267080.4	ASB16-AS1	-4.15	3.97e-05	0.00646	-0.15	-0.19	Total body bone mineral density;	chr17:44184220	chr17:44175973~44186717:-
HNSC	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	4.15	3.97e-05	0.00646	0.19	0.19	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
HNSC	cis	rs761746	0.739	rs131225	ENSG00000236132.1	CTA-440B3.1	-4.15	3.97e-05	0.00646	-0.23	-0.19	Intelligence;	chr22:31717863	chr22:31816379~31817491:-
HNSC	cis	rs4356203	0.875	rs527810	ENSG00000260196.1	RP1-239B22.5	-4.15	3.97e-05	0.00646	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs589319	ENSG00000260196.1	RP1-239B22.5	-4.15	3.97e-05	0.00646	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17380649~17383531:+
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000223705.8	NSUN5P1	-4.15	3.98e-05	0.00647	-0.14	-0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75410322~75416787:+
HNSC	cis	rs9650657	0.645	rs11774552	ENSG00000255310.2	AF131215.2	-4.15	3.98e-05	0.00647	-0.18	-0.19	Neuroticism;	chr8:10658169	chr8:11107788~11109726:-
HNSC	cis	rs7819412	0.668	rs2409714	ENSG00000269918.1	AF131215.9	-4.15	3.98e-05	0.00647	-0.19	-0.19	Triglycerides;	chr8:11152608	chr8:11104691~11106704:-
HNSC	cis	rs7178909	0.872	rs10852124	ENSG00000259677.1	RP11-493E3.1	4.15	3.98e-05	0.00647	0.21	0.19	Common traits (Other);	chr15:89887232	chr15:89876540~89877285:+
HNSC	cis	rs2239557	0.508	rs11159044	ENSG00000259065.1	RP5-1021I20.1	-4.15	3.98e-05	0.00647	-0.27	-0.19	Common traits (Other);	chr14:73901158	chr14:73787360~73803270:+
HNSC	cis	rs35000415	0.688	rs59110799	ENSG00000275106.1	RP11-309L24.10	-4.15	3.98e-05	0.00647	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129075953	chr7:128952527~128953316:-
HNSC	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	4.15	3.98e-05	0.00647	0.22	0.19	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	4.15	3.98e-05	0.00647	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	4.15	3.98e-05	0.00647	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
HNSC	cis	rs755249	0.567	rs72661940	ENSG00000228060.1	RP11-69E11.8	-4.15	3.98e-05	0.00647	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39565160~39573203:+
HNSC	cis	rs7572733	0.935	rs696814	ENSG00000222017.1	AC011997.1	4.15	3.98e-05	0.00647	0.23	0.19	Dermatomyositis;	chr2:197823175	chr2:197693106~197774823:+
HNSC	cis	rs1602565	0.858	rs2933158	ENSG00000255450.1	CTD-2063L20.1	-4.15	3.98e-05	0.00647	-0.29	-0.19	Schizophrenia;	chr11:29137962	chr11:29275655~29276565:+
HNSC	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-4.15	3.98e-05	0.00647	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
HNSC	cis	rs116095464	0.558	rs10068203	ENSG00000250848.1	CTD-2083E4.5	-4.15	3.98e-05	0.00648	-0.26	-0.19	Breast cancer;	chr5:206503	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs73029475	ENSG00000250848.1	CTD-2083E4.5	-4.15	3.98e-05	0.00648	-0.26	-0.19	Breast cancer;	chr5:206854	chr5:288833~290321:-
HNSC	cis	rs4356203	0.519	rs214082	ENSG00000272034.1	SNORD14A	-4.15	3.98e-05	0.00648	-0.15	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17074654~17074744:-
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000224373.3	IGHV4-59	4.15	3.99e-05	0.00648	0.11	0.19	Kawasaki disease;	chr14:106782219	chr14:106627249~106627825:-
HNSC	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-4.15	3.99e-05	0.00648	-0.29	-0.19	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
HNSC	cis	rs1865760	0.622	rs9968910	ENSG00000272810.1	U91328.22	-4.15	3.99e-05	0.00648	-0.18	-0.19	Height;	chr6:26071867	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.622	rs10946807	ENSG00000272810.1	U91328.22	-4.15	3.99e-05	0.00648	-0.18	-0.19	Height;	chr6:26079410	chr6:26013241~26013757:+
HNSC	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-4.15	3.99e-05	0.00648	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
HNSC	cis	rs3748022	1	rs12124627	ENSG00000261000.1	RP11-534L20.5	4.15	3.99e-05	0.00648	0.22	0.19	Lymphocyte counts;	chr1:206513930	chr1:206503948~206504456:+
HNSC	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-4.15	3.99e-05	0.00648	-0.19	-0.19	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
HNSC	cis	rs11723261	0.582	rs11248005	ENSG00000211553.1	AC253576.2	-4.15	3.99e-05	0.00648	-0.28	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:136461~136568:+
HNSC	cis	rs11723261	0.582	rs11733927	ENSG00000211553.1	AC253576.2	-4.15	3.99e-05	0.00648	-0.28	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:136461~136568:+
HNSC	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	4.15	3.99e-05	0.00648	0.26	0.19	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	4.15	3.99e-05	0.00648	0.26	0.19	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	4.15	3.99e-05	0.00648	0.26	0.19	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
HNSC	cis	rs9287719	0.967	rs10206225	ENSG00000243819.4	RN7SL832P	4.15	3.99e-05	0.00648	0.18	0.19	Prostate cancer;	chr2:10618531	chr2:10690344~10692099:+
HNSC	cis	rs10266483	0.545	rs1812912	ENSG00000228653.2	HNRNPCP7	4.15	3.99e-05	0.00648	0.23	0.19	Response to statin therapy;	chr7:64282891	chr7:64500825~64501729:+
HNSC	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.15	3.99e-05	0.00648	0.32	0.19	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
HNSC	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-4.15	3.99e-05	0.00648	-0.24	-0.19	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
HNSC	cis	rs2333194	0.875	rs28716532	ENSG00000258695.2	RP3-414A15.2	-4.15	3.99e-05	0.00649	-0.19	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73302547	chr14:73522878~73530610:+
HNSC	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	4.15	3.99e-05	0.00649	0.24	0.19	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	4.15	3.99e-05	0.00649	0.24	0.19	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	4.15	3.99e-05	0.00649	0.24	0.19	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
HNSC	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	4.15	3.99e-05	0.00649	0.27	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
HNSC	cis	rs9910055	0.659	rs3826412	ENSG00000267080.4	ASB16-AS1	-4.15	4e-05	0.00649	-0.15	-0.19	Total body bone mineral density;	chr17:44177729	chr17:44175973~44186717:-
HNSC	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-4.15	4e-05	0.00649	-0.18	-0.19	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
HNSC	cis	rs853679	0.882	rs3757188	ENSG00000219891.2	ZSCAN12P1	4.15	4e-05	0.0065	0.33	0.19	Depression;	chr6:28139579	chr6:28091154~28093664:+
HNSC	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-4.15	4e-05	0.0065	-0.19	-0.19	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
HNSC	cis	rs442309	0.687	rs10995282	ENSG00000238280.1	RP11-436D10.3	-4.15	4e-05	0.0065	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62711531	chr10:62793562~62805887:-
HNSC	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-4.15	4e-05	0.0065	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
HNSC	cis	rs2243480	1	rs1499614	ENSG00000229886.1	RP5-1132H15.3	4.15	4e-05	0.0065	0.32	0.19	Diabetic kidney disease;	chr7:66265811	chr7:66025126~66031544:-
HNSC	cis	rs6964587	0.626	rs7785941	ENSG00000188693.7	CYP51A1-AS1	4.15	4e-05	0.0065	0.2	0.19	Breast cancer;	chr7:91901710	chr7:92134604~92180725:+
HNSC	cis	rs11157436	0.602	rs11157437	ENSG00000211812.1	TRAV26-2	-4.15	4e-05	0.00651	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22202583~22203368:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-4.15	4.01e-05	0.00651	-0.25	-0.19	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
HNSC	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	4.15	4.01e-05	0.00651	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	4.15	4.01e-05	0.00651	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	4.15	4.01e-05	0.00651	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
HNSC	cis	rs6688613	0.959	rs112416021	ENSG00000215834.7	FMO9P	4.15	4.01e-05	0.00651	0.23	0.19	Refractive astigmatism;	chr1:166975508	chr1:166603675~166631400:+
HNSC	cis	rs56804039	0.524	rs7016459	ENSG00000173295.6	FAM86B3P	-4.15	4.01e-05	0.00651	-0.33	-0.19	Cervical cancer;	chr8:8509006	chr8:8228595~8244865:+
HNSC	cis	rs56804039	0.524	rs66989459	ENSG00000173295.6	FAM86B3P	-4.15	4.01e-05	0.00651	-0.33	-0.19	Cervical cancer;	chr8:8510401	chr8:8228595~8244865:+
HNSC	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-4.15	4.01e-05	0.00651	-0.24	-0.19	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
HNSC	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-4.15	4.01e-05	0.00651	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
HNSC	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-4.15	4.01e-05	0.00651	-0.24	-0.19	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
HNSC	cis	rs6001482	0.507	rs62234784	ENSG00000274422.1	LL22NC03-2H8.5	4.15	4.01e-05	0.00651	0.19	0.19	Diastolic blood pressure;	chr22:22234610	chr22:22283928~22287220:-
HNSC	cis	rs7927592	0.956	rs10896348	ENSG00000255031.4	RP11-802E16.3	4.15	4.01e-05	0.00651	0.16	0.19	Total body bone mineral density;	chr11:68589900	chr11:68050740~68053762:+
HNSC	cis	rs526231	0.697	rs422115	ENSG00000250682.4	LINC00491	4.15	4.01e-05	0.00651	0.27	0.19	Primary biliary cholangitis;	chr5:103298639	chr5:102609156~102671559:-
HNSC	cis	rs6688613	1	rs7550698	ENSG00000215834.7	FMO9P	4.15	4.01e-05	0.00651	0.23	0.19	Refractive astigmatism;	chr1:166981844	chr1:166603675~166631400:+
HNSC	cis	rs4853525	0.59	rs10198852	ENSG00000228509.4	AC006460.2	4.15	4.01e-05	0.00652	0.26	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863606	chr2:190676944~190708716:-
HNSC	cis	rs7765004	0.887	rs6923574	ENSG00000228624.6	RP3-399L15.3	-4.15	4.01e-05	0.00652	-0.19	-0.19	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113756814	chr6:113969701~114471705:+
HNSC	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	4.15	4.01e-05	0.00652	0.26	0.19	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
HNSC	cis	rs10504130	0.569	rs60153173	ENSG00000253844.1	RP11-546K22.1	-4.15	4.01e-05	0.00652	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51961458~52022974:+
HNSC	cis	rs9926296	0.744	rs164749	ENSG00000274627.1	RP11-104N10.2	4.15	4.01e-05	0.00652	0.18	0.19	Vitiligo;	chr16:89641816	chr16:89516797~89522217:+
HNSC	cis	rs9584850	0.834	rs12869627	ENSG00000231194.1	FARP1-AS1	4.15	4.02e-05	0.00652	0.23	0.19	Neuroticism;	chr13:98468198	chr13:98435405~98435840:-
HNSC	cis	rs11098499	0.954	rs10017543	ENSG00000250412.1	KLHL2P1	4.15	4.02e-05	0.00652	0.24	0.19	Corneal astigmatism;	chr4:119400265	chr4:119334329~119378233:+
HNSC	cis	rs8014204	0.587	rs6574201	ENSG00000279594.1	RP11-950C14.10	-4.15	4.02e-05	0.00652	-0.23	-0.19	Caffeine consumption;	chr14:74920553	chr14:75011269~75012851:-
HNSC	cis	rs6500395	0.963	rs4785528	ENSG00000261267.1	RP11-44I10.3	4.15	4.02e-05	0.00652	0.23	0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48653997	chr16:48559661~48587403:+
HNSC	cis	rs7824557	0.564	rs7839307	ENSG00000255020.1	AF131216.5	4.15	4.02e-05	0.00652	0.2	0.19	Retinal vascular caliber;	chr8:11341283	chr8:11345748~11347502:-
HNSC	cis	rs9487051	0.872	rs9487033	ENSG00000219700.1	PTCHD3P3	-4.15	4.02e-05	0.00652	-0.18	-0.19	Reticulocyte fraction of red cells;	chr6:109284185	chr6:109288571~109290503:-
HNSC	cis	rs3096299	0.967	rs2965932	ENSG00000261574.1	RP1-168P16.2	-4.15	4.02e-05	0.00653	-0.24	-0.19	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89392375~89412564:-
HNSC	cis	rs7824557	1	rs2736371	ENSG00000269918.1	AF131215.9	-4.15	4.02e-05	0.00653	-0.19	-0.19	Retinal vascular caliber;	chr8:11248020	chr8:11104691~11106704:-
HNSC	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	4.15	4.02e-05	0.00653	0.23	0.19	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
HNSC	cis	rs3015497	0.603	rs2934675	ENSG00000269906.1	RP11-248J18.2	-4.15	4.02e-05	0.00653	-0.25	-0.19	Mean platelet volume;	chr14:50615499	chr14:50662511~50663178:-
HNSC	cis	rs10504130	0.569	rs4418329	ENSG00000253844.1	RP11-546K22.1	-4.15	4.02e-05	0.00653	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs4442134	ENSG00000253844.1	RP11-546K22.1	-4.15	4.02e-05	0.00653	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51961458~52022974:+
HNSC	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-4.15	4.03e-05	0.00653	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-4.15	4.03e-05	0.00653	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-4.15	4.03e-05	0.00653	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-4.15	4.03e-05	0.00653	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
HNSC	cis	rs9313772	0.722	rs7734896	ENSG00000254350.1	RP11-542A14.1	-4.15	4.03e-05	0.00653	-0.2	-0.19	Blood pressure;	chr5:158431003	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs17694648	ENSG00000254350.1	RP11-542A14.1	-4.15	4.03e-05	0.00653	-0.2	-0.19	Blood pressure;	chr5:158432625	chr5:158424585~158452758:+
HNSC	cis	rs67478160	0.634	rs2144080	ENSG00000259515.1	RP11-365N19.2	4.15	4.03e-05	0.00653	0.17	0.19	Schizophrenia;	chr14:103792424	chr14:102933574~102937177:+
HNSC	cis	rs67478160	0.634	rs2144079	ENSG00000259515.1	RP11-365N19.2	4.15	4.03e-05	0.00653	0.17	0.19	Schizophrenia;	chr14:103792547	chr14:102933574~102937177:+
HNSC	cis	rs7015630	0.657	rs10094579	ENSG00000251136.7	RP11-37B2.1	-4.15	4.03e-05	0.00654	-0.22	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89837077	chr8:89609409~89757727:-
HNSC	cis	rs597480	0.747	rs4944538	ENSG00000279742.1	RP11-700A24.1	4.15	4.03e-05	0.00654	0.21	0.19	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85807080	chr11:85852557~85854943:-
HNSC	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-4.15	4.03e-05	0.00654	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
HNSC	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	4.15	4.03e-05	0.00655	0.22	0.19	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	4.15	4.03e-05	0.00655	0.22	0.19	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
HNSC	cis	rs4356203	0.905	rs6486354	ENSG00000260196.1	RP1-239B22.5	-4.15	4.03e-05	0.00655	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17380649~17383531:+
HNSC	cis	rs9650657	0.537	rs11250092	ENSG00000255310.2	AF131215.2	4.15	4.03e-05	0.00655	0.18	0.19	Neuroticism;	chr8:10929033	chr8:11107788~11109726:-
HNSC	cis	rs6095360	0.966	rs13037557	ENSG00000222365.1	SNORD12B	-4.15	4.04e-05	0.00655	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:48918053	chr20:49280319~49280409:+
HNSC	cis	rs1568657	0.778	rs12102041	ENSG00000278603.1	RP13-608F4.5	-4.15	4.04e-05	0.00655	-0.28	-0.19	Kawasaki disease;	chr15:83033712	chr15:82472203~82472426:+
HNSC	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-4.14	4.04e-05	0.00655	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
HNSC	cis	rs9611565	0.649	rs202645	ENSG00000235513.1	RP4-756G23.5	-4.14	4.04e-05	0.00655	-0.23	-0.19	Vitiligo;	chr22:41402516	chr22:41209122~41217627:-
HNSC	cis	rs10466239	0.892	rs7909500	ENSG00000230555.2	RP11-517P14.2	4.14	4.04e-05	0.00655	0.33	0.19	Telomere length;	chr10:43332205	chr10:43420738~43422100:+
HNSC	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-4.14	4.04e-05	0.00655	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-4.14	4.04e-05	0.00655	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000211976.2	IGHV3-73	4.14	4.04e-05	0.00655	0.13	0.19	Kawasaki disease;	chr14:106779612	chr14:106802694~106803233:-
HNSC	cis	rs7429990	0.965	rs6791834	ENSG00000228638.1	FCF1P2	4.14	4.04e-05	0.00655	0.17	0.19	Educational attainment (years of education);	chr3:48073598	chr3:48290793~48291375:-
HNSC	cis	rs4924935	1	rs9905565	ENSG00000264885.1	RP11-815I9.4	-4.14	4.04e-05	0.00655	-0.21	-0.19	Pancreatic cancer;	chr17:18855328	chr17:18667629~18669461:-
HNSC	cis	rs948562	0.585	rs17472536	ENSG00000280010.1	AP001350.4	4.14	4.04e-05	0.00655	0.32	0.19	Lymphoma;	chr11:58346066	chr11:58627435~58628528:+
HNSC	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	4.14	4.04e-05	0.00655	0.22	0.19	Height;	chr14:75145380	chr14:75011269~75012851:-
HNSC	cis	rs6688613	1	rs12569084	ENSG00000215834.7	FMO9P	4.14	4.04e-05	0.00656	0.23	0.19	Refractive astigmatism;	chr1:166974115	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs7533688	ENSG00000215834.7	FMO9P	4.14	4.04e-05	0.00656	0.23	0.19	Refractive astigmatism;	chr1:166974886	chr1:166603675~166631400:+
HNSC	cis	rs2070074	0.591	rs72737110	ENSG00000230074.1	RP11-195F19.9	-4.14	4.04e-05	0.00656	-0.52	-0.19	CTACK levels;	chr9:34587705	chr9:34665665~34681298:+
HNSC	cis	rs6095360	0.727	rs34841991	ENSG00000222365.1	SNORD12B	-4.14	4.04e-05	0.00656	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49130437	chr20:49280319~49280409:+
HNSC	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	4.14	4.04e-05	0.00656	0.18	0.19	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
HNSC	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-4.14	4.04e-05	0.00656	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
HNSC	cis	rs11673344	0.504	rs6510588	ENSG00000276846.1	CTD-3220F14.3	-4.14	4.05e-05	0.00656	-0.2	-0.19	Obesity-related traits;	chr19:37106493	chr19:37314868~37315620:-
HNSC	cis	rs55823223	0.564	rs12103594	ENSG00000267801.1	RP11-552F3.9	4.14	4.05e-05	0.00656	0.22	0.19	Psoriasis;	chr17:75859198	chr17:75876372~75879546:+
HNSC	cis	rs4356203	0.519	rs214082	ENSG00000260196.1	RP1-239B22.5	-4.14	4.05e-05	0.00656	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17380649~17383531:+
HNSC	cis	rs3808502	0.526	rs36048422	ENSG00000255310.2	AF131215.2	-4.14	4.05e-05	0.00657	-0.18	-0.19	Neuroticism;	chr8:11559635	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.526	rs11783065	ENSG00000255310.2	AF131215.2	-4.14	4.05e-05	0.00657	-0.18	-0.19	Neuroticism;	chr8:11559748	chr8:11107788~11109726:-
HNSC	cis	rs7927592	0.956	rs7113287	ENSG00000255031.4	RP11-802E16.3	4.14	4.05e-05	0.00657	0.16	0.19	Total body bone mineral density;	chr11:68604718	chr11:68050740~68053762:+
HNSC	cis	rs6701713	0.879	rs4562624	ENSG00000274245.1	RP11-357P18.2	-4.14	4.05e-05	0.00657	-0.32	-0.19	Alzheimer's disease (late onset);	chr1:207512620	chr1:207372559~207373252:+
HNSC	cis	rs889398	0.741	rs10852461	ENSG00000196696.11	PDXDC2P	-4.14	4.05e-05	0.00657	-0.13	-0.19	Body mass index;	chr16:69894943	chr16:69976297~70065948:-
HNSC	cis	rs11673344	0.504	rs8109501	ENSG00000276846.1	CTD-3220F14.3	4.14	4.05e-05	0.00657	0.21	0.19	Obesity-related traits;	chr19:37102194	chr19:37314868~37315620:-
HNSC	cis	rs67981189	0.574	rs2526848	ENSG00000274818.1	RP1-292L20.3	-4.14	4.05e-05	0.00657	-0.2	-0.19	Schizophrenia;	chr14:70953025	chr14:70906657~70907111:-
HNSC	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-4.14	4.05e-05	0.00657	-0.24	-0.19	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
HNSC	cis	rs6840258	1	rs7682652	ENSG00000251411.1	RP11-397E7.4	-4.14	4.05e-05	0.00657	-0.24	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86992292	chr4:86913266~86914817:-
HNSC	cis	rs4862750	0.914	rs1346127	ENSG00000250971.1	RP11-696F12.1	-4.14	4.05e-05	0.00657	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr4:186955235	chr4:187060099~187060930:+
HNSC	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	4.14	4.05e-05	0.00658	0.25	0.19	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	4.14	4.05e-05	0.00658	0.25	0.19	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	4.14	4.05e-05	0.00658	0.25	0.19	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	4.14	4.05e-05	0.00658	0.25	0.19	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	4.14	4.05e-05	0.00658	0.25	0.19	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
HNSC	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	4.14	4.06e-05	0.00658	0.26	0.19	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
HNSC	cis	rs9926296	0.712	rs2434872	ENSG00000274627.1	RP11-104N10.2	4.14	4.06e-05	0.00658	0.19	0.19	Vitiligo;	chr16:89650507	chr16:89516797~89522217:+
HNSC	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-4.14	4.06e-05	0.00658	-0.14	-0.19	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-4.14	4.06e-05	0.00658	-0.14	-0.19	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
HNSC	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	4.14	4.06e-05	0.00658	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	4.14	4.06e-05	0.00658	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
HNSC	cis	rs6601327	0.613	rs12547642	ENSG00000233609.3	RP11-62H7.2	-4.14	4.06e-05	0.00658	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9636417	chr8:8961200~8979025:+
HNSC	cis	rs12478296	0.892	rs60545379	ENSG00000261186.2	RP11-341N2.1	-4.14	4.06e-05	0.00658	-0.31	-0.19	Obesity-related traits;	chr2:242092239	chr2:242087351~242088457:-
HNSC	cis	rs9531006	0.752	rs7994328	ENSG00000227676.3	LINC01068	4.14	4.06e-05	0.00658	0.27	0.19	Sleep duration;	chr13:79983571	chr13:79566727~79571436:+
HNSC	cis	rs2762353	0.808	rs1165150	ENSG00000272462.2	U91328.19	-4.14	4.06e-05	0.00658	-0.18	-0.19	Blood metabolite levels;	chr6:25841804	chr6:25992662~26001775:+
HNSC	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-4.14	4.06e-05	0.00658	-0.18	-0.19	Longevity;	chr3:48373517	chr3:48256350~48256938:-
HNSC	cis	rs11673344	0.504	rs4806409	ENSG00000276846.1	CTD-3220F14.3	4.14	4.06e-05	0.00659	0.21	0.19	Obesity-related traits;	chr19:37097923	chr19:37314868~37315620:-
HNSC	cis	rs739496	0.579	rs7314870	ENSG00000226469.1	ADAM1B	4.14	4.06e-05	0.00659	0.22	0.19	Platelet count;	chr12:111838660	chr12:111927018~111929017:+
HNSC	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-4.14	4.06e-05	0.00659	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
HNSC	cis	rs17189998	0.73	rs7836026	ENSG00000253636.1	RP11-531A24.5	-4.14	4.06e-05	0.00659	-0.26	-0.19	Colonoscopy-negative controls vs population controls;	chr8:72871963	chr8:73052178~73063061:+
HNSC	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-4.14	4.07e-05	0.00659	-0.16	-0.19	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
HNSC	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	4.14	4.07e-05	0.00659	0.22	0.19	Height;	chr14:75078517	chr14:75011269~75012851:-
HNSC	cis	rs9487051	0.597	rs12664455	ENSG00000243587.6	C6orf183	-4.14	4.07e-05	0.00659	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109269536	chr6:109165833~109271014:+
HNSC	cis	rs11577354	0.548	rs11301	ENSG00000207181.1	SNORA14B	4.14	4.07e-05	0.00659	0.24	0.19	Obesity-related traits;	chr1:235109864	chr1:235127803~235127937:-
HNSC	cis	rs656319	0.559	rs55683917	ENSG00000255310.2	AF131215.2	-4.14	4.07e-05	0.00659	-0.18	-0.19	Myopia (pathological);	chr8:10118969	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.526	rs1042701	ENSG00000255310.2	AF131215.2	-4.14	4.07e-05	0.00659	-0.18	-0.19	Neuroticism;	chr8:11564536	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.526	rs7843987	ENSG00000255310.2	AF131215.2	-4.14	4.07e-05	0.00659	-0.18	-0.19	Neuroticism;	chr8:11564621	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.526	rs7823100	ENSG00000255310.2	AF131215.2	-4.14	4.07e-05	0.00659	-0.18	-0.19	Neuroticism;	chr8:11564982	chr8:11107788~11109726:-
HNSC	cis	rs3808502	0.526	rs7823101	ENSG00000255310.2	AF131215.2	-4.14	4.07e-05	0.00659	-0.18	-0.19	Neuroticism;	chr8:11564983	chr8:11107788~11109726:-
HNSC	cis	rs12047808	0.556	rs78183476	ENSG00000227141.2	RP11-545A16.3	-4.14	4.07e-05	0.00659	-0.32	-0.19	Multiple sclerosis (age of onset);	chr1:179593385	chr1:179586705~179589175:+
HNSC	cis	rs7829975	0.774	rs1039915	ENSG00000233609.3	RP11-62H7.2	4.14	4.07e-05	0.0066	0.18	0.19	Mood instability;	chr8:8822104	chr8:8961200~8979025:+
HNSC	cis	rs2898681	0.519	rs3811781	ENSG00000248375.1	RP11-177B4.1	-4.14	4.07e-05	0.0066	-0.31	-0.19	Optic nerve measurement (cup area);	chr4:52862999	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.519	rs6554057	ENSG00000248375.1	RP11-177B4.1	-4.14	4.07e-05	0.0066	-0.31	-0.19	Optic nerve measurement (cup area);	chr4:52863980	chr4:52720081~52720831:-
HNSC	cis	rs2898681	0.519	rs6848200	ENSG00000248375.1	RP11-177B4.1	-4.14	4.07e-05	0.0066	-0.31	-0.19	Optic nerve measurement (cup area);	chr4:52864014	chr4:52720081~52720831:-
HNSC	cis	rs2136613	0.533	rs10995332	ENSG00000238280.1	RP11-436D10.3	-4.14	4.07e-05	0.0066	-0.22	-0.19	Selective IgA deficiency;	chr10:62857905	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10995333	ENSG00000238280.1	RP11-436D10.3	-4.14	4.07e-05	0.0066	-0.22	-0.19	Selective IgA deficiency;	chr10:62858034	chr10:62793562~62805887:-
HNSC	cis	rs9982086	0.793	rs73336046	ENSG00000260583.1	AP000223.42	-4.14	4.07e-05	0.0066	-0.37	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25554713	chr21:25582770~25583326:-
HNSC	cis	rs453301	0.571	rs330057	ENSG00000233609.3	RP11-62H7.2	-4.14	4.07e-05	0.0066	-0.17	-0.19	Joint mobility (Beighton score);	chr8:9232283	chr8:8961200~8979025:+
HNSC	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	4.14	4.07e-05	0.0066	0.29	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
HNSC	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	4.14	4.07e-05	0.0066	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
HNSC	cis	rs4699052	0.59	rs4698892	ENSG00000246560.2	RP11-10L12.4	4.14	4.07e-05	0.0066	0.21	0.19	Testicular germ cell tumor;	chr4:103340114	chr4:102828055~102844075:+
HNSC	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-4.14	4.07e-05	0.0066	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
HNSC	cis	rs12285276	1	rs12285276	ENSG00000205106.4	DKFZp779M0652	4.14	4.07e-05	0.0066	0.24	0.19	Visceral fat;	chr11:45792030	chr11:45771432~45772358:+
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-4.14	4.07e-05	0.0066	-0.18	-0.19	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
HNSC	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-4.14	4.07e-05	0.0066	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
HNSC	cis	rs11098499	0.739	rs951570	ENSG00000250412.1	KLHL2P1	-4.14	4.08e-05	0.0066	-0.23	-0.19	Corneal astigmatism;	chr4:119229312	chr4:119334329~119378233:+
HNSC	cis	rs6500395	1	rs34844432	ENSG00000261267.1	RP11-44I10.3	-4.14	4.08e-05	0.0066	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48648507	chr16:48559661~48587403:+
HNSC	cis	rs10078	0.571	rs2241597	ENSG00000225138.6	CTD-2228K2.7	4.14	4.08e-05	0.0066	0.32	0.19	Fat distribution (HIV);	chr5:480394	chr5:473236~480884:+
HNSC	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-4.14	4.08e-05	0.00661	-0.22	-0.19	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-4.14	4.08e-05	0.00661	-0.22	-0.19	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
HNSC	cis	rs2251260	1	rs2251260	ENSG00000250548.5	RP11-47I22.2	-4.14	4.08e-05	0.00661	-0.23	-0.19	Yeast infection;	chr14:61557049	chr14:61556313~61570653:-
HNSC	cis	rs2136613	0.505	rs10761674	ENSG00000238280.1	RP11-436D10.3	-4.14	4.08e-05	0.00661	-0.22	-0.19	Selective IgA deficiency;	chr10:62858580	chr10:62793562~62805887:-
HNSC	cis	rs9903692	0.657	rs1452665	ENSG00000263412.1	RP5-890E16.2	-4.14	4.08e-05	0.00661	-0.18	-0.19	Pulse pressure;	chr17:48219789	chr17:48045141~48048073:-
HNSC	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-4.14	4.08e-05	0.00661	-0.25	-0.19	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
HNSC	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-4.14	4.08e-05	0.00661	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
HNSC	cis	rs4256159	0.696	rs35128094	ENSG00000228956.7	SATB1-AS1	4.14	4.08e-05	0.00661	0.27	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18720621	chr3:18445024~18920401:+
HNSC	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-4.14	4.08e-05	0.00661	-0.33	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
HNSC	cis	rs116095464	0.558	rs10056628	ENSG00000250848.1	CTD-2083E4.5	-4.14	4.08e-05	0.00661	-0.26	-0.19	Breast cancer;	chr5:279397	chr5:288833~290321:-
HNSC	cis	rs2835345	0.563	rs74439245	ENSG00000230479.1	AP000695.6	4.14	4.08e-05	0.00661	0.2	0.19	Pulmonary function;	chr21:36452322	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs76422022	ENSG00000230479.1	AP000695.6	4.14	4.08e-05	0.00661	0.2	0.19	Pulmonary function;	chr21:36452328	chr21:36430360~36481070:+
HNSC	cis	rs202072	1	rs202073	ENSG00000215022.6	RP1-257A7.4	4.14	4.08e-05	0.00662	0.24	0.19	HIV-1 viral setpoint;	chr6:13268373	chr6:13264861~13295586:-
HNSC	cis	rs2486288	0.656	rs7162022	ENSG00000259479.5	SORD2P	-4.14	4.08e-05	0.00662	-0.22	-0.19	Glomerular filtration rate;	chr15:45273055	chr15:44826371~44884694:-
HNSC	cis	rs9611565	0.765	rs9607800	ENSG00000235513.1	RP4-756G23.5	4.14	4.08e-05	0.00662	0.23	0.19	Vitiligo;	chr22:41388558	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.802	rs73176692	ENSG00000235513.1	RP4-756G23.5	4.14	4.08e-05	0.00662	0.23	0.19	Vitiligo;	chr22:41389731	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs28604950	ENSG00000235513.1	RP4-756G23.5	4.14	4.08e-05	0.00662	0.23	0.19	Vitiligo;	chr22:41389808	chr22:41209122~41217627:-
HNSC	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	4.14	4.09e-05	0.00662	0.22	0.19	Height;	chr14:75132944	chr14:75011269~75012851:-
HNSC	cis	rs7572733	0.935	rs10931797	ENSG00000222017.1	AC011997.1	4.14	4.09e-05	0.00662	0.22	0.19	Dermatomyositis;	chr2:197976069	chr2:197693106~197774823:+
HNSC	cis	rs11951515	0.933	rs7701642	ENSG00000249286.1	CTD-2210P15.2	4.14	4.09e-05	0.00662	0.21	0.19	Metabolite levels  (X-11787);	chr5:43394676	chr5:43586918~43588223:-
HNSC	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-4.14	4.09e-05	0.00662	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-4.14	4.09e-05	0.00662	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
HNSC	cis	rs7824557	0.527	rs2572446	ENSG00000255310.2	AF131215.2	-4.14	4.09e-05	0.00662	-0.18	-0.19	Retinal vascular caliber;	chr8:11382056	chr8:11107788~11109726:-
HNSC	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-4.14	4.09e-05	0.00662	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
HNSC	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-4.14	4.09e-05	0.00662	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
HNSC	cis	rs11673344	0.504	rs12984458	ENSG00000276846.1	CTD-3220F14.3	-4.14	4.09e-05	0.00662	-0.2	-0.19	Obesity-related traits;	chr19:37138189	chr19:37314868~37315620:-
HNSC	cis	rs17345786	0.861	rs74768235	ENSG00000244119.1	PDCL3P4	4.14	4.09e-05	0.00662	0.21	0.19	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101712472~101713191:+
HNSC	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-4.14	4.09e-05	0.00662	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
HNSC	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-4.14	4.09e-05	0.00663	-0.3	-0.19	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
HNSC	cis	rs6787172	0.755	rs9819134	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158510483	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs9857535	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158511008	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs6780010	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158517627	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.677	rs6441206	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158523282	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.748	rs7639678	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158523664	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs1595029	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158523978	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.777	rs1595028	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158524109	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.755	rs58733163	ENSG00000272087.1	RP11-379F4.7	4.14	4.09e-05	0.00663	0.2	0.19	Subjective well-being;	chr3:158526407	chr3:158693120~158693768:-
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000211976.2	IGHV3-73	-4.14	4.09e-05	0.00663	-0.14	-0.19	Kawasaki disease;	chr14:106778135	chr14:106802694~106803233:-
HNSC	cis	rs9467711	0.79	rs35162296	ENSG00000241549.7	GUSBP2	4.14	4.09e-05	0.00663	0.31	0.19	Autism spectrum disorder or schizophrenia;	chr6:26318034	chr6:26871484~26956554:-
HNSC	cis	rs11157436	0.918	rs12437004	ENSG00000211812.1	TRAV26-2	-4.14	4.1e-05	0.00663	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22202583~22203368:+
HNSC	cis	rs4523957	0.559	rs216174	ENSG00000262333.1	HNRNPA1P16	-4.14	4.1e-05	0.00664	-0.18	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2261604	chr17:2306761~2307715:+
HNSC	cis	rs8028182	0.636	rs12708519	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75510859	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs8029112	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75516631	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs4886712	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75520547	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs8030802	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75520812	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.577	rs8023268	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75522331	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs8023815	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75522363	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs11636031	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75523417	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs8036758	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.1e-05	0.00664	-0.24	-0.19	Sudden cardiac arrest;	chr15:75525221	chr15:75527150~75601205:-
HNSC	cis	rs1478897	0.804	rs9329246	ENSG00000255046.1	RP11-297N6.4	-4.14	4.1e-05	0.00664	-0.2	-0.19	Systemic lupus erythematosus;	chr8:11535371	chr8:11797928~11802568:-
HNSC	cis	rs6840258	1	rs56050898	ENSG00000251411.1	RP11-397E7.4	-4.14	4.1e-05	0.00664	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87024223	chr4:86913266~86914817:-
HNSC	cis	rs4356203	0.875	rs667984	ENSG00000260196.1	RP1-239B22.5	-4.14	4.1e-05	0.00664	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17380649~17383531:+
HNSC	cis	rs9611565	0.694	rs202639	ENSG00000235513.1	RP4-756G23.5	-4.14	4.1e-05	0.00664	-0.23	-0.19	Vitiligo;	chr22:41460133	chr22:41209122~41217627:-
HNSC	cis	rs9914988	0.509	rs17794628	ENSG00000264577.1	AC010761.8	4.14	4.1e-05	0.00664	0.19	0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28933127	chr17:28721487~28722877:-
HNSC	cis	rs6601327	0.54	rs6982148	ENSG00000233609.3	RP11-62H7.2	-4.14	4.1e-05	0.00664	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9723560	chr8:8961200~8979025:+
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	4.14	4.1e-05	0.00664	0.26	0.19	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000254153.1	CTA-398F10.2	4.14	4.1e-05	0.00664	0.21	0.19	Mood instability;	chr8:8788736	chr8:8456909~8461337:-
HNSC	cis	rs60617249	0.862	rs7794123	ENSG00000228204.2	RP4-724E13.2	4.14	4.1e-05	0.00664	0.2	0.19	Major depression and alcohol dependence;	chr7:50928377	chr7:50866747~51022990:+
HNSC	cis	rs11098499	0.675	rs11098534	ENSG00000250412.1	KLHL2P1	4.14	4.1e-05	0.00664	0.24	0.19	Corneal astigmatism;	chr4:119635617	chr4:119334329~119378233:+
HNSC	cis	rs3096299	0.781	rs2170839	ENSG00000261574.1	RP1-168P16.2	4.14	4.11e-05	0.00665	0.24	0.19	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89392375~89412564:-
HNSC	cis	rs2835345	0.563	rs12482257	ENSG00000230479.1	AP000695.6	4.14	4.11e-05	0.00665	0.2	0.19	Pulmonary function;	chr21:36451660	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs12482140	ENSG00000230479.1	AP000695.6	4.14	4.11e-05	0.00665	0.2	0.19	Pulmonary function;	chr21:36451735	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.528	rs73204243	ENSG00000230479.1	AP000695.6	4.14	4.11e-05	0.00665	0.2	0.19	Pulmonary function;	chr21:36451776	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.595	rs78237434	ENSG00000230479.1	AP000695.6	4.14	4.11e-05	0.00665	0.2	0.19	Pulmonary function;	chr21:36451826	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs78113480	ENSG00000230479.1	AP000695.6	4.14	4.11e-05	0.00665	0.2	0.19	Pulmonary function;	chr21:36452022	chr21:36430360~36481070:+
HNSC	cis	rs67981189	0.574	rs2010713	ENSG00000274818.1	RP1-292L20.3	-4.14	4.11e-05	0.00665	-0.2	-0.19	Schizophrenia;	chr14:70902018	chr14:70906657~70907111:-
HNSC	cis	rs12664251	0.66	rs7738420	ENSG00000253194.1	RP11-351A11.1	-4.14	4.11e-05	0.00665	-0.22	-0.19	Schizophrenia;	chr6:119028371	chr6:118934785~119031541:+
HNSC	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-4.14	4.11e-05	0.00665	-0.14	-0.19	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	4.14	4.11e-05	0.00665	0.24	0.19	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
HNSC	cis	rs6951245	0.744	rs1133122	ENSG00000225146.1	AC073957.15	-4.14	4.11e-05	0.00666	-0.31	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1029025~1043891:+
HNSC	cis	rs4321325	0.733	rs4510165	ENSG00000236682.1	AC068282.3	-4.14	4.11e-05	0.00666	-0.32	-0.19	Protein C levels;	chr2:127178708	chr2:127389130~127400580:+
HNSC	cis	rs860295	0.58	rs7528441	ENSG00000203761.5	MSTO2P	-4.14	4.11e-05	0.00666	-0.15	-0.19	Body mass index;	chr1:155873465	chr1:155745829~155750137:+
HNSC	cis	rs801193	1	rs62466793	ENSG00000272831.1	RP11-792A8.4	4.14	4.11e-05	0.00666	0.16	0.19	Aortic root size;	chr7:66726530	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs62466794	ENSG00000272831.1	RP11-792A8.4	4.14	4.11e-05	0.00666	0.16	0.19	Aortic root size;	chr7:66726592	chr7:66739829~66740385:-
HNSC	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-4.14	4.11e-05	0.00666	-0.25	-0.19	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
HNSC	cis	rs1580019	0.961	rs6949851	ENSG00000226468.2	AC018641.7	-4.14	4.11e-05	0.00666	-0.25	-0.19	Cognitive ability;	chr7:32454195	chr7:32456963~32457758:-
HNSC	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	4.14	4.11e-05	0.00666	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
HNSC	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-4.14	4.11e-05	0.00666	-0.23	-0.19	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
HNSC	cis	rs7824557	0.527	rs2572369	ENSG00000255310.2	AF131215.2	-4.14	4.12e-05	0.00666	-0.18	-0.19	Retinal vascular caliber;	chr8:11381088	chr8:11107788~11109726:-
HNSC	cis	rs13325613	0.834	rs13096307	ENSG00000223552.1	RP11-24F11.2	-4.14	4.12e-05	0.00666	-0.33	-0.19	Monocyte count;	chr3:46205462	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.749	rs13096371	ENSG00000223552.1	RP11-24F11.2	-4.14	4.12e-05	0.00666	-0.33	-0.19	Monocyte count;	chr3:46205605	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs34865316	ENSG00000223552.1	RP11-24F11.2	-4.14	4.12e-05	0.00666	-0.33	-0.19	Monocyte count;	chr3:46205965	chr3:46364955~46407059:-
HNSC	cis	rs4356203	0.905	rs214906	ENSG00000260196.1	RP1-239B22.5	4.14	4.12e-05	0.00666	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17380649~17383531:+
HNSC	cis	rs7829975	0.774	rs57312668	ENSG00000233609.3	RP11-62H7.2	4.14	4.12e-05	0.00666	0.18	0.19	Mood instability;	chr8:8822967	chr8:8961200~8979025:+
HNSC	cis	rs4924935	0.692	rs2428365	ENSG00000264885.1	RP11-815I9.4	4.14	4.12e-05	0.00666	0.2	0.19	Pancreatic cancer;	chr17:18919157	chr17:18667629~18669461:-
HNSC	cis	rs1602565	0.764	rs7105790	ENSG00000255450.1	CTD-2063L20.1	-4.14	4.12e-05	0.00666	-0.28	-0.19	Schizophrenia;	chr11:29103082	chr11:29275655~29276565:+
HNSC	cis	rs1552244	0.882	rs13064570	ENSG00000180385.7	EMC3-AS1	4.14	4.12e-05	0.00667	0.21	0.19	Alzheimer's disease;	chr3:9955861	chr3:9986893~10006990:+
HNSC	cis	rs4927850	1	rs10881564	ENSG00000226155.1	AC124944.3	-4.14	4.13e-05	0.00667	-0.23	-0.19	Pancreatic cancer;	chr3:196023455	chr3:195912049~195913986:+
HNSC	cis	rs2548724	0.755	rs78368500	ENSG00000250682.4	LINC00491	4.14	4.13e-05	0.00667	0.26	0.19	Type 2 diabetes;	chr5:102332591	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.755	rs76146936	ENSG00000250682.4	LINC00491	4.14	4.13e-05	0.00667	0.26	0.19	Type 2 diabetes;	chr5:102332592	chr5:102609156~102671559:-
HNSC	cis	rs4713118	0.513	rs149989	ENSG00000219891.2	ZSCAN12P1	4.14	4.13e-05	0.00667	0.25	0.19	Parkinson's disease;	chr6:28030406	chr6:28091154~28093664:+
HNSC	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-4.14	4.13e-05	0.00667	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
HNSC	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	4.14	4.13e-05	0.00667	0.22	0.19	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
HNSC	cis	rs9313772	0.722	rs4473756	ENSG00000254350.1	RP11-542A14.1	-4.14	4.13e-05	0.00668	-0.2	-0.19	Blood pressure;	chr5:158436296	chr5:158424585~158452758:+
HNSC	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-4.14	4.13e-05	0.00668	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
HNSC	cis	rs950027	0.549	rs9920634	ENSG00000259479.5	SORD2P	-4.14	4.13e-05	0.00668	-0.22	-0.19	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:44826371~44884694:-
HNSC	cis	rs2098713	0.535	rs10941358	ENSG00000250155.1	CTD-2353F22.1	4.14	4.13e-05	0.00668	0.18	0.19	Telomere length;	chr5:37637276	chr5:36666214~36725195:-
HNSC	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	4.14	4.13e-05	0.00668	0.2	0.19	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
HNSC	cis	rs2098713	0.537	rs517694	ENSG00000250155.1	CTD-2353F22.1	4.14	4.13e-05	0.00668	0.2	0.19	Telomere length;	chr5:37536951	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs578236	ENSG00000250155.1	CTD-2353F22.1	4.14	4.13e-05	0.00668	0.2	0.19	Telomere length;	chr5:37538958	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs668889	ENSG00000250155.1	CTD-2353F22.1	4.14	4.13e-05	0.00668	0.2	0.19	Telomere length;	chr5:37540023	chr5:36666214~36725195:-
HNSC	cis	rs6430585	0.583	rs12472293	ENSG00000231890.6	DARS-AS1	-4.14	4.13e-05	0.00668	-0.33	-0.19	Corneal structure;	chr2:135890507	chr2:135985176~136022593:+
HNSC	cis	rs11098499	0.863	rs3822195	ENSG00000250412.1	KLHL2P1	4.14	4.13e-05	0.00668	0.24	0.19	Corneal astigmatism;	chr4:119550505	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775854	ENSG00000250412.1	KLHL2P1	4.14	4.13e-05	0.00668	0.24	0.19	Corneal astigmatism;	chr4:119550816	chr4:119334329~119378233:+
HNSC	cis	rs516805	0.596	rs1531186	ENSG00000279453.1	RP3-425C14.4	-4.14	4.13e-05	0.00668	-0.26	-0.19	Lymphocyte counts;	chr6:122208219	chr6:122436789~122439223:-
HNSC	cis	rs8028182	0.636	rs62027209	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.13e-05	0.00668	-0.24	-0.19	Sudden cardiac arrest;	chr15:75579285	chr15:75527150~75601205:-
HNSC	cis	rs10510102	0.516	rs11200301	ENSG00000226864.1	ATE1-AS1	4.14	4.13e-05	0.00668	0.34	0.19	Breast cancer;	chr10:121977976	chr10:121928312~121951965:+
HNSC	cis	rs6142618	0.935	rs4911198	ENSG00000275576.1	RP5-836N17.4	4.14	4.13e-05	0.00668	0.19	0.19	Inflammatory bowel disease;	chr20:32139880	chr20:32116171~32116629:+
HNSC	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	4.14	4.13e-05	0.00668	0.23	0.19	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
HNSC	cis	rs79478560	0.599	rs11057390	ENSG00000269938.1	RP11-214K3.20	-4.14	4.13e-05	0.00668	-0.22	-0.19	Lymphocyte counts;	chr12:123899266	chr12:123968023~123968579:-
HNSC	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-4.14	4.13e-05	0.00668	-0.23	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
HNSC	cis	rs10129255	0.83	rs61997609	ENSG00000211974.3	IGHV2-70	4.14	4.13e-05	0.00668	0.17	0.19	Kawasaki disease;	chr14:106692376	chr14:106723574~106724093:-
HNSC	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	4.14	4.13e-05	0.00668	0.18	0.19	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
HNSC	cis	rs721917	0.506	rs2475756	ENSG00000244733.5	RP11-506M13.3	-4.14	4.13e-05	0.00669	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79660891~79677996:+
HNSC	cis	rs7824557	0.628	rs17797894	ENSG00000255310.2	AF131215.2	4.14	4.13e-05	0.00669	0.18	0.19	Retinal vascular caliber;	chr8:11354572	chr8:11107788~11109726:-
HNSC	cis	rs2518049	0.904	rs4881397	ENSG00000224034.1	RP11-445P17.8	4.14	4.14e-05	0.00669	0.25	0.19	Metabolic traits;	chr10:5079680	chr10:5266033~5271236:-
HNSC	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-4.14	4.14e-05	0.00669	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
HNSC	cis	rs9467773	0.587	rs10946812	ENSG00000241549.7	GUSBP2	4.14	4.14e-05	0.00669	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26344747	chr6:26871484~26956554:-
HNSC	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	4.14	4.14e-05	0.00669	0.23	0.19	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
HNSC	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	4.14	4.14e-05	0.00669	0.23	0.19	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
HNSC	cis	rs36052053	0.521	rs71558356	ENSG00000203799.9	CCDC162P	4.14	4.14e-05	0.00669	0.31	0.19	Red cell distribution width;	chr6:109224908	chr6:109285485~109355063:+
HNSC	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-4.14	4.14e-05	0.00669	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-4.14	4.14e-05	0.00669	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-4.14	4.14e-05	0.00669	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
HNSC	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-4.14	4.14e-05	0.00669	-0.24	-0.19	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
HNSC	cis	rs4356203	0.905	rs6486352	ENSG00000260196.1	RP1-239B22.5	4.14	4.14e-05	0.0067	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17380649~17383531:+
HNSC	cis	rs12403795	0.505	rs3850839	ENSG00000228126.1	FALEC	-4.14	4.14e-05	0.0067	-0.24	-0.19	Illicit drug use;	chr1:150261883	chr1:150515757~150518032:+
HNSC	cis	rs2835345	0.561	rs5026478	ENSG00000230479.1	AP000695.6	4.14	4.14e-05	0.0067	0.2	0.19	Pulmonary function;	chr21:36453531	chr21:36430360~36481070:+
HNSC	cis	rs7520050	0.933	rs12045165	ENSG00000280836.1	AL355480.1	4.14	4.14e-05	0.0067	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45581219~45581321:-
HNSC	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-4.14	4.14e-05	0.0067	-0.18	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
HNSC	cis	rs11021221	0.645	rs2156468	ENSG00000233536.2	RP11-867G2.5	4.14	4.14e-05	0.0067	0.23	0.19	Immature fraction of reticulocytes;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;	chr11:95594248	chr11:94638038~94640833:+
HNSC	cis	rs8067545	0.616	rs203477	ENSG00000266126.1	RP11-209D14.4	4.14	4.14e-05	0.0067	0.21	0.19	Schizophrenia;	chr17:19928506	chr17:19929372~19929737:-
HNSC	cis	rs442309	0.807	rs224029	ENSG00000238280.1	RP11-436D10.3	-4.14	4.15e-05	0.0067	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62759539	chr10:62793562~62805887:-
HNSC	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-4.14	4.15e-05	0.0067	-0.22	-0.19	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-4.14	4.15e-05	0.0067	-0.22	-0.19	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
HNSC	cis	rs7688540	0.771	rs4129956	ENSG00000211553.1	AC253576.2	-4.14	4.15e-05	0.0067	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:136461~136568:+
HNSC	cis	rs7324557	0.684	rs9510871	ENSG00000205861.10	C1QTNF9B-AS1	-4.14	4.15e-05	0.00671	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23810713	chr13:23888889~23897263:+
HNSC	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	4.14	4.15e-05	0.00671	0.18	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
HNSC	cis	rs73607972	0.799	rs112105499	ENSG00000275191.1	RP11-36I17.2	-4.14	4.15e-05	0.00671	-0.27	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577948	chr16:53628256~53628816:-
HNSC	cis	rs4925386	0.84	rs8124907	ENSG00000275437.1	RP5-908M14.10	4.14	4.15e-05	0.00671	0.2	0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62402236~62405935:-
HNSC	cis	rs10927875	0.726	rs1763603	ENSG00000226029.1	RP4-798A10.2	-4.14	4.15e-05	0.00671	-0.19	-0.19	Dilated cardiomyopathy;	chr1:16013314	chr1:16460948~16468481:+
HNSC	cis	rs13434995	0.513	rs62310862	ENSG00000273257.1	RP11-177J6.1	-4.14	4.15e-05	0.00671	-0.26	-0.19	Adiponectin levels;	chr4:55572594	chr4:55387949~55388271:+
HNSC	cis	rs4523957	0.855	rs1231206	ENSG00000262333.1	HNRNPA1P16	4.14	4.15e-05	0.00671	0.15	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2222311	chr17:2306761~2307715:+
HNSC	cis	rs11673344	0.563	rs55825113	ENSG00000276846.1	CTD-3220F14.3	4.14	4.15e-05	0.00671	0.21	0.19	Obesity-related traits;	chr19:37191523	chr19:37314868~37315620:-
HNSC	cis	rs10773046	0.566	rs10773042	ENSG00000269938.1	RP11-214K3.20	-4.14	4.15e-05	0.00671	-0.21	-0.19	Osteoarthritis (hip);	chr12:123863567	chr12:123968023~123968579:-
HNSC	cis	rs17772222	0.793	rs7143853	ENSG00000258789.1	RP11-507K2.3	-4.14	4.15e-05	0.00671	-0.23	-0.19	Coronary artery calcification;	chr14:88578477	chr14:88551597~88552493:+
HNSC	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.14	4.15e-05	0.00671	-0.21	-0.19	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
HNSC	cis	rs9313772	0.722	rs2419917	ENSG00000254350.1	RP11-542A14.1	-4.14	4.15e-05	0.00671	-0.2	-0.19	Blood pressure;	chr5:158434455	chr5:158424585~158452758:+
HNSC	cis	rs116095464	0.558	rs7713524	ENSG00000250848.1	CTD-2083E4.5	4.14	4.15e-05	0.00671	0.26	0.19	Breast cancer;	chr5:276085	chr5:288833~290321:-
HNSC	cis	rs8180040	0.805	rs17410853	ENSG00000276925.1	RP11-708J19.3	4.14	4.16e-05	0.00671	0.18	0.19	Colorectal cancer;	chr3:47322481	chr3:47469777~47469987:+
HNSC	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	4.14	4.16e-05	0.00671	0.32	0.19	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	4.14	4.16e-05	0.00671	0.32	0.19	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
HNSC	cis	rs7619708	1	rs7619708	ENSG00000207650.1	MIR570	-4.14	4.16e-05	0.00671	-0.21	-0.19	Red cell distribution width;	chr3:196083316	chr3:195699401~195699497:+
HNSC	cis	rs7824557	0.606	rs2736270	ENSG00000269918.1	AF131215.9	4.14	4.16e-05	0.00671	0.18	0.19	Retinal vascular caliber;	chr8:11335084	chr8:11104691~11106704:-
HNSC	cis	rs8010715	0.848	rs8009511	ENSG00000259321.1	RP11-468E2.5	4.14	4.16e-05	0.00671	0.16	0.19	IgG glycosylation;	chr14:24124771	chr14:24139445~24140444:+
HNSC	cis	rs8010715	0.804	rs1134334	ENSG00000259321.1	RP11-468E2.5	4.14	4.16e-05	0.00671	0.16	0.19	IgG glycosylation;	chr14:24124905	chr14:24139445~24140444:+
HNSC	cis	rs7824557	0.614	rs2736286	ENSG00000255495.1	AC145124.2	-4.14	4.16e-05	0.00671	-0.2	-0.19	Retinal vascular caliber;	chr8:11369595	chr8:12194467~12196280:+
HNSC	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-4.14	4.16e-05	0.00672	-0.22	-0.19	Height;	chr14:75136861	chr14:75011269~75012851:-
HNSC	cis	rs896655	0.631	rs10965117	ENSG00000244230.3	RN7SL151P	4.14	4.16e-05	0.00672	0.2	0.19	Coronary artery disease;	chr9:21730411	chr9:21699314~21699596:+
HNSC	cis	rs71520386	0.796	rs71530697	ENSG00000221740.1	SNORD93	-4.14	4.16e-05	0.00672	-0.25	-0.19	Fibrinogen levels;	chr7:22799134	chr7:22856613~22856686:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000229886.1	RP5-1132H15.3	4.14	4.16e-05	0.00672	0.32	0.19	Diabetic kidney disease;	chr7:65940221	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35046236	ENSG00000229886.1	RP5-1132H15.3	4.14	4.16e-05	0.00672	0.32	0.19	Diabetic kidney disease;	chr7:65943626	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs36068983	ENSG00000229886.1	RP5-1132H15.3	4.14	4.16e-05	0.00672	0.32	0.19	Diabetic kidney disease;	chr7:65944004	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs68189316	ENSG00000229886.1	RP5-1132H15.3	4.14	4.16e-05	0.00672	0.32	0.19	Diabetic kidney disease;	chr7:65944182	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000229886.1	RP5-1132H15.3	4.14	4.16e-05	0.00672	0.32	0.19	Diabetic kidney disease;	chr7:65947955	chr7:66025126~66031544:-
HNSC	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	4.14	4.16e-05	0.00672	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000106610.13	STAG3L4	-4.14	4.16e-05	0.00672	-0.38	-0.19	Gout;	chr7:66671562	chr7:67302621~67321526:+
HNSC	cis	rs35963943	0.6	rs11920460	ENSG00000228956.7	SATB1-AS1	4.14	4.17e-05	0.00673	0.22	0.19	Lymphocyte counts;	chr3:18676576	chr3:18445024~18920401:+
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	4.14	4.17e-05	0.00673	0.2	0.19	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
HNSC	cis	rs924712	0.522	rs12194012	ENSG00000224984.1	RP11-524H19.2	4.14	4.17e-05	0.00673	0.21	0.19	Breast cancer;	chr6:54845053	chr6:54840118~54840855:-
HNSC	cis	rs10504130	0.569	rs11775611	ENSG00000253844.1	RP11-546K22.1	-4.14	4.17e-05	0.00673	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51961458~52022974:+
HNSC	cis	rs9400271	0.632	rs9374069	ENSG00000243587.6	C6orf183	-4.14	4.17e-05	0.00673	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109265131	chr6:109165833~109271014:+
HNSC	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	4.14	4.17e-05	0.00673	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
HNSC	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	4.14	4.17e-05	0.00673	0.2	0.19	QT interval;	chr12:29260560	chr12:29280418~29317848:-
HNSC	cis	rs7572733	0.515	rs1518368	ENSG00000231621.1	AC013264.2	-4.14	4.17e-05	0.00673	-0.18	-0.19	Dermatomyositis;	chr2:197974421	chr2:197197991~197199273:+
HNSC	cis	rs656319	0.513	rs17746245	ENSG00000269918.1	AF131215.9	4.14	4.17e-05	0.00674	0.19	0.19	Myopia (pathological);	chr8:10124176	chr8:11104691~11106704:-
HNSC	cis	rs9531006	0.752	rs12868561	ENSG00000227676.3	LINC01068	4.14	4.18e-05	0.00674	0.28	0.19	Sleep duration;	chr13:79977272	chr13:79566727~79571436:+
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000224373.3	IGHV4-59	4.14	4.18e-05	0.00674	0.11	0.19	Kawasaki disease;	chr14:106785139	chr14:106627249~106627825:-
HNSC	cis	rs7948661	1	rs9332871	ENSG00000278376.1	RP11-158I9.8	4.14	4.18e-05	0.00674	0.34	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118523141	chr11:118791254~118793137:+
HNSC	cis	rs4356203	0.792	rs620241	ENSG00000260196.1	RP1-239B22.5	-4.14	4.18e-05	0.00674	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17380649~17383531:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000233609.3	RP11-62H7.2	4.14	4.18e-05	0.00674	0.18	0.19	Mood instability;	chr8:8786764	chr8:8961200~8979025:+
HNSC	cis	rs6831352	1	rs6822348	ENSG00000263923.1	RP11-571L19.7	-4.14	4.18e-05	0.00674	-0.19	-0.19	Alcohol dependence;	chr4:99132743	chr4:98928897~98994994:+
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000241439.1	RP11-666A20.3	4.14	4.18e-05	0.00674	0.21	0.19	Blood pressure (smoking interaction);	chr3:125991896	chr3:125958556~125958817:+
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000224373.3	IGHV4-59	4.14	4.18e-05	0.00675	0.11	0.19	Kawasaki disease;	chr14:106783693	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000224373.3	IGHV4-59	4.14	4.18e-05	0.00675	0.11	0.19	Kawasaki disease;	chr14:106784065	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000224373.3	IGHV4-59	4.14	4.18e-05	0.00675	0.11	0.19	Kawasaki disease;	chr14:106784149	chr14:106627249~106627825:-
HNSC	cis	rs7071275	0.525	rs1696813	ENSG00000223432.1	RP11-62L18.3	4.14	4.18e-05	0.00675	0.24	0.19	Dupuytren's disease;	chr10:121617683	chr10:121615425~121615839:-
HNSC	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.18e-05	0.00675	-0.24	-0.19	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000250412.1	KLHL2P1	4.14	4.18e-05	0.00675	0.24	0.19	Corneal astigmatism;	chr4:119334771	chr4:119334329~119378233:+
HNSC	cis	rs78366141	0.649	rs7674009	ENSG00000248019.2	FAM13A-AS1	4.14	4.18e-05	0.00675	0.27	0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88762173	chr4:88709789~88730103:+
HNSC	cis	rs8063160	0.756	rs34878706	ENSG00000260259.1	RP11-368I7.4	-4.14	4.18e-05	0.00675	-0.43	-0.19	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89657462	chr16:89682620~89686569:-
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.18e-05	0.00675	-0.32	-0.19	Diabetic kidney disease;	chr7:65928187	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs78803505	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65917585	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34933526	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65918212	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34577383	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65920739	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6949812	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65922114	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6970243	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65923503	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7794661	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65924743	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7795242	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65925107	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65925372	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35058610	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65925938	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2177703	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65926730	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35432774	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65928032	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs56985706	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65929575	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs60683927	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65929781	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs58062456	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65929865	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34529418	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00675	0.32	0.19	Diabetic kidney disease;	chr7:65938222	chr7:66025126~66031544:-
HNSC	cis	rs73198271	0.613	rs11249892	ENSG00000233609.3	RP11-62H7.2	-4.14	4.18e-05	0.00675	-0.2	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8961200~8979025:+
HNSC	cis	rs55823223	0.618	rs11867339	ENSG00000267801.1	RP11-552F3.9	4.14	4.18e-05	0.00675	0.24	0.19	Psoriasis;	chr17:75866012	chr17:75876372~75879546:+
HNSC	cis	rs2548724	0.796	rs12055218	ENSG00000250682.4	LINC00491	4.14	4.18e-05	0.00675	0.25	0.19	Type 2 diabetes;	chr5:102378049	chr5:102609156~102671559:-
HNSC	cis	rs57502260	0.704	rs55975204	ENSG00000212093.1	AP000807.1	4.14	4.18e-05	0.00675	0.28	0.19	Total body bone mineral density (age 45-60);	chr11:68481656	chr11:68506083~68506166:-
HNSC	cis	rs2253762	0.54	rs75670246	ENSG00000276742.1	RP11-500G22.4	4.14	4.18e-05	0.00675	0.28	0.19	Breast cancer;	chr10:122032687	chr10:121956782~121957098:+
HNSC	cis	rs7688540	0.771	rs2353605	ENSG00000211553.1	AC253576.2	-4.14	4.18e-05	0.00675	-0.28	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:136461~136568:+
HNSC	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	4.14	4.18e-05	0.00675	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
HNSC	cis	rs240993	0.715	rs399219	ENSG00000230177.1	RP5-1112D6.4	-4.14	4.18e-05	0.00675	-0.24	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111371880	chr6:111277932~111278742:+
HNSC	cis	rs1555322	1	rs2425027	ENSG00000279253.1	RP4-614O4.13	-4.14	4.19e-05	0.00675	-0.28	-0.19	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35262727~35264187:-
HNSC	cis	rs6026584	1	rs15754	ENSG00000270951.1	RP1-309F20.4	-4.14	4.19e-05	0.00675	-0.2	-0.19	Renal function-related traits (BUN);	chr20:58894172	chr20:58876592~58876981:-
HNSC	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-4.14	4.19e-05	0.00676	-0.2	-0.19	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
HNSC	cis	rs4713118	0.824	rs9468223	ENSG00000216901.1	AL022393.7	4.14	4.19e-05	0.00676	0.24	0.19	Parkinson's disease;	chr6:27772887	chr6:28176188~28176674:+
HNSC	cis	rs7572733	0.935	rs1607376	ENSG00000222017.1	AC011997.1	4.14	4.19e-05	0.00676	0.22	0.19	Dermatomyositis;	chr2:197963190	chr2:197693106~197774823:+
HNSC	cis	rs8091660	0.624	rs9948328	ENSG00000278983.1	RP11-426J5.3	4.14	4.19e-05	0.00676	0.27	0.19	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569613	chr18:48564795~48568342:+
HNSC	cis	rs7637230	1	rs4683950	ENSG00000244119.1	PDCL3P4	-4.14	4.19e-05	0.00676	-0.2	-0.19	Psoriasis vulgaris;Psoriasis;	chr3:101935114	chr3:101712472~101713191:+
HNSC	cis	rs10078	0.515	rs6872510	ENSG00000225138.6	CTD-2228K2.7	4.14	4.19e-05	0.00676	0.33	0.19	Fat distribution (HIV);	chr5:481495	chr5:473236~480884:+
HNSC	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.14	4.19e-05	0.00676	-0.2	-0.19	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
HNSC	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	4.14	4.19e-05	0.00676	0.25	0.19	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
HNSC	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-4.14	4.19e-05	0.00677	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
HNSC	cis	rs8028182	0.636	rs7163451	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.19e-05	0.00677	-0.24	-0.19	Sudden cardiac arrest;	chr15:75568735	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs8036884	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.19e-05	0.00677	-0.24	-0.19	Sudden cardiac arrest;	chr15:75570552	chr15:75527150~75601205:-
HNSC	cis	rs7819412	0.505	rs17726209	ENSG00000255310.2	AF131215.2	4.14	4.2e-05	0.00677	0.19	0.19	Triglycerides;	chr8:11164675	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-4.14	4.2e-05	0.00677	-0.22	-0.19	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
HNSC	cis	rs4218	0.505	rs6494064	ENSG00000277144.1	RP11-59H7.4	4.14	4.2e-05	0.00677	0.22	0.19	Social communication problems;	chr15:59053192	chr15:59115547~59116089:-
HNSC	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	4.14	4.2e-05	0.00677	0.21	0.19	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
HNSC	cis	rs6095360	0.727	rs111235329	ENSG00000222365.1	SNORD12B	-4.14	4.2e-05	0.00677	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:48891540	chr20:49280319~49280409:+
HNSC	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	4.14	4.2e-05	0.00677	0.16	0.19	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
HNSC	cis	rs4908760	0.827	rs6692693	ENSG00000232912.4	RP5-1115A15.1	4.14	4.2e-05	0.00677	0.2	0.19	Vitiligo;	chr1:8647057	chr1:8424645~8434838:+
HNSC	cis	rs853679	0.607	rs34396849	ENSG00000226314.6	ZNF192P1	-4.14	4.2e-05	0.00678	-0.35	-0.19	Depression;	chr6:28283178	chr6:28161781~28169594:+
HNSC	cis	rs792448	0.581	rs1663626	ENSG00000226251.4	RP11-15I11.3	-4.14	4.2e-05	0.00678	-0.22	-0.19	White blood cell count (basophil);	chr1:212249225	chr1:212225278~212238977:-
HNSC	cis	rs7824557	0.606	rs2736273	ENSG00000269918.1	AF131215.9	4.14	4.2e-05	0.00678	0.18	0.19	Retinal vascular caliber;	chr8:11342429	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000211974.3	IGHV2-70	-4.14	4.2e-05	0.00678	-0.17	-0.19	Kawasaki disease;	chr14:106684476	chr14:106723574~106724093:-
HNSC	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-4.14	4.2e-05	0.00678	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
HNSC	cis	rs9903692	1	rs9903692	ENSG00000263412.1	RP5-890E16.2	-4.14	4.21e-05	0.00678	-0.18	-0.19	Pulse pressure;	chr17:48196567	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs9909933	ENSG00000263412.1	RP5-890E16.2	-4.14	4.21e-05	0.00678	-0.18	-0.19	Pulse pressure;	chr17:48202870	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.909	rs2325885	ENSG00000263412.1	RP5-890E16.2	-4.14	4.21e-05	0.00678	-0.18	-0.19	Pulse pressure;	chr17:48213013	chr17:48045141~48048073:-
HNSC	cis	rs2337406	1	rs78857163	ENSG00000280411.1	IGHV1-69-2	-4.14	4.21e-05	0.00678	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106707435	chr14:106762092~106762588:-
HNSC	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	4.14	4.21e-05	0.00678	0.19	0.19	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
HNSC	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	4.14	4.21e-05	0.00678	0.19	0.19	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
HNSC	cis	rs116095464	0.558	rs7714335	ENSG00000250848.1	CTD-2083E4.5	-4.13	4.21e-05	0.00679	-0.26	-0.19	Breast cancer;	chr5:263398	chr5:288833~290321:-
HNSC	cis	rs4622329	0.595	rs7978722	ENSG00000258033.1	RP11-350G24.2	4.13	4.21e-05	0.00679	0.21	0.19	Systemic lupus erythematosus;	chr12:101895174	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs7137913	ENSG00000258033.1	RP11-350G24.2	4.13	4.21e-05	0.00679	0.21	0.19	Systemic lupus erythematosus;	chr12:101897599	chr12:101066734~101069232:+
HNSC	cis	rs7824557	0.564	rs2736304	ENSG00000255310.2	AF131215.2	-4.13	4.21e-05	0.00679	-0.18	-0.19	Retinal vascular caliber;	chr8:11379455	chr8:11107788~11109726:-
HNSC	cis	rs828999	0.872	rs663045	ENSG00000280186.1	RP11-483I13.6	4.13	4.21e-05	0.00679	0.2	0.19	Monocyte percentage of white cells;	chr1:108200437	chr1:108200413~108202743:+
HNSC	cis	rs6500395	0.962	rs9927888	ENSG00000261267.1	RP11-44I10.3	-4.13	4.21e-05	0.00679	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48523853	chr16:48559661~48587403:+
HNSC	cis	rs7720894	0.935	rs7732234	ENSG00000215032.2	GNL3LP1	-4.13	4.21e-05	0.00679	-0.21	-0.19	Body mass index;	chr5:61491053	chr5:60891935~60893577:-
HNSC	cis	rs1065852	0.906	rs5751230	ENSG00000227370.1	RP4-669P10.19	4.13	4.22e-05	0.00679	0.22	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42157347	chr22:42132543~42132998:+
HNSC	cis	rs1075232	0.655	rs80220087	ENSG00000270055.1	CTD-3092A11.2	-4.13	4.22e-05	0.00679	-0.38	-0.19	Survival in colorectal cancer (non-distant metastatic);	chr15:31263614	chr15:30487963~30490313:+
HNSC	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	4.13	4.22e-05	0.0068	0.18	0.19	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
HNSC	cis	rs9650657	0.771	rs6601513	ENSG00000255310.2	AF131215.2	-4.13	4.22e-05	0.0068	-0.18	-0.19	Neuroticism;	chr8:10737333	chr8:11107788~11109726:-
HNSC	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-4.13	4.22e-05	0.0068	-0.21	-0.19	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
HNSC	cis	rs10791097	0.694	rs4370948	ENSG00000254842.5	RP11-890B15.2	-4.13	4.22e-05	0.0068	-0.16	-0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885805	chr11:130844191~130865561:-
HNSC	cis	rs4862750	0.872	rs9997374	ENSG00000250971.1	RP11-696F12.1	4.13	4.22e-05	0.0068	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186956395	chr4:187060099~187060930:+
HNSC	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	4.13	4.22e-05	0.0068	0.29	0.19	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
HNSC	cis	rs5758511	0.773	rs10154700	ENSG00000226450.2	CYP2D8P	4.13	4.22e-05	0.0068	0.18	0.19	Birth weight;	chr22:41969069	chr22:42149886~42155001:-
HNSC	cis	rs442309	0.841	rs224030	ENSG00000238280.1	RP11-436D10.3	-4.13	4.22e-05	0.0068	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62760375	chr10:62793562~62805887:-
HNSC	cis	rs6496044	0.507	rs1471455	ENSG00000259407.1	RP11-158M2.3	4.13	4.22e-05	0.0068	0.21	0.19	Interstitial lung disease;	chr15:85611496	chr15:85744109~85750281:-
HNSC	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	4.13	4.22e-05	0.0068	0.16	0.19	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
HNSC	cis	rs9304742	0.962	rs1808106	ENSG00000242779.5	ZNF702P	4.13	4.22e-05	0.00681	0.22	0.19	Psoriasis;	chr19:52949691	chr19:52968251~53037898:-
HNSC	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	4.13	4.22e-05	0.00681	0.25	0.19	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
HNSC	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-4.13	4.22e-05	0.00681	-0.29	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
HNSC	cis	rs4356203	0.818	rs214927	ENSG00000260196.1	RP1-239B22.5	-4.13	4.22e-05	0.00681	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17380649~17383531:+
HNSC	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-4.13	4.22e-05	0.00681	-0.24	-0.19	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
HNSC	cis	rs9313772	0.722	rs6889870	ENSG00000254350.1	RP11-542A14.1	-4.13	4.23e-05	0.00681	-0.2	-0.19	Blood pressure;	chr5:158429798	chr5:158424585~158452758:+
HNSC	cis	rs11098499	0.863	rs11947234	ENSG00000250412.1	KLHL2P1	4.13	4.23e-05	0.00681	0.24	0.19	Corneal astigmatism;	chr4:119553704	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs11933966	ENSG00000250412.1	KLHL2P1	4.13	4.23e-05	0.00681	0.24	0.19	Corneal astigmatism;	chr4:119555560	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs36040693	ENSG00000250412.1	KLHL2P1	4.13	4.23e-05	0.00681	0.24	0.19	Corneal astigmatism;	chr4:119556461	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs1552092	ENSG00000250412.1	KLHL2P1	4.13	4.23e-05	0.00681	0.24	0.19	Corneal astigmatism;	chr4:119567341	chr4:119334329~119378233:+
HNSC	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-4.13	4.23e-05	0.00681	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
HNSC	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-4.13	4.23e-05	0.00681	-0.24	-0.19	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-4.13	4.23e-05	0.00681	-0.24	-0.19	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
HNSC	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	4.13	4.23e-05	0.00681	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
HNSC	cis	rs62246343	0.605	rs17746498	ENSG00000206573.7	THUMPD3-AS1	-4.13	4.23e-05	0.00681	-0.17	-0.19	Fibrinogen levels;	chr3:9411976	chr3:9349689~9398579:-
HNSC	cis	rs4256159	1	rs11929091	ENSG00000228956.7	SATB1-AS1	4.13	4.23e-05	0.00681	0.33	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18780072	chr3:18445024~18920401:+
HNSC	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	4.13	4.23e-05	0.00681	0.25	0.19	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
HNSC	cis	rs116095464	0.558	rs9687621	ENSG00000250848.1	CTD-2083E4.5	-4.13	4.23e-05	0.00681	-0.26	-0.19	Breast cancer;	chr5:229079	chr5:288833~290321:-
HNSC	cis	rs11098499	0.863	rs10030660	ENSG00000250412.1	KLHL2P1	4.13	4.23e-05	0.00681	0.24	0.19	Corneal astigmatism;	chr4:119515549	chr4:119334329~119378233:+
HNSC	cis	rs2657294	0.62	rs9783273	ENSG00000233313.2	HMGA1P5	-4.13	4.23e-05	0.00681	-0.2	-0.19	Pneumonia;	chr10:75081982	chr10:75276376~75276646:-
HNSC	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	4.13	4.24e-05	0.00682	0.19	0.19	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
HNSC	cis	rs7178375	0.607	rs12903674	ENSG00000259845.1	HERC2P10	4.13	4.24e-05	0.00682	0.33	0.19	Hypertriglyceridemia;	chr15:30902349	chr15:30815271~30844153:+
HNSC	cis	rs2919009	0.607	rs41287984	ENSG00000271670.1	RP11-95I16.4	4.13	4.24e-05	0.00682	0.24	0.19	Obesity-related traits;	chr10:120852958	chr10:120879256~120880667:-
HNSC	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	4.13	4.24e-05	0.00683	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	4.13	4.24e-05	0.00683	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	4.13	4.24e-05	0.00683	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
HNSC	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-4.13	4.24e-05	0.00683	-0.29	-0.19	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
HNSC	cis	rs72843166	0.562	rs72841389	ENSG00000265282.1	RP11-269G24.4	4.13	4.24e-05	0.00683	0.28	0.19	Intelligence (multi-trait analysis);	chr17:63360578	chr17:63430468~63432211:-
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000250412.1	KLHL2P1	4.13	4.24e-05	0.00683	0.24	0.19	Corneal astigmatism;	chr4:119333147	chr4:119334329~119378233:+
HNSC	cis	rs8067545	0.532	rs4925074	ENSG00000261033.1	RP11-209D14.2	-4.13	4.24e-05	0.00683	-0.22	-0.19	Schizophrenia;	chr17:20059241	chr17:20008051~20009234:-
HNSC	cis	rs7178909	0.902	rs8038480	ENSG00000259677.1	RP11-493E3.1	4.13	4.24e-05	0.00683	0.21	0.19	Common traits (Other);	chr15:89898365	chr15:89876540~89877285:+
HNSC	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	4.13	4.24e-05	0.00683	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	4.13	4.24e-05	0.00683	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
HNSC	cis	rs10761256	0.621	rs2398869	ENSG00000227603.1	RP11-165J3.6	-4.13	4.24e-05	0.00683	-0.19	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr9:93720870	chr9:93435332~93437121:-
HNSC	cis	rs7688540	0.771	rs61792114	ENSG00000211553.1	AC253576.2	-4.13	4.24e-05	0.00683	-0.28	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:136461~136568:+
HNSC	cis	rs853679	1	rs853679	ENSG00000219891.2	ZSCAN12P1	4.13	4.25e-05	0.00684	0.29	0.19	Depression;	chr6:28329086	chr6:28091154~28093664:+
HNSC	cis	rs853679	1	rs853678	ENSG00000219891.2	ZSCAN12P1	4.13	4.25e-05	0.00684	0.29	0.19	Depression;	chr6:28329536	chr6:28091154~28093664:+
HNSC	cis	rs4660261	0.526	rs2485997	ENSG00000237950.1	RP11-7O11.3	4.13	4.25e-05	0.00684	0.21	0.19	Intelligence (multi-trait analysis);	chr1:43880169	chr1:43944370~43946551:-
HNSC	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	4.13	4.25e-05	0.00684	0.22	0.19	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
HNSC	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-4.13	4.25e-05	0.00684	-0.19	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
HNSC	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.13	4.25e-05	0.00684	0.29	0.19	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
HNSC	cis	rs17507216	0.667	rs72753916	ENSG00000255769.6	GOLGA2P10	-4.13	4.25e-05	0.00684	-0.28	-0.19	Excessive daytime sleepiness;	chr15:82684001	chr15:82472993~82513950:-
HNSC	cis	rs5752326	1	rs5761529	ENSG00000261188.1	CTA-445C9.14	4.13	4.25e-05	0.00685	0.3	0.19	Ischemic stroke;	chr22:26447742	chr22:26512537~26514568:+
HNSC	cis	rs5752326	1	rs5752326	ENSG00000261188.1	CTA-445C9.14	4.13	4.25e-05	0.00685	0.3	0.19	Ischemic stroke;	chr22:26448024	chr22:26512537~26514568:+
HNSC	cis	rs5752326	1	rs722997	ENSG00000261188.1	CTA-445C9.14	4.13	4.25e-05	0.00685	0.3	0.19	Ischemic stroke;	chr22:26453700	chr22:26512537~26514568:+
HNSC	cis	rs5752326	0.867	rs1894705	ENSG00000261188.1	CTA-445C9.14	4.13	4.25e-05	0.00685	0.3	0.19	Ischemic stroke;	chr22:26458014	chr22:26512537~26514568:+
HNSC	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-4.13	4.25e-05	0.00685	-0.22	-0.19	Height;	chr14:75189865	chr14:75011269~75012851:-
HNSC	cis	rs11992162	0.636	rs4841645	ENSG00000227888.4	FAM66A	-4.13	4.25e-05	0.00685	-0.19	-0.19	Monocyte count;	chr8:11941175	chr8:12362019~12388296:+
HNSC	cis	rs1218582	0.688	rs2135219	ENSG00000270361.1	RP11-307C12.13	-4.13	4.25e-05	0.00685	-0.21	-0.19	Prostate cancer;	chr1:154884741	chr1:154937370~154938059:+
HNSC	cis	rs988913	0.957	rs932452	ENSG00000224984.1	RP11-524H19.2	4.13	4.25e-05	0.00685	0.21	0.19	Menarche (age at onset);	chr6:54937130	chr6:54840118~54840855:-
HNSC	cis	rs9329221	0.505	rs7840347	ENSG00000269918.1	AF131215.9	-4.13	4.26e-05	0.00685	-0.19	-0.19	Neuroticism;	chr8:10214840	chr8:11104691~11106704:-
HNSC	cis	rs35740288	0.651	rs34257708	ENSG00000259407.1	RP11-158M2.3	-4.13	4.26e-05	0.00685	-0.3	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85641036	chr15:85744109~85750281:-
HNSC	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-4.13	4.26e-05	0.00686	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
HNSC	cis	rs4713118	0.629	rs203887	ENSG00000219891.2	ZSCAN12P1	4.13	4.26e-05	0.00686	0.28	0.19	Parkinson's disease;	chr6:28053491	chr6:28091154~28093664:+
HNSC	cis	rs7829975	0.684	rs474892	ENSG00000254153.1	CTA-398F10.2	-4.13	4.26e-05	0.00686	-0.21	-0.19	Mood instability;	chr8:8739221	chr8:8456909~8461337:-
HNSC	cis	rs4660214	0.666	rs11205839	ENSG00000182109.6	RP11-69E11.4	-4.13	4.26e-05	0.00686	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39522280~39546187:-
HNSC	cis	rs10129255	0.518	rs12590732	ENSG00000224373.3	IGHV4-59	-4.13	4.26e-05	0.00686	-0.11	-0.19	Kawasaki disease;	chr14:106779612	chr14:106627249~106627825:-
HNSC	cis	rs16873450	0.527	rs7807397	ENSG00000234800.2	PCMTD1P3	-4.13	4.27e-05	0.00686	-0.18	-0.19	Verbal memory performance (residualized delayed recall level);	chr7:23758366	chr7:23721311~23721782:-
HNSC	cis	rs16873450	0.506	rs4566942	ENSG00000234800.2	PCMTD1P3	-4.13	4.27e-05	0.00686	-0.18	-0.19	Verbal memory performance (residualized delayed recall level);	chr7:23759488	chr7:23721311~23721782:-
HNSC	cis	rs12745968	0.589	rs7540564	ENSG00000223787.2	RP4-593M8.1	-4.13	4.27e-05	0.00687	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92492269	chr1:92580476~92580821:-
HNSC	cis	rs9650657	0.645	rs4841407	ENSG00000255310.2	AF131215.2	-4.13	4.27e-05	0.00687	-0.18	-0.19	Neuroticism;	chr8:10658675	chr8:11107788~11109726:-
HNSC	cis	rs1499614	1	rs1267817	ENSG00000106610.13	STAG3L4	-4.13	4.27e-05	0.00687	-0.38	-0.19	Gout;	chr7:66645053	chr7:67302621~67321526:+
HNSC	cis	rs17666538	0.585	rs1703927	ENSG00000254207.1	RP11-43A14.1	-4.13	4.27e-05	0.00687	-0.38	-0.19	IgG glycosylation;	chr8:663620	chr8:725188~725877:-
HNSC	cis	rs9650657	0.812	rs4240669	ENSG00000269918.1	AF131215.9	-4.13	4.27e-05	0.00687	-0.19	-0.19	Neuroticism;	chr8:10772477	chr8:11104691~11106704:-
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000233609.3	RP11-62H7.2	-4.13	4.27e-05	0.00687	-0.19	-0.19	Recombination measurement;	chr8:9212778	chr8:8961200~8979025:+
HNSC	cis	rs6500395	0.926	rs8057164	ENSG00000261267.1	RP11-44I10.3	-4.13	4.27e-05	0.00687	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48529555	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.888	rs8057165	ENSG00000261267.1	RP11-44I10.3	-4.13	4.27e-05	0.00687	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48529556	chr16:48559661~48587403:+
HNSC	cis	rs35306767	0.668	rs72760914	ENSG00000229869.1	RP11-363N22.2	-4.13	4.27e-05	0.00687	-0.26	-0.19	Eosinophil percentage of granulocytes;	chr10:1025012	chr10:933026~942743:+
HNSC	cis	rs728616	0.867	rs57257258	ENSG00000225484.5	NUTM2B-AS1	-4.13	4.27e-05	0.00687	-0.38	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79663088~79826594:-
HNSC	cis	rs919433	0.519	rs700656	ENSG00000231621.1	AC013264.2	-4.13	4.27e-05	0.00687	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197788943	chr2:197197991~197199273:+
HNSC	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-4.13	4.27e-05	0.00687	-0.18	-0.19	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
HNSC	cis	rs12188164	1	rs72717412	ENSG00000215246.5	RP11-43F13.3	-4.13	4.27e-05	0.00688	-0.21	-0.19	Cystic fibrosis severity;	chr5:429266	chr5:987180~997308:-
HNSC	cis	rs7829975	0.871	rs777709	ENSG00000233609.3	RP11-62H7.2	-4.13	4.27e-05	0.00688	-0.18	-0.19	Mood instability;	chr8:8726362	chr8:8961200~8979025:+
HNSC	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-4.13	4.27e-05	0.00688	-0.29	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000250412.1	KLHL2P1	4.13	4.28e-05	0.00688	0.24	0.19	Corneal astigmatism;	chr4:119637453	chr4:119334329~119378233:+
HNSC	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-4.13	4.28e-05	0.00688	-0.18	-0.19	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
HNSC	cis	rs9298506	1	rs10087526	ENSG00000254142.2	RP11-53M11.3	4.13	4.28e-05	0.00688	0.28	0.19	Intracranial aneurysm;	chr8:54520591	chr8:54554361~54561927:+
HNSC	cis	rs9298506	1	rs10112582	ENSG00000254142.2	RP11-53M11.3	4.13	4.28e-05	0.00688	0.28	0.19	Intracranial aneurysm;	chr8:54520592	chr8:54554361~54561927:+
HNSC	cis	rs6460942	0.597	rs13221702	ENSG00000226690.5	AC005281.1	-4.13	4.28e-05	0.00688	-0.3	-0.19	Coronary artery disease;	chr7:12479450	chr7:12496429~12541910:+
HNSC	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-4.13	4.28e-05	0.00689	-0.21	-0.19	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
HNSC	cis	rs17761864	1	rs1555569	ENSG00000262333.1	HNRNPA1P16	-4.13	4.28e-05	0.00689	-0.17	-0.19	Esophageal cancer (squamous cell);	chr17:2246131	chr17:2306761~2307715:+
HNSC	cis	rs394563	0.601	rs382720	ENSG00000231760.4	RP11-350J20.5	-4.13	4.29e-05	0.00689	-0.25	-0.19	Dupuytren's disease;	chr6:149474125	chr6:149796151~149826294:-
HNSC	cis	rs67311347	1	rs11715214	ENSG00000280739.1	EIF1B-AS1	4.13	4.29e-05	0.00689	0.21	0.19	Renal cell carcinoma;	chr3:40361513	chr3:40173145~40309698:-
HNSC	cis	rs17818399	0.547	rs13020299	ENSG00000279254.1	RP11-536C12.1	-4.13	4.29e-05	0.00689	-0.22	-0.19	Height;	chr2:46531578	chr2:46668870~46670778:+
HNSC	cis	rs8010715	0.771	rs2277481	ENSG00000259321.1	RP11-468E2.5	4.13	4.29e-05	0.00689	0.16	0.19	IgG glycosylation;	chr14:24118336	chr14:24139445~24140444:+
HNSC	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	4.13	4.29e-05	0.00689	0.23	0.19	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
HNSC	cis	rs988913	0.793	rs995851	ENSG00000224984.1	RP11-524H19.2	4.13	4.29e-05	0.0069	0.22	0.19	Menarche (age at onset);	chr6:54870796	chr6:54840118~54840855:-
HNSC	cis	rs2274273	0.712	rs1002054	ENSG00000233924.1	AL160471.6	-4.13	4.29e-05	0.0069	-0.21	-0.19	Protein biomarker;	chr14:55062195	chr14:55004813~55005687:-
HNSC	cis	rs10462794	0.738	rs1816421	ENSG00000260763.1	RP11-445O3.3	4.13	4.29e-05	0.0069	0.23	0.19	DNA methylation (variation);	chr5:4478759	chr5:4436850~4440259:-
HNSC	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-4.13	4.29e-05	0.0069	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
HNSC	cis	rs1602565	0.858	rs617346	ENSG00000255450.1	CTD-2063L20.1	-4.13	4.29e-05	0.00691	-0.29	-0.19	Schizophrenia;	chr11:29160912	chr11:29275655~29276565:+
HNSC	cis	rs11098499	0.865	rs28634456	ENSG00000250412.1	KLHL2P1	4.13	4.3e-05	0.00691	0.24	0.19	Corneal astigmatism;	chr4:119454623	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs78332141	ENSG00000250412.1	KLHL2P1	4.13	4.3e-05	0.00691	0.24	0.19	Corneal astigmatism;	chr4:119454627	chr4:119334329~119378233:+
HNSC	cis	rs6964587	0.692	rs2299233	ENSG00000188693.7	CYP51A1-AS1	4.13	4.3e-05	0.00691	0.2	0.19	Breast cancer;	chr7:91997639	chr7:92134604~92180725:+
HNSC	cis	rs7552167	0.925	rs4489498	ENSG00000230023.2	RP11-10N16.2	-4.13	4.3e-05	0.00691	-0.29	-0.19	Psoriasis vulgaris;	chr1:24185565	chr1:24200240~24211693:+
HNSC	cis	rs964611	0.882	rs11854679	ENSG00000259488.2	RP11-154J22.1	-4.13	4.3e-05	0.00691	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48265376	chr15:48312353~48331856:-
HNSC	cis	rs2645424	0.762	rs2294139	ENSG00000255046.1	RP11-297N6.4	4.13	4.3e-05	0.00691	0.21	0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr8:11797928~11802568:-
HNSC	cis	rs12893668	0.703	rs4906335	ENSG00000269940.1	RP11-73M18.7	4.13	4.3e-05	0.00691	0.19	0.19	Reticulocyte count;	chr14:103554804	chr14:103694560~103695170:+
HNSC	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	4.13	4.3e-05	0.00691	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
HNSC	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-4.13	4.3e-05	0.00692	-0.18	-0.19	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-4.13	4.3e-05	0.00692	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
HNSC	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-4.13	4.31e-05	0.00692	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-4.13	4.31e-05	0.00692	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-4.13	4.31e-05	0.00692	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-4.13	4.31e-05	0.00692	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
HNSC	cis	rs7927592	0.956	rs12281742	ENSG00000255031.4	RP11-802E16.3	-4.13	4.31e-05	0.00692	-0.16	-0.19	Total body bone mineral density;	chr11:68536161	chr11:68050740~68053762:+
HNSC	cis	rs1387259	0.723	rs2732488	ENSG00000257763.1	OR5BK1P	4.13	4.31e-05	0.00692	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48355792~48356614:-
HNSC	cis	rs7735319	0.932	rs1479644	ENSG00000251281.1	CTD-2066L21.2	4.13	4.31e-05	0.00692	0.22	0.19	Systolic blood pressure;	chr5:33170717	chr5:33011322~33017607:-
HNSC	cis	rs11098499	0.863	rs13149407	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00692	0.24	0.19	Corneal astigmatism;	chr4:119516670	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs34868248	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00692	0.24	0.19	Corneal astigmatism;	chr4:119521275	chr4:119334329~119378233:+
HNSC	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-4.13	4.31e-05	0.00692	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000224373.3	IGHV4-59	4.13	4.31e-05	0.00692	0.11	0.19	Kawasaki disease;	chr14:106783414	chr14:106627249~106627825:-
HNSC	cis	rs2835345	0.563	rs73204246	ENSG00000230479.1	AP000695.6	4.13	4.31e-05	0.00692	0.2	0.19	Pulmonary function;	chr21:36452402	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs73204248	ENSG00000230479.1	AP000695.6	4.13	4.31e-05	0.00692	0.2	0.19	Pulmonary function;	chr21:36452411	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs4481073	ENSG00000230479.1	AP000695.6	4.13	4.31e-05	0.00692	0.2	0.19	Pulmonary function;	chr21:36452657	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.563	rs2835361	ENSG00000230479.1	AP000695.6	4.13	4.31e-05	0.00692	0.2	0.19	Pulmonary function;	chr21:36452699	chr21:36430360~36481070:+
HNSC	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-4.13	4.31e-05	0.00692	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
HNSC	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	4.13	4.31e-05	0.00693	0.26	0.19	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
HNSC	cis	rs73198271	0.855	rs57301822	ENSG00000254340.1	RP11-10A14.3	-4.13	4.31e-05	0.00693	-0.27	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:9141424~9145435:+
HNSC	cis	rs35963943	0.625	rs13093487	ENSG00000228956.7	SATB1-AS1	4.13	4.31e-05	0.00693	0.22	0.19	Lymphocyte counts;	chr3:18709029	chr3:18445024~18920401:+
HNSC	cis	rs3736485	0.966	rs8042221	ENSG00000259438.1	CTD-2650P22.1	4.13	4.31e-05	0.00693	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51482416	chr15:52010999~52019095:-
HNSC	cis	rs12745968	0.623	rs1886684	ENSG00000223787.2	RP4-593M8.1	-4.13	4.31e-05	0.00693	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92510381	chr1:92580476~92580821:-
HNSC	cis	rs11098499	0.863	rs7664986	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119508797	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.818	rs10008791	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119510314	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs11736416	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119510506	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775845	ENSG00000250412.1	KLHL2P1	4.13	4.31e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119511292	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.644	rs34835603	ENSG00000250412.1	KLHL2P1	4.13	4.32e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119632273	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.615	rs28850368	ENSG00000250412.1	KLHL2P1	4.13	4.32e-05	0.00693	0.24	0.19	Corneal astigmatism;	chr4:119633158	chr4:119334329~119378233:+
HNSC	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-4.13	4.32e-05	0.00693	-0.22	-0.19	Height;	chr14:75193177	chr14:75011269~75012851:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66093177	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs462853	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66093180	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs160644	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66093199	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs160642	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66093386	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66100154	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000229886.1	RP5-1132H15.3	4.13	4.32e-05	0.00693	0.31	0.19	Diabetic kidney disease;	chr7:66100518	chr7:66025126~66031544:-
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000211976.2	IGHV3-73	-4.13	4.32e-05	0.00694	-0.14	-0.19	Kawasaki disease;	chr14:106778866	chr14:106802694~106803233:-
HNSC	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	4.13	4.32e-05	0.00694	0.24	0.19	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
HNSC	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-4.13	4.32e-05	0.00694	-0.23	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
HNSC	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	4.13	4.32e-05	0.00694	0.2	0.19	QT interval;	chr12:29272168	chr12:29280418~29317848:-
HNSC	cis	rs6163	0.588	rs12763284	ENSG00000213061.2	PFN1P11	-4.13	4.32e-05	0.00694	-0.23	-0.19	Waist circumference;Hip circumference;	chr10:102748445	chr10:102838011~102845473:-
HNSC	cis	rs73201462	1	rs61044849	ENSG00000231305.3	RP11-723O4.2	-4.13	4.32e-05	0.00694	-0.27	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346623	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs57735707	ENSG00000231305.3	RP11-723O4.2	-4.13	4.32e-05	0.00694	-0.27	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346972	chr3:128861313~128871540:-
HNSC	cis	rs9487051	0.872	rs1521908	ENSG00000219700.1	PTCHD3P3	4.13	4.32e-05	0.00694	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109292783	chr6:109288571~109290503:-
HNSC	cis	rs7246657	0.524	rs10411251	ENSG00000276846.1	CTD-3220F14.3	4.13	4.32e-05	0.00694	0.26	0.19	Coronary artery calcification;	chr19:36937853	chr19:37314868~37315620:-
HNSC	cis	rs4713118	0.615	rs57252182	ENSG00000219392.1	RP1-265C24.5	-4.13	4.32e-05	0.00694	-0.22	-0.19	Parkinson's disease;	chr6:27752470	chr6:28115628~28116551:+
HNSC	cis	rs34034915	1	rs34034915	ENSG00000219392.1	RP1-265C24.5	-4.13	4.32e-05	0.00694	-0.22	-0.19	Hepatitis A;	chr6:27752924	chr6:28115628~28116551:+
HNSC	cis	rs4713118	0.527	rs36042294	ENSG00000219392.1	RP1-265C24.5	-4.13	4.32e-05	0.00694	-0.22	-0.19	Parkinson's disease;	chr6:27752933	chr6:28115628~28116551:+
HNSC	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	4.13	4.32e-05	0.00694	0.24	0.19	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
HNSC	cis	rs853679	0.517	rs1904841	ENSG00000219891.2	ZSCAN12P1	4.13	4.33e-05	0.00695	0.26	0.19	Depression;	chr6:28140307	chr6:28091154~28093664:+
HNSC	cis	rs757081	0.648	rs214923	ENSG00000260196.1	RP1-239B22.5	-4.13	4.33e-05	0.00695	-0.2	-0.19	Systolic blood pressure;	chr11:17215533	chr11:17380649~17383531:+
HNSC	cis	rs17345786	0.906	rs59359251	ENSG00000244119.1	PDCL3P4	4.13	4.33e-05	0.00695	0.21	0.19	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101712472~101713191:+
HNSC	cis	rs9329221	0.527	rs10903328	ENSG00000255310.2	AF131215.2	4.13	4.33e-05	0.00695	0.19	0.19	Neuroticism;	chr8:10474657	chr8:11107788~11109726:-
HNSC	cis	rs11148252	0.595	rs4885325	ENSG00000198384.8	TPTE2P3	4.13	4.33e-05	0.00695	0.23	0.19	Lewy body disease;	chr13:52597182	chr13:52522632~52586906:+
HNSC	cis	rs3015469	0.671	rs2883951	ENSG00000269906.1	RP11-248J18.2	4.13	4.33e-05	0.00695	0.25	0.19	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50687775	chr14:50662511~50663178:-
HNSC	cis	rs7615952	0.546	rs2979340	ENSG00000248787.1	RP11-666A20.4	-4.13	4.33e-05	0.00695	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125622540	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.546	rs2979338	ENSG00000248787.1	RP11-666A20.4	-4.13	4.33e-05	0.00695	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125624282	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.546	rs2922171	ENSG00000248787.1	RP11-666A20.4	-4.13	4.33e-05	0.00695	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125624349	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.546	rs112919177	ENSG00000248787.1	RP11-666A20.4	-4.13	4.33e-05	0.00695	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125627226	chr3:125908005~125910272:-
HNSC	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.505	rs75122014	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119441271	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	4.13	4.33e-05	0.00695	0.24	0.19	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
HNSC	cis	rs7824557	0.603	rs2736278	ENSG00000269918.1	AF131215.9	4.13	4.33e-05	0.00695	0.18	0.19	Retinal vascular caliber;	chr8:11362272	chr8:11104691~11106704:-
HNSC	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	4.13	4.33e-05	0.00695	0.21	0.19	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
HNSC	cis	rs853679	0.546	rs35353359	ENSG00000204709.4	LINC01556	4.13	4.33e-05	0.00695	0.39	0.19	Depression;	chr6:28356601	chr6:28943877~28944537:+
HNSC	cis	rs3768716	0.583	rs6712055	ENSG00000229267.2	AC072062.1	-4.13	4.33e-05	0.00695	-0.23	-0.19	Neuroblastoma;	chr2:214802180	chr2:214810229~214963274:+
HNSC	cis	rs1056107	0.933	rs6477912	ENSG00000225513.1	RP11-165N19.2	-4.13	4.33e-05	0.00695	-0.2	-0.19	Colorectal cancer;	chr9:112308937	chr9:112173522~112173971:-
HNSC	cis	rs9611565	0.649	rs202657	ENSG00000235513.1	RP4-756G23.5	-4.13	4.33e-05	0.00696	-0.23	-0.19	Vitiligo;	chr22:41448782	chr22:41209122~41217627:-
HNSC	cis	rs6921919	0.562	rs13198809	ENSG00000204709.4	LINC01556	4.13	4.33e-05	0.00696	0.39	0.19	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28943877~28944537:+
HNSC	cis	rs72843506	0.722	rs9897161	ENSG00000261033.1	RP11-209D14.2	4.13	4.33e-05	0.00696	0.33	0.19	Schizophrenia;	chr17:20130957	chr17:20008051~20009234:-
HNSC	cis	rs72843506	0.722	rs9897168	ENSG00000261033.1	RP11-209D14.2	4.13	4.33e-05	0.00696	0.33	0.19	Schizophrenia;	chr17:20130961	chr17:20008051~20009234:-
HNSC	cis	rs2292864	0.681	rs35735886	ENSG00000228782.6	CTD-2026D20.3	-4.13	4.34e-05	0.00696	-0.3	-0.19	Left atrial antero-posterior diameter;	chr17:47296911	chr17:47450568~47492492:-
HNSC	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	4.13	4.34e-05	0.00696	0.16	0.19	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
HNSC	cis	rs9859260	0.744	rs539816	ENSG00000242086.7	LINC00969	-4.13	4.34e-05	0.00696	-0.15	-0.19	Mean corpuscular volume;	chr3:196057205	chr3:195658062~195739964:+
HNSC	cis	rs9859260	0.744	rs492349	ENSG00000242086.7	LINC00969	-4.13	4.34e-05	0.00696	-0.15	-0.19	Mean corpuscular volume;	chr3:196057321	chr3:195658062~195739964:+
HNSC	cis	rs9859260	0.744	rs492288	ENSG00000242086.7	LINC00969	-4.13	4.34e-05	0.00696	-0.15	-0.19	Mean corpuscular volume;	chr3:196057339	chr3:195658062~195739964:+
HNSC	cis	rs1665050	0.545	rs59540276	ENSG00000277144.1	RP11-59H7.4	-4.13	4.34e-05	0.00696	-0.24	-0.19	Atopic dermatitis;	chr15:59037559	chr15:59115547~59116089:-
HNSC	cis	rs35306767	0.903	rs11813210	ENSG00000229869.1	RP11-363N22.2	-4.13	4.34e-05	0.00696	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:873856	chr10:933026~942743:+
HNSC	cis	rs427691	0.625	rs845740	ENSG00000271849.1	CTC-332L22.1	-4.13	4.34e-05	0.00696	-0.3	-0.19	Autism spectrum disorder or schizophrenia;	chr5:109683201	chr5:109687802~109688329:-
HNSC	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.13	4.34e-05	0.00696	-0.28	-0.19	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
HNSC	cis	rs2243480	1	rs1638734	ENSG00000229886.1	RP5-1132H15.3	4.13	4.34e-05	0.00696	0.32	0.19	Diabetic kidney disease;	chr7:66632552	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs1267818	ENSG00000229886.1	RP5-1132H15.3	4.13	4.34e-05	0.00696	0.32	0.19	Gout;	chr7:66642037	chr7:66025126~66031544:-
HNSC	cis	rs9450351	0.744	rs9450299	ENSG00000203875.9	SNHG5	-4.13	4.34e-05	0.00696	-0.44	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85562103	chr6:85660950~85678736:-
HNSC	cis	rs9450351	0.744	rs6930543	ENSG00000203875.9	SNHG5	-4.13	4.34e-05	0.00696	-0.44	-0.19	Interferon gamma-induced protein 10 levels;	chr6:85562658	chr6:85660950~85678736:-
HNSC	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-4.13	4.34e-05	0.00696	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
HNSC	cis	rs4713118	0.513	rs149897	ENSG00000219891.2	ZSCAN12P1	4.13	4.34e-05	0.00696	0.25	0.19	Parkinson's disease;	chr6:28038872	chr6:28091154~28093664:+
HNSC	cis	rs2333194	0.875	rs10220356	ENSG00000258695.2	RP3-414A15.2	4.13	4.34e-05	0.00697	0.19	0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73342768	chr14:73522878~73530610:+
HNSC	cis	rs929354	0.772	rs2023975	ENSG00000224629.1	RP5-1142J19.2	-4.13	4.34e-05	0.00697	-0.19	-0.19	Body mass index;	chr7:157219402	chr7:157263022~157263229:-
HNSC	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	4.13	4.34e-05	0.00697	0.22	0.19	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	4.13	4.34e-05	0.00697	0.22	0.19	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
HNSC	cis	rs7937890	0.967	rs963212	ENSG00000251991.1	RNU7-49P	-4.13	4.34e-05	0.00697	-0.2	-0.19	Mitochondrial DNA levels;	chr11:14303186	chr11:14478892~14478953:+
HNSC	cis	rs1329650	1	rs4933206	ENSG00000228701.1	TNKS2-AS1	-4.13	4.34e-05	0.00697	-0.24	-0.19	Smoking behavior;	chr10:91578843	chr10:91782839~91798291:-
HNSC	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	4.13	4.35e-05	0.00697	0.24	0.19	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
HNSC	cis	rs9487051	0.872	rs9386793	ENSG00000219700.1	PTCHD3P3	4.13	4.35e-05	0.00697	0.18	0.19	Reticulocyte fraction of red cells;	chr6:109288799	chr6:109288571~109290503:-
HNSC	cis	rs11638815	0.626	rs1367841	ENSG00000259429.4	UBE2Q2P2	4.13	4.35e-05	0.00697	0.18	0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:82355142~82420075:+
HNSC	cis	rs4908768	0.501	rs6577492	ENSG00000232912.4	RP5-1115A15.1	4.13	4.35e-05	0.00698	0.19	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8424645~8434838:+
HNSC	cis	rs2408955	0.515	rs10875742	ENSG00000257763.1	OR5BK1P	-4.13	4.35e-05	0.00698	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48099591	chr12:48355792~48356614:-
HNSC	cis	rs6095360	0.727	rs755588	ENSG00000222365.1	SNORD12B	-4.13	4.35e-05	0.00698	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49104491	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs13040292	ENSG00000222365.1	SNORD12B	-4.13	4.35e-05	0.00698	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49105045	chr20:49280319~49280409:+
HNSC	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-4.13	4.35e-05	0.00698	-0.24	-0.19	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
HNSC	cis	rs6604026	0.883	rs7514280	ENSG00000223787.2	RP4-593M8.1	4.13	4.35e-05	0.00698	0.25	0.19	Multiple sclerosis;	chr1:92855312	chr1:92580476~92580821:-
HNSC	cis	rs2835345	0.563	rs60511692	ENSG00000230479.1	AP000695.6	4.13	4.35e-05	0.00698	0.2	0.19	Pulmonary function;	chr21:36454091	chr21:36430360~36481070:+
HNSC	cis	rs9400271	0.632	rs9374070	ENSG00000243587.6	C6orf183	-4.13	4.35e-05	0.00698	-0.19	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109265252	chr6:109165833~109271014:+
HNSC	cis	rs46522	0.585	rs79049364	ENSG00000270781.1	RP11-501C14.9	-4.13	4.36e-05	0.00698	-0.2	-0.19	Coronary heart disease;	chr17:48937629	chr17:48899131~48899748:+
HNSC	cis	rs79349575	0.811	rs80032154	ENSG00000270781.1	RP11-501C14.9	-4.13	4.36e-05	0.00698	-0.2	-0.19	Type 2 diabetes;	chr17:48937630	chr17:48899131~48899748:+
HNSC	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-4.13	4.36e-05	0.00698	-0.18	-0.19	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-4.13	4.36e-05	0.00698	-0.18	-0.19	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-4.13	4.36e-05	0.00698	-0.18	-0.19	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
HNSC	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-4.13	4.36e-05	0.00698	-0.14	-0.19	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
HNSC	cis	rs7224668	0.647	rs2292184	ENSG00000280407.2	RP13-516M14.8	4.13	4.36e-05	0.00699	0.15	0.19	IgG glycosylation;	chr17:81271002	chr17:82249067~82251844:+
HNSC	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	4.13	4.36e-05	0.00699	0.24	0.19	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
HNSC	cis	rs13256369	1	rs4841016	ENSG00000173295.6	FAM86B3P	4.13	4.36e-05	0.00699	0.24	0.19	Obesity-related traits;	chr8:8715051	chr8:8228595~8244865:+
HNSC	cis	rs6095360	1	rs34984028	ENSG00000222365.1	SNORD12B	-4.13	4.36e-05	0.00699	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48932510	chr20:49280319~49280409:+
HNSC	cis	rs2732480	0.538	rs1387260	ENSG00000257763.1	OR5BK1P	4.13	4.36e-05	0.00699	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48355792~48356614:-
HNSC	cis	rs17818399	0.716	rs62134741	ENSG00000279254.1	RP11-536C12.1	-4.13	4.36e-05	0.00699	-0.23	-0.19	Height;	chr2:46555050	chr2:46668870~46670778:+
HNSC	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	4.13	4.36e-05	0.00699	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
HNSC	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	4.13	4.36e-05	0.00699	0.19	0.19	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
HNSC	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	4.13	4.36e-05	0.00699	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
HNSC	cis	rs7162943	0.887	rs293366	ENSG00000260123.1	RP11-326A19.4	4.13	4.37e-05	0.007	0.21	0.19	Mean platelet volume;	chr15:89072556	chr15:89041223~89082819:+
HNSC	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	4.13	4.37e-05	0.007	0.21	0.19	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
HNSC	cis	rs9313772	0.722	rs10037337	ENSG00000254350.1	RP11-542A14.1	4.13	4.37e-05	0.007	0.2	0.19	Blood pressure;	chr5:158435384	chr5:158424585~158452758:+
HNSC	cis	rs7615952	0.546	rs4428131	ENSG00000248787.1	RP11-666A20.4	-4.13	4.37e-05	0.007	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125627635	chr3:125908005~125910272:-
HNSC	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	4.13	4.37e-05	0.007	0.22	0.19	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
HNSC	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	-4.13	4.37e-05	0.00701	-0.3	-0.19	Depression;	chr6:28119105	chr6:28161781~28169594:+
HNSC	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-4.13	4.37e-05	0.00701	-0.24	-0.19	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
HNSC	cis	rs11673344	0.504	rs11666786	ENSG00000276846.1	CTD-3220F14.3	4.13	4.37e-05	0.00701	0.2	0.19	Obesity-related traits;	chr19:37133947	chr19:37314868~37315620:-
HNSC	cis	rs1008375	1	rs10939746	ENSG00000249502.1	AC006160.5	4.13	4.37e-05	0.00701	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683328	chr4:17587467~17614571:-
HNSC	cis	rs7005380	0.581	rs2017310	ENSG00000279347.1	RP11-85I17.2	4.13	4.37e-05	0.00701	0.17	0.19	Interstitial lung disease;	chr8:119921101	chr8:119838736~119840385:-
HNSC	cis	rs11250098	0.583	rs66724331	ENSG00000269918.1	AF131215.9	-4.13	4.37e-05	0.00701	-0.18	-0.19	Morning vs. evening chronotype;	chr8:10931835	chr8:11104691~11106704:-
HNSC	cis	rs9531006	0.752	rs11840648	ENSG00000227676.3	LINC01068	4.13	4.38e-05	0.00701	0.26	0.19	Sleep duration;	chr13:79981687	chr13:79566727~79571436:+
HNSC	cis	rs442309	0.875	rs224068	ENSG00000238280.1	RP11-436D10.3	-4.13	4.38e-05	0.00701	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62748340	chr10:62793562~62805887:-
HNSC	cis	rs4523957	0.89	rs2281727	ENSG00000262333.1	HNRNPA1P16	4.13	4.38e-05	0.00702	0.15	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2214651	chr17:2306761~2307715:+
HNSC	cis	rs7829975	0.84	rs555617	ENSG00000233609.3	RP11-62H7.2	-4.13	4.38e-05	0.00702	-0.18	-0.19	Mood instability;	chr8:8735335	chr8:8961200~8979025:+
HNSC	cis	rs2239557	0.508	rs1974582	ENSG00000259065.1	RP5-1021I20.1	-4.13	4.38e-05	0.00702	-0.27	-0.19	Common traits (Other);	chr14:73900601	chr14:73787360~73803270:+
HNSC	cis	rs853679	0.599	rs156743	ENSG00000204709.4	LINC01556	4.13	4.38e-05	0.00702	0.33	0.19	Depression;	chr6:27999311	chr6:28943877~28944537:+
HNSC	cis	rs67981189	0.593	rs2810109	ENSG00000274818.1	RP1-292L20.3	-4.13	4.38e-05	0.00702	-0.21	-0.19	Schizophrenia;	chr14:70953175	chr14:70906657~70907111:-
HNSC	cis	rs853679	1	rs853676	ENSG00000204709.4	LINC01556	4.13	4.38e-05	0.00702	0.29	0.19	Depression;	chr6:28331910	chr6:28943877~28944537:+
HNSC	cis	rs73198271	0.71	rs3827808	ENSG00000173295.6	FAM86B3P	-4.13	4.38e-05	0.00702	-0.23	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8228595~8244865:+
HNSC	cis	rs17507216	0.588	rs4778687	ENSG00000276710.3	CSPG4P8	-4.13	4.38e-05	0.00702	-0.26	-0.19	Excessive daytime sleepiness;	chr15:82649085	chr15:82459472~82477258:+
HNSC	cis	rs6095360	0.727	rs13040426	ENSG00000222365.1	SNORD12B	-4.13	4.39e-05	0.00703	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49097916	chr20:49280319~49280409:+
HNSC	cis	rs1528149	0.78	rs28422957	ENSG00000224683.1	RPL36AP29	4.13	4.39e-05	0.00703	0.21	0.19	Sitting height ratio;	chr7:16059895	chr7:16208945~16209265:+
HNSC	cis	rs9982086	0.793	rs77803127	ENSG00000260583.1	AP000223.42	-4.13	4.39e-05	0.00703	-0.43	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25620286	chr21:25582770~25583326:-
HNSC	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	4.13	4.39e-05	0.00703	0.21	0.19	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
HNSC	cis	rs3096299	0.809	rs2911264	ENSG00000261118.1	RP11-104N10.1	4.13	4.39e-05	0.00703	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89492017~89504460:-
HNSC	cis	rs4388249	1	rs12656748	ENSG00000271849.1	CTC-332L22.1	-4.13	4.39e-05	0.00703	-0.31	-0.19	Schizophrenia;	chr5:109707528	chr5:109687802~109688329:-
HNSC	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-4.12	4.39e-05	0.00703	-0.24	-0.19	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
HNSC	cis	rs6988985	0.791	rs13276226	ENSG00000247317.3	RP11-273G15.2	4.12	4.39e-05	0.00703	0.21	0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142917246	chr8:142981738~143018437:-
HNSC	cis	rs2732480	0.5	rs11168464	ENSG00000257763.1	OR5BK1P	4.12	4.39e-05	0.00703	0.18	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48355792~48356614:-
HNSC	cis	rs4356203	0.87	rs214926	ENSG00000260196.1	RP1-239B22.5	-4.12	4.39e-05	0.00704	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17380649~17383531:+
HNSC	cis	rs9650657	0.812	rs6601522	ENSG00000269918.1	AF131215.9	-4.12	4.39e-05	0.00704	-0.19	-0.19	Neuroticism;	chr8:10771551	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.509	rs6962213	ENSG00000226816.2	AC005082.12	4.12	4.39e-05	0.00704	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23206013~23208045:+
HNSC	cis	rs9896933	0.775	rs615630	ENSG00000262663.1	RP11-497H17.1	-4.12	4.4e-05	0.00704	-0.25	-0.19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82772651	chr17:82918282~82918785:+
HNSC	cis	rs9313772	0.722	rs4613687	ENSG00000254350.1	RP11-542A14.1	-4.12	4.4e-05	0.00704	-0.2	-0.19	Blood pressure;	chr5:158436306	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs4473757	ENSG00000254350.1	RP11-542A14.1	-4.12	4.4e-05	0.00704	-0.2	-0.19	Blood pressure;	chr5:158436577	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs4466144	ENSG00000254350.1	RP11-542A14.1	-4.12	4.4e-05	0.00704	-0.2	-0.19	Blood pressure;	chr5:158437119	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs2901007	ENSG00000254350.1	RP11-542A14.1	-4.12	4.4e-05	0.00704	-0.2	-0.19	Blood pressure;	chr5:158437326	chr5:158424585~158452758:+
HNSC	cis	rs988913	0.706	rs13208701	ENSG00000224984.1	RP11-524H19.2	4.12	4.4e-05	0.00704	0.22	0.19	Menarche (age at onset);	chr6:55015670	chr6:54840118~54840855:-
HNSC	cis	rs8067545	0.641	rs203455	ENSG00000266126.1	RP11-209D14.4	4.12	4.4e-05	0.00704	0.21	0.19	Schizophrenia;	chr17:19917872	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.641	rs203481	ENSG00000266126.1	RP11-209D14.4	4.12	4.4e-05	0.00704	0.21	0.19	Schizophrenia;	chr17:19925415	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.641	rs203479	ENSG00000266126.1	RP11-209D14.4	4.12	4.4e-05	0.00704	0.21	0.19	Schizophrenia;	chr17:19925998	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.641	rs850623	ENSG00000266126.1	RP11-209D14.4	4.12	4.4e-05	0.00704	0.21	0.19	Schizophrenia;	chr17:19933817	chr17:19929372~19929737:-
HNSC	cis	rs1665050	0.895	rs8028752	ENSG00000277144.1	RP11-59H7.4	-4.12	4.4e-05	0.00705	-0.26	-0.19	Atopic dermatitis;	chr15:59003803	chr15:59115547~59116089:-
HNSC	cis	rs4356203	0.543	rs214081	ENSG00000260196.1	RP1-239B22.5	-4.12	4.4e-05	0.00705	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17380649~17383531:+
HNSC	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	4.12	4.4e-05	0.00705	0.24	0.19	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
HNSC	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-4.12	4.4e-05	0.00705	-0.23	-0.19	Height;	chr20:49283420	chr20:49280319~49280409:+
HNSC	cis	rs7824557	0.527	rs2736305	ENSG00000255310.2	AF131215.2	-4.12	4.41e-05	0.00705	-0.18	-0.19	Retinal vascular caliber;	chr8:11380264	chr8:11107788~11109726:-
HNSC	cis	rs60617249	0.895	rs11526296	ENSG00000228204.2	RP4-724E13.2	4.12	4.41e-05	0.00705	0.2	0.19	Major depression and alcohol dependence;	chr7:50933107	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.862	rs61471556	ENSG00000228204.2	RP4-724E13.2	4.12	4.41e-05	0.00705	0.2	0.19	Major depression and alcohol dependence;	chr7:50936046	chr7:50866747~51022990:+
HNSC	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-4.12	4.41e-05	0.00706	-0.22	-0.19	Height;	chr14:75122121	chr14:75011269~75012851:-
HNSC	cis	rs6095360	0.903	rs1022688	ENSG00000222365.1	SNORD12B	-4.12	4.41e-05	0.00706	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49032319	chr20:49280319~49280409:+
HNSC	cis	rs889398	0.967	rs244417	ENSG00000226232.7	RP11-419C5.2	4.12	4.41e-05	0.00706	0.17	0.19	Body mass index;	chr16:69629616	chr16:69976388~69996188:-
HNSC	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4.12	4.41e-05	0.00706	-0.28	-0.19	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000250412.1	KLHL2P1	4.12	4.41e-05	0.00706	0.24	0.19	Corneal astigmatism;	chr4:119333200	chr4:119334329~119378233:+
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000106610.13	STAG3L4	-4.12	4.41e-05	0.00706	-0.24	-0.19	Aortic root size;	chr7:66768636	chr7:67302621~67321526:+
HNSC	cis	rs4388249	1	rs13180361	ENSG00000271849.1	CTC-332L22.1	-4.12	4.41e-05	0.00706	-0.31	-0.19	Schizophrenia;	chr5:109707287	chr5:109687802~109688329:-
HNSC	cis	rs227275	0.554	rs223371	ENSG00000230069.3	LRRC37A15P	-4.12	4.41e-05	0.00706	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102727274~102730721:-
HNSC	cis	rs9880211	0.8	rs35422852	ENSG00000273486.1	RP11-731C17.2	4.12	4.41e-05	0.00706	0.18	0.19	Height;Body mass index;	chr3:136787073	chr3:136837338~136839021:-
HNSC	cis	rs9880211	0.8	rs35880395	ENSG00000273486.1	RP11-731C17.2	4.12	4.41e-05	0.00706	0.18	0.19	Height;Body mass index;	chr3:136788248	chr3:136837338~136839021:-
HNSC	cis	rs3096299	0.781	rs2965819	ENSG00000261574.1	RP1-168P16.2	-4.12	4.41e-05	0.00707	-0.23	-0.19	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89392375~89412564:-
HNSC	cis	rs11098499	0.863	rs6833334	ENSG00000250412.1	KLHL2P1	4.12	4.42e-05	0.00707	0.24	0.19	Corneal astigmatism;	chr4:119583072	chr4:119334329~119378233:+
HNSC	cis	rs1555322	1	rs2425027	ENSG00000126005.14	MMP24-AS1	-4.12	4.42e-05	0.00707	-0.35	-0.19	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35216462~35278131:-
HNSC	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-4.12	4.42e-05	0.00707	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-4.12	4.42e-05	0.00707	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
HNSC	cis	rs442309	0.875	rs382424	ENSG00000238280.1	RP11-436D10.3	-4.12	4.42e-05	0.00707	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62730014	chr10:62793562~62805887:-
HNSC	cis	rs9921222	0.597	rs7193109	ENSG00000268836.1	LA16c-OS12.2	4.12	4.42e-05	0.00707	0.19	0.19	Bone mineral density (spine);Bone mineral density;	chr16:363523	chr16:185748~186294:-
HNSC	cis	rs12745968	0.653	rs6660136	ENSG00000223787.2	RP4-593M8.1	-4.12	4.42e-05	0.00707	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92699650	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.623	rs6604007	ENSG00000223787.2	RP4-593M8.1	-4.12	4.42e-05	0.00707	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92705007	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.653	rs12123935	ENSG00000223787.2	RP4-593M8.1	-4.12	4.42e-05	0.00707	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92710257	chr1:92580476~92580821:-
HNSC	cis	rs11648785	0.661	rs870856	ENSG00000274627.1	RP11-104N10.2	4.12	4.42e-05	0.00707	0.19	0.19	Tanning;	chr16:90023055	chr16:89516797~89522217:+
HNSC	cis	rs3736485	0.899	rs6493505	ENSG00000259438.1	CTD-2650P22.1	4.12	4.42e-05	0.00707	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51552975	chr15:52010999~52019095:-
HNSC	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	4.12	4.42e-05	0.00708	0.24	0.19	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
HNSC	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	4.12	4.42e-05	0.00708	0.19	0.19	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
HNSC	cis	rs748404	0.666	rs17780417	ENSG00000166763.7	STRCP1	4.12	4.43e-05	0.00708	0.26	0.19	Lung cancer;	chr15:43347264	chr15:43699488~43718184:-
HNSC	cis	rs1387259	0.758	rs2634670	ENSG00000257763.1	OR5BK1P	4.12	4.43e-05	0.00708	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48355792~48356614:-
HNSC	cis	rs6831352	1	rs6831352	ENSG00000263923.1	RP11-571L19.7	-4.12	4.43e-05	0.00708	-0.19	-0.19	Alcohol dependence;	chr4:99142374	chr4:98928897~98994994:+
HNSC	cis	rs11633886	0.565	rs28567025	ENSG00000273972.1	CTD-2306A12.1	4.12	4.43e-05	0.00708	0.23	0.19	Diisocyanate-induced asthma;	chr15:45767239	chr15:45702640~45703183:+
HNSC	cis	rs1131351	0.62	rs11895809	ENSG00000234378.1	AC098828.2	-4.12	4.43e-05	0.00708	-0.22	-0.19	Seasonality;	chr2:20199293	chr2:20063856~20106829:-
HNSC	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	4.12	4.43e-05	0.00708	0.27	0.19	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
HNSC	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	4.12	4.43e-05	0.00708	0.27	0.19	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
HNSC	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-4.12	4.43e-05	0.00708	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
HNSC	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-4.12	4.43e-05	0.00709	-0.24	-0.19	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
HNSC	cis	rs6928289	0.81	rs11154921	ENSG00000234956.4	RP11-356I2.1	4.12	4.43e-05	0.00709	0.2	0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137327065	chr6:137730170~137738983:-
HNSC	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	4.12	4.43e-05	0.00709	0.21	0.19	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
HNSC	cis	rs1048497	1	rs1048497	ENSG00000269938.1	RP11-214K3.20	4.12	4.43e-05	0.00709	0.3	0.19	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:124014995	chr12:123968023~123968579:-
HNSC	cis	rs6430585	0.528	rs6743537	ENSG00000231890.6	DARS-AS1	-4.12	4.44e-05	0.0071	-0.31	-0.19	Corneal structure;	chr2:135945031	chr2:135985176~136022593:+
HNSC	cis	rs10510102	0.516	rs78586895	ENSG00000226864.1	ATE1-AS1	4.12	4.44e-05	0.0071	0.35	0.19	Breast cancer;	chr10:121977081	chr10:121928312~121951965:+
HNSC	cis	rs700651	0.789	rs5007118	ENSG00000231621.1	AC013264.2	-4.12	4.44e-05	0.0071	-0.18	-0.19	Intracranial aneurysm;	chr2:198045014	chr2:197197991~197199273:+
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	4.12	4.44e-05	0.0071	0.32	0.19	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	4.12	4.44e-05	0.0071	0.32	0.19	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	4.12	4.44e-05	0.0071	0.32	0.19	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
HNSC	cis	rs7751419	0.606	rs4711578	ENSG00000217165.1	ANKRD18EP	4.12	4.44e-05	0.0071	0.17	0.19	Cardiovascular disease in hypertension (calcium channel blocker interaction);	chr6:39149178	chr6:39110321~39112952:+
HNSC	cis	rs60617249	0.929	rs11973328	ENSG00000228204.2	RP4-724E13.2	4.12	4.44e-05	0.0071	0.2	0.19	Major depression and alcohol dependence;	chr7:50935596	chr7:50866747~51022990:+
HNSC	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-4.12	4.44e-05	0.0071	-0.24	-0.19	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
HNSC	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-4.12	4.44e-05	0.0071	-0.22	-0.19	Height;	chr14:75173700	chr14:75011269~75012851:-
HNSC	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	4.12	4.44e-05	0.0071	0.21	0.19	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
HNSC	cis	rs933688	1	rs60513756	ENSG00000281357.1	ARRDC3-AS1	4.12	4.44e-05	0.0071	0.28	0.19	Smoking behavior;	chr5:91431875	chr5:91380349~91439085:+
HNSC	cis	rs11773103	0.867	rs17149389	ENSG00000224046.1	AC005076.5	4.12	4.45e-05	0.00711	0.35	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87340122	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.867	rs17149393	ENSG00000224046.1	AC005076.5	4.12	4.45e-05	0.00711	0.35	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87342238	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.609	rs73194669	ENSG00000224046.1	AC005076.5	4.12	4.45e-05	0.00711	0.35	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87343113	chr7:87151423~87152420:-
HNSC	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	4.12	4.45e-05	0.00711	0.21	0.19	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
HNSC	cis	rs897984	0.646	rs9938088	ENSG00000279196.1	RP11-1072A3.3	4.12	4.45e-05	0.00711	0.21	0.19	Dementia with Lewy bodies;	chr16:30818683	chr16:30984630~30988270:-
HNSC	cis	rs12745968	0.589	rs7530780	ENSG00000223787.2	RP4-593M8.1	-4.12	4.45e-05	0.00711	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92664711	chr1:92580476~92580821:-
HNSC	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	4.12	4.45e-05	0.00711	0.29	0.19	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
HNSC	cis	rs11673344	0.523	rs2891766	ENSG00000276846.1	CTD-3220F14.3	4.12	4.45e-05	0.00711	0.2	0.19	Obesity-related traits;	chr19:37037057	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.523	rs7245453	ENSG00000276846.1	CTD-3220F14.3	4.12	4.45e-05	0.00711	0.2	0.19	Obesity-related traits;	chr19:37043447	chr19:37314868~37315620:-
HNSC	cis	rs9650657	0.707	rs1115867	ENSG00000269918.1	AF131215.9	-4.12	4.45e-05	0.00711	-0.19	-0.19	Neuroticism;	chr8:10781240	chr8:11104691~11106704:-
HNSC	cis	rs964611	0.882	rs7162774	ENSG00000259488.2	RP11-154J22.1	4.12	4.45e-05	0.00711	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48367336	chr15:48312353~48331856:-
HNSC	cis	rs4930561	0.739	rs10896303	ENSG00000184795.9	UNC93B5	-4.12	4.45e-05	0.00711	-0.21	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr11:67711702~67716005:-
HNSC	cis	rs4930561	0.739	rs12225316	ENSG00000184795.9	UNC93B5	-4.12	4.45e-05	0.00711	-0.21	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr11:67711702~67716005:-
HNSC	cis	rs2760061	0.583	rs708123	ENSG00000270110.1	RP5-1139B12.4	-4.12	4.45e-05	0.00711	-0.2	-0.19	Diastolic blood pressure;	chr1:228032794	chr1:228295911~228302998:-
HNSC	cis	rs7985	1	rs3752603	ENSG00000244625.4	MIATNB	4.12	4.45e-05	0.00712	0.22	0.19	Electroencephalogram traits;	chr22:26668531	chr22:26672767~26780207:+
HNSC	cis	rs7985	1	rs7985	ENSG00000244625.4	MIATNB	4.12	4.45e-05	0.00712	0.22	0.19	Electroencephalogram traits;	chr22:26670572	chr22:26672767~26780207:+
HNSC	cis	rs7985	0.967	rs73163299	ENSG00000244625.4	MIATNB	4.12	4.45e-05	0.00712	0.22	0.19	Electroencephalogram traits;	chr22:26671680	chr22:26672767~26780207:+
HNSC	cis	rs7824557	0.591	rs2060457	ENSG00000269918.1	AF131215.9	4.12	4.45e-05	0.00712	0.18	0.19	Retinal vascular caliber;	chr8:11355741	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.614	rs2060456	ENSG00000269918.1	AF131215.9	4.12	4.45e-05	0.00712	0.18	0.19	Retinal vascular caliber;	chr8:11355854	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.614	rs5029571	ENSG00000269918.1	AF131215.9	4.12	4.45e-05	0.00712	0.18	0.19	Retinal vascular caliber;	chr8:11355880	chr8:11104691~11106704:-
HNSC	cis	rs13434995	0.513	rs2412658	ENSG00000273257.1	RP11-177J6.1	4.12	4.45e-05	0.00712	0.25	0.19	Adiponectin levels;	chr4:55577050	chr4:55387949~55388271:+
HNSC	cis	rs12745968	0.589	rs4484938	ENSG00000223787.2	RP4-593M8.1	-4.12	4.45e-05	0.00712	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92490264	chr1:92580476~92580821:-
HNSC	cis	rs3806843	0.576	rs246002	ENSG00000276545.1	PCDHGB9P	4.12	4.45e-05	0.00712	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140961519	chr5:141439853~141442449:+
HNSC	cis	rs227275	0.554	rs223381	ENSG00000230069.3	LRRC37A15P	-4.12	4.45e-05	0.00712	-0.19	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-4.12	4.45e-05	0.00712	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-4.12	4.45e-05	0.00712	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
HNSC	cis	rs74781061	0.932	rs11629749	ENSG00000260103.2	RP11-10O17.1	-4.12	4.45e-05	0.00712	-0.21	-0.19	Endometriosis;	chr15:74627252	chr15:74478070~74490286:-
HNSC	cis	rs9650657	0.769	rs1115866	ENSG00000269918.1	AF131215.9	-4.12	4.45e-05	0.00712	-0.19	-0.19	Neuroticism;	chr8:10780823	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs7005469	ENSG00000255310.2	AF131215.2	4.12	4.45e-05	0.00712	0.17	0.19	Retinal vascular caliber;	chr8:11336948	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.628	rs6988922	ENSG00000255310.2	AF131215.2	4.12	4.45e-05	0.00712	0.17	0.19	Retinal vascular caliber;	chr8:11337402	chr8:11107788~11109726:-
HNSC	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-4.12	4.46e-05	0.00712	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-4.12	4.46e-05	0.00712	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
HNSC	cis	rs853679	1	rs1936365	ENSG00000219891.2	ZSCAN12P1	-4.12	4.46e-05	0.00712	-0.29	-0.19	Depression;	chr6:28300675	chr6:28091154~28093664:+
HNSC	cis	rs6095360	0.625	rs2426132	ENSG00000227431.4	CSE1L-AS1	-4.12	4.46e-05	0.00712	-0.21	-0.19	Intelligence (multi-trait analysis);	chr20:49106590	chr20:49040463~49046044:-
HNSC	cis	rs2243480	1	rs937108	ENSG00000229886.1	RP5-1132H15.3	4.12	4.46e-05	0.00712	0.32	0.19	Diabetic kidney disease;	chr7:65963465	chr7:66025126~66031544:-
HNSC	cis	rs11976180	1	rs1919951	ENSG00000244479.5	OR2A1-AS1	4.12	4.46e-05	0.00712	0.22	0.19	Obesity-related traits;	chr7:144071798	chr7:144251264~144356181:-
HNSC	cis	rs6095360	0.689	rs7274851	ENSG00000222365.1	SNORD12B	-4.12	4.46e-05	0.00712	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49177818	chr20:49280319~49280409:+
HNSC	cis	rs8014204	0.604	rs12147862	ENSG00000279594.1	RP11-950C14.10	-4.12	4.46e-05	0.00712	-0.23	-0.19	Caffeine consumption;	chr14:74917768	chr14:75011269~75012851:-
HNSC	cis	rs72843166	0.617	rs17760362	ENSG00000265282.1	RP11-269G24.4	4.12	4.46e-05	0.00713	0.28	0.19	Intelligence (multi-trait analysis);	chr17:63341306	chr17:63430468~63432211:-
HNSC	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	4.12	4.46e-05	0.00713	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
HNSC	cis	rs13256369	1	rs873064	ENSG00000173295.6	FAM86B3P	4.12	4.46e-05	0.00713	0.24	0.19	Obesity-related traits;	chr8:8714870	chr8:8228595~8244865:+
HNSC	cis	rs13256369	1	rs873063	ENSG00000173295.6	FAM86B3P	4.12	4.46e-05	0.00713	0.24	0.19	Obesity-related traits;	chr8:8714937	chr8:8228595~8244865:+
HNSC	cis	rs8072100	0.837	rs62074055	ENSG00000263293.2	RP11-290H9.4	4.12	4.46e-05	0.00713	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47303460~47323613:-
HNSC	cis	rs8077577	0.671	rs12450760	ENSG00000273018.4	CTD-2303H24.2	-4.12	4.46e-05	0.00713	-0.26	-0.19	Obesity-related traits;	chr17:18350508	chr17:18511221~18551705:-
HNSC	cis	rs638893	1	rs73005500	ENSG00000255422.1	AP002954.4	4.12	4.46e-05	0.00713	0.33	0.19	Vitiligo;	chr11:118826666	chr11:118704607~118750263:+
HNSC	cis	rs240993	0.761	rs462832	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.46e-05	0.00713	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111365088	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs459147	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.46e-05	0.00713	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111370285	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs455650	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.46e-05	0.00713	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111370320	chr6:111277932~111278742:+
HNSC	cis	rs1602565	0.858	rs600628	ENSG00000255450.1	CTD-2063L20.1	-4.12	4.46e-05	0.00713	-0.29	-0.19	Schizophrenia;	chr11:29166333	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs661878	ENSG00000255450.1	CTD-2063L20.1	-4.12	4.46e-05	0.00713	-0.29	-0.19	Schizophrenia;	chr11:29167144	chr11:29275655~29276565:+
HNSC	cis	rs73607972	0.935	rs7186069	ENSG00000275191.1	RP11-36I17.2	-4.12	4.46e-05	0.00713	-0.28	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563693	chr16:53628256~53628816:-
HNSC	cis	rs73607972	0.935	rs7193194	ENSG00000275191.1	RP11-36I17.2	-4.12	4.46e-05	0.00713	-0.28	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563802	chr16:53628256~53628816:-
HNSC	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-4.12	4.46e-05	0.00713	-0.23	-0.19	Height;	chr20:49286304	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-4.12	4.46e-05	0.00713	-0.23	-0.19	Height;	chr20:49295502	chr20:49280319~49280409:+
HNSC	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-4.12	4.47e-05	0.00713	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
HNSC	cis	rs1387259	0.759	rs7960122	ENSG00000257763.1	OR5BK1P	-4.12	4.47e-05	0.00714	-0.2	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48355792~48356614:-
HNSC	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	4.12	4.47e-05	0.00714	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
HNSC	cis	rs12745968	0.56	rs1325434	ENSG00000223787.2	RP4-593M8.1	-4.12	4.47e-05	0.00714	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr1:92495775	chr1:92580476~92580821:-
HNSC	cis	rs4763879	0.778	rs2895989	ENSG00000278635.1	CTD-2318O12.1	4.12	4.47e-05	0.00714	0.14	0.19	Type 1 diabetes;	chr12:9688735	chr12:9415641~9416718:+
HNSC	cis	rs5758511	0.541	rs6002494	ENSG00000235513.1	RP4-756G23.5	4.12	4.47e-05	0.00714	0.2	0.19	Birth weight;	chr22:41803856	chr22:41209122~41217627:-
HNSC	cis	rs2243480	1	rs4718317	ENSG00000229886.1	RP5-1132H15.3	-4.12	4.47e-05	0.00714	-0.31	-0.19	Diabetic kidney disease;	chr7:66183914	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00714	0.32	0.19	Diabetic kidney disease;	chr7:65956884	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35542501	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00714	0.32	0.19	Diabetic kidney disease;	chr7:65966228	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00714	0.32	0.19	Diabetic kidney disease;	chr7:65973566	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs781142	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00714	0.32	0.19	Diabetic kidney disease;	chr7:65973791	chr7:66025126~66031544:-
HNSC	cis	rs9952991	0.883	rs2847293	ENSG00000260302.1	RP11-973H7.1	-4.12	4.47e-05	0.00714	-0.31	-0.19	Inflammatory skin disease;	chr18:12782449	chr18:12774651~12775923:-
HNSC	cis	rs7789940	0.817	rs6946310	ENSG00000231087.2	FDPSP7	-4.12	4.47e-05	0.00714	-0.22	-0.19	Multiple sclerosis;	chr7:76306782	chr7:76968197~76969250:-
HNSC	cis	rs7937890	1	rs2970334	ENSG00000251991.1	RNU7-49P	-4.12	4.48e-05	0.00715	-0.2	-0.19	Mitochondrial DNA levels;	chr11:14307809	chr11:14478892~14478953:+
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	4.12	4.48e-05	0.00715	0.23	0.19	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
HNSC	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-4.12	4.48e-05	0.00715	-0.2	-0.19	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
HNSC	cis	rs889398	0.802	rs12921407	ENSG00000226232.7	RP11-419C5.2	4.12	4.48e-05	0.00715	0.17	0.19	Body mass index;	chr16:69827030	chr16:69976388~69996188:-
HNSC	cis	rs12935418	0.616	rs9921448	ENSG00000261061.1	RP11-303E16.2	-4.12	4.48e-05	0.00715	-0.2	-0.19	Mean corpuscular volume;	chr16:80975593	chr16:81030770~81031485:+
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000224373.3	IGHV4-59	4.12	4.48e-05	0.00716	0.12	0.19	Kawasaki disease;	chr14:106785589	chr14:106627249~106627825:-
HNSC	cis	rs11673344	0.542	rs826328	ENSG00000267698.1	AC002116.7	4.12	4.48e-05	0.00716	0.16	0.19	Obesity-related traits;	chr19:37004479	chr19:36014508~36045972:+
HNSC	cis	rs7296418	0.699	rs11608297	ENSG00000280120.1	RP11-546D6.3	4.12	4.49e-05	0.00716	0.16	0.19	Platelet count;	chr12:123342095	chr12:123152324~123153377:-
HNSC	cis	rs748404	0.666	rs12911569	ENSG00000166763.7	STRCP1	4.12	4.49e-05	0.00716	0.27	0.19	Lung cancer;	chr15:43305099	chr15:43699488~43718184:-
HNSC	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-4.12	4.49e-05	0.00716	-0.24	-0.19	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
HNSC	cis	rs853679	1	rs9986596	ENSG00000226314.6	ZNF192P1	-4.12	4.49e-05	0.00716	-0.26	-0.19	Depression;	chr6:28251883	chr6:28161781~28169594:+
HNSC	cis	rs36052053	0.521	rs13219673	ENSG00000203799.9	CCDC162P	4.12	4.49e-05	0.00716	0.33	0.19	Red cell distribution width;	chr6:109233713	chr6:109285485~109355063:+
HNSC	cis	rs516805	0.667	rs2045352	ENSG00000279453.1	RP3-425C14.4	-4.12	4.49e-05	0.00716	-0.26	-0.19	Lymphocyte counts;	chr6:122119694	chr6:122436789~122439223:-
HNSC	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	4.12	4.49e-05	0.00717	0.23	0.19	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
HNSC	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-4.12	4.49e-05	0.00717	-0.26	-0.19	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
HNSC	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-4.12	4.49e-05	0.00717	-0.2	-0.19	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
HNSC	cis	rs2274273	0.713	rs56725788	ENSG00000233924.1	AL160471.6	-4.12	4.49e-05	0.00717	-0.21	-0.19	Protein biomarker;	chr14:55073383	chr14:55004813~55005687:-
HNSC	cis	rs2274273	0.743	rs13379159	ENSG00000233924.1	AL160471.6	-4.12	4.49e-05	0.00717	-0.21	-0.19	Protein biomarker;	chr14:55074083	chr14:55004813~55005687:-
HNSC	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.12	4.49e-05	0.00717	0.22	0.19	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
HNSC	cis	rs597539	0.616	rs10896386	ENSG00000261625.1	RP11-554A11.4	-4.12	4.49e-05	0.00717	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:69000765~69002048:-
HNSC	cis	rs12745968	0.561	rs10874726	ENSG00000223787.2	RP4-593M8.1	-4.12	4.49e-05	0.00717	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92637542	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.589	rs10782937	ENSG00000223787.2	RP4-593M8.1	-4.12	4.49e-05	0.00717	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92637644	chr1:92580476~92580821:-
HNSC	cis	rs1799949	0.55	rs2343818	ENSG00000236383.6	LINC00854	-4.12	4.5e-05	0.00718	-0.18	-0.19	Menopause (age at onset);	chr17:43332406	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.526	rs4352088	ENSG00000236383.6	LINC00854	-4.12	4.5e-05	0.00718	-0.18	-0.19	Menopause (age at onset);	chr17:43337311	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs34633610	ENSG00000236383.6	LINC00854	-4.12	4.5e-05	0.00718	-0.18	-0.19	Menopause (age at onset);	chr17:43342017	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.965	rs11654051	ENSG00000236383.6	LINC00854	-4.12	4.5e-05	0.00718	-0.18	-0.19	Menopause (age at onset);	chr17:43342288	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.93	rs56729776	ENSG00000236383.6	LINC00854	-4.12	4.5e-05	0.00718	-0.18	-0.19	Menopause (age at onset);	chr17:43344763	chr17:43216941~43305976:-
HNSC	cis	rs11673344	0.542	rs826331	ENSG00000267698.1	AC002116.7	4.12	4.5e-05	0.00718	0.16	0.19	Obesity-related traits;	chr19:37007360	chr19:36014508~36045972:+
HNSC	cis	rs9297145	0.678	rs62473007	ENSG00000272950.1	RP11-307C18.1	-4.12	4.5e-05	0.00718	-0.28	-0.19	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99151975	chr7:98322853~98323430:+
HNSC	cis	rs2834288	0.7	rs2834292	ENSG00000273102.1	AP000569.9	-4.12	4.5e-05	0.00718	-0.22	-0.19	Gut microbiota (bacterial taxa);	chr21:33901909	chr21:33967101~33968573:-
HNSC	cis	rs6710503	0.962	rs56186499	ENSG00000271936.1	RP11-443B20.1	-4.12	4.5e-05	0.00718	-0.2	-0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24741590	chr2:24825610~24826717:+
HNSC	cis	rs4763879	0.729	rs10844472	ENSG00000278635.1	CTD-2318O12.1	4.12	4.5e-05	0.00718	0.14	0.19	Type 1 diabetes;	chr12:9691137	chr12:9415641~9416718:+
HNSC	cis	rs889398	0.771	rs11075732	ENSG00000196696.11	PDXDC2P	4.12	4.5e-05	0.00718	0.13	0.19	Body mass index;	chr16:69732135	chr16:69976297~70065948:-
HNSC	cis	rs12908161	0.959	rs2175567	ENSG00000229212.6	RP11-561C5.4	-4.12	4.5e-05	0.00718	-0.27	-0.19	Schizophrenia;	chr15:84657715	chr15:85205440~85234795:-
HNSC	cis	rs6988985	0.791	rs11779229	ENSG00000247317.3	RP11-273G15.2	4.12	4.5e-05	0.00718	0.22	0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142916791	chr8:142981738~143018437:-
HNSC	cis	rs6500395	0.584	rs8059077	ENSG00000261267.1	RP11-44I10.3	-4.12	4.5e-05	0.00718	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48708118	chr16:48559661~48587403:+
HNSC	cis	rs1832007	0.671	rs3750569	ENSG00000224034.1	RP11-445P17.8	-4.12	4.5e-05	0.00718	-0.23	-0.19	Triglyceride levels;Triglycerides;	chr10:5205567	chr10:5266033~5271236:-
HNSC	cis	rs9329221	0.537	rs1351876	ENSG00000254340.1	RP11-10A14.3	-4.12	4.5e-05	0.00719	-0.22	-0.19	Neuroticism;	chr8:10127267	chr8:9141424~9145435:+
HNSC	cis	rs561341	1	rs554078	ENSG00000278867.1	RP11-640N20.4	-4.12	4.5e-05	0.00719	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:32003090	chr17:32051030~32053208:+
HNSC	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	4.12	4.51e-05	0.00719	0.23	0.19	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
HNSC	cis	rs2243480	1	rs316322	ENSG00000229886.1	RP5-1132H15.3	4.12	4.51e-05	0.00719	0.32	0.19	Diabetic kidney disease;	chr7:66146246	chr7:66025126~66031544:-
HNSC	cis	rs72843166	0.562	rs72841392	ENSG00000265282.1	RP11-269G24.4	4.12	4.51e-05	0.00719	0.28	0.19	Intelligence (multi-trait analysis);	chr17:63373705	chr17:63430468~63432211:-
HNSC	cis	rs7572733	0.935	rs4410288	ENSG00000222017.1	AC011997.1	4.12	4.51e-05	0.00719	0.22	0.19	Dermatomyositis;	chr2:197955100	chr2:197693106~197774823:+
HNSC	cis	rs8044868	0.566	rs3812984	ENSG00000259209.3	RP5-991G20.2	4.12	4.51e-05	0.00719	0.2	0.19	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72173898	chr16:72805998~72809872:+
HNSC	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-4.12	4.51e-05	0.00719	-0.15	-0.19	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
HNSC	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-4.12	4.51e-05	0.00719	-0.15	-0.19	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
HNSC	cis	rs73198271	0.74	rs10098636	ENSG00000233609.3	RP11-62H7.2	-4.12	4.51e-05	0.00719	-0.21	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8961200~8979025:+
HNSC	cis	rs28830936	0.966	rs62002090	ENSG00000250379.1	RP11-23P13.4	4.12	4.51e-05	0.00719	0.23	0.19	Diastolic blood pressure;	chr15:41800128	chr15:41825099~41827936:-
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000241278.1	ENPP7P4	-4.12	4.51e-05	0.00719	-0.31	-0.19	Blood pressure (smoking interaction);	chr3:125883870	chr3:125848223~125909372:+
HNSC	cis	rs240993	0.812	rs240955	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.52e-05	0.0072	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.761	rs453776	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.52e-05	0.0072	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111277932~111278742:+
HNSC	cis	rs6657613	0.68	rs10887990	ENSG00000186715.9	MST1L	-4.12	4.52e-05	0.0072	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17032891	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs11579925	ENSG00000186715.9	MST1L	-4.12	4.52e-05	0.0072	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17036210	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs10788650	ENSG00000186715.9	MST1L	-4.12	4.52e-05	0.0072	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17036364	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.649	rs2179793	ENSG00000186715.9	MST1L	-4.12	4.52e-05	0.0072	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17039238	chr1:16754910~16770237:-
HNSC	cis	rs9925964	0.744	rs12716979	ENSG00000232748.3	RP11-196G11.6	4.12	4.52e-05	0.0072	0.25	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:31056460~31062803:+
HNSC	cis	rs13325613	0.834	rs34423195	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46208231	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs3181080	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46208438	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34919616	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46208517	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs3181078	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46209093	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs3181076	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46209242	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.831	rs35354367	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46209308	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34280313	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46211014	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.749	rs13070099	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46211723	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34047458	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46212108	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35429781	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46212116	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13095946	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46212321	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35614049	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46213985	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs71327039	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46215805	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34531115	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46216205	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35617677	ENSG00000223552.1	RP11-24F11.2	-4.12	4.52e-05	0.0072	-0.33	-0.19	Monocyte count;	chr3:46217249	chr3:46364955~46407059:-
HNSC	cis	rs10819861	0.547	rs10760781	ENSG00000175611.10	LINC00476	4.12	4.52e-05	0.00721	0.19	0.19	Electrocardiographic traits;	chr9:96110549	chr9:95759231~95875977:-
HNSC	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-4.12	4.52e-05	0.00721	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
HNSC	cis	rs253959	0.672	rs4921056	ENSG00000271918.1	CTD-2287O16.5	4.12	4.52e-05	0.00721	0.15	0.19	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116083807~116085416:-
HNSC	cis	rs9929218	0.529	rs8060790	ENSG00000260459.2	FTLP14	4.12	4.52e-05	0.00721	0.24	0.19	Colorectal cancer;	chr16:68695209	chr16:68822587~68823070:+
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-4.12	4.52e-05	0.00721	-0.25	-0.19	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-4.12	4.52e-05	0.00721	-0.25	-0.19	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-4.12	4.52e-05	0.00721	-0.25	-0.19	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-4.12	4.52e-05	0.00721	-0.25	-0.19	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-4.12	4.52e-05	0.00721	-0.25	-0.19	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
HNSC	cis	rs739496	0.615	rs4646778	ENSG00000226469.1	ADAM1B	4.12	4.52e-05	0.00721	0.22	0.19	Platelet count;	chr12:111797979	chr12:111927018~111929017:+
HNSC	cis	rs9313772	0.748	rs2419912	ENSG00000254350.1	RP11-542A14.1	-4.12	4.52e-05	0.00721	-0.2	-0.19	Blood pressure;	chr5:158417527	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs2419913	ENSG00000254350.1	RP11-542A14.1	-4.12	4.52e-05	0.00721	-0.2	-0.19	Blood pressure;	chr5:158417548	chr5:158424585~158452758:+
HNSC	cis	rs8028182	0.636	rs4322627	ENSG00000260269.4	CTD-2323K18.1	-4.12	4.52e-05	0.00721	-0.24	-0.19	Sudden cardiac arrest;	chr15:75518318	chr15:75527150~75601205:-
HNSC	cis	rs4930561	0.677	rs7946212	ENSG00000184795.9	UNC93B5	-4.12	4.52e-05	0.00721	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214720	chr11:67711702~67716005:-
HNSC	cis	rs6500395	1	rs11076573	ENSG00000261267.1	RP11-44I10.3	-4.12	4.53e-05	0.00721	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48598847	chr16:48559661~48587403:+
HNSC	cis	rs7005380	0.58	rs11781657	ENSG00000279347.1	RP11-85I17.2	-4.12	4.53e-05	0.00721	-0.15	-0.19	Interstitial lung disease;	chr8:119877002	chr8:119838736~119840385:-
HNSC	cis	rs2486288	0.656	rs9921035	ENSG00000259479.5	SORD2P	-4.12	4.53e-05	0.00721	-0.21	-0.19	Glomerular filtration rate;	chr15:45254462	chr15:44826371~44884694:-
HNSC	cis	rs656319	0.559	rs17689289	ENSG00000255310.2	AF131215.2	4.12	4.53e-05	0.00722	0.18	0.19	Myopia (pathological);	chr8:10120470	chr8:11107788~11109726:-
HNSC	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-4.12	4.53e-05	0.00722	-0.23	-0.19	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
HNSC	cis	rs7085104	0.7	rs743572	ENSG00000213061.2	PFN1P11	4.12	4.53e-05	0.00722	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102838011~102845473:-
HNSC	cis	rs929354	0.772	rs933344	ENSG00000224629.1	RP5-1142J19.2	-4.12	4.53e-05	0.00722	-0.19	-0.19	Body mass index;	chr7:157218571	chr7:157263022~157263229:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000224373.3	IGHV4-59	4.12	4.53e-05	0.00722	0.11	0.19	Kawasaki disease;	chr14:106782288	chr14:106627249~106627825:-
HNSC	cis	rs9531006	0.719	rs34622893	ENSG00000227676.3	LINC01068	4.12	4.53e-05	0.00722	0.28	0.19	Sleep duration;	chr13:79965612	chr13:79566727~79571436:+
HNSC	cis	rs3736485	0.578	rs2305716	ENSG00000259438.1	CTD-2650P22.1	4.12	4.53e-05	0.00722	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689094	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.578	rs1456300	ENSG00000259438.1	CTD-2650P22.1	4.12	4.53e-05	0.00722	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689819	chr15:52010999~52019095:-
HNSC	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	4.12	4.53e-05	0.00722	0.28	0.19	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
HNSC	cis	rs17345786	1	rs3804775	ENSG00000244119.1	PDCL3P4	4.12	4.53e-05	0.00723	0.2	0.19	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101712472~101713191:+
HNSC	cis	rs57502260	0.79	rs7128942	ENSG00000212093.1	AP000807.1	4.12	4.53e-05	0.00723	0.26	0.19	Total body bone mineral density (age 45-60);	chr11:68620516	chr11:68506083~68506166:-
HNSC	cis	rs860818	1	rs858247	ENSG00000226816.2	AC005082.12	4.12	4.54e-05	0.00723	0.49	0.19	Initial pursuit acceleration;	chr7:23181664	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858245	ENSG00000226816.2	AC005082.12	4.12	4.54e-05	0.00723	0.49	0.19	Initial pursuit acceleration;	chr7:23183108	chr7:23206013~23208045:+
HNSC	cis	rs7027203	0.576	rs4424329	ENSG00000227603.1	RP11-165J3.6	4.12	4.54e-05	0.00723	0.17	0.19	DNA methylation (variation);	chr9:93798524	chr9:93435332~93437121:-
HNSC	cis	rs4356203	0.905	rs7396382	ENSG00000272034.1	SNORD14A	4.12	4.54e-05	0.00723	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17074654~17074744:-
HNSC	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	4.12	4.54e-05	0.00723	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	4.12	4.54e-05	0.00723	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
HNSC	cis	rs11098499	0.82	rs28535956	ENSG00000250412.1	KLHL2P1	-4.12	4.54e-05	0.00723	-0.24	-0.19	Corneal astigmatism;	chr4:119615703	chr4:119334329~119378233:+
HNSC	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-4.12	4.54e-05	0.00723	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.954	rs67265404	ENSG00000250412.1	KLHL2P1	4.12	4.54e-05	0.00723	0.24	0.19	Corneal astigmatism;	chr4:119438115	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775843	ENSG00000250412.1	KLHL2P1	4.12	4.54e-05	0.00723	0.24	0.19	Corneal astigmatism;	chr4:119506689	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775844	ENSG00000250412.1	KLHL2P1	4.12	4.54e-05	0.00723	0.24	0.19	Corneal astigmatism;	chr4:119506878	chr4:119334329~119378233:+
HNSC	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	4.12	4.54e-05	0.00723	0.19	0.19	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
HNSC	cis	rs8067545	0.641	rs203462	ENSG00000266126.1	RP11-209D14.4	4.12	4.54e-05	0.00723	0.21	0.19	Schizophrenia;	chr17:19909228	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.641	rs203460	ENSG00000266126.1	RP11-209D14.4	4.12	4.54e-05	0.00723	0.21	0.19	Schizophrenia;	chr17:19911973	chr17:19929372~19929737:-
HNSC	cis	rs6496044	0.507	rs62022863	ENSG00000259407.1	RP11-158M2.3	4.12	4.54e-05	0.00723	0.21	0.19	Interstitial lung disease;	chr15:85618822	chr15:85744109~85750281:-
HNSC	cis	rs795484	0.926	rs353893	ENSG00000275409.1	RP11-131L12.4	-4.12	4.54e-05	0.00724	-0.22	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118193960	chr12:118430147~118430699:+
HNSC	cis	rs17739794	1	rs17739794	ENSG00000254207.1	RP11-43A14.1	-4.12	4.54e-05	0.00724	-0.21	-0.19	Clozapine-induced cytotoxicity;	chr8:862946	chr8:725188~725877:-
HNSC	cis	rs7475343	0.501	rs3750568	ENSG00000224034.1	RP11-445P17.8	-4.12	4.54e-05	0.00724	-0.26	-0.19	Intelligence;	chr10:5205668	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs3750567	ENSG00000224034.1	RP11-445P17.8	-4.12	4.54e-05	0.00724	-0.26	-0.19	Intelligence;	chr10:5205671	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7921838	ENSG00000224034.1	RP11-445P17.8	-4.12	4.54e-05	0.00724	-0.26	-0.19	Intelligence;	chr10:5205738	chr10:5266033~5271236:-
HNSC	cis	rs9863	0.861	rs7958691	ENSG00000270028.1	RP11-380L11.4	4.12	4.54e-05	0.00724	0.21	0.19	White blood cell count;	chr12:123956196	chr12:123925461~123926083:-
HNSC	cis	rs9500256	0.715	rs7769674	ENSG00000225096.1	XXbac-BPG55C20.7	4.12	4.55e-05	0.00724	0.2	0.19	Eosinophilic esophagitis (pediatric);	chr6:58020586	chr6:57965630~57972218:+
HNSC	cis	rs9500256	0.669	rs7770369	ENSG00000225096.1	XXbac-BPG55C20.7	4.12	4.55e-05	0.00724	0.2	0.19	Eosinophilic esophagitis (pediatric);	chr6:58021043	chr6:57965630~57972218:+
HNSC	cis	rs210138	0.706	rs3916279	ENSG00000197251.3	LINC00336	4.12	4.55e-05	0.00724	0.21	0.19	Testicular germ cell tumor;	chr6:33607173	chr6:33586106~33593338:-
HNSC	cis	rs471144	0.881	rs12089980	ENSG00000232678.2	SPTLC1P4	-4.12	4.55e-05	0.00724	-0.32	-0.19	Inflammatory skin disease;	chr1:152459455	chr1:152077952~152078211:+
HNSC	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	4.12	4.55e-05	0.00724	0.24	0.19	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
HNSC	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-4.12	4.55e-05	0.00724	-0.22	-0.19	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
HNSC	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	4.12	4.55e-05	0.00724	0.18	0.19	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
HNSC	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-4.12	4.55e-05	0.00725	-0.23	-0.19	Height;	chr20:49282748	chr20:49280319~49280409:+
HNSC	cis	rs4356203	0.905	rs214937	ENSG00000260196.1	RP1-239B22.5	4.12	4.55e-05	0.00725	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17380649~17383531:+
HNSC	cis	rs1979679	0.879	rs55996833	ENSG00000247934.4	RP11-967K21.1	-4.12	4.55e-05	0.00725	-0.2	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28163298~28190738:-
HNSC	cis	rs2975734	0.68	rs10503406	ENSG00000269918.1	AF131215.9	-4.12	4.55e-05	0.00725	-0.2	-0.19	Chronotype;Morning vs. evening chronotype;	chr8:10251462	chr8:11104691~11106704:-
HNSC	cis	rs67981189	0.593	rs2526883	ENSG00000274818.1	RP1-292L20.3	-4.12	4.55e-05	0.00725	-0.2	-0.19	Schizophrenia;	chr14:70902858	chr14:70906657~70907111:-
HNSC	cis	rs240993	0.812	rs9487626	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.55e-05	0.00725	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.715	rs9487627	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.55e-05	0.00725	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111277932~111278742:+
HNSC	cis	rs12545109	0.8	rs2582404	ENSG00000246430.5	LINC00968	-4.12	4.55e-05	0.00725	-0.24	-0.19	Obesity-related traits;	chr8:56474809	chr8:56496246~56559823:-
HNSC	cis	rs4356203	0.905	rs651513	ENSG00000260196.1	RP1-239B22.5	-4.12	4.55e-05	0.00725	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17380649~17383531:+
HNSC	cis	rs61160187	0.51	rs4482855	ENSG00000272308.1	RP11-231G3.1	-4.12	4.56e-05	0.00725	-0.18	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60866457~60866935:-
HNSC	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	4.12	4.56e-05	0.00725	0.19	0.19	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
HNSC	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	4.12	4.56e-05	0.00725	0.19	0.19	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	4.12	4.56e-05	0.00725	0.19	0.19	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
HNSC	cis	rs57502260	0.915	rs7106320	ENSG00000212093.1	AP000807.1	4.12	4.56e-05	0.00726	0.27	0.19	Total body bone mineral density (age 45-60);	chr11:68442650	chr11:68506083~68506166:-
HNSC	cis	rs12188164	1	rs12188678	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:428116	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs12188164	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:428121	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs72717411	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:429009	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs72717414	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:429703	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs72717415	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:429944	chr5:987180~997308:-
HNSC	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.56e-05	0.00726	-0.19	-0.19	Height;	chr5:37266341	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.56e-05	0.00726	-0.19	-0.19	Height;	chr5:37275173	chr5:36666214~36725195:-
HNSC	cis	rs2292864	0.764	rs3785872	ENSG00000228782.6	CTD-2026D20.3	-4.12	4.56e-05	0.00726	-0.3	-0.19	Left atrial antero-posterior diameter;	chr17:47294709	chr17:47450568~47492492:-
HNSC	cis	rs9313772	0.928	rs12187017	ENSG00000254350.1	RP11-542A14.1	-4.12	4.56e-05	0.00726	-0.22	-0.19	Blood pressure;	chr5:158422287	chr5:158424585~158452758:+
HNSC	cis	rs9487051	0.646	rs4548045	ENSG00000243587.6	C6orf183	-4.12	4.56e-05	0.00726	-0.2	-0.19	Reticulocyte fraction of red cells;	chr6:109254932	chr6:109165833~109271014:+
HNSC	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	4.12	4.56e-05	0.00726	0.23	0.19	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
HNSC	cis	rs6693567	0.826	rs1260387	ENSG00000228126.1	FALEC	4.12	4.56e-05	0.00726	0.25	0.19	Migraine;	chr1:150398972	chr1:150515757~150518032:+
HNSC	cis	rs7107174	0.901	rs2511159	ENSG00000251323.2	RP11-452H21.4	-4.12	4.56e-05	0.00726	-0.27	-0.19	Testicular germ cell tumor;	chr11:78263147	chr11:78423982~78429836:-
HNSC	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-4.12	4.56e-05	0.00726	-0.23	-0.19	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
HNSC	cis	rs12188164	0.965	rs56182240	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:423054	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs56346498	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:423480	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs55948934	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:423556	chr5:987180~997308:-
HNSC	cis	rs12188164	0.897	rs55932239	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:423791	chr5:987180~997308:-
HNSC	cis	rs12188164	0.931	rs72717407	ENSG00000215246.5	RP11-43F13.3	-4.12	4.56e-05	0.00726	-0.21	-0.19	Cystic fibrosis severity;	chr5:424538	chr5:987180~997308:-
HNSC	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	4.12	4.56e-05	0.00727	0.32	0.19	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
HNSC	cis	rs526231	0.697	rs168820	ENSG00000250682.4	LINC00491	4.12	4.57e-05	0.00727	0.27	0.19	Primary biliary cholangitis;	chr5:103306972	chr5:102609156~102671559:-
HNSC	cis	rs3808502	0.563	rs12549150	ENSG00000269918.1	AF131215.9	4.12	4.57e-05	0.00727	0.18	0.19	Neuroticism;	chr8:11565427	chr8:11104691~11106704:-
HNSC	cis	rs62025270	0.688	rs62025272	ENSG00000259762.1	RP11-158M2.4	-4.12	4.57e-05	0.00727	-0.25	-0.19	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85750336~85752901:-
HNSC	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-4.12	4.57e-05	0.00727	-0.14	-0.19	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
HNSC	cis	rs72949976	0.934	rs10197392	ENSG00000270659.1	RP11-105N14.1	4.12	4.57e-05	0.00727	0.19	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213173454	chr2:213152970~213153659:+
HNSC	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-4.12	4.57e-05	0.00727	-0.21	-0.19	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
HNSC	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	4.12	4.57e-05	0.00727	0.16	0.19	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
HNSC	cis	rs67311347	0.544	rs9877105	ENSG00000280739.1	EIF1B-AS1	4.12	4.57e-05	0.00728	0.2	0.19	Renal cell carcinoma;	chr3:40291875	chr3:40173145~40309698:-
HNSC	cis	rs9847710	1	rs13088455	ENSG00000242142.1	SERBP1P3	-4.12	4.57e-05	0.00728	-0.21	-0.19	Ulcerative colitis;	chr3:53053466	chr3:53064283~53065091:-
HNSC	cis	rs9847710	1	rs4687697	ENSG00000242142.1	SERBP1P3	-4.12	4.57e-05	0.00728	-0.21	-0.19	Ulcerative colitis;	chr3:53056474	chr3:53064283~53065091:-
HNSC	cis	rs6688613	1	rs6656999	ENSG00000215834.7	FMO9P	4.12	4.57e-05	0.00728	0.23	0.19	Refractive astigmatism;	chr1:166987570	chr1:166603675~166631400:+
HNSC	cis	rs10504130	0.932	rs16916856	ENSG00000272024.1	RP11-546K22.3	-4.12	4.57e-05	0.00728	-0.33	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51826590	chr8:51950284~51950690:+
HNSC	cis	rs9531006	0.636	rs12323035	ENSG00000227676.3	LINC01068	4.12	4.57e-05	0.00728	0.27	0.19	Sleep duration;	chr13:79902481	chr13:79566727~79571436:+
HNSC	cis	rs2055729	0.645	rs12056944	ENSG00000254340.1	RP11-10A14.3	4.12	4.57e-05	0.00728	0.27	0.19	Multiple myeloma (hyperdiploidy);	chr8:9885015	chr8:9141424~9145435:+
HNSC	cis	rs11098499	0.863	rs3822190	ENSG00000250412.1	KLHL2P1	4.12	4.58e-05	0.00728	0.24	0.19	Corneal astigmatism;	chr4:119506943	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3822191	ENSG00000250412.1	KLHL2P1	4.12	4.58e-05	0.00728	0.24	0.19	Corneal astigmatism;	chr4:119506946	chr4:119334329~119378233:+
HNSC	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-4.12	4.58e-05	0.00728	-0.23	-0.19	Height;	chr20:49310154	chr20:49280319~49280409:+
HNSC	cis	rs9313772	1	rs9313772	ENSG00000254350.1	RP11-542A14.1	-4.11	4.58e-05	0.00728	-0.22	-0.19	Blood pressure;	chr5:158377449	chr5:158424585~158452758:+
HNSC	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-4.11	4.58e-05	0.00729	-0.25	-0.19	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
HNSC	cis	rs9921338	0.961	rs4780357	ENSG00000263080.1	RP11-485G7.5	4.11	4.58e-05	0.00729	0.21	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11341809~11345211:-
HNSC	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	4.11	4.58e-05	0.00729	0.21	0.19	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
HNSC	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	4.11	4.58e-05	0.00729	0.32	0.19	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
HNSC	cis	rs7169223	0.653	rs1976007	ENSG00000261762.1	RP11-650L12.2	-4.11	4.58e-05	0.00729	-0.25	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792681	chr15:78589123~78591276:-
HNSC	cis	rs36052053	0.908	rs13203020	ENSG00000203799.9	CCDC162P	4.11	4.58e-05	0.00729	0.28	0.19	Red cell distribution width;	chr6:109263442	chr6:109285485~109355063:+
HNSC	cis	rs8077577	0.945	rs11655731	ENSG00000273018.4	CTD-2303H24.2	-4.11	4.58e-05	0.0073	-0.29	-0.19	Obesity-related traits;	chr17:18204211	chr17:18511221~18551705:-
HNSC	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-4.11	4.59e-05	0.0073	-0.18	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
HNSC	cis	rs6163	0.588	rs10786706	ENSG00000236937.2	PTGES3P4	4.11	4.59e-05	0.0073	0.22	0.19	Waist circumference;Hip circumference;	chr10:102740902	chr10:102845595~102845950:+
HNSC	cis	rs35000415	0.688	rs17340542	ENSG00000275106.1	RP11-309L24.10	4.11	4.59e-05	0.0073	0.38	0.19	Systemic lupus erythematosus;	chr7:129079991	chr7:128952527~128953316:-
HNSC	cis	rs9990343	0.783	rs4683205	ENSG00000223552.1	RP11-24F11.2	4.11	4.59e-05	0.0073	0.16	0.19	Brain structure;	chr3:46293179	chr3:46364955~46407059:-
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	4.11	4.59e-05	0.0073	0.21	0.19	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
HNSC	cis	rs9329221	0.657	rs17694485	ENSG00000269918.1	AF131215.9	4.11	4.59e-05	0.0073	0.19	0.19	Neuroticism;	chr8:10256948	chr8:11104691~11106704:-
HNSC	cis	rs2070074	1	rs2070074	ENSG00000230074.1	RP11-195F19.9	-4.11	4.59e-05	0.0073	-0.34	-0.19	CTACK levels;	chr9:34649445	chr9:34665665~34681298:+
HNSC	cis	rs72843166	0.589	rs72841385	ENSG00000265282.1	RP11-269G24.4	4.11	4.59e-05	0.0073	0.28	0.19	Intelligence (multi-trait analysis);	chr17:63349519	chr17:63430468~63432211:-
HNSC	cis	rs700651	0.789	rs1976772	ENSG00000231621.1	AC013264.2	-4.11	4.59e-05	0.00731	-0.18	-0.19	Intracranial aneurysm;	chr2:198003477	chr2:197197991~197199273:+
HNSC	cis	rs614226	0.935	rs17431717	ENSG00000202538.1	RNU4-2	4.11	4.59e-05	0.00731	0.31	0.19	Type 1 diabetes nephropathy;	chr12:120474407	chr12:120291763~120291903:-
HNSC	cis	rs4356203	0.875	rs214935	ENSG00000260196.1	RP1-239B22.5	-4.11	4.59e-05	0.00731	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17380649~17383531:+
HNSC	cis	rs4256159	0.696	rs11711478	ENSG00000228956.7	SATB1-AS1	4.11	4.59e-05	0.00731	0.28	0.19	Crohn's disease;Inflammatory bowel disease;	chr3:18722209	chr3:18445024~18920401:+
HNSC	cis	rs4356203	0.905	rs7938820	ENSG00000260196.1	RP1-239B22.5	4.11	4.59e-05	0.00731	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17380649~17383531:+
HNSC	cis	rs62025270	0.632	rs3169119	ENSG00000259762.1	RP11-158M2.4	-4.11	4.59e-05	0.00731	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85750336~85752901:-
HNSC	cis	rs9584850	0.789	rs7988345	ENSG00000231194.1	FARP1-AS1	4.11	4.59e-05	0.00731	0.23	0.19	Neuroticism;	chr13:98465431	chr13:98435405~98435840:-
HNSC	cis	rs7520050	0.966	rs10890361	ENSG00000280836.1	AL355480.1	4.11	4.6e-05	0.00731	0.2	0.19	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45581219~45581321:-
HNSC	cis	rs10504130	1	rs16916820	ENSG00000272024.1	RP11-546K22.3	-4.11	4.6e-05	0.00731	-0.33	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51800156	chr8:51950284~51950690:+
HNSC	cis	rs2835345	0.563	rs73204244	ENSG00000230479.1	AP000695.6	4.11	4.6e-05	0.00731	0.2	0.19	Pulmonary function;	chr21:36452373	chr21:36430360~36481070:+
HNSC	cis	rs4253772	0.591	rs6008365	ENSG00000277232.2	GTSE1-AS1	-4.11	4.6e-05	0.00731	-0.23	-0.19	Cholesterol, total;LDL cholesterol;	chr22:46257032	chr22:46295143~46296660:-
HNSC	cis	rs9611565	0.729	rs73176686	ENSG00000235513.1	RP4-756G23.5	4.11	4.6e-05	0.00731	0.23	0.19	Vitiligo;	chr22:41386115	chr22:41209122~41217627:-
HNSC	cis	rs10504130	0.569	rs9650305	ENSG00000253844.1	RP11-546K22.1	-4.11	4.6e-05	0.00732	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs9650180	ENSG00000253844.1	RP11-546K22.1	-4.11	4.6e-05	0.00732	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51961458~52022974:+
HNSC	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	4.11	4.6e-05	0.00732	0.25	0.19	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	4.11	4.6e-05	0.00732	0.25	0.19	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	4.11	4.6e-05	0.00732	0.25	0.19	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	4.11	4.6e-05	0.00732	0.25	0.19	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
HNSC	cis	rs35306767	0.903	rs11253458	ENSG00000229869.1	RP11-363N22.2	-4.11	4.6e-05	0.00732	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:836903	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs13377166	ENSG00000229869.1	RP11-363N22.2	-4.11	4.6e-05	0.00732	-0.28	-0.19	Eosinophil percentage of granulocytes;	chr10:840319	chr10:933026~942743:+
HNSC	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	4.11	4.6e-05	0.00732	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
HNSC	cis	rs12545912	0.569	rs616021	ENSG00000254340.1	RP11-10A14.3	-4.11	4.61e-05	0.00732	-0.3	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9938864	chr8:9141424~9145435:+
HNSC	cis	rs4356203	0.905	rs511119	ENSG00000260196.1	RP1-239B22.5	-4.11	4.61e-05	0.00732	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214901	ENSG00000260196.1	RP1-239B22.5	4.11	4.61e-05	0.00733	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17380649~17383531:+
HNSC	cis	rs7246657	0.551	rs10419174	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.29	0.19	Coronary artery calcification;	chr19:37114439	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.509	rs10426093	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.29	0.19	Coronary artery calcification;	chr19:37124727	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.551	rs4806413	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.29	0.19	Coronary artery calcification;	chr19:37126814	chr19:37314868~37315620:-
HNSC	cis	rs6831352	0.819	rs13832	ENSG00000263923.1	RP11-571L19.7	-4.11	4.61e-05	0.00733	-0.19	-0.19	Alcohol dependence;	chr4:99071924	chr4:98928897~98994994:+
HNSC	cis	rs67311347	1	rs9860162	ENSG00000280739.1	EIF1B-AS1	4.11	4.61e-05	0.00733	0.21	0.19	Renal cell carcinoma;	chr3:40362384	chr3:40173145~40309698:-
HNSC	cis	rs6095360	1	rs6019600	ENSG00000222365.1	SNORD12B	-4.11	4.61e-05	0.00733	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49030395	chr20:49280319~49280409:+
HNSC	cis	rs9847710	1	rs12488768	ENSG00000242142.1	SERBP1P3	-4.11	4.61e-05	0.00733	-0.21	-0.19	Ulcerative colitis;	chr3:53052218	chr3:53064283~53065091:-
HNSC	cis	rs11976180	1	rs2961120	ENSG00000244479.5	OR2A1-AS1	4.11	4.61e-05	0.00733	0.21	0.19	Obesity-related traits;	chr7:144059492	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2951360	ENSG00000244479.5	OR2A1-AS1	4.11	4.61e-05	0.00733	0.21	0.19	Obesity-related traits;	chr7:144060256	chr7:144251264~144356181:-
HNSC	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-4.11	4.61e-05	0.00733	-0.18	-0.19	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
HNSC	cis	rs28489187	0.667	rs233114	ENSG00000223653.4	RP11-131L23.1	4.11	4.61e-05	0.00733	0.26	0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321274	chr1:85276715~85448124:+
HNSC	cis	rs10504130	0.569	rs34372756	ENSG00000253844.1	RP11-546K22.1	-4.11	4.61e-05	0.00733	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51961458~52022974:+
HNSC	cis	rs9302065	1	rs7490267	ENSG00000223298.1	RNY3P8	4.11	4.61e-05	0.00733	0.18	0.19	Blood metabolite levels;	chr13:95318004	chr13:95310830~95310955:-
HNSC	cis	rs889398	0.741	rs7192213	ENSG00000196696.11	PDXDC2P	-4.11	4.61e-05	0.00733	-0.13	-0.19	Body mass index;	chr16:69892377	chr16:69976297~70065948:-
HNSC	cis	rs9329221	0.51	rs6995837	ENSG00000269918.1	AF131215.9	4.11	4.61e-05	0.00733	0.18	0.19	Neuroticism;	chr8:10118165	chr8:11104691~11106704:-
HNSC	cis	rs9329221	0.537	rs6995859	ENSG00000269918.1	AF131215.9	4.11	4.61e-05	0.00733	0.18	0.19	Neuroticism;	chr8:10118199	chr8:11104691~11106704:-
HNSC	cis	rs11673344	0.504	rs6510593	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.2	0.19	Obesity-related traits;	chr19:37143153	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.504	rs7259332	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.2	0.19	Obesity-related traits;	chr19:37143389	chr19:37314868~37315620:-
HNSC	cis	rs10761256	0.621	rs2398871	ENSG00000227603.1	RP11-165J3.6	-4.11	4.61e-05	0.00733	-0.18	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr9:93721938	chr9:93435332~93437121:-
HNSC	cis	rs9859260	0.614	rs493661	ENSG00000242086.7	LINC00969	-4.11	4.61e-05	0.00733	-0.15	-0.19	Mean corpuscular volume;	chr3:196059618	chr3:195658062~195739964:+
HNSC	cis	rs10083777	1	rs10083777	ENSG00000261838.4	RP11-303E16.6	4.11	4.61e-05	0.00733	0.32	0.19	Metabolite levels (small molecules and protein measures);	chr16:81031677	chr16:81069854~81076598:+
HNSC	cis	rs4356203	0.905	rs621246	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs635802	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs662711	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs598946	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs545773	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.792	rs677540	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs512852	ENSG00000260196.1	RP1-239B22.5	-4.11	4.62e-05	0.00734	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17380649~17383531:+
HNSC	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	4.11	4.62e-05	0.00734	0.16	0.19	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
HNSC	cis	rs10504130	0.569	rs11775587	ENSG00000253844.1	RP11-546K22.1	4.11	4.62e-05	0.00734	0.27	0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51961458~52022974:+
HNSC	cis	rs5758511	0.508	rs58099562	ENSG00000205702.9	CYP2D7	4.11	4.62e-05	0.00734	0.17	0.19	Birth weight;	chr22:42057768	chr22:42140203~42144577:-
HNSC	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-4.11	4.62e-05	0.00734	-0.22	-0.19	Height;	chr14:75190804	chr14:75011269~75012851:-
HNSC	cis	rs1009181	0.585	rs2066295	ENSG00000272462.2	U91328.19	-4.11	4.62e-05	0.00734	-0.21	-0.19	Childhood ear infection;	chr6:26168675	chr6:25992662~26001775:+
HNSC	cis	rs2439831	0.867	rs2447208	ENSG00000201136.1	RNU6-353P	-4.11	4.62e-05	0.00734	-0.28	-0.19	Lung cancer in ever smokers;	chr15:43641697	chr15:43702363~43702470:+
HNSC	cis	rs561341	1	rs550264	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31990521	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs111454793	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31992248	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs527256	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31994274	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs473356	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31994743	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs576985	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31996304	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs15654	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31999341	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs550923	ENSG00000278867.1	RP11-640N20.4	-4.11	4.62e-05	0.00735	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31999994	chr17:32051030~32053208:+
HNSC	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-4.11	4.62e-05	0.00735	-0.14	-0.19	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
HNSC	cis	rs6674176	0.593	rs6675620	ENSG00000237950.1	RP11-7O11.3	4.11	4.62e-05	0.00735	0.21	0.19	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43951958	chr1:43944370~43946551:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-4.11	4.63e-05	0.00735	-0.25	-0.19	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-4.11	4.63e-05	0.00735	-0.25	-0.19	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-4.11	4.63e-05	0.00735	-0.25	-0.19	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-4.11	4.63e-05	0.00735	-0.25	-0.19	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
HNSC	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-4.11	4.63e-05	0.00735	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
HNSC	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-4.11	4.63e-05	0.00735	-0.14	-0.19	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
HNSC	cis	rs1580019	0.844	rs1376290	ENSG00000226468.2	AC018641.7	-4.11	4.63e-05	0.00735	-0.26	-0.19	Cognitive ability;	chr7:32447310	chr7:32456963~32457758:-
HNSC	cis	rs17345786	0.906	rs56171035	ENSG00000244119.1	PDCL3P4	4.11	4.63e-05	0.00735	0.2	0.19	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101712472~101713191:+
HNSC	cis	rs853679	0.607	rs33932084	ENSG00000204709.4	LINC01556	4.11	4.63e-05	0.00735	0.39	0.19	Depression;	chr6:28301047	chr6:28943877~28944537:+
HNSC	cis	rs6710503	0.823	rs56139148	ENSG00000271936.1	RP11-443B20.1	-4.11	4.63e-05	0.00735	-0.19	-0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24750898	chr2:24825610~24826717:+
HNSC	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	4.11	4.63e-05	0.00735	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	4.11	4.63e-05	0.00735	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	4.11	4.63e-05	0.00735	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	4.11	4.63e-05	0.00735	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
HNSC	cis	rs8028182	0.549	rs7402293	ENSG00000260269.4	CTD-2323K18.1	4.11	4.63e-05	0.00735	0.25	0.19	Sudden cardiac arrest;	chr15:75343796	chr15:75527150~75601205:-
HNSC	cis	rs1008375	1	rs7673500	ENSG00000249502.1	AC006160.5	-4.11	4.63e-05	0.00736	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17619760	chr4:17587467~17614571:-
HNSC	cis	rs757081	0.658	rs214076	ENSG00000260196.1	RP1-239B22.5	-4.11	4.63e-05	0.00736	-0.2	-0.19	Systolic blood pressure;	chr11:17278710	chr11:17380649~17383531:+
HNSC	cis	rs10761256	0.621	rs4744275	ENSG00000227603.1	RP11-165J3.6	-4.11	4.63e-05	0.00736	-0.19	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr9:93720351	chr9:93435332~93437121:-
HNSC	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-4.11	4.63e-05	0.00736	-0.19	-0.19	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
HNSC	cis	rs2239557	0.645	rs3742810	ENSG00000259065.1	RP5-1021I20.1	4.11	4.63e-05	0.00736	0.25	0.19	Common traits (Other);	chr14:74010785	chr14:73787360~73803270:+
HNSC	cis	rs739496	0.579	rs75080921	ENSG00000226469.1	ADAM1B	4.11	4.63e-05	0.00736	0.21	0.19	Platelet count;	chr12:111861168	chr12:111927018~111929017:+
HNSC	cis	rs17253792	0.822	rs12323476	ENSG00000186615.9	KTN1-AS1	4.11	4.63e-05	0.00736	0.33	0.19	Putamen volume;	chr14:55706004	chr14:55499278~55580110:-
HNSC	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.11	4.63e-05	0.00736	0.29	0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
HNSC	cis	rs8028182	0.636	rs12708520	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.63e-05	0.00736	-0.24	-0.19	Sudden cardiac arrest;	chr15:75538198	chr15:75527150~75601205:-
HNSC	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	4.11	4.64e-05	0.00736	0.18	0.19	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
HNSC	cis	rs913655	0.508	rs7894191	ENSG00000225527.1	RP11-383B4.4	4.11	4.64e-05	0.00736	0.22	0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18716871	chr10:18531849~18533336:-
HNSC	cis	rs9910055	0.529	rs425038	ENSG00000267080.4	ASB16-AS1	4.11	4.64e-05	0.00737	0.15	0.19	Total body bone mineral density;	chr17:44104660	chr17:44175973~44186717:-
HNSC	cis	rs6095360	0.727	rs17450430	ENSG00000222365.1	SNORD12B	-4.11	4.64e-05	0.00737	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49155727	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-4.11	4.64e-05	0.00737	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-4.11	4.64e-05	0.00737	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
HNSC	cis	rs853679	1	rs7740487	ENSG00000226314.6	ZNF192P1	-4.11	4.64e-05	0.00737	-0.26	-0.19	Depression;	chr6:28248708	chr6:28161781~28169594:+
HNSC	cis	rs853679	1	rs68141011	ENSG00000226314.6	ZNF192P1	-4.11	4.64e-05	0.00737	-0.26	-0.19	Depression;	chr6:28250019	chr6:28161781~28169594:+
HNSC	cis	rs853679	1	rs13200462	ENSG00000226314.6	ZNF192P1	-4.11	4.64e-05	0.00737	-0.26	-0.19	Depression;	chr6:28250421	chr6:28161781~28169594:+
HNSC	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	4.11	4.64e-05	0.00737	0.19	0.19	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
HNSC	cis	rs442309	0.846	rs224133	ENSG00000238280.1	RP11-436D10.3	-4.11	4.64e-05	0.00737	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62706743	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.819	rs224134	ENSG00000238280.1	RP11-436D10.3	-4.11	4.64e-05	0.00737	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62706867	chr10:62793562~62805887:-
HNSC	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	4.11	4.64e-05	0.00737	0.16	0.19	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
HNSC	cis	rs11673344	0.523	rs7255724	ENSG00000276846.1	CTD-3220F14.3	4.11	4.64e-05	0.00737	0.21	0.19	Obesity-related traits;	chr19:37158675	chr19:37314868~37315620:-
HNSC	cis	rs4851870	0.514	rs4851840	ENSG00000272994.1	RP11-332H14.2	-4.11	4.65e-05	0.00738	-0.15	-0.19	Addiction;	chr2:105752796	chr2:105334027~105337475:-
HNSC	cis	rs7178375	1	rs7176351	ENSG00000270015.1	RP11-540B6.6	4.11	4.65e-05	0.00738	0.23	0.19	Hypertriglyceridemia;	chr15:30916524	chr15:30926514~30928407:+
HNSC	cis	rs1062753	0.527	rs6519296	ENSG00000227370.1	RP4-669P10.19	4.11	4.65e-05	0.00738	0.18	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41952598	chr22:42132543~42132998:+
HNSC	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-4.11	4.65e-05	0.00738	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
HNSC	cis	rs12600394	1	rs2323244	ENSG00000236088.8	COX10-AS1	4.11	4.65e-05	0.00738	0.27	0.19	Response to platinum-based chemotherapy (cisplatin);	chr17:14609386	chr17:13756478~14069495:-
HNSC	cis	rs4819052	0.851	rs7275468	ENSG00000223768.1	LINC00205	-4.11	4.65e-05	0.00738	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45293285~45297354:+
HNSC	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	4.11	4.65e-05	0.00738	0.23	0.19	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
HNSC	cis	rs2908197	1	rs2908197	ENSG00000186704.9	DTX2P1	-4.11	4.65e-05	0.00738	-0.18	-0.19	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76307732	chr7:76978617~77004308:+
HNSC	cis	rs12666612	0.833	rs1528683	ENSG00000237773.4	AC003075.4	4.11	4.65e-05	0.00738	0.39	0.19	Obesity-related traits;	chr7:18196884	chr7:17279834~17299357:-
HNSC	cis	rs6586111	0.967	rs6586106	ENSG00000226659.1	RP11-137H2.4	-4.11	4.65e-05	0.00738	-0.22	-0.19	Capecitabine sensitivity;	chr10:80612544	chr10:80529597~80535942:-
HNSC	cis	rs9921338	0.961	rs4781055	ENSG00000263080.1	RP11-485G7.5	4.11	4.66e-05	0.00739	0.21	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11341809~11345211:-
HNSC	cis	rs7520050	0.966	rs7539932	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs61783200	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6680380	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs6697557	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6701614	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.933	rs11211203	ENSG00000280836.1	AL355480.1	4.11	4.66e-05	0.00739	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45581219~45581321:-
HNSC	cis	rs4699052	0.662	rs1996346	ENSG00000246560.2	RP11-10L12.4	4.11	4.66e-05	0.00739	0.22	0.19	Testicular germ cell tumor;	chr4:103329167	chr4:102828055~102844075:+
HNSC	cis	rs10129255	1	rs10134517	ENSG00000224373.3	IGHV4-59	4.11	4.66e-05	0.0074	0.12	0.19	Kawasaki disease;	chr14:106718498	chr14:106627249~106627825:-
HNSC	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	4.11	4.66e-05	0.0074	0.19	0.19	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
HNSC	cis	rs10129255	0.834	rs10139893	ENSG00000280411.1	IGHV1-69-2	-4.11	4.66e-05	0.0074	-0.14	-0.19	Kawasaki disease;	chr14:106711377	chr14:106762092~106762588:-
HNSC	cis	rs7246760	1	rs10412903	ENSG00000267289.1	CTD-2623N2.11	4.11	4.66e-05	0.0074	0.3	0.19	Pursuit maintenance gain;	chr19:9770251	chr19:9834079~9835013:-
HNSC	cis	rs516805	0.63	rs696651	ENSG00000279453.1	RP3-425C14.4	-4.11	4.67e-05	0.0074	-0.25	-0.19	Lymphocyte counts;	chr6:122280069	chr6:122436789~122439223:-
HNSC	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-4.11	4.67e-05	0.00741	-0.21	-0.19	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-4.11	4.67e-05	0.00741	-0.21	-0.19	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
HNSC	cis	rs6964587	0.597	rs975707	ENSG00000188693.7	CYP51A1-AS1	-4.11	4.67e-05	0.00741	-0.2	-0.19	Breast cancer;	chr7:92245213	chr7:92134604~92180725:+
HNSC	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-4.11	4.67e-05	0.00741	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
HNSC	cis	rs7178909	0.831	rs1910587	ENSG00000259677.1	RP11-493E3.1	4.11	4.67e-05	0.00741	0.21	0.19	Common traits (Other);	chr15:89897255	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.797	rs1910586	ENSG00000259677.1	RP11-493E3.1	4.11	4.67e-05	0.00741	0.21	0.19	Common traits (Other);	chr15:89897257	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.872	rs7179633	ENSG00000259677.1	RP11-493E3.1	4.11	4.67e-05	0.00742	0.21	0.19	Common traits (Other);	chr15:89891645	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.872	rs28865973	ENSG00000259677.1	RP11-493E3.1	4.11	4.67e-05	0.00742	0.21	0.19	Common traits (Other);	chr15:89891946	chr15:89876540~89877285:+
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-4.11	4.67e-05	0.00742	-0.21	-0.19	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
HNSC	cis	rs4862750	0.872	rs7671914	ENSG00000250971.1	RP11-696F12.1	4.11	4.67e-05	0.00742	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr4:186957011	chr4:187060099~187060930:+
HNSC	cis	rs9611565	0.694	rs202656	ENSG00000235513.1	RP4-756G23.5	-4.11	4.67e-05	0.00742	-0.23	-0.19	Vitiligo;	chr22:41446199	chr22:41209122~41217627:-
HNSC	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	4.11	4.67e-05	0.00742	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
HNSC	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-4.11	4.68e-05	0.00742	-0.22	-0.19	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-4.11	4.68e-05	0.00742	-0.22	-0.19	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
HNSC	cis	rs11157436	0.874	rs35951144	ENSG00000211812.1	TRAV26-2	-4.11	4.68e-05	0.00742	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22202583~22203368:+
HNSC	cis	rs28489187	0.706	rs233113	ENSG00000223653.4	RP11-131L23.1	4.11	4.68e-05	0.00742	0.26	0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85320616	chr1:85276715~85448124:+
HNSC	cis	rs4713118	0.869	rs9283883	ENSG00000216901.1	AL022393.7	4.11	4.68e-05	0.00742	0.23	0.19	Parkinson's disease;	chr6:27747691	chr6:28176188~28176674:+
HNSC	cis	rs7246657	0.508	rs1644702	ENSG00000276846.1	CTD-3220F14.3	4.11	4.68e-05	0.00742	0.28	0.19	Coronary artery calcification;	chr19:37001005	chr19:37314868~37315620:-
HNSC	cis	rs7520050	0.966	rs10890354	ENSG00000280836.1	AL355480.1	4.11	4.68e-05	0.00743	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45581219~45581321:-
HNSC	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-4.11	4.68e-05	0.00743	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
HNSC	cis	rs9611565	0.625	rs12483991	ENSG00000235513.1	RP4-756G23.5	4.11	4.68e-05	0.00743	0.21	0.19	Vitiligo;	chr22:41539281	chr22:41209122~41217627:-
HNSC	cis	rs8067545	0.641	rs203457	ENSG00000266126.1	RP11-209D14.4	-4.11	4.69e-05	0.00743	-0.21	-0.19	Schizophrenia;	chr17:19915025	chr17:19929372~19929737:-
HNSC	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	4.11	4.69e-05	0.00743	0.27	0.19	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-4.11	4.69e-05	0.00743	-0.14	-0.19	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
HNSC	cis	rs1538138	0.609	rs13203503	ENSG00000226453.1	RP11-379B8.1	-4.11	4.69e-05	0.00743	-0.22	-0.19	Corneal structure;	chr6:82097269	chr6:81845185~81933480:-
HNSC	cis	rs1538138	0.609	rs9449409	ENSG00000226453.1	RP11-379B8.1	-4.11	4.69e-05	0.00743	-0.22	-0.19	Corneal structure;	chr6:82097804	chr6:81845185~81933480:-
HNSC	cis	rs1538138	0.609	rs945854	ENSG00000226453.1	RP11-379B8.1	-4.11	4.69e-05	0.00743	-0.22	-0.19	Corneal structure;	chr6:82098133	chr6:81845185~81933480:-
HNSC	cis	rs1538138	0.586	rs1002783	ENSG00000226453.1	RP11-379B8.1	-4.11	4.69e-05	0.00743	-0.22	-0.19	Corneal structure;	chr6:82098313	chr6:81845185~81933480:-
HNSC	cis	rs2548724	0.796	rs62369304	ENSG00000250682.4	LINC00491	4.11	4.69e-05	0.00743	0.25	0.19	Type 2 diabetes;	chr5:102375694	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.614	rs17741537	ENSG00000269918.1	AF131215.9	4.11	4.69e-05	0.00743	0.18	0.19	Retinal vascular caliber;	chr8:11355583	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.606	rs2736270	ENSG00000255020.1	AF131216.5	4.11	4.69e-05	0.00744	0.2	0.19	Retinal vascular caliber;	chr8:11335084	chr8:11345748~11347502:-
HNSC	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	4.11	4.69e-05	0.00744	0.2	0.19	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
HNSC	cis	rs11083475	0.557	rs2368519	ENSG00000269486.2	CTC-360G5.9	4.11	4.69e-05	0.00744	0.2	0.19	Heart rate;	chr19:38768601	chr19:38935297~38938632:-
HNSC	cis	rs10078	0.51	rs2278248	ENSG00000225138.6	CTD-2228K2.7	4.11	4.69e-05	0.00744	0.29	0.19	Fat distribution (HIV);	chr5:469455	chr5:473236~480884:+
HNSC	cis	rs73222236	0.782	rs1484250	ENSG00000273486.1	RP11-731C17.2	4.11	4.69e-05	0.00744	0.16	0.19	Coronary artery disease;	chr3:136650695	chr3:136837338~136839021:-
HNSC	cis	rs7267979	0.509	rs6115218	ENSG00000231081.1	RP4-760C5.3	-4.11	4.69e-05	0.00744	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:26008791~26010531:-
HNSC	cis	rs2274273	0.522	rs2251366	ENSG00000233924.1	AL160471.6	-4.11	4.69e-05	0.00744	-0.21	-0.19	Protein biomarker;	chr14:55051438	chr14:55004813~55005687:-
HNSC	cis	rs2974760	0.606	rs2858918	ENSG00000268836.1	LA16c-OS12.2	4.11	4.69e-05	0.00744	0.21	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:185748~186294:-
HNSC	cis	rs2686555	0.502	rs693074	ENSG00000200795.1	RNU4-1	4.11	4.69e-05	0.00744	0.25	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr12:120639925	chr12:120293097~120293237:-
HNSC	cis	rs748404	0.666	rs7181634	ENSG00000166763.7	STRCP1	4.11	4.69e-05	0.00744	0.26	0.19	Lung cancer;	chr15:43351703	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.626	rs72707530	ENSG00000166763.7	STRCP1	4.11	4.69e-05	0.00744	0.26	0.19	Lung cancer;	chr15:43353622	chr15:43699488~43718184:-
HNSC	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-4.11	4.7e-05	0.00745	-0.18	-0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
HNSC	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-4.11	4.7e-05	0.00745	-0.24	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
HNSC	cis	rs16858210	0.607	rs953419	ENSG00000234371.6	RPSAP31	-4.11	4.7e-05	0.00745	-0.25	-0.19	Menopause (age at onset);	chr3:183868095	chr3:183884924~183888449:+
HNSC	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-4.11	4.7e-05	0.00745	-0.22	-0.19	Height;	chr14:75193421	chr14:75011269~75012851:-
HNSC	cis	rs1538970	0.847	rs781230	ENSG00000234329.1	RP11-767N6.2	-4.11	4.7e-05	0.00745	-0.21	-0.19	Platelet count;	chr1:45415079	chr1:45651039~45651826:-
HNSC	cis	rs11089937	0.616	rs5995616	ENSG00000211638.2	IGLV8-61	4.11	4.7e-05	0.00745	0.17	0.19	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22098700~22099212:+
HNSC	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	4.11	4.7e-05	0.00745	0.26	0.19	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
HNSC	cis	rs11638352	1	rs2615297	ENSG00000205771.5	CATSPER2P1	4.11	4.7e-05	0.00745	0.51	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44113823	chr15:43726918~43747094:-
HNSC	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-4.11	4.7e-05	0.00745	-0.21	-0.19	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-4.11	4.7e-05	0.00745	-0.21	-0.19	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
HNSC	cis	rs62432291	0.681	rs433786	ENSG00000235086.1	FNDC1-IT1	-4.11	4.7e-05	0.00746	-0.26	-0.19	Joint mobility (Beighton score);	chr6:159244914	chr6:159240786~159243329:+
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.11	4.7e-05	0.00746	0.2	0.19	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
HNSC	cis	rs853679	0.607	rs35072899	ENSG00000204709.4	LINC01556	4.11	4.7e-05	0.00746	0.39	0.19	Depression;	chr6:28313764	chr6:28943877~28944537:+
HNSC	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	4.11	4.7e-05	0.00746	0.2	0.19	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	4.11	4.7e-05	0.00746	0.2	0.19	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
HNSC	cis	rs72634501	0.642	rs67452844	ENSG00000182109.6	RP11-69E11.4	4.11	4.7e-05	0.00746	0.21	0.19	HDL cholesterol;	chr1:39150610	chr1:39522280~39546187:-
HNSC	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-4.11	4.71e-05	0.00746	-0.23	-0.19	Height;	chr20:49279650	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-4.11	4.71e-05	0.00746	-0.23	-0.19	Height;	chr20:49282024	chr20:49280319~49280409:+
HNSC	cis	rs6500395	0.735	rs16946340	ENSG00000261267.1	RP11-44I10.3	-4.11	4.71e-05	0.00746	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48633806	chr16:48559661~48587403:+
HNSC	cis	rs4356203	0.905	rs214939	ENSG00000260196.1	RP1-239B22.5	4.11	4.71e-05	0.00746	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs214936	ENSG00000260196.1	RP1-239B22.5	4.11	4.71e-05	0.00746	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17380649~17383531:+
HNSC	cis	rs6095360	1	rs6019671	ENSG00000222365.1	SNORD12B	4.11	4.71e-05	0.00746	0.21	0.19	Intelligence (multi-trait analysis);	chr20:49198690	chr20:49280319~49280409:+
HNSC	cis	rs4388249	1	rs12189512	ENSG00000271849.1	CTC-332L22.1	-4.11	4.71e-05	0.00747	-0.31	-0.19	Schizophrenia;	chr5:109714412	chr5:109687802~109688329:-
HNSC	cis	rs2835345	0.596	rs62229441	ENSG00000230479.1	AP000695.6	4.11	4.71e-05	0.00747	0.21	0.19	Pulmonary function;	chr21:36447559	chr21:36430360~36481070:+
HNSC	cis	rs7735319	0.735	rs3909866	ENSG00000250697.1	CTD-2066L21.3	4.11	4.71e-05	0.00747	0.22	0.19	Systolic blood pressure;	chr5:33050454	chr5:32925639~33297910:-
HNSC	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	4.11	4.71e-05	0.00747	0.25	0.19	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
HNSC	cis	rs2865126	0.818	rs4519388	ENSG00000264714.1	RP11-21G15.1	-4.11	4.71e-05	0.00747	-0.22	-0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10762277	chr18:10724619~10728539:+
HNSC	cis	rs8067545	0.641	rs203458	ENSG00000266126.1	RP11-209D14.4	4.11	4.71e-05	0.00747	0.21	0.19	Schizophrenia;	chr17:19913585	chr17:19929372~19929737:-
HNSC	cis	rs4776997	0.545	rs12592195	ENSG00000270964.1	RP11-502I4.3	4.11	4.72e-05	0.00747	0.2	0.19	Verbal declarative memory;	chr15:67848266	chr15:67541072~67542604:-
HNSC	cis	rs6723108	0.678	rs578384	ENSG00000224043.6	CCNT2-AS1	-4.11	4.72e-05	0.00747	-0.24	-0.19	Type 2 diabetes;	chr2:134530343	chr2:134735464~134918710:-
HNSC	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	4.11	4.72e-05	0.00748	0.27	0.19	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	4.11	4.72e-05	0.00748	0.27	0.19	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	4.11	4.72e-05	0.00748	0.27	0.19	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	4.11	4.72e-05	0.00748	0.27	0.19	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
HNSC	cis	rs9650657	0.737	rs4551304	ENSG00000255310.2	AF131215.2	-4.11	4.72e-05	0.00748	-0.18	-0.19	Neuroticism;	chr8:10807559	chr8:11107788~11109726:-
HNSC	cis	rs5758659	0.652	rs6519301	ENSG00000182057.4	OGFRP1	4.11	4.72e-05	0.00748	0.18	0.19	Cognitive function;	chr22:41989963	chr22:42269753~42275196:+
HNSC	cis	rs9859260	1	rs2284890	ENSG00000231464.1	AC024937.4	4.11	4.72e-05	0.00748	0.2	0.19	Mean corpuscular volume;	chr3:196061276	chr3:195996738~195998233:+
HNSC	cis	rs9859260	1	rs2284889	ENSG00000231464.1	AC024937.4	4.11	4.72e-05	0.00748	0.2	0.19	Mean corpuscular volume;	chr3:196061376	chr3:195996738~195998233:+
HNSC	cis	rs7824557	1	rs7824557	ENSG00000255310.2	AF131215.2	-4.11	4.72e-05	0.00748	-0.18	-0.19	Retinal vascular caliber;	chr8:11246602	chr8:11107788~11109726:-
HNSC	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	4.11	4.72e-05	0.00748	0.19	0.19	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
HNSC	cis	rs2929451	0.566	rs17658270	ENSG00000254153.1	CTA-398F10.2	4.11	4.72e-05	0.00748	0.21	0.19	Nose size;	chr8:9296109	chr8:8456909~8461337:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	4.11	4.72e-05	0.00748	0.22	0.19	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	4.11	4.72e-05	0.00748	0.22	0.19	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
HNSC	cis	rs11711311	0.824	rs35952547	ENSG00000241529.3	RN7SL767P	-4.11	4.73e-05	0.00749	-0.25	-0.19	IgG glycosylation;	chr3:113633654	chr3:113632704~113632998:+
HNSC	cis	rs67478160	0.609	rs1547604	ENSG00000259515.1	RP11-365N19.2	4.11	4.73e-05	0.00749	0.17	0.19	Schizophrenia;	chr14:103804322	chr14:102933574~102937177:+
HNSC	cis	rs12047808	0.558	rs115243371	ENSG00000227141.2	RP11-545A16.3	-4.11	4.73e-05	0.00749	-0.32	-0.19	Multiple sclerosis (age of onset);	chr1:179198168	chr1:179586705~179589175:+
HNSC	cis	rs860295	0.702	rs3851912	ENSG00000225855.5	RUSC1-AS1	4.11	4.73e-05	0.0075	0.13	0.19	Body mass index;	chr1:155616653	chr1:155316863~155324176:-
HNSC	cis	rs283610	0.603	rs10035637	ENSG00000182383.8	RPL27AP5	-4.11	4.74e-05	0.0075	-0.16	-0.19	Obesity-related traits;	chr5:73993783	chr5:74990189~74990637:-
HNSC	cis	rs36093844	0.527	rs17745248	ENSG00000279742.1	RP11-700A24.1	-4.11	4.74e-05	0.0075	-0.25	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86042309	chr11:85852557~85854943:-
HNSC	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-4.11	4.74e-05	0.0075	-0.21	-0.19	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66226660	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7778911	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66229519	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1979823	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66239626	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1392104	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66294120	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-4.11	4.74e-05	0.0075	-0.32	-0.19	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
HNSC	cis	rs539096	0.5	rs2367804	ENSG00000237950.1	RP11-7O11.3	4.11	4.74e-05	0.0075	0.2	0.19	Intelligence (multi-trait analysis);	chr1:43848594	chr1:43944370~43946551:-
HNSC	cis	rs28830936	1	rs17676742	ENSG00000250379.1	RP11-23P13.4	4.11	4.74e-05	0.0075	0.23	0.19	Diastolic blood pressure;	chr15:41610850	chr15:41825099~41827936:-
HNSC	cis	rs28830936	1	rs11629485	ENSG00000250379.1	RP11-23P13.4	4.11	4.74e-05	0.0075	0.23	0.19	Diastolic blood pressure;	chr15:41612371	chr15:41825099~41827936:-
HNSC	cis	rs4853525	0.59	rs1921911	ENSG00000228509.4	AC006460.2	4.11	4.74e-05	0.0075	0.26	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855644	chr2:190676944~190708716:-
HNSC	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-4.11	4.74e-05	0.0075	-0.22	-0.19	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
HNSC	cis	rs7475343	0.538	rs4880710	ENSG00000224034.1	RP11-445P17.8	4.11	4.74e-05	0.00751	0.25	0.19	Intelligence;	chr10:5109373	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.538	rs4622159	ENSG00000224034.1	RP11-445P17.8	4.11	4.74e-05	0.00751	0.25	0.19	Intelligence;	chr10:5115704	chr10:5266033~5271236:-
HNSC	cis	rs10863681	0.817	rs1890757	ENSG00000238042.4	RP11-815M8.1	4.11	4.74e-05	0.00751	0.2	0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222075340	chr1:221880981~221978523:-
HNSC	cis	rs1665050	0.546	rs7175490	ENSG00000277144.1	RP11-59H7.4	-4.11	4.74e-05	0.00751	-0.22	-0.19	Atopic dermatitis;	chr15:59041735	chr15:59115547~59116089:-
HNSC	cis	rs6657613	0.68	rs7517920	ENSG00000186715.9	MST1L	-4.11	4.74e-05	0.00751	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17042820	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs11203284	ENSG00000186715.9	MST1L	-4.11	4.74e-05	0.00751	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17043457	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs10887992	ENSG00000186715.9	MST1L	-4.11	4.74e-05	0.00751	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17043718	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs10887993	ENSG00000186715.9	MST1L	-4.11	4.74e-05	0.00751	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17043746	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.649	rs11203286	ENSG00000186715.9	MST1L	-4.11	4.74e-05	0.00751	-0.16	-0.19	Hip circumference adjusted for BMI;	chr1:17044302	chr1:16754910~16770237:-
HNSC	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-4.11	4.75e-05	0.00751	-0.28	-0.19	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
HNSC	cis	rs1602565	0.858	rs3459	ENSG00000255450.1	CTD-2063L20.1	-4.11	4.75e-05	0.00751	-0.29	-0.19	Schizophrenia;	chr11:29097499	chr11:29275655~29276565:+
HNSC	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-4.11	4.75e-05	0.00752	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
HNSC	cis	rs36052053	0.908	rs1812230	ENSG00000203799.9	CCDC162P	4.11	4.75e-05	0.00752	0.28	0.19	Red cell distribution width;	chr6:109268132	chr6:109285485~109355063:+
HNSC	cis	rs36052053	0.908	rs34854922	ENSG00000203799.9	CCDC162P	4.11	4.75e-05	0.00752	0.28	0.19	Red cell distribution width;	chr6:109272953	chr6:109285485~109355063:+
HNSC	cis	rs7475343	0.573	rs75857264	ENSG00000224034.1	RP11-445P17.8	-4.11	4.75e-05	0.00752	-0.25	-0.19	Intelligence;	chr10:5283345	chr10:5266033~5271236:-
HNSC	cis	rs72627123	0.881	rs17094011	ENSG00000259065.1	RP5-1021I20.1	-4.11	4.75e-05	0.00752	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73925425	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs7148538	ENSG00000259065.1	RP5-1021I20.1	-4.11	4.75e-05	0.00752	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73925639	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs59363432	ENSG00000259065.1	RP5-1021I20.1	-4.11	4.75e-05	0.00752	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73930842	chr14:73787360~73803270:+
HNSC	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-4.11	4.75e-05	0.00752	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
HNSC	cis	rs116095464	0.558	rs10059907	ENSG00000250848.1	CTD-2083E4.5	-4.11	4.75e-05	0.00752	-0.26	-0.19	Breast cancer;	chr5:205245	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10060089	ENSG00000250848.1	CTD-2083E4.5	-4.11	4.75e-05	0.00752	-0.26	-0.19	Breast cancer;	chr5:205450	chr5:288833~290321:-
HNSC	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	4.11	4.75e-05	0.00752	0.18	0.19	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
HNSC	cis	rs1028883	1	rs7318906	ENSG00000228295.1	LINC00392	4.11	4.75e-05	0.00752	0.2	0.19	Lean body mass;	chr13:73531994	chr13:73564244~73588070:+
HNSC	cis	rs8077577	0.895	rs11654741	ENSG00000273018.4	CTD-2303H24.2	-4.11	4.75e-05	0.00752	-0.28	-0.19	Obesity-related traits;	chr17:18221156	chr17:18511221~18551705:-
HNSC	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-4.11	4.75e-05	0.00752	-0.27	-0.19	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
HNSC	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	4.11	4.75e-05	0.00752	0.2	0.19	QT interval;	chr12:29255074	chr12:29280418~29317848:-
HNSC	cis	rs4820294	0.669	rs9622678	ENSG00000225867.1	RP5-1177I5.3	-4.11	4.75e-05	0.00753	-0.21	-0.19	Fat distribution (HIV);	chr22:37661331	chr22:37550026~37551735:+
HNSC	cis	rs6688613	1	rs6699159	ENSG00000215834.7	FMO9P	4.11	4.76e-05	0.00753	0.23	0.19	Refractive astigmatism;	chr1:166976835	chr1:166603675~166631400:+
HNSC	cis	rs6688613	1	rs6665341	ENSG00000215834.7	FMO9P	4.11	4.76e-05	0.00753	0.23	0.19	Refractive astigmatism;	chr1:166977781	chr1:166603675~166631400:+
HNSC	cis	rs1008375	0.932	rs11935124	ENSG00000249502.1	AC006160.5	4.11	4.76e-05	0.00753	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666577	chr4:17587467~17614571:-
HNSC	cis	rs656319	0.586	rs35013996	ENSG00000254340.1	RP11-10A14.3	-4.11	4.76e-05	0.00753	-0.24	-0.19	Myopia (pathological);	chr8:10089635	chr8:9141424~9145435:+
HNSC	cis	rs1799949	1	rs2037075	ENSG00000236383.6	LINC00854	-4.11	4.76e-05	0.00753	-0.18	-0.19	Menopause (age at onset);	chr17:43153809	chr17:43216941~43305976:-
HNSC	cis	rs7615952	0.546	rs2922197	ENSG00000241288.6	RP11-379B18.5	-4.11	4.76e-05	0.00754	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125603188	chr3:125827238~125916384:-
HNSC	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-4.11	4.76e-05	0.00754	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
HNSC	cis	rs7552167	0.925	rs3932666	ENSG00000230023.2	RP11-10N16.2	4.11	4.76e-05	0.00754	0.31	0.19	Psoriasis vulgaris;	chr1:24185076	chr1:24200240~24211693:+
HNSC	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-4.11	4.77e-05	0.00754	-0.22	-0.19	Height;	chr14:75157285	chr14:75011269~75012851:-
HNSC	cis	rs8077577	0.671	rs4925177	ENSG00000273018.4	CTD-2303H24.2	-4.11	4.77e-05	0.00754	-0.26	-0.19	Obesity-related traits;	chr17:18349554	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.671	rs4925178	ENSG00000273018.4	CTD-2303H24.2	-4.11	4.77e-05	0.00754	-0.26	-0.19	Obesity-related traits;	chr17:18349597	chr17:18511221~18551705:-
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000250412.1	KLHL2P1	-4.11	4.77e-05	0.00754	-0.23	-0.19	Corneal astigmatism;	chr4:119331651	chr4:119334329~119378233:+
HNSC	cis	rs6964587	0.626	rs2106745	ENSG00000188693.7	CYP51A1-AS1	4.11	4.77e-05	0.00754	0.2	0.19	Breast cancer;	chr7:91877321	chr7:92134604~92180725:+
HNSC	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-4.11	4.77e-05	0.00754	-0.29	-0.19	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
HNSC	cis	rs28489187	0.617	rs233118	ENSG00000223653.4	RP11-131L23.1	-4.11	4.77e-05	0.00754	-0.25	-0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322284	chr1:85276715~85448124:+
HNSC	cis	rs6095360	0.727	rs13044004	ENSG00000222365.1	SNORD12B	-4.11	4.77e-05	0.00754	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49101834	chr20:49280319~49280409:+
HNSC	cis	rs7648466	0.513	rs2201150	ENSG00000223552.1	RP11-24F11.2	4.11	4.77e-05	0.00755	0.16	0.19	Eotaxin levels;	chr3:46217411	chr3:46364955~46407059:-
HNSC	cis	rs7829975	0.539	rs71537846	ENSG00000253893.2	FAM85B	4.11	4.77e-05	0.00755	0.24	0.19	Mood instability;	chr8:8684610	chr8:8167819~8226614:-
HNSC	cis	rs800888	0.547	rs2737219	ENSG00000249917.2	LINC00536	-4.11	4.77e-05	0.00755	-0.24	-0.19	Monocyte percentage of white cells;	chr8:115623461	chr8:115950511~116325059:-
HNSC	cis	rs656319	0.559	rs17689007	ENSG00000255310.2	AF131215.2	-4.11	4.77e-05	0.00755	-0.18	-0.19	Myopia (pathological);	chr8:10117314	chr8:11107788~11109726:-
HNSC	cis	rs34864796	0.547	rs200476	ENSG00000216901.1	AL022393.7	4.1	4.77e-05	0.00755	0.25	0.19	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28176188~28176674:+
HNSC	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-4.1	4.77e-05	0.00755	-0.19	-0.19	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
HNSC	cis	rs516805	0.63	rs1379098	ENSG00000279453.1	RP3-425C14.4	-4.1	4.77e-05	0.00755	-0.26	-0.19	Lymphocyte counts;	chr6:122121672	chr6:122436789~122439223:-
HNSC	cis	rs683257	0.714	rs9495866	ENSG00000234147.1	RP3-460G2.2	-4.1	4.77e-05	0.00755	-0.4	-0.19	Facial emotion recognition (angry faces);	chr6:140933740	chr6:140845958~140852924:-
HNSC	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	4.1	4.77e-05	0.00755	0.15	0.19	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
HNSC	cis	rs7224668	0.647	rs7219382	ENSG00000280407.2	RP13-516M14.8	4.1	4.78e-05	0.00755	0.15	0.19	IgG glycosylation;	chr17:81267297	chr17:82249067~82251844:+
HNSC	cis	rs889398	0.741	rs2362642	ENSG00000196696.11	PDXDC2P	-4.1	4.78e-05	0.00755	-0.13	-0.19	Body mass index;	chr16:69897555	chr16:69976297~70065948:-
HNSC	cis	rs1023500	1	rs3752591	ENSG00000205702.9	CYP2D7	-4.1	4.78e-05	0.00755	-0.16	-0.19	Schizophrenia;	chr22:41943512	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.908	rs7696649	ENSG00000250412.1	KLHL2P1	4.1	4.78e-05	0.00756	0.24	0.19	Corneal astigmatism;	chr4:119401022	chr4:119334329~119378233:+
HNSC	cis	rs2253762	0.54	rs10887053	ENSG00000276742.1	RP11-500G22.4	4.1	4.78e-05	0.00756	0.28	0.19	Breast cancer;	chr10:122030997	chr10:121956782~121957098:+
HNSC	cis	rs12701220	0.689	rs12701824	ENSG00000224079.1	AC091729.7	4.1	4.78e-05	0.00756	0.29	0.19	Bronchopulmonary dysplasia;	chr7:1062728	chr7:1074450~1078036:+
HNSC	cis	rs7572733	0.534	rs700685	ENSG00000231621.1	AC013264.2	-4.1	4.78e-05	0.00756	-0.18	-0.19	Dermatomyositis;	chr2:197851248	chr2:197197991~197199273:+
HNSC	cis	rs7085104	0.7	rs6163	ENSG00000213061.2	PFN1P11	4.1	4.78e-05	0.00756	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102838011~102845473:-
HNSC	cis	rs72634501	0.568	rs6679564	ENSG00000182109.6	RP11-69E11.4	-4.1	4.78e-05	0.00756	-0.19	-0.19	HDL cholesterol;	chr1:39151408	chr1:39522280~39546187:-
HNSC	cis	rs2255336	0.873	rs7397310	ENSG00000245648.1	RP11-277P12.20	4.1	4.78e-05	0.00756	0.26	0.19	Blood protein levels;	chr12:10368394	chr12:10363769~10398506:+
HNSC	cis	rs4321325	0.733	rs78238478	ENSG00000236682.1	AC068282.3	-4.1	4.78e-05	0.00756	-0.32	-0.19	Protein C levels;	chr2:127178730	chr2:127389130~127400580:+
HNSC	cis	rs6580649	0.598	rs1793913	ENSG00000278385.1	RP11-89H19.2	4.1	4.78e-05	0.00756	0.29	0.19	Lung cancer;	chr12:47993242	chr12:47905122~47906865:+
HNSC	cis	rs80130819	0.515	rs1793912	ENSG00000278385.1	RP11-89H19.2	4.1	4.78e-05	0.00756	0.29	0.19	Prostate cancer;	chr12:47993269	chr12:47905122~47906865:+
HNSC	cis	rs988913	0.736	rs4588693	ENSG00000224984.1	RP11-524H19.2	4.1	4.78e-05	0.00756	0.22	0.19	Menarche (age at onset);	chr6:55013421	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.706	rs6908568	ENSG00000224984.1	RP11-524H19.2	4.1	4.78e-05	0.00756	0.22	0.19	Menarche (age at onset);	chr6:55016766	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.706	rs10948880	ENSG00000224984.1	RP11-524H19.2	4.1	4.78e-05	0.00756	0.22	0.19	Menarche (age at onset);	chr6:55017205	chr6:54840118~54840855:-
HNSC	cis	rs6964587	0.626	rs2188841	ENSG00000188693.7	CYP51A1-AS1	4.1	4.78e-05	0.00756	0.2	0.19	Breast cancer;	chr7:91893327	chr7:92134604~92180725:+
HNSC	cis	rs859767	0.54	rs17789633	ENSG00000224043.6	CCNT2-AS1	-4.1	4.78e-05	0.00757	-0.22	-0.19	Neuroticism;	chr2:134628904	chr2:134735464~134918710:-
HNSC	cis	rs1009077	0.716	rs34601943	ENSG00000245958.5	RP11-33B1.1	4.1	4.78e-05	0.00757	0.22	0.19	Endometriosis;	chr4:119607869	chr4:119454791~119552025:+
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-4.1	4.79e-05	0.00757	-0.25	-0.19	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
HNSC	cis	rs4862750	0.957	rs6858853	ENSG00000250971.1	RP11-696F12.1	-4.1	4.79e-05	0.00757	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr4:186982258	chr4:187060099~187060930:+
HNSC	cis	rs793571	0.738	rs12595482	ENSG00000245975.2	RP11-30K9.6	4.1	4.79e-05	0.00757	0.31	0.19	Schizophrenia;	chr15:58903480	chr15:58768072~58770974:-
HNSC	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	4.1	4.79e-05	0.00758	0.16	0.19	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
HNSC	cis	rs36052053	0.908	rs13203987	ENSG00000203799.9	CCDC162P	4.1	4.79e-05	0.00758	0.28	0.19	Red cell distribution width;	chr6:109264037	chr6:109285485~109355063:+
HNSC	cis	rs7023329	0.619	rs7846749	ENSG00000244230.3	RN7SL151P	-4.1	4.79e-05	0.00758	-0.19	-0.19	Melanoma;	chr9:21780252	chr9:21699314~21699596:+
HNSC	cis	rs2286313	0.51	rs12892577	ENSG00000266869.1	RP6-114E22.1	4.1	4.79e-05	0.00758	0.47	0.19	Colorectal cancer;	chr14:70975141	chr14:71848606~71908430:+
HNSC	cis	rs1113500	0.636	rs3853493	ENSG00000226822.1	RP11-356N1.2	4.1	4.79e-05	0.00758	0.2	0.19	Growth-regulated protein alpha levels;	chr1:108094571	chr1:108071482~108074519:+
HNSC	cis	rs60617249	0.772	rs4948024	ENSG00000228204.2	RP4-724E13.2	4.1	4.79e-05	0.00758	0.2	0.19	Major depression and alcohol dependence;	chr7:50906025	chr7:50866747~51022990:+
HNSC	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	4.1	4.79e-05	0.00758	0.19	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
HNSC	cis	rs7665090	0.84	rs7674640	ENSG00000246560.2	RP11-10L12.4	4.1	4.8e-05	0.00758	0.22	0.19	Primary biliary cholangitis;	chr4:102619623	chr4:102828055~102844075:+
HNSC	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-4.1	4.8e-05	0.00758	-0.24	-0.19	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
HNSC	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	4.1	4.8e-05	0.00758	0.24	0.19	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
HNSC	cis	rs6601327	0.613	rs12677507	ENSG00000254340.1	RP11-10A14.3	-4.1	4.8e-05	0.00758	-0.22	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9624177	chr8:9141424~9145435:+
HNSC	cis	rs60617249	0.772	rs6942429	ENSG00000228204.2	RP4-724E13.2	4.1	4.8e-05	0.00759	0.2	0.19	Major depression and alcohol dependence;	chr7:50911535	chr7:50866747~51022990:+
HNSC	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-4.1	4.8e-05	0.00759	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
HNSC	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	4.1	4.8e-05	0.00759	0.18	0.19	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	4.1	4.8e-05	0.00759	0.18	0.19	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	4.1	4.8e-05	0.00759	0.18	0.19	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
HNSC	cis	rs9487051	0.646	rs11153167	ENSG00000243587.6	C6orf183	4.1	4.8e-05	0.00759	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109301379	chr6:109165833~109271014:+
HNSC	cis	rs9650657	0.665	rs7002117	ENSG00000255310.2	AF131215.2	4.1	4.8e-05	0.00759	0.18	0.19	Neuroticism;	chr8:10758659	chr8:11107788~11109726:-
HNSC	cis	rs9910055	0.676	rs11079983	ENSG00000267080.4	ASB16-AS1	-4.1	4.8e-05	0.00759	-0.15	-0.19	Total body bone mineral density;	chr17:44120802	chr17:44175973~44186717:-
HNSC	cis	rs11247915	0.501	rs34209692	ENSG00000236782.4	RP11-96L14.7	-4.1	4.8e-05	0.00759	-0.22	-0.19	Obesity-related traits;	chr1:26282291	chr1:26169947~26171821:-
HNSC	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-4.1	4.8e-05	0.00759	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
HNSC	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-4.1	4.8e-05	0.00759	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-4.1	4.8e-05	0.00759	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-4.1	4.8e-05	0.00759	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-4.1	4.8e-05	0.00759	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
HNSC	cis	rs1790761	0.505	rs34802338	ENSG00000184224.3	C11orf72	-4.1	4.8e-05	0.00759	-0.23	-0.19	Mean corpuscular volume;	chr11:67544995	chr11:67602880~67606706:-
HNSC	cis	rs7113874	0.659	rs7935453	ENSG00000212607.1	SNORA45B	4.1	4.8e-05	0.00759	0.19	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr11:8685439~8685569:+
HNSC	cis	rs10462794	0.789	rs6862041	ENSG00000260763.1	RP11-445O3.3	4.1	4.8e-05	0.00759	0.23	0.19	DNA methylation (variation);	chr5:4477695	chr5:4436850~4440259:-
HNSC	cis	rs7765004	0.887	rs7760821	ENSG00000228624.6	RP3-399L15.3	4.1	4.8e-05	0.00759	0.19	0.19	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113757201	chr6:113969701~114471705:+
HNSC	cis	rs3738443	0.83	rs6684181	ENSG00000259865.1	RP11-488L18.10	4.1	4.8e-05	0.00759	0.18	0.19	Alcohol dependence;	chr1:247184669	chr1:247187281~247188526:-
HNSC	cis	rs9313772	0.802	rs13436194	ENSG00000254350.1	RP11-542A14.1	-4.1	4.81e-05	0.00759	-0.2	-0.19	Blood pressure;	chr5:158376580	chr5:158424585~158452758:+
HNSC	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	4.1	4.81e-05	0.00759	0.27	0.19	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	4.1	4.81e-05	0.00759	0.27	0.19	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	4.1	4.81e-05	0.00759	0.27	0.19	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
HNSC	cis	rs870825	0.929	rs55746424	ENSG00000254233.1	RP11-242J7.1	4.1	4.81e-05	0.00759	0.32	0.19	Blood protein levels;	chr4:184668449	chr4:184584093~184625030:-
HNSC	cis	rs12935418	0.672	rs12446304	ENSG00000278985.1	RP11-303E16.9	4.1	4.81e-05	0.00759	0.19	0.19	Mean corpuscular volume;	chr16:81012730	chr16:80982319~80984094:-
HNSC	cis	rs898123	1	rs898123	ENSG00000234896.1	OR7E62P	-4.1	4.81e-05	0.0076	-0.23	-0.19	Coronary artery disease;	chr2:71152220	chr2:71055527~71056003:+
HNSC	cis	rs6500395	1	rs871902	ENSG00000261267.1	RP11-44I10.3	-4.1	4.81e-05	0.0076	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48559868	chr16:48559661~48587403:+
HNSC	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-4.1	4.81e-05	0.0076	-0.26	-0.19	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
HNSC	cis	rs67340775	0.541	rs200979	ENSG00000219392.1	RP1-265C24.5	-4.1	4.81e-05	0.0076	-0.28	-0.19	Lung cancer in ever smokers;	chr6:27884579	chr6:28115628~28116551:+
HNSC	cis	rs739496	0.615	rs59905228	ENSG00000226469.1	ADAM1B	4.1	4.81e-05	0.0076	0.22	0.19	Platelet count;	chr12:111743422	chr12:111927018~111929017:+
HNSC	cis	rs964611	0.882	rs4630496	ENSG00000259488.2	RP11-154J22.1	-4.1	4.81e-05	0.00761	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48366466	chr15:48312353~48331856:-
HNSC	cis	rs67311347	0.956	rs11714871	ENSG00000280739.1	EIF1B-AS1	4.1	4.81e-05	0.00761	0.2	0.19	Renal cell carcinoma;	chr3:40387447	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs2305521	ENSG00000280739.1	EIF1B-AS1	4.1	4.81e-05	0.00761	0.2	0.19	Renal cell carcinoma;	chr3:40387692	chr3:40173145~40309698:-
HNSC	cis	rs2742234	1	rs1864395	ENSG00000273008.1	RP11-351D16.3	-4.1	4.82e-05	0.00761	-0.22	-0.19	Hirschsprung disease;	chr10:43160249	chr10:43136824~43138334:-
HNSC	cis	rs1790761	0.505	rs6591245	ENSG00000184224.3	C11orf72	-4.1	4.82e-05	0.00761	-0.23	-0.19	Mean corpuscular volume;	chr11:67543465	chr11:67602880~67606706:-
HNSC	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	4.1	4.82e-05	0.00762	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
HNSC	cis	rs6710503	0.962	rs56200610	ENSG00000271936.1	RP11-443B20.1	-4.1	4.82e-05	0.00762	-0.2	-0.19	Lung cancer in ever smokers;Breast cancer;	chr2:24743704	chr2:24825610~24826717:+
HNSC	cis	rs2304003	1	rs980231	ENSG00000235192.1	AC009495.2	4.1	4.82e-05	0.00762	0.24	0.19	Social communication problems;	chr2:165824612	chr2:165794851~165810010:+
HNSC	cis	rs6095360	0.727	rs35989889	ENSG00000222365.1	SNORD12B	-4.1	4.83e-05	0.00762	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49100816	chr20:49280319~49280409:+
HNSC	cis	rs9467711	0.79	rs34158769	ENSG00000241549.7	GUSBP2	4.1	4.83e-05	0.00762	0.31	0.19	Autism spectrum disorder or schizophrenia;	chr6:26336344	chr6:26871484~26956554:-
HNSC	cis	rs7735319	0.735	rs3909866	ENSG00000251281.1	CTD-2066L21.2	4.1	4.83e-05	0.00762	0.22	0.19	Systolic blood pressure;	chr5:33050454	chr5:33011322~33017607:-
HNSC	cis	rs9914544	0.583	rs35783872	ENSG00000264885.1	RP11-815I9.4	-4.1	4.83e-05	0.00763	-0.19	-0.19	Educational attainment (years of education);	chr17:18845507	chr17:18667629~18669461:-
HNSC	cis	rs728616	1	rs56317427	ENSG00000225484.5	NUTM2B-AS1	-4.1	4.83e-05	0.00763	-0.39	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79663088~79826594:-
HNSC	cis	rs240993	0.812	rs2025269	ENSG00000230177.1	RP5-1112D6.4	-4.1	4.83e-05	0.00763	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111277932~111278742:+
HNSC	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-4.1	4.83e-05	0.00763	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
HNSC	cis	rs793571	0.822	rs11858989	ENSG00000245975.2	RP11-30K9.6	4.1	4.83e-05	0.00763	0.28	0.19	Schizophrenia;	chr15:58883029	chr15:58768072~58770974:-
HNSC	cis	rs6787172	0.811	rs6795376	ENSG00000272087.1	RP11-379F4.7	4.1	4.83e-05	0.00763	0.19	0.19	Subjective well-being;	chr3:158496682	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs6762860	ENSG00000272087.1	RP11-379F4.7	4.1	4.83e-05	0.00763	0.19	0.19	Subjective well-being;	chr3:158497753	chr3:158693120~158693768:-
HNSC	cis	rs11951515	0.966	rs7706402	ENSG00000249286.1	CTD-2210P15.2	4.1	4.83e-05	0.00763	0.2	0.19	Metabolite levels  (X-11787);	chr5:43381478	chr5:43586918~43588223:-
HNSC	cis	rs11098499	0.863	rs1383533	ENSG00000250412.1	KLHL2P1	4.1	4.83e-05	0.00763	0.24	0.19	Corneal astigmatism;	chr4:119513421	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs2291185	ENSG00000250412.1	KLHL2P1	4.1	4.83e-05	0.00763	0.24	0.19	Corneal astigmatism;	chr4:119513678	chr4:119334329~119378233:+
HNSC	cis	rs2342371	0.756	rs4916492	ENSG00000243339.3	RN7SL738P	-4.1	4.84e-05	0.00764	-0.26	-0.19	Fat distribution (HIV);	chr3:196379435	chr3:196399911~196400207:+
HNSC	cis	rs1387259	0.69	rs1601985	ENSG00000257763.1	OR5BK1P	4.1	4.84e-05	0.00764	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48355792~48356614:-
HNSC	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	4.1	4.84e-05	0.00764	0.4	0.19	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
HNSC	cis	rs1555322	1	rs2425041	ENSG00000279253.1	RP4-614O4.13	-4.1	4.84e-05	0.00764	-0.28	-0.19	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35262727~35264187:-
HNSC	cis	rs12449000	1	rs12449000	ENSG00000261812.4	TUBB8P7	-4.1	4.84e-05	0.00764	-0.21	-0.19	Schizophrenia;	chr16:89806562	chr16:90093154~90096354:+
HNSC	cis	rs4713118	0.869	rs6922574	ENSG00000216901.1	AL022393.7	4.1	4.84e-05	0.00764	0.23	0.19	Parkinson's disease;	chr6:27725224	chr6:28176188~28176674:+
HNSC	cis	rs3736485	0.934	rs4143721	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51574584	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs4143723	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51574975	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs28393906	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51575408	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs17609693	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51575803	chr15:52010999~52019095:-
HNSC	cis	rs929354	0.772	rs1182362	ENSG00000224629.1	RP5-1142J19.2	4.1	4.84e-05	0.00764	0.19	0.19	Body mass index;	chr7:157226841	chr7:157263022~157263229:-
HNSC	cis	rs3736485	0.934	rs2414106	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51576544	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs4143724	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51578216	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs11634999	ENSG00000259438.1	CTD-2650P22.1	4.1	4.84e-05	0.00764	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51579264	chr15:52010999~52019095:-
HNSC	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-4.1	4.84e-05	0.00764	-0.14	-0.19	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
HNSC	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-4.1	4.84e-05	0.00764	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
HNSC	cis	rs9910055	0.529	rs228748	ENSG00000267080.4	ASB16-AS1	4.1	4.84e-05	0.00765	0.15	0.19	Total body bone mineral density;	chr17:44097022	chr17:44175973~44186717:-
HNSC	cis	rs9880211	1	rs28718456	ENSG00000273486.1	RP11-731C17.2	4.1	4.84e-05	0.00765	0.18	0.19	Height;Body mass index;	chr3:136485164	chr3:136837338~136839021:-
HNSC	cis	rs11673344	0.504	rs2595555	ENSG00000267698.1	AC002116.7	4.1	4.84e-05	0.00765	0.16	0.19	Obesity-related traits;	chr19:37000219	chr19:36014508~36045972:+
HNSC	cis	rs11673344	0.504	rs1667377	ENSG00000267698.1	AC002116.7	4.1	4.84e-05	0.00765	0.16	0.19	Obesity-related traits;	chr19:37000966	chr19:36014508~36045972:+
HNSC	cis	rs11673344	0.523	rs1667379	ENSG00000267698.1	AC002116.7	4.1	4.84e-05	0.00765	0.16	0.19	Obesity-related traits;	chr19:37001192	chr19:36014508~36045972:+
HNSC	cis	rs1552244	1	rs67852463	ENSG00000180385.7	EMC3-AS1	4.1	4.85e-05	0.00765	0.22	0.19	Alzheimer's disease;	chr3:10115521	chr3:9986893~10006990:+
HNSC	cis	rs9467711	0.79	rs10484439	ENSG00000241549.7	GUSBP2	4.1	4.85e-05	0.00765	0.31	0.19	Autism spectrum disorder or schizophrenia;	chr6:26309680	chr6:26871484~26956554:-
HNSC	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-4.1	4.85e-05	0.00765	-0.25	-0.19	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
HNSC	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-4.1	4.85e-05	0.00765	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
HNSC	cis	rs131805	0.794	rs131813	ENSG00000205559.3	CHKB-AS1	-4.1	4.85e-05	0.00765	-0.25	-0.19	Granulocyte percentage of myeloid white cells;	chr22:50522740	chr22:50583026~50583877:+
HNSC	cis	rs6095360	0.727	rs1983528	ENSG00000222365.1	SNORD12B	4.1	4.85e-05	0.00765	0.23	0.19	Intelligence (multi-trait analysis);	chr20:49069753	chr20:49280319~49280409:+
HNSC	cis	rs28489187	0.577	rs729655	ENSG00000223653.4	RP11-131L23.1	4.1	4.85e-05	0.00765	0.24	0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85378934	chr1:85276715~85448124:+
HNSC	cis	rs9981595	1	rs9981595	ENSG00000255568.3	BRWD1-AS2	4.1	4.85e-05	0.00765	0.24	0.19	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39313935~39314962:+
HNSC	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-4.1	4.85e-05	0.00765	-0.18	-0.19	Asthma;	chr2:102351615	chr2:102438713~102440475:+
HNSC	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	4.1	4.85e-05	0.00766	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
HNSC	cis	rs988913	0.957	rs9296771	ENSG00000224984.1	RP11-524H19.2	4.1	4.85e-05	0.00766	0.22	0.19	Menarche (age at onset);	chr6:54917476	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.957	rs2064432	ENSG00000224984.1	RP11-524H19.2	4.1	4.85e-05	0.00766	0.22	0.19	Menarche (age at onset);	chr6:54917854	chr6:54840118~54840855:-
HNSC	cis	rs459482	0.576	rs461448	ENSG00000228318.3	AP001610.5	-4.1	4.86e-05	0.00766	-0.21	-0.19	IgG glycosylation;	chr21:41428996	chr21:41441056~41445708:-
HNSC	cis	rs6928977	0.897	rs6570001	ENSG00000231028.7	LINC00271	4.1	4.86e-05	0.00766	0.23	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135330583	chr6:135497801~135716055:+
HNSC	cis	rs6504108	0.624	rs1316657	ENSG00000278765.1	RP5-890E16.5	-4.1	4.86e-05	0.00766	-0.23	-0.19	Body mass index;	chr17:48174029	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs1002330	ENSG00000278765.1	RP5-890E16.5	-4.1	4.86e-05	0.00766	-0.23	-0.19	Body mass index;	chr17:48176153	chr17:48066704~48067293:-
HNSC	cis	rs9393777	0.623	rs34313099	ENSG00000241549.7	GUSBP2	4.1	4.86e-05	0.00766	0.24	0.19	Intelligence (multi-trait analysis);	chr6:26489379	chr6:26871484~26956554:-
HNSC	cis	rs10829156	1	rs10829157	ENSG00000240291.1	RP11-499P20.2	4.1	4.86e-05	0.00766	0.2	0.19	Sudden cardiac arrest;	chr10:18662534	chr10:18513115~18545651:-
HNSC	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	4.1	4.86e-05	0.00766	0.41	0.19	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
HNSC	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	4.1	4.86e-05	0.00766	0.41	0.19	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
HNSC	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-4.1	4.86e-05	0.00766	-0.21	-0.19	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
HNSC	cis	rs516805	0.59	rs1430816	ENSG00000279453.1	RP3-425C14.4	-4.1	4.86e-05	0.00766	-0.28	-0.19	Lymphocyte counts;	chr6:122591978	chr6:122436789~122439223:-
HNSC	cis	rs11168618	0.846	rs11168580	ENSG00000240399.1	RP1-228P16.1	4.1	4.86e-05	0.00767	0.16	0.19	Adiponectin levels;	chr12:48456641	chr12:48054813~48055591:-
HNSC	cis	rs7520050	0.966	rs7522601	ENSG00000280836.1	AL355480.1	4.1	4.86e-05	0.00767	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs10789487	ENSG00000280836.1	AL355480.1	4.1	4.86e-05	0.00767	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs34102169	ENSG00000280836.1	AL355480.1	4.1	4.86e-05	0.00767	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45581219~45581321:-
HNSC	cis	rs6493858	0.839	rs2460648	ENSG00000277245.1	RP11-48G14.3	-4.1	4.86e-05	0.00767	-0.22	-0.19	Relative hand skill in reading disability;	chr15:56241573	chr15:56447120~56447697:+
HNSC	cis	rs4947019	0.609	rs116647873	ENSG00000260273.1	RP11-425D10.10	4.1	4.86e-05	0.00767	0.5	0.19	Hematological parameters;	chr6:109398216	chr6:109382795~109383666:+
HNSC	cis	rs10773046	0.74	rs10846567	ENSG00000269938.1	RP11-214K3.20	4.1	4.86e-05	0.00767	0.21	0.19	Osteoarthritis (hip);	chr12:123875570	chr12:123968023~123968579:-
HNSC	cis	rs16873450	0.527	rs28406908	ENSG00000234800.2	PCMTD1P3	-4.1	4.87e-05	0.00768	-0.18	-0.19	Verbal memory performance (residualized delayed recall level);	chr7:23759574	chr7:23721311~23721782:-
HNSC	cis	rs911555	0.57	rs11625397	ENSG00000269940.1	RP11-73M18.7	-4.1	4.87e-05	0.00768	-0.18	-0.19	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694560~103695170:+
HNSC	cis	rs9910055	0.614	rs12944572	ENSG00000267080.4	ASB16-AS1	-4.1	4.87e-05	0.00768	-0.15	-0.19	Total body bone mineral density;	chr17:44167873	chr17:44175973~44186717:-
HNSC	cis	rs7735319	0.966	rs16890746	ENSG00000251281.1	CTD-2066L21.2	4.1	4.87e-05	0.00768	0.22	0.19	Systolic blood pressure;	chr5:33118567	chr5:33011322~33017607:-
HNSC	cis	rs875971	0.54	rs736270	ENSG00000272831.1	RP11-792A8.4	4.1	4.87e-05	0.00768	0.16	0.19	Aortic root size;	chr7:65963835	chr7:66739829~66740385:-
HNSC	cis	rs4713118	0.869	rs6901520	ENSG00000216901.1	AL022393.7	4.1	4.87e-05	0.00768	0.23	0.19	Parkinson's disease;	chr6:27746796	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9283880	ENSG00000216901.1	AL022393.7	4.1	4.87e-05	0.00768	0.23	0.19	Parkinson's disease;	chr6:27747464	chr6:28176188~28176674:+
HNSC	cis	rs4761470	0.577	rs3803070	ENSG00000258365.1	RP11-1105G2.3	-4.1	4.87e-05	0.00768	-0.2	-0.19	Estradiol plasma levels (breast cancer);	chr12:94294912	chr12:94277758~94282844:-
HNSC	cis	rs6163	0.588	rs12763284	ENSG00000236937.2	PTGES3P4	-4.1	4.87e-05	0.00769	-0.22	-0.19	Waist circumference;Hip circumference;	chr10:102748445	chr10:102845595~102845950:+
HNSC	cis	rs8035957	0.963	rs7173565	ENSG00000259747.1	RP11-275I4.2	4.1	4.88e-05	0.00769	0.2	0.19	Type 1 diabetes;	chr15:38558129	chr15:38671847~38689191:+
HNSC	cis	rs57502260	0.704	rs12286536	ENSG00000212093.1	AP000807.1	4.1	4.88e-05	0.00769	0.28	0.19	Total body bone mineral density (age 45-60);	chr11:68522766	chr11:68506083~68506166:-
HNSC	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-4.1	4.88e-05	0.0077	-0.18	-0.19	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-4.1	4.88e-05	0.0077	-0.18	-0.19	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
HNSC	cis	rs72627509	0.638	rs1608165	ENSG00000269949.1	RP11-738E22.3	4.1	4.88e-05	0.0077	0.3	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57028551	chr4:56960927~56961373:-
HNSC	cis	rs2732480	0.5	rs2932093	ENSG00000257763.1	OR5BK1P	4.1	4.88e-05	0.0077	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48355792~48356614:-
HNSC	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	4.1	4.88e-05	0.0077	0.21	0.19	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
HNSC	cis	rs910316	0.692	rs7156586	ENSG00000279594.1	RP11-950C14.10	4.1	4.88e-05	0.0077	0.23	0.19	Height;	chr14:75039527	chr14:75011269~75012851:-
HNSC	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-4.1	4.88e-05	0.0077	-0.32	-0.19	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
HNSC	cis	rs12893668	0.703	rs4906335	ENSG00000269910.1	RP11-73M18.10	4.1	4.88e-05	0.0077	0.19	0.19	Reticulocyte count;	chr14:103554804	chr14:103694516~103695050:-
HNSC	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-4.1	4.88e-05	0.0077	-0.2	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
HNSC	cis	rs2905347	1	rs2905347	ENSG00000179428.2	AC073072.5	-4.1	4.89e-05	0.0077	-0.22	-0.19	Major depression and alcohol dependence;	chr7:22580700	chr7:22725395~22727620:-
HNSC	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-4.1	4.89e-05	0.0077	-0.26	-0.19	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
HNSC	cis	rs11638352	1	rs2623017	ENSG00000205771.5	CATSPER2P1	4.1	4.89e-05	0.0077	0.51	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44111087	chr15:43726918~43747094:-
HNSC	cis	rs6095360	0.727	rs1556876	ENSG00000222365.1	SNORD12B	-4.1	4.89e-05	0.0077	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49099914	chr20:49280319~49280409:+
HNSC	cis	rs853679	0.882	rs9468300	ENSG00000226314.6	ZNF192P1	-4.1	4.89e-05	0.0077	-0.3	-0.19	Depression;	chr6:28159062	chr6:28161781~28169594:+
HNSC	cis	rs6568686	0.53	rs56340018	ENSG00000255389.1	C6orf3	4.1	4.89e-05	0.0077	0.26	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111620092	chr6:111599875~111602295:+
HNSC	cis	rs2274273	0.682	rs1201378	ENSG00000233924.1	AL160471.6	4.1	4.89e-05	0.00771	0.21	0.19	Protein biomarker;	chr14:55026690	chr14:55004813~55005687:-
HNSC	cis	rs9467773	0.595	rs3846845	ENSG00000241549.7	GUSBP2	4.1	4.89e-05	0.00771	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26444687	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.572	rs3846846	ENSG00000241549.7	GUSBP2	4.1	4.89e-05	0.00771	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26444811	chr6:26871484~26956554:-
HNSC	cis	rs7688540	0.771	rs11722197	ENSG00000211553.1	AC253576.2	-4.1	4.89e-05	0.00771	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs11723261	ENSG00000211553.1	AC253576.2	-4.1	4.89e-05	0.00771	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:136461~136568:+
HNSC	cis	rs8077577	0.945	rs9916193	ENSG00000273018.4	CTD-2303H24.2	-4.1	4.89e-05	0.00771	-0.28	-0.19	Obesity-related traits;	chr17:18153901	chr17:18511221~18551705:-
HNSC	cis	rs10484434	0.792	rs9689245	ENSG00000272810.1	U91328.22	4.1	4.89e-05	0.00771	0.23	0.19	HIV-1 viral setpoint;	chr6:26050617	chr6:26013241~26013757:+
HNSC	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	4.1	4.9e-05	0.00772	0.31	0.19	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
HNSC	cis	rs55823223	0.59	rs11870142	ENSG00000267801.1	RP11-552F3.9	4.1	4.9e-05	0.00772	0.22	0.19	Psoriasis;	chr17:75862921	chr17:75876372~75879546:+
HNSC	cis	rs13434995	0.513	rs2101476	ENSG00000273257.1	RP11-177J6.1	-4.1	4.9e-05	0.00772	-0.26	-0.19	Adiponectin levels;	chr4:55578961	chr4:55387949~55388271:+
HNSC	cis	rs6928977	0.932	rs6931735	ENSG00000217482.2	HMGB1P17	4.1	4.9e-05	0.00772	0.2	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135636086~135636713:-
HNSC	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-4.1	4.9e-05	0.00772	-0.21	-0.19	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
HNSC	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-4.1	4.9e-05	0.00772	-0.3	-0.19	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000233609.3	RP11-62H7.2	-4.1	4.9e-05	0.00772	-0.19	-0.19	Recombination measurement;	chr8:9208015	chr8:8961200~8979025:+
HNSC	cis	rs11098499	0.909	rs9759478	ENSG00000250412.1	KLHL2P1	4.1	4.9e-05	0.00772	0.24	0.19	Corneal astigmatism;	chr4:119446843	chr4:119334329~119378233:+
HNSC	cis	rs10129255	0.912	rs730099	ENSG00000224373.3	IGHV4-59	4.1	4.9e-05	0.00772	0.12	0.19	Kawasaki disease;	chr14:106711838	chr14:106627249~106627825:-
HNSC	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	4.1	4.9e-05	0.00772	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	4.1	4.9e-05	0.00772	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
HNSC	cis	rs6088580	0.601	rs6059827	ENSG00000276073.1	RP5-1125A11.7	-4.1	4.9e-05	0.00772	-0.19	-0.19	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:33985617~33988989:-
HNSC	cis	rs4356203	0.87	rs214919	ENSG00000260196.1	RP1-239B22.5	-4.1	4.9e-05	0.00772	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17380649~17383531:+
HNSC	cis	rs6460942	0.659	rs13247370	ENSG00000226690.5	AC005281.1	4.1	4.9e-05	0.00772	0.29	0.19	Coronary artery disease;	chr7:12475006	chr7:12496429~12541910:+
HNSC	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	4.1	4.9e-05	0.00772	0.17	0.19	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
HNSC	cis	rs6995541	0.518	rs13254592	ENSG00000269918.1	AF131215.9	-4.1	4.9e-05	0.00773	-0.2	-0.19	Triglyceride levels;	chr8:10849761	chr8:11104691~11106704:-
HNSC	cis	rs8035957	1	rs7170151	ENSG00000259747.1	RP11-275I4.2	-4.1	4.91e-05	0.00773	-0.21	-0.19	Type 1 diabetes;	chr15:38554477	chr15:38671847~38689191:+
HNSC	cis	rs757081	0.648	rs7940253	ENSG00000260196.1	RP1-239B22.5	-4.1	4.91e-05	0.00774	-0.2	-0.19	Systolic blood pressure;	chr11:17259049	chr11:17380649~17383531:+
HNSC	cis	rs72843506	0.652	rs28550747	ENSG00000261033.1	RP11-209D14.2	4.1	4.91e-05	0.00774	0.31	0.19	Schizophrenia;	chr17:20274999	chr17:20008051~20009234:-
HNSC	cis	rs7572733	0.84	rs700655	ENSG00000222017.1	AC011997.1	4.1	4.91e-05	0.00774	0.22	0.19	Dermatomyositis;	chr2:197778907	chr2:197693106~197774823:+
HNSC	cis	rs516805	0.667	rs2606624	ENSG00000279453.1	RP3-425C14.4	-4.1	4.91e-05	0.00774	-0.26	-0.19	Lymphocyte counts;	chr6:122168693	chr6:122436789~122439223:-
HNSC	cis	rs11098499	0.863	rs2306456	ENSG00000250412.1	KLHL2P1	4.1	4.92e-05	0.00774	0.24	0.19	Corneal astigmatism;	chr4:119551267	chr4:119334329~119378233:+
HNSC	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	4.1	4.92e-05	0.00775	0.19	0.19	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
HNSC	cis	rs6651255	0.738	rs61199848	ENSG00000224110.3	MTRF1LP2	-4.1	4.92e-05	0.00775	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129745574	chr8:129728744~129730445:+
HNSC	cis	rs442309	0.783	rs10822059	ENSG00000238280.1	RP11-436D10.3	4.1	4.92e-05	0.00775	0.23	0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62767937	chr10:62793562~62805887:-
HNSC	cis	rs5758511	0.514	rs5758580	ENSG00000205702.9	CYP2D7	4.1	4.92e-05	0.00775	0.17	0.19	Birth weight;	chr22:42097871	chr22:42140203~42144577:-
HNSC	cis	rs67981189	0.593	rs12896829	ENSG00000274818.1	RP1-292L20.3	4.1	4.92e-05	0.00775	0.2	0.19	Schizophrenia;	chr14:70996959	chr14:70906657~70907111:-
HNSC	cis	rs561341	1	rs72823787	ENSG00000278867.1	RP11-640N20.4	-4.1	4.92e-05	0.00775	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31956790	chr17:32051030~32053208:+
HNSC	cis	rs929354	0.772	rs1182364	ENSG00000224629.1	RP5-1142J19.2	4.1	4.92e-05	0.00775	0.19	0.19	Body mass index;	chr7:157225218	chr7:157263022~157263229:-
HNSC	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-4.1	4.92e-05	0.00775	-0.22	-0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
HNSC	cis	rs4294134	0.608	rs12707239	ENSG00000223718.3	AC093107.7	4.1	4.92e-05	0.00775	0.28	0.19	Paget's disease;	chr7:135562435	chr7:135660039~135660647:+
HNSC	cis	rs36052053	0.521	rs13200680	ENSG00000219700.1	PTCHD3P3	4.1	4.92e-05	0.00775	0.36	0.19	Red cell distribution width;	chr6:109192842	chr6:109288571~109290503:-
HNSC	cis	rs6493858	0.839	rs2713933	ENSG00000277245.1	RP11-48G14.3	-4.1	4.92e-05	0.00775	-0.22	-0.19	Relative hand skill in reading disability;	chr15:56246364	chr15:56447120~56447697:+
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	4.1	4.92e-05	0.00775	0.22	0.19	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	4.1	4.92e-05	0.00775	0.22	0.19	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
HNSC	cis	rs2243480	1	rs35820085	ENSG00000229886.1	RP5-1132H15.3	4.1	4.92e-05	0.00775	0.32	0.19	Diabetic kidney disease;	chr7:65977771	chr7:66025126~66031544:-
HNSC	cis	rs3808502	0.525	rs9650661	ENSG00000255310.2	AF131215.2	-4.1	4.93e-05	0.00776	-0.18	-0.19	Neuroticism;	chr8:11569624	chr8:11107788~11109726:-
HNSC	cis	rs442309	0.875	rs224067	ENSG00000238280.1	RP11-436D10.3	4.1	4.93e-05	0.00776	0.22	0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62747211	chr10:62793562~62805887:-
HNSC	cis	rs1488902	0.785	rs4002152	ENSG00000280385.1	AP000648.5	4.1	4.93e-05	0.00776	0.21	0.19	Amyotrophic lateral sclerosis;	chr11:89617352	chr11:90193614~90198120:+
HNSC	cis	rs7475343	0.501	rs6601924	ENSG00000224034.1	RP11-445P17.8	4.1	4.93e-05	0.00776	0.26	0.19	Intelligence;	chr10:5205339	chr10:5266033~5271236:-
HNSC	cis	rs1008375	0.897	rs67455495	ENSG00000249502.1	AC006160.5	4.1	4.93e-05	0.00776	0.21	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663615	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs6845288	ENSG00000249502.1	AC006160.5	4.1	4.93e-05	0.00776	0.21	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663875	chr4:17587467~17614571:-
HNSC	cis	rs7824557	0.602	rs1435273	ENSG00000255310.2	AF131215.2	4.1	4.93e-05	0.00776	0.18	0.19	Retinal vascular caliber;	chr8:11351990	chr8:11107788~11109726:-
HNSC	cis	rs792448	1	rs518793	ENSG00000226251.4	RP11-15I11.3	-4.1	4.93e-05	0.00776	-0.24	-0.19	White blood cell count (basophil);	chr1:212414864	chr1:212225278~212238977:-
HNSC	cis	rs950169	0.545	rs4842841	ENSG00000230373.7	GOLGA6L5P	-4.1	4.93e-05	0.00776	-0.22	-0.19	Schizophrenia;	chr15:83972373	chr15:84507885~84516814:-
HNSC	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	4.1	4.93e-05	0.00776	0.23	0.19	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
HNSC	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	4.1	4.93e-05	0.00776	0.28	0.19	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
HNSC	cis	rs5758659	0.652	rs133303	ENSG00000182057.4	OGFRP1	4.1	4.93e-05	0.00776	0.19	0.19	Cognitive function;	chr22:41999238	chr22:42269753~42275196:+
HNSC	cis	rs8028182	0.636	rs7184046	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.93e-05	0.00777	-0.24	-0.19	Sudden cardiac arrest;	chr15:75573809	chr15:75527150~75601205:-
HNSC	cis	rs202072	0.872	rs202042	ENSG00000215022.6	RP1-257A7.4	4.1	4.93e-05	0.00777	0.23	0.19	HIV-1 viral setpoint;	chr6:13277482	chr6:13264861~13295586:-
HNSC	cis	rs11673344	0.543	rs12980849	ENSG00000276846.1	CTD-3220F14.3	4.1	4.93e-05	0.00777	0.2	0.19	Obesity-related traits;	chr19:37160812	chr19:37314868~37315620:-
HNSC	cis	rs7178909	0.835	rs12437459	ENSG00000259677.1	RP11-493E3.1	4.1	4.93e-05	0.00777	0.21	0.19	Common traits (Other);	chr15:89877541	chr15:89876540~89877285:+
HNSC	cis	rs8028182	0.636	rs12909863	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.94e-05	0.00777	-0.24	-0.19	Sudden cardiac arrest;	chr15:75533481	chr15:75527150~75601205:-
HNSC	cis	rs12893668	0.572	rs2273175	ENSG00000269910.1	RP11-73M18.10	4.1	4.94e-05	0.00777	0.18	0.19	Reticulocyte count;	chr14:103693804	chr14:103694516~103695050:-
HNSC	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	4.1	4.94e-05	0.00777	0.13	0.19	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
HNSC	cis	rs9652601	0.691	rs7186145	ENSG00000274038.1	RP11-66H6.4	-4.1	4.94e-05	0.00777	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11117021	chr16:11056556~11057034:+
HNSC	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	4.1	4.94e-05	0.00778	0.22	0.19	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
HNSC	cis	rs8028182	0.636	rs62027181	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.94e-05	0.00778	-0.24	-0.19	Sudden cardiac arrest;	chr15:75547611	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.636	rs28623700	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.94e-05	0.00778	-0.24	-0.19	Sudden cardiac arrest;	chr15:75557373	chr15:75527150~75601205:-
HNSC	cis	rs8028182	0.577	rs28693593	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.94e-05	0.00778	-0.24	-0.19	Sudden cardiac arrest;	chr15:75557435	chr15:75527150~75601205:-
HNSC	cis	rs11648785	0.506	rs3743829	ENSG00000221819.5	GAS8-AS1	4.1	4.94e-05	0.00778	0.19	0.19	Tanning;	chr16:90027561	chr16:90028908~90029367:-
HNSC	cis	rs4356203	0.87	rs10832751	ENSG00000272034.1	SNORD14A	-4.1	4.94e-05	0.00778	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17074654~17074744:-
HNSC	cis	rs7824557	0.602	rs7815463	ENSG00000255310.2	AF131215.2	4.1	4.94e-05	0.00778	0.18	0.19	Retinal vascular caliber;	chr8:11353474	chr8:11107788~11109726:-
HNSC	cis	rs5758511	0.514	rs5751211	ENSG00000205702.9	CYP2D7	4.1	4.94e-05	0.00778	0.17	0.19	Birth weight;	chr22:42090052	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.514	rs3985938	ENSG00000205702.9	CYP2D7	4.1	4.94e-05	0.00778	0.17	0.19	Birth weight;	chr22:42115723	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.514	rs5751221	ENSG00000205702.9	CYP2D7	4.1	4.94e-05	0.00778	0.17	0.19	Birth weight;	chr22:42120362	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.514	rs5758586	ENSG00000205702.9	CYP2D7	4.1	4.94e-05	0.00778	0.17	0.19	Birth weight;	chr22:42121467	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.514	rs5751222	ENSG00000205702.9	CYP2D7	4.1	4.94e-05	0.00778	0.17	0.19	Birth weight;	chr22:42121918	chr22:42140203~42144577:-
HNSC	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-4.1	4.95e-05	0.00778	-0.2	-0.19	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
HNSC	cis	rs793571	0.822	rs2279719	ENSG00000245975.2	RP11-30K9.6	4.1	4.95e-05	0.00779	0.31	0.19	Schizophrenia;	chr15:58933619	chr15:58768072~58770974:-
HNSC	cis	rs1865760	0.686	rs12210098	ENSG00000272810.1	U91328.22	-4.1	4.95e-05	0.00779	-0.18	-0.19	Height;	chr6:25963738	chr6:26013241~26013757:+
HNSC	cis	rs1008375	0.8	rs35463363	ENSG00000249502.1	AC006160.5	-4.1	4.95e-05	0.00779	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17611800	chr4:17587467~17614571:-
HNSC	cis	rs7475343	0.501	rs7893850	ENSG00000224034.1	RP11-445P17.8	-4.1	4.95e-05	0.00779	-0.26	-0.19	Intelligence;	chr10:5209519	chr10:5266033~5271236:-
HNSC	cis	rs4803480	0.63	rs16975338	ENSG00000270164.1	LINC01480	4.1	4.95e-05	0.00779	0.22	0.19	Schizophrenia;	chr19:41551655	chr19:41535183~41536904:+
HNSC	cis	rs17076726	0.519	rs6556093	ENSG00000253785.1	CTC-308K20.3	-4.1	4.95e-05	0.00779	-0.2	-0.19	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173906583	chr5:172975511~172976374:+
HNSC	cis	rs929354	0.772	rs6459741	ENSG00000224629.1	RP5-1142J19.2	-4.1	4.95e-05	0.0078	-0.19	-0.19	Body mass index;	chr7:157221859	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.772	rs1182365	ENSG00000224629.1	RP5-1142J19.2	4.1	4.95e-05	0.0078	0.19	0.19	Body mass index;	chr7:157224561	chr7:157263022~157263229:-
HNSC	cis	rs929354	0.709	rs1182363	ENSG00000224629.1	RP5-1142J19.2	4.1	4.95e-05	0.0078	0.19	0.19	Body mass index;	chr7:157226457	chr7:157263022~157263229:-
HNSC	cis	rs1790761	0.587	rs4930431	ENSG00000184224.3	C11orf72	-4.1	4.95e-05	0.0078	-0.22	-0.19	Mean corpuscular volume;	chr11:67526837	chr11:67602880~67606706:-
HNSC	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	4.1	4.96e-05	0.0078	0.23	0.19	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
HNSC	cis	rs12893668	0.603	rs61637848	ENSG00000269910.1	RP11-73M18.10	4.1	4.96e-05	0.0078	0.18	0.19	Reticulocyte count;	chr14:103629694	chr14:103694516~103695050:-
HNSC	cis	rs4819052	1	rs733739	ENSG00000223768.1	LINC00205	-4.1	4.96e-05	0.0078	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45293285~45297354:+
HNSC	cis	rs12893668	0.572	rs11846404	ENSG00000269910.1	RP11-73M18.10	4.1	4.96e-05	0.0078	0.18	0.19	Reticulocyte count;	chr14:103689771	chr14:103694516~103695050:-
HNSC	cis	rs3736485	0.868	rs9744054	ENSG00000274528.1	CTD-2650P22.2	4.1	4.96e-05	0.0078	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51640966	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.932	rs2899477	ENSG00000274528.1	CTD-2650P22.2	4.1	4.96e-05	0.0078	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51645504	chr15:52017167~52018032:-
HNSC	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-4.1	4.96e-05	0.0078	-0.24	-0.19	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
HNSC	cis	rs1008375	1	rs2315561	ENSG00000249502.1	AC006160.5	-4.1	4.96e-05	0.0078	-0.2	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678072	chr4:17587467~17614571:-
HNSC	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	4.1	4.96e-05	0.0078	0.22	0.19	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
HNSC	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	4.1	4.96e-05	0.0078	0.16	0.19	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
HNSC	cis	rs9329221	0.532	rs2062333	ENSG00000269918.1	AF131215.9	4.1	4.96e-05	0.00781	0.18	0.19	Neuroticism;	chr8:10123639	chr8:11104691~11106704:-
HNSC	cis	rs4853525	0.59	rs11893307	ENSG00000228509.4	AC006460.2	-4.1	4.96e-05	0.00781	-0.26	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863318	chr2:190676944~190708716:-
HNSC	cis	rs7572733	0.534	rs700664	ENSG00000231621.1	AC013264.2	-4.1	4.96e-05	0.00781	-0.18	-0.19	Dermatomyositis;	chr2:197806421	chr2:197197991~197199273:+
HNSC	cis	rs700651	0.821	rs700666	ENSG00000231621.1	AC013264.2	-4.1	4.96e-05	0.00781	-0.18	-0.19	Intracranial aneurysm;	chr2:197808820	chr2:197197991~197199273:+
HNSC	cis	rs9584850	0.834	rs12463	ENSG00000231194.1	FARP1-AS1	4.1	4.96e-05	0.00781	0.23	0.19	Neuroticism;	chr13:98453048	chr13:98435405~98435840:-
HNSC	cis	rs9584850	0.834	rs8481	ENSG00000231194.1	FARP1-AS1	4.1	4.96e-05	0.00781	0.23	0.19	Neuroticism;	chr13:98453141	chr13:98435405~98435840:-
HNSC	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-4.1	4.97e-05	0.00781	-0.21	-0.19	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-4.1	4.97e-05	0.00781	-0.21	-0.19	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
HNSC	cis	rs1832007	0.809	rs17134604	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Triglyceride levels;Triglycerides;	chr10:5219293	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.519	rs77896903	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Metabolic traits;	chr10:5219528	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs17134608	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220056	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs79849481	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220133	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs79717793	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220304	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs78231592	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220527	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs75529951	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220549	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs112455458	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220920	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs111932715	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5220978	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs17134610	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5221060	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs75413156	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5221531	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs80011059	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5221553	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs17134617	ENSG00000224034.1	RP11-445P17.8	-4.1	4.97e-05	0.00781	-0.26	-0.19	Intelligence;	chr10:5221739	chr10:5266033~5271236:-
HNSC	cis	rs7716219	0.751	rs1983189	ENSG00000251307.1	RP11-506H20.1	-4.1	4.97e-05	0.00781	-0.2	-0.19	Height;	chr5:55590853	chr5:55233934~55295201:+
HNSC	cis	rs4308124	0.708	rs2137168	ENSG00000230499.1	AC108463.1	-4.1	4.97e-05	0.00781	-0.22	-0.19	Vitiligo;	chr2:111228932	chr2:111195963~111206494:+
HNSC	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	4.1	4.97e-05	0.00781	0.24	0.19	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
HNSC	cis	rs4763879	0.778	rs11052497	ENSG00000278635.1	CTD-2318O12.1	4.1	4.97e-05	0.00781	0.14	0.19	Type 1 diabetes;	chr12:9696679	chr12:9415641~9416718:+
HNSC	cis	rs4761470	0.577	rs55836966	ENSG00000258365.1	RP11-1105G2.3	-4.1	4.97e-05	0.00781	-0.21	-0.19	Estradiol plasma levels (breast cancer);	chr12:94287384	chr12:94277758~94282844:-
HNSC	cis	rs17772222	0.917	rs61984708	ENSG00000258789.1	RP11-507K2.3	-4.1	4.97e-05	0.00782	-0.22	-0.19	Coronary artery calcification;	chr14:88565523	chr14:88551597~88552493:+
HNSC	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	4.1	4.97e-05	0.00782	0.22	0.19	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
HNSC	cis	rs11098499	0.863	rs3733525	ENSG00000250412.1	KLHL2P1	4.1	4.97e-05	0.00782	0.24	0.19	Corneal astigmatism;	chr4:119525893	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775847	ENSG00000250412.1	KLHL2P1	4.1	4.97e-05	0.00782	0.24	0.19	Corneal astigmatism;	chr4:119526487	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775848	ENSG00000250412.1	KLHL2P1	4.1	4.97e-05	0.00782	0.24	0.19	Corneal astigmatism;	chr4:119526569	chr4:119334329~119378233:+
HNSC	cis	rs10129255	0.917	rs7142373	ENSG00000280411.1	IGHV1-69-2	-4.1	4.97e-05	0.00782	-0.14	-0.19	Kawasaki disease;	chr14:106708947	chr14:106762092~106762588:-
HNSC	cis	rs9952991	0.941	rs9952749	ENSG00000260302.1	RP11-973H7.1	-4.1	4.98e-05	0.00782	-0.31	-0.19	Inflammatory skin disease;	chr18:12780457	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.943	rs9952753	ENSG00000260302.1	RP11-973H7.1	-4.1	4.98e-05	0.00782	-0.31	-0.19	Inflammatory skin disease;	chr18:12780464	chr18:12774651~12775923:-
HNSC	cis	rs17412738	0.607	rs10935011	ENSG00000248724.5	NPHP3-AS1	-4.09	4.98e-05	0.00782	-0.31	-0.19	Blood protein levels;	chr3:132449977	chr3:132721750~132874223:+
HNSC	cis	rs4356203	0.905	rs594034	ENSG00000272034.1	SNORD14A	-4.09	4.98e-05	0.00782	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17074654~17074744:-
HNSC	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-4.09	4.98e-05	0.00782	-0.21	-0.19	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
HNSC	cis	rs6586111	1	rs4934371	ENSG00000226659.1	RP11-137H2.4	4.09	4.98e-05	0.00783	0.23	0.19	Capecitabine sensitivity;	chr10:80613039	chr10:80529597~80535942:-
HNSC	cis	rs10504130	0.569	rs35032384	ENSG00000253844.1	RP11-546K22.1	-4.09	4.98e-05	0.00783	-0.28	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51961458~52022974:+
HNSC	cis	rs1008375	0.932	rs7697329	ENSG00000249502.1	AC006160.5	-4.09	4.98e-05	0.00783	-0.21	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656230	chr4:17587467~17614571:-
HNSC	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	4.09	4.98e-05	0.00783	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	4.09	4.98e-05	0.00783	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	4.09	4.98e-05	0.00783	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
HNSC	cis	rs1979679	1	rs11049506	ENSG00000247934.4	RP11-967K21.1	4.09	4.98e-05	0.00783	0.2	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28289141	chr12:28163298~28190738:-
HNSC	cis	rs7927592	0.731	rs11228288	ENSG00000255031.4	RP11-802E16.3	4.09	4.98e-05	0.00783	0.15	0.19	Total body bone mineral density;	chr11:68586082	chr11:68050740~68053762:+
HNSC	cis	rs1538138	0.565	rs2105123	ENSG00000226453.1	RP11-379B8.1	-4.09	4.98e-05	0.00783	-0.21	-0.19	Corneal structure;	chr6:82099113	chr6:81845185~81933480:-
HNSC	cis	rs7824557	0.527	rs2736298	ENSG00000255310.2	AF131215.2	-4.09	4.98e-05	0.00783	-0.17	-0.19	Retinal vascular caliber;	chr8:11377627	chr8:11107788~11109726:-
HNSC	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	4.09	4.98e-05	0.00783	0.23	0.19	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	4.09	4.99e-05	0.00784	0.24	0.19	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
HNSC	cis	rs1062753	0.527	rs2187959	ENSG00000227370.1	RP4-669P10.19	4.09	4.99e-05	0.00784	0.18	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41951840	chr22:42132543~42132998:+
HNSC	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	4.09	4.99e-05	0.00784	0.23	0.19	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
HNSC	cis	rs8035957	0.824	rs11073334	ENSG00000259747.1	RP11-275I4.2	4.09	4.99e-05	0.00784	0.23	0.19	Type 1 diabetes;	chr15:38528949	chr15:38671847~38689191:+
HNSC	cis	rs2239557	0.539	rs2302117	ENSG00000259065.1	RP5-1021I20.1	-4.09	4.99e-05	0.00784	-0.27	-0.19	Common traits (Other);	chr14:73988110	chr14:73787360~73803270:+
HNSC	cis	rs2239557	0.539	rs62005063	ENSG00000259065.1	RP5-1021I20.1	-4.09	4.99e-05	0.00784	-0.27	-0.19	Common traits (Other);	chr14:73989276	chr14:73787360~73803270:+
HNSC	cis	rs11992186	0.597	rs77717027	ENSG00000173295.6	FAM86B3P	-4.09	4.99e-05	0.00784	-0.22	-0.19	Neuroticism;	chr8:8734122	chr8:8228595~8244865:+
HNSC	cis	rs2243480	1	rs34560516	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65939105	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs57057549	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65940751	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65946971	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2961102	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65959671	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34970380	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65966506	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65966800	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs906134	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65979301	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	4.09	4.99e-05	0.00785	0.32	0.19	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-4.09	4.99e-05	0.00785	-0.25	-0.19	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-4.09	4.99e-05	0.00785	-0.25	-0.19	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-4.09	4.99e-05	0.00785	-0.25	-0.19	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-4.09	4.99e-05	0.00785	-0.25	-0.19	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
HNSC	cis	rs6601327	0.641	rs7462070	ENSG00000254340.1	RP11-10A14.3	-4.09	4.99e-05	0.00785	-0.22	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:9141424~9145435:+
HNSC	cis	rs3808502	0.563	rs12549144	ENSG00000255310.2	AF131215.2	4.09	4.99e-05	0.00785	0.18	0.19	Neuroticism;	chr8:11565352	chr8:11107788~11109726:-
HNSC	cis	rs9313772	0.928	rs7721599	ENSG00000254350.1	RP11-542A14.1	-4.09	5e-05	0.00785	-0.21	-0.19	Blood pressure;	chr5:158392983	chr5:158424585~158452758:+
HNSC	cis	rs7824557	0.603	rs11250130	ENSG00000255310.2	AF131215.2	-4.09	5e-05	0.00785	-0.18	-0.19	Retinal vascular caliber;	chr8:11356946	chr8:11107788~11109726:-
HNSC	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	4.09	5e-05	0.00785	0.18	0.19	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
HNSC	cis	rs240993	0.68	rs2075965	ENSG00000255389.1	C6orf3	4.09	5e-05	0.00785	0.24	0.19	Inflammatory skin disease;Psoriasis;	chr6:111563386	chr6:111599875~111602295:+
HNSC	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	4.09	5e-05	0.00785	0.17	0.19	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
HNSC	cis	rs516805	0.631	rs2606647	ENSG00000279453.1	RP3-425C14.4	-4.09	5e-05	0.00785	-0.26	-0.19	Lymphocyte counts;	chr6:122118967	chr6:122436789~122439223:-
HNSC	cis	rs13325613	0.834	rs13095940	ENSG00000223552.1	RP11-24F11.2	-4.09	5e-05	0.00785	-0.33	-0.19	Monocyte count;	chr3:46205325	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs3176826	ENSG00000223552.1	RP11-24F11.2	-4.09	5e-05	0.00785	-0.33	-0.19	Monocyte count;	chr3:46206093	chr3:46364955~46407059:-
HNSC	cis	rs2834288	0.645	rs2032313	ENSG00000273102.1	AP000569.9	4.09	5e-05	0.00785	0.2	0.19	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33967101~33968573:-
HNSC	cis	rs73201462	1	rs11715394	ENSG00000231305.3	RP11-723O4.2	-4.09	5e-05	0.00785	-0.28	-0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128174721	chr3:128861313~128871540:-
HNSC	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	4.09	5e-05	0.00785	0.2	0.19	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
HNSC	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	4.09	5e-05	0.00785	0.26	0.19	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
HNSC	cis	rs897984	0.644	rs73524556	ENSG00000279196.1	RP11-1072A3.3	4.09	5e-05	0.00786	0.21	0.19	Dementia with Lewy bodies;	chr16:30811841	chr16:30984630~30988270:-
HNSC	cis	rs911555	0.755	rs2756122	ENSG00000269940.1	RP11-73M18.7	4.09	5e-05	0.00786	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103694560~103695170:+
HNSC	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	4.09	5e-05	0.00786	0.48	0.19	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
HNSC	cis	rs4144743	1	rs2015049	ENSG00000228782.6	CTD-2026D20.3	-4.09	5e-05	0.00786	-0.22	-0.19	Body mass index;	chr17:47254865	chr17:47450568~47492492:-
HNSC	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-4.09	5.01e-05	0.00786	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
HNSC	cis	rs1009077	0.582	rs3756155	ENSG00000245958.5	RP11-33B1.1	4.09	5.01e-05	0.00786	0.22	0.19	Endometriosis;	chr4:119602915	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs78520912	ENSG00000245958.5	RP11-33B1.1	4.09	5.01e-05	0.00786	0.22	0.19	Endometriosis;	chr4:119604576	chr4:119454791~119552025:+
HNSC	cis	rs143985986	1	rs143985986	ENSG00000273493.1	RP11-80H18.4	4.09	5.01e-05	0.00787	0.21	0.19	Hematocrit;	chr3:58414160	chr3:58329965~58330118:+
HNSC	cis	rs71520386	0.807	rs10263435	ENSG00000230658.1	KLHL7-AS1	4.09	5.01e-05	0.00787	0.27	0.19	Fibrinogen levels;	chr7:22790243	chr7:23101228~23105703:-
HNSC	cis	rs11098499	0.739	rs2203039	ENSG00000250412.1	KLHL2P1	-4.09	5.01e-05	0.00787	-0.22	-0.19	Corneal astigmatism;	chr4:119211192	chr4:119334329~119378233:+
HNSC	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	4.09	5.01e-05	0.00787	0.27	0.19	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
HNSC	cis	rs4906332	1	rs8004780	ENSG00000244691.1	RPL10AP1	-4.09	5.02e-05	0.00787	-0.22	-0.19	Coronary artery disease;	chr14:103387023	chr14:103412119~103412761:-
HNSC	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	4.09	5.02e-05	0.00788	0.2	0.19	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
HNSC	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-4.09	5.02e-05	0.00788	-0.24	-0.19	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
HNSC	cis	rs7927592	0.912	rs55767696	ENSG00000255031.4	RP11-802E16.3	4.09	5.02e-05	0.00788	0.17	0.19	Total body bone mineral density;	chr11:68607652	chr11:68050740~68053762:+
HNSC	cis	rs11893307	0.536	rs6719798	ENSG00000235852.1	AC005540.3	4.09	5.02e-05	0.00788	0.26	0.19	Mean platelet volume;	chr2:190812938	chr2:190880797~190882059:-
HNSC	cis	rs9611565	0.659	rs73178641	ENSG00000235513.1	RP4-756G23.5	4.09	5.02e-05	0.00788	0.22	0.19	Vitiligo;	chr22:41556071	chr22:41209122~41217627:-
HNSC	cis	rs7777677	0.925	rs6969951	ENSG00000276953.1	TRBV12-4	-4.09	5.02e-05	0.00788	-0.17	-0.19	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142563740~142564245:+
HNSC	cis	rs9733	0.744	rs12568757	ENSG00000236713.1	RP11-363I22.3	4.09	5.02e-05	0.00788	0.2	0.19	Tonsillectomy;	chr1:150757317	chr1:150780272~150780644:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000229886.1	RP5-1132H15.3	4.09	5.02e-05	0.00788	0.32	0.19	Diabetic kidney disease;	chr7:65918494	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs56291018	ENSG00000229886.1	RP5-1132H15.3	4.09	5.02e-05	0.00788	0.32	0.19	Diabetic kidney disease;	chr7:65925352	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs36033484	ENSG00000229886.1	RP5-1132H15.3	4.09	5.02e-05	0.00788	0.32	0.19	Diabetic kidney disease;	chr7:65925571	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34193460	ENSG00000229886.1	RP5-1132H15.3	4.09	5.02e-05	0.00788	0.32	0.19	Diabetic kidney disease;	chr7:65928123	chr7:66025126~66031544:-
HNSC	cis	rs12762955	0.528	rs10903358	ENSG00000229869.1	RP11-363N22.2	-4.09	5.02e-05	0.00788	-0.27	-0.19	Response to angiotensin II receptor blocker therapy;	chr10:1056446	chr10:933026~942743:+
HNSC	cis	rs11722228	0.522	rs1109472	ENSG00000250413.1	RP11-448G15.1	-4.09	5.02e-05	0.00788	-0.27	-0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10006482~10009725:+
HNSC	cis	rs8024893	0.764	rs8036245	ENSG00000270055.1	CTD-3092A11.2	4.09	5.02e-05	0.00788	0.26	0.19	Red cell distribution width;	chr15:31242211	chr15:30487963~30490313:+
HNSC	cis	rs7824557	0.564	rs13260727	ENSG00000269918.1	AF131215.9	4.09	5.02e-05	0.00789	0.18	0.19	Retinal vascular caliber;	chr8:11375351	chr8:11104691~11106704:-
HNSC	cis	rs9487051	0.621	rs351726	ENSG00000243587.6	C6orf183	-4.09	5.02e-05	0.00789	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109227101	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs830552	ENSG00000243587.6	C6orf183	-4.09	5.02e-05	0.00789	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109228711	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs351722	ENSG00000243587.6	C6orf183	-4.09	5.02e-05	0.00789	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109229736	chr6:109165833~109271014:+
HNSC	cis	rs35306767	0.714	rs11250228	ENSG00000229869.1	RP11-363N22.2	-4.09	5.03e-05	0.00789	-0.25	-0.19	Eosinophil percentage of granulocytes;	chr10:1028947	chr10:933026~942743:+
HNSC	cis	rs889398	0.771	rs1500337	ENSG00000196696.11	PDXDC2P	4.09	5.03e-05	0.00789	0.13	0.19	Body mass index;	chr16:69867981	chr16:69976297~70065948:-
HNSC	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-4.09	5.03e-05	0.00789	-0.22	-0.19	Height;	chr14:75199326	chr14:75011269~75012851:-
HNSC	cis	rs240993	0.812	rs455645	ENSG00000230177.1	RP5-1112D6.4	-4.09	5.03e-05	0.00789	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111373870	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs462779	ENSG00000230177.1	RP5-1112D6.4	-4.09	5.03e-05	0.00789	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111374684	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs461646	ENSG00000230177.1	RP5-1112D6.4	-4.09	5.03e-05	0.00789	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111375054	chr6:111277932~111278742:+
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	4.09	5.03e-05	0.00789	0.22	0.19	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
HNSC	cis	rs6651255	0.738	rs4633026	ENSG00000224110.3	MTRF1LP2	-4.09	5.03e-05	0.00789	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129740162	chr8:129728744~129730445:+
HNSC	cis	rs6651255	0.738	rs4367506	ENSG00000224110.3	MTRF1LP2	-4.09	5.03e-05	0.00789	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129740479	chr8:129728744~129730445:+
HNSC	cis	rs6651255	0.738	rs7844275	ENSG00000224110.3	MTRF1LP2	-4.09	5.03e-05	0.00789	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129741357	chr8:129728744~129730445:+
HNSC	cis	rs6651255	0.688	rs4559213	ENSG00000224110.3	MTRF1LP2	-4.09	5.03e-05	0.00789	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129741496	chr8:129728744~129730445:+
HNSC	cis	rs6651255	0.738	rs4733737	ENSG00000224110.3	MTRF1LP2	-4.09	5.03e-05	0.00789	-0.21	-0.19	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129742473	chr8:129728744~129730445:+
HNSC	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	4.09	5.03e-05	0.00789	0.17	0.19	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
HNSC	cis	rs1941023	0.967	rs10897077	ENSG00000279632.1	RP11-286N22.6	-4.09	5.03e-05	0.00789	-0.2	-0.19	Congenital heart disease (maternal effect);	chr11:60517309	chr11:61426448~61427325:-
HNSC	cis	rs11673344	0.523	rs36096221	ENSG00000276846.1	CTD-3220F14.3	4.09	5.03e-05	0.00789	0.2	0.19	Obesity-related traits;	chr19:37060838	chr19:37314868~37315620:-
HNSC	cis	rs913655	0.508	rs10829297	ENSG00000225527.1	RP11-383B4.4	-4.09	5.03e-05	0.00789	-0.22	-0.19	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18725041	chr10:18531849~18533336:-
HNSC	cis	rs597539	0.652	rs667989	ENSG00000261625.1	RP11-554A11.4	-4.09	5.03e-05	0.0079	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:69000765~69002048:-
HNSC	cis	rs10073892	0.701	rs10055840	ENSG00000250682.4	LINC00491	-4.09	5.03e-05	0.0079	-0.25	-0.19	Cognitive decline (age-related);	chr5:102388744	chr5:102609156~102671559:-
HNSC	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-4.09	5.03e-05	0.0079	-0.21	-0.19	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-4.09	5.03e-05	0.0079	-0.21	-0.19	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-4.09	5.03e-05	0.0079	-0.21	-0.19	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
HNSC	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-4.09	5.03e-05	0.0079	-0.21	-0.19	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
HNSC	cis	rs9910055	0.659	rs227584	ENSG00000267080.4	ASB16-AS1	-4.09	5.03e-05	0.0079	-0.15	-0.19	Total body bone mineral density;	chr17:44148179	chr17:44175973~44186717:-
HNSC	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-4.09	5.03e-05	0.0079	-0.24	-0.19	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
HNSC	cis	rs9863	0.861	rs12317176	ENSG00000270028.1	RP11-380L11.4	4.09	5.04e-05	0.0079	0.22	0.19	White blood cell count;	chr12:123920171	chr12:123925461~123926083:-
HNSC	cis	rs9329221	0.508	rs6601455	ENSG00000269918.1	AF131215.9	4.09	5.04e-05	0.0079	0.19	0.19	Neuroticism;	chr8:10415916	chr8:11104691~11106704:-
HNSC	cis	rs4144743	0.759	rs16941731	ENSG00000228782.6	CTD-2026D20.3	4.09	5.04e-05	0.0079	0.25	0.19	Body mass index;	chr17:47239656	chr17:47450568~47492492:-
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000211976.2	IGHV3-73	-4.09	5.04e-05	0.0079	-0.13	-0.19	Kawasaki disease;	chr14:106781985	chr14:106802694~106803233:-
HNSC	cis	rs2243480	1	rs55895244	ENSG00000229886.1	RP5-1132H15.3	4.09	5.04e-05	0.00791	0.32	0.19	Diabetic kidney disease;	chr7:65922691	chr7:66025126~66031544:-
HNSC	cis	rs7475343	0.538	rs4881403	ENSG00000224034.1	RP11-445P17.8	4.09	5.04e-05	0.00791	0.25	0.19	Intelligence;	chr10:5126498	chr10:5266033~5271236:-
HNSC	cis	rs35000415	0.688	rs13222044	ENSG00000275106.1	RP11-309L24.10	-4.09	5.04e-05	0.00791	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129076471	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.688	rs12536719	ENSG00000275106.1	RP11-309L24.10	-4.09	5.04e-05	0.00791	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129077686	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.688	rs12537284	ENSG00000275106.1	RP11-309L24.10	-4.09	5.04e-05	0.00791	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129077852	chr7:128952527~128953316:-
HNSC	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	4.09	5.04e-05	0.00791	0.18	0.19	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	4.09	5.04e-05	0.00791	0.18	0.19	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
HNSC	cis	rs7005380	0.581	rs28461628	ENSG00000279347.1	RP11-85I17.2	4.09	5.04e-05	0.00791	0.17	0.19	Interstitial lung disease;	chr8:119928627	chr8:119838736~119840385:-
HNSC	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-4.09	5.05e-05	0.00792	-0.24	-0.19	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
HNSC	cis	rs11951515	0.738	rs1564196	ENSG00000249286.1	CTD-2210P15.2	-4.09	5.05e-05	0.00792	-0.19	-0.19	Metabolite levels  (X-11787);	chr5:43338774	chr5:43586918~43588223:-
HNSC	cis	rs6460942	0.597	rs7808537	ENSG00000226690.5	AC005281.1	4.09	5.05e-05	0.00792	0.29	0.19	Coronary artery disease;	chr7:12481287	chr7:12496429~12541910:+
HNSC	cis	rs929354	0.739	rs12533082	ENSG00000224629.1	RP5-1142J19.2	-4.09	5.05e-05	0.00792	-0.19	-0.19	Body mass index;	chr7:157221478	chr7:157263022~157263229:-
HNSC	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	4.09	5.05e-05	0.00792	0.18	0.19	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
HNSC	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-4.09	5.05e-05	0.00792	-0.19	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
HNSC	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-4.09	5.05e-05	0.00792	-0.29	-0.19	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
HNSC	cis	rs1602565	0.858	rs10835487	ENSG00000255450.1	CTD-2063L20.1	-4.09	5.05e-05	0.00792	-0.28	-0.19	Schizophrenia;	chr11:29126571	chr11:29275655~29276565:+
HNSC	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-4.09	5.05e-05	0.00792	-0.2	-0.19	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
HNSC	cis	rs9903692	0.954	rs6847	ENSG00000263412.1	RP5-890E16.2	4.09	5.05e-05	0.00793	0.18	0.19	Pulse pressure;	chr17:48070445	chr17:48045141~48048073:-
HNSC	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-4.09	5.05e-05	0.00793	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-4.09	5.06e-05	0.00793	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-4.09	5.06e-05	0.00793	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-4.09	5.06e-05	0.00793	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
HNSC	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	4.09	5.06e-05	0.00793	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	4.09	5.06e-05	0.00793	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
HNSC	cis	rs988913	0.793	rs9370332	ENSG00000224984.1	RP11-524H19.2	4.09	5.06e-05	0.00793	0.22	0.19	Menarche (age at onset);	chr6:54862277	chr6:54840118~54840855:-
HNSC	cis	rs1979679	0.918	rs1586868	ENSG00000247934.4	RP11-967K21.1	-4.09	5.06e-05	0.00793	-0.2	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28163298~28190738:-
HNSC	cis	rs17489649	0.915	rs6892181	ENSG00000271849.1	CTC-332L22.1	4.09	5.06e-05	0.00793	0.24	0.19	Intelligence (multi-trait analysis);	chr5:109707981	chr5:109687802~109688329:-
HNSC	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	4.09	5.06e-05	0.00793	0.21	0.19	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
HNSC	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-4.09	5.06e-05	0.00793	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-4.09	5.06e-05	0.00793	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-4.09	5.06e-05	0.00793	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-4.09	5.06e-05	0.00793	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
HNSC	cis	rs1218582	0.741	rs7544528	ENSG00000270361.1	RP11-307C12.13	-4.09	5.06e-05	0.00793	-0.21	-0.19	Prostate cancer;	chr1:154872109	chr1:154937370~154938059:+
HNSC	cis	rs6688613	1	rs7545911	ENSG00000215834.7	FMO9P	4.09	5.06e-05	0.00794	0.23	0.19	Refractive astigmatism;	chr1:166978444	chr1:166603675~166631400:+
HNSC	cis	rs7178375	1	rs1474381	ENSG00000215302.7	CTD-3092A11.1	-4.09	5.06e-05	0.00794	-0.28	-0.19	Hypertriglyceridemia;	chr15:30922788	chr15:30470779~30507623:+
HNSC	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-4.09	5.06e-05	0.00794	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
HNSC	cis	rs4873772	0.834	rs4873546	ENSG00000253330.1	RP11-697N18.3	-4.09	5.06e-05	0.00794	-0.24	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47664103	chr8:47511034~47512141:-
HNSC	cis	rs4834770	0.718	rs4833618	ENSG00000250412.1	KLHL2P1	-4.09	5.07e-05	0.00794	-0.21	-0.19	Blood protein levels;	chr4:119388345	chr4:119334329~119378233:+
HNSC	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	4.09	5.07e-05	0.00794	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
HNSC	cis	rs11992162	0.56	rs7846248	ENSG00000255495.1	AC145124.2	4.09	5.07e-05	0.00794	0.21	0.19	Monocyte count;	chr8:11936540	chr8:12194467~12196280:+
HNSC	cis	rs7201929	0.542	rs1131543	ENSG00000214725.6	CDIPT-AS1	4.09	5.07e-05	0.00794	0.21	0.19	QT interval;	chr16:28986676	chr16:29863593~29868053:+
HNSC	cis	rs9650657	0.707	rs2005309	ENSG00000255310.2	AF131215.2	-4.09	5.07e-05	0.00795	-0.18	-0.19	Neuroticism;	chr8:10794660	chr8:11107788~11109726:-
HNSC	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-4.09	5.07e-05	0.00795	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
HNSC	cis	rs12935418	0.583	rs2549841	ENSG00000278985.1	RP11-303E16.9	-4.09	5.07e-05	0.00795	-0.18	-0.19	Mean corpuscular volume;	chr16:80989967	chr16:80982319~80984094:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	4.09	5.07e-05	0.00795	0.32	0.19	Gout;	chr7:66671562	chr7:66025126~66031544:-
HNSC	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	4.09	5.07e-05	0.00795	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
HNSC	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	4.09	5.07e-05	0.00795	0.14	0.19	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
HNSC	cis	rs988913	0.793	rs9370333	ENSG00000224984.1	RP11-524H19.2	4.09	5.08e-05	0.00795	0.22	0.19	Menarche (age at onset);	chr6:54873448	chr6:54840118~54840855:-
HNSC	cis	rs561341	1	rs72823789	ENSG00000278867.1	RP11-640N20.4	-4.09	5.08e-05	0.00795	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31957065	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs2470243	ENSG00000278867.1	RP11-640N20.4	-4.09	5.08e-05	0.00795	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31963936	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs483301	ENSG00000278867.1	RP11-640N20.4	-4.09	5.08e-05	0.00795	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31966379	chr17:32051030~32053208:+
HNSC	cis	rs1559040	1	rs10176342	ENSG00000272156.1	RP11-477N3.1	-4.09	5.08e-05	0.00796	-0.32	-0.19	Sudden cardiac arrest;	chr2:54105941	chr2:54082554~54085066:+
HNSC	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	4.09	5.08e-05	0.00796	0.18	0.19	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
HNSC	cis	rs3806843	0.576	rs246024	ENSG00000276545.1	PCDHGB9P	4.09	5.08e-05	0.00796	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140954367	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.546	rs246023	ENSG00000276545.1	PCDHGB9P	4.09	5.08e-05	0.00796	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140954405	chr5:141439853~141442449:+
HNSC	cis	rs1387259	0.79	rs2732445	ENSG00000257763.1	OR5BK1P	4.09	5.08e-05	0.00796	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48355792~48356614:-
HNSC	cis	rs4763879	0.778	rs7977940	ENSG00000278635.1	CTD-2318O12.1	4.09	5.08e-05	0.00796	0.14	0.19	Type 1 diabetes;	chr12:9686320	chr12:9415641~9416718:+
HNSC	cis	rs11951515	0.7	rs3733769	ENSG00000249286.1	CTD-2210P15.2	4.09	5.08e-05	0.00796	0.2	0.19	Metabolite levels  (X-11787);	chr5:43297042	chr5:43586918~43588223:-
HNSC	cis	rs10129255	0.5	rs4774189	ENSG00000224373.3	IGHV4-59	4.09	5.08e-05	0.00796	0.11	0.19	Kawasaki disease;	chr14:106768275	chr14:106627249~106627825:-
HNSC	cis	rs4388249	1	rs17638392	ENSG00000271849.1	CTC-332L22.1	-4.09	5.08e-05	0.00796	-0.3	-0.19	Schizophrenia;	chr5:109716385	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs2269201	ENSG00000271849.1	CTC-332L22.1	-4.09	5.08e-05	0.00796	-0.3	-0.19	Schizophrenia;	chr5:109716958	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.898	rs2269203	ENSG00000271849.1	CTC-332L22.1	-4.09	5.08e-05	0.00796	-0.3	-0.19	Schizophrenia;	chr5:109717432	chr5:109687802~109688329:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000229886.1	RP5-1132H15.3	4.09	5.08e-05	0.00796	0.32	0.19	Diabetic kidney disease;	chr7:65985932	chr7:66025126~66031544:-
HNSC	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-4.09	5.08e-05	0.00796	-0.24	-0.19	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
HNSC	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	4.09	5.08e-05	0.00796	0.18	0.19	Height;	chr5:37425888	chr5:36666214~36725195:-
HNSC	cis	rs4356203	0.87	rs214922	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.811	rs214920	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214918	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214915	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214914	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.84	rs214911	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214910	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214909	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs618331	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs7949699	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs11024204	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs10741724	ENSG00000260196.1	RP1-239B22.5	-4.09	5.08e-05	0.00796	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17380649~17383531:+
HNSC	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	4.09	5.08e-05	0.00796	0.24	0.19	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	4.09	5.08e-05	0.00796	0.24	0.19	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
HNSC	cis	rs1941023	0.615	rs2298556	ENSG00000279632.1	RP11-286N22.6	4.09	5.09e-05	0.00797	0.2	0.19	Congenital heart disease (maternal effect);	chr11:60503852	chr11:61426448~61427325:-
HNSC	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-4.09	5.09e-05	0.00797	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-4.09	5.09e-05	0.00797	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-4.09	5.09e-05	0.00797	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
HNSC	cis	rs8067545	0.532	rs12946508	ENSG00000261033.1	RP11-209D14.2	-4.09	5.09e-05	0.00797	-0.22	-0.19	Schizophrenia;	chr17:20048746	chr17:20008051~20009234:-
HNSC	cis	rs8067545	0.512	rs4925071	ENSG00000261033.1	RP11-209D14.2	-4.09	5.09e-05	0.00797	-0.22	-0.19	Schizophrenia;	chr17:20051186	chr17:20008051~20009234:-
HNSC	cis	rs8067545	0.532	rs3862151	ENSG00000261033.1	RP11-209D14.2	-4.09	5.09e-05	0.00797	-0.22	-0.19	Schizophrenia;	chr17:20053976	chr17:20008051~20009234:-
HNSC	cis	rs8067545	0.532	rs17759041	ENSG00000261033.1	RP11-209D14.2	-4.09	5.09e-05	0.00797	-0.22	-0.19	Schizophrenia;	chr17:20056653	chr17:20008051~20009234:-
HNSC	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-4.09	5.09e-05	0.00797	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
HNSC	cis	rs7243790	0.805	rs7243441	ENSG00000277324.1	RP11-850A17.1	-4.09	5.09e-05	0.00797	-0.21	-0.19	Diastolic blood pressure;	chr18:54391363	chr18:54268346~54270028:-
HNSC	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-4.09	5.09e-05	0.00798	-0.25	-0.19	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
HNSC	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	4.09	5.1e-05	0.00798	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
HNSC	cis	rs6095360	1	rs1997854	ENSG00000222365.1	SNORD12B	4.09	5.1e-05	0.00798	0.2	0.19	Intelligence (multi-trait analysis);	chr20:48985802	chr20:49280319~49280409:+
HNSC	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-4.09	5.1e-05	0.00798	-0.23	-0.19	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
HNSC	cis	rs57502260	0.704	rs60538784	ENSG00000212093.1	AP000807.1	4.09	5.1e-05	0.00798	0.27	0.19	Total body bone mineral density (age 45-60);	chr11:68619267	chr11:68506083~68506166:-
HNSC	cis	rs10995245	0.84	rs4746525	ENSG00000238280.1	RP11-436D10.3	4.09	5.1e-05	0.00798	0.23	0.19	Narcolepsy;	chr10:62678511	chr10:62793562~62805887:-
HNSC	cis	rs7572733	0.935	rs11675025	ENSG00000222017.1	AC011997.1	4.09	5.1e-05	0.00798	0.22	0.19	Dermatomyositis;	chr2:197973591	chr2:197693106~197774823:+
HNSC	cis	rs4253772	0.53	rs6008662	ENSG00000277232.2	GTSE1-AS1	-4.09	5.1e-05	0.00799	-0.24	-0.19	Cholesterol, total;LDL cholesterol;	chr22:46318020	chr22:46295143~46296660:-
HNSC	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-4.09	5.1e-05	0.00799	-0.21	-0.19	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
HNSC	cis	rs6496044	0.507	rs8034676	ENSG00000259407.1	RP11-158M2.3	-4.09	5.1e-05	0.00799	-0.2	-0.19	Interstitial lung disease;	chr15:85616031	chr15:85744109~85750281:-
HNSC	cis	rs1538138	0.586	rs2016754	ENSG00000226453.1	RP11-379B8.1	-4.09	5.1e-05	0.00799	-0.21	-0.19	Corneal structure;	chr6:82090750	chr6:81845185~81933480:-
HNSC	cis	rs72949976	0.898	rs6732233	ENSG00000270659.1	RP11-105N14.1	4.09	5.11e-05	0.00799	0.19	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213158110	chr2:213152970~213153659:+
HNSC	cis	rs12468579	0.503	rs2355571	ENSG00000235852.1	AC005540.3	-4.09	5.11e-05	0.00799	-0.22	-0.19	JT interval (sulfonylurea treatment interaction);	chr2:190910037	chr2:190880797~190882059:-
HNSC	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	4.09	5.11e-05	0.00799	0.24	0.19	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000272831.1	RP11-792A8.4	4.09	5.11e-05	0.008	0.15	0.19	Aortic root size;	chr7:66712111	chr7:66739829~66740385:-
HNSC	cis	rs1580019	0.922	rs59938271	ENSG00000226468.2	AC018641.7	-4.09	5.11e-05	0.008	-0.26	-0.19	Cognitive ability;	chr7:32445232	chr7:32456963~32457758:-
HNSC	cis	rs2877187	0.576	rs4724170	ENSG00000232006.7	AC005537.2	-4.09	5.11e-05	0.008	-0.21	-0.19	Lung cancer in ever smokers;	chr7:43047003	chr7:42954135~43113931:-
HNSC	cis	rs11148252	0.904	rs9568734	ENSG00000198384.8	TPTE2P3	4.09	5.11e-05	0.008	0.23	0.19	Lewy body disease;	chr13:52430087	chr13:52522632~52586906:+
HNSC	cis	rs11098499	0.863	rs12498539	ENSG00000250412.1	KLHL2P1	4.09	5.11e-05	0.008	0.24	0.19	Corneal astigmatism;	chr4:119547215	chr4:119334329~119378233:+
HNSC	cis	rs3018712	0.532	rs2513289	ENSG00000255031.4	RP11-802E16.3	-4.09	5.11e-05	0.008	-0.21	-0.19	Total body bone mineral density;	chr11:68652187	chr11:68050740~68053762:+
HNSC	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-4.09	5.11e-05	0.008	-0.24	-0.19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
HNSC	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1723270	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:66004843	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	4.09	5.11e-05	0.008	0.32	0.19	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
HNSC	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-4.09	5.11e-05	0.008	-0.25	-0.19	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
HNSC	cis	rs2548724	0.716	rs62371033	ENSG00000250682.4	LINC00491	4.09	5.11e-05	0.008	0.24	0.19	Type 2 diabetes;	chr5:102477424	chr5:102609156~102671559:-
HNSC	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	4.09	5.11e-05	0.008	0.19	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
HNSC	cis	rs5758511	0.513	rs7292782	ENSG00000235513.1	RP4-756G23.5	4.09	5.12e-05	0.00801	0.19	0.19	Birth weight;	chr22:41804320	chr22:41209122~41217627:-
HNSC	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	4.09	5.12e-05	0.00801	0.18	0.19	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	4.09	5.12e-05	0.00801	0.18	0.19	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
HNSC	cis	rs28472312	0.667	rs3922668	ENSG00000259982.1	CDC37P1	-4.09	5.12e-05	0.00801	-0.22	-0.19	Intelligence (multi-trait analysis);	chr16:28981325	chr16:28700294~28701540:-
HNSC	cis	rs7169223	0.653	rs12905740	ENSG00000261762.1	RP11-650L12.2	4.09	5.12e-05	0.00801	0.26	0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78790022	chr15:78589123~78591276:-
HNSC	cis	rs2253762	0.54	rs11200357	ENSG00000276742.1	RP11-500G22.4	4.09	5.12e-05	0.00801	0.28	0.19	Breast cancer;	chr10:122034390	chr10:121956782~121957098:+
HNSC	cis	rs1538138	0.609	rs1556778	ENSG00000226453.1	RP11-379B8.1	-4.09	5.12e-05	0.00801	-0.21	-0.19	Corneal structure;	chr6:82096097	chr6:81845185~81933480:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000224373.3	IGHV4-59	4.09	5.12e-05	0.00801	0.12	0.19	Kawasaki disease;	chr14:106767996	chr14:106627249~106627825:-
HNSC	cis	rs6500602	0.592	rs8051780	ENSG00000280063.1	RP11-295D4.3	4.09	5.12e-05	0.00801	0.15	0.19	Schizophrenia;	chr16:4384373	chr16:4346694~4348648:-
HNSC	cis	rs2342371	0.756	rs12637868	ENSG00000243339.3	RN7SL738P	-4.09	5.12e-05	0.00801	-0.26	-0.19	Fat distribution (HIV);	chr3:196379883	chr3:196399911~196400207:+
HNSC	cis	rs597539	0.652	rs674654	ENSG00000261625.1	RP11-554A11.4	-4.09	5.12e-05	0.00801	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.616	rs513476	ENSG00000261625.1	RP11-554A11.4	-4.09	5.12e-05	0.00801	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:69000765~69002048:-
HNSC	cis	rs67311347	0.544	rs12635762	ENSG00000280739.1	EIF1B-AS1	-4.09	5.12e-05	0.00802	-0.2	-0.19	Renal cell carcinoma;	chr3:40291268	chr3:40173145~40309698:-
HNSC	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-4.09	5.12e-05	0.00802	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
HNSC	cis	rs7688540	0.771	rs11723615	ENSG00000211553.1	AC253576.2	-4.09	5.12e-05	0.00802	-0.29	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:136461~136568:+
HNSC	cis	rs1925953	0.711	rs11209273	ENSG00000233589.1	RP4-694A7.2	-4.09	5.13e-05	0.00802	-0.23	-0.19	Vertical cup-disc ratio;	chr1:68379520	chr1:68479129~68483539:+
HNSC	cis	rs6095360	1	rs6019618	ENSG00000222365.1	SNORD12B	-4.09	5.13e-05	0.00802	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49055001	chr20:49280319~49280409:+
HNSC	cis	rs561341	1	rs561341	ENSG00000278867.1	RP11-640N20.4	-4.09	5.13e-05	0.00802	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31989366	chr17:32051030~32053208:+
HNSC	cis	rs9926296	0.533	rs9938865	ENSG00000261812.4	TUBB8P7	-4.09	5.13e-05	0.00802	-0.2	-0.19	Vitiligo;	chr16:89801389	chr16:90093154~90096354:+
HNSC	cis	rs7520050	0.966	rs6668284	ENSG00000280836.1	AL355480.1	4.09	5.13e-05	0.00802	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45581219~45581321:-
HNSC	cis	rs1113500	0.787	rs4571989	ENSG00000226822.1	RP11-356N1.2	4.09	5.13e-05	0.00802	0.2	0.19	Growth-regulated protein alpha levels;	chr1:108088722	chr1:108071482~108074519:+
HNSC	cis	rs7615952	0.546	rs4428131	ENSG00000241288.6	RP11-379B18.5	-4.09	5.13e-05	0.00802	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125627635	chr3:125827238~125916384:-
HNSC	cis	rs896655	1	rs10811586	ENSG00000229835.2	KHSRPP1	-4.09	5.13e-05	0.00802	-0.19	-0.19	Coronary artery disease;	chr9:21701943	chr9:21695176~21696943:+
HNSC	cis	rs7824557	0.564	rs2572389	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11378883	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs2736301	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11378904	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs2736302	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11378910	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs7821459	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11379172	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs7834572	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11379176	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs4631424	ENSG00000255310.2	AF131215.2	-4.09	5.13e-05	0.00802	-0.17	-0.19	Retinal vascular caliber;	chr8:11379300	chr8:11107788~11109726:-
HNSC	cis	rs5758511	0.508	rs2413667	ENSG00000205702.9	CYP2D7	4.09	5.13e-05	0.00803	0.17	0.19	Birth weight;	chr22:42076233	chr22:42140203~42144577:-
HNSC	cis	rs170183	0.679	rs9636632	ENSG00000233818.1	AP000695.4	-4.09	5.13e-05	0.00803	-0.19	-0.19	Bone mineral density;	chr21:36483462	chr21:36445731~36532408:+
HNSC	cis	rs9584850	0.874	rs7988959	ENSG00000231194.1	FARP1-AS1	4.09	5.13e-05	0.00803	0.23	0.19	Neuroticism;	chr13:98451750	chr13:98435405~98435840:-
HNSC	cis	rs3806843	0.576	rs251370	ENSG00000276545.1	PCDHGB9P	-4.09	5.13e-05	0.00803	-0.22	-0.19	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr5:141439853~141442449:+
HNSC	cis	rs10510102	0.516	rs11200300	ENSG00000226864.1	ATE1-AS1	4.09	5.14e-05	0.00803	0.34	0.19	Breast cancer;	chr10:121977489	chr10:121928312~121951965:+
HNSC	cis	rs17594362	0.697	rs9562318	ENSG00000229473.2	RGS17P1	-4.09	5.14e-05	0.00804	-0.26	-0.19	Multiple sclerosis;	chr13:41563187	chr13:40992779~40993331:-
HNSC	cis	rs17666538	0.585	rs6559063	ENSG00000254207.1	RP11-43A14.1	4.09	5.14e-05	0.00804	0.4	0.19	IgG glycosylation;	chr8:673051	chr8:725188~725877:-
HNSC	cis	rs3015497	0.789	rs3015496	ENSG00000277050.1	RP11-102G14.1	-4.09	5.14e-05	0.00804	-0.18	-0.19	Mean platelet volume;	chr14:50647333	chr14:51637348~51637947:-
HNSC	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	4.09	5.14e-05	0.00804	0.25	0.19	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
HNSC	cis	rs10504130	0.569	rs13275967	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs13274159	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs4436115	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs4573262	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs11785467	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs34004633	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs12679983	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs12680128	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.53	rs4292674	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs4292675	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs76746661	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs71513549	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.502	rs4321994	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.66	rs79691523	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs12676345	ENSG00000253844.1	RP11-546K22.1	-4.09	5.14e-05	0.00804	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs4534123	ENSG00000253844.1	RP11-546K22.1	4.09	5.14e-05	0.00804	0.27	0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51961458~52022974:+
HNSC	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-4.09	5.14e-05	0.00804	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
HNSC	cis	rs11673344	0.542	rs1667380	ENSG00000267698.1	AC002116.7	4.09	5.14e-05	0.00804	0.16	0.19	Obesity-related traits;	chr19:37001848	chr19:36014508~36045972:+
HNSC	cis	rs11098499	0.532	rs4833624	ENSG00000250412.1	KLHL2P1	4.09	5.14e-05	0.00804	0.25	0.19	Corneal astigmatism;	chr4:119664342	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.532	rs12512646	ENSG00000250412.1	KLHL2P1	4.09	5.14e-05	0.00804	0.25	0.19	Corneal astigmatism;	chr4:119664578	chr4:119334329~119378233:+
HNSC	cis	rs2243480	1	rs2420171	ENSG00000229886.1	RP5-1132H15.3	-4.09	5.14e-05	0.00804	-0.32	-0.19	Diabetic kidney disease;	chr7:66172773	chr7:66025126~66031544:-
HNSC	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	4.09	5.15e-05	0.00805	0.15	0.19	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
HNSC	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-4.09	5.15e-05	0.00805	-0.17	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
HNSC	cis	rs11992186	0.597	rs11781841	ENSG00000173295.6	FAM86B3P	-4.09	5.15e-05	0.00805	-0.22	-0.19	Neuroticism;	chr8:8737753	chr8:8228595~8244865:+
HNSC	cis	rs9313772	0.928	rs10045018	ENSG00000254350.1	RP11-542A14.1	4.09	5.15e-05	0.00805	0.2	0.19	Blood pressure;	chr5:158391010	chr5:158424585~158452758:+
HNSC	cis	rs1008375	0.932	rs11941874	ENSG00000249502.1	AC006160.5	4.09	5.15e-05	0.00805	0.2	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17664793	chr4:17587467~17614571:-
HNSC	cis	rs2292864	0.764	rs36046953	ENSG00000228782.6	CTD-2026D20.3	-4.09	5.15e-05	0.00805	-0.3	-0.19	Left atrial antero-posterior diameter;	chr17:47304425	chr17:47450568~47492492:-
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	4.09	5.15e-05	0.00805	0.26	0.19	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
HNSC	cis	rs11673344	0.598	rs826326	ENSG00000267698.1	AC002116.7	4.09	5.15e-05	0.00805	0.16	0.19	Obesity-related traits;	chr19:37003863	chr19:36014508~36045972:+
HNSC	cis	rs6504950	0.579	rs17712917	ENSG00000275710.1	RP11-257O5.4	4.09	5.15e-05	0.00806	0.26	0.19	Breast cancer;	chr17:55194004	chr17:54964474~54964679:+
HNSC	cis	rs7829975	0.774	rs11775523	ENSG00000233609.3	RP11-62H7.2	4.09	5.15e-05	0.00806	0.18	0.19	Mood instability;	chr8:8821666	chr8:8961200~8979025:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-4.09	5.15e-05	0.00806	-0.25	-0.19	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
HNSC	cis	rs7475343	0.505	rs12775468	ENSG00000224034.1	RP11-445P17.8	4.09	5.16e-05	0.00806	0.25	0.19	Intelligence;	chr10:5122084	chr10:5266033~5271236:-
HNSC	cis	rs67981189	0.634	rs221896	ENSG00000274818.1	RP1-292L20.3	-4.09	5.16e-05	0.00806	-0.21	-0.19	Schizophrenia;	chr14:71139951	chr14:70906657~70907111:-
HNSC	cis	rs1925953	0.711	rs4926337	ENSG00000233589.1	RP4-694A7.2	4.09	5.16e-05	0.00806	0.23	0.19	Vertical cup-disc ratio;	chr1:68379753	chr1:68479129~68483539:+
HNSC	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-4.09	5.16e-05	0.00806	-0.24	-0.19	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
HNSC	cis	rs2548724	0.755	rs11950639	ENSG00000250682.4	LINC00491	4.09	5.16e-05	0.00806	0.24	0.19	Type 2 diabetes;	chr5:102442092	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.755	rs1376907	ENSG00000250682.4	LINC00491	4.09	5.16e-05	0.00806	0.24	0.19	Type 2 diabetes;	chr5:102443332	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.716	rs10434748	ENSG00000250682.4	LINC00491	4.09	5.16e-05	0.00806	0.24	0.19	Type 2 diabetes;	chr5:102455814	chr5:102609156~102671559:-
HNSC	cis	rs9313772	0.68	rs6556348	ENSG00000254350.1	RP11-542A14.1	-4.09	5.16e-05	0.00806	-0.2	-0.19	Blood pressure;	chr5:158448223	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.655	rs7733138	ENSG00000254350.1	RP11-542A14.1	-4.09	5.16e-05	0.00806	-0.2	-0.19	Blood pressure;	chr5:158448385	chr5:158424585~158452758:+
HNSC	cis	rs10510102	0.516	rs12242799	ENSG00000226864.1	ATE1-AS1	4.09	5.16e-05	0.00806	0.34	0.19	Breast cancer;	chr10:121980067	chr10:121928312~121951965:+
HNSC	cis	rs3736485	0.966	rs11070856	ENSG00000259438.1	CTD-2650P22.1	4.09	5.16e-05	0.00806	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51561620	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs7182977	ENSG00000259438.1	CTD-2650P22.1	4.09	5.16e-05	0.00806	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51561933	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs7161973	ENSG00000259438.1	CTD-2650P22.1	4.09	5.16e-05	0.00806	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51561966	chr15:52010999~52019095:-
HNSC	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-4.09	5.16e-05	0.00806	-0.18	-0.19	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-4.09	5.16e-05	0.00806	-0.18	-0.19	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
HNSC	cis	rs7735319	0.966	rs35317495	ENSG00000250697.1	CTD-2066L21.3	4.09	5.16e-05	0.00807	0.22	0.19	Systolic blood pressure;	chr5:33155097	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.901	rs7731489	ENSG00000250697.1	CTD-2066L21.3	4.09	5.16e-05	0.00807	0.22	0.19	Systolic blood pressure;	chr5:33156621	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.87	rs7735427	ENSG00000250697.1	CTD-2066L21.3	4.09	5.16e-05	0.00807	0.22	0.19	Systolic blood pressure;	chr5:33156782	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs62368014	ENSG00000250697.1	CTD-2066L21.3	4.09	5.16e-05	0.00807	0.22	0.19	Systolic blood pressure;	chr5:33157378	chr5:32925639~33297910:-
HNSC	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	4.09	5.16e-05	0.00807	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
HNSC	cis	rs3740713	1	rs79199586	ENSG00000256464.1	YWHABP2	4.09	5.16e-05	0.00807	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr11:18490243~18490955:-
HNSC	cis	rs9313772	0.722	rs6882996	ENSG00000254350.1	RP11-542A14.1	-4.09	5.16e-05	0.00807	-0.2	-0.19	Blood pressure;	chr5:158440587	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs10036622	ENSG00000254350.1	RP11-542A14.1	-4.09	5.16e-05	0.00807	-0.2	-0.19	Blood pressure;	chr5:158434957	chr5:158424585~158452758:+
HNSC	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-4.09	5.17e-05	0.00807	-0.18	-0.19	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-4.09	5.17e-05	0.00807	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
HNSC	cis	rs9650657	0.74	rs12676417	ENSG00000269918.1	AF131215.9	4.09	5.17e-05	0.00807	0.18	0.19	Neuroticism;	chr8:10811124	chr8:11104691~11106704:-
HNSC	cis	rs72827839	0.615	rs72827864	ENSG00000272763.1	RP11-357H14.17	-4.09	5.17e-05	0.00807	-0.26	-0.19	Ease of getting up in the morning;	chr17:48415516	chr17:48635923~48647023:-
HNSC	cis	rs72827839	0.779	rs59386258	ENSG00000272763.1	RP11-357H14.17	-4.09	5.17e-05	0.00807	-0.26	-0.19	Ease of getting up in the morning;	chr17:48422556	chr17:48635923~48647023:-
HNSC	cis	rs801193	1	rs2659906	ENSG00000272831.1	RP11-792A8.4	4.09	5.17e-05	0.00807	0.15	0.19	Aortic root size;	chr7:66700323	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000272831.1	RP11-792A8.4	4.09	5.17e-05	0.00807	0.15	0.19	Aortic root size;	chr7:66721734	chr7:66739829~66740385:-
HNSC	cis	rs228769	0.543	rs170634	ENSG00000267080.4	ASB16-AS1	4.09	5.17e-05	0.00807	0.15	0.19	Bone mineral density (hip);Bone mineral density (spine);	chr17:44098453	chr17:44175973~44186717:-
HNSC	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	4.09	5.17e-05	0.00807	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
HNSC	cis	rs2115630	0.967	rs10438428	ENSG00000259295.5	CSPG4P12	-4.09	5.17e-05	0.00807	-0.21	-0.19	P wave terminal force;	chr15:84787514	chr15:85191438~85213905:+
HNSC	cis	rs795484	0.926	rs383371	ENSG00000275409.1	RP11-131L12.4	4.09	5.17e-05	0.00807	0.21	0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118187446	chr12:118430147~118430699:+
HNSC	cis	rs1665050	0.534	rs4465553	ENSG00000277144.1	RP11-59H7.4	-4.09	5.17e-05	0.00808	-0.23	-0.19	Atopic dermatitis;	chr15:58954621	chr15:59115547~59116089:-
HNSC	cis	rs889398	0.802	rs12919094	ENSG00000196696.11	PDXDC2P	4.09	5.17e-05	0.00808	0.13	0.19	Body mass index;	chr16:69809454	chr16:69976297~70065948:-
HNSC	cis	rs7572733	0.773	rs6757852	ENSG00000222017.1	AC011997.1	4.09	5.17e-05	0.00808	0.22	0.19	Dermatomyositis;	chr2:197665569	chr2:197693106~197774823:+
HNSC	cis	rs9987353	0.519	rs2929465	ENSG00000254153.1	CTA-398F10.2	-4.09	5.17e-05	0.00808	-0.21	-0.19	Recombination measurement;	chr8:9206492	chr8:8456909~8461337:-
HNSC	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	4.09	5.17e-05	0.00808	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
HNSC	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	4.09	5.17e-05	0.00808	0.18	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
HNSC	cis	rs2145598	0.617	rs9323328	ENSG00000279636.2	LINC00216	4.09	5.17e-05	0.00808	0.19	0.19	Coronary artery disease;	chr14:58186796	chr14:58288033~58289158:+
HNSC	cis	rs3808502	0.526	rs11985709	ENSG00000255310.2	AF131215.2	-4.09	5.17e-05	0.00808	-0.18	-0.19	Neuroticism;	chr8:11565574	chr8:11107788~11109726:-
HNSC	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	4.09	5.17e-05	0.00808	0.19	0.19	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
HNSC	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	4.09	5.17e-05	0.00808	0.19	0.19	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	4.09	5.17e-05	0.00808	0.19	0.19	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
HNSC	cis	rs55823223	0.503	rs55699990	ENSG00000267801.1	RP11-552F3.9	4.09	5.17e-05	0.00808	0.22	0.19	Psoriasis;	chr17:75863105	chr17:75876372~75879546:+
HNSC	cis	rs12745968	0.653	rs1003116	ENSG00000223787.2	RP4-593M8.1	-4.09	5.18e-05	0.00808	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92700844	chr1:92580476~92580821:-
HNSC	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	4.09	5.18e-05	0.00808	0.22	0.19	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
HNSC	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-4.09	5.18e-05	0.00809	-0.22	-0.19	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
HNSC	cis	rs3736485	0.966	rs7173880	ENSG00000259438.1	CTD-2650P22.1	4.09	5.18e-05	0.00809	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51493236	chr15:52010999~52019095:-
HNSC	cis	rs4873772	0.932	rs7462209	ENSG00000253330.1	RP11-697N18.3	-4.09	5.18e-05	0.00809	-0.24	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47697536	chr8:47511034~47512141:-
HNSC	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	4.09	5.18e-05	0.00809	0.22	0.19	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	4.09	5.18e-05	0.00809	0.22	0.19	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	4.09	5.18e-05	0.00809	0.22	0.19	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
HNSC	cis	rs12600394	1	rs2109174	ENSG00000236088.8	COX10-AS1	-4.09	5.18e-05	0.00809	-0.28	-0.19	Response to platinum-based chemotherapy (cisplatin);	chr17:14609993	chr17:13756478~14069495:-
HNSC	cis	rs6568686	0.627	rs174387	ENSG00000255389.1	C6orf3	4.09	5.18e-05	0.00809	0.23	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111593820	chr6:111599875~111602295:+
HNSC	cis	rs6601327	0.606	rs4841204	ENSG00000233609.3	RP11-62H7.2	-4.09	5.19e-05	0.0081	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9725897	chr8:8961200~8979025:+
HNSC	cis	rs4356203	0.84	rs7942094	ENSG00000260196.1	RP1-239B22.5	-4.09	5.19e-05	0.0081	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17237862	chr11:17380649~17383531:+
HNSC	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	4.09	5.19e-05	0.0081	0.31	0.19	QT interval;	chr4:75106902	chr4:75081702~75084717:-
HNSC	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	4.09	5.19e-05	0.0081	0.31	0.19	QT interval;	chr4:75107557	chr4:75081702~75084717:-
HNSC	cis	rs9329221	0.537	rs12678797	ENSG00000269918.1	AF131215.9	-4.08	5.19e-05	0.0081	-0.18	-0.19	Neuroticism;	chr8:10121409	chr8:11104691~11106704:-
HNSC	cis	rs3096299	0.809	rs2911264	ENSG00000224888.4	RP5-1142A6.2	4.08	5.19e-05	0.0081	0.18	0.19	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:88731180~88741425:+
HNSC	cis	rs10129255	0.536	rs3944157	ENSG00000224373.3	IGHV4-59	4.08	5.19e-05	0.00811	0.1	0.19	Kawasaki disease;	chr14:106682286	chr14:106627249~106627825:-
HNSC	cis	rs11098499	0.82	rs28394116	ENSG00000250412.1	KLHL2P1	4.08	5.19e-05	0.00811	0.24	0.19	Corneal astigmatism;	chr4:119603128	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.866	rs3756156	ENSG00000250412.1	KLHL2P1	4.08	5.19e-05	0.00811	0.24	0.19	Corneal astigmatism;	chr4:119603686	chr4:119334329~119378233:+
HNSC	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.08	5.2e-05	0.00811	0.18	0.19	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
HNSC	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-4.08	5.2e-05	0.00811	-0.36	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
HNSC	cis	rs7735319	0.966	rs7709083	ENSG00000249102.1	CTD-2066L21.1	4.08	5.2e-05	0.00811	0.21	0.19	Systolic blood pressure;	chr5:33159470	chr5:33008994~33025724:+
HNSC	cis	rs7615952	0.546	rs2979340	ENSG00000241288.6	RP11-379B18.5	-4.08	5.2e-05	0.00811	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125622540	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.546	rs2979338	ENSG00000241288.6	RP11-379B18.5	-4.08	5.2e-05	0.00811	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125624282	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.546	rs2922171	ENSG00000241288.6	RP11-379B18.5	-4.08	5.2e-05	0.00811	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125624349	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.546	rs112919177	ENSG00000241288.6	RP11-379B18.5	-4.08	5.2e-05	0.00811	-0.28	-0.19	Blood pressure (smoking interaction);	chr3:125627226	chr3:125827238~125916384:-
HNSC	cis	rs7107174	1	rs2511166	ENSG00000251323.2	RP11-452H21.4	4.08	5.2e-05	0.00811	0.27	0.19	Testicular germ cell tumor;	chr11:78253285	chr11:78423982~78429836:-
HNSC	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	4.08	5.2e-05	0.00811	0.12	0.19	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
HNSC	cis	rs35963943	0.625	rs11918322	ENSG00000228956.7	SATB1-AS1	-4.08	5.2e-05	0.00812	-0.21	-0.19	Lymphocyte counts;	chr3:18674641	chr3:18445024~18920401:+
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000250412.1	KLHL2P1	4.08	5.2e-05	0.00812	0.24	0.19	Corneal astigmatism;	chr4:119331892	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000250412.1	KLHL2P1	4.08	5.2e-05	0.00812	0.24	0.19	Corneal astigmatism;	chr4:119332022	chr4:119334329~119378233:+
HNSC	cis	rs988913	0.957	rs9367597	ENSG00000224984.1	RP11-524H19.2	4.08	5.2e-05	0.00812	0.22	0.19	Menarche (age at onset);	chr6:54919854	chr6:54840118~54840855:-
HNSC	cis	rs12745968	0.594	rs10735781	ENSG00000223787.2	RP4-593M8.1	-4.08	5.2e-05	0.00812	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92655550	chr1:92580476~92580821:-
HNSC	cis	rs755249	0.567	rs1537817	ENSG00000182109.6	RP11-69E11.4	-4.08	5.2e-05	0.00812	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39522280~39546187:-
HNSC	cis	rs11098499	0.644	rs7693919	ENSG00000250412.1	KLHL2P1	4.08	5.21e-05	0.00812	0.24	0.19	Corneal astigmatism;	chr4:119619416	chr4:119334329~119378233:+
HNSC	cis	rs9311676	0.632	rs1126735	ENSG00000273493.1	RP11-80H18.4	4.08	5.21e-05	0.00812	0.21	0.19	Systemic lupus erythematosus;	chr3:58427681	chr3:58329965~58330118:+
HNSC	cis	rs9303401	0.573	rs67378767	ENSG00000266701.1	AC005702.4	4.08	5.21e-05	0.00813	0.26	0.19	Cognitive test performance;	chr17:59116876	chr17:60042546~60042627:-
HNSC	cis	rs2300747	0.769	rs3850814	ENSG00000177173.5	NAP1L4P1	4.08	5.21e-05	0.00813	0.31	0.19	Primary biliary cholangitis;Multiple sclerosis;	chr1:116500422	chr1:116532936~116534092:-
HNSC	cis	rs3806843	0.548	rs246056	ENSG00000276545.1	PCDHGB9P	4.08	5.21e-05	0.00813	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140946015	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.607	rs246044	ENSG00000276545.1	PCDHGB9P	4.08	5.21e-05	0.00813	0.23	0.19	Depressive symptoms (multi-trait analysis);	chr5:140951071	chr5:141439853~141442449:+
HNSC	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	4.08	5.21e-05	0.00813	0.32	0.19	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000229886.1	RP5-1132H15.3	4.08	5.21e-05	0.00813	0.32	0.19	Diabetic kidney disease;	chr7:65739282	chr7:66025126~66031544:-
HNSC	cis	rs9863	0.931	rs4765335	ENSG00000270028.1	RP11-380L11.4	4.08	5.21e-05	0.00813	0.22	0.19	White blood cell count;	chr12:123946265	chr12:123925461~123926083:-
HNSC	cis	rs6890684	0.544	rs581318	ENSG00000215032.2	GNL3LP1	-4.08	5.21e-05	0.00813	-0.2	-0.19	Intelligence (multi-trait analysis);	chr5:61219967	chr5:60891935~60893577:-
HNSC	cis	rs1218582	0.774	rs4845679	ENSG00000270361.1	RP11-307C12.13	-4.08	5.21e-05	0.00813	-0.2	-0.19	Prostate cancer;	chr1:154888711	chr1:154937370~154938059:+
HNSC	cis	rs6095360	1	rs2295027	ENSG00000222365.1	SNORD12B	-4.08	5.21e-05	0.00813	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48966347	chr20:49280319~49280409:+
HNSC	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	4.08	5.21e-05	0.00813	0.22	0.19	Height;	chr14:75082053	chr14:75011269~75012851:-
HNSC	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	4.08	5.21e-05	0.00813	0.22	0.19	Height;	chr14:75082667	chr14:75011269~75012851:-
HNSC	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	4.08	5.21e-05	0.00813	0.26	0.19	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
HNSC	cis	rs35000415	0.688	rs34350562	ENSG00000275106.1	RP11-309L24.10	-4.08	5.21e-05	0.00813	-0.39	-0.19	Systemic lupus erythematosus;	chr7:129078654	chr7:128952527~128953316:-
HNSC	cis	rs865483	0.895	rs878520	ENSG00000276054.1	RP11-378E13.3	-4.08	5.21e-05	0.00813	-0.22	-0.19	Monocyte count;	chr17:37402018	chr17:37386886~37387926:+
HNSC	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-4.08	5.22e-05	0.00814	-0.21	-0.19	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
HNSC	cis	rs6964587	1	rs9690208	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00814	-0.19	-0.19	Breast cancer;	chr7:92106299	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs60147309	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00814	-0.19	-0.19	Breast cancer;	chr7:92106784	chr7:92134604~92180725:+
HNSC	cis	rs3736485	0.934	rs28648597	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51563869	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs17609666	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51565841	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs7170330	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51567116	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs11635592	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51567589	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs8036609	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51569229	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs8036904	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51569241	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs8036821	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51569449	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.966	rs8041514	ENSG00000259438.1	CTD-2650P22.1	4.08	5.22e-05	0.00814	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51573857	chr15:52010999~52019095:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-4.08	5.22e-05	0.00814	-0.14	-0.19	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
HNSC	cis	rs7735319	0.966	rs6895701	ENSG00000250697.1	CTD-2066L21.3	4.08	5.22e-05	0.00814	0.22	0.19	Systolic blood pressure;	chr5:33130367	chr5:32925639~33297910:-
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	4.08	5.22e-05	0.00815	0.31	0.19	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
HNSC	cis	rs9929218	0.551	rs3785133	ENSG00000260459.2	FTLP14	4.08	5.22e-05	0.00815	0.24	0.19	Colorectal cancer;	chr16:68694708	chr16:68822587~68823070:+
HNSC	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-4.08	5.23e-05	0.00815	-0.23	-0.19	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
HNSC	cis	rs9611565	0.877	rs3817999	ENSG00000235513.1	RP4-756G23.5	-4.08	5.23e-05	0.00815	-0.2	-0.19	Vitiligo;	chr22:41351713	chr22:41209122~41217627:-
HNSC	cis	rs10773046	0.619	rs10846565	ENSG00000269938.1	RP11-214K3.20	-4.08	5.23e-05	0.00815	-0.21	-0.19	Osteoarthritis (hip);	chr12:123867791	chr12:123968023~123968579:-
HNSC	cis	rs4356203	0.87	rs214921	ENSG00000260196.1	RP1-239B22.5	-4.08	5.23e-05	0.00816	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17380649~17383531:+
HNSC	cis	rs17594362	0.697	rs9562319	ENSG00000229473.2	RGS17P1	-4.08	5.23e-05	0.00816	-0.25	-0.19	Multiple sclerosis;	chr13:41563311	chr13:40992779~40993331:-
HNSC	cis	rs6095360	0.934	rs3818224	ENSG00000222365.1	SNORD12B	-4.08	5.23e-05	0.00816	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49011633	chr20:49280319~49280409:+
HNSC	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-4.08	5.24e-05	0.00816	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
HNSC	cis	rs2486288	0.656	rs11629858	ENSG00000259479.5	SORD2P	-4.08	5.24e-05	0.00816	-0.21	-0.19	Glomerular filtration rate;	chr15:45254916	chr15:44826371~44884694:-
HNSC	cis	rs2486288	0.656	rs11629859	ENSG00000259479.5	SORD2P	-4.08	5.24e-05	0.00816	-0.21	-0.19	Glomerular filtration rate;	chr15:45254923	chr15:44826371~44884694:-
HNSC	cis	rs10742752	0.535	rs12224037	ENSG00000255267.3	RP11-430H10.2	4.08	5.24e-05	0.00816	0.25	0.19	Body mass index;	chr11:45383813	chr11:45371397~45388508:+
HNSC	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-4.08	5.24e-05	0.00816	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
HNSC	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	4.08	5.24e-05	0.00817	0.24	0.19	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
HNSC	cis	rs17653722	1	rs17653722	ENSG00000258279.2	LINC00592	4.08	5.24e-05	0.00817	0.27	0.19	Telomere length;	chr12:52193734	chr12:52210930~52223804:+
HNSC	cis	rs1979679	0.842	rs12049916	ENSG00000247934.4	RP11-967K21.1	-4.08	5.24e-05	0.00817	-0.21	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28163298~28190738:-
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66651646	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs6975195	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66659787	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs3857688	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66662819	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2286684	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66664843	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66664856	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs10274773	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66668591	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs7785213	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66673991	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs11773829	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66676087	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66682191	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2003301	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66682669	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs7788576	ENSG00000272831.1	RP11-792A8.4	-4.08	5.24e-05	0.00817	-0.15	-0.19	Aortic root size;	chr7:66683315	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs6958520	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66686466	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66687725	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66692033	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2707836	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66695448	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs4717310	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66696020	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66696803	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs1553609	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66732152	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs1553610	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66732246	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2707845	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66733811	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2707850	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66738883	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66740595	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs7783924	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66744070	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs7789184	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66745208	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2707854	ENSG00000272831.1	RP11-792A8.4	4.08	5.24e-05	0.00817	0.15	0.19	Aortic root size;	chr7:66747610	chr7:66739829~66740385:-
HNSC	cis	rs9863	0.861	rs9971695	ENSG00000270028.1	RP11-380L11.4	4.08	5.24e-05	0.00817	0.22	0.19	White blood cell count;	chr12:123928944	chr12:123925461~123926083:-
HNSC	cis	rs58873874	0.579	rs75099611	ENSG00000251405.2	CTB-109A12.1	4.08	5.24e-05	0.00817	0.36	0.19	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157362615~157460078:-
HNSC	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	4.08	5.24e-05	0.00817	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	4.08	5.24e-05	0.00817	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
HNSC	cis	rs11638815	0.639	rs6603030	ENSG00000255769.6	GOLGA2P10	-4.08	5.24e-05	0.00817	-0.29	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82561353	chr15:82472993~82513950:-
HNSC	cis	rs9611565	0.659	rs73178626	ENSG00000235513.1	RP4-756G23.5	4.08	5.24e-05	0.00817	0.22	0.19	Vitiligo;	chr22:41532367	chr22:41209122~41217627:-
HNSC	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-4.08	5.24e-05	0.00817	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
HNSC	cis	rs516805	0.63	rs2606656	ENSG00000279453.1	RP3-425C14.4	-4.08	5.24e-05	0.00817	-0.25	-0.19	Lymphocyte counts;	chr6:122153088	chr6:122436789~122439223:-
HNSC	cis	rs35847492	1	rs17730481	ENSG00000254340.1	RP11-10A14.3	-4.08	5.25e-05	0.00817	-0.25	-0.19	Neuroticism;	chr8:9418653	chr8:9141424~9145435:+
HNSC	cis	rs72627123	1	rs72627120	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.25e-05	0.00817	-0.32	-0.19	Morning vs. evening chronotype;	chr14:73896777	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627122	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.25e-05	0.00817	-0.32	-0.19	Morning vs. evening chronotype;	chr14:73901533	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627123	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.25e-05	0.00817	-0.32	-0.19	Morning vs. evening chronotype;	chr14:73901628	chr14:73787360~73803270:+
HNSC	cis	rs7572733	0.534	rs1983359	ENSG00000231621.1	AC013264.2	-4.08	5.25e-05	0.00818	-0.18	-0.19	Dermatomyositis;	chr2:197940374	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs11887138	ENSG00000231621.1	AC013264.2	-4.08	5.25e-05	0.00818	-0.18	-0.19	Dermatomyositis;	chr2:197941114	chr2:197197991~197199273:+
HNSC	cis	rs2865126	0.818	rs35033671	ENSG00000264714.1	RP11-21G15.1	4.08	5.25e-05	0.00818	0.23	0.19	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10759842	chr18:10724619~10728539:+
HNSC	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-4.08	5.25e-05	0.00818	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
HNSC	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-4.08	5.25e-05	0.00818	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
HNSC	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-4.08	5.25e-05	0.00818	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
HNSC	cis	rs865483	0.929	rs853225	ENSG00000276054.1	RP11-378E13.3	4.08	5.25e-05	0.00818	0.23	0.19	Monocyte count;	chr17:37431406	chr17:37386886~37387926:+
HNSC	cis	rs7302981	0.692	rs1979702	ENSG00000272368.2	RP4-605O3.4	-4.08	5.25e-05	0.00818	-0.18	-0.19	Systolic blood pressure;	chr12:50068864	chr12:50112197~50165618:+
HNSC	cis	rs1602565	0.858	rs2958628	ENSG00000255450.1	CTD-2063L20.1	-4.08	5.25e-05	0.00818	-0.29	-0.19	Schizophrenia;	chr11:29144232	chr11:29275655~29276565:+
HNSC	cis	rs12701220	0.542	rs6957866	ENSG00000229043.2	AC091729.9	-4.08	5.25e-05	0.00818	-0.28	-0.19	Bronchopulmonary dysplasia;	chr7:1072038	chr7:1160374~1165267:+
HNSC	cis	rs12701220	0.689	rs6973645	ENSG00000229043.2	AC091729.9	-4.08	5.25e-05	0.00818	-0.28	-0.19	Bronchopulmonary dysplasia;	chr7:1072610	chr7:1160374~1165267:+
HNSC	cis	rs7829975	0.606	rs6422352	ENSG00000253981.4	ALG1L13P	-4.08	5.25e-05	0.00818	-0.2	-0.19	Mood instability;	chr8:8936683	chr8:8236003~8244667:-
HNSC	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-4.08	5.25e-05	0.00818	-0.2	-0.19	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
HNSC	cis	rs1538138	1	rs9986372	ENSG00000226453.1	RP11-379B8.1	-4.08	5.25e-05	0.00818	-0.24	-0.19	Corneal structure;	chr6:82078134	chr6:81845185~81933480:-
HNSC	cis	rs12893668	0.703	rs7148456	ENSG00000269910.1	RP11-73M18.10	-4.08	5.26e-05	0.00819	-0.18	-0.19	Reticulocyte count;	chr14:103561933	chr14:103694516~103695050:-
HNSC	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	4.08	5.26e-05	0.00819	0.22	0.19	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
HNSC	cis	rs7824557	0.564	rs6601584	ENSG00000269918.1	AF131215.9	-4.08	5.26e-05	0.00819	-0.18	-0.19	Retinal vascular caliber;	chr8:11374834	chr8:11104691~11106704:-
HNSC	cis	rs739496	0.546	rs11066055	ENSG00000226469.1	ADAM1B	4.08	5.26e-05	0.00819	0.21	0.19	Platelet count;	chr12:111875412	chr12:111927018~111929017:+
HNSC	cis	rs2835345	0.563	rs60727080	ENSG00000230479.1	AP000695.6	4.08	5.26e-05	0.00819	0.2	0.19	Pulmonary function;	chr21:36454876	chr21:36430360~36481070:+
HNSC	cis	rs4937076	0.69	rs634053	ENSG00000254967.5	RP11-680F20.6	-4.08	5.26e-05	0.00819	-0.2	-0.19	Primary tooth development (time to first tooth eruption);	chr11:125948804	chr11:125950116~125956319:+
HNSC	cis	rs7735319	0.966	rs1842248	ENSG00000250697.1	CTD-2066L21.3	4.08	5.26e-05	0.00819	0.22	0.19	Systolic blood pressure;	chr5:33165734	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs2101014	ENSG00000250697.1	CTD-2066L21.3	4.08	5.26e-05	0.00819	0.22	0.19	Systolic blood pressure;	chr5:33166307	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs62368018	ENSG00000250697.1	CTD-2066L21.3	4.08	5.26e-05	0.00819	0.22	0.19	Systolic blood pressure;	chr5:33167320	chr5:32925639~33297910:-
HNSC	cis	rs6095360	0.966	rs6019557	ENSG00000222365.1	SNORD12B	-4.08	5.26e-05	0.00819	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48966835	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019558	ENSG00000222365.1	SNORD12B	-4.08	5.26e-05	0.00819	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48966943	chr20:49280319~49280409:+
HNSC	cis	rs2762353	0.524	rs9467596	ENSG00000272462.2	U91328.19	4.08	5.26e-05	0.00819	0.17	0.19	Blood metabolite levels;	chr6:25782794	chr6:25992662~26001775:+
HNSC	cis	rs7475343	0.501	rs74827952	ENSG00000224034.1	RP11-445P17.8	-4.08	5.26e-05	0.0082	-0.26	-0.19	Intelligence;	chr10:5203233	chr10:5266033~5271236:-
HNSC	cis	rs4927850	1	rs10881563	ENSG00000226155.1	AC124944.3	-4.08	5.26e-05	0.0082	-0.23	-0.19	Pancreatic cancer;	chr3:196023354	chr3:195912049~195913986:+
HNSC	cis	rs17345786	0.861	rs11707689	ENSG00000244119.1	PDCL3P4	4.08	5.26e-05	0.0082	0.2	0.19	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101712472~101713191:+
HNSC	cis	rs11773103	0.786	rs73203002	ENSG00000224046.1	AC005076.5	4.08	5.27e-05	0.0082	0.26	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87129584	chr7:87151423~87152420:-
HNSC	cis	rs6831352	0.959	rs6532795	ENSG00000263923.1	RP11-571L19.7	4.08	5.27e-05	0.0082	0.19	0.19	Alcohol dependence;	chr4:99121070	chr4:98928897~98994994:+
HNSC	cis	rs10504130	0.932	rs79196243	ENSG00000272024.1	RP11-546K22.3	-4.08	5.27e-05	0.0082	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51834855	chr8:51950284~51950690:+
HNSC	cis	rs7688540	0.8	rs11731285	ENSG00000211553.1	AC253576.2	-4.08	5.27e-05	0.0082	-0.25	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:136461~136568:+
HNSC	cis	rs6095360	0.727	rs2075677	ENSG00000222365.1	SNORD12B	-4.08	5.27e-05	0.0082	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49084487	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-4.08	5.27e-05	0.0082	-0.23	-0.19	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
HNSC	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	4.08	5.27e-05	0.0082	0.26	0.19	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
HNSC	cis	rs929354	0.742	rs7807556	ENSG00000224629.1	RP5-1142J19.2	-4.08	5.27e-05	0.0082	-0.18	-0.19	Body mass index;	chr7:157141635	chr7:157263022~157263229:-
HNSC	cis	rs8046011	0.537	rs1613211	ENSG00000280153.1	RP11-876N24.3	4.08	5.27e-05	0.0082	0.18	0.19	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11227283	chr16:10933903~10936280:+
HNSC	cis	rs4356203	0.87	rs214919	ENSG00000272034.1	SNORD14A	-4.08	5.27e-05	0.00821	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17074654~17074744:-
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000250412.1	KLHL2P1	4.08	5.27e-05	0.00821	0.24	0.19	Corneal astigmatism;	chr4:119629930	chr4:119334329~119378233:+
HNSC	cis	rs10090774	0.813	rs11787221	ENSG00000279766.1	RP11-642A1.2	-4.08	5.27e-05	0.00821	-0.19	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708995	chr8:140572142~140572812:-
HNSC	cis	rs250677	0.524	rs183140	ENSG00000250072.4	CTC-529P8.1	-4.08	5.28e-05	0.00821	-0.22	-0.19	Breast cancer;	chr5:149059240	chr5:149063317~149109787:+
HNSC	cis	rs1580019	0.961	rs766660	ENSG00000226468.2	AC018641.7	-4.08	5.28e-05	0.00821	-0.25	-0.19	Cognitive ability;	chr7:32459465	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.922	rs766658	ENSG00000226468.2	AC018641.7	-4.08	5.28e-05	0.00821	-0.25	-0.19	Cognitive ability;	chr7:32459779	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs766657	ENSG00000226468.2	AC018641.7	-4.08	5.28e-05	0.00821	-0.25	-0.19	Cognitive ability;	chr7:32459898	chr7:32456963~32457758:-
HNSC	cis	rs394563	0.625	rs384306	ENSG00000231760.4	RP11-350J20.5	4.08	5.28e-05	0.00822	0.25	0.19	Dupuytren's disease;	chr6:149475004	chr6:149796151~149826294:-
HNSC	cis	rs1799949	1	rs11651341	ENSG00000236383.6	LINC00854	-4.08	5.28e-05	0.00822	-0.17	-0.19	Menopause (age at onset);	chr17:43350693	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs34572725	ENSG00000236383.6	LINC00854	-4.08	5.28e-05	0.00822	-0.17	-0.19	Menopause (age at onset);	chr17:43351298	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs4534897	ENSG00000236383.6	LINC00854	-4.08	5.28e-05	0.00822	-0.17	-0.19	Menopause (age at onset);	chr17:43354440	chr17:43216941~43305976:-
HNSC	cis	rs7178909	0.872	rs3867167	ENSG00000259677.1	RP11-493E3.1	4.08	5.28e-05	0.00822	0.21	0.19	Common traits (Other);	chr15:89890558	chr15:89876540~89877285:+
HNSC	cis	rs1580019	0.961	rs2392056	ENSG00000226468.2	AC018641.7	-4.08	5.28e-05	0.00822	-0.25	-0.19	Cognitive ability;	chr7:32459341	chr7:32456963~32457758:-
HNSC	cis	rs6081541	1	rs3827976	ENSG00000179447.2	RP5-1027G4.3	-4.08	5.28e-05	0.00822	-0.25	-0.19	Psychosis (atypical);	chr20:19244211	chr20:19242302~19284596:-
HNSC	cis	rs16858210	0.874	rs35717944	ENSG00000234371.6	RPSAP31	4.08	5.28e-05	0.00822	0.22	0.19	Menopause (age at onset);	chr3:183889573	chr3:183884924~183888449:+
HNSC	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-4.08	5.28e-05	0.00822	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
HNSC	cis	rs7561149	0.624	rs7591759	ENSG00000270574.1	RP11-171I2.2	-4.08	5.28e-05	0.00822	-0.23	-0.19	QT interval;	chr2:178828240	chr2:178578790~178580906:+
HNSC	cis	rs793571	0.866	rs11071401	ENSG00000245975.2	RP11-30K9.6	4.08	5.28e-05	0.00822	0.29	0.19	Schizophrenia;	chr15:58918736	chr15:58768072~58770974:-
HNSC	cis	rs516805	0.63	rs170422	ENSG00000279453.1	RP3-425C14.4	-4.08	5.29e-05	0.00823	-0.25	-0.19	Lymphocyte counts;	chr6:122261422	chr6:122436789~122439223:-
HNSC	cis	rs7246657	0.508	rs1628959	ENSG00000276846.1	CTD-3220F14.3	4.08	5.29e-05	0.00823	0.28	0.19	Coronary artery calcification;	chr19:36999474	chr19:37314868~37315620:-
HNSC	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	4.08	5.29e-05	0.00823	0.22	0.19	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
HNSC	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	4.08	5.29e-05	0.00823	0.21	0.19	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
HNSC	cis	rs4356203	0.905	rs7946010	ENSG00000272034.1	SNORD14A	4.08	5.29e-05	0.00823	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17074654~17074744:-
HNSC	cis	rs1028883	0.935	rs9318187	ENSG00000228295.1	LINC00392	-4.08	5.29e-05	0.00823	-0.19	-0.19	Lean body mass;	chr13:73536275	chr13:73564244~73588070:+
HNSC	cis	rs1028883	0.935	rs9318188	ENSG00000228295.1	LINC00392	-4.08	5.29e-05	0.00823	-0.19	-0.19	Lean body mass;	chr13:73536279	chr13:73564244~73588070:+
HNSC	cis	rs9487051	0.621	rs351721	ENSG00000243587.6	C6orf183	-4.08	5.29e-05	0.00823	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109229906	chr6:109165833~109271014:+
HNSC	cis	rs7572733	0.515	rs6752458	ENSG00000231621.1	AC013264.2	-4.08	5.29e-05	0.00823	-0.18	-0.19	Dermatomyositis;	chr2:197970382	chr2:197197991~197199273:+
HNSC	cis	rs7735319	0.899	rs13168108	ENSG00000250697.1	CTD-2066L21.3	4.08	5.29e-05	0.00823	0.22	0.19	Systolic blood pressure;	chr5:33119232	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs13169007	ENSG00000250697.1	CTD-2066L21.3	4.08	5.29e-05	0.00823	0.22	0.19	Systolic blood pressure;	chr5:33119553	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs13182741	ENSG00000250697.1	CTD-2066L21.3	4.08	5.29e-05	0.00823	0.22	0.19	Systolic blood pressure;	chr5:33134293	chr5:32925639~33297910:-
HNSC	cis	rs9907295	0.71	rs4796113	ENSG00000270977.1	AC015849.16	-4.08	5.29e-05	0.00823	-0.3	-0.19	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.818	rs4796114	ENSG00000270977.1	AC015849.16	-4.08	5.29e-05	0.00823	-0.3	-0.19	Fibroblast growth factor basic levels;	chr17:35832653	chr17:35893707~35911023:-
HNSC	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-4.08	5.29e-05	0.00824	-0.33	-0.19	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
HNSC	cis	rs4843747	0.671	rs28671027	ENSG00000260750.4	RP11-482M8.1	4.08	5.3e-05	0.00824	0.23	0.19	Menopause (age at onset);	chr16:88082717	chr16:87492555~87515635:+
HNSC	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	4.08	5.3e-05	0.00824	0.17	0.19	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
HNSC	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	4.08	5.3e-05	0.00824	0.17	0.19	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
HNSC	cis	rs7085104	0.632	rs4290163	ENSG00000236937.2	PTGES3P4	4.08	5.3e-05	0.00824	0.23	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102845595~102845950:+
HNSC	cis	rs1538970	0.924	rs12037201	ENSG00000234329.1	RP11-767N6.2	4.08	5.3e-05	0.00824	0.21	0.19	Platelet count;	chr1:45475677	chr1:45651039~45651826:-
HNSC	cis	rs6964587	0.626	rs12704631	ENSG00000188693.7	CYP51A1-AS1	4.08	5.3e-05	0.00824	0.2	0.19	Breast cancer;	chr7:91894211	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.626	rs10280301	ENSG00000188693.7	CYP51A1-AS1	4.08	5.3e-05	0.00824	0.2	0.19	Breast cancer;	chr7:91894944	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.626	rs10225241	ENSG00000188693.7	CYP51A1-AS1	4.08	5.3e-05	0.00824	0.2	0.19	Breast cancer;	chr7:91895626	chr7:92134604~92180725:+
HNSC	cis	rs860295	0.639	rs10908469	ENSG00000225855.5	RUSC1-AS1	4.08	5.3e-05	0.00824	0.13	0.19	Body mass index;	chr1:155498941	chr1:155316863~155324176:-
HNSC	cis	rs35264875	0.851	rs7933746	ENSG00000259799.1	RP11-554A11.9	4.08	5.3e-05	0.00824	0.25	0.19	Blond vs. brown hair color;	chr11:69100254	chr11:69155910~69159752:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000204709.4	LINC01556	-4.08	5.3e-05	0.00824	-0.29	-0.19	Depression;	chr6:28260564	chr6:28943877~28944537:+
HNSC	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-4.08	5.3e-05	0.00824	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
HNSC	cis	rs11638815	0.639	rs783542	ENSG00000255769.6	GOLGA2P10	-4.08	5.3e-05	0.00824	-0.29	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82567264	chr15:82472993~82513950:-
HNSC	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-4.08	5.3e-05	0.00825	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
HNSC	cis	rs6500395	0.651	rs28432694	ENSG00000261267.1	RP11-44I10.3	-4.08	5.31e-05	0.00825	-0.23	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr16:48632399	chr16:48559661~48587403:+
HNSC	cis	rs116095464	0.558	rs28558836	ENSG00000277812.1	AC021087.1	4.08	5.31e-05	0.00825	0.31	0.19	Breast cancer;	chr5:285633	chr5:262769~262881:+
HNSC	cis	rs6964587	0.626	rs7807765	ENSG00000188693.7	CYP51A1-AS1	4.08	5.31e-05	0.00825	0.2	0.19	Breast cancer;	chr7:91902660	chr7:92134604~92180725:+
HNSC	cis	rs7520050	0.966	rs6669522	ENSG00000280836.1	AL355480.1	4.08	5.31e-05	0.00825	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6677007	ENSG00000280836.1	AL355480.1	4.08	5.31e-05	0.00825	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs4660898	ENSG00000280836.1	AL355480.1	4.08	5.31e-05	0.00825	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs11211230	ENSG00000280836.1	AL355480.1	4.08	5.31e-05	0.00825	0.19	0.19	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45581219~45581321:-
HNSC	cis	rs6964587	0.867	rs12704637	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.31e-05	0.00826	-0.2	-0.19	Breast cancer;	chr7:92245372	chr7:92134604~92180725:+
HNSC	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-4.08	5.31e-05	0.00826	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-4.08	5.31e-05	0.00826	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
HNSC	cis	rs2179367	0.959	rs489551	ENSG00000216906.2	RP11-350J20.9	4.08	5.31e-05	0.00826	0.23	0.19	Dupuytren's disease;	chr6:149368321	chr6:149904243~149906418:+
HNSC	cis	rs9400271	0.632	rs6899616	ENSG00000243587.6	C6orf183	-4.08	5.31e-05	0.00826	-0.18	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109263682	chr6:109165833~109271014:+
HNSC	cis	rs4372836	1	rs6547872	ENSG00000226833.4	AC097724.3	4.08	5.31e-05	0.00826	0.23	0.19	Body mass index;	chr2:28755208	chr2:28708953~28736205:-
HNSC	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	4.08	5.31e-05	0.00826	0.21	0.19	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	4.08	5.31e-05	0.00826	0.21	0.19	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	4.08	5.31e-05	0.00826	0.21	0.19	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	4.08	5.31e-05	0.00826	0.21	0.19	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
HNSC	cis	rs7688540	0.8	rs28429717	ENSG00000211553.1	AC253576.2	-4.08	5.31e-05	0.00826	-0.25	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:136461~136568:+
HNSC	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	4.08	5.31e-05	0.00826	0.18	0.19	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
HNSC	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	4.08	5.31e-05	0.00826	0.19	0.19	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
HNSC	cis	rs4356203	0.905	rs10832733	ENSG00000272034.1	SNORD14A	-4.08	5.31e-05	0.00826	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17074654~17074744:-
HNSC	cis	rs911555	0.504	rs4906340	ENSG00000269940.1	RP11-73M18.7	-4.08	5.32e-05	0.00827	-0.19	-0.19	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103694560~103695170:+
HNSC	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	4.08	5.32e-05	0.00827	0.19	0.19	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
HNSC	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	4.08	5.32e-05	0.00827	0.26	0.19	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	4.08	5.32e-05	0.00827	0.26	0.19	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	4.08	5.32e-05	0.00827	0.26	0.19	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	4.08	5.32e-05	0.00827	0.26	0.19	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
HNSC	cis	rs12935418	0.504	rs1549288	ENSG00000261061.1	RP11-303E16.2	-4.08	5.32e-05	0.00827	-0.19	-0.19	Mean corpuscular volume;	chr16:81027156	chr16:81030770~81031485:+
HNSC	cis	rs2562456	0.617	rs34203148	ENSG00000268081.1	RP11-678G14.2	4.08	5.32e-05	0.00827	0.25	0.19	Pain;	chr19:21590743	chr19:21554640~21569237:-
HNSC	cis	rs860295	0.702	rs12043132	ENSG00000225855.5	RUSC1-AS1	4.08	5.32e-05	0.00827	0.13	0.19	Body mass index;	chr1:155592576	chr1:155316863~155324176:-
HNSC	cis	rs4356203	0.818	rs214927	ENSG00000272034.1	SNORD14A	-4.08	5.32e-05	0.00827	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17074654~17074744:-
HNSC	cis	rs853679	0.517	rs9283884	ENSG00000219891.2	ZSCAN12P1	-4.08	5.32e-05	0.00827	-0.26	-0.19	Depression;	chr6:28167882	chr6:28091154~28093664:+
HNSC	cis	rs6964587	0.61	rs6942852	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.32e-05	0.00827	-0.19	-0.19	Breast cancer;	chr7:91808569	chr7:92134604~92180725:+
HNSC	cis	rs7735319	1	rs7735319	ENSG00000251281.1	CTD-2066L21.2	4.08	5.32e-05	0.00827	0.21	0.19	Systolic blood pressure;	chr5:33156863	chr5:33011322~33017607:-
HNSC	cis	rs240993	0.812	rs118202	ENSG00000230177.1	RP5-1112D6.4	-4.08	5.32e-05	0.00827	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111277932~111278742:+
HNSC	cis	rs944002	1	rs10131298	ENSG00000259444.1	RP11-736N17.8	4.08	5.32e-05	0.00827	0.22	0.19	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102277	chr14:103094723~103098885:+
HNSC	cis	rs9863	0.861	rs7961449	ENSG00000270028.1	RP11-380L11.4	-4.08	5.32e-05	0.00828	-0.21	-0.19	White blood cell count;	chr12:123952668	chr12:123925461~123926083:-
HNSC	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	4.08	5.32e-05	0.00828	0.24	0.19	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000224373.3	IGHV4-59	4.08	5.32e-05	0.00828	0.11	0.19	Kawasaki disease;	chr14:106782523	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000224373.3	IGHV4-59	4.08	5.32e-05	0.00828	0.11	0.19	Kawasaki disease;	chr14:106782559	chr14:106627249~106627825:-
HNSC	cis	rs7615952	0.515	rs4441610	ENSG00000250012.1	RP11-124N2.1	-4.08	5.33e-05	0.00828	-0.2	-0.19	Blood pressure (smoking interaction);	chr3:125962464	chr3:126084220~126095349:+
HNSC	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-4.08	5.33e-05	0.00828	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
HNSC	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	4.08	5.33e-05	0.00828	0.31	0.19	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	4.08	5.33e-05	0.00828	0.31	0.19	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
HNSC	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-4.08	5.33e-05	0.00828	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000250412.1	KLHL2P1	4.08	5.33e-05	0.00829	0.24	0.19	Corneal astigmatism;	chr4:119637984	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	4.08	5.33e-05	0.00829	0.23	0.19	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
HNSC	cis	rs1023500	1	rs9620001	ENSG00000205702.9	CYP2D7	-4.08	5.33e-05	0.00829	-0.15	-0.19	Schizophrenia;	chr22:41934225	chr22:42140203~42144577:-
HNSC	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.08	5.33e-05	0.00829	-0.27	-0.19	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
HNSC	cis	rs7255436	0.965	rs11666233	ENSG00000269386.4	RAB11B-AS1	4.08	5.33e-05	0.00829	0.17	0.19	HDL cholesterol;	chr19:8387161	chr19:8374373~8390685:-
HNSC	cis	rs4356203	0.519	rs214092	ENSG00000260196.1	RP1-239B22.5	-4.08	5.34e-05	0.00829	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17380649~17383531:+
HNSC	cis	rs73201462	1	rs2811416	ENSG00000231305.3	RP11-723O4.2	4.08	5.34e-05	0.00829	0.28	0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273095	chr3:128861313~128871540:-
HNSC	cis	rs2548724	0.796	rs2400800	ENSG00000250682.4	LINC00491	4.08	5.34e-05	0.0083	0.25	0.19	Type 2 diabetes;	chr5:102343026	chr5:102609156~102671559:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.08	5.34e-05	0.0083	0.2	0.19	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
HNSC	cis	rs2412819	0.571	rs7174260	ENSG00000166763.7	STRCP1	4.08	5.34e-05	0.0083	0.27	0.19	Lung cancer;	chr15:43751988	chr15:43699488~43718184:-
HNSC	cis	rs11997175	0.656	rs2350007	ENSG00000272338.2	RP11-722E23.2	4.08	5.34e-05	0.0083	0.18	0.19	Body mass index;	chr8:33727835	chr8:33360839~33361415:-
HNSC	cis	rs13179617	0.928	rs1445980	ENSG00000215032.2	GNL3LP1	-4.08	5.34e-05	0.0083	-0.22	-0.19	Intelligence (multi-trait analysis);	chr5:61502906	chr5:60891935~60893577:-
HNSC	cis	rs2998286	0.813	rs2790430	ENSG00000254635.4	WAC-AS1	-4.08	5.34e-05	0.0083	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28498865	chr10:28522652~28532743:-
HNSC	cis	rs7178909	0.872	rs3931863	ENSG00000259677.1	RP11-493E3.1	4.08	5.34e-05	0.0083	0.21	0.19	Common traits (Other);	chr15:89890681	chr15:89876540~89877285:+
HNSC	cis	rs7716219	0.672	rs10940473	ENSG00000251307.1	RP11-506H20.1	4.08	5.34e-05	0.0083	0.2	0.19	Height;	chr5:55577457	chr5:55233934~55295201:+
HNSC	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-4.08	5.34e-05	0.0083	-0.22	-0.19	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
HNSC	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	4.08	5.35e-05	0.00831	0.22	0.19	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
HNSC	cis	rs9650657	0.836	rs3905581	ENSG00000269918.1	AF131215.9	-4.08	5.35e-05	0.00831	-0.18	-0.19	Neuroticism;	chr8:10746195	chr8:11104691~11106704:-
HNSC	cis	rs6095360	1	rs1983639	ENSG00000222365.1	SNORD12B	-4.08	5.35e-05	0.00831	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48955745	chr20:49280319~49280409:+
HNSC	cis	rs2098713	0.586	rs61435914	ENSG00000250155.1	CTD-2353F22.1	4.08	5.35e-05	0.00831	0.18	0.19	Telomere length;	chr5:37607239	chr5:36666214~36725195:-
HNSC	cis	rs6964587	0.626	rs1011372	ENSG00000188693.7	CYP51A1-AS1	4.08	5.35e-05	0.00831	0.2	0.19	Breast cancer;	chr7:91880553	chr7:92134604~92180725:+
HNSC	cis	rs67981189	0.593	rs221924	ENSG00000274818.1	RP1-292L20.3	-4.08	5.35e-05	0.00831	-0.2	-0.19	Schizophrenia;	chr14:71114061	chr14:70906657~70907111:-
HNSC	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-4.08	5.35e-05	0.00831	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
HNSC	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	4.08	5.35e-05	0.00831	0.16	0.19	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
HNSC	cis	rs6964587	0.626	rs6979235	ENSG00000188693.7	CYP51A1-AS1	4.08	5.35e-05	0.00831	0.2	0.19	Breast cancer;	chr7:91882462	chr7:92134604~92180725:+
HNSC	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	4.08	5.35e-05	0.00831	0.4	0.19	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
HNSC	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	4.08	5.35e-05	0.00831	0.4	0.19	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
HNSC	cis	rs804280	1	rs804281	ENSG00000269918.1	AF131215.9	4.08	5.35e-05	0.00832	0.18	0.19	Myopia (pathological);	chr8:11754356	chr8:11104691~11106704:-
HNSC	cis	rs561341	1	rs530209	ENSG00000278867.1	RP11-640N20.4	-4.08	5.36e-05	0.00832	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:31988268	chr17:32051030~32053208:+
HNSC	cis	rs3015469	0.507	rs10144496	ENSG00000269906.1	RP11-248J18.2	-4.08	5.36e-05	0.00832	-0.24	-0.19	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50615465	chr14:50662511~50663178:-
HNSC	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-4.08	5.36e-05	0.00832	-0.22	-0.19	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
HNSC	cis	rs7572733	0.515	rs11891555	ENSG00000231621.1	AC013264.2	-4.08	5.36e-05	0.00832	-0.18	-0.19	Dermatomyositis;	chr2:197988816	chr2:197197991~197199273:+
HNSC	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-4.08	5.36e-05	0.00833	-0.18	-0.19	Height;	chr5:37239138	chr5:36666214~36725195:-
HNSC	cis	rs11336847	1	rs11336847	ENSG00000234072.1	AC074117.10	-4.08	5.36e-05	0.00833	-0.16	-0.19	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:27526126	chr2:27356246~27367622:+
HNSC	cis	rs10129255	0.5	rs8022547	ENSG00000224373.3	IGHV4-59	4.08	5.36e-05	0.00833	0.11	0.19	Kawasaki disease;	chr14:106781985	chr14:106627249~106627825:-
HNSC	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-4.08	5.36e-05	0.00833	-0.27	-0.19	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-4.08	5.36e-05	0.00833	-0.2	-0.19	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
HNSC	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-4.08	5.36e-05	0.00833	-0.25	-0.19	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
HNSC	cis	rs853679	0.513	rs9468296	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28145952	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4711164	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28147378	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4711165	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28147406	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713148	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28148143	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9348794	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28149979	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9468297	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28151096	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9295758	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28152885	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs17774663	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28153120	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9468298	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28154567	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9295759	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28156691	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9348796	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28158424	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs11552219	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28159056	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380058	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28159666	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393895	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28159843	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393896	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28159925	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393897	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28159932	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9357065	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28161802	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9357066	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28162053	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393898	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28162598	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368556	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28163375	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368557	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28163759	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380059	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28164580	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380060	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28164825	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs35227624	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28164948	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380061	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28165025	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368558	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28165528	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.587	rs9393899	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Parkinson's disease;	chr6:28165750	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713150	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28168434	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.527	rs4713151	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Parkinson's disease;	chr6:28168578	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393901	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28169019	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs3173443	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28169249	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713152	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28169676	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9348797	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28169755	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380062	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28169791	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.542	rs9380063	ENSG00000219891.2	ZSCAN12P1	4.08	5.37e-05	0.00833	0.26	0.19	Depression;	chr6:28170075	chr6:28091154~28093664:+
HNSC	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	4.08	5.37e-05	0.00833	0.21	0.19	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
HNSC	cis	rs9847710	0.933	rs1529544	ENSG00000242142.1	SERBP1P3	-4.08	5.37e-05	0.00833	-0.21	-0.19	Ulcerative colitis;	chr3:53005439	chr3:53064283~53065091:-
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.08	5.37e-05	0.00833	0.21	0.19	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
HNSC	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-4.08	5.37e-05	0.00833	-0.22	-0.19	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
HNSC	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	4.08	5.37e-05	0.00834	0.22	0.19	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
HNSC	cis	rs6095360	0.933	rs6019620	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49062763	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019621	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49063426	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs2075675	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49068956	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019624	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49069278	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6512567	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49072083	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs2075676	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49074674	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.901	rs2426120	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49080716	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.933	rs2426122	ENSG00000222365.1	SNORD12B	-4.08	5.37e-05	0.00834	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49081402	chr20:49280319~49280409:+
HNSC	cis	rs748404	0.666	rs55748552	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43359428	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.63	rs35278805	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43361124	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs35160541	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43365601	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.626	rs62021176	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43388014	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs35158584	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43392876	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs16957680	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43396207	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs7180812	ENSG00000166763.7	STRCP1	4.08	5.37e-05	0.00834	0.26	0.19	Lung cancer;	chr15:43403033	chr15:43699488~43718184:-
HNSC	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	4.08	5.37e-05	0.00834	0.18	0.19	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	4.08	5.37e-05	0.00834	0.18	0.19	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
HNSC	cis	rs6601327	0.632	rs6980595	ENSG00000233609.3	RP11-62H7.2	-4.08	5.37e-05	0.00834	-0.18	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9793652	chr8:8961200~8979025:+
HNSC	cis	rs597539	0.652	rs622082	ENSG00000261625.1	RP11-554A11.4	-4.08	5.37e-05	0.00834	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.652	rs546382	ENSG00000261625.1	RP11-554A11.4	-4.08	5.37e-05	0.00834	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:69000765~69002048:-
HNSC	cis	rs72827839	0.779	rs16955073	ENSG00000244649.3	CTD-2377D24.6	-4.08	5.37e-05	0.00834	-0.24	-0.19	Ease of getting up in the morning;	chr17:48304384	chr17:48646923~48707346:+
HNSC	cis	rs11951515	0.509	rs12521249	ENSG00000249286.1	CTD-2210P15.2	-4.08	5.37e-05	0.00834	-0.19	-0.19	Metabolite levels  (X-11787);	chr5:43558527	chr5:43586918~43588223:-
HNSC	cis	rs1665050	0.842	rs1665049	ENSG00000259732.1	RP11-59H7.3	4.08	5.37e-05	0.00834	0.27	0.19	Atopic dermatitis;	chr15:58998453	chr15:59121034~59133250:+
HNSC	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-4.08	5.38e-05	0.00835	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-4.08	5.38e-05	0.00835	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-4.08	5.38e-05	0.00835	-0.18	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
HNSC	cis	rs12935418	0.672	rs7197370	ENSG00000278985.1	RP11-303E16.9	4.08	5.38e-05	0.00835	0.18	0.19	Mean corpuscular volume;	chr16:81017520	chr16:80982319~80984094:-
HNSC	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	4.08	5.38e-05	0.00835	0.26	0.19	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	4.08	5.38e-05	0.00835	0.26	0.19	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
HNSC	cis	rs9487051	0.582	rs830556	ENSG00000243587.6	C6orf183	-4.08	5.38e-05	0.00835	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109223712	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.621	rs351727	ENSG00000243587.6	C6orf183	-4.08	5.38e-05	0.00835	-0.19	-0.19	Reticulocyte fraction of red cells;	chr6:109227634	chr6:109165833~109271014:+
HNSC	cis	rs11098499	0.863	rs3822194	ENSG00000250412.1	KLHL2P1	4.08	5.38e-05	0.00835	0.24	0.19	Corneal astigmatism;	chr4:119550493	chr4:119334329~119378233:+
HNSC	cis	rs2733201	1	rs2733201	ENSG00000205771.5	CATSPER2P1	4.08	5.38e-05	0.00835	0.51	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44116203	chr15:43726918~43747094:-
HNSC	cis	rs9910055	0.571	rs28897216	ENSG00000267080.4	ASB16-AS1	-4.08	5.38e-05	0.00835	-0.15	-0.19	Total body bone mineral density;	chr17:44163456	chr17:44175973~44186717:-
HNSC	cis	rs36093844	0.664	rs111395809	ENSG00000279742.1	RP11-700A24.1	-4.08	5.38e-05	0.00835	-0.25	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86055093	chr11:85852557~85854943:-
HNSC	cis	rs6831352	0.819	rs2851274	ENSG00000263923.1	RP11-571L19.7	-4.08	5.38e-05	0.00835	-0.19	-0.19	Alcohol dependence;	chr4:99104715	chr4:98928897~98994994:+
HNSC	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-4.08	5.39e-05	0.00836	-0.25	-0.19	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
HNSC	cis	rs17818399	0.612	rs4952834	ENSG00000279254.1	RP11-536C12.1	-4.08	5.39e-05	0.00836	-0.22	-0.19	Height;	chr2:46550323	chr2:46668870~46670778:+
HNSC	cis	rs4819052	0.851	rs4819040	ENSG00000223768.1	LINC00205	-4.08	5.39e-05	0.00836	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45293285~45297354:+
HNSC	cis	rs3736485	0.873	rs11630336	ENSG00000259438.1	CTD-2650P22.1	4.08	5.39e-05	0.00836	0.19	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51579446	chr15:52010999~52019095:-
HNSC	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	4.08	5.39e-05	0.00836	0.24	0.19	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
HNSC	cis	rs17772222	0.917	rs57889459	ENSG00000258789.1	RP11-507K2.3	-4.08	5.39e-05	0.00836	-0.22	-0.19	Coronary artery calcification;	chr14:88770820	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs61982733	ENSG00000258789.1	RP11-507K2.3	-4.08	5.39e-05	0.00836	-0.22	-0.19	Coronary artery calcification;	chr14:88776244	chr14:88551597~88552493:+
HNSC	cis	rs9650657	0.801	rs718741	ENSG00000269918.1	AF131215.9	-4.08	5.39e-05	0.00836	-0.19	-0.19	Neuroticism;	chr8:10756874	chr8:11104691~11106704:-
HNSC	cis	rs10504130	0.569	rs4626585	ENSG00000253844.1	RP11-546K22.1	4.08	5.39e-05	0.00836	0.28	0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51961458~52022974:+
HNSC	cis	rs11638815	0.689	rs1267656	ENSG00000255769.6	GOLGA2P10	-4.08	5.39e-05	0.00837	-0.29	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82551349	chr15:82472993~82513950:-
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000254174.1	IGHV1-12	-4.08	5.39e-05	0.00837	-0.15	-0.19	Rheumatic heart disease;	chr14:106622776	chr14:106122420~106122709:-
HNSC	cis	rs72627123	1	rs2302139	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.39e-05	0.00837	-0.32	-0.19	Morning vs. evening chronotype;	chr14:73896232	chr14:73787360~73803270:+
HNSC	cis	rs4763879	0.739	rs2114871	ENSG00000278635.1	CTD-2318O12.1	4.08	5.4e-05	0.00837	0.14	0.19	Type 1 diabetes;	chr12:9676842	chr12:9415641~9416718:+
HNSC	cis	rs11098499	0.863	rs1010740	ENSG00000250412.1	KLHL2P1	-4.08	5.4e-05	0.00837	-0.24	-0.19	Corneal astigmatism;	chr4:119542254	chr4:119334329~119378233:+
HNSC	cis	rs2921073	0.51	rs2976945	ENSG00000233609.3	RP11-62H7.2	4.08	5.4e-05	0.00837	0.18	0.19	Parkinson's disease;	chr8:8413361	chr8:8961200~8979025:+
HNSC	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	4.08	5.4e-05	0.00837	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
HNSC	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-4.08	5.4e-05	0.00837	-0.22	-0.19	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
HNSC	cis	rs7107174	1	rs1942352	ENSG00000251323.2	RP11-452H21.4	4.08	5.4e-05	0.00838	0.28	0.19	Testicular germ cell tumor;	chr11:78259517	chr11:78423982~78429836:-
HNSC	cis	rs6964587	0.626	rs4729011	ENSG00000188693.7	CYP51A1-AS1	4.08	5.4e-05	0.00838	0.2	0.19	Breast cancer;	chr7:91886105	chr7:92134604~92180725:+
HNSC	cis	rs73198271	0.653	rs10087742	ENSG00000173295.6	FAM86B3P	-4.08	5.4e-05	0.00838	-0.23	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8228595~8244865:+
HNSC	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	4.08	5.4e-05	0.00838	0.19	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
HNSC	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-4.08	5.4e-05	0.00838	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-4.08	5.4e-05	0.00838	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-4.08	5.4e-05	0.00838	-0.18	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
HNSC	cis	rs71636778	0.509	rs78581866	ENSG00000260063.1	RP5-968P14.2	-4.08	5.4e-05	0.00838	-0.41	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921075	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs11538549	ENSG00000260063.1	RP5-968P14.2	-4.08	5.4e-05	0.00838	-0.41	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921792	chr1:26692132~26694131:-
HNSC	cis	rs6543140	0.964	rs6736135	ENSG00000234389.1	AC007278.3	4.08	5.4e-05	0.00838	0.19	0.19	Blood protein levels;	chr2:102448464	chr2:102438713~102440475:+
HNSC	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.08	5.4e-05	0.00838	0.25	0.19	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
HNSC	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	4.07	5.41e-05	0.00839	0.22	0.19	Height;	chr14:75075251	chr14:75011269~75012851:-
HNSC	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-4.07	5.41e-05	0.00839	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-4.07	5.41e-05	0.00839	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-4.07	5.41e-05	0.00839	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-4.07	5.41e-05	0.00839	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-4.07	5.41e-05	0.00839	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
HNSC	cis	rs41307935	0.818	rs34339345	ENSG00000260063.1	RP5-968P14.2	-4.07	5.41e-05	0.00839	-0.41	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26899598	chr1:26692132~26694131:-
HNSC	cis	rs7824557	0.606	rs2736273	ENSG00000255020.1	AF131216.5	4.07	5.41e-05	0.00839	0.2	0.19	Retinal vascular caliber;	chr8:11342429	chr8:11345748~11347502:-
HNSC	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	4.07	5.41e-05	0.00839	0.29	0.19	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
HNSC	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	4.07	5.41e-05	0.00839	0.16	0.19	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	4.07	5.41e-05	0.00839	0.16	0.19	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
HNSC	cis	rs354225	0.608	rs168505	ENSG00000237887.1	AC092839.1	-4.07	5.41e-05	0.00839	-0.21	-0.19	Schizophrenia;	chr2:54693831	chr2:54529343~54529801:+
HNSC	cis	rs2117029	0.782	rs10459232	ENSG00000258101.2	RP11-977B10.2	4.07	5.41e-05	0.00839	0.23	0.19	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49232790~49264756:-
HNSC	cis	rs11723261	0.582	rs11732336	ENSG00000211553.1	AC253576.2	-4.07	5.41e-05	0.0084	-0.27	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:136461~136568:+
HNSC	cis	rs3750965	0.734	rs11604251	ENSG00000265539.1	MIR3164	4.07	5.42e-05	0.0084	0.21	0.19	Hair color;	chr11:69052961	chr11:69083176~69083258:+
HNSC	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-4.07	5.42e-05	0.0084	-0.17	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
HNSC	cis	rs7819412	0.875	rs11250121	ENSG00000255495.1	AC145124.2	-4.07	5.42e-05	0.0084	-0.21	-0.19	Triglycerides;	chr8:11202802	chr8:12194467~12196280:+
HNSC	cis	rs2274273	0.712	rs9806049	ENSG00000233924.1	AL160471.6	-4.07	5.42e-05	0.00841	-0.21	-0.19	Protein biomarker;	chr14:55058871	chr14:55004813~55005687:-
HNSC	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	4.07	5.42e-05	0.00841	0.18	0.19	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
HNSC	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	4.07	5.42e-05	0.00841	0.21	0.19	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
HNSC	cis	rs9584850	0.708	rs4411372	ENSG00000231194.1	FARP1-AS1	4.07	5.42e-05	0.00841	0.23	0.19	Neuroticism;	chr13:98478169	chr13:98435405~98435840:-
HNSC	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-4.07	5.42e-05	0.00841	-0.18	-0.19	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
HNSC	cis	rs72827839	0.744	rs16955463	ENSG00000244649.3	CTD-2377D24.6	-4.07	5.42e-05	0.00841	-0.24	-0.19	Ease of getting up in the morning;	chr17:48322135	chr17:48646923~48707346:+
HNSC	cis	rs561341	1	rs497479	ENSG00000278867.1	RP11-640N20.4	-4.07	5.43e-05	0.00841	-0.25	-0.19	Hip circumference adjusted for BMI;	chr17:32001586	chr17:32051030~32053208:+
HNSC	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	4.07	5.43e-05	0.00841	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
HNSC	cis	rs2239557	0.508	rs12587320	ENSG00000259065.1	RP5-1021I20.1	4.07	5.43e-05	0.00841	0.26	0.19	Common traits (Other);	chr14:73901591	chr14:73787360~73803270:+
HNSC	cis	rs2279168	0.867	rs74024892	ENSG00000259295.5	CSPG4P12	-4.07	5.43e-05	0.00841	-0.38	-0.19	Response to platinum-based chemotherapy (carboplatin);	chr15:85502076	chr15:85191438~85213905:+
HNSC	cis	rs1659258	0.568	rs1659262	ENSG00000232508.1	MRPL45P1	4.07	5.43e-05	0.00841	0.33	0.19	Visceral fat;	chr2:88300861	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.568	rs1258438	ENSG00000232508.1	MRPL45P1	4.07	5.43e-05	0.00841	0.33	0.19	Visceral fat;	chr2:88306248	chr2:88364695~88365608:-
HNSC	cis	rs10504130	0.569	rs6473653	ENSG00000253844.1	RP11-546K22.1	4.07	5.43e-05	0.00842	0.28	0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51961458~52022974:+
HNSC	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-4.07	5.43e-05	0.00842	-0.27	-0.19	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
HNSC	cis	rs988913	0.874	rs9382398	ENSG00000224984.1	RP11-524H19.2	4.07	5.43e-05	0.00842	0.22	0.19	Menarche (age at onset);	chr6:54918468	chr6:54840118~54840855:-
HNSC	cis	rs72949976	1	rs62186568	ENSG00000270659.1	RP11-105N14.1	4.07	5.43e-05	0.00842	0.19	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213169231	chr2:213152970~213153659:+
HNSC	cis	rs72949976	1	rs62186569	ENSG00000270659.1	RP11-105N14.1	4.07	5.43e-05	0.00842	0.19	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213169427	chr2:213152970~213153659:+
HNSC	cis	rs6840258	1	rs75550773	ENSG00000251411.1	RP11-397E7.4	-4.07	5.43e-05	0.00842	-0.24	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034271	chr4:86913266~86914817:-
HNSC	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	4.07	5.43e-05	0.00842	0.23	0.19	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
HNSC	cis	rs12682352	0.602	rs28399241	ENSG00000254153.1	CTA-398F10.2	4.07	5.43e-05	0.00842	0.21	0.19	Neuroticism;	chr8:8805705	chr8:8456909~8461337:-
HNSC	cis	rs7572733	0.773	rs16866970	ENSG00000222017.1	AC011997.1	4.07	5.44e-05	0.00843	0.23	0.19	Dermatomyositis;	chr2:197646362	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.773	rs11690491	ENSG00000222017.1	AC011997.1	4.07	5.44e-05	0.00843	0.23	0.19	Dermatomyositis;	chr2:197650200	chr2:197693106~197774823:+
HNSC	cis	rs5752326	1	rs5752327	ENSG00000261188.1	CTA-445C9.14	4.07	5.44e-05	0.00843	0.29	0.19	Ischemic stroke;	chr22:26448104	chr22:26512537~26514568:+
HNSC	cis	rs9584850	0.794	rs72655609	ENSG00000231194.1	FARP1-AS1	4.07	5.44e-05	0.00843	0.23	0.19	Neuroticism;	chr13:98476368	chr13:98435405~98435840:-
HNSC	cis	rs35306767	0.903	rs12763396	ENSG00000229869.1	RP11-363N22.2	-4.07	5.44e-05	0.00843	-0.27	-0.19	Eosinophil percentage of granulocytes;	chr10:881417	chr10:933026~942743:+
HNSC	cis	rs72843506	0.591	rs74319100	ENSG00000261033.1	RP11-209D14.2	4.07	5.44e-05	0.00843	0.31	0.19	Schizophrenia;	chr17:20318079	chr17:20008051~20009234:-
HNSC	cis	rs964611	0.938	rs7163887	ENSG00000259488.2	RP11-154J22.1	4.07	5.44e-05	0.00843	0.19	0.19	Metabolite levels (Pyroglutamine);	chr15:48367357	chr15:48312353~48331856:-
HNSC	cis	rs6964587	0.626	rs6951795	ENSG00000188693.7	CYP51A1-AS1	4.07	5.44e-05	0.00843	0.2	0.19	Breast cancer;	chr7:91914450	chr7:92134604~92180725:+
HNSC	cis	rs6587515	0.901	rs61820166	ENSG00000274963.1	Metazoa_SRP	4.07	5.44e-05	0.00843	0.3	0.19	Pericardial adipose tissue adjusted for height and weight;	chr1:150583560	chr1:150568971~150569269:-
HNSC	cis	rs7005380	0.556	rs11984866	ENSG00000279347.1	RP11-85I17.2	4.07	5.44e-05	0.00843	0.19	0.19	Interstitial lung disease;	chr8:119924485	chr8:119838736~119840385:-
HNSC	cis	rs9313772	0.928	rs71585962	ENSG00000254350.1	RP11-542A14.1	-4.07	5.44e-05	0.00843	-0.22	-0.19	Blood pressure;	chr5:158417097	chr5:158424585~158452758:+
HNSC	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-4.07	5.44e-05	0.00843	-0.21	-0.19	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000211976.2	IGHV3-73	-4.07	5.44e-05	0.00844	-0.13	-0.19	Kawasaki disease;	chr14:106777987	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000211976.2	IGHV3-73	-4.07	5.44e-05	0.00844	-0.13	-0.19	Kawasaki disease;	chr14:106777997	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000211976.2	IGHV3-73	-4.07	5.44e-05	0.00844	-0.13	-0.19	Kawasaki disease;	chr14:106778016	chr14:106802694~106803233:-
HNSC	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-4.07	5.44e-05	0.00844	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
HNSC	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-4.07	5.44e-05	0.00844	-0.23	-0.19	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
HNSC	cis	rs9531006	0.571	rs12583025	ENSG00000227676.3	LINC01068	4.07	5.44e-05	0.00844	0.28	0.19	Sleep duration;	chr13:79930017	chr13:79566727~79571436:+
HNSC	cis	rs6586111	0.935	rs4933463	ENSG00000226659.1	RP11-137H2.4	-4.07	5.45e-05	0.00844	-0.22	-0.19	Capecitabine sensitivity;	chr10:80613110	chr10:80529597~80535942:-
HNSC	cis	rs10129255	1	rs10129407	ENSG00000224373.3	IGHV4-59	4.07	5.45e-05	0.00844	0.12	0.19	Kawasaki disease;	chr14:106767956	chr14:106627249~106627825:-
HNSC	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	4.07	5.45e-05	0.00844	0.26	0.19	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
HNSC	cis	rs72627123	1	rs17093141	ENSG00000259065.1	RP5-1021I20.1	-4.07	5.45e-05	0.00844	-0.33	-0.19	Morning vs. evening chronotype;	chr14:73860200	chr14:73787360~73803270:+
HNSC	cis	rs72717009	0.756	rs10494359	ENSG00000225217.1	HSPA7	-4.07	5.45e-05	0.00844	-0.31	-0.19	Rheumatoid arthritis;	chr1:161494086	chr1:161606291~161608217:+
HNSC	cis	rs860295	0.535	rs2297649	ENSG00000203761.5	MSTO2P	4.07	5.45e-05	0.00844	0.15	0.19	Body mass index;	chr1:155965453	chr1:155745829~155750137:+
HNSC	cis	rs2364403	1	rs2364403	ENSG00000225855.5	RUSC1-AS1	4.07	5.45e-05	0.00844	0.14	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:155957961	chr1:155316863~155324176:-
HNSC	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	4.07	5.45e-05	0.00844	0.24	0.19	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
HNSC	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	4.07	5.45e-05	0.00844	0.18	0.19	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
HNSC	cis	rs12478296	1	rs6743297	ENSG00000261186.2	RP11-341N2.1	-4.07	5.45e-05	0.00844	-0.29	-0.19	Obesity-related traits;	chr2:242071663	chr2:242087351~242088457:-
HNSC	cis	rs35306767	0.715	rs17221463	ENSG00000229869.1	RP11-363N22.2	-4.07	5.45e-05	0.00844	-0.27	-0.19	Eosinophil percentage of granulocytes;	chr10:992100	chr10:933026~942743:+
HNSC	cis	rs3736485	0.899	rs7183479	ENSG00000274528.1	CTD-2650P22.2	4.07	5.45e-05	0.00845	0.18	0.19	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51650010	chr15:52017167~52018032:-
HNSC	cis	rs4356203	0.905	rs511119	ENSG00000272034.1	SNORD14A	-4.07	5.45e-05	0.00845	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17074654~17074744:-
HNSC	cis	rs728616	0.867	rs17098720	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.45e-05	0.00845	-0.38	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.717	rs12414332	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.45e-05	0.00845	-0.38	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79663088~79826594:-
HNSC	cis	rs12893668	0.703	rs4906336	ENSG00000269958.1	RP11-73M18.8	4.07	5.46e-05	0.00845	0.18	0.19	Reticulocyte count;	chr14:103566928	chr14:103696353~103697163:+
HNSC	cis	rs11951515	0.7	rs1545753	ENSG00000249286.1	CTD-2210P15.2	4.07	5.46e-05	0.00845	0.2	0.19	Metabolite levels  (X-11787);	chr5:43288264	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.7	rs6814	ENSG00000249286.1	CTD-2210P15.2	4.07	5.46e-05	0.00845	0.2	0.19	Metabolite levels  (X-11787);	chr5:43289606	chr5:43586918~43588223:-
HNSC	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-4.07	5.46e-05	0.00845	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
HNSC	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-4.07	5.46e-05	0.00846	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-4.07	5.46e-05	0.00846	-0.18	-0.19	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
HNSC	cis	rs62027291	0.898	rs2404232	ENSG00000259422.1	RP11-593F23.1	-4.07	5.46e-05	0.00846	-0.3	-0.19	Plateletcrit;	chr15:76968234	chr15:76174891~76181486:-
HNSC	cis	rs2179367	0.92	rs560051	ENSG00000216906.2	RP11-350J20.9	4.07	5.46e-05	0.00846	0.23	0.19	Dupuytren's disease;	chr6:149345841	chr6:149904243~149906418:+
HNSC	cis	rs4713118	0.516	rs4713142	ENSG00000219891.2	ZSCAN12P1	4.07	5.46e-05	0.00846	0.26	0.19	Parkinson's disease;	chr6:28138569	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713143	ENSG00000219891.2	ZSCAN12P1	4.07	5.46e-05	0.00846	0.26	0.19	Depression;	chr6:28138981	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713144	ENSG00000219891.2	ZSCAN12P1	4.07	5.46e-05	0.00846	0.26	0.19	Depression;	chr6:28139012	chr6:28091154~28093664:+
HNSC	cis	rs2905347	0.895	rs2961283	ENSG00000179428.2	AC073072.5	-4.07	5.46e-05	0.00846	-0.22	-0.19	Major depression and alcohol dependence;	chr7:22600879	chr7:22725395~22727620:-
HNSC	cis	rs13325613	0.834	rs3176824	ENSG00000223552.1	RP11-24F11.2	-4.07	5.46e-05	0.00846	-0.32	-0.19	Monocyte count;	chr3:46206894	chr3:46364955~46407059:-
HNSC	cis	rs8058578	1	rs13338946	ENSG00000279196.1	RP11-1072A3.3	4.07	5.46e-05	0.00846	0.23	0.19	Multiple myeloma;	chr16:30689537	chr16:30984630~30988270:-
HNSC	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-4.07	5.46e-05	0.00846	-0.25	-0.19	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
HNSC	cis	rs4356203	0.905	rs536628	ENSG00000260196.1	RP1-239B22.5	-4.07	5.47e-05	0.00846	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17380649~17383531:+
HNSC	cis	rs9903692	0.954	rs8076380	ENSG00000263412.1	RP5-890E16.2	4.07	5.47e-05	0.00846	0.17	0.19	Pulse pressure;	chr17:48113028	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.754	rs12602948	ENSG00000263412.1	RP5-890E16.2	4.07	5.47e-05	0.00846	0.17	0.19	Pulse pressure;	chr17:48113567	chr17:48045141~48048073:-
HNSC	cis	rs5769707	0.777	rs8141219	ENSG00000235111.1	RP1-29C18.8	-4.07	5.47e-05	0.00847	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49612657~49615716:-
HNSC	cis	rs2098713	0.561	rs4869440	ENSG00000250155.1	CTD-2353F22.1	4.07	5.47e-05	0.00847	0.18	0.19	Telomere length;	chr5:37600839	chr5:36666214~36725195:-
HNSC	cis	rs4356203	0.905	rs615358	ENSG00000260196.1	RP1-239B22.5	-4.07	5.47e-05	0.00847	-0.2	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17188885	chr11:17380649~17383531:+
HNSC	cis	rs4144743	1	rs7218524	ENSG00000228782.6	CTD-2026D20.3	-4.07	5.47e-05	0.00847	-0.22	-0.19	Body mass index;	chr17:47249199	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.877	rs7223766	ENSG00000228782.6	CTD-2026D20.3	-4.07	5.47e-05	0.00847	-0.22	-0.19	Body mass index;	chr17:47249368	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs7224990	ENSG00000228782.6	CTD-2026D20.3	-4.07	5.47e-05	0.00847	-0.22	-0.19	Body mass index;	chr17:47249512	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.938	rs7225134	ENSG00000228782.6	CTD-2026D20.3	-4.07	5.47e-05	0.00847	-0.22	-0.19	Body mass index;	chr17:47249566	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs35704663	ENSG00000228782.6	CTD-2026D20.3	-4.07	5.47e-05	0.00847	-0.22	-0.19	Body mass index;	chr17:47249955	chr17:47450568~47492492:-
HNSC	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	4.07	5.47e-05	0.00847	0.28	0.19	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
HNSC	cis	rs7572733	0.935	rs7571869	ENSG00000222017.1	AC011997.1	4.07	5.47e-05	0.00847	0.22	0.19	Dermatomyositis;	chr2:197976891	chr2:197693106~197774823:+
HNSC	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-4.07	5.47e-05	0.00847	-0.22	-0.19	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	4.07	5.47e-05	0.00847	0.11	0.19	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
HNSC	cis	rs9487051	0.646	rs11153166	ENSG00000243587.6	C6orf183	4.07	5.47e-05	0.00847	0.19	0.19	Reticulocyte fraction of red cells;	chr6:109301291	chr6:109165833~109271014:+
HNSC	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	4.07	5.48e-05	0.00848	0.21	0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
HNSC	cis	rs8042849	1	rs8042849	ENSG00000261762.1	RP11-650L12.2	4.07	5.48e-05	0.00848	0.21	0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;Parental lifespan;	chr15:78525587	chr15:78589123~78591276:-
HNSC	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	4.07	5.48e-05	0.00848	0.17	0.19	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
HNSC	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-4.07	5.48e-05	0.00848	-0.19	-0.19	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
HNSC	cis	rs10504130	0.569	rs34364864	ENSG00000253844.1	RP11-546K22.1	-4.07	5.48e-05	0.00848	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51961458~52022974:+
HNSC	cis	rs36093844	0.848	rs55836023	ENSG00000279742.1	RP11-700A24.1	-4.07	5.48e-05	0.00848	-0.25	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85855114	chr11:85852557~85854943:-
HNSC	cis	rs10256972	0.694	rs7784701	ENSG00000225146.1	AC073957.15	4.07	5.48e-05	0.00849	0.24	0.19	Endometriosis;Longevity;	chr7:963405	chr7:1029025~1043891:+
HNSC	cis	rs8002861	0.664	rs2325089	ENSG00000274001.1	RP11-5G9.5	-4.07	5.48e-05	0.00849	-0.19	-0.19	Leprosy;	chr13:43876086	chr13:43877715~43878163:-
HNSC	cis	rs6831352	0.691	rs2602887	ENSG00000263923.1	RP11-571L19.7	-4.07	5.48e-05	0.00849	-0.2	-0.19	Alcohol dependence;	chr4:99120322	chr4:98928897~98994994:+
HNSC	cis	rs651907	0.514	rs34301719	ENSG00000244119.1	PDCL3P4	4.07	5.48e-05	0.00849	0.18	0.19	Colorectal cancer;	chr3:101699149	chr3:101712472~101713191:+
HNSC	cis	rs12745968	0.532	rs4970704	ENSG00000223787.2	RP4-593M8.1	-4.07	5.49e-05	0.00849	-0.22	-0.19	Bipolar disorder and schizophrenia;	chr1:92506145	chr1:92580476~92580821:-
HNSC	cis	rs7819412	0.522	rs3021495	ENSG00000269918.1	AF131215.9	-4.07	5.49e-05	0.00849	-0.19	-0.19	Triglycerides;	chr8:11137233	chr8:11104691~11106704:-
HNSC	cis	rs13325613	0.834	rs3176825	ENSG00000223552.1	RP11-24F11.2	-4.07	5.49e-05	0.00849	-0.32	-0.19	Monocyte count;	chr3:46206733	chr3:46364955~46407059:-
HNSC	cis	rs2847297	1	rs2847297	ENSG00000260302.1	RP11-973H7.1	4.07	5.49e-05	0.0085	0.24	0.19	Rheumatoid arthritis;	chr18:12797695	chr18:12774651~12775923:-
HNSC	cis	rs5758659	0.652	rs133358	ENSG00000270083.1	RP1-257I20.14	4.07	5.49e-05	0.0085	0.17	0.19	Cognitive function;	chr22:42046535	chr22:42089630~42090028:-
HNSC	cis	rs478304	0.593	rs4645933	ENSG00000255120.4	OVOL1-AS1	-4.07	5.49e-05	0.0085	-0.2	-0.19	Acne (severe);	chr11:65717649	chr11:65789051~65790868:-
HNSC	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	4.07	5.49e-05	0.0085	0.21	0.19	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
HNSC	cis	rs9903692	0.954	rs11079808	ENSG00000263412.1	RP5-890E16.2	4.07	5.49e-05	0.0085	0.17	0.19	Pulse pressure;	chr17:48102870	chr17:48045141~48048073:-
HNSC	cis	rs9903692	0.954	rs8077860	ENSG00000263412.1	RP5-890E16.2	4.07	5.49e-05	0.0085	0.17	0.19	Pulse pressure;	chr17:48107973	chr17:48045141~48048073:-
HNSC	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	4.07	5.49e-05	0.0085	0.18	0.19	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
HNSC	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-4.07	5.49e-05	0.0085	-0.22	-0.19	Height;	chr14:75157431	chr14:75011269~75012851:-
HNSC	cis	rs9311676	0.656	rs11708895	ENSG00000273493.1	RP11-80H18.4	4.07	5.49e-05	0.0085	0.21	0.19	Systemic lupus erythematosus;	chr3:58417315	chr3:58329965~58330118:+
HNSC	cis	rs7824557	0.628	rs11777746	ENSG00000255020.1	AF131216.5	4.07	5.5e-05	0.00851	0.2	0.19	Retinal vascular caliber;	chr8:11347246	chr8:11345748~11347502:-
HNSC	cis	rs10510102	0.566	rs885543	ENSG00000226864.1	ATE1-AS1	4.07	5.5e-05	0.00851	0.34	0.19	Breast cancer;	chr10:121973536	chr10:121928312~121951965:+
HNSC	cis	rs4356203	0.905	rs621246	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs635802	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs662711	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs598946	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs545773	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.792	rs677540	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs512852	ENSG00000272034.1	SNORD14A	-4.07	5.5e-05	0.00851	-0.14	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs1989405	ENSG00000260196.1	RP1-239B22.5	4.07	5.5e-05	0.00851	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17380649~17383531:+
HNSC	cis	rs62246343	0.605	rs17050395	ENSG00000254485.4	RP11-380O24.1	4.07	5.5e-05	0.00851	0.22	0.19	Fibrinogen levels;	chr3:9492290	chr3:9292588~9363303:-
HNSC	cis	rs9880211	0.613	rs1393786	ENSG00000239213.4	NCK1-AS1	4.07	5.5e-05	0.00851	0.18	0.19	Height;Body mass index;	chr3:136135193	chr3:136841726~136862054:-
HNSC	cis	rs4819052	0.851	rs1999334	ENSG00000223768.1	LINC00205	-4.07	5.5e-05	0.00851	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45293285~45297354:+
HNSC	cis	rs7005380	0.965	rs11988434	ENSG00000279347.1	RP11-85I17.2	4.07	5.5e-05	0.00851	0.16	0.19	Interstitial lung disease;	chr8:119932982	chr8:119838736~119840385:-
HNSC	cis	rs7005380	1	rs11995536	ENSG00000279347.1	RP11-85I17.2	4.07	5.5e-05	0.00851	0.16	0.19	Interstitial lung disease;	chr8:119933028	chr8:119838736~119840385:-
HNSC	cis	rs7429990	0.965	rs4296617	ENSG00000228638.1	FCF1P2	4.07	5.5e-05	0.00851	0.18	0.19	Educational attainment (years of education);	chr3:48026818	chr3:48290793~48291375:-
HNSC	cis	rs7267979	0.789	rs62213729	ENSG00000231081.1	RP4-760C5.3	4.07	5.5e-05	0.00851	0.19	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26008791~26010531:-
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-4.07	5.5e-05	0.00852	-0.25	-0.19	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
HNSC	cis	rs9650657	0.812	rs11250072	ENSG00000269918.1	AF131215.9	-4.07	5.51e-05	0.00852	-0.19	-0.19	Neuroticism;	chr8:10774611	chr8:11104691~11106704:-
HNSC	cis	rs9650657	0.812	rs11250073	ENSG00000269918.1	AF131215.9	-4.07	5.51e-05	0.00852	-0.19	-0.19	Neuroticism;	chr8:10774726	chr8:11104691~11106704:-
HNSC	cis	rs4356203	0.905	rs7123301	ENSG00000260196.1	RP1-239B22.5	-4.07	5.51e-05	0.00852	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17380649~17383531:+
HNSC	cis	rs2279168	0.867	rs74024885	ENSG00000259295.5	CSPG4P12	-4.07	5.51e-05	0.00852	-0.38	-0.19	Response to platinum-based chemotherapy (carboplatin);	chr15:85498149	chr15:85191438~85213905:+
HNSC	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-4.07	5.51e-05	0.00852	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
HNSC	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	4.07	5.51e-05	0.00852	0.24	0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
HNSC	cis	rs700651	0.856	rs9288280	ENSG00000231621.1	AC013264.2	-4.07	5.51e-05	0.00852	-0.18	-0.19	Intracranial aneurysm;	chr2:197879600	chr2:197197991~197199273:+
HNSC	cis	rs5758659	0.652	rs1063392	ENSG00000270083.1	RP1-257I20.14	-4.07	5.51e-05	0.00852	-0.17	-0.19	Cognitive function;	chr22:42058946	chr22:42089630~42090028:-
HNSC	cis	rs2835345	0.563	rs12483690	ENSG00000230479.1	AP000695.6	4.07	5.51e-05	0.00853	0.2	0.19	Pulmonary function;	chr21:36451265	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.596	rs12482097	ENSG00000230479.1	AP000695.6	4.07	5.51e-05	0.00853	0.2	0.19	Pulmonary function;	chr21:36451592	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.596	rs12482138	ENSG00000230479.1	AP000695.6	4.07	5.51e-05	0.00853	0.2	0.19	Pulmonary function;	chr21:36451608	chr21:36430360~36481070:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.07	5.51e-05	0.00853	0.2	0.19	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.07	5.51e-05	0.00853	0.2	0.19	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
HNSC	cis	rs10888838	0.652	rs11577661	ENSG00000198711.5	SSBP3-AS1	4.07	5.52e-05	0.00853	0.25	0.19	Mitochondrial DNA levels;	chr1:54227863	chr1:54236440~54239063:+
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000250412.1	KLHL2P1	4.07	5.52e-05	0.00853	0.24	0.19	Corneal astigmatism;	chr4:119320491	chr4:119334329~119378233:+
HNSC	cis	rs9467773	0.55	rs4712987	ENSG00000241549.7	GUSBP2	4.07	5.52e-05	0.00853	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26399387	chr6:26871484~26956554:-
HNSC	cis	rs6787172	0.811	rs9810114	ENSG00000272087.1	RP11-379F4.7	4.07	5.52e-05	0.00854	0.19	0.19	Subjective well-being;	chr3:158494266	chr3:158693120~158693768:-
HNSC	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	4.07	5.52e-05	0.00854	0.19	0.19	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
HNSC	cis	rs4372836	0.964	rs55721532	ENSG00000226833.4	AC097724.3	-4.07	5.52e-05	0.00854	-0.24	-0.19	Body mass index;	chr2:28716102	chr2:28708953~28736205:-
HNSC	cis	rs71520386	0.583	rs28799344	ENSG00000228649.7	AC005682.5	-4.07	5.52e-05	0.00854	-0.2	-0.19	Fibrinogen levels;	chr7:22805647	chr7:22854178~22861579:+
HNSC	cis	rs71520386	0.583	rs35322907	ENSG00000228649.7	AC005682.5	-4.07	5.52e-05	0.00854	-0.2	-0.19	Fibrinogen levels;	chr7:22806592	chr7:22854178~22861579:+
HNSC	cis	rs2304003	0.95	rs1863199	ENSG00000235192.1	AC009495.2	4.07	5.52e-05	0.00854	0.25	0.19	Social communication problems;	chr2:165810140	chr2:165794851~165810010:+
HNSC	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-4.07	5.52e-05	0.00854	-0.2	-0.19	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
HNSC	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-4.07	5.52e-05	0.00854	-0.23	-0.19	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
HNSC	cis	rs4763879	0.739	rs2895988	ENSG00000278635.1	CTD-2318O12.1	4.07	5.52e-05	0.00854	0.14	0.19	Type 1 diabetes;	chr12:9675831	chr12:9415641~9416718:+
HNSC	cis	rs4321325	0.733	rs4284778	ENSG00000236682.1	AC068282.3	-4.07	5.52e-05	0.00854	-0.31	-0.19	Protein C levels;	chr2:127188750	chr2:127389130~127400580:+
HNSC	cis	rs4356203	0.905	rs11024148	ENSG00000260196.1	RP1-239B22.5	-4.07	5.53e-05	0.00854	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17380649~17383531:+
HNSC	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	4.07	5.53e-05	0.00854	0.18	0.19	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
HNSC	cis	rs2070074	0.591	rs3739882	ENSG00000261215.1	RP11-195F19.30	4.07	5.53e-05	0.00855	0.38	0.19	CTACK levels;	chr9:34653112	chr9:34661903~34666029:-
HNSC	cis	rs2253762	0.54	rs11200357	ENSG00000226864.1	ATE1-AS1	4.07	5.53e-05	0.00855	0.32	0.19	Breast cancer;	chr10:122034390	chr10:121928312~121951965:+
HNSC	cis	rs6928977	0.897	rs2614258	ENSG00000217482.2	HMGB1P17	-4.07	5.53e-05	0.00855	-0.21	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356064	chr6:135636086~135636713:-
HNSC	cis	rs9921338	0.961	rs66555362	ENSG00000263080.1	RP11-485G7.5	4.07	5.53e-05	0.00855	0.2	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11341809~11345211:-
HNSC	cis	rs71520386	0.796	rs71520381	ENSG00000221740.1	SNORD93	-4.07	5.53e-05	0.00855	-0.25	-0.19	Fibrinogen levels;	chr7:22776388	chr7:22856613~22856686:+
HNSC	cis	rs7688540	0.8	rs28429717	ENSG00000250892.1	RP11-1365D11.1	-4.07	5.53e-05	0.00855	-0.29	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:201409~205009:-
HNSC	cis	rs28489187	0.706	rs233119	ENSG00000223653.4	RP11-131L23.1	4.07	5.53e-05	0.00855	0.25	0.19	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322369	chr1:85276715~85448124:+
HNSC	cis	rs67981189	0.593	rs7143595	ENSG00000274818.1	RP1-292L20.3	4.07	5.53e-05	0.00855	0.2	0.19	Schizophrenia;	chr14:71055284	chr14:70906657~70907111:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000229886.1	RP5-1132H15.3	4.07	5.54e-05	0.00855	0.34	0.19	Diabetic kidney disease;	chr7:66138186	chr7:66025126~66031544:-
HNSC	cis	rs10504130	0.932	rs75990306	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51837641	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.935	rs76813841	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51848253	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs12675786	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51852132	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs11781330	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51853231	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75221577	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51856812	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs74681723	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51857932	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75371481	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51863252	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs77082359	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51866587	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs74769823	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51867608	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs79727212	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51868528	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs77534642	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51868956	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs16916906	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51869133	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.935	rs112132091	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51869344	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs77532876	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51873542	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs11777714	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51874273	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs10958300	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51875389	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs10958301	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51875676	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.932	rs77153951	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51878837	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.932	rs77140083	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51880352	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75061868	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51883380	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs2176120	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51885462	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs80340160	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51885628	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs9792352	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51886862	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs2037138	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51892153	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs2037139	ENSG00000272024.1	RP11-546K22.3	-4.07	5.54e-05	0.00855	-0.31	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51892324	chr8:51950284~51950690:+
HNSC	cis	rs7005380	0.965	rs9918814	ENSG00000279347.1	RP11-85I17.2	4.07	5.54e-05	0.00856	0.16	0.19	Interstitial lung disease;	chr8:119939362	chr8:119838736~119840385:-
HNSC	cis	rs459482	0.587	rs469083	ENSG00000228318.3	AP001610.5	4.07	5.54e-05	0.00856	0.2	0.19	IgG glycosylation;	chr21:41436789	chr21:41441056~41445708:-
HNSC	cis	rs2686555	0.553	rs1616213	ENSG00000200795.1	RNU4-1	4.07	5.54e-05	0.00856	0.25	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr12:120639705	chr12:120293097~120293237:-
HNSC	cis	rs9650657	0.812	rs10107289	ENSG00000269918.1	AF131215.9	-4.07	5.54e-05	0.00856	-0.19	-0.19	Neuroticism;	chr8:10776738	chr8:11104691~11106704:-
HNSC	cis	rs17739794	0.557	rs7823906	ENSG00000254207.1	RP11-43A14.1	4.07	5.54e-05	0.00856	0.22	0.19	Clozapine-induced cytotoxicity;	chr8:864710	chr8:725188~725877:-
HNSC	cis	rs7027203	0.595	rs7846827	ENSG00000227603.1	RP11-165J3.6	4.07	5.55e-05	0.00857	0.17	0.19	DNA methylation (variation);	chr9:93784243	chr9:93435332~93437121:-
HNSC	cis	rs6504108	1	rs6504108	ENSG00000264920.1	RP11-6N17.4	-4.07	5.55e-05	0.00857	-0.24	-0.19	Body mass index;	chr17:48215561	chr17:47891255~47895812:-
HNSC	cis	rs9313772	0.722	rs4273587	ENSG00000254350.1	RP11-542A14.1	-4.07	5.55e-05	0.00857	-0.2	-0.19	Blood pressure;	chr5:158426514	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs7710580	ENSG00000254350.1	RP11-542A14.1	-4.07	5.55e-05	0.00857	-0.2	-0.19	Blood pressure;	chr5:158428645	chr5:158424585~158452758:+
HNSC	cis	rs72634501	0.542	rs2134472	ENSG00000182109.6	RP11-69E11.4	-4.07	5.55e-05	0.00857	-0.19	-0.19	HDL cholesterol;	chr1:39137542	chr1:39522280~39546187:-
HNSC	cis	rs11168618	0.846	rs11168586	ENSG00000240399.1	RP1-228P16.1	4.07	5.55e-05	0.00858	0.16	0.19	Adiponectin levels;	chr12:48460229	chr12:48054813~48055591:-
HNSC	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	4.07	5.55e-05	0.00858	0.24	0.19	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000229886.1	RP5-1132H15.3	4.07	5.55e-05	0.00858	0.32	0.19	Diabetic kidney disease;	chr7:65970805	chr7:66025126~66031544:-
HNSC	cis	rs4356203	0.905	rs1989405	ENSG00000272034.1	SNORD14A	4.07	5.56e-05	0.00858	0.14	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17074654~17074744:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000254153.1	CTA-398F10.2	4.07	5.56e-05	0.00859	0.21	0.19	Mood instability;	chr8:8786428	chr8:8456909~8461337:-
HNSC	cis	rs853679	0.517	rs9380065	ENSG00000219891.2	ZSCAN12P1	4.07	5.56e-05	0.00859	0.26	0.19	Depression;	chr6:28176973	chr6:28091154~28093664:+
HNSC	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-4.07	5.56e-05	0.00859	-0.18	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
HNSC	cis	rs442309	0.783	rs224111	ENSG00000238280.1	RP11-436D10.3	4.07	5.56e-05	0.00859	0.23	0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62792250	chr10:62793562~62805887:-
HNSC	cis	rs10129255	0.957	rs28887506	ENSG00000211974.3	IGHV2-70	4.07	5.56e-05	0.00859	0.17	0.19	Kawasaki disease;	chr14:106785589	chr14:106723574~106724093:-
HNSC	cis	rs57502260	1	rs57502260	ENSG00000212093.1	AP000807.1	4.07	5.56e-05	0.00859	0.26	0.18	Total body bone mineral density (age 45-60);	chr11:68453437	chr11:68506083~68506166:-
HNSC	cis	rs16858210	0.657	rs73177515	ENSG00000234371.6	RPSAP31	4.07	5.57e-05	0.00859	0.25	0.18	Menopause (age at onset);	chr3:183849037	chr3:183884924~183888449:+
HNSC	cis	rs73198271	0.71	rs11779561	ENSG00000173295.6	FAM86B3P	-4.07	5.57e-05	0.00859	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8228595~8244865:+
HNSC	cis	rs4356203	0.905	rs214939	ENSG00000272034.1	SNORD14A	4.07	5.57e-05	0.00859	0.14	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs214936	ENSG00000272034.1	SNORD14A	4.07	5.57e-05	0.00859	0.14	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17074654~17074744:-
HNSC	cis	rs35306767	0.903	rs11816064	ENSG00000229869.1	RP11-363N22.2	-4.07	5.57e-05	0.0086	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:885236	chr10:933026~942743:+
HNSC	cis	rs7777677	0.925	rs4726540	ENSG00000276953.1	TRBV12-4	4.07	5.57e-05	0.0086	0.17	0.18	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142563740~142564245:+
HNSC	cis	rs913655	0.508	rs4576719	ENSG00000225527.1	RP11-383B4.4	-4.07	5.57e-05	0.0086	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719746	chr10:18531849~18533336:-
HNSC	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-4.07	5.57e-05	0.0086	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
HNSC	cis	rs4253772	0.638	rs6007845	ENSG00000277232.2	GTSE1-AS1	4.07	5.57e-05	0.0086	0.23	0.18	Cholesterol, total;LDL cholesterol;	chr22:46322520	chr22:46295143~46296660:-
HNSC	cis	rs453301	0.686	rs6987107	ENSG00000253981.4	ALG1L13P	-4.07	5.57e-05	0.00861	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9036071	chr8:8236003~8244667:-
HNSC	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-4.07	5.58e-05	0.00861	-0.19	-0.18	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
HNSC	cis	rs6651255	0.738	rs4509279	ENSG00000224110.3	MTRF1LP2	4.07	5.58e-05	0.00861	0.21	0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129745338	chr8:129728744~129730445:+
HNSC	cis	rs9611565	0.918	rs7290404	ENSG00000235513.1	RP4-756G23.5	4.07	5.58e-05	0.00861	0.21	0.18	Vitiligo;	chr22:41353792	chr22:41209122~41217627:-
HNSC	cis	rs28489187	0.597	rs506082	ENSG00000223653.4	RP11-131L23.1	-4.07	5.58e-05	0.00861	-0.25	-0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85433532	chr1:85276715~85448124:+
HNSC	cis	rs700651	0.757	rs6748683	ENSG00000231621.1	AC013264.2	-4.07	5.58e-05	0.00861	-0.18	-0.18	Intracranial aneurysm;	chr2:198013284	chr2:197197991~197199273:+
HNSC	cis	rs7267979	0.789	rs6083810	ENSG00000231081.1	RP4-760C5.3	4.07	5.58e-05	0.00861	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26008791~26010531:-
HNSC	cis	rs7267979	0.789	rs6083820	ENSG00000231081.1	RP4-760C5.3	4.07	5.58e-05	0.00861	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26008791~26010531:-
HNSC	cis	rs7267979	0.789	rs6083841	ENSG00000231081.1	RP4-760C5.3	4.07	5.58e-05	0.00861	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26008791~26010531:-
HNSC	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-4.07	5.58e-05	0.00861	-0.27	-0.18	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
HNSC	cis	rs116095464	1	rs28416084	ENSG00000250848.1	CTD-2083E4.5	-4.07	5.58e-05	0.00862	-0.26	-0.18	Breast cancer;	chr5:217525	chr5:288833~290321:-
HNSC	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-4.07	5.58e-05	0.00862	-0.17	-0.18	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
HNSC	cis	rs7824557	0.606	rs1435277	ENSG00000255020.1	AF131216.5	4.07	5.58e-05	0.00862	0.19	0.18	Retinal vascular caliber;	chr8:11339461	chr8:11345748~11347502:-
HNSC	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-4.07	5.58e-05	0.00862	-0.19	-0.18	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
HNSC	cis	rs11673344	0.504	rs8105065	ENSG00000276846.1	CTD-3220F14.3	4.07	5.59e-05	0.00862	0.2	0.18	Obesity-related traits;	chr19:37141003	chr19:37314868~37315620:-
HNSC	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-4.07	5.59e-05	0.00862	-0.16	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
HNSC	cis	rs7735319	0.966	rs3860752	ENSG00000249102.1	CTD-2066L21.1	4.07	5.59e-05	0.00863	0.21	0.18	Systolic blood pressure;	chr5:33114871	chr5:33008994~33025724:+
HNSC	cis	rs10504130	0.866	rs74738864	ENSG00000272024.1	RP11-546K22.3	-4.07	5.59e-05	0.00863	-0.31	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51878654	chr8:51950284~51950690:+
HNSC	cis	rs853679	1	rs1679732	ENSG00000204709.4	LINC01556	-4.07	5.59e-05	0.00863	-0.28	-0.18	Depression;	chr6:28253486	chr6:28943877~28944537:+
HNSC	cis	rs11168618	0.81	rs35338015	ENSG00000240399.1	RP1-228P16.1	4.07	5.59e-05	0.00863	0.16	0.18	Adiponectin levels;	chr12:48445618	chr12:48054813~48055591:-
HNSC	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	4.07	5.59e-05	0.00863	0.21	0.18	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
HNSC	cis	rs757081	0.648	rs11024231	ENSG00000260196.1	RP1-239B22.5	-4.07	5.59e-05	0.00863	-0.2	-0.18	Systolic blood pressure;	chr11:17265703	chr11:17380649~17383531:+
HNSC	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-4.07	5.59e-05	0.00863	-0.19	-0.18	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
HNSC	cis	rs3736485	0.578	rs4775968	ENSG00000259438.1	CTD-2650P22.1	-4.07	5.59e-05	0.00863	-0.19	-0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51688624	chr15:52010999~52019095:-
HNSC	cis	rs17292804	0.506	rs71417868	ENSG00000269958.1	RP11-73M18.8	4.07	5.6e-05	0.00863	0.17	0.18	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103696353~103697163:+
HNSC	cis	rs12468226	0.689	rs73989731	ENSG00000226261.1	AC064836.3	4.07	5.6e-05	0.00863	0.27	0.18	Urate levels;	chr2:202109309	chr2:202336024~202336727:-
HNSC	cis	rs897984	0.762	rs12931046	ENSG00000279196.1	RP11-1072A3.3	-4.07	5.6e-05	0.00864	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30975823	chr16:30984630~30988270:-
HNSC	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-4.07	5.6e-05	0.00864	-0.21	-0.18	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000254153.1	CTA-398F10.2	-4.07	5.6e-05	0.00864	-0.22	-0.18	Recombination measurement;	chr8:9208015	chr8:8456909~8461337:-
HNSC	cis	rs6601450	0.54	rs7824225	ENSG00000255310.2	AF131215.2	-4.07	5.6e-05	0.00864	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10415736	chr8:11107788~11109726:-
HNSC	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	4.07	5.6e-05	0.00864	0.18	0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
HNSC	cis	rs4713118	0.869	rs9283881	ENSG00000216901.1	AL022393.7	4.07	5.6e-05	0.00864	0.23	0.18	Parkinson's disease;	chr6:27747476	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9283882	ENSG00000216901.1	AL022393.7	4.07	5.6e-05	0.00864	0.23	0.18	Parkinson's disease;	chr6:27747479	chr6:28176188~28176674:+
HNSC	cis	rs1552244	0.872	rs115331527	ENSG00000180385.7	EMC3-AS1	4.07	5.6e-05	0.00864	0.21	0.18	Alzheimer's disease;	chr3:10112820	chr3:9986893~10006990:+
HNSC	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	4.07	5.6e-05	0.00864	0.3	0.18	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
HNSC	cis	rs6601327	0.606	rs7006985	ENSG00000254340.1	RP11-10A14.3	-4.07	5.6e-05	0.00864	-0.22	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9706927	chr8:9141424~9145435:+
HNSC	cis	rs36093924	0.646	rs7285557	ENSG00000227370.1	RP4-669P10.19	4.07	5.6e-05	0.00864	0.17	0.18	Intelligence;	chr22:41952786	chr22:42132543~42132998:+
HNSC	cis	rs12887734	0.546	rs12885509	ENSG00000269940.1	RP11-73M18.7	4.07	5.6e-05	0.00864	0.18	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103694560~103695170:+
HNSC	cis	rs8024893	0.764	rs7178760	ENSG00000215302.7	CTD-3092A11.1	4.07	5.6e-05	0.00864	0.3	0.18	Red cell distribution width;	chr15:31239170	chr15:30470779~30507623:+
HNSC	cis	rs7948661	1	rs7113959	ENSG00000278376.1	RP11-158I9.8	4.07	5.6e-05	0.00864	0.3	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118508381	chr11:118791254~118793137:+
HNSC	cis	rs8077577	0.895	rs16960983	ENSG00000273018.4	CTD-2303H24.2	-4.07	5.6e-05	0.00864	-0.28	-0.18	Obesity-related traits;	chr17:18201254	chr17:18511221~18551705:-
HNSC	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-4.07	5.6e-05	0.00864	-0.22	-0.18	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-4.07	5.6e-05	0.00864	-0.22	-0.18	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
HNSC	cis	rs6601327	0.606	rs4841203	ENSG00000233609.3	RP11-62H7.2	-4.07	5.6e-05	0.00864	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.539	rs883647	ENSG00000254340.1	RP11-10A14.3	-4.07	5.6e-05	0.00864	-0.24	-0.18	Mood instability;	chr8:8712214	chr8:9141424~9145435:+
HNSC	cis	rs4256159	1	rs75407508	ENSG00000228956.7	SATB1-AS1	4.07	5.61e-05	0.00865	0.33	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18784120	chr3:18445024~18920401:+
HNSC	cis	rs7751419	0.606	rs7773754	ENSG00000217165.1	ANKRD18EP	4.07	5.61e-05	0.00865	0.17	0.18	Cardiovascular disease in hypertension (calcium channel blocker interaction);	chr6:39152061	chr6:39110321~39112952:+
HNSC	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	4.07	5.61e-05	0.00865	0.21	0.18	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
HNSC	cis	rs4713118	0.513	rs156734	ENSG00000219891.2	ZSCAN12P1	4.07	5.61e-05	0.00865	0.24	0.18	Parkinson's disease;	chr6:28039579	chr6:28091154~28093664:+
HNSC	cis	rs7809950	0.678	rs2237661	ENSG00000238832.1	snoU109	-4.07	5.61e-05	0.00865	-0.27	-0.18	Coronary artery disease;	chr7:107222678	chr7:107603363~107603507:+
HNSC	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	4.07	5.61e-05	0.00865	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	4.07	5.61e-05	0.00865	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	4.07	5.61e-05	0.00865	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
HNSC	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	4.07	5.61e-05	0.00865	0.17	0.18	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
HNSC	cis	rs12188164	0.965	rs11742144	ENSG00000215246.5	RP11-43F13.3	-4.07	5.61e-05	0.00865	-0.21	-0.18	Cystic fibrosis severity;	chr5:422063	chr5:987180~997308:-
HNSC	cis	rs11168618	0.81	rs6580671	ENSG00000240399.1	RP1-228P16.1	4.07	5.61e-05	0.00865	0.16	0.18	Adiponectin levels;	chr12:48447274	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.846	rs11168577	ENSG00000240399.1	RP1-228P16.1	4.07	5.61e-05	0.00865	0.16	0.18	Adiponectin levels;	chr12:48448809	chr12:48054813~48055591:-
HNSC	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-4.07	5.61e-05	0.00865	-0.18	-0.18	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
HNSC	cis	rs7572733	0.534	rs1436131	ENSG00000231621.1	AC013264.2	-4.07	5.61e-05	0.00865	-0.18	-0.18	Dermatomyositis;	chr2:197866506	chr2:197197991~197199273:+
HNSC	cis	rs3738443	0.953	rs61839997	ENSG00000259865.1	RP11-488L18.10	4.07	5.61e-05	0.00866	0.18	0.18	Alcohol dependence;	chr1:247197867	chr1:247187281~247188526:-
HNSC	cis	rs13325613	0.834	rs13084175	ENSG00000223552.1	RP11-24F11.2	-4.07	5.61e-05	0.00866	-0.3	-0.18	Monocyte count;	chr3:46143147	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13083914	ENSG00000223552.1	RP11-24F11.2	-4.07	5.61e-05	0.00866	-0.3	-0.18	Monocyte count;	chr3:46143188	chr3:46364955~46407059:-
HNSC	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	4.07	5.62e-05	0.00866	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	4.07	5.62e-05	0.00866	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	4.07	5.62e-05	0.00866	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
HNSC	cis	rs1620921	0.563	rs2489936	ENSG00000231863.1	RP3-428L16.1	-4.07	5.62e-05	0.00867	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160859293	chr6:160931080~160969771:+
HNSC	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	4.07	5.62e-05	0.00867	0.16	0.18	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
HNSC	cis	rs913655	0.508	rs4748513	ENSG00000225527.1	RP11-383B4.4	-4.07	5.62e-05	0.00867	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18736370	chr10:18531849~18533336:-
HNSC	cis	rs17345786	1	rs11715368	ENSG00000244119.1	PDCL3P4	4.07	5.62e-05	0.00867	0.21	0.18	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101712472~101713191:+
HNSC	cis	rs2865126	0.743	rs1941551	ENSG00000264714.1	RP11-21G15.1	-4.07	5.62e-05	0.00867	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10744622	chr18:10724619~10728539:+
HNSC	cis	rs4919687	0.55	rs12780827	ENSG00000236937.2	PTGES3P4	4.07	5.62e-05	0.00867	0.24	0.18	Colorectal cancer;	chr10:102708197	chr10:102845595~102845950:+
HNSC	cis	rs7520050	0.931	rs35743647	ENSG00000280836.1	AL355480.1	4.07	5.62e-05	0.00867	0.19	0.18	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45581219~45581321:-
HNSC	cis	rs1862618	0.641	rs170733	ENSG00000271828.1	CTD-2310F14.1	-4.07	5.62e-05	0.00867	-0.22	-0.18	Initial pursuit acceleration;	chr5:56953424	chr5:56927874~56929573:+
HNSC	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	4.07	5.62e-05	0.00867	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
HNSC	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	4.07	5.62e-05	0.00867	0.21	0.18	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
HNSC	cis	rs7178909	0.872	rs57715404	ENSG00000259677.1	RP11-493E3.1	4.07	5.63e-05	0.00867	0.21	0.18	Common traits (Other);	chr15:89890726	chr15:89876540~89877285:+
HNSC	cis	rs9907295	0.901	rs78905197	ENSG00000270977.1	AC015849.16	-4.07	5.63e-05	0.00867	-0.31	-0.18	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35893707~35911023:-
HNSC	cis	rs9907295	0.901	rs3760326	ENSG00000270977.1	AC015849.16	-4.07	5.63e-05	0.00867	-0.31	-0.18	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35893707~35911023:-
HNSC	cis	rs12931792	0.712	rs4787495	ENSG00000273724.1	RP11-347C12.12	-4.07	5.63e-05	0.00867	-0.2	-0.18	Tonsillectomy;	chr16:30154404	chr16:30336400~30343336:+
HNSC	cis	rs2307394	0.964	rs1424946	ENSG00000281469.1	RP11-567F11.1	4.07	5.63e-05	0.00867	0.21	0.18	Urate levels;	chr2:147790296	chr2:148044380~148044894:+
HNSC	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-4.07	5.63e-05	0.00867	-0.2	-0.18	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
HNSC	cis	rs2439831	0.85	rs2957637	ENSG00000201136.1	RNU6-353P	-4.07	5.63e-05	0.00867	-0.29	-0.18	Lung cancer in ever smokers;	chr15:43658920	chr15:43702363~43702470:+
HNSC	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-4.07	5.63e-05	0.00867	-0.15	-0.18	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
HNSC	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-4.07	5.63e-05	0.00867	-0.14	-0.18	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
HNSC	cis	rs6840258	1	rs114701347	ENSG00000251411.1	RP11-397E7.4	-4.07	5.63e-05	0.00868	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043849	chr4:86913266~86914817:-
HNSC	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-4.07	5.63e-05	0.00868	-0.21	-0.18	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
HNSC	cis	rs5758659	0.622	rs5758527	ENSG00000182057.4	OGFRP1	4.07	5.63e-05	0.00868	0.18	0.18	Cognitive function;	chr22:41979757	chr22:42269753~42275196:+
HNSC	cis	rs4713118	0.739	rs2893931	ENSG00000224843.5	LINC00240	4.07	5.63e-05	0.00868	0.22	0.18	Parkinson's disease;	chr6:27780231	chr6:26956992~27023924:+
HNSC	cis	rs11668609	0.81	rs9305015	ENSG00000268442.1	CTD-2027I19.2	-4.07	5.63e-05	0.00868	-0.25	-0.18	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24162370~24163425:-
HNSC	cis	rs5758659	0.652	rs133303	ENSG00000227370.1	RP4-669P10.19	-4.07	5.63e-05	0.00868	-0.18	-0.18	Cognitive function;	chr22:41999238	chr22:42132543~42132998:+
HNSC	cis	rs9527	0.551	rs28606370	ENSG00000236937.2	PTGES3P4	4.07	5.63e-05	0.00868	0.23	0.18	Arsenic metabolism;	chr10:102911075	chr10:102845595~102845950:+
HNSC	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	4.07	5.63e-05	0.00868	0.26	0.18	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
HNSC	cis	rs11846409	0.932	rs73378155	ENSG00000280411.1	IGHV1-69-2	-4.07	5.63e-05	0.00868	-0.16	-0.18	Rheumatic heart disease;	chr14:106637840	chr14:106762092~106762588:-
HNSC	cis	rs3015497	0.594	rs35637875	ENSG00000277050.1	RP11-102G14.1	-4.07	5.64e-05	0.00868	-0.18	-0.18	Mean platelet volume;	chr14:50665815	chr14:51637348~51637947:-
HNSC	cis	rs2069426	0.778	rs662463	ENSG00000266446.1	RP11-149I2.4	-4.06	5.64e-05	0.00868	-0.3	-0.18	Acute lymphoblastic leukemia (childhood);	chr9:22030439	chr9:21995482~21996013:+
HNSC	cis	rs2518049	0.861	rs4881396	ENSG00000224034.1	RP11-445P17.8	4.06	5.64e-05	0.00869	0.25	0.18	Metabolic traits;	chr10:5077965	chr10:5266033~5271236:-
HNSC	cis	rs6568686	0.578	rs56103131	ENSG00000255389.1	C6orf3	4.06	5.64e-05	0.00869	0.25	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111614545	chr6:111599875~111602295:+
HNSC	cis	rs1602565	0.858	rs10835491	ENSG00000255450.1	CTD-2063L20.1	4.06	5.64e-05	0.0087	0.29	0.18	Schizophrenia;	chr11:29150332	chr11:29275655~29276565:+
HNSC	cis	rs1994321	0.657	rs12224959	ENSG00000254991.1	RP13-631K18.3	-4.06	5.65e-05	0.0087	-0.21	-0.18	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12063803	chr11:12066929~12073014:+
HNSC	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.65e-05	0.0087	-0.25	-0.18	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
HNSC	cis	rs13434995	0.513	rs9993599	ENSG00000273257.1	RP11-177J6.1	4.06	5.65e-05	0.0087	0.25	0.18	Adiponectin levels;	chr4:55586798	chr4:55387949~55388271:+
HNSC	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-4.06	5.65e-05	0.0087	-0.25	-0.18	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-4.06	5.65e-05	0.0087	-0.25	-0.18	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-4.06	5.65e-05	0.0087	-0.25	-0.18	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-4.06	5.65e-05	0.0087	-0.25	-0.18	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
HNSC	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	4.06	5.65e-05	0.0087	0.26	0.18	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
HNSC	cis	rs7520050	0.966	rs12139630	ENSG00000280836.1	AL355480.1	4.06	5.65e-05	0.0087	0.19	0.18	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs12144263	ENSG00000280836.1	AL355480.1	4.06	5.65e-05	0.0087	0.19	0.18	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45581219~45581321:-
HNSC	cis	rs453301	0.719	rs34004903	ENSG00000253981.4	ALG1L13P	-4.06	5.65e-05	0.0087	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9035094	chr8:8236003~8244667:-
HNSC	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-4.06	5.65e-05	0.0087	-0.22	-0.18	Height;	chr14:75198250	chr14:75011269~75012851:-
HNSC	cis	rs62025270	0.632	rs13379832	ENSG00000259762.1	RP11-158M2.4	-4.06	5.65e-05	0.0087	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85750336~85752901:-
HNSC	cis	rs964611	0.872	rs11855410	ENSG00000259488.2	RP11-154J22.1	-4.06	5.65e-05	0.0087	-0.18	-0.18	Metabolite levels (Pyroglutamine);	chr15:48301657	chr15:48312353~48331856:-
HNSC	cis	rs10242455	0.702	rs1045012	ENSG00000078319.8	PMS2P1	-4.06	5.65e-05	0.0087	-0.39	-0.18	Blood metabolite levels;	chr7:99386731	chr7:100320992~100341908:-
HNSC	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-4.06	5.65e-05	0.00871	-0.22	-0.18	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
HNSC	cis	rs4356203	0.783	rs7113964	ENSG00000260196.1	RP1-239B22.5	-4.06	5.65e-05	0.00871	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17380649~17383531:+
HNSC	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66679692	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66692349	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66693433	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66694214	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66701371	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66702658	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66706390	chr7:66025126~66031544:-
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	4.06	5.65e-05	0.00871	0.32	0.18	Gout;	chr7:66710076	chr7:66025126~66031544:-
HNSC	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.65e-05	0.00871	-0.32	-0.18	Gout;	chr7:66682070	chr7:66025126~66031544:-
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.65e-05	0.00871	-0.32	-0.18	Gout;	chr7:66682162	chr7:66025126~66031544:-
HNSC	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-4.06	5.66e-05	0.00871	-0.23	-0.18	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
HNSC	cis	rs1602565	1	rs1602565	ENSG00000255450.1	CTD-2063L20.1	4.06	5.66e-05	0.00871	0.29	0.18	Schizophrenia;	chr11:29140589	chr11:29275655~29276565:+
HNSC	cis	rs929354	0.772	rs1182442	ENSG00000224629.1	RP5-1142J19.2	4.06	5.66e-05	0.00871	0.19	0.18	Body mass index;	chr7:157233939	chr7:157263022~157263229:-
HNSC	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-4.06	5.66e-05	0.00871	-0.2	-0.18	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
HNSC	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	4.06	5.66e-05	0.00871	0.22	0.18	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
HNSC	cis	rs4699052	0.626	rs10017383	ENSG00000246560.2	RP11-10L12.4	4.06	5.66e-05	0.00872	0.21	0.18	Testicular germ cell tumor;	chr4:103328800	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.662	rs6848091	ENSG00000246560.2	RP11-10L12.4	4.06	5.66e-05	0.00872	0.21	0.18	Testicular germ cell tumor;	chr4:103328944	chr4:102828055~102844075:+
HNSC	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-4.06	5.66e-05	0.00872	-0.24	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-4.06	5.66e-05	0.00872	-0.24	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-4.06	5.66e-05	0.00872	-0.24	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-4.06	5.66e-05	0.00872	-0.24	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-4.06	5.66e-05	0.00872	-0.24	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
HNSC	cis	rs7552167	0.852	rs10794647	ENSG00000230023.2	RP11-10N16.2	4.06	5.67e-05	0.00872	0.3	0.18	Psoriasis vulgaris;	chr1:24182643	chr1:24200240~24211693:+
HNSC	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	4.06	5.67e-05	0.00872	0.25	0.18	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	4.06	5.67e-05	0.00872	0.25	0.18	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
HNSC	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	4.06	5.67e-05	0.00872	0.25	0.18	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
HNSC	cis	rs6840258	0.628	rs9715807	ENSG00000251411.1	RP11-397E7.4	4.06	5.67e-05	0.00873	0.21	0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86991479	chr4:86913266~86914817:-
HNSC	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	4.06	5.67e-05	0.00873	0.22	0.18	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
HNSC	cis	rs28830936	0.966	rs1107858	ENSG00000250379.1	RP11-23P13.4	4.06	5.67e-05	0.00873	0.23	0.18	Diastolic blood pressure;	chr15:41676028	chr15:41825099~41827936:-
HNSC	cis	rs847649	0.694	rs11770319	ENSG00000239969.4	RP11-163E9.2	4.06	5.67e-05	0.00873	0.22	0.18	Morning vs. evening chronotype;	chr7:103129723	chr7:102364162~102380633:+
HNSC	cis	rs72717009	0.825	rs9427398	ENSG00000225217.1	HSPA7	-4.06	5.67e-05	0.00873	-0.33	-0.18	Rheumatoid arthritis;	chr1:161506415	chr1:161606291~161608217:+
HNSC	cis	rs9393777	0.623	rs7773938	ENSG00000241549.7	GUSBP2	4.06	5.67e-05	0.00873	0.22	0.18	Intelligence (multi-trait analysis);	chr6:26473816	chr6:26871484~26956554:-
HNSC	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	4.06	5.67e-05	0.00873	0.23	0.18	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
HNSC	cis	rs761746	0.739	rs9621317	ENSG00000236132.1	CTA-440B3.1	-4.06	5.68e-05	0.00873	-0.23	-0.18	Intelligence;	chr22:31698060	chr22:31816379~31817491:-
HNSC	cis	rs7578199	1	rs7578199	ENSG00000223374.1	AC005104.3	4.06	5.68e-05	0.00874	0.16	0.18	Chronic lymphocytic leukemia;	chr2:241253433	chr2:241351340~241353104:-
HNSC	cis	rs7781557	0.591	rs56314487	ENSG00000239969.4	RP11-163E9.2	-4.06	5.68e-05	0.00874	-0.28	-0.18	Colorectal adenoma (advanced);	chr7:102895274	chr7:102364162~102380633:+
HNSC	cis	rs7781557	0.696	rs73192019	ENSG00000239969.4	RP11-163E9.2	-4.06	5.68e-05	0.00874	-0.28	-0.18	Colorectal adenoma (advanced);	chr7:102906634	chr7:102364162~102380633:+
HNSC	cis	rs7781557	0.64	rs7779854	ENSG00000239969.4	RP11-163E9.2	-4.06	5.68e-05	0.00874	-0.28	-0.18	Colorectal adenoma (advanced);	chr7:102911135	chr7:102364162~102380633:+
HNSC	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-4.06	5.68e-05	0.00874	-0.28	-0.18	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
HNSC	cis	rs870825	0.616	rs10006828	ENSG00000254233.1	RP11-242J7.1	4.06	5.68e-05	0.00874	0.27	0.18	Blood protein levels;	chr4:184730262	chr4:184584093~184625030:-
HNSC	cis	rs7429990	0.965	rs4858880	ENSG00000228638.1	FCF1P2	4.06	5.68e-05	0.00874	0.17	0.18	Educational attainment (years of education);	chr3:48062959	chr3:48290793~48291375:-
HNSC	cis	rs516805	0.748	rs197680	ENSG00000279453.1	RP3-425C14.4	-4.06	5.68e-05	0.00874	-0.27	-0.18	Lymphocyte counts;	chr6:122548987	chr6:122436789~122439223:-
HNSC	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-4.06	5.68e-05	0.00874	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
HNSC	cis	rs12745968	0.569	rs7521752	ENSG00000223787.2	RP4-593M8.1	-4.06	5.68e-05	0.00875	-0.23	-0.18	Bipolar disorder and schizophrenia;	chr1:92551584	chr1:92580476~92580821:-
HNSC	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-4.06	5.68e-05	0.00875	-0.25	-0.18	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
HNSC	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-4.06	5.69e-05	0.00875	-0.13	-0.18	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.511	rs2980426	ENSG00000233609.3	RP11-62H7.2	4.06	5.69e-05	0.00875	0.18	0.18	Mood instability;	chr8:8288087	chr8:8961200~8979025:+
HNSC	cis	rs36093924	0.646	rs5996094	ENSG00000182057.4	OGFRP1	-4.06	5.69e-05	0.00875	-0.18	-0.18	Intelligence;	chr22:41951056	chr22:42269753~42275196:+
HNSC	cis	rs7255436	1	rs7255436	ENSG00000269386.4	RAB11B-AS1	4.06	5.69e-05	0.00876	0.17	0.18	HDL cholesterol;	chr19:8368312	chr19:8374373~8390685:-
HNSC	cis	rs72843506	0.656	rs16959946	ENSG00000261033.1	RP11-209D14.2	4.06	5.69e-05	0.00876	0.31	0.18	Schizophrenia;	chr17:20269134	chr17:20008051~20009234:-
HNSC	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-4.06	5.7e-05	0.00876	-0.27	-0.18	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
HNSC	cis	rs6928977	0.675	rs9399148	ENSG00000231028.7	LINC00271	4.06	5.7e-05	0.00876	0.22	0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135497801~135716055:+
HNSC	cis	rs2239557	0.508	rs56120998	ENSG00000259065.1	RP5-1021I20.1	-4.06	5.7e-05	0.00876	-0.28	-0.18	Common traits (Other);	chr14:73844011	chr14:73787360~73803270:+
HNSC	cis	rs7572733	0.935	rs1607373	ENSG00000222017.1	AC011997.1	4.06	5.7e-05	0.00876	0.22	0.18	Dermatomyositis;	chr2:197935808	chr2:197693106~197774823:+
HNSC	cis	rs2865126	0.743	rs1941550	ENSG00000264714.1	RP11-21G15.1	-4.06	5.7e-05	0.00876	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10747592	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.743	rs10502403	ENSG00000264714.1	RP11-21G15.1	-4.06	5.7e-05	0.00876	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10749142	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.743	rs8084621	ENSG00000264714.1	RP11-21G15.1	-4.06	5.7e-05	0.00876	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10749431	chr18:10724619~10728539:+
HNSC	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-4.06	5.7e-05	0.00876	-0.22	-0.18	Height;	chr14:75173651	chr14:75011269~75012851:-
HNSC	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-4.06	5.7e-05	0.00877	-0.21	-0.18	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
HNSC	cis	rs13256369	0.802	rs12541520	ENSG00000173295.6	FAM86B3P	4.06	5.7e-05	0.00877	0.24	0.18	Obesity-related traits;	chr8:8706636	chr8:8228595~8244865:+
HNSC	cis	rs12745968	0.589	rs722356	ENSG00000223787.2	RP4-593M8.1	-4.06	5.7e-05	0.00877	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92516848	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.589	rs3903212	ENSG00000223787.2	RP4-593M8.1	-4.06	5.7e-05	0.00877	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92518498	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.623	rs4847432	ENSG00000223787.2	RP4-593M8.1	-4.06	5.7e-05	0.00877	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92653327	chr1:92580476~92580821:-
HNSC	cis	rs71636778	0.509	rs12739698	ENSG00000260063.1	RP5-968P14.2	-4.06	5.71e-05	0.00877	-0.41	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903542	chr1:26692132~26694131:-
HNSC	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.06	5.71e-05	0.00877	-0.21	-0.18	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
HNSC	cis	rs35306767	0.903	rs11253492	ENSG00000229869.1	RP11-363N22.2	-4.06	5.71e-05	0.00878	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:890933	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs11253493	ENSG00000229869.1	RP11-363N22.2	-4.06	5.71e-05	0.00878	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:890991	chr10:933026~942743:+
HNSC	cis	rs516805	0.667	rs2606609	ENSG00000279453.1	RP3-425C14.4	4.06	5.71e-05	0.00878	0.25	0.18	Lymphocyte counts;	chr6:122190346	chr6:122436789~122439223:-
HNSC	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-4.06	5.71e-05	0.00878	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-4.06	5.71e-05	0.00878	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-4.06	5.71e-05	0.00878	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
HNSC	cis	rs9867325	0.895	rs9879531	ENSG00000239213.4	NCK1-AS1	4.06	5.72e-05	0.00879	0.19	0.18	Body mass index;	chr3:136920133	chr3:136841726~136862054:-
HNSC	cis	rs870825	0.932	rs2696059	ENSG00000254233.1	RP11-242J7.1	-4.06	5.72e-05	0.00879	-0.3	-0.18	Blood protein levels;	chr4:184653973	chr4:184584093~184625030:-
HNSC	cis	rs2098713	0.561	rs11949124	ENSG00000250155.1	CTD-2353F22.1	4.06	5.72e-05	0.00879	0.18	0.18	Telomere length;	chr5:37590362	chr5:36666214~36725195:-
HNSC	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-4.06	5.72e-05	0.00879	-0.21	-0.18	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
HNSC	cis	rs1008375	0.9	rs13144986	ENSG00000249502.1	AC006160.5	4.06	5.72e-05	0.00879	0.21	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673396	chr4:17587467~17614571:-
HNSC	cis	rs6710503	0.692	rs2083389	ENSG00000271936.1	RP11-443B20.1	-4.06	5.72e-05	0.00879	-0.2	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24744855	chr2:24825610~24826717:+
HNSC	cis	rs9921338	0.961	rs4356497	ENSG00000263080.1	RP11-485G7.5	-4.06	5.72e-05	0.00879	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11341809~11345211:-
HNSC	cis	rs2286492	0.748	rs75064321	ENSG00000230658.1	KLHL7-AS1	4.06	5.72e-05	0.0088	0.4	0.18	Bipolar disorder;	chr7:22920672	chr7:23101228~23105703:-
HNSC	cis	rs17076726	0.519	rs10059384	ENSG00000253785.1	CTC-308K20.3	-4.06	5.72e-05	0.0088	-0.2	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173922113	chr5:172975511~172976374:+
HNSC	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	4.06	5.72e-05	0.0088	0.17	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
HNSC	cis	rs16846053	0.515	rs1510094	ENSG00000227403.1	AC009299.3	4.06	5.72e-05	0.0088	0.33	0.18	Blood osmolality (transformed sodium);	chr2:161632681	chr2:161244739~161249050:+
HNSC	cis	rs7688540	0.771	rs6599318	ENSG00000211553.1	AC253576.2	-4.06	5.73e-05	0.0088	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:136461~136568:+
HNSC	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-4.06	5.73e-05	0.0088	-0.23	-0.18	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
HNSC	cis	rs67981189	0.593	rs1558097	ENSG00000274818.1	RP1-292L20.3	4.06	5.73e-05	0.0088	0.2	0.18	Schizophrenia;	chr14:71090550	chr14:70906657~70907111:-
HNSC	cis	rs897984	0.684	rs6950	ENSG00000279196.1	RP11-1072A3.3	-4.06	5.73e-05	0.0088	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30984348	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.645	rs9938550	ENSG00000279196.1	RP11-1072A3.3	-4.06	5.73e-05	0.0088	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30987821	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.762	rs2305880	ENSG00000279196.1	RP11-1072A3.3	-4.06	5.73e-05	0.0088	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30988141	chr16:30984630~30988270:-
HNSC	cis	rs1113500	0.73	rs1781080	ENSG00000226822.1	RP11-356N1.2	-4.06	5.73e-05	0.00881	-0.21	-0.18	Growth-regulated protein alpha levels;	chr1:108050793	chr1:108071482~108074519:+
HNSC	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-4.06	5.73e-05	0.00881	-0.22	-0.18	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
HNSC	cis	rs2933343	0.7	rs1680779	ENSG00000231305.3	RP11-723O4.2	4.06	5.73e-05	0.00881	0.19	0.18	IgG glycosylation;	chr3:128895927	chr3:128861313~128871540:-
HNSC	cis	rs72717009	0.825	rs867624	ENSG00000225217.1	HSPA7	-4.06	5.73e-05	0.00881	-0.31	-0.18	Rheumatoid arthritis;	chr1:161498047	chr1:161606291~161608217:+
HNSC	cis	rs7819412	0.645	rs4841508	ENSG00000255310.2	AF131215.2	-4.06	5.73e-05	0.00881	-0.19	-0.18	Triglycerides;	chr8:11207494	chr8:11107788~11109726:-
HNSC	cis	rs4388249	1	rs13172735	ENSG00000271849.1	CTC-332L22.1	4.06	5.73e-05	0.00881	0.29	0.18	Schizophrenia;	chr5:109724132	chr5:109687802~109688329:-
HNSC	cis	rs2921073	0.605	rs2976933	ENSG00000254340.1	RP11-10A14.3	4.06	5.73e-05	0.00881	0.23	0.18	Parkinson's disease;	chr8:8397365	chr8:9141424~9145435:+
HNSC	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	4.06	5.73e-05	0.00881	0.2	0.18	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
HNSC	cis	rs13179617	0.928	rs13156100	ENSG00000215032.2	GNL3LP1	-4.06	5.74e-05	0.00881	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61505130	chr5:60891935~60893577:-
HNSC	cis	rs6890684	0.544	rs194369	ENSG00000215032.2	GNL3LP1	4.06	5.74e-05	0.00881	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61203358	chr5:60891935~60893577:-
HNSC	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-4.06	5.74e-05	0.00882	-0.16	-0.18	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.955	rs11944880	ENSG00000250412.1	KLHL2P1	-4.06	5.74e-05	0.00882	-0.23	-0.18	Corneal astigmatism;	chr4:119238179	chr4:119334329~119378233:+
HNSC	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	4.06	5.74e-05	0.00882	0.24	0.18	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
HNSC	cis	rs8028182	0.636	rs4886715	ENSG00000260269.4	CTD-2323K18.1	-4.06	5.74e-05	0.00882	-0.24	-0.18	Sudden cardiac arrest;	chr15:75539108	chr15:75527150~75601205:-
HNSC	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	4.06	5.74e-05	0.00882	0.28	0.18	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
HNSC	cis	rs859767	0.501	rs10928507	ENSG00000224043.6	CCNT2-AS1	-4.06	5.74e-05	0.00882	-0.22	-0.18	Neuroticism;	chr2:134639061	chr2:134735464~134918710:-
HNSC	cis	rs1538970	0.847	rs1771550	ENSG00000234329.1	RP11-767N6.2	-4.06	5.74e-05	0.00882	-0.21	-0.18	Platelet count;	chr1:45417893	chr1:45651039~45651826:-
HNSC	cis	rs761746	0.739	rs140078	ENSG00000236132.1	CTA-440B3.1	4.06	5.74e-05	0.00882	0.23	0.18	Intelligence;	chr22:31714177	chr22:31816379~31817491:-
HNSC	cis	rs7580658	1	rs7580658	ENSG00000236682.1	AC068282.3	-4.06	5.74e-05	0.00882	-0.22	-0.18	Protein C levels;	chr2:127401685	chr2:127389130~127400580:+
HNSC	cis	rs6095360	0.932	rs7264180	ENSG00000222365.1	SNORD12B	-4.06	5.75e-05	0.00883	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:48963243	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.934	rs2295031	ENSG00000222365.1	SNORD12B	-4.06	5.75e-05	0.00883	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:48963810	chr20:49280319~49280409:+
HNSC	cis	rs853679	0.599	rs149990	ENSG00000219891.2	ZSCAN12P1	4.06	5.75e-05	0.00883	0.33	0.18	Depression;	chr6:28030480	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.599	rs149943	ENSG00000219891.2	ZSCAN12P1	4.06	5.75e-05	0.00883	0.33	0.18	Depression;	chr6:28034610	chr6:28091154~28093664:+
HNSC	cis	rs6490294	0.528	rs11066126	ENSG00000226469.1	ADAM1B	4.06	5.75e-05	0.00883	0.26	0.18	Mean platelet volume;	chr12:112007087	chr12:111927018~111929017:+
HNSC	cis	rs10504130	0.502	rs71513552	ENSG00000253844.1	RP11-546K22.1	-4.06	5.75e-05	0.00884	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs34073804	ENSG00000253844.1	RP11-546K22.1	-4.06	5.75e-05	0.00884	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs34319820	ENSG00000253844.1	RP11-546K22.1	-4.06	5.75e-05	0.00884	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51961458~52022974:+
HNSC	cis	rs17345786	0.602	rs11923273	ENSG00000244119.1	PDCL3P4	4.06	5.75e-05	0.00884	0.19	0.18	Colonoscopy-negative controls vs population controls;	chr3:101619019	chr3:101712472~101713191:+
HNSC	cis	rs13434995	0.755	rs1488941	ENSG00000273257.1	RP11-177J6.1	-4.06	5.76e-05	0.00884	-0.29	-0.18	Adiponectin levels;	chr4:55517799	chr4:55387949~55388271:+
HNSC	cis	rs11168618	0.875	rs7972785	ENSG00000240399.1	RP1-228P16.1	4.06	5.76e-05	0.00884	0.16	0.18	Adiponectin levels;	chr12:48483273	chr12:48054813~48055591:-
HNSC	cis	rs9313772	0.722	rs11954492	ENSG00000254350.1	RP11-542A14.1	-4.06	5.76e-05	0.00885	-0.2	-0.18	Blood pressure;	chr5:158449386	chr5:158424585~158452758:+
HNSC	cis	rs442309	0.807	rs224073	ENSG00000238280.1	RP11-436D10.3	-4.06	5.76e-05	0.00885	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62750344	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.841	rs224074	ENSG00000238280.1	RP11-436D10.3	-4.06	5.76e-05	0.00885	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62750627	chr10:62793562~62805887:-
HNSC	cis	rs9867325	1	rs9867325	ENSG00000239213.4	NCK1-AS1	4.06	5.76e-05	0.00885	0.19	0.18	Body mass index;	chr3:136900067	chr3:136841726~136862054:-
HNSC	cis	rs9867325	1	rs9840500	ENSG00000239213.4	NCK1-AS1	4.06	5.76e-05	0.00885	0.19	0.18	Body mass index;	chr3:136902496	chr3:136841726~136862054:-
HNSC	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	4.06	5.77e-05	0.00885	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
HNSC	cis	rs13256369	1	rs12547721	ENSG00000173295.6	FAM86B3P	4.06	5.77e-05	0.00885	0.24	0.18	Obesity-related traits;	chr8:8713161	chr8:8228595~8244865:+
HNSC	cis	rs6674176	0.628	rs3828146	ENSG00000237950.1	RP11-7O11.3	4.06	5.77e-05	0.00885	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43963043	chr1:43944370~43946551:-
HNSC	cis	rs6674176	0.628	rs3791119	ENSG00000237950.1	RP11-7O11.3	4.06	5.77e-05	0.00885	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43965690	chr1:43944370~43946551:-
HNSC	cis	rs6674176	0.593	rs3791120	ENSG00000237950.1	RP11-7O11.3	4.06	5.77e-05	0.00885	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966043	chr1:43944370~43946551:-
HNSC	cis	rs6674176	0.628	rs4660759	ENSG00000237950.1	RP11-7O11.3	4.06	5.77e-05	0.00885	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966828	chr1:43944370~43946551:-
HNSC	cis	rs1602565	0.858	rs2958627	ENSG00000255450.1	CTD-2063L20.1	-4.06	5.77e-05	0.00885	-0.28	-0.18	Schizophrenia;	chr11:29144488	chr11:29275655~29276565:+
HNSC	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	4.06	5.77e-05	0.00886	0.22	0.18	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
HNSC	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	4.06	5.77e-05	0.00886	0.22	0.18	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
HNSC	cis	rs1552244	1	rs2272125	ENSG00000180385.7	EMC3-AS1	4.06	5.77e-05	0.00886	0.2	0.18	Alzheimer's disease;	chr3:10096385	chr3:9986893~10006990:+
HNSC	cis	rs11722779	0.844	rs7694724	ENSG00000230069.3	LRRC37A15P	-4.06	5.78e-05	0.00887	-0.18	-0.18	Schizophrenia;	chr4:103041375	chr4:102727274~102730721:-
HNSC	cis	rs2898681	0.519	rs73814886	ENSG00000248375.1	RP11-177B4.1	-4.06	5.78e-05	0.00887	-0.3	-0.18	Optic nerve measurement (cup area);	chr4:52867084	chr4:52720081~52720831:-
HNSC	cis	rs1008375	1	rs10032326	ENSG00000249502.1	AC006160.5	-4.06	5.78e-05	0.00887	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629094	chr4:17587467~17614571:-
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000280054.1	RP1-197B17.7	4.06	5.78e-05	0.00888	0.45	0.18	Pneumonia;	chr12:47713564	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000280054.1	RP1-197B17.7	4.06	5.78e-05	0.00888	0.45	0.18	Pneumonia;	chr12:47714734	chr12:47728151~47730598:-
HNSC	cis	rs12893668	0.572	rs34000399	ENSG00000269910.1	RP11-73M18.10	4.06	5.78e-05	0.00888	0.18	0.18	Reticulocyte count;	chr14:103635080	chr14:103694516~103695050:-
HNSC	cis	rs7475343	0.505	rs10752005	ENSG00000224034.1	RP11-445P17.8	4.06	5.78e-05	0.00888	0.25	0.18	Intelligence;	chr10:5118307	chr10:5266033~5271236:-
HNSC	cis	rs57502260	0.764	rs7105218	ENSG00000212093.1	AP000807.1	4.06	5.78e-05	0.00888	0.26	0.18	Total body bone mineral density (age 45-60);	chr11:68454993	chr11:68506083~68506166:-
HNSC	cis	rs950169	0.519	rs7237	ENSG00000229212.6	RP11-561C5.4	-4.06	5.78e-05	0.00888	-0.26	-0.18	Schizophrenia;	chr15:84643346	chr15:85205440~85234795:-
HNSC	cis	rs9527	0.571	rs4917985	ENSG00000236937.2	PTGES3P4	4.06	5.79e-05	0.00888	0.23	0.18	Arsenic metabolism;	chr10:102864315	chr10:102845595~102845950:+
HNSC	cis	rs2055375	0.818	rs190947	ENSG00000215032.2	GNL3LP1	4.06	5.79e-05	0.00888	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61209988	chr5:60891935~60893577:-
HNSC	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	4.06	5.79e-05	0.00888	0.22	0.18	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
HNSC	cis	rs9584850	0.874	rs3742137	ENSG00000231194.1	FARP1-AS1	4.06	5.79e-05	0.00888	0.23	0.18	Neuroticism;	chr13:98450195	chr13:98435405~98435840:-
HNSC	cis	rs74781061	0.932	rs7161903	ENSG00000260103.2	RP11-10O17.1	-4.06	5.79e-05	0.00888	-0.21	-0.18	Endometriosis;	chr15:74647929	chr15:74478070~74490286:-
HNSC	cis	rs116095464	0.558	rs7714335	ENSG00000277812.1	AC021087.1	4.06	5.79e-05	0.00888	0.32	0.18	Breast cancer;	chr5:263398	chr5:262769~262881:+
HNSC	cis	rs6500395	0.584	rs4028684	ENSG00000261267.1	RP11-44I10.3	-4.06	5.79e-05	0.00888	-0.24	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48707311	chr16:48559661~48587403:+
HNSC	cis	rs870825	0.616	rs6818447	ENSG00000254233.1	RP11-242J7.1	4.06	5.79e-05	0.00888	0.27	0.18	Blood protein levels;	chr4:184729000	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs61539306	ENSG00000254233.1	RP11-242J7.1	4.06	5.79e-05	0.00888	0.27	0.18	Blood protein levels;	chr4:184729122	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28579226	ENSG00000254233.1	RP11-242J7.1	4.06	5.79e-05	0.00888	0.27	0.18	Blood protein levels;	chr4:184729304	chr4:184584093~184625030:-
HNSC	cis	rs7568498	0.517	rs11678856	ENSG00000235724.7	AC009299.2	4.06	5.79e-05	0.00889	0.25	0.18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161222785~161308303:-
HNSC	cis	rs6601327	0.575	rs6994574	ENSG00000233609.3	RP11-62H7.2	-4.06	5.79e-05	0.00889	-0.18	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9720745	chr8:8961200~8979025:+
HNSC	cis	rs6071166	0.901	rs6027421	ENSG00000224635.1	RP4-564F22.5	-4.06	5.79e-05	0.00889	-0.22	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703616	chr20:38406011~38416797:-
HNSC	cis	rs7735319	0.966	rs35408434	ENSG00000250697.1	CTD-2066L21.3	4.06	5.8e-05	0.00889	0.22	0.18	Systolic blood pressure;	chr5:33163321	chr5:32925639~33297910:-
HNSC	cis	rs12545109	0.8	rs1913278	ENSG00000246430.5	LINC00968	-4.06	5.8e-05	0.00889	-0.23	-0.18	Obesity-related traits;	chr8:56491166	chr8:56496246~56559823:-
HNSC	cis	rs12935418	0.672	rs12446810	ENSG00000278985.1	RP11-303E16.9	4.06	5.8e-05	0.00889	0.19	0.18	Mean corpuscular volume;	chr16:81009369	chr16:80982319~80984094:-
HNSC	cis	rs9487051	0.582	rs9386779	ENSG00000243587.6	C6orf183	-4.06	5.8e-05	0.0089	-0.2	-0.18	Reticulocyte fraction of red cells;	chr6:109262453	chr6:109165833~109271014:+
HNSC	cis	rs9584850	0.834	rs745639	ENSG00000231194.1	FARP1-AS1	4.06	5.8e-05	0.0089	0.23	0.18	Neuroticism;	chr13:98467025	chr13:98435405~98435840:-
HNSC	cis	rs11633886	0.585	rs2460628	ENSG00000273972.1	CTD-2306A12.1	4.06	5.8e-05	0.0089	0.22	0.18	Diisocyanate-induced asthma;	chr15:45795754	chr15:45702640~45703183:+
HNSC	cis	rs10483853	0.579	rs66992833	ENSG00000258695.2	RP3-414A15.2	-4.06	5.8e-05	0.0089	-0.26	-0.18	Coronary artery calcification;	chr14:73471638	chr14:73522878~73530610:+
HNSC	cis	rs73607972	0.877	rs8055188	ENSG00000275191.1	RP11-36I17.2	4.06	5.8e-05	0.0089	0.28	0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53655975	chr16:53628256~53628816:-
HNSC	cis	rs7572733	0.773	rs13413470	ENSG00000222017.1	AC011997.1	4.06	5.8e-05	0.0089	0.23	0.18	Dermatomyositis;	chr2:197648125	chr2:197693106~197774823:+
HNSC	cis	rs7824557	0.806	rs6601573	ENSG00000269918.1	AF131215.9	-4.06	5.8e-05	0.0089	-0.18	-0.18	Retinal vascular caliber;	chr8:11237242	chr8:11104691~11106704:-
HNSC	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-4.06	5.8e-05	0.0089	-0.26	-0.18	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
HNSC	cis	rs2921036	0.529	rs2979192	ENSG00000254340.1	RP11-10A14.3	4.06	5.8e-05	0.0089	0.22	0.18	Neuroticism;	chr8:8480637	chr8:9141424~9145435:+
HNSC	cis	rs656319	0.58	rs13279701	ENSG00000255310.2	AF131215.2	-4.06	5.8e-05	0.0089	-0.18	-0.18	Myopia (pathological);	chr8:10111940	chr8:11107788~11109726:-
HNSC	cis	rs11951515	0.966	rs11741797	ENSG00000249286.1	CTD-2210P15.2	4.06	5.81e-05	0.00891	0.2	0.18	Metabolite levels  (X-11787);	chr5:43379690	chr5:43586918~43588223:-
HNSC	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-4.06	5.81e-05	0.00891	-0.23	-0.18	Height;	chr20:49279608	chr20:49280319~49280409:+
HNSC	cis	rs7015630	0.738	rs34642426	ENSG00000251136.7	RP11-37B2.1	-4.06	5.81e-05	0.00891	-0.2	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89842618	chr8:89609409~89757727:-
HNSC	cis	rs9379850	1	rs9379850	ENSG00000241549.7	GUSBP2	4.06	5.81e-05	0.00891	0.25	0.18	Intelligence (multi-trait analysis);	chr6:26342829	chr6:26871484~26956554:-
HNSC	cis	rs9298506	1	rs10103996	ENSG00000254142.2	RP11-53M11.3	4.06	5.81e-05	0.00891	0.28	0.18	Intracranial aneurysm;	chr8:54509864	chr8:54554361~54561927:+
HNSC	cis	rs35306767	0.903	rs12240651	ENSG00000229869.1	RP11-363N22.2	-4.06	5.82e-05	0.00892	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:897716	chr10:933026~942743:+
HNSC	cis	rs2548724	0.755	rs56218837	ENSG00000250682.4	LINC00491	4.06	5.82e-05	0.00892	0.25	0.18	Type 2 diabetes;	chr5:102464083	chr5:102609156~102671559:-
HNSC	cis	rs72772090	0.71	rs17400685	ENSG00000248734.2	CTD-2260A17.1	4.06	5.82e-05	0.00893	0.29	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730662	chr5:96784777~96785999:+
HNSC	cis	rs2115630	0.967	rs8028490	ENSG00000259295.5	CSPG4P12	-4.06	5.82e-05	0.00893	-0.21	-0.18	P wave terminal force;	chr15:84734657	chr15:85191438~85213905:+
HNSC	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-4.06	5.82e-05	0.00893	-0.22	-0.18	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
HNSC	cis	rs1991651	0.507	rs17778581	ENSG00000269918.1	AF131215.9	-4.06	5.82e-05	0.00893	-0.18	-0.18	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:11104691~11106704:-
HNSC	cis	rs453301	0.686	rs6748	ENSG00000253981.4	ALG1L13P	-4.06	5.82e-05	0.00893	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9033292	chr8:8236003~8244667:-
HNSC	cis	rs1045529	0.524	rs34251783	ENSG00000253981.4	ALG1L13P	-4.06	5.82e-05	0.00893	-0.2	-0.18	Myopia (pathological);Myopia;	chr8:9033866	chr8:8236003~8244667:-
HNSC	cis	rs240993	0.516	rs414763	ENSG00000230177.1	RP5-1112D6.4	-4.06	5.82e-05	0.00893	-0.26	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111277932~111278742:+
HNSC	cis	rs227275	0.525	rs7660298	ENSG00000230069.3	LRRC37A15P	-4.06	5.82e-05	0.00893	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102727274~102730721:-
HNSC	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	4.06	5.83e-05	0.00893	0.28	0.18	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
HNSC	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	4.06	5.83e-05	0.00893	0.18	0.18	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
HNSC	cis	rs988913	0.914	rs9396006	ENSG00000224984.1	RP11-524H19.2	4.06	5.83e-05	0.00893	0.21	0.18	Menarche (age at onset);	chr6:54923090	chr6:54840118~54840855:-
HNSC	cis	rs1799949	1	rs9646412	ENSG00000236383.6	LINC00854	-4.06	5.83e-05	0.00894	-0.18	-0.18	Menopause (age at onset);	chr17:43348525	chr17:43216941~43305976:-
HNSC	cis	rs73201462	1	rs58986862	ENSG00000231305.3	RP11-723O4.2	-4.06	5.83e-05	0.00894	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128342846	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs56850662	ENSG00000231305.3	RP11-723O4.2	-4.06	5.83e-05	0.00894	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343079	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs60399786	ENSG00000231305.3	RP11-723O4.2	-4.06	5.83e-05	0.00894	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343227	chr3:128861313~128871540:-
HNSC	cis	rs9896933	0.832	rs77512810	ENSG00000262663.1	RP11-497H17.1	4.06	5.83e-05	0.00894	0.24	0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846713	chr17:82918282~82918785:+
HNSC	cis	rs11089937	0.616	rs12484482	ENSG00000211639.2	IGLV4-60	4.06	5.83e-05	0.00895	0.18	0.18	Periodontitis (PAL4Q3);	chr22:22180158	chr22:22162199~22162681:+
HNSC	cis	rs2098713	0.537	rs562154	ENSG00000250155.1	CTD-2353F22.1	4.06	5.83e-05	0.00895	0.2	0.18	Telomere length;	chr5:37540947	chr5:36666214~36725195:-
HNSC	cis	rs240993	0.761	rs6920014	ENSG00000230177.1	RP5-1112D6.4	-4.06	5.84e-05	0.00895	-0.23	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111277932~111278742:+
HNSC	cis	rs970821	0.667	rs11774647	ENSG00000253106.1	RP11-158K1.3	4.06	5.84e-05	0.00895	0.17	0.18	Breast cancer;	chr8:123731655	chr8:124488510~124491643:+
HNSC	cis	rs970821	0.667	rs2891798	ENSG00000253106.1	RP11-158K1.3	4.06	5.84e-05	0.00895	0.17	0.18	Breast cancer;	chr8:123731856	chr8:124488510~124491643:+
HNSC	cis	rs36052053	0.521	rs71558356	ENSG00000219700.1	PTCHD3P3	4.06	5.84e-05	0.00895	0.33	0.18	Red cell distribution width;	chr6:109224908	chr6:109288571~109290503:-
HNSC	cis	rs1008375	0.932	rs2302394	ENSG00000249502.1	AC006160.5	-4.06	5.84e-05	0.00895	-0.21	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17639565	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.966	rs6832962	ENSG00000249502.1	AC006160.5	-4.06	5.84e-05	0.00895	-0.21	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650510	chr4:17587467~17614571:-
HNSC	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	4.06	5.84e-05	0.00895	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
HNSC	cis	rs6568686	0.53	rs76540042	ENSG00000255389.1	C6orf3	4.06	5.84e-05	0.00896	0.25	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111616177	chr6:111599875~111602295:+
HNSC	cis	rs10510102	0.516	rs79528809	ENSG00000226864.1	ATE1-AS1	4.06	5.84e-05	0.00896	0.33	0.18	Breast cancer;	chr10:121980309	chr10:121928312~121951965:+
HNSC	cis	rs7005380	0.733	rs2037346	ENSG00000279347.1	RP11-85I17.2	-4.06	5.84e-05	0.00896	-0.15	-0.18	Interstitial lung disease;	chr8:119923212	chr8:119838736~119840385:-
HNSC	cis	rs539096	0.54	rs3011219	ENSG00000237950.1	RP11-7O11.3	4.06	5.84e-05	0.00896	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43840448	chr1:43944370~43946551:-
HNSC	cis	rs16858210	0.874	rs11918588	ENSG00000234371.6	RPSAP31	4.06	5.84e-05	0.00896	0.21	0.18	Menopause (age at onset);	chr3:183883927	chr3:183884924~183888449:+
HNSC	cis	rs700651	0.821	rs771005	ENSG00000231621.1	AC013264.2	-4.06	5.85e-05	0.00896	-0.18	-0.18	Intracranial aneurysm;	chr2:197811224	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs700667	ENSG00000231621.1	AC013264.2	-4.06	5.85e-05	0.00896	-0.18	-0.18	Dermatomyositis;	chr2:197812784	chr2:197197991~197199273:+
HNSC	cis	rs7429990	0.727	rs319695	ENSG00000228638.1	FCF1P2	4.06	5.85e-05	0.00896	0.17	0.18	Educational attainment (years of education);	chr3:47842749	chr3:48290793~48291375:-
HNSC	cis	rs12545912	0.609	rs12549128	ENSG00000254340.1	RP11-10A14.3	4.06	5.85e-05	0.00896	0.28	0.18	Multiple myeloma (hyperdiploidy);	chr8:9942259	chr8:9141424~9145435:+
HNSC	cis	rs7520050	0.966	rs6661910	ENSG00000280836.1	AL355480.1	4.06	5.85e-05	0.00896	0.19	0.18	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45581219~45581321:-
HNSC	cis	rs7824557	0.591	rs2572452	ENSG00000255495.1	AC145124.2	-4.06	5.85e-05	0.00896	-0.2	-0.18	Retinal vascular caliber;	chr8:11370745	chr8:12194467~12196280:+
HNSC	cis	rs9313772	0.926	rs10051330	ENSG00000254350.1	RP11-542A14.1	-4.06	5.85e-05	0.00897	-0.21	-0.18	Blood pressure;	chr5:158392616	chr5:158424585~158452758:+
HNSC	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-4.06	5.85e-05	0.00897	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-4.06	5.85e-05	0.00897	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-4.06	5.85e-05	0.00897	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
HNSC	cis	rs6928977	0.897	rs2614258	ENSG00000231028.7	LINC00271	4.06	5.85e-05	0.00897	0.23	0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356064	chr6:135497801~135716055:+
HNSC	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	4.06	5.85e-05	0.00897	0.24	0.18	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
HNSC	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	4.06	5.85e-05	0.00897	0.21	0.18	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
HNSC	cis	rs9313772	0.775	rs4490571	ENSG00000254350.1	RP11-542A14.1	-4.06	5.86e-05	0.00897	-0.2	-0.18	Blood pressure;	chr5:158403039	chr5:158424585~158452758:+
HNSC	cis	rs7824557	0.564	rs2572399	ENSG00000269918.1	AF131215.9	-4.06	5.86e-05	0.00898	-0.18	-0.18	Retinal vascular caliber;	chr8:11377011	chr8:11104691~11106704:-
HNSC	cis	rs12893668	0.608	rs12889721	ENSG00000269958.1	RP11-73M18.8	4.06	5.86e-05	0.00898	0.17	0.18	Reticulocyte count;	chr14:103568526	chr14:103696353~103697163:+
HNSC	cis	rs10492096	1	rs11064210	ENSG00000215039.5	CD27-AS1	4.06	5.86e-05	0.00898	0.18	0.18	Hip geometry;	chr12:6467555	chr12:6439001~6451567:-
HNSC	cis	rs9584850	1	rs9584850	ENSG00000231194.1	FARP1-AS1	4.06	5.86e-05	0.00898	0.23	0.18	Neuroticism;	chr13:98449172	chr13:98435405~98435840:-
HNSC	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-4.06	5.86e-05	0.00898	-0.21	-0.18	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
HNSC	cis	rs10844682	0.603	rs10844673	ENSG00000256975.1	RP11-525E9.1	4.06	5.86e-05	0.00898	0.25	0.18	Monocyte percentage of white cells;	chr12:9744969	chr12:9506347~9508440:-
HNSC	cis	rs889398	0.967	rs35967356	ENSG00000196696.11	PDXDC2P	4.06	5.86e-05	0.00898	0.13	0.18	Body mass index;	chr16:69547451	chr16:69976297~70065948:-
HNSC	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	4.06	5.86e-05	0.00899	0.25	0.18	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
HNSC	cis	rs4356203	0.87	rs11024208	ENSG00000260196.1	RP1-239B22.5	-4.06	5.86e-05	0.00899	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs214916	ENSG00000260196.1	RP1-239B22.5	-4.06	5.87e-05	0.00899	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs2171615	ENSG00000260196.1	RP1-239B22.5	-4.06	5.87e-05	0.00899	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17380649~17383531:+
HNSC	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-4.06	5.87e-05	0.00899	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
HNSC	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	4.06	5.87e-05	0.00899	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
HNSC	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	4.06	5.87e-05	0.00899	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
HNSC	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	4.06	5.87e-05	0.00899	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
HNSC	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	4.06	5.87e-05	0.00899	0.21	0.18	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
HNSC	cis	rs10783487	0.749	rs2272485	ENSG00000257542.4	OR7E47P	4.06	5.87e-05	0.00899	0.22	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52092107	chr12:52079696~52108261:+
HNSC	cis	rs6586111	1	rs7086576	ENSG00000226659.1	RP11-137H2.4	-4.06	5.87e-05	0.00899	-0.22	-0.18	Capecitabine sensitivity;	chr10:80612389	chr10:80529597~80535942:-
HNSC	cis	rs6586111	0.904	rs6586105	ENSG00000226659.1	RP11-137H2.4	-4.06	5.87e-05	0.00899	-0.22	-0.18	Capecitabine sensitivity;	chr10:80612492	chr10:80529597~80535942:-
HNSC	cis	rs4947019	1	rs4947015	ENSG00000260273.1	RP11-425D10.10	4.06	5.87e-05	0.00899	0.43	0.18	Hematological parameters;	chr6:109731312	chr6:109382795~109383666:+
HNSC	cis	rs7107174	0.901	rs2510053	ENSG00000251323.2	RP11-452H21.4	4.06	5.87e-05	0.009	0.26	0.18	Testicular germ cell tumor;	chr11:78248389	chr11:78423982~78429836:-
HNSC	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	4.05	5.87e-05	0.009	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
HNSC	cis	rs8067545	0.616	rs203465	ENSG00000266126.1	RP11-209D14.4	4.05	5.88e-05	0.009	0.21	0.18	Schizophrenia;	chr17:19907407	chr17:19929372~19929737:-
HNSC	cis	rs6714900	0.888	rs2160783	ENSG00000205847.5	OR7E91P	-4.05	5.88e-05	0.009	-0.22	-0.18	Blood protein levels;	chr2:71056337	chr2:71029028~71029893:+
HNSC	cis	rs9400271	0.504	rs9784763	ENSG00000243587.6	C6orf183	4.05	5.88e-05	0.009	0.18	0.18	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109303734	chr6:109165833~109271014:+
HNSC	cis	rs7824557	0.628	rs2572387	ENSG00000269918.1	AF131215.9	4.05	5.88e-05	0.009	0.18	0.18	Retinal vascular caliber;	chr8:11346656	chr8:11104691~11106704:-
HNSC	cis	rs7572733	0.534	rs2574832	ENSG00000231621.1	AC013264.2	-4.05	5.88e-05	0.009	-0.18	-0.18	Dermatomyositis;	chr2:197840094	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs700678	ENSG00000231621.1	AC013264.2	-4.05	5.88e-05	0.009	-0.18	-0.18	Dermatomyositis;	chr2:197841096	chr2:197197991~197199273:+
HNSC	cis	rs11673344	0.504	rs35579954	ENSG00000276846.1	CTD-3220F14.3	4.05	5.88e-05	0.00901	0.2	0.18	Obesity-related traits;	chr19:37139308	chr19:37314868~37315620:-
HNSC	cis	rs2253762	0.54	rs75670246	ENSG00000226864.1	ATE1-AS1	4.05	5.88e-05	0.00901	0.32	0.18	Breast cancer;	chr10:122032687	chr10:121928312~121951965:+
HNSC	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-4.05	5.88e-05	0.00901	-0.2	-0.18	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
HNSC	cis	rs72634501	0.517	rs7522362	ENSG00000182109.6	RP11-69E11.4	-4.05	5.88e-05	0.00901	-0.18	-0.18	HDL cholesterol;	chr1:39139419	chr1:39522280~39546187:-
HNSC	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	4.05	5.88e-05	0.00901	0.28	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	4.05	5.88e-05	0.00901	0.28	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
HNSC	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-4.05	5.88e-05	0.00901	-0.22	-0.18	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
HNSC	cis	rs7590368	0.6	rs56143168	ENSG00000272275.1	RP11-791G15.2	4.05	5.88e-05	0.00901	0.32	0.18	Educational attainment (years of education);	chr2:10776107	chr2:10767875~10770058:-
HNSC	cis	rs2762353	0.776	rs1165190	ENSG00000272462.2	U91328.19	-4.05	5.88e-05	0.00901	-0.18	-0.18	Blood metabolite levels;	chr6:25847791	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.776	rs942379	ENSG00000272462.2	U91328.19	-4.05	5.88e-05	0.00901	-0.18	-0.18	Blood metabolite levels;	chr6:25849392	chr6:25992662~26001775:+
HNSC	cis	rs7824557	0.806	rs7007394	ENSG00000269918.1	AF131215.9	-4.05	5.88e-05	0.00901	-0.18	-0.18	Retinal vascular caliber;	chr8:11237057	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.806	rs6601574	ENSG00000269918.1	AF131215.9	-4.05	5.88e-05	0.00901	-0.18	-0.18	Retinal vascular caliber;	chr8:11237376	chr8:11104691~11106704:-
HNSC	cis	rs4356203	0.905	rs7930058	ENSG00000260196.1	RP1-239B22.5	-4.05	5.89e-05	0.00901	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17380649~17383531:+
HNSC	cis	rs11673344	0.504	rs7252940	ENSG00000276846.1	CTD-3220F14.3	4.05	5.89e-05	0.00901	0.2	0.18	Obesity-related traits;	chr19:37138589	chr19:37314868~37315620:-
HNSC	cis	rs561341	1	rs4795669	ENSG00000278867.1	RP11-640N20.4	-4.05	5.89e-05	0.00901	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31917682	chr17:32051030~32053208:+
HNSC	cis	rs11992162	1	rs7460395	ENSG00000255310.2	AF131215.2	4.05	5.89e-05	0.00901	0.18	0.18	Monocyte count;	chr8:11977866	chr8:11107788~11109726:-
HNSC	cis	rs1602565	0.858	rs675833	ENSG00000255450.1	CTD-2063L20.1	-4.05	5.89e-05	0.00902	-0.29	-0.18	Schizophrenia;	chr11:29163664	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs612330	ENSG00000255450.1	CTD-2063L20.1	-4.05	5.89e-05	0.00902	-0.29	-0.18	Schizophrenia;	chr11:29164726	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.8	rs601169	ENSG00000255450.1	CTD-2063L20.1	-4.05	5.89e-05	0.00902	-0.29	-0.18	Schizophrenia;	chr11:29164970	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs599370	ENSG00000255450.1	CTD-2063L20.1	-4.05	5.89e-05	0.00902	-0.29	-0.18	Schizophrenia;	chr11:29165328	chr11:29275655~29276565:+
HNSC	cis	rs865483	0.861	rs56186148	ENSG00000276054.1	RP11-378E13.3	-4.05	5.89e-05	0.00902	-0.22	-0.18	Monocyte count;	chr17:37408740	chr17:37386886~37387926:+
HNSC	cis	rs870825	0.929	rs1405939	ENSG00000254233.1	RP11-242J7.1	4.05	5.89e-05	0.00902	0.3	0.18	Blood protein levels;	chr4:184670290	chr4:184584093~184625030:-
HNSC	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-4.05	5.89e-05	0.00902	-0.21	-0.18	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
HNSC	cis	rs9298506	1	rs9298506	ENSG00000254142.2	RP11-53M11.3	4.05	5.89e-05	0.00902	0.27	0.18	Intracranial aneurysm;	chr8:54524964	chr8:54554361~54561927:+
HNSC	cis	rs6504950	0.579	rs8075983	ENSG00000275710.1	RP11-257O5.4	4.05	5.89e-05	0.00902	0.26	0.18	Breast cancer;	chr17:55194557	chr17:54964474~54964679:+
HNSC	cis	rs9573567	0.881	rs6562898	ENSG00000261553.4	RP11-29G8.3	-4.05	5.89e-05	0.00902	-0.35	-0.18	Red blood cell count;Mean corpuscular volume;	chr13:75502232	chr13:75549773~75807120:+
HNSC	cis	rs62458065	0.713	rs62463967	ENSG00000226468.2	AC018641.7	4.05	5.89e-05	0.00902	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32458717	chr7:32456963~32457758:-
HNSC	cis	rs454217	0.502	rs11106515	ENSG00000277851.1	RP11-756G20.1	4.05	5.9e-05	0.00903	0.2	0.18	Smoking quantity;	chr12:92336894	chr12:92247756~92363832:-
HNSC	cis	rs67981189	0.593	rs2251394	ENSG00000274818.1	RP1-292L20.3	-4.05	5.9e-05	0.00903	-0.2	-0.18	Schizophrenia;	chr14:70969357	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs7147862	ENSG00000274818.1	RP1-292L20.3	-4.05	5.9e-05	0.00903	-0.2	-0.18	Schizophrenia;	chr14:70971485	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs8005160	ENSG00000274818.1	RP1-292L20.3	4.05	5.9e-05	0.00903	0.2	0.18	Schizophrenia;	chr14:70979777	chr14:70906657~70907111:-
HNSC	cis	rs17250963	0.645	rs149391	ENSG00000249485.1	RBBP4P1	-4.05	5.9e-05	0.00903	-0.18	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14745159	chr5:14797125~14798400:-
HNSC	cis	rs7937890	1	rs2970335	ENSG00000251991.1	RNU7-49P	4.05	5.9e-05	0.00903	0.2	0.18	Mitochondrial DNA levels;	chr11:14303855	chr11:14478892~14478953:+
HNSC	cis	rs67311347	1	rs9849992	ENSG00000280739.1	EIF1B-AS1	4.05	5.9e-05	0.00903	0.2	0.18	Renal cell carcinoma;	chr3:40360649	chr3:40173145~40309698:-
HNSC	cis	rs755249	0.53	rs4660475	ENSG00000182109.6	RP11-69E11.4	4.05	5.9e-05	0.00903	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.53	rs66848709	ENSG00000182109.6	RP11-69E11.4	4.05	5.9e-05	0.00903	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39522280~39546187:-
HNSC	cis	rs72634501	0.716	rs67062906	ENSG00000182109.6	RP11-69E11.4	4.05	5.9e-05	0.00903	0.21	0.18	HDL cholesterol;	chr1:39151018	chr1:39522280~39546187:-
HNSC	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-4.05	5.9e-05	0.00903	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
HNSC	cis	rs6095360	0.966	rs6019545	ENSG00000222365.1	SNORD12B	-4.05	5.9e-05	0.00903	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:48940477	chr20:49280319~49280409:+
HNSC	cis	rs4253772	0.55	rs9615913	ENSG00000277232.2	GTSE1-AS1	4.05	5.9e-05	0.00903	0.23	0.18	Cholesterol, total;LDL cholesterol;	chr22:46272618	chr22:46295143~46296660:-
HNSC	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-4.05	5.9e-05	0.00904	-0.26	-0.18	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
HNSC	cis	rs6651255	0.738	rs6470766	ENSG00000224110.3	MTRF1LP2	4.05	5.9e-05	0.00904	0.21	0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129724608	chr8:129728744~129730445:+
HNSC	cis	rs10462794	0.756	rs1347199	ENSG00000260763.1	RP11-445O3.3	4.05	5.9e-05	0.00904	0.23	0.18	DNA methylation (variation);	chr5:4478693	chr5:4436850~4440259:-
HNSC	cis	rs7243790	0.805	rs12458280	ENSG00000277324.1	RP11-850A17.1	-4.05	5.91e-05	0.00904	-0.21	-0.18	Diastolic blood pressure;	chr18:54386772	chr18:54268346~54270028:-
HNSC	cis	rs4294134	0.608	rs11535331	ENSG00000223718.3	AC093107.7	4.05	5.91e-05	0.00904	0.28	0.18	Paget's disease;	chr7:135560918	chr7:135660039~135660647:+
HNSC	cis	rs6493858	0.839	rs2713936	ENSG00000277245.1	RP11-48G14.3	-4.05	5.91e-05	0.00904	-0.22	-0.18	Relative hand skill in reading disability;	chr15:56253787	chr15:56447120~56447697:+
HNSC	cis	rs11098499	0.909	rs73842633	ENSG00000250412.1	KLHL2P1	4.05	5.91e-05	0.00904	0.24	0.18	Corneal astigmatism;	chr4:119454309	chr4:119334329~119378233:+
HNSC	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-4.05	5.91e-05	0.00904	-0.22	-0.18	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
HNSC	cis	rs970821	0.667	rs2385506	ENSG00000253106.1	RP11-158K1.3	4.05	5.91e-05	0.00905	0.17	0.18	Breast cancer;	chr8:123732364	chr8:124488510~124491643:+
HNSC	cis	rs970821	0.667	rs2385507	ENSG00000253106.1	RP11-158K1.3	4.05	5.91e-05	0.00905	0.17	0.18	Breast cancer;	chr8:123732399	chr8:124488510~124491643:+
HNSC	cis	rs970821	0.667	rs2385508	ENSG00000253106.1	RP11-158K1.3	4.05	5.91e-05	0.00905	0.17	0.18	Breast cancer;	chr8:123732442	chr8:124488510~124491643:+
HNSC	cis	rs561341	0.714	rs111760509	ENSG00000278867.1	RP11-640N20.4	-4.05	5.91e-05	0.00905	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31977301	chr17:32051030~32053208:+
HNSC	cis	rs17270561	1	rs17270561	ENSG00000272810.1	U91328.22	4.05	5.91e-05	0.00905	0.2	0.18	Iron status biomarkers;	chr6:25820211	chr6:26013241~26013757:+
HNSC	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-4.05	5.92e-05	0.00905	-0.19	-0.18	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
HNSC	cis	rs4713118	0.621	rs9295756	ENSG00000219891.2	ZSCAN12P1	4.05	5.92e-05	0.00906	0.26	0.18	Parkinson's disease;	chr6:28065618	chr6:28091154~28093664:+
HNSC	cis	rs13315649	0.724	rs7624610	ENSG00000242551.2	POU5F1P6	-4.05	5.92e-05	0.00906	-0.2	-0.18	Sum eosinophil basophil counts;	chr3:128698450	chr3:128674735~128677005:-
HNSC	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-4.05	5.92e-05	0.00906	-0.18	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
HNSC	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-4.05	5.92e-05	0.00906	-0.22	-0.18	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
HNSC	cis	rs3736485	0.844	rs6493501	ENSG00000259438.1	CTD-2650P22.1	-4.05	5.92e-05	0.00906	-0.19	-0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51523446	chr15:52010999~52019095:-
HNSC	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	4.05	5.92e-05	0.00906	0.2	0.18	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
HNSC	cis	rs7429990	0.965	rs7653368	ENSG00000228638.1	FCF1P2	-4.05	5.92e-05	0.00906	-0.16	-0.18	Educational attainment (years of education);	chr3:47943871	chr3:48290793~48291375:-
HNSC	cis	rs6500395	1	rs11643264	ENSG00000261267.1	RP11-44I10.3	-4.05	5.92e-05	0.00906	-0.23	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48524551	chr16:48559661~48587403:+
HNSC	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	4.05	5.92e-05	0.00906	0.19	0.18	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
HNSC	cis	rs4938303	0.788	rs17092642	ENSG00000254851.1	RP11-109L13.1	4.05	5.92e-05	0.00906	0.28	0.18	Triglycerides;	chr11:116686532	chr11:117135528~117138582:+
HNSC	cis	rs6887276	0.504	rs17764688	ENSG00000245937.6	LINC01184	-4.05	5.92e-05	0.00906	-0.22	-0.18	Height;	chr5:128011187	chr5:127940426~128083172:-
HNSC	cis	rs6601327	0.67	rs6601338	ENSG00000254340.1	RP11-10A14.3	4.05	5.93e-05	0.00906	0.22	0.18	Multiple myeloma (hyperdiploidy);	chr8:9581418	chr8:9141424~9145435:+
HNSC	cis	rs10995245	0.879	rs7075349	ENSG00000238280.1	RP11-436D10.3	4.05	5.93e-05	0.00906	0.23	0.18	Narcolepsy;	chr10:62667889	chr10:62793562~62805887:-
HNSC	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	4.05	5.93e-05	0.00906	0.26	0.18	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
HNSC	cis	rs1185460	0.967	rs1784302	ENSG00000272186.1	RP11-110I1.13	-4.05	5.93e-05	0.00907	-0.21	-0.18	Coronary artery disease;	chr11:119070247	chr11:119067374~119067698:-
HNSC	cis	rs924712	0.522	rs9464146	ENSG00000224984.1	RP11-524H19.2	-4.05	5.93e-05	0.00907	-0.21	-0.18	Breast cancer;	chr6:54834441	chr6:54840118~54840855:-
HNSC	cis	rs62458065	0.713	rs3801329	ENSG00000226468.2	AC018641.7	4.05	5.93e-05	0.00907	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32457344	chr7:32456963~32457758:-
HNSC	cis	rs4699052	0.662	rs6825489	ENSG00000246560.2	RP11-10L12.4	4.05	5.93e-05	0.00907	0.21	0.18	Testicular germ cell tumor;	chr4:103329027	chr4:102828055~102844075:+
HNSC	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-4.05	5.93e-05	0.00907	-0.23	-0.18	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
HNSC	cis	rs4356203	0.875	rs214935	ENSG00000272034.1	SNORD14A	-4.05	5.93e-05	0.00907	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17074654~17074744:-
HNSC	cis	rs9880211	1	rs6805316	ENSG00000239213.4	NCK1-AS1	4.05	5.93e-05	0.00907	0.19	0.18	Height;Body mass index;	chr3:136233270	chr3:136841726~136862054:-
HNSC	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	4.05	5.93e-05	0.00907	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
HNSC	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-4.05	5.93e-05	0.00907	-0.19	-0.18	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
HNSC	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.05	5.93e-05	0.00907	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	-4.05	5.93e-05	0.00907	-0.23	-0.18	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
HNSC	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	4.05	5.93e-05	0.00907	0.15	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
HNSC	cis	rs6674176	0.628	rs2301993	ENSG00000237950.1	RP11-7O11.3	4.05	5.93e-05	0.00907	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43960353	chr1:43944370~43946551:-
HNSC	cis	rs2120243	0.533	rs1392798	ENSG00000244515.1	KRT18P34	4.05	5.94e-05	0.00908	0.18	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157162663~157163932:-
HNSC	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.05	5.94e-05	0.00908	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
HNSC	cis	rs7429990	0.901	rs6442091	ENSG00000228638.1	FCF1P2	4.05	5.94e-05	0.00908	0.17	0.18	Educational attainment (years of education);	chr3:48001568	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.965	rs4858810	ENSG00000228638.1	FCF1P2	4.05	5.94e-05	0.00908	0.17	0.18	Educational attainment (years of education);	chr3:48002247	chr3:48290793~48291375:-
HNSC	cis	rs28829049	0.536	rs2073106	ENSG00000270728.1	RP4-657E11.10	-4.05	5.94e-05	0.00908	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222849	chr1:19297080~19297903:+
HNSC	cis	rs7552167	0.925	rs7546025	ENSG00000230023.2	RP11-10N16.2	4.05	5.94e-05	0.00908	0.3	0.18	Psoriasis vulgaris;	chr1:24183762	chr1:24200240~24211693:+
HNSC	cis	rs4523957	0.671	rs9910849	ENSG00000262333.1	HNRNPA1P16	-4.05	5.94e-05	0.00908	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2272474	chr17:2306761~2307715:+
HNSC	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-4.05	5.94e-05	0.00909	-0.28	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
HNSC	cis	rs889398	0.802	rs2291959	ENSG00000226232.7	RP11-419C5.2	-4.05	5.95e-05	0.00909	-0.16	-0.18	Body mass index;	chr16:69840089	chr16:69976388~69996188:-
HNSC	cis	rs28829049	0.597	rs2066002	ENSG00000270728.1	RP4-657E11.10	-4.05	5.95e-05	0.00909	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19177806	chr1:19297080~19297903:+
HNSC	cis	rs73198271	0.653	rs3827811	ENSG00000233609.3	RP11-62H7.2	-4.05	5.95e-05	0.00909	-0.2	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8961200~8979025:+
HNSC	cis	rs11231017	0.507	rs10897266	ENSG00000250659.2	RP11-864I4.3	-4.05	5.95e-05	0.00909	-0.23	-0.18	HIV-1 viral setpoint;	chr11:62387640	chr11:62537312~62542018:+
HNSC	cis	rs853679	0.882	rs4713139	ENSG00000219891.2	ZSCAN12P1	4.05	5.95e-05	0.00909	0.33	0.18	Depression;	chr6:28124907	chr6:28091154~28093664:+
HNSC	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-4.05	5.95e-05	0.00909	-0.32	-0.18	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
HNSC	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	4.05	5.95e-05	0.00909	0.41	0.18	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
HNSC	cis	rs8028182	0.636	rs4243034	ENSG00000260269.4	CTD-2323K18.1	-4.05	5.95e-05	0.00909	-0.23	-0.18	Sudden cardiac arrest;	chr15:75458628	chr15:75527150~75601205:-
HNSC	cis	rs1552244	0.572	rs6797536	ENSG00000180385.7	EMC3-AS1	-4.05	5.95e-05	0.0091	-0.22	-0.18	Alzheimer's disease;	chr3:10127118	chr3:9986893~10006990:+
HNSC	cis	rs11098499	0.863	rs1383532	ENSG00000250412.1	KLHL2P1	-4.05	5.95e-05	0.0091	-0.24	-0.18	Corneal astigmatism;	chr4:119513249	chr4:119334329~119378233:+
HNSC	cis	rs73201462	0.901	rs16843876	ENSG00000231305.3	RP11-723O4.2	-4.05	5.95e-05	0.0091	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128313697	chr3:128861313~128871540:-
HNSC	cis	rs17407555	0.683	rs7676442	ENSG00000250413.1	RP11-448G15.1	-4.05	5.95e-05	0.0091	-0.24	-0.18	Schizophrenia (age at onset);	chr4:10270967	chr4:10006482~10009725:+
HNSC	cis	rs2342371	0.599	rs7618690	ENSG00000243339.3	RN7SL738P	-4.05	5.96e-05	0.0091	-0.25	-0.18	Fat distribution (HIV);	chr3:196419168	chr3:196399911~196400207:+
HNSC	cis	rs10865541	0.934	rs4627605	ENSG00000234171.2	RNASEH1-AS1	4.05	5.96e-05	0.0091	0.19	0.18	Obesity-related traits;	chr2:3408152	chr2:3558492~3561745:+
HNSC	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-4.05	5.96e-05	0.0091	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
HNSC	cis	rs10504130	1	rs118116154	ENSG00000272024.1	RP11-546K22.3	-4.05	5.96e-05	0.00911	-0.3	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51833124	chr8:51950284~51950690:+
HNSC	cis	rs7552167	0.925	rs78312791	ENSG00000230023.2	RP11-10N16.2	-4.05	5.96e-05	0.00911	-0.3	-0.18	Psoriasis vulgaris;	chr1:24187123	chr1:24200240~24211693:+
HNSC	cis	rs6081541	1	rs6081541	ENSG00000179447.2	RP5-1027G4.3	4.05	5.96e-05	0.00911	0.25	0.18	Psychosis (atypical);	chr20:19232246	chr20:19242302~19284596:-
HNSC	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	4.05	5.96e-05	0.00911	0.19	0.18	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
HNSC	cis	rs1485395	0.945	rs3852552	ENSG00000270175.1	RP11-793H13.11	-4.05	5.97e-05	0.00911	-0.22	-0.18	Migraine without aura;	chr12:53615611	chr12:53500162~53500936:-
HNSC	cis	rs6787172	0.622	rs6797629	ENSG00000272087.1	RP11-379F4.7	4.05	5.97e-05	0.00911	0.19	0.18	Subjective well-being;	chr3:158347882	chr3:158693120~158693768:-
HNSC	cis	rs1799949	1	rs9646417	ENSG00000236383.6	LINC00854	-4.05	5.97e-05	0.00911	-0.18	-0.18	Menopause (age at onset);	chr17:43346885	chr17:43216941~43305976:-
HNSC	cis	rs1799949	1	rs1545764	ENSG00000236383.6	LINC00854	-4.05	5.97e-05	0.00911	-0.18	-0.18	Menopause (age at onset);	chr17:43347197	chr17:43216941~43305976:-
HNSC	cis	rs1799949	0.859	rs11657004	ENSG00000236383.6	LINC00854	-4.05	5.97e-05	0.00911	-0.17	-0.18	Menopause (age at onset);	chr17:43365383	chr17:43216941~43305976:-
HNSC	cis	rs9926296	0.682	rs645019	ENSG00000274627.1	RP11-104N10.2	4.05	5.97e-05	0.00912	0.18	0.18	Vitiligo;	chr16:89650475	chr16:89516797~89522217:+
HNSC	cis	rs2762353	0.808	rs1165151	ENSG00000272462.2	U91328.19	-4.05	5.97e-05	0.00912	-0.18	-0.18	Blood metabolite levels;	chr6:25821388	chr6:25992662~26001775:+
HNSC	cis	rs2554380	0.843	rs1365198	ENSG00000259570.1	RP11-671M22.4	4.05	5.97e-05	0.00912	0.25	0.18	Height;	chr15:83730151	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.843	rs2554386	ENSG00000259570.1	RP11-671M22.4	4.05	5.97e-05	0.00912	0.25	0.18	Height;	chr15:83734770	chr15:84394512~84395514:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000241278.1	ENPP7P4	-4.05	5.97e-05	0.00912	-0.31	-0.18	Blood pressure (smoking interaction);	chr3:125880752	chr3:125848223~125909372:+
HNSC	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-4.05	5.97e-05	0.00912	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
HNSC	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	4.05	5.97e-05	0.00912	0.21	0.18	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	4.05	5.97e-05	0.00912	0.21	0.18	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
HNSC	cis	rs6142618	0.967	rs6061195	ENSG00000275576.1	RP5-836N17.4	-4.05	5.97e-05	0.00912	-0.19	-0.18	Inflammatory bowel disease;	chr20:32158445	chr20:32116171~32116629:+
HNSC	cis	rs8028182	0.636	rs11637586	ENSG00000260269.4	CTD-2323K18.1	-4.05	5.97e-05	0.00912	-0.24	-0.18	Sudden cardiac arrest;	chr15:75498771	chr15:75527150~75601205:-
HNSC	cis	rs7178909	0.872	rs28468074	ENSG00000259677.1	RP11-493E3.1	4.05	5.97e-05	0.00912	0.21	0.18	Common traits (Other);	chr15:89892368	chr15:89876540~89877285:+
HNSC	cis	rs7178909	0.872	rs61345389	ENSG00000259677.1	RP11-493E3.1	4.05	5.97e-05	0.00912	0.21	0.18	Common traits (Other);	chr15:89892653	chr15:89876540~89877285:+
HNSC	cis	rs3733585	0.563	rs881971	ENSG00000250413.1	RP11-448G15.1	4.05	5.98e-05	0.00912	0.22	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9929338	chr4:10006482~10009725:+
HNSC	cis	rs7178375	1	rs28693590	ENSG00000270015.1	RP11-540B6.6	4.05	5.98e-05	0.00912	0.24	0.18	Hypertriglyceridemia;	chr15:30902818	chr15:30926514~30928407:+
HNSC	cis	rs9584850	0.874	rs9168	ENSG00000231194.1	FARP1-AS1	4.05	5.98e-05	0.00913	0.23	0.18	Neuroticism;	chr13:98449329	chr13:98435405~98435840:-
HNSC	cis	rs929354	1	rs1182389	ENSG00000224629.1	RP5-1142J19.2	-4.05	5.98e-05	0.00913	-0.18	-0.18	Body mass index;	chr7:157246109	chr7:157263022~157263229:-
HNSC	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-4.05	5.98e-05	0.00913	-0.22	-0.18	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-4.05	5.98e-05	0.00913	-0.22	-0.18	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
HNSC	cis	rs17229494	0.635	rs41399945	ENSG00000231231.4	LINC01423	-4.05	5.98e-05	0.00913	-0.46	-0.18	Interleukin-12p70 levels;	chr21:37496627	chr21:38323635~38333421:-
HNSC	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	4.05	5.98e-05	0.00913	0.24	0.18	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
HNSC	cis	rs6496044	0.507	rs410522	ENSG00000259407.1	RP11-158M2.3	4.05	5.98e-05	0.00914	0.2	0.18	Interstitial lung disease;	chr15:85663813	chr15:85744109~85750281:-
HNSC	cis	rs7572733	0.773	rs11690844	ENSG00000222017.1	AC011997.1	4.05	5.99e-05	0.00914	0.23	0.18	Dermatomyositis;	chr2:197650812	chr2:197693106~197774823:+
HNSC	cis	rs2835345	0.596	rs2409817	ENSG00000230479.1	AP000695.6	4.05	5.99e-05	0.00914	0.2	0.18	Pulmonary function;	chr21:36455410	chr21:36430360~36481070:+
HNSC	cis	rs11976180	1	rs11976180	ENSG00000244479.5	OR2A1-AS1	4.05	5.99e-05	0.00914	0.22	0.18	Obesity-related traits;	chr7:144044487	chr7:144251264~144356181:-
HNSC	cis	rs12887734	0.524	rs4906363	ENSG00000269940.1	RP11-73M18.7	4.05	5.99e-05	0.00914	0.18	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694560~103695170:+
HNSC	cis	rs10927875	1	rs3979179	ENSG00000238142.1	RP11-108M9.4	-4.05	5.99e-05	0.00914	-0.23	-0.18	Dilated cardiomyopathy;	chr1:15980351	chr1:16888538~16889649:-
HNSC	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	4.05	5.99e-05	0.00914	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
HNSC	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	4.05	5.99e-05	0.00914	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
HNSC	cis	rs9925964	0.933	rs749671	ENSG00000232748.3	RP11-196G11.6	4.05	5.99e-05	0.00914	0.25	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:31056460~31062803:+
HNSC	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-4.05	5.99e-05	0.00915	-0.19	-0.18	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
HNSC	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-4.05	5.99e-05	0.00915	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-4.05	5.99e-05	0.00915	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-4.05	5.99e-05	0.00915	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-4.05	5.99e-05	0.00915	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-4.05	5.99e-05	0.00915	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
HNSC	cis	rs6674176	0.628	rs3791116	ENSG00000237950.1	RP11-7O11.3	4.05	6e-05	0.00915	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43948484	chr1:43944370~43946551:-
HNSC	cis	rs6504950	0.83	rs12949538	ENSG00000279059.1	RP11-257O5.2	4.05	6e-05	0.00915	0.16	0.18	Breast cancer;	chr17:54933309	chr17:54956760~54958426:-
HNSC	cis	rs35306767	0.903	rs11253485	ENSG00000229869.1	RP11-363N22.2	-4.05	6e-05	0.00915	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:873422	chr10:933026~942743:+
HNSC	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	4.05	6e-05	0.00915	0.22	0.18	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
HNSC	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-4.05	6e-05	0.00915	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
HNSC	cis	rs10462794	0.686	rs12652129	ENSG00000260763.1	RP11-445O3.3	4.05	6e-05	0.00915	0.23	0.18	DNA methylation (variation);	chr5:4494709	chr5:4436850~4440259:-
HNSC	cis	rs436483	1	rs401966	ENSG00000213385.3	RP11-577H5.1	-4.05	6e-05	0.00916	-0.19	-0.18	Lobe attachment (rater-scored or self-reported);	chr7:102052537	chr7:102755146~102755939:+
HNSC	cis	rs4356203	0.519	rs214097	ENSG00000260196.1	RP1-239B22.5	-4.05	6e-05	0.00916	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17380649~17383531:+
HNSC	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	4.05	6e-05	0.00916	0.4	0.18	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000250412.1	KLHL2P1	4.05	6e-05	0.00916	0.24	0.18	Corneal astigmatism;	chr4:119327251	chr4:119334329~119378233:+
HNSC	cis	rs72772090	0.71	rs17400741	ENSG00000248734.2	CTD-2260A17.1	-4.05	6e-05	0.00916	-0.28	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96784777~96785999:+
HNSC	cis	rs3015497	0.789	rs3015502	ENSG00000277050.1	RP11-102G14.1	-4.05	6e-05	0.00916	-0.18	-0.18	Mean platelet volume;	chr14:50641709	chr14:51637348~51637947:-
HNSC	cis	rs4392868	0.514	rs4329243	ENSG00000245080.5	RP11-320N21.1	-4.05	6e-05	0.00916	-0.22	-0.18	Radiation response;	chr8:95093463	chr8:95066808~95073182:-
HNSC	cis	rs721917	0.506	rs2493722	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.545	rs2758542	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs7914360	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2493725	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2254025	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.525	rs2254017	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2254013	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2253875	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.544	rs9325567	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.525	rs2250652	ENSG00000244733.5	RP11-506M13.3	-4.05	6.01e-05	0.00916	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79660891~79677996:+
HNSC	cis	rs9611565	0.694	rs2142505	ENSG00000235513.1	RP4-756G23.5	-4.05	6.01e-05	0.00916	-0.23	-0.18	Vitiligo;	chr22:41424537	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.729	rs12165508	ENSG00000235513.1	RP4-756G23.5	-4.05	6.01e-05	0.00917	-0.21	-0.18	Vitiligo;	chr22:41423956	chr22:41209122~41217627:-
HNSC	cis	rs4908768	0.501	rs2045820	ENSG00000232912.4	RP5-1115A15.1	4.05	6.01e-05	0.00917	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8424645~8434838:+
HNSC	cis	rs11951515	0.626	rs10805671	ENSG00000249286.1	CTD-2210P15.2	4.05	6.01e-05	0.00917	0.19	0.18	Metabolite levels  (X-11787);	chr5:43271445	chr5:43586918~43588223:-
HNSC	cis	rs442309	0.841	rs224076	ENSG00000238280.1	RP11-436D10.3	-4.05	6.01e-05	0.00917	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62751881	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.841	rs224078	ENSG00000238280.1	RP11-436D10.3	-4.05	6.01e-05	0.00917	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62752000	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.775	rs7893375	ENSG00000238280.1	RP11-436D10.3	-4.05	6.01e-05	0.00917	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62757846	chr10:62793562~62805887:-
HNSC	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	4.05	6.01e-05	0.00917	0.19	0.18	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	4.05	6.02e-05	0.00918	0.2	0.18	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
HNSC	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-4.05	6.02e-05	0.00918	-0.24	-0.18	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
HNSC	cis	rs865483	0.895	rs72828253	ENSG00000276054.1	RP11-378E13.3	-4.05	6.02e-05	0.00918	-0.23	-0.18	Monocyte count;	chr17:37423316	chr17:37386886~37387926:+
HNSC	cis	rs865483	0.895	rs7501983	ENSG00000276054.1	RP11-378E13.3	-4.05	6.02e-05	0.00918	-0.23	-0.18	Monocyte count;	chr17:37423712	chr17:37386886~37387926:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000280411.1	IGHV1-69-2	-4.05	6.02e-05	0.00918	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106704673	chr14:106762092~106762588:-
HNSC	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-4.05	6.02e-05	0.00918	-0.17	-0.18	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
HNSC	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-4.05	6.02e-05	0.00918	-0.17	-0.18	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
HNSC	cis	rs4853525	0.59	rs1921910	ENSG00000228509.4	AC006460.2	4.05	6.02e-05	0.00918	0.26	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859206	chr2:190676944~190708716:-
HNSC	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-4.05	6.02e-05	0.00918	-0.26	-0.18	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
HNSC	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-4.05	6.02e-05	0.00918	-0.26	-0.18	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
HNSC	cis	rs6688613	0.84	rs6699294	ENSG00000215834.7	FMO9P	4.05	6.02e-05	0.00918	0.25	0.18	Refractive astigmatism;	chr1:166985937	chr1:166603675~166631400:+
HNSC	cis	rs6688613	0.84	rs6669886	ENSG00000215834.7	FMO9P	4.05	6.02e-05	0.00918	0.25	0.18	Refractive astigmatism;	chr1:166987473	chr1:166603675~166631400:+
HNSC	cis	rs1445130	0.585	rs16985408	ENSG00000260331.1	RP11-111J6.2	4.05	6.02e-05	0.00919	0.31	0.18	Bulimia nervosa;	chr2:18666090	chr2:18547386~18548204:-
HNSC	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-4.05	6.03e-05	0.00919	-0.23	-0.18	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
HNSC	cis	rs9487051	0.872	rs9487043	ENSG00000219700.1	PTCHD3P3	4.05	6.03e-05	0.00919	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109289271	chr6:109288571~109290503:-
HNSC	cis	rs9313772	0.775	rs2900952	ENSG00000254350.1	RP11-542A14.1	-4.05	6.03e-05	0.00919	-0.2	-0.18	Blood pressure;	chr5:158391866	chr5:158424585~158452758:+
HNSC	cis	rs7637230	1	rs28854485	ENSG00000244119.1	PDCL3P4	-4.05	6.03e-05	0.00919	-0.2	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101909693	chr3:101712472~101713191:+
HNSC	cis	rs12935418	0.672	rs9923948	ENSG00000278985.1	RP11-303E16.9	4.05	6.03e-05	0.0092	0.19	0.18	Mean corpuscular volume;	chr16:81013814	chr16:80982319~80984094:-
HNSC	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-4.05	6.03e-05	0.0092	-0.28	-0.18	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
HNSC	cis	rs516805	0.667	rs2606650	ENSG00000279453.1	RP3-425C14.4	-4.05	6.03e-05	0.0092	-0.25	-0.18	Lymphocyte counts;	chr6:122123443	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.562	rs2816156	ENSG00000279453.1	RP3-425C14.4	-4.05	6.03e-05	0.0092	-0.25	-0.18	Lymphocyte counts;	chr6:122124569	chr6:122436789~122439223:-
HNSC	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	4.05	6.03e-05	0.0092	0.23	0.18	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
HNSC	cis	rs7086627	0.515	rs10887896	ENSG00000226659.1	RP11-137H2.4	-4.05	6.03e-05	0.0092	-0.23	-0.18	Post bronchodilator FEV1;	chr10:80450388	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.515	rs10887899	ENSG00000226659.1	RP11-137H2.4	-4.05	6.03e-05	0.0092	-0.23	-0.18	Post bronchodilator FEV1;	chr10:80450458	chr10:80529597~80535942:-
HNSC	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-4.05	6.04e-05	0.0092	-0.24	-0.18	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
HNSC	cis	rs1585471	0.897	rs10516571	ENSG00000249532.3	RP11-148B6.1	-4.05	6.04e-05	0.0092	-0.22	-0.18	Myopia (pathological);	chr4:111679413	chr4:112646476~112650051:-
HNSC	cis	rs62355901	0.505	rs62355912	ENSG00000271828.1	CTD-2310F14.1	4.05	6.04e-05	0.0092	0.39	0.18	Breast cancer;	chr5:56788004	chr5:56927874~56929573:+
HNSC	cis	rs6142102	0.59	rs6059691	ENSG00000275784.1	RP5-1125A11.6	4.05	6.04e-05	0.0092	0.24	0.18	Skin pigmentation;	chr20:34149161	chr20:33989480~33991818:-
HNSC	cis	rs2243480	1	rs67728539	ENSG00000229886.1	RP5-1132H15.3	4.05	6.04e-05	0.0092	0.32	0.18	Diabetic kidney disease;	chr7:65913137	chr7:66025126~66031544:-
HNSC	cis	rs6601327	0.606	rs7006985	ENSG00000233609.3	RP11-62H7.2	-4.05	6.04e-05	0.00921	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9706927	chr8:8961200~8979025:+
HNSC	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	4.05	6.04e-05	0.00921	0.16	0.18	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
HNSC	cis	rs8077577	1	rs62073605	ENSG00000273018.4	CTD-2303H24.2	-4.05	6.04e-05	0.00921	-0.28	-0.18	Obesity-related traits;	chr17:18163477	chr17:18511221~18551705:-
HNSC	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	4.05	6.05e-05	0.00921	0.33	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
HNSC	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	4.05	6.05e-05	0.00921	0.2	0.18	QT interval;	chr12:29300269	chr12:29280418~29317848:-
HNSC	cis	rs7011507	0.662	rs56348830	ENSG00000253608.1	RP11-770E5.1	-4.05	6.05e-05	0.00921	-0.34	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48429435	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.662	rs55914945	ENSG00000253608.1	RP11-770E5.1	-4.05	6.05e-05	0.00921	-0.34	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48430399	chr8:48551567~48698510:+
HNSC	cis	rs7819412	0.595	rs10503416	ENSG00000255310.2	AF131215.2	4.05	6.05e-05	0.00922	0.18	0.18	Triglycerides;	chr8:11130043	chr8:11107788~11109726:-
HNSC	cis	rs12545109	0.732	rs1973629	ENSG00000246430.5	LINC00968	-4.05	6.05e-05	0.00922	-0.24	-0.18	Obesity-related traits;	chr8:56517024	chr8:56496246~56559823:-
HNSC	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	4.05	6.06e-05	0.00923	0.24	0.18	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
HNSC	cis	rs8046011	0.537	rs1646070	ENSG00000280153.1	RP11-876N24.3	4.05	6.06e-05	0.00923	0.18	0.18	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11227066	chr16:10933903~10936280:+
HNSC	cis	rs970821	1	rs17258588	ENSG00000253106.1	RP11-158K1.3	4.05	6.06e-05	0.00923	0.16	0.18	Breast cancer;	chr8:123734378	chr8:124488510~124491643:+
HNSC	cis	rs1555322	1	rs2425031	ENSG00000126005.14	MMP24-AS1	-4.05	6.06e-05	0.00923	-0.33	-0.18	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35216462~35278131:-
HNSC	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	4.05	6.06e-05	0.00923	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
HNSC	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	4.05	6.06e-05	0.00924	0.21	0.18	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	4.05	6.06e-05	0.00924	0.21	0.18	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
HNSC	cis	rs2279168	0.867	rs55857625	ENSG00000259295.5	CSPG4P12	-4.05	6.07e-05	0.00924	-0.38	-0.18	Response to platinum-based chemotherapy (carboplatin);	chr15:85501207	chr15:85191438~85213905:+
HNSC	cis	rs7520050	0.933	rs6661163	ENSG00000280836.1	AL355480.1	4.05	6.07e-05	0.00924	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45581219~45581321:-
HNSC	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-4.05	6.07e-05	0.00924	-0.23	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
HNSC	cis	rs11098499	0.863	rs11098531	ENSG00000250412.1	KLHL2P1	4.05	6.07e-05	0.00924	0.24	0.18	Corneal astigmatism;	chr4:119543846	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs28718422	ENSG00000250412.1	KLHL2P1	4.05	6.07e-05	0.00924	0.24	0.18	Corneal astigmatism;	chr4:119545149	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.818	rs12498599	ENSG00000250412.1	KLHL2P1	4.05	6.07e-05	0.00924	0.24	0.18	Corneal astigmatism;	chr4:119547348	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs10009626	ENSG00000250412.1	KLHL2P1	4.05	6.07e-05	0.00924	0.24	0.18	Corneal astigmatism;	chr4:119548850	chr4:119334329~119378233:+
HNSC	cis	rs10256972	0.758	rs7789093	ENSG00000225146.1	AC073957.15	4.05	6.07e-05	0.00924	0.24	0.18	Endometriosis;Longevity;	chr7:963345	chr7:1029025~1043891:+
HNSC	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	4.05	6.07e-05	0.00924	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
HNSC	cis	rs6496044	0.507	rs7175731	ENSG00000259407.1	RP11-158M2.3	4.05	6.07e-05	0.00925	0.2	0.18	Interstitial lung disease;	chr15:85611115	chr15:85744109~85750281:-
HNSC	cis	rs8028182	0.636	rs28432989	ENSG00000260269.4	CTD-2323K18.1	-4.05	6.07e-05	0.00925	-0.24	-0.18	Sudden cardiac arrest;	chr15:75475956	chr15:75527150~75601205:-
HNSC	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-4.05	6.08e-05	0.00925	-0.38	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
HNSC	cis	rs5758511	0.573	rs2267438	ENSG00000235513.1	RP4-756G23.5	4.05	6.08e-05	0.00925	0.2	0.18	Birth weight;	chr22:41841561	chr22:41209122~41217627:-
HNSC	cis	rs5758511	0.573	rs2267439	ENSG00000235513.1	RP4-756G23.5	4.05	6.08e-05	0.00925	0.2	0.18	Birth weight;	chr22:41841765	chr22:41209122~41217627:-
HNSC	cis	rs5758511	0.573	rs2284082	ENSG00000235513.1	RP4-756G23.5	4.05	6.08e-05	0.00925	0.2	0.18	Birth weight;	chr22:41844793	chr22:41209122~41217627:-
HNSC	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	4.05	6.08e-05	0.00926	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
HNSC	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	4.05	6.08e-05	0.00926	0.18	0.18	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
HNSC	cis	rs447735	0.587	rs11640702	ENSG00000274627.1	RP11-104N10.2	-4.05	6.08e-05	0.00926	-0.18	-0.18	Hemoglobin concentration;	chr16:89662761	chr16:89516797~89522217:+
HNSC	cis	rs704795	0.702	rs11689803	ENSG00000234072.1	AC074117.10	-4.05	6.08e-05	0.00926	-0.18	-0.18	Menopause (age at onset);	chr2:27343653	chr2:27356246~27367622:+
HNSC	cis	rs1991601	0.957	rs6759870	ENSG00000236449.1	AC018890.6	-4.05	6.09e-05	0.00926	-0.26	-0.18	QRS complex (12-leadsum);	chr2:174601999	chr2:174547141~174774827:+
HNSC	cis	rs6504108	0.624	rs4794517	ENSG00000278765.1	RP5-890E16.5	-4.05	6.09e-05	0.00926	-0.23	-0.18	Body mass index;	chr17:48214491	chr17:48066704~48067293:-
HNSC	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-4.05	6.09e-05	0.00926	-0.25	-0.18	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
HNSC	cis	rs6543140	0.964	rs6543136	ENSG00000234389.1	AC007278.3	4.05	6.09e-05	0.00927	0.19	0.18	Blood protein levels;	chr2:102449087	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs6543138	ENSG00000234389.1	AC007278.3	4.05	6.09e-05	0.00927	0.19	0.18	Blood protein levels;	chr2:102449672	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs918000	ENSG00000234389.1	AC007278.3	4.05	6.09e-05	0.00927	0.19	0.18	Blood protein levels;	chr2:102451402	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.927	rs917999	ENSG00000234389.1	AC007278.3	4.05	6.09e-05	0.00927	0.19	0.18	Blood protein levels;	chr2:102451409	chr2:102438713~102440475:+
HNSC	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-4.05	6.09e-05	0.00927	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
HNSC	cis	rs4356203	0.87	rs603618	ENSG00000260196.1	RP1-239B22.5	-4.05	6.09e-05	0.00927	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs10832745	ENSG00000260196.1	RP1-239B22.5	-4.05	6.09e-05	0.00927	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.87	rs10832747	ENSG00000260196.1	RP1-239B22.5	-4.05	6.09e-05	0.00927	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17380649~17383531:+
HNSC	cis	rs544991	0.687	rs6661190	ENSG00000239670.1	RP4-803A2.2	-4.05	6.09e-05	0.00927	-0.23	-0.18	Intelligence;	chr1:33738088	chr1:32986952~32988233:+
HNSC	cis	rs28830936	1	rs28830936	ENSG00000250379.1	RP11-23P13.4	4.05	6.09e-05	0.00927	0.22	0.18	Diastolic blood pressure;	chr15:41614210	chr15:41825099~41827936:-
HNSC	cis	rs28830936	1	rs4923905	ENSG00000250379.1	RP11-23P13.4	4.05	6.09e-05	0.00927	0.22	0.18	Diastolic blood pressure;	chr15:41617691	chr15:41825099~41827936:-
HNSC	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-4.05	6.09e-05	0.00927	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-4.05	6.09e-05	0.00927	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-4.05	6.09e-05	0.00927	-0.18	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-4.05	6.09e-05	0.00927	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
HNSC	cis	rs7255436	0.965	rs4044435	ENSG00000269386.4	RAB11B-AS1	4.05	6.09e-05	0.00927	0.17	0.18	HDL cholesterol;	chr19:8383293	chr19:8374373~8390685:-
HNSC	cis	rs12047808	0.73	rs3738423	ENSG00000227141.2	RP11-545A16.3	-4.05	6.09e-05	0.00927	-0.29	-0.18	Multiple sclerosis (age of onset);	chr1:179564780	chr1:179586705~179589175:+
HNSC	cis	rs9531006	0.752	rs12853769	ENSG00000227676.3	LINC01068	4.05	6.09e-05	0.00927	0.27	0.18	Sleep duration;	chr13:79978955	chr13:79566727~79571436:+
HNSC	cis	rs1642645	0.606	rs638734	ENSG00000228452.1	RP5-994D16.9	-4.05	6.09e-05	0.00927	-0.26	-0.18	Left ventricular obstructive tract defect (maternal effect);	chr1:41994910	chr1:42775813~42776790:-
HNSC	cis	rs889398	0.741	rs4146819	ENSG00000196696.11	PDXDC2P	-4.05	6.1e-05	0.00928	-0.13	-0.18	Body mass index;	chr16:69889660	chr16:69976297~70065948:-
HNSC	cis	rs889398	0.741	rs7193038	ENSG00000196696.11	PDXDC2P	-4.05	6.1e-05	0.00928	-0.13	-0.18	Body mass index;	chr16:69892231	chr16:69976297~70065948:-
HNSC	cis	rs9926296	0.744	rs164747	ENSG00000274627.1	RP11-104N10.2	4.05	6.1e-05	0.00928	0.18	0.18	Vitiligo;	chr16:89642272	chr16:89516797~89522217:+
HNSC	cis	rs9859260	1	rs2239641	ENSG00000231464.1	AC024937.4	4.05	6.1e-05	0.00928	0.19	0.18	Mean corpuscular volume;	chr3:196062543	chr3:195996738~195998233:+
HNSC	cis	rs9859260	1	rs2239640	ENSG00000231464.1	AC024937.4	4.05	6.1e-05	0.00928	0.19	0.18	Mean corpuscular volume;	chr3:196062837	chr3:195996738~195998233:+
HNSC	cis	rs144691710	1	rs144691710	ENSG00000267340.1	RP11-242D8.3	-4.05	6.1e-05	0.00928	-0.39	-0.18	Total body bone mineral density;	chr17:43742194	chr17:43169880~43170077:-
HNSC	cis	rs897984	0.762	rs897986	ENSG00000279196.1	RP11-1072A3.3	-4.05	6.1e-05	0.00928	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30969581	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.721	rs28360557	ENSG00000279196.1	RP11-1072A3.3	-4.05	6.1e-05	0.00928	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30971939	chr16:30984630~30988270:-
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000211976.2	IGHV3-73	-4.05	6.1e-05	0.00928	-0.13	-0.18	Kawasaki disease;	chr14:106778539	chr14:106802694~106803233:-
HNSC	cis	rs516805	0.667	rs17729938	ENSG00000279453.1	RP3-425C14.4	4.05	6.1e-05	0.00928	0.24	0.18	Lymphocyte counts;	chr6:122340364	chr6:122436789~122439223:-
HNSC	cis	rs9914988	0.56	rs731970	ENSG00000264577.1	AC010761.8	4.05	6.1e-05	0.00929	0.18	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28939422	chr17:28721487~28722877:-
HNSC	cis	rs11098499	0.57	rs6832740	ENSG00000250412.1	KLHL2P1	4.05	6.11e-05	0.00929	0.24	0.18	Corneal astigmatism;	chr4:119624981	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.644	rs6855918	ENSG00000250412.1	KLHL2P1	4.05	6.11e-05	0.00929	0.24	0.18	Corneal astigmatism;	chr4:119625144	chr4:119334329~119378233:+
HNSC	cis	rs7819412	0.645	rs10156356	ENSG00000255310.2	AF131215.2	-4.05	6.11e-05	0.00929	-0.18	-0.18	Triglycerides;	chr8:11188700	chr8:11107788~11109726:-
HNSC	cis	rs2384207	0.524	rs13367	ENSG00000201208.1	Y_RNA	-4.05	6.11e-05	0.00929	-0.28	-0.18	Response to fenofibrate (adiponectin levels);	chr12:113298292	chr12:113178423~113178519:-
HNSC	cis	rs2384207	0.524	rs16934252	ENSG00000201208.1	Y_RNA	-4.05	6.11e-05	0.00929	-0.28	-0.18	Response to fenofibrate (adiponectin levels);	chr12:113298593	chr12:113178423~113178519:-
HNSC	cis	rs2384207	0.584	rs16934253	ENSG00000201208.1	Y_RNA	-4.05	6.11e-05	0.00929	-0.28	-0.18	Response to fenofibrate (adiponectin levels);	chr12:113299420	chr12:113178423~113178519:-
HNSC	cis	rs561341	1	rs72823785	ENSG00000278867.1	RP11-640N20.4	-4.05	6.11e-05	0.00929	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31946765	chr17:32051030~32053208:+
HNSC	cis	rs683257	0.636	rs72988149	ENSG00000234147.1	RP3-460G2.2	-4.05	6.11e-05	0.00929	-0.32	-0.18	Facial emotion recognition (angry faces);	chr6:140829500	chr6:140845958~140852924:-
HNSC	cis	rs11992162	0.591	rs35657308	ENSG00000227888.4	FAM66A	-4.05	6.11e-05	0.0093	-0.19	-0.18	Monocyte count;	chr8:11946893	chr8:12362019~12388296:+
HNSC	cis	rs1979679	0.842	rs11049380	ENSG00000247934.4	RP11-967K21.1	-4.05	6.11e-05	0.0093	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28163298~28190738:-
HNSC	cis	rs8028182	0.636	rs28783769	ENSG00000260269.4	CTD-2323K18.1	-4.05	6.11e-05	0.0093	-0.24	-0.18	Sudden cardiac arrest;	chr15:75556668	chr15:75527150~75601205:-
HNSC	cis	rs4144743	1	rs11871407	ENSG00000228782.6	CTD-2026D20.3	-4.05	6.11e-05	0.0093	-0.22	-0.18	Body mass index;	chr17:47253992	chr17:47450568~47492492:-
HNSC	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-4.05	6.12e-05	0.0093	-0.19	-0.18	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
HNSC	cis	rs9611565	0.649	rs5758434	ENSG00000233903.2	Z83851.4	4.05	6.12e-05	0.0093	0.25	0.18	Vitiligo;	chr22:41720159	chr22:42276355~42277052:+
HNSC	cis	rs988913	0.957	rs72645372	ENSG00000224984.1	RP11-524H19.2	4.05	6.12e-05	0.0093	0.21	0.18	Menarche (age at onset);	chr6:54924024	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.957	rs12525787	ENSG00000224984.1	RP11-524H19.2	4.05	6.12e-05	0.0093	0.21	0.18	Menarche (age at onset);	chr6:54924274	chr6:54840118~54840855:-
HNSC	cis	rs7829975	0.564	rs2976855	ENSG00000233609.3	RP11-62H7.2	4.05	6.12e-05	0.0093	0.18	0.18	Mood instability;	chr8:8444284	chr8:8961200~8979025:+
HNSC	cis	rs11239930	0.934	rs10900313	ENSG00000230832.3	RP11-325P15.2	-4.05	6.12e-05	0.0093	-0.2	-0.18	AIDS progression;	chr1:147089200	chr1:147082338~147083578:-
HNSC	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-4.05	6.12e-05	0.0093	-0.22	-0.18	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
HNSC	cis	rs10789207	0.531	rs7545674	ENSG00000248458.2	RP4-598P13.1	4.05	6.12e-05	0.00931	0.27	0.18	Resting heart rate;	chr1:66648034	chr1:66665864~66677027:-
HNSC	cis	rs6504108	0.624	rs11079814	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48191077	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.602	rs11872095	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48193810	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs12452956	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48196575	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs8075270	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48197648	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs8072282	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48199496	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs8069064	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48203301	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs4794505	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48205944	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.647	rs12150533	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48210179	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.624	rs17620033	ENSG00000278765.1	RP5-890E16.5	-4.05	6.12e-05	0.00931	-0.23	-0.18	Body mass index;	chr17:48214052	chr17:48066704~48067293:-
HNSC	cis	rs7829975	0.502	rs11785183	ENSG00000253893.2	FAM85B	4.05	6.12e-05	0.00931	0.24	0.18	Mood instability;	chr8:8708447	chr8:8167819~8226614:-
HNSC	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	4.05	6.12e-05	0.00931	0.22	0.18	Height;	chr14:75143467	chr14:75011269~75012851:-
HNSC	cis	rs9313772	0.775	rs1958605	ENSG00000254350.1	RP11-542A14.1	4.05	6.12e-05	0.00931	0.2	0.18	Blood pressure;	chr5:158386865	chr5:158424585~158452758:+
HNSC	cis	rs12893668	0.703	rs4906337	ENSG00000269958.1	RP11-73M18.8	4.04	6.12e-05	0.00931	0.17	0.18	Reticulocyte count;	chr14:103574077	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.703	rs7140568	ENSG00000269958.1	RP11-73M18.8	4.04	6.12e-05	0.00931	0.17	0.18	Reticulocyte count;	chr14:103575037	chr14:103696353~103697163:+
HNSC	cis	rs6831352	0.819	rs1230158	ENSG00000263923.1	RP11-571L19.7	-4.04	6.12e-05	0.00931	-0.19	-0.18	Alcohol dependence;	chr4:99069035	chr4:98928897~98994994:+
HNSC	cis	rs61270009	0.955	rs10214154	ENSG00000247828.6	TMEM161B-AS1	-4.04	6.13e-05	0.00932	-0.18	-0.18	Depressive symptoms;	chr5:88249502	chr5:88268895~88436685:+
HNSC	cis	rs929354	0.772	rs10229630	ENSG00000224629.1	RP5-1142J19.2	-4.04	6.13e-05	0.00932	-0.18	-0.18	Body mass index;	chr7:157212096	chr7:157263022~157263229:-
HNSC	cis	rs2762353	0.808	rs1747522	ENSG00000272462.2	U91328.19	-4.04	6.13e-05	0.00932	-0.18	-0.18	Blood metabolite levels;	chr6:25821579	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.779	rs3799352	ENSG00000272462.2	U91328.19	-4.04	6.13e-05	0.00932	-0.18	-0.18	Blood metabolite levels;	chr6:25822392	chr6:25992662~26001775:+
HNSC	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-4.04	6.13e-05	0.00932	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
HNSC	cis	rs62246343	0.605	rs34665459	ENSG00000206573.7	THUMPD3-AS1	-4.04	6.13e-05	0.00932	-0.16	-0.18	Fibrinogen levels;	chr3:9423041	chr3:9349689~9398579:-
HNSC	cis	rs7927592	0.913	rs6591346	ENSG00000255031.4	RP11-802E16.3	4.04	6.13e-05	0.00932	0.16	0.18	Total body bone mineral density;	chr11:68617150	chr11:68050740~68053762:+
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000254340.1	RP11-10A14.3	-4.04	6.13e-05	0.00932	-0.24	-0.18	Neuroticism;	chr8:8504313	chr8:9141424~9145435:+
HNSC	cis	rs7824557	0.564	rs2572394	ENSG00000255310.2	AF131215.2	-4.04	6.13e-05	0.00932	-0.17	-0.18	Retinal vascular caliber;	chr8:11377884	chr8:11107788~11109726:-
HNSC	cis	rs1316952	0.831	rs78156958	ENSG00000269938.1	RP11-214K3.20	-4.04	6.13e-05	0.00932	-0.39	-0.18	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123956899	chr12:123968023~123968579:-
HNSC	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	4.04	6.13e-05	0.00932	0.17	0.18	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
HNSC	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	4.04	6.13e-05	0.00932	0.2	0.18	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
HNSC	cis	rs9422860	0.831	rs11596972	ENSG00000236991.5	EDRF1-AS1	4.04	6.13e-05	0.00932	0.26	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr10:125218251	chr10:125725634~125752110:-
HNSC	cis	rs72827839	0.615	rs72827864	ENSG00000244649.3	CTD-2377D24.6	-4.04	6.13e-05	0.00932	-0.24	-0.18	Ease of getting up in the morning;	chr17:48415516	chr17:48646923~48707346:+
HNSC	cis	rs72827839	0.779	rs59386258	ENSG00000244649.3	CTD-2377D24.6	-4.04	6.13e-05	0.00932	-0.24	-0.18	Ease of getting up in the morning;	chr17:48422556	chr17:48646923~48707346:+
HNSC	cis	rs12999542	0.636	rs17821875	ENSG00000234389.1	AC007278.3	4.04	6.13e-05	0.00932	0.31	0.18	Serum protein levels (sST2);	chr2:102454570	chr2:102438713~102440475:+
HNSC	cis	rs2439831	0.85	rs10438303	ENSG00000201136.1	RNU6-353P	-4.04	6.13e-05	0.00933	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43724219	chr15:43702363~43702470:+
HNSC	cis	rs9611565	0.659	rs4822035	ENSG00000235513.1	RP4-756G23.5	-4.04	6.13e-05	0.00933	-0.22	-0.18	Vitiligo;	chr22:41539908	chr22:41209122~41217627:-
HNSC	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	4.04	6.14e-05	0.00933	0.26	0.18	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
HNSC	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	4.04	6.14e-05	0.00933	0.21	0.18	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
HNSC	cis	rs1979679	0.918	rs7977429	ENSG00000247934.4	RP11-967K21.1	-4.04	6.14e-05	0.00933	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28163298~28190738:-
HNSC	cis	rs4906332	1	rs11541718	ENSG00000244691.1	RPL10AP1	-4.04	6.14e-05	0.00933	-0.22	-0.18	Coronary artery disease;	chr14:103385827	chr14:103412119~103412761:-
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000211976.2	IGHV3-73	-4.04	6.14e-05	0.00933	-0.13	-0.18	Kawasaki disease;	chr14:106779186	chr14:106802694~106803233:-
HNSC	cis	rs5758659	0.569	rs133294	ENSG00000227370.1	RP4-669P10.19	-4.04	6.14e-05	0.00933	-0.18	-0.18	Cognitive function;	chr22:41986801	chr22:42132543~42132998:+
HNSC	cis	rs240993	0.812	rs9387012	ENSG00000230177.1	RP5-1112D6.4	4.04	6.14e-05	0.00934	0.23	0.18	Inflammatory skin disease;Psoriasis;	chr6:111465824	chr6:111277932~111278742:+
HNSC	cis	rs739496	0.579	rs57046217	ENSG00000226469.1	ADAM1B	4.04	6.14e-05	0.00934	0.21	0.18	Platelet count;	chr12:111847312	chr12:111927018~111929017:+
HNSC	cis	rs2518049	0.904	rs4881395	ENSG00000224034.1	RP11-445P17.8	4.04	6.14e-05	0.00934	0.25	0.18	Metabolic traits;	chr10:5077790	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.904	rs11252922	ENSG00000224034.1	RP11-445P17.8	4.04	6.14e-05	0.00934	0.25	0.18	Metabolic traits;	chr10:5078522	chr10:5266033~5271236:-
HNSC	cis	rs4218	0.543	rs11852461	ENSG00000277144.1	RP11-59H7.4	-4.04	6.15e-05	0.00934	-0.23	-0.18	Social communication problems;	chr15:59021728	chr15:59115547~59116089:-
HNSC	cis	rs889398	0.933	rs244418	ENSG00000226232.7	RP11-419C5.2	4.04	6.15e-05	0.00934	0.16	0.18	Body mass index;	chr16:69588859	chr16:69976388~69996188:-
HNSC	cis	rs9329221	0.621	rs12156350	ENSG00000255310.2	AF131215.2	-4.04	6.15e-05	0.00934	-0.17	-0.18	Neuroticism;	chr8:10411006	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.82	rs13128602	ENSG00000250412.1	KLHL2P1	-4.04	6.15e-05	0.00934	-0.24	-0.18	Corneal astigmatism;	chr4:119538211	chr4:119334329~119378233:+
HNSC	cis	rs2865126	0.644	rs5024299	ENSG00000264714.1	RP11-21G15.1	-4.04	6.15e-05	0.00935	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10741013	chr18:10724619~10728539:+
HNSC	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-4.04	6.15e-05	0.00935	-0.28	-0.18	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
HNSC	cis	rs7027203	0.557	rs2487023	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93747661	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2487021	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93748018	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2263354	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93748791	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.538	rs2265570	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93749887	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2265569	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93750223	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2265568	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93750816	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.514	rs2487018	ENSG00000227603.1	RP11-165J3.6	-4.04	6.15e-05	0.00935	-0.16	-0.18	DNA methylation (variation);	chr9:93751637	chr9:93435332~93437121:-
HNSC	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-4.04	6.15e-05	0.00935	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
HNSC	cis	rs1015213	0.609	rs117144627	ENSG00000272024.1	RP11-546K22.3	-4.04	6.16e-05	0.00936	-0.41	-0.18	Glaucoma (primary angle closure);	chr8:51910597	chr8:51950284~51950690:+
HNSC	cis	rs6928977	0.897	rs6570001	ENSG00000217482.2	HMGB1P17	-4.04	6.16e-05	0.00936	-0.21	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135330583	chr6:135636086~135636713:-
HNSC	cis	rs11157436	0.602	rs2075493	ENSG00000211814.1	TRAV35	-4.04	6.16e-05	0.00936	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22221896~22222475:+
HNSC	cis	rs17189998	0.73	rs16938461	ENSG00000253636.1	RP11-531A24.5	4.04	6.17e-05	0.00937	0.27	0.18	Colonoscopy-negative controls vs population controls;	chr8:72882234	chr8:73052178~73063061:+
HNSC	cis	rs7824557	0.578	rs2060458	ENSG00000269918.1	AF131215.9	4.04	6.17e-05	0.00937	0.18	0.18	Retinal vascular caliber;	chr8:11355302	chr8:11104691~11106704:-
HNSC	cis	rs11148252	0.904	rs9568732	ENSG00000198384.8	TPTE2P3	-4.04	6.17e-05	0.00937	-0.22	-0.18	Lewy body disease;	chr13:52419277	chr13:52522632~52586906:+
HNSC	cis	rs1602565	0.858	rs1337615	ENSG00000255450.1	CTD-2063L20.1	-4.04	6.17e-05	0.00937	-0.28	-0.18	Schizophrenia;	chr11:29159748	chr11:29275655~29276565:+
HNSC	cis	rs801193	0.742	rs9969300	ENSG00000273142.1	RP11-458F8.4	4.04	6.17e-05	0.00937	0.16	0.18	Aortic root size;	chr7:66316659	chr7:66902857~66906297:+
HNSC	cis	rs5758511	0.514	rs5758626	ENSG00000227370.1	RP4-669P10.19	4.04	6.17e-05	0.00937	0.23	0.18	Birth weight;	chr22:42176357	chr22:42132543~42132998:+
HNSC	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	4.04	6.17e-05	0.00937	0.4	0.18	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
HNSC	cis	rs700651	0.786	rs58224025	ENSG00000231621.1	AC013264.2	-4.04	6.17e-05	0.00937	-0.18	-0.18	Intracranial aneurysm;	chr2:197957264	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs13408411	ENSG00000231621.1	AC013264.2	-4.04	6.17e-05	0.00937	-0.18	-0.18	Dermatomyositis;	chr2:197960738	chr2:197197991~197199273:+
HNSC	cis	rs700651	0.752	rs1850631	ENSG00000231621.1	AC013264.2	-4.04	6.17e-05	0.00937	-0.18	-0.18	Intracranial aneurysm;	chr2:197964744	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs1356542	ENSG00000231621.1	AC013264.2	-4.04	6.17e-05	0.00937	-0.18	-0.18	Dermatomyositis;	chr2:197970978	chr2:197197991~197199273:+
HNSC	cis	rs7688540	0.515	rs28415975	ENSG00000250892.1	RP11-1365D11.1	-4.04	6.17e-05	0.00937	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:201409~205009:-
HNSC	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-4.04	6.17e-05	0.00938	-0.21	-0.18	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
HNSC	cis	rs453301	0.686	rs1045527	ENSG00000253981.4	ALG1L13P	-4.04	6.17e-05	0.00938	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9032531	chr8:8236003~8244667:-
HNSC	cis	rs679515	1	rs679515	ENSG00000274245.1	RP11-357P18.2	-4.04	6.18e-05	0.00938	-0.32	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr1:207577223	chr1:207372559~207373252:+
HNSC	cis	rs7027203	0.514	rs2265806	ENSG00000227603.1	RP11-165J3.6	-4.04	6.18e-05	0.00939	-0.16	-0.18	DNA methylation (variation);	chr9:93744621	chr9:93435332~93437121:-
HNSC	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-4.04	6.18e-05	0.00939	-0.23	-0.18	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
HNSC	cis	rs2898290	0.622	rs11250140	ENSG00000269918.1	AF131215.9	-4.04	6.18e-05	0.00939	-0.18	-0.18	Systolic blood pressure;	chr8:11489083	chr8:11104691~11106704:-
HNSC	cis	rs4356203	0.87	rs10832746	ENSG00000260196.1	RP1-239B22.5	-4.04	6.18e-05	0.00939	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17380649~17383531:+
HNSC	cis	rs859767	0.741	rs883964	ENSG00000224043.6	CCNT2-AS1	4.04	6.18e-05	0.00939	0.22	0.18	Neuroticism;	chr2:134678630	chr2:134735464~134918710:-
HNSC	cis	rs853679	1	rs1679732	ENSG00000226314.6	ZNF192P1	4.04	6.18e-05	0.00939	0.26	0.18	Depression;	chr6:28253486	chr6:28161781~28169594:+
HNSC	cis	rs1585471	0.931	rs10034228	ENSG00000249532.3	RP11-148B6.1	-4.04	6.18e-05	0.00939	-0.22	-0.18	Myopia (pathological);	chr4:111690594	chr4:112646476~112650051:-
HNSC	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-4.04	6.18e-05	0.00939	-0.25	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000272831.1	RP11-792A8.4	4.04	6.18e-05	0.00939	0.15	0.18	Aortic root size;	chr7:66771620	chr7:66739829~66740385:-
HNSC	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	4.04	6.19e-05	0.00939	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
HNSC	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-4.04	6.19e-05	0.00939	-0.17	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
HNSC	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-4.04	6.19e-05	0.00939	-0.22	-0.18	Height;	chr14:75195278	chr14:75011269~75012851:-
HNSC	cis	rs8007643	1	rs8007643	ENSG00000211778.2	TRAV4	4.04	6.19e-05	0.00939	0.23	0.18	Nose morphology;	chr14:20897642	chr14:21736152~21736982:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000224373.3	IGHV4-59	4.04	6.19e-05	0.0094	0.11	0.18	Kawasaki disease;	chr14:106776119	chr14:106627249~106627825:-
HNSC	cis	rs12468226	0.689	rs60584169	ENSG00000226261.1	AC064836.3	4.04	6.19e-05	0.0094	0.27	0.18	Urate levels;	chr2:202111695	chr2:202336024~202336727:-
HNSC	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-4.04	6.19e-05	0.0094	-0.22	-0.18	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
HNSC	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	4.04	6.19e-05	0.0094	0.19	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
HNSC	cis	rs6840258	1	rs56390363	ENSG00000251411.1	RP11-397E7.4	-4.04	6.19e-05	0.0094	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87021935	chr4:86913266~86914817:-
HNSC	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	4.04	6.19e-05	0.0094	0.18	0.18	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
HNSC	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	4.04	6.19e-05	0.0094	0.18	0.18	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
HNSC	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	4.04	6.19e-05	0.0094	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
HNSC	cis	rs853679	0.546	rs35017208	ENSG00000204709.4	LINC01556	4.04	6.19e-05	0.0094	0.39	0.18	Depression;	chr6:28377505	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs36092177	ENSG00000204709.4	LINC01556	4.04	6.19e-05	0.0094	0.39	0.18	Depression;	chr6:28390030	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs2232429	ENSG00000204709.4	LINC01556	4.04	6.19e-05	0.0094	0.39	0.18	Depression;	chr6:28391855	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs2232426	ENSG00000204709.4	LINC01556	4.04	6.19e-05	0.0094	0.39	0.18	Depression;	chr6:28392882	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs2232423	ENSG00000204709.4	LINC01556	4.04	6.19e-05	0.0094	0.39	0.18	Depression;	chr6:28398374	chr6:28943877~28944537:+
HNSC	cis	rs35306767	0.714	rs10508206	ENSG00000229869.1	RP11-363N22.2	-4.04	6.2e-05	0.00941	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1029837	chr10:933026~942743:+
HNSC	cis	rs7735319	0.932	rs11532635	ENSG00000251281.1	CTD-2066L21.2	4.04	6.2e-05	0.00941	0.22	0.18	Systolic blood pressure;	chr5:33095140	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.933	rs7708185	ENSG00000251281.1	CTD-2066L21.2	4.04	6.2e-05	0.00941	0.22	0.18	Systolic blood pressure;	chr5:33104477	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs62367969	ENSG00000251281.1	CTD-2066L21.2	4.04	6.2e-05	0.00941	0.22	0.18	Systolic blood pressure;	chr5:33105461	chr5:33011322~33017607:-
HNSC	cis	rs4356203	0.905	rs7946165	ENSG00000260196.1	RP1-239B22.5	-4.04	6.2e-05	0.00941	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17380649~17383531:+
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	4.04	6.2e-05	0.00941	0.31	0.18	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
HNSC	cis	rs875971	0.789	rs28815324	ENSG00000164669.11	INTS4P1	4.04	6.2e-05	0.00941	0.27	0.18	Aortic root size;	chr7:66100789	chr7:65141225~65234216:+
HNSC	cis	rs1620921	0.657	rs7383738	ENSG00000231863.1	RP3-428L16.1	-4.04	6.2e-05	0.00941	-0.22	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855015	chr6:160931080~160969771:+
HNSC	cis	rs7572733	0.84	rs13029495	ENSG00000222017.1	AC011997.1	-4.04	6.2e-05	0.00941	-0.22	-0.18	Dermatomyositis;	chr2:197717877	chr2:197693106~197774823:+
HNSC	cis	rs11893307	0.851	rs62182472	ENSG00000228509.4	AC006460.2	4.04	6.2e-05	0.00941	0.26	0.18	Mean platelet volume;	chr2:190868102	chr2:190676944~190708716:-
HNSC	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-4.04	6.2e-05	0.00941	-0.26	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
HNSC	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-4.04	6.2e-05	0.00942	-0.21	-0.18	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
HNSC	cis	rs6490294	0.571	rs57168159	ENSG00000226469.1	ADAM1B	4.04	6.21e-05	0.00942	0.27	0.18	Mean platelet volume;	chr12:112189041	chr12:111927018~111929017:+
HNSC	cis	rs442309	0.812	rs224090	ENSG00000238280.1	RP11-436D10.3	4.04	6.21e-05	0.00942	0.22	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62781559	chr10:62793562~62805887:-
HNSC	cis	rs2055729	0.645	rs6989793	ENSG00000254340.1	RP11-10A14.3	-4.04	6.21e-05	0.00942	-0.27	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9887140	chr8:9141424~9145435:+
HNSC	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	4.04	6.21e-05	0.00942	0.18	0.18	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
HNSC	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	4.04	6.21e-05	0.00942	0.25	0.18	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
HNSC	cis	rs5758659	0.652	rs133349	ENSG00000270083.1	RP1-257I20.14	4.04	6.21e-05	0.00942	0.17	0.18	Cognitive function;	chr22:42032723	chr22:42089630~42090028:-
HNSC	cis	rs6657613	0.68	rs7536679	ENSG00000186715.9	MST1L	4.04	6.21e-05	0.00942	0.15	0.18	Hip circumference adjusted for BMI;	chr1:17048168	chr1:16754910~16770237:-
HNSC	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-4.04	6.21e-05	0.00943	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
HNSC	cis	rs6601327	0.6	rs10103925	ENSG00000233609.3	RP11-62H7.2	-4.04	6.21e-05	0.00943	-0.18	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9794701	chr8:8961200~8979025:+
HNSC	cis	rs10791097	0.694	rs3190331	ENSG00000254842.5	RP11-890B15.2	4.04	6.22e-05	0.00943	0.16	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130878236	chr11:130844191~130865561:-
HNSC	cis	rs2439831	1	rs2254321	ENSG00000275601.1	AC011330.13	-4.04	6.22e-05	0.00943	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43415344	chr15:43642389~43643023:-
HNSC	cis	rs12545109	0.8	rs1440747	ENSG00000246430.5	LINC00968	4.04	6.22e-05	0.00944	0.23	0.18	Obesity-related traits;	chr8:56505365	chr8:56496246~56559823:-
HNSC	cis	rs6787172	0.811	rs9859129	ENSG00000272087.1	RP11-379F4.7	4.04	6.22e-05	0.00944	0.19	0.18	Subjective well-being;	chr3:158506005	chr3:158693120~158693768:-
HNSC	cis	rs2836974	0.897	rs8132295	ENSG00000255568.3	BRWD1-AS2	-4.04	6.22e-05	0.00944	-0.16	-0.18	Cognitive function;	chr21:39155848	chr21:39313935~39314962:+
HNSC	cis	rs1008375	0.932	rs6814465	ENSG00000249502.1	AC006160.5	-4.04	6.23e-05	0.00944	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657411	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.932	rs6844593	ENSG00000249502.1	AC006160.5	-4.04	6.23e-05	0.00944	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657416	chr4:17587467~17614571:-
HNSC	cis	rs2243480	1	rs1618893	ENSG00000229886.1	RP5-1132H15.3	4.04	6.23e-05	0.00944	0.29	0.18	Diabetic kidney disease;	chr7:66631132	chr7:66025126~66031544:-
HNSC	cis	rs6012564	0.963	rs6125551	ENSG00000227431.4	CSE1L-AS1	-4.04	6.23e-05	0.00945	-0.21	-0.18	Anger;	chr20:49103849	chr20:49040463~49046044:-
HNSC	cis	rs10129255	0.5	rs10131875	ENSG00000211976.2	IGHV3-73	-4.04	6.23e-05	0.00945	-0.13	-0.18	Kawasaki disease;	chr14:106792798	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs11628999	ENSG00000211976.2	IGHV3-73	-4.04	6.23e-05	0.00945	-0.13	-0.18	Kawasaki disease;	chr14:106800208	chr14:106802694~106803233:-
HNSC	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-4.04	6.23e-05	0.00945	-0.23	-0.18	Height;	chr20:49254660	chr20:49280319~49280409:+
HNSC	cis	rs1538970	0.739	rs4660863	ENSG00000234329.1	RP11-767N6.2	4.04	6.23e-05	0.00945	0.22	0.18	Platelet count;	chr1:45490196	chr1:45651039~45651826:-
HNSC	cis	rs2136613	0.533	rs1412554	ENSG00000238280.1	RP11-436D10.3	4.04	6.23e-05	0.00945	0.21	0.18	Selective IgA deficiency;	chr10:62850180	chr10:62793562~62805887:-
HNSC	cis	rs2209875	0.64	rs1303776	ENSG00000224945.1	RP11-82L18.2	4.04	6.23e-05	0.00946	0.25	0.18	Pelvic organ prolapse (moderate/severe);	chr9:89141290	chr9:89088604~89109934:-
HNSC	cis	rs889398	0.741	rs8049373	ENSG00000196696.11	PDXDC2P	-4.04	6.24e-05	0.00946	-0.13	-0.18	Body mass index;	chr16:69905802	chr16:69976297~70065948:-
HNSC	cis	rs9611565	0.694	rs5751107	ENSG00000235513.1	RP4-756G23.5	-4.04	6.24e-05	0.00946	-0.23	-0.18	Vitiligo;	chr22:41461808	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.649	rs5751108	ENSG00000235513.1	RP4-756G23.5	-4.04	6.24e-05	0.00946	-0.23	-0.18	Vitiligo;	chr22:41462031	chr22:41209122~41217627:-
HNSC	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-4.04	6.24e-05	0.00946	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
HNSC	cis	rs1665050	0.534	rs56402153	ENSG00000259732.1	RP11-59H7.3	-4.04	6.24e-05	0.00946	-0.24	-0.18	Atopic dermatitis;	chr15:58941113	chr15:59121034~59133250:+
HNSC	cis	rs865483	0.86	rs853220	ENSG00000276054.1	RP11-378E13.3	4.04	6.24e-05	0.00946	0.22	0.18	Monocyte count;	chr17:37427567	chr17:37386886~37387926:+
HNSC	cis	rs4073405	0.92	rs12791607	ENSG00000254651.1	RP11-430H10.3	4.04	6.24e-05	0.00947	0.23	0.18	Schizophrenia;	chr11:45298860	chr11:45399448~45400528:+
HNSC	cis	rs7927592	0.763	rs2513277	ENSG00000255031.4	RP11-802E16.3	4.04	6.24e-05	0.00947	0.15	0.18	Total body bone mineral density;	chr11:68593419	chr11:68050740~68053762:+
HNSC	cis	rs3736485	0.932	rs4775946	ENSG00000259438.1	CTD-2650P22.1	4.04	6.24e-05	0.00947	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51483733	chr15:52010999~52019095:-
HNSC	cis	rs4489787	1	rs4489787	ENSG00000240399.1	RP1-228P16.1	4.04	6.25e-05	0.00947	0.26	0.18	Prostate cancer (SNP x SNP interaction);	chr12:48417317	chr12:48054813~48055591:-
HNSC	cis	rs442309	0.875	rs224055	ENSG00000238280.1	RP11-436D10.3	-4.04	6.25e-05	0.00947	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62737110	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.875	rs224056	ENSG00000238280.1	RP11-436D10.3	-4.04	6.25e-05	0.00947	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62737240	chr10:62793562~62805887:-
HNSC	cis	rs9733	0.744	rs11204737	ENSG00000236713.1	RP11-363I22.3	4.04	6.25e-05	0.00947	0.2	0.18	Tonsillectomy;	chr1:150875171	chr1:150780272~150780644:+
HNSC	cis	rs9467773	0.609	rs12663780	ENSG00000241549.7	GUSBP2	4.04	6.25e-05	0.00947	0.18	0.18	Intelligence (multi-trait analysis);	chr6:26397345	chr6:26871484~26956554:-
HNSC	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	4.04	6.25e-05	0.00947	0.19	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
HNSC	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	4.04	6.25e-05	0.00948	0.23	0.18	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
HNSC	cis	rs1979679	0.918	rs1257741	ENSG00000247934.4	RP11-967K21.1	-4.04	6.25e-05	0.00948	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28163298~28190738:-
HNSC	cis	rs10492201	0.529	rs10878724	ENSG00000255733.4	IFNG-AS1	-4.04	6.26e-05	0.00948	-0.17	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006091	chr12:67989445~68234686:+
HNSC	cis	rs6504108	0.624	rs3792694	ENSG00000278765.1	RP5-890E16.5	4.04	6.26e-05	0.00948	0.23	0.18	Body mass index;	chr17:48183080	chr17:48066704~48067293:-
HNSC	cis	rs2548724	0.716	rs10515326	ENSG00000250682.4	LINC00491	4.04	6.26e-05	0.00948	0.23	0.18	Type 2 diabetes;	chr5:102478044	chr5:102609156~102671559:-
HNSC	cis	rs860295	0.665	rs12079134	ENSG00000225855.5	RUSC1-AS1	4.04	6.26e-05	0.00948	0.12	0.18	Body mass index;	chr1:155496993	chr1:155316863~155324176:-
HNSC	cis	rs1941023	0.677	rs4939383	ENSG00000279632.1	RP11-286N22.6	4.04	6.26e-05	0.00948	0.2	0.18	Congenital heart disease (maternal effect);	chr11:60504901	chr11:61426448~61427325:-
HNSC	cis	rs6723108	0.664	rs6741007	ENSG00000224043.6	CCNT2-AS1	-4.04	6.26e-05	0.00948	-0.23	-0.18	Type 2 diabetes;	chr2:134779549	chr2:134735464~134918710:-
HNSC	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	4.04	6.26e-05	0.00949	0.16	0.18	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
HNSC	cis	rs10462794	0.686	rs2060701	ENSG00000260763.1	RP11-445O3.3	-4.04	6.26e-05	0.00949	-0.23	-0.18	DNA methylation (variation);	chr5:4503401	chr5:4436850~4440259:-
HNSC	cis	rs924607	1	rs2455331	ENSG00000225138.6	CTD-2228K2.7	4.04	6.26e-05	0.00949	0.2	0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:643478	chr5:473236~480884:+
HNSC	cis	rs73201462	1	rs73201462	ENSG00000231305.3	RP11-723O4.2	-4.04	6.26e-05	0.0095	-0.27	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128340450	chr3:128861313~128871540:-
HNSC	cis	rs889398	0.56	rs4985445	ENSG00000226232.7	RP11-419C5.2	-4.04	6.27e-05	0.0095	-0.16	-0.18	Body mass index;	chr16:69833932	chr16:69976388~69996188:-
HNSC	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	4.04	6.27e-05	0.00951	0.21	0.18	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000229886.1	RP5-1132H15.3	-4.04	6.27e-05	0.00951	-0.31	-0.18	Diabetic kidney disease;	chr7:66189722	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2420170	ENSG00000229886.1	RP5-1132H15.3	-4.04	6.27e-05	0.00951	-0.31	-0.18	Diabetic kidney disease;	chr7:66191066	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6958289	ENSG00000229886.1	RP5-1132H15.3	-4.04	6.27e-05	0.00951	-0.31	-0.18	Diabetic kidney disease;	chr7:66192124	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7804223	ENSG00000229886.1	RP5-1132H15.3	-4.04	6.27e-05	0.00951	-0.31	-0.18	Diabetic kidney disease;	chr7:66199572	chr7:66025126~66031544:-
HNSC	cis	rs6095360	0.934	rs2295578	ENSG00000222365.1	SNORD12B	-4.04	6.28e-05	0.00951	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49010064	chr20:49280319~49280409:+
HNSC	cis	rs2898290	0.593	rs1600252	ENSG00000269918.1	AF131215.9	-4.04	6.28e-05	0.00951	-0.18	-0.18	Systolic blood pressure;	chr8:11488135	chr8:11104691~11106704:-
HNSC	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-4.04	6.28e-05	0.00951	-0.19	-0.18	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
HNSC	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.04	6.28e-05	0.00951	-0.22	-0.18	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
HNSC	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	4.04	6.28e-05	0.00951	0.26	0.18	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
HNSC	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-4.04	6.28e-05	0.00951	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
HNSC	cis	rs700651	0.789	rs882954	ENSG00000231621.1	AC013264.2	-4.04	6.28e-05	0.00951	-0.18	-0.18	Intracranial aneurysm;	chr2:198042720	chr2:197197991~197199273:+
HNSC	cis	rs9583531	0.527	rs12875067	ENSG00000259831.1	LINC00567	4.04	6.28e-05	0.00951	0.21	0.18	Coronary artery disease;	chr13:110712757	chr13:110809676~110813084:-
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000250412.1	KLHL2P1	4.04	6.28e-05	0.00952	0.23	0.18	Educational attainment;	chr4:119335313	chr4:119334329~119378233:+
HNSC	cis	rs79349575	0.749	rs1057902	ENSG00000270781.1	RP11-501C14.9	-4.04	6.28e-05	0.00952	-0.19	-0.18	Type 2 diabetes;	chr17:48928226	chr17:48899131~48899748:+
HNSC	cis	rs11951515	0.7	rs12520012	ENSG00000249286.1	CTD-2210P15.2	4.04	6.28e-05	0.00952	0.19	0.18	Metabolite levels  (X-11787);	chr5:43296063	chr5:43586918~43588223:-
HNSC	cis	rs3736485	0.966	rs4775944	ENSG00000259438.1	CTD-2650P22.1	4.04	6.28e-05	0.00952	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51483413	chr15:52010999~52019095:-
HNSC	cis	rs76076331	0.887	rs13387062	ENSG00000234818.1	AC092687.5	4.04	6.29e-05	0.00952	0.27	0.18	Educational attainment (college completion);Educational attainment (years of education);	chr2:10846989	chr2:10589166~10604830:+
HNSC	cis	rs6964587	0.677	rs62467839	ENSG00000188693.7	CYP51A1-AS1	-4.04	6.29e-05	0.00952	-0.2	-0.18	Breast cancer;	chr7:92338057	chr7:92134604~92180725:+
HNSC	cis	rs853679	1	rs853679	ENSG00000204709.4	LINC01556	4.04	6.29e-05	0.00952	0.28	0.18	Depression;	chr6:28329086	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs853678	ENSG00000204709.4	LINC01556	4.04	6.29e-05	0.00952	0.28	0.18	Depression;	chr6:28329536	chr6:28943877~28944537:+
HNSC	cis	rs11098499	0.754	rs11732087	ENSG00000250412.1	KLHL2P1	4.04	6.29e-05	0.00952	0.24	0.18	Corneal astigmatism;	chr4:119318676	chr4:119334329~119378233:+
HNSC	cis	rs9313772	0.928	rs1958603	ENSG00000254350.1	RP11-542A14.1	-4.04	6.29e-05	0.00952	-0.21	-0.18	Blood pressure;	chr5:158395106	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.928	rs7700842	ENSG00000254350.1	RP11-542A14.1	-4.04	6.29e-05	0.00952	-0.21	-0.18	Blood pressure;	chr5:158397175	chr5:158424585~158452758:+
HNSC	cis	rs6964587	0.626	rs9008	ENSG00000188693.7	CYP51A1-AS1	4.04	6.29e-05	0.00953	0.2	0.18	Breast cancer;	chr7:91873093	chr7:92134604~92180725:+
HNSC	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.04	6.29e-05	0.00953	-0.22	-0.18	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
HNSC	cis	rs853679	0.517	rs17711344	ENSG00000219891.2	ZSCAN12P1	-4.04	6.29e-05	0.00953	-0.26	-0.18	Depression;	chr6:28109824	chr6:28091154~28093664:+
HNSC	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	4.04	6.29e-05	0.00953	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
HNSC	cis	rs6964587	1	rs4644173	ENSG00000188693.7	CYP51A1-AS1	-4.04	6.29e-05	0.00953	-0.19	-0.18	Breast cancer;	chr7:92130283	chr7:92134604~92180725:+
HNSC	cis	rs2048656	0.605	rs11989726	ENSG00000254340.1	RP11-10A14.3	4.04	6.29e-05	0.00953	0.24	0.18	Schizophrenia;	chr8:9791177	chr8:9141424~9145435:+
HNSC	cis	rs12935418	0.672	rs9938541	ENSG00000278985.1	RP11-303E16.9	4.04	6.29e-05	0.00953	0.19	0.18	Mean corpuscular volume;	chr16:81011623	chr16:80982319~80984094:-
HNSC	cis	rs2762353	0.779	rs1165182	ENSG00000272462.2	U91328.19	-4.04	6.3e-05	0.00954	-0.18	-0.18	Blood metabolite levels;	chr6:25837601	chr6:25992662~26001775:+
HNSC	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-4.04	6.3e-05	0.00954	-0.24	-0.18	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
HNSC	cis	rs7726839	0.555	rs4541696	ENSG00000271781.1	CTD-2589H19.6	-4.04	6.3e-05	0.00954	-0.23	-0.18	Obesity-related traits;	chr5:580938	chr5:675826~676616:+
HNSC	cis	rs2243480	1	rs1404147	ENSG00000164669.11	INTS4P1	4.04	6.3e-05	0.00954	0.33	0.18	Diabetic kidney disease;	chr7:65799537	chr7:65141225~65234216:+
HNSC	cis	rs4356203	0.543	rs214093	ENSG00000260196.1	RP1-239B22.5	-4.04	6.3e-05	0.00954	-0.2	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17380649~17383531:+
HNSC	cis	rs7903456	0.512	rs4460730	ENSG00000200253.1	RNU6-529P	4.04	6.3e-05	0.00954	0.24	0.18	Gout;Renal underexcretion gout;	chr10:87076289	chr10:87041238~87041341:-
HNSC	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	4.04	6.3e-05	0.00954	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
HNSC	cis	rs3096299	0.933	rs2965939	ENSG00000224888.4	RP5-1142A6.2	4.04	6.3e-05	0.00955	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:88731180~88741425:+
HNSC	cis	rs9926296	0.744	rs154657	ENSG00000274627.1	RP11-104N10.2	-4.04	6.3e-05	0.00955	-0.18	-0.18	Vitiligo;	chr16:89641688	chr16:89516797~89522217:+
HNSC	cis	rs12047808	0.73	rs913516	ENSG00000227141.2	RP11-545A16.3	-4.04	6.31e-05	0.00955	-0.29	-0.18	Multiple sclerosis (age of onset);	chr1:179555515	chr1:179586705~179589175:+
HNSC	cis	rs2933343	0.553	rs35979399	ENSG00000261159.1	RP11-723O4.9	4.04	6.31e-05	0.00955	0.19	0.18	IgG glycosylation;	chr3:128978470	chr3:128859716~128860526:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000280411.1	IGHV1-69-2	-4.04	6.31e-05	0.00955	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106704924	chr14:106762092~106762588:-
HNSC	cis	rs7615952	0.546	rs2922194	ENSG00000241288.6	RP11-379B18.5	-4.04	6.31e-05	0.00955	-0.28	-0.18	Blood pressure (smoking interaction);	chr3:125613419	chr3:125827238~125916384:-
HNSC	cis	rs12745968	0.653	rs11164796	ENSG00000223787.2	RP4-593M8.1	-4.04	6.31e-05	0.00955	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92678523	chr1:92580476~92580821:-
HNSC	cis	rs9487051	0.872	rs9480922	ENSG00000219700.1	PTCHD3P3	4.04	6.31e-05	0.00956	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109286008	chr6:109288571~109290503:-
HNSC	cis	rs5758659	0.652	rs5758553	ENSG00000270083.1	RP1-257I20.14	4.04	6.31e-05	0.00956	0.17	0.18	Cognitive function;	chr22:42035425	chr22:42089630~42090028:-
HNSC	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-4.04	6.31e-05	0.00956	-0.23	-0.18	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-4.04	6.31e-05	0.00956	-0.23	-0.18	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-4.04	6.31e-05	0.00956	-0.23	-0.18	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
HNSC	cis	rs9652601	0.959	rs12708715	ENSG00000274038.1	RP11-66H6.4	-4.04	6.31e-05	0.00956	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11083967	chr16:11056556~11057034:+
HNSC	cis	rs12600394	1	rs9894527	ENSG00000236088.8	COX10-AS1	4.04	6.32e-05	0.00956	0.27	0.18	Response to platinum-based chemotherapy (cisplatin);	chr17:14611227	chr17:13756478~14069495:-
HNSC	cis	rs12600394	1	rs9894940	ENSG00000236088.8	COX10-AS1	4.04	6.32e-05	0.00956	0.27	0.18	Response to platinum-based chemotherapy (cisplatin);	chr17:14611306	chr17:13756478~14069495:-
HNSC	cis	rs9611565	0.659	rs4822037	ENSG00000235513.1	RP4-756G23.5	4.04	6.32e-05	0.00956	0.22	0.18	Vitiligo;	chr22:41549109	chr22:41209122~41217627:-
HNSC	cis	rs2483519	0.806	rs2483607	ENSG00000236799.1	RP11-383C6.2	-4.04	6.32e-05	0.00956	-0.19	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114628477	chr10:114994657~114996593:+
HNSC	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	4.04	6.32e-05	0.00957	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.754	rs12711071	ENSG00000250412.1	KLHL2P1	4.04	6.32e-05	0.00957	0.24	0.18	Corneal astigmatism;	chr4:119319779	chr4:119334329~119378233:+
HNSC	cis	rs6651255	0.738	rs6470771	ENSG00000224110.3	MTRF1LP2	-4.04	6.32e-05	0.00957	-0.21	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129731480	chr8:129728744~129730445:+
HNSC	cis	rs11168618	0.776	rs7955785	ENSG00000240399.1	RP1-228P16.1	4.04	6.32e-05	0.00957	0.16	0.18	Adiponectin levels;	chr12:48468755	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.846	rs11168592	ENSG00000240399.1	RP1-228P16.1	4.04	6.32e-05	0.00957	0.16	0.18	Adiponectin levels;	chr12:48471296	chr12:48054813~48055591:-
HNSC	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.32e-05	0.00957	-0.19	-0.18	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
HNSC	cis	rs7005380	0.58	rs1467044	ENSG00000279347.1	RP11-85I17.2	-4.04	6.32e-05	0.00957	-0.15	-0.18	Interstitial lung disease;	chr8:119874801	chr8:119838736~119840385:-
HNSC	cis	rs11773103	0.881	rs73204816	ENSG00000224046.1	AC005076.5	4.04	6.32e-05	0.00957	0.27	0.18	Bipolar disorder or major depressive disorder (combined);	chr7:87139556	chr7:87151423~87152420:-
HNSC	cis	rs1113500	0.73	rs1361829	ENSG00000226822.1	RP11-356N1.2	-4.04	6.33e-05	0.00958	-0.21	-0.18	Growth-regulated protein alpha levels;	chr1:108051273	chr1:108071482~108074519:+
HNSC	cis	rs9392556	0.626	rs626080	ENSG00000230648.1	RP3-406P24.3	-4.04	6.33e-05	0.00958	-0.2	-0.18	Blood metabolite levels;	chr6:4101333	chr6:4018843~4021215:-
HNSC	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	4.04	6.33e-05	0.00958	0.23	0.18	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
HNSC	cis	rs7572733	0.514	rs770659	ENSG00000231621.1	AC013264.2	-4.04	6.33e-05	0.00958	-0.18	-0.18	Dermatomyositis;	chr2:197805030	chr2:197197991~197199273:+
HNSC	cis	rs700651	0.821	rs700663	ENSG00000231621.1	AC013264.2	-4.04	6.33e-05	0.00958	-0.18	-0.18	Intracranial aneurysm;	chr2:197805754	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs770657	ENSG00000231621.1	AC013264.2	-4.04	6.33e-05	0.00958	-0.18	-0.18	Dermatomyositis;	chr2:197809460	chr2:197197991~197199273:+
HNSC	cis	rs4622329	0.636	rs10860812	ENSG00000258033.1	RP11-350G24.2	-4.04	6.33e-05	0.00958	-0.2	-0.18	Systemic lupus erythematosus;	chr12:101894592	chr12:101066734~101069232:+
HNSC	cis	rs8028182	0.636	rs4299117	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.33e-05	0.00958	-0.24	-0.18	Sudden cardiac arrest;	chr15:75497103	chr15:75527150~75601205:-
HNSC	cis	rs9650657	0.771	rs4240670	ENSG00000255310.2	AF131215.2	-4.04	6.33e-05	0.00958	-0.18	-0.18	Neuroticism;	chr8:10808338	chr8:11107788~11109726:-
HNSC	cis	rs71520386	0.625	rs10265548	ENSG00000230658.1	KLHL7-AS1	4.04	6.33e-05	0.00958	0.24	0.18	Fibrinogen levels;	chr7:22772959	chr7:23101228~23105703:-
HNSC	cis	rs7735319	0.704	rs2331145	ENSG00000251281.1	CTD-2066L21.2	4.04	6.33e-05	0.00959	0.22	0.18	Systolic blood pressure;	chr5:33051976	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.704	rs11750792	ENSG00000251281.1	CTD-2066L21.2	4.04	6.33e-05	0.00959	0.22	0.18	Systolic blood pressure;	chr5:33053996	chr5:33011322~33017607:-
HNSC	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-4.04	6.33e-05	0.00959	-0.32	-0.18	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
HNSC	cis	rs2333021	0.934	rs4903092	ENSG00000258376.2	RP4-647C14.2	-4.04	6.34e-05	0.00959	-0.22	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:73242651~73245979:-
HNSC	cis	rs9907295	0.605	rs11652192	ENSG00000270977.1	AC015849.16	-4.04	6.34e-05	0.00959	-0.29	-0.18	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35893707~35911023:-
HNSC	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-4.04	6.34e-05	0.00959	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
HNSC	cis	rs11098499	0.913	rs10006304	ENSG00000250412.1	KLHL2P1	4.04	6.34e-05	0.00959	0.23	0.18	Corneal astigmatism;	chr4:119203150	chr4:119334329~119378233:+
HNSC	cis	rs6710503	1	rs6545698	ENSG00000271936.1	RP11-443B20.1	4.04	6.34e-05	0.0096	0.2	0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24736392	chr2:24825610~24826717:+
HNSC	cis	rs12285276	0.536	rs4411261	ENSG00000205106.4	DKFZp779M0652	4.04	6.34e-05	0.0096	0.21	0.18	Visceral fat;	chr11:45785530	chr11:45771432~45772358:+
HNSC	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-4.04	6.34e-05	0.0096	-0.18	-0.18	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-4.04	6.34e-05	0.0096	-0.18	-0.18	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-4.04	6.34e-05	0.0096	-0.18	-0.18	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
HNSC	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	4.04	6.34e-05	0.0096	0.18	0.18	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
HNSC	cis	rs35306767	0.855	rs2050944	ENSG00000229869.1	RP11-363N22.2	-4.04	6.34e-05	0.0096	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:872970	chr10:933026~942743:+
HNSC	cis	rs304029	0.716	rs2307068	ENSG00000231249.1	ITPR1-AS1	4.04	6.34e-05	0.0096	0.2	0.18	Diabetic kidney disease;	chr3:4491276	chr3:4490891~4493163:-
HNSC	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-4.04	6.34e-05	0.0096	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
HNSC	cis	rs792448	0.743	rs351378	ENSG00000226251.4	RP11-15I11.3	-4.04	6.34e-05	0.0096	-0.22	-0.18	White blood cell count (basophil);	chr1:212251854	chr1:212225278~212238977:-
HNSC	cis	rs10791097	0.694	rs2155752	ENSG00000254842.5	RP11-890B15.2	-4.04	6.34e-05	0.0096	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886103	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs10894275	ENSG00000254842.5	RP11-890B15.2	-4.04	6.34e-05	0.0096	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886356	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs1893017	ENSG00000254842.5	RP11-890B15.2	-4.04	6.34e-05	0.0096	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886358	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.667	rs1893019	ENSG00000254842.5	RP11-890B15.2	-4.04	6.34e-05	0.0096	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886769	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs10791103	ENSG00000254842.5	RP11-890B15.2	-4.04	6.34e-05	0.0096	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130887266	chr11:130844191~130865561:-
HNSC	cis	rs728616	0.51	rs12768957	ENSG00000225484.5	NUTM2B-AS1	-4.04	6.35e-05	0.0096	-0.32	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79663088~79826594:-
HNSC	cis	rs4489787	1	rs10875804	ENSG00000257763.1	OR5BK1P	-4.04	6.35e-05	0.0096	-0.32	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48391191	chr12:48355792~48356614:-
HNSC	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-4.04	6.35e-05	0.0096	-0.13	-0.18	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-4.04	6.35e-05	0.0096	-0.13	-0.18	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-4.04	6.35e-05	0.0096	-0.13	-0.18	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-4.04	6.35e-05	0.0096	-0.13	-0.18	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
HNSC	cis	rs72627123	1	rs17094021	ENSG00000259065.1	RP5-1021I20.1	-4.04	6.35e-05	0.00961	-0.33	-0.18	Morning vs. evening chronotype;	chr14:73927592	chr14:73787360~73803270:+
HNSC	cis	rs853679	0.517	rs9295761	ENSG00000219891.2	ZSCAN12P1	4.04	6.35e-05	0.00961	0.26	0.18	Depression;	chr6:28180209	chr6:28091154~28093664:+
HNSC	cis	rs11098499	0.697	rs35280960	ENSG00000250412.1	KLHL2P1	4.04	6.35e-05	0.00961	0.24	0.18	Corneal astigmatism;	chr4:119335904	chr4:119334329~119378233:+
HNSC	cis	rs9859260	0.961	rs2300780	ENSG00000231464.1	AC024937.4	4.04	6.35e-05	0.00961	0.19	0.18	Mean corpuscular volume;	chr3:196063420	chr3:195996738~195998233:+
HNSC	cis	rs9859260	1	rs2300778	ENSG00000231464.1	AC024937.4	4.04	6.35e-05	0.00961	0.19	0.18	Mean corpuscular volume;	chr3:196063866	chr3:195996738~195998233:+
HNSC	cis	rs9859260	1	rs2300777	ENSG00000231464.1	AC024937.4	4.04	6.35e-05	0.00961	0.19	0.18	Mean corpuscular volume;	chr3:196063940	chr3:195996738~195998233:+
HNSC	cis	rs7572733	0.534	rs1607374	ENSG00000231621.1	AC013264.2	-4.04	6.36e-05	0.00961	-0.18	-0.18	Dermatomyositis;	chr2:197935716	chr2:197197991~197199273:+
HNSC	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-4.04	6.36e-05	0.00961	-0.23	-0.18	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-4.04	6.36e-05	0.00961	-0.23	-0.18	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-4.04	6.36e-05	0.00961	-0.23	-0.18	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
HNSC	cis	rs9896933	0.732	rs590886	ENSG00000262663.1	RP11-497H17.1	-4.04	6.36e-05	0.00961	-0.23	-0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82809474	chr17:82918282~82918785:+
HNSC	cis	rs35306767	0.715	rs12777801	ENSG00000229869.1	RP11-363N22.2	-4.04	6.36e-05	0.00962	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:990345	chr10:933026~942743:+
HNSC	cis	rs35306767	0.715	rs17221456	ENSG00000229869.1	RP11-363N22.2	-4.04	6.36e-05	0.00962	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:991294	chr10:933026~942743:+
HNSC	cis	rs11711311	0.824	rs9876528	ENSG00000241529.3	RN7SL767P	-4.04	6.36e-05	0.00962	-0.25	-0.18	IgG glycosylation;	chr3:113638349	chr3:113632704~113632998:+
HNSC	cis	rs792448	0.743	rs2516331	ENSG00000226251.4	RP11-15I11.3	-4.04	6.36e-05	0.00962	-0.22	-0.18	White blood cell count (basophil);	chr1:212243647	chr1:212225278~212238977:-
HNSC	cis	rs6504950	0.679	rs2628298	ENSG00000279059.1	RP11-257O5.2	4.04	6.36e-05	0.00962	0.16	0.18	Breast cancer;	chr17:55086117	chr17:54956760~54958426:-
HNSC	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	4.04	6.36e-05	0.00962	0.26	0.18	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
HNSC	cis	rs7246657	0.551	rs62108899	ENSG00000276846.1	CTD-3220F14.3	4.04	6.36e-05	0.00962	0.31	0.18	Coronary artery calcification;	chr19:37104281	chr19:37314868~37315620:-
HNSC	cis	rs4938303	0.756	rs4938301	ENSG00000280143.1	AP000892.6	-4.04	6.36e-05	0.00962	-0.23	-0.18	Triglycerides;	chr11:116704757	chr11:117204967~117210292:+
HNSC	cis	rs9807989	0.839	rs4988955	ENSG00000234389.1	AC007278.3	4.04	6.36e-05	0.00962	0.18	0.18	Asthma;	chr2:102351468	chr2:102438713~102440475:+
HNSC	cis	rs9583531	0.6	rs3809344	ENSG00000259831.1	LINC00567	4.04	6.37e-05	0.00962	0.21	0.18	Coronary artery disease;	chr13:110706358	chr13:110809676~110813084:-
HNSC	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-4.04	6.37e-05	0.00962	-0.21	-0.18	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
HNSC	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-4.04	6.37e-05	0.00962	-0.21	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
HNSC	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-4.04	6.37e-05	0.00962	-0.21	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
HNSC	cis	rs988913	0.957	rs9382397	ENSG00000224984.1	RP11-524H19.2	4.04	6.37e-05	0.00963	0.21	0.18	Menarche (age at onset);	chr6:54918095	chr6:54840118~54840855:-
HNSC	cis	rs11648785	0.526	rs4530137	ENSG00000221819.5	GAS8-AS1	4.04	6.37e-05	0.00963	0.19	0.18	Tanning;	chr16:90028093	chr16:90028908~90029367:-
HNSC	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-4.04	6.37e-05	0.00963	-0.23	-0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
HNSC	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-4.04	6.37e-05	0.00964	-0.24	-0.18	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
HNSC	cis	rs2762353	0.776	rs1165178	ENSG00000272462.2	U91328.19	-4.04	6.38e-05	0.00964	-0.18	-0.18	Blood metabolite levels;	chr6:25827288	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1165176	ENSG00000272462.2	U91328.19	-4.04	6.38e-05	0.00964	-0.18	-0.18	Blood metabolite levels;	chr6:25830070	chr6:25992662~26001775:+
HNSC	cis	rs7824557	0.606	rs2736270	ENSG00000255310.2	AF131215.2	4.03	6.38e-05	0.00964	0.17	0.18	Retinal vascular caliber;	chr8:11335084	chr8:11107788~11109726:-
HNSC	cis	rs8028182	0.636	rs7163907	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.38e-05	0.00964	-0.24	-0.18	Sudden cardiac arrest;	chr15:75552756	chr15:75527150~75601205:-
HNSC	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	4.03	6.38e-05	0.00964	0.28	0.18	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
HNSC	cis	rs10078	0.571	rs2721014	ENSG00000225138.6	CTD-2228K2.7	4.03	6.38e-05	0.00964	0.32	0.18	Fat distribution (HIV);	chr5:463424	chr5:473236~480884:+
HNSC	cis	rs10078	0.515	rs1053299	ENSG00000225138.6	CTD-2228K2.7	4.03	6.38e-05	0.00964	0.32	0.18	Fat distribution (HIV);	chr5:470645	chr5:473236~480884:+
HNSC	cis	rs10078	0.571	rs890973	ENSG00000225138.6	CTD-2228K2.7	4.03	6.38e-05	0.00964	0.32	0.18	Fat distribution (HIV);	chr5:471379	chr5:473236~480884:+
HNSC	cis	rs6430585	0.583	rs59213715	ENSG00000231890.6	DARS-AS1	-4.03	6.38e-05	0.00964	-0.33	-0.18	Corneal structure;	chr2:135889012	chr2:135985176~136022593:+
HNSC	cis	rs4713118	0.824	rs2092075	ENSG00000224843.5	LINC00240	4.03	6.38e-05	0.00964	0.21	0.18	Parkinson's disease;	chr6:27781551	chr6:26956992~27023924:+
HNSC	cis	rs4713118	0.824	rs13211701	ENSG00000224843.5	LINC00240	4.03	6.38e-05	0.00964	0.21	0.18	Parkinson's disease;	chr6:27782300	chr6:26956992~27023924:+
HNSC	cis	rs4713118	0.824	rs9468229	ENSG00000224843.5	LINC00240	4.03	6.38e-05	0.00964	0.21	0.18	Parkinson's disease;	chr6:27782307	chr6:26956992~27023924:+
HNSC	cis	rs116095464	0.558	rs9312978	ENSG00000250848.1	CTD-2083E4.5	-4.03	6.38e-05	0.00964	-0.26	-0.18	Breast cancer;	chr5:221815	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs9312979	ENSG00000250848.1	CTD-2083E4.5	-4.03	6.38e-05	0.00964	-0.26	-0.18	Breast cancer;	chr5:221942	chr5:288833~290321:-
HNSC	cis	rs7005380	0.581	rs9649949	ENSG00000279347.1	RP11-85I17.2	-4.03	6.39e-05	0.00965	-0.17	-0.18	Interstitial lung disease;	chr8:119901335	chr8:119838736~119840385:-
HNSC	cis	rs2060793	0.659	rs1839834	ENSG00000254418.1	RP11-21L19.1	4.03	6.39e-05	0.00965	0.21	0.18	Vitamin D levels;	chr11:14807914	chr11:14262846~14273691:-
HNSC	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-4.03	6.39e-05	0.00965	-0.21	-0.18	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-4.03	6.39e-05	0.00965	-0.21	-0.18	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-4.03	6.39e-05	0.00965	-0.21	-0.18	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
HNSC	cis	rs11951515	0.637	rs4866813	ENSG00000249286.1	CTD-2210P15.2	4.03	6.39e-05	0.00965	0.19	0.18	Metabolite levels  (X-11787);	chr5:43300642	chr5:43586918~43588223:-
HNSC	cis	rs1009077	0.68	rs13121569	ENSG00000245958.5	RP11-33B1.1	-4.03	6.39e-05	0.00965	-0.19	-0.18	Endometriosis;	chr4:119507249	chr4:119454791~119552025:+
HNSC	cis	rs7824557	0.564	rs2572379	ENSG00000255310.2	AF131215.2	-4.03	6.39e-05	0.00966	-0.17	-0.18	Retinal vascular caliber;	chr8:11379971	chr8:11107788~11109726:-
HNSC	cis	rs2762353	0.808	rs1185978	ENSG00000272462.2	U91328.19	-4.03	6.39e-05	0.00966	-0.18	-0.18	Blood metabolite levels;	chr6:25835667	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1165183	ENSG00000272462.2	U91328.19	-4.03	6.39e-05	0.00966	-0.18	-0.18	Blood metabolite levels;	chr6:25836152	chr6:25992662~26001775:+
HNSC	cis	rs2980439	0.525	rs2980508	ENSG00000254340.1	RP11-10A14.3	4.03	6.39e-05	0.00966	0.21	0.18	Neuroticism;	chr8:8314210	chr8:9141424~9145435:+
HNSC	cis	rs11157436	0.918	rs1983518	ENSG00000211812.1	TRAV26-2	-4.03	6.4e-05	0.00966	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149336	chr14:22202583~22203368:+
HNSC	cis	rs7623291	0.887	rs6789584	ENSG00000271131.1	RP11-33A14.3	4.03	6.4e-05	0.00966	0.22	0.18	Left ventricular obstructive tract defect (inherited effect);	chr3:178647133	chr3:178493327~178493810:-
HNSC	cis	rs6787172	0.811	rs7648618	ENSG00000272087.1	RP11-379F4.7	4.03	6.4e-05	0.00966	0.19	0.18	Subjective well-being;	chr3:158505049	chr3:158693120~158693768:-
HNSC	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-4.03	6.4e-05	0.00967	-0.18	-0.18	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
HNSC	cis	rs153852	1	rs153851	ENSG00000243806.1	RPL7P18	-4.03	6.4e-05	0.00967	-0.22	-0.18	Cancer;	chr5:94840912	chr5:94825961~94826694:-
HNSC	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-4.03	6.4e-05	0.00967	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
HNSC	cis	rs11951515	0.7	rs13659	ENSG00000249286.1	CTD-2210P15.2	4.03	6.4e-05	0.00967	0.19	0.18	Metabolite levels  (X-11787);	chr5:43290598	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.7	rs55794239	ENSG00000249286.1	CTD-2210P15.2	4.03	6.4e-05	0.00967	0.19	0.18	Metabolite levels  (X-11787);	chr5:43292806	chr5:43586918~43588223:-
HNSC	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	4.03	6.4e-05	0.00967	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	4.03	6.4e-05	0.00967	0.22	0.18	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
HNSC	cis	rs2463822	0.92	rs11828383	ENSG00000250659.2	RP11-864I4.3	4.03	6.4e-05	0.00967	0.36	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62300346	chr11:62537312~62542018:+
HNSC	cis	rs8058578	1	rs2289442	ENSG00000279196.1	RP11-1072A3.3	4.03	6.4e-05	0.00967	0.22	0.18	Multiple myeloma;	chr16:30728598	chr16:30984630~30988270:-
HNSC	cis	rs12893668	0.616	rs58033365	ENSG00000269958.1	RP11-73M18.8	4.03	6.41e-05	0.00968	0.17	0.18	Reticulocyte count;	chr14:103564564	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.645	rs12889403	ENSG00000269958.1	RP11-73M18.8	4.03	6.41e-05	0.00968	0.17	0.18	Reticulocyte count;	chr14:103568409	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.703	rs12894729	ENSG00000269958.1	RP11-73M18.8	4.03	6.41e-05	0.00968	0.17	0.18	Reticulocyte count;	chr14:103568955	chr14:103696353~103697163:+
HNSC	cis	rs72634501	0.517	rs6600289	ENSG00000182109.6	RP11-69E11.4	-4.03	6.41e-05	0.00968	-0.19	-0.18	HDL cholesterol;	chr1:39148140	chr1:39522280~39546187:-
HNSC	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	4.03	6.41e-05	0.00968	0.22	0.18	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.539	rs883647	ENSG00000173295.6	FAM86B3P	-4.03	6.41e-05	0.00968	-0.22	-0.18	Mood instability;	chr8:8712214	chr8:8228595~8244865:+
HNSC	cis	rs11951515	0.7	rs35239179	ENSG00000249286.1	CTD-2210P15.2	4.03	6.41e-05	0.00968	0.19	0.18	Metabolite levels  (X-11787);	chr5:43298455	chr5:43586918~43588223:-
HNSC	cis	rs10504130	0.569	rs9650179	ENSG00000253844.1	RP11-546K22.1	-4.03	6.42e-05	0.00969	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51961458~52022974:+
HNSC	cis	rs5758659	0.652	rs5751195	ENSG00000182057.4	OGFRP1	4.03	6.42e-05	0.00969	0.18	0.18	Cognitive function;	chr22:41983997	chr22:42269753~42275196:+
HNSC	cis	rs964611	0.816	rs1426722	ENSG00000259488.2	RP11-154J22.1	-4.03	6.42e-05	0.0097	-0.17	-0.18	Metabolite levels (Pyroglutamine);	chr15:48277212	chr15:48312353~48331856:-
HNSC	cis	rs859767	0.519	rs6707326	ENSG00000224043.6	CCNT2-AS1	4.03	6.42e-05	0.0097	0.22	0.18	Neuroticism;	chr2:134600135	chr2:134735464~134918710:-
HNSC	cis	rs9921338	0.961	rs12934968	ENSG00000263080.1	RP11-485G7.5	-4.03	6.43e-05	0.0097	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11341809~11345211:-
HNSC	cis	rs9921338	0.961	rs4315353	ENSG00000263080.1	RP11-485G7.5	-4.03	6.43e-05	0.0097	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11341809~11345211:-
HNSC	cis	rs12468226	1	rs13426118	ENSG00000226261.1	AC064836.3	4.03	6.43e-05	0.0097	0.24	0.18	Urate levels;	chr2:202390762	chr2:202336024~202336727:-
HNSC	cis	rs6500395	0.584	rs2098422	ENSG00000261267.1	RP11-44I10.3	-4.03	6.43e-05	0.00971	-0.24	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48710189	chr16:48559661~48587403:+
HNSC	cis	rs9921338	0.886	rs4780363	ENSG00000263080.1	RP11-485G7.5	-4.03	6.43e-05	0.00971	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11341809~11345211:-
HNSC	cis	rs6071166	0.683	rs1475095	ENSG00000224635.1	RP4-564F22.5	-4.03	6.43e-05	0.00971	-0.22	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38684071	chr20:38406011~38416797:-
HNSC	cis	rs9859260	0.961	rs9846149	ENSG00000231464.1	AC024937.4	4.03	6.43e-05	0.00971	0.19	0.18	Mean corpuscular volume;	chr3:196060437	chr3:195996738~195998233:+
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000224373.3	IGHV4-59	4.03	6.43e-05	0.00971	0.11	0.18	Kawasaki disease;	chr14:106781490	chr14:106627249~106627825:-
HNSC	cis	rs3736485	0.966	rs10775144	ENSG00000259438.1	CTD-2650P22.1	4.03	6.43e-05	0.00971	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51598937	chr15:52010999~52019095:-
HNSC	cis	rs9298506	1	rs28600710	ENSG00000254142.2	RP11-53M11.3	4.03	6.43e-05	0.00971	0.27	0.18	Intracranial aneurysm;	chr8:54524233	chr8:54554361~54561927:+
HNSC	cis	rs442309	0.687	rs11815005	ENSG00000238280.1	RP11-436D10.3	-4.03	6.43e-05	0.00971	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62696987	chr10:62793562~62805887:-
HNSC	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	4.03	6.44e-05	0.00972	0.18	0.18	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
HNSC	cis	rs9611565	0.659	rs12483998	ENSG00000235513.1	RP4-756G23.5	4.03	6.44e-05	0.00972	0.21	0.18	Vitiligo;	chr22:41539358	chr22:41209122~41217627:-
HNSC	cis	rs9584850	0.834	rs9584855	ENSG00000231194.1	FARP1-AS1	-4.03	6.44e-05	0.00972	-0.22	-0.18	Neuroticism;	chr13:98466746	chr13:98435405~98435840:-
HNSC	cis	rs761746	0.739	rs5998072	ENSG00000236132.1	CTA-440B3.1	-4.03	6.44e-05	0.00972	-0.23	-0.18	Intelligence;	chr22:31652388	chr22:31816379~31817491:-
HNSC	cis	rs9311676	0.632	rs56033718	ENSG00000273493.1	RP11-80H18.4	4.03	6.44e-05	0.00972	0.2	0.18	Systemic lupus erythematosus;	chr3:58460671	chr3:58329965~58330118:+
HNSC	cis	rs73198271	0.813	rs17697237	ENSG00000233609.3	RP11-62H7.2	4.03	6.44e-05	0.00972	0.2	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8961200~8979025:+
HNSC	cis	rs4256159	1	rs61286160	ENSG00000228956.7	SATB1-AS1	4.03	6.44e-05	0.00972	0.3	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18734594	chr3:18445024~18920401:+
HNSC	cis	rs8077577	0.671	rs9910090	ENSG00000273018.4	CTD-2303H24.2	-4.03	6.44e-05	0.00973	-0.25	-0.18	Obesity-related traits;	chr17:18347085	chr17:18511221~18551705:-
HNSC	cis	rs2136613	0.533	rs1509958	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62856390	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs12258444	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62856825	chr10:62793562~62805887:-
HNSC	cis	rs16858210	0.913	rs1879255	ENSG00000234371.6	RPSAP31	4.03	6.45e-05	0.00973	0.22	0.18	Menopause (age at onset);	chr3:183891657	chr3:183884924~183888449:+
HNSC	cis	rs1387259	0.839	rs7486941	ENSG00000257763.1	OR5BK1P	-4.03	6.45e-05	0.00973	-0.17	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48355792~48356614:-
HNSC	cis	rs13256369	1	rs4840352	ENSG00000173295.6	FAM86B3P	4.03	6.45e-05	0.00973	0.24	0.18	Obesity-related traits;	chr8:8715998	chr8:8228595~8244865:+
HNSC	cis	rs4218	0.543	rs8027536	ENSG00000277144.1	RP11-59H7.4	-4.03	6.45e-05	0.00973	-0.22	-0.18	Social communication problems;	chr15:59022364	chr15:59115547~59116089:-
HNSC	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	4.03	6.45e-05	0.00973	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
HNSC	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-4.03	6.45e-05	0.00973	-0.19	-0.18	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
HNSC	cis	rs2136613	0.533	rs1571922	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62851189	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822066	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62851432	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10740091	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62851628	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822067	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62851949	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10761669	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62852050	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10509173	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62852129	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822068	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62852505	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822069	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62853482	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10995331	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62853948	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822070	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62854149	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs4141617	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62854308	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822071	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62855716	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10822072	ENSG00000238280.1	RP11-436D10.3	-4.03	6.45e-05	0.00973	-0.21	-0.18	Selective IgA deficiency;	chr10:62856010	chr10:62793562~62805887:-
HNSC	cis	rs9611565	0.694	rs202617	ENSG00000235513.1	RP4-756G23.5	-4.03	6.45e-05	0.00974	-0.22	-0.18	Vitiligo;	chr22:41426789	chr22:41209122~41217627:-
HNSC	cis	rs792448	0.743	rs351386	ENSG00000226251.4	RP11-15I11.3	-4.03	6.45e-05	0.00974	-0.22	-0.18	White blood cell count (basophil);	chr1:212248429	chr1:212225278~212238977:-
HNSC	cis	rs683257	0.866	rs72984119	ENSG00000234147.1	RP3-460G2.2	-4.03	6.45e-05	0.00974	-0.37	-0.18	Facial emotion recognition (angry faces);	chr6:140695392	chr6:140845958~140852924:-
HNSC	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-4.03	6.45e-05	0.00974	-0.18	-0.18	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-4.03	6.45e-05	0.00974	-0.18	-0.18	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
HNSC	cis	rs10073892	0.743	rs2218926	ENSG00000250682.4	LINC00491	4.03	6.46e-05	0.00974	0.25	0.18	Cognitive decline (age-related);	chr5:102314292	chr5:102609156~102671559:-
HNSC	cis	rs10773046	0.566	rs11057380	ENSG00000269938.1	RP11-214K3.20	-4.03	6.46e-05	0.00974	-0.21	-0.18	Osteoarthritis (hip);	chr12:123871150	chr12:123968023~123968579:-
HNSC	cis	rs1015213	1	rs7816406	ENSG00000272024.1	RP11-546K22.3	-4.03	6.46e-05	0.00974	-0.33	-0.18	Glaucoma (primary angle closure);	chr8:51978116	chr8:51950284~51950690:+
HNSC	cis	rs1015213	0.737	rs7817432	ENSG00000272024.1	RP11-546K22.3	-4.03	6.46e-05	0.00974	-0.33	-0.18	Glaucoma (primary angle closure);	chr8:51978123	chr8:51950284~51950690:+
HNSC	cis	rs7726839	0.54	rs72705097	ENSG00000225138.6	CTD-2228K2.7	4.03	6.46e-05	0.00974	0.27	0.18	Obesity-related traits;	chr5:654952	chr5:473236~480884:+
HNSC	cis	rs7726839	0.54	rs12520279	ENSG00000225138.6	CTD-2228K2.7	4.03	6.46e-05	0.00974	0.27	0.18	Obesity-related traits;	chr5:657176	chr5:473236~480884:+
HNSC	cis	rs7726839	0.54	rs4957083	ENSG00000225138.6	CTD-2228K2.7	4.03	6.46e-05	0.00974	0.27	0.18	Obesity-related traits;	chr5:659228	chr5:473236~480884:+
HNSC	cis	rs7726839	0.54	rs7558	ENSG00000225138.6	CTD-2228K2.7	4.03	6.46e-05	0.00974	0.27	0.18	Obesity-related traits;	chr5:660376	chr5:473236~480884:+
HNSC	cis	rs8044868	0.548	rs3909541	ENSG00000259209.3	RP5-991G20.2	-4.03	6.46e-05	0.00974	-0.19	-0.18	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72167220	chr16:72805998~72809872:+
HNSC	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-4.03	6.46e-05	0.00975	-0.19	-0.18	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
HNSC	cis	rs7824557	0.564	rs2572400	ENSG00000269918.1	AF131215.9	-4.03	6.46e-05	0.00975	-0.18	-0.18	Retinal vascular caliber;	chr8:11376858	chr8:11104691~11106704:-
HNSC	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	4.03	6.47e-05	0.00975	0.17	0.18	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
HNSC	cis	rs442309	0.812	rs224089	ENSG00000238280.1	RP11-436D10.3	-4.03	6.47e-05	0.00975	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62780161	chr10:62793562~62805887:-
HNSC	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	4.03	6.47e-05	0.00975	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
HNSC	cis	rs1551277	0.538	rs55652830	ENSG00000146666.5	LINC00525	4.03	6.47e-05	0.00975	0.25	0.18	Anxiety disorder;	chr7:47805887	chr7:47761476~47766772:+
HNSC	cis	rs6964587	0.626	rs68009402	ENSG00000188693.7	CYP51A1-AS1	4.03	6.47e-05	0.00975	0.2	0.18	Breast cancer;	chr7:91886912	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.626	rs10234074	ENSG00000188693.7	CYP51A1-AS1	4.03	6.47e-05	0.00975	0.2	0.18	Breast cancer;	chr7:91890805	chr7:92134604~92180725:+
HNSC	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	4.03	6.47e-05	0.00975	0.23	0.18	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
HNSC	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-4.03	6.47e-05	0.00975	-0.21	-0.18	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
HNSC	cis	rs11168618	0.686	rs11168574	ENSG00000240399.1	RP1-228P16.1	4.03	6.47e-05	0.00976	0.16	0.18	Adiponectin levels;	chr12:48445186	chr12:48054813~48055591:-
HNSC	cis	rs2760061	0.505	rs708109	ENSG00000270110.1	RP5-1139B12.4	-4.03	6.47e-05	0.00976	-0.19	-0.18	Diastolic blood pressure;	chr1:228002956	chr1:228295911~228302998:-
HNSC	cis	rs2760061	0.583	rs708110	ENSG00000270110.1	RP5-1139B12.4	-4.03	6.47e-05	0.00976	-0.19	-0.18	Diastolic blood pressure;	chr1:228003104	chr1:228295911~228302998:-
HNSC	cis	rs2760061	0.603	rs697761	ENSG00000270110.1	RP5-1139B12.4	-4.03	6.47e-05	0.00976	-0.19	-0.18	Diastolic blood pressure;	chr1:228004696	chr1:228295911~228302998:-
HNSC	cis	rs2760061	0.583	rs697763	ENSG00000270110.1	RP5-1139B12.4	-4.03	6.47e-05	0.00976	-0.19	-0.18	Diastolic blood pressure;	chr1:228004921	chr1:228295911~228302998:-
HNSC	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-4.03	6.47e-05	0.00976	-0.23	-0.18	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
HNSC	cis	rs1008375	0.606	rs6828925	ENSG00000249502.1	AC006160.5	-4.03	6.48e-05	0.00977	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17559516	chr4:17587467~17614571:-
HNSC	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-4.03	6.48e-05	0.00977	-0.22	-0.18	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
HNSC	cis	rs7948661	1	rs9332819	ENSG00000278376.1	RP11-158I9.8	-4.03	6.48e-05	0.00977	-0.29	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494548	chr11:118791254~118793137:+
HNSC	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	4.03	6.48e-05	0.00977	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	4.03	6.48e-05	0.00977	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
HNSC	cis	rs2439831	1	rs690263	ENSG00000275601.1	AC011330.13	-4.03	6.48e-05	0.00978	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43412267	chr15:43642389~43643023:-
HNSC	cis	rs11157436	0.918	rs1983520	ENSG00000211812.1	TRAV26-2	-4.03	6.48e-05	0.00978	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.918	rs1983522	ENSG00000211812.1	TRAV26-2	-4.03	6.48e-05	0.00978	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.918	rs12586393	ENSG00000211812.1	TRAV26-2	-4.03	6.48e-05	0.00978	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.918	rs2178788	ENSG00000211812.1	TRAV26-2	-4.03	6.48e-05	0.00978	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.83	rs61972214	ENSG00000211812.1	TRAV26-2	-4.03	6.48e-05	0.00978	-0.19	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22202583~22203368:+
HNSC	cis	rs6490294	0.95	rs7313892	ENSG00000226469.1	ADAM1B	4.03	6.49e-05	0.00978	0.21	0.18	Mean platelet volume;	chr12:111983548	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs73426401	ENSG00000226469.1	ADAM1B	4.03	6.49e-05	0.00978	0.21	0.18	Mean platelet volume;	chr12:111985482	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.904	rs7956483	ENSG00000226469.1	ADAM1B	4.03	6.49e-05	0.00978	0.21	0.18	Mean platelet volume;	chr12:111986766	chr12:111927018~111929017:+
HNSC	cis	rs13178541	0.81	rs4457070	ENSG00000250378.1	RP11-119J18.1	4.03	6.49e-05	0.00978	0.24	0.18	IgG glycosylation;	chr5:135814396	chr5:135812667~135826582:+
HNSC	cis	rs3822625	0.541	rs12655019	ENSG00000271828.1	CTD-2310F14.1	4.03	6.49e-05	0.00978	0.37	0.18	Breast cancer (early onset);	chr5:56899963	chr5:56927874~56929573:+
HNSC	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-4.03	6.49e-05	0.00978	-0.14	-0.18	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
HNSC	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	4.03	6.49e-05	0.00979	0.31	0.18	QT interval;	chr4:75107209	chr4:75081702~75084717:-
HNSC	cis	rs5758511	0.514	rs5758638	ENSG00000226450.2	CYP2D8P	4.03	6.49e-05	0.00979	0.17	0.18	Birth weight;	chr22:42186388	chr22:42149886~42155001:-
HNSC	cis	rs2268667	0.647	rs11161609	ENSG00000223653.4	RP11-131L23.1	-4.03	6.49e-05	0.00979	-0.23	-0.18	Asymmetrical dimethylarginine levels;	chr1:85397053	chr1:85276715~85448124:+
HNSC	cis	rs7178909	0.933	rs7183156	ENSG00000259677.1	RP11-493E3.1	4.03	6.5e-05	0.00979	0.21	0.18	Common traits (Other);	chr15:89902214	chr15:89876540~89877285:+
HNSC	cis	rs67981189	0.613	rs221892	ENSG00000274818.1	RP1-292L20.3	-4.03	6.5e-05	0.00979	-0.2	-0.18	Schizophrenia;	chr14:71144889	chr14:70906657~70907111:-
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000233609.3	RP11-62H7.2	-4.03	6.5e-05	0.0098	-0.17	-0.18	Mean corpuscular volume;	chr8:8996725	chr8:8961200~8979025:+
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	4.03	6.5e-05	0.0098	0.29	0.18	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
HNSC	cis	rs3736485	0.873	rs12101920	ENSG00000259438.1	CTD-2650P22.1	4.03	6.5e-05	0.0098	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51528712	chr15:52010999~52019095:-
HNSC	cis	rs2179367	0.959	rs579789	ENSG00000216906.2	RP11-350J20.9	4.03	6.51e-05	0.0098	0.23	0.18	Dupuytren's disease;	chr6:149358235	chr6:149904243~149906418:+
HNSC	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-4.03	6.51e-05	0.0098	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
HNSC	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-4.03	6.51e-05	0.00981	-0.22	-0.18	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
HNSC	cis	rs9437689	0.932	rs10493880	ENSG00000237416.5	RP11-465K1.2	4.03	6.51e-05	0.00981	0.22	0.18	Phospholipid levels (plasma);	chr1:94960691	chr1:94836748~94855426:-
HNSC	cis	rs7777677	0.925	rs4726544	ENSG00000276557.1	TRBV18	4.03	6.51e-05	0.00982	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142615716~142616415:+
HNSC	cis	rs35306767	0.714	rs67205460	ENSG00000229869.1	RP11-363N22.2	-4.03	6.52e-05	0.00982	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:1044426	chr10:933026~942743:+
HNSC	cis	rs35306767	0.714	rs66797613	ENSG00000229869.1	RP11-363N22.2	-4.03	6.52e-05	0.00982	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:1044529	chr10:933026~942743:+
HNSC	cis	rs35306767	0.714	rs67696450	ENSG00000229869.1	RP11-363N22.2	-4.03	6.52e-05	0.00982	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:1044744	chr10:933026~942743:+
HNSC	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-4.03	6.52e-05	0.00982	-0.22	-0.18	Height;	chr14:75191310	chr14:75011269~75012851:-
HNSC	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-4.03	6.52e-05	0.00982	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-4.03	6.52e-05	0.00982	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-4.03	6.52e-05	0.00982	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-4.03	6.52e-05	0.00982	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
HNSC	cis	rs13179617	0.862	rs10939905	ENSG00000215032.2	GNL3LP1	-4.03	6.52e-05	0.00982	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61514783	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.779	rs11742658	ENSG00000215032.2	GNL3LP1	-4.03	6.52e-05	0.00982	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61514890	chr5:60891935~60893577:-
HNSC	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	4.03	6.52e-05	0.00983	0.26	0.18	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
HNSC	cis	rs11098499	0.954	rs3733520	ENSG00000250412.1	KLHL2P1	4.03	6.52e-05	0.00983	0.23	0.18	Corneal astigmatism;	chr4:119502325	chr4:119334329~119378233:+
HNSC	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	4.03	6.52e-05	0.00983	0.26	0.18	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
HNSC	cis	rs17189998	0.73	rs11780116	ENSG00000253636.1	RP11-531A24.5	4.03	6.52e-05	0.00983	0.27	0.18	Colonoscopy-negative controls vs population controls;	chr8:72883021	chr8:73052178~73063061:+
HNSC	cis	rs6088590	0.748	rs6142206	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.52e-05	0.00983	-0.2	-0.18	Coronary artery disease;	chr20:34624251	chr20:33985617~33988989:-
HNSC	cis	rs11250098	0.574	rs4240672	ENSG00000255310.2	AF131215.2	-4.03	6.52e-05	0.00983	-0.17	-0.18	Morning vs. evening chronotype;	chr8:10910407	chr8:11107788~11109726:-
HNSC	cis	rs1962073	0.528	rs9329223	ENSG00000269918.1	AF131215.9	-4.03	6.52e-05	0.00983	-0.18	-0.18	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10474244	chr8:11104691~11106704:-
HNSC	cis	rs10435719	0.805	rs13269417	ENSG00000227888.4	FAM66A	4.03	6.52e-05	0.00983	0.19	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:12362019~12388296:+
HNSC	cis	rs3740713	1	rs3740713	ENSG00000256464.1	YWHABP2	4.03	6.53e-05	0.00983	0.35	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr11:18490243~18490955:-
HNSC	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-4.03	6.53e-05	0.00983	-0.22	-0.18	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
HNSC	cis	rs3736485	0.816	rs6493503	ENSG00000259438.1	CTD-2650P22.1	4.03	6.53e-05	0.00984	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51528844	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.837	rs4774593	ENSG00000259438.1	CTD-2650P22.1	4.03	6.53e-05	0.00984	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51529648	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.808	rs2124875	ENSG00000259438.1	CTD-2650P22.1	4.03	6.53e-05	0.00984	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51541172	chr15:52010999~52019095:-
HNSC	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	4.03	6.53e-05	0.00984	0.16	0.18	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
HNSC	cis	rs67981189	0.537	rs1978164	ENSG00000274818.1	RP1-292L20.3	-4.03	6.53e-05	0.00984	-0.2	-0.18	Schizophrenia;	chr14:70894650	chr14:70906657~70907111:-
HNSC	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	4.03	6.53e-05	0.00984	0.21	0.18	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
HNSC	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-4.03	6.53e-05	0.00984	-0.35	-0.18	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
HNSC	cis	rs6142618	0.967	rs6061182	ENSG00000275576.1	RP5-836N17.4	-4.03	6.53e-05	0.00984	-0.19	-0.18	Inflammatory bowel disease;	chr20:32139433	chr20:32116171~32116629:+
HNSC	cis	rs7572733	0.773	rs56858593	ENSG00000222017.1	AC011997.1	4.03	6.53e-05	0.00984	0.22	0.18	Dermatomyositis;	chr2:197629744	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.742	rs3828317	ENSG00000222017.1	AC011997.1	4.03	6.53e-05	0.00984	0.22	0.18	Dermatomyositis;	chr2:197630707	chr2:197693106~197774823:+
HNSC	cis	rs3015497	0.562	rs8011264	ENSG00000269906.1	RP11-248J18.2	-4.03	6.54e-05	0.00984	-0.25	-0.18	Mean platelet volume;	chr14:50624781	chr14:50662511~50663178:-
HNSC	cis	rs6095360	1	rs7270848	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49023200	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019591	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49023492	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs66970580	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49024802	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs7262379	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49026042	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.933	rs6019594	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49027017	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019595	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49027495	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6095400	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49029452	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.87	rs6095401	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49030084	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs13042947	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49031339	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019602	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49034955	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs707533	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49035717	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs707534	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49035801	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.901	rs16994347	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49036824	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6019603	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49036869	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.966	rs927160	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49038027	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.933	rs3817652	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49046831	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6090939	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49049288	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs6012590	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49050700	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.901	rs6012591	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49050805	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs7509369	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49051500	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs2869694	ENSG00000222365.1	SNORD12B	-4.03	6.54e-05	0.00984	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49051846	chr20:49280319~49280409:+
HNSC	cis	rs11157436	0.602	rs1894371	ENSG00000211812.1	TRAV26-2	4.03	6.54e-05	0.00985	0.16	0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22202583~22203368:+
HNSC	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-4.03	6.54e-05	0.00985	-0.23	-0.18	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
HNSC	cis	rs1642645	1	rs1642645	ENSG00000228452.1	RP5-994D16.9	-4.03	6.54e-05	0.00985	-0.26	-0.18	Left ventricular obstructive tract defect (maternal effect);	chr1:42036610	chr1:42775813~42776790:-
HNSC	cis	rs155076	1	rs261431	ENSG00000233325.3	MIPEPP3	-4.03	6.54e-05	0.00985	-0.31	-0.18	White matter hyperintensity burden;	chr13:21291599	chr13:21298139~21306373:+
HNSC	cis	rs9925964	0.748	rs11640961	ENSG00000232748.3	RP11-196G11.6	4.03	6.54e-05	0.00985	0.25	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:31056460~31062803:+
HNSC	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	4.03	6.54e-05	0.00985	0.28	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
HNSC	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	4.03	6.54e-05	0.00985	0.29	0.18	QT interval;	chr4:75108836	chr4:75081702~75084717:-
HNSC	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	4.03	6.55e-05	0.00986	0.19	0.18	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
HNSC	cis	rs11638352	1	rs2706471	ENSG00000205771.5	CATSPER2P1	4.03	6.55e-05	0.00986	0.5	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44122172	chr15:43726918~43747094:-
HNSC	cis	rs2554380	0.657	rs11259916	ENSG00000259570.1	RP11-671M22.4	4.03	6.55e-05	0.00986	0.24	0.18	Height;	chr15:83692766	chr15:84394512~84395514:+
HNSC	cis	rs16858210	0.837	rs1879254	ENSG00000234371.6	RPSAP31	4.03	6.55e-05	0.00986	0.22	0.18	Menopause (age at onset);	chr3:183891683	chr3:183884924~183888449:+
HNSC	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-4.03	6.55e-05	0.00986	-0.25	-0.18	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
HNSC	cis	rs10829156	0.947	rs7081435	ENSG00000240291.1	RP11-499P20.2	4.03	6.55e-05	0.00987	0.18	0.18	Sudden cardiac arrest;	chr10:18667411	chr10:18513115~18545651:-
HNSC	cis	rs28472312	0.667	rs9937676	ENSG00000259982.1	CDC37P1	-4.03	6.56e-05	0.00987	-0.21	-0.18	Intelligence (multi-trait analysis);	chr16:28958159	chr16:28700294~28701540:-
HNSC	cis	rs6919534	0.516	rs72901705	ENSG00000272374.1	RP3-329A5.8	4.03	6.56e-05	0.00987	0.24	0.18	Height;	chr6:35152114	chr6:35220370~35224630:-
HNSC	cis	rs2762353	0.808	rs1165180	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25826119	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1165179	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25826286	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.776	rs765285	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25828014	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.776	rs1165177	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25829431	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1185569	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25831375	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1185568	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25834200	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1185153	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25834320	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.808	rs1184803	ENSG00000272462.2	U91328.19	-4.03	6.56e-05	0.00987	-0.18	-0.18	Blood metabolite levels;	chr6:25834430	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-4.03	6.56e-05	0.00987	-0.22	-0.18	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-4.03	6.56e-05	0.00987	-0.22	-0.18	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
HNSC	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	4.03	6.56e-05	0.00987	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
HNSC	cis	rs75422866	0.764	rs67201012	ENSG00000280054.1	RP1-197B17.7	4.03	6.56e-05	0.00987	0.44	0.18	Pneumonia;	chr12:47715881	chr12:47728151~47730598:-
HNSC	cis	rs7475343	0.538	rs4330990	ENSG00000224034.1	RP11-445P17.8	-4.03	6.56e-05	0.00987	-0.25	-0.18	Intelligence;	chr10:5164222	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.538	rs61854684	ENSG00000224034.1	RP11-445P17.8	-4.03	6.56e-05	0.00987	-0.25	-0.18	Intelligence;	chr10:5165720	chr10:5266033~5271236:-
HNSC	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-4.03	6.56e-05	0.00988	-0.21	-0.18	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000253981.4	ALG1L13P	4.03	6.56e-05	0.00988	0.21	0.18	Neuroticism;	chr8:8866905	chr8:8236003~8244667:-
HNSC	cis	rs10129255	0.509	rs756583	ENSG00000224373.3	IGHV4-59	4.03	6.56e-05	0.00988	0.1	0.18	Kawasaki disease;	chr14:106680002	chr14:106627249~106627825:-
HNSC	cis	rs2243480	1	rs1723269	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66007799	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs781150	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66015986	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313798	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66028044	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313809	ENSG00000229886.1	RP5-1132H15.3	4.03	6.56e-05	0.00988	0.31	0.18	Diabetic kidney disease;	chr7:66034996	chr7:66025126~66031544:-
HNSC	cis	rs9368481	0.761	rs12661756	ENSG00000238621.1	TRI-TAT2-2	-4.03	6.56e-05	0.00988	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:27020335~27020447:+
HNSC	cis	rs73607972	0.935	rs73603987	ENSG00000275191.1	RP11-36I17.2	-4.03	6.56e-05	0.00988	-0.26	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577714	chr16:53628256~53628816:-
HNSC	cis	rs853679	0.599	rs149949	ENSG00000219891.2	ZSCAN12P1	4.03	6.56e-05	0.00988	0.32	0.18	Depression;	chr6:28043738	chr6:28091154~28093664:+
HNSC	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-4.03	6.57e-05	0.00988	-0.24	-0.18	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
HNSC	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-4.03	6.57e-05	0.00988	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-4.03	6.57e-05	0.00988	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
HNSC	cis	rs28571765	1	rs28571765	ENSG00000254142.2	RP11-53M11.3	4.03	6.57e-05	0.00988	0.27	0.18	Multiple myeloma;	chr8:54536721	chr8:54554361~54561927:+
HNSC	cis	rs7674212	0.541	rs2251322	ENSG00000251288.2	RP11-10L12.2	-4.03	6.57e-05	0.00989	-0.21	-0.18	Type 2 diabetes;	chr4:103158267	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.541	rs2615539	ENSG00000251288.2	RP11-10L12.2	-4.03	6.57e-05	0.00989	-0.21	-0.18	Type 2 diabetes;	chr4:103159949	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.57	rs2251634	ENSG00000251288.2	RP11-10L12.2	-4.03	6.57e-05	0.00989	-0.21	-0.18	Type 2 diabetes;	chr4:103161192	chr4:102751401~102752641:+
HNSC	cis	rs10504130	1	rs75219463	ENSG00000272024.1	RP11-546K22.3	-4.03	6.57e-05	0.00989	-0.3	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51852803	chr8:51950284~51950690:+
HNSC	cis	rs853679	0.599	rs202906	ENSG00000219891.2	ZSCAN12P1	-4.03	6.57e-05	0.00989	-0.3	-0.18	Depression;	chr6:28043874	chr6:28091154~28093664:+
HNSC	cis	rs11089937	0.554	rs5995628	ENSG00000211639.2	IGLV4-60	4.03	6.57e-05	0.00989	0.18	0.18	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22162199~22162681:+
HNSC	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	4.03	6.57e-05	0.00989	0.17	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
HNSC	cis	rs1979679	0.918	rs11049562	ENSG00000247934.4	RP11-967K21.1	-4.03	6.57e-05	0.00989	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28163298~28190738:-
HNSC	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	4.03	6.57e-05	0.00989	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
HNSC	cis	rs860295	0.541	rs11264359	ENSG00000203761.5	MSTO2P	-4.03	6.57e-05	0.00989	-0.14	-0.18	Body mass index;	chr1:155313038	chr1:155745829~155750137:+
HNSC	cis	rs792448	0.743	rs351379	ENSG00000226251.4	RP11-15I11.3	-4.03	6.57e-05	0.00989	-0.22	-0.18	White blood cell count (basophil);	chr1:212250447	chr1:212225278~212238977:-
HNSC	cis	rs2337406	0.866	rs7153964	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106790480	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs7144369	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106793065	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs78525520	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106795643	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs7140974	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106795976	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs76871148	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106799722	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs61521632	ENSG00000280411.1	IGHV1-69-2	-4.03	6.58e-05	0.00989	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106801091	chr14:106762092~106762588:-
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000241278.1	ENPP7P4	-4.03	6.58e-05	0.00989	-0.31	-0.18	Blood pressure (smoking interaction);	chr3:125880966	chr3:125848223~125909372:+
HNSC	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-4.03	6.58e-05	0.00989	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
HNSC	cis	rs4853525	0.859	rs11897136	ENSG00000228509.4	AC006460.2	4.03	6.58e-05	0.00989	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846354	chr2:190676944~190708716:-
HNSC	cis	rs1009077	0.716	rs62319606	ENSG00000245958.5	RP11-33B1.1	4.03	6.58e-05	0.00989	0.21	0.18	Endometriosis;	chr4:119544091	chr4:119454791~119552025:+
HNSC	cis	rs7572733	0.935	rs10189897	ENSG00000222017.1	AC011997.1	-4.03	6.58e-05	0.00989	-0.22	-0.18	Dermatomyositis;	chr2:197948686	chr2:197693106~197774823:+
HNSC	cis	rs67311347	1	rs10510708	ENSG00000280739.1	EIF1B-AS1	4.03	6.58e-05	0.0099	0.2	0.18	Renal cell carcinoma;	chr3:40363279	chr3:40173145~40309698:-
HNSC	cis	rs3850699	0.666	rs7905481	ENSG00000236937.2	PTGES3P4	4.03	6.58e-05	0.0099	0.24	0.18	Prostate cancer;	chr10:102716535	chr10:102845595~102845950:+
HNSC	cis	rs11098499	0.644	rs7676296	ENSG00000250412.1	KLHL2P1	4.03	6.58e-05	0.0099	0.24	0.18	Corneal astigmatism;	chr4:119634532	chr4:119334329~119378233:+
HNSC	cis	rs3736485	0.816	rs11632853	ENSG00000259438.1	CTD-2650P22.1	4.03	6.58e-05	0.0099	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51563736	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.816	rs4143722	ENSG00000259438.1	CTD-2650P22.1	4.03	6.58e-05	0.0099	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51574994	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.816	rs8038341	ENSG00000259438.1	CTD-2650P22.1	4.03	6.58e-05	0.0099	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51578551	chr15:52010999~52019095:-
HNSC	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	4.03	6.59e-05	0.0099	0.17	0.18	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	4.03	6.59e-05	0.0099	0.17	0.18	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
HNSC	cis	rs3733585	0.682	rs13124563	ENSG00000250413.1	RP11-448G15.1	-4.03	6.59e-05	0.0099	-0.23	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9925929	chr4:10006482~10009725:+
HNSC	cis	rs10504130	0.597	rs4598243	ENSG00000253844.1	RP11-546K22.1	-4.03	6.59e-05	0.00991	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51961458~52022974:+
HNSC	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-4.03	6.59e-05	0.00991	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
HNSC	cis	rs4356203	0.87	rs7925692	ENSG00000260196.1	RP1-239B22.5	4.03	6.59e-05	0.00991	0.19	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17380649~17383531:+
HNSC	cis	rs11673344	0.504	rs2385374	ENSG00000276846.1	CTD-3220F14.3	4.03	6.59e-05	0.00991	0.2	0.18	Obesity-related traits;	chr19:37092115	chr19:37314868~37315620:-
HNSC	cis	rs7824557	0.564	rs2572392	ENSG00000255310.2	AF131215.2	-4.03	6.59e-05	0.00991	-0.17	-0.18	Retinal vascular caliber;	chr8:11378096	chr8:11107788~11109726:-
HNSC	cis	rs6968419	1	rs2402053	ENSG00000237870.5	AC073130.1	4.03	6.59e-05	0.00991	0.2	0.18	Intraocular pressure;	chr7:116196743	chr7:116275606~116286734:-
HNSC	cis	rs13434995	0.842	rs9790448	ENSG00000273257.1	RP11-177J6.1	-4.03	6.59e-05	0.00991	-0.29	-0.18	Adiponectin levels;	chr4:55592918	chr4:55387949~55388271:+
HNSC	cis	rs4356203	0.84	rs7942094	ENSG00000272034.1	SNORD14A	-4.03	6.59e-05	0.00991	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17237862	chr11:17074654~17074744:-
HNSC	cis	rs7771547	0.573	rs664370	ENSG00000219023.1	RP3-340B19.2	4.03	6.59e-05	0.00991	0.16	0.18	Platelet distribution width;	chr6:36426039	chr6:35555873~35556264:+
HNSC	cis	rs8077577	1	rs62073606	ENSG00000273018.4	CTD-2303H24.2	-4.03	6.59e-05	0.00991	-0.28	-0.18	Obesity-related traits;	chr17:18165828	chr17:18511221~18551705:-
HNSC	cis	rs1065852	0.861	rs5758627	ENSG00000227370.1	RP4-669P10.19	4.03	6.59e-05	0.00991	0.22	0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42132543~42132998:+
HNSC	cis	rs2980439	0.818	rs2945249	ENSG00000233609.3	RP11-62H7.2	4.03	6.59e-05	0.00991	0.17	0.18	Neuroticism;	chr8:8237204	chr8:8961200~8979025:+
HNSC	cis	rs67981189	0.593	rs1468470	ENSG00000274818.1	RP1-292L20.3	4.03	6.6e-05	0.00991	0.2	0.18	Schizophrenia;	chr14:71088814	chr14:70906657~70907111:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-4.03	6.6e-05	0.00992	-0.25	-0.18	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
HNSC	cis	rs4938303	0.788	rs61906112	ENSG00000254851.1	RP11-109L13.1	4.03	6.6e-05	0.00992	0.28	0.18	Triglycerides;	chr11:116685049	chr11:117135528~117138582:+
HNSC	cis	rs7475343	0.501	rs3750572	ENSG00000224034.1	RP11-445P17.8	-4.03	6.6e-05	0.00992	-0.26	-0.18	Intelligence;	chr10:5205413	chr10:5266033~5271236:-
HNSC	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	4.03	6.6e-05	0.00992	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
HNSC	cis	rs12893668	0.673	rs2296482	ENSG00000269958.1	RP11-73M18.8	4.03	6.6e-05	0.00992	0.17	0.18	Reticulocyte count;	chr14:103563482	chr14:103696353~103697163:+
HNSC	cis	rs597539	0.652	rs516425	ENSG00000261625.1	RP11-554A11.4	-4.03	6.6e-05	0.00992	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:69000765~69002048:-
HNSC	cis	rs4906332	1	rs12147655	ENSG00000244691.1	RPL10AP1	-4.03	6.6e-05	0.00992	-0.22	-0.18	Coronary artery disease;	chr14:103384569	chr14:103412119~103412761:-
HNSC	cis	rs1799955	0.935	rs9634672	ENSG00000215515.2	IFIT1P1	-4.03	6.6e-05	0.00992	-0.25	-0.18	LDL cholesterol levels;	chr13:32369919	chr13:32384660~32386108:+
HNSC	cis	rs1799955	0.935	rs9567609	ENSG00000215515.2	IFIT1P1	-4.03	6.6e-05	0.00992	-0.25	-0.18	LDL cholesterol levels;	chr13:32371580	chr13:32384660~32386108:+
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000250412.1	KLHL2P1	4.03	6.6e-05	0.00992	0.23	0.18	Corneal astigmatism;	chr4:119317722	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000250412.1	KLHL2P1	4.03	6.6e-05	0.00992	0.23	0.18	Corneal astigmatism;	chr4:119317725	chr4:119334329~119378233:+
HNSC	cis	rs12893668	0.703	rs35026580	ENSG00000269958.1	RP11-73M18.8	4.03	6.6e-05	0.00993	0.17	0.18	Reticulocyte count;	chr14:103576416	chr14:103696353~103697163:+
HNSC	cis	rs62292953	0.535	rs62292475	ENSG00000248724.5	NPHP3-AS1	-4.03	6.6e-05	0.00993	-0.42	-0.18	Red cell distribution width;	chr3:132718190	chr3:132721750~132874223:+
HNSC	cis	rs9487051	0.502	rs9386781	ENSG00000243587.6	C6orf183	-4.03	6.6e-05	0.00993	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109263317	chr6:109165833~109271014:+
HNSC	cis	rs12745968	0.653	rs11164791	ENSG00000223787.2	RP4-593M8.1	-4.03	6.6e-05	0.00993	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92654077	chr1:92580476~92580821:-
HNSC	cis	rs710913	0.618	rs12030495	ENSG00000182109.6	RP11-69E11.4	4.03	6.61e-05	0.00993	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39522280~39546187:-
HNSC	cis	rs2898290	0.622	rs978803	ENSG00000269918.1	AF131215.9	4.03	6.61e-05	0.00993	0.17	0.18	Systolic blood pressure;	chr8:11485966	chr8:11104691~11106704:-
HNSC	cis	rs2032447	0.867	rs9295683	ENSG00000272462.2	U91328.19	-4.03	6.61e-05	0.00993	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26069267	chr6:25992662~26001775:+
HNSC	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-4.03	6.61e-05	0.00993	-0.18	-0.18	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
HNSC	cis	rs1862618	0.671	rs2591958	ENSG00000271828.1	CTD-2310F14.1	-4.03	6.61e-05	0.00993	-0.23	-0.18	Initial pursuit acceleration;	chr5:56943542	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.671	rs72644088	ENSG00000271828.1	CTD-2310F14.1	-4.03	6.61e-05	0.00993	-0.23	-0.18	Initial pursuit acceleration;	chr5:56945192	chr5:56927874~56929573:+
HNSC	cis	rs224278	0.584	rs752602	ENSG00000238280.1	RP11-436D10.3	-4.03	6.61e-05	0.00993	-0.22	-0.18	Ewing sarcoma;	chr10:62831797	chr10:62793562~62805887:-
HNSC	cis	rs4853525	0.59	rs2355576	ENSG00000228509.4	AC006460.2	4.03	6.61e-05	0.00993	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850374	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.59	rs4513327	ENSG00000228509.4	AC006460.2	4.03	6.61e-05	0.00993	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850695	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.561	rs17746911	ENSG00000228509.4	AC006460.2	4.03	6.61e-05	0.00993	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854640	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.59	rs12614693	ENSG00000228509.4	AC006460.2	4.03	6.61e-05	0.00993	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854882	chr2:190676944~190708716:-
HNSC	cis	rs12439619	0.508	rs17354842	ENSG00000259429.4	UBE2Q2P2	4.03	6.61e-05	0.00993	0.17	0.18	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82355142~82420075:+
HNSC	cis	rs7809950	0.559	rs2248465	ENSG00000238832.1	snoU109	4.03	6.61e-05	0.00993	0.25	0.18	Coronary artery disease;	chr7:107663183	chr7:107603363~107603507:+
HNSC	cis	rs17818399	0.547	rs35178974	ENSG00000279254.1	RP11-536C12.1	-4.03	6.61e-05	0.00993	-0.22	-0.18	Height;	chr2:46536759	chr2:46668870~46670778:+
HNSC	cis	rs7688540	0.771	rs77078697	ENSG00000250892.1	RP11-1365D11.1	-4.03	6.61e-05	0.00993	-0.32	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:201409~205009:-
HNSC	cis	rs7688540	0.771	rs61795006	ENSG00000250892.1	RP11-1365D11.1	-4.03	6.61e-05	0.00993	-0.32	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:201409~205009:-
HNSC	cis	rs7688540	0.771	rs61795007	ENSG00000250892.1	RP11-1365D11.1	-4.03	6.61e-05	0.00993	-0.32	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:201409~205009:-
HNSC	cis	rs67311347	1	rs6599094	ENSG00000280739.1	EIF1B-AS1	4.03	6.61e-05	0.00993	0.2	0.18	Renal cell carcinoma;	chr3:40358102	chr3:40173145~40309698:-
HNSC	cis	rs1190596	0.581	rs1190571	ENSG00000271780.1	RP11-1017G21.5	-4.03	6.61e-05	0.00993	-0.18	-0.18	Behavioural disinhibition (generation interaction);	chr14:102168564	chr14:101948347~101949425:+
HNSC	cis	rs7824557	0.627	rs7838897	ENSG00000255310.2	AF131215.2	4.03	6.61e-05	0.00994	0.17	0.18	Retinal vascular caliber;	chr8:11349817	chr8:11107788~11109726:-
HNSC	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	4.03	6.61e-05	0.00994	0.19	0.18	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
HNSC	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-4.03	6.62e-05	0.00994	-0.21	-0.18	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
HNSC	cis	rs748404	0.666	rs7177892	ENSG00000166763.7	STRCP1	4.03	6.62e-05	0.00994	0.26	0.18	Lung cancer;	chr15:43321171	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs7181545	ENSG00000166763.7	STRCP1	4.03	6.62e-05	0.00994	0.26	0.18	Lung cancer;	chr15:43321363	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs17723479	ENSG00000166763.7	STRCP1	4.03	6.62e-05	0.00994	0.26	0.18	Lung cancer;	chr15:43322114	chr15:43699488~43718184:-
HNSC	cis	rs11951515	0.7	rs10941620	ENSG00000249286.1	CTD-2210P15.2	4.03	6.62e-05	0.00994	0.19	0.18	Metabolite levels  (X-11787);	chr5:43283594	chr5:43586918~43588223:-
HNSC	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-4.03	6.62e-05	0.00994	-0.27	-0.18	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
HNSC	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-4.03	6.62e-05	0.00994	-0.22	-0.18	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-4.03	6.62e-05	0.00994	-0.22	-0.18	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
HNSC	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	4.03	6.62e-05	0.00994	0.23	0.18	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
HNSC	cis	rs9513627	0.915	rs7327204	ENSG00000280710.1	RP11-214F16.8	-4.03	6.62e-05	0.00995	-0.27	-0.18	Obesity-related traits;	chr13:99474698	chr13:99498524~99501315:+
HNSC	cis	rs62292953	1	rs16839317	ENSG00000248724.5	NPHP3-AS1	-4.03	6.62e-05	0.00995	-0.33	-0.18	Red cell distribution width;	chr3:132500039	chr3:132721750~132874223:+
HNSC	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	4.03	6.63e-05	0.00995	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
HNSC	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	4.03	6.63e-05	0.00995	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
HNSC	cis	rs442309	0.846	rs224143	ENSG00000238280.1	RP11-436D10.3	-4.03	6.63e-05	0.00996	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62718076	chr10:62793562~62805887:-
HNSC	cis	rs9859260	0.925	rs2300775	ENSG00000231464.1	AC024937.4	4.03	6.63e-05	0.00996	0.19	0.18	Mean corpuscular volume;	chr3:196066468	chr3:195996738~195998233:+
HNSC	cis	rs9859260	0.921	rs2300774	ENSG00000231464.1	AC024937.4	4.03	6.63e-05	0.00996	0.19	0.18	Mean corpuscular volume;	chr3:196066841	chr3:195996738~195998233:+
HNSC	cis	rs2645424	0.635	rs6980952	ENSG00000255046.1	RP11-297N6.4	-4.03	6.63e-05	0.00996	-0.2	-0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11858964	chr8:11797928~11802568:-
HNSC	cis	rs1979679	0.918	rs1586867	ENSG00000247934.4	RP11-967K21.1	-4.03	6.63e-05	0.00996	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28163298~28190738:-
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000211976.2	IGHV3-73	-4.03	6.64e-05	0.00996	-0.13	-0.18	Kawasaki disease;	chr14:106778120	chr14:106802694~106803233:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000229886.1	RP5-1132H15.3	4.03	6.64e-05	0.00996	0.31	0.18	Diabetic kidney disease;	chr7:65895144	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35391607	ENSG00000229886.1	RP5-1132H15.3	4.03	6.64e-05	0.00996	0.31	0.18	Diabetic kidney disease;	chr7:65895842	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs13220979	ENSG00000229886.1	RP5-1132H15.3	4.03	6.64e-05	0.00996	0.31	0.18	Diabetic kidney disease;	chr7:65898217	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34974928	ENSG00000229886.1	RP5-1132H15.3	4.03	6.64e-05	0.00996	0.31	0.18	Diabetic kidney disease;	chr7:65899019	chr7:66025126~66031544:-
HNSC	cis	rs13178541	0.626	rs4510575	ENSG00000250378.1	RP11-119J18.1	-4.03	6.64e-05	0.00996	-0.25	-0.18	IgG glycosylation;	chr5:135770111	chr5:135812667~135826582:+
HNSC	cis	rs9313772	0.722	rs12716344	ENSG00000254350.1	RP11-542A14.1	4.03	6.64e-05	0.00997	0.19	0.18	Blood pressure;	chr5:158449900	chr5:158424585~158452758:+
HNSC	cis	rs6787172	0.87	rs1714524	ENSG00000272087.1	RP11-379F4.7	4.03	6.64e-05	0.00997	0.19	0.18	Subjective well-being;	chr3:158555307	chr3:158693120~158693768:-
HNSC	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	4.03	6.64e-05	0.00997	0.21	0.18	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
HNSC	cis	rs597539	0.616	rs473997	ENSG00000261625.1	RP11-554A11.4	-4.03	6.64e-05	0.00997	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:69000765~69002048:-
HNSC	cis	rs61160187	0.673	rs10062240	ENSG00000215032.2	GNL3LP1	-4.03	6.64e-05	0.00997	-0.21	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60891935~60893577:-
HNSC	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-4.03	6.65e-05	0.00997	-0.22	-0.18	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
HNSC	cis	rs7824557	0.564	rs2437152	ENSG00000255310.2	AF131215.2	-4.02	6.65e-05	0.00998	-0.17	-0.18	Retinal vascular caliber;	chr8:11377988	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs2736300	ENSG00000255310.2	AF131215.2	-4.02	6.65e-05	0.00998	-0.17	-0.18	Retinal vascular caliber;	chr8:11378070	chr8:11107788~11109726:-
HNSC	cis	rs67981189	0.593	rs2526847	ENSG00000274818.1	RP1-292L20.3	-4.02	6.65e-05	0.00998	-0.2	-0.18	Schizophrenia;	chr14:70955557	chr14:70906657~70907111:-
HNSC	cis	rs17507216	0.56	rs28493687	ENSG00000276710.3	CSPG4P8	-4.02	6.65e-05	0.00998	-0.21	-0.18	Excessive daytime sleepiness;	chr15:82560062	chr15:82459472~82477258:+
HNSC	cis	rs1538970	0.962	rs2487442	ENSG00000234329.1	RP11-767N6.2	-4.02	6.65e-05	0.00998	-0.2	-0.18	Platelet count;	chr1:45391504	chr1:45651039~45651826:-
HNSC	cis	rs67981189	0.593	rs2286311	ENSG00000274818.1	RP1-292L20.3	4.02	6.65e-05	0.00998	0.2	0.18	Schizophrenia;	chr14:71056238	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs7152845	ENSG00000274818.1	RP1-292L20.3	4.02	6.65e-05	0.00998	0.2	0.18	Schizophrenia;	chr14:71060506	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs8020480	ENSG00000274818.1	RP1-292L20.3	4.02	6.65e-05	0.00998	0.2	0.18	Schizophrenia;	chr14:71061327	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs6573994	ENSG00000274818.1	RP1-292L20.3	4.02	6.65e-05	0.00998	0.2	0.18	Schizophrenia;	chr14:71069945	chr14:70906657~70907111:-
HNSC	cis	rs6504108	0.581	rs55982346	ENSG00000278765.1	RP5-890E16.5	-4.02	6.65e-05	0.00998	-0.23	-0.18	Body mass index;	chr17:48198512	chr17:48066704~48067293:-
HNSC	cis	rs453301	0.624	rs6987558	ENSG00000253981.4	ALG1L13P	4.02	6.65e-05	0.00998	0.2	0.18	Joint mobility (Beighton score);	chr8:9005011	chr8:8236003~8244667:-
HNSC	cis	rs6928977	0.932	rs6914831	ENSG00000217482.2	HMGB1P17	-4.02	6.65e-05	0.00998	-0.2	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135636086~135636713:-
HNSC	cis	rs6142618	0.967	rs6058527	ENSG00000275576.1	RP5-836N17.4	-4.02	6.65e-05	0.00998	-0.19	-0.18	Inflammatory bowel disease;	chr20:32121088	chr20:32116171~32116629:+
HNSC	cis	rs10028773	0.632	rs34481394	ENSG00000250412.1	KLHL2P1	4.02	6.65e-05	0.00998	0.24	0.18	Educational attainment;	chr4:119327219	chr4:119334329~119378233:+
HNSC	cis	rs10028773	0.666	rs35231872	ENSG00000250412.1	KLHL2P1	4.02	6.65e-05	0.00998	0.24	0.18	Educational attainment;	chr4:119327221	chr4:119334329~119378233:+
HNSC	cis	rs10028773	0.7	rs35653026	ENSG00000250412.1	KLHL2P1	4.02	6.65e-05	0.00998	0.24	0.18	Educational attainment;	chr4:119327223	chr4:119334329~119378233:+
HNSC	cis	rs2307394	0.964	rs13000983	ENSG00000281469.1	RP11-567F11.1	4.02	6.65e-05	0.00998	0.21	0.18	Urate levels;	chr2:147803814	chr2:148044380~148044894:+
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66370832	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs778704	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66398480	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66407358	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs778691	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66408105	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs13235972	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66418618	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34192067	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66422670	chr7:66025126~66031544:-
HNSC	cis	rs9313772	0.722	rs11954486	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449351	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs11954487	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449367	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs11960819	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449397	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs11959259	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449578	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs13157568	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449774	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs12716343	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158449876	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.722	rs10044821	ENSG00000254350.1	RP11-542A14.1	-4.02	6.66e-05	0.00999	-0.19	-0.18	Blood pressure;	chr5:158450060	chr5:158424585~158452758:+
HNSC	cis	rs7005380	0.62	rs10217083	ENSG00000279347.1	RP11-85I17.2	-4.02	6.66e-05	0.00999	-0.15	-0.18	Interstitial lung disease;	chr8:119911045	chr8:119838736~119840385:-
HNSC	cis	rs7296418	0.663	rs11057276	ENSG00000280120.1	RP11-546D6.3	-4.02	6.66e-05	0.00999	-0.15	-0.18	Platelet count;	chr12:123335850	chr12:123152324~123153377:-
HNSC	cis	rs2070419	0.724	rs9984450	ENSG00000261610.1	AP000265.1	4.02	6.66e-05	0.00999	0.22	0.18	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31562799	chr21:32259804~32261585:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	4.02	6.66e-05	0.00999	0.31	0.18	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
HNSC	cis	rs7829975	0.593	rs2921077	ENSG00000233609.3	RP11-62H7.2	4.02	6.66e-05	0.00999	0.17	0.18	Mood instability;	chr8:8446992	chr8:8961200~8979025:+
HNSC	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-4.02	6.66e-05	0.01	-0.27	-0.18	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
HNSC	cis	rs3015497	0.789	rs3015500	ENSG00000277050.1	RP11-102G14.1	-4.02	6.66e-05	0.01	-0.17	-0.18	Mean platelet volume;	chr14:50642159	chr14:51637348~51637947:-
HNSC	cis	rs2115630	1	rs58581703	ENSG00000259295.5	CSPG4P12	-4.02	6.66e-05	0.01	-0.21	-0.18	P wave terminal force;	chr15:84733704	chr15:85191438~85213905:+
HNSC	cis	rs9733	0.687	rs11204735	ENSG00000236713.1	RP11-363I22.3	4.02	6.67e-05	0.01	0.2	0.18	Tonsillectomy;	chr1:150869191	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.744	rs12758227	ENSG00000236713.1	RP11-363I22.3	4.02	6.67e-05	0.01	0.2	0.18	Tonsillectomy;	chr1:150872107	chr1:150780272~150780644:+
HNSC	cis	rs56114371	0.53	rs169262	ENSG00000216901.1	AL022393.7	4.02	6.67e-05	0.01	0.25	0.18	Breast cancer;	chr6:27803112	chr6:28176188~28176674:+
HNSC	cis	rs9914988	0.565	rs66811679	ENSG00000264577.1	AC010761.8	4.02	6.67e-05	0.01	0.18	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28969403	chr17:28721487~28722877:-
HNSC	cis	rs9914988	0.613	rs67436963	ENSG00000264577.1	AC010761.8	4.02	6.67e-05	0.01	0.18	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28969490	chr17:28721487~28722877:-
HNSC	cis	rs9914988	0.509	rs12453166	ENSG00000264577.1	AC010761.8	4.02	6.67e-05	0.01	0.18	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28971691	chr17:28721487~28722877:-
HNSC	cis	rs9914988	0.613	rs1873477	ENSG00000264577.1	AC010761.8	4.02	6.67e-05	0.01	0.18	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28984514	chr17:28721487~28722877:-
HNSC	cis	rs897984	0.762	rs2054213	ENSG00000279196.1	RP11-1072A3.3	-4.02	6.67e-05	0.01	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30960489	chr16:30984630~30988270:-
HNSC	cis	rs8031584	0.958	rs34294266	ENSG00000270015.1	RP11-540B6.6	-4.02	6.67e-05	0.01	-0.19	-0.18	Huntington's disease progression;	chr15:30954637	chr15:30926514~30928407:+
HNSC	cis	rs34792	0.525	rs12708795	ENSG00000207425.1	Y_RNA	-4.02	6.67e-05	0.01	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14915457~14915556:-
HNSC	cis	rs656319	0.674	rs1484639	ENSG00000255310.2	AF131215.2	4.02	6.67e-05	0.01	0.17	0.18	Myopia (pathological);	chr8:10125714	chr8:11107788~11109726:-
HNSC	cis	rs853679	1	rs1778511	ENSG00000204709.4	LINC01556	-4.02	6.67e-05	0.01	-0.28	-0.18	Depression;	chr6:28261633	chr6:28943877~28944537:+
HNSC	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-4.02	6.67e-05	0.01	-0.25	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
HNSC	cis	rs3736485	0.966	rs12372948	ENSG00000259438.1	CTD-2650P22.1	4.02	6.68e-05	0.01	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51602114	chr15:52010999~52019095:-
HNSC	cis	rs4321325	0.733	rs79208542	ENSG00000236682.1	AC068282.3	-4.02	6.68e-05	0.01	-0.31	-0.18	Protein C levels;	chr2:127178110	chr2:127389130~127400580:+
HNSC	cis	rs28830936	1	rs9672298	ENSG00000250379.1	RP11-23P13.4	4.02	6.68e-05	0.01	0.22	0.18	Diastolic blood pressure;	chr15:41620170	chr15:41825099~41827936:-
HNSC	cis	rs4713118	0.866	rs2179094	ENSG00000224843.5	LINC00240	4.02	6.68e-05	0.01	0.21	0.18	Parkinson's disease;	chr6:27774046	chr6:26956992~27023924:+
HNSC	cis	rs9910055	0.659	rs7216294	ENSG00000267080.4	ASB16-AS1	-4.02	6.68e-05	0.01	-0.15	-0.18	Total body bone mineral density;	chr17:44173727	chr17:44175973~44186717:-
HNSC	cis	rs72627123	1	rs2302138	ENSG00000259065.1	RP5-1021I20.1	-4.02	6.68e-05	0.01	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73896602	chr14:73787360~73803270:+
HNSC	cis	rs7005380	0.733	rs4871787	ENSG00000279347.1	RP11-85I17.2	4.02	6.68e-05	0.01	0.15	0.18	Interstitial lung disease;	chr8:119924178	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.746	rs1464276	ENSG00000279347.1	RP11-85I17.2	4.02	6.68e-05	0.01	0.15	0.18	Interstitial lung disease;	chr8:119924801	chr8:119838736~119840385:-
HNSC	cis	rs2548724	0.773	rs261098	ENSG00000250682.4	LINC00491	-4.02	6.68e-05	0.01	-0.24	-0.18	Type 2 diabetes;	chr5:102258642	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.606	rs1047950	ENSG00000255020.1	AF131216.5	4.02	6.68e-05	0.01	0.19	0.18	Retinal vascular caliber;	chr8:11327587	chr8:11345748~11347502:-
HNSC	cis	rs11148252	0.574	rs2038826	ENSG00000198384.8	TPTE2P3	4.02	6.69e-05	0.01	0.22	0.18	Lewy body disease;	chr13:52705878	chr13:52522632~52586906:+
HNSC	cis	rs9652601	1	rs9652601	ENSG00000274038.1	RP11-66H6.4	-4.02	6.69e-05	0.01	-0.23	-0.18	Systemic lupus erythematosus;	chr16:11080508	chr16:11056556~11057034:+
HNSC	cis	rs1008375	0.863	rs4698632	ENSG00000249502.1	AC006160.5	-4.02	6.69e-05	0.01	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613271	chr4:17587467~17614571:-
HNSC	cis	rs2865126	0.743	rs2865120	ENSG00000264714.1	RP11-21G15.1	-4.02	6.69e-05	0.01	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10754923	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.779	rs4796905	ENSG00000264714.1	RP11-21G15.1	-4.02	6.69e-05	0.01	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10755253	chr18:10724619~10728539:+
HNSC	cis	rs7178375	0.607	rs12903674	ENSG00000270015.1	RP11-540B6.6	4.02	6.69e-05	0.01	0.28	0.18	Hypertriglyceridemia;	chr15:30902349	chr15:30926514~30928407:+
HNSC	cis	rs9531006	1	rs7333430	ENSG00000227676.3	LINC01068	-4.02	6.69e-05	0.01	-0.23	-0.18	Sleep duration;	chr13:80001883	chr13:79566727~79571436:+
HNSC	cis	rs9303029	0.932	rs9905527	ENSG00000265458.1	RP13-20L14.6	4.02	6.69e-05	0.01	0.31	0.18	Protein quantitative trait loci;	chr17:82482049	chr17:82454273~82458521:-
HNSC	cis	rs6490294	0.904	rs76300790	ENSG00000226469.1	ADAM1B	4.02	6.69e-05	0.01	0.22	0.18	Mean platelet volume;	chr12:111964865	chr12:111927018~111929017:+
HNSC	cis	rs7829975	0.711	rs1039916	ENSG00000254153.1	CTA-398F10.2	4.02	6.69e-05	0.01	0.21	0.18	Mood instability;	chr8:8828344	chr8:8456909~8461337:-
HNSC	cis	rs1962073	0.528	rs4582610	ENSG00000269918.1	AF131215.9	-4.02	6.69e-05	0.01	-0.18	-0.18	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10460833	chr8:11104691~11106704:-
HNSC	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	4.02	6.7e-05	0.01	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
HNSC	cis	rs9393777	0.623	rs9366658	ENSG00000241549.7	GUSBP2	4.02	6.7e-05	0.01	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26469638	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs9358944	ENSG00000241549.7	GUSBP2	4.02	6.7e-05	0.01	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26469647	chr6:26871484~26956554:-
HNSC	cis	rs9929218	0.529	rs8059194	ENSG00000260459.2	FTLP14	4.02	6.7e-05	0.01	0.24	0.18	Colorectal cancer;	chr16:68715760	chr16:68822587~68823070:+
HNSC	cis	rs6504108	0.647	rs3805370	ENSG00000278765.1	RP5-890E16.5	-4.02	6.7e-05	0.01	-0.23	-0.18	Body mass index;	chr17:48181731	chr17:48066704~48067293:-
HNSC	cis	rs6504108	0.647	rs3805371	ENSG00000278765.1	RP5-890E16.5	-4.02	6.7e-05	0.01	-0.23	-0.18	Body mass index;	chr17:48181739	chr17:48066704~48067293:-
HNSC	cis	rs13179617	0.928	rs7717082	ENSG00000215032.2	GNL3LP1	4.02	6.7e-05	0.01	0.21	0.18	Intelligence (multi-trait analysis);	chr5:61473584	chr5:60891935~60893577:-
HNSC	cis	rs700651	0.789	rs62277902	ENSG00000231621.1	AC013264.2	4.02	6.7e-05	0.01	0.18	0.18	Intracranial aneurysm;	chr2:198014719	chr2:197197991~197199273:+
HNSC	cis	rs792448	0.743	rs351373	ENSG00000226251.4	RP11-15I11.3	-4.02	6.7e-05	0.01	-0.22	-0.18	White blood cell count (basophil);	chr1:212253289	chr1:212225278~212238977:-
HNSC	cis	rs9611565	0.568	rs5758441	ENSG00000233903.2	Z83851.4	4.02	6.7e-05	0.0101	0.25	0.18	Vitiligo;	chr22:41736884	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.649	rs5758442	ENSG00000233903.2	Z83851.4	4.02	6.7e-05	0.0101	0.25	0.18	Vitiligo;	chr22:41737056	chr22:42276355~42277052:+
HNSC	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-4.02	6.71e-05	0.0101	-0.27	-0.18	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-4.02	6.71e-05	0.0101	-0.27	-0.18	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-4.02	6.71e-05	0.0101	-0.27	-0.18	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
HNSC	cis	rs12908161	0.92	rs12904605	ENSG00000229212.6	RP11-561C5.4	-4.02	6.71e-05	0.0101	-0.26	-0.18	Schizophrenia;	chr15:84658188	chr15:85205440~85234795:-
HNSC	cis	rs71520386	0.561	rs10274260	ENSG00000228649.7	AC005682.5	-4.02	6.71e-05	0.0101	-0.2	-0.18	Fibrinogen levels;	chr7:22805227	chr7:22854178~22861579:+
HNSC	cis	rs56114371	0.53	rs9357045	ENSG00000219392.1	RP1-265C24.5	-4.02	6.71e-05	0.0101	-0.25	-0.18	Breast cancer;	chr6:27721148	chr6:28115628~28116551:+
HNSC	cis	rs2333194	0.875	rs7140876	ENSG00000258695.2	RP3-414A15.2	-4.02	6.71e-05	0.0101	-0.19	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr14:73326230	chr14:73522878~73530610:+
HNSC	cis	rs1009077	0.716	rs17358524	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119570559	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs34676199	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119589154	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs2389868	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119594344	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs35850447	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119597610	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs62319647	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119597862	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs35999787	ENSG00000245958.5	RP11-33B1.1	4.02	6.71e-05	0.0101	0.21	0.18	Endometriosis;	chr4:119597949	chr4:119454791~119552025:+
HNSC	cis	rs9304742	1	rs9304742	ENSG00000242779.5	ZNF702P	4.02	6.71e-05	0.0101	0.22	0.18	Psoriasis;	chr19:52948038	chr19:52968251~53037898:-
HNSC	cis	rs7771547	0.573	rs522179	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36423828	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs584418	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36427660	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs566742	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36427891	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.542	rs597153	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36428220	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs9470274	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36429452	chr6:35555873~35556264:+
HNSC	cis	rs515186	1	rs515186	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Mean platelet volume;	chr6:36429715	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs517890	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36430009	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs629297	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36430369	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs629721	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36430452	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs544267	ENSG00000219023.1	RP3-340B19.2	4.02	6.71e-05	0.0101	0.16	0.18	Platelet distribution width;	chr6:36430525	chr6:35555873~35556264:+
HNSC	cis	rs3736485	0.934	rs4775953	ENSG00000259438.1	CTD-2650P22.1	4.02	6.71e-05	0.0101	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51580976	chr15:52010999~52019095:-
HNSC	cis	rs10078	0.528	rs2434697	ENSG00000225138.6	CTD-2228K2.7	4.02	6.71e-05	0.0101	0.32	0.18	Fat distribution (HIV);	chr5:466696	chr5:473236~480884:+
HNSC	cis	rs7829975	0.806	rs2428	ENSG00000254153.1	CTA-398F10.2	4.02	6.71e-05	0.0101	0.2	0.18	Mood instability;	chr8:8783635	chr8:8456909~8461337:-
HNSC	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	4.02	6.71e-05	0.0101	0.21	0.18	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000241549.7	GUSBP2	4.02	6.71e-05	0.0101	0.2	0.18	Parkinson's disease;	chr6:27891675	chr6:26871484~26956554:-
HNSC	cis	rs4144743	0.759	rs34251886	ENSG00000228782.6	CTD-2026D20.3	-4.02	6.71e-05	0.0101	-0.24	-0.18	Body mass index;	chr17:47242933	chr17:47450568~47492492:-
HNSC	cis	rs4700393	0.967	rs4700394	ENSG00000272308.1	RP11-231G3.1	4.02	6.71e-05	0.0101	0.18	0.18	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60866457~60866935:-
HNSC	cis	rs11098499	0.863	rs1480939	ENSG00000250412.1	KLHL2P1	4.02	6.71e-05	0.0101	0.24	0.18	Corneal astigmatism;	chr4:119535772	chr4:119334329~119378233:+
HNSC	cis	rs875971	0.52	rs160645	ENSG00000164669.11	INTS4P1	4.02	6.72e-05	0.0101	0.26	0.18	Aortic root size;	chr7:66091320	chr7:65141225~65234216:+
HNSC	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-4.02	6.72e-05	0.0101	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
HNSC	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-4.02	6.72e-05	0.0101	-0.23	-0.18	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
HNSC	cis	rs354225	0.785	rs2567834	ENSG00000237887.1	AC092839.1	-4.02	6.72e-05	0.0101	-0.23	-0.18	Schizophrenia;	chr2:54706232	chr2:54529343~54529801:+
HNSC	cis	rs2518049	0.654	rs17134523	ENSG00000224034.1	RP11-445P17.8	-4.02	6.72e-05	0.0101	-0.26	-0.18	Metabolic traits;	chr10:5197337	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.654	rs7074004	ENSG00000224034.1	RP11-445P17.8	-4.02	6.72e-05	0.0101	-0.26	-0.18	Metabolic traits;	chr10:5197743	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.654	rs7087111	ENSG00000224034.1	RP11-445P17.8	-4.02	6.72e-05	0.0101	-0.26	-0.18	Metabolic traits;	chr10:5197861	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.654	rs7070862	ENSG00000224034.1	RP11-445P17.8	-4.02	6.72e-05	0.0101	-0.26	-0.18	Metabolic traits;	chr10:5197995	chr10:5266033~5271236:-
HNSC	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	4.02	6.72e-05	0.0101	0.21	0.18	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
HNSC	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-4.02	6.72e-05	0.0101	-0.18	-0.18	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
HNSC	cis	rs35963943	0.625	rs13099145	ENSG00000228956.7	SATB1-AS1	4.02	6.72e-05	0.0101	0.22	0.18	Lymphocyte counts;	chr3:18709825	chr3:18445024~18920401:+
HNSC	cis	rs2518049	0.904	rs2398186	ENSG00000224034.1	RP11-445P17.8	4.02	6.72e-05	0.0101	0.25	0.18	Metabolic traits;	chr10:5080378	chr10:5266033~5271236:-
HNSC	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-4.02	6.72e-05	0.0101	-0.23	-0.18	Height;	chr20:49280020	chr20:49280319~49280409:+
HNSC	cis	rs988913	0.957	rs9475068	ENSG00000224984.1	RP11-524H19.2	4.02	6.73e-05	0.0101	0.21	0.18	Menarche (age at onset);	chr6:54926783	chr6:54840118~54840855:-
HNSC	cis	rs9611565	0.765	rs132905	ENSG00000235513.1	RP4-756G23.5	-4.02	6.73e-05	0.0101	-0.22	-0.18	Vitiligo;	chr22:41403102	chr22:41209122~41217627:-
HNSC	cis	rs13073817	0.543	rs336613	ENSG00000228956.7	SATB1-AS1	4.02	6.73e-05	0.0101	0.19	0.18	Crohn's disease;	chr3:18590533	chr3:18445024~18920401:+
HNSC	cis	rs1538970	0.816	rs3790583	ENSG00000234329.1	RP11-767N6.2	4.02	6.73e-05	0.0101	0.22	0.18	Platelet count;	chr1:45491156	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.816	rs11211123	ENSG00000234329.1	RP11-767N6.2	4.02	6.73e-05	0.0101	0.22	0.18	Platelet count;	chr1:45491937	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.816	rs10789464	ENSG00000234329.1	RP11-767N6.2	4.02	6.73e-05	0.0101	0.22	0.18	Platelet count;	chr1:45493430	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.816	rs11211124	ENSG00000234329.1	RP11-767N6.2	4.02	6.73e-05	0.0101	0.22	0.18	Platelet count;	chr1:45496737	chr1:45651039~45651826:-
HNSC	cis	rs1555322	1	rs2425040	ENSG00000279253.1	RP4-614O4.13	-4.02	6.73e-05	0.0101	-0.27	-0.18	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35262727~35264187:-
HNSC	cis	rs12745968	0.589	rs7513775	ENSG00000223787.2	RP4-593M8.1	-4.02	6.73e-05	0.0101	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92538940	chr1:92580476~92580821:-
HNSC	cis	rs1941023	0.619	rs11230342	ENSG00000279632.1	RP11-286N22.6	4.02	6.73e-05	0.0101	0.2	0.18	Congenital heart disease (maternal effect);	chr11:60494449	chr11:61426448~61427325:-
HNSC	cis	rs6840258	0.825	rs72667751	ENSG00000251411.1	RP11-397E7.4	-4.02	6.73e-05	0.0101	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87015227	chr4:86913266~86914817:-
HNSC	cis	rs9329221	0.532	rs2062333	ENSG00000254340.1	RP11-10A14.3	4.02	6.73e-05	0.0101	0.22	0.18	Neuroticism;	chr8:10123639	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-4.02	6.74e-05	0.0101	-0.25	-0.18	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
HNSC	cis	rs9733	0.744	rs2039590	ENSG00000236713.1	RP11-363I22.3	4.02	6.74e-05	0.0101	0.2	0.18	Tonsillectomy;	chr1:150840839	chr1:150780272~150780644:+
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000250412.1	KLHL2P1	4.02	6.74e-05	0.0101	0.23	0.18	Corneal astigmatism;	chr4:119327779	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000250412.1	KLHL2P1	4.02	6.74e-05	0.0101	0.23	0.18	Corneal astigmatism;	chr4:119328085	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000250412.1	KLHL2P1	4.02	6.74e-05	0.0101	0.23	0.18	Corneal astigmatism;	chr4:119328133	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000250412.1	KLHL2P1	4.02	6.74e-05	0.0101	0.23	0.18	Corneal astigmatism;	chr4:119328146	chr4:119334329~119378233:+
HNSC	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	4.02	6.74e-05	0.0101	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
HNSC	cis	rs116095464	0.614	rs10059220	ENSG00000250848.1	CTD-2083E4.5	-4.02	6.74e-05	0.0101	-0.26	-0.18	Breast cancer;	chr5:242698	chr5:288833~290321:-
HNSC	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-4.02	6.74e-05	0.0101	-0.24	-0.18	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	4.02	6.74e-05	0.0101	0.31	0.18	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
HNSC	cis	rs7688540	0.771	rs11730202	ENSG00000250892.1	RP11-1365D11.1	-4.02	6.74e-05	0.0101	-0.31	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:201409~205009:-
HNSC	cis	rs7674212	0.54	rs2720469	ENSG00000251288.2	RP11-10L12.2	-4.02	6.74e-05	0.0101	-0.21	-0.18	Type 2 diabetes;	chr4:103165327	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.57	rs6810571	ENSG00000251288.2	RP11-10L12.2	-4.02	6.74e-05	0.0101	-0.21	-0.18	Type 2 diabetes;	chr4:103165630	chr4:102751401~102752641:+
HNSC	cis	rs13256369	0.76	rs7816171	ENSG00000173295.6	FAM86B3P	4.02	6.74e-05	0.0101	0.24	0.18	Obesity-related traits;	chr8:8718325	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.76	rs7839473	ENSG00000173295.6	FAM86B3P	4.02	6.74e-05	0.0101	0.24	0.18	Obesity-related traits;	chr8:8718326	chr8:8228595~8244865:+
HNSC	cis	rs4388249	0.898	rs35780891	ENSG00000271849.1	CTC-332L22.1	-4.02	6.74e-05	0.0101	-0.28	-0.18	Schizophrenia;	chr5:109765425	chr5:109687802~109688329:-
HNSC	cis	rs7572733	0.935	rs1105078	ENSG00000222017.1	AC011997.1	4.02	6.75e-05	0.0101	0.22	0.18	Dermatomyositis;	chr2:197943161	chr2:197693106~197774823:+
HNSC	cis	rs2834288	0.618	rs9977699	ENSG00000273102.1	AP000569.9	-4.02	6.75e-05	0.0101	-0.2	-0.18	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33967101~33968573:-
HNSC	cis	rs62432291	0.681	rs294913	ENSG00000235086.1	FNDC1-IT1	-4.02	6.75e-05	0.0101	-0.26	-0.18	Joint mobility (Beighton score);	chr6:159246195	chr6:159240786~159243329:+
HNSC	cis	rs2919009	0.664	rs57078496	ENSG00000271670.1	RP11-95I16.4	4.02	6.75e-05	0.0101	0.24	0.18	Obesity-related traits;	chr10:120881877	chr10:120879256~120880667:-
HNSC	cis	rs2075555	0.679	rs12939159	ENSG00000250107.1	CACNA1G-AS1	4.02	6.75e-05	0.0101	0.32	0.18	Breast cancer;	chr17:50167170	chr17:50556207~50562108:-
HNSC	cis	rs2153535	0.585	rs1033803	ENSG00000230939.1	RP11-314C16.1	-4.02	6.75e-05	0.0101	-0.21	-0.18	Motion sickness;	chr6:8674779	chr6:8784178~8785445:+
HNSC	cis	rs7688540	0.771	rs61792114	ENSG00000250892.1	RP11-1365D11.1	-4.02	6.75e-05	0.0101	-0.32	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:201409~205009:-
HNSC	cis	rs7121616	0.96	rs12361252	ENSG00000200879.1	SNORD14E	4.02	6.75e-05	0.0101	0.24	0.18	Breast cancer;	chr11:123091564	chr11:123058077~123058161:-
HNSC	cis	rs889398	0.967	rs1437134	ENSG00000226232.7	RP11-419C5.2	-4.02	6.75e-05	0.0101	-0.16	-0.18	Body mass index;	chr16:69696523	chr16:69976388~69996188:-
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000233609.3	RP11-62H7.2	-4.02	6.76e-05	0.0101	-0.19	-0.18	Recombination measurement;	chr8:9208000	chr8:8961200~8979025:+
HNSC	cis	rs61270009	0.955	rs780397	ENSG00000247828.6	TMEM161B-AS1	-4.02	6.76e-05	0.0101	-0.18	-0.18	Depressive symptoms;	chr5:88233841	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.874	rs780403	ENSG00000247828.6	TMEM161B-AS1	-4.02	6.76e-05	0.0101	-0.18	-0.18	Depressive symptoms;	chr5:88244989	chr5:88268895~88436685:+
HNSC	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	4.02	6.76e-05	0.0101	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
HNSC	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	4.02	6.76e-05	0.0101	0.27	0.18	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
HNSC	cis	rs2253762	0.54	rs11200351	ENSG00000276742.1	RP11-500G22.4	4.02	6.76e-05	0.0101	0.27	0.18	Breast cancer;	chr10:122029957	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs11200353	ENSG00000276742.1	RP11-500G22.4	4.02	6.76e-05	0.0101	0.27	0.18	Breast cancer;	chr10:122030181	chr10:121956782~121957098:+
HNSC	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-4.02	6.76e-05	0.0101	-0.23	-0.18	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
HNSC	cis	rs2342371	0.756	rs28712197	ENSG00000243339.3	RN7SL738P	-4.02	6.76e-05	0.0101	-0.25	-0.18	Fat distribution (HIV);	chr3:196380343	chr3:196399911~196400207:+
HNSC	cis	rs17660992	0.584	rs11672561	ENSG00000273837.1	LLNLR-470E3.1	-4.02	6.76e-05	0.0101	-0.21	-0.18	Blood protein levels;	chr19:51656353	chr19:51639478~51639931:-
HNSC	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	4.02	6.76e-05	0.0101	0.21	0.18	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	4.02	6.76e-05	0.0101	0.21	0.18	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
HNSC	cis	rs7572733	0.773	rs7588831	ENSG00000222017.1	AC011997.1	4.02	6.76e-05	0.0101	0.22	0.18	Dermatomyositis;	chr2:197643292	chr2:197693106~197774823:+
HNSC	cis	rs683257	0.636	rs58922657	ENSG00000234147.1	RP3-460G2.2	-4.02	6.77e-05	0.0101	-0.32	-0.18	Facial emotion recognition (angry faces);	chr6:140831739	chr6:140845958~140852924:-
HNSC	cis	rs10791097	0.694	rs4459316	ENSG00000254842.5	RP11-890B15.2	-4.02	6.77e-05	0.0101	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886281	chr11:130844191~130865561:-
HNSC	cis	rs1190596	0.526	rs1190572	ENSG00000271780.1	RP11-1017G21.5	-4.02	6.77e-05	0.0101	-0.18	-0.18	Behavioural disinhibition (generation interaction);	chr14:102168252	chr14:101948347~101949425:+
HNSC	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-4.02	6.77e-05	0.0101	-0.23	-0.18	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
HNSC	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	4.02	6.77e-05	0.0101	0.21	0.18	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
HNSC	cis	rs12745968	0.589	rs6695638	ENSG00000223787.2	RP4-593M8.1	-4.02	6.77e-05	0.0101	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92557929	chr1:92580476~92580821:-
HNSC	cis	rs924607	0.931	rs1709556	ENSG00000225138.6	CTD-2228K2.7	4.02	6.77e-05	0.0101	0.2	0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:636943	chr5:473236~480884:+
HNSC	cis	rs924607	0.966	rs1709554	ENSG00000225138.6	CTD-2228K2.7	4.02	6.77e-05	0.0101	0.2	0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:637328	chr5:473236~480884:+
HNSC	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-4.02	6.77e-05	0.0101	-0.2	-0.18	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
HNSC	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-4.02	6.78e-05	0.0101	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
HNSC	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-4.02	6.78e-05	0.0101	-0.22	-0.18	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
HNSC	cis	rs2013441	0.866	rs2703811	ENSG00000261033.1	RP11-209D14.2	4.02	6.78e-05	0.0101	0.21	0.18	Obesity-related traits;	chr17:20210662	chr17:20008051~20009234:-
HNSC	cis	rs12893668	0.543	rs12147645	ENSG00000269910.1	RP11-73M18.10	4.02	6.78e-05	0.0101	0.18	0.18	Reticulocyte count;	chr14:103633871	chr14:103694516~103695050:-
HNSC	cis	rs1185460	0.967	rs1184902	ENSG00000272186.1	RP11-110I1.13	-4.02	6.78e-05	0.0101	-0.21	-0.18	Coronary artery disease;	chr11:119074627	chr11:119067374~119067698:-
HNSC	cis	rs9903692	0.954	rs1860866	ENSG00000263412.1	RP5-890E16.2	4.02	6.78e-05	0.0101	0.17	0.18	Pulse pressure;	chr17:48123669	chr17:48045141~48048073:-
HNSC	cis	rs4622329	0.615	rs7306175	ENSG00000258033.1	RP11-350G24.2	4.02	6.78e-05	0.0101	0.2	0.18	Systemic lupus erythematosus;	chr12:101900840	chr12:101066734~101069232:+
HNSC	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	4.02	6.78e-05	0.0101	0.19	0.18	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
HNSC	cis	rs7824557	0.527	rs57629785	ENSG00000255310.2	AF131215.2	-4.02	6.79e-05	0.0101	-0.17	-0.18	Retinal vascular caliber;	chr8:11377641	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs2572395	ENSG00000255310.2	AF131215.2	-4.02	6.79e-05	0.0101	-0.17	-0.18	Retinal vascular caliber;	chr8:11377851	chr8:11107788~11109726:-
HNSC	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	4.02	6.79e-05	0.0102	0.22	0.18	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
HNSC	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	4.02	6.79e-05	0.0102	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
HNSC	cis	rs6095360	0.934	rs730544	ENSG00000222365.1	SNORD12B	-4.02	6.79e-05	0.0102	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49019281	chr20:49280319~49280409:+
HNSC	cis	rs638893	0.636	rs6589687	ENSG00000255422.1	AP002954.4	-4.02	6.79e-05	0.0102	-0.31	-0.18	Vitiligo;	chr11:118744951	chr11:118704607~118750263:+
HNSC	cis	rs3738443	1	rs74152976	ENSG00000259865.1	RP11-488L18.10	4.02	6.79e-05	0.0102	0.17	0.18	Alcohol dependence;	chr1:247183504	chr1:247187281~247188526:-
HNSC	cis	rs12545912	0.569	rs499005	ENSG00000254340.1	RP11-10A14.3	-4.02	6.79e-05	0.0102	-0.29	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9939120	chr8:9141424~9145435:+
HNSC	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	4.02	6.79e-05	0.0102	0.28	0.18	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
HNSC	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	4.02	6.79e-05	0.0102	0.21	0.18	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000272831.1	RP11-792A8.4	4.02	6.79e-05	0.0102	0.15	0.18	Calcium levels;	chr7:65974892	chr7:66739829~66740385:-
HNSC	cis	rs1580019	0.961	rs11768506	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32455176	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs11765387	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32455178	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs4320456	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456391	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs4357201	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456721	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs4255041	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456771	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.885	rs4460269	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456833	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.885	rs4460270	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456838	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs4460271	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32456891	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs3801328	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32457318	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs1580021	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32458090	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs1580022	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32458100	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.921	rs1580023	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32458269	chr7:32456963~32457758:-
HNSC	cis	rs1580019	0.961	rs1610143	ENSG00000226468.2	AC018641.7	-4.02	6.8e-05	0.0102	-0.24	-0.18	Cognitive ability;	chr7:32458719	chr7:32456963~32457758:-
HNSC	cis	rs4578769	0.55	rs9961760	ENSG00000265943.1	RP11-739L10.1	4.02	6.8e-05	0.0102	0.21	0.18	Eosinophil percentage of white cells;	chr18:23021545	chr18:22699481~22933764:-
HNSC	cis	rs2467099	0.679	rs59867239	ENSG00000267801.1	RP11-552F3.9	4.02	6.8e-05	0.0102	0.24	0.18	Systolic blood pressure;	chr17:75935706	chr17:75876372~75879546:+
HNSC	cis	rs2467099	0.679	rs2608882	ENSG00000267801.1	RP11-552F3.9	4.02	6.8e-05	0.0102	0.24	0.18	Systolic blood pressure;	chr17:75938049	chr17:75876372~75879546:+
HNSC	cis	rs16858210	0.529	rs10937154	ENSG00000234371.6	RPSAP31	4.02	6.8e-05	0.0102	0.25	0.18	Menopause (age at onset);	chr3:183851701	chr3:183884924~183888449:+
HNSC	cis	rs4242434	0.819	rs6558173	ENSG00000253837.1	RP11-177H13.2	4.02	6.8e-05	0.0102	0.19	0.18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22634590	chr8:23336171~23366125:+
HNSC	cis	rs11148252	0.574	rs61958118	ENSG00000198384.8	TPTE2P3	4.02	6.8e-05	0.0102	0.22	0.18	Lewy body disease;	chr13:52596091	chr13:52522632~52586906:+
HNSC	cis	rs964611	0.882	rs1820491	ENSG00000259488.2	RP11-154J22.1	4.02	6.8e-05	0.0102	0.16	0.18	Metabolite levels (Pyroglutamine);	chr15:48311245	chr15:48312353~48331856:-
HNSC	cis	rs442309	0.749	rs224109	ENSG00000238280.1	RP11-436D10.3	-4.02	6.8e-05	0.0102	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62790311	chr10:62793562~62805887:-
HNSC	cis	rs3015497	0.789	rs3015498	ENSG00000277050.1	RP11-102G14.1	-4.02	6.8e-05	0.0102	-0.17	-0.18	Mean platelet volume;	chr14:50646106	chr14:51637348~51637947:-
HNSC	cis	rs10484434	1	rs17596719	ENSG00000218690.1	HIST1H2APS4	-4.02	6.8e-05	0.0102	-0.31	-0.18	HIV-1 viral setpoint;	chr6:26096966	chr6:26272193~26272540:-
HNSC	cis	rs847649	0.765	rs10953383	ENSG00000239969.4	RP11-163E9.2	4.02	6.8e-05	0.0102	0.22	0.18	Morning vs. evening chronotype;	chr7:103133629	chr7:102364162~102380633:+
HNSC	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	4.02	6.81e-05	0.0102	0.31	0.18	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
HNSC	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-4.02	6.81e-05	0.0102	-0.21	-0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
HNSC	cis	rs4713118	0.696	rs2394002	ENSG00000224843.5	LINC00240	4.02	6.81e-05	0.0102	0.21	0.18	Parkinson's disease;	chr6:27780236	chr6:26956992~27023924:+
HNSC	cis	rs728616	0.867	rs56271768	ENSG00000225484.5	NUTM2B-AS1	-4.02	6.81e-05	0.0102	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79663088~79826594:-
HNSC	cis	rs3822625	0.541	rs12657353	ENSG00000271828.1	CTD-2310F14.1	4.02	6.81e-05	0.0102	0.4	0.18	Breast cancer (early onset);	chr5:56900449	chr5:56927874~56929573:+
HNSC	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	4.02	6.81e-05	0.0102	0.23	0.18	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
HNSC	cis	rs6787172	0.783	rs12638438	ENSG00000272087.1	RP11-379F4.7	4.02	6.81e-05	0.0102	0.19	0.18	Subjective well-being;	chr3:158502045	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs9810887	ENSG00000272087.1	RP11-379F4.7	4.02	6.81e-05	0.0102	0.19	0.18	Subjective well-being;	chr3:158503921	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs7623732	ENSG00000272087.1	RP11-379F4.7	4.02	6.81e-05	0.0102	0.19	0.18	Subjective well-being;	chr3:158504647	chr3:158693120~158693768:-
HNSC	cis	rs4713118	0.696	rs2394002	ENSG00000216901.1	AL022393.7	4.02	6.82e-05	0.0102	0.24	0.18	Parkinson's disease;	chr6:27780236	chr6:28176188~28176674:+
HNSC	cis	rs7572733	0.773	rs970551	ENSG00000222017.1	AC011997.1	4.02	6.82e-05	0.0102	0.22	0.18	Dermatomyositis;	chr2:197632985	chr2:197693106~197774823:+
HNSC	cis	rs11098499	0.863	rs10013305	ENSG00000250412.1	KLHL2P1	4.02	6.82e-05	0.0102	0.24	0.18	Corneal astigmatism;	chr4:119529269	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775849	ENSG00000250412.1	KLHL2P1	4.02	6.82e-05	0.0102	0.24	0.18	Corneal astigmatism;	chr4:119529753	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.818	rs7688802	ENSG00000250412.1	KLHL2P1	4.02	6.82e-05	0.0102	0.24	0.18	Corneal astigmatism;	chr4:119530513	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs7695620	ENSG00000250412.1	KLHL2P1	4.02	6.82e-05	0.0102	0.24	0.18	Corneal astigmatism;	chr4:119531621	chr4:119334329~119378233:+
HNSC	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	4.02	6.82e-05	0.0102	0.25	0.18	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
HNSC	cis	rs9437689	0.934	rs4847220	ENSG00000237416.5	RP11-465K1.2	4.02	6.82e-05	0.0102	0.22	0.18	Phospholipid levels (plasma);	chr1:94998429	chr1:94836748~94855426:-
HNSC	cis	rs2548724	0.661	rs7716398	ENSG00000250682.4	LINC00491	4.02	6.83e-05	0.0102	0.24	0.18	Type 2 diabetes;	chr5:102468541	chr5:102609156~102671559:-
HNSC	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-4.02	6.83e-05	0.0102	-0.24	-0.18	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
HNSC	cis	rs73222236	0.817	rs9845950	ENSG00000273486.1	RP11-731C17.2	4.02	6.83e-05	0.0102	0.15	0.18	Coronary artery disease;	chr3:136637756	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.817	rs7644346	ENSG00000273486.1	RP11-731C17.2	4.02	6.83e-05	0.0102	0.15	0.18	Coronary artery disease;	chr3:136639645	chr3:136837338~136839021:-
HNSC	cis	rs73222236	0.817	rs28682370	ENSG00000273486.1	RP11-731C17.2	4.02	6.83e-05	0.0102	0.15	0.18	Coronary artery disease;	chr3:136644222	chr3:136837338~136839021:-
HNSC	cis	rs2274273	0.712	rs7144652	ENSG00000233924.1	AL160471.6	-4.02	6.83e-05	0.0102	-0.21	-0.18	Protein biomarker;	chr14:55071000	chr14:55004813~55005687:-
HNSC	cis	rs34421088	0.678	rs35726503	ENSG00000269918.1	AF131215.9	-4.02	6.83e-05	0.0102	-0.18	-0.18	Neuroticism;	chr8:11734407	chr8:11104691~11106704:-
HNSC	cis	rs60617249	0.811	rs6947872	ENSG00000228204.2	RP4-724E13.2	4.02	6.83e-05	0.0102	0.19	0.18	Major depression and alcohol dependence;	chr7:50912641	chr7:50866747~51022990:+
HNSC	cis	rs9880211	0.8	rs9865995	ENSG00000239213.4	NCK1-AS1	4.02	6.83e-05	0.0102	0.19	0.18	Height;Body mass index;	chr3:136794508	chr3:136841726~136862054:-
HNSC	cis	rs4356203	0.87	rs7925692	ENSG00000272034.1	SNORD14A	4.02	6.83e-05	0.0102	0.14	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17074654~17074744:-
HNSC	cis	rs897984	0.647	rs8060857	ENSG00000260911.2	RP11-196G11.2	-4.02	6.83e-05	0.0102	-0.17	-0.18	Dementia with Lewy bodies;	chr16:30991399	chr16:31043150~31049868:+
HNSC	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	4.02	6.83e-05	0.0102	0.18	0.18	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	4.02	6.83e-05	0.0102	0.18	0.18	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
HNSC	cis	rs6928977	0.863	rs6918097	ENSG00000217482.2	HMGB1P17	-4.02	6.84e-05	0.0102	-0.2	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135314411	chr6:135636086~135636713:-
HNSC	cis	rs6710503	0.632	rs9309308	ENSG00000271936.1	RP11-443B20.1	4.02	6.84e-05	0.0102	0.22	0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24771701	chr2:24825610~24826717:+
HNSC	cis	rs3736485	0.932	rs4774592	ENSG00000259438.1	CTD-2650P22.1	4.02	6.84e-05	0.0102	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51486682	chr15:52010999~52019095:-
HNSC	cis	rs7612445	0.536	rs73043474	ENSG00000260743.1	RP11-255C15.3	4.02	6.84e-05	0.0102	0.26	0.18	Resting heart rate;Heart rate;	chr3:179357272	chr3:179340322~179341887:+
HNSC	cis	rs7809950	0.635	rs62483629	ENSG00000238832.1	snoU109	-4.02	6.84e-05	0.0102	-0.27	-0.18	Coronary artery disease;	chr7:107225733	chr7:107603363~107603507:+
HNSC	cis	rs6095360	0.966	rs6090940	ENSG00000222365.1	SNORD12B	-4.02	6.84e-05	0.0102	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:49049490	chr20:49280319~49280409:+
HNSC	cis	rs875971	0.545	rs313828	ENSG00000164669.11	INTS4P1	4.02	6.84e-05	0.0102	0.26	0.18	Aortic root size;	chr7:66087627	chr7:65141225~65234216:+
HNSC	cis	rs875971	0.571	rs160647	ENSG00000164669.11	INTS4P1	4.02	6.84e-05	0.0102	0.26	0.18	Aortic root size;	chr7:66089365	chr7:65141225~65234216:+
HNSC	cis	rs11168618	0.81	rs11168595	ENSG00000240399.1	RP1-228P16.1	4.02	6.84e-05	0.0102	0.16	0.18	Adiponectin levels;	chr12:48474428	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.743	rs12815151	ENSG00000240399.1	RP1-228P16.1	4.02	6.84e-05	0.0102	0.16	0.18	Adiponectin levels;	chr12:48481053	chr12:48054813~48055591:-
HNSC	cis	rs6061231	0.837	rs6121558	ENSG00000275437.1	RP5-908M14.10	4.02	6.84e-05	0.0102	0.2	0.18	Colorectal cancer;	chr20:62386309	chr20:62402236~62405935:-
HNSC	cis	rs7824557	0.583	rs2263511	ENSG00000269918.1	AF131215.9	-4.02	6.84e-05	0.0102	-0.18	-0.18	Retinal vascular caliber;	chr8:11375809	chr8:11104691~11106704:-
HNSC	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-4.02	6.84e-05	0.0102	-0.22	-0.18	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
HNSC	cis	rs9379945	1	rs9379945	ENSG00000241549.7	GUSBP2	4.02	6.84e-05	0.0102	0.26	0.18	Intelligence (multi-trait analysis);	chr6:26940052	chr6:26871484~26956554:-
HNSC	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	4.02	6.85e-05	0.0102	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
HNSC	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-4.02	6.85e-05	0.0102	-0.22	-0.18	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-4.02	6.85e-05	0.0102	-0.22	-0.18	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
HNSC	cis	rs4873772	0.834	rs6986054	ENSG00000253330.1	RP11-697N18.3	-4.02	6.85e-05	0.0102	-0.23	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47661576	chr8:47511034~47512141:-
HNSC	cis	rs75422866	0.867	rs73104112	ENSG00000280054.1	RP1-197B17.7	4.02	6.85e-05	0.0102	0.42	0.18	Pneumonia;	chr12:47680969	chr12:47728151~47730598:-
HNSC	cis	rs544991	0.687	rs4282780	ENSG00000239670.1	RP4-803A2.2	4.02	6.85e-05	0.0102	0.23	0.18	Intelligence;	chr1:33745230	chr1:32986952~32988233:+
HNSC	cis	rs9907295	0.71	rs9894083	ENSG00000270977.1	AC015849.16	-4.02	6.85e-05	0.0102	-0.3	-0.18	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35893707~35911023:-
HNSC	cis	rs3736485	0.966	rs10467924	ENSG00000259438.1	CTD-2650P22.1	4.02	6.85e-05	0.0102	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51495382	chr15:52010999~52019095:-
HNSC	cis	rs17407555	0.683	rs6833035	ENSG00000250413.1	RP11-448G15.1	-4.02	6.85e-05	0.0102	-0.24	-0.18	Schizophrenia (age at onset);	chr4:10270645	chr4:10006482~10009725:+
HNSC	cis	rs944002	0.951	rs7151779	ENSG00000259444.1	RP11-736N17.8	4.02	6.85e-05	0.0102	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099825	chr14:103094723~103098885:+
HNSC	cis	rs7819412	0.875	rs6981523	ENSG00000255495.1	AC145124.2	-4.02	6.85e-05	0.0102	-0.21	-0.18	Triglycerides;	chr8:11204283	chr8:12194467~12196280:+
HNSC	cis	rs2446066	0.605	rs7298336	ENSG00000270175.1	RP11-793H13.11	-4.02	6.85e-05	0.0102	-0.24	-0.18	Red blood cell count;	chr12:53563546	chr12:53500162~53500936:-
HNSC	cis	rs6651255	0.58	rs72718336	ENSG00000224110.3	MTRF1LP2	-4.02	6.85e-05	0.0102	-0.24	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129779820	chr8:129728744~129730445:+
HNSC	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	4.02	6.85e-05	0.0102	0.22	0.18	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
HNSC	cis	rs56114371	0.568	rs200468	ENSG00000224843.5	LINC00240	4.02	6.85e-05	0.0102	0.22	0.18	Breast cancer;	chr6:27790076	chr6:26956992~27023924:+
HNSC	cis	rs6586111	1	rs4933462	ENSG00000226659.1	RP11-137H2.4	-4.02	6.85e-05	0.0102	-0.22	-0.18	Capecitabine sensitivity;	chr10:80612856	chr10:80529597~80535942:-
HNSC	cis	rs1008375	1	rs4235388	ENSG00000249502.1	AC006160.5	-4.02	6.86e-05	0.0102	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680407	chr4:17587467~17614571:-
HNSC	cis	rs2898290	0.622	rs7822109	ENSG00000269918.1	AF131215.9	-4.02	6.86e-05	0.0102	-0.18	-0.18	Systolic blood pressure;	chr8:11491638	chr8:11104691~11106704:-
HNSC	cis	rs924607	1	rs12523022	ENSG00000225138.6	CTD-2228K2.7	-4.02	6.86e-05	0.0102	-0.2	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:598528	chr5:473236~480884:+
HNSC	cis	rs4713118	0.738	rs200465	ENSG00000224843.5	LINC00240	4.02	6.86e-05	0.0102	0.21	0.18	Parkinson's disease;	chr6:27789875	chr6:26956992~27023924:+
HNSC	cis	rs10771431	0.935	rs1117735	ENSG00000256427.1	RP11-118B22.4	4.02	6.86e-05	0.0102	0.19	0.18	Breast size;	chr12:9220132	chr12:9246497~9257960:+
HNSC	cis	rs2732480	0.5	rs7966829	ENSG00000257763.1	OR5BK1P	4.02	6.86e-05	0.0102	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48355792~48356614:-
HNSC	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	4.02	6.86e-05	0.0102	0.26	0.18	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
HNSC	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-4.02	6.86e-05	0.0102	-0.19	-0.18	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
HNSC	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-4.02	6.86e-05	0.0102	-0.24	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
HNSC	cis	rs7572733	0.534	rs1464211	ENSG00000231621.1	AC013264.2	-4.02	6.87e-05	0.0102	-0.18	-0.18	Dermatomyositis;	chr2:197933906	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1607375	ENSG00000231621.1	AC013264.2	-4.02	6.87e-05	0.0102	-0.18	-0.18	Dermatomyositis;	chr2:197935663	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs4369854	ENSG00000231621.1	AC013264.2	-4.02	6.87e-05	0.0102	-0.18	-0.18	Dermatomyositis;	chr2:197935906	chr2:197197991~197199273:+
HNSC	cis	rs7829975	0.508	rs4841006	ENSG00000173295.6	FAM86B3P	-4.02	6.87e-05	0.0103	-0.21	-0.18	Mood instability;	chr8:8643964	chr8:8228595~8244865:+
HNSC	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	4.02	6.87e-05	0.0103	0.18	0.18	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
HNSC	cis	rs7429990	0.833	rs869508	ENSG00000228638.1	FCF1P2	-4.02	6.87e-05	0.0103	-0.17	-0.18	Educational attainment (years of education);	chr3:47571812	chr3:48290793~48291375:-
HNSC	cis	rs2908197	0.866	rs2961048	ENSG00000186704.9	DTX2P1	4.02	6.87e-05	0.0103	0.18	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76305691	chr7:76978617~77004308:+
HNSC	cis	rs1620921	0.563	rs2243944	ENSG00000231863.1	RP3-428L16.1	-4.02	6.87e-05	0.0103	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160859734	chr6:160931080~160969771:+
HNSC	cis	rs7586673	0.893	rs889925	ENSG00000235724.7	AC009299.2	-4.02	6.87e-05	0.0103	-0.23	-0.18	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161222785~161308303:-
HNSC	cis	rs7586673	0.93	rs2884364	ENSG00000235724.7	AC009299.2	-4.02	6.87e-05	0.0103	-0.23	-0.18	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161222785~161308303:-
HNSC	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	4.02	6.87e-05	0.0103	0.18	0.18	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
HNSC	cis	rs6500395	0.962	rs9937623	ENSG00000261267.1	RP11-44I10.3	4.02	6.87e-05	0.0103	0.23	0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48537679	chr16:48559661~48587403:+
HNSC	cis	rs4919687	0.55	rs12784517	ENSG00000236937.2	PTGES3P4	4.02	6.87e-05	0.0103	0.24	0.18	Colorectal cancer;	chr10:102705213	chr10:102845595~102845950:+
HNSC	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-4.02	6.87e-05	0.0103	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
HNSC	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-4.02	6.87e-05	0.0103	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
HNSC	cis	rs4713118	0.824	rs2179095	ENSG00000216901.1	AL022393.7	-4.02	6.87e-05	0.0103	-0.23	-0.18	Parkinson's disease;	chr6:27783079	chr6:28176188~28176674:+
HNSC	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	4.02	6.87e-05	0.0103	0.48	0.18	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	4.02	6.87e-05	0.0103	0.48	0.18	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	4.02	6.87e-05	0.0103	0.48	0.18	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	4.02	6.87e-05	0.0103	0.22	0.18	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
HNSC	cis	rs60617249	0.862	rs11982677	ENSG00000228204.2	RP4-724E13.2	4.02	6.87e-05	0.0103	0.19	0.18	Major depression and alcohol dependence;	chr7:50921205	chr7:50866747~51022990:+
HNSC	cis	rs11168618	0.626	rs11609074	ENSG00000240399.1	RP1-228P16.1	4.02	6.88e-05	0.0103	0.16	0.18	Adiponectin levels;	chr12:48425552	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.626	rs11514105	ENSG00000240399.1	RP1-228P16.1	4.02	6.88e-05	0.0103	0.16	0.18	Adiponectin levels;	chr12:48427151	chr12:48054813~48055591:-
HNSC	cis	rs9611565	0.694	rs202622	ENSG00000235513.1	RP4-756G23.5	-4.02	6.88e-05	0.0103	-0.23	-0.18	Vitiligo;	chr22:41429338	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.649	rs202625	ENSG00000235513.1	RP4-756G23.5	-4.02	6.88e-05	0.0103	-0.23	-0.18	Vitiligo;	chr22:41431078	chr22:41209122~41217627:-
HNSC	cis	rs9368481	0.761	rs6918835	ENSG00000224843.5	LINC00240	4.02	6.88e-05	0.0103	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26956992~27023924:+
HNSC	cis	rs9650657	0.769	rs2116094	ENSG00000269918.1	AF131215.9	-4.02	6.88e-05	0.0103	-0.18	-0.18	Neuroticism;	chr8:10741312	chr8:11104691~11106704:-
HNSC	cis	rs3736485	0.808	rs4462537	ENSG00000259438.1	CTD-2650P22.1	4.02	6.88e-05	0.0103	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51534321	chr15:52010999~52019095:-
HNSC	cis	rs9368481	0.761	rs9379952	ENSG00000238621.1	TRI-TAT2-2	4.02	6.88e-05	0.0103	0.21	0.18	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:27020335~27020447:+
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.0103	-0.25	-0.18	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.0103	-0.25	-0.18	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.0103	-0.25	-0.18	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
HNSC	cis	rs853679	0.546	rs13214023	ENSG00000226314.6	ZNF192P1	4.02	6.89e-05	0.0103	0.32	0.18	Depression;	chr6:28364364	chr6:28161781~28169594:+
HNSC	cis	rs12887734	0.569	rs66953418	ENSG00000269940.1	RP11-73M18.7	4.02	6.89e-05	0.0103	0.17	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103694560~103695170:+
HNSC	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-4.02	6.89e-05	0.0103	-0.16	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
HNSC	cis	rs913655	0.508	rs2358186	ENSG00000225527.1	RP11-383B4.4	-4.02	6.89e-05	0.0103	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719571	chr10:18531849~18533336:-
HNSC	cis	rs12893668	0.572	rs1606	ENSG00000269958.1	RP11-73M18.8	4.02	6.89e-05	0.0103	0.17	0.18	Reticulocyte count;	chr14:103694944	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.543	rs1799796	ENSG00000269958.1	RP11-73M18.8	4.02	6.89e-05	0.0103	0.17	0.18	Reticulocyte count;	chr14:103699590	chr14:103696353~103697163:+
HNSC	cis	rs793571	0.779	rs28641638	ENSG00000245975.2	RP11-30K9.6	4.02	6.9e-05	0.0103	0.29	0.18	Schizophrenia;	chr15:58923034	chr15:58768072~58770974:-
HNSC	cis	rs1941023	0.619	rs112473092	ENSG00000279632.1	RP11-286N22.6	4.02	6.9e-05	0.0103	0.2	0.18	Congenital heart disease (maternal effect);	chr11:60491556	chr11:61426448~61427325:-
HNSC	cis	rs28489187	0.706	rs233120	ENSG00000223653.4	RP11-131L23.1	4.02	6.9e-05	0.0103	0.25	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322807	chr1:85276715~85448124:+
HNSC	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-4.02	6.9e-05	0.0103	-0.22	-0.18	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
HNSC	cis	rs67072384	0.892	rs67034709	ENSG00000213365.3	AP000593.6	4.02	6.9e-05	0.0103	0.31	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739959	chr11:72280151~72281178:+
HNSC	cis	rs73198271	1	rs11774744	ENSG00000254340.1	RP11-10A14.3	-4.02	6.9e-05	0.0103	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:9141424~9145435:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66121618	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316313	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66128561	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316312	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66131504	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs419603	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66132354	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs387676	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66133233	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs13310597	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66133553	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs431076	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66135333	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2257790	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66135463	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2460422	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66136518	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316334	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66137139	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316332	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66139312	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316330	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66140385	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316329	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66143429	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316326	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66144466	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316325	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66144531	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316321	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66146626	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316318	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66147917	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316317	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66148650	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs316304	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66151907	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs2465120	ENSG00000229886.1	RP5-1132H15.3	4.02	6.91e-05	0.0103	0.31	0.18	Diabetic kidney disease;	chr7:66155987	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66157859	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66158142	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs4718309	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66162777	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6460274	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66163497	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7787230	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66164112	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66170354	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6974723	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66172952	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs9769882	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66177938	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6966322	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66181767	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs4145008	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66182524	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs4718315	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66183554	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs4718316	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66183744	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs1873494	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66184912	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6959002	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.91e-05	0.0103	-0.31	-0.18	Diabetic kidney disease;	chr7:66185509	chr7:66025126~66031544:-
HNSC	cis	rs3096299	0.746	rs9931120	ENSG00000261574.1	RP1-168P16.2	4.02	6.91e-05	0.0103	0.22	0.18	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89392375~89412564:-
HNSC	cis	rs8077577	0.895	rs16960986	ENSG00000273018.4	CTD-2303H24.2	4.02	6.91e-05	0.0103	0.28	0.18	Obesity-related traits;	chr17:18205248	chr17:18511221~18551705:-
HNSC	cis	rs9531006	0.636	rs4052505	ENSG00000227676.3	LINC01068	4.02	6.91e-05	0.0103	0.28	0.18	Sleep duration;	chr13:79938352	chr13:79566727~79571436:+
HNSC	cis	rs10073892	0.581	rs1027660	ENSG00000250682.4	LINC00491	-4.02	6.91e-05	0.0103	-0.25	-0.18	Cognitive decline (age-related);	chr5:102598127	chr5:102609156~102671559:-
HNSC	cis	rs10771431	0.967	rs7137443	ENSG00000256427.1	RP11-118B22.4	4.02	6.91e-05	0.0103	0.19	0.18	Breast size;	chr12:9219433	chr12:9246497~9257960:+
HNSC	cis	rs10771431	0.935	rs1988852	ENSG00000256427.1	RP11-118B22.4	4.02	6.91e-05	0.0103	0.19	0.18	Breast size;	chr12:9220266	chr12:9246497~9257960:+
HNSC	cis	rs10466239	0.892	rs11238514	ENSG00000230555.2	RP11-517P14.2	4.02	6.91e-05	0.0103	0.31	0.18	Telomere length;	chr10:43331011	chr10:43420738~43422100:+
HNSC	cis	rs6601327	0.67	rs4128198	ENSG00000254340.1	RP11-10A14.3	4.02	6.92e-05	0.0103	0.22	0.18	Multiple myeloma (hyperdiploidy);	chr8:9575989	chr8:9141424~9145435:+
HNSC	cis	rs4908760	0.669	rs4908506	ENSG00000232912.4	RP5-1115A15.1	4.02	6.92e-05	0.0103	0.19	0.18	Vitiligo;	chr1:8668919	chr1:8424645~8434838:+
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000254153.1	CTA-398F10.2	-4.02	6.92e-05	0.0103	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9183348	chr8:8456909~8461337:-
HNSC	cis	rs12545109	0.8	rs1371936	ENSG00000246430.5	LINC00968	-4.02	6.92e-05	0.0103	-0.24	-0.18	Obesity-related traits;	chr8:56510156	chr8:56496246~56559823:-
HNSC	cis	rs116095464	0.558	rs55776650	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:273711	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs59113266	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:279850	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs11959126	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:283765	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs7356696	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:284136	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs7356561	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:284266	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs59284383	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:284410	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs7731089	ENSG00000277812.1	AC021087.1	4.02	6.92e-05	0.0103	0.31	0.18	Breast cancer;	chr5:290307	chr5:262769~262881:+
HNSC	cis	rs1387259	0.859	rs2054905	ENSG00000257763.1	OR5BK1P	4.02	6.92e-05	0.0103	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48355792~48356614:-
HNSC	cis	rs7520050	0.966	rs4076006	ENSG00000280836.1	AL355480.1	4.02	6.92e-05	0.0103	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45581219~45581321:-
HNSC	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-4.01	6.93e-05	0.0103	-0.21	-0.18	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	4.01	6.93e-05	0.0103	0.21	0.18	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
HNSC	cis	rs17345786	1	rs55641278	ENSG00000244119.1	PDCL3P4	4.01	6.93e-05	0.0103	0.21	0.18	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101712472~101713191:+
HNSC	cis	rs4841134	0.745	rs13278594	ENSG00000233609.3	RP11-62H7.2	-4.01	6.93e-05	0.0103	-0.17	-0.18	Age-related disease endophenotypes;	chr8:9338956	chr8:8961200~8979025:+
HNSC	cis	rs6500395	1	rs2129243	ENSG00000261267.1	RP11-44I10.3	-4.01	6.93e-05	0.0103	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48612941	chr16:48559661~48587403:+
HNSC	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	4.01	6.93e-05	0.0103	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
HNSC	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-4.01	6.93e-05	0.0103	-0.21	-0.18	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
HNSC	cis	rs889398	0.683	rs8047682	ENSG00000196696.11	PDXDC2P	-4.01	6.93e-05	0.0103	-0.13	-0.18	Body mass index;	chr16:69879543	chr16:69976297~70065948:-
HNSC	cis	rs62025270	0.688	rs56388190	ENSG00000259762.1	RP11-158M2.4	-4.01	6.93e-05	0.0103	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85750336~85752901:-
HNSC	cis	rs7535099	0.523	rs1805134	ENSG00000224570.1	RP11-430H12.2	-4.01	6.93e-05	0.0103	-0.24	-0.18	Blood protein levels;	chr1:65601426	chr1:65576129~65578380:-
HNSC	cis	rs1485395	1	rs7132466	ENSG00000270175.1	RP11-793H13.11	-4.01	6.93e-05	0.0103	-0.21	-0.18	Migraine without aura;	chr12:53603039	chr12:53500162~53500936:-
HNSC	cis	rs72717009	0.825	rs7529425	ENSG00000225217.1	HSPA7	-4.01	6.93e-05	0.0103	-0.32	-0.18	Rheumatoid arthritis;	chr1:161509809	chr1:161606291~161608217:+
HNSC	cis	rs73198271	0.562	rs55961293	ENSG00000253893.2	FAM85B	4.01	6.93e-05	0.0103	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817968	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.562	rs55657655	ENSG00000253893.2	FAM85B	4.01	6.93e-05	0.0103	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817981	chr8:8167819~8226614:-
HNSC	cis	rs950169	0.58	rs11635597	ENSG00000229212.6	RP11-561C5.4	-4.01	6.93e-05	0.0103	-0.26	-0.18	Schizophrenia;	chr15:84622468	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.544	rs62021193	ENSG00000229212.6	RP11-561C5.4	-4.01	6.93e-05	0.0103	-0.26	-0.18	Schizophrenia;	chr15:84627352	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs17598114	ENSG00000229212.6	RP11-561C5.4	-4.01	6.93e-05	0.0103	-0.26	-0.18	Schizophrenia;	chr15:84628086	chr15:85205440~85234795:-
HNSC	cis	rs6504108	0.624	rs3792692	ENSG00000278765.1	RP5-890E16.5	-4.01	6.93e-05	0.0103	-0.23	-0.18	Body mass index;	chr17:48177730	chr17:48066704~48067293:-
HNSC	cis	rs7735319	0.704	rs2331145	ENSG00000250697.1	CTD-2066L21.3	4.01	6.93e-05	0.0103	0.22	0.18	Systolic blood pressure;	chr5:33051976	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.704	rs11750792	ENSG00000250697.1	CTD-2066L21.3	4.01	6.93e-05	0.0103	0.22	0.18	Systolic blood pressure;	chr5:33053996	chr5:32925639~33297910:-
HNSC	cis	rs6500395	1	rs2883475	ENSG00000261267.1	RP11-44I10.3	-4.01	6.93e-05	0.0103	-0.23	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48526404	chr16:48559661~48587403:+
HNSC	cis	rs2865126	0.818	rs2865128	ENSG00000264714.1	RP11-21G15.1	-4.01	6.93e-05	0.0103	-0.23	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10764031	chr18:10724619~10728539:+
HNSC	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	4.01	6.94e-05	0.0103	0.16	0.18	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
HNSC	cis	rs739496	0.579	rs7294902	ENSG00000226469.1	ADAM1B	4.01	6.94e-05	0.0103	0.21	0.18	Platelet count;	chr12:111916727	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.615	rs7312260	ENSG00000226469.1	ADAM1B	4.01	6.94e-05	0.0103	0.21	0.18	Platelet count;	chr12:111920859	chr12:111927018~111929017:+
HNSC	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-4.01	6.94e-05	0.0103	-0.2	-0.18	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
HNSC	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	4.01	6.94e-05	0.0103	0.21	0.18	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
HNSC	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-4.01	6.94e-05	0.0103	-0.18	-0.18	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
HNSC	cis	rs1580019	0.885	rs4580942	ENSG00000226468.2	AC018641.7	-4.01	6.94e-05	0.0103	-0.24	-0.18	Cognitive ability;	chr7:32456823	chr7:32456963~32457758:-
HNSC	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-4.01	6.94e-05	0.0103	-0.2	-0.18	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
HNSC	cis	rs4403732	1	rs4237333	ENSG00000230526.1	RP11-472G21.2	4.01	6.94e-05	0.0103	0.28	0.18	Coronary artery disease;	chr10:71877468	chr10:71878356~71879107:+
HNSC	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-4.01	6.94e-05	0.0103	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
HNSC	cis	rs10819861	0.645	rs4743527	ENSG00000271384.1	RP11-435O5.7	4.01	6.94e-05	0.0103	0.18	0.18	Electrocardiographic traits;	chr9:96088793	chr9:95406990~95407662:-
HNSC	cis	rs6651255	0.738	rs4236748	ENSG00000224110.3	MTRF1LP2	-4.01	6.95e-05	0.0103	-0.2	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129742641	chr8:129728744~129730445:+
HNSC	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	4.01	6.95e-05	0.0103	0.21	0.18	QT interval;	chr12:29304617	chr12:29280418~29317848:-
HNSC	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	4.01	6.95e-05	0.0103	0.21	0.18	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	4.01	6.95e-05	0.0103	0.21	0.18	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	4.01	6.95e-05	0.0103	0.21	0.18	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
HNSC	cis	rs897984	0.762	rs7204459	ENSG00000279196.1	RP11-1072A3.3	-4.01	6.95e-05	0.0103	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30972891	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.762	rs4889604	ENSG00000279196.1	RP11-1072A3.3	-4.01	6.95e-05	0.0103	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30974673	chr16:30984630~30988270:-
HNSC	cis	rs6540731	0.905	rs6695681	ENSG00000226251.4	RP11-15I11.3	-4.01	6.95e-05	0.0104	-0.21	-0.18	Intelligence (childhood);	chr1:212215114	chr1:212225278~212238977:-
HNSC	cis	rs6540731	0.905	rs7537062	ENSG00000226251.4	RP11-15I11.3	-4.01	6.95e-05	0.0104	-0.21	-0.18	Intelligence (childhood);	chr1:212215270	chr1:212225278~212238977:-
HNSC	cis	rs10242455	0.702	rs917152	ENSG00000078319.8	PMS2P1	-4.01	6.95e-05	0.0104	-0.38	-0.18	Blood metabolite levels;	chr7:99406874	chr7:100320992~100341908:-
HNSC	cis	rs1485395	1	rs7302357	ENSG00000270175.1	RP11-793H13.11	-4.01	6.95e-05	0.0104	-0.21	-0.18	Migraine without aura;	chr12:53601754	chr12:53500162~53500936:-
HNSC	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	4.01	6.96e-05	0.0104	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000254153.1	CTA-398F10.2	-4.01	6.96e-05	0.0104	-0.21	-0.18	Recombination measurement;	chr8:9212778	chr8:8456909~8461337:-
HNSC	cis	rs4295623	0.559	rs4841600	ENSG00000269918.1	AF131215.9	4.01	6.96e-05	0.0104	0.18	0.18	Morning vs. evening chronotype;	chr8:11830639	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.5	rs8021941	ENSG00000211976.2	IGHV3-73	-4.01	6.96e-05	0.0104	-0.13	-0.18	Kawasaki disease;	chr14:106781490	chr14:106802694~106803233:-
HNSC	cis	rs17253792	0.822	rs12100753	ENSG00000186615.9	KTN1-AS1	-4.01	6.97e-05	0.0104	-0.35	-0.18	Putamen volume;	chr14:55576152	chr14:55499278~55580110:-
HNSC	cis	rs13325613	0.834	rs35178150	ENSG00000223552.1	RP11-24F11.2	-4.01	6.97e-05	0.0104	-0.32	-0.18	Monocyte count;	chr3:46153277	chr3:46364955~46407059:-
HNSC	cis	rs17076726	0.519	rs12513923	ENSG00000253785.1	CTC-308K20.3	-4.01	6.97e-05	0.0104	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173930533	chr5:172975511~172976374:+
HNSC	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	4.01	6.97e-05	0.0104	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
HNSC	cis	rs2304003	1	rs2241462	ENSG00000235192.1	AC009495.2	4.01	6.97e-05	0.0104	0.24	0.18	Social communication problems;	chr2:165833126	chr2:165794851~165810010:+
HNSC	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	4.01	6.97e-05	0.0104	0.23	0.18	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	4.01	6.97e-05	0.0104	0.23	0.18	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
HNSC	cis	rs2342371	0.756	rs3973	ENSG00000243339.3	RN7SL738P	4.01	6.97e-05	0.0104	0.24	0.18	Fat distribution (HIV);	chr3:196397407	chr3:196399911~196400207:+
HNSC	cis	rs950169	0.58	rs4603535	ENSG00000229212.6	RP11-561C5.4	-4.01	6.97e-05	0.0104	-0.27	-0.18	Schizophrenia;	chr15:84630641	chr15:85205440~85234795:-
HNSC	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	4.01	6.97e-05	0.0104	0.21	0.18	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
HNSC	cis	rs2243480	1	rs35283677	ENSG00000229886.1	RP5-1132H15.3	4.01	6.97e-05	0.0104	0.32	0.18	Diabetic kidney disease;	chr7:65894246	chr7:66025126~66031544:-
HNSC	cis	rs763512	0.532	rs3094499	ENSG00000276054.1	RP11-378E13.3	4.01	6.98e-05	0.0104	0.26	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37531234	chr17:37386886~37387926:+
HNSC	cis	rs643506	0.79	rs688095	ENSG00000230911.1	PPIHP1	-4.01	6.98e-05	0.0104	-0.24	-0.18	Breast cancer;	chr11:111808047	chr11:112029858~112030367:-
HNSC	cis	rs11951515	0.844	rs7727047	ENSG00000249286.1	CTD-2210P15.2	4.01	6.98e-05	0.0104	0.19	0.18	Metabolite levels  (X-11787);	chr5:43374831	chr5:43586918~43588223:-
HNSC	cis	rs77140172	0.677	rs28435799	ENSG00000248019.2	FAM13A-AS1	-4.01	6.98e-05	0.0104	-0.29	-0.18	Post bronchodilator FEV1;	chr4:88696780	chr4:88709789~88730103:+
HNSC	cis	rs62025270	0.593	rs7166540	ENSG00000259762.1	RP11-158M2.4	-4.01	6.98e-05	0.0104	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85750336~85752901:-
HNSC	cis	rs941408	0.515	rs4624312	ENSG00000261342.1	AC006538.1	4.01	6.99e-05	0.0104	0.25	0.18	Total cholesterol levels;	chr19:2774462	chr19:2727743~2729327:-
HNSC	cis	rs4919687	0.55	rs10748828	ENSG00000236937.2	PTGES3P4	-4.01	6.99e-05	0.0104	-0.24	-0.18	Colorectal cancer;	chr10:102697037	chr10:102845595~102845950:+
HNSC	cis	rs3736485	0.808	rs28485410	ENSG00000274528.1	CTD-2650P22.2	4.01	6.99e-05	0.0104	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51657688	chr15:52017167~52018032:-
HNSC	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	4.01	6.99e-05	0.0104	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
HNSC	cis	rs4908760	0.864	rs1953827	ENSG00000232912.4	RP5-1115A15.1	4.01	6.99e-05	0.0104	0.2	0.18	Vitiligo;	chr1:8619789	chr1:8424645~8434838:+
HNSC	cis	rs17076726	0.519	rs17052039	ENSG00000253785.1	CTC-308K20.3	4.01	6.99e-05	0.0104	0.19	0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173916897	chr5:172975511~172976374:+
HNSC	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	4.01	7e-05	0.0104	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.954	rs9993199	ENSG00000250412.1	KLHL2P1	-4.01	7e-05	0.0104	-0.24	-0.18	Corneal astigmatism;	chr4:119471718	chr4:119334329~119378233:+
HNSC	cis	rs11809443	0.569	rs11800309	ENSG00000269890.1	RP5-1139B12.2	4.01	7e-05	0.0104	0.24	0.18	Coronary artery disease;	chr1:228204107	chr1:228270443~228274397:-
HNSC	cis	rs11098499	0.754	rs1511025	ENSG00000250412.1	KLHL2P1	4.01	7e-05	0.0104	0.23	0.18	Corneal astigmatism;	chr4:119319083	chr4:119334329~119378233:+
HNSC	cis	rs8049634	0.913	rs4150115	ENSG00000250685.6	RP11-486L19.2	-4.01	7e-05	0.0104	-0.17	-0.18	Small cell lung carcinoma;	chr16:84186726	chr16:84192558~84197053:-
HNSC	cis	rs4256159	0.696	rs35642101	ENSG00000228956.7	SATB1-AS1	4.01	7e-05	0.0104	0.26	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18719697	chr3:18445024~18920401:+
HNSC	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	4.01	7e-05	0.0104	0.21	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	4.01	7e-05	0.0104	0.21	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
HNSC	cis	rs2253762	0.54	rs10887051	ENSG00000226864.1	ATE1-AS1	4.01	7e-05	0.0104	0.31	0.18	Breast cancer;	chr10:122026030	chr10:121928312~121951965:+
HNSC	cis	rs7189233	0.956	rs62048478	ENSG00000279344.1	RP11-44F14.7	4.01	7.01e-05	0.0104	0.18	0.18	Intelligence (multi-trait analysis);	chr16:53395268	chr16:53478957~53481550:-
HNSC	cis	rs9611565	0.729	rs4822027	ENSG00000235513.1	RP4-756G23.5	4.01	7.01e-05	0.0104	0.22	0.18	Vitiligo;	chr22:41390223	chr22:41209122~41217627:-
HNSC	cis	rs35306767	0.903	rs12244355	ENSG00000229869.1	RP11-363N22.2	-4.01	7.01e-05	0.0104	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:898525	chr10:933026~942743:+
HNSC	cis	rs11969893	1	rs4629692	ENSG00000270987.1	RP3-467N11.2	4.01	7.01e-05	0.0104	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101175674	chr6:100889603~100890338:+
HNSC	cis	rs853679	0.607	rs67998226	ENSG00000204709.4	LINC01556	4.01	7.01e-05	0.0104	0.37	0.18	Depression;	chr6:28270281	chr6:28943877~28944537:+
HNSC	cis	rs2762353	0.808	rs1183201	ENSG00000272462.2	U91328.19	-4.01	7.02e-05	0.0104	-0.18	-0.18	Blood metabolite levels;	chr6:25823216	chr6:25992662~26001775:+
HNSC	cis	rs9583531	0.6	rs4773240	ENSG00000259831.1	LINC00567	4.01	7.02e-05	0.0104	0.21	0.18	Coronary artery disease;	chr13:110708238	chr13:110809676~110813084:-
HNSC	cis	rs9583531	0.6	rs6492305	ENSG00000259831.1	LINC00567	4.01	7.02e-05	0.0104	0.21	0.18	Coronary artery disease;	chr13:110709053	chr13:110809676~110813084:-
HNSC	cis	rs9583531	0.6	rs7984468	ENSG00000259831.1	LINC00567	4.01	7.02e-05	0.0104	0.21	0.18	Coronary artery disease;	chr13:110709746	chr13:110809676~110813084:-
HNSC	cis	rs9583531	0.6	rs9521909	ENSG00000259831.1	LINC00567	4.01	7.02e-05	0.0104	0.21	0.18	Coronary artery disease;	chr13:110709823	chr13:110809676~110813084:-
HNSC	cis	rs847649	0.548	rs10953380	ENSG00000239969.4	RP11-163E9.2	4.01	7.02e-05	0.0104	0.21	0.18	Morning vs. evening chronotype;	chr7:103106702	chr7:102364162~102380633:+
HNSC	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-4.01	7.02e-05	0.0104	-0.21	-0.18	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
HNSC	cis	rs10519937	0.799	rs1363631	ENSG00000230929.5	RP11-395C3.1	-4.01	7.02e-05	0.0104	-0.27	-0.18	IgG glycosylation;	chr5:127401140	chr5:126628019~126628319:-
HNSC	cis	rs10519937	0.935	rs56006993	ENSG00000230929.5	RP11-395C3.1	-4.01	7.02e-05	0.0104	-0.27	-0.18	IgG glycosylation;	chr5:127401494	chr5:126628019~126628319:-
HNSC	cis	rs10519937	1	rs12234066	ENSG00000230929.5	RP11-395C3.1	-4.01	7.02e-05	0.0104	-0.27	-0.18	IgG glycosylation;	chr5:127401858	chr5:126628019~126628319:-
HNSC	cis	rs10519937	0.935	rs11952552	ENSG00000230929.5	RP11-395C3.1	-4.01	7.02e-05	0.0104	-0.27	-0.18	IgG glycosylation;	chr5:127402349	chr5:126628019~126628319:-
HNSC	cis	rs4281086	0.587	rs56225449	ENSG00000255310.2	AF131215.2	4.01	7.02e-05	0.0104	0.18	0.18	Obesity-related traits;	chr8:10507671	chr8:11107788~11109726:-
HNSC	cis	rs7267979	0.753	rs404148	ENSG00000204556.4	CTD-2514C3.1	-4.01	7.02e-05	0.0104	-0.23	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26018832~26020684:+
HNSC	cis	rs597539	0.69	rs635529	ENSG00000255741.1	RP11-757G1.5	-4.01	7.02e-05	0.0104	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68941503~68942852:-
HNSC	cis	rs6840360	0.557	rs4696261	ENSG00000251611.1	RP11-610P16.1	-4.01	7.03e-05	0.0104	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151407551~151408835:-
HNSC	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-4.01	7.03e-05	0.0104	-0.18	-0.18	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
HNSC	cis	rs4356203	0.875	rs667984	ENSG00000272034.1	SNORD14A	-4.01	7.03e-05	0.0104	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17074654~17074744:-
HNSC	cis	rs9910055	0.639	rs227583	ENSG00000267080.4	ASB16-AS1	-4.01	7.03e-05	0.0104	-0.15	-0.18	Total body bone mineral density;	chr17:44154330	chr17:44175973~44186717:-
HNSC	cis	rs7927592	0.731	rs7108376	ENSG00000255031.4	RP11-802E16.3	-4.01	7.03e-05	0.0104	-0.15	-0.18	Total body bone mineral density;	chr11:68580402	chr11:68050740~68053762:+
HNSC	cis	rs1015213	0.619	rs7814773	ENSG00000272024.1	RP11-546K22.3	-4.01	7.03e-05	0.0104	-0.33	-0.18	Glaucoma (primary angle closure);	chr8:51980506	chr8:51950284~51950690:+
HNSC	cis	rs853679	0.599	rs156743	ENSG00000219891.2	ZSCAN12P1	4.01	7.03e-05	0.0105	0.33	0.18	Depression;	chr6:27999311	chr6:28091154~28093664:+
HNSC	cis	rs7615952	0.546	rs2979333	ENSG00000241288.6	RP11-379B18.5	-4.01	7.03e-05	0.0105	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125641499	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.546	rs111812401	ENSG00000241288.6	RP11-379B18.5	-4.01	7.03e-05	0.0105	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125642651	chr3:125827238~125916384:-
HNSC	cis	rs7615952	0.546	rs2979350	ENSG00000241288.6	RP11-379B18.5	-4.01	7.03e-05	0.0105	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125643371	chr3:125827238~125916384:-
HNSC	cis	rs11098499	0.863	rs1480940	ENSG00000250412.1	KLHL2P1	4.01	7.03e-05	0.0105	0.24	0.18	Corneal astigmatism;	chr4:119536527	chr4:119334329~119378233:+
HNSC	cis	rs73198271	1	rs4840356	ENSG00000254340.1	RP11-10A14.3	-4.01	7.03e-05	0.0105	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:9141424~9145435:+
HNSC	cis	rs67072384	1	rs2365441	ENSG00000213365.3	AP000593.6	4.01	7.03e-05	0.0105	0.31	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739181	chr11:72280151~72281178:+
HNSC	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	4.01	7.04e-05	0.0105	0.22	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
HNSC	cis	rs10510102	0.516	rs10887034	ENSG00000226864.1	ATE1-AS1	4.01	7.04e-05	0.0105	0.34	0.18	Breast cancer;	chr10:121973996	chr10:121928312~121951965:+
HNSC	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-4.01	7.04e-05	0.0105	-0.23	-0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000250412.1	KLHL2P1	4.01	7.04e-05	0.0105	0.23	0.18	Educational attainment;	chr4:119327002	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000250412.1	KLHL2P1	4.01	7.04e-05	0.0105	0.23	0.18	Corneal astigmatism;	chr4:119327388	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000250412.1	KLHL2P1	4.01	7.04e-05	0.0105	0.23	0.18	Corneal astigmatism;	chr4:119327430	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000250412.1	KLHL2P1	4.01	7.04e-05	0.0105	0.23	0.18	Corneal astigmatism;	chr4:119328457	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000250412.1	KLHL2P1	4.01	7.04e-05	0.0105	0.23	0.18	Corneal astigmatism;	chr4:119328505	chr4:119334329~119378233:+
HNSC	cis	rs748404	0.629	rs34657657	ENSG00000166763.7	STRCP1	4.01	7.04e-05	0.0105	0.26	0.18	Lung cancer;	chr15:43315763	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.626	rs62019432	ENSG00000166763.7	STRCP1	4.01	7.04e-05	0.0105	0.26	0.18	Lung cancer;	chr15:43316482	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs7176923	ENSG00000166763.7	STRCP1	4.01	7.04e-05	0.0105	0.26	0.18	Lung cancer;	chr15:43317679	chr15:43699488~43718184:-
HNSC	cis	rs793571	0.822	rs11630160	ENSG00000245975.2	RP11-30K9.6	-4.01	7.04e-05	0.0105	-0.29	-0.18	Schizophrenia;	chr15:58921479	chr15:58768072~58770974:-
HNSC	cis	rs7819412	0.505	rs67849263	ENSG00000255310.2	AF131215.2	-4.01	7.05e-05	0.0105	-0.19	-0.18	Triglycerides;	chr8:11150034	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.518	rs8004895	ENSG00000211976.2	IGHV3-73	-4.01	7.05e-05	0.0105	-0.13	-0.18	Kawasaki disease;	chr14:106785139	chr14:106802694~106803233:-
HNSC	cis	rs7824557	0.564	rs1435275	ENSG00000255310.2	AF131215.2	-4.01	7.05e-05	0.0105	-0.17	-0.18	Retinal vascular caliber;	chr8:11378226	chr8:11107788~11109726:-
HNSC	cis	rs7637230	0.891	rs4683946	ENSG00000244119.1	PDCL3P4	-4.01	7.05e-05	0.0105	-0.2	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101896982	chr3:101712472~101713191:+
HNSC	cis	rs11648785	0.59	rs10431948	ENSG00000221819.5	GAS8-AS1	-4.01	7.05e-05	0.0105	-0.19	-0.18	Tanning;	chr16:90033163	chr16:90028908~90029367:-
HNSC	cis	rs12600394	0.543	rs11651550	ENSG00000231595.1	AC005224.2	4.01	7.05e-05	0.0105	0.23	0.18	Response to platinum-based chemotherapy (cisplatin);	chr17:14632966	chr17:14210488~14217922:+
HNSC	cis	rs1476670	0.683	rs2057967	ENSG00000230615.5	RP5-1198O20.4	-4.01	7.05e-05	0.0105	-0.23	-0.18	Eotaxin levels;	chr1:44049774	chr1:44030443~44115913:+
HNSC	cis	rs7005380	0.581	rs4871793	ENSG00000279347.1	RP11-85I17.2	-4.01	7.05e-05	0.0105	-0.17	-0.18	Interstitial lung disease;	chr8:119929288	chr8:119838736~119840385:-
HNSC	cis	rs6504108	0.624	rs7223867	ENSG00000278765.1	RP5-890E16.5	-4.01	7.05e-05	0.0105	-0.23	-0.18	Body mass index;	chr17:48152794	chr17:48066704~48067293:-
HNSC	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	4.01	7.05e-05	0.0105	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
HNSC	cis	rs9467711	0.559	rs6920256	ENSG00000241549.7	GUSBP2	4.01	7.05e-05	0.0105	0.28	0.18	Autism spectrum disorder or schizophrenia;	chr6:26537573	chr6:26871484~26956554:-
HNSC	cis	rs73198271	0.71	rs11779561	ENSG00000233609.3	RP11-62H7.2	-4.01	7.05e-05	0.0105	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8961200~8979025:+
HNSC	cis	rs4356203	0.905	rs7927240	ENSG00000260196.1	RP1-239B22.5	-4.01	7.05e-05	0.0105	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17380649~17383531:+
HNSC	cis	rs11089937	0.616	rs4991798	ENSG00000211639.2	IGLV4-60	4.01	7.06e-05	0.0105	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs4991799	ENSG00000211639.2	IGLV4-60	4.01	7.06e-05	0.0105	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs4991800	ENSG00000211639.2	IGLV4-60	4.01	7.06e-05	0.0105	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22162199~22162681:+
HNSC	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-4.01	7.06e-05	0.0105	-0.19	-0.18	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
HNSC	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-4.01	7.06e-05	0.0105	-0.19	-0.18	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
HNSC	cis	rs9487051	0.621	rs377436	ENSG00000243587.6	C6orf183	4.01	7.06e-05	0.0105	0.19	0.18	Reticulocyte fraction of red cells;	chr6:109205901	chr6:109165833~109271014:+
HNSC	cis	rs748404	0.666	rs34515241	ENSG00000166763.7	STRCP1	4.01	7.06e-05	0.0105	0.25	0.18	Lung cancer;	chr15:43342011	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.626	rs35992154	ENSG00000166763.7	STRCP1	4.01	7.06e-05	0.0105	0.25	0.18	Lung cancer;	chr15:43345669	chr15:43699488~43718184:-
HNSC	cis	rs17818399	0.788	rs17818315	ENSG00000279254.1	RP11-536C12.1	-4.01	7.07e-05	0.0105	-0.23	-0.18	Height;	chr2:46591853	chr2:46668870~46670778:+
HNSC	cis	rs9914988	0.613	rs1806982	ENSG00000264577.1	AC010761.8	4.01	7.07e-05	0.0105	0.17	0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28939125	chr17:28721487~28722877:-
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	4.01	7.07e-05	0.0105	0.21	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
HNSC	cis	rs4820294	0.669	rs9622677	ENSG00000225867.1	RP5-1177I5.3	-4.01	7.07e-05	0.0105	-0.2	-0.18	Fat distribution (HIV);	chr22:37658255	chr22:37550026~37551735:+
HNSC	cis	rs970821	0.645	rs6470180	ENSG00000253106.1	RP11-158K1.3	-4.01	7.07e-05	0.0105	-0.16	-0.18	Breast cancer;	chr8:123739344	chr8:124488510~124491643:+
HNSC	cis	rs9329221	0.51	rs4841282	ENSG00000269918.1	AF131215.9	4.01	7.07e-05	0.0105	0.18	0.18	Neuroticism;	chr8:10118094	chr8:11104691~11106704:-
HNSC	cis	rs9313772	0.775	rs10042219	ENSG00000254350.1	RP11-542A14.1	-4.01	7.07e-05	0.0105	-0.2	-0.18	Blood pressure;	chr5:158391072	chr5:158424585~158452758:+
HNSC	cis	rs13325613	0.585	rs17216717	ENSG00000223552.1	RP11-24F11.2	-4.01	7.07e-05	0.0105	-0.32	-0.18	Monocyte count;	chr3:46144831	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13075836	ENSG00000223552.1	RP11-24F11.2	-4.01	7.07e-05	0.0105	-0.32	-0.18	Monocyte count;	chr3:46145146	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13096325	ENSG00000223552.1	RP11-24F11.2	-4.01	7.07e-05	0.0105	-0.32	-0.18	Monocyte count;	chr3:46145346	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13097340	ENSG00000223552.1	RP11-24F11.2	-4.01	7.07e-05	0.0105	-0.32	-0.18	Monocyte count;	chr3:46145626	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.764	rs3091314	ENSG00000223552.1	RP11-24F11.2	-4.01	7.07e-05	0.0105	-0.32	-0.18	Monocyte count;	chr3:46147261	chr3:46364955~46407059:-
HNSC	cis	rs6088580	0.634	rs6142164	ENSG00000276073.1	RP5-1125A11.7	4.01	7.07e-05	0.0105	0.19	0.18	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:33985617~33988989:-
HNSC	cis	rs9487051	0.872	rs9480923	ENSG00000219700.1	PTCHD3P3	4.01	7.07e-05	0.0105	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109286166	chr6:109288571~109290503:-
HNSC	cis	rs9925964	0.933	rs2303222	ENSG00000232748.3	RP11-196G11.6	4.01	7.07e-05	0.0105	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31056460~31062803:+
HNSC	cis	rs6714900	0.888	rs2160783	ENSG00000234896.1	OR7E62P	-4.01	7.07e-05	0.0105	-0.21	-0.18	Blood protein levels;	chr2:71056337	chr2:71055527~71056003:+
HNSC	cis	rs7475343	0.538	rs61854687	ENSG00000224034.1	RP11-445P17.8	-4.01	7.07e-05	0.0105	-0.25	-0.18	Intelligence;	chr10:5171289	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs61854697	ENSG00000224034.1	RP11-445P17.8	-4.01	7.07e-05	0.0105	-0.25	-0.18	Intelligence;	chr10:5172504	chr10:5266033~5271236:-
HNSC	cis	rs1008375	0.8	rs62296338	ENSG00000249502.1	AC006160.5	-4.01	7.07e-05	0.0105	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17611802	chr4:17587467~17614571:-
HNSC	cis	rs6095360	0.727	rs7274221	ENSG00000222365.1	SNORD12B	-4.01	7.07e-05	0.0105	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:49006961	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.727	rs35752040	ENSG00000222365.1	SNORD12B	-4.01	7.07e-05	0.0105	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:49008063	chr20:49280319~49280409:+
HNSC	cis	rs6840258	1	rs10516788	ENSG00000251411.1	RP11-397E7.4	-4.01	7.07e-05	0.0105	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039705	chr4:86913266~86914817:-
HNSC	cis	rs10129255	0.518	rs28378320	ENSG00000211976.2	IGHV3-73	-4.01	7.07e-05	0.0105	-0.13	-0.18	Kawasaki disease;	chr14:106808609	chr14:106802694~106803233:-
HNSC	cis	rs875971	0.545	rs73136346	ENSG00000164669.11	INTS4P1	4.01	7.08e-05	0.0105	0.26	0.18	Aortic root size;	chr7:66101095	chr7:65141225~65234216:+
HNSC	cis	rs1994321	0.609	rs4757148	ENSG00000254991.1	RP13-631K18.3	4.01	7.08e-05	0.0105	0.2	0.18	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12066233	chr11:12066929~12073014:+
HNSC	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-4.01	7.08e-05	0.0105	-0.31	-0.18	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
HNSC	cis	rs763512	0.532	rs3110626	ENSG00000276054.1	RP11-378E13.3	-4.01	7.08e-05	0.0105	-0.26	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37386886~37387926:+
HNSC	cis	rs8705	0.711	rs7932088	ENSG00000273415.1	RP11-702B10.2	4.01	7.08e-05	0.0105	0.22	0.18	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr11:128447273	chr11:128180427~128183554:+
HNSC	cis	rs4819052	1	rs9984901	ENSG00000223768.1	LINC00205	-4.01	7.08e-05	0.0105	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45293285~45297354:+
HNSC	cis	rs72717009	0.825	rs9427397	ENSG00000225217.1	HSPA7	-4.01	7.08e-05	0.0105	-0.33	-0.18	Rheumatoid arthritis;	chr1:161506414	chr1:161606291~161608217:+
HNSC	cis	rs6095360	0.934	rs2273531	ENSG00000222365.1	SNORD12B	-4.01	7.08e-05	0.0105	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49011897	chr20:49280319~49280409:+
HNSC	cis	rs72843166	0.537	rs10491168	ENSG00000265282.1	RP11-269G24.4	4.01	7.09e-05	0.0105	0.27	0.18	Intelligence (multi-trait analysis);	chr17:63364102	chr17:63430468~63432211:-
HNSC	cis	rs2243480	1	rs160646	ENSG00000229886.1	RP5-1132H15.3	4.01	7.09e-05	0.0105	0.3	0.18	Diabetic kidney disease;	chr7:66091293	chr7:66025126~66031544:-
HNSC	cis	rs9487051	0.836	rs9487036	ENSG00000219700.1	PTCHD3P3	4.01	7.09e-05	0.0105	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109286246	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.836	rs9400270	ENSG00000219700.1	PTCHD3P3	4.01	7.09e-05	0.0105	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109286285	chr6:109288571~109290503:-
HNSC	cis	rs7781557	1	rs7781557	ENSG00000239969.4	RP11-163E9.2	4.01	7.09e-05	0.0105	0.26	0.18	Colorectal adenoma (advanced);	chr7:102841444	chr7:102364162~102380633:+
HNSC	cis	rs6430585	0.528	rs7573555	ENSG00000231890.6	DARS-AS1	4.01	7.09e-05	0.0105	0.31	0.18	Corneal structure;	chr2:135937335	chr2:135985176~136022593:+
HNSC	cis	rs10504130	0.569	rs34213209	ENSG00000253844.1	RP11-546K22.1	-4.01	7.1e-05	0.0105	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51961458~52022974:+
HNSC	cis	rs7314031	1	rs7314031	ENSG00000226469.1	ADAM1B	4.01	7.1e-05	0.0105	0.27	0.18	Reticulocyte count;Reticulocyte fraction of red cells;	chr12:112392775	chr12:111927018~111929017:+
HNSC	cis	rs889398	0.934	rs12923231	ENSG00000226232.7	RP11-419C5.2	4.01	7.1e-05	0.0105	0.17	0.18	Body mass index;	chr16:69538989	chr16:69976388~69996188:-
HNSC	cis	rs73198271	0.653	rs10087633	ENSG00000173295.6	FAM86B3P	-4.01	7.1e-05	0.0105	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8228595~8244865:+
HNSC	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-4.01	7.1e-05	0.0105	-0.23	-0.18	Height;	chr20:49299758	chr20:49280319~49280409:+
HNSC	cis	rs4356203	0.87	rs214916	ENSG00000272034.1	SNORD14A	-4.01	7.1e-05	0.0105	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.87	rs2171615	ENSG00000272034.1	SNORD14A	-4.01	7.1e-05	0.0105	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17074654~17074744:-
HNSC	cis	rs5758659	0.652	rs133335	ENSG00000182057.4	OGFRP1	-4.01	7.1e-05	0.0105	-0.18	-0.18	Cognitive function;	chr22:42020052	chr22:42269753~42275196:+
HNSC	cis	rs11893307	0.537	rs61345672	ENSG00000228509.4	AC006460.2	4.01	7.1e-05	0.0105	0.25	0.18	Mean platelet volume;	chr2:190642288	chr2:190676944~190708716:-
HNSC	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	4.01	7.1e-05	0.0105	0.23	0.18	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
HNSC	cis	rs9568867	1	rs9568867	ENSG00000273784.3	RP11-78J21.7	-4.01	7.11e-05	0.0105	-0.28	-0.18	Obesity;Body mass index;	chr13:53533217	chr13:52600042~52642542:+
HNSC	cis	rs9568867	1	rs9568868	ENSG00000273784.3	RP11-78J21.7	-4.01	7.11e-05	0.0105	-0.28	-0.18	Obesity;Body mass index;	chr13:53533448	chr13:52600042~52642542:+
HNSC	cis	rs4356203	0.792	rs620241	ENSG00000272034.1	SNORD14A	-4.01	7.11e-05	0.0105	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17074654~17074744:-
HNSC	cis	rs2115630	0.764	rs11073716	ENSG00000225151.9	GOLGA2P7	4.01	7.11e-05	0.0105	0.22	0.18	P wave terminal force;	chr15:84792543	chr15:84199311~84230136:-
HNSC	cis	rs7107174	1	rs4134379	ENSG00000251323.2	RP11-452H21.4	4.01	7.11e-05	0.0105	0.27	0.18	Testicular germ cell tumor;	chr11:78281542	chr11:78423982~78429836:-
HNSC	cis	rs7572733	0.576	rs1865586	ENSG00000231621.1	AC013264.2	4.01	7.11e-05	0.0105	0.17	0.18	Dermatomyositis;	chr2:197894144	chr2:197197991~197199273:+
HNSC	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-4.01	7.11e-05	0.0105	-0.21	-0.18	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
HNSC	cis	rs7475343	0.501	rs17134592	ENSG00000224034.1	RP11-445P17.8	-4.01	7.11e-05	0.0106	-0.25	-0.18	Intelligence;	chr10:5218719	chr10:5266033~5271236:-
HNSC	cis	rs897984	0.759	rs13708	ENSG00000279196.1	RP11-1072A3.3	-4.01	7.11e-05	0.0106	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30989488	chr16:30984630~30988270:-
HNSC	cis	rs9611565	0.659	rs56319767	ENSG00000235513.1	RP4-756G23.5	4.01	7.11e-05	0.0106	0.22	0.18	Vitiligo;	chr22:41537833	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs73178632	ENSG00000235513.1	RP4-756G23.5	4.01	7.11e-05	0.0106	0.22	0.18	Vitiligo;	chr22:41538569	chr22:41209122~41217627:-
HNSC	cis	rs2742234	0.794	rs17153156	ENSG00000273008.1	RP11-351D16.3	4.01	7.11e-05	0.0106	0.21	0.18	Hirschsprung disease;	chr10:43209189	chr10:43136824~43138334:-
HNSC	cis	rs6831352	0.842	rs1230156	ENSG00000263923.1	RP11-571L19.7	-4.01	7.11e-05	0.0106	-0.19	-0.18	Alcohol dependence;	chr4:99068475	chr4:98928897~98994994:+
HNSC	cis	rs6005807	0.543	rs6005866	ENSG00000226471.5	CTA-292E10.6	-4.01	7.11e-05	0.0106	-0.3	-0.18	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28766952	chr22:28800683~28848559:+
HNSC	cis	rs72627123	0.5	rs7359018	ENSG00000259065.1	RP5-1021I20.1	-4.01	7.12e-05	0.0106	-0.25	-0.18	Morning vs. evening chronotype;	chr14:74054305	chr14:73787360~73803270:+
HNSC	cis	rs9313772	0.775	rs7708993	ENSG00000254350.1	RP11-542A14.1	-4.01	7.12e-05	0.0106	-0.2	-0.18	Blood pressure;	chr5:158395668	chr5:158424585~158452758:+
HNSC	cis	rs9907295	0.901	rs4796119	ENSG00000270977.1	AC015849.16	4.01	7.12e-05	0.0106	0.28	0.18	Fibroblast growth factor basic levels;	chr17:35866084	chr17:35893707~35911023:-
HNSC	cis	rs9313772	0.928	rs10042238	ENSG00000254350.1	RP11-542A14.1	-4.01	7.12e-05	0.0106	-0.2	-0.18	Blood pressure;	chr5:158391142	chr5:158424585~158452758:+
HNSC	cis	rs6095360	1	rs6019604	ENSG00000222365.1	SNORD12B	-4.01	7.12e-05	0.0106	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49036961	chr20:49280319~49280409:+
HNSC	cis	rs11552145	1	rs11552145	ENSG00000124224.15	PPP4R1L	4.01	7.12e-05	0.0106	0.23	0.18	Prudent dietary pattern;	chr20:57563592	chr20:58228940~58309439:-
HNSC	cis	rs9611565	0.644	rs2413652	ENSG00000233903.2	Z83851.4	4.01	7.12e-05	0.0106	0.25	0.18	Vitiligo;	chr22:41701234	chr22:42276355~42277052:+
HNSC	cis	rs853679	0.769	rs7752448	ENSG00000219392.1	RP1-265C24.5	-4.01	7.12e-05	0.0106	-0.31	-0.18	Depression;	chr6:28333322	chr6:28115628~28116551:+
HNSC	cis	rs9422860	0.831	rs7911417	ENSG00000236991.5	EDRF1-AS1	-4.01	7.12e-05	0.0106	-0.24	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr10:125217431	chr10:125725634~125752110:-
HNSC	cis	rs6787172	0.811	rs9812624	ENSG00000272087.1	RP11-379F4.7	4.01	7.12e-05	0.0106	0.19	0.18	Subjective well-being;	chr3:158491861	chr3:158693120~158693768:-
HNSC	cis	rs6504108	0.624	rs10853098	ENSG00000278765.1	RP5-890E16.5	-4.01	7.12e-05	0.0106	-0.23	-0.18	Body mass index;	chr17:48159219	chr17:48066704~48067293:-
HNSC	cis	rs4948102	0.551	rs4275190	ENSG00000273720.1	RP11-613E4.4	-4.01	7.13e-05	0.0106	-0.22	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55743073~55743457:+
HNSC	cis	rs4819052	1	rs4818769	ENSG00000223768.1	LINC00205	-4.01	7.13e-05	0.0106	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45293285~45297354:+
HNSC	cis	rs867371	0.571	rs2654222	ENSG00000276710.3	CSPG4P8	4.01	7.13e-05	0.0106	0.23	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82137496	chr15:82459472~82477258:+
HNSC	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	4.01	7.13e-05	0.0106	0.21	0.18	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
HNSC	cis	rs9929218	0.581	rs12185157	ENSG00000260459.2	FTLP14	4.01	7.13e-05	0.0106	0.24	0.18	Colorectal cancer;	chr16:68750684	chr16:68822587~68823070:+
HNSC	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	4.01	7.13e-05	0.0106	0.21	0.18	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
HNSC	cis	rs516805	0.748	rs1989254	ENSG00000279453.1	RP3-425C14.4	-4.01	7.13e-05	0.0106	-0.26	-0.18	Lymphocyte counts;	chr6:122556317	chr6:122436789~122439223:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	4.01	7.13e-05	0.0106	0.31	0.18	Gout;	chr7:66693028	chr7:66025126~66031544:-
HNSC	cis	rs10129255	0.5	rs6576231	ENSG00000211976.2	IGHV3-73	-4.01	7.13e-05	0.0106	-0.13	-0.18	Kawasaki disease;	chr14:106783693	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs8014529	ENSG00000211976.2	IGHV3-73	-4.01	7.13e-05	0.0106	-0.13	-0.18	Kawasaki disease;	chr14:106784065	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs12101190	ENSG00000211976.2	IGHV3-73	-4.01	7.13e-05	0.0106	-0.13	-0.18	Kawasaki disease;	chr14:106784149	chr14:106802694~106803233:-
HNSC	cis	rs2439831	0.867	rs28729853	ENSG00000275601.1	AC011330.13	-4.01	7.14e-05	0.0106	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43381482	chr15:43642389~43643023:-
HNSC	cis	rs2098713	0.569	rs477420	ENSG00000250155.1	CTD-2353F22.1	4.01	7.14e-05	0.0106	0.2	0.18	Telomere length;	chr5:37541476	chr5:36666214~36725195:-
HNSC	cis	rs3015469	0.542	rs1565838	ENSG00000269906.1	RP11-248J18.2	-4.01	7.14e-05	0.0106	-0.23	-0.18	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50539968	chr14:50662511~50663178:-
HNSC	cis	rs34421088	0.678	rs35928010	ENSG00000269918.1	AF131215.9	-4.01	7.14e-05	0.0106	-0.18	-0.18	Neuroticism;	chr8:11734367	chr8:11104691~11106704:-
HNSC	cis	rs7005380	0.785	rs7814294	ENSG00000279347.1	RP11-85I17.2	4.01	7.14e-05	0.0106	0.15	0.18	Interstitial lung disease;	chr8:119927196	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.733	rs10808505	ENSG00000279347.1	RP11-85I17.2	4.01	7.14e-05	0.0106	0.15	0.18	Interstitial lung disease;	chr8:119927966	chr8:119838736~119840385:-
HNSC	cis	rs4760636	1	rs4760636	ENSG00000268069.2	RP5-1057I20.4	4.01	7.14e-05	0.0106	0.21	0.18	Urate levels;	chr12:47779569	chr12:47784923~47786002:+
HNSC	cis	rs7819412	0.595	rs10503416	ENSG00000269918.1	AF131215.9	4.01	7.15e-05	0.0106	0.18	0.18	Triglycerides;	chr8:11130043	chr8:11104691~11106704:-
HNSC	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	4.01	7.15e-05	0.0106	0.22	0.18	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
HNSC	cis	rs7005380	0.733	rs6469878	ENSG00000279347.1	RP11-85I17.2	4.01	7.15e-05	0.0106	0.15	0.18	Interstitial lung disease;	chr8:119926208	chr8:119838736~119840385:-
HNSC	cis	rs73198271	0.813	rs17697237	ENSG00000254340.1	RP11-10A14.3	4.01	7.15e-05	0.0106	0.25	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:9141424~9145435:+
HNSC	cis	rs2518049	0.852	rs7071638	ENSG00000224034.1	RP11-445P17.8	4.01	7.15e-05	0.0106	0.25	0.18	Metabolic traits;	chr10:5076650	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.852	rs10752002	ENSG00000224034.1	RP11-445P17.8	4.01	7.15e-05	0.0106	0.25	0.18	Metabolic traits;	chr10:5076726	chr10:5266033~5271236:-
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	4.01	7.15e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
HNSC	cis	rs516805	0.667	rs225080	ENSG00000279453.1	RP3-425C14.4	-4.01	7.16e-05	0.0106	-0.25	-0.18	Lymphocyte counts;	chr6:122295949	chr6:122436789~122439223:-
HNSC	cis	rs6088580	0.634	rs6059824	ENSG00000276073.1	RP5-1125A11.7	-4.01	7.16e-05	0.0106	-0.19	-0.18	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6058041	ENSG00000276073.1	RP5-1125A11.7	-4.01	7.16e-05	0.0106	-0.19	-0.18	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:33985617~33988989:-
HNSC	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-4.01	7.16e-05	0.0106	-0.13	-0.18	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
HNSC	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	4.01	7.16e-05	0.0106	0.31	0.18	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
HNSC	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	4.01	7.16e-05	0.0106	0.19	0.18	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
HNSC	cis	rs6787172	0.811	rs1369562	ENSG00000272087.1	RP11-379F4.7	4.01	7.16e-05	0.0106	0.19	0.18	Subjective well-being;	chr3:158490771	chr3:158693120~158693768:-
HNSC	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	4.01	7.16e-05	0.0106	0.2	0.18	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
HNSC	cis	rs8180040	0.726	rs2385867	ENSG00000276925.1	RP11-708J19.3	-4.01	7.16e-05	0.0106	-0.17	-0.18	Colorectal cancer;	chr3:47017833	chr3:47469777~47469987:+
HNSC	cis	rs7520050	0.966	rs7550746	ENSG00000280836.1	AL355480.1	4.01	7.16e-05	0.0106	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45581219~45581321:-
HNSC	cis	rs7804306	0.579	rs13245462	ENSG00000233264.2	AC006042.8	4.01	7.17e-05	0.0106	0.27	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8034978	chr7:7980312~7982228:+
HNSC	cis	rs870825	0.929	rs10015218	ENSG00000254233.1	RP11-242J7.1	4.01	7.17e-05	0.0106	0.31	0.18	Blood protein levels;	chr4:184668635	chr4:184584093~184625030:-
HNSC	cis	rs7927592	0.763	rs11822059	ENSG00000255031.4	RP11-802E16.3	4.01	7.17e-05	0.0106	0.15	0.18	Total body bone mineral density;	chr11:68533354	chr11:68050740~68053762:+
HNSC	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	4.01	7.17e-05	0.0106	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	4.01	7.17e-05	0.0106	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	4.01	7.17e-05	0.0106	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	4.01	7.17e-05	0.0106	0.23	0.18	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
HNSC	cis	rs7520050	0.966	rs11211234	ENSG00000280836.1	AL355480.1	4.01	7.17e-05	0.0106	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs11211241	ENSG00000280836.1	AL355480.1	4.01	7.17e-05	0.0106	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45581219~45581321:-
HNSC	cis	rs7824557	0.602	rs7839053	ENSG00000255310.2	AF131215.2	4.01	7.18e-05	0.0106	0.17	0.18	Retinal vascular caliber;	chr8:11349922	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.602	rs10110557	ENSG00000255310.2	AF131215.2	4.01	7.18e-05	0.0106	0.17	0.18	Retinal vascular caliber;	chr8:11349999	chr8:11107788~11109726:-
HNSC	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-4.01	7.18e-05	0.0106	-0.13	-0.18	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
HNSC	cis	rs860818	1	rs858302	ENSG00000226816.2	AC005082.12	4.01	7.18e-05	0.0106	0.47	0.18	Initial pursuit acceleration;	chr7:23204624	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858301	ENSG00000226816.2	AC005082.12	4.01	7.18e-05	0.0106	0.47	0.18	Initial pursuit acceleration;	chr7:23204704	chr7:23206013~23208045:+
HNSC	cis	rs7015630	0.738	rs11785163	ENSG00000251136.7	RP11-37B2.1	-4.01	7.18e-05	0.0106	-0.2	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89857181	chr8:89609409~89757727:-
HNSC	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	4.01	7.18e-05	0.0106	0.22	0.18	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
HNSC	cis	rs4761470	0.577	rs4761602	ENSG00000258365.1	RP11-1105G2.3	-4.01	7.18e-05	0.0106	-0.2	-0.18	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94277758~94282844:-
HNSC	cis	rs67072384	0.688	rs66948758	ENSG00000213365.3	AP000593.6	4.01	7.18e-05	0.0106	0.29	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72729029	chr11:72280151~72281178:+
HNSC	cis	rs3808502	0.549	rs7831039	ENSG00000255310.2	AF131215.2	-4.01	7.18e-05	0.0106	-0.17	-0.18	Neuroticism;	chr8:11570128	chr8:11107788~11109726:-
HNSC	cis	rs6964587	0.758	rs35963176	ENSG00000188693.7	CYP51A1-AS1	-4.01	7.19e-05	0.0106	-0.22	-0.18	Breast cancer;	chr7:91987801	chr7:92134604~92180725:+
HNSC	cis	rs2518049	1	rs2211624	ENSG00000224034.1	RP11-445P17.8	4.01	7.19e-05	0.0106	0.24	0.18	Metabolic traits;	chr10:5090948	chr10:5266033~5271236:-
HNSC	cis	rs35000415	0.688	rs35429892	ENSG00000275106.1	RP11-309L24.10	-4.01	7.19e-05	0.0106	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129073576	chr7:128952527~128953316:-
HNSC	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-4.01	7.19e-05	0.0106	-0.21	-0.18	Height;	chr14:75159428	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-4.01	7.19e-05	0.0106	-0.21	-0.18	Height;	chr14:75160616	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-4.01	7.19e-05	0.0106	-0.21	-0.18	Height;	chr14:75170648	chr14:75011269~75012851:-
HNSC	cis	rs61160187	0.583	rs6449503	ENSG00000215032.2	GNL3LP1	-4.01	7.19e-05	0.0107	-0.2	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60891935~60893577:-
HNSC	cis	rs427691	0.625	rs372062	ENSG00000271849.1	CTC-332L22.1	-4.01	7.19e-05	0.0107	-0.28	-0.18	Autism spectrum disorder or schizophrenia;	chr5:109674826	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.516	rs435494	ENSG00000271849.1	CTC-332L22.1	-4.01	7.19e-05	0.0107	-0.28	-0.18	Schizophrenia;	chr5:109674877	chr5:109687802~109688329:-
HNSC	cis	rs7688540	0.771	rs4582105	ENSG00000211553.1	AC253576.2	-4.01	7.19e-05	0.0107	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:136461~136568:+
HNSC	cis	rs7615952	0.546	rs2922197	ENSG00000248787.1	RP11-666A20.4	-4.01	7.19e-05	0.0107	-0.29	-0.18	Blood pressure (smoking interaction);	chr3:125603188	chr3:125908005~125910272:-
HNSC	cis	rs516805	0.667	rs197679	ENSG00000279453.1	RP3-425C14.4	-4.01	7.19e-05	0.0107	-0.26	-0.18	Lymphocyte counts;	chr6:122548188	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs197681	ENSG00000279453.1	RP3-425C14.4	-4.01	7.19e-05	0.0107	-0.26	-0.18	Lymphocyte counts;	chr6:122551788	chr6:122436789~122439223:-
HNSC	cis	rs67311347	0.544	rs4974040	ENSG00000280739.1	EIF1B-AS1	4.01	7.19e-05	0.0107	0.19	0.18	Renal cell carcinoma;	chr3:40289568	chr3:40173145~40309698:-
HNSC	cis	rs447735	0.507	rs11645271	ENSG00000274627.1	RP11-104N10.2	-4.01	7.2e-05	0.0107	-0.18	-0.18	Hemoglobin concentration;	chr16:89662717	chr16:89516797~89522217:+
HNSC	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	4.01	7.2e-05	0.0107	0.26	0.18	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
HNSC	cis	rs11098499	0.789	rs9991166	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119316696	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.708	rs10005237	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119316742	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs878372	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119317625	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs10213267	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119317919	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs10212775	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119318089	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs2964	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119318976	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs1546503	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119320012	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs12506610	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119320504	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.743	rs10003567	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119320519	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs10006259	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119320990	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs28652763	ENSG00000250412.1	KLHL2P1	4.01	7.2e-05	0.0107	0.23	0.18	Corneal astigmatism;	chr4:119321157	chr4:119334329~119378233:+
HNSC	cis	rs7429990	0.864	rs13091913	ENSG00000228638.1	FCF1P2	4.01	7.21e-05	0.0107	0.17	0.18	Educational attainment (years of education);	chr3:47762307	chr3:48290793~48291375:-
HNSC	cis	rs7701440	0.512	rs7714712	ENSG00000215032.2	GNL3LP1	-4.01	7.21e-05	0.0107	-0.21	-0.18	Educational attainment;	chr5:61436725	chr5:60891935~60893577:-
HNSC	cis	rs1559040	1	rs67951010	ENSG00000272156.1	RP11-477N3.1	-4.01	7.21e-05	0.0107	-0.32	-0.18	Sudden cardiac arrest;	chr2:54102818	chr2:54082554~54085066:+
HNSC	cis	rs1559040	1	rs10166363	ENSG00000272156.1	RP11-477N3.1	-4.01	7.21e-05	0.0107	-0.32	-0.18	Sudden cardiac arrest;	chr2:54103105	chr2:54082554~54085066:+
HNSC	cis	rs1559040	1	rs10169648	ENSG00000272156.1	RP11-477N3.1	-4.01	7.21e-05	0.0107	-0.32	-0.18	Sudden cardiac arrest;	chr2:54103980	chr2:54082554~54085066:+
HNSC	cis	rs10510102	0.516	rs12256693	ENSG00000226864.1	ATE1-AS1	4.01	7.21e-05	0.0107	0.34	0.18	Breast cancer;	chr10:121976839	chr10:121928312~121951965:+
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000241549.7	GUSBP2	4	7.21e-05	0.0107	0.2	0.18	Parkinson's disease;	chr6:27881898	chr6:26871484~26956554:-
HNSC	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	4	7.22e-05	0.0107	0.2	0.18	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
HNSC	cis	rs656319	0.607	rs12156030	ENSG00000255310.2	AF131215.2	-4	7.22e-05	0.0107	-0.18	-0.18	Myopia (pathological);	chr8:10240012	chr8:11107788~11109726:-
HNSC	cis	rs34421088	0.532	rs1369368	ENSG00000269918.1	AF131215.9	4	7.22e-05	0.0107	0.19	0.18	Neuroticism;	chr8:11292704	chr8:11104691~11106704:-
HNSC	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	4	7.22e-05	0.0107	0.18	0.18	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
HNSC	cis	rs2243480	1	rs73142162	ENSG00000229886.1	RP5-1132H15.3	4	7.22e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65909309	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs73142166	ENSG00000229886.1	RP5-1132H15.3	4	7.22e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65910845	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000229886.1	RP5-1132H15.3	4	7.22e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65914813	chr7:66025126~66031544:-
HNSC	cis	rs10760158	0.62	rs10739596	ENSG00000226752.6	PSMD5-AS1	-4	7.22e-05	0.0107	-0.18	-0.18	Pulse pressure;	chr9:121327845	chr9:120824828~120854385:+
HNSC	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	4	7.22e-05	0.0107	0.22	0.18	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
HNSC	cis	rs9487051	0.724	rs13196219	ENSG00000243587.6	C6orf183	-4	7.22e-05	0.0107	-0.19	-0.18	Reticulocyte fraction of red cells;	chr6:109314584	chr6:109165833~109271014:+
HNSC	cis	rs1009077	0.536	rs35708340	ENSG00000245958.5	RP11-33B1.1	4	7.23e-05	0.0107	0.22	0.18	Endometriosis;	chr4:119442215	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.536	rs13116789	ENSG00000245958.5	RP11-33B1.1	4	7.23e-05	0.0107	0.22	0.18	Endometriosis;	chr4:119494057	chr4:119454791~119552025:+
HNSC	cis	rs721917	0.525	rs2258874	ENSG00000244733.5	RP11-506M13.3	-4	7.23e-05	0.0107	-0.22	-0.18	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79660891~79677996:+
HNSC	cis	rs739496	0.615	rs4648328	ENSG00000226469.1	ADAM1B	4	7.23e-05	0.0107	0.22	0.18	Platelet count;	chr12:111784984	chr12:111927018~111929017:+
HNSC	cis	rs73198271	0.92	rs11781542	ENSG00000254340.1	RP11-10A14.3	-4	7.23e-05	0.0107	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8759671	chr8:9141424~9145435:+
HNSC	cis	rs10791097	0.694	rs7106973	ENSG00000254842.5	RP11-890B15.2	-4	7.23e-05	0.0107	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130888218	chr11:130844191~130865561:-
HNSC	cis	rs12541595	0.93	rs34866937	ENSG00000255491.1	RP11-1082L8.4	4	7.23e-05	0.0107	0.23	0.18	Left ventricle diastolic internal dimension;	chr8:124847608	chr8:124811618~124815682:-
HNSC	cis	rs7735319	0.933	rs4030363	ENSG00000251281.1	CTD-2066L21.2	4	7.24e-05	0.0107	0.21	0.18	Systolic blood pressure;	chr5:33111244	chr5:33011322~33017607:-
HNSC	cis	rs964611	0.938	rs1820494	ENSG00000259488.2	RP11-154J22.1	4	7.24e-05	0.0107	0.16	0.18	Metabolite levels (Pyroglutamine);	chr15:48310977	chr15:48312353~48331856:-
HNSC	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	4	7.24e-05	0.0107	0.21	0.18	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
HNSC	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	4	7.24e-05	0.0107	0.21	0.18	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
HNSC	cis	rs2919009	0.766	rs56102659	ENSG00000271670.1	RP11-95I16.4	4	7.24e-05	0.0107	0.22	0.18	Obesity-related traits;	chr10:120786205	chr10:120879256~120880667:-
HNSC	cis	rs35306767	0.714	rs17293608	ENSG00000229869.1	RP11-363N22.2	-4	7.24e-05	0.0107	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1010312	chr10:933026~942743:+
HNSC	cis	rs4838594	1	rs4838594	ENSG00000273760.1	CH17-360D5.3	4	7.24e-05	0.0107	0.23	0.18	Daytime sleep phenotypes;	chr10:48461099	chr10:47970043~47973496:-
HNSC	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	4	7.25e-05	0.0107	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
HNSC	cis	rs6543140	0.964	rs10193485	ENSG00000234389.1	AC007278.3	4	7.25e-05	0.0107	0.19	0.18	Blood protein levels;	chr2:102473114	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs10196334	ENSG00000234389.1	AC007278.3	4	7.25e-05	0.0107	0.19	0.18	Blood protein levels;	chr2:102473582	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs10200081	ENSG00000234389.1	AC007278.3	4	7.25e-05	0.0107	0.19	0.18	Blood protein levels;	chr2:102475097	chr2:102438713~102440475:+
HNSC	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-4	7.25e-05	0.0107	-0.25	-0.18	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-4	7.25e-05	0.0107	-0.25	-0.18	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
HNSC	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-4	7.25e-05	0.0107	-0.22	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
HNSC	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	4	7.25e-05	0.0107	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
HNSC	cis	rs11951515	0.527	rs10462047	ENSG00000249286.1	CTD-2210P15.2	-4	7.25e-05	0.0107	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43258358	chr5:43586918~43588223:-
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000272831.1	RP11-792A8.4	-4	7.25e-05	0.0107	-0.15	-0.18	Calcium levels;	chr7:66040056	chr7:66739829~66740385:-
HNSC	cis	rs4713118	0.513	rs2294480	ENSG00000219392.1	RP1-265C24.5	-4	7.25e-05	0.0107	-0.21	-0.18	Parkinson's disease;	chr6:27616182	chr6:28115628~28116551:+
HNSC	cis	rs67981189	0.513	rs7154395	ENSG00000274818.1	RP1-292L20.3	4	7.25e-05	0.0107	0.2	0.18	Schizophrenia;	chr14:71099583	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs2877714	ENSG00000274818.1	RP1-292L20.3	4	7.26e-05	0.0107	0.2	0.18	Schizophrenia;	chr14:71101498	chr14:70906657~70907111:-
HNSC	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	4	7.26e-05	0.0107	0.16	0.18	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
HNSC	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	4	7.26e-05	0.0107	0.22	0.18	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
HNSC	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	4	7.26e-05	0.0107	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
HNSC	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	4	7.26e-05	0.0107	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
HNSC	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	4	7.26e-05	0.0107	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
HNSC	cis	rs6964587	0.839	rs62466809	ENSG00000188693.7	CYP51A1-AS1	-4	7.26e-05	0.0107	-0.2	-0.18	Breast cancer;	chr7:91843487	chr7:92134604~92180725:+
HNSC	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	4	7.26e-05	0.0107	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
HNSC	cis	rs11951515	0.663	rs10462048	ENSG00000249286.1	CTD-2210P15.2	4	7.27e-05	0.0107	0.19	0.18	Metabolite levels  (X-11787);	chr5:43258426	chr5:43586918~43588223:-
HNSC	cis	rs7829975	0.681	rs2271342	ENSG00000233609.3	RP11-62H7.2	4	7.27e-05	0.0107	0.18	0.18	Mood instability;	chr8:8786428	chr8:8961200~8979025:+
HNSC	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-4	7.27e-05	0.0108	-0.21	-0.18	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
HNSC	cis	rs1035144	0.606	rs12896769	ENSG00000258841.1	EEF1A1P2	4	7.27e-05	0.0108	0.2	0.18	Male sexual orientation;	chr14:81000708	chr14:81661428~81662874:+
HNSC	cis	rs1035144	0.606	rs929630	ENSG00000258841.1	EEF1A1P2	4	7.27e-05	0.0108	0.2	0.18	Male sexual orientation;	chr14:81001114	chr14:81661428~81662874:+
HNSC	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-4	7.28e-05	0.0108	-0.21	-0.18	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
HNSC	cis	rs7610312	0.681	rs1554125	ENSG00000273493.1	RP11-80H18.4	4	7.28e-05	0.0108	0.21	0.18	Red blood cell count;	chr3:58291774	chr3:58329965~58330118:+
HNSC	cis	rs9326246	0.556	rs662799	ENSG00000280143.1	AP000892.6	4	7.28e-05	0.0108	0.36	0.18	Coronary artery disease;	chr11:116792991	chr11:117204967~117210292:+
HNSC	cis	rs6504108	0.624	rs2021811	ENSG00000278765.1	RP5-890E16.5	-4	7.28e-05	0.0108	-0.23	-0.18	Body mass index;	chr17:48160420	chr17:48066704~48067293:-
HNSC	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-4	7.28e-05	0.0108	-0.2	-0.18	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119329650	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119329663	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119329966	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119330093	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119330488	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119330840	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119330862	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119330908	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119331175	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000250412.1	KLHL2P1	4	7.29e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119331206	chr4:119334329~119378233:+
HNSC	cis	rs561341	0.882	rs2521594	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31975068	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs548957	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31975392	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs542132	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31980174	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.556	rs542244	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31980223	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs484175	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31982022	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.941	rs4525554	ENSG00000278867.1	RP11-640N20.4	-4	7.29e-05	0.0108	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31985800	chr17:32051030~32053208:+
HNSC	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-4	7.29e-05	0.0108	-0.13	-0.18	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
HNSC	cis	rs10819861	0.679	rs4743525	ENSG00000271384.1	RP11-435O5.7	-4	7.29e-05	0.0108	-0.18	-0.18	Electrocardiographic traits;	chr9:96086727	chr9:95406990~95407662:-
HNSC	cis	rs12935418	0.672	rs12448656	ENSG00000278985.1	RP11-303E16.9	4	7.29e-05	0.0108	0.19	0.18	Mean corpuscular volume;	chr16:81008876	chr16:80982319~80984094:-
HNSC	cis	rs9329221	0.572	rs4841295	ENSG00000255310.2	AF131215.2	4	7.29e-05	0.0108	0.18	0.18	Neuroticism;	chr8:10247605	chr8:11107788~11109726:-
HNSC	cis	rs36093924	0.646	rs5996094	ENSG00000227370.1	RP4-669P10.19	4	7.29e-05	0.0108	0.17	0.18	Intelligence;	chr22:41951056	chr22:42132543~42132998:+
HNSC	cis	rs897984	0.683	rs13337900	ENSG00000279196.1	RP11-1072A3.3	4	7.29e-05	0.0108	0.2	0.18	Dementia with Lewy bodies;	chr16:30811088	chr16:30984630~30988270:-
HNSC	cis	rs11633886	0.565	rs17554726	ENSG00000273972.1	CTD-2306A12.1	4	7.29e-05	0.0108	0.22	0.18	Diisocyanate-induced asthma;	chr15:45759272	chr15:45702640~45703183:+
HNSC	cis	rs62432291	0.681	rs294912	ENSG00000235086.1	FNDC1-IT1	-4	7.3e-05	0.0108	-0.25	-0.18	Joint mobility (Beighton score);	chr6:159246305	chr6:159240786~159243329:+
HNSC	cis	rs72827839	0.779	rs16955073	ENSG00000272763.1	RP11-357H14.17	-4	7.3e-05	0.0108	-0.26	-0.18	Ease of getting up in the morning;	chr17:48304384	chr17:48635923~48647023:-
HNSC	cis	rs9400271	0.632	rs9384704	ENSG00000243587.6	C6orf183	-4	7.3e-05	0.0108	-0.18	-0.18	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109266006	chr6:109165833~109271014:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000211976.2	IGHV3-73	-4	7.3e-05	0.0108	-0.13	-0.18	Kawasaki disease;	chr14:106776758	chr14:106802694~106803233:-
HNSC	cis	rs7688540	0.771	rs11729365	ENSG00000211553.1	AC253576.2	-4	7.3e-05	0.0108	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs11722521	ENSG00000211553.1	AC253576.2	-4	7.3e-05	0.0108	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:136461~136568:+
HNSC	cis	rs7735319	0.966	rs16890746	ENSG00000249102.1	CTD-2066L21.1	4	7.31e-05	0.0108	0.21	0.18	Systolic blood pressure;	chr5:33118567	chr5:33008994~33025724:+
HNSC	cis	rs67981189	0.574	rs4467005	ENSG00000274818.1	RP1-292L20.3	4	7.31e-05	0.0108	0.2	0.18	Schizophrenia;	chr14:71031939	chr14:70906657~70907111:-
HNSC	cis	rs757081	0.658	rs214075	ENSG00000260196.1	RP1-239B22.5	-4	7.31e-05	0.0108	-0.19	-0.18	Systolic blood pressure;	chr11:17278870	chr11:17380649~17383531:+
HNSC	cis	rs860295	0.58	rs66466805	ENSG00000225855.5	RUSC1-AS1	4	7.31e-05	0.0108	0.12	0.18	Body mass index;	chr1:155918875	chr1:155316863~155324176:-
HNSC	cis	rs10269006	0.727	rs6960857	ENSG00000234695.1	AC002076.10	4	7.31e-05	0.0108	0.21	0.18	Breast cancer;	chr7:94742997	chr7:93890913~93893601:+
HNSC	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-4	7.31e-05	0.0108	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-4	7.31e-05	0.0108	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-4	7.31e-05	0.0108	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
HNSC	cis	rs12935418	0.616	rs9936366	ENSG00000278985.1	RP11-303E16.9	4	7.31e-05	0.0108	0.19	0.18	Mean corpuscular volume;	chr16:81011657	chr16:80982319~80984094:-
HNSC	cis	rs1008375	0.932	rs11938710	ENSG00000249502.1	AC006160.5	4	7.31e-05	0.0108	0.2	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17669041	chr4:17587467~17614571:-
HNSC	cis	rs1937680	0.613	rs7899527	ENSG00000236671.6	PRKG1-AS1	-4	7.31e-05	0.0108	-0.26	-0.18	Breast cancer;	chr10:51908554	chr10:52230742~52314128:-
HNSC	cis	rs1580019	0.922	rs34545272	ENSG00000226468.2	AC018641.7	-4	7.31e-05	0.0108	-0.25	-0.18	Cognitive ability;	chr7:32421018	chr7:32456963~32457758:-
HNSC	cis	rs9487051	0.724	rs11966072	ENSG00000243587.6	C6orf183	-4	7.31e-05	0.0108	-0.19	-0.18	Reticulocyte fraction of red cells;	chr6:109313625	chr6:109165833~109271014:+
HNSC	cis	rs2554380	0.8	rs2585068	ENSG00000259570.1	RP11-671M22.4	4	7.31e-05	0.0108	0.24	0.18	Height;	chr15:83735705	chr15:84394512~84395514:+
HNSC	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-4	7.31e-05	0.0108	-0.25	-0.18	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
HNSC	cis	rs78579285	0.704	rs61742623	ENSG00000278341.1	RP5-1142A6.10	-4	7.31e-05	0.0108	-0.34	-0.18	Joint mobility (Beighton score);	chr16:88736340	chr16:88708956~88710437:-
HNSC	cis	rs4919687	0.55	rs12761195	ENSG00000236937.2	PTGES3P4	4	7.32e-05	0.0108	0.24	0.18	Colorectal cancer;	chr10:102705617	chr10:102845595~102845950:+
HNSC	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	4	7.32e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
HNSC	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-4	7.32e-05	0.0108	-0.18	-0.18	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
HNSC	cis	rs988913	1	rs9475081	ENSG00000224984.1	RP11-524H19.2	4	7.32e-05	0.0108	0.21	0.18	Menarche (age at onset);	chr6:54948940	chr6:54840118~54840855:-
HNSC	cis	rs9611565	0.694	rs7285041	ENSG00000235513.1	RP4-756G23.5	-4	7.32e-05	0.0108	-0.23	-0.18	Vitiligo;	chr22:41433145	chr22:41209122~41217627:-
HNSC	cis	rs11098499	0.863	rs7678400	ENSG00000250412.1	KLHL2P1	4	7.32e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119540802	chr4:119334329~119378233:+
HNSC	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	4	7.32e-05	0.0108	0.18	0.18	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
HNSC	cis	rs62292953	1	rs56705566	ENSG00000248724.5	NPHP3-AS1	-4	7.33e-05	0.0108	-0.32	-0.18	Red cell distribution width;	chr3:132548460	chr3:132721750~132874223:+
HNSC	cis	rs4489787	0.892	rs4448729	ENSG00000257763.1	OR5BK1P	-4	7.33e-05	0.0108	-0.3	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48428545	chr12:48355792~48356614:-
HNSC	cis	rs11098499	0.913	rs68128210	ENSG00000250412.1	KLHL2P1	4	7.33e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119216664	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.913	rs13126596	ENSG00000250412.1	KLHL2P1	4	7.33e-05	0.0108	0.23	0.18	Corneal astigmatism;	chr4:119219574	chr4:119334329~119378233:+
HNSC	cis	rs2518049	0.852	rs10795242	ENSG00000224034.1	RP11-445P17.8	4	7.33e-05	0.0108	0.24	0.18	Metabolic traits;	chr10:5076835	chr10:5266033~5271236:-
HNSC	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	4	7.33e-05	0.0108	0.3	0.18	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
HNSC	cis	rs3812049	0.611	rs251393	ENSG00000245937.6	LINC01184	4	7.33e-05	0.0108	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128197393	chr5:127940426~128083172:-
HNSC	cis	rs7824557	0.544	rs1865521	ENSG00000255310.2	AF131215.2	4	7.33e-05	0.0108	0.17	0.18	Retinal vascular caliber;	chr8:11373740	chr8:11107788~11109726:-
HNSC	cis	rs1124609	1	rs1124609	ENSG00000244879.4	GABPB1-AS1	4	7.34e-05	0.0108	0.26	0.18	Subjective well-being;	chr15:50193820	chr15:50354959~50372202:+
HNSC	cis	rs889398	0.935	rs1364063	ENSG00000226232.7	RP11-419C5.2	4	7.34e-05	0.0108	0.16	0.18	Body mass index;	chr16:69554669	chr16:69976388~69996188:-
HNSC	cis	rs970821	0.667	rs6470182	ENSG00000253106.1	RP11-158K1.3	-4	7.34e-05	0.0108	-0.16	-0.18	Breast cancer;	chr8:123739465	chr8:124488510~124491643:+
HNSC	cis	rs3740713	1	rs35593189	ENSG00000256464.1	YWHABP2	4	7.34e-05	0.0108	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18490243~18490955:-
HNSC	cis	rs2562152	0.654	rs216600	ENSG00000226942.2	IL9RP3	-4	7.34e-05	0.0108	-0.27	-0.18	Glioblastoma;	chr16:60167	chr16:29336~38321:-
HNSC	cis	rs1009077	0.716	rs35967840	ENSG00000245958.5	RP11-33B1.1	4	7.34e-05	0.0108	0.21	0.18	Endometriosis;	chr4:119612287	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.716	rs13106925	ENSG00000245958.5	RP11-33B1.1	4	7.34e-05	0.0108	0.21	0.18	Endometriosis;	chr4:119617953	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.669	rs11730798	ENSG00000245958.5	RP11-33B1.1	4	7.34e-05	0.0108	0.21	0.18	Endometriosis;	chr4:119618704	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.626	rs11731568	ENSG00000245958.5	RP11-33B1.1	4	7.34e-05	0.0108	0.21	0.18	Endometriosis;	chr4:119618796	chr4:119454791~119552025:+
HNSC	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	4	7.34e-05	0.0108	0.22	0.18	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	4	7.34e-05	0.0108	0.22	0.18	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
HNSC	cis	rs11951515	0.663	rs7734293	ENSG00000249286.1	CTD-2210P15.2	4	7.34e-05	0.0108	0.19	0.18	Metabolite levels  (X-11787);	chr5:43283100	chr5:43586918~43588223:-
HNSC	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	4	7.34e-05	0.0108	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
HNSC	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	4	7.34e-05	0.0108	0.16	0.18	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	4	7.34e-05	0.0108	0.16	0.18	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	4	7.34e-05	0.0108	0.16	0.18	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
HNSC	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-4	7.35e-05	0.0109	-0.25	-0.18	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
HNSC	cis	rs73201462	0.901	rs6771646	ENSG00000231305.3	RP11-723O4.2	-4	7.35e-05	0.0109	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128315692	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs55989768	ENSG00000231305.3	RP11-723O4.2	-4	7.35e-05	0.0109	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324161	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs55675294	ENSG00000231305.3	RP11-723O4.2	-4	7.35e-05	0.0109	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324207	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6772407	ENSG00000231305.3	RP11-723O4.2	-4	7.35e-05	0.0109	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325529	chr3:128861313~128871540:-
HNSC	cis	rs6095360	1	rs6019535	ENSG00000222365.1	SNORD12B	-4	7.35e-05	0.0109	-0.2	-0.18	Intelligence (multi-trait analysis);	chr20:48924980	chr20:49280319~49280409:+
HNSC	cis	rs56346965	0.506	rs929566	ENSG00000235852.1	AC005540.3	4	7.35e-05	0.0109	0.22	0.18	Bone mineral density (Ward's triangle area);	chr2:190656715	chr2:190880797~190882059:-
HNSC	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-4	7.36e-05	0.0109	-0.22	-0.18	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
HNSC	cis	rs12935418	0.673	rs2549886	ENSG00000278985.1	RP11-303E16.9	-4	7.36e-05	0.0109	-0.18	-0.18	Mean corpuscular volume;	chr16:81027627	chr16:80982319~80984094:-
HNSC	cis	rs2911132	0.564	rs7356594	ENSG00000248734.2	CTD-2260A17.1	4	7.36e-05	0.0109	0.2	0.18	Urate levels (BMI interaction);	chr5:96760485	chr5:96784777~96785999:+
HNSC	cis	rs6688613	0.84	rs10918607	ENSG00000215834.7	FMO9P	4	7.36e-05	0.0109	0.25	0.18	Refractive astigmatism;	chr1:166988566	chr1:166603675~166631400:+
HNSC	cis	rs755249	0.835	rs4660877	ENSG00000182109.6	RP11-69E11.4	4	7.37e-05	0.0109	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613574	chr1:39522280~39546187:-
HNSC	cis	rs62025270	0.747	rs12324721	ENSG00000259762.1	RP11-158M2.4	-4	7.37e-05	0.0109	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85750336~85752901:-
HNSC	cis	rs2253762	0.54	rs10887053	ENSG00000226864.1	ATE1-AS1	4	7.37e-05	0.0109	0.31	0.18	Breast cancer;	chr10:122030997	chr10:121928312~121951965:+
HNSC	cis	rs478304	0.651	rs12225620	ENSG00000255120.4	OVOL1-AS1	-4	7.37e-05	0.0109	-0.19	-0.18	Acne (severe);	chr11:65737977	chr11:65789051~65790868:-
HNSC	cis	rs478304	0.58	rs11606947	ENSG00000255120.4	OVOL1-AS1	-4	7.37e-05	0.0109	-0.19	-0.18	Acne (severe);	chr11:65740766	chr11:65789051~65790868:-
HNSC	cis	rs853679	0.599	rs188015	ENSG00000219891.2	ZSCAN12P1	4	7.37e-05	0.0109	0.33	0.18	Depression;	chr6:27909668	chr6:28091154~28093664:+
HNSC	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-4	7.37e-05	0.0109	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
HNSC	cis	rs9650657	0.711	rs35091929	ENSG00000269918.1	AF131215.9	-4	7.37e-05	0.0109	-0.18	-0.18	Neuroticism;	chr8:10835982	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.581	rs17255433	ENSG00000211814.1	TRAV35	-4	7.37e-05	0.0109	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22221896~22222475:+
HNSC	cis	rs11157436	0.602	rs17255440	ENSG00000211814.1	TRAV35	-4	7.37e-05	0.0109	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22221896~22222475:+
HNSC	cis	rs11098499	0.863	rs58452170	ENSG00000250412.1	KLHL2P1	4	7.37e-05	0.0109	0.23	0.18	Corneal astigmatism;	chr4:119538519	chr4:119334329~119378233:+
HNSC	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-4	7.37e-05	0.0109	-0.22	-0.18	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
HNSC	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	4	7.37e-05	0.0109	0.32	0.18	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
HNSC	cis	rs7085104	0.513	rs619824	ENSG00000213061.2	PFN1P11	4	7.37e-05	0.0109	0.22	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102838011~102845473:-
HNSC	cis	rs3736485	0.966	rs10851500	ENSG00000259438.1	CTD-2650P22.1	4	7.37e-05	0.0109	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51491623	chr15:52010999~52019095:-
HNSC	cis	rs4947019	0.609	rs9480934	ENSG00000260273.1	RP11-425D10.10	4	7.38e-05	0.0109	0.52	0.18	Hematological parameters;	chr6:109350845	chr6:109382795~109383666:+
HNSC	cis	rs2526882	0.541	rs2526859	ENSG00000274818.1	RP1-292L20.3	-4	7.38e-05	0.0109	-0.2	-0.18	Schizophrenia;	chr14:70945490	chr14:70906657~70907111:-
HNSC	cis	rs6601327	0.613	rs4612345	ENSG00000233609.3	RP11-62H7.2	-4	7.38e-05	0.0109	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:8961200~8979025:+
HNSC	cis	rs924607	1	rs4045344	ENSG00000225138.6	CTD-2228K2.7	-4	7.38e-05	0.0109	-0.2	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:595755	chr5:473236~480884:+
HNSC	cis	rs7824557	0.65	rs2572406	ENSG00000255310.2	AF131215.2	4	7.38e-05	0.0109	0.17	0.18	Retinal vascular caliber;	chr8:11234743	chr8:11107788~11109726:-
HNSC	cis	rs5167	0.539	rs4803783	ENSG00000214855.8	APOC1P1	-4	7.38e-05	0.0109	-0.2	-0.18	Blood protein levels;	chr19:44967201	chr19:44926804~44931386:+
HNSC	cis	rs10129255	0.5	rs59939897	ENSG00000211976.2	IGHV3-73	-4	7.38e-05	0.0109	-0.13	-0.18	Kawasaki disease;	chr14:106783414	chr14:106802694~106803233:-
HNSC	cis	rs9393777	0.623	rs56296968	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26474343	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs3757150	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26476554	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs16891717	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26476915	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs9358946	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26478699	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs9358947	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26478772	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs7756567	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26481414	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.623	rs9358948	ENSG00000241549.7	GUSBP2	4	7.38e-05	0.0109	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26483578	chr6:26871484~26956554:-
HNSC	cis	rs1476670	0.683	rs813642	ENSG00000230615.5	RP5-1198O20.4	-4	7.38e-05	0.0109	-0.23	-0.18	Eotaxin levels;	chr1:44040748	chr1:44030443~44115913:+
HNSC	cis	rs13256369	0.865	rs13282523	ENSG00000173295.6	FAM86B3P	4	7.38e-05	0.0109	0.23	0.18	Obesity-related traits;	chr8:8719783	chr8:8228595~8244865:+
HNSC	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-4	7.38e-05	0.0109	-0.27	-0.18	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
HNSC	cis	rs6601327	0.573	rs13278824	ENSG00000233609.3	RP11-62H7.2	4	7.38e-05	0.0109	0.17	0.18	Multiple myeloma (hyperdiploidy);	chr8:9788609	chr8:8961200~8979025:+
HNSC	cis	rs597539	0.652	rs569777	ENSG00000261625.1	RP11-554A11.4	-4	7.39e-05	0.0109	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:69000765~69002048:-
HNSC	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-4	7.39e-05	0.0109	-0.23	-0.18	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
HNSC	cis	rs859767	0.501	rs11898465	ENSG00000224043.6	CCNT2-AS1	4	7.39e-05	0.0109	0.21	0.18	Neuroticism;	chr2:134673879	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.501	rs4954160	ENSG00000224043.6	CCNT2-AS1	4	7.39e-05	0.0109	0.21	0.18	Neuroticism;	chr2:134674122	chr2:134735464~134918710:-
HNSC	cis	rs7829975	0.84	rs572366	ENSG00000233609.3	RP11-62H7.2	4	7.39e-05	0.0109	0.17	0.18	Mood instability;	chr8:8721284	chr8:8961200~8979025:+
HNSC	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	4	7.39e-05	0.0109	0.16	0.18	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
HNSC	cis	rs9584850	0.794	rs17470961	ENSG00000231194.1	FARP1-AS1	4	7.39e-05	0.0109	0.22	0.18	Neuroticism;	chr13:98483060	chr13:98435405~98435840:-
HNSC	cis	rs72634501	0.568	rs590214	ENSG00000228060.1	RP11-69E11.8	-4	7.39e-05	0.0109	-0.19	-0.18	HDL cholesterol;	chr1:39146821	chr1:39565160~39573203:+
HNSC	cis	rs7824557	0.564	rs55758514	ENSG00000269918.1	AF131215.9	-4	7.4e-05	0.0109	-0.18	-0.18	Retinal vascular caliber;	chr8:11372750	chr8:11104691~11106704:-
HNSC	cis	rs6543140	0.964	rs62154972	ENSG00000234389.1	AC007278.3	4	7.4e-05	0.0109	0.19	0.18	Blood protein levels;	chr2:102432278	chr2:102438713~102440475:+
HNSC	cis	rs6500602	0.653	rs4786487	ENSG00000280063.1	RP11-295D4.3	-4	7.4e-05	0.0109	-0.14	-0.18	Schizophrenia;	chr16:4390396	chr16:4346694~4348648:-
HNSC	cis	rs2998286	0.813	rs2790431	ENSG00000254635.4	WAC-AS1	-4	7.4e-05	0.0109	-0.27	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28500266	chr10:28522652~28532743:-
HNSC	cis	rs924712	0.522	rs6931473	ENSG00000224984.1	RP11-524H19.2	-4	7.4e-05	0.0109	-0.21	-0.18	Breast cancer;	chr6:54833971	chr6:54840118~54840855:-
HNSC	cis	rs12449000	1	rs12449000	ENSG00000260259.1	RP11-368I7.4	-4	7.4e-05	0.0109	-0.21	-0.18	Schizophrenia;	chr16:89806562	chr16:89682620~89686569:-
HNSC	cis	rs6500395	0.735	rs2883641	ENSG00000261267.1	RP11-44I10.3	-4	7.4e-05	0.0109	-0.23	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630535	chr16:48559661~48587403:+
HNSC	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-4	7.4e-05	0.0109	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
HNSC	cis	rs293377	0.961	rs293370	ENSG00000260123.1	RP11-326A19.4	-4	7.41e-05	0.0109	-0.2	-0.18	Gut microbiota (beta diversity);	chr15:89087245	chr15:89041223~89082819:+
HNSC	cis	rs561341	0.714	rs473535	ENSG00000278867.1	RP11-640N20.4	-4	7.41e-05	0.0109	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31985346	chr17:32051030~32053208:+
HNSC	cis	rs1218582	0.628	rs12130132	ENSG00000270361.1	RP11-307C12.13	-4	7.41e-05	0.0109	-0.21	-0.18	Prostate cancer;	chr1:154907910	chr1:154937370~154938059:+
HNSC	cis	rs10938353	0.911	rs4330385	ENSG00000273369.1	RP11-700J17.1	-4	7.41e-05	0.0109	-0.22	-0.18	Body mass index;	chr4:44585482	chr4:44693946~44694386:-
HNSC	cis	rs10938353	0.911	rs4504296	ENSG00000273369.1	RP11-700J17.1	-4	7.41e-05	0.0109	-0.22	-0.18	Body mass index;	chr4:44585515	chr4:44693946~44694386:-
HNSC	cis	rs11157436	0.602	rs928954	ENSG00000211814.1	TRAV35	-4	7.41e-05	0.0109	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22221896~22222475:+
HNSC	cis	rs28829049	0.566	rs59681755	ENSG00000270728.1	RP4-657E11.10	-4	7.41e-05	0.0109	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19202491	chr1:19297080~19297903:+
HNSC	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	4	7.41e-05	0.0109	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
HNSC	cis	rs2342371	0.72	rs61345811	ENSG00000243339.3	RN7SL738P	-4	7.41e-05	0.0109	-0.25	-0.18	Fat distribution (HIV);	chr3:196416159	chr3:196399911~196400207:+
HNSC	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-4	7.41e-05	0.0109	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
HNSC	cis	rs7572733	0.576	rs6734781	ENSG00000231621.1	AC013264.2	-4	7.42e-05	0.0109	-0.17	-0.18	Dermatomyositis;	chr2:197895249	chr2:197197991~197199273:+
HNSC	cis	rs7829975	0.871	rs7829826	ENSG00000233609.3	RP11-62H7.2	-4	7.42e-05	0.0109	-0.18	-0.18	Mood instability;	chr8:8720610	chr8:8961200~8979025:+
HNSC	cis	rs6964587	1	rs7802788	ENSG00000188693.7	CYP51A1-AS1	-4	7.42e-05	0.0109	-0.19	-0.18	Breast cancer;	chr7:92107560	chr7:92134604~92180725:+
HNSC	cis	rs10129255	0.5	rs2027903	ENSG00000211976.2	IGHV3-73	-4	7.42e-05	0.0109	-0.13	-0.18	Kawasaki disease;	chr14:106807047	chr14:106802694~106803233:-
HNSC	cis	rs988913	0.957	rs9475098	ENSG00000224984.1	RP11-524H19.2	4	7.42e-05	0.0109	0.21	0.18	Menarche (age at onset);	chr6:54968379	chr6:54840118~54840855:-
HNSC	cis	rs2013441	0.67	rs4924802	ENSG00000261033.1	RP11-209D14.2	-4	7.43e-05	0.0109	-0.21	-0.18	Obesity-related traits;	chr17:20052582	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.67	rs35317166	ENSG00000261033.1	RP11-209D14.2	-4	7.43e-05	0.0109	-0.21	-0.18	Obesity-related traits;	chr17:20056507	chr17:20008051~20009234:-
HNSC	cis	rs8067545	0.532	rs56371654	ENSG00000261033.1	RP11-209D14.2	-4	7.43e-05	0.0109	-0.21	-0.18	Schizophrenia;	chr17:20057049	chr17:20008051~20009234:-
HNSC	cis	rs36093924	0.646	rs5996092	ENSG00000182057.4	OGFRP1	-4	7.43e-05	0.011	-0.18	-0.18	Intelligence;	chr22:41948404	chr22:42269753~42275196:+
HNSC	cis	rs72843506	0.591	rs75334890	ENSG00000261033.1	RP11-209D14.2	4	7.43e-05	0.011	0.31	0.18	Schizophrenia;	chr17:20318087	chr17:20008051~20009234:-
HNSC	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	4	7.43e-05	0.011	0.25	0.18	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
HNSC	cis	rs2439831	0.867	rs3213991	ENSG00000275601.1	AC011330.13	-4	7.43e-05	0.011	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43378082	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs7163245	ENSG00000275601.1	AC011330.13	-4	7.43e-05	0.011	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43379096	chr15:43642389~43643023:-
HNSC	cis	rs10129255	0.5	rs34326748	ENSG00000211976.2	IGHV3-73	-4	7.43e-05	0.011	-0.13	-0.18	Kawasaki disease;	chr14:106782523	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs10143385	ENSG00000211976.2	IGHV3-73	-4	7.43e-05	0.011	-0.13	-0.18	Kawasaki disease;	chr14:106782559	chr14:106802694~106803233:-
HNSC	cis	rs516805	0.665	rs2606648	ENSG00000279453.1	RP3-425C14.4	-4	7.43e-05	0.011	-0.25	-0.18	Lymphocyte counts;	chr6:122119554	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.597	rs2816157	ENSG00000279453.1	RP3-425C14.4	-4	7.43e-05	0.011	-0.25	-0.18	Lymphocyte counts;	chr6:122124400	chr6:122436789~122439223:-
HNSC	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	4	7.44e-05	0.011	0.18	0.18	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
HNSC	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-4	7.44e-05	0.011	-0.25	-0.18	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
HNSC	cis	rs2898290	0.622	rs1600250	ENSG00000269918.1	AF131215.9	-4	7.44e-05	0.011	-0.18	-0.18	Systolic blood pressure;	chr8:11487916	chr8:11104691~11106704:-
HNSC	cis	rs60695258	0.512	rs2053769	ENSG00000251411.1	RP11-397E7.4	4	7.44e-05	0.011	0.19	0.18	Hematocrit;	chr4:86986855	chr4:86913266~86914817:-
HNSC	cis	rs970821	0.667	rs7013258	ENSG00000253106.1	RP11-158K1.3	-4	7.44e-05	0.011	-0.16	-0.18	Breast cancer;	chr8:123733201	chr8:124488510~124491643:+
HNSC	cis	rs12285276	0.673	rs12283175	ENSG00000205106.4	DKFZp779M0652	4	7.44e-05	0.011	0.27	0.18	Visceral fat;	chr11:45781619	chr11:45771432~45772358:+
HNSC	cis	rs73198271	0.843	rs11775888	ENSG00000253893.2	FAM85B	4	7.44e-05	0.011	0.27	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8167819~8226614:-
HNSC	cis	rs72827839	0.744	rs16955463	ENSG00000272763.1	RP11-357H14.17	-4	7.44e-05	0.011	-0.26	-0.18	Ease of getting up in the morning;	chr17:48322135	chr17:48635923~48647023:-
HNSC	cis	rs6928977	0.896	rs2614287	ENSG00000217482.2	HMGB1P17	-4	7.44e-05	0.011	-0.2	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135636086~135636713:-
HNSC	cis	rs1602565	0.858	rs618767	ENSG00000255450.1	CTD-2063L20.1	-4	7.44e-05	0.011	-0.29	-0.18	Schizophrenia;	chr11:29161240	chr11:29275655~29276565:+
HNSC	cis	rs9487051	0.621	rs351720	ENSG00000243587.6	C6orf183	-4	7.44e-05	0.011	-0.19	-0.18	Reticulocyte fraction of red cells;	chr6:109229944	chr6:109165833~109271014:+
HNSC	cis	rs853679	1	rs2799077	ENSG00000204709.4	LINC01556	4	7.45e-05	0.011	0.28	0.18	Depression;	chr6:28266819	chr6:28943877~28944537:+
HNSC	cis	rs9287719	0.649	rs58633964	ENSG00000243819.4	RN7SL832P	4	7.45e-05	0.011	0.18	0.18	Prostate cancer;	chr2:10596256	chr2:10690344~10692099:+
HNSC	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	4	7.45e-05	0.011	0.22	0.18	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
HNSC	cis	rs8010715	0.816	rs11574503	ENSG00000259321.1	RP11-468E2.5	-4	7.45e-05	0.011	-0.15	-0.18	IgG glycosylation;	chr14:24132109	chr14:24139445~24140444:+
HNSC	cis	rs6142618	0.935	rs6061184	ENSG00000275576.1	RP5-836N17.4	-4	7.45e-05	0.011	-0.18	-0.18	Inflammatory bowel disease;	chr20:32142435	chr20:32116171~32116629:+
HNSC	cis	rs7829975	0.711	rs4481596	ENSG00000233609.3	RP11-62H7.2	4	7.46e-05	0.011	0.18	0.18	Mood instability;	chr8:8846820	chr8:8961200~8979025:+
HNSC	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-4	7.46e-05	0.011	-0.16	-0.18	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
HNSC	cis	rs7189233	0.955	rs11540358	ENSG00000279344.1	RP11-44F14.7	4	7.46e-05	0.011	0.18	0.18	Intelligence (multi-trait analysis);	chr16:53470031	chr16:53478957~53481550:-
HNSC	cis	rs8077577	0.747	rs11078415	ENSG00000273018.4	CTD-2303H24.2	-4	7.46e-05	0.011	-0.26	-0.18	Obesity-related traits;	chr17:18352184	chr17:18511221~18551705:-
HNSC	cis	rs2820651	1	rs2820651	ENSG00000229869.1	RP11-363N22.2	-4	7.46e-05	0.011	-0.35	-0.18	Migraine with aura;	chr10:1429570	chr10:933026~942743:+
HNSC	cis	rs3096299	0.967	rs2911257	ENSG00000261118.1	RP11-104N10.1	4	7.46e-05	0.011	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89492017~89504460:-
HNSC	cis	rs4356203	0.875	rs7939614	ENSG00000260196.1	RP1-239B22.5	-4	7.46e-05	0.011	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs9919540	ENSG00000260196.1	RP1-239B22.5	-4	7.46e-05	0.011	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17380649~17383531:+
HNSC	cis	rs897984	0.762	rs4889599	ENSG00000279196.1	RP11-1072A3.3	-4	7.47e-05	0.011	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30957268	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.721	rs2305884	ENSG00000279196.1	RP11-1072A3.3	-4	7.47e-05	0.011	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30959420	chr16:30984630~30988270:-
HNSC	cis	rs9650657	0.571	rs11783247	ENSG00000255310.2	AF131215.2	-4	7.47e-05	0.011	-0.17	-0.18	Neuroticism;	chr8:10931365	chr8:11107788~11109726:-
HNSC	cis	rs1065852	0.51	rs5758666	ENSG00000227370.1	RP4-669P10.19	4	7.47e-05	0.011	0.19	0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42132543~42132998:+
HNSC	cis	rs7688540	0.771	rs77078697	ENSG00000211553.1	AC253576.2	-4	7.47e-05	0.011	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs61795006	ENSG00000211553.1	AC253576.2	-4	7.47e-05	0.011	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs61795007	ENSG00000211553.1	AC253576.2	-4	7.47e-05	0.011	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:136461~136568:+
HNSC	cis	rs35000415	0.688	rs13237546	ENSG00000275106.1	RP11-309L24.10	-4	7.47e-05	0.011	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129080379	chr7:128952527~128953316:-
HNSC	cis	rs919433	0.927	rs1429418	ENSG00000231621.1	AC013264.2	4	7.47e-05	0.011	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293427	chr2:197197991~197199273:+
HNSC	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-4	7.47e-05	0.011	-0.21	-0.18	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
HNSC	cis	rs870825	0.872	rs12507711	ENSG00000254233.1	RP11-242J7.1	4	7.47e-05	0.011	0.29	0.18	Blood protein levels;	chr4:184650622	chr4:184584093~184625030:-
HNSC	cis	rs4356203	0.905	rs550667	ENSG00000260196.1	RP1-239B22.5	-4	7.47e-05	0.011	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs656623	ENSG00000260196.1	RP1-239B22.5	-4	7.47e-05	0.011	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17380649~17383531:+
HNSC	cis	rs7824557	0.564	rs11781637	ENSG00000269918.1	AF131215.9	-4	7.47e-05	0.011	-0.18	-0.18	Retinal vascular caliber;	chr8:11357463	chr8:11104691~11106704:-
HNSC	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-4	7.47e-05	0.011	-0.21	-0.18	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
HNSC	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4	7.47e-05	0.011	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
HNSC	cis	rs17818399	0.547	rs4952833	ENSG00000279254.1	RP11-536C12.1	-4	7.48e-05	0.011	-0.22	-0.18	Height;	chr2:46534895	chr2:46668870~46670778:+
HNSC	cis	rs28830936	0.967	rs9672671	ENSG00000250379.1	RP11-23P13.4	4	7.48e-05	0.011	0.22	0.18	Diastolic blood pressure;	chr15:41624877	chr15:41825099~41827936:-
HNSC	cis	rs56346965	0.506	rs2159818	ENSG00000235852.1	AC005540.3	4	7.48e-05	0.011	0.22	0.18	Bone mineral density (Ward's triangle area);	chr2:190668063	chr2:190880797~190882059:-
HNSC	cis	rs801193	1	rs3778909	ENSG00000272831.1	RP11-792A8.4	4	7.48e-05	0.011	0.15	0.18	Aortic root size;	chr7:66790659	chr7:66739829~66740385:-
HNSC	cis	rs36093844	0.527	rs17817588	ENSG00000279742.1	RP11-700A24.1	-4	7.48e-05	0.011	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965788	chr11:85852557~85854943:-
HNSC	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-4	7.48e-05	0.011	-0.24	-0.18	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
HNSC	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-4	7.48e-05	0.011	-0.24	-0.18	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
HNSC	cis	rs2243480	1	rs6964530	ENSG00000229886.1	RP5-1132H15.3	-4	7.48e-05	0.011	-0.31	-0.18	Diabetic kidney disease;	chr7:66253864	chr7:66025126~66031544:-
HNSC	cis	rs4713118	0.621	rs10484403	ENSG00000219891.2	ZSCAN12P1	4	7.49e-05	0.011	0.26	0.18	Parkinson's disease;	chr6:28065745	chr6:28091154~28093664:+
HNSC	cis	rs72827839	0.744	rs16955463	ENSG00000210741.1	MIR196A1	-4	7.49e-05	0.011	-0.23	-0.18	Ease of getting up in the morning;	chr17:48322135	chr17:48632490~48632559:-
HNSC	cis	rs7169223	0.615	rs8038189	ENSG00000261762.1	RP11-650L12.2	-4	7.49e-05	0.011	-0.24	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78806684	chr15:78589123~78591276:-
HNSC	cis	rs889398	0.869	rs862320	ENSG00000226232.7	RP11-419C5.2	4	7.49e-05	0.011	0.16	0.18	Body mass index;	chr16:69617963	chr16:69976388~69996188:-
HNSC	cis	rs67478160	0.643	rs2887282	ENSG00000259515.1	RP11-365N19.2	4	7.49e-05	0.011	0.16	0.18	Schizophrenia;	chr14:103814397	chr14:102933574~102937177:+
HNSC	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-4	7.49e-05	0.011	-0.23	-0.18	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
HNSC	cis	rs2239557	0.508	rs61245231	ENSG00000259065.1	RP5-1021I20.1	-4	7.49e-05	0.011	-0.27	-0.18	Common traits (Other);	chr14:73845492	chr14:73787360~73803270:+
HNSC	cis	rs561341	1	rs498391	ENSG00000278867.1	RP11-640N20.4	-4	7.49e-05	0.011	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:32001685	chr17:32051030~32053208:+
HNSC	cis	rs4356203	0.905	rs17472886	ENSG00000260196.1	RP1-239B22.5	-4	7.49e-05	0.011	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17380649~17383531:+
HNSC	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	4	7.49e-05	0.011	0.28	0.18	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
HNSC	cis	rs6787172	0.806	rs1435641	ENSG00000272087.1	RP11-379F4.7	4	7.49e-05	0.011	0.19	0.18	Subjective well-being;	chr3:158558132	chr3:158693120~158693768:-
HNSC	cis	rs9896933	0.832	rs75552659	ENSG00000262663.1	RP11-497H17.1	4	7.49e-05	0.011	0.24	0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846754	chr17:82918282~82918785:+
HNSC	cis	rs748404	0.666	rs12908460	ENSG00000166763.7	STRCP1	4	7.49e-05	0.011	0.25	0.18	Lung cancer;	chr15:43413472	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs2230451	ENSG00000166763.7	STRCP1	4	7.49e-05	0.011	0.25	0.18	Lung cancer;	chr15:43415610	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs62021180	ENSG00000166763.7	STRCP1	4	7.49e-05	0.011	0.25	0.18	Lung cancer;	chr15:43420139	chr15:43699488~43718184:-
HNSC	cis	rs1015213	1	rs6473669	ENSG00000272024.1	RP11-546K22.3	-4	7.49e-05	0.011	-0.32	-0.18	Glaucoma (primary angle closure);	chr8:51983558	chr8:51950284~51950690:+
HNSC	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	4	7.49e-05	0.011	0.23	0.18	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	4	7.49e-05	0.011	0.23	0.18	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
HNSC	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-4	7.49e-05	0.011	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
HNSC	cis	rs240993	0.812	rs9487639	ENSG00000230177.1	RP5-1112D6.4	-4	7.49e-05	0.011	-0.23	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111277932~111278742:+
HNSC	cis	rs394563	0.534	rs388335	ENSG00000231760.4	RP11-350J20.5	4	7.5e-05	0.011	0.25	0.18	Dupuytren's disease;	chr6:149470850	chr6:149796151~149826294:-
HNSC	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	4	7.5e-05	0.011	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	4	7.5e-05	0.011	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	4	7.5e-05	0.011	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	4	7.5e-05	0.011	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
HNSC	cis	rs4763879	0.739	rs12582584	ENSG00000278635.1	CTD-2318O12.1	4	7.5e-05	0.011	0.14	0.18	Type 1 diabetes;	chr12:9671542	chr12:9415641~9416718:+
HNSC	cis	rs73219805	1	rs3808581	ENSG00000228451.3	SDAD1P1	-4	7.5e-05	0.011	-0.28	-0.18	Schizophrenia;	chr8:26392531	chr8:26379259~26382953:-
HNSC	cis	rs2998286	0.541	rs332180	ENSG00000254635.4	WAC-AS1	-4	7.5e-05	0.011	-0.28	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28522652~28532743:-
HNSC	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	4	7.5e-05	0.011	0.22	0.18	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	4	7.5e-05	0.011	0.22	0.18	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	4	7.5e-05	0.011	0.22	0.18	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	4	7.5e-05	0.011	0.22	0.18	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
HNSC	cis	rs4930561	0.739	rs7118045	ENSG00000184795.9	UNC93B5	-4	7.5e-05	0.011	-0.21	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68211267	chr11:67711702~67716005:-
HNSC	cis	rs9611565	0.694	rs202637	ENSG00000235513.1	RP4-756G23.5	-4	7.5e-05	0.011	-0.23	-0.18	Vitiligo;	chr22:41457924	chr22:41209122~41217627:-
HNSC	cis	rs2439831	0.867	rs8039638	ENSG00000275601.1	AC011330.13	-4	7.5e-05	0.011	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43342207	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs28415933	ENSG00000275601.1	AC011330.13	-4	7.5e-05	0.011	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43343602	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs12324572	ENSG00000275601.1	AC011330.13	-4	7.5e-05	0.011	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43344002	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2412780	ENSG00000275601.1	AC011330.13	-4	7.5e-05	0.011	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43363596	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2899082	ENSG00000275601.1	AC011330.13	-4	7.5e-05	0.011	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43363845	chr15:43642389~43643023:-
HNSC	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	4	7.5e-05	0.011	0.32	0.18	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
HNSC	cis	rs7829975	0.688	rs7817376	ENSG00000233609.3	RP11-62H7.2	-4	7.51e-05	0.011	-0.17	-0.18	Mood instability;	chr8:8523020	chr8:8961200~8979025:+
HNSC	cis	rs9813712	0.595	rs1453240	ENSG00000228252.7	COL6A4P2	-4	7.51e-05	0.011	-0.18	-0.18	Response to amphetamines;	chr3:130282849	chr3:130212823~130273806:+
HNSC	cis	rs4924935	0.851	rs17743944	ENSG00000264885.1	RP11-815I9.4	4	7.51e-05	0.0111	0.22	0.18	Pancreatic cancer;	chr17:18905955	chr17:18667629~18669461:-
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66108952	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313820	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66109479	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs160639	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66115000	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313824	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66116220	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs186378	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66117071	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs160637	ENSG00000229886.1	RP5-1132H15.3	4	7.51e-05	0.0111	0.3	0.18	Diabetic kidney disease;	chr7:66119331	chr7:66025126~66031544:-
HNSC	cis	rs4356203	0.875	rs11024136	ENSG00000260196.1	RP1-239B22.5	-4	7.51e-05	0.0111	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17380649~17383531:+
HNSC	cis	rs6651255	0.58	rs12675465	ENSG00000224110.3	MTRF1LP2	-4	7.51e-05	0.0111	-0.24	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129773845	chr8:129728744~129730445:+
HNSC	cis	rs539096	0.54	rs3011217	ENSG00000237950.1	RP11-7O11.3	-4	7.51e-05	0.0111	-0.2	-0.18	Intelligence (multi-trait analysis);	chr1:43837594	chr1:43944370~43946551:-
HNSC	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
HNSC	cis	rs7027203	0.514	rs2265807	ENSG00000227603.1	RP11-165J3.6	-3.99	7.52e-05	0.0111	-0.16	-0.18	DNA methylation (variation);	chr9:93744474	chr9:93435332~93437121:-
HNSC	cis	rs800888	0.518	rs2737220	ENSG00000249917.2	LINC00536	-3.99	7.52e-05	0.0111	-0.24	-0.18	Monocyte percentage of white cells;	chr8:115625458	chr8:115950511~116325059:-
HNSC	cis	rs800888	0.518	rs2721942	ENSG00000249917.2	LINC00536	-3.99	7.52e-05	0.0111	-0.24	-0.18	Monocyte percentage of white cells;	chr8:115625517	chr8:115950511~116325059:-
HNSC	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	3.99	7.52e-05	0.0111	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
HNSC	cis	rs853679	1	rs1936365	ENSG00000204709.4	LINC01556	-3.99	7.52e-05	0.0111	-0.27	-0.18	Depression;	chr6:28300675	chr6:28943877~28944537:+
HNSC	cis	rs2742234	0.759	rs12241923	ENSG00000273008.1	RP11-351D16.3	3.99	7.52e-05	0.0111	0.21	0.18	Hirschsprung disease;	chr10:43217599	chr10:43136824~43138334:-
HNSC	cis	rs1799949	0.931	rs34474989	ENSG00000236383.6	LINC00854	-3.99	7.52e-05	0.0111	-0.17	-0.18	Menopause (age at onset);	chr17:43368042	chr17:43216941~43305976:-
HNSC	cis	rs1113500	0.787	rs12047429	ENSG00000226822.1	RP11-356N1.2	3.99	7.52e-05	0.0111	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108090617	chr1:108071482~108074519:+
HNSC	cis	rs4760636	1	rs7960153	ENSG00000268069.2	RP5-1057I20.4	3.99	7.52e-05	0.0111	0.22	0.18	Urate levels;	chr12:47779704	chr12:47784923~47786002:+
HNSC	cis	rs4760636	1	rs7973372	ENSG00000268069.2	RP5-1057I20.4	3.99	7.52e-05	0.0111	0.22	0.18	Urate levels;	chr12:47779745	chr12:47784923~47786002:+
HNSC	cis	rs2548724	0.947	rs438617	ENSG00000250682.4	LINC00491	-3.99	7.53e-05	0.0111	-0.25	-0.18	Type 2 diabetes;	chr5:102249030	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.947	rs420900	ENSG00000250682.4	LINC00491	-3.99	7.53e-05	0.0111	-0.25	-0.18	Type 2 diabetes;	chr5:102250985	chr5:102609156~102671559:-
HNSC	cis	rs2307394	0.964	rs4972316	ENSG00000281469.1	RP11-567F11.1	3.99	7.53e-05	0.0111	0.2	0.18	Urate levels;	chr2:147785940	chr2:148044380~148044894:+
HNSC	cis	rs2526882	0.562	rs12893492	ENSG00000274818.1	RP1-292L20.3	3.99	7.53e-05	0.0111	0.2	0.18	Schizophrenia;	chr14:71040058	chr14:70906657~70907111:-
HNSC	cis	rs1387259	0.929	rs11168460	ENSG00000257763.1	OR5BK1P	3.99	7.53e-05	0.0111	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.5	rs7297824	ENSG00000257763.1	OR5BK1P	3.99	7.53e-05	0.0111	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.5	rs7315820	ENSG00000257763.1	OR5BK1P	3.99	7.53e-05	0.0111	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48355792~48356614:-
HNSC	cis	rs1387259	0.899	rs7307566	ENSG00000257763.1	OR5BK1P	3.99	7.53e-05	0.0111	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48355792~48356614:-
HNSC	cis	rs11711311	0.911	rs3773681	ENSG00000241529.3	RN7SL767P	-3.99	7.53e-05	0.0111	-0.23	-0.18	IgG glycosylation;	chr3:113805054	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs12637066	ENSG00000241529.3	RN7SL767P	-3.99	7.53e-05	0.0111	-0.23	-0.18	IgG glycosylation;	chr3:113808727	chr3:113632704~113632998:+
HNSC	cis	rs2645424	0.53	rs1293303	ENSG00000255046.1	RP11-297N6.4	-3.99	7.53e-05	0.0111	-0.2	-0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11862718	chr8:11797928~11802568:-
HNSC	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	3.99	7.53e-05	0.0111	0.26	0.18	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	3.99	7.53e-05	0.0111	0.26	0.18	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	3.99	7.53e-05	0.0111	0.26	0.18	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
HNSC	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	3.99	7.53e-05	0.0111	0.26	0.18	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
HNSC	cis	rs9925964	0.933	rs11150604	ENSG00000232748.3	RP11-196G11.6	3.99	7.53e-05	0.0111	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:31056460~31062803:+
HNSC	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-3.99	7.54e-05	0.0111	-0.16	-0.18	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
HNSC	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-3.99	7.54e-05	0.0111	-0.16	-0.18	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
HNSC	cis	rs6500395	0.584	rs1420698	ENSG00000261267.1	RP11-44I10.3	-3.99	7.54e-05	0.0111	-0.24	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48706797	chr16:48559661~48587403:+
HNSC	cis	rs6657613	0.68	rs10887994	ENSG00000186715.9	MST1L	3.99	7.54e-05	0.0111	0.15	0.18	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16754910~16770237:-
HNSC	cis	rs561341	1	rs4795668	ENSG00000278867.1	RP11-640N20.4	-3.99	7.54e-05	0.0111	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31917535	chr17:32051030~32053208:+
HNSC	cis	rs7829975	0.545	rs13261926	ENSG00000253893.2	FAM85B	3.99	7.54e-05	0.0111	0.23	0.18	Mood instability;	chr8:8694100	chr8:8167819~8226614:-
HNSC	cis	rs4144743	1	rs11871447	ENSG00000228782.6	CTD-2026D20.3	-3.99	7.54e-05	0.0111	-0.22	-0.18	Body mass index;	chr17:47254252	chr17:47450568~47492492:-
HNSC	cis	rs6787172	0.84	rs1656376	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158566892	chr3:158693120~158693768:-
HNSC	cis	rs7712401	0.569	rs10080185	ENSG00000260686.1	CTB-36H16.2	3.99	7.54e-05	0.0111	0.16	0.18	Mean platelet volume;	chr5:123016161	chr5:122832356~122834533:+
HNSC	cis	rs4873772	0.873	rs10109984	ENSG00000253330.1	RP11-697N18.3	3.99	7.54e-05	0.0111	0.22	0.18	Lobe attachment (rater-scored or self-reported);	chr8:47891114	chr8:47511034~47512141:-
HNSC	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	3.99	7.54e-05	0.0111	0.28	0.18	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
HNSC	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	3.99	7.54e-05	0.0111	0.28	0.18	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
HNSC	cis	rs72827839	0.779	rs16955073	ENSG00000210741.1	MIR196A1	-3.99	7.54e-05	0.0111	-0.23	-0.18	Ease of getting up in the morning;	chr17:48304384	chr17:48632490~48632559:-
HNSC	cis	rs6964587	0.605	rs6956022	ENSG00000188693.7	CYP51A1-AS1	3.99	7.55e-05	0.0111	0.19	0.18	Breast cancer;	chr7:91923885	chr7:92134604~92180725:+
HNSC	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-3.99	7.55e-05	0.0111	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
HNSC	cis	rs9880211	0.8	rs9845862	ENSG00000273486.1	RP11-731C17.2	3.99	7.55e-05	0.0111	0.18	0.18	Height;Body mass index;	chr3:136753731	chr3:136837338~136839021:-
HNSC	cis	rs17489649	0.869	rs2043831	ENSG00000271849.1	CTC-332L22.1	3.99	7.55e-05	0.0111	0.23	0.18	Intelligence (multi-trait analysis);	chr5:109721127	chr5:109687802~109688329:-
HNSC	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	3.99	7.55e-05	0.0111	0.14	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
HNSC	cis	rs1009077	0.536	rs13124532	ENSG00000245958.5	RP11-33B1.1	3.99	7.55e-05	0.0111	0.21	0.18	Endometriosis;	chr4:119495290	chr4:119454791~119552025:+
HNSC	cis	rs67981189	0.552	rs8021824	ENSG00000274818.1	RP1-292L20.3	3.99	7.55e-05	0.0111	0.2	0.18	Schizophrenia;	chr14:71070521	chr14:70906657~70907111:-
HNSC	cis	rs12492269	0.702	rs41381644	ENSG00000240429.1	LRRFIP1P1	3.99	7.55e-05	0.0111	0.32	0.18	Plasma clusterin levels;	chr3:178443826	chr3:179259028~179261273:-
HNSC	cis	rs544991	0.687	rs10798984	ENSG00000239670.1	RP4-803A2.2	3.99	7.56e-05	0.0111	0.23	0.18	Intelligence;	chr1:33751017	chr1:32986952~32988233:+
HNSC	cis	rs9813712	0.953	rs7619208	ENSG00000228252.7	COL6A4P2	-3.99	7.56e-05	0.0111	-0.19	-0.18	Response to amphetamines;	chr3:130258163	chr3:130212823~130273806:+
HNSC	cis	rs2548724	0.812	rs2600828	ENSG00000250682.4	LINC00491	-3.99	7.56e-05	0.0111	-0.25	-0.18	Type 2 diabetes;	chr5:102271899	chr5:102609156~102671559:-
HNSC	cis	rs853679	0.567	rs1005126	ENSG00000226314.6	ZNF192P1	-3.99	7.56e-05	0.0111	-0.21	-0.18	Depression;	chr6:28399846	chr6:28161781~28169594:+
HNSC	cis	rs7085104	0.66	rs3781286	ENSG00000213061.2	PFN1P11	3.99	7.56e-05	0.0111	0.23	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102838011~102845473:-
HNSC	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-3.99	7.56e-05	0.0111	-0.21	-0.18	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
HNSC	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	3.99	7.56e-05	0.0111	0.17	0.18	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
HNSC	cis	rs11711311	1	rs12637067	ENSG00000241529.3	RN7SL767P	-3.99	7.56e-05	0.0111	-0.23	-0.18	IgG glycosylation;	chr3:113808759	chr3:113632704~113632998:+
HNSC	cis	rs897984	0.762	rs11150601	ENSG00000279196.1	RP11-1072A3.3	-3.99	7.56e-05	0.0111	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30966478	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.721	rs4889525	ENSG00000279196.1	RP11-1072A3.3	-3.99	7.56e-05	0.0111	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30978537	chr16:30984630~30988270:-
HNSC	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-3.99	7.57e-05	0.0111	-0.23	-0.18	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
HNSC	cis	rs748404	0.666	rs34178146	ENSG00000166763.7	STRCP1	3.99	7.57e-05	0.0111	0.25	0.18	Lung cancer;	chr15:43384406	chr15:43699488~43718184:-
HNSC	cis	rs3015497	0.537	rs2934663	ENSG00000277050.1	RP11-102G14.1	-3.99	7.57e-05	0.0111	-0.18	-0.18	Mean platelet volume;	chr14:50689277	chr14:51637348~51637947:-
HNSC	cis	rs4908769	0.627	rs2252865	ENSG00000232912.4	RP5-1115A15.1	-3.99	7.57e-05	0.0111	-0.2	-0.18	Allergy;	chr1:8362616	chr1:8424645~8434838:+
HNSC	cis	rs6071166	0.683	rs1830609	ENSG00000224635.1	RP4-564F22.5	-3.99	7.57e-05	0.0111	-0.22	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38696382	chr20:38406011~38416797:-
HNSC	cis	rs2898681	0.561	rs2200225	ENSG00000248375.1	RP11-177B4.1	-3.99	7.57e-05	0.0111	-0.29	-0.18	Optic nerve measurement (cup area);	chr4:52872244	chr4:52720081~52720831:-
HNSC	cis	rs11711311	0.911	rs13321446	ENSG00000241529.3	RN7SL767P	-3.99	7.57e-05	0.0111	-0.24	-0.18	IgG glycosylation;	chr3:113803697	chr3:113632704~113632998:+
HNSC	cis	rs440932	1	rs365309	ENSG00000233609.3	RP11-62H7.2	-3.99	7.57e-05	0.0111	-0.18	-0.18	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8961200~8979025:+
HNSC	cis	rs62344088	0.59	rs62346174	ENSG00000250848.1	CTD-2083E4.5	-3.99	7.57e-05	0.0111	-0.39	-0.18	Asthma (childhood onset);	chr5:296193	chr5:288833~290321:-
HNSC	cis	rs2016266	0.784	rs12424778	ENSG00000270175.1	RP11-793H13.11	-3.99	7.58e-05	0.0111	-0.18	-0.18	Bone mineral density;Bone mineral density (spine);	chr12:53344056	chr12:53500162~53500936:-
HNSC	cis	rs2016266	0.859	rs7953656	ENSG00000270175.1	RP11-793H13.11	-3.99	7.58e-05	0.0111	-0.18	-0.18	Bone mineral density;Bone mineral density (spine);	chr12:53344649	chr12:53500162~53500936:-
HNSC	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-3.99	7.58e-05	0.0111	-0.23	-0.18	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
HNSC	cis	rs67478160	0.634	rs2024669	ENSG00000259515.1	RP11-365N19.2	3.99	7.58e-05	0.0111	0.16	0.18	Schizophrenia;	chr14:103809265	chr14:102933574~102937177:+
HNSC	cis	rs35847492	1	rs35847492	ENSG00000254340.1	RP11-10A14.3	3.99	7.58e-05	0.0111	0.24	0.18	Neuroticism;	chr8:9418515	chr8:9141424~9145435:+
HNSC	cis	rs7475343	0.501	rs75406471	ENSG00000224034.1	RP11-445P17.8	-3.99	7.58e-05	0.0111	-0.25	-0.18	Intelligence;	chr10:5215684	chr10:5266033~5271236:-
HNSC	cis	rs11168187	0.506	rs12812960	ENSG00000257433.4	RP1-197B17.3	3.99	7.58e-05	0.0111	0.24	0.18	Vertical cup-disc ratio;	chr12:47729395	chr12:47706085~47742294:+
HNSC	cis	rs561341	1	rs501312	ENSG00000278867.1	RP11-640N20.4	-3.99	7.58e-05	0.0111	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:32002047	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.941	rs72825736	ENSG00000278867.1	RP11-640N20.4	-3.99	7.58e-05	0.0111	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:32003267	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.941	rs8081016	ENSG00000278867.1	RP11-640N20.4	-3.99	7.58e-05	0.0111	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:32004732	chr17:32051030~32053208:+
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000224373.3	IGHV4-59	3.99	7.59e-05	0.0111	0.11	0.18	Kawasaki disease;	chr14:106776442	chr14:106627249~106627825:-
HNSC	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-3.99	7.59e-05	0.0111	-0.22	-0.18	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
HNSC	cis	rs929354	1	rs8101	ENSG00000224629.1	RP5-1142J19.2	3.99	7.59e-05	0.0111	0.18	0.18	Body mass index;	chr7:157268780	chr7:157263022~157263229:-
HNSC	cis	rs9880211	0.8	rs115050567	ENSG00000239213.4	NCK1-AS1	3.99	7.59e-05	0.0112	0.18	0.18	Height;Body mass index;	chr3:136796817	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs9858560	ENSG00000239213.4	NCK1-AS1	3.99	7.59e-05	0.0112	0.18	0.18	Height;Body mass index;	chr3:136798312	chr3:136841726~136862054:-
HNSC	cis	rs4356203	0.905	rs10832743	ENSG00000260196.1	RP1-239B22.5	-3.99	7.59e-05	0.0112	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17380649~17383531:+
HNSC	cis	rs7107174	1	rs2512546	ENSG00000251323.2	RP11-452H21.4	3.99	7.59e-05	0.0112	0.26	0.18	Testicular germ cell tumor;	chr11:78246230	chr11:78423982~78429836:-
HNSC	cis	rs8035957	0.784	rs7403531	ENSG00000259747.1	RP11-275I4.2	3.99	7.59e-05	0.0112	0.21	0.18	Type 1 diabetes;	chr15:38530704	chr15:38671847~38689191:+
HNSC	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	3.99	7.59e-05	0.0112	0.27	0.18	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
HNSC	cis	rs9487051	1	rs1341271	ENSG00000219700.1	PTCHD3P3	3.99	7.59e-05	0.0112	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109296339	chr6:109288571~109290503:-
HNSC	cis	rs597539	0.654	rs7107137	ENSG00000255741.1	RP11-757G1.5	-3.99	7.59e-05	0.0112	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68941503~68942852:-
HNSC	cis	rs1488902	0.709	rs4145712	ENSG00000280385.1	AP000648.5	3.99	7.59e-05	0.0112	0.2	0.18	Amyotrophic lateral sclerosis;	chr11:89621418	chr11:90193614~90198120:+
HNSC	cis	rs2098713	0.569	rs12523333	ENSG00000250155.1	CTD-2353F22.1	3.99	7.59e-05	0.0112	0.19	0.18	Telomere length;	chr5:37498871	chr5:36666214~36725195:-
HNSC	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-3.99	7.59e-05	0.0112	-0.16	-0.18	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
HNSC	cis	rs12285276	0.75	rs4756024	ENSG00000205106.4	DKFZp779M0652	3.99	7.6e-05	0.0112	0.26	0.18	Visceral fat;	chr11:45789727	chr11:45771432~45772358:+
HNSC	cis	rs62025270	0.522	rs338519	ENSG00000259295.5	CSPG4P12	-3.99	7.6e-05	0.0112	-0.23	-0.18	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85191438~85213905:+
HNSC	cis	rs929354	1	rs1182410	ENSG00000224629.1	RP5-1142J19.2	3.99	7.6e-05	0.0112	0.18	0.18	Body mass index;	chr7:157271143	chr7:157263022~157263229:-
HNSC	cis	rs9467773	0.529	rs7356988	ENSG00000241549.7	GUSBP2	3.99	7.6e-05	0.0112	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26396499	chr6:26871484~26956554:-
HNSC	cis	rs2098713	0.535	rs1126290	ENSG00000250155.1	CTD-2353F22.1	3.99	7.6e-05	0.0112	0.18	0.18	Telomere length;	chr5:37588398	chr5:36666214~36725195:-
HNSC	cis	rs62344088	0.744	rs76038312	ENSG00000250848.1	CTD-2083E4.5	-3.99	7.6e-05	0.0112	-0.37	-0.18	Asthma (childhood onset);	chr5:228890	chr5:288833~290321:-
HNSC	cis	rs7848679	0.799	rs10991466	ENSG00000230013.1	RP11-217B7.3	-3.99	7.6e-05	0.0112	-0.32	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr9:105015831	chr9:104990796~104991781:-
HNSC	cis	rs17076726	0.519	rs6556094	ENSG00000253785.1	CTC-308K20.3	-3.99	7.6e-05	0.0112	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173907576	chr5:172975511~172976374:+
HNSC	cis	rs2060793	0.741	rs1542291	ENSG00000254418.1	RP11-21L19.1	3.99	7.61e-05	0.0112	0.21	0.18	Vitamin D levels;	chr11:14784720	chr11:14262846~14273691:-
HNSC	cis	rs9487051	0.646	rs7773490	ENSG00000243587.6	C6orf183	-3.99	7.61e-05	0.0112	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109301845	chr6:109165833~109271014:+
HNSC	cis	rs6939532	0.522	rs13218591	ENSG00000241549.7	GUSBP2	3.99	7.61e-05	0.0112	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr6:26376604	chr6:26871484~26956554:-
HNSC	cis	rs2483519	0.806	rs1041623	ENSG00000236799.1	RP11-383C6.2	-3.99	7.61e-05	0.0112	-0.19	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114618239	chr10:114994657~114996593:+
HNSC	cis	rs1476670	0.71	rs751442	ENSG00000230615.5	RP5-1198O20.4	-3.99	7.61e-05	0.0112	-0.23	-0.18	Eotaxin levels;	chr1:44043879	chr1:44030443~44115913:+
HNSC	cis	rs4266144	0.581	rs1806867	ENSG00000241770.1	RP11-555M1.3	-3.99	7.61e-05	0.0112	-0.21	-0.18	Coronary artery disease;	chr3:157110513	chr3:157163452~157169133:+
HNSC	cis	rs9291683	0.692	rs1558489	ENSG00000250413.1	RP11-448G15.1	3.99	7.61e-05	0.0112	0.22	0.18	Bone mineral density;	chr4:10323865	chr4:10006482~10009725:+
HNSC	cis	rs4660261	0.562	rs3011223	ENSG00000237950.1	RP11-7O11.3	3.99	7.62e-05	0.0112	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43852614	chr1:43944370~43946551:-
HNSC	cis	rs4660261	0.526	rs2906466	ENSG00000237950.1	RP11-7O11.3	3.99	7.62e-05	0.0112	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43856548	chr1:43944370~43946551:-
HNSC	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	3.99	7.62e-05	0.0112	0.21	0.18	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	3.99	7.62e-05	0.0112	0.21	0.18	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
HNSC	cis	rs7107174	1	rs10793295	ENSG00000251323.2	RP11-452H21.4	-3.99	7.62e-05	0.0112	-0.26	-0.18	Testicular germ cell tumor;	chr11:78285475	chr11:78423982~78429836:-
HNSC	cis	rs4388249	1	rs1370957	ENSG00000271849.1	CTC-332L22.1	-3.99	7.62e-05	0.0112	-0.29	-0.18	Schizophrenia;	chr5:109726259	chr5:109687802~109688329:-
HNSC	cis	rs6601327	0.548	rs13271796	ENSG00000233609.3	RP11-62H7.2	3.99	7.62e-05	0.0112	0.18	0.18	Multiple myeloma (hyperdiploidy);	chr8:9795992	chr8:8961200~8979025:+
HNSC	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	3.99	7.62e-05	0.0112	0.21	0.18	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	3.99	7.62e-05	0.0112	0.21	0.18	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
HNSC	cis	rs10773046	0.74	rs11057381	ENSG00000269938.1	RP11-214K3.20	-3.99	7.62e-05	0.0112	-0.2	-0.18	Osteoarthritis (hip);	chr12:123873310	chr12:123968023~123968579:-
HNSC	cis	rs67478160	0.608	rs4906368	ENSG00000259515.1	RP11-365N19.2	3.99	7.62e-05	0.0112	0.16	0.18	Schizophrenia;	chr14:103776060	chr14:102933574~102937177:+
HNSC	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	3.99	7.62e-05	0.0112	0.22	0.18	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
HNSC	cis	rs7612445	0.536	rs116226990	ENSG00000260743.1	RP11-255C15.3	3.99	7.62e-05	0.0112	0.26	0.18	Resting heart rate;Heart rate;	chr3:179359977	chr3:179340322~179341887:+
HNSC	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-3.99	7.63e-05	0.0112	-0.19	-0.18	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
HNSC	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	3.99	7.63e-05	0.0112	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
HNSC	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	3.99	7.63e-05	0.0112	0.23	0.18	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
HNSC	cis	rs694739	0.536	rs671976	ENSG00000236935.1	AP003774.1	3.99	7.63e-05	0.0112	0.17	0.18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64278557	chr11:64325050~64329504:-
HNSC	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-3.99	7.63e-05	0.0112	-0.19	-0.18	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
HNSC	cis	rs17660992	1	rs17660992	ENSG00000273837.1	LLNLR-470E3.1	-3.99	7.63e-05	0.0112	-0.2	-0.18	Blood protein levels;	chr19:51660695	chr19:51639478~51639931:-
HNSC	cis	rs17772222	0.917	rs2145120	ENSG00000258789.1	RP11-507K2.3	-3.99	7.63e-05	0.0112	-0.22	-0.18	Coronary artery calcification;	chr14:88777699	chr14:88551597~88552493:+
HNSC	cis	rs1620921	0.625	rs67391812	ENSG00000231863.1	RP3-428L16.1	-3.99	7.63e-05	0.0112	-0.22	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852202	chr6:160931080~160969771:+
HNSC	cis	rs3018712	0.532	rs7116363	ENSG00000255031.4	RP11-802E16.3	-3.99	7.64e-05	0.0112	-0.2	-0.18	Total body bone mineral density;	chr11:68645330	chr11:68050740~68053762:+
HNSC	cis	rs7829975	0.774	rs13259216	ENSG00000233609.3	RP11-62H7.2	3.99	7.64e-05	0.0112	0.17	0.18	Mood instability;	chr8:8816091	chr8:8961200~8979025:+
HNSC	cis	rs1979679	0.918	rs11049529	ENSG00000247934.4	RP11-967K21.1	-3.99	7.64e-05	0.0112	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28163298~28190738:-
HNSC	cis	rs7637230	0.945	rs9846228	ENSG00000244119.1	PDCL3P4	-3.99	7.64e-05	0.0112	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101911290	chr3:101712472~101713191:+
HNSC	cis	rs344364	0.511	rs337286	ENSG00000277602.1	AC005363.11	-3.99	7.64e-05	0.0112	-0.28	-0.18	Glomerular filtration rate in chronic kidney disease;	chr16:1915718	chr16:1971655~1971896:-
HNSC	cis	rs6493858	0.839	rs2682053	ENSG00000277245.1	RP11-48G14.3	-3.99	7.64e-05	0.0112	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56252719	chr15:56447120~56447697:+
HNSC	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	3.99	7.64e-05	0.0112	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
HNSC	cis	rs2933343	0.533	rs11915889	ENSG00000261159.1	RP11-723O4.9	3.99	7.64e-05	0.0112	0.19	0.18	IgG glycosylation;	chr3:128982023	chr3:128859716~128860526:-
HNSC	cis	rs7688540	0.771	rs7669892	ENSG00000211553.1	AC253576.2	3.99	7.65e-05	0.0112	0.22	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:136461~136568:+
HNSC	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	3.99	7.65e-05	0.0112	0.32	0.18	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
HNSC	cis	rs2518049	0.654	rs3812616	ENSG00000224034.1	RP11-445P17.8	-3.99	7.65e-05	0.0112	-0.25	-0.18	Metabolic traits;	chr10:5196309	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.654	rs3812617	ENSG00000224034.1	RP11-445P17.8	-3.99	7.65e-05	0.0112	-0.25	-0.18	Metabolic traits;	chr10:5196320	chr10:5266033~5271236:-
HNSC	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-3.99	7.65e-05	0.0112	-0.26	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
HNSC	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-3.99	7.65e-05	0.0112	-0.26	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000273009.1	RP11-352G9.1	-3.99	7.65e-05	0.0112	-0.23	-0.18	Pancreatic cancer;	chr3:195925837	chr3:195913078~195913683:-
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000273009.1	RP11-352G9.1	-3.99	7.65e-05	0.0112	-0.23	-0.18	Pancreatic cancer;	chr3:195925980	chr3:195913078~195913683:-
HNSC	cis	rs5758511	0.508	rs28715885	ENSG00000205702.9	CYP2D7	3.99	7.66e-05	0.0112	0.17	0.18	Birth weight;	chr22:42045087	chr22:42140203~42144577:-
HNSC	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	3.99	7.66e-05	0.0112	0.25	0.18	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
HNSC	cis	rs9611565	0.694	rs202618	ENSG00000235513.1	RP4-756G23.5	-3.99	7.66e-05	0.0112	-0.23	-0.18	Vitiligo;	chr22:41426852	chr22:41209122~41217627:-
HNSC	cis	rs6430585	0.528	rs6430594	ENSG00000231890.6	DARS-AS1	3.99	7.66e-05	0.0112	0.3	0.18	Corneal structure;	chr2:135961603	chr2:135985176~136022593:+
HNSC	cis	rs35851103	0.6	rs4841662	ENSG00000269918.1	AF131215.9	-3.99	7.66e-05	0.0112	-0.17	-0.18	Neuroticism;	chr8:11986249	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000250412.1	KLHL2P1	3.99	7.66e-05	0.0112	0.23	0.18	Corneal astigmatism;	chr4:119320085	chr4:119334329~119378233:+
HNSC	cis	rs6095360	1	rs1048590	ENSG00000222365.1	SNORD12B	-3.99	7.66e-05	0.0112	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:48993760	chr20:49280319~49280409:+
HNSC	cis	rs6095360	1	rs2295033	ENSG00000222365.1	SNORD12B	-3.99	7.66e-05	0.0112	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:48994359	chr20:49280319~49280409:+
HNSC	cis	rs3750965	0.92	rs10896420	ENSG00000265539.1	MIR3164	-3.99	7.66e-05	0.0112	-0.2	-0.18	Hair color;	chr11:69095579	chr11:69083176~69083258:+
HNSC	cis	rs3750965	0.92	rs10896421	ENSG00000265539.1	MIR3164	-3.99	7.66e-05	0.0112	-0.2	-0.18	Hair color;	chr11:69095580	chr11:69083176~69083258:+
HNSC	cis	rs2153535	0.585	rs9393057	ENSG00000230939.1	RP11-314C16.1	3.99	7.67e-05	0.0112	0.21	0.18	Motion sickness;	chr6:8668067	chr6:8784178~8785445:+
HNSC	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	3.99	7.67e-05	0.0112	0.28	0.18	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
HNSC	cis	rs3743772	0.5	rs11859135	ENSG00000279344.1	RP11-44F14.7	3.99	7.67e-05	0.0112	0.25	0.18	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53478957~53481550:-
HNSC	cis	rs60617249	0.862	rs34996868	ENSG00000228204.2	RP4-724E13.2	3.99	7.67e-05	0.0113	0.19	0.18	Major depression and alcohol dependence;	chr7:50920783	chr7:50866747~51022990:+
HNSC	cis	rs6500395	0.708	rs28449353	ENSG00000261267.1	RP11-44I10.3	-3.99	7.67e-05	0.0113	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48521223	chr16:48559661~48587403:+
HNSC	cis	rs4388249	1	rs67906234	ENSG00000271849.1	CTC-332L22.1	-3.99	7.67e-05	0.0113	-0.29	-0.18	Schizophrenia;	chr5:109730081	chr5:109687802~109688329:-
HNSC	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-3.99	7.67e-05	0.0113	-0.24	-0.18	Pain;	chr19:21493313	chr19:21554640~21569237:-
HNSC	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	3.99	7.68e-05	0.0113	0.23	0.18	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	3.99	7.68e-05	0.0113	0.23	0.18	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	3.99	7.68e-05	0.0113	0.23	0.18	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
HNSC	cis	rs9329221	0.651	rs2975648	ENSG00000269918.1	AF131215.9	-3.99	7.68e-05	0.0113	-0.17	-0.18	Neuroticism;	chr8:10278466	chr8:11104691~11106704:-
HNSC	cis	rs9910055	0.683	rs7220138	ENSG00000267080.4	ASB16-AS1	-3.99	7.68e-05	0.0113	-0.15	-0.18	Total body bone mineral density;	chr17:44176643	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.639	rs7217858	ENSG00000267080.4	ASB16-AS1	-3.99	7.68e-05	0.0113	-0.15	-0.18	Total body bone mineral density;	chr17:44177159	chr17:44175973~44186717:-
HNSC	cis	rs9910055	0.659	rs7214540	ENSG00000267080.4	ASB16-AS1	-3.99	7.68e-05	0.0113	-0.15	-0.18	Total body bone mineral density;	chr17:44179236	chr17:44175973~44186717:-
HNSC	cis	rs6504950	0.83	rs17817847	ENSG00000279059.1	RP11-257O5.2	-3.99	7.68e-05	0.0113	-0.16	-0.18	Breast cancer;	chr17:54940920	chr17:54956760~54958426:-
HNSC	cis	rs6471393	0.798	rs62525169	ENSG00000279331.1	RBM12B-AS1	-3.99	7.68e-05	0.0113	-0.19	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93740121~93740773:+
HNSC	cis	rs12682352	0.605	rs60707155	ENSG00000254153.1	CTA-398F10.2	3.99	7.68e-05	0.0113	0.2	0.18	Neuroticism;	chr8:8866905	chr8:8456909~8461337:-
HNSC	cis	rs7927592	0.763	rs10896351	ENSG00000255031.4	RP11-802E16.3	3.99	7.68e-05	0.0113	0.15	0.18	Total body bone mineral density;	chr11:68619428	chr11:68050740~68053762:+
HNSC	cis	rs62458065	0.713	rs28421905	ENSG00000226468.2	AC018641.7	3.99	7.68e-05	0.0113	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32449889	chr7:32456963~32457758:-
HNSC	cis	rs12545109	0.8	rs1837617	ENSG00000246430.5	LINC00968	-3.99	7.68e-05	0.0113	-0.22	-0.18	Obesity-related traits;	chr8:56505033	chr8:56496246~56559823:-
HNSC	cis	rs11168618	0.967	rs1895996	ENSG00000240399.1	RP1-228P16.1	3.99	7.69e-05	0.0113	0.15	0.18	Adiponectin levels;	chr12:48561788	chr12:48054813~48055591:-
HNSC	cis	rs36715	1	rs36715	ENSG00000245937.6	LINC01184	3.99	7.69e-05	0.0113	0.22	0.18	Breast cancer;	chr5:128227188	chr5:127940426~128083172:-
HNSC	cis	rs7868228	1	rs7855793	ENSG00000240498.5	CDKN2B-AS1	-3.99	7.69e-05	0.0113	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21664624	chr9:21994778~22121097:+
HNSC	cis	rs7868228	1	rs7855610	ENSG00000240498.5	CDKN2B-AS1	-3.99	7.69e-05	0.0113	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21664644	chr9:21994778~22121097:+
HNSC	cis	rs7809950	0.678	rs79902674	ENSG00000238832.1	snoU109	-3.99	7.69e-05	0.0113	-0.27	-0.18	Coronary artery disease;	chr7:107226053	chr7:107603363~107603507:+
HNSC	cis	rs6787172	0.837	rs1656373	ENSG00000272087.1	RP11-379F4.7	3.99	7.69e-05	0.0113	0.19	0.18	Subjective well-being;	chr3:158555732	chr3:158693120~158693768:-
HNSC	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-3.99	7.69e-05	0.0113	-0.21	-0.18	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
HNSC	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	3.99	7.69e-05	0.0113	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
HNSC	cis	rs9611565	0.729	rs73176689	ENSG00000235513.1	RP4-756G23.5	3.99	7.69e-05	0.0113	0.22	0.18	Vitiligo;	chr22:41386629	chr22:41209122~41217627:-
HNSC	cis	rs9650657	0.682	rs6989160	ENSG00000269918.1	AF131215.9	-3.99	7.69e-05	0.0113	-0.18	-0.18	Neuroticism;	chr8:10847850	chr8:11104691~11106704:-
HNSC	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-3.99	7.7e-05	0.0113	-0.21	-0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
HNSC	cis	rs7015630	0.657	rs13278954	ENSG00000251136.7	RP11-37B2.1	-3.99	7.7e-05	0.0113	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89839830	chr8:89609409~89757727:-
HNSC	cis	rs7015630	0.697	rs34699769	ENSG00000251136.7	RP11-37B2.1	-3.99	7.7e-05	0.0113	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89841119	chr8:89609409~89757727:-
HNSC	cis	rs28830936	0.966	rs1918310	ENSG00000250379.1	RP11-23P13.4	3.99	7.7e-05	0.0113	0.22	0.18	Diastolic blood pressure;	chr15:41773055	chr15:41825099~41827936:-
HNSC	cis	rs4321325	0.733	rs4284779	ENSG00000236682.1	AC068282.3	-3.99	7.7e-05	0.0113	-0.31	-0.18	Protein C levels;	chr2:127188924	chr2:127389130~127400580:+
HNSC	cis	rs6095360	0.934	rs6012581	ENSG00000222365.1	SNORD12B	-3.99	7.7e-05	0.0113	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49011308	chr20:49280319~49280409:+
HNSC	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-3.99	7.71e-05	0.0113	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
HNSC	cis	rs1008375	1	rs10027755	ENSG00000249502.1	AC006160.5	-3.99	7.71e-05	0.0113	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614331	chr4:17587467~17614571:-
HNSC	cis	rs72634501	0.568	rs590214	ENSG00000182109.6	RP11-69E11.4	3.99	7.71e-05	0.0113	0.19	0.18	HDL cholesterol;	chr1:39146821	chr1:39522280~39546187:-
HNSC	cis	rs913655	0.508	rs12245924	ENSG00000225527.1	RP11-383B4.4	-3.99	7.71e-05	0.0113	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18720830	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.508	rs7921519	ENSG00000225527.1	RP11-383B4.4	-3.99	7.71e-05	0.0113	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18721540	chr10:18531849~18533336:-
HNSC	cis	rs6890684	0.551	rs589794	ENSG00000215032.2	GNL3LP1	3.99	7.71e-05	0.0113	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61220292	chr5:60891935~60893577:-
HNSC	cis	rs6890684	0.576	rs702565	ENSG00000215032.2	GNL3LP1	3.99	7.71e-05	0.0113	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61221243	chr5:60891935~60893577:-
HNSC	cis	rs6095360	0.727	rs8119476	ENSG00000222365.1	SNORD12B	-3.99	7.71e-05	0.0113	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:49073599	chr20:49280319~49280409:+
HNSC	cis	rs71520386	0.846	rs77741999	ENSG00000221740.1	SNORD93	-3.99	7.71e-05	0.0113	-0.24	-0.18	Fibrinogen levels;	chr7:22775785	chr7:22856613~22856686:+
HNSC	cis	rs4938303	0.671	rs12806224	ENSG00000254851.1	RP11-109L13.1	3.99	7.71e-05	0.0113	0.28	0.18	Triglycerides;	chr11:116682098	chr11:117135528~117138582:+
HNSC	cis	rs4938303	0.788	rs12805061	ENSG00000254851.1	RP11-109L13.1	3.99	7.71e-05	0.0113	0.28	0.18	Triglycerides;	chr11:116682308	chr11:117135528~117138582:+
HNSC	cis	rs4938303	0.788	rs11826999	ENSG00000254851.1	RP11-109L13.1	3.99	7.71e-05	0.0113	0.28	0.18	Triglycerides;	chr11:116683062	chr11:117135528~117138582:+
HNSC	cis	rs7278690	0.777	rs4816413	ENSG00000281903.1	AF127936.7	3.99	7.71e-05	0.0113	0.41	0.18	Breast cancer;	chr21:14865487	chr21:14819699~14918552:-
HNSC	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	3.99	7.72e-05	0.0113	0.2	0.18	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
HNSC	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	3.99	7.72e-05	0.0113	0.21	0.18	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000272831.1	RP11-792A8.4	3.99	7.72e-05	0.0113	0.15	0.18	Aortic root size;	chr7:66686365	chr7:66739829~66740385:-
HNSC	cis	rs60695258	0.512	rs2053770	ENSG00000251411.1	RP11-397E7.4	3.99	7.72e-05	0.0113	0.18	0.18	Hematocrit;	chr4:86986933	chr4:86913266~86914817:-
HNSC	cis	rs7572733	0.935	rs6434942	ENSG00000222017.1	AC011997.1	3.99	7.72e-05	0.0113	0.22	0.18	Dermatomyositis;	chr2:197891964	chr2:197693106~197774823:+
HNSC	cis	rs7131987	0.565	rs1991113	ENSG00000257176.2	RP11-996F15.2	-3.99	7.72e-05	0.0113	-0.19	-0.18	QT interval;	chr12:29239070	chr12:29280418~29317848:-
HNSC	cis	rs6995541	0.647	rs7833128	ENSG00000269918.1	AF131215.9	-3.99	7.72e-05	0.0113	-0.19	-0.18	Triglyceride levels;	chr8:10826912	chr8:11104691~11106704:-
HNSC	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	3.99	7.72e-05	0.0113	0.21	0.18	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
HNSC	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-3.99	7.72e-05	0.0113	-0.13	-0.18	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
HNSC	cis	rs6840258	1	rs767315	ENSG00000251411.1	RP11-397E7.4	-3.99	7.72e-05	0.0113	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039283	chr4:86913266~86914817:-
HNSC	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-3.99	7.72e-05	0.0113	-0.19	-0.18	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
HNSC	cis	rs11976180	1	rs2961134	ENSG00000244479.5	OR2A1-AS1	3.99	7.72e-05	0.0113	0.21	0.18	Obesity-related traits;	chr7:144073969	chr7:144251264~144356181:-
HNSC	cis	rs6964587	0.869	rs10242792	ENSG00000188693.7	CYP51A1-AS1	-3.99	7.72e-05	0.0113	-0.19	-0.18	Breast cancer;	chr7:91862789	chr7:92134604~92180725:+
HNSC	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	3.99	7.72e-05	0.0113	0.19	0.18	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
HNSC	cis	rs683257	0.714	rs72991723	ENSG00000234147.1	RP3-460G2.2	-3.99	7.72e-05	0.0113	-0.39	-0.18	Facial emotion recognition (angry faces);	chr6:140945138	chr6:140845958~140852924:-
HNSC	cis	rs7829975	0.714	rs60315134	ENSG00000233609.3	RP11-62H7.2	3.99	7.73e-05	0.0113	0.17	0.18	Mood instability;	chr8:8813089	chr8:8961200~8979025:+
HNSC	cis	rs9329221	0.537	rs13254175	ENSG00000255310.2	AF131215.2	3.99	7.73e-05	0.0113	0.17	0.18	Neuroticism;	chr8:10121262	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-3.99	7.73e-05	0.0113	-0.22	-0.18	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
HNSC	cis	rs6500395	1	rs9933187	ENSG00000261267.1	RP11-44I10.3	3.99	7.73e-05	0.0113	0.23	0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48522662	chr16:48559661~48587403:+
HNSC	cis	rs12893668	0.514	rs3212090	ENSG00000269958.1	RP11-73M18.8	3.99	7.73e-05	0.0113	0.17	0.18	Reticulocyte count;	chr14:103702526	chr14:103696353~103697163:+
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	3.99	7.73e-05	0.0113	0.22	0.18	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	3.99	7.73e-05	0.0113	0.22	0.18	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	3.99	7.73e-05	0.0113	0.22	0.18	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
HNSC	cis	rs7824557	0.606	rs1047950	ENSG00000255310.2	AF131215.2	3.99	7.73e-05	0.0113	0.17	0.18	Retinal vascular caliber;	chr8:11327587	chr8:11107788~11109726:-
HNSC	cis	rs6657613	0.68	rs9435745	ENSG00000186715.9	MST1L	-3.99	7.73e-05	0.0113	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17044999	chr1:16754910~16770237:-
HNSC	cis	rs5758511	0.68	rs5758687	ENSG00000205702.9	CYP2D7	3.99	7.74e-05	0.0113	0.16	0.18	Birth weight;	chr22:42260582	chr22:42140203~42144577:-
HNSC	cis	rs10510102	0.688	rs56094144	ENSG00000226864.1	ATE1-AS1	3.99	7.74e-05	0.0113	0.3	0.18	Breast cancer;	chr10:121903941	chr10:121928312~121951965:+
HNSC	cis	rs12682352	0.602	rs6988939	ENSG00000173295.6	FAM86B3P	3.99	7.74e-05	0.0113	0.21	0.18	Neuroticism;	chr8:8809406	chr8:8228595~8244865:+
HNSC	cis	rs9290663	0.504	rs6443567	ENSG00000271131.1	RP11-33A14.3	3.99	7.74e-05	0.0113	0.21	0.18	Acute lymphoblastic leukemia (childhood);	chr3:178709928	chr3:178493327~178493810:-
HNSC	cis	rs7824557	0.628	rs7815802	ENSG00000255310.2	AF131215.2	3.99	7.74e-05	0.0113	0.17	0.18	Retinal vascular caliber;	chr8:11333138	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.593	rs11774673	ENSG00000255310.2	AF131215.2	3.99	7.74e-05	0.0113	0.17	0.18	Retinal vascular caliber;	chr8:11334028	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.628	rs7831346	ENSG00000255310.2	AF131215.2	3.99	7.74e-05	0.0113	0.17	0.18	Retinal vascular caliber;	chr8:11336021	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.628	rs6601580	ENSG00000255310.2	AF131215.2	3.99	7.74e-05	0.0113	0.17	0.18	Retinal vascular caliber;	chr8:11336227	chr8:11107788~11109726:-
HNSC	cis	rs7948661	1	rs9332781	ENSG00000278376.1	RP11-158I9.8	3.99	7.75e-05	0.0113	0.34	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118475884	chr11:118791254~118793137:+
HNSC	cis	rs2098713	0.537	rs682825	ENSG00000250155.1	CTD-2353F22.1	3.99	7.75e-05	0.0113	0.2	0.18	Telomere length;	chr5:37580716	chr5:36666214~36725195:-
HNSC	cis	rs1620921	0.625	rs67998011	ENSG00000231863.1	RP3-428L16.1	-3.99	7.75e-05	0.0113	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852295	chr6:160931080~160969771:+
HNSC	cis	rs793571	0.822	rs11637077	ENSG00000245975.2	RP11-30K9.6	3.99	7.75e-05	0.0114	0.29	0.18	Schizophrenia;	chr15:58906197	chr15:58768072~58770974:-
HNSC	cis	rs9650657	0.537	rs7016385	ENSG00000255310.2	AF131215.2	3.99	7.75e-05	0.0114	0.17	0.18	Neuroticism;	chr8:10921962	chr8:11107788~11109726:-
HNSC	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	3.99	7.75e-05	0.0114	0.18	0.18	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
HNSC	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	3.99	7.75e-05	0.0114	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	3.99	7.75e-05	0.0114	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	3.99	7.75e-05	0.0114	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	3.99	7.75e-05	0.0114	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	3.99	7.75e-05	0.0114	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
HNSC	cis	rs471144	0.881	rs12081541	ENSG00000232678.2	SPTLC1P4	-3.99	7.75e-05	0.0114	-0.31	-0.18	Inflammatory skin disease;	chr1:152468890	chr1:152077952~152078211:+
HNSC	cis	rs453301	0.686	rs11785634	ENSG00000253981.4	ALG1L13P	-3.99	7.75e-05	0.0114	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9035087	chr8:8236003~8244667:-
HNSC	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-3.99	7.75e-05	0.0114	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
HNSC	cis	rs8028182	0.636	rs4886716	ENSG00000260269.4	CTD-2323K18.1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Sudden cardiac arrest;	chr15:75563681	chr15:75527150~75601205:-
HNSC	cis	rs4930561	0.765	rs1894204	ENSG00000184795.9	UNC93B5	-3.99	7.76e-05	0.0114	-0.2	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr11:67711702~67716005:-
HNSC	cis	rs10129255	0.5	rs8006888	ENSG00000211976.2	IGHV3-73	-3.99	7.76e-05	0.0114	-0.13	-0.18	Kawasaki disease;	chr14:106782219	chr14:106802694~106803233:-
HNSC	cis	rs9611565	0.694	rs5758347	ENSG00000235513.1	RP4-756G23.5	-3.99	7.76e-05	0.0114	-0.22	-0.18	Vitiligo;	chr22:41425015	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.694	rs202613	ENSG00000235513.1	RP4-756G23.5	-3.99	7.76e-05	0.0114	-0.22	-0.18	Vitiligo;	chr22:41425989	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.649	rs202614	ENSG00000235513.1	RP4-756G23.5	-3.99	7.76e-05	0.0114	-0.22	-0.18	Vitiligo;	chr22:41426146	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.694	rs202616	ENSG00000235513.1	RP4-756G23.5	-3.99	7.76e-05	0.0114	-0.22	-0.18	Vitiligo;	chr22:41426217	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.569	rs188057	ENSG00000235513.1	RP4-756G23.5	-3.99	7.76e-05	0.0114	-0.22	-0.18	Vitiligo;	chr22:41426301	chr22:41209122~41217627:-
HNSC	cis	rs13256369	0.901	rs12681298	ENSG00000173295.6	FAM86B3P	-3.99	7.76e-05	0.0114	-0.24	-0.18	Obesity-related traits;	chr8:8708725	chr8:8228595~8244865:+
HNSC	cis	rs4253772	0.637	rs9627295	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46254203	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.637	rs6008339	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46254949	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.591	rs6007726	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46254961	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.591	rs6007727	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46255062	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.591	rs8135363	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46255816	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.637	rs6008357	ENSG00000277232.2	GTSE1-AS1	-3.99	7.76e-05	0.0114	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46256207	chr22:46295143~46296660:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	3.99	7.76e-05	0.0114	0.31	0.18	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
HNSC	cis	rs17660992	0.603	rs2167422	ENSG00000273837.1	LLNLR-470E3.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Blood protein levels;	chr19:51661130	chr19:51639478~51639931:-
HNSC	cis	rs17407555	0.683	rs2192095	ENSG00000250413.1	RP11-448G15.1	-3.99	7.76e-05	0.0114	-0.24	-0.18	Schizophrenia (age at onset);	chr4:10272549	chr4:10006482~10009725:+
HNSC	cis	rs7121616	0.576	rs11218967	ENSG00000200879.1	SNORD14E	3.99	7.76e-05	0.0114	0.23	0.18	Breast cancer;	chr11:123087551	chr11:123058077~123058161:-
HNSC	cis	rs3096644	0.544	rs112734318	ENSG00000239552.2	HOXB-AS2	3.99	7.76e-05	0.0114	0.19	0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr17:48687101	chr17:48557262~48560333:+
HNSC	cis	rs12370275	0.58	rs68037208	ENSG00000257528.1	KRT8P19	-3.99	7.77e-05	0.0114	-0.25	-0.18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61355471	chr12:61879318~61880772:+
HNSC	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-3.99	7.77e-05	0.0114	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
HNSC	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-3.99	7.77e-05	0.0114	-0.19	-0.18	Height;	chr2:231516587	chr2:231501990~231502201:-
HNSC	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-3.99	7.77e-05	0.0114	-0.23	-0.18	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
HNSC	cis	rs1979679	0.842	rs10492370	ENSG00000247934.4	RP11-967K21.1	-3.99	7.77e-05	0.0114	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28163298~28190738:-
HNSC	cis	rs6005807	0.543	rs6005868	ENSG00000226471.5	CTA-292E10.6	-3.99	7.78e-05	0.0114	-0.3	-0.18	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28769778	chr22:28800683~28848559:+
HNSC	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-3.99	7.78e-05	0.0114	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
HNSC	cis	rs7829975	0.523	rs9644774	ENSG00000253893.2	FAM85B	3.99	7.78e-05	0.0114	0.23	0.18	Mood instability;	chr8:8702322	chr8:8167819~8226614:-
HNSC	cis	rs55823223	0.564	rs1463485	ENSG00000267801.1	RP11-552F3.9	3.99	7.78e-05	0.0114	0.21	0.18	Psoriasis;	chr17:75855710	chr17:75876372~75879546:+
HNSC	cis	rs4144743	1	rs61312893	ENSG00000228782.6	CTD-2026D20.3	-3.99	7.78e-05	0.0114	-0.21	-0.18	Body mass index;	chr17:47247657	chr17:47450568~47492492:-
HNSC	cis	rs889398	0.967	rs7359336	ENSG00000196696.11	PDXDC2P	-3.99	7.78e-05	0.0114	-0.13	-0.18	Body mass index;	chr16:69699557	chr16:69976297~70065948:-
HNSC	cis	rs7552167	0.789	rs6424162	ENSG00000230023.2	RP11-10N16.2	3.99	7.78e-05	0.0114	0.29	0.18	Psoriasis vulgaris;	chr1:24186086	chr1:24200240~24211693:+
HNSC	cis	rs7552167	0.925	rs11249020	ENSG00000230023.2	RP11-10N16.2	3.99	7.78e-05	0.0114	0.29	0.18	Psoriasis vulgaris;	chr1:24186314	chr1:24200240~24211693:+
HNSC	cis	rs9907295	0.818	rs4796109	ENSG00000270977.1	AC015849.16	-3.99	7.78e-05	0.0114	-0.29	-0.18	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35893707~35911023:-
HNSC	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-3.99	7.79e-05	0.0114	-0.23	-0.18	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
HNSC	cis	rs116095464	0.558	rs10055993	ENSG00000277812.1	AC021087.1	3.99	7.79e-05	0.0114	0.33	0.18	Breast cancer;	chr5:264181	chr5:262769~262881:+
HNSC	cis	rs7824557	0.564	rs2736290	ENSG00000269918.1	AF131215.9	-3.99	7.79e-05	0.0114	-0.18	-0.18	Retinal vascular caliber;	chr8:11376789	chr8:11104691~11106704:-
HNSC	cis	rs72627123	1	rs72627129	ENSG00000259065.1	RP5-1021I20.1	-3.99	7.79e-05	0.0114	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73908102	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627130	ENSG00000259065.1	RP5-1021I20.1	-3.99	7.79e-05	0.0114	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73908194	chr14:73787360~73803270:+
HNSC	cis	rs9880211	0.613	rs12330335	ENSG00000239213.4	NCK1-AS1	3.99	7.79e-05	0.0114	0.17	0.18	Height;Body mass index;	chr3:136134690	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.644	rs6799320	ENSG00000239213.4	NCK1-AS1	3.99	7.8e-05	0.0114	0.17	0.18	Height;Body mass index;	chr3:136083597	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.613	rs9653930	ENSG00000239213.4	NCK1-AS1	3.99	7.8e-05	0.0114	0.17	0.18	Height;Body mass index;	chr3:136091472	chr3:136841726~136862054:-
HNSC	cis	rs1113500	0.787	rs11185266	ENSG00000226822.1	RP11-356N1.2	3.99	7.8e-05	0.0114	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108100042	chr1:108071482~108074519:+
HNSC	cis	rs4841134	0.967	rs11778929	ENSG00000233609.3	RP11-62H7.2	-3.99	7.8e-05	0.0114	-0.17	-0.18	Age-related disease endophenotypes;	chr8:9327019	chr8:8961200~8979025:+
HNSC	cis	rs12144094	1	rs12139860	ENSG00000260941.1	LINC00622	-3.99	7.8e-05	0.0114	-0.23	-0.18	Height;	chr1:119720225	chr1:119597702~119599271:-
HNSC	cis	rs4073405	0.813	rs4755960	ENSG00000254651.1	RP11-430H10.3	-3.99	7.8e-05	0.0114	-0.23	-0.18	Schizophrenia;	chr11:45298430	chr11:45399448~45400528:+
HNSC	cis	rs853679	0.542	rs6934769	ENSG00000219891.2	ZSCAN12P1	3.99	7.8e-05	0.0114	0.25	0.18	Depression;	chr6:28123153	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs17711801	ENSG00000219891.2	ZSCAN12P1	3.99	7.8e-05	0.0114	0.25	0.18	Depression;	chr6:28124529	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.527	rs9461433	ENSG00000219891.2	ZSCAN12P1	3.99	7.8e-05	0.0114	0.25	0.18	Parkinson's disease;	chr6:28127394	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9468292	ENSG00000219891.2	ZSCAN12P1	3.99	7.8e-05	0.0114	0.25	0.18	Depression;	chr6:28127577	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs1947863	ENSG00000219891.2	ZSCAN12P1	3.99	7.8e-05	0.0114	0.25	0.18	Depression;	chr6:28131566	chr6:28091154~28093664:+
HNSC	cis	rs539096	0.501	rs713191	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43848881	chr1:43944370~43946551:-
HNSC	cis	rs3011225	0.71	rs3011222	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43851873	chr1:43944370~43946551:-
HNSC	cis	rs3011225	0.71	rs3011224	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43852811	chr1:43944370~43946551:-
HNSC	cis	rs4660261	0.526	rs3094954	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43855247	chr1:43944370~43946551:-
HNSC	cis	rs3011225	0.683	rs4660753	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43855372	chr1:43944370~43946551:-
HNSC	cis	rs4660261	0.526	rs3011228	ENSG00000237950.1	RP11-7O11.3	3.99	7.8e-05	0.0114	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43860323	chr1:43944370~43946551:-
HNSC	cis	rs11098499	0.821	rs56155624	ENSG00000248280.1	RP11-33B1.2	3.99	7.8e-05	0.0114	0.23	0.18	Corneal astigmatism;	chr4:119369871	chr4:119440561~119450157:-
HNSC	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	3.99	7.81e-05	0.0114	0.21	0.18	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
HNSC	cis	rs7726839	0.54	rs7434	ENSG00000225138.6	CTD-2228K2.7	-3.99	7.81e-05	0.0114	-0.26	-0.18	Obesity-related traits;	chr5:660689	chr5:473236~480884:+
HNSC	cis	rs7726839	0.54	rs3762951	ENSG00000225138.6	CTD-2228K2.7	3.99	7.81e-05	0.0114	0.26	0.18	Obesity-related traits;	chr5:662498	chr5:473236~480884:+
HNSC	cis	rs7302981	0.746	rs2272391	ENSG00000272368.2	RP4-605O3.4	-3.99	7.81e-05	0.0114	-0.17	-0.18	Systolic blood pressure;	chr12:50077847	chr12:50112197~50165618:+
HNSC	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-3.99	7.81e-05	0.0114	-0.23	-0.18	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
HNSC	cis	rs11098499	0.754	rs66900435	ENSG00000250412.1	KLHL2P1	3.99	7.81e-05	0.0114	0.23	0.18	Corneal astigmatism;	chr4:119328270	chr4:119334329~119378233:+
HNSC	cis	rs11773103	0.786	rs17161323	ENSG00000224046.1	AC005076.5	3.99	7.81e-05	0.0114	0.25	0.18	Bipolar disorder or major depressive disorder (combined);	chr7:87129922	chr7:87151423~87152420:-
HNSC	cis	rs35306767	0.903	rs35968821	ENSG00000229869.1	RP11-363N22.2	-3.99	7.82e-05	0.0114	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:864285	chr10:933026~942743:+
HNSC	cis	rs72717009	0.825	rs10494360	ENSG00000225217.1	HSPA7	-3.99	7.82e-05	0.0114	-0.32	-0.18	Rheumatoid arthritis;	chr1:161505960	chr1:161606291~161608217:+
HNSC	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	3.99	7.82e-05	0.0114	0.23	0.18	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	3.99	7.82e-05	0.0114	0.23	0.18	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
HNSC	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	3.99	7.82e-05	0.0114	0.23	0.18	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
HNSC	cis	rs8067545	0.641	rs119672	ENSG00000266126.1	RP11-209D14.4	3.99	7.82e-05	0.0114	0.2	0.18	Schizophrenia;	chr17:19915288	chr17:19929372~19929737:-
HNSC	cis	rs11168618	0.567	rs7314569	ENSG00000240399.1	RP1-228P16.1	3.99	7.83e-05	0.0114	0.16	0.18	Adiponectin levels;	chr12:48423198	chr12:48054813~48055591:-
HNSC	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	3.98	7.83e-05	0.0114	0.19	0.18	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
HNSC	cis	rs36093844	0.527	rs56187740	ENSG00000279742.1	RP11-700A24.1	-3.98	7.83e-05	0.0114	-0.25	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86053608	chr11:85852557~85854943:-
HNSC	cis	rs9903692	0.954	rs8080662	ENSG00000263412.1	RP5-890E16.2	3.98	7.83e-05	0.0115	0.17	0.18	Pulse pressure;	chr17:48113457	chr17:48045141~48048073:-
HNSC	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	3.98	7.83e-05	0.0115	0.21	0.18	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	3.98	7.83e-05	0.0115	0.21	0.18	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	3.98	7.83e-05	0.0115	0.21	0.18	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
HNSC	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	3.98	7.83e-05	0.0115	0.28	0.18	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
HNSC	cis	rs28829049	0.597	rs2296107	ENSG00000270728.1	RP4-657E11.10	-3.98	7.84e-05	0.0115	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19150155	chr1:19297080~19297903:+
HNSC	cis	rs73201462	1	rs2955088	ENSG00000231305.3	RP11-723O4.2	3.98	7.84e-05	0.0115	0.26	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244867	chr3:128861313~128871540:-
HNSC	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	3.98	7.84e-05	0.0115	0.23	0.18	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
HNSC	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	3.98	7.84e-05	0.0115	0.14	0.18	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
HNSC	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-3.98	7.84e-05	0.0115	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
HNSC	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	3.98	7.84e-05	0.0115	0.16	0.18	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
HNSC	cis	rs3736485	0.844	rs28878886	ENSG00000274528.1	CTD-2650P22.2	3.98	7.84e-05	0.0115	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51468695	chr15:52017167~52018032:-
HNSC	cis	rs865483	0.828	rs1016680	ENSG00000276054.1	RP11-378E13.3	-3.98	7.84e-05	0.0115	-0.22	-0.18	Monocyte count;	chr17:37514283	chr17:37386886~37387926:+
HNSC	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	3.98	7.84e-05	0.0115	0.25	0.18	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
HNSC	cis	rs116095464	0.558	rs1541822	ENSG00000277812.1	AC021087.1	-3.98	7.84e-05	0.0115	-0.3	-0.18	Breast cancer;	chr5:269119	chr5:262769~262881:+
HNSC	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	3.98	7.85e-05	0.0115	0.2	0.18	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
HNSC	cis	rs5758343	1	rs5758343	ENSG00000235513.1	RP4-756G23.5	-3.98	7.85e-05	0.0115	-0.23	-0.18	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.649	rs5758344	ENSG00000235513.1	RP4-756G23.5	-3.98	7.85e-05	0.0115	-0.23	-0.18	Vitiligo;	chr22:41421681	chr22:41209122~41217627:-
HNSC	cis	rs860818	1	rs858232	ENSG00000226816.2	AC005082.12	3.98	7.85e-05	0.0115	0.49	0.18	Initial pursuit acceleration;	chr7:23202100	chr7:23206013~23208045:+
HNSC	cis	rs2439831	0.867	rs2412779	ENSG00000275601.1	AC011330.13	-3.98	7.85e-05	0.0115	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43363729	chr15:43642389~43643023:-
HNSC	cis	rs4076943	0.537	rs10831560	ENSG00000255260.1	CTD-3224I3.3	3.98	7.86e-05	0.0115	0.22	0.18	Post bronchodilator FEV1;	chr11:11264632	chr11:11243188~11243715:-
HNSC	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-3.98	7.86e-05	0.0115	-0.2	-0.18	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-3.98	7.86e-05	0.0115	-0.2	-0.18	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
HNSC	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-3.98	7.86e-05	0.0115	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
HNSC	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-3.98	7.86e-05	0.0115	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
HNSC	cis	rs13179617	0.928	rs6890351	ENSG00000215032.2	GNL3LP1	3.98	7.86e-05	0.0115	0.21	0.18	Intelligence (multi-trait analysis);	chr5:61523648	chr5:60891935~60893577:-
HNSC	cis	rs67981189	0.593	rs7160958	ENSG00000274818.1	RP1-292L20.3	3.98	7.86e-05	0.0115	0.2	0.18	Schizophrenia;	chr14:70975809	chr14:70906657~70907111:-
HNSC	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-3.98	7.86e-05	0.0115	-0.24	-0.18	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
HNSC	cis	rs9611565	0.592	rs5751101	ENSG00000235513.1	RP4-756G23.5	-3.98	7.86e-05	0.0115	-0.23	-0.18	Vitiligo;	chr22:41432107	chr22:41209122~41217627:-
HNSC	cis	rs1008375	0.966	rs6449325	ENSG00000249502.1	AC006160.5	3.98	7.86e-05	0.0115	0.19	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697886	chr4:17587467~17614571:-
HNSC	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-3.98	7.87e-05	0.0115	-0.24	-0.18	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
HNSC	cis	rs11976180	1	rs6464573	ENSG00000244479.5	OR2A1-AS1	-3.98	7.87e-05	0.0115	-0.21	-0.18	Obesity-related traits;	chr7:144051005	chr7:144251264~144356181:-
HNSC	cis	rs9652601	0.649	rs7403919	ENSG00000274038.1	RP11-66H6.4	3.98	7.87e-05	0.0115	0.22	0.18	Systemic lupus erythematosus;	chr16:10992111	chr16:11056556~11057034:+
HNSC	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-3.98	7.87e-05	0.0115	-0.28	-0.18	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
HNSC	cis	rs41308713	0.606	rs77984335	ENSG00000224635.1	RP4-564F22.5	-3.98	7.87e-05	0.0115	-0.43	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38444643	chr20:38406011~38416797:-
HNSC	cis	rs58873874	0.579	rs35536103	ENSG00000251405.2	CTB-109A12.1	3.98	7.87e-05	0.0115	0.35	0.18	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157362615~157460078:-
HNSC	cis	rs11096990	0.964	rs6831700	ENSG00000249685.1	RP11-360F5.3	3.98	7.87e-05	0.0115	0.22	0.18	Cognitive function;	chr4:39255344	chr4:39133913~39135608:+
HNSC	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	3.98	7.87e-05	0.0115	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
HNSC	cis	rs889398	0.741	rs3790075	ENSG00000196696.11	PDXDC2P	-3.98	7.87e-05	0.0115	-0.13	-0.18	Body mass index;	chr16:69873908	chr16:69976297~70065948:-
HNSC	cis	rs889398	0.741	rs7190013	ENSG00000196696.11	PDXDC2P	-3.98	7.87e-05	0.0115	-0.13	-0.18	Body mass index;	chr16:69874345	chr16:69976297~70065948:-
HNSC	cis	rs6787172	0.622	rs9827781	ENSG00000272087.1	RP11-379F4.7	3.98	7.87e-05	0.0115	0.19	0.18	Subjective well-being;	chr3:158332407	chr3:158693120~158693768:-
HNSC	cis	rs2562152	0.613	rs216599	ENSG00000226942.2	IL9RP3	-3.98	7.88e-05	0.0115	-0.27	-0.18	Glioblastoma;	chr16:59673	chr16:29336~38321:-
HNSC	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	3.98	7.88e-05	0.0115	0.26	0.18	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
HNSC	cis	rs7178375	0.607	rs7171212	ENSG00000270015.1	RP11-540B6.6	3.98	7.88e-05	0.0115	0.28	0.18	Hypertriglyceridemia;	chr15:30915508	chr15:30926514~30928407:+
HNSC	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-3.98	7.88e-05	0.0115	-0.18	-0.18	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
HNSC	cis	rs859767	0.501	rs1568121	ENSG00000224043.6	CCNT2-AS1	3.98	7.88e-05	0.0115	0.22	0.18	Neuroticism;	chr2:134649036	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.501	rs1568120	ENSG00000224043.6	CCNT2-AS1	3.98	7.88e-05	0.0115	0.22	0.18	Neuroticism;	chr2:134649320	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.54	rs6739706	ENSG00000224043.6	CCNT2-AS1	3.98	7.88e-05	0.0115	0.22	0.18	Neuroticism;	chr2:134649839	chr2:134735464~134918710:-
HNSC	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	3.98	7.88e-05	0.0115	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000233609.3	RP11-62H7.2	3.98	7.89e-05	0.0115	0.18	0.18	Systolic blood pressure;	chr8:8488071	chr8:8961200~8979025:+
HNSC	cis	rs1538970	0.884	rs781226	ENSG00000234329.1	RP11-767N6.2	-3.98	7.89e-05	0.0115	-0.21	-0.18	Platelet count;	chr1:45406990	chr1:45651039~45651826:-
HNSC	cis	rs7674212	1	rs7674212	ENSG00000251288.2	RP11-10L12.2	-3.98	7.89e-05	0.0115	-0.21	-0.18	Type 2 diabetes;	chr4:103067742	chr4:102751401~102752641:+
HNSC	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-3.98	7.89e-05	0.0115	-0.21	-0.18	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
HNSC	cis	rs11250098	0.516	rs7843666	ENSG00000269918.1	AF131215.9	-3.98	7.89e-05	0.0115	-0.18	-0.18	Morning vs. evening chronotype;	chr8:10884549	chr8:11104691~11106704:-
HNSC	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	3.98	7.89e-05	0.0115	0.23	0.18	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
HNSC	cis	rs1620921	0.563	rs2465850	ENSG00000231863.1	RP3-428L16.1	-3.98	7.89e-05	0.0115	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160860143	chr6:160931080~160969771:+
HNSC	cis	rs11168618	0.567	rs12372687	ENSG00000240399.1	RP1-228P16.1	3.98	7.89e-05	0.0115	0.16	0.18	Adiponectin levels;	chr12:48418016	chr12:48054813~48055591:-
HNSC	cis	rs7646881	0.544	rs12638363	ENSG00000272087.1	RP11-379F4.7	3.98	7.9e-05	0.0115	0.26	0.18	Tetralogy of Fallot;	chr3:158686969	chr3:158693120~158693768:-
HNSC	cis	rs9652601	0.959	rs9931397	ENSG00000274038.1	RP11-66H6.4	-3.98	7.9e-05	0.0115	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11083537	chr16:11056556~11057034:+
HNSC	cis	rs11089937	0.616	rs6001227	ENSG00000211638.2	IGLV8-61	-3.98	7.9e-05	0.0115	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22098700~22099212:+
HNSC	cis	rs643506	0.874	rs631318	ENSG00000230911.1	PPIHP1	3.98	7.9e-05	0.0115	0.23	0.18	Breast cancer;	chr11:111806971	chr11:112029858~112030367:-
HNSC	cis	rs4815617	1	rs4815617	ENSG00000275491.1	RP5-1009E24.8	-3.98	7.9e-05	0.0115	-0.34	-0.18	Asthma;	chr20:3846662	chr20:3808357~3812434:+
HNSC	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	3.98	7.9e-05	0.0115	0.21	0.18	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
HNSC	cis	rs6496044	1	rs6496044	ENSG00000259295.5	CSPG4P12	3.98	7.9e-05	0.0115	0.22	0.18	Interstitial lung disease;	chr15:85524075	chr15:85191438~85213905:+
HNSC	cis	rs859767	0.603	rs842359	ENSG00000224043.6	CCNT2-AS1	-3.98	7.9e-05	0.0115	-0.22	-0.18	Neuroticism;	chr2:134587998	chr2:134735464~134918710:-
HNSC	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-3.98	7.9e-05	0.0115	-0.23	-0.18	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
HNSC	cis	rs6490294	0.571	rs7973898	ENSG00000226469.1	ADAM1B	3.98	7.9e-05	0.0115	0.26	0.18	Mean platelet volume;	chr12:112178363	chr12:111927018~111929017:+
HNSC	cis	rs13260300	0.645	rs7017318	ENSG00000254349.4	FLJ39080	3.98	7.9e-05	0.0115	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74602520	chr8:74599775~74823313:+
HNSC	cis	rs6460942	0.597	rs6944517	ENSG00000226690.5	AC005281.1	3.98	7.91e-05	0.0115	0.29	0.18	Coronary artery disease;	chr7:12475657	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs6968664	ENSG00000226690.5	AC005281.1	3.98	7.91e-05	0.0115	0.29	0.18	Coronary artery disease;	chr7:12475867	chr7:12496429~12541910:+
HNSC	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	3.98	7.91e-05	0.0115	0.22	0.18	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
HNSC	cis	rs870825	0.929	rs10003354	ENSG00000254233.1	RP11-242J7.1	3.98	7.91e-05	0.0115	0.3	0.18	Blood protein levels;	chr4:184668628	chr4:184584093~184625030:-
HNSC	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-3.98	7.91e-05	0.0115	-0.21	-0.18	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
HNSC	cis	rs6832769	0.922	rs28726308	ENSG00000249700.7	SRD5A3-AS1	3.98	7.91e-05	0.0115	0.21	0.18	Personality dimensions;	chr4:55368239	chr4:55363971~55395847:-
HNSC	cis	rs10510102	0.516	rs3936070	ENSG00000226864.1	ATE1-AS1	3.98	7.91e-05	0.0116	0.33	0.18	Breast cancer;	chr10:121974440	chr10:121928312~121951965:+
HNSC	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-3.98	7.91e-05	0.0116	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
HNSC	cis	rs13179617	0.928	rs13185783	ENSG00000215032.2	GNL3LP1	-3.98	7.92e-05	0.0116	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61455697	chr5:60891935~60893577:-
HNSC	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	3.98	7.92e-05	0.0116	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
HNSC	cis	rs58873874	0.737	rs9313608	ENSG00000248544.2	CTB-47B11.3	-3.98	7.92e-05	0.0116	-0.42	-0.18	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157375741~157384950:-
HNSC	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	3.98	7.92e-05	0.0116	0.21	0.18	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	3.98	7.92e-05	0.0116	0.21	0.18	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
HNSC	cis	rs9921338	0.961	rs9937269	ENSG00000263080.1	RP11-485G7.5	-3.98	7.92e-05	0.0116	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11341809~11345211:-
HNSC	cis	rs9921338	1	rs9921338	ENSG00000263080.1	RP11-485G7.5	-3.98	7.92e-05	0.0116	-0.2	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11341809~11345211:-
HNSC	cis	rs10805346	0.505	rs35995899	ENSG00000261490.1	RP11-448G15.3	3.98	7.92e-05	0.0116	0.14	0.18	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10111238	chr4:10068089~10073019:-
HNSC	cis	rs2732480	0.5	rs11168468	ENSG00000257763.1	OR5BK1P	3.98	7.92e-05	0.0116	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48355792~48356614:-
HNSC	cis	rs13179617	0.928	rs1445981	ENSG00000215032.2	GNL3LP1	-3.98	7.92e-05	0.0116	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61503059	chr5:60891935~60893577:-
HNSC	cis	rs17666538	0.585	rs336437	ENSG00000254207.1	RP11-43A14.1	3.98	7.92e-05	0.0116	0.4	0.18	IgG glycosylation;	chr8:686251	chr8:725188~725877:-
HNSC	cis	rs3741151	0.686	rs7118982	ENSG00000256448.4	RP11-809N8.4	3.98	7.93e-05	0.0116	0.26	0.18	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73399623	chr11:73405297~73410682:+
HNSC	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	3.98	7.93e-05	0.0116	0.18	0.18	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
HNSC	cis	rs67072384	1	rs72966113	ENSG00000213365.3	AP000593.6	3.98	7.93e-05	0.0116	0.31	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739925	chr11:72280151~72281178:+
HNSC	cis	rs67072384	1	rs12294368	ENSG00000213365.3	AP000593.6	3.98	7.93e-05	0.0116	0.31	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72740194	chr11:72280151~72281178:+
HNSC	cis	rs853679	0.517	rs12174753	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28074687	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs55747925	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28076559	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs56310871	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28076704	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs34716816	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28078391	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380049	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28080757	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380050	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.0116	0.25	0.18	Depression;	chr6:28080760	chr6:28091154~28093664:+
HNSC	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-3.98	7.93e-05	0.0116	-0.17	-0.18	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
HNSC	cis	rs7224668	0.647	rs8070092	ENSG00000280407.2	RP13-516M14.8	3.98	7.93e-05	0.0116	0.15	0.18	IgG glycosylation;	chr17:81273018	chr17:82249067~82251844:+
HNSC	cis	rs703842	0.616	rs7489290	ENSG00000270039.1	RP11-571M6.17	-3.98	7.93e-05	0.0116	-0.22	-0.18	Multiple sclerosis;	chr12:57834805	chr12:57803838~57804415:+
HNSC	cis	rs10504130	0.569	rs13265006	ENSG00000253844.1	RP11-546K22.1	-3.98	7.93e-05	0.0116	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.597	rs34058697	ENSG00000253844.1	RP11-546K22.1	-3.98	7.93e-05	0.0116	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51961458~52022974:+
HNSC	cis	rs6723108	0.651	rs6724774	ENSG00000224043.6	CCNT2-AS1	3.98	7.93e-05	0.0116	0.22	0.18	Type 2 diabetes;	chr2:134649715	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.501	rs6724777	ENSG00000224043.6	CCNT2-AS1	3.98	7.93e-05	0.0116	0.22	0.18	Neuroticism;	chr2:134649722	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.651	rs6724866	ENSG00000224043.6	CCNT2-AS1	3.98	7.93e-05	0.0116	0.22	0.18	Type 2 diabetes;	chr2:134649740	chr2:134735464~134918710:-
HNSC	cis	rs6723108	0.616	rs6752634	ENSG00000224043.6	CCNT2-AS1	3.98	7.93e-05	0.0116	0.22	0.18	Type 2 diabetes;	chr2:134649785	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.501	rs6742638	ENSG00000224043.6	CCNT2-AS1	3.98	7.93e-05	0.0116	0.22	0.18	Neuroticism;	chr2:134649790	chr2:134735464~134918710:-
HNSC	cis	rs58873874	0.737	rs75326191	ENSG00000248544.2	CTB-47B11.3	3.98	7.94e-05	0.0116	0.44	0.18	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157375741~157384950:-
HNSC	cis	rs4948102	0.731	rs4689	ENSG00000226278.1	PSPHP1	-3.98	7.94e-05	0.0116	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr7:55764797~55773288:+
HNSC	cis	rs7246657	0.722	rs12974225	ENSG00000276846.1	CTD-3220F14.3	-3.98	7.94e-05	0.0116	-0.24	-0.18	Coronary artery calcification;	chr19:37749458	chr19:37314868~37315620:-
HNSC	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	3.98	7.94e-05	0.0116	0.3	0.18	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
HNSC	cis	rs9298506	0.948	rs28387039	ENSG00000254142.2	RP11-53M11.3	3.98	7.94e-05	0.0116	0.31	0.18	Intracranial aneurysm;	chr8:54524077	chr8:54554361~54561927:+
HNSC	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	3.98	7.94e-05	0.0116	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
HNSC	cis	rs6860806	0.507	rs270614	ENSG00000233006.5	AC034220.3	3.98	7.94e-05	0.0116	0.21	0.18	Breast cancer;	chr5:132305120	chr5:132311285~132369916:-
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000211976.2	IGHV3-73	-3.98	7.94e-05	0.0116	-0.13	-0.18	Kawasaki disease;	chr14:106776448	chr14:106802694~106803233:-
HNSC	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	3.98	7.94e-05	0.0116	0.23	0.18	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
HNSC	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-3.98	7.94e-05	0.0116	-0.24	-0.18	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
HNSC	cis	rs7189233	0.956	rs62048486	ENSG00000279344.1	RP11-44F14.7	3.98	7.94e-05	0.0116	0.18	0.18	Intelligence (multi-trait analysis);	chr16:53414427	chr16:53478957~53481550:-
HNSC	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-3.98	7.94e-05	0.0116	-0.18	-0.18	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
HNSC	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	3.98	7.95e-05	0.0116	0.33	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
HNSC	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-3.98	7.95e-05	0.0116	-0.24	-0.18	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
HNSC	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	3.98	7.95e-05	0.0116	0.22	0.18	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000229886.1	RP5-1132H15.3	3.98	7.95e-05	0.0116	0.31	0.18	Diabetic kidney disease;	chr7:65924813	chr7:66025126~66031544:-
HNSC	cis	rs913672	0.609	rs6122895	ENSG00000224397.4	LINC01272	3.98	7.95e-05	0.0116	0.24	0.18	Monocyte count;	chr20:50283557	chr20:50267486~50279795:+
HNSC	cis	rs6090919	0.501	rs17366795	ENSG00000222365.1	SNORD12B	3.98	7.95e-05	0.0116	0.24	0.18	Intelligence (multi-trait analysis);	chr20:48865294	chr20:49280319~49280409:+
HNSC	cis	rs853679	0.517	rs36078605	ENSG00000219891.2	ZSCAN12P1	3.98	7.95e-05	0.0116	0.26	0.18	Depression;	chr6:28110254	chr6:28091154~28093664:+
HNSC	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-3.98	7.96e-05	0.0116	-0.19	-0.18	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
HNSC	cis	rs3015497	0.537	rs2934664	ENSG00000277050.1	RP11-102G14.1	-3.98	7.96e-05	0.0116	-0.18	-0.18	Mean platelet volume;	chr14:50688767	chr14:51637348~51637947:-
HNSC	cis	rs11168618	0.846	rs7958521	ENSG00000240399.1	RP1-228P16.1	3.98	7.96e-05	0.0116	0.16	0.18	Adiponectin levels;	chr12:48483617	chr12:48054813~48055591:-
HNSC	cis	rs16873450	0.527	rs1017192	ENSG00000234800.2	PCMTD1P3	-3.98	7.96e-05	0.0116	-0.18	-0.18	Verbal memory performance (residualized delayed recall level);	chr7:23770067	chr7:23721311~23721782:-
HNSC	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	3.98	7.96e-05	0.0116	0.22	0.18	Depression;	chr6:28251492	chr6:28176188~28176674:+
HNSC	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	3.98	7.96e-05	0.0116	0.24	0.18	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
HNSC	cis	rs2243480	1	rs13247184	ENSG00000229886.1	RP5-1132H15.3	3.98	7.96e-05	0.0116	0.31	0.18	Diabetic kidney disease;	chr7:65893941	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35421653	ENSG00000229886.1	RP5-1132H15.3	3.98	7.96e-05	0.0116	0.31	0.18	Diabetic kidney disease;	chr7:65898442	chr7:66025126~66031544:-
HNSC	cis	rs256438	0.526	rs10057390	ENSG00000251050.1	RP11-168A11.4	-3.98	7.96e-05	0.0116	-0.21	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80032159	chr5:80019609~80019920:+
HNSC	cis	rs870825	0.932	rs10034861	ENSG00000254233.1	RP11-242J7.1	3.98	7.96e-05	0.0116	0.32	0.18	Blood protein levels;	chr4:184656296	chr4:184584093~184625030:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000272831.1	RP11-792A8.4	3.98	7.96e-05	0.0116	0.15	0.18	Calcium levels;	chr7:65996954	chr7:66739829~66740385:-
HNSC	cis	rs7085104	0.7	rs10883785	ENSG00000213061.2	PFN1P11	3.98	7.96e-05	0.0116	0.23	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102838011~102845473:-
HNSC	cis	rs1538970	0.816	rs4633317	ENSG00000234329.1	RP11-767N6.2	3.98	7.97e-05	0.0116	0.21	0.18	Platelet count;	chr1:45519485	chr1:45651039~45651826:-
HNSC	cis	rs3736485	0.808	rs55982453	ENSG00000274528.1	CTD-2650P22.2	3.98	7.97e-05	0.0116	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659048	chr15:52017167~52018032:-
HNSC	cis	rs2286503	0.752	rs59538378	ENSG00000226329.2	AC005682.6	3.98	7.97e-05	0.0116	0.23	0.18	Fibrinogen;	chr7:22837478	chr7:22863874~22881350:-
HNSC	cis	rs6540731	0.905	rs6540729	ENSG00000226251.4	RP11-15I11.3	-3.98	7.97e-05	0.0116	-0.21	-0.18	Intelligence (childhood);	chr1:212214566	chr1:212225278~212238977:-
HNSC	cis	rs7166081	0.672	rs3865018	ENSG00000270964.1	RP11-502I4.3	3.98	7.97e-05	0.0116	0.2	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67600428	chr15:67541072~67542604:-
HNSC	cis	rs4144743	1	rs11871251	ENSG00000228782.6	CTD-2026D20.3	-3.98	7.97e-05	0.0116	-0.22	-0.18	Body mass index;	chr17:47254061	chr17:47450568~47492492:-
HNSC	cis	rs11673344	0.542	rs826325	ENSG00000267698.1	AC002116.7	3.98	7.97e-05	0.0116	0.16	0.18	Obesity-related traits;	chr19:37003580	chr19:36014508~36045972:+
HNSC	cis	rs9880211	0.8	rs13314357	ENSG00000239213.4	NCK1-AS1	3.98	7.97e-05	0.0116	0.18	0.18	Height;Body mass index;	chr3:136768717	chr3:136841726~136862054:-
HNSC	cis	rs9311676	0.594	rs55954186	ENSG00000273493.1	RP11-80H18.4	3.98	7.98e-05	0.0116	0.2	0.18	Systemic lupus erythematosus;	chr3:58450749	chr3:58329965~58330118:+
HNSC	cis	rs7927592	0.956	rs11228277	ENSG00000255031.4	RP11-802E16.3	3.98	7.98e-05	0.0116	0.16	0.18	Total body bone mineral density;	chr11:68540856	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.956	rs11228278	ENSG00000255031.4	RP11-802E16.3	3.98	7.98e-05	0.0116	0.16	0.18	Total body bone mineral density;	chr11:68541062	chr11:68050740~68053762:+
HNSC	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-3.98	7.98e-05	0.0116	-0.21	-0.18	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
HNSC	cis	rs9313772	0.722	rs10075240	ENSG00000254350.1	RP11-542A14.1	-3.98	7.98e-05	0.0116	-0.19	-0.18	Blood pressure;	chr5:158420184	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.574	rs12189195	ENSG00000254350.1	RP11-542A14.1	-3.98	7.98e-05	0.0116	-0.19	-0.18	Blood pressure;	chr5:158420351	chr5:158424585~158452758:+
HNSC	cis	rs116095464	0.558	rs113796397	ENSG00000277812.1	AC021087.1	3.98	7.98e-05	0.0116	0.31	0.18	Breast cancer;	chr5:246388	chr5:262769~262881:+
HNSC	cis	rs1519814	0.696	rs2139439	ENSG00000254343.2	RP11-760H22.2	-3.98	7.98e-05	0.0116	-0.24	-0.18	Breast cancer;	chr8:120024852	chr8:120052180~120056201:+
HNSC	cis	rs6095360	0.899	rs6019544	ENSG00000222365.1	SNORD12B	-3.98	7.98e-05	0.0116	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:48940476	chr20:49280319~49280409:+
HNSC	cis	rs13260300	0.614	rs4735715	ENSG00000254349.4	FLJ39080	3.98	7.98e-05	0.0116	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74602319	chr8:74599775~74823313:+
HNSC	cis	rs6095360	0.727	rs35334143	ENSG00000222365.1	SNORD12B	-3.98	7.98e-05	0.0116	-0.23	-0.18	Intelligence (multi-trait analysis);	chr20:48914171	chr20:49280319~49280409:+
HNSC	cis	rs11951515	0.7	rs12518032	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43311252	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.675	rs9790987	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43306131	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.663	rs66691321	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43308353	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.638	rs10941621	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43308533	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.676	rs10941622	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43308588	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.7	rs10512825	ENSG00000249286.1	CTD-2210P15.2	3.98	7.99e-05	0.0116	0.19	0.18	Metabolite levels  (X-11787);	chr5:43309088	chr5:43586918~43588223:-
HNSC	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-3.98	7.99e-05	0.0116	-0.19	-0.18	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
HNSC	cis	rs8072100	0.512	rs3809863	ENSG00000263293.2	RP11-290H9.4	3.98	7.99e-05	0.0116	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47303460~47323613:-
HNSC	cis	rs1881509	0.702	rs4963079	ENSG00000255153.1	TOLLIP-AS1	-3.98	7.99e-05	0.0116	-0.19	-0.18	Heroin dependence;	chr11:1414149	chr11:1309769~1310707:+
HNSC	cis	rs12701220	0.503	rs13222294	ENSG00000224079.1	AC091729.7	3.98	7.99e-05	0.0116	0.28	0.18	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1074450~1078036:+
HNSC	cis	rs35306767	0.903	rs11253460	ENSG00000229869.1	RP11-363N22.2	-3.98	7.99e-05	0.0116	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:841442	chr10:933026~942743:+
HNSC	cis	rs4356203	0.905	rs651513	ENSG00000272034.1	SNORD14A	-3.98	7.99e-05	0.0116	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17074654~17074744:-
HNSC	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-3.98	8e-05	0.0117	-0.2	-0.18	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
HNSC	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-3.98	8e-05	0.0117	-0.2	-0.18	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
HNSC	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-3.98	8e-05	0.0117	-0.2	-0.18	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
HNSC	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-3.98	8e-05	0.0117	-0.26	-0.18	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
HNSC	cis	rs913655	0.508	rs1552609	ENSG00000225527.1	RP11-383B4.4	-3.98	8e-05	0.0117	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18723230	chr10:18531849~18533336:-
HNSC	cis	rs9393777	0.92	rs67859638	ENSG00000226314.6	ZNF192P1	-3.98	8e-05	0.0117	-0.36	-0.18	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28161781~28169594:+
HNSC	cis	rs7927592	0.956	rs6591341	ENSG00000255031.4	RP11-802E16.3	3.98	8e-05	0.0117	0.16	0.18	Total body bone mineral density;	chr11:68568010	chr11:68050740~68053762:+
HNSC	cis	rs656319	0.564	rs11776035	ENSG00000255310.2	AF131215.2	-3.98	8e-05	0.0117	-0.18	-0.18	Myopia (pathological);	chr8:10214017	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.5	rs2027902	ENSG00000211976.2	IGHV3-73	-3.98	8e-05	0.0117	-0.13	-0.18	Kawasaki disease;	chr14:106807157	chr14:106802694~106803233:-
HNSC	cis	rs9650657	0.769	rs2116093	ENSG00000269918.1	AF131215.9	-3.98	8e-05	0.0117	-0.18	-0.18	Neuroticism;	chr8:10755789	chr8:11104691~11106704:-
HNSC	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-3.98	8e-05	0.0117	-0.24	-0.18	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
HNSC	cis	rs11951515	0.7	rs10805672	ENSG00000249286.1	CTD-2210P15.2	3.98	8e-05	0.0117	0.19	0.18	Metabolite levels  (X-11787);	chr5:43303646	chr5:43586918~43588223:-
HNSC	cis	rs12701220	0.842	rs10236293	ENSG00000224079.1	AC091729.7	3.98	8e-05	0.0117	0.28	0.18	Bronchopulmonary dysplasia;	chr7:993001	chr7:1074450~1078036:+
HNSC	cis	rs7558911	0.801	rs10188598	ENSG00000183308.6	AC005037.3	3.98	8e-05	0.0117	0.22	0.18	Chronic lymphocytic leukemia;	chr2:201212890	chr2:200963263~201009102:+
HNSC	cis	rs10875746	0.859	rs12305511	ENSG00000257763.1	OR5BK1P	3.98	8e-05	0.0117	0.22	0.18	Longevity (90 years and older);	chr12:48188933	chr12:48355792~48356614:-
HNSC	cis	rs7819412	0.502	rs4840548	ENSG00000269918.1	AF131215.9	-3.98	8.01e-05	0.0117	-0.19	-0.18	Triglycerides;	chr8:11135373	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000211976.2	IGHV3-73	-3.98	8.01e-05	0.0117	-0.13	-0.18	Kawasaki disease;	chr14:106776698	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000211976.2	IGHV3-73	-3.98	8.01e-05	0.0117	-0.13	-0.18	Kawasaki disease;	chr14:106776724	chr14:106802694~106803233:-
HNSC	cis	rs6061231	0.793	rs6061512	ENSG00000275437.1	RP5-908M14.10	3.98	8.01e-05	0.0117	0.2	0.18	Colorectal cancer;	chr20:62401873	chr20:62402236~62405935:-
HNSC	cis	rs897984	0.683	rs12447534	ENSG00000279196.1	RP11-1072A3.3	-3.98	8.01e-05	0.0117	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30792936	chr16:30984630~30988270:-
HNSC	cis	rs12893668	0.572	rs4906356	ENSG00000269958.1	RP11-73M18.8	3.98	8.01e-05	0.0117	0.17	0.18	Reticulocyte count;	chr14:103672364	chr14:103696353~103697163:+
HNSC	cis	rs2310173	0.966	rs7588933	ENSG00000281162.1	LINC01127	-3.98	8.01e-05	0.0117	-0.23	-0.18	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102046190	chr2:101962056~101987167:+
HNSC	cis	rs6163	0.588	rs3818708	ENSG00000236937.2	PTGES3P4	3.98	8.02e-05	0.0117	0.21	0.18	Waist circumference;Hip circumference;	chr10:102743827	chr10:102845595~102845950:+
HNSC	cis	rs67311347	1	rs4571217	ENSG00000280739.1	EIF1B-AS1	3.98	8.02e-05	0.0117	0.2	0.18	Renal cell carcinoma;	chr3:40480482	chr3:40173145~40309698:-
HNSC	cis	rs12745968	0.589	rs10874710	ENSG00000223787.2	RP4-593M8.1	-3.98	8.02e-05	0.0117	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92552206	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.589	rs10874711	ENSG00000223787.2	RP4-593M8.1	-3.98	8.02e-05	0.0117	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92552431	chr1:92580476~92580821:-
HNSC	cis	rs4073405	0.813	rs7478750	ENSG00000254651.1	RP11-430H10.3	-3.98	8.02e-05	0.0117	-0.22	-0.18	Schizophrenia;	chr11:45327439	chr11:45399448~45400528:+
HNSC	cis	rs897984	0.683	rs8046001	ENSG00000279196.1	RP11-1072A3.3	3.98	8.02e-05	0.0117	0.2	0.18	Dementia with Lewy bodies;	chr16:30822000	chr16:30984630~30988270:-
HNSC	cis	rs72949976	1	rs72949976	ENSG00000270659.1	RP11-105N14.1	3.98	8.02e-05	0.0117	0.18	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213169380	chr2:213152970~213153659:+
HNSC	cis	rs4356203	0.87	rs10832751	ENSG00000260196.1	RP1-239B22.5	-3.98	8.02e-05	0.0117	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17380649~17383531:+
HNSC	cis	rs11846409	0.86	rs1858692	ENSG00000280411.1	IGHV1-69-2	3.98	8.03e-05	0.0117	0.17	0.18	Rheumatic heart disease;	chr14:106622776	chr14:106762092~106762588:-
HNSC	cis	rs597480	0.963	rs290173	ENSG00000279742.1	RP11-700A24.1	-3.98	8.03e-05	0.0117	-0.2	-0.18	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85697789	chr11:85852557~85854943:-
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000211974.3	IGHV2-70	3.98	8.03e-05	0.0117	0.17	0.18	Kawasaki disease;	chr14:106815190	chr14:106723574~106724093:-
HNSC	cis	rs2760061	0.583	rs708121	ENSG00000270110.1	RP5-1139B12.4	-3.98	8.03e-05	0.0117	-0.19	-0.18	Diastolic blood pressure;	chr1:228020556	chr1:228295911~228302998:-
HNSC	cis	rs2760061	0.583	rs1774757	ENSG00000270110.1	RP5-1139B12.4	-3.98	8.03e-05	0.0117	-0.19	-0.18	Diastolic blood pressure;	chr1:228023434	chr1:228295911~228302998:-
HNSC	cis	rs1979679	0.918	rs78500430	ENSG00000247934.4	RP11-967K21.1	-3.98	8.03e-05	0.0117	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28163298~28190738:-
HNSC	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-3.98	8.03e-05	0.0117	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-3.98	8.03e-05	0.0117	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
HNSC	cis	rs237743	0.671	rs13037209	ENSG00000222365.1	SNORD12B	-3.98	8.03e-05	0.0117	-0.31	-0.18	Height;	chr20:49313692	chr20:49280319~49280409:+
HNSC	cis	rs2877187	0.576	rs10235654	ENSG00000232006.7	AC005537.2	-3.98	8.04e-05	0.0117	-0.21	-0.18	Lung cancer in ever smokers;	chr7:43041084	chr7:42954135~43113931:-
HNSC	cis	rs1979679	0.808	rs71452082	ENSG00000247934.4	RP11-967K21.1	-3.98	8.04e-05	0.0117	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28163298~28190738:-
HNSC	cis	rs860295	0.58	rs6672284	ENSG00000203761.5	MSTO2P	-3.98	8.04e-05	0.0117	-0.15	-0.18	Body mass index;	chr1:155308172	chr1:155745829~155750137:+
HNSC	cis	rs6651255	0.58	rs900367	ENSG00000224110.3	MTRF1LP2	-3.98	8.04e-05	0.0117	-0.23	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129776644	chr8:129728744~129730445:+
HNSC	cis	rs526231	0.575	rs55652053	ENSG00000250682.4	LINC00491	3.98	8.04e-05	0.0117	0.24	0.18	Primary biliary cholangitis;	chr5:103001466	chr5:102609156~102671559:-
HNSC	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-3.98	8.04e-05	0.0117	-0.13	-0.18	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
HNSC	cis	rs12893668	0.572	rs12590968	ENSG00000269958.1	RP11-73M18.8	3.98	8.04e-05	0.0117	0.17	0.18	Reticulocyte count;	chr14:103670296	chr14:103696353~103697163:+
HNSC	cis	rs3733585	0.657	rs62286568	ENSG00000250413.1	RP11-448G15.1	3.98	8.04e-05	0.0117	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10123265	chr4:10006482~10009725:+
HNSC	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-3.98	8.04e-05	0.0117	-0.24	-0.18	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
HNSC	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-3.98	8.04e-05	0.0117	-0.24	-0.18	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
HNSC	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-3.98	8.04e-05	0.0117	-0.24	-0.18	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
HNSC	cis	rs6504950	0.83	rs56175787	ENSG00000279059.1	RP11-257O5.2	-3.98	8.04e-05	0.0117	-0.15	-0.18	Breast cancer;	chr17:54940386	chr17:54956760~54958426:-
HNSC	cis	rs870825	0.556	rs6552811	ENSG00000254233.1	RP11-242J7.1	-3.98	8.05e-05	0.0117	-0.27	-0.18	Blood protein levels;	chr4:184732197	chr4:184584093~184625030:-
HNSC	cis	rs11711311	1	rs1043132	ENSG00000241529.3	RN7SL767P	-3.98	8.05e-05	0.0117	-0.23	-0.18	IgG glycosylation;	chr3:113809842	chr3:113632704~113632998:+
HNSC	cis	rs9467773	0.595	rs6907924	ENSG00000241549.7	GUSBP2	3.98	8.05e-05	0.0117	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26438589	chr6:26871484~26956554:-
HNSC	cis	rs9467773	0.55	rs9379874	ENSG00000241549.7	GUSBP2	3.98	8.05e-05	0.0117	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26440201	chr6:26871484~26956554:-
HNSC	cis	rs6493858	0.839	rs2713926	ENSG00000277245.1	RP11-48G14.3	-3.98	8.05e-05	0.0117	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56239023	chr15:56447120~56447697:+
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000250412.1	KLHL2P1	3.98	8.05e-05	0.0117	0.23	0.18	Corneal astigmatism;	chr4:119324087	chr4:119334329~119378233:+
HNSC	cis	rs9880211	0.8	rs9871184	ENSG00000239213.4	NCK1-AS1	3.98	8.05e-05	0.0117	0.18	0.18	Height;Body mass index;	chr3:136795468	chr3:136841726~136862054:-
HNSC	cis	rs5758511	0.573	rs738248	ENSG00000235513.1	RP4-756G23.5	3.98	8.06e-05	0.0117	0.19	0.18	Birth weight;	chr22:41800463	chr22:41209122~41217627:-
HNSC	cis	rs5758511	0.573	rs5996069	ENSG00000235513.1	RP4-756G23.5	3.98	8.06e-05	0.0117	0.19	0.18	Birth weight;	chr22:41805181	chr22:41209122~41217627:-
HNSC	cis	rs7107174	1	rs2511185	ENSG00000251323.2	RP11-452H21.4	3.98	8.06e-05	0.0117	0.26	0.18	Testicular germ cell tumor;	chr11:78271450	chr11:78423982~78429836:-
HNSC	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	3.98	8.06e-05	0.0117	0.18	0.18	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
HNSC	cis	rs12468226	0.752	rs34829484	ENSG00000226261.1	AC064836.3	-3.98	8.06e-05	0.0117	-0.26	-0.18	Urate levels;	chr2:202137267	chr2:202336024~202336727:-
HNSC	cis	rs380904	0.552	rs10099003	ENSG00000214733.7	RP11-429J17.8	3.98	8.06e-05	0.0117	0.22	0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143788920~143790459:+
HNSC	cis	rs6903823	0.508	rs1150726	ENSG00000219392.1	RP1-265C24.5	-3.98	8.07e-05	0.0117	-0.21	-0.18	Pulmonary function;	chr6:28275265	chr6:28115628~28116551:+
HNSC	cis	rs7781557	1	rs12113073	ENSG00000239969.4	RP11-163E9.2	-3.98	8.07e-05	0.0117	-0.26	-0.18	Colorectal adenoma (advanced);	chr7:102842080	chr7:102364162~102380633:+
HNSC	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	3.98	8.07e-05	0.0117	0.26	0.18	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
HNSC	cis	rs853679	1	rs2799077	ENSG00000226314.6	ZNF192P1	-3.98	8.07e-05	0.0117	-0.26	-0.18	Depression;	chr6:28266819	chr6:28161781~28169594:+
HNSC	cis	rs7868228	0.945	rs7859292	ENSG00000240498.5	CDKN2B-AS1	-3.98	8.07e-05	0.0117	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21665137	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.891	rs16938518	ENSG00000240498.5	CDKN2B-AS1	-3.98	8.07e-05	0.0117	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21665241	chr9:21994778~22121097:+
HNSC	cis	rs6787172	0.593	rs73170315	ENSG00000272087.1	RP11-379F4.7	3.98	8.07e-05	0.0117	0.19	0.18	Subjective well-being;	chr3:158339812	chr3:158693120~158693768:-
HNSC	cis	rs6142618	0.583	rs2235904	ENSG00000275576.1	RP5-836N17.4	-3.98	8.07e-05	0.0117	-0.18	-0.18	Inflammatory bowel disease;	chr20:32133909	chr20:32116171~32116629:+
HNSC	cis	rs853679	0.517	rs9380056	ENSG00000219891.2	ZSCAN12P1	3.98	8.07e-05	0.0117	0.25	0.18	Depression;	chr6:28136698	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380057	ENSG00000219891.2	ZSCAN12P1	3.98	8.07e-05	0.0117	0.25	0.18	Depression;	chr6:28136856	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs1947862	ENSG00000219891.2	ZSCAN12P1	3.98	8.07e-05	0.0117	0.25	0.18	Depression;	chr6:28137418	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs6941992	ENSG00000219891.2	ZSCAN12P1	3.98	8.07e-05	0.0117	0.25	0.18	Depression;	chr6:28138363	chr6:28091154~28093664:+
HNSC	cis	rs5786757	1	rs5786757	ENSG00000200253.1	RNU6-529P	3.98	8.08e-05	0.0117	0.24	0.18	Nose morphology;	chr10:87076396	chr10:87041238~87041341:-
HNSC	cis	rs73191547	0.501	rs6986885	ENSG00000254340.1	RP11-10A14.3	3.98	8.08e-05	0.0117	0.21	0.18	Schizophrenia;	chr8:10120961	chr8:9141424~9145435:+
HNSC	cis	rs9487051	0.646	rs9487049	ENSG00000243587.6	C6orf183	-3.98	8.08e-05	0.0118	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109294702	chr6:109165833~109271014:+
HNSC	cis	rs4713118	0.869	rs7773070	ENSG00000216901.1	AL022393.7	3.98	8.08e-05	0.0118	0.23	0.18	Parkinson's disease;	chr6:27761048	chr6:28176188~28176674:+
HNSC	cis	rs7824557	0.614	rs4394351	ENSG00000269918.1	AF131215.9	3.98	8.08e-05	0.0118	0.17	0.18	Retinal vascular caliber;	chr8:11355366	chr8:11104691~11106704:-
HNSC	cis	rs2074409	0.572	rs4074605	ENSG00000276054.1	RP11-378E13.3	-3.98	8.08e-05	0.0118	-0.26	-0.18	Response to angiotensin II receptor blocker therapy;	chr17:37562341	chr17:37386886~37387926:+
HNSC	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	3.98	8.08e-05	0.0118	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
HNSC	cis	rs3809863	0.602	rs7225700	ENSG00000263293.2	RP11-290H9.4	3.98	8.09e-05	0.0118	0.21	0.18	Glaucoma (primary open-angle);	chr17:47314438	chr17:47303460~47323613:-
HNSC	cis	rs3809863	0.602	rs2317677	ENSG00000263293.2	RP11-290H9.4	3.98	8.09e-05	0.0118	0.21	0.18	Glaucoma (primary open-angle);	chr17:47316041	chr17:47303460~47323613:-
HNSC	cis	rs2286313	0.51	rs35432764	ENSG00000266869.1	RP6-114E22.1	-3.98	8.09e-05	0.0118	-0.44	-0.18	Colorectal cancer;	chr14:70982060	chr14:71848606~71908430:+
HNSC	cis	rs2286313	0.558	rs35561518	ENSG00000266869.1	RP6-114E22.1	-3.98	8.09e-05	0.0118	-0.44	-0.18	Colorectal cancer;	chr14:71002768	chr14:71848606~71908430:+
HNSC	cis	rs2286313	0.51	rs12100735	ENSG00000266869.1	RP6-114E22.1	-3.98	8.09e-05	0.0118	-0.44	-0.18	Colorectal cancer;	chr14:71004481	chr14:71848606~71908430:+
HNSC	cis	rs35264875	0.808	rs921675	ENSG00000259799.1	RP11-554A11.9	-3.98	8.09e-05	0.0118	-0.22	-0.18	Blond vs. brown hair color;	chr11:69101566	chr11:69155910~69159752:+
HNSC	cis	rs4256159	1	rs71314411	ENSG00000228956.7	SATB1-AS1	3.98	8.09e-05	0.0118	0.31	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18702699	chr3:18445024~18920401:+
HNSC	cis	rs1602565	1	rs11030606	ENSG00000255450.1	CTD-2063L20.1	-3.98	8.09e-05	0.0118	-0.31	-0.18	Schizophrenia;	chr11:29192865	chr11:29275655~29276565:+
HNSC	cis	rs6831352	0.879	rs1230154	ENSG00000263923.1	RP11-571L19.7	-3.98	8.1e-05	0.0118	-0.18	-0.18	Alcohol dependence;	chr4:99067508	chr4:98928897~98994994:+
HNSC	cis	rs202072	0.652	rs1223393	ENSG00000215022.6	RP1-257A7.4	3.98	8.1e-05	0.0118	0.25	0.18	HIV-1 viral setpoint;	chr6:13265102	chr6:13264861~13295586:-
HNSC	cis	rs2562152	0.53	rs216604	ENSG00000226942.2	IL9RP3	-3.98	8.1e-05	0.0118	-0.27	-0.18	Glioblastoma;	chr16:62515	chr16:29336~38321:-
HNSC	cis	rs853679	0.517	rs12332979	ENSG00000219891.2	ZSCAN12P1	3.98	8.11e-05	0.0118	0.26	0.18	Depression;	chr6:28173770	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs67878650	ENSG00000219891.2	ZSCAN12P1	3.98	8.11e-05	0.0118	0.26	0.18	Depression;	chr6:28174809	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.569	rs9348798	ENSG00000219891.2	ZSCAN12P1	3.98	8.11e-05	0.0118	0.26	0.18	Depression;	chr6:28175233	chr6:28091154~28093664:+
HNSC	cis	rs6500395	0.775	rs7191225	ENSG00000261267.1	RP11-44I10.3	-3.98	8.11e-05	0.0118	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48628764	chr16:48559661~48587403:+
HNSC	cis	rs9652601	0.959	rs9888908	ENSG00000274038.1	RP11-66H6.4	-3.98	8.11e-05	0.0118	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11087387	chr16:11056556~11057034:+
HNSC	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-3.98	8.11e-05	0.0118	-0.16	-0.18	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
HNSC	cis	rs6493858	0.839	rs2718941	ENSG00000277245.1	RP11-48G14.3	-3.98	8.11e-05	0.0118	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56229983	chr15:56447120~56447697:+
HNSC	cis	rs2333194	0.846	rs6574118	ENSG00000258695.2	RP3-414A15.2	-3.98	8.11e-05	0.0118	-0.19	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr14:73345284	chr14:73522878~73530610:+
HNSC	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	3.98	8.11e-05	0.0118	0.2	0.18	Height;	chr14:75172868	chr14:75011269~75012851:-
HNSC	cis	rs9611565	0.921	rs761366	ENSG00000235513.1	RP4-756G23.5	3.98	8.11e-05	0.0118	0.21	0.18	Vitiligo;	chr22:41348018	chr22:41209122~41217627:-
HNSC	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	3.98	8.11e-05	0.0118	0.25	0.18	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
HNSC	cis	rs7178909	0.835	rs8035374	ENSG00000259677.1	RP11-493E3.1	3.98	8.11e-05	0.0118	0.21	0.18	Common traits (Other);	chr15:89851966	chr15:89876540~89877285:+
HNSC	cis	rs1131351	0.62	rs4432408	ENSG00000234378.1	AC098828.2	-3.98	8.11e-05	0.0118	-0.22	-0.18	Seasonality;	chr2:20200539	chr2:20063856~20106829:-
HNSC	cis	rs10129255	0.536	rs6576223	ENSG00000224373.3	IGHV4-59	3.98	8.11e-05	0.0118	0.11	0.18	Kawasaki disease;	chr14:106776448	chr14:106627249~106627825:-
HNSC	cis	rs10504130	0.569	rs2069119	ENSG00000253844.1	RP11-546K22.1	-3.98	8.11e-05	0.0118	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs35603537	ENSG00000253844.1	RP11-546K22.1	-3.98	8.11e-05	0.0118	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51961458~52022974:+
HNSC	cis	rs3799379	0.55	rs9467736	ENSG00000241549.7	GUSBP2	3.98	8.12e-05	0.0118	0.18	0.18	Intelligence (multi-trait analysis);	chr6:26379804	chr6:26871484~26956554:-
HNSC	cis	rs7937890	0.599	rs2597204	ENSG00000254418.1	RP11-21L19.1	3.98	8.12e-05	0.0118	0.23	0.18	Mitochondrial DNA levels;	chr11:14459471	chr11:14262846~14273691:-
HNSC	cis	rs12534093	0.67	rs13229167	ENSG00000234286.1	AC006026.13	-3.98	8.12e-05	0.0118	-0.21	-0.18	Infant length;Height;	chr7:23552243	chr7:23680195~23680786:-
HNSC	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-3.98	8.12e-05	0.0118	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
HNSC	cis	rs7819412	0.505	rs17782536	ENSG00000269918.1	AF131215.9	-3.98	8.12e-05	0.0118	-0.19	-0.18	Triglycerides;	chr8:11164172	chr8:11104691~11106704:-
HNSC	cis	rs7429990	0.965	rs35012836	ENSG00000228638.1	FCF1P2	-3.98	8.12e-05	0.0118	-0.2	-0.18	Educational attainment (years of education);	chr3:47670000	chr3:48290793~48291375:-
HNSC	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-3.98	8.13e-05	0.0118	-0.25	-0.18	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
HNSC	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	3.98	8.13e-05	0.0118	0.22	0.18	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-3.98	8.13e-05	0.0118	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
HNSC	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-3.98	8.13e-05	0.0118	-0.18	-0.18	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
HNSC	cis	rs7826238	0.502	rs10503377	ENSG00000254340.1	RP11-10A14.3	3.98	8.13e-05	0.0118	0.24	0.18	Systolic blood pressure;	chr8:8520912	chr8:9141424~9145435:+
HNSC	cis	rs2518049	0.654	rs61854739	ENSG00000224034.1	RP11-445P17.8	-3.98	8.13e-05	0.0118	-0.25	-0.18	Metabolic traits;	chr10:5200008	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.95	rs10904419	ENSG00000224034.1	RP11-445P17.8	3.98	8.13e-05	0.0118	0.24	0.18	Metabolic traits;	chr10:5102407	chr10:5266033~5271236:-
HNSC	cis	rs60617249	0.862	rs985339	ENSG00000228204.2	RP4-724E13.2	3.98	8.13e-05	0.0118	0.19	0.18	Major depression and alcohol dependence;	chr7:50927410	chr7:50866747~51022990:+
HNSC	cis	rs67981189	0.593	rs7145285	ENSG00000274818.1	RP1-292L20.3	3.98	8.13e-05	0.0118	0.2	0.18	Schizophrenia;	chr14:71094757	chr14:70906657~70907111:-
HNSC	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-3.98	8.14e-05	0.0118	-0.23	-0.18	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
HNSC	cis	rs969413	0.624	rs9914093	ENSG00000262115.1	RP11-455O6.2	-3.98	8.14e-05	0.0118	-0.18	-0.18	Frontotemporal dementia;	chr17:81286853	chr17:81197393~81200288:+
HNSC	cis	rs1620921	0.563	rs1806449	ENSG00000231863.1	RP3-428L16.1	-3.98	8.14e-05	0.0118	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160859900	chr6:160931080~160969771:+
HNSC	cis	rs7005380	0.733	rs56864850	ENSG00000279347.1	RP11-85I17.2	3.98	8.14e-05	0.0118	0.15	0.18	Interstitial lung disease;	chr8:119931204	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.785	rs55892034	ENSG00000279347.1	RP11-85I17.2	3.98	8.14e-05	0.0118	0.15	0.18	Interstitial lung disease;	chr8:119931267	chr8:119838736~119840385:-
HNSC	cis	rs2439831	0.85	rs28504496	ENSG00000201136.1	RNU6-353P	-3.98	8.14e-05	0.0118	-0.29	-0.18	Lung cancer in ever smokers;	chr15:43724685	chr15:43702363~43702470:+
HNSC	cis	rs2688482	0.512	rs3103953	ENSG00000185485.13	SDHAP1	-3.98	8.15e-05	0.0118	-0.2	-0.18	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195959748~195990318:-
HNSC	cis	rs11633886	0.585	rs11070473	ENSG00000273972.1	CTD-2306A12.1	-3.98	8.15e-05	0.0118	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45789560	chr15:45702640~45703183:+
HNSC	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-3.98	8.15e-05	0.0118	-0.2	-0.18	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
HNSC	cis	rs7587476	0.626	rs10177334	ENSG00000229267.2	AC072062.1	3.98	8.15e-05	0.0118	0.22	0.18	Neuroblastoma;	chr2:214790563	chr2:214810229~214963274:+
HNSC	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	3.98	8.15e-05	0.0118	0.23	0.18	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
HNSC	cis	rs12534093	0.67	rs11764404	ENSG00000234286.1	AC006026.13	-3.97	8.15e-05	0.0118	-0.21	-0.18	Infant length;Height;	chr7:23547541	chr7:23680195~23680786:-
HNSC	cis	rs516805	0.667	rs1456706	ENSG00000279453.1	RP3-425C14.4	-3.97	8.15e-05	0.0118	-0.25	-0.18	Lymphocyte counts;	chr6:122134801	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.667	rs2606651	ENSG00000279453.1	RP3-425C14.4	-3.97	8.15e-05	0.0118	-0.25	-0.18	Lymphocyte counts;	chr6:122136475	chr6:122436789~122439223:-
HNSC	cis	rs5758511	0.514	rs5758638	ENSG00000227370.1	RP4-669P10.19	3.97	8.16e-05	0.0118	0.21	0.18	Birth weight;	chr22:42186388	chr22:42132543~42132998:+
HNSC	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-3.97	8.16e-05	0.0118	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
HNSC	cis	rs7868228	1	rs12340629	ENSG00000240498.5	CDKN2B-AS1	-3.97	8.16e-05	0.0119	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21663530	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.945	rs12345466	ENSG00000240498.5	CDKN2B-AS1	-3.97	8.16e-05	0.0119	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21663698	chr9:21994778~22121097:+
HNSC	cis	rs7868228	1	rs11789795	ENSG00000240498.5	CDKN2B-AS1	-3.97	8.16e-05	0.0119	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21663845	chr9:21994778~22121097:+
HNSC	cis	rs7868228	1	rs11790232	ENSG00000240498.5	CDKN2B-AS1	-3.97	8.16e-05	0.0119	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21664041	chr9:21994778~22121097:+
HNSC	cis	rs7868228	1	rs10811580	ENSG00000240498.5	CDKN2B-AS1	-3.97	8.16e-05	0.0119	-0.25	-0.18	Gut microbiome composition (winter);	chr9:21664308	chr9:21994778~22121097:+
HNSC	cis	rs4073405	0.92	rs11038388	ENSG00000254651.1	RP11-430H10.3	3.97	8.16e-05	0.0119	0.23	0.18	Schizophrenia;	chr11:45298504	chr11:45399448~45400528:+
HNSC	cis	rs1065852	0.906	rs9611734	ENSG00000205702.9	CYP2D7	3.97	8.16e-05	0.0119	0.16	0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42140203~42144577:-
HNSC	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-3.97	8.16e-05	0.0119	-0.18	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000224373.3	IGHV4-59	3.97	8.16e-05	0.0119	0.11	0.18	Kawasaki disease;	chr14:106777494	chr14:106627249~106627825:-
HNSC	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-3.97	8.16e-05	0.0119	-0.22	-0.18	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
HNSC	cis	rs4713118	0.506	rs9366697	ENSG00000219392.1	RP1-265C24.5	-3.97	8.17e-05	0.0119	-0.21	-0.18	Parkinson's disease;	chr6:27665239	chr6:28115628~28116551:+
HNSC	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-3.97	8.17e-05	0.0119	-0.17	-0.18	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-3.97	8.17e-05	0.0119	-0.17	-0.18	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
HNSC	cis	rs9313772	0.722	rs17694395	ENSG00000254350.1	RP11-542A14.1	3.97	8.17e-05	0.0119	0.19	0.18	Blood pressure;	chr5:158424572	chr5:158424585~158452758:+
HNSC	cis	rs12289961	0.634	rs11229433	ENSG00000280010.1	AP001350.4	3.97	8.17e-05	0.0119	0.31	0.18	Lymphoma;	chr11:58417863	chr11:58627435~58628528:+
HNSC	cis	rs3018712	0.59	rs4930236	ENSG00000255031.4	RP11-802E16.3	-3.97	8.17e-05	0.0119	-0.2	-0.18	Total body bone mineral density;	chr11:68646532	chr11:68050740~68053762:+
HNSC	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-3.97	8.17e-05	0.0119	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
HNSC	cis	rs9329221	0.662	rs34155841	ENSG00000269918.1	AF131215.9	3.97	8.17e-05	0.0119	0.19	0.18	Neuroticism;	chr8:10390019	chr8:11104691~11106704:-
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000233609.3	RP11-62H7.2	-3.97	8.18e-05	0.0119	-0.18	-0.18	Mood instability;	chr8:8828136	chr8:8961200~8979025:+
HNSC	cis	rs6787172	0.811	rs1978779	ENSG00000272087.1	RP11-379F4.7	3.97	8.18e-05	0.0119	0.19	0.18	Subjective well-being;	chr3:158493502	chr3:158693120~158693768:-
HNSC	cis	rs8077577	0.747	rs11869582	ENSG00000260647.1	RP1-178F10.1	3.97	8.18e-05	0.0119	0.27	0.18	Obesity-related traits;	chr17:18233267	chr17:18268080~18268828:+
HNSC	cis	rs5758659	0.652	rs133340	ENSG00000227370.1	RP4-669P10.19	3.97	8.18e-05	0.0119	0.17	0.18	Cognitive function;	chr22:42021683	chr22:42132543~42132998:+
HNSC	cis	rs2098713	0.569	rs58038848	ENSG00000250155.1	CTD-2353F22.1	3.97	8.18e-05	0.0119	0.19	0.18	Telomere length;	chr5:37502860	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.535	rs4541679	ENSG00000250155.1	CTD-2353F22.1	3.97	8.18e-05	0.0119	0.19	0.18	Telomere length;	chr5:37503120	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs7707460	ENSG00000250155.1	CTD-2353F22.1	3.97	8.18e-05	0.0119	0.19	0.18	Telomere length;	chr5:37504164	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.534	rs4086257	ENSG00000250155.1	CTD-2353F22.1	3.97	8.18e-05	0.0119	0.19	0.18	Telomere length;	chr5:37504695	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.501	rs1829293	ENSG00000250155.1	CTD-2353F22.1	3.97	8.18e-05	0.0119	0.19	0.18	Telomere length;	chr5:37505469	chr5:36666214~36725195:-
HNSC	cis	rs3929778	0.848	rs6054318	ENSG00000278192.1	RP5-1056H1.2	3.97	8.18e-05	0.0119	0.24	0.18	QRS complex (Cornell);	chr20:6508786	chr20:6065966~6067897:-
HNSC	cis	rs3929778	0.883	rs6054323	ENSG00000278192.1	RP5-1056H1.2	3.97	8.18e-05	0.0119	0.24	0.18	QRS complex (Cornell);	chr20:6513615	chr20:6065966~6067897:-
HNSC	cis	rs9914544	0.505	rs59633160	ENSG00000264885.1	RP11-815I9.4	-3.97	8.19e-05	0.0119	-0.18	-0.18	Educational attainment (years of education);	chr17:18858083	chr17:18667629~18669461:-
HNSC	cis	rs13434995	0.513	rs73236153	ENSG00000273257.1	RP11-177J6.1	-3.97	8.19e-05	0.0119	-0.25	-0.18	Adiponectin levels;	chr4:55585600	chr4:55387949~55388271:+
HNSC	cis	rs12935418	0.673	rs2602428	ENSG00000278985.1	RP11-303E16.9	-3.97	8.19e-05	0.0119	-0.19	-0.18	Mean corpuscular volume;	chr16:81028566	chr16:80982319~80984094:-
HNSC	cis	rs8058578	1	rs8058578	ENSG00000279196.1	RP11-1072A3.3	3.97	8.19e-05	0.0119	0.22	0.18	Multiple myeloma;	chr16:30714927	chr16:30984630~30988270:-
HNSC	cis	rs9611565	0.58	rs5758449	ENSG00000233903.2	Z83851.4	3.97	8.19e-05	0.0119	0.25	0.18	Vitiligo;	chr22:41744156	chr22:42276355~42277052:+
HNSC	cis	rs7107174	1	rs2512550	ENSG00000251323.2	RP11-452H21.4	3.97	8.2e-05	0.0119	0.26	0.18	Testicular germ cell tumor;	chr11:78232802	chr11:78423982~78429836:-
HNSC	cis	rs2280018	1	rs2280017	ENSG00000263335.1	AF001548.5	3.97	8.2e-05	0.0119	0.23	0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15726674~15732993:+
HNSC	cis	rs7577696	0.962	rs11124275	ENSG00000272716.1	RP11-563N4.1	-3.97	8.2e-05	0.0119	-0.18	-0.18	Inflammatory biomarkers;	chr2:32078693	chr2:32165046~32165757:-
HNSC	cis	rs7577696	0.925	rs11683931	ENSG00000272716.1	RP11-563N4.1	-3.97	8.2e-05	0.0119	-0.18	-0.18	Inflammatory biomarkers;	chr2:32078999	chr2:32165046~32165757:-
HNSC	cis	rs10504130	0.569	rs10958305	ENSG00000253844.1	RP11-546K22.1	-3.97	8.2e-05	0.0119	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51961458~52022974:+
HNSC	cis	rs10504130	0.569	rs11784869	ENSG00000253844.1	RP11-546K22.1	-3.97	8.2e-05	0.0119	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51961458~52022974:+
HNSC	cis	rs4388249	1	rs2284990	ENSG00000271849.1	CTC-332L22.1	-3.97	8.2e-05	0.0119	-0.28	-0.18	Schizophrenia;	chr5:109743666	chr5:109687802~109688329:-
HNSC	cis	rs7829975	0.502	rs11785183	ENSG00000254340.1	RP11-10A14.3	-3.97	8.2e-05	0.0119	-0.24	-0.18	Mood instability;	chr8:8708447	chr8:9141424~9145435:+
HNSC	cis	rs9313772	0.775	rs7714739	ENSG00000254350.1	RP11-542A14.1	-3.97	8.2e-05	0.0119	-0.2	-0.18	Blood pressure;	chr5:158396949	chr5:158424585~158452758:+
HNSC	cis	rs11992162	0.597	rs7016320	ENSG00000227888.4	FAM66A	-3.97	8.2e-05	0.0119	-0.18	-0.18	Monocyte count;	chr8:11923543	chr8:12362019~12388296:+
HNSC	cis	rs2645424	1	rs962366	ENSG00000255046.1	RP11-297N6.4	3.97	8.2e-05	0.0119	0.18	0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr8:11797928~11802568:-
HNSC	cis	rs17076726	0.519	rs2561748	ENSG00000253785.1	CTC-308K20.3	-3.97	8.2e-05	0.0119	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173886009	chr5:172975511~172976374:+
HNSC	cis	rs7027203	0.521	rs9299412	ENSG00000227603.1	RP11-165J3.6	-3.97	8.21e-05	0.0119	-0.16	-0.18	DNA methylation (variation);	chr9:93760986	chr9:93435332~93437121:-
HNSC	cis	rs7824557	0.564	rs2572386	ENSG00000255310.2	AF131215.2	-3.97	8.21e-05	0.0119	-0.17	-0.18	Retinal vascular caliber;	chr8:11379466	chr8:11107788~11109726:-
HNSC	cis	rs1799949	1	rs4793231	ENSG00000236383.6	LINC00854	-3.97	8.21e-05	0.0119	-0.17	-0.18	Menopause (age at onset);	chr17:43350101	chr17:43216941~43305976:-
HNSC	cis	rs71520386	0.846	rs61997069	ENSG00000221740.1	SNORD93	-3.97	8.21e-05	0.0119	-0.24	-0.18	Fibrinogen levels;	chr7:22773966	chr7:22856613~22856686:+
HNSC	cis	rs4356203	0.905	rs7107283	ENSG00000260196.1	RP1-239B22.5	3.97	8.21e-05	0.0119	0.19	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17380649~17383531:+
HNSC	cis	rs4321325	0.668	rs56346774	ENSG00000236682.1	AC068282.3	-3.97	8.21e-05	0.0119	-0.32	-0.18	Protein C levels;	chr2:127174975	chr2:127389130~127400580:+
HNSC	cis	rs1620921	0.565	rs28544460	ENSG00000231863.1	RP3-428L16.1	-3.97	8.21e-05	0.0119	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850745	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.537	rs28655734	ENSG00000231863.1	RP3-428L16.1	-3.97	8.21e-05	0.0119	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850751	chr6:160931080~160969771:+
HNSC	cis	rs1559040	1	rs10176406	ENSG00000272156.1	RP11-477N3.1	-3.97	8.21e-05	0.0119	-0.31	-0.18	Sudden cardiac arrest;	chr2:54106211	chr2:54082554~54085066:+
HNSC	cis	rs7615952	0.609	rs13088451	ENSG00000241278.1	ENPP7P4	-3.97	8.21e-05	0.0119	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125834656	chr3:125848223~125909372:+
HNSC	cis	rs11673344	0.543	rs1818748	ENSG00000276846.1	CTD-3220F14.3	3.97	8.21e-05	0.0119	0.2	0.18	Obesity-related traits;	chr19:37065416	chr19:37314868~37315620:-
HNSC	cis	rs6651255	0.657	rs4733738	ENSG00000224110.3	MTRF1LP2	-3.97	8.21e-05	0.0119	-0.2	-0.18	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129747753	chr8:129728744~129730445:+
HNSC	cis	rs1538970	0.774	rs67683090	ENSG00000234329.1	RP11-767N6.2	3.97	8.22e-05	0.0119	0.21	0.18	Platelet count;	chr1:45512131	chr1:45651039~45651826:-
HNSC	cis	rs67981189	0.593	rs8008111	ENSG00000274818.1	RP1-292L20.3	3.97	8.22e-05	0.0119	0.2	0.18	Schizophrenia;	chr14:71064529	chr14:70906657~70907111:-
HNSC	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-3.97	8.22e-05	0.0119	-0.23	-0.18	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
HNSC	cis	rs73607972	0.935	rs73605911	ENSG00000275191.1	RP11-36I17.2	-3.97	8.22e-05	0.0119	-0.27	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53597184	chr16:53628256~53628816:-
HNSC	cis	rs6964587	0.692	rs10271430	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.22e-05	0.0119	-0.19	-0.18	Breast cancer;	chr7:92081152	chr7:92134604~92180725:+
HNSC	cis	rs55823223	0.648	rs11867560	ENSG00000267801.1	RP11-552F3.9	3.97	8.22e-05	0.0119	0.22	0.18	Psoriasis;	chr17:75861125	chr17:75876372~75879546:+
HNSC	cis	rs55823223	0.648	rs11867582	ENSG00000267801.1	RP11-552F3.9	3.97	8.22e-05	0.0119	0.22	0.18	Psoriasis;	chr17:75861225	chr17:75876372~75879546:+
HNSC	cis	rs4253772	0.591	rs6007740	ENSG00000277232.2	GTSE1-AS1	3.97	8.22e-05	0.0119	0.22	0.18	Cholesterol, total;LDL cholesterol;	chr22:46258426	chr22:46295143~46296660:-
HNSC	cis	rs7646881	0.544	rs2291594	ENSG00000272087.1	RP11-379F4.7	3.97	8.22e-05	0.0119	0.26	0.18	Tetralogy of Fallot;	chr3:158661047	chr3:158693120~158693768:-
HNSC	cis	rs3015469	0.51	rs8009295	ENSG00000269906.1	RP11-248J18.2	-3.97	8.22e-05	0.0119	-0.22	-0.18	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50531065	chr14:50662511~50663178:-
HNSC	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-3.97	8.22e-05	0.0119	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-3.97	8.22e-05	0.0119	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-3.97	8.22e-05	0.0119	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
HNSC	cis	rs1316952	0.665	rs79657287	ENSG00000269938.1	RP11-214K3.20	-3.97	8.22e-05	0.0119	-0.38	-0.18	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:124009981	chr12:123968023~123968579:-
HNSC	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-3.97	8.22e-05	0.0119	-0.21	-0.18	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-3.97	8.22e-05	0.0119	-0.21	-0.18	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
HNSC	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-3.97	8.22e-05	0.0119	-0.13	-0.18	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
HNSC	cis	rs7011507	0.594	rs72639023	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48430984	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs72639024	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48431018	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs72639025	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48431574	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs55656120	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48432697	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs72639027	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48434070	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs56054674	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48435628	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs72639028	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48437205	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs56308602	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48437956	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.594	rs72639030	ENSG00000253608.1	RP11-770E5.1	-3.97	8.22e-05	0.0119	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48438854	chr8:48551567~48698510:+
HNSC	cis	rs9329221	0.543	rs2952205	ENSG00000269918.1	AF131215.9	3.97	8.23e-05	0.0119	0.18	0.18	Neuroticism;	chr8:10282355	chr8:11104691~11106704:-
HNSC	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-3.97	8.23e-05	0.0119	-0.27	-0.18	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
HNSC	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-3.97	8.23e-05	0.0119	-0.27	-0.18	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
HNSC	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-3.97	8.23e-05	0.0119	-0.27	-0.18	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
HNSC	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-3.97	8.23e-05	0.0119	-0.27	-0.18	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
HNSC	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	3.97	8.23e-05	0.0119	0.26	0.18	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
HNSC	cis	rs60617249	0.895	rs34522932	ENSG00000228204.2	RP4-724E13.2	3.97	8.23e-05	0.0119	0.19	0.18	Major depression and alcohol dependence;	chr7:50929294	chr7:50866747~51022990:+
HNSC	cis	rs1994321	0.657	rs11022142	ENSG00000254991.1	RP13-631K18.3	-3.97	8.23e-05	0.0119	-0.21	-0.18	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12062256	chr11:12066929~12073014:+
HNSC	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	3.97	8.23e-05	0.0119	0.25	0.18	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
HNSC	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	3.97	8.23e-05	0.0119	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
HNSC	cis	rs6500395	1	rs6500397	ENSG00000261267.1	RP11-44I10.3	-3.97	8.23e-05	0.0119	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48608324	chr16:48559661~48587403:+
HNSC	cis	rs34792	0.637	rs34793	ENSG00000207425.1	Y_RNA	3.97	8.23e-05	0.0119	0.21	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:14915457~14915556:-
HNSC	cis	rs4879656	0.741	rs10758183	ENSG00000225693.1	LAGE3P1	3.97	8.24e-05	0.012	0.2	0.18	Menopause (age at onset);	chr9:33055473	chr9:33019682~33020165:-
HNSC	cis	rs72627123	0.5	rs68148895	ENSG00000259065.1	RP5-1021I20.1	-3.97	8.24e-05	0.012	-0.25	-0.18	Morning vs. evening chronotype;	chr14:74062820	chr14:73787360~73803270:+
HNSC	cis	rs10938353	0.911	rs1583729	ENSG00000273369.1	RP11-700J17.1	3.97	8.24e-05	0.012	0.22	0.18	Body mass index;	chr4:44583904	chr4:44693946~44694386:-
HNSC	cis	rs7772486	0.84	rs2814864	ENSG00000235652.6	RP11-545I5.3	3.97	8.24e-05	0.012	0.19	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145799409~145886585:+
HNSC	cis	rs7615952	0.546	rs11717632	ENSG00000241288.6	RP11-379B18.5	-3.97	8.24e-05	0.012	-0.28	-0.18	Blood pressure (smoking interaction);	chr3:125602286	chr3:125827238~125916384:-
HNSC	cis	rs7824557	0.602	rs7834139	ENSG00000255310.2	AF131215.2	3.97	8.25e-05	0.012	0.17	0.18	Retinal vascular caliber;	chr8:11348854	chr8:11107788~11109726:-
HNSC	cis	rs3785309	0.519	rs111739409	ENSG00000268836.1	LA16c-OS12.2	-3.97	8.25e-05	0.012	-0.33	-0.18	Immature fraction of reticulocytes;	chr16:233956	chr16:185748~186294:-
HNSC	cis	rs10129255	0.518	rs8009594	ENSG00000211976.2	IGHV3-73	-3.97	8.25e-05	0.012	-0.13	-0.18	Kawasaki disease;	chr14:106777494	chr14:106802694~106803233:-
HNSC	cis	rs34286592	1	rs13332078	ENSG00000196796.5	CTB-134H23.2	3.97	8.25e-05	0.012	0.26	0.18	Multiple sclerosis;	chr16:29839384	chr16:29038655~29052726:+
HNSC	cis	rs6142618	0.935	rs6061183	ENSG00000275576.1	RP5-836N17.4	-3.97	8.25e-05	0.012	-0.18	-0.18	Inflammatory bowel disease;	chr20:32140133	chr20:32116171~32116629:+
HNSC	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	3.97	8.26e-05	0.012	0.25	0.18	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
HNSC	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	3.97	8.26e-05	0.012	0.25	0.18	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
HNSC	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	3.97	8.26e-05	0.012	0.25	0.18	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
HNSC	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	3.97	8.26e-05	0.012	0.25	0.18	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
HNSC	cis	rs795484	0.926	rs191626	ENSG00000275409.1	RP11-131L12.4	-3.97	8.26e-05	0.012	-0.21	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191665	chr12:118430147~118430699:+
HNSC	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-3.97	8.26e-05	0.012	-0.24	-0.18	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
HNSC	cis	rs12468579	0.503	rs3088307	ENSG00000235852.1	AC005540.3	-3.97	8.26e-05	0.012	-0.2	-0.18	JT interval (sulfonylurea treatment interaction);	chr2:190964686	chr2:190880797~190882059:-
HNSC	cis	rs13325613	0.834	rs6765904	ENSG00000223552.1	RP11-24F11.2	-3.97	8.26e-05	0.012	-0.29	-0.18	Monocyte count;	chr3:46154389	chr3:46364955~46407059:-
HNSC	cis	rs12545912	0.569	rs509820	ENSG00000254340.1	RP11-10A14.3	-3.97	8.26e-05	0.012	-0.29	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9936583	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.525	rs582491	ENSG00000254340.1	RP11-10A14.3	-3.97	8.26e-05	0.012	-0.29	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9936593	chr8:9141424~9145435:+
HNSC	cis	rs4523957	0.855	rs12601834	ENSG00000262333.1	HNRNPA1P16	3.97	8.26e-05	0.012	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2209137	chr17:2306761~2307715:+
HNSC	cis	rs4713118	0.739	rs2893931	ENSG00000216901.1	AL022393.7	3.97	8.26e-05	0.012	0.23	0.18	Parkinson's disease;	chr6:27780231	chr6:28176188~28176674:+
HNSC	cis	rs17818399	0.547	rs7607633	ENSG00000279254.1	RP11-536C12.1	-3.97	8.26e-05	0.012	-0.22	-0.18	Height;	chr2:46532288	chr2:46668870~46670778:+
HNSC	cis	rs9611565	0.765	rs132909	ENSG00000235513.1	RP4-756G23.5	-3.97	8.26e-05	0.012	-0.21	-0.18	Vitiligo;	chr22:41406027	chr22:41209122~41217627:-
HNSC	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-3.97	8.27e-05	0.012	-0.19	-0.18	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	3.97	8.27e-05	0.012	0.21	0.18	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
HNSC	cis	rs17818399	0.547	rs4952831	ENSG00000279254.1	RP11-536C12.1	-3.97	8.27e-05	0.012	-0.22	-0.18	Height;	chr2:46534042	chr2:46668870~46670778:+
HNSC	cis	rs7824557	0.583	rs2263512	ENSG00000269918.1	AF131215.9	-3.97	8.27e-05	0.012	-0.17	-0.18	Retinal vascular caliber;	chr8:11375910	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.583	rs6601585	ENSG00000269918.1	AF131215.9	-3.97	8.27e-05	0.012	-0.17	-0.18	Retinal vascular caliber;	chr8:11376150	chr8:11104691~11106704:-
HNSC	cis	rs116095464	0.614	rs28736753	ENSG00000277812.1	AC021087.1	3.97	8.27e-05	0.012	0.31	0.18	Breast cancer;	chr5:273966	chr5:262769~262881:+
HNSC	cis	rs9531006	0.636	rs9593421	ENSG00000227676.3	LINC01068	-3.97	8.27e-05	0.012	-0.26	-0.18	Sleep duration;	chr13:79915151	chr13:79566727~79571436:+
HNSC	cis	rs2074409	0.509	rs2411157	ENSG00000276054.1	RP11-378E13.3	3.97	8.27e-05	0.012	0.2	0.18	Response to angiotensin II receptor blocker therapy;	chr17:37424298	chr17:37386886~37387926:+
HNSC	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	3.97	8.27e-05	0.012	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
HNSC	cis	rs78366141	0.536	rs76432068	ENSG00000248019.2	FAM13A-AS1	-3.97	8.27e-05	0.012	-0.3	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88703068	chr4:88709789~88730103:+
HNSC	cis	rs11976180	1	rs2961119	ENSG00000244479.5	OR2A1-AS1	3.97	8.27e-05	0.012	0.21	0.18	Obesity-related traits;	chr7:144058759	chr7:144251264~144356181:-
HNSC	cis	rs870825	0.79	rs12513128	ENSG00000254233.1	RP11-242J7.1	3.97	8.27e-05	0.012	0.31	0.18	Blood protein levels;	chr4:184655575	chr4:184584093~184625030:-
HNSC	cis	rs8031584	0.678	rs4779790	ENSG00000270015.1	RP11-540B6.6	-3.97	8.27e-05	0.012	-0.19	-0.18	Huntington's disease progression;	chr15:30872392	chr15:30926514~30928407:+
HNSC	cis	rs9467773	0.595	rs2237236	ENSG00000241549.7	GUSBP2	3.97	8.27e-05	0.012	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26451325	chr6:26871484~26956554:-
HNSC	cis	rs801193	1	rs2659912	ENSG00000272831.1	RP11-792A8.4	3.97	8.28e-05	0.012	0.15	0.18	Aortic root size;	chr7:66693012	chr7:66739829~66740385:-
HNSC	cis	rs72627123	0.737	rs2240632	ENSG00000259065.1	RP5-1021I20.1	-3.97	8.28e-05	0.012	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73904463	chr14:73787360~73803270:+
HNSC	cis	rs9990333	1	rs9990333	ENSG00000231464.1	AC024937.4	-3.97	8.28e-05	0.012	-0.19	-0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195996738~195998233:+
HNSC	cis	rs7561149	0.646	rs6433735	ENSG00000270574.1	RP11-171I2.2	-3.97	8.28e-05	0.012	-0.22	-0.18	QT interval;	chr2:178825506	chr2:178578790~178580906:+
HNSC	cis	rs1555322	1	rs2425041	ENSG00000126005.14	MMP24-AS1	-3.97	8.28e-05	0.012	-0.34	-0.18	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35216462~35278131:-
HNSC	cis	rs11148252	0.904	rs7990581	ENSG00000198384.8	TPTE2P3	3.97	8.28e-05	0.012	0.22	0.18	Lewy body disease;	chr13:52445298	chr13:52522632~52586906:+
HNSC	cis	rs35000415	0.566	rs34644138	ENSG00000275106.1	RP11-309L24.10	-3.97	8.29e-05	0.012	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129080913	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.566	rs35144535	ENSG00000275106.1	RP11-309L24.10	-3.97	8.29e-05	0.012	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129081723	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.638	rs77508372	ENSG00000275106.1	RP11-309L24.10	-3.97	8.29e-05	0.012	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129081743	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.683	rs66872377	ENSG00000275106.1	RP11-309L24.10	-3.97	8.29e-05	0.012	-0.38	-0.18	Systemic lupus erythematosus;	chr7:129082118	chr7:128952527~128953316:-
HNSC	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	3.97	8.29e-05	0.012	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
HNSC	cis	rs13256369	1	rs10098234	ENSG00000173295.6	FAM86B3P	3.97	8.29e-05	0.012	0.23	0.18	Obesity-related traits;	chr8:8719182	chr8:8228595~8244865:+
HNSC	cis	rs6601327	0.67	rs10092751	ENSG00000254340.1	RP11-10A14.3	3.97	8.29e-05	0.012	0.22	0.18	Multiple myeloma (hyperdiploidy);	chr8:9568815	chr8:9141424~9145435:+
HNSC	cis	rs6995541	0.647	rs6984388	ENSG00000269918.1	AF131215.9	-3.97	8.29e-05	0.012	-0.19	-0.18	Triglyceride levels;	chr8:10828159	chr8:11104691~11106704:-
HNSC	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-3.97	8.29e-05	0.012	-0.13	-0.18	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
HNSC	cis	rs2877187	0.557	rs7455870	ENSG00000232006.7	AC005537.2	-3.97	8.29e-05	0.012	-0.21	-0.18	Lung cancer in ever smokers;	chr7:43030177	chr7:42954135~43113931:-
HNSC	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-3.97	8.3e-05	0.012	-0.14	-0.18	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
HNSC	cis	rs9880211	1	rs6774964	ENSG00000239213.4	NCK1-AS1	3.97	8.3e-05	0.012	0.18	0.18	Height;Body mass index;	chr3:136556740	chr3:136841726~136862054:-
HNSC	cis	rs9880211	1	rs6775314	ENSG00000239213.4	NCK1-AS1	3.97	8.3e-05	0.012	0.18	0.18	Height;Body mass index;	chr3:136557106	chr3:136841726~136862054:-
HNSC	cis	rs11168618	1	rs10875833	ENSG00000240399.1	RP1-228P16.1	3.97	8.3e-05	0.012	0.15	0.18	Adiponectin levels;	chr12:48559585	chr12:48054813~48055591:-
HNSC	cis	rs11168618	1	rs11168637	ENSG00000240399.1	RP1-228P16.1	3.97	8.3e-05	0.012	0.15	0.18	Adiponectin levels;	chr12:48559721	chr12:48054813~48055591:-
HNSC	cis	rs889398	0.967	rs12599391	ENSG00000226232.7	RP11-419C5.2	-3.97	8.31e-05	0.012	-0.16	-0.18	Body mass index;	chr16:69571446	chr16:69976388~69996188:-
HNSC	cis	rs3018712	0.547	rs4930237	ENSG00000255031.4	RP11-802E16.3	-3.97	8.31e-05	0.012	-0.2	-0.18	Total body bone mineral density;	chr11:68646570	chr11:68050740~68053762:+
HNSC	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-3.97	8.31e-05	0.012	-0.23	-0.18	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
HNSC	cis	rs12745968	0.623	rs10874732	ENSG00000223787.2	RP4-593M8.1	-3.97	8.31e-05	0.012	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92658002	chr1:92580476~92580821:-
HNSC	cis	rs4908760	0.827	rs7556169	ENSG00000232912.4	RP5-1115A15.1	-3.97	8.31e-05	0.012	-0.19	-0.18	Vitiligo;	chr1:8681342	chr1:8424645~8434838:+
HNSC	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	3.97	8.31e-05	0.012	0.29	0.18	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000211976.2	IGHV3-73	-3.97	8.32e-05	0.012	-0.13	-0.18	Kawasaki disease;	chr14:106777510	chr14:106802694~106803233:-
HNSC	cis	rs7781557	1	rs2041094	ENSG00000239969.4	RP11-163E9.2	-3.97	8.32e-05	0.012	-0.26	-0.18	Colorectal adenoma (advanced);	chr7:102854987	chr7:102364162~102380633:+
HNSC	cis	rs9910055	0.54	rs609292	ENSG00000267080.4	ASB16-AS1	3.97	8.32e-05	0.0121	0.15	0.18	Total body bone mineral density;	chr17:44103068	chr17:44175973~44186717:-
HNSC	cis	rs4924935	0.748	rs9915894	ENSG00000264885.1	RP11-815I9.4	-3.97	8.32e-05	0.0121	-0.24	-0.18	Pancreatic cancer;	chr17:18849465	chr17:18667629~18669461:-
HNSC	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-3.97	8.32e-05	0.0121	-0.22	-0.18	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
HNSC	cis	rs561341	0.882	rs28649357	ENSG00000278867.1	RP11-640N20.4	-3.97	8.32e-05	0.0121	-0.22	-0.18	Hip circumference adjusted for BMI;	chr17:32040171	chr17:32051030~32053208:+
HNSC	cis	rs6860540	0.796	rs6861100	ENSG00000251405.2	CTB-109A12.1	-3.97	8.32e-05	0.0121	-0.2	-0.18	Inflammatory skin disease;	chr5:157504344	chr5:157362615~157460078:-
HNSC	cis	rs67311347	1	rs17078511	ENSG00000280739.1	EIF1B-AS1	3.97	8.32e-05	0.0121	0.2	0.18	Renal cell carcinoma;	chr3:40354763	chr3:40173145~40309698:-
HNSC	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	3.97	8.32e-05	0.0121	0.21	0.18	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
HNSC	cis	rs11089937	0.616	rs1076851	ENSG00000211639.2	IGLV4-60	3.97	8.33e-05	0.0121	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22177442	chr22:22162199~22162681:+
HNSC	cis	rs7572733	0.534	rs1435568	ENSG00000231621.1	AC013264.2	-3.97	8.33e-05	0.0121	-0.17	-0.18	Dermatomyositis;	chr2:197898155	chr2:197197991~197199273:+
HNSC	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-3.97	8.33e-05	0.0121	-0.23	-0.18	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
HNSC	cis	rs1559040	0.858	rs10192403	ENSG00000272156.1	RP11-477N3.1	-3.97	8.33e-05	0.0121	-0.31	-0.18	Sudden cardiac arrest;	chr2:54086370	chr2:54082554~54085066:+
HNSC	cis	rs1559040	0.932	rs10205315	ENSG00000272156.1	RP11-477N3.1	-3.97	8.33e-05	0.0121	-0.31	-0.18	Sudden cardiac arrest;	chr2:54086864	chr2:54082554~54085066:+
HNSC	cis	rs62025270	0.632	rs7177107	ENSG00000259762.1	RP11-158M2.4	-3.97	8.33e-05	0.0121	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85750336~85752901:-
HNSC	cis	rs1799949	0.931	rs9912203	ENSG00000236383.6	LINC00854	3.97	8.33e-05	0.0121	0.17	0.18	Menopause (age at onset);	chr17:43367777	chr17:43216941~43305976:-
HNSC	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	3.97	8.34e-05	0.0121	0.48	0.18	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
HNSC	cis	rs7224668	0.647	rs8070549	ENSG00000280407.2	RP13-516M14.8	3.97	8.34e-05	0.0121	0.15	0.18	IgG glycosylation;	chr17:81273299	chr17:82249067~82251844:+
HNSC	cis	rs2304003	1	rs12473573	ENSG00000235192.1	AC009495.2	3.97	8.34e-05	0.0121	0.24	0.18	Social communication problems;	chr2:165832382	chr2:165794851~165810010:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000233609.3	RP11-62H7.2	-3.97	8.34e-05	0.0121	-0.17	-0.18	Joint mobility (Beighton score);	chr8:9225923	chr8:8961200~8979025:+
HNSC	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-3.97	8.34e-05	0.0121	-0.31	-0.18	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
HNSC	cis	rs6543140	0.964	rs4851593	ENSG00000234389.1	AC007278.3	-3.97	8.35e-05	0.0121	-0.19	-0.18	Blood protein levels;	chr2:102472767	chr2:102438713~102440475:+
HNSC	cis	rs2028299	0.881	rs11629791	ENSG00000259677.1	RP11-493E3.1	3.97	8.35e-05	0.0121	0.22	0.18	Type 2 diabetes;	chr15:89905903	chr15:89876540~89877285:+
HNSC	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-3.97	8.35e-05	0.0121	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
HNSC	cis	rs58873874	0.579	rs80253028	ENSG00000251405.2	CTB-109A12.1	3.97	8.35e-05	0.0121	0.34	0.18	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157362615~157460078:-
HNSC	cis	rs11098499	0.754	rs9999724	ENSG00000250412.1	KLHL2P1	3.97	8.35e-05	0.0121	0.23	0.18	Corneal astigmatism;	chr4:119318789	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs714899	ENSG00000250412.1	KLHL2P1	3.97	8.35e-05	0.0121	0.23	0.18	Corneal astigmatism;	chr4:119321880	chr4:119334329~119378233:+
HNSC	cis	rs7911264	0.765	rs7092522	ENSG00000232709.1	MARK2P9	-3.97	8.35e-05	0.0121	-0.21	-0.18	Inflammatory bowel disease;	chr10:92583226	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.765	rs2421941	ENSG00000232709.1	MARK2P9	-3.97	8.35e-05	0.0121	-0.21	-0.18	Inflammatory bowel disease;	chr10:92586152	chr10:92418667~92420875:+
HNSC	cis	rs720475	0.732	rs7784282	ENSG00000170356.8	OR2A20P	3.97	8.35e-05	0.0121	0.25	0.18	Breast cancer;	chr7:144431561	chr7:144250045~144252957:-
HNSC	cis	rs889398	0.677	rs68161338	ENSG00000226232.7	RP11-419C5.2	3.97	8.36e-05	0.0121	0.16	0.18	Body mass index;	chr16:69789875	chr16:69976388~69996188:-
HNSC	cis	rs4646450	0.838	rs10229569	ENSG00000244219.5	GS1-259H13.2	-3.97	8.36e-05	0.0121	-0.28	-0.18	Blood metabolite levels;	chr7:99586081	chr7:99598066~99610813:+
HNSC	cis	rs67981189	0.593	rs9806042	ENSG00000274818.1	RP1-292L20.3	3.97	8.36e-05	0.0121	0.2	0.18	Schizophrenia;	chr14:71064276	chr14:70906657~70907111:-
HNSC	cis	rs4489787	1	rs2705126	ENSG00000257763.1	OR5BK1P	3.97	8.36e-05	0.0121	0.29	0.18	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48355792~48356614:-
HNSC	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	3.97	8.36e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	3.97	8.36e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	3.97	8.36e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
HNSC	cis	rs1555322	1	rs2425032	ENSG00000279253.1	RP4-614O4.13	-3.97	8.36e-05	0.0121	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35262727~35264187:-
HNSC	cis	rs6890684	0.503	rs256377	ENSG00000215032.2	GNL3LP1	3.97	8.36e-05	0.0121	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61210447	chr5:60891935~60893577:-
HNSC	cis	rs35306767	0.668	rs12356612	ENSG00000229869.1	RP11-363N22.2	-3.97	8.36e-05	0.0121	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1009115	chr10:933026~942743:+
HNSC	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-3.97	8.36e-05	0.0121	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
HNSC	cis	rs12745968	0.589	rs3936945	ENSG00000223787.2	RP4-593M8.1	-3.97	8.36e-05	0.0121	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92641314	chr1:92580476~92580821:-
HNSC	cis	rs7781557	1	rs11496066	ENSG00000239969.4	RP11-163E9.2	-3.97	8.37e-05	0.0121	-0.26	-0.18	Colorectal adenoma (advanced);	chr7:102845807	chr7:102364162~102380633:+
HNSC	cis	rs11098499	0.818	rs55825515	ENSG00000250412.1	KLHL2P1	3.97	8.37e-05	0.0121	0.24	0.18	Corneal astigmatism;	chr4:119565247	chr4:119334329~119378233:+
HNSC	cis	rs4853525	0.62	rs6718902	ENSG00000228509.4	AC006460.2	-3.97	8.37e-05	0.0121	-0.25	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190973478	chr2:190676944~190708716:-
HNSC	cis	rs7572733	0.555	rs6729473	ENSG00000231621.1	AC013264.2	-3.97	8.37e-05	0.0121	-0.17	-0.18	Dermatomyositis;	chr2:197899204	chr2:197197991~197199273:+
HNSC	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-3.97	8.37e-05	0.0121	-0.24	-0.18	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
HNSC	cis	rs859767	0.704	rs7558554	ENSG00000224043.6	CCNT2-AS1	-3.97	8.37e-05	0.0121	-0.22	-0.18	Neuroticism;	chr2:134599633	chr2:134735464~134918710:-
HNSC	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	3.97	8.38e-05	0.0121	0.2	0.18	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
HNSC	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	3.97	8.38e-05	0.0121	0.19	0.18	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
HNSC	cis	rs17076726	0.5	rs28391057	ENSG00000253785.1	CTC-308K20.3	-3.97	8.38e-05	0.0121	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173946329	chr5:172975511~172976374:+
HNSC	cis	rs17076726	0.519	rs9313662	ENSG00000253785.1	CTC-308K20.3	-3.97	8.38e-05	0.0121	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173947458	chr5:172975511~172976374:+
HNSC	cis	rs9910055	0.529	rs2523161	ENSG00000267080.4	ASB16-AS1	3.97	8.38e-05	0.0121	0.15	0.18	Total body bone mineral density;	chr17:44102037	chr17:44175973~44186717:-
HNSC	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-3.97	8.39e-05	0.0121	-0.18	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
HNSC	cis	rs889398	0.935	rs244420	ENSG00000226232.7	RP11-419C5.2	3.97	8.39e-05	0.0121	0.16	0.18	Body mass index;	chr16:69624093	chr16:69976388~69996188:-
HNSC	cis	rs7572733	0.534	rs700674	ENSG00000231621.1	AC013264.2	-3.97	8.39e-05	0.0121	-0.17	-0.18	Dermatomyositis;	chr2:197828979	chr2:197197991~197199273:+
HNSC	cis	rs7475343	0.501	rs78686304	ENSG00000224034.1	RP11-445P17.8	-3.97	8.39e-05	0.0121	-0.25	-0.18	Intelligence;	chr10:5215834	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.501	rs7912751	ENSG00000224034.1	RP11-445P17.8	-3.97	8.39e-05	0.0121	-0.25	-0.18	Intelligence;	chr10:5215978	chr10:5266033~5271236:-
HNSC	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	3.97	8.39e-05	0.0121	0.22	0.18	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
HNSC	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	3.97	8.39e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	3.97	8.39e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	3.97	8.39e-05	0.0121	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
HNSC	cis	rs17772222	0.917	rs58550317	ENSG00000258789.1	RP11-507K2.3	-3.97	8.39e-05	0.0121	-0.22	-0.18	Coronary artery calcification;	chr14:88775243	chr14:88551597~88552493:+
HNSC	cis	rs72827839	0.779	rs57583172	ENSG00000244649.3	CTD-2377D24.6	-3.97	8.39e-05	0.0121	-0.24	-0.18	Ease of getting up in the morning;	chr17:48404601	chr17:48646923~48707346:+
HNSC	cis	rs7716219	0.58	rs1396611	ENSG00000251307.1	RP11-506H20.1	3.97	8.39e-05	0.0121	0.19	0.18	Height;	chr5:55582943	chr5:55233934~55295201:+
HNSC	cis	rs3096299	0.933	rs2930219	ENSG00000224888.4	RP5-1142A6.2	3.97	8.4e-05	0.0121	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:88731180~88741425:+
HNSC	cis	rs5758659	1	rs134869	ENSG00000273366.1	CTA-989H11.1	-3.97	8.4e-05	0.0121	-0.21	-0.18	Cognitive function;	chr22:42256068	chr22:42278188~42278846:+
HNSC	cis	rs6460942	0.597	rs17448913	ENSG00000226690.5	AC005281.1	3.97	8.4e-05	0.0121	0.28	0.18	Coronary artery disease;	chr7:12494358	chr7:12496429~12541910:+
HNSC	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	3.97	8.4e-05	0.0121	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
HNSC	cis	rs73198271	0.562	rs35432123	ENSG00000253893.2	FAM85B	3.97	8.4e-05	0.0121	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8813508	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.531	rs112930476	ENSG00000253893.2	FAM85B	3.97	8.4e-05	0.0121	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8814041	chr8:8167819~8226614:-
HNSC	cis	rs67981189	0.593	rs2240531	ENSG00000274818.1	RP1-292L20.3	3.97	8.4e-05	0.0121	0.2	0.18	Schizophrenia;	chr14:71086889	chr14:70906657~70907111:-
HNSC	cis	rs4699052	0.662	rs1400363	ENSG00000246560.2	RP11-10L12.4	3.97	8.4e-05	0.0121	0.21	0.18	Testicular germ cell tumor;	chr4:103329565	chr4:102828055~102844075:+
HNSC	cis	rs4388249	0.651	rs31607	ENSG00000271849.1	CTC-332L22.1	3.97	8.4e-05	0.0122	0.29	0.18	Schizophrenia;	chr5:109663965	chr5:109687802~109688329:-
HNSC	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	3.97	8.4e-05	0.0122	0.25	0.18	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
HNSC	cis	rs354225	0.546	rs10170646	ENSG00000237887.1	AC092839.1	-3.97	8.4e-05	0.0122	-0.2	-0.18	Schizophrenia;	chr2:54572469	chr2:54529343~54529801:+
HNSC	cis	rs62458065	0.85	rs62458066	ENSG00000226468.2	AC018641.7	3.97	8.41e-05	0.0122	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32456963~32457758:-
HNSC	cis	rs597480	0.963	rs290174	ENSG00000279742.1	RP11-700A24.1	-3.97	8.41e-05	0.0122	-0.2	-0.18	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85696896	chr11:85852557~85854943:-
HNSC	cis	rs10129255	0.556	rs6576222	ENSG00000211976.2	IGHV3-73	-3.97	8.41e-05	0.0122	-0.13	-0.18	Kawasaki disease;	chr14:106776442	chr14:106802694~106803233:-
HNSC	cis	rs4713118	0.505	rs276371	ENSG00000217862.2	HIST1H4PS1	-3.97	8.41e-05	0.0122	-0.19	-0.18	Parkinson's disease;	chr6:27942930	chr6:27807075~27807339:+
HNSC	cis	rs10129255	0.5	rs7157975	ENSG00000211976.2	IGHV3-73	-3.97	8.41e-05	0.0122	-0.13	-0.18	Kawasaki disease;	chr14:106804049	chr14:106802694~106803233:-
HNSC	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	3.97	8.41e-05	0.0122	0.21	0.18	Height;	chr14:75148524	chr14:75011269~75012851:-
HNSC	cis	rs7824557	0.815	rs2736372	ENSG00000255310.2	AF131215.2	-3.97	8.41e-05	0.0122	-0.17	-0.18	Retinal vascular caliber;	chr8:11248532	chr8:11107788~11109726:-
HNSC	cis	rs7637230	0.945	rs7652038	ENSG00000244119.1	PDCL3P4	-3.97	8.41e-05	0.0122	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101894589	chr3:101712472~101713191:+
HNSC	cis	rs7637230	0.945	rs7612823	ENSG00000244119.1	PDCL3P4	-3.97	8.41e-05	0.0122	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101895079	chr3:101712472~101713191:+
HNSC	cis	rs2179367	0.959	rs562428	ENSG00000216906.2	RP11-350J20.9	3.97	8.41e-05	0.0122	0.23	0.18	Dupuytren's disease;	chr6:149326389	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.959	rs540538	ENSG00000216906.2	RP11-350J20.9	3.97	8.41e-05	0.0122	0.23	0.18	Dupuytren's disease;	chr6:149326808	chr6:149904243~149906418:+
HNSC	cis	rs8072100	0.512	rs9303533	ENSG00000263293.2	RP11-290H9.4	3.97	8.41e-05	0.0122	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47303460~47323613:-
HNSC	cis	rs3806843	0.576	rs246009	ENSG00000276545.1	PCDHGB9P	-3.97	8.42e-05	0.0122	-0.22	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140958484	chr5:141439853~141442449:+
HNSC	cis	rs853679	1	rs1778511	ENSG00000270326.1	RP5-874C20.6	3.97	8.42e-05	0.0122	0.27	0.18	Depression;	chr6:28261633	chr6:28319660~28319852:-
HNSC	cis	rs1023500	0.551	rs4822076	ENSG00000205702.9	CYP2D7	3.97	8.42e-05	0.0122	0.14	0.18	Schizophrenia;	chr22:41968053	chr22:42140203~42144577:-
HNSC	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	3.97	8.42e-05	0.0122	0.21	0.18	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
HNSC	cis	rs10927875	0.965	rs3961710	ENSG00000238142.1	RP11-108M9.4	3.97	8.42e-05	0.0122	0.22	0.18	Dilated cardiomyopathy;	chr1:15986677	chr1:16888538~16889649:-
HNSC	cis	rs2239557	0.57	rs7157377	ENSG00000259065.1	RP5-1021I20.1	-3.97	8.42e-05	0.0122	-0.27	-0.18	Common traits (Other);	chr14:73974473	chr14:73787360~73803270:+
HNSC	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	3.97	8.42e-05	0.0122	0.12	0.18	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
HNSC	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	3.97	8.42e-05	0.0122	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
HNSC	cis	rs10789207	0.501	rs2182110	ENSG00000248458.2	RP4-598P13.1	-3.97	8.42e-05	0.0122	-0.27	-0.18	Resting heart rate;	chr1:66648440	chr1:66665864~66677027:-
HNSC	cis	rs7429990	0.965	rs17785248	ENSG00000228638.1	FCF1P2	-3.97	8.42e-05	0.0122	-0.2	-0.18	Educational attainment (years of education);	chr3:47631425	chr3:48290793~48291375:-
HNSC	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-3.97	8.42e-05	0.0122	-0.27	-0.18	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
HNSC	cis	rs2985684	0.901	rs7146248	ENSG00000278009.1	RP11-649E7.8	3.97	8.42e-05	0.0122	0.23	0.18	Carotid intima media thickness;	chr14:49645349	chr14:49601011~49601124:-
HNSC	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-3.97	8.43e-05	0.0122	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
HNSC	cis	rs10129255	0.518	rs8009612	ENSG00000224373.3	IGHV4-59	3.97	8.43e-05	0.0122	0.11	0.18	Kawasaki disease;	chr14:106777510	chr14:106627249~106627825:-
HNSC	cis	rs67981189	0.593	rs3784067	ENSG00000274818.1	RP1-292L20.3	3.97	8.43e-05	0.0122	0.2	0.18	Schizophrenia;	chr14:71013461	chr14:70906657~70907111:-
HNSC	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	3.97	8.43e-05	0.0122	0.22	0.18	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
HNSC	cis	rs7429990	0.864	rs319693	ENSG00000228638.1	FCF1P2	-3.97	8.43e-05	0.0122	-0.17	-0.18	Educational attainment (years of education);	chr3:47845090	chr3:48290793~48291375:-
HNSC	cis	rs9650657	0.683	rs7005905	ENSG00000269918.1	AF131215.9	3.97	8.43e-05	0.0122	0.18	0.18	Neuroticism;	chr8:10727634	chr8:11104691~11106704:-
HNSC	cis	rs4713118	0.621	rs9368548	ENSG00000219891.2	ZSCAN12P1	3.97	8.43e-05	0.0122	0.26	0.18	Parkinson's disease;	chr6:28066959	chr6:28091154~28093664:+
HNSC	cis	rs9313772	0.722	rs10044792	ENSG00000254350.1	RP11-542A14.1	3.97	8.44e-05	0.0122	0.19	0.18	Blood pressure;	chr5:158434831	chr5:158424585~158452758:+
HNSC	cis	rs7015630	0.657	rs6984540	ENSG00000251136.7	RP11-37B2.1	-3.97	8.44e-05	0.0122	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89835724	chr8:89609409~89757727:-
HNSC	cis	rs7646881	0.544	rs17630785	ENSG00000272087.1	RP11-379F4.7	3.97	8.44e-05	0.0122	0.26	0.18	Tetralogy of Fallot;	chr3:158674437	chr3:158693120~158693768:-
HNSC	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-3.97	8.44e-05	0.0122	-0.32	-0.18	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
HNSC	cis	rs6601327	0.635	rs10099122	ENSG00000254340.1	RP11-10A14.3	-3.97	8.44e-05	0.0122	-0.22	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9710493	chr8:9141424~9145435:+
HNSC	cis	rs988913	0.957	rs960835	ENSG00000224984.1	RP11-524H19.2	3.97	8.44e-05	0.0122	0.21	0.18	Menarche (age at onset);	chr6:54958624	chr6:54840118~54840855:-
HNSC	cis	rs2944755	0.919	rs2944753	ENSG00000279766.1	RP11-642A1.2	3.97	8.44e-05	0.0122	0.21	0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140566264	chr8:140572142~140572812:-
HNSC	cis	rs1642645	0.872	rs604145	ENSG00000228452.1	RP5-994D16.9	-3.97	8.44e-05	0.0122	-0.25	-0.18	Left ventricular obstructive tract defect (maternal effect);	chr1:41979442	chr1:42775813~42776790:-
HNSC	cis	rs7005380	0.62	rs7462302	ENSG00000279347.1	RP11-85I17.2	-3.97	8.44e-05	0.0122	-0.14	-0.18	Interstitial lung disease;	chr8:119905531	chr8:119838736~119840385:-
HNSC	cis	rs6081541	0.921	rs6035258	ENSG00000179447.2	RP5-1027G4.3	3.97	8.45e-05	0.0122	0.25	0.18	Psychosis (atypical);	chr20:19225186	chr20:19242302~19284596:-
HNSC	cis	rs67981189	0.593	rs2877708	ENSG00000274818.1	RP1-292L20.3	3.97	8.45e-05	0.0122	0.2	0.18	Schizophrenia;	chr14:71017409	chr14:70906657~70907111:-
HNSC	cis	rs11242704	0.508	rs2569866	ENSG00000272279.1	RP11-157J24.2	-3.97	8.45e-05	0.0122	-0.21	-0.18	Response to hepatitis C treatment;	chr6:1529817	chr6:1528364~1528911:-
HNSC	cis	rs2904524	0.541	rs11178215	ENSG00000257815.4	RP11-611E13.2	-3.97	8.45e-05	0.0122	-0.19	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70390913	chr12:69904033~70243360:-
HNSC	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-3.97	8.45e-05	0.0122	-0.22	-0.18	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
HNSC	cis	rs6710503	1	rs3731629	ENSG00000271936.1	RP11-443B20.1	-3.97	8.45e-05	0.0122	-0.19	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24732291	chr2:24825610~24826717:+
HNSC	cis	rs9313772	0.775	rs6878174	ENSG00000254350.1	RP11-542A14.1	-3.97	8.45e-05	0.0122	-0.2	-0.18	Blood pressure;	chr5:158401218	chr5:158424585~158452758:+
HNSC	cis	rs1913185	0.787	rs59850864	ENSG00000240032.1	RP11-274H2.3	-3.97	8.45e-05	0.0122	-0.3	-0.18	Obesity-related traits;	chr3:146111375	chr3:146066344~146069185:-
HNSC	cis	rs11098499	0.754	rs17595608	ENSG00000250412.1	KLHL2P1	3.97	8.45e-05	0.0122	0.23	0.18	Corneal astigmatism;	chr4:119329351	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs1980027	ENSG00000250412.1	KLHL2P1	3.97	8.45e-05	0.0122	0.23	0.18	Corneal astigmatism;	chr4:119330422	chr4:119334329~119378233:+
HNSC	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-3.97	8.46e-05	0.0122	-0.21	-0.18	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
HNSC	cis	rs911555	0.546	rs28798508	ENSG00000269958.1	RP11-73M18.8	3.97	8.46e-05	0.0122	0.17	0.18	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103696353~103697163:+
HNSC	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	3.97	8.46e-05	0.0122	0.16	0.18	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
HNSC	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	3.97	8.46e-05	0.0122	0.16	0.18	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
HNSC	cis	rs913655	0.536	rs10764729	ENSG00000225527.1	RP11-383B4.4	-3.97	8.47e-05	0.0122	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18733911	chr10:18531849~18533336:-
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000233609.3	RP11-62H7.2	-3.97	8.47e-05	0.0122	-0.17	-0.18	Joint mobility (Beighton score);	chr8:9226831	chr8:8961200~8979025:+
HNSC	cis	rs847649	0.699	rs7794668	ENSG00000239969.4	RP11-163E9.2	3.97	8.47e-05	0.0122	0.21	0.18	Morning vs. evening chronotype;	chr7:102869969	chr7:102364162~102380633:+
HNSC	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	3.97	8.47e-05	0.0122	0.14	0.18	Breast size;	chr12:9206399	chr12:9277235~9313241:+
HNSC	cis	rs7572733	0.534	rs6760891	ENSG00000231621.1	AC013264.2	-3.97	8.47e-05	0.0122	-0.17	-0.18	Dermatomyositis;	chr2:197903442	chr2:197197991~197199273:+
HNSC	cis	rs853679	0.517	rs9393894	ENSG00000219891.2	ZSCAN12P1	3.97	8.48e-05	0.0122	0.26	0.18	Depression;	chr6:28144784	chr6:28091154~28093664:+
HNSC	cis	rs6500395	0.925	rs16946342	ENSG00000261267.1	RP11-44I10.3	-3.97	8.48e-05	0.0122	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48634631	chr16:48559661~48587403:+
HNSC	cis	rs9321637	1	rs6570197	ENSG00000226004.1	RP11-10J5.1	3.97	8.48e-05	0.0122	0.21	0.18	Cardiac Troponin-T levels;	chr6:137944595	chr6:137943079~137945802:-
HNSC	cis	rs9987353	0.784	rs330014	ENSG00000254340.1	RP11-10A14.3	-3.97	8.48e-05	0.0122	-0.24	-0.18	Recombination measurement;	chr8:9271334	chr8:9141424~9145435:+
HNSC	cis	rs7520050	0.933	rs6694340	ENSG00000280836.1	AL355480.1	3.97	8.48e-05	0.0123	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45581219~45581321:-
HNSC	cis	rs1602565	1	rs1552719	ENSG00000255450.1	CTD-2063L20.1	-3.97	8.49e-05	0.0123	-0.31	-0.18	Schizophrenia;	chr11:29177186	chr11:29275655~29276565:+
HNSC	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-3.96	8.49e-05	0.0123	-0.19	-0.18	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-3.96	8.49e-05	0.0123	-0.19	-0.18	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
HNSC	cis	rs7829975	0.682	rs7013471	ENSG00000254340.1	RP11-10A14.3	-3.96	8.49e-05	0.0123	-0.22	-0.18	Mood instability;	chr8:8829815	chr8:9141424~9145435:+
HNSC	cis	rs1499614	0.522	rs13247442	ENSG00000230295.1	RP11-458F8.2	-3.96	8.49e-05	0.0123	-0.31	-0.18	Gout;	chr7:66723871	chr7:66880708~66882981:+
HNSC	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	3.96	8.49e-05	0.0123	0.2	0.18	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
HNSC	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	3.96	8.5e-05	0.0123	0.18	0.18	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
HNSC	cis	rs10129255	0.536	rs10142951	ENSG00000211976.2	IGHV3-73	-3.96	8.5e-05	0.0123	-0.13	-0.18	Kawasaki disease;	chr14:106782337	chr14:106802694~106803233:-
HNSC	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	3.96	8.5e-05	0.0123	0.25	0.18	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
HNSC	cis	rs2284553	0.516	rs2834208	ENSG00000272659.1	AP000295.10	3.96	8.5e-05	0.0123	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr21:33380457	chr21:33309491~33310181:+
HNSC	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-3.96	8.5e-05	0.0123	-0.2	-0.18	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
HNSC	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-3.96	8.51e-05	0.0123	-0.21	-0.18	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000211972.2	IGHV3-66	3.96	8.51e-05	0.0123	0.14	0.18	Kawasaki disease;	chr14:106656426	chr14:106675017~106675544:-
HNSC	cis	rs13260300	0.657	rs3802201	ENSG00000254349.4	FLJ39080	3.96	8.51e-05	0.0123	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74603964	chr8:74599775~74823313:+
HNSC	cis	rs11756659	0.653	rs199729	ENSG00000218690.1	HIST1H2APS4	3.96	8.51e-05	0.0123	0.24	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:26272193~26272540:-
HNSC	cis	rs11021221	0.645	rs2254645	ENSG00000233536.2	RP11-867G2.5	3.96	8.51e-05	0.0123	0.22	0.18	Immature fraction of reticulocytes;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;	chr11:95593735	chr11:94638038~94640833:+
HNSC	cis	rs11021221	0.645	rs2254643	ENSG00000233536.2	RP11-867G2.5	3.96	8.51e-05	0.0123	0.22	0.18	Immature fraction of reticulocytes;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;	chr11:95593789	chr11:94638038~94640833:+
HNSC	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	3.96	8.51e-05	0.0123	0.29	0.18	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	3.96	8.51e-05	0.0123	0.29	0.18	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	3.96	8.51e-05	0.0123	0.29	0.18	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	3.96	8.51e-05	0.0123	0.29	0.18	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	3.96	8.51e-05	0.0123	0.29	0.18	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000211974.3	IGHV2-70	3.96	8.51e-05	0.0123	0.17	0.18	Kawasaki disease;	chr14:106777278	chr14:106723574~106724093:-
HNSC	cis	rs1620921	0.653	rs62435277	ENSG00000231863.1	RP3-428L16.1	-3.96	8.51e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844300	chr6:160931080~160969771:+
HNSC	cis	rs8077577	0.945	rs62072496	ENSG00000273018.4	CTD-2303H24.2	-3.96	8.51e-05	0.0123	-0.28	-0.18	Obesity-related traits;	chr17:18221429	chr17:18511221~18551705:-
HNSC	cis	rs7005380	0.556	rs7813263	ENSG00000279347.1	RP11-85I17.2	3.96	8.51e-05	0.0123	0.18	0.18	Interstitial lung disease;	chr8:119926691	chr8:119838736~119840385:-
HNSC	cis	rs62025270	0.688	rs7179917	ENSG00000259762.1	RP11-158M2.4	-3.96	8.52e-05	0.0123	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85750336~85752901:-
HNSC	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	3.96	8.52e-05	0.0123	0.18	0.18	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
HNSC	cis	rs6968419	0.674	rs1918911	ENSG00000237870.5	AC073130.1	3.96	8.52e-05	0.0123	0.22	0.18	Intraocular pressure;	chr7:116266694	chr7:116275606~116286734:-
HNSC	cis	rs3736485	0.966	rs10467923	ENSG00000259438.1	CTD-2650P22.1	3.96	8.52e-05	0.0123	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51475068	chr15:52010999~52019095:-
HNSC	cis	rs2944755	0.686	rs6983414	ENSG00000279766.1	RP11-642A1.2	-3.96	8.52e-05	0.0123	-0.21	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140580093	chr8:140572142~140572812:-
HNSC	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	3.96	8.52e-05	0.0123	0.18	0.18	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
HNSC	cis	rs12986445	0.846	rs2176182	ENSG00000218682.1	AC010150.1	3.96	8.52e-05	0.0123	0.24	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25886533	chr2:25856461~25856966:-
HNSC	cis	rs62292953	0.589	rs62292471	ENSG00000248724.5	NPHP3-AS1	-3.96	8.52e-05	0.0123	-0.41	-0.18	Red cell distribution width;	chr3:132710603	chr3:132721750~132874223:+
HNSC	cis	rs847649	0.804	rs4729866	ENSG00000239969.4	RP11-163E9.2	3.96	8.52e-05	0.0123	0.21	0.18	Morning vs. evening chronotype;	chr7:103045114	chr7:102364162~102380633:+
HNSC	cis	rs1008375	0.932	rs6835077	ENSG00000249502.1	AC006160.5	-3.96	8.52e-05	0.0123	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17651662	chr4:17587467~17614571:-
HNSC	cis	rs7829975	0.714	rs4840362	ENSG00000233609.3	RP11-62H7.2	-3.96	8.52e-05	0.0123	-0.17	-0.18	Mood instability;	chr8:8812572	chr8:8961200~8979025:+
HNSC	cis	rs11756659	0.653	rs62394537	ENSG00000272462.2	U91328.19	3.96	8.53e-05	0.0123	0.23	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963715	chr6:25992662~26001775:+
HNSC	cis	rs870825	1	rs72689245	ENSG00000254233.1	RP11-242J7.1	3.96	8.53e-05	0.0123	0.32	0.18	Blood protein levels;	chr4:184658634	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs871254	ENSG00000254233.1	RP11-242J7.1	3.96	8.53e-05	0.0123	0.31	0.18	Blood protein levels;	chr4:184668072	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs871253	ENSG00000254233.1	RP11-242J7.1	3.96	8.53e-05	0.0123	0.31	0.18	Blood protein levels;	chr4:184668080	chr4:184584093~184625030:-
HNSC	cis	rs7572733	0.534	rs4550664	ENSG00000231621.1	AC013264.2	-3.96	8.53e-05	0.0123	-0.17	-0.18	Dermatomyositis;	chr2:197826681	chr2:197197991~197199273:+
HNSC	cis	rs7772486	0.774	rs2748503	ENSG00000235652.6	RP11-545I5.3	3.96	8.54e-05	0.0123	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145799409~145886585:+
HNSC	cis	rs4713118	0.621	rs4713132	ENSG00000219891.2	ZSCAN12P1	3.96	8.54e-05	0.0123	0.26	0.18	Parkinson's disease;	chr6:28066257	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.621	rs4713133	ENSG00000219891.2	ZSCAN12P1	3.96	8.54e-05	0.0123	0.26	0.18	Parkinson's disease;	chr6:28066263	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.621	rs4713134	ENSG00000219891.2	ZSCAN12P1	3.96	8.54e-05	0.0123	0.26	0.18	Parkinson's disease;	chr6:28066343	chr6:28091154~28093664:+
HNSC	cis	rs10129255	0.518	rs11847766	ENSG00000224373.3	IGHV4-59	3.96	8.54e-05	0.0123	0.1	0.18	Kawasaki disease;	chr14:106779186	chr14:106627249~106627825:-
HNSC	cis	rs6500395	0.775	rs13331298	ENSG00000261267.1	RP11-44I10.3	-3.96	8.54e-05	0.0123	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48627578	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.802	rs13330784	ENSG00000261267.1	RP11-44I10.3	-3.96	8.54e-05	0.0123	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48627619	chr16:48559661~48587403:+
HNSC	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-3.96	8.54e-05	0.0123	-0.22	-0.18	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
HNSC	cis	rs116139393	0.505	rs3801033	ENSG00000187953.9	PMS2CL	3.96	8.54e-05	0.0123	0.2	0.18	Alzheimer's disease (APOE e4 interaction);	chr7:6694472	chr7:6710128~6753862:+
HNSC	cis	rs748404	0.55	rs12912505	ENSG00000166763.7	STRCP1	3.96	8.54e-05	0.0123	0.26	0.18	Lung cancer;	chr15:43525206	chr15:43699488~43718184:-
HNSC	cis	rs10744422	0.541	rs7306948	ENSG00000247373.3	RP11-486O12.2	3.96	8.55e-05	0.0123	0.22	0.18	Schizophrenia;	chr12:122860800	chr12:123575891~123585115:-
HNSC	cis	rs950027	0.549	rs11070452	ENSG00000259479.5	SORD2P	-3.96	8.55e-05	0.0123	-0.21	-0.18	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:44826371~44884694:-
HNSC	cis	rs67311347	0.868	rs10865895	ENSG00000280739.1	EIF1B-AS1	3.96	8.55e-05	0.0123	0.2	0.18	Renal cell carcinoma;	chr3:40337186	chr3:40173145~40309698:-
HNSC	cis	rs1790761	0.505	rs7938563	ENSG00000184224.3	C11orf72	-3.96	8.55e-05	0.0123	-0.22	-0.18	Mean corpuscular volume;	chr11:67536660	chr11:67602880~67606706:-
HNSC	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0123	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0123	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
HNSC	cis	rs16846053	0.515	rs3849355	ENSG00000227403.1	AC009299.3	-3.96	8.55e-05	0.0123	-0.32	-0.18	Blood osmolality (transformed sodium);	chr2:161531204	chr2:161244739~161249050:+
HNSC	cis	rs17164851	0.778	rs968404	ENSG00000273329.1	RP11-448A19.1	3.96	8.55e-05	0.0123	0.22	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr7:130382200	chr7:129604548~129611630:-
HNSC	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-3.96	8.56e-05	0.0123	-0.22	-0.18	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
HNSC	cis	rs9611565	0.659	rs202653	ENSG00000235513.1	RP4-756G23.5	-3.96	8.56e-05	0.0123	-0.21	-0.18	Vitiligo;	chr22:41444154	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.649	rs202655	ENSG00000235513.1	RP4-756G23.5	-3.96	8.56e-05	0.0123	-0.21	-0.18	Vitiligo;	chr22:41445560	chr22:41209122~41217627:-
HNSC	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	3.96	8.56e-05	0.0123	0.25	0.18	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
HNSC	cis	rs1620921	0.621	rs11753103	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160846054	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.533	rs11753560	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160846090	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs10945702	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160846142	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs9355842	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160846410	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9766412	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847223	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.622	rs67876803	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847289	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.622	rs73029748	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847376	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.564	rs67591610	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847442	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.653	rs62435284	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847538	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs28533078	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847698	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs28670241	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847704	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9365215	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847756	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.593	rs9355844	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847935	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9355845	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848065	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9355846	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848172	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs9355320	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848224	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.533	rs9347447	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848339	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9365219	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160849038	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9347451	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160849068	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs2465855	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160849587	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs2489930	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850279	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs2465856	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850337	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs28597670	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850611	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.565	rs28448569	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160850674	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs28711930	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851125	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs9456598	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851251	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.595	rs9458048	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851285	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs9456599	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851369	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs68027339	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851781	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs57127570	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851964	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.595	rs68142848	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852225	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.535	rs66533808	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852270	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs67136969	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852401	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.511	rs2489931	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852596	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs2465864	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852753	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.622	rs12153973	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852859	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs12153845	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160852955	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.619	rs7381975	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854222	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.624	rs13216274	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854277	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.624	rs13200798	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854478	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.624	rs13219765	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854484	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.624	rs13203412	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854839	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.657	rs13203427	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160854860	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.652	rs7382318	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855096	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.624	rs7381442	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855183	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.657	rs7382435	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855402	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.653	rs7382456	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855551	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.653	rs9365221	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855644	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs9347455	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855720	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.592	rs9347456	ENSG00000231863.1	RP3-428L16.1	-3.96	8.56e-05	0.0123	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160855933	chr6:160931080~160969771:+
HNSC	cis	rs11089937	0.616	rs5750675	ENSG00000211639.2	IGLV4-60	3.96	8.56e-05	0.0123	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22162199~22162681:+
HNSC	cis	rs2898681	0.519	rs7670068	ENSG00000248375.1	RP11-177B4.1	-3.96	8.57e-05	0.0123	-0.29	-0.18	Optic nerve measurement (cup area);	chr4:52867817	chr4:52720081~52720831:-
HNSC	cis	rs28830936	1	rs11070343	ENSG00000250379.1	RP11-23P13.4	3.96	8.57e-05	0.0123	0.22	0.18	Diastolic blood pressure;	chr15:41647948	chr15:41825099~41827936:-
HNSC	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-3.96	8.57e-05	0.0123	-0.24	-0.18	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
HNSC	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-3.96	8.57e-05	0.0124	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
HNSC	cis	rs853679	0.607	rs13211507	ENSG00000226314.6	ZNF192P1	-3.96	8.57e-05	0.0124	-0.34	-0.18	Depression;	chr6:28289600	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs34691223	ENSG00000226314.6	ZNF192P1	-3.96	8.57e-05	0.0124	-0.34	-0.18	Depression;	chr6:28290431	chr6:28161781~28169594:+
HNSC	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-3.96	8.58e-05	0.0124	-0.19	-0.18	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
HNSC	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-3.96	8.58e-05	0.0124	-0.15	-0.18	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
HNSC	cis	rs17818399	0.502	rs1451152	ENSG00000279254.1	RP11-536C12.1	-3.96	8.58e-05	0.0124	-0.2	-0.18	Height;	chr2:46573011	chr2:46668870~46670778:+
HNSC	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	3.96	8.58e-05	0.0124	0.21	0.18	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
HNSC	cis	rs2136613	0.533	rs10761663	ENSG00000238280.1	RP11-436D10.3	-3.96	8.58e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62845239	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs1475084	ENSG00000238280.1	RP11-436D10.3	-3.96	8.58e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62845974	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs7088066	ENSG00000238280.1	RP11-436D10.3	-3.96	8.58e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62846097	chr10:62793562~62805887:-
HNSC	cis	rs72843506	0.656	rs73981807	ENSG00000261033.1	RP11-209D14.2	3.96	8.58e-05	0.0124	0.3	0.18	Schizophrenia;	chr17:20092917	chr17:20008051~20009234:-
HNSC	cis	rs2136613	0.533	rs10995327	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62842814	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs1967747	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62844205	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10740087	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62847511	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs7093716	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62847717	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs7097383	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62848279	chr10:62793562~62805887:-
HNSC	cis	rs6674176	0.628	rs2240447	ENSG00000237950.1	RP11-7O11.3	3.96	8.59e-05	0.0124	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43949743	chr1:43944370~43946551:-
HNSC	cis	rs6674176	0.628	rs7556565	ENSG00000237950.1	RP11-7O11.3	3.96	8.59e-05	0.0124	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43950418	chr1:43944370~43946551:-
HNSC	cis	rs9813712	0.953	rs1453258	ENSG00000228252.7	COL6A4P2	3.96	8.59e-05	0.0124	0.19	0.18	Response to amphetamines;	chr3:130256454	chr3:130212823~130273806:+
HNSC	cis	rs2136613	0.533	rs1475082	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62845621	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs1475083	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62845638	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs7089121	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62846850	chr10:62793562~62805887:-
HNSC	cis	rs4947019	0.609	rs9487099	ENSG00000260273.1	RP11-425D10.10	3.96	8.59e-05	0.0124	0.5	0.18	Hematological parameters;	chr6:109423803	chr6:109382795~109383666:+
HNSC	cis	rs2136613	0.533	rs10740088	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62849651	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10740089	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62849674	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10761668	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62849983	chr10:62793562~62805887:-
HNSC	cis	rs2136613	0.533	rs10740090	ENSG00000238280.1	RP11-436D10.3	-3.96	8.59e-05	0.0124	-0.21	-0.18	Selective IgA deficiency;	chr10:62850027	chr10:62793562~62805887:-
HNSC	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-3.96	8.59e-05	0.0124	-0.21	-0.18	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
HNSC	cis	rs77926410	0.604	rs11053801	ENSG00000245648.1	RP11-277P12.20	-3.96	8.59e-05	0.0124	-0.23	-0.18	Mean corpuscular volume;	chr12:10443518	chr12:10363769~10398506:+
HNSC	cis	rs2463822	0.92	rs7924998	ENSG00000250659.2	RP11-864I4.3	3.96	8.59e-05	0.0124	0.36	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62306508	chr11:62537312~62542018:+
HNSC	cis	rs12935418	0.616	rs2549854	ENSG00000278985.1	RP11-303E16.9	3.96	8.6e-05	0.0124	0.18	0.18	Mean corpuscular volume;	chr16:80993034	chr16:80982319~80984094:-
HNSC	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-3.96	8.6e-05	0.0124	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
HNSC	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	3.96	8.6e-05	0.0124	0.25	0.18	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
HNSC	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	3.96	8.6e-05	0.0124	0.25	0.18	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
HNSC	cis	rs4763879	0.778	rs1056151	ENSG00000278635.1	CTD-2318O12.1	3.96	8.6e-05	0.0124	0.14	0.18	Type 1 diabetes;	chr12:9698427	chr12:9415641~9416718:+
HNSC	cis	rs853679	0.766	rs9368561	ENSG00000219891.2	ZSCAN12P1	3.96	8.6e-05	0.0124	0.33	0.18	Depression;	chr6:28200565	chr6:28091154~28093664:+
HNSC	cis	rs28830936	1	rs28754734	ENSG00000250379.1	RP11-23P13.4	3.96	8.61e-05	0.0124	0.22	0.18	Diastolic blood pressure;	chr15:41800954	chr15:41825099~41827936:-
HNSC	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-3.96	8.61e-05	0.0124	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
HNSC	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-3.96	8.61e-05	0.0124	-0.18	-0.18	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
HNSC	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	3.96	8.61e-05	0.0124	0.2	0.18	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
HNSC	cis	rs10129255	0.5	rs988134	ENSG00000224373.3	IGHV4-59	3.96	8.61e-05	0.0124	0.1	0.18	Kawasaki disease;	chr14:106776698	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.5	rs988133	ENSG00000224373.3	IGHV4-59	3.96	8.61e-05	0.0124	0.1	0.18	Kawasaki disease;	chr14:106776724	chr14:106627249~106627825:-
HNSC	cis	rs860295	0.557	rs915181	ENSG00000225855.5	RUSC1-AS1	3.96	8.61e-05	0.0124	0.12	0.18	Body mass index;	chr1:155944981	chr1:155316863~155324176:-
HNSC	cis	rs853679	0.517	rs4713141	ENSG00000219891.2	ZSCAN12P1	3.96	8.61e-05	0.0124	0.25	0.18	Depression;	chr6:28133900	chr6:28091154~28093664:+
HNSC	cis	rs3808502	0.563	rs12549144	ENSG00000255495.1	AC145124.2	3.96	8.61e-05	0.0124	0.2	0.18	Neuroticism;	chr8:11565352	chr8:12194467~12196280:+
HNSC	cis	rs792448	1	rs792448	ENSG00000226251.4	RP11-15I11.3	3.96	8.61e-05	0.0124	0.23	0.18	White blood cell count (basophil);	chr1:212385055	chr1:212225278~212238977:-
HNSC	cis	rs9611565	0.729	rs2413647	ENSG00000235513.1	RP4-756G23.5	3.96	8.61e-05	0.0124	0.22	0.18	Vitiligo;	chr22:41511144	chr22:41209122~41217627:-
HNSC	cis	rs76076331	0.838	rs77966298	ENSG00000234818.1	AC092687.5	3.96	8.61e-05	0.0124	0.31	0.18	Educational attainment (college completion);Educational attainment (years of education);	chr2:10844388	chr2:10589166~10604830:+
HNSC	cis	rs72627509	0.68	rs3733309	ENSG00000269949.1	RP11-738E22.3	3.96	8.62e-05	0.0124	0.3	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56991022	chr4:56960927~56961373:-
HNSC	cis	rs73201462	0.831	rs2999036	ENSG00000231305.3	RP11-723O4.2	3.96	8.62e-05	0.0124	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128301858	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811390	ENSG00000231305.3	RP11-723O4.2	3.96	8.62e-05	0.0124	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128302638	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811391	ENSG00000231305.3	RP11-723O4.2	3.96	8.62e-05	0.0124	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128303525	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811393	ENSG00000231305.3	RP11-723O4.2	3.96	8.62e-05	0.0124	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305156	chr3:128861313~128871540:-
HNSC	cis	rs5758511	0.524	rs738257	ENSG00000227370.1	RP4-669P10.19	3.96	8.62e-05	0.0124	0.22	0.18	Birth weight;	chr22:42173292	chr22:42132543~42132998:+
HNSC	cis	rs35000415	0.683	rs71581969	ENSG00000275106.1	RP11-309L24.10	-3.96	8.62e-05	0.0124	-0.37	-0.18	Systemic lupus erythematosus;	chr7:129082183	chr7:128952527~128953316:-
HNSC	cis	rs6601327	0.613	rs33994795	ENSG00000233609.3	RP11-62H7.2	-3.96	8.62e-05	0.0124	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9615919	chr8:8961200~8979025:+
HNSC	cis	rs875971	0.66	rs1860468	ENSG00000272831.1	RP11-792A8.4	-3.96	8.62e-05	0.0124	-0.15	-0.18	Aortic root size;	chr7:66642265	chr7:66739829~66740385:-
HNSC	cis	rs2657294	0.861	rs6480769	ENSG00000233313.2	HMGA1P5	-3.96	8.62e-05	0.0124	-0.2	-0.18	Pneumonia;	chr10:75091745	chr10:75276376~75276646:-
HNSC	cis	rs4713118	0.869	rs10214440	ENSG00000216901.1	AL022393.7	3.96	8.63e-05	0.0124	0.22	0.18	Parkinson's disease;	chr6:27734661	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs6902689	ENSG00000216901.1	AL022393.7	3.96	8.63e-05	0.0124	0.22	0.18	Parkinson's disease;	chr6:27741662	chr6:28176188~28176674:+
HNSC	cis	rs10129255	1	rs10141557	ENSG00000211974.3	IGHV2-70	3.96	8.63e-05	0.0124	0.17	0.18	Kawasaki disease;	chr14:106767990	chr14:106723574~106724093:-
HNSC	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	3.96	8.63e-05	0.0124	0.23	0.18	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
HNSC	cis	rs1979679	0.837	rs2881860	ENSG00000247934.4	RP11-967K21.1	-3.96	8.63e-05	0.0124	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28163298~28190738:-
HNSC	cis	rs11951515	0.7	rs57392430	ENSG00000249286.1	CTD-2210P15.2	3.96	8.63e-05	0.0124	0.19	0.18	Metabolite levels  (X-11787);	chr5:43284329	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.7	rs56029402	ENSG00000249286.1	CTD-2210P15.2	3.96	8.63e-05	0.0124	0.19	0.18	Metabolite levels  (X-11787);	chr5:43284353	chr5:43586918~43588223:-
HNSC	cis	rs71520386	0.752	rs34015725	ENSG00000221740.1	SNORD93	-3.96	8.63e-05	0.0124	-0.24	-0.18	Fibrinogen levels;	chr7:22773665	chr7:22856613~22856686:+
HNSC	cis	rs11157436	0.602	rs1894370	ENSG00000211814.1	TRAV35	-3.96	8.63e-05	0.0124	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22221896~22222475:+
HNSC	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	3.96	8.63e-05	0.0124	0.23	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
HNSC	cis	rs11951515	0.7	rs56023994	ENSG00000249286.1	CTD-2210P15.2	3.96	8.63e-05	0.0124	0.19	0.18	Metabolite levels  (X-11787);	chr5:43285291	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.676	rs55647314	ENSG00000249286.1	CTD-2210P15.2	3.96	8.63e-05	0.0124	0.19	0.18	Metabolite levels  (X-11787);	chr5:43285294	chr5:43586918~43588223:-
HNSC	cis	rs4660261	0.526	rs2040950	ENSG00000237950.1	RP11-7O11.3	3.96	8.63e-05	0.0124	0.2	0.18	Intelligence (multi-trait analysis);	chr1:43849441	chr1:43944370~43946551:-
HNSC	cis	rs597539	0.58	rs7935851	ENSG00000255741.1	RP11-757G1.5	-3.96	8.64e-05	0.0124	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68941503~68942852:-
HNSC	cis	rs9304742	0.924	rs8111196	ENSG00000242779.5	ZNF702P	3.96	8.64e-05	0.0124	0.22	0.18	Psoriasis;	chr19:52953970	chr19:52968251~53037898:-
HNSC	cis	rs9304742	0.888	rs8111514	ENSG00000242779.5	ZNF702P	3.96	8.64e-05	0.0124	0.22	0.18	Psoriasis;	chr19:52953993	chr19:52968251~53037898:-
HNSC	cis	rs9304742	0.888	rs8112137	ENSG00000242779.5	ZNF702P	3.96	8.64e-05	0.0124	0.22	0.18	Psoriasis;	chr19:52954002	chr19:52968251~53037898:-
HNSC	cis	rs7429990	0.965	rs4599334	ENSG00000228638.1	FCF1P2	3.96	8.64e-05	0.0124	0.17	0.18	Educational attainment (years of education);	chr3:48024910	chr3:48290793~48291375:-
HNSC	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	3.96	8.64e-05	0.0124	0.3	0.18	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	3.96	8.64e-05	0.0124	0.3	0.18	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
HNSC	cis	rs4814920	0.756	rs6075586	ENSG00000233895.1	RP1-122P22.2	-3.96	8.64e-05	0.0124	-0.24	-0.18	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19757708~19809675:+
HNSC	cis	rs5758659	0.652	rs133347	ENSG00000270083.1	RP1-257I20.14	3.96	8.64e-05	0.0124	0.16	0.18	Cognitive function;	chr22:42027641	chr22:42089630~42090028:-
HNSC	cis	rs62458065	0.713	rs921406	ENSG00000226468.2	AC018641.7	3.96	8.65e-05	0.0124	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32446593	chr7:32456963~32457758:-
HNSC	cis	rs9788333	0.695	rs12871086	ENSG00000236953.1	ZDHHC20-IT1	-3.96	8.65e-05	0.0124	-0.2	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21316085	chr13:21376977~21377874:-
HNSC	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-3.96	8.65e-05	0.0124	-0.21	-0.18	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
HNSC	cis	rs1602565	1	rs11030594	ENSG00000255450.1	CTD-2063L20.1	-3.96	8.65e-05	0.0124	-0.3	-0.18	Schizophrenia;	chr11:29150667	chr11:29275655~29276565:+
HNSC	cis	rs6840258	0.76	rs10032244	ENSG00000251411.1	RP11-397E7.4	-3.96	8.65e-05	0.0124	-0.21	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86996779	chr4:86913266~86914817:-
HNSC	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	3.96	8.65e-05	0.0124	0.19	0.18	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
HNSC	cis	rs1930961	0.558	rs5996951	ENSG00000100058.11	CRYBB2P1	3.96	8.65e-05	0.0124	0.3	0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25448105~25520854:+
HNSC	cis	rs597539	0.69	rs608810	ENSG00000255741.1	RP11-757G1.5	-3.96	8.65e-05	0.0124	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68941503~68942852:-
HNSC	cis	rs240993	0.812	rs458806	ENSG00000230177.1	RP5-1112D6.4	-3.96	8.65e-05	0.0124	-0.23	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111354825	chr6:111277932~111278742:+
HNSC	cis	rs4356203	0.87	rs10766381	ENSG00000272034.1	SNORD14A	-3.96	8.65e-05	0.0124	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17074654~17074744:-
HNSC	cis	rs12478296	1	rs56136197	ENSG00000261186.2	RP11-341N2.1	-3.96	8.66e-05	0.0125	-0.3	-0.18	Obesity-related traits;	chr2:242101726	chr2:242087351~242088457:-
HNSC	cis	rs12478296	1	rs56387669	ENSG00000261186.2	RP11-341N2.1	-3.96	8.66e-05	0.0125	-0.3	-0.18	Obesity-related traits;	chr2:242101738	chr2:242087351~242088457:-
HNSC	cis	rs12478296	0.786	rs72620862	ENSG00000261186.2	RP11-341N2.1	-3.96	8.66e-05	0.0125	-0.3	-0.18	Obesity-related traits;	chr2:242102636	chr2:242087351~242088457:-
HNSC	cis	rs12478296	0.901	rs56318767	ENSG00000261186.2	RP11-341N2.1	-3.96	8.66e-05	0.0125	-0.3	-0.18	Obesity-related traits;	chr2:242104440	chr2:242087351~242088457:-
HNSC	cis	rs2179367	0.919	rs577001	ENSG00000216906.2	RP11-350J20.9	3.96	8.66e-05	0.0125	0.23	0.18	Dupuytren's disease;	chr6:149325172	chr6:149904243~149906418:+
HNSC	cis	rs656319	0.513	rs1484641	ENSG00000255310.2	AF131215.2	3.96	8.66e-05	0.0125	0.18	0.18	Myopia (pathological);	chr8:10129014	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	3.96	8.66e-05	0.0125	0.22	0.18	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	3.96	8.66e-05	0.0125	0.22	0.18	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	3.96	8.66e-05	0.0125	0.22	0.18	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	3.96	8.66e-05	0.0125	0.22	0.18	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
HNSC	cis	rs67340775	0.541	rs169287	ENSG00000219392.1	RP1-265C24.5	-3.96	8.66e-05	0.0125	-0.27	-0.18	Lung cancer in ever smokers;	chr6:27886982	chr6:28115628~28116551:+
HNSC	cis	rs11157436	0.602	rs928955	ENSG00000211814.1	TRAV35	-3.96	8.66e-05	0.0125	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22221896~22222475:+
HNSC	cis	rs11157436	0.602	rs12587826	ENSG00000211814.1	TRAV35	-3.96	8.66e-05	0.0125	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22221896~22222475:+
HNSC	cis	rs7829975	0.51	rs332037	ENSG00000233609.3	RP11-62H7.2	3.96	8.66e-05	0.0125	0.17	0.18	Mood instability;	chr8:8865165	chr8:8961200~8979025:+
HNSC	cis	rs1555322	0.932	rs1205411	ENSG00000279253.1	RP4-614O4.13	-3.96	8.66e-05	0.0125	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35262727~35264187:-
HNSC	cis	rs870825	1	rs870823	ENSG00000254233.1	RP11-242J7.1	3.96	8.67e-05	0.0125	0.31	0.18	Blood protein levels;	chr4:184667041	chr4:184584093~184625030:-
HNSC	cis	rs2760061	0.583	rs1745413	ENSG00000270110.1	RP5-1139B12.4	-3.96	8.67e-05	0.0125	-0.19	-0.18	Diastolic blood pressure;	chr1:228024755	chr1:228295911~228302998:-
HNSC	cis	rs4144743	1	rs55827077	ENSG00000228782.6	CTD-2026D20.3	-3.96	8.67e-05	0.0125	-0.21	-0.18	Body mass index;	chr17:47253717	chr17:47450568~47492492:-
HNSC	cis	rs11089937	0.651	rs2877023	ENSG00000211638.2	IGLV8-61	-3.96	8.67e-05	0.0125	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22182414	chr22:22098700~22099212:+
HNSC	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-3.96	8.67e-05	0.0125	-0.21	-0.18	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-3.96	8.67e-05	0.0125	-0.21	-0.18	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-3.96	8.67e-05	0.0125	-0.21	-0.18	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-3.96	8.67e-05	0.0125	-0.21	-0.18	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
HNSC	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	3.96	8.67e-05	0.0125	0.25	0.18	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
HNSC	cis	rs2247572	0.667	rs2246780	ENSG00000250295.5	RP11-434I12.2	3.96	8.67e-05	0.0125	0.23	0.18	Cognitive performance;	chr8:72667975	chr8:73297711~73356461:-
HNSC	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	3.96	8.67e-05	0.0125	0.2	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
HNSC	cis	rs12745968	0.652	rs4294422	ENSG00000223787.2	RP4-593M8.1	3.96	8.67e-05	0.0125	0.22	0.18	Bipolar disorder and schizophrenia;	chr1:92639098	chr1:92580476~92580821:-
HNSC	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	3.96	8.67e-05	0.0125	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
HNSC	cis	rs1476670	0.71	rs4660763	ENSG00000230615.5	RP5-1198O20.4	-3.96	8.68e-05	0.0125	-0.23	-0.18	Eotaxin levels;	chr1:44037904	chr1:44030443~44115913:+
HNSC	cis	rs1925953	0.711	rs11209271	ENSG00000233589.1	RP4-694A7.2	-3.96	8.68e-05	0.0125	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68364014	chr1:68479129~68483539:+
HNSC	cis	rs330071	0.5	rs17662123	ENSG00000254340.1	RP11-10A14.3	3.96	8.68e-05	0.0125	0.23	0.18	Acne (severe);	chr8:9389327	chr8:9141424~9145435:+
HNSC	cis	rs2944755	0.845	rs2977459	ENSG00000279766.1	RP11-642A1.2	3.96	8.68e-05	0.0125	0.21	0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140565770	chr8:140572142~140572812:-
HNSC	cis	rs10791097	0.694	rs2155751	ENSG00000254842.5	RP11-890B15.2	-3.96	8.68e-05	0.0125	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885345	chr11:130844191~130865561:-
HNSC	cis	rs1962073	0.529	rs13258627	ENSG00000269918.1	AF131215.9	3.96	8.68e-05	0.0125	0.19	0.18	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10417068	chr8:11104691~11106704:-
HNSC	cis	rs11711311	1	rs1073040	ENSG00000241529.3	RN7SL767P	-3.96	8.68e-05	0.0125	-0.23	-0.18	IgG glycosylation;	chr3:113803276	chr3:113632704~113632998:+
HNSC	cis	rs2732480	0.5	rs2450986	ENSG00000257763.1	OR5BK1P	3.96	8.68e-05	0.0125	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48355792~48356614:-
HNSC	cis	rs1387259	0.929	rs2634666	ENSG00000257763.1	OR5BK1P	3.96	8.68e-05	0.0125	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48355792~48356614:-
HNSC	cis	rs1387259	0.929	rs2956703	ENSG00000257763.1	OR5BK1P	3.96	8.68e-05	0.0125	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48355792~48356614:-
HNSC	cis	rs1387259	0.931	rs1107654	ENSG00000257763.1	OR5BK1P	3.96	8.68e-05	0.0125	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48355792~48356614:-
HNSC	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	3.96	8.68e-05	0.0125	0.18	0.18	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-3.96	8.68e-05	0.0125	-0.24	-0.18	Depression;	chr6:28103220	chr6:28170845~28172521:+
HNSC	cis	rs6601327	0.543	rs11249948	ENSG00000233609.3	RP11-62H7.2	3.96	8.68e-05	0.0125	0.18	0.18	Multiple myeloma (hyperdiploidy);	chr8:9791176	chr8:8961200~8979025:+
HNSC	cis	rs17407555	0.71	rs10489072	ENSG00000250413.1	RP11-448G15.1	-3.96	8.69e-05	0.0125	-0.24	-0.18	Schizophrenia (age at onset);	chr4:10271620	chr4:10006482~10009725:+
HNSC	cis	rs67311347	0.544	rs1902073	ENSG00000280739.1	EIF1B-AS1	3.96	8.69e-05	0.0125	0.19	0.18	Renal cell carcinoma;	chr3:40292006	chr3:40173145~40309698:-
HNSC	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	3.96	8.69e-05	0.0125	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
HNSC	cis	rs847649	0.767	rs11972261	ENSG00000239969.4	RP11-163E9.2	3.96	8.69e-05	0.0125	0.21	0.18	Morning vs. evening chronotype;	chr7:103000797	chr7:102364162~102380633:+
HNSC	cis	rs847649	0.842	rs11976237	ENSG00000239969.4	RP11-163E9.2	3.96	8.69e-05	0.0125	0.21	0.18	Morning vs. evening chronotype;	chr7:103000936	chr7:102364162~102380633:+
HNSC	cis	rs11098499	0.863	rs17050695	ENSG00000250412.1	KLHL2P1	3.96	8.69e-05	0.0125	0.22	0.18	Corneal astigmatism;	chr4:119568372	chr4:119334329~119378233:+
HNSC	cis	rs35306767	0.903	rs11812523	ENSG00000229869.1	RP11-363N22.2	-3.96	8.7e-05	0.0125	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:869698	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs35567307	ENSG00000229869.1	RP11-363N22.2	-3.96	8.7e-05	0.0125	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:869864	chr10:933026~942743:+
HNSC	cis	rs889398	0.774	rs6499263	ENSG00000196696.11	PDXDC2P	-3.96	8.7e-05	0.0125	-0.13	-0.18	Body mass index;	chr16:69856246	chr16:69976297~70065948:-
HNSC	cis	rs13179617	0.928	rs2053693	ENSG00000215032.2	GNL3LP1	-3.96	8.7e-05	0.0125	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61510192	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.851	rs13159018	ENSG00000215032.2	GNL3LP1	-3.96	8.7e-05	0.0125	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61510662	chr5:60891935~60893577:-
HNSC	cis	rs7011507	0.7	rs72639004	ENSG00000253608.1	RP11-770E5.1	-3.96	8.7e-05	0.0125	-0.34	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48406519	chr8:48551567~48698510:+
HNSC	cis	rs8024893	0.764	rs8036245	ENSG00000259448.2	RP11-16E12.1	-3.96	8.7e-05	0.0125	-0.25	-0.18	Red cell distribution width;	chr15:31242211	chr15:31216020~31224445:+
HNSC	cis	rs847649	0.842	rs869332	ENSG00000239969.4	RP11-163E9.2	-3.96	8.7e-05	0.0125	-0.21	-0.18	Morning vs. evening chronotype;	chr7:102991800	chr7:102364162~102380633:+
HNSC	cis	rs8031584	0.678	rs8035703	ENSG00000270015.1	RP11-540B6.6	-3.96	8.7e-05	0.0125	-0.19	-0.18	Huntington's disease progression;	chr15:30876269	chr15:30926514~30928407:+
HNSC	cis	rs12539814	1	rs12666210	ENSG00000244198.4	RP4-545C24.1	-3.96	8.7e-05	0.0125	-0.29	-0.18	Diastolic blood pressure;	chr7:144435635	chr7:144194858~144280547:+
HNSC	cis	rs9880211	0.699	rs9809269	ENSG00000239213.4	NCK1-AS1	3.96	8.7e-05	0.0125	0.19	0.18	Height;Body mass index;	chr3:136711064	chr3:136841726~136862054:-
HNSC	cis	rs17507216	0.56	rs2871011	ENSG00000276710.3	CSPG4P8	-3.96	8.7e-05	0.0125	-0.2	-0.18	Excessive daytime sleepiness;	chr15:82560792	chr15:82459472~82477258:+
HNSC	cis	rs12597458	0.789	rs7186207	ENSG00000261008.5	LINC01572	3.96	8.7e-05	0.0125	0.2	0.18	Prostate cancer;	chr16:72001460	chr16:72283301~72665009:-
HNSC	cis	rs4713118	0.505	rs276371	ENSG00000224843.5	LINC00240	3.96	8.7e-05	0.0125	0.18	0.18	Parkinson's disease;	chr6:27942930	chr6:26956992~27023924:+
HNSC	cis	rs12893668	0.572	rs4900591	ENSG00000269958.1	RP11-73M18.8	3.96	8.7e-05	0.0125	0.17	0.18	Reticulocyte count;	chr14:103688541	chr14:103696353~103697163:+
HNSC	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-3.96	8.7e-05	0.0125	-0.31	-0.18	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
HNSC	cis	rs6840360	0.582	rs4473638	ENSG00000251611.1	RP11-610P16.1	-3.96	8.7e-05	0.0125	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.548	rs4254751	ENSG00000251611.1	RP11-610P16.1	-3.96	8.7e-05	0.0125	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151407551~151408835:-
HNSC	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-3.96	8.71e-05	0.0125	-0.19	-0.18	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
HNSC	cis	rs17345786	0.861	rs17402964	ENSG00000244119.1	PDCL3P4	3.96	8.71e-05	0.0125	0.2	0.18	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101712472~101713191:+
HNSC	cis	rs34864796	0.547	rs200476	ENSG00000224843.5	LINC00240	3.96	8.71e-05	0.0125	0.22	0.18	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:26956992~27023924:+
HNSC	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	3.96	8.71e-05	0.0125	0.18	0.18	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
HNSC	cis	rs7621025	0.599	rs13063987	ENSG00000239213.4	NCK1-AS1	-3.96	8.71e-05	0.0125	-0.17	-0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136841726~136862054:-
HNSC	cis	rs544991	0.652	rs475622	ENSG00000239670.1	RP4-803A2.2	3.96	8.71e-05	0.0125	0.23	0.18	Intelligence;	chr1:33741869	chr1:32986952~32988233:+
HNSC	cis	rs1642645	0.872	rs348139	ENSG00000228452.1	RP5-994D16.9	-3.96	8.71e-05	0.0125	-0.25	-0.18	Left ventricular obstructive tract defect (maternal effect);	chr1:42005230	chr1:42775813~42776790:-
HNSC	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	3.96	8.71e-05	0.0125	0.21	0.18	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000241278.1	ENPP7P4	-3.96	8.72e-05	0.0125	-0.31	-0.18	Blood pressure (smoking interaction);	chr3:125893222	chr3:125848223~125909372:+
HNSC	cis	rs2898290	0.622	rs7829381	ENSG00000269918.1	AF131215.9	-3.96	8.72e-05	0.0125	-0.17	-0.18	Systolic blood pressure;	chr8:11487064	chr8:11104691~11106704:-
HNSC	cis	rs73198271	0.562	rs76960788	ENSG00000253893.2	FAM85B	3.96	8.72e-05	0.0125	0.27	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8816539	chr8:8167819~8226614:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	3.96	8.72e-05	0.0125	0.31	0.18	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
HNSC	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-3.96	8.72e-05	0.0125	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
HNSC	cis	rs28489187	0.706	rs2268667	ENSG00000223653.4	RP11-131L23.1	-3.96	8.72e-05	0.0125	-0.25	-0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85328063	chr1:85276715~85448124:+
HNSC	cis	rs2439831	0.867	rs4583210	ENSG00000275601.1	AC011330.13	-3.96	8.72e-05	0.0125	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43368727	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs28461955	ENSG00000275601.1	AC011330.13	-3.96	8.72e-05	0.0125	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43369261	chr15:43642389~43643023:-
HNSC	cis	rs62432291	0.681	rs3003173	ENSG00000235086.1	FNDC1-IT1	-3.96	8.72e-05	0.0125	-0.25	-0.18	Joint mobility (Beighton score);	chr6:159244660	chr6:159240786~159243329:+
HNSC	cis	rs1941023	0.619	rs1051594	ENSG00000279632.1	RP11-286N22.6	3.96	8.72e-05	0.0125	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60470581	chr11:61426448~61427325:-
HNSC	cis	rs3096299	0.9	rs4785666	ENSG00000261574.1	RP1-168P16.2	3.96	8.72e-05	0.0125	0.23	0.18	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89392375~89412564:-
HNSC	cis	rs871012	0.502	rs11951889	ENSG00000251405.2	CTB-109A12.1	-3.96	8.73e-05	0.0125	-0.21	-0.18	IgG glycosylation;	chr5:157449776	chr5:157362615~157460078:-
HNSC	cis	rs1580019	0.961	rs958217	ENSG00000226468.2	AC018641.7	-3.96	8.73e-05	0.0125	-0.24	-0.18	Cognitive ability;	chr7:32453805	chr7:32456963~32457758:-
HNSC	cis	rs597539	0.652	rs686390	ENSG00000261625.1	RP11-554A11.4	-3.96	8.73e-05	0.0125	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:69000765~69002048:-
HNSC	cis	rs9611565	0.918	rs9538	ENSG00000235513.1	RP4-756G23.5	3.96	8.73e-05	0.0125	0.21	0.18	Vitiligo;	chr22:41359853	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.918	rs9611561	ENSG00000235513.1	RP4-756G23.5	3.96	8.73e-05	0.0125	0.21	0.18	Vitiligo;	chr22:41361230	chr22:41209122~41217627:-
HNSC	cis	rs17122278	1	rs2277292	ENSG00000255422.1	AP002954.4	3.96	8.73e-05	0.0125	0.3	0.18	Total cholesterol levels;	chr11:118554704	chr11:118704607~118750263:+
HNSC	cis	rs9908552	0.586	rs7207377	ENSG00000262810.1	RP11-667K14.5	3.96	8.73e-05	0.0125	0.2	0.18	Schizophrenia;	chr17:1337800	chr17:2089681~2101560:+
HNSC	cis	rs1008375	1	rs10939740	ENSG00000249502.1	AC006160.5	-3.96	8.73e-05	0.0125	-0.2	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17615867	chr4:17587467~17614571:-
HNSC	cis	rs7927592	0.731	rs10896350	ENSG00000255031.4	RP11-802E16.3	3.96	8.73e-05	0.0125	0.15	0.18	Total body bone mineral density;	chr11:68618905	chr11:68050740~68053762:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000253981.4	ALG1L13P	3.96	8.73e-05	0.0125	0.2	0.18	Systolic blood pressure;	chr8:8488264	chr8:8236003~8244667:-
HNSC	cis	rs57502260	0.68	rs55654976	ENSG00000212093.1	AP000807.1	3.96	8.73e-05	0.0125	0.26	0.18	Total body bone mineral density (age 45-60);	chr11:68626073	chr11:68506083~68506166:-
HNSC	cis	rs9611565	0.571	rs2050032	ENSG00000233903.2	Z83851.4	3.96	8.74e-05	0.0125	0.25	0.18	Vitiligo;	chr22:41756425	chr22:42276355~42277052:+
HNSC	cis	rs12745968	0.589	rs4970707	ENSG00000223787.2	RP4-593M8.1	-3.96	8.74e-05	0.0125	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr1:92520889	chr1:92580476~92580821:-
HNSC	cis	rs950027	0.62	rs1145077	ENSG00000259479.5	SORD2P	-3.96	8.74e-05	0.0125	-0.21	-0.18	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:44826371~44884694:-
HNSC	cis	rs60617249	0.831	rs11980778	ENSG00000228204.2	RP4-724E13.2	3.96	8.74e-05	0.0125	0.19	0.18	Major depression and alcohol dependence;	chr7:50919306	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.831	rs10486747	ENSG00000228204.2	RP4-724E13.2	3.96	8.74e-05	0.0125	0.19	0.18	Major depression and alcohol dependence;	chr7:50919779	chr7:50866747~51022990:+
HNSC	cis	rs755249	0.51	rs599892	ENSG00000182109.6	RP11-69E11.4	3.96	8.74e-05	0.0125	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39522280~39546187:-
HNSC	cis	rs7819412	0.505	rs17782554	ENSG00000269918.1	AF131215.9	-3.96	8.74e-05	0.0126	-0.18	-0.18	Triglycerides;	chr8:11164596	chr8:11104691~11106704:-
HNSC	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	3.96	8.75e-05	0.0126	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	3.96	8.75e-05	0.0126	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
HNSC	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-3.96	8.75e-05	0.0126	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
HNSC	cis	rs1620921	0.625	rs2489961	ENSG00000231863.1	RP3-428L16.1	-3.96	8.75e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160840351	chr6:160931080~160969771:+
HNSC	cis	rs442309	0.875	rs192004	ENSG00000238280.1	RP11-436D10.3	-3.96	8.75e-05	0.0126	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62745965	chr10:62793562~62805887:-
HNSC	cis	rs442309	0.875	rs224066	ENSG00000238280.1	RP11-436D10.3	-3.96	8.75e-05	0.0126	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62746419	chr10:62793562~62805887:-
HNSC	cis	rs4937076	0.653	rs634072	ENSG00000254967.5	RP11-680F20.6	-3.96	8.75e-05	0.0126	-0.2	-0.18	Primary tooth development (time to first tooth eruption);	chr11:125948788	chr11:125950116~125956319:+
HNSC	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-3.96	8.75e-05	0.0126	-0.21	-0.18	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-3.96	8.75e-05	0.0126	-0.21	-0.18	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-3.96	8.75e-05	0.0126	-0.21	-0.18	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-3.96	8.75e-05	0.0126	-0.21	-0.18	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-3.96	8.75e-05	0.0126	-0.21	-0.18	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
HNSC	cis	rs4938303	0.589	rs11216100	ENSG00000280143.1	AP000892.6	-3.96	8.75e-05	0.0126	-0.21	-0.18	Triglycerides;	chr11:116701814	chr11:117204967~117210292:+
HNSC	cis	rs6787172	0.644	rs67286798	ENSG00000272087.1	RP11-379F4.7	3.96	8.76e-05	0.0126	0.19	0.18	Subjective well-being;	chr3:158496414	chr3:158693120~158693768:-
HNSC	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	3.96	8.76e-05	0.0126	0.26	0.18	Pain;	chr19:21294601	chr19:21554640~21569237:-
HNSC	cis	rs11711311	1	rs9828099	ENSG00000241529.3	RN7SL767P	-3.96	8.76e-05	0.0126	-0.23	-0.18	IgG glycosylation;	chr3:113799555	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9828449	ENSG00000241529.3	RN7SL767P	-3.96	8.76e-05	0.0126	-0.23	-0.18	IgG glycosylation;	chr3:113799755	chr3:113632704~113632998:+
HNSC	cis	rs9300255	0.602	rs1727313	ENSG00000280120.1	RP11-546D6.3	3.96	8.76e-05	0.0126	0.18	0.18	Neutrophil percentage of white cells;	chr12:123156306	chr12:123152324~123153377:-
HNSC	cis	rs5758659	0.652	rs4822084	ENSG00000273366.1	CTA-989H11.1	3.96	8.76e-05	0.0126	0.21	0.18	Cognitive function;	chr22:42039864	chr22:42278188~42278846:+
HNSC	cis	rs7829975	0.502	rs11785183	ENSG00000173295.6	FAM86B3P	-3.96	8.76e-05	0.0126	-0.22	-0.18	Mood instability;	chr8:8708447	chr8:8228595~8244865:+
HNSC	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-3.96	8.76e-05	0.0126	-0.28	-0.18	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
HNSC	cis	rs75422866	0.867	rs7303895	ENSG00000276691.1	RP5-1057I20.5	3.96	8.76e-05	0.0126	0.31	0.18	Pneumonia;	chr12:47683290	chr12:47788426~47788971:+
HNSC	cis	rs35000415	0.938	rs35234849	ENSG00000244556.1	ODCP	3.96	8.76e-05	0.0126	0.36	0.18	Systemic lupus erythematosus;	chr7:129008899	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs12539476	ENSG00000244556.1	ODCP	3.96	8.76e-05	0.0126	0.36	0.18	Systemic lupus erythematosus;	chr7:129017429	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs13236009	ENSG00000244556.1	ODCP	3.96	8.76e-05	0.0126	0.36	0.18	Systemic lupus erythematosus;	chr7:129023119	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs71581958	ENSG00000244556.1	ODCP	3.96	8.76e-05	0.0126	0.36	0.18	Systemic lupus erythematosus;	chr7:129025488	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs34381587	ENSG00000244556.1	ODCP	3.96	8.76e-05	0.0126	0.36	0.18	Systemic lupus erythematosus;	chr7:129026771	chr7:129028889~129030527:+
HNSC	cis	rs2836974	0.932	rs2150415	ENSG00000255568.3	BRWD1-AS2	3.96	8.76e-05	0.0126	0.17	0.18	Cognitive function;	chr21:39243441	chr21:39313935~39314962:+
HNSC	cis	rs9840812	0.577	rs503973	ENSG00000239213.4	NCK1-AS1	-3.96	8.76e-05	0.0126	-0.17	-0.18	Fibrinogen levels;	chr3:136340695	chr3:136841726~136862054:-
HNSC	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	3.96	8.76e-05	0.0126	0.21	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
HNSC	cis	rs55823223	0.648	rs11869977	ENSG00000267801.1	RP11-552F3.9	3.96	8.77e-05	0.0126	0.22	0.18	Psoriasis;	chr17:75861301	chr17:75876372~75879546:+
HNSC	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	3.96	8.77e-05	0.0126	0.22	0.18	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
HNSC	cis	rs638893	1	rs113641235	ENSG00000255422.1	AP002954.4	3.96	8.77e-05	0.0126	0.32	0.18	Vitiligo;	chr11:118829555	chr11:118704607~118750263:+
HNSC	cis	rs3736485	0.934	rs12442803	ENSG00000259438.1	CTD-2650P22.1	3.96	8.77e-05	0.0126	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51606557	chr15:52010999~52019095:-
HNSC	cis	rs561341	1	rs113115092	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31957145	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.783	rs512698	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31965488	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs555629	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31967117	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.769	rs559228	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31967508	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs1681718	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31969426	chr17:32051030~32053208:+
HNSC	cis	rs561341	0.882	rs2428337	ENSG00000278867.1	RP11-640N20.4	-3.96	8.77e-05	0.0126	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31972448	chr17:32051030~32053208:+
HNSC	cis	rs1009077	0.671	rs13120581	ENSG00000245958.5	RP11-33B1.1	3.96	8.77e-05	0.0126	0.21	0.18	Endometriosis;	chr4:119602481	chr4:119454791~119552025:+
HNSC	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-3.96	8.77e-05	0.0126	-0.18	-0.18	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
HNSC	cis	rs875971	0.545	rs313830	ENSG00000164669.11	INTS4P1	3.96	8.77e-05	0.0126	0.26	0.18	Aortic root size;	chr7:66086944	chr7:65141225~65234216:+
HNSC	cis	rs2548724	0.796	rs62372300	ENSG00000250682.4	LINC00491	3.96	8.77e-05	0.0126	0.24	0.18	Type 2 diabetes;	chr5:102340441	chr5:102609156~102671559:-
HNSC	cis	rs10129255	0.5	rs6576230	ENSG00000224373.3	IGHV4-59	3.96	8.77e-05	0.0126	0.1	0.18	Kawasaki disease;	chr14:106778539	chr14:106627249~106627825:-
HNSC	cis	rs6088580	0.634	rs6141465	ENSG00000276073.1	RP5-1125A11.7	3.96	8.78e-05	0.0126	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6142157	ENSG00000276073.1	RP5-1125A11.7	3.96	8.78e-05	0.0126	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs4142007	ENSG00000276073.1	RP5-1125A11.7	3.96	8.78e-05	0.0126	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6142159	ENSG00000276073.1	RP5-1125A11.7	3.96	8.78e-05	0.0126	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:33985617~33988989:-
HNSC	cis	rs4660214	0.568	rs967530	ENSG00000182109.6	RP11-69E11.4	-3.96	8.78e-05	0.0126	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39522280~39546187:-
HNSC	cis	rs10519937	0.935	rs59745967	ENSG00000230929.5	RP11-395C3.1	-3.96	8.78e-05	0.0126	-0.27	-0.18	IgG glycosylation;	chr5:127404360	chr5:126628019~126628319:-
HNSC	cis	rs6674176	0.561	rs4660263	ENSG00000237950.1	RP11-7O11.3	3.96	8.78e-05	0.0126	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43955761	chr1:43944370~43946551:-
HNSC	cis	rs11773103	0.867	rs11767948	ENSG00000224046.1	AC005076.5	3.96	8.78e-05	0.0126	0.33	0.18	Bipolar disorder or major depressive disorder (combined);	chr7:87352875	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.609	rs73194676	ENSG00000224046.1	AC005076.5	3.96	8.78e-05	0.0126	0.33	0.18	Bipolar disorder or major depressive disorder (combined);	chr7:87353117	chr7:87151423~87152420:-
HNSC	cis	rs765751	0.767	rs2605105	ENSG00000228536.1	RP11-392O17.1	-3.96	8.78e-05	0.0126	-0.21	-0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219472881	chr1:219409681~219411941:-
HNSC	cis	rs4908768	0.501	rs910581	ENSG00000232912.4	RP5-1115A15.1	3.96	8.78e-05	0.0126	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8424645~8434838:+
HNSC	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	3.96	8.78e-05	0.0126	0.14	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
HNSC	cis	rs950169	0.545	rs4354897	ENSG00000230373.7	GOLGA6L5P	-3.96	8.78e-05	0.0126	-0.21	-0.18	Schizophrenia;	chr15:83976219	chr15:84507885~84516814:-
HNSC	cis	rs7824557	0.602	rs11784544	ENSG00000255310.2	AF131215.2	3.96	8.78e-05	0.0126	0.17	0.18	Retinal vascular caliber;	chr8:11346994	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.602	rs11781375	ENSG00000255310.2	AF131215.2	3.96	8.78e-05	0.0126	0.17	0.18	Retinal vascular caliber;	chr8:11347023	chr8:11107788~11109726:-
HNSC	cis	rs2732480	0.5	rs2732461	ENSG00000257763.1	OR5BK1P	3.96	8.78e-05	0.0126	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48355792~48356614:-
HNSC	cis	rs436483	1	rs411656	ENSG00000213385.3	RP11-577H5.1	-3.96	8.78e-05	0.0126	-0.19	-0.18	Lobe attachment (rater-scored or self-reported);	chr7:102053448	chr7:102755146~102755939:+
HNSC	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-3.96	8.78e-05	0.0126	-0.22	-0.18	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
HNSC	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-3.96	8.78e-05	0.0126	-0.22	-0.18	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
HNSC	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	3.96	8.79e-05	0.0126	0.22	0.18	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
HNSC	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-3.96	8.79e-05	0.0126	-0.23	-0.18	Height;	chr5:128014053	chr5:127940426~128083172:-
HNSC	cis	rs859767	0.501	rs1123184	ENSG00000224043.6	CCNT2-AS1	3.96	8.79e-05	0.0126	0.21	0.18	Neuroticism;	chr2:134673487	chr2:134735464~134918710:-
HNSC	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	3.96	8.79e-05	0.0126	0.19	0.18	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
HNSC	cis	rs4906332	0.84	rs34161327	ENSG00000244691.1	RPL10AP1	-3.96	8.79e-05	0.0126	-0.21	-0.18	Coronary artery disease;	chr14:103390988	chr14:103412119~103412761:-
HNSC	cis	rs7027203	0.538	rs2244395	ENSG00000227603.1	RP11-165J3.6	-3.96	8.79e-05	0.0126	-0.16	-0.18	DNA methylation (variation);	chr9:93758441	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2487015	ENSG00000227603.1	RP11-165J3.6	-3.96	8.79e-05	0.0126	-0.16	-0.18	DNA methylation (variation);	chr9:93758958	chr9:93435332~93437121:-
HNSC	cis	rs7027203	0.557	rs2490997	ENSG00000227603.1	RP11-165J3.6	-3.96	8.79e-05	0.0126	-0.16	-0.18	DNA methylation (variation);	chr9:93759827	chr9:93435332~93437121:-
HNSC	cis	rs13020137	1	rs13020137	ENSG00000231240.1	KLF2P1	-3.96	8.79e-05	0.0126	-0.18	-0.18	Schizophrenia;	chr2:129999731	chr2:130036958~130038422:+
HNSC	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-3.96	8.79e-05	0.0126	-0.22	-0.18	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
HNSC	cis	rs1979679	0.842	rs2035271	ENSG00000247934.4	RP11-967K21.1	-3.96	8.79e-05	0.0126	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28163298~28190738:-
HNSC	cis	rs9487051	0.724	rs11751953	ENSG00000243587.6	C6orf183	-3.96	8.8e-05	0.0126	-0.19	-0.18	Reticulocyte fraction of red cells;	chr6:109314783	chr6:109165833~109271014:+
HNSC	cis	rs7586673	0.621	rs4999196	ENSG00000227403.1	AC009299.3	-3.96	8.8e-05	0.0126	-0.34	-0.18	Intelligence (multi-trait analysis);	chr2:161114824	chr2:161244739~161249050:+
HNSC	cis	rs9313772	0.775	rs10476244	ENSG00000254350.1	RP11-542A14.1	3.96	8.8e-05	0.0126	0.19	0.18	Blood pressure;	chr5:158402678	chr5:158424585~158452758:+
HNSC	cis	rs12545109	0.8	rs2582401	ENSG00000246430.5	LINC00968	-3.96	8.8e-05	0.0126	-0.23	-0.18	Obesity-related traits;	chr8:56489097	chr8:56496246~56559823:-
HNSC	cis	rs4713118	0.869	rs9468214	ENSG00000216901.1	AL022393.7	3.96	8.8e-05	0.0126	0.22	0.18	Parkinson's disease;	chr6:27745520	chr6:28176188~28176674:+
HNSC	cis	rs7005380	0.581	rs4871795	ENSG00000279347.1	RP11-85I17.2	3.96	8.8e-05	0.0126	0.16	0.18	Interstitial lung disease;	chr8:119929425	chr8:119838736~119840385:-
HNSC	cis	rs28830936	1	rs4924570	ENSG00000250379.1	RP11-23P13.4	3.96	8.8e-05	0.0126	0.23	0.18	Diastolic blood pressure;	chr15:41682462	chr15:41825099~41827936:-
HNSC	cis	rs11838725	1	rs11838725	ENSG00000215482.3	CALM2P3	-3.96	8.8e-05	0.0126	-0.21	-0.18	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:41170700~41171148:-
HNSC	cis	rs427691	0.625	rs845738	ENSG00000271849.1	CTC-332L22.1	-3.96	8.8e-05	0.0126	-0.28	-0.18	Autism spectrum disorder or schizophrenia;	chr5:109682414	chr5:109687802~109688329:-
HNSC	cis	rs72827839	0.779	rs72827844	ENSG00000244649.3	CTD-2377D24.6	-3.96	8.8e-05	0.0126	-0.23	-0.18	Ease of getting up in the morning;	chr17:48357079	chr17:48646923~48707346:+
HNSC	cis	rs5758511	0.514	rs5758622	ENSG00000227370.1	RP4-669P10.19	3.96	8.81e-05	0.0126	0.22	0.18	Birth weight;	chr22:42167927	chr22:42132543~42132998:+
HNSC	cis	rs1065852	0.906	rs5751232	ENSG00000227370.1	RP4-669P10.19	3.96	8.81e-05	0.0126	0.22	0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs9607882	ENSG00000227370.1	RP4-669P10.19	3.96	8.81e-05	0.0126	0.22	0.18	Birth weight;	chr22:42171445	chr22:42132543~42132998:+
HNSC	cis	rs9313772	0.775	rs1952650	ENSG00000254350.1	RP11-542A14.1	3.96	8.81e-05	0.0126	0.2	0.18	Blood pressure;	chr5:158386459	chr5:158424585~158452758:+
HNSC	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	3.96	8.81e-05	0.0126	0.29	0.18	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
HNSC	cis	rs765751	0.767	rs2605101	ENSG00000228536.1	RP11-392O17.1	-3.96	8.81e-05	0.0126	-0.21	-0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219471154	chr1:219409681~219411941:-
HNSC	cis	rs13179617	0.928	rs6874264	ENSG00000215032.2	GNL3LP1	-3.96	8.81e-05	0.0126	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61500329	chr5:60891935~60893577:-
HNSC	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	3.96	8.81e-05	0.0126	0.22	0.18	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
HNSC	cis	rs2243480	0.522	rs778717	ENSG00000230295.1	RP11-458F8.2	-3.96	8.81e-05	0.0126	-0.3	-0.18	Diabetic kidney disease;	chr7:66383164	chr7:66880708~66882981:+
HNSC	cis	rs12701220	0.739	rs2293523	ENSG00000229043.2	AC091729.9	-3.96	8.81e-05	0.0126	-0.27	-0.18	Bronchopulmonary dysplasia;	chr7:1058882	chr7:1160374~1165267:+
HNSC	cis	rs17739794	0.502	rs3860879	ENSG00000254207.1	RP11-43A14.1	-3.96	8.81e-05	0.0126	-0.21	-0.18	Clozapine-induced cytotoxicity;	chr8:859489	chr8:725188~725877:-
HNSC	cis	rs11098499	0.863	rs12502389	ENSG00000250412.1	KLHL2P1	3.96	8.82e-05	0.0126	0.23	0.18	Corneal astigmatism;	chr4:119533036	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.821	rs3775852	ENSG00000250412.1	KLHL2P1	3.96	8.82e-05	0.0126	0.23	0.18	Corneal astigmatism;	chr4:119533401	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.82	rs6534140	ENSG00000250412.1	KLHL2P1	3.96	8.82e-05	0.0126	0.23	0.18	Corneal astigmatism;	chr4:119534156	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs10034450	ENSG00000250412.1	KLHL2P1	3.96	8.82e-05	0.0126	0.23	0.18	Corneal astigmatism;	chr4:119534494	chr4:119334329~119378233:+
HNSC	cis	rs6088580	0.634	rs6087580	ENSG00000276073.1	RP5-1125A11.7	3.96	8.82e-05	0.0126	0.19	0.18	Glomerular filtration rate (creatinine);	chr20:34404786	chr20:33985617~33988989:-
HNSC	cis	rs62025270	0.688	rs62022940	ENSG00000259762.1	RP11-158M2.4	-3.96	8.82e-05	0.0126	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85750336~85752901:-
HNSC	cis	rs6142618	0.905	rs6121352	ENSG00000275576.1	RP5-836N17.4	3.96	8.82e-05	0.0126	0.18	0.18	Inflammatory bowel disease;	chr20:32127894	chr20:32116171~32116629:+
HNSC	cis	rs11711311	1	rs7622403	ENSG00000241529.3	RN7SL767P	3.96	8.82e-05	0.0126	0.23	0.18	IgG glycosylation;	chr3:113753587	chr3:113632704~113632998:+
HNSC	cis	rs73607972	0.866	rs111763946	ENSG00000275191.1	RP11-36I17.2	-3.96	8.82e-05	0.0126	-0.26	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602740	chr16:53628256~53628816:-
HNSC	cis	rs1620921	0.594	rs2465863	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160839937	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs2489958	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160840077	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.595	rs2465862	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160840166	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs2489960	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160840283	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs2465861	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160840454	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs9458045	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841051	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.621	rs9458046	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841101	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs9458047	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841304	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.622	rs2489965	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841575	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.621	rs2489966	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841842	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.653	rs2489967	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160841845	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs2997097	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842168	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs59942091	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842370	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs12215233	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842421	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.621	rs12194479	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842453	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs12189741	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842496	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.591	rs12191314	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842689	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs12209829	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160842906	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs12196112	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843032	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.621	rs2489968	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843376	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.591	rs2489969	ENSG00000231863.1	RP3-428L16.1	-3.96	8.82e-05	0.0126	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843572	chr6:160931080~160969771:+
HNSC	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	3.96	8.82e-05	0.0126	0.24	0.18	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
HNSC	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-3.96	8.82e-05	0.0126	-0.22	-0.18	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
HNSC	cis	rs6490294	0.571	rs2272308	ENSG00000226469.1	ADAM1B	3.96	8.82e-05	0.0126	0.26	0.18	Mean platelet volume;	chr12:112163446	chr12:111927018~111929017:+
HNSC	cis	rs7824557	0.564	rs11781637	ENSG00000255310.2	AF131215.2	-3.96	8.82e-05	0.0126	-0.17	-0.18	Retinal vascular caliber;	chr8:11357463	chr8:11107788~11109726:-
HNSC	cis	rs482329	0.86	rs611634	ENSG00000224939.1	LINC00184	-3.96	8.82e-05	0.0126	-0.23	-0.18	Life threatening arrhythmia;	chr1:234660117	chr1:234629311~234634780:+
HNSC	cis	rs4356203	0.905	rs594034	ENSG00000260196.1	RP1-239B22.5	-3.96	8.83e-05	0.0126	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17380649~17383531:+
HNSC	cis	rs4308124	0.708	rs6716091	ENSG00000230499.1	AC108463.1	-3.96	8.83e-05	0.0126	-0.21	-0.18	Vitiligo;	chr2:111233556	chr2:111195963~111206494:+
HNSC	cis	rs4906332	0.782	rs12891288	ENSG00000269940.1	RP11-73M18.7	3.96	8.83e-05	0.0126	0.2	0.18	Coronary artery disease;	chr14:103533413	chr14:103694560~103695170:+
HNSC	cis	rs9987353	0.566	rs34389718	ENSG00000253893.2	FAM85B	3.96	8.83e-05	0.0126	0.23	0.18	Recombination measurement;	chr8:9208015	chr8:8167819~8226614:-
HNSC	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	3.96	8.83e-05	0.0127	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
HNSC	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-3.96	8.83e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-3.96	8.83e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-3.96	8.83e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-3.96	8.83e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-3.96	8.83e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
HNSC	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-3.96	8.83e-05	0.0127	-0.23	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
HNSC	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-3.96	8.83e-05	0.0127	-0.23	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
HNSC	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-3.96	8.83e-05	0.0127	-0.23	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
HNSC	cis	rs4760636	0.954	rs7960277	ENSG00000268069.2	RP5-1057I20.4	3.96	8.83e-05	0.0127	0.21	0.18	Urate levels;	chr12:47779787	chr12:47784923~47786002:+
HNSC	cis	rs4760636	1	rs4760652	ENSG00000268069.2	RP5-1057I20.4	3.96	8.83e-05	0.0127	0.21	0.18	Urate levels;	chr12:47781821	chr12:47784923~47786002:+
HNSC	cis	rs4760636	0.911	rs4760654	ENSG00000268069.2	RP5-1057I20.4	3.96	8.83e-05	0.0127	0.21	0.18	Urate levels;	chr12:47782054	chr12:47784923~47786002:+
HNSC	cis	rs4760636	1	rs2408874	ENSG00000268069.2	RP5-1057I20.4	3.96	8.83e-05	0.0127	0.21	0.18	Urate levels;	chr12:47783290	chr12:47784923~47786002:+
HNSC	cis	rs7735319	1	rs7735319	ENSG00000249102.1	CTD-2066L21.1	3.96	8.83e-05	0.0127	0.2	0.18	Systolic blood pressure;	chr5:33156863	chr5:33008994~33025724:+
HNSC	cis	rs7107174	1	rs4128206	ENSG00000251323.2	RP11-452H21.4	3.96	8.83e-05	0.0127	0.26	0.18	Testicular germ cell tumor;	chr11:78304906	chr11:78423982~78429836:-
HNSC	cis	rs8058578	1	rs8051050	ENSG00000279196.1	RP11-1072A3.3	3.96	8.84e-05	0.0127	0.22	0.18	Multiple myeloma;	chr16:30676588	chr16:30984630~30988270:-
HNSC	cis	rs6500602	0.653	rs4786488	ENSG00000280063.1	RP11-295D4.3	3.96	8.84e-05	0.0127	0.14	0.18	Schizophrenia;	chr16:4392526	chr16:4346694~4348648:-
HNSC	cis	rs12887734	0.566	rs8548	ENSG00000269910.1	RP11-73M18.10	3.96	8.84e-05	0.0127	0.17	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694516~103695050:-
HNSC	cis	rs11157436	0.56	rs2031071	ENSG00000211814.1	TRAV35	-3.96	8.84e-05	0.0127	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157547	chr14:22221896~22222475:+
HNSC	cis	rs2098713	0.534	rs57424532	ENSG00000250155.1	CTD-2353F22.1	3.96	8.84e-05	0.0127	0.19	0.18	Telomere length;	chr5:37497184	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs2102828	ENSG00000250155.1	CTD-2353F22.1	3.96	8.84e-05	0.0127	0.19	0.18	Telomere length;	chr5:37498313	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.501	rs10805626	ENSG00000250155.1	CTD-2353F22.1	3.96	8.84e-05	0.0127	0.19	0.18	Height;	chr5:37499115	chr5:36666214~36725195:-
HNSC	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-3.96	8.84e-05	0.0127	-0.21	-0.18	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
HNSC	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-3.95	8.84e-05	0.0127	-0.25	-0.18	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
HNSC	cis	rs7572733	0.555	rs700671	ENSG00000231621.1	AC013264.2	-3.95	8.84e-05	0.0127	-0.17	-0.18	Dermatomyositis;	chr2:197825277	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs700673	ENSG00000231621.1	AC013264.2	-3.95	8.84e-05	0.0127	-0.17	-0.18	Dermatomyositis;	chr2:197828205	chr2:197197991~197199273:+
HNSC	cis	rs12935418	0.524	rs9933697	ENSG00000278985.1	RP11-303E16.9	3.95	8.85e-05	0.0127	0.18	0.18	Mean corpuscular volume;	chr16:80939637	chr16:80982319~80984094:-
HNSC	cis	rs61160187	0.582	rs17419290	ENSG00000272308.1	RP11-231G3.1	3.95	8.85e-05	0.0127	0.18	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60866457~60866935:-
HNSC	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	3.95	8.85e-05	0.0127	0.26	0.18	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
HNSC	cis	rs57502260	0.704	rs72936599	ENSG00000212093.1	AP000807.1	3.95	8.85e-05	0.0127	0.27	0.18	Total body bone mineral density (age 45-60);	chr11:68552937	chr11:68506083~68506166:-
HNSC	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-3.95	8.85e-05	0.0127	-0.19	-0.18	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-3.95	8.85e-05	0.0127	-0.19	-0.18	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-3.95	8.85e-05	0.0127	-0.19	-0.18	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
HNSC	cis	rs6890684	0.544	rs34634	ENSG00000215032.2	GNL3LP1	3.95	8.85e-05	0.0127	0.2	0.18	Intelligence (multi-trait analysis);	chr5:61217739	chr5:60891935~60893577:-
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000254174.1	IGHV1-12	-3.95	8.85e-05	0.0127	-0.14	-0.18	Rheumatic heart disease;	chr14:106630013	chr14:106122420~106122709:-
HNSC	cis	rs2179367	0.959	rs537354	ENSG00000216906.2	RP11-350J20.9	3.95	8.85e-05	0.0127	0.23	0.18	Dupuytren's disease;	chr6:149344801	chr6:149904243~149906418:+
HNSC	cis	rs853679	1	rs1778508	ENSG00000226314.6	ZNF192P1	3.95	8.85e-05	0.0127	0.25	0.18	Depression;	chr6:28262103	chr6:28161781~28169594:+
HNSC	cis	rs2439831	1	rs537115	ENSG00000275601.1	AC011330.13	-3.95	8.85e-05	0.0127	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43437750	chr15:43642389~43643023:-
HNSC	cis	rs2439831	1	rs2245908	ENSG00000275601.1	AC011330.13	-3.95	8.85e-05	0.0127	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43439256	chr15:43642389~43643023:-
HNSC	cis	rs60617249	0.791	rs12531763	ENSG00000228204.2	RP4-724E13.2	3.95	8.86e-05	0.0127	0.19	0.18	Major depression and alcohol dependence;	chr7:50931662	chr7:50866747~51022990:+
HNSC	cis	rs1642645	0.872	rs689277	ENSG00000228452.1	RP5-994D16.9	3.95	8.86e-05	0.0127	0.25	0.18	Left ventricular obstructive tract defect (maternal effect);	chr1:41984700	chr1:42775813~42776790:-
HNSC	cis	rs67981189	0.593	rs7154437	ENSG00000274818.1	RP1-292L20.3	3.95	8.86e-05	0.0127	0.2	0.18	Schizophrenia;	chr14:70974668	chr14:70906657~70907111:-
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-3.95	8.86e-05	0.0127	-0.21	-0.18	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
HNSC	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-3.95	8.86e-05	0.0127	-0.26	-0.18	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-3.95	8.86e-05	0.0127	-0.26	-0.18	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-3.95	8.86e-05	0.0127	-0.26	-0.18	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
HNSC	cis	rs7178375	0.607	rs7171212	ENSG00000259845.1	HERC2P10	3.95	8.86e-05	0.0127	0.32	0.18	Hypertriglyceridemia;	chr15:30915508	chr15:30815271~30844153:+
HNSC	cis	rs1113500	0.73	rs1781077	ENSG00000226822.1	RP11-356N1.2	-3.95	8.86e-05	0.0127	-0.2	-0.18	Growth-regulated protein alpha levels;	chr1:108046967	chr1:108071482~108074519:+
HNSC	cis	rs2337406	0.866	rs2301536	ENSG00000280411.1	IGHV1-69-2	-3.95	8.86e-05	0.0127	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106790636	chr14:106762092~106762588:-
HNSC	cis	rs11098499	0.863	rs13136462	ENSG00000250412.1	KLHL2P1	3.95	8.87e-05	0.0127	0.23	0.18	Corneal astigmatism;	chr4:119622018	chr4:119334329~119378233:+
HNSC	cis	rs8098244	0.597	rs57266464	ENSG00000264745.1	TTC39C-AS1	-3.95	8.87e-05	0.0127	-0.21	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989811	chr18:23994213~24015339:-
HNSC	cis	rs2736345	0.516	rs9657551	ENSG00000255046.1	RP11-297N6.4	-3.95	8.87e-05	0.0127	-0.19	-0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540674	chr8:11797928~11802568:-
HNSC	cis	rs2243480	0.522	rs12698511	ENSG00000230295.1	RP11-458F8.2	-3.95	8.87e-05	0.0127	-0.29	-0.18	Diabetic kidney disease;	chr7:66009932	chr7:66880708~66882981:+
HNSC	cis	rs6587515	0.901	rs12045807	ENSG00000274963.1	Metazoa_SRP	-3.95	8.87e-05	0.0127	-0.28	-0.18	Pericardial adipose tissue adjusted for height and weight;	chr1:150612358	chr1:150568971~150569269:-
HNSC	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-3.95	8.87e-05	0.0127	-0.22	-0.18	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
HNSC	cis	rs6088580	0.668	rs1205340	ENSG00000276073.1	RP5-1125A11.7	3.95	8.87e-05	0.0127	0.19	0.18	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:33985617~33988989:-
HNSC	cis	rs3754214	0.769	rs509345	ENSG00000228126.1	FALEC	-3.95	8.87e-05	0.0127	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr1:150303594	chr1:150515757~150518032:+
HNSC	cis	rs9329221	0.537	rs6986911	ENSG00000255310.2	AF131215.2	3.95	8.88e-05	0.0127	0.17	0.18	Neuroticism;	chr8:10121013	chr8:11107788~11109726:-
HNSC	cis	rs9313772	0.775	rs10051614	ENSG00000254350.1	RP11-542A14.1	-3.95	8.88e-05	0.0127	-0.2	-0.18	Blood pressure;	chr5:158395244	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.775	rs10076304	ENSG00000254350.1	RP11-542A14.1	-3.95	8.88e-05	0.0127	-0.2	-0.18	Blood pressure;	chr5:158395246	chr5:158424585~158452758:+
HNSC	cis	rs4713118	0.869	rs7776351	ENSG00000216901.1	AL022393.7	-3.95	8.88e-05	0.0127	-0.22	-0.18	Parkinson's disease;	chr6:27758952	chr6:28176188~28176674:+
HNSC	cis	rs1009077	0.68	rs3775850	ENSG00000245958.5	RP11-33B1.1	3.95	8.88e-05	0.0127	0.19	0.18	Endometriosis;	chr4:119529863	chr4:119454791~119552025:+
HNSC	cis	rs7824557	0.638	rs4413734	ENSG00000269918.1	AF131215.9	3.95	8.88e-05	0.0127	0.17	0.18	Retinal vascular caliber;	chr8:11355269	chr8:11104691~11106704:-
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000106610.13	STAG3L4	-3.95	8.88e-05	0.0127	-0.23	-0.18	Aortic root size;	chr7:66773096	chr7:67302621~67321526:+
HNSC	cis	rs7027203	0.521	rs2265567	ENSG00000227603.1	RP11-165J3.6	-3.95	8.89e-05	0.0127	-0.16	-0.18	DNA methylation (variation);	chr9:93752961	chr9:93435332~93437121:-
HNSC	cis	rs28489187	0.706	rs233127	ENSG00000223653.4	RP11-131L23.1	3.95	8.89e-05	0.0127	0.25	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85328118	chr1:85276715~85448124:+
HNSC	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-3.95	8.89e-05	0.0127	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
HNSC	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	3.95	8.89e-05	0.0127	0.21	0.18	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
HNSC	cis	rs5758511	0.514	rs5758629	ENSG00000227370.1	RP4-669P10.19	3.95	8.89e-05	0.0127	0.22	0.18	Birth weight;	chr22:42178549	chr22:42132543~42132998:+
HNSC	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	3.95	8.89e-05	0.0127	0.22	0.18	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
HNSC	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	3.95	8.89e-05	0.0127	0.22	0.18	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
HNSC	cis	rs7777677	0.925	rs2156964	ENSG00000276953.1	TRBV12-4	3.95	8.89e-05	0.0127	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142563740~142564245:+
HNSC	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	3.95	8.89e-05	0.0127	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
HNSC	cis	rs2857078	0.72	rs9901595	ENSG00000267080.4	ASB16-AS1	-3.95	8.89e-05	0.0127	-0.14	-0.18	Red cell distribution width;Reticulocyte count;	chr17:44228331	chr17:44175973~44186717:-
HNSC	cis	rs2857078	0.72	rs9906669	ENSG00000267080.4	ASB16-AS1	-3.95	8.89e-05	0.0127	-0.14	-0.18	Red cell distribution width;Reticulocyte count;	chr17:44228338	chr17:44175973~44186717:-
HNSC	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-3.95	8.89e-05	0.0127	-0.21	-0.18	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-3.95	8.89e-05	0.0127	-0.21	-0.18	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
HNSC	cis	rs7927592	0.763	rs1193699	ENSG00000255031.4	RP11-802E16.3	3.95	8.9e-05	0.0127	0.15	0.18	Total body bone mineral density;	chr11:68482012	chr11:68050740~68053762:+
HNSC	cis	rs172166	0.561	rs149971	ENSG00000217862.2	HIST1H4PS1	-3.95	8.9e-05	0.0127	-0.19	-0.18	Cardiac Troponin-T levels;	chr6:28014374	chr6:27807075~27807339:+
HNSC	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	3.95	8.9e-05	0.0127	0.18	0.18	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
HNSC	cis	rs9368481	0.594	rs2636425	ENSG00000238621.1	TRI-TAT2-2	-3.95	8.91e-05	0.0127	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:27020335~27020447:+
HNSC	cis	rs9650657	0.648	rs7833945	ENSG00000269918.1	AF131215.9	-3.95	8.91e-05	0.0127	-0.18	-0.18	Neuroticism;	chr8:10842756	chr8:11104691~11106704:-
HNSC	cis	rs6867032	0.57	rs13166888	ENSG00000248597.1	RP11-259O2.2	3.95	8.91e-05	0.0127	0.25	0.18	Gut microbiome composition (winter);	chr5:1982852	chr5:1963609~1967154:-
HNSC	cis	rs28714278	0.762	rs12050884	ENSG00000248508.5	SRP14-AS1	-3.95	8.91e-05	0.0127	-0.22	-0.18	Mean corpuscular hemoglobin;	chr15:40014133	chr15:40039311~40067290:+
HNSC	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-3.95	8.91e-05	0.0127	-0.18	-0.18	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
HNSC	cis	rs7927592	0.763	rs4340059	ENSG00000255031.4	RP11-802E16.3	3.95	8.91e-05	0.0127	0.15	0.18	Total body bone mineral density;	chr11:68594965	chr11:68050740~68053762:+
HNSC	cis	rs7819412	0.505	rs17782554	ENSG00000255310.2	AF131215.2	-3.95	8.91e-05	0.0128	-0.18	-0.18	Triglycerides;	chr8:11164596	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.603	rs2736278	ENSG00000255310.2	AF131215.2	3.95	8.92e-05	0.0128	0.17	0.18	Retinal vascular caliber;	chr8:11362272	chr8:11107788~11109726:-
HNSC	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-3.95	8.92e-05	0.0128	-0.19	-0.18	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
HNSC	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	3.95	8.92e-05	0.0128	0.22	0.18	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	3.95	8.92e-05	0.0128	0.22	0.18	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	3.95	8.92e-05	0.0128	0.22	0.18	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	3.95	8.92e-05	0.0128	0.22	0.18	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	3.95	8.92e-05	0.0128	0.22	0.18	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
HNSC	cis	rs61542988	0.532	rs12673996	ENSG00000226329.2	AC005682.6	3.95	8.92e-05	0.0128	0.26	0.18	Fibrinogen levels;	chr7:22793781	chr7:22863874~22881350:-
HNSC	cis	rs865483	0.86	rs860468	ENSG00000276054.1	RP11-378E13.3	3.95	8.92e-05	0.0128	0.22	0.18	Monocyte count;	chr17:37433186	chr17:37386886~37387926:+
HNSC	cis	rs2446066	0.872	rs2683524	ENSG00000257379.1	RP11-793H13.8	3.95	8.92e-05	0.0128	0.26	0.18	Red blood cell count;	chr12:53421069	chr12:53441741~53467528:+
HNSC	cis	rs11992162	0.967	rs10088415	ENSG00000269918.1	AF131215.9	-3.95	8.92e-05	0.0128	-0.17	-0.18	Monocyte count;	chr8:11973316	chr8:11104691~11106704:-
HNSC	cis	rs853679	1	rs11965538	ENSG00000204709.4	LINC01556	3.95	8.92e-05	0.0128	0.28	0.18	Depression;	chr6:28272137	chr6:28943877~28944537:+
HNSC	cis	rs7674212	0.57	rs6813563	ENSG00000251288.2	RP11-10L12.2	-3.95	8.92e-05	0.0128	-0.21	-0.18	Type 2 diabetes;	chr4:103177953	chr4:102751401~102752641:+
HNSC	cis	rs10519937	0.935	rs60153933	ENSG00000230929.5	RP11-395C3.1	-3.95	8.92e-05	0.0128	-0.27	-0.18	IgG glycosylation;	chr5:127403735	chr5:126628019~126628319:-
HNSC	cis	rs11021221	0.645	rs2254634	ENSG00000233536.2	RP11-867G2.5	3.95	8.92e-05	0.0128	0.22	0.18	Immature fraction of reticulocytes;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;	chr11:95593966	chr11:94638038~94640833:+
HNSC	cis	rs7824557	0.583	rs4448232	ENSG00000269918.1	AF131215.9	3.95	8.92e-05	0.0128	0.18	0.18	Retinal vascular caliber;	chr8:11373845	chr8:11104691~11106704:-
HNSC	cis	rs11089937	0.616	rs66651705	ENSG00000211639.2	IGLV4-60	3.95	8.92e-05	0.0128	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22162199~22162681:+
HNSC	cis	rs853679	0.882	rs9468300	ENSG00000219891.2	ZSCAN12P1	3.95	8.92e-05	0.0128	0.32	0.18	Depression;	chr6:28159062	chr6:28091154~28093664:+
HNSC	cis	rs950169	0.922	rs4586394	ENSG00000230373.7	GOLGA6L5P	3.95	8.93e-05	0.0128	0.2	0.18	Schizophrenia;	chr15:84153633	chr15:84507885~84516814:-
HNSC	cis	rs9907295	0.818	rs4796115	ENSG00000270977.1	AC015849.16	-3.95	8.93e-05	0.0128	-0.3	-0.18	Fibroblast growth factor basic levels;	chr17:35841315	chr17:35893707~35911023:-
HNSC	cis	rs478304	0.514	rs75601653	ENSG00000255120.4	OVOL1-AS1	-3.95	8.93e-05	0.0128	-0.19	-0.18	Acne (severe);	chr11:65715899	chr11:65789051~65790868:-
HNSC	cis	rs7520050	0.933	rs6656022	ENSG00000280836.1	AL355480.1	3.95	8.93e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs4134386	ENSG00000280836.1	AL355480.1	3.95	8.93e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs12561806	ENSG00000280836.1	AL355480.1	3.95	8.93e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45581219~45581321:-
HNSC	cis	rs9467711	0.606	rs16891725	ENSG00000241549.7	GUSBP2	3.95	8.93e-05	0.0128	0.28	0.18	Autism spectrum disorder or schizophrenia;	chr6:26478922	chr6:26871484~26956554:-
HNSC	cis	rs2518049	0.654	rs61854738	ENSG00000224034.1	RP11-445P17.8	-3.95	8.93e-05	0.0128	-0.25	-0.18	Metabolic traits;	chr10:5199509	chr10:5266033~5271236:-
HNSC	cis	rs1714507	0.533	rs1435642	ENSG00000272087.1	RP11-379F4.7	-3.95	8.93e-05	0.0128	-0.19	-0.18	Subjective well-being;	chr3:158582432	chr3:158693120~158693768:-
HNSC	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-3.95	8.93e-05	0.0128	-0.2	-0.18	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
HNSC	cis	rs6493858	0.78	rs2713941	ENSG00000277245.1	RP11-48G14.3	-3.95	8.93e-05	0.0128	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56195329	chr15:56447120~56447697:+
HNSC	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-3.95	8.93e-05	0.0128	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-3.95	8.93e-05	0.0128	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-3.95	8.93e-05	0.0128	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-3.95	8.93e-05	0.0128	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
HNSC	cis	rs9910055	0.509	rs9916444	ENSG00000267080.4	ASB16-AS1	-3.95	8.93e-05	0.0128	-0.14	-0.18	Total body bone mineral density;	chr17:44236144	chr17:44175973~44186717:-
HNSC	cis	rs7637230	1	rs1473857	ENSG00000244119.1	PDCL3P4	-3.95	8.94e-05	0.0128	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101916801	chr3:101712472~101713191:+
HNSC	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-3.95	8.94e-05	0.0128	-0.26	-0.18	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-3.95	8.94e-05	0.0128	-0.26	-0.18	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
HNSC	cis	rs4908768	0.501	rs1024197	ENSG00000232912.4	RP5-1115A15.1	3.95	8.94e-05	0.0128	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8424645~8434838:+
HNSC	cis	rs442309	0.875	rs224065	ENSG00000238280.1	RP11-436D10.3	-3.95	8.94e-05	0.0128	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62745688	chr10:62793562~62805887:-
HNSC	cis	rs7027203	0.557	rs9299411	ENSG00000227603.1	RP11-165J3.6	-3.95	8.95e-05	0.0128	-0.16	-0.18	DNA methylation (variation);	chr9:93760822	chr9:93435332~93437121:-
HNSC	cis	rs8180040	0.62	rs2278963	ENSG00000276925.1	RP11-708J19.3	3.95	8.95e-05	0.0128	0.18	0.18	Colorectal cancer;	chr3:47013379	chr3:47469777~47469987:+
HNSC	cis	rs9880211	0.613	rs28519617	ENSG00000239213.4	NCK1-AS1	3.95	8.95e-05	0.0128	0.17	0.18	Height;Body mass index;	chr3:136156088	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.613	rs28669017	ENSG00000239213.4	NCK1-AS1	3.95	8.95e-05	0.0128	0.17	0.18	Height;Body mass index;	chr3:136156090	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.613	rs10222451	ENSG00000239213.4	NCK1-AS1	3.95	8.95e-05	0.0128	0.17	0.18	Height;Body mass index;	chr3:136158571	chr3:136841726~136862054:-
HNSC	cis	rs73198271	0.751	rs55816468	ENSG00000254340.1	RP11-10A14.3	-3.95	8.95e-05	0.0128	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:9141424~9145435:+
HNSC	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	3.95	8.95e-05	0.0128	0.14	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
HNSC	cis	rs4947019	0.609	rs17070590	ENSG00000260273.1	RP11-425D10.10	3.95	8.95e-05	0.0128	0.5	0.18	Hematological parameters;	chr6:109424420	chr6:109382795~109383666:+
HNSC	cis	rs4713118	0.669	rs200997	ENSG00000224843.5	LINC00240	3.95	8.95e-05	0.0128	0.19	0.18	Parkinson's disease;	chr6:27844037	chr6:26956992~27023924:+
HNSC	cis	rs79349575	0.756	rs937301	ENSG00000270781.1	RP11-501C14.9	3.95	8.95e-05	0.0128	0.19	0.18	Type 2 diabetes;	chr17:48968914	chr17:48899131~48899748:+
HNSC	cis	rs748404	0.666	rs12905220	ENSG00000166763.7	STRCP1	3.95	8.95e-05	0.0128	0.25	0.18	Lung cancer;	chr15:43465641	chr15:43699488~43718184:-
HNSC	cis	rs12285276	0.75	rs7116816	ENSG00000205106.4	DKFZp779M0652	3.95	8.95e-05	0.0128	0.26	0.18	Visceral fat;	chr11:45783444	chr11:45771432~45772358:+
HNSC	cis	rs12285276	0.711	rs12274152	ENSG00000205106.4	DKFZp779M0652	3.95	8.95e-05	0.0128	0.26	0.18	Visceral fat;	chr11:45786272	chr11:45771432~45772358:+
HNSC	cis	rs793571	0.822	rs17302045	ENSG00000245975.2	RP11-30K9.6	-3.95	8.95e-05	0.0128	-0.28	-0.18	Schizophrenia;	chr15:58907738	chr15:58768072~58770974:-
HNSC	cis	rs8031584	0.678	rs798127	ENSG00000270015.1	RP11-540B6.6	3.95	8.96e-05	0.0128	0.19	0.18	Huntington's disease progression;	chr15:30825200	chr15:30926514~30928407:+
HNSC	cis	rs9400271	0.632	rs4427037	ENSG00000243587.6	C6orf183	-3.95	8.96e-05	0.0128	-0.18	-0.18	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109264409	chr6:109165833~109271014:+
HNSC	cis	rs7085104	0.7	rs3740397	ENSG00000213061.2	PFN1P11	3.95	8.96e-05	0.0128	0.23	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102838011~102845473:-
HNSC	cis	rs7572733	0.534	rs700680	ENSG00000231621.1	AC013264.2	3.95	8.96e-05	0.0128	0.17	0.18	Dermatomyositis;	chr2:197843226	chr2:197197991~197199273:+
HNSC	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-3.95	8.97e-05	0.0128	-0.15	-0.18	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
HNSC	cis	rs2286492	1	rs75393023	ENSG00000230658.1	KLHL7-AS1	3.95	8.97e-05	0.0128	0.41	0.18	Bipolar disorder;	chr7:22942323	chr7:23101228~23105703:-
HNSC	cis	rs2279440	0.759	rs7642020	ENSG00000206573.7	THUMPD3-AS1	3.95	8.97e-05	0.0128	0.17	0.18	Glucose homeostasis traits;	chr3:9480796	chr3:9349689~9398579:-
HNSC	cis	rs7302981	0.746	rs706793	ENSG00000272368.2	RP4-605O3.4	3.95	8.97e-05	0.0128	0.18	0.18	Systolic blood pressure;	chr12:50073986	chr12:50112197~50165618:+
HNSC	cis	rs3808502	0.647	rs7821302	ENSG00000255310.2	AF131215.2	-3.95	8.97e-05	0.0128	-0.17	-0.18	Neuroticism;	chr8:11379063	chr8:11107788~11109726:-
HNSC	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-3.95	8.97e-05	0.0128	-0.21	-0.18	Height;	chr14:75132452	chr14:75011269~75012851:-
HNSC	cis	rs4713118	0.869	rs9366700	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27729172	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs6456802	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27730576	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9393851	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27731802	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9461400	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27732780	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9295742	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27735053	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs9461401	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27735512	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.869	rs6914924	ENSG00000216901.1	AL022393.7	3.95	8.97e-05	0.0128	0.22	0.18	Parkinson's disease;	chr6:27743751	chr6:28176188~28176674:+
HNSC	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	3.95	8.97e-05	0.0128	0.3	0.18	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
HNSC	cis	rs73219805	0.793	rs1564576	ENSG00000228451.3	SDAD1P1	-3.95	8.98e-05	0.0128	-0.27	-0.18	Schizophrenia;	chr8:26333320	chr8:26379259~26382953:-
HNSC	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-3.95	8.98e-05	0.0128	-0.22	-0.18	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
HNSC	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-3.95	8.98e-05	0.0128	-0.35	-0.18	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
HNSC	cis	rs7674212	0.57	rs2126470	ENSG00000251288.2	RP11-10L12.2	-3.95	8.98e-05	0.0128	-0.21	-0.18	Type 2 diabetes;	chr4:103140605	chr4:102751401~102752641:+
HNSC	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-3.95	8.98e-05	0.0128	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
HNSC	cis	rs11969893	1	rs74777923	ENSG00000270987.1	RP3-467N11.2	3.95	8.98e-05	0.0128	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101204940	chr6:100889603~100890338:+
HNSC	cis	rs1555322	1	rs2425032	ENSG00000126005.14	MMP24-AS1	-3.95	8.98e-05	0.0128	-0.33	-0.18	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35216462~35278131:-
HNSC	cis	rs9880211	0.613	rs9834966	ENSG00000239213.4	NCK1-AS1	3.95	8.99e-05	0.0128	0.17	0.18	Height;Body mass index;	chr3:136089778	chr3:136841726~136862054:-
HNSC	cis	rs13256369	1	rs7004438	ENSG00000173295.6	FAM86B3P	3.95	8.99e-05	0.0128	0.23	0.18	Obesity-related traits;	chr8:8716869	chr8:8228595~8244865:+
HNSC	cis	rs34792	0.554	rs4597346	ENSG00000207425.1	Y_RNA	-3.95	8.99e-05	0.0128	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14915457~14915556:-
HNSC	cis	rs10462794	0.789	rs6885641	ENSG00000260763.1	RP11-445O3.3	3.95	8.99e-05	0.0128	0.22	0.18	DNA methylation (variation);	chr5:4491160	chr5:4436850~4440259:-
HNSC	cis	rs7572733	0.773	rs10196961	ENSG00000222017.1	AC011997.1	3.95	8.99e-05	0.0128	0.22	0.18	Dermatomyositis;	chr2:197649206	chr2:197693106~197774823:+
HNSC	cis	rs7520050	0.966	rs12564541	ENSG00000280836.1	AL355480.1	3.95	8.99e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs61102033	ENSG00000280836.1	AL355480.1	3.95	8.99e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs12405451	ENSG00000280836.1	AL355480.1	3.95	8.99e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs11211224	ENSG00000280836.1	AL355480.1	3.95	8.99e-05	0.0128	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45581219~45581321:-
HNSC	cis	rs17428076	0.536	rs62182438	ENSG00000228389.1	AC068039.4	-3.95	9e-05	0.0128	-0.22	-0.18	Myopia;	chr2:171940254	chr2:171773482~171775844:+
HNSC	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	3.95	9e-05	0.0128	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
HNSC	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-3.95	9e-05	0.0129	-0.2	-0.18	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
HNSC	cis	rs2548724	0.812	rs452857	ENSG00000250682.4	LINC00491	3.95	9e-05	0.0129	0.24	0.18	Type 2 diabetes;	chr5:102260929	chr5:102609156~102671559:-
HNSC	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-3.95	9e-05	0.0129	-0.19	-0.18	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
HNSC	cis	rs3736485	0.808	rs28576876	ENSG00000274528.1	CTD-2650P22.2	3.95	9e-05	0.0129	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659055	chr15:52017167~52018032:-
HNSC	cis	rs2333021	0.711	rs34518714	ENSG00000258376.2	RP4-647C14.2	-3.95	9e-05	0.0129	-0.22	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:73242651~73245979:-
HNSC	cis	rs2333021	0.801	rs4903086	ENSG00000258376.2	RP4-647C14.2	-3.95	9e-05	0.0129	-0.22	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:73242651~73245979:-
HNSC	cis	rs28829049	0.597	rs71645438	ENSG00000270728.1	RP4-657E11.10	-3.95	9e-05	0.0129	-0.16	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175855	chr1:19297080~19297903:+
HNSC	cis	rs28829049	0.597	rs34219832	ENSG00000270728.1	RP4-657E11.10	-3.95	9e-05	0.0129	-0.16	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175938	chr1:19297080~19297903:+
HNSC	cis	rs7113211	0.817	rs2054267	ENSG00000176343.5	RPL37AP8	3.95	9.01e-05	0.0129	0.19	0.18	Expressive vocabulary in infants;	chr11:112763903	chr11:111889199~111889474:-
HNSC	cis	rs7475343	0.573	rs61854731	ENSG00000224034.1	RP11-445P17.8	-3.95	9.01e-05	0.0129	-0.26	-0.18	Intelligence;	chr10:5192198	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs76848149	ENSG00000224034.1	RP11-445P17.8	-3.95	9.01e-05	0.0129	-0.26	-0.18	Intelligence;	chr10:5192443	chr10:5266033~5271236:-
HNSC	cis	rs889398	0.967	rs2032912	ENSG00000226232.7	RP11-419C5.2	3.95	9.01e-05	0.0129	0.16	0.18	Body mass index;	chr16:69534400	chr16:69976388~69996188:-
HNSC	cis	rs7674212	0.556	rs6533039	ENSG00000248740.4	RP11-328K4.1	3.95	9.01e-05	0.0129	0.19	0.18	Type 2 diabetes;	chr4:102938381	chr4:103256159~103453658:+
HNSC	cis	rs1862618	0.671	rs2591968	ENSG00000271828.1	CTD-2310F14.1	3.95	9.01e-05	0.0129	0.22	0.18	Initial pursuit acceleration;	chr5:56937714	chr5:56927874~56929573:+
HNSC	cis	rs7688540	0.8	rs7694325	ENSG00000211553.1	AC253576.2	-3.95	9.01e-05	0.0129	-0.24	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:136461~136568:+
HNSC	cis	rs597539	0.521	rs2060982	ENSG00000255741.1	RP11-757G1.5	-3.95	9.01e-05	0.0129	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68845459	chr11:68941503~68942852:-
HNSC	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	3.95	9.01e-05	0.0129	0.26	0.18	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
HNSC	cis	rs7716219	0.672	rs1396610	ENSG00000251307.1	RP11-506H20.1	3.95	9.02e-05	0.0129	0.19	0.18	Height;	chr5:55582791	chr5:55233934~55295201:+
HNSC	cis	rs2300747	0.769	rs9651076	ENSG00000177173.5	NAP1L4P1	-3.95	9.02e-05	0.0129	-0.29	-0.18	Primary biliary cholangitis;Multiple sclerosis;	chr1:116500680	chr1:116532936~116534092:-
HNSC	cis	rs11098499	0.863	rs1480936	ENSG00000250412.1	KLHL2P1	3.95	9.02e-05	0.0129	0.23	0.18	Corneal astigmatism;	chr4:119541706	chr4:119334329~119378233:+
HNSC	cis	rs9329221	0.592	rs7832708	ENSG00000270076.1	AF131215.8	3.95	9.02e-05	0.0129	0.2	0.18	Neuroticism;	chr8:10332530	chr8:11202965~11203671:+
HNSC	cis	rs2518049	0.852	rs10752001	ENSG00000224034.1	RP11-445P17.8	3.95	9.02e-05	0.0129	0.24	0.18	Metabolic traits;	chr10:5076653	chr10:5266033~5271236:-
HNSC	cis	rs347412	0.588	rs347418	ENSG00000237263.1	MAPK6PS3	3.95	9.02e-05	0.0129	0.22	0.18	Pulmonary function in asthmatics;	chr13:42214119	chr13:42068932~42071093:-
HNSC	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-3.95	9.02e-05	0.0129	-0.18	-0.18	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
HNSC	cis	rs801193	0.935	rs2659916	ENSG00000273142.1	RP11-458F8.4	-3.95	9.02e-05	0.0129	-0.15	-0.18	Aortic root size;	chr7:66686365	chr7:66902857~66906297:+
HNSC	cis	rs67311347	1	rs9865348	ENSG00000280739.1	EIF1B-AS1	3.95	9.02e-05	0.0129	0.2	0.18	Renal cell carcinoma;	chr3:40356167	chr3:40173145~40309698:-
HNSC	cis	rs10484434	0.892	rs62394556	ENSG00000272810.1	U91328.22	3.95	9.02e-05	0.0129	0.22	0.18	HIV-1 viral setpoint;	chr6:26072668	chr6:26013241~26013757:+
HNSC	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	3.95	9.03e-05	0.0129	0.41	0.18	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	3.95	9.03e-05	0.0129	0.41	0.18	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	3.95	9.03e-05	0.0129	0.41	0.18	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	3.95	9.03e-05	0.0129	0.41	0.18	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
HNSC	cis	rs4908768	0.581	rs2784739	ENSG00000232912.4	RP5-1115A15.1	-3.95	9.03e-05	0.0129	-0.23	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8437498	chr1:8424645~8434838:+
HNSC	cis	rs8028182	0.666	rs4886708	ENSG00000275645.1	RP11-817O13.9	3.95	9.03e-05	0.0129	0.19	0.18	Sudden cardiac arrest;	chr15:75470267	chr15:75346744~75347161:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	3.95	9.03e-05	0.0129	0.2	0.18	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
HNSC	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	3.95	9.03e-05	0.0129	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	3.95	9.03e-05	0.0129	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	3.95	9.03e-05	0.0129	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
HNSC	cis	rs7868228	0.891	rs7874493	ENSG00000240498.5	CDKN2B-AS1	-3.95	9.03e-05	0.0129	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21665033	chr9:21994778~22121097:+
HNSC	cis	rs3018712	0.59	rs2156464	ENSG00000212093.1	AP000807.1	-3.95	9.03e-05	0.0129	-0.24	-0.18	Total body bone mineral density;	chr11:68659776	chr11:68506083~68506166:-
HNSC	cis	rs11893307	0.599	rs12617417	ENSG00000228509.4	AC006460.2	3.95	9.03e-05	0.0129	0.26	0.18	Mean platelet volume;	chr2:190798845	chr2:190676944~190708716:-
HNSC	cis	rs5758511	0.773	rs62241023	ENSG00000227370.1	RP4-669P10.19	3.95	9.04e-05	0.0129	0.21	0.18	Birth weight;	chr22:41989425	chr22:42132543~42132998:+
HNSC	cis	rs7572733	0.534	rs6434943	ENSG00000231621.1	AC013264.2	-3.95	9.04e-05	0.0129	-0.17	-0.18	Dermatomyositis;	chr2:197897468	chr2:197197991~197199273:+
HNSC	cis	rs6490294	0.528	rs7970181	ENSG00000226469.1	ADAM1B	3.95	9.04e-05	0.0129	0.26	0.18	Mean platelet volume;	chr12:112172194	chr12:111927018~111929017:+
HNSC	cis	rs7824557	0.602	rs7833966	ENSG00000255310.2	AF131215.2	3.95	9.04e-05	0.0129	0.17	0.18	Retinal vascular caliber;	chr8:11348711	chr8:11107788~11109726:-
HNSC	cis	rs847649	0.618	rs6465880	ENSG00000239969.4	RP11-163E9.2	-3.95	9.04e-05	0.0129	-0.21	-0.18	Morning vs. evening chronotype;	chr7:102874790	chr7:102364162~102380633:+
HNSC	cis	rs7005380	0.556	rs6995862	ENSG00000279347.1	RP11-85I17.2	3.95	9.04e-05	0.0129	0.18	0.18	Interstitial lung disease;	chr8:119934609	chr8:119838736~119840385:-
HNSC	cis	rs7475343	0.505	rs1781929	ENSG00000224034.1	RP11-445P17.8	3.95	9.04e-05	0.0129	0.24	0.18	Intelligence;	chr10:5153924	chr10:5266033~5271236:-
HNSC	cis	rs3811273	1	rs17255612	ENSG00000211816.2	TRAV38-1	-3.95	9.04e-05	0.0129	-0.24	-0.18	Periodontal disease-related phenotypes;	chr14:22255053	chr14:22271968~22272563:+
HNSC	cis	rs35306767	0.903	rs12769431	ENSG00000229869.1	RP11-363N22.2	-3.95	9.05e-05	0.0129	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:876693	chr10:933026~942743:+
HNSC	cis	rs6460942	0.597	rs4721105	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495255	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs4721106	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495427	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs4721107	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495479	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs6977059	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495531	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs4721108	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495621	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs6961238	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12495802	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs35589221	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12496215	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.544	rs34644264	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12496464	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs17277369	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12496566	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs12699388	ENSG00000226690.5	AC005281.1	3.95	9.05e-05	0.0129	0.29	0.18	Coronary artery disease;	chr7:12496710	chr7:12496429~12541910:+
HNSC	cis	rs6444931	1	rs6444931	ENSG00000240704.1	KLF7P1	3.95	9.05e-05	0.0129	0.27	0.18	Bipolar disorder and schizophrenia;	chr3:170445686	chr3:170952850~170953897:-
HNSC	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-3.95	9.05e-05	0.0129	-0.17	-0.18	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
HNSC	cis	rs7475343	0.538	rs1761603	ENSG00000224034.1	RP11-445P17.8	3.95	9.05e-05	0.0129	0.24	0.18	Intelligence;	chr10:5157010	chr10:5266033~5271236:-
HNSC	cis	rs1008375	1	rs10939750	ENSG00000249502.1	AC006160.5	-3.95	9.05e-05	0.0129	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690799	chr4:17587467~17614571:-
HNSC	cis	rs3736485	0.844	rs8041197	ENSG00000259438.1	CTD-2650P22.1	3.95	9.05e-05	0.0129	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51573680	chr15:52010999~52019095:-
HNSC	cis	rs9921338	0.923	rs72771877	ENSG00000263080.1	RP11-485G7.5	3.95	9.05e-05	0.0129	0.2	0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11341809~11345211:-
HNSC	cis	rs7027203	0.538	rs10125195	ENSG00000227603.1	RP11-165J3.6	-3.95	9.06e-05	0.0129	-0.16	-0.18	DNA methylation (variation);	chr9:93760942	chr9:93435332~93437121:-
HNSC	cis	rs6995541	0.647	rs6987199	ENSG00000269918.1	AF131215.9	-3.95	9.06e-05	0.0129	-0.19	-0.18	Triglyceride levels;	chr8:10831151	chr8:11104691~11106704:-
HNSC	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	3.95	9.06e-05	0.0129	0.24	0.18	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
HNSC	cis	rs6540731	0.905	rs12028026	ENSG00000226251.4	RP11-15I11.3	-3.95	9.06e-05	0.0129	-0.2	-0.18	Intelligence (childhood);	chr1:212216793	chr1:212225278~212238977:-
HNSC	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-3.95	9.06e-05	0.0129	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
HNSC	cis	rs7735319	0.966	rs16890712	ENSG00000251281.1	CTD-2066L21.2	3.95	9.06e-05	0.0129	0.21	0.18	Systolic blood pressure;	chr5:33082260	chr5:33011322~33017607:-
HNSC	cis	rs7735319	0.966	rs16890717	ENSG00000251281.1	CTD-2066L21.2	3.95	9.06e-05	0.0129	0.21	0.18	Systolic blood pressure;	chr5:33085578	chr5:33011322~33017607:-
HNSC	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-3.95	9.07e-05	0.0129	-0.21	-0.18	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-3.95	9.07e-05	0.0129	-0.21	-0.18	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
HNSC	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-3.95	9.07e-05	0.0129	-0.18	-0.18	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
HNSC	cis	rs17250963	0.704	rs4702047	ENSG00000249485.1	RBBP4P1	-3.95	9.07e-05	0.0129	-0.17	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14750372	chr5:14797125~14798400:-
HNSC	cis	rs4947019	0.609	rs749621	ENSG00000260273.1	RP11-425D10.10	3.95	9.07e-05	0.0129	0.5	0.18	Hematological parameters;	chr6:109441397	chr6:109382795~109383666:+
HNSC	cis	rs950027	0.549	rs2899375	ENSG00000259479.5	SORD2P	-3.95	9.07e-05	0.0129	-0.21	-0.18	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:44826371~44884694:-
HNSC	cis	rs7169223	0.653	rs3971703	ENSG00000261762.1	RP11-650L12.2	-3.95	9.07e-05	0.0129	-0.24	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78800139	chr15:78589123~78591276:-
HNSC	cis	rs8010715	0.848	rs927494	ENSG00000259321.1	RP11-468E2.5	3.95	9.07e-05	0.0129	0.16	0.18	IgG glycosylation;	chr14:24131181	chr14:24139445~24140444:+
HNSC	cis	rs35306767	0.761	rs11253540	ENSG00000229869.1	RP11-363N22.2	3.95	9.08e-05	0.0129	0.25	0.18	Eosinophil percentage of granulocytes;	chr10:966018	chr10:933026~942743:+
HNSC	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-3.95	9.08e-05	0.0129	-0.21	-0.18	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
HNSC	cis	rs11168351	0.926	rs10875719	ENSG00000257763.1	OR5BK1P	3.95	9.08e-05	0.0129	0.17	0.18	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48355792~48356614:-
HNSC	cis	rs1050631	0.96	rs3826603	ENSG00000278986.1	RP11-723J4.3	3.95	9.08e-05	0.0129	0.21	0.18	Esophageal squamous cell cancer (length of survival);	chr18:36108407	chr18:35972151~35973916:+
HNSC	cis	rs2548724	0.716	rs62371032	ENSG00000250682.4	LINC00491	3.95	9.08e-05	0.0129	0.24	0.18	Type 2 diabetes;	chr5:102477185	chr5:102609156~102671559:-
HNSC	cis	rs860818	1	rs858278	ENSG00000226816.2	AC005082.12	3.95	9.08e-05	0.0129	0.47	0.18	Initial pursuit acceleration;	chr7:23212583	chr7:23206013~23208045:+
HNSC	cis	rs72843166	0.562	rs17760841	ENSG00000265282.1	RP11-269G24.4	3.95	9.08e-05	0.0129	0.26	0.18	Intelligence (multi-trait analysis);	chr17:63395459	chr17:63430468~63432211:-
HNSC	cis	rs9329221	0.537	rs6601415	ENSG00000269918.1	AF131215.9	3.95	9.08e-05	0.0129	0.18	0.18	Neuroticism;	chr8:10119295	chr8:11104691~11106704:-
HNSC	cis	rs7720894	0.935	rs6879809	ENSG00000215032.2	GNL3LP1	-3.95	9.08e-05	0.0129	-0.2	-0.18	Body mass index;	chr5:61531129	chr5:60891935~60893577:-
HNSC	cis	rs17407555	1	rs17407324	ENSG00000250413.1	RP11-448G15.1	-3.95	9.08e-05	0.0129	-0.27	-0.18	Schizophrenia (age at onset);	chr4:10271419	chr4:10006482~10009725:+
HNSC	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	3.95	9.08e-05	0.013	0.16	0.18	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	3.95	9.08e-05	0.013	0.16	0.18	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
HNSC	cis	rs7615952	0.546	rs11711150	ENSG00000241288.6	RP11-379B18.5	-3.95	9.08e-05	0.013	-0.27	-0.18	Blood pressure (smoking interaction);	chr3:125596819	chr3:125827238~125916384:-
HNSC	cis	rs2028299	1	rs2351707	ENSG00000259677.1	RP11-493E3.1	3.95	9.09e-05	0.013	0.22	0.18	Type 2 diabetes;	chr15:89840813	chr15:89876540~89877285:+
HNSC	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-3.95	9.09e-05	0.013	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
HNSC	cis	rs11992162	1	rs11784499	ENSG00000255310.2	AF131215.2	3.95	9.09e-05	0.013	0.17	0.18	Monocyte count;	chr8:11977030	chr8:11107788~11109726:-
HNSC	cis	rs72627123	1	rs72627124	ENSG00000259065.1	RP5-1021I20.1	-3.95	9.09e-05	0.013	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73902425	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627125	ENSG00000259065.1	RP5-1021I20.1	-3.95	9.09e-05	0.013	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73902920	chr14:73787360~73803270:+
HNSC	cis	rs72627123	1	rs72627127	ENSG00000259065.1	RP5-1021I20.1	-3.95	9.09e-05	0.013	-0.32	-0.18	Morning vs. evening chronotype;	chr14:73903395	chr14:73787360~73803270:+
HNSC	cis	rs516805	0.715	rs197691	ENSG00000279453.1	RP3-425C14.4	-3.95	9.1e-05	0.013	-0.25	-0.18	Lymphocyte counts;	chr6:122513394	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.748	rs197692	ENSG00000279453.1	RP3-425C14.4	-3.95	9.1e-05	0.013	-0.25	-0.18	Lymphocyte counts;	chr6:122515260	chr6:122436789~122439223:-
HNSC	cis	rs7615952	0.546	rs2922194	ENSG00000248787.1	RP11-666A20.4	-3.95	9.1e-05	0.013	-0.29	-0.18	Blood pressure (smoking interaction);	chr3:125613419	chr3:125908005~125910272:-
HNSC	cis	rs9921222	0.521	rs757460	ENSG00000268836.1	LA16c-OS12.2	3.95	9.1e-05	0.013	0.19	0.18	Bone mineral density (spine);Bone mineral density;	chr16:317174	chr16:185748~186294:-
HNSC	cis	rs2929282	1	rs2929282	ENSG00000205771.5	CATSPER2P1	-3.95	9.1e-05	0.013	-0.44	-0.18	Triglycerides;Triglyceride levels;	chr15:43953733	chr15:43726918~43747094:-
HNSC	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	3.95	9.1e-05	0.013	0.22	0.18	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
HNSC	cis	rs10519937	0.935	rs17165090	ENSG00000230929.5	RP11-395C3.1	-3.95	9.11e-05	0.013	-0.27	-0.18	IgG glycosylation;	chr5:127404624	chr5:126628019~126628319:-
HNSC	cis	rs10519937	0.935	rs111615826	ENSG00000230929.5	RP11-395C3.1	-3.95	9.11e-05	0.013	-0.27	-0.18	IgG glycosylation;	chr5:127404809	chr5:126628019~126628319:-
HNSC	cis	rs10519937	1	rs74381320	ENSG00000230929.5	RP11-395C3.1	-3.95	9.11e-05	0.013	-0.27	-0.18	IgG glycosylation;	chr5:127405143	chr5:126628019~126628319:-
HNSC	cis	rs17739794	0.557	rs7823711	ENSG00000254207.1	RP11-43A14.1	3.95	9.11e-05	0.013	0.22	0.18	Clozapine-induced cytotoxicity;	chr8:864529	chr8:725188~725877:-
HNSC	cis	rs330048	0.545	rs11774353	ENSG00000254153.1	CTA-398F10.2	3.95	9.12e-05	0.013	0.2	0.18	Systemic lupus erythematosus;	chr8:9295617	chr8:8456909~8461337:-
HNSC	cis	rs4081724	0.565	rs7253994	ENSG00000267296.2	CEBPA-AS1	3.95	9.12e-05	0.013	0.34	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33314772	chr19:33302857~33305054:+
HNSC	cis	rs13256369	1	rs13267501	ENSG00000173295.6	FAM86B3P	3.95	9.12e-05	0.013	0.23	0.18	Obesity-related traits;	chr8:8716548	chr8:8228595~8244865:+
HNSC	cis	rs13256369	0.95	rs13270006	ENSG00000173295.6	FAM86B3P	3.95	9.12e-05	0.013	0.23	0.18	Obesity-related traits;	chr8:8716687	chr8:8228595~8244865:+
HNSC	cis	rs7520050	0.931	rs6686134	ENSG00000280836.1	AL355480.1	3.95	9.12e-05	0.013	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45581219~45581321:-
HNSC	cis	rs9487051	0.646	rs55677234	ENSG00000243587.6	C6orf183	-3.95	9.12e-05	0.013	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109300771	chr6:109165833~109271014:+
HNSC	cis	rs10129255	0.5	rs7161740	ENSG00000211976.2	IGHV3-73	-3.95	9.12e-05	0.013	-0.13	-0.18	Kawasaki disease;	chr14:106776119	chr14:106802694~106803233:-
HNSC	cis	rs516805	0.748	rs155461	ENSG00000279453.1	RP3-425C14.4	-3.95	9.13e-05	0.013	-0.26	-0.18	Lymphocyte counts;	chr6:122499547	chr6:122436789~122439223:-
HNSC	cis	rs2439831	0.717	rs9806227	ENSG00000275601.1	AC011330.13	-3.95	9.13e-05	0.013	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43387917	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs12323999	ENSG00000275601.1	AC011330.13	-3.95	9.13e-05	0.013	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43390917	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2584702	ENSG00000275601.1	AC011330.13	-3.95	9.13e-05	0.013	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43392716	chr15:43642389~43643023:-
HNSC	cis	rs1937680	0.613	rs6480572	ENSG00000236671.6	PRKG1-AS1	-3.95	9.13e-05	0.013	-0.26	-0.18	Breast cancer;	chr10:51909884	chr10:52230742~52314128:-
HNSC	cis	rs28829049	0.536	rs2073105	ENSG00000270728.1	RP4-657E11.10	-3.95	9.13e-05	0.013	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19223370	chr1:19297080~19297903:+
HNSC	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-3.95	9.13e-05	0.013	-0.22	-0.18	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
HNSC	cis	rs10129255	0.5	rs8011115	ENSG00000211976.2	IGHV3-73	-3.95	9.13e-05	0.013	-0.13	-0.18	Kawasaki disease;	chr14:106786292	chr14:106802694~106803233:-
HNSC	cis	rs11148252	0.904	rs9536079	ENSG00000198384.8	TPTE2P3	3.95	9.13e-05	0.013	0.22	0.18	Lewy body disease;	chr13:52456430	chr13:52522632~52586906:+
HNSC	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-3.95	9.14e-05	0.013	-0.18	-0.18	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
HNSC	cis	rs2732480	0.5	rs1387257	ENSG00000257763.1	OR5BK1P	3.95	9.14e-05	0.013	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48355792~48356614:-
HNSC	cis	rs7927592	0.913	rs7107622	ENSG00000255031.4	RP11-802E16.3	3.95	9.14e-05	0.013	0.16	0.18	Total body bone mineral density;	chr11:68606715	chr11:68050740~68053762:+
HNSC	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	3.95	9.14e-05	0.013	0.22	0.18	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
HNSC	cis	rs7429990	0.803	rs6776963	ENSG00000228638.1	FCF1P2	3.95	9.14e-05	0.013	0.17	0.18	Educational attainment (years of education);	chr3:47789251	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs4858863	ENSG00000228638.1	FCF1P2	3.95	9.14e-05	0.013	0.17	0.18	Educational attainment (years of education);	chr3:47814143	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7629850	ENSG00000228638.1	FCF1P2	3.95	9.14e-05	0.013	0.17	0.18	Educational attainment (years of education);	chr3:47815592	chr3:48290793~48291375:-
HNSC	cis	rs1538970	0.781	rs713358	ENSG00000234329.1	RP11-767N6.2	3.95	9.14e-05	0.013	0.21	0.18	Platelet count;	chr1:45522595	chr1:45651039~45651826:-
HNSC	cis	rs10875746	0.859	rs4760622	ENSG00000257763.1	OR5BK1P	-3.95	9.14e-05	0.013	-0.22	-0.18	Longevity (90 years and older);	chr12:48198177	chr12:48355792~48356614:-
HNSC	cis	rs11976180	1	rs1533266	ENSG00000244479.5	OR2A1-AS1	3.95	9.14e-05	0.013	0.2	0.18	Obesity-related traits;	chr7:144069621	chr7:144251264~144356181:-
HNSC	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-3.95	9.15e-05	0.013	-0.21	-0.18	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
HNSC	cis	rs1555322	1	rs2425036	ENSG00000279253.1	RP4-614O4.13	-3.95	9.15e-05	0.013	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35262727~35264187:-
HNSC	cis	rs2060793	0.741	rs10734227	ENSG00000254418.1	RP11-21L19.1	3.95	9.15e-05	0.013	0.21	0.18	Vitamin D levels;	chr11:14767471	chr11:14262846~14273691:-
HNSC	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	3.95	9.15e-05	0.013	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
HNSC	cis	rs7572733	0.534	rs7572123	ENSG00000231621.1	AC013264.2	-3.95	9.15e-05	0.013	-0.17	-0.18	Dermatomyositis;	chr2:197904913	chr2:197197991~197199273:+
HNSC	cis	rs7824557	0.603	rs2246606	ENSG00000269918.1	AF131215.9	3.95	9.16e-05	0.013	0.18	0.18	Retinal vascular caliber;	chr8:11361825	chr8:11104691~11106704:-
HNSC	cis	rs853679	0.527	rs853693	ENSG00000219392.1	RP1-265C24.5	-3.95	9.16e-05	0.013	-0.21	-0.18	Depression;	chr6:28314871	chr6:28115628~28116551:+
HNSC	cis	rs11969893	1	rs6915173	ENSG00000270987.1	RP3-467N11.2	3.95	9.16e-05	0.013	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101184753	chr6:100889603~100890338:+
HNSC	cis	rs11969893	1	rs6915336	ENSG00000270987.1	RP3-467N11.2	3.95	9.16e-05	0.013	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101184826	chr6:100889603~100890338:+
HNSC	cis	rs11969893	1	rs60868805	ENSG00000270987.1	RP3-467N11.2	3.95	9.16e-05	0.013	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101194976	chr6:100889603~100890338:+
HNSC	cis	rs11969893	1	rs9498532	ENSG00000270987.1	RP3-467N11.2	3.95	9.16e-05	0.013	0.44	0.18	Economic and political preferences (immigration/crime);	chr6:101197328	chr6:100889603~100890338:+
HNSC	cis	rs4713118	0.869	rs6930992	ENSG00000216901.1	AL022393.7	3.95	9.16e-05	0.013	0.22	0.18	Parkinson's disease;	chr6:27744341	chr6:28176188~28176674:+
HNSC	cis	rs9329221	0.512	rs7843924	ENSG00000269918.1	AF131215.9	3.95	9.16e-05	0.013	0.18	0.18	Neuroticism;	chr8:10119030	chr8:11104691~11106704:-
HNSC	cis	rs6604026	0.883	rs77741804	ENSG00000223787.2	RP4-593M8.1	3.95	9.16e-05	0.013	0.24	0.18	Multiple sclerosis;	chr1:92858481	chr1:92580476~92580821:-
HNSC	cis	rs7867456	0.9	rs12006112	ENSG00000229835.2	KHSRPP1	-3.95	9.16e-05	0.013	-0.18	-0.18	Axial length;	chr9:21042300	chr9:21695176~21696943:+
HNSC	cis	rs853679	0.55	rs1233701	ENSG00000219891.2	ZSCAN12P1	-3.95	9.17e-05	0.013	-0.24	-0.18	Depression;	chr6:28200948	chr6:28091154~28093664:+
HNSC	cis	rs4841097	0.806	rs6992247	ENSG00000253981.4	ALG1L13P	3.95	9.17e-05	0.0131	0.2	0.18	Platelet distribution width;	chr8:9090959	chr8:8236003~8244667:-
HNSC	cis	rs2548724	0.755	rs62371010	ENSG00000250682.4	LINC00491	3.95	9.17e-05	0.0131	0.24	0.18	Type 2 diabetes;	chr5:102460569	chr5:102609156~102671559:-
HNSC	cis	rs60617249	0.795	rs6968511	ENSG00000228204.2	RP4-724E13.2	3.95	9.17e-05	0.0131	0.19	0.18	Major depression and alcohol dependence;	chr7:50917521	chr7:50866747~51022990:+
HNSC	cis	rs2760061	0.545	rs1636196	ENSG00000270110.1	RP5-1139B12.4	-3.95	9.17e-05	0.0131	-0.19	-0.18	Diastolic blood pressure;	chr1:228016329	chr1:228295911~228302998:-
HNSC	cis	rs2483519	0.834	rs1591214	ENSG00000236799.1	RP11-383C6.2	-3.95	9.17e-05	0.0131	-0.19	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114671987	chr10:114994657~114996593:+
HNSC	cis	rs71636778	0.509	rs41307935	ENSG00000260063.1	RP5-968P14.2	-3.95	9.17e-05	0.0131	-0.38	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26854576	chr1:26692132~26694131:-
HNSC	cis	rs830124	1	rs830124	ENSG00000280138.1	RP11-463O12.5	3.95	9.17e-05	0.0131	0.21	0.18	Urinary metabolites;	chr12:121957871	chr12:122870059~122888720:-
HNSC	cis	rs2342371	0.715	rs9846106	ENSG00000243339.3	RN7SL738P	-3.95	9.17e-05	0.0131	-0.25	-0.18	Fat distribution (HIV);	chr3:196399668	chr3:196399911~196400207:+
HNSC	cis	rs886126	0.95	rs2078851	ENSG00000257595.2	RP3-473L9.4	-3.95	9.18e-05	0.0131	-0.23	-0.18	Coronary heart disease;	chr12:111252775	chr12:111369282~111403310:+
HNSC	cis	rs7005380	0.733	rs9987332	ENSG00000279347.1	RP11-85I17.2	3.95	9.18e-05	0.0131	0.15	0.18	Interstitial lung disease;	chr8:119921723	chr8:119838736~119840385:-
HNSC	cis	rs9813712	0.953	rs9847910	ENSG00000228252.7	COL6A4P2	3.95	9.18e-05	0.0131	0.2	0.18	Response to amphetamines;	chr3:130248174	chr3:130212823~130273806:+
HNSC	cis	rs116095464	1	rs7723693	ENSG00000250848.1	CTD-2083E4.5	-3.95	9.18e-05	0.0131	-0.31	-0.18	Breast cancer;	chr5:305917	chr5:288833~290321:-
HNSC	cis	rs4820294	0.669	rs7287340	ENSG00000225867.1	RP5-1177I5.3	-3.95	9.18e-05	0.0131	-0.2	-0.18	Fat distribution (HIV);	chr22:37658318	chr22:37550026~37551735:+
HNSC	cis	rs4820294	0.669	rs7287358	ENSG00000225867.1	RP5-1177I5.3	-3.95	9.18e-05	0.0131	-0.2	-0.18	Fat distribution (HIV);	chr22:37658396	chr22:37550026~37551735:+
HNSC	cis	rs8067545	0.641	rs203466	ENSG00000266126.1	RP11-209D14.4	-3.95	9.18e-05	0.0131	-0.21	-0.18	Schizophrenia;	chr17:19906640	chr17:19929372~19929737:-
HNSC	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-3.95	9.18e-05	0.0131	-0.24	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
HNSC	cis	rs449789	0.857	rs10455775	ENSG00000235086.1	FNDC1-IT1	-3.95	9.18e-05	0.0131	-0.21	-0.18	Pulse pressure;	chr6:159302689	chr6:159240786~159243329:+
HNSC	cis	rs9910055	0.659	rs227578	ENSG00000267080.4	ASB16-AS1	3.95	9.18e-05	0.0131	0.14	0.18	Total body bone mineral density;	chr17:44132821	chr17:44175973~44186717:-
HNSC	cis	rs7475343	0.561	rs1781930	ENSG00000224034.1	RP11-445P17.8	3.95	9.19e-05	0.0131	0.24	0.18	Intelligence;	chr10:5154078	chr10:5266033~5271236:-
HNSC	cis	rs10129255	0.5	rs6576225	ENSG00000224373.3	IGHV4-59	3.95	9.19e-05	0.0131	0.1	0.18	Kawasaki disease;	chr14:106778120	chr14:106627249~106627825:-
HNSC	cis	rs1555322	0.932	rs1205411	ENSG00000126005.14	MMP24-AS1	-3.95	9.19e-05	0.0131	-0.33	-0.18	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35216462~35278131:-
HNSC	cis	rs3741151	0.686	rs12288753	ENSG00000256448.4	RP11-809N8.4	3.95	9.19e-05	0.0131	0.25	0.18	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73425216	chr11:73405297~73410682:+
HNSC	cis	rs3741151	0.686	rs11828904	ENSG00000256448.4	RP11-809N8.4	3.95	9.19e-05	0.0131	0.25	0.18	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73428071	chr11:73405297~73410682:+
HNSC	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	3.95	9.19e-05	0.0131	0.18	0.18	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
HNSC	cis	rs67981189	0.555	rs11623266	ENSG00000274818.1	RP1-292L20.3	-3.95	9.19e-05	0.0131	-0.2	-0.18	Schizophrenia;	chr14:70899223	chr14:70906657~70907111:-
HNSC	cis	rs10888838	0.756	rs11589005	ENSG00000198711.5	SSBP3-AS1	3.95	9.19e-05	0.0131	0.25	0.18	Mitochondrial DNA levels;	chr1:54227752	chr1:54236440~54239063:+
HNSC	cis	rs74781061	0.932	rs2198843	ENSG00000260103.2	RP11-10O17.1	-3.95	9.19e-05	0.0131	-0.21	-0.18	Endometriosis;	chr15:74708889	chr15:74478070~74490286:-
HNSC	cis	rs7824557	0.602	rs7817658	ENSG00000255310.2	AF131215.2	3.95	9.19e-05	0.0131	0.17	0.18	Retinal vascular caliber;	chr8:11349034	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.568	rs35747588	ENSG00000255310.2	AF131215.2	3.95	9.19e-05	0.0131	0.17	0.18	Retinal vascular caliber;	chr8:11349118	chr8:11107788~11109726:-
HNSC	cis	rs73173548	0.502	rs7726289	ENSG00000247828.6	TMEM161B-AS1	3.95	9.2e-05	0.0131	0.19	0.18	Macular telangiectasia type 2;	chr5:88437392	chr5:88268895~88436685:+
HNSC	cis	rs58873874	0.649	rs75791619	ENSG00000248544.2	CTB-47B11.3	3.95	9.2e-05	0.0131	0.34	0.18	Bipolar disorder (body mass index interaction);	chr5:157370204	chr5:157375741~157384950:-
HNSC	cis	rs10819861	0.645	rs4078421	ENSG00000271384.1	RP11-435O5.7	3.95	9.2e-05	0.0131	0.18	0.18	Electrocardiographic traits;	chr9:96100887	chr9:95406990~95407662:-
HNSC	cis	rs4699052	0.662	rs6848593	ENSG00000246560.2	RP11-10L12.4	3.95	9.2e-05	0.0131	0.21	0.18	Testicular germ cell tumor;	chr4:103328956	chr4:102828055~102844075:+
HNSC	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	3.95	9.21e-05	0.0131	0.19	0.18	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
HNSC	cis	rs792448	0.692	rs351407	ENSG00000226251.4	RP11-15I11.3	-3.95	9.21e-05	0.0131	-0.22	-0.18	White blood cell count (basophil);	chr1:212264100	chr1:212225278~212238977:-
HNSC	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	3.94	9.21e-05	0.0131	0.17	0.18	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
HNSC	cis	rs950169	0.959	rs12911210	ENSG00000230373.7	GOLGA6L5P	-3.94	9.21e-05	0.0131	-0.19	-0.18	Schizophrenia;	chr15:84123331	chr15:84507885~84516814:-
HNSC	cis	rs597480	0.652	rs2044391	ENSG00000279742.1	RP11-700A24.1	3.94	9.21e-05	0.0131	0.2	0.18	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85810786	chr11:85852557~85854943:-
HNSC	cis	rs6674176	0.935	rs4314918	ENSG00000237950.1	RP11-7O11.3	3.94	9.21e-05	0.0131	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43911831	chr1:43944370~43946551:-
HNSC	cis	rs6674176	1	rs6674176	ENSG00000237950.1	RP11-7O11.3	3.94	9.21e-05	0.0131	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43914285	chr1:43944370~43946551:-
HNSC	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	3.94	9.21e-05	0.0131	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
HNSC	cis	rs6964587	0.626	rs4729014	ENSG00000188693.7	CYP51A1-AS1	3.94	9.21e-05	0.0131	0.19	0.18	Breast cancer;	chr7:91921393	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.626	rs34404183	ENSG00000188693.7	CYP51A1-AS1	3.94	9.21e-05	0.0131	0.19	0.18	Breast cancer;	chr7:91921935	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.626	rs10243083	ENSG00000188693.7	CYP51A1-AS1	3.94	9.21e-05	0.0131	0.19	0.18	Breast cancer;	chr7:91923216	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.585	rs10266481	ENSG00000188693.7	CYP51A1-AS1	3.94	9.21e-05	0.0131	0.19	0.18	Breast cancer;	chr7:91925024	chr7:92134604~92180725:+
HNSC	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-3.94	9.21e-05	0.0131	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000272831.1	RP11-792A8.4	3.94	9.21e-05	0.0131	0.15	0.18	Aortic root size;	chr7:66765184	chr7:66739829~66740385:-
HNSC	cis	rs9650657	0.648	rs6601512	ENSG00000255310.2	AF131215.2	-3.94	9.21e-05	0.0131	-0.18	-0.18	Neuroticism;	chr8:10728086	chr8:11107788~11109726:-
HNSC	cis	rs9929218	0.551	rs7201437	ENSG00000260459.2	FTLP14	3.94	9.21e-05	0.0131	0.23	0.18	Colorectal cancer;	chr16:68693227	chr16:68822587~68823070:+
HNSC	cis	rs9393777	0.623	rs9348719	ENSG00000241549.7	GUSBP2	3.94	9.21e-05	0.0131	0.22	0.18	Intelligence (multi-trait analysis);	chr6:26469804	chr6:26871484~26956554:-
HNSC	cis	rs11157436	0.602	rs2075492	ENSG00000211814.1	TRAV35	-3.94	9.22e-05	0.0131	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163321	chr14:22221896~22222475:+
HNSC	cis	rs4144743	1	rs66738981	ENSG00000228782.6	CTD-2026D20.3	-3.94	9.22e-05	0.0131	-0.21	-0.18	Body mass index;	chr17:47248172	chr17:47450568~47492492:-
HNSC	cis	rs116095464	0.558	rs7703803	ENSG00000277812.1	AC021087.1	3.94	9.22e-05	0.0131	0.31	0.18	Breast cancer;	chr5:292196	chr5:262769~262881:+
HNSC	cis	rs9329221	0.527	rs34259385	ENSG00000255020.1	AF131216.5	-3.94	9.22e-05	0.0131	-0.2	-0.18	Neuroticism;	chr8:10467946	chr8:11345748~11347502:-
HNSC	cis	rs870825	0.929	rs56106324	ENSG00000254233.1	RP11-242J7.1	3.94	9.22e-05	0.0131	0.3	0.18	Blood protein levels;	chr4:184668747	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689254	ENSG00000254233.1	RP11-242J7.1	3.94	9.22e-05	0.0131	0.3	0.18	Blood protein levels;	chr4:184668787	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs55635512	ENSG00000254233.1	RP11-242J7.1	3.94	9.22e-05	0.0131	0.3	0.18	Blood protein levels;	chr4:184668828	chr4:184584093~184625030:-
HNSC	cis	rs12545109	0.842	rs2609975	ENSG00000246430.5	LINC00968	-3.94	9.22e-05	0.0131	-0.22	-0.18	Obesity-related traits;	chr8:56489108	chr8:56496246~56559823:-
HNSC	cis	rs56114371	0.53	rs169262	ENSG00000224843.5	LINC00240	3.94	9.22e-05	0.0131	0.22	0.18	Breast cancer;	chr6:27803112	chr6:26956992~27023924:+
HNSC	cis	rs793571	0.822	rs28538484	ENSG00000245975.2	RP11-30K9.6	3.94	9.22e-05	0.0131	0.29	0.18	Schizophrenia;	chr15:58909023	chr15:58768072~58770974:-
HNSC	cis	rs793571	0.822	rs10518992	ENSG00000245975.2	RP11-30K9.6	3.94	9.22e-05	0.0131	0.29	0.18	Schizophrenia;	chr15:58911416	chr15:58768072~58770974:-
HNSC	cis	rs897984	0.683	rs9932572	ENSG00000279196.1	RP11-1072A3.3	3.94	9.22e-05	0.0131	0.2	0.18	Dementia with Lewy bodies;	chr16:30830321	chr16:30984630~30988270:-
HNSC	cis	rs11089937	0.616	rs7286793	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs7291684	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs6001219	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs5995615	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs6001223	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs928895	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs928896	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22098700~22099212:+
HNSC	cis	rs11089937	0.616	rs6001224	ENSG00000211638.2	IGLV8-61	-3.94	9.22e-05	0.0131	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22098700~22099212:+
HNSC	cis	rs2030746	0.899	rs940688	ENSG00000237614.1	AC073257.2	3.94	9.22e-05	0.0131	0.21	0.18	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553424	chr2:120542909~120544326:-
HNSC	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	3.94	9.23e-05	0.0131	0.19	0.18	QT interval;	chr12:29255006	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	3.94	9.23e-05	0.0131	0.19	0.18	QT interval;	chr12:29256797	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	3.94	9.23e-05	0.0131	0.19	0.18	QT interval;	chr12:29256859	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	3.94	9.23e-05	0.0131	0.19	0.18	QT interval;	chr12:29257066	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	3.94	9.23e-05	0.0131	0.19	0.18	QT interval;	chr12:29258881	chr12:29280418~29317848:-
HNSC	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	3.94	9.23e-05	0.0131	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
HNSC	cis	rs2237234	0.848	rs2237235	ENSG00000241549.7	GUSBP2	3.94	9.23e-05	0.0131	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr6:26391167	chr6:26871484~26956554:-
HNSC	cis	rs7015630	0.657	rs34970073	ENSG00000251136.7	RP11-37B2.1	-3.94	9.23e-05	0.0131	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89825134	chr8:89609409~89757727:-
HNSC	cis	rs10435719	0.647	rs10092605	ENSG00000227888.4	FAM66A	3.94	9.23e-05	0.0131	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:12362019~12388296:+
HNSC	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	3.94	9.23e-05	0.0131	0.21	0.18	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
HNSC	cis	rs1620921	0.564	rs12196838	ENSG00000231863.1	RP3-428L16.1	-3.94	9.23e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160851733	chr6:160931080~160969771:+
HNSC	cis	rs2243480	1	rs6460260	ENSG00000229886.1	RP5-1132H15.3	-3.94	9.23e-05	0.0131	-0.31	-0.18	Diabetic kidney disease;	chr7:65750468	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs6460261	ENSG00000229886.1	RP5-1132H15.3	-3.94	9.23e-05	0.0131	-0.31	-0.18	Diabetic kidney disease;	chr7:65750593	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-3.94	9.23e-05	0.0131	-0.31	-0.18	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
HNSC	cis	rs62025270	0.848	rs62025269	ENSG00000259762.1	RP11-158M2.4	-3.94	9.23e-05	0.0131	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85750336~85752901:-
HNSC	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	3.94	9.23e-05	0.0131	0.29	0.18	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
HNSC	cis	rs11098499	0.575	rs907204	ENSG00000250412.1	KLHL2P1	3.94	9.24e-05	0.0131	0.23	0.18	Corneal astigmatism;	chr4:119317499	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.575	rs907205	ENSG00000250412.1	KLHL2P1	3.94	9.24e-05	0.0131	0.23	0.18	Corneal astigmatism;	chr4:119317509	chr4:119334329~119378233:+
HNSC	cis	rs11711311	1	rs6792447	ENSG00000241529.3	RN7SL767P	-3.94	9.24e-05	0.0131	-0.23	-0.18	IgG glycosylation;	chr3:113789488	chr3:113632704~113632998:+
HNSC	cis	rs4253772	0.591	rs6008362	ENSG00000277232.2	GTSE1-AS1	-3.94	9.24e-05	0.0131	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46256840	chr22:46295143~46296660:-
HNSC	cis	rs1602565	0.858	rs2958625	ENSG00000255450.1	CTD-2063L20.1	3.94	9.24e-05	0.0131	0.27	0.18	Schizophrenia;	chr11:29145921	chr11:29275655~29276565:+
HNSC	cis	rs6657613	0.649	rs11203285	ENSG00000186715.9	MST1L	-3.94	9.24e-05	0.0131	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17043625	chr1:16754910~16770237:-
HNSC	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-3.94	9.24e-05	0.0131	-0.18	-0.18	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
HNSC	cis	rs7688540	0.771	rs10027325	ENSG00000211553.1	AC253576.2	-3.94	9.24e-05	0.0131	-0.26	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs1986557	ENSG00000211553.1	AC253576.2	-3.94	9.24e-05	0.0131	-0.26	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:136461~136568:+
HNSC	cis	rs6787172	0.811	rs1978781	ENSG00000272087.1	RP11-379F4.7	3.94	9.24e-05	0.0131	0.19	0.18	Subjective well-being;	chr3:158488994	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.782	rs4431160	ENSG00000272087.1	RP11-379F4.7	3.94	9.24e-05	0.0131	0.19	0.18	Subjective well-being;	chr3:158491277	chr3:158693120~158693768:-
HNSC	cis	rs453301	0.686	rs6601281	ENSG00000253981.4	ALG1L13P	-3.94	9.25e-05	0.0131	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9053494	chr8:8236003~8244667:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000229886.1	RP5-1132H15.3	3.94	9.25e-05	0.0131	0.3	0.18	Diabetic kidney disease;	chr7:66360703	chr7:66025126~66031544:-
HNSC	cis	rs1620921	0.594	rs11753819	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843743	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.653	rs62435278	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844427	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs28698869	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844860	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs28488549	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845003	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs28715036	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845013	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs12176296	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845375	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs12173853	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845396	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs12173859	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845481	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs10945699	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845716	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs10945700	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845732	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs11753537	ENSG00000231863.1	RP3-428L16.1	-3.94	9.25e-05	0.0131	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845990	chr6:160931080~160969771:+
HNSC	cis	rs12893668	0.703	rs729438	ENSG00000269940.1	RP11-73M18.7	-3.94	9.25e-05	0.0131	-0.17	-0.18	Reticulocyte count;	chr14:103626452	chr14:103694560~103695170:+
HNSC	cis	rs4713118	0.516	rs6931858	ENSG00000204709.4	LINC01556	3.94	9.25e-05	0.0131	0.25	0.18	Parkinson's disease;	chr6:28110633	chr6:28943877~28944537:+
HNSC	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	3.94	9.26e-05	0.0131	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
HNSC	cis	rs7267979	0.789	rs6083810	ENSG00000204556.4	CTD-2514C3.1	3.94	9.26e-05	0.0131	0.23	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26018832~26020684:+
HNSC	cis	rs7267979	0.789	rs6083820	ENSG00000204556.4	CTD-2514C3.1	3.94	9.26e-05	0.0131	0.23	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26018832~26020684:+
HNSC	cis	rs7267979	0.789	rs6083841	ENSG00000204556.4	CTD-2514C3.1	3.94	9.26e-05	0.0131	0.23	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26018832~26020684:+
HNSC	cis	rs9859260	0.961	rs9846149	ENSG00000207650.1	MIR570	3.94	9.26e-05	0.0132	0.16	0.18	Mean corpuscular volume;	chr3:196060437	chr3:195699401~195699497:+
HNSC	cis	rs9650657	0.746	rs4841441	ENSG00000255310.2	AF131215.2	-3.94	9.26e-05	0.0132	-0.18	-0.18	Neuroticism;	chr8:10773388	chr8:11107788~11109726:-
HNSC	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	3.94	9.27e-05	0.0132	0.25	0.18	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
HNSC	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	3.94	9.27e-05	0.0132	0.21	0.18	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	3.94	9.27e-05	0.0132	0.21	0.18	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	3.94	9.27e-05	0.0132	0.21	0.18	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
HNSC	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	3.94	9.27e-05	0.0132	0.21	0.18	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
HNSC	cis	rs9880211	0.613	rs6767060	ENSG00000239213.4	NCK1-AS1	3.94	9.27e-05	0.0132	0.17	0.18	Height;Body mass index;	chr3:136148248	chr3:136841726~136862054:-
HNSC	cis	rs8180991	0.744	rs12679547	ENSG00000254431.1	RP11-550A5.2	-3.94	9.27e-05	0.0132	-0.27	-0.18	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125480843	chr8:125348196~125351416:-
HNSC	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	3.94	9.27e-05	0.0132	0.22	0.18	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
HNSC	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-3.94	9.27e-05	0.0132	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
HNSC	cis	rs67981189	0.593	rs10140225	ENSG00000274818.1	RP1-292L20.3	3.94	9.27e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71024404	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs10140917	ENSG00000274818.1	RP1-292L20.3	3.94	9.27e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71025103	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs8006046	ENSG00000274818.1	RP1-292L20.3	3.94	9.27e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71032274	chr14:70906657~70907111:-
HNSC	cis	rs757081	0.676	rs677042	ENSG00000260196.1	RP1-239B22.5	-3.94	9.27e-05	0.0132	-0.19	-0.18	Systolic blood pressure;	chr11:17185533	chr11:17380649~17383531:+
HNSC	cis	rs13179617	0.851	rs6873712	ENSG00000215032.2	GNL3LP1	-3.94	9.27e-05	0.0132	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61499965	chr5:60891935~60893577:-
HNSC	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	3.94	9.27e-05	0.0132	0.18	0.18	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	3.94	9.27e-05	0.0132	0.18	0.18	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
HNSC	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	3.94	9.28e-05	0.0132	0.21	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	3.94	9.28e-05	0.0132	0.21	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
HNSC	cis	rs748404	0.666	rs16957715	ENSG00000166763.7	STRCP1	3.94	9.28e-05	0.0132	0.24	0.18	Lung cancer;	chr15:43416539	chr15:43699488~43718184:-
HNSC	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-3.94	9.28e-05	0.0132	-0.19	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
HNSC	cis	rs7829975	0.667	rs1877119	ENSG00000254153.1	CTA-398F10.2	3.94	9.28e-05	0.0132	0.2	0.18	Mood instability;	chr8:8849687	chr8:8456909~8461337:-
HNSC	cis	rs67981189	0.679	rs221901	ENSG00000274818.1	RP1-292L20.3	-3.94	9.28e-05	0.0132	-0.2	-0.18	Schizophrenia;	chr14:71135509	chr14:70906657~70907111:-
HNSC	cis	rs1667255	0.505	rs1941931	ENSG00000266521.1	RP11-650P15.1	3.94	9.28e-05	0.0132	0.2	0.18	Retinol levels;	chr18:31570512	chr18:31496645~31497195:-
HNSC	cis	rs9573567	0.881	rs6562897	ENSG00000261553.4	RP11-29G8.3	3.94	9.28e-05	0.0132	0.34	0.18	Red blood cell count;Mean corpuscular volume;	chr13:75502157	chr13:75549773~75807120:+
HNSC	cis	rs9573567	1	rs4242961	ENSG00000261553.4	RP11-29G8.3	3.94	9.28e-05	0.0132	0.34	0.18	Red blood cell count;Mean corpuscular volume;	chr13:75503772	chr13:75549773~75807120:+
HNSC	cis	rs6674176	0.628	rs12145999	ENSG00000237950.1	RP11-7O11.3	3.94	9.29e-05	0.0132	0.21	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43962960	chr1:43944370~43946551:-
HNSC	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-3.94	9.29e-05	0.0132	-0.22	-0.18	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
HNSC	cis	rs7824557	0.51	rs2736297	ENSG00000255310.2	AF131215.2	-3.94	9.29e-05	0.0132	-0.17	-0.18	Retinal vascular caliber;	chr8:11377376	chr8:11107788~11109726:-
HNSC	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	3.94	9.29e-05	0.0132	0.21	0.18	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
HNSC	cis	rs8024893	1	rs8038787	ENSG00000270055.1	CTD-3092A11.2	3.94	9.29e-05	0.0132	0.25	0.18	Red cell distribution width;	chr15:31246171	chr15:30487963~30490313:+
HNSC	cis	rs2760061	0.583	rs1636195	ENSG00000270110.1	RP5-1139B12.4	-3.94	9.29e-05	0.0132	-0.19	-0.18	Diastolic blood pressure;	chr1:228023888	chr1:228295911~228302998:-
HNSC	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	3.94	9.3e-05	0.0132	0.29	0.18	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
HNSC	cis	rs9611565	0.729	rs2413646	ENSG00000235513.1	RP4-756G23.5	3.94	9.3e-05	0.0132	0.22	0.18	Vitiligo;	chr22:41510321	chr22:41209122~41217627:-
HNSC	cis	rs35306767	0.714	rs7075188	ENSG00000229869.1	RP11-363N22.2	3.94	9.3e-05	0.0132	0.24	0.18	Eosinophil percentage of granulocytes;	chr10:1042806	chr10:933026~942743:+
HNSC	cis	rs9650657	0.836	rs1073913	ENSG00000269918.1	AF131215.9	-3.94	9.31e-05	0.0132	-0.18	-0.18	Neuroticism;	chr8:10754198	chr8:11104691~11106704:-
HNSC	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-3.94	9.31e-05	0.0132	-0.18	-0.18	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
HNSC	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	3.94	9.31e-05	0.0132	0.19	0.18	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
HNSC	cis	rs7674212	0.57	rs12501621	ENSG00000251288.2	RP11-10L12.2	-3.94	9.31e-05	0.0132	-0.2	-0.18	Type 2 diabetes;	chr4:103174348	chr4:102751401~102752641:+
HNSC	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	3.94	9.31e-05	0.0132	0.19	0.18	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
HNSC	cis	rs1008375	1	rs2058337	ENSG00000249502.1	AC006160.5	-3.94	9.31e-05	0.0132	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17677026	chr4:17587467~17614571:-
HNSC	cis	rs597539	0.727	rs632984	ENSG00000255741.1	RP11-757G1.5	-3.94	9.31e-05	0.0132	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68941503~68942852:-
HNSC	cis	rs1485395	1	rs1485395	ENSG00000270175.1	RP11-793H13.11	-3.94	9.32e-05	0.0132	-0.21	-0.18	Migraine without aura;	chr12:53601293	chr12:53500162~53500936:-
HNSC	cis	rs9611565	0.649	rs5751144	ENSG00000233903.2	Z83851.4	-3.94	9.32e-05	0.0132	-0.25	-0.18	Vitiligo;	chr22:41732093	chr22:42276355~42277052:+
HNSC	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-3.94	9.33e-05	0.0132	-0.18	-0.18	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
HNSC	cis	rs67981189	0.593	rs10132984	ENSG00000274818.1	RP1-292L20.3	3.94	9.33e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71010510	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs10132789	ENSG00000274818.1	RP1-292L20.3	3.94	9.33e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71013562	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs2097975	ENSG00000274818.1	RP1-292L20.3	3.94	9.33e-05	0.0132	0.2	0.18	Schizophrenia;	chr14:71013687	chr14:70906657~70907111:-
HNSC	cis	rs10742752	0.702	rs10838464	ENSG00000254651.1	RP11-430H10.3	-3.94	9.33e-05	0.0132	-0.21	-0.18	Body mass index;	chr11:45404445	chr11:45399448~45400528:+
HNSC	cis	rs4919687	0.55	rs10437480	ENSG00000236937.2	PTGES3P4	3.94	9.33e-05	0.0132	0.24	0.18	Colorectal cancer;	chr10:102693267	chr10:102845595~102845950:+
HNSC	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-3.94	9.33e-05	0.0132	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
HNSC	cis	rs913655	0.508	rs11015839	ENSG00000225527.1	RP11-383B4.4	-3.94	9.33e-05	0.0132	-0.22	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18713958	chr10:18531849~18533336:-
HNSC	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	3.94	9.33e-05	0.0132	0.26	0.18	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
HNSC	cis	rs1538970	0.924	rs4660858	ENSG00000234329.1	RP11-767N6.2	3.94	9.33e-05	0.0132	0.2	0.18	Platelet count;	chr1:45470679	chr1:45651039~45651826:-
HNSC	cis	rs801193	1	rs2707856	ENSG00000272831.1	RP11-792A8.4	3.94	9.33e-05	0.0132	0.15	0.18	Aortic root size;	chr7:66746023	chr7:66739829~66740385:-
HNSC	cis	rs7005380	0.62	rs7459671	ENSG00000279347.1	RP11-85I17.2	-3.94	9.34e-05	0.0132	-0.14	-0.18	Interstitial lung disease;	chr8:119896646	chr8:119838736~119840385:-
HNSC	cis	rs4256159	0.562	rs113261052	ENSG00000228956.7	SATB1-AS1	3.94	9.34e-05	0.0132	0.26	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18718566	chr3:18445024~18920401:+
HNSC	cis	rs6493858	0.868	rs2682059	ENSG00000277245.1	RP11-48G14.3	-3.94	9.34e-05	0.0132	-0.2	-0.18	Relative hand skill in reading disability;	chr15:56264752	chr15:56447120~56447697:+
HNSC	cis	rs988913	0.706	rs10948884	ENSG00000224984.1	RP11-524H19.2	3.94	9.34e-05	0.0132	0.21	0.18	Menarche (age at onset);	chr6:55077043	chr6:54840118~54840855:-
HNSC	cis	rs9611565	0.625	rs9607819	ENSG00000235513.1	RP4-756G23.5	3.94	9.34e-05	0.0132	0.2	0.18	Vitiligo;	chr22:41562858	chr22:41209122~41217627:-
HNSC	cis	rs227275	0.526	rs223497	ENSG00000230069.3	LRRC37A15P	-3.94	9.34e-05	0.0133	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102727274~102730721:-
HNSC	cis	rs4356203	0.87	rs7937176	ENSG00000260196.1	RP1-239B22.5	-3.94	9.34e-05	0.0133	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17380649~17383531:+
HNSC	cis	rs853679	0.825	rs8180562	ENSG00000226314.6	ZNF192P1	-3.94	9.35e-05	0.0133	-0.29	-0.18	Depression;	chr6:28173682	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.882	rs9380064	ENSG00000226314.6	ZNF192P1	-3.94	9.35e-05	0.0133	-0.29	-0.18	Depression;	chr6:28175340	chr6:28161781~28169594:+
HNSC	cis	rs6558530	0.666	rs4242539	ENSG00000253982.1	CTD-2336O2.1	3.94	9.35e-05	0.0133	0.23	0.18	Systolic blood pressure;	chr8:1746070	chr8:1761990~1764502:-
HNSC	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	3.94	9.35e-05	0.0133	0.25	0.18	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
HNSC	cis	rs597539	0.69	rs7129960	ENSG00000255741.1	RP11-757G1.5	-3.94	9.35e-05	0.0133	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68941503~68942852:-
HNSC	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	3.94	9.35e-05	0.0133	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
HNSC	cis	rs11976180	0.953	rs2951355	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144063469	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2951354	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144063908	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2961125	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144064677	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2961126	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144065643	chr7:144251264~144356181:-
HNSC	cis	rs11976180	0.953	rs2961127	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144065644	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs1919948	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144065750	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2961128	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144066390	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2371248	ENSG00000244479.5	OR2A1-AS1	3.94	9.35e-05	0.0133	0.2	0.18	Obesity-related traits;	chr7:144067096	chr7:144251264~144356181:-
HNSC	cis	rs889398	0.9	rs62052815	ENSG00000226232.7	RP11-419C5.2	3.94	9.35e-05	0.0133	0.16	0.18	Body mass index;	chr16:69527923	chr16:69976388~69996188:-
HNSC	cis	rs12403795	0.505	rs11811787	ENSG00000228126.1	FALEC	-3.94	9.35e-05	0.0133	-0.24	-0.18	Illicit drug use;	chr1:150228155	chr1:150515757~150518032:+
HNSC	cis	rs10888576	1	rs10888576	ENSG00000228126.1	FALEC	-3.94	9.35e-05	0.0133	-0.24	-0.18	Morning vs. evening chronotype;	chr1:150228460	chr1:150515757~150518032:+
HNSC	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-3.94	9.35e-05	0.0133	-0.23	-0.18	Height;	chr20:49218618	chr20:49280319~49280409:+
HNSC	cis	rs8031584	0.697	rs798080	ENSG00000270015.1	RP11-540B6.6	3.94	9.35e-05	0.0133	0.19	0.18	Huntington's disease progression;	chr15:30829966	chr15:30926514~30928407:+
HNSC	cis	rs28489187	0.597	rs10489513	ENSG00000223653.4	RP11-131L23.1	-3.94	9.36e-05	0.0133	-0.24	-0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85389939	chr1:85276715~85448124:+
HNSC	cis	rs2446066	0.605	rs8938	ENSG00000270175.1	RP11-793H13.11	-3.94	9.36e-05	0.0133	-0.23	-0.18	Red blood cell count;	chr12:53543094	chr12:53500162~53500936:-
HNSC	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	3.94	9.36e-05	0.0133	0.21	0.18	Height;	chr14:75159339	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-3.94	9.36e-05	0.0133	-0.21	-0.18	Height;	chr14:75163675	chr14:75011269~75012851:-
HNSC	cis	rs28489187	0.617	rs11161606	ENSG00000223653.4	RP11-131L23.1	3.94	9.36e-05	0.0133	0.23	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85388219	chr1:85276715~85448124:+
HNSC	cis	rs340630	0.967	rs13126334	ENSG00000251411.1	RP11-397E7.4	3.94	9.36e-05	0.0133	0.18	0.18	Systemic lupus erythematosus;	chr4:86988738	chr4:86913266~86914817:-
HNSC	cis	rs2835345	0.507	rs7280011	ENSG00000230479.1	AP000695.6	3.94	9.36e-05	0.0133	0.2	0.18	Pulmonary function;	chr21:36455256	chr21:36430360~36481070:+
HNSC	cis	rs9650657	0.771	rs12542888	ENSG00000269918.1	AF131215.9	-3.94	9.36e-05	0.0133	-0.18	-0.18	Neuroticism;	chr8:10805045	chr8:11104691~11106704:-
HNSC	cis	rs897984	0.806	rs8050588	ENSG00000279196.1	RP11-1072A3.3	3.94	9.36e-05	0.0133	0.2	0.18	Dementia with Lewy bodies;	chr16:30926478	chr16:30984630~30988270:-
HNSC	cis	rs7726839	0.54	rs11738281	ENSG00000225138.6	CTD-2228K2.7	3.94	9.37e-05	0.0133	0.26	0.18	Obesity-related traits;	chr5:662432	chr5:473236~480884:+
HNSC	cis	rs597539	0.503	rs7131462	ENSG00000255741.1	RP11-757G1.5	3.94	9.37e-05	0.0133	0.22	0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68842675	chr11:68941503~68942852:-
HNSC	cis	rs3015497	0.537	rs3015470	ENSG00000277050.1	RP11-102G14.1	-3.94	9.37e-05	0.0133	-0.18	-0.18	Mean platelet volume;	chr14:50689069	chr14:51637348~51637947:-
HNSC	cis	rs13256369	0.853	rs13256216	ENSG00000173295.6	FAM86B3P	3.94	9.37e-05	0.0133	0.24	0.18	Obesity-related traits;	chr8:8720373	chr8:8228595~8244865:+
HNSC	cis	rs1620921	0.563	rs13217026	ENSG00000231863.1	RP3-428L16.1	-3.94	9.38e-05	0.0133	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848919	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs13220254	ENSG00000231863.1	RP3-428L16.1	-3.94	9.38e-05	0.0133	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848926	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.506	rs13201433	ENSG00000231863.1	RP3-428L16.1	-3.94	9.38e-05	0.0133	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848927	chr6:160931080~160969771:+
HNSC	cis	rs7688540	0.771	rs7665727	ENSG00000211553.1	AC253576.2	-3.94	9.38e-05	0.0133	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:136461~136568:+
HNSC	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-3.94	9.39e-05	0.0133	-0.2	-0.18	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
HNSC	cis	rs7189233	0.592	rs2024449	ENSG00000261056.2	RP11-454F8.2	-3.94	9.39e-05	0.0133	-0.19	-0.18	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53298224~53299792:+
HNSC	cis	rs10466239	0.892	rs4648316	ENSG00000230555.2	RP11-517P14.2	3.94	9.39e-05	0.0133	0.31	0.18	Telomere length;	chr10:43364487	chr10:43420738~43422100:+
HNSC	cis	rs10466239	0.892	rs10899791	ENSG00000230555.2	RP11-517P14.2	3.94	9.39e-05	0.0133	0.31	0.18	Telomere length;	chr10:43364606	chr10:43420738~43422100:+
HNSC	cis	rs10466239	0.803	rs10899793	ENSG00000230555.2	RP11-517P14.2	3.94	9.39e-05	0.0133	0.31	0.18	Telomere length;	chr10:43364754	chr10:43420738~43422100:+
HNSC	cis	rs73198271	1	rs11774744	ENSG00000253893.2	FAM85B	3.94	9.39e-05	0.0133	0.26	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8167819~8226614:-
HNSC	cis	rs1979679	0.842	rs10459091	ENSG00000247934.4	RP11-967K21.1	-3.94	9.39e-05	0.0133	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28163298~28190738:-
HNSC	cis	rs73219805	0.793	rs3808573	ENSG00000228451.3	SDAD1P1	-3.94	9.39e-05	0.0133	-0.27	-0.18	Schizophrenia;	chr8:26339117	chr8:26379259~26382953:-
HNSC	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-3.94	9.4e-05	0.0133	-0.13	-0.18	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-3.94	9.4e-05	0.0133	-0.13	-0.18	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
HNSC	cis	rs4660456	0.576	rs2780948	ENSG00000237899.1	RP4-739H11.3	-3.94	9.4e-05	0.0133	-0.2	-0.18	Platelet count;	chr1:40776205	chr1:40669089~40687588:-
HNSC	cis	rs919433	0.854	rs13013049	ENSG00000231621.1	AC013264.2	3.94	9.4e-05	0.0133	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343940	chr2:197197991~197199273:+
HNSC	cis	rs2013441	0.83	rs2526469	ENSG00000261033.1	RP11-209D14.2	3.94	9.4e-05	0.0133	0.21	0.18	Obesity-related traits;	chr17:20259435	chr17:20008051~20009234:-
HNSC	cis	rs36093844	0.527	rs17745273	ENSG00000279742.1	RP11-700A24.1	-3.94	9.4e-05	0.0133	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86044496	chr11:85852557~85854943:-
HNSC	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	3.94	9.4e-05	0.0133	0.25	0.18	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
HNSC	cis	rs911555	0.755	rs2756122	ENSG00000269910.1	RP11-73M18.10	3.94	9.4e-05	0.0133	0.17	0.18	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103694516~103695050:-
HNSC	cis	rs9583531	0.6	rs7986286	ENSG00000259831.1	LINC00567	3.94	9.4e-05	0.0133	0.21	0.18	Coronary artery disease;	chr13:110704860	chr13:110809676~110813084:-
HNSC	cis	rs4253772	0.637	rs8135997	ENSG00000277232.2	GTSE1-AS1	-3.94	9.4e-05	0.0133	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46255469	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.637	rs8139035	ENSG00000277232.2	GTSE1-AS1	-3.94	9.4e-05	0.0133	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46255470	chr22:46295143~46296660:-
HNSC	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-3.94	9.4e-05	0.0133	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
HNSC	cis	rs17407555	0.779	rs17250843	ENSG00000250413.1	RP11-448G15.1	3.94	9.4e-05	0.0133	0.28	0.18	Schizophrenia (age at onset);	chr4:10126354	chr4:10006482~10009725:+
HNSC	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	3.94	9.41e-05	0.0133	0.25	0.18	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
HNSC	cis	rs865483	0.861	rs72828246	ENSG00000276054.1	RP11-378E13.3	-3.94	9.41e-05	0.0133	-0.22	-0.18	Monocyte count;	chr17:37406385	chr17:37386886~37387926:+
HNSC	cis	rs2013441	0.866	rs9898295	ENSG00000261033.1	RP11-209D14.2	3.94	9.41e-05	0.0133	0.21	0.18	Obesity-related traits;	chr17:20217281	chr17:20008051~20009234:-
HNSC	cis	rs6964587	0.626	rs10266424	ENSG00000188693.7	CYP51A1-AS1	3.94	9.41e-05	0.0133	0.19	0.18	Breast cancer;	chr7:91873914	chr7:92134604~92180725:+
HNSC	cis	rs12908161	1	rs12908161	ENSG00000229212.6	RP11-561C5.4	-3.94	9.41e-05	0.0133	-0.26	-0.18	Schizophrenia;	chr15:84664594	chr15:85205440~85234795:-
HNSC	cis	rs889398	0.967	rs12929503	ENSG00000226232.7	RP11-419C5.2	3.94	9.41e-05	0.0133	0.16	0.18	Body mass index;	chr16:69531558	chr16:69976388~69996188:-
HNSC	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	3.94	9.41e-05	0.0133	0.24	0.18	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
HNSC	cis	rs2439831	0.85	rs558656	ENSG00000275601.1	AC011330.13	-3.94	9.42e-05	0.0133	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43431316	chr15:43642389~43643023:-
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000272831.1	RP11-792A8.4	3.94	9.42e-05	0.0133	0.15	0.18	Aortic root size;	chr7:66749023	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2659889	ENSG00000272831.1	RP11-792A8.4	3.94	9.42e-05	0.0133	0.15	0.18	Aortic root size;	chr7:66752125	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs3800812	ENSG00000272831.1	RP11-792A8.4	3.94	9.42e-05	0.0133	0.15	0.18	Aortic root size;	chr7:66758474	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs4279493	ENSG00000272831.1	RP11-792A8.4	3.94	9.42e-05	0.0133	0.15	0.18	Aortic root size;	chr7:66761633	chr7:66739829~66740385:-
HNSC	cis	rs60695258	0.55	rs4693798	ENSG00000251411.1	RP11-397E7.4	3.94	9.42e-05	0.0133	0.18	0.18	Hematocrit;	chr4:86993136	chr4:86913266~86914817:-
HNSC	cis	rs60695258	0.55	rs4693800	ENSG00000251411.1	RP11-397E7.4	3.94	9.42e-05	0.0133	0.18	0.18	Hematocrit;	chr4:86994468	chr4:86913266~86914817:-
HNSC	cis	rs656900	0.647	rs600671	ENSG00000261229.4	MTHFS	-3.94	9.42e-05	0.0133	-0.19	-0.18	Cerebrospinal P-tau181p levels;	chr15:79824890	chr15:79843547~79897285:-
HNSC	cis	rs853679	1	rs1778511	ENSG00000226314.6	ZNF192P1	3.94	9.42e-05	0.0133	0.25	0.18	Depression;	chr6:28261633	chr6:28161781~28169594:+
HNSC	cis	rs2834288	0.7	rs2834298	ENSG00000273102.1	AP000569.9	-3.94	9.42e-05	0.0133	-0.21	-0.18	Gut microbiota (bacterial taxa);	chr21:33911251	chr21:33967101~33968573:-
HNSC	cis	rs7005380	0.531	rs4871010	ENSG00000279347.1	RP11-85I17.2	3.94	9.42e-05	0.0133	0.18	0.18	Interstitial lung disease;	chr8:119895399	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.531	rs13263147	ENSG00000279347.1	RP11-85I17.2	-3.94	9.42e-05	0.0133	-0.18	-0.18	Interstitial lung disease;	chr8:119895229	chr8:119838736~119840385:-
HNSC	cis	rs7572733	0.935	rs2060489	ENSG00000222017.1	AC011997.1	3.94	9.43e-05	0.0133	0.21	0.18	Dermatomyositis;	chr2:197887562	chr2:197693106~197774823:+
HNSC	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	3.94	9.43e-05	0.0134	0.47	0.18	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	3.94	9.43e-05	0.0134	0.47	0.18	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
HNSC	cis	rs62292953	0.591	rs55916362	ENSG00000248724.5	NPHP3-AS1	-3.94	9.43e-05	0.0134	-0.42	-0.18	Red cell distribution width;	chr3:132540744	chr3:132721750~132874223:+
HNSC	cis	rs62292953	0.591	rs55726578	ENSG00000248724.5	NPHP3-AS1	-3.94	9.43e-05	0.0134	-0.42	-0.18	Red cell distribution width;	chr3:132540748	chr3:132721750~132874223:+
HNSC	cis	rs2847281	0.587	rs2542157	ENSG00000260302.1	RP11-973H7.1	-3.94	9.43e-05	0.0134	-0.23	-0.18	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12787248	chr18:12774651~12775923:-
HNSC	cis	rs11148252	0.595	rs9526968	ENSG00000198384.8	TPTE2P3	3.94	9.43e-05	0.0134	0.22	0.18	Lewy body disease;	chr13:52666048	chr13:52522632~52586906:+
HNSC	cis	rs11148252	0.574	rs7139495	ENSG00000198384.8	TPTE2P3	3.94	9.43e-05	0.0134	0.22	0.18	Lewy body disease;	chr13:52709183	chr13:52522632~52586906:+
HNSC	cis	rs801193	0.591	rs721717	ENSG00000106610.13	STAG3L4	3.94	9.43e-05	0.0134	0.23	0.18	Aortic root size;	chr7:66665305	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000106610.13	STAG3L4	3.94	9.43e-05	0.0134	0.23	0.18	Aortic root size;	chr7:66667525	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000106610.13	STAG3L4	3.94	9.43e-05	0.0134	0.23	0.18	Aortic root size;	chr7:66670470	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000106610.13	STAG3L4	-3.94	9.43e-05	0.0134	-0.23	-0.18	Aortic root size;	chr7:66695835	chr7:67302621~67321526:+
HNSC	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	3.94	9.43e-05	0.0134	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
HNSC	cis	rs2337406	0.866	rs2301535	ENSG00000280411.1	IGHV1-69-2	-3.94	9.43e-05	0.0134	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106790663	chr14:106762092~106762588:-
HNSC	cis	rs875971	0.522	rs1701760	ENSG00000272831.1	RP11-792A8.4	3.94	9.43e-05	0.0134	0.15	0.18	Aortic root size;	chr7:66008701	chr7:66739829~66740385:-
HNSC	cis	rs1799955	0.935	rs3764792	ENSG00000215515.2	IFIT1P1	-3.94	9.43e-05	0.0134	-0.25	-0.18	LDL cholesterol levels;	chr13:32376978	chr13:32384660~32386108:+
HNSC	cis	rs7688540	0.771	rs79366248	ENSG00000211553.1	AC253576.2	-3.94	9.43e-05	0.0134	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs78343340	ENSG00000211553.1	AC253576.2	-3.94	9.43e-05	0.0134	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:136461~136568:+
HNSC	cis	rs1979679	0.842	rs60025108	ENSG00000247934.4	RP11-967K21.1	-3.94	9.44e-05	0.0134	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28163298~28190738:-
HNSC	cis	rs1979679	0.842	rs7487773	ENSG00000247934.4	RP11-967K21.1	-3.94	9.44e-05	0.0134	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28163298~28190738:-
HNSC	cis	rs4713118	0.824	rs2092075	ENSG00000216901.1	AL022393.7	3.94	9.44e-05	0.0134	0.23	0.18	Parkinson's disease;	chr6:27781551	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.824	rs13211701	ENSG00000216901.1	AL022393.7	3.94	9.44e-05	0.0134	0.23	0.18	Parkinson's disease;	chr6:27782300	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.824	rs9468229	ENSG00000216901.1	AL022393.7	3.94	9.44e-05	0.0134	0.23	0.18	Parkinson's disease;	chr6:27782307	chr6:28176188~28176674:+
HNSC	cis	rs6558174	0.863	rs17746902	ENSG00000253837.1	RP11-177H13.2	3.94	9.44e-05	0.0134	0.18	0.18	Breast cancer;	chr8:22634467	chr8:23336171~23366125:+
HNSC	cis	rs853679	0.517	rs4713146	ENSG00000219891.2	ZSCAN12P1	3.94	9.44e-05	0.0134	0.26	0.18	Depression;	chr6:28143758	chr6:28091154~28093664:+
HNSC	cis	rs2657294	0.895	rs2395137	ENSG00000233313.2	HMGA1P5	-3.94	9.44e-05	0.0134	-0.2	-0.18	Pneumonia;	chr10:75088235	chr10:75276376~75276646:-
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000272831.1	RP11-792A8.4	-3.94	9.44e-05	0.0134	-0.15	-0.18	Aortic root size;	chr7:65950660	chr7:66739829~66740385:-
HNSC	cis	rs1008375	1	rs13106338	ENSG00000249502.1	AC006160.5	3.94	9.44e-05	0.0134	0.19	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675248	chr4:17587467~17614571:-
HNSC	cis	rs2337406	0.538	rs2015470	ENSG00000280411.1	IGHV1-69-2	-3.94	9.44e-05	0.0134	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106631885	chr14:106762092~106762588:-
HNSC	cis	rs6490294	0.571	rs12425329	ENSG00000226469.1	ADAM1B	3.94	9.44e-05	0.0134	0.25	0.18	Mean platelet volume;	chr12:112004628	chr12:111927018~111929017:+
HNSC	cis	rs8058578	0.945	rs8058961	ENSG00000279196.1	RP11-1072A3.3	3.94	9.44e-05	0.0134	0.22	0.18	Multiple myeloma;	chr16:30797742	chr16:30984630~30988270:-
HNSC	cis	rs1620921	0.594	rs9347450	ENSG00000231863.1	RP3-428L16.1	-3.94	9.44e-05	0.0134	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848858	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.533	rs9365218	ENSG00000231863.1	RP3-428L16.1	-3.94	9.44e-05	0.0134	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160848871	chr6:160931080~160969771:+
HNSC	cis	rs9494145	0.667	rs1331309	ENSG00000232876.1	CTA-212D2.2	-3.94	9.44e-05	0.0134	-0.26	-0.18	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135085040	chr6:135055033~135060550:+
HNSC	cis	rs10492201	0.529	rs740420	ENSG00000255733.4	IFNG-AS1	-3.94	9.45e-05	0.0134	-0.17	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:67989445~68234686:+
HNSC	cis	rs10492201	0.554	rs2870962	ENSG00000255733.4	IFNG-AS1	-3.94	9.45e-05	0.0134	-0.17	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:67989445~68234686:+
HNSC	cis	rs597539	0.69	rs11228383	ENSG00000255741.1	RP11-757G1.5	-3.94	9.45e-05	0.0134	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68941503~68942852:-
HNSC	cis	rs12682352	0.602	rs11783966	ENSG00000254153.1	CTA-398F10.2	-3.94	9.45e-05	0.0134	-0.2	-0.18	Neuroticism;	chr8:8807637	chr8:8456909~8461337:-
HNSC	cis	rs4356203	0.905	rs9919600	ENSG00000260196.1	RP1-239B22.5	-3.94	9.45e-05	0.0134	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.905	rs7939750	ENSG00000260196.1	RP1-239B22.5	-3.94	9.45e-05	0.0134	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17380649~17383531:+
HNSC	cis	rs4356203	0.543	rs214081	ENSG00000272034.1	SNORD14A	-3.94	9.45e-05	0.0134	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17074654~17074744:-
HNSC	cis	rs6968419	1	rs6979486	ENSG00000237870.5	AC073130.1	3.94	9.45e-05	0.0134	0.2	0.18	Intraocular pressure;	chr7:116192384	chr7:116275606~116286734:-
HNSC	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-3.94	9.45e-05	0.0134	-0.22	-0.18	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
HNSC	cis	rs11976180	1	rs11976037	ENSG00000244479.5	OR2A1-AS1	3.94	9.45e-05	0.0134	0.21	0.18	Obesity-related traits;	chr7:144043931	chr7:144251264~144356181:-
HNSC	cis	rs9313772	0.928	rs7737275	ENSG00000254350.1	RP11-542A14.1	-3.94	9.46e-05	0.0134	-0.2	-0.18	Blood pressure;	chr5:158389134	chr5:158424585~158452758:+
HNSC	cis	rs35000415	0.873	rs12539741	ENSG00000275106.1	RP11-309L24.10	-3.94	9.46e-05	0.0134	-0.4	-0.18	Systemic lupus erythematosus;	chr7:128956751	chr7:128952527~128953316:-
HNSC	cis	rs9925964	0.933	rs12448321	ENSG00000232748.3	RP11-196G11.6	3.94	9.46e-05	0.0134	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:31056460~31062803:+
HNSC	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-3.94	9.46e-05	0.0134	-0.23	-0.18	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
HNSC	cis	rs913672	0.637	rs12625213	ENSG00000224397.4	LINC01272	3.94	9.46e-05	0.0134	0.24	0.18	Monocyte count;	chr20:50278382	chr20:50267486~50279795:+
HNSC	cis	rs4873772	0.634	rs13279327	ENSG00000253330.1	RP11-697N18.3	3.94	9.46e-05	0.0134	0.25	0.18	Lobe attachment (rater-scored or self-reported);	chr8:47529822	chr8:47511034~47512141:-
HNSC	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-3.94	9.46e-05	0.0134	-0.18	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
HNSC	cis	rs8077577	0.671	rs9909104	ENSG00000273018.4	CTD-2303H24.2	-3.94	9.46e-05	0.0134	-0.24	-0.18	Obesity-related traits;	chr17:18344707	chr17:18511221~18551705:-
HNSC	cis	rs2436845	0.603	rs2679753	ENSG00000253320.4	KB-1507C5.2	-3.94	9.46e-05	0.0134	-0.2	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102864300~102977876:+
HNSC	cis	rs7824557	0.602	rs35807737	ENSG00000255310.2	AF131215.2	3.94	9.47e-05	0.0134	0.17	0.18	Retinal vascular caliber;	chr8:11346902	chr8:11107788~11109726:-
HNSC	cis	rs7352944	0.896	rs6067322	ENSG00000229222.1	KRT18P4	-3.94	9.47e-05	0.0134	-0.2	-0.18	Psoriasis;	chr20:50023773	chr20:49956745~49958032:+
HNSC	cis	rs870825	0.616	rs7668009	ENSG00000254233.1	RP11-242J7.1	3.94	9.47e-05	0.0134	0.26	0.18	Blood protein levels;	chr4:184720844	chr4:184584093~184625030:-
HNSC	cis	rs6688613	0.84	rs6695609	ENSG00000215834.7	FMO9P	-3.94	9.47e-05	0.0134	-0.24	-0.18	Refractive astigmatism;	chr1:166984629	chr1:166603675~166631400:+
HNSC	cis	rs9425766	0.626	rs6691053	ENSG00000227373.4	RP11-160H22.5	3.94	9.47e-05	0.0134	0.26	0.18	Life satisfaction;	chr1:173899817	chr1:174115300~174160004:-
HNSC	cis	rs35306767	0.714	rs12783621	ENSG00000229869.1	RP11-363N22.2	-3.94	9.47e-05	0.0134	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1037364	chr10:933026~942743:+
HNSC	cis	rs35306767	0.668	rs12784928	ENSG00000229869.1	RP11-363N22.2	-3.94	9.47e-05	0.0134	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1037677	chr10:933026~942743:+
HNSC	cis	rs4144743	1	rs67923812	ENSG00000228782.6	CTD-2026D20.3	-3.94	9.47e-05	0.0134	-0.21	-0.18	Body mass index;	chr17:47248785	chr17:47450568~47492492:-
HNSC	cis	rs17253792	0.915	rs17832389	ENSG00000186615.9	KTN1-AS1	-3.94	9.47e-05	0.0134	-0.36	-0.18	Putamen volume;	chr14:55719118	chr14:55499278~55580110:-
HNSC	cis	rs453301	0.598	rs10104303	ENSG00000253981.4	ALG1L13P	3.94	9.47e-05	0.0134	0.19	0.18	Joint mobility (Beighton score);	chr8:8977018	chr8:8236003~8244667:-
HNSC	cis	rs60617249	0.862	rs12718995	ENSG00000228204.2	RP4-724E13.2	-3.94	9.47e-05	0.0134	-0.19	-0.18	Major depression and alcohol dependence;	chr7:50936845	chr7:50866747~51022990:+
HNSC	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-3.94	9.47e-05	0.0134	-0.22	-0.18	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
HNSC	cis	rs10895275	0.606	rs2846837	ENSG00000277459.1	RP11-732A21.3	3.94	9.47e-05	0.0134	0.2	0.18	Migraine;	chr11:102234874	chr11:102109827~102110457:-
HNSC	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	3.94	9.47e-05	0.0134	0.28	0.18	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
HNSC	cis	rs7107174	1	rs2510041	ENSG00000251323.2	RP11-452H21.4	3.94	9.48e-05	0.0134	0.26	0.18	Testicular germ cell tumor;	chr11:78234238	chr11:78423982~78429836:-
HNSC	cis	rs853679	0.517	rs9380047	ENSG00000219891.2	ZSCAN12P1	3.94	9.48e-05	0.0134	0.25	0.18	Depression;	chr6:28070115	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs7755442	ENSG00000219891.2	ZSCAN12P1	3.94	9.48e-05	0.0134	0.25	0.18	Depression;	chr6:28071237	chr6:28091154~28093664:+
HNSC	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-3.94	9.48e-05	0.0134	-0.22	-0.18	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
HNSC	cis	rs62025270	0.688	rs10163064	ENSG00000259762.1	RP11-158M2.4	-3.94	9.49e-05	0.0134	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85750336~85752901:-
HNSC	cis	rs1559040	1	rs61572658	ENSG00000272156.1	RP11-477N3.1	-3.94	9.49e-05	0.0134	-0.31	-0.18	Sudden cardiac arrest;	chr2:54097606	chr2:54082554~54085066:+
HNSC	cis	rs28489187	0.706	rs233115	ENSG00000223653.4	RP11-131L23.1	3.94	9.49e-05	0.0134	0.25	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321294	chr1:85276715~85448124:+
HNSC	cis	rs7819412	0.703	rs2409713	ENSG00000255310.2	AF131215.2	-3.94	9.49e-05	0.0134	-0.18	-0.18	Triglycerides;	chr8:11152287	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	3.94	9.49e-05	0.0134	0.21	0.18	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
HNSC	cis	rs116095464	0.558	rs56081398	ENSG00000250848.1	CTD-2083E4.5	-3.94	9.49e-05	0.0134	-0.25	-0.18	Breast cancer;	chr5:247203	chr5:288833~290321:-
HNSC	cis	rs116095464	0.558	rs10065584	ENSG00000250848.1	CTD-2083E4.5	-3.94	9.49e-05	0.0134	-0.25	-0.18	Breast cancer;	chr5:253882	chr5:288833~290321:-
HNSC	cis	rs7674212	0.57	rs1031804	ENSG00000251288.2	RP11-10L12.2	-3.94	9.49e-05	0.0134	-0.2	-0.18	Type 2 diabetes;	chr4:103144892	chr4:102751401~102752641:+
HNSC	cis	rs4073405	0.847	rs7483751	ENSG00000254651.1	RP11-430H10.3	3.94	9.49e-05	0.0134	0.21	0.18	Schizophrenia;	chr11:45326815	chr11:45399448~45400528:+
HNSC	cis	rs9467773	0.595	rs9366657	ENSG00000241549.7	GUSBP2	-3.94	9.49e-05	0.0134	-0.17	-0.18	Intelligence (multi-trait analysis);	chr6:26434686	chr6:26871484~26956554:-
HNSC	cis	rs2451932	0.555	rs10064975	ENSG00000251050.1	RP11-168A11.4	-3.94	9.5e-05	0.0134	-0.17	-0.18	LDL peak particle diameter (total fat intake interaction);	chr5:79981392	chr5:80019609~80019920:+
HNSC	cis	rs8031584	0.723	rs711224	ENSG00000270015.1	RP11-540B6.6	3.94	9.5e-05	0.0134	0.19	0.18	Huntington's disease progression;	chr15:30835718	chr15:30926514~30928407:+
HNSC	cis	rs62432291	0.681	rs436277	ENSG00000235086.1	FNDC1-IT1	3.94	9.5e-05	0.0134	0.24	0.18	Joint mobility (Beighton score);	chr6:159213110	chr6:159240786~159243329:+
HNSC	cis	rs58873874	0.579	rs77042939	ENSG00000251405.2	CTB-109A12.1	3.94	9.5e-05	0.0134	0.36	0.18	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157362615~157460078:-
HNSC	cis	rs2304003	0.95	rs6742727	ENSG00000235192.1	AC009495.2	3.94	9.51e-05	0.0134	0.24	0.18	Social communication problems;	chr2:165836176	chr2:165794851~165810010:+
HNSC	cis	rs4908768	0.501	rs4908760	ENSG00000232912.4	RP5-1115A15.1	3.94	9.51e-05	0.0134	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8424645~8434838:+
HNSC	cis	rs10129255	1	rs10141557	ENSG00000224373.3	IGHV4-59	3.94	9.51e-05	0.0134	0.12	0.18	Kawasaki disease;	chr14:106767990	chr14:106627249~106627825:-
HNSC	cis	rs11089937	0.555	rs6001226	ENSG00000211638.2	IGLV8-61	-3.94	9.51e-05	0.0134	-0.17	-0.18	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22098700~22099212:+
HNSC	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	3.94	9.51e-05	0.0134	0.25	0.18	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
HNSC	cis	rs4523957	0.719	rs1532292	ENSG00000262333.1	HNRNPA1P16	3.94	9.51e-05	0.0134	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2194189	chr17:2306761~2307715:+
HNSC	cis	rs4523957	0.757	rs1002135	ENSG00000262333.1	HNRNPA1P16	3.94	9.51e-05	0.0134	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2194289	chr17:2306761~2307715:+
HNSC	cis	rs4820294	0.646	rs9622675	ENSG00000225867.1	RP5-1177I5.3	-3.94	9.51e-05	0.0135	-0.2	-0.18	Fat distribution (HIV);	chr22:37657658	chr22:37550026~37551735:+
HNSC	cis	rs11758351	1	rs80095925	ENSG00000241549.7	GUSBP2	-3.94	9.52e-05	0.0135	-0.26	-0.18	Renal underexcretion gout;Gout;	chr6:26184714	chr6:26871484~26956554:-
HNSC	cis	rs17076726	0.519	rs2561766	ENSG00000253785.1	CTC-308K20.3	-3.94	9.52e-05	0.0135	-0.19	-0.18	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173875406	chr5:172975511~172976374:+
HNSC	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	3.94	9.52e-05	0.0135	0.2	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
HNSC	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	3.94	9.52e-05	0.0135	0.2	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
HNSC	cis	rs7615952	0.546	rs11718647	ENSG00000241288.6	RP11-379B18.5	-3.94	9.52e-05	0.0135	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:125633178	chr3:125827238~125916384:-
HNSC	cis	rs2048656	0.57	rs7814635	ENSG00000254340.1	RP11-10A14.3	3.94	9.52e-05	0.0135	0.23	0.18	Schizophrenia;	chr8:9789110	chr8:9141424~9145435:+
HNSC	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-3.94	9.52e-05	0.0135	-0.18	-0.18	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-3.94	9.52e-05	0.0135	-0.18	-0.18	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
HNSC	cis	rs6928977	0.863	rs7772681	ENSG00000231028.7	LINC00271	-3.94	9.52e-05	0.0135	-0.21	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135327875	chr6:135497801~135716055:+
HNSC	cis	rs7903456	0.648	rs2146720	ENSG00000200253.1	RNU6-529P	3.94	9.52e-05	0.0135	0.24	0.18	Gout;Renal underexcretion gout;	chr10:87074325	chr10:87041238~87041341:-
HNSC	cis	rs7637230	1	rs10511191	ENSG00000244119.1	PDCL3P4	-3.94	9.52e-05	0.0135	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101927008	chr3:101712472~101713191:+
HNSC	cis	rs4819052	0.918	rs34886433	ENSG00000215447.6	BX322557.10	-3.94	9.52e-05	0.0135	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45288052~45291738:+
HNSC	cis	rs1979679	0.918	rs2348234	ENSG00000247934.4	RP11-967K21.1	-3.94	9.52e-05	0.0135	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28163298~28190738:-
HNSC	cis	rs9329221	0.513	rs4841296	ENSG00000255310.2	AF131215.2	-3.94	9.52e-05	0.0135	-0.17	-0.18	Neuroticism;	chr8:10247937	chr8:11107788~11109726:-
HNSC	cis	rs10129255	0.5	rs8004923	ENSG00000211976.2	IGHV3-73	-3.94	9.53e-05	0.0135	-0.13	-0.18	Kawasaki disease;	chr14:106785926	chr14:106802694~106803233:-
HNSC	cis	rs10129255	0.5	rs6576232	ENSG00000211976.2	IGHV3-73	-3.94	9.53e-05	0.0135	-0.13	-0.18	Kawasaki disease;	chr14:106787090	chr14:106802694~106803233:-
HNSC	cis	rs9952991	0.941	rs8096138	ENSG00000260302.1	RP11-973H7.1	3.94	9.53e-05	0.0135	0.31	0.18	Inflammatory skin disease;	chr18:12808141	chr18:12774651~12775923:-
HNSC	cis	rs7637230	1	rs78913826	ENSG00000244119.1	PDCL3P4	-3.94	9.53e-05	0.0135	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101913794	chr3:101712472~101713191:+
HNSC	cis	rs62025270	0.688	rs17638180	ENSG00000259762.1	RP11-158M2.4	-3.94	9.53e-05	0.0135	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85750336~85752901:-
HNSC	cis	rs74054849	0.85	rs6679358	ENSG00000215908.6	CROCCP2	3.94	9.53e-05	0.0135	0.25	0.18	Alcoholic chronic pancreatitis;	chr1:15691581	chr1:16618262~16644683:-
HNSC	cis	rs897984	0.806	rs10782002	ENSG00000260911.2	RP11-196G11.2	-3.94	9.53e-05	0.0135	-0.16	-0.18	Dementia with Lewy bodies;	chr16:30935185	chr16:31043150~31049868:+
HNSC	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	3.94	9.53e-05	0.0135	0.2	0.18	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
HNSC	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	3.94	9.53e-05	0.0135	0.2	0.18	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
HNSC	cis	rs6697139	1	rs10917686	ENSG00000215840.3	RP11-122G18.7	3.94	9.53e-05	0.0135	0.24	0.18	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;	chr1:161688700	chr1:161406068~161407082:+
HNSC	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-3.94	9.53e-05	0.0135	-0.22	-0.18	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
HNSC	cis	rs4388249	1	rs3797680	ENSG00000271849.1	CTC-332L22.1	-3.94	9.53e-05	0.0135	-0.28	-0.18	Schizophrenia;	chr5:109824550	chr5:109687802~109688329:-
HNSC	cis	rs35306767	0.715	rs1250891	ENSG00000229869.1	RP11-363N22.2	-3.94	9.54e-05	0.0135	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:994219	chr10:933026~942743:+
HNSC	cis	rs7005380	0.62	rs9649947	ENSG00000279347.1	RP11-85I17.2	-3.94	9.54e-05	0.0135	-0.14	-0.18	Interstitial lung disease;	chr8:119901117	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13279398	ENSG00000279347.1	RP11-85I17.2	-3.94	9.54e-05	0.0135	-0.14	-0.18	Interstitial lung disease;	chr8:119902030	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13277947	ENSG00000279347.1	RP11-85I17.2	-3.94	9.54e-05	0.0135	-0.14	-0.18	Interstitial lung disease;	chr8:119902192	chr8:119838736~119840385:-
HNSC	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-3.94	9.54e-05	0.0135	-0.19	-0.18	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
HNSC	cis	rs11098499	0.954	rs6820115	ENSG00000260091.1	RP11-33B1.4	3.94	9.54e-05	0.0135	0.17	0.18	Corneal astigmatism;	chr4:119477027	chr4:119409333~119410233:+
HNSC	cis	rs6500602	0.584	rs11646063	ENSG00000280063.1	RP11-295D4.3	-3.94	9.54e-05	0.0135	-0.14	-0.18	Schizophrenia;	chr16:4389208	chr16:4346694~4348648:-
HNSC	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	3.94	9.54e-05	0.0135	0.19	0.18	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	3.94	9.54e-05	0.0135	0.19	0.18	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
HNSC	cis	rs6787172	0.628	rs58363161	ENSG00000272087.1	RP11-379F4.7	3.94	9.54e-05	0.0135	0.19	0.18	Subjective well-being;	chr3:158540523	chr3:158693120~158693768:-
HNSC	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	3.94	9.54e-05	0.0135	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
HNSC	cis	rs6142618	0.562	rs6089193	ENSG00000275576.1	RP5-836N17.4	-3.94	9.54e-05	0.0135	-0.18	-0.18	Inflammatory bowel disease;	chr20:32141685	chr20:32116171~32116629:+
HNSC	cis	rs4081724	0.565	rs56355036	ENSG00000267296.2	CEBPA-AS1	3.94	9.54e-05	0.0135	0.35	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33306352	chr19:33302857~33305054:+
HNSC	cis	rs11657639	0.515	rs1027895	ENSG00000228782.6	CTD-2026D20.3	-3.94	9.55e-05	0.0135	-0.18	-0.18	Red blood cell count;	chr17:48433335	chr17:47450568~47492492:-
HNSC	cis	rs9329221	0.537	rs6601414	ENSG00000269918.1	AF131215.9	3.94	9.55e-05	0.0135	0.18	0.18	Neuroticism;	chr8:10119238	chr8:11104691~11106704:-
HNSC	cis	rs12291225	0.877	rs2303974	ENSG00000251991.1	RNU7-49P	3.94	9.55e-05	0.0135	0.21	0.18	Sense of smell;	chr11:14243433	chr11:14478892~14478953:+
HNSC	cis	rs11711311	1	rs12636577	ENSG00000241529.3	RN7SL767P	-3.94	9.55e-05	0.0135	-0.23	-0.18	IgG glycosylation;	chr3:113778660	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9848993	ENSG00000241529.3	RN7SL767P	-3.94	9.55e-05	0.0135	-0.23	-0.18	IgG glycosylation;	chr3:113779067	chr3:113632704~113632998:+
HNSC	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	3.94	9.55e-05	0.0135	0.24	0.18	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	3.94	9.55e-05	0.0135	0.24	0.18	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	3.94	9.55e-05	0.0135	0.24	0.18	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	3.94	9.55e-05	0.0135	0.24	0.18	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	3.94	9.55e-05	0.0135	0.24	0.18	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
HNSC	cis	rs73198271	1	rs11776513	ENSG00000254340.1	RP11-10A14.3	-3.94	9.55e-05	0.0135	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:9141424~9145435:+
HNSC	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	3.94	9.55e-05	0.0135	0.25	0.18	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
HNSC	cis	rs11157436	0.56	rs11623957	ENSG00000211814.1	TRAV35	-3.94	9.56e-05	0.0135	-0.16	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22221896~22222475:+
HNSC	cis	rs6460942	0.659	rs17192500	ENSG00000226690.5	AC005281.1	3.94	9.56e-05	0.0135	0.28	0.18	Coronary artery disease;	chr7:12505753	chr7:12496429~12541910:+
HNSC	cis	rs9907295	0.688	rs2526327	ENSG00000271013.1	AC015849.15	3.94	9.56e-05	0.0135	0.21	0.18	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35912635~35918010:-
HNSC	cis	rs17014483	0.749	rs2924350	ENSG00000248019.2	FAM13A-AS1	-3.94	9.56e-05	0.0135	-0.23	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88705240	chr4:88709789~88730103:+
HNSC	cis	rs11711311	0.736	rs2278941	ENSG00000241529.3	RN7SL767P	-3.94	9.56e-05	0.0135	-0.24	-0.18	IgG glycosylation;	chr3:113631661	chr3:113632704~113632998:+
HNSC	cis	rs7572733	0.935	rs1401090	ENSG00000222017.1	AC011997.1	3.94	9.56e-05	0.0135	0.22	0.18	Dermatomyositis;	chr2:197943854	chr2:197693106~197774823:+
HNSC	cis	rs4372836	0.964	rs11683296	ENSG00000226833.4	AC097724.3	-3.94	9.56e-05	0.0135	-0.23	-0.18	Body mass index;	chr2:28702538	chr2:28708953~28736205:-
HNSC	cis	rs2070419	0.724	rs62222907	ENSG00000261610.1	AP000265.1	3.94	9.57e-05	0.0135	0.22	0.18	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31569039	chr21:32259804~32261585:-
HNSC	cis	rs2070419	0.724	rs62222909	ENSG00000261610.1	AP000265.1	3.94	9.57e-05	0.0135	0.22	0.18	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31569160	chr21:32259804~32261585:-
HNSC	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	3.94	9.57e-05	0.0135	0.33	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
HNSC	cis	rs12682352	0.65	rs13265731	ENSG00000173295.6	FAM86B3P	3.94	9.57e-05	0.0135	0.2	0.18	Neuroticism;	chr8:8815810	chr8:8228595~8244865:+
HNSC	cis	rs1008375	0.932	rs13127157	ENSG00000249502.1	AC006160.5	3.94	9.57e-05	0.0135	0.2	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616426	chr4:17587467~17614571:-
HNSC	cis	rs7267979	0.789	rs6076347	ENSG00000231081.1	RP4-760C5.3	3.94	9.58e-05	0.0135	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26008791~26010531:-
HNSC	cis	rs41307935	0.822	rs71636786	ENSG00000260063.1	RP5-968P14.2	-3.94	9.58e-05	0.0135	-0.37	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26851434	chr1:26692132~26694131:-
HNSC	cis	rs73198271	0.96	rs11776546	ENSG00000253893.2	FAM85B	3.94	9.58e-05	0.0135	0.26	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr8:8167819~8226614:-
HNSC	cis	rs7572733	0.935	rs10497809	ENSG00000222017.1	AC011997.1	3.94	9.58e-05	0.0135	0.21	0.18	Dermatomyositis;	chr2:197960944	chr2:197693106~197774823:+
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000233609.3	RP11-62H7.2	3.93	9.59e-05	0.0135	0.17	0.18	Systolic blood pressure;	chr8:8487658	chr8:8961200~8979025:+
HNSC	cis	rs5758659	0.967	rs5751250	ENSG00000273366.1	CTA-989H11.1	-3.93	9.59e-05	0.0135	-0.21	-0.18	Cognitive function;	chr22:42243639	chr22:42278188~42278846:+
HNSC	cis	rs7824557	0.603	rs2250028	ENSG00000255310.2	AF131215.2	3.93	9.59e-05	0.0135	0.17	0.18	Retinal vascular caliber;	chr8:11356080	chr8:11107788~11109726:-
HNSC	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	3.93	9.59e-05	0.0135	0.21	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
HNSC	cis	rs9467711	0.79	rs35942569	ENSG00000241549.7	GUSBP2	3.93	9.59e-05	0.0135	0.3	0.18	Autism spectrum disorder or schizophrenia;	chr6:26338903	chr6:26871484~26956554:-
HNSC	cis	rs1445130	0.636	rs4832445	ENSG00000260331.1	RP11-111J6.2	3.93	9.59e-05	0.0135	0.25	0.18	Bulimia nervosa;	chr2:18654815	chr2:18547386~18548204:-
HNSC	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-3.93	9.59e-05	0.0135	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
HNSC	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-3.93	9.59e-05	0.0135	-0.23	-0.18	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
HNSC	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	3.93	9.6e-05	0.0135	0.19	0.18	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
HNSC	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	3.93	9.6e-05	0.0136	0.2	0.18	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
HNSC	cis	rs7429990	0.901	rs7433678	ENSG00000228638.1	FCF1P2	3.93	9.6e-05	0.0136	0.16	0.18	Educational attainment (years of education);	chr3:47995588	chr3:48290793~48291375:-
HNSC	cis	rs28830936	0.934	rs3959569	ENSG00000250379.1	RP11-23P13.4	3.93	9.6e-05	0.0136	0.22	0.18	Diastolic blood pressure;	chr15:41823549	chr15:41825099~41827936:-
HNSC	cis	rs988913	0.874	rs12662124	ENSG00000224984.1	RP11-524H19.2	3.93	9.6e-05	0.0136	0.21	0.18	Menarche (age at onset);	chr6:54937538	chr6:54840118~54840855:-
HNSC	cis	rs988913	1	rs9396007	ENSG00000224984.1	RP11-524H19.2	3.93	9.6e-05	0.0136	0.21	0.18	Menarche (age at onset);	chr6:54942824	chr6:54840118~54840855:-
HNSC	cis	rs6500395	1	rs9924078	ENSG00000261267.1	RP11-44I10.3	3.93	9.6e-05	0.0136	0.23	0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48524007	chr16:48559661~48587403:+
HNSC	cis	rs4835473	0.932	rs11734290	ENSG00000249741.2	RP11-673E1.3	3.93	9.6e-05	0.0136	0.2	0.18	Immature fraction of reticulocytes;	chr4:143823636	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs11734383	ENSG00000249741.2	RP11-673E1.3	3.93	9.6e-05	0.0136	0.2	0.18	Immature fraction of reticulocytes;	chr4:143824093	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.868	rs11735295	ENSG00000249741.2	RP11-673E1.3	3.93	9.6e-05	0.0136	0.2	0.18	Immature fraction of reticulocytes;	chr4:143824150	chr4:143911514~143912053:-
HNSC	cis	rs2976388	1	rs2976396	ENSG00000253741.1	CTD-2292P10.4	-3.93	9.6e-05	0.0136	-0.17	-0.18	Urinary tract infection frequency;	chr8:142682583	chr8:142702252~142726973:-
HNSC	cis	rs2732480	1	rs2732480	ENSG00000257763.1	OR5BK1P	-3.93	9.61e-05	0.0136	-0.17	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48355792~48356614:-
HNSC	cis	rs7005380	0.62	rs10093230	ENSG00000279347.1	RP11-85I17.2	-3.93	9.61e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119900606	chr8:119838736~119840385:-
HNSC	cis	rs4256159	1	rs59096832	ENSG00000228956.7	SATB1-AS1	3.93	9.61e-05	0.0136	0.3	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18732336	chr3:18445024~18920401:+
HNSC	cis	rs5758659	0.737	rs10854749	ENSG00000270083.1	RP1-257I20.14	3.93	9.61e-05	0.0136	0.17	0.18	Cognitive function;	chr22:42051337	chr22:42089630~42090028:-
HNSC	cis	rs1538970	0.884	rs1771551	ENSG00000234329.1	RP11-767N6.2	3.93	9.61e-05	0.0136	0.2	0.18	Platelet count;	chr1:45417971	chr1:45651039~45651826:-
HNSC	cis	rs1862618	0.671	rs2591961	ENSG00000271828.1	CTD-2310F14.1	-3.93	9.61e-05	0.0136	-0.22	-0.18	Initial pursuit acceleration;	chr5:56942770	chr5:56927874~56929573:+
HNSC	cis	rs9903692	0.954	rs7209730	ENSG00000263412.1	RP5-890E16.2	3.93	9.61e-05	0.0136	0.17	0.18	Pulse pressure;	chr17:48130137	chr17:48045141~48048073:-
HNSC	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	3.93	9.61e-05	0.0136	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	3.93	9.61e-05	0.0136	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
HNSC	cis	rs853679	0.517	rs9393885	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28082231	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393886	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28082261	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.515	rs9368549	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Parkinson's disease;	chr6:28082269	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs56364346	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28082984	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9357061	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28083994	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368550	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28084025	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.542	rs2295594	ENSG00000219891.2	ZSCAN12P1	3.93	9.61e-05	0.0136	0.25	0.18	Depression;	chr6:28085319	chr6:28091154~28093664:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000254340.1	RP11-10A14.3	3.93	9.61e-05	0.0136	0.22	0.18	Neuroticism;	chr8:8252414	chr8:9141424~9145435:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000211974.3	IGHV2-70	3.93	9.62e-05	0.0136	0.17	0.18	Kawasaki disease;	chr14:106779116	chr14:106723574~106724093:-
HNSC	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-3.93	9.62e-05	0.0136	-0.22	-0.18	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
HNSC	cis	rs2337406	0.866	rs4774019	ENSG00000280411.1	IGHV1-69-2	-3.93	9.62e-05	0.0136	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106805386	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs58850145	ENSG00000280411.1	IGHV1-69-2	-3.93	9.62e-05	0.0136	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106806185	chr14:106762092~106762588:-
HNSC	cis	rs7176527	1	rs7176527	ENSG00000259570.1	RP11-671M22.4	-3.93	9.62e-05	0.0136	-0.27	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84394512~84395514:+
HNSC	cis	rs467650	0.553	rs469731	ENSG00000248489.1	CTD-2007H13.3	-3.93	9.62e-05	0.0136	-0.23	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98651703	chr5:98929171~98995013:+
HNSC	cis	rs6787172	0.622	rs4680426	ENSG00000272087.1	RP11-379F4.7	3.93	9.62e-05	0.0136	0.18	0.18	Subjective well-being;	chr3:158335659	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.535	rs2176893	ENSG00000272087.1	RP11-379F4.7	3.93	9.62e-05	0.0136	0.18	0.18	Subjective well-being;	chr3:158344238	chr3:158693120~158693768:-
HNSC	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-3.93	9.62e-05	0.0136	-0.28	-0.18	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
HNSC	cis	rs72827839	0.615	rs72827864	ENSG00000210741.1	MIR196A1	-3.93	9.62e-05	0.0136	-0.22	-0.18	Ease of getting up in the morning;	chr17:48415516	chr17:48632490~48632559:-
HNSC	cis	rs72827839	0.779	rs59386258	ENSG00000210741.1	MIR196A1	-3.93	9.62e-05	0.0136	-0.22	-0.18	Ease of getting up in the morning;	chr17:48422556	chr17:48632490~48632559:-
HNSC	cis	rs7005380	0.62	rs6993375	ENSG00000279347.1	RP11-85I17.2	-3.93	9.62e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119899390	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs6993797	ENSG00000279347.1	RP11-85I17.2	-3.93	9.62e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119899405	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6989741	ENSG00000279347.1	RP11-85I17.2	-3.93	9.62e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119899914	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs13257252	ENSG00000279347.1	RP11-85I17.2	-3.93	9.62e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119899993	chr8:119838736~119840385:-
HNSC	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	3.93	9.62e-05	0.0136	0.23	0.18	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
HNSC	cis	rs9923283	0.673	rs4788173	ENSG00000183604.13	SMG1P5	3.93	9.62e-05	0.0136	0.31	0.18	Plateletcrit;	chr16:29659415	chr16:30267553~30335374:-
HNSC	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-3.93	9.62e-05	0.0136	-0.27	-0.18	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
HNSC	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-3.93	9.62e-05	0.0136	-0.24	-0.18	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
HNSC	cis	rs7572733	0.534	rs1464209	ENSG00000231621.1	AC013264.2	-3.93	9.63e-05	0.0136	-0.17	-0.18	Dermatomyositis;	chr2:197949672	chr2:197197991~197199273:+
HNSC	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-3.93	9.63e-05	0.0136	-0.25	-0.18	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
HNSC	cis	rs6787172	0.811	rs9858318	ENSG00000272087.1	RP11-379F4.7	3.93	9.63e-05	0.0136	0.19	0.18	Subjective well-being;	chr3:158505502	chr3:158693120~158693768:-
HNSC	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	3.93	9.63e-05	0.0136	0.31	0.18	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
HNSC	cis	rs4862750	0.872	rs6553029	ENSG00000250971.1	RP11-696F12.1	-3.93	9.63e-05	0.0136	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr4:186955316	chr4:187060099~187060930:+
HNSC	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	3.93	9.63e-05	0.0136	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	3.93	9.63e-05	0.0136	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
HNSC	cis	rs7868228	0.945	rs7858867	ENSG00000240498.5	CDKN2B-AS1	-3.93	9.64e-05	0.0136	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21665064	chr9:21994778~22121097:+
HNSC	cis	rs7429990	0.965	rs35199727	ENSG00000228638.1	FCF1P2	-3.93	9.64e-05	0.0136	-0.17	-0.18	Educational attainment (years of education);	chr3:47905218	chr3:48290793~48291375:-
HNSC	cis	rs7868228	1	rs10119076	ENSG00000240498.5	CDKN2B-AS1	-3.93	9.64e-05	0.0136	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21665605	chr9:21994778~22121097:+
HNSC	cis	rs9813712	0.953	rs1453256	ENSG00000228252.7	COL6A4P2	-3.93	9.64e-05	0.0136	-0.19	-0.18	Response to amphetamines;	chr3:130258787	chr3:130212823~130273806:+
HNSC	cis	rs9813712	0.953	rs935916	ENSG00000228252.7	COL6A4P2	-3.93	9.64e-05	0.0136	-0.19	-0.18	Response to amphetamines;	chr3:130258931	chr3:130212823~130273806:+
HNSC	cis	rs17739794	0.557	rs35400327	ENSG00000254207.1	RP11-43A14.1	-3.93	9.65e-05	0.0136	-0.22	-0.18	Clozapine-induced cytotoxicity;	chr8:858789	chr8:725188~725877:-
HNSC	cis	rs9487051	0.55	rs9384701	ENSG00000243587.6	C6orf183	-3.93	9.65e-05	0.0136	-0.2	-0.18	Reticulocyte fraction of red cells;	chr6:109236339	chr6:109165833~109271014:+
HNSC	cis	rs67981189	0.552	rs9323556	ENSG00000274818.1	RP1-292L20.3	3.93	9.65e-05	0.0136	0.2	0.18	Schizophrenia;	chr14:71002795	chr14:70906657~70907111:-
HNSC	cis	rs6071166	0.683	rs6027333	ENSG00000224635.1	RP4-564F22.5	-3.93	9.65e-05	0.0136	-0.22	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694620	chr20:38406011~38416797:-
HNSC	cis	rs6088580	0.634	rs62212172	ENSG00000276073.1	RP5-1125A11.7	3.93	9.65e-05	0.0136	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:33985617~33988989:-
HNSC	cis	rs2253762	0.54	rs11200324	ENSG00000226864.1	ATE1-AS1	-3.93	9.65e-05	0.0136	-0.3	-0.18	Breast cancer;	chr10:122009999	chr10:121928312~121951965:+
HNSC	cis	rs9611565	0.681	rs5751094	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41407275	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs132914	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41409745	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs132915	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41409778	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.722	rs202635	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41413633	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs132920	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41414166	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs202659	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41415616	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs202663	ENSG00000235513.1	RP4-756G23.5	-3.93	9.65e-05	0.0136	-0.21	-0.18	Vitiligo;	chr22:41416815	chr22:41209122~41217627:-
HNSC	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	3.93	9.65e-05	0.0136	0.2	0.18	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
HNSC	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	3.93	9.65e-05	0.0136	0.37	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66735006	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66735318	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66736127	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66737884	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66744266	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66752983	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66753209	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000106610.13	STAG3L4	-3.93	9.66e-05	0.0136	-0.23	-0.18	Aortic root size;	chr7:66758701	chr7:67302621~67321526:+
HNSC	cis	rs12893668	0.703	rs4906338	ENSG00000269958.1	RP11-73M18.8	3.93	9.66e-05	0.0136	0.17	0.18	Reticulocyte count;	chr14:103584020	chr14:103696353~103697163:+
HNSC	cis	rs2307394	0.964	rs13014926	ENSG00000281469.1	RP11-567F11.1	3.93	9.66e-05	0.0136	0.2	0.18	Urate levels;	chr2:147784512	chr2:148044380~148044894:+
HNSC	cis	rs9880211	0.679	rs9818740	ENSG00000239213.4	NCK1-AS1	3.93	9.66e-05	0.0136	0.17	0.18	Height;Body mass index;	chr3:136220744	chr3:136841726~136862054:-
HNSC	cis	rs9467773	0.587	rs3208733	ENSG00000241549.7	GUSBP2	3.93	9.67e-05	0.0136	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26414197	chr6:26871484~26956554:-
HNSC	cis	rs2762353	0.524	rs3923	ENSG00000272462.2	U91328.19	3.93	9.67e-05	0.0136	0.17	0.18	Blood metabolite levels;	chr6:25783087	chr6:25992662~26001775:+
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000272831.1	RP11-792A8.4	-3.93	9.67e-05	0.0136	-0.15	-0.18	Aortic root size;	chr7:65800193	chr7:66739829~66740385:-
HNSC	cis	rs11951515	0.7	rs11739665	ENSG00000249286.1	CTD-2210P15.2	3.93	9.67e-05	0.0136	0.19	0.18	Metabolite levels  (X-11787);	chr5:43301791	chr5:43586918~43588223:-
HNSC	cis	rs5758511	0.773	rs9623482	ENSG00000226450.2	CYP2D8P	3.93	9.67e-05	0.0136	0.17	0.18	Birth weight;	chr22:41964570	chr22:42149886~42155001:-
HNSC	cis	rs875971	0.66	rs3764903	ENSG00000272831.1	RP11-792A8.4	-3.93	9.68e-05	0.0136	-0.15	-0.18	Aortic root size;	chr7:66633495	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs1860470	ENSG00000272831.1	RP11-792A8.4	-3.93	9.68e-05	0.0136	-0.15	-0.18	Aortic root size;	chr7:66638707	chr7:66739829~66740385:-
HNSC	cis	rs10791097	0.694	rs7107595	ENSG00000254842.5	RP11-890B15.2	-3.93	9.68e-05	0.0136	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130888661	chr11:130844191~130865561:-
HNSC	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-3.93	9.68e-05	0.0136	-0.19	-0.18	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
HNSC	cis	rs853679	1	rs2799079	ENSG00000226314.6	ZNF192P1	-3.93	9.68e-05	0.0136	-0.24	-0.18	Depression;	chr6:28267398	chr6:28161781~28169594:+
HNSC	cis	rs9329221	0.537	rs2062331	ENSG00000255310.2	AF131215.2	-3.93	9.68e-05	0.0136	-0.17	-0.18	Neuroticism;	chr8:10122482	chr8:11107788~11109726:-
HNSC	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-3.93	9.68e-05	0.0137	-0.22	-0.18	Height;	chr20:49311346	chr20:49280319~49280409:+
HNSC	cis	rs516805	0.748	rs197693	ENSG00000279453.1	RP3-425C14.4	-3.93	9.68e-05	0.0137	-0.25	-0.18	Lymphocyte counts;	chr6:122521294	chr6:122436789~122439223:-
HNSC	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	3.93	9.68e-05	0.0137	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
HNSC	cis	rs795484	0.783	rs521048	ENSG00000275409.1	RP11-131L12.4	-3.93	9.68e-05	0.0137	-0.22	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118393153	chr12:118430147~118430699:+
HNSC	cis	rs6840258	0.941	rs6854749	ENSG00000251411.1	RP11-397E7.4	-3.93	9.69e-05	0.0137	-0.23	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047646	chr4:86913266~86914817:-
HNSC	cis	rs5167	0.566	rs204905	ENSG00000269148.1	AC092301.3	3.93	9.69e-05	0.0137	0.16	0.18	Blood protein levels;	chr19:44957507	chr19:45830164~45831108:+
HNSC	cis	rs72843166	0.562	rs72841395	ENSG00000265282.1	RP11-269G24.4	3.93	9.69e-05	0.0137	0.26	0.18	Intelligence (multi-trait analysis);	chr17:63393685	chr17:63430468~63432211:-
HNSC	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	3.93	9.69e-05	0.0137	0.3	0.18	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
HNSC	cis	rs9650657	0.645	rs4841408	ENSG00000255310.2	AF131215.2	-3.93	9.69e-05	0.0137	-0.17	-0.18	Neuroticism;	chr8:10658826	chr8:11107788~11109726:-
HNSC	cis	rs10789207	0.501	rs55895340	ENSG00000248458.2	RP4-598P13.1	-3.93	9.69e-05	0.0137	-0.27	-0.18	Resting heart rate;	chr1:66649947	chr1:66665864~66677027:-
HNSC	cis	rs10789207	0.531	rs72669463	ENSG00000248458.2	RP4-598P13.1	-3.93	9.69e-05	0.0137	-0.27	-0.18	Resting heart rate;	chr1:66650152	chr1:66665864~66677027:-
HNSC	cis	rs4144743	1	rs67615769	ENSG00000228782.6	CTD-2026D20.3	-3.93	9.69e-05	0.0137	-0.21	-0.18	Body mass index;	chr17:47248112	chr17:47450568~47492492:-
HNSC	cis	rs9583531	0.6	rs6492303	ENSG00000259831.1	LINC00567	3.93	9.7e-05	0.0137	0.2	0.18	Coronary artery disease;	chr13:110704453	chr13:110809676~110813084:-
HNSC	cis	rs6831352	0.819	rs1230155	ENSG00000263923.1	RP11-571L19.7	-3.93	9.7e-05	0.0137	-0.18	-0.18	Alcohol dependence;	chr4:99068108	chr4:98928897~98994994:+
HNSC	cis	rs73201462	1	rs2811392	ENSG00000231305.3	RP11-723O4.2	3.93	9.7e-05	0.0137	0.26	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305133	chr3:128861313~128871540:-
HNSC	cis	rs4073405	0.881	rs7102384	ENSG00000254651.1	RP11-430H10.3	3.93	9.7e-05	0.0137	0.22	0.18	Schizophrenia;	chr11:45297634	chr11:45399448~45400528:+
HNSC	cis	rs7824557	0.675	rs2736265	ENSG00000255020.1	AF131216.5	3.93	9.7e-05	0.0137	0.19	0.18	Retinal vascular caliber;	chr8:11329165	chr8:11345748~11347502:-
HNSC	cis	rs1665050	0.534	rs11855896	ENSG00000259732.1	RP11-59H7.3	-3.93	9.7e-05	0.0137	-0.24	-0.18	Atopic dermatitis;	chr15:58942447	chr15:59121034~59133250:+
HNSC	cis	rs1665050	0.534	rs8028502	ENSG00000259732.1	RP11-59H7.3	-3.93	9.7e-05	0.0137	-0.24	-0.18	Atopic dermatitis;	chr15:58943677	chr15:59121034~59133250:+
HNSC	cis	rs1941023	0.619	rs55924472	ENSG00000279632.1	RP11-286N22.6	3.93	9.7e-05	0.0137	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60487130	chr11:61426448~61427325:-
HNSC	cis	rs4853525	0.59	rs1860168	ENSG00000228509.4	AC006460.2	3.93	9.71e-05	0.0137	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859774	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.59	rs9973507	ENSG00000228509.4	AC006460.2	3.93	9.71e-05	0.0137	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190860922	chr2:190676944~190708716:-
HNSC	cis	rs9914544	0.545	rs8067882	ENSG00000264885.1	RP11-815I9.4	-3.93	9.71e-05	0.0137	-0.19	-0.18	Educational attainment (years of education);	chr17:18903818	chr17:18667629~18669461:-
HNSC	cis	rs4699052	0.739	rs11936824	ENSG00000246560.2	RP11-10L12.4	3.93	9.71e-05	0.0137	0.2	0.18	Testicular germ cell tumor;	chr4:103316846	chr4:102828055~102844075:+
HNSC	cis	rs4873772	0.8	rs4873478	ENSG00000253330.1	RP11-697N18.3	-3.93	9.71e-05	0.0137	-0.23	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47610734	chr8:47511034~47512141:-
HNSC	cis	rs7615952	0.546	rs11717632	ENSG00000248787.1	RP11-666A20.4	-3.93	9.71e-05	0.0137	-0.29	-0.18	Blood pressure (smoking interaction);	chr3:125602286	chr3:125908005~125910272:-
HNSC	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	3.93	9.72e-05	0.0137	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
HNSC	cis	rs911555	0.511	rs8007489	ENSG00000269958.1	RP11-73M18.8	-3.93	9.72e-05	0.0137	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103696353~103697163:+
HNSC	cis	rs1937680	0.613	rs1937669	ENSG00000236671.6	PRKG1-AS1	-3.93	9.72e-05	0.0137	-0.25	-0.18	Breast cancer;	chr10:51892986	chr10:52230742~52314128:-
HNSC	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-3.93	9.72e-05	0.0137	-0.19	-0.18	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
HNSC	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	3.93	9.72e-05	0.0137	0.29	0.18	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
HNSC	cis	rs12817549	0.817	rs4761739	ENSG00000213250.5	RBMS2P1	3.93	9.72e-05	0.0137	0.16	0.18	Hip circumference adjusted for BMI;	chr12:93712590	chr12:94423744~94424969:-
HNSC	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-3.93	9.72e-05	0.0137	-0.2	-0.18	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
HNSC	cis	rs12682352	0.602	rs6993494	ENSG00000254153.1	CTA-398F10.2	3.93	9.73e-05	0.0137	0.2	0.18	Neuroticism;	chr8:8809934	chr8:8456909~8461337:-
HNSC	cis	rs2032366	1	rs1894095	ENSG00000267279.1	RP11-879F14.2	-3.93	9.73e-05	0.0137	-0.22	-0.18	Obesity-related traits;	chr18:61605988	chr18:61585746~61606916:-
HNSC	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-3.93	9.73e-05	0.0137	-0.19	-0.18	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
HNSC	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	3.93	9.73e-05	0.0137	0.18	0.18	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
HNSC	cis	rs6142618	0.783	rs6057548	ENSG00000275576.1	RP5-836N17.4	3.93	9.73e-05	0.0137	0.18	0.18	Inflammatory bowel disease;	chr20:32266575	chr20:32116171~32116629:+
HNSC	cis	rs3015469	0.517	rs11625096	ENSG00000269906.1	RP11-248J18.2	-3.93	9.73e-05	0.0137	-0.23	-0.18	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50480660	chr14:50662511~50663178:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000233609.3	RP11-62H7.2	3.93	9.73e-05	0.0137	0.17	0.18	Mood instability;	chr8:8460105	chr8:8961200~8979025:+
HNSC	cis	rs6964587	0.692	rs10236483	ENSG00000188693.7	CYP51A1-AS1	-3.93	9.74e-05	0.0137	-0.19	-0.18	Breast cancer;	chr7:92167982	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.692	rs12536220	ENSG00000188693.7	CYP51A1-AS1	-3.93	9.74e-05	0.0137	-0.19	-0.18	Breast cancer;	chr7:92176281	chr7:92134604~92180725:+
HNSC	cis	rs467650	0.549	rs162676	ENSG00000246763.5	RGMB-AS1	-3.93	9.74e-05	0.0137	-0.2	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98655799	chr5:98769618~98773469:-
HNSC	cis	rs7572733	0.515	rs1401096	ENSG00000231621.1	AC013264.2	-3.93	9.74e-05	0.0137	-0.17	-0.18	Dermatomyositis;	chr2:197959104	chr2:197197991~197199273:+
HNSC	cis	rs7674212	0.507	rs223317	ENSG00000248740.4	RP11-328K4.1	3.93	9.74e-05	0.0137	0.19	0.18	Type 2 diabetes;	chr4:102881667	chr4:103256159~103453658:+
HNSC	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	3.93	9.74e-05	0.0137	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	3.93	9.74e-05	0.0137	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	3.93	9.74e-05	0.0137	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
HNSC	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	3.93	9.74e-05	0.0137	0.22	0.18	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
HNSC	cis	rs9487051	0.698	rs4301336	ENSG00000243587.6	C6orf183	3.93	9.74e-05	0.0137	0.18	0.18	Reticulocyte fraction of red cells;	chr6:109328937	chr6:109165833~109271014:+
HNSC	cis	rs847649	0.924	rs6960428	ENSG00000239969.4	RP11-163E9.2	3.93	9.74e-05	0.0137	0.2	0.18	Morning vs. evening chronotype;	chr7:102949259	chr7:102364162~102380633:+
HNSC	cis	rs847649	1	rs4620204	ENSG00000239969.4	RP11-163E9.2	3.93	9.74e-05	0.0137	0.2	0.18	Morning vs. evening chronotype;	chr7:102953770	chr7:102364162~102380633:+
HNSC	cis	rs7735319	0.735	rs34458865	ENSG00000250697.1	CTD-2066L21.3	3.93	9.75e-05	0.0137	0.22	0.18	Systolic blood pressure;	chr5:33049683	chr5:32925639~33297910:-
HNSC	cis	rs2638953	0.893	rs10771432	ENSG00000257176.2	RP11-996F15.2	3.93	9.75e-05	0.0137	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507798	chr12:29280418~29317848:-
HNSC	cis	rs1005277	0.602	rs1831315	ENSG00000099251.13	HSD17B7P2	3.93	9.75e-05	0.0137	0.18	0.18	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38356380~38378505:+
HNSC	cis	rs9650657	0.74	rs6980805	ENSG00000269918.1	AF131215.9	-3.93	9.75e-05	0.0137	-0.18	-0.18	Neuroticism;	chr8:10822332	chr8:11104691~11106704:-
HNSC	cis	rs4927850	0.529	rs6800500	ENSG00000207650.1	MIR570	3.93	9.75e-05	0.0137	0.18	0.18	Pancreatic cancer;	chr3:196106636	chr3:195699401~195699497:+
HNSC	cis	rs7572733	0.534	rs1518365	ENSG00000231621.1	AC013264.2	-3.93	9.76e-05	0.0137	-0.17	-0.18	Dermatomyositis;	chr2:197944686	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1518363	ENSG00000231621.1	AC013264.2	-3.93	9.76e-05	0.0137	-0.17	-0.18	Dermatomyositis;	chr2:197945407	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1518361	ENSG00000231621.1	AC013264.2	-3.93	9.76e-05	0.0137	-0.17	-0.18	Dermatomyositis;	chr2:197948150	chr2:197197991~197199273:+
HNSC	cis	rs10129255	0.5	rs988132	ENSG00000224373.3	IGHV4-59	3.93	9.76e-05	0.0137	0.1	0.18	Kawasaki disease;	chr14:106776758	chr14:106627249~106627825:-
HNSC	cis	rs656319	0.625	rs4526366	ENSG00000254340.1	RP11-10A14.3	-3.93	9.76e-05	0.0137	-0.22	-0.18	Myopia (pathological);	chr8:10032669	chr8:9141424~9145435:+
HNSC	cis	rs17489649	0.868	rs2301009	ENSG00000271849.1	CTC-332L22.1	3.93	9.76e-05	0.0137	0.24	0.18	Intelligence (multi-trait analysis);	chr5:109796377	chr5:109687802~109688329:-
HNSC	cis	rs1538970	0.816	rs12029322	ENSG00000234329.1	RP11-767N6.2	3.93	9.76e-05	0.0137	0.21	0.18	Platelet count;	chr1:45504774	chr1:45651039~45651826:-
HNSC	cis	rs3096299	0.866	rs4238829	ENSG00000261574.1	RP1-168P16.2	3.93	9.76e-05	0.0137	0.23	0.18	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89392375~89412564:-
HNSC	cis	rs35306767	0.715	rs1871622	ENSG00000229869.1	RP11-363N22.2	-3.93	9.76e-05	0.0137	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1003369	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs1871621	ENSG00000229869.1	RP11-363N22.2	-3.93	9.76e-05	0.0137	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1003656	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs12770910	ENSG00000229869.1	RP11-363N22.2	-3.93	9.76e-05	0.0137	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1004378	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs12771539	ENSG00000229869.1	RP11-363N22.2	-3.93	9.76e-05	0.0137	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:1004713	chr10:933026~942743:+
HNSC	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-3.93	9.76e-05	0.0137	-0.21	-0.18	Height;	chr14:74458749	chr14:74471930~74472360:-
HNSC	cis	rs6090919	0.501	rs6019454	ENSG00000222365.1	SNORD12B	-3.93	9.76e-05	0.0138	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:48847766	chr20:49280319~49280409:+
HNSC	cis	rs739496	0.615	rs847895	ENSG00000226469.1	ADAM1B	3.93	9.77e-05	0.0138	0.2	0.18	Platelet count;	chr12:111680772	chr12:111927018~111929017:+
HNSC	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	3.93	9.77e-05	0.0138	0.19	0.18	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
HNSC	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	3.93	9.77e-05	0.0138	0.19	0.18	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
HNSC	cis	rs9313772	0.862	rs7442660	ENSG00000254350.1	RP11-542A14.1	-3.93	9.78e-05	0.0138	-0.2	-0.18	Blood pressure;	chr5:158376622	chr5:158424585~158452758:+
HNSC	cis	rs7615952	0.546	rs11711150	ENSG00000248787.1	RP11-666A20.4	-3.93	9.78e-05	0.0138	-0.29	-0.18	Blood pressure (smoking interaction);	chr3:125596819	chr3:125908005~125910272:-
HNSC	cis	rs9368481	0.729	rs9379950	ENSG00000238621.1	TRI-TAT2-2	3.93	9.78e-05	0.0138	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:27020335~27020447:+
HNSC	cis	rs9368481	1	rs9368481	ENSG00000238621.1	TRI-TAT2-2	3.93	9.78e-05	0.0138	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:27020335~27020447:+
HNSC	cis	rs9368481	0.554	rs2754603	ENSG00000238621.1	TRI-TAT2-2	3.93	9.78e-05	0.0138	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:27020335~27020447:+
HNSC	cis	rs9368481	0.761	rs9357028	ENSG00000238621.1	TRI-TAT2-2	3.93	9.78e-05	0.0138	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:27020335~27020447:+
HNSC	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-3.93	9.78e-05	0.0138	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
HNSC	cis	rs9611565	0.659	rs17367849	ENSG00000235513.1	RP4-756G23.5	3.93	9.78e-05	0.0138	0.21	0.18	Vitiligo;	chr22:41527640	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs1810461	ENSG00000235513.1	RP4-756G23.5	3.93	9.78e-05	0.0138	0.21	0.18	Vitiligo;	chr22:41531816	chr22:41209122~41217627:-
HNSC	cis	rs12893668	0.603	rs12896171	ENSG00000269958.1	RP11-73M18.8	3.93	9.78e-05	0.0138	0.16	0.18	Reticulocyte count;	chr14:103669629	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.572	rs7148857	ENSG00000269958.1	RP11-73M18.8	3.93	9.78e-05	0.0138	0.16	0.18	Reticulocyte count;	chr14:103676900	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.572	rs11540512	ENSG00000269958.1	RP11-73M18.8	3.93	9.78e-05	0.0138	0.16	0.18	Reticulocyte count;	chr14:103681040	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.572	rs35011804	ENSG00000269958.1	RP11-73M18.8	3.93	9.78e-05	0.0138	0.16	0.18	Reticulocyte count;	chr14:103685063	chr14:103696353~103697163:+
HNSC	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-3.93	9.78e-05	0.0138	-0.15	-0.18	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
HNSC	cis	rs7824557	0.628	rs7005469	ENSG00000269918.1	AF131215.9	3.93	9.78e-05	0.0138	0.17	0.18	Retinal vascular caliber;	chr8:11336948	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs6988922	ENSG00000269918.1	AF131215.9	3.93	9.78e-05	0.0138	0.17	0.18	Retinal vascular caliber;	chr8:11337402	chr8:11104691~11106704:-
HNSC	cis	rs2029239	1	rs2029239	ENSG00000253330.1	RP11-697N18.3	-3.93	9.79e-05	0.0138	-0.23	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47669945	chr8:47511034~47512141:-
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000254153.1	CTA-398F10.2	-3.93	9.79e-05	0.0138	-0.2	-0.18	Recombination measurement;	chr8:9213523	chr8:8456909~8461337:-
HNSC	cis	rs12745968	0.623	rs10874733	ENSG00000223787.2	RP4-593M8.1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Bipolar disorder and schizophrenia;	chr1:92658176	chr1:92580476~92580821:-
HNSC	cis	rs4948102	0.731	rs6593292	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.731	rs4535700	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.731	rs4543497	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.767	rs4948096	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.727	rs4948097	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr7:55764797~55773288:+
HNSC	cis	rs1015213	0.609	rs117452492	ENSG00000272024.1	RP11-546K22.3	-3.93	9.8e-05	0.0138	-0.42	-0.18	Glaucoma (primary angle closure);	chr8:51905091	chr8:51950284~51950690:+
HNSC	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	3.93	9.8e-05	0.0138	0.15	0.18	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
HNSC	cis	rs4948102	0.655	rs4947533	ENSG00000226278.1	PSPHP1	-3.93	9.8e-05	0.0138	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr7:55764797~55773288:+
HNSC	cis	rs2016266	0.787	rs4520636	ENSG00000270175.1	RP11-793H13.11	-3.93	9.8e-05	0.0138	-0.18	-0.18	Bone mineral density;Bone mineral density (spine);	chr12:53358349	chr12:53500162~53500936:-
HNSC	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-3.93	9.8e-05	0.0138	-0.2	-0.18	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
HNSC	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	3.93	9.8e-05	0.0138	0.2	0.18	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
HNSC	cis	rs13434995	0.842	rs55869433	ENSG00000273257.1	RP11-177J6.1	-3.93	9.81e-05	0.0138	-0.29	-0.18	Adiponectin levels;	chr4:55544770	chr4:55387949~55388271:+
HNSC	cis	rs728616	0.681	rs55855057	ENSG00000225484.5	NUTM2B-AS1	-3.93	9.81e-05	0.0138	-0.34	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80274973	chr10:79663088~79826594:-
HNSC	cis	rs9914544	0.564	rs9907723	ENSG00000264885.1	RP11-815I9.4	-3.93	9.81e-05	0.0138	-0.18	-0.18	Educational attainment (years of education);	chr17:18855540	chr17:18667629~18669461:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000224373.3	IGHV4-59	3.93	9.81e-05	0.0138	0.11	0.18	Kawasaki disease;	chr14:106767441	chr14:106627249~106627825:-
HNSC	cis	rs1862618	0.671	rs28397234	ENSG00000271828.1	CTD-2310F14.1	-3.93	9.81e-05	0.0138	-0.22	-0.18	Initial pursuit acceleration;	chr5:56952601	chr5:56927874~56929573:+
HNSC	cis	rs9921338	0.886	rs3931015	ENSG00000263080.1	RP11-485G7.5	-3.93	9.81e-05	0.0138	-0.19	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11341809~11345211:-
HNSC	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-3.93	9.81e-05	0.0138	-0.19	-0.18	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
HNSC	cis	rs2013441	0.866	rs8070401	ENSG00000261033.1	RP11-209D14.2	3.93	9.81e-05	0.0138	0.21	0.18	Obesity-related traits;	chr17:20311179	chr17:20008051~20009234:-
HNSC	cis	rs28489187	0.577	rs3920521	ENSG00000223653.4	RP11-131L23.1	3.93	9.81e-05	0.0138	0.23	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383183	chr1:85276715~85448124:+
HNSC	cis	rs7429990	0.965	rs4392441	ENSG00000228638.1	FCF1P2	3.93	9.82e-05	0.0138	0.16	0.18	Educational attainment (years of education);	chr3:48036211	chr3:48290793~48291375:-
HNSC	cis	rs950169	0.614	rs12903883	ENSG00000230373.7	GOLGA6L5P	-3.93	9.82e-05	0.0138	-0.21	-0.18	Schizophrenia;	chr15:84011801	chr15:84507885~84516814:-
HNSC	cis	rs804280	0.509	rs10109241	ENSG00000227888.4	FAM66A	3.93	9.82e-05	0.0138	0.18	0.18	Myopia (pathological);	chr8:11927476	chr8:12362019~12388296:+
HNSC	cis	rs10484434	0.901	rs2230654	ENSG00000272462.2	U91328.19	-3.93	9.82e-05	0.0138	-0.22	-0.18	HIV-1 viral setpoint;	chr6:26033413	chr6:25992662~26001775:+
HNSC	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	3.93	9.82e-05	0.0138	0.2	0.18	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
HNSC	cis	rs889398	0.835	rs12925429	ENSG00000196696.11	PDXDC2P	3.93	9.82e-05	0.0138	0.13	0.18	Body mass index;	chr16:69767636	chr16:69976297~70065948:-
HNSC	cis	rs7429990	0.965	rs11709289	ENSG00000228638.1	FCF1P2	-3.93	9.82e-05	0.0138	-0.2	-0.18	Educational attainment (years of education);	chr3:47765159	chr3:48290793~48291375:-
HNSC	cis	rs28830936	1	rs17734856	ENSG00000250379.1	RP11-23P13.4	3.93	9.83e-05	0.0138	0.22	0.18	Diastolic blood pressure;	chr15:41752962	chr15:41825099~41827936:-
HNSC	cis	rs793571	0.822	rs11636723	ENSG00000245975.2	RP11-30K9.6	3.93	9.83e-05	0.0138	0.3	0.18	Schizophrenia;	chr15:58914319	chr15:58768072~58770974:-
HNSC	cis	rs1659258	0.527	rs59365089	ENSG00000232508.1	MRPL45P1	3.93	9.83e-05	0.0138	0.29	0.18	Visceral fat;	chr2:88386750	chr2:88364695~88365608:-
HNSC	cis	rs889398	0.967	rs62052816	ENSG00000226232.7	RP11-419C5.2	3.93	9.83e-05	0.0138	0.16	0.18	Body mass index;	chr16:69529503	chr16:69976388~69996188:-
HNSC	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-3.93	9.83e-05	0.0138	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
HNSC	cis	rs6860806	0.531	rs270612	ENSG00000233006.5	AC034220.3	3.93	9.83e-05	0.0138	0.21	0.18	Breast cancer;	chr5:132301645	chr5:132311285~132369916:-
HNSC	cis	rs11976180	1	rs1540894	ENSG00000244479.5	OR2A1-AS1	3.93	9.83e-05	0.0138	0.21	0.18	Obesity-related traits;	chr7:144070583	chr7:144251264~144356181:-
HNSC	cis	rs875971	0.54	rs1723268	ENSG00000272831.1	RP11-792A8.4	3.93	9.83e-05	0.0138	0.15	0.18	Aortic root size;	chr7:66008093	chr7:66739829~66740385:-
HNSC	cis	rs7824557	0.778	rs6601572	ENSG00000255310.2	AF131215.2	-3.93	9.83e-05	0.0138	-0.17	-0.18	Retinal vascular caliber;	chr8:11235828	chr8:11107788~11109726:-
HNSC	cis	rs11976180	1	rs2951372	ENSG00000244479.5	OR2A1-AS1	3.93	9.83e-05	0.0138	0.21	0.18	Obesity-related traits;	chr7:144052410	chr7:144251264~144356181:-
HNSC	cis	rs9393777	0.545	rs56303243	ENSG00000241549.7	GUSBP2	3.93	9.84e-05	0.0138	0.23	0.18	Intelligence (multi-trait analysis);	chr6:26485499	chr6:26871484~26956554:-
HNSC	cis	rs3764021	1	rs3764021	ENSG00000278635.1	CTD-2318O12.1	-3.93	9.84e-05	0.0138	-0.14	-0.18	Type 1 diabetes;	chr12:9681032	chr12:9415641~9416718:+
HNSC	cis	rs8062405	1	rs8062405	ENSG00000261089.1	RP11-435I10.3	-3.93	9.84e-05	0.0138	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28413703~28415018:+
HNSC	cis	rs7829975	0.539	rs883647	ENSG00000254153.1	CTA-398F10.2	-3.93	9.84e-05	0.0138	-0.21	-0.18	Mood instability;	chr8:8712214	chr8:8456909~8461337:-
HNSC	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-3.93	9.84e-05	0.0138	-0.22	-0.18	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
HNSC	cis	rs6995541	0.59	rs718742	ENSG00000269918.1	AF131215.9	3.93	9.84e-05	0.0138	0.19	0.18	Triglyceride levels;	chr8:10756765	chr8:11104691~11106704:-
HNSC	cis	rs9880211	0.562	rs13068210	ENSG00000239213.4	NCK1-AS1	3.93	9.84e-05	0.0138	0.17	0.18	Height;Body mass index;	chr3:136186704	chr3:136841726~136862054:-
HNSC	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-3.93	9.85e-05	0.0138	-0.25	-0.18	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
HNSC	cis	rs1602565	0.841	rs11030609	ENSG00000255450.1	CTD-2063L20.1	-3.93	9.85e-05	0.0138	-0.31	-0.18	Schizophrenia;	chr11:29195836	chr11:29275655~29276565:+
HNSC	cis	rs72843506	0.722	rs74658636	ENSG00000189423.10	USP32P3	3.93	9.86e-05	0.0139	0.28	0.18	Schizophrenia;	chr17:20294669	chr17:20415547~20431008:+
HNSC	cis	rs7572733	0.534	rs11890137	ENSG00000231621.1	AC013264.2	-3.93	9.86e-05	0.0139	-0.17	-0.18	Dermatomyositis;	chr2:197951938	chr2:197197991~197199273:+
HNSC	cis	rs780096	0.814	rs780093	ENSG00000234072.1	AC074117.10	-3.93	9.86e-05	0.0139	-0.15	-0.18	Total body bone mineral density;	chr2:27519736	chr2:27356246~27367622:+
HNSC	cis	rs36093844	0.626	rs10898431	ENSG00000279742.1	RP11-700A24.1	-3.93	9.86e-05	0.0139	-0.22	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86036539	chr11:85852557~85854943:-
HNSC	cis	rs17253792	0.731	rs3736876	ENSG00000186615.9	KTN1-AS1	-3.93	9.86e-05	0.0139	-0.35	-0.18	Putamen volume;	chr14:55653460	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.749	rs79713967	ENSG00000186615.9	KTN1-AS1	-3.93	9.86e-05	0.0139	-0.35	-0.18	Putamen volume;	chr14:55657468	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.749	rs17747301	ENSG00000186615.9	KTN1-AS1	-3.93	9.86e-05	0.0139	-0.35	-0.18	Putamen volume;	chr14:55658312	chr14:55499278~55580110:-
HNSC	cis	rs9813712	0.571	rs11715351	ENSG00000253540.4	FAM86HP	-3.93	9.86e-05	0.0139	-0.17	-0.18	Response to amphetamines;	chr3:130214704	chr3:130099092~130111472:-
HNSC	cis	rs72827839	0.779	rs72827858	ENSG00000244649.3	CTD-2377D24.6	-3.93	9.87e-05	0.0139	-0.24	-0.18	Ease of getting up in the morning;	chr17:48396999	chr17:48646923~48707346:+
HNSC	cis	rs12935418	0.672	rs78895138	ENSG00000278985.1	RP11-303E16.9	3.93	9.87e-05	0.0139	0.19	0.18	Mean corpuscular volume;	chr16:81014820	chr16:80982319~80984094:-
HNSC	cis	rs28830936	1	rs9672360	ENSG00000250379.1	RP11-23P13.4	3.93	9.87e-05	0.0139	0.22	0.18	Diastolic blood pressure;	chr15:41620213	chr15:41825099~41827936:-
HNSC	cis	rs28830936	1	rs11632424	ENSG00000250379.1	RP11-23P13.4	3.93	9.88e-05	0.0139	0.22	0.18	Diastolic blood pressure;	chr15:41803153	chr15:41825099~41827936:-
HNSC	cis	rs10078	0.571	rs2561664	ENSG00000225138.6	CTD-2228K2.7	3.93	9.88e-05	0.0139	0.32	0.18	Fat distribution (HIV);	chr5:459678	chr5:473236~480884:+
HNSC	cis	rs3758785	0.665	rs7933565	ENSG00000255893.1	RP11-685N10.1	3.93	9.89e-05	0.0139	0.21	0.18	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94378642	chr11:94472908~94473570:-
HNSC	cis	rs11951515	0.738	rs12514393	ENSG00000249286.1	CTD-2210P15.2	3.93	9.89e-05	0.0139	0.19	0.18	Metabolite levels  (X-11787);	chr5:43313429	chr5:43586918~43588223:-
HNSC	cis	rs795484	0.889	rs353884	ENSG00000275409.1	RP11-131L12.4	-3.93	9.89e-05	0.0139	-0.21	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118225962	chr12:118430147~118430699:+
HNSC	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	3.93	9.9e-05	0.0139	0.18	0.18	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
HNSC	cis	rs7819412	0.505	rs17726209	ENSG00000269918.1	AF131215.9	3.93	9.9e-05	0.0139	0.18	0.18	Triglycerides;	chr8:11164675	chr8:11104691~11106704:-
HNSC	cis	rs5758659	1	rs5758659	ENSG00000273366.1	CTA-989H11.1	-3.93	9.9e-05	0.0139	-0.21	-0.18	Cognitive function;	chr22:42225997	chr22:42278188~42278846:+
HNSC	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	3.93	9.9e-05	0.0139	0.19	0.18	QT interval;	chr12:29243072	chr12:29280418~29317848:-
HNSC	cis	rs4930561	0.765	rs4930229	ENSG00000184795.9	UNC93B5	-3.93	9.9e-05	0.0139	-0.2	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr11:67711702~67716005:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	3.93	9.9e-05	0.0139	0.2	0.18	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
HNSC	cis	rs447735	0.587	rs7188458	ENSG00000274627.1	RP11-104N10.2	3.93	9.9e-05	0.0139	0.17	0.18	Hemoglobin concentration;	chr16:89660076	chr16:89516797~89522217:+
HNSC	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	3.93	9.9e-05	0.0139	0.2	0.18	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
HNSC	cis	rs9584850	0.794	rs17574433	ENSG00000231194.1	FARP1-AS1	-3.93	9.9e-05	0.0139	-0.21	-0.18	Neuroticism;	chr13:98485803	chr13:98435405~98435840:-
HNSC	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-3.93	9.9e-05	0.0139	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
HNSC	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-3.93	9.9e-05	0.0139	-0.23	-0.18	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
HNSC	cis	rs804280	0.509	rs9886639	ENSG00000227888.4	FAM66A	3.93	9.91e-05	0.0139	0.18	0.18	Myopia (pathological);	chr8:11927020	chr8:12362019~12388296:+
HNSC	cis	rs9393777	0.623	rs9358945	ENSG00000241549.7	GUSBP2	-3.93	9.91e-05	0.0139	-0.23	-0.18	Intelligence (multi-trait analysis);	chr6:26471886	chr6:26871484~26956554:-
HNSC	cis	rs1665050	0.534	rs12900291	ENSG00000259732.1	RP11-59H7.3	-3.93	9.91e-05	0.0139	-0.23	-0.18	Atopic dermatitis;	chr15:58948220	chr15:59121034~59133250:+
HNSC	cis	rs9313772	0.722	rs34070773	ENSG00000254350.1	RP11-542A14.1	-3.93	9.91e-05	0.0139	-0.19	-0.18	Blood pressure;	chr5:158424413	chr5:158424585~158452758:+
HNSC	cis	rs35306767	0.714	rs7072554	ENSG00000229869.1	RP11-363N22.2	-3.93	9.91e-05	0.0139	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1045048	chr10:933026~942743:+
HNSC	cis	rs700651	0.754	rs1518367	ENSG00000231621.1	AC013264.2	-3.93	9.92e-05	0.0139	-0.17	-0.18	Intracranial aneurysm;	chr2:197942291	chr2:197197991~197199273:+
HNSC	cis	rs12893668	0.644	rs12890820	ENSG00000269958.1	RP11-73M18.8	3.93	9.92e-05	0.0139	0.17	0.18	Reticulocyte count;	chr14:103568512	chr14:103696353~103697163:+
HNSC	cis	rs9313772	0.775	rs1952651	ENSG00000254350.1	RP11-542A14.1	-3.93	9.92e-05	0.0139	-0.19	-0.18	Blood pressure;	chr5:158384407	chr5:158424585~158452758:+
HNSC	cis	rs847649	0.599	rs13232194	ENSG00000239969.4	RP11-163E9.2	3.93	9.92e-05	0.0139	0.21	0.18	Morning vs. evening chronotype;	chr7:103102107	chr7:102364162~102380633:+
HNSC	cis	rs2820651	1	rs2820656	ENSG00000229869.1	RP11-363N22.2	3.93	9.93e-05	0.0139	0.35	0.18	Migraine with aura;	chr10:1424412	chr10:933026~942743:+
HNSC	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-3.93	9.93e-05	0.0139	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
HNSC	cis	rs7948661	0.661	rs113028342	ENSG00000278376.1	RP11-158I9.8	3.93	9.93e-05	0.0139	0.33	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118462822	chr11:118791254~118793137:+
HNSC	cis	rs3740713	1	rs73438686	ENSG00000256464.1	YWHABP2	3.93	9.93e-05	0.0139	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr11:18490243~18490955:-
HNSC	cis	rs5167	0.506	rs35193317	ENSG00000269148.1	AC092301.3	-3.93	9.94e-05	0.014	-0.16	-0.18	Blood protein levels;	chr19:44967087	chr19:45830164~45831108:+
HNSC	cis	rs67311347	0.866	rs56331709	ENSG00000280739.1	EIF1B-AS1	3.93	9.94e-05	0.014	0.19	0.18	Renal cell carcinoma;	chr3:40315067	chr3:40173145~40309698:-
HNSC	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	3.93	9.94e-05	0.014	0.24	0.18	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
HNSC	cis	rs828999	0.583	rs10494090	ENSG00000280186.1	RP11-483I13.6	-3.93	9.94e-05	0.014	-0.19	-0.18	Monocyte percentage of white cells;	chr1:108150714	chr1:108200413~108202743:+
HNSC	cis	rs73198271	0.562	rs2048420	ENSG00000253893.2	FAM85B	3.93	9.94e-05	0.014	0.27	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8810093	chr8:8167819~8226614:-
HNSC	cis	rs1665050	0.534	rs10444841	ENSG00000259732.1	RP11-59H7.3	-3.93	9.94e-05	0.014	-0.23	-0.18	Atopic dermatitis;	chr15:58941849	chr15:59121034~59133250:+
HNSC	cis	rs1665050	0.534	rs8028828	ENSG00000259732.1	RP11-59H7.3	-3.93	9.94e-05	0.014	-0.23	-0.18	Atopic dermatitis;	chr15:58943853	chr15:59121034~59133250:+
HNSC	cis	rs1665050	0.534	rs12911441	ENSG00000259732.1	RP11-59H7.3	-3.93	9.94e-05	0.014	-0.23	-0.18	Atopic dermatitis;	chr15:58944341	chr15:59121034~59133250:+
HNSC	cis	rs1665050	0.534	rs4775106	ENSG00000259732.1	RP11-59H7.3	-3.93	9.94e-05	0.014	-0.23	-0.18	Atopic dermatitis;	chr15:58946062	chr15:59121034~59133250:+
HNSC	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	3.93	9.94e-05	0.014	0.23	0.18	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
HNSC	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	3.93	9.94e-05	0.014	0.23	0.18	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
HNSC	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	3.93	9.94e-05	0.014	0.23	0.18	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
HNSC	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-3.93	9.95e-05	0.014	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
HNSC	cis	rs11951515	0.676	rs10941623	ENSG00000249286.1	CTD-2210P15.2	3.93	9.95e-05	0.014	0.19	0.18	Metabolite levels  (X-11787);	chr5:43308739	chr5:43586918~43588223:-
HNSC	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	3.93	9.95e-05	0.014	0.2	0.18	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
HNSC	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	3.93	9.95e-05	0.014	0.21	0.18	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
HNSC	cis	rs250677	0.652	rs1422582	ENSG00000250072.4	CTC-529P8.1	-3.93	9.95e-05	0.014	-0.25	-0.18	Breast cancer;	chr5:149057362	chr5:149063317~149109787:+
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000211974.3	IGHV2-70	3.93	9.95e-05	0.014	0.17	0.18	Kawasaki disease;	chr14:106816039	chr14:106723574~106724093:-
HNSC	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-3.93	9.95e-05	0.014	-0.19	-0.18	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
HNSC	cis	rs9313772	0.802	rs4998992	ENSG00000254350.1	RP11-542A14.1	-3.93	9.95e-05	0.014	-0.19	-0.18	Blood pressure;	chr5:158383828	chr5:158424585~158452758:+
HNSC	cis	rs7005380	0.62	rs7387264	ENSG00000279347.1	RP11-85I17.2	-3.93	9.96e-05	0.014	-0.15	-0.18	Interstitial lung disease;	chr8:119913758	chr8:119838736~119840385:-
HNSC	cis	rs1552244	1	rs56394721	ENSG00000180385.7	EMC3-AS1	3.93	9.96e-05	0.014	0.21	0.18	Alzheimer's disease;	chr3:10109111	chr3:9986893~10006990:+
HNSC	cis	rs4308124	0.708	rs6747657	ENSG00000230499.1	AC108463.1	-3.93	9.96e-05	0.014	-0.2	-0.18	Vitiligo;	chr2:111245586	chr2:111195963~111206494:+
HNSC	cis	rs1799955	0.554	rs9567578	ENSG00000215515.2	IFIT1P1	3.93	9.96e-05	0.014	0.21	0.18	LDL cholesterol levels;	chr13:32347807	chr13:32384660~32386108:+
HNSC	cis	rs172166	0.694	rs203884	ENSG00000219891.2	ZSCAN12P1	3.93	9.96e-05	0.014	0.23	0.18	Cardiac Troponin-T levels;	chr6:28109596	chr6:28091154~28093664:+
HNSC	cis	rs7829975	0.572	rs28730413	ENSG00000253981.4	ALG1L13P	-3.93	9.96e-05	0.014	-0.2	-0.18	Mood instability;	chr8:8937937	chr8:8236003~8244667:-
HNSC	cis	rs6688613	0.685	rs2235184	ENSG00000215834.7	FMO9P	-3.93	9.96e-05	0.014	-0.25	-0.18	Refractive astigmatism;	chr1:166901291	chr1:166603675~166631400:+
HNSC	cis	rs3764400	0.567	rs2325784	ENSG00000228782.6	CTD-2026D20.3	3.93	9.96e-05	0.014	0.27	0.18	Body mass index;	chr17:48134947	chr17:47450568~47492492:-
HNSC	cis	rs138087875	1	rs138087875	ENSG00000264247.1	LINC00909	-3.93	9.96e-05	0.014	-0.35	-0.18	Brain volume in infants (grey matter);	chr18:74593493	chr18:74591774~74598508:-
HNSC	cis	rs1602565	1	rs72880104	ENSG00000255450.1	CTD-2063L20.1	-3.93	9.96e-05	0.014	-0.29	-0.18	Schizophrenia;	chr11:29105410	chr11:29275655~29276565:+
HNSC	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-3.93	9.97e-05	0.014	-0.19	-0.18	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-3.93	9.97e-05	0.014	-0.19	-0.18	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
HNSC	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-3.93	9.97e-05	0.014	-0.19	-0.18	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
HNSC	cis	rs5770917	1	rs762677	ENSG00000272821.1	CTA-384D8.36	-3.93	9.97e-05	0.014	-0.27	-0.18	Narcolepsy;	chr22:50579284	chr22:50523926~50524780:+
HNSC	cis	rs10819861	0.679	rs10819868	ENSG00000271384.1	RP11-435O5.7	3.93	9.97e-05	0.014	0.18	0.18	Electrocardiographic traits;	chr9:96109096	chr9:95406990~95407662:-
HNSC	cis	rs2919917	0.59	rs2919919	ENSG00000260398.1	RP11-594N15.3	-3.93	9.97e-05	0.014	-0.24	-0.18	Lymphocyte counts;	chr8:78745274	chr8:78605952~78609705:+
HNSC	cis	rs847649	0.842	rs7789252	ENSG00000239969.4	RP11-163E9.2	-3.93	9.97e-05	0.014	-0.21	-0.18	Morning vs. evening chronotype;	chr7:102983780	chr7:102364162~102380633:+
HNSC	cis	rs4718428	0.672	rs4718412	ENSG00000179406.6	LINC00174	3.93	9.97e-05	0.014	0.26	0.18	Corneal structure;	chr7:66821880	chr7:66376044~66401338:-
HNSC	cis	rs1620921	0.653	rs55968870	ENSG00000231863.1	RP3-428L16.1	-3.93	9.97e-05	0.014	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843771	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs56238146	ENSG00000231863.1	RP3-428L16.1	-3.93	9.97e-05	0.014	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843834	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs55900705	ENSG00000231863.1	RP3-428L16.1	-3.93	9.97e-05	0.014	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160843888	chr6:160931080~160969771:+
HNSC	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	3.92	9.98e-05	0.014	0.17	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
HNSC	cis	rs10510102	1	rs11200181	ENSG00000273891.1	RP11-500G22.5	3.92	9.98e-05	0.014	0.19	0.18	Breast cancer;	chr10:121828528	chr10:121965764~121967700:+
HNSC	cis	rs889398	0.771	rs8048550	ENSG00000196696.11	PDXDC2P	-3.92	9.98e-05	0.014	-0.13	-0.18	Body mass index;	chr16:69857856	chr16:69976297~70065948:-
HNSC	cis	rs7005380	0.58	rs13265546	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119907735	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs13267896	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119908414	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13275524	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119908701	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs6469867	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119909172	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.58	rs6469868	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119909601	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.606	rs6469869	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119909696	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469870	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119909773	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469871	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119909839	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs6469872	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119910007	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs7015470	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119910101	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6995139	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119910157	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10217077	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119910943	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs939242	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119912030	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs939241	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119912297	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10216503	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119912843	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs7824545	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119913381	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.561	rs7818471	ENSG00000279347.1	RP11-85I17.2	-3.92	9.99e-05	0.014	-0.14	-0.18	Interstitial lung disease;	chr8:119897596	chr8:119838736~119840385:-
HNSC	cis	rs10742752	0.557	rs7928480	ENSG00000254651.1	RP11-430H10.3	3.92	9.99e-05	0.014	0.22	0.18	Body mass index;	chr11:45385943	chr11:45399448~45400528:+
HNSC	cis	rs7674212	0.541	rs2720460	ENSG00000251288.2	RP11-10L12.2	3.92	9.99e-05	0.014	0.2	0.18	Type 2 diabetes;	chr4:103133529	chr4:102751401~102752641:+
HNSC	cis	rs9329221	0.521	rs17693945	ENSG00000255310.2	AF131215.2	-3.92	1e-04	0.014	-0.18	-0.18	Neuroticism;	chr8:10248500	chr8:11107788~11109726:-
HNSC	cis	rs11711311	1	rs11719303	ENSG00000241529.3	RN7SL767P	-3.92	1e-04	0.014	-0.23	-0.18	IgG glycosylation;	chr3:113775677	chr3:113632704~113632998:+
HNSC	cis	rs859767	0.501	rs10171371	ENSG00000224043.6	CCNT2-AS1	3.92	1e-04	0.014	0.21	0.18	Neuroticism;	chr2:134614589	chr2:134735464~134918710:-
HNSC	cis	rs4489787	0.892	rs4448729	ENSG00000240399.1	RP1-228P16.1	-3.92	1e-04	0.014	-0.26	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48428545	chr12:48054813~48055591:-
HNSC	cis	rs17014483	0.749	rs3017905	ENSG00000248019.2	FAM13A-AS1	-3.92	1e-04	0.014	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88710981	chr4:88709789~88730103:+
HNSC	cis	rs17014483	0.749	rs2924348	ENSG00000248019.2	FAM13A-AS1	-3.92	1e-04	0.014	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88711759	chr4:88709789~88730103:+
HNSC	cis	rs1937680	0.657	rs7097348	ENSG00000236671.6	PRKG1-AS1	-3.92	1e-04	0.014	-0.26	-0.18	Breast cancer;	chr10:51903555	chr10:52230742~52314128:-
HNSC	cis	rs6493858	0.839	rs1829542	ENSG00000277245.1	RP11-48G14.3	-3.92	1e-04	0.014	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56204458	chr15:56447120~56447697:+
HNSC	cis	rs1028883	0.935	rs9285285	ENSG00000228295.1	LINC00392	-3.92	1e-04	0.014	-0.18	-0.18	Lean body mass;	chr13:73536321	chr13:73564244~73588070:+
HNSC	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-3.92	1e-04	0.014	-0.19	-0.18	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
HNSC	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-3.92	1e-04	0.014	-0.17	-0.18	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-3.92	1e-04	0.014	-0.17	-0.18	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-3.92	1e-04	0.014	-0.17	-0.18	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-3.92	1e-04	0.014	-0.17	-0.18	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-3.92	1e-04	0.014	-0.17	-0.18	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
HNSC	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	3.92	1e-04	0.014	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
HNSC	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	3.92	1e-04	0.014	0.21	0.18	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
HNSC	cis	rs2098713	0.534	rs10941338	ENSG00000250155.1	CTD-2353F22.1	3.92	1e-04	0.014	0.18	0.18	Telomere length;	chr5:37488313	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.534	rs12522043	ENSG00000250155.1	CTD-2353F22.1	3.92	1e-04	0.014	0.18	0.18	Telomere length;	chr5:37488317	chr5:36666214~36725195:-
HNSC	cis	rs889398	0.771	rs4985448	ENSG00000196696.11	PDXDC2P	-3.92	1e-04	0.014	-0.13	-0.18	Body mass index;	chr16:69865492	chr16:69976297~70065948:-
HNSC	cis	rs9903692	0.908	rs9807087	ENSG00000263412.1	RP5-890E16.2	3.92	1e-04	0.014	0.17	0.18	Pulse pressure;	chr17:48126776	chr17:48045141~48048073:-
HNSC	cis	rs10771431	1	rs10771431	ENSG00000256427.1	RP11-118B22.4	3.92	1e-04	0.014	0.18	0.18	Breast size;	chr12:9228263	chr12:9246497~9257960:+
HNSC	cis	rs67311347	0.544	rs6804545	ENSG00000280739.1	EIF1B-AS1	3.92	1e-04	0.014	0.19	0.18	Renal cell carcinoma;	chr3:40312549	chr3:40173145~40309698:-
HNSC	cis	rs3750965	0.959	rs3376	ENSG00000265539.1	MIR3164	-3.92	1e-04	0.014	-0.19	-0.18	Hair color;	chr11:69089212	chr11:69083176~69083258:+
HNSC	cis	rs3750965	0.959	rs2253658	ENSG00000265539.1	MIR3164	-3.92	1e-04	0.014	-0.19	-0.18	Hair color;	chr11:69089336	chr11:69083176~69083258:+
HNSC	cis	rs853679	0.517	rs6922063	ENSG00000219891.2	ZSCAN12P1	3.92	1e-04	0.0141	0.25	0.18	Depression;	chr6:28126588	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs2275508	ENSG00000219891.2	ZSCAN12P1	3.92	1e-04	0.0141	0.25	0.18	Depression;	chr6:28126953	chr6:28091154~28093664:+
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000233609.3	RP11-62H7.2	-3.92	1e-04	0.0141	-0.17	-0.18	Mood instability;	chr8:8804024	chr8:8961200~8979025:+
HNSC	cis	rs73198271	1	rs73198271	ENSG00000254340.1	RP11-10A14.3	-3.92	1e-04	0.0141	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:9141424~9145435:+
HNSC	cis	rs73198271	1	rs73198272	ENSG00000254340.1	RP11-10A14.3	-3.92	1e-04	0.0141	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:9141424~9145435:+
HNSC	cis	rs73198271	1	rs4841030	ENSG00000254340.1	RP11-10A14.3	-3.92	1e-04	0.0141	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:9141424~9145435:+
HNSC	cis	rs7520050	0.966	rs4660321	ENSG00000280836.1	AL355480.1	3.92	1e-04	0.0141	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs6698247	ENSG00000280836.1	AL355480.1	3.92	1e-04	0.0141	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6675946	ENSG00000280836.1	AL355480.1	3.92	1e-04	0.0141	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs7526678	ENSG00000280836.1	AL355480.1	3.92	1e-04	0.0141	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45581219~45581321:-
HNSC	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	3.92	1e-04	0.0141	0.21	0.18	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	3.92	1e-04	0.0141	0.21	0.18	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
HNSC	cis	rs3750965	1	rs61881024	ENSG00000265539.1	MIR3164	-3.92	1e-04	0.0141	-0.2	-0.18	Hair color;	chr11:69070326	chr11:69083176~69083258:+
HNSC	cis	rs13260300	0.688	rs7008779	ENSG00000254349.4	FLJ39080	3.92	1e-04	0.0141	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74618886	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.536	rs2588299	ENSG00000254349.4	FLJ39080	3.92	1e-04	0.0141	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74619150	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.613	rs2553717	ENSG00000254349.4	FLJ39080	3.92	1e-04	0.0141	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74619729	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.614	rs1582725	ENSG00000254349.4	FLJ39080	3.92	1e-04	0.0141	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74620731	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.657	rs2553716	ENSG00000254349.4	FLJ39080	3.92	1e-04	0.0141	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74622083	chr8:74599775~74823313:+
HNSC	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-3.92	1e-04	0.0141	-0.26	-0.18	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-3.92	1e-04	0.0141	-0.26	-0.18	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-3.92	1e-04	0.0141	-0.26	-0.18	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
HNSC	cis	rs4713118	0.955	rs9380010	ENSG00000217862.2	HIST1H4PS1	-3.92	1e-04	0.0141	-0.21	-0.18	Parkinson's disease;	chr6:27715793	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs9368528	ENSG00000217862.2	HIST1H4PS1	-3.92	1e-04	0.0141	-0.21	-0.18	Parkinson's disease;	chr6:27716019	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs9380011	ENSG00000217862.2	HIST1H4PS1	-3.92	1e-04	0.0141	-0.21	-0.18	Parkinson's disease;	chr6:27716145	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs9368529	ENSG00000217862.2	HIST1H4PS1	-3.92	1e-04	0.0141	-0.21	-0.18	Parkinson's disease;	chr6:27716852	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs9380012	ENSG00000217862.2	HIST1H4PS1	-3.92	1e-04	0.0141	-0.21	-0.18	Parkinson's disease;	chr6:27716875	chr6:27807075~27807339:+
HNSC	cis	rs10073892	0.701	rs10067136	ENSG00000250682.4	LINC00491	-3.92	1e-04	0.0141	-0.25	-0.18	Cognitive decline (age-related);	chr5:102386616	chr5:102609156~102671559:-
HNSC	cis	rs76076331	0.887	rs10184911	ENSG00000234818.1	AC092687.5	3.92	1e-04	0.0141	0.26	0.18	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848391	chr2:10589166~10604830:+
HNSC	cis	rs76076331	0.887	rs9287724	ENSG00000234818.1	AC092687.5	3.92	1e-04	0.0141	0.26	0.18	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848462	chr2:10589166~10604830:+
HNSC	cis	rs929354	0.713	rs6459733	ENSG00000224629.1	RP5-1142J19.2	-3.92	1e-04	0.0141	-0.18	-0.18	Body mass index;	chr7:157137856	chr7:157263022~157263229:-
HNSC	cis	rs7246657	0.551	rs10407224	ENSG00000276846.1	CTD-3220F14.3	3.92	1e-04	0.0141	0.28	0.18	Coronary artery calcification;	chr19:37160568	chr19:37314868~37315620:-
HNSC	cis	rs4841134	1	rs12542898	ENSG00000233609.3	RP11-62H7.2	-3.92	1e-04	0.0141	-0.17	-0.18	Age-related disease endophenotypes;	chr8:9329325	chr8:8961200~8979025:+
HNSC	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-3.92	1e-04	0.0141	-0.19	-0.18	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
HNSC	cis	rs6840258	0.689	rs340639	ENSG00000251411.1	RP11-397E7.4	3.92	1e-04	0.0141	0.2	0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87003827	chr4:86913266~86914817:-
HNSC	cis	rs11867934	0.731	rs9908767	ENSG00000223979.2	SMCR2	3.92	0.000101	0.0141	0.25	0.18	Diabetic retinopathy;	chr17:17101772	chr17:17674026~17677688:-
HNSC	cis	rs1620921	0.594	rs9355843	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000101	0.0141	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847773	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.594	rs9365216	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000101	0.0141	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160847786	chr6:160931080~160969771:+
HNSC	cis	rs13256369	1	rs13266699	ENSG00000173295.6	FAM86B3P	-3.92	0.000101	0.0141	-0.23	-0.18	Obesity-related traits;	chr8:8712803	chr8:8228595~8244865:+
HNSC	cis	rs4919687	0.55	rs7904396	ENSG00000236937.2	PTGES3P4	3.92	0.000101	0.0141	0.23	0.18	Colorectal cancer;	chr10:102697081	chr10:102845595~102845950:+
HNSC	cis	rs1799955	0.554	rs11571662	ENSG00000215515.2	IFIT1P1	-3.92	0.000101	0.0141	-0.21	-0.18	LDL cholesterol levels;	chr13:32341387	chr13:32384660~32386108:+
HNSC	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	3.92	0.000101	0.0141	0.25	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
HNSC	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-3.92	0.000101	0.0141	-0.19	-0.18	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
HNSC	cis	rs494453	0.807	rs2786966	ENSG00000227811.2	FAM212B-AS1	3.92	0.000101	0.0141	0.21	0.18	Osteoporosis-related phenotypes;	chr1:111638035	chr1:111739841~111747798:+
HNSC	cis	rs17818399	0.547	rs62134736	ENSG00000279254.1	RP11-536C12.1	-3.92	0.000101	0.0141	-0.23	-0.18	Height;	chr2:46539307	chr2:46668870~46670778:+
HNSC	cis	rs11756659	0.653	rs412968	ENSG00000218690.1	HIST1H2APS4	3.92	0.000101	0.0141	0.24	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25953965	chr6:26272193~26272540:-
HNSC	cis	rs35306767	0.714	rs12767171	ENSG00000229869.1	RP11-363N22.2	-3.92	0.000101	0.0141	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1038551	chr10:933026~942743:+
HNSC	cis	rs8031584	0.706	rs798084	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000101	0.0141	-0.19	-0.18	Huntington's disease progression;	chr15:30834732	chr15:30926514~30928407:+
HNSC	cis	rs67072384	1	rs72964185	ENSG00000213365.3	AP000593.6	3.92	0.000101	0.0141	0.32	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72732132	chr11:72280151~72281178:+
HNSC	cis	rs2179367	0.959	rs9377212	ENSG00000216906.2	RP11-350J20.9	3.92	0.000101	0.0141	0.22	0.18	Dupuytren's disease;	chr6:149383765	chr6:149904243~149906418:+
HNSC	cis	rs1941023	0.648	rs4939368	ENSG00000279632.1	RP11-286N22.6	3.92	0.000101	0.0141	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60488575	chr11:61426448~61427325:-
HNSC	cis	rs1941023	0.648	rs11604104	ENSG00000279632.1	RP11-286N22.6	3.92	0.000101	0.0141	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60489828	chr11:61426448~61427325:-
HNSC	cis	rs1941023	0.648	rs4939370	ENSG00000279632.1	RP11-286N22.6	3.92	0.000101	0.0141	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60489927	chr11:61426448~61427325:-
HNSC	cis	rs1941023	0.677	rs7951049	ENSG00000279632.1	RP11-286N22.6	3.92	0.000101	0.0141	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60494869	chr11:61426448~61427325:-
HNSC	cis	rs7178375	1	rs28881289	ENSG00000215302.7	CTD-3092A11.1	-3.92	0.000101	0.0141	-0.27	-0.18	Hypertriglyceridemia;	chr15:30931752	chr15:30470779~30507623:+
HNSC	cis	rs7178375	0.941	rs35497908	ENSG00000215302.7	CTD-3092A11.1	-3.92	0.000101	0.0141	-0.27	-0.18	Hypertriglyceridemia;	chr15:30931868	chr15:30470779~30507623:+
HNSC	cis	rs6012564	1	rs6122763	ENSG00000227431.4	CSE1L-AS1	-3.92	0.000101	0.0141	-0.2	-0.18	Anger;	chr20:49181116	chr20:49040463~49046044:-
HNSC	cis	rs9859260	0.701	rs9872347	ENSG00000207650.1	MIR570	3.92	0.000101	0.0141	0.18	0.18	Mean corpuscular volume;	chr3:196104366	chr3:195699401~195699497:+
HNSC	cis	rs11098499	0.82	rs28578366	ENSG00000250412.1	KLHL2P1	-3.92	0.000101	0.0141	-0.23	-0.18	Corneal astigmatism;	chr4:119615750	chr4:119334329~119378233:+
HNSC	cis	rs4947019	0.609	rs4946975	ENSG00000260273.1	RP11-425D10.10	3.92	0.000101	0.0141	0.5	0.18	Hematological parameters;	chr6:109448013	chr6:109382795~109383666:+
HNSC	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	3.92	0.000101	0.0141	0.15	0.18	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
HNSC	cis	rs67981189	0.593	rs7144986	ENSG00000274818.1	RP1-292L20.3	3.92	0.000101	0.0141	0.2	0.18	Schizophrenia;	chr14:71006714	chr14:70906657~70907111:-
HNSC	cis	rs1925953	0.711	rs55754988	ENSG00000233589.1	RP4-694A7.2	-3.92	0.000101	0.0141	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68377696	chr1:68479129~68483539:+
HNSC	cis	rs1937680	0.613	rs7899670	ENSG00000236671.6	PRKG1-AS1	-3.92	0.000101	0.0141	-0.26	-0.18	Breast cancer;	chr10:51908601	chr10:52230742~52314128:-
HNSC	cis	rs202072	0.722	rs202068	ENSG00000215022.6	RP1-257A7.4	-3.92	0.000101	0.0141	-0.26	-0.18	HIV-1 viral setpoint;	chr6:13266818	chr6:13264861~13295586:-
HNSC	cis	rs597539	0.652	rs507520	ENSG00000255741.1	RP11-757G1.5	-3.92	0.000101	0.0141	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68941503~68942852:-
HNSC	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	3.92	0.000101	0.0141	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
HNSC	cis	rs17596685	1	rs1325800	ENSG00000271216.1	LINC01050	-3.92	0.000101	0.0141	-0.23	-0.18	C-reactive protein levels;	chr13:42568165	chr13:42810366~42812562:-
HNSC	cis	rs1580019	1	rs1580019	ENSG00000229358.3	DPY19L1P1	3.92	0.000101	0.0141	0.2	0.18	Cognitive ability;	chr7:32453557	chr7:32580949~32761787:-
HNSC	cis	rs853679	0.517	rs9393884	ENSG00000219891.2	ZSCAN12P1	3.92	0.000101	0.0141	0.25	0.18	Depression;	chr6:28079011	chr6:28091154~28093664:+
HNSC	cis	rs6500395	0.775	rs11640119	ENSG00000261267.1	RP11-44I10.3	-3.92	0.000101	0.0141	-0.22	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48628929	chr16:48559661~48587403:+
HNSC	cis	rs2279168	0.737	rs59763908	ENSG00000259295.5	CSPG4P12	-3.92	0.000101	0.0141	-0.38	-0.18	Response to platinum-based chemotherapy (carboplatin);	chr15:85421592	chr15:85191438~85213905:+
HNSC	cis	rs1316952	0.504	rs75621075	ENSG00000269938.1	RP11-214K3.20	-3.92	0.000101	0.0141	-0.37	-0.18	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123992913	chr12:123968023~123968579:-
HNSC	cis	rs748404	0.666	rs12906481	ENSG00000166763.7	STRCP1	3.92	0.000101	0.0141	0.26	0.18	Lung cancer;	chr15:43467356	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs35958032	ENSG00000166763.7	STRCP1	3.92	0.000101	0.0141	0.26	0.18	Lung cancer;	chr15:43494397	chr15:43699488~43718184:-
HNSC	cis	rs12285276	0.75	rs11038658	ENSG00000205106.4	DKFZp779M0652	-3.92	0.000101	0.0141	-0.25	-0.18	Visceral fat;	chr11:45791762	chr11:45771432~45772358:+
HNSC	cis	rs889398	0.771	rs1566454	ENSG00000196696.11	PDXDC2P	-3.92	0.000101	0.0141	-0.13	-0.18	Body mass index;	chr16:69866180	chr16:69976297~70065948:-
HNSC	cis	rs889398	0.651	rs1566455	ENSG00000196696.11	PDXDC2P	-3.92	0.000101	0.0141	-0.13	-0.18	Body mass index;	chr16:69866261	chr16:69976297~70065948:-
HNSC	cis	rs4253772	0.591	rs8143066	ENSG00000277232.2	GTSE1-AS1	-3.92	0.000101	0.0141	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46260710	chr22:46295143~46296660:-
HNSC	cis	rs7927592	0.763	rs3740628	ENSG00000255031.4	RP11-802E16.3	3.92	0.000101	0.0141	0.14	0.18	Total body bone mineral density;	chr11:68613947	chr11:68050740~68053762:+
HNSC	cis	rs67478160	0.634	rs941473	ENSG00000259515.1	RP11-365N19.2	3.92	0.000101	0.0141	0.16	0.18	Schizophrenia;	chr14:103735532	chr14:102933574~102937177:+
HNSC	cis	rs11711311	1	rs3773682	ENSG00000241529.3	RN7SL767P	-3.92	0.000101	0.0141	-0.23	-0.18	IgG glycosylation;	chr3:113801729	chr3:113632704~113632998:+
HNSC	cis	rs6142618	0.811	rs6058611	ENSG00000275576.1	RP5-836N17.4	-3.92	0.000101	0.0141	-0.18	-0.18	Inflammatory bowel disease;	chr20:32273297	chr20:32116171~32116629:+
HNSC	cis	rs2032366	0.592	rs59304542	ENSG00000267279.1	RP11-879F14.2	3.92	0.000101	0.0141	0.24	0.18	Obesity-related traits;	chr18:61581456	chr18:61585746~61606916:-
HNSC	cis	rs7005380	0.62	rs7002839	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000101	0.0141	-0.14	-0.18	Interstitial lung disease;	chr8:119906508	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs7006905	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000101	0.0141	-0.14	-0.18	Interstitial lung disease;	chr8:119906683	chr8:119838736~119840385:-
HNSC	cis	rs933688	1	rs332529	ENSG00000281357.1	ARRDC3-AS1	3.92	0.000101	0.0141	0.28	0.18	Smoking behavior;	chr5:91493653	chr5:91380349~91439085:+
HNSC	cis	rs889398	0.874	rs2917677	ENSG00000226232.7	RP11-419C5.2	3.92	0.000101	0.0141	0.16	0.18	Body mass index;	chr16:69716946	chr16:69976388~69996188:-
HNSC	cis	rs7824557	0.564	rs2736293	ENSG00000255310.2	AF131215.2	-3.92	0.000101	0.0141	-0.17	-0.18	Retinal vascular caliber;	chr8:11377104	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs2736294	ENSG00000255310.2	AF131215.2	-3.92	0.000101	0.0141	-0.17	-0.18	Retinal vascular caliber;	chr8:11377117	chr8:11107788~11109726:-
HNSC	cis	rs7005380	0.531	rs4871011	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000101	0.0141	-0.18	-0.18	Interstitial lung disease;	chr8:119895531	chr8:119838736~119840385:-
HNSC	cis	rs913655	0.574	rs1329236	ENSG00000225527.1	RP11-383B4.4	-3.92	0.000101	0.0141	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18784702	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.545	rs1329235	ENSG00000225527.1	RP11-383B4.4	-3.92	0.000101	0.0141	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18784915	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.545	rs2495833	ENSG00000225527.1	RP11-383B4.4	-3.92	0.000101	0.0141	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18785044	chr10:18531849~18533336:-
HNSC	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	3.92	0.000101	0.0141	0.2	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
HNSC	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	3.92	0.000101	0.0142	0.17	0.18	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
HNSC	cis	rs10129255	0.536	rs10139058	ENSG00000224373.3	IGHV4-59	3.92	0.000101	0.0142	0.1	0.18	Kawasaki disease;	chr14:106685899	chr14:106627249~106627825:-
HNSC	cis	rs9813712	0.904	rs6439223	ENSG00000228252.7	COL6A4P2	3.92	0.000101	0.0142	0.19	0.18	Response to amphetamines;	chr3:130256697	chr3:130212823~130273806:+
HNSC	cis	rs10791097	0.694	rs1893018	ENSG00000254842.5	RP11-890B15.2	-3.92	0.000101	0.0142	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130886737	chr11:130844191~130865561:-
HNSC	cis	rs3743772	0.5	rs9924562	ENSG00000279344.1	RP11-44F14.7	3.92	0.000101	0.0142	0.25	0.18	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53478957~53481550:-
HNSC	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	3.92	0.000101	0.0142	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
HNSC	cis	rs8098244	0.52	rs6508073	ENSG00000264745.1	TTC39C-AS1	-3.92	0.000101	0.0142	-0.21	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23988403	chr18:23994213~24015339:-
HNSC	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-3.92	0.000101	0.0142	-0.22	-0.18	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
HNSC	cis	rs36052053	0.521	rs35370422	ENSG00000219700.1	PTCHD3P3	3.92	0.000101	0.0142	0.34	0.18	Red cell distribution width;	chr6:109210537	chr6:109288571~109290503:-
HNSC	cis	rs5758511	0.773	rs62241023	ENSG00000226450.2	CYP2D8P	3.92	0.000101	0.0142	0.17	0.18	Birth weight;	chr22:41989425	chr22:42149886~42155001:-
HNSC	cis	rs12122100	0.696	rs12752148	ENSG00000230832.3	RP11-325P15.2	3.92	0.000101	0.0142	0.23	0.18	HIV-1 control;	chr1:147085526	chr1:147082338~147083578:-
HNSC	cis	rs853679	0.882	rs9461432	ENSG00000219891.2	ZSCAN12P1	3.92	0.000101	0.0142	0.32	0.18	Depression;	chr6:28119105	chr6:28091154~28093664:+
HNSC	cis	rs9650657	0.77	rs6601529	ENSG00000269918.1	AF131215.9	-3.92	0.000101	0.0142	-0.17	-0.18	Neuroticism;	chr8:10813040	chr8:11104691~11106704:-
HNSC	cis	rs2833693	0.524	rs8129993	ENSG00000261610.1	AP000265.1	3.92	0.000101	0.0142	0.21	0.18	Temperament;	chr21:32268841	chr21:32259804~32261585:-
HNSC	cis	rs3096299	0.967	rs2911256	ENSG00000261118.1	RP11-104N10.1	3.92	0.000101	0.0142	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89492017~89504460:-
HNSC	cis	rs73201462	1	rs2811536	ENSG00000231305.3	RP11-723O4.2	3.92	0.000101	0.0142	0.26	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128270076	chr3:128861313~128871540:-
HNSC	cis	rs1008375	0.966	rs10939755	ENSG00000249502.1	AC006160.5	-3.92	0.000101	0.0142	-0.19	-0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692132	chr4:17587467~17614571:-
HNSC	cis	rs7211079	0.879	rs7221505	ENSG00000275479.1	RP11-334C17.6	3.92	0.000101	0.0142	0.21	0.18	Myocardial infarction;	chr17:80154432	chr17:80149627~80149798:+
HNSC	cis	rs35306767	0.715	rs17293580	ENSG00000229869.1	RP11-363N22.2	-3.92	0.000101	0.0142	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:988955	chr10:933026~942743:+
HNSC	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	3.92	0.000101	0.0142	0.21	0.18	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
HNSC	cis	rs765751	0.73	rs2605092	ENSG00000228536.1	RP11-392O17.1	-3.92	0.000101	0.0142	-0.21	-0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219467047	chr1:219409681~219411941:-
HNSC	cis	rs889398	1	rs889398	ENSG00000226232.7	RP11-419C5.2	3.92	0.000102	0.0142	0.16	0.18	Body mass index;	chr16:69522812	chr16:69976388~69996188:-
HNSC	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-3.92	0.000102	0.0142	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
HNSC	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-3.92	0.000102	0.0142	-0.21	-0.18	Height;	chr14:75188649	chr14:75011269~75012851:-
HNSC	cis	rs9487051	0.646	rs11153165	ENSG00000243587.6	C6orf183	-3.92	0.000102	0.0142	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109300956	chr6:109165833~109271014:+
HNSC	cis	rs853679	1	rs853694	ENSG00000219891.2	ZSCAN12P1	3.92	0.000102	0.0142	0.28	0.18	Depression;	chr6:28311323	chr6:28091154~28093664:+
HNSC	cis	rs8031584	0.678	rs3122	ENSG00000270015.1	RP11-540B6.6	3.92	0.000102	0.0142	0.18	0.18	Huntington's disease progression;	chr15:30878087	chr15:30926514~30928407:+
HNSC	cis	rs2098713	0.534	rs11746259	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37488801	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.502	rs55872839	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37488967	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.501	rs12652895	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37489269	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs12657090	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37489340	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.501	rs55758219	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37489681	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.534	rs56307385	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37490062	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs7727005	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37490325	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs7727685	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37490694	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs11958226	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37491418	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs7733244	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0142	0.18	0.18	Telomere length;	chr5:37491825	chr5:36666214~36725195:-
HNSC	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	3.92	0.000102	0.0142	0.25	0.18	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
HNSC	cis	rs8031584	0.678	rs4779497	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000102	0.0142	-0.19	-0.18	Huntington's disease progression;	chr15:30859162	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.678	rs8028173	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000102	0.0142	-0.19	-0.18	Huntington's disease progression;	chr15:30863546	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.706	rs2177670	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000102	0.0142	-0.19	-0.18	Huntington's disease progression;	chr15:30865548	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.678	rs36047941	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000102	0.0142	-0.19	-0.18	Huntington's disease progression;	chr15:30867032	chr15:30926514~30928407:+
HNSC	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	3.92	0.000102	0.0142	0.17	0.18	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
HNSC	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	3.92	0.000102	0.0142	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	3.92	0.000102	0.0142	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
HNSC	cis	rs886126	1	rs886126	ENSG00000257595.2	RP3-473L9.4	3.92	0.000102	0.0142	0.23	0.18	Coronary heart disease;	chr12:111241410	chr12:111369282~111403310:+
HNSC	cis	rs17594362	0.945	rs9566791	ENSG00000229473.2	RGS17P1	-3.92	0.000102	0.0142	-0.26	-0.18	Multiple sclerosis;	chr13:41570344	chr13:40992779~40993331:-
HNSC	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-3.92	0.000102	0.0142	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-3.92	0.000102	0.0142	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
HNSC	cis	rs1009077	0.68	rs11724055	ENSG00000245958.5	RP11-33B1.1	3.92	0.000102	0.0142	0.19	0.18	Endometriosis;	chr4:119548880	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.68	rs13140150	ENSG00000245958.5	RP11-33B1.1	3.92	0.000102	0.0142	0.19	0.18	Endometriosis;	chr4:119552036	chr4:119454791~119552025:+
HNSC	cis	rs1009077	0.68	rs62319609	ENSG00000245958.5	RP11-33B1.1	3.92	0.000102	0.0142	0.19	0.18	Endometriosis;	chr4:119570485	chr4:119454791~119552025:+
HNSC	cis	rs793571	0.822	rs35477914	ENSG00000245975.2	RP11-30K9.6	3.92	0.000102	0.0142	0.29	0.18	Schizophrenia;	chr15:58905470	chr15:58768072~58770974:-
HNSC	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-3.92	0.000102	0.0142	-0.2	-0.18	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
HNSC	cis	rs2524005	1	rs2524005	ENSG00000204622.9	HLA-J	-3.92	0.000102	0.0142	-0.27	-0.18	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30006583~30009956:+
HNSC	cis	rs4947019	0.609	rs9487109	ENSG00000260273.1	RP11-425D10.10	3.92	0.000102	0.0142	0.49	0.18	Hematological parameters;	chr6:109436323	chr6:109382795~109383666:+
HNSC	cis	rs1602565	0.858	rs2101642	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29146552	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.8	rs1580630	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29147112	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2035842	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29150935	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs1491804	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29151419	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2958620	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29153034	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2933164	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29153166	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2933165	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29153299	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs1580631	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29157407	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs2131053	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29157832	chr11:29275655~29276565:+
HNSC	cis	rs1602565	0.858	rs666959	ENSG00000255450.1	CTD-2063L20.1	-3.92	0.000102	0.0142	-0.27	-0.18	Schizophrenia;	chr11:29158567	chr11:29275655~29276565:+
HNSC	cis	rs7824557	0.527	rs2736296	ENSG00000255310.2	AF131215.2	-3.92	0.000102	0.0142	-0.17	-0.18	Retinal vascular caliber;	chr8:11377335	chr8:11107788~11109726:-
HNSC	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	3.92	0.000102	0.0142	0.17	0.18	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
HNSC	cis	rs11846409	0.932	rs10151046	ENSG00000280411.1	IGHV1-69-2	-3.92	0.000102	0.0142	-0.16	-0.18	Rheumatic heart disease;	chr14:106633095	chr14:106762092~106762588:-
HNSC	cis	rs4699052	0.662	rs1516731	ENSG00000246560.2	RP11-10L12.4	3.92	0.000102	0.0142	0.21	0.18	Testicular germ cell tumor;	chr4:103331537	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.625	rs11734836	ENSG00000246560.2	RP11-10L12.4	3.92	0.000102	0.0142	0.21	0.18	Testicular germ cell tumor;	chr4:103332046	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.625	rs4481237	ENSG00000246560.2	RP11-10L12.4	3.92	0.000102	0.0142	0.21	0.18	Testicular germ cell tumor;	chr4:103332852	chr4:102828055~102844075:+
HNSC	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-3.92	0.000102	0.0142	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
HNSC	cis	rs8072100	0.512	rs9674670	ENSG00000263293.2	RP11-290H9.4	3.92	0.000102	0.0143	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47303460~47323613:-
HNSC	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-3.92	0.000102	0.0143	-0.23	-0.18	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
HNSC	cis	rs9467711	0.606	rs2073529	ENSG00000241549.7	GUSBP2	-3.92	0.000102	0.0143	-0.27	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26374931	chr6:26871484~26956554:-
HNSC	cis	rs74781061	0.932	rs11072496	ENSG00000260103.2	RP11-10O17.1	-3.92	0.000102	0.0143	-0.21	-0.18	Endometriosis;	chr15:74628191	chr15:74478070~74490286:-
HNSC	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	3.92	0.000102	0.0143	0.19	0.18	QT interval;	chr12:29259743	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	3.92	0.000102	0.0143	0.19	0.18	QT interval;	chr12:29260002	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	3.92	0.000102	0.0143	0.19	0.18	QT interval;	chr12:29263297	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	3.92	0.000102	0.0143	0.19	0.18	QT interval;	chr12:29264237	chr12:29280418~29317848:-
HNSC	cis	rs11148252	0.553	rs9536219	ENSG00000198384.8	TPTE2P3	3.92	0.000102	0.0143	0.22	0.18	Lewy body disease;	chr13:52653166	chr13:52522632~52586906:+
HNSC	cis	rs4713118	0.869	rs9348775	ENSG00000216901.1	AL022393.7	3.92	0.000102	0.0143	0.22	0.18	Parkinson's disease;	chr6:27727550	chr6:28176188~28176674:+
HNSC	cis	rs79220007	0.557	rs9467550	ENSG00000272462.2	U91328.19	-3.92	0.000102	0.0143	-0.31	-0.18	Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr6:25653173	chr6:25992662~26001775:+
HNSC	cis	rs6968419	0.674	rs11767092	ENSG00000237870.5	AC073130.1	3.92	0.000102	0.0143	0.21	0.18	Intraocular pressure;	chr7:116267811	chr7:116275606~116286734:-
HNSC	cis	rs2439831	1	rs565007	ENSG00000275601.1	AC011330.13	-3.92	0.000102	0.0143	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43424443	chr15:43642389~43643023:-
HNSC	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-3.92	0.000102	0.0143	-0.2	-0.18	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
HNSC	cis	rs9859260	1	rs2284890	ENSG00000207650.1	MIR570	3.92	0.000102	0.0143	0.16	0.18	Mean corpuscular volume;	chr3:196061276	chr3:195699401~195699497:+
HNSC	cis	rs9859260	1	rs2284889	ENSG00000207650.1	MIR570	3.92	0.000102	0.0143	0.16	0.18	Mean corpuscular volume;	chr3:196061376	chr3:195699401~195699497:+
HNSC	cis	rs6787172	0.592	rs10936129	ENSG00000272087.1	RP11-379F4.7	3.92	0.000102	0.0143	0.18	0.18	Subjective well-being;	chr3:158338442	chr3:158693120~158693768:-
HNSC	cis	rs4906332	0.782	rs12891288	ENSG00000269910.1	RP11-73M18.10	3.92	0.000102	0.0143	0.19	0.18	Coronary artery disease;	chr14:103533413	chr14:103694516~103695050:-
HNSC	cis	rs9611565	0.918	rs9611562	ENSG00000235513.1	RP4-756G23.5	3.92	0.000102	0.0143	0.21	0.18	Vitiligo;	chr22:41364168	chr22:41209122~41217627:-
HNSC	cis	rs1941023	0.541	rs7109412	ENSG00000279632.1	RP11-286N22.6	3.92	0.000102	0.0143	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60497156	chr11:61426448~61427325:-
HNSC	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-3.92	0.000102	0.0143	-0.22	-0.18	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
HNSC	cis	rs11758351	1	rs77961951	ENSG00000241549.7	GUSBP2	-3.92	0.000102	0.0143	-0.25	-0.18	Renal underexcretion gout;Gout;	chr6:26185847	chr6:26871484~26956554:-
HNSC	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-3.92	0.000102	0.0143	-0.18	-0.18	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
HNSC	cis	rs847649	0.699	rs10271157	ENSG00000239969.4	RP11-163E9.2	-3.92	0.000102	0.0143	-0.21	-0.18	Morning vs. evening chronotype;	chr7:102887144	chr7:102364162~102380633:+
HNSC	cis	rs847649	0.699	rs10242028	ENSG00000239969.4	RP11-163E9.2	-3.92	0.000102	0.0143	-0.21	-0.18	Morning vs. evening chronotype;	chr7:102887338	chr7:102364162~102380633:+
HNSC	cis	rs17772222	0.917	rs1956406	ENSG00000258789.1	RP11-507K2.3	-3.92	0.000102	0.0143	-0.21	-0.18	Coronary artery calcification;	chr14:88749711	chr14:88551597~88552493:+
HNSC	cis	rs10742752	0.702	rs10838464	ENSG00000255267.3	RP11-430H10.2	-3.92	0.000102	0.0143	-0.23	-0.18	Body mass index;	chr11:45404445	chr11:45371397~45388508:+
HNSC	cis	rs8031584	0.678	rs4779496	ENSG00000270015.1	RP11-540B6.6	-3.92	0.000102	0.0143	-0.19	-0.18	Huntington's disease progression;	chr15:30858851	chr15:30926514~30928407:+
HNSC	cis	rs7615952	0.605	rs11708269	ENSG00000248787.1	RP11-666A20.4	-3.92	0.000102	0.0143	-0.34	-0.18	Blood pressure (smoking interaction);	chr3:125613306	chr3:125908005~125910272:-
HNSC	cis	rs2836974	0.897	rs13047678	ENSG00000255568.3	BRWD1-AS2	3.92	0.000102	0.0143	0.17	0.18	Cognitive function;	chr21:39336927	chr21:39313935~39314962:+
HNSC	cis	rs6558530	0.666	rs7845723	ENSG00000253982.1	CTD-2336O2.1	3.92	0.000102	0.0143	0.23	0.18	Systolic blood pressure;	chr8:1748920	chr8:1761990~1764502:-
HNSC	cis	rs12545109	0.8	rs1968551	ENSG00000246430.5	LINC00968	-3.92	0.000102	0.0143	-0.23	-0.18	Obesity-related traits;	chr8:56495201	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.8	rs1530218	ENSG00000246430.5	LINC00968	-3.92	0.000102	0.0143	-0.23	-0.18	Obesity-related traits;	chr8:56495305	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.8	rs1530217	ENSG00000246430.5	LINC00968	-3.92	0.000102	0.0143	-0.23	-0.18	Obesity-related traits;	chr8:56495538	chr8:56496246~56559823:-
HNSC	cis	rs12545109	0.8	rs2610058	ENSG00000246430.5	LINC00968	-3.92	0.000102	0.0143	-0.23	-0.18	Obesity-related traits;	chr8:56496561	chr8:56496246~56559823:-
HNSC	cis	rs843532	0.925	rs1718414	ENSG00000236833.1	AC024560.2	-3.92	0.000102	0.0143	-0.3	-0.18	Glucose homeostasis traits;	chr3:196787765	chr3:197660565~197665757:-
HNSC	cis	rs4853525	0.59	rs12619138	ENSG00000228509.4	AC006460.2	3.92	0.000102	0.0143	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865474	chr2:190676944~190708716:-
HNSC	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	3.92	0.000102	0.0143	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
HNSC	cis	rs4489787	1	rs12231229	ENSG00000257763.1	OR5BK1P	-3.92	0.000102	0.0143	-0.29	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48416125	chr12:48355792~48356614:-
HNSC	cis	rs4489787	1	rs17122979	ENSG00000257763.1	OR5BK1P	-3.92	0.000102	0.0143	-0.29	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48419914	chr12:48355792~48356614:-
HNSC	cis	rs75422866	0.764	rs67201012	ENSG00000276691.1	RP5-1057I20.5	3.92	0.000102	0.0143	0.33	0.18	Pneumonia;	chr12:47715881	chr12:47788426~47788971:+
HNSC	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-3.92	0.000102	0.0143	-0.21	-0.18	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
HNSC	cis	rs9788333	0.707	rs12584557	ENSG00000236953.1	ZDHHC20-IT1	-3.92	0.000102	0.0143	-0.2	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312032	chr13:21376977~21377874:-
HNSC	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-3.92	0.000102	0.0143	-0.19	-0.18	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
HNSC	cis	rs9925964	0.933	rs10871454	ENSG00000232748.3	RP11-196G11.6	3.92	0.000102	0.0143	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:31056460~31062803:+
HNSC	cis	rs11098499	0.663	rs9996501	ENSG00000250412.1	KLHL2P1	3.92	0.000102	0.0143	0.23	0.18	Corneal astigmatism;	chr4:119317763	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs28458294	ENSG00000250412.1	KLHL2P1	3.92	0.000102	0.0143	0.23	0.18	Corneal astigmatism;	chr4:119317769	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.663	rs28369503	ENSG00000250412.1	KLHL2P1	3.92	0.000102	0.0143	0.23	0.18	Corneal astigmatism;	chr4:119317770	chr4:119334329~119378233:+
HNSC	cis	rs7520050	0.966	rs4073846	ENSG00000280836.1	AL355480.1	-3.92	0.000102	0.0143	-0.18	-0.18	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45581219~45581321:-
HNSC	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	3.92	0.000102	0.0143	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
HNSC	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-3.92	0.000103	0.0143	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
HNSC	cis	rs4841097	0.876	rs6601288	ENSG00000254153.1	CTA-398F10.2	3.92	0.000103	0.0143	0.2	0.18	Platelet distribution width;	chr8:9085920	chr8:8456909~8461337:-
HNSC	cis	rs755249	0.567	rs16826069	ENSG00000182109.6	RP11-69E11.4	3.92	0.000103	0.0143	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39522280~39546187:-
HNSC	cis	rs5758659	0.737	rs10854749	ENSG00000227370.1	RP4-669P10.19	-3.92	0.000103	0.0143	-0.18	-0.18	Cognitive function;	chr22:42051337	chr22:42132543~42132998:+
HNSC	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	3.92	0.000103	0.0143	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
HNSC	cis	rs860295	0.812	rs7556519	ENSG00000225855.5	RUSC1-AS1	3.92	0.000103	0.0143	0.12	0.18	Body mass index;	chr1:155857755	chr1:155316863~155324176:-
HNSC	cis	rs970821	1	rs13279803	ENSG00000253106.1	RP11-158K1.3	3.92	0.000103	0.0143	0.16	0.18	Breast cancer;	chr8:123738281	chr8:124488510~124491643:+
HNSC	cis	rs1602565	1	rs11030597	ENSG00000255450.1	CTD-2063L20.1	3.92	0.000103	0.0143	0.31	0.18	Schizophrenia;	chr11:29168981	chr11:29275655~29276565:+
HNSC	cis	rs3850699	0.926	rs12570611	ENSG00000236937.2	PTGES3P4	3.92	0.000103	0.0143	0.24	0.18	Prostate cancer;	chr10:102661922	chr10:102845595~102845950:+
HNSC	cis	rs7824557	0.628	rs58283816	ENSG00000255310.2	AF131215.2	3.92	0.000103	0.0143	0.17	0.18	Retinal vascular caliber;	chr8:11335042	chr8:11107788~11109726:-
HNSC	cis	rs17739794	0.502	rs12155843	ENSG00000254207.1	RP11-43A14.1	-3.92	0.000103	0.0144	-0.21	-0.18	Clozapine-induced cytotoxicity;	chr8:861750	chr8:725188~725877:-
HNSC	cis	rs7005380	0.62	rs7388508	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000103	0.0144	-0.14	-0.18	Interstitial lung disease;	chr8:119913913	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs1607624	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000103	0.0144	-0.14	-0.18	Interstitial lung disease;	chr8:119917049	chr8:119838736~119840385:-
HNSC	cis	rs853679	0.882	rs9393908	ENSG00000204709.4	LINC01556	3.92	0.000103	0.0144	0.31	0.18	Depression;	chr6:28223052	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.882	rs9366717	ENSG00000204709.4	LINC01556	3.92	0.000103	0.0144	0.31	0.18	Depression;	chr6:28223279	chr6:28943877~28944537:+
HNSC	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-3.92	0.000103	0.0144	-0.21	-0.18	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
HNSC	cis	rs7005380	0.579	rs7465181	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000103	0.0144	-0.14	-0.18	Interstitial lung disease;	chr8:119896349	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs7462250	ENSG00000279347.1	RP11-85I17.2	-3.92	0.000103	0.0144	-0.14	-0.18	Interstitial lung disease;	chr8:119896367	chr8:119838736~119840385:-
HNSC	cis	rs6710503	0.715	rs79682290	ENSG00000271936.1	RP11-443B20.1	-3.92	0.000103	0.0144	-0.2	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24818697	chr2:24825610~24826717:+
HNSC	cis	rs7688014	1	rs7688014	ENSG00000251288.2	RP11-10L12.2	-3.92	0.000103	0.0144	-0.21	-0.18	Schizophrenia;	chr4:103053903	chr4:102751401~102752641:+
HNSC	cis	rs10504130	0.569	rs35509250	ENSG00000253844.1	RP11-546K22.1	-3.92	0.000103	0.0144	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51961458~52022974:+
HNSC	cis	rs73201462	0.908	rs2811388	ENSG00000231305.3	RP11-723O4.2	-3.92	0.000103	0.0144	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128299604	chr3:128861313~128871540:-
HNSC	cis	rs2253762	0.54	rs11200351	ENSG00000226864.1	ATE1-AS1	3.92	0.000103	0.0144	0.31	0.18	Breast cancer;	chr10:122029957	chr10:121928312~121951965:+
HNSC	cis	rs2253762	0.54	rs11200353	ENSG00000226864.1	ATE1-AS1	3.92	0.000103	0.0144	0.31	0.18	Breast cancer;	chr10:122030181	chr10:121928312~121951965:+
HNSC	cis	rs11893307	0.599	rs13423600	ENSG00000228509.4	AC006460.2	3.92	0.000103	0.0144	0.25	0.18	Mean platelet volume;	chr2:190803575	chr2:190676944~190708716:-
HNSC	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-3.92	0.000103	0.0144	-0.26	-0.18	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-3.92	0.000103	0.0144	-0.26	-0.18	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
HNSC	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-3.92	0.000103	0.0144	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
HNSC	cis	rs12478296	1	rs67535150	ENSG00000261186.2	RP11-341N2.1	-3.92	0.000103	0.0144	-0.3	-0.18	Obesity-related traits;	chr2:242103948	chr2:242087351~242088457:-
HNSC	cis	rs950169	0.614	rs12911536	ENSG00000230373.7	GOLGA6L5P	-3.92	0.000103	0.0144	-0.21	-0.18	Schizophrenia;	chr15:84004278	chr15:84507885~84516814:-
HNSC	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-3.92	0.000103	0.0144	-0.2	-0.18	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
HNSC	cis	rs5758511	0.514	rs2899354	ENSG00000227370.1	RP4-669P10.19	3.92	0.000103	0.0144	0.22	0.18	Birth weight;	chr22:42158403	chr22:42132543~42132998:+
HNSC	cis	rs9467711	0.659	rs3734542	ENSG00000241549.7	GUSBP2	3.92	0.000103	0.0144	0.3	0.18	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:26871484~26956554:-
HNSC	cis	rs539096	0.54	rs37452	ENSG00000237950.1	RP11-7O11.3	3.92	0.000103	0.0144	0.19	0.18	Intelligence (multi-trait analysis);	chr1:43831901	chr1:43944370~43946551:-
HNSC	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	3.92	0.000103	0.0144	0.18	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
HNSC	cis	rs7572733	0.534	rs10211202	ENSG00000231621.1	AC013264.2	-3.92	0.000103	0.0144	-0.17	-0.18	Dermatomyositis;	chr2:197907217	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs4850813	ENSG00000231621.1	AC013264.2	3.92	0.000103	0.0144	0.17	0.18	Dermatomyositis;	chr2:197911258	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs10931794	ENSG00000231621.1	AC013264.2	3.92	0.000103	0.0144	0.17	0.18	Dermatomyositis;	chr2:197911416	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.555	rs2341778	ENSG00000231621.1	AC013264.2	3.92	0.000103	0.0144	0.17	0.18	Dermatomyositis;	chr2:197911822	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1401095	ENSG00000231621.1	AC013264.2	3.92	0.000103	0.0144	0.17	0.18	Dermatomyositis;	chr2:197915143	chr2:197197991~197199273:+
HNSC	cis	rs28489187	0.617	rs233109	ENSG00000223653.4	RP11-131L23.1	3.92	0.000103	0.0144	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85317418	chr1:85276715~85448124:+
HNSC	cis	rs237743	0.508	rs79186842	ENSG00000222365.1	SNORD12B	-3.92	0.000103	0.0144	-0.3	-0.18	Height;	chr20:49072499	chr20:49280319~49280409:+
HNSC	cis	rs2361718	0.631	rs4889989	ENSG00000275479.1	RP11-334C17.6	-3.92	0.000103	0.0144	-0.18	-0.18	Yeast infection;	chr17:80178061	chr17:80149627~80149798:+
HNSC	cis	rs9650657	0.801	rs7018334	ENSG00000269918.1	AF131215.9	-3.92	0.000103	0.0144	-0.18	-0.18	Neuroticism;	chr8:10754565	chr8:11104691~11106704:-
HNSC	cis	rs9313772	0.775	rs13172797	ENSG00000254350.1	RP11-542A14.1	-3.92	0.000103	0.0144	-0.19	-0.18	Blood pressure;	chr5:158406009	chr5:158424585~158452758:+
HNSC	cis	rs7405404	0.672	rs6498448	ENSG00000262454.1	RP11-65J21.3	-3.92	0.000103	0.0144	-0.16	-0.18	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645962	chr16:14302288~14326353:+
HNSC	cis	rs4081724	0.63	rs17529595	ENSG00000267296.2	CEBPA-AS1	3.92	0.000103	0.0144	0.33	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315233	chr19:33302857~33305054:+
HNSC	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-3.92	0.000103	0.0144	-0.17	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
HNSC	cis	rs6493858	0.809	rs4310792	ENSG00000277245.1	RP11-48G14.3	-3.92	0.000103	0.0144	-0.2	-0.18	Relative hand skill in reading disability;	chr15:56134475	chr15:56447120~56447697:+
HNSC	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	3.92	0.000103	0.0144	0.18	0.18	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
HNSC	cis	rs6570726	0.846	rs4896824	ENSG00000270638.1	RP3-466P17.1	3.92	0.000103	0.0144	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145735570~145737218:+
HNSC	cis	rs10143078	0.661	rs11848791	ENSG00000258689.1	LINC01269	3.92	0.000103	0.0144	0.37	0.18	Blood pressure;	chr14:70472497	chr14:70698698~70712153:+
HNSC	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	3.92	0.000103	0.0144	0.24	0.18	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
HNSC	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	3.92	0.000103	0.0144	0.24	0.18	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
HNSC	cis	rs8054556	0.787	rs12325539	ENSG00000250616.2	RP11-455F5.3	3.92	0.000103	0.0144	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30096430~30104116:+
HNSC	cis	rs9487051	0.646	rs13203365	ENSG00000243587.6	C6orf183	-3.92	0.000103	0.0144	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109293607	chr6:109165833~109271014:+
HNSC	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-3.92	0.000103	0.0144	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
HNSC	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	3.92	0.000103	0.0144	0.25	0.18	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
HNSC	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-3.92	0.000103	0.0144	-0.15	-0.18	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
HNSC	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-3.92	0.000103	0.0144	-0.22	-0.18	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
HNSC	cis	rs6071166	0.683	rs6064884	ENSG00000224635.1	RP4-564F22.5	-3.92	0.000103	0.0144	-0.22	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38691352	chr20:38406011~38416797:-
HNSC	cis	rs10875746	0.859	rs11558768	ENSG00000257763.1	OR5BK1P	-3.92	0.000103	0.0144	-0.22	-0.18	Longevity (90 years and older);	chr12:48184006	chr12:48355792~48356614:-
HNSC	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-3.92	0.000103	0.0144	-0.25	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
HNSC	cis	rs2074409	0.571	rs67499664	ENSG00000276054.1	RP11-378E13.3	3.92	0.000103	0.0144	0.25	0.18	Response to angiotensin II receptor blocker therapy;	chr17:37533543	chr17:37386886~37387926:+
HNSC	cis	rs7809615	0.515	rs3843540	ENSG00000244219.5	GS1-259H13.2	-3.92	0.000103	0.0144	-0.28	-0.18	Blood metabolite ratios;	chr7:99529017	chr7:99598066~99610813:+
HNSC	cis	rs1620921	0.625	rs10945701	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000103	0.0144	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160845780	chr6:160931080~160969771:+
HNSC	cis	rs6674970	0.966	rs2091219	ENSG00000228126.1	FALEC	-3.92	0.000103	0.0144	-0.23	-0.18	Childhood ear infection;	chr1:151039584	chr1:150515757~150518032:+
HNSC	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-3.92	0.000103	0.0144	-0.18	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
HNSC	cis	rs4906332	1	rs12889703	ENSG00000244691.1	RPL10AP1	-3.92	0.000103	0.0144	-0.21	-0.18	Coronary artery disease;	chr14:103406614	chr14:103412119~103412761:-
HNSC	cis	rs2505998	0.716	rs1864401	ENSG00000273008.1	RP11-351D16.3	-3.92	0.000103	0.0144	-0.23	-0.18	Hirschsprung disease;	chr10:43110454	chr10:43136824~43138334:-
HNSC	cis	rs889398	0.967	rs7359336	ENSG00000226232.7	RP11-419C5.2	-3.92	0.000104	0.0144	-0.16	-0.18	Body mass index;	chr16:69699557	chr16:69976388~69996188:-
HNSC	cis	rs757081	0.648	rs12276859	ENSG00000260196.1	RP1-239B22.5	-3.92	0.000104	0.0144	-0.19	-0.18	Systolic blood pressure;	chr11:17255418	chr11:17380649~17383531:+
HNSC	cis	rs6490294	0.615	rs78729142	ENSG00000226469.1	ADAM1B	3.92	0.000104	0.0144	0.27	0.18	Mean platelet volume;	chr12:111919456	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.528	rs79976090	ENSG00000226469.1	ADAM1B	3.92	0.000104	0.0144	0.27	0.18	Mean platelet volume;	chr12:111928314	chr12:111927018~111929017:+
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000241549.7	GUSBP2	3.92	0.000104	0.0144	0.2	0.18	Parkinson's disease;	chr6:27885390	chr6:26871484~26956554:-
HNSC	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-3.92	0.000104	0.0144	-0.22	-0.18	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-3.92	0.000104	0.0144	-0.22	-0.18	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-3.92	0.000104	0.0144	-0.22	-0.18	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
HNSC	cis	rs28489187	0.73	rs233130	ENSG00000223653.4	RP11-131L23.1	3.92	0.000104	0.0144	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329429	chr1:85276715~85448124:+
HNSC	cis	rs9910055	0.659	rs7207464	ENSG00000267080.4	ASB16-AS1	-3.92	0.000104	0.0145	-0.14	-0.18	Total body bone mineral density;	chr17:44167665	chr17:44175973~44186717:-
HNSC	cis	rs1555322	0.929	rs2247828	ENSG00000126005.14	MMP24-AS1	3.92	0.000104	0.0145	0.32	0.18	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35216462~35278131:-
HNSC	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-3.92	0.000104	0.0145	-0.23	-0.18	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
HNSC	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-3.92	0.000104	0.0145	-0.23	-0.18	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
HNSC	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	3.92	0.000104	0.0145	0.21	0.18	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
HNSC	cis	rs10090774	0.841	rs4562374	ENSG00000279766.1	RP11-642A1.2	-3.92	0.000104	0.0145	-0.18	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722145	chr8:140572142~140572812:-
HNSC	cis	rs7824557	0.628	rs2572387	ENSG00000255020.1	AF131216.5	3.92	0.000104	0.0145	0.19	0.18	Retinal vascular caliber;	chr8:11346656	chr8:11345748~11347502:-
HNSC	cis	rs8031584	0.652	rs2691683	ENSG00000270015.1	RP11-540B6.6	3.92	0.000104	0.0145	0.19	0.18	Huntington's disease progression;	chr15:30842857	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.578	rs1088473	ENSG00000270015.1	RP11-540B6.6	3.92	0.000104	0.0145	0.19	0.18	Huntington's disease progression;	chr15:30847095	chr15:30926514~30928407:+
HNSC	cis	rs10090774	0.87	rs7834669	ENSG00000279766.1	RP11-642A1.2	-3.92	0.000104	0.0145	-0.18	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724287	chr8:140572142~140572812:-
HNSC	cis	rs9611565	0.527	rs73178638	ENSG00000235513.1	RP4-756G23.5	3.92	0.000104	0.0145	0.22	0.18	Vitiligo;	chr22:41546900	chr22:41209122~41217627:-
HNSC	cis	rs1620921	0.682	rs66561051	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000104	0.0145	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844112	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs67613705	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000104	0.0145	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844123	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.625	rs66940842	ENSG00000231863.1	RP3-428L16.1	-3.92	0.000104	0.0145	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160844158	chr6:160931080~160969771:+
HNSC	cis	rs4704187	0.663	rs1422697	ENSG00000272040.1	CTC-366B18.4	-3.92	0.000104	0.0145	-0.16	-0.18	Response to amphetamines;	chr5:75149992	chr5:75608817~75609983:+
HNSC	cis	rs7824557	0.569	rs35418978	ENSG00000255310.2	AF131215.2	3.92	0.000104	0.0145	0.17	0.18	Retinal vascular caliber;	chr8:11328944	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.606	rs2736264	ENSG00000255310.2	AF131215.2	3.92	0.000104	0.0145	0.17	0.18	Retinal vascular caliber;	chr8:11329130	chr8:11107788~11109726:-
HNSC	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-3.92	0.000104	0.0145	-0.22	-0.18	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
HNSC	cis	rs6088580	0.634	rs6088475	ENSG00000276073.1	RP5-1125A11.7	3.91	0.000104	0.0145	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6142153	ENSG00000276073.1	RP5-1125A11.7	3.91	0.000104	0.0145	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs7271970	ENSG00000276073.1	RP5-1125A11.7	3.91	0.000104	0.0145	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:33985617~33988989:-
HNSC	cis	rs10832169	0.565	rs1919312	ENSG00000254418.1	RP11-21L19.1	3.91	0.000104	0.0145	0.22	0.18	Blood protein levels;	chr11:14030967	chr11:14262846~14273691:-
HNSC	cis	rs10510102	1	rs6585764	ENSG00000273891.1	RP11-500G22.5	3.91	0.000104	0.0145	0.19	0.18	Breast cancer;	chr10:121837308	chr10:121965764~121967700:+
HNSC	cis	rs17594362	0.697	rs1023031	ENSG00000229473.2	RGS17P1	-3.91	0.000104	0.0145	-0.25	-0.18	Multiple sclerosis;	chr13:41578269	chr13:40992779~40993331:-
HNSC	cis	rs72717009	0.825	rs12722986	ENSG00000225217.1	HSPA7	-3.91	0.000104	0.0145	-0.3	-0.18	Rheumatoid arthritis;	chr1:161495630	chr1:161606291~161608217:+
HNSC	cis	rs1028883	0.87	rs12876036	ENSG00000228295.1	LINC00392	3.91	0.000104	0.0145	0.19	0.18	Lean body mass;	chr13:73550539	chr13:73564244~73588070:+
HNSC	cis	rs913655	0.508	rs10826382	ENSG00000225527.1	RP11-383B4.4	-3.91	0.000104	0.0145	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18763671	chr10:18531849~18533336:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000104	0.0145	-0.25	-0.18	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
HNSC	cis	rs13256369	1	rs4840351	ENSG00000173295.6	FAM86B3P	3.91	0.000104	0.0145	0.23	0.18	Obesity-related traits;	chr8:8715638	chr8:8228595~8244865:+
HNSC	cis	rs1552244	1	rs55822690	ENSG00000180385.7	EMC3-AS1	3.91	0.000104	0.0145	0.2	0.18	Alzheimer's disease;	chr3:10086319	chr3:9986893~10006990:+
HNSC	cis	rs7572733	0.515	rs35730302	ENSG00000231621.1	AC013264.2	3.91	0.000104	0.0145	0.17	0.18	Dermatomyositis;	chr2:197953902	chr2:197197991~197199273:+
HNSC	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-3.91	0.000104	0.0145	-0.21	-0.18	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
HNSC	cis	rs2016266	0.859	rs10747668	ENSG00000270175.1	RP11-793H13.11	-3.91	0.000104	0.0145	-0.18	-0.18	Bone mineral density;Bone mineral density (spine);	chr12:53343677	chr12:53500162~53500936:-
HNSC	cis	rs728616	0.867	rs17606361	ENSG00000225484.5	NUTM2B-AS1	-3.91	0.000104	0.0145	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.764	rs61859016	ENSG00000225484.5	NUTM2B-AS1	-3.91	0.000104	0.0145	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79663088~79826594:-
HNSC	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-3.91	0.000104	0.0145	-0.21	-0.18	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
HNSC	cis	rs516805	0.561	rs7772659	ENSG00000279453.1	RP3-425C14.4	3.91	0.000104	0.0145	0.27	0.18	Lymphocyte counts;	chr6:122608055	chr6:122436789~122439223:-
HNSC	cis	rs4713118	0.955	rs9468201	ENSG00000226314.6	ZNF192P1	-3.91	0.000104	0.0145	-0.22	-0.18	Parkinson's disease;	chr6:27719256	chr6:28161781~28169594:+
HNSC	cis	rs868153	0.625	rs1456696	ENSG00000275339.1	RP3-425C14.6	3.91	0.000104	0.0145	0.19	0.18	Vertical cup-disc ratio;	chr6:122189741	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.59	rs1947540	ENSG00000275339.1	RP3-425C14.6	3.91	0.000104	0.0145	0.19	0.18	Vertical cup-disc ratio;	chr6:122191029	chr6:122454358~122454612:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000272831.1	RP11-792A8.4	3.91	0.000104	0.0145	0.15	0.18	Calcium levels;	chr7:65977808	chr7:66739829~66740385:-
HNSC	cis	rs4713118	0.523	rs2179096	ENSG00000219392.1	RP1-265C24.5	-3.91	0.000104	0.0145	-0.2	-0.18	Parkinson's disease;	chr6:27698141	chr6:28115628~28116551:+
HNSC	cis	rs3736485	0.966	rs4144941	ENSG00000259438.1	CTD-2650P22.1	3.91	0.000104	0.0145	0.19	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51504609	chr15:52010999~52019095:-
HNSC	cis	rs1937680	0.644	rs10823860	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51907683	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7081919	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51907716	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7083138	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51907826	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs6480564	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51908107	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs6480565	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51908125	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs6480566	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51908215	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7922170	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51909173	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7908238	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51909298	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7100489	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000104	0.0145	-0.26	-0.18	Breast cancer;	chr10:51909411	chr10:52230742~52314128:-
HNSC	cis	rs6430585	0.591	rs3098103	ENSG00000231890.6	DARS-AS1	-3.91	0.000104	0.0145	-0.31	-0.18	Corneal structure;	chr2:135898524	chr2:135985176~136022593:+
HNSC	cis	rs2919009	0.607	rs61872773	ENSG00000271670.1	RP11-95I16.4	3.91	0.000104	0.0145	0.23	0.18	Obesity-related traits;	chr10:120946998	chr10:120879256~120880667:-
HNSC	cis	rs1799949	0.965	rs4793234	ENSG00000236383.6	LINC00854	-3.91	0.000104	0.0145	-0.17	-0.18	Menopause (age at onset);	chr17:43358815	chr17:43216941~43305976:-
HNSC	cis	rs4388249	1	rs59909009	ENSG00000271849.1	CTC-332L22.1	-3.91	0.000104	0.0145	-0.28	-0.18	Schizophrenia;	chr5:109763460	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs34247538	ENSG00000271849.1	CTC-332L22.1	-3.91	0.000104	0.0145	-0.28	-0.18	Schizophrenia;	chr5:109763834	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs13189235	ENSG00000271849.1	CTC-332L22.1	-3.91	0.000104	0.0145	-0.28	-0.18	Schizophrenia;	chr5:109764190	chr5:109687802~109688329:-
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000226314.6	ZNF192P1	-3.91	0.000104	0.0145	-0.2	-0.18	Depression;	chr6:28386473	chr6:28161781~28169594:+
HNSC	cis	rs7621025	0.586	rs34553037	ENSG00000273486.1	RP11-731C17.2	-3.91	0.000104	0.0146	-0.17	-0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136837338~136839021:-
HNSC	cis	rs11951515	0.738	rs12515072	ENSG00000249286.1	CTD-2210P15.2	3.91	0.000104	0.0146	0.19	0.18	Metabolite levels  (X-11787);	chr5:43313974	chr5:43586918~43588223:-
HNSC	cis	rs3736485	0.934	rs11635216	ENSG00000259438.1	CTD-2650P22.1	-3.91	0.000104	0.0146	-0.18	-0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51579750	chr15:52010999~52019095:-
HNSC	cis	rs62025270	0.632	rs62022943	ENSG00000259762.1	RP11-158M2.4	-3.91	0.000104	0.0146	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85750336~85752901:-
HNSC	cis	rs2439831	1	rs2467739	ENSG00000275601.1	AC011330.13	-3.91	0.000105	0.0146	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43447998	chr15:43642389~43643023:-
HNSC	cis	rs4704187	0.687	rs1600074	ENSG00000272040.1	CTC-366B18.4	-3.91	0.000105	0.0146	-0.16	-0.18	Response to amphetamines;	chr5:75140749	chr5:75608817~75609983:+
HNSC	cis	rs4388249	1	rs2300999	ENSG00000271849.1	CTC-332L22.1	3.91	0.000105	0.0146	0.29	0.18	Schizophrenia;	chr5:109749106	chr5:109687802~109688329:-
HNSC	cis	rs172166	0.516	rs1225715	ENSG00000219392.1	RP1-265C24.5	3.91	0.000105	0.0146	0.21	0.18	Cardiac Troponin-T levels;	chr6:28145595	chr6:28115628~28116551:+
HNSC	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000105	0.0146	-0.22	-0.18	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
HNSC	cis	rs7824557	0.564	rs34964435	ENSG00000269918.1	AF131215.9	-3.91	0.000105	0.0146	-0.17	-0.18	Retinal vascular caliber;	chr8:11372697	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	3.91	0.000105	0.0146	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
HNSC	cis	rs739496	0.615	rs630616	ENSG00000226469.1	ADAM1B	3.91	0.000105	0.0146	0.21	0.18	Platelet count;	chr12:111721162	chr12:111927018~111929017:+
HNSC	cis	rs2518049	0.852	rs6601899	ENSG00000224034.1	RP11-445P17.8	-3.91	0.000105	0.0146	-0.24	-0.18	Metabolic traits;	chr10:5076130	chr10:5266033~5271236:-
HNSC	cis	rs240993	0.516	rs240981	ENSG00000230177.1	RP5-1112D6.4	-3.91	0.000105	0.0146	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111277932~111278742:+
HNSC	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	3.91	0.000105	0.0146	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
HNSC	cis	rs1028883	0.571	rs9530210	ENSG00000228295.1	LINC00392	3.91	0.000105	0.0146	0.18	0.18	Lean body mass;	chr13:73605775	chr13:73564244~73588070:+
HNSC	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	3.91	0.000105	0.0146	0.19	0.18	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
HNSC	cis	rs7189233	0.955	rs72801821	ENSG00000279344.1	RP11-44F14.7	3.91	0.000105	0.0146	0.17	0.18	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53478957~53481550:-
HNSC	cis	rs7429990	0.896	rs34448818	ENSG00000228638.1	FCF1P2	-3.91	0.000105	0.0146	-0.19	-0.18	Educational attainment (years of education);	chr3:47799822	chr3:48290793~48291375:-
HNSC	cis	rs10129255	0.913	rs10140943	ENSG00000211974.3	IGHV2-70	3.91	0.000105	0.0146	0.17	0.18	Kawasaki disease;	chr14:106767441	chr14:106723574~106724093:-
HNSC	cis	rs73173548	0.528	rs13161403	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000105	0.0146	0.18	0.18	Macular telangiectasia type 2;	chr5:88471144	chr5:88268895~88436685:+
HNSC	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	3.91	0.000105	0.0146	0.25	0.18	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	3.91	0.000105	0.0146	0.25	0.18	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
HNSC	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-3.91	0.000105	0.0146	-0.19	-0.18	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
HNSC	cis	rs6710503	0.527	rs10432678	ENSG00000271936.1	RP11-443B20.1	3.91	0.000105	0.0146	0.17	0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24540940	chr2:24825610~24826717:+
HNSC	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	3.91	0.000105	0.0146	0.3	0.18	QT interval;	chr4:75108738	chr4:75081702~75084717:-
HNSC	cis	rs11846409	0.872	rs74091715	ENSG00000280411.1	IGHV1-69-2	-3.91	0.000105	0.0146	-0.16	-0.18	Rheumatic heart disease;	chr14:106637731	chr14:106762092~106762588:-
HNSC	cis	rs12935418	0.616	rs12446053	ENSG00000261061.1	RP11-303E16.2	3.91	0.000105	0.0146	0.24	0.18	Mean corpuscular volume;	chr16:80930234	chr16:81030770~81031485:+
HNSC	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-3.91	0.000105	0.0146	-0.2	-0.18	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
HNSC	cis	rs924712	0.513	rs12210299	ENSG00000224984.1	RP11-524H19.2	-3.91	0.000105	0.0146	-0.21	-0.18	Breast cancer;	chr6:54851386	chr6:54840118~54840855:-
HNSC	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	3.91	0.000105	0.0146	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
HNSC	cis	rs10849893	0.576	rs7296507	ENSG00000258435.1	RP11-711D18.2	-3.91	0.000105	0.0146	-0.18	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121409332	chr12:121391962~121399859:+
HNSC	cis	rs13434995	0.842	rs62309730	ENSG00000273257.1	RP11-177J6.1	-3.91	0.000105	0.0146	-0.29	-0.18	Adiponectin levels;	chr4:55541530	chr4:55387949~55388271:+
HNSC	cis	rs739496	0.615	rs11609628	ENSG00000226469.1	ADAM1B	3.91	0.000105	0.0146	0.21	0.18	Platelet count;	chr12:111779404	chr12:111927018~111929017:+
HNSC	cis	rs6490294	0.651	rs440	ENSG00000226469.1	ADAM1B	3.91	0.000105	0.0146	0.21	0.18	Mean platelet volume;	chr12:111790910	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.615	rs4646777	ENSG00000226469.1	ADAM1B	3.91	0.000105	0.0146	0.21	0.18	Platelet count;	chr12:111792232	chr12:111927018~111929017:+
HNSC	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	3.91	0.000105	0.0146	0.24	0.18	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
HNSC	cis	rs11893307	0.537	rs1558473	ENSG00000228509.4	AC006460.2	3.91	0.000105	0.0146	0.23	0.18	Mean platelet volume;	chr2:190639338	chr2:190676944~190708716:-
HNSC	cis	rs6570726	0.846	rs7762536	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.0146	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs952406	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.0146	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.818	rs952405	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.0146	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145735570~145737218:+
HNSC	cis	rs638893	0.53	rs1961138	ENSG00000255422.1	AP002954.4	-3.91	0.000105	0.0146	-0.29	-0.18	Vitiligo;	chr11:118748714	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.578	rs485901	ENSG00000255422.1	AP002954.4	-3.91	0.000105	0.0146	-0.29	-0.18	Vitiligo;	chr11:118751536	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.578	rs580079	ENSG00000255422.1	AP002954.4	-3.91	0.000105	0.0146	-0.29	-0.18	Vitiligo;	chr11:118754900	chr11:118704607~118750263:+
HNSC	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-3.91	0.000105	0.0146	-0.17	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
HNSC	cis	rs11867934	0.861	rs4985740	ENSG00000223979.2	SMCR2	-3.91	0.000105	0.0146	-0.22	-0.18	Diabetic retinopathy;	chr17:17181334	chr17:17674026~17677688:-
HNSC	cis	rs35851103	0.6	rs4841662	ENSG00000255310.2	AF131215.2	-3.91	0.000105	0.0146	-0.16	-0.18	Neuroticism;	chr8:11986249	chr8:11107788~11109726:-
HNSC	cis	rs870825	0.616	rs6833858	ENSG00000254233.1	RP11-242J7.1	3.91	0.000105	0.0146	0.25	0.18	Blood protein levels;	chr4:184718807	chr4:184584093~184625030:-
HNSC	cis	rs67981189	0.593	rs4147077	ENSG00000274818.1	RP1-292L20.3	3.91	0.000105	0.0146	0.2	0.18	Schizophrenia;	chr14:70988153	chr14:70906657~70907111:-
HNSC	cis	rs6697139	1	rs6697139	ENSG00000215840.3	RP11-122G18.7	3.91	0.000105	0.0146	0.24	0.18	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;	chr1:161690906	chr1:161406068~161407082:+
HNSC	cis	rs478304	0.651	rs11227299	ENSG00000255120.4	OVOL1-AS1	-3.91	0.000105	0.0146	-0.19	-0.18	Acne (severe);	chr11:65782099	chr11:65789051~65790868:-
HNSC	cis	rs6928977	0.869	rs6912933	ENSG00000231028.7	LINC00271	3.91	0.000105	0.0146	0.21	0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306396	chr6:135497801~135716055:+
HNSC	cis	rs792448	0.717	rs1992643	ENSG00000226251.4	RP11-15I11.3	-3.91	0.000105	0.0146	-0.22	-0.18	White blood cell count (basophil);	chr1:212281682	chr1:212225278~212238977:-
HNSC	cis	rs1912702	0.824	rs7102569	ENSG00000255345.1	CTD-2337I7.1	3.91	0.000105	0.0146	0.21	0.18	Hair greying;	chr11:79473855	chr11:79092848~79098003:+
HNSC	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-3.91	0.000105	0.0146	-0.2	-0.18	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
HNSC	cis	rs72827839	0.779	rs58953228	ENSG00000272763.1	RP11-357H14.17	-3.91	0.000105	0.0146	-0.26	-0.18	Ease of getting up in the morning;	chr17:48436452	chr17:48635923~48647023:-
HNSC	cis	rs9611565	0.659	rs4822034	ENSG00000235513.1	RP4-756G23.5	3.91	0.000105	0.0146	0.21	0.18	Vitiligo;	chr22:41535006	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.625	rs9611606	ENSG00000235513.1	RP4-756G23.5	3.91	0.000105	0.0146	0.21	0.18	Vitiligo;	chr22:41535070	chr22:41209122~41217627:-
HNSC	cis	rs7121616	0.961	rs11218976	ENSG00000200879.1	SNORD14E	3.91	0.000105	0.0146	0.22	0.18	Breast cancer;	chr11:123090950	chr11:123058077~123058161:-
HNSC	cis	rs4834770	0.668	rs6833072	ENSG00000249244.1	RP11-548H18.2	-3.91	0.000105	0.0146	-0.2	-0.18	Blood protein levels;	chr4:119212737	chr4:119391831~119395335:-
HNSC	cis	rs9880211	0.718	rs35320690	ENSG00000239213.4	NCK1-AS1	-3.91	0.000105	0.0146	-0.17	-0.18	Height;Body mass index;	chr3:136213652	chr3:136841726~136862054:-
HNSC	cis	rs6787172	0.782	rs6780782	ENSG00000272087.1	RP11-379F4.7	3.91	0.000105	0.0146	0.19	0.18	Subjective well-being;	chr3:158468546	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.728	rs7649463	ENSG00000272087.1	RP11-379F4.7	3.91	0.000105	0.0146	0.19	0.18	Subjective well-being;	chr3:158472524	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs1595030	ENSG00000272087.1	RP11-379F4.7	3.91	0.000105	0.0146	0.19	0.18	Subjective well-being;	chr3:158475878	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs6441203	ENSG00000272087.1	RP11-379F4.7	3.91	0.000105	0.0146	0.19	0.18	Subjective well-being;	chr3:158476351	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs11714821	ENSG00000272087.1	RP11-379F4.7	3.91	0.000105	0.0146	0.19	0.18	Subjective well-being;	chr3:158476896	chr3:158693120~158693768:-
HNSC	cis	rs4081724	0.63	rs41344151	ENSG00000267296.2	CEBPA-AS1	3.91	0.000105	0.0146	0.34	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33304803	chr19:33302857~33305054:+
HNSC	cis	rs12030196	0.827	rs12025175	ENSG00000230812.4	LINC01358	3.91	0.000105	0.0146	0.2	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967225	chr1:59020387~59044614:+
HNSC	cis	rs7246657	0.722	rs1291	ENSG00000276846.1	CTD-3220F14.3	-3.91	0.000105	0.0147	-0.23	-0.18	Coronary artery calcification;	chr19:37738477	chr19:37314868~37315620:-
HNSC	cis	rs1620921	0.563	rs2465848	ENSG00000231863.1	RP3-428L16.1	-3.91	0.000105	0.0147	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160858991	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.563	rs2465849	ENSG00000231863.1	RP3-428L16.1	-3.91	0.000105	0.0147	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160859135	chr6:160931080~160969771:+
HNSC	cis	rs6430585	0.583	rs2839740	ENSG00000231890.6	DARS-AS1	-3.91	0.000105	0.0147	-0.32	-0.18	Corneal structure;	chr2:135891313	chr2:135985176~136022593:+
HNSC	cis	rs80130819	0.515	rs1635536	ENSG00000278385.1	RP11-89H19.2	3.91	0.000105	0.0147	0.29	0.18	Prostate cancer;	chr12:47992162	chr12:47905122~47906865:+
HNSC	cis	rs1665050	0.534	rs8031213	ENSG00000259732.1	RP11-59H7.3	-3.91	0.000105	0.0147	-0.23	-0.18	Atopic dermatitis;	chr15:58947698	chr15:59121034~59133250:+
HNSC	cis	rs683257	0.81	rs72984118	ENSG00000234147.1	RP3-460G2.2	-3.91	0.000105	0.0147	-0.36	-0.18	Facial emotion recognition (angry faces);	chr6:140695169	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.789	rs72984124	ENSG00000234147.1	RP3-460G2.2	-3.91	0.000105	0.0147	-0.36	-0.18	Facial emotion recognition (angry faces);	chr6:140700308	chr6:140845958~140852924:-
HNSC	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-3.91	0.000105	0.0147	-0.18	-0.18	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
HNSC	cis	rs17292804	0.527	rs12887734	ENSG00000269958.1	RP11-73M18.8	3.91	0.000105	0.0147	0.17	0.18	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103696353~103697163:+
HNSC	cis	rs295490	0.748	rs41399544	ENSG00000272656.1	RP11-219D15.3	3.91	0.000105	0.0147	0.39	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139349024~139349371:-
HNSC	cis	rs17594362	0.697	rs2875448	ENSG00000229473.2	RGS17P1	-3.91	0.000105	0.0147	-0.25	-0.18	Multiple sclerosis;	chr13:41569686	chr13:40992779~40993331:-
HNSC	cis	rs17594362	0.697	rs9562321	ENSG00000229473.2	RGS17P1	-3.91	0.000105	0.0147	-0.25	-0.18	Multiple sclerosis;	chr13:41570717	chr13:40992779~40993331:-
HNSC	cis	rs1620921	0.625	rs9355841	ENSG00000231863.1	RP3-428L16.1	-3.91	0.000105	0.0147	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160846303	chr6:160931080~160969771:+
HNSC	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-3.91	0.000105	0.0147	-0.18	-0.18	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
HNSC	cis	rs801193	1	rs4717319	ENSG00000272831.1	RP11-792A8.4	3.91	0.000106	0.0147	0.15	0.18	Aortic root size;	chr7:66777606	chr7:66739829~66740385:-
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000272831.1	RP11-792A8.4	3.91	0.000106	0.0147	0.15	0.18	Aortic root size;	chr7:66777742	chr7:66739829~66740385:-
HNSC	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000106	0.0147	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
HNSC	cis	rs67981189	0.572	rs2810079	ENSG00000274818.1	RP1-292L20.3	-3.91	0.000106	0.0147	-0.2	-0.18	Schizophrenia;	chr14:70892554	chr14:70906657~70907111:-
HNSC	cis	rs1799949	0.965	rs4793233	ENSG00000236383.6	LINC00854	-3.91	0.000106	0.0147	-0.17	-0.18	Menopause (age at onset);	chr17:43358069	chr17:43216941~43305976:-
HNSC	cis	rs10742752	0.676	rs7943688	ENSG00000254651.1	RP11-430H10.3	-3.91	0.000106	0.0147	-0.21	-0.18	Body mass index;	chr11:45425174	chr11:45399448~45400528:+
HNSC	cis	rs2657294	0.895	rs4746262	ENSG00000233313.2	HMGA1P5	-3.91	0.000106	0.0147	-0.2	-0.18	Pneumonia;	chr10:75093631	chr10:75276376~75276646:-
HNSC	cis	rs72827839	0.779	rs57583172	ENSG00000210741.1	MIR196A1	-3.91	0.000106	0.0147	-0.22	-0.18	Ease of getting up in the morning;	chr17:48404601	chr17:48632490~48632559:-
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000106610.13	STAG3L4	-3.91	0.000106	0.0147	-0.35	-0.18	Diabetic kidney disease;	chr7:66357373	chr7:67302621~67321526:+
HNSC	cis	rs13043901	0.95	rs2766664	ENSG00000197670.6	RP4-724E16.2	3.91	0.000106	0.0147	0.17	0.18	Type 2 diabetes (age of onset);	chr20:53554702	chr20:53552770~53575863:+
HNSC	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-3.91	0.000106	0.0147	-0.21	-0.18	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
HNSC	cis	rs987724	0.515	rs11914959	ENSG00000243926.1	TIPARP-AS1	3.91	0.000106	0.0147	0.2	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898616	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.501	rs4680313	ENSG00000243926.1	TIPARP-AS1	3.91	0.000106	0.0147	0.2	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901348	chr3:156671862~156674378:-
HNSC	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	3.91	0.000106	0.0147	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
HNSC	cis	rs11098499	0.73	rs12505735	ENSG00000250412.1	KLHL2P1	3.91	0.000106	0.0147	0.23	0.18	Corneal astigmatism;	chr4:119611801	chr4:119334329~119378233:+
HNSC	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-3.91	0.000106	0.0147	-0.23	-0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
HNSC	cis	rs1713985	0.8	rs4280804	ENSG00000269949.1	RP11-738E22.3	-3.91	0.000106	0.0147	-0.35	-0.18	Age-related macular degeneration;	chr4:56928204	chr4:56960927~56961373:-
HNSC	cis	rs7824557	0.564	rs34389419	ENSG00000269918.1	AF131215.9	-3.91	0.000106	0.0147	-0.17	-0.18	Retinal vascular caliber;	chr8:11371810	chr8:11104691~11106704:-
HNSC	cis	rs1008375	1	rs2872959	ENSG00000249502.1	AC006160.5	3.91	0.000106	0.0147	0.19	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675540	chr4:17587467~17614571:-
HNSC	cis	rs10129255	0.5	rs10142931	ENSG00000211976.2	IGHV3-73	-3.91	0.000106	0.0147	-0.13	-0.18	Kawasaki disease;	chr14:106782288	chr14:106802694~106803233:-
HNSC	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-3.91	0.000106	0.0147	-0.18	-0.18	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
HNSC	cis	rs6490294	0.904	rs76300790	ENSG00000234608.6	MAPKAPK5-AS1	3.91	0.000106	0.0147	0.14	0.18	Mean platelet volume;	chr12:111964865	chr12:111839764~111842902:-
HNSC	cis	rs4930561	0.714	rs7126326	ENSG00000184795.9	UNC93B5	-3.91	0.000106	0.0147	-0.21	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68179808	chr11:67711702~67716005:-
HNSC	cis	rs11951515	0.663	rs11746629	ENSG00000249286.1	CTD-2210P15.2	3.91	0.000106	0.0147	0.19	0.18	Metabolite levels  (X-11787);	chr5:43284109	chr5:43586918~43588223:-
HNSC	cis	rs67981189	0.634	rs221891	ENSG00000274818.1	RP1-292L20.3	-3.91	0.000106	0.0147	-0.2	-0.18	Schizophrenia;	chr14:71144910	chr14:70906657~70907111:-
HNSC	cis	rs11231017	0.507	rs11231058	ENSG00000250659.2	RP11-864I4.3	-3.91	0.000106	0.0147	-0.22	-0.18	HIV-1 viral setpoint;	chr11:62371418	chr11:62537312~62542018:+
HNSC	cis	rs6601327	0.602	rs12678014	ENSG00000233609.3	RP11-62H7.2	3.91	0.000106	0.0147	0.17	0.18	Multiple myeloma (hyperdiploidy);	chr8:9791655	chr8:8961200~8979025:+
HNSC	cis	rs2179367	0.959	rs585022	ENSG00000216906.2	RP11-350J20.9	3.91	0.000106	0.0147	0.22	0.18	Dupuytren's disease;	chr6:149432168	chr6:149904243~149906418:+
HNSC	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-3.91	0.000106	0.0147	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
HNSC	cis	rs987724	0.57	rs4680318	ENSG00000243926.1	TIPARP-AS1	3.91	0.000106	0.0147	0.21	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953850	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs4234315	ENSG00000243926.1	TIPARP-AS1	3.91	0.000106	0.0147	0.21	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955749	chr3:156671862~156674378:-
HNSC	cis	rs913672	0.637	rs2274951	ENSG00000224397.4	LINC01272	3.91	0.000106	0.0147	0.24	0.18	Monocyte count;	chr20:50277933	chr20:50267486~50279795:+
HNSC	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	3.91	0.000106	0.0147	0.18	0.18	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
HNSC	cis	rs12986445	0.947	rs12713690	ENSG00000218682.1	AC010150.1	3.91	0.000106	0.0147	0.24	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25895227	chr2:25856461~25856966:-
HNSC	cis	rs3018712	0.532	rs948861	ENSG00000212093.1	AP000807.1	-3.91	0.000106	0.0147	-0.26	-0.18	Total body bone mineral density;	chr11:68653154	chr11:68506083~68506166:-
HNSC	cis	rs3018712	0.532	rs948863	ENSG00000212093.1	AP000807.1	-3.91	0.000106	0.0147	-0.26	-0.18	Total body bone mineral density;	chr11:68653506	chr11:68506083~68506166:-
HNSC	cis	rs4835473	0.9	rs6834494	ENSG00000249741.2	RP11-673E1.3	3.91	0.000106	0.0147	0.2	0.18	Immature fraction of reticulocytes;	chr4:143822257	chr4:143911514~143912053:-
HNSC	cis	rs6710503	0.962	rs56293917	ENSG00000271936.1	RP11-443B20.1	-3.91	0.000106	0.0147	-0.19	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24713548	chr2:24825610~24826717:+
HNSC	cis	rs9987353	0.83	rs7010108	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000106	0.0147	-0.25	-0.18	Recombination measurement;	chr8:9273164	chr8:9141424~9145435:+
HNSC	cis	rs9925964	0.9	rs56813533	ENSG00000232748.3	RP11-196G11.6	3.91	0.000106	0.0147	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:31056460~31062803:+
HNSC	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000106	0.0147	0.18	0.18	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000106	0.0147	0.18	0.18	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000106	0.0147	0.18	0.18	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
HNSC	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-3.91	0.000106	0.0147	-0.18	-0.18	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
HNSC	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-3.91	0.000106	0.0147	-0.22	-0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
HNSC	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-3.91	0.000106	0.0148	-0.2	-0.18	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-3.91	0.000106	0.0148	-0.2	-0.18	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
HNSC	cis	rs2013441	0.795	rs6587064	ENSG00000261033.1	RP11-209D14.2	3.91	0.000106	0.0148	0.21	0.18	Obesity-related traits;	chr17:20304571	chr17:20008051~20009234:-
HNSC	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	3.91	0.000106	0.0148	0.18	0.18	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
HNSC	cis	rs6601327	0.641	rs12542457	ENSG00000233609.3	RP11-62H7.2	-3.91	0.000106	0.0148	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9707090	chr8:8961200~8979025:+
HNSC	cis	rs828999	0.583	rs12047398	ENSG00000280186.1	RP11-483I13.6	-3.91	0.000106	0.0148	-0.19	-0.18	Monocyte percentage of white cells;	chr1:108150683	chr1:108200413~108202743:+
HNSC	cis	rs6095360	0.87	rs1569749	ENSG00000222365.1	SNORD12B	-3.91	0.000106	0.0148	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:48984972	chr20:49280319~49280409:+
HNSC	cis	rs73201462	1	rs2999076	ENSG00000231305.3	RP11-723O4.2	3.91	0.000106	0.0148	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239849	chr3:128861313~128871540:-
HNSC	cis	rs11992162	0.551	rs59191504	ENSG00000255495.1	AC145124.2	-3.91	0.000106	0.0148	-0.2	-0.18	Monocyte count;	chr8:11927572	chr8:12194467~12196280:+
HNSC	cis	rs7011507	0.7	rs72639010	ENSG00000253608.1	RP11-770E5.1	-3.91	0.000106	0.0148	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48417761	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs72639011	ENSG00000253608.1	RP11-770E5.1	-3.91	0.000106	0.0148	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48419755	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs72639012	ENSG00000253608.1	RP11-770E5.1	-3.91	0.000106	0.0148	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48419869	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs72639013	ENSG00000253608.1	RP11-770E5.1	-3.91	0.000106	0.0148	-0.33	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr8:48420070	chr8:48551567~48698510:+
HNSC	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-3.91	0.000106	0.0148	-0.14	-0.18	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
HNSC	cis	rs11083475	0.714	rs7248584	ENSG00000207296.1	RNU6-140P	-3.91	0.000106	0.0148	-0.18	-0.18	Heart rate;	chr19:38767470	chr19:38797002~38797109:-
HNSC	cis	rs72627123	1	rs72627126	ENSG00000259065.1	RP5-1021I20.1	-3.91	0.000106	0.0148	-0.31	-0.18	Morning vs. evening chronotype;	chr14:73903321	chr14:73787360~73803270:+
HNSC	cis	rs12701220	0.894	rs12701348	ENSG00000224079.1	AC091729.7	3.91	0.000106	0.0148	0.27	0.18	Bronchopulmonary dysplasia;	chr7:999821	chr7:1074450~1078036:+
HNSC	cis	rs7615952	0.515	rs7637246	ENSG00000248787.1	RP11-666A20.4	-3.91	0.000106	0.0148	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125959863	chr3:125908005~125910272:-
HNSC	cis	rs9914544	0.545	rs8066636	ENSG00000264885.1	RP11-815I9.4	-3.91	0.000106	0.0148	-0.18	-0.18	Educational attainment (years of education);	chr17:18857796	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.564	rs11548434	ENSG00000264885.1	RP11-815I9.4	-3.91	0.000106	0.0148	-0.18	-0.18	Educational attainment (years of education);	chr17:18858195	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.678	rs28374894	ENSG00000264885.1	RP11-815I9.4	-3.91	0.000106	0.0148	-0.18	-0.18	Educational attainment (years of education);	chr17:18858346	chr17:18667629~18669461:-
HNSC	cis	rs4924935	0.509	rs28540773	ENSG00000264885.1	RP11-815I9.4	-3.91	0.000106	0.0148	-0.18	-0.18	Pancreatic cancer;	chr17:18858441	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs8068683	ENSG00000264885.1	RP11-815I9.4	-3.91	0.000106	0.0148	-0.18	-0.18	Educational attainment (years of education);	chr17:18858514	chr17:18667629~18669461:-
HNSC	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-3.91	0.000106	0.0148	-0.19	-0.18	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
HNSC	cis	rs6071524	0.5	rs2247054	ENSG00000224635.1	RP4-564F22.5	3.91	0.000106	0.0148	0.21	0.18	Autism spectrum disorder or schizophrenia;	chr20:38736338	chr20:38406011~38416797:-
HNSC	cis	rs75422866	0.764	rs67408202	ENSG00000276691.1	RP5-1057I20.5	3.91	0.000106	0.0148	0.33	0.18	Pneumonia;	chr12:47713564	chr12:47788426~47788971:+
HNSC	cis	rs75422866	0.867	rs57848393	ENSG00000276691.1	RP5-1057I20.5	3.91	0.000106	0.0148	0.33	0.18	Pneumonia;	chr12:47714734	chr12:47788426~47788971:+
HNSC	cis	rs202072	0.722	rs202069	ENSG00000215022.6	RP1-257A7.4	-3.91	0.000106	0.0148	-0.26	-0.18	HIV-1 viral setpoint;	chr6:13267009	chr6:13264861~13295586:-
HNSC	cis	rs7267979	0.789	rs62213729	ENSG00000204556.4	CTD-2514C3.1	3.91	0.000106	0.0148	0.23	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26018832~26020684:+
HNSC	cis	rs10129255	0.5	rs6576226	ENSG00000224373.3	IGHV4-59	3.91	0.000106	0.0148	0.1	0.18	Kawasaki disease;	chr14:106778135	chr14:106627249~106627825:-
HNSC	cis	rs10754283	0.557	rs1215508	ENSG00000231613.1	RP5-943J3.1	3.91	0.000106	0.0148	0.2	0.18	Amyotrophic lateral sclerosis (sporadic);	chr1:89623138	chr1:89788914~89790492:+
HNSC	cis	rs597539	0.552	rs6591360	ENSG00000261625.1	RP11-554A11.4	-3.91	0.000106	0.0148	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:69000765~69002048:-
HNSC	cis	rs1937680	0.572	rs7082269	ENSG00000236671.6	PRKG1-AS1	-3.91	0.000106	0.0148	-0.25	-0.18	Breast cancer;	chr10:51891203	chr10:52230742~52314128:-
HNSC	cis	rs2274089	0.737	rs990850	ENSG00000272462.2	U91328.19	-3.91	0.000106	0.0148	-0.32	-0.18	Iron status biomarkers;	chr6:25628283	chr6:25992662~26001775:+
HNSC	cis	rs4713118	0.869	rs9461405	ENSG00000216901.1	AL022393.7	3.91	0.000106	0.0148	0.22	0.18	Parkinson's disease;	chr6:27751596	chr6:28176188~28176674:+
HNSC	cis	rs11976180	1	rs2961118	ENSG00000244479.5	OR2A1-AS1	3.91	0.000106	0.0148	0.2	0.18	Obesity-related traits;	chr7:144058350	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2371244	ENSG00000244479.5	OR2A1-AS1	3.91	0.000106	0.0148	0.2	0.18	Obesity-related traits;	chr7:144060518	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs4726669	ENSG00000244479.5	OR2A1-AS1	3.91	0.000106	0.0148	0.2	0.18	Obesity-related traits;	chr7:144061098	chr7:144251264~144356181:-
HNSC	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-3.91	0.000106	0.0148	-0.16	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
HNSC	cis	rs8024893	0.764	rs8035110	ENSG00000259448.2	RP11-16E12.1	-3.91	0.000106	0.0148	-0.25	-0.18	Red cell distribution width;	chr15:31241884	chr15:31216020~31224445:+
HNSC	cis	rs6688613	0.765	rs56229522	ENSG00000215834.7	FMO9P	3.91	0.000106	0.0148	0.23	0.18	Refractive astigmatism;	chr1:166846871	chr1:166603675~166631400:+
HNSC	cis	rs832540	0.931	rs331499	ENSG00000265665.1	AC008391.1	3.91	0.000106	0.0148	0.2	0.18	Coronary artery disease;	chr5:56915096	chr5:56457038~56457138:-
HNSC	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-3.91	0.000107	0.0148	-0.18	-0.18	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
HNSC	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-3.91	0.000107	0.0148	-0.18	-0.18	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
HNSC	cis	rs28489187	0.706	rs3087894	ENSG00000223653.4	RP11-131L23.1	3.91	0.000107	0.0148	0.25	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321435	chr1:85276715~85448124:+
HNSC	cis	rs11098499	0.863	rs10004484	ENSG00000250412.1	KLHL2P1	3.91	0.000107	0.0148	0.22	0.18	Corneal astigmatism;	chr4:119521273	chr4:119334329~119378233:+
HNSC	cis	rs10875746	0.951	rs8804	ENSG00000257763.1	OR5BK1P	-3.91	0.000107	0.0148	-0.23	-0.18	Longevity (90 years and older);	chr12:48147974	chr12:48355792~48356614:-
HNSC	cis	rs4919687	0.55	rs4264100	ENSG00000236937.2	PTGES3P4	3.91	0.000107	0.0148	0.23	0.18	Colorectal cancer;	chr10:102694356	chr10:102845595~102845950:+
HNSC	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	3.91	0.000107	0.0148	0.21	0.18	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
HNSC	cis	rs9929218	0.551	rs6499193	ENSG00000260459.2	FTLP14	3.91	0.000107	0.0148	0.23	0.18	Colorectal cancer;	chr16:68693166	chr16:68822587~68823070:+
HNSC	cis	rs4908760	0.759	rs6577514	ENSG00000232912.4	RP5-1115A15.1	3.91	0.000107	0.0148	0.19	0.18	Vitiligo;	chr1:8652684	chr1:8424645~8434838:+
HNSC	cis	rs4489787	1	rs10459230	ENSG00000257763.1	OR5BK1P	-3.91	0.000107	0.0148	-0.3	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48457213	chr12:48355792~48356614:-
HNSC	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	3.91	0.000107	0.0148	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
HNSC	cis	rs73198271	0.96	rs10503392	ENSG00000253893.2	FAM85B	3.91	0.000107	0.0148	0.26	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:8167819~8226614:-
HNSC	cis	rs1003719	0.628	rs2252402	ENSG00000242553.1	AP001432.14	-3.91	0.000107	0.0148	-0.2	-0.18	Eye color traits;	chr21:37148420	chr21:37221419~37237744:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000272831.1	RP11-792A8.4	-3.91	0.000107	0.0148	-0.15	-0.18	Calcium levels;	chr7:66045710	chr7:66739829~66740385:-
HNSC	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000107	0.0148	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
HNSC	cis	rs1979679	0.842	rs34043014	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000107	0.0148	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28163298~28190738:-
HNSC	cis	rs4713118	0.513	rs202908	ENSG00000219891.2	ZSCAN12P1	3.91	0.000107	0.0148	0.24	0.18	Parkinson's disease;	chr6:28043773	chr6:28091154~28093664:+
HNSC	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	3.91	0.000107	0.0148	0.27	0.18	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
HNSC	cis	rs1555322	1	rs2425031	ENSG00000279253.1	RP4-614O4.13	-3.91	0.000107	0.0148	-0.25	-0.18	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35262727~35264187:-
HNSC	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000107	0.0148	-0.23	-0.18	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
HNSC	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	3.91	0.000107	0.0148	0.18	0.18	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
HNSC	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	3.91	0.000107	0.0148	0.24	0.18	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
HNSC	cis	rs3758785	0.596	rs7933335	ENSG00000255893.1	RP11-685N10.1	3.91	0.000107	0.0148	0.21	0.18	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94378461	chr11:94472908~94473570:-
HNSC	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-3.91	0.000107	0.0148	-0.25	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
HNSC	cis	rs853679	0.607	rs35030260	ENSG00000226314.6	ZNF192P1	-3.91	0.000107	0.0148	-0.33	-0.18	Depression;	chr6:28337731	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs13217619	ENSG00000226314.6	ZNF192P1	-3.91	0.000107	0.0148	-0.33	-0.18	Depression;	chr6:28338894	chr6:28161781~28169594:+
HNSC	cis	rs72843506	0.722	rs74255392	ENSG00000261033.1	RP11-209D14.2	3.91	0.000107	0.0148	0.31	0.18	Schizophrenia;	chr17:20425739	chr17:20008051~20009234:-
HNSC	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	3.91	0.000107	0.0148	0.18	0.18	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
HNSC	cis	rs6601327	0.613	rs12677507	ENSG00000233609.3	RP11-62H7.2	-3.91	0.000107	0.0148	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9624177	chr8:8961200~8979025:+
HNSC	cis	rs1023500	0.505	rs134874	ENSG00000182057.4	OGFRP1	3.91	0.000107	0.0148	0.19	0.18	Schizophrenia;	chr22:42265138	chr22:42269753~42275196:+
HNSC	cis	rs2337406	0.641	rs10133227	ENSG00000211974.3	IGHV2-70	3.91	0.000107	0.0148	0.21	0.18	Alzheimer's disease (late onset);	chr14:106814260	chr14:106723574~106724093:-
HNSC	cis	rs5752326	0.681	rs4822721	ENSG00000261188.1	CTA-445C9.14	3.91	0.000107	0.0148	0.26	0.18	Ischemic stroke;	chr22:26456191	chr22:26512537~26514568:+
HNSC	cis	rs67981189	0.593	rs10145824	ENSG00000274818.1	RP1-292L20.3	3.91	0.000107	0.0148	0.2	0.18	Schizophrenia;	chr14:70981015	chr14:70906657~70907111:-
HNSC	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	3.91	0.000107	0.0148	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
HNSC	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-3.91	0.000107	0.0148	-0.21	-0.18	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
HNSC	cis	rs1538138	1	rs6910919	ENSG00000226453.1	RP11-379B8.1	-3.91	0.000107	0.0148	-0.24	-0.18	Corneal structure;	chr6:82071672	chr6:81845185~81933480:-
HNSC	cis	rs7927592	0.956	rs7102273	ENSG00000255031.4	RP11-802E16.3	3.91	0.000107	0.0149	0.16	0.18	Total body bone mineral density;	chr11:68618111	chr11:68050740~68053762:+
HNSC	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	3.91	0.000107	0.0149	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
HNSC	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	3.91	0.000107	0.0149	0.19	0.18	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
HNSC	cis	rs9813712	0.571	rs9855426	ENSG00000253540.4	FAM86HP	3.91	0.000107	0.0149	0.17	0.18	Response to amphetamines;	chr3:130214475	chr3:130099092~130111472:-
HNSC	cis	rs7674212	0.537	rs2623060	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000107	0.0149	-0.2	-0.18	Type 2 diabetes;	chr4:103126347	chr4:102751401~102752641:+
HNSC	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	3.91	0.000107	0.0149	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
HNSC	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-3.91	0.000107	0.0149	-0.16	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
HNSC	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	3.91	0.000107	0.0149	0.21	0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
HNSC	cis	rs7829975	0.501	rs4840353	ENSG00000173295.6	FAM86B3P	-3.91	0.000107	0.0149	-0.21	-0.18	Mood instability;	chr8:8723060	chr8:8228595~8244865:+
HNSC	cis	rs1555322	1	rs2425036	ENSG00000126005.14	MMP24-AS1	-3.91	0.000107	0.0149	-0.33	-0.18	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35216462~35278131:-
HNSC	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-3.91	0.000107	0.0149	-0.21	-0.18	Height;	chr14:75166305	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-3.91	0.000107	0.0149	-0.21	-0.18	Height;	chr14:75170264	chr14:75011269~75012851:-
HNSC	cis	rs11893307	0.537	rs6731208	ENSG00000228509.4	AC006460.2	3.91	0.000107	0.0149	0.24	0.18	Mean platelet volume;	chr2:190638499	chr2:190676944~190708716:-
HNSC	cis	rs77972916	0.561	rs13411485	ENSG00000234936.1	AC010883.5	-3.91	0.000107	0.0149	-0.27	-0.18	Granulocyte percentage of myeloid white cells;	chr2:43348845	chr2:43229573~43233394:+
HNSC	cis	rs9836270	0.533	rs924947	ENSG00000242899.1	RPL7P16	3.91	0.000107	0.0149	0.2	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:132268462	chr3:132243528~132244265:-
HNSC	cis	rs6430585	0.528	rs3099429	ENSG00000231890.6	DARS-AS1	-3.91	0.000107	0.0149	-0.31	-0.18	Corneal structure;	chr2:135898012	chr2:135985176~136022593:+
HNSC	cis	rs1799949	0.864	rs60309406	ENSG00000236383.6	LINC00854	-3.91	0.000107	0.0149	-0.17	-0.18	Menopause (age at onset);	chr17:43358297	chr17:43216941~43305976:-
HNSC	cis	rs346291	0.631	rs346299	ENSG00000270362.1	HMGN3-AS1	3.91	0.000107	0.0149	0.25	0.18	Partial epilepsies;	chr6:79863784	chr6:79233718~79236797:+
HNSC	cis	rs12935418	0.552	rs2549842	ENSG00000261061.1	RP11-303E16.2	-3.91	0.000107	0.0149	-0.2	-0.18	Mean corpuscular volume;	chr16:80990054	chr16:81030770~81031485:+
HNSC	cis	rs11089937	0.522	rs2005239	ENSG00000211639.2	IGLV4-60	3.91	0.000107	0.0149	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs743520	ENSG00000211639.2	IGLV4-60	3.91	0.000107	0.0149	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	3.91	0.000107	0.0149	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
HNSC	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-3.91	0.000107	0.0149	-0.22	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
HNSC	cis	rs28475163	0.958	rs7395116	ENSG00000251661.3	RP11-326C3.11	-3.91	0.000107	0.0149	-0.21	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:318640~325631:+
HNSC	cis	rs1602565	0.858	rs2172225	ENSG00000255450.1	CTD-2063L20.1	3.91	0.000107	0.0149	0.28	0.18	Schizophrenia;	chr11:29144655	chr11:29275655~29276565:+
HNSC	cis	rs10073892	0.511	rs7708617	ENSG00000250682.4	LINC00491	-3.91	0.000107	0.0149	-0.24	-0.18	Cognitive decline (age-related);	chr5:102544584	chr5:102609156~102671559:-
HNSC	cis	rs3758785	0.586	rs481597	ENSG00000255893.1	RP11-685N10.1	3.91	0.000107	0.0149	0.21	0.18	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94336850	chr11:94472908~94473570:-
HNSC	cis	rs1005277	0.579	rs1780130	ENSG00000099251.13	HSD17B7P2	3.91	0.000107	0.0149	0.18	0.18	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38356380~38378505:+
HNSC	cis	rs11711311	1	rs2603793	ENSG00000241529.3	RN7SL767P	-3.91	0.000107	0.0149	-0.23	-0.18	IgG glycosylation;	chr3:113777571	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs2305545	ENSG00000241529.3	RN7SL767P	-3.91	0.000107	0.0149	-0.23	-0.18	IgG glycosylation;	chr3:113780886	chr3:113632704~113632998:+
HNSC	cis	rs7572733	0.555	rs7561950	ENSG00000231621.1	AC013264.2	-3.91	0.000107	0.0149	-0.17	-0.18	Dermatomyositis;	chr2:197889520	chr2:197197991~197199273:+
HNSC	cis	rs11783469	0.524	rs17089281	ENSG00000253390.1	CTC-756D1.2	-3.91	0.000107	0.0149	-0.26	-0.18	Reticulocyte count;	chr8:23477638	chr8:23458601~23484971:+
HNSC	cis	rs7429990	0.965	rs319689	ENSG00000228638.1	FCF1P2	-3.91	0.000107	0.0149	-0.16	-0.18	Educational attainment (years of education);	chr3:47886677	chr3:48290793~48291375:-
HNSC	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-3.91	0.000107	0.0149	-0.21	-0.18	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-3.91	0.000107	0.0149	-0.21	-0.18	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-3.91	0.000107	0.0149	-0.21	-0.18	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
HNSC	cis	rs2657294	0.895	rs3088142	ENSG00000233313.2	HMGA1P5	-3.91	0.000107	0.0149	-0.2	-0.18	Pneumonia;	chr10:75094806	chr10:75276376~75276646:-
HNSC	cis	rs11756659	0.653	rs199738	ENSG00000272810.1	U91328.22	3.91	0.000107	0.0149	0.19	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963228	chr6:26013241~26013757:+
HNSC	cis	rs4523957	0.715	rs6503321	ENSG00000262333.1	HNRNPA1P16	3.91	0.000107	0.0149	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2193286	chr17:2306761~2307715:+
HNSC	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	3.91	0.000107	0.0149	0.18	0.18	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
HNSC	cis	rs442309	0.841	rs224079	ENSG00000238280.1	RP11-436D10.3	-3.91	0.000107	0.0149	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62753470	chr10:62793562~62805887:-
HNSC	cis	rs11668609	1	rs10412517	ENSG00000268442.1	CTD-2027I19.2	3.91	0.000108	0.0149	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24119111	chr19:24162370~24163425:-
HNSC	cis	rs17739794	0.537	rs7816826	ENSG00000254207.1	RP11-43A14.1	-3.91	0.000108	0.0149	-0.22	-0.18	Clozapine-induced cytotoxicity;	chr8:864492	chr8:725188~725877:-
HNSC	cis	rs3015497	0.646	rs2934698	ENSG00000277050.1	RP11-102G14.1	-3.91	0.000108	0.0149	-0.19	-0.18	Mean platelet volume;	chr14:50671165	chr14:51637348~51637947:-
HNSC	cis	rs447735	0.566	rs258337	ENSG00000274627.1	RP11-104N10.2	3.91	0.000108	0.0149	0.17	0.18	Hemoglobin concentration;	chr16:89654302	chr16:89516797~89522217:+
HNSC	cis	rs6493858	0.839	rs7174823	ENSG00000277245.1	RP11-48G14.3	-3.91	0.000108	0.0149	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56158693	chr15:56447120~56447697:+
HNSC	cis	rs62025270	0.632	rs62022942	ENSG00000259762.1	RP11-158M2.4	-3.91	0.000108	0.0149	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85750336~85752901:-
HNSC	cis	rs67311347	0.955	rs9821036	ENSG00000280739.1	EIF1B-AS1	3.91	0.000108	0.0149	0.19	0.18	Renal cell carcinoma;	chr3:40337516	chr3:40173145~40309698:-
HNSC	cis	rs1925953	0.711	rs1952124	ENSG00000233589.1	RP4-694A7.2	-3.91	0.000108	0.0149	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68376385	chr1:68479129~68483539:+
HNSC	cis	rs4767841	0.718	rs203329	ENSG00000277283.1	RP1-267D11.6	3.91	0.000108	0.0149	0.17	0.18	Urgency urinary incontinence;	chr12:119771874	chr12:120116907~120119000:+
HNSC	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	3.91	0.000108	0.0149	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	3.91	0.000108	0.0149	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
HNSC	cis	rs11668609	0.81	rs8105851	ENSG00000268442.1	CTD-2027I19.2	3.91	0.000108	0.0149	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:24162370~24163425:-
HNSC	cis	rs10090774	0.76	rs13276886	ENSG00000279766.1	RP11-642A1.2	-3.91	0.000108	0.0149	-0.19	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720791	chr8:140572142~140572812:-
HNSC	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	3.91	0.000108	0.0149	0.2	0.18	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
HNSC	cis	rs853679	0.607	rs34218844	ENSG00000226314.6	ZNF192P1	-3.91	0.000108	0.0149	-0.33	-0.18	Depression;	chr6:28322870	chr6:28161781~28169594:+
HNSC	cis	rs10129255	0.536	rs8004835	ENSG00000224373.3	IGHV4-59	3.91	0.000108	0.0149	0.1	0.18	Kawasaki disease;	chr14:106686361	chr14:106627249~106627825:-
HNSC	cis	rs7615952	0.688	rs12638224	ENSG00000241278.1	ENPP7P4	-3.91	0.000108	0.015	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125822477	chr3:125848223~125909372:+
HNSC	cis	rs710865	0.541	rs2073104	ENSG00000270728.1	RP4-657E11.10	-3.91	0.000108	0.015	-0.18	-0.18	Brain structure;	chr1:19238156	chr1:19297080~19297903:+
HNSC	cis	rs72772090	0.71	rs17479052	ENSG00000248734.2	CTD-2260A17.1	-3.91	0.000108	0.015	-0.28	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96784777~96785999:+
HNSC	cis	rs35000415	0.938	rs17339836	ENSG00000244556.1	ODCP	3.91	0.000108	0.015	0.36	0.18	Systemic lupus erythematosus;	chr7:129041008	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs35188261	ENSG00000244556.1	ODCP	3.91	0.000108	0.015	0.36	0.18	Systemic lupus erythematosus;	chr7:129043485	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.873	rs62478615	ENSG00000244556.1	ODCP	3.91	0.000108	0.015	0.36	0.18	Systemic lupus erythematosus;	chr7:129044262	chr7:129028889~129030527:+
HNSC	cis	rs12545109	0.842	rs2582379	ENSG00000246430.5	LINC00968	3.91	0.000108	0.015	0.23	0.18	Obesity-related traits;	chr8:56482684	chr8:56496246~56559823:-
HNSC	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-3.91	0.000108	0.015	-0.22	-0.18	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
HNSC	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	3.91	0.000108	0.015	0.2	0.18	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
HNSC	cis	rs10073892	0.62	rs36059004	ENSG00000250682.4	LINC00491	-3.91	0.000108	0.015	-0.24	-0.18	Cognitive decline (age-related);	chr5:102608304	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.62	rs57189793	ENSG00000250682.4	LINC00491	-3.91	0.000108	0.015	-0.24	-0.18	Cognitive decline (age-related);	chr5:102608474	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.66	rs7723461	ENSG00000250682.4	LINC00491	-3.91	0.000108	0.015	-0.24	-0.18	Cognitive decline (age-related);	chr5:102609089	chr5:102609156~102671559:-
HNSC	cis	rs4660214	0.724	rs3931300	ENSG00000182109.6	RP11-69E11.4	-3.91	0.000108	0.015	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39522280~39546187:-
HNSC	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	3.91	0.000108	0.015	0.25	0.18	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
HNSC	cis	rs72827839	0.779	rs16954581	ENSG00000244649.3	CTD-2377D24.6	3.91	0.000108	0.015	0.24	0.18	Ease of getting up in the morning;	chr17:48282140	chr17:48646923~48707346:+
HNSC	cis	rs757081	0.676	rs567033	ENSG00000260196.1	RP1-239B22.5	-3.91	0.000108	0.015	-0.19	-0.18	Systolic blood pressure;	chr11:17185463	chr11:17380649~17383531:+
HNSC	cis	rs10242455	0.702	rs73397481	ENSG00000078319.8	PMS2P1	-3.91	0.000108	0.015	-0.38	-0.18	Blood metabolite levels;	chr7:99432485	chr7:100320992~100341908:-
HNSC	cis	rs35306767	0.668	rs35657988	ENSG00000229869.1	RP11-363N22.2	-3.91	0.000108	0.015	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1057650	chr10:933026~942743:+
HNSC	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	3.91	0.000108	0.015	0.18	0.18	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
HNSC	cis	rs9300255	0.602	rs6488864	ENSG00000280120.1	RP11-546D6.3	3.91	0.000108	0.015	0.17	0.18	Neutrophil percentage of white cells;	chr12:123133815	chr12:123152324~123153377:-
HNSC	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	3.9	0.000108	0.015	0.22	0.18	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
HNSC	cis	rs2239557	1	rs11628710	ENSG00000258769.1	RAP1AP	-3.9	0.000108	0.015	-0.19	-0.18	Common traits (Other);	chr14:74182577	chr14:74482985~74483435:+
HNSC	cis	rs7572733	0.534	rs13026569	ENSG00000231621.1	AC013264.2	3.9	0.000108	0.015	0.17	0.18	Dermatomyositis;	chr2:197918606	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs4850815	ENSG00000231621.1	AC013264.2	3.9	0.000108	0.015	0.17	0.18	Dermatomyositis;	chr2:197921443	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.515	rs12619300	ENSG00000231621.1	AC013264.2	3.9	0.000108	0.015	0.17	0.18	Dermatomyositis;	chr2:197921766	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1401091	ENSG00000231621.1	AC013264.2	3.9	0.000108	0.015	0.17	0.18	Dermatomyositis;	chr2:197925699	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs1401092	ENSG00000231621.1	AC013264.2	3.9	0.000108	0.015	0.17	0.18	Dermatomyositis;	chr2:197927596	chr2:197197991~197199273:+
HNSC	cis	rs4356203	0.87	rs10766381	ENSG00000260196.1	RP1-239B22.5	-3.9	0.000108	0.015	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17380649~17383531:+
HNSC	cis	rs3015497	0.561	rs3015469	ENSG00000277050.1	RP11-102G14.1	-3.9	0.000108	0.015	-0.18	-0.18	Mean platelet volume;	chr14:50690442	chr14:51637348~51637947:-
HNSC	cis	rs12600394	0.767	rs11655908	ENSG00000231595.1	AC005224.2	-3.9	0.000108	0.015	-0.22	-0.18	Response to platinum-based chemotherapy (cisplatin);	chr17:14629386	chr17:14210488~14217922:+
HNSC	cis	rs8067545	0.532	rs35915823	ENSG00000261033.1	RP11-209D14.2	-3.9	0.000108	0.015	-0.21	-0.18	Schizophrenia;	chr17:20070084	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.67	rs12937327	ENSG00000261033.1	RP11-209D14.2	-3.9	0.000108	0.015	-0.21	-0.18	Obesity-related traits;	chr17:20075671	chr17:20008051~20009234:-
HNSC	cis	rs34421088	0.702	rs7838131	ENSG00000269918.1	AF131215.9	-3.9	0.000108	0.015	-0.18	-0.18	Neuroticism;	chr8:11738654	chr8:11104691~11106704:-
HNSC	cis	rs8077577	0.945	rs62073611	ENSG00000273018.4	CTD-2303H24.2	-3.9	0.000108	0.015	-0.28	-0.18	Obesity-related traits;	chr17:18168647	chr17:18511221~18551705:-
HNSC	cis	rs7824557	0.507	rs7010590	ENSG00000255495.1	AC145124.2	3.9	0.000108	0.015	0.2	0.18	Retinal vascular caliber;	chr8:11205373	chr8:12194467~12196280:+
HNSC	cis	rs2554380	0.783	rs2554385	ENSG00000259570.1	RP11-671M22.4	3.9	0.000108	0.015	0.24	0.18	Height;	chr15:83737835	chr15:84394512~84395514:+
HNSC	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-3.9	0.000108	0.015	-0.23	-0.18	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
HNSC	cis	rs683257	0.925	rs116795862	ENSG00000234147.1	RP3-460G2.2	-3.9	0.000108	0.015	-0.36	-0.18	Facial emotion recognition (angry faces);	chr6:140683270	chr6:140845958~140852924:-
HNSC	cis	rs6693567	0.874	rs698915	ENSG00000228126.1	FALEC	-3.9	0.000108	0.015	-0.24	-0.18	Migraine;	chr1:150415842	chr1:150515757~150518032:+
HNSC	cis	rs17772222	0.636	rs77528165	ENSG00000258789.1	RP11-507K2.3	-3.9	0.000108	0.015	-0.22	-0.18	Coronary artery calcification;	chr14:88794249	chr14:88551597~88552493:+
HNSC	cis	rs896655	0.747	rs10811585	ENSG00000229835.2	KHSRPP1	3.9	0.000108	0.015	0.18	0.18	Coronary artery disease;	chr9:21701535	chr9:21695176~21696943:+
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000227888.4	FAM66A	3.9	0.000109	0.015	0.18	0.18	Neuroticism;	chr8:11935465	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000227888.4	FAM66A	3.9	0.000109	0.015	0.18	0.18	Neuroticism;	chr8:11935469	chr8:12362019~12388296:+
HNSC	cis	rs28489187	0.597	rs1001604	ENSG00000223653.4	RP11-131L23.1	-3.9	0.000109	0.015	-0.24	-0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85413841	chr1:85276715~85448124:+
HNSC	cis	rs7824557	0.628	rs34237267	ENSG00000255310.2	AF131215.2	3.9	0.000109	0.015	0.16	0.18	Retinal vascular caliber;	chr8:11339792	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.628	rs7008205	ENSG00000255310.2	AF131215.2	3.9	0.000109	0.015	0.16	0.18	Retinal vascular caliber;	chr8:11339814	chr8:11107788~11109726:-
HNSC	cis	rs62458065	0.568	rs62463963	ENSG00000226468.2	AC018641.7	3.9	0.000109	0.015	0.29	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32447079	chr7:32456963~32457758:-
HNSC	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-3.9	0.000109	0.015	-0.19	-0.18	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-3.9	0.000109	0.015	-0.19	-0.18	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
HNSC	cis	rs9859260	0.961	rs2300780	ENSG00000207650.1	MIR570	3.9	0.000109	0.015	0.16	0.18	Mean corpuscular volume;	chr3:196063420	chr3:195699401~195699497:+
HNSC	cis	rs9859260	1	rs2300778	ENSG00000207650.1	MIR570	3.9	0.000109	0.015	0.16	0.18	Mean corpuscular volume;	chr3:196063866	chr3:195699401~195699497:+
HNSC	cis	rs9859260	1	rs2300777	ENSG00000207650.1	MIR570	3.9	0.000109	0.015	0.16	0.18	Mean corpuscular volume;	chr3:196063940	chr3:195699401~195699497:+
HNSC	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-3.9	0.000109	0.015	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
HNSC	cis	rs9925964	0.933	rs2303223	ENSG00000232748.3	RP11-196G11.6	3.9	0.000109	0.015	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:31056460~31062803:+
HNSC	cis	rs9926296	0.533	rs10852623	ENSG00000261812.4	TUBB8P7	-3.9	0.000109	0.015	-0.19	-0.18	Vitiligo;	chr16:89798834	chr16:90093154~90096354:+
HNSC	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	3.9	0.000109	0.015	0.21	0.18	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
HNSC	cis	rs4523957	0.855	rs11078883	ENSG00000262333.1	HNRNPA1P16	3.9	0.000109	0.015	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2235534	chr17:2306761~2307715:+
HNSC	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	3.9	0.000109	0.015	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
HNSC	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	3.9	0.000109	0.0151	0.2	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
HNSC	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.18	0.18	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
HNSC	cis	rs10789207	0.531	rs74085003	ENSG00000248458.2	RP4-598P13.1	-3.9	0.000109	0.0151	-0.27	-0.18	Resting heart rate;	chr1:66656672	chr1:66665864~66677027:-
HNSC	cis	rs2518049	0.654	rs76656738	ENSG00000224034.1	RP11-445P17.8	-3.9	0.000109	0.0151	-0.25	-0.18	Metabolic traits;	chr10:5196057	chr10:5266033~5271236:-
HNSC	cis	rs11951515	0.738	rs17244818	ENSG00000249286.1	CTD-2210P15.2	-3.9	0.000109	0.0151	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43339433	chr5:43586918~43588223:-
HNSC	cis	rs755249	0.529	rs3768299	ENSG00000228060.1	RP11-69E11.8	-3.9	0.000109	0.0151	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39565160~39573203:+
HNSC	cis	rs2408955	0.522	rs6580650	ENSG00000257763.1	OR5BK1P	-3.9	0.000109	0.0151	-0.17	-0.18	Glycated hemoglobin levels;	chr12:48024773	chr12:48355792~48356614:-
HNSC	cis	rs11168618	1	rs11168618	ENSG00000240399.1	RP1-228P16.1	3.9	0.000109	0.0151	0.15	0.18	Adiponectin levels;	chr12:48539450	chr12:48054813~48055591:-
HNSC	cis	rs453301	0.571	rs2929456	ENSG00000253981.4	ALG1L13P	-3.9	0.000109	0.0151	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9225906	chr8:8236003~8244667:-
HNSC	cis	rs2439831	0.702	rs8033995	ENSG00000201136.1	RNU6-353P	-3.9	0.000109	0.0151	-0.29	-0.18	Lung cancer in ever smokers;	chr15:43721311	chr15:43702363~43702470:+
HNSC	cis	rs870825	1	rs870825	ENSG00000254233.1	RP11-242J7.1	3.9	0.000109	0.0151	0.29	0.18	Blood protein levels;	chr4:184666891	chr4:184584093~184625030:-
HNSC	cis	rs9910055	0.639	rs11656871	ENSG00000267080.4	ASB16-AS1	-3.9	0.000109	0.0151	-0.14	-0.18	Total body bone mineral density;	chr17:44191773	chr17:44175973~44186717:-
HNSC	cis	rs1552244	1	rs113153120	ENSG00000180385.7	EMC3-AS1	3.9	0.000109	0.0151	0.2	0.18	Alzheimer's disease;	chr3:10114714	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs112509186	ENSG00000180385.7	EMC3-AS1	3.9	0.000109	0.0151	0.2	0.18	Alzheimer's disease;	chr3:10114849	chr3:9986893~10006990:+
HNSC	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	3.9	0.000109	0.0151	0.19	0.18	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
HNSC	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-3.9	0.000109	0.0151	-0.26	-0.18	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
HNSC	cis	rs9880211	0.613	rs34864445	ENSG00000239213.4	NCK1-AS1	3.9	0.000109	0.0151	0.17	0.18	Height;Body mass index;	chr3:136104082	chr3:136841726~136862054:-
HNSC	cis	rs597539	0.69	rs615644	ENSG00000255741.1	RP11-757G1.5	-3.9	0.000109	0.0151	-0.26	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68941503~68942852:-
HNSC	cis	rs7211079	0.833	rs7220523	ENSG00000275479.1	RP11-334C17.6	3.9	0.000109	0.0151	0.21	0.18	Myocardial infarction;	chr17:80153896	chr17:80149627~80149798:+
HNSC	cis	rs6180	0.54	rs4866968	ENSG00000271788.1	CTD-2201E18.5	-3.9	0.000109	0.0151	-0.18	-0.18	Height;	chr5:42851081	chr5:43006733~43007543:-
HNSC	cis	rs7937890	0.681	rs4756784	ENSG00000254418.1	RP11-21L19.1	-3.9	0.000109	0.0151	-0.21	-0.18	Mitochondrial DNA levels;	chr11:14249358	chr11:14262846~14273691:-
HNSC	cis	rs2239557	0.961	rs4903200	ENSG00000258769.1	RAP1AP	3.9	0.000109	0.0151	0.19	0.18	Common traits (Other);	chr14:74192934	chr14:74482985~74483435:+
HNSC	cis	rs11951515	0.663	rs4395639	ENSG00000249286.1	CTD-2210P15.2	3.9	0.000109	0.0151	0.19	0.18	Metabolite levels  (X-11787);	chr5:43286361	chr5:43586918~43588223:-
HNSC	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-3.9	0.000109	0.0151	-0.18	-0.18	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
HNSC	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	3.9	0.000109	0.0151	0.29	0.18	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
HNSC	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	3.9	0.000109	0.0151	0.21	0.18	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
HNSC	cis	rs35306767	0.903	rs10904577	ENSG00000229869.1	RP11-363N22.2	-3.9	0.000109	0.0151	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:876137	chr10:933026~942743:+
HNSC	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-3.9	0.000109	0.0151	-0.25	-0.18	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
HNSC	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	3.9	0.000109	0.0151	0.18	0.18	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
HNSC	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-3.9	0.000109	0.0151	-0.2	-0.18	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
HNSC	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	3.9	0.000109	0.0151	0.19	0.18	QT interval;	chr12:29253828	chr12:29280418~29317848:-
HNSC	cis	rs6180	0.816	rs34417548	ENSG00000272144.1	CTD-2035E11.5	-3.9	0.000109	0.0151	-0.17	-0.18	Height;	chr5:42842127	chr5:43061395~43062441:+
HNSC	cis	rs5758659	1	rs5758677	ENSG00000273366.1	CTA-989H11.1	-3.9	0.000109	0.0151	-0.21	-0.18	Cognitive function;	chr22:42247033	chr22:42278188~42278846:+
HNSC	cis	rs6657613	0.649	rs9435746	ENSG00000186715.9	MST1L	-3.9	0.000109	0.0151	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17045622	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs9435747	ENSG00000186715.9	MST1L	-3.9	0.000109	0.0151	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17045972	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs11582579	ENSG00000186715.9	MST1L	-3.9	0.000109	0.0151	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17046016	chr1:16754910~16770237:-
HNSC	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-3.9	0.000109	0.0151	-0.21	-0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
HNSC	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000109	0.0151	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000109	0.0151	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000109	0.0151	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
HNSC	cis	rs6471393	0.792	rs7839522	ENSG00000279331.1	RBM12B-AS1	3.9	0.000109	0.0151	0.18	0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93827906	chr8:93740121~93740773:+
HNSC	cis	rs5758659	0.967	rs5758670	ENSG00000273366.1	CTA-989H11.1	-3.9	0.000109	0.0151	-0.21	-0.18	Cognitive function;	chr22:42240681	chr22:42278188~42278846:+
HNSC	cis	rs11976180	1	rs1320894	ENSG00000244479.5	OR2A1-AS1	3.9	0.000109	0.0151	0.2	0.18	Obesity-related traits;	chr7:144054709	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2951369	ENSG00000244479.5	OR2A1-AS1	3.9	0.000109	0.0151	0.2	0.18	Obesity-related traits;	chr7:144055545	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2951364	ENSG00000244479.5	OR2A1-AS1	3.9	0.000109	0.0151	0.2	0.18	Obesity-related traits;	chr7:144057390	chr7:144251264~144356181:-
HNSC	cis	rs6968419	0.674	rs12669768	ENSG00000237870.5	AC073130.1	3.9	0.000109	0.0151	0.21	0.18	Intraocular pressure;	chr7:116267086	chr7:116275606~116286734:-
HNSC	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	3.9	0.000109	0.0151	0.12	0.18	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
HNSC	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	3.9	0.000109	0.0151	0.12	0.18	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
HNSC	cis	rs6964587	0.869	rs11769726	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000109	0.0151	0.19	0.18	Breast cancer;	chr7:91855917	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.839	rs10236107	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000109	0.0151	0.19	0.18	Breast cancer;	chr7:91856147	chr7:92134604~92180725:+
HNSC	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	3.9	0.000109	0.0151	0.21	0.18	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
HNSC	cis	rs73222236	0.746	rs28889583	ENSG00000273486.1	RP11-731C17.2	3.9	0.000109	0.0151	0.15	0.18	Coronary artery disease;	chr3:136460690	chr3:136837338~136839021:-
HNSC	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	3.9	0.000109	0.0151	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
HNSC	cis	rs11976180	1	rs1320893	ENSG00000244479.5	OR2A1-AS1	3.9	0.000109	0.0151	0.21	0.18	Obesity-related traits;	chr7:144055019	chr7:144251264~144356181:-
HNSC	cis	rs4392868	0.514	rs12548426	ENSG00000245080.5	RP11-320N21.1	-3.9	0.000109	0.0151	-0.21	-0.18	Radiation response;	chr8:95092958	chr8:95066808~95073182:-
HNSC	cis	rs546131	0.642	rs58210900	ENSG00000271369.1	RP11-350D17.3	-3.9	0.000109	0.0151	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34816500	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs61881104	ENSG00000271369.1	RP11-350D17.3	-3.9	0.000109	0.0151	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34816836	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs7131074	ENSG00000271369.1	RP11-350D17.3	-3.9	0.000109	0.0151	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34817558	chr11:34709600~34710161:+
HNSC	cis	rs889398	0.771	rs1566453	ENSG00000196696.11	PDXDC2P	-3.9	0.000109	0.0151	-0.12	-0.18	Body mass index;	chr16:69865884	chr16:69976297~70065948:-
HNSC	cis	rs36093844	0.527	rs4943935	ENSG00000279742.1	RP11-700A24.1	-3.9	0.000109	0.0151	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86040813	chr11:85852557~85854943:-
HNSC	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	3.9	0.000109	0.0151	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
HNSC	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-3.9	0.000109	0.0151	-0.2	-0.18	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-3.9	0.000109	0.0151	-0.2	-0.18	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
HNSC	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-3.9	0.000109	0.0151	-0.2	-0.18	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
HNSC	cis	rs2554380	0.843	rs2098904	ENSG00000259570.1	RP11-671M22.4	3.9	0.000109	0.0151	0.24	0.18	Height;	chr15:83737503	chr15:84394512~84395514:+
HNSC	cis	rs2832077	0.689	rs2832055	ENSG00000232855.5	AF131217.1	-3.9	0.000109	0.0151	-0.21	-0.18	Cognitive test performance;	chr21:28760060	chr21:28439346~28674848:-
HNSC	cis	rs3738443	0.904	rs12562191	ENSG00000259865.1	RP11-488L18.10	3.9	0.000109	0.0151	0.17	0.18	Alcohol dependence;	chr1:247234227	chr1:247187281~247188526:-
HNSC	cis	rs9907295	0.591	rs4239252	ENSG00000271013.1	AC015849.15	3.9	0.00011	0.0151	0.2	0.18	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35912635~35918010:-
HNSC	cis	rs870825	0.929	rs72689256	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669020	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689258	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669396	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689260	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669502	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689261	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669743	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689262	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669796	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689263	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669807	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689265	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669828	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689266	ENSG00000254233.1	RP11-242J7.1	3.9	0.00011	0.0151	0.3	0.18	Blood protein levels;	chr4:184669899	chr4:184584093~184625030:-
HNSC	cis	rs1853665	1	rs1853665	ENSG00000231760.4	RP11-350J20.5	3.9	0.00011	0.0151	0.29	0.18	Radiation response;	chr6:149977706	chr6:149796151~149826294:-
HNSC	cis	rs459482	0.587	rs468207	ENSG00000228318.3	AP001610.5	3.9	0.00011	0.0151	0.19	0.18	IgG glycosylation;	chr21:41436088	chr21:41441056~41445708:-
HNSC	cis	rs4908769	0.66	rs10779702	ENSG00000232912.4	RP5-1115A15.1	-3.9	0.00011	0.0152	-0.2	-0.18	Allergy;	chr1:8363450	chr1:8424645~8434838:+
HNSC	cis	rs6657613	0.68	rs6690934	ENSG00000186715.9	MST1L	-3.9	0.00011	0.0152	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17046127	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs6690919	ENSG00000186715.9	MST1L	-3.9	0.00011	0.0152	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17046710	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.621	rs9435749	ENSG00000186715.9	MST1L	-3.9	0.00011	0.0152	-0.15	-0.18	Hip circumference adjusted for BMI;	chr1:17047464	chr1:16754910~16770237:-
HNSC	cis	rs35000415	0.938	rs12706861	ENSG00000244556.1	ODCP	3.9	0.00011	0.0152	0.35	0.18	Systemic lupus erythematosus;	chr7:128976528	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs17338998	ENSG00000244556.1	ODCP	3.9	0.00011	0.0152	0.35	0.18	Systemic lupus erythematosus;	chr7:128978505	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs12535158	ENSG00000244556.1	ODCP	3.9	0.00011	0.0152	0.35	0.18	Systemic lupus erythematosus;	chr7:128984965	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs34725944	ENSG00000244556.1	ODCP	3.9	0.00011	0.0152	0.35	0.18	Systemic lupus erythematosus;	chr7:129001599	chr7:129028889~129030527:+
HNSC	cis	rs35000415	0.938	rs13227075	ENSG00000244556.1	ODCP	3.9	0.00011	0.0152	0.35	0.18	Systemic lupus erythematosus;	chr7:129003243	chr7:129028889~129030527:+
HNSC	cis	rs9650657	0.585	rs4841401	ENSG00000255310.2	AF131215.2	-3.9	0.00011	0.0152	-0.17	-0.18	Neuroticism;	chr8:10632082	chr8:11107788~11109726:-
HNSC	cis	rs1485395	0.945	rs2365344	ENSG00000270175.1	RP11-793H13.11	-3.9	0.00011	0.0152	-0.21	-0.18	Migraine without aura;	chr12:53616193	chr12:53500162~53500936:-
HNSC	cis	rs7824557	0.603	rs2250028	ENSG00000269918.1	AF131215.9	3.9	0.00011	0.0152	0.17	0.18	Retinal vascular caliber;	chr8:11356080	chr8:11104691~11106704:-
HNSC	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-3.9	0.00011	0.0152	-0.21	-0.18	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
HNSC	cis	rs9914544	0.545	rs4290526	ENSG00000264885.1	RP11-815I9.4	-3.9	0.00011	0.0152	-0.18	-0.18	Educational attainment (years of education);	chr17:18869654	chr17:18667629~18669461:-
HNSC	cis	rs870825	0.616	rs6817521	ENSG00000254233.1	RP11-242J7.1	-3.9	0.00011	0.0152	-0.25	-0.18	Blood protein levels;	chr4:184728673	chr4:184584093~184625030:-
HNSC	cis	rs67981189	0.572	rs7156009	ENSG00000274818.1	RP1-292L20.3	3.9	0.00011	0.0152	0.2	0.18	Schizophrenia;	chr14:71048714	chr14:70906657~70907111:-
HNSC	cis	rs7829975	0.539	rs883647	ENSG00000253893.2	FAM85B	3.9	0.00011	0.0152	0.23	0.18	Mood instability;	chr8:8712214	chr8:8167819~8226614:-
HNSC	cis	rs6570726	0.791	rs4896820	ENSG00000270638.1	RP3-466P17.1	3.9	0.00011	0.0152	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145735570~145737218:+
HNSC	cis	rs2243480	1	rs4149468	ENSG00000106610.13	STAG3L4	-3.9	0.00011	0.0152	-0.35	-0.18	Diabetic kidney disease;	chr7:66360703	chr7:67302621~67321526:+
HNSC	cis	rs4930561	0.765	rs10896304	ENSG00000184795.9	UNC93B5	-3.9	0.00011	0.0152	-0.2	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr11:67711702~67716005:-
HNSC	cis	rs7945705	0.87	rs4910156	ENSG00000254860.4	TMEM9B-AS1	-3.9	0.00011	0.0152	-0.2	-0.18	Hemoglobin concentration;	chr11:8919650	chr11:8964675~8977527:+
HNSC	cis	rs4948102	0.731	rs4948099	ENSG00000213650.3	RP11-760D2.7	-3.9	0.00011	0.0152	-0.19	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr7:56567906~56568858:-
HNSC	cis	rs2239557	0.539	rs35864336	ENSG00000259065.1	RP5-1021I20.1	-3.9	0.00011	0.0152	-0.27	-0.18	Common traits (Other);	chr14:73987492	chr14:73787360~73803270:+
HNSC	cis	rs57502260	0.834	rs3736228	ENSG00000255031.4	RP11-802E16.3	-3.9	0.00011	0.0152	-0.19	-0.18	Total body bone mineral density (age 45-60);	chr11:68433827	chr11:68050740~68053762:+
HNSC	cis	rs847649	1	rs13233521	ENSG00000239969.4	RP11-163E9.2	3.9	0.00011	0.0152	0.2	0.18	Morning vs. evening chronotype;	chr7:102953347	chr7:102364162~102380633:+
HNSC	cis	rs72827839	0.779	rs16954581	ENSG00000272763.1	RP11-357H14.17	3.9	0.00011	0.0152	0.26	0.18	Ease of getting up in the morning;	chr17:48282140	chr17:48635923~48647023:-
HNSC	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-3.9	0.00011	0.0152	-0.18	-0.18	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
HNSC	cis	rs11098499	0.863	rs10018280	ENSG00000250412.1	KLHL2P1	3.9	0.00011	0.0152	0.22	0.18	Corneal astigmatism;	chr4:119556984	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs6534141	ENSG00000250412.1	KLHL2P1	3.9	0.00011	0.0152	0.22	0.18	Corneal astigmatism;	chr4:119564068	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs2127823	ENSG00000250412.1	KLHL2P1	3.9	0.00011	0.0152	0.22	0.18	Corneal astigmatism;	chr4:119564515	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.863	rs3775858	ENSG00000250412.1	KLHL2P1	3.9	0.00011	0.0152	0.22	0.18	Corneal astigmatism;	chr4:119564873	chr4:119334329~119378233:+
HNSC	cis	rs7208859	0.573	rs8070182	ENSG00000264538.5	SUZ12P1	-3.9	0.00011	0.0152	-0.16	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30709299~30790908:+
HNSC	cis	rs11976180	1	rs2951353	ENSG00000244479.5	OR2A1-AS1	3.9	0.00011	0.0152	0.2	0.18	Obesity-related traits;	chr7:144064023	chr7:144251264~144356181:-
HNSC	cis	rs7688540	0.771	rs7674560	ENSG00000211553.1	AC253576.2	-3.9	0.00011	0.0152	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:136461~136568:+
HNSC	cis	rs6968419	0.674	rs4730723	ENSG00000237870.5	AC073130.1	3.9	0.00011	0.0152	0.21	0.18	Intraocular pressure;	chr7:116263998	chr7:116275606~116286734:-
HNSC	cis	rs302972	0.826	rs79229624	ENSG00000168405.13	CMAHP	3.9	0.00011	0.0152	0.29	0.18	Creatinine levels in ischemic stroke;	chr6:25074428	chr6:25081068~25166555:-
HNSC	cis	rs9859260	1	rs2239641	ENSG00000207650.1	MIR570	3.9	0.00011	0.0152	0.16	0.18	Mean corpuscular volume;	chr3:196062543	chr3:195699401~195699497:+
HNSC	cis	rs9859260	1	rs2239640	ENSG00000207650.1	MIR570	3.9	0.00011	0.0152	0.16	0.18	Mean corpuscular volume;	chr3:196062837	chr3:195699401~195699497:+
HNSC	cis	rs7085104	0.684	rs7092690	ENSG00000213061.2	PFN1P11	3.9	0.00011	0.0152	0.22	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102838011~102845473:-
HNSC	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-3.9	0.00011	0.0152	-0.22	-0.18	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
HNSC	cis	rs1258763	0.678	rs2123066	ENSG00000259721.1	RP11-758N13.1	3.9	0.00011	0.0152	0.2	0.18	Orofacial clefts;	chr15:32753811	chr15:32717270~32719007:-
HNSC	cis	rs4713118	0.824	rs9366702	ENSG00000216901.1	AL022393.7	3.9	0.00011	0.0152	0.23	0.18	Parkinson's disease;	chr6:27766691	chr6:28176188~28176674:+
HNSC	cis	rs7429990	0.965	rs11707679	ENSG00000228638.1	FCF1P2	-3.9	0.00011	0.0152	-0.17	-0.18	Educational attainment (years of education);	chr3:47915016	chr3:48290793~48291375:-
HNSC	cis	rs62458065	0.64	rs6950077	ENSG00000226468.2	AC018641.7	-3.9	0.00011	0.0152	-0.29	-0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32463283	chr7:32456963~32457758:-
HNSC	cis	rs2835345	0.63	rs73204235	ENSG00000230479.1	AP000695.6	3.9	0.00011	0.0152	0.2	0.18	Pulmonary function;	chr21:36446920	chr21:36430360~36481070:+
HNSC	cis	rs2835345	0.63	rs73204236	ENSG00000230479.1	AP000695.6	3.9	0.00011	0.0152	0.2	0.18	Pulmonary function;	chr21:36446921	chr21:36430360~36481070:+
HNSC	cis	rs12893668	0.572	rs4906350	ENSG00000269958.1	RP11-73M18.8	3.9	0.00011	0.0152	0.16	0.18	Reticulocyte count;	chr14:103645457	chr14:103696353~103697163:+
HNSC	cis	rs10771431	0.817	rs17202253	ENSG00000256427.1	RP11-118B22.4	3.9	0.00011	0.0152	0.19	0.18	Breast size;	chr12:9209254	chr12:9246497~9257960:+
HNSC	cis	rs7714670	0.704	rs12653477	ENSG00000184084.7	CTD-2372A4.1	-3.9	0.00011	0.0152	-0.19	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:73794264	chr5:73803296~73803599:-
HNSC	cis	rs8010715	0.816	rs1134340	ENSG00000259321.1	RP11-468E2.5	3.9	0.00011	0.0152	0.15	0.18	IgG glycosylation;	chr14:24125004	chr14:24139445~24140444:+
HNSC	cis	rs72387598	1	rs72387598	ENSG00000234329.1	RP11-767N6.2	3.9	0.00011	0.0152	0.21	0.18	Platelet distribution width;	chr1:45457307	chr1:45651039~45651826:-
HNSC	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-3.9	0.00011	0.0152	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
HNSC	cis	rs12999542	0.706	rs6756407	ENSG00000234389.1	AC007278.3	3.9	0.00011	0.0152	0.3	0.18	Serum protein levels (sST2);	chr2:102419641	chr2:102438713~102440475:+
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	-3.9	0.00011	0.0152	-0.22	-0.18	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
HNSC	cis	rs950169	0.58	rs11633762	ENSG00000229212.6	RP11-561C5.4	-3.9	0.00011	0.0152	-0.26	-0.18	Schizophrenia;	chr15:84643921	chr15:85205440~85234795:-
HNSC	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-3.9	0.00011	0.0152	-0.2	-0.18	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-3.9	0.00011	0.0152	-0.19	-0.18	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
HNSC	cis	rs7572733	0.534	rs771009	ENSG00000231621.1	AC013264.2	-3.9	0.00011	0.0152	-0.17	-0.18	Dermatomyositis;	chr2:197826358	chr2:197197991~197199273:+
HNSC	cis	rs2303759	0.507	rs1465696	ENSG00000268686.1	AC010524.2	-3.9	0.00011	0.0152	-0.26	-0.18	Multiple sclerosis;	chr19:49334182	chr19:49368705~49388081:-
HNSC	cis	rs561341	1	rs4795667	ENSG00000278867.1	RP11-640N20.4	-3.9	0.00011	0.0152	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31917424	chr17:32051030~32053208:+
HNSC	cis	rs4648045	0.734	rs4648055	ENSG00000230069.3	LRRC37A15P	-3.9	0.00011	0.0152	-0.19	-0.18	Lymphocyte percentage of white cells;	chr4:102594156	chr4:102727274~102730721:-
HNSC	cis	rs2657294	0.62	rs7903537	ENSG00000226051.5	ZNF503-AS1	-3.9	0.00011	0.0152	-0.23	-0.18	Pneumonia;	chr10:75087732	chr10:75269819~75373500:+
HNSC	cis	rs2337406	0.866	rs2027901	ENSG00000280411.1	IGHV1-69-2	-3.9	0.00011	0.0152	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106807164	chr14:106762092~106762588:-
HNSC	cis	rs10504130	1	rs61326367	ENSG00000272024.1	RP11-546K22.3	-3.9	0.00011	0.0152	-0.3	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51775466	chr8:51950284~51950690:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000217862.2	HIST1H4PS1	-3.9	0.000111	0.0153	-0.18	-0.18	Cardiac Troponin-T levels;	chr6:27951465	chr6:27807075~27807339:+
HNSC	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-3.9	0.000111	0.0153	-0.21	-0.18	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
HNSC	cis	rs656319	0.513	rs34748716	ENSG00000255310.2	AF131215.2	-3.9	0.000111	0.0153	-0.18	-0.18	Myopia (pathological);	chr8:10116208	chr8:11107788~11109726:-
HNSC	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-3.9	0.000111	0.0153	-0.18	-0.18	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
HNSC	cis	rs7777677	0.925	rs6969951	ENSG00000276557.1	TRBV18	-3.9	0.000111	0.0153	-0.15	-0.18	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142615716~142616415:+
HNSC	cis	rs11976180	1	rs67239267	ENSG00000244479.5	OR2A1-AS1	3.9	0.000111	0.0153	0.21	0.18	Obesity-related traits;	chr7:144048023	chr7:144251264~144356181:-
HNSC	cis	rs7674212	0.541	rs2720471	ENSG00000251288.2	RP11-10L12.2	-3.9	0.000111	0.0153	-0.2	-0.18	Type 2 diabetes;	chr4:103102683	chr4:102751401~102752641:+
HNSC	cis	rs7809615	0.515	rs10257273	ENSG00000244219.5	GS1-259H13.2	-3.9	0.000111	0.0153	-0.28	-0.18	Blood metabolite ratios;	chr7:99590966	chr7:99598066~99610813:+
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000227888.4	FAM66A	3.9	0.000111	0.0153	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000227888.4	FAM66A	3.9	0.000111	0.0153	0.18	0.18	Neuroticism;	chr8:11935587	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000227888.4	FAM66A	3.9	0.000111	0.0153	0.18	0.18	Neuroticism;	chr8:11935631	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000227888.4	FAM66A	3.9	0.000111	0.0153	0.18	0.18	Neuroticism;	chr8:11935669	chr8:12362019~12388296:+
HNSC	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-3.9	0.000111	0.0153	-0.21	-0.18	Height;	chr14:75141980	chr14:75011269~75012851:-
HNSC	cis	rs17253792	0.822	rs76472022	ENSG00000186615.9	KTN1-AS1	-3.9	0.000111	0.0153	-0.36	-0.18	Putamen volume;	chr14:55586942	chr14:55499278~55580110:-
HNSC	cis	rs859767	0.741	rs11684785	ENSG00000224043.6	CCNT2-AS1	3.9	0.000111	0.0153	0.21	0.18	Neuroticism;	chr2:134635540	chr2:134735464~134918710:-
HNSC	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	3.9	0.000111	0.0153	0.23	0.18	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
HNSC	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-3.9	0.000111	0.0153	-0.2	-0.18	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-3.9	0.000111	0.0153	-0.2	-0.18	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
HNSC	cis	rs6964587	0.621	rs38799	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000111	0.0153	0.18	0.18	Breast cancer;	chr7:92415825	chr7:92134604~92180725:+
HNSC	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	3.9	0.000111	0.0153	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	3.9	0.000111	0.0153	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	3.9	0.000111	0.0153	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	3.9	0.000111	0.0153	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	3.9	0.000111	0.0153	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
HNSC	cis	rs11231017	0.507	rs2178260	ENSG00000250659.2	RP11-864I4.3	-3.9	0.000111	0.0153	-0.21	-0.18	HIV-1 viral setpoint;	chr11:62301893	chr11:62537312~62542018:+
HNSC	cis	rs9300255	0.602	rs1727317	ENSG00000280120.1	RP11-546D6.3	3.9	0.000111	0.0153	0.17	0.18	Neutrophil percentage of white cells;	chr12:123134395	chr12:123152324~123153377:-
HNSC	cis	rs1559040	0.929	rs13418039	ENSG00000272156.1	RP11-477N3.1	-3.9	0.000111	0.0153	-0.31	-0.18	Sudden cardiac arrest;	chr2:54093114	chr2:54082554~54085066:+
HNSC	cis	rs1559040	1	rs13418839	ENSG00000272156.1	RP11-477N3.1	-3.9	0.000111	0.0153	-0.31	-0.18	Sudden cardiac arrest;	chr2:54093638	chr2:54082554~54085066:+
HNSC	cis	rs1559040	0.929	rs13418658	ENSG00000272156.1	RP11-477N3.1	-3.9	0.000111	0.0153	-0.31	-0.18	Sudden cardiac arrest;	chr2:54093662	chr2:54082554~54085066:+
HNSC	cis	rs12887734	0.524	rs4900599	ENSG00000269940.1	RP11-73M18.7	3.9	0.000111	0.0153	0.17	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103694560~103695170:+
HNSC	cis	rs1015213	1	rs16917014	ENSG00000253844.1	RP11-546K22.1	-3.9	0.000111	0.0153	-0.33	-0.18	Glaucoma (primary angle closure);	chr8:51978562	chr8:51961458~52022974:+
HNSC	cis	rs34421088	0.532	rs11782742	ENSG00000269918.1	AF131215.9	3.9	0.000111	0.0153	0.18	0.18	Neuroticism;	chr8:11307500	chr8:11104691~11106704:-
HNSC	cis	rs67072384	0.892	rs7104664	ENSG00000213365.3	AP000593.6	3.9	0.000111	0.0153	0.3	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733405	chr11:72280151~72281178:+
HNSC	cis	rs7829975	0.523	rs9644774	ENSG00000173295.6	FAM86B3P	-3.9	0.000111	0.0153	-0.21	-0.18	Mood instability;	chr8:8702322	chr8:8228595~8244865:+
HNSC	cis	rs7824557	0.545	rs2572380	ENSG00000255310.2	AF131215.2	-3.9	0.000111	0.0153	-0.17	-0.18	Retinal vascular caliber;	chr8:11379968	chr8:11107788~11109726:-
HNSC	cis	rs1150668	0.799	rs1150705	ENSG00000219392.1	RP1-265C24.5	-3.9	0.000111	0.0153	-0.2	-0.18	Pubertal anthropometrics;	chr6:28226008	chr6:28115628~28116551:+
HNSC	cis	rs870825	0.616	rs4616798	ENSG00000254233.1	RP11-242J7.1	-3.9	0.000111	0.0153	-0.26	-0.18	Blood protein levels;	chr4:184712990	chr4:184584093~184625030:-
HNSC	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	3.9	0.000111	0.0153	0.29	0.18	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
HNSC	cis	rs11673344	0.523	rs7248948	ENSG00000276846.1	CTD-3220F14.3	3.9	0.000111	0.0153	0.19	0.18	Obesity-related traits;	chr19:37056317	chr19:37314868~37315620:-
HNSC	cis	rs757081	0.648	rs214102	ENSG00000260196.1	RP1-239B22.5	-3.9	0.000111	0.0153	-0.19	-0.18	Systolic blood pressure;	chr11:17266751	chr11:17380649~17383531:+
HNSC	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	3.9	0.000111	0.0153	0.18	0.18	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
HNSC	cis	rs6500395	0.775	rs1968902	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630063	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.775	rs1968903	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630103	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.735	rs74017013	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630209	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.775	rs4277341	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630476	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.775	rs7185541	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48630770	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.775	rs8050844	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48631785	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.775	rs4471681	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48632035	chr16:48559661~48587403:+
HNSC	cis	rs6500395	0.963	rs12444902	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0153	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48633215	chr16:48559661~48587403:+
HNSC	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-3.9	0.000111	0.0153	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
HNSC	cis	rs9650657	0.769	rs1968400	ENSG00000255310.2	AF131215.2	-3.9	0.000111	0.0153	-0.17	-0.18	Neuroticism;	chr8:10757921	chr8:11107788~11109726:-
HNSC	cis	rs9297145	0.724	rs62473013	ENSG00000272950.1	RP11-307C18.1	-3.9	0.000111	0.0153	-0.27	-0.18	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99164795	chr7:98322853~98323430:+
HNSC	cis	rs9297145	0.761	rs62473015	ENSG00000272950.1	RP11-307C18.1	-3.9	0.000111	0.0153	-0.27	-0.18	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99165678	chr7:98322853~98323430:+
HNSC	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	3.9	0.000111	0.0153	0.18	0.18	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
HNSC	cis	rs11951515	0.738	rs4866818	ENSG00000249286.1	CTD-2210P15.2	3.9	0.000111	0.0153	0.19	0.18	Metabolite levels  (X-11787);	chr5:43337432	chr5:43586918~43588223:-
HNSC	cis	rs950169	0.579	rs881983	ENSG00000230373.7	GOLGA6L5P	-3.9	0.000111	0.0153	-0.21	-0.18	Schizophrenia;	chr15:83978556	chr15:84507885~84516814:-
HNSC	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	3.9	0.000111	0.0153	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	3.9	0.000111	0.0153	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	3.9	0.000111	0.0153	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
HNSC	cis	rs9487051	0.698	rs9400276	ENSG00000243587.6	C6orf183	-3.9	0.000111	0.0153	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109326202	chr6:109165833~109271014:+
HNSC	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	3.9	0.000111	0.0153	0.21	0.18	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
HNSC	cis	rs1979679	0.879	rs980920	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000111	0.0153	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28163298~28190738:-
HNSC	cis	rs7824557	0.569	rs35418978	ENSG00000269918.1	AF131215.9	3.9	0.000111	0.0153	0.17	0.18	Retinal vascular caliber;	chr8:11328944	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.606	rs2736264	ENSG00000269918.1	AF131215.9	3.9	0.000111	0.0153	0.17	0.18	Retinal vascular caliber;	chr8:11329130	chr8:11104691~11106704:-
HNSC	cis	rs5758659	1	rs134873	ENSG00000273366.1	CTA-989H11.1	-3.9	0.000111	0.0153	-0.21	-0.18	Cognitive function;	chr22:42261560	chr22:42278188~42278846:+
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000272831.1	RP11-792A8.4	3.9	0.000111	0.0153	0.15	0.18	Calcium levels;	chr7:65751755	chr7:66739829~66740385:-
HNSC	cis	rs2239557	0.614	rs73303112	ENSG00000259065.1	RP5-1021I20.1	-3.9	0.000111	0.0153	-0.24	-0.18	Common traits (Other);	chr14:74013433	chr14:73787360~73803270:+
HNSC	cis	rs7819412	0.645	rs4841508	ENSG00000269918.1	AF131215.9	-3.9	0.000111	0.0153	-0.19	-0.18	Triglycerides;	chr8:11207494	chr8:11104691~11106704:-
HNSC	cis	rs748404	0.666	rs16957730	ENSG00000166763.7	STRCP1	3.9	0.000111	0.0153	0.25	0.18	Lung cancer;	chr15:43438288	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs12913977	ENSG00000166763.7	STRCP1	3.9	0.000111	0.0153	0.25	0.18	Lung cancer;	chr15:43438913	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs12914122	ENSG00000166763.7	STRCP1	3.9	0.000111	0.0153	0.25	0.18	Lung cancer;	chr15:43438956	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs34697113	ENSG00000166763.7	STRCP1	3.9	0.000111	0.0153	0.25	0.18	Lung cancer;	chr15:43442041	chr15:43699488~43718184:-
HNSC	cis	rs1555322	1	rs2425040	ENSG00000126005.14	MMP24-AS1	-3.9	0.000111	0.0154	-0.33	-0.18	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35216462~35278131:-
HNSC	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-3.9	0.000111	0.0154	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
HNSC	cis	rs4760636	0.954	rs9859	ENSG00000268069.2	RP5-1057I20.4	3.9	0.000111	0.0154	0.21	0.18	Urate levels;	chr12:47783117	chr12:47784923~47786002:+
HNSC	cis	rs6095360	0.934	rs6019580	ENSG00000222365.1	SNORD12B	-3.9	0.000111	0.0154	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49009368	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.899	rs3818223	ENSG00000222365.1	SNORD12B	-3.9	0.000111	0.0154	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49009948	chr20:49280319~49280409:+
HNSC	cis	rs347412	1	rs347414	ENSG00000237263.1	MAPK6PS3	-3.9	0.000111	0.0154	-0.22	-0.18	Pulmonary function in asthmatics;	chr13:42213264	chr13:42068932~42071093:-
HNSC	cis	rs2209875	0.64	rs7037454	ENSG00000224945.1	RP11-82L18.2	-3.9	0.000111	0.0154	-0.23	-0.18	Pelvic organ prolapse (moderate/severe);	chr9:89095423	chr9:89088604~89109934:-
HNSC	cis	rs7824557	0.872	rs2572431	ENSG00000269918.1	AF131215.9	-3.9	0.000111	0.0154	-0.17	-0.18	Retinal vascular caliber;	chr8:11247568	chr8:11104691~11106704:-
HNSC	cis	rs763512	0.532	rs1416	ENSG00000276054.1	RP11-378E13.3	3.9	0.000111	0.0154	0.25	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37534709	chr17:37386886~37387926:+
HNSC	cis	rs597539	0.652	rs668576	ENSG00000255741.1	RP11-757G1.5	-3.9	0.000111	0.0154	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs482172	ENSG00000255741.1	RP11-757G1.5	-3.9	0.000111	0.0154	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68941503~68942852:-
HNSC	cis	rs6500395	0.775	rs28481630	ENSG00000261267.1	RP11-44I10.3	-3.9	0.000111	0.0154	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48629753	chr16:48559661~48587403:+
HNSC	cis	rs6601327	0.641	rs12542457	ENSG00000254340.1	RP11-10A14.3	-3.9	0.000111	0.0154	-0.21	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9707090	chr8:9141424~9145435:+
HNSC	cis	rs865483	0.86	rs853228	ENSG00000276054.1	RP11-378E13.3	3.9	0.000111	0.0154	0.22	0.18	Monocyte count;	chr17:37439788	chr17:37386886~37387926:+
HNSC	cis	rs865483	0.895	rs853229	ENSG00000276054.1	RP11-378E13.3	3.9	0.000111	0.0154	0.22	0.18	Monocyte count;	chr17:37440818	chr17:37386886~37387926:+
HNSC	cis	rs1585471	0.931	rs13131617	ENSG00000249532.3	RP11-148B6.1	-3.9	0.000111	0.0154	-0.21	-0.18	Myopia (pathological);	chr4:111680852	chr4:112646476~112650051:-
HNSC	cis	rs2911132	0.568	rs3797814	ENSG00000248734.2	CTD-2260A17.1	3.9	0.000112	0.0154	0.19	0.18	Urate levels (BMI interaction);	chr5:96756222	chr5:96784777~96785999:+
HNSC	cis	rs6088580	0.634	rs6120642	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000112	0.0154	-0.19	-0.18	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:33985617~33988989:-
HNSC	cis	rs5770917	1	rs762676	ENSG00000272821.1	CTA-384D8.36	-3.9	0.000112	0.0154	-0.26	-0.18	Narcolepsy;	chr22:50579365	chr22:50523926~50524780:+
HNSC	cis	rs62025270	0.576	rs62022925	ENSG00000259762.1	RP11-158M2.4	-3.9	0.000112	0.0154	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85750336~85752901:-
HNSC	cis	rs757081	0.667	rs214933	ENSG00000260196.1	RP1-239B22.5	-3.9	0.000112	0.0154	-0.21	-0.18	Systolic blood pressure;	chr11:17173037	chr11:17380649~17383531:+
HNSC	cis	rs4622329	0.615	rs6539019	ENSG00000258033.1	RP11-350G24.2	3.9	0.000112	0.0154	0.2	0.18	Systemic lupus erythematosus;	chr12:101909308	chr12:101066734~101069232:+
HNSC	cis	rs3740713	1	rs76586692	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs57311859	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.92	rs112973292	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.92	rs73438656	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.92	rs73438659	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438666	ENSG00000256464.1	YWHABP2	3.9	0.000112	0.0154	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr11:18490243~18490955:-
HNSC	cis	rs1155750	0.72	rs239849	ENSG00000224984.1	RP11-524H19.2	-3.9	0.000112	0.0154	-0.26	-0.18	Colorectal cancer;	chr6:54897524	chr6:54840118~54840855:-
HNSC	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-3.9	0.000112	0.0154	-0.2	-0.18	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
HNSC	cis	rs11168351	0.927	rs10875716	ENSG00000257763.1	OR5BK1P	3.9	0.000112	0.0154	0.17	0.18	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48355792~48356614:-
HNSC	cis	rs72949976	0.966	rs6752061	ENSG00000270659.1	RP11-105N14.1	3.9	0.000112	0.0154	0.18	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213163094	chr2:213152970~213153659:+
HNSC	cis	rs4948102	0.691	rs4470984	ENSG00000226278.1	PSPHP1	-3.9	0.000112	0.0154	-0.21	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55965865	chr7:55764797~55773288:+
HNSC	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	3.9	0.000112	0.0154	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
HNSC	cis	rs2554380	0.55	rs62025854	ENSG00000259570.1	RP11-671M22.4	-3.9	0.000112	0.0154	-0.23	-0.18	Height;	chr15:83883763	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.55	rs17296856	ENSG00000259570.1	RP11-671M22.4	-3.9	0.000112	0.0154	-0.23	-0.18	Height;	chr15:83888698	chr15:84394512~84395514:+
HNSC	cis	rs748404	0.666	rs12900259	ENSG00000166763.7	STRCP1	3.9	0.000112	0.0154	0.25	0.18	Lung cancer;	chr15:43427369	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs34921640	ENSG00000166763.7	STRCP1	3.9	0.000112	0.0154	0.25	0.18	Lung cancer;	chr15:43429187	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs62020574	ENSG00000166763.7	STRCP1	3.9	0.000112	0.0154	0.25	0.18	Lung cancer;	chr15:43429380	chr15:43699488~43718184:-
HNSC	cis	rs9516	0.966	rs2887135	ENSG00000254974.1	RP11-702H23.2	3.9	0.000112	0.0154	0.17	0.18	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74485580~74486051:-
HNSC	cis	rs11992162	0.967	rs11250185	ENSG00000269918.1	AF131215.9	3.9	0.000112	0.0154	0.18	0.18	Monocyte count;	chr8:11975614	chr8:11104691~11106704:-
HNSC	cis	rs11992162	1	rs12334769	ENSG00000269918.1	AF131215.9	3.9	0.000112	0.0154	0.18	0.18	Monocyte count;	chr8:11975652	chr8:11104691~11106704:-
HNSC	cis	rs9863	0.794	rs7133378	ENSG00000270028.1	RP11-380L11.4	3.9	0.000112	0.0154	0.21	0.18	White blood cell count;	chr12:123924955	chr12:123925461~123926083:-
HNSC	cis	rs7637230	1	rs4683948	ENSG00000244119.1	PDCL3P4	-3.9	0.000112	0.0154	-0.19	-0.18	Psoriasis vulgaris;Psoriasis;	chr3:101931344	chr3:101712472~101713191:+
HNSC	cis	rs17772222	0.917	rs11159868	ENSG00000258789.1	RP11-507K2.3	-3.9	0.000112	0.0154	-0.21	-0.18	Coronary artery calcification;	chr14:88760528	chr14:88551597~88552493:+
HNSC	cis	rs2948294	0.588	rs4840913	ENSG00000254153.1	CTA-398F10.2	3.9	0.000112	0.0154	0.2	0.18	Red cell distribution width;	chr8:8259384	chr8:8456909~8461337:-
HNSC	cis	rs1925953	0.711	rs728893	ENSG00000233589.1	RP4-694A7.2	-3.9	0.000112	0.0154	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68377059	chr1:68479129~68483539:+
HNSC	cis	rs5167	0.505	rs7257468	ENSG00000269148.1	AC092301.3	3.9	0.000112	0.0154	0.16	0.18	Blood protein levels;	chr19:44949887	chr19:45830164~45831108:+
HNSC	cis	rs5167	0.504	rs7258345	ENSG00000269148.1	AC092301.3	3.9	0.000112	0.0154	0.16	0.18	Blood protein levels;	chr19:44949894	chr19:45830164~45831108:+
HNSC	cis	rs5167	0.504	rs7257476	ENSG00000269148.1	AC092301.3	3.9	0.000112	0.0154	0.16	0.18	Blood protein levels;	chr19:44949908	chr19:45830164~45831108:+
HNSC	cis	rs6964587	0.626	rs4422709	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000112	0.0154	0.19	0.18	Breast cancer;	chr7:91881654	chr7:92134604~92180725:+
HNSC	cis	rs7577696	0.962	rs4952249	ENSG00000272716.1	RP11-563N4.1	-3.9	0.000112	0.0154	-0.17	-0.18	Inflammatory biomarkers;	chr2:32118604	chr2:32165046~32165757:-
HNSC	cis	rs10791097	0.694	rs4456262	ENSG00000254842.5	RP11-890B15.2	3.9	0.000112	0.0154	0.16	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885918	chr11:130844191~130865561:-
HNSC	cis	rs28489187	0.706	rs233131	ENSG00000223653.4	RP11-131L23.1	3.9	0.000112	0.0154	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329576	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs423105	ENSG00000223653.4	RP11-131L23.1	3.9	0.000112	0.0154	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85330744	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.666	rs233132	ENSG00000223653.4	RP11-131L23.1	3.9	0.000112	0.0154	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85330862	chr1:85276715~85448124:+
HNSC	cis	rs62025270	0.688	rs79083718	ENSG00000259762.1	RP11-158M2.4	-3.9	0.000112	0.0154	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85750336~85752901:-
HNSC	cis	rs3096299	0.967	rs2965937	ENSG00000224888.4	RP5-1142A6.2	3.9	0.000112	0.0154	0.17	0.18	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:88731180~88741425:+
HNSC	cis	rs6504950	0.83	rs35097996	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54944562	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.79	rs8066833	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54948114	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.821	rs8066588	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54948328	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs8073158	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54951254	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs3087650	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54951967	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs12937006	ENSG00000279059.1	RP11-257O5.2	-3.9	0.000112	0.0154	-0.15	-0.18	Breast cancer;	chr17:54953100	chr17:54956760~54958426:-
HNSC	cis	rs6430585	0.528	rs309172	ENSG00000231890.6	DARS-AS1	-3.9	0.000112	0.0154	-0.3	-0.18	Corneal structure;	chr2:135916458	chr2:135985176~136022593:+
HNSC	cis	rs6964587	0.626	rs2269810	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000112	0.0154	0.19	0.18	Breast cancer;	chr7:91879523	chr7:92134604~92180725:+
HNSC	cis	rs5167	0.504	rs4803781	ENSG00000269148.1	AC092301.3	3.9	0.000112	0.0154	0.16	0.18	Blood protein levels;	chr19:44956414	chr19:45830164~45831108:+
HNSC	cis	rs11157436	0.918	rs3811285	ENSG00000211812.1	TRAV26-2	-3.9	0.000112	0.0154	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155322	chr14:22202583~22203368:+
HNSC	cis	rs7178375	1	rs9806159	ENSG00000215302.7	CTD-3092A11.1	-3.9	0.000112	0.0154	-0.27	-0.18	Hypertriglyceridemia;	chr15:30917451	chr15:30470779~30507623:+
HNSC	cis	rs9329221	0.597	rs17751178	ENSG00000255310.2	AF131215.2	3.9	0.000112	0.0154	0.17	0.18	Neuroticism;	chr8:10259220	chr8:11107788~11109726:-
HNSC	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	3.9	0.000112	0.0154	0.25	0.18	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
HNSC	cis	rs6570726	0.846	rs6919684	ENSG00000270638.1	RP3-466P17.1	3.9	0.000112	0.0154	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	3.9	0.000112	0.0154	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
HNSC	cis	rs4356203	0.846	rs1685932	ENSG00000260196.1	RP1-239B22.5	-3.9	0.000112	0.0154	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17380649~17383531:+
HNSC	cis	rs7829975	1	rs7829975	ENSG00000233609.3	RP11-62H7.2	-3.9	0.000112	0.0154	-0.17	-0.18	Mood instability;	chr8:8690607	chr8:8961200~8979025:+
HNSC	cis	rs58873874	0.737	rs75022277	ENSG00000248544.2	CTB-47B11.3	3.9	0.000112	0.0154	0.42	0.18	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157375741~157384950:-
HNSC	cis	rs6968419	0.674	rs4730724	ENSG00000237870.5	AC073130.1	3.9	0.000112	0.0154	0.21	0.18	Intraocular pressure;	chr7:116265285	chr7:116275606~116286734:-
HNSC	cis	rs8024893	1	rs7180114	ENSG00000259448.2	RP11-16E12.1	-3.9	0.000112	0.0154	-0.24	-0.18	Red cell distribution width;	chr15:31247976	chr15:31216020~31224445:+
HNSC	cis	rs12893668	0.703	rs34186780	ENSG00000269958.1	RP11-73M18.8	3.9	0.000112	0.0154	0.17	0.18	Reticulocyte count;	chr14:103561258	chr14:103696353~103697163:+
HNSC	cis	rs55823223	0.564	rs936396	ENSG00000267801.1	RP11-552F3.9	3.9	0.000112	0.0154	0.2	0.18	Psoriasis;	chr17:75850748	chr17:75876372~75879546:+
HNSC	cis	rs4144743	1	rs2037150	ENSG00000228782.6	CTD-2026D20.3	-3.9	0.000112	0.0154	-0.21	-0.18	Body mass index;	chr17:47251352	chr17:47450568~47492492:-
HNSC	cis	rs9329221	0.655	rs4316191	ENSG00000269918.1	AF131215.9	-3.9	0.000112	0.0154	-0.18	-0.18	Neuroticism;	chr8:10401719	chr8:11104691~11106704:-
HNSC	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-3.9	0.000112	0.0154	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
HNSC	cis	rs1665050	0.534	rs7167050	ENSG00000259732.1	RP11-59H7.3	-3.9	0.000112	0.0154	-0.23	-0.18	Atopic dermatitis;	chr15:58948602	chr15:59121034~59133250:+
HNSC	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-3.9	0.000112	0.0154	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
HNSC	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	3.9	0.000112	0.0154	0.22	0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
HNSC	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-3.9	0.000112	0.0154	-0.17	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
HNSC	cis	rs2439831	0.867	rs11856184	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43626964	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.867	rs2927072	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43630200	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.867	rs2920781	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43632484	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.764	rs2447193	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43637535	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.867	rs2447211	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43644153	chr15:43702363~43702470:+
HNSC	cis	rs2439831	0.571	rs2470121	ENSG00000201136.1	RNU6-353P	-3.9	0.000112	0.0154	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43645420	chr15:43702363~43702470:+
HNSC	cis	rs4356203	0.905	rs615358	ENSG00000272034.1	SNORD14A	-3.9	0.000112	0.0155	-0.14	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17188885	chr11:17074654~17074744:-
HNSC	cis	rs11148252	0.595	rs9526974	ENSG00000198384.8	TPTE2P3	3.9	0.000112	0.0155	0.22	0.18	Lewy body disease;	chr13:52676905	chr13:52522632~52586906:+
HNSC	cis	rs1275468	1	rs1148000	ENSG00000257497.2	RP11-585P4.5	-3.9	0.000112	0.0155	-0.26	-0.18	Polycystic ovary syndrome;	chr12:75542521	chr12:75483454~75489820:-
HNSC	cis	rs10090774	0.76	rs13257090	ENSG00000279766.1	RP11-642A1.2	-3.9	0.000112	0.0155	-0.18	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140719364	chr8:140572142~140572812:-
HNSC	cis	rs1859596	0.966	rs4730881	ENSG00000234456.6	MAGI2-AS3	3.9	0.000112	0.0155	0.14	0.18	Reading or mathematical ability;	chr7:79482675	chr7:79452877~79471208:+
HNSC	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-3.9	0.000112	0.0155	-0.18	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
HNSC	cis	rs2836974	0.583	rs9636957	ENSG00000255568.3	BRWD1-AS2	-3.9	0.000112	0.0155	-0.15	-0.18	Cognitive function;	chr21:39333921	chr21:39313935~39314962:+
HNSC	cis	rs58785573	0.57	rs1824652	ENSG00000231160.8	KLF3-AS1	-3.9	0.000112	0.0155	-0.16	-0.18	Lymphocyte percentage of white cells;	chr4:38642976	chr4:38612701~38664883:-
HNSC	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	3.9	0.000112	0.0155	0.19	0.18	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
HNSC	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-3.9	0.000112	0.0155	-0.2	-0.18	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
HNSC	cis	rs4908760	0.827	rs1463053	ENSG00000232912.4	RP5-1115A15.1	3.9	0.000112	0.0155	0.18	0.18	Vitiligo;	chr1:8644978	chr1:8424645~8434838:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-3.9	0.000112	0.0155	-0.25	-0.18	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
HNSC	cis	rs5758659	0.904	rs5758653	ENSG00000273366.1	CTA-989H11.1	-3.9	0.000112	0.0155	-0.21	-0.18	Cognitive function;	chr22:42217479	chr22:42278188~42278846:+
HNSC	cis	rs8044868	0.53	rs7186155	ENSG00000259209.3	RP5-991G20.2	3.9	0.000112	0.0155	0.19	0.18	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72144297	chr16:72805998~72809872:+
HNSC	cis	rs17345786	0.628	rs11718446	ENSG00000244119.1	PDCL3P4	3.89	0.000113	0.0155	0.18	0.18	Colonoscopy-negative controls vs population controls;	chr3:101833709	chr3:101712472~101713191:+
HNSC	cis	rs17594362	0.512	rs348247	ENSG00000229473.2	RGS17P1	3.89	0.000113	0.0155	0.31	0.18	Multiple sclerosis;	chr13:41552478	chr13:40992779~40993331:-
HNSC	cis	rs138024639	1	rs138024639	ENSG00000204709.4	LINC01556	3.89	0.000113	0.0155	0.39	0.18	Breast cancer;	chr6:28468244	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs55690788	ENSG00000204709.4	LINC01556	3.89	0.000113	0.0155	0.39	0.18	Depression;	chr6:28468368	chr6:28943877~28944537:+
HNSC	cis	rs7005380	0.62	rs4871012	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119895734	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs4871013	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119895750	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13281299	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897253	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs7832923	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897540	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469861	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897673	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469862	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897796	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469863	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897910	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469864	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897985	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs6469865	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000113	0.0155	-0.14	-0.18	Interstitial lung disease;	chr8:119897995	chr8:119838736~119840385:-
HNSC	cis	rs9329221	0.521	rs4841294	ENSG00000269918.1	AF131215.9	-3.89	0.000113	0.0155	-0.17	-0.18	Neuroticism;	chr8:10247558	chr8:11104691~11106704:-
HNSC	cis	rs1387259	0.839	rs7487682	ENSG00000257763.1	OR5BK1P	-3.89	0.000113	0.0155	-0.17	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48355792~48356614:-
HNSC	cis	rs868153	0.662	rs7738124	ENSG00000275339.1	RP3-425C14.6	3.89	0.000113	0.0155	0.19	0.18	Vertical cup-disc ratio;	chr6:122201695	chr6:122454358~122454612:+
HNSC	cis	rs453301	0.522	rs2929455	ENSG00000253981.4	ALG1L13P	-3.89	0.000113	0.0155	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9225923	chr8:8236003~8244667:-
HNSC	cis	rs4427176	0.507	rs13269437	ENSG00000254340.1	RP11-10A14.3	-3.89	0.000113	0.0155	-0.24	-0.18	Mosquito bite size;	chr8:9721780	chr8:9141424~9145435:+
HNSC	cis	rs6968419	0.609	rs73716708	ENSG00000237870.5	AC073130.1	3.89	0.000113	0.0155	0.21	0.18	Intraocular pressure;	chr7:116265689	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.609	rs73716710	ENSG00000237870.5	AC073130.1	3.89	0.000113	0.0155	0.21	0.18	Intraocular pressure;	chr7:116265690	chr7:116275606~116286734:-
HNSC	cis	rs12291225	0.877	rs2303974	ENSG00000254418.1	RP11-21L19.1	3.89	0.000113	0.0155	0.22	0.18	Sense of smell;	chr11:14243433	chr11:14262846~14273691:-
HNSC	cis	rs28489187	0.683	rs233093	ENSG00000223653.4	RP11-131L23.1	3.89	0.000113	0.0155	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85357437	chr1:85276715~85448124:+
HNSC	cis	rs9313772	1	rs6867081	ENSG00000254350.1	RP11-542A14.1	-3.89	0.000113	0.0155	-0.2	-0.18	Blood pressure;	chr5:158386005	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.962	rs6863179	ENSG00000254350.1	RP11-542A14.1	-3.89	0.000113	0.0155	-0.2	-0.18	Blood pressure;	chr5:158386140	chr5:158424585~158452758:+
HNSC	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	3.89	0.000113	0.0155	0.2	0.18	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
HNSC	cis	rs4853525	0.59	rs7587672	ENSG00000228509.4	AC006460.2	3.89	0.000113	0.0155	0.25	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190858549	chr2:190676944~190708716:-
HNSC	cis	rs4908760	0.965	rs10864354	ENSG00000232912.4	RP5-1115A15.1	3.89	0.000113	0.0155	0.19	0.18	Vitiligo;	chr1:8489681	chr1:8424645~8434838:+
HNSC	cis	rs2975734	0.709	rs6988826	ENSG00000269918.1	AF131215.9	-3.89	0.000113	0.0155	-0.19	-0.18	Chronotype;Morning vs. evening chronotype;	chr8:10252115	chr8:11104691~11106704:-
HNSC	cis	rs870825	0.929	rs72689255	ENSG00000254233.1	RP11-242J7.1	3.89	0.000113	0.0155	0.31	0.18	Blood protein levels;	chr4:184668987	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs55880126	ENSG00000254233.1	RP11-242J7.1	3.89	0.000113	0.0155	0.31	0.18	Blood protein levels;	chr4:184670083	chr4:184584093~184625030:-
HNSC	cis	rs12908161	1	rs12905057	ENSG00000229212.6	RP11-561C5.4	-3.89	0.000113	0.0155	-0.26	-0.18	Schizophrenia;	chr15:84667534	chr15:85205440~85234795:-
HNSC	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	3.89	0.000113	0.0155	0.15	0.18	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000227888.4	FAM66A	3.89	0.000113	0.0155	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12362019~12388296:+
HNSC	cis	rs1075232	1	rs12439239	ENSG00000103832.10	GOLGA8UP	-3.89	0.000113	0.0155	-0.37	-0.18	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30791573~30801859:+
HNSC	cis	rs3764400	0.567	rs8071879	ENSG00000228782.6	CTD-2026D20.3	3.89	0.000113	0.0155	0.25	0.18	Body mass index;	chr17:48140095	chr17:47450568~47492492:-
HNSC	cis	rs6940638	0.688	rs2022272	ENSG00000224843.5	LINC00240	3.89	0.000113	0.0155	0.18	0.18	Intelligence (multi-trait analysis);	chr6:27135801	chr6:26956992~27023924:+
HNSC	cis	rs6981523	0.553	rs2409730	ENSG00000255310.2	AF131215.2	-3.89	0.000113	0.0155	-0.18	-0.18	Neuroticism;	chr8:11203129	chr8:11107788~11109726:-
HNSC	cis	rs897984	0.647	rs8060857	ENSG00000279196.1	RP11-1072A3.3	-3.89	0.000113	0.0155	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30991399	chr16:30984630~30988270:-
HNSC	cis	rs7674212	1	rs7691873	ENSG00000251288.2	RP11-10L12.2	3.89	0.000113	0.0155	0.2	0.18	Type 2 diabetes;	chr4:103066742	chr4:102751401~102752641:+
HNSC	cis	rs792448	0.743	rs351408	ENSG00000226251.4	RP11-15I11.3	-3.89	0.000113	0.0155	-0.22	-0.18	White blood cell count (basophil);	chr1:212267786	chr1:212225278~212238977:-
HNSC	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-3.89	0.000113	0.0155	-0.22	-0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
HNSC	cis	rs3134425	0.583	rs11218856	ENSG00000199709.1	RNU4-23P	3.89	0.000113	0.0155	0.21	0.18	Small cell lung carcinoma;	chr11:122837181	chr11:122927034~122927173:+
HNSC	cis	rs6493858	0.839	rs35749329	ENSG00000277245.1	RP11-48G14.3	-3.89	0.000113	0.0156	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56168935	chr15:56447120~56447697:+
HNSC	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-3.89	0.000113	0.0156	-0.17	-0.18	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
HNSC	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	3.89	0.000113	0.0156	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
HNSC	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000113	0.0156	-0.2	-0.18	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
HNSC	cis	rs72843166	0.562	rs2286571	ENSG00000265282.1	RP11-269G24.4	3.89	0.000113	0.0156	0.25	0.18	Intelligence (multi-trait analysis);	chr17:63440859	chr17:63430468~63432211:-
HNSC	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	3.89	0.000113	0.0156	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
HNSC	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	3.89	0.000113	0.0156	0.19	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
HNSC	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-3.89	0.000113	0.0156	-0.23	-0.18	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
HNSC	cis	rs7927592	0.626	rs11228279	ENSG00000255031.4	RP11-802E16.3	-3.89	0.000113	0.0156	-0.15	-0.18	Total body bone mineral density;	chr11:68542212	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.763	rs10896340	ENSG00000255031.4	RP11-802E16.3	-3.89	0.000113	0.0156	-0.15	-0.18	Total body bone mineral density;	chr11:68545177	chr11:68050740~68053762:+
HNSC	cis	rs2384207	0.584	rs7966103	ENSG00000201208.1	Y_RNA	-3.89	0.000113	0.0156	-0.26	-0.18	Response to fenofibrate (adiponectin levels);	chr12:113302662	chr12:113178423~113178519:-
HNSC	cis	rs73198271	0.71	rs11779565	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000113	0.0156	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8961200~8979025:+
HNSC	cis	rs748404	0.626	rs60367691	ENSG00000166763.7	STRCP1	3.89	0.000113	0.0156	0.25	0.18	Lung cancer;	chr15:43559201	chr15:43699488~43718184:-
HNSC	cis	rs3806843	0.576	rs246066	ENSG00000276545.1	PCDHGB9P	3.89	0.000113	0.0156	0.22	0.18	Depressive symptoms (multi-trait analysis);	chr5:140943562	chr5:141439853~141442449:+
HNSC	cis	rs7720894	0.935	rs1445976	ENSG00000215032.2	GNL3LP1	-3.89	0.000113	0.0156	-0.2	-0.18	Body mass index;	chr5:61511907	chr5:60891935~60893577:-
HNSC	cis	rs11951515	0.691	rs56206275	ENSG00000249286.1	CTD-2210P15.2	3.89	0.000113	0.0156	0.19	0.18	Metabolite levels  (X-11787);	chr5:43335468	chr5:43586918~43588223:-
HNSC	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-3.89	0.000113	0.0156	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
HNSC	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
HNSC	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000113	0.0156	-0.18	-0.18	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
HNSC	cis	rs1113500	0.787	rs10881501	ENSG00000226822.1	RP11-356N1.2	3.89	0.000113	0.0156	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108099123	chr1:108071482~108074519:+
HNSC	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-3.89	0.000114	0.0156	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-3.89	0.000114	0.0156	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
HNSC	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	3.89	0.000114	0.0156	0.23	0.18	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
HNSC	cis	rs7824557	0.628	rs11991153	ENSG00000255310.2	AF131215.2	3.89	0.000114	0.0156	0.17	0.18	Retinal vascular caliber;	chr8:11345598	chr8:11107788~11109726:-
HNSC	cis	rs7267979	0.78	rs6050679	ENSG00000231081.1	RP4-760C5.3	-3.89	0.000114	0.0156	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26008791~26010531:-
HNSC	cis	rs6688613	0.759	rs61815132	ENSG00000215834.7	FMO9P	3.89	0.000114	0.0156	0.24	0.18	Refractive astigmatism;	chr1:166951674	chr1:166603675~166631400:+
HNSC	cis	rs7085104	0.7	rs7096183	ENSG00000213061.2	PFN1P11	3.89	0.000114	0.0156	0.22	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102838011~102845473:-
HNSC	cis	rs6500395	1	rs1004909	ENSG00000261267.1	RP11-44I10.3	3.89	0.000114	0.0156	0.22	0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48691669	chr16:48559661~48587403:+
HNSC	cis	rs2117029	0.782	rs11168850	ENSG00000258101.2	RP11-977B10.2	3.89	0.000114	0.0156	0.22	0.18	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49232790~49264756:-
HNSC	cis	rs3806843	0.606	rs251377	ENSG00000276545.1	PCDHGB9P	-3.89	0.000114	0.0156	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140876207	chr5:141439853~141442449:+
HNSC	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	3.89	0.000114	0.0156	0.17	0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
HNSC	cis	rs950027	0.62	rs872192	ENSG00000259479.5	SORD2P	3.89	0.000114	0.0156	0.2	0.18	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:44826371~44884694:-
HNSC	cis	rs4699052	0.625	rs1850321	ENSG00000246560.2	RP11-10L12.4	3.89	0.000114	0.0156	0.21	0.18	Testicular germ cell tumor;	chr4:103331608	chr4:102828055~102844075:+
HNSC	cis	rs2732480	0.5	rs2450991	ENSG00000257763.1	OR5BK1P	3.89	0.000114	0.0156	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48355792~48356614:-
HNSC	cis	rs2048656	0.605	rs7837008	ENSG00000254340.1	RP11-10A14.3	3.89	0.000114	0.0156	0.23	0.18	Schizophrenia;	chr8:9788996	chr8:9141424~9145435:+
HNSC	cis	rs2048656	0.605	rs7814507	ENSG00000254340.1	RP11-10A14.3	3.89	0.000114	0.0156	0.23	0.18	Schizophrenia;	chr8:9789050	chr8:9141424~9145435:+
HNSC	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-3.89	0.000114	0.0156	-0.2	-0.18	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
HNSC	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	3.89	0.000114	0.0156	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	3.89	0.000114	0.0156	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
HNSC	cis	rs1937680	0.657	rs10762471	ENSG00000236671.6	PRKG1-AS1	-3.89	0.000114	0.0156	-0.25	-0.18	Breast cancer;	chr10:51887663	chr10:52230742~52314128:-
HNSC	cis	rs62246343	0.605	rs4308263	ENSG00000254485.4	RP11-380O24.1	3.89	0.000114	0.0156	0.22	0.18	Fibrinogen levels;	chr3:9415674	chr3:9292588~9363303:-
HNSC	cis	rs4648045	0.734	rs11722146	ENSG00000230069.3	LRRC37A15P	-3.89	0.000114	0.0156	-0.19	-0.18	Lymphocyte percentage of white cells;	chr4:102603472	chr4:102727274~102730721:-
HNSC	cis	rs4648045	0.734	rs12509517	ENSG00000230069.3	LRRC37A15P	-3.89	0.000114	0.0156	-0.19	-0.18	Lymphocyte percentage of white cells;	chr4:102604351	chr4:102727274~102730721:-
HNSC	cis	rs4648045	0.734	rs4235406	ENSG00000230069.3	LRRC37A15P	-3.89	0.000114	0.0156	-0.19	-0.18	Lymphocyte percentage of white cells;	chr4:102605374	chr4:102727274~102730721:-
HNSC	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-3.89	0.000114	0.0156	-0.25	-0.18	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
HNSC	cis	rs11951515	0.626	rs3733768	ENSG00000249286.1	CTD-2210P15.2	-3.89	0.000114	0.0156	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43296930	chr5:43586918~43588223:-
HNSC	cis	rs11098499	0.913	rs56122576	ENSG00000250412.1	KLHL2P1	3.89	0.000114	0.0156	0.23	0.18	Corneal astigmatism;	chr4:119208181	chr4:119334329~119378233:+
HNSC	cis	rs4660214	0.666	rs1180376	ENSG00000182109.6	RP11-69E11.4	3.89	0.000114	0.0156	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39522280~39546187:-
HNSC	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-3.89	0.000114	0.0156	-0.18	-0.18	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
HNSC	cis	rs442309	0.875	rs224061	ENSG00000238280.1	RP11-436D10.3	-3.89	0.000114	0.0156	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62742409	chr10:62793562~62805887:-
HNSC	cis	rs17014483	0.749	rs2924934	ENSG00000248019.2	FAM13A-AS1	-3.89	0.000114	0.0156	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88707091	chr4:88709789~88730103:+
HNSC	cis	rs1665050	0.534	rs7167050	ENSG00000277144.1	RP11-59H7.4	-3.89	0.000114	0.0157	-0.22	-0.18	Atopic dermatitis;	chr15:58948602	chr15:59115547~59116089:-
HNSC	cis	rs3733585	0.605	rs56178126	ENSG00000250413.1	RP11-448G15.1	3.89	0.000114	0.0157	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10121957	chr4:10006482~10009725:+
HNSC	cis	rs6840360	0.681	rs4519779	ENSG00000251611.1	RP11-610P16.1	-3.89	0.000114	0.0157	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151407551~151408835:-
HNSC	cis	rs3738443	0.904	rs12569090	ENSG00000259865.1	RP11-488L18.10	3.89	0.000114	0.0157	0.17	0.18	Alcohol dependence;	chr1:247234370	chr1:247187281~247188526:-
HNSC	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	3.89	0.000114	0.0157	0.2	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
HNSC	cis	rs2919009	0.545	rs11199680	ENSG00000271670.1	RP11-95I16.4	-3.89	0.000114	0.0157	-0.19	-0.18	Obesity-related traits;	chr10:120957788	chr10:120879256~120880667:-
HNSC	cis	rs1620921	0.711	rs2489951	ENSG00000231863.1	RP3-428L16.1	-3.89	0.000114	0.0157	-0.21	-0.18	Lipoprotein (a) - cholesterol levels;	chr6:160838767	chr6:160931080~160969771:+
HNSC	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	3.89	0.000114	0.0157	0.19	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
HNSC	cis	rs4834770	0.792	rs7676969	ENSG00000250412.1	KLHL2P1	3.89	0.000114	0.0157	0.21	0.18	Blood protein levels;	chr4:119252569	chr4:119334329~119378233:+
HNSC	cis	rs4834770	0.685	rs4496567	ENSG00000250412.1	KLHL2P1	3.89	0.000114	0.0157	0.21	0.18	Blood protein levels;	chr4:119254470	chr4:119334329~119378233:+
HNSC	cis	rs7429990	0.864	rs13061412	ENSG00000228638.1	FCF1P2	3.89	0.000114	0.0157	0.16	0.18	Educational attainment (years of education);	chr3:47660092	chr3:48290793~48291375:-
HNSC	cis	rs8031584	0.651	rs28664821	ENSG00000270015.1	RP11-540B6.6	3.89	0.000114	0.0157	0.18	0.18	Huntington's disease progression;	chr15:30880120	chr15:30926514~30928407:+
HNSC	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-3.89	0.000114	0.0157	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
HNSC	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-3.89	0.000114	0.0157	-0.21	-0.18	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
HNSC	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	3.89	0.000114	0.0157	0.17	0.18	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
HNSC	cis	rs7005380	0.62	rs6988011	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000114	0.0157	-0.14	-0.18	Interstitial lung disease;	chr8:119898298	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs35272074	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000114	0.0157	-0.14	-0.18	Interstitial lung disease;	chr8:119898543	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs10103660	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000114	0.0157	-0.14	-0.18	Interstitial lung disease;	chr8:119898547	chr8:119838736~119840385:-
HNSC	cis	rs8180991	0.744	rs34604874	ENSG00000254431.1	RP11-550A5.2	-3.89	0.000114	0.0157	-0.27	-0.18	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125475615	chr8:125348196~125351416:-
HNSC	cis	rs13260300	0.657	rs10957733	ENSG00000254349.4	FLJ39080	-3.89	0.000114	0.0157	-0.21	-0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74611053	chr8:74599775~74823313:+
HNSC	cis	rs7781557	1	rs10487284	ENSG00000239969.4	RP11-163E9.2	-3.89	0.000114	0.0157	-0.25	-0.18	Colorectal adenoma (advanced);	chr7:102829828	chr7:102364162~102380633:+
HNSC	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-3.89	0.000114	0.0157	-0.25	-0.18	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
HNSC	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000114	0.0157	-0.21	-0.18	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
HNSC	cis	rs62292953	0.535	rs17414558	ENSG00000248724.5	NPHP3-AS1	-3.89	0.000114	0.0157	-0.4	-0.18	Red cell distribution width;	chr3:132715312	chr3:132721750~132874223:+
HNSC	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-3.89	0.000114	0.0157	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
HNSC	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-3.89	0.000114	0.0157	-0.18	-0.18	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
HNSC	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-3.89	0.000114	0.0157	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
HNSC	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-3.89	0.000114	0.0157	-0.17	-0.18	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
HNSC	cis	rs2280018	0.526	rs2941257	ENSG00000263335.1	AF001548.5	-3.89	0.000114	0.0157	-0.24	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15726674~15732993:+
HNSC	cis	rs2280018	0.526	rs1510148	ENSG00000263335.1	AF001548.5	-3.89	0.000114	0.0157	-0.24	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15726674~15732993:+
HNSC	cis	rs17407555	0.657	rs16895675	ENSG00000250413.1	RP11-448G15.1	-3.89	0.000114	0.0157	-0.23	-0.18	Schizophrenia (age at onset);	chr4:10270431	chr4:10006482~10009725:+
HNSC	cis	rs853679	0.517	rs9393891	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28111382	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9468286	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28111650	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.516	rs7739216	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Parkinson's disease;	chr6:28112168	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs35512245	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28112175	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9380055	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28113851	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368553	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28114487	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368554	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28114933	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs4713137	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28115743	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9348793	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Depression;	chr6:28116411	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.586	rs6905516	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Parkinson's disease;	chr6:28118700	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.586	rs6905522	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Parkinson's disease;	chr6:28118701	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.586	rs9468290	ENSG00000219891.2	ZSCAN12P1	3.89	0.000114	0.0157	0.25	0.18	Parkinson's disease;	chr6:28119896	chr6:28091154~28093664:+
HNSC	cis	rs7572733	0.534	rs7604700	ENSG00000231621.1	AC013264.2	-3.89	0.000114	0.0157	-0.17	-0.18	Dermatomyositis;	chr2:197853906	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.555	rs1435569	ENSG00000231621.1	AC013264.2	-3.89	0.000114	0.0157	-0.17	-0.18	Dermatomyositis;	chr2:197853943	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.514	rs700686	ENSG00000231621.1	AC013264.2	-3.89	0.000114	0.0157	-0.17	-0.18	Dermatomyositis;	chr2:197856330	chr2:197197991~197199273:+
HNSC	cis	rs7927592	0.83	rs10896339	ENSG00000255031.4	RP11-802E16.3	3.89	0.000114	0.0157	0.16	0.18	Total body bone mineral density;	chr11:68535378	chr11:68050740~68053762:+
HNSC	cis	rs9531006	0.636	rs9593420	ENSG00000227676.3	LINC01068	-3.89	0.000114	0.0157	-0.26	-0.18	Sleep duration;	chr13:79905269	chr13:79566727~79571436:+
HNSC	cis	rs7735319	0.932	rs1479644	ENSG00000249572.1	CTD-2203K17.1	3.89	0.000115	0.0157	0.2	0.18	Systolic blood pressure;	chr5:33170717	chr5:33424025~33440619:-
HNSC	cis	rs847649	0.767	rs7796678	ENSG00000239969.4	RP11-163E9.2	3.89	0.000115	0.0157	0.21	0.18	Morning vs. evening chronotype;	chr7:103138000	chr7:102364162~102380633:+
HNSC	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	3.89	0.000115	0.0157	0.25	0.18	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
HNSC	cis	rs9487051	0.582	rs351717	ENSG00000243587.6	C6orf183	-3.89	0.000115	0.0157	-0.18	-0.18	Reticulocyte fraction of red cells;	chr6:109232515	chr6:109165833~109271014:+
HNSC	cis	rs10510102	1	rs7923678	ENSG00000273891.1	RP11-500G22.5	3.89	0.000115	0.0157	0.19	0.18	Breast cancer;	chr10:121832546	chr10:121965764~121967700:+
HNSC	cis	rs3806843	0.576	rs251373	ENSG00000276545.1	PCDHGB9P	-3.89	0.000115	0.0157	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140873030	chr5:141439853~141442449:+
HNSC	cis	rs3806843	0.545	rs251375	ENSG00000276545.1	PCDHGB9P	-3.89	0.000115	0.0157	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140873375	chr5:141439853~141442449:+
HNSC	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	3.89	0.000115	0.0157	0.2	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
HNSC	cis	rs748404	0.666	rs34591748	ENSG00000166763.7	STRCP1	3.89	0.000115	0.0157	0.24	0.18	Lung cancer;	chr15:43334917	chr15:43699488~43718184:-
HNSC	cis	rs7429990	0.965	rs34507589	ENSG00000228638.1	FCF1P2	-3.89	0.000115	0.0157	-0.19	-0.18	Educational attainment (years of education);	chr3:47832552	chr3:48290793~48291375:-
HNSC	cis	rs12745968	0.589	rs10782936	ENSG00000223787.2	RP4-593M8.1	-3.89	0.000115	0.0157	-0.21	-0.18	Bipolar disorder and schizophrenia;	chr1:92576349	chr1:92580476~92580821:-
HNSC	cis	rs2991971	0.81	rs6657237	ENSG00000234329.1	RP11-767N6.2	3.89	0.000115	0.0157	0.18	0.18	High light scatter reticulocyte count;	chr1:45454436	chr1:45651039~45651826:-
HNSC	cis	rs73201462	1	rs2037965	ENSG00000231305.3	RP11-723O4.2	3.89	0.000115	0.0157	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128306201	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811397	ENSG00000231305.3	RP11-723O4.2	3.89	0.000115	0.0157	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128308394	chr3:128861313~128871540:-
HNSC	cis	rs3785309	0.519	rs72765807	ENSG00000268836.1	LA16c-OS12.2	-3.89	0.000115	0.0157	-0.32	-0.18	Immature fraction of reticulocytes;	chr16:229886	chr16:185748~186294:-
HNSC	cis	rs4144743	1	rs2317385	ENSG00000228782.6	CTD-2026D20.3	-3.89	0.000115	0.0157	-0.21	-0.18	Body mass index;	chr17:47252316	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs2317384	ENSG00000228782.6	CTD-2026D20.3	-3.89	0.000115	0.0157	-0.21	-0.18	Body mass index;	chr17:47252404	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs3809861	ENSG00000228782.6	CTD-2026D20.3	-3.89	0.000115	0.0157	-0.21	-0.18	Body mass index;	chr17:47252700	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs3809862	ENSG00000228782.6	CTD-2026D20.3	-3.89	0.000115	0.0157	-0.21	-0.18	Body mass index;	chr17:47253062	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs7208170	ENSG00000228782.6	CTD-2026D20.3	-3.89	0.000115	0.0157	-0.21	-0.18	Body mass index;	chr17:47253393	chr17:47450568~47492492:-
HNSC	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	3.89	0.000115	0.0157	0.2	0.18	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
HNSC	cis	rs17660992	0.603	rs8108345	ENSG00000273837.1	LLNLR-470E3.1	-3.89	0.000115	0.0158	-0.2	-0.18	Blood protein levels;	chr19:51661033	chr19:51639478~51639931:-
HNSC	cis	rs7927592	0.913	rs2236708	ENSG00000255031.4	RP11-802E16.3	3.89	0.000115	0.0158	0.16	0.18	Total body bone mineral density;	chr11:68610577	chr11:68050740~68053762:+
HNSC	cis	rs721917	0.506	rs2254016	ENSG00000244733.5	RP11-506M13.3	-3.89	0.000115	0.0158	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79660891~79677996:+
HNSC	cis	rs11711311	1	rs7645473	ENSG00000241529.3	RN7SL767P	-3.89	0.000115	0.0158	-0.22	-0.18	IgG glycosylation;	chr3:113797340	chr3:113632704~113632998:+
HNSC	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-3.89	0.000115	0.0158	-0.21	-0.18	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
HNSC	cis	rs860818	1	rs858277	ENSG00000226816.2	AC005082.12	-3.89	0.000115	0.0158	-0.46	-0.18	Initial pursuit acceleration;	chr7:23212642	chr7:23206013~23208045:+
HNSC	cis	rs2098713	0.544	rs2056871	ENSG00000250155.1	CTD-2353F22.1	3.89	0.000115	0.0158	0.19	0.18	Telomere length;	chr5:37424753	chr5:36666214~36725195:-
HNSC	cis	rs73201462	1	rs56287882	ENSG00000231305.3	RP11-723O4.2	-3.89	0.000115	0.0158	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311500	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs73197383	ENSG00000231305.3	RP11-723O4.2	-3.89	0.000115	0.0158	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311631	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs56328893	ENSG00000231305.3	RP11-723O4.2	-3.89	0.000115	0.0158	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128322987	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs11706304	ENSG00000231305.3	RP11-723O4.2	-3.89	0.000115	0.0158	-0.26	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128331771	chr3:128861313~128871540:-
HNSC	cis	rs4840086	1	rs34085222	ENSG00000219755.1	RP1-199J3.5	3.89	0.000115	0.0158	0.22	0.18	Menarche (age at onset);	chr6:99758601	chr6:99575712~99576456:+
HNSC	cis	rs478304	0.651	rs4930319	ENSG00000255120.4	OVOL1-AS1	-3.89	0.000115	0.0158	-0.19	-0.18	Acne (severe);	chr11:65787987	chr11:65789051~65790868:-
HNSC	cis	rs11168618	0.904	rs11495273	ENSG00000240399.1	RP1-228P16.1	3.89	0.000115	0.0158	0.15	0.18	Adiponectin levels;	chr12:48535407	chr12:48054813~48055591:-
HNSC	cis	rs28830936	0.966	rs28432037	ENSG00000250379.1	RP11-23P13.4	3.89	0.000115	0.0158	0.22	0.18	Diastolic blood pressure;	chr15:41834581	chr15:41825099~41827936:-
HNSC	cis	rs6012564	0.749	rs8120015	ENSG00000227431.4	CSE1L-AS1	3.89	0.000115	0.0158	0.2	0.18	Anger;	chr20:49128772	chr20:49040463~49046044:-
HNSC	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-3.89	0.000115	0.0158	-0.22	-0.18	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
HNSC	cis	rs67072384	1	rs61489692	ENSG00000213365.3	AP000593.6	3.89	0.000115	0.0158	0.3	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734269	chr11:72280151~72281178:+
HNSC	cis	rs17270561	0.887	rs9358870	ENSG00000272810.1	U91328.22	-3.89	0.000115	0.0158	-0.2	-0.18	Iron status biomarkers;	chr6:25718982	chr6:26013241~26013757:+
HNSC	cis	rs6697139	1	rs10917688	ENSG00000215840.3	RP11-122G18.7	-3.89	0.000115	0.0158	-0.23	-0.18	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;	chr1:161688990	chr1:161406068~161407082:+
HNSC	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	3.89	0.000115	0.0158	0.13	0.18	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
HNSC	cis	rs1941023	0.739	rs1051593	ENSG00000279632.1	RP11-286N22.6	3.89	0.000115	0.0158	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60470518	chr11:61426448~61427325:-
HNSC	cis	rs6968419	1	rs6967663	ENSG00000237870.5	AC073130.1	3.89	0.000115	0.0158	0.2	0.18	Intraocular pressure;	chr7:116195756	chr7:116275606~116286734:-
HNSC	cis	rs12701220	0.52	rs7803208	ENSG00000224079.1	AC091729.7	3.89	0.000115	0.0158	0.24	0.18	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1074450~1078036:+
HNSC	cis	rs4489787	1	rs12231229	ENSG00000240399.1	RP1-228P16.1	-3.89	0.000115	0.0158	-0.25	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48416125	chr12:48054813~48055591:-
HNSC	cis	rs4489787	1	rs17122979	ENSG00000240399.1	RP1-228P16.1	-3.89	0.000115	0.0158	-0.25	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:48419914	chr12:48054813~48055591:-
HNSC	cis	rs9650657	0.504	rs6601566	ENSG00000255310.2	AF131215.2	-3.89	0.000115	0.0158	-0.17	-0.18	Neuroticism;	chr8:11185465	chr8:11107788~11109726:-
HNSC	cis	rs4356203	0.87	rs1979603	ENSG00000260196.1	RP1-239B22.5	-3.89	0.000115	0.0158	-0.19	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17380649~17383531:+
HNSC	cis	rs7829975	0.711	rs12682352	ENSG00000233609.3	RP11-62H7.2	3.89	0.000115	0.0158	0.17	0.18	Mood instability;	chr8:8788736	chr8:8961200~8979025:+
HNSC	cis	rs10875746	0.859	rs4760695	ENSG00000257763.1	OR5BK1P	-3.89	0.000115	0.0158	-0.22	-0.18	Longevity (90 years and older);	chr12:48198065	chr12:48355792~48356614:-
HNSC	cis	rs7572733	0.935	rs11692344	ENSG00000222017.1	AC011997.1	3.89	0.000115	0.0158	0.21	0.18	Dermatomyositis;	chr2:197931139	chr2:197693106~197774823:+
HNSC	cis	rs886774	1	rs10215418	ENSG00000273055.1	CTB-13F3.1	-3.89	0.000115	0.0158	-0.18	-0.18	Ulcerative colitis;	chr7:107855593	chr7:107942116~107942740:+
HNSC	cis	rs860295	0.702	rs11264397	ENSG00000225855.5	RUSC1-AS1	3.89	0.000116	0.0158	0.12	0.18	Body mass index;	chr1:155641694	chr1:155316863~155324176:-
HNSC	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000116	0.0158	-0.21	-0.18	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
HNSC	cis	rs13256369	1	rs13271966	ENSG00000173295.6	FAM86B3P	3.89	0.000116	0.0158	0.23	0.18	Obesity-related traits;	chr8:8717962	chr8:8228595~8244865:+
HNSC	cis	rs17407555	0.657	rs6856199	ENSG00000250413.1	RP11-448G15.1	-3.89	0.000116	0.0158	-0.23	-0.18	Schizophrenia (age at onset);	chr4:10269968	chr4:10006482~10009725:+
HNSC	cis	rs599083	0.59	rs10791984	ENSG00000212093.1	AP000807.1	-3.89	0.000116	0.0158	-0.19	-0.18	Bone mineral density (spine);	chr11:68640367	chr11:68506083~68506166:-
HNSC	cis	rs7688540	0.739	rs11729659	ENSG00000211553.1	AC253576.2	-3.89	0.000116	0.0158	-0.26	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:136461~136568:+
HNSC	cis	rs9437689	0.966	rs6687450	ENSG00000237416.5	RP11-465K1.2	3.89	0.000116	0.0158	0.22	0.18	Phospholipid levels (plasma);	chr1:95015020	chr1:94836748~94855426:-
HNSC	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	3.89	0.000116	0.0159	0.22	0.18	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
HNSC	cis	rs1602565	1	rs1907605	ENSG00000255450.1	CTD-2063L20.1	3.89	0.000116	0.0159	0.25	0.18	Schizophrenia;	chr11:29136960	chr11:29275655~29276565:+
HNSC	cis	rs2304003	1	rs1560594	ENSG00000235192.1	AC009495.2	3.89	0.000116	0.0159	0.24	0.18	Social communication problems;	chr2:165843288	chr2:165794851~165810010:+
HNSC	cis	rs4927850	1	rs7630875	ENSG00000185485.13	SDHAP1	3.89	0.000116	0.0159	0.15	0.18	Pancreatic cancer;	chr3:196026895	chr3:195959748~195990318:-
HNSC	cis	rs2439831	1	rs2444029	ENSG00000275601.1	AC011330.13	-3.89	0.000116	0.0159	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43445286	chr15:43642389~43643023:-
HNSC	cis	rs7572733	0.534	rs700692	ENSG00000231621.1	AC013264.2	-3.89	0.000116	0.0159	-0.17	-0.18	Dermatomyositis;	chr2:197863776	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs770662	ENSG00000231621.1	AC013264.2	-3.89	0.000116	0.0159	-0.17	-0.18	Dermatomyositis;	chr2:197864559	chr2:197197991~197199273:+
HNSC	cis	rs240993	0.516	rs1002481	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000116	0.0159	-0.25	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111277932~111278742:+
HNSC	cis	rs7735319	0.966	rs3860754	ENSG00000249102.1	CTD-2066L21.1	-3.89	0.000116	0.0159	-0.2	-0.18	Systolic blood pressure;	chr5:33149343	chr5:33008994~33025724:+
HNSC	cis	rs3764400	0.567	rs8079616	ENSG00000228782.6	CTD-2026D20.3	3.89	0.000116	0.0159	0.27	0.18	Body mass index;	chr17:48136126	chr17:47450568~47492492:-
HNSC	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	3.89	0.000116	0.0159	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
HNSC	cis	rs6840360	0.642	rs2709825	ENSG00000251611.1	RP11-610P16.1	-3.89	0.000116	0.0159	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.607	rs2724547	ENSG00000251611.1	RP11-610P16.1	-3.89	0.000116	0.0159	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151407551~151408835:-
HNSC	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000116	0.0159	-0.21	-0.18	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000116	0.0159	-0.21	-0.18	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
HNSC	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	3.89	0.000116	0.0159	0.22	0.18	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
HNSC	cis	rs7520050	0.933	rs4504835	ENSG00000280836.1	AL355480.1	3.89	0.000116	0.0159	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45581219~45581321:-
HNSC	cis	rs2239557	0.508	rs12588108	ENSG00000259065.1	RP5-1021I20.1	-3.89	0.000116	0.0159	-0.26	-0.18	Common traits (Other);	chr14:73865775	chr14:73787360~73803270:+
HNSC	cis	rs11250098	0.503	rs13270870	ENSG00000255310.2	AF131215.2	-3.89	0.000116	0.0159	-0.17	-0.18	Morning vs. evening chronotype;	chr8:10913272	chr8:11107788~11109726:-
HNSC	cis	rs2975734	0.736	rs4841300	ENSG00000269918.1	AF131215.9	-3.89	0.000116	0.0159	-0.19	-0.18	Chronotype;Morning vs. evening chronotype;	chr8:10255085	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.564	rs13274106	ENSG00000269918.1	AF131215.9	-3.89	0.000116	0.0159	-0.17	-0.18	Retinal vascular caliber;	chr8:11376449	chr8:11104691~11106704:-
HNSC	cis	rs4073405	0.855	rs7118844	ENSG00000254651.1	RP11-430H10.3	-3.89	0.000116	0.0159	-0.21	-0.18	Schizophrenia;	chr11:45301131	chr11:45399448~45400528:+
HNSC	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	3.89	0.000116	0.0159	0.22	0.18	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
HNSC	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	3.89	0.000116	0.0159	0.21	0.18	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
HNSC	cis	rs7765004	0.887	rs6568807	ENSG00000228624.6	RP3-399L15.3	3.89	0.000116	0.0159	0.18	0.18	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113761340	chr6:113969701~114471705:+
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000272831.1	RP11-792A8.4	3.89	0.000116	0.0159	0.15	0.18	Calcium levels;	chr7:65967580	chr7:66739829~66740385:-
HNSC	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-3.89	0.000116	0.0159	-0.13	-0.18	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
HNSC	cis	rs72827839	0.779	rs16954581	ENSG00000210741.1	MIR196A1	3.89	0.000116	0.0159	0.23	0.18	Ease of getting up in the morning;	chr17:48282140	chr17:48632490~48632559:-
HNSC	cis	rs12034383	0.818	rs61822977	ENSG00000274245.1	RP11-357P18.2	-3.89	0.000116	0.0159	-0.23	-0.18	Erythrocyte sedimentation rate;	chr1:207622720	chr1:207372559~207373252:+
HNSC	cis	rs12034383	0.875	rs11579070	ENSG00000274245.1	RP11-357P18.2	-3.89	0.000116	0.0159	-0.23	-0.18	Erythrocyte sedimentation rate;	chr1:207625796	chr1:207372559~207373252:+
HNSC	cis	rs2013441	0.866	rs2703773	ENSG00000261033.1	RP11-209D14.2	3.89	0.000116	0.0159	0.2	0.18	Obesity-related traits;	chr17:20228501	chr17:20008051~20009234:-
HNSC	cis	rs17660992	0.603	rs59485321	ENSG00000273837.1	LLNLR-470E3.1	-3.89	0.000116	0.0159	-0.2	-0.18	Blood protein levels;	chr19:51660710	chr19:51639478~51639931:-
HNSC	cis	rs1908814	0.51	rs57655799	ENSG00000227888.4	FAM66A	3.89	0.000116	0.0159	0.18	0.18	Neuroticism;	chr8:11924908	chr8:12362019~12388296:+
HNSC	cis	rs7735319	0.735	rs34458865	ENSG00000251281.1	CTD-2066L21.2	3.89	0.000116	0.0159	0.21	0.18	Systolic blood pressure;	chr5:33049683	chr5:33011322~33017607:-
HNSC	cis	rs7927592	0.731	rs2156463	ENSG00000255031.4	RP11-802E16.3	3.89	0.000116	0.0159	0.15	0.18	Total body bone mineral density;	chr11:68618843	chr11:68050740~68053762:+
HNSC	cis	rs12893668	0.703	rs2274267	ENSG00000269958.1	RP11-73M18.8	3.89	0.000116	0.0159	0.17	0.18	Reticulocyte count;	chr14:103563112	chr14:103696353~103697163:+
HNSC	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	3.89	0.000116	0.0159	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
HNSC	cis	rs1553477	0.535	rs1986932	ENSG00000272123.1	CTD-2366F13.2	3.89	0.000116	0.0159	0.21	0.18	Monobrow;	chr5:53810633	chr5:53089016~53089468:-
HNSC	cis	rs7107174	0.792	rs2888465	ENSG00000251323.2	RP11-452H21.4	3.89	0.000116	0.0159	0.27	0.18	Testicular germ cell tumor;	chr11:78234761	chr11:78423982~78429836:-
HNSC	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-3.89	0.000116	0.0159	-0.22	-0.18	Height;	chr20:49249247	chr20:49280319~49280409:+
HNSC	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	3.89	0.000116	0.0159	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
HNSC	cis	rs67072384	0.688	rs66948758	ENSG00000245148.2	ARAP1-AS2	3.89	0.000116	0.0159	0.23	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72729029	chr11:72700474~72705607:+
HNSC	cis	rs6964587	0.839	rs12536702	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000116	0.0159	-0.19	-0.18	Breast cancer;	chr7:91842262	chr7:92134604~92180725:+
HNSC	cis	rs10819861	0.645	rs4743537	ENSG00000271384.1	RP11-435O5.7	3.89	0.000116	0.0159	0.17	0.18	Electrocardiographic traits;	chr9:96100579	chr9:95406990~95407662:-
HNSC	cis	rs7561149	0.528	rs3816849	ENSG00000270574.1	RP11-171I2.2	-3.89	0.000116	0.0159	-0.22	-0.18	QT interval;	chr2:178802363	chr2:178578790~178580906:+
HNSC	cis	rs865483	0.895	rs853234	ENSG00000276054.1	RP11-378E13.3	-3.89	0.000116	0.0159	-0.21	-0.18	Monocyte count;	chr17:37482945	chr17:37386886~37387926:+
HNSC	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-3.89	0.000116	0.0159	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
HNSC	cis	rs2028299	1	rs2351706	ENSG00000259677.1	RP11-493E3.1	3.89	0.000116	0.0159	0.22	0.18	Type 2 diabetes;	chr15:89840883	chr15:89876540~89877285:+
HNSC	cis	rs2439831	0.85	rs2439832	ENSG00000275601.1	AC011330.13	-3.89	0.000116	0.0159	-0.28	-0.18	Lung cancer in ever smokers;	chr15:43487488	chr15:43642389~43643023:-
HNSC	cis	rs7005380	0.556	rs11984773	ENSG00000279347.1	RP11-85I17.2	3.89	0.000116	0.0159	0.18	0.18	Interstitial lung disease;	chr8:119924346	chr8:119838736~119840385:-
HNSC	cis	rs6538678	0.824	rs4762633	ENSG00000199172.2	MIR331	-3.89	0.000117	0.0159	-0.22	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95308410~95308520:+
HNSC	cis	rs17489649	0.915	rs6897334	ENSG00000271849.1	CTC-332L22.1	3.89	0.000117	0.0159	0.22	0.18	Intelligence (multi-trait analysis);	chr5:109708857	chr5:109687802~109688329:-
HNSC	cis	rs7577696	0.695	rs6716179	ENSG00000272716.1	RP11-563N4.1	-3.89	0.000117	0.0159	-0.17	-0.18	Inflammatory biomarkers;	chr2:32168007	chr2:32165046~32165757:-
HNSC	cis	rs12893668	0.697	rs67899457	ENSG00000269958.1	RP11-73M18.8	3.89	0.000117	0.0159	0.16	0.18	Reticulocyte count;	chr14:103593729	chr14:103696353~103697163:+
HNSC	cis	rs11976180	1	rs1533268	ENSG00000244479.5	OR2A1-AS1	3.89	0.000117	0.0159	0.2	0.18	Obesity-related traits;	chr7:144069265	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs1533267	ENSG00000244479.5	OR2A1-AS1	3.89	0.000117	0.0159	0.2	0.18	Obesity-related traits;	chr7:144069347	chr7:144251264~144356181:-
HNSC	cis	rs10056811	0.538	rs56174528	ENSG00000271815.1	CTD-2235C13.3	-3.89	0.000117	0.0159	-0.3	-0.18	Coronary artery disease;	chr5:75104691	chr5:75363760~75364242:+
HNSC	cis	rs10056811	0.51	rs10058171	ENSG00000271815.1	CTD-2235C13.3	-3.89	0.000117	0.0159	-0.3	-0.18	Coronary artery disease;	chr5:75112166	chr5:75363760~75364242:+
HNSC	cis	rs3176789	1	rs3176789	ENSG00000256673.1	RP11-599J14.2	3.89	0.000117	0.0159	0.19	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9760134	chr12:9398355~9414851:-
HNSC	cis	rs2991971	0.776	rs12139364	ENSG00000234329.1	RP11-767N6.2	-3.89	0.000117	0.016	-0.18	-0.18	High light scatter reticulocyte count;	chr1:45424483	chr1:45651039~45651826:-
HNSC	cis	rs7777677	0.925	rs4726542	ENSG00000276953.1	TRBV12-4	3.89	0.000117	0.016	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142563740~142564245:+
HNSC	cis	rs546131	0.642	rs34999475	ENSG00000271369.1	RP11-350D17.3	-3.89	0.000117	0.016	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34808301	chr11:34709600~34710161:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000270326.1	RP5-874C20.6	3.89	0.000117	0.016	0.27	0.18	Depression;	chr6:28260564	chr6:28319660~28319852:-
HNSC	cis	rs2836974	0.627	rs8127986	ENSG00000255568.3	BRWD1-AS2	-3.89	0.000117	0.016	-0.15	-0.18	Cognitive function;	chr21:39315285	chr21:39313935~39314962:+
HNSC	cis	rs9650657	0.74	rs34653170	ENSG00000269918.1	AF131215.9	-3.89	0.000117	0.016	-0.18	-0.18	Neuroticism;	chr8:10819032	chr8:11104691~11106704:-
HNSC	cis	rs9650657	0.707	rs10098699	ENSG00000269918.1	AF131215.9	-3.89	0.000117	0.016	-0.18	-0.18	Neuroticism;	chr8:10819246	chr8:11104691~11106704:-
HNSC	cis	rs7577696	0.925	rs12474443	ENSG00000272716.1	RP11-563N4.1	-3.89	0.000117	0.016	-0.17	-0.18	Inflammatory biomarkers;	chr2:32112803	chr2:32165046~32165757:-
HNSC	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-3.89	0.000117	0.016	-0.21	-0.18	Height;	chr14:75204004	chr14:75011269~75012851:-
HNSC	cis	rs7429990	0.965	rs5016900	ENSG00000228638.1	FCF1P2	-3.89	0.000117	0.016	-0.19	-0.18	Educational attainment (years of education);	chr3:47781387	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.93	rs13072132	ENSG00000228638.1	FCF1P2	-3.89	0.000117	0.016	-0.19	-0.18	Educational attainment (years of education);	chr3:47824671	chr3:48290793~48291375:-
HNSC	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-3.89	0.000117	0.016	-0.21	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
HNSC	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	3.89	0.000117	0.016	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
HNSC	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-3.89	0.000117	0.016	-0.17	-0.18	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
HNSC	cis	rs7178909	0.872	rs17241560	ENSG00000259677.1	RP11-493E3.1	3.89	0.000117	0.016	0.2	0.18	Common traits (Other);	chr15:89885970	chr15:89876540~89877285:+
HNSC	cis	rs614226	1	rs12310837	ENSG00000202538.1	RNU4-2	-3.89	0.000117	0.016	-0.29	-0.18	Type 1 diabetes nephropathy;	chr12:120442769	chr12:120291763~120291903:-
HNSC	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	3.89	0.000117	0.016	0.2	0.18	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
HNSC	cis	rs4819052	1	rs13053002	ENSG00000215447.6	BX322557.10	-3.89	0.000117	0.016	-0.18	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45288052~45291738:+
HNSC	cis	rs896655	0.598	rs10811603	ENSG00000244230.3	RN7SL151P	3.89	0.000117	0.016	0.19	0.18	Coronary artery disease;	chr9:21735764	chr9:21699314~21699596:+
HNSC	cis	rs2518049	1	rs1937848	ENSG00000224034.1	RP11-445P17.8	3.89	0.000117	0.016	0.24	0.18	Metabolic traits;	chr10:5091851	chr10:5266033~5271236:-
HNSC	cis	rs1113500	0.814	rs12039712	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.016	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108098577	chr1:108071482~108074519:+
HNSC	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-3.89	0.000117	0.016	-0.17	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
HNSC	cis	rs950169	0.58	rs11630887	ENSG00000229212.6	RP11-561C5.4	-3.89	0.000117	0.016	-0.26	-0.18	Schizophrenia;	chr15:84649784	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs11636189	ENSG00000229212.6	RP11-561C5.4	-3.89	0.000117	0.016	-0.26	-0.18	Schizophrenia;	chr15:84650323	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs35516100	ENSG00000229212.6	RP11-561C5.4	-3.89	0.000117	0.016	-0.26	-0.18	Schizophrenia;	chr15:84652199	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs62021208	ENSG00000229212.6	RP11-561C5.4	-3.89	0.000117	0.016	-0.26	-0.18	Schizophrenia;	chr15:84653013	chr15:85205440~85234795:-
HNSC	cis	rs4356203	0.875	rs680205	ENSG00000260196.1	RP1-239B22.5	-3.89	0.000117	0.016	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17380649~17383531:+
HNSC	cis	rs5770917	1	rs1056964	ENSG00000272821.1	CTA-384D8.36	-3.89	0.000117	0.016	-0.26	-0.18	Narcolepsy;	chr22:50579047	chr22:50523926~50524780:+
HNSC	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	3.89	0.000117	0.016	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
HNSC	cis	rs546131	0.614	rs35357012	ENSG00000271369.1	RP11-350D17.3	-3.89	0.000117	0.016	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34771837	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.571	rs11601422	ENSG00000271369.1	RP11-350D17.3	-3.89	0.000117	0.016	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34772212	chr11:34709600~34710161:+
HNSC	cis	rs853679	0.824	rs34712084	ENSG00000204709.4	LINC01556	3.89	0.000117	0.016	0.31	0.18	Depression;	chr6:28076050	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.824	rs1321505	ENSG00000204709.4	LINC01556	3.89	0.000117	0.016	0.31	0.18	Depression;	chr6:28085045	chr6:28943877~28944537:+
HNSC	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-3.89	0.000117	0.016	-0.19	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
HNSC	cis	rs9959145	1	rs9967026	ENSG00000267249.1	RP11-973H7.3	-3.89	0.000117	0.016	-0.27	-0.18	Immune response to smallpox vaccine (IL-6);	chr18:12566484	chr18:12670426~12671145:-
HNSC	cis	rs10129255	0.556	rs9324093	ENSG00000224373.3	IGHV4-59	3.89	0.000117	0.016	0.1	0.18	Kawasaki disease;	chr14:106683893	chr14:106627249~106627825:-
HNSC	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	3.88	0.000117	0.016	0.44	0.18	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
HNSC	cis	rs7772486	0.686	rs4896833	ENSG00000270638.1	RP3-466P17.1	3.88	0.000117	0.016	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145735570~145737218:+
HNSC	cis	rs2243480	1	rs73142121	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000117	0.016	0.3	0.18	Diabetic kidney disease;	chr7:65846219	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000117	0.016	0.3	0.18	Diabetic kidney disease;	chr7:65847191	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35825738	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000117	0.016	0.3	0.18	Diabetic kidney disease;	chr7:65853040	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs34702770	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000117	0.016	0.3	0.18	Diabetic kidney disease;	chr7:65879836	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000117	0.016	0.3	0.18	Diabetic kidney disease;	chr7:65892097	chr7:66025126~66031544:-
HNSC	cis	rs8098244	0.597	rs1154247	ENSG00000264745.1	TTC39C-AS1	-3.88	0.000117	0.016	-0.21	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984452	chr18:23994213~24015339:-
HNSC	cis	rs9393777	0.72	rs56401801	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000117	0.016	-0.36	-0.18	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28115628~28116551:+
HNSC	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	3.88	0.000117	0.016	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
HNSC	cis	rs9313772	1	rs4704775	ENSG00000254350.1	RP11-542A14.1	-3.88	0.000117	0.016	-0.2	-0.18	Blood pressure;	chr5:158397548	chr5:158424585~158452758:+
HNSC	cis	rs2933343	0.553	rs35076317	ENSG00000261159.1	RP11-723O4.9	3.88	0.000117	0.016	0.18	0.18	IgG glycosylation;	chr3:128996692	chr3:128859716~128860526:-
HNSC	cis	rs1476670	0.71	rs753637	ENSG00000230615.5	RP5-1198O20.4	-3.88	0.000117	0.016	-0.23	-0.18	Eotaxin levels;	chr1:44043255	chr1:44030443~44115913:+
HNSC	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-3.88	0.000117	0.016	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
HNSC	cis	rs561341	0.882	rs504887	ENSG00000278867.1	RP11-640N20.4	-3.88	0.000117	0.016	-0.23	-0.18	Hip circumference adjusted for BMI;	chr17:31995862	chr17:32051030~32053208:+
HNSC	cis	rs4489787	1	rs4489787	ENSG00000257763.1	OR5BK1P	3.88	0.000117	0.016	0.28	0.18	Prostate cancer (SNP x SNP interaction);	chr12:48417317	chr12:48355792~48356614:-
HNSC	cis	rs28830936	0.934	rs2412641	ENSG00000250379.1	RP11-23P13.4	3.88	0.000117	0.016	0.22	0.18	Diastolic blood pressure;	chr15:41832201	chr15:41825099~41827936:-
HNSC	cis	rs28830936	0.966	rs11635067	ENSG00000250379.1	RP11-23P13.4	3.88	0.000117	0.016	0.22	0.18	Diastolic blood pressure;	chr15:41832475	chr15:41825099~41827936:-
HNSC	cis	rs28830936	0.966	rs1531140	ENSG00000250379.1	RP11-23P13.4	3.88	0.000117	0.016	0.22	0.18	Diastolic blood pressure;	chr15:41833036	chr15:41825099~41827936:-
HNSC	cis	rs4835473	0.932	rs10857415	ENSG00000249741.2	RP11-673E1.3	-3.88	0.000117	0.016	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143908753	chr4:143911514~143912053:-
HNSC	cis	rs597539	0.652	rs559032	ENSG00000261625.1	RP11-554A11.4	-3.88	0.000117	0.016	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:69000765~69002048:-
HNSC	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	3.88	0.000117	0.016	0.21	0.18	Height;	chr14:75083881	chr14:75011269~75012851:-
HNSC	cis	rs4073405	0.882	rs7117634	ENSG00000254651.1	RP11-430H10.3	3.88	0.000117	0.0161	0.22	0.18	Schizophrenia;	chr11:45297012	chr11:45399448~45400528:+
HNSC	cis	rs116095464	0.542	rs28650039	ENSG00000277812.1	AC021087.1	3.88	0.000118	0.0161	0.3	0.18	Breast cancer;	chr5:273839	chr5:262769~262881:+
HNSC	cis	rs7777677	0.925	rs4726540	ENSG00000276557.1	TRBV18	3.88	0.000118	0.0161	0.15	0.18	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142615716~142616415:+
HNSC	cis	rs4388249	1	rs3797695	ENSG00000271849.1	CTC-332L22.1	-3.88	0.000118	0.0161	-0.28	-0.18	Schizophrenia;	chr5:109741816	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs12656571	ENSG00000271849.1	CTC-332L22.1	-3.88	0.000118	0.0161	-0.28	-0.18	Schizophrenia;	chr5:109742339	chr5:109687802~109688329:-
HNSC	cis	rs73201462	1	rs2955086	ENSG00000231305.3	RP11-723O4.2	3.88	0.000118	0.0161	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244348	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999071	ENSG00000231305.3	RP11-723O4.2	3.88	0.000118	0.0161	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244772	chr3:128861313~128871540:-
HNSC	cis	rs7335046	0.901	rs7332358	ENSG00000280710.1	RP11-214F16.8	3.88	0.000118	0.0161	0.3	0.18	Basal cell carcinoma;	chr13:99371275	chr13:99498524~99501315:+
HNSC	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-3.88	0.000118	0.0161	-0.19	-0.18	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
HNSC	cis	rs913672	0.637	rs6125965	ENSG00000224397.4	LINC01272	3.88	0.000118	0.0161	0.23	0.18	Monocyte count;	chr20:50282076	chr20:50267486~50279795:+
HNSC	cis	rs7005380	0.581	rs6469866	ENSG00000279347.1	RP11-85I17.2	-3.88	0.000118	0.0161	-0.16	-0.18	Interstitial lung disease;	chr8:119899057	chr8:119838736~119840385:-
HNSC	cis	rs739496	0.615	rs617044	ENSG00000226469.1	ADAM1B	3.88	0.000118	0.0161	0.21	0.18	Platelet count;	chr12:111695071	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.615	rs602276	ENSG00000226469.1	ADAM1B	3.88	0.000118	0.0161	0.21	0.18	Platelet count;	chr12:111696120	chr12:111927018~111929017:+
HNSC	cis	rs11157436	0.602	rs1894369	ENSG00000211814.1	TRAV35	3.88	0.000118	0.0161	0.16	0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22221896~22222475:+
HNSC	cis	rs4937076	0.69	rs2471473	ENSG00000254967.5	RP11-680F20.6	-3.88	0.000118	0.0161	-0.2	-0.18	Primary tooth development (time to first tooth eruption);	chr11:125949163	chr11:125950116~125956319:+
HNSC	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-3.88	0.000118	0.0161	-0.26	-0.18	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
HNSC	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	3.88	0.000118	0.0161	0.17	0.18	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
HNSC	cis	rs4489787	1	rs2731073	ENSG00000257763.1	OR5BK1P	3.88	0.000118	0.0161	0.31	0.18	Prostate cancer (SNP x SNP interaction);	chr12:48525773	chr12:48355792~48356614:-
HNSC	cis	rs7005380	0.556	rs62528677	ENSG00000279347.1	RP11-85I17.2	3.88	0.000118	0.0161	0.18	0.18	Interstitial lung disease;	chr8:119928634	chr8:119838736~119840385:-
HNSC	cis	rs597539	0.652	rs11603827	ENSG00000261625.1	RP11-554A11.4	-3.88	0.000118	0.0161	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:69000765~69002048:-
HNSC	cis	rs9611565	0.659	rs116959331	ENSG00000235513.1	RP4-756G23.5	3.88	0.000118	0.0161	0.21	0.18	Vitiligo;	chr22:41536770	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.573	rs9306355	ENSG00000233903.2	Z83851.4	3.88	0.000118	0.0161	0.24	0.18	Vitiligo;	chr22:41715892	chr22:42276355~42277052:+
HNSC	cis	rs9925964	0.933	rs881929	ENSG00000232748.3	RP11-196G11.6	3.88	0.000118	0.0161	0.24	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:31056460~31062803:+
HNSC	cis	rs1538970	0.851	rs61788285	ENSG00000234329.1	RP11-767N6.2	3.88	0.000118	0.0161	0.21	0.18	Platelet count;	chr1:45453562	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.781	rs10890330	ENSG00000234329.1	RP11-767N6.2	3.88	0.000118	0.0161	0.21	0.18	Platelet count;	chr1:45454734	chr1:45651039~45651826:-
HNSC	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	3.88	0.000118	0.0161	0.3	0.18	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
HNSC	cis	rs6493858	0.839	rs11629483	ENSG00000277245.1	RP11-48G14.3	-3.88	0.000118	0.0161	-0.21	-0.18	Relative hand skill in reading disability;	chr15:56167073	chr15:56447120~56447697:+
HNSC	cis	rs62458065	0.713	rs62463968	ENSG00000226468.2	AC018641.7	3.88	0.000118	0.0161	0.29	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32461630	chr7:32456963~32457758:-
HNSC	cis	rs17772222	0.876	rs58655091	ENSG00000258789.1	RP11-507K2.3	-3.88	0.000118	0.0161	-0.21	-0.18	Coronary artery calcification;	chr14:88748567	chr14:88551597~88552493:+
HNSC	cis	rs860295	0.702	rs11264380	ENSG00000225855.5	RUSC1-AS1	3.88	0.000118	0.0161	0.12	0.18	Body mass index;	chr1:155550353	chr1:155316863~155324176:-
HNSC	cis	rs6180	0.594	rs1833906	ENSG00000271788.1	CTD-2201E18.5	-3.88	0.000118	0.0161	-0.18	-0.18	Height;	chr5:42852117	chr5:43006733~43007543:-
HNSC	cis	rs9859260	0.925	rs2300775	ENSG00000207650.1	MIR570	3.88	0.000118	0.0161	0.16	0.18	Mean corpuscular volume;	chr3:196066468	chr3:195699401~195699497:+
HNSC	cis	rs9859260	0.921	rs2300774	ENSG00000207650.1	MIR570	3.88	0.000118	0.0161	0.16	0.18	Mean corpuscular volume;	chr3:196066841	chr3:195699401~195699497:+
HNSC	cis	rs4308124	1	rs56830046	ENSG00000227992.1	AC108463.2	-3.88	0.000118	0.0161	-0.17	-0.18	Vitiligo;	chr2:111252513	chr2:111203964~111206215:-
HNSC	cis	rs7824557	0.602	rs7816636	ENSG00000255495.1	AC145124.2	3.88	0.000118	0.0161	0.2	0.18	Retinal vascular caliber;	chr8:11348145	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.602	rs7828711	ENSG00000255495.1	AC145124.2	3.88	0.000118	0.0161	0.2	0.18	Retinal vascular caliber;	chr8:11348156	chr8:12194467~12196280:+
HNSC	cis	rs12999542	0.706	rs11465673	ENSG00000234389.1	AC007278.3	3.88	0.000118	0.0161	0.3	0.18	Serum protein levels (sST2);	chr2:102418915	chr2:102438713~102440475:+
HNSC	cis	rs6601327	0.571	rs35874762	ENSG00000233609.3	RP11-62H7.2	-3.88	0.000118	0.0161	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9707882	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs10109886	ENSG00000233609.3	RP11-62H7.2	-3.88	0.000118	0.0161	-0.2	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8961200~8979025:+
HNSC	cis	rs11951515	0.7	rs7720165	ENSG00000249286.1	CTD-2210P15.2	-3.88	0.000118	0.0161	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43301442	chr5:43586918~43588223:-
HNSC	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-3.88	0.000118	0.0161	-0.2	-0.18	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
HNSC	cis	rs13179617	0.889	rs2034239	ENSG00000215032.2	GNL3LP1	-3.88	0.000118	0.0161	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61519940	chr5:60891935~60893577:-
HNSC	cis	rs17253792	0.822	rs10129890	ENSG00000186615.9	KTN1-AS1	-3.88	0.000118	0.0162	-0.37	-0.18	Putamen volume;	chr14:55573695	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs12100949	ENSG00000186615.9	KTN1-AS1	-3.88	0.000118	0.0162	-0.37	-0.18	Putamen volume;	chr14:55574069	chr14:55499278~55580110:-
HNSC	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-3.88	0.000118	0.0162	-0.14	-0.18	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
HNSC	cis	rs6163	0.588	rs67506723	ENSG00000236937.2	PTGES3P4	3.88	0.000118	0.0162	0.21	0.18	Waist circumference;Hip circumference;	chr10:102749307	chr10:102845595~102845950:+
HNSC	cis	rs6430585	0.528	rs309162	ENSG00000231890.6	DARS-AS1	-3.88	0.000118	0.0162	-0.3	-0.18	Corneal structure;	chr2:135933213	chr2:135985176~136022593:+
HNSC	cis	rs9687846	0.877	rs3936511	ENSG00000265665.1	AC008391.1	3.88	0.000118	0.0162	0.26	0.18	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr5:56564954	chr5:56457038~56457138:-
HNSC	cis	rs9611565	0.659	rs169361	ENSG00000235513.1	RP4-756G23.5	-3.88	0.000118	0.0162	-0.22	-0.18	Vitiligo;	chr22:41481985	chr22:41209122~41217627:-
HNSC	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	3.88	0.000118	0.0162	0.25	0.18	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
HNSC	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	3.88	0.000118	0.0162	0.25	0.18	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
HNSC	cis	rs78545713	0.536	rs80202565	ENSG00000241549.7	GUSBP2	-3.88	0.000118	0.0162	-0.29	-0.18	Iron status biomarkers (total iron binding capacity);	chr6:26233654	chr6:26871484~26956554:-
HNSC	cis	rs7824557	0.628	rs11994376	ENSG00000255310.2	AF131215.2	3.88	0.000118	0.0162	0.17	0.18	Retinal vascular caliber;	chr8:11345451	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-3.88	0.000118	0.0162	-0.25	-0.18	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
HNSC	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	3.88	0.000118	0.0162	0.18	0.18	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
HNSC	cis	rs9329221	0.506	rs6993610	ENSG00000255310.2	AF131215.2	-3.88	0.000118	0.0162	-0.18	-0.18	Neuroticism;	chr8:10473484	chr8:11107788~11109726:-
HNSC	cis	rs3018712	0.532	rs2513282	ENSG00000212093.1	AP000807.1	-3.88	0.000119	0.0162	-0.26	-0.18	Total body bone mineral density;	chr11:68650843	chr11:68506083~68506166:-
HNSC	cis	rs853679	0.517	rs4713135	ENSG00000219891.2	ZSCAN12P1	3.88	0.000119	0.0162	0.25	0.18	Depression;	chr6:28071808	chr6:28091154~28093664:+
HNSC	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000119	0.0162	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
HNSC	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000119	0.0162	-0.18	-0.18	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
HNSC	cis	rs6568686	0.527	rs174407	ENSG00000255389.1	C6orf3	3.88	0.000119	0.0162	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610484	chr6:111599875~111602295:+
HNSC	cis	rs67072384	1	rs7122017	ENSG00000213365.3	AP000593.6	3.88	0.000119	0.0162	0.3	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737513	chr11:72280151~72281178:+
HNSC	cis	rs7166081	0.704	rs2414952	ENSG00000270964.1	RP11-502I4.3	-3.88	0.000119	0.0162	-0.19	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67432054	chr15:67541072~67542604:-
HNSC	cis	rs1023500	0.551	rs4822076	ENSG00000182057.4	OGFRP1	3.88	0.000119	0.0162	0.19	0.18	Schizophrenia;	chr22:41968053	chr22:42269753~42275196:+
HNSC	cis	rs950027	0.549	rs11636114	ENSG00000259479.5	SORD2P	3.88	0.000119	0.0162	0.2	0.18	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:44826371~44884694:-
HNSC	cis	rs1925953	0.711	rs12117816	ENSG00000233589.1	RP4-694A7.2	-3.88	0.000119	0.0162	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68370097	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs12405436	ENSG00000233589.1	RP4-694A7.2	-3.88	0.000119	0.0162	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68372372	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs12127240	ENSG00000233589.1	RP4-694A7.2	-3.88	0.000119	0.0162	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68375036	chr1:68479129~68483539:+
HNSC	cis	rs73201462	1	rs2999070	ENSG00000231305.3	RP11-723O4.2	3.88	0.000119	0.0162	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128245808	chr3:128861313~128871540:-
HNSC	cis	rs28489187	0.683	rs1554597	ENSG00000223653.4	RP11-131L23.1	-3.88	0.000119	0.0162	-0.24	-0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85411415	chr1:85276715~85448124:+
HNSC	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	3.88	0.000119	0.0162	0.17	0.18	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
HNSC	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	3.88	0.000119	0.0162	0.18	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	3.88	0.000119	0.0162	0.18	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
HNSC	cis	rs6090919	0.501	rs11907750	ENSG00000222365.1	SNORD12B	3.88	0.000119	0.0162	0.23	0.18	Intelligence (multi-trait analysis);	chr20:48840477	chr20:49280319~49280409:+
HNSC	cis	rs10078	0.515	rs890984	ENSG00000225138.6	CTD-2228K2.7	3.88	0.000119	0.0162	0.31	0.18	Fat distribution (HIV);	chr5:479425	chr5:473236~480884:+
HNSC	cis	rs17253792	0.822	rs112418863	ENSG00000186615.9	KTN1-AS1	-3.88	0.000119	0.0162	-0.35	-0.18	Putamen volume;	chr14:55647361	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78922774	ENSG00000186615.9	KTN1-AS1	-3.88	0.000119	0.0162	-0.35	-0.18	Putamen volume;	chr14:55648584	chr14:55499278~55580110:-
HNSC	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-3.88	0.000119	0.0162	-0.35	-0.18	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-3.88	0.000119	0.0162	-0.35	-0.18	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-3.88	0.000119	0.0162	-0.35	-0.18	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
HNSC	cis	rs889398	0.935	rs12933292	ENSG00000226232.7	RP11-419C5.2	3.88	0.000119	0.0162	0.16	0.18	Body mass index;	chr16:69532406	chr16:69976388~69996188:-
HNSC	cis	rs17596685	1	rs17639305	ENSG00000271216.1	LINC01050	-3.88	0.000119	0.0162	-0.22	-0.18	C-reactive protein levels;	chr13:42572051	chr13:42810366~42812562:-
HNSC	cis	rs4873772	0.932	rs7827571	ENSG00000253330.1	RP11-697N18.3	3.88	0.000119	0.0162	0.23	0.18	Lobe attachment (rater-scored or self-reported);	chr8:47631195	chr8:47511034~47512141:-
HNSC	cis	rs638893	0.588	rs2508929	ENSG00000255422.1	AP002954.4	-3.88	0.000119	0.0162	-0.29	-0.18	Vitiligo;	chr11:118770742	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.636	rs548167	ENSG00000255422.1	AP002954.4	-3.88	0.000119	0.0162	-0.29	-0.18	Vitiligo;	chr11:118777687	chr11:118704607~118750263:+
HNSC	cis	rs638893	0.685	rs486651	ENSG00000255422.1	AP002954.4	-3.88	0.000119	0.0162	-0.29	-0.18	Vitiligo;	chr11:118779150	chr11:118704607~118750263:+
HNSC	cis	rs6095360	0.934	rs2295579	ENSG00000222365.1	SNORD12B	3.88	0.000119	0.0162	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49010199	chr20:49280319~49280409:+
HNSC	cis	rs4073405	0.584	rs7395357	ENSG00000254651.1	RP11-430H10.3	3.88	0.000119	0.0162	0.21	0.18	Schizophrenia;	chr11:45287311	chr11:45399448~45400528:+
HNSC	cis	rs479844	1	rs479844	ENSG00000255120.4	OVOL1-AS1	-3.88	0.000119	0.0162	-0.18	-0.18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);Atopic march;	chr11:65784486	chr11:65789051~65790868:-
HNSC	cis	rs9859260	0.555	rs9877493	ENSG00000207650.1	MIR570	3.88	0.000119	0.0162	0.17	0.18	Mean corpuscular volume;	chr3:196105276	chr3:195699401~195699497:+
HNSC	cis	rs8024893	1	rs6493544	ENSG00000270055.1	CTD-3092A11.2	3.88	0.000119	0.0162	0.24	0.18	Red cell distribution width;	chr15:31245356	chr15:30487963~30490313:+
HNSC	cis	rs10888838	1	rs10888840	ENSG00000198711.5	SSBP3-AS1	3.88	0.000119	0.0162	0.23	0.18	Mitochondrial DNA levels;	chr1:54217740	chr1:54236440~54239063:+
HNSC	cis	rs6504950	0.83	rs12936860	ENSG00000279059.1	RP11-257O5.2	-3.88	0.000119	0.0162	-0.15	-0.18	Breast cancer;	chr17:54952865	chr17:54956760~54958426:-
HNSC	cis	rs17655565	0.537	rs7975165	ENSG00000257500.1	RP11-1020M18.10	-3.88	0.000119	0.0162	-0.29	-0.18	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52411414	chr12:52407580~52428494:+
HNSC	cis	rs1941023	0.967	rs2186919	ENSG00000279632.1	RP11-286N22.6	3.88	0.000119	0.0162	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60530495	chr11:61426448~61427325:-
HNSC	cis	rs10789207	0.531	rs17129252	ENSG00000248458.2	RP4-598P13.1	-3.88	0.000119	0.0162	-0.25	-0.18	Resting heart rate;	chr1:66650227	chr1:66665864~66677027:-
HNSC	cis	rs10129255	0.556	rs8010005	ENSG00000224373.3	IGHV4-59	3.88	0.000119	0.0162	0.1	0.18	Kawasaki disease;	chr14:106777987	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.556	rs6576224	ENSG00000224373.3	IGHV4-59	3.88	0.000119	0.0162	0.1	0.18	Kawasaki disease;	chr14:106777997	chr14:106627249~106627825:-
HNSC	cis	rs10129255	0.518	rs8010020	ENSG00000224373.3	IGHV4-59	3.88	0.000119	0.0162	0.1	0.18	Kawasaki disease;	chr14:106778016	chr14:106627249~106627825:-
HNSC	cis	rs12887734	0.566	rs3742366	ENSG00000269910.1	RP11-73M18.10	3.88	0.000119	0.0162	0.17	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694516~103695050:-
HNSC	cis	rs7777677	0.925	rs73543808	ENSG00000276953.1	TRBV12-4	3.88	0.000119	0.0162	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142563740~142564245:+
HNSC	cis	rs7646881	0.544	rs17630223	ENSG00000272087.1	RP11-379F4.7	-3.88	0.000119	0.0162	-0.24	-0.18	Tetralogy of Fallot;	chr3:158661383	chr3:158693120~158693768:-
HNSC	cis	rs6460942	0.597	rs35317839	ENSG00000226690.5	AC005281.1	3.88	0.000119	0.0162	0.28	0.18	Coronary artery disease;	chr7:12484771	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs13227809	ENSG00000226690.5	AC005281.1	3.88	0.000119	0.0162	0.28	0.18	Coronary artery disease;	chr7:12485931	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs17448193	ENSG00000226690.5	AC005281.1	3.88	0.000119	0.0162	0.28	0.18	Coronary artery disease;	chr7:12486015	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs4719315	ENSG00000226690.5	AC005281.1	3.88	0.000119	0.0162	0.28	0.18	Coronary artery disease;	chr7:12489008	chr7:12496429~12541910:+
HNSC	cis	rs250677	0.641	rs2915807	ENSG00000250072.4	CTC-529P8.1	-3.88	0.000119	0.0162	-0.25	-0.18	Breast cancer;	chr5:149071387	chr5:149063317~149109787:+
HNSC	cis	rs2645424	0.686	rs2294140	ENSG00000255046.1	RP11-297N6.4	-3.88	0.000119	0.0162	-0.18	-0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr8:11797928~11802568:-
HNSC	cis	rs6570726	0.72	rs412623	ENSG00000270638.1	RP3-466P17.1	3.88	0.000119	0.0162	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145735570~145737218:+
HNSC	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-3.88	0.000119	0.0162	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
HNSC	cis	rs853679	1	rs853685	ENSG00000219891.2	ZSCAN12P1	3.88	0.000119	0.0162	0.28	0.18	Depression;	chr6:28321008	chr6:28091154~28093664:+
HNSC	cis	rs4388249	1	rs13157374	ENSG00000271849.1	CTC-332L22.1	-3.88	0.000119	0.0163	-0.28	-0.18	Schizophrenia;	chr5:109782503	chr5:109687802~109688329:-
HNSC	cis	rs6493858	0.839	rs2725870	ENSG00000277245.1	RP11-48G14.3	-3.88	0.000119	0.0163	-0.2	-0.18	Relative hand skill in reading disability;	chr15:56183191	chr15:56447120~56447697:+
HNSC	cis	rs7429990	0.833	rs6442072	ENSG00000228638.1	FCF1P2	3.88	0.000119	0.0163	0.16	0.18	Educational attainment (years of education);	chr3:47642960	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs2882611	ENSG00000228638.1	FCF1P2	3.88	0.000119	0.0163	0.16	0.18	Educational attainment (years of education);	chr3:47651532	chr3:48290793~48291375:-
HNSC	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000119	0.0163	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000119	0.0163	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
HNSC	cis	rs889398	0.802	rs8050414	ENSG00000196696.11	PDXDC2P	-3.88	0.000119	0.0163	-0.12	-0.18	Body mass index;	chr16:69852910	chr16:69976297~70065948:-
HNSC	cis	rs889398	0.802	rs8051168	ENSG00000196696.11	PDXDC2P	-3.88	0.000119	0.0163	-0.12	-0.18	Body mass index;	chr16:69853371	chr16:69976297~70065948:-
HNSC	cis	rs2732480	0.5	rs12828309	ENSG00000257763.1	OR5BK1P	3.88	0.000119	0.0163	0.17	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48355792~48356614:-
HNSC	cis	rs2732480	0.5	rs1552550	ENSG00000257763.1	OR5BK1P	3.88	0.000119	0.0163	0.17	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48355792~48356614:-
HNSC	cis	rs73607972	0.696	rs7201237	ENSG00000275191.1	RP11-36I17.2	-3.88	0.000119	0.0163	-0.24	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53628256~53628816:-
HNSC	cis	rs72717009	0.825	rs11810143	ENSG00000225217.1	HSPA7	-3.88	0.000119	0.0163	-0.31	-0.18	Rheumatoid arthritis;	chr1:161510859	chr1:161606291~161608217:+
HNSC	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-3.88	0.000119	0.0163	-0.15	-0.18	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
HNSC	cis	rs67981189	0.574	rs8004452	ENSG00000274818.1	RP1-292L20.3	-3.88	0.000119	0.0163	-0.2	-0.18	Schizophrenia;	chr14:70949323	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	3.88	0.000119	0.0163	0.22	0.18	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
HNSC	cis	rs13179617	0.963	rs11747564	ENSG00000215032.2	GNL3LP1	-3.88	0.000119	0.0163	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61482984	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.851	rs55838118	ENSG00000215032.2	GNL3LP1	-3.88	0.000119	0.0163	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61485605	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.928	rs7443602	ENSG00000215032.2	GNL3LP1	-3.88	0.000119	0.0163	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61487673	chr5:60891935~60893577:-
HNSC	cis	rs35264875	1	rs35264875	ENSG00000259799.1	RP11-554A11.9	3.88	0.000119	0.0163	0.25	0.18	Blond vs. brown hair color;	chr11:69078931	chr11:69155910~69159752:+
HNSC	cis	rs35264875	1	rs72928636	ENSG00000259799.1	RP11-554A11.9	3.88	0.000119	0.0163	0.25	0.18	Blond vs. brown hair color;	chr11:69080918	chr11:69155910~69159752:+
HNSC	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-3.88	0.000119	0.0163	-0.22	-0.18	Height;	chr20:49257468	chr20:49280319~49280409:+
HNSC	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-3.88	0.000119	0.0163	-0.24	-0.18	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-3.88	0.000119	0.0163	-0.24	-0.18	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-3.88	0.000119	0.0163	-0.24	-0.18	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
HNSC	cis	rs9368481	0.761	rs9348746	ENSG00000238621.1	TRI-TAT2-2	3.88	0.000119	0.0163	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:27020335~27020447:+
HNSC	cis	rs36093844	0.576	rs17745236	ENSG00000279742.1	RP11-700A24.1	-3.88	0.000119	0.0163	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86035580	chr11:85852557~85854943:-
HNSC	cis	rs77972916	0.561	rs13411629	ENSG00000234936.1	AC010883.5	3.88	0.000119	0.0163	0.25	0.18	Granulocyte percentage of myeloid white cells;	chr2:43339851	chr2:43229573~43233394:+
HNSC	cis	rs330048	0.545	rs11781008	ENSG00000233609.3	RP11-62H7.2	3.88	0.000119	0.0163	0.17	0.18	Systemic lupus erythematosus;	chr8:9295729	chr8:8961200~8979025:+
HNSC	cis	rs10502219	0.634	rs10431079	ENSG00000235910.1	APOA1-AS	3.88	0.00012	0.0163	0.23	0.18	Mitochondrial DNA levels;	chr11:116569961	chr11:116836117~116855729:+
HNSC	cis	rs73198271	0.92	rs11783112	ENSG00000254340.1	RP11-10A14.3	-3.88	0.00012	0.0163	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:9141424~9145435:+
HNSC	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-3.88	0.00012	0.0163	-0.2	-0.18	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
HNSC	cis	rs7572733	0.515	rs700675	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0163	-0.17	-0.18	Dermatomyositis;	chr2:197835492	chr2:197197991~197199273:+
HNSC	cis	rs4927850	1	rs4927850	ENSG00000226155.1	AC124944.3	3.88	0.00012	0.0163	0.21	0.18	Pancreatic cancer;	chr3:196024759	chr3:195912049~195913986:+
HNSC	cis	rs9467773	0.595	rs4320356	ENSG00000241549.7	GUSBP2	3.88	0.00012	0.0163	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26423332	chr6:26871484~26956554:-
HNSC	cis	rs301901	0.581	rs10941343	ENSG00000250155.1	CTD-2353F22.1	3.88	0.00012	0.0163	0.18	0.18	Height;	chr5:37543239	chr5:36666214~36725195:-
HNSC	cis	rs301901	0.573	rs12652433	ENSG00000250155.1	CTD-2353F22.1	3.88	0.00012	0.0163	0.18	0.18	Height;	chr5:37543358	chr5:36666214~36725195:-
HNSC	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	3.88	0.00012	0.0163	0.2	0.18	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
HNSC	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-3.88	0.00012	0.0163	-0.19	-0.18	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
HNSC	cis	rs2243480	1	rs34703416	ENSG00000229886.1	RP5-1132H15.3	3.88	0.00012	0.0163	0.3	0.18	Diabetic kidney disease;	chr7:65835655	chr7:66025126~66031544:-
HNSC	cis	rs9500256	0.934	rs1343391	ENSG00000225096.1	XXbac-BPG55C20.7	-3.88	0.00012	0.0163	-0.2	-0.18	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57965630~57972218:+
HNSC	cis	rs2337406	0.778	rs56658355	ENSG00000280411.1	IGHV1-69-2	-3.88	0.00012	0.0163	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106662151	chr14:106762092~106762588:-
HNSC	cis	rs870825	0.616	rs35818632	ENSG00000254233.1	RP11-242J7.1	3.88	0.00012	0.0163	0.27	0.18	Blood protein levels;	chr4:184728507	chr4:184584093~184625030:-
HNSC	cis	rs4947019	0.534	rs9487087	ENSG00000260273.1	RP11-425D10.10	3.88	0.00012	0.0163	0.48	0.18	Hematological parameters;	chr6:109401184	chr6:109382795~109383666:+
HNSC	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	3.88	0.00012	0.0163	0.27	0.18	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
HNSC	cis	rs12908161	0.959	rs17598603	ENSG00000275120.1	RP11-182J1.17	-3.88	0.00012	0.0163	-0.25	-0.18	Schizophrenia;	chr15:84656980	chr15:84599434~84606463:-
HNSC	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-3.88	0.00012	0.0163	-0.2	-0.18	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
HNSC	cis	rs58873874	0.579	rs56666304	ENSG00000248544.2	CTB-47B11.3	3.88	0.00012	0.0163	0.34	0.18	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157375741~157384950:-
HNSC	cis	rs7572733	0.534	rs700684	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0163	-0.17	-0.18	Dermatomyositis;	chr2:197848375	chr2:197197991~197199273:+
HNSC	cis	rs5758659	0.569	rs133293	ENSG00000182057.4	OGFRP1	3.88	0.00012	0.0163	0.18	0.18	Cognitive function;	chr22:41986793	chr22:42269753~42275196:+
HNSC	cis	rs6840360	0.642	rs2724574	ENSG00000251611.1	RP11-610P16.1	3.88	0.00012	0.0163	0.17	0.18	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151407551~151408835:-
HNSC	cis	rs2333021	0.833	rs10141389	ENSG00000258376.2	RP4-647C14.2	-3.88	0.00012	0.0163	-0.21	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:73242651~73245979:-
HNSC	cis	rs2333021	0.866	rs10133784	ENSG00000258376.2	RP4-647C14.2	-3.88	0.00012	0.0163	-0.21	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:73242651~73245979:-
HNSC	cis	rs526231	0.543	rs34379	ENSG00000250682.4	LINC00491	-3.88	0.00012	0.0163	-0.23	-0.18	Primary biliary cholangitis;	chr5:103062994	chr5:102609156~102671559:-
HNSC	cis	rs1485395	0.588	rs7969195	ENSG00000270175.1	RP11-793H13.11	-3.88	0.00012	0.0163	-0.22	-0.18	Migraine without aura;	chr12:53549005	chr12:53500162~53500936:-
HNSC	cis	rs11098499	0.82	rs13122709	ENSG00000250412.1	KLHL2P1	3.88	0.00012	0.0163	0.23	0.18	Corneal astigmatism;	chr4:119634201	chr4:119334329~119378233:+
HNSC	cis	rs6088590	0.542	rs6059956	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.00012	0.0163	-0.18	-0.18	Coronary artery disease;	chr20:34632266	chr20:33985617~33988989:-
HNSC	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	3.88	0.00012	0.0163	0.31	0.18	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
HNSC	cis	rs1602565	1	rs7933990	ENSG00000255450.1	CTD-2063L20.1	3.88	0.00012	0.0163	0.3	0.18	Schizophrenia;	chr11:29187132	chr11:29275655~29276565:+
HNSC	cis	rs4820294	0.669	rs1894532	ENSG00000225867.1	RP5-1177I5.3	-3.88	0.00012	0.0163	-0.2	-0.18	Fat distribution (HIV);	chr22:37663743	chr22:37550026~37551735:+
HNSC	cis	rs4660214	0.666	rs598415	ENSG00000182109.6	RP11-69E11.4	3.88	0.00012	0.0163	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39522280~39546187:-
HNSC	cis	rs889398	0.802	rs12598642	ENSG00000196696.11	PDXDC2P	3.88	0.00012	0.0163	0.13	0.18	Body mass index;	chr16:69814869	chr16:69976297~70065948:-
HNSC	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-3.88	0.00012	0.0163	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-3.88	0.00012	0.0163	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-3.88	0.00012	0.0163	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
HNSC	cis	rs11986414	1	rs11986414	ENSG00000253982.1	CTD-2336O2.1	3.88	0.00012	0.0163	0.23	0.18	Gaucher disease severity;	chr8:1798784	chr8:1761990~1764502:-
HNSC	cis	rs28830936	1	rs17677199	ENSG00000250379.1	RP11-23P13.4	3.88	0.00012	0.0163	0.22	0.18	Diastolic blood pressure;	chr15:41662415	chr15:41825099~41827936:-
HNSC	cis	rs28830936	1	rs11637341	ENSG00000250379.1	RP11-23P13.4	3.88	0.00012	0.0163	0.22	0.18	Diastolic blood pressure;	chr15:41663627	chr15:41825099~41827936:-
HNSC	cis	rs5758511	0.514	rs9611746	ENSG00000227370.1	RP4-669P10.19	3.88	0.00012	0.0163	0.22	0.18	Birth weight;	chr22:42165359	chr22:42132543~42132998:+
HNSC	cis	rs597480	0.652	rs10898415	ENSG00000279742.1	RP11-700A24.1	3.88	0.00012	0.0163	0.19	0.18	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85810189	chr11:85852557~85854943:-
HNSC	cis	rs2732480	0.5	rs2450989	ENSG00000257763.1	OR5BK1P	-3.88	0.00012	0.0163	-0.17	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48355792~48356614:-
HNSC	cis	rs7572733	0.534	rs734037	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0163	-0.17	-0.18	Dermatomyositis;	chr2:197884545	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.555	rs13395030	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0163	-0.17	-0.18	Dermatomyositis;	chr2:197886082	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs2060488	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0163	-0.17	-0.18	Dermatomyositis;	chr2:197886913	chr2:197197991~197199273:+
HNSC	cis	rs9467711	0.606	rs9379871	ENSG00000241549.7	GUSBP2	3.88	0.00012	0.0163	0.27	0.18	Autism spectrum disorder or schizophrenia;	chr6:26375626	chr6:26871484~26956554:-
HNSC	cis	rs7572733	1	rs7572733	ENSG00000222017.1	AC011997.1	3.88	0.00012	0.0163	0.21	0.18	Dermatomyositis;	chr2:198065082	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.875	rs11690149	ENSG00000222017.1	AC011997.1	3.88	0.00012	0.0163	0.21	0.18	Dermatomyositis;	chr2:198069080	chr2:197693106~197774823:+
HNSC	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	3.88	0.00012	0.0164	0.26	0.18	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
HNSC	cis	rs9297145	0.761	rs112155177	ENSG00000272950.1	RP11-307C18.1	-3.88	0.00012	0.0164	-0.27	-0.18	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99150340	chr7:98322853~98323430:+
HNSC	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-3.88	0.00012	0.0164	-0.16	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
HNSC	cis	rs139515701	1	rs139515701	ENSG00000224034.1	RP11-445P17.8	3.88	0.00012	0.0164	0.24	0.18	Pursuit maintenance gain;	chr10:5177576	chr10:5266033~5271236:-
HNSC	cis	rs11976180	1	rs2371247	ENSG00000244479.5	OR2A1-AS1	3.88	0.00012	0.0164	0.2	0.18	Obesity-related traits;	chr7:144067086	chr7:144251264~144356181:-
HNSC	cis	rs62025270	0.632	rs62022924	ENSG00000259762.1	RP11-158M2.4	-3.88	0.00012	0.0164	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85750336~85752901:-
HNSC	cis	rs60695258	0.55	rs340648	ENSG00000251411.1	RP11-397E7.4	3.88	0.00012	0.0164	0.18	0.18	Hematocrit;	chr4:87019788	chr4:86913266~86914817:-
HNSC	cis	rs58873874	0.737	rs76634949	ENSG00000248544.2	CTB-47B11.3	3.88	0.00012	0.0164	0.42	0.18	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs79339674	ENSG00000248544.2	CTB-47B11.3	3.88	0.00012	0.0164	0.42	0.18	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157375741~157384950:-
HNSC	cis	rs16858210	0.607	rs57874587	ENSG00000234371.6	RPSAP31	3.88	0.00012	0.0164	0.24	0.18	Menopause (age at onset);	chr3:183866961	chr3:183884924~183888449:+
HNSC	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	3.88	0.00012	0.0164	0.22	0.18	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
HNSC	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-3.88	0.00012	0.0164	-0.17	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
HNSC	cis	rs72827839	0.779	rs58953228	ENSG00000244649.3	CTD-2377D24.6	-3.88	0.00012	0.0164	-0.23	-0.18	Ease of getting up in the morning;	chr17:48436452	chr17:48646923~48707346:+
HNSC	cis	rs2439831	0.618	rs8023508	ENSG00000201136.1	RNU6-353P	3.88	0.00012	0.0164	0.25	0.18	Lung cancer in ever smokers;	chr15:43883905	chr15:43702363~43702470:+
HNSC	cis	rs4908760	0.827	rs7513420	ENSG00000232912.4	RP5-1115A15.1	3.88	0.00012	0.0164	0.19	0.18	Vitiligo;	chr1:8620985	chr1:8424645~8434838:+
HNSC	cis	rs73198271	1	rs4840356	ENSG00000253893.2	FAM85B	3.88	0.00012	0.0164	0.26	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8167819~8226614:-
HNSC	cis	rs1028883	0.837	rs12428061	ENSG00000228295.1	LINC00392	3.88	0.00012	0.0164	0.19	0.18	Lean body mass;	chr13:73553153	chr13:73564244~73588070:+
HNSC	cis	rs17818399	0.547	rs12997164	ENSG00000279254.1	RP11-536C12.1	-3.88	0.00012	0.0164	-0.21	-0.18	Height;	chr2:46531607	chr2:46668870~46670778:+
HNSC	cis	rs4388249	0.95	rs34097054	ENSG00000271849.1	CTC-332L22.1	-3.88	0.00012	0.0164	-0.27	-0.18	Schizophrenia;	chr5:109759753	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.95	rs34837720	ENSG00000271849.1	CTC-332L22.1	-3.88	0.00012	0.0164	-0.27	-0.18	Schizophrenia;	chr5:109759863	chr5:109687802~109688329:-
HNSC	cis	rs11231017	0.501	rs11231053	ENSG00000250659.2	RP11-864I4.3	-3.88	0.00012	0.0164	-0.22	-0.18	HIV-1 viral setpoint;	chr11:62365748	chr11:62537312~62542018:+
HNSC	cis	rs7824557	0.569	rs7816601	ENSG00000255495.1	AC145124.2	3.88	0.00012	0.0164	0.2	0.18	Retinal vascular caliber;	chr8:11348084	chr8:12194467~12196280:+
HNSC	cis	rs2028299	0.959	rs748508	ENSG00000259677.1	RP11-493E3.1	3.88	0.000121	0.0164	0.22	0.18	Type 2 diabetes;	chr15:89838026	chr15:89876540~89877285:+
HNSC	cis	rs2028299	0.959	rs893617	ENSG00000259677.1	RP11-493E3.1	3.88	0.000121	0.0164	0.22	0.18	Type 2 diabetes;	chr15:89838046	chr15:89876540~89877285:+
HNSC	cis	rs9402743	0.673	rs9483860	ENSG00000234084.1	RP3-388E23.2	3.88	0.000121	0.0164	0.18	0.18	Systemic lupus erythematosus;	chr6:135646872	chr6:135301568~135307158:+
HNSC	cis	rs10056811	0.538	rs4632781	ENSG00000271815.1	CTD-2235C13.3	-3.88	0.000121	0.0164	-0.3	-0.18	Coronary artery disease;	chr5:75080833	chr5:75363760~75364242:+
HNSC	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-3.88	0.000121	0.0164	-0.21	-0.18	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
HNSC	cis	rs3809863	0.646	rs9899121	ENSG00000263293.2	RP11-290H9.4	3.88	0.000121	0.0164	0.2	0.18	Glaucoma (primary open-angle);	chr17:47317778	chr17:47303460~47323613:-
HNSC	cis	rs7005380	0.62	rs6987580	ENSG00000279347.1	RP11-85I17.2	3.88	0.000121	0.0164	0.14	0.18	Interstitial lung disease;	chr8:119898140	chr8:119838736~119840385:-
HNSC	cis	rs2136613	0.563	rs1509957	ENSG00000238280.1	RP11-436D10.3	-3.88	0.000121	0.0164	-0.2	-0.18	Selective IgA deficiency;	chr10:62850958	chr10:62793562~62805887:-
HNSC	cis	rs9611565	0.659	rs4822036	ENSG00000235513.1	RP4-756G23.5	3.88	0.000121	0.0164	0.21	0.18	Vitiligo;	chr22:41540015	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs12484228	ENSG00000235513.1	RP4-756G23.5	3.88	0.000121	0.0164	0.21	0.18	Vitiligo;	chr22:41543735	chr22:41209122~41217627:-
HNSC	cis	rs4865169	0.811	rs6841086	ENSG00000269949.1	RP11-738E22.3	3.88	0.000121	0.0164	0.2	0.18	Breast cancer;	chr4:57037102	chr4:56960927~56961373:-
HNSC	cis	rs3018712	0.532	rs2510397	ENSG00000212093.1	AP000807.1	-3.88	0.000121	0.0164	-0.26	-0.18	Total body bone mineral density;	chr11:68652091	chr11:68506083~68506166:-
HNSC	cis	rs250677	0.687	rs171636	ENSG00000250072.4	CTC-529P8.1	-3.88	0.000121	0.0164	-0.25	-0.18	Breast cancer;	chr5:149054982	chr5:149063317~149109787:+
HNSC	cis	rs643955	0.583	rs13250399	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000121	0.0164	-0.22	-0.18	Systemic lupus erythematosus;	chr8:10015300	chr8:9141424~9145435:+
HNSC	cis	rs34792	0.688	rs153785	ENSG00000207425.1	Y_RNA	3.88	0.000121	0.0164	0.21	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:14915457~14915556:-
HNSC	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	3.88	0.000121	0.0164	0.21	0.18	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
HNSC	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-3.88	0.000121	0.0164	-0.29	-0.18	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
HNSC	cis	rs8031584	0.678	rs798125	ENSG00000270015.1	RP11-540B6.6	3.88	0.000121	0.0164	0.18	0.18	Huntington's disease progression;	chr15:30824597	chr15:30926514~30928407:+
HNSC	cis	rs7572733	0.792	rs1064213	ENSG00000222017.1	AC011997.1	3.88	0.000121	0.0164	0.22	0.18	Dermatomyositis;	chr2:198085516	chr2:197693106~197774823:+
HNSC	cis	rs36093844	0.527	rs10128700	ENSG00000279742.1	RP11-700A24.1	-3.88	0.000121	0.0164	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86043350	chr11:85852557~85854943:-
HNSC	cis	rs7615952	0.673	rs16834637	ENSG00000241278.1	ENPP7P4	-3.88	0.000121	0.0164	-0.3	-0.18	Blood pressure (smoking interaction);	chr3:125886628	chr3:125848223~125909372:+
HNSC	cis	rs1008375	1	rs7688682	ENSG00000249502.1	AC006160.5	3.88	0.000121	0.0164	0.19	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692171	chr4:17587467~17614571:-
HNSC	cis	rs73198271	0.843	rs11775888	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000121	0.0164	-0.27	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:9141424~9145435:+
HNSC	cis	rs7760535	0.93	rs7742244	ENSG00000255389.1	C6orf3	-3.88	0.000121	0.0164	-0.17	-0.18	Metabolic traits;	chr6:111531459	chr6:111599875~111602295:+
HNSC	cis	rs3738443	0.904	rs61840000	ENSG00000259865.1	RP11-488L18.10	3.88	0.000121	0.0164	0.17	0.18	Alcohol dependence;	chr1:247199027	chr1:247187281~247188526:-
HNSC	cis	rs35306767	0.855	rs55708963	ENSG00000229869.1	RP11-363N22.2	-3.88	0.000121	0.0164	-0.27	-0.18	Eosinophil percentage of granulocytes;	chr10:879772	chr10:933026~942743:+
HNSC	cis	rs6840360	0.642	rs2724567	ENSG00000251611.1	RP11-610P16.1	3.88	0.000121	0.0164	0.17	0.18	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151407551~151408835:-
HNSC	cis	rs7688540	0.771	rs17164747	ENSG00000211553.1	AC253576.2	-3.88	0.000121	0.0164	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:136461~136568:+
HNSC	cis	rs957448	0.848	rs113630732	ENSG00000253704.1	RP11-267M23.4	3.88	0.000121	0.0165	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94483802	chr8:94553722~94569745:+
HNSC	cis	rs4840086	1	rs6902345	ENSG00000219755.1	RP1-199J3.5	3.88	0.000121	0.0165	0.21	0.18	Menarche (age at onset);	chr6:99751901	chr6:99575712~99576456:+
HNSC	cis	rs950169	0.922	rs4842940	ENSG00000230373.7	GOLGA6L5P	3.88	0.000121	0.0165	0.2	0.18	Schizophrenia;	chr15:84162473	chr15:84507885~84516814:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000272831.1	RP11-792A8.4	3.88	0.000121	0.0165	0.15	0.18	Aortic root size;	chr7:65966699	chr7:66739829~66740385:-
HNSC	cis	rs9329221	0.525	rs4394398	ENSG00000255310.2	AF131215.2	-3.88	0.000121	0.0165	-0.18	-0.18	Neuroticism;	chr8:10226884	chr8:11107788~11109726:-
HNSC	cis	rs3738443	0.904	rs61840474	ENSG00000259865.1	RP11-488L18.10	3.88	0.000121	0.0165	0.17	0.18	Alcohol dependence;	chr1:247225109	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.904	rs61840475	ENSG00000259865.1	RP11-488L18.10	3.88	0.000121	0.0165	0.17	0.18	Alcohol dependence;	chr1:247225818	chr1:247187281~247188526:-
HNSC	cis	rs941408	0.515	rs12610096	ENSG00000261342.1	AC006538.1	3.88	0.000121	0.0165	0.25	0.18	Total cholesterol levels;	chr19:2778131	chr19:2727743~2729327:-
HNSC	cis	rs67072384	1	rs72964181	ENSG00000213365.3	AP000593.6	3.88	0.000121	0.0165	0.32	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72729079	chr11:72280151~72281178:+
HNSC	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	3.88	0.000121	0.0165	0.18	0.18	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
HNSC	cis	rs9313772	0.928	rs12188031	ENSG00000254350.1	RP11-542A14.1	-3.88	0.000121	0.0165	-0.19	-0.18	Blood pressure;	chr5:158385012	chr5:158424585~158452758:+
HNSC	cis	rs6005807	0.543	rs2235432	ENSG00000226471.5	CTA-292E10.6	-3.88	0.000121	0.0165	-0.28	-0.18	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28773432	chr22:28800683~28848559:+
HNSC	cis	rs459482	0.534	rs458255	ENSG00000228318.3	AP001610.5	-3.88	0.000121	0.0165	-0.2	-0.18	IgG glycosylation;	chr21:41429201	chr21:41441056~41445708:-
HNSC	cis	rs28489187	0.706	rs1498375	ENSG00000223653.4	RP11-131L23.1	3.88	0.000121	0.0165	0.25	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321640	chr1:85276715~85448124:+
HNSC	cis	rs897984	0.806	rs10782002	ENSG00000279196.1	RP11-1072A3.3	-3.88	0.000121	0.0165	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30935185	chr16:30984630~30988270:-
HNSC	cis	rs6968419	0.674	rs6466571	ENSG00000237870.5	AC073130.1	-3.88	0.000121	0.0165	-0.21	-0.18	Intraocular pressure;	chr7:116269991	chr7:116275606~116286734:-
HNSC	cis	rs2288912	0.807	rs10423208	ENSG00000269148.1	AC092301.3	3.88	0.000121	0.0165	0.16	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44950399	chr19:45830164~45831108:+
HNSC	cis	rs7324557	0.717	rs9318064	ENSG00000205861.10	C1QTNF9B-AS1	-3.88	0.000121	0.0165	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23822010	chr13:23888889~23897263:+
HNSC	cis	rs7324557	0.717	rs9510876	ENSG00000205861.10	C1QTNF9B-AS1	-3.88	0.000121	0.0165	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23822149	chr13:23888889~23897263:+
HNSC	cis	rs116095464	0.718	rs62331563	ENSG00000250848.1	CTD-2083E4.5	-3.88	0.000121	0.0165	-0.36	-0.18	Breast cancer;	chr5:355171	chr5:288833~290321:-
HNSC	cis	rs1223397	0.938	rs9381884	ENSG00000215022.6	RP1-257A7.4	-3.88	0.000121	0.0165	-0.22	-0.18	Blood pressure;	chr6:13278556	chr6:13264861~13295586:-
HNSC	cis	rs792448	0.717	rs7544225	ENSG00000226251.4	RP11-15I11.3	3.88	0.000121	0.0165	0.21	0.18	White blood cell count (basophil);	chr1:212235666	chr1:212225278~212238977:-
HNSC	cis	rs1964356	0.967	rs2953802	ENSG00000253981.4	ALG1L13P	3.88	0.000121	0.0165	0.2	0.18	Mean corpuscular volume;	chr8:8994371	chr8:8236003~8244667:-
HNSC	cis	rs853679	0.882	rs2743555	ENSG00000226314.6	ZNF192P1	-3.88	0.000121	0.0165	-0.25	-0.18	Depression;	chr6:28273304	chr6:28161781~28169594:+
HNSC	cis	rs853679	1	rs1419183	ENSG00000226314.6	ZNF192P1	-3.88	0.000121	0.0165	-0.25	-0.18	Depression;	chr6:28275017	chr6:28161781~28169594:+
HNSC	cis	rs6540731	0.875	rs10863953	ENSG00000226251.4	RP11-15I11.3	-3.88	0.000121	0.0165	-0.2	-0.18	Intelligence (childhood);	chr1:212192458	chr1:212225278~212238977:-
HNSC	cis	rs733592	0.599	rs12819124	ENSG00000257763.1	OR5BK1P	3.88	0.000121	0.0165	0.16	0.18	Plateletcrit;	chr12:48015271	chr12:48355792~48356614:-
HNSC	cis	rs3740713	1	rs73436638	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436642	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436666	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438611	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs2643872	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs75381502	ENSG00000256464.1	YWHABP2	3.88	0.000121	0.0165	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr11:18490243~18490955:-
HNSC	cis	rs9908552	0.586	rs12940852	ENSG00000262810.1	RP11-667K14.5	-3.88	0.000121	0.0165	-0.2	-0.18	Schizophrenia;	chr17:1339729	chr17:2089681~2101560:+
HNSC	cis	rs7015630	0.657	rs12155807	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000121	0.0165	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89835484	chr8:89609409~89757727:-
HNSC	cis	rs73607972	0.696	rs7194983	ENSG00000275191.1	RP11-36I17.2	-3.88	0.000121	0.0165	-0.25	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525100	chr16:53628256~53628816:-
HNSC	cis	rs964611	0.751	rs2291340	ENSG00000259488.2	RP11-154J22.1	-3.88	0.000121	0.0165	-0.16	-0.18	Metabolite levels (Pyroglutamine);	chr15:48255779	chr15:48312353~48331856:-
HNSC	cis	rs2436845	0.627	rs1897787	ENSG00000253320.4	KB-1507C5.2	3.88	0.000121	0.0165	0.2	0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102864300~102977876:+
HNSC	cis	rs6964587	0.626	rs35849169	ENSG00000188693.7	CYP51A1-AS1	-3.88	0.000122	0.0165	-0.19	-0.18	Breast cancer;	chr7:91877999	chr7:92134604~92180725:+
HNSC	cis	rs73198271	1	rs4841031	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000122	0.0165	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:9141424~9145435:+
HNSC	cis	rs73198271	1	rs11784958	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000122	0.0165	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:9141424~9145435:+
HNSC	cis	rs8010715	0.816	rs6573573	ENSG00000259321.1	RP11-468E2.5	3.88	0.000122	0.0165	0.15	0.18	IgG glycosylation;	chr14:24130048	chr14:24139445~24140444:+
HNSC	cis	rs10771431	0.817	rs10843149	ENSG00000256427.1	RP11-118B22.4	3.88	0.000122	0.0165	0.19	0.18	Breast size;	chr12:9209471	chr12:9246497~9257960:+
HNSC	cis	rs3812049	0.532	rs251216	ENSG00000245937.6	LINC01184	3.88	0.000122	0.0165	0.23	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128207588	chr5:127940426~128083172:-
HNSC	cis	rs9925964	0.933	rs9939417	ENSG00000232748.3	RP11-196G11.6	3.88	0.000122	0.0165	0.23	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:31056460~31062803:+
HNSC	cis	rs2288884	0.505	rs2278415	ENSG00000267879.1	CTB-147C22.9	3.88	0.000122	0.0165	0.27	0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:50968210~51012129:+
HNSC	cis	rs2288884	0.505	rs3764538	ENSG00000267879.1	CTB-147C22.9	3.88	0.000122	0.0165	0.27	0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:50968210~51012129:+
HNSC	cis	rs2919009	0.607	rs61088531	ENSG00000271670.1	RP11-95I16.4	3.88	0.000122	0.0165	0.23	0.18	Obesity-related traits;	chr10:120946696	chr10:120879256~120880667:-
HNSC	cis	rs6568686	0.527	rs174406	ENSG00000255389.1	C6orf3	3.88	0.000122	0.0165	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610125	chr6:111599875~111602295:+
HNSC	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-3.88	0.000122	0.0165	-0.19	-0.18	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
HNSC	cis	rs3736485	0.966	rs11070852	ENSG00000259438.1	CTD-2650P22.1	3.88	0.000122	0.0165	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51490097	chr15:52010999~52019095:-
HNSC	cis	rs7937890	1	rs7937890	ENSG00000254418.1	RP11-21L19.1	3.88	0.000122	0.0165	0.21	0.18	Mitochondrial DNA levels;	chr11:14374939	chr11:14262846~14273691:-
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000226314.6	ZNF192P1	-3.88	0.000122	0.0165	-0.2	-0.18	Depression;	chr6:28391932	chr6:28161781~28169594:+
HNSC	cis	rs12545912	0.82	rs7844450	ENSG00000254340.1	RP11-10A14.3	3.88	0.000122	0.0165	0.25	0.18	Multiple myeloma (hyperdiploidy);	chr8:9574600	chr8:9141424~9145435:+
HNSC	cis	rs6543140	0.964	rs4851589	ENSG00000234389.1	AC007278.3	3.88	0.000122	0.0165	0.17	0.18	Blood protein levels;	chr2:102460685	chr2:102438713~102440475:+
HNSC	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-3.88	0.000122	0.0165	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
HNSC	cis	rs3018712	0.532	rs2513281	ENSG00000212093.1	AP000807.1	-3.88	0.000122	0.0166	-0.26	-0.18	Total body bone mineral density;	chr11:68649626	chr11:68506083~68506166:-
HNSC	cis	rs1950832	0.595	rs8013838	ENSG00000251363.2	RP11-129M6.1	-3.87	0.000122	0.0166	-0.22	-0.18	Urate levels in obese individuals;	chr14:41549831	chr14:40954898~40975877:+
HNSC	cis	rs28830936	0.966	rs28451764	ENSG00000250379.1	RP11-23P13.4	3.87	0.000122	0.0166	0.21	0.18	Diastolic blood pressure;	chr15:41834385	chr15:41825099~41827936:-
HNSC	cis	rs28830936	0.966	rs28373318	ENSG00000250379.1	RP11-23P13.4	3.87	0.000122	0.0166	0.21	0.18	Diastolic blood pressure;	chr15:41834527	chr15:41825099~41827936:-
HNSC	cis	rs656900	0.647	rs898436	ENSG00000261229.4	MTHFS	3.87	0.000122	0.0166	0.19	0.18	Cerebrospinal P-tau181p levels;	chr15:79824790	chr15:79843547~79897285:-
HNSC	cis	rs7429990	0.965	rs34750113	ENSG00000228638.1	FCF1P2	-3.87	0.000122	0.0166	-0.17	-0.18	Educational attainment (years of education);	chr3:47944902	chr3:48290793~48291375:-
HNSC	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	3.87	0.000122	0.0166	0.14	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
HNSC	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-3.87	0.000122	0.0166	-0.16	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
HNSC	cis	rs6430585	0.583	rs7581814	ENSG00000231890.6	DARS-AS1	3.87	0.000122	0.0166	0.3	0.18	Corneal structure;	chr2:135884023	chr2:135985176~136022593:+
HNSC	cis	rs2013441	1	rs2703816	ENSG00000261033.1	RP11-209D14.2	3.87	0.000122	0.0166	0.2	0.18	Obesity-related traits;	chr17:20215574	chr17:20008051~20009234:-
HNSC	cis	rs860295	0.58	rs10908483	ENSG00000225855.5	RUSC1-AS1	3.87	0.000122	0.0166	0.12	0.18	Body mass index;	chr1:155897043	chr1:155316863~155324176:-
HNSC	cis	rs7809615	0.515	rs6961634	ENSG00000244219.5	GS1-259H13.2	-3.87	0.000122	0.0166	-0.28	-0.18	Blood metabolite ratios;	chr7:99584216	chr7:99598066~99610813:+
HNSC	cis	rs853679	0.517	rs9366715	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Depression;	chr6:28096855	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.598	rs9380054	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Depression;	chr6:28099759	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.547	rs2116981	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Parkinson's disease;	chr6:28100173	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368552	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Depression;	chr6:28100648	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs2281588	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Depression;	chr6:28104824	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.542	rs34131763	ENSG00000219891.2	ZSCAN12P1	3.87	0.000122	0.0166	0.25	0.18	Depression;	chr6:28107222	chr6:28091154~28093664:+
HNSC	cis	rs1925953	0.683	rs1597	ENSG00000233589.1	RP4-694A7.2	-3.87	0.000122	0.0166	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68364992	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs12131381	ENSG00000233589.1	RP4-694A7.2	-3.87	0.000122	0.0166	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68365068	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs12143083	ENSG00000233589.1	RP4-694A7.2	-3.87	0.000122	0.0166	-0.22	-0.18	Vertical cup-disc ratio;	chr1:68365279	chr1:68479129~68483539:+
HNSC	cis	rs73198271	0.751	rs55816468	ENSG00000254153.1	CTA-398F10.2	-3.87	0.000122	0.0166	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8456909~8461337:-
HNSC	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	3.87	0.000122	0.0166	0.23	0.18	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
HNSC	cis	rs2074409	0.509	rs853231	ENSG00000276054.1	RP11-378E13.3	3.87	0.000122	0.0166	0.2	0.18	Response to angiotensin II receptor blocker therapy;	chr17:37454281	chr17:37386886~37387926:+
HNSC	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	3.87	0.000122	0.0166	0.2	0.18	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
HNSC	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	3.87	0.000122	0.0166	0.2	0.18	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
HNSC	cis	rs2904524	1	rs78509050	ENSG00000257815.4	RP11-611E13.2	-3.87	0.000122	0.0166	-0.23	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359589	chr12:69904033~70243360:-
HNSC	cis	rs2904524	1	rs75899653	ENSG00000257815.4	RP11-611E13.2	-3.87	0.000122	0.0166	-0.23	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359894	chr12:69904033~70243360:-
HNSC	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-3.87	0.000122	0.0166	-0.26	-0.18	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-3.87	0.000122	0.0166	-0.26	-0.18	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-3.87	0.000122	0.0166	-0.26	-0.18	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
HNSC	cis	rs67311347	0.869	rs9832311	ENSG00000280739.1	EIF1B-AS1	3.87	0.000122	0.0166	0.19	0.18	Renal cell carcinoma;	chr3:40339831	chr3:40173145~40309698:-
HNSC	cis	rs17221829	0.702	rs2075536	ENSG00000280385.1	AP000648.5	3.87	0.000122	0.0166	0.2	0.18	Anxiety in major depressive disorder;	chr11:89674223	chr11:90193614~90198120:+
HNSC	cis	rs9863	0.861	rs4930723	ENSG00000270028.1	RP11-380L11.4	3.87	0.000122	0.0166	0.21	0.18	White blood cell count;	chr12:123939053	chr12:123925461~123926083:-
HNSC	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000122	0.0166	-0.2	-0.18	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000122	0.0166	-0.2	-0.18	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000122	0.0166	-0.2	-0.18	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
HNSC	cis	rs2980436	1	rs2980436	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000122	0.0166	-0.17	-0.18	Schizophrenia;	chr8:8234503	chr8:8961200~8979025:+
HNSC	cis	rs6500395	0.89	rs9936271	ENSG00000261267.1	RP11-44I10.3	-3.87	0.000122	0.0166	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48567380	chr16:48559661~48587403:+
HNSC	cis	rs73198271	0.74	rs964771	ENSG00000254153.1	CTA-398F10.2	3.87	0.000122	0.0166	0.22	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8456909~8461337:-
HNSC	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-3.87	0.000122	0.0166	-0.26	-0.18	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
HNSC	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000122	0.0166	-0.17	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
HNSC	cis	rs597539	0.652	rs553875	ENSG00000261625.1	RP11-554A11.4	-3.87	0.000122	0.0166	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.652	rs627731	ENSG00000261625.1	RP11-554A11.4	-3.87	0.000122	0.0166	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:69000765~69002048:-
HNSC	cis	rs1387259	0.931	rs11168474	ENSG00000257763.1	OR5BK1P	3.87	0.000122	0.0166	0.17	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48355792~48356614:-
HNSC	cis	rs7572733	0.935	rs10207433	ENSG00000222017.1	AC011997.1	3.87	0.000122	0.0166	0.21	0.18	Dermatomyositis;	chr2:197941206	chr2:197693106~197774823:+
HNSC	cis	rs5758659	1	rs134900	ENSG00000273366.1	CTA-989H11.1	-3.87	0.000122	0.0166	-0.21	-0.18	Cognitive function;	chr22:42287337	chr22:42278188~42278846:+
HNSC	cis	rs11992186	0.57	rs17628941	ENSG00000254340.1	RP11-10A14.3	-3.87	0.000122	0.0166	-0.23	-0.18	Neuroticism;	chr8:8730024	chr8:9141424~9145435:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000229886.1	RP5-1132H15.3	3.87	0.000122	0.0166	0.3	0.18	Diabetic kidney disease;	chr7:66136229	chr7:66025126~66031544:-
HNSC	cis	rs41307935	0.73	rs12753968	ENSG00000260063.1	RP5-968P14.2	-3.87	0.000123	0.0166	-0.39	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26870872	chr1:26692132~26694131:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	3.87	0.000123	0.0166	0.2	0.18	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
HNSC	cis	rs7005380	0.6	rs4871772	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000123	0.0166	-0.14	-0.18	Interstitial lung disease;	chr8:119895655	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs4871773	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000123	0.0166	-0.14	-0.18	Interstitial lung disease;	chr8:119895671	chr8:119838736~119840385:-
HNSC	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-3.87	0.000123	0.0166	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
HNSC	cis	rs4713118	0.587	rs61471148	ENSG00000219891.2	ZSCAN12P1	3.87	0.000123	0.0166	0.25	0.18	Parkinson's disease;	chr6:28069254	chr6:28091154~28093664:+
HNSC	cis	rs516805	0.667	rs1339532	ENSG00000279453.1	RP3-425C14.4	3.87	0.000123	0.0166	0.23	0.18	Lymphocyte counts;	chr6:122345249	chr6:122436789~122439223:-
HNSC	cis	rs6787172	0.811	rs11714869	ENSG00000272087.1	RP11-379F4.7	-3.87	0.000123	0.0166	-0.18	-0.18	Subjective well-being;	chr3:158476931	chr3:158693120~158693768:-
HNSC	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	3.87	0.000123	0.0166	0.29	0.18	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
HNSC	cis	rs73201462	1	rs11721213	ENSG00000231305.3	RP11-723O4.2	3.87	0.000123	0.0166	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348598	chr3:128861313~128871540:-
HNSC	cis	rs4760636	0.863	rs3815136	ENSG00000268069.2	RP5-1057I20.4	3.87	0.000123	0.0166	0.21	0.18	Urate levels;	chr12:47785126	chr12:47784923~47786002:+
HNSC	cis	rs4947019	0.609	rs79097132	ENSG00000260273.1	RP11-425D10.10	3.87	0.000123	0.0166	0.48	0.18	Hematological parameters;	chr6:109404619	chr6:109382795~109383666:+
HNSC	cis	rs889398	0.967	rs1437134	ENSG00000196696.11	PDXDC2P	-3.87	0.000123	0.0166	-0.12	-0.18	Body mass index;	chr16:69696523	chr16:69976297~70065948:-
HNSC	cis	rs6964587	0.626	rs6972945	ENSG00000188693.7	CYP51A1-AS1	3.87	0.000123	0.0166	0.19	0.18	Breast cancer;	chr7:91920262	chr7:92134604~92180725:+
HNSC	cis	rs67311347	0.955	rs4974067	ENSG00000280739.1	EIF1B-AS1	3.87	0.000123	0.0166	0.19	0.18	Renal cell carcinoma;	chr3:40333060	chr3:40173145~40309698:-
HNSC	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-3.87	0.000123	0.0166	-0.26	-0.18	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
HNSC	cis	rs4852324	0.536	rs13387174	ENSG00000237883.1	DGUOK-AS1	-3.87	0.000123	0.0167	-0.36	-0.18	Systemic lupus erythematosus;	chr2:73979558	chr2:73947642~73981441:-
HNSC	cis	rs58873874	0.737	rs11745566	ENSG00000248544.2	CTB-47B11.3	3.87	0.000123	0.0167	0.41	0.18	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157375741~157384950:-
HNSC	cis	rs2307394	0.964	rs2161985	ENSG00000281469.1	RP11-567F11.1	3.87	0.000123	0.0167	0.2	0.18	Urate levels;	chr2:147781262	chr2:148044380~148044894:+
HNSC	cis	rs516805	0.748	rs647178	ENSG00000279453.1	RP3-425C14.4	-3.87	0.000123	0.0167	-0.25	-0.18	Lymphocyte counts;	chr6:122543602	chr6:122436789~122439223:-
HNSC	cis	rs73198271	1	rs11775476	ENSG00000254340.1	RP11-10A14.3	-3.87	0.000123	0.0167	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:9141424~9145435:+
HNSC	cis	rs2518049	0.563	rs79618354	ENSG00000224034.1	RP11-445P17.8	-3.87	0.000123	0.0167	-0.25	-0.18	Metabolic traits;	chr10:5278987	chr10:5266033~5271236:-
HNSC	cis	rs897984	0.683	rs729482	ENSG00000275263.1	RP11-1072A3.4	-3.87	0.000123	0.0167	-0.2	-0.18	Dementia with Lewy bodies;	chr16:31005649	chr16:30956872~30957199:-
HNSC	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	3.87	0.000123	0.0167	0.22	0.18	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
HNSC	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	3.87	0.000123	0.0167	0.2	0.18	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
HNSC	cis	rs2688482	0.557	rs2550236	ENSG00000185485.13	SDHAP1	3.87	0.000123	0.0167	0.19	0.18	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195959748~195990318:-
HNSC	cis	rs656319	0.605	rs60278284	ENSG00000255310.2	AF131215.2	-3.87	0.000123	0.0167	-0.17	-0.18	Myopia (pathological);	chr8:10145700	chr8:11107788~11109726:-
HNSC	cis	rs7107174	1	rs731600	ENSG00000251323.2	RP11-452H21.4	3.87	0.000123	0.0167	0.26	0.18	Testicular germ cell tumor;	chr11:78252087	chr11:78423982~78429836:-
HNSC	cis	rs2307394	0.964	rs13019386	ENSG00000281469.1	RP11-567F11.1	3.87	0.000123	0.0167	0.2	0.18	Urate levels;	chr2:147797740	chr2:148044380~148044894:+
HNSC	cis	rs5758511	0.514	rs5751211	ENSG00000227370.1	RP4-669P10.19	3.87	0.000123	0.0167	0.22	0.18	Birth weight;	chr22:42090052	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs3985938	ENSG00000227370.1	RP4-669P10.19	3.87	0.000123	0.0167	0.22	0.18	Birth weight;	chr22:42115723	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs5751221	ENSG00000227370.1	RP4-669P10.19	3.87	0.000123	0.0167	0.22	0.18	Birth weight;	chr22:42120362	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs5758586	ENSG00000227370.1	RP4-669P10.19	3.87	0.000123	0.0167	0.22	0.18	Birth weight;	chr22:42121467	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.514	rs5751222	ENSG00000227370.1	RP4-669P10.19	3.87	0.000123	0.0167	0.22	0.18	Birth weight;	chr22:42121918	chr22:42132543~42132998:+
HNSC	cis	rs9393777	0.92	rs34196306	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000123	0.0167	-0.4	-0.18	Intelligence (multi-trait analysis);	chr6:27457865	chr6:28115628~28116551:+
HNSC	cis	rs10090774	0.87	rs4563941	ENSG00000279766.1	RP11-642A1.2	-3.87	0.000123	0.0167	-0.18	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722653	chr8:140572142~140572812:-
HNSC	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-3.87	0.000123	0.0167	-0.21	-0.18	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
HNSC	cis	rs924607	1	rs1697978	ENSG00000225138.6	CTD-2228K2.7	3.87	0.000123	0.0167	0.19	0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:642714	chr5:473236~480884:+
HNSC	cis	rs546131	0.642	rs11602886	ENSG00000271369.1	RP11-350D17.3	-3.87	0.000123	0.0167	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34820296	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs11602870	ENSG00000271369.1	RP11-350D17.3	-3.87	0.000123	0.0167	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34820355	chr11:34709600~34710161:+
HNSC	cis	rs11951515	0.738	rs12189447	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000123	0.0167	0.18	0.18	Metabolite levels  (X-11787);	chr5:43335882	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4574553	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000123	0.0167	0.18	0.18	Metabolite levels  (X-11787);	chr5:43336316	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.675	rs72754530	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000123	0.0167	0.18	0.18	Metabolite levels  (X-11787);	chr5:43339370	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs55673816	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000123	0.0167	0.18	0.18	Metabolite levels  (X-11787);	chr5:43339682	chr5:43586918~43588223:-
HNSC	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000123	0.0167	-0.2	-0.18	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
HNSC	cis	rs2657294	0.796	rs7082123	ENSG00000233313.2	HMGA1P5	-3.87	0.000123	0.0167	-0.19	-0.18	Pneumonia;	chr10:75091101	chr10:75276376~75276646:-
HNSC	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	3.87	0.000123	0.0167	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
HNSC	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000123	0.0167	-0.19	-0.18	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000123	0.0167	-0.19	-0.18	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000123	0.0167	-0.19	-0.18	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-3.87	0.000123	0.0167	-0.19	-0.18	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
HNSC	cis	rs17253792	0.822	rs74412558	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55587593	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs112238223	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55589426	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs80174205	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55591976	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78261053	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55595066	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.731	rs8008528	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55595334	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs8009239	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55595772	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs79291233	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55598584	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.818	rs78393484	ENSG00000186615.9	KTN1-AS1	-3.87	0.000123	0.0167	-0.35	-0.18	Putamen volume;	chr14:55599084	chr14:55499278~55580110:-
HNSC	cis	rs2439831	1	rs28666488	ENSG00000275601.1	AC011330.13	-3.87	0.000123	0.0167	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43448892	chr15:43642389~43643023:-
HNSC	cis	rs153852	0.59	rs36733	ENSG00000243806.1	RPL7P18	3.87	0.000123	0.0167	0.23	0.18	Cancer;	chr5:94832585	chr5:94825961~94826694:-
HNSC	cis	rs7475343	0.543	rs77353068	ENSG00000224034.1	RP11-445P17.8	-3.87	0.000123	0.0167	-0.25	-0.18	Intelligence;	chr10:5219263	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs80264034	ENSG00000224034.1	RP11-445P17.8	-3.87	0.000123	0.0167	-0.25	-0.18	Intelligence;	chr10:5219613	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs74404998	ENSG00000224034.1	RP11-445P17.8	-3.87	0.000123	0.0167	-0.25	-0.18	Intelligence;	chr10:5219720	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs17134607	ENSG00000224034.1	RP11-445P17.8	-3.87	0.000123	0.0167	-0.25	-0.18	Intelligence;	chr10:5219947	chr10:5266033~5271236:-
HNSC	cis	rs67311347	0.568	rs57287242	ENSG00000280739.1	EIF1B-AS1	3.87	0.000123	0.0167	0.19	0.18	Renal cell carcinoma;	chr3:40294047	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs35112505	ENSG00000280739.1	EIF1B-AS1	3.87	0.000123	0.0167	0.19	0.18	Renal cell carcinoma;	chr3:40295584	chr3:40173145~40309698:-
HNSC	cis	rs16873450	0.548	rs6953133	ENSG00000234800.2	PCMTD1P3	3.87	0.000123	0.0167	0.17	0.18	Verbal memory performance (residualized delayed recall level);	chr7:23761171	chr7:23721311~23721782:-
HNSC	cis	rs516805	0.706	rs9490431	ENSG00000279453.1	RP3-425C14.4	3.87	0.000123	0.0167	0.24	0.18	Lymphocyte counts;	chr6:122361132	chr6:122436789~122439223:-
HNSC	cis	rs6095360	0.727	rs13037063	ENSG00000222365.1	SNORD12B	-3.87	0.000123	0.0167	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48909128	chr20:49280319~49280409:+
HNSC	cis	rs2274273	0.745	rs748017	ENSG00000233924.1	AL160471.6	-3.87	0.000123	0.0167	-0.2	-0.18	Protein biomarker;	chr14:55075582	chr14:55004813~55005687:-
HNSC	cis	rs2243480	1	rs4718269	ENSG00000229886.1	RP5-1132H15.3	-3.87	0.000123	0.0167	-0.3	-0.18	Diabetic kidney disease;	chr7:65735810	chr7:66025126~66031544:-
HNSC	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	3.87	0.000123	0.0167	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
HNSC	cis	rs988913	0.813	rs2143798	ENSG00000224984.1	RP11-524H19.2	3.87	0.000123	0.0167	0.2	0.18	Menarche (age at onset);	chr6:54888256	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.768	rs2179786	ENSG00000224984.1	RP11-524H19.2	3.87	0.000123	0.0167	0.2	0.18	Menarche (age at onset);	chr6:54888542	chr6:54840118~54840855:-
HNSC	cis	rs2032366	0.967	rs6650736	ENSG00000267279.1	RP11-879F14.2	-3.87	0.000123	0.0167	-0.22	-0.18	Obesity-related traits;	chr18:61601711	chr18:61585746~61606916:-
HNSC	cis	rs2032366	0.967	rs9965804	ENSG00000267279.1	RP11-879F14.2	-3.87	0.000123	0.0167	-0.22	-0.18	Obesity-related traits;	chr18:61602021	chr18:61585746~61606916:-
HNSC	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	3.87	0.000123	0.0167	0.29	0.18	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
HNSC	cis	rs17404153	0.599	rs72992311	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.0167	-0.3	-0.18	LDL cholesterol;HDL cholesterol;	chr3:132439422	chr3:132721750~132874223:+
HNSC	cis	rs12931792	0.712	rs56399904	ENSG00000273724.1	RP11-347C12.12	3.87	0.000123	0.0167	0.19	0.18	Tonsillectomy;	chr16:30154862	chr16:30336400~30343336:+
HNSC	cis	rs656900	0.74	rs1675181	ENSG00000261229.4	MTHFS	3.87	0.000123	0.0167	0.2	0.18	Cerebrospinal P-tau181p levels;	chr15:79819296	chr15:79843547~79897285:-
HNSC	cis	rs889398	0.77	rs8052225	ENSG00000196696.11	PDXDC2P	-3.87	0.000123	0.0167	-0.12	-0.18	Body mass index;	chr16:69849750	chr16:69976297~70065948:-
HNSC	cis	rs868153	0.595	rs35859246	ENSG00000275339.1	RP3-425C14.6	3.87	0.000123	0.0167	0.19	0.18	Vertical cup-disc ratio;	chr6:122189329	chr6:122454358~122454612:+
HNSC	cis	rs6001482	0.507	rs5750779	ENSG00000274422.1	LL22NC03-2H8.5	3.87	0.000123	0.0167	0.18	0.18	Diastolic blood pressure;	chr22:22230928	chr22:22283928~22287220:-
HNSC	cis	rs2836974	0.563	rs997147	ENSG00000255568.3	BRWD1-AS2	-3.87	0.000123	0.0167	-0.15	-0.18	Cognitive function;	chr21:39323399	chr21:39313935~39314962:+
HNSC	cis	rs60695258	0.55	rs340636	ENSG00000251411.1	RP11-397E7.4	3.87	0.000123	0.0167	0.18	0.18	Hematocrit;	chr4:87009608	chr4:86913266~86914817:-
HNSC	cis	rs2436845	0.627	rs1019976	ENSG00000253320.4	KB-1507C5.2	3.87	0.000123	0.0167	0.2	0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852043	chr8:102864300~102977876:+
HNSC	cis	rs17772222	1	rs17772288	ENSG00000258789.1	RP11-507K2.3	-3.87	0.000124	0.0167	-0.22	-0.18	Coronary artery calcification;	chr14:88361022	chr14:88551597~88552493:+
HNSC	cis	rs6951245	0.554	rs10246354	ENSG00000225146.1	AC073957.15	-3.87	0.000124	0.0167	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1029025~1043891:+
HNSC	cis	rs9313772	0.775	rs7711233	ENSG00000254350.1	RP11-542A14.1	-3.87	0.000124	0.0167	-0.19	-0.18	Blood pressure;	chr5:158398988	chr5:158424585~158452758:+
HNSC	cis	rs10791097	0.568	rs4411284	ENSG00000254842.5	RP11-890B15.2	-3.87	0.000124	0.0167	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130868673	chr11:130844191~130865561:-
HNSC	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	3.87	0.000124	0.0167	0.21	0.18	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
HNSC	cis	rs6180	0.816	rs34417548	ENSG00000215068.6	AC025171.1	-3.87	0.000124	0.0167	-0.18	-0.18	Height;	chr5:42842127	chr5:43041575~43045390:+
HNSC	cis	rs7015630	0.657	rs62530908	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000124	0.0167	-0.22	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89835235	chr8:89609409~89757727:-
HNSC	cis	rs1008375	0.9	rs3822235	ENSG00000249502.1	AC006160.5	3.87	0.000124	0.0168	0.19	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693293	chr4:17587467~17614571:-
HNSC	cis	rs755249	0.761	rs61781390	ENSG00000182109.6	RP11-69E11.4	3.87	0.000124	0.0168	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.876	rs61781391	ENSG00000182109.6	RP11-69E11.4	3.87	0.000124	0.0168	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.917	rs61781392	ENSG00000182109.6	RP11-69E11.4	3.87	0.000124	0.0168	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.917	rs61232586	ENSG00000182109.6	RP11-69E11.4	3.87	0.000124	0.0168	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.917	rs61781393	ENSG00000182109.6	RP11-69E11.4	3.87	0.000124	0.0168	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39522280~39546187:-
HNSC	cis	rs6878727	0.85	rs2408163	ENSG00000253807.4	LINC01170	-3.87	0.000124	0.0168	-0.22	-0.18	Breast cancer;	chr5:124371323	chr5:124059794~124405079:-
HNSC	cis	rs6878727	0.85	rs1363308	ENSG00000253807.4	LINC01170	-3.87	0.000124	0.0168	-0.22	-0.18	Breast cancer;	chr5:124371529	chr5:124059794~124405079:-
HNSC	cis	rs1602565	0.841	rs11030610	ENSG00000255450.1	CTD-2063L20.1	-3.87	0.000124	0.0168	-0.31	-0.18	Schizophrenia;	chr11:29196239	chr11:29275655~29276565:+
HNSC	cis	rs11951515	0.738	rs12514399	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43313468	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs67817333	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43314947	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs2126949	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43316288	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.646	rs2126948	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43316367	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4866738	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43317354	chr5:43586918~43588223:-
HNSC	cis	rs2548724	0.716	rs62370977	ENSG00000250682.4	LINC00491	3.87	0.000124	0.0168	0.23	0.18	Type 2 diabetes;	chr5:102433366	chr5:102609156~102671559:-
HNSC	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	3.87	0.000124	0.0168	0.18	0.18	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
HNSC	cis	rs11098499	0.82	rs2389885	ENSG00000250412.1	KLHL2P1	3.87	0.000124	0.0168	0.23	0.18	Corneal astigmatism;	chr4:119612776	chr4:119334329~119378233:+
HNSC	cis	rs11722228	1	rs6825187	ENSG00000250413.1	RP11-448G15.1	3.87	0.000124	0.0168	0.23	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:9913701	chr4:10006482~10009725:+
HNSC	cis	rs9487051	0.837	rs6568561	ENSG00000219700.1	PTCHD3P3	3.87	0.000124	0.0168	0.17	0.18	Reticulocyte fraction of red cells;	chr6:109271706	chr6:109288571~109290503:-
HNSC	cis	rs546131	0.642	rs1897203	ENSG00000271369.1	RP11-350D17.3	-3.87	0.000124	0.0168	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34800441	chr11:34709600~34710161:+
HNSC	cis	rs17253792	0.822	rs79398217	ENSG00000186615.9	KTN1-AS1	-3.87	0.000124	0.0168	-0.35	-0.18	Putamen volume;	chr14:55600632	chr14:55499278~55580110:-
HNSC	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-3.87	0.000124	0.0168	-0.23	-0.18	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
HNSC	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-3.87	0.000124	0.0168	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
HNSC	cis	rs482329	0.719	rs610843	ENSG00000224939.1	LINC00184	3.87	0.000124	0.0168	0.22	0.18	Life threatening arrhythmia;	chr1:234666662	chr1:234629311~234634780:+
HNSC	cis	rs6444931	0.882	rs34814917	ENSG00000240704.1	KLF7P1	3.87	0.000124	0.0168	0.28	0.18	Bipolar disorder and schizophrenia;	chr3:170444391	chr3:170952850~170953897:-
HNSC	cis	rs12370275	0.58	rs17124819	ENSG00000257528.1	KRT8P19	-3.87	0.000124	0.0168	-0.24	-0.18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61350840	chr12:61879318~61880772:+
HNSC	cis	rs9500256	0.966	rs1322446	ENSG00000225096.1	XXbac-BPG55C20.7	-3.87	0.000124	0.0168	-0.19	-0.18	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57965630~57972218:+
HNSC	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-3.87	0.000124	0.0168	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
HNSC	cis	rs9487051	0.807	rs7748641	ENSG00000219700.1	PTCHD3P3	3.87	0.000124	0.0168	0.17	0.18	Reticulocyte fraction of red cells;	chr6:109271178	chr6:109288571~109290503:-
HNSC	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	3.87	0.000124	0.0168	0.24	0.18	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
HNSC	cis	rs988913	0.706	rs9396034	ENSG00000224984.1	RP11-524H19.2	3.87	0.000124	0.0168	0.2	0.18	Menarche (age at onset);	chr6:55065311	chr6:54840118~54840855:-
HNSC	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-3.87	0.000124	0.0168	-0.23	-0.18	Pain;	chr19:21469158	chr19:21554640~21569237:-
HNSC	cis	rs7005380	0.6	rs13277992	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119902287	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13253140	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119902668	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs11777705	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119902992	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs12681402	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119903622	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs7461290	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119904154	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.58	rs4073560	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000124	0.0168	-0.14	-0.18	Interstitial lung disease;	chr8:119905148	chr8:119838736~119840385:-
HNSC	cis	rs7819412	0.54	rs2409726	ENSG00000255310.2	AF131215.2	-3.87	0.000124	0.0168	-0.18	-0.18	Triglycerides;	chr8:11185629	chr8:11107788~11109726:-
HNSC	cis	rs1538970	0.816	rs34673142	ENSG00000234329.1	RP11-767N6.2	3.87	0.000124	0.0168	0.21	0.18	Platelet count;	chr1:45519889	chr1:45651039~45651826:-
HNSC	cis	rs7824557	0.583	rs4448232	ENSG00000255310.2	AF131215.2	3.87	0.000124	0.0168	0.17	0.18	Retinal vascular caliber;	chr8:11373845	chr8:11107788~11109726:-
HNSC	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-3.87	0.000124	0.0168	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
HNSC	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-3.87	0.000124	0.0168	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-3.87	0.000124	0.0168	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
HNSC	cis	rs6568686	0.527	rs174408	ENSG00000255389.1	C6orf3	3.87	0.000124	0.0168	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611146	chr6:111599875~111602295:+
HNSC	cis	rs6568686	0.527	rs174409	ENSG00000255389.1	C6orf3	3.87	0.000124	0.0168	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611181	chr6:111599875~111602295:+
HNSC	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-3.87	0.000124	0.0168	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
HNSC	cis	rs116095464	0.558	rs9654453	ENSG00000277812.1	AC021087.1	3.87	0.000124	0.0168	0.32	0.18	Breast cancer;	chr5:299506	chr5:262769~262881:+
HNSC	cis	rs1009077	0.514	rs13126170	ENSG00000245958.5	RP11-33B1.1	3.87	0.000124	0.0168	0.19	0.18	Endometriosis;	chr4:119402033	chr4:119454791~119552025:+
HNSC	cis	rs442309	0.812	rs448355	ENSG00000238280.1	RP11-436D10.3	-3.87	0.000124	0.0168	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62772835	chr10:62793562~62805887:-
HNSC	cis	rs4713118	0.955	rs9468204	ENSG00000226314.6	ZNF192P1	-3.87	0.000124	0.0168	-0.21	-0.18	Parkinson's disease;	chr6:27721030	chr6:28161781~28169594:+
HNSC	cis	rs12468226	0.606	rs79092351	ENSG00000226261.1	AC064836.3	3.87	0.000124	0.0168	0.23	0.18	Urate levels;	chr2:202204388	chr2:202336024~202336727:-
HNSC	cis	rs9467711	0.606	rs9358932	ENSG00000241549.7	GUSBP2	-3.87	0.000124	0.0168	-0.28	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26362477	chr6:26871484~26956554:-
HNSC	cis	rs4906332	1	rs12885762	ENSG00000244691.1	RPL10AP1	-3.87	0.000124	0.0168	-0.2	-0.18	Coronary artery disease;	chr14:103415863	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs12892062	ENSG00000244691.1	RPL10AP1	-3.87	0.000124	0.0168	-0.2	-0.18	Coronary artery disease;	chr14:103417175	chr14:103412119~103412761:-
HNSC	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	3.87	0.000124	0.0168	0.29	0.18	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
HNSC	cis	rs929354	0.772	rs10228145	ENSG00000224629.1	RP5-1142J19.2	-3.87	0.000124	0.0168	-0.18	-0.18	Body mass index;	chr7:157214643	chr7:157263022~157263229:-
HNSC	cis	rs12986445	0.947	rs2072695	ENSG00000218682.1	AC010150.1	3.87	0.000124	0.0168	0.23	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25928774	chr2:25856461~25856966:-
HNSC	cis	rs57502260	0.68	rs7104806	ENSG00000212093.1	AP000807.1	3.87	0.000124	0.0168	0.25	0.18	Total body bone mineral density (age 45-60);	chr11:68454720	chr11:68506083~68506166:-
HNSC	cis	rs35264875	0.796	rs72928657	ENSG00000259799.1	RP11-554A11.9	3.87	0.000124	0.0168	0.25	0.18	Blond vs. brown hair color;	chr11:69084868	chr11:69155910~69159752:+
HNSC	cis	rs35264875	0.95	rs72928659	ENSG00000259799.1	RP11-554A11.9	3.87	0.000124	0.0168	0.25	0.18	Blond vs. brown hair color;	chr11:69084890	chr11:69155910~69159752:+
HNSC	cis	rs7824557	0.614	rs2060459	ENSG00000269918.1	AF131215.9	3.87	0.000124	0.0168	0.17	0.18	Retinal vascular caliber;	chr8:11355090	chr8:11104691~11106704:-
HNSC	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-3.87	0.000124	0.0168	-0.21	-0.18	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
HNSC	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000124	0.0168	-0.2	-0.18	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
HNSC	cis	rs66887589	0.748	rs28439855	ENSG00000249244.1	RP11-548H18.2	3.87	0.000124	0.0168	0.2	0.18	Diastolic blood pressure;	chr4:119341101	chr4:119391831~119395335:-
HNSC	cis	rs67981189	0.574	rs2526880	ENSG00000274818.1	RP1-292L20.3	-3.87	0.000124	0.0168	-0.2	-0.18	Schizophrenia;	chr14:70908621	chr14:70906657~70907111:-
HNSC	cis	rs597539	0.552	rs6591361	ENSG00000261625.1	RP11-554A11.4	-3.87	0.000124	0.0168	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:69000765~69002048:-
HNSC	cis	rs10090774	0.841	rs13438888	ENSG00000279766.1	RP11-642A1.2	3.87	0.000124	0.0168	0.19	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831843	chr8:140572142~140572812:-
HNSC	cis	rs9650657	0.707	rs7814757	ENSG00000269918.1	AF131215.9	-3.87	0.000124	0.0168	-0.18	-0.18	Neuroticism;	chr8:10817678	chr8:11104691~11106704:-
HNSC	cis	rs8063160	0.666	rs12918773	ENSG00000260259.1	RP11-368I7.4	-3.87	0.000124	0.0168	-0.39	-0.18	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89674995	chr16:89682620~89686569:-
HNSC	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.0168	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
HNSC	cis	rs1050631	1	rs3110564	ENSG00000278986.1	RP11-723J4.3	-3.87	0.000124	0.0168	-0.19	-0.18	Esophageal squamous cell cancer (length of survival);	chr18:36121626	chr18:35972151~35973916:+
HNSC	cis	rs4906332	0.754	rs34235720	ENSG00000269910.1	RP11-73M18.10	3.87	0.000124	0.0168	0.19	0.18	Coronary artery disease;	chr14:103538631	chr14:103694516~103695050:-
HNSC	cis	rs8024893	0.764	rs7182721	ENSG00000215302.7	CTD-3092A11.1	3.87	0.000124	0.0168	0.29	0.18	Red cell distribution width;	chr15:31239730	chr15:30470779~30507623:+
HNSC	cis	rs5770917	1	rs3213446	ENSG00000272821.1	CTA-384D8.36	-3.87	0.000124	0.0168	-0.26	-0.18	Narcolepsy;	chr22:50577245	chr22:50523926~50524780:+
HNSC	cis	rs41307935	0.915	rs34696599	ENSG00000260063.1	RP5-968P14.2	-3.87	0.000124	0.0168	-0.39	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26877237	chr1:26692132~26694131:-
HNSC	cis	rs67072384	0.786	rs58424437	ENSG00000213365.3	AP000593.6	3.87	0.000124	0.0168	0.3	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737211	chr11:72280151~72281178:+
HNSC	cis	rs17253792	0.822	rs80328469	ENSG00000186615.9	KTN1-AS1	-3.87	0.000124	0.0168	-0.35	-0.18	Putamen volume;	chr14:55600983	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77420254	ENSG00000186615.9	KTN1-AS1	-3.87	0.000124	0.0168	-0.35	-0.18	Putamen volume;	chr14:55602928	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78395034	ENSG00000186615.9	KTN1-AS1	-3.87	0.000124	0.0168	-0.35	-0.18	Putamen volume;	chr14:55603065	chr14:55499278~55580110:-
HNSC	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	3.87	0.000124	0.0168	0.21	0.18	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
HNSC	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	3.87	0.000124	0.0168	0.18	0.18	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
HNSC	cis	rs34421088	0.623	rs2572433	ENSG00000269918.1	AF131215.9	3.87	0.000124	0.0168	0.19	0.18	Neuroticism;	chr8:11243532	chr8:11104691~11106704:-
HNSC	cis	rs11951515	0.738	rs11739009	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43318536	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs57401732	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43320567	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.714	rs67497876	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43320746	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.714	rs66914803	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43320754	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs55634155	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43321417	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs67651757	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43322815	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4866740	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43328588	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4866817	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43328956	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.668	rs56055740	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43330672	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.668	rs55722964	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43330684	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs56690587	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43331789	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.714	rs56063506	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43332496	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs59078439	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43332847	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.607	rs11747834	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43332919	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs11741246	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43333091	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs10941628	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43333635	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.714	rs4591755	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000124	0.0168	0.18	0.18	Metabolite levels  (X-11787);	chr5:43333931	chr5:43586918~43588223:-
HNSC	cis	rs2333021	0.934	rs12879195	ENSG00000258376.2	RP4-647C14.2	-3.87	0.000124	0.0168	-0.21	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:73242651~73245979:-
HNSC	cis	rs2548724	1	rs2548724	ENSG00000175749.11	EIF3KP1	-3.87	0.000124	0.0168	-0.26	-0.18	Type 2 diabetes;	chr5:102284470	chr5:103032376~103033031:+
HNSC	cis	rs7674212	0.772	rs13113099	ENSG00000251288.2	RP11-10L12.2	-3.87	0.000124	0.0168	-0.2	-0.18	Type 2 diabetes;	chr4:103052965	chr4:102751401~102752641:+
HNSC	cis	rs9313772	0.722	rs12189105	ENSG00000254350.1	RP11-542A14.1	-3.87	0.000124	0.0168	-0.19	-0.18	Blood pressure;	chr5:158425323	chr5:158424585~158452758:+
HNSC	cis	rs6951245	0.744	rs10275401	ENSG00000225146.1	AC073957.15	-3.87	0.000125	0.0168	-0.29	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1029025~1043891:+
HNSC	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	3.87	0.000125	0.0168	0.27	0.18	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
HNSC	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	3.87	0.000125	0.0168	0.18	0.18	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
HNSC	cis	rs3764400	0.508	rs757353	ENSG00000228782.6	CTD-2026D20.3	-3.87	0.000125	0.0169	-0.27	-0.18	Body mass index;	chr17:48044908	chr17:47450568~47492492:-
HNSC	cis	rs7824557	1	rs2736371	ENSG00000255310.2	AF131215.2	-3.87	0.000125	0.0169	-0.17	-0.18	Retinal vascular caliber;	chr8:11248020	chr8:11107788~11109726:-
HNSC	cis	rs4388249	1	rs11960226	ENSG00000271849.1	CTC-332L22.1	-3.87	0.000125	0.0169	-0.27	-0.18	Schizophrenia;	chr5:109747980	chr5:109687802~109688329:-
HNSC	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	3.87	0.000125	0.0169	0.26	0.18	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
HNSC	cis	rs1023500	0.505	rs134887	ENSG00000182057.4	OGFRP1	3.87	0.000125	0.0169	0.18	0.18	Schizophrenia;	chr22:42278233	chr22:42269753~42275196:+
HNSC	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	3.87	0.000125	0.0169	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
HNSC	cis	rs868153	0.591	rs71571139	ENSG00000275339.1	RP3-425C14.6	3.87	0.000125	0.0169	0.19	0.18	Vertical cup-disc ratio;	chr6:122199314	chr6:122454358~122454612:+
HNSC	cis	rs17250963	0.704	rs6864641	ENSG00000249485.1	RBBP4P1	3.87	0.000125	0.0169	0.17	0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14750142	chr5:14797125~14798400:-
HNSC	cis	rs116095464	1	rs2721025	ENSG00000250848.1	CTD-2083E4.5	-3.87	0.000125	0.0169	-0.33	-0.18	Breast cancer;	chr5:347329	chr5:288833~290321:-
HNSC	cis	rs4906332	0.899	rs12888042	ENSG00000244691.1	RPL10AP1	-3.87	0.000125	0.0169	-0.2	-0.18	Coronary artery disease;	chr14:103425372	chr14:103412119~103412761:-
HNSC	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	3.87	0.000125	0.0169	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
HNSC	cis	rs9329221	0.655	rs4292737	ENSG00000269918.1	AF131215.9	-3.87	0.000125	0.0169	-0.18	-0.18	Neuroticism;	chr8:10401605	chr8:11104691~11106704:-
HNSC	cis	rs5758659	0.714	rs133376	ENSG00000270083.1	RP1-257I20.14	3.87	0.000125	0.0169	0.17	0.18	Cognitive function;	chr22:42070901	chr22:42089630~42090028:-
HNSC	cis	rs5758659	0.653	rs133383	ENSG00000270083.1	RP1-257I20.14	3.87	0.000125	0.0169	0.17	0.18	Cognitive function;	chr22:42077599	chr22:42089630~42090028:-
HNSC	cis	rs13178541	0.81	rs4566785	ENSG00000250378.1	RP11-119J18.1	-3.87	0.000125	0.0169	-0.24	-0.18	IgG glycosylation;	chr5:135774028	chr5:135812667~135826582:+
HNSC	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-3.87	0.000125	0.0169	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
HNSC	cis	rs7829975	0.535	rs4841005	ENSG00000173295.6	FAM86B3P	-3.87	0.000125	0.0169	-0.2	-0.18	Mood instability;	chr8:8643720	chr8:8228595~8244865:+
HNSC	cis	rs7735319	0.932	rs1479644	ENSG00000249102.1	CTD-2066L21.1	3.87	0.000125	0.0169	0.2	0.18	Systolic blood pressure;	chr5:33170717	chr5:33008994~33025724:+
HNSC	cis	rs2055729	0.807	rs36102779	ENSG00000254340.1	RP11-10A14.3	-3.87	0.000125	0.0169	-0.23	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9892099	chr8:9141424~9145435:+
HNSC	cis	rs4308124	0.708	rs6749633	ENSG00000230499.1	AC108463.1	3.87	0.000125	0.0169	0.2	0.18	Vitiligo;	chr2:111230439	chr2:111195963~111206494:+
HNSC	cis	rs116095464	1	rs3777237	ENSG00000250848.1	CTD-2083E4.5	-3.87	0.000125	0.0169	-0.34	-0.18	Breast cancer;	chr5:307526	chr5:288833~290321:-
HNSC	cis	rs11711311	1	rs9288984	ENSG00000241529.3	RN7SL767P	-3.87	0.000125	0.0169	-0.22	-0.18	IgG glycosylation;	chr3:113807109	chr3:113632704~113632998:+
HNSC	cis	rs6787172	0.596	rs1714518	ENSG00000272087.1	RP11-379F4.7	-3.87	0.000125	0.0169	-0.18	-0.18	Subjective well-being;	chr3:158495634	chr3:158693120~158693768:-
HNSC	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-3.87	0.000125	0.0169	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.597	rs11771318	ENSG00000236529.1	RP13-254B10.1	-3.87	0.000125	0.0169	-0.19	-0.18	Aortic root size;	chr7:66597493	chr7:65840212~65840596:+
HNSC	cis	rs3733585	0.605	rs4697710	ENSG00000250413.1	RP11-448G15.1	3.87	0.000125	0.0169	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10121025	chr4:10006482~10009725:+
HNSC	cis	rs4908760	0.827	rs10864362	ENSG00000232912.4	RP5-1115A15.1	3.87	0.000125	0.0169	0.18	0.18	Vitiligo;	chr1:8672395	chr1:8424645~8434838:+
HNSC	cis	rs72843506	0.722	rs16964352	ENSG00000189423.10	USP32P3	3.87	0.000125	0.0169	0.27	0.18	Schizophrenia;	chr17:20245095	chr17:20415547~20431008:+
HNSC	cis	rs911555	0.504	rs4444269	ENSG00000269958.1	RP11-73M18.8	3.87	0.000125	0.0169	0.16	0.18	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103696353~103697163:+
HNSC	cis	rs911555	0.504	rs8021368	ENSG00000269958.1	RP11-73M18.8	3.87	0.000125	0.0169	0.16	0.18	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103696353~103697163:+
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000227888.4	FAM66A	3.87	0.000125	0.0169	0.18	0.18	Neuroticism;	chr8:11939481	chr8:12362019~12388296:+
HNSC	cis	rs10056811	0.527	rs55798253	ENSG00000271815.1	CTD-2235C13.3	-3.87	0.000125	0.0169	-0.29	-0.18	Coronary artery disease;	chr5:75085132	chr5:75363760~75364242:+
HNSC	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	3.87	0.000125	0.0169	0.24	0.18	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
HNSC	cis	rs7937890	0.559	rs6486193	ENSG00000254418.1	RP11-21L19.1	3.87	0.000125	0.0169	0.21	0.18	Mitochondrial DNA levels;	chr11:14416061	chr11:14262846~14273691:-
HNSC	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	3.87	0.000125	0.0169	0.18	0.18	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
HNSC	cis	rs4853525	0.818	rs4853520	ENSG00000235852.1	AC005540.3	3.87	0.000125	0.0169	0.21	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854772	chr2:190880797~190882059:-
HNSC	cis	rs12144094	0.873	rs12121447	ENSG00000260941.1	LINC00622	-3.87	0.000125	0.0169	-0.25	-0.18	Height;	chr1:119674348	chr1:119597702~119599271:-
HNSC	cis	rs9299	0.502	rs4793944	ENSG00000239552.2	HOXB-AS2	3.87	0.000125	0.0169	0.18	0.18	Obesity;	chr17:48589942	chr17:48557262~48560333:+
HNSC	cis	rs6601327	0.613	rs12682175	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000125	0.0169	-0.17	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9621651	chr8:8961200~8979025:+
HNSC	cis	rs2762353	0.718	rs1165205	ENSG00000272462.2	U91328.19	3.87	0.000125	0.0169	0.17	0.18	Blood metabolite levels;	chr6:25870314	chr6:25992662~26001775:+
HNSC	cis	rs35063026	1	rs35063026	ENSG00000260259.1	RP11-368I7.4	-3.87	0.000125	0.0169	-0.45	-0.18	Facial pigmentation;Squamous cell carcinoma;	chr16:89669749	chr16:89682620~89686569:-
HNSC	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000125	0.0169	-0.21	-0.18	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
HNSC	cis	rs11951515	0.714	rs12519001	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000125	0.0169	0.18	0.18	Metabolite levels  (X-11787);	chr5:43329953	chr5:43586918~43588223:-
HNSC	cis	rs4704187	0.687	rs9293650	ENSG00000272040.1	CTC-366B18.4	-3.87	0.000125	0.0169	-0.16	-0.18	Response to amphetamines;	chr5:75201259	chr5:75608817~75609983:+
HNSC	cis	rs804280	0.517	rs7815179	ENSG00000227888.4	FAM66A	3.87	0.000125	0.0169	0.18	0.18	Myopia (pathological);	chr8:11934539	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.871	rs7815186	ENSG00000227888.4	FAM66A	3.87	0.000125	0.0169	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs7833079	ENSG00000227888.4	FAM66A	3.87	0.000125	0.0169	0.18	0.18	Neuroticism;	chr8:11934620	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.899	rs7815595	ENSG00000227888.4	FAM66A	3.87	0.000125	0.0169	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12362019~12388296:+
HNSC	cis	rs11098499	0.863	rs7657849	ENSG00000250412.1	KLHL2P1	3.87	0.000125	0.0169	0.23	0.18	Corneal astigmatism;	chr4:119534339	chr4:119334329~119378233:+
HNSC	cis	rs9313772	0.775	rs4704937	ENSG00000254350.1	RP11-542A14.1	-3.87	0.000125	0.0169	-0.19	-0.18	Blood pressure;	chr5:158407612	chr5:158424585~158452758:+
HNSC	cis	rs28489187	0.638	rs233055	ENSG00000223653.4	RP11-131L23.1	3.87	0.000125	0.0169	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85332803	chr1:85276715~85448124:+
HNSC	cis	rs6570726	0.764	rs4896821	ENSG00000270638.1	RP3-466P17.1	3.87	0.000125	0.0169	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145735570~145737218:+
HNSC	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-3.87	0.000125	0.0169	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
HNSC	cis	rs6088580	0.634	rs2225837	ENSG00000276073.1	RP5-1125A11.7	3.87	0.000125	0.0169	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:33985617~33988989:-
HNSC	cis	rs160451	0.745	rs218898	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000125	0.0169	-0.17	-0.18	Leprosy;	chr8:89717140	chr8:89609409~89757727:-
HNSC	cis	rs3096299	0.934	rs9927904	ENSG00000261574.1	RP1-168P16.2	3.87	0.000125	0.0169	0.23	0.18	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89392375~89412564:-
HNSC	cis	rs7824557	0.603	rs2249804	ENSG00000269918.1	AF131215.9	3.87	0.000125	0.0169	0.17	0.18	Retinal vascular caliber;	chr8:11358108	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	3.87	0.000125	0.0169	0.22	0.18	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
HNSC	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	3.87	0.000125	0.0169	0.35	0.18	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	3.87	0.000125	0.0169	0.35	0.18	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
HNSC	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	3.87	0.000125	0.0169	0.17	0.18	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
HNSC	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	3.87	0.000125	0.0169	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	3.87	0.000125	0.0169	0.16	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
HNSC	cis	rs1028883	0.839	rs2095646	ENSG00000228295.1	LINC00392	3.87	0.000125	0.0169	0.18	0.18	Lean body mass;	chr13:73574231	chr13:73564244~73588070:+
HNSC	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	3.87	0.000125	0.0169	0.13	0.18	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
HNSC	cis	rs6787172	0.811	rs9865460	ENSG00000272087.1	RP11-379F4.7	3.87	0.000125	0.0169	0.19	0.18	Subjective well-being;	chr3:158494230	chr3:158693120~158693768:-
HNSC	cis	rs1009077	0.68	rs35289699	ENSG00000245958.5	RP11-33B1.1	3.87	0.000125	0.0169	0.18	0.18	Endometriosis;	chr4:119529235	chr4:119454791~119552025:+
HNSC	cis	rs28829049	0.535	rs12565185	ENSG00000270728.1	RP4-657E11.10	-3.87	0.000125	0.0169	-0.16	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171815	chr1:19297080~19297903:+
HNSC	cis	rs7735319	0.932	rs11532635	ENSG00000249102.1	CTD-2066L21.1	3.87	0.000125	0.017	0.2	0.18	Systolic blood pressure;	chr5:33095140	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.933	rs7708185	ENSG00000249102.1	CTD-2066L21.1	3.87	0.000125	0.017	0.2	0.18	Systolic blood pressure;	chr5:33104477	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs62367969	ENSG00000249102.1	CTD-2066L21.1	3.87	0.000125	0.017	0.2	0.18	Systolic blood pressure;	chr5:33105461	chr5:33008994~33025724:+
HNSC	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	3.87	0.000125	0.017	0.22	0.18	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
HNSC	cis	rs4853525	0.859	rs1882397	ENSG00000235852.1	AC005540.3	3.87	0.000125	0.017	0.21	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855406	chr2:190880797~190882059:-
HNSC	cis	rs7927592	0.763	rs10896326	ENSG00000255031.4	RP11-802E16.3	3.87	0.000126	0.017	0.15	0.18	Total body bone mineral density;	chr11:68467103	chr11:68050740~68053762:+
HNSC	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000126	0.017	-0.23	-0.18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
HNSC	cis	rs73201462	1	rs2955077	ENSG00000231305.3	RP11-723O4.2	3.87	0.000126	0.017	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240026	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955078	ENSG00000231305.3	RP11-723O4.2	3.87	0.000126	0.017	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240343	chr3:128861313~128871540:-
HNSC	cis	rs2955081	1	rs2955081	ENSG00000231305.3	RP11-723O4.2	3.87	0.000126	0.017	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241456	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955085	ENSG00000231305.3	RP11-723O4.2	3.87	0.000126	0.017	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243914	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999072	ENSG00000231305.3	RP11-723O4.2	3.87	0.000126	0.017	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244033	chr3:128861313~128871540:-
HNSC	cis	rs4900538	0.963	rs1190554	ENSG00000272533.1	SNORA28	-3.87	0.000126	0.017	-0.18	-0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102452349	chr14:103337849~103337974:+
HNSC	cis	rs12701220	0.59	rs1881124	ENSG00000229043.2	AC091729.9	-3.87	0.000126	0.017	-0.27	-0.18	Bronchopulmonary dysplasia;	chr7:1057130	chr7:1160374~1165267:+
HNSC	cis	rs4449834	0.816	rs11992809	ENSG00000254432.1	RP11-33I11.2	-3.87	0.000126	0.017	-0.22	-0.18	Sum eosinophil basophil counts;	chr8:60759071	chr8:60808735~60809606:-
HNSC	cis	rs11893307	0.537	rs6731208	ENSG00000235852.1	AC005540.3	3.87	0.000126	0.017	0.23	0.18	Mean platelet volume;	chr2:190638499	chr2:190880797~190882059:-
HNSC	cis	rs6968419	0.963	rs10261818	ENSG00000237870.5	AC073130.1	3.87	0.000126	0.017	0.2	0.18	Intraocular pressure;	chr7:116185232	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.781	rs10261823	ENSG00000237870.5	AC073130.1	3.87	0.000126	0.017	0.2	0.18	Intraocular pressure;	chr7:116185237	chr7:116275606~116286734:-
HNSC	cis	rs6968419	1	rs6947586	ENSG00000237870.5	AC073130.1	3.87	0.000126	0.017	0.2	0.18	Intraocular pressure;	chr7:116186706	chr7:116275606~116286734:-
HNSC	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	3.87	0.000126	0.017	0.23	0.18	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
HNSC	cis	rs17014483	0.749	rs3017902	ENSG00000248019.2	FAM13A-AS1	-3.87	0.000126	0.017	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88716931	chr4:88709789~88730103:+
HNSC	cis	rs17014483	0.749	rs2860408	ENSG00000248019.2	FAM13A-AS1	-3.87	0.000126	0.017	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio;	chr4:88717881	chr4:88709789~88730103:+
HNSC	cis	rs12887734	0.546	rs4906376	ENSG00000269940.1	RP11-73M18.7	3.87	0.000126	0.017	0.17	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103694560~103695170:+
HNSC	cis	rs72827839	0.779	rs72827844	ENSG00000272763.1	RP11-357H14.17	-3.87	0.000126	0.017	-0.25	-0.18	Ease of getting up in the morning;	chr17:48357079	chr17:48635923~48647023:-
HNSC	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-3.87	0.000126	0.017	-0.18	-0.18	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
HNSC	cis	rs9926296	0.585	rs8058009	ENSG00000260259.1	RP11-368I7.4	-3.87	0.000126	0.017	-0.22	-0.18	Vitiligo;	chr16:89790031	chr16:89682620~89686569:-
HNSC	cis	rs4919687	0.55	rs11191372	ENSG00000236937.2	PTGES3P4	3.87	0.000126	0.017	0.23	0.18	Colorectal cancer;	chr10:102702430	chr10:102845595~102845950:+
HNSC	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000126	0.017	-0.13	-0.18	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
HNSC	cis	rs4713118	0.869	rs9295743	ENSG00000216901.1	AL022393.7	3.87	0.000126	0.017	0.22	0.18	Parkinson's disease;	chr6:27747323	chr6:28176188~28176674:+
HNSC	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	3.87	0.000126	0.017	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	3.87	0.000126	0.017	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
HNSC	cis	rs7572733	0.534	rs700672	ENSG00000231621.1	AC013264.2	-3.87	0.000126	0.017	-0.17	-0.18	Dermatomyositis;	chr2:197826731	chr2:197197991~197199273:+
HNSC	cis	rs11871801	0.915	rs647397	ENSG00000267151.3	RP11-100E5.2	3.87	0.000126	0.017	0.25	0.18	Crohn's disease;	chr17:42527380	chr17:43444707~43451200:+
HNSC	cis	rs2286313	0.51	rs12880570	ENSG00000266869.1	RP6-114E22.1	-3.87	0.000126	0.017	-0.43	-0.18	Colorectal cancer;	chr14:70950203	chr14:71848606~71908430:+
HNSC	cis	rs2286313	0.51	rs12897499	ENSG00000266869.1	RP6-114E22.1	-3.87	0.000126	0.017	-0.43	-0.18	Colorectal cancer;	chr14:70953127	chr14:71848606~71908430:+
HNSC	cis	rs442309	0.841	rs377859	ENSG00000238280.1	RP11-436D10.3	-3.87	0.000126	0.017	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62756305	chr10:62793562~62805887:-
HNSC	cis	rs10504130	0.569	rs7820177	ENSG00000228801.5	RP11-110G21.1	-3.87	0.000126	0.017	-0.21	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51899325~51947173:+
HNSC	cis	rs116095464	0.558	rs9654452	ENSG00000277812.1	AC021087.1	3.87	0.000126	0.017	0.3	0.18	Breast cancer;	chr5:299446	chr5:262769~262881:+
HNSC	cis	rs2136613	0.533	rs7088601	ENSG00000238280.1	RP11-436D10.3	-3.87	0.000126	0.017	-0.2	-0.18	Selective IgA deficiency;	chr10:62846627	chr10:62793562~62805887:-
HNSC	cis	rs2243480	1	rs2462569	ENSG00000232546.1	RP11-458F8.1	3.87	0.000126	0.017	0.25	0.18	Diabetic kidney disease;	chr7:66009859	chr7:66848496~66858136:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000226314.6	ZNF192P1	3.87	0.000126	0.017	0.25	0.18	Depression;	chr6:28260564	chr6:28161781~28169594:+
HNSC	cis	rs4906332	1	rs2065018	ENSG00000244691.1	RPL10AP1	3.87	0.000126	0.017	0.2	0.18	Coronary artery disease;	chr14:103412850	chr14:103412119~103412761:-
HNSC	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	3.87	0.000126	0.017	0.22	0.18	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
HNSC	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000126	0.017	-0.2	-0.18	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000126	0.017	-0.2	-0.18	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
HNSC	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-3.87	0.000126	0.017	-0.18	-0.18	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
HNSC	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-3.87	0.000126	0.017	-0.2	-0.18	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
HNSC	cis	rs7777677	0.925	rs4726540	ENSG00000211727.3	TRBV7-6	3.87	0.000126	0.017	0.15	0.18	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142492132~142492673:+
HNSC	cis	rs55823223	0.564	rs4572466	ENSG00000267801.1	RP11-552F3.9	3.87	0.000126	0.017	0.2	0.18	Psoriasis;	chr17:75850233	chr17:75876372~75879546:+
HNSC	cis	rs67072384	1	rs7128364	ENSG00000213365.3	AP000593.6	3.87	0.000126	0.017	0.29	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72740896	chr11:72280151~72281178:+
HNSC	cis	rs889398	0.874	rs2917677	ENSG00000196696.11	PDXDC2P	3.87	0.000126	0.017	0.12	0.18	Body mass index;	chr16:69716946	chr16:69976297~70065948:-
HNSC	cis	rs28573326	0.813	rs11732933	ENSG00000121089.4	NACA3P	-3.87	0.000126	0.017	-0.22	-0.18	Pelvic organ prolapse (moderate/severe);	chr4:165403329	chr4:164943290~164943937:+
HNSC	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-3.87	0.000126	0.017	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
HNSC	cis	rs1496653	0.544	rs71322182	ENSG00000206728.1	Y_RNA	3.87	0.000126	0.017	0.35	0.18	Type 2 diabetes;	chr3:23396333	chr3:23273807~23273910:+
HNSC	cis	rs6878727	0.962	rs10045630	ENSG00000253807.4	LINC01170	-3.87	0.000126	0.017	-0.23	-0.18	Breast cancer;	chr5:124400542	chr5:124059794~124405079:-
HNSC	cis	rs847649	1	rs847649	ENSG00000239969.4	RP11-163E9.2	-3.87	0.000126	0.017	-0.2	-0.18	Morning vs. evening chronotype;	chr7:102915564	chr7:102364162~102380633:+
HNSC	cis	rs793571	0.822	rs10518991	ENSG00000245975.2	RP11-30K9.6	3.87	0.000126	0.017	0.28	0.18	Schizophrenia;	chr15:58898731	chr15:58768072~58770974:-
HNSC	cis	rs9987353	1	rs9987353	ENSG00000254340.1	RP11-10A14.3	-3.87	0.000126	0.017	-0.24	-0.18	Recombination measurement;	chr8:9258839	chr8:9141424~9145435:+
HNSC	cis	rs1941023	0.517	rs11230344	ENSG00000279632.1	RP11-286N22.6	3.87	0.000126	0.017	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60496936	chr11:61426448~61427325:-
HNSC	cis	rs889398	0.771	rs11075732	ENSG00000226232.7	RP11-419C5.2	3.87	0.000126	0.017	0.16	0.18	Body mass index;	chr16:69732135	chr16:69976388~69996188:-
HNSC	cis	rs7714670	0.706	rs2973549	ENSG00000184084.7	CTD-2372A4.1	-3.87	0.000126	0.017	-0.2	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:73795301	chr5:73803296~73803599:-
HNSC	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-3.87	0.000126	0.017	-0.25	-0.18	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
HNSC	cis	rs7338174	0.655	rs9316535	ENSG00000233672.5	RNASEH2B-AS1	3.87	0.000126	0.017	0.39	0.18	Mitochondrial DNA levels;	chr13:51329329	chr13:50862172~50910764:-
HNSC	cis	rs748404	0.666	rs12906017	ENSG00000166763.7	STRCP1	3.87	0.000126	0.017	0.25	0.18	Lung cancer;	chr15:43504710	chr15:43699488~43718184:-
HNSC	cis	rs67981189	0.593	rs2810074	ENSG00000274818.1	RP1-292L20.3	-3.87	0.000126	0.017	-0.2	-0.18	Schizophrenia;	chr14:70911816	chr14:70906657~70907111:-
HNSC	cis	rs67981189	0.593	rs2526873	ENSG00000274818.1	RP1-292L20.3	-3.87	0.000126	0.017	-0.2	-0.18	Schizophrenia;	chr14:70914954	chr14:70906657~70907111:-
HNSC	cis	rs847649	1	rs11514917	ENSG00000239969.4	RP11-163E9.2	-3.87	0.000126	0.017	-0.2	-0.18	Morning vs. evening chronotype;	chr7:102968774	chr7:102364162~102380633:+
HNSC	cis	rs4760636	0.871	rs3782906	ENSG00000268069.2	RP5-1057I20.4	3.87	0.000126	0.017	0.22	0.18	Urate levels;	chr12:47776389	chr12:47784923~47786002:+
HNSC	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-3.87	0.000126	0.017	-0.18	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
HNSC	cis	rs11871801	0.915	rs36023314	ENSG00000267151.3	RP11-100E5.2	3.87	0.000126	0.0171	0.27	0.18	Crohn's disease;	chr17:42497342	chr17:43444707~43451200:+
HNSC	cis	rs2212361	0.558	rs12294732	ENSG00000255893.1	RP11-685N10.1	-3.87	0.000126	0.0171	-0.25	-0.18	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531716	chr11:94472908~94473570:-
HNSC	cis	rs7829975	0.539	rs71537846	ENSG00000173295.6	FAM86B3P	-3.87	0.000126	0.0171	-0.21	-0.18	Mood instability;	chr8:8684610	chr8:8228595~8244865:+
HNSC	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	3.87	0.000127	0.0171	0.17	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
HNSC	cis	rs3764400	0.567	rs741058	ENSG00000228782.6	CTD-2026D20.3	3.87	0.000127	0.0171	0.25	0.18	Body mass index;	chr17:48127991	chr17:47450568~47492492:-
HNSC	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000127	0.0171	-0.13	-0.18	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
HNSC	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000127	0.0171	-0.13	-0.18	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
HNSC	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000127	0.0171	-0.13	-0.18	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
HNSC	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000127	0.0171	-0.13	-0.18	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
HNSC	cis	rs10519937	0.935	rs17839693	ENSG00000230929.5	RP11-395C3.1	-3.87	0.000127	0.0171	-0.26	-0.18	IgG glycosylation;	chr5:127400179	chr5:126628019~126628319:-
HNSC	cis	rs71636778	0.509	rs34556682	ENSG00000260063.1	RP5-968P14.2	-3.87	0.000127	0.0171	-0.37	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859658	chr1:26692132~26694131:-
HNSC	cis	rs35306767	0.903	rs12769873	ENSG00000229869.1	RP11-363N22.2	-3.87	0.000127	0.0171	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:890586	chr10:933026~942743:+
HNSC	cis	rs11951515	0.738	rs10805673	ENSG00000249286.1	CTD-2210P15.2	3.87	0.000127	0.0171	0.18	0.18	Metabolite levels  (X-11787);	chr5:43347921	chr5:43586918~43588223:-
HNSC	cis	rs73201462	1	rs2811528	ENSG00000231305.3	RP11-723O4.2	3.87	0.000127	0.0171	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275593	chr3:128861313~128871540:-
HNSC	cis	rs9611565	0.608	rs202652	ENSG00000235513.1	RP4-756G23.5	-3.87	0.000127	0.0171	-0.2	-0.18	Vitiligo;	chr22:41442788	chr22:41209122~41217627:-
HNSC	cis	rs11711311	1	rs62268169	ENSG00000241529.3	RN7SL767P	-3.87	0.000127	0.0171	-0.23	-0.18	IgG glycosylation;	chr3:113775013	chr3:113632704~113632998:+
HNSC	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-3.87	0.000127	0.0171	-0.19	-0.18	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
HNSC	cis	rs988913	0.837	rs9475109	ENSG00000224984.1	RP11-524H19.2	3.87	0.000127	0.0171	0.2	0.18	Menarche (age at onset);	chr6:54997115	chr6:54840118~54840855:-
HNSC	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	3.87	0.000127	0.0171	0.24	0.18	Pain;	chr19:21468580	chr19:21554640~21569237:-
HNSC	cis	rs13434995	0.842	rs62309759	ENSG00000273257.1	RP11-177J6.1	-3.87	0.000127	0.0171	-0.28	-0.18	Adiponectin levels;	chr4:55557826	chr4:55387949~55388271:+
HNSC	cis	rs853679	1	rs1936365	ENSG00000270326.1	RP5-874C20.6	3.87	0.000127	0.0171	0.25	0.18	Depression;	chr6:28300675	chr6:28319660~28319852:-
HNSC	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-3.87	0.000127	0.0171	-0.2	-0.18	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-3.87	0.000127	0.0171	-0.2	-0.18	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
HNSC	cis	rs9880211	0.752	rs67145204	ENSG00000239213.4	NCK1-AS1	3.87	0.000127	0.0171	0.18	0.18	Height;Body mass index;	chr3:136609823	chr3:136841726~136862054:-
HNSC	cis	rs12682352	0.652	rs3789843	ENSG00000233609.3	RP11-62H7.2	3.87	0.000127	0.0171	0.17	0.18	Neuroticism;	chr8:8866747	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.652	rs3827806	ENSG00000233609.3	RP11-62H7.2	3.87	0.000127	0.0171	0.17	0.18	Neuroticism;	chr8:8866766	chr8:8961200~8979025:+
HNSC	cis	rs944002	1	rs59643720	ENSG00000259444.1	RP11-736N17.8	3.87	0.000127	0.0171	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098470	chr14:103094723~103098885:+
HNSC	cis	rs944002	1	rs61462345	ENSG00000259444.1	RP11-736N17.8	3.87	0.000127	0.0171	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098598	chr14:103094723~103098885:+
HNSC	cis	rs7824557	0.564	rs13268126	ENSG00000269918.1	AF131215.9	-3.86	0.000127	0.0171	-0.17	-0.18	Retinal vascular caliber;	chr8:11373065	chr8:11104691~11106704:-
HNSC	cis	rs2028299	1	rs7111	ENSG00000259677.1	RP11-493E3.1	3.86	0.000127	0.0171	0.22	0.18	Type 2 diabetes;	chr15:89830641	chr15:89876540~89877285:+
HNSC	cis	rs2028299	1	rs2028299	ENSG00000259677.1	RP11-493E3.1	3.86	0.000127	0.0171	0.22	0.18	Type 2 diabetes;	chr15:89831025	chr15:89876540~89877285:+
HNSC	cis	rs11098499	0.604	rs2389887	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.24	0.18	Corneal astigmatism;	chr4:119649489	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.604	rs34278750	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.24	0.18	Corneal astigmatism;	chr4:119649981	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.604	rs10022185	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.24	0.18	Corneal astigmatism;	chr4:119650610	chr4:119334329~119378233:+
HNSC	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	3.86	0.000127	0.0171	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	3.86	0.000127	0.0171	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
HNSC	cis	rs67981189	0.593	rs116016	ENSG00000274818.1	RP1-292L20.3	-3.86	0.000127	0.0171	-0.19	-0.18	Schizophrenia;	chr14:71110763	chr14:70906657~70907111:-
HNSC	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	3.86	0.000127	0.0171	0.22	0.18	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
HNSC	cis	rs172166	0.61	rs156737	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000127	0.0171	-0.2	-0.18	Cardiac Troponin-T levels;	chr6:27927435	chr6:28115628~28116551:+
HNSC	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-3.86	0.000127	0.0171	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
HNSC	cis	rs6504950	0.8	rs35647022	ENSG00000279059.1	RP11-257O5.2	-3.86	0.000127	0.0171	-0.15	-0.18	Breast cancer;	chr17:54930710	chr17:54956760~54958426:-
HNSC	cis	rs9513627	0.573	rs12431100	ENSG00000280710.1	RP11-214F16.8	-3.86	0.000127	0.0171	-0.24	-0.18	Obesity-related traits;	chr13:99532664	chr13:99498524~99501315:+
HNSC	cis	rs11250098	0.574	rs7015168	ENSG00000269918.1	AF131215.9	-3.86	0.000127	0.0171	-0.17	-0.18	Morning vs. evening chronotype;	chr8:10914700	chr8:11104691~11106704:-
HNSC	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-3.86	0.000127	0.0171	-0.18	-0.18	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-3.86	0.000127	0.0171	-0.18	-0.18	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
HNSC	cis	rs11711311	1	rs9863050	ENSG00000241529.3	RN7SL767P	-3.86	0.000127	0.0171	-0.23	-0.18	IgG glycosylation;	chr3:113790041	chr3:113632704~113632998:+
HNSC	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	3.86	0.000127	0.0171	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000227888.4	FAM66A	3.86	0.000127	0.0171	0.18	0.18	Myopia (pathological);	chr8:11929423	chr8:12362019~12388296:+
HNSC	cis	rs6787172	0.811	rs28375539	ENSG00000272087.1	RP11-379F4.7	3.86	0.000127	0.0171	0.18	0.18	Subjective well-being;	chr3:158527108	chr3:158693120~158693768:-
HNSC	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	3.86	0.000127	0.0171	0.17	0.18	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
HNSC	cis	rs73198271	1	rs73198279	ENSG00000254340.1	RP11-10A14.3	-3.86	0.000127	0.0171	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:9141424~9145435:+
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000253981.4	ALG1L13P	-3.86	0.000127	0.0171	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9183348	chr8:8236003~8244667:-
HNSC	cis	rs9926296	0.512	rs11076626	ENSG00000261812.4	TUBB8P7	-3.86	0.000127	0.0171	-0.19	-0.18	Vitiligo;	chr16:89798695	chr16:90093154~90096354:+
HNSC	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-3.86	0.000127	0.0171	-0.17	-0.18	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
HNSC	cis	rs11992162	0.967	rs10112888	ENSG00000269918.1	AF131215.9	3.86	0.000127	0.0171	0.17	0.18	Monocyte count;	chr8:11972699	chr8:11104691~11106704:-
HNSC	cis	rs526231	0.543	rs152134	ENSG00000250682.4	LINC00491	3.86	0.000127	0.0171	0.23	0.18	Primary biliary cholangitis;	chr5:103176745	chr5:102609156~102671559:-
HNSC	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	3.86	0.000127	0.0171	0.22	0.18	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
HNSC	cis	rs10504130	0.542	rs1589079	ENSG00000228801.5	RP11-110G21.1	-3.86	0.000127	0.0172	-0.21	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51899325~51947173:+
HNSC	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	3.86	0.000127	0.0172	0.19	0.18	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
HNSC	cis	rs9611565	0.694	rs202664	ENSG00000235513.1	RP4-756G23.5	-3.86	0.000127	0.0172	-0.21	-0.18	Vitiligo;	chr22:41417882	chr22:41209122~41217627:-
HNSC	cis	rs13126694	0.65	rs10028808	ENSG00000248429.4	RP11-597D13.9	3.86	0.000127	0.0172	0.2	0.18	Blood osmolality (transformed sodium);	chr4:157939488	chr4:158170752~158202877:+
HNSC	cis	rs1799949	1	rs2271573	ENSG00000236383.6	LINC00854	-3.86	0.000127	0.0172	-0.17	-0.18	Menopause (age at onset);	chr17:43175604	chr17:43216941~43305976:-
HNSC	cis	rs10039254	0.712	rs10066034	ENSG00000225051.5	HMGB3P22	3.86	0.000127	0.0172	0.19	0.18	Attention deficit hyperactivity disorder (time to onset);	chr5:179148428	chr5:179679032~179694768:+
HNSC	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	3.86	0.000127	0.0172	0.31	0.18	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
HNSC	cis	rs6001482	0.638	rs5757569	ENSG00000253818.1	IGLV1-41	-3.86	0.000127	0.0172	-0.14	-0.18	Diastolic blood pressure;	chr22:22230282	chr22:22404207~22404721:+
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000241549.7	GUSBP2	3.86	0.000127	0.0172	0.18	0.18	Parkinson's disease;	chr6:27910960	chr6:26871484~26956554:-
HNSC	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-3.86	0.000127	0.0172	-0.2	-0.18	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
HNSC	cis	rs72717009	0.825	rs12746613	ENSG00000225217.1	HSPA7	3.86	0.000127	0.0172	0.3	0.18	Rheumatoid arthritis;	chr1:161497252	chr1:161606291~161608217:+
HNSC	cis	rs792448	0.743	rs3767863	ENSG00000226251.4	RP11-15I11.3	-3.86	0.000127	0.0172	-0.21	-0.18	White blood cell count (basophil);	chr1:212364365	chr1:212225278~212238977:-
HNSC	cis	rs2492286	0.597	rs2712384	ENSG00000242551.2	POU5F1P6	-3.86	0.000127	0.0172	-0.19	-0.18	Eosinophil counts;	chr3:128615429	chr3:128674735~128677005:-
HNSC	cis	rs4660214	0.666	rs625384	ENSG00000182109.6	RP11-69E11.4	3.86	0.000127	0.0172	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39522280~39546187:-
HNSC	cis	rs853679	0.546	rs13213152	ENSG00000204709.4	LINC01556	3.86	0.000127	0.0172	0.37	0.18	Depression;	chr6:28381921	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs13213986	ENSG00000204709.4	LINC01556	3.86	0.000127	0.0172	0.37	0.18	Depression;	chr6:28390232	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs34546986	ENSG00000204709.4	LINC01556	3.86	0.000127	0.0172	0.37	0.18	Depression;	chr6:28394532	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs34871267	ENSG00000204709.4	LINC01556	3.86	0.000127	0.0172	0.37	0.18	Depression;	chr6:28396455	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.546	rs35883476	ENSG00000204709.4	LINC01556	3.86	0.000127	0.0172	0.37	0.18	Depression;	chr6:28400731	chr6:28943877~28944537:+
HNSC	cis	rs9611565	0.659	rs12484175	ENSG00000235513.1	RP4-756G23.5	3.86	0.000127	0.0172	0.21	0.18	Vitiligo;	chr22:41557735	chr22:41209122~41217627:-
HNSC	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-3.86	0.000127	0.0172	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-3.86	0.000127	0.0172	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-3.86	0.000127	0.0172	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-3.86	0.000127	0.0172	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
HNSC	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-3.86	0.000127	0.0172	-0.29	-0.18	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
HNSC	cis	rs6061231	0.74	rs11698650	ENSG00000275437.1	RP5-908M14.10	3.86	0.000128	0.0172	0.17	0.18	Colorectal cancer;	chr20:62383318	chr20:62402236~62405935:-
HNSC	cis	rs6061231	0.755	rs11699160	ENSG00000275437.1	RP5-908M14.10	3.86	0.000128	0.0172	0.17	0.18	Colorectal cancer;	chr20:62383595	chr20:62402236~62405935:-
HNSC	cis	rs6601327	0.602	rs7820917	ENSG00000233609.3	RP11-62H7.2	3.86	0.000128	0.0172	0.17	0.18	Multiple myeloma (hyperdiploidy);	chr8:9790358	chr8:8961200~8979025:+
HNSC	cis	rs11779988	0.501	rs3760	ENSG00000253671.1	RP11-806O11.1	-3.86	0.000128	0.0172	-0.19	-0.18	Breast cancer;	chr8:18028836	chr8:17808941~17820868:+
HNSC	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-3.86	0.000128	0.0172	-0.2	-0.18	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
HNSC	cis	rs6543140	0.964	rs6543144	ENSG00000234389.1	AC007278.3	3.86	0.000128	0.0172	0.18	0.18	Blood protein levels;	chr2:102476116	chr2:102438713~102440475:+
HNSC	cis	rs4523957	0.788	rs11651451	ENSG00000262333.1	HNRNPA1P16	3.86	0.000128	0.0172	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2195123	chr17:2306761~2307715:+
HNSC	cis	rs2436845	0.627	rs1991928	ENSG00000253320.4	KB-1507C5.2	-3.86	0.000128	0.0172	-0.2	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102860863	chr8:102864300~102977876:+
HNSC	cis	rs4835473	0.932	rs1973608	ENSG00000249741.2	RP11-673E1.3	-3.86	0.000128	0.0172	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143913057	chr4:143911514~143912053:-
HNSC	cis	rs35306767	0.903	rs12254002	ENSG00000229869.1	RP11-363N22.2	3.86	0.000128	0.0172	0.25	0.18	Eosinophil percentage of granulocytes;	chr10:883193	chr10:933026~942743:+
HNSC	cis	rs2548724	1	rs2263376	ENSG00000250682.4	LINC00491	-3.86	0.000128	0.0172	-0.24	-0.18	Type 2 diabetes;	chr5:102269476	chr5:102609156~102671559:-
HNSC	cis	rs5758659	0.714	rs6002607	ENSG00000270083.1	RP1-257I20.14	-3.86	0.000128	0.0172	-0.17	-0.18	Cognitive function;	chr22:42100502	chr22:42089630~42090028:-
HNSC	cis	rs7429990	0.803	rs6773732	ENSG00000228638.1	FCF1P2	3.86	0.000128	0.0172	0.16	0.18	Educational attainment (years of education);	chr3:47677772	chr3:48290793~48291375:-
HNSC	cis	rs9650657	0.836	rs4841438	ENSG00000255310.2	AF131215.2	-3.86	0.000128	0.0172	-0.17	-0.18	Neuroticism;	chr8:10749246	chr8:11107788~11109726:-
HNSC	cis	rs9650657	0.836	rs11250067	ENSG00000255310.2	AF131215.2	-3.86	0.000128	0.0172	-0.17	-0.18	Neuroticism;	chr8:10749444	chr8:11107788~11109726:-
HNSC	cis	rs2115630	0.967	rs10438428	ENSG00000275120.1	RP11-182J1.17	-3.86	0.000128	0.0172	-0.19	-0.18	P wave terminal force;	chr15:84787514	chr15:84599434~84606463:-
HNSC	cis	rs2337406	0.85	rs10131280	ENSG00000280411.1	IGHV1-69-2	-3.86	0.000128	0.0172	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106665591	chr14:106762092~106762588:-
HNSC	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	3.86	0.000128	0.0172	0.2	0.18	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
HNSC	cis	rs1941023	0.739	rs11230334	ENSG00000279632.1	RP11-286N22.6	3.86	0.000128	0.0172	0.19	0.18	Congenital heart disease (maternal effect);	chr11:60465538	chr11:61426448~61427325:-
HNSC	cis	rs57502260	0.704	rs17149179	ENSG00000212093.1	AP000807.1	3.86	0.000128	0.0172	0.26	0.18	Total body bone mineral density (age 45-60);	chr11:68584254	chr11:68506083~68506166:-
HNSC	cis	rs6968419	0.642	rs67251819	ENSG00000237870.5	AC073130.1	3.86	0.000128	0.0172	0.21	0.18	Intraocular pressure;	chr7:116265532	chr7:116275606~116286734:-
HNSC	cis	rs7587476	0.626	rs4672729	ENSG00000229267.2	AC072062.1	3.86	0.000128	0.0172	0.21	0.18	Neuroblastoma;	chr2:214778759	chr2:214810229~214963274:+
HNSC	cis	rs9303029	1	rs12450240	ENSG00000265458.1	RP13-20L14.6	3.86	0.000128	0.0172	0.28	0.18	Protein quantitative trait loci;	chr17:82465836	chr17:82454273~82458521:-
HNSC	cis	rs11157436	0.602	rs1894371	ENSG00000211814.1	TRAV35	3.86	0.000128	0.0172	0.15	0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22221896~22222475:+
HNSC	cis	rs3018712	0.532	rs2510396	ENSG00000255031.4	RP11-802E16.3	-3.86	0.000128	0.0172	-0.2	-0.18	Total body bone mineral density;	chr11:68650184	chr11:68050740~68053762:+
HNSC	cis	rs2136613	0.533	rs10761665	ENSG00000238280.1	RP11-436D10.3	-3.86	0.000128	0.0172	-0.2	-0.18	Selective IgA deficiency;	chr10:62848538	chr10:62793562~62805887:-
HNSC	cis	rs7005380	0.556	rs12548248	ENSG00000279347.1	RP11-85I17.2	-3.86	0.000128	0.0172	-0.17	-0.18	Interstitial lung disease;	chr8:119920081	chr8:119838736~119840385:-
HNSC	cis	rs28829049	0.597	rs72651403	ENSG00000270728.1	RP4-657E11.10	-3.86	0.000128	0.0172	-0.16	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19193393	chr1:19297080~19297903:+
HNSC	cis	rs2836974	0.568	rs4816620	ENSG00000255568.3	BRWD1-AS2	-3.86	0.000128	0.0172	-0.15	-0.18	Cognitive function;	chr21:39241860	chr21:39313935~39314962:+
HNSC	cis	rs35264875	1	rs72928652	ENSG00000259799.1	RP11-554A11.9	3.86	0.000128	0.0172	0.25	0.18	Blond vs. brown hair color;	chr11:69084079	chr11:69155910~69159752:+
HNSC	cis	rs7688540	0.771	rs7674560	ENSG00000250892.1	RP11-1365D11.1	-3.86	0.000128	0.0172	-0.31	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:201409~205009:-
HNSC	cis	rs2304003	1	rs2060167	ENSG00000235192.1	AC009495.2	3.86	0.000128	0.0172	0.23	0.18	Social communication problems;	chr2:165832832	chr2:165794851~165810010:+
HNSC	cis	rs62246343	0.605	rs4328788	ENSG00000254485.4	RP11-380O24.1	3.86	0.000128	0.0172	0.22	0.18	Fibrinogen levels;	chr3:9415577	chr3:9292588~9363303:-
HNSC	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	3.86	0.000128	0.0172	0.25	0.18	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
HNSC	cis	rs2446066	0.605	rs7302835	ENSG00000270175.1	RP11-793H13.11	-3.86	0.000128	0.0172	-0.22	-0.18	Red blood cell count;	chr12:53561282	chr12:53500162~53500936:-
HNSC	cis	rs2446066	0.538	rs1485394	ENSG00000270175.1	RP11-793H13.11	-3.86	0.000128	0.0172	-0.22	-0.18	Red blood cell count;	chr12:53561701	chr12:53500162~53500936:-
HNSC	cis	rs11098499	0.863	rs6534139	ENSG00000250412.1	KLHL2P1	-3.86	0.000128	0.0172	-0.23	-0.18	Corneal astigmatism;	chr4:119528301	chr4:119334329~119378233:+
HNSC	cis	rs67311347	0.544	rs2278929	ENSG00000280739.1	EIF1B-AS1	-3.86	0.000128	0.0172	-0.18	-0.18	Renal cell carcinoma;	chr3:40309517	chr3:40173145~40309698:-
HNSC	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	3.86	0.000128	0.0172	0.19	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
HNSC	cis	rs2098713	0.502	rs1985183	ENSG00000250155.1	CTD-2353F22.1	3.86	0.000128	0.0172	0.19	0.18	Telomere length;	chr5:37541779	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs512562	ENSG00000250155.1	CTD-2353F22.1	3.86	0.000128	0.0172	0.19	0.18	Telomere length;	chr5:37543019	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs538209	ENSG00000250155.1	CTD-2353F22.1	3.86	0.000128	0.0172	0.19	0.18	Telomere length;	chr5:37543495	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.537	rs565691	ENSG00000250155.1	CTD-2353F22.1	3.86	0.000128	0.0172	0.19	0.18	Telomere length;	chr5:37544232	chr5:36666214~36725195:-
HNSC	cis	rs9650657	0.812	rs7834466	ENSG00000269918.1	AF131215.9	-3.86	0.000128	0.0172	-0.18	-0.18	Neuroticism;	chr8:10777295	chr8:11104691~11106704:-
HNSC	cis	rs2436845	0.627	rs2679750	ENSG00000253320.4	KB-1507C5.2	-3.86	0.000128	0.0172	-0.2	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102864300~102977876:+
HNSC	cis	rs683257	0.81	rs7770900	ENSG00000234147.1	RP3-460G2.2	-3.86	0.000128	0.0172	-0.32	-0.18	Facial emotion recognition (angry faces);	chr6:140896625	chr6:140845958~140852924:-
HNSC	cis	rs10504130	1	rs11780891	ENSG00000272024.1	RP11-546K22.3	-3.86	0.000128	0.0172	-0.3	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51762067	chr8:51950284~51950690:+
HNSC	cis	rs868153	0.625	rs35492344	ENSG00000275339.1	RP3-425C14.6	3.86	0.000128	0.0172	0.19	0.18	Vertical cup-disc ratio;	chr6:122126007	chr6:122454358~122454612:+
HNSC	cis	rs12030196	0.827	rs932773	ENSG00000230812.4	LINC01358	-3.86	0.000128	0.0172	-0.19	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967949	chr1:59020387~59044614:+
HNSC	cis	rs7688540	0.771	rs11724417	ENSG00000211553.1	AC253576.2	-3.86	0.000128	0.0172	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:136461~136568:+
HNSC	cis	rs7688540	0.771	rs11724176	ENSG00000211553.1	AC253576.2	-3.86	0.000128	0.0172	-0.27	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:136461~136568:+
HNSC	cis	rs1050631	0.96	rs3826602	ENSG00000278986.1	RP11-723J4.3	-3.86	0.000128	0.0172	-0.2	-0.18	Esophageal squamous cell cancer (length of survival);	chr18:36108400	chr18:35972151~35973916:+
HNSC	cis	rs7868228	0.891	rs16938527	ENSG00000240498.5	CDKN2B-AS1	-3.86	0.000128	0.0173	-0.24	-0.18	Gut microbiome composition (winter);	chr9:21673609	chr9:21994778~22121097:+
HNSC	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	3.86	0.000128	0.0173	0.2	0.18	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
HNSC	cis	rs9329221	0.537	rs12678800	ENSG00000255310.2	AF131215.2	3.86	0.000128	0.0173	0.16	0.18	Neuroticism;	chr8:10121430	chr8:11107788~11109726:-
HNSC	cis	rs4947019	1	rs4947019	ENSG00000260273.1	RP11-425D10.10	3.86	0.000128	0.0173	0.42	0.18	Hematological parameters;	chr6:109768846	chr6:109382795~109383666:+
HNSC	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-3.86	0.000128	0.0173	-0.26	-0.18	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
HNSC	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	3.86	0.000128	0.0173	0.18	0.18	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
HNSC	cis	rs10516173	1	rs10516173	ENSG00000280310.1	RP11-326I19.2	3.86	0.000128	0.0173	0.21	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr4:5151418	chr4:4820405~4821452:+
HNSC	cis	rs875971	0.66	rs10229345	ENSG00000273142.1	RP11-458F8.4	-3.86	0.000128	0.0173	-0.15	-0.18	Aortic root size;	chr7:66517181	chr7:66902857~66906297:+
HNSC	cis	rs6088580	0.634	rs2424992	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000128	0.0173	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6119497	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000128	0.0173	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6059829	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000128	0.0173	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.602	rs6059834	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000128	0.0173	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6059835	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000128	0.0173	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:33985617~33988989:-
HNSC	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	3.86	0.000128	0.0173	0.28	0.18	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	3.86	0.000128	0.0173	0.28	0.18	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
HNSC	cis	rs240993	0.669	rs6935759	ENSG00000230177.1	RP5-1112D6.4	-3.86	0.000128	0.0173	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111457517	chr6:111277932~111278742:+
HNSC	cis	rs6787172	0.84	rs1656374	ENSG00000272087.1	RP11-379F4.7	3.86	0.000128	0.0173	0.19	0.18	Subjective well-being;	chr3:158565271	chr3:158693120~158693768:-
HNSC	cis	rs7927592	0.956	rs7116899	ENSG00000255031.4	RP11-802E16.3	3.86	0.000128	0.0173	0.16	0.18	Total body bone mineral density;	chr11:68618067	chr11:68050740~68053762:+
HNSC	cis	rs5758511	0.68	rs5758681	ENSG00000205702.9	CYP2D7	3.86	0.000128	0.0173	0.16	0.18	Birth weight;	chr22:42249085	chr22:42140203~42144577:-
HNSC	cis	rs870825	0.616	rs10428373	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.26	0.18	Blood protein levels;	chr4:184717848	chr4:184584093~184625030:-
HNSC	cis	rs7824557	0.591	rs2293859	ENSG00000269918.1	AF131215.9	3.86	0.000129	0.0173	0.17	0.18	Retinal vascular caliber;	chr8:11359252	chr8:11104691~11106704:-
HNSC	cis	rs4822044	0.617	rs13054514	ENSG00000233903.2	Z83851.4	3.86	0.000129	0.0173	0.24	0.18	Cannabis dependence symptom count;	chr22:41734379	chr22:42276355~42277052:+
HNSC	cis	rs10540	0.908	rs71487293	ENSG00000279672.1	CMB9-55F22.1	3.86	0.000129	0.0173	0.3	0.18	Body mass index;	chr11:486414	chr11:779617~780755:+
HNSC	cis	rs10540	1	rs61876332	ENSG00000279672.1	CMB9-55F22.1	3.86	0.000129	0.0173	0.3	0.18	Body mass index;	chr11:487101	chr11:779617~780755:+
HNSC	cis	rs10540	1	rs61876334	ENSG00000279672.1	CMB9-55F22.1	3.86	0.000129	0.0173	0.3	0.18	Body mass index;	chr11:487201	chr11:779617~780755:+
HNSC	cis	rs597539	0.652	rs513615	ENSG00000261625.1	RP11-554A11.4	-3.86	0.000129	0.0173	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:69000765~69002048:-
HNSC	cis	rs17253792	0.732	rs79014965	ENSG00000186615.9	KTN1-AS1	-3.86	0.000129	0.0173	-0.35	-0.18	Putamen volume;	chr14:55650833	chr14:55499278~55580110:-
HNSC	cis	rs9287638	0.552	rs6753990	ENSG00000279484.1	KLHL30-AS1	-3.86	0.000129	0.0173	-0.22	-0.18	Male-pattern baldness;	chr2:238739949	chr2:238152889~238155994:-
HNSC	cis	rs4853525	0.544	rs61187415	ENSG00000228509.4	AC006460.2	3.86	0.000129	0.0173	0.24	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846184	chr2:190676944~190708716:-
HNSC	cis	rs7819412	0.645	rs10156356	ENSG00000269918.1	AF131215.9	-3.86	0.000129	0.0173	-0.18	-0.18	Triglycerides;	chr8:11188700	chr8:11104691~11106704:-
HNSC	cis	rs35264875	1	rs7110274	ENSG00000259799.1	RP11-554A11.9	3.86	0.000129	0.0173	0.25	0.18	Blond vs. brown hair color;	chr11:69075236	chr11:69155910~69159752:+
HNSC	cis	rs35264875	1	rs72928644	ENSG00000259799.1	RP11-554A11.9	3.86	0.000129	0.0173	0.25	0.18	Blond vs. brown hair color;	chr11:69082377	chr11:69155910~69159752:+
HNSC	cis	rs35264875	1	rs1542334	ENSG00000259799.1	RP11-554A11.9	3.86	0.000129	0.0173	0.25	0.18	Blond vs. brown hair color;	chr11:69083305	chr11:69155910~69159752:+
HNSC	cis	rs1962073	0.528	rs4582610	ENSG00000255310.2	AF131215.2	-3.86	0.000129	0.0173	-0.17	-0.18	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10460833	chr8:11107788~11109726:-
HNSC	cis	rs7324557	0.717	rs7318360	ENSG00000205861.10	C1QTNF9B-AS1	-3.86	0.000129	0.0173	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23818143	chr13:23888889~23897263:+
HNSC	cis	rs12049351	0.665	rs1853808	ENSG00000177788.5	RP5-1061H20.4	-3.86	0.000129	0.0173	-0.23	-0.18	Circulating myeloperoxidase levels (plasma);	chr1:229456585	chr1:229258281~229271028:-
HNSC	cis	rs924607	1	rs924607	ENSG00000225138.6	CTD-2228K2.7	-3.86	0.000129	0.0173	-0.19	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:609978	chr5:473236~480884:+
HNSC	cis	rs4523957	0.788	rs7217687	ENSG00000262333.1	HNRNPA1P16	3.86	0.000129	0.0173	0.14	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2194978	chr17:2306761~2307715:+
HNSC	cis	rs870825	0.616	rs2130394	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184721423	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552808	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184721711	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6419939	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184721715	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4594761	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184721848	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4623061	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722007	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4437299	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722069	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4437295	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722182	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs1401360	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722417	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs1401361	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722588	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs1401362	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722621	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552810	ENSG00000254233.1	RP11-242J7.1	3.86	0.000129	0.0173	0.25	0.18	Blood protein levels;	chr4:184722989	chr4:184584093~184625030:-
HNSC	cis	rs6968419	0.641	rs17138519	ENSG00000237870.5	AC073130.1	3.86	0.000129	0.0173	0.21	0.18	Intraocular pressure;	chr7:116266124	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.674	rs1918912	ENSG00000237870.5	AC073130.1	3.86	0.000129	0.0173	0.21	0.18	Intraocular pressure;	chr7:116266319	chr7:116275606~116286734:-
HNSC	cis	rs17507216	0.56	rs2871011	ENSG00000252690.3	SCARNA15	3.86	0.000129	0.0173	0.14	0.18	Excessive daytime sleepiness;	chr15:82560792	chr15:82752884~82757208:+
HNSC	cis	rs6088580	0.634	rs4911153	ENSG00000276073.1	RP5-1125A11.7	3.86	0.000129	0.0173	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:33985617~33988989:-
HNSC	cis	rs6471393	0.964	rs16916191	ENSG00000279331.1	RBM12B-AS1	-3.86	0.000129	0.0173	-0.16	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93740121~93740773:+
HNSC	cis	rs6471393	0.798	rs55680024	ENSG00000279331.1	RBM12B-AS1	-3.86	0.000129	0.0173	-0.18	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93740121~93740773:+
HNSC	cis	rs10742752	0.702	rs10838467	ENSG00000254651.1	RP11-430H10.3	3.86	0.000129	0.0173	0.21	0.18	Body mass index;	chr11:45419703	chr11:45399448~45400528:+
HNSC	cis	rs283610	0.624	rs9283790	ENSG00000182383.8	RPL27AP5	3.86	0.000129	0.0173	0.15	0.18	Obesity-related traits;	chr5:73993142	chr5:74990189~74990637:-
HNSC	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	3.86	0.000129	0.0173	0.4	0.18	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
HNSC	cis	rs7572733	0.773	rs13429970	ENSG00000222017.1	AC011997.1	3.86	0.000129	0.0173	0.21	0.18	Dermatomyositis;	chr2:197657911	chr2:197693106~197774823:+
HNSC	cis	rs8063160	0.756	rs35749174	ENSG00000260259.1	RP11-368I7.4	-3.86	0.000129	0.0173	-0.45	-0.18	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89650085	chr16:89682620~89686569:-
HNSC	cis	rs8063160	0.74	rs35850949	ENSG00000260259.1	RP11-368I7.4	-3.86	0.000129	0.0173	-0.45	-0.18	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89654316	chr16:89682620~89686569:-
HNSC	cis	rs8063160	0.74	rs71396950	ENSG00000260259.1	RP11-368I7.4	-3.86	0.000129	0.0173	-0.45	-0.18	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89660142	chr16:89682620~89686569:-
HNSC	cis	rs8063160	0.756	rs71396951	ENSG00000260259.1	RP11-368I7.4	-3.86	0.000129	0.0173	-0.45	-0.18	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89660185	chr16:89682620~89686569:-
HNSC	cis	rs11951515	0.714	rs60445501	ENSG00000249286.1	CTD-2210P15.2	3.86	0.000129	0.0173	0.18	0.18	Metabolite levels  (X-11787);	chr5:43321234	chr5:43586918~43588223:-
HNSC	cis	rs7587476	0.768	rs9789462	ENSG00000229267.2	AC072062.1	-3.86	0.000129	0.0173	-0.22	-0.18	Neuroblastoma;	chr2:214778216	chr2:214810229~214963274:+
HNSC	cis	rs9788721	1	rs10519203	ENSG00000261762.1	RP11-650L12.2	3.86	0.000129	0.0173	0.2	0.18	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78521704	chr15:78589123~78591276:-
HNSC	cis	rs9487051	0.872	rs1111863	ENSG00000219700.1	PTCHD3P3	-3.86	0.000129	0.0174	-0.17	-0.18	Reticulocyte fraction of red cells;	chr6:109290003	chr6:109288571~109290503:-
HNSC	cis	rs73198271	0.813	rs56007835	ENSG00000233609.3	RP11-62H7.2	-3.86	0.000129	0.0174	-0.2	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8961200~8979025:+
HNSC	cis	rs8072100	0.676	rs7221345	ENSG00000263293.2	RP11-290H9.4	3.86	0.000129	0.0174	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47303460~47323613:-
HNSC	cis	rs8072100	0.676	rs9905308	ENSG00000263293.2	RP11-290H9.4	3.86	0.000129	0.0174	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47303460~47323613:-
HNSC	cis	rs73198271	0.562	rs964772	ENSG00000173295.6	FAM86B3P	-3.86	0.000129	0.0174	-0.25	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793796	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.562	rs964773	ENSG00000173295.6	FAM86B3P	-3.86	0.000129	0.0174	-0.25	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793804	chr8:8228595~8244865:+
HNSC	cis	rs330071	0.622	rs898797	ENSG00000254340.1	RP11-10A14.3	3.86	0.000129	0.0174	0.22	0.18	Acne (severe);	chr8:9372179	chr8:9141424~9145435:+
HNSC	cis	rs1799955	0.529	rs9567576	ENSG00000215515.2	IFIT1P1	-3.86	0.000129	0.0174	-0.21	-0.18	LDL cholesterol levels;	chr13:32345500	chr13:32384660~32386108:+
HNSC	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-3.86	0.000129	0.0174	-0.18	-0.18	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
HNSC	cis	rs2834288	0.575	rs2239564	ENSG00000273102.1	AP000569.9	-3.86	0.000129	0.0174	-0.2	-0.18	Gut microbiota (bacterial taxa);	chr21:33908245	chr21:33967101~33968573:-
HNSC	cis	rs8055167	1	rs8055167	ENSG00000280152.1	RP11-331F4.5	3.86	0.000129	0.0174	0.23	0.18	Alcoholic chronic pancreatitis;	chr16:75220991	chr16:75245994~75250077:-
HNSC	cis	rs17739794	0.557	rs35185084	ENSG00000254207.1	RP11-43A14.1	-3.86	0.000129	0.0174	-0.21	-0.18	Clozapine-induced cytotoxicity;	chr8:858721	chr8:725188~725877:-
HNSC	cis	rs67311347	0.955	rs6764102	ENSG00000280739.1	EIF1B-AS1	3.86	0.000129	0.0174	0.19	0.18	Renal cell carcinoma;	chr3:40336662	chr3:40173145~40309698:-
HNSC	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-3.86	0.000129	0.0174	-0.25	-0.18	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
HNSC	cis	rs11711311	1	rs12736	ENSG00000241529.3	RN7SL767P	-3.86	0.000129	0.0174	-0.22	-0.18	IgG glycosylation;	chr3:113811364	chr3:113632704~113632998:+
HNSC	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	3.86	0.000129	0.0174	0.22	0.18	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
HNSC	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	3.86	0.000129	0.0174	0.14	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
HNSC	cis	rs17373728	0.71	rs12544686	ENSG00000249395.2	CASC9	3.86	0.000129	0.0174	0.23	0.18	Diabetic kidney disease;	chr8:75305839	chr8:75223404~75324741:-
HNSC	cis	rs35306767	0.715	rs12772979	ENSG00000229869.1	RP11-363N22.2	-3.86	0.000129	0.0174	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:988472	chr10:933026~942743:+
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	3.86	0.000129	0.0174	0.2	0.18	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
HNSC	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-3.86	0.000129	0.0174	-0.2	-0.18	Height;	chr14:75152415	chr14:75011269~75012851:-
HNSC	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	3.86	0.00013	0.0174	0.27	0.18	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	3.86	0.00013	0.0174	0.27	0.18	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
HNSC	cis	rs9611565	0.694	rs5758368	ENSG00000235513.1	RP4-756G23.5	3.86	0.00013	0.0174	0.21	0.18	Vitiligo;	chr22:41466284	chr22:41209122~41217627:-
HNSC	cis	rs561341	1	rs117029332	ENSG00000278867.1	RP11-640N20.4	-3.86	0.00013	0.0174	-0.25	-0.18	Hip circumference adjusted for BMI;	chr17:31939066	chr17:32051030~32053208:+
HNSC	cis	rs7189233	0.955	rs72801817	ENSG00000279344.1	RP11-44F14.7	3.86	0.00013	0.0174	0.17	0.18	Intelligence (multi-trait analysis);	chr16:53440656	chr16:53478957~53481550:-
HNSC	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-3.86	0.00013	0.0174	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
HNSC	cis	rs9329221	0.537	rs2062332	ENSG00000255310.2	AF131215.2	3.86	0.00013	0.0174	0.16	0.18	Neuroticism;	chr8:10122514	chr8:11107788~11109726:-
HNSC	cis	rs2865126	0.818	rs2178100	ENSG00000264714.1	RP11-21G15.1	-3.86	0.00013	0.0174	-0.22	-0.18	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10765354	chr18:10724619~10728539:+
HNSC	cis	rs189798	0.807	rs9949	ENSG00000254153.1	CTA-398F10.2	3.86	0.00013	0.0174	0.22	0.18	Myopia (pathological);	chr8:9137002	chr8:8456909~8461337:-
HNSC	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	3.86	0.00013	0.0174	0.3	0.18	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
HNSC	cis	rs6988985	0.678	rs7011889	ENSG00000247317.3	RP11-273G15.2	-3.86	0.00013	0.0174	-0.19	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142923844	chr8:142981738~143018437:-
HNSC	cis	rs7726839	0.54	rs12517638	ENSG00000225138.6	CTD-2228K2.7	3.86	0.00013	0.0174	0.26	0.18	Obesity-related traits;	chr5:645369	chr5:473236~480884:+
HNSC	cis	rs7726839	0.54	rs4957081	ENSG00000225138.6	CTD-2228K2.7	3.86	0.00013	0.0174	0.26	0.18	Obesity-related traits;	chr5:646303	chr5:473236~480884:+
HNSC	cis	rs9611565	0.659	rs28530678	ENSG00000235513.1	RP4-756G23.5	3.86	0.00013	0.0174	0.21	0.18	Vitiligo;	chr22:41538957	chr22:41209122~41217627:-
HNSC	cis	rs6071524	0.611	rs4812272	ENSG00000224635.1	RP4-564F22.5	3.86	0.00013	0.0174	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr20:38794083	chr20:38406011~38416797:-
HNSC	cis	rs9952991	1	rs9952991	ENSG00000260302.1	RP11-973H7.1	-3.86	0.00013	0.0174	-0.29	-0.18	Inflammatory skin disease;	chr18:12780465	chr18:12774651~12775923:-
HNSC	cis	rs556990	0.57	rs5960	ENSG00000269125.1	RP11-98F14.11	3.86	0.00013	0.0174	0.23	0.18	Blood protein levels;	chr13:113147423	chr13:113165002~113165183:-
HNSC	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	3.86	0.00013	0.0174	0.25	0.18	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
HNSC	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	3.86	0.00013	0.0174	0.18	0.18	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
HNSC	cis	rs67311347	1	rs7636719	ENSG00000280739.1	EIF1B-AS1	3.86	0.00013	0.0174	0.19	0.18	Renal cell carcinoma;	chr3:40390593	chr3:40173145~40309698:-
HNSC	cis	rs12541491	0.506	rs11250007	ENSG00000269918.1	AF131215.9	-3.86	0.00013	0.0174	-0.18	-0.18	Schizophrenia;	chr8:10427576	chr8:11104691~11106704:-
HNSC	cis	rs2098713	0.534	rs482695	ENSG00000250155.1	CTD-2353F22.1	3.86	0.00013	0.0174	0.19	0.18	Telomere length;	chr5:37551448	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.501	rs525463	ENSG00000250155.1	CTD-2353F22.1	3.86	0.00013	0.0174	0.19	0.18	Telomere length;	chr5:37556180	chr5:36666214~36725195:-
HNSC	cis	rs17250963	0.645	rs697566	ENSG00000249485.1	RBBP4P1	-3.86	0.00013	0.0175	-0.17	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14745395	chr5:14797125~14798400:-
HNSC	cis	rs17250963	0.645	rs891050	ENSG00000249485.1	RBBP4P1	-3.86	0.00013	0.0175	-0.17	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14745435	chr5:14797125~14798400:-
HNSC	cis	rs17250963	0.645	rs891051	ENSG00000249485.1	RBBP4P1	-3.86	0.00013	0.0175	-0.17	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14745437	chr5:14797125~14798400:-
HNSC	cis	rs17250963	0.645	rs696035	ENSG00000249485.1	RBBP4P1	-3.86	0.00013	0.0175	-0.17	-0.18	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14745444	chr5:14797125~14798400:-
HNSC	cis	rs1316453	1	rs1316453	ENSG00000262585.1	RP11-353N14.5	-3.86	0.00013	0.0175	-0.2	-0.18	Self-reported allergy;	chr17:79414777	chr17:79915252~79926725:-
HNSC	cis	rs36093844	0.626	rs72963077	ENSG00000279742.1	RP11-700A24.1	-3.86	0.00013	0.0175	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86026023	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.527	rs111309964	ENSG00000279742.1	RP11-700A24.1	-3.86	0.00013	0.0175	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86027529	chr11:85852557~85854943:-
HNSC	cis	rs2243480	1	rs34815098	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.3	0.18	Diabetic kidney disease;	chr7:65827267	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs7456042	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.3	0.18	Diabetic kidney disease;	chr7:65834791	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs35735127	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.3	0.18	Diabetic kidney disease;	chr7:65835436	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.3	0.18	Diabetic kidney disease;	chr7:65841418	chr7:66025126~66031544:-
HNSC	cis	rs9813712	0.909	rs1453257	ENSG00000228252.7	COL6A4P2	-3.86	0.00013	0.0175	-0.19	-0.18	Response to amphetamines;	chr3:130258730	chr3:130212823~130273806:+
HNSC	cis	rs7688540	0.723	rs9684973	ENSG00000211553.1	AC253576.2	-3.86	0.00013	0.0175	-0.24	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:136461~136568:+
HNSC	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	3.86	0.00013	0.0175	0.29	0.18	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	3.86	0.00013	0.0175	0.29	0.18	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	3.86	0.00013	0.0175	0.29	0.18	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	3.86	0.00013	0.0175	0.29	0.18	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
HNSC	cis	rs6995541	0.647	rs6991526	ENSG00000269918.1	AF131215.9	-3.86	0.00013	0.0175	-0.18	-0.18	Triglyceride levels;	chr8:10831540	chr8:11104691~11106704:-
HNSC	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	3.86	0.00013	0.0175	0.18	0.18	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
HNSC	cis	rs6939532	0.522	rs6933583	ENSG00000241549.7	GUSBP2	3.86	0.00013	0.0175	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr6:26355055	chr6:26871484~26956554:-
HNSC	cis	rs7324557	0.651	rs9510875	ENSG00000205861.10	C1QTNF9B-AS1	-3.86	0.00013	0.0175	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23820351	chr13:23888889~23897263:+
HNSC	cis	rs7324557	0.717	rs729137	ENSG00000205861.10	C1QTNF9B-AS1	-3.86	0.00013	0.0175	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23821523	chr13:23888889~23897263:+
HNSC	cis	rs9813712	0.548	rs9880123	ENSG00000253540.4	FAM86HP	-3.86	0.00013	0.0175	-0.16	-0.18	Response to amphetamines;	chr3:130215275	chr3:130099092~130111472:-
HNSC	cis	rs10242455	0.571	rs117370443	ENSG00000078319.8	PMS2P1	-3.86	0.00013	0.0175	-0.37	-0.18	Blood metabolite levels;	chr7:99377635	chr7:100320992~100341908:-
HNSC	cis	rs1790761	0.505	rs4320958	ENSG00000184224.3	C11orf72	-3.86	0.00013	0.0175	-0.21	-0.18	Mean corpuscular volume;	chr11:67542863	chr11:67602880~67606706:-
HNSC	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	3.86	0.00013	0.0175	0.19	0.18	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
HNSC	cis	rs739496	0.615	rs7978737	ENSG00000226469.1	ADAM1B	3.86	0.00013	0.0175	0.2	0.18	Platelet count;	chr12:111758807	chr12:111927018~111929017:+
HNSC	cis	rs2243480	1	rs316307	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.3	0.18	Diabetic kidney disease;	chr7:66105184	chr7:66025126~66031544:-
HNSC	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	3.86	0.00013	0.0175	0.19	0.18	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
HNSC	cis	rs9910055	0.636	rs7089	ENSG00000267080.4	ASB16-AS1	-3.86	0.00013	0.0175	-0.14	-0.18	Total body bone mineral density;	chr17:44191649	chr17:44175973~44186717:-
HNSC	cis	rs13256369	1	rs4841017	ENSG00000173295.6	FAM86B3P	3.86	0.00013	0.0175	0.22	0.18	Obesity-related traits;	chr8:8719583	chr8:8228595~8244865:+
HNSC	cis	rs7520050	0.933	rs12565042	ENSG00000280836.1	AL355480.1	3.86	0.00013	0.0175	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs10789475	ENSG00000280836.1	AL355480.1	3.86	0.00013	0.0175	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.933	rs6666743	ENSG00000280836.1	AL355480.1	3.86	0.00013	0.0175	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.933	rs9787208	ENSG00000280836.1	AL355480.1	3.86	0.00013	0.0175	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.933	rs6680211	ENSG00000280836.1	AL355480.1	3.86	0.00013	0.0175	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45581219~45581321:-
HNSC	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	3.86	0.00013	0.0175	0.18	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
HNSC	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	3.86	0.000131	0.0175	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	3.86	0.000131	0.0175	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	3.86	0.000131	0.0175	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
HNSC	cis	rs13260300	0.657	rs10957730	ENSG00000254349.4	FLJ39080	3.86	0.000131	0.0175	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74610166	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.573	rs10957732	ENSG00000254349.4	FLJ39080	3.86	0.000131	0.0175	0.21	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74610888	chr8:74599775~74823313:+
HNSC	cis	rs189798	0.807	rs330912	ENSG00000253981.4	ALG1L13P	3.86	0.000131	0.0175	0.21	0.18	Myopia (pathological);	chr8:9138784	chr8:8236003~8244667:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000131	0.0175	-0.25	-0.18	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
HNSC	cis	rs5758511	0.573	rs1569451	ENSG00000235513.1	RP4-756G23.5	3.86	0.000131	0.0175	0.19	0.18	Birth weight;	chr22:41836287	chr22:41209122~41217627:-
HNSC	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-3.86	0.000131	0.0175	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
HNSC	cis	rs2243480	0.522	rs73150635	ENSG00000229886.1	RP5-1132H15.3	3.86	0.000131	0.0175	0.38	0.18	Diabetic kidney disease;	chr7:66507503	chr7:66025126~66031544:-
HNSC	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-3.86	0.000131	0.0175	-0.26	-0.18	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
HNSC	cis	rs2337406	0.704	rs1858679	ENSG00000211972.2	IGHV3-66	3.86	0.000131	0.0175	0.18	0.18	Alzheimer's disease (late onset);	chr14:106706726	chr14:106675017~106675544:-
HNSC	cis	rs73201462	1	rs2811530	ENSG00000231305.3	RP11-723O4.2	3.86	0.000131	0.0175	0.25	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274323	chr3:128861313~128871540:-
HNSC	cis	rs9313772	1	rs12716338	ENSG00000254350.1	RP11-542A14.1	-3.86	0.000131	0.0175	-0.2	-0.18	Blood pressure;	chr5:158405741	chr5:158424585~158452758:+
HNSC	cis	rs67981189	0.574	rs2526867	ENSG00000274818.1	RP1-292L20.3	-3.86	0.000131	0.0175	-0.2	-0.18	Schizophrenia;	chr14:70929249	chr14:70906657~70907111:-
HNSC	cis	rs875971	0.522	rs2949690	ENSG00000272831.1	RP11-792A8.4	-3.86	0.000131	0.0175	-0.15	-0.18	Aortic root size;	chr7:66018255	chr7:66739829~66740385:-
HNSC	cis	rs6095360	0.727	rs11906450	ENSG00000222365.1	SNORD12B	-3.86	0.000131	0.0175	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48938545	chr20:49280319~49280409:+
HNSC	cis	rs11157436	0.918	rs11157426	ENSG00000211812.1	TRAV26-2	-3.86	0.000131	0.0175	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.918	rs11157427	ENSG00000211812.1	TRAV26-2	-3.86	0.000131	0.0175	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22202583~22203368:+
HNSC	cis	rs11157436	0.792	rs12433875	ENSG00000211812.1	TRAV26-2	-3.86	0.000131	0.0175	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22202583~22203368:+
HNSC	cis	rs3733585	0.579	rs4235353	ENSG00000250413.1	RP11-448G15.1	3.86	0.000131	0.0175	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10121310	chr4:10006482~10009725:+
HNSC	cis	rs3733585	0.605	rs4235354	ENSG00000250413.1	RP11-448G15.1	3.86	0.000131	0.0175	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10121318	chr4:10006482~10009725:+
HNSC	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-3.86	0.000131	0.0175	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
HNSC	cis	rs5167	0.504	rs8100120	ENSG00000269148.1	AC092301.3	3.86	0.000131	0.0176	0.15	0.18	Blood protein levels;	chr19:44962801	chr19:45830164~45831108:+
HNSC	cis	rs656319	0.559	rs17689037	ENSG00000269918.1	AF131215.9	-3.86	0.000131	0.0176	-0.18	-0.18	Myopia (pathological);	chr8:10117348	chr8:11104691~11106704:-
HNSC	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	3.86	0.000131	0.0176	0.18	0.18	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
HNSC	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-3.86	0.000131	0.0176	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-3.86	0.000131	0.0176	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-3.86	0.000131	0.0176	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
HNSC	cis	rs2898290	0.622	rs4840567	ENSG00000269918.1	AF131215.9	-3.86	0.000131	0.0176	-0.17	-0.18	Systolic blood pressure;	chr8:11490116	chr8:11104691~11106704:-
HNSC	cis	rs2013441	0.866	rs2526473	ENSG00000261033.1	RP11-209D14.2	3.86	0.000131	0.0176	0.2	0.18	Obesity-related traits;	chr17:20234165	chr17:20008051~20009234:-
HNSC	cis	rs12291225	0.679	rs7934671	ENSG00000254418.1	RP11-21L19.1	3.86	0.000131	0.0176	0.21	0.18	Sense of smell;	chr11:14283555	chr11:14262846~14273691:-
HNSC	cis	rs6058526	0.631	rs6119230	ENSG00000224628.2	RP5-854E16.2	-3.86	0.000131	0.0176	-0.25	-0.18	Chronic obstructive pulmonary disease;	chr20:32262171	chr20:31285317~31286835:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000272831.1	RP11-792A8.4	3.86	0.000131	0.0176	0.15	0.18	Aortic root size;	chr7:65964026	chr7:66739829~66740385:-
HNSC	cis	rs6088580	0.634	rs6120644	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000131	0.0176	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.624	rs6120645	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000131	0.0176	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:33985617~33988989:-
HNSC	cis	rs7674212	0.531	rs2866416	ENSG00000248740.4	RP11-328K4.1	3.86	0.000131	0.0176	0.19	0.18	Type 2 diabetes;	chr4:102959554	chr4:103256159~103453658:+
HNSC	cis	rs7829975	0.591	rs12677543	ENSG00000254153.1	CTA-398F10.2	3.86	0.000131	0.0176	0.2	0.18	Mood instability;	chr8:8786764	chr8:8456909~8461337:-
HNSC	cis	rs2277027	1	rs11134779	ENSG00000251405.2	CTB-109A12.1	-3.86	0.000131	0.0176	-0.2	-0.18	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509758	chr5:157362615~157460078:-
HNSC	cis	rs853679	0.607	rs56075693	ENSG00000226314.6	ZNF192P1	-3.86	0.000131	0.0176	-0.33	-0.18	Depression;	chr6:28322551	chr6:28161781~28169594:+
HNSC	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-3.86	0.000131	0.0176	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-3.86	0.000131	0.0176	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
HNSC	cis	rs35306767	0.761	rs11253559	ENSG00000229869.1	RP11-363N22.2	-3.86	0.000131	0.0176	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:998869	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs11253560	ENSG00000229869.1	RP11-363N22.2	-3.86	0.000131	0.0176	-0.24	-0.18	Eosinophil percentage of granulocytes;	chr10:1001286	chr10:933026~942743:+
HNSC	cis	rs4256159	0.696	rs58259836	ENSG00000228956.7	SATB1-AS1	3.86	0.000131	0.0176	0.26	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18718222	chr3:18445024~18920401:+
HNSC	cis	rs987724	0.515	rs6787457	ENSG00000243926.1	TIPARP-AS1	3.86	0.000131	0.0176	0.2	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156891157	chr3:156671862~156674378:-
HNSC	cis	rs11976180	1	rs1919949	ENSG00000244479.5	OR2A1-AS1	3.86	0.000131	0.0176	0.2	0.18	Obesity-related traits;	chr7:144070630	chr7:144251264~144356181:-
HNSC	cis	rs2212361	0.527	rs12282965	ENSG00000255893.1	RP11-685N10.1	-3.86	0.000131	0.0176	-0.25	-0.18	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94528348	chr11:94472908~94473570:-
HNSC	cis	rs240993	0.812	rs4945881	ENSG00000230177.1	RP5-1112D6.4	3.86	0.000131	0.0176	0.22	0.18	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111277932~111278742:+
HNSC	cis	rs3018712	0.532	rs2510398	ENSG00000212093.1	AP000807.1	-3.86	0.000131	0.0176	-0.26	-0.18	Total body bone mineral density;	chr11:68653948	chr11:68506083~68506166:-
HNSC	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	3.86	0.000131	0.0176	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
HNSC	cis	rs807669	0.807	rs807431	ENSG00000185065.6	AC000068.5	3.86	0.000131	0.0176	0.18	0.18	Metabolite levels;	chr22:19254838	chr22:19447893~19450105:+
HNSC	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-3.86	0.000131	0.0176	-0.21	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
HNSC	cis	rs4253772	0.591	rs6008384	ENSG00000277232.2	GTSE1-AS1	-3.86	0.000131	0.0176	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46260051	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.591	rs6519993	ENSG00000277232.2	GTSE1-AS1	-3.86	0.000131	0.0176	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46260582	chr22:46295143~46296660:-
HNSC	cis	rs4253772	0.591	rs9627324	ENSG00000277232.2	GTSE1-AS1	-3.86	0.000131	0.0176	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46260614	chr22:46295143~46296660:-
HNSC	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	3.86	0.000131	0.0176	0.19	0.18	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
HNSC	cis	rs6657613	0.68	rs7545518	ENSG00000186715.9	MST1L	3.86	0.000131	0.0176	0.14	0.18	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16754910~16770237:-
HNSC	cis	rs1538970	0.924	rs11211117	ENSG00000234329.1	RP11-767N6.2	3.86	0.000131	0.0176	0.2	0.18	Platelet count;	chr1:45464574	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.924	rs11211118	ENSG00000234329.1	RP11-767N6.2	3.86	0.000131	0.0176	0.2	0.18	Platelet count;	chr1:45464598	chr1:45651039~45651826:-
HNSC	cis	rs7824557	0.564	rs35009431	ENSG00000269918.1	AF131215.9	-3.86	0.000131	0.0176	-0.17	-0.18	Retinal vascular caliber;	chr8:11375279	chr8:11104691~11106704:-
HNSC	cis	rs6840360	0.642	rs2724568	ENSG00000251611.1	RP11-610P16.1	-3.86	0.000131	0.0176	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151407551~151408835:-
HNSC	cis	rs301901	0.581	rs6881383	ENSG00000250155.1	CTD-2353F22.1	3.86	0.000131	0.0176	0.18	0.18	Height;	chr5:37545897	chr5:36666214~36725195:-
HNSC	cis	rs4704187	0.687	rs4361493	ENSG00000271815.1	CTD-2235C13.3	-3.86	0.000131	0.0176	-0.22	-0.18	Response to amphetamines;	chr5:75109272	chr5:75363760~75364242:+
HNSC	cis	rs4660214	0.756	rs11205823	ENSG00000182109.6	RP11-69E11.4	-3.86	0.000131	0.0176	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39522280~39546187:-
HNSC	cis	rs1865760	0.566	rs9366634	ENSG00000272810.1	U91328.22	-3.86	0.000131	0.0176	-0.16	-0.18	Height;	chr6:26072168	chr6:26013241~26013757:+
HNSC	cis	rs66887589	0.777	rs2017058	ENSG00000249244.1	RP11-548H18.2	3.86	0.000131	0.0176	0.2	0.18	Diastolic blood pressure;	chr4:119336584	chr4:119391831~119395335:-
HNSC	cis	rs66887589	0.777	rs1814815	ENSG00000249244.1	RP11-548H18.2	3.86	0.000131	0.0176	0.2	0.18	Diastolic blood pressure;	chr4:119336936	chr4:119391831~119395335:-
HNSC	cis	rs7716219	0.751	rs6869221	ENSG00000251307.1	RP11-506H20.1	3.86	0.000131	0.0176	0.19	0.18	Height;	chr5:55585384	chr5:55233934~55295201:+
HNSC	cis	rs1602565	1	rs12362162	ENSG00000255450.1	CTD-2063L20.1	-3.86	0.000132	0.0176	-0.29	-0.18	Schizophrenia;	chr11:29191926	chr11:29275655~29276565:+
HNSC	cis	rs9910055	0.659	rs7212573	ENSG00000267080.4	ASB16-AS1	-3.86	0.000132	0.0176	-0.14	-0.18	Total body bone mineral density;	chr17:44176913	chr17:44175973~44186717:-
HNSC	cis	rs1602565	0.858	rs10835482	ENSG00000255450.1	CTD-2063L20.1	-3.86	0.000132	0.0176	-0.27	-0.18	Schizophrenia;	chr11:29101155	chr11:29275655~29276565:+
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000272831.1	RP11-792A8.4	3.86	0.000132	0.0176	0.15	0.18	Aortic root size;	chr7:65951183	chr7:66739829~66740385:-
HNSC	cis	rs2070419	0.671	rs9974848	ENSG00000261610.1	AP000265.1	3.86	0.000132	0.0176	0.22	0.18	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31566737	chr21:32259804~32261585:-
HNSC	cis	rs614226	1	rs616157	ENSG00000202538.1	RNU4-2	3.86	0.000132	0.0176	0.29	0.18	Type 1 diabetes nephropathy;	chr12:120487992	chr12:120291763~120291903:-
HNSC	cis	rs11098499	0.644	rs2389880	ENSG00000250412.1	KLHL2P1	3.86	0.000132	0.0176	0.23	0.18	Corneal astigmatism;	chr4:119638715	chr4:119334329~119378233:+
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	3.86	0.000132	0.0176	0.19	0.18	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
HNSC	cis	rs4388249	1	rs3797690	ENSG00000271849.1	CTC-332L22.1	-3.86	0.000132	0.0177	-0.27	-0.18	Schizophrenia;	chr5:109762320	chr5:109687802~109688329:-
HNSC	cis	rs495337	0.76	rs2769982	ENSG00000229222.1	KRT18P4	3.86	0.000132	0.0177	0.19	0.18	Psoriasis;	chr20:49908290	chr20:49956745~49958032:+
HNSC	cis	rs1185460	1	rs1784305	ENSG00000272186.1	RP11-110I1.13	-3.86	0.000132	0.0177	-0.2	-0.18	Coronary artery disease;	chr11:119071338	chr11:119067374~119067698:-
HNSC	cis	rs9393777	0.92	rs72839445	ENSG00000226314.6	ZNF192P1	-3.86	0.000132	0.0177	-0.35	-0.18	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28161781~28169594:+
HNSC	cis	rs2976388	0.967	rs2585183	ENSG00000253741.1	CTD-2292P10.4	3.86	0.000132	0.0177	0.17	0.18	Urinary tract infection frequency;	chr8:142684641	chr8:142702252~142726973:-
HNSC	cis	rs4392868	0.514	rs2341400	ENSG00000245080.5	RP11-320N21.1	-3.86	0.000132	0.0177	-0.21	-0.18	Radiation response;	chr8:95091310	chr8:95066808~95073182:-
HNSC	cis	rs1602565	0.748	rs2452144	ENSG00000255450.1	CTD-2063L20.1	3.86	0.000132	0.0177	0.25	0.18	Schizophrenia;	chr11:29176837	chr11:29275655~29276565:+
HNSC	cis	rs4906332	1	rs34479426	ENSG00000244691.1	RPL10AP1	-3.86	0.000132	0.0177	-0.2	-0.18	Coronary artery disease;	chr14:103415486	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs12885234	ENSG00000244691.1	RPL10AP1	-3.86	0.000132	0.0177	-0.2	-0.18	Coronary artery disease;	chr14:103422844	chr14:103412119~103412761:-
HNSC	cis	rs13179617	1	rs13179617	ENSG00000215032.2	GNL3LP1	-3.86	0.000132	0.0177	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:61527343	chr5:60891935~60893577:-
HNSC	cis	rs28489187	0.706	rs233057	ENSG00000223653.4	RP11-131L23.1	3.86	0.000132	0.0177	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333172	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs233058	ENSG00000223653.4	RP11-131L23.1	3.86	0.000132	0.0177	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333182	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs233059	ENSG00000223653.4	RP11-131L23.1	3.86	0.000132	0.0177	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333253	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs233060	ENSG00000223653.4	RP11-131L23.1	3.86	0.000132	0.0177	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333260	chr1:85276715~85448124:+
HNSC	cis	rs4787484	1	rs12930239	ENSG00000214725.6	CDIPT-AS1	-3.86	0.000132	0.0177	-0.19	-0.18	Response to taxane treatment (placlitaxel);	chr16:29897456	chr16:29863593~29868053:+
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000272831.1	RP11-792A8.4	3.86	0.000132	0.0177	0.15	0.18	Calcium levels;	chr7:65941231	chr7:66739829~66740385:-
HNSC	cis	rs853679	0.542	rs9393892	ENSG00000219891.2	ZSCAN12P1	3.85	0.000132	0.0177	0.25	0.18	Depression;	chr6:28113616	chr6:28091154~28093664:+
HNSC	cis	rs4834770	0.792	rs6823331	ENSG00000250412.1	KLHL2P1	3.85	0.000132	0.0177	0.21	0.18	Blood protein levels;	chr4:119259635	chr4:119334329~119378233:+
HNSC	cis	rs10791097	0.694	rs10791100	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130869051	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs2236711	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130869389	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs2236717	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130869992	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs4937581	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130870440	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.667	rs2155358	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130870462	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs4937583	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130871711	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.667	rs4937584	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130871866	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.667	rs4937585	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130872045	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs10894273	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130872260	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs1054869	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130872735	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs10160281	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130872893	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs7125622	ENSG00000254842.5	RP11-890B15.2	-3.85	0.000132	0.0177	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130873493	chr11:130844191~130865561:-
HNSC	cis	rs2991971	0.81	rs2036021	ENSG00000234329.1	RP11-767N6.2	-3.85	0.000132	0.0177	-0.18	-0.18	High light scatter reticulocyte count;	chr1:45435698	chr1:45651039~45651826:-
HNSC	cis	rs3736485	1	rs3736485	ENSG00000259438.1	CTD-2650P22.1	3.85	0.000132	0.0177	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51456413	chr15:52010999~52019095:-
HNSC	cis	rs1009077	0.68	rs3775856	ENSG00000245958.5	RP11-33B1.1	3.85	0.000132	0.0177	0.18	0.18	Endometriosis;	chr4:119562006	chr4:119454791~119552025:+
HNSC	cis	rs11168351	0.927	rs7971880	ENSG00000257763.1	OR5BK1P	3.85	0.000132	0.0177	0.17	0.18	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48355792~48356614:-
HNSC	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	3.85	0.000132	0.0177	0.19	0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
HNSC	cis	rs7178375	1	rs7169064	ENSG00000270015.1	RP11-540B6.6	3.85	0.000132	0.0177	0.23	0.18	Hypertriglyceridemia;	chr15:30918659	chr15:30926514~30928407:+
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000227888.4	FAM66A	3.85	0.000132	0.0177	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12362019~12388296:+
HNSC	cis	rs73198271	1	rs11775821	ENSG00000254340.1	RP11-10A14.3	-3.85	0.000132	0.0177	-0.26	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:9141424~9145435:+
HNSC	cis	rs11657639	0.507	rs9747116	ENSG00000228782.6	CTD-2026D20.3	-3.85	0.000132	0.0177	-0.17	-0.18	Red blood cell count;	chr17:48443782	chr17:47450568~47492492:-
HNSC	cis	rs597539	0.616	rs631001	ENSG00000255741.1	RP11-757G1.5	-3.85	0.000132	0.0177	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68941503~68942852:-
HNSC	cis	rs10875746	0.859	rs12305647	ENSG00000257763.1	OR5BK1P	-3.85	0.000132	0.0177	-0.21	-0.18	Longevity (90 years and older);	chr12:48189178	chr12:48355792~48356614:-
HNSC	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	3.85	0.000132	0.0177	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	3.85	0.000132	0.0177	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
HNSC	cis	rs73198271	0.653	rs3827811	ENSG00000173295.6	FAM86B3P	-3.85	0.000132	0.0177	-0.22	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8228595~8244865:+
HNSC	cis	rs7572733	0.534	rs1435570	ENSG00000231621.1	AC013264.2	-3.85	0.000132	0.0177	-0.17	-0.18	Dermatomyositis;	chr2:197866647	chr2:197197991~197199273:+
HNSC	cis	rs62025270	0.632	rs62022919	ENSG00000259762.1	RP11-158M2.4	-3.85	0.000132	0.0177	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.632	rs17636096	ENSG00000259762.1	RP11-158M2.4	-3.85	0.000132	0.0177	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85750336~85752901:-
HNSC	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-3.85	0.000132	0.0177	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
HNSC	cis	rs17772222	0.917	rs77382318	ENSG00000258789.1	RP11-507K2.3	-3.85	0.000132	0.0177	-0.22	-0.18	Coronary artery calcification;	chr14:88355785	chr14:88551597~88552493:+
HNSC	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-3.85	0.000132	0.0177	-0.26	-0.18	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
HNSC	cis	rs9400271	0.632	rs949882	ENSG00000243587.6	C6orf183	3.85	0.000132	0.0177	0.17	0.18	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109264859	chr6:109165833~109271014:+
HNSC	cis	rs5758511	0.68	rs5751243	ENSG00000205702.9	CYP2D7	3.85	0.000132	0.0177	0.16	0.18	Birth weight;	chr22:42221171	chr22:42140203~42144577:-
HNSC	cis	rs5758511	0.637	rs5751244	ENSG00000205702.9	CYP2D7	3.85	0.000132	0.0177	0.16	0.18	Birth weight;	chr22:42221405	chr22:42140203~42144577:-
HNSC	cis	rs6088580	0.602	rs6059840	ENSG00000276073.1	RP5-1125A11.7	-3.85	0.000132	0.0177	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:33985617~33988989:-
HNSC	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	3.85	0.000132	0.0177	0.21	0.18	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
HNSC	cis	rs1580019	0.961	rs1868776	ENSG00000226468.2	AC018641.7	3.85	0.000132	0.0177	0.23	0.18	Cognitive ability;	chr7:32454823	chr7:32456963~32457758:-
HNSC	cis	rs988913	0.706	rs9349748	ENSG00000224984.1	RP11-524H19.2	3.85	0.000132	0.0177	0.2	0.18	Menarche (age at onset);	chr6:55067204	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.736	rs9367607	ENSG00000224984.1	RP11-524H19.2	3.85	0.000132	0.0177	0.2	0.18	Menarche (age at onset);	chr6:55067659	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.706	rs9396036	ENSG00000224984.1	RP11-524H19.2	3.85	0.000132	0.0177	0.2	0.18	Menarche (age at onset);	chr6:55067708	chr6:54840118~54840855:-
HNSC	cis	rs4356203	0.87	rs1979603	ENSG00000272034.1	SNORD14A	-3.85	0.000133	0.0177	-0.13	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17074654~17074744:-
HNSC	cis	rs12541595	0.93	rs35006907	ENSG00000255491.1	RP11-1082L8.4	3.85	0.000133	0.0177	0.22	0.18	Left ventricle diastolic internal dimension;	chr8:124847575	chr8:124811618~124815682:-
HNSC	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	3.85	0.000133	0.0177	0.18	0.18	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
HNSC	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	3.85	0.000133	0.0177	0.18	0.18	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
HNSC	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	3.85	0.000133	0.0177	0.18	0.18	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
HNSC	cis	rs6988985	0.765	rs6433	ENSG00000247317.3	RP11-273G15.2	-3.85	0.000133	0.0177	-0.2	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142912224	chr8:142981738~143018437:-
HNSC	cis	rs6988985	0.765	rs6431	ENSG00000247317.3	RP11-273G15.2	-3.85	0.000133	0.0177	-0.2	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142912349	chr8:142981738~143018437:-
HNSC	cis	rs2013441	0.965	rs7207611	ENSG00000261033.1	RP11-209D14.2	-3.85	0.000133	0.0177	-0.2	-0.18	Obesity-related traits;	chr17:20301203	chr17:20008051~20009234:-
HNSC	cis	rs897984	0.762	rs12930545	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.0177	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30927490	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.806	rs10782001	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.0177	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30931304	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.806	rs12928852	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.0177	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30932667	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.806	rs4889571	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.0177	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30937726	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.806	rs11640534	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.0177	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30938194	chr16:30984630~30988270:-
HNSC	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	3.85	0.000133	0.0177	0.15	0.18	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
HNSC	cis	rs3764400	0.508	rs2240121	ENSG00000278765.1	RP5-890E16.5	3.85	0.000133	0.0177	0.34	0.18	Body mass index;	chr17:48074960	chr17:48066704~48067293:-
HNSC	cis	rs2998286	0.678	rs332114	ENSG00000254635.4	WAC-AS1	3.85	0.000133	0.0178	0.23	0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28636772	chr10:28522652~28532743:-
HNSC	cis	rs12310399	0.534	rs7308376	ENSG00000258365.1	RP11-1105G2.3	-3.85	0.000133	0.0178	-0.18	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr12:94967223	chr12:94277758~94282844:-
HNSC	cis	rs12310399	0.534	rs7308787	ENSG00000258365.1	RP11-1105G2.3	-3.85	0.000133	0.0178	-0.18	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr12:94967275	chr12:94277758~94282844:-
HNSC	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	3.85	0.000133	0.0178	0.24	0.18	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
HNSC	cis	rs13325613	0.834	rs34897745	ENSG00000223552.1	RP11-24F11.2	-3.85	0.000133	0.0178	-0.31	-0.18	Monocyte count;	chr3:46156884	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35853141	ENSG00000223552.1	RP11-24F11.2	-3.85	0.000133	0.0178	-0.31	-0.18	Monocyte count;	chr3:46156896	chr3:46364955~46407059:-
HNSC	cis	rs6545883	0.831	rs9309336	ENSG00000271889.1	RP11-493E12.1	3.85	0.000133	0.0178	0.2	0.18	Tuberculosis;	chr2:61536030	chr2:61151433~61162105:-
HNSC	cis	rs863750	0.687	rs825481	ENSG00000275389.1	RP11-214K3.24	3.85	0.000133	0.0178	0.24	0.18	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091012	chr12:124085761~124088598:+
HNSC	cis	rs7178909	0.872	rs7174330	ENSG00000259677.1	RP11-493E3.1	-3.85	0.000133	0.0178	-0.2	-0.18	Common traits (Other);	chr15:89891347	chr15:89876540~89877285:+
HNSC	cis	rs494003	0.951	rs11227303	ENSG00000255120.4	OVOL1-AS1	3.85	0.000133	0.0178	0.24	0.18	Systemic lupus erythematosus;	chr11:65797455	chr11:65789051~65790868:-
HNSC	cis	rs12935418	0.561	rs2287991	ENSG00000278985.1	RP11-303E16.9	3.85	0.000133	0.0178	0.18	0.18	Mean corpuscular volume;	chr16:81006950	chr16:80982319~80984094:-
HNSC	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-3.85	0.000133	0.0178	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
HNSC	cis	rs62458065	0.925	rs10243243	ENSG00000226468.2	AC018641.7	3.85	0.000133	0.0178	0.28	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32421097	chr7:32456963~32457758:-
HNSC	cis	rs8031584	0.918	rs3817498	ENSG00000270015.1	RP11-540B6.6	-3.85	0.000133	0.0178	-0.18	-0.18	Huntington's disease progression;	chr15:30976578	chr15:30926514~30928407:+
HNSC	cis	rs546131	0.642	rs35617374	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34810826	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs1039841	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34811592	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs1594426	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34811912	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs12793173	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34812657	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.614	rs12791769	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34812721	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.614	rs35264793	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34813297	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.614	rs7106579	ENSG00000271369.1	RP11-350D17.3	-3.85	0.000133	0.0178	-0.24	-0.18	Lung disease severity in cystic fibrosis;	chr11:34813955	chr11:34709600~34710161:+
HNSC	cis	rs6504950	0.76	rs7214573	ENSG00000279059.1	RP11-257O5.2	-3.85	0.000133	0.0178	-0.15	-0.18	Breast cancer;	chr17:54929293	chr17:54956760~54958426:-
HNSC	cis	rs11168618	0.904	rs7135125	ENSG00000240399.1	RP1-228P16.1	3.85	0.000133	0.0178	0.15	0.18	Adiponectin levels;	chr12:48532485	chr12:48054813~48055591:-
HNSC	cis	rs6090919	0.501	rs71351945	ENSG00000222365.1	SNORD12B	-3.85	0.000133	0.0178	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:48846161	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs35902471	ENSG00000222365.1	SNORD12B	-3.85	0.000133	0.0178	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:48846796	chr20:49280319~49280409:+
HNSC	cis	rs516805	0.667	rs2606617	ENSG00000279453.1	RP3-425C14.4	-3.85	0.000133	0.0178	-0.24	-0.18	Lymphocyte counts;	chr6:122182619	chr6:122436789~122439223:-
HNSC	cis	rs1823874	0.605	rs1840300	ENSG00000182397.13	DNM1P46	-3.85	0.000133	0.0178	-0.18	-0.18	IgG glycosylation;	chr15:99826739	chr15:99790156~99806927:-
HNSC	cis	rs4760636	1	rs13632	ENSG00000268069.2	RP5-1057I20.4	3.85	0.000133	0.0178	0.21	0.18	Urate levels;	chr12:47783455	chr12:47784923~47786002:+
HNSC	cis	rs4760636	0.953	rs3815138	ENSG00000268069.2	RP5-1057I20.4	3.85	0.000133	0.0178	0.21	0.18	Urate levels;	chr12:47784682	chr12:47784923~47786002:+
HNSC	cis	rs12545109	0.917	rs10098993	ENSG00000246430.5	LINC00968	-3.85	0.000133	0.0178	-0.22	-0.18	Obesity-related traits;	chr8:56410557	chr8:56496246~56559823:-
HNSC	cis	rs1555322	1	rs6058219	ENSG00000126005.14	MMP24-AS1	-3.85	0.000133	0.0178	-0.32	-0.18	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35216462~35278131:-
HNSC	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-3.85	0.000133	0.0178	-0.25	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
HNSC	cis	rs4900538	0.927	rs1190547	ENSG00000272533.1	SNORA28	3.85	0.000133	0.0178	0.18	0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102438750	chr14:103337849~103337974:+
HNSC	cis	rs941408	0.515	rs878893	ENSG00000261342.1	AC006538.1	3.85	0.000133	0.0178	0.25	0.18	Total cholesterol levels;	chr19:2781327	chr19:2727743~2729327:-
HNSC	cis	rs7765004	0.887	rs4574672	ENSG00000228624.6	RP3-399L15.3	3.85	0.000133	0.0178	0.18	0.18	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113758576	chr6:113969701~114471705:+
HNSC	cis	rs36093924	0.646	rs5996092	ENSG00000227370.1	RP4-669P10.19	3.85	0.000133	0.0178	0.16	0.18	Intelligence;	chr22:41948404	chr22:42132543~42132998:+
HNSC	cis	rs3750965	1	rs3750965	ENSG00000265539.1	MIR3164	-3.85	0.000133	0.0178	-0.19	-0.18	Hair color;	chr11:69072692	chr11:69083176~69083258:+
HNSC	cis	rs6921919	0.583	rs9468355	ENSG00000227214.2	HCG15	3.85	0.000133	0.0178	0.21	0.18	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28986203~28987484:+
HNSC	cis	rs2032366	0.592	rs12455039	ENSG00000267279.1	RP11-879F14.2	3.85	0.000133	0.0178	0.23	0.18	Obesity-related traits;	chr18:61583101	chr18:61585746~61606916:-
HNSC	cis	rs924712	0.574	rs9370328	ENSG00000224984.1	RP11-524H19.2	-3.85	0.000133	0.0178	-0.21	-0.18	Breast cancer;	chr6:54815888	chr6:54840118~54840855:-
HNSC	cis	rs13108904	0.521	rs4974609	ENSG00000254094.1	AC078852.1	3.85	0.000133	0.0178	0.2	0.18	Obesity-related traits;	chr4:1363136	chr4:1356581~1358075:+
HNSC	cis	rs11893307	0.599	rs11900857	ENSG00000228509.4	AC006460.2	3.85	0.000133	0.0178	0.25	0.18	Mean platelet volume;	chr2:190794285	chr2:190676944~190708716:-
HNSC	cis	rs830124	0.639	rs1971955	ENSG00000280138.1	RP11-463O12.5	-3.85	0.000133	0.0178	-0.2	-0.18	Urinary metabolites;	chr12:121982531	chr12:122870059~122888720:-
HNSC	cis	rs8072100	1	rs8065669	ENSG00000263293.2	RP11-290H9.4	3.85	0.000133	0.0178	0.19	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47303460~47323613:-
HNSC	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	3.85	0.000133	0.0178	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	3.85	0.000133	0.0178	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
HNSC	cis	rs4908760	0.795	rs6693009	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000133	0.0178	0.19	0.18	Vitiligo;	chr1:8683651	chr1:8424645~8434838:+
HNSC	cis	rs35306767	0.903	rs11815185	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000133	0.0178	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:877677	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs12260800	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000133	0.0178	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:881993	chr10:933026~942743:+
HNSC	cis	rs1009077	0.514	rs71614451	ENSG00000245958.5	RP11-33B1.1	3.85	0.000133	0.0178	0.19	0.18	Endometriosis;	chr4:119483305	chr4:119454791~119552025:+
HNSC	cis	rs9393777	0.844	rs72839477	ENSG00000226314.6	ZNF192P1	-3.85	0.000134	0.0178	-0.34	-0.18	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28161781~28169594:+
HNSC	cis	rs9914988	0.613	rs2277664	ENSG00000264577.1	AC010761.8	-3.85	0.000134	0.0178	-0.17	-0.18	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28959644	chr17:28721487~28722877:-
HNSC	cis	rs4388249	0.95	rs35342188	ENSG00000271849.1	CTC-332L22.1	-3.85	0.000134	0.0178	-0.27	-0.18	Schizophrenia;	chr5:109755916	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.95	rs17638690	ENSG00000271849.1	CTC-332L22.1	-3.85	0.000134	0.0178	-0.27	-0.18	Schizophrenia;	chr5:109756113	chr5:109687802~109688329:-
HNSC	cis	rs3738443	0.868	rs17269923	ENSG00000259865.1	RP11-488L18.10	3.85	0.000134	0.0179	0.15	0.18	Alcohol dependence;	chr1:247208861	chr1:247187281~247188526:-
HNSC	cis	rs4253772	0.591	rs6007747	ENSG00000277232.2	GTSE1-AS1	-3.85	0.000134	0.0179	-0.22	-0.18	Cholesterol, total;LDL cholesterol;	chr22:46261364	chr22:46295143~46296660:-
HNSC	cis	rs9313772	0.928	rs12716337	ENSG00000254350.1	RP11-542A14.1	-3.85	0.000134	0.0179	-0.2	-0.18	Blood pressure;	chr5:158387220	chr5:158424585~158452758:+
HNSC	cis	rs354225	0.785	rs354222	ENSG00000237887.1	AC092839.1	-3.85	0.000134	0.0179	-0.22	-0.18	Schizophrenia;	chr2:54698043	chr2:54529343~54529801:+
HNSC	cis	rs10742752	0.603	rs11038428	ENSG00000254651.1	RP11-430H10.3	3.85	0.000134	0.0179	0.21	0.18	Body mass index;	chr11:45382767	chr11:45399448~45400528:+
HNSC	cis	rs4835473	0.932	rs7669198	ENSG00000249741.2	RP11-673E1.3	3.85	0.000134	0.0179	0.19	0.18	Immature fraction of reticulocytes;	chr4:143821229	chr4:143911514~143912053:-
HNSC	cis	rs1028883	1	rs1028883	ENSG00000228295.1	LINC00392	-3.85	0.000134	0.0179	-0.18	-0.18	Lean body mass;	chr13:73534450	chr13:73564244~73588070:+
HNSC	cis	rs6095360	0.934	rs6019582	ENSG00000222365.1	SNORD12B	-3.85	0.000134	0.0179	-0.18	-0.18	Intelligence (multi-trait analysis);	chr20:49011068	chr20:49280319~49280409:+
HNSC	cis	rs28489187	0.706	rs233062	ENSG00000223653.4	RP11-131L23.1	3.85	0.000134	0.0179	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85334702	chr1:85276715~85448124:+
HNSC	cis	rs73219805	0.818	rs117325001	ENSG00000228451.3	SDAD1P1	-3.85	0.000134	0.0179	-0.27	-0.18	Schizophrenia;	chr8:26384756	chr8:26379259~26382953:-
HNSC	cis	rs7405404	0.672	rs1894391	ENSG00000262454.1	RP11-65J21.3	-3.85	0.000134	0.0179	-0.15	-0.18	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13640256	chr16:14302288~14326353:+
HNSC	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	3.85	0.000134	0.0179	0.25	0.18	Pain;	chr19:21430595	chr19:21554640~21569237:-
HNSC	cis	rs1478897	0.898	rs2248700	ENSG00000255046.1	RP11-297N6.4	3.85	0.000134	0.0179	0.19	0.18	Systemic lupus erythematosus;	chr8:11536236	chr8:11797928~11802568:-
HNSC	cis	rs35264875	1	rs6591370	ENSG00000259799.1	RP11-554A11.9	3.85	0.000134	0.0179	0.25	0.18	Blond vs. brown hair color;	chr11:69075535	chr11:69155910~69159752:+
HNSC	cis	rs1131351	0.644	rs35973557	ENSG00000234378.1	AC098828.2	-3.85	0.000134	0.0179	-0.21	-0.18	Seasonality;	chr2:20199805	chr2:20063856~20106829:-
HNSC	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-3.85	0.000134	0.0179	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
HNSC	cis	rs924607	0.9	rs1697950	ENSG00000225138.6	CTD-2228K2.7	-3.85	0.000134	0.0179	-0.19	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:616775	chr5:473236~480884:+
HNSC	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	3.85	0.000134	0.0179	0.21	0.18	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
HNSC	cis	rs2436845	1	rs2679752	ENSG00000253669.3	KB-1732A1.1	-3.85	0.000134	0.0179	-0.16	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102851890	chr8:102805517~102809971:+
HNSC	cis	rs7572733	0.935	rs4850817	ENSG00000222017.1	AC011997.1	-3.85	0.000134	0.0179	-0.21	-0.18	Dermatomyositis;	chr2:197930480	chr2:197693106~197774823:+
HNSC	cis	rs250677	0.687	rs250664	ENSG00000250072.4	CTC-529P8.1	-3.85	0.000134	0.0179	-0.23	-0.18	Breast cancer;	chr5:149074260	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs250666	ENSG00000250072.4	CTC-529P8.1	-3.85	0.000134	0.0179	-0.23	-0.18	Breast cancer;	chr5:149075059	chr5:149063317~149109787:+
HNSC	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-3.85	0.000134	0.0179	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-3.85	0.000134	0.0179	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-3.85	0.000134	0.0179	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
HNSC	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	3.85	0.000134	0.0179	0.24	0.18	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
HNSC	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	3.85	0.000134	0.0179	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
HNSC	cis	rs7772486	0.654	rs702321	ENSG00000270638.1	RP3-466P17.1	-3.85	0.000134	0.0179	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145735570~145737218:+
HNSC	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-3.85	0.000134	0.0179	-0.22	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
HNSC	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-3.85	0.000134	0.0179	-0.27	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
HNSC	cis	rs10875943	0.751	rs56222401	ENSG00000258017.1	RP11-386G11.10	-3.85	0.000134	0.0179	-0.23	-0.18	Prostate cancer;	chr12:49278931	chr12:49127782~49147869:+
HNSC	cis	rs12682352	0.602	rs13260419	ENSG00000173295.6	FAM86B3P	3.85	0.000134	0.0179	0.2	0.18	Neuroticism;	chr8:8817666	chr8:8228595~8244865:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000233609.3	RP11-62H7.2	3.85	0.000134	0.0179	0.17	0.18	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8961200~8979025:+
HNSC	cis	rs7824557	0.806	rs6601573	ENSG00000255310.2	AF131215.2	-3.85	0.000134	0.0179	-0.17	-0.18	Retinal vascular caliber;	chr8:11237242	chr8:11107788~11109726:-
HNSC	cis	rs2341917	0.643	rs6744628	ENSG00000227992.1	AC108463.2	-3.85	0.000134	0.0179	-0.3	-0.18	Attention function in attention deficit hyperactive disorder;	chr2:110865295	chr2:111203964~111206215:-
HNSC	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000134	0.0179	0.18	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
HNSC	cis	rs9650657	0.77	rs9969626	ENSG00000255310.2	AF131215.2	-3.85	0.000134	0.0179	-0.17	-0.18	Neuroticism;	chr8:10813291	chr8:11107788~11109726:-
HNSC	cis	rs721917	0.525	rs1054053	ENSG00000244733.5	RP11-506M13.3	-3.85	0.000134	0.0179	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79660891~79677996:+
HNSC	cis	rs721917	0.506	rs2758558	ENSG00000244733.5	RP11-506M13.3	-3.85	0.000134	0.0179	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79660891~79677996:+
HNSC	cis	rs7829975	0.714	rs12544992	ENSG00000233609.3	RP11-62H7.2	3.85	0.000134	0.0179	0.17	0.18	Mood instability;	chr8:8804171	chr8:8961200~8979025:+
HNSC	cis	rs1050631	0.96	rs1789512	ENSG00000278986.1	RP11-723J4.3	-3.85	0.000134	0.0179	-0.19	-0.18	Esophageal squamous cell cancer (length of survival);	chr18:36114579	chr18:35972151~35973916:+
HNSC	cis	rs9437689	0.899	rs6683112	ENSG00000237416.5	RP11-465K1.2	-3.85	0.000134	0.0179	-0.21	-0.18	Phospholipid levels (plasma);	chr1:95069890	chr1:94836748~94855426:-
HNSC	cis	rs739525	0.518	rs178268	ENSG00000272829.1	XXbac-B135H6.18	3.85	0.000134	0.0179	0.16	0.18	Testicular germ cell tumor;	chr22:20975977	chr22:20981361~20981755:-
HNSC	cis	rs10510102	0.872	rs3862129	ENSG00000226864.1	ATE1-AS1	3.85	0.000134	0.0179	0.29	0.18	Breast cancer;	chr10:121824460	chr10:121928312~121951965:+
HNSC	cis	rs8035957	1	rs4924273	ENSG00000259747.1	RP11-275I4.2	3.85	0.000134	0.0179	0.2	0.18	Type 1 diabetes;	chr15:38554537	chr15:38671847~38689191:+
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000134	0.0179	0.3	0.18	Diabetic kidney disease;	chr7:66358338	chr7:66025126~66031544:-
HNSC	cis	rs13325613	0.915	rs3136668	ENSG00000223552.1	RP11-24F11.2	-3.85	0.000134	0.0179	-0.31	-0.18	Monocyte count;	chr3:46202789	chr3:46364955~46407059:-
HNSC	cis	rs1023500	1	rs6002552	ENSG00000205702.9	CYP2D7	-3.85	0.000134	0.0179	-0.15	-0.18	Schizophrenia;	chr22:41942347	chr22:42140203~42144577:-
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	3.85	0.000134	0.0179	0.2	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
HNSC	cis	rs7572733	0.935	rs1518366	ENSG00000222017.1	AC011997.1	3.85	0.000134	0.0179	0.21	0.18	Dermatomyositis;	chr2:197944472	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs1914690	ENSG00000222017.1	AC011997.1	3.85	0.000134	0.0179	0.21	0.18	Dermatomyositis;	chr2:197944644	chr2:197693106~197774823:+
HNSC	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	3.85	0.000134	0.0179	0.3	0.18	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
HNSC	cis	rs7520050	0.966	rs785495	ENSG00000280836.1	AL355480.1	3.85	0.000134	0.0179	0.18	0.18	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45581219~45581321:-
HNSC	cis	rs12234571	0.744	rs2301938	ENSG00000214293.7	APTR	3.85	0.000134	0.0179	0.24	0.18	Obesity-related traits;	chr7:77696032	chr7:77657660~77696265:-
HNSC	cis	rs9329221	0.51	rs6995837	ENSG00000255310.2	AF131215.2	3.85	0.000134	0.0179	0.17	0.18	Neuroticism;	chr8:10118165	chr8:11107788~11109726:-
HNSC	cis	rs9329221	0.537	rs6995859	ENSG00000255310.2	AF131215.2	3.85	0.000134	0.0179	0.17	0.18	Neuroticism;	chr8:10118199	chr8:11107788~11109726:-
HNSC	cis	rs4256159	0.696	rs71314412	ENSG00000228956.7	SATB1-AS1	3.85	0.000134	0.018	0.26	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18713874	chr3:18445024~18920401:+
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000211974.3	IGHV2-70	3.85	0.000134	0.018	0.16	0.18	Kawasaki disease;	chr14:106779660	chr14:106723574~106724093:-
HNSC	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000135	0.018	0.18	0.18	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
HNSC	cis	rs7824557	0.806	rs7007394	ENSG00000255310.2	AF131215.2	-3.85	0.000135	0.018	-0.17	-0.18	Retinal vascular caliber;	chr8:11237057	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.806	rs6601574	ENSG00000255310.2	AF131215.2	-3.85	0.000135	0.018	-0.17	-0.18	Retinal vascular caliber;	chr8:11237376	chr8:11107788~11109726:-
HNSC	cis	rs1190596	0.567	rs8005884	ENSG00000272444.1	RP11-1017G21.6	3.85	0.000135	0.018	0.22	0.18	Behavioural disinhibition (generation interaction);	chr14:102226670	chr14:101952416~101953063:+
HNSC	cis	rs7107174	1	rs2512535	ENSG00000251323.2	RP11-452H21.4	3.85	0.000135	0.018	0.25	0.18	Testicular germ cell tumor;	chr11:78260422	chr11:78423982~78429836:-
HNSC	cis	rs964611	0.751	rs58922278	ENSG00000259488.2	RP11-154J22.1	-3.85	0.000135	0.018	-0.16	-0.18	Metabolite levels (Pyroglutamine);	chr15:48257357	chr15:48312353~48331856:-
HNSC	cis	rs8044868	0.586	rs6499564	ENSG00000259209.3	RP5-991G20.2	3.85	0.000135	0.018	0.19	0.18	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72155756	chr16:72805998~72809872:+
HNSC	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	3.85	0.000135	0.018	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
HNSC	cis	rs2286313	0.51	rs35806656	ENSG00000266869.1	RP6-114E22.1	-3.85	0.000135	0.018	-0.43	-0.18	Colorectal cancer;	chr14:70933292	chr14:71848606~71908430:+
HNSC	cis	rs10927875	0.793	rs1763619	ENSG00000226029.1	RP4-798A10.2	-3.85	0.000135	0.018	-0.17	-0.18	Dilated cardiomyopathy;	chr1:16000440	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.8	rs1627145	ENSG00000226029.1	RP4-798A10.2	-3.85	0.000135	0.018	-0.17	-0.18	Dilated cardiomyopathy;	chr1:16001621	chr1:16460948~16468481:+
HNSC	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	3.85	0.000135	0.018	0.2	0.18	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
HNSC	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	3.85	0.000135	0.018	0.25	0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
HNSC	cis	rs2179367	0.959	rs564961	ENSG00000216906.2	RP11-350J20.9	3.85	0.000135	0.018	0.22	0.18	Dupuytren's disease;	chr6:149336091	chr6:149904243~149906418:+
HNSC	cis	rs2179367	0.959	rs504985	ENSG00000216906.2	RP11-350J20.9	3.85	0.000135	0.018	0.22	0.18	Dupuytren's disease;	chr6:149337842	chr6:149904243~149906418:+
HNSC	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-3.85	0.000135	0.018	-0.23	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-3.85	0.000135	0.018	-0.23	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
HNSC	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-3.85	0.000135	0.018	-0.23	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
HNSC	cis	rs1023500	1	rs1023497	ENSG00000205702.9	CYP2D7	-3.85	0.000135	0.018	-0.15	-0.18	Schizophrenia;	chr22:41944504	chr22:42140203~42144577:-
HNSC	cis	rs73201462	1	rs6805582	ENSG00000231305.3	RP11-723O4.2	-3.85	0.000135	0.018	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310165	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6805621	ENSG00000231305.3	RP11-723O4.2	-3.85	0.000135	0.018	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310361	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6794591	ENSG00000231305.3	RP11-723O4.2	-3.85	0.000135	0.018	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128312376	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs11706852	ENSG00000231305.3	RP11-723O4.2	-3.85	0.000135	0.018	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314044	chr3:128861313~128871540:-
HNSC	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-3.85	0.000135	0.018	-0.32	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
HNSC	cis	rs847649	1	rs847648	ENSG00000239969.4	RP11-163E9.2	-3.85	0.000135	0.018	-0.2	-0.18	Morning vs. evening chronotype;	chr7:102913403	chr7:102364162~102380633:+
HNSC	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	3.85	0.000135	0.018	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
HNSC	cis	rs11992162	0.636	rs4841644	ENSG00000255495.1	AC145124.2	3.85	0.000135	0.018	0.2	0.18	Monocyte count;	chr8:11940924	chr8:12194467~12196280:+
HNSC	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	3.85	0.000135	0.018	0.29	0.18	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
HNSC	cis	rs12144094	1	rs12144094	ENSG00000260941.1	LINC00622	-3.85	0.000135	0.018	-0.23	-0.18	Height;	chr1:119722200	chr1:119597702~119599271:-
HNSC	cis	rs10435719	0.867	rs62493601	ENSG00000227888.4	FAM66A	3.85	0.000135	0.018	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.753	rs9694940	ENSG00000227888.4	FAM66A	3.85	0.000135	0.018	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.78	rs9692662	ENSG00000227888.4	FAM66A	3.85	0.000135	0.018	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.899	rs9693925	ENSG00000227888.4	FAM66A	3.85	0.000135	0.018	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:12362019~12388296:+
HNSC	cis	rs748404	0.666	rs7183708	ENSG00000166763.7	STRCP1	3.85	0.000135	0.018	0.24	0.18	Lung cancer;	chr15:43355226	chr15:43699488~43718184:-
HNSC	cis	rs17596685	0.932	rs6561058	ENSG00000271216.1	LINC01050	3.85	0.000135	0.018	0.22	0.18	C-reactive protein levels;	chr13:42552037	chr13:42810366~42812562:-
HNSC	cis	rs4763879	0.739	rs7310460	ENSG00000278635.1	CTD-2318O12.1	3.85	0.000135	0.018	0.13	0.18	Type 1 diabetes;	chr12:9688177	chr12:9415641~9416718:+
HNSC	cis	rs35306767	0.903	rs12244253	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000135	0.018	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr10:843380	chr10:933026~942743:+
HNSC	cis	rs879620	0.89	rs2601781	ENSG00000262185.1	RP11-462G12.1	-3.85	0.000135	0.018	-0.22	-0.18	Hip circumference;Body mass index;	chr16:3967391	chr16:3947609~3950444:-
HNSC	cis	rs2288912	0.838	rs2239375	ENSG00000269148.1	AC092301.3	3.85	0.000135	0.018	0.15	0.18	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44956594	chr19:45830164~45831108:+
HNSC	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	3.85	0.000135	0.018	0.22	0.18	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
HNSC	cis	rs2904967	0.526	rs171193	ENSG00000254614.2	AP003068.23	-3.85	0.000135	0.018	-0.28	-0.18	Mean corpuscular volume;	chr11:65215128	chr11:65177606~65181834:-
HNSC	cis	rs792448	0.717	rs17042034	ENSG00000226251.4	RP11-15I11.3	-3.85	0.000135	0.018	-0.22	-0.18	White blood cell count (basophil);	chr1:212285673	chr1:212225278~212238977:-
HNSC	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-3.85	0.000135	0.018	-0.19	-0.18	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
HNSC	cis	rs9880211	0.563	rs9881400	ENSG00000239213.4	NCK1-AS1	3.85	0.000135	0.018	0.17	0.18	Height;Body mass index;	chr3:136142824	chr3:136841726~136862054:-
HNSC	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	3.85	0.000135	0.018	0.19	0.18	QT interval;	chr12:29266228	chr12:29280418~29317848:-
HNSC	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	3.85	0.000135	0.018	0.15	0.18	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
HNSC	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	3.85	0.000135	0.018	0.15	0.18	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
HNSC	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	3.85	0.000135	0.018	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
HNSC	cis	rs10131894	0.611	rs175002	ENSG00000279594.1	RP11-950C14.10	3.85	0.000135	0.018	0.21	0.18	Coronary artery disease;	chr14:74969763	chr14:75011269~75012851:-
HNSC	cis	rs2115630	0.875	rs8039472	ENSG00000259295.5	CSPG4P12	-3.85	0.000135	0.018	-0.2	-0.18	P wave terminal force;	chr15:84818413	chr15:85191438~85213905:+
HNSC	cis	rs7577696	0.695	rs11676475	ENSG00000272716.1	RP11-563N4.1	-3.85	0.000135	0.018	-0.17	-0.18	Inflammatory biomarkers;	chr2:32164121	chr2:32165046~32165757:-
HNSC	cis	rs7577696	0.695	rs12997026	ENSG00000272716.1	RP11-563N4.1	-3.85	0.000135	0.018	-0.17	-0.18	Inflammatory biomarkers;	chr2:32169238	chr2:32165046~32165757:-
HNSC	cis	rs1941023	0.967	rs10897085	ENSG00000279632.1	RP11-286N22.6	-3.85	0.000135	0.018	-0.19	-0.18	Congenital heart disease (maternal effect);	chr11:60541484	chr11:61426448~61427325:-
HNSC	cis	rs3806843	0.521	rs192231	ENSG00000276545.1	PCDHGB9P	-3.85	0.000135	0.018	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140868954	chr5:141439853~141442449:+
HNSC	cis	rs2239557	1	rs4903201	ENSG00000258769.1	RAP1AP	3.85	0.000135	0.018	0.19	0.18	Common traits (Other);	chr14:74192987	chr14:74482985~74483435:+
HNSC	cis	rs2239557	1	rs10140433	ENSG00000258769.1	RAP1AP	3.85	0.000135	0.018	0.19	0.18	Common traits (Other);	chr14:74193286	chr14:74482985~74483435:+
HNSC	cis	rs2239557	1	rs4903202	ENSG00000258769.1	RAP1AP	3.85	0.000135	0.018	0.19	0.18	Common traits (Other);	chr14:74193599	chr14:74482985~74483435:+
HNSC	cis	rs2239557	1	rs4903203	ENSG00000258769.1	RAP1AP	3.85	0.000135	0.018	0.19	0.18	Common traits (Other);	chr14:74193805	chr14:74482985~74483435:+
HNSC	cis	rs36093844	0.576	rs17745153	ENSG00000279742.1	RP11-700A24.1	-3.85	0.000135	0.018	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012484	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.626	rs4944552	ENSG00000279742.1	RP11-700A24.1	-3.85	0.000135	0.018	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012763	chr11:85852557~85854943:-
HNSC	cis	rs10435719	0.867	rs35778860	ENSG00000227888.4	FAM66A	3.85	0.000135	0.018	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:12362019~12388296:+
HNSC	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-3.85	0.000135	0.018	-0.19	-0.18	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
HNSC	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000135	0.018	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
HNSC	cis	rs9650657	0.771	rs4840516	ENSG00000255310.2	AF131215.2	3.85	0.000135	0.018	0.17	0.18	Neuroticism;	chr8:10809825	chr8:11107788~11109726:-
HNSC	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	3.85	0.000135	0.018	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
HNSC	cis	rs1799955	0.529	rs1801406	ENSG00000215515.2	IFIT1P1	-3.85	0.000135	0.018	-0.21	-0.18	LDL cholesterol levels;	chr13:32337751	chr13:32384660~32386108:+
HNSC	cis	rs28489187	0.706	rs233108	ENSG00000223653.4	RP11-131L23.1	3.85	0.000135	0.018	0.24	0.18	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85316037	chr1:85276715~85448124:+
HNSC	cis	rs11089937	0.616	rs4145537	ENSG00000211638.2	IGLV8-61	3.85	0.000135	0.018	0.16	0.18	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22098700~22099212:+
HNSC	cis	rs11157436	0.918	rs12433895	ENSG00000211812.1	TRAV26-2	-3.85	0.000135	0.018	-0.18	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154577	chr14:22202583~22203368:+
HNSC	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	3.85	0.000135	0.018	0.17	0.18	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
HNSC	cis	rs62025270	0.806	rs62025266	ENSG00000259762.1	RP11-158M2.4	-3.85	0.000135	0.018	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.848	rs2554	ENSG00000259762.1	RP11-158M2.4	-3.85	0.000135	0.018	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85750336~85752901:-
HNSC	cis	rs12819124	0.502	rs10875718	ENSG00000257763.1	OR5BK1P	3.85	0.000135	0.018	0.17	0.18	Glycated hemoglobin levels;	chr12:48017319	chr12:48355792~48356614:-
HNSC	cis	rs138249	0.527	rs138251	ENSG00000273253.2	RP3-402G11.26	-3.85	0.000135	0.018	-0.21	-0.18	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50132423	chr22:50199090~50200837:-
HNSC	cis	rs4713118	0.662	rs149970	ENSG00000204709.4	LINC01556	3.85	0.000135	0.018	0.23	0.18	Parkinson's disease;	chr6:28012442	chr6:28943877~28944537:+
HNSC	cis	rs2310173	0.966	rs10185424	ENSG00000281162.1	LINC01127	-3.85	0.000135	0.0181	-0.22	-0.18	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102046427	chr2:101962056~101987167:+
HNSC	cis	rs35306767	0.761	rs11253537	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000135	0.0181	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:964795	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs12773961	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000135	0.0181	-0.25	-0.18	Eosinophil percentage of granulocytes;	chr10:967275	chr10:933026~942743:+
HNSC	cis	rs2048656	0.535	rs2014514	ENSG00000233609.3	RP11-62H7.2	3.85	0.000135	0.0181	0.17	0.18	Schizophrenia;	chr8:9789686	chr8:8961200~8979025:+
HNSC	cis	rs683257	0.636	rs6918856	ENSG00000234147.1	RP3-460G2.2	-3.85	0.000135	0.0181	-0.31	-0.18	Facial emotion recognition (angry faces);	chr6:140851609	chr6:140845958~140852924:-
HNSC	cis	rs853679	1	rs2799079	ENSG00000204709.4	LINC01556	3.85	0.000135	0.0181	0.26	0.18	Depression;	chr6:28267398	chr6:28943877~28944537:+
HNSC	cis	rs924712	1	rs924712	ENSG00000224984.1	RP11-524H19.2	-3.85	0.000135	0.0181	-0.2	-0.18	Breast cancer;	chr6:54862053	chr6:54840118~54840855:-
HNSC	cis	rs3808502	0.563	rs12549150	ENSG00000255310.2	AF131215.2	3.85	0.000135	0.0181	0.17	0.18	Neuroticism;	chr8:11565427	chr8:11107788~11109726:-
HNSC	cis	rs62025270	0.688	rs76902341	ENSG00000259762.1	RP11-158M2.4	-3.85	0.000135	0.0181	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85750336~85752901:-
HNSC	cis	rs72827839	0.744	rs16956892	ENSG00000272763.1	RP11-357H14.17	-3.85	0.000136	0.0181	-0.25	-0.18	Ease of getting up in the morning;	chr17:48446557	chr17:48635923~48647023:-
HNSC	cis	rs2948294	0.588	rs7011221	ENSG00000254153.1	CTA-398F10.2	3.85	0.000136	0.0181	0.21	0.18	Red cell distribution width;	chr8:8256724	chr8:8456909~8461337:-
HNSC	cis	rs913655	0.508	rs11015860	ENSG00000225527.1	RP11-383B4.4	-3.85	0.000136	0.0181	-0.21	-0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18716110	chr10:18531849~18533336:-
HNSC	cis	rs7085104	0.632	rs3781287	ENSG00000213061.2	PFN1P11	3.85	0.000136	0.0181	0.21	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102838011~102845473:-
HNSC	cis	rs516805	0.667	rs197676	ENSG00000279453.1	RP3-425C14.4	-3.85	0.000136	0.0181	-0.25	-0.18	Lymphocyte counts;	chr6:122532410	chr6:122436789~122439223:-
HNSC	cis	rs7688540	0.771	rs4549329	ENSG00000211553.1	AC253576.2	-3.85	0.000136	0.0181	-0.26	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:136461~136568:+
HNSC	cis	rs950169	0.541	rs10795	ENSG00000229212.6	RP11-561C5.4	-3.85	0.000136	0.0181	-0.26	-0.18	Schizophrenia;	chr15:84634066	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs36126054	ENSG00000229212.6	RP11-561C5.4	-3.85	0.000136	0.0181	-0.26	-0.18	Schizophrenia;	chr15:84634492	chr15:85205440~85234795:-
HNSC	cis	rs950169	0.58	rs1061737	ENSG00000229212.6	RP11-561C5.4	-3.85	0.000136	0.0181	-0.26	-0.18	Schizophrenia;	chr15:84640559	chr15:85205440~85234795:-
HNSC	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	3.85	0.000136	0.0181	0.3	0.18	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
HNSC	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-3.85	0.000136	0.0181	-0.2	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
HNSC	cis	rs6840360	0.642	rs1470280	ENSG00000251611.1	RP11-610P16.1	-3.85	0.000136	0.0181	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151407551~151408835:-
HNSC	cis	rs7267979	0.668	rs4815398	ENSG00000204556.4	CTD-2514C3.1	3.85	0.000136	0.0181	0.22	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26018832~26020684:+
HNSC	cis	rs4144743	0.759	rs4289057	ENSG00000228782.6	CTD-2026D20.3	-3.85	0.000136	0.0181	-0.22	-0.18	Body mass index;	chr17:47243664	chr17:47450568~47492492:-
HNSC	cis	rs28829049	0.597	rs1009806	ENSG00000270728.1	RP4-657E11.10	-3.85	0.000136	0.0181	-0.16	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19174057	chr1:19297080~19297903:+
HNSC	cis	rs9687846	0.877	rs3843467	ENSG00000265665.1	AC008391.1	-3.85	0.000136	0.0181	-0.23	-0.18	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr5:56560548	chr5:56457038~56457138:-
HNSC	cis	rs7735319	0.966	rs3860752	ENSG00000250697.1	CTD-2066L21.3	3.85	0.000136	0.0181	0.21	0.18	Systolic blood pressure;	chr5:33114871	chr5:32925639~33297910:-
HNSC	cis	rs3741151	0.686	rs2298469	ENSG00000256448.4	RP11-809N8.4	3.85	0.000136	0.0181	0.24	0.18	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73421985	chr11:73405297~73410682:+
HNSC	cis	rs3741151	0.686	rs11823913	ENSG00000256448.4	RP11-809N8.4	3.85	0.000136	0.0181	0.24	0.18	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73430582	chr11:73405297~73410682:+
HNSC	cis	rs12701220	0.689	rs12530960	ENSG00000229043.2	AC091729.9	-3.85	0.000136	0.0181	-0.27	-0.18	Bronchopulmonary dysplasia;	chr7:1055835	chr7:1160374~1165267:+
HNSC	cis	rs544991	0.724	rs12041652	ENSG00000239670.1	RP4-803A2.2	3.85	0.000136	0.0181	0.2	0.18	Intelligence;	chr1:33740798	chr1:32986952~32988233:+
HNSC	cis	rs8089099	0.546	rs623357	ENSG00000273352.1	RP11-61L19.3	-3.85	0.000136	0.0181	-0.2	-0.18	Pulmonary function (smoking interaction);	chr18:10088893	chr18:9519449~9520199:+
HNSC	cis	rs10129255	0.957	rs12590735	ENSG00000224373.3	IGHV4-59	3.85	0.000136	0.0181	0.11	0.18	Kawasaki disease;	chr14:106779660	chr14:106627249~106627825:-
HNSC	cis	rs16846053	0.515	rs4664047	ENSG00000227403.1	AC009299.3	-3.85	0.000136	0.0181	-0.31	-0.18	Blood osmolality (transformed sodium);	chr2:161649360	chr2:161244739~161249050:+
HNSC	cis	rs16846053	0.515	rs6432699	ENSG00000227403.1	AC009299.3	-3.85	0.000136	0.0181	-0.31	-0.18	Blood osmolality (transformed sodium);	chr2:161652729	chr2:161244739~161249050:+
HNSC	cis	rs16846053	0.515	rs6758760	ENSG00000227403.1	AC009299.3	-3.85	0.000136	0.0181	-0.31	-0.18	Blood osmolality (transformed sodium);	chr2:161654331	chr2:161244739~161249050:+
HNSC	cis	rs16846053	0.551	rs12692640	ENSG00000227403.1	AC009299.3	-3.85	0.000136	0.0181	-0.31	-0.18	Blood osmolality (transformed sodium);	chr2:161669405	chr2:161244739~161249050:+
HNSC	cis	rs9650657	0.836	rs2898252	ENSG00000255310.2	AF131215.2	-3.85	0.000136	0.0181	-0.17	-0.18	Neuroticism;	chr8:10746654	chr8:11107788~11109726:-
HNSC	cis	rs4930561	0.714	rs10896300	ENSG00000184795.9	UNC93B5	3.85	0.000136	0.0181	0.2	0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68186305	chr11:67711702~67716005:-
HNSC	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	3.85	0.000136	0.0181	0.26	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
HNSC	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	3.85	0.000136	0.0181	0.4	0.18	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
HNSC	cis	rs58873874	0.737	rs78565801	ENSG00000248544.2	CTB-47B11.3	3.85	0.000136	0.0181	0.41	0.18	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs79951742	ENSG00000248544.2	CTB-47B11.3	3.85	0.000136	0.0181	0.41	0.18	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157375741~157384950:-
HNSC	cis	rs17253792	0.915	rs78089630	ENSG00000186615.9	KTN1-AS1	-3.85	0.000136	0.0181	-0.35	-0.18	Putamen volume;	chr14:55711866	chr14:55499278~55580110:-
HNSC	cis	rs17253792	1	rs28616134	ENSG00000186615.9	KTN1-AS1	-3.85	0.000136	0.0181	-0.35	-0.18	Putamen volume;	chr14:55712084	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs28375514	ENSG00000186615.9	KTN1-AS1	-3.85	0.000136	0.0181	-0.35	-0.18	Putamen volume;	chr14:55713223	chr14:55499278~55580110:-
HNSC	cis	rs17772222	0.958	rs891749	ENSG00000258789.1	RP11-507K2.3	-3.85	0.000136	0.0181	-0.21	-0.18	Coronary artery calcification;	chr14:88550893	chr14:88551597~88552493:+
HNSC	cis	rs2028299	1	rs6496609	ENSG00000259677.1	RP11-493E3.1	3.85	0.000136	0.0181	0.22	0.18	Type 2 diabetes;	chr15:89836400	chr15:89876540~89877285:+
HNSC	cis	rs6840360	0.642	rs2709822	ENSG00000251611.1	RP11-610P16.1	-3.85	0.000136	0.0181	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151407551~151408835:-
HNSC	cis	rs13179617	0.928	rs13157831	ENSG00000215032.2	GNL3LP1	-3.85	0.000136	0.0181	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61493218	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.889	rs1363892	ENSG00000215032.2	GNL3LP1	-3.85	0.000136	0.0181	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61493693	chr5:60891935~60893577:-
HNSC	cis	rs11846409	0.818	rs2516909	ENSG00000280411.1	IGHV1-69-2	3.85	0.000136	0.0181	0.16	0.18	Rheumatic heart disease;	chr14:106630317	chr14:106762092~106762588:-
HNSC	cis	rs9568867	1	rs4477562	ENSG00000273784.3	RP11-78J21.7	-3.85	0.000136	0.0181	-0.27	-0.18	Obesity;Body mass index;	chr13:53530833	chr13:52600042~52642542:+
HNSC	cis	rs67072384	1	rs7125722	ENSG00000213365.3	AP000593.6	3.85	0.000136	0.0181	0.3	0.18	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72738671	chr11:72280151~72281178:+
HNSC	cis	rs7429990	0.965	rs1060407	ENSG00000228638.1	FCF1P2	-3.85	0.000136	0.0181	-0.17	-0.18	Educational attainment (years of education);	chr3:47916547	chr3:48290793~48291375:-
HNSC	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-3.85	0.000136	0.0181	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
HNSC	cis	rs3750965	1	rs1466222	ENSG00000265539.1	MIR3164	-3.85	0.000136	0.0181	-0.19	-0.18	Hair color;	chr11:69065380	chr11:69083176~69083258:+
HNSC	cis	rs3750965	1	rs7950657	ENSG00000265539.1	MIR3164	-3.85	0.000136	0.0181	-0.19	-0.18	Hair color;	chr11:69067363	chr11:69083176~69083258:+
HNSC	cis	rs11951515	0.738	rs12518127	ENSG00000249286.1	CTD-2210P15.2	-3.85	0.000136	0.0181	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43369286	chr5:43586918~43588223:-
HNSC	cis	rs12410462	0.681	rs115959512	ENSG00000224834.1	BTF3P9	3.85	0.000136	0.0181	0.31	0.18	Major depressive disorder;	chr1:227411877	chr1:227434064~227434346:+
HNSC	cis	rs10995356	0.565	rs6479858	ENSG00000238280.1	RP11-436D10.3	3.85	0.000136	0.0181	0.21	0.18	Temperament;	chr10:62964336	chr10:62793562~62805887:-
HNSC	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000136	0.0181	0.18	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
HNSC	cis	rs7735319	0.933	rs4030363	ENSG00000249102.1	CTD-2066L21.1	3.85	0.000136	0.0181	0.2	0.18	Systolic blood pressure;	chr5:33111244	chr5:33008994~33025724:+
HNSC	cis	rs6500395	0.735	rs7204345	ENSG00000261267.1	RP11-44I10.3	-3.85	0.000136	0.0181	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr16:48632815	chr16:48559661~48587403:+
HNSC	cis	rs913672	0.609	rs4811019	ENSG00000224397.4	LINC01272	-3.85	0.000136	0.0181	-0.23	-0.18	Monocyte count;	chr20:50281932	chr20:50267486~50279795:+
HNSC	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	3.85	0.000136	0.0181	0.27	0.18	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	3.85	0.000136	0.0181	0.27	0.18	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
HNSC	cis	rs9329221	0.537	rs13264586	ENSG00000255310.2	AF131215.2	3.85	0.000136	0.0181	0.16	0.18	Neuroticism;	chr8:10121875	chr8:11107788~11109726:-
HNSC	cis	rs36093844	0.527	rs72950456	ENSG00000279742.1	RP11-700A24.1	-3.85	0.000136	0.0181	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86063820	chr11:85852557~85854943:-
HNSC	cis	rs73607972	0.501	rs73614583	ENSG00000275191.1	RP11-36I17.2	-3.85	0.000136	0.0181	-0.23	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554597	chr16:53628256~53628816:-
HNSC	cis	rs7176527	1	rs3762169	ENSG00000259570.1	RP11-671M22.4	-3.85	0.000136	0.0181	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84394512~84395514:+
HNSC	cis	rs7005380	0.733	rs10107579	ENSG00000279347.1	RP11-85I17.2	3.85	0.000136	0.0182	0.14	0.18	Interstitial lung disease;	chr8:119922329	chr8:119838736~119840385:-
HNSC	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	3.85	0.000136	0.0182	0.18	0.18	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
HNSC	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	3.85	0.000136	0.0182	0.18	0.18	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
HNSC	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	3.85	0.000136	0.0182	0.15	0.18	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
HNSC	cis	rs13179617	0.928	rs13179091	ENSG00000215032.2	GNL3LP1	-3.85	0.000136	0.0182	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61527170	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.928	rs13159166	ENSG00000215032.2	GNL3LP1	-3.85	0.000136	0.0182	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61531912	chr5:60891935~60893577:-
HNSC	cis	rs4256159	0.696	rs35170982	ENSG00000228956.7	SATB1-AS1	3.85	0.000136	0.0182	0.25	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18721075	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs36022132	ENSG00000228956.7	SATB1-AS1	3.85	0.000136	0.0182	0.25	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18721297	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs4260464	ENSG00000228956.7	SATB1-AS1	3.85	0.000136	0.0182	0.25	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18721440	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs11711354	ENSG00000228956.7	SATB1-AS1	3.85	0.000136	0.0182	0.25	0.18	Crohn's disease;Inflammatory bowel disease;	chr3:18721838	chr3:18445024~18920401:+
HNSC	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-3.85	0.000136	0.0182	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
HNSC	cis	rs1009077	0.68	rs13103899	ENSG00000245958.5	RP11-33B1.1	3.85	0.000136	0.0182	0.18	0.18	Endometriosis;	chr4:119517147	chr4:119454791~119552025:+
HNSC	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	3.85	0.000136	0.0182	0.24	0.18	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
HNSC	cis	rs72949976	0.934	rs1441172	ENSG00000270659.1	RP11-105N14.1	3.85	0.000136	0.0182	0.17	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213172979	chr2:213152970~213153659:+
HNSC	cis	rs7824557	0.628	rs3779891	ENSG00000255310.2	AF131215.2	3.85	0.000136	0.0182	0.16	0.18	Retinal vascular caliber;	chr8:11325996	chr8:11107788~11109726:-
HNSC	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-3.85	0.000137	0.0182	-0.24	-0.18	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
HNSC	cis	rs72843166	0.562	rs10491167	ENSG00000265282.1	RP11-269G24.4	3.85	0.000137	0.0182	0.26	0.18	Intelligence (multi-trait analysis);	chr17:63349337	chr17:63430468~63432211:-
HNSC	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-3.85	0.000137	0.0182	-0.22	-0.18	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
HNSC	cis	rs11711311	0.955	rs9881563	ENSG00000241529.3	RN7SL767P	3.85	0.000137	0.0182	0.22	0.18	IgG glycosylation;	chr3:113695184	chr3:113632704~113632998:+
HNSC	cis	rs300890	0.664	rs7690761	ENSG00000250326.1	RP11-284M14.1	-3.85	0.000137	0.0182	-0.2	-0.18	Nasopharyngeal carcinoma;	chr4:143287609	chr4:142933195~143184861:-
HNSC	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	3.85	0.000137	0.0182	0.18	0.18	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
HNSC	cis	rs3015497	0.528	rs3015467	ENSG00000277050.1	RP11-102G14.1	-3.85	0.000137	0.0182	-0.18	-0.18	Mean platelet volume;	chr14:50692130	chr14:51637348~51637947:-
HNSC	cis	rs3015497	0.561	rs4578563	ENSG00000277050.1	RP11-102G14.1	-3.85	0.000137	0.0182	-0.18	-0.18	Mean platelet volume;	chr14:50692867	chr14:51637348~51637947:-
HNSC	cis	rs9402743	0.634	rs4896156	ENSG00000231028.7	LINC00271	-3.85	0.000137	0.0182	-0.21	-0.18	Systemic lupus erythematosus;	chr6:135605725	chr6:135497801~135716055:+
HNSC	cis	rs2760061	0.583	rs3094911	ENSG00000270110.1	RP5-1139B12.4	-3.85	0.000137	0.0182	-0.18	-0.18	Diastolic blood pressure;	chr1:228022478	chr1:228295911~228302998:-
HNSC	cis	rs17818399	0.653	rs34050156	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000137	0.0182	-0.22	-0.18	Height;	chr2:46550507	chr2:46668870~46670778:+
HNSC	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	3.85	0.000137	0.0182	0.25	0.18	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
HNSC	cis	rs4853525	0.522	rs6434412	ENSG00000228509.4	AC006460.2	3.85	0.000137	0.0182	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190720549	chr2:190676944~190708716:-
HNSC	cis	rs9437689	0.966	rs2766011	ENSG00000237416.5	RP11-465K1.2	3.85	0.000137	0.0182	0.21	0.18	Phospholipid levels (plasma);	chr1:94979223	chr1:94836748~94855426:-
HNSC	cis	rs7615952	0.546	rs11718647	ENSG00000248787.1	RP11-666A20.4	-3.85	0.000137	0.0182	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125633178	chr3:125908005~125910272:-
HNSC	cis	rs442309	0.846	rs224127	ENSG00000238280.1	RP11-436D10.3	-3.85	0.000137	0.0182	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62701513	chr10:62793562~62805887:-
HNSC	cis	rs11756659	0.653	rs11757088	ENSG00000218690.1	HIST1H2APS4	3.85	0.000137	0.0182	0.26	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25948230	chr6:26272193~26272540:-
HNSC	cis	rs9500256	0.967	rs1012500	ENSG00000225096.1	XXbac-BPG55C20.7	-3.85	0.000137	0.0182	-0.19	-0.18	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57965630~57972218:+
HNSC	cis	rs2713936	0.538	rs8040189	ENSG00000277245.1	RP11-48G14.3	-3.85	0.000137	0.0182	-0.18	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr15:56062847	chr15:56447120~56447697:+
HNSC	cis	rs72827839	0.779	rs72827808	ENSG00000244649.3	CTD-2377D24.6	-3.85	0.000137	0.0182	-0.23	-0.18	Ease of getting up in the morning;	chr17:48274718	chr17:48646923~48707346:+
HNSC	cis	rs6710503	0.632	rs56239133	ENSG00000271936.1	RP11-443B20.1	-3.85	0.000137	0.0182	-0.22	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24765012	chr2:24825610~24826717:+
HNSC	cis	rs7107174	1	rs2511169	ENSG00000251323.2	RP11-452H21.4	3.85	0.000137	0.0182	0.26	0.18	Testicular germ cell tumor;	chr11:78254275	chr11:78423982~78429836:-
HNSC	cis	rs6928977	0.896	rs2179779	ENSG00000217482.2	HMGB1P17	-3.85	0.000137	0.0182	-0.19	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135328678	chr6:135636086~135636713:-
HNSC	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-3.85	0.000137	0.0182	-0.19	-0.18	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
HNSC	cis	rs11626933	0.885	rs6575125	ENSG00000275198.1	RP11-471B22.3	-3.85	0.000137	0.0182	-0.2	-0.18	Gut microbiota (bacterial taxa);	chr14:90336119	chr14:90383365~90387973:+
HNSC	cis	rs4906332	1	rs17617094	ENSG00000244691.1	RPL10AP1	-3.85	0.000137	0.0182	-0.2	-0.18	Coronary artery disease;	chr14:103427091	chr14:103412119~103412761:-
HNSC	cis	rs13113518	0.51	rs6858749	ENSG00000249700.7	SRD5A3-AS1	3.85	0.000137	0.0182	0.2	0.18	Height;	chr4:55424270	chr4:55363971~55395847:-
HNSC	cis	rs7824557	0.564	rs13260727	ENSG00000255310.2	AF131215.2	3.85	0.000137	0.0182	0.17	0.18	Retinal vascular caliber;	chr8:11375351	chr8:11107788~11109726:-
HNSC	cis	rs638893	0.636	rs583213	ENSG00000255422.1	AP002954.4	-3.85	0.000137	0.0182	-0.29	-0.18	Vitiligo;	chr11:118798469	chr11:118704607~118750263:+
HNSC	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-3.85	0.000137	0.0182	-0.2	-0.18	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
HNSC	cis	rs6964587	0.967	rs10231496	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000137	0.0182	-0.18	-0.18	Breast cancer;	chr7:92111818	chr7:92134604~92180725:+
HNSC	cis	rs11668609	1	rs7260280	ENSG00000268442.1	CTD-2027I19.2	3.85	0.000137	0.0183	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:24162370~24163425:-
HNSC	cis	rs2439831	0.867	rs3101443	ENSG00000201136.1	RNU6-353P	-3.85	0.000137	0.0183	-0.27	-0.18	Lung cancer in ever smokers;	chr15:43620174	chr15:43702363~43702470:+
HNSC	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	3.85	0.000137	0.0183	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
HNSC	cis	rs2304003	1	rs10930182	ENSG00000235192.1	AC009495.2	3.85	0.000137	0.0183	0.23	0.18	Social communication problems;	chr2:165831678	chr2:165794851~165810010:+
HNSC	cis	rs116095464	0.614	rs4371799	ENSG00000277812.1	AC021087.1	3.84	0.000137	0.0183	0.29	0.18	Breast cancer;	chr5:268077	chr5:262769~262881:+
HNSC	cis	rs9313772	0.928	rs11960210	ENSG00000254350.1	RP11-542A14.1	-3.84	0.000137	0.0183	-0.19	-0.18	Blood pressure;	chr5:158390626	chr5:158424585~158452758:+
HNSC	cis	rs2408955	0.522	rs10875721	ENSG00000257763.1	OR5BK1P	-3.84	0.000137	0.0183	-0.17	-0.18	Glycated hemoglobin levels;	chr12:48019810	chr12:48355792~48356614:-
HNSC	cis	rs58873874	0.579	rs35536103	ENSG00000248544.2	CTB-47B11.3	3.84	0.000137	0.0183	0.33	0.18	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157375741~157384950:-
HNSC	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	3.84	0.000137	0.0183	0.2	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
HNSC	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-3.84	0.000137	0.0183	-0.19	-0.18	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
HNSC	cis	rs950169	0.922	rs6603022	ENSG00000230373.7	GOLGA6L5P	3.84	0.000137	0.0183	0.2	0.18	Schizophrenia;	chr15:84161418	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.922	rs11639244	ENSG00000230373.7	GOLGA6L5P	-3.84	0.000137	0.0183	-0.2	-0.18	Schizophrenia;	chr15:84163898	chr15:84507885~84516814:-
HNSC	cis	rs240993	0.812	rs28770304	ENSG00000230177.1	RP5-1112D6.4	3.84	0.000137	0.0183	0.22	0.18	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111277932~111278742:+
HNSC	cis	rs17264034	0.95	rs74982463	ENSG00000250786.1	SNHG18	3.84	0.000137	0.0183	0.3	0.18	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543473	chr5:9546200~9550609:+
HNSC	cis	rs9928842	0.765	rs8055472	ENSG00000261783.1	RP11-252K23.2	3.84	0.000138	0.0183	0.31	0.18	Alcoholic chronic pancreatitis;	chr16:75191650	chr16:75379818~75381260:-
HNSC	cis	rs9880211	0.563	rs1393787	ENSG00000239213.4	NCK1-AS1	3.84	0.000138	0.0183	0.17	0.18	Height;Body mass index;	chr3:136135359	chr3:136841726~136862054:-
HNSC	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-3.84	0.000138	0.0183	-0.25	-0.18	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
HNSC	cis	rs453301	0.658	rs9329175	ENSG00000253981.4	ALG1L13P	-3.84	0.000138	0.0183	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9009151	chr8:8236003~8244667:-
HNSC	cis	rs172166	0.61	rs276369	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0183	-0.2	-0.18	Cardiac Troponin-T levels;	chr6:27951465	chr6:28115628~28116551:+
HNSC	cis	rs10435719	0.867	rs6999030	ENSG00000227888.4	FAM66A	3.84	0.000138	0.0183	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.834	rs6985792	ENSG00000227888.4	FAM66A	3.84	0.000138	0.0183	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12362019~12388296:+
HNSC	cis	rs28829049	0.536	rs12405382	ENSG00000270728.1	RP4-657E11.10	-3.84	0.000138	0.0183	-0.17	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222487	chr1:19297080~19297903:+
HNSC	cis	rs67311347	1	rs12638199	ENSG00000280739.1	EIF1B-AS1	3.84	0.000138	0.0183	0.19	0.18	Renal cell carcinoma;	chr3:40433794	chr3:40173145~40309698:-
HNSC	cis	rs4081724	0.565	rs59527310	ENSG00000267296.2	CEBPA-AS1	3.84	0.000138	0.0183	0.32	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33307487	chr19:33302857~33305054:+
HNSC	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	3.84	0.000138	0.0183	0.31	0.18	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
HNSC	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-3.84	0.000138	0.0183	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
HNSC	cis	rs12682352	0.602	rs1473029	ENSG00000254153.1	CTA-398F10.2	3.84	0.000138	0.0183	0.19	0.18	Neuroticism;	chr8:8811407	chr8:8456909~8461337:-
HNSC	cis	rs597539	0.652	rs686390	ENSG00000255741.1	RP11-757G1.5	-3.84	0.000138	0.0183	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68941503~68942852:-
HNSC	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	3.84	0.000138	0.0183	0.24	0.18	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	3.84	0.000138	0.0183	0.19	0.18	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
HNSC	cis	rs7927592	0.871	rs17603185	ENSG00000255031.4	RP11-802E16.3	3.84	0.000138	0.0183	0.16	0.18	Total body bone mineral density;	chr11:68608773	chr11:68050740~68053762:+
HNSC	cis	rs7824557	0.675	rs2736265	ENSG00000255310.2	AF131215.2	3.84	0.000138	0.0183	0.16	0.18	Retinal vascular caliber;	chr8:11329165	chr8:11107788~11109726:-
HNSC	cis	rs886126	0.65	rs4766566	ENSG00000257595.2	RP3-473L9.4	3.84	0.000138	0.0183	0.21	0.18	Coronary heart disease;	chr12:111269073	chr12:111369282~111403310:+
HNSC	cis	rs1979679	0.842	rs1841964	ENSG00000247934.4	RP11-967K21.1	3.84	0.000138	0.0183	0.19	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28163298~28190738:-
HNSC	cis	rs944002	1	rs2297066	ENSG00000259444.1	RP11-736N17.8	3.84	0.000138	0.0183	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100498	chr14:103094723~103098885:+
HNSC	cis	rs13179617	0.851	rs13188685	ENSG00000215032.2	GNL3LP1	-3.84	0.000138	0.0183	-0.2	-0.18	Intelligence (multi-trait analysis);	chr5:61528579	chr5:60891935~60893577:-
HNSC	cis	rs193541	0.509	rs12109789	ENSG00000260686.1	CTB-36H16.2	-3.84	0.000138	0.0183	-0.16	-0.18	Glucose homeostasis traits;	chr5:122810924	chr5:122832356~122834533:+
HNSC	cis	rs1862618	0.671	rs2591964	ENSG00000271828.1	CTD-2310F14.1	-3.84	0.000138	0.0183	-0.22	-0.18	Initial pursuit acceleration;	chr5:56941073	chr5:56927874~56929573:+
HNSC	cis	rs80130819	0.515	rs917055	ENSG00000278385.1	RP11-89H19.2	3.84	0.000138	0.0183	0.29	0.18	Prostate cancer;	chr12:47991793	chr12:47905122~47906865:+
HNSC	cis	rs2904524	0.541	rs10784840	ENSG00000257815.4	RP11-611E13.2	-3.84	0.000138	0.0183	-0.19	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70388944	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.5	rs11178214	ENSG00000257815.4	RP11-611E13.2	-3.84	0.000138	0.0183	-0.19	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70389327	chr12:69904033~70243360:-
HNSC	cis	rs11098499	0.865	rs4001305	ENSG00000250412.1	KLHL2P1	3.84	0.000138	0.0183	0.22	0.18	Corneal astigmatism;	chr4:119438081	chr4:119334329~119378233:+
HNSC	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-3.84	0.000138	0.0184	-0.2	-0.18	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
HNSC	cis	rs78487399	0.71	rs74382177	ENSG00000234936.1	AC010883.5	3.84	0.000138	0.0184	0.31	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43300918	chr2:43229573~43233394:+
HNSC	cis	rs57502260	0.764	rs3867143	ENSG00000212093.1	AP000807.1	3.84	0.000138	0.0184	0.25	0.18	Total body bone mineral density (age 45-60);	chr11:68455606	chr11:68506083~68506166:-
HNSC	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-3.84	0.000138	0.0184	-0.17	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
HNSC	cis	rs442309	0.846	rs224072	ENSG00000238280.1	RP11-436D10.3	-3.84	0.000138	0.0184	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62748961	chr10:62793562~62805887:-
HNSC	cis	rs453301	0.658	rs13271797	ENSG00000253981.4	ALG1L13P	-3.84	0.000138	0.0184	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9028444	chr8:8236003~8244667:-
HNSC	cis	rs7586673	0.93	rs7591506	ENSG00000235724.7	AC009299.2	-3.84	0.000138	0.0184	-0.23	-0.18	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161222785~161308303:-
HNSC	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	3.84	0.000138	0.0184	0.29	0.18	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000227888.4	FAM66A	3.84	0.000138	0.0184	0.18	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12362019~12388296:+
HNSC	cis	rs2898290	0.622	rs1382567	ENSG00000269918.1	AF131215.9	-3.84	0.000138	0.0184	-0.17	-0.18	Systolic blood pressure;	chr8:11493390	chr8:11104691~11106704:-
HNSC	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-3.84	0.000138	0.0184	-0.17	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
HNSC	cis	rs2904524	1	rs17108038	ENSG00000257815.4	RP11-611E13.2	-3.84	0.000138	0.0184	-0.23	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70347828	chr12:69904033~70243360:-
HNSC	cis	rs250677	0.687	rs42364	ENSG00000250072.4	CTC-529P8.1	-3.84	0.000138	0.0184	-0.22	-0.18	Breast cancer;	chr5:149059295	chr5:149063317~149109787:+
HNSC	cis	rs597539	0.652	rs501799	ENSG00000255741.1	RP11-757G1.5	-3.84	0.000138	0.0184	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68941503~68942852:-
HNSC	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-3.84	0.000138	0.0184	-0.18	-0.18	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
HNSC	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-3.84	0.000138	0.0184	-0.19	-0.18	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-3.84	0.000138	0.0184	-0.19	-0.18	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
HNSC	cis	rs6071524	0.534	rs12625702	ENSG00000224635.1	RP4-564F22.5	-3.84	0.000138	0.0184	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr20:38813292	chr20:38406011~38416797:-
HNSC	cis	rs6444931	1	rs6444930	ENSG00000240704.1	KLF7P1	3.84	0.000138	0.0184	0.27	0.18	Bipolar disorder and schizophrenia;	chr3:170444896	chr3:170952850~170953897:-
HNSC	cis	rs8077577	0.836	rs11652964	ENSG00000273018.4	CTD-2303H24.2	-3.84	0.000138	0.0184	-0.28	-0.18	Obesity-related traits;	chr17:18137090	chr17:18511221~18551705:-
HNSC	cis	rs11971779	0.625	rs10260850	ENSG00000273391.1	RP11-634H22.1	3.84	0.000138	0.0184	0.19	0.18	Diisocyanate-induced asthma;	chr7:139318856	chr7:139359032~139359566:-
HNSC	cis	rs897984	0.762	rs7206511	ENSG00000279196.1	RP11-1072A3.3	-3.84	0.000138	0.0184	-0.2	-0.18	Dementia with Lewy bodies;	chr16:30939031	chr16:30984630~30988270:-
HNSC	cis	rs4908768	0.501	rs7530745	ENSG00000232912.4	RP5-1115A15.1	3.84	0.000138	0.0184	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8424645~8434838:+
HNSC	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	3.84	0.000138	0.0184	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
HNSC	cis	rs6088580	0.634	rs4911420	ENSG00000276073.1	RP5-1125A11.7	3.84	0.000139	0.0184	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:33985617~33988989:-
HNSC	cis	rs11153306	1	rs11153306	ENSG00000255389.1	C6orf3	-3.84	0.000139	0.0184	-0.16	-0.18	Tonsillectomy;	chr6:111629446	chr6:111599875~111602295:+
HNSC	cis	rs7824557	0.602	rs10096194	ENSG00000255310.2	AF131215.2	3.84	0.000139	0.0184	0.17	0.18	Retinal vascular caliber;	chr8:11350163	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	3.84	0.000139	0.0184	0.2	0.18	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
HNSC	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-3.84	0.000139	0.0184	-0.26	-0.18	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
HNSC	cis	rs7777677	0.925	rs6956269	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0184	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.925	rs4726547	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0184	0.16	0.18	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142563740~142564245:+
HNSC	cis	rs62025270	0.688	rs7164373	ENSG00000259762.1	RP11-158M2.4	-3.84	0.000139	0.0184	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85750336~85752901:-
HNSC	cis	rs11846409	0.932	rs28617526	ENSG00000280411.1	IGHV1-69-2	-3.84	0.000139	0.0184	-0.16	-0.18	Rheumatic heart disease;	chr14:106637322	chr14:106762092~106762588:-
HNSC	cis	rs2657294	0.62	rs2395136	ENSG00000226051.5	ZNF503-AS1	-3.84	0.000139	0.0184	-0.22	-0.18	Pneumonia;	chr10:75088213	chr10:75269819~75373500:+
HNSC	cis	rs6554196	0.965	rs2282778	ENSG00000272650.1	RP11-571I18.4	-3.84	0.000139	0.0184	-0.21	-0.18	Monocyte count;	chr4:54667455	chr4:53997415~53997712:-
HNSC	cis	rs1028883	0.571	rs9543408	ENSG00000228295.1	LINC00392	-3.84	0.000139	0.0184	-0.18	-0.18	Lean body mass;	chr13:73595540	chr13:73564244~73588070:+
HNSC	cis	rs17264034	0.95	rs17328863	ENSG00000250786.1	SNHG18	-3.84	0.000139	0.0184	-0.28	-0.18	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9542919	chr5:9546200~9550609:+
HNSC	cis	rs6840360	0.557	rs1143036	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000139	0.0184	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151407551~151408835:-
HNSC	cis	rs10791097	0.694	rs7106995	ENSG00000254842.5	RP11-890B15.2	-3.84	0.000139	0.0184	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130888257	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs7106684	ENSG00000254842.5	RP11-890B15.2	-3.84	0.000139	0.0184	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130888258	chr11:130844191~130865561:-
HNSC	cis	rs7674212	0.57	rs2711899	ENSG00000251288.2	RP11-10L12.2	-3.84	0.000139	0.0184	-0.2	-0.18	Type 2 diabetes;	chr4:103141257	chr4:102751401~102752641:+
HNSC	cis	rs6090919	0.501	rs2093349	ENSG00000222365.1	SNORD12B	-3.84	0.000139	0.0184	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:48860076	chr20:49280319~49280409:+
HNSC	cis	rs4073405	0.889	rs7130748	ENSG00000254651.1	RP11-430H10.3	3.84	0.000139	0.0184	0.21	0.18	Schizophrenia;	chr11:45300326	chr11:45399448~45400528:+
HNSC	cis	rs5758511	0.573	rs139558	ENSG00000235513.1	RP4-756G23.5	3.84	0.000139	0.0184	0.19	0.18	Birth weight;	chr22:41793547	chr22:41209122~41217627:-
HNSC	cis	rs9650657	0.538	rs6984496	ENSG00000255310.2	AF131215.2	-3.84	0.000139	0.0184	-0.16	-0.18	Neuroticism;	chr8:10938583	chr8:11107788~11109726:-
HNSC	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	3.84	0.000139	0.0184	0.19	0.18	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
HNSC	cis	rs11098499	0.78	rs7680914	ENSG00000250412.1	KLHL2P1	3.84	0.000139	0.0184	0.23	0.18	Corneal astigmatism;	chr4:119641898	chr4:119334329~119378233:+
HNSC	cis	rs4820294	0.669	rs35662099	ENSG00000225867.1	RP5-1177I5.3	-3.84	0.000139	0.0184	-0.2	-0.18	Fat distribution (HIV);	chr22:37657902	chr22:37550026~37551735:+
HNSC	cis	rs1979679	0.959	rs75757272	ENSG00000247934.4	RP11-967K21.1	-3.84	0.000139	0.0184	-0.2	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28163298~28190738:-
HNSC	cis	rs2013441	1	rs2703818	ENSG00000261033.1	RP11-209D14.2	3.84	0.000139	0.0185	0.2	0.18	Obesity-related traits;	chr17:20216663	chr17:20008051~20009234:-
HNSC	cis	rs4853525	0.859	rs1882396	ENSG00000235852.1	AC005540.3	3.84	0.000139	0.0185	0.21	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851286	chr2:190880797~190882059:-
HNSC	cis	rs4853525	0.859	rs1894775	ENSG00000235852.1	AC005540.3	3.84	0.000139	0.0185	0.21	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851980	chr2:190880797~190882059:-
HNSC	cis	rs7819412	0.54	rs11777355	ENSG00000255310.2	AF131215.2	-3.84	0.000139	0.0185	-0.18	-0.18	Triglycerides;	chr8:11187180	chr8:11107788~11109726:-
HNSC	cis	rs7085104	0.7	rs10786712	ENSG00000213061.2	PFN1P11	-3.84	0.000139	0.0185	-0.22	-0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102838011~102845473:-
HNSC	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	3.84	0.000139	0.0185	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-3.84	0.000139	0.0185	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	3.84	0.000139	0.0185	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	3.84	0.000139	0.0185	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
HNSC	cis	rs6061231	0.724	rs1570027	ENSG00000275437.1	RP5-908M14.10	3.84	0.000139	0.0185	0.19	0.18	Colorectal cancer;	chr20:62393540	chr20:62402236~62405935:-
HNSC	cis	rs1937680	0.613	rs2105442	ENSG00000236671.6	PRKG1-AS1	-3.84	0.000139	0.0185	-0.25	-0.18	Breast cancer;	chr10:51910520	chr10:52230742~52314128:-
HNSC	cis	rs7429990	0.864	rs2049301	ENSG00000228638.1	FCF1P2	3.84	0.000139	0.0185	0.16	0.18	Educational attainment (years of education);	chr3:47681369	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7429162	ENSG00000228638.1	FCF1P2	3.84	0.000139	0.0185	0.16	0.18	Educational attainment (years of education);	chr3:47683845	chr3:48290793~48291375:-
HNSC	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	3.84	0.000139	0.0185	0.21	0.18	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
HNSC	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	3.84	0.000139	0.0185	0.21	0.18	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
HNSC	cis	rs9923283	1	rs9923283	ENSG00000183604.13	SMG1P5	3.84	0.000139	0.0185	0.26	0.18	Plateletcrit;	chr16:29649973	chr16:30267553~30335374:-
HNSC	cis	rs2562456	0.833	rs55961038	ENSG00000268081.1	RP11-678G14.2	3.84	0.000139	0.0185	0.26	0.18	Pain;	chr19:21375205	chr19:21554640~21569237:-
HNSC	cis	rs7429990	0.901	rs7431567	ENSG00000228638.1	FCF1P2	3.84	0.000139	0.0185	0.17	0.18	Educational attainment (years of education);	chr3:47986342	chr3:48290793~48291375:-
HNSC	cis	rs7927592	0.763	rs10896327	ENSG00000255031.4	RP11-802E16.3	3.84	0.000139	0.0185	0.15	0.18	Total body bone mineral density;	chr11:68467807	chr11:68050740~68053762:+
HNSC	cis	rs859767	0.679	rs1104801	ENSG00000224043.6	CCNT2-AS1	3.84	0.000139	0.0185	0.21	0.18	Neuroticism;	chr2:134679031	chr2:134735464~134918710:-
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000226314.6	ZNF192P1	-3.84	0.000139	0.0185	-0.2	-0.18	Depression;	chr6:28402301	chr6:28161781~28169594:+
HNSC	cis	rs516805	0.561	rs9490494	ENSG00000279453.1	RP3-425C14.4	3.84	0.000139	0.0185	0.26	0.18	Lymphocyte counts;	chr6:122612860	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.561	rs9490495	ENSG00000279453.1	RP3-425C14.4	3.84	0.000139	0.0185	0.26	0.18	Lymphocyte counts;	chr6:122613043	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.561	rs9320881	ENSG00000279453.1	RP3-425C14.4	3.84	0.000139	0.0185	0.26	0.18	Lymphocyte counts;	chr6:122613577	chr6:122436789~122439223:-
HNSC	cis	rs6878727	0.815	rs9885338	ENSG00000253807.4	LINC01170	-3.84	0.000139	0.0185	-0.22	-0.18	Breast cancer;	chr5:124389627	chr5:124059794~124405079:-
HNSC	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-3.84	0.000139	0.0185	-0.14	-0.18	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
HNSC	cis	rs4704187	0.687	rs13359143	ENSG00000272040.1	CTC-366B18.4	-3.84	0.000139	0.0185	-0.16	-0.18	Response to amphetamines;	chr5:75137535	chr5:75608817~75609983:+
HNSC	cis	rs6142618	0.935	rs4911552	ENSG00000275576.1	RP5-836N17.4	-3.84	0.000139	0.0185	-0.18	-0.18	Inflammatory bowel disease;	chr20:32159270	chr20:32116171~32116629:+
HNSC	cis	rs10504130	1	rs41453644	ENSG00000272024.1	RP11-546K22.3	3.84	0.000139	0.0185	0.29	0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51820984	chr8:51950284~51950690:+
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000106610.13	STAG3L4	-3.84	0.000139	0.0185	-0.22	-0.18	Aortic root size;	chr7:66699045	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000106610.13	STAG3L4	-3.84	0.000139	0.0185	-0.22	-0.18	Aortic root size;	chr7:66701485	chr7:67302621~67321526:+
HNSC	cis	rs2462686	0.965	rs1534151	ENSG00000234536.1	AC096582.7	3.84	0.000139	0.0185	0.19	0.18	Major depressive disorder;	chr7:45945046	chr7:45773595~45783157:+
HNSC	cis	rs58873874	0.579	rs75099611	ENSG00000248544.2	CTB-47B11.3	3.84	0.000139	0.0185	0.33	0.18	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157375741~157384950:-
HNSC	cis	rs7246760	0.867	rs73011937	ENSG00000267289.1	CTD-2623N2.11	3.84	0.000139	0.0185	0.29	0.18	Pursuit maintenance gain;	chr19:9721854	chr19:9834079~9835013:-
HNSC	cis	rs11098499	0.866	rs72676074	ENSG00000250412.1	KLHL2P1	3.84	0.000139	0.0185	0.22	0.18	Corneal astigmatism;	chr4:119438686	chr4:119334329~119378233:+
HNSC	cis	rs889398	0.933	rs244418	ENSG00000196696.11	PDXDC2P	3.84	0.000139	0.0185	0.12	0.18	Body mass index;	chr16:69588859	chr16:69976297~70065948:-
HNSC	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000139	0.0185	0.17	0.18	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
HNSC	cis	rs7824557	0.564	rs7828263	ENSG00000269918.1	AF131215.9	-3.84	0.000139	0.0185	-0.17	-0.18	Retinal vascular caliber;	chr8:11374377	chr8:11104691~11106704:-
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-3.84	0.000139	0.0185	-0.2	-0.17	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
HNSC	cis	rs72949976	1	rs6747328	ENSG00000270659.1	RP11-105N14.1	3.84	0.000139	0.0185	0.17	0.17	Squamous cell lung carcinoma;Lung cancer;	chr2:213167432	chr2:213152970~213153659:+
HNSC	cis	rs7665090	0.806	rs7674004	ENSG00000246560.2	RP11-10L12.4	3.84	0.000139	0.0185	0.2	0.17	Primary biliary cholangitis;	chr4:102619156	chr4:102828055~102844075:+
HNSC	cis	rs11976180	1	rs2951363	ENSG00000244479.5	OR2A1-AS1	3.84	0.000139	0.0185	0.2	0.17	Obesity-related traits;	chr7:144057631	chr7:144251264~144356181:-
HNSC	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-3.84	0.00014	0.0185	-0.21	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
HNSC	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-3.84	0.00014	0.0185	-0.22	-0.17	Height;	chr15:75639788	chr15:75527150~75601205:-
HNSC	cis	rs1799955	0.935	rs9567623	ENSG00000215515.2	IFIT1P1	-3.84	0.00014	0.0185	-0.25	-0.17	LDL cholesterol levels;	chr13:32377317	chr13:32384660~32386108:+
HNSC	cis	rs2904524	0.541	rs10879133	ENSG00000257815.4	RP11-611E13.2	-3.84	0.00014	0.0185	-0.19	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70386680	chr12:69904033~70243360:-
HNSC	cis	rs11951515	0.663	rs67415672	ENSG00000249286.1	CTD-2210P15.2	3.84	0.00014	0.0185	0.19	0.17	Metabolite levels  (X-11787);	chr5:43287059	chr5:43586918~43588223:-
HNSC	cis	rs6545883	0.859	rs2600661	ENSG00000271889.1	RP11-493E12.1	-3.84	0.00014	0.0185	-0.2	-0.17	Tuberculosis;	chr2:61315946	chr2:61151433~61162105:-
HNSC	cis	rs67311347	0.866	rs11712426	ENSG00000280739.1	EIF1B-AS1	3.84	0.00014	0.0185	0.19	0.17	Renal cell carcinoma;	chr3:40288831	chr3:40173145~40309698:-
HNSC	cis	rs2070615	0.833	rs6580695	ENSG00000258017.1	RP11-386G11.10	-3.84	0.00014	0.0185	-0.21	-0.17	Bipolar disorder;	chr12:48807424	chr12:49127782~49147869:+
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000226314.6	ZNF192P1	-3.84	0.00014	0.0185	-0.2	-0.17	Depression;	chr6:28379133	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000226314.6	ZNF192P1	-3.84	0.00014	0.0185	-0.2	-0.17	Depression;	chr6:28379168	chr6:28161781~28169594:+
HNSC	cis	rs7927592	0.673	rs2510392	ENSG00000255031.4	RP11-802E16.3	3.84	0.00014	0.0185	0.15	0.17	Total body bone mineral density;	chr11:68626989	chr11:68050740~68053762:+
HNSC	cis	rs7824557	0.628	rs11777746	ENSG00000255495.1	AC145124.2	3.84	0.00014	0.0185	0.2	0.17	Retinal vascular caliber;	chr8:11347246	chr8:12194467~12196280:+
HNSC	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	3.84	0.00014	0.0185	0.22	0.17	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
HNSC	cis	rs73173548	0.528	rs6872276	ENSG00000247828.6	TMEM161B-AS1	3.84	0.00014	0.0185	0.18	0.17	Macular telangiectasia type 2;	chr5:88473903	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.557	rs71580759	ENSG00000247828.6	TMEM161B-AS1	3.84	0.00014	0.0185	0.18	0.17	Macular telangiectasia type 2;	chr5:88474306	chr5:88268895~88436685:+
HNSC	cis	rs757081	0.671	rs214072	ENSG00000260196.1	RP1-239B22.5	-3.84	0.00014	0.0185	-0.22	-0.17	Systolic blood pressure;	chr11:17283723	chr11:17380649~17383531:+
HNSC	cis	rs757081	0.671	rs214070	ENSG00000260196.1	RP1-239B22.5	-3.84	0.00014	0.0185	-0.22	-0.17	Systolic blood pressure;	chr11:17283770	chr11:17380649~17383531:+
HNSC	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	3.84	0.00014	0.0185	0.18	0.17	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
HNSC	cis	rs9329221	0.618	rs4314693	ENSG00000269918.1	AF131215.9	-3.84	0.00014	0.0185	-0.17	-0.17	Neuroticism;	chr8:10401422	chr8:11104691~11106704:-
HNSC	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-3.84	0.00014	0.0185	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-3.84	0.00014	0.0185	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
HNSC	cis	rs7829975	0.744	rs2409092	ENSG00000233609.3	RP11-62H7.2	3.84	0.00014	0.0185	0.17	0.17	Mood instability;	chr8:8824682	chr8:8961200~8979025:+
HNSC	cis	rs2562456	0.833	rs2359145	ENSG00000268081.1	RP11-678G14.2	3.84	0.00014	0.0185	0.26	0.17	Pain;	chr19:21409791	chr19:21554640~21569237:-
HNSC	cis	rs17407555	1	rs73224414	ENSG00000250413.1	RP11-448G15.1	3.84	0.00014	0.0185	0.25	0.17	Schizophrenia (age at onset);	chr4:10296055	chr4:10006482~10009725:+
HNSC	cis	rs2337406	0.925	rs10131226	ENSG00000280411.1	IGHV1-69-2	-3.84	0.00014	0.0186	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106665764	chr14:106762092~106762588:-
HNSC	cis	rs748404	0.666	rs12907870	ENSG00000166763.7	STRCP1	3.84	0.00014	0.0186	0.24	0.17	Lung cancer;	chr15:43453971	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs72709850	ENSG00000166763.7	STRCP1	3.84	0.00014	0.0186	0.24	0.17	Lung cancer;	chr15:43462486	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs34633582	ENSG00000166763.7	STRCP1	3.84	0.00014	0.0186	0.24	0.17	Lung cancer;	chr15:43462683	chr15:43699488~43718184:-
HNSC	cis	rs1937680	0.613	rs6480573	ENSG00000236671.6	PRKG1-AS1	-3.84	0.00014	0.0186	-0.25	-0.17	Breast cancer;	chr10:51909920	chr10:52230742~52314128:-
HNSC	cis	rs73198271	0.74	rs10109886	ENSG00000173295.6	FAM86B3P	-3.84	0.00014	0.0186	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8228595~8244865:+
HNSC	cis	rs67311347	0.544	rs67533651	ENSG00000280739.1	EIF1B-AS1	3.84	0.00014	0.0186	0.19	0.17	Renal cell carcinoma;	chr3:40296876	chr3:40173145~40309698:-
HNSC	cis	rs9393777	0.777	rs56114371	ENSG00000226314.6	ZNF192P1	-3.84	0.00014	0.0186	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28161781~28169594:+
HNSC	cis	rs293377	0.961	rs293370	ENSG00000261407.1	RP11-326A19.3	-3.84	0.00014	0.0186	-0.19	-0.17	Gut microbiota (beta diversity);	chr15:89087245	chr15:89087078~89088267:-
HNSC	cis	rs2337406	0.778	rs56965016	ENSG00000280411.1	IGHV1-69-2	-3.84	0.00014	0.0186	-0.17	-0.17	Alzheimer's disease (late onset);	chr14:106656649	chr14:106762092~106762588:-
HNSC	cis	rs7772486	0.686	rs1337839	ENSG00000270638.1	RP3-466P17.1	-3.84	0.00014	0.0186	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145735570~145737218:+
HNSC	cis	rs10045431	0.519	rs254843	ENSG00000253256.1	CTB-11I22.1	3.84	0.00014	0.0186	0.27	0.17	Crohn's disease;	chr5:159246311	chr5:159209921~159248796:+
HNSC	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-3.84	0.00014	0.0186	-0.22	-0.17	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
HNSC	cis	rs970821	0.667	rs6470183	ENSG00000253106.1	RP11-158K1.3	-3.84	0.00014	0.0186	-0.16	-0.17	Breast cancer;	chr8:123740168	chr8:124488510~124491643:+
HNSC	cis	rs614226	1	rs580016	ENSG00000202538.1	RNU4-2	3.84	0.00014	0.0186	0.31	0.17	Type 1 diabetes nephropathy;	chr12:120496174	chr12:120291763~120291903:-
HNSC	cis	rs1665050	0.901	rs1665051	ENSG00000259732.1	RP11-59H7.3	-3.84	0.00014	0.0186	-0.23	-0.17	Atopic dermatitis;	chr15:59003025	chr15:59121034~59133250:+
HNSC	cis	rs9298506	1	rs10102164	ENSG00000254142.2	RP11-53M11.3	3.84	0.00014	0.0186	0.26	0.17	Intracranial aneurysm;	chr8:54509054	chr8:54554361~54561927:+
HNSC	cis	rs9298506	1	rs56204645	ENSG00000254142.2	RP11-53M11.3	3.84	0.00014	0.0186	0.26	0.17	Intracranial aneurysm;	chr8:54509209	chr8:54554361~54561927:+
HNSC	cis	rs4073405	0.889	rs7123438	ENSG00000254651.1	RP11-430H10.3	3.84	0.00014	0.0186	0.21	0.17	Schizophrenia;	chr11:45302226	chr11:45399448~45400528:+
HNSC	cis	rs2439831	0.681	rs11858152	ENSG00000275601.1	AC011330.13	-3.84	0.00014	0.0186	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43341998	chr15:43642389~43643023:-
HNSC	cis	rs6840360	0.617	rs2724563	ENSG00000251611.1	RP11-610P16.1	-3.84	0.00014	0.0186	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.617	rs2724564	ENSG00000251611.1	RP11-610P16.1	-3.84	0.00014	0.0186	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.607	rs2724565	ENSG00000251611.1	RP11-610P16.1	-3.84	0.00014	0.0186	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151407551~151408835:-
HNSC	cis	rs9611565	0.659	rs9611604	ENSG00000235513.1	RP4-756G23.5	3.84	0.00014	0.0186	0.21	0.17	Vitiligo;	chr22:41519997	chr22:41209122~41217627:-
HNSC	cis	rs12893668	0.645	rs35229468	ENSG00000269958.1	RP11-73M18.8	3.84	0.00014	0.0186	0.17	0.17	Reticulocyte count;	chr14:103585720	chr14:103696353~103697163:+
HNSC	cis	rs4853525	0.59	rs3771310	ENSG00000228509.4	AC006460.2	3.84	0.00014	0.0186	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190908462	chr2:190676944~190708716:-
HNSC	cis	rs2209875	0.64	rs7864748	ENSG00000224945.1	RP11-82L18.2	-3.84	0.00014	0.0186	-0.23	-0.17	Pelvic organ prolapse (moderate/severe);	chr9:89098472	chr9:89088604~89109934:-
HNSC	cis	rs2028299	1	rs3960018	ENSG00000259677.1	RP11-493E3.1	3.84	0.00014	0.0186	0.22	0.17	Type 2 diabetes;	chr15:89840075	chr15:89876540~89877285:+
HNSC	cis	rs36093844	0.527	rs4944555	ENSG00000279742.1	RP11-700A24.1	-3.84	0.00014	0.0186	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86049574	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.527	rs17817956	ENSG00000279742.1	RP11-700A24.1	-3.84	0.00014	0.0186	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86050328	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.527	rs55791429	ENSG00000279742.1	RP11-700A24.1	-3.84	0.00014	0.0186	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86050864	chr11:85852557~85854943:-
HNSC	cis	rs853679	0.517	rs9393890	ENSG00000219891.2	ZSCAN12P1	3.84	0.00014	0.0186	0.25	0.17	Depression;	chr6:28096077	chr6:28091154~28093664:+
HNSC	cis	rs71636778	0.509	rs34889971	ENSG00000260063.1	RP5-968P14.2	-3.84	0.00014	0.0186	-0.37	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26861566	chr1:26692132~26694131:-
HNSC	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-3.84	0.00014	0.0186	-0.17	-0.17	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-3.84	0.00014	0.0186	-0.17	-0.17	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
HNSC	cis	rs9313772	0.928	rs10076730	ENSG00000254350.1	RP11-542A14.1	-3.84	0.00014	0.0186	-0.19	-0.17	Blood pressure;	chr5:158389984	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.928	rs13178245	ENSG00000254350.1	RP11-542A14.1	-3.84	0.00014	0.0186	-0.19	-0.17	Blood pressure;	chr5:158390285	chr5:158424585~158452758:+
HNSC	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	3.84	0.00014	0.0186	0.18	0.17	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
HNSC	cis	rs7615952	0.515	rs7630575	ENSG00000250012.1	RP11-124N2.1	-3.84	0.00014	0.0186	-0.19	-0.17	Blood pressure (smoking interaction);	chr3:125963487	chr3:126084220~126095349:+
HNSC	cis	rs6493858	0.839	rs2682044	ENSG00000277245.1	RP11-48G14.3	-3.84	0.00014	0.0186	-0.2	-0.17	Relative hand skill in reading disability;	chr15:56211610	chr15:56447120~56447697:+
HNSC	cis	rs73198271	0.613	rs11249892	ENSG00000173295.6	FAM86B3P	-3.84	0.00014	0.0186	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8228595~8244865:+
HNSC	cis	rs4843185	0.763	rs9534	ENSG00000275393.1	RP11-568J23.8	-3.84	0.000141	0.0186	-0.18	-0.17	Platelet distribution width;	chr16:85677896	chr16:85697335~85697868:-
HNSC	cis	rs2980439	0.846	rs2980437	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000141	0.0186	-0.21	-0.17	Neuroticism;	chr8:8237241	chr8:9141424~9145435:+
HNSC	cis	rs868153	0.625	rs7772537	ENSG00000275339.1	RP3-425C14.6	3.84	0.000141	0.0186	0.19	0.17	Vertical cup-disc ratio;	chr6:122185396	chr6:122454358~122454612:+
HNSC	cis	rs72827839	0.744	rs16956892	ENSG00000244649.3	CTD-2377D24.6	-3.84	0.000141	0.0186	-0.23	-0.17	Ease of getting up in the morning;	chr17:48446557	chr17:48646923~48707346:+
HNSC	cis	rs2209875	0.64	rs1331188	ENSG00000224945.1	RP11-82L18.2	-3.84	0.000141	0.0186	-0.23	-0.17	Pelvic organ prolapse (moderate/severe);	chr9:89110472	chr9:89088604~89109934:-
HNSC	cis	rs2625529	0.652	rs2034879	ENSG00000260037.4	CTD-2524L6.3	-3.84	0.000141	0.0186	-0.23	-0.17	Red blood cell count;	chr15:72137648	chr15:71818396~71823384:+
HNSC	cis	rs8042680	0.522	rs10775251	ENSG00000213471.7	TTLL13P	-3.84	0.000141	0.0186	-0.22	-0.17	Type 2 diabetes;	chr15:91011195	chr15:90249530~90265482:+
HNSC	cis	rs1659258	0.568	rs1258408	ENSG00000232508.1	MRPL45P1	-3.84	0.000141	0.0186	-0.29	-0.17	Visceral fat;	chr2:88319975	chr2:88364695~88365608:-
HNSC	cis	rs1445130	0.688	rs4832444	ENSG00000260331.1	RP11-111J6.2	3.84	0.000141	0.0186	0.25	0.17	Bulimia nervosa;	chr2:18654494	chr2:18547386~18548204:-
HNSC	cis	rs4853525	0.522	rs7574840	ENSG00000228509.4	AC006460.2	3.84	0.000141	0.0186	0.22	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190719510	chr2:190676944~190708716:-
HNSC	cis	rs17057718	0.898	rs1077034	ENSG00000272146.4	RP11-755B10.4	-3.84	0.000141	0.0186	-0.28	-0.17	Cerebrospinal fluid biomarker levels;	chr3:57104200	chr3:57597715~57600927:+
HNSC	cis	rs7688540	0.713	rs12511388	ENSG00000250892.1	RP11-1365D11.1	-3.84	0.000141	0.0186	-0.31	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:201409~205009:-
HNSC	cis	rs1665050	0.534	rs10444841	ENSG00000277144.1	RP11-59H7.4	-3.84	0.000141	0.0186	-0.22	-0.17	Atopic dermatitis;	chr15:58941849	chr15:59115547~59116089:-
HNSC	cis	rs1665050	0.534	rs8028828	ENSG00000277144.1	RP11-59H7.4	-3.84	0.000141	0.0186	-0.22	-0.17	Atopic dermatitis;	chr15:58943853	chr15:59115547~59116089:-
HNSC	cis	rs1665050	0.534	rs12911441	ENSG00000277144.1	RP11-59H7.4	-3.84	0.000141	0.0186	-0.22	-0.17	Atopic dermatitis;	chr15:58944341	chr15:59115547~59116089:-
HNSC	cis	rs1665050	0.534	rs4775106	ENSG00000277144.1	RP11-59H7.4	-3.84	0.000141	0.0186	-0.22	-0.17	Atopic dermatitis;	chr15:58946062	chr15:59115547~59116089:-
HNSC	cis	rs6504950	0.83	rs72831295	ENSG00000279059.1	RP11-257O5.2	-3.84	0.000141	0.0186	-0.15	-0.17	Breast cancer;	chr17:54966443	chr17:54956760~54958426:-
HNSC	cis	rs453301	0.686	rs4840389	ENSG00000253981.4	ALG1L13P	-3.84	0.000141	0.0186	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9026993	chr8:8236003~8244667:-
HNSC	cis	rs10484434	1	rs11751732	ENSG00000217159.2	LARP1P1	3.84	0.000141	0.0186	0.27	0.17	HIV-1 viral setpoint;	chr6:26043836	chr6:26164072~26164363:+
HNSC	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	3.84	0.000141	0.0186	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
HNSC	cis	rs62025270	0.649	rs12148610	ENSG00000259762.1	RP11-158M2.4	-3.84	0.000141	0.0186	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85750336~85752901:-
HNSC	cis	rs7720894	0.967	rs13169711	ENSG00000215032.2	GNL3LP1	-3.84	0.000141	0.0186	-0.19	-0.17	Body mass index;	chr5:61364574	chr5:60891935~60893577:-
HNSC	cis	rs12623288	0.51	rs7589861	ENSG00000233845.1	AC093732.1	3.84	0.000141	0.0186	0.37	0.17	Hair morphology;	chr2:46383340	chr2:47035279~47040524:-
HNSC	cis	rs13178541	0.81	rs7379100	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135773790	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs11959707	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135775123	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.745	rs11950987	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135776266	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.745	rs4513690	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135776703	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs11242275	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135777234	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs11242278	ENSG00000250378.1	RP11-119J18.1	-3.84	0.000141	0.0186	-0.24	-0.17	IgG glycosylation;	chr5:135778043	chr5:135812667~135826582:+
HNSC	cis	rs6973609	0.627	rs1003248	ENSG00000271122.1	RP11-379H18.1	3.84	0.000141	0.0186	0.16	0.17	Obesity-related traits;	chr7:35570153	chr7:35695214~35699413:+
HNSC	cis	rs6001482	0.679	rs5750786	ENSG00000253818.1	IGLV1-41	-3.84	0.000141	0.0186	-0.14	-0.17	Diastolic blood pressure;	chr22:22235358	chr22:22404207~22404721:+
HNSC	cis	rs2657294	0.895	rs2002023	ENSG00000233313.2	HMGA1P5	-3.84	0.000141	0.0186	-0.19	-0.17	Pneumonia;	chr10:75088766	chr10:75276376~75276646:-
HNSC	cis	rs2554380	0.843	rs2562779	ENSG00000259570.1	RP11-671M22.4	3.84	0.000141	0.0186	0.24	0.17	Height;	chr15:83722223	chr15:84394512~84395514:+
HNSC	cis	rs7720894	1	rs7709645	ENSG00000215032.2	GNL3LP1	-3.84	0.000141	0.0186	-0.19	-0.17	Body mass index;	chr5:61435631	chr5:60891935~60893577:-
HNSC	cis	rs853679	0.766	rs9368561	ENSG00000226314.6	ZNF192P1	-3.84	0.000141	0.0186	-0.28	-0.17	Depression;	chr6:28200565	chr6:28161781~28169594:+
HNSC	cis	rs35306767	0.855	rs61830931	ENSG00000229869.1	RP11-363N22.2	-3.84	0.000141	0.0186	-0.27	-0.17	Eosinophil percentage of granulocytes;	chr10:886557	chr10:933026~942743:+
HNSC	cis	rs35306767	0.807	rs34527494	ENSG00000229869.1	RP11-363N22.2	-3.84	0.000141	0.0186	-0.27	-0.17	Eosinophil percentage of granulocytes;	chr10:889252	chr10:933026~942743:+
HNSC	cis	rs10829156	0.732	rs10741086	ENSG00000240291.1	RP11-499P20.2	3.84	0.000141	0.0187	0.19	0.17	Sudden cardiac arrest;	chr10:18505027	chr10:18513115~18545651:-
HNSC	cis	rs2310173	0.575	rs719248	ENSG00000281162.1	LINC01127	-3.84	0.000141	0.0187	-0.23	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102007413	chr2:101962056~101987167:+
HNSC	cis	rs9467711	0.72	rs35627490	ENSG00000241549.7	GUSBP2	3.84	0.000141	0.0187	0.29	0.17	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr6:26871484~26956554:-
HNSC	cis	rs7688540	0.8	rs2353599	ENSG00000250892.1	RP11-1365D11.1	-3.84	0.000141	0.0187	-0.26	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:201409~205009:-
HNSC	cis	rs2060793	0.741	rs4757268	ENSG00000251991.1	RNU7-49P	3.84	0.000141	0.0187	0.19	0.17	Vitamin D levels;	chr11:14789216	chr11:14478892~14478953:+
HNSC	cis	rs12793173	0.711	rs61881129	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000141	0.0187	-0.27	-0.17	Cystic fibrosis severity;	chr11:34834716	chr11:34709600~34710161:+
HNSC	cis	rs870825	0.932	rs28702958	ENSG00000254233.1	RP11-242J7.1	3.84	0.000141	0.0187	0.3	0.17	Blood protein levels;	chr4:184654408	chr4:184584093~184625030:-
HNSC	cis	rs7735319	0.966	rs7712171	ENSG00000251281.1	CTD-2066L21.2	3.84	0.000141	0.0187	0.21	0.17	Systolic blood pressure;	chr5:33104850	chr5:33011322~33017607:-
HNSC	cis	rs7005380	0.62	rs7387694	ENSG00000279347.1	RP11-85I17.2	-3.84	0.000141	0.0187	-0.14	-0.17	Interstitial lung disease;	chr8:119885261	chr8:119838736~119840385:-
HNSC	cis	rs6460942	0.597	rs10273045	ENSG00000226690.5	AC005281.1	3.84	0.000141	0.0187	0.27	0.17	Coronary artery disease;	chr7:12479745	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs17544637	ENSG00000226690.5	AC005281.1	3.84	0.000141	0.0187	0.27	0.17	Coronary artery disease;	chr7:12482245	chr7:12496429~12541910:+
HNSC	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	3.84	0.000141	0.0187	0.24	0.17	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
HNSC	cis	rs6840360	0.642	rs7698816	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs7677131	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs7657670	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709828	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2724551	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.667	rs2709829	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151407551~151408835:-
HNSC	cis	rs871012	0.502	rs57064749	ENSG00000251405.2	CTB-109A12.1	-3.84	0.000141	0.0187	-0.2	-0.17	IgG glycosylation;	chr5:157462690	chr5:157362615~157460078:-
HNSC	cis	rs964611	0.872	rs2279366	ENSG00000259488.2	RP11-154J22.1	-3.84	0.000141	0.0187	-0.16	-0.17	Metabolite levels (Pyroglutamine);	chr15:48249830	chr15:48312353~48331856:-
HNSC	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-3.84	0.000141	0.0187	-0.2	-0.17	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-3.84	0.000141	0.0187	-0.2	-0.17	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
HNSC	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-3.84	0.000141	0.0187	-0.2	-0.17	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
HNSC	cis	rs7824557	0.547	rs2736287	ENSG00000255310.2	AF131215.2	-3.84	0.000141	0.0187	-0.16	-0.17	Retinal vascular caliber;	chr8:11370497	chr8:11107788~11109726:-
HNSC	cis	rs73198271	0.96	rs11778970	ENSG00000253893.2	FAM85B	3.84	0.000141	0.0187	0.26	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:8167819~8226614:-
HNSC	cis	rs38055	0.629	rs62357405	ENSG00000247796.2	CTD-2366F13.1	3.84	0.000141	0.0187	0.21	0.17	Acne (severe);	chr5:53199127	chr5:53109842~53115126:+
HNSC	cis	rs2243480	1	rs3885839	ENSG00000229886.1	RP5-1132H15.3	3.84	0.000141	0.0187	0.3	0.17	Diabetic kidney disease;	chr7:65825416	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs3813708	ENSG00000229886.1	RP5-1132H15.3	3.84	0.000141	0.0187	0.3	0.17	Diabetic kidney disease;	chr7:65840645	chr7:66025126~66031544:-
HNSC	cis	rs2243480	1	rs73142122	ENSG00000229886.1	RP5-1132H15.3	3.84	0.000141	0.0187	0.3	0.17	Diabetic kidney disease;	chr7:65846311	chr7:66025126~66031544:-
HNSC	cis	rs2243480	0.901	rs73142137	ENSG00000229886.1	RP5-1132H15.3	3.84	0.000141	0.0187	0.3	0.17	Diabetic kidney disease;	chr7:65878455	chr7:66025126~66031544:-
HNSC	cis	rs1150668	0.764	rs9368565	ENSG00000217862.2	HIST1H4PS1	3.84	0.000141	0.0187	0.18	0.17	Pubertal anthropometrics;	chr6:28377433	chr6:27807075~27807339:+
HNSC	cis	rs1150668	0.796	rs1052215	ENSG00000217862.2	HIST1H4PS1	3.84	0.000141	0.0187	0.18	0.17	Pubertal anthropometrics;	chr6:28380381	chr6:27807075~27807339:+
HNSC	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	3.84	0.000141	0.0187	0.22	0.17	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
HNSC	cis	rs7011507	0.7	rs76497882	ENSG00000253608.1	RP11-770E5.1	-3.84	0.000141	0.0187	-0.33	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48404590	chr8:48551567~48698510:+
HNSC	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-3.84	0.000141	0.0187	-0.23	-0.17	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
HNSC	cis	rs546131	0.642	rs566798	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000141	0.0187	-0.22	-0.17	Lung disease severity in cystic fibrosis;	chr11:34830730	chr11:34709600~34710161:+
HNSC	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-3.84	0.000141	0.0187	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
HNSC	cis	rs7429990	0.864	rs883663	ENSG00000228638.1	FCF1P2	3.84	0.000141	0.0187	0.16	0.17	Educational attainment (years of education);	chr3:47619306	chr3:48290793~48291375:-
HNSC	cis	rs10484434	0.792	rs11961143	ENSG00000272462.2	U91328.19	3.84	0.000141	0.0187	0.22	0.17	HIV-1 viral setpoint;	chr6:26032645	chr6:25992662~26001775:+
HNSC	cis	rs67311347	0.544	rs9864664	ENSG00000280739.1	EIF1B-AS1	3.84	0.000141	0.0187	0.19	0.17	Renal cell carcinoma;	chr3:40294735	chr3:40173145~40309698:-
HNSC	cis	rs71520386	0.898	rs12536144	ENSG00000221740.1	SNORD93	-3.84	0.000141	0.0187	-0.23	-0.17	Fibrinogen levels;	chr7:22782890	chr7:22856613~22856686:+
HNSC	cis	rs67311347	0.544	rs7644181	ENSG00000280739.1	EIF1B-AS1	-3.84	0.000141	0.0187	-0.18	-0.17	Renal cell carcinoma;	chr3:40314174	chr3:40173145~40309698:-
HNSC	cis	rs6601327	0.571	rs35874762	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000141	0.0187	-0.21	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9707882	chr8:9141424~9145435:+
HNSC	cis	rs7299940	0.694	rs12296337	ENSG00000256250.1	RP11-989F5.1	3.84	0.000141	0.0187	0.19	0.17	Panic disorder;	chr12:130891406	chr12:130810606~130812438:+
HNSC	cis	rs41369048	0.669	rs11589654	ENSG00000238078.1	LINC01352	-3.84	0.000141	0.0187	-0.23	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220829255~220832429:+
HNSC	cis	rs1799949	0.602	rs8176257	ENSG00000236383.6	LINC00854	-3.84	0.000141	0.0187	-0.18	-0.17	Menopause (age at onset);	chr17:43064188	chr17:43216941~43305976:-
HNSC	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-3.84	0.000141	0.0187	-0.18	-0.17	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
HNSC	cis	rs2736345	1	rs2736345	ENSG00000255354.1	RP11-148O21.2	-3.84	0.000141	0.0187	-0.16	-0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494976	chr8:11558466~11560020:-
HNSC	cis	rs2412819	0.571	rs28410121	ENSG00000166763.7	STRCP1	-3.84	0.000141	0.0187	-0.24	-0.17	Lung cancer;	chr15:43777831	chr15:43699488~43718184:-
HNSC	cis	rs4835473	0.932	rs6813011	ENSG00000249741.2	RP11-673E1.3	-3.84	0.000141	0.0187	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143914496	chr4:143911514~143912053:-
HNSC	cis	rs7302981	0.719	rs836189	ENSG00000272368.2	RP4-605O3.4	3.84	0.000141	0.0187	0.18	0.17	Systolic blood pressure;	chr12:50067715	chr12:50112197~50165618:+
HNSC	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	3.84	0.000141	0.0187	0.2	0.17	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
HNSC	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	3.84	0.000141	0.0187	0.22	0.17	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
HNSC	cis	rs2274273	0.588	rs17128145	ENSG00000233924.1	AL160471.6	3.84	0.000141	0.0187	0.2	0.17	Protein biomarker;	chr14:55069688	chr14:55004813~55005687:-
HNSC	cis	rs6840360	0.642	rs7678823	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.606	rs2709813	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.606	rs2724550	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709815	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2724580	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.693	rs28622593	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709834	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs6845648	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2724571	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709833	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000141	0.0187	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151407551~151408835:-
HNSC	cis	rs9303542	0.569	rs8065535	ENSG00000272763.1	RP11-357H14.17	3.84	0.000142	0.0187	0.21	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48394053	chr17:48635923~48647023:-
HNSC	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0187	0.29	0.17	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
HNSC	cis	rs62025270	0.688	rs62022939	ENSG00000259762.1	RP11-158M2.4	-3.84	0.000142	0.0187	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85750336~85752901:-
HNSC	cis	rs12658240	1	rs16899276	ENSG00000247572.6	CKMT2-AS1	3.84	0.000142	0.0187	0.2	0.17	Cognitive function;	chr5:81869885	chr5:81204084~81301560:-
HNSC	cis	rs9329221	0.537	rs13282106	ENSG00000255310.2	AF131215.2	3.84	0.000142	0.0187	0.17	0.17	Neuroticism;	chr8:10124390	chr8:11107788~11109726:-
HNSC	cis	rs8062405	1	rs80275162	ENSG00000261089.1	RP11-435I10.3	3.84	0.000142	0.0187	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28413703~28415018:+
HNSC	cis	rs13179617	0.928	rs6865624	ENSG00000215032.2	GNL3LP1	-3.84	0.000142	0.0187	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61510831	chr5:60891935~60893577:-
HNSC	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	3.84	0.000142	0.0187	0.25	0.17	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	3.84	0.000142	0.0187	0.25	0.17	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	3.84	0.000142	0.0187	0.25	0.17	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	3.84	0.000142	0.0187	0.25	0.17	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
HNSC	cis	rs2991971	0.81	rs12738318	ENSG00000234329.1	RP11-767N6.2	3.84	0.000142	0.0187	0.18	0.17	High light scatter reticulocyte count;	chr1:45463917	chr1:45651039~45651826:-
HNSC	cis	rs2013441	1	rs2703804	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20203882	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703806	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20204926	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.965	rs2703808	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20206352	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526483	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20208903	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703810	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20210402	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.965	rs1544421	ENSG00000261033.1	RP11-209D14.2	3.84	0.000142	0.0187	0.2	0.17	Obesity-related traits;	chr17:20210904	chr17:20008051~20009234:-
HNSC	cis	rs6601327	0.571	rs7838571	ENSG00000233609.3	RP11-62H7.2	3.84	0.000142	0.0187	0.17	0.17	Multiple myeloma (hyperdiploidy);	chr8:9790286	chr8:8961200~8979025:+
HNSC	cis	rs11992162	0.56	rs13276386	ENSG00000255495.1	AC145124.2	3.84	0.000142	0.0187	0.2	0.17	Monocyte count;	chr8:11939912	chr8:12194467~12196280:+
HNSC	cis	rs11992162	0.621	rs13268810	ENSG00000255495.1	AC145124.2	3.84	0.000142	0.0187	0.2	0.17	Monocyte count;	chr8:11939921	chr8:12194467~12196280:+
HNSC	cis	rs6095360	0.727	rs13037942	ENSG00000222365.1	SNORD12B	-3.84	0.000142	0.0187	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48909134	chr20:49280319~49280409:+
HNSC	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	3.84	0.000142	0.0187	0.25	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
HNSC	cis	rs4713118	0.824	rs7759217	ENSG00000216901.1	AL022393.7	3.84	0.000142	0.0187	0.22	0.17	Parkinson's disease;	chr6:27762684	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.784	rs9468219	ENSG00000216901.1	AL022393.7	3.84	0.000142	0.0187	0.22	0.17	Parkinson's disease;	chr6:27763976	chr6:28176188~28176674:+
HNSC	cis	rs6500395	0.775	rs7198145	ENSG00000261267.1	RP11-44I10.3	-3.84	0.000142	0.0187	-0.21	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48632589	chr16:48559661~48587403:+
HNSC	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-3.84	0.000142	0.0187	-0.15	-0.17	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
HNSC	cis	rs2518049	0.852	rs6601898	ENSG00000224034.1	RP11-445P17.8	3.84	0.000142	0.0187	0.24	0.17	Metabolic traits;	chr10:5076039	chr10:5266033~5271236:-
HNSC	cis	rs870825	1	rs9995633	ENSG00000254233.1	RP11-242J7.1	3.84	0.000142	0.0188	0.29	0.17	Blood protein levels;	chr4:184663287	chr4:184584093~184625030:-
HNSC	cis	rs67981189	0.613	rs4366661	ENSG00000274818.1	RP1-292L20.3	-3.84	0.000142	0.0188	-0.19	-0.17	Schizophrenia;	chr14:70985599	chr14:70906657~70907111:-
HNSC	cis	rs4936099	0.897	rs11222084	ENSG00000255262.3	TCEB2P2	-3.84	0.000142	0.0188	-0.2	-0.17	Optic cup area;Vertical cup-disc ratio;	chr11:130403335	chr11:130032866~130033220:-
HNSC	cis	rs863750	0.687	rs825483	ENSG00000275389.1	RP11-214K3.24	3.84	0.000142	0.0188	0.24	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091431	chr12:124085761~124088598:+
HNSC	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	3.84	0.000142	0.0188	0.4	0.17	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
HNSC	cis	rs6504108	0.874	rs4794447	ENSG00000264920.1	RP11-6N17.4	-3.84	0.000142	0.0188	-0.23	-0.17	Body mass index;	chr17:48103362	chr17:47891255~47895812:-
HNSC	cis	rs9907295	0.818	rs4251702	ENSG00000270977.1	AC015849.16	3.84	0.000142	0.0188	0.28	0.17	Fibroblast growth factor basic levels;	chr17:35807933	chr17:35893707~35911023:-
HNSC	cis	rs11711311	1	rs2603792	ENSG00000241529.3	RN7SL767P	-3.84	0.000142	0.0188	-0.22	-0.17	IgG glycosylation;	chr3:113790340	chr3:113632704~113632998:+
HNSC	cis	rs6471393	0.964	rs2914959	ENSG00000279331.1	RBM12B-AS1	-3.84	0.000142	0.0188	-0.18	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93740121~93740773:+
HNSC	cis	rs13325613	0.834	rs35960950	ENSG00000223552.1	RP11-24F11.2	-3.84	0.000142	0.0188	-0.26	-0.17	Monocyte count;	chr3:46158188	chr3:46364955~46407059:-
HNSC	cis	rs13098911	0.51	rs75549687	ENSG00000223552.1	RP11-24F11.2	-3.84	0.000142	0.0188	-0.26	-0.17	Celiac disease;	chr3:46159434	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34198655	ENSG00000223552.1	RP11-24F11.2	-3.84	0.000142	0.0188	-0.26	-0.17	Monocyte count;	chr3:46173615	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34013035	ENSG00000223552.1	RP11-24F11.2	-3.84	0.000142	0.0188	-0.26	-0.17	Monocyte count;	chr3:46179190	chr3:46364955~46407059:-
HNSC	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	3.84	0.000142	0.0188	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
HNSC	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	3.84	0.000142	0.0188	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
HNSC	cis	rs62025270	0.576	rs62022947	ENSG00000259762.1	RP11-158M2.4	-3.84	0.000142	0.0188	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85750336~85752901:-
HNSC	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-3.84	0.000142	0.0188	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
HNSC	cis	rs4840086	0.935	rs9403057	ENSG00000219755.1	RP1-199J3.5	3.84	0.000142	0.0188	0.22	0.17	Menarche (age at onset);	chr6:99756625	chr6:99575712~99576456:+
HNSC	cis	rs1553477	0.64	rs10072767	ENSG00000272123.1	CTD-2366F13.2	3.84	0.000142	0.0188	0.2	0.17	Monobrow;	chr5:53822988	chr5:53089016~53089468:-
HNSC	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	3.84	0.000142	0.0188	0.2	0.17	Height;	chr14:74458694	chr14:74471930~74472360:-
HNSC	cis	rs7615952	0.599	rs7652883	ENSG00000241278.1	ENPP7P4	-3.84	0.000142	0.0188	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125989134	chr3:125848223~125909372:+
HNSC	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	3.84	0.000142	0.0188	0.24	0.17	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
HNSC	cis	rs4840086	0.967	rs4240582	ENSG00000219755.1	RP1-199J3.5	3.84	0.000142	0.0188	0.22	0.17	Menarche (age at onset);	chr6:99753713	chr6:99575712~99576456:+
HNSC	cis	rs4840086	0.967	rs4240583	ENSG00000219755.1	RP1-199J3.5	3.84	0.000142	0.0188	0.22	0.17	Menarche (age at onset);	chr6:99753719	chr6:99575712~99576456:+
HNSC	cis	rs3764400	0.567	rs2229369	ENSG00000228782.6	CTD-2026D20.3	-3.84	0.000142	0.0188	-0.26	-0.17	Body mass index;	chr17:48058771	chr17:47450568~47492492:-
HNSC	cis	rs6490294	0.8	rs78783055	ENSG00000226469.1	ADAM1B	3.84	0.000142	0.0188	0.21	0.17	Mean platelet volume;	chr12:111795691	chr12:111927018~111929017:+
HNSC	cis	rs7189233	1	rs16952251	ENSG00000279344.1	RP11-44F14.7	3.84	0.000142	0.0188	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53449226	chr16:53478957~53481550:-
HNSC	cis	rs5758511	0.514	rs4453786	ENSG00000205702.9	CYP2D7	3.84	0.000142	0.0188	0.16	0.17	Birth weight;	chr22:42167302	chr22:42140203~42144577:-
HNSC	cis	rs7714670	0.736	rs2973548	ENSG00000184084.7	CTD-2372A4.1	-3.84	0.000142	0.0188	-0.2	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73795403	chr5:73803296~73803599:-
HNSC	cis	rs4900538	0.963	rs1190553	ENSG00000272533.1	SNORA28	3.84	0.000142	0.0188	0.18	0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102448994	chr14:103337849~103337974:+
HNSC	cis	rs73201462	1	rs2955089	ENSG00000231305.3	RP11-723O4.2	3.84	0.000142	0.0188	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250487	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955090	ENSG00000231305.3	RP11-723O4.2	3.84	0.000142	0.0188	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250528	chr3:128861313~128871540:-
HNSC	cis	rs73081554	0.611	rs4681851	ENSG00000273493.1	RP11-80H18.4	-3.84	0.000142	0.0188	-0.3	-0.17	Rheumatoid arthritis;	chr3:58410164	chr3:58329965~58330118:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	3.84	0.000142	0.0188	0.2	0.17	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
HNSC	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.29	0.17	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
HNSC	cis	rs10078	0.571	rs890977	ENSG00000225138.6	CTD-2228K2.7	3.84	0.000142	0.0188	0.31	0.17	Fat distribution (HIV);	chr5:476795	chr5:473236~480884:+
HNSC	cis	rs9313772	0.775	rs13153555	ENSG00000254350.1	RP11-542A14.1	-3.84	0.000142	0.0188	-0.19	-0.17	Blood pressure;	chr5:158406985	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.775	rs4704938	ENSG00000254350.1	RP11-542A14.1	-3.84	0.000142	0.0188	-0.19	-0.17	Blood pressure;	chr5:158407623	chr5:158424585~158452758:+
HNSC	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	3.84	0.000142	0.0188	0.3	0.17	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
HNSC	cis	rs7011507	0.7	rs72639005	ENSG00000253608.1	RP11-770E5.1	-3.84	0.000142	0.0188	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48409401	chr8:48551567~48698510:+
HNSC	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	3.84	0.000142	0.0188	0.15	0.17	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
HNSC	cis	rs4427176	0.507	rs12680578	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000142	0.0188	-0.24	-0.17	Mosquito bite size;	chr8:9741106	chr8:9141424~9145435:+
HNSC	cis	rs72827839	0.779	rs72827858	ENSG00000210741.1	MIR196A1	-3.84	0.000142	0.0188	-0.22	-0.17	Ease of getting up in the morning;	chr17:48396999	chr17:48632490~48632559:-
HNSC	cis	rs1009077	0.514	rs62319578	ENSG00000245958.5	RP11-33B1.1	3.84	0.000142	0.0188	0.19	0.17	Endometriosis;	chr4:119487266	chr4:119454791~119552025:+
HNSC	cis	rs2865126	0.61	rs6505587	ENSG00000264714.1	RP11-21G15.1	-3.84	0.000142	0.0188	-0.22	-0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10734807	chr18:10724619~10728539:+
HNSC	cis	rs1620921	0.625	rs67391812	ENSG00000233342.1	RP11-235G24.3	-3.84	0.000142	0.0188	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160852202	chr6:160926369~160927162:+
HNSC	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	3.84	0.000142	0.0188	0.21	0.17	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	3.84	0.000142	0.0188	0.21	0.17	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
HNSC	cis	rs7688540	0.713	rs12511388	ENSG00000211553.1	AC253576.2	-3.84	0.000142	0.0188	-0.26	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:136461~136568:+
HNSC	cis	rs4947019	0.609	rs752260	ENSG00000260273.1	RP11-425D10.10	3.84	0.000142	0.0188	0.48	0.17	Hematological parameters;	chr6:109449605	chr6:109382795~109383666:+
HNSC	cis	rs7429990	0.965	rs184388	ENSG00000228638.1	FCF1P2	-3.84	0.000142	0.0188	-0.16	-0.17	Educational attainment (years of education);	chr3:47898136	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.965	rs319696	ENSG00000228638.1	FCF1P2	-3.84	0.000142	0.0188	-0.16	-0.17	Educational attainment (years of education);	chr3:47902371	chr3:48290793~48291375:-
HNSC	cis	rs870825	0.616	rs12498890	ENSG00000254233.1	RP11-242J7.1	-3.84	0.000142	0.0188	-0.26	-0.17	Blood protein levels;	chr4:184714942	chr4:184584093~184625030:-
HNSC	cis	rs12935418	0.672	rs9934957	ENSG00000278985.1	RP11-303E16.9	-3.84	0.000142	0.0188	-0.18	-0.17	Mean corpuscular volume;	chr16:81016078	chr16:80982319~80984094:-
HNSC	cis	rs453301	0.682	rs2929308	ENSG00000253981.4	ALG1L13P	-3.84	0.000142	0.0188	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9226611	chr8:8236003~8244667:-
HNSC	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-3.84	0.000142	0.0188	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
HNSC	cis	rs2337406	0.85	rs1858678	ENSG00000211972.2	IGHV3-66	3.84	0.000142	0.0188	0.18	0.17	Alzheimer's disease (late onset);	chr14:106706790	chr14:106675017~106675544:-
HNSC	cis	rs4648045	0.501	rs3774964	ENSG00000230069.3	LRRC37A15P	-3.84	0.000142	0.0188	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102598330	chr4:102727274~102730721:-
HNSC	cis	rs6787172	0.622	rs3845981	ENSG00000272087.1	RP11-379F4.7	3.84	0.000143	0.0188	0.18	0.17	Subjective well-being;	chr3:158364717	chr3:158693120~158693768:-
HNSC	cis	rs2836974	0.644	rs11088472	ENSG00000255568.3	BRWD1-AS2	-3.84	0.000143	0.0188	-0.15	-0.17	Cognitive function;	chr21:39327450	chr21:39313935~39314962:+
HNSC	cis	rs875971	0.66	rs801193	ENSG00000273142.1	RP11-458F8.4	3.84	0.000143	0.0188	0.14	0.17	Aortic root size;	chr7:66565625	chr7:66902857~66906297:+
HNSC	cis	rs1476670	0.545	rs2158822	ENSG00000230615.5	RP5-1198O20.4	3.84	0.000143	0.0188	0.2	0.17	Eotaxin levels;	chr1:44053775	chr1:44030443~44115913:+
HNSC	cis	rs35306767	0.761	rs12359796	ENSG00000229869.1	RP11-363N22.2	-3.84	0.000143	0.0188	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:975539	chr10:933026~942743:+
HNSC	cis	rs35306767	0.761	rs12770173	ENSG00000229869.1	RP11-363N22.2	-3.84	0.000143	0.0188	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:981168	chr10:933026~942743:+
HNSC	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	3.84	0.000143	0.0188	0.15	0.17	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000106610.13	STAG3L4	-3.84	0.000143	0.0188	-0.22	-0.17	Aortic root size;	chr7:66713338	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000106610.13	STAG3L4	-3.84	0.000143	0.0188	-0.22	-0.17	Aortic root size;	chr7:66716086	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000106610.13	STAG3L4	-3.84	0.000143	0.0188	-0.22	-0.17	Aortic root size;	chr7:66724256	chr7:67302621~67321526:+
HNSC	cis	rs12701220	0.901	rs12701710	ENSG00000224079.1	AC091729.7	-3.84	0.000143	0.0188	-0.25	-0.17	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1074450~1078036:+
HNSC	cis	rs9611565	0.649	rs139553	ENSG00000235513.1	RP4-756G23.5	-3.84	0.000143	0.0188	-0.2	-0.17	Vitiligo;	chr22:41791195	chr22:41209122~41217627:-
HNSC	cis	rs10540	1	rs61876336	ENSG00000279672.1	CMB9-55F22.1	3.84	0.000143	0.0188	0.3	0.17	Body mass index;	chr11:489537	chr11:779617~780755:+
HNSC	cis	rs73173548	0.528	rs34857793	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000143	0.0188	0.19	0.17	Macular telangiectasia type 2;	chr5:88467749	chr5:88268895~88436685:+
HNSC	cis	rs11610143	0.53	rs10783481	ENSG00000135477.10	KRT87P	3.84	0.000143	0.0188	0.19	0.17	Lung cancer;Adenocarcinoma;	chr12:51935985	chr12:52250466~52258867:-
HNSC	cis	rs3096299	0.685	rs4785676	ENSG00000261118.1	RP11-104N10.1	3.84	0.000143	0.0188	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89492017~89504460:-
HNSC	cis	rs11711311	1	rs62268168	ENSG00000241529.3	RN7SL767P	-3.84	0.000143	0.0189	-0.22	-0.17	IgG glycosylation;	chr3:113770600	chr3:113632704~113632998:+
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000219891.2	ZSCAN12P1	3.84	0.000143	0.0189	0.3	0.17	Depression;	chr6:28129415	chr6:28091154~28093664:+
HNSC	cis	rs2412819	0.571	rs12900924	ENSG00000166763.7	STRCP1	3.84	0.000143	0.0189	0.26	0.17	Lung cancer;	chr15:43737329	chr15:43699488~43718184:-
HNSC	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-3.84	0.000143	0.0189	-0.22	-0.17	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
HNSC	cis	rs7927592	0.763	rs7129248	ENSG00000255031.4	RP11-802E16.3	3.83	0.000143	0.0189	0.14	0.17	Total body bone mineral density;	chr11:68495808	chr11:68050740~68053762:+
HNSC	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-3.83	0.000143	0.0189	-0.2	-0.17	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
HNSC	cis	rs6840360	0.681	rs9968292	ENSG00000251611.1	RP11-610P16.1	-3.83	0.000143	0.0189	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151407551~151408835:-
HNSC	cis	rs10783487	1	rs10747626	ENSG00000257542.4	OR7E47P	-3.83	0.000143	0.0189	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52066640	chr12:52079696~52108261:+
HNSC	cis	rs7558911	1	rs12693927	ENSG00000183308.6	AC005037.3	3.83	0.000143	0.0189	0.21	0.17	Chronic lymphocytic leukemia;	chr2:201161992	chr2:200963263~201009102:+
HNSC	cis	rs6993244	1	rs6993244	ENSG00000253981.4	ALG1L13P	3.83	0.000143	0.0189	0.2	0.17	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8236003~8244667:-
HNSC	cis	rs2548724	0.947	rs1593077	ENSG00000250682.4	LINC00491	-3.83	0.000143	0.0189	-0.24	-0.17	Type 2 diabetes;	chr5:102267021	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.853	rs3096194	ENSG00000250682.4	LINC00491	-3.83	0.000143	0.0189	-0.24	-0.17	Type 2 diabetes;	chr5:102267707	chr5:102609156~102671559:-
HNSC	cis	rs2439831	1	rs2467743	ENSG00000275601.1	AC011330.13	-3.83	0.000143	0.0189	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43458148	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2245176	ENSG00000275601.1	AC011330.13	-3.83	0.000143	0.0189	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43458564	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs2264876	ENSG00000275601.1	AC011330.13	-3.83	0.000143	0.0189	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43465221	chr15:43642389~43643023:-
HNSC	cis	rs9925964	0.804	rs4889606	ENSG00000232748.3	RP11-196G11.6	-3.83	0.000143	0.0189	-0.23	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:31056460~31062803:+
HNSC	cis	rs478304	0.651	rs11227279	ENSG00000255120.4	OVOL1-AS1	-3.83	0.000143	0.0189	-0.18	-0.17	Acne (severe);	chr11:65727740	chr11:65789051~65790868:-
HNSC	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	3.83	0.000143	0.0189	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
HNSC	cis	rs9611565	0.659	rs9607815	ENSG00000235513.1	RP4-756G23.5	3.83	0.000143	0.0189	0.21	0.17	Vitiligo;	chr22:41554667	chr22:41209122~41217627:-
HNSC	cis	rs7829975	0.623	rs10087493	ENSG00000233609.3	RP11-62H7.2	-3.83	0.000143	0.0189	-0.17	-0.17	Mood instability;	chr8:8516047	chr8:8961200~8979025:+
HNSC	cis	rs3213758	0.541	rs7192060	ENSG00000275191.1	RP11-36I17.2	3.83	0.000143	0.0189	0.27	0.17	Vitiligo (non-segmental);	chr16:53658287	chr16:53628256~53628816:-
HNSC	cis	rs1790761	0.505	rs7103713	ENSG00000184224.3	C11orf72	-3.83	0.000143	0.0189	-0.22	-0.17	Mean corpuscular volume;	chr11:67570771	chr11:67602880~67606706:-
HNSC	cis	rs73191547	0.501	rs6986885	ENSG00000269918.1	AF131215.9	3.83	0.000143	0.0189	0.17	0.17	Schizophrenia;	chr8:10120961	chr8:11104691~11106704:-
HNSC	cis	rs9313772	0.775	rs6891063	ENSG00000254350.1	RP11-542A14.1	-3.83	0.000143	0.0189	-0.19	-0.17	Blood pressure;	chr5:158400378	chr5:158424585~158452758:+
HNSC	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	3.83	0.000143	0.0189	0.19	0.17	QT interval;	chr12:29262863	chr12:29280418~29317848:-
HNSC	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	3.83	0.000143	0.0189	0.19	0.17	QT interval;	chr12:29264843	chr12:29280418~29317848:-
HNSC	cis	rs67981189	0.634	rs2526875	ENSG00000274818.1	RP1-292L20.3	-3.83	0.000143	0.0189	-0.19	-0.17	Schizophrenia;	chr14:70911643	chr14:70906657~70907111:-
HNSC	cis	rs6710503	0.632	rs55797001	ENSG00000271936.1	RP11-443B20.1	-3.83	0.000143	0.0189	-0.22	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24757713	chr2:24825610~24826717:+
HNSC	cis	rs6964587	0.967	rs6465353	ENSG00000188693.7	CYP51A1-AS1	3.83	0.000143	0.0189	0.18	0.17	Breast cancer;	chr7:92150657	chr7:92134604~92180725:+
HNSC	cis	rs9611565	0.5	rs2011053	ENSG00000233903.2	Z83851.4	3.83	0.000143	0.0189	0.24	0.17	Vitiligo;	chr22:41725274	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.649	rs738422	ENSG00000233903.2	Z83851.4	3.83	0.000143	0.0189	0.24	0.17	Vitiligo;	chr22:41727395	chr22:42276355~42277052:+
HNSC	cis	rs9650657	0.529	rs6601521	ENSG00000269918.1	AF131215.9	-3.83	0.000143	0.0189	-0.17	-0.17	Neuroticism;	chr8:10771437	chr8:11104691~11106704:-
HNSC	cis	rs1925953	0.711	rs4508052	ENSG00000233589.1	RP4-694A7.2	3.83	0.000143	0.0189	0.22	0.17	Vertical cup-disc ratio;	chr1:68366431	chr1:68479129~68483539:+
HNSC	cis	rs1279094	0.965	rs372412	ENSG00000270372.1	RP11-109M17.2	3.83	0.000143	0.0189	0.19	0.17	Systemic juvenile idiopathic arthritis;	chr9:11707012	chr9:10948372~10948481:-
HNSC	cis	rs6180	0.622	rs1423650	ENSG00000271788.1	CTD-2201E18.5	-3.83	0.000143	0.0189	-0.17	-0.17	Height;	chr5:42854626	chr5:43006733~43007543:-
HNSC	cis	rs7688540	0.8	rs11731285	ENSG00000250892.1	RP11-1365D11.1	-3.83	0.000143	0.0189	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:201409~205009:-
HNSC	cis	rs12893668	0.703	rs34896432	ENSG00000269958.1	RP11-73M18.8	3.83	0.000143	0.0189	0.17	0.17	Reticulocyte count;	chr14:103561658	chr14:103696353~103697163:+
HNSC	cis	rs6545883	0.894	rs778144	ENSG00000271889.1	RP11-493E12.1	-3.83	0.000144	0.0189	-0.2	-0.17	Tuberculosis;	chr2:61355993	chr2:61151433~61162105:-
HNSC	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-3.83	0.000144	0.0189	-0.17	-0.17	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
HNSC	cis	rs8067545	0.693	rs8066150	ENSG00000266126.1	RP11-209D14.4	3.83	0.000144	0.0189	0.2	0.17	Schizophrenia;	chr17:19983635	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.72	rs11204419	ENSG00000266126.1	RP11-209D14.4	3.83	0.000144	0.0189	0.2	0.17	Schizophrenia;	chr17:19985684	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.72	rs11204420	ENSG00000266126.1	RP11-209D14.4	3.83	0.000144	0.0189	0.2	0.17	Schizophrenia;	chr17:19985707	chr17:19929372~19929737:-
HNSC	cis	rs886774	0.834	rs10215427	ENSG00000273055.1	CTB-13F3.1	3.83	0.000144	0.0189	0.17	0.17	Ulcerative colitis;	chr7:107857797	chr7:107942116~107942740:+
HNSC	cis	rs3758785	0.679	rs11819857	ENSG00000255893.1	RP11-685N10.1	-3.83	0.000144	0.0189	-0.28	-0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94495070	chr11:94472908~94473570:-
HNSC	cis	rs7688540	0.723	rs80316648	ENSG00000211553.1	AC253576.2	-3.83	0.000144	0.0189	-0.26	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:136461~136568:+
HNSC	cis	rs868153	0.625	rs6569252	ENSG00000275339.1	RP3-425C14.6	3.83	0.000144	0.019	0.19	0.17	Vertical cup-disc ratio;	chr6:122199027	chr6:122454358~122454612:+
HNSC	cis	rs172166	0.61	rs156737	ENSG00000217862.2	HIST1H4PS1	-3.83	0.000144	0.019	-0.18	-0.17	Cardiac Troponin-T levels;	chr6:27927435	chr6:27807075~27807339:+
HNSC	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-3.83	0.000144	0.019	-0.2	-0.17	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
HNSC	cis	rs9896933	0.775	rs79299098	ENSG00000262663.1	RP11-497H17.1	3.83	0.000144	0.019	0.23	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82873068	chr17:82918282~82918785:+
HNSC	cis	rs440932	1	rs365309	ENSG00000254153.1	CTA-398F10.2	-3.83	0.000144	0.019	-0.2	-0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8456909~8461337:-
HNSC	cis	rs6710503	1	rs6710503	ENSG00000271936.1	RP11-443B20.1	-3.83	0.000144	0.019	-0.2	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24748307	chr2:24825610~24826717:+
HNSC	cis	rs6787172	0.622	rs2222326	ENSG00000272087.1	RP11-379F4.7	3.83	0.000144	0.019	0.18	0.17	Subjective well-being;	chr3:158350743	chr3:158693120~158693768:-
HNSC	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	3.83	0.000144	0.019	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	3.83	0.000144	0.019	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
HNSC	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-3.83	0.000144	0.019	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-3.83	0.000144	0.019	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
HNSC	cis	rs2836974	0.602	rs2037925	ENSG00000255568.3	BRWD1-AS2	-3.83	0.000144	0.019	-0.15	-0.17	Cognitive function;	chr21:39328005	chr21:39313935~39314962:+
HNSC	cis	rs11951515	0.738	rs10805674	ENSG00000249286.1	CTD-2210P15.2	3.83	0.000144	0.019	0.18	0.17	Metabolite levels  (X-11787);	chr5:43349758	chr5:43586918~43588223:-
HNSC	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	3.83	0.000144	0.019	0.25	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
HNSC	cis	rs4853525	0.59	rs13414554	ENSG00000228509.4	AC006460.2	3.83	0.000144	0.019	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929215	chr2:190676944~190708716:-
HNSC	cis	rs9880211	0.613	rs13079205	ENSG00000239213.4	NCK1-AS1	3.83	0.000144	0.019	0.17	0.17	Height;Body mass index;	chr3:136081851	chr3:136841726~136862054:-
HNSC	cis	rs10504130	1	rs763550	ENSG00000272024.1	RP11-546K22.3	3.83	0.000144	0.019	0.29	0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51802905	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs58561048	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51789982	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs11778849	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51795694	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.932	rs76877865	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51803967	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.932	rs80143499	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51808915	chr8:51950284~51950690:+
HNSC	cis	rs10504130	0.932	rs79612913	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51808916	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75257860	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51811887	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs79299366	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51812800	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs77712895	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000144	0.019	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51821121	chr8:51950284~51950690:+
HNSC	cis	rs2548724	0.812	rs261101	ENSG00000250682.4	LINC00491	3.83	0.000144	0.019	0.22	0.17	Type 2 diabetes;	chr5:102257105	chr5:102609156~102671559:-
HNSC	cis	rs9487051	0.799	rs351725	ENSG00000243587.6	C6orf183	-3.83	0.000144	0.019	-0.17	-0.17	Reticulocyte fraction of red cells;	chr6:109226736	chr6:109165833~109271014:+
HNSC	cis	rs4449834	0.816	rs7838426	ENSG00000254432.1	RP11-33I11.2	-3.83	0.000144	0.019	-0.22	-0.17	Sum eosinophil basophil counts;	chr8:60755879	chr8:60808735~60809606:-
HNSC	cis	rs228769	1	rs12937692	ENSG00000267080.4	ASB16-AS1	-3.83	0.000144	0.019	-0.15	-0.17	Bone mineral density (hip);Bone mineral density (spine);	chr17:44179062	chr17:44175973~44186717:-
HNSC	cis	rs1799949	0.965	rs1842147	ENSG00000236383.6	LINC00854	-3.83	0.000144	0.019	-0.17	-0.17	Menopause (age at onset);	chr17:43357824	chr17:43216941~43305976:-
HNSC	cis	rs9652601	0.779	rs7203793	ENSG00000274038.1	RP11-66H6.4	-3.83	0.000144	0.019	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11088277	chr16:11056556~11057034:+
HNSC	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	3.83	0.000144	0.019	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
HNSC	cis	rs7131987	0.565	rs7968883	ENSG00000257176.2	RP11-996F15.2	3.83	0.000144	0.019	0.18	0.17	QT interval;	chr12:29241258	chr12:29280418~29317848:-
HNSC	cis	rs7615952	0.688	rs12638240	ENSG00000241278.1	ENPP7P4	-3.83	0.000144	0.019	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:125822395	chr3:125848223~125909372:+
HNSC	cis	rs9329221	0.527	rs4841351	ENSG00000255310.2	AF131215.2	-3.83	0.000144	0.019	-0.17	-0.17	Neuroticism;	chr8:10469857	chr8:11107788~11109726:-
HNSC	cis	rs9500256	1	rs9500256	ENSG00000225096.1	XXbac-BPG55C20.7	-3.83	0.000144	0.019	-0.19	-0.17	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57965630~57972218:+
HNSC	cis	rs12623288	0.51	rs17035085	ENSG00000233845.1	AC093732.1	3.83	0.000144	0.019	0.43	0.17	Hair morphology;	chr2:46378148	chr2:47035279~47040524:-
HNSC	cis	rs941408	0.515	rs759067	ENSG00000261342.1	AC006538.1	3.83	0.000144	0.019	0.25	0.17	Total cholesterol levels;	chr19:2775670	chr19:2727743~2729327:-
HNSC	cis	rs7572733	0.806	rs10169453	ENSG00000222017.1	AC011997.1	3.83	0.000144	0.019	0.21	0.17	Dermatomyositis;	chr2:197970488	chr2:197693106~197774823:+
HNSC	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000144	0.019	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000144	0.019	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000144	0.019	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
HNSC	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000144	0.019	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
HNSC	cis	rs7429990	0.965	rs796566	ENSG00000228638.1	FCF1P2	-3.83	0.000144	0.019	-0.16	-0.17	Educational attainment (years of education);	chr3:47896864	chr3:48290793~48291375:-
HNSC	cis	rs240993	0.812	rs6937734	ENSG00000230177.1	RP5-1112D6.4	3.83	0.000144	0.019	0.22	0.17	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111277932~111278742:+
HNSC	cis	rs1665050	0.534	rs11855896	ENSG00000277144.1	RP11-59H7.4	-3.83	0.000144	0.019	-0.22	-0.17	Atopic dermatitis;	chr15:58942447	chr15:59115547~59116089:-
HNSC	cis	rs1665050	0.534	rs8028502	ENSG00000277144.1	RP11-59H7.4	-3.83	0.000144	0.019	-0.22	-0.17	Atopic dermatitis;	chr15:58943677	chr15:59115547~59116089:-
HNSC	cis	rs11098499	0.532	rs4504231	ENSG00000250412.1	KLHL2P1	3.83	0.000144	0.019	0.23	0.17	Corneal astigmatism;	chr4:119665736	chr4:119334329~119378233:+
HNSC	cis	rs73201462	0.908	rs2955092	ENSG00000231305.3	RP11-723O4.2	3.83	0.000144	0.019	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128253685	chr3:128861313~128871540:-
HNSC	cis	rs4820294	0.669	rs12628135	ENSG00000225867.1	RP5-1177I5.3	-3.83	0.000144	0.019	-0.19	-0.17	Fat distribution (HIV);	chr22:37669648	chr22:37550026~37551735:+
HNSC	cis	rs9313772	0.722	rs9313775	ENSG00000254350.1	RP11-542A14.1	-3.83	0.000144	0.019	-0.18	-0.17	Blood pressure;	chr5:158429768	chr5:158424585~158452758:+
HNSC	cis	rs67072384	1	rs11235577	ENSG00000213365.3	AP000593.6	3.83	0.000144	0.019	0.29	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72740335	chr11:72280151~72281178:+
HNSC	cis	rs17407555	0.821	rs17198197	ENSG00000250413.1	RP11-448G15.1	-3.83	0.000144	0.019	-0.27	-0.17	Schizophrenia (age at onset);	chr4:10137533	chr4:10006482~10009725:+
HNSC	cis	rs10849893	0.538	rs7961855	ENSG00000258435.1	RP11-711D18.2	-3.83	0.000144	0.019	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121392140	chr12:121391962~121399859:+
HNSC	cis	rs1602565	1	rs12366025	ENSG00000255450.1	CTD-2063L20.1	-3.83	0.000144	0.019	-0.29	-0.17	Schizophrenia;	chr11:29127343	chr11:29275655~29276565:+
HNSC	cis	rs7558911	0.899	rs13013222	ENSG00000183308.6	AC005037.3	3.83	0.000144	0.019	0.21	0.17	Chronic lymphocytic leukemia;	chr2:201167461	chr2:200963263~201009102:+
HNSC	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-3.83	0.000144	0.019	-0.37	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
HNSC	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	3.83	0.000144	0.019	0.16	0.17	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
HNSC	cis	rs4835473	0.778	rs2622380	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143814571	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs35792820	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143814806	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.864	rs62337300	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143815897	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs7697498	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143816854	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs7656455	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143817005	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.9	rs13133239	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143818894	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.9	rs13106488	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143818969	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.868	rs13105118	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143819077	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs35271123	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143819629	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs1383443	ENSG00000249741.2	RP11-673E1.3	3.83	0.000144	0.019	0.19	0.17	Immature fraction of reticulocytes;	chr4:143819940	chr4:143911514~143912053:-
HNSC	cis	rs727563	0.58	rs202626	ENSG00000235513.1	RP4-756G23.5	-3.83	0.000144	0.019	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.532	rs202627	ENSG00000235513.1	RP4-756G23.5	-3.83	0.000144	0.019	-0.2	-0.17	Vitiligo;	chr22:41451363	chr22:41209122~41217627:-
HNSC	cis	rs202629	1	rs202629	ENSG00000235513.1	RP4-756G23.5	-3.83	0.000144	0.019	-0.2	-0.17	Cannabis dependence symptom count;	chr22:41453971	chr22:41209122~41217627:-
HNSC	cis	rs793571	0.611	rs1446240	ENSG00000245975.2	RP11-30K9.6	3.83	0.000144	0.019	0.28	0.17	Schizophrenia;	chr15:59004292	chr15:58768072~58770974:-
HNSC	cis	rs36093844	0.527	rs72965166	ENSG00000279742.1	RP11-700A24.1	-3.83	0.000145	0.019	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86056758	chr11:85852557~85854943:-
HNSC	cis	rs6710503	0.632	rs62144583	ENSG00000271936.1	RP11-443B20.1	-3.83	0.000145	0.019	-0.23	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24780609	chr2:24825610~24826717:+
HNSC	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	3.83	0.000145	0.019	0.29	0.17	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
HNSC	cis	rs11668609	1	rs4452076	ENSG00000268442.1	CTD-2027I19.2	3.83	0.000145	0.019	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:24162370~24163425:-
HNSC	cis	rs13256369	1	rs12550762	ENSG00000173295.6	FAM86B3P	3.83	0.000145	0.0191	0.22	0.17	Obesity-related traits;	chr8:8719025	chr8:8228595~8244865:+
HNSC	cis	rs2865126	0.61	rs11873643	ENSG00000264714.1	RP11-21G15.1	-3.83	0.000145	0.0191	-0.23	-0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10735750	chr18:10724619~10728539:+
HNSC	cis	rs2439831	0.867	rs2614811	ENSG00000201136.1	RNU6-353P	-3.83	0.000145	0.0191	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43621289	chr15:43702363~43702470:+
HNSC	cis	rs1737890	0.673	rs6119231	ENSG00000224628.2	RP5-854E16.2	-3.83	0.000145	0.0191	-0.24	-0.17	Chronic obstructive pulmonary disease;	chr20:32276789	chr20:31285317~31286835:-
HNSC	cis	rs9813712	0.83	rs9755184	ENSG00000228252.7	COL6A4P2	-3.83	0.000145	0.0191	-0.19	-0.17	Response to amphetamines;	chr3:130262278	chr3:130212823~130273806:+
HNSC	cis	rs17489649	0.915	rs3797699	ENSG00000271849.1	CTC-332L22.1	3.83	0.000145	0.0191	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109714733	chr5:109687802~109688329:-
HNSC	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000145	0.0191	0.29	0.17	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
HNSC	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	3.83	0.000145	0.0191	0.19	0.17	QT interval;	chr12:29252691	chr12:29280418~29317848:-
HNSC	cis	rs11657639	0.507	rs4794674	ENSG00000228782.6	CTD-2026D20.3	-3.83	0.000145	0.0191	-0.17	-0.17	Red blood cell count;	chr17:48439117	chr17:47450568~47492492:-
HNSC	cis	rs2486288	0.656	rs7167146	ENSG00000259479.5	SORD2P	3.83	0.000145	0.0191	0.21	0.17	Glomerular filtration rate;	chr15:45279188	chr15:44826371~44884694:-
HNSC	cis	rs6688613	0.685	rs742048	ENSG00000215834.7	FMO9P	-3.83	0.000145	0.0191	-0.24	-0.17	Refractive astigmatism;	chr1:166940908	chr1:166603675~166631400:+
HNSC	cis	rs67311347	1	rs6599102	ENSG00000280739.1	EIF1B-AS1	3.83	0.000145	0.0191	0.19	0.17	Renal cell carcinoma;	chr3:40426915	chr3:40173145~40309698:-
HNSC	cis	rs4873772	0.535	rs12547497	ENSG00000253330.1	RP11-697N18.3	-3.83	0.000145	0.0191	-0.23	-0.17	Lobe attachment (rater-scored or self-reported);	chr8:47466818	chr8:47511034~47512141:-
HNSC	cis	rs17489649	1	rs2269199	ENSG00000271849.1	CTC-332L22.1	3.83	0.000145	0.0191	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109701831	chr5:109687802~109688329:-
HNSC	cis	rs17489649	1	rs929749	ENSG00000271849.1	CTC-332L22.1	3.83	0.000145	0.0191	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109696816	chr5:109687802~109688329:-
HNSC	cis	rs3018712	0.532	rs4930587	ENSG00000212093.1	AP000807.1	-3.83	0.000145	0.0191	-0.25	-0.17	Total body bone mineral density;	chr11:68647667	chr11:68506083~68506166:-
HNSC	cis	rs3018712	0.532	rs4930589	ENSG00000212093.1	AP000807.1	-3.83	0.000145	0.0191	-0.25	-0.17	Total body bone mineral density;	chr11:68647789	chr11:68506083~68506166:-
HNSC	cis	rs3018712	0.532	rs11228312	ENSG00000212093.1	AP000807.1	-3.83	0.000145	0.0191	-0.25	-0.17	Total body bone mineral density;	chr11:68648049	chr11:68506083~68506166:-
HNSC	cis	rs3018712	0.532	rs10791988	ENSG00000212093.1	AP000807.1	-3.83	0.000145	0.0191	-0.25	-0.17	Total body bone mineral density;	chr11:68648583	chr11:68506083~68506166:-
HNSC	cis	rs6012564	0.783	rs6125575	ENSG00000227431.4	CSE1L-AS1	3.83	0.000145	0.0191	0.2	0.17	Anger;	chr20:49159159	chr20:49040463~49046044:-
HNSC	cis	rs4835473	0.808	rs6831401	ENSG00000249741.2	RP11-673E1.3	3.83	0.000145	0.0191	0.19	0.17	Immature fraction of reticulocytes;	chr4:143801038	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.778	rs6853798	ENSG00000249741.2	RP11-673E1.3	3.83	0.000145	0.0191	0.19	0.17	Immature fraction of reticulocytes;	chr4:143801153	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.9	rs12502940	ENSG00000249741.2	RP11-673E1.3	3.83	0.000145	0.0191	0.19	0.17	Immature fraction of reticulocytes;	chr4:143812117	chr4:143911514~143912053:-
HNSC	cis	rs7085104	0.632	rs6162	ENSG00000213061.2	PFN1P11	3.83	0.000145	0.0191	0.21	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102838011~102845473:-
HNSC	cis	rs10484434	0.818	rs61289224	ENSG00000217159.2	LARP1P1	3.83	0.000145	0.0191	0.27	0.17	HIV-1 viral setpoint;	chr6:26049068	chr6:26164072~26164363:+
HNSC	cis	rs2001970	0.773	rs8049196	ENSG00000259711.1	CTD-3032H12.2	-3.83	0.000145	0.0191	-0.19	-0.17	Visceral fat;	chr16:55211948	chr16:54934913~54954665:+
HNSC	cis	rs9788333	0.762	rs4441120	ENSG00000236953.1	ZDHHC20-IT1	-3.83	0.000145	0.0191	-0.2	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312724	chr13:21376977~21377874:-
HNSC	cis	rs58873874	0.579	rs11551374	ENSG00000248544.2	CTB-47B11.3	3.83	0.000145	0.0191	0.31	0.17	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157375741~157384950:-
HNSC	cis	rs1908814	0.516	rs4841641	ENSG00000227888.4	FAM66A	3.83	0.000145	0.0191	0.18	0.17	Neuroticism;	chr8:11940718	chr8:12362019~12388296:+
HNSC	cis	rs7824557	0.602	rs11784458	ENSG00000255310.2	AF131215.2	3.83	0.000145	0.0191	0.17	0.17	Retinal vascular caliber;	chr8:11346675	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	3.83	0.000145	0.0191	0.26	0.17	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-3.83	0.000145	0.0191	-0.16	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
HNSC	cis	rs17404153	0.599	rs72990500	ENSG00000248724.5	NPHP3-AS1	-3.83	0.000145	0.0191	-0.3	-0.17	LDL cholesterol;HDL cholesterol;	chr3:132434768	chr3:132721750~132874223:+
HNSC	cis	rs10484434	0.818	rs66536062	ENSG00000217159.2	LARP1P1	3.83	0.000145	0.0191	0.27	0.17	HIV-1 viral setpoint;	chr6:26012479	chr6:26164072~26164363:+
HNSC	cis	rs6995541	0.647	rs7846449	ENSG00000269918.1	AF131215.9	-3.83	0.000145	0.0191	-0.18	-0.17	Triglyceride levels;	chr8:10827160	chr8:11104691~11106704:-
HNSC	cis	rs61160187	0.517	rs7709522	ENSG00000272308.1	RP11-231G3.1	-3.83	0.000145	0.0191	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60866457~60866935:-
HNSC	cis	rs9611565	0.802	rs132916	ENSG00000235513.1	RP4-756G23.5	-3.83	0.000145	0.0191	-0.2	-0.17	Vitiligo;	chr22:41410764	chr22:41209122~41217627:-
HNSC	cis	rs7824557	0.628	rs11250129	ENSG00000255310.2	AF131215.2	3.83	0.000145	0.0191	0.16	0.17	Retinal vascular caliber;	chr8:11344645	chr8:11107788~11109726:-
HNSC	cis	rs1941023	0.677	rs2298553	ENSG00000279632.1	RP11-286N22.6	3.83	0.000145	0.0191	0.19	0.17	Congenital heart disease (maternal effect);	chr11:60497529	chr11:61426448~61427325:-
HNSC	cis	rs9487051	0.799	rs351724	ENSG00000243587.6	C6orf183	-3.83	0.000145	0.0191	-0.17	-0.17	Reticulocyte fraction of red cells;	chr6:109225374	chr6:109165833~109271014:+
HNSC	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	3.83	0.000145	0.0191	0.2	0.17	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	3.83	0.000145	0.0191	0.2	0.17	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
HNSC	cis	rs889398	0.802	rs9940315	ENSG00000196696.11	PDXDC2P	-3.83	0.000145	0.0191	-0.12	-0.17	Body mass index;	chr16:69842261	chr16:69976297~70065948:-
HNSC	cis	rs7716219	0.707	rs6450318	ENSG00000251307.1	RP11-506H20.1	3.83	0.000145	0.0191	0.19	0.17	Height;	chr5:55585487	chr5:55233934~55295201:+
HNSC	cis	rs12893668	0.703	rs34026011	ENSG00000269958.1	RP11-73M18.8	3.83	0.000145	0.0191	0.16	0.17	Reticulocyte count;	chr14:103584546	chr14:103696353~103697163:+
HNSC	cis	rs2548724	0.716	rs78857908	ENSG00000250682.4	LINC00491	3.83	0.000145	0.0191	0.23	0.17	Type 2 diabetes;	chr5:102364919	chr5:102609156~102671559:-
HNSC	cis	rs7520050	0.902	rs4638056	ENSG00000280836.1	AL355480.1	3.83	0.000145	0.0191	0.18	0.17	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs11576305	ENSG00000280836.1	AL355480.1	3.83	0.000145	0.0191	0.18	0.17	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45581219~45581321:-
HNSC	cis	rs6995541	0.647	rs6987200	ENSG00000269918.1	AF131215.9	-3.83	0.000145	0.0191	-0.18	-0.17	Triglyceride levels;	chr8:10831156	chr8:11104691~11106704:-
HNSC	cis	rs9584850	0.874	rs4584	ENSG00000231194.1	FARP1-AS1	3.83	0.000145	0.0191	0.21	0.17	Neuroticism;	chr13:98449615	chr13:98435405~98435840:-
HNSC	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-3.83	0.000145	0.0191	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
HNSC	cis	rs7615952	0.558	rs17334039	ENSG00000241278.1	ENPP7P4	-3.83	0.000146	0.0191	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:125821465	chr3:125848223~125909372:+
HNSC	cis	rs870825	0.932	rs28594349	ENSG00000254233.1	RP11-242J7.1	3.83	0.000146	0.0192	0.3	0.17	Blood protein levels;	chr4:184653261	chr4:184584093~184625030:-
HNSC	cis	rs57502260	0.915	rs75202638	ENSG00000212093.1	AP000807.1	3.83	0.000146	0.0192	0.25	0.17	Total body bone mineral density (age 45-60);	chr11:68442953	chr11:68506083~68506166:-
HNSC	cis	rs6088590	0.561	rs11167239	ENSG00000276073.1	RP5-1125A11.7	-3.83	0.000146	0.0192	-0.18	-0.17	Coronary artery disease;	chr20:34552668	chr20:33985617~33988989:-
HNSC	cis	rs4906332	0.966	rs35799018	ENSG00000244691.1	RPL10AP1	-3.83	0.000146	0.0192	-0.2	-0.17	Coronary artery disease;	chr14:103427138	chr14:103412119~103412761:-
HNSC	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000146	0.0192	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
HNSC	cis	rs38055	0.668	rs62357407	ENSG00000247796.2	CTD-2366F13.1	3.83	0.000146	0.0192	0.21	0.17	Acne (severe);	chr5:53200622	chr5:53109842~53115126:+
HNSC	cis	rs28489187	0.683	rs6657817	ENSG00000223653.4	RP11-131L23.1	-3.83	0.000146	0.0192	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85408931	chr1:85276715~85448124:+
HNSC	cis	rs2836974	0.83	rs2735309	ENSG00000255568.3	BRWD1-AS2	3.83	0.000146	0.0192	0.16	0.17	Cognitive function;	chr21:39343387	chr21:39313935~39314962:+
HNSC	cis	rs7824557	0.592	rs2572371	ENSG00000255310.2	AF131215.2	3.83	0.000146	0.0192	0.16	0.17	Retinal vascular caliber;	chr8:11366284	chr8:11107788~11109726:-
HNSC	cis	rs17253792	0.915	rs78498383	ENSG00000186615.9	KTN1-AS1	-3.83	0.000146	0.0192	-0.35	-0.17	Putamen volume;	chr14:55710867	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs77252471	ENSG00000186615.9	KTN1-AS1	-3.83	0.000146	0.0192	-0.35	-0.17	Putamen volume;	chr14:55711357	chr14:55499278~55580110:-
HNSC	cis	rs7005380	0.531	rs6469860	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000146	0.0192	-0.18	-0.17	Interstitial lung disease;	chr8:119897108	chr8:119838736~119840385:-
HNSC	cis	rs544991	0.652	rs58101699	ENSG00000239670.1	RP4-803A2.2	3.83	0.000146	0.0192	0.21	0.17	Intelligence;	chr1:33746951	chr1:32986952~32988233:+
HNSC	cis	rs919433	1	rs1560277	ENSG00000231621.1	AC013264.2	-3.83	0.000146	0.0192	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197197991~197199273:+
HNSC	cis	rs7824557	0.628	rs11782706	ENSG00000255310.2	AF131215.2	3.83	0.000146	0.0192	0.16	0.17	Retinal vascular caliber;	chr8:11328706	chr8:11107788~11109726:-
HNSC	cis	rs1790761	0.505	rs34721562	ENSG00000184224.3	C11orf72	-3.83	0.000146	0.0192	-0.21	-0.17	Mean corpuscular volume;	chr11:67545237	chr11:67602880~67606706:-
HNSC	cis	rs6840360	0.582	rs6535796	ENSG00000251611.1	RP11-610P16.1	-3.83	0.000146	0.0192	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151407551~151408835:-
HNSC	cis	rs2084881	0.527	rs9913760	ENSG00000272763.1	RP11-357H14.17	3.83	0.000146	0.0192	0.22	0.17	Ovarian cancer;	chr17:48288456	chr17:48635923~48647023:-
HNSC	cis	rs300890	0.544	rs17686361	ENSG00000250326.1	RP11-284M14.1	-3.83	0.000146	0.0192	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143286533	chr4:142933195~143184861:-
HNSC	cis	rs300890	0.562	rs28589653	ENSG00000250326.1	RP11-284M14.1	-3.83	0.000146	0.0192	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143286637	chr4:142933195~143184861:-
HNSC	cis	rs11976180	1	rs2951368	ENSG00000244479.5	OR2A1-AS1	3.83	0.000146	0.0192	0.2	0.17	Obesity-related traits;	chr7:144055728	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2961115	ENSG00000244479.5	OR2A1-AS1	3.83	0.000146	0.0192	0.2	0.17	Obesity-related traits;	chr7:144056278	chr7:144251264~144356181:-
HNSC	cis	rs7824557	0.628	rs3174048	ENSG00000255310.2	AF131215.2	3.83	0.000146	0.0192	0.16	0.17	Retinal vascular caliber;	chr8:11327428	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.579	rs10098322	ENSG00000255310.2	AF131215.2	3.83	0.000146	0.0192	0.16	0.17	Retinal vascular caliber;	chr8:11338786	chr8:11107788~11109726:-
HNSC	cis	rs9952991	0.941	rs1893217	ENSG00000260302.1	RP11-973H7.1	3.83	0.000146	0.0192	0.3	0.17	Inflammatory skin disease;	chr18:12809341	chr18:12774651~12775923:-
HNSC	cis	rs7015630	0.657	rs16900888	ENSG00000251136.7	RP11-37B2.1	3.83	0.000146	0.0192	0.2	0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89825519	chr8:89609409~89757727:-
HNSC	cis	rs1411478	1	rs1044595	ENSG00000243155.1	RP11-46A10.5	3.83	0.000146	0.0192	0.19	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180974393	chr1:180944042~180976482:-
HNSC	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	3.83	0.000146	0.0192	0.18	0.17	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
HNSC	cis	rs61160187	0.582	rs17444495	ENSG00000272308.1	RP11-231G3.1	-3.83	0.000146	0.0192	-0.18	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60866457~60866935:-
HNSC	cis	rs12291225	0.753	rs1431374	ENSG00000254418.1	RP11-21L19.1	3.83	0.000146	0.0192	0.21	0.17	Sense of smell;	chr11:14282429	chr11:14262846~14273691:-
HNSC	cis	rs12291225	0.679	rs10832240	ENSG00000254418.1	RP11-21L19.1	3.83	0.000146	0.0192	0.21	0.17	Sense of smell;	chr11:14283198	chr11:14262846~14273691:-
HNSC	cis	rs860818	1	rs1728344	ENSG00000226816.2	AC005082.12	3.83	0.000146	0.0192	0.46	0.17	Initial pursuit acceleration;	chr7:23210425	chr7:23206013~23208045:+
HNSC	cis	rs860818	1	rs858281	ENSG00000226816.2	AC005082.12	3.83	0.000146	0.0192	0.46	0.17	Initial pursuit acceleration;	chr7:23210948	chr7:23206013~23208045:+
HNSC	cis	rs7735319	0.704	rs1428216	ENSG00000251281.1	CTD-2066L21.2	3.83	0.000146	0.0192	0.21	0.17	Systolic blood pressure;	chr5:33056239	chr5:33011322~33017607:-
HNSC	cis	rs1602565	0.841	rs55937300	ENSG00000255450.1	CTD-2063L20.1	-3.83	0.000146	0.0192	-0.3	-0.17	Schizophrenia;	chr11:29178402	chr11:29275655~29276565:+
HNSC	cis	rs1602565	1	rs11030602	ENSG00000255450.1	CTD-2063L20.1	-3.83	0.000146	0.0192	-0.3	-0.17	Schizophrenia;	chr11:29179433	chr11:29275655~29276565:+
HNSC	cis	rs1602565	1	rs11030603	ENSG00000255450.1	CTD-2063L20.1	-3.83	0.000146	0.0192	-0.3	-0.17	Schizophrenia;	chr11:29179670	chr11:29275655~29276565:+
HNSC	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-3.83	0.000146	0.0192	-0.18	-0.17	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
HNSC	cis	rs7615952	0.932	rs11922218	ENSG00000241278.1	ENPP7P4	-3.83	0.000146	0.0192	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125912446	chr3:125848223~125909372:+
HNSC	cis	rs7615952	0.866	rs11922276	ENSG00000241278.1	ENPP7P4	-3.83	0.000146	0.0192	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125912483	chr3:125848223~125909372:+
HNSC	cis	rs442309	0.846	rs224050	ENSG00000238280.1	RP11-436D10.3	3.83	0.000146	0.0192	0.21	0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62733462	chr10:62793562~62805887:-
HNSC	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	3.83	0.000146	0.0192	0.18	0.17	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
HNSC	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	3.83	0.000146	0.0192	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	3.83	0.000146	0.0192	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
HNSC	cis	rs3750965	1	rs731974	ENSG00000265539.1	MIR3164	-3.83	0.000146	0.0192	-0.19	-0.17	Hair color;	chr11:69079688	chr11:69083176~69083258:+
HNSC	cis	rs10073892	0.66	rs13357340	ENSG00000250682.4	LINC00491	-3.83	0.000146	0.0192	-0.24	-0.17	Cognitive decline (age-related);	chr5:102309210	chr5:102609156~102671559:-
HNSC	cis	rs268134	0.53	rs13023210	ENSG00000235725.1	AC007389.3	-3.83	0.000146	0.0192	-0.32	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65405641	chr2:65589566~65640177:-
HNSC	cis	rs11626933	1	rs3825661	ENSG00000275198.1	RP11-471B22.3	3.83	0.000146	0.0192	0.19	0.17	Gut microbiota (bacterial taxa);	chr14:90301263	chr14:90383365~90387973:+
HNSC	cis	rs853679	0.666	rs200956	ENSG00000226314.6	ZNF192P1	-3.83	0.000146	0.0192	-0.23	-0.17	Depression;	chr6:27871968	chr6:28161781~28169594:+
HNSC	cis	rs597539	0.652	rs660614	ENSG00000255741.1	RP11-757G1.5	-3.83	0.000146	0.0192	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68941503~68942852:-
HNSC	cis	rs8072100	1	rs11650372	ENSG00000263293.2	RP11-290H9.4	3.83	0.000146	0.0192	0.19	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47303460~47323613:-
HNSC	cis	rs2070419	0.826	rs62222908	ENSG00000261610.1	AP000265.1	3.83	0.000146	0.0192	0.23	0.17	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31569132	chr21:32259804~32261585:-
HNSC	cis	rs2070419	0.826	rs62222910	ENSG00000261610.1	AP000265.1	3.83	0.000146	0.0192	0.23	0.17	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31569183	chr21:32259804~32261585:-
HNSC	cis	rs6840360	0.582	rs11732918	ENSG00000251611.1	RP11-610P16.1	-3.83	0.000146	0.0193	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151407551~151408835:-
HNSC	cis	rs11711311	1	rs9811746	ENSG00000241529.3	RN7SL767P	-3.83	0.000147	0.0193	-0.22	-0.17	IgG glycosylation;	chr3:113796213	chr3:113632704~113632998:+
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000103832.10	GOLGA8UP	-3.83	0.000147	0.0193	-0.36	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30791573~30801859:+
HNSC	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-3.83	0.000147	0.0193	-0.23	-0.17	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
HNSC	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-3.83	0.000147	0.0193	-0.23	-0.17	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
HNSC	cis	rs2976388	0.934	rs2920279	ENSG00000253741.1	CTD-2292P10.4	3.83	0.000147	0.0193	0.16	0.17	Urinary tract infection frequency;	chr8:142680717	chr8:142702252~142726973:-
HNSC	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	3.83	0.000147	0.0193	0.25	0.17	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
HNSC	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-3.83	0.000147	0.0193	-0.19	-0.17	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-3.83	0.000147	0.0193	-0.19	-0.17	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
HNSC	cis	rs4948102	0.691	rs10435504	ENSG00000226278.1	PSPHP1	-3.83	0.000147	0.0193	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr7:55764797~55773288:+
HNSC	cis	rs4948102	0.653	rs6593294	ENSG00000226278.1	PSPHP1	-3.83	0.000147	0.0193	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr7:55764797~55773288:+
HNSC	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
HNSC	cis	rs7405404	0.672	rs1126144	ENSG00000262454.1	RP11-65J21.3	3.83	0.000147	0.0193	0.15	0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13640009	chr16:14302288~14326353:+
HNSC	cis	rs944002	1	rs56956502	ENSG00000259444.1	RP11-736N17.8	3.83	0.000147	0.0193	0.21	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098707	chr14:103094723~103098885:+
HNSC	cis	rs1862618	0.62	rs2591967	ENSG00000271828.1	CTD-2310F14.1	-3.83	0.000147	0.0193	-0.22	-0.17	Initial pursuit acceleration;	chr5:56937724	chr5:56927874~56929573:+
HNSC	cis	rs225675	0.729	rs225624	ENSG00000229017.5	LINC01277	3.83	0.000147	0.0193	0.22	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142150203	chr6:142966421~143038077:-
HNSC	cis	rs67311347	0.955	rs11719205	ENSG00000280739.1	EIF1B-AS1	3.83	0.000147	0.0193	0.19	0.17	Renal cell carcinoma;	chr3:40375767	chr3:40173145~40309698:-
HNSC	cis	rs4427176	0.507	rs4305907	ENSG00000254340.1	RP11-10A14.3	-3.83	0.000147	0.0193	-0.24	-0.17	Mosquito bite size;	chr8:9728958	chr8:9141424~9145435:+
HNSC	cis	rs7027203	0.576	rs11790754	ENSG00000227603.1	RP11-165J3.6	3.83	0.000147	0.0193	0.16	0.17	DNA methylation (variation);	chr9:93773427	chr9:93435332~93437121:-
HNSC	cis	rs28829049	0.539	rs34441374	ENSG00000270728.1	RP4-657E11.10	-3.83	0.000147	0.0193	-0.15	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19066195	chr1:19297080~19297903:+
HNSC	cis	rs10783487	1	rs10783487	ENSG00000257542.4	OR7E47P	-3.83	0.000147	0.0193	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52068035	chr12:52079696~52108261:+
HNSC	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
HNSC	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-3.83	0.000147	0.0193	-0.17	-0.17	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
HNSC	cis	rs988913	0.915	rs9475107	ENSG00000224984.1	RP11-524H19.2	3.83	0.000147	0.0193	0.2	0.17	Menarche (age at onset);	chr6:54988544	chr6:54840118~54840855:-
HNSC	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
HNSC	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	3.83	0.000147	0.0193	0.17	0.17	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
HNSC	cis	rs6995541	0.606	rs13274017	ENSG00000269918.1	AF131215.9	-3.83	0.000147	0.0193	-0.18	-0.17	Triglyceride levels;	chr8:10827675	chr8:11104691~11106704:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000272831.1	RP11-792A8.4	3.83	0.000147	0.0193	0.15	0.17	Calcium levels;	chr7:65800652	chr7:66739829~66740385:-
HNSC	cis	rs8030379	0.967	rs10520573	ENSG00000230373.7	GOLGA6L5P	-3.83	0.000147	0.0193	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922823	chr15:84507885~84516814:-
HNSC	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-3.83	0.000147	0.0193	-0.21	-0.17	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
HNSC	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-3.83	0.000147	0.0193	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
HNSC	cis	rs12935418	0.672	rs9889194	ENSG00000278985.1	RP11-303E16.9	3.83	0.000147	0.0193	0.18	0.17	Mean corpuscular volume;	chr16:81017212	chr16:80982319~80984094:-
HNSC	cis	rs792448	0.717	rs1389371	ENSG00000226251.4	RP11-15I11.3	-3.83	0.000147	0.0193	-0.2	-0.17	White blood cell count (basophil);	chr1:212236813	chr1:212225278~212238977:-
HNSC	cis	rs3806843	0.576	rs251368	ENSG00000276545.1	PCDHGB9P	-3.83	0.000147	0.0193	-0.21	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140861442	chr5:141439853~141442449:+
HNSC	cis	rs17772222	1	rs61977049	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000147	0.0193	-0.22	-0.17	Coronary artery calcification;	chr14:88360656	chr14:88551597~88552493:+
HNSC	cis	rs17772222	1	rs12587386	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000147	0.0193	-0.22	-0.17	Coronary artery calcification;	chr14:88361420	chr14:88551597~88552493:+
HNSC	cis	rs9863	0.828	rs11057413	ENSG00000270028.1	RP11-380L11.4	3.83	0.000147	0.0193	0.21	0.17	White blood cell count;	chr12:124004615	chr12:123925461~123926083:-
HNSC	cis	rs61160187	0.582	rs62367903	ENSG00000272308.1	RP11-231G3.1	-3.83	0.000147	0.0193	-0.18	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60866457~60866935:-
HNSC	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-3.83	0.000147	0.0193	-0.32	-0.17	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
HNSC	cis	rs73198271	0.71	rs3827808	ENSG00000233609.3	RP11-62H7.2	-3.83	0.000147	0.0193	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8961200~8979025:+
HNSC	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000147	0.0193	-0.25	-0.17	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
HNSC	cis	rs2486288	0.656	rs12908581	ENSG00000259479.5	SORD2P	-3.83	0.000147	0.0193	-0.2	-0.17	Glomerular filtration rate;	chr15:45256437	chr15:44826371~44884694:-
HNSC	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-3.83	0.000147	0.0193	-0.22	-0.17	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
HNSC	cis	rs13178541	0.81	rs4976465	ENSG00000250378.1	RP11-119J18.1	-3.83	0.000147	0.0193	-0.22	-0.17	IgG glycosylation;	chr5:135815226	chr5:135812667~135826582:+
HNSC	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-3.83	0.000147	0.0193	-0.22	-0.17	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
HNSC	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	3.83	0.000147	0.0193	0.29	0.17	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	3.83	0.000147	0.0193	0.29	0.17	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
HNSC	cis	rs12893668	0.703	rs2403197	ENSG00000269958.1	RP11-73M18.8	3.83	0.000147	0.0194	0.16	0.17	Reticulocyte count;	chr14:103587427	chr14:103696353~103697163:+
HNSC	cis	rs6496044	0.963	rs7165300	ENSG00000259295.5	CSPG4P12	3.83	0.000147	0.0194	0.21	0.17	Interstitial lung disease;	chr15:85526838	chr15:85191438~85213905:+
HNSC	cis	rs6430585	0.528	rs75753154	ENSG00000231890.6	DARS-AS1	-3.83	0.000147	0.0194	-0.3	-0.17	Corneal structure;	chr2:135908141	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs7606267	ENSG00000231890.6	DARS-AS1	-3.83	0.000147	0.0194	-0.3	-0.17	Corneal structure;	chr2:135910553	chr2:135985176~136022593:+
HNSC	cis	rs10540	1	rs117339389	ENSG00000279672.1	CMB9-55F22.1	3.83	0.000147	0.0194	0.3	0.17	Body mass index;	chr11:505025	chr11:779617~780755:+
HNSC	cis	rs11992162	0.551	rs35010200	ENSG00000227888.4	FAM66A	-3.83	0.000147	0.0194	-0.18	-0.17	Monocyte count;	chr8:11928146	chr8:12362019~12388296:+
HNSC	cis	rs1620921	0.622	rs60507137	ENSG00000231863.1	RP3-428L16.1	-3.83	0.000147	0.0194	-0.21	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160852034	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.565	rs66542006	ENSG00000231863.1	RP3-428L16.1	-3.83	0.000147	0.0194	-0.21	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160852220	chr6:160931080~160969771:+
HNSC	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	3.83	0.000147	0.0194	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
HNSC	cis	rs56804039	1	rs17616779	ENSG00000254153.1	CTA-398F10.2	3.83	0.000147	0.0194	0.22	0.17	Cervical cancer;	chr8:8524864	chr8:8456909~8461337:-
HNSC	cis	rs7572733	0.534	rs1589162	ENSG00000231621.1	AC013264.2	-3.83	0.000147	0.0194	-0.17	-0.17	Dermatomyositis;	chr2:197917968	chr2:197197991~197199273:+
HNSC	cis	rs7027203	0.595	rs2398876	ENSG00000227603.1	RP11-165J3.6	3.83	0.000147	0.0194	0.16	0.17	DNA methylation (variation);	chr9:93774571	chr9:93435332~93437121:-
HNSC	cis	rs1015213	0.737	rs1040142	ENSG00000272024.1	RP11-546K22.3	-3.83	0.000147	0.0194	-0.45	-0.17	Glaucoma (primary angle closure);	chr8:51985559	chr8:51950284~51950690:+
HNSC	cis	rs6088590	0.523	rs6059913	ENSG00000276073.1	RP5-1125A11.7	-3.83	0.000148	0.0194	-0.18	-0.17	Coronary artery disease;	chr20:34555484	chr20:33985617~33988989:-
HNSC	cis	rs2439831	0.867	rs2255051	ENSG00000275601.1	AC011330.13	-3.83	0.000148	0.0194	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43553963	chr15:43642389~43643023:-
HNSC	cis	rs6088580	0.634	rs6141471	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000148	0.0194	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:33985617~33988989:-
HNSC	cis	rs6090919	0.501	rs13037086	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48856358	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs13043085	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48857456	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs13038134	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48858014	chr20:49280319~49280409:+
HNSC	cis	rs6012542	0.526	rs7267399	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48861003	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs11908314	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48864357	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs6512547	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48864755	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs75616158	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48865188	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs17366753	ENSG00000222365.1	SNORD12B	-3.83	0.000148	0.0194	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48865280	chr20:49280319~49280409:+
HNSC	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	3.83	0.000148	0.0194	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	3.83	0.000148	0.0194	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
HNSC	cis	rs4388249	1	rs12656080	ENSG00000271849.1	CTC-332L22.1	-3.83	0.000148	0.0194	-0.27	-0.17	Schizophrenia;	chr5:109776981	chr5:109687802~109688329:-
HNSC	cis	rs871012	0.502	rs60416963	ENSG00000251405.2	CTB-109A12.1	-3.83	0.000148	0.0194	-0.21	-0.17	IgG glycosylation;	chr5:157441157	chr5:157362615~157460078:-
HNSC	cis	rs6995541	0.647	rs11776767	ENSG00000269918.1	AF131215.9	-3.83	0.000148	0.0194	-0.18	-0.17	Triglyceride levels;	chr8:10826419	chr8:11104691~11106704:-
HNSC	cis	rs6995541	0.606	rs7829089	ENSG00000269918.1	AF131215.9	-3.83	0.000148	0.0194	-0.18	-0.17	Triglyceride levels;	chr8:10826629	chr8:11104691~11106704:-
HNSC	cis	rs6995541	0.631	rs7829201	ENSG00000269918.1	AF131215.9	-3.83	0.000148	0.0194	-0.18	-0.17	Triglyceride levels;	chr8:10826673	chr8:11104691~11106704:-
HNSC	cis	rs224278	0.509	rs1912369	ENSG00000238280.1	RP11-436D10.3	-3.83	0.000148	0.0194	-0.25	-0.17	Ewing sarcoma;	chr10:62960133	chr10:62793562~62805887:-
HNSC	cis	rs6840258	0.943	rs72667748	ENSG00000251411.1	RP11-397E7.4	-3.83	0.000148	0.0194	-0.23	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87005882	chr4:86913266~86914817:-
HNSC	cis	rs1862618	0.641	rs252893	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000148	0.0194	0.22	0.17	Initial pursuit acceleration;	chr5:56928887	chr5:56927874~56929573:+
HNSC	cis	rs1555322	1	rs6058219	ENSG00000279253.1	RP4-614O4.13	-3.83	0.000148	0.0194	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35262727~35264187:-
HNSC	cis	rs7107174	1	rs7117238	ENSG00000251323.2	RP11-452H21.4	3.83	0.000148	0.0194	0.24	0.17	Testicular germ cell tumor;	chr11:78329213	chr11:78423982~78429836:-
HNSC	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	3.83	0.000148	0.0194	0.25	0.17	Pain;	chr19:21416270	chr19:21554640~21569237:-
HNSC	cis	rs60695258	0.55	rs340641	ENSG00000251411.1	RP11-397E7.4	3.83	0.000148	0.0194	0.18	0.17	Hematocrit;	chr4:87030241	chr4:86913266~86914817:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000227888.4	FAM66A	3.83	0.000148	0.0194	0.18	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:12362019~12388296:+
HNSC	cis	rs8077577	0.895	rs16960980	ENSG00000273018.4	CTD-2303H24.2	-3.83	0.000148	0.0194	-0.25	-0.17	Obesity-related traits;	chr17:18197544	chr17:18511221~18551705:-
HNSC	cis	rs9329221	0.537	rs1484640	ENSG00000255310.2	AF131215.2	3.83	0.000148	0.0194	0.17	0.17	Neuroticism;	chr8:10125733	chr8:11107788~11109726:-
HNSC	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	3.83	0.000148	0.0194	0.17	0.17	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
HNSC	cis	rs67311347	1	rs2305522	ENSG00000280739.1	EIF1B-AS1	3.83	0.000148	0.0194	0.19	0.17	Renal cell carcinoma;	chr3:40387867	chr3:40173145~40309698:-
HNSC	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-3.83	0.000148	0.0194	-0.2	-0.17	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
HNSC	cis	rs10463554	0.553	rs72785712	ENSG00000250682.4	LINC00491	3.83	0.000148	0.0194	0.22	0.17	Parkinson's disease;	chr5:102988693	chr5:102609156~102671559:-
HNSC	cis	rs638893	0.588	rs529717	ENSG00000255422.1	AP002954.4	-3.83	0.000148	0.0194	-0.29	-0.17	Vitiligo;	chr11:118769372	chr11:118704607~118750263:+
HNSC	cis	rs73201462	1	rs2955129	ENSG00000231305.3	RP11-723O4.2	3.83	0.000148	0.0194	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128210364	chr3:128861313~128871540:-
HNSC	cis	rs11992162	0.636	rs4841642	ENSG00000255495.1	AC145124.2	3.83	0.000148	0.0194	0.2	0.17	Monocyte count;	chr8:11940825	chr8:12194467~12196280:+
HNSC	cis	rs11992162	0.636	rs4841646	ENSG00000255495.1	AC145124.2	3.83	0.000148	0.0194	0.2	0.17	Monocyte count;	chr8:11941198	chr8:12194467~12196280:+
HNSC	cis	rs11992162	0.613	rs6998690	ENSG00000255495.1	AC145124.2	3.83	0.000148	0.0194	0.2	0.17	Monocyte count;	chr8:11941287	chr8:12194467~12196280:+
HNSC	cis	rs1023500	1	rs10154646	ENSG00000205702.9	CYP2D7	-3.83	0.000148	0.0194	-0.15	-0.17	Schizophrenia;	chr22:41935405	chr22:42140203~42144577:-
HNSC	cis	rs964611	0.935	rs2291341	ENSG00000259488.2	RP11-154J22.1	-3.83	0.000148	0.0194	-0.17	-0.17	Metabolite levels (Pyroglutamine);	chr15:48291640	chr15:48312353~48331856:-
HNSC	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	3.83	0.000148	0.0194	0.31	0.17	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
HNSC	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-3.83	0.000148	0.0194	-0.18	-0.17	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
HNSC	cis	rs941408	0.515	rs2110118	ENSG00000261342.1	AC006538.1	3.83	0.000148	0.0194	0.24	0.17	Total cholesterol levels;	chr19:2775146	chr19:2727743~2729327:-
HNSC	cis	rs7824557	0.527	rs11785394	ENSG00000269918.1	AF131215.9	-3.83	0.000148	0.0194	-0.17	-0.17	Retinal vascular caliber;	chr8:11380520	chr8:11104691~11106704:-
HNSC	cis	rs73198271	0.53	rs11778326	ENSG00000173295.6	FAM86B3P	-3.83	0.000148	0.0194	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794056	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.562	rs113730597	ENSG00000173295.6	FAM86B3P	-3.83	0.000148	0.0194	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794063	chr8:8228595~8244865:+
HNSC	cis	rs12935418	0.672	rs9925780	ENSG00000278985.1	RP11-303E16.9	3.83	0.000148	0.0194	0.18	0.17	Mean corpuscular volume;	chr16:81011571	chr16:80982319~80984094:-
HNSC	cis	rs561341	1	rs55643307	ENSG00000278867.1	RP11-640N20.4	-3.83	0.000148	0.0194	-0.26	-0.17	Hip circumference adjusted for BMI;	chr17:31936055	chr17:32051030~32053208:+
HNSC	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.0194	0.19	0.17	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
HNSC	cis	rs4648045	0.582	rs2168805	ENSG00000230069.3	LRRC37A15P	-3.83	0.000148	0.0194	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102489877	chr4:102727274~102730721:-
HNSC	cis	rs28830936	0.841	rs4923914	ENSG00000250379.1	RP11-23P13.4	3.83	0.000148	0.0195	0.21	0.17	Diastolic blood pressure;	chr15:41827405	chr15:41825099~41827936:-
HNSC	cis	rs28830936	0.934	rs4923915	ENSG00000250379.1	RP11-23P13.4	3.83	0.000148	0.0195	0.21	0.17	Diastolic blood pressure;	chr15:41827408	chr15:41825099~41827936:-
HNSC	cis	rs4906332	0.966	rs12588705	ENSG00000244691.1	RPL10AP1	-3.83	0.000148	0.0195	-0.21	-0.17	Coronary artery disease;	chr14:103399140	chr14:103412119~103412761:-
HNSC	cis	rs4906332	0.966	rs59858038	ENSG00000244691.1	RPL10AP1	-3.83	0.000148	0.0195	-0.21	-0.17	Coronary artery disease;	chr14:103400765	chr14:103412119~103412761:-
HNSC	cis	rs9393777	0.623	rs2093169	ENSG00000241549.7	GUSBP2	3.83	0.000148	0.0195	0.22	0.17	Intelligence (multi-trait analysis);	chr6:26494871	chr6:26871484~26956554:-
HNSC	cis	rs2274273	0.682	rs7141975	ENSG00000233924.1	AL160471.6	-3.83	0.000148	0.0195	-0.2	-0.17	Protein biomarker;	chr14:55075498	chr14:55004813~55005687:-
HNSC	cis	rs72827839	0.802	rs12951323	ENSG00000228782.6	CTD-2026D20.3	-3.83	0.000148	0.0195	-0.2	-0.17	Ease of getting up in the morning;	chr17:47950199	chr17:47450568~47492492:-
HNSC	cis	rs4925386	0.559	rs2427291	ENSG00000275437.1	RP5-908M14.10	3.83	0.000148	0.0195	0.22	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346268	chr20:62402236~62405935:-
HNSC	cis	rs17772222	1	rs60310240	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000148	0.0195	-0.21	-0.17	Coronary artery calcification;	chr14:88356365	chr14:88551597~88552493:+
HNSC	cis	rs11098499	0.863	rs9997631	ENSG00000250412.1	KLHL2P1	3.83	0.000148	0.0195	0.22	0.17	Corneal astigmatism;	chr4:119548840	chr4:119334329~119378233:+
HNSC	cis	rs4853525	0.59	rs12619017	ENSG00000228509.4	AC006460.2	3.83	0.000148	0.0195	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865167	chr2:190676944~190708716:-
HNSC	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	3.83	0.000148	0.0195	0.16	0.17	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
HNSC	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	3.83	0.000149	0.0195	0.21	0.17	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	3.83	0.000149	0.0195	0.21	0.17	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
HNSC	cis	rs11020821	0.884	rs12286498	ENSG00000255893.1	RP11-685N10.1	-3.82	0.000149	0.0195	-0.24	-0.17	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94529857	chr11:94472908~94473570:-
HNSC	cis	rs11649653	0.502	rs4889490	ENSG00000262766.1	RP11-196G11.4	3.82	0.000149	0.0195	0.14	0.17	Triglycerides;	chr16:30811726	chr16:31118078~31118747:+
HNSC	cis	rs28830936	0.966	rs17678552	ENSG00000250379.1	RP11-23P13.4	3.82	0.000149	0.0195	0.21	0.17	Diastolic blood pressure;	chr15:41773992	chr15:41825099~41827936:-
HNSC	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-3.82	0.000149	0.0195	-0.2	-0.17	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
HNSC	cis	rs2948294	0.588	rs12544596	ENSG00000254153.1	CTA-398F10.2	3.82	0.000149	0.0195	0.2	0.17	Red cell distribution width;	chr8:8258824	chr8:8456909~8461337:-
HNSC	cis	rs2836974	0.605	rs2836988	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000149	0.0195	-0.15	-0.17	Cognitive function;	chr21:39336049	chr21:39313935~39314962:+
HNSC	cis	rs804280	0.509	rs13276433	ENSG00000227888.4	FAM66A	3.82	0.000149	0.0195	0.18	0.17	Myopia (pathological);	chr8:11925527	chr8:12362019~12388296:+
HNSC	cis	rs10510102	0.872	rs12244199	ENSG00000226864.1	ATE1-AS1	3.82	0.000149	0.0195	0.3	0.17	Breast cancer;	chr10:121965117	chr10:121928312~121951965:+
HNSC	cis	rs2307394	0.716	rs1919441	ENSG00000281469.1	RP11-567F11.1	3.82	0.000149	0.0195	0.19	0.17	Urate levels;	chr2:147762337	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.685	rs7564409	ENSG00000281469.1	RP11-567F11.1	3.82	0.000149	0.0195	0.19	0.17	Urate levels;	chr2:147763000	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.716	rs7590862	ENSG00000281469.1	RP11-567F11.1	3.82	0.000149	0.0195	0.19	0.17	Urate levels;	chr2:147763011	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.716	rs6728992	ENSG00000281469.1	RP11-567F11.1	3.82	0.000149	0.0195	0.19	0.17	Urate levels;	chr2:147763357	chr2:148044380~148044894:+
HNSC	cis	rs2865126	0.644	rs8098584	ENSG00000264714.1	RP11-21G15.1	-3.82	0.000149	0.0195	-0.22	-0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10736936	chr18:10724619~10728539:+
HNSC	cis	rs2310173	0.933	rs4851534	ENSG00000281162.1	LINC01127	-3.82	0.000149	0.0195	-0.22	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102037937	chr2:101962056~101987167:+
HNSC	cis	rs73201462	1	rs2955130	ENSG00000231305.3	RP11-723O4.2	3.82	0.000149	0.0195	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128218971	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811549	ENSG00000231305.3	RP11-723O4.2	3.82	0.000149	0.0195	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128219865	chr3:128861313~128871540:-
HNSC	cis	rs4908760	0.86	rs11121202	ENSG00000232912.4	RP5-1115A15.1	3.82	0.000149	0.0195	0.18	0.17	Vitiligo;	chr1:8579298	chr1:8424645~8434838:+
HNSC	cis	rs17253792	0.915	rs74580958	ENSG00000186615.9	KTN1-AS1	-3.82	0.000149	0.0195	-0.35	-0.17	Putamen volume;	chr14:55714793	chr14:55499278~55580110:-
HNSC	cis	rs950169	0.579	rs12912716	ENSG00000230373.7	GOLGA6L5P	-3.82	0.000149	0.0195	-0.2	-0.17	Schizophrenia;	chr15:83995511	chr15:84507885~84516814:-
HNSC	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	3.82	0.000149	0.0195	0.2	0.17	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
HNSC	cis	rs12600121	0.622	rs9937465	ENSG00000261008.5	LINC01572	-3.82	0.000149	0.0195	-0.2	-0.17	Intelligence (multi-trait analysis);	chr16:71987739	chr16:72283301~72665009:-
HNSC	cis	rs8062405	0.964	rs78613234	ENSG00000261089.1	RP11-435I10.3	3.82	0.000149	0.0195	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62036624	ENSG00000261089.1	RP11-435I10.3	3.82	0.000149	0.0195	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28413703~28415018:+
HNSC	cis	rs202072	1	rs202053	ENSG00000215022.6	RP1-257A7.4	-3.82	0.000149	0.0195	-0.22	-0.17	HIV-1 viral setpoint;	chr6:13273411	chr6:13264861~13295586:-
HNSC	cis	rs7246657	0.508	rs10419845	ENSG00000276846.1	CTD-3220F14.3	3.82	0.000149	0.0195	0.28	0.17	Coronary artery calcification;	chr19:37000290	chr19:37314868~37315620:-
HNSC	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	3.82	0.000149	0.0195	0.3	0.17	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
HNSC	cis	rs7637230	0.891	rs9850918	ENSG00000244119.1	PDCL3P4	3.82	0.000149	0.0195	0.18	0.17	Psoriasis vulgaris;Psoriasis;	chr3:101948003	chr3:101712472~101713191:+
HNSC	cis	rs7302981	0.719	rs836188	ENSG00000272368.2	RP4-605O3.4	3.82	0.000149	0.0195	0.17	0.17	Systolic blood pressure;	chr12:50067569	chr12:50112197~50165618:+
HNSC	cis	rs4713118	0.662	rs4713120	ENSG00000219392.1	RP1-265C24.5	-3.82	0.000149	0.0195	-0.2	-0.17	Parkinson's disease;	chr6:27754056	chr6:28115628~28116551:+
HNSC	cis	rs516805	0.748	rs11154070	ENSG00000279453.1	RP3-425C14.4	3.82	0.000149	0.0195	0.23	0.17	Lymphocyte counts;	chr6:122362886	chr6:122436789~122439223:-
HNSC	cis	rs4820294	0.77	rs7285699	ENSG00000225867.1	RP5-1177I5.3	-3.82	0.000149	0.0196	-0.19	-0.17	Fat distribution (HIV);	chr22:37670549	chr22:37550026~37551735:+
HNSC	cis	rs860295	0.557	rs6696019	ENSG00000225855.5	RUSC1-AS1	3.82	0.000149	0.0196	0.12	0.17	Body mass index;	chr1:155895186	chr1:155316863~155324176:-
HNSC	cis	rs7011507	0.7	rs55847910	ENSG00000253608.1	RP11-770E5.1	-3.82	0.000149	0.0196	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422172	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs72639020	ENSG00000253608.1	RP11-770E5.1	-3.82	0.000149	0.0196	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422306	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs55927958	ENSG00000253608.1	RP11-770E5.1	-3.82	0.000149	0.0196	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422714	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs55864946	ENSG00000253608.1	RP11-770E5.1	-3.82	0.000149	0.0196	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48427958	chr8:48551567~48698510:+
HNSC	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	3.82	0.000149	0.0196	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
HNSC	cis	rs1538970	0.851	rs2055145	ENSG00000234329.1	RP11-767N6.2	3.82	0.000149	0.0196	0.2	0.17	Platelet count;	chr1:45460823	chr1:45651039~45651826:-
HNSC	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-3.82	0.000149	0.0196	-0.21	-0.17	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
HNSC	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	3.82	0.000149	0.0196	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	3.82	0.000149	0.0196	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	3.82	0.000149	0.0196	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
HNSC	cis	rs1218582	0.741	rs11264281	ENSG00000270361.1	RP11-307C12.13	-3.82	0.000149	0.0196	-0.19	-0.17	Prostate cancer;	chr1:154894745	chr1:154937370~154938059:+
HNSC	cis	rs7927592	1	rs7927592	ENSG00000255031.4	RP11-802E16.3	3.82	0.00015	0.0196	0.16	0.17	Total body bone mineral density;	chr11:68602492	chr11:68050740~68053762:+
HNSC	cis	rs9650657	0.871	rs7814142	ENSG00000255310.2	AF131215.2	-3.82	0.00015	0.0196	-0.17	-0.17	Neuroticism;	chr8:10780042	chr8:11107788~11109726:-
HNSC	cis	rs4906332	1	rs55731474	ENSG00000244691.1	RPL10AP1	-3.82	0.00015	0.0196	-0.2	-0.17	Coronary artery disease;	chr14:103412144	chr14:103412119~103412761:-
HNSC	cis	rs7508	0.511	rs208025	ENSG00000253671.1	RP11-806O11.1	-3.82	0.00015	0.0196	-0.19	-0.17	Atrial fibrillation;	chr8:18020661	chr8:17808941~17820868:+
HNSC	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-3.82	0.00015	0.0196	-0.22	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
HNSC	cis	rs7246760	1	rs1592997	ENSG00000267289.1	CTD-2623N2.11	3.82	0.00015	0.0196	0.3	0.17	Pursuit maintenance gain;	chr19:9790307	chr19:9834079~9835013:-
HNSC	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	3.82	0.00015	0.0196	0.16	0.17	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
HNSC	cis	rs1275468	0.954	rs1148002	ENSG00000257497.2	RP11-585P4.5	3.82	0.00015	0.0196	0.25	0.17	Polycystic ovary syndrome;	chr12:75539244	chr12:75483454~75489820:-
HNSC	cis	rs792448	0.743	rs12033246	ENSG00000226251.4	RP11-15I11.3	-3.82	0.00015	0.0196	-0.21	-0.17	White blood cell count (basophil);	chr1:212339906	chr1:212225278~212238977:-
HNSC	cis	rs10129255	0.5	rs11627315	ENSG00000211976.2	IGHV3-73	-3.82	0.00015	0.0196	-0.13	-0.17	Kawasaki disease;	chr14:106802182	chr14:106802694~106803233:-
HNSC	cis	rs651907	0.617	rs797776	ENSG00000244119.1	PDCL3P4	3.82	0.00015	0.0196	0.17	0.17	Colorectal cancer;	chr3:101891399	chr3:101712472~101713191:+
HNSC	cis	rs7772486	0.686	rs1415744	ENSG00000270638.1	RP3-466P17.1	3.82	0.00015	0.0196	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145735570~145737218:+
HNSC	cis	rs1387259	0.64	rs10783243	ENSG00000257763.1	OR5BK1P	-3.82	0.00015	0.0196	-0.16	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48355792~48356614:-
HNSC	cis	rs28829049	0.597	rs12566296	ENSG00000270728.1	RP4-657E11.10	-3.82	0.00015	0.0196	-0.16	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171949	chr1:19297080~19297903:+
HNSC	cis	rs2976388	1	rs2572910	ENSG00000253741.1	CTD-2292P10.4	3.82	0.00015	0.0196	0.16	0.17	Urinary tract infection frequency;	chr8:142688717	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2585179	ENSG00000253741.1	CTD-2292P10.4	3.82	0.00015	0.0196	0.16	0.17	Urinary tract infection frequency;	chr8:142692775	chr8:142702252~142726973:-
HNSC	cis	rs7873102	0.967	rs7025303	ENSG00000281649.1	EBLN3	3.82	0.00015	0.0196	0.17	0.17	Brain structure;	chr9:38040098	chr9:37079857~37090507:+
HNSC	cis	rs9987353	0.519	rs13276350	ENSG00000254153.1	CTA-398F10.2	-3.82	0.00015	0.0196	-0.2	-0.17	Recombination measurement;	chr8:9205647	chr8:8456909~8461337:-
HNSC	cis	rs6012564	0.963	rs6063359	ENSG00000227431.4	CSE1L-AS1	3.82	0.00015	0.0196	0.2	0.17	Anger;	chr20:49128547	chr20:49040463~49046044:-
HNSC	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-3.82	0.00015	0.0196	-0.19	-0.17	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
HNSC	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-3.82	0.00015	0.0196	-0.21	-0.17	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
HNSC	cis	rs11633886	0.585	rs1949575	ENSG00000273972.1	CTD-2306A12.1	3.82	0.00015	0.0196	0.21	0.17	Diisocyanate-induced asthma;	chr15:45784002	chr15:45702640~45703183:+
HNSC	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	3.82	0.00015	0.0196	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
HNSC	cis	rs4835473	0.742	rs7695853	ENSG00000249741.2	RP11-673E1.3	-3.82	0.00015	0.0196	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143883243	chr4:143911514~143912053:-
HNSC	cis	rs4388249	1	rs3756597	ENSG00000271849.1	CTC-332L22.1	-3.82	0.00015	0.0196	-0.28	-0.17	Schizophrenia;	chr5:109739808	chr5:109687802~109688329:-
HNSC	cis	rs1595825	0.891	rs1440086	ENSG00000231621.1	AC013264.2	-3.82	0.00015	0.0196	-0.21	-0.17	Ulcerative colitis;	chr2:198041630	chr2:197197991~197199273:+
HNSC	cis	rs9298506	1	rs10104003	ENSG00000254142.2	RP11-53M11.3	3.82	0.00015	0.0196	0.26	0.17	Intracranial aneurysm;	chr8:54509880	chr8:54554361~54561927:+
HNSC	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-3.82	0.00015	0.0196	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
HNSC	cis	rs4704187	0.687	rs10942729	ENSG00000272040.1	CTC-366B18.4	-3.82	0.00015	0.0196	-0.16	-0.17	Response to amphetamines;	chr5:75068475	chr5:75608817~75609983:+
HNSC	cis	rs4908760	0.73	rs10779704	ENSG00000232912.4	RP5-1115A15.1	3.82	0.00015	0.0196	0.19	0.17	Vitiligo;	chr1:8633478	chr1:8424645~8434838:+
HNSC	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
HNSC	cis	rs11250098	0.567	rs4326350	ENSG00000255310.2	AF131215.2	3.82	0.00015	0.0197	0.17	0.17	Morning vs. evening chronotype;	chr8:10906145	chr8:11107788~11109726:-
HNSC	cis	rs7688540	0.771	rs11737268	ENSG00000250892.1	RP11-1365D11.1	-3.82	0.00015	0.0197	-0.29	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:201409~205009:-
HNSC	cis	rs7688540	0.771	rs11726829	ENSG00000250892.1	RP11-1365D11.1	-3.82	0.00015	0.0197	-0.29	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:201409~205009:-
HNSC	cis	rs11098499	0.863	rs6858592	ENSG00000250412.1	KLHL2P1	3.82	0.00015	0.0197	0.22	0.17	Corneal astigmatism;	chr4:119537537	chr4:119334329~119378233:+
HNSC	cis	rs453301	0.522	rs1964356	ENSG00000253981.4	ALG1L13P	3.82	0.00015	0.0197	0.2	0.17	Joint mobility (Beighton score);	chr8:8995760	chr8:8236003~8244667:-
HNSC	cis	rs860295	0.702	rs475550	ENSG00000225855.5	RUSC1-AS1	3.82	0.00015	0.0197	0.12	0.17	Body mass index;	chr1:155682290	chr1:155316863~155324176:-
HNSC	cis	rs919433	0.726	rs11904247	ENSG00000231621.1	AC013264.2	-3.82	0.00015	0.0197	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373700	chr2:197197991~197199273:+
HNSC	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00015	0.0197	-0.22	-0.17	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
HNSC	cis	rs7572733	1	rs1866666	ENSG00000222017.1	AC011997.1	3.82	0.00015	0.0197	0.21	0.17	Dermatomyositis;	chr2:198075883	chr2:197693106~197774823:+
HNSC	cis	rs2439831	1	rs2245790	ENSG00000275601.1	AC011330.13	-3.82	0.00015	0.0197	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43452259	chr15:43642389~43643023:-
HNSC	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-3.82	0.00015	0.0197	-0.2	-0.17	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
HNSC	cis	rs11992162	0.55	rs61426048	ENSG00000227888.4	FAM66A	-3.82	0.00015	0.0197	-0.18	-0.17	Monocyte count;	chr8:11927447	chr8:12362019~12388296:+
HNSC	cis	rs9992667	0.563	rs10026640	ENSG00000231160.8	KLF3-AS1	3.82	0.00015	0.0197	0.17	0.17	Eosinophil percentage of granulocytes;	chr4:38701352	chr4:38612701~38664883:-
HNSC	cis	rs4906332	1	rs35862113	ENSG00000244691.1	RPL10AP1	-3.82	0.00015	0.0197	-0.21	-0.17	Coronary artery disease;	chr14:103390892	chr14:103412119~103412761:-
HNSC	cis	rs860295	0.702	rs10796945	ENSG00000225855.5	RUSC1-AS1	3.82	0.00015	0.0197	0.12	0.17	Body mass index;	chr1:155457897	chr1:155316863~155324176:-
HNSC	cis	rs7572733	0.935	rs1518360	ENSG00000222017.1	AC011997.1	-3.82	0.00015	0.0197	-0.21	-0.17	Dermatomyositis;	chr2:197950579	chr2:197693106~197774823:+
HNSC	cis	rs3096299	0.933	rs2965939	ENSG00000261118.1	RP11-104N10.1	3.82	0.00015	0.0197	0.19	0.17	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89492017~89504460:-
HNSC	cis	rs6732189	0.74	rs1975999	ENSG00000279844.1	RP11-20F18.1	-3.82	0.00015	0.0197	-0.17	-0.17	Educational attainment;	chr2:160747758	chr2:160849313~160850676:-
HNSC	cis	rs7005380	0.62	rs13260933	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000151	0.0197	-0.14	-0.17	Interstitial lung disease;	chr8:119895010	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs13261304	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000151	0.0197	-0.14	-0.17	Interstitial lung disease;	chr8:119895180	chr8:119838736~119840385:-
HNSC	cis	rs7107174	1	rs1893448	ENSG00000251323.2	RP11-452H21.4	3.82	0.000151	0.0197	0.25	0.17	Testicular germ cell tumor;	chr11:78258134	chr11:78423982~78429836:-
HNSC	cis	rs9987353	0.589	rs1053036	ENSG00000254153.1	CTA-398F10.2	-3.82	0.000151	0.0197	-0.19	-0.17	Recombination measurement;	chr8:9202567	chr8:8456909~8461337:-
HNSC	cis	rs748404	0.626	rs17780920	ENSG00000166763.7	STRCP1	3.82	0.000151	0.0197	0.24	0.17	Lung cancer;	chr15:43370164	chr15:43699488~43718184:-
HNSC	cis	rs2247572	0.667	rs2439331	ENSG00000250295.5	RP11-434I12.2	3.82	0.000151	0.0197	0.23	0.17	Cognitive performance;	chr8:72676213	chr8:73297711~73356461:-
HNSC	cis	rs2247572	0.667	rs2439332	ENSG00000250295.5	RP11-434I12.2	3.82	0.000151	0.0197	0.23	0.17	Cognitive performance;	chr8:72676239	chr8:73297711~73356461:-
HNSC	cis	rs28489187	0.756	rs233047	ENSG00000223653.4	RP11-131L23.1	3.82	0.000151	0.0197	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85364887	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.558	rs6576763	ENSG00000223653.4	RP11-131L23.1	-3.82	0.000151	0.0197	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85393693	chr1:85276715~85448124:+
HNSC	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000151	0.0197	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
HNSC	cis	rs7209700	0.547	rs884696	ENSG00000262879.4	RP11-156P1.3	3.82	0.000151	0.0197	0.24	0.17	IgG glycosylation;	chr17:47263878	chr17:46984045~47100323:-
HNSC	cis	rs3176789	1	rs2071647	ENSG00000256673.1	RP11-599J14.2	3.82	0.000151	0.0197	0.19	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9761409	chr12:9398355~9414851:-
HNSC	cis	rs12600394	1	rs62059972	ENSG00000231595.1	AC005224.2	3.82	0.000151	0.0197	0.26	0.17	Response to platinum-based chemotherapy (cisplatin);	chr17:14616319	chr17:14210488~14217922:+
HNSC	cis	rs4256159	0.866	rs59741663	ENSG00000228956.7	SATB1-AS1	3.82	0.000151	0.0197	0.28	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18731903	chr3:18445024~18920401:+
HNSC	cis	rs13179617	0.928	rs13186194	ENSG00000215032.2	GNL3LP1	-3.82	0.000151	0.0197	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61499658	chr5:60891935~60893577:-
HNSC	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-3.82	0.000151	0.0197	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
HNSC	cis	rs7615952	0.605	rs34865555	ENSG00000241288.6	RP11-379B18.5	-3.82	0.000151	0.0197	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125585290	chr3:125827238~125916384:-
HNSC	cis	rs34792	0.678	rs153787	ENSG00000207425.1	Y_RNA	3.82	0.000151	0.0197	0.21	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:14915457~14915556:-
HNSC	cis	rs853679	1	rs2799077	ENSG00000270326.1	RP5-874C20.6	-3.82	0.000151	0.0197	-0.26	-0.17	Depression;	chr6:28266819	chr6:28319660~28319852:-
HNSC	cis	rs1799955	0.935	rs7337784	ENSG00000215515.2	IFIT1P1	-3.82	0.000151	0.0197	-0.24	-0.17	LDL cholesterol levels;	chr13:32383835	chr13:32384660~32386108:+
HNSC	cis	rs3002142	0.524	rs2378585	ENSG00000272750.1	RP11-378J18.8	3.82	0.000151	0.0197	0.25	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222608480	chr1:222658867~222661512:-
HNSC	cis	rs228769	0.673	rs228787	ENSG00000267080.4	ASB16-AS1	3.82	0.000151	0.0197	0.16	0.17	Bone mineral density (hip);Bone mineral density (spine);	chr17:44022120	chr17:44175973~44186717:-
HNSC	cis	rs2337406	1	rs78857163	ENSG00000211972.2	IGHV3-66	3.82	0.000151	0.0197	0.17	0.17	Alzheimer's disease (late onset);	chr14:106707435	chr14:106675017~106675544:-
HNSC	cis	rs7005380	0.531	rs7837823	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000151	0.0197	-0.18	-0.17	Interstitial lung disease;	chr8:119898539	chr8:119838736~119840385:-
HNSC	cis	rs2212361	0.527	rs7931179	ENSG00000255893.1	RP11-685N10.1	-3.82	0.000151	0.0198	-0.24	-0.17	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531037	chr11:94472908~94473570:-
HNSC	cis	rs2212361	0.558	rs7934286	ENSG00000255893.1	RP11-685N10.1	-3.82	0.000151	0.0198	-0.24	-0.17	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531347	chr11:94472908~94473570:-
HNSC	cis	rs7829975	0.688	rs7837587	ENSG00000233609.3	RP11-62H7.2	3.82	0.000151	0.0198	0.17	0.17	Mood instability;	chr8:8521482	chr8:8961200~8979025:+
HNSC	cis	rs913672	0.553	rs8184807	ENSG00000224397.4	LINC01272	3.82	0.000151	0.0198	0.24	0.17	Monocyte count;	chr20:50292379	chr20:50267486~50279795:+
HNSC	cis	rs2904524	1	rs4761195	ENSG00000257815.4	RP11-611E13.2	-3.82	0.000151	0.0198	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70306967	chr12:69904033~70243360:-
HNSC	cis	rs38055	0.668	rs17241927	ENSG00000247796.2	CTD-2366F13.1	3.82	0.000151	0.0198	0.21	0.17	Acne (severe);	chr5:53197103	chr5:53109842~53115126:+
HNSC	cis	rs9321637	1	rs9321637	ENSG00000226004.1	RP11-10J5.1	3.82	0.000151	0.0198	0.2	0.17	Cardiac Troponin-T levels;	chr6:137945548	chr6:137943079~137945802:-
HNSC	cis	rs11148252	0.904	rs3892337	ENSG00000198384.8	TPTE2P3	3.82	0.000151	0.0198	0.21	0.17	Lewy body disease;	chr13:52455350	chr13:52522632~52586906:+
HNSC	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-3.82	0.000151	0.0198	-0.21	-0.17	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
HNSC	cis	rs12545912	0.909	rs4240626	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000151	0.0198	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9613550	chr8:9141424~9145435:+
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000241549.7	GUSBP2	3.82	0.000151	0.0198	0.18	0.17	Parkinson's disease;	chr6:27879739	chr6:26871484~26956554:-
HNSC	cis	rs4853525	0.859	rs11897136	ENSG00000235852.1	AC005540.3	3.82	0.000151	0.0198	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846354	chr2:190880797~190882059:-
HNSC	cis	rs868153	0.625	rs9482226	ENSG00000275339.1	RP3-425C14.6	3.82	0.000151	0.0198	0.19	0.17	Vertical cup-disc ratio;	chr6:122126483	chr6:122454358~122454612:+
HNSC	cis	rs2904524	1	rs2904524	ENSG00000257815.4	RP11-611E13.2	-3.82	0.000151	0.0198	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70296305	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.867	rs77337632	ENSG00000257815.4	RP11-611E13.2	-3.82	0.000151	0.0198	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70297167	chr12:69904033~70243360:-
HNSC	cis	rs865483	0.895	rs1112173	ENSG00000276054.1	RP11-378E13.3	-3.82	0.000151	0.0198	-0.21	-0.17	Monocyte count;	chr17:37399966	chr17:37386886~37387926:+
HNSC	cis	rs924712	0.522	rs7752214	ENSG00000224984.1	RP11-524H19.2	3.82	0.000151	0.0198	0.2	0.17	Breast cancer;	chr6:54834954	chr6:54840118~54840855:-
HNSC	cis	rs9393777	0.588	rs6933213	ENSG00000241549.7	GUSBP2	3.82	0.000151	0.0198	0.21	0.17	Intelligence (multi-trait analysis);	chr6:26493681	chr6:26871484~26956554:-
HNSC	cis	rs12701220	0.595	rs12532837	ENSG00000224079.1	AC091729.7	3.82	0.000151	0.0198	0.27	0.17	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1074450~1078036:+
HNSC	cis	rs6921919	0.832	rs17312661	ENSG00000217862.2	HIST1H4PS1	-3.82	0.000151	0.0198	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:27807075~27807339:+
HNSC	cis	rs4873772	0.558	rs6472452	ENSG00000253330.1	RP11-697N18.3	-3.82	0.000151	0.0198	-0.23	-0.17	Lobe attachment (rater-scored or self-reported);	chr8:47464657	chr8:47511034~47512141:-
HNSC	cis	rs950169	1	rs62026530	ENSG00000230373.7	GOLGA6L5P	-3.82	0.000151	0.0198	-0.19	-0.17	Schizophrenia;	chr15:84107088	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs11638394	ENSG00000230373.7	GOLGA6L5P	-3.82	0.000151	0.0198	-0.19	-0.17	Schizophrenia;	chr15:84110176	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs35658069	ENSG00000230373.7	GOLGA6L5P	-3.82	0.000151	0.0198	-0.19	-0.17	Schizophrenia;	chr15:84111394	chr15:84507885~84516814:-
HNSC	cis	rs62246343	0.605	rs4308263	ENSG00000206573.7	THUMPD3-AS1	-3.82	0.000151	0.0198	-0.15	-0.17	Fibrinogen levels;	chr3:9415674	chr3:9349689~9398579:-
HNSC	cis	rs865483	0.895	rs853208	ENSG00000276054.1	RP11-378E13.3	3.82	0.000151	0.0198	0.21	0.17	Monocyte count;	chr17:37466352	chr17:37386886~37387926:+
HNSC	cis	rs1937680	0.613	rs1937667	ENSG00000236671.6	PRKG1-AS1	-3.82	0.000151	0.0198	-0.24	-0.17	Breast cancer;	chr10:51894239	chr10:52230742~52314128:-
HNSC	cis	rs73198271	0.53	rs113160067	ENSG00000173295.6	FAM86B3P	-3.82	0.000151	0.0198	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797011	chr8:8228595~8244865:+
HNSC	cis	rs11992162	0.636	rs13265816	ENSG00000255495.1	AC145124.2	3.82	0.000152	0.0198	0.2	0.17	Monocyte count;	chr8:11939976	chr8:12194467~12196280:+
HNSC	cis	rs4699052	0.787	rs2169508	ENSG00000251288.2	RP11-10L12.2	-3.82	0.000152	0.0198	-0.2	-0.17	Testicular germ cell tumor;	chr4:103145733	chr4:102751401~102752641:+
HNSC	cis	rs6543140	0.964	rs4851578	ENSG00000234389.1	AC007278.3	3.82	0.000152	0.0198	0.18	0.17	Blood protein levels;	chr2:102412491	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs6761350	ENSG00000234389.1	AC007278.3	3.82	0.000152	0.0198	0.18	0.17	Blood protein levels;	chr2:102414316	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.929	rs7602207	ENSG00000234389.1	AC007278.3	3.82	0.000152	0.0198	0.18	0.17	Blood protein levels;	chr2:102415906	chr2:102438713~102440475:+
HNSC	cis	rs6543140	0.964	rs2160200	ENSG00000234389.1	AC007278.3	3.82	0.000152	0.0198	0.18	0.17	Blood protein levels;	chr2:102417503	chr2:102438713~102440475:+
HNSC	cis	rs62246343	0.541	rs17050396	ENSG00000206573.7	THUMPD3-AS1	-3.82	0.000152	0.0198	-0.15	-0.17	Fibrinogen levels;	chr3:9492652	chr3:9349689~9398579:-
HNSC	cis	rs13221576	0.569	rs2188266	ENSG00000236453.4	AC003092.1	3.82	0.000152	0.0198	0.31	0.17	Intelligence;	chr7:94355267	chr7:94022833~94066661:+
HNSC	cis	rs3096299	0.719	rs2965945	ENSG00000261118.1	RP11-104N10.1	3.82	0.000152	0.0198	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89492017~89504460:-
HNSC	cis	rs4073405	0.813	rs7482739	ENSG00000254651.1	RP11-430H10.3	-3.82	0.000152	0.0198	-0.21	-0.17	Schizophrenia;	chr11:45332615	chr11:45399448~45400528:+
HNSC	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-3.82	0.000152	0.0198	-0.18	-0.17	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
HNSC	cis	rs11756659	0.653	rs185635	ENSG00000218690.1	HIST1H2APS4	3.82	0.000152	0.0198	0.24	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:26272193~26272540:-
HNSC	cis	rs9329221	0.655	rs656319	ENSG00000233609.3	RP11-62H7.2	-3.82	0.000152	0.0198	-0.16	-0.17	Neuroticism;	chr8:9956901	chr8:8961200~8979025:+
HNSC	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-3.82	0.000152	0.0198	-0.29	-0.17	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
HNSC	cis	rs6558174	0.965	rs1564595	ENSG00000253986.1	CTC-756D1.3	-3.82	0.000152	0.0198	-0.2	-0.17	Breast cancer;	chr8:22631426	chr8:23493009~23494198:-
HNSC	cis	rs12545912	0.866	rs4841211	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000152	0.0198	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9742002	chr8:9141424~9145435:+
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000226314.6	ZNF192P1	-3.82	0.000152	0.0198	-0.2	-0.17	Depression;	chr6:28364057	chr6:28161781~28169594:+
HNSC	cis	rs28830936	0.966	rs4924576	ENSG00000250379.1	RP11-23P13.4	3.82	0.000152	0.0199	0.21	0.17	Diastolic blood pressure;	chr15:41827395	chr15:41825099~41827936:-
HNSC	cis	rs7572733	0.534	rs700670	ENSG00000231621.1	AC013264.2	-3.82	0.000152	0.0199	-0.17	-0.17	Dermatomyositis;	chr2:197822560	chr2:197197991~197199273:+
HNSC	cis	rs3850699	0.886	rs12773833	ENSG00000236937.2	PTGES3P4	3.82	0.000152	0.0199	0.23	0.17	Prostate cancer;	chr10:102658593	chr10:102845595~102845950:+
HNSC	cis	rs73173548	0.528	rs34182576	ENSG00000247828.6	TMEM161B-AS1	3.82	0.000152	0.0199	0.18	0.17	Macular telangiectasia type 2;	chr5:88438321	chr5:88268895~88436685:+
HNSC	cis	rs9611565	0.694	rs202665	ENSG00000235513.1	RP4-756G23.5	-3.82	0.000152	0.0199	-0.21	-0.17	Vitiligo;	chr22:41418397	chr22:41209122~41217627:-
HNSC	cis	rs1125355	0.69	rs11679019	ENSG00000204380.3	AC005042.4	3.82	0.000152	0.0199	0.2	0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158804999	chr2:158658337~158735002:-
HNSC	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-3.82	0.000152	0.0199	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
HNSC	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-3.82	0.000152	0.0199	-0.2	-0.17	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
HNSC	cis	rs35306767	0.859	rs11817793	ENSG00000229869.1	RP11-363N22.2	-3.82	0.000152	0.0199	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:832955	chr10:933026~942743:+
HNSC	cis	rs7474896	0.616	rs2474561	ENSG00000263064.2	RP11-291L22.7	3.82	0.000152	0.0199	0.25	0.17	Obesity (extreme);	chr10:38084616	chr10:38448689~38448949:+
HNSC	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	3.82	0.000152	0.0199	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
HNSC	cis	rs4356203	0.905	rs550667	ENSG00000272034.1	SNORD14A	-3.82	0.000152	0.0199	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs656623	ENSG00000272034.1	SNORD14A	-3.82	0.000152	0.0199	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17074654~17074744:-
HNSC	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-3.82	0.000152	0.0199	-0.17	-0.17	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
HNSC	cis	rs116095464	0.558	rs55664502	ENSG00000277812.1	AC021087.1	3.82	0.000152	0.0199	0.29	0.17	Breast cancer;	chr5:270370	chr5:262769~262881:+
HNSC	cis	rs116095464	0.51	rs7723883	ENSG00000277812.1	AC021087.1	3.82	0.000152	0.0199	0.29	0.17	Breast cancer;	chr5:270683	chr5:262769~262881:+
HNSC	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000152	0.0199	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
HNSC	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-3.82	0.000152	0.0199	-0.17	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
HNSC	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	3.82	0.000152	0.0199	0.22	0.17	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
HNSC	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	3.82	0.000152	0.0199	0.23	0.17	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
HNSC	cis	rs6928977	0.863	rs2179780	ENSG00000231028.7	LINC00271	3.82	0.000152	0.0199	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135329128	chr6:135497801~135716055:+
HNSC	cis	rs11846409	0.86	rs4774167	ENSG00000280411.1	IGHV1-69-2	-3.82	0.000152	0.0199	-0.16	-0.17	Rheumatic heart disease;	chr14:106619987	chr14:106762092~106762588:-
HNSC	cis	rs34286592	1	rs4788187	ENSG00000196796.5	CTB-134H23.2	-3.82	0.000152	0.0199	-0.24	-0.17	Multiple sclerosis;	chr16:29834364	chr16:29038655~29052726:+
HNSC	cis	rs1832007	0.554	rs11594448	ENSG00000224034.1	RP11-445P17.8	-3.82	0.000152	0.0199	-0.21	-0.17	Triglyceride levels;Triglycerides;	chr10:5203328	chr10:5266033~5271236:-
HNSC	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-3.82	0.000152	0.0199	-0.18	-0.17	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
HNSC	cis	rs9329221	0.621	rs522483	ENSG00000233609.3	RP11-62H7.2	-3.82	0.000152	0.0199	-0.16	-0.17	Neuroticism;	chr8:9955459	chr8:8961200~8979025:+
HNSC	cis	rs988913	0.678	rs9382440	ENSG00000224984.1	RP11-524H19.2	3.82	0.000152	0.0199	0.2	0.17	Menarche (age at onset);	chr6:55065576	chr6:54840118~54840855:-
HNSC	cis	rs4356203	0.905	rs10832743	ENSG00000272034.1	SNORD14A	-3.82	0.000152	0.0199	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17074654~17074744:-
HNSC	cis	rs1979679	0.801	rs2881787	ENSG00000247934.4	RP11-967K21.1	3.82	0.000152	0.0199	0.18	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28163298~28190738:-
HNSC	cis	rs9650657	0.836	rs891556	ENSG00000255310.2	AF131215.2	-3.82	0.000152	0.0199	-0.17	-0.17	Neuroticism;	chr8:10766123	chr8:11107788~11109726:-
HNSC	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	3.82	0.000152	0.0199	0.24	0.17	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	3.82	0.000152	0.0199	0.24	0.17	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	3.82	0.000152	0.0199	0.24	0.17	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
HNSC	cis	rs6142618	0.905	rs1546922	ENSG00000275576.1	RP5-836N17.4	-3.82	0.000152	0.0199	-0.18	-0.17	Inflammatory bowel disease;	chr20:32167895	chr20:32116171~32116629:+
HNSC	cis	rs875971	0.642	rs35526611	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000153	0.0199	-0.14	-0.17	Aortic root size;	chr7:66629021	chr7:66739829~66740385:-
HNSC	cis	rs10129255	0.957	rs8009073	ENSG00000224373.3	IGHV4-59	3.82	0.000153	0.0199	0.11	0.17	Kawasaki disease;	chr14:106777278	chr14:106627249~106627825:-
HNSC	cis	rs11098499	0.535	rs10005542	ENSG00000250412.1	KLHL2P1	3.82	0.000153	0.0199	0.22	0.17	Corneal astigmatism;	chr4:119347147	chr4:119334329~119378233:+
HNSC	cis	rs2013441	1	rs2703821	ENSG00000261033.1	RP11-209D14.2	3.82	0.000153	0.0199	0.2	0.17	Obesity-related traits;	chr17:20218213	chr17:20008051~20009234:-
HNSC	cis	rs4427176	0.507	rs13276965	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000153	0.0199	-0.24	-0.17	Mosquito bite size;	chr8:9721742	chr8:9141424~9145435:+
HNSC	cis	rs1387259	0.619	rs7134565	ENSG00000257763.1	OR5BK1P	-3.82	0.000153	0.0199	-0.16	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48355792~48356614:-
HNSC	cis	rs4648045	0.796	rs9790601	ENSG00000230069.3	LRRC37A15P	-3.82	0.000153	0.0199	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102608806	chr4:102727274~102730721:-
HNSC	cis	rs924607	1	rs11746907	ENSG00000225138.6	CTD-2228K2.7	-3.82	0.000153	0.0199	-0.19	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:598109	chr5:473236~480884:+
HNSC	cis	rs6787172	0.905	rs1714507	ENSG00000272087.1	RP11-379F4.7	3.82	0.000153	0.0199	0.18	0.17	Subjective well-being;	chr3:158533643	chr3:158693120~158693768:-
HNSC	cis	rs11668609	1	rs10413344	ENSG00000268442.1	CTD-2027I19.2	3.82	0.000153	0.0199	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24186158	chr19:24162370~24163425:-
HNSC	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	3.82	0.000153	0.0199	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
HNSC	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-3.82	0.000153	0.0199	-0.16	-0.17	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
HNSC	cis	rs4835473	0.932	rs12503900	ENSG00000249741.2	RP11-673E1.3	3.82	0.000153	0.0199	0.19	0.17	Immature fraction of reticulocytes;	chr4:143812459	chr4:143911514~143912053:-
HNSC	cis	rs17253792	0.822	rs8018142	ENSG00000186615.9	KTN1-AS1	-3.82	0.000153	0.0199	-0.32	-0.17	Putamen volume;	chr14:55706570	chr14:55499278~55580110:-
HNSC	cis	rs62246343	0.63	rs3774063	ENSG00000206573.7	THUMPD3-AS1	-3.82	0.000153	0.0199	-0.23	-0.17	Fibrinogen levels;	chr3:9470052	chr3:9349689~9398579:-
HNSC	cis	rs62246343	0.63	rs62246320	ENSG00000206573.7	THUMPD3-AS1	-3.82	0.000153	0.0199	-0.23	-0.17	Fibrinogen levels;	chr3:9470291	chr3:9349689~9398579:-
HNSC	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	3.82	0.000153	0.0199	0.24	0.17	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-3.82	0.000153	0.0199	-0.25	-0.17	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
HNSC	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-3.82	0.000153	0.0199	-0.28	-0.17	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
HNSC	cis	rs6565653	1	rs6565653	ENSG00000262580.4	RP11-334C17.5	3.82	0.000153	0.0199	0.13	0.17	Ischemic stroke;	chr17:80227984	chr17:80200673~80205949:-
HNSC	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	3.82	0.000153	0.0199	0.29	0.17	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
HNSC	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	3.82	0.000153	0.0199	0.29	0.17	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
HNSC	cis	rs4840086	0.967	rs62434874	ENSG00000219755.1	RP1-199J3.5	3.82	0.000153	0.0199	0.22	0.17	Menarche (age at onset);	chr6:99754532	chr6:99575712~99576456:+
HNSC	cis	rs4840086	0.967	rs4840084	ENSG00000219755.1	RP1-199J3.5	3.82	0.000153	0.0199	0.22	0.17	Menarche (age at onset);	chr6:99755093	chr6:99575712~99576456:+
HNSC	cis	rs4840086	1	rs13215012	ENSG00000219755.1	RP1-199J3.5	3.82	0.000153	0.0199	0.22	0.17	Menarche (age at onset);	chr6:99755281	chr6:99575712~99576456:+
HNSC	cis	rs4840086	0.967	rs11969653	ENSG00000219755.1	RP1-199J3.5	3.82	0.000153	0.0199	0.22	0.17	Menarche (age at onset);	chr6:99755334	chr6:99575712~99576456:+
HNSC	cis	rs865483	0.86	rs2522968	ENSG00000276054.1	RP11-378E13.3	3.82	0.000153	0.0199	0.21	0.17	Monocyte count;	chr17:37470196	chr17:37386886~37387926:+
HNSC	cis	rs865483	0.895	rs6607275	ENSG00000276054.1	RP11-378E13.3	3.82	0.000153	0.0199	0.21	0.17	Monocyte count;	chr17:37473104	chr17:37386886~37387926:+
HNSC	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-3.82	0.000153	0.02	-0.18	-0.17	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
HNSC	cis	rs1185460	0.967	rs3825061	ENSG00000272186.1	RP11-110I1.13	-3.82	0.000153	0.02	-0.2	-0.17	Coronary artery disease;	chr11:119073965	chr11:119067374~119067698:-
HNSC	cis	rs12144094	1	rs41276626	ENSG00000260941.1	LINC00622	-3.82	0.000153	0.02	-0.22	-0.17	Height;	chr1:119719489	chr1:119597702~119599271:-
HNSC	cis	rs224278	0.509	rs1571918	ENSG00000238280.1	RP11-436D10.3	3.82	0.000153	0.02	0.25	0.17	Ewing sarcoma;	chr10:62961764	chr10:62793562~62805887:-
HNSC	cis	rs35000415	0.938	rs12536266	ENSG00000275106.1	RP11-309L24.10	-3.82	0.000153	0.02	-0.39	-0.17	Systemic lupus erythematosus;	chr7:128970981	chr7:128952527~128953316:-
HNSC	cis	rs397969	0.646	rs6813	ENSG00000266126.1	RP11-209D14.4	-3.82	0.000153	0.02	-0.22	-0.17	Platelet count;	chr17:19905132	chr17:19929372~19929737:-
HNSC	cis	rs6565653	0.967	rs6565652	ENSG00000262580.4	RP11-334C17.5	3.82	0.000153	0.02	0.14	0.17	Ischemic stroke;	chr17:80227755	chr17:80200673~80205949:-
HNSC	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	3.82	0.000153	0.02	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
HNSC	cis	rs7615952	0.673	rs9289270	ENSG00000241439.1	RP11-666A20.3	3.82	0.000153	0.02	0.26	0.17	Blood pressure (smoking interaction);	chr3:125918136	chr3:125958556~125958817:+
HNSC	cis	rs7572733	0.935	rs1518364	ENSG00000222017.1	AC011997.1	3.82	0.000153	0.02	0.21	0.17	Dermatomyositis;	chr2:197945251	chr2:197693106~197774823:+
HNSC	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-3.82	0.000153	0.02	-0.19	-0.17	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-3.82	0.000153	0.02	-0.19	-0.17	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
HNSC	cis	rs12541595	0.93	rs55679363	ENSG00000255491.1	RP11-1082L8.4	3.82	0.000153	0.02	0.22	0.17	Left ventricle diastolic internal dimension;	chr8:124855592	chr8:124811618~124815682:-
HNSC	cis	rs9656709	0.528	rs4948054	ENSG00000273720.1	RP11-613E4.4	3.82	0.000153	0.02	0.22	0.17	Behavioural disinhibition (generation interaction);	chr7:55663907	chr7:55743073~55743457:+
HNSC	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	3.82	0.000153	0.02	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	3.82	0.000153	0.02	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
HNSC	cis	rs7475343	0.543	rs117488242	ENSG00000224034.1	RP11-445P17.8	-3.82	0.000153	0.02	-0.25	-0.17	Intelligence;	chr10:5219869	chr10:5266033~5271236:-
HNSC	cis	rs4713118	0.614	rs9380007	ENSG00000219392.1	RP1-265C24.5	-3.82	0.000153	0.02	-0.2	-0.17	Parkinson's disease;	chr6:27692729	chr6:28115628~28116551:+
HNSC	cis	rs3764400	0.506	rs2036521	ENSG00000228782.6	CTD-2026D20.3	-3.82	0.000153	0.02	-0.27	-0.17	Body mass index;	chr17:48251614	chr17:47450568~47492492:-
HNSC	cis	rs6988985	0.818	rs6471583	ENSG00000247317.3	RP11-273G15.2	-3.82	0.000153	0.02	-0.2	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142909676	chr8:142981738~143018437:-
HNSC	cis	rs897984	0.806	rs9319588	ENSG00000279196.1	RP11-1072A3.3	-3.82	0.000153	0.02	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30919662	chr16:30984630~30988270:-
HNSC	cis	rs1620921	0.563	rs2489936	ENSG00000233342.1	RP11-235G24.3	-3.82	0.000153	0.02	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160859293	chr6:160926369~160927162:+
HNSC	cis	rs12291225	0.679	rs11023178	ENSG00000254418.1	RP11-21L19.1	3.82	0.000153	0.02	0.21	0.17	Sense of smell;	chr11:14288736	chr11:14262846~14273691:-
HNSC	cis	rs9467773	0.595	rs3799379	ENSG00000241549.7	GUSBP2	3.82	0.000153	0.02	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26404466	chr6:26871484~26956554:-
HNSC	cis	rs4760636	0.906	rs3815133	ENSG00000268069.2	RP5-1057I20.4	3.82	0.000153	0.02	0.21	0.17	Urate levels;	chr12:47785261	chr12:47784923~47786002:+
HNSC	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	3.82	0.000153	0.02	0.36	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
HNSC	cis	rs3740713	1	rs73440606	ENSG00000256464.1	YWHABP2	3.82	0.000153	0.02	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73440615	ENSG00000256464.1	YWHABP2	3.82	0.000153	0.02	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr11:18490243~18490955:-
HNSC	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	3.82	0.000153	0.02	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	3.82	0.000153	0.02	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
HNSC	cis	rs4234284	0.556	rs7650549	ENSG00000239620.1	RP11-88I21.1	3.82	0.000153	0.02	0.24	0.17	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);	chr3:127249445	chr3:127284081~127284681:-
HNSC	cis	rs9329221	0.682	rs6982308	ENSG00000270076.1	AF131215.8	-3.82	0.000153	0.02	-0.19	-0.17	Neuroticism;	chr8:10336262	chr8:11202965~11203671:+
HNSC	cis	rs913655	0.785	rs2493617	ENSG00000225527.1	RP11-383B4.4	3.82	0.000153	0.02	0.22	0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18781759	chr10:18531849~18533336:-
HNSC	cis	rs10927875	1	rs4307563	ENSG00000238142.1	RP11-108M9.4	3.82	0.000153	0.02	0.22	0.17	Dilated cardiomyopathy;	chr1:15987293	chr1:16888538~16889649:-
HNSC	cis	rs11610143	0.53	rs10783482	ENSG00000135477.10	KRT87P	3.82	0.000153	0.02	0.19	0.17	Lung cancer;Adenocarcinoma;	chr12:51936018	chr12:52250466~52258867:-
HNSC	cis	rs7735319	0.966	rs35958302	ENSG00000249572.1	CTD-2203K17.1	3.82	0.000153	0.02	0.2	0.17	Systolic blood pressure;	chr5:33157849	chr5:33424025~33440619:-
HNSC	cis	rs12745968	0.62	rs6603992	ENSG00000223787.2	RP4-593M8.1	-3.82	0.000153	0.02	-0.21	-0.17	Bipolar disorder and schizophrenia;	chr1:92572885	chr1:92580476~92580821:-
HNSC	cis	rs4295623	0.789	rs12541318	ENSG00000255310.2	AF131215.2	-3.82	0.000153	0.02	-0.17	-0.17	Morning vs. evening chronotype;	chr8:11737461	chr8:11107788~11109726:-
HNSC	cis	rs11756659	0.653	rs11757088	ENSG00000272462.2	U91328.19	3.82	0.000153	0.02	0.22	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25948230	chr6:25992662~26001775:+
HNSC	cis	rs4853525	0.59	rs13399044	ENSG00000228509.4	AC006460.2	3.82	0.000153	0.02	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944844	chr2:190676944~190708716:-
HNSC	cis	rs17416285	0.559	rs1319274	ENSG00000260971.3	RP11-504A18.1	3.82	0.000153	0.02	0.23	0.17	Coronary artery disease;	chr1:56508419	chr1:56248294~56258571:-
HNSC	cis	rs6095360	0.934	rs2295580	ENSG00000222365.1	SNORD12B	-3.82	0.000153	0.02	-0.18	-0.17	Intelligence (multi-trait analysis);	chr20:49010310	chr20:49280319~49280409:+
HNSC	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-3.82	0.000153	0.02	-0.21	-0.17	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
HNSC	cis	rs75968099	0.765	rs73068044	ENSG00000236411.1	NDUFAF4P3	3.82	0.000153	0.02	0.19	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:36877990	chr3:37789921~37790445:-
HNSC	cis	rs4144743	1	rs34182248	ENSG00000228782.6	CTD-2026D20.3	-3.82	0.000154	0.02	-0.2	-0.17	Body mass index;	chr17:47243993	chr17:47450568~47492492:-
HNSC	cis	rs765751	0.775	rs2605110	ENSG00000228536.1	RP11-392O17.1	-3.82	0.000154	0.02	-0.21	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219481050	chr1:219409681~219411941:-
HNSC	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	3.82	0.000154	0.02	0.24	0.17	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
HNSC	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	3.82	0.000154	0.02	0.24	0.17	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
HNSC	cis	rs889398	0.742	rs12446197	ENSG00000196696.11	PDXDC2P	3.82	0.000154	0.02	0.12	0.17	Body mass index;	chr16:69820966	chr16:69976297~70065948:-
HNSC	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-3.82	0.000154	0.02	-0.21	-0.17	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
HNSC	cis	rs11722228	0.522	rs12503195	ENSG00000261490.1	RP11-448G15.3	3.82	0.000154	0.02	0.15	0.17	Urate levels;Serum uric acid levels;Gout;	chr4:10081148	chr4:10068089~10073019:-
HNSC	cis	rs656319	0.513	rs34990153	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000154	0.02	-0.22	-0.17	Myopia (pathological);	chr8:10138879	chr8:9141424~9145435:+
HNSC	cis	rs7572733	0.773	rs7601762	ENSG00000222017.1	AC011997.1	3.82	0.000154	0.02	0.21	0.17	Dermatomyositis;	chr2:197664513	chr2:197693106~197774823:+
HNSC	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	3.82	0.000154	0.02	0.17	0.17	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
HNSC	cis	rs7726839	0.54	rs72705102	ENSG00000225138.6	CTD-2228K2.7	3.82	0.000154	0.02	0.26	0.17	Obesity-related traits;	chr5:659322	chr5:473236~480884:+
HNSC	cis	rs6657613	0.68	rs6698160	ENSG00000186715.9	MST1L	-3.82	0.000154	0.02	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17049067	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs6701200	ENSG00000186715.9	MST1L	-3.82	0.000154	0.02	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17049085	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs12122144	ENSG00000186715.9	MST1L	-3.82	0.000154	0.02	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17049279	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs1546925	ENSG00000186715.9	MST1L	-3.82	0.000154	0.02	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17049801	chr1:16754910~16770237:-
HNSC	cis	rs6657613	0.68	rs6700594	ENSG00000186715.9	MST1L	-3.82	0.000154	0.02	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17050016	chr1:16754910~16770237:-
HNSC	cis	rs9313772	0.775	rs9313774	ENSG00000254350.1	RP11-542A14.1	-3.82	0.000154	0.02	-0.19	-0.17	Blood pressure;	chr5:158400233	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.706	rs6876925	ENSG00000254350.1	RP11-542A14.1	-3.82	0.000154	0.02	-0.19	-0.17	Blood pressure;	chr5:158400509	chr5:158424585~158452758:+
HNSC	cis	rs792448	0.701	rs3099112	ENSG00000226251.4	RP11-15I11.3	-3.82	0.000154	0.02	-0.22	-0.17	White blood cell count (basophil);	chr1:212369068	chr1:212225278~212238977:-
HNSC	cis	rs1799955	0.935	rs11571787	ENSG00000215515.2	IFIT1P1	-3.82	0.000154	0.02	-0.24	-0.17	LDL cholesterol levels;	chr13:32384329	chr13:32384660~32386108:+
HNSC	cis	rs1799955	0.935	rs9567639	ENSG00000215515.2	IFIT1P1	-3.82	0.000154	0.02	-0.24	-0.17	LDL cholesterol levels;	chr13:32384512	chr13:32384660~32386108:+
HNSC	cis	rs4073405	0.691	rs7123698	ENSG00000254651.1	RP11-430H10.3	3.82	0.000154	0.0201	0.21	0.17	Schizophrenia;	chr11:45267542	chr11:45399448~45400528:+
HNSC	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	3.82	0.000154	0.0201	0.2	0.17	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
HNSC	cis	rs2013441	1	rs2263175	ENSG00000261033.1	RP11-209D14.2	3.82	0.000154	0.0201	0.2	0.17	Obesity-related traits;	chr17:20224716	chr17:20008051~20009234:-
HNSC	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	3.82	0.000154	0.0201	0.21	0.17	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	3.82	0.000154	0.0201	0.21	0.17	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	3.82	0.000154	0.0201	0.21	0.17	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	3.82	0.000154	0.0201	0.21	0.17	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	3.82	0.000154	0.0201	0.21	0.17	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
HNSC	cis	rs12534093	1	rs35319316	ENSG00000234286.1	AC006026.13	-3.82	0.000154	0.0201	-0.21	-0.17	Infant length;Height;	chr7:23462137	chr7:23680195~23680786:-
HNSC	cis	rs11648785	0.777	rs4433810	ENSG00000274627.1	RP11-104N10.2	3.82	0.000154	0.0201	0.19	0.17	Tanning;	chr16:90032058	chr16:89516797~89522217:+
HNSC	cis	rs17373728	0.739	rs7835101	ENSG00000249395.2	CASC9	3.82	0.000154	0.0201	0.23	0.17	Diabetic kidney disease;	chr8:75256950	chr8:75223404~75324741:-
HNSC	cis	rs7937890	0.631	rs7118886	ENSG00000254418.1	RP11-21L19.1	3.82	0.000154	0.0201	0.21	0.17	Mitochondrial DNA levels;	chr11:14405971	chr11:14262846~14273691:-
HNSC	cis	rs4648045	0.796	rs12509403	ENSG00000230069.3	LRRC37A15P	-3.82	0.000154	0.0201	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102604193	chr4:102727274~102730721:-
HNSC	cis	rs4648045	0.765	rs3774967	ENSG00000230069.3	LRRC37A15P	-3.82	0.000154	0.0201	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102604774	chr4:102727274~102730721:-
HNSC	cis	rs2257011	1	rs1896797	ENSG00000230373.7	GOLGA6L5P	3.82	0.000154	0.0201	0.17	0.17	Height;	chr15:83605839	chr15:84507885~84516814:-
HNSC	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-3.82	0.000154	0.0201	-0.32	-0.17	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
HNSC	cis	rs72717009	0.825	rs61802846	ENSG00000225217.1	HSPA7	-3.82	0.000154	0.0201	-0.31	-0.17	Rheumatoid arthritis;	chr1:161504083	chr1:161606291~161608217:+
HNSC	cis	rs1023500	1	rs6002548	ENSG00000205702.9	CYP2D7	-3.82	0.000154	0.0201	-0.15	-0.17	Schizophrenia;	chr22:41941036	chr22:42140203~42144577:-
HNSC	cis	rs9487051	0.698	rs35849756	ENSG00000243587.6	C6orf183	-3.82	0.000154	0.0201	-0.18	-0.17	Reticulocyte fraction of red cells;	chr6:109323407	chr6:109165833~109271014:+
HNSC	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000154	0.0201	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
HNSC	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-3.82	0.000154	0.0201	-0.18	-0.17	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
HNSC	cis	rs67981189	0.593	rs8007425	ENSG00000274818.1	RP1-292L20.3	3.82	0.000154	0.0201	0.19	0.17	Schizophrenia;	chr14:71041483	chr14:70906657~70907111:-
HNSC	cis	rs11231017	0.507	rs1009052	ENSG00000250659.2	RP11-864I4.3	-3.82	0.000154	0.0201	-0.22	-0.17	HIV-1 viral setpoint;	chr11:62299679	chr11:62537312~62542018:+
HNSC	cis	rs897984	0.76	rs11076	ENSG00000279196.1	RP11-1072A3.3	-3.82	0.000154	0.0201	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30984207	chr16:30984630~30988270:-
HNSC	cis	rs10502219	0.634	rs4938286	ENSG00000235910.1	APOA1-AS	3.82	0.000154	0.0201	0.23	0.17	Mitochondrial DNA levels;	chr11:116569319	chr11:116836117~116855729:+
HNSC	cis	rs2554380	0.527	rs7164782	ENSG00000259570.1	RP11-671M22.4	3.82	0.000154	0.0201	0.23	0.17	Height;	chr15:83833447	chr15:84394512~84395514:+
HNSC	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	3.82	0.000154	0.0201	0.24	0.17	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
HNSC	cis	rs7824557	0.527	rs2572449	ENSG00000255495.1	AC145124.2	3.82	0.000154	0.0201	0.19	0.17	Retinal vascular caliber;	chr8:11381628	chr8:12194467~12196280:+
HNSC	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	3.82	0.000154	0.0201	0.26	0.17	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
HNSC	cis	rs453301	0.624	rs2288671	ENSG00000253981.4	ALG1L13P	3.82	0.000154	0.0201	0.19	0.17	Joint mobility (Beighton score);	chr8:9003384	chr8:8236003~8244667:-
HNSC	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	3.82	0.000154	0.0201	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
HNSC	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	3.82	0.000154	0.0201	0.16	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	3.82	0.000154	0.0201	0.16	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
HNSC	cis	rs853679	0.574	rs1233705	ENSG00000219891.2	ZSCAN12P1	3.82	0.000154	0.0201	0.24	0.17	Depression;	chr6:28198669	chr6:28091154~28093664:+
HNSC	cis	rs116095464	0.614	rs62344292	ENSG00000277812.1	AC021087.1	3.82	0.000154	0.0201	0.29	0.17	Breast cancer;	chr5:244515	chr5:262769~262881:+
HNSC	cis	rs860295	0.58	rs867548	ENSG00000225855.5	RUSC1-AS1	3.82	0.000154	0.0201	0.12	0.17	Body mass index;	chr1:155910217	chr1:155316863~155324176:-
HNSC	cis	rs860295	0.58	rs867550	ENSG00000225855.5	RUSC1-AS1	3.82	0.000154	0.0201	0.12	0.17	Body mass index;	chr1:155910600	chr1:155316863~155324176:-
HNSC	cis	rs75757892	0.621	rs1983851	ENSG00000225092.2	RP11-405O10.2	3.81	0.000155	0.0201	0.33	0.17	Hematocrit;Red blood cell count;	chr6:7293309	chr6:7183083~7185287:+
HNSC	cis	rs172166	0.694	rs2791332	ENSG00000219891.2	ZSCAN12P1	3.81	0.000155	0.0201	0.23	0.17	Cardiac Troponin-T levels;	chr6:28141010	chr6:28091154~28093664:+
HNSC	cis	rs2976388	0.967	rs2976397	ENSG00000253741.1	CTD-2292P10.4	3.81	0.000155	0.0201	0.16	0.17	Urinary tract infection frequency;	chr8:142683195	chr8:142702252~142726973:-
HNSC	cis	rs11951515	0.738	rs4866737	ENSG00000249286.1	CTD-2210P15.2	3.81	0.000155	0.0201	0.18	0.17	Metabolite levels  (X-11787);	chr5:43317279	chr5:43586918~43588223:-
HNSC	cis	rs73201462	1	rs55925538	ENSG00000231305.3	RP11-723O4.2	-3.81	0.000155	0.0201	-0.25	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324034	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs73197388	ENSG00000231305.3	RP11-723O4.2	-3.81	0.000155	0.0201	-0.25	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325077	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs11710627	ENSG00000231305.3	RP11-723O4.2	-3.81	0.000155	0.0201	-0.25	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328166	chr3:128861313~128871540:-
HNSC	cis	rs9611565	0.694	rs9607816	ENSG00000235513.1	RP4-756G23.5	3.81	0.000155	0.0201	0.2	0.17	Vitiligo;	chr22:41554893	chr22:41209122~41217627:-
HNSC	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-3.81	0.000155	0.0201	-0.19	-0.17	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
HNSC	cis	rs10938353	0.871	rs7677605	ENSG00000273369.1	RP11-700J17.1	-3.81	0.000155	0.0201	-0.22	-0.17	Body mass index;	chr4:44592074	chr4:44693946~44694386:-
HNSC	cis	rs3809863	0.602	rs11650072	ENSG00000263293.2	RP11-290H9.4	3.81	0.000155	0.0201	0.2	0.17	Glaucoma (primary open-angle);	chr17:47316299	chr17:47303460~47323613:-
HNSC	cis	rs1056107	0.572	rs10981383	ENSG00000225513.1	RP11-165N19.2	-3.81	0.000155	0.0201	-0.18	-0.17	Colorectal cancer;	chr9:112394505	chr9:112173522~112173971:-
HNSC	cis	rs250677	0.652	rs36042	ENSG00000250072.4	CTC-529P8.1	-3.81	0.000155	0.0201	-0.24	-0.17	Breast cancer;	chr5:149060219	chr5:149063317~149109787:+
HNSC	cis	rs8030379	0.967	rs6603001	ENSG00000230373.7	GOLGA6L5P	-3.81	0.000155	0.0201	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84507885~84516814:-
HNSC	cis	rs78773383	0.505	rs13123782	ENSG00000249685.1	RP11-360F5.3	-3.81	0.000155	0.0201	-0.2	-0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39133913~39135608:+
HNSC	cis	rs73173548	0.502	rs13165428	ENSG00000247828.6	TMEM161B-AS1	-3.81	0.000155	0.0202	-0.18	-0.17	Macular telangiectasia type 2;	chr5:88443945	chr5:88268895~88436685:+
HNSC	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	3.81	0.000155	0.0202	0.19	0.17	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
HNSC	cis	rs9788721	1	rs931794	ENSG00000261762.1	RP11-650L12.2	3.81	0.000155	0.0202	0.2	0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78533838	chr15:78589123~78591276:-
HNSC	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-3.81	0.000155	0.0202	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-3.81	0.000155	0.0202	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
HNSC	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-3.81	0.000155	0.0202	-0.18	-0.17	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-3.81	0.000155	0.0202	-0.18	-0.17	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
HNSC	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-3.81	0.000155	0.0202	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
HNSC	cis	rs4930561	0.714	rs7130844	ENSG00000184795.9	UNC93B5	-3.81	0.000155	0.0202	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68160050	chr11:67711702~67716005:-
HNSC	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	3.81	0.000155	0.0202	0.25	0.17	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
HNSC	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	3.81	0.000155	0.0202	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
HNSC	cis	rs2548724	1	rs2600834	ENSG00000250682.4	LINC00491	-3.81	0.000155	0.0202	-0.24	-0.17	Type 2 diabetes;	chr5:102269937	chr5:102609156~102671559:-
HNSC	cis	rs2548724	1	rs2600830	ENSG00000250682.4	LINC00491	-3.81	0.000155	0.0202	-0.24	-0.17	Type 2 diabetes;	chr5:102270466	chr5:102609156~102671559:-
HNSC	cis	rs2548724	1	rs1098806	ENSG00000250682.4	LINC00491	-3.81	0.000155	0.0202	-0.24	-0.17	Type 2 diabetes;	chr5:102278952	chr5:102609156~102671559:-
HNSC	cis	rs6723108	0.583	rs479980	ENSG00000224043.6	CCNT2-AS1	-3.81	0.000155	0.0202	-0.23	-0.17	Type 2 diabetes;	chr2:134526467	chr2:134735464~134918710:-
HNSC	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	3.81	0.000155	0.0202	0.3	0.17	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
HNSC	cis	rs597539	0.652	rs514296	ENSG00000255741.1	RP11-757G1.5	-3.81	0.000155	0.0202	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68941503~68942852:-
HNSC	cis	rs250677	0.687	rs40522	ENSG00000250072.4	CTC-529P8.1	-3.81	0.000155	0.0202	-0.22	-0.17	Breast cancer;	chr5:149062732	chr5:149063317~149109787:+
HNSC	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	3.81	0.000155	0.0202	0.25	0.17	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
HNSC	cis	rs7100689	0.524	rs7902460	ENSG00000226659.1	RP11-137H2.4	-3.81	0.000155	0.0202	-0.22	-0.17	Post bronchodilator FEV1;	chr10:80439507	chr10:80529597~80535942:-
HNSC	cis	rs2904524	1	rs7487329	ENSG00000257815.4	RP11-611E13.2	-3.81	0.000155	0.0202	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70310025	chr12:69904033~70243360:-
HNSC	cis	rs7615952	0.932	rs13065725	ENSG00000241278.1	ENPP7P4	-3.81	0.000155	0.0202	-0.27	-0.17	Blood pressure (smoking interaction);	chr3:125913446	chr3:125848223~125909372:+
HNSC	cis	rs12541595	0.93	rs7461129	ENSG00000255491.1	RP11-1082L8.4	3.81	0.000155	0.0202	0.22	0.17	Left ventricle diastolic internal dimension;	chr8:124849132	chr8:124811618~124815682:-
HNSC	cis	rs74054849	0.85	rs61555804	ENSG00000215908.6	CROCCP2	3.81	0.000155	0.0202	0.24	0.17	Alcoholic chronic pancreatitis;	chr1:15717258	chr1:16618262~16644683:-
HNSC	cis	rs12049351	0.665	rs12143267	ENSG00000177788.5	RP5-1061H20.4	-3.81	0.000155	0.0202	-0.23	-0.17	Circulating myeloperoxidase levels (plasma);	chr1:229459059	chr1:229258281~229271028:-
HNSC	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	3.81	0.000155	0.0202	0.18	0.17	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
HNSC	cis	rs10742752	0.702	rs59678781	ENSG00000254651.1	RP11-430H10.3	3.81	0.000155	0.0202	0.21	0.17	Body mass index;	chr11:45413276	chr11:45399448~45400528:+
HNSC	cis	rs62027291	0.654	rs62028181	ENSG00000259422.1	RP11-593F23.1	-3.81	0.000155	0.0202	-0.33	-0.17	Plateletcrit;	chr15:76713952	chr15:76174891~76181486:-
HNSC	cis	rs34792	0.688	rs13339072	ENSG00000207425.1	Y_RNA	-3.81	0.000155	0.0202	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:14915457~14915556:-
HNSC	cis	rs16846053	0.515	rs971027	ENSG00000227403.1	AC009299.3	-3.81	0.000155	0.0202	-0.31	-0.17	Blood osmolality (transformed sodium);	chr2:161588104	chr2:161244739~161249050:+
HNSC	cis	rs62246343	0.63	rs11542009	ENSG00000206573.7	THUMPD3-AS1	-3.81	0.000155	0.0202	-0.23	-0.17	Fibrinogen levels;	chr3:9475685	chr3:9349689~9398579:-
HNSC	cis	rs9926296	0.744	rs164746	ENSG00000268218.1	AC137932.4	3.81	0.000156	0.0202	0.13	0.17	Vitiligo;	chr16:89642611	chr16:89268104~89273044:+
HNSC	cis	rs6995541	0.606	rs6990055	ENSG00000269918.1	AF131215.9	-3.81	0.000156	0.0202	-0.18	-0.17	Triglyceride levels;	chr8:10828739	chr8:11104691~11106704:-
HNSC	cis	rs1023500	0.956	rs1894713	ENSG00000205702.9	CYP2D7	-3.81	0.000156	0.0202	-0.15	-0.17	Schizophrenia;	chr22:41939617	chr22:42140203~42144577:-
HNSC	cis	rs5752326	0.717	rs739290	ENSG00000261188.1	CTA-445C9.14	3.81	0.000156	0.0202	0.25	0.17	Ischemic stroke;	chr22:26468692	chr22:26512537~26514568:+
HNSC	cis	rs138249	0.902	rs138240	ENSG00000273253.2	RP3-402G11.26	3.81	0.000156	0.0202	0.17	0.17	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50125752	chr22:50199090~50200837:-
HNSC	cis	rs7107174	1	rs2450123	ENSG00000251323.2	RP11-452H21.4	3.81	0.000156	0.0202	0.27	0.17	Testicular germ cell tumor;	chr11:78241725	chr11:78423982~78429836:-
HNSC	cis	rs17495987	0.626	rs73055864	ENSG00000227719.1	AC006042.6	3.81	0.000156	0.0202	0.21	0.17	Tonsillectomy;	chr7:7830971	chr7:8114025~8116561:+
HNSC	cis	rs597539	0.652	rs602805	ENSG00000255741.1	RP11-757G1.5	-3.81	0.000156	0.0202	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs602364	ENSG00000255741.1	RP11-757G1.5	-3.81	0.000156	0.0202	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68941503~68942852:-
HNSC	cis	rs2347867	0.614	rs4869749	ENSG00000218996.1	RP1-99E18.2	3.81	0.000156	0.0203	0.24	0.17	Age at first birth;	chr6:151909933	chr6:150934968~150935566:+
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000227888.4	FAM66A	3.81	0.000156	0.0203	0.18	0.17	Neuroticism;	chr8:11939165	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000227888.4	FAM66A	3.81	0.000156	0.0203	0.18	0.17	Neuroticism;	chr8:11939166	chr8:12362019~12388296:+
HNSC	cis	rs62458065	0.85	rs62458100	ENSG00000226468.2	AC018641.7	3.81	0.000156	0.0203	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32456963~32457758:-
HNSC	cis	rs11711311	1	rs9288983	ENSG00000241529.3	RN7SL767P	-3.81	0.000156	0.0203	-0.22	-0.17	IgG glycosylation;	chr3:113769852	chr3:113632704~113632998:+
HNSC	cis	rs792448	0.743	rs351401	ENSG00000226251.4	RP11-15I11.3	-3.81	0.000156	0.0203	-0.22	-0.17	White blood cell count (basophil);	chr1:212290450	chr1:212225278~212238977:-
HNSC	cis	rs7520050	0.966	rs7515491	ENSG00000280836.1	AL355480.1	3.81	0.000156	0.0203	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45581219~45581321:-
HNSC	cis	rs12887734	0.546	rs12886637	ENSG00000269940.1	RP11-73M18.7	-3.81	0.000156	0.0203	-0.17	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103694560~103695170:+
HNSC	cis	rs765751	0.767	rs2605093	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219467179	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.767	rs2820436	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219467338	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.767	rs2605095	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219468108	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.767	rs2605096	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219468558	chr1:219409681~219411941:-
HNSC	cis	rs5781117	1	rs5781117	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Nose size;	chr1:219468845	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.767	rs1982499	ENSG00000228536.1	RP11-392O17.1	-3.81	0.000156	0.0203	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219469176	chr1:219409681~219411941:-
HNSC	cis	rs7824557	0.603	rs2249804	ENSG00000255310.2	AF131215.2	3.81	0.000156	0.0203	0.16	0.17	Retinal vascular caliber;	chr8:11358108	chr8:11107788~11109726:-
HNSC	cis	rs875971	1	rs697970	ENSG00000272831.1	RP11-792A8.4	-3.81	0.000156	0.0203	-0.15	-0.17	Aortic root size;	chr7:66095065	chr7:66739829~66740385:-
HNSC	cis	rs62025270	0.632	rs17571078	ENSG00000259762.1	RP11-158M2.4	-3.81	0.000156	0.0203	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85750336~85752901:-
HNSC	cis	rs35306767	0.903	rs11253494	ENSG00000229869.1	RP11-363N22.2	-3.81	0.000156	0.0203	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:891107	chr10:933026~942743:+
HNSC	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	3.81	0.000156	0.0203	0.15	0.17	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
HNSC	cis	rs1925953	0.711	rs4508053	ENSG00000233589.1	RP4-694A7.2	-3.81	0.000156	0.0203	-0.22	-0.17	Vertical cup-disc ratio;	chr1:68366465	chr1:68479129~68483539:+
HNSC	cis	rs6968419	0.674	rs17138528	ENSG00000237870.5	AC073130.1	3.81	0.000156	0.0203	0.21	0.17	Intraocular pressure;	chr7:116267235	chr7:116275606~116286734:-
HNSC	cis	rs964611	0.882	rs7179535	ENSG00000259488.2	RP11-154J22.1	-3.81	0.000156	0.0203	-0.16	-0.17	Metabolite levels (Pyroglutamine);	chr15:48287507	chr15:48312353~48331856:-
HNSC	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	3.81	0.000156	0.0203	0.15	0.17	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
HNSC	cis	rs10849893	0.557	rs10849890	ENSG00000258435.1	RP11-711D18.2	-3.81	0.000156	0.0203	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121464922	chr12:121391962~121399859:+
HNSC	cis	rs61629263	0.503	rs9783806	ENSG00000260793.2	RP5-882C2.2	3.81	0.000156	0.0203	0.15	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43736261	chr17:44221401~44223710:+
HNSC	cis	rs9611565	0.568	rs2413656	ENSG00000233903.2	Z83851.4	3.81	0.000156	0.0203	0.24	0.17	Vitiligo;	chr22:41733353	chr22:42276355~42277052:+
HNSC	cis	rs870825	0.616	rs6552809	ENSG00000254233.1	RP11-242J7.1	3.81	0.000156	0.0203	0.25	0.17	Blood protein levels;	chr4:184722830	chr4:184584093~184625030:-
HNSC	cis	rs10791097	0.748	rs2282579	ENSG00000254842.5	RP11-890B15.2	-3.81	0.000156	0.0203	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130865587	chr11:130844191~130865561:-
HNSC	cis	rs988913	0.957	rs4437472	ENSG00000224984.1	RP11-524H19.2	3.81	0.000156	0.0203	0.2	0.17	Menarche (age at onset);	chr6:54973640	chr6:54840118~54840855:-
HNSC	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	3.81	0.000156	0.0203	0.2	0.17	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
HNSC	cis	rs10849893	0.557	rs61955091	ENSG00000258435.1	RP11-711D18.2	-3.81	0.000156	0.0203	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121396172	chr12:121391962~121399859:+
HNSC	cis	rs9834975	0.544	rs9811581	ENSG00000272758.4	RP11-299J3.8	-3.81	0.000156	0.0203	-0.16	-0.17	Diastolic blood pressure;	chr3:122561899	chr3:122416207~122443180:+
HNSC	cis	rs9880211	0.699	rs34804893	ENSG00000239213.4	NCK1-AS1	3.81	0.000156	0.0203	0.18	0.17	Height;Body mass index;	chr3:136621128	chr3:136841726~136862054:-
HNSC	cis	rs896655	0.631	rs1335503	ENSG00000244230.3	RN7SL151P	3.81	0.000156	0.0203	0.18	0.17	Coronary artery disease;	chr9:21737823	chr9:21699314~21699596:+
HNSC	cis	rs12157904	1	rs12157904	ENSG00000225867.1	RP5-1177I5.3	3.81	0.000156	0.0203	0.47	0.17	Response to anti-depressant treatment in major depressive disorder;	chr22:37586005	chr22:37550026~37551735:+
HNSC	cis	rs1908814	0.516	rs11250178	ENSG00000227888.4	FAM66A	3.81	0.000156	0.0203	0.18	0.17	Neuroticism;	chr8:11942725	chr8:12362019~12388296:+
HNSC	cis	rs67072384	1	rs7124056	ENSG00000213365.3	AP000593.6	-3.81	0.000156	0.0203	-0.29	-0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733702	chr11:72280151~72281178:+
HNSC	cis	rs7429990	0.93	rs71323371	ENSG00000228638.1	FCF1P2	-3.81	0.000156	0.0203	-0.16	-0.17	Educational attainment (years of education);	chr3:47904327	chr3:48290793~48291375:-
HNSC	cis	rs2562456	0.833	rs11669790	ENSG00000268081.1	RP11-678G14.2	3.81	0.000156	0.0203	0.25	0.17	Pain;	chr19:21328980	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62107534	ENSG00000268081.1	RP11-678G14.2	3.81	0.000156	0.0203	0.25	0.17	Pain;	chr19:21329389	chr19:21554640~21569237:-
HNSC	cis	rs10791097	0.694	rs6590520	ENSG00000254842.5	RP11-890B15.2	-3.81	0.000156	0.0203	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130877491	chr11:130844191~130865561:-
HNSC	cis	rs526231	0.543	rs171558	ENSG00000250682.4	LINC00491	3.81	0.000156	0.0203	0.23	0.17	Primary biliary cholangitis;	chr5:103242193	chr5:102609156~102671559:-
HNSC	cis	rs4908760	0.864	rs6701331	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000156	0.0203	0.18	0.17	Vitiligo;	chr1:8610147	chr1:8424645~8434838:+
HNSC	cis	rs853679	1	rs6905391	ENSG00000219891.2	ZSCAN12P1	3.81	0.000156	0.0203	0.28	0.17	Depression;	chr6:28294909	chr6:28091154~28093664:+
HNSC	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	3.81	0.000156	0.0203	0.23	0.17	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
HNSC	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	3.81	0.000156	0.0203	0.37	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
HNSC	cis	rs11992162	0.636	rs11250182	ENSG00000255495.1	AC145124.2	-3.81	0.000156	0.0203	-0.19	-0.17	Monocyte count;	chr8:11950067	chr8:12194467~12196280:+
HNSC	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	3.81	0.000156	0.0203	0.39	0.17	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
HNSC	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	3.81	0.000156	0.0203	0.39	0.17	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
HNSC	cis	rs875971	0.666	rs13242072	ENSG00000273142.1	RP11-458F8.4	3.81	0.000156	0.0203	0.15	0.17	Aortic root size;	chr7:66301001	chr7:66902857~66906297:+
HNSC	cis	rs72827839	0.779	rs72827808	ENSG00000272763.1	RP11-357H14.17	-3.81	0.000156	0.0203	-0.25	-0.17	Ease of getting up in the morning;	chr17:48274718	chr17:48635923~48647023:-
HNSC	cis	rs2762353	0.718	rs1184804	ENSG00000272462.2	U91328.19	-3.81	0.000156	0.0203	-0.17	-0.17	Blood metabolite levels;	chr6:25867998	chr6:25992662~26001775:+
HNSC	cis	rs6995541	0.565	rs6601533	ENSG00000269918.1	AF131215.9	-3.81	0.000156	0.0203	-0.18	-0.17	Triglyceride levels;	chr8:10830338	chr8:11104691~11106704:-
HNSC	cis	rs6995541	0.647	rs6982769	ENSG00000269918.1	AF131215.9	-3.81	0.000156	0.0203	-0.18	-0.17	Triglyceride levels;	chr8:10830890	chr8:11104691~11106704:-
HNSC	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-3.81	0.000156	0.0203	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
HNSC	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	3.81	0.000156	0.0203	0.25	0.17	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	3.81	0.000156	0.0203	0.25	0.17	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	3.81	0.000156	0.0203	0.25	0.17	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
HNSC	cis	rs9467711	0.659	rs3823158	ENSG00000241549.7	GUSBP2	3.81	0.000156	0.0203	0.29	0.17	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.659	rs13195509	ENSG00000241549.7	GUSBP2	3.81	0.000156	0.0203	0.29	0.17	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:26871484~26956554:-
HNSC	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000156	0.0203	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
HNSC	cis	rs9611565	0.649	rs202666	ENSG00000235513.1	RP4-756G23.5	-3.81	0.000156	0.0203	-0.21	-0.17	Vitiligo;	chr22:41418715	chr22:41209122~41217627:-
HNSC	cis	rs442309	0.807	rs224069	ENSG00000238280.1	RP11-436D10.3	-3.81	0.000156	0.0203	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62748366	chr10:62793562~62805887:-
HNSC	cis	rs12908161	1	rs35316992	ENSG00000229212.6	RP11-561C5.4	-3.81	0.000156	0.0203	-0.25	-0.17	Schizophrenia;	chr15:84704902	chr15:85205440~85234795:-
HNSC	cis	rs12908161	1	rs4643294	ENSG00000229212.6	RP11-561C5.4	-3.81	0.000156	0.0203	-0.25	-0.17	Schizophrenia;	chr15:84707022	chr15:85205440~85234795:-
HNSC	cis	rs847649	0.732	rs56269620	ENSG00000239969.4	RP11-163E9.2	-3.81	0.000156	0.0203	-0.2	-0.17	Morning vs. evening chronotype;	chr7:102849009	chr7:102364162~102380633:+
HNSC	cis	rs11992186	0.505	rs7845203	ENSG00000233609.3	RP11-62H7.2	3.81	0.000156	0.0203	0.17	0.17	Neuroticism;	chr8:8287918	chr8:8961200~8979025:+
HNSC	cis	rs9487051	0.735	rs1341272	ENSG00000243587.6	C6orf183	3.81	0.000156	0.0203	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109186330	chr6:109165833~109271014:+
HNSC	cis	rs10865541	0.935	rs4971502	ENSG00000234171.2	RNASEH1-AS1	3.81	0.000157	0.0203	0.18	0.17	Obesity-related traits;	chr2:3410258	chr2:3558492~3561745:+
HNSC	cis	rs2904524	0.541	rs77082716	ENSG00000257815.4	RP11-611E13.2	-3.81	0.000157	0.0203	-0.18	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70385171	chr12:69904033~70243360:-
HNSC	cis	rs12545109	0.671	rs35500854	ENSG00000246430.5	LINC00968	-3.81	0.000157	0.0203	-0.23	-0.17	Obesity-related traits;	chr8:56511744	chr8:56496246~56559823:-
HNSC	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	3.81	0.000157	0.0203	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	3.81	0.000157	0.0203	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
HNSC	cis	rs9650657	0.707	rs6984744	ENSG00000255310.2	AF131215.2	-3.81	0.000157	0.0203	-0.17	-0.17	Neuroticism;	chr8:10758755	chr8:11107788~11109726:-
HNSC	cis	rs6071166	0.838	rs6027258	ENSG00000224635.1	RP4-564F22.5	-3.81	0.000157	0.0204	-0.21	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38686031	chr20:38406011~38416797:-
HNSC	cis	rs11976180	1	rs11975942	ENSG00000244479.5	OR2A1-AS1	3.81	0.000157	0.0204	0.2	0.17	Obesity-related traits;	chr7:144043487	chr7:144251264~144356181:-
HNSC	cis	rs7746199	0.736	rs13202295	ENSG00000280107.1	AL022393.9	-3.81	0.000157	0.0204	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28170845~28172521:+
HNSC	cis	rs13113518	0.507	rs4549456	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000157	0.0204	0.2	0.17	Height;	chr4:55398586	chr4:55363971~55395847:-
HNSC	cis	rs7829975	0.617	rs4841071	ENSG00000253981.4	ALG1L13P	3.81	0.000157	0.0204	0.19	0.17	Mood instability;	chr8:8933634	chr8:8236003~8244667:-
HNSC	cis	rs6787172	0.811	rs939117	ENSG00000272087.1	RP11-379F4.7	-3.81	0.000157	0.0204	-0.18	-0.17	Subjective well-being;	chr3:158483080	chr3:158693120~158693768:-
HNSC	cis	rs9656709	0.528	rs4320501	ENSG00000273720.1	RP11-613E4.4	3.81	0.000157	0.0204	0.22	0.17	Behavioural disinhibition (generation interaction);	chr7:55662529	chr7:55743073~55743457:+
HNSC	cis	rs12887734	0.524	rs4906364	ENSG00000269940.1	RP11-73M18.7	3.81	0.000157	0.0204	0.17	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103694560~103695170:+
HNSC	cis	rs6012564	0.964	rs6125577	ENSG00000227431.4	CSE1L-AS1	3.81	0.000157	0.0204	0.19	0.17	Anger;	chr20:49166558	chr20:49040463~49046044:-
HNSC	cis	rs11951515	0.7	rs1548097	ENSG00000249286.1	CTD-2210P15.2	3.81	0.000157	0.0204	0.18	0.17	Metabolite levels  (X-11787);	chr5:43310713	chr5:43586918~43588223:-
HNSC	cis	rs13256369	1	rs9329166	ENSG00000173295.6	FAM86B3P	3.81	0.000157	0.0204	0.22	0.17	Obesity-related traits;	chr8:8719145	chr8:8228595~8244865:+
HNSC	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-3.81	0.000157	0.0204	-0.24	-0.17	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
HNSC	cis	rs6928289	0.81	rs3908195	ENSG00000234956.4	RP11-356I2.1	3.81	0.000157	0.0204	0.18	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137323397	chr6:137730170~137738983:-
HNSC	cis	rs9880211	0.563	rs6769762	ENSG00000239213.4	NCK1-AS1	3.81	0.000157	0.0204	0.16	0.17	Height;Body mass index;	chr3:136189336	chr3:136841726~136862054:-
HNSC	cis	rs7405404	0.672	rs6498449	ENSG00000262454.1	RP11-65J21.3	-3.81	0.000157	0.0204	-0.16	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13646036	chr16:14302288~14326353:+
HNSC	cis	rs757081	0.636	rs664382	ENSG00000260196.1	RP1-239B22.5	-3.81	0.000157	0.0204	-0.2	-0.17	Systolic blood pressure;	chr11:17184972	chr11:17380649~17383531:+
HNSC	cis	rs6995541	0.505	rs1055329	ENSG00000269918.1	AF131215.9	-3.81	0.000157	0.0204	-0.18	-0.17	Triglyceride levels;	chr8:10846399	chr8:11104691~11106704:-
HNSC	cis	rs4427176	0.507	rs7462910	ENSG00000254340.1	RP11-10A14.3	3.81	0.000157	0.0204	0.23	0.17	Mosquito bite size;	chr8:9722476	chr8:9141424~9145435:+
HNSC	cis	rs4835473	0.932	rs13105102	ENSG00000249741.2	RP11-673E1.3	3.81	0.000157	0.0204	0.19	0.17	Immature fraction of reticulocytes;	chr4:143819046	chr4:143911514~143912053:-
HNSC	cis	rs860295	0.702	rs3738590	ENSG00000225855.5	RUSC1-AS1	3.81	0.000157	0.0204	0.12	0.17	Body mass index;	chr1:155660961	chr1:155316863~155324176:-
HNSC	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	3.81	0.000157	0.0204	0.26	0.17	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
HNSC	cis	rs792448	0.743	rs10019	ENSG00000226251.4	RP11-15I11.3	-3.81	0.000157	0.0204	-0.22	-0.17	White blood cell count (basophil);	chr1:212361035	chr1:212225278~212238977:-
HNSC	cis	rs792448	0.743	rs3767861	ENSG00000226251.4	RP11-15I11.3	-3.81	0.000157	0.0204	-0.22	-0.17	White blood cell count (basophil);	chr1:212364211	chr1:212225278~212238977:-
HNSC	cis	rs792448	0.743	rs3767862	ENSG00000226251.4	RP11-15I11.3	-3.81	0.000157	0.0204	-0.22	-0.17	White blood cell count (basophil);	chr1:212364360	chr1:212225278~212238977:-
HNSC	cis	rs28829049	0.597	rs34215816	ENSG00000270728.1	RP4-657E11.10	-3.81	0.000157	0.0204	-0.16	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19107459	chr1:19297080~19297903:+
HNSC	cis	rs11893307	0.537	rs1558473	ENSG00000235852.1	AC005540.3	3.81	0.000157	0.0204	0.22	0.17	Mean platelet volume;	chr2:190639338	chr2:190880797~190882059:-
HNSC	cis	rs72827839	0.779	rs57583172	ENSG00000272763.1	RP11-357H14.17	-3.81	0.000157	0.0204	-0.25	-0.17	Ease of getting up in the morning;	chr17:48404601	chr17:48635923~48647023:-
HNSC	cis	rs11168618	0.904	rs10875829	ENSG00000240399.1	RP1-228P16.1	3.81	0.000157	0.0204	0.14	0.17	Adiponectin levels;	chr12:48533414	chr12:48054813~48055591:-
HNSC	cis	rs2179367	0.959	rs536203	ENSG00000216906.2	RP11-350J20.9	3.81	0.000157	0.0204	0.22	0.17	Dupuytren's disease;	chr6:149330128	chr6:149904243~149906418:+
HNSC	cis	rs4787491	0.729	rs3814878	ENSG00000250616.2	RP11-455F5.3	3.81	0.000157	0.0204	0.18	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30096430~30104116:+
HNSC	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	3.81	0.000157	0.0204	0.18	0.17	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
HNSC	cis	rs9611565	0.802	rs9611577	ENSG00000235513.1	RP4-756G23.5	3.81	0.000157	0.0204	0.21	0.17	Vitiligo;	chr22:41397086	chr22:41209122~41217627:-
HNSC	cis	rs5758511	0.68	rs5758699	ENSG00000227370.1	RP4-669P10.19	3.81	0.000157	0.0204	0.2	0.17	Birth weight;	chr22:42292028	chr22:42132543~42132998:+
HNSC	cis	rs10740039	0.583	rs10740042	ENSG00000254271.1	RP11-131N11.4	3.81	0.000157	0.0204	0.18	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60736828	chr10:60734342~60741828:+
HNSC	cis	rs17772222	0.917	rs17260415	ENSG00000258789.1	RP11-507K2.3	-3.81	0.000157	0.0204	-0.21	-0.17	Coronary artery calcification;	chr14:88745629	chr14:88551597~88552493:+
HNSC	cis	rs67981189	0.593	rs2810072	ENSG00000274818.1	RP1-292L20.3	-3.81	0.000157	0.0204	-0.19	-0.17	Schizophrenia;	chr14:70920476	chr14:70906657~70907111:-
HNSC	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-3.81	0.000157	0.0204	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
HNSC	cis	rs7405404	0.672	rs1126142	ENSG00000262454.1	RP11-65J21.3	-3.81	0.000157	0.0204	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13639874	chr16:14302288~14326353:+
HNSC	cis	rs7405404	0.672	rs1126143	ENSG00000262454.1	RP11-65J21.3	-3.81	0.000157	0.0204	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13639904	chr16:14302288~14326353:+
HNSC	cis	rs9329221	0.868	rs7831557	ENSG00000255310.2	AF131215.2	-3.81	0.000158	0.0205	-0.17	-0.17	Neuroticism;	chr8:10422718	chr8:11107788~11109726:-
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000272831.1	RP11-792A8.4	3.81	0.000158	0.0205	0.15	0.17	Aortic root size;	chr7:65931217	chr7:66739829~66740385:-
HNSC	cis	rs7178375	1	rs12907055	ENSG00000270015.1	RP11-540B6.6	3.81	0.000158	0.0205	0.22	0.17	Hypertriglyceridemia;	chr15:30912091	chr15:30926514~30928407:+
HNSC	cis	rs7927592	0.763	rs624003	ENSG00000255031.4	RP11-802E16.3	3.81	0.000158	0.0205	0.14	0.17	Total body bone mineral density;	chr11:68463772	chr11:68050740~68053762:+
HNSC	cis	rs12997796	0.556	rs13004867	ENSG00000273080.1	RP11-301O19.1	3.81	0.000158	0.0205	0.25	0.17	Schizophrenia;	chr2:86755381	chr2:86195590~86196049:+
HNSC	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	3.81	0.000158	0.0205	0.19	0.17	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
HNSC	cis	rs9611565	0.579	rs73178621	ENSG00000235513.1	RP4-756G23.5	3.81	0.000158	0.0205	0.21	0.17	Vitiligo;	chr22:41525661	chr22:41209122~41217627:-
HNSC	cis	rs73201462	1	rs2999077	ENSG00000231305.3	RP11-723O4.2	3.81	0.000158	0.0205	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239571	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811525	ENSG00000231305.3	RP11-723O4.2	3.81	0.000158	0.0205	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128280587	chr3:128861313~128871540:-
HNSC	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000158	0.0205	-0.22	-0.17	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
HNSC	cis	rs7824557	0.564	rs11782430	ENSG00000255310.2	AF131215.2	-3.81	0.000158	0.0205	-0.16	-0.17	Retinal vascular caliber;	chr8:11368562	chr8:11107788~11109726:-
HNSC	cis	rs6964587	0.839	rs9656002	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000158	0.0205	0.19	0.17	Breast cancer;	chr7:91845693	chr7:92134604~92180725:+
HNSC	cis	rs597480	0.51	rs11607789	ENSG00000279742.1	RP11-700A24.1	3.81	0.000158	0.0205	0.21	0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85815108	chr11:85852557~85854943:-
HNSC	cis	rs12047808	0.73	rs12048994	ENSG00000227141.2	RP11-545A16.3	-3.81	0.000158	0.0205	-0.25	-0.17	Multiple sclerosis (age of onset);	chr1:179565405	chr1:179586705~179589175:+
HNSC	cis	rs9914544	0.545	rs34417974	ENSG00000264885.1	RP11-815I9.4	-3.81	0.000158	0.0205	-0.18	-0.17	Educational attainment (years of education);	chr17:18870323	chr17:18667629~18669461:-
HNSC	cis	rs9611565	0.571	rs7364123	ENSG00000233903.2	Z83851.4	-3.81	0.000158	0.0205	-0.23	-0.17	Vitiligo;	chr22:41820322	chr22:42276355~42277052:+
HNSC	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	3.81	0.000158	0.0205	0.23	0.17	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
HNSC	cis	rs896655	0.631	rs7038523	ENSG00000244230.3	RN7SL151P	3.81	0.000158	0.0205	0.18	0.17	Coronary artery disease;	chr9:21767008	chr9:21699314~21699596:+
HNSC	cis	rs950169	0.579	rs11633088	ENSG00000230373.7	GOLGA6L5P	3.81	0.000158	0.0205	0.2	0.17	Schizophrenia;	chr15:84003429	chr15:84507885~84516814:-
HNSC	cis	rs9573567	0.541	rs2328945	ENSG00000261553.4	RP11-29G8.3	3.81	0.000158	0.0205	0.34	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75501017	chr13:75549773~75807120:+
HNSC	cis	rs9573567	0.881	rs2328946	ENSG00000261553.4	RP11-29G8.3	3.81	0.000158	0.0205	0.34	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75501096	chr13:75549773~75807120:+
HNSC	cis	rs9573567	0.881	rs2328947	ENSG00000261553.4	RP11-29G8.3	3.81	0.000158	0.0205	0.34	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75501191	chr13:75549773~75807120:+
HNSC	cis	rs9573567	0.881	rs7318786	ENSG00000261553.4	RP11-29G8.3	3.81	0.000158	0.0205	0.34	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75501461	chr13:75549773~75807120:+
HNSC	cis	rs9573567	0.881	rs6562896	ENSG00000261553.4	RP11-29G8.3	3.81	0.000158	0.0205	0.34	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75501794	chr13:75549773~75807120:+
HNSC	cis	rs929354	0.935	rs1182392	ENSG00000224629.1	RP5-1142J19.2	3.81	0.000158	0.0205	0.17	0.17	Body mass index;	chr7:157243506	chr7:157263022~157263229:-
HNSC	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-3.81	0.000158	0.0205	-0.18	-0.17	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
HNSC	cis	rs10832963	0.686	rs11024743	ENSG00000256282.1	RP11-504G3.4	-3.81	0.000158	0.0205	-0.17	-0.17	Breast cancer;	chr11:18632165	chr11:18595459~18599683:-
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	3.81	0.000158	0.0205	0.34	0.17	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
HNSC	cis	rs1075232	1	rs12439239	ENSG00000260382.1	RP11-540B6.2	-3.81	0.000158	0.0205	-0.38	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30882267~30883231:-
HNSC	cis	rs17214007	0.627	rs28593034	ENSG00000263065.1	AF001548.6	-3.81	0.000158	0.0205	-0.25	-0.17	Cognitive function;	chr16:15597329	chr16:15741151~15741791:+
HNSC	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	3.81	0.000158	0.0205	0.2	0.17	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
HNSC	cis	rs1009077	0.68	rs3775851	ENSG00000245958.5	RP11-33B1.1	3.81	0.000158	0.0205	0.18	0.17	Endometriosis;	chr4:119532261	chr4:119454791~119552025:+
HNSC	cis	rs2048656	0.523	rs7825286	ENSG00000254340.1	RP11-10A14.3	3.81	0.000158	0.0205	0.23	0.17	Schizophrenia;	chr8:9791031	chr8:9141424~9145435:+
HNSC	cis	rs1585471	0.931	rs922212	ENSG00000249532.3	RP11-148B6.1	-3.81	0.000158	0.0205	-0.21	-0.17	Myopia (pathological);	chr4:111697659	chr4:112646476~112650051:-
HNSC	cis	rs4660214	0.666	rs636083	ENSG00000228060.1	RP11-69E11.8	-3.81	0.000158	0.0205	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39565160~39573203:+
HNSC	cis	rs1832007	0.706	rs11253048	ENSG00000224034.1	RP11-445P17.8	-3.81	0.000158	0.0205	-0.25	-0.17	Triglyceride levels;Triglycerides;	chr10:5219196	chr10:5266033~5271236:-
HNSC	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-3.81	0.000158	0.0205	-0.2	-0.17	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
HNSC	cis	rs865483	0.895	rs4795203	ENSG00000276054.1	RP11-378E13.3	3.81	0.000158	0.0205	0.21	0.17	Monocyte count;	chr17:37468868	chr17:37386886~37387926:+
HNSC	cis	rs9650657	0.812	rs10089615	ENSG00000269918.1	AF131215.9	-3.81	0.000158	0.0205	-0.17	-0.17	Neuroticism;	chr8:10776622	chr8:11104691~11106704:-
HNSC	cis	rs12745968	0.623	rs4294424	ENSG00000223787.2	RP4-593M8.1	-3.81	0.000158	0.0205	-0.21	-0.17	Bipolar disorder and schizophrenia;	chr1:92673817	chr1:92580476~92580821:-
HNSC	cis	rs1979679	0.842	rs10459090	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000158	0.0205	-0.19	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28163298~28190738:-
HNSC	cis	rs7824557	0.564	rs2572400	ENSG00000255310.2	AF131215.2	-3.81	0.000158	0.0205	-0.16	-0.17	Retinal vascular caliber;	chr8:11376858	chr8:11107788~11109726:-
HNSC	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-3.81	0.000158	0.0205	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
HNSC	cis	rs6928977	0.86	rs2746426	ENSG00000217482.2	HMGB1P17	-3.81	0.000158	0.0205	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135345294	chr6:135636086~135636713:-
HNSC	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	3.81	0.000158	0.0205	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.688	rs7826654	ENSG00000233609.3	RP11-62H7.2	3.81	0.000158	0.0205	0.17	0.17	Mood instability;	chr8:8521596	chr8:8961200~8979025:+
HNSC	cis	rs7829975	0.688	rs7826660	ENSG00000233609.3	RP11-62H7.2	3.81	0.000158	0.0205	0.17	0.17	Mood instability;	chr8:8521597	chr8:8961200~8979025:+
HNSC	cis	rs2307394	1	rs4972356	ENSG00000281469.1	RP11-567F11.1	3.81	0.000158	0.0205	0.2	0.17	Urate levels;	chr2:147824740	chr2:148044380~148044894:+
HNSC	cis	rs6001482	0.679	rs1894238	ENSG00000253818.1	IGLV1-41	-3.81	0.000158	0.0205	-0.14	-0.17	Diastolic blood pressure;	chr22:22235704	chr22:22404207~22404721:+
HNSC	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-3.81	0.000158	0.0205	-0.23	-0.17	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
HNSC	cis	rs9925964	0.933	rs4889530	ENSG00000232748.3	RP11-196G11.6	3.81	0.000158	0.0205	0.23	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31056460~31062803:+
HNSC	cis	rs7005380	0.531	rs9649948	ENSG00000279347.1	RP11-85I17.2	-3.81	0.000158	0.0205	-0.17	-0.17	Interstitial lung disease;	chr8:119901295	chr8:119838736~119840385:-
HNSC	cis	rs11773103	0.881	rs56226963	ENSG00000224046.1	AC005076.5	3.81	0.000158	0.0205	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87142615	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.881	rs56209936	ENSG00000224046.1	AC005076.5	3.81	0.000158	0.0205	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87142700	chr7:87151423~87152420:-
HNSC	cis	rs11773103	1	rs73204824	ENSG00000224046.1	AC005076.5	3.81	0.000158	0.0205	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87144095	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.881	rs73204825	ENSG00000224046.1	AC005076.5	3.81	0.000158	0.0205	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87144132	chr7:87151423~87152420:-
HNSC	cis	rs4427176	0.507	rs6601361	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9722233	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs7016561	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9722983	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.863	rs7015787	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9723202	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs7015963	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9723344	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.908	rs35159871	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9723424	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs7006785	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9723460	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs6983608	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9723817	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.908	rs6983762	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9723890	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.909	rs12676827	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9723922	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs11989409	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9724256	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.908	rs10465002	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9724707	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs4841202	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000158	0.0205	-0.24	-0.17	Mosquito bite size;	chr8:9725193	chr8:9141424~9145435:+
HNSC	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000158	0.0205	0.18	0.17	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
HNSC	cis	rs61629263	0.521	rs9915878	ENSG00000260793.2	RP5-882C2.2	3.81	0.000158	0.0205	0.15	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43737608	chr17:44221401~44223710:+
HNSC	cis	rs6840258	0.723	rs340642	ENSG00000251411.1	RP11-397E7.4	3.81	0.000158	0.0205	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87028261	chr4:86913266~86914817:-
HNSC	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-3.81	0.000158	0.0205	-0.33	-0.17	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
HNSC	cis	rs8058578	0.832	rs7500719	ENSG00000279196.1	RP11-1072A3.3	3.81	0.000158	0.0205	0.21	0.17	Multiple myeloma;	chr16:30829556	chr16:30984630~30988270:-
HNSC	cis	rs160451	0.782	rs218920	ENSG00000251136.7	RP11-37B2.1	3.81	0.000158	0.0205	0.17	0.17	Leprosy;	chr8:89696607	chr8:89609409~89757727:-
HNSC	cis	rs250677	0.687	rs2915809	ENSG00000250072.4	CTC-529P8.1	-3.81	0.000158	0.0205	-0.22	-0.17	Breast cancer;	chr5:149072548	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs250663	ENSG00000250072.4	CTC-529P8.1	-3.81	0.000158	0.0205	-0.22	-0.17	Breast cancer;	chr5:149073554	chr5:149063317~149109787:+
HNSC	cis	rs2944755	0.723	rs11996672	ENSG00000279766.1	RP11-642A1.2	-3.81	0.000158	0.0205	-0.2	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576900	chr8:140572142~140572812:-
HNSC	cis	rs2944755	0.686	rs11997913	ENSG00000279766.1	RP11-642A1.2	-3.81	0.000158	0.0205	-0.2	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578561	chr8:140572142~140572812:-
HNSC	cis	rs34421088	0.506	rs2572426	ENSG00000269918.1	AF131215.9	3.81	0.000158	0.0205	0.18	0.17	Neuroticism;	chr8:11289614	chr8:11104691~11106704:-
HNSC	cis	rs67340775	0.541	rs200966	ENSG00000241549.7	GUSBP2	3.81	0.000158	0.0205	0.22	0.17	Lung cancer in ever smokers;	chr6:27894374	chr6:26871484~26956554:-
HNSC	cis	rs11633886	0.585	rs12915174	ENSG00000273972.1	CTD-2306A12.1	3.81	0.000158	0.0206	0.21	0.17	Diisocyanate-induced asthma;	chr15:45787505	chr15:45702640~45703183:+
HNSC	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	3.81	0.000159	0.0206	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
HNSC	cis	rs4660214	0.666	rs587404	ENSG00000182109.6	RP11-69E11.4	3.81	0.000159	0.0206	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39522280~39546187:-
HNSC	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-3.81	0.000159	0.0206	-0.22	-0.17	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
HNSC	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000159	0.0206	-0.22	-0.17	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
HNSC	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-3.81	0.000159	0.0206	-0.17	-0.17	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
HNSC	cis	rs2904524	0.867	rs10879121	ENSG00000257815.4	RP11-611E13.2	-3.81	0.000159	0.0206	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70277447	chr12:69904033~70243360:-
HNSC	cis	rs7829975	0.501	rs4840353	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000159	0.0206	-0.23	-0.17	Mood instability;	chr8:8723060	chr8:9141424~9145435:+
HNSC	cis	rs11951515	0.7	rs7714919	ENSG00000249286.1	CTD-2210P15.2	3.81	0.000159	0.0206	0.19	0.17	Metabolite levels  (X-11787);	chr5:43293248	chr5:43586918~43588223:-
HNSC	cis	rs10132760	0.774	rs72688056	ENSG00000211778.2	TRAV4	-3.81	0.000159	0.0206	-0.16	-0.17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21722564	chr14:21736152~21736982:+
HNSC	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-3.81	0.000159	0.0206	-0.18	-0.17	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
HNSC	cis	rs3736485	0.868	rs1531155	ENSG00000274528.1	CTD-2650P22.2	3.81	0.000159	0.0206	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51639936	chr15:52017167~52018032:-
HNSC	cis	rs853679	0.546	rs71537572	ENSG00000226314.6	ZNF192P1	-3.81	0.000159	0.0206	-0.32	-0.17	Depression;	chr6:28002937	chr6:28161781~28169594:+
HNSC	cis	rs7558911	1	rs7558911	ENSG00000183308.6	AC005037.3	3.81	0.000159	0.0206	0.21	0.17	Chronic lymphocytic leukemia;	chr2:201159226	chr2:200963263~201009102:+
HNSC	cis	rs72843506	0.722	rs75226250	ENSG00000189423.10	USP32P3	3.81	0.000159	0.0206	0.28	0.17	Schizophrenia;	chr17:20229004	chr17:20415547~20431008:+
HNSC	cis	rs138544659	1	rs138544659	ENSG00000261762.1	RP11-650L12.2	-3.81	0.000159	0.0206	-0.21	-0.17	Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78608359	chr15:78589123~78591276:-
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000269918.1	AF131215.9	-3.81	0.000159	0.0206	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11104691~11106704:-
HNSC	cis	rs7324557	0.719	rs7325364	ENSG00000205861.10	C1QTNF9B-AS1	-3.81	0.000159	0.0206	-0.24	-0.17	Visceral adipose tissue adjusted for BMI;	chr13:23805008	chr13:23888889~23897263:+
HNSC	cis	rs2439831	1	rs2467426	ENSG00000275601.1	AC011330.13	-3.81	0.000159	0.0206	-0.29	-0.17	Lung cancer in ever smokers;	chr15:43697320	chr15:43642389~43643023:-
HNSC	cis	rs2548724	0.773	rs432190	ENSG00000250682.4	LINC00491	-3.81	0.000159	0.0206	-0.22	-0.17	Type 2 diabetes;	chr5:102252254	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.773	rs261102	ENSG00000250682.4	LINC00491	-3.81	0.000159	0.0206	-0.22	-0.17	Type 2 diabetes;	chr5:102256197	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs402846	ENSG00000250682.4	LINC00491	-3.81	0.000159	0.0206	-0.22	-0.17	Type 2 diabetes;	chr5:102256781	chr5:102609156~102671559:-
HNSC	cis	rs35306767	0.761	rs11253558	ENSG00000229869.1	RP11-363N22.2	-3.81	0.000159	0.0206	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:998043	chr10:933026~942743:+
HNSC	cis	rs28489187	0.617	rs233124	ENSG00000223653.4	RP11-131L23.1	3.81	0.000159	0.0206	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85325975	chr1:85276715~85448124:+
HNSC	cis	rs2243480	0.803	rs55700941	ENSG00000164669.11	INTS4P1	3.81	0.000159	0.0206	0.35	0.17	Diabetic kidney disease;	chr7:65924813	chr7:65141225~65234216:+
HNSC	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	3.81	0.000159	0.0206	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
HNSC	cis	rs9329221	0.537	rs12678797	ENSG00000255310.2	AF131215.2	-3.81	0.000159	0.0206	-0.16	-0.17	Neuroticism;	chr8:10121409	chr8:11107788~11109726:-
HNSC	cis	rs4930561	0.714	rs1540209	ENSG00000184795.9	UNC93B5	-3.81	0.000159	0.0206	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68161053	chr11:67711702~67716005:-
HNSC	cis	rs6981523	0.553	rs2409730	ENSG00000255495.1	AC145124.2	-3.81	0.000159	0.0206	-0.21	-0.17	Neuroticism;	chr8:11203129	chr8:12194467~12196280:+
HNSC	cis	rs12237653	0.72	rs10812210	ENSG00000236404.7	VLDLR-AS1	-3.81	0.000159	0.0206	-0.31	-0.17	Gambling;	chr9:2536828	chr9:2422702~2643359:-
HNSC	cis	rs860295	0.58	rs2282301	ENSG00000225855.5	RUSC1-AS1	-3.81	0.000159	0.0206	-0.12	-0.17	Body mass index;	chr1:155898834	chr1:155316863~155324176:-
HNSC	cis	rs1167827	0.68	rs1167796	ENSG00000205583.12	STAG3L1	-3.81	0.000159	0.0206	-0.2	-0.17	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75359194~75395383:+
HNSC	cis	rs12908161	1	rs62021219	ENSG00000229212.6	RP11-561C5.4	-3.81	0.000159	0.0206	-0.25	-0.17	Schizophrenia;	chr15:84712928	chr15:85205440~85234795:-
HNSC	cis	rs12908161	1	rs34900908	ENSG00000229212.6	RP11-561C5.4	-3.81	0.000159	0.0206	-0.25	-0.17	Schizophrenia;	chr15:84714368	chr15:85205440~85234795:-
HNSC	cis	rs12908161	1	rs35524990	ENSG00000229212.6	RP11-561C5.4	-3.81	0.000159	0.0206	-0.25	-0.17	Schizophrenia;	chr15:84714972	chr15:85205440~85234795:-
HNSC	cis	rs5758511	0.514	rs5758638	ENSG00000205702.9	CYP2D7	3.81	0.000159	0.0206	0.15	0.17	Birth weight;	chr22:42186388	chr22:42140203~42144577:-
HNSC	cis	rs62025270	0.747	rs17639314	ENSG00000259762.1	RP11-158M2.4	-3.81	0.000159	0.0206	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85750336~85752901:-
HNSC	cis	rs59072263	0.688	rs6959703	ENSG00000233264.2	AC006042.8	-3.81	0.000159	0.0206	-0.23	-0.17	Intraocular pressure;	chr7:8106010	chr7:7980312~7982228:+
HNSC	cis	rs950027	0.62	rs1426932	ENSG00000259479.5	SORD2P	3.81	0.000159	0.0206	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:44826371~44884694:-
HNSC	cis	rs116095464	0.558	rs13357299	ENSG00000277812.1	AC021087.1	3.81	0.000159	0.0206	0.29	0.17	Breast cancer;	chr5:242096	chr5:262769~262881:+
HNSC	cis	rs2439831	0.717	rs10518820	ENSG00000275601.1	AC011330.13	-3.81	0.000159	0.0206	-0.3	-0.17	Lung cancer in ever smokers;	chr15:43596778	chr15:43642389~43643023:-
HNSC	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	3.81	0.000159	0.0206	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	3.81	0.000159	0.0206	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
HNSC	cis	rs3736485	0.868	rs8023455	ENSG00000274528.1	CTD-2650P22.2	3.81	0.000159	0.0206	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51644313	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.868	rs60060794	ENSG00000274528.1	CTD-2650P22.2	3.81	0.000159	0.0206	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51644984	chr15:52017167~52018032:-
HNSC	cis	rs10484434	0.818	rs11756400	ENSG00000217159.2	LARP1P1	3.81	0.000159	0.0206	0.27	0.17	HIV-1 viral setpoint;	chr6:26040625	chr6:26164072~26164363:+
HNSC	cis	rs13325613	0.834	rs13059906	ENSG00000223552.1	RP11-24F11.2	-3.81	0.000159	0.0206	-0.25	-0.17	Monocyte count;	chr3:46167366	chr3:46364955~46407059:-
HNSC	cis	rs6504950	0.79	rs8076984	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54958067	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs17745231	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54959168	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs12938118	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54959998	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs1802212	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54961293	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs17817901	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54961384	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs12150038	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54964159	chr17:54956760~54958426:-
HNSC	cis	rs6504950	0.83	rs12951542	ENSG00000279059.1	RP11-257O5.2	-3.81	0.000159	0.0206	-0.15	-0.17	Breast cancer;	chr17:54964604	chr17:54956760~54958426:-
HNSC	cis	rs7824557	0.602	rs7816636	ENSG00000255310.2	AF131215.2	3.81	0.000159	0.0207	0.16	0.17	Retinal vascular caliber;	chr8:11348145	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.602	rs7828711	ENSG00000255310.2	AF131215.2	3.81	0.000159	0.0207	0.16	0.17	Retinal vascular caliber;	chr8:11348156	chr8:11107788~11109726:-
HNSC	cis	rs73201462	1	rs2811414	ENSG00000231305.3	RP11-723O4.2	3.81	0.000159	0.0207	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272334	chr3:128861313~128871540:-
HNSC	cis	rs2239557	1	rs10150201	ENSG00000258769.1	RAP1AP	3.81	0.000159	0.0207	0.19	0.17	Common traits (Other);	chr14:74182454	chr14:74482985~74483435:+
HNSC	cis	rs7302981	0.719	rs835592	ENSG00000272368.2	RP4-605O3.4	3.81	0.000159	0.0207	0.17	0.17	Systolic blood pressure;	chr12:50067048	chr12:50112197~50165618:+
HNSC	cis	rs6500395	1	rs8052640	ENSG00000261267.1	RP11-44I10.3	-3.81	0.000159	0.0207	-0.21	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48570185	chr16:48559661~48587403:+
HNSC	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-3.81	0.000159	0.0207	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
HNSC	cis	rs7646881	0.544	rs74821076	ENSG00000272087.1	RP11-379F4.7	3.81	0.00016	0.0207	0.25	0.17	Tetralogy of Fallot;	chr3:158683377	chr3:158693120~158693768:-
HNSC	cis	rs7646881	0.589	rs17631016	ENSG00000272087.1	RP11-379F4.7	3.81	0.00016	0.0207	0.25	0.17	Tetralogy of Fallot;	chr3:158685696	chr3:158693120~158693768:-
HNSC	cis	rs7646881	0.508	rs17631078	ENSG00000272087.1	RP11-379F4.7	3.81	0.00016	0.0207	0.25	0.17	Tetralogy of Fallot;	chr3:158687916	chr3:158693120~158693768:-
HNSC	cis	rs28830936	1	rs112896623	ENSG00000250379.1	RP11-23P13.4	3.81	0.00016	0.0207	0.21	0.17	Diastolic blood pressure;	chr15:41709647	chr15:41825099~41827936:-
HNSC	cis	rs10497399	0.527	rs7591449	ENSG00000271151.1	RP11-394I13.2	-3.81	0.00016	0.0207	-0.17	-0.17	Adiponectin levels;	chr2:173251401	chr2:173968351~173969418:+
HNSC	cis	rs2888830	1	rs2888830	ENSG00000188693.7	CYP51A1-AS1	3.81	0.00016	0.0207	0.19	0.17	Dental caries;	chr7:91286039	chr7:92134604~92180725:+
HNSC	cis	rs2074409	0.509	rs9890344	ENSG00000276054.1	RP11-378E13.3	-3.81	0.00016	0.0207	-0.19	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37405930	chr17:37386886~37387926:+
HNSC	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	3.81	0.00016	0.0207	0.16	0.17	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
HNSC	cis	rs12986445	0.947	rs6728684	ENSG00000218682.1	AC010150.1	3.81	0.00016	0.0207	0.22	0.17	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25927904	chr2:25856461~25856966:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000213640.3	EEF1DP4	-3.81	0.00016	0.0207	-0.21	-0.17	Calcium levels;	chr7:65800652	chr7:64862999~64864370:+
HNSC	cis	rs7178909	0.902	rs3853638	ENSG00000259677.1	RP11-493E3.1	-3.81	0.00016	0.0207	-0.19	-0.17	Common traits (Other);	chr15:89899908	chr15:89876540~89877285:+
HNSC	cis	rs6088590	0.561	rs6059918	ENSG00000276073.1	RP5-1125A11.7	-3.81	0.00016	0.0207	-0.18	-0.17	Coronary artery disease;	chr20:34562699	chr20:33985617~33988989:-
HNSC	cis	rs7324557	0.683	rs9507167	ENSG00000205861.10	C1QTNF9B-AS1	3.81	0.00016	0.0207	0.23	0.17	Visceral adipose tissue adjusted for BMI;	chr13:23829525	chr13:23888889~23897263:+
HNSC	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	3.81	0.00016	0.0207	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
HNSC	cis	rs10938353	0.911	rs6447356	ENSG00000273369.1	RP11-700J17.1	-3.81	0.00016	0.0207	-0.22	-0.17	Body mass index;	chr4:44588558	chr4:44693946~44694386:-
HNSC	cis	rs10938353	0.911	rs6447357	ENSG00000273369.1	RP11-700J17.1	-3.81	0.00016	0.0207	-0.22	-0.17	Body mass index;	chr4:44588577	chr4:44693946~44694386:-
HNSC	cis	rs2834512	0.673	rs2298348	ENSG00000214955.5	AP000318.2	3.81	0.00016	0.0207	0.28	0.17	Cancer;	chr21:34549048	chr21:34205055~34325034:+
HNSC	cis	rs1937680	0.613	rs1937677	ENSG00000236671.6	PRKG1-AS1	-3.81	0.00016	0.0207	-0.25	-0.17	Breast cancer;	chr10:51912005	chr10:52230742~52314128:-
HNSC	cis	rs73198271	1	rs73198279	ENSG00000253893.2	FAM85B	3.81	0.00016	0.0207	0.25	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8167819~8226614:-
HNSC	cis	rs2904524	0.881	rs77987335	ENSG00000257815.4	RP11-611E13.2	-3.81	0.00016	0.0207	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70348180	chr12:69904033~70243360:-
HNSC	cis	rs792448	0.66	rs12035647	ENSG00000226251.4	RP11-15I11.3	-3.81	0.00016	0.0207	-0.21	-0.17	White blood cell count (basophil);	chr1:212313969	chr1:212225278~212238977:-
HNSC	cis	rs792448	0.743	rs4951589	ENSG00000226251.4	RP11-15I11.3	-3.81	0.00016	0.0207	-0.21	-0.17	White blood cell count (basophil);	chr1:212327351	chr1:212225278~212238977:-
HNSC	cis	rs10484434	0.901	rs1800758	ENSG00000218690.1	HIST1H2APS4	3.81	0.00016	0.0207	0.28	0.17	HIV-1 viral setpoint;	chr6:26093008	chr6:26272193~26272540:-
HNSC	cis	rs9487051	0.714	rs9487053	ENSG00000219700.1	PTCHD3P3	3.81	0.00016	0.0207	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109298494	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.714	rs6927569	ENSG00000219700.1	PTCHD3P3	3.81	0.00016	0.0207	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109300291	chr6:109288571~109290503:-
HNSC	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-3.81	0.00016	0.0207	-0.26	-0.17	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-3.81	0.00016	0.0207	-0.26	-0.17	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-3.81	0.00016	0.0207	-0.26	-0.17	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-3.81	0.00016	0.0207	-0.26	-0.17	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
HNSC	cis	rs9402743	0.673	rs9483858	ENSG00000234084.1	RP3-388E23.2	-3.81	0.00016	0.0207	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135642670	chr6:135301568~135307158:+
HNSC	cis	rs7178375	1	rs1474382	ENSG00000215302.7	CTD-3092A11.1	-3.81	0.00016	0.0207	-0.27	-0.17	Hypertriglyceridemia;	chr15:30922446	chr15:30470779~30507623:+
HNSC	cis	rs7246760	0.737	rs57296518	ENSG00000267289.1	CTD-2623N2.11	3.81	0.00016	0.0207	0.29	0.17	Pursuit maintenance gain;	chr19:9709274	chr19:9834079~9835013:-
HNSC	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	3.81	0.00016	0.0207	0.22	0.17	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
HNSC	cis	rs116095464	0.614	rs78905930	ENSG00000277812.1	AC021087.1	3.81	0.00016	0.0207	0.29	0.17	Breast cancer;	chr5:246445	chr5:262769~262881:+
HNSC	cis	rs1552244	1	rs17032396	ENSG00000180385.7	EMC3-AS1	-3.81	0.00016	0.0207	-0.2	-0.17	Alzheimer's disease;	chr3:10111875	chr3:9986893~10006990:+
HNSC	cis	rs112158604	1	rs112158604	ENSG00000236713.1	RP11-363I22.3	3.81	0.00016	0.0207	0.19	0.17	Lymphocyte counts;	chr1:150724325	chr1:150780272~150780644:+
HNSC	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-3.81	0.00016	0.0207	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
HNSC	cis	rs28489187	0.66	rs6576767	ENSG00000223653.4	RP11-131L23.1	-3.81	0.00016	0.0207	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85410633	chr1:85276715~85448124:+
HNSC	cis	rs8067545	0.603	rs10083830	ENSG00000261033.1	RP11-209D14.2	-3.81	0.00016	0.0208	-0.2	-0.17	Schizophrenia;	chr17:20062570	chr17:20008051~20009234:-
HNSC	cis	rs7937890	0.732	rs7946902	ENSG00000254418.1	RP11-21L19.1	-3.81	0.000161	0.0208	-0.21	-0.17	Mitochondrial DNA levels;	chr11:14251762	chr11:14262846~14273691:-
HNSC	cis	rs2337406	1	rs17113331	ENSG00000211972.2	IGHV3-66	3.81	0.000161	0.0208	0.18	0.17	Alzheimer's disease (late onset);	chr14:106703843	chr14:106675017~106675544:-
HNSC	cis	rs8028182	0.636	rs11638974	ENSG00000260269.4	CTD-2323K18.1	-3.81	0.000161	0.0208	-0.23	-0.17	Sudden cardiac arrest;	chr15:75506965	chr15:75527150~75601205:-
HNSC	cis	rs6545883	0.929	rs55806663	ENSG00000271889.1	RP11-493E12.1	3.81	0.000161	0.0208	0.2	0.17	Tuberculosis;	chr2:61513352	chr2:61151433~61162105:-
HNSC	cis	rs7011507	0.7	rs6989759	ENSG00000253608.1	RP11-770E5.1	-3.81	0.000161	0.0208	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48384318	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.7	rs72637700	ENSG00000253608.1	RP11-770E5.1	-3.81	0.000161	0.0208	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48392064	chr8:48551567~48698510:+
HNSC	cis	rs72627509	0.638	rs78933653	ENSG00000269949.1	RP11-738E22.3	3.81	0.000161	0.0208	0.29	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56988674	chr4:56960927~56961373:-
HNSC	cis	rs2905347	0.895	rs2961282	ENSG00000179428.2	AC073072.5	3.81	0.000161	0.0208	0.2	0.17	Major depression and alcohol dependence;	chr7:22600770	chr7:22725395~22727620:-
HNSC	cis	rs4144743	0.528	rs11868894	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000161	0.0208	-0.21	-0.17	Body mass index;	chr17:47275823	chr17:47450568~47492492:-
HNSC	cis	rs516805	0.706	rs9490430	ENSG00000279453.1	RP3-425C14.4	3.8	0.000161	0.0208	0.23	0.17	Lymphocyte counts;	chr6:122360951	chr6:122436789~122439223:-
HNSC	cis	rs210138	0.706	rs444697	ENSG00000197251.3	LINC00336	3.8	0.000161	0.0208	0.2	0.17	Testicular germ cell tumor;	chr6:33607232	chr6:33586106~33593338:-
HNSC	cis	rs1056107	0.513	rs10817338	ENSG00000225513.1	RP11-165N19.2	-3.8	0.000161	0.0208	-0.18	-0.17	Colorectal cancer;	chr9:112419933	chr9:112173522~112173971:-
HNSC	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-3.8	0.000161	0.0208	-0.24	-0.17	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
HNSC	cis	rs9611565	0.649	rs79005	ENSG00000235513.1	RP4-756G23.5	-3.8	0.000161	0.0208	-0.2	-0.17	Vitiligo;	chr22:41439540	chr22:41209122~41217627:-
HNSC	cis	rs7189233	0.531	rs7199401	ENSG00000261056.2	RP11-454F8.2	-3.8	0.000161	0.0208	-0.19	-0.17	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53298224~53299792:+
HNSC	cis	rs7989332	1	rs7329823	ENSG00000226633.2	PPIAP28	-3.8	0.000161	0.0208	-0.23	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20475988	chr13:20178978~20179462:-
HNSC	cis	rs7989332	1	rs7989332	ENSG00000226633.2	PPIAP28	-3.8	0.000161	0.0208	-0.23	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20476436	chr13:20178978~20179462:-
HNSC	cis	rs17407555	0.71	rs7696388	ENSG00000250413.1	RP11-448G15.1	-3.8	0.000161	0.0208	-0.23	-0.17	Schizophrenia (age at onset);	chr4:10271309	chr4:10006482~10009725:+
HNSC	cis	rs1555322	1	rs2425034	ENSG00000279253.1	RP4-614O4.13	-3.8	0.000161	0.0208	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35262727~35264187:-
HNSC	cis	rs1555322	0.858	rs2425035	ENSG00000279253.1	RP4-614O4.13	-3.8	0.000161	0.0208	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35262727~35264187:-
HNSC	cis	rs9923283	0.673	rs4788173	ENSG00000205534.6	SMG1P2	3.8	0.000161	0.0208	0.36	0.17	Plateletcrit;	chr16:29659415	chr16:29527568~29594966:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000272831.1	RP11-792A8.4	-3.8	0.000161	0.0208	-0.14	-0.17	Aortic root size;	chr7:66032447	chr7:66739829~66740385:-
HNSC	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	3.8	0.000161	0.0208	0.18	0.17	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
HNSC	cis	rs62458065	0.85	rs10239812	ENSG00000226468.2	AC018641.7	3.8	0.000161	0.0208	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32456963~32457758:-
HNSC	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-3.8	0.000161	0.0208	-0.21	-0.17	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
HNSC	cis	rs2518049	0.904	rs7898263	ENSG00000224034.1	RP11-445P17.8	-3.8	0.000161	0.0208	-0.23	-0.17	Metabolic traits;	chr10:5079014	chr10:5266033~5271236:-
HNSC	cis	rs7809615	0.515	rs11772470	ENSG00000244219.5	GS1-259H13.2	-3.8	0.000161	0.0208	-0.27	-0.17	Blood metabolite ratios;	chr7:99583473	chr7:99598066~99610813:+
HNSC	cis	rs897984	0.806	rs11150600	ENSG00000279196.1	RP11-1072A3.3	-3.8	0.000161	0.0208	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30929010	chr16:30984630~30988270:-
HNSC	cis	rs755249	0.53	rs1472662	ENSG00000182109.6	RP11-69E11.4	3.8	0.000161	0.0208	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39522280~39546187:-
HNSC	cis	rs804280	0.509	rs13268030	ENSG00000227888.4	FAM66A	3.8	0.000161	0.0208	0.17	0.17	Myopia (pathological);	chr8:11925564	chr8:12362019~12388296:+
HNSC	cis	rs3740713	1	rs73438631	ENSG00000256464.1	YWHABP2	3.8	0.000161	0.0208	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr11:18490243~18490955:-
HNSC	cis	rs6556416	0.538	rs254839	ENSG00000253256.1	CTB-11I22.1	-3.8	0.000161	0.0208	-0.27	-0.17	Ankylosing spondylitis;	chr5:159248135	chr5:159209921~159248796:+
HNSC	cis	rs10805346	0.531	rs12498927	ENSG00000261490.1	RP11-448G15.3	-3.8	0.000161	0.0208	-0.14	-0.17	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113899	chr4:10068089~10073019:-
HNSC	cis	rs7429990	0.932	rs34025851	ENSG00000228638.1	FCF1P2	-3.8	0.000161	0.0208	-0.16	-0.17	Educational attainment (years of education);	chr3:47912243	chr3:48290793~48291375:-
HNSC	cis	rs12893668	0.667	rs8017628	ENSG00000269958.1	RP11-73M18.8	3.8	0.000161	0.0208	0.16	0.17	Reticulocyte count;	chr14:103581091	chr14:103696353~103697163:+
HNSC	cis	rs62560775	0.688	rs3217986	ENSG00000240498.5	CDKN2B-AS1	3.8	0.000161	0.0208	0.33	0.17	Lung cancer;Lung adenocarcinoma;	chr9:22005331	chr9:21994778~22121097:+
HNSC	cis	rs748404	0.666	rs10518812	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0208	-0.24	-0.17	Lung cancer;	chr15:43360739	chr15:43699488~43718184:-
HNSC	cis	rs11711311	1	rs9827682	ENSG00000241529.3	RN7SL767P	-3.8	0.000161	0.0208	-0.22	-0.17	IgG glycosylation;	chr3:113731404	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs12497716	ENSG00000241529.3	RN7SL767P	-3.8	0.000161	0.0208	-0.22	-0.17	IgG glycosylation;	chr3:113734411	chr3:113632704~113632998:+
HNSC	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-3.8	0.000161	0.0208	-0.22	-0.17	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
HNSC	cis	rs7429990	0.864	rs4410463	ENSG00000228638.1	FCF1P2	3.8	0.000161	0.0208	0.16	0.17	Educational attainment (years of education);	chr3:47693907	chr3:48290793~48291375:-
HNSC	cis	rs739496	0.615	rs609230	ENSG00000226469.1	ADAM1B	-3.8	0.000161	0.0208	-0.2	-0.17	Platelet count;	chr12:111709107	chr12:111927018~111929017:+
HNSC	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-3.8	0.000161	0.0208	-0.21	-0.17	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
HNSC	cis	rs11992162	0.933	rs10108075	ENSG00000269918.1	AF131215.9	3.8	0.000161	0.0209	0.17	0.17	Monocyte count;	chr8:11974570	chr8:11104691~11106704:-
HNSC	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-3.8	0.000161	0.0209	-0.19	-0.17	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
HNSC	cis	rs10129255	0.518	rs10136903	ENSG00000224373.3	IGHV4-59	3.8	0.000161	0.0209	0.1	0.17	Kawasaki disease;	chr14:106778866	chr14:106627249~106627825:-
HNSC	cis	rs9329221	0.527	rs6989657	ENSG00000255310.2	AF131215.2	3.8	0.000161	0.0209	0.17	0.17	Neuroticism;	chr8:10473363	chr8:11107788~11109726:-
HNSC	cis	rs4081724	0.565	rs73026209	ENSG00000267296.2	CEBPA-AS1	3.8	0.000161	0.0209	0.32	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315704	chr19:33302857~33305054:+
HNSC	cis	rs4081724	0.565	rs118046236	ENSG00000267296.2	CEBPA-AS1	3.8	0.000161	0.0209	0.32	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33316199	chr19:33302857~33305054:+
HNSC	cis	rs250677	0.687	rs40149	ENSG00000250072.4	CTC-529P8.1	-3.8	0.000161	0.0209	-0.22	-0.17	Breast cancer;	chr5:149064712	chr5:149063317~149109787:+
HNSC	cis	rs6090919	0.501	rs17445251	ENSG00000222365.1	SNORD12B	-3.8	0.000161	0.0209	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48865401	chr20:49280319~49280409:+
HNSC	cis	rs67311347	0.544	rs4974047	ENSG00000280739.1	EIF1B-AS1	3.8	0.000161	0.0209	0.18	0.17	Renal cell carcinoma;	chr3:40298162	chr3:40173145~40309698:-
HNSC	cis	rs12047808	0.73	rs2274624	ENSG00000227141.2	RP11-545A16.3	-3.8	0.000161	0.0209	-0.27	-0.17	Multiple sclerosis (age of onset);	chr1:179551525	chr1:179586705~179589175:+
HNSC	cis	rs8077577	0.789	rs62072546	ENSG00000260647.1	RP1-178F10.1	3.8	0.000161	0.0209	0.25	0.17	Obesity-related traits;	chr17:18350525	chr17:18268080~18268828:+
HNSC	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	3.8	0.000161	0.0209	0.19	0.17	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
HNSC	cis	rs4927850	0.529	rs6800500	ENSG00000226155.1	AC124944.3	-3.8	0.000161	0.0209	-0.21	-0.17	Pancreatic cancer;	chr3:196106636	chr3:195912049~195913986:+
HNSC	cis	rs449789	0.817	rs1875814	ENSG00000235086.1	FNDC1-IT1	-3.8	0.000162	0.0209	-0.21	-0.17	Pulse pressure;	chr6:159299234	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs1875816	ENSG00000235086.1	FNDC1-IT1	-3.8	0.000162	0.0209	-0.21	-0.17	Pulse pressure;	chr6:159299282	chr6:159240786~159243329:+
HNSC	cis	rs7824557	0.569	rs7816601	ENSG00000255310.2	AF131215.2	3.8	0.000162	0.0209	0.16	0.17	Retinal vascular caliber;	chr8:11348084	chr8:11107788~11109726:-
HNSC	cis	rs7927592	0.956	rs948315	ENSG00000255031.4	RP11-802E16.3	3.8	0.000162	0.0209	0.16	0.17	Total body bone mineral density;	chr11:68541672	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.956	rs10896343	ENSG00000255031.4	RP11-802E16.3	3.8	0.000162	0.0209	0.16	0.17	Total body bone mineral density;	chr11:68550392	chr11:68050740~68053762:+
HNSC	cis	rs6565653	0.967	rs9891253	ENSG00000262580.4	RP11-334C17.5	3.8	0.000162	0.0209	0.14	0.17	Ischemic stroke;	chr17:80226377	chr17:80200673~80205949:-
HNSC	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	3.8	0.000162	0.0209	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
HNSC	cis	rs860295	0.58	rs867549	ENSG00000225855.5	RUSC1-AS1	3.8	0.000162	0.0209	0.12	0.17	Body mass index;	chr1:155910368	chr1:155316863~155324176:-
HNSC	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	3.8	0.000162	0.0209	0.18	0.17	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
HNSC	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-3.8	0.000162	0.0209	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
HNSC	cis	rs7989332	0.961	rs7321826	ENSG00000226633.2	PPIAP28	-3.8	0.000162	0.0209	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20479227	chr13:20178978~20179462:-
HNSC	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	3.8	0.000162	0.0209	0.2	0.17	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
HNSC	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	3.8	0.000162	0.0209	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
HNSC	cis	rs9437689	0.902	rs10874902	ENSG00000237416.5	RP11-465K1.2	3.8	0.000162	0.0209	0.21	0.17	Phospholipid levels (plasma);	chr1:95040705	chr1:94836748~94855426:-
HNSC	cis	rs73201462	1	rs11709611	ENSG00000231305.3	RP11-723O4.2	-3.8	0.000162	0.0209	-0.25	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348432	chr3:128861313~128871540:-
HNSC	cis	rs11773103	0.581	rs73202987	ENSG00000224046.1	AC005076.5	3.8	0.000162	0.0209	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87126637	chr7:87151423~87152420:-
HNSC	cis	rs7572733	0.534	rs700687	ENSG00000231621.1	AC013264.2	-3.8	0.000162	0.0209	-0.17	-0.17	Dermatomyositis;	chr2:197856836	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs696817	ENSG00000231621.1	AC013264.2	-3.8	0.000162	0.0209	-0.17	-0.17	Dermatomyositis;	chr2:197857501	chr2:197197991~197199273:+
HNSC	cis	rs7646881	0.544	rs16847130	ENSG00000272087.1	RP11-379F4.7	3.8	0.000162	0.0209	0.23	0.17	Tetralogy of Fallot;	chr3:158705785	chr3:158693120~158693768:-
HNSC	cis	rs73198271	0.563	rs3748143	ENSG00000173295.6	FAM86B3P	3.8	0.000162	0.0209	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797727	chr8:8228595~8244865:+
HNSC	cis	rs7927592	0.956	rs12277225	ENSG00000255031.4	RP11-802E16.3	3.8	0.000162	0.0209	0.16	0.17	Total body bone mineral density;	chr11:68573499	chr11:68050740~68053762:+
HNSC	cis	rs9650657	0.615	rs11986845	ENSG00000269918.1	AF131215.9	-3.8	0.000162	0.0209	-0.17	-0.17	Neuroticism;	chr8:10833808	chr8:11104691~11106704:-
HNSC	cis	rs7027071	0.73	rs10986072	ENSG00000235204.1	RP11-121A14.2	3.8	0.000162	0.0209	0.32	0.17	Morning vs. evening chronotype;	chr9:123606141	chr9:124259250~124261156:-
HNSC	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-3.8	0.000162	0.0209	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
HNSC	cis	rs1316952	0.568	rs74816775	ENSG00000269938.1	RP11-214K3.20	-3.8	0.000162	0.0209	-0.39	-0.17	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123980129	chr12:123968023~123968579:-
HNSC	cis	rs591584	0.73	rs7342170	ENSG00000255893.1	RP11-685N10.1	-3.8	0.000162	0.0209	-0.25	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94581311	chr11:94472908~94473570:-
HNSC	cis	rs3018712	0.532	rs2513280	ENSG00000212093.1	AP000807.1	-3.8	0.000162	0.0209	-0.26	-0.17	Total body bone mineral density;	chr11:68649439	chr11:68506083~68506166:-
HNSC	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	3.8	0.000162	0.0209	0.19	0.17	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
HNSC	cis	rs4388249	1	rs3753176	ENSG00000271849.1	CTC-332L22.1	-3.8	0.000162	0.0209	-0.27	-0.17	Schizophrenia;	chr5:109772581	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.95	rs2042164	ENSG00000271849.1	CTC-332L22.1	-3.8	0.000162	0.0209	-0.27	-0.17	Schizophrenia;	chr5:109776323	chr5:109687802~109688329:-
HNSC	cis	rs4427176	0.507	rs11783635	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000162	0.0209	-0.24	-0.17	Mosquito bite size;	chr8:9730293	chr8:9141424~9145435:+
HNSC	cis	rs656319	0.559	rs60384372	ENSG00000269918.1	AF131215.9	-3.8	0.000162	0.0209	-0.17	-0.17	Myopia (pathological);	chr8:10117074	chr8:11104691~11106704:-
HNSC	cis	rs2307394	0.716	rs7568718	ENSG00000281469.1	RP11-567F11.1	3.8	0.000162	0.0209	0.19	0.17	Urate levels;	chr2:147757290	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.716	rs4662293	ENSG00000281469.1	RP11-567F11.1	3.8	0.000162	0.0209	0.19	0.17	Urate levels;	chr2:147757996	chr2:148044380~148044894:+
HNSC	cis	rs6493858	0.839	rs4310791	ENSG00000277245.1	RP11-48G14.3	-3.8	0.000162	0.0209	-0.2	-0.17	Relative hand skill in reading disability;	chr15:56134303	chr15:56447120~56447697:+
HNSC	cis	rs913655	0.508	rs7910310	ENSG00000225527.1	RP11-383B4.4	-3.8	0.000162	0.0209	-0.21	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18748414	chr10:18531849~18533336:-
HNSC	cis	rs11846409	0.932	rs74091721	ENSG00000280411.1	IGHV1-69-2	-3.8	0.000162	0.0209	-0.16	-0.17	Rheumatic heart disease;	chr14:106638262	chr14:106762092~106762588:-
HNSC	cis	rs2548724	0.796	rs7734060	ENSG00000175749.11	EIF3KP1	3.8	0.000162	0.0209	0.25	0.17	Type 2 diabetes;	chr5:102444775	chr5:103032376~103033031:+
HNSC	cis	rs853679	0.517	rs1340004	ENSG00000219891.2	ZSCAN12P1	3.8	0.000162	0.0209	0.24	0.17	Depression;	chr6:28135913	chr6:28091154~28093664:+
HNSC	cis	rs62025270	0.632	rs111906684	ENSG00000259762.1	RP11-158M2.4	-3.8	0.000162	0.0209	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85750336~85752901:-
HNSC	cis	rs950169	0.845	rs4106951	ENSG00000230373.7	GOLGA6L5P	-3.8	0.000162	0.0209	-0.19	-0.17	Schizophrenia;	chr15:84164642	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.922	rs4842941	ENSG00000230373.7	GOLGA6L5P	3.8	0.000162	0.0209	0.19	0.17	Schizophrenia;	chr15:84162560	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.922	rs12911223	ENSG00000230373.7	GOLGA6L5P	3.8	0.000162	0.0209	0.19	0.17	Schizophrenia;	chr15:84162919	chr15:84507885~84516814:-
HNSC	cis	rs8028182	1	rs8028182	ENSG00000260269.4	CTD-2323K18.1	-3.8	0.000162	0.0209	-0.23	-0.17	Sudden cardiac arrest;	chr15:75426328	chr15:75527150~75601205:-
HNSC	cis	rs6935502	1	rs6935502	ENSG00000224984.1	RP11-524H19.2	-3.8	0.000162	0.0209	-0.2	-0.17	Subjective well-being;	chr6:54788742	chr6:54840118~54840855:-
HNSC	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	3.8	0.000162	0.0209	0.19	0.17	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	3.8	0.000162	0.0209	0.19	0.17	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	3.8	0.000162	0.0209	0.19	0.17	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	3.8	0.000162	0.0209	0.19	0.17	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
HNSC	cis	rs4840086	0.967	rs4840083	ENSG00000219755.1	RP1-199J3.5	3.8	0.000162	0.0209	0.22	0.17	Menarche (age at onset);	chr6:99752323	chr6:99575712~99576456:+
HNSC	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-3.8	0.000162	0.021	-0.25	-0.17	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
HNSC	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-3.8	0.000162	0.021	-0.2	-0.17	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
HNSC	cis	rs354225	0.565	rs2971880	ENSG00000237887.1	AC092839.1	-3.8	0.000162	0.021	-0.2	-0.17	Schizophrenia;	chr2:54658503	chr2:54529343~54529801:+
HNSC	cis	rs7824557	0.592	rs2736280	ENSG00000255310.2	AF131215.2	3.8	0.000162	0.021	0.16	0.17	Retinal vascular caliber;	chr8:11365513	chr8:11107788~11109726:-
HNSC	cis	rs35000415	0.938	rs12531054	ENSG00000275106.1	RP11-309L24.10	3.8	0.000162	0.021	0.38	0.17	Systemic lupus erythematosus;	chr7:129004197	chr7:128952527~128953316:-
HNSC	cis	rs34286592	1	rs13331733	ENSG00000196796.5	CTB-134H23.2	3.8	0.000162	0.021	0.25	0.17	Multiple sclerosis;	chr16:29837096	chr16:29038655~29052726:+
HNSC	cis	rs7829975	0.572	rs28446104	ENSG00000253981.4	ALG1L13P	-3.8	0.000162	0.021	-0.19	-0.17	Mood instability;	chr8:8938391	chr8:8236003~8244667:-
HNSC	cis	rs7824557	0.603	rs2246606	ENSG00000255310.2	AF131215.2	3.8	0.000162	0.021	0.16	0.17	Retinal vascular caliber;	chr8:11361825	chr8:11107788~11109726:-
HNSC	cis	rs9402743	0.702	rs9399150	ENSG00000231028.7	LINC00271	-3.8	0.000162	0.021	-0.2	-0.17	Systemic lupus erythematosus;	chr6:135599752	chr6:135497801~135716055:+
HNSC	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	3.8	0.000162	0.021	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	3.8	0.000162	0.021	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
HNSC	cis	rs6918586	0.565	rs198855	ENSG00000272810.1	U91328.22	-3.8	0.000162	0.021	-0.16	-0.17	Schizophrenia;	chr6:26103170	chr6:26013241~26013757:+
HNSC	cis	rs17253792	0.822	rs76819679	ENSG00000186615.9	KTN1-AS1	-3.8	0.000162	0.021	-0.34	-0.17	Putamen volume;	chr14:55667954	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs74940664	ENSG00000186615.9	KTN1-AS1	-3.8	0.000162	0.021	-0.34	-0.17	Putamen volume;	chr14:55668347	chr14:55499278~55580110:-
HNSC	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	3.8	0.000162	0.021	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
HNSC	cis	rs860818	1	rs858304	ENSG00000226816.2	AC005082.12	-3.8	0.000162	0.021	-0.44	-0.17	Initial pursuit acceleration;	chr7:23203534	chr7:23206013~23208045:+
HNSC	cis	rs1881509	0.702	rs7102832	ENSG00000255153.1	TOLLIP-AS1	-3.8	0.000162	0.021	-0.19	-0.17	Heroin dependence;	chr11:1413913	chr11:1309769~1310707:+
HNSC	cis	rs2836974	0.602	rs8130854	ENSG00000255568.3	BRWD1-AS2	-3.8	0.000163	0.021	-0.15	-0.17	Cognitive function;	chr21:39335115	chr21:39313935~39314962:+
HNSC	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-3.8	0.000163	0.021	-0.22	-0.17	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
HNSC	cis	rs757081	0.658	rs190046	ENSG00000260196.1	RP1-239B22.5	-3.8	0.000163	0.021	-0.18	-0.17	Systolic blood pressure;	chr11:17271809	chr11:17380649~17383531:+
HNSC	cis	rs250677	0.687	rs2963484	ENSG00000250072.4	CTC-529P8.1	-3.8	0.000163	0.021	-0.22	-0.17	Breast cancer;	chr5:149071564	chr5:149063317~149109787:+
HNSC	cis	rs7824557	0.564	rs7828263	ENSG00000255310.2	AF131215.2	-3.8	0.000163	0.021	-0.16	-0.17	Retinal vascular caliber;	chr8:11374377	chr8:11107788~11109726:-
HNSC	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	3.8	0.000163	0.021	0.25	0.17	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
HNSC	cis	rs4840086	0.935	rs17059754	ENSG00000219755.1	RP1-199J3.5	3.8	0.000163	0.021	0.22	0.17	Menarche (age at onset);	chr6:99754758	chr6:99575712~99576456:+
HNSC	cis	rs4948102	0.731	rs7800001	ENSG00000226278.1	PSPHP1	-3.8	0.000163	0.021	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56004317	chr7:55764797~55773288:+
HNSC	cis	rs9437689	0.966	rs2797622	ENSG00000237416.5	RP11-465K1.2	3.8	0.000163	0.021	0.21	0.17	Phospholipid levels (plasma);	chr1:94978646	chr1:94836748~94855426:-
HNSC	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	3.8	0.000163	0.021	0.26	0.17	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	3.8	0.000163	0.021	0.26	0.17	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
HNSC	cis	rs9313772	0.775	rs7724820	ENSG00000254350.1	RP11-542A14.1	-3.8	0.000163	0.021	-0.19	-0.17	Blood pressure;	chr5:158399245	chr5:158424585~158452758:+
HNSC	cis	rs73198271	0.813	rs56007835	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000163	0.021	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:9141424~9145435:+
HNSC	cis	rs72627509	0.638	rs78272732	ENSG00000269949.1	RP11-738E22.3	3.8	0.000163	0.021	0.29	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57004371	chr4:56960927~56961373:-
HNSC	cis	rs1023500	1	rs6002554	ENSG00000205702.9	CYP2D7	-3.8	0.000163	0.021	-0.14	-0.17	Schizophrenia;	chr22:41943091	chr22:42140203~42144577:-
HNSC	cis	rs2292864	0.764	rs1969269	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000163	0.021	-0.28	-0.17	Left atrial antero-posterior diameter;	chr17:47258171	chr17:47450568~47492492:-
HNSC	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-3.8	0.000163	0.021	-0.21	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
HNSC	cis	rs2307394	0.928	rs12989596	ENSG00000281469.1	RP11-567F11.1	3.8	0.000163	0.021	0.19	0.17	Urate levels;	chr2:147833663	chr2:148044380~148044894:+
HNSC	cis	rs709400	0.859	rs7154948	ENSG00000270108.1	RP11-73M18.6	3.8	0.000163	0.021	0.19	0.17	Body mass index;	chr14:103556607	chr14:103687576~103688127:+
HNSC	cis	rs3750965	0.959	rs3168115	ENSG00000265539.1	MIR3164	3.8	0.000163	0.021	0.18	0.17	Hair color;	chr11:69090622	chr11:69083176~69083258:+
HNSC	cis	rs1555322	1	rs2425034	ENSG00000126005.14	MMP24-AS1	-3.8	0.000163	0.021	-0.32	-0.17	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35216462~35278131:-
HNSC	cis	rs1555322	0.858	rs2425035	ENSG00000126005.14	MMP24-AS1	-3.8	0.000163	0.021	-0.32	-0.17	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35216462~35278131:-
HNSC	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-3.8	0.000163	0.021	-0.24	-0.17	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
HNSC	cis	rs478304	0.654	rs12289836	ENSG00000255120.4	OVOL1-AS1	3.8	0.000163	0.021	0.18	0.17	Acne (severe);	chr11:65669417	chr11:65789051~65790868:-
HNSC	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-3.8	0.000163	0.021	-0.24	-0.17	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
HNSC	cis	rs3018712	0.532	rs2510396	ENSG00000212093.1	AP000807.1	-3.8	0.000163	0.021	-0.26	-0.17	Total body bone mineral density;	chr11:68650184	chr11:68506083~68506166:-
HNSC	cis	rs17076726	0.519	rs6860414	ENSG00000253785.1	CTC-308K20.3	-3.8	0.000163	0.021	-0.18	-0.17	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173947952	chr5:172975511~172976374:+
HNSC	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	3.8	0.000163	0.021	0.17	0.17	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
HNSC	cis	rs12468579	0.503	rs1168	ENSG00000235852.1	AC005540.3	-3.8	0.000163	0.021	-0.2	-0.17	JT interval (sulfonylurea treatment interaction);	chr2:190965051	chr2:190880797~190882059:-
HNSC	cis	rs897984	0.806	rs8052245	ENSG00000279196.1	RP11-1072A3.3	-3.8	0.000163	0.021	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30905109	chr16:30984630~30988270:-
HNSC	cis	rs6928977	0.896	rs2746425	ENSG00000217482.2	HMGB1P17	-3.8	0.000163	0.021	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135343227	chr6:135636086~135636713:-
HNSC	cis	rs36093844	0.527	rs111955441	ENSG00000279742.1	RP11-700A24.1	-3.8	0.000163	0.021	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86048610	chr11:85852557~85854943:-
HNSC	cis	rs868153	0.625	rs225089	ENSG00000275339.1	RP3-425C14.6	3.8	0.000163	0.021	0.18	0.17	Vertical cup-disc ratio;	chr6:122257910	chr6:122454358~122454612:+
HNSC	cis	rs3733585	0.604	rs73215003	ENSG00000250413.1	RP11-448G15.1	3.8	0.000163	0.021	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10124693	chr4:10006482~10009725:+
HNSC	cis	rs2439831	0.717	rs2447198	ENSG00000201136.1	RNU6-353P	-3.8	0.000163	0.021	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43602920	chr15:43702363~43702470:+
HNSC	cis	rs10504130	0.502	rs12674620	ENSG00000253844.1	RP11-546K22.1	3.8	0.000163	0.021	0.26	0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51755043	chr8:51961458~52022974:+
HNSC	cis	rs5758659	1	rs5758660	ENSG00000273366.1	CTA-989H11.1	-3.8	0.000163	0.0211	-0.2	-0.17	Cognitive function;	chr22:42227712	chr22:42278188~42278846:+
HNSC	cis	rs9925964	0.804	rs9926533	ENSG00000232748.3	RP11-196G11.6	3.8	0.000163	0.0211	0.23	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:31056460~31062803:+
HNSC	cis	rs3740713	1	rs73438690	ENSG00000256464.1	YWHABP2	3.8	0.000163	0.0211	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr11:18490243~18490955:-
HNSC	cis	rs9393777	0.92	rs35768595	ENSG00000226314.6	ZNF192P1	-3.8	0.000163	0.0211	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28161781~28169594:+
HNSC	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-3.8	0.000163	0.0211	-0.18	-0.17	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
HNSC	cis	rs7005380	0.531	rs7838578	ENSG00000279347.1	RP11-85I17.2	-3.8	0.000163	0.0211	-0.18	-0.17	Interstitial lung disease;	chr8:119894807	chr8:119838736~119840385:-
HNSC	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	3.8	0.000163	0.0211	0.26	0.17	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
HNSC	cis	rs2762353	0.779	rs6905614	ENSG00000272462.2	U91328.19	-3.8	0.000163	0.0211	-0.17	-0.17	Blood metabolite levels;	chr6:25840257	chr6:25992662~26001775:+
HNSC	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0211	0.3	0.17	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0211	0.3	0.17	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0211	0.3	0.17	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0211	0.3	0.17	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
HNSC	cis	rs1881509	0.66	rs7102279	ENSG00000255153.1	TOLLIP-AS1	-3.8	0.000163	0.0211	-0.19	-0.17	Heroin dependence;	chr11:1413450	chr11:1309769~1310707:+
HNSC	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-3.8	0.000163	0.0211	-0.21	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
HNSC	cis	rs792448	0.728	rs2252044	ENSG00000226251.4	RP11-15I11.3	-3.8	0.000163	0.0211	-0.21	-0.17	White blood cell count (basophil);	chr1:212342903	chr1:212225278~212238977:-
HNSC	cis	rs442309	0.783	rs224095	ENSG00000238280.1	RP11-436D10.3	-3.8	0.000163	0.0211	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62782299	chr10:62793562~62805887:-
HNSC	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	3.8	0.000163	0.0211	0.18	0.17	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
HNSC	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	3.8	0.000163	0.0211	0.18	0.17	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
HNSC	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	3.8	0.000163	0.0211	0.21	0.17	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
HNSC	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	3.8	0.000163	0.0211	0.17	0.17	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
HNSC	cis	rs10875746	0.768	rs12305182	ENSG00000257763.1	OR5BK1P	-3.8	0.000163	0.0211	-0.2	-0.17	Longevity (90 years and older);	chr12:48027624	chr12:48355792~48356614:-
HNSC	cis	rs7720894	0.935	rs13170135	ENSG00000215032.2	GNL3LP1	-3.8	0.000163	0.0211	-0.19	-0.17	Body mass index;	chr5:61365115	chr5:60891935~60893577:-
HNSC	cis	rs28830936	1	rs11629678	ENSG00000250379.1	RP11-23P13.4	3.8	0.000163	0.0211	0.22	0.17	Diastolic blood pressure;	chr15:41640332	chr15:41825099~41827936:-
HNSC	cis	rs868153	0.625	rs13216675	ENSG00000275339.1	RP3-425C14.6	3.8	0.000163	0.0211	0.19	0.17	Vertical cup-disc ratio;	chr6:122131183	chr6:122454358~122454612:+
HNSC	cis	rs700651	0.821	rs700690	ENSG00000231621.1	AC013264.2	-3.8	0.000163	0.0211	-0.17	-0.17	Intracranial aneurysm;	chr2:197862902	chr2:197197991~197199273:+
HNSC	cis	rs4924935	1	rs11658555	ENSG00000264885.1	RP11-815I9.4	3.8	0.000163	0.0211	0.19	0.17	Pancreatic cancer;	chr17:18914173	chr17:18667629~18669461:-
HNSC	cis	rs2921036	0.545	rs4840975	ENSG00000253981.4	ALG1L13P	-3.8	0.000163	0.0211	-0.2	-0.17	Neuroticism;	chr8:8505748	chr8:8236003~8244667:-
HNSC	cis	rs1150668	0.796	rs2531825	ENSG00000217862.2	HIST1H4PS1	-3.8	0.000163	0.0211	-0.17	-0.17	Pubertal anthropometrics;	chr6:28381487	chr6:27807075~27807339:+
HNSC	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	3.8	0.000163	0.0211	0.18	0.17	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
HNSC	cis	rs13217239	0.511	rs3800314	ENSG00000216901.1	AL022393.7	3.8	0.000164	0.0211	0.19	0.17	Schizophrenia;	chr6:27268269	chr6:28176188~28176674:+
HNSC	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	3.8	0.000164	0.0211	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
HNSC	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-3.8	0.000164	0.0211	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
HNSC	cis	rs2562456	0.833	rs2359145	ENSG00000268119.4	CTD-2561J22.5	3.8	0.000164	0.0211	0.27	0.17	Pain;	chr19:21409791	chr19:21444241~21463908:-
HNSC	cis	rs2243480	1	rs383402	ENSG00000164669.11	INTS4P1	-3.8	0.000164	0.0211	-0.33	-0.17	Diabetic kidney disease;	chr7:66121666	chr7:65141225~65234216:+
HNSC	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	3.8	0.000164	0.0211	0.18	0.17	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
HNSC	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	3.8	0.000164	0.0211	0.17	0.17	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
HNSC	cis	rs6095360	0.966	rs3795082	ENSG00000222365.1	SNORD12B	-3.8	0.000164	0.0211	-0.19	-0.17	Intelligence (multi-trait analysis);	chr20:49056465	chr20:49280319~49280409:+
HNSC	cis	rs4256159	0.696	rs13092972	ENSG00000228956.7	SATB1-AS1	3.8	0.000164	0.0211	0.24	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18719392	chr3:18445024~18920401:+
HNSC	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-3.8	0.000164	0.0211	-0.18	-0.17	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
HNSC	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-3.8	0.000164	0.0211	-0.18	-0.17	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
HNSC	cis	rs9859260	0.744	rs557527	ENSG00000273009.1	RP11-352G9.1	3.8	0.000164	0.0211	0.2	0.17	Mean corpuscular volume;	chr3:196053838	chr3:195913078~195913683:-
HNSC	cis	rs11951515	0.626	rs9292871	ENSG00000249286.1	CTD-2210P15.2	3.8	0.000164	0.0211	0.19	0.17	Metabolite levels  (X-11787);	chr5:43304300	chr5:43586918~43588223:-
HNSC	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-3.8	0.000164	0.0211	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-3.8	0.000164	0.0211	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
HNSC	cis	rs67981189	0.634	rs221900	ENSG00000274818.1	RP1-292L20.3	3.8	0.000164	0.0211	0.19	0.17	Schizophrenia;	chr14:71137637	chr14:70906657~70907111:-
HNSC	cis	rs6088590	0.561	rs6059934	ENSG00000276073.1	RP5-1125A11.7	-3.8	0.000164	0.0211	-0.18	-0.17	Coronary artery disease;	chr20:34590520	chr20:33985617~33988989:-
HNSC	cis	rs7131987	0.565	rs6487797	ENSG00000257176.2	RP11-996F15.2	3.8	0.000164	0.0211	0.18	0.17	QT interval;	chr12:29270063	chr12:29280418~29317848:-
HNSC	cis	rs7989332	0.89	rs4769114	ENSG00000226633.2	PPIAP28	-3.8	0.000164	0.0211	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20477163	chr13:20178978~20179462:-
HNSC	cis	rs7989332	0.925	rs4769115	ENSG00000226633.2	PPIAP28	-3.8	0.000164	0.0211	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20477276	chr13:20178978~20179462:-
HNSC	cis	rs988913	0.957	rs9382405	ENSG00000224984.1	RP11-524H19.2	3.8	0.000164	0.0211	0.2	0.17	Menarche (age at onset);	chr6:54971815	chr6:54840118~54840855:-
HNSC	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-3.8	0.000164	0.0211	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
HNSC	cis	rs16953946	0.881	rs7187300	ENSG00000278985.1	RP11-303E16.9	-3.8	0.000164	0.0211	-0.24	-0.17	Inflammatory bowel disease;	chr16:80734969	chr16:80982319~80984094:-
HNSC	cis	rs4853525	0.59	rs2355570	ENSG00000228509.4	AC006460.2	3.8	0.000164	0.0211	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190916443	chr2:190676944~190708716:-
HNSC	cis	rs656319	0.629	rs11774276	ENSG00000255310.2	AF131215.2	-3.8	0.000164	0.0211	-0.17	-0.17	Myopia (pathological);	chr8:10212799	chr8:11107788~11109726:-
HNSC	cis	rs929354	1	rs929354	ENSG00000224629.1	RP5-1142J19.2	3.8	0.000164	0.0211	0.17	0.17	Body mass index;	chr7:157252863	chr7:157263022~157263229:-
HNSC	cis	rs61542988	1	rs61542988	ENSG00000226329.2	AC005682.6	3.8	0.000164	0.0211	0.23	0.17	Fibrinogen levels;	chr7:22842672	chr7:22863874~22881350:-
HNSC	cis	rs17489649	0.955	rs2216555	ENSG00000271849.1	CTC-332L22.1	3.8	0.000164	0.0211	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109800930	chr5:109687802~109688329:-
HNSC	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	3.8	0.000164	0.0211	0.21	0.17	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	3.8	0.000164	0.0211	0.21	0.17	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
HNSC	cis	rs12144094	1	rs55899400	ENSG00000260941.1	LINC00622	-3.8	0.000164	0.0212	-0.23	-0.17	Height;	chr1:119724808	chr1:119597702~119599271:-
HNSC	cis	rs6001482	0.679	rs5995706	ENSG00000253818.1	IGLV1-41	-3.8	0.000164	0.0212	-0.14	-0.17	Diastolic blood pressure;	chr22:22236371	chr22:22404207~22404721:+
HNSC	cis	rs6001482	0.702	rs7286018	ENSG00000253818.1	IGLV1-41	-3.8	0.000164	0.0212	-0.14	-0.17	Diastolic blood pressure;	chr22:22236464	chr22:22404207~22404721:+
HNSC	cis	rs6012564	1	rs6063360	ENSG00000227431.4	CSE1L-AS1	3.8	0.000164	0.0212	0.19	0.17	Anger;	chr20:49131838	chr20:49040463~49046044:-
HNSC	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-3.8	0.000164	0.0212	-0.21	-0.17	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
HNSC	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-3.8	0.000164	0.0212	-0.21	-0.17	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
HNSC	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-3.8	0.000164	0.0212	-0.2	-0.17	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
HNSC	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-3.8	0.000164	0.0212	-0.2	-0.17	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
HNSC	cis	rs7572733	0.935	rs1369512	ENSG00000222017.1	AC011997.1	3.8	0.000164	0.0212	0.21	0.17	Dermatomyositis;	chr2:197902408	chr2:197693106~197774823:+
HNSC	cis	rs227584	0.501	rs62078931	ENSG00000267080.4	ASB16-AS1	3.8	0.000164	0.0212	0.14	0.17	Bone mineral density;Bone mineral density (hip);	chr17:44120691	chr17:44175973~44186717:-
HNSC	cis	rs6787172	0.755	rs6778202	ENSG00000272087.1	RP11-379F4.7	3.8	0.000164	0.0212	0.18	0.17	Subjective well-being;	chr3:158482786	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs10936146	ENSG00000272087.1	RP11-379F4.7	3.8	0.000164	0.0212	0.18	0.17	Subjective well-being;	chr3:158485679	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.811	rs9835244	ENSG00000272087.1	RP11-379F4.7	3.8	0.000164	0.0212	0.18	0.17	Subjective well-being;	chr3:158486005	chr3:158693120~158693768:-
HNSC	cis	rs1862618	0.671	rs2591970	ENSG00000271828.1	CTD-2310F14.1	-3.8	0.000164	0.0212	-0.22	-0.17	Initial pursuit acceleration;	chr5:56936768	chr5:56927874~56929573:+
HNSC	cis	rs11098499	0.78	rs12504773	ENSG00000250412.1	KLHL2P1	3.8	0.000164	0.0212	0.23	0.17	Corneal astigmatism;	chr4:119640994	chr4:119334329~119378233:+
HNSC	cis	rs853679	0.545	rs35949109	ENSG00000219891.2	ZSCAN12P1	3.8	0.000164	0.0212	0.32	0.17	Depression;	chr6:28058148	chr6:28091154~28093664:+
HNSC	cis	rs6095360	0.649	rs34832487	ENSG00000222365.1	SNORD12B	-3.8	0.000164	0.0212	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48930575	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs67777906	ENSG00000222365.1	SNORD12B	-3.8	0.000164	0.0212	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48940592	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs13040589	ENSG00000222365.1	SNORD12B	-3.8	0.000164	0.0212	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48853494	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs8116854	ENSG00000222365.1	SNORD12B	-3.8	0.000164	0.0212	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:48854320	chr20:49280319~49280409:+
HNSC	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	3.8	0.000164	0.0212	0.16	0.17	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
HNSC	cis	rs4256159	0.735	rs35797240	ENSG00000228956.7	SATB1-AS1	3.8	0.000164	0.0212	0.25	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18711984	chr3:18445024~18920401:+
HNSC	cis	rs7688540	0.623	rs11735968	ENSG00000211553.1	AC253576.2	-3.8	0.000164	0.0212	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:136461~136568:+
HNSC	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	3.8	0.000164	0.0212	0.18	0.17	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
HNSC	cis	rs67311347	1	rs12494022	ENSG00000280739.1	EIF1B-AS1	3.8	0.000164	0.0212	0.21	0.17	Renal cell carcinoma;	chr3:40385161	chr3:40173145~40309698:-
HNSC	cis	rs865483	1	rs865483	ENSG00000276054.1	RP11-378E13.3	3.8	0.000164	0.0212	0.21	0.17	Monocyte count;	chr17:37491071	chr17:37386886~37387926:+
HNSC	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-3.8	0.000164	0.0212	-0.17	-0.17	Breast cancer;	chr11:743813	chr11:777578~784297:+
HNSC	cis	rs6012564	1	rs4810909	ENSG00000227431.4	CSE1L-AS1	-3.8	0.000164	0.0212	-0.2	-0.17	Anger;	chr20:49004835	chr20:49040463~49046044:-
HNSC	cis	rs6540731	0.905	rs11119883	ENSG00000226251.4	RP11-15I11.3	-3.8	0.000164	0.0212	-0.2	-0.17	Intelligence (childhood);	chr1:212213918	chr1:212225278~212238977:-
HNSC	cis	rs7011507	0.7	rs72639016	ENSG00000253608.1	RP11-770E5.1	-3.8	0.000164	0.0212	-0.32	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48420518	chr8:48551567~48698510:+
HNSC	cis	rs11098499	0.863	rs1155576	ENSG00000250412.1	KLHL2P1	3.8	0.000164	0.0212	0.22	0.17	Corneal astigmatism;	chr4:119529004	chr4:119334329~119378233:+
HNSC	cis	rs804280	0.543	rs13261205	ENSG00000227888.4	FAM66A	3.8	0.000164	0.0212	0.18	0.17	Myopia (pathological);	chr8:11933707	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.867	rs34465618	ENSG00000227888.4	FAM66A	3.8	0.000164	0.0212	0.18	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.867	rs34583868	ENSG00000227888.4	FAM66A	3.8	0.000164	0.0212	0.18	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:12362019~12388296:+
HNSC	cis	rs804280	0.518	rs34266352	ENSG00000227888.4	FAM66A	3.8	0.000164	0.0212	0.18	0.17	Myopia (pathological);	chr8:11933953	chr8:12362019~12388296:+
HNSC	cis	rs804280	0.542	rs36100659	ENSG00000227888.4	FAM66A	3.8	0.000164	0.0212	0.18	0.17	Myopia (pathological);	chr8:11934144	chr8:12362019~12388296:+
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Gout;	chr7:66715944	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Gout;	chr7:66721259	chr7:66848496~66858136:+
HNSC	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-3.8	0.000165	0.0212	-0.25	-0.17	Gout;	chr7:66732812	chr7:66848496~66858136:+
HNSC	cis	rs17711722	0.653	rs2460421	ENSG00000164669.11	INTS4P1	3.8	0.000165	0.0212	0.2	0.17	Calcium levels;	chr7:66026136	chr7:65141225~65234216:+
HNSC	cis	rs988913	0.706	rs12664361	ENSG00000224984.1	RP11-524H19.2	-3.8	0.000165	0.0212	-0.2	-0.17	Menarche (age at onset);	chr6:55046164	chr6:54840118~54840855:-
HNSC	cis	rs859767	0.501	rs6705916	ENSG00000224043.6	CCNT2-AS1	3.8	0.000165	0.0212	0.21	0.17	Neuroticism;	chr2:134639999	chr2:134735464~134918710:-
HNSC	cis	rs2836974	0.932	rs2836953	ENSG00000255568.3	BRWD1-AS2	3.8	0.000165	0.0212	0.16	0.17	Cognitive function;	chr21:39245557	chr21:39313935~39314962:+
HNSC	cis	rs10073892	0.511	rs6596506	ENSG00000250682.4	LINC00491	-3.8	0.000165	0.0212	-0.23	-0.17	Cognitive decline (age-related);	chr5:102545676	chr5:102609156~102671559:-
HNSC	cis	rs28489187	0.706	rs233095	ENSG00000223653.4	RP11-131L23.1	3.8	0.000165	0.0212	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85359133	chr1:85276715~85448124:+
HNSC	cis	rs9567406	0.588	rs7325084	ENSG00000227258.4	SMIM2-AS1	3.8	0.000165	0.0212	0.27	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr13:44269455	chr13:44110451~44240517:+
HNSC	cis	rs7558911	1	rs13035714	ENSG00000183308.6	AC005037.3	3.8	0.000165	0.0212	0.2	0.17	Chronic lymphocytic leukemia;	chr2:201164988	chr2:200963263~201009102:+
HNSC	cis	rs9437689	0.966	rs2766010	ENSG00000237416.5	RP11-465K1.2	3.8	0.000165	0.0212	0.21	0.17	Phospholipid levels (plasma);	chr1:94976986	chr1:94836748~94855426:-
HNSC	cis	rs4908768	0.52	rs7520025	ENSG00000232912.4	RP5-1115A15.1	3.8	0.000165	0.0212	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8424645~8434838:+
HNSC	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-3.8	0.000165	0.0212	-0.22	-0.17	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
HNSC	cis	rs2075677	0.506	rs2273101	ENSG00000222365.1	SNORD12B	-3.8	0.000165	0.0212	-0.22	-0.17	Subjective well-being;	chr20:48921796	chr20:49280319~49280409:+
HNSC	cis	rs1028883	0.837	rs1337298	ENSG00000228295.1	LINC00392	3.8	0.000165	0.0212	0.18	0.17	Lean body mass;	chr13:73556538	chr13:73564244~73588070:+
HNSC	cis	rs6496044	0.963	rs6496050	ENSG00000259295.5	CSPG4P12	3.8	0.000165	0.0212	0.21	0.17	Interstitial lung disease;	chr15:85526019	chr15:85191438~85213905:+
HNSC	cis	rs8077577	0.895	rs11078412	ENSG00000273018.4	CTD-2303H24.2	3.8	0.000165	0.0212	0.26	0.17	Obesity-related traits;	chr17:18197304	chr17:18511221~18551705:-
HNSC	cis	rs6968419	0.925	rs11764793	ENSG00000237870.5	AC073130.1	3.8	0.000165	0.0212	0.19	0.17	Intraocular pressure;	chr7:116191206	chr7:116275606~116286734:-
HNSC	cis	rs6558530	0.666	rs10113471	ENSG00000253982.1	CTD-2336O2.1	3.8	0.000165	0.0212	0.22	0.17	Systolic blood pressure;	chr8:1747661	chr8:1761990~1764502:-
HNSC	cis	rs17412738	0.564	rs60074228	ENSG00000248724.5	NPHP3-AS1	-3.8	0.000165	0.0212	-0.3	-0.17	Blood protein levels;	chr3:132408416	chr3:132721750~132874223:+
HNSC	cis	rs17404153	0.527	rs16839219	ENSG00000248724.5	NPHP3-AS1	-3.8	0.000165	0.0212	-0.3	-0.17	LDL cholesterol;HDL cholesterol;	chr3:132408616	chr3:132721750~132874223:+
HNSC	cis	rs9329221	0.967	rs7005363	ENSG00000270076.1	AF131215.8	-3.8	0.000165	0.0212	-0.2	-0.17	Neuroticism;	chr8:10426238	chr8:11202965~11203671:+
HNSC	cis	rs338389	0.516	rs17308514	ENSG00000260657.2	RP11-315D16.4	3.8	0.000165	0.0212	0.19	0.17	Survival in rectal cancer;	chr15:68020833	chr15:68267792~68277994:-
HNSC	cis	rs2074409	0.54	rs853202	ENSG00000276054.1	RP11-378E13.3	3.8	0.000165	0.0212	0.19	0.17	Response to angiotensin II receptor blocker therapy;	chr17:37445289	chr17:37386886~37387926:+
HNSC	cis	rs2526882	0.542	rs714421	ENSG00000274818.1	RP1-292L20.3	-3.8	0.000165	0.0212	-0.19	-0.17	Schizophrenia;	chr14:70892868	chr14:70906657~70907111:-
HNSC	cis	rs6504950	0.83	rs17817877	ENSG00000279059.1	RP11-257O5.2	-3.8	0.000165	0.0212	-0.15	-0.17	Breast cancer;	chr17:54957267	chr17:54956760~54958426:-
HNSC	cis	rs10462794	0.789	rs10043704	ENSG00000248973.1	RP11-445O3.2	3.8	0.000165	0.0212	0.22	0.17	DNA methylation (variation);	chr5:4491020	chr5:4451930~4866221:-
HNSC	cis	rs9925964	0.591	rs11649653	ENSG00000232748.3	RP11-196G11.6	3.8	0.000165	0.0212	0.23	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30907166	chr16:31056460~31062803:+
HNSC	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.26	0.17	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
HNSC	cis	rs17660992	0.525	rs10421946	ENSG00000273837.1	LLNLR-470E3.1	-3.8	0.000165	0.0213	-0.2	-0.17	Blood protein levels;	chr19:51661797	chr19:51639478~51639931:-
HNSC	cis	rs526231	0.697	rs253754	ENSG00000250682.4	LINC00491	3.8	0.000165	0.0213	0.25	0.17	Primary biliary cholangitis;	chr5:103296261	chr5:102609156~102671559:-
HNSC	cis	rs73198271	0.729	rs66564323	ENSG00000173295.6	FAM86B3P	-3.8	0.000165	0.0213	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747486	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.729	rs67653033	ENSG00000173295.6	FAM86B3P	-3.8	0.000165	0.0213	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747534	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.729	rs67000451	ENSG00000173295.6	FAM86B3P	-3.8	0.000165	0.0213	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747573	chr8:8228595~8244865:+
HNSC	cis	rs9987353	0.824	rs55688575	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000165	0.0213	-0.25	-0.17	Recombination measurement;	chr8:9275641	chr8:9141424~9145435:+
HNSC	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	3.8	0.000165	0.0213	0.24	0.17	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
HNSC	cis	rs6787172	0.622	rs4309677	ENSG00000272087.1	RP11-379F4.7	3.8	0.000165	0.0213	0.18	0.17	Subjective well-being;	chr3:158336014	chr3:158693120~158693768:-
HNSC	cis	rs6088580	0.634	rs945673	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000165	0.0213	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:33985617~33988989:-
HNSC	cis	rs28830936	1	rs2412622	ENSG00000250379.1	RP11-23P13.4	3.8	0.000165	0.0213	0.21	0.17	Diastolic blood pressure;	chr15:41668113	chr15:41825099~41827936:-
HNSC	cis	rs10971721	0.584	rs10971936	ENSG00000260947.1	RP11-384P7.7	3.8	0.000165	0.0213	0.29	0.17	Body mass index;	chr9:34118988	chr9:33697459~33700986:+
HNSC	cis	rs17264034	0.95	rs11951006	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539123	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs11951779	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539567	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs11958229	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539877	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs78826326	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539890	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs75336098	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9540744	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs17262778	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541048	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs77836114	ENSG00000250786.1	SNHG18	3.8	0.000165	0.0213	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541339	chr5:9546200~9550609:+
HNSC	cis	rs859767	0.501	rs10210052	ENSG00000224043.6	CCNT2-AS1	3.8	0.000165	0.0213	0.21	0.17	Neuroticism;	chr2:134659780	chr2:134735464~134918710:-
HNSC	cis	rs73198271	0.92	rs11783112	ENSG00000233609.3	RP11-62H7.2	-3.8	0.000165	0.0213	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:8961200~8979025:+
HNSC	cis	rs28489187	0.683	rs6671599	ENSG00000223653.4	RP11-131L23.1	-3.8	0.000165	0.0213	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85393174	chr1:85276715~85448124:+
HNSC	cis	rs703842	0.585	rs10877022	ENSG00000270039.1	RP11-571M6.17	-3.8	0.000165	0.0213	-0.21	-0.17	Multiple sclerosis;	chr12:57830154	chr12:57803838~57804415:+
HNSC	cis	rs703842	0.616	rs10877023	ENSG00000270039.1	RP11-571M6.17	-3.8	0.000165	0.0213	-0.21	-0.17	Multiple sclerosis;	chr12:57830416	chr12:57803838~57804415:+
HNSC	cis	rs2271001	0.955	rs7111105	ENSG00000257043.1	RP11-137N23.1	-3.8	0.000165	0.0213	-0.21	-0.17	Gut microbiome composition (winter);	chr11:19134007	chr11:18665050~18665548:+
HNSC	cis	rs62025270	0.688	rs11073516	ENSG00000259762.1	RP11-158M2.4	-3.8	0.000165	0.0213	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85750336~85752901:-
HNSC	cis	rs950027	0.596	rs2467853	ENSG00000259479.5	SORD2P	3.8	0.000165	0.0213	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:44826371~44884694:-
HNSC	cis	rs4073405	0.889	rs7122933	ENSG00000254651.1	RP11-430H10.3	3.8	0.000165	0.0213	0.2	0.17	Schizophrenia;	chr11:45302019	chr11:45399448~45400528:+
HNSC	cis	rs17489649	1	rs2042165	ENSG00000271849.1	CTC-332L22.1	3.8	0.000165	0.0213	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109801619	chr5:109687802~109688329:-
HNSC	cis	rs792448	0.798	rs7521853	ENSG00000226251.4	RP11-15I11.3	-3.8	0.000165	0.0213	-0.21	-0.17	White blood cell count (basophil);	chr1:212330862	chr1:212225278~212238977:-
HNSC	cis	rs7405404	0.672	rs8046122	ENSG00000262454.1	RP11-65J21.3	-3.8	0.000165	0.0213	-0.16	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645789	chr16:14302288~14326353:+
HNSC	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	3.8	0.000165	0.0213	0.17	0.17	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
HNSC	cis	rs7665090	0.51	rs223498	ENSG00000230069.3	LRRC37A15P	3.8	0.000165	0.0213	0.17	0.17	Primary biliary cholangitis;	chr4:102730805	chr4:102727274~102730721:-
HNSC	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-3.8	0.000166	0.0213	-0.2	-0.17	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-3.8	0.000166	0.0213	-0.2	-0.17	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
HNSC	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	3.8	0.000166	0.0213	0.21	0.17	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
HNSC	cis	rs4144743	1	rs4144743	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000166	0.0213	-0.19	-0.17	Body mass index;	chr17:47245759	chr17:47450568~47492492:-
HNSC	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	3.8	0.000166	0.0213	0.24	0.17	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
HNSC	cis	rs7777677	0.925	rs4726546	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.925	rs6960743	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.925	rs6956756	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.889	rs6975391	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.925	rs9655661	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.888	rs9655574	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.963	rs4726550	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142563740~142564245:+
HNSC	cis	rs7777677	0.963	rs7796324	ENSG00000276953.1	TRBV12-4	3.8	0.000166	0.0213	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142563740~142564245:+
HNSC	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	3.8	0.000166	0.0213	0.25	0.17	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
HNSC	cis	rs17772222	0.958	rs1123421	ENSG00000258789.1	RP11-507K2.3	-3.8	0.000166	0.0213	-0.21	-0.17	Coronary artery calcification;	chr14:88524651	chr14:88551597~88552493:+
HNSC	cis	rs62025270	0.632	rs1807309	ENSG00000259762.1	RP11-158M2.4	-3.8	0.000166	0.0213	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.632	rs62022915	ENSG00000259762.1	RP11-158M2.4	-3.8	0.000166	0.0213	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85750336~85752901:-
HNSC	cis	rs2013441	0.932	rs2526488	ENSG00000261033.1	RP11-209D14.2	3.8	0.000166	0.0213	0.2	0.17	Obesity-related traits;	chr17:20195304	chr17:20008051~20009234:-
HNSC	cis	rs9313772	0.775	rs7708926	ENSG00000254350.1	RP11-542A14.1	-3.8	0.000166	0.0213	-0.19	-0.17	Blood pressure;	chr5:158410759	chr5:158424585~158452758:+
HNSC	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-3.8	0.000166	0.0213	-0.19	-0.17	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
HNSC	cis	rs10502219	0.634	rs7943469	ENSG00000235910.1	APOA1-AS	3.8	0.000166	0.0213	0.23	0.17	Mitochondrial DNA levels;	chr11:116569075	chr11:116836117~116855729:+
HNSC	cis	rs919433	0.783	rs55725278	ENSG00000231621.1	AC013264.2	-3.8	0.000166	0.0213	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373499	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.783	rs787980	ENSG00000231621.1	AC013264.2	-3.8	0.000166	0.0213	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197374501	chr2:197197991~197199273:+
HNSC	cis	rs7824557	0.564	rs2572399	ENSG00000255310.2	AF131215.2	-3.8	0.000166	0.0213	-0.16	-0.17	Retinal vascular caliber;	chr8:11377011	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.602	rs1435273	ENSG00000269918.1	AF131215.9	3.8	0.000166	0.0213	0.17	0.17	Retinal vascular caliber;	chr8:11351990	chr8:11104691~11106704:-
HNSC	cis	rs11711311	0.911	rs9817327	ENSG00000241529.3	RN7SL767P	-3.8	0.000166	0.0213	-0.22	-0.17	IgG glycosylation;	chr3:113759653	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9811353	ENSG00000241529.3	RN7SL767P	-3.8	0.000166	0.0213	-0.22	-0.17	IgG glycosylation;	chr3:113765132	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs28394480	ENSG00000241529.3	RN7SL767P	-3.8	0.000166	0.0213	-0.22	-0.17	IgG glycosylation;	chr3:113766296	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9830975	ENSG00000241529.3	RN7SL767P	-3.8	0.000166	0.0213	-0.22	-0.17	IgG glycosylation;	chr3:113767172	chr3:113632704~113632998:+
HNSC	cis	rs765751	0.767	rs2605102	ENSG00000228536.1	RP11-392O17.1	-3.8	0.000166	0.0213	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219471651	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.798	rs2605104	ENSG00000228536.1	RP11-392O17.1	-3.8	0.000166	0.0213	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219471855	chr1:219409681~219411941:-
HNSC	cis	rs6601327	0.635	rs10099122	ENSG00000233609.3	RP11-62H7.2	-3.8	0.000166	0.0213	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9710493	chr8:8961200~8979025:+
HNSC	cis	rs11951515	0.626	rs6863360	ENSG00000249286.1	CTD-2210P15.2	3.8	0.000166	0.0213	0.19	0.17	Metabolite levels  (X-11787);	chr5:43298413	chr5:43586918~43588223:-
HNSC	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-3.8	0.000166	0.0213	-0.18	-0.17	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
HNSC	cis	rs8072100	1	rs8065437	ENSG00000263293.2	RP11-290H9.4	3.8	0.000166	0.0213	0.19	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47303460~47323613:-
HNSC	cis	rs7520050	0.966	rs7556436	ENSG00000280836.1	AL355480.1	-3.8	0.000166	0.0213	-0.17	-0.17	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45581219~45581321:-
HNSC	cis	rs72949976	0.864	rs62186566	ENSG00000270659.1	RP11-105N14.1	3.8	0.000166	0.0213	0.18	0.17	Squamous cell lung carcinoma;Lung cancer;	chr2:213159697	chr2:213152970~213153659:+
HNSC	cis	rs7937890	0.572	rs2597218	ENSG00000254418.1	RP11-21L19.1	3.8	0.000166	0.0213	0.22	0.17	Mitochondrial DNA levels;	chr11:14510792	chr11:14262846~14273691:-
HNSC	cis	rs73198271	0.855	rs57301822	ENSG00000254153.1	CTA-398F10.2	-3.8	0.000166	0.0213	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8456909~8461337:-
HNSC	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	3.8	0.000166	0.0213	0.25	0.17	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
HNSC	cis	rs17253792	0.822	rs112739186	ENSG00000186615.9	KTN1-AS1	-3.8	0.000166	0.0214	-0.35	-0.17	Putamen volume;	chr14:55598449	chr14:55499278~55580110:-
HNSC	cis	rs7221109	0.682	rs7216890	ENSG00000278834.1	RP11-458J1.1	-3.8	0.000166	0.0214	-0.16	-0.17	Type 1 diabetes;	chr17:40600717	chr17:40648300~40649718:+
HNSC	cis	rs72843506	0.722	rs79590067	ENSG00000189423.10	USP32P3	3.8	0.000166	0.0214	0.28	0.17	Schizophrenia;	chr17:20204101	chr17:20415547~20431008:+
HNSC	cis	rs2836974	0.897	rs2776308	ENSG00000255568.3	BRWD1-AS2	3.8	0.000166	0.0214	0.16	0.17	Cognitive function;	chr21:39343249	chr21:39313935~39314962:+
HNSC	cis	rs11951515	0.738	rs58679159	ENSG00000249286.1	CTD-2210P15.2	3.8	0.000166	0.0214	0.18	0.17	Metabolite levels  (X-11787);	chr5:43319720	chr5:43586918~43588223:-
HNSC	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	3.8	0.000166	0.0214	0.2	0.17	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
HNSC	cis	rs5770917	1	rs2073605	ENSG00000272821.1	CTA-384D8.36	-3.8	0.000166	0.0214	-0.26	-0.17	Narcolepsy;	chr22:50570421	chr22:50523926~50524780:+
HNSC	cis	rs12047808	0.722	rs13306729	ENSG00000227141.2	RP11-545A16.3	-3.8	0.000166	0.0214	-0.26	-0.17	Multiple sclerosis (age of onset);	chr1:179347552	chr1:179586705~179589175:+
HNSC	cis	rs6928977	0.832	rs2746427	ENSG00000217482.2	HMGB1P17	-3.8	0.000166	0.0214	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135347959	chr6:135636086~135636713:-
HNSC	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
HNSC	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
HNSC	cis	rs7178375	0.607	rs34178381	ENSG00000270015.1	RP11-540B6.6	3.8	0.000166	0.0214	0.28	0.17	Hypertriglyceridemia;	chr15:30930382	chr15:30926514~30928407:+
HNSC	cis	rs3026445	0.962	rs10774599	ENSG00000241413.3	RN7SL441P	-3.8	0.000166	0.0214	-0.18	-0.17	QT interval;	chr12:110259643	chr12:109866214~109866509:-
HNSC	cis	rs853679	0.766	rs9368561	ENSG00000204709.4	LINC01556	3.8	0.000166	0.0214	0.31	0.17	Depression;	chr6:28200565	chr6:28943877~28944537:+
HNSC	cis	rs4356203	0.87	rs7342262	ENSG00000260196.1	RP1-239B22.5	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17380649~17383531:+
HNSC	cis	rs1881509	0.702	rs4963078	ENSG00000255153.1	TOLLIP-AS1	-3.8	0.000166	0.0214	-0.19	-0.17	Heroin dependence;	chr11:1414099	chr11:1309769~1310707:+
HNSC	cis	rs5751168	0.606	rs2156886	ENSG00000274422.1	LL22NC03-2H8.5	3.8	0.000166	0.0214	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22498420	chr22:22283928~22287220:-
HNSC	cis	rs2904524	0.541	rs10784839	ENSG00000257815.4	RP11-611E13.2	-3.8	0.000166	0.0214	-0.18	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70380985	chr12:69904033~70243360:-
HNSC	cis	rs988913	0.957	rs1393774	ENSG00000224984.1	RP11-524H19.2	3.8	0.000166	0.0214	0.2	0.17	Menarche (age at onset);	chr6:54973651	chr6:54840118~54840855:-
HNSC	cis	rs12701220	0.744	rs10499317	ENSG00000224079.1	AC091729.7	3.8	0.000166	0.0214	0.25	0.17	Bronchopulmonary dysplasia;	chr7:972467	chr7:1074450~1078036:+
HNSC	cis	rs859767	0.501	rs12691869	ENSG00000224043.6	CCNT2-AS1	3.8	0.000166	0.0214	0.21	0.17	Neuroticism;	chr2:134650071	chr2:134735464~134918710:-
HNSC	cis	rs6601327	1	rs6601327	ENSG00000233609.3	RP11-62H7.2	-3.8	0.000166	0.0214	-0.16	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.65	rs13265731	ENSG00000254153.1	CTA-398F10.2	3.8	0.000166	0.0214	0.19	0.17	Neuroticism;	chr8:8815810	chr8:8456909~8461337:-
HNSC	cis	rs6493858	0.809	rs4774847	ENSG00000277245.1	RP11-48G14.3	-3.8	0.000167	0.0214	-0.2	-0.17	Relative hand skill in reading disability;	chr15:56144851	chr15:56447120~56447697:+
HNSC	cis	rs4947019	0.534	rs13437492	ENSG00000260273.1	RP11-425D10.10	-3.8	0.000167	0.0214	-0.45	-0.17	Hematological parameters;	chr6:109365424	chr6:109382795~109383666:+
HNSC	cis	rs870825	0.86	rs11132253	ENSG00000254233.1	RP11-242J7.1	3.8	0.000167	0.0214	0.26	0.17	Blood protein levels;	chr4:184674318	chr4:184584093~184625030:-
HNSC	cis	rs7178375	1	rs4779797	ENSG00000215302.7	CTD-3092A11.1	3.8	0.000167	0.0214	0.26	0.17	Hypertriglyceridemia;	chr15:30916222	chr15:30470779~30507623:+
HNSC	cis	rs9348739	1	rs9348739	ENSG00000241549.7	GUSBP2	3.8	0.000167	0.0214	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:26955320	chr6:26871484~26956554:-
HNSC	cis	rs17253792	0.822	rs17685078	ENSG00000186615.9	KTN1-AS1	-3.8	0.000167	0.0214	-0.34	-0.17	Putamen volume;	chr14:55660484	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs17685102	ENSG00000186615.9	KTN1-AS1	-3.8	0.000167	0.0214	-0.34	-0.17	Putamen volume;	chr14:55662496	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77033617	ENSG00000186615.9	KTN1-AS1	-3.8	0.000167	0.0214	-0.34	-0.17	Putamen volume;	chr14:55663028	chr14:55499278~55580110:-
HNSC	cis	rs9393777	0.92	rs13207689	ENSG00000226314.6	ZNF192P1	-3.8	0.000167	0.0214	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28161781~28169594:+
HNSC	cis	rs757110	0.524	rs214095	ENSG00000260196.1	RP1-239B22.5	-3.8	0.000167	0.0214	-0.18	-0.17	Type 2 diabetes;	chr11:17271915	chr11:17380649~17383531:+
HNSC	cis	rs12908161	0.959	rs17598603	ENSG00000229212.6	RP11-561C5.4	3.8	0.000167	0.0214	0.26	0.17	Schizophrenia;	chr15:84656980	chr15:85205440~85234795:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000272831.1	RP11-792A8.4	3.8	0.000167	0.0214	0.14	0.17	Calcium levels;	chr7:65975383	chr7:66739829~66740385:-
HNSC	cis	rs7508	0.511	rs2237853	ENSG00000253671.1	RP11-806O11.1	-3.8	0.000167	0.0214	-0.19	-0.17	Atrial fibrillation;	chr8:18020371	chr8:17808941~17820868:+
HNSC	cis	rs1937680	0.613	rs6480574	ENSG00000236671.6	PRKG1-AS1	-3.8	0.000167	0.0214	-0.25	-0.17	Breast cancer;	chr10:51910010	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7923342	ENSG00000236671.6	PRKG1-AS1	-3.8	0.000167	0.0214	-0.25	-0.17	Breast cancer;	chr10:51910013	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs6480575	ENSG00000236671.6	PRKG1-AS1	-3.8	0.000167	0.0214	-0.25	-0.17	Breast cancer;	chr10:51910046	chr10:52230742~52314128:-
HNSC	cis	rs6840258	1	rs17604480	ENSG00000251411.1	RP11-397E7.4	-3.8	0.000167	0.0214	-0.22	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87048975	chr4:86913266~86914817:-
HNSC	cis	rs4648045	0.734	rs4648051	ENSG00000230069.3	LRRC37A15P	-3.8	0.000167	0.0214	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102593836	chr4:102727274~102730721:-
HNSC	cis	rs9329221	0.662	rs9650650	ENSG00000269918.1	AF131215.9	3.8	0.000167	0.0214	0.18	0.17	Neuroticism;	chr8:10390466	chr8:11104691~11106704:-
HNSC	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-3.8	0.000167	0.0214	-0.2	-0.17	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
HNSC	cis	rs7429990	0.833	rs3755637	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0214	0.16	0.17	Educational attainment (years of education);	chr3:47580720	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs6785669	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47715771	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.833	rs6442079	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47721044	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs13094264	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47722723	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.833	rs34777284	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47726585	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.833	rs7649393	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47727501	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7638103	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47727585	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs11130148	ENSG00000228638.1	FCF1P2	3.8	0.000167	0.0215	0.16	0.17	Educational attainment (years of education);	chr3:47729797	chr3:48290793~48291375:-
HNSC	cis	rs9863	0.861	rs11057399	ENSG00000270028.1	RP11-380L11.4	3.8	0.000167	0.0215	0.21	0.17	White blood cell count;	chr12:123940531	chr12:123925461~123926083:-
HNSC	cis	rs3736485	1	rs11631408	ENSG00000259438.1	CTD-2650P22.1	3.8	0.000167	0.0215	0.18	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51454039	chr15:52010999~52019095:-
HNSC	cis	rs2462686	1	rs2965071	ENSG00000234536.1	AC096582.7	-3.8	0.000167	0.0215	-0.18	-0.17	Major depressive disorder;	chr7:45961783	chr7:45773595~45783157:+
HNSC	cis	rs12030196	1	rs12030196	ENSG00000230812.4	LINC01358	3.8	0.000167	0.0215	0.2	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017648	chr1:59020387~59044614:+
HNSC	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	3.8	0.000167	0.0215	0.25	0.17	Pain;	chr19:21430609	chr19:21554640~21569237:-
HNSC	cis	rs2836974	0.59	rs9974757	ENSG00000255568.3	BRWD1-AS2	-3.8	0.000167	0.0215	-0.15	-0.17	Cognitive function;	chr21:39245318	chr21:39313935~39314962:+
HNSC	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-3.79	0.000167	0.0215	-0.22	-0.17	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
HNSC	cis	rs3740713	1	rs74741949	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs113497813	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs61081934	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.92	rs112818034	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs76708296	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438668	ENSG00000256464.1	YWHABP2	3.79	0.000167	0.0215	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr11:18490243~18490955:-
HNSC	cis	rs11951515	0.738	rs4866739	ENSG00000249286.1	CTD-2210P15.2	3.79	0.000167	0.0215	0.18	0.17	Metabolite levels  (X-11787);	chr5:43324272	chr5:43586918~43588223:-
HNSC	cis	rs17404153	0.599	rs6794333	ENSG00000248724.5	NPHP3-AS1	3.79	0.000167	0.0215	0.29	0.17	LDL cholesterol;HDL cholesterol;	chr3:132441813	chr3:132721750~132874223:+
HNSC	cis	rs6787172	0.579	rs6799272	ENSG00000272087.1	RP11-379F4.7	3.79	0.000167	0.0215	0.18	0.17	Subjective well-being;	chr3:158470614	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.667	rs7627374	ENSG00000272087.1	RP11-379F4.7	3.79	0.000167	0.0215	0.18	0.17	Subjective well-being;	chr3:158472275	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.667	rs7617165	ENSG00000272087.1	RP11-379F4.7	3.79	0.000167	0.0215	0.18	0.17	Subjective well-being;	chr3:158474414	chr3:158693120~158693768:-
HNSC	cis	rs10742752	0.676	rs7943688	ENSG00000255267.3	RP11-430H10.2	-3.79	0.000167	0.0215	-0.22	-0.17	Body mass index;	chr11:45425174	chr11:45371397~45388508:+
HNSC	cis	rs17253792	0.822	rs2147114	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55610400	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77555779	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55611712	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs74653073	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55612810	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75560658	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55613178	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs112308750	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55613355	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs8007065	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55614554	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs113692713	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55620706	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs113649689	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55621347	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs7145064	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55622142	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs7150841	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55622268	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75049893	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55622440	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78429067	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55625833	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77741349	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55630744	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.749	rs74979160	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55630850	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10483645	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55637048	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.642	rs10483648	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55637560	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs79807559	ENSG00000186615.9	KTN1-AS1	-3.79	0.000167	0.0215	-0.35	-0.17	Putamen volume;	chr14:55641399	chr14:55499278~55580110:-
HNSC	cis	rs2919917	0.628	rs1036751	ENSG00000260398.1	RP11-594N15.3	-3.79	0.000167	0.0215	-0.23	-0.17	Lymphocyte counts;	chr8:78729671	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.628	rs2583759	ENSG00000260398.1	RP11-594N15.3	-3.79	0.000167	0.0215	-0.23	-0.17	Lymphocyte counts;	chr8:78732729	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.628	rs894222	ENSG00000260398.1	RP11-594N15.3	-3.79	0.000167	0.0215	-0.23	-0.17	Lymphocyte counts;	chr8:78737034	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.628	rs2583778	ENSG00000260398.1	RP11-594N15.3	-3.79	0.000167	0.0215	-0.23	-0.17	Lymphocyte counts;	chr8:78738906	chr8:78605952~78609705:+
HNSC	cis	rs10760158	0.62	rs767769	ENSG00000226752.6	PSMD5-AS1	3.79	0.000167	0.0215	0.17	0.17	Pulse pressure;	chr9:121336058	chr9:120824828~120854385:+
HNSC	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-3.79	0.000167	0.0215	-0.21	-0.17	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
HNSC	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	3.79	0.000167	0.0215	0.26	0.17	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	3.79	0.000167	0.0215	0.26	0.17	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	3.79	0.000167	0.0215	0.26	0.17	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	3.79	0.000167	0.0215	0.26	0.17	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	3.79	0.000167	0.0215	0.26	0.17	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
HNSC	cis	rs7113211	0.817	rs55874851	ENSG00000176343.5	RPL37AP8	3.79	0.000167	0.0215	0.18	0.17	Expressive vocabulary in infants;	chr11:112767146	chr11:111889199~111889474:-
HNSC	cis	rs11951515	0.738	rs12189016	ENSG00000249286.1	CTD-2210P15.2	3.79	0.000167	0.0215	0.18	0.17	Metabolite levels  (X-11787);	chr5:43334686	chr5:43586918~43588223:-
HNSC	cis	rs13179617	0.928	rs13170262	ENSG00000215032.2	GNL3LP1	-3.79	0.000167	0.0215	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61473894	chr5:60891935~60893577:-
HNSC	cis	rs526231	0.543	rs34787	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.23	0.17	Primary biliary cholangitis;	chr5:103123199	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs34789	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.23	0.17	Primary biliary cholangitis;	chr5:103125035	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs34791	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.23	0.17	Primary biliary cholangitis;	chr5:103126400	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs26525	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.23	0.17	Primary biliary cholangitis;	chr5:103129219	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs32851	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.23	0.17	Primary biliary cholangitis;	chr5:103132967	chr5:102609156~102671559:-
HNSC	cis	rs11098499	0.69	rs7674713	ENSG00000250412.1	KLHL2P1	3.79	0.000167	0.0215	0.22	0.17	Corneal astigmatism;	chr4:119401102	chr4:119334329~119378233:+
HNSC	cis	rs12545109	0.876	rs4738494	ENSG00000246430.5	LINC00968	-3.79	0.000167	0.0215	-0.22	-0.17	Obesity-related traits;	chr8:56414879	chr8:56496246~56559823:-
HNSC	cis	rs5167	0.506	rs7257916	ENSG00000269148.1	AC092301.3	-3.79	0.000167	0.0215	-0.16	-0.17	Blood protein levels;	chr19:44979627	chr19:45830164~45831108:+
HNSC	cis	rs950169	0.959	rs12902070	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000167	0.0215	-0.19	-0.17	Schizophrenia;	chr15:84124806	chr15:84507885~84516814:-
HNSC	cis	rs6657613	0.68	rs2295059	ENSG00000186715.9	MST1L	-3.79	0.000167	0.0215	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17050914	chr1:16754910~16770237:-
HNSC	cis	rs11250098	0.574	rs4554431	ENSG00000255310.2	AF131215.2	-3.79	0.000167	0.0215	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10914128	chr8:11107788~11109726:-
HNSC	cis	rs67478160	0.634	rs941475	ENSG00000259515.1	RP11-365N19.2	3.79	0.000167	0.0215	0.15	0.17	Schizophrenia;	chr14:103774281	chr14:102933574~102937177:+
HNSC	cis	rs870825	0.616	rs28450662	ENSG00000254233.1	RP11-242J7.1	3.79	0.000168	0.0215	0.25	0.17	Blood protein levels;	chr4:184717746	chr4:184584093~184625030:-
HNSC	cis	rs9880211	0.563	rs67589653	ENSG00000239213.4	NCK1-AS1	3.79	0.000168	0.0215	0.17	0.17	Height;Body mass index;	chr3:136092732	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.563	rs10512990	ENSG00000239213.4	NCK1-AS1	3.79	0.000168	0.0215	0.17	0.17	Height;Body mass index;	chr3:136095785	chr3:136841726~136862054:-
HNSC	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-3.79	0.000168	0.0215	-0.2	-0.17	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
HNSC	cis	rs564349	1	rs477748	ENSG00000253768.1	CTB-33O18.1	3.79	0.000168	0.0215	0.21	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr5:172898112	chr5:173562478~173573199:+
HNSC	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	3.79	0.000168	0.0215	0.2	0.17	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
HNSC	cis	rs58873874	0.737	rs78738433	ENSG00000248544.2	CTB-47B11.3	3.79	0.000168	0.0215	0.39	0.17	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157375741~157384950:-
HNSC	cis	rs12664251	0.66	rs794249	ENSG00000253194.1	RP11-351A11.1	-3.79	0.000168	0.0215	-0.2	-0.17	Schizophrenia;	chr6:119027102	chr6:118934785~119031541:+
HNSC	cis	rs2762353	0.562	rs1165206	ENSG00000272462.2	U91328.19	-3.79	0.000168	0.0215	-0.16	-0.17	Blood metabolite levels;	chr6:25867338	chr6:25992662~26001775:+
HNSC	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	3.79	0.000168	0.0215	0.38	0.17	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
HNSC	cis	rs67981189	0.593	rs4132848	ENSG00000274818.1	RP1-292L20.3	3.79	0.000168	0.0215	0.19	0.17	Schizophrenia;	chr14:70992642	chr14:70906657~70907111:-
HNSC	cis	rs8010715	0.816	rs7153156	ENSG00000259321.1	RP11-468E2.5	3.79	0.000168	0.0215	0.15	0.17	IgG glycosylation;	chr14:24129637	chr14:24139445~24140444:+
HNSC	cis	rs8010715	0.816	rs6573572	ENSG00000259321.1	RP11-468E2.5	3.79	0.000168	0.0215	0.15	0.17	IgG glycosylation;	chr14:24130021	chr14:24139445~24140444:+
HNSC	cis	rs656900	0.715	rs673079	ENSG00000261229.4	MTHFS	3.79	0.000168	0.0215	0.19	0.17	Cerebrospinal P-tau181p levels;	chr15:79823064	chr15:79843547~79897285:-
HNSC	cis	rs1799955	0.935	rs7337574	ENSG00000215515.2	IFIT1P1	-3.79	0.000168	0.0215	-0.24	-0.17	LDL cholesterol levels;	chr13:32383682	chr13:32384660~32386108:+
HNSC	cis	rs28830936	0.934	rs28401754	ENSG00000250379.1	RP11-23P13.4	3.79	0.000168	0.0215	0.21	0.17	Diastolic blood pressure;	chr15:41824705	chr15:41825099~41827936:-
HNSC	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-3.79	0.000168	0.0215	-0.17	-0.17	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
HNSC	cis	rs4427176	0.507	rs4841206	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Mosquito bite size;	chr8:9726117	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs10464998	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Mosquito bite size;	chr8:9726940	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.866	rs10903318	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9727973	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs11785927	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Mosquito bite size;	chr8:9730230	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.82	rs11779335	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9730344	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.866	rs4626603	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9730597	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.866	rs4626604	ENSG00000254340.1	RP11-10A14.3	-3.79	0.000168	0.0215	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9730602	chr8:9141424~9145435:+
HNSC	cis	rs5758511	0.514	rs5758637	ENSG00000226450.2	CYP2D8P	3.79	0.000168	0.0216	0.16	0.17	Birth weight;	chr22:42184927	chr22:42149886~42155001:-
HNSC	cis	rs2412819	0.597	rs7181912	ENSG00000166763.7	STRCP1	-3.79	0.000168	0.0216	-0.24	-0.17	Lung cancer;	chr15:43770676	chr15:43699488~43718184:-
HNSC	cis	rs7572733	0.935	rs1878732	ENSG00000222017.1	AC011997.1	3.79	0.000168	0.0216	0.21	0.17	Dermatomyositis;	chr2:197944821	chr2:197693106~197774823:+
HNSC	cis	rs6001482	0.533	rs12484704	ENSG00000274422.1	LL22NC03-2H8.5	3.79	0.000168	0.0216	0.18	0.17	Diastolic blood pressure;	chr22:22228856	chr22:22283928~22287220:-
HNSC	cis	rs240993	0.812	rs9374262	ENSG00000230177.1	RP5-1112D6.4	3.79	0.000168	0.0216	0.22	0.17	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111277932~111278742:+
HNSC	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-3.79	0.000168	0.0216	-0.19	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
HNSC	cis	rs10090774	0.965	rs4961234	ENSG00000279766.1	RP11-642A1.2	3.79	0.000168	0.0216	0.18	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830782	chr8:140572142~140572812:-
HNSC	cis	rs36093844	0.898	rs11234463	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000168	0.0216	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886042	chr11:85852557~85854943:-
HNSC	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	3.79	0.000168	0.0216	0.21	0.17	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
HNSC	cis	rs11723261	0.582	rs6830247	ENSG00000211553.1	AC253576.2	-3.79	0.000168	0.0216	-0.25	-0.17	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:136461~136568:+
HNSC	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	3.79	0.000168	0.0216	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
HNSC	cis	rs7819412	0.691	rs73198970	ENSG00000255310.2	AF131215.2	-3.79	0.000168	0.0216	-0.17	-0.17	Triglycerides;	chr8:11182707	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000227888.4	FAM66A	3.79	0.000168	0.0216	0.17	0.17	Neuroticism;	chr8:11939219	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000227888.4	FAM66A	3.79	0.000168	0.0216	0.17	0.17	Neuroticism;	chr8:11939586	chr8:12362019~12388296:+
HNSC	cis	rs2944755	0.58	rs13251004	ENSG00000279766.1	RP11-642A1.2	-3.79	0.000168	0.0216	-0.2	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576027	chr8:140572142~140572812:-
HNSC	cis	rs5770917	1	rs3180872	ENSG00000272821.1	CTA-384D8.36	-3.79	0.000168	0.0216	-0.26	-0.17	Narcolepsy;	chr22:50578965	chr22:50523926~50524780:+
HNSC	cis	rs1853665	1	rs1951931	ENSG00000231760.4	RP11-350J20.5	3.79	0.000168	0.0216	0.29	0.17	Radiation response;	chr6:149975762	chr6:149796151~149826294:-
HNSC	cis	rs4073405	0.889	rs7480175	ENSG00000254651.1	RP11-430H10.3	3.79	0.000168	0.0216	0.2	0.17	Schizophrenia;	chr11:45302829	chr11:45399448~45400528:+
HNSC	cis	rs4144743	0.938	rs35069360	ENSG00000228782.6	CTD-2026D20.3	-3.79	0.000168	0.0216	-0.2	-0.17	Body mass index;	chr17:47243904	chr17:47450568~47492492:-
HNSC	cis	rs2832077	0.689	rs2832052	ENSG00000232855.5	AF131217.1	3.79	0.000168	0.0216	0.21	0.17	Cognitive test performance;	chr21:28757751	chr21:28439346~28674848:-
HNSC	cis	rs8002861	0.619	rs1337203	ENSG00000274001.1	RP11-5G9.5	3.79	0.000168	0.0216	0.18	0.17	Leprosy;	chr13:43849485	chr13:43877715~43878163:-
HNSC	cis	rs8030379	1	rs8024418	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000168	0.0216	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs8042970	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000168	0.0216	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259937	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000168	0.0216	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11637866	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000168	0.0216	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2135880	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000168	0.0216	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84507885~84516814:-
HNSC	cis	rs2179367	0.959	rs480034	ENSG00000216906.2	RP11-350J20.9	-3.79	0.000168	0.0216	-0.21	-0.17	Dupuytren's disease;	chr6:149414294	chr6:149904243~149906418:+
HNSC	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	3.79	0.000168	0.0216	0.23	0.17	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
HNSC	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-3.79	0.000168	0.0216	-0.22	-0.17	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
HNSC	cis	rs11711311	1	rs12631232	ENSG00000241529.3	RN7SL767P	-3.79	0.000168	0.0216	-0.22	-0.17	IgG glycosylation;	chr3:113778539	chr3:113632704~113632998:+
HNSC	cis	rs988913	0.957	rs7746965	ENSG00000224984.1	RP11-524H19.2	3.79	0.000168	0.0216	0.2	0.17	Menarche (age at onset);	chr6:54979634	chr6:54840118~54840855:-
HNSC	cis	rs17264034	0.95	rs17328904	ENSG00000250786.1	SNHG18	3.79	0.000168	0.0216	0.29	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543158	chr5:9546200~9550609:+
HNSC	cis	rs17264034	0.95	rs17328932	ENSG00000250786.1	SNHG18	3.79	0.000168	0.0216	0.29	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543337	chr5:9546200~9550609:+
HNSC	cis	rs6012564	1	rs11696870	ENSG00000227431.4	CSE1L-AS1	3.79	0.000168	0.0216	0.19	0.17	Anger;	chr20:49109070	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.963	rs6063355	ENSG00000227431.4	CSE1L-AS1	3.79	0.000168	0.0216	0.19	0.17	Anger;	chr20:49109592	chr20:49040463~49046044:-
HNSC	cis	rs6180	0.594	rs1833906	ENSG00000215068.6	AC025171.1	-3.79	0.000168	0.0216	-0.17	-0.17	Height;	chr5:42852117	chr5:43041575~43045390:+
HNSC	cis	rs7278690	0.714	rs7278138	ENSG00000281903.1	AF127936.7	3.79	0.000168	0.0216	0.4	0.17	Breast cancer;	chr21:14863163	chr21:14819699~14918552:-
HNSC	cis	rs17250963	0.673	rs875525	ENSG00000249485.1	RBBP4P1	-3.79	0.000168	0.0216	-0.17	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14747138	chr5:14797125~14798400:-
HNSC	cis	rs7781557	1	rs17135875	ENSG00000239969.4	RP11-163E9.2	-3.79	0.000168	0.0216	-0.24	-0.17	Colorectal adenoma (advanced);	chr7:102878584	chr7:102364162~102380633:+
HNSC	cis	rs792448	0.743	rs351380	ENSG00000226251.4	RP11-15I11.3	-3.79	0.000168	0.0216	-0.21	-0.17	White blood cell count (basophil);	chr1:212309510	chr1:212225278~212238977:-
HNSC	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	3.79	0.000168	0.0216	0.25	0.17	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
HNSC	cis	rs6988985	0.818	rs3802230	ENSG00000247317.3	RP11-273G15.2	-3.79	0.000169	0.0216	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911448	chr8:142981738~143018437:-
HNSC	cis	rs597480	0.963	rs290202	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000169	0.0216	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85712157	chr11:85852557~85854943:-
HNSC	cis	rs886126	1	rs4766451	ENSG00000257595.2	RP3-473L9.4	3.79	0.000169	0.0216	0.22	0.17	Coronary heart disease;	chr12:111232878	chr12:111369282~111403310:+
HNSC	cis	rs2239557	0.508	rs34774275	ENSG00000259065.1	RP5-1021I20.1	-3.79	0.000169	0.0216	-0.26	-0.17	Common traits (Other);	chr14:73867013	chr14:73787360~73803270:+
HNSC	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	3.79	0.000169	0.0216	0.17	0.17	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
HNSC	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-3.79	0.000169	0.0216	-0.26	-0.17	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
HNSC	cis	rs2179367	0.959	rs521845	ENSG00000216906.2	RP11-350J20.9	-3.79	0.000169	0.0216	-0.21	-0.17	Dupuytren's disease;	chr6:149350562	chr6:149904243~149906418:+
HNSC	cis	rs11976180	1	rs1919950	ENSG00000244479.5	OR2A1-AS1	3.79	0.000169	0.0216	0.2	0.17	Obesity-related traits;	chr7:144070805	chr7:144251264~144356181:-
HNSC	cis	rs11976180	1	rs2961132	ENSG00000244479.5	OR2A1-AS1	3.79	0.000169	0.0216	0.2	0.17	Obesity-related traits;	chr7:144071035	chr7:144251264~144356181:-
HNSC	cis	rs62202398	0.618	rs59268725	ENSG00000276923.1	RP11-321P16.1	-3.79	0.000169	0.0216	-0.31	-0.17	Alcohol consumption;	chr20:48154932	chr20:48073869~48074188:+
HNSC	cis	rs6088580	0.634	rs6088502	ENSG00000276073.1	RP5-1125A11.7	-3.79	0.000169	0.0216	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:33985617~33988989:-
HNSC	cis	rs847649	0.842	rs4729873	ENSG00000239969.4	RP11-163E9.2	3.79	0.000169	0.0216	0.2	0.17	Morning vs. evening chronotype;	chr7:103091334	chr7:102364162~102380633:+
HNSC	cis	rs3809912	0.546	rs4797730	ENSG00000267654.1	RP11-973H7.4	-3.79	0.000169	0.0216	-0.23	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:13178097	chr18:12739490~12749421:-
HNSC	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	3.79	0.000169	0.0216	0.25	0.17	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000272831.1	RP11-792A8.4	-3.79	0.000169	0.0216	-0.14	-0.17	Aortic root size;	chr7:66624003	chr7:66739829~66740385:-
HNSC	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	3.79	0.000169	0.0216	0.18	0.17	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
HNSC	cis	rs546131	0.642	rs11603640	ENSG00000271369.1	RP11-350D17.3	-3.79	0.000169	0.0216	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34811360	chr11:34709600~34710161:+
HNSC	cis	rs73607972	0.696	rs9931018	ENSG00000275191.1	RP11-36I17.2	-3.79	0.000169	0.0216	-0.23	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529205	chr16:53628256~53628816:-
HNSC	cis	rs4356203	0.905	rs536628	ENSG00000272034.1	SNORD14A	-3.79	0.000169	0.0216	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17074654~17074744:-
HNSC	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	3.79	0.000169	0.0216	0.2	0.17	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
HNSC	cis	rs7688540	0.771	rs61795001	ENSG00000211553.1	AC253576.2	-3.79	0.000169	0.0216	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:136461~136568:+
HNSC	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	3.79	0.000169	0.0216	0.19	0.17	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
HNSC	cis	rs6867032	0.527	rs4371796	ENSG00000248597.1	RP11-259O2.2	3.79	0.000169	0.0216	0.26	0.17	Gut microbiome composition (winter);	chr5:1977671	chr5:1963609~1967154:-
HNSC	cis	rs7429990	0.931	rs62262084	ENSG00000228638.1	FCF1P2	-3.79	0.000169	0.0216	-0.19	-0.17	Educational attainment (years of education);	chr3:47612332	chr3:48290793~48291375:-
HNSC	cis	rs3738443	0.951	rs4551629	ENSG00000259865.1	RP11-488L18.10	3.79	0.000169	0.0216	0.16	0.17	Alcohol dependence;	chr1:247211748	chr1:247187281~247188526:-
HNSC	cis	rs11893307	0.507	rs1465305	ENSG00000228509.4	AC006460.2	3.79	0.000169	0.0216	0.22	0.17	Mean platelet volume;	chr2:190720666	chr2:190676944~190708716:-
HNSC	cis	rs11893307	0.507	rs1465303	ENSG00000228509.4	AC006460.2	3.79	0.000169	0.0216	0.22	0.17	Mean platelet volume;	chr2:190720714	chr2:190676944~190708716:-
HNSC	cis	rs6995541	0.647	rs2271357	ENSG00000269918.1	AF131215.9	-3.79	0.000169	0.0216	-0.18	-0.17	Triglyceride levels;	chr8:10826113	chr8:11104691~11106704:-
HNSC	cis	rs11773103	0.881	rs73204826	ENSG00000224046.1	AC005076.5	3.79	0.000169	0.0216	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87144942	chr7:87151423~87152420:-
HNSC	cis	rs17489649	1	rs3753174	ENSG00000271849.1	CTC-332L22.1	3.79	0.000169	0.0216	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109772236	chr5:109687802~109688329:-
HNSC	cis	rs792448	0.701	rs1774247	ENSG00000226251.4	RP11-15I11.3	-3.79	0.000169	0.0216	-0.21	-0.17	White blood cell count (basophil);	chr1:212376015	chr1:212225278~212238977:-
HNSC	cis	rs4760636	1	rs3192737	ENSG00000268069.2	RP5-1057I20.4	3.79	0.000169	0.0216	0.21	0.17	Urate levels;	chr12:47784344	chr12:47784923~47786002:+
HNSC	cis	rs7429990	0.965	rs319692	ENSG00000228638.1	FCF1P2	-3.79	0.000169	0.0217	-0.16	-0.17	Educational attainment (years of education);	chr3:47882827	chr3:48290793~48291375:-
HNSC	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-3.79	0.000169	0.0217	-0.23	-0.17	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
HNSC	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-3.79	0.000169	0.0217	-0.23	-0.17	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
HNSC	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-3.79	0.000169	0.0217	-0.23	-0.17	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
HNSC	cis	rs3809863	0.602	rs6504833	ENSG00000263293.2	RP11-290H9.4	3.79	0.000169	0.0217	0.2	0.17	Glaucoma (primary open-angle);	chr17:47318721	chr17:47303460~47323613:-
HNSC	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	3.79	0.000169	0.0217	0.36	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
HNSC	cis	rs12893668	0.572	rs4900590	ENSG00000269958.1	RP11-73M18.8	3.79	0.000169	0.0217	0.16	0.17	Reticulocyte count;	chr14:103680084	chr14:103696353~103697163:+
HNSC	cis	rs853679	0.55	rs1150689	ENSG00000219891.2	ZSCAN12P1	3.79	0.000169	0.0217	0.24	0.17	Depression;	chr6:28197321	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.55	rs1225599	ENSG00000219891.2	ZSCAN12P1	3.79	0.000169	0.0217	0.24	0.17	Depression;	chr6:28197412	chr6:28091154~28093664:+
HNSC	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-3.79	0.000169	0.0217	-0.16	-0.17	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
HNSC	cis	rs7735319	0.966	rs7709083	ENSG00000249572.1	CTD-2203K17.1	3.79	0.000169	0.0217	0.19	0.17	Systolic blood pressure;	chr5:33159470	chr5:33424025~33440619:-
HNSC	cis	rs73198271	0.751	rs617813	ENSG00000233609.3	RP11-62H7.2	-3.79	0.000169	0.0217	-0.19	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8961200~8979025:+
HNSC	cis	rs3018712	0.532	rs7932726	ENSG00000255031.4	RP11-802E16.3	-3.79	0.000169	0.0217	-0.19	-0.17	Total body bone mineral density;	chr11:68647259	chr11:68050740~68053762:+
HNSC	cis	rs17772222	0.501	rs17124889	ENSG00000258789.1	RP11-507K2.3	-3.79	0.000169	0.0217	-0.19	-0.17	Coronary artery calcification;	chr14:88834557	chr14:88551597~88552493:+
HNSC	cis	rs7572733	0.534	rs700681	ENSG00000231621.1	AC013264.2	-3.79	0.000169	0.0217	-0.17	-0.17	Dermatomyositis;	chr2:197846778	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs700682	ENSG00000231621.1	AC013264.2	-3.79	0.000169	0.0217	-0.17	-0.17	Dermatomyositis;	chr2:197847586	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.534	rs700683	ENSG00000231621.1	AC013264.2	-3.79	0.000169	0.0217	-0.17	-0.17	Dermatomyositis;	chr2:197847608	chr2:197197991~197199273:+
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000272831.1	RP11-792A8.4	-3.79	0.000169	0.0217	-0.14	-0.17	Aortic root size;	chr7:66622178	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000272831.1	RP11-792A8.4	-3.79	0.000169	0.0217	-0.14	-0.17	Aortic root size;	chr7:66622208	chr7:66739829~66740385:-
HNSC	cis	rs597539	0.652	rs584108	ENSG00000255741.1	RP11-757G1.5	3.79	0.000169	0.0217	0.23	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68941503~68942852:-
HNSC	cis	rs36093844	0.527	rs4943934	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000169	0.0217	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86023807	chr11:85852557~85854943:-
HNSC	cis	rs2115630	0.645	rs4842978	ENSG00000259295.5	CSPG4P12	-3.79	0.000169	0.0217	-0.2	-0.17	P wave terminal force;	chr15:84654022	chr15:85191438~85213905:+
HNSC	cis	rs7824557	0.564	rs2736290	ENSG00000255495.1	AC145124.2	-3.79	0.000169	0.0217	-0.19	-0.17	Retinal vascular caliber;	chr8:11376789	chr8:12194467~12196280:+
HNSC	cis	rs10742752	0.676	rs34042421	ENSG00000254651.1	RP11-430H10.3	3.79	0.000169	0.0217	0.21	0.17	Body mass index;	chr11:45398683	chr11:45399448~45400528:+
HNSC	cis	rs61160187	0.505	rs4235482	ENSG00000272308.1	RP11-231G3.1	-3.79	0.000169	0.0217	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60866457~60866935:-
HNSC	cis	rs17489649	1	rs1370960	ENSG00000271849.1	CTC-332L22.1	3.79	0.000169	0.0217	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109703598	chr5:109687802~109688329:-
HNSC	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-3.79	0.000169	0.0217	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
HNSC	cis	rs683257	0.636	rs17070386	ENSG00000234147.1	RP3-460G2.2	3.79	0.000169	0.0217	0.31	0.17	Facial emotion recognition (angry faces);	chr6:140850424	chr6:140845958~140852924:-
HNSC	cis	rs7746199	0.736	rs13212093	ENSG00000226314.6	ZNF192P1	-3.79	0.000169	0.0217	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs34038546	ENSG00000226314.6	ZNF192P1	-3.79	0.000169	0.0217	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28161781~28169594:+
HNSC	cis	rs141342723	1	rs141342723	ENSG00000226314.6	ZNF192P1	-3.79	0.000169	0.0217	-0.32	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs34543938	ENSG00000226314.6	ZNF192P1	-3.79	0.000169	0.0217	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs56405707	ENSG00000226314.6	ZNF192P1	-3.79	0.000169	0.0217	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28161781~28169594:+
HNSC	cis	rs2048656	0.605	rs13249234	ENSG00000233609.3	RP11-62H7.2	3.79	0.000169	0.0217	0.18	0.17	Schizophrenia;	chr8:9792891	chr8:8961200~8979025:+
HNSC	cis	rs1665050	0.534	rs12900291	ENSG00000277144.1	RP11-59H7.4	-3.79	0.000169	0.0217	-0.22	-0.17	Atopic dermatitis;	chr15:58948220	chr15:59115547~59116089:-
HNSC	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-3.79	0.000169	0.0217	-0.18	-0.17	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
HNSC	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	3.79	0.000169	0.0217	0.2	0.17	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
HNSC	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	3.79	0.000169	0.0217	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	3.79	0.000169	0.0217	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
HNSC	cis	rs10073892	0.511	rs6596505	ENSG00000250682.4	LINC00491	-3.79	0.000169	0.0217	-0.23	-0.17	Cognitive decline (age-related);	chr5:102545462	chr5:102609156~102671559:-
HNSC	cis	rs67311347	0.911	rs6776044	ENSG00000280739.1	EIF1B-AS1	3.79	0.000169	0.0217	0.19	0.17	Renal cell carcinoma;	chr3:40336012	chr3:40173145~40309698:-
HNSC	cis	rs12893668	0.542	rs12884809	ENSG00000269910.1	RP11-73M18.10	3.79	0.00017	0.0217	0.16	0.17	Reticulocyte count;	chr14:103628983	chr14:103694516~103695050:-
HNSC	cis	rs700651	0.821	rs770661	ENSG00000231621.1	AC013264.2	-3.79	0.00017	0.0217	-0.17	-0.17	Intracranial aneurysm;	chr2:197860720	chr2:197197991~197199273:+
HNSC	cis	rs7824557	0.592	rs2572371	ENSG00000255495.1	AC145124.2	3.79	0.00017	0.0217	0.18	0.17	Retinal vascular caliber;	chr8:11366284	chr8:12194467~12196280:+
HNSC	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-3.79	0.00017	0.0217	-0.19	-0.17	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
HNSC	cis	rs9907295	0.901	rs9898132	ENSG00000270977.1	AC015849.16	-3.79	0.00017	0.0217	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35869187	chr17:35893707~35911023:-
HNSC	cis	rs3736485	0.966	rs8040538	ENSG00000274528.1	CTD-2650P22.2	3.79	0.00017	0.0217	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51612387	chr15:52017167~52018032:-
HNSC	cis	rs34286592	0.929	rs9923649	ENSG00000214725.6	CDIPT-AS1	-3.79	0.00017	0.0217	-0.24	-0.17	Multiple sclerosis;	chr16:29820817	chr16:29863593~29868053:+
HNSC	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-3.79	0.00017	0.0217	-0.2	-0.17	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-3.79	0.00017	0.0217	-0.2	-0.17	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-3.79	0.00017	0.0217	-0.2	-0.17	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
HNSC	cis	rs950169	0.922	rs8037078	ENSG00000230373.7	GOLGA6L5P	3.79	0.00017	0.0217	0.19	0.17	Schizophrenia;	chr15:84150119	chr15:84507885~84516814:-
HNSC	cis	rs6940729	1	rs6940729	ENSG00000270761.1	RP11-385F7.1	-3.79	0.00017	0.0217	-0.16	-0.17	Plasma homocysteine levels;	chr6:47585184	chr6:47477243~47477572:-
HNSC	cis	rs2239557	0.508	rs9646165	ENSG00000259065.1	RP5-1021I20.1	-3.79	0.00017	0.0217	-0.26	-0.17	Common traits (Other);	chr14:73858104	chr14:73787360~73803270:+
HNSC	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	3.79	0.00017	0.0217	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
HNSC	cis	rs9611565	0.592	rs6519270	ENSG00000233903.2	Z83851.4	3.79	0.00017	0.0217	0.24	0.17	Vitiligo;	chr22:41682662	chr22:42276355~42277052:+
HNSC	cis	rs526231	0.543	rs34785	ENSG00000250682.4	LINC00491	3.79	0.00017	0.0217	0.23	0.17	Primary biliary cholangitis;	chr5:103122399	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.578	rs34786	ENSG00000250682.4	LINC00491	3.79	0.00017	0.0217	0.23	0.17	Primary biliary cholangitis;	chr5:103122409	chr5:102609156~102671559:-
HNSC	cis	rs4427176	0.507	rs7837815	ENSG00000254340.1	RP11-10A14.3	-3.79	0.00017	0.0218	-0.24	-0.17	Mosquito bite size;	chr8:9718627	chr8:9141424~9145435:+
HNSC	cis	rs9611565	0.918	rs73176685	ENSG00000235513.1	RP4-756G23.5	3.79	0.00017	0.0218	0.19	0.17	Vitiligo;	chr22:41385090	chr22:41209122~41217627:-
HNSC	cis	rs56077333	1	rs56077333	ENSG00000261762.1	RP11-650L12.2	-3.79	0.00017	0.0218	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78606661	chr15:78589123~78591276:-
HNSC	cis	rs7615952	0.673	rs9841194	ENSG00000241439.1	RP11-666A20.3	3.79	0.00017	0.0218	0.26	0.17	Blood pressure (smoking interaction);	chr3:125916896	chr3:125958556~125958817:+
HNSC	cis	rs67311347	0.544	rs9821440	ENSG00000280739.1	EIF1B-AS1	3.79	0.00017	0.0218	0.18	0.17	Renal cell carcinoma;	chr3:40300856	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs9864601	ENSG00000280739.1	EIF1B-AS1	3.79	0.00017	0.0218	0.18	0.17	Renal cell carcinoma;	chr3:40303827	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs9868700	ENSG00000280739.1	EIF1B-AS1	3.79	0.00017	0.0218	0.18	0.17	Renal cell carcinoma;	chr3:40303917	chr3:40173145~40309698:-
HNSC	cis	rs3784143	0.57	rs17107061	ENSG00000259038.1	CTD-2325P2.4	-3.79	0.00017	0.0218	-0.34	-0.17	Asthma;	chr14:69530342	chr14:68627166~68628445:-
HNSC	cis	rs919433	0.617	rs700646	ENSG00000231621.1	AC013264.2	-3.79	0.00017	0.0218	-0.17	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197743787	chr2:197197991~197199273:+
HNSC	cis	rs6061231	0.798	rs2427308	ENSG00000275437.1	RP5-908M14.10	3.79	0.00017	0.0218	0.19	0.17	Colorectal cancer;	chr20:62394395	chr20:62402236~62405935:-
HNSC	cis	rs3736485	0.609	rs744039	ENSG00000274528.1	CTD-2650P22.2	3.79	0.00017	0.0218	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51681176	chr15:52017167~52018032:-
HNSC	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-3.79	0.00017	0.0218	-0.22	-0.17	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
HNSC	cis	rs4352251	0.778	rs6543033	ENSG00000205716.4	FAM183DP	3.79	0.00017	0.0218	0.3	0.17	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101354889	chr2:102249857~102250255:-
HNSC	cis	rs801193	0.967	rs34356500	ENSG00000273142.1	RP11-458F8.4	-3.79	0.00017	0.0218	-0.15	-0.17	Aortic root size;	chr7:66771620	chr7:66902857~66906297:+
HNSC	cis	rs9990333	1	rs9990333	ENSG00000242086.7	LINC00969	-3.79	0.00017	0.0218	-0.14	-0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195658062~195739964:+
HNSC	cis	rs2070074	0.591	rs7037232	ENSG00000230074.1	RP11-195F19.9	-3.79	0.00017	0.0218	-0.36	-0.17	CTACK levels;	chr9:34587487	chr9:34665665~34681298:+
HNSC	cis	rs1821002	1	rs1821002	ENSG00000255310.2	AF131215.2	-3.79	0.00017	0.0218	-0.17	-0.17	Systolic blood pressure;	chr8:10782555	chr8:11107788~11109726:-
HNSC	cis	rs10927875	0.557	rs1572381	ENSG00000226029.1	RP4-798A10.2	-3.79	0.00017	0.0218	-0.16	-0.17	Dilated cardiomyopathy;	chr1:16017999	chr1:16460948~16468481:+
HNSC	cis	rs1737890	0.623	rs6087361	ENSG00000224628.2	RP5-854E16.2	-3.79	0.00017	0.0218	-0.24	-0.17	Chronic obstructive pulmonary disease;	chr20:32286409	chr20:31285317~31286835:-
HNSC	cis	rs950169	0.579	rs62027818	ENSG00000230373.7	GOLGA6L5P	-3.79	0.00017	0.0218	-0.2	-0.17	Schizophrenia;	chr15:83992393	chr15:84507885~84516814:-
HNSC	cis	rs9611565	0.659	rs28623192	ENSG00000235513.1	RP4-756G23.5	3.79	0.00017	0.0218	0.2	0.17	Vitiligo;	chr22:41544520	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs9607812	ENSG00000235513.1	RP4-756G23.5	3.79	0.00017	0.0218	0.2	0.17	Vitiligo;	chr22:41545239	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs9607813	ENSG00000235513.1	RP4-756G23.5	3.79	0.00017	0.0218	0.2	0.17	Vitiligo;	chr22:41545475	chr22:41209122~41217627:-
HNSC	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-3.79	0.00017	0.0218	-0.21	-0.17	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-3.79	0.00017	0.0218	-0.21	-0.17	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
HNSC	cis	rs913655	0.545	rs9416775	ENSG00000225527.1	RP11-383B4.4	-3.79	0.00017	0.0218	-0.21	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18787916	chr10:18531849~18533336:-
HNSC	cis	rs10540	1	rs35898083	ENSG00000279672.1	CMB9-55F22.1	3.79	0.00017	0.0218	0.3	0.17	Body mass index;	chr11:484469	chr11:779617~780755:+
HNSC	cis	rs860295	0.702	rs2175391	ENSG00000225855.5	RUSC1-AS1	-3.79	0.00017	0.0218	-0.12	-0.17	Body mass index;	chr1:155655811	chr1:155316863~155324176:-
HNSC	cis	rs35306767	0.903	rs7067865	ENSG00000229869.1	RP11-363N22.2	-3.79	0.00017	0.0218	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:862447	chr10:933026~942743:+
HNSC	cis	rs546131	0.642	rs12794294	ENSG00000271369.1	RP11-350D17.3	-3.79	0.00017	0.0218	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34805971	chr11:34709600~34710161:+
HNSC	cis	rs3736485	0.966	rs6493513	ENSG00000274528.1	CTD-2650P22.2	3.79	0.00017	0.0218	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51617977	chr15:52017167~52018032:-
HNSC	cis	rs2016266	0.929	rs7486393	ENSG00000270175.1	RP11-793H13.11	-3.79	0.000171	0.0218	-0.16	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53259101	chr12:53500162~53500936:-
HNSC	cis	rs1859596	0.966	rs726655	ENSG00000234456.6	MAGI2-AS3	3.79	0.000171	0.0218	0.13	0.17	Reading or mathematical ability;	chr7:79467259	chr7:79452877~79471208:+
HNSC	cis	rs36093844	0.527	rs10501605	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000171	0.0218	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86032331	chr11:85852557~85854943:-
HNSC	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	3.79	0.000171	0.0218	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
HNSC	cis	rs2243480	1	rs464895	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000171	0.0218	-0.25	-0.17	Diabetic kidney disease;	chr7:66062119	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000171	0.0218	-0.25	-0.17	Diabetic kidney disease;	chr7:66063241	chr7:66848496~66858136:+
HNSC	cis	rs4853525	0.559	rs10167514	ENSG00000233654.1	AC093388.3	3.79	0.000171	0.0218	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190995803	chr2:190534855~190568102:+
HNSC	cis	rs6840360	0.582	rs11733820	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0218	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151407551~151408835:-
HNSC	cis	rs9813712	0.953	rs896822	ENSG00000228252.7	COL6A4P2	-3.79	0.000171	0.0218	-0.19	-0.17	Response to amphetamines;	chr3:130259987	chr3:130212823~130273806:+
HNSC	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	3.79	0.000171	0.0219	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
HNSC	cis	rs62025270	0.547	rs8035496	ENSG00000259295.5	CSPG4P12	-3.79	0.000171	0.0219	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85191438~85213905:+
HNSC	cis	rs12701220	0.689	rs12533004	ENSG00000229043.2	AC091729.9	-3.79	0.000171	0.0219	-0.26	-0.17	Bronchopulmonary dysplasia;	chr7:1055774	chr7:1160374~1165267:+
HNSC	cis	rs7520050	0.966	rs7556615	ENSG00000280836.1	AL355480.1	3.79	0.000171	0.0219	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45581219~45581321:-
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000250412.1	KLHL2P1	-3.79	0.000171	0.0219	-0.21	-0.17	Corneal astigmatism;	chr4:119337052	chr4:119334329~119378233:+
HNSC	cis	rs6012564	1	rs6066977	ENSG00000227431.4	CSE1L-AS1	3.79	0.000171	0.0219	0.19	0.17	Anger;	chr20:49138538	chr20:49040463~49046044:-
HNSC	cis	rs651907	0.712	rs796410	ENSG00000244119.1	PDCL3P4	3.79	0.000171	0.0219	0.16	0.17	Colorectal cancer;	chr3:101891345	chr3:101712472~101713191:+
HNSC	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-3.79	0.000171	0.0219	-0.22	-0.17	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
HNSC	cis	rs6457807	0.722	rs28522747	ENSG00000272374.1	RP3-329A5.8	3.79	0.000171	0.0219	0.2	0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr6:35166952	chr6:35220370~35224630:-
HNSC	cis	rs13325613	0.834	rs13083881	ENSG00000223552.1	RP11-24F11.2	-3.79	0.000171	0.0219	-0.3	-0.17	Monocyte count;	chr3:46143128	chr3:46364955~46407059:-
HNSC	cis	rs9859260	0.701	rs9872347	ENSG00000226155.1	AC124944.3	-3.79	0.000171	0.0219	-0.21	-0.17	Mean corpuscular volume;	chr3:196104366	chr3:195912049~195913986:+
HNSC	cis	rs10514995	1	rs16895200	ENSG00000248846.2	CTD-2016O11.1	3.79	0.000171	0.0219	0.18	0.17	RR interval (heart rate);	chr5:66451464	chr5:66206212~66209447:-
HNSC	cis	rs3736485	0.966	rs2305708	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000171	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51617763	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs4774596	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000171	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51618778	chr15:52017167~52018032:-
HNSC	cis	rs950169	1	rs1911155	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000171	0.0219	-0.19	-0.17	Schizophrenia;	chr15:84118883	chr15:84507885~84516814:-
HNSC	cis	rs72827839	0.779	rs72827808	ENSG00000210741.1	MIR196A1	-3.79	0.000171	0.0219	-0.22	-0.17	Ease of getting up in the morning;	chr17:48274718	chr17:48632490~48632559:-
HNSC	cis	rs17666538	0.539	rs1703925	ENSG00000254207.1	RP11-43A14.1	3.79	0.000171	0.0219	0.38	0.17	IgG glycosylation;	chr8:658279	chr8:725188~725877:-
HNSC	cis	rs6787172	0.622	rs6773939	ENSG00000272087.1	RP11-379F4.7	3.79	0.000171	0.0219	0.18	0.17	Subjective well-being;	chr3:158351917	chr3:158693120~158693768:-
HNSC	cis	rs6570726	0.846	rs439035	ENSG00000270638.1	RP3-466P17.1	3.79	0.000171	0.0219	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145735570~145737218:+
HNSC	cis	rs11231017	0.507	rs10792351	ENSG00000250659.2	RP11-864I4.3	-3.79	0.000171	0.0219	-0.22	-0.17	HIV-1 viral setpoint;	chr11:62390000	chr11:62537312~62542018:+
HNSC	cis	rs516805	0.564	rs2679658	ENSG00000279453.1	RP3-425C14.4	-3.79	0.000171	0.0219	-0.24	-0.17	Lymphocyte counts;	chr6:122109293	chr6:122436789~122439223:-
HNSC	cis	rs3736485	0.966	rs11633713	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000171	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51615855	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs4775965	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000171	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616054	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs9920124	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000171	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616745	chr15:52017167~52018032:-
HNSC	cis	rs9437689	0.934	rs9661031	ENSG00000237416.5	RP11-465K1.2	3.79	0.000171	0.0219	0.21	0.17	Phospholipid levels (plasma);	chr1:95039016	chr1:94836748~94855426:-
HNSC	cis	rs2462686	1	rs2462327	ENSG00000234536.1	AC096582.7	3.79	0.000171	0.0219	0.18	0.17	Major depressive disorder;	chr7:45953440	chr7:45773595~45783157:+
HNSC	cis	rs1003719	0.591	rs2040125	ENSG00000242553.1	AP001432.14	-3.79	0.000171	0.0219	-0.2	-0.17	Eye color traits;	chr21:37176934	chr21:37221419~37237744:+
HNSC	cis	rs61160187	0.582	rs11740632	ENSG00000272308.1	RP11-231G3.1	-3.79	0.000171	0.0219	-0.18	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60866457~60866935:-
HNSC	cis	rs863750	0.687	rs825482	ENSG00000275389.1	RP11-214K3.24	-3.79	0.000171	0.0219	-0.24	-0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091069	chr12:124085761~124088598:+
HNSC	cis	rs910316	0.836	rs6574212	ENSG00000279594.1	RP11-950C14.10	-3.79	0.000171	0.0219	-0.2	-0.17	Height;	chr14:75204956	chr14:75011269~75012851:-
HNSC	cis	rs4908768	0.539	rs1318218	ENSG00000232912.4	RP5-1115A15.1	3.79	0.000171	0.0219	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8424645~8434838:+
HNSC	cis	rs9611565	0.504	rs5758452	ENSG00000233903.2	Z83851.4	3.79	0.000171	0.0219	0.24	0.17	Vitiligo;	chr22:41748923	chr22:42276355~42277052:+
HNSC	cis	rs28829049	0.597	rs12740975	ENSG00000270728.1	RP4-657E11.10	-3.79	0.000171	0.0219	-0.16	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111429	chr1:19297080~19297903:+
HNSC	cis	rs11951515	0.714	rs56071328	ENSG00000249286.1	CTD-2210P15.2	3.79	0.000171	0.0219	0.18	0.17	Metabolite levels  (X-11787);	chr5:43341225	chr5:43586918~43588223:-
HNSC	cis	rs2836974	0.644	rs1882779	ENSG00000255568.3	BRWD1-AS2	-3.79	0.000172	0.0219	-0.15	-0.17	Cognitive function;	chr21:39319012	chr21:39313935~39314962:+
HNSC	cis	rs853679	0.517	rs2273564	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28089816	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs1853097	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28090857	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9393888	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28091439	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs3734573	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28091659	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9357063	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28092227	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs3823180	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28093966	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.517	rs9368551	ENSG00000219891.2	ZSCAN12P1	3.79	0.000172	0.0219	0.24	0.17	Depression;	chr6:28094014	chr6:28091154~28093664:+
HNSC	cis	rs5769765	0.72	rs138820	ENSG00000229409.1	RP11-494O16.3	3.79	0.000172	0.0219	0.23	0.17	Schizophrenia;	chr22:49770430	chr22:49845929~49846090:+
HNSC	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	3.79	0.000172	0.0219	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
HNSC	cis	rs10256972	0.713	rs10435026	ENSG00000225146.1	AC073957.15	3.79	0.000172	0.0219	0.2	0.17	Endometriosis;Longevity;	chr7:1026312	chr7:1029025~1043891:+
HNSC	cis	rs2337406	1	rs74090714	ENSG00000211972.2	IGHV3-66	3.79	0.000172	0.0219	0.17	0.17	Alzheimer's disease (late onset);	chr14:106691225	chr14:106675017~106675544:-
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-3.79	0.000172	0.0219	-0.2	-0.17	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
HNSC	cis	rs3736485	0.966	rs2124877	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000172	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614078	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs2124878	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000172	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614140	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.903	rs750162	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000172	0.0219	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51614956	chr15:52017167~52018032:-
HNSC	cis	rs913655	0.508	rs11006743	ENSG00000225527.1	RP11-383B4.4	-3.79	0.000172	0.022	-0.21	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18747357	chr10:18531849~18533336:-
HNSC	cis	rs828999	1	rs828999	ENSG00000280186.1	RP11-483I13.6	-3.79	0.000172	0.022	-0.18	-0.17	Monocyte percentage of white cells;	chr1:108202312	chr1:108200413~108202743:+
HNSC	cis	rs6012564	0.793	rs6125552	ENSG00000227431.4	CSE1L-AS1	3.79	0.000172	0.022	0.19	0.17	Anger;	chr20:49107788	chr20:49040463~49046044:-
HNSC	cis	rs2562456	0.833	rs11666828	ENSG00000268081.1	RP11-678G14.2	3.79	0.000172	0.022	0.25	0.17	Pain;	chr19:21342218	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62110367	ENSG00000268081.1	RP11-678G14.2	3.79	0.000172	0.022	0.25	0.17	Pain;	chr19:21365829	chr19:21554640~21569237:-
HNSC	cis	rs7246760	0.5	rs4325679	ENSG00000267289.1	CTD-2623N2.11	3.79	0.000172	0.022	0.26	0.17	Pursuit maintenance gain;	chr19:9874003	chr19:9834079~9835013:-
HNSC	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	3.79	0.000172	0.022	0.19	0.17	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	3.79	0.000172	0.022	0.19	0.17	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	3.79	0.000172	0.022	0.19	0.17	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
HNSC	cis	rs870825	0.932	rs13136635	ENSG00000254233.1	RP11-242J7.1	-3.79	0.000172	0.022	-0.28	-0.17	Blood protein levels;	chr4:184653653	chr4:184584093~184625030:-
HNSC	cis	rs347412	0.509	rs9566940	ENSG00000237263.1	MAPK6PS3	3.79	0.000172	0.022	0.22	0.17	Pulmonary function in asthmatics;	chr13:42213801	chr13:42068932~42071093:-
HNSC	cis	rs35306767	0.903	rs61830933	ENSG00000229869.1	RP11-363N22.2	-3.79	0.000172	0.022	-0.27	-0.17	Eosinophil percentage of granulocytes;	chr10:888255	chr10:933026~942743:+
HNSC	cis	rs757081	0.671	rs214090	ENSG00000260196.1	RP1-239B22.5	-3.79	0.000172	0.022	-0.22	-0.17	Systolic blood pressure;	chr11:17275614	chr11:17380649~17383531:+
HNSC	cis	rs9611565	0.694	rs202641	ENSG00000235513.1	RP4-756G23.5	-3.79	0.000172	0.022	-0.2	-0.17	Vitiligo;	chr22:41437112	chr22:41209122~41217627:-
HNSC	cis	rs748404	0.666	rs35326382	ENSG00000166763.7	STRCP1	3.79	0.000172	0.022	0.24	0.17	Lung cancer;	chr15:43338686	chr15:43699488~43718184:-
HNSC	cis	rs9863	0.828	rs56041971	ENSG00000270028.1	RP11-380L11.4	3.79	0.000172	0.022	0.21	0.17	White blood cell count;	chr12:123996319	chr12:123925461~123926083:-
HNSC	cis	rs9329221	0.537	rs1351876	ENSG00000255310.2	AF131215.2	-3.79	0.000172	0.022	-0.16	-0.17	Neuroticism;	chr8:10127267	chr8:11107788~11109726:-
HNSC	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	3.79	0.000172	0.022	0.18	0.17	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
HNSC	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	3.79	0.000172	0.022	0.18	0.17	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
HNSC	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	3.79	0.000172	0.022	0.18	0.17	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
HNSC	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-3.79	0.000172	0.022	-0.18	-0.17	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
HNSC	cis	rs8010715	0.816	rs8015168	ENSG00000259321.1	RP11-468E2.5	3.79	0.000172	0.022	0.15	0.17	IgG glycosylation;	chr14:24130663	chr14:24139445~24140444:+
HNSC	cis	rs3808502	0.527	rs4410870	ENSG00000269918.1	AF131215.9	-3.79	0.000172	0.022	-0.18	-0.17	Neuroticism;	chr8:11298611	chr8:11104691~11106704:-
HNSC	cis	rs6570726	0.846	rs453834	ENSG00000270638.1	RP3-466P17.1	3.79	0.000172	0.022	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.846	rs409553	ENSG00000270638.1	RP3-466P17.1	3.79	0.000172	0.022	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.846	rs371186	ENSG00000270638.1	RP3-466P17.1	3.79	0.000172	0.022	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145735570~145737218:+
HNSC	cis	rs3736485	0.966	rs8040080	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000172	0.022	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51612262	chr15:52017167~52018032:-
HNSC	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	3.79	0.000172	0.022	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
HNSC	cis	rs9611565	0.659	rs56364401	ENSG00000235513.1	RP4-756G23.5	3.79	0.000172	0.022	0.2	0.17	Vitiligo;	chr22:41555239	chr22:41209122~41217627:-
HNSC	cis	rs6601450	0.579	rs11775625	ENSG00000255310.2	AF131215.2	3.79	0.000172	0.022	0.16	0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10414929	chr8:11107788~11109726:-
HNSC	cis	rs35146811	0.735	rs1637001	ENSG00000235077.1	AC073842.19	-3.79	0.000172	0.022	-0.21	-0.17	Coronary artery disease;	chr7:100210528	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.695	rs1623264	ENSG00000235077.1	AC073842.19	-3.79	0.000172	0.022	-0.21	-0.17	Coronary artery disease;	chr7:100213581	chr7:100130964~100140439:+
HNSC	cis	rs36093844	0.626	rs10501603	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000172	0.022	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85970873	chr11:85852557~85854943:-
HNSC	cis	rs9611565	0.649	rs2064189	ENSG00000233903.2	Z83851.4	3.79	0.000172	0.022	0.24	0.17	Vitiligo;	chr22:41731995	chr22:42276355~42277052:+
HNSC	cis	rs7777677	0.925	rs2156964	ENSG00000276557.1	TRBV18	3.79	0.000172	0.022	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142615716~142616415:+
HNSC	cis	rs17253792	0.915	rs76952651	ENSG00000186615.9	KTN1-AS1	-3.79	0.000172	0.022	-0.35	-0.17	Putamen volume;	chr14:55722276	chr14:55499278~55580110:-
HNSC	cis	rs17772222	1	rs7145588	ENSG00000258789.1	RP11-507K2.3	-3.79	0.000172	0.022	-0.21	-0.17	Coronary artery calcification;	chr14:88360452	chr14:88551597~88552493:+
HNSC	cis	rs8031584	0.678	rs35098644	ENSG00000270015.1	RP11-540B6.6	-3.79	0.000172	0.022	-0.18	-0.17	Huntington's disease progression;	chr15:30853237	chr15:30926514~30928407:+
HNSC	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-3.79	0.000172	0.022	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
HNSC	cis	rs138249	0.505	rs138218	ENSG00000273253.2	RP3-402G11.26	-3.79	0.000172	0.022	-0.2	-0.17	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50109129	chr22:50199090~50200837:-
HNSC	cis	rs6430585	0.528	rs586964	ENSG00000231890.6	DARS-AS1	-3.79	0.000172	0.022	-0.3	-0.17	Corneal structure;	chr2:135894921	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs499483	ENSG00000231890.6	DARS-AS1	-3.79	0.000172	0.022	-0.3	-0.17	Corneal structure;	chr2:135894954	chr2:135985176~136022593:+
HNSC	cis	rs7824557	0.628	rs7815802	ENSG00000269918.1	AF131215.9	3.79	0.000172	0.022	0.17	0.17	Retinal vascular caliber;	chr8:11333138	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.593	rs11774673	ENSG00000269918.1	AF131215.9	3.79	0.000172	0.022	0.17	0.17	Retinal vascular caliber;	chr8:11334028	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs7831346	ENSG00000269918.1	AF131215.9	3.79	0.000172	0.022	0.17	0.17	Retinal vascular caliber;	chr8:11336021	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs6601580	ENSG00000269918.1	AF131215.9	3.79	0.000172	0.022	0.17	0.17	Retinal vascular caliber;	chr8:11336227	chr8:11104691~11106704:-
HNSC	cis	rs1667255	0.505	rs9963820	ENSG00000266521.1	RP11-650P15.1	-3.79	0.000172	0.022	-0.2	-0.17	Retinol levels;	chr18:31567005	chr18:31496645~31497195:-
HNSC	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	3.79	0.000172	0.022	0.39	0.17	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
HNSC	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	3.79	0.000172	0.022	0.2	0.17	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
HNSC	cis	rs7819412	0.595	rs2409712	ENSG00000255310.2	AF131215.2	-3.79	0.000173	0.022	-0.16	-0.17	Triglycerides;	chr8:11129327	chr8:11107788~11109726:-
HNSC	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	3.79	0.000173	0.022	0.2	0.17	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
HNSC	cis	rs7777677	0.925	rs6956269	ENSG00000276557.1	TRBV18	3.79	0.000173	0.022	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.925	rs4726547	ENSG00000276557.1	TRBV18	3.79	0.000173	0.022	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142615716~142616415:+
HNSC	cis	rs2998286	0.723	rs2807729	ENSG00000254635.4	WAC-AS1	3.79	0.000173	0.022	0.26	0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526427	chr10:28522652~28532743:-
HNSC	cis	rs11168351	0.75	rs11168366	ENSG00000257763.1	OR5BK1P	-3.79	0.000173	0.022	-0.17	-0.17	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48355792~48356614:-
HNSC	cis	rs61542988	0.797	rs4329182	ENSG00000221740.1	SNORD93	3.79	0.000173	0.022	0.21	0.17	Fibrinogen levels;	chr7:22843002	chr7:22856613~22856686:+
HNSC	cis	rs61542988	0.756	rs5013587	ENSG00000221740.1	SNORD93	3.79	0.000173	0.022	0.21	0.17	Fibrinogen levels;	chr7:22843041	chr7:22856613~22856686:+
HNSC	cis	rs9313772	0.775	rs13163917	ENSG00000254350.1	RP11-542A14.1	-3.79	0.000173	0.022	-0.19	-0.17	Blood pressure;	chr5:158405292	chr5:158424585~158452758:+
HNSC	cis	rs4919687	0.55	rs11191371	ENSG00000236937.2	PTGES3P4	3.79	0.000173	0.0221	0.22	0.17	Colorectal cancer;	chr10:102700140	chr10:102845595~102845950:+
HNSC	cis	rs3096299	0.685	rs8050512	ENSG00000261118.1	RP11-104N10.1	3.79	0.000173	0.0221	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89492017~89504460:-
HNSC	cis	rs7903456	0.512	rs7076542	ENSG00000200253.1	RNU6-529P	3.79	0.000173	0.0221	0.23	0.17	Gout;Renal underexcretion gout;	chr10:87067342	chr10:87041238~87041341:-
HNSC	cis	rs7903456	0.512	rs7076857	ENSG00000200253.1	RNU6-529P	3.79	0.000173	0.0221	0.23	0.17	Gout;Renal underexcretion gout;	chr10:87067496	chr10:87041238~87041341:-
HNSC	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-3.79	0.000173	0.0221	-0.24	-0.17	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
HNSC	cis	rs919433	0.783	rs787979	ENSG00000231621.1	AC013264.2	-3.79	0.000173	0.0221	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197378144	chr2:197197991~197199273:+
HNSC	cis	rs801193	1	rs2707856	ENSG00000273142.1	RP11-458F8.4	-3.79	0.000173	0.0221	-0.15	-0.17	Aortic root size;	chr7:66746023	chr7:66902857~66906297:+
HNSC	cis	rs6840258	0.76	rs340643	ENSG00000251411.1	RP11-397E7.4	-3.79	0.000173	0.0221	-0.2	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87026006	chr4:86913266~86914817:-
HNSC	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	3.79	0.000173	0.0221	0.2	0.17	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
HNSC	cis	rs868153	0.625	rs1531187	ENSG00000275339.1	RP3-425C14.6	3.79	0.000173	0.0221	0.19	0.17	Vertical cup-disc ratio;	chr6:122207329	chr6:122454358~122454612:+
HNSC	cis	rs853679	0.546	rs35016036	ENSG00000226314.6	ZNF192P1	-3.79	0.000173	0.0221	-0.33	-0.17	Depression;	chr6:28347103	chr6:28161781~28169594:+
HNSC	cis	rs1865760	0.534	rs72834629	ENSG00000272810.1	U91328.22	-3.79	0.000173	0.0221	-0.17	-0.17	Height;	chr6:26022804	chr6:26013241~26013757:+
HNSC	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	3.79	0.000173	0.0221	0.17	0.17	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
HNSC	cis	rs17666538	0.535	rs1669613	ENSG00000254207.1	RP11-43A14.1	3.79	0.000173	0.0221	0.38	0.17	IgG glycosylation;	chr8:667565	chr8:725188~725877:-
HNSC	cis	rs7927592	0.956	rs2155730	ENSG00000255031.4	RP11-802E16.3	3.79	0.000173	0.0221	0.15	0.17	Total body bone mineral density;	chr11:68562006	chr11:68050740~68053762:+
HNSC	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-3.79	0.000173	0.0221	-0.23	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
HNSC	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	3.79	0.000173	0.0221	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	3.79	0.000173	0.0221	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	3.79	0.000173	0.0221	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	3.79	0.000173	0.0221	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	3.79	0.000173	0.0221	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
HNSC	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	3.79	0.000173	0.0221	0.25	0.17	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	3.79	0.000173	0.0221	0.25	0.17	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	3.79	0.000173	0.0221	0.25	0.17	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	3.79	0.000173	0.0221	0.25	0.17	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	3.79	0.000173	0.0221	0.25	0.17	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
HNSC	cis	rs16953946	0.881	rs8047203	ENSG00000278985.1	RP11-303E16.9	-3.79	0.000173	0.0221	-0.24	-0.17	Inflammatory bowel disease;	chr16:80734323	chr16:80982319~80984094:-
HNSC	cis	rs7324557	0.652	rs7332811	ENSG00000205861.10	C1QTNF9B-AS1	3.79	0.000173	0.0221	0.24	0.17	Visceral adipose tissue adjusted for BMI;	chr13:23823066	chr13:23888889~23897263:+
HNSC	cis	rs700651	0.821	rs4850812	ENSG00000231621.1	AC013264.2	3.79	0.000173	0.0221	0.17	0.17	Intracranial aneurysm;	chr2:197878931	chr2:197197991~197199273:+
HNSC	cis	rs7829975	0.688	rs7827182	ENSG00000233609.3	RP11-62H7.2	3.79	0.000173	0.0221	0.16	0.17	Mood instability;	chr8:8522961	chr8:8961200~8979025:+
HNSC	cis	rs6012564	0.89	rs6066976	ENSG00000227431.4	CSE1L-AS1	3.79	0.000173	0.0221	0.19	0.17	Anger;	chr20:49134464	chr20:49040463~49046044:-
HNSC	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	3.79	0.000173	0.0221	0.22	0.17	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
HNSC	cis	rs7824557	0.564	rs2736288	ENSG00000255495.1	AC145124.2	-3.79	0.000173	0.0221	-0.19	-0.17	Retinal vascular caliber;	chr8:11370591	chr8:12194467~12196280:+
HNSC	cis	rs2016266	0.859	rs4759061	ENSG00000270175.1	RP11-793H13.11	3.79	0.000173	0.0221	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53344430	chr12:53500162~53500936:-
HNSC	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-3.79	0.000173	0.0221	-0.13	-0.17	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
HNSC	cis	rs10742752	0.702	rs2046733	ENSG00000254651.1	RP11-430H10.3	3.79	0.000173	0.0221	0.21	0.17	Body mass index;	chr11:45426540	chr11:45399448~45400528:+
HNSC	cis	rs2554380	0.628	rs2401130	ENSG00000259570.1	RP11-671M22.4	3.79	0.000173	0.0221	0.21	0.17	Height;	chr15:83801983	chr15:84394512~84395514:+
HNSC	cis	rs870825	0.616	rs2696037	ENSG00000254233.1	RP11-242J7.1	-3.79	0.000173	0.0221	-0.26	-0.17	Blood protein levels;	chr4:184689786	chr4:184584093~184625030:-
HNSC	cis	rs11846409	0.932	rs73378158	ENSG00000280411.1	IGHV1-69-2	-3.79	0.000173	0.0221	-0.15	-0.17	Rheumatic heart disease;	chr14:106638433	chr14:106762092~106762588:-
HNSC	cis	rs36093844	0.527	rs10501607	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000173	0.0221	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86032963	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.527	rs17817883	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000173	0.0221	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86033195	chr11:85852557~85854943:-
HNSC	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	3.79	0.000173	0.0221	0.18	0.17	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
HNSC	cis	rs3736485	0.932	rs2278990	ENSG00000274528.1	CTD-2650P22.2	3.79	0.000173	0.0221	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51622465	chr15:52017167~52018032:-
HNSC	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	3.79	0.000173	0.0221	0.25	0.17	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
HNSC	cis	rs591584	0.666	rs1939139	ENSG00000255893.1	RP11-685N10.1	-3.79	0.000174	0.0221	-0.25	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94573836	chr11:94472908~94473570:-
HNSC	cis	rs17772222	0.958	rs12436326	ENSG00000258789.1	RP11-507K2.3	-3.79	0.000174	0.0221	-0.21	-0.17	Coronary artery calcification;	chr14:88533632	chr14:88551597~88552493:+
HNSC	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-3.79	0.000174	0.0221	-0.18	-0.17	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
HNSC	cis	rs7688540	0.8	rs7694325	ENSG00000250892.1	RP11-1365D11.1	-3.79	0.000174	0.0221	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:201409~205009:-
HNSC	cis	rs11951515	0.577	rs7701391	ENSG00000249286.1	CTD-2210P15.2	3.79	0.000174	0.0221	0.18	0.17	Metabolite levels  (X-11787);	chr5:43306688	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs11738086	ENSG00000249286.1	CTD-2210P15.2	3.79	0.000174	0.0221	0.18	0.17	Metabolite levels  (X-11787);	chr5:43352399	chr5:43586918~43588223:-
HNSC	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	3.79	0.000174	0.0221	0.17	0.17	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
HNSC	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	3.79	0.000174	0.0222	0.26	0.17	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
HNSC	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	3.79	0.000174	0.0222	0.18	0.17	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
HNSC	cis	rs853679	0.517	rs35193936	ENSG00000219891.2	ZSCAN12P1	3.79	0.000174	0.0222	0.24	0.17	Depression;	chr6:28108492	chr6:28091154~28093664:+
HNSC	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	3.79	0.000174	0.0222	0.21	0.17	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
HNSC	cis	rs1155750	0.72	rs239845	ENSG00000224984.1	RP11-524H19.2	-3.78	0.000174	0.0222	-0.25	-0.17	Colorectal cancer;	chr6:54899559	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239844	ENSG00000224984.1	RP11-524H19.2	-3.78	0.000174	0.0222	-0.25	-0.17	Colorectal cancer;	chr6:54899862	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239843	ENSG00000224984.1	RP11-524H19.2	-3.78	0.000174	0.0222	-0.25	-0.17	Colorectal cancer;	chr6:54900657	chr6:54840118~54840855:-
HNSC	cis	rs1443512	0.773	rs2366146	ENSG00000249641.2	HOXC13-AS	-3.78	0.000174	0.0222	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53937218	chr12:53935328~53939643:-
HNSC	cis	rs7107174	1	rs2510050	ENSG00000251323.2	RP11-452H21.4	3.78	0.000174	0.0222	0.26	0.17	Testicular germ cell tumor;	chr11:78271518	chr11:78423982~78429836:-
HNSC	cis	rs442309	0.875	rs224063	ENSG00000238280.1	RP11-436D10.3	3.78	0.000174	0.0222	0.21	0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62743589	chr10:62793562~62805887:-
HNSC	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000174	0.0222	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
HNSC	cis	rs11711311	1	rs7633832	ENSG00000241529.3	RN7SL767P	-3.78	0.000174	0.0222	-0.22	-0.17	IgG glycosylation;	chr3:113753445	chr3:113632704~113632998:+
HNSC	cis	rs11711311	0.955	rs12636536	ENSG00000241529.3	RN7SL767P	-3.78	0.000174	0.0222	-0.22	-0.17	IgG glycosylation;	chr3:113755379	chr3:113632704~113632998:+
HNSC	cis	rs6012564	0.806	rs4810903	ENSG00000227431.4	CSE1L-AS1	-3.78	0.000174	0.0222	-0.19	-0.17	Anger;	chr20:48982668	chr20:49040463~49046044:-
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	3.78	0.000174	0.0222	0.19	0.17	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
HNSC	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	3.78	0.000174	0.0222	0.24	0.17	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
HNSC	cis	rs9847710	1	rs6770152	ENSG00000242142.1	SERBP1P3	3.78	0.000174	0.0222	0.19	0.17	Ulcerative colitis;	chr3:53066198	chr3:53064283~53065091:-
HNSC	cis	rs72827839	0.802	rs1986693	ENSG00000228782.6	CTD-2026D20.3	-3.78	0.000174	0.0222	-0.2	-0.17	Ease of getting up in the morning;	chr17:47948790	chr17:47450568~47492492:-
HNSC	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	3.78	0.000174	0.0222	0.17	0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
HNSC	cis	rs4938303	0.589	rs11601584	ENSG00000280143.1	AP000892.6	-3.78	0.000174	0.0222	-0.2	-0.17	Triglycerides;	chr11:116700568	chr11:117204967~117210292:+
HNSC	cis	rs9467711	0.559	rs9393727	ENSG00000241549.7	GUSBP2	3.78	0.000174	0.0222	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26499783	chr6:26871484~26956554:-
HNSC	cis	rs7580658	0.751	rs1799808	ENSG00000236682.1	AC068282.3	-3.78	0.000174	0.0222	-0.2	-0.17	Protein C levels;	chr2:127418286	chr2:127389130~127400580:+
HNSC	cis	rs710865	0.723	rs710870	ENSG00000270728.1	RP4-657E11.10	-3.78	0.000174	0.0222	-0.15	-0.17	Brain structure;	chr1:19223265	chr1:19297080~19297903:+
HNSC	cis	rs516805	0.596	rs2606625	ENSG00000279453.1	RP3-425C14.4	-3.78	0.000174	0.0222	-0.25	-0.17	Lymphocyte counts;	chr6:122165363	chr6:122436789~122439223:-
HNSC	cis	rs6430585	0.528	rs6750549	ENSG00000231890.6	DARS-AS1	-3.78	0.000174	0.0222	-0.29	-0.17	Corneal structure;	chr2:135949910	chr2:135985176~136022593:+
HNSC	cis	rs7688540	0.771	rs61794997	ENSG00000211553.1	AC253576.2	-3.78	0.000174	0.0222	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:136461~136568:+
HNSC	cis	rs5751168	0.831	rs5758484	ENSG00000274422.1	LL22NC03-2H8.5	3.78	0.000174	0.0222	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22490315	chr22:22283928~22287220:-
HNSC	cis	rs1476670	0.661	rs10157253	ENSG00000230615.5	RP5-1198O20.4	-3.78	0.000174	0.0222	-0.21	-0.17	Eotaxin levels;	chr1:44039974	chr1:44030443~44115913:+
HNSC	cis	rs1476670	0.69	rs6677372	ENSG00000230615.5	RP5-1198O20.4	-3.78	0.000174	0.0222	-0.21	-0.17	Eotaxin levels;	chr1:44040117	chr1:44030443~44115913:+
HNSC	cis	rs792448	0.743	rs7415843	ENSG00000226251.4	RP11-15I11.3	-3.78	0.000174	0.0222	-0.21	-0.17	White blood cell count (basophil);	chr1:212336420	chr1:212225278~212238977:-
HNSC	cis	rs442309	0.846	rs224049	ENSG00000238280.1	RP11-436D10.3	-3.78	0.000174	0.0222	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62732673	chr10:62793562~62805887:-
HNSC	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-3.78	0.000174	0.0222	-0.24	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
HNSC	cis	rs1620921	0.565	rs67368974	ENSG00000231863.1	RP3-428L16.1	-3.78	0.000174	0.0222	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160843092	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.565	rs59536962	ENSG00000231863.1	RP3-428L16.1	-3.78	0.000174	0.0222	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160843099	chr6:160931080~160969771:+
HNSC	cis	rs748404	0.666	rs12899865	ENSG00000166763.7	STRCP1	3.78	0.000174	0.0222	0.24	0.17	Lung cancer;	chr15:43448819	chr15:43699488~43718184:-
HNSC	cis	rs9925964	0.869	rs2288004	ENSG00000232748.3	RP11-196G11.6	3.78	0.000174	0.0222	0.22	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31056460~31062803:+
HNSC	cis	rs9925964	0.933	rs9929899	ENSG00000232748.3	RP11-196G11.6	3.78	0.000174	0.0222	0.22	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31056460~31062803:+
HNSC	cis	rs7824557	0.675	rs2736265	ENSG00000269918.1	AF131215.9	3.78	0.000174	0.0222	0.17	0.17	Retinal vascular caliber;	chr8:11329165	chr8:11104691~11106704:-
HNSC	cis	rs7429990	0.813	rs7627568	ENSG00000228638.1	FCF1P2	3.78	0.000174	0.0222	0.16	0.17	Educational attainment (years of education);	chr3:48051562	chr3:48290793~48291375:-
HNSC	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	3.78	0.000174	0.0222	0.22	0.17	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
HNSC	cis	rs4792901	0.959	rs4792997	ENSG00000279602.1	CTD-3014M21.1	3.78	0.000174	0.0222	0.2	0.17	Dupuytren's disease;	chr17:43574708	chr17:43360041~43361361:-
HNSC	cis	rs2052670	1	rs1160706	ENSG00000232164.1	AC092669.3	-3.78	0.000174	0.0222	-0.18	-0.17	Waist circumference adjusted for body mass index;	chr2:65999841	chr2:66383306~66392450:+
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000241549.7	GUSBP2	3.78	0.000174	0.0222	0.18	0.17	Parkinson's disease;	chr6:27894349	chr6:26871484~26956554:-
HNSC	cis	rs2976388	1	rs10216533	ENSG00000253741.1	CTD-2292P10.4	3.78	0.000174	0.0222	0.16	0.17	Urinary tract infection frequency;	chr8:142682272	chr8:142702252~142726973:-
HNSC	cis	rs7572733	0.935	rs7558450	ENSG00000222017.1	AC011997.1	3.78	0.000174	0.0222	0.21	0.17	Dermatomyositis;	chr2:197973042	chr2:197693106~197774823:+
HNSC	cis	rs7777677	0.925	rs4726546	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.925	rs6960743	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.925	rs6956756	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.889	rs6975391	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.925	rs9655661	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.888	rs9655574	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.963	rs4726550	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142615716~142616415:+
HNSC	cis	rs7777677	0.963	rs7796324	ENSG00000276557.1	TRBV18	3.78	0.000174	0.0222	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142615716~142616415:+
HNSC	cis	rs34421088	0.506	rs2572428	ENSG00000269918.1	AF131215.9	3.78	0.000174	0.0222	0.18	0.17	Neuroticism;	chr8:11289163	chr8:11104691~11106704:-
HNSC	cis	rs73198271	1	rs11775476	ENSG00000233609.3	RP11-62H7.2	-3.78	0.000174	0.0222	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8961200~8979025:+
HNSC	cis	rs2048656	0.523	rs7825286	ENSG00000233609.3	RP11-62H7.2	3.78	0.000174	0.0222	0.18	0.17	Schizophrenia;	chr8:9791031	chr8:8961200~8979025:+
HNSC	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	3.78	0.000174	0.0222	0.17	0.17	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
HNSC	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-3.78	0.000174	0.0222	-0.18	-0.17	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
HNSC	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-3.78	0.000174	0.0222	-0.13	-0.17	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
HNSC	cis	rs2944755	0.723	rs13273553	ENSG00000279766.1	RP11-642A1.2	-3.78	0.000174	0.0222	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578166	chr8:140572142~140572812:-
HNSC	cis	rs2836974	0.931	rs2776307	ENSG00000255568.3	BRWD1-AS2	-3.78	0.000174	0.0222	-0.16	-0.17	Cognitive function;	chr21:39341907	chr21:39313935~39314962:+
HNSC	cis	rs36052053	0.521	rs13219673	ENSG00000219700.1	PTCHD3P3	3.78	0.000175	0.0222	0.33	0.17	Red cell distribution width;	chr6:109233713	chr6:109288571~109290503:-
HNSC	cis	rs36093844	0.654	rs7106460	ENSG00000279742.1	RP11-700A24.1	-3.78	0.000175	0.0223	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85904506	chr11:85852557~85854943:-
HNSC	cis	rs7208859	0.673	rs9889755	ENSG00000264538.5	SUZ12P1	3.78	0.000175	0.0223	0.14	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30709299~30790908:+
HNSC	cis	rs12701220	0.894	rs34712249	ENSG00000224079.1	AC091729.7	3.78	0.000175	0.0223	0.26	0.17	Bronchopulmonary dysplasia;	chr7:996998	chr7:1074450~1078036:+
HNSC	cis	rs17253792	0.822	rs75995456	ENSG00000186615.9	KTN1-AS1	-3.78	0.000175	0.0223	-0.35	-0.17	Putamen volume;	chr14:55606476	chr14:55499278~55580110:-
HNSC	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-3.78	0.000175	0.0223	-0.21	-0.17	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
HNSC	cis	rs73201462	1	rs2811527	ENSG00000231305.3	RP11-723O4.2	3.78	0.000175	0.0223	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275761	chr3:128861313~128871540:-
HNSC	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	3.78	0.000175	0.0223	0.19	0.17	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
HNSC	cis	rs449789	0.857	rs591953	ENSG00000235086.1	FNDC1-IT1	-3.78	0.000175	0.0223	-0.21	-0.17	Pulse pressure;	chr6:159295714	chr6:159240786~159243329:+
HNSC	cis	rs7829975	0.564	rs2921057	ENSG00000254340.1	RP11-10A14.3	3.78	0.000175	0.0223	0.21	0.17	Mood instability;	chr8:8461157	chr8:9141424~9145435:+
HNSC	cis	rs9583531	0.6	rs4773241	ENSG00000259831.1	LINC00567	3.78	0.000175	0.0223	0.2	0.17	Coronary artery disease;	chr13:110710674	chr13:110809676~110813084:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000213640.3	EEF1DP4	-3.78	0.000175	0.0223	-0.21	-0.17	Calcium levels;	chr7:65806798	chr7:64862999~64864370:+
HNSC	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	3.78	0.000175	0.0223	0.36	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
HNSC	cis	rs950169	0.922	rs62029585	ENSG00000259295.5	CSPG4P12	3.78	0.000175	0.0223	0.25	0.17	Schizophrenia;	chr15:84397176	chr15:85191438~85213905:+
HNSC	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	3.78	0.000175	0.0223	0.24	0.17	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	3.78	0.000175	0.0223	0.24	0.17	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
HNSC	cis	rs471144	0.881	rs12089980	ENSG00000237975.5	FLG-AS1	-3.78	0.000175	0.0223	-0.33	-0.17	Inflammatory skin disease;	chr1:152459455	chr1:152168125~152445456:+
HNSC	cis	rs950027	0.595	rs2486288	ENSG00000259479.5	SORD2P	3.78	0.000175	0.0223	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:44826371~44884694:-
HNSC	cis	rs2274273	0.529	rs7149965	ENSG00000233924.1	AL160471.6	-3.78	0.000175	0.0223	-0.19	-0.17	Protein biomarker;	chr14:55041473	chr14:55004813~55005687:-
HNSC	cis	rs13287066	0.716	rs4744239	ENSG00000227603.1	RP11-165J3.6	3.78	0.000175	0.0223	0.15	0.17	Intelligence (multi-trait analysis);	chr9:93404100	chr9:93435332~93437121:-
HNSC	cis	rs2243480	1	rs56016656	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65918494	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs56291018	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65925352	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs36033484	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65925571	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
HNSC	cis	rs12893668	0.703	rs55751606	ENSG00000269958.1	RP11-73M18.8	3.78	0.000175	0.0223	0.17	0.17	Reticulocyte count;	chr14:103562469	chr14:103696353~103697163:+
HNSC	cis	rs7364180	1	rs7364180	ENSG00000205702.9	CYP2D7	-3.78	0.000175	0.0223	-0.13	-0.17	Alzheimer's disease biomarkers;	chr22:41822852	chr22:42140203~42144577:-
HNSC	cis	rs7829975	0.502	rs7820738	ENSG00000254153.1	CTA-398F10.2	-3.78	0.000175	0.0223	-0.19	-0.17	Mood instability;	chr8:8845097	chr8:8456909~8461337:-
HNSC	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	3.78	0.000175	0.0223	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
HNSC	cis	rs516805	0.561	rs9482260	ENSG00000279453.1	RP3-425C14.4	3.78	0.000175	0.0223	0.26	0.17	Lymphocyte counts;	chr6:122606981	chr6:122436789~122439223:-
HNSC	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	3.78	0.000175	0.0223	0.24	0.17	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
HNSC	cis	rs16846053	0.515	rs6750756	ENSG00000227403.1	AC009299.3	-3.78	0.000175	0.0223	-0.31	-0.17	Blood osmolality (transformed sodium);	chr2:161659798	chr2:161244739~161249050:+
HNSC	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	3.78	0.000175	0.0223	0.23	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
HNSC	cis	rs10791097	0.748	rs4937580	ENSG00000254842.5	RP11-890B15.2	-3.78	0.000175	0.0223	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130864375	chr11:130844191~130865561:-
HNSC	cis	rs10783487	1	rs12824536	ENSG00000257542.4	OR7E47P	-3.78	0.000175	0.0223	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52068321	chr12:52079696~52108261:+
HNSC	cis	rs11645898	0.511	rs72787023	ENSG00000261008.5	LINC01572	-3.78	0.000175	0.0223	-0.24	-0.17	Blood protein levels;	chr16:71997206	chr16:72283301~72665009:-
HNSC	cis	rs250677	0.687	rs36048	ENSG00000250072.4	CTC-529P8.1	-3.78	0.000175	0.0223	-0.22	-0.17	Breast cancer;	chr5:149062150	chr5:149063317~149109787:+
HNSC	cis	rs17772222	0.958	rs891750	ENSG00000258789.1	RP11-507K2.3	-3.78	0.000175	0.0223	-0.21	-0.17	Coronary artery calcification;	chr14:88550856	chr14:88551597~88552493:+
HNSC	cis	rs2548724	0.812	rs3096196	ENSG00000250682.4	LINC00491	-3.78	0.000175	0.0223	-0.23	-0.17	Type 2 diabetes;	chr5:102268210	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs2113091	ENSG00000250682.4	LINC00491	-3.78	0.000175	0.0223	-0.23	-0.17	Type 2 diabetes;	chr5:102268835	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs2161601	ENSG00000250682.4	LINC00491	-3.78	0.000175	0.0223	-0.23	-0.17	Type 2 diabetes;	chr5:102269167	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs2600835	ENSG00000250682.4	LINC00491	-3.78	0.000175	0.0223	-0.23	-0.17	Type 2 diabetes;	chr5:102269730	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs2600832	ENSG00000250682.4	LINC00491	-3.78	0.000175	0.0223	-0.23	-0.17	Type 2 diabetes;	chr5:102270298	chr5:102609156~102671559:-
HNSC	cis	rs1912702	0.824	rs11237851	ENSG00000255345.1	CTD-2337I7.1	3.78	0.000175	0.0223	0.2	0.17	Hair greying;	chr11:79472333	chr11:79092848~79098003:+
HNSC	cis	rs9768139	0.634	rs56389048	ENSG00000223872.1	AC006372.5	-3.78	0.000175	0.0223	-0.19	-0.17	Calcium levels;	chr7:158328676	chr7:157501322~157503577:+
HNSC	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	3.78	0.000175	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
HNSC	cis	rs12908161	0.959	rs1051168	ENSG00000229212.6	RP11-561C5.4	-3.78	0.000175	0.0223	-0.25	-0.17	Schizophrenia;	chr15:84657289	chr15:85205440~85234795:-
HNSC	cis	rs2243480	1	rs34560516	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65939105	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.808	rs12698508	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65946971	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs2961102	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65959671	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34970380	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65966506	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs73148097	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65966800	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs906134	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65979301	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
HNSC	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-3.78	0.000176	0.0223	-0.17	-0.17	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-3.78	0.000176	0.0223	-0.17	-0.17	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
HNSC	cis	rs3018712	0.532	rs7932726	ENSG00000212093.1	AP000807.1	-3.78	0.000176	0.0223	-0.25	-0.17	Total body bone mineral density;	chr11:68647259	chr11:68506083~68506166:-
HNSC	cis	rs7772486	0.686	rs9403739	ENSG00000270638.1	RP3-466P17.1	-3.78	0.000176	0.0224	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145735570~145737218:+
HNSC	cis	rs7927592	0.871	rs871212	ENSG00000255031.4	RP11-802E16.3	3.78	0.000176	0.0224	0.15	0.17	Total body bone mineral density;	chr11:68581227	chr11:68050740~68053762:+
HNSC	cis	rs72759215	1	rs72759215	ENSG00000272308.1	RP11-231G3.1	-3.78	0.000176	0.0224	-0.18	-0.17	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60866457~60866935:-
HNSC	cis	rs597539	0.652	rs514833	ENSG00000255741.1	RP11-757G1.5	-3.78	0.000176	0.0224	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs488363	ENSG00000255741.1	RP11-757G1.5	-3.78	0.000176	0.0224	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68941503~68942852:-
HNSC	cis	rs7819412	0.595	rs2409712	ENSG00000269918.1	AF131215.9	-3.78	0.000176	0.0224	-0.17	-0.17	Triglycerides;	chr8:11129327	chr8:11104691~11106704:-
HNSC	cis	rs9422860	0.831	rs11245548	ENSG00000236991.5	EDRF1-AS1	-3.78	0.000176	0.0224	-0.25	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr10:125218816	chr10:125725634~125752110:-
HNSC	cis	rs9422860	0.831	rs11245549	ENSG00000236991.5	EDRF1-AS1	-3.78	0.000176	0.0224	-0.25	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr10:125218878	chr10:125725634~125752110:-
HNSC	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-3.78	0.000176	0.0224	-0.2	-0.17	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
HNSC	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	3.78	0.000176	0.0224	0.21	0.17	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
HNSC	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	3.78	0.000176	0.0224	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
HNSC	cis	rs12545912	0.909	rs7461376	ENSG00000254340.1	RP11-10A14.3	-3.78	0.000176	0.0224	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9735959	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.789	rs56369100	ENSG00000254340.1	RP11-10A14.3	-3.78	0.000176	0.0224	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9736097	chr8:9141424~9145435:+
HNSC	cis	rs4427176	0.507	rs11249942	ENSG00000254340.1	RP11-10A14.3	-3.78	0.000176	0.0224	-0.24	-0.17	Mosquito bite size;	chr8:9736239	chr8:9141424~9145435:+
HNSC	cis	rs17818399	0.501	rs13413254	ENSG00000279254.1	RP11-536C12.1	-3.78	0.000176	0.0224	-0.19	-0.17	Height;	chr2:46575795	chr2:46668870~46670778:+
HNSC	cis	rs4919687	0.55	rs12783444	ENSG00000236937.2	PTGES3P4	3.78	0.000176	0.0224	0.22	0.17	Colorectal cancer;	chr10:102720902	chr10:102845595~102845950:+
HNSC	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	3.78	0.000176	0.0224	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	3.78	0.000176	0.0224	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	3.78	0.000176	0.0224	0.34	0.17	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
HNSC	cis	rs7809950	0.678	rs12672451	ENSG00000238832.1	snoU109	-3.78	0.000176	0.0224	-0.25	-0.17	Coronary artery disease;	chr7:107213372	chr7:107603363~107603507:+
HNSC	cis	rs494453	0.922	rs500184	ENSG00000227811.2	FAM212B-AS1	3.78	0.000176	0.0224	0.2	0.17	Osteoporosis-related phenotypes;	chr1:111620924	chr1:111739841~111747798:+
HNSC	cis	rs9921222	0.502	rs12929878	ENSG00000268836.1	LA16c-OS12.2	3.78	0.000176	0.0224	0.19	0.17	Bone mineral density (spine);Bone mineral density;	chr16:362447	chr16:185748~186294:-
HNSC	cis	rs2030746	1	rs2030746	ENSG00000237614.1	AC073257.2	3.78	0.000176	0.0224	0.2	0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551912	chr2:120542909~120544326:-
HNSC	cis	rs2032366	1	rs8088329	ENSG00000267279.1	RP11-879F14.2	-3.78	0.000176	0.0224	-0.21	-0.17	Obesity-related traits;	chr18:61595758	chr18:61585746~61606916:-
HNSC	cis	rs919433	0.75	rs788010	ENSG00000231621.1	AC013264.2	-3.78	0.000176	0.0224	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366225	chr2:197197991~197199273:+
HNSC	cis	rs11250098	0.541	rs6997997	ENSG00000255310.2	AF131215.2	-3.78	0.000176	0.0224	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10908572	chr8:11107788~11109726:-
HNSC	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	3.78	0.000176	0.0224	0.21	0.17	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
HNSC	cis	rs1150668	0.796	rs9468372	ENSG00000217862.2	HIST1H4PS1	-3.78	0.000176	0.0224	-0.17	-0.17	Pubertal anthropometrics;	chr6:28411584	chr6:27807075~27807339:+
HNSC	cis	rs9303029	1	rs72859125	ENSG00000265458.1	RP13-20L14.6	3.78	0.000176	0.0224	0.29	0.17	Protein quantitative trait loci;	chr17:82470099	chr17:82454273~82458521:-
HNSC	cis	rs7824557	0.564	rs2043508	ENSG00000255495.1	AC145124.2	-3.78	0.000176	0.0224	-0.19	-0.17	Retinal vascular caliber;	chr8:11369897	chr8:12194467~12196280:+
HNSC	cis	rs467650	0.553	rs469946	ENSG00000248489.1	CTD-2007H13.3	3.78	0.000176	0.0224	0.21	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98653345	chr5:98929171~98995013:+
HNSC	cis	rs6840258	0.76	rs340650	ENSG00000251411.1	RP11-397E7.4	3.78	0.000176	0.0224	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87017533	chr4:86913266~86914817:-
HNSC	cis	rs853679	0.769	rs17720293	ENSG00000280107.1	AL022393.9	-3.78	0.000176	0.0224	-0.27	-0.17	Depression;	chr6:28246920	chr6:28170845~28172521:+
HNSC	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	3.78	0.000176	0.0224	0.26	0.17	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	3.78	0.000176	0.0224	0.26	0.17	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	3.78	0.000176	0.0224	0.26	0.17	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	3.78	0.000176	0.0224	0.26	0.17	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	3.78	0.000176	0.0224	0.26	0.17	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
HNSC	cis	rs10789207	0.531	rs17129269	ENSG00000248458.2	RP4-598P13.1	-3.78	0.000176	0.0224	-0.27	-0.17	Resting heart rate;	chr1:66654381	chr1:66665864~66677027:-
HNSC	cis	rs74781061	0.86	rs1456432	ENSG00000260103.2	RP11-10O17.1	-3.78	0.000176	0.0224	-0.2	-0.17	Endometriosis;	chr15:74710710	chr15:74478070~74490286:-
HNSC	cis	rs9402743	0.577	rs111373814	ENSG00000234084.1	RP3-388E23.2	-3.78	0.000176	0.0224	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135644459	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.608	rs6918917	ENSG00000234084.1	RP3-388E23.2	-3.78	0.000176	0.0224	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135644473	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.673	rs56071012	ENSG00000234084.1	RP3-388E23.2	-3.78	0.000176	0.0224	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135646213	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.673	rs56976899	ENSG00000234084.1	RP3-388E23.2	-3.78	0.000176	0.0224	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135646262	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.673	rs9494312	ENSG00000234084.1	RP3-388E23.2	-3.78	0.000176	0.0224	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135646826	chr6:135301568~135307158:+
HNSC	cis	rs1570884	0.714	rs2038881	ENSG00000225131.2	PSME2P2	3.78	0.000176	0.0224	0.15	0.17	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr13:49561041	chr13:48771128~48771827:+
HNSC	cis	rs10090774	0.67	rs13273943	ENSG00000279766.1	RP11-642A1.2	-3.78	0.000176	0.0224	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724786	chr8:140572142~140572812:-
HNSC	cis	rs3736485	0.966	rs8042840	ENSG00000274528.1	CTD-2650P22.2	3.78	0.000176	0.0224	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51616301	chr15:52017167~52018032:-
HNSC	cis	rs12545912	0.908	rs6994557	ENSG00000254340.1	RP11-10A14.3	-3.78	0.000176	0.0224	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9720720	chr8:9141424~9145435:+
HNSC	cis	rs3018712	0.532	rs2513294	ENSG00000212093.1	AP000807.1	-3.78	0.000176	0.0224	-0.25	-0.17	Total body bone mineral density;	chr11:68653726	chr11:68506083~68506166:-
HNSC	cis	rs28830936	1	rs2004162	ENSG00000250379.1	RP11-23P13.4	3.78	0.000176	0.0224	0.21	0.17	Diastolic blood pressure;	chr15:41673344	chr15:41825099~41827936:-
HNSC	cis	rs7178375	1	rs7178375	ENSG00000215302.7	CTD-3092A11.1	-3.78	0.000176	0.0224	-0.27	-0.17	Hypertriglyceridemia;	chr15:30923732	chr15:30470779~30507623:+
HNSC	cis	rs864537	0.646	rs1773542	ENSG00000233411.1	RP11-104L21.2	3.78	0.000176	0.0224	0.19	0.17	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167463712	chr1:167457383~167458661:-
HNSC	cis	rs864537	0.646	rs1723016	ENSG00000233411.1	RP11-104L21.2	3.78	0.000176	0.0224	0.19	0.17	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167463819	chr1:167457383~167458661:-
HNSC	cis	rs6088580	0.634	rs6088488	ENSG00000276073.1	RP5-1125A11.7	3.78	0.000176	0.0224	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:33985617~33988989:-
HNSC	cis	rs73198271	0.531	rs17154758	ENSG00000173295.6	FAM86B3P	-3.78	0.000176	0.0224	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795833	chr8:8228595~8244865:+
HNSC	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	3.78	0.000177	0.0224	0.21	0.17	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
HNSC	cis	rs597539	0.652	rs496616	ENSG00000255741.1	RP11-757G1.5	-3.78	0.000177	0.0224	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68941503~68942852:-
HNSC	cis	rs2115630	0.754	rs12595321	ENSG00000225151.9	GOLGA2P7	3.78	0.000177	0.0224	0.21	0.17	P wave terminal force;	chr15:84788038	chr15:84199311~84230136:-
HNSC	cis	rs298182	1	rs192721	ENSG00000254102.1	RP11-21C4.1	-3.78	0.000177	0.0225	-0.28	-0.17	Verbal declarative memory;	chr8:64378496	chr8:64574306~64581888:-
HNSC	cis	rs298182	1	rs298213	ENSG00000254102.1	RP11-21C4.1	-3.78	0.000177	0.0225	-0.28	-0.17	Verbal declarative memory;	chr8:64378709	chr8:64574306~64581888:-
HNSC	cis	rs298182	1	rs298215	ENSG00000254102.1	RP11-21C4.1	-3.78	0.000177	0.0225	-0.28	-0.17	Verbal declarative memory;	chr8:64380498	chr8:64574306~64581888:-
HNSC	cis	rs298182	0.892	rs298218	ENSG00000254102.1	RP11-21C4.1	-3.78	0.000177	0.0225	-0.28	-0.17	Verbal declarative memory;	chr8:64382115	chr8:64574306~64581888:-
HNSC	cis	rs73198271	0.531	rs17154756	ENSG00000173295.6	FAM86B3P	-3.78	0.000177	0.0225	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794884	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.531	rs11985640	ENSG00000173295.6	FAM86B3P	-3.78	0.000177	0.0225	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794994	chr8:8228595~8244865:+
HNSC	cis	rs73198271	0.531	rs56100346	ENSG00000173295.6	FAM86B3P	-3.78	0.000177	0.0225	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795334	chr8:8228595~8244865:+
HNSC	cis	rs2013441	0.866	rs2526492	ENSG00000261033.1	RP11-209D14.2	3.78	0.000177	0.0225	0.2	0.17	Obesity-related traits;	chr17:20192302	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.835	rs2526491	ENSG00000261033.1	RP11-209D14.2	3.78	0.000177	0.0225	0.2	0.17	Obesity-related traits;	chr17:20194149	chr17:20008051~20009234:-
HNSC	cis	rs35000415	0.938	rs12706861	ENSG00000275106.1	RP11-309L24.10	-3.78	0.000177	0.0225	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128976528	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs17338998	ENSG00000275106.1	RP11-309L24.10	-3.78	0.000177	0.0225	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128978505	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs12535158	ENSG00000275106.1	RP11-309L24.10	-3.78	0.000177	0.0225	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128984965	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs34725944	ENSG00000275106.1	RP11-309L24.10	-3.78	0.000177	0.0225	-0.38	-0.17	Systemic lupus erythematosus;	chr7:129001599	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs13227075	ENSG00000275106.1	RP11-309L24.10	-3.78	0.000177	0.0225	-0.38	-0.17	Systemic lupus erythematosus;	chr7:129003243	chr7:128952527~128953316:-
HNSC	cis	rs5758659	0.714	rs5758578	ENSG00000182057.4	OGFRP1	-3.78	0.000177	0.0225	-0.18	-0.17	Cognitive function;	chr22:42094288	chr22:42269753~42275196:+
HNSC	cis	rs6710503	0.632	rs2119117	ENSG00000271936.1	RP11-443B20.1	-3.78	0.000177	0.0225	-0.22	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24761266	chr2:24825610~24826717:+
HNSC	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-3.78	0.000177	0.0225	-0.14	-0.17	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
HNSC	cis	rs72827839	0.711	rs11650615	ENSG00000228782.6	CTD-2026D20.3	3.78	0.000177	0.0225	0.18	0.17	Ease of getting up in the morning;	chr17:48046336	chr17:47450568~47492492:-
HNSC	cis	rs9652601	0.959	rs12919083	ENSG00000274038.1	RP11-66H6.4	3.78	0.000177	0.0225	0.21	0.17	Systemic lupus erythematosus;	chr16:11095073	chr16:11056556~11057034:+
HNSC	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	3.78	0.000177	0.0225	0.18	0.17	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
HNSC	cis	rs11032090	1	rs11032090	ENSG00000225101.4	OR52K3P	3.78	0.000177	0.0225	0.26	0.17	Lung cancer;	chr11:4395899	chr11:4474813~4475755:+
HNSC	cis	rs757081	0.514	rs214087	ENSG00000260196.1	RP1-239B22.5	-3.78	0.000177	0.0225	-0.18	-0.17	Systolic blood pressure;	chr11:17276818	chr11:17380649~17383531:+
HNSC	cis	rs9859260	0.555	rs9877493	ENSG00000226155.1	AC124944.3	-3.78	0.000177	0.0225	-0.21	-0.17	Mean corpuscular volume;	chr3:196105276	chr3:195912049~195913986:+
HNSC	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	3.78	0.000177	0.0225	0.25	0.17	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
HNSC	cis	rs7572733	0.935	rs6434946	ENSG00000222017.1	AC011997.1	3.78	0.000177	0.0225	0.21	0.17	Dermatomyositis;	chr2:197933773	chr2:197693106~197774823:+
HNSC	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	3.78	0.000177	0.0225	0.17	0.17	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	3.78	0.000177	0.0225	0.17	0.17	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	3.78	0.000177	0.0225	0.17	0.17	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	3.78	0.000177	0.0225	0.17	0.17	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
HNSC	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	3.78	0.000177	0.0225	0.25	0.17	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	3.78	0.000177	0.0225	0.25	0.17	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	3.78	0.000177	0.0225	0.25	0.17	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	3.78	0.000177	0.0225	0.25	0.17	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
HNSC	cis	rs13438327	1	rs7789181	ENSG00000183444.10	OR7E38P	3.78	0.000177	0.0225	0.36	0.17	Sudden cardiac arrest;	chr7:97991951	chr7:97966090~97967074:-
HNSC	cis	rs6787172	0.622	rs60336101	ENSG00000272087.1	RP11-379F4.7	3.78	0.000177	0.0225	0.18	0.17	Subjective well-being;	chr3:158348506	chr3:158693120~158693768:-
HNSC	cis	rs9303542	0.531	rs7209556	ENSG00000272763.1	RP11-357H14.17	3.78	0.000177	0.0225	0.21	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48388801	chr17:48635923~48647023:-
HNSC	cis	rs999943	0.846	rs10947420	ENSG00000224557.6	HLA-DPB2	-3.78	0.000177	0.0225	-0.23	-0.17	Obesity (extreme);	chr6:33643284	chr6:33112451~33129084:+
HNSC	cis	rs870825	0.616	rs28463742	ENSG00000254233.1	RP11-242J7.1	3.78	0.000177	0.0225	0.25	0.17	Blood protein levels;	chr4:184689851	chr4:184584093~184625030:-
HNSC	cis	rs2337406	1	rs7145172	ENSG00000211972.2	IGHV3-66	3.78	0.000177	0.0225	0.17	0.17	Alzheimer's disease (late onset);	chr14:106704924	chr14:106675017~106675544:-
HNSC	cis	rs6088590	0.55	rs12624640	ENSG00000276073.1	RP5-1125A11.7	-3.78	0.000177	0.0225	-0.19	-0.17	Coronary artery disease;	chr20:34364319	chr20:33985617~33988989:-
HNSC	cis	rs6012564	1	rs755587	ENSG00000227431.4	CSE1L-AS1	3.78	0.000177	0.0225	0.19	0.17	Anger;	chr20:49104420	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs6066968	ENSG00000227431.4	CSE1L-AS1	3.78	0.000177	0.0225	0.19	0.17	Anger;	chr20:49110804	chr20:49040463~49046044:-
HNSC	cis	rs7804306	0.522	rs11981425	ENSG00000233264.2	AC006042.8	3.78	0.000177	0.0225	0.25	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8045298	chr7:7980312~7982228:+
HNSC	cis	rs224278	0.509	rs1115705	ENSG00000238280.1	RP11-436D10.3	-3.78	0.000177	0.0225	-0.24	-0.17	Ewing sarcoma;	chr10:62945426	chr10:62793562~62805887:-
HNSC	cis	rs13108904	0.935	rs2293633	ENSG00000272588.1	RP11-440L14.4	3.78	0.000177	0.0225	0.17	0.17	Obesity-related traits;	chr4:1297852	chr4:757022~757740:-
HNSC	cis	rs2944755	0.723	rs13250299	ENSG00000279766.1	RP11-642A1.2	-3.78	0.000177	0.0225	-0.2	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140579485	chr8:140572142~140572812:-
HNSC	cis	rs11976180	1	rs7777389	ENSG00000244479.5	OR2A1-AS1	3.78	0.000177	0.0225	0.2	0.17	Obesity-related traits;	chr7:144047709	chr7:144251264~144356181:-
HNSC	cis	rs561341	0.714	rs55925849	ENSG00000278867.1	RP11-640N20.4	-3.78	0.000177	0.0225	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31926066	chr17:32051030~32053208:+
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000224373.3	IGHV4-59	-3.78	0.000177	0.0225	-0.11	-0.17	Kawasaki disease;	chr14:106771605	chr14:106627249~106627825:-
HNSC	cis	rs12544026	0.515	rs508386	ENSG00000253633.1	KB-1980E6.3	-3.78	0.000177	0.0225	-0.21	-0.17	Major depression and alcohol dependence;	chr8:101887222	chr8:102528740~102538668:+
HNSC	cis	rs41369048	0.858	rs11578466	ENSG00000238078.1	LINC01352	-3.78	0.000177	0.0225	-0.24	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220884397	chr1:220829255~220832429:+
HNSC	cis	rs8063160	0.561	rs12922197	ENSG00000260259.1	RP11-368I7.4	-3.78	0.000177	0.0225	-0.38	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89678401	chr16:89682620~89686569:-
HNSC	cis	rs8063160	0.533	rs58656226	ENSG00000260259.1	RP11-368I7.4	-3.78	0.000177	0.0225	-0.38	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89678683	chr16:89682620~89686569:-
HNSC	cis	rs7927592	0.956	rs60212556	ENSG00000255031.4	RP11-802E16.3	3.78	0.000178	0.0225	0.15	0.17	Total body bone mineral density;	chr11:68538026	chr11:68050740~68053762:+
HNSC	cis	rs2098713	0.569	rs56305849	ENSG00000250155.1	CTD-2353F22.1	3.78	0.000178	0.0225	0.18	0.17	Telomere length;	chr5:37506445	chr5:36666214~36725195:-
HNSC	cis	rs9650657	0.783	rs28570522	ENSG00000255310.2	AF131215.2	-3.78	0.000178	0.0225	-0.17	-0.17	Neuroticism;	chr8:10773058	chr8:11107788~11109726:-
HNSC	cis	rs7772486	0.622	rs1292333	ENSG00000270638.1	RP3-466P17.1	-3.78	0.000178	0.0225	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145735570~145737218:+
HNSC	cis	rs2253762	0.609	rs10887057	ENSG00000226864.1	ATE1-AS1	3.78	0.000178	0.0226	0.27	0.17	Breast cancer;	chr10:122043799	chr10:121928312~121951965:+
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000241549.7	GUSBP2	3.78	0.000178	0.0226	0.18	0.17	Parkinson's disease;	chr6:27891126	chr6:26871484~26956554:-
HNSC	cis	rs8002861	0.664	rs1808097	ENSG00000274001.1	RP11-5G9.5	3.78	0.000178	0.0226	0.17	0.17	Leprosy;	chr13:43850630	chr13:43877715~43878163:-
HNSC	cis	rs8002861	0.664	rs2218497	ENSG00000274001.1	RP11-5G9.5	3.78	0.000178	0.0226	0.17	0.17	Leprosy;	chr13:43854657	chr13:43877715~43878163:-
HNSC	cis	rs8002861	0.664	rs9533662	ENSG00000274001.1	RP11-5G9.5	3.78	0.000178	0.0226	0.17	0.17	Leprosy;	chr13:43861852	chr13:43877715~43878163:-
HNSC	cis	rs8002861	0.619	rs9567289	ENSG00000274001.1	RP11-5G9.5	3.78	0.000178	0.0226	0.17	0.17	Leprosy;	chr13:43862968	chr13:43877715~43878163:-
HNSC	cis	rs12893668	0.703	rs35498576	ENSG00000269958.1	RP11-73M18.8	3.78	0.000178	0.0226	0.17	0.17	Reticulocyte count;	chr14:103559556	chr14:103696353~103697163:+
HNSC	cis	rs17407555	0.955	rs10489074	ENSG00000250413.1	RP11-448G15.1	3.78	0.000178	0.0226	0.25	0.17	Schizophrenia (age at onset);	chr4:10270981	chr4:10006482~10009725:+
HNSC	cis	rs6586111	1	rs6586107	ENSG00000226659.1	RP11-137H2.4	3.78	0.000178	0.0226	0.2	0.17	Capecitabine sensitivity;	chr10:80613760	chr10:80529597~80535942:-
HNSC	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	3.78	0.000178	0.0226	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	3.78	0.000178	0.0226	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	3.78	0.000178	0.0226	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
HNSC	cis	rs36093924	0.646	rs7285557	ENSG00000207457.1	RNU6-476P	-3.78	0.000178	0.0226	-0.18	-0.17	Intelligence;	chr22:41952786	chr22:41679711~41679817:+
HNSC	cis	rs853679	0.607	rs67662114	ENSG00000226314.6	ZNF192P1	-3.78	0.000178	0.0226	-0.32	-0.17	Depression;	chr6:27964523	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs13216117	ENSG00000226314.6	ZNF192P1	-3.78	0.000178	0.0226	-0.32	-0.17	Depression;	chr6:27970706	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs36101351	ENSG00000226314.6	ZNF192P1	-3.78	0.000178	0.0226	-0.32	-0.17	Depression;	chr6:27975591	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs28360499	ENSG00000226314.6	ZNF192P1	-3.78	0.000178	0.0226	-0.32	-0.17	Depression;	chr6:27977618	chr6:28161781~28169594:+
HNSC	cis	rs1003719	0.628	rs2835635	ENSG00000242553.1	AP001432.14	3.78	0.000178	0.0226	0.2	0.17	Eye color traits;	chr21:37156565	chr21:37221419~37237744:+
HNSC	cis	rs3096299	0.719	rs2911262	ENSG00000261118.1	RP11-104N10.1	3.78	0.000178	0.0226	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89492017~89504460:-
HNSC	cis	rs1009077	0.514	rs988146	ENSG00000245958.5	RP11-33B1.1	3.78	0.000178	0.0226	0.18	0.17	Endometriosis;	chr4:119478350	chr4:119454791~119552025:+
HNSC	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-3.78	0.000178	0.0226	-0.22	-0.17	Height;	chr20:49267648	chr20:49280319~49280409:+
HNSC	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-3.78	0.000178	0.0226	-0.22	-0.17	Height;	chr20:49272073	chr20:49280319~49280409:+
HNSC	cis	rs6001482	0.533	rs5757621	ENSG00000253590.1	IGLV3-13	-3.78	0.000178	0.0226	-0.15	-0.17	Diastolic blood pressure;	chr22:22240976	chr22:22762294~22762516:+
HNSC	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	3.78	0.000178	0.0226	0.2	0.17	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
HNSC	cis	rs2439831	0.85	rs7181039	ENSG00000275601.1	AC011330.13	-3.78	0.000178	0.0226	-0.3	-0.17	Lung cancer in ever smokers;	chr15:43886914	chr15:43642389~43643023:-
HNSC	cis	rs9487051	0.714	rs13209277	ENSG00000219700.1	PTCHD3P3	3.78	0.000178	0.0226	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109303760	chr6:109288571~109290503:-
HNSC	cis	rs8077577	0.895	rs62073602	ENSG00000273018.4	CTD-2303H24.2	-3.78	0.000178	0.0226	-0.26	-0.17	Obesity-related traits;	chr17:18154593	chr17:18511221~18551705:-
HNSC	cis	rs1476670	0.71	rs2477616	ENSG00000230615.5	RP5-1198O20.4	-3.78	0.000178	0.0226	-0.22	-0.17	Eotaxin levels;	chr1:44039137	chr1:44030443~44115913:+
HNSC	cis	rs7819412	0.745	rs4841498	ENSG00000270076.1	AF131215.8	-3.78	0.000178	0.0226	-0.19	-0.17	Triglycerides;	chr8:11127922	chr8:11202965~11203671:+
HNSC	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0226	0.18	0.17	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0226	0.18	0.17	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0226	0.18	0.17	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0226	0.18	0.17	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0226	0.18	0.17	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
HNSC	cis	rs7572733	0.719	rs4417706	ENSG00000222017.1	AC011997.1	3.78	0.000178	0.0226	0.21	0.17	Dermatomyositis;	chr2:198079931	chr2:197693106~197774823:+
HNSC	cis	rs4449834	0.816	rs7012450	ENSG00000254432.1	RP11-33I11.2	-3.78	0.000178	0.0226	-0.21	-0.17	Sum eosinophil basophil counts;	chr8:60754868	chr8:60808735~60809606:-
HNSC	cis	rs16953946	0.881	rs7187075	ENSG00000278985.1	RP11-303E16.9	-3.78	0.000178	0.0226	-0.23	-0.17	Inflammatory bowel disease;	chr16:80734830	chr16:80982319~80984094:-
HNSC	cis	rs6012542	0.553	rs71351946	ENSG00000222365.1	SNORD12B	-3.78	0.000178	0.0226	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48848300	chr20:49280319~49280409:+
HNSC	cis	rs1387259	0.619	rs2130095	ENSG00000257763.1	OR5BK1P	-3.78	0.000178	0.0226	-0.16	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48355792~48356614:-
HNSC	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	3.78	0.000178	0.0226	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
HNSC	cis	rs12960472	0.524	rs1523868	ENSG00000277324.1	RP11-850A17.1	3.78	0.000178	0.0226	0.24	0.17	Positive affect;	chr18:54436456	chr18:54268346~54270028:-
HNSC	cis	rs34286592	1	rs4788187	ENSG00000214725.6	CDIPT-AS1	3.78	0.000178	0.0226	0.23	0.17	Multiple sclerosis;	chr16:29834364	chr16:29863593~29868053:+
HNSC	cis	rs7027203	0.576	rs7851269	ENSG00000227603.1	RP11-165J3.6	3.78	0.000178	0.0226	0.15	0.17	DNA methylation (variation);	chr9:93778248	chr9:93435332~93437121:-
HNSC	cis	rs2436845	1	rs2513919	ENSG00000253669.3	KB-1732A1.1	-3.78	0.000178	0.0226	-0.16	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819526	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs972142	ENSG00000253669.3	KB-1732A1.1	-3.78	0.000178	0.0226	-0.16	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102824025	chr8:102805517~102809971:+
HNSC	cis	rs80130819	0.515	rs1793917	ENSG00000278385.1	RP11-89H19.2	3.78	0.000178	0.0226	0.28	0.17	Prostate cancer;	chr12:47991161	chr12:47905122~47906865:+
HNSC	cis	rs4725617	0.822	rs7792901	ENSG00000204959.4	ARHGEF34P	-3.78	0.000178	0.0226	-0.33	-0.17	Blood protein levels;	chr7:143410226	chr7:144272445~144286966:-
HNSC	cis	rs9611565	0.694	rs202628	ENSG00000235513.1	RP4-756G23.5	3.78	0.000178	0.0226	0.2	0.17	Vitiligo;	chr22:41453509	chr22:41209122~41217627:-
HNSC	cis	rs1150668	0.796	rs1005125	ENSG00000217862.2	HIST1H4PS1	-3.78	0.000178	0.0226	-0.17	-0.17	Pubertal anthropometrics;	chr6:28399578	chr6:27807075~27807339:+
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000227888.4	FAM66A	3.78	0.000178	0.0226	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12362019~12388296:+
HNSC	cis	rs859767	0.679	rs4954158	ENSG00000224043.6	CCNT2-AS1	3.78	0.000179	0.0226	0.2	0.17	Neuroticism;	chr2:134669048	chr2:134735464~134918710:-
HNSC	cis	rs2048656	0.634	rs13259344	ENSG00000233609.3	RP11-62H7.2	3.78	0.000179	0.0226	0.18	0.17	Schizophrenia;	chr8:9794490	chr8:8961200~8979025:+
HNSC	cis	rs868153	0.625	rs1456694	ENSG00000275339.1	RP3-425C14.6	3.78	0.000179	0.0226	0.19	0.17	Vertical cup-disc ratio;	chr6:122233433	chr6:122454358~122454612:+
HNSC	cis	rs2032366	1	rs10439023	ENSG00000267279.1	RP11-879F14.2	-3.78	0.000179	0.0227	-0.21	-0.17	Obesity-related traits;	chr18:61597073	chr18:61585746~61606916:-
HNSC	cis	rs60617249	0.862	rs9642409	ENSG00000228204.2	RP4-724E13.2	3.78	0.000179	0.0227	0.18	0.17	Major depression and alcohol dependence;	chr7:50927881	chr7:50866747~51022990:+
HNSC	cis	rs4287000	0.508	rs17533702	ENSG00000227603.1	RP11-165J3.6	-3.78	0.000179	0.0227	-0.15	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr9:93598946	chr9:93435332~93437121:-
HNSC	cis	rs2762353	0.718	rs1165160	ENSG00000272462.2	U91328.19	-3.78	0.000179	0.0227	-0.17	-0.17	Blood metabolite levels;	chr6:25864228	chr6:25992662~26001775:+
HNSC	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-3.78	0.000179	0.0227	-0.23	-0.17	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
HNSC	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-3.78	0.000179	0.0227	-0.23	-0.17	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
HNSC	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-3.78	0.000179	0.0227	-0.23	-0.17	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
HNSC	cis	rs34286592	1	rs62056375	ENSG00000183604.13	SMG1P5	-3.78	0.000179	0.0227	-0.24	-0.17	Multiple sclerosis;	chr16:29846580	chr16:30267553~30335374:-
HNSC	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	3.78	0.000179	0.0227	0.19	0.17	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
HNSC	cis	rs7735319	0.966	rs16890712	ENSG00000249102.1	CTD-2066L21.1	3.78	0.000179	0.0227	0.2	0.17	Systolic blood pressure;	chr5:33082260	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.966	rs16890717	ENSG00000249102.1	CTD-2066L21.1	3.78	0.000179	0.0227	0.2	0.17	Systolic blood pressure;	chr5:33085578	chr5:33008994~33025724:+
HNSC	cis	rs858239	0.509	rs57611130	ENSG00000226816.2	AC005082.12	3.78	0.000179	0.0227	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23206013~23208045:+
HNSC	cis	rs9393777	0.513	rs6924727	ENSG00000241549.7	GUSBP2	3.78	0.000179	0.0227	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26491006	chr6:26871484~26956554:-
HNSC	cis	rs9393777	0.588	rs6941920	ENSG00000241549.7	GUSBP2	3.78	0.000179	0.0227	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26491921	chr6:26871484~26956554:-
HNSC	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	3.78	0.000179	0.0227	0.17	0.17	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
HNSC	cis	rs10771431	0.738	rs11049697	ENSG00000256427.1	RP11-118B22.4	3.78	0.000179	0.0227	0.19	0.17	Breast size;	chr12:9232743	chr12:9246497~9257960:+
HNSC	cis	rs9952991	0.941	rs7237497	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12777326	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-3.78	0.000179	0.0227	-0.28	-0.17	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
HNSC	cis	rs546131	0.642	rs12272777	ENSG00000271369.1	RP11-350D17.3	-3.78	0.000179	0.0227	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34829355	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs12293044	ENSG00000271369.1	RP11-350D17.3	-3.78	0.000179	0.0227	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34829502	chr11:34709600~34710161:+
HNSC	cis	rs9467711	0.606	rs9358938	ENSG00000241549.7	GUSBP2	3.78	0.000179	0.0227	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26387318	chr6:26871484~26956554:-
HNSC	cis	rs4704187	0.532	rs75392670	ENSG00000271815.1	CTD-2235C13.3	-3.78	0.000179	0.0227	-0.22	-0.17	Response to amphetamines;	chr5:75099143	chr5:75363760~75364242:+
HNSC	cis	rs8002861	0.641	rs2325085	ENSG00000274001.1	RP11-5G9.5	3.78	0.000179	0.0227	0.17	0.17	Leprosy;	chr13:43835924	chr13:43877715~43878163:-
HNSC	cis	rs2836974	0.932	rs8129416	ENSG00000255568.3	BRWD1-AS2	3.78	0.000179	0.0227	0.16	0.17	Cognitive function;	chr21:39245219	chr21:39313935~39314962:+
HNSC	cis	rs12291225	0.679	rs11369	ENSG00000254418.1	RP11-21L19.1	3.78	0.000179	0.0227	0.2	0.17	Sense of smell;	chr11:14266550	chr11:14262846~14273691:-
HNSC	cis	rs7826238	0.601	rs2976907	ENSG00000254340.1	RP11-10A14.3	3.78	0.000179	0.0227	0.21	0.17	Systolic blood pressure;	chr8:8487658	chr8:9141424~9145435:+
HNSC	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	3.78	0.000179	0.0227	0.29	0.17	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	3.78	0.000179	0.0227	0.29	0.17	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	3.78	0.000179	0.0227	0.29	0.17	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	3.78	0.000179	0.0227	0.29	0.17	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	3.78	0.000179	0.0227	0.28	0.17	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
HNSC	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-3.78	0.000179	0.0227	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
HNSC	cis	rs3764400	0.508	rs55696440	ENSG00000228782.6	CTD-2026D20.3	-3.78	0.000179	0.0227	-0.26	-0.17	Body mass index;	chr17:48193784	chr17:47450568~47492492:-
HNSC	cis	rs7113211	1	rs7113211	ENSG00000176343.5	RPL37AP8	3.78	0.000179	0.0227	0.18	0.17	Expressive vocabulary in infants;	chr11:112771909	chr11:111889199~111889474:-
HNSC	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-3.78	0.000179	0.0227	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
HNSC	cis	rs6498068	0.633	rs7194566	ENSG00000260468.1	LINC01290	-3.78	0.000179	0.0227	-0.21	-0.17	Metabolite levels (MHPG);	chr16:10532140	chr16:10514842~10528202:-
HNSC	cis	rs2408955	0.521	rs11168437	ENSG00000257763.1	OR5BK1P	3.78	0.000179	0.0227	0.17	0.17	Glycated hemoglobin levels;	chr12:48172373	chr12:48355792~48356614:-
HNSC	cis	rs3096299	0.685	rs4329923	ENSG00000261118.1	RP11-104N10.1	3.78	0.000179	0.0227	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89492017~89504460:-
HNSC	cis	rs755249	0.583	rs61779328	ENSG00000182109.6	RP11-69E11.4	3.78	0.000179	0.0227	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39522280~39546187:-
HNSC	cis	rs9907295	0.688	rs2251660	ENSG00000271013.1	AC015849.15	-3.78	0.000179	0.0227	-0.21	-0.17	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35912635~35918010:-
HNSC	cis	rs62025270	0.632	rs6496109	ENSG00000259762.1	RP11-158M2.4	-3.78	0.000179	0.0227	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85750336~85752901:-
HNSC	cis	rs2274273	0.653	rs1209087	ENSG00000233924.1	AL160471.6	3.78	0.000179	0.0227	0.19	0.17	Protein biomarker;	chr14:55026502	chr14:55004813~55005687:-
HNSC	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	3.78	0.000179	0.0227	0.26	0.17	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
HNSC	cis	rs17264034	0.95	rs17263150	ENSG00000250786.1	SNHG18	3.78	0.000179	0.0227	0.3	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544166	chr5:9546200~9550609:+
HNSC	cis	rs2877187	0.576	rs4724169	ENSG00000232006.7	AC005537.2	-3.78	0.000179	0.0227	-0.19	-0.17	Lung cancer in ever smokers;	chr7:43042451	chr7:42954135~43113931:-
HNSC	cis	rs964611	0.748	rs61248772	ENSG00000259488.2	RP11-154J22.1	-3.78	0.000179	0.0227	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48306529	chr15:48312353~48331856:-
HNSC	cis	rs4523957	0.57	rs2126202	ENSG00000262333.1	HNRNPA1P16	-3.78	0.000179	0.0227	-0.13	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2192418	chr17:2306761~2307715:+
HNSC	cis	rs911555	0.504	rs8006526	ENSG00000269958.1	RP11-73M18.8	3.78	0.000179	0.0227	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103696353~103697163:+
HNSC	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	3.78	0.000179	0.0227	0.21	0.17	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
HNSC	cis	rs853679	1	rs10456362	ENSG00000219891.2	ZSCAN12P1	-3.78	0.000179	0.0227	-0.27	-0.17	Depression;	chr6:28254038	chr6:28091154~28093664:+
HNSC	cis	rs34792	0.554	rs28393495	ENSG00000207425.1	Y_RNA	-3.78	0.000179	0.0227	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:14915457~14915556:-
HNSC	cis	rs9650657	0.803	rs13276026	ENSG00000255310.2	AF131215.2	-3.78	0.000179	0.0227	-0.16	-0.17	Neuroticism;	chr8:10752445	chr8:11107788~11109726:-
HNSC	cis	rs12777098	1	rs2610805	ENSG00000268549.1	RP11-295P9.8	-3.78	0.000179	0.0227	-0.41	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:13877031	chr10:13682521~13684874:+
HNSC	cis	rs757081	0.684	rs214071	ENSG00000260196.1	RP1-239B22.5	-3.78	0.000179	0.0227	-0.18	-0.17	Systolic blood pressure;	chr11:17283747	chr11:17380649~17383531:+
HNSC	cis	rs886126	0.684	rs10083213	ENSG00000257595.2	RP3-473L9.4	-3.78	0.000179	0.0227	-0.21	-0.17	Coronary heart disease;	chr12:111216559	chr12:111369282~111403310:+
HNSC	cis	rs79040073	0.599	rs73394331	ENSG00000259531.2	RP11-295H24.3	3.78	0.000179	0.0227	0.22	0.17	Lung cancer in ever smokers;	chr15:49278236	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.637	rs73394333	ENSG00000259531.2	RP11-295H24.3	3.78	0.000179	0.0227	0.22	0.17	Lung cancer in ever smokers;	chr15:49278719	chr15:49365124~49366685:-
HNSC	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-3.78	0.000179	0.0227	-0.19	-0.17	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-3.78	0.000179	0.0227	-0.19	-0.17	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
HNSC	cis	rs73607972	0.696	rs7197014	ENSG00000275191.1	RP11-36I17.2	-3.78	0.00018	0.0227	-0.24	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53628256~53628816:-
HNSC	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	3.78	0.00018	0.0227	0.17	0.17	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
HNSC	cis	rs2347867	0.536	rs6557170	ENSG00000218996.1	RP1-99E18.2	3.78	0.00018	0.0227	0.24	0.17	Age at first birth;	chr6:151881969	chr6:150934968~150935566:+
HNSC	cis	rs6122940	0.643	rs6126034	ENSG00000203999.7	LINC01270	-3.78	0.00018	0.0227	-0.31	-0.17	Lymphocyte counts;	chr20:50529644	chr20:50292720~50314922:+
HNSC	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	3.78	0.00018	0.0227	0.17	0.17	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
HNSC	cis	rs7829975	0.593	rs2921061	ENSG00000254340.1	RP11-10A14.3	3.78	0.00018	0.0227	0.21	0.17	Mood instability;	chr8:8460105	chr8:9141424~9145435:+
HNSC	cis	rs17253792	0.822	rs77182097	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55669977	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs45501402	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55673397	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76164147	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55673651	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs74935793	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55676559	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.749	rs45458197	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55678300	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs10483650	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55678594	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75936910	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55682633	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78143160	ENSG00000186615.9	KTN1-AS1	-3.78	0.00018	0.0227	-0.34	-0.17	Putamen volume;	chr14:55683379	chr14:55499278~55580110:-
HNSC	cis	rs10895275	0.649	rs11225169	ENSG00000277459.1	RP11-732A21.3	3.78	0.00018	0.0227	0.19	0.17	Migraine;	chr11:102220901	chr11:102109827~102110457:-
HNSC	cis	rs5758511	0.689	rs62240864	ENSG00000227370.1	RP4-669P10.19	3.78	0.00018	0.0228	0.22	0.17	Birth weight;	chr22:42167883	chr22:42132543~42132998:+
HNSC	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	3.78	0.00018	0.0228	0.2	0.17	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
HNSC	cis	rs2836974	0.644	rs2836982	ENSG00000255568.3	BRWD1-AS2	-3.78	0.00018	0.0228	-0.15	-0.17	Cognitive function;	chr21:39317245	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.644	rs4818017	ENSG00000255568.3	BRWD1-AS2	-3.78	0.00018	0.0228	-0.15	-0.17	Cognitive function;	chr21:39318635	chr21:39313935~39314962:+
HNSC	cis	rs11250098	0.541	rs6997839	ENSG00000255310.2	AF131215.2	-3.78	0.00018	0.0228	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10908518	chr8:11107788~11109726:-
HNSC	cis	rs2307394	0.964	rs1364660	ENSG00000281469.1	RP11-567F11.1	3.78	0.00018	0.0228	0.2	0.17	Urate levels;	chr2:147780580	chr2:148044380~148044894:+
HNSC	cis	rs11690935	0.632	rs12987931	ENSG00000228389.1	AC068039.4	-3.78	0.00018	0.0228	-0.19	-0.17	Schizophrenia;	chr2:172036045	chr2:171773482~171775844:+
HNSC	cis	rs6460942	0.545	rs17448114	ENSG00000226690.5	AC005281.1	3.78	0.00018	0.0228	0.27	0.17	Coronary artery disease;	chr7:12484832	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs17545416	ENSG00000226690.5	AC005281.1	3.78	0.00018	0.0228	0.27	0.17	Coronary artery disease;	chr7:12486318	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs13245635	ENSG00000226690.5	AC005281.1	3.78	0.00018	0.0228	0.27	0.17	Coronary artery disease;	chr7:12486828	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs12699381	ENSG00000226690.5	AC005281.1	3.78	0.00018	0.0228	0.27	0.17	Coronary artery disease;	chr7:12487400	chr7:12496429~12541910:+
HNSC	cis	rs9611565	0.592	rs5751129	ENSG00000233903.2	Z83851.4	3.78	0.00018	0.0228	0.24	0.17	Vitiligo;	chr22:41619761	chr22:42276355~42277052:+
HNSC	cis	rs11648785	0.777	rs12932473	ENSG00000274627.1	RP11-104N10.2	3.78	0.00018	0.0228	0.19	0.17	Tanning;	chr16:90033981	chr16:89516797~89522217:+
HNSC	cis	rs17596685	0.818	rs7984965	ENSG00000271216.1	LINC01050	3.78	0.00018	0.0228	0.22	0.17	C-reactive protein levels;	chr13:42558231	chr13:42810366~42812562:-
HNSC	cis	rs17596685	1	rs9525639	ENSG00000271216.1	LINC01050	3.78	0.00018	0.0228	0.22	0.17	C-reactive protein levels;	chr13:42558743	chr13:42810366~42812562:-
HNSC	cis	rs17596685	1	rs4572282	ENSG00000271216.1	LINC01050	3.78	0.00018	0.0228	0.22	0.17	C-reactive protein levels;	chr13:42560846	chr13:42810366~42812562:-
HNSC	cis	rs17596685	1	rs4531631	ENSG00000271216.1	LINC01050	3.78	0.00018	0.0228	0.22	0.17	C-reactive protein levels;	chr13:42560995	chr13:42810366~42812562:-
HNSC	cis	rs1218582	0.774	rs12036859	ENSG00000270361.1	RP11-307C12.13	3.78	0.00018	0.0228	0.19	0.17	Prostate cancer;	chr1:154887464	chr1:154937370~154938059:+
HNSC	cis	rs8062405	1	rs4451951	ENSG00000261089.1	RP11-435I10.3	3.78	0.00018	0.0228	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28413703~28415018:+
HNSC	cis	rs7746199	0.673	rs72845046	ENSG00000226314.6	ZNF192P1	-3.78	0.00018	0.0228	-0.33	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs67652222	ENSG00000226314.6	ZNF192P1	-3.78	0.00018	0.0228	-0.33	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28161781~28169594:+
HNSC	cis	rs2919917	0.628	rs12544041	ENSG00000260398.1	RP11-594N15.3	-3.78	0.00018	0.0228	-0.23	-0.17	Lymphocyte counts;	chr8:78731404	chr8:78605952~78609705:+
HNSC	cis	rs8077577	0.945	rs8065026	ENSG00000273018.4	CTD-2303H24.2	-3.78	0.00018	0.0228	-0.26	-0.17	Obesity-related traits;	chr17:18142976	chr17:18511221~18551705:-
HNSC	cis	rs116095464	0.558	rs28635197	ENSG00000277812.1	AC021087.1	3.78	0.00018	0.0228	0.29	0.17	Breast cancer;	chr5:278956	chr5:262769~262881:+
HNSC	cis	rs853679	0.825	rs8180562	ENSG00000204709.4	LINC01556	3.78	0.00018	0.0228	0.31	0.17	Depression;	chr6:28173682	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.882	rs9380064	ENSG00000204709.4	LINC01556	3.78	0.00018	0.0228	0.31	0.17	Depression;	chr6:28175340	chr6:28943877~28944537:+
HNSC	cis	rs853679	0.76	rs967005	ENSG00000270326.1	RP5-874C20.6	-3.78	0.00018	0.0228	-0.24	-0.17	Depression;	chr6:28242910	chr6:28319660~28319852:-
HNSC	cis	rs4930561	0.69	rs6591334	ENSG00000184795.9	UNC93B5	-3.78	0.00018	0.0228	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68157092	chr11:67711702~67716005:-
HNSC	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	3.78	0.00018	0.0228	0.29	0.17	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
HNSC	cis	rs2117029	0.782	rs7969091	ENSG00000258101.2	RP11-977B10.2	3.78	0.00018	0.0228	0.22	0.17	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49232790~49264756:-
HNSC	cis	rs12234571	1	rs998537	ENSG00000214293.7	APTR	3.78	0.00018	0.0228	0.23	0.17	Obesity-related traits;	chr7:77860939	chr7:77657660~77696265:-
HNSC	cis	rs9487051	0.735	rs352837	ENSG00000243587.6	C6orf183	3.78	0.00018	0.0228	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109200603	chr6:109165833~109271014:+
HNSC	cis	rs8072100	0.869	rs4439799	ENSG00000263293.2	RP11-290H9.4	3.78	0.00018	0.0228	0.19	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47303460~47323613:-
HNSC	cis	rs330048	0.545	rs11249913	ENSG00000233609.3	RP11-62H7.2	-3.78	0.00018	0.0228	-0.17	-0.17	Systemic lupus erythematosus;	chr8:9286011	chr8:8961200~8979025:+
HNSC	cis	rs11096990	0.964	rs4974999	ENSG00000249685.1	RP11-360F5.3	3.78	0.00018	0.0228	0.21	0.17	Cognitive function;	chr4:39262294	chr4:39133913~39135608:+
HNSC	cis	rs897984	0.806	rs1458202	ENSG00000279196.1	RP11-1072A3.3	3.78	0.00018	0.0228	0.2	0.17	Dementia with Lewy bodies;	chr16:30941881	chr16:30984630~30988270:-
HNSC	cis	rs17122278	1	rs2277293	ENSG00000255422.1	AP002954.4	3.78	0.00018	0.0228	0.3	0.17	Total cholesterol levels;	chr11:118552153	chr11:118704607~118750263:+
HNSC	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-3.78	0.00018	0.0228	-0.18	-0.17	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-3.78	0.00018	0.0228	-0.18	-0.17	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
HNSC	cis	rs944002	1	rs944002	ENSG00000259444.1	RP11-736N17.8	3.78	0.00018	0.0228	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103106478	chr14:103094723~103098885:+
HNSC	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-3.78	0.00018	0.0228	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
HNSC	cis	rs11723261	0.582	rs3747693	ENSG00000211553.1	AC253576.2	-3.78	0.00018	0.0228	-0.25	-0.17	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:136461~136568:+
HNSC	cis	rs7178375	1	rs7176351	ENSG00000215302.7	CTD-3092A11.1	-3.78	0.00018	0.0228	-0.26	-0.17	Hypertriglyceridemia;	chr15:30916524	chr15:30470779~30507623:+
HNSC	cis	rs34286592	0.929	rs1045968	ENSG00000214725.6	CDIPT-AS1	-3.78	0.00018	0.0228	-0.24	-0.17	Multiple sclerosis;	chr16:29815044	chr16:29863593~29868053:+
HNSC	cis	rs5758511	0.514	rs5751240	ENSG00000205702.9	CYP2D7	3.78	0.00018	0.0228	0.16	0.17	Birth weight;	chr22:42199252	chr22:42140203~42144577:-
HNSC	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	3.78	0.00018	0.0228	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
HNSC	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-3.78	0.00018	0.0228	-0.18	-0.17	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
HNSC	cis	rs13256369	1	rs4841017	ENSG00000254153.1	CTA-398F10.2	3.78	0.00018	0.0228	0.21	0.17	Obesity-related traits;	chr8:8719583	chr8:8456909~8461337:-
HNSC	cis	rs8010715	0.785	rs2877611	ENSG00000259321.1	RP11-468E2.5	3.78	0.00018	0.0228	0.15	0.17	IgG glycosylation;	chr14:24126221	chr14:24139445~24140444:+
HNSC	cis	rs13325613	0.834	rs34693386	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46153910	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34101673	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46155794	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34409248	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46156579	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34996127	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46156681	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13069467	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46160383	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34567015	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46160720	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs78124692	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46160745	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs80007414	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46160746	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35685805	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46161286	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35162796	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46162887	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs35942803	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46167291	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35288652	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46167935	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35566550	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46169020	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.749	rs79948053	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46169568	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs35919278	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46172102	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34523728	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46178341	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34570200	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46179008	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.666	rs35560301	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46179014	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34134191	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46180039	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13069750	ENSG00000223552.1	RP11-24F11.2	-3.78	0.00018	0.0228	-0.3	-0.17	Monocyte count;	chr3:46183358	chr3:46364955~46407059:-
HNSC	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-3.78	0.000181	0.0228	-0.22	-0.17	Height;	chr20:49246745	chr20:49280319~49280409:+
HNSC	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	3.78	0.000181	0.0228	0.18	0.17	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	3.78	0.000181	0.0228	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
HNSC	cis	rs4906332	1	rs7155980	ENSG00000244691.1	RPL10AP1	-3.78	0.000181	0.0228	-0.2	-0.17	Coronary artery disease;	chr14:103456082	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs10459573	ENSG00000244691.1	RPL10AP1	-3.78	0.000181	0.0228	-0.2	-0.17	Coronary artery disease;	chr14:103459120	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs4906327	ENSG00000244691.1	RPL10AP1	-3.78	0.000181	0.0228	-0.2	-0.17	Coronary artery disease;	chr14:103462702	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs8012623	ENSG00000244691.1	RPL10AP1	-3.78	0.000181	0.0228	-0.2	-0.17	Coronary artery disease;	chr14:103470749	chr14:103412119~103412761:-
HNSC	cis	rs36093844	0.527	rs17817690	ENSG00000279742.1	RP11-700A24.1	-3.78	0.000181	0.0228	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85981018	chr11:85852557~85854943:-
HNSC	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	3.77	0.000181	0.0229	0.17	0.17	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
HNSC	cis	rs2554380	0.6	rs6602986	ENSG00000259570.1	RP11-671M22.4	3.77	0.000181	0.0229	0.21	0.17	Height;	chr15:83778347	chr15:84394512~84395514:+
HNSC	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-3.77	0.000181	0.0229	-0.19	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
HNSC	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-3.77	0.000181	0.0229	-0.23	-0.17	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
HNSC	cis	rs1497406	0.744	rs924203	ENSG00000227959.1	RP11-276H7.2	3.77	0.000181	0.0229	0.18	0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16185044	chr1:16155211~16157329:+
HNSC	cis	rs67478160	0.634	rs2295140	ENSG00000259515.1	RP11-365N19.2	3.77	0.000181	0.0229	0.15	0.17	Schizophrenia;	chr14:103749956	chr14:102933574~102937177:+
HNSC	cis	rs67478160	0.634	rs7141928	ENSG00000259515.1	RP11-365N19.2	3.77	0.000181	0.0229	0.15	0.17	Schizophrenia;	chr14:103753612	chr14:102933574~102937177:+
HNSC	cis	rs36093844	0.527	rs80333693	ENSG00000279742.1	RP11-700A24.1	-3.77	0.000181	0.0229	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86056863	chr11:85852557~85854943:-
HNSC	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	3.77	0.000181	0.0229	0.2	0.17	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
HNSC	cis	rs2554380	0.55	rs6602997	ENSG00000259570.1	RP11-671M22.4	3.77	0.000181	0.0229	0.22	0.17	Height;	chr15:83852646	chr15:84394512~84395514:+
HNSC	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-3.77	0.000181	0.0229	-0.18	-0.17	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
HNSC	cis	rs6601327	0.548	rs13271796	ENSG00000254340.1	RP11-10A14.3	3.77	0.000181	0.0229	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9795992	chr8:9141424~9145435:+
HNSC	cis	rs6840360	0.642	rs7658169	ENSG00000251611.1	RP11-610P16.1	-3.77	0.000181	0.0229	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151407551~151408835:-
HNSC	cis	rs1275468	1	rs1679381	ENSG00000257497.2	RP11-585P4.5	-3.77	0.000181	0.0229	-0.25	-0.17	Polycystic ovary syndrome;	chr12:75552344	chr12:75483454~75489820:-
HNSC	cis	rs9925964	0.869	rs749670	ENSG00000232748.3	RP11-196G11.6	3.77	0.000181	0.0229	0.23	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:31056460~31062803:+
HNSC	cis	rs9329221	0.712	rs1962073	ENSG00000255310.2	AF131215.2	-3.77	0.000181	0.0229	-0.16	-0.17	Neuroticism;	chr8:10403043	chr8:11107788~11109726:-
HNSC	cis	rs7429990	0.932	rs9862913	ENSG00000228638.1	FCF1P2	-3.77	0.000181	0.0229	-0.15	-0.17	Educational attainment (years of education);	chr3:47974682	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.965	rs7426976	ENSG00000228638.1	FCF1P2	3.77	0.000181	0.0229	0.15	0.17	Educational attainment (years of education);	chr3:47981083	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.965	rs1013431	ENSG00000228638.1	FCF1P2	3.77	0.000181	0.0229	0.15	0.17	Educational attainment (years of education);	chr3:47987628	chr3:48290793~48291375:-
HNSC	cis	rs4906332	1	rs34347076	ENSG00000244691.1	RPL10AP1	-3.77	0.000181	0.0229	-0.2	-0.17	Coronary artery disease;	chr14:103488732	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs35344594	ENSG00000244691.1	RPL10AP1	-3.77	0.000181	0.0229	-0.2	-0.17	Coronary artery disease;	chr14:103489455	chr14:103412119~103412761:-
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000211976.2	IGHV3-73	-3.77	0.000181	0.0229	-0.12	-0.17	Kawasaki disease;	chr14:106767802	chr14:106802694~106803233:-
HNSC	cis	rs7824557	0.628	rs2572387	ENSG00000255495.1	AC145124.2	3.77	0.000181	0.0229	0.19	0.17	Retinal vascular caliber;	chr8:11346656	chr8:12194467~12196280:+
HNSC	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-3.77	0.000181	0.0229	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000233609.3	RP11-62H7.2	-3.77	0.000181	0.0229	-0.18	-0.17	Neuroticism;	chr8:8504313	chr8:8961200~8979025:+
HNSC	cis	rs57561814	0.655	rs8180726	ENSG00000179428.2	AC073072.5	-3.77	0.000181	0.0229	-0.33	-0.17	Tonsillectomy;	chr7:22709687	chr7:22725395~22727620:-
HNSC	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	3.77	0.000181	0.0229	0.23	0.17	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
HNSC	cis	rs6095360	1	rs6019601	ENSG00000222365.1	SNORD12B	-3.77	0.000181	0.0229	-0.19	-0.17	Intelligence (multi-trait analysis);	chr20:49031125	chr20:49280319~49280409:+
HNSC	cis	rs62025270	0.688	rs12148571	ENSG00000259762.1	RP11-158M2.4	-3.77	0.000181	0.0229	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85750336~85752901:-
HNSC	cis	rs2115630	0.967	rs8028490	ENSG00000275120.1	RP11-182J1.17	-3.77	0.000181	0.0229	-0.19	-0.17	P wave terminal force;	chr15:84734657	chr15:84599434~84606463:-
HNSC	cis	rs4795519	0.614	rs1829663	ENSG00000265646.2	TUFMP1	3.77	0.000181	0.0229	0.22	0.17	Chronic myeloid leukemia;	chr17:27075243	chr17:27082690~27084036:-
HNSC	cis	rs8024893	1	rs7180114	ENSG00000270055.1	CTD-3092A11.2	3.77	0.000181	0.0229	0.24	0.17	Red cell distribution width;	chr15:31247976	chr15:30487963~30490313:+
HNSC	cis	rs868153	0.625	rs6907053	ENSG00000275339.1	RP3-425C14.6	3.77	0.000181	0.0229	0.19	0.17	Vertical cup-disc ratio;	chr6:122155549	chr6:122454358~122454612:+
HNSC	cis	rs11098499	0.566	rs7664440	ENSG00000250412.1	KLHL2P1	3.77	0.000181	0.0229	0.23	0.17	Corneal astigmatism;	chr4:119657385	chr4:119334329~119378233:+
HNSC	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	3.77	0.000182	0.0229	0.18	0.17	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
HNSC	cis	rs10888838	0.756	rs59455983	ENSG00000198711.5	SSBP3-AS1	3.77	0.000182	0.0229	0.25	0.17	Mitochondrial DNA levels;	chr1:54229275	chr1:54236440~54239063:+
HNSC	cis	rs8062405	1	rs55991577	ENSG00000261089.1	RP11-435I10.3	3.77	0.000182	0.0229	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs56358680	ENSG00000261089.1	RP11-435I10.3	3.77	0.000182	0.0229	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62036626	ENSG00000261089.1	RP11-435I10.3	3.77	0.000182	0.0229	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62036657	ENSG00000261089.1	RP11-435I10.3	3.77	0.000182	0.0229	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28413703~28415018:+
HNSC	cis	rs3740713	1	rs73436645	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.925	rs73436650	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436655	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr11:18490243~18490955:-
HNSC	cis	rs3740713	0.92	rs80254575	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436662	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs113725670	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436682	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436685	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs2056781	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73436701	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438604	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438607	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs75010364	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438627	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438634	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs113036885	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs112410494	ENSG00000256464.1	YWHABP2	3.77	0.000182	0.0229	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr11:18490243~18490955:-
HNSC	cis	rs7824557	0.628	rs17797894	ENSG00000269918.1	AF131215.9	3.77	0.000182	0.0229	0.17	0.17	Retinal vascular caliber;	chr8:11354572	chr8:11104691~11106704:-
HNSC	cis	rs11668609	0.938	rs28720079	ENSG00000268442.1	CTD-2027I19.2	3.77	0.000182	0.0229	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24184823	chr19:24162370~24163425:-
HNSC	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-3.77	0.000182	0.0229	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
HNSC	cis	rs7619708	1	rs7619708	ENSG00000231464.1	AC024937.4	-3.77	0.000182	0.0229	-0.22	-0.17	Red cell distribution width;	chr3:196083316	chr3:195996738~195998233:+
HNSC	cis	rs62246343	0.605	rs4328788	ENSG00000206573.7	THUMPD3-AS1	-3.77	0.000182	0.0229	-0.14	-0.17	Fibrinogen levels;	chr3:9415577	chr3:9349689~9398579:-
HNSC	cis	rs597480	0.783	rs667275	ENSG00000279742.1	RP11-700A24.1	-3.77	0.000182	0.0229	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85773373	chr11:85852557~85854943:-
HNSC	cis	rs868153	0.625	rs12661882	ENSG00000275339.1	RP3-425C14.6	3.77	0.000182	0.0229	0.18	0.17	Vertical cup-disc ratio;	chr6:122234943	chr6:122454358~122454612:+
HNSC	cis	rs919433	0.783	rs2565155	ENSG00000231621.1	AC013264.2	-3.77	0.000182	0.023	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371701	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.662	rs2043018	ENSG00000231621.1	AC013264.2	-3.77	0.000182	0.023	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372234	chr2:197197991~197199273:+
HNSC	cis	rs12999542	0.636	rs62151904	ENSG00000234389.1	AC007278.3	3.77	0.000182	0.023	0.29	0.17	Serum protein levels (sST2);	chr2:102474247	chr2:102438713~102440475:+
HNSC	cis	rs4704187	0.663	rs1477935	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000182	0.023	-0.16	-0.17	Response to amphetamines;	chr5:75152669	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.617	rs1477936	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000182	0.023	-0.16	-0.17	Response to amphetamines;	chr5:75152677	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs2059159	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000182	0.023	-0.16	-0.17	Response to amphetamines;	chr5:75155353	chr5:75608817~75609983:+
HNSC	cis	rs4906332	1	rs2065017	ENSG00000244691.1	RPL10AP1	-3.77	0.000182	0.023	-0.2	-0.17	Coronary artery disease;	chr14:103413242	chr14:103412119~103412761:-
HNSC	cis	rs12935418	0.634	rs9934940	ENSG00000278985.1	RP11-303E16.9	3.77	0.000182	0.023	0.18	0.17	Mean corpuscular volume;	chr16:81016021	chr16:80982319~80984094:-
HNSC	cis	rs6088580	0.634	rs1205336	ENSG00000276073.1	RP5-1125A11.7	3.77	0.000182	0.023	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:33985617~33988989:-
HNSC	cis	rs1552244	0.81	rs7612908	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10047464	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.935	rs7649243	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10047786	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7615646	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10048089	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.81	rs6809572	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10058461	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs112847840	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10059968	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs722509	ENSG00000180385.7	EMC3-AS1	3.77	0.000182	0.023	0.19	0.17	Alzheimer's disease;	chr3:10060693	chr3:9986893~10006990:+
HNSC	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-3.77	0.000182	0.023	-0.24	-0.17	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
HNSC	cis	rs1185460	0.934	rs10892328	ENSG00000272186.1	RP11-110I1.13	-3.77	0.000182	0.023	-0.2	-0.17	Coronary artery disease;	chr11:119071944	chr11:119067374~119067698:-
HNSC	cis	rs7772486	0.624	rs6930154	ENSG00000270638.1	RP3-466P17.1	-3.77	0.000182	0.023	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145735570~145737218:+
HNSC	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-3.77	0.000182	0.023	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
HNSC	cis	rs7178909	0.902	rs3853640	ENSG00000259677.1	RP11-493E3.1	3.77	0.000182	0.023	0.19	0.17	Common traits (Other);	chr15:89900488	chr15:89876540~89877285:+
HNSC	cis	rs17203016	0.731	rs11684690	ENSG00000231908.1	IDH1-AS1	-3.77	0.000182	0.023	-0.25	-0.17	Body mass index;	chr2:207365367	chr2:208255247~208256181:+
HNSC	cis	rs8180991	0.744	rs4567059	ENSG00000254431.1	RP11-550A5.2	3.77	0.000182	0.023	0.25	0.17	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125474045	chr8:125348196~125351416:-
HNSC	cis	rs7746199	0.736	rs34105070	ENSG00000226314.6	ZNF192P1	-3.77	0.000182	0.023	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28161781~28169594:+
HNSC	cis	rs9768139	0.733	rs12698209	ENSG00000223872.1	AC006372.5	3.77	0.000182	0.023	0.18	0.17	Calcium levels;	chr7:158324903	chr7:157501322~157503577:+
HNSC	cis	rs7178375	0.678	rs34678577	ENSG00000215302.7	CTD-3092A11.1	-3.77	0.000182	0.023	-0.26	-0.17	Hypertriglyceridemia;	chr15:30885262	chr15:30470779~30507623:+
HNSC	cis	rs55823223	0.648	rs936393	ENSG00000267801.1	RP11-552F3.9	3.77	0.000182	0.023	0.21	0.17	Psoriasis;	chr17:75851532	chr17:75876372~75879546:+
HNSC	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-3.77	0.000182	0.023	-0.17	-0.17	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
HNSC	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-3.77	0.000182	0.023	-0.17	-0.17	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-3.77	0.000182	0.023	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-3.77	0.000182	0.023	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
HNSC	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-3.77	0.000182	0.023	-0.18	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
HNSC	cis	rs11098499	0.661	rs10015965	ENSG00000250412.1	KLHL2P1	3.77	0.000182	0.023	0.22	0.17	Corneal astigmatism;	chr4:119347082	chr4:119334329~119378233:+
HNSC	cis	rs9487051	0.714	rs7744284	ENSG00000219700.1	PTCHD3P3	3.77	0.000182	0.023	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109295015	chr6:109288571~109290503:-
HNSC	cis	rs2247572	0.673	rs2218179	ENSG00000250295.5	RP11-434I12.2	3.77	0.000182	0.023	0.23	0.17	Cognitive performance;	chr8:72696168	chr8:73297711~73356461:-
HNSC	cis	rs964611	0.872	rs60820695	ENSG00000259488.2	RP11-154J22.1	-3.77	0.000182	0.023	-0.17	-0.17	Metabolite levels (Pyroglutamine);	chr15:48292686	chr15:48312353~48331856:-
HNSC	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	3.77	0.000182	0.023	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
HNSC	cis	rs4704187	0.663	rs9654428	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000182	0.023	-0.16	-0.17	Response to amphetamines;	chr5:75171059	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs9654429	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000182	0.023	-0.16	-0.17	Response to amphetamines;	chr5:75171100	chr5:75608817~75609983:+
HNSC	cis	rs442309	0.875	rs224064	ENSG00000238280.1	RP11-436D10.3	-3.77	0.000182	0.023	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62744452	chr10:62793562~62805887:-
HNSC	cis	rs10073892	0.619	rs10041015	ENSG00000250682.4	LINC00491	3.77	0.000182	0.023	0.21	0.17	Cognitive decline (age-related);	chr5:102376620	chr5:102609156~102671559:-
HNSC	cis	rs4947019	1	rs12206574	ENSG00000260273.1	RP11-425D10.10	3.77	0.000182	0.023	0.41	0.17	Hematological parameters;	chr6:109746570	chr6:109382795~109383666:+
HNSC	cis	rs2337406	1	rs7145100	ENSG00000211972.2	IGHV3-66	3.77	0.000182	0.023	0.17	0.17	Alzheimer's disease (late onset);	chr14:106704673	chr14:106675017~106675544:-
HNSC	cis	rs4713118	0.588	rs200994	ENSG00000241549.7	GUSBP2	-3.77	0.000182	0.023	-0.19	-0.17	Parkinson's disease;	chr6:27846035	chr6:26871484~26956554:-
HNSC	cis	rs1050631	0.538	rs2155827	ENSG00000260552.1	RP11-49I11.1	-3.77	0.000182	0.023	-0.2	-0.17	Esophageal squamous cell cancer (length of survival);	chr18:36123911	chr18:36179996~36187448:-
HNSC	cis	rs526231	0.543	rs246913	ENSG00000250682.4	LINC00491	3.77	0.000182	0.023	0.24	0.17	Primary biliary cholangitis;	chr5:103224669	chr5:102609156~102671559:-
HNSC	cis	rs12893668	0.603	rs61637848	ENSG00000269958.1	RP11-73M18.8	3.77	0.000182	0.023	0.16	0.17	Reticulocyte count;	chr14:103629694	chr14:103696353~103697163:+
HNSC	cis	rs12893668	0.542	rs12884809	ENSG00000269958.1	RP11-73M18.8	3.77	0.000182	0.023	0.15	0.17	Reticulocyte count;	chr14:103628983	chr14:103696353~103697163:+
HNSC	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-3.77	0.000182	0.023	-0.18	-0.17	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
HNSC	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	3.77	0.000182	0.023	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
HNSC	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-3.77	0.000182	0.023	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
HNSC	cis	rs2253762	0.736	rs2459082	ENSG00000226864.1	ATE1-AS1	3.77	0.000182	0.023	0.23	0.17	Breast cancer;	chr10:122036570	chr10:121928312~121951965:+
HNSC	cis	rs2341917	0.818	rs71431127	ENSG00000227992.1	AC108463.2	-3.77	0.000182	0.023	-0.29	-0.17	Attention function in attention deficit hyperactive disorder;	chr2:110895451	chr2:111203964~111206215:-
HNSC	cis	rs889398	0.933	rs6499240	ENSG00000196696.11	PDXDC2P	-3.77	0.000182	0.023	-0.12	-0.17	Body mass index;	chr16:69653009	chr16:69976297~70065948:-
HNSC	cis	rs62202398	0.618	rs2869347	ENSG00000276923.1	RP11-321P16.1	-3.77	0.000182	0.023	-0.29	-0.17	Alcohol consumption;	chr20:48155014	chr20:48073869~48074188:+
HNSC	cis	rs727563	0.636	rs2187795	ENSG00000213857.3	RP11-12M9.4	-3.77	0.000183	0.023	-0.23	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr22:41074180~41075239:-
HNSC	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	3.77	0.000183	0.023	0.29	0.17	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	3.77	0.000183	0.023	0.29	0.17	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	3.77	0.000183	0.023	0.29	0.17	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
HNSC	cis	rs7829975	0.755	rs3789849	ENSG00000254340.1	RP11-10A14.3	3.77	0.000183	0.0231	0.21	0.17	Mood instability;	chr8:8829544	chr8:9141424~9145435:+
HNSC	cis	rs72827839	0.779	rs72827844	ENSG00000210741.1	MIR196A1	-3.77	0.000183	0.0231	-0.22	-0.17	Ease of getting up in the morning;	chr17:48357079	chr17:48632490~48632559:-
HNSC	cis	rs516805	0.748	rs155466	ENSG00000279453.1	RP3-425C14.4	-3.77	0.000183	0.0231	-0.26	-0.17	Lymphocyte counts;	chr6:122512286	chr6:122436789~122439223:-
HNSC	cis	rs2274273	0.623	rs1187877	ENSG00000233924.1	AL160471.6	3.77	0.000183	0.0231	0.19	0.17	Protein biomarker;	chr14:55028443	chr14:55004813~55005687:-
HNSC	cis	rs4820294	0.669	rs732857	ENSG00000225867.1	RP5-1177I5.3	-3.77	0.000183	0.0231	-0.19	-0.17	Fat distribution (HIV);	chr22:37664843	chr22:37550026~37551735:+
HNSC	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	3.77	0.000183	0.0231	0.19	0.17	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
HNSC	cis	rs8062405	1	rs62036617	ENSG00000261089.1	RP11-435I10.3	3.77	0.000183	0.0231	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs4788095	ENSG00000261089.1	RP11-435I10.3	3.77	0.000183	0.0231	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000261089.1	RP11-435I10.3	3.77	0.000183	0.0231	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62036620	ENSG00000261089.1	RP11-435I10.3	3.77	0.000183	0.0231	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62036621	ENSG00000261089.1	RP11-435I10.3	3.77	0.000183	0.0231	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28413703~28415018:+
HNSC	cis	rs9896933	0.723	rs7224189	ENSG00000262663.1	RP11-497H17.1	3.77	0.000183	0.0231	0.21	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82824351	chr17:82918282~82918785:+
HNSC	cis	rs11231017	0.507	rs2178258	ENSG00000250659.2	RP11-864I4.3	-3.77	0.000183	0.0231	-0.21	-0.17	HIV-1 viral setpoint;	chr11:62302421	chr11:62537312~62542018:+
HNSC	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	3.77	0.000183	0.0231	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	3.77	0.000183	0.0231	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
HNSC	cis	rs13438327	1	rs13308002	ENSG00000243554.1	AC004967.7	3.77	0.000183	0.0231	0.34	0.17	Sudden cardiac arrest;	chr7:97990935	chr7:97969005~97972254:-
HNSC	cis	rs7189233	0.531	rs8049033	ENSG00000261056.2	RP11-454F8.2	-3.77	0.000183	0.0231	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53298224~53299792:+
HNSC	cis	rs10851478	0.872	rs925104	ENSG00000259656.1	RP11-325E5.1	3.77	0.000183	0.0231	0.2	0.17	Oral cavity cancer;	chr15:49624458	chr15:49101791~49103264:+
HNSC	cis	rs2239557	1	rs2239557	ENSG00000258769.1	RAP1AP	-3.77	0.000183	0.0231	-0.19	-0.17	Common traits (Other);	chr14:74085267	chr14:74482985~74483435:+
HNSC	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-3.77	0.000183	0.0231	-0.17	-0.17	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
HNSC	cis	rs2153535	0.56	rs7750064	ENSG00000230939.1	RP11-314C16.1	-3.77	0.000183	0.0231	-0.2	-0.17	Motion sickness;	chr6:8632012	chr6:8784178~8785445:+
HNSC	cis	rs7772486	0.686	rs1045820	ENSG00000270638.1	RP3-466P17.1	3.77	0.000183	0.0231	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs4896828	ENSG00000270638.1	RP3-466P17.1	3.77	0.000183	0.0231	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs6570701	ENSG00000270638.1	RP3-466P17.1	3.77	0.000183	0.0231	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.754	rs6570703	ENSG00000270638.1	RP3-466P17.1	3.77	0.000183	0.0231	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs6570705	ENSG00000270638.1	RP3-466P17.1	3.77	0.000183	0.0231	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145735570~145737218:+
HNSC	cis	rs950169	1	rs79318564	ENSG00000230373.7	GOLGA6L5P	-3.77	0.000183	0.0231	-0.19	-0.17	Schizophrenia;	chr15:84117398	chr15:84507885~84516814:-
HNSC	cis	rs2153535	0.585	rs9502734	ENSG00000230939.1	RP11-314C16.1	-3.77	0.000183	0.0231	-0.2	-0.17	Motion sickness;	chr6:8631618	chr6:8784178~8785445:+
HNSC	cis	rs7324557	0.621	rs9507166	ENSG00000205861.10	C1QTNF9B-AS1	3.77	0.000183	0.0231	0.23	0.17	Visceral adipose tissue adjusted for BMI;	chr13:23824844	chr13:23888889~23897263:+
HNSC	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	3.77	0.000183	0.0231	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
HNSC	cis	rs1912483	0.505	rs3760372	ENSG00000263293.2	RP11-290H9.4	3.77	0.000183	0.0231	0.21	0.17	Coronary artery disease;	chr17:47302636	chr17:47303460~47323613:-
HNSC	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-3.77	0.000183	0.0231	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
HNSC	cis	rs4906332	1	rs8012127	ENSG00000244691.1	RPL10AP1	-3.77	0.000183	0.0231	-0.2	-0.17	Coronary artery disease;	chr14:103476425	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs78316803	ENSG00000244691.1	RPL10AP1	-3.77	0.000183	0.0231	-0.2	-0.17	Coronary artery disease;	chr14:103476526	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs17617832	ENSG00000244691.1	RPL10AP1	-3.77	0.000183	0.0231	-0.2	-0.17	Coronary artery disease;	chr14:103476803	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs11625172	ENSG00000244691.1	RPL10AP1	-3.77	0.000183	0.0231	-0.2	-0.17	Coronary artery disease;	chr14:103478575	chr14:103412119~103412761:-
HNSC	cis	rs9911578	0.967	rs6416932	ENSG00000224738.1	AC099850.1	3.77	0.000183	0.0231	0.18	0.17	Intelligence (multi-trait analysis);	chr17:59071630	chr17:59106598~59118267:+
HNSC	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	3.77	0.000183	0.0231	0.19	0.17	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
HNSC	cis	rs2692947	0.696	rs1724121	ENSG00000231584.7	FAHD2CP	-3.77	0.000183	0.0231	-0.15	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96142810	chr2:96010551~96023380:+
HNSC	cis	rs11098499	1	rs1011054	ENSG00000250412.1	KLHL2P1	-3.77	0.000183	0.0231	-0.22	-0.17	Corneal astigmatism;	chr4:119281232	chr4:119334329~119378233:+
HNSC	cis	rs440932	0.747	rs330946	ENSG00000254153.1	CTA-398F10.2	3.77	0.000183	0.0231	0.19	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8456909~8461337:-
HNSC	cis	rs12291225	0.679	rs11023170	ENSG00000254418.1	RP11-21L19.1	3.77	0.000183	0.0231	0.2	0.17	Sense of smell;	chr11:14273363	chr11:14262846~14273691:-
HNSC	cis	rs12291225	0.679	rs11023172	ENSG00000254418.1	RP11-21L19.1	3.77	0.000183	0.0231	0.2	0.17	Sense of smell;	chr11:14273821	chr11:14262846~14273691:-
HNSC	cis	rs12291225	0.679	rs4757245	ENSG00000254418.1	RP11-21L19.1	3.77	0.000183	0.0231	0.2	0.17	Sense of smell;	chr11:14276326	chr11:14262846~14273691:-
HNSC	cis	rs3213758	0.541	rs7200859	ENSG00000275191.1	RP11-36I17.2	-3.77	0.000183	0.0231	-0.27	-0.17	Vitiligo (non-segmental);	chr16:53634663	chr16:53628256~53628816:-
HNSC	cis	rs11603691	1	rs10896598	ENSG00000254662.1	RP11-872D17.4	-3.77	0.000183	0.0231	-0.36	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57284533	chr11:57325603~57327958:+
HNSC	cis	rs17489649	1	rs17162081	ENSG00000271849.1	CTC-332L22.1	3.77	0.000183	0.0231	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109698914	chr5:109687802~109688329:-
HNSC	cis	rs853679	1	rs11965538	ENSG00000226314.6	ZNF192P1	-3.77	0.000183	0.0231	-0.25	-0.17	Depression;	chr6:28272137	chr6:28161781~28169594:+
HNSC	cis	rs258322	0.636	rs4968051	ENSG00000260259.1	RP11-368I7.4	-3.77	0.000183	0.0231	-0.39	-0.17	Melanoma;Black vs. red hair color;	chr16:89648573	chr16:89682620~89686569:-
HNSC	cis	rs9313772	0.928	rs12187074	ENSG00000254350.1	RP11-542A14.1	3.77	0.000183	0.0231	0.19	0.17	Blood pressure;	chr5:158384927	chr5:158424585~158452758:+
HNSC	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	3.77	0.000183	0.0231	0.28	0.17	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	3.77	0.000183	0.0231	0.28	0.17	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
HNSC	cis	rs240993	0.812	rs9400481	ENSG00000230177.1	RP5-1112D6.4	3.77	0.000183	0.0231	0.22	0.17	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111277932~111278742:+
HNSC	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	3.77	0.000183	0.0231	0.15	0.17	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	3.77	0.000183	0.0231	0.15	0.17	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
HNSC	cis	rs853679	0.513	rs13437444	ENSG00000219891.2	ZSCAN12P1	3.77	0.000183	0.0231	0.28	0.17	Depression;	chr6:28103220	chr6:28091154~28093664:+
HNSC	cis	rs4873772	0.653	rs7014443	ENSG00000253330.1	RP11-697N18.3	-3.77	0.000183	0.0231	-0.21	-0.17	Lobe attachment (rater-scored or self-reported);	chr8:47684382	chr8:47511034~47512141:-
HNSC	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	3.77	0.000183	0.0231	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
HNSC	cis	rs7646881	0.509	rs56321207	ENSG00000272087.1	RP11-379F4.7	3.77	0.000183	0.0231	0.24	0.17	Tetralogy of Fallot;	chr3:158666944	chr3:158693120~158693768:-
HNSC	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	3.77	0.000183	0.0231	0.29	0.17	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
HNSC	cis	rs7169223	0.653	rs1564499	ENSG00000261762.1	RP11-650L12.2	3.77	0.000183	0.0231	0.23	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792466	chr15:78589123~78591276:-
HNSC	cis	rs67311347	0.544	rs2278930	ENSG00000280739.1	EIF1B-AS1	3.77	0.000183	0.0231	0.18	0.17	Renal cell carcinoma;	chr3:40309601	chr3:40173145~40309698:-
HNSC	cis	rs7558911	0.801	rs7576306	ENSG00000183308.6	AC005037.3	3.77	0.000184	0.0231	0.21	0.17	Chronic lymphocytic leukemia;	chr2:201209805	chr2:200963263~201009102:+
HNSC	cis	rs911555	0.504	rs745079	ENSG00000269958.1	RP11-73M18.8	3.77	0.000184	0.0231	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103696353~103697163:+
HNSC	cis	rs911555	0.504	rs61995761	ENSG00000269958.1	RP11-73M18.8	3.77	0.000184	0.0231	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103696353~103697163:+
HNSC	cis	rs17489649	1	rs2284988	ENSG00000271849.1	CTC-332L22.1	3.77	0.000184	0.0232	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109705607	chr5:109687802~109688329:-
HNSC	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	3.77	0.000184	0.0232	0.19	0.17	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	3.77	0.000184	0.0232	0.19	0.17	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
HNSC	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	3.77	0.000184	0.0232	0.21	0.17	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
HNSC	cis	rs3764400	0.517	rs7224461	ENSG00000228782.6	CTD-2026D20.3	3.77	0.000184	0.0232	0.25	0.17	Body mass index;	chr17:48126068	chr17:47450568~47492492:-
HNSC	cis	rs2243480	1	rs958550	ENSG00000229886.1	RP5-1132H15.3	-3.77	0.000184	0.0232	-0.3	-0.17	Diabetic kidney disease;	chr7:66170692	chr7:66025126~66031544:-
HNSC	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	3.77	0.000184	0.0232	0.18	0.17	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	3.77	0.000184	0.0232	0.18	0.17	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
HNSC	cis	rs2863171	1	rs2863171	ENSG00000254651.1	RP11-430H10.3	3.77	0.000184	0.0232	0.25	0.17	Lung function (forced vital capacity);	chr11:45229181	chr11:45399448~45400528:+
HNSC	cis	rs7726839	0.574	rs72707007	ENSG00000225138.6	CTD-2228K2.7	3.77	0.000184	0.0232	0.25	0.17	Obesity-related traits;	chr5:661741	chr5:473236~480884:+
HNSC	cis	rs73201462	1	rs2955079	ENSG00000231305.3	RP11-723O4.2	3.77	0.000184	0.0232	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240981	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955080	ENSG00000231305.3	RP11-723O4.2	3.77	0.000184	0.0232	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241022	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955082	ENSG00000231305.3	RP11-723O4.2	3.77	0.000184	0.0232	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241491	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999073	ENSG00000231305.3	RP11-723O4.2	3.77	0.000184	0.0232	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243486	chr3:128861313~128871540:-
HNSC	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-3.77	0.000184	0.0232	-0.18	-0.17	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
HNSC	cis	rs2836974	0.932	rs56306759	ENSG00000255568.3	BRWD1-AS2	3.77	0.000184	0.0232	0.16	0.17	Cognitive function;	chr21:39236180	chr21:39313935~39314962:+
HNSC	cis	rs17772222	0.958	rs10134008	ENSG00000258789.1	RP11-507K2.3	-3.77	0.000184	0.0232	-0.21	-0.17	Coronary artery calcification;	chr14:88549183	chr14:88551597~88552493:+
HNSC	cis	rs793571	0.536	rs7183336	ENSG00000245975.2	RP11-30K9.6	3.77	0.000184	0.0232	0.23	0.17	Schizophrenia;	chr15:58674037	chr15:58768072~58770974:-
HNSC	cis	rs950169	0.919	rs17300292	ENSG00000230373.7	GOLGA6L5P	-3.77	0.000184	0.0232	-0.19	-0.17	Schizophrenia;	chr15:84093816	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs12916348	ENSG00000230373.7	GOLGA6L5P	-3.77	0.000184	0.0232	-0.19	-0.17	Schizophrenia;	chr15:84096775	chr15:84507885~84516814:-
HNSC	cis	rs2055729	0.601	rs12546952	ENSG00000254340.1	RP11-10A14.3	-3.77	0.000184	0.0232	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9886492	chr8:9141424~9145435:+
HNSC	cis	rs2548724	0.812	rs431778	ENSG00000250682.4	LINC00491	-3.77	0.000184	0.0232	-0.22	-0.17	Type 2 diabetes;	chr5:102255718	chr5:102609156~102671559:-
HNSC	cis	rs11992162	0.529	rs6995037	ENSG00000227888.4	FAM66A	-3.77	0.000184	0.0232	-0.18	-0.17	Monocyte count;	chr8:11923378	chr8:12362019~12388296:+
HNSC	cis	rs2337406	0.539	rs2583290	ENSG00000280411.1	IGHV1-69-2	3.77	0.000184	0.0232	0.16	0.17	Alzheimer's disease (late onset);	chr14:106650277	chr14:106762092~106762588:-
HNSC	cis	rs546131	0.642	rs12291580	ENSG00000271369.1	RP11-350D17.3	-3.77	0.000184	0.0232	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34825185	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs61881107	ENSG00000271369.1	RP11-350D17.3	-3.77	0.000184	0.0232	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34826473	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.614	rs35953213	ENSG00000271369.1	RP11-350D17.3	-3.77	0.000184	0.0232	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34827222	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs34191151	ENSG00000271369.1	RP11-350D17.3	-3.77	0.000184	0.0232	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34828962	chr11:34709600~34710161:+
HNSC	cis	rs67478160	0.634	rs2368558	ENSG00000259515.1	RP11-365N19.2	3.77	0.000184	0.0232	0.15	0.17	Schizophrenia;	chr14:103764181	chr14:102933574~102937177:+
HNSC	cis	rs67478160	0.634	rs2368559	ENSG00000259515.1	RP11-365N19.2	3.77	0.000184	0.0232	0.15	0.17	Schizophrenia;	chr14:103764198	chr14:102933574~102937177:+
HNSC	cis	rs67478160	0.619	rs12437066	ENSG00000259515.1	RP11-365N19.2	3.77	0.000184	0.0232	0.15	0.17	Schizophrenia;	chr14:103770507	chr14:102933574~102937177:+
HNSC	cis	rs2280018	0.963	rs12928424	ENSG00000263335.1	AF001548.5	-3.77	0.000184	0.0232	-0.22	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15726674~15732993:+
HNSC	cis	rs12999542	0.706	rs17651485	ENSG00000234389.1	AC007278.3	3.77	0.000184	0.0232	0.29	0.17	Serum protein levels (sST2);	chr2:102385190	chr2:102438713~102440475:+
HNSC	cis	rs763512	0.504	rs6607279	ENSG00000276054.1	RP11-378E13.3	3.77	0.000184	0.0232	0.25	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37564796	chr17:37386886~37387926:+
HNSC	cis	rs28539243	0.738	rs7205346	ENSG00000260936.1	FTO-IT1	3.77	0.000184	0.0232	0.24	0.17	Breast cancer;	chr16:54645756	chr16:54039393~54040726:+
HNSC	cis	rs28830936	0.966	rs28680296	ENSG00000250379.1	RP11-23P13.4	3.77	0.000184	0.0232	0.21	0.17	Diastolic blood pressure;	chr15:41829340	chr15:41825099~41827936:-
HNSC	cis	rs919433	0.783	rs2565165	ENSG00000231621.1	AC013264.2	-3.77	0.000184	0.0232	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368851	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.783	rs788007	ENSG00000231621.1	AC013264.2	-3.77	0.000184	0.0232	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368952	chr2:197197991~197199273:+
HNSC	cis	rs865483	0.895	rs2107105	ENSG00000276054.1	RP11-378E13.3	3.77	0.000184	0.0232	0.21	0.17	Monocyte count;	chr17:37474975	chr17:37386886~37387926:+
HNSC	cis	rs7646881	0.544	rs59492803	ENSG00000272087.1	RP11-379F4.7	3.77	0.000184	0.0232	0.25	0.17	Tetralogy of Fallot;	chr3:158702908	chr3:158693120~158693768:-
HNSC	cis	rs7520050	0.966	rs4545281	ENSG00000280836.1	AL355480.1	3.77	0.000184	0.0232	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45581219~45581321:-
HNSC	cis	rs526231	0.543	rs62362544	ENSG00000250682.4	LINC00491	3.77	0.000184	0.0232	0.22	0.17	Primary biliary cholangitis;	chr5:102998543	chr5:102609156~102671559:-
HNSC	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	3.77	0.000184	0.0232	0.24	0.17	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	3.77	0.000184	0.0232	0.24	0.17	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
HNSC	cis	rs7688540	0.771	rs61795002	ENSG00000211553.1	AC253576.2	-3.77	0.000184	0.0232	-0.27	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:136461~136568:+
HNSC	cis	rs11083475	0.714	rs1471432	ENSG00000207296.1	RNU6-140P	-3.77	0.000184	0.0232	-0.17	-0.17	Heart rate;	chr19:38769642	chr19:38797002~38797109:-
HNSC	cis	rs3740713	1	rs73438695	ENSG00000256464.1	YWHABP2	3.77	0.000184	0.0232	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs76062966	ENSG00000256464.1	YWHABP2	3.77	0.000184	0.0232	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr11:18490243~18490955:-
HNSC	cis	rs28573326	0.962	rs67650739	ENSG00000121089.4	NACA3P	-3.77	0.000184	0.0232	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415564	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs73005556	ENSG00000121089.4	NACA3P	-3.77	0.000184	0.0232	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415869	chr4:164943290~164943937:+
HNSC	cis	rs442309	0.812	rs224092	ENSG00000238280.1	RP11-436D10.3	-3.77	0.000184	0.0232	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62781644	chr10:62793562~62805887:-
HNSC	cis	rs6601327	0.641	rs9644704	ENSG00000233609.3	RP11-62H7.2	-3.77	0.000184	0.0232	-0.16	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9702659	chr8:8961200~8979025:+
HNSC	cis	rs2384207	0.523	rs12425388	ENSG00000201208.1	Y_RNA	-3.77	0.000184	0.0232	-0.27	-0.17	Response to fenofibrate (adiponectin levels);	chr12:113293717	chr12:113178423~113178519:-
HNSC	cis	rs897984	0.77	rs12930657	ENSG00000279196.1	RP11-1072A3.3	-3.77	0.000184	0.0232	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30920647	chr16:30984630~30988270:-
HNSC	cis	rs897984	0.77	rs3813020	ENSG00000279196.1	RP11-1072A3.3	-3.77	0.000184	0.0232	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30922754	chr16:30984630~30988270:-
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000272831.1	RP11-792A8.4	3.77	0.000184	0.0232	0.14	0.17	Aortic root size;	chr7:65943052	chr7:66739829~66740385:-
HNSC	cis	rs1925953	0.711	rs747252	ENSG00000233589.1	RP4-694A7.2	3.77	0.000184	0.0232	0.22	0.17	Vertical cup-disc ratio;	chr1:68377102	chr1:68479129~68483539:+
HNSC	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-3.77	0.000184	0.0232	-0.18	-0.17	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
HNSC	cis	rs9467711	0.606	rs9379873	ENSG00000241549.7	GUSBP2	3.77	0.000184	0.0232	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26402489	chr6:26871484~26956554:-
HNSC	cis	rs28573326	0.962	rs11732618	ENSG00000121089.4	NACA3P	-3.77	0.000184	0.0232	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415406	chr4:164943290~164943937:+
HNSC	cis	rs1510510	0.742	rs35690621	ENSG00000186235.9	AC016757.3	-3.77	0.000184	0.0232	-0.25	-0.17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238693224	chr2:238224552~238231677:-
HNSC	cis	rs4512344	0.514	rs13255193	ENSG00000269918.1	AF131215.9	-3.77	0.000184	0.0232	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:11104691~11106704:-
HNSC	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	3.77	0.000184	0.0232	0.28	0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
HNSC	cis	rs656900	0.715	rs1870576	ENSG00000261229.4	MTHFS	-3.77	0.000184	0.0232	-0.19	-0.17	Cerebrospinal P-tau181p levels;	chr15:79814786	chr15:79843547~79897285:-
HNSC	cis	rs6840360	0.642	rs2709838	ENSG00000251611.1	RP11-610P16.1	-3.77	0.000184	0.0232	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151407551~151408835:-
HNSC	cis	rs160451	0.782	rs7828553	ENSG00000251136.7	RP11-37B2.1	3.77	0.000184	0.0232	0.16	0.17	Leprosy;	chr8:89700193	chr8:89609409~89757727:-
HNSC	cis	rs2554380	0.55	rs12904106	ENSG00000259570.1	RP11-671M22.4	3.77	0.000184	0.0232	0.22	0.17	Height;	chr15:83842571	chr15:84394512~84395514:+
HNSC	cis	rs61160187	0.51	rs6872863	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000184	0.0232	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.527	rs6873181	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000184	0.0232	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.527	rs6894672	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000184	0.0232	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60866457~60866935:-
HNSC	cis	rs67311347	0.544	rs1454492	ENSG00000280739.1	EIF1B-AS1	3.77	0.000184	0.0232	0.18	0.17	Renal cell carcinoma;	chr3:40311393	chr3:40173145~40309698:-
HNSC	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-3.77	0.000184	0.0232	-0.21	-0.17	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
HNSC	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-3.77	0.000184	0.0232	-0.21	-0.17	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
HNSC	cis	rs6545883	0.931	rs11125885	ENSG00000271889.1	RP11-493E12.1	3.77	0.000185	0.0232	0.2	0.17	Tuberculosis;	chr2:61528593	chr2:61151433~61162105:-
HNSC	cis	rs7291412	0.662	rs6520015	ENSG00000273289.1	RP6-109B7.5	-3.77	0.000185	0.0232	-0.19	-0.17	Dupuytren's disease;Subjective well-being;	chr22:46067551	chr22:46053093~46053560:+
HNSC	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	3.77	0.000185	0.0233	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
HNSC	cis	rs12188164	0.515	rs11745246	ENSG00000225138.6	CTD-2228K2.7	3.77	0.000185	0.0233	0.21	0.17	Cystic fibrosis severity;	chr5:410828	chr5:473236~480884:+
HNSC	cis	rs9880211	0.635	rs10048942	ENSG00000273486.1	RP11-731C17.2	3.77	0.000185	0.0233	0.16	0.17	Height;Body mass index;	chr3:136066649	chr3:136837338~136839021:-
HNSC	cis	rs7178909	0.872	rs2165070	ENSG00000259677.1	RP11-493E3.1	3.77	0.000185	0.0233	0.2	0.17	Common traits (Other);	chr15:89865744	chr15:89876540~89877285:+
HNSC	cis	rs11098499	0.618	rs35265692	ENSG00000250412.1	KLHL2P1	3.77	0.000185	0.0233	0.22	0.17	Corneal astigmatism;	chr4:119403980	chr4:119334329~119378233:+
HNSC	cis	rs9300255	0.602	rs10744147	ENSG00000280120.1	RP11-546D6.3	3.77	0.000185	0.0233	0.16	0.17	Neutrophil percentage of white cells;	chr12:123159182	chr12:123152324~123153377:-
HNSC	cis	rs6580649	0.771	rs1635535	ENSG00000278385.1	RP11-89H19.2	3.77	0.000185	0.0233	0.27	0.17	Lung cancer;	chr12:47992458	chr12:47905122~47906865:+
HNSC	cis	rs28830936	0.966	rs3743024	ENSG00000250379.1	RP11-23P13.4	3.77	0.000185	0.0233	0.21	0.17	Diastolic blood pressure;	chr15:41826773	chr15:41825099~41827936:-
HNSC	cis	rs9313772	0.775	rs10060888	ENSG00000254350.1	RP11-542A14.1	-3.77	0.000185	0.0233	-0.18	-0.17	Blood pressure;	chr5:158407873	chr5:158424585~158452758:+
HNSC	cis	rs12664873	0.755	rs7773091	ENSG00000275339.1	RP3-425C14.6	3.77	0.000185	0.0233	0.18	0.17	Atrial fibrillation;	chr6:122188878	chr6:122454358~122454612:+
HNSC	cis	rs950027	0.62	rs1145089	ENSG00000259479.5	SORD2P	3.77	0.000185	0.0233	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:44826371~44884694:-
HNSC	cis	rs821367	0.879	rs680822	ENSG00000280042.1	RP11-71H17.8	-3.77	0.000185	0.0233	-0.21	-0.17	Platelet distribution width;	chr3:124683518	chr3:124791119~124793104:-
HNSC	cis	rs8072100	0.846	rs4264433	ENSG00000263293.2	RP11-290H9.4	-3.77	0.000185	0.0233	-0.19	-0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47303460~47323613:-
HNSC	cis	rs889398	0.741	rs6499269	ENSG00000196696.11	PDXDC2P	-3.77	0.000185	0.0233	-0.12	-0.17	Body mass index;	chr16:69875015	chr16:69976297~70065948:-
HNSC	cis	rs2919009	0.664	rs2289337	ENSG00000271670.1	RP11-95I16.4	3.77	0.000185	0.0233	0.21	0.17	Obesity-related traits;	chr10:120889970	chr10:120879256~120880667:-
HNSC	cis	rs868153	0.625	rs12664347	ENSG00000275339.1	RP3-425C14.6	3.77	0.000185	0.0233	0.19	0.17	Vertical cup-disc ratio;	chr6:122211070	chr6:122454358~122454612:+
HNSC	cis	rs964611	0.786	rs5020564	ENSG00000259488.2	RP11-154J22.1	-3.77	0.000185	0.0233	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48372356	chr15:48312353~48331856:-
HNSC	cis	rs853679	0.546	rs35744819	ENSG00000226314.6	ZNF192P1	-3.77	0.000185	0.0233	-0.33	-0.17	Depression;	chr6:28350554	chr6:28161781~28169594:+
HNSC	cis	rs2554380	0.843	rs1019665	ENSG00000259570.1	RP11-671M22.4	3.77	0.000185	0.0233	0.23	0.17	Height;	chr15:83711867	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.843	rs1019667	ENSG00000259570.1	RP11-671M22.4	3.77	0.000185	0.0233	0.23	0.17	Height;	chr15:83712097	chr15:84394512~84395514:+
HNSC	cis	rs2877187	0.538	rs11762758	ENSG00000232006.7	AC005537.2	-3.77	0.000185	0.0233	-0.19	-0.17	Lung cancer in ever smokers;	chr7:43031533	chr7:42954135~43113931:-
HNSC	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	3.77	0.000185	0.0233	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	3.77	0.000185	0.0233	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
HNSC	cis	rs9487051	0.714	rs6932503	ENSG00000219700.1	PTCHD3P3	3.77	0.000185	0.0233	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109286755	chr6:109288571~109290503:-
HNSC	cis	rs889398	0.741	rs6499268	ENSG00000196696.11	PDXDC2P	-3.77	0.000185	0.0233	-0.12	-0.17	Body mass index;	chr16:69872626	chr16:69976297~70065948:-
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000217862.2	HIST1H4PS1	-3.77	0.000185	0.0233	-0.19	-0.17	Depression;	chr6:28379133	chr6:27807075~27807339:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000217862.2	HIST1H4PS1	-3.77	0.000185	0.0233	-0.19	-0.17	Depression;	chr6:28379168	chr6:27807075~27807339:+
HNSC	cis	rs643506	0.874	rs673679	ENSG00000230911.1	PPIHP1	-3.77	0.000185	0.0233	-0.23	-0.17	Breast cancer;	chr11:111816076	chr11:112029858~112030367:-
HNSC	cis	rs41369048	0.669	rs111238725	ENSG00000238078.1	LINC01352	-3.77	0.000185	0.0233	-0.23	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220829255~220832429:+
HNSC	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-3.77	0.000185	0.0233	-0.2	-0.17	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
HNSC	cis	rs71520386	0.898	rs12536091	ENSG00000230658.1	KLHL7-AS1	3.77	0.000185	0.0233	0.26	0.17	Fibrinogen levels;	chr7:22788581	chr7:23101228~23105703:-
HNSC	cis	rs8007643	0.85	rs74034667	ENSG00000211778.2	TRAV4	3.77	0.000185	0.0233	0.2	0.17	Nose morphology;	chr14:20879807	chr14:21736152~21736982:+
HNSC	cis	rs17772222	0.958	rs76559451	ENSG00000258789.1	RP11-507K2.3	-3.77	0.000185	0.0233	-0.21	-0.17	Coronary artery calcification;	chr14:88523193	chr14:88551597~88552493:+
HNSC	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-3.77	0.000185	0.0233	-0.19	-0.17	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-3.77	0.000185	0.0233	-0.19	-0.17	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-3.77	0.000185	0.0233	-0.19	-0.17	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
HNSC	cis	rs7781557	0.64	rs6955064	ENSG00000239969.4	RP11-163E9.2	-3.77	0.000185	0.0233	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102939124	chr7:102364162~102380633:+
HNSC	cis	rs6988985	0.818	rs7463212	ENSG00000247317.3	RP11-273G15.2	3.77	0.000185	0.0233	0.19	0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910442	chr8:142981738~143018437:-
HNSC	cis	rs6988985	0.818	rs3802228	ENSG00000247317.3	RP11-273G15.2	-3.77	0.000185	0.0233	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910802	chr8:142981738~143018437:-
HNSC	cis	rs988913	1	rs9475106	ENSG00000224984.1	RP11-524H19.2	3.77	0.000185	0.0233	0.2	0.17	Menarche (age at onset);	chr6:54986657	chr6:54840118~54840855:-
HNSC	cis	rs17495987	0.63	rs17496524	ENSG00000219545.8	UMAD1	3.77	0.000185	0.0233	0.23	0.17	Tonsillectomy;	chr7:7868543	chr7:7640711~8004059:+
HNSC	cis	rs11867934	0.773	rs4247118	ENSG00000223979.2	SMCR2	-3.77	0.000185	0.0233	-0.22	-0.17	Diabetic retinopathy;	chr17:17107909	chr17:17674026~17677688:-
HNSC	cis	rs16873450	0.571	rs10268973	ENSG00000234800.2	PCMTD1P3	3.77	0.000185	0.0233	0.17	0.17	Verbal memory performance (residualized delayed recall level);	chr7:23763696	chr7:23721311~23721782:-
HNSC	cis	rs871012	0.502	rs951959	ENSG00000251405.2	CTB-109A12.1	-3.77	0.000186	0.0234	-0.2	-0.17	IgG glycosylation;	chr5:157462211	chr5:157362615~157460078:-
HNSC	cis	rs10819861	0.679	rs10819868	ENSG00000175611.10	LINC00476	3.77	0.000186	0.0234	0.17	0.17	Electrocardiographic traits;	chr9:96109096	chr9:95759231~95875977:-
HNSC	cis	rs11671005	0.57	rs73062110	ENSG00000269473.1	CTD-2619J13.19	3.77	0.000186	0.0234	0.28	0.17	Mean platelet volume;	chr19:58425275	chr19:58440448~58445849:+
HNSC	cis	rs4906332	0.868	rs4900578	ENSG00000244691.1	RPL10AP1	-3.77	0.000186	0.0234	-0.2	-0.17	Coronary artery disease;	chr14:103459673	chr14:103412119~103412761:-
HNSC	cis	rs9733	0.681	rs7412746	ENSG00000236713.1	RP11-363I22.3	3.77	0.000186	0.0234	0.18	0.17	Tonsillectomy;	chr1:150887995	chr1:150780272~150780644:+
HNSC	cis	rs9987353	0.62	rs34455383	ENSG00000254153.1	CTA-398F10.2	-3.77	0.000186	0.0234	-0.21	-0.17	Recombination measurement;	chr8:9208948	chr8:8456909~8461337:-
HNSC	cis	rs526231	0.543	rs34779	ENSG00000250682.4	LINC00491	3.77	0.000186	0.0234	0.23	0.17	Primary biliary cholangitis;	chr5:103117064	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.547	rs34780	ENSG00000250682.4	LINC00491	3.77	0.000186	0.0234	0.23	0.17	Primary biliary cholangitis;	chr5:103117853	chr5:102609156~102671559:-
HNSC	cis	rs10463554	0.759	rs34781	ENSG00000250682.4	LINC00491	3.77	0.000186	0.0234	0.23	0.17	Parkinson's disease;	chr5:103118735	chr5:102609156~102671559:-
HNSC	cis	rs870825	0.55	rs10000507	ENSG00000254233.1	RP11-242J7.1	3.77	0.000186	0.0234	0.25	0.17	Blood protein levels;	chr4:184698127	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs10022818	ENSG00000254233.1	RP11-242J7.1	3.77	0.000186	0.0234	0.25	0.17	Blood protein levels;	chr4:184698128	chr4:184584093~184625030:-
HNSC	cis	rs73173548	0.502	rs6867204	ENSG00000247828.6	TMEM161B-AS1	3.77	0.000186	0.0234	0.18	0.17	Macular telangiectasia type 2;	chr5:88446423	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs34933255	ENSG00000247828.6	TMEM161B-AS1	3.77	0.000186	0.0234	0.18	0.17	Macular telangiectasia type 2;	chr5:88446492	chr5:88268895~88436685:+
HNSC	cis	rs35306767	0.903	rs12250936	ENSG00000229869.1	RP11-363N22.2	-3.77	0.000186	0.0234	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:824169	chr10:933026~942743:+
HNSC	cis	rs2944755	0.723	rs13274041	ENSG00000279766.1	RP11-642A1.2	-3.77	0.000186	0.0234	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577816	chr8:140572142~140572812:-
HNSC	cis	rs2944755	0.723	rs13274321	ENSG00000279766.1	RP11-642A1.2	-3.77	0.000186	0.0234	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578107	chr8:140572142~140572812:-
HNSC	cis	rs889398	0.904	rs4783721	ENSG00000226232.7	RP11-419C5.2	3.77	0.000186	0.0234	0.16	0.17	Body mass index;	chr16:69527253	chr16:69976388~69996188:-
HNSC	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-3.77	0.000186	0.0234	-0.21	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
HNSC	cis	rs728616	0.867	rs56235549	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0234	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79663088~79826594:-
HNSC	cis	rs3736485	0.808	rs28813458	ENSG00000274528.1	CTD-2650P22.2	3.77	0.000186	0.0234	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51654826	chr15:52017167~52018032:-
HNSC	cis	rs7572733	0.534	rs11899188	ENSG00000231621.1	AC013264.2	-3.77	0.000186	0.0234	-0.16	-0.17	Dermatomyositis;	chr2:197875397	chr2:197197991~197199273:+
HNSC	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	3.77	0.000186	0.0234	0.17	0.17	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
HNSC	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	3.77	0.000186	0.0234	0.2	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
HNSC	cis	rs11992162	0.967	rs7461062	ENSG00000269918.1	AF131215.9	3.77	0.000186	0.0234	0.17	0.17	Monocyte count;	chr8:11974439	chr8:11104691~11106704:-
HNSC	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-3.77	0.000186	0.0234	-0.22	-0.17	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
HNSC	cis	rs1620921	0.711	rs9346839	ENSG00000231863.1	RP3-428L16.1	-3.77	0.000186	0.0234	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160834014	chr6:160931080~160969771:+
HNSC	cis	rs5758511	0.514	rs5758580	ENSG00000227370.1	RP4-669P10.19	3.77	0.000186	0.0234	0.21	0.17	Birth weight;	chr22:42097871	chr22:42132543~42132998:+
HNSC	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-3.77	0.000186	0.0234	-0.2	-0.17	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
HNSC	cis	rs10849893	0.576	rs889970	ENSG00000258435.1	RP11-711D18.2	-3.77	0.000186	0.0234	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121418414	chr12:121391962~121399859:+
HNSC	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-3.77	0.000186	0.0234	-0.19	-0.17	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
HNSC	cis	rs7826238	0.566	rs2945886	ENSG00000233609.3	RP11-62H7.2	3.77	0.000186	0.0234	0.16	0.17	Systolic blood pressure;	chr8:8290748	chr8:8961200~8979025:+
HNSC	cis	rs28489187	0.683	rs1498373	ENSG00000223653.4	RP11-131L23.1	3.77	0.000186	0.0234	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85324950	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs2300634	ENSG00000223653.4	RP11-131L23.1	3.77	0.000186	0.0234	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85325574	chr1:85276715~85448124:+
HNSC	cis	rs13256369	1	rs7843488	ENSG00000173295.6	FAM86B3P	3.77	0.000186	0.0234	0.22	0.17	Obesity-related traits;	chr8:8718707	chr8:8228595~8244865:+
HNSC	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-3.77	0.000186	0.0234	-0.2	-0.17	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
HNSC	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-3.77	0.000186	0.0234	-0.27	-0.17	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	3.77	0.000186	0.0234	0.28	0.17	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
HNSC	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	3.77	0.000186	0.0234	0.26	0.17	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
HNSC	cis	rs6723108	0.651	rs35215000	ENSG00000224043.6	CCNT2-AS1	3.77	0.000186	0.0234	0.21	0.17	Type 2 diabetes;	chr2:134610086	chr2:134735464~134918710:-
HNSC	cis	rs7824557	0.628	rs34237267	ENSG00000269918.1	AF131215.9	3.77	0.000186	0.0234	0.16	0.17	Retinal vascular caliber;	chr8:11339792	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.628	rs7008205	ENSG00000269918.1	AF131215.9	3.77	0.000186	0.0234	0.16	0.17	Retinal vascular caliber;	chr8:11339814	chr8:11104691~11106704:-
HNSC	cis	rs11976180	1	rs13243677	ENSG00000244479.5	OR2A1-AS1	3.77	0.000186	0.0234	0.2	0.17	Obesity-related traits;	chr7:144049479	chr7:144251264~144356181:-
HNSC	cis	rs12370275	0.58	rs34046684	ENSG00000257528.1	KRT8P19	-3.77	0.000186	0.0234	-0.24	-0.17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61357746	chr12:61879318~61880772:+
HNSC	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-3.77	0.000186	0.0234	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
HNSC	cis	rs6928977	0.66	rs9373131	ENSG00000231028.7	LINC00271	3.77	0.000186	0.0234	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135497801~135716055:+
HNSC	cis	rs28489187	0.558	rs12044537	ENSG00000223653.4	RP11-131L23.1	3.77	0.000186	0.0234	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85380702	chr1:85276715~85448124:+
HNSC	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	3.77	0.000186	0.0234	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
HNSC	cis	rs1930961	0.558	rs12160908	ENSG00000100058.11	CRYBB2P1	3.77	0.000186	0.0234	0.28	0.17	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25448105~25520854:+
HNSC	cis	rs656900	0.715	rs673018	ENSG00000261229.4	MTHFS	3.77	0.000186	0.0234	0.19	0.17	Cerebrospinal P-tau181p levels;	chr15:79823005	chr15:79843547~79897285:-
HNSC	cis	rs4704187	0.687	rs1477933	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000187	0.0234	-0.16	-0.17	Response to amphetamines;	chr5:75141328	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs1422699	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000187	0.0234	-0.16	-0.17	Response to amphetamines;	chr5:75146585	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6888707	ENSG00000272040.1	CTC-366B18.4	-3.77	0.000187	0.0234	-0.16	-0.17	Response to amphetamines;	chr5:75147095	chr5:75608817~75609983:+
HNSC	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	3.77	0.000187	0.0235	0.16	0.17	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
HNSC	cis	rs919433	0.783	rs2565158	ENSG00000231621.1	AC013264.2	-3.77	0.000187	0.0235	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371379	chr2:197197991~197199273:+
HNSC	cis	rs4713118	0.786	rs200503	ENSG00000226314.6	ZNF192P1	-3.77	0.000187	0.0235	-0.22	-0.17	Parkinson's disease;	chr6:27818104	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.55	rs1233704	ENSG00000219891.2	ZSCAN12P1	-3.77	0.000187	0.0235	-0.24	-0.17	Depression;	chr6:28199145	chr6:28091154~28093664:+
HNSC	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	3.77	0.000187	0.0235	0.24	0.17	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	3.77	0.000187	0.0235	0.24	0.17	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	3.77	0.000187	0.0235	0.24	0.17	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
HNSC	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	3.77	0.000187	0.0235	0.24	0.17	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
HNSC	cis	rs9393777	0.588	rs6926677	ENSG00000241549.7	GUSBP2	3.77	0.000187	0.0235	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26478597	chr6:26871484~26956554:-
HNSC	cis	rs897984	0.574	rs11647284	ENSG00000275263.1	RP11-1072A3.4	-3.77	0.000187	0.0235	-0.19	-0.17	Dementia with Lewy bodies;	chr16:31066014	chr16:30956872~30957199:-
HNSC	cis	rs2865126	0.644	rs10775415	ENSG00000264714.1	RP11-21G15.1	3.77	0.000187	0.0235	0.21	0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10737375	chr18:10724619~10728539:+
HNSC	cis	rs7688540	0.723	rs7687112	ENSG00000211553.1	AC253576.2	-3.77	0.000187	0.0235	-0.24	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:136461~136568:+
HNSC	cis	rs7777677	0.925	rs73543808	ENSG00000276557.1	TRBV18	3.77	0.000187	0.0235	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142615716~142616415:+
HNSC	cis	rs13043901	0.861	rs2766666	ENSG00000197670.6	RP4-724E16.2	-3.77	0.000187	0.0235	-0.17	-0.17	Type 2 diabetes (age of onset);	chr20:53555602	chr20:53552770~53575863:+
HNSC	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	3.77	0.000187	0.0235	0.16	0.17	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	3.77	0.000187	0.0235	0.16	0.17	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
HNSC	cis	rs7714670	1	rs6871548	ENSG00000184084.7	CTD-2372A4.1	-3.77	0.000187	0.0235	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73780199	chr5:73803296~73803599:-
HNSC	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-3.77	0.000187	0.0235	-0.25	-0.17	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
HNSC	cis	rs12908161	0.959	rs11637728	ENSG00000229212.6	RP11-561C5.4	-3.77	0.000187	0.0235	-0.25	-0.17	Schizophrenia;	chr15:84660161	chr15:85205440~85234795:-
HNSC	cis	rs11773103	1	rs11769063	ENSG00000224046.1	AC005076.5	-3.77	0.000187	0.0235	-0.31	-0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87289287	chr7:87151423~87152420:-
HNSC	cis	rs9329221	0.527	rs34308302	ENSG00000255310.2	AF131215.2	-3.77	0.000187	0.0235	-0.17	-0.17	Neuroticism;	chr8:10474512	chr8:11107788~11109726:-
HNSC	cis	rs4713118	0.786	rs200502	ENSG00000226314.6	ZNF192P1	-3.77	0.000187	0.0235	-0.22	-0.17	Parkinson's disease;	chr6:27820284	chr6:28161781~28169594:+
HNSC	cis	rs1878526	0.614	rs4613284	ENSG00000279227.1	AC009303.2	-3.77	0.000187	0.0235	-0.2	-0.17	Bone mineral density;	chr2:118353100	chr2:118014174~118015673:+
HNSC	cis	rs12188164	0.714	rs11741954	ENSG00000215246.5	RP11-43F13.3	-3.77	0.000187	0.0235	-0.2	-0.17	Cystic fibrosis severity;	chr5:421340	chr5:987180~997308:-
HNSC	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-3.77	0.000187	0.0235	-0.2	-0.17	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
HNSC	cis	rs36715	0.909	rs152906	ENSG00000245937.6	LINC01184	3.77	0.000187	0.0235	0.21	0.17	Breast cancer;	chr5:128216148	chr5:127940426~128083172:-
HNSC	cis	rs2164273	0.565	rs2736387	ENSG00000269918.1	AF131215.9	3.77	0.000187	0.0235	0.17	0.17	Extraversion;	chr8:11299862	chr8:11104691~11106704:-
HNSC	cis	rs6928977	0.863	rs2614255	ENSG00000231028.7	LINC00271	3.77	0.000187	0.0235	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135342443	chr6:135497801~135716055:+
HNSC	cis	rs10504130	0.932	rs77831588	ENSG00000272024.1	RP11-546K22.3	-3.77	0.000187	0.0235	-0.3	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51946419	chr8:51950284~51950690:+
HNSC	cis	rs3758785	0.586	rs637114	ENSG00000255893.1	RP11-685N10.1	3.77	0.000187	0.0235	0.2	0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94337519	chr11:94472908~94473570:-
HNSC	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	3.77	0.000187	0.0235	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
HNSC	cis	rs2919009	0.509	rs12255639	ENSG00000271670.1	RP11-95I16.4	3.77	0.000187	0.0235	0.2	0.17	Obesity-related traits;	chr10:120784075	chr10:120879256~120880667:-
HNSC	cis	rs13201294	1	rs13201294	ENSG00000241549.7	GUSBP2	3.77	0.000187	0.0235	0.25	0.17	Squamous cell lung carcinoma;	chr6:27588362	chr6:26871484~26956554:-
HNSC	cis	rs2243480	1	rs35820085	ENSG00000164669.11	INTS4P1	3.77	0.000187	0.0235	0.34	0.17	Diabetic kidney disease;	chr7:65977771	chr7:65141225~65234216:+
HNSC	cis	rs4356203	0.87	rs7935219	ENSG00000260196.1	RP1-239B22.5	3.77	0.000187	0.0235	0.18	0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17380649~17383531:+
HNSC	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	3.77	0.000187	0.0235	0.21	0.17	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
HNSC	cis	rs11951515	0.614	rs7716091	ENSG00000249286.1	CTD-2210P15.2	3.77	0.000187	0.0235	0.18	0.17	Metabolite levels  (X-11787);	chr5:43348156	chr5:43586918~43588223:-
HNSC	cis	rs4356203	0.905	rs214937	ENSG00000272034.1	SNORD14A	3.77	0.000187	0.0235	0.13	0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17074654~17074744:-
HNSC	cis	rs8014252	0.803	rs73282126	ENSG00000269927.1	RP6-91H8.3	-3.77	0.000187	0.0235	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519324	chr14:71141125~71143253:-
HNSC	cis	rs8014252	0.803	rs74062726	ENSG00000269927.1	RP6-91H8.3	-3.77	0.000187	0.0235	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519462	chr14:71141125~71143253:-
HNSC	cis	rs8014252	0.803	rs73282127	ENSG00000269927.1	RP6-91H8.3	-3.77	0.000187	0.0235	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519696	chr14:71141125~71143253:-
HNSC	cis	rs2347867	0.524	rs7356921	ENSG00000218996.1	RP1-99E18.2	3.77	0.000187	0.0235	0.24	0.17	Age at first birth;	chr6:151901868	chr6:150934968~150935566:+
HNSC	cis	rs1553477	0.535	rs7447502	ENSG00000272123.1	CTD-2366F13.2	3.77	0.000187	0.0235	0.2	0.17	Monobrow;	chr5:53802940	chr5:53089016~53089468:-
HNSC	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-3.77	0.000187	0.0235	-0.26	-0.17	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
HNSC	cis	rs116095464	0.558	rs1971229	ENSG00000277812.1	AC021087.1	3.77	0.000187	0.0235	0.29	0.17	Breast cancer;	chr5:268072	chr5:262769~262881:+
HNSC	cis	rs2070419	0.723	rs12481806	ENSG00000261610.1	AP000265.1	3.77	0.000187	0.0235	0.21	0.17	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31566484	chr21:32259804~32261585:-
HNSC	cis	rs9650657	0.737	rs4841436	ENSG00000255310.2	AF131215.2	3.77	0.000187	0.0235	0.16	0.17	Neuroticism;	chr8:10736964	chr8:11107788~11109726:-
HNSC	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	3.77	0.000187	0.0235	0.24	0.17	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
HNSC	cis	rs1585471	0.931	rs2218817	ENSG00000249532.3	RP11-148B6.1	-3.77	0.000187	0.0235	-0.21	-0.17	Myopia (pathological);	chr4:111689850	chr4:112646476~112650051:-
HNSC	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	3.77	0.000188	0.0236	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
HNSC	cis	rs860295	0.529	rs1475766	ENSG00000272068.1	RP11-284F21.9	3.77	0.000188	0.0236	0.2	0.17	Body mass index;	chr1:156011698	chr1:156637783~156641004:-
HNSC	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-3.77	0.000188	0.0236	-0.24	-0.17	QT interval;	chr1:6219310	chr1:6236240~6239444:+
HNSC	cis	rs7829975	0.514	rs2920983	ENSG00000233609.3	RP11-62H7.2	3.77	0.000188	0.0236	0.16	0.17	Mood instability;	chr8:8410553	chr8:8961200~8979025:+
HNSC	cis	rs11098499	0.69	rs34818745	ENSG00000250412.1	KLHL2P1	3.77	0.000188	0.0236	0.22	0.17	Corneal astigmatism;	chr4:119335900	chr4:119334329~119378233:+
HNSC	cis	rs7302981	0.681	rs706792	ENSG00000272368.2	RP4-605O3.4	3.77	0.000188	0.0236	0.17	0.17	Systolic blood pressure;	chr12:50073861	chr12:50112197~50165618:+
HNSC	cis	rs7824557	0.583	rs2736306	ENSG00000255495.1	AC145124.2	3.77	0.000188	0.0236	0.19	0.17	Retinal vascular caliber;	chr8:11382253	chr8:12194467~12196280:+
HNSC	cis	rs11976180	1	rs2961117	ENSG00000244479.5	OR2A1-AS1	3.77	0.000188	0.0236	0.2	0.17	Obesity-related traits;	chr7:144058160	chr7:144251264~144356181:-
HNSC	cis	rs9611565	0.649	rs139540	ENSG00000235513.1	RP4-756G23.5	3.77	0.000188	0.0236	0.2	0.17	Vitiligo;	chr22:41782036	chr22:41209122~41217627:-
HNSC	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-3.77	0.000188	0.0236	-0.18	-0.17	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
HNSC	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-3.77	0.000188	0.0236	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
HNSC	cis	rs7927592	0.763	rs7120876	ENSG00000255031.4	RP11-802E16.3	3.77	0.000188	0.0236	0.14	0.17	Total body bone mineral density;	chr11:68493930	chr11:68050740~68053762:+
HNSC	cis	rs6674970	1	rs61819219	ENSG00000261168.1	RP11-68I18.10	-3.77	0.000188	0.0236	-0.21	-0.17	Childhood ear infection;	chr1:151111899	chr1:151130075~151131610:-
HNSC	cis	rs17508449	0.819	rs17359468	ENSG00000232450.1	RP4-730K3.3	-3.77	0.000188	0.0236	-0.3	-0.17	Leprosy;	chr1:113700084	chr1:113698884~113699631:-
HNSC	cis	rs3738443	1	rs61840059	ENSG00000259865.1	RP11-488L18.10	3.77	0.000188	0.0236	0.16	0.17	Alcohol dependence;	chr1:247207676	chr1:247187281~247188526:-
HNSC	cis	rs853679	0.55	rs9295762	ENSG00000219891.2	ZSCAN12P1	-3.76	0.000188	0.0236	-0.23	-0.17	Depression;	chr6:28187640	chr6:28091154~28093664:+
HNSC	cis	rs67311347	1	rs34762643	ENSG00000280739.1	EIF1B-AS1	3.76	0.000188	0.0236	0.19	0.17	Renal cell carcinoma;	chr3:40433942	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs9841335	ENSG00000280739.1	EIF1B-AS1	3.76	0.000188	0.0236	0.19	0.17	Renal cell carcinoma;	chr3:40434367	chr3:40173145~40309698:-
HNSC	cis	rs1937680	0.582	rs10762470	ENSG00000236671.6	PRKG1-AS1	-3.76	0.000188	0.0236	-0.24	-0.17	Breast cancer;	chr10:51887369	chr10:52230742~52314128:-
HNSC	cis	rs13178541	0.748	rs9327727	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000188	0.0236	-0.22	-0.17	IgG glycosylation;	chr5:135725997	chr5:135812667~135826582:+
HNSC	cis	rs36093844	0.527	rs17817859	ENSG00000279742.1	RP11-700A24.1	-3.76	0.000188	0.0236	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86029600	chr11:85852557~85854943:-
HNSC	cis	rs1620921	0.711	rs2565724	ENSG00000231863.1	RP3-428L16.1	-3.76	0.000188	0.0236	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160820857	chr6:160931080~160969771:+
HNSC	cis	rs5751168	0.652	rs5758513	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22502059	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.765	rs2032416	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22503437	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.834	rs5758522	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22504088	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.749	rs2032417	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22504803	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.749	rs4820450	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22505080	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.915	rs5758528	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22505806	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.765	rs5751192	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22505893	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.834	rs2330097	ENSG00000274422.1	LL22NC03-2H8.5	3.76	0.000188	0.0236	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22506261	chr22:22283928~22287220:-
HNSC	cis	rs4356203	0.875	rs680205	ENSG00000272034.1	SNORD14A	-3.76	0.000188	0.0236	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17074654~17074744:-
HNSC	cis	rs4648045	0.501	rs4648052	ENSG00000230069.3	LRRC37A15P	-3.76	0.000188	0.0236	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102593898	chr4:102727274~102730721:-
HNSC	cis	rs2562784	0.638	rs2730100	ENSG00000225151.9	GOLGA2P7	-3.76	0.000188	0.0236	-0.32	-0.17	Height;	chr15:83630141	chr15:84199311~84230136:-
HNSC	cis	rs11756659	0.653	rs199729	ENSG00000272810.1	U91328.22	3.76	0.000188	0.0236	0.18	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:26013241~26013757:+
HNSC	cis	rs7714670	0.736	rs2973547	ENSG00000184084.7	CTD-2372A4.1	-3.76	0.000188	0.0236	-0.2	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73796590	chr5:73803296~73803599:-
HNSC	cis	rs72799341	0.706	rs11865499	ENSG00000279196.1	RP11-1072A3.3	3.76	0.000188	0.0236	0.2	0.17	Diastolic blood pressure;	chr16:31120929	chr16:30984630~30988270:-
HNSC	cis	rs72799341	0.706	rs59735493	ENSG00000279196.1	RP11-1072A3.3	3.76	0.000188	0.0236	0.2	0.17	Diastolic blood pressure;	chr16:31121779	chr16:30984630~30988270:-
HNSC	cis	rs4713118	0.824	rs9468223	ENSG00000224843.5	LINC00240	3.76	0.000188	0.0236	0.2	0.17	Parkinson's disease;	chr6:27772887	chr6:26956992~27023924:+
HNSC	cis	rs2016266	0.859	rs56225815	ENSG00000270175.1	RP11-793H13.11	3.76	0.000188	0.0236	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53346306	chr12:53500162~53500936:-
HNSC	cis	rs2016266	0.859	rs11170507	ENSG00000270175.1	RP11-793H13.11	3.76	0.000188	0.0236	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53346898	chr12:53500162~53500936:-
HNSC	cis	rs2016266	0.826	rs61928079	ENSG00000270175.1	RP11-793H13.11	3.76	0.000188	0.0236	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53347684	chr12:53500162~53500936:-
HNSC	cis	rs11711311	1	rs2305546	ENSG00000241529.3	RN7SL767P	-3.76	0.000188	0.0236	-0.22	-0.17	IgG glycosylation;	chr3:113784507	chr3:113632704~113632998:+
HNSC	cis	rs1862618	0.671	rs173763	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000188	0.0236	0.21	0.17	Initial pursuit acceleration;	chr5:56929591	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.62	rs189695	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000188	0.0236	0.21	0.17	Initial pursuit acceleration;	chr5:56929942	chr5:56927874~56929573:+
HNSC	cis	rs1862618	0.613	rs252889	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000188	0.0236	0.21	0.17	Initial pursuit acceleration;	chr5:56931242	chr5:56927874~56929573:+
HNSC	cis	rs2013441	0.965	rs2703820	ENSG00000261033.1	RP11-209D14.2	3.76	0.000188	0.0236	0.2	0.17	Obesity-related traits;	chr17:20218166	chr17:20008051~20009234:-
HNSC	cis	rs6657613	0.651	rs2295057	ENSG00000186715.9	MST1L	-3.76	0.000188	0.0236	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17051061	chr1:16754910~16770237:-
HNSC	cis	rs911263	0.961	rs2208397	ENSG00000240210.3	RP11-204K16.1	3.76	0.000188	0.0236	0.2	0.17	Primary biliary cholangitis;	chr14:68286570	chr14:68338728~68339528:-
HNSC	cis	rs2904524	0.541	rs11531260	ENSG00000257815.4	RP11-611E13.2	-3.76	0.000188	0.0236	-0.18	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70379155	chr12:69904033~70243360:-
HNSC	cis	rs2904524	0.541	rs1603221	ENSG00000257815.4	RP11-611E13.2	-3.76	0.000188	0.0236	-0.18	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70379617	chr12:69904033~70243360:-
HNSC	cis	rs7211079	0.879	rs66693363	ENSG00000275479.1	RP11-334C17.6	3.76	0.000188	0.0236	0.2	0.17	Myocardial infarction;	chr17:80155136	chr17:80149627~80149798:+
HNSC	cis	rs17596685	1	rs12585014	ENSG00000271216.1	LINC01050	-3.76	0.000188	0.0236	-0.22	-0.17	C-reactive protein levels;	chr13:42566423	chr13:42810366~42812562:-
HNSC	cis	rs5758511	0.514	rs1989375	ENSG00000227370.1	RP4-669P10.19	3.76	0.000188	0.0236	0.2	0.17	Birth weight;	chr22:42177133	chr22:42132543~42132998:+
HNSC	cis	rs9650657	0.74	rs2277130	ENSG00000269918.1	AF131215.9	-3.76	0.000188	0.0236	-0.17	-0.17	Neuroticism;	chr8:10820091	chr8:11104691~11106704:-
HNSC	cis	rs9437689	0.899	rs6687388	ENSG00000237416.5	RP11-465K1.2	-3.76	0.000188	0.0236	-0.21	-0.17	Phospholipid levels (plasma);	chr1:95049568	chr1:94836748~94855426:-
HNSC	cis	rs73201462	1	rs2811381	ENSG00000231305.3	RP11-723O4.2	3.76	0.000188	0.0236	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128279069	chr3:128861313~128871540:-
HNSC	cis	rs9926296	0.632	rs1800286	ENSG00000261812.4	TUBB8P7	-3.76	0.000188	0.0236	-0.2	-0.17	Vitiligo;	chr16:89803353	chr16:90093154~90096354:+
HNSC	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	3.76	0.000188	0.0236	0.26	0.17	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	3.76	0.000188	0.0236	0.26	0.17	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
HNSC	cis	rs4819052	0.851	rs2838826	ENSG00000215447.6	BX322557.10	-3.76	0.000188	0.0236	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45288052~45291738:+
HNSC	cis	rs9393777	1	rs9393777	ENSG00000241549.7	GUSBP2	3.76	0.000188	0.0236	0.24	0.17	Intelligence (multi-trait analysis);	chr6:26974248	chr6:26871484~26956554:-
HNSC	cis	rs1941023	0.967	rs10501386	ENSG00000279632.1	RP11-286N22.6	-3.76	0.000188	0.0236	-0.19	-0.17	Congenital heart disease (maternal effect);	chr11:60543650	chr11:61426448~61427325:-
HNSC	cis	rs755249	0.53	rs4660443	ENSG00000182109.6	RP11-69E11.4	3.76	0.000188	0.0236	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39522280~39546187:-
HNSC	cis	rs35000415	0.938	rs10488631	ENSG00000275106.1	RP11-309L24.10	-3.76	0.000188	0.0236	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128954129	chr7:128952527~128953316:-
HNSC	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	3.76	0.000188	0.0237	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
HNSC	cis	rs9487051	0.807	rs1915835	ENSG00000219700.1	PTCHD3P3	3.76	0.000189	0.0237	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109276280	chr6:109288571~109290503:-
HNSC	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	3.76	0.000189	0.0237	0.34	0.17	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	3.76	0.000189	0.0237	0.34	0.17	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.908	rs55876148	ENSG00000164669.11	INTS4P1	3.76	0.000189	0.0237	0.34	0.17	Diabetic kidney disease;	chr7:65914813	chr7:65141225~65234216:+
HNSC	cis	rs860295	0.702	rs11264386	ENSG00000225855.5	RUSC1-AS1	3.76	0.000189	0.0237	0.12	0.17	Body mass index;	chr1:155589379	chr1:155316863~155324176:-
HNSC	cis	rs4906332	1	rs35224956	ENSG00000244691.1	RPL10AP1	-3.76	0.000189	0.0237	-0.2	-0.17	Coronary artery disease;	chr14:103434144	chr14:103412119~103412761:-
HNSC	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	3.76	0.000189	0.0237	0.17	0.17	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
HNSC	cis	rs4853525	0.522	rs10490538	ENSG00000228509.4	AC006460.2	-3.76	0.000189	0.0237	-0.22	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190725340	chr2:190676944~190708716:-
HNSC	cis	rs10742752	0.676	rs34042421	ENSG00000255267.3	RP11-430H10.2	3.76	0.000189	0.0237	0.23	0.17	Body mass index;	chr11:45398683	chr11:45371397~45388508:+
HNSC	cis	rs929354	1	rs1182413	ENSG00000224629.1	RP5-1142J19.2	3.76	0.000189	0.0237	0.17	0.17	Body mass index;	chr7:157265863	chr7:157263022~157263229:-
HNSC	cis	rs2921073	0.509	rs2976931	ENSG00000233609.3	RP11-62H7.2	3.76	0.000189	0.0237	0.16	0.17	Parkinson's disease;	chr8:8399807	chr8:8961200~8979025:+
HNSC	cis	rs9650657	0.504	rs6601566	ENSG00000269918.1	AF131215.9	-3.76	0.000189	0.0237	-0.17	-0.17	Neuroticism;	chr8:11185465	chr8:11104691~11106704:-
HNSC	cis	rs801193	0.613	rs2016325	ENSG00000273142.1	RP11-458F8.4	3.76	0.000189	0.0237	0.15	0.17	Aortic root size;	chr7:66858513	chr7:66902857~66906297:+
HNSC	cis	rs11711311	1	rs2712348	ENSG00000241529.3	RN7SL767P	-3.76	0.000189	0.0237	-0.22	-0.17	IgG glycosylation;	chr3:113741767	chr3:113632704~113632998:+
HNSC	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-3.76	0.000189	0.0237	-0.14	-0.17	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
HNSC	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-3.76	0.000189	0.0237	-0.25	-0.17	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
HNSC	cis	rs2436845	0.614	rs2436854	ENSG00000253320.4	KB-1507C5.2	-3.76	0.000189	0.0237	-0.18	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813809	chr8:102864300~102977876:+
HNSC	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-3.76	0.000189	0.0237	-0.17	-0.17	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
HNSC	cis	rs2562456	0.833	rs55961038	ENSG00000268119.4	CTD-2561J22.5	3.76	0.000189	0.0237	0.26	0.17	Pain;	chr19:21375205	chr19:21444241~21463908:-
HNSC	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	3.76	0.000189	0.0237	0.21	0.17	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
HNSC	cis	rs9487051	0.837	rs1915834	ENSG00000219700.1	PTCHD3P3	3.76	0.000189	0.0237	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109276421	chr6:109288571~109290503:-
HNSC	cis	rs6001482	0.679	rs8142710	ENSG00000253818.1	IGLV1-41	-3.76	0.000189	0.0237	-0.14	-0.17	Diastolic blood pressure;	chr22:22233044	chr22:22404207~22404721:+
HNSC	cis	rs11603691	0.901	rs12361969	ENSG00000254662.1	RP11-872D17.4	-3.76	0.000189	0.0237	-0.34	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57314012	chr11:57325603~57327958:+
HNSC	cis	rs17214007	0.518	rs8047940	ENSG00000263065.1	AF001548.6	-3.76	0.000189	0.0237	-0.23	-0.17	Cognitive function;	chr16:15691787	chr16:15741151~15741791:+
HNSC	cis	rs4767841	0.806	rs1122119	ENSG00000277283.1	RP1-267D11.6	3.76	0.000189	0.0237	0.17	0.17	Urgency urinary incontinence;	chr12:119748903	chr12:120116907~120119000:+
HNSC	cis	rs875971	0.706	rs1643374	ENSG00000273142.1	RP11-458F8.4	-3.76	0.000189	0.0237	-0.15	-0.17	Aortic root size;	chr7:66407695	chr7:66902857~66906297:+
HNSC	cis	rs11756659	0.653	rs412968	ENSG00000216331.1	HIST1H1PS1	3.76	0.000189	0.0237	0.26	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25953965	chr6:26195566~26195771:+
HNSC	cis	rs9321453	0.962	rs9321446	ENSG00000231971.4	RP11-557H15.3	3.76	0.000189	0.0237	0.2	0.17	Urate levels;	chr6:134439166	chr6:134428240~134520585:-
HNSC	cis	rs2548724	0.812	rs2600827	ENSG00000250682.4	LINC00491	-3.76	0.000189	0.0238	-0.23	-0.17	Type 2 diabetes;	chr5:102272642	chr5:102609156~102671559:-
HNSC	cis	rs17407555	0.71	rs10939814	ENSG00000250413.1	RP11-448G15.1	-3.76	0.000189	0.0238	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10271705	chr4:10006482~10009725:+
HNSC	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	3.76	0.000189	0.0238	0.21	0.17	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
HNSC	cis	rs800888	0.548	rs2721939	ENSG00000249917.2	LINC00536	-3.76	0.000189	0.0238	-0.22	-0.17	Monocyte percentage of white cells;	chr8:115623715	chr8:115950511~116325059:-
HNSC	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-3.76	0.00019	0.0238	-0.18	-0.17	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
HNSC	cis	rs12291225	0.679	rs4756786	ENSG00000254418.1	RP11-21L19.1	3.76	0.00019	0.0238	0.2	0.17	Sense of smell;	chr11:14264354	chr11:14262846~14273691:-
HNSC	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-3.76	0.00019	0.0238	-0.18	-0.17	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
HNSC	cis	rs2638953	0.815	rs10843188	ENSG00000257176.2	RP11-996F15.2	3.76	0.00019	0.0238	0.19	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504200	chr12:29280418~29317848:-
HNSC	cis	rs4930561	0.714	rs7945995	ENSG00000184795.9	UNC93B5	-3.76	0.00019	0.0238	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68170835	chr11:67711702~67716005:-
HNSC	cis	rs4930561	0.714	rs7122250	ENSG00000184795.9	UNC93B5	-3.76	0.00019	0.0238	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68179005	chr11:67711702~67716005:-
HNSC	cis	rs4930561	0.714	rs11228151	ENSG00000184795.9	UNC93B5	-3.76	0.00019	0.0238	-0.2	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68181904	chr11:67711702~67716005:-
HNSC	cis	rs12047808	0.512	rs75869925	ENSG00000227141.2	RP11-545A16.3	-3.76	0.00019	0.0238	-0.28	-0.17	Multiple sclerosis (age of onset);	chr1:179276155	chr1:179586705~179589175:+
HNSC	cis	rs10484434	0.818	rs61289224	ENSG00000272462.2	U91328.19	3.76	0.00019	0.0238	0.22	0.17	HIV-1 viral setpoint;	chr6:26049068	chr6:25992662~26001775:+
HNSC	cis	rs72627123	0.5	rs67852564	ENSG00000259065.1	RP5-1021I20.1	-3.76	0.00019	0.0238	-0.24	-0.17	Morning vs. evening chronotype;	chr14:74093217	chr14:73787360~73803270:+
HNSC	cis	rs7927592	0.913	rs11228292	ENSG00000255031.4	RP11-802E16.3	3.76	0.00019	0.0238	0.15	0.17	Total body bone mineral density;	chr11:68612304	chr11:68050740~68053762:+
HNSC	cis	rs2013441	0.866	rs2703784	ENSG00000261033.1	RP11-209D14.2	3.76	0.00019	0.0238	0.2	0.17	Obesity-related traits;	chr17:20248007	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.866	rs2526471	ENSG00000261033.1	RP11-209D14.2	3.76	0.00019	0.0238	0.2	0.17	Obesity-related traits;	chr17:20248360	chr17:20008051~20009234:-
HNSC	cis	rs11700980	0.551	rs2832011	ENSG00000232855.5	AF131217.1	3.76	0.00019	0.0238	0.24	0.17	QRS complex (12-leadsum);	chr21:28738368	chr21:28439346~28674848:-
HNSC	cis	rs1595825	0.786	rs16826740	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198029203	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.786	rs79490184	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198029495	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.786	rs74484541	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198029499	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs10497810	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198031008	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs59990242	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198031144	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.838	rs73058883	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198031531	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs1992313	ENSG00000231621.1	AC013264.2	-3.76	0.00019	0.0238	-0.2	-0.17	Ulcerative colitis;	chr2:198032042	chr2:197197991~197199273:+
HNSC	cis	rs35079454	1	rs35079454	ENSG00000223653.4	RP11-131L23.1	3.76	0.00019	0.0238	0.24	0.17	Lobe attachment (rater-scored or self-reported);	chr1:85315181	chr1:85276715~85448124:+
HNSC	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-3.76	0.00019	0.0238	-0.2	-0.17	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-3.76	0.00019	0.0238	-0.2	-0.17	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
HNSC	cis	rs11157436	0.602	rs2032441	ENSG00000211814.1	TRAV35	-3.76	0.00019	0.0238	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22221896~22222475:+
HNSC	cis	rs757110	0.524	rs214067	ENSG00000260196.1	RP1-239B22.5	-3.76	0.00019	0.0238	-0.18	-0.17	Type 2 diabetes;	chr11:17284284	chr11:17380649~17383531:+
HNSC	cis	rs1925953	0.711	rs4926338	ENSG00000233589.1	RP4-694A7.2	-3.76	0.00019	0.0238	-0.22	-0.17	Vertical cup-disc ratio;	chr1:68379928	chr1:68479129~68483539:+
HNSC	cis	rs116095464	0.558	rs10057299	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:242020	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs13354585	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:242148	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs13356367	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:242280	chr5:262769~262881:+
HNSC	cis	rs116095464	0.85	rs10055295	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:243634	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10055354	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:243679	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs60251075	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:245177	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs62344300	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:246221	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10462754	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:246554	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10462755	ENSG00000277812.1	AC021087.1	3.76	0.00019	0.0238	0.29	0.17	Breast cancer;	chr5:246633	chr5:262769~262881:+
HNSC	cis	rs6540731	0.805	rs7530375	ENSG00000226251.4	RP11-15I11.3	-3.76	0.00019	0.0238	-0.2	-0.17	Intelligence (childhood);	chr1:212197963	chr1:212225278~212238977:-
HNSC	cis	rs6540731	0.595	rs61828662	ENSG00000226251.4	RP11-15I11.3	-3.76	0.00019	0.0238	-0.2	-0.17	Intelligence (childhood);	chr1:212198822	chr1:212225278~212238977:-
HNSC	cis	rs6540731	0.536	rs61828663	ENSG00000226251.4	RP11-15I11.3	-3.76	0.00019	0.0238	-0.2	-0.17	Intelligence (childhood);	chr1:212198823	chr1:212225278~212238977:-
HNSC	cis	rs6540731	0.84	rs11119879	ENSG00000226251.4	RP11-15I11.3	-3.76	0.00019	0.0238	-0.2	-0.17	Intelligence (childhood);	chr1:212199006	chr1:212225278~212238977:-
HNSC	cis	rs6540731	0.84	rs10863954	ENSG00000226251.4	RP11-15I11.3	-3.76	0.00019	0.0238	-0.2	-0.17	Intelligence (childhood);	chr1:212199944	chr1:212225278~212238977:-
HNSC	cis	rs73201462	1	rs2811526	ENSG00000231305.3	RP11-723O4.2	3.76	0.00019	0.0238	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128276875	chr3:128861313~128871540:-
HNSC	cis	rs73201462	0.908	rs2811373	ENSG00000231305.3	RP11-723O4.2	3.76	0.00019	0.0238	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128278586	chr3:128861313~128871540:-
HNSC	cis	rs7772486	0.686	rs702305	ENSG00000270638.1	RP3-466P17.1	-3.76	0.00019	0.0238	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs857875	ENSG00000270638.1	RP3-466P17.1	-3.76	0.00019	0.0238	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145735570~145737218:+
HNSC	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-3.76	0.00019	0.0238	-0.22	-0.17	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
HNSC	cis	rs2661868	0.918	rs2636314	ENSG00000232912.4	RP5-1115A15.1	-3.76	0.00019	0.0238	-0.22	-0.17	Life satisfaction;	chr1:8380583	chr1:8424645~8434838:+
HNSC	cis	rs2518049	1	rs1937849	ENSG00000224034.1	RP11-445P17.8	3.76	0.00019	0.0238	0.22	0.17	Metabolic traits;	chr10:5091647	chr10:5266033~5271236:-
HNSC	cis	rs10736390	0.538	rs72668296	ENSG00000233203.5	RP11-67L3.4	-3.76	0.00019	0.0238	-0.23	-0.17	Survival in pancreatic cancer;	chr1:54638682	chr1:54887563~54888850:+
HNSC	cis	rs2243480	1	rs3885839	ENSG00000164669.11	INTS4P1	3.76	0.00019	0.0238	0.34	0.17	Diabetic kidney disease;	chr7:65825416	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	3.76	0.00019	0.0238	0.34	0.17	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs73142122	ENSG00000164669.11	INTS4P1	3.76	0.00019	0.0238	0.34	0.17	Diabetic kidney disease;	chr7:65846311	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs73142137	ENSG00000164669.11	INTS4P1	3.76	0.00019	0.0238	0.34	0.17	Diabetic kidney disease;	chr7:65878455	chr7:65141225~65234216:+
HNSC	cis	rs4081724	0.565	rs12150908	ENSG00000267296.2	CEBPA-AS1	3.76	0.00019	0.0238	0.32	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33317239	chr19:33302857~33305054:+
HNSC	cis	rs2337406	0.925	rs11851094	ENSG00000211972.2	IGHV3-66	3.76	0.00019	0.0238	0.17	0.17	Alzheimer's disease (late onset);	chr14:106688967	chr14:106675017~106675544:-
HNSC	cis	rs10829156	0.732	rs4747348	ENSG00000240291.1	RP11-499P20.2	3.76	0.00019	0.0238	0.19	0.17	Sudden cardiac arrest;	chr10:18506126	chr10:18513115~18545651:-
HNSC	cis	rs7726839	0.54	rs3792720	ENSG00000225138.6	CTD-2228K2.7	3.76	0.00019	0.0238	0.26	0.17	Obesity-related traits;	chr5:642913	chr5:473236~480884:+
HNSC	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	3.76	0.00019	0.0238	0.17	0.17	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
HNSC	cis	rs1799949	0.602	rs8176235	ENSG00000236383.6	LINC00854	-3.76	0.00019	0.0238	-0.18	-0.17	Menopause (age at onset);	chr17:43067543	chr17:43216941~43305976:-
HNSC	cis	rs36093844	0.565	rs17744938	ENSG00000279742.1	RP11-700A24.1	-3.76	0.00019	0.0238	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965523	chr11:85852557~85854943:-
HNSC	cis	rs2462686	1	rs1534150	ENSG00000234536.1	AC096582.7	3.76	0.00019	0.0238	0.18	0.17	Major depressive disorder;	chr7:45945691	chr7:45773595~45783157:+
HNSC	cis	rs597539	0.617	rs672853	ENSG00000255741.1	RP11-757G1.5	-3.76	0.00019	0.0238	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68941503~68942852:-
HNSC	cis	rs72843506	0.722	rs78477504	ENSG00000189423.10	USP32P3	3.76	0.00019	0.0238	0.27	0.17	Schizophrenia;	chr17:20235034	chr17:20415547~20431008:+
HNSC	cis	rs67981189	0.613	rs4531677	ENSG00000274818.1	RP1-292L20.3	3.76	0.00019	0.0238	0.19	0.17	Schizophrenia;	chr14:70985144	chr14:70906657~70907111:-
HNSC	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	3.76	0.00019	0.0238	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
HNSC	cis	rs3736485	0.673	rs8033234	ENSG00000274528.1	CTD-2650P22.2	3.76	0.00019	0.0238	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51663920	chr15:52017167~52018032:-
HNSC	cis	rs12893668	0.572	rs2273175	ENSG00000269958.1	RP11-73M18.8	3.76	0.00019	0.0238	0.16	0.17	Reticulocyte count;	chr14:103693804	chr14:103696353~103697163:+
HNSC	cis	rs56804039	1	rs11777086	ENSG00000254153.1	CTA-398F10.2	-3.76	0.00019	0.0238	-0.22	-0.17	Cervical cancer;	chr8:8526969	chr8:8456909~8461337:-
HNSC	cis	rs911555	0.755	rs11620897	ENSG00000244691.1	RPL10AP1	-3.76	0.00019	0.0238	-0.21	-0.17	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103412119~103412761:-
HNSC	cis	rs8014204	0.604	rs11625594	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0239	0.19	0.17	Caffeine consumption;	chr14:74923130	chr14:75127153~75136930:+
HNSC	cis	rs7224668	0.647	rs7219316	ENSG00000280407.2	RP13-516M14.8	3.76	0.00019	0.0239	0.14	0.17	IgG glycosylation;	chr17:81274520	chr17:82249067~82251844:+
HNSC	cis	rs11231017	0.507	rs10792346	ENSG00000250659.2	RP11-864I4.3	3.76	0.00019	0.0239	0.22	0.17	HIV-1 viral setpoint;	chr11:62372597	chr11:62537312~62542018:+
HNSC	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	3.76	0.00019	0.0239	0.16	0.17	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
HNSC	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	3.76	0.00019	0.0239	0.16	0.17	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
HNSC	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-3.76	0.00019	0.0239	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
HNSC	cis	rs6840360	0.642	rs2724578	ENSG00000251611.1	RP11-610P16.1	-3.76	0.000191	0.0239	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.574	rs2709844	ENSG00000251611.1	RP11-610P16.1	-3.76	0.000191	0.0239	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151407551~151408835:-
HNSC	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	3.76	0.000191	0.0239	0.23	0.17	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
HNSC	cis	rs1665050	0.534	rs8031213	ENSG00000277144.1	RP11-59H7.4	-3.76	0.000191	0.0239	-0.21	-0.17	Atopic dermatitis;	chr15:58947698	chr15:59115547~59116089:-
HNSC	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	3.76	0.000191	0.0239	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
HNSC	cis	rs7475343	0.543	rs117849125	ENSG00000224034.1	RP11-445P17.8	-3.76	0.000191	0.0239	-0.24	-0.17	Intelligence;	chr10:5219866	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.543	rs117146235	ENSG00000224034.1	RP11-445P17.8	-3.76	0.000191	0.0239	-0.24	-0.17	Intelligence;	chr10:5219867	chr10:5266033~5271236:-
HNSC	cis	rs6657613	0.621	rs11578903	ENSG00000186715.9	MST1L	-3.76	0.000191	0.0239	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17051461	chr1:16754910~16770237:-
HNSC	cis	rs394563	0.601	rs432582	ENSG00000216906.2	RP11-350J20.9	3.76	0.000191	0.0239	0.22	0.17	Dupuytren's disease;	chr6:149473007	chr6:149904243~149906418:+
HNSC	cis	rs7735319	0.966	rs3860754	ENSG00000250697.1	CTD-2066L21.3	-3.76	0.000191	0.0239	-0.2	-0.17	Systolic blood pressure;	chr5:33149343	chr5:32925639~33297910:-
HNSC	cis	rs6928977	0.863	rs9389286	ENSG00000231028.7	LINC00271	3.76	0.000191	0.0239	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135319827	chr6:135497801~135716055:+
HNSC	cis	rs7555523	0.673	rs4657472	ENSG00000224358.1	RP11-466F5.8	-3.76	0.000191	0.0239	-0.28	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717722	chr1:165768929~165775176:+
HNSC	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	3.76	0.000191	0.0239	0.17	0.17	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000191	0.0239	-0.2	-0.17	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
HNSC	cis	rs865483	0.764	rs113593735	ENSG00000276054.1	RP11-378E13.3	-3.76	0.000191	0.0239	-0.21	-0.17	Monocyte count;	chr17:37398591	chr17:37386886~37387926:+
HNSC	cis	rs2032447	0.832	rs10425	ENSG00000272462.2	U91328.19	-3.76	0.000191	0.0239	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26056321	chr6:25992662~26001775:+
HNSC	cis	rs6088580	0.634	rs4911418	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6579165	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs4911419	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.561	rs3761147	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs4911421	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs4911422	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000191	0.0239	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:33985617~33988989:-
HNSC	cis	rs9487051	0.802	rs6568558	ENSG00000219700.1	PTCHD3P3	3.76	0.000191	0.0239	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109271498	chr6:109288571~109290503:-
HNSC	cis	rs889398	0.771	rs3790080	ENSG00000196696.11	PDXDC2P	-3.76	0.000191	0.0239	-0.12	-0.17	Body mass index;	chr16:69868236	chr16:69976297~70065948:-
HNSC	cis	rs7189233	0.531	rs8062535	ENSG00000261056.2	RP11-454F8.2	-3.76	0.000191	0.0239	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53298224~53299792:+
HNSC	cis	rs8054556	0.76	rs12598856	ENSG00000261367.1	RP11-455F5.4	-3.76	0.000191	0.0239	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30107675~30110541:+
HNSC	cis	rs1859596	1	rs1859596	ENSG00000234456.6	MAGI2-AS3	-3.76	0.000191	0.0239	-0.13	-0.17	Reading or mathematical ability;	chr7:79480326	chr7:79452877~79471208:+
HNSC	cis	rs4840086	1	rs10485227	ENSG00000219755.1	RP1-199J3.5	-3.76	0.000191	0.0239	-0.21	-0.17	Menarche (age at onset);	chr6:99759451	chr6:99575712~99576456:+
HNSC	cis	rs683257	0.673	rs72990126	ENSG00000234147.1	RP3-460G2.2	-3.76	0.000191	0.0239	-0.3	-0.17	Facial emotion recognition (angry faces);	chr6:140850534	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.636	rs6934165	ENSG00000234147.1	RP3-460G2.2	-3.76	0.000191	0.0239	-0.3	-0.17	Facial emotion recognition (angry faces);	chr6:140851191	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.636	rs56295525	ENSG00000234147.1	RP3-460G2.2	-3.76	0.000191	0.0239	-0.3	-0.17	Facial emotion recognition (angry faces);	chr6:140853380	chr6:140845958~140852924:-
HNSC	cis	rs9910055	0.659	rs8079310	ENSG00000267080.4	ASB16-AS1	-3.76	0.000191	0.0239	-0.14	-0.17	Total body bone mineral density;	chr17:44192923	chr17:44175973~44186717:-
HNSC	cis	rs1642645	0.872	rs639559	ENSG00000228452.1	RP5-994D16.9	-3.76	0.000191	0.0239	-0.24	-0.17	Left ventricular obstructive tract defect (maternal effect);	chr1:41959825	chr1:42775813~42776790:-
HNSC	cis	rs442309	0.875	rs224147	ENSG00000238280.1	RP11-436D10.3	3.76	0.000191	0.0239	0.2	0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62726055	chr10:62793562~62805887:-
HNSC	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-3.76	0.000191	0.0239	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
HNSC	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	3.76	0.000191	0.0239	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
HNSC	cis	rs6575836	0.571	rs17100016	ENSG00000259031.1	CTD-2062F14.3	3.76	0.000191	0.0239	0.3	0.17	Tuberculosis;	chr14:101203059	chr14:100538939~100540409:+
HNSC	cis	rs9300255	0.602	rs1617434	ENSG00000280120.1	RP11-546D6.3	3.76	0.000191	0.0239	0.16	0.17	Neutrophil percentage of white cells;	chr12:123164939	chr12:123152324~123153377:-
HNSC	cis	rs1185460	0.967	rs11217137	ENSG00000272186.1	RP11-110I1.13	-3.76	0.000191	0.0239	-0.2	-0.17	Coronary artery disease;	chr11:119060319	chr11:119067374~119067698:-
HNSC	cis	rs6568686	0.735	rs7762054	ENSG00000255389.1	C6orf3	3.76	0.000191	0.0239	0.22	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111549539	chr6:111599875~111602295:+
HNSC	cis	rs6740322	0.748	rs13402621	ENSG00000234936.1	AC010883.5	3.76	0.000191	0.0239	0.19	0.17	Coronary artery disease;	chr2:43231472	chr2:43229573~43233394:+
HNSC	cis	rs10435719	0.764	rs10103485	ENSG00000227888.4	FAM66A	3.76	0.000191	0.0239	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:12362019~12388296:+
HNSC	cis	rs270601	0.817	rs460089	ENSG00000233006.5	AC034220.3	3.76	0.000191	0.0239	0.2	0.17	Acylcarnitine levels;	chr5:132294079	chr5:132311285~132369916:-
HNSC	cis	rs9611565	0.659	rs9611609	ENSG00000235513.1	RP4-756G23.5	3.76	0.000191	0.0239	0.2	0.17	Vitiligo;	chr22:41549353	chr22:41209122~41217627:-
HNSC	cis	rs225675	0.739	rs225629	ENSG00000229017.5	LINC01277	3.76	0.000191	0.0239	0.21	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142152824	chr6:142966421~143038077:-
HNSC	cis	rs2307394	0.714	rs4972270	ENSG00000281469.1	RP11-567F11.1	3.76	0.000191	0.0239	0.19	0.17	Urate levels;	chr2:147785762	chr2:148044380~148044894:+
HNSC	cis	rs6732189	0.74	rs1026236	ENSG00000279844.1	RP11-20F18.1	-3.76	0.000191	0.0239	-0.17	-0.17	Educational attainment;	chr2:160748915	chr2:160849313~160850676:-
HNSC	cis	rs6787172	0.622	rs11718056	ENSG00000272087.1	RP11-379F4.7	3.76	0.000191	0.0239	0.18	0.17	Subjective well-being;	chr3:158375204	chr3:158693120~158693768:-
HNSC	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-3.76	0.000191	0.0239	-0.19	-0.17	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
HNSC	cis	rs12208357	1	rs112201728	ENSG00000213073.4	RP11-288H12.3	3.76	0.000191	0.0239	0.36	0.17	Cholesterol, total;	chr6:160130454	chr6:160093082~160096212:+
HNSC	cis	rs1513670	0.785	rs35174738	ENSG00000260793.2	RP5-882C2.2	3.76	0.000191	0.0239	0.15	0.17	Bone mineral density (hip);	chr17:43740056	chr17:44221401~44223710:+
HNSC	cis	rs2243480	0.901	rs778732	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000191	0.0239	0.29	0.17	Diabetic kidney disease;	chr7:66357373	chr7:66025126~66031544:-
HNSC	cis	rs924712	0.521	rs4712073	ENSG00000224984.1	RP11-524H19.2	-3.76	0.000191	0.0239	-0.2	-0.17	Breast cancer;	chr6:54808429	chr6:54840118~54840855:-
HNSC	cis	rs870825	0.929	rs1405940	ENSG00000254233.1	RP11-242J7.1	3.76	0.000191	0.024	0.28	0.17	Blood protein levels;	chr4:184670327	chr4:184584093~184625030:-
HNSC	cis	rs3750965	0.806	rs7107680	ENSG00000265539.1	MIR3164	-3.76	0.000191	0.024	-0.19	-0.17	Hair color;	chr11:69092426	chr11:69083176~69083258:+
HNSC	cis	rs60695258	0.55	rs388401	ENSG00000251411.1	RP11-397E7.4	3.76	0.000191	0.024	0.18	0.17	Hematocrit;	chr4:87053263	chr4:86913266~86914817:-
HNSC	cis	rs6964587	0.869	rs6964050	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000191	0.024	0.18	0.17	Breast cancer;	chr7:91853104	chr7:92134604~92180725:+
HNSC	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-3.76	0.000191	0.024	-0.27	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
HNSC	cis	rs28489187	0.706	rs2300637	ENSG00000223653.4	RP11-131L23.1	3.76	0.000192	0.024	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85357089	chr1:85276715~85448124:+
HNSC	cis	rs4906332	0.966	rs17679729	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103457975	chr14:103412119~103412761:-
HNSC	cis	rs4906332	0.933	rs35999760	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103458144	chr14:103412119~103412761:-
HNSC	cis	rs4906332	0.966	rs12185021	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103461468	chr14:103412119~103412761:-
HNSC	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-3.76	0.000192	0.024	-0.13	-0.17	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
HNSC	cis	rs17404153	0.599	rs10490863	ENSG00000248724.5	NPHP3-AS1	-3.76	0.000192	0.024	-0.29	-0.17	LDL cholesterol;HDL cholesterol;	chr3:132412118	chr3:132721750~132874223:+
HNSC	cis	rs72827839	1	rs72827839	ENSG00000210741.1	MIR196A1	-3.76	0.000192	0.024	-0.25	-0.17	Ease of getting up in the morning;	chr17:48343634	chr17:48632490~48632559:-
HNSC	cis	rs7429990	0.864	rs12495520	ENSG00000228638.1	FCF1P2	3.76	0.000192	0.024	0.16	0.17	Educational attainment (years of education);	chr3:47766269	chr3:48290793~48291375:-
HNSC	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	3.76	0.000192	0.024	0.29	0.17	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
HNSC	cis	rs10783487	0.749	rs11169998	ENSG00000257542.4	OR7E47P	-3.76	0.000192	0.024	-0.21	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52092733	chr12:52079696~52108261:+
HNSC	cis	rs911555	0.57	rs11625397	ENSG00000269910.1	RP11-73M18.10	-3.76	0.000192	0.024	-0.16	-0.17	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694516~103695050:-
HNSC	cis	rs17250963	0.645	rs153931	ENSG00000249485.1	RBBP4P1	-3.76	0.000192	0.024	-0.17	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14742193	chr5:14797125~14798400:-
HNSC	cis	rs73201462	1	rs2955100	ENSG00000231305.3	RP11-723O4.2	3.76	0.000192	0.024	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274482	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999062	ENSG00000231305.3	RP11-723O4.2	3.76	0.000192	0.024	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274763	chr3:128861313~128871540:-
HNSC	cis	rs5758511	0.689	rs17478227	ENSG00000227370.1	RP4-669P10.19	-3.76	0.000192	0.024	-0.23	-0.17	Birth weight;	chr22:42258321	chr22:42132543~42132998:+
HNSC	cis	rs12655019	0.92	rs7725377	ENSG00000265665.1	AC008391.1	3.76	0.000192	0.024	0.33	0.17	Breast cancer (early onset);	chr5:56960769	chr5:56457038~56457138:-
HNSC	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-3.76	0.000192	0.024	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
HNSC	cis	rs793571	0.779	rs8026474	ENSG00000245975.2	RP11-30K9.6	3.76	0.000192	0.024	0.29	0.17	Schizophrenia;	chr15:58978423	chr15:58768072~58770974:-
HNSC	cis	rs62005083	0.541	rs61059815	ENSG00000259065.1	RP5-1021I20.1	-3.76	0.000192	0.024	-0.25	-0.17	Mean corpuscular volume;	chr14:74069762	chr14:73787360~73803270:+
HNSC	cis	rs2948294	0.545	rs11776397	ENSG00000254153.1	CTA-398F10.2	3.76	0.000192	0.024	0.2	0.17	Red cell distribution width;	chr8:8257639	chr8:8456909~8461337:-
HNSC	cis	rs35000415	0.938	rs12536266	ENSG00000244556.1	ODCP	3.76	0.000192	0.024	0.34	0.17	Systemic lupus erythematosus;	chr7:128970981	chr7:129028889~129030527:+
HNSC	cis	rs853679	0.546	rs35353359	ENSG00000226314.6	ZNF192P1	-3.76	0.000192	0.024	-0.33	-0.17	Depression;	chr6:28356601	chr6:28161781~28169594:+
HNSC	cis	rs28489187	0.706	rs12124170	ENSG00000223653.4	RP11-131L23.1	3.76	0.000192	0.024	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85345499	chr1:85276715~85448124:+
HNSC	cis	rs6570726	0.818	rs9399555	ENSG00000270638.1	RP3-466P17.1	3.76	0.000192	0.024	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs441290	ENSG00000270638.1	RP3-466P17.1	3.76	0.000192	0.024	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145735570~145737218:+
HNSC	cis	rs17253792	0.915	rs75862063	ENSG00000186615.9	KTN1-AS1	-3.76	0.000192	0.024	-0.35	-0.17	Putamen volume;	chr14:55711051	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs77161327	ENSG00000186615.9	KTN1-AS1	-3.76	0.000192	0.024	-0.35	-0.17	Putamen volume;	chr14:55711847	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs28663681	ENSG00000186615.9	KTN1-AS1	-3.76	0.000192	0.024	-0.35	-0.17	Putamen volume;	chr14:55712102	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs79100824	ENSG00000186615.9	KTN1-AS1	-3.76	0.000192	0.024	-0.35	-0.17	Putamen volume;	chr14:55712888	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.915	rs79894275	ENSG00000186615.9	KTN1-AS1	-3.76	0.000192	0.024	-0.35	-0.17	Putamen volume;	chr14:55713567	chr14:55499278~55580110:-
HNSC	cis	rs7735319	0.966	rs16890746	ENSG00000250697.1	CTD-2066L21.3	3.76	0.000192	0.024	0.21	0.17	Systolic blood pressure;	chr5:33118567	chr5:32925639~33297910:-
HNSC	cis	rs853679	0.517	rs9380052	ENSG00000219891.2	ZSCAN12P1	3.76	0.000192	0.024	0.24	0.17	Depression;	chr6:28096845	chr6:28091154~28093664:+
HNSC	cis	rs1476670	0.565	rs942756	ENSG00000230615.5	RP5-1198O20.4	-3.76	0.000192	0.024	-0.2	-0.17	Eotaxin levels;	chr1:44056602	chr1:44030443~44115913:+
HNSC	cis	rs7714670	1	rs13172686	ENSG00000184084.7	CTD-2372A4.1	-3.76	0.000192	0.024	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73777599	chr5:73803296~73803599:-
HNSC	cis	rs3736485	0.932	rs8037167	ENSG00000274528.1	CTD-2650P22.2	3.76	0.000192	0.024	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51625929	chr15:52017167~52018032:-
HNSC	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-3.76	0.000192	0.024	-0.22	-0.17	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
HNSC	cis	rs17489649	0.911	rs2269205	ENSG00000271849.1	CTC-332L22.1	3.76	0.000192	0.024	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109786878	chr5:109687802~109688329:-
HNSC	cis	rs495337	0.76	rs624115	ENSG00000229222.1	KRT18P4	-3.76	0.000192	0.024	-0.19	-0.17	Psoriasis;	chr20:49907091	chr20:49956745~49958032:+
HNSC	cis	rs853679	0.599	rs149949	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000192	0.024	-0.28	-0.17	Depression;	chr6:28043738	chr6:28115628~28116551:+
HNSC	cis	rs7771547	0.642	rs629560	ENSG00000219023.1	RP3-340B19.2	3.76	0.000192	0.024	0.16	0.17	Platelet distribution width;	chr6:36543614	chr6:35555873~35556264:+
HNSC	cis	rs61990749	0.597	rs8016447	ENSG00000239272.1	RPL21P10	3.76	0.000192	0.024	0.25	0.17	Fibroblast growth factor basic levels;	chr14:77755725	chr14:77683202~77683989:-
HNSC	cis	rs4906332	1	rs17617935	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103486549	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs17680085	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103486817	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs12896919	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103490376	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs35126287	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103493095	chr14:103412119~103412761:-
HNSC	cis	rs4906332	1	rs55930273	ENSG00000244691.1	RPL10AP1	-3.76	0.000192	0.024	-0.2	-0.17	Coronary artery disease;	chr14:103493961	chr14:103412119~103412761:-
HNSC	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	3.76	0.000192	0.024	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
HNSC	cis	rs58873874	0.579	rs10040318	ENSG00000251405.2	CTB-109A12.1	3.76	0.000192	0.024	0.32	0.17	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157362615~157460078:-
HNSC	cis	rs72717009	0.825	rs7552317	ENSG00000225217.1	HSPA7	-3.76	0.000192	0.024	-0.28	-0.17	Rheumatoid arthritis;	chr1:161509648	chr1:161606291~161608217:+
HNSC	cis	rs61160187	0.582	rs12653132	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000192	0.024	-0.18	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60866457~60866935:-
HNSC	cis	rs2279168	0.867	rs7173944	ENSG00000259407.1	RP11-158M2.3	3.76	0.000192	0.024	0.28	0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85536226	chr15:85744109~85750281:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000232546.1	RP11-458F8.1	-3.76	0.000192	0.024	-0.25	-0.17	Diabetic kidney disease;	chr7:66073444	chr7:66848496~66858136:+
HNSC	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	3.76	0.000192	0.024	0.17	0.17	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
HNSC	cis	rs7243790	1	rs10502990	ENSG00000277324.1	RP11-850A17.1	3.76	0.000192	0.0241	0.2	0.17	Diastolic blood pressure;	chr18:54438168	chr18:54268346~54270028:-
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000270326.1	RP5-874C20.6	-3.76	0.000192	0.0241	-0.24	-0.17	Depression;	chr6:28241324	chr6:28319660~28319852:-
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000270326.1	RP5-874C20.6	-3.76	0.000192	0.0241	-0.24	-0.17	Depression;	chr6:28241753	chr6:28319660~28319852:-
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000270326.1	RP5-874C20.6	-3.76	0.000192	0.0241	-0.24	-0.17	Depression;	chr6:28242515	chr6:28319660~28319852:-
HNSC	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-3.76	0.000192	0.0241	-0.25	-0.17	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
HNSC	cis	rs12899811	0.512	rs7164916	ENSG00000213471.7	TTLL13P	-3.76	0.000192	0.0241	-0.21	-0.17	Type 2 diabetes;	chr15:91018216	chr15:90249530~90265482:+
HNSC	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
HNSC	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	3.76	0.000193	0.0241	0.21	0.17	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
HNSC	cis	rs867371	0.502	rs8025964	ENSG00000259429.4	UBE2Q2P2	-3.76	0.000193	0.0241	-0.16	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82355142~82420075:+
HNSC	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-3.76	0.000193	0.0241	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
HNSC	cis	rs2247572	0.778	rs2253667	ENSG00000250295.5	RP11-434I12.2	3.76	0.000193	0.0241	0.22	0.17	Cognitive performance;	chr8:72740413	chr8:73297711~73356461:-
HNSC	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	3.76	0.000193	0.0241	0.25	0.17	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
HNSC	cis	rs160451	0.739	rs218904	ENSG00000251136.7	RP11-37B2.1	-3.76	0.000193	0.0241	-0.16	-0.17	Leprosy;	chr8:89722278	chr8:89609409~89757727:-
HNSC	cis	rs4906332	0.966	rs2065016	ENSG00000244691.1	RPL10AP1	-3.76	0.000193	0.0241	-0.2	-0.17	Coronary artery disease;	chr14:103413319	chr14:103412119~103412761:-
HNSC	cis	rs4835473	0.9	rs12503074	ENSG00000249741.2	RP11-673E1.3	3.76	0.000193	0.0241	0.19	0.17	Immature fraction of reticulocytes;	chr4:143812560	chr4:143911514~143912053:-
HNSC	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-3.76	0.000193	0.0241	-0.24	-0.17	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
HNSC	cis	rs5770917	1	rs8137478	ENSG00000272821.1	CTA-384D8.36	-3.76	0.000193	0.0241	-0.26	-0.17	Narcolepsy;	chr22:50578867	chr22:50523926~50524780:+
HNSC	cis	rs250677	0.687	rs36044	ENSG00000250072.4	CTC-529P8.1	-3.76	0.000193	0.0241	-0.22	-0.17	Breast cancer;	chr5:149061565	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs36046	ENSG00000250072.4	CTC-529P8.1	-3.76	0.000193	0.0241	-0.22	-0.17	Breast cancer;	chr5:149061694	chr5:149063317~149109787:+
HNSC	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	3.76	0.000193	0.0241	0.19	0.17	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
HNSC	cis	rs8062405	1	rs12444171	ENSG00000261089.1	RP11-435I10.3	3.76	0.000193	0.0241	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs56404918	ENSG00000261089.1	RP11-435I10.3	3.76	0.000193	0.0241	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs55719896	ENSG00000261089.1	RP11-435I10.3	3.76	0.000193	0.0241	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28413703~28415018:+
HNSC	cis	rs6088590	0.582	rs6059909	ENSG00000276073.1	RP5-1125A11.7	-3.76	0.000193	0.0241	-0.18	-0.17	Coronary artery disease;	chr20:34551887	chr20:33985617~33988989:-
HNSC	cis	rs61160187	0.582	rs56284222	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000193	0.0241	-0.18	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60866457~60866935:-
HNSC	cis	rs1865760	0.515	rs2003208	ENSG00000272810.1	U91328.22	-3.76	0.000193	0.0241	-0.15	-0.17	Height;	chr6:25940491	chr6:26013241~26013757:+
HNSC	cis	rs61160187	0.582	rs67555188	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000193	0.0241	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.582	rs67858932	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000193	0.0241	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60866457~60866935:-
HNSC	cis	rs2030746	0.899	rs2030745	ENSG00000237614.1	AC073257.2	-3.76	0.000193	0.0241	-0.2	-0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551706	chr2:120542909~120544326:-
HNSC	cis	rs12188164	0.515	rs2672744	ENSG00000225138.6	CTD-2228K2.7	-3.76	0.000193	0.0241	-0.2	-0.17	Cystic fibrosis severity;	chr5:410932	chr5:473236~480884:+
HNSC	cis	rs16852403	0.505	rs316270	ENSG00000273062.1	RP11-428K3.1	-3.76	0.000193	0.0241	-0.19	-0.17	Childhood ear infection;	chr1:178195622	chr1:178724306~178726285:-
HNSC	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-3.76	0.000193	0.0241	-0.17	-0.17	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
HNSC	cis	rs73201462	1	rs6765233	ENSG00000231305.3	RP11-723O4.2	3.76	0.000193	0.0241	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128284007	chr3:128861313~128871540:-
HNSC	cis	rs755249	0.53	rs112205225	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0241	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39522280~39546187:-
HNSC	cis	rs1925953	0.711	rs4309020	ENSG00000233589.1	RP4-694A7.2	-3.76	0.000193	0.0241	-0.22	-0.17	Vertical cup-disc ratio;	chr1:68366479	chr1:68479129~68483539:+
HNSC	cis	rs56804039	1	rs59620654	ENSG00000254153.1	CTA-398F10.2	-3.76	0.000193	0.0241	-0.22	-0.17	Cervical cancer;	chr8:8525122	chr8:8456909~8461337:-
HNSC	cis	rs56804039	1	rs34154295	ENSG00000254153.1	CTA-398F10.2	-3.76	0.000193	0.0241	-0.22	-0.17	Cervical cancer;	chr8:8525967	chr8:8456909~8461337:-
HNSC	cis	rs7720894	0.967	rs11954859	ENSG00000215032.2	GNL3LP1	-3.76	0.000193	0.0241	-0.19	-0.17	Body mass index;	chr5:61329131	chr5:60891935~60893577:-
HNSC	cis	rs3096299	0.967	rs2911253	ENSG00000224888.4	RP5-1142A6.2	3.76	0.000193	0.0241	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:88731180~88741425:+
HNSC	cis	rs1124609	1	rs111705530	ENSG00000244879.4	GABPB1-AS1	3.76	0.000193	0.0241	0.24	0.17	Subjective well-being;	chr15:50186235	chr15:50354959~50372202:+
HNSC	cis	rs9467711	0.606	rs1978	ENSG00000241549.7	GUSBP2	3.76	0.000193	0.0241	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377345	chr6:26871484~26956554:-
HNSC	cis	rs6860540	0.796	rs55635824	ENSG00000251405.2	CTB-109A12.1	-3.76	0.000193	0.0241	-0.2	-0.17	Inflammatory skin disease;	chr5:157466414	chr5:157362615~157460078:-
HNSC	cis	rs8010715	0.816	rs762093	ENSG00000259321.1	RP11-468E2.5	3.76	0.000193	0.0241	0.15	0.17	IgG glycosylation;	chr14:24122709	chr14:24139445~24140444:+
HNSC	cis	rs35146811	0.695	rs1618851	ENSG00000235077.1	AC073842.19	-3.76	0.000193	0.0241	-0.21	-0.17	Coronary artery disease;	chr7:100213020	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs1727130	ENSG00000235077.1	AC073842.19	-3.76	0.000193	0.0241	-0.21	-0.17	Coronary artery disease;	chr7:100213841	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs1636975	ENSG00000235077.1	AC073842.19	-3.76	0.000193	0.0241	-0.21	-0.17	Coronary artery disease;	chr7:100214466	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.695	rs1727132	ENSG00000235077.1	AC073842.19	-3.76	0.000193	0.0241	-0.21	-0.17	Coronary artery disease;	chr7:100214674	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs1727133	ENSG00000235077.1	AC073842.19	-3.76	0.000193	0.0241	-0.21	-0.17	Coronary artery disease;	chr7:100215247	chr7:100130964~100140439:+
HNSC	cis	rs720475	0.732	rs62483106	ENSG00000170356.8	OR2A20P	3.76	0.000193	0.0241	0.24	0.17	Breast cancer;	chr7:144439533	chr7:144250045~144252957:-
HNSC	cis	rs34286592	0.929	rs11864180	ENSG00000214725.6	CDIPT-AS1	-3.76	0.000193	0.0241	-0.24	-0.17	Multiple sclerosis;	chr16:29819508	chr16:29863593~29868053:+
HNSC	cis	rs9467773	0.572	rs2076029	ENSG00000241549.7	GUSBP2	3.76	0.000193	0.0242	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26390602	chr6:26871484~26956554:-
HNSC	cis	rs2834288	1	rs2834288	ENSG00000273102.1	AP000569.9	3.76	0.000193	0.0242	0.18	0.17	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33967101~33968573:-
HNSC	cis	rs1937680	0.613	rs10823818	ENSG00000236671.6	PRKG1-AS1	-3.76	0.000193	0.0242	-0.24	-0.17	Breast cancer;	chr10:51886930	chr10:52230742~52314128:-
HNSC	cis	rs73201462	0.901	rs2955133	ENSG00000231305.3	RP11-723O4.2	3.76	0.000193	0.0242	0.25	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128226479	chr3:128861313~128871540:-
HNSC	cis	rs9836270	0.533	rs7645134	ENSG00000242899.1	RPL7P16	-3.76	0.000193	0.0242	-0.2	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:132268136	chr3:132243528~132244265:-
HNSC	cis	rs4919687	0.55	rs7907503	ENSG00000236937.2	PTGES3P4	3.76	0.000193	0.0242	0.22	0.17	Colorectal cancer;	chr10:102680293	chr10:102845595~102845950:+
HNSC	cis	rs10791097	0.608	rs12363140	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874373	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs61910787	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874578	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs12361892	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874595	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.667	rs12363163	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874614	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs11222369	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874775	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs11222370	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130874872	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.668	rs10791102	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130875082	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs7926167	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130875150	chr11:130844191~130865561:-
HNSC	cis	rs10791097	0.694	rs7940027	ENSG00000254842.5	RP11-890B15.2	-3.76	0.000194	0.0242	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130875696	chr11:130844191~130865561:-
HNSC	cis	rs7561149	0.528	rs10497523	ENSG00000270574.1	RP11-171I2.2	-3.76	0.000194	0.0242	-0.21	-0.17	QT interval;	chr2:178788075	chr2:178578790~178580906:+
HNSC	cis	rs67981189	0.574	rs2810118	ENSG00000274818.1	RP1-292L20.3	-3.76	0.000194	0.0242	-0.19	-0.17	Schizophrenia;	chr14:70921858	chr14:70906657~70907111:-
HNSC	cis	rs12935418	0.672	rs9888895	ENSG00000278985.1	RP11-303E16.9	3.76	0.000194	0.0242	0.17	0.17	Mean corpuscular volume;	chr16:81017496	chr16:80982319~80984094:-
HNSC	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-3.76	0.000194	0.0242	-0.18	-0.17	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
HNSC	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	3.76	0.000194	0.0242	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
HNSC	cis	rs1620921	0.657	rs7383363	ENSG00000233342.1	RP11-235G24.3	-3.76	0.000194	0.0242	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160853930	chr6:160926369~160927162:+
HNSC	cis	rs6545883	0.965	rs12713439	ENSG00000271889.1	RP11-493E12.1	3.76	0.000194	0.0242	0.2	0.17	Tuberculosis;	chr2:61525019	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.965	rs7421663	ENSG00000271889.1	RP11-493E12.1	3.76	0.000194	0.0242	0.2	0.17	Tuberculosis;	chr2:61526651	chr2:61151433~61162105:-
HNSC	cis	rs4144743	0.941	rs7211563	ENSG00000228782.6	CTD-2026D20.3	-3.76	0.000194	0.0242	-0.2	-0.17	Body mass index;	chr17:47246695	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.941	rs7222617	ENSG00000228782.6	CTD-2026D20.3	-3.76	0.000194	0.0242	-0.2	-0.17	Body mass index;	chr17:47246714	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.877	rs7218773	ENSG00000228782.6	CTD-2026D20.3	-3.76	0.000194	0.0242	-0.2	-0.17	Body mass index;	chr17:47246845	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs7223003	ENSG00000228782.6	CTD-2026D20.3	-3.76	0.000194	0.0242	-0.2	-0.17	Body mass index;	chr17:47246927	chr17:47450568~47492492:-
HNSC	cis	rs9313772	0.928	rs2149954	ENSG00000254350.1	RP11-542A14.1	-3.76	0.000194	0.0242	-0.19	-0.17	Blood pressure;	chr5:158393594	chr5:158424585~158452758:+
HNSC	cis	rs453301	0.624	rs7014430	ENSG00000253981.4	ALG1L13P	3.76	0.000194	0.0242	0.19	0.17	Joint mobility (Beighton score);	chr8:8970227	chr8:8236003~8244667:-
HNSC	cis	rs7819412	0.54	rs2409725	ENSG00000255310.2	AF131215.2	-3.76	0.000194	0.0242	-0.17	-0.17	Triglycerides;	chr8:11184152	chr8:11107788~11109726:-
HNSC	cis	rs3733585	0.631	rs4697707	ENSG00000250413.1	RP11-448G15.1	3.76	0.000194	0.0242	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10118163	chr4:10006482~10009725:+
HNSC	cis	rs9929218	0.551	rs9888942	ENSG00000260459.2	FTLP14	3.76	0.000194	0.0242	0.22	0.17	Colorectal cancer;	chr16:68693669	chr16:68822587~68823070:+
HNSC	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	3.76	0.000194	0.0242	0.24	0.17	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
HNSC	cis	rs860295	0.702	rs3892792	ENSG00000225855.5	RUSC1-AS1	3.76	0.000194	0.0242	0.12	0.17	Body mass index;	chr1:155588874	chr1:155316863~155324176:-
HNSC	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-3.76	0.000194	0.0242	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
HNSC	cis	rs910316	0.967	rs175432	ENSG00000279594.1	RP11-950C14.10	-3.76	0.000194	0.0242	-0.2	-0.17	Height;	chr14:75148543	chr14:75011269~75012851:-
HNSC	cis	rs4906332	1	rs3783397	ENSG00000244691.1	RPL10AP1	-3.76	0.000194	0.0242	-0.2	-0.17	Coronary artery disease;	chr14:103480952	chr14:103412119~103412761:-
HNSC	cis	rs4787491	0.729	rs7191849	ENSG00000250616.2	RP11-455F5.3	3.76	0.000194	0.0242	0.17	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30096430~30104116:+
HNSC	cis	rs16958440	0.867	rs57744138	ENSG00000267724.1	RP11-49K24.8	3.76	0.000194	0.0242	0.34	0.17	Sitting height ratio;	chr18:47174111	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs16949275	ENSG00000267724.1	RP11-49K24.8	3.76	0.000194	0.0242	0.34	0.17	Sitting height ratio;	chr18:47174332	chr18:47105946~47108062:+
HNSC	cis	rs60617249	0.801	rs2189819	ENSG00000228204.2	RP4-724E13.2	3.76	0.000194	0.0242	0.18	0.17	Major depression and alcohol dependence;	chr7:50937365	chr7:50866747~51022990:+
HNSC	cis	rs2657294	0.965	rs7899946	ENSG00000233313.2	HMGA1P5	-3.76	0.000194	0.0242	-0.19	-0.17	Pneumonia;	chr10:75166013	chr10:75276376~75276646:-
HNSC	cis	rs10742752	0.651	rs35072015	ENSG00000254651.1	RP11-430H10.3	3.76	0.000194	0.0242	0.21	0.17	Body mass index;	chr11:45405378	chr11:45399448~45400528:+
HNSC	cis	rs12188164	0.686	rs72711369	ENSG00000215246.5	RP11-43F13.3	-3.76	0.000194	0.0242	-0.2	-0.17	Cystic fibrosis severity;	chr5:420402	chr5:987180~997308:-
HNSC	cis	rs12188164	0.686	rs72711370	ENSG00000215246.5	RP11-43F13.3	-3.76	0.000194	0.0242	-0.2	-0.17	Cystic fibrosis severity;	chr5:420942	chr5:987180~997308:-
HNSC	cis	rs933688	1	rs11959525	ENSG00000281357.1	ARRDC3-AS1	3.76	0.000194	0.0242	0.25	0.17	Smoking behavior;	chr5:91408023	chr5:91380349~91439085:+
HNSC	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-3.76	0.000194	0.0242	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
HNSC	cis	rs4834770	0.765	rs1511016	ENSG00000250412.1	KLHL2P1	3.76	0.000194	0.0242	0.21	0.17	Blood protein levels;	chr4:119249200	chr4:119334329~119378233:+
HNSC	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-3.76	0.000194	0.0242	-0.18	-0.17	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
HNSC	cis	rs478304	0.651	rs948494	ENSG00000255120.4	OVOL1-AS1	-3.76	0.000194	0.0242	-0.18	-0.17	Acne (severe);	chr11:65784647	chr11:65789051~65790868:-
HNSC	cis	rs478304	0.651	rs948493	ENSG00000255120.4	OVOL1-AS1	-3.76	0.000194	0.0242	-0.18	-0.17	Acne (severe);	chr11:65784683	chr11:65789051~65790868:-
HNSC	cis	rs6601327	0.571	rs7820675	ENSG00000233609.3	RP11-62H7.2	3.76	0.000194	0.0242	0.17	0.17	Multiple myeloma (hyperdiploidy);	chr8:9790238	chr8:8961200~8979025:+
HNSC	cis	rs7720894	0.967	rs4700418	ENSG00000215032.2	GNL3LP1	-3.76	0.000194	0.0242	-0.19	-0.17	Body mass index;	chr5:61326012	chr5:60891935~60893577:-
HNSC	cis	rs198426	0.81	rs12794220	ENSG00000257058.1	RP11-864I4.4	-3.76	0.000194	0.0242	-0.22	-0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61694940	chr11:62545999~62547699:+
HNSC	cis	rs3764021	0.87	rs7956831	ENSG00000256673.1	RP11-599J14.2	3.76	0.000194	0.0242	0.16	0.17	Type 1 diabetes;	chr12:9736561	chr12:9398355~9414851:-
HNSC	cis	rs9457247	0.555	rs2247325	ENSG00000227598.1	RP1-167A14.2	3.76	0.000194	0.0242	0.19	0.17	Crohn's disease;	chr6:166956504	chr6:166969626~166999065:-
HNSC	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	3.76	0.000194	0.0242	0.22	0.17	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
HNSC	cis	rs11651753	1	rs11651753	ENSG00000228782.6	CTD-2026D20.3	-3.76	0.000194	0.0242	-0.17	-0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47951723	chr17:47450568~47492492:-
HNSC	cis	rs614226	1	rs591992	ENSG00000202538.1	RNU4-2	-3.76	0.000194	0.0242	-0.29	-0.17	Type 1 diabetes nephropathy;	chr12:120581520	chr12:120291763~120291903:-
HNSC	cis	rs614226	0.935	rs588132	ENSG00000202538.1	RNU4-2	-3.76	0.000194	0.0242	-0.29	-0.17	Type 1 diabetes nephropathy;	chr12:120586263	chr12:120291763~120291903:-
HNSC	cis	rs2243480	1	rs4548056	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000194	0.0243	0.29	0.17	Diabetic kidney disease;	chr7:65833886	chr7:66025126~66031544:-
HNSC	cis	rs7178375	1	rs10163148	ENSG00000270015.1	RP11-540B6.6	3.76	0.000194	0.0243	0.22	0.17	Hypertriglyceridemia;	chr15:30920481	chr15:30926514~30928407:+
HNSC	cis	rs2412819	0.545	rs3862143	ENSG00000166763.7	STRCP1	-3.76	0.000194	0.0243	-0.24	-0.17	Lung cancer;	chr15:43779282	chr15:43699488~43718184:-
HNSC	cis	rs7720894	0.935	rs10041978	ENSG00000215032.2	GNL3LP1	-3.76	0.000194	0.0243	-0.19	-0.17	Body mass index;	chr5:61446378	chr5:60891935~60893577:-
HNSC	cis	rs440932	1	rs440932	ENSG00000233609.3	RP11-62H7.2	3.76	0.000194	0.0243	0.17	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8961200~8979025:+
HNSC	cis	rs10005067	0.788	rs12513126	ENSG00000248180.1	GAPDHP60	3.76	0.000194	0.0243	0.15	0.17	Total body bone mineral density (age 30-45);	chr4:87896923	chr4:87207092~87208086:+
HNSC	cis	rs35306767	0.903	rs765867	ENSG00000229869.1	RP11-363N22.2	-3.76	0.000194	0.0243	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:823961	chr10:933026~942743:+
HNSC	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	3.76	0.000194	0.0243	0.29	0.17	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	3.76	0.000194	0.0243	0.29	0.17	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
HNSC	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-3.76	0.000195	0.0243	-0.18	-0.17	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
HNSC	cis	rs10484434	0.818	rs61289224	ENSG00000272810.1	U91328.22	3.76	0.000195	0.0243	0.2	0.17	HIV-1 viral setpoint;	chr6:26049068	chr6:26013241~26013757:+
HNSC	cis	rs3018712	0.505	rs7102308	ENSG00000212093.1	AP000807.1	-3.76	0.000195	0.0243	-0.25	-0.17	Total body bone mineral density;	chr11:68645762	chr11:68506083~68506166:-
HNSC	cis	rs748404	0.697	rs546722	ENSG00000224055.1	GAPDHP55	3.76	0.000195	0.0243	0.2	0.17	Lung cancer;	chr15:43288621	chr15:44063511~44064313:+
HNSC	cis	rs116095464	0.558	rs56127718	ENSG00000277812.1	AC021087.1	3.76	0.000195	0.0243	0.29	0.17	Breast cancer;	chr5:270158	chr5:262769~262881:+
HNSC	cis	rs116095464	0.614	rs10061564	ENSG00000277812.1	AC021087.1	3.76	0.000195	0.0243	0.29	0.17	Breast cancer;	chr5:271214	chr5:262769~262881:+
HNSC	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	3.76	0.000195	0.0243	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	3.76	0.000195	0.0243	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
HNSC	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	3.76	0.000195	0.0243	0.26	0.17	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	3.76	0.000195	0.0243	0.26	0.17	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	3.76	0.000195	0.0243	0.26	0.17	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
HNSC	cis	rs7781557	0.64	rs55681588	ENSG00000239969.4	RP11-163E9.2	-3.76	0.000195	0.0243	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102936891	chr7:102364162~102380633:+
HNSC	cis	rs7781557	0.696	rs55849741	ENSG00000239969.4	RP11-163E9.2	-3.76	0.000195	0.0243	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102943622	chr7:102364162~102380633:+
HNSC	cis	rs2243480	1	rs35283677	ENSG00000164669.11	INTS4P1	3.76	0.000195	0.0243	0.34	0.17	Diabetic kidney disease;	chr7:65894246	chr7:65141225~65234216:+
HNSC	cis	rs7610312	0.681	rs2363688	ENSG00000273493.1	RP11-80H18.4	3.76	0.000195	0.0243	0.21	0.17	Red blood cell count;	chr3:58296401	chr3:58329965~58330118:+
HNSC	cis	rs7914558	0.505	rs12260436	ENSG00000269609.4	RPARP-AS1	-3.76	0.000195	0.0243	-0.13	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:102449817~102461106:+
HNSC	cis	rs526231	0.511	rs34823	ENSG00000250682.4	LINC00491	-3.76	0.000195	0.0243	-0.23	-0.17	Primary biliary cholangitis;	chr5:103102587	chr5:102609156~102671559:-
HNSC	cis	rs6090919	0.501	rs11908325	ENSG00000222365.1	SNORD12B	-3.76	0.000195	0.0243	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48864170	chr20:49280319~49280409:+
HNSC	cis	rs7772486	0.686	rs1292336	ENSG00000270638.1	RP3-466P17.1	-3.76	0.000195	0.0243	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145735570~145737218:+
HNSC	cis	rs4853525	0.59	rs6740086	ENSG00000228509.4	AC006460.2	3.76	0.000195	0.0243	0.24	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190871204	chr2:190676944~190708716:-
HNSC	cis	rs7829975	0.502	rs11785183	ENSG00000254153.1	CTA-398F10.2	-3.76	0.000195	0.0243	-0.2	-0.17	Mood instability;	chr8:8708447	chr8:8456909~8461337:-
HNSC	cis	rs865483	0.895	rs2107104	ENSG00000276054.1	RP11-378E13.3	3.76	0.000195	0.0243	0.21	0.17	Monocyte count;	chr17:37474926	chr17:37386886~37387926:+
HNSC	cis	rs2976388	1	rs2976398	ENSG00000253741.1	CTD-2292P10.4	3.76	0.000195	0.0243	0.16	0.17	Urinary tract infection frequency;	chr8:142683461	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920294	ENSG00000253741.1	CTD-2292P10.4	3.76	0.000195	0.0243	0.16	0.17	Urinary tract infection frequency;	chr8:142683908	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920293	ENSG00000253741.1	CTD-2292P10.4	3.76	0.000195	0.0243	0.16	0.17	Urinary tract infection frequency;	chr8:142683996	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920292	ENSG00000253741.1	CTD-2292P10.4	3.76	0.000195	0.0243	0.16	0.17	Urinary tract infection frequency;	chr8:142684281	chr8:142702252~142726973:-
HNSC	cis	rs871012	0.502	rs17658198	ENSG00000251405.2	CTB-109A12.1	-3.76	0.000195	0.0243	-0.2	-0.17	IgG glycosylation;	chr5:157458669	chr5:157362615~157460078:-
HNSC	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	3.76	0.000195	0.0243	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
HNSC	cis	rs2839186	0.709	rs2156117	ENSG00000239415.1	AP001469.9	3.76	0.000195	0.0243	0.15	0.17	Testicular germ cell tumor;	chr21:46249386	chr21:46251549~46254133:-
HNSC	cis	rs7735319	0.932	rs1479644	ENSG00000250697.1	CTD-2066L21.3	3.76	0.000195	0.0243	0.2	0.17	Systolic blood pressure;	chr5:33170717	chr5:32925639~33297910:-
HNSC	cis	rs597480	1	rs597480	ENSG00000279742.1	RP11-700A24.1	3.76	0.000195	0.0243	0.19	0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85725825	chr11:85852557~85854943:-
HNSC	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-3.76	0.000195	0.0243	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-3.76	0.000195	0.0243	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
HNSC	cis	rs240993	0.516	rs465646	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000195	0.0243	-0.22	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111277932~111278742:+
HNSC	cis	rs3213758	0.5	rs8054063	ENSG00000275191.1	RP11-36I17.2	-3.75	0.000195	0.0243	-0.27	-0.17	Vitiligo (non-segmental);	chr16:53628978	chr16:53628256~53628816:-
HNSC	cis	rs7735319	0.966	rs1842248	ENSG00000249572.1	CTD-2203K17.1	3.75	0.000195	0.0243	0.19	0.17	Systolic blood pressure;	chr5:33165734	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.966	rs2101014	ENSG00000249572.1	CTD-2203K17.1	3.75	0.000195	0.0243	0.19	0.17	Systolic blood pressure;	chr5:33166307	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.966	rs62368018	ENSG00000249572.1	CTD-2203K17.1	3.75	0.000195	0.0243	0.19	0.17	Systolic blood pressure;	chr5:33167320	chr5:33424025~33440619:-
HNSC	cis	rs73173548	0.502	rs10505855	ENSG00000247828.6	TMEM161B-AS1	3.75	0.000195	0.0243	0.18	0.17	Macular telangiectasia type 2;	chr5:88440962	chr5:88268895~88436685:+
HNSC	cis	rs6558174	0.863	rs17746902	ENSG00000253986.1	CTC-756D1.3	3.75	0.000195	0.0243	0.19	0.17	Breast cancer;	chr8:22634467	chr8:23493009~23494198:-
HNSC	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	3.75	0.000195	0.0243	0.25	0.17	Pain;	chr19:21430854	chr19:21554640~21569237:-
HNSC	cis	rs4718428	0.705	rs3800817	ENSG00000179406.6	LINC00174	-3.75	0.000195	0.0243	-0.25	-0.17	Corneal structure;	chr7:66798563	chr7:66376044~66401338:-
HNSC	cis	rs9300255	0.602	rs1106240	ENSG00000280120.1	RP11-546D6.3	3.75	0.000195	0.0243	0.17	0.17	Neutrophil percentage of white cells;	chr12:123142435	chr12:123152324~123153377:-
HNSC	cis	rs950169	0.512	rs4374136	ENSG00000230373.7	GOLGA6L5P	-3.75	0.000195	0.0244	-0.2	-0.17	Schizophrenia;	chr15:83976255	chr15:84507885~84516814:-
HNSC	cis	rs546131	0.642	rs1949048	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000195	0.0244	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34815427	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs1949046	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000195	0.0244	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34815442	chr11:34709600~34710161:+
HNSC	cis	rs12893668	0.572	rs11846404	ENSG00000269958.1	RP11-73M18.8	3.75	0.000195	0.0244	0.16	0.17	Reticulocyte count;	chr14:103689771	chr14:103696353~103697163:+
HNSC	cis	rs793571	0.822	rs2013117	ENSG00000245975.2	RP11-30K9.6	-3.75	0.000195	0.0244	-0.27	-0.17	Schizophrenia;	chr15:58881111	chr15:58768072~58770974:-
HNSC	cis	rs2904524	1	rs80024915	ENSG00000257815.4	RP11-611E13.2	-3.75	0.000195	0.0244	-0.23	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70353430	chr12:69904033~70243360:-
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000269918.1	AF131215.9	-3.75	0.000195	0.0244	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11104691~11106704:-
HNSC	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-3.75	0.000195	0.0244	-0.18	-0.17	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
HNSC	cis	rs597480	0.963	rs290190	ENSG00000279742.1	RP11-700A24.1	-3.75	0.000195	0.0244	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85716407	chr11:85852557~85854943:-
HNSC	cis	rs597480	0.929	rs290191	ENSG00000279742.1	RP11-700A24.1	-3.75	0.000195	0.0244	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85716598	chr11:85852557~85854943:-
HNSC	cis	rs10888838	0.756	rs11206309	ENSG00000198711.5	SSBP3-AS1	3.75	0.000196	0.0244	0.24	0.17	Mitochondrial DNA levels;	chr1:54228581	chr1:54236440~54239063:+
HNSC	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	3.75	0.000196	0.0244	0.16	0.17	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
HNSC	cis	rs970821	1	rs17349815	ENSG00000253106.1	RP11-158K1.3	3.75	0.000196	0.0244	0.15	0.17	Breast cancer;	chr8:123734177	chr8:124488510~124491643:+
HNSC	cis	rs17122278	1	rs2277295	ENSG00000255422.1	AP002954.4	3.75	0.000196	0.0244	0.31	0.17	Total cholesterol levels;	chr11:118545538	chr11:118704607~118750263:+
HNSC	cis	rs9611565	0.694	rs202631	ENSG00000235513.1	RP4-756G23.5	-3.75	0.000196	0.0244	-0.2	-0.17	Vitiligo;	chr22:41467419	chr22:41209122~41217627:-
HNSC	cis	rs10819861	0.575	rs10760780	ENSG00000271384.1	RP11-435O5.7	-3.75	0.000196	0.0244	-0.17	-0.17	Electrocardiographic traits;	chr9:96110509	chr9:95406990~95407662:-
HNSC	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	3.75	0.000196	0.0244	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
HNSC	cis	rs4660214	0.671	rs16826012	ENSG00000182109.6	RP11-69E11.4	-3.75	0.000196	0.0244	-0.22	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39522280~39546187:-
HNSC	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-3.75	0.000196	0.0244	-0.17	-0.17	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
HNSC	cis	rs11711311	1	rs2242109	ENSG00000241529.3	RN7SL767P	-3.75	0.000196	0.0244	-0.22	-0.17	IgG glycosylation;	chr3:113715253	chr3:113632704~113632998:+
HNSC	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000196	0.0244	-0.23	-0.17	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
HNSC	cis	rs66887589	0.777	rs10015883	ENSG00000249244.1	RP11-548H18.2	3.75	0.000196	0.0244	0.2	0.17	Diastolic blood pressure;	chr4:119346991	chr4:119391831~119395335:-
HNSC	cis	rs10865541	0.902	rs12474836	ENSG00000234171.2	RNASEH1-AS1	3.75	0.000196	0.0244	0.18	0.17	Obesity-related traits;	chr2:3415103	chr2:3558492~3561745:+
HNSC	cis	rs10865541	0.902	rs33997548	ENSG00000234171.2	RNASEH1-AS1	3.75	0.000196	0.0244	0.18	0.17	Obesity-related traits;	chr2:3415595	chr2:3558492~3561745:+
HNSC	cis	rs224278	0.509	rs1888968	ENSG00000238280.1	RP11-436D10.3	-3.75	0.000196	0.0244	-0.24	-0.17	Ewing sarcoma;	chr10:62943608	chr10:62793562~62805887:-
HNSC	cis	rs224278	0.509	rs4237316	ENSG00000238280.1	RP11-436D10.3	-3.75	0.000196	0.0244	-0.24	-0.17	Ewing sarcoma;	chr10:62943764	chr10:62793562~62805887:-
HNSC	cis	rs6568686	0.627	rs174377	ENSG00000255389.1	C6orf3	3.75	0.000196	0.0244	0.22	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111587443	chr6:111599875~111602295:+
HNSC	cis	rs1560104	0.709	rs6498334	ENSG00000261216.1	RP11-166B2.5	-3.75	0.000196	0.0244	-0.2	-0.17	Obesity-related traits;	chr16:12602789	chr16:11908208~11908916:+
HNSC	cis	rs5758659	0.935	rs134879	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000196	0.0244	-0.2	-0.17	Cognitive function;	chr22:42268195	chr22:42278188~42278846:+
HNSC	cis	rs35306767	0.904	rs35667562	ENSG00000229869.1	RP11-363N22.2	-3.75	0.000196	0.0244	-0.27	-0.17	Eosinophil percentage of granulocytes;	chr10:904690	chr10:933026~942743:+
HNSC	cis	rs9393777	0.764	rs35565446	ENSG00000226314.6	ZNF192P1	-3.75	0.000196	0.0244	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28161781~28169594:+
HNSC	cis	rs9584850	0.834	rs7985565	ENSG00000231194.1	FARP1-AS1	3.75	0.000196	0.0244	0.21	0.17	Neuroticism;	chr13:98461217	chr13:98435405~98435840:-
HNSC	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	3.75	0.000196	0.0244	0.22	0.17	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
HNSC	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	3.75	0.000196	0.0244	0.24	0.17	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
HNSC	cis	rs4281086	0.544	rs6601476	ENSG00000269918.1	AF131215.9	3.75	0.000196	0.0244	0.18	0.17	Obesity-related traits;	chr8:10497669	chr8:11104691~11106704:-
HNSC	cis	rs13438327	1	rs13438327	ENSG00000243554.1	AC004967.7	3.75	0.000196	0.0244	0.32	0.17	Sudden cardiac arrest;	chr7:97991379	chr7:97969005~97972254:-
HNSC	cis	rs4381823	0.867	rs78878238	ENSG00000230979.3	AC079250.1	-3.75	0.000196	0.0244	-0.26	-0.17	Schizophrenia;	chr2:47867971	chr2:47690716~47691246:-
HNSC	cis	rs9393777	0.588	rs4518487	ENSG00000241549.7	GUSBP2	3.75	0.000196	0.0245	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26467303	chr6:26871484~26956554:-
HNSC	cis	rs2243480	1	rs316331	ENSG00000164669.11	INTS4P1	-3.75	0.000196	0.0245	-0.33	-0.17	Diabetic kidney disease;	chr7:66139635	chr7:65141225~65234216:+
HNSC	cis	rs8002861	0.713	rs7339417	ENSG00000274001.1	RP11-5G9.5	3.75	0.000196	0.0245	0.17	0.17	Leprosy;	chr13:43839360	chr13:43877715~43878163:-
HNSC	cis	rs2554380	0.628	rs6602993	ENSG00000259570.1	RP11-671M22.4	3.75	0.000196	0.0245	0.21	0.17	Height;	chr15:83813610	chr15:84394512~84395514:+
HNSC	cis	rs9313772	0.928	rs7719885	ENSG00000254350.1	RP11-542A14.1	-3.75	0.000197	0.0245	-0.19	-0.17	Blood pressure;	chr5:158389119	chr5:158424585~158452758:+
HNSC	cis	rs9313772	0.928	rs7720317	ENSG00000254350.1	RP11-542A14.1	-3.75	0.000197	0.0245	-0.19	-0.17	Blood pressure;	chr5:158389335	chr5:158424585~158452758:+
HNSC	cis	rs2412819	0.571	rs4923965	ENSG00000166763.7	STRCP1	-3.75	0.000197	0.0245	-0.24	-0.17	Lung cancer;	chr15:43790232	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs4644832	ENSG00000166763.7	STRCP1	-3.75	0.000197	0.0245	-0.24	-0.17	Lung cancer;	chr15:43792507	chr15:43699488~43718184:-
HNSC	cis	rs1552244	1	rs35741213	ENSG00000180385.7	EMC3-AS1	3.75	0.000197	0.0245	0.19	0.17	Alzheimer's disease;	chr3:10045977	chr3:9986893~10006990:+
HNSC	cis	rs7085104	0.632	rs7096475	ENSG00000213061.2	PFN1P11	3.75	0.000197	0.0245	0.21	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102838011~102845473:-
HNSC	cis	rs853679	0.76	rs2299029	ENSG00000270326.1	RP5-874C20.6	-3.75	0.000197	0.0245	-0.24	-0.17	Depression;	chr6:28231053	chr6:28319660~28319852:-
HNSC	cis	rs28830936	1	rs17678138	ENSG00000250379.1	RP11-23P13.4	3.75	0.000197	0.0245	0.2	0.17	Diastolic blood pressure;	chr15:41750869	chr15:41825099~41827936:-
HNSC	cis	rs11098499	0.909	rs10017335	ENSG00000250412.1	KLHL2P1	-3.75	0.000197	0.0245	-0.22	-0.17	Corneal astigmatism;	chr4:119460368	chr4:119334329~119378233:+
HNSC	cis	rs4713118	0.955	rs9468200	ENSG00000217862.2	HIST1H4PS1	-3.75	0.000197	0.0245	-0.2	-0.17	Parkinson's disease;	chr6:27715284	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs34752872	ENSG00000217862.2	HIST1H4PS1	-3.75	0.000197	0.0245	-0.2	-0.17	Parkinson's disease;	chr6:27715465	chr6:27807075~27807339:+
HNSC	cis	rs656319	0.559	rs55683917	ENSG00000254340.1	RP11-10A14.3	-3.75	0.000197	0.0245	-0.21	-0.17	Myopia (pathological);	chr8:10118969	chr8:9141424~9145435:+
HNSC	cis	rs1519814	0.696	rs7832657	ENSG00000254343.2	RP11-760H22.2	-3.75	0.000197	0.0245	-0.23	-0.17	Breast cancer;	chr8:120024393	chr8:120052180~120056201:+
HNSC	cis	rs1519814	0.696	rs2875927	ENSG00000254343.2	RP11-760H22.2	-3.75	0.000197	0.0245	-0.23	-0.17	Breast cancer;	chr8:120024602	chr8:120052180~120056201:+
HNSC	cis	rs10129255	0.536	rs6576201	ENSG00000224373.3	IGHV4-59	-3.75	0.000197	0.0245	-0.1	-0.17	Kawasaki disease;	chr14:106683696	chr14:106627249~106627825:-
HNSC	cis	rs1555322	1	rs2425037	ENSG00000279253.1	RP4-614O4.13	3.75	0.000197	0.0245	0.25	0.17	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35262727~35264187:-
HNSC	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	3.75	0.000197	0.0245	0.2	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
HNSC	cis	rs11871801	0.517	rs34138141	ENSG00000267151.3	RP11-100E5.2	3.75	0.000197	0.0245	0.25	0.17	Crohn's disease;	chr17:42629543	chr17:43444707~43451200:+
HNSC	cis	rs160451	0.782	rs1603288	ENSG00000251136.7	RP11-37B2.1	-3.75	0.000197	0.0245	-0.16	-0.17	Leprosy;	chr8:89701036	chr8:89609409~89757727:-
HNSC	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-3.75	0.000197	0.0245	-0.29	-0.17	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
HNSC	cis	rs7688540	0.8	rs10028482	ENSG00000250892.1	RP11-1365D11.1	-3.75	0.000197	0.0245	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:201409~205009:-
HNSC	cis	rs3736485	0.966	rs17609917	ENSG00000274528.1	CTD-2650P22.2	3.75	0.000197	0.0245	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51619290	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.934	rs17609924	ENSG00000274528.1	CTD-2650P22.2	3.75	0.000197	0.0245	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51619395	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs8028017	ENSG00000274528.1	CTD-2650P22.2	3.75	0.000197	0.0245	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620511	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs10519312	ENSG00000274528.1	CTD-2650P22.2	3.75	0.000197	0.0245	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620774	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs28428679	ENSG00000274528.1	CTD-2650P22.2	3.75	0.000197	0.0245	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51620843	chr15:52017167~52018032:-
HNSC	cis	rs2074409	0.509	rs853219	ENSG00000276054.1	RP11-378E13.3	-3.75	0.000197	0.0245	-0.19	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37427296	chr17:37386886~37387926:+
HNSC	cis	rs9880211	0.66	rs34645606	ENSG00000240695.1	RP11-102M11.1	-3.75	0.000197	0.0245	-0.29	-0.17	Height;Body mass index;	chr3:136811260	chr3:136736500~136737229:-
HNSC	cis	rs853679	0.567	rs6905380	ENSG00000226314.6	ZNF192P1	-3.75	0.000197	0.0245	-0.2	-0.17	Depression;	chr6:28407125	chr6:28161781~28169594:+
HNSC	cis	rs34286592	1	rs34127220	ENSG00000196796.5	CTB-134H23.2	3.75	0.000197	0.0245	0.25	0.17	Multiple sclerosis;	chr16:29831570	chr16:29038655~29052726:+
HNSC	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	3.75	0.000197	0.0245	0.12	0.17	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
HNSC	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	3.75	0.000197	0.0245	0.12	0.17	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
HNSC	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	3.75	0.000197	0.0245	0.12	0.17	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
HNSC	cis	rs7735319	0.966	rs35408434	ENSG00000249572.1	CTD-2203K17.1	3.75	0.000197	0.0245	0.19	0.17	Systolic blood pressure;	chr5:33163321	chr5:33424025~33440619:-
HNSC	cis	rs546131	0.642	rs11603751	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000197	0.0245	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34799262	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.642	rs11600239	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000197	0.0245	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34800152	chr11:34709600~34710161:+
HNSC	cis	rs67311347	1	rs9834052	ENSG00000280739.1	EIF1B-AS1	3.75	0.000197	0.0245	0.18	0.17	Renal cell carcinoma;	chr3:40357569	chr3:40173145~40309698:-
HNSC	cis	rs4704187	0.687	rs6894048	ENSG00000272040.1	CTC-366B18.4	-3.75	0.000197	0.0245	-0.16	-0.17	Response to amphetamines;	chr5:75161013	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs4704179	ENSG00000272040.1	CTC-366B18.4	-3.75	0.000197	0.0245	-0.16	-0.17	Response to amphetamines;	chr5:75161448	chr5:75608817~75609983:+
HNSC	cis	rs700651	0.789	rs892514	ENSG00000231621.1	AC013264.2	-3.75	0.000197	0.0245	-0.16	-0.17	Intracranial aneurysm;	chr2:198040546	chr2:197197991~197199273:+
HNSC	cis	rs2462686	1	rs2462686	ENSG00000234536.1	AC096582.7	3.75	0.000197	0.0245	0.18	0.17	Major depressive disorder;	chr7:45942861	chr7:45773595~45783157:+
HNSC	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	3.75	0.000197	0.0245	0.17	0.17	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
HNSC	cis	rs6657613	0.649	rs2295060	ENSG00000186715.9	MST1L	-3.75	0.000197	0.0246	-0.14	-0.17	Hip circumference adjusted for BMI;	chr1:17050295	chr1:16754910~16770237:-
HNSC	cis	rs228614	0.51	rs170565	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000197	0.0246	-0.19	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102751401~102752641:+
HNSC	cis	rs17666538	0.585	rs4448252	ENSG00000254207.1	RP11-43A14.1	3.75	0.000197	0.0246	0.37	0.17	IgG glycosylation;	chr8:665597	chr8:725188~725877:-
HNSC	cis	rs17666538	0.535	rs4338080	ENSG00000254207.1	RP11-43A14.1	3.75	0.000197	0.0246	0.37	0.17	IgG glycosylation;	chr8:665598	chr8:725188~725877:-
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000270326.1	RP5-874C20.6	-3.75	0.000197	0.0246	-0.24	-0.17	Depression;	chr6:28240414	chr6:28319660~28319852:-
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000270326.1	RP5-874C20.6	-3.75	0.000197	0.0246	-0.24	-0.17	Depression;	chr6:28240780	chr6:28319660~28319852:-
HNSC	cis	rs9880211	0.613	rs6439629	ENSG00000239213.4	NCK1-AS1	3.75	0.000197	0.0246	0.16	0.17	Height;Body mass index;	chr3:136182428	chr3:136841726~136862054:-
HNSC	cis	rs1799949	0.827	rs74252763	ENSG00000236383.6	LINC00854	-3.75	0.000197	0.0246	-0.16	-0.17	Menopause (age at onset);	chr17:43324652	chr17:43216941~43305976:-
HNSC	cis	rs9880211	0.563	rs6792630	ENSG00000239213.4	NCK1-AS1	3.75	0.000197	0.0246	0.17	0.17	Height;Body mass index;	chr3:136106059	chr3:136841726~136862054:-
HNSC	cis	rs67311347	1	rs951560	ENSG00000280739.1	EIF1B-AS1	3.75	0.000197	0.0246	0.19	0.17	Renal cell carcinoma;	chr3:40421980	chr3:40173145~40309698:-
HNSC	cis	rs6878727	0.85	rs12658088	ENSG00000253807.4	LINC01170	-3.75	0.000197	0.0246	-0.21	-0.17	Breast cancer;	chr5:124383755	chr5:124059794~124405079:-
HNSC	cis	rs6012564	1	rs3091497	ENSG00000227431.4	CSE1L-AS1	-3.75	0.000197	0.0246	-0.2	-0.17	Anger;	chr20:49028890	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.858	rs3091427	ENSG00000227431.4	CSE1L-AS1	-3.75	0.000197	0.0246	-0.2	-0.17	Anger;	chr20:49046845	chr20:49040463~49046044:-
HNSC	cis	rs78487399	0.71	rs74616425	ENSG00000234936.1	AC010883.5	3.75	0.000197	0.0246	0.31	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43386443	chr2:43229573~43233394:+
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000213640.3	EEF1DP4	-3.75	0.000197	0.0246	-0.21	-0.17	Calcium levels;	chr7:65751755	chr7:64862999~64864370:+
HNSC	cis	rs4356203	0.87	rs7935219	ENSG00000272034.1	SNORD14A	3.75	0.000198	0.0246	0.13	0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17074654~17074744:-
HNSC	cis	rs10865541	0.806	rs4971503	ENSG00000234171.2	RNASEH1-AS1	3.75	0.000198	0.0246	0.18	0.17	Obesity-related traits;	chr2:3413450	chr2:3558492~3561745:+
HNSC	cis	rs964611	1	rs964611	ENSG00000259488.2	RP11-154J22.1	-3.75	0.000198	0.0246	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48305317	chr15:48312353~48331856:-
HNSC	cis	rs807669	0.807	rs698422	ENSG00000185065.6	AC000068.5	3.75	0.000198	0.0246	0.17	0.17	Metabolite levels;	chr22:19218317	chr22:19447893~19450105:+
HNSC	cis	rs807669	0.742	rs1206544	ENSG00000185065.6	AC000068.5	3.75	0.000198	0.0246	0.17	0.17	Metabolite levels;	chr22:19227516	chr22:19447893~19450105:+
HNSC	cis	rs28489187	0.617	rs233097	ENSG00000223653.4	RP11-131L23.1	3.75	0.000198	0.0246	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85359790	chr1:85276715~85448124:+
HNSC	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-3.75	0.000198	0.0246	-0.19	-0.17	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
HNSC	cis	rs875971	0.862	rs7783779	ENSG00000106610.13	STAG3L4	3.75	0.000198	0.0246	0.22	0.17	Aortic root size;	chr7:66331639	chr7:67302621~67321526:+
HNSC	cis	rs61160187	0.548	rs68104763	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000198	0.0246	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60866457~60866935:-
HNSC	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	3.75	0.000198	0.0246	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
HNSC	cis	rs78905543	0.555	rs10095594	ENSG00000253616.4	RP11-875O11.3	3.75	0.000198	0.0246	0.21	0.17	Mean corpuscular volume;	chr8:23057378	chr8:23071377~23074488:-
HNSC	cis	rs13434995	0.842	rs56139168	ENSG00000273257.1	RP11-177J6.1	-3.75	0.000198	0.0246	-0.29	-0.17	Adiponectin levels;	chr4:55407120	chr4:55387949~55388271:+
HNSC	cis	rs848490	0.722	rs6976860	ENSG00000214293.7	APTR	3.75	0.000198	0.0246	0.14	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77822829	chr7:77657660~77696265:-
HNSC	cis	rs6540731	0.905	rs12073206	ENSG00000226251.4	RP11-15I11.3	-3.75	0.000198	0.0246	-0.19	-0.17	Intelligence (childhood);	chr1:212214294	chr1:212225278~212238977:-
HNSC	cis	rs6688613	0.84	rs6660048	ENSG00000215834.7	FMO9P	-3.75	0.000198	0.0246	-0.23	-0.17	Refractive astigmatism;	chr1:166984949	chr1:166603675~166631400:+
HNSC	cis	rs10078	0.559	rs2671891	ENSG00000225138.6	CTD-2228K2.7	3.75	0.000198	0.0246	0.3	0.17	Fat distribution (HIV);	chr5:456271	chr5:473236~480884:+
HNSC	cis	rs10078	0.571	rs2671890	ENSG00000225138.6	CTD-2228K2.7	3.75	0.000198	0.0246	0.3	0.17	Fat distribution (HIV);	chr5:456342	chr5:473236~480884:+
HNSC	cis	rs7107174	1	rs2512544	ENSG00000251323.2	RP11-452H21.4	3.75	0.000198	0.0246	0.26	0.17	Testicular germ cell tumor;	chr11:78275325	chr11:78423982~78429836:-
HNSC	cis	rs1595825	0.891	rs73058876	ENSG00000231621.1	AC013264.2	-3.75	0.000198	0.0246	-0.2	-0.17	Ulcerative colitis;	chr2:198030298	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.838	rs73058878	ENSG00000231621.1	AC013264.2	-3.75	0.000198	0.0246	-0.2	-0.17	Ulcerative colitis;	chr2:198030354	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs16826791	ENSG00000231621.1	AC013264.2	-3.75	0.000198	0.0246	-0.2	-0.17	Ulcerative colitis;	chr2:198030409	chr2:197197991~197199273:+
HNSC	cis	rs3764400	0.506	rs72827851	ENSG00000228782.6	CTD-2026D20.3	-3.75	0.000198	0.0246	-0.27	-0.17	Body mass index;	chr17:48375133	chr17:47450568~47492492:-
HNSC	cis	rs34421088	0.564	rs6983129	ENSG00000269918.1	AF131215.9	3.75	0.000198	0.0246	0.17	0.17	Neuroticism;	chr8:11733627	chr8:11104691~11106704:-
HNSC	cis	rs17596685	1	rs7324200	ENSG00000271216.1	LINC01050	3.75	0.000198	0.0246	0.22	0.17	C-reactive protein levels;	chr13:42563388	chr13:42810366~42812562:-
HNSC	cis	rs17596685	1	rs7996068	ENSG00000271216.1	LINC01050	3.75	0.000198	0.0246	0.22	0.17	C-reactive protein levels;	chr13:42565254	chr13:42810366~42812562:-
HNSC	cis	rs17596685	1	rs8000846	ENSG00000271216.1	LINC01050	3.75	0.000198	0.0246	0.22	0.17	C-reactive protein levels;	chr13:42565450	chr13:42810366~42812562:-
HNSC	cis	rs17489649	1	rs2068964	ENSG00000271849.1	CTC-332L22.1	3.75	0.000198	0.0246	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109779300	chr5:109687802~109688329:-
HNSC	cis	rs2836974	0.931	rs2735306	ENSG00000255568.3	BRWD1-AS2	-3.75	0.000198	0.0246	-0.16	-0.17	Cognitive function;	chr21:39341208	chr21:39313935~39314962:+
HNSC	cis	rs10865541	0.902	rs12476309	ENSG00000234171.2	RNASEH1-AS1	3.75	0.000198	0.0246	0.18	0.17	Obesity-related traits;	chr2:3401074	chr2:3558492~3561745:+
HNSC	cis	rs10789207	0.531	rs6588211	ENSG00000248458.2	RP4-598P13.1	-3.75	0.000198	0.0246	-0.25	-0.17	Resting heart rate;	chr1:66621066	chr1:66665864~66677027:-
HNSC	cis	rs10789207	0.531	rs6588212	ENSG00000248458.2	RP4-598P13.1	-3.75	0.000198	0.0246	-0.25	-0.17	Resting heart rate;	chr1:66621198	chr1:66665864~66677027:-
HNSC	cis	rs67311347	0.869	rs6790495	ENSG00000280739.1	EIF1B-AS1	3.75	0.000198	0.0246	0.19	0.17	Renal cell carcinoma;	chr3:40325279	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.869	rs7646899	ENSG00000280739.1	EIF1B-AS1	3.75	0.000198	0.0246	0.19	0.17	Renal cell carcinoma;	chr3:40325491	chr3:40173145~40309698:-
HNSC	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000198	0.0246	-0.24	-0.17	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000198	0.0246	-0.24	-0.17	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
HNSC	cis	rs7592578	0.713	rs60915953	ENSG00000228509.4	AC006460.2	3.75	0.000198	0.0247	0.27	0.17	Diastolic blood pressure;	chr2:190466578	chr2:190676944~190708716:-
HNSC	cis	rs6547741	0.844	rs9941696	ENSG00000272148.1	RP11-195B17.1	-3.75	0.000198	0.0247	-0.17	-0.17	Oral cavity cancer;	chr2:27697197	chr2:27062428~27062907:-
HNSC	cis	rs6968419	1	rs10953813	ENSG00000237870.5	AC073130.1	3.75	0.000198	0.0247	0.19	0.17	Intraocular pressure;	chr7:116183926	chr7:116275606~116286734:-
HNSC	cis	rs11154271	1	rs9388383	ENSG00000236548.1	RNF217-AS1	-3.75	0.000198	0.0247	-0.23	-0.17	Subcutaneous adipose tissue;	chr6:124835744	chr6:124909093~124963039:-
HNSC	cis	rs11951515	0.738	rs10941630	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000198	0.0247	0.18	0.17	Metabolite levels  (X-11787);	chr5:43350116	chr5:43586918~43588223:-
HNSC	cis	rs4131099	0.793	rs12448968	ENSG00000270120.1	RP11-327F22.6	3.75	0.000198	0.0247	0.21	0.17	Personality dimensions;	chr16:51350661	chr16:50712844~50713589:+
HNSC	cis	rs868153	0.625	rs2606592	ENSG00000275339.1	RP3-425C14.6	3.75	0.000198	0.0247	0.18	0.17	Vertical cup-disc ratio;	chr6:122252666	chr6:122454358~122454612:+
HNSC	cis	rs478304	0.593	rs4645927	ENSG00000255120.4	OVOL1-AS1	-3.75	0.000198	0.0247	-0.18	-0.17	Acne (severe);	chr11:65715356	chr11:65789051~65790868:-
HNSC	cis	rs12701220	0.725	rs13242971	ENSG00000224079.1	AC091729.7	3.75	0.000198	0.0247	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1074450~1078036:+
HNSC	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	3.75	0.000199	0.0247	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	3.75	0.000199	0.0247	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
HNSC	cis	rs10256972	0.721	rs4720249	ENSG00000225146.1	AC073957.15	3.75	0.000199	0.0247	0.2	0.17	Endometriosis;Longevity;	chr7:1032927	chr7:1029025~1043891:+
HNSC	cis	rs7646881	0.544	rs73028934	ENSG00000272087.1	RP11-379F4.7	3.75	0.000199	0.0247	0.24	0.17	Tetralogy of Fallot;	chr3:158655761	chr3:158693120~158693768:-
HNSC	cis	rs6516091	0.565	rs6053888	ENSG00000278192.1	RP5-1056H1.2	3.75	0.000199	0.0247	0.25	0.17	Abdominal aortic aneurysm;	chr20:6081683	chr20:6065966~6067897:-
HNSC	cis	rs9863	0.896	rs12829951	ENSG00000270028.1	RP11-380L11.4	3.75	0.000199	0.0247	0.2	0.17	White blood cell count;	chr12:123941294	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs7131882	ENSG00000270028.1	RP11-380L11.4	3.75	0.000199	0.0247	0.2	0.17	White blood cell count;	chr12:123942189	chr12:123925461~123926083:-
HNSC	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	3.75	0.000199	0.0247	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
HNSC	cis	rs6088580	0.634	rs6058052	ENSG00000276073.1	RP5-1125A11.7	-3.75	0.000199	0.0247	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:33985617~33988989:-
HNSC	cis	rs1015213	1	rs57182175	ENSG00000272024.1	RP11-546K22.3	-3.75	0.000199	0.0247	-0.3	-0.17	Glaucoma (primary angle closure);	chr8:51977171	chr8:51950284~51950690:+
HNSC	cis	rs868153	0.625	rs12662844	ENSG00000275339.1	RP3-425C14.6	3.75	0.000199	0.0247	0.18	0.17	Vertical cup-disc ratio;	chr6:122211127	chr6:122454358~122454612:+
HNSC	cis	rs34792	0.637	rs2450356	ENSG00000207425.1	Y_RNA	3.75	0.000199	0.0247	0.2	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14915457~14915556:-
HNSC	cis	rs597539	0.615	rs629426	ENSG00000255741.1	RP11-757G1.5	-3.75	0.000199	0.0247	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68941503~68942852:-
HNSC	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-3.75	0.000199	0.0247	-0.22	-0.17	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
HNSC	cis	rs2048656	0.561	rs12544371	ENSG00000233609.3	RP11-62H7.2	-3.75	0.000199	0.0247	-0.17	-0.17	Schizophrenia;	chr8:9684561	chr8:8961200~8979025:+
HNSC	cis	rs2919917	0.628	rs1021157	ENSG00000260398.1	RP11-594N15.3	3.75	0.000199	0.0247	0.23	0.17	Lymphocyte counts;	chr8:78662938	chr8:78605952~78609705:+
HNSC	cis	rs7824557	0.815	rs2572430	ENSG00000269918.1	AF131215.9	3.75	0.000199	0.0247	0.17	0.17	Retinal vascular caliber;	chr8:11247795	chr8:11104691~11106704:-
HNSC	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-3.75	0.000199	0.0247	-0.26	-0.17	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.838	rs2173570	ENSG00000272831.1	RP11-792A8.4	-3.75	0.000199	0.0247	-0.15	-0.17	Aortic root size;	chr7:66297976	chr7:66739829~66740385:-
HNSC	cis	rs4853525	0.561	rs13414648	ENSG00000228509.4	AC006460.2	3.75	0.000199	0.0247	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929310	chr2:190676944~190708716:-
HNSC	cis	rs62027291	1	rs112503392	ENSG00000259422.1	RP11-593F23.1	-3.75	0.000199	0.0247	-0.26	-0.17	Plateletcrit;	chr15:76983305	chr15:76174891~76181486:-
HNSC	cis	rs1595825	0.891	rs7585709	ENSG00000231621.1	AC013264.2	-3.75	0.000199	0.0247	-0.2	-0.17	Ulcerative colitis;	chr2:198018958	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.786	rs116046984	ENSG00000231621.1	AC013264.2	-3.75	0.000199	0.0247	-0.2	-0.17	Ulcerative colitis;	chr2:198019689	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs73058864	ENSG00000231621.1	AC013264.2	-3.75	0.000199	0.0247	-0.2	-0.17	Ulcerative colitis;	chr2:198024863	chr2:197197991~197199273:+
HNSC	cis	rs12291225	0.639	rs61883858	ENSG00000254418.1	RP11-21L19.1	3.75	0.000199	0.0248	0.2	0.17	Sense of smell;	chr11:14273162	chr11:14262846~14273691:-
HNSC	cis	rs9990333	0.622	rs57783901	ENSG00000278820.1	AC024937.1	3.75	0.000199	0.0248	0.15	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195960500~195960612:-
HNSC	cis	rs7162943	0.708	rs293365	ENSG00000260123.1	RP11-326A19.4	-3.75	0.000199	0.0248	-0.19	-0.17	Mean platelet volume;	chr15:89070777	chr15:89041223~89082819:+
HNSC	cis	rs67311347	1	rs6795475	ENSG00000280739.1	EIF1B-AS1	3.75	0.000199	0.0248	0.19	0.17	Renal cell carcinoma;	chr3:40447790	chr3:40173145~40309698:-
HNSC	cis	rs6968419	0.963	rs4436065	ENSG00000237870.5	AC073130.1	3.75	0.000199	0.0248	0.19	0.17	Intraocular pressure;	chr7:116181326	chr7:116275606~116286734:-
HNSC	cis	rs35306767	0.761	rs11253538	ENSG00000229869.1	RP11-363N22.2	-3.75	0.000199	0.0248	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:965226	chr10:933026~942743:+
HNSC	cis	rs35306767	0.715	rs11253539	ENSG00000229869.1	RP11-363N22.2	-3.75	0.000199	0.0248	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:965407	chr10:933026~942743:+
HNSC	cis	rs3740713	1	rs73440637	ENSG00000256464.1	YWHABP2	3.75	0.000199	0.0248	0.33	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr11:18490243~18490955:-
HNSC	cis	rs12478296	1	rs56162244	ENSG00000261186.2	RP11-341N2.1	-3.75	0.000199	0.0248	-0.27	-0.17	Obesity-related traits;	chr2:242076539	chr2:242087351~242088457:-
HNSC	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	3.75	0.000199	0.0248	0.25	0.17	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	3.75	0.000199	0.0248	0.25	0.17	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
HNSC	cis	rs2341917	0.732	rs113543050	ENSG00000227992.1	AC108463.2	-3.75	0.000199	0.0248	-0.28	-0.17	Attention function in attention deficit hyperactive disorder;	chr2:110860425	chr2:111203964~111206215:-
HNSC	cis	rs1476670	0.565	rs2428965	ENSG00000230615.5	RP5-1198O20.4	-3.75	0.000199	0.0248	-0.2	-0.17	Eotaxin levels;	chr1:44037237	chr1:44030443~44115913:+
HNSC	cis	rs62246343	0.605	rs17746498	ENSG00000254485.4	RP11-380O24.1	3.75	0.000199	0.0248	0.23	0.17	Fibrinogen levels;	chr3:9411976	chr3:9292588~9363303:-
HNSC	cis	rs6088580	0.634	rs6059856	ENSG00000276073.1	RP5-1125A11.7	-3.75	0.000199	0.0248	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:33985617~33988989:-
HNSC	cis	rs17489649	1	rs2269206	ENSG00000271849.1	CTC-332L22.1	3.75	0.000199	0.0248	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109786985	chr5:109687802~109688329:-
HNSC	cis	rs67311347	1	rs9857824	ENSG00000280739.1	EIF1B-AS1	3.75	0.000199	0.0248	0.19	0.17	Renal cell carcinoma;	chr3:40417921	chr3:40173145~40309698:-
HNSC	cis	rs12664251	0.638	rs2782573	ENSG00000253194.1	RP11-351A11.1	-3.75	0.000199	0.0248	-0.19	-0.17	Schizophrenia;	chr6:119031549	chr6:118934785~119031541:+
HNSC	cis	rs10742752	0.535	rs12224037	ENSG00000254651.1	RP11-430H10.3	3.75	0.000199	0.0248	0.21	0.17	Body mass index;	chr11:45383813	chr11:45399448~45400528:+
HNSC	cis	rs73173548	0.502	rs10942532	ENSG00000247828.6	TMEM161B-AS1	3.75	2e-04	0.0248	0.18	0.17	Macular telangiectasia type 2;	chr5:88462015	chr5:88268895~88436685:+
HNSC	cis	rs73173548	0.502	rs74429030	ENSG00000247828.6	TMEM161B-AS1	3.75	2e-04	0.0248	0.18	0.17	Macular telangiectasia type 2;	chr5:88474689	chr5:88268895~88436685:+
HNSC	cis	rs11098499	0.954	rs13145352	ENSG00000250412.1	KLHL2P1	-3.75	2e-04	0.0248	-0.23	-0.17	Corneal astigmatism;	chr4:119488808	chr4:119334329~119378233:+
HNSC	cis	rs7824557	0.564	rs12550129	ENSG00000269918.1	AF131215.9	-3.75	2e-04	0.0248	-0.16	-0.17	Retinal vascular caliber;	chr8:11376408	chr8:11104691~11106704:-
HNSC	cis	rs17772222	0.917	rs1950806	ENSG00000258789.1	RP11-507K2.3	-3.75	2e-04	0.0248	-0.21	-0.17	Coronary artery calcification;	chr14:88774412	chr14:88551597~88552493:+
HNSC	cis	rs11083475	0.681	rs62121377	ENSG00000207296.1	RNU6-140P	-3.75	2e-04	0.0248	-0.17	-0.17	Heart rate;	chr19:38766656	chr19:38797002~38797109:-
HNSC	cis	rs9896933	0.83	rs8074277	ENSG00000262663.1	RP11-497H17.1	3.75	2e-04	0.0248	0.21	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82831752	chr17:82918282~82918785:+
HNSC	cis	rs4073405	0.96	rs7131438	ENSG00000254651.1	RP11-430H10.3	3.75	2e-04	0.0248	0.21	0.17	Schizophrenia;	chr11:45300850	chr11:45399448~45400528:+
HNSC	cis	rs6088580	0.634	rs6087588	ENSG00000276073.1	RP5-1125A11.7	-3.75	2e-04	0.0248	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:33985617~33988989:-
HNSC	cis	rs9329221	0.662	rs35472251	ENSG00000269918.1	AF131215.9	3.75	2e-04	0.0248	0.18	0.17	Neuroticism;	chr8:10389159	chr8:11104691~11106704:-
HNSC	cis	rs10938353	0.911	rs13138228	ENSG00000273369.1	RP11-700J17.1	3.75	2e-04	0.0248	0.21	0.17	Body mass index;	chr4:44590043	chr4:44693946~44694386:-
HNSC	cis	rs13179617	0.928	rs12514375	ENSG00000215032.2	GNL3LP1	-3.75	2e-04	0.0248	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61505601	chr5:60891935~60893577:-
HNSC	cis	rs853679	0.607	rs13208096	ENSG00000226314.6	ZNF192P1	-3.75	2e-04	0.0248	-0.31	-0.17	Depression;	chr6:28257533	chr6:28161781~28169594:+
HNSC	cis	rs7688540	0.771	rs77234191	ENSG00000211553.1	AC253576.2	-3.75	2e-04	0.0248	-0.28	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:136461~136568:+
HNSC	cis	rs60617249	0.801	rs4947522	ENSG00000228204.2	RP4-724E13.2	-3.75	2e-04	0.0248	-0.18	-0.17	Major depression and alcohol dependence;	chr7:50937822	chr7:50866747~51022990:+
HNSC	cis	rs7824557	0.602	rs7815463	ENSG00000255495.1	AC145124.2	3.75	2e-04	0.0248	0.19	0.17	Retinal vascular caliber;	chr8:11353474	chr8:12194467~12196280:+
HNSC	cis	rs2976388	0.967	rs2976393	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682200	chr8:142702252~142726973:-
HNSC	cis	rs13438327	1	rs35481514	ENSG00000243554.1	AC004967.7	3.75	2e-04	0.0248	0.35	0.17	Sudden cardiac arrest;	chr7:97990785	chr7:97969005~97972254:-
HNSC	cis	rs1979679	0.842	rs11049411	ENSG00000247934.4	RP11-967K21.1	-3.75	2e-04	0.0248	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28163298~28190738:-
HNSC	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	3.75	2e-04	0.0248	0.18	0.17	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
HNSC	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	3.75	2e-04	0.0248	0.19	0.17	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
HNSC	cis	rs72843506	0.722	rs5025290	ENSG00000189423.10	USP32P3	3.75	2e-04	0.0248	0.27	0.17	Schizophrenia;	chr17:20302504	chr17:20415547~20431008:+
HNSC	cis	rs72843506	0.722	rs9895177	ENSG00000189423.10	USP32P3	3.75	2e-04	0.0248	0.27	0.17	Schizophrenia;	chr17:20304281	chr17:20415547~20431008:+
HNSC	cis	rs2212361	0.558	rs7934178	ENSG00000255893.1	RP11-685N10.1	-3.75	2e-04	0.0248	-0.24	-0.17	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531307	chr11:94472908~94473570:-
HNSC	cis	rs2212361	0.558	rs7934183	ENSG00000255893.1	RP11-685N10.1	-3.75	2e-04	0.0248	-0.24	-0.17	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531321	chr11:94472908~94473570:-
HNSC	cis	rs10040610	0.524	rs271422	ENSG00000250490.1	FLJ33360	-3.75	2e-04	0.0248	-0.22	-0.17	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6355594	chr5:6310441~6339884:-
HNSC	cis	rs2243480	1	rs13247184	ENSG00000164669.11	INTS4P1	3.75	2e-04	0.0248	0.34	0.17	Diabetic kidney disease;	chr7:65893941	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35421653	ENSG00000164669.11	INTS4P1	3.75	2e-04	0.0248	0.34	0.17	Diabetic kidney disease;	chr7:65898442	chr7:65141225~65234216:+
HNSC	cis	rs4852324	0.536	rs13390332	ENSG00000237883.1	DGUOK-AS1	-3.75	2e-04	0.0248	-0.34	-0.17	Systemic lupus erythematosus;	chr2:73980230	chr2:73947642~73981441:-
HNSC	cis	rs6088590	0.523	rs6088536	ENSG00000276073.1	RP5-1125A11.7	-3.75	2e-04	0.0248	-0.18	-0.17	Coronary artery disease;	chr20:34601302	chr20:33985617~33988989:-
HNSC	cis	rs950169	1	rs1818950	ENSG00000230373.7	GOLGA6L5P	-3.75	2e-04	0.0248	-0.19	-0.17	Schizophrenia;	chr15:84053769	chr15:84507885~84516814:-
HNSC	cis	rs2976388	1	rs2920298	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142681625	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920297	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142681665	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920296	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142681691	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs1045531	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682129	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2976394	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682204	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.967	rs2976395	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682332	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs1045547	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682339	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs1045605	ENSG00000253741.1	CTD-2292P10.4	3.75	2e-04	0.0248	0.16	0.17	Urinary tract infection frequency;	chr8:142682683	chr8:142702252~142726973:-
HNSC	cis	rs2548724	0.738	rs398228	ENSG00000250682.4	LINC00491	-3.75	2e-04	0.0248	-0.22	-0.17	Type 2 diabetes;	chr5:102257782	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.812	rs416734	ENSG00000250682.4	LINC00491	-3.75	2e-04	0.0248	-0.22	-0.17	Type 2 diabetes;	chr5:102257783	chr5:102609156~102671559:-
HNSC	cis	rs2548724	0.773	rs261100	ENSG00000250682.4	LINC00491	-3.75	2e-04	0.0248	-0.22	-0.17	Type 2 diabetes;	chr5:102258482	chr5:102609156~102671559:-
HNSC	cis	rs7178375	1	rs35162264	ENSG00000270015.1	RP11-540B6.6	3.75	2e-04	0.0248	0.22	0.17	Hypertriglyceridemia;	chr15:30908480	chr15:30926514~30928407:+
HNSC	cis	rs9859260	0.71	rs41298097	ENSG00000273009.1	RP11-352G9.1	3.75	2e-04	0.0248	0.2	0.17	Mean corpuscular volume;	chr3:196052284	chr3:195913078~195913683:-
HNSC	cis	rs9859260	0.71	rs34906439	ENSG00000273009.1	RP11-352G9.1	3.75	2e-04	0.0248	0.2	0.17	Mean corpuscular volume;	chr3:196052835	chr3:195913078~195913683:-
HNSC	cis	rs9487051	0.724	rs13200047	ENSG00000243587.6	C6orf183	-3.75	2e-04	0.0248	-0.17	-0.17	Reticulocyte fraction of red cells;	chr6:109312041	chr6:109165833~109271014:+
HNSC	cis	rs9467711	0.606	rs2072803	ENSG00000241549.7	GUSBP2	3.75	2e-04	0.0249	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26392287	chr6:26871484~26956554:-
HNSC	cis	rs2919917	0.628	rs979564	ENSG00000260398.1	RP11-594N15.3	3.75	2e-04	0.0249	0.23	0.17	Lymphocyte counts;	chr8:78663924	chr8:78605952~78609705:+
HNSC	cis	rs12541595	0.928	rs72716972	ENSG00000255491.1	RP11-1082L8.4	3.75	2e-04	0.0249	0.22	0.17	Left ventricle diastolic internal dimension;	chr8:124846279	chr8:124811618~124815682:-
HNSC	cis	rs6710503	0.926	rs2289393	ENSG00000271936.1	RP11-443B20.1	-3.75	2e-04	0.0249	-0.19	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24705710	chr2:24825610~24826717:+
HNSC	cis	rs9487051	0.768	rs351742	ENSG00000243587.6	C6orf183	3.75	2e-04	0.0249	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109206122	chr6:109165833~109271014:+
HNSC	cis	rs62202398	0.618	rs2869348	ENSG00000276923.1	RP11-321P16.1	-3.75	2e-04	0.0249	-0.32	-0.17	Alcohol consumption;	chr20:48155037	chr20:48073869~48074188:+
HNSC	cis	rs867371	0.571	rs2654222	ENSG00000259429.4	UBE2Q2P2	3.75	2e-04	0.0249	0.18	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82137496	chr15:82355142~82420075:+
HNSC	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	3.75	2e-04	0.0249	0.21	0.17	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
HNSC	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	3.75	2e-04	0.0249	0.19	0.17	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
HNSC	cis	rs73198271	0.562	rs11774860	ENSG00000173295.6	FAM86B3P	-3.75	2e-04	0.0249	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794369	chr8:8228595~8244865:+
HNSC	cis	rs478304	0.651	rs11532071	ENSG00000255120.4	OVOL1-AS1	-3.75	2e-04	0.0249	-0.18	-0.17	Acne (severe);	chr11:65732727	chr11:65789051~65790868:-
HNSC	cis	rs478304	0.651	rs10896038	ENSG00000255120.4	OVOL1-AS1	-3.75	2e-04	0.0249	-0.18	-0.17	Acne (severe);	chr11:65738057	chr11:65789051~65790868:-
HNSC	cis	rs478304	0.651	rs11600918	ENSG00000255120.4	OVOL1-AS1	-3.75	2e-04	0.0249	-0.18	-0.17	Acne (severe);	chr11:65744494	chr11:65789051~65790868:-
HNSC	cis	rs72843506	0.722	rs76309839	ENSG00000189423.10	USP32P3	3.75	2e-04	0.0249	0.27	0.17	Schizophrenia;	chr17:20272147	chr17:20415547~20431008:+
HNSC	cis	rs1979679	0.918	rs10843176	ENSG00000247934.4	RP11-967K21.1	3.75	2e-04	0.0249	0.18	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28163298~28190738:-
HNSC	cis	rs4648045	0.565	rs62327181	ENSG00000230069.3	LRRC37A15P	-3.75	0.000201	0.0249	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102727274~102730721:-
HNSC	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-3.75	0.000201	0.0249	-0.32	-0.17	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000273142.1	RP11-458F8.4	3.75	0.000201	0.0249	0.14	0.17	Aortic root size;	chr7:66581737	chr7:66902857~66906297:+
HNSC	cis	rs11671005	0.695	rs11673069	ENSG00000269473.1	CTD-2619J13.19	3.75	0.000201	0.0249	0.27	0.17	Mean platelet volume;	chr19:58423551	chr19:58440448~58445849:+
HNSC	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	3.75	0.000201	0.0249	0.22	0.17	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
HNSC	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	3.75	0.000201	0.0249	0.22	0.17	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
HNSC	cis	rs7324557	0.683	rs7325328	ENSG00000205861.10	C1QTNF9B-AS1	3.75	0.000201	0.0249	0.24	0.17	Visceral adipose tissue adjusted for BMI;	chr13:23822955	chr13:23888889~23897263:+
HNSC	cis	rs6540731	0.87	rs1967114	ENSG00000226251.4	RP11-15I11.3	3.75	0.000201	0.0249	0.19	0.17	Intelligence (childhood);	chr1:212201994	chr1:212225278~212238977:-
HNSC	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	3.75	0.000201	0.0249	0.21	0.17	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
HNSC	cis	rs2865126	0.818	rs1881088	ENSG00000264714.1	RP11-21G15.1	-3.75	0.000201	0.0249	-0.21	-0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10765794	chr18:10724619~10728539:+
HNSC	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-3.75	0.000201	0.0249	-0.26	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
HNSC	cis	rs4845875	0.534	rs4846052	ENSG00000242349.4	NPPA-AS1	3.75	0.000201	0.0249	0.17	0.17	Midregional pro atrial natriuretic peptide levels;	chr1:11797894	chr1:11841017~11848079:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000272831.1	RP11-792A8.4	3.75	0.000201	0.0249	0.15	0.17	Calcium levels;	chr7:65829754	chr7:66739829~66740385:-
HNSC	cis	rs9908552	0.621	rs9908013	ENSG00000262810.1	RP11-667K14.5	-3.75	0.000201	0.0249	-0.19	-0.17	Schizophrenia;	chr17:1340146	chr17:2089681~2101560:+
HNSC	cis	rs453301	0.624	rs2288673	ENSG00000253981.4	ALG1L13P	3.75	0.000201	0.0249	0.19	0.17	Joint mobility (Beighton score);	chr8:9002766	chr8:8236003~8244667:-
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000204709.4	LINC01556	3.75	0.000201	0.0249	0.27	0.17	Depression;	chr6:28235522	chr6:28943877~28944537:+
HNSC	cis	rs6519955	0.765	rs7292527	ENSG00000231711.2	LINC00899	-3.75	0.000201	0.0249	-0.17	-0.17	Dupuytren's disease;	chr22:46027245	chr22:46039907~46044853:-
HNSC	cis	rs8063160	0.688	rs12924124	ENSG00000260259.1	RP11-368I7.4	-3.75	0.000201	0.0249	-0.43	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89724718	chr16:89682620~89686569:-
HNSC	cis	rs10851478	0.872	rs7172906	ENSG00000259656.1	RP11-325E5.1	3.75	0.000201	0.0249	0.2	0.17	Oral cavity cancer;	chr15:49630578	chr15:49101791~49103264:+
HNSC	cis	rs3018712	0.505	rs7102308	ENSG00000255031.4	RP11-802E16.3	-3.75	0.000201	0.0249	-0.19	-0.17	Total body bone mineral density;	chr11:68645762	chr11:68050740~68053762:+
HNSC	cis	rs6840360	0.87	rs6814554	ENSG00000251611.1	RP11-610P16.1	-3.75	0.000201	0.0249	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151533182	chr4:151407551~151408835:-
HNSC	cis	rs3015497	0.543	rs3015493	ENSG00000277050.1	RP11-102G14.1	-3.75	0.000201	0.0249	-0.18	-0.17	Mean platelet volume;	chr14:50657635	chr14:51637348~51637947:-
HNSC	cis	rs7824557	0.62	rs6996368	ENSG00000255310.2	AF131215.2	3.75	0.000201	0.0249	0.16	0.17	Retinal vascular caliber;	chr8:11325195	chr8:11107788~11109726:-
HNSC	cis	rs7688540	0.8	rs9328738	ENSG00000250892.1	RP11-1365D11.1	3.75	0.000201	0.0249	0.26	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:201409~205009:-
HNSC	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	3.75	0.000201	0.0249	0.18	0.17	QT interval;	chr12:29241487	chr12:29280418~29317848:-
HNSC	cis	rs2735413	0.563	rs2072663	ENSG00000261837.1	RP11-264L1.3	-3.75	0.000201	0.0249	-0.28	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78030836	chr16:78534374~78535648:+
HNSC	cis	rs12611088	0.571	rs2305375	ENSG00000267163.1	AC084219.3	-3.75	0.000201	0.0249	-0.16	-0.17	Plasma amyloid beta peptide concentrations (ABx-42);	chr19:43509108	chr19:44094350~44099711:-
HNSC	cis	rs12546962	0.626	rs17149797	ENSG00000233609.3	RP11-62H7.2	-3.75	0.000201	0.0249	-0.2	-0.17	Body mass index;	chr8:9332461	chr8:8961200~8979025:+
HNSC	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000201	0.0249	-0.24	-0.17	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
HNSC	cis	rs11951515	0.628	rs57066570	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000201	0.025	0.18	0.17	Metabolite levels  (X-11787);	chr5:43355217	chr5:43586918~43588223:-
HNSC	cis	rs1476670	0.545	rs11210948	ENSG00000230615.5	RP5-1198O20.4	-3.75	0.000201	0.025	-0.2	-0.17	Eotaxin levels;	chr1:44054441	chr1:44030443~44115913:+
HNSC	cis	rs793571	0.736	rs34629633	ENSG00000245975.2	RP11-30K9.6	3.75	0.000201	0.025	0.29	0.17	Schizophrenia;	chr15:58977064	chr15:58768072~58770974:-
HNSC	cis	rs9437689	0.934	rs10735790	ENSG00000237416.5	RP11-465K1.2	3.75	0.000201	0.025	0.21	0.17	Phospholipid levels (plasma);	chr1:95038121	chr1:94836748~94855426:-
HNSC	cis	rs7688540	0.771	rs74984113	ENSG00000250892.1	RP11-1365D11.1	-3.75	0.000201	0.025	-0.31	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:201409~205009:-
HNSC	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	3.75	0.000201	0.025	0.2	0.17	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
HNSC	cis	rs300890	0.544	rs13136521	ENSG00000250326.1	RP11-284M14.1	3.75	0.000201	0.025	0.2	0.17	Nasopharyngeal carcinoma;	chr4:143284411	chr4:142933195~143184861:-
HNSC	cis	rs17772222	1	rs79579293	ENSG00000258789.1	RP11-507K2.3	-3.75	0.000201	0.025	-0.21	-0.17	Coronary artery calcification;	chr14:88355724	chr14:88551597~88552493:+
HNSC	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	3.75	0.000202	0.025	0.34	0.17	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
HNSC	cis	rs1971762	0.931	rs12818213	ENSG00000270175.1	RP11-793H13.11	-3.75	0.000202	0.025	-0.16	-0.17	Height;	chr12:53678223	chr12:53500162~53500936:-
HNSC	cis	rs11951515	0.663	rs11742171	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000202	0.025	0.18	0.17	Metabolite levels  (X-11787);	chr5:43358607	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs7708779	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000202	0.025	0.18	0.17	Metabolite levels  (X-11787);	chr5:43359181	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4866824	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000202	0.025	0.18	0.17	Metabolite levels  (X-11787);	chr5:43359343	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs4866825	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000202	0.025	0.18	0.17	Metabolite levels  (X-11787);	chr5:43359517	chr5:43586918~43588223:-
HNSC	cis	rs2976388	1	rs2717562	ENSG00000253741.1	CTD-2292P10.4	3.75	0.000202	0.025	0.16	0.17	Urinary tract infection frequency;	chr8:142695250	chr8:142702252~142726973:-
HNSC	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-3.75	0.000202	0.025	-0.19	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
HNSC	cis	rs67340775	0.541	rs200973	ENSG00000241549.7	GUSBP2	3.75	0.000202	0.025	0.21	0.17	Lung cancer in ever smokers;	chr6:27890643	chr6:26871484~26956554:-
HNSC	cis	rs2439831	0.85	rs16965120	ENSG00000201136.1	RNU6-353P	-3.75	0.000202	0.025	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43808144	chr15:43702363~43702470:+
HNSC	cis	rs2975734	0.674	rs6983870	ENSG00000269918.1	AF131215.9	-3.75	0.000202	0.025	-0.18	-0.17	Chronotype;Morning vs. evening chronotype;	chr8:10253784	chr8:11104691~11106704:-
HNSC	cis	rs67981189	0.593	rs2526871	ENSG00000274818.1	RP1-292L20.3	-3.75	0.000202	0.025	-0.19	-0.17	Schizophrenia;	chr14:70918396	chr14:70906657~70907111:-
HNSC	cis	rs870825	0.616	rs12502860	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184714951	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28459754	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184715126	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6844146	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184715242	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs2003994	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184715414	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs2017101	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184716227	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs745656	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184716369	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552804	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184716545	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552805	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184716740	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552806	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184717077	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs28604350	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184717569	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.698	rs28412823	ENSG00000254233.1	RP11-242J7.1	3.75	0.000202	0.025	0.25	0.17	Blood protein levels;	chr4:184717675	chr4:184584093~184625030:-
HNSC	cis	rs4908760	0.864	rs6674832	ENSG00000232912.4	RP5-1115A15.1	3.75	0.000202	0.025	0.18	0.17	Vitiligo;	chr1:8631820	chr1:8424645~8434838:+
HNSC	cis	rs9896933	0.623	rs77166830	ENSG00000262663.1	RP11-497H17.1	3.75	0.000202	0.025	0.23	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82875649	chr17:82918282~82918785:+
HNSC	cis	rs6095360	0.727	rs35971376	ENSG00000222365.1	SNORD12B	-3.75	0.000202	0.025	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:49105171	chr20:49280319~49280409:+
HNSC	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	3.75	0.000202	0.025	0.22	0.17	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
HNSC	cis	rs830124	1	rs1185260	ENSG00000280138.1	RP11-463O12.5	-3.75	0.000202	0.025	-0.21	-0.17	Urinary metabolites;	chr12:121951342	chr12:122870059~122888720:-
HNSC	cis	rs28830936	0.966	rs2277535	ENSG00000250379.1	RP11-23P13.4	3.75	0.000202	0.025	0.21	0.17	Diastolic blood pressure;	chr15:41827513	chr15:41825099~41827936:-
HNSC	cis	rs10832963	1	rs10832956	ENSG00000256282.1	RP11-504G3.4	-3.75	0.000202	0.025	-0.17	-0.17	Breast cancer;	chr11:18624121	chr11:18595459~18599683:-
HNSC	cis	rs73201462	1	rs13069054	ENSG00000231305.3	RP11-723O4.2	-3.75	0.000202	0.025	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137139	chr3:128861313~128871540:-
HNSC	cis	rs17014483	0.749	rs2924935	ENSG00000248019.2	FAM13A-AS1	-3.75	0.000202	0.025	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88719416	chr4:88709789~88730103:+
HNSC	cis	rs137699	0.652	rs2413589	ENSG00000261202.1	RP3-496C20.1	3.75	0.000202	0.025	0.22	0.17	IgG glycosylation;	chr22:39359684	chr22:40043068~40044530:-
HNSC	cis	rs597539	0.652	rs592697	ENSG00000255741.1	RP11-757G1.5	-3.75	0.000202	0.025	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs654071	ENSG00000255741.1	RP11-757G1.5	-3.75	0.000202	0.025	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68941503~68942852:-
HNSC	cis	rs10888838	0.567	rs3766453	ENSG00000198711.5	SSBP3-AS1	3.75	0.000202	0.025	0.19	0.17	Mitochondrial DNA levels;	chr1:54237196	chr1:54236440~54239063:+
HNSC	cis	rs1497406	0.744	rs12562207	ENSG00000227959.1	RP11-276H7.2	3.75	0.000202	0.025	0.18	0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181564	chr1:16155211~16157329:+
HNSC	cis	rs8063160	0.622	rs34659644	ENSG00000260259.1	RP11-368I7.4	-3.75	0.000202	0.025	-0.43	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89729609	chr16:89682620~89686569:-
HNSC	cis	rs7621025	0.586	rs34553037	ENSG00000239213.4	NCK1-AS1	-3.75	0.000202	0.025	-0.17	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136841726~136862054:-
HNSC	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	3.75	0.000202	0.025	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
HNSC	cis	rs9298506	1	rs10104997	ENSG00000254142.2	RP11-53M11.3	3.75	0.000202	0.025	0.26	0.17	Intracranial aneurysm;	chr8:54527508	chr8:54554361~54561927:+
HNSC	cis	rs9298506	1	rs28503706	ENSG00000254142.2	RP11-53M11.3	3.75	0.000202	0.025	0.26	0.17	Intracranial aneurysm;	chr8:54529239	chr8:54554361~54561927:+
HNSC	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-3.75	0.000202	0.025	-0.21	-0.17	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
HNSC	cis	rs17489649	0.955	rs6894260	ENSG00000271849.1	CTC-332L22.1	3.75	0.000202	0.025	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109774836	chr5:109687802~109688329:-
HNSC	cis	rs4253772	0.591	rs6008545	ENSG00000277232.2	GTSE1-AS1	-3.75	0.000202	0.025	-0.21	-0.17	Cholesterol, total;LDL cholesterol;	chr22:46290478	chr22:46295143~46296660:-
HNSC	cis	rs7572733	0.755	rs6716898	ENSG00000222017.1	AC011997.1	3.75	0.000202	0.025	0.21	0.17	Dermatomyositis;	chr2:198079547	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.792	rs1440089	ENSG00000222017.1	AC011997.1	3.75	0.000202	0.025	0.21	0.17	Dermatomyositis;	chr2:198080223	chr2:197693106~197774823:+
HNSC	cis	rs546131	0.642	rs10836315	ENSG00000271369.1	RP11-350D17.3	3.75	0.000202	0.025	0.23	0.17	Lung disease severity in cystic fibrosis;	chr11:34831799	chr11:34709600~34710161:+
HNSC	cis	rs2408955	0.522	rs4760612	ENSG00000257763.1	OR5BK1P	-3.75	0.000202	0.025	-0.16	-0.17	Glycated hemoglobin levels;	chr12:48028073	chr12:48355792~48356614:-
HNSC	cis	rs8030379	1	rs8024628	ENSG00000230373.7	GOLGA6L5P	-3.75	0.000202	0.025	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917711	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs8029016	ENSG00000230373.7	GOLGA6L5P	-3.75	0.000202	0.025	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917712	chr15:84507885~84516814:-
HNSC	cis	rs1862618	0.671	rs2034244	ENSG00000271828.1	CTD-2310F14.1	-3.75	0.000202	0.025	-0.21	-0.17	Initial pursuit acceleration;	chr5:56946947	chr5:56927874~56929573:+
HNSC	cis	rs6570726	0.791	rs6902404	ENSG00000270638.1	RP3-466P17.1	3.75	0.000202	0.0251	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145735570~145737218:+
HNSC	cis	rs11723261	0.621	rs7692530	ENSG00000211553.1	AC253576.2	-3.75	0.000202	0.0251	-0.25	-0.17	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:136461~136568:+
HNSC	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-3.75	0.000202	0.0251	-0.17	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
HNSC	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-3.75	0.000202	0.0251	-0.17	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
HNSC	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-3.75	0.000202	0.0251	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
HNSC	cis	rs6095360	1	rs1048590	ENSG00000227431.4	CSE1L-AS1	-3.75	0.000202	0.0251	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48993760	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs2295033	ENSG00000227431.4	CSE1L-AS1	-3.75	0.000202	0.0251	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48994359	chr20:49040463~49046044:-
HNSC	cis	rs17014483	0.749	rs2860422	ENSG00000248019.2	FAM13A-AS1	-3.75	0.000202	0.0251	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88723780	chr4:88709789~88730103:+
HNSC	cis	rs683257	0.866	rs118084505	ENSG00000234147.1	RP3-460G2.2	-3.75	0.000202	0.0251	-0.34	-0.17	Facial emotion recognition (angry faces);	chr6:140703974	chr6:140845958~140852924:-
HNSC	cis	rs870825	0.616	rs2141257	ENSG00000254233.1	RP11-242J7.1	-3.75	0.000202	0.0251	-0.27	-0.17	Blood protein levels;	chr4:184688309	chr4:184584093~184625030:-
HNSC	cis	rs11098499	0.604	rs17051352	ENSG00000250412.1	KLHL2P1	3.75	0.000202	0.0251	0.23	0.17	Corneal astigmatism;	chr4:119660272	chr4:119334329~119378233:+
HNSC	cis	rs8063160	0.756	rs35026726	ENSG00000260259.1	RP11-368I7.4	-3.75	0.000203	0.0251	-0.43	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89724871	chr16:89682620~89686569:-
HNSC	cis	rs11951515	0.738	rs11951584	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000203	0.0251	0.18	0.17	Metabolite levels  (X-11787);	chr5:43348904	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs6863246	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000203	0.0251	0.18	0.17	Metabolite levels  (X-11787);	chr5:43349398	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs6887351	ENSG00000249286.1	CTD-2210P15.2	3.75	0.000203	0.0251	0.18	0.17	Metabolite levels  (X-11787);	chr5:43350203	chr5:43586918~43588223:-
HNSC	cis	rs1925953	0.711	rs4511160	ENSG00000233589.1	RP4-694A7.2	-3.75	0.000203	0.0251	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68366693	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs12406972	ENSG00000233589.1	RP4-694A7.2	-3.75	0.000203	0.0251	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68366763	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs4313432	ENSG00000233589.1	RP4-694A7.2	-3.75	0.000203	0.0251	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68366840	chr1:68479129~68483539:+
HNSC	cis	rs1925953	0.711	rs4290098	ENSG00000233589.1	RP4-694A7.2	-3.75	0.000203	0.0251	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68366852	chr1:68479129~68483539:+
HNSC	cis	rs1667255	0.505	rs9963742	ENSG00000266521.1	RP11-650P15.1	3.75	0.000203	0.0251	0.2	0.17	Retinol levels;	chr18:31567021	chr18:31496645~31497195:-
HNSC	cis	rs1667255	0.505	rs4315413	ENSG00000266521.1	RP11-650P15.1	3.75	0.000203	0.0251	0.2	0.17	Retinol levels;	chr18:31567263	chr18:31496645~31497195:-
HNSC	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	3.75	0.000203	0.0251	0.14	0.17	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
HNSC	cis	rs17666538	0.585	rs1669615	ENSG00000254207.1	RP11-43A14.1	3.75	0.000203	0.0251	0.37	0.17	IgG glycosylation;	chr8:666665	chr8:725188~725877:-
HNSC	cis	rs17666538	0.535	rs896522	ENSG00000254207.1	RP11-43A14.1	3.75	0.000203	0.0251	0.37	0.17	IgG glycosylation;	chr8:666991	chr8:725188~725877:-
HNSC	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	3.75	0.000203	0.0251	0.29	0.17	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
HNSC	cis	rs13256369	1	rs7820159	ENSG00000173295.6	FAM86B3P	3.75	0.000203	0.0251	0.22	0.17	Obesity-related traits;	chr8:8718705	chr8:8228595~8244865:+
HNSC	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	3.75	0.000203	0.0251	0.17	0.17	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
HNSC	cis	rs7824557	0.564	rs13274106	ENSG00000255495.1	AC145124.2	-3.75	0.000203	0.0251	-0.19	-0.17	Retinal vascular caliber;	chr8:11376449	chr8:12194467~12196280:+
HNSC	cis	rs4906332	0.933	rs34606394	ENSG00000244691.1	RPL10AP1	-3.75	0.000203	0.0251	-0.2	-0.17	Coronary artery disease;	chr14:103449299	chr14:103412119~103412761:-
HNSC	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000203	0.0251	-0.21	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
HNSC	cis	rs865483	0.895	rs2522965	ENSG00000276054.1	RP11-378E13.3	3.75	0.000203	0.0251	0.21	0.17	Monocyte count;	chr17:37456216	chr17:37386886~37387926:+
HNSC	cis	rs865483	0.895	rs2680718	ENSG00000276054.1	RP11-378E13.3	3.75	0.000203	0.0251	0.21	0.17	Monocyte count;	chr17:37456349	chr17:37386886~37387926:+
HNSC	cis	rs4919687	0.577	rs12765459	ENSG00000236937.2	PTGES3P4	3.75	0.000203	0.0251	0.24	0.17	Colorectal cancer;	chr10:102705930	chr10:102845595~102845950:+
HNSC	cis	rs2048656	0.526	rs6981831	ENSG00000254340.1	RP11-10A14.3	-3.75	0.000203	0.0251	-0.24	-0.17	Schizophrenia;	chr8:9697026	chr8:9141424~9145435:+
HNSC	cis	rs4648045	0.796	rs4648068	ENSG00000230069.3	LRRC37A15P	-3.75	0.000203	0.0251	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102597148	chr4:102727274~102730721:-
HNSC	cis	rs7405404	0.672	rs7404071	ENSG00000262454.1	RP11-65J21.3	-3.75	0.000203	0.0251	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645558	chr16:14302288~14326353:+
HNSC	cis	rs28489187	0.73	rs12140103	ENSG00000223653.4	RP11-131L23.1	3.75	0.000203	0.0251	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383806	chr1:85276715~85448124:+
HNSC	cis	rs73173548	0.502	rs12188494	ENSG00000247828.6	TMEM161B-AS1	3.74	0.000203	0.0251	0.18	0.17	Macular telangiectasia type 2;	chr5:88447747	chr5:88268895~88436685:+
HNSC	cis	rs2919917	0.628	rs2887482	ENSG00000260398.1	RP11-594N15.3	3.74	0.000203	0.0251	0.23	0.17	Lymphocyte counts;	chr8:78659633	chr8:78605952~78609705:+
HNSC	cis	rs60695258	0.726	rs1471251	ENSG00000251411.1	RP11-397E7.4	3.74	0.000203	0.0251	0.17	0.17	Hematocrit;	chr4:87055207	chr4:86913266~86914817:-
HNSC	cis	rs41369048	0.669	rs6660867	ENSG00000238078.1	LINC01352	-3.74	0.000203	0.0251	-0.23	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220829255~220832429:+
HNSC	cis	rs28489187	0.706	rs233091	ENSG00000223653.4	RP11-131L23.1	3.74	0.000203	0.0251	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85357361	chr1:85276715~85448124:+
HNSC	cis	rs1155750	0.72	rs239805	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000203	0.0251	-0.25	-0.17	Colorectal cancer;	chr6:54916590	chr6:54840118~54840855:-
HNSC	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	3.74	0.000203	0.0251	0.19	0.17	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
HNSC	cis	rs3929778	0.848	rs35625351	ENSG00000278192.1	RP5-1056H1.2	3.74	0.000203	0.0251	0.23	0.17	QRS complex (Cornell);	chr20:6525903	chr20:6065966~6067897:-
HNSC	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.000203	0.0252	-0.19	-0.17	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
HNSC	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	3.74	0.000203	0.0252	0.34	0.17	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
HNSC	cis	rs36093844	0.626	rs72959197	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000203	0.0252	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85999953	chr11:85852557~85854943:-
HNSC	cis	rs6071166	0.683	rs6071101	ENSG00000224635.1	RP4-564F22.5	-3.74	0.000203	0.0252	-0.21	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689335	chr20:38406011~38416797:-
HNSC	cis	rs6071166	0.683	rs6015637	ENSG00000224635.1	RP4-564F22.5	-3.74	0.000203	0.0252	-0.21	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689862	chr20:38406011~38416797:-
HNSC	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
HNSC	cis	rs870825	0.616	rs7678900	ENSG00000254233.1	RP11-242J7.1	3.74	0.000203	0.0252	0.25	0.17	Blood protein levels;	chr4:184714095	chr4:184584093~184625030:-
HNSC	cis	rs7819412	0.521	rs10110684	ENSG00000255310.2	AF131215.2	-3.74	0.000203	0.0252	-0.17	-0.17	Triglycerides;	chr8:11181650	chr8:11107788~11109726:-
HNSC	cis	rs17783634	0.509	rs11775489	ENSG00000255310.2	AF131215.2	-3.74	0.000203	0.0252	-0.17	-0.17	Subjective well-being;	chr8:11179334	chr8:11107788~11109726:-
HNSC	cis	rs728616	0.558	rs34268041	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000203	0.0252	-0.32	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79663088~79826594:-
HNSC	cis	rs62025270	0.58	rs62022938	ENSG00000259762.1	RP11-158M2.4	-3.74	0.000203	0.0252	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85750336~85752901:-
HNSC	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	3.74	0.000203	0.0252	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
HNSC	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	3.74	0.000203	0.0252	0.13	0.17	Breast size;	chr12:9205627	chr12:9277235~9313241:+
HNSC	cis	rs1008375	0.9	rs10019460	ENSG00000249502.1	AC006160.5	3.74	0.000203	0.0252	0.19	0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684714	chr4:17587467~17614571:-
HNSC	cis	rs2905347	0.755	rs2961288	ENSG00000179428.2	AC073072.5	3.74	0.000203	0.0252	0.21	0.17	Major depression and alcohol dependence;	chr7:22625510	chr7:22725395~22727620:-
HNSC	cis	rs2486288	0.539	rs2433601	ENSG00000259479.5	SORD2P	3.74	0.000204	0.0252	0.2	0.17	Glomerular filtration rate;	chr15:45424227	chr15:44826371~44884694:-
HNSC	cis	rs2013441	1	rs2107566	ENSG00000261033.1	RP11-209D14.2	3.74	0.000204	0.0252	0.19	0.17	Obesity-related traits;	chr17:20199939	chr17:20008051~20009234:-
HNSC	cis	rs2944755	1	rs2944755	ENSG00000279766.1	RP11-642A1.2	3.74	0.000204	0.0252	0.21	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564095	chr8:140572142~140572812:-
HNSC	cis	rs56804039	1	rs67180327	ENSG00000254153.1	CTA-398F10.2	-3.74	0.000204	0.0252	-0.22	-0.17	Cervical cancer;	chr8:8523244	chr8:8456909~8461337:-
HNSC	cis	rs9959145	1	rs28815517	ENSG00000267249.1	RP11-973H7.3	-3.74	0.000204	0.0252	-0.25	-0.17	Immune response to smallpox vaccine (IL-6);	chr18:12558747	chr18:12670426~12671145:-
HNSC	cis	rs870825	0.655	rs28726376	ENSG00000254233.1	RP11-242J7.1	3.74	0.000204	0.0252	0.25	0.17	Blood protein levels;	chr4:184717800	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs35764203	ENSG00000254233.1	RP11-242J7.1	3.74	0.000204	0.0252	0.25	0.17	Blood protein levels;	chr4:184717924	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs35397385	ENSG00000254233.1	RP11-242J7.1	3.74	0.000204	0.0252	0.25	0.17	Blood protein levels;	chr4:184717941	chr4:184584093~184625030:-
HNSC	cis	rs67981189	0.634	rs221898	ENSG00000274818.1	RP1-292L20.3	3.74	0.000204	0.0252	0.19	0.17	Schizophrenia;	chr14:71138799	chr14:70906657~70907111:-
HNSC	cis	rs7302981	0.775	rs706790	ENSG00000272368.2	RP4-605O3.4	3.74	0.000204	0.0252	0.17	0.17	Systolic blood pressure;	chr12:50070687	chr12:50112197~50165618:+
HNSC	cis	rs6968419	0.755	rs2896181	ENSG00000237870.5	AC073130.1	-3.74	0.000204	0.0252	-0.21	-0.17	Intraocular pressure;	chr7:116257830	chr7:116275606~116286734:-
HNSC	cis	rs6012564	0.927	rs6019570	ENSG00000227431.4	CSE1L-AS1	-3.74	0.000204	0.0252	-0.19	-0.17	Anger;	chr20:48983153	chr20:49040463~49046044:-
HNSC	cis	rs10791097	0.547	rs3829271	ENSG00000254842.5	RP11-890B15.2	-3.74	0.000204	0.0252	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130884017	chr11:130844191~130865561:-
HNSC	cis	rs7989332	0.925	rs7324188	ENSG00000226633.2	PPIAP28	-3.74	0.000204	0.0252	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20476031	chr13:20178978~20179462:-
HNSC	cis	rs12534093	0.921	rs11762335	ENSG00000234286.1	AC006026.13	-3.74	0.000204	0.0252	-0.21	-0.17	Infant length;Height;	chr7:23455577	chr7:23680195~23680786:-
HNSC	cis	rs12534093	0.921	rs12700441	ENSG00000234286.1	AC006026.13	-3.74	0.000204	0.0252	-0.21	-0.17	Infant length;Height;	chr7:23456292	chr7:23680195~23680786:-
HNSC	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
HNSC	cis	rs889398	0.677	rs68161338	ENSG00000196696.11	PDXDC2P	3.74	0.000204	0.0252	0.12	0.17	Body mass index;	chr16:69789875	chr16:69976297~70065948:-
HNSC	cis	rs17122278	1	rs55857590	ENSG00000255422.1	AP002954.4	3.74	0.000204	0.0252	0.3	0.17	Total cholesterol levels;	chr11:118554348	chr11:118704607~118750263:+
HNSC	cis	rs526231	0.819	rs2288788	ENSG00000250682.4	LINC00491	3.74	0.000204	0.0252	0.24	0.17	Primary biliary cholangitis;	chr5:103264868	chr5:102609156~102671559:-
HNSC	cis	rs7772486	0.686	rs9403741	ENSG00000270638.1	RP3-466P17.1	-3.74	0.000204	0.0252	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145735570~145737218:+
HNSC	cis	rs2562456	0.833	rs17680605	ENSG00000268081.1	RP11-678G14.2	3.74	0.000204	0.0252	0.25	0.17	Pain;	chr19:21379646	chr19:21554640~21569237:-
HNSC	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
HNSC	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-3.74	0.000204	0.0252	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
HNSC	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-3.74	0.000204	0.0252	-0.22	-0.17	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
HNSC	cis	rs6545883	0.894	rs778157	ENSG00000271889.1	RP11-493E12.1	3.74	0.000204	0.0252	0.2	0.17	Tuberculosis;	chr2:61327154	chr2:61151433~61162105:-
HNSC	cis	rs11992162	0.597	rs7011924	ENSG00000227888.4	FAM66A	-3.74	0.000204	0.0252	-0.18	-0.17	Monocyte count;	chr8:11923084	chr8:12362019~12388296:+
HNSC	cis	rs6964587	0.869	rs55811257	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000204	0.0252	0.18	0.17	Breast cancer;	chr7:91855485	chr7:92134604~92180725:+
HNSC	cis	rs8044868	0.512	rs4788461	ENSG00000259209.3	RP5-991G20.2	3.74	0.000204	0.0252	0.18	0.17	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72122101	chr16:72805998~72809872:+
HNSC	cis	rs11024102	0.962	rs34927905	ENSG00000260196.1	RP1-239B22.5	-3.74	0.000204	0.0252	-0.22	-0.17	Glaucoma (primary angle closure);	chr11:16979880	chr11:17380649~17383531:+
HNSC	cis	rs35306767	0.903	rs11253475	ENSG00000229869.1	RP11-363N22.2	-3.74	0.000204	0.0252	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:861322	chr10:933026~942743:+
HNSC	cis	rs643506	0.874	rs687152	ENSG00000230911.1	PPIHP1	-3.74	0.000204	0.0252	-0.22	-0.17	Breast cancer;	chr11:111850950	chr11:112029858~112030367:-
HNSC	cis	rs643506	0.874	rs4936786	ENSG00000230911.1	PPIHP1	-3.74	0.000204	0.0252	-0.22	-0.17	Breast cancer;	chr11:111856504	chr11:112029858~112030367:-
HNSC	cis	rs2384207	0.584	rs56801977	ENSG00000201208.1	Y_RNA	-3.74	0.000204	0.0252	-0.26	-0.17	Response to fenofibrate (adiponectin levels);	chr12:113319304	chr12:113178423~113178519:-
HNSC	cis	rs2384207	0.584	rs67188229	ENSG00000201208.1	Y_RNA	-3.74	0.000204	0.0252	-0.26	-0.17	Response to fenofibrate (adiponectin levels);	chr12:113321915	chr12:113178423~113178519:-
HNSC	cis	rs2384207	0.584	rs10507238	ENSG00000201208.1	Y_RNA	3.74	0.000204	0.0252	0.26	0.17	Response to fenofibrate (adiponectin levels);	chr12:113311975	chr12:113178423~113178519:-
HNSC	cis	rs1155750	0.72	rs239847	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000204	0.0252	-0.25	-0.17	Colorectal cancer;	chr6:54899240	chr6:54840118~54840855:-
HNSC	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	3.74	0.000204	0.0252	0.2	0.17	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
HNSC	cis	rs11722228	1	rs11722228	ENSG00000250413.1	RP11-448G15.1	-3.74	0.000204	0.0252	-0.22	-0.17	Urate levels;Serum uric acid levels;Gout;	chr4:9914117	chr4:10006482~10009725:+
HNSC	cis	rs7824557	0.62	rs6996368	ENSG00000255020.1	AF131216.5	3.74	0.000204	0.0252	0.18	0.17	Retinal vascular caliber;	chr8:11325195	chr8:11345748~11347502:-
HNSC	cis	rs28489187	0.66	rs2207368	ENSG00000223653.4	RP11-131L23.1	3.74	0.000204	0.0253	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85382000	chr1:85276715~85448124:+
HNSC	cis	rs6504950	0.76	rs17745189	ENSG00000279059.1	RP11-257O5.2	-3.74	0.000204	0.0253	-0.15	-0.17	Breast cancer;	chr17:54936619	chr17:54956760~54958426:-
HNSC	cis	rs7809950	0.678	rs3801966	ENSG00000238832.1	snoU109	-3.74	0.000204	0.0253	-0.26	-0.17	Coronary artery disease;	chr7:107184135	chr7:107603363~107603507:+
HNSC	cis	rs10789207	0.531	rs72669465	ENSG00000248458.2	RP4-598P13.1	-3.74	0.000204	0.0253	-0.27	-0.17	Resting heart rate;	chr1:66650273	chr1:66665864~66677027:-
HNSC	cis	rs656900	0.647	rs1615963	ENSG00000261229.4	MTHFS	3.74	0.000204	0.0253	0.19	0.17	Cerebrospinal P-tau181p levels;	chr15:79823484	chr15:79843547~79897285:-
HNSC	cis	rs4356203	0.846	rs1685932	ENSG00000272034.1	SNORD14A	-3.74	0.000204	0.0253	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17074654~17074744:-
HNSC	cis	rs11168618	0.967	rs11168619	ENSG00000240399.1	RP1-228P16.1	3.74	0.000204	0.0253	0.14	0.17	Adiponectin levels;	chr12:48539822	chr12:48054813~48055591:-
HNSC	cis	rs9652601	0.779	rs12935413	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000204	0.0253	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11116590	chr16:11056556~11057034:+
HNSC	cis	rs2239557	1	rs2358633	ENSG00000258769.1	RAP1AP	3.74	0.000204	0.0253	0.18	0.17	Common traits (Other);	chr14:74180715	chr14:74482985~74483435:+
HNSC	cis	rs6568686	0.627	rs403667	ENSG00000255389.1	C6orf3	3.74	0.000205	0.0253	0.22	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111589401	chr6:111599875~111602295:+
HNSC	cis	rs896655	0.629	rs10965144	ENSG00000244230.3	RN7SL151P	3.74	0.000205	0.0253	0.19	0.17	Coronary artery disease;	chr9:21808914	chr9:21699314~21699596:+
HNSC	cis	rs6964587	0.967	rs2040499	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000205	0.0253	0.18	0.17	Breast cancer;	chr7:92180343	chr7:92134604~92180725:+
HNSC	cis	rs11002791	0.607	rs10824705	ENSG00000224596.6	ZMIZ1-AS1	3.74	0.000205	0.0253	0.21	0.17	Red blood cell count;	chr10:79032771	chr10:78943328~79067895:-
HNSC	cis	rs7306455	0.558	rs12809276	ENSG00000237774.3	RP11-129B9.1	-3.74	0.000205	0.0253	-0.4	-0.17	Coronary artery disease;	chr12:94930510	chr12:95125760~95126389:+
HNSC	cis	rs865483	0.895	rs853211	ENSG00000276054.1	RP11-378E13.3	3.74	0.000205	0.0253	0.21	0.17	Monocyte count;	chr17:37468060	chr17:37386886~37387926:+
HNSC	cis	rs6012564	1	rs2295028	ENSG00000227431.4	CSE1L-AS1	-3.74	0.000205	0.0253	-0.19	-0.17	Anger;	chr20:48966421	chr20:49040463~49046044:-
HNSC	cis	rs2836974	0.644	rs11088471	ENSG00000255568.3	BRWD1-AS2	-3.74	0.000205	0.0253	-0.15	-0.17	Cognitive function;	chr21:39327387	chr21:39313935~39314962:+
HNSC	cis	rs6120141	1	rs73904623	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000205	0.0253	-0.4	-0.17	Smooth-surface caries;	chr20:33182478	chr20:33985617~33988989:-
HNSC	cis	rs6120141	1	rs73904625	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000205	0.0253	-0.4	-0.17	Smooth-surface caries;	chr20:33182598	chr20:33985617~33988989:-
HNSC	cis	rs250677	0.617	rs166106	ENSG00000250072.4	CTC-529P8.1	-3.74	0.000205	0.0253	-0.23	-0.17	Breast cancer;	chr5:149067498	chr5:149063317~149109787:+
HNSC	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000205	0.0253	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
HNSC	cis	rs4841134	0.902	rs6999153	ENSG00000233609.3	RP11-62H7.2	-3.74	0.000205	0.0253	-0.16	-0.17	Age-related disease endophenotypes;	chr8:9335991	chr8:8961200~8979025:+
HNSC	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	3.74	0.000205	0.0253	0.15	0.17	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	3.74	0.000205	0.0253	0.15	0.17	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	3.74	0.000205	0.0253	0.15	0.17	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	3.74	0.000205	0.0253	0.15	0.17	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
HNSC	cis	rs889398	0.9	rs4783722	ENSG00000226232.7	RP11-419C5.2	3.74	0.000205	0.0253	0.15	0.17	Body mass index;	chr16:69548009	chr16:69976388~69996188:-
HNSC	cis	rs73201462	0.908	rs2955094	ENSG00000231305.3	RP11-723O4.2	3.74	0.000205	0.0253	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258080	chr3:128861313~128871540:-
HNSC	cis	rs853679	1	rs853676	ENSG00000219891.2	ZSCAN12P1	3.74	0.000205	0.0253	0.27	0.17	Depression;	chr6:28331910	chr6:28091154~28093664:+
HNSC	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	3.74	0.000205	0.0253	0.18	0.17	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
HNSC	cis	rs2307394	0.716	rs12468864	ENSG00000281469.1	RP11-567F11.1	3.74	0.000205	0.0253	0.19	0.17	Urate levels;	chr2:147759109	chr2:148044380~148044894:+
HNSC	cis	rs2016266	0.75	rs10876432	ENSG00000270175.1	RP11-793H13.11	-3.74	0.000205	0.0253	-0.17	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53338107	chr12:53500162~53500936:-
HNSC	cis	rs2243480	1	rs316331	ENSG00000232546.1	RP11-458F8.1	3.74	0.000205	0.0253	0.24	0.17	Diabetic kidney disease;	chr7:66139635	chr7:66848496~66858136:+
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000272831.1	RP11-792A8.4	3.74	0.000205	0.0253	0.15	0.17	Calcium levels;	chr7:65806798	chr7:66739829~66740385:-
HNSC	cis	rs17253792	0.732	rs75796044	ENSG00000186615.9	KTN1-AS1	-3.74	0.000205	0.0253	-0.36	-0.17	Putamen volume;	chr14:55567410	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs77761669	ENSG00000186615.9	KTN1-AS1	-3.74	0.000205	0.0253	-0.36	-0.17	Putamen volume;	chr14:55567498	chr14:55499278~55580110:-
HNSC	cis	rs2836974	0.583	rs2410124	ENSG00000255568.3	BRWD1-AS2	-3.74	0.000205	0.0253	-0.15	-0.17	Cognitive function;	chr21:39332834	chr21:39313935~39314962:+
HNSC	cis	rs3096299	0.933	rs2930219	ENSG00000261118.1	RP11-104N10.1	3.74	0.000205	0.0253	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89492017~89504460:-
HNSC	cis	rs12534093	0.96	rs11769151	ENSG00000234286.1	AC006026.13	-3.74	0.000205	0.0253	-0.21	-0.17	Infant length;Height;	chr7:23464689	chr7:23680195~23680786:-
HNSC	cis	rs13179617	0.928	rs1477355	ENSG00000215032.2	GNL3LP1	-3.74	0.000205	0.0253	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61464873	chr5:60891935~60893577:-
HNSC	cis	rs6430585	0.528	rs309159	ENSG00000231890.6	DARS-AS1	-3.74	0.000205	0.0253	-0.29	-0.17	Corneal structure;	chr2:135927370	chr2:135985176~136022593:+
HNSC	cis	rs865483	0.895	rs853192	ENSG00000276054.1	RP11-378E13.3	3.74	0.000205	0.0253	0.21	0.17	Monocyte count;	chr17:37461827	chr17:37386886~37387926:+
HNSC	cis	rs860295	0.702	rs4971095	ENSG00000225855.5	RUSC1-AS1	-3.74	0.000205	0.0253	-0.12	-0.17	Body mass index;	chr1:155636433	chr1:155316863~155324176:-
HNSC	cis	rs6688613	0.729	rs2072742	ENSG00000215834.7	FMO9P	3.74	0.000205	0.0253	0.24	0.17	Refractive astigmatism;	chr1:166960436	chr1:166603675~166631400:+
HNSC	cis	rs6688613	0.729	rs10918603	ENSG00000215834.7	FMO9P	3.74	0.000205	0.0253	0.24	0.17	Refractive astigmatism;	chr1:166967266	chr1:166603675~166631400:+
HNSC	cis	rs6688613	0.729	rs7545806	ENSG00000215834.7	FMO9P	3.74	0.000205	0.0253	0.24	0.17	Refractive astigmatism;	chr1:166969318	chr1:166603675~166631400:+
HNSC	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	3.74	0.000205	0.0254	0.21	0.17	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
HNSC	cis	rs11168618	0.904	rs12371700	ENSG00000240399.1	RP1-228P16.1	-3.74	0.000205	0.0254	-0.14	-0.17	Adiponectin levels;	chr12:48525430	chr12:48054813~48055591:-
HNSC	cis	rs3929778	0.816	rs2876037	ENSG00000275632.1	RP5-967N21.11	-3.74	0.000205	0.0254	-0.18	-0.17	QRS complex (Cornell);	chr20:6554912	chr20:6000418~6000941:+
HNSC	cis	rs6852435	1	rs34717346	ENSG00000234801.3	MORF4	3.74	0.000205	0.0254	0.27	0.17	Response to acetaminophen (hepatotoxicity);	chr4:174374908	chr4:173615936~173616906:-
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-3.74	0.000205	0.0254	-0.15	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
HNSC	cis	rs7007970	1	rs11785712	ENSG00000279347.1	RP11-85I17.2	3.74	0.000205	0.0254	0.23	0.17	Height;	chr8:119662980	chr8:119838736~119840385:-
HNSC	cis	rs8063160	0.621	rs12925026	ENSG00000260259.1	RP11-368I7.4	-3.74	0.000205	0.0254	-0.43	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89726448	chr16:89682620~89686569:-
HNSC	cis	rs12291225	0.645	rs3763950	ENSG00000254418.1	RP11-21L19.1	3.74	0.000205	0.0254	0.2	0.17	Sense of smell;	chr11:14256503	chr11:14262846~14273691:-
HNSC	cis	rs61629263	0.503	rs9303539	ENSG00000260793.2	RP5-882C2.2	3.74	0.000205	0.0254	0.15	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43738398	chr17:44221401~44223710:+
HNSC	cis	rs7674212	0.531	rs10006474	ENSG00000248740.4	RP11-328K4.1	3.74	0.000205	0.0254	0.18	0.17	Type 2 diabetes;	chr4:103006890	chr4:103256159~103453658:+
HNSC	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	3.74	0.000205	0.0254	0.23	0.17	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
HNSC	cis	rs8062405	1	rs55830740	ENSG00000261089.1	RP11-435I10.3	3.74	0.000206	0.0254	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28413703~28415018:+
HNSC	cis	rs9859260	0.744	rs406271	ENSG00000273009.1	RP11-352G9.1	3.74	0.000206	0.0254	0.2	0.17	Mean corpuscular volume;	chr3:196050105	chr3:195913078~195913683:-
HNSC	cis	rs62458065	0.85	rs7808992	ENSG00000226468.2	AC018641.7	3.74	0.000206	0.0254	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32456963~32457758:-
HNSC	cis	rs62458065	0.85	rs62458098	ENSG00000226468.2	AC018641.7	3.74	0.000206	0.0254	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32456963~32457758:-
HNSC	cis	rs62458065	0.85	rs73096034	ENSG00000226468.2	AC018641.7	3.74	0.000206	0.0254	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32456963~32457758:-
HNSC	cis	rs62458065	0.85	rs62458099	ENSG00000226468.2	AC018641.7	3.74	0.000206	0.0254	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32456963~32457758:-
HNSC	cis	rs4388249	0.904	rs12187114	ENSG00000271849.1	CTC-332L22.1	-3.74	0.000206	0.0254	-0.27	-0.17	Schizophrenia;	chr5:109864270	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.904	rs11241042	ENSG00000271849.1	CTC-332L22.1	-3.74	0.000206	0.0254	-0.27	-0.17	Schizophrenia;	chr5:109864280	chr5:109687802~109688329:-
HNSC	cis	rs889398	0.617	rs4985450	ENSG00000226232.7	RP11-419C5.2	3.74	0.000206	0.0254	0.15	0.17	Body mass index;	chr16:69867203	chr16:69976388~69996188:-
HNSC	cis	rs6787172	0.651	rs4680436	ENSG00000272087.1	RP11-379F4.7	3.74	0.000206	0.0254	0.18	0.17	Subjective well-being;	chr3:158441528	chr3:158693120~158693768:-
HNSC	cis	rs2307394	1	rs13012455	ENSG00000281469.1	RP11-567F11.1	3.74	0.000206	0.0254	0.2	0.17	Urate levels;	chr2:148030667	chr2:148044380~148044894:+
HNSC	cis	rs10463554	0.501	rs6860813	ENSG00000250682.4	LINC00491	3.74	0.000206	0.0254	0.21	0.17	Parkinson's disease;	chr5:103353125	chr5:102609156~102671559:-
HNSC	cis	rs804280	0.542	rs35647515	ENSG00000227888.4	FAM66A	3.74	0.000206	0.0254	0.17	0.17	Myopia (pathological);	chr8:11934120	chr8:12362019~12388296:+
HNSC	cis	rs4930561	0.765	rs4930564	ENSG00000184795.9	UNC93B5	3.74	0.000206	0.0254	0.19	0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr11:67711702~67716005:-
HNSC	cis	rs2048656	0.605	rs11989726	ENSG00000233609.3	RP11-62H7.2	3.74	0.000206	0.0254	0.18	0.17	Schizophrenia;	chr8:9791177	chr8:8961200~8979025:+
HNSC	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-3.74	0.000206	0.0254	-0.2	-0.17	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
HNSC	cis	rs62025270	0.632	rs56153788	ENSG00000259762.1	RP11-158M2.4	-3.74	0.000206	0.0254	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85750336~85752901:-
HNSC	cis	rs12893668	0.667	rs71417869	ENSG00000269910.1	RP11-73M18.10	3.74	0.000206	0.0254	0.17	0.17	Reticulocyte count;	chr14:103611097	chr14:103694516~103695050:-
HNSC	cis	rs4947019	1	rs11153170	ENSG00000260273.1	RP11-425D10.10	-3.74	0.000206	0.0254	-0.36	-0.17	Hematological parameters;	chr6:109331325	chr6:109382795~109383666:+
HNSC	cis	rs4372836	0.964	rs4665431	ENSG00000226833.4	AC097724.3	-3.74	0.000206	0.0254	-0.21	-0.17	Body mass index;	chr2:28715302	chr2:28708953~28736205:-
HNSC	cis	rs62292953	0.86	rs10935018	ENSG00000248724.5	NPHP3-AS1	-3.74	0.000206	0.0254	-0.3	-0.17	Red cell distribution width;	chr3:132549625	chr3:132721750~132874223:+
HNSC	cis	rs61160187	0.51	rs10057395	ENSG00000215032.2	GNL3LP1	3.74	0.000206	0.0254	0.19	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792967	chr5:60891935~60893577:-
HNSC	cis	rs9907295	0.901	rs4796120	ENSG00000270977.1	AC015849.16	3.74	0.000206	0.0254	0.27	0.17	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35893707~35911023:-
HNSC	cis	rs12291225	0.637	rs8570	ENSG00000254418.1	RP11-21L19.1	3.74	0.000206	0.0254	0.2	0.17	Sense of smell;	chr11:14279213	chr11:14262846~14273691:-
HNSC	cis	rs2013441	0.932	rs2526479	ENSG00000261033.1	RP11-209D14.2	3.74	0.000206	0.0254	0.19	0.17	Obesity-related traits;	chr17:20226908	chr17:20008051~20009234:-
HNSC	cis	rs10242455	0.557	rs59672032	ENSG00000078319.8	PMS2P1	-3.74	0.000206	0.0254	-0.33	-0.17	Blood metabolite levels;	chr7:99461074	chr7:100320992~100341908:-
HNSC	cis	rs6968419	0.674	rs4730726	ENSG00000237870.5	AC073130.1	3.74	0.000206	0.0254	0.21	0.17	Intraocular pressure;	chr7:116273282	chr7:116275606~116286734:-
HNSC	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	3.74	0.000206	0.0254	0.24	0.17	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
HNSC	cis	rs9532669	0.89	rs4941999	ENSG00000168852.11	TPTE2P5	3.74	0.000206	0.0254	0.17	0.17	Cervical cancer;	chr13:40859926	chr13:40822296~40921749:-
HNSC	cis	rs3750965	0.919	rs12280942	ENSG00000265539.1	MIR3164	3.74	0.000206	0.0254	0.18	0.17	Hair color;	chr11:69092215	chr11:69083176~69083258:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000206	0.0254	-0.19	-0.17	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000206	0.0254	-0.19	-0.17	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
HNSC	cis	rs700651	0.789	rs1371663	ENSG00000231621.1	AC013264.2	3.74	0.000206	0.0255	0.17	0.17	Intracranial aneurysm;	chr2:198035581	chr2:197197991~197199273:+
HNSC	cis	rs7868228	0.838	rs13301949	ENSG00000240498.5	CDKN2B-AS1	-3.74	0.000206	0.0255	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21671322	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.891	rs16938523	ENSG00000240498.5	CDKN2B-AS1	-3.74	0.000206	0.0255	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21671605	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.891	rs62557244	ENSG00000240498.5	CDKN2B-AS1	-3.74	0.000206	0.0255	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21671749	chr9:21994778~22121097:+
HNSC	cis	rs4256159	1	rs4600836	ENSG00000228956.7	SATB1-AS1	3.74	0.000206	0.0255	0.27	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18727359	chr3:18445024~18920401:+
HNSC	cis	rs12285276	0.504	rs7120278	ENSG00000205106.4	DKFZp779M0652	3.74	0.000206	0.0255	0.24	0.17	Visceral fat;	chr11:45796560	chr11:45771432~45772358:+
HNSC	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	3.74	0.000206	0.0255	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
HNSC	cis	rs970821	0.667	rs10956146	ENSG00000253106.1	RP11-158K1.3	-3.74	0.000206	0.0255	-0.15	-0.17	Breast cancer;	chr8:123737464	chr8:124488510~124491643:+
HNSC	cis	rs4648045	0.647	rs11097787	ENSG00000230069.3	LRRC37A15P	-3.74	0.000206	0.0255	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102486185	chr4:102727274~102730721:-
HNSC	cis	rs6840360	0.642	rs7684462	ENSG00000251611.1	RP11-610P16.1	-3.74	0.000206	0.0255	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151407551~151408835:-
HNSC	cis	rs11711311	0.955	rs9866806	ENSG00000241529.3	RN7SL767P	3.74	0.000206	0.0255	0.22	0.17	IgG glycosylation;	chr3:113661018	chr3:113632704~113632998:+
HNSC	cis	rs6600671	0.967	rs11249347	ENSG00000272583.1	RP11-344P13.6	-3.74	0.000206	0.0255	-0.19	-0.17	Hip geometry;	chr1:121446489	chr1:121518366~121518829:-
HNSC	cis	rs6600671	1	rs12047116	ENSG00000272583.1	RP11-344P13.6	-3.74	0.000206	0.0255	-0.19	-0.17	Hip geometry;	chr1:121443912	chr1:121518366~121518829:-
HNSC	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	3.74	0.000206	0.0255	0.17	0.17	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
HNSC	cis	rs9733	0.818	rs4970926	ENSG00000236713.1	RP11-363I22.3	3.74	0.000206	0.0255	0.18	0.17	Tonsillectomy;	chr1:150701208	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs12403609	ENSG00000236713.1	RP11-363I22.3	3.74	0.000206	0.0255	0.18	0.17	Tonsillectomy;	chr1:150704009	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs6694531	ENSG00000236713.1	RP11-363I22.3	3.74	0.000206	0.0255	0.18	0.17	Tonsillectomy;	chr1:150711036	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs10888388	ENSG00000236713.1	RP11-363I22.3	3.74	0.000206	0.0255	0.18	0.17	Tonsillectomy;	chr1:150714820	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs12130363	ENSG00000236713.1	RP11-363I22.3	3.74	0.000206	0.0255	0.18	0.17	Tonsillectomy;	chr1:150716120	chr1:150780272~150780644:+
HNSC	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	3.74	0.000207	0.0255	0.17	0.17	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
HNSC	cis	rs4648045	0.621	rs747559	ENSG00000230069.3	LRRC37A15P	3.74	0.000207	0.0255	0.17	0.17	Lymphocyte percentage of white cells;	chr4:102493018	chr4:102727274~102730721:-
HNSC	cis	rs7937890	0.967	rs963212	ENSG00000254418.1	RP11-21L19.1	-3.74	0.000207	0.0255	-0.2	-0.17	Mitochondrial DNA levels;	chr11:14303186	chr11:14262846~14273691:-
HNSC	cis	rs2836974	0.623	rs7280326	ENSG00000255568.3	BRWD1-AS2	-3.74	0.000207	0.0255	-0.15	-0.17	Cognitive function;	chr21:39328482	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.644	rs2836986	ENSG00000255568.3	BRWD1-AS2	-3.74	0.000207	0.0255	-0.15	-0.17	Cognitive function;	chr21:39330210	chr21:39313935~39314962:+
HNSC	cis	rs2030746	0.899	rs11686154	ENSG00000237614.1	AC073257.2	3.74	0.000207	0.0255	0.2	0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553361	chr2:120542909~120544326:-
HNSC	cis	rs7781557	0.64	rs66712128	ENSG00000239969.4	RP11-163E9.2	-3.74	0.000207	0.0255	-0.24	-0.17	Colorectal adenoma (advanced);	chr7:102976540	chr7:102364162~102380633:+
HNSC	cis	rs2836974	0.796	rs77153312	ENSG00000255568.3	BRWD1-AS2	3.74	0.000207	0.0255	0.16	0.17	Cognitive function;	chr21:39323573	chr21:39313935~39314962:+
HNSC	cis	rs6710503	0.632	rs62140560	ENSG00000271936.1	RP11-443B20.1	-3.74	0.000207	0.0255	-0.22	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24785409	chr2:24825610~24826717:+
HNSC	cis	rs6088580	0.634	rs2184836	ENSG00000276073.1	RP5-1125A11.7	3.74	0.000207	0.0255	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.609	rs6058029	ENSG00000276073.1	RP5-1125A11.7	3.74	0.000207	0.0255	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6088478	ENSG00000276073.1	RP5-1125A11.7	3.74	0.000207	0.0255	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.608	rs2105109	ENSG00000276073.1	RP5-1125A11.7	3.74	0.000207	0.0255	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:33985617~33988989:-
HNSC	cis	rs7572733	0.905	rs1866664	ENSG00000222017.1	AC011997.1	3.74	0.000207	0.0255	0.2	0.17	Dermatomyositis;	chr2:197995704	chr2:197693106~197774823:+
HNSC	cis	rs1859596	1	rs2158706	ENSG00000234456.6	MAGI2-AS3	3.74	0.000207	0.0255	0.13	0.17	Reading or mathematical ability;	chr7:79469955	chr7:79452877~79471208:+
HNSC	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	3.74	0.000207	0.0255	0.15	0.17	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	3.74	0.000207	0.0255	0.15	0.17	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
HNSC	cis	rs6928977	0.863	rs2746419	ENSG00000217482.2	HMGB1P17	-3.74	0.000207	0.0255	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135332717	chr6:135636086~135636713:-
HNSC	cis	rs36093924	0.586	rs6002561	ENSG00000182057.4	OGFRP1	-3.74	0.000207	0.0255	-0.17	-0.17	Intelligence;	chr22:41963200	chr22:42269753~42275196:+
HNSC	cis	rs859767	0.741	rs4954159	ENSG00000224043.6	CCNT2-AS1	3.74	0.000207	0.0255	0.2	0.17	Neuroticism;	chr2:134669212	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.741	rs7571113	ENSG00000224043.6	CCNT2-AS1	3.74	0.000207	0.0255	0.2	0.17	Neuroticism;	chr2:134669822	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.741	rs11898084	ENSG00000224043.6	CCNT2-AS1	3.74	0.000207	0.0255	0.2	0.17	Neuroticism;	chr2:134670484	chr2:134735464~134918710:-
HNSC	cis	rs1023500	1	rs7293091	ENSG00000205702.9	CYP2D7	-3.74	0.000207	0.0255	-0.14	-0.17	Schizophrenia;	chr22:41945304	chr22:42140203~42144577:-
HNSC	cis	rs7824557	0.806	rs34171564	ENSG00000269918.1	AF131215.9	-3.74	0.000207	0.0255	-0.17	-0.17	Retinal vascular caliber;	chr8:11237837	chr8:11104691~11106704:-
HNSC	cis	rs6587515	1	rs61820168	ENSG00000274963.1	Metazoa_SRP	3.74	0.000207	0.0255	0.29	0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150590369	chr1:150568971~150569269:-
HNSC	cis	rs950169	0.579	rs12913054	ENSG00000230373.7	GOLGA6L5P	-3.74	0.000207	0.0255	-0.2	-0.17	Schizophrenia;	chr15:83995704	chr15:84507885~84516814:-
HNSC	cis	rs28573326	0.886	rs13125832	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412565	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs13149935	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412578	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs13126038	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412637	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10517843	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412866	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10517844	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413239	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs9992011	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413294	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10014827	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413331	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.849	rs1866222	ENSG00000121089.4	NACA3P	-3.74	0.000207	0.0255	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413423	chr4:164943290~164943937:+
HNSC	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	3.74	0.000207	0.0255	0.22	0.17	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
HNSC	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-3.74	0.000207	0.0255	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
HNSC	cis	rs868153	0.625	rs6929586	ENSG00000275339.1	RP3-425C14.6	3.74	0.000207	0.0255	0.18	0.17	Vertical cup-disc ratio;	chr6:122155469	chr6:122454358~122454612:+
HNSC	cis	rs9650657	0.596	rs6989370	ENSG00000269918.1	AF131215.9	3.74	0.000207	0.0255	0.17	0.17	Neuroticism;	chr8:10759070	chr8:11104691~11106704:-
HNSC	cis	rs6012564	1	rs6125576	ENSG00000227431.4	CSE1L-AS1	3.74	0.000207	0.0256	0.2	0.17	Anger;	chr20:49160382	chr20:49040463~49046044:-
HNSC	cis	rs72627509	0.68	rs79641006	ENSG00000269949.1	RP11-738E22.3	3.74	0.000207	0.0256	0.29	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56981277	chr4:56960927~56961373:-
HNSC	cis	rs2836974	0.897	rs8128102	ENSG00000255568.3	BRWD1-AS2	3.74	0.000207	0.0256	0.16	0.17	Cognitive function;	chr21:39234488	chr21:39313935~39314962:+
HNSC	cis	rs12546962	0.551	rs28457812	ENSG00000233609.3	RP11-62H7.2	3.74	0.000207	0.0256	0.18	0.17	Body mass index;	chr8:9353656	chr8:8961200~8979025:+
HNSC	cis	rs9304742	0.854	rs11084211	ENSG00000242779.5	ZNF702P	3.74	0.000207	0.0256	0.2	0.17	Psoriasis;	chr19:52957608	chr19:52968251~53037898:-
HNSC	cis	rs2032366	1	rs2032366	ENSG00000267279.1	RP11-879F14.2	-3.74	0.000207	0.0256	-0.21	-0.17	Obesity-related traits;	chr18:61599138	chr18:61585746~61606916:-
HNSC	cis	rs7107174	1	rs901103	ENSG00000251323.2	RP11-452H21.4	3.74	0.000207	0.0256	0.26	0.17	Testicular germ cell tumor;	chr11:78220300	chr11:78423982~78429836:-
HNSC	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66679692	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66692349	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66693433	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66694214	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66701371	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66702658	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66706390	chr7:66848496~66858136:+
HNSC	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000207	0.0256	-0.25	-0.17	Gout;	chr7:66710076	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	3.74	0.000207	0.0256	0.25	0.17	Gout;	chr7:66682070	chr7:66848496~66858136:+
HNSC	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	3.74	0.000207	0.0256	0.25	0.17	Gout;	chr7:66682162	chr7:66848496~66858136:+
HNSC	cis	rs17416285	0.559	rs1261412	ENSG00000260971.3	RP11-504A18.1	3.74	0.000207	0.0256	0.23	0.17	Coronary artery disease;	chr1:56510170	chr1:56248294~56258571:-
HNSC	cis	rs62025270	0.632	rs16943251	ENSG00000259762.1	RP11-158M2.4	-3.74	0.000207	0.0256	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85750336~85752901:-
HNSC	cis	rs13256369	0.853	rs13256216	ENSG00000254153.1	CTA-398F10.2	3.74	0.000207	0.0256	0.22	0.17	Obesity-related traits;	chr8:8720373	chr8:8456909~8461337:-
HNSC	cis	rs1595825	0.636	rs111540926	ENSG00000231621.1	AC013264.2	-3.74	0.000207	0.0256	-0.2	-0.17	Ulcerative colitis;	chr2:198020854	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs58111212	ENSG00000231621.1	AC013264.2	-3.74	0.000207	0.0256	-0.2	-0.17	Ulcerative colitis;	chr2:198025172	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs73058867	ENSG00000231621.1	AC013264.2	-3.74	0.000207	0.0256	-0.2	-0.17	Ulcerative colitis;	chr2:198026844	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.891	rs7573687	ENSG00000231621.1	AC013264.2	-3.74	0.000207	0.0256	-0.2	-0.17	Ulcerative colitis;	chr2:198028652	chr2:197197991~197199273:+
HNSC	cis	rs6982751	0.935	rs7008460	ENSG00000269918.1	AF131215.9	-3.74	0.000208	0.0256	-0.23	-0.17	Asthma and hay fever;	chr8:10951479	chr8:11104691~11106704:-
HNSC	cis	rs9611565	0.659	rs1569516	ENSG00000235513.1	RP4-756G23.5	3.74	0.000208	0.0256	0.21	0.17	Vitiligo;	chr22:41514240	chr22:41209122~41217627:-
HNSC	cis	rs34526934	0.591	rs13029402	ENSG00000226363.3	HAGLROS	3.74	0.000208	0.0256	0.23	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176201913	chr2:176177717~176179008:+
HNSC	cis	rs853679	0.882	rs2743555	ENSG00000204709.4	LINC01556	3.74	0.000208	0.0256	0.27	0.17	Depression;	chr6:28273304	chr6:28943877~28944537:+
HNSC	cis	rs853679	1	rs1419183	ENSG00000204709.4	LINC01556	3.74	0.000208	0.0256	0.27	0.17	Depression;	chr6:28275017	chr6:28943877~28944537:+
HNSC	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	3.74	0.000208	0.0256	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
HNSC	cis	rs60617249	0.772	rs2329559	ENSG00000228204.2	RP4-724E13.2	3.74	0.000208	0.0256	0.18	0.17	Major depression and alcohol dependence;	chr7:50898703	chr7:50866747~51022990:+
HNSC	cis	rs17253792	0.731	rs79483151	ENSG00000186615.9	KTN1-AS1	-3.74	0.000208	0.0256	-0.34	-0.17	Putamen volume;	chr14:55582133	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78826571	ENSG00000186615.9	KTN1-AS1	-3.74	0.000208	0.0256	-0.34	-0.17	Putamen volume;	chr14:55582188	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.731	rs74823888	ENSG00000186615.9	KTN1-AS1	-3.74	0.000208	0.0256	-0.34	-0.17	Putamen volume;	chr14:55583082	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs75016910	ENSG00000186615.9	KTN1-AS1	-3.74	0.000208	0.0256	-0.34	-0.17	Putamen volume;	chr14:55583748	chr14:55499278~55580110:-
HNSC	cis	rs9925964	0.748	rs11640961	ENSG00000279196.1	RP11-1072A3.3	-3.74	0.000208	0.0256	-0.2	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:30984630~30988270:-
HNSC	cis	rs73201462	0.901	rs35347185	ENSG00000231305.3	RP11-723O4.2	-3.74	0.000208	0.0256	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128135684	chr3:128861313~128871540:-
HNSC	cis	rs116095464	0.558	rs12173244	ENSG00000277812.1	AC021087.1	3.74	0.000208	0.0256	0.29	0.17	Breast cancer;	chr5:269409	chr5:262769~262881:+
HNSC	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	3.74	0.000208	0.0256	0.24	0.17	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
HNSC	cis	rs7927592	0.913	rs11228293	ENSG00000255031.4	RP11-802E16.3	3.74	0.000208	0.0256	0.15	0.17	Total body bone mineral density;	chr11:68617178	chr11:68050740~68053762:+
HNSC	cis	rs4853525	0.522	rs6744420	ENSG00000228509.4	AC006460.2	-3.74	0.000208	0.0256	-0.21	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190724356	chr2:190676944~190708716:-
HNSC	cis	rs2446066	0.872	rs11170516	ENSG00000270175.1	RP11-793H13.11	-3.74	0.000208	0.0256	-0.21	-0.17	Red blood cell count;	chr12:53358908	chr12:53500162~53500936:-
HNSC	cis	rs7178375	1	rs7178533	ENSG00000270015.1	RP11-540B6.6	3.74	0.000208	0.0256	0.22	0.17	Hypertriglyceridemia;	chr15:30923773	chr15:30926514~30928407:+
HNSC	cis	rs1881509	0.66	rs7926201	ENSG00000255153.1	TOLLIP-AS1	-3.74	0.000208	0.0256	-0.19	-0.17	Heroin dependence;	chr11:1407550	chr11:1309769~1310707:+
HNSC	cis	rs9487051	0.714	rs7755970	ENSG00000219700.1	PTCHD3P3	3.74	0.000208	0.0256	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109281156	chr6:109288571~109290503:-
HNSC	cis	rs2836974	0.666	rs4818015	ENSG00000255568.3	BRWD1-AS2	3.74	0.000208	0.0256	0.14	0.17	Cognitive function;	chr21:39303567	chr21:39313935~39314962:+
HNSC	cis	rs73198271	1	rs11775476	ENSG00000253893.2	FAM85B	3.74	0.000208	0.0256	0.25	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.955	rs4974068	ENSG00000280739.1	EIF1B-AS1	3.74	0.000208	0.0256	0.19	0.17	Renal cell carcinoma;	chr3:40335438	chr3:40173145~40309698:-
HNSC	cis	rs711830	1	rs2113559	ENSG00000226363.3	HAGLROS	-3.74	0.000208	0.0256	-0.23	-0.17	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166371	chr2:176177717~176179008:+
HNSC	cis	rs792448	0.743	rs351393	ENSG00000226251.4	RP11-15I11.3	3.74	0.000208	0.0256	0.21	0.17	White blood cell count (basophil);	chr1:212303177	chr1:212225278~212238977:-
HNSC	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	3.74	0.000208	0.0256	0.25	0.17	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
HNSC	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	3.74	0.000208	0.0256	0.28	0.17	QT interval;	chr4:75108576	chr4:75081702~75084717:-
HNSC	cis	rs17014483	0.749	rs3017900	ENSG00000248019.2	FAM13A-AS1	-3.74	0.000208	0.0256	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88718315	chr4:88709789~88730103:+
HNSC	cis	rs897984	0.806	rs12924903	ENSG00000260911.2	RP11-196G11.2	3.74	0.000208	0.0256	0.16	0.17	Dementia with Lewy bodies;	chr16:30917649	chr16:31043150~31049868:+
HNSC	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-3.74	0.000208	0.0256	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
HNSC	cis	rs6088580	0.609	rs6059845	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000208	0.0256	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:33985617~33988989:-
HNSC	cis	rs683257	0.81	rs6570429	ENSG00000234147.1	RP3-460G2.2	-3.74	0.000208	0.0256	-0.31	-0.17	Facial emotion recognition (angry faces);	chr6:140893165	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.81	rs6570430	ENSG00000234147.1	RP3-460G2.2	-3.74	0.000208	0.0256	-0.31	-0.17	Facial emotion recognition (angry faces);	chr6:140893167	chr6:140845958~140852924:-
HNSC	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	3.74	0.000208	0.0256	0.25	0.17	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
HNSC	cis	rs9652601	0.691	rs3893661	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000208	0.0256	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11100023	chr16:11056556~11057034:+
HNSC	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	3.74	0.000208	0.0256	0.21	0.17	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
HNSC	cis	rs7615952	0.546	rs2979333	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000208	0.0256	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125641499	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.546	rs111812401	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000208	0.0256	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125642651	chr3:125908005~125910272:-
HNSC	cis	rs7615952	0.546	rs2979350	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000208	0.0256	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125643371	chr3:125908005~125910272:-
HNSC	cis	rs11250097	0.535	rs11250086	ENSG00000255310.2	AF131215.2	-3.74	0.000208	0.0256	-0.16	-0.17	Neuroticism;	chr8:10912273	chr8:11107788~11109726:-
HNSC	cis	rs863750	0.687	rs825484	ENSG00000275389.1	RP11-214K3.24	3.74	0.000208	0.0256	0.24	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091607	chr12:124085761~124088598:+
HNSC	cis	rs12701220	0.894	rs10257744	ENSG00000224079.1	AC091729.7	3.74	0.000208	0.0256	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1074450~1078036:+
HNSC	cis	rs12701220	0.847	rs10272002	ENSG00000224079.1	AC091729.7	3.74	0.000208	0.0256	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1074450~1078036:+
HNSC	cis	rs4835473	0.932	rs7670010	ENSG00000249741.2	RP11-673E1.3	-3.74	0.000208	0.0256	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143821679	chr4:143911514~143912053:-
HNSC	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	3.74	0.000208	0.0256	0.19	0.17	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
HNSC	cis	rs801193	1	rs7782320	ENSG00000273142.1	RP11-458F8.4	-3.74	0.000208	0.0256	-0.14	-0.17	Aortic root size;	chr7:66712111	chr7:66902857~66906297:+
HNSC	cis	rs73198271	1	rs11776513	ENSG00000233609.3	RP11-62H7.2	-3.74	0.000208	0.0256	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8961200~8979025:+
HNSC	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000208	0.0257	-0.24	-0.17	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000208	0.0257	-0.24	-0.17	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000208	0.0257	-0.24	-0.17	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
HNSC	cis	rs9859260	0.71	rs419068	ENSG00000273009.1	RP11-352G9.1	3.74	0.000208	0.0257	0.2	0.17	Mean corpuscular volume;	chr3:196055305	chr3:195913078~195913683:-
HNSC	cis	rs9859260	0.71	rs366268	ENSG00000273009.1	RP11-352G9.1	3.74	0.000208	0.0257	0.2	0.17	Mean corpuscular volume;	chr3:196055306	chr3:195913078~195913683:-
HNSC	cis	rs9859260	0.744	rs419059	ENSG00000273009.1	RP11-352G9.1	3.74	0.000208	0.0257	0.2	0.17	Mean corpuscular volume;	chr3:196055313	chr3:195913078~195913683:-
HNSC	cis	rs440932	0.798	rs330942	ENSG00000233609.3	RP11-62H7.2	3.74	0.000208	0.0257	0.16	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8961200~8979025:+
HNSC	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	3.74	0.000208	0.0257	0.22	0.17	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
HNSC	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	3.74	0.000208	0.0257	0.21	0.17	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
HNSC	cis	rs62184315	0.832	rs12466395	ENSG00000253559.1	OSGEPL1-AS1	-3.74	0.000208	0.0257	-0.19	-0.17	Alcohol dependence (age at onset);	chr2:189915972	chr2:189762704~189765556:+
HNSC	cis	rs35146811	0.735	rs2272345	ENSG00000235077.1	AC073842.19	3.74	0.000208	0.0257	0.21	0.17	Coronary artery disease;	chr7:100199408	chr7:100130964~100140439:+
HNSC	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	3.74	0.000208	0.0257	0.21	0.17	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
HNSC	cis	rs948562	0.744	rs11229438	ENSG00000280010.1	AP001350.4	3.74	0.000208	0.0257	0.27	0.17	Lymphoma;	chr11:58423730	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.744	rs11229440	ENSG00000280010.1	AP001350.4	3.74	0.000208	0.0257	0.27	0.17	Lymphoma;	chr11:58426719	chr11:58627435~58628528:+
HNSC	cis	rs442309	0.846	rs224145	ENSG00000238280.1	RP11-436D10.3	-3.74	0.000208	0.0257	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62718695	chr10:62793562~62805887:-
HNSC	cis	rs7720894	0.967	rs4604142	ENSG00000215032.2	GNL3LP1	-3.74	0.000208	0.0257	-0.19	-0.17	Body mass index;	chr5:61346768	chr5:60891935~60893577:-
HNSC	cis	rs7720894	0.967	rs6449529	ENSG00000215032.2	GNL3LP1	-3.74	0.000208	0.0257	-0.19	-0.17	Body mass index;	chr5:61347686	chr5:60891935~60893577:-
HNSC	cis	rs7720894	0.967	rs7724551	ENSG00000215032.2	GNL3LP1	-3.74	0.000208	0.0257	-0.19	-0.17	Body mass index;	chr5:61353641	chr5:60891935~60893577:-
HNSC	cis	rs35146811	0.538	rs3823642	ENSG00000235077.1	AC073842.19	3.74	0.000208	0.0257	0.21	0.17	Coronary artery disease;	chr7:100198449	chr7:100130964~100140439:+
HNSC	cis	rs9834975	0.565	rs11553085	ENSG00000272758.4	RP11-299J3.8	3.74	0.000208	0.0257	0.15	0.17	Diastolic blood pressure;	chr3:122411904	chr3:122416207~122443180:+
HNSC	cis	rs8010715	1	rs8010715	ENSG00000259321.1	RP11-468E2.5	3.74	0.000208	0.0257	0.15	0.17	IgG glycosylation;	chr14:24139938	chr14:24139445~24140444:+
HNSC	cis	rs10073892	0.511	rs17334060	ENSG00000250682.4	LINC00491	-3.74	0.000208	0.0257	-0.23	-0.17	Cognitive decline (age-related);	chr5:102547383	chr5:102609156~102671559:-
HNSC	cis	rs656900	0.874	rs685487	ENSG00000261229.4	MTHFS	3.74	0.000208	0.0257	0.19	0.17	Cerebrospinal P-tau181p levels;	chr15:79843787	chr15:79843547~79897285:-
HNSC	cis	rs2944755	0.919	rs2944754	ENSG00000279766.1	RP11-642A1.2	3.74	0.000208	0.0257	0.21	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564251	chr8:140572142~140572812:-
HNSC	cis	rs7829975	0.688	rs6601703	ENSG00000233609.3	RP11-62H7.2	3.74	0.000208	0.0257	0.16	0.17	Mood instability;	chr8:8522714	chr8:8961200~8979025:+
HNSC	cis	rs9487051	0.768	rs351729	ENSG00000243587.6	C6orf183	3.74	0.000208	0.0257	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109190465	chr6:109165833~109271014:+
HNSC	cis	rs6600671	1	rs4844607	ENSG00000272583.1	RP11-344P13.6	3.74	0.000208	0.0257	0.19	0.17	Hip geometry;	chr1:121442201	chr1:121518366~121518829:-
HNSC	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	3.74	0.000208	0.0257	0.18	0.17	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
HNSC	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	3.74	0.000208	0.0257	0.18	0.17	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
HNSC	cis	rs11098499	0.874	rs13123591	ENSG00000250412.1	KLHL2P1	3.74	0.000208	0.0257	0.22	0.17	Corneal astigmatism;	chr4:119184835	chr4:119334329~119378233:+
HNSC	cis	rs17416285	0.559	rs56198059	ENSG00000260971.3	RP11-504A18.1	3.74	0.000209	0.0257	0.23	0.17	Coronary artery disease;	chr1:56508862	chr1:56248294~56258571:-
HNSC	cis	rs5015933	0.815	rs13297440	ENSG00000232630.1	PRPS1P2	-3.74	0.000209	0.0257	-0.16	-0.17	Body mass index;	chr9:125324921	chr9:125150653~125151589:+
HNSC	cis	rs1665050	0.534	rs35124643	ENSG00000259732.1	RP11-59H7.3	-3.74	0.000209	0.0257	-0.23	-0.17	Atopic dermatitis;	chr15:58949802	chr15:59121034~59133250:+
HNSC	cis	rs1665050	0.534	rs11858479	ENSG00000259732.1	RP11-59H7.3	-3.74	0.000209	0.0257	-0.23	-0.17	Atopic dermatitis;	chr15:58950507	chr15:59121034~59133250:+
HNSC	cis	rs1155750	0.656	rs239842	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54901591	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239841	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54901678	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239840	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54901742	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.655	rs239839	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54901933	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239832	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54904602	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239824	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54909449	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239823	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000209	0.0257	-0.25	-0.17	Colorectal cancer;	chr6:54909647	chr6:54840118~54840855:-
HNSC	cis	rs3738443	0.951	rs4269806	ENSG00000259865.1	RP11-488L18.10	3.74	0.000209	0.0257	0.16	0.17	Alcohol dependence;	chr1:247211721	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.951	rs41315860	ENSG00000259865.1	RP11-488L18.10	3.74	0.000209	0.0257	0.16	0.17	Alcohol dependence;	chr1:247212558	chr1:247187281~247188526:-
HNSC	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	3.74	0.000209	0.0257	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
HNSC	cis	rs7554547	0.63	rs4845889	ENSG00000242349.4	NPPA-AS1	-3.74	0.000209	0.0257	-0.17	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr1:11841017~11848079:+
HNSC	cis	rs11711311	1	rs2242108	ENSG00000241529.3	RN7SL767P	-3.74	0.000209	0.0257	-0.22	-0.17	IgG glycosylation;	chr3:113715056	chr3:113632704~113632998:+
HNSC	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	3.74	0.000209	0.0257	0.24	0.17	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
HNSC	cis	rs28489187	0.597	rs233053	ENSG00000223653.4	RP11-131L23.1	3.74	0.000209	0.0257	0.22	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85373824	chr1:85276715~85448124:+
HNSC	cis	rs9928842	0.712	rs10871304	ENSG00000261783.1	RP11-252K23.2	3.74	0.000209	0.0257	0.27	0.17	Alcoholic chronic pancreatitis;	chr16:75189593	chr16:75379818~75381260:-
HNSC	cis	rs11711311	0.955	rs9830102	ENSG00000241529.3	RN7SL767P	-3.74	0.000209	0.0257	-0.22	-0.17	IgG glycosylation;	chr3:113689455	chr3:113632704~113632998:+
HNSC	cis	rs1979679	0.918	rs786711	ENSG00000247934.4	RP11-967K21.1	-3.74	0.000209	0.0257	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28163298~28190738:-
HNSC	cis	rs7107174	1	rs2511171	ENSG00000251323.2	RP11-452H21.4	3.74	0.000209	0.0257	0.26	0.17	Testicular germ cell tumor;	chr11:78219889	chr11:78423982~78429836:-
HNSC	cis	rs10903027	0.791	rs12033794	ENSG00000261349.1	RP3-465N24.5	3.74	0.000209	0.0257	0.21	0.17	IgG glycosylation;	chr1:25077607	chr1:25266102~25267136:-
HNSC	cis	rs7554547	0.667	rs4846072	ENSG00000242349.4	NPPA-AS1	-3.74	0.000209	0.0257	-0.17	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr1:11841017~11848079:+
HNSC	cis	rs7824557	0.564	rs7839307	ENSG00000255495.1	AC145124.2	3.74	0.000209	0.0257	0.19	0.17	Retinal vascular caliber;	chr8:11341283	chr8:12194467~12196280:+
HNSC	cis	rs2483519	0.897	rs4752090	ENSG00000236799.1	RP11-383C6.2	3.74	0.000209	0.0257	0.18	0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114669133	chr10:114994657~114996593:+
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000272831.1	RP11-792A8.4	-3.74	0.000209	0.0257	-0.14	-0.17	Aortic root size;	chr7:66619753	chr7:66739829~66740385:-
HNSC	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-3.74	0.000209	0.0257	-0.2	-0.17	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000227888.4	FAM66A	3.74	0.000209	0.0257	0.17	0.17	Neuroticism;	chr8:11942522	chr8:12362019~12388296:+
HNSC	cis	rs10791097	0.72	rs4936121	ENSG00000254842.5	RP11-890B15.2	-3.74	0.000209	0.0257	-0.15	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863983	chr11:130844191~130865561:-
HNSC	cis	rs73198271	0.74	rs11781430	ENSG00000254153.1	CTA-398F10.2	-3.74	0.000209	0.0257	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8456909~8461337:-
HNSC	cis	rs36093844	0.527	rs2084077	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000209	0.0257	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85941884	chr11:85852557~85854943:-
HNSC	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	3.74	0.000209	0.0257	0.17	0.17	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
HNSC	cis	rs853679	1	rs1679732	ENSG00000219891.2	ZSCAN12P1	-3.74	0.000209	0.0257	-0.27	-0.17	Depression;	chr6:28253486	chr6:28091154~28093664:+
HNSC	cis	rs683257	0.683	rs9495859	ENSG00000234147.1	RP3-460G2.2	-3.74	0.000209	0.0257	-0.31	-0.17	Facial emotion recognition (angry faces);	chr6:140894388	chr6:140845958~140852924:-
HNSC	cis	rs12999542	0.706	rs11465623	ENSG00000234389.1	AC007278.3	3.74	0.000209	0.0257	0.29	0.17	Serum protein levels (sST2);	chr2:102376579	chr2:102438713~102440475:+
HNSC	cis	rs3096299	0.642	rs12934829	ENSG00000261118.1	RP11-104N10.1	3.74	0.000209	0.0257	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89492017~89504460:-
HNSC	cis	rs17253792	0.822	rs78824140	ENSG00000186615.9	KTN1-AS1	-3.74	0.000209	0.0257	-0.34	-0.17	Putamen volume;	chr14:55575997	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78323463	ENSG00000186615.9	KTN1-AS1	-3.74	0.000209	0.0257	-0.34	-0.17	Putamen volume;	chr14:55578733	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs111467375	ENSG00000186615.9	KTN1-AS1	-3.74	0.000209	0.0257	-0.34	-0.17	Putamen volume;	chr14:55579441	chr14:55499278~55580110:-
HNSC	cis	rs13434995	0.842	rs6828474	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000209	0.0257	-0.28	-0.17	Adiponectin levels;	chr4:55475740	chr4:55387949~55388271:+
HNSC	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-3.74	0.000209	0.0257	-0.2	-0.17	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
HNSC	cis	rs10073892	0.619	rs1901515	ENSG00000250682.4	LINC00491	-3.74	0.000209	0.0257	-0.21	-0.17	Cognitive decline (age-related);	chr5:102375545	chr5:102609156~102671559:-
HNSC	cis	rs757081	0.658	rs105290	ENSG00000260196.1	RP1-239B22.5	-3.74	0.000209	0.0258	-0.18	-0.17	Systolic blood pressure;	chr11:17270521	chr11:17380649~17383531:+
HNSC	cis	rs6545883	0.931	rs7557230	ENSG00000271889.1	RP11-493E12.1	3.74	0.000209	0.0258	0.19	0.17	Tuberculosis;	chr2:61509517	chr2:61151433~61162105:-
HNSC	cis	rs35306767	0.761	rs34480046	ENSG00000229869.1	RP11-363N22.2	-3.74	0.000209	0.0258	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:981500	chr10:933026~942743:+
HNSC	cis	rs35306767	0.715	rs11253550	ENSG00000229869.1	RP11-363N22.2	-3.74	0.000209	0.0258	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:982348	chr10:933026~942743:+
HNSC	cis	rs12701220	0.817	rs1058729	ENSG00000224079.1	AC091729.7	3.74	0.000209	0.0258	0.24	0.17	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1074450~1078036:+
HNSC	cis	rs870825	0.929	rs1405941	ENSG00000254233.1	RP11-242J7.1	-3.74	0.000209	0.0258	-0.27	-0.17	Blood protein levels;	chr4:184670364	chr4:184584093~184625030:-
HNSC	cis	rs13256369	0.95	rs1522839	ENSG00000254153.1	CTA-398F10.2	3.74	0.000209	0.0258	0.22	0.17	Obesity-related traits;	chr8:8722943	chr8:8456909~8461337:-
HNSC	cis	rs12908161	1	rs11638290	ENSG00000229212.6	RP11-561C5.4	-3.74	0.000209	0.0258	-0.25	-0.17	Schizophrenia;	chr15:84684405	chr15:85205440~85234795:-
HNSC	cis	rs12908161	0.959	rs34028043	ENSG00000229212.6	RP11-561C5.4	-3.74	0.000209	0.0258	-0.25	-0.17	Schizophrenia;	chr15:84688354	chr15:85205440~85234795:-
HNSC	cis	rs12908161	0.959	rs34784022	ENSG00000229212.6	RP11-561C5.4	-3.74	0.000209	0.0258	-0.25	-0.17	Schizophrenia;	chr15:84688675	chr15:85205440~85234795:-
HNSC	cis	rs12908161	0.959	rs12908699	ENSG00000229212.6	RP11-561C5.4	-3.74	0.000209	0.0258	-0.25	-0.17	Schizophrenia;	chr15:84697172	chr15:85205440~85234795:-
HNSC	cis	rs11250098	0.503	rs7821826	ENSG00000255310.2	AF131215.2	-3.74	0.00021	0.0258	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10911929	chr8:11107788~11109726:-
HNSC	cis	rs11779988	0.545	rs208753	ENSG00000253671.1	RP11-806O11.1	-3.74	0.00021	0.0258	-0.19	-0.17	Breast cancer;	chr8:17957406	chr8:17808941~17820868:+
HNSC	cis	rs62292953	0.591	rs11915472	ENSG00000248724.5	NPHP3-AS1	-3.74	0.00021	0.0258	-0.41	-0.17	Red cell distribution width;	chr3:132532097	chr3:132721750~132874223:+
HNSC	cis	rs55823223	0.564	rs58363746	ENSG00000267801.1	RP11-552F3.9	3.74	0.00021	0.0258	0.19	0.17	Psoriasis;	chr17:75854738	chr17:75876372~75879546:+
HNSC	cis	rs2554380	0.628	rs7179507	ENSG00000230373.7	GOLGA6L5P	-3.74	0.00021	0.0258	-0.17	-0.17	Height;	chr15:83804779	chr15:84507885~84516814:-
HNSC	cis	rs1023500	0.505	rs134878	ENSG00000182057.4	OGFRP1	3.74	0.00021	0.0258	0.18	0.17	Schizophrenia;	chr22:42267868	chr22:42269753~42275196:+
HNSC	cis	rs7829975	0.564	rs2921060	ENSG00000233609.3	RP11-62H7.2	-3.74	0.00021	0.0258	-0.16	-0.17	Mood instability;	chr8:8460307	chr8:8961200~8979025:+
HNSC	cis	rs6787172	0.811	rs4510417	ENSG00000272087.1	RP11-379F4.7	-3.74	0.00021	0.0258	-0.17	-0.17	Subjective well-being;	chr3:158491764	chr3:158693120~158693768:-
HNSC	cis	rs73198271	0.531	rs3827812	ENSG00000253893.2	FAM85B	3.74	0.00021	0.0258	0.27	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797388	chr8:8167819~8226614:-
HNSC	cis	rs2834288	0.734	rs8126592	ENSG00000273102.1	AP000569.9	-3.74	0.00021	0.0258	-0.2	-0.17	Gut microbiota (bacterial taxa);	chr21:33895961	chr21:33967101~33968573:-
HNSC	cis	rs765751	0.667	rs1563352	ENSG00000228536.1	RP11-392O17.1	-3.74	0.00021	0.0258	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219479453	chr1:219409681~219411941:-
HNSC	cis	rs7824557	0.628	rs58283816	ENSG00000269918.1	AF131215.9	3.74	0.00021	0.0258	0.16	0.17	Retinal vascular caliber;	chr8:11335042	chr8:11104691~11106704:-
HNSC	cis	rs9611565	0.659	rs11090049	ENSG00000235513.1	RP4-756G23.5	3.74	0.00021	0.0258	0.21	0.17	Vitiligo;	chr22:41519325	chr22:41209122~41217627:-
HNSC	cis	rs7824557	0.628	rs17797894	ENSG00000255495.1	AC145124.2	3.74	0.00021	0.0258	0.19	0.17	Retinal vascular caliber;	chr8:11354572	chr8:12194467~12196280:+
HNSC	cis	rs28489187	0.66	rs4949900	ENSG00000223653.4	RP11-131L23.1	-3.74	0.00021	0.0258	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85395351	chr1:85276715~85448124:+
HNSC	cis	rs73173548	0.502	rs12189343	ENSG00000247828.6	TMEM161B-AS1	3.74	0.00021	0.0258	0.18	0.17	Macular telangiectasia type 2;	chr5:88447510	chr5:88268895~88436685:+
HNSC	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	3.74	0.00021	0.0258	0.22	0.17	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
HNSC	cis	rs10090774	0.87	rs12234950	ENSG00000279766.1	RP11-642A1.2	3.74	0.00021	0.0258	0.17	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140746229	chr8:140572142~140572812:-
HNSC	cis	rs9329221	0.51	rs4841282	ENSG00000255310.2	AF131215.2	3.74	0.00021	0.0258	0.16	0.17	Neuroticism;	chr8:10118094	chr8:11107788~11109726:-
HNSC	cis	rs6968419	0.747	rs1004109	ENSG00000237870.5	AC073130.1	-3.74	0.00021	0.0258	-0.21	-0.17	Intraocular pressure;	chr7:116222242	chr7:116275606~116286734:-
HNSC	cis	rs864537	0.622	rs2949661	ENSG00000233411.1	RP11-104L21.2	3.74	0.00021	0.0258	0.2	0.17	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167455687	chr1:167457383~167458661:-
HNSC	cis	rs10129255	0.789	rs61997796	ENSG00000211974.3	IGHV2-70	3.74	0.00021	0.0258	0.16	0.17	Kawasaki disease;	chr14:106813798	chr14:106723574~106724093:-
HNSC	cis	rs67478160	0.619	rs12897150	ENSG00000259515.1	RP11-365N19.2	3.74	0.00021	0.0258	0.15	0.17	Schizophrenia;	chr14:103853193	chr14:102933574~102937177:+
HNSC	cis	rs9926296	0.605	rs8046243	ENSG00000261812.4	TUBB8P7	-3.74	0.00021	0.0258	-0.19	-0.17	Vitiligo;	chr16:89785725	chr16:90093154~90096354:+
HNSC	cis	rs9733	0.818	rs4970924	ENSG00000236713.1	RP11-363I22.3	3.74	0.00021	0.0258	0.18	0.17	Tonsillectomy;	chr1:150660603	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.791	rs11800059	ENSG00000236713.1	RP11-363I22.3	3.74	0.00021	0.0258	0.18	0.17	Tonsillectomy;	chr1:150678699	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs11204695	ENSG00000236713.1	RP11-363I22.3	3.74	0.00021	0.0258	0.18	0.17	Tonsillectomy;	chr1:150684535	chr1:150780272~150780644:+
HNSC	cis	rs9733	0.818	rs11204702	ENSG00000236713.1	RP11-363I22.3	3.74	0.00021	0.0258	0.18	0.17	Tonsillectomy;	chr1:150691031	chr1:150780272~150780644:+
HNSC	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	3.74	0.00021	0.0258	0.19	0.17	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
HNSC	cis	rs11951515	0.789	rs55759722	ENSG00000249286.1	CTD-2210P15.2	3.74	0.00021	0.0258	0.18	0.17	Metabolite levels  (X-11787);	chr5:43356812	chr5:43586918~43588223:-
HNSC	cis	rs11509153	0.648	rs1019306	ENSG00000226690.5	AC005281.1	3.74	0.00021	0.0258	0.18	0.17	Residual cognition;	chr7:12212200	chr7:12496429~12541910:+
HNSC	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-3.74	0.00021	0.0259	-0.25	-0.17	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
HNSC	cis	rs28551159	1	rs28551159	ENSG00000241549.7	GUSBP2	3.74	0.00021	0.0259	0.26	0.17	Urinary tract infection frequency;	chr6:26376140	chr6:26871484~26956554:-
HNSC	cis	rs359027	1	rs359032	ENSG00000206573.7	THUMPD3-AS1	3.74	0.00021	0.0259	0.14	0.17	Low high density lipoprotein cholesterol levels;	chr3:8415693	chr3:9349689~9398579:-
HNSC	cis	rs73222236	0.782	rs13433980	ENSG00000273486.1	RP11-731C17.2	-3.74	0.00021	0.0259	-0.14	-0.17	Coronary artery disease;	chr3:136631959	chr3:136837338~136839021:-
HNSC	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-3.74	0.00021	0.0259	-0.22	-0.17	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
HNSC	cis	rs7520050	0.966	rs946529	ENSG00000280836.1	AL355480.1	3.74	0.00021	0.0259	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs2275426	ENSG00000280836.1	AL355480.1	3.74	0.00021	0.0259	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45581219~45581321:-
HNSC	cis	rs9487051	0.799	rs830553	ENSG00000243587.6	C6orf183	-3.74	0.00021	0.0259	-0.16	-0.17	Reticulocyte fraction of red cells;	chr6:109228814	chr6:109165833~109271014:+
HNSC	cis	rs7189233	1	rs62048520	ENSG00000279344.1	RP11-44F14.7	3.74	0.00021	0.0259	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53457183	chr16:53478957~53481550:-
HNSC	cis	rs889398	1	rs889399	ENSG00000226232.7	RP11-419C5.2	3.74	0.00021	0.0259	0.15	0.17	Body mass index;	chr16:69522680	chr16:69976388~69996188:-
HNSC	cis	rs886126	1	rs3809286	ENSG00000257595.2	RP3-473L9.4	3.74	0.00021	0.0259	0.22	0.17	Coronary heart disease;	chr12:111226600	chr12:111369282~111403310:+
HNSC	cis	rs924607	0.966	rs1621827	ENSG00000225138.6	CTD-2228K2.7	3.74	0.00021	0.0259	0.19	0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:634959	chr5:473236~480884:+
HNSC	cis	rs924607	0.898	rs905193	ENSG00000225138.6	CTD-2228K2.7	3.74	0.00021	0.0259	0.19	0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:634980	chr5:473236~480884:+
HNSC	cis	rs9733	0.791	rs11204693	ENSG00000236713.1	RP11-363I22.3	3.74	0.00021	0.0259	0.18	0.17	Tonsillectomy;	chr1:150675511	chr1:150780272~150780644:+
HNSC	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	3.74	0.000211	0.0259	0.19	0.17	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	3.74	0.000211	0.0259	0.19	0.17	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
HNSC	cis	rs6001482	0.523	rs5757595	ENSG00000253818.1	IGLV1-41	-3.74	0.000211	0.0259	-0.14	-0.17	Diastolic blood pressure;	chr22:22235017	chr22:22404207~22404721:+
HNSC	cis	rs8067545	0.72	rs9916675	ENSG00000266126.1	RP11-209D14.4	3.74	0.000211	0.0259	0.2	0.17	Schizophrenia;	chr17:19996855	chr17:19929372~19929737:-
HNSC	cis	rs1155750	0.655	rs239853	ENSG00000224984.1	RP11-524H19.2	3.74	0.000211	0.0259	0.24	0.17	Colorectal cancer;	chr6:54894216	chr6:54840118~54840855:-
HNSC	cis	rs7819412	0.668	rs2409715	ENSG00000255310.2	AF131215.2	-3.74	0.000211	0.0259	-0.17	-0.17	Triglycerides;	chr8:11152626	chr8:11107788~11109726:-
HNSC	cis	rs2337406	0.587	rs10150642	ENSG00000280411.1	IGHV1-69-2	3.74	0.000211	0.0259	0.15	0.17	Alzheimer's disease (late onset);	chr14:106647269	chr14:106762092~106762588:-
HNSC	cis	rs35000415	0.872	rs2070197	ENSG00000275106.1	RP11-309L24.10	-3.74	0.000211	0.0259	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128948946	chr7:128952527~128953316:-
HNSC	cis	rs66887589	0.967	rs2892869	ENSG00000249244.1	RP11-548H18.2	-3.74	0.000211	0.0259	-0.19	-0.17	Diastolic blood pressure;	chr4:119600142	chr4:119391831~119395335:-
HNSC	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	3.74	0.000211	0.0259	0.19	0.17	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
HNSC	cis	rs1979679	0.842	rs7139154	ENSG00000247934.4	RP11-967K21.1	-3.74	0.000211	0.0259	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28163298~28190738:-
HNSC	cis	rs7772486	0.686	rs9390357	ENSG00000270638.1	RP3-466P17.1	3.74	0.000211	0.0259	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145735570~145737218:+
HNSC	cis	rs2554380	0.628	rs4843158	ENSG00000259570.1	RP11-671M22.4	3.74	0.000211	0.0259	0.21	0.17	Height;	chr15:83802884	chr15:84394512~84395514:+
HNSC	cis	rs6840360	0.582	rs2709823	ENSG00000251611.1	RP11-610P16.1	-3.74	0.000211	0.0259	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151407551~151408835:-
HNSC	cis	rs9329221	0.537	rs6601415	ENSG00000255310.2	AF131215.2	3.74	0.000211	0.0259	0.16	0.17	Neuroticism;	chr8:10119295	chr8:11107788~11109726:-
HNSC	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	3.74	0.000211	0.0259	0.15	0.17	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
HNSC	cis	rs6499755	0.862	rs2588994	ENSG00000260135.5	RP11-212I21.2	-3.74	0.000211	0.0259	-0.2	-0.17	Hypospadias;	chr16:55323769	chr16:55426797~55462297:-
HNSC	cis	rs12530	0.534	rs78301253	ENSG00000214076.3	CPSF1P1	-3.74	0.000211	0.0259	-0.21	-0.17	IgG glycosylation;	chr22:32328001	chr22:32269381~32273110:+
HNSC	cis	rs6928977	0.896	rs2746421	ENSG00000217482.2	HMGB1P17	-3.74	0.000211	0.0259	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135340491	chr6:135636086~135636713:-
HNSC	cis	rs6540731	0.54	rs7548606	ENSG00000226251.4	RP11-15I11.3	-3.74	0.000211	0.0259	-0.2	-0.17	Intelligence (childhood);	chr1:212215265	chr1:212225278~212238977:-
HNSC	cis	rs61160187	0.51	rs10072745	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000211	0.0259	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.527	rs6449500	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000211	0.0259	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60866457~60866935:-
HNSC	cis	rs2280018	1	rs2280018	ENSG00000263335.1	AF001548.5	-3.73	0.000211	0.0259	-0.22	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15726674~15732993:+
HNSC	cis	rs2274273	0.682	rs1187876	ENSG00000233924.1	AL160471.6	3.73	0.000211	0.0259	0.19	0.17	Protein biomarker;	chr14:55028481	chr14:55004813~55005687:-
HNSC	cis	rs2976388	1	rs2976388	ENSG00000253741.1	CTD-2292P10.4	3.73	0.000211	0.0259	0.16	0.17	Urinary tract infection frequency;	chr8:142678838	chr8:142702252~142726973:-
HNSC	cis	rs73173548	0.502	rs6865869	ENSG00000247828.6	TMEM161B-AS1	3.73	0.000211	0.0259	0.18	0.17	Macular telangiectasia type 2;	chr5:88449645	chr5:88268895~88436685:+
HNSC	cis	rs61270009	0.738	rs12659772	ENSG00000247828.6	TMEM161B-AS1	3.73	0.000211	0.0259	0.18	0.17	Depressive symptoms;	chr5:88451917	chr5:88268895~88436685:+
HNSC	cis	rs6088590	0.561	rs6059932	ENSG00000276073.1	RP5-1125A11.7	-3.73	0.000211	0.0259	-0.18	-0.17	Coronary artery disease;	chr20:34587662	chr20:33985617~33988989:-
HNSC	cis	rs172166	0.561	rs149976	ENSG00000217862.2	HIST1H4PS1	3.73	0.000211	0.0259	0.17	0.17	Cardiac Troponin-T levels;	chr6:28019998	chr6:27807075~27807339:+
HNSC	cis	rs11992162	0.591	rs4240678	ENSG00000227888.4	FAM66A	-3.73	0.000211	0.0259	-0.17	-0.17	Monocyte count;	chr8:11944917	chr8:12362019~12388296:+
HNSC	cis	rs6545883	0.894	rs2694632	ENSG00000271889.1	RP11-493E12.1	-3.73	0.000211	0.0259	-0.19	-0.17	Tuberculosis;	chr2:61331547	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.825	rs7578139	ENSG00000271889.1	RP11-493E12.1	-3.73	0.000211	0.0259	-0.19	-0.17	Tuberculosis;	chr2:61336986	chr2:61151433~61162105:-
HNSC	cis	rs9487051	0.714	rs7774377	ENSG00000219700.1	PTCHD3P3	3.73	0.000211	0.0259	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109281240	chr6:109288571~109290503:-
HNSC	cis	rs11951515	0.738	rs4866821	ENSG00000249286.1	CTD-2210P15.2	3.73	0.000211	0.026	0.18	0.17	Metabolite levels  (X-11787);	chr5:43353719	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.603	rs58358642	ENSG00000249286.1	CTD-2210P15.2	3.73	0.000211	0.026	0.18	0.17	Metabolite levels  (X-11787);	chr5:43355066	chr5:43586918~43588223:-
HNSC	cis	rs4648045	0.822	rs62328536	ENSG00000230069.3	LRRC37A15P	-3.73	0.000211	0.026	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102477892	chr4:102727274~102730721:-
HNSC	cis	rs7923837	0.656	rs6583826	ENSG00000232709.1	MARK2P9	-3.73	0.000211	0.026	-0.19	-0.17	Multiple sclerosis;Body mass index;	chr10:92588073	chr10:92418667~92420875:+
HNSC	cis	rs561341	0.943	rs508566	ENSG00000278867.1	RP11-640N20.4	-3.73	0.000211	0.026	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31962842	chr17:32051030~32053208:+
HNSC	cis	rs2430307	0.556	rs3930019	ENSG00000233448.2	PMS2P9	-3.73	0.000211	0.026	-0.25	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912293	chr7:77039944~77043776:+
HNSC	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	3.73	0.000211	0.026	0.18	0.17	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
HNSC	cis	rs9467711	0.606	rs2072806	ENSG00000241549.7	GUSBP2	3.73	0.000211	0.026	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26384865	chr6:26871484~26956554:-
HNSC	cis	rs12701220	0.894	rs13224488	ENSG00000224079.1	AC091729.7	3.73	0.000211	0.026	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1074450~1078036:+
HNSC	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-3.73	0.000211	0.026	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
HNSC	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-3.73	0.000211	0.026	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
HNSC	cis	rs870825	0.929	rs10027213	ENSG00000254233.1	RP11-242J7.1	3.73	0.000211	0.026	0.28	0.17	Blood protein levels;	chr4:184658717	chr4:184584093~184625030:-
HNSC	cis	rs62158211	0.955	rs1823125	ENSG00000234997.1	AC016745.3	3.73	0.000211	0.026	0.23	0.17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113424495~113425324:+
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000217862.2	HIST1H4PS1	-3.73	0.000211	0.026	-0.19	-0.17	Depression;	chr6:28391932	chr6:27807075~27807339:+
HNSC	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	3.73	0.000211	0.026	0.29	0.17	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
HNSC	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	3.73	0.000211	0.026	0.19	0.17	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
HNSC	cis	rs7829975	0.623	rs10092965	ENSG00000233609.3	RP11-62H7.2	3.73	0.000211	0.026	0.16	0.17	Mood instability;	chr8:8515975	chr8:8961200~8979025:+
HNSC	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000211	0.026	-0.22	-0.17	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000211	0.026	-0.22	-0.17	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000211	0.026	-0.22	-0.17	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
HNSC	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-3.73	0.000211	0.026	-0.29	-0.17	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
HNSC	cis	rs1799949	0.794	rs116409325	ENSG00000236383.6	LINC00854	-3.73	0.000211	0.026	-0.16	-0.17	Menopause (age at onset);	chr17:43368092	chr17:43216941~43305976:-
HNSC	cis	rs2834288	0.7	rs2834299	ENSG00000273102.1	AP000569.9	-3.73	0.000211	0.026	-0.2	-0.17	Gut microbiota (bacterial taxa);	chr21:33912198	chr21:33967101~33968573:-
HNSC	cis	rs6012564	1	rs11696396	ENSG00000227431.4	CSE1L-AS1	3.73	0.000211	0.026	0.19	0.17	Anger;	chr20:49136482	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs6066978	ENSG00000227431.4	CSE1L-AS1	3.73	0.000211	0.026	0.19	0.17	Anger;	chr20:49139205	chr20:49040463~49046044:-
HNSC	cis	rs11672691	0.871	rs2191139	ENSG00000269843.1	CTC-490E21.10	3.73	0.000212	0.026	0.22	0.17	Prostate cancer;	chr19:41495302	chr19:40831221~40837210:-
HNSC	cis	rs11773103	0.786	rs73202985	ENSG00000224046.1	AC005076.5	3.73	0.000212	0.026	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87126604	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.786	rs73202988	ENSG00000224046.1	AC005076.5	3.73	0.000212	0.026	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87127087	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.786	rs73202994	ENSG00000224046.1	AC005076.5	3.73	0.000212	0.026	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87127312	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.786	rs73202997	ENSG00000224046.1	AC005076.5	3.73	0.000212	0.026	0.25	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87127363	chr7:87151423~87152420:-
HNSC	cis	rs7927592	0.913	rs3758643	ENSG00000255031.4	RP11-802E16.3	3.73	0.000212	0.026	0.16	0.17	Total body bone mineral density;	chr11:68599725	chr11:68050740~68053762:+
HNSC	cis	rs16873450	0.527	rs12700462	ENSG00000234800.2	PCMTD1P3	-3.73	0.000212	0.026	-0.16	-0.17	Verbal memory performance (residualized delayed recall level);	chr7:23753221	chr7:23721311~23721782:-
HNSC	cis	rs614226	1	rs541126	ENSG00000202538.1	RNU4-2	3.73	0.000212	0.026	0.29	0.17	Type 1 diabetes nephropathy;	chr12:120534593	chr12:120291763~120291903:-
HNSC	cis	rs7005380	0.62	rs13250594	ENSG00000279347.1	RP11-85I17.2	-3.73	0.000212	0.026	-0.14	-0.17	Interstitial lung disease;	chr8:119894151	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13259990	ENSG00000279347.1	RP11-85I17.2	-3.73	0.000212	0.026	-0.14	-0.17	Interstitial lung disease;	chr8:119894943	chr8:119838736~119840385:-
HNSC	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	3.73	0.000212	0.026	0.33	0.17	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
HNSC	cis	rs6951245	0.706	rs28685743	ENSG00000225146.1	AC073957.15	-3.73	0.000212	0.026	-0.28	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1029025~1043891:+
HNSC	cis	rs9583531	0.6	rs9555724	ENSG00000259831.1	LINC00567	-3.73	0.000212	0.026	-0.19	-0.17	Coronary artery disease;	chr13:110701763	chr13:110809676~110813084:-
HNSC	cis	rs7324557	0.717	rs7139473	ENSG00000205861.10	C1QTNF9B-AS1	-3.73	0.000212	0.026	-0.23	-0.17	Visceral adipose tissue adjusted for BMI;	chr13:23824083	chr13:23888889~23897263:+
HNSC	cis	rs6545883	0.894	rs2694649	ENSG00000271889.1	RP11-493E12.1	-3.73	0.000212	0.026	-0.2	-0.17	Tuberculosis;	chr2:61346691	chr2:61151433~61162105:-
HNSC	cis	rs6565653	0.901	rs7216510	ENSG00000262580.4	RP11-334C17.5	3.73	0.000212	0.026	0.13	0.17	Ischemic stroke;	chr17:80226111	chr17:80200673~80205949:-
HNSC	cis	rs6565653	0.934	rs7209632	ENSG00000262580.4	RP11-334C17.5	3.73	0.000212	0.026	0.13	0.17	Ischemic stroke;	chr17:80226114	chr17:80200673~80205949:-
HNSC	cis	rs2836974	0.605	rs2836971	ENSG00000255568.3	BRWD1-AS2	-3.73	0.000212	0.026	-0.14	-0.17	Cognitive function;	chr21:39280114	chr21:39313935~39314962:+
HNSC	cis	rs2412819	0.571	rs12443084	ENSG00000166763.7	STRCP1	-3.73	0.000212	0.026	-0.24	-0.17	Lung cancer;	chr15:43748767	chr15:43699488~43718184:-
HNSC	cis	rs2412819	0.571	rs10163069	ENSG00000166763.7	STRCP1	-3.73	0.000212	0.026	-0.24	-0.17	Lung cancer;	chr15:43755372	chr15:43699488~43718184:-
HNSC	cis	rs2929278	0.617	rs3986209	ENSG00000166763.7	STRCP1	-3.73	0.000212	0.026	-0.24	-0.17	Schizophrenia;	chr15:43758675	chr15:43699488~43718184:-
HNSC	cis	rs988913	0.706	rs7749072	ENSG00000224984.1	RP11-524H19.2	3.73	0.000212	0.026	0.2	0.17	Menarche (age at onset);	chr6:55087120	chr6:54840118~54840855:-
HNSC	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-3.73	0.000212	0.026	-0.21	-0.17	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000212	0.026	-0.14	-0.17	Aortic root size;	chr7:66519618	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000212	0.026	-0.14	-0.17	Aortic root size;	chr7:66521858	chr7:66902857~66906297:+
HNSC	cis	rs853679	0.567	rs3799499	ENSG00000217862.2	HIST1H4PS1	-3.73	0.000212	0.026	-0.19	-0.17	Depression;	chr6:28386473	chr6:27807075~27807339:+
HNSC	cis	rs10805346	0.501	rs4604059	ENSG00000261490.1	RP11-448G15.3	-3.73	0.000212	0.026	-0.14	-0.17	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113441	chr4:10068089~10073019:-
HNSC	cis	rs868153	0.591	rs35085009	ENSG00000275339.1	RP3-425C14.6	3.73	0.000212	0.026	0.18	0.17	Vertical cup-disc ratio;	chr6:122205908	chr6:122454358~122454612:+
HNSC	cis	rs10927875	1	rs12138117	ENSG00000238142.1	RP11-108M9.4	3.73	0.000212	0.026	0.21	0.17	Dilated cardiomyopathy;	chr1:15978784	chr1:16888538~16889649:-
HNSC	cis	rs16846053	0.515	rs1399650	ENSG00000227403.1	AC009299.3	-3.73	0.000212	0.026	-0.31	-0.17	Blood osmolality (transformed sodium);	chr2:161695208	chr2:161244739~161249050:+
HNSC	cis	rs442309	0.812	rs224135	ENSG00000238280.1	RP11-436D10.3	-3.73	0.000212	0.0261	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62707042	chr10:62793562~62805887:-
HNSC	cis	rs868153	0.558	rs6569253	ENSG00000275339.1	RP3-425C14.6	3.73	0.000212	0.0261	0.18	0.17	Vertical cup-disc ratio;	chr6:122212671	chr6:122454358~122454612:+
HNSC	cis	rs1167827	1	rs1167827	ENSG00000205583.12	STAG3L1	3.73	0.000212	0.0261	0.19	0.17	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75359194~75395383:+
HNSC	cis	rs2665103	0.61	rs1972460	ENSG00000276710.3	CSPG4P8	-3.73	0.000212	0.0261	-0.18	-0.17	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82459472~82477258:+
HNSC	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000212	0.0261	-0.23	-0.17	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
HNSC	cis	rs9611565	0.659	rs1810460	ENSG00000235513.1	RP4-756G23.5	3.73	0.000212	0.0261	0.2	0.17	Vitiligo;	chr22:41531696	chr22:41209122~41217627:-
HNSC	cis	rs34792	0.688	rs153783	ENSG00000207425.1	Y_RNA	3.73	0.000212	0.0261	0.2	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508509	chr16:14915457~14915556:-
HNSC	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-3.73	0.000212	0.0261	-0.21	-0.17	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
HNSC	cis	rs12908161	1	rs12911736	ENSG00000229212.6	RP11-561C5.4	-3.73	0.000212	0.0261	-0.24	-0.17	Schizophrenia;	chr15:84696777	chr15:85205440~85234795:-
HNSC	cis	rs73198271	1	rs4841031	ENSG00000233609.3	RP11-62H7.2	-3.73	0.000212	0.0261	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:8961200~8979025:+
HNSC	cis	rs73198271	1	rs11784958	ENSG00000233609.3	RP11-62H7.2	-3.73	0.000212	0.0261	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8961200~8979025:+
HNSC	cis	rs807669	0.772	rs809901	ENSG00000185065.6	AC000068.5	3.73	0.000212	0.0261	0.17	0.17	Metabolite levels;	chr22:19241213	chr22:19447893~19450105:+
HNSC	cis	rs4835473	0.838	rs6838981	ENSG00000249741.2	RP11-673E1.3	3.73	0.000212	0.0261	0.19	0.17	Immature fraction of reticulocytes;	chr4:143826484	chr4:143911514~143912053:-
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-3.73	0.000212	0.0261	-0.2	-0.17	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
HNSC	cis	rs2554380	0.628	rs12914377	ENSG00000259570.1	RP11-671M22.4	3.73	0.000212	0.0261	0.2	0.17	Height;	chr15:83791941	chr15:84394512~84395514:+
HNSC	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	3.73	0.000212	0.0261	0.26	0.17	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
HNSC	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
HNSC	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	3.73	0.000213	0.0261	0.17	0.17	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
HNSC	cis	rs2179367	0.959	rs237034	ENSG00000216906.2	RP11-350J20.9	3.73	0.000213	0.0261	0.21	0.17	Dupuytren's disease;	chr6:149390726	chr6:149904243~149906418:+
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-3.73	0.000213	0.0261	-0.15	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-3.73	0.000213	0.0261	-0.15	-0.17	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
HNSC	cis	rs720475	0.732	rs17195725	ENSG00000170356.8	OR2A20P	-3.73	0.000213	0.0261	-0.24	-0.17	Breast cancer;	chr7:144440044	chr7:144250045~144252957:-
HNSC	cis	rs67072384	1	rs7124056	ENSG00000245148.2	ARAP1-AS2	-3.73	0.000213	0.0261	-0.23	-0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733702	chr11:72700474~72705607:+
HNSC	cis	rs12893668	0.638	rs11851616	ENSG00000269910.1	RP11-73M18.10	3.73	0.000213	0.0261	0.17	0.17	Reticulocyte count;	chr14:103599263	chr14:103694516~103695050:-
HNSC	cis	rs950027	0.62	rs1153862	ENSG00000259479.5	SORD2P	3.73	0.000213	0.0261	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:44826371~44884694:-
HNSC	cis	rs1979679	0.842	rs1118097	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000213	0.0261	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28163298~28190738:-
HNSC	cis	rs3740713	1	rs73440610	ENSG00000256464.1	YWHABP2	3.73	0.000213	0.0261	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr11:18490243~18490955:-
HNSC	cis	rs2919917	0.628	rs9298314	ENSG00000260398.1	RP11-594N15.3	3.73	0.000213	0.0261	0.23	0.17	Lymphocyte counts;	chr8:78660874	chr8:78605952~78609705:+
HNSC	cis	rs1859596	1	rs1017039	ENSG00000234456.6	MAGI2-AS3	3.73	0.000213	0.0261	0.13	0.17	Reading or mathematical ability;	chr7:79481476	chr7:79452877~79471208:+
HNSC	cis	rs1859596	1	rs1017040	ENSG00000234456.6	MAGI2-AS3	3.73	0.000213	0.0261	0.13	0.17	Reading or mathematical ability;	chr7:79481522	chr7:79452877~79471208:+
HNSC	cis	rs56804039	1	rs67611618	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000213	0.0261	-0.22	-0.17	Cervical cancer;	chr8:8523429	chr8:8456909~8461337:-
HNSC	cis	rs56804039	1	rs58361948	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000213	0.0261	-0.22	-0.17	Cervical cancer;	chr8:8523485	chr8:8456909~8461337:-
HNSC	cis	rs56804039	1	rs56804039	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000213	0.0261	-0.22	-0.17	Cervical cancer;	chr8:8523519	chr8:8456909~8461337:-
HNSC	cis	rs1990950	0.933	rs11747685	ENSG00000248544.2	CTB-47B11.3	-3.73	0.000213	0.0261	-0.18	-0.17	Lung function (FEV1/FVC);	chr5:157476582	chr5:157375741~157384950:-
HNSC	cis	rs2562456	0.833	rs11666828	ENSG00000268119.4	CTD-2561J22.5	3.73	0.000213	0.0261	0.26	0.17	Pain;	chr19:21342218	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62110367	ENSG00000268119.4	CTD-2561J22.5	3.73	0.000213	0.0261	0.26	0.17	Pain;	chr19:21365829	chr19:21444241~21463908:-
HNSC	cis	rs950027	0.62	rs2486274	ENSG00000259479.5	SORD2P	3.73	0.000213	0.0261	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:44826371~44884694:-
HNSC	cis	rs1799955	0.554	rs1029304	ENSG00000215515.2	IFIT1P1	-3.73	0.000213	0.0261	-0.2	-0.17	LDL cholesterol levels;	chr13:32334492	chr13:32384660~32386108:+
HNSC	cis	rs7592578	0.766	rs35818159	ENSG00000228509.4	AC006460.2	3.73	0.000213	0.0261	0.27	0.17	Diastolic blood pressure;	chr2:190544890	chr2:190676944~190708716:-
HNSC	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0261	-0.22	-0.17	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
HNSC	cis	rs28489187	0.683	rs67611930	ENSG00000223653.4	RP11-131L23.1	3.73	0.000213	0.0261	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85380909	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.706	rs72724606	ENSG00000223653.4	RP11-131L23.1	3.73	0.000213	0.0261	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85384563	chr1:85276715~85448124:+
HNSC	cis	rs9487051	0.7	rs7773815	ENSG00000219700.1	PTCHD3P3	3.73	0.000213	0.0261	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109281140	chr6:109288571~109290503:-
HNSC	cis	rs7824557	0.602	rs7815463	ENSG00000269918.1	AF131215.9	3.73	0.000213	0.0261	0.17	0.17	Retinal vascular caliber;	chr8:11353474	chr8:11104691~11106704:-
HNSC	cis	rs7405404	0.672	rs11644055	ENSG00000262454.1	RP11-65J21.3	-3.73	0.000213	0.0261	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13642260	chr16:14302288~14326353:+
HNSC	cis	rs7405404	0.672	rs11075207	ENSG00000262454.1	RP11-65J21.3	-3.73	0.000213	0.0261	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13642382	chr16:14302288~14326353:+
HNSC	cis	rs73201462	0.901	rs2811532	ENSG00000231305.3	RP11-723O4.2	3.73	0.000213	0.0261	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273327	chr3:128861313~128871540:-
HNSC	cis	rs73201462	0.908	rs2811531	ENSG00000231305.3	RP11-723O4.2	3.73	0.000213	0.0261	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273652	chr3:128861313~128871540:-
HNSC	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	3.73	0.000213	0.0261	0.28	0.17	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	3.73	0.000213	0.0261	0.28	0.17	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
HNSC	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	3.73	0.000213	0.0261	0.28	0.17	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
HNSC	cis	rs7107174	0.892	rs2510031	ENSG00000251323.2	RP11-452H21.4	3.73	0.000213	0.0261	0.25	0.17	Testicular germ cell tumor;	chr11:78258910	chr11:78423982~78429836:-
HNSC	cis	rs6787172	0.593	rs9876322	ENSG00000272087.1	RP11-379F4.7	-3.73	0.000213	0.0261	-0.17	-0.17	Subjective well-being;	chr3:158401449	chr3:158693120~158693768:-
HNSC	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	3.73	0.000213	0.0261	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
HNSC	cis	rs7181649	0.735	rs7176340	ENSG00000278737.1	RP11-325L12.7	3.73	0.000213	0.0261	0.2	0.17	Mean corpuscular hemoglobin;	chr15:65567300	chr15:65083042~65083663:-
HNSC	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	3.73	0.000213	0.0261	0.2	0.17	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
HNSC	cis	rs2554380	0.843	rs1426162	ENSG00000259570.1	RP11-671M22.4	3.73	0.000213	0.0261	0.23	0.17	Height;	chr15:83717251	chr15:84394512~84395514:+
HNSC	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-3.73	0.000213	0.0261	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
HNSC	cis	rs60617249	0.831	rs7794941	ENSG00000228204.2	RP4-724E13.2	3.73	0.000213	0.0262	0.18	0.17	Major depression and alcohol dependence;	chr7:50912040	chr7:50866747~51022990:+
HNSC	cis	rs5751168	0.915	rs5758470	ENSG00000274422.1	LL22NC03-2H8.5	3.73	0.000213	0.0262	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22486760	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.834	rs5758477	ENSG00000274422.1	LL22NC03-2H8.5	3.73	0.000213	0.0262	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22487295	chr22:22283928~22287220:-
HNSC	cis	rs6723108	0.591	rs13399952	ENSG00000224043.6	CCNT2-AS1	3.73	0.000213	0.0262	0.2	0.17	Type 2 diabetes;	chr2:134636834	chr2:134735464~134918710:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	3.73	0.000213	0.0262	0.34	0.17	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
HNSC	cis	rs7903456	0.512	rs7083075	ENSG00000200253.1	RNU6-529P	3.73	0.000213	0.0262	0.22	0.17	Gout;Renal underexcretion gout;	chr10:87056203	chr10:87041238~87041341:-
HNSC	cis	rs10090774	0.735	rs10108814	ENSG00000279766.1	RP11-642A1.2	-3.73	0.000213	0.0262	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708215	chr8:140572142~140572812:-
HNSC	cis	rs6012564	1	rs6063361	ENSG00000227431.4	CSE1L-AS1	3.73	0.000213	0.0262	0.19	0.17	Anger;	chr20:49141426	chr20:49040463~49046044:-
HNSC	cis	rs1440410	0.83	rs300939	ENSG00000250326.1	RP11-284M14.1	-3.73	0.000213	0.0262	-0.19	-0.17	Ischemic stroke;	chr4:143252059	chr4:142933195~143184861:-
HNSC	cis	rs17014483	0.749	rs2924936	ENSG00000248019.2	FAM13A-AS1	-3.73	0.000213	0.0262	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88720363	chr4:88709789~88730103:+
HNSC	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	3.73	0.000213	0.0262	0.2	0.17	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000217862.2	HIST1H4PS1	-3.73	0.000213	0.0262	-0.19	-0.17	Depression;	chr6:28402301	chr6:27807075~27807339:+
HNSC	cis	rs10045431	0.519	rs4921200	ENSG00000253256.1	CTB-11I22.1	3.73	0.000213	0.0262	0.27	0.17	Crohn's disease;	chr5:159251216	chr5:159209921~159248796:+
HNSC	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	3.73	0.000214	0.0262	0.17	0.17	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
HNSC	cis	rs1275468	0.731	rs1480002	ENSG00000257497.2	RP11-585P4.5	-3.73	0.000214	0.0262	-0.26	-0.17	Polycystic ovary syndrome;	chr12:75587184	chr12:75483454~75489820:-
HNSC	cis	rs2599510	0.783	rs2568464	ENSG00000272716.1	RP11-563N4.1	-3.73	0.000214	0.0262	-0.16	-0.17	Interleukin-18 levels;	chr2:32623591	chr2:32165046~32165757:-
HNSC	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-3.73	0.000214	0.0262	-0.26	-0.17	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
HNSC	cis	rs4713118	0.513	rs156739	ENSG00000219891.2	ZSCAN12P1	3.73	0.000214	0.0262	0.23	0.17	Parkinson's disease;	chr6:28045632	chr6:28091154~28093664:+
HNSC	cis	rs9990333	0.622	rs57783901	ENSG00000242086.7	LINC00969	3.73	0.000214	0.0262	0.14	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195658062~195739964:+
HNSC	cis	rs7927592	0.913	rs7118897	ENSG00000255031.4	RP11-802E16.3	3.73	0.000214	0.0262	0.15	0.17	Total body bone mineral density;	chr11:68593212	chr11:68050740~68053762:+
HNSC	cis	rs997295	0.713	rs3784695	ENSG00000270964.1	RP11-502I4.3	-3.73	0.000214	0.0262	-0.17	-0.17	Motion sickness;	chr15:67710264	chr15:67541072~67542604:-
HNSC	cis	rs17507216	0.628	rs4513065	ENSG00000252690.3	SCARNA15	3.73	0.000214	0.0262	0.17	0.17	Excessive daytime sleepiness;	chr15:82712096	chr15:82752884~82757208:+
HNSC	cis	rs7178375	0.941	rs4779796	ENSG00000215302.7	CTD-3092A11.1	-3.73	0.000214	0.0262	-0.26	-0.17	Hypertriglyceridemia;	chr15:30915847	chr15:30470779~30507623:+
HNSC	cis	rs2436845	1	rs2679749	ENSG00000253669.3	KB-1732A1.1	-3.73	0.000214	0.0262	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102846260	chr8:102805517~102809971:+
HNSC	cis	rs28489187	0.617	rs233133	ENSG00000223653.4	RP11-131L23.1	3.73	0.000214	0.0262	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85330874	chr1:85276715~85448124:+
HNSC	cis	rs2762353	0.935	rs1165213	ENSG00000272462.2	U91328.19	3.73	0.000214	0.0262	0.16	0.17	Blood metabolite levels;	chr6:25799448	chr6:25992662~26001775:+
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000253981.4	ALG1L13P	-3.73	0.000214	0.0262	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9226261	chr8:8236003~8244667:-
HNSC	cis	rs1865760	0.593	rs9393676	ENSG00000272810.1	U91328.22	-3.73	0.000214	0.0262	-0.15	-0.17	Height;	chr6:25936716	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.593	rs9295678	ENSG00000272810.1	U91328.22	-3.73	0.000214	0.0262	-0.15	-0.17	Height;	chr6:25936805	chr6:26013241~26013757:+
HNSC	cis	rs2307394	0.648	rs16827722	ENSG00000281469.1	RP11-567F11.1	-3.73	0.000214	0.0262	-0.19	-0.17	Urate levels;	chr2:147713893	chr2:148044380~148044894:+
HNSC	cis	rs950169	1	rs35297609	ENSG00000230373.7	GOLGA6L5P	-3.73	0.000214	0.0262	-0.19	-0.17	Schizophrenia;	chr15:84104144	chr15:84507885~84516814:-
HNSC	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-3.73	0.000214	0.0262	-0.19	-0.17	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
HNSC	cis	rs6498068	0.594	rs3087620	ENSG00000260468.1	LINC01290	-3.73	0.000214	0.0262	-0.2	-0.17	Metabolite levels (MHPG);	chr16:10529475	chr16:10514842~10528202:-
HNSC	cis	rs67311347	0.955	rs60554147	ENSG00000280739.1	EIF1B-AS1	3.73	0.000214	0.0262	0.18	0.17	Renal cell carcinoma;	chr3:40431012	chr3:40173145~40309698:-
HNSC	cis	rs6180	0.54	rs4866968	ENSG00000215068.6	AC025171.1	-3.73	0.000214	0.0262	-0.17	-0.17	Height;	chr5:42851081	chr5:43041575~43045390:+
HNSC	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-3.73	0.000214	0.0262	-0.18	-0.17	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
HNSC	cis	rs3738443	1	rs75028588	ENSG00000259865.1	RP11-488L18.10	3.73	0.000214	0.0262	0.16	0.17	Alcohol dependence;	chr1:247208350	chr1:247187281~247188526:-
HNSC	cis	rs3738443	1	rs56340510	ENSG00000259865.1	RP11-488L18.10	3.73	0.000214	0.0262	0.16	0.17	Alcohol dependence;	chr1:247208707	chr1:247187281~247188526:-
HNSC	cis	rs6547741	0.844	rs7586655	ENSG00000272148.1	RP11-195B17.1	-3.73	0.000214	0.0262	-0.17	-0.17	Oral cavity cancer;	chr2:27692792	chr2:27062428~27062907:-
HNSC	cis	rs10849893	0.557	rs10774593	ENSG00000258435.1	RP11-711D18.2	-3.73	0.000214	0.0262	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121390960	chr12:121391962~121399859:+
HNSC	cis	rs10849893	0.557	rs7976840	ENSG00000258435.1	RP11-711D18.2	-3.73	0.000214	0.0262	-0.18	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121392169	chr12:121391962~121399859:+
HNSC	cis	rs9304742	0.821	rs2011496	ENSG00000242779.5	ZNF702P	3.73	0.000214	0.0262	0.2	0.17	Psoriasis;	chr19:52952624	chr19:52968251~53037898:-
HNSC	cis	rs7201929	1	rs7201929	ENSG00000251417.2	RP11-1348G14.4	-3.73	0.000214	0.0262	-0.22	-0.17	QT interval;	chr16:28860645	chr16:28802743~28817828:+
HNSC	cis	rs863750	0.634	rs825475	ENSG00000275389.1	RP11-214K3.24	3.73	0.000214	0.0262	0.23	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124082761	chr12:124085761~124088598:+
HNSC	cis	rs8072100	0.745	rs7214410	ENSG00000263293.2	RP11-290H9.4	3.73	0.000214	0.0263	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47303460~47323613:-
HNSC	cis	rs6095360	0.966	rs6019545	ENSG00000227431.4	CSE1L-AS1	-3.73	0.000214	0.0263	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48940477	chr20:49040463~49046044:-
HNSC	cis	rs343604	1	rs2797529	ENSG00000258634.3	RP4-773N10.4	-3.73	0.000214	0.0263	-0.33	-0.17	Acute lymphoblastic leukemia (childhood);	chr1:110696508	chr1:110058340~110062555:+
HNSC	cis	rs1443512	0.812	rs1992563	ENSG00000249641.2	HOXC13-AS	-3.73	0.000214	0.0263	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53936657	chr12:53935328~53939643:-
HNSC	cis	rs9880211	0.8	rs66509730	ENSG00000273486.1	RP11-731C17.2	3.73	0.000214	0.0263	0.16	0.17	Height;Body mass index;	chr3:136785416	chr3:136837338~136839021:-
HNSC	cis	rs71520386	0.846	rs17778126	ENSG00000230658.1	KLHL7-AS1	3.73	0.000214	0.0263	0.26	0.17	Fibrinogen levels;	chr7:22779340	chr7:23101228~23105703:-
HNSC	cis	rs268134	0.53	rs62139126	ENSG00000235725.1	AC007389.3	-3.73	0.000214	0.0263	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376292	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs62139127	ENSG00000235725.1	AC007389.3	-3.73	0.000214	0.0263	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376303	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs62139128	ENSG00000235725.1	AC007389.3	-3.73	0.000214	0.0263	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376529	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs34723587	ENSG00000235725.1	AC007389.3	-3.73	0.000214	0.0263	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65377150	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs34928603	ENSG00000235725.1	AC007389.3	-3.73	0.000214	0.0263	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65377777	chr2:65589566~65640177:-
HNSC	cis	rs2439831	1	rs2467426	ENSG00000201136.1	RNU6-353P	-3.73	0.000214	0.0263	-0.27	-0.17	Lung cancer in ever smokers;	chr15:43697320	chr15:43702363~43702470:+
HNSC	cis	rs4256159	1	rs4626115	ENSG00000228956.7	SATB1-AS1	-3.73	0.000214	0.0263	-0.27	-0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18731278	chr3:18445024~18920401:+
HNSC	cis	rs8063160	0.688	rs75570604	ENSG00000260259.1	RP11-368I7.4	-3.73	0.000214	0.0263	-0.43	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89780269	chr16:89682620~89686569:-
HNSC	cis	rs7558911	0.711	rs12693930	ENSG00000183308.6	AC005037.3	3.73	0.000214	0.0263	0.2	0.17	Chronic lymphocytic leukemia;	chr2:201179509	chr2:200963263~201009102:+
HNSC	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-3.73	0.000214	0.0263	-0.21	-0.17	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
HNSC	cis	rs12999542	0.706	rs11465650	ENSG00000234389.1	AC007278.3	3.73	0.000214	0.0263	0.29	0.17	Serum protein levels (sST2);	chr2:102387249	chr2:102438713~102440475:+
HNSC	cis	rs12999542	0.706	rs56151044	ENSG00000234389.1	AC007278.3	3.73	0.000214	0.0263	0.29	0.17	Serum protein levels (sST2);	chr2:102394869	chr2:102438713~102440475:+
HNSC	cis	rs12999542	0.706	rs11465660	ENSG00000234389.1	AC007278.3	3.73	0.000214	0.0263	0.29	0.17	Serum protein levels (sST2);	chr2:102397854	chr2:102438713~102440475:+
HNSC	cis	rs7405404	0.672	rs4780532	ENSG00000262454.1	RP11-65J21.3	-3.73	0.000214	0.0263	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13644447	chr16:14302288~14326353:+
HNSC	cis	rs939574	0.512	rs2276638	ENSG00000243910.6	TUBA4B	3.73	0.000214	0.0263	0.28	0.17	Platelet distribution width;	chr2:219280564	chr2:219253243~219272188:+
HNSC	cis	rs35306767	0.807	rs34885925	ENSG00000229869.1	RP11-363N22.2	-3.73	0.000215	0.0263	-0.27	-0.17	Eosinophil percentage of granulocytes;	chr10:873092	chr10:933026~942743:+
HNSC	cis	rs7592578	0.882	rs16832765	ENSG00000228509.4	AC006460.2	3.73	0.000215	0.0263	0.27	0.17	Diastolic blood pressure;	chr2:190604036	chr2:190676944~190708716:-
HNSC	cis	rs919433	0.963	rs12693815	ENSG00000231621.1	AC013264.2	3.73	0.000215	0.0263	0.16	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197303679	chr2:197197991~197199273:+
HNSC	cis	rs919433	0.963	rs4850428	ENSG00000231621.1	AC013264.2	3.73	0.000215	0.0263	0.16	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305048	chr2:197197991~197199273:+
HNSC	cis	rs73198271	0.96	rs17154702	ENSG00000173295.6	FAM86B3P	-3.73	0.000215	0.0263	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8228595~8244865:+
HNSC	cis	rs236352	0.527	rs831480	ENSG00000232598.2	RP1-90K10.4	-3.73	0.000215	0.0263	-0.2	-0.17	Heart rate;	chr6:36929052	chr6:36940071~36944675:-
HNSC	cis	rs6095360	1	rs1983639	ENSG00000227431.4	CSE1L-AS1	-3.73	0.000215	0.0263	-0.21	-0.17	Intelligence (multi-trait analysis);	chr20:48955745	chr20:49040463~49046044:-
HNSC	cis	rs11992162	0.597	rs6996342	ENSG00000227888.4	FAM66A	-3.73	0.000215	0.0263	-0.17	-0.17	Monocyte count;	chr8:11927032	chr8:12362019~12388296:+
HNSC	cis	rs2657294	0.965	rs10824286	ENSG00000233313.2	HMGA1P5	-3.73	0.000215	0.0263	-0.18	-0.17	Pneumonia;	chr10:75172251	chr10:75276376~75276646:-
HNSC	cis	rs67311347	1	rs11706148	ENSG00000280739.1	EIF1B-AS1	3.73	0.000215	0.0263	0.2	0.17	Renal cell carcinoma;	chr3:40365752	chr3:40173145~40309698:-
HNSC	cis	rs6580649	0.771	rs1034762	ENSG00000278385.1	RP11-89H19.2	-3.73	0.000215	0.0263	-0.27	-0.17	Lung cancer;	chr12:47995860	chr12:47905122~47906865:+
HNSC	cis	rs7189233	1	rs7194519	ENSG00000279344.1	RP11-44F14.7	3.73	0.000215	0.0263	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53501364	chr16:53478957~53481550:-
HNSC	cis	rs4761470	0.577	rs7302972	ENSG00000258365.1	RP11-1105G2.3	-3.73	0.000215	0.0263	-0.19	-0.17	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94277758~94282844:-
HNSC	cis	rs4388249	1	rs2284989	ENSG00000271849.1	CTC-332L22.1	-3.73	0.000215	0.0263	-0.27	-0.17	Schizophrenia;	chr5:109740787	chr5:109687802~109688329:-
HNSC	cis	rs1065852	0.51	rs5751247	ENSG00000227370.1	RP4-669P10.19	3.73	0.000215	0.0263	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42132543~42132998:+
HNSC	cis	rs6107845	0.667	rs1407033	ENSG00000275632.1	RP5-967N21.11	-3.73	0.000215	0.0263	-0.14	-0.17	Vertical cup-disc ratio;	chr20:6564010	chr20:6000418~6000941:+
HNSC	cis	rs4767841	0.805	rs10849696	ENSG00000277283.1	RP1-267D11.6	3.73	0.000215	0.0263	0.17	0.17	Urgency urinary incontinence;	chr12:119771207	chr12:120116907~120119000:+
HNSC	cis	rs10484434	0.818	rs62000984	ENSG00000217159.2	LARP1P1	3.73	0.000215	0.0263	0.29	0.17	HIV-1 viral setpoint;	chr6:26017447	chr6:26164072~26164363:+
HNSC	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	3.73	0.000215	0.0263	0.16	0.17	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
HNSC	cis	rs138249	0.934	rs138228	ENSG00000273253.2	RP3-402G11.26	3.73	0.000215	0.0263	0.17	0.17	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118691	chr22:50199090~50200837:-
HNSC	cis	rs897984	1	rs897984	ENSG00000279196.1	RP11-1072A3.3	-3.73	0.000215	0.0263	-0.19	-0.17	Dementia with Lewy bodies;	chr16:30875322	chr16:30984630~30988270:-
HNSC	cis	rs6580649	0.824	rs1635534	ENSG00000278385.1	RP11-89H19.2	3.73	0.000215	0.0263	0.27	0.17	Lung cancer;	chr12:47992770	chr12:47905122~47906865:+
HNSC	cis	rs80130819	0.515	rs1793915	ENSG00000278385.1	RP11-89H19.2	3.73	0.000215	0.0263	0.27	0.17	Prostate cancer;	chr12:47992794	chr12:47905122~47906865:+
HNSC	cis	rs210138	0.832	rs375555	ENSG00000197251.3	LINC00336	3.73	0.000215	0.0263	0.23	0.17	Testicular germ cell tumor;	chr6:33589964	chr6:33586106~33593338:-
HNSC	cis	rs2554380	0.8	rs8034055	ENSG00000259570.1	RP11-671M22.4	3.73	0.000215	0.0263	0.23	0.17	Height;	chr15:83743143	chr15:84394512~84395514:+
HNSC	cis	rs7974353	0.755	rs6580642	ENSG00000269514.1	RP11-370I10.12	-3.73	0.000215	0.0263	-0.26	-0.17	Gut microbiota (beta diversity);	chr12:47876813	chr12:48198387~48202031:+
HNSC	cis	rs28830936	1	rs17677991	ENSG00000250379.1	RP11-23P13.4	3.73	0.000215	0.0263	0.2	0.17	Diastolic blood pressure;	chr15:41740185	chr15:41825099~41827936:-
HNSC	cis	rs442309	0.846	rs382412	ENSG00000238280.1	RP11-436D10.3	-3.73	0.000215	0.0263	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62730004	chr10:62793562~62805887:-
HNSC	cis	rs7364180	0.515	rs6002503	ENSG00000235513.1	RP4-756G23.5	3.73	0.000215	0.0263	0.17	0.17	Alzheimer's disease biomarkers;	chr22:41812668	chr22:41209122~41217627:-
HNSC	cis	rs432925	0.529	rs2885415	ENSG00000219274.1	RPS20P2	3.73	0.000215	0.0263	0.21	0.17	Morning vs. evening chronotype;	chr16:345396	chr16:1329078~1329777:+
HNSC	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000215	0.0263	-0.22	-0.17	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
HNSC	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	3.73	0.000215	0.0264	0.25	0.17	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
HNSC	cis	rs690037	0.809	rs690023	ENSG00000272529.1	RP11-415F23.4	3.73	0.000215	0.0264	0.14	0.17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16344847	chr3:16345126~16346440:+
HNSC	cis	rs9611565	0.545	rs5758432	ENSG00000235513.1	RP4-756G23.5	-3.73	0.000215	0.0264	-0.21	-0.17	Vitiligo;	chr22:41715689	chr22:41209122~41217627:-
HNSC	cis	rs9535495	0.965	rs7988805	ENSG00000233672.5	RNASEH2B-AS1	-3.73	0.000215	0.0264	-0.16	-0.17	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50830764	chr13:50862172~50910764:-
HNSC	cis	rs2013441	1	rs2243732	ENSG00000261033.1	RP11-209D14.2	3.73	0.000215	0.0264	0.19	0.17	Obesity-related traits;	chr17:20185276	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526458	ENSG00000261033.1	RP11-209D14.2	3.73	0.000215	0.0264	0.19	0.17	Obesity-related traits;	chr17:20188887	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.965	rs2386485	ENSG00000261033.1	RP11-209D14.2	3.73	0.000215	0.0264	0.19	0.17	Obesity-related traits;	chr17:20191933	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526490	ENSG00000261033.1	RP11-209D14.2	3.73	0.000215	0.0264	0.19	0.17	Obesity-related traits;	chr17:20194213	chr17:20008051~20009234:-
HNSC	cis	rs7572733	0.935	rs11690205	ENSG00000222017.1	AC011997.1	3.73	0.000215	0.0264	0.2	0.17	Dermatomyositis;	chr2:198069224	chr2:197693106~197774823:+
HNSC	cis	rs859767	0.501	rs10193171	ENSG00000224043.6	CCNT2-AS1	-3.73	0.000215	0.0264	-0.2	-0.17	Neuroticism;	chr2:134645629	chr2:134735464~134918710:-
HNSC	cis	rs2735413	0.563	rs11640933	ENSG00000261837.1	RP11-264L1.3	-3.73	0.000215	0.0264	-0.27	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78031710	chr16:78534374~78535648:+
HNSC	cis	rs28489187	0.643	rs2011825	ENSG00000223653.4	RP11-131L23.1	3.73	0.000215	0.0264	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85378988	chr1:85276715~85448124:+
HNSC	cis	rs7572733	0.792	rs1036333	ENSG00000222017.1	AC011997.1	3.73	0.000216	0.0264	0.21	0.17	Dermatomyositis;	chr2:198079063	chr2:197693106~197774823:+
HNSC	cis	rs2243480	1	rs160634	ENSG00000230295.1	RP11-458F8.2	3.73	0.000216	0.0264	0.22	0.17	Diabetic kidney disease;	chr7:66063677	chr7:66880708~66882981:+
HNSC	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-3.73	0.000216	0.0264	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
HNSC	cis	rs7274811	0.625	rs293727	ENSG00000277301.1	RP5-1184F4.7	-3.73	0.000216	0.0264	-0.18	-0.17	Height;	chr20:33345258	chr20:32509959~32520285:+
HNSC	cis	rs944002	1	rs36027406	ENSG00000259444.1	RP11-736N17.8	3.73	0.000216	0.0264	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098743	chr14:103094723~103098885:+
HNSC	cis	rs7829975	0.742	rs12547493	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000216	0.0264	-0.19	-0.17	Mood instability;	chr8:8804024	chr8:8456909~8461337:-
HNSC	cis	rs4908760	0.864	rs1463052	ENSG00000232912.4	RP5-1115A15.1	3.73	0.000216	0.0264	0.18	0.17	Vitiligo;	chr1:8641172	chr1:8424645~8434838:+
HNSC	cis	rs875971	0.638	rs6960778	ENSG00000272831.1	RP11-792A8.4	-3.73	0.000216	0.0264	-0.14	-0.17	Aortic root size;	chr7:66606610	chr7:66739829~66740385:-
HNSC	cis	rs2179367	0.959	rs2262617	ENSG00000216906.2	RP11-350J20.9	3.73	0.000216	0.0264	0.21	0.17	Dupuytren's disease;	chr6:149438590	chr6:149904243~149906418:+
HNSC	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	3.73	0.000216	0.0264	0.16	0.17	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
HNSC	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-3.73	0.000216	0.0264	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
HNSC	cis	rs11711311	1	rs13061150	ENSG00000241529.3	RN7SL767P	-3.73	0.000216	0.0264	-0.22	-0.17	IgG glycosylation;	chr3:113787887	chr3:113632704~113632998:+
HNSC	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-3.73	0.000216	0.0264	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
HNSC	cis	rs9863	0.828	rs11057409	ENSG00000270028.1	RP11-380L11.4	-3.73	0.000216	0.0264	-0.2	-0.17	White blood cell count;	chr12:123994784	chr12:123925461~123926083:-
HNSC	cis	rs9329221	0.712	rs1962073	ENSG00000269918.1	AF131215.9	-3.73	0.000216	0.0264	-0.17	-0.17	Neuroticism;	chr8:10403043	chr8:11104691~11106704:-
HNSC	cis	rs11773103	0.881	rs73204817	ENSG00000224046.1	AC005076.5	3.73	0.000216	0.0264	0.24	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87140388	chr7:87151423~87152420:-
HNSC	cis	rs397969	0.621	rs203449	ENSG00000266126.1	RP11-209D14.4	3.73	0.000216	0.0264	0.21	0.17	Platelet count;	chr17:19921308	chr17:19929372~19929737:-
HNSC	cis	rs67311347	0.544	rs2278927	ENSG00000280739.1	EIF1B-AS1	3.73	0.000216	0.0264	0.18	0.17	Renal cell carcinoma;	chr3:40308956	chr3:40173145~40309698:-
HNSC	cis	rs17489649	1	rs2301012	ENSG00000271849.1	CTC-332L22.1	3.73	0.000216	0.0264	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109800567	chr5:109687802~109688329:-
HNSC	cis	rs17057718	1	rs17057718	ENSG00000272146.4	RP11-755B10.4	-3.73	0.000216	0.0264	-0.27	-0.17	Cerebrospinal fluid biomarker levels;	chr3:57102557	chr3:57597715~57600927:+
HNSC	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	3.73	0.000216	0.0264	0.18	0.17	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
HNSC	cis	rs4388249	0.861	rs55968726	ENSG00000271849.1	CTC-332L22.1	-3.73	0.000216	0.0264	-0.27	-0.17	Schizophrenia;	chr5:109867595	chr5:109687802~109688329:-
HNSC	cis	rs4388249	0.904	rs2241693	ENSG00000271849.1	CTC-332L22.1	-3.73	0.000216	0.0264	-0.27	-0.17	Schizophrenia;	chr5:109868220	chr5:109687802~109688329:-
HNSC	cis	rs886774	0.74	rs10271497	ENSG00000273055.1	CTB-13F3.1	-3.73	0.000216	0.0264	-0.17	-0.17	Ulcerative colitis;	chr7:107939229	chr7:107942116~107942740:+
HNSC	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	3.73	0.000216	0.0264	0.22	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
HNSC	cis	rs17489649	1	rs1015975	ENSG00000271849.1	CTC-332L22.1	3.73	0.000216	0.0264	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109699629	chr5:109687802~109688329:-
HNSC	cis	rs7937890	0.559	rs4369365	ENSG00000254418.1	RP11-21L19.1	3.73	0.000216	0.0264	0.2	0.17	Mitochondrial DNA levels;	chr11:14422969	chr11:14262846~14273691:-
HNSC	cis	rs11098499	0.78	rs7692994	ENSG00000260091.1	RP11-33B1.4	3.73	0.000216	0.0264	0.16	0.17	Corneal astigmatism;	chr4:119506334	chr4:119409333~119410233:+
HNSC	cis	rs13179617	0.928	rs13163970	ENSG00000215032.2	GNL3LP1	3.73	0.000216	0.0265	0.2	0.17	Intelligence (multi-trait analysis);	chr5:61481518	chr5:60891935~60893577:-
HNSC	cis	rs8072100	0.875	rs4794047	ENSG00000263293.2	RP11-290H9.4	-3.73	0.000216	0.0265	-0.18	-0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47303460~47323613:-
HNSC	cis	rs10851478	0.872	rs12902960	ENSG00000259656.1	RP11-325E5.1	3.73	0.000216	0.0265	0.2	0.17	Oral cavity cancer;	chr15:49632844	chr15:49101791~49103264:+
HNSC	cis	rs11668609	1	rs11668609	ENSG00000268442.1	CTD-2027I19.2	3.73	0.000216	0.0265	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24172691	chr19:24162370~24163425:-
HNSC	cis	rs12997796	0.556	rs34353387	ENSG00000273080.1	RP11-301O19.1	3.73	0.000216	0.0265	0.25	0.17	Schizophrenia;	chr2:86747711	chr2:86195590~86196049:+
HNSC	cis	rs3018712	0.547	rs4930237	ENSG00000212093.1	AP000807.1	-3.73	0.000216	0.0265	-0.25	-0.17	Total body bone mineral density;	chr11:68646570	chr11:68506083~68506166:-
HNSC	cis	rs9303401	0.614	rs2333409	ENSG00000266701.1	AC005702.4	3.73	0.000216	0.0265	0.23	0.17	Cognitive test performance;	chr17:59061773	chr17:60042546~60042627:-
HNSC	cis	rs12887734	0.524	rs12888002	ENSG00000269910.1	RP11-73M18.10	3.73	0.000216	0.0265	0.16	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694516~103695050:-
HNSC	cis	rs4819052	1	rs3746980	ENSG00000215447.6	BX322557.10	-3.73	0.000216	0.0265	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45288052~45291738:+
HNSC	cis	rs526231	0.543	rs152137	ENSG00000250682.4	LINC00491	3.73	0.000216	0.0265	0.24	0.17	Primary biliary cholangitis;	chr5:103224362	chr5:102609156~102671559:-
HNSC	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	3.73	0.000216	0.0265	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
HNSC	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	3.73	0.000216	0.0265	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
HNSC	cis	rs11867934	0.861	rs7217091	ENSG00000223979.2	SMCR2	-3.73	0.000216	0.0265	-0.21	-0.17	Diabetic retinopathy;	chr17:17157491	chr17:17674026~17677688:-
HNSC	cis	rs1316952	0.831	rs73424827	ENSG00000269938.1	RP11-214K3.20	-3.73	0.000216	0.0265	-0.33	-0.17	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123901175	chr12:123968023~123968579:-
HNSC	cis	rs7267979	0.668	rs4815398	ENSG00000231081.1	RP4-760C5.3	3.73	0.000216	0.0265	0.17	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26008791~26010531:-
HNSC	cis	rs7200786	0.567	rs6498166	ENSG00000274038.1	RP11-66H6.4	-3.73	0.000216	0.0265	-0.22	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11120259	chr16:11056556~11057034:+
HNSC	cis	rs35306767	0.716	rs34487581	ENSG00000229869.1	RP11-363N22.2	-3.73	0.000216	0.0265	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:851261	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs35370435	ENSG00000229869.1	RP11-363N22.2	-3.73	0.000216	0.0265	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:852265	chr10:933026~942743:+
HNSC	cis	rs35306767	0.807	rs12768348	ENSG00000229869.1	RP11-363N22.2	-3.73	0.000216	0.0265	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:853284	chr10:933026~942743:+
HNSC	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-3.73	0.000217	0.0265	-0.19	-0.17	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
HNSC	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-3.73	0.000217	0.0265	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
HNSC	cis	rs7927592	0.913	rs12283755	ENSG00000255031.4	RP11-802E16.3	3.73	0.000217	0.0265	0.16	0.17	Total body bone mineral density;	chr11:68604190	chr11:68050740~68053762:+
HNSC	cis	rs17507216	0.628	rs28371837	ENSG00000252690.3	SCARNA15	3.73	0.000217	0.0265	0.17	0.17	Excessive daytime sleepiness;	chr15:82714435	chr15:82752884~82757208:+
HNSC	cis	rs73198271	0.641	rs34473848	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000217	0.0265	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.601	rs11997731	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000217	0.0265	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8456909~8461337:-
HNSC	cis	rs11776767	0.828	rs1991650	ENSG00000248896.2	CTD-2135J3.3	-3.73	0.000217	0.0265	-0.21	-0.17	Triglycerides;	chr8:10848813	chr8:10729314~10771392:+
HNSC	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-3.73	0.000217	0.0265	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-3.73	0.000217	0.0265	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
HNSC	cis	rs1062753	0.771	rs5751245	ENSG00000227370.1	RP4-669P10.19	3.73	0.000217	0.0265	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42132543~42132998:+
HNSC	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000217	0.0265	-0.2	-0.17	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
HNSC	cis	rs1519814	0.659	rs6469891	ENSG00000254343.2	RP11-760H22.2	-3.73	0.000217	0.0265	-0.22	-0.17	Breast cancer;	chr8:120025178	chr8:120052180~120056201:+
HNSC	cis	rs7572733	0.935	rs10204166	ENSG00000222017.1	AC011997.1	3.73	0.000217	0.0265	0.2	0.17	Dermatomyositis;	chr2:197970540	chr2:197693106~197774823:+
HNSC	cis	rs7829975	0.774	rs35431455	ENSG00000233609.3	RP11-62H7.2	3.73	0.000217	0.0265	0.16	0.17	Mood instability;	chr8:8816226	chr8:8961200~8979025:+
HNSC	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-3.73	0.000217	0.0265	-0.2	-0.17	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
HNSC	cis	rs853679	0.517	rs9393887	ENSG00000219891.2	ZSCAN12P1	3.73	0.000217	0.0265	0.24	0.17	Depression;	chr6:28091242	chr6:28091154~28093664:+
HNSC	cis	rs9914544	0.545	rs7212905	ENSG00000264885.1	RP11-815I9.4	-3.73	0.000217	0.0265	-0.17	-0.17	Educational attainment (years of education);	chr17:18870958	chr17:18667629~18669461:-
HNSC	cis	rs1595825	0.891	rs1016883	ENSG00000231621.1	AC013264.2	3.73	0.000217	0.0265	0.2	0.17	Ulcerative colitis;	chr2:198016944	chr2:197197991~197199273:+
HNSC	cis	rs1665050	0.534	rs4600408	ENSG00000277144.1	RP11-59H7.4	-3.73	0.000217	0.0265	-0.21	-0.17	Atopic dermatitis;	chr15:58954601	chr15:59115547~59116089:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	3.73	0.000217	0.0265	0.34	0.17	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
HNSC	cis	rs6088590	0.523	rs6058084	ENSG00000276073.1	RP5-1125A11.7	-3.73	0.000217	0.0265	-0.18	-0.17	Coronary artery disease;	chr20:34596000	chr20:33985617~33988989:-
HNSC	cis	rs7948661	0.661	rs2017122	ENSG00000278376.1	RP11-158I9.8	3.73	0.000217	0.0265	0.32	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118444134	chr11:118791254~118793137:+
HNSC	cis	rs765751	0.767	rs2605094	ENSG00000228536.1	RP11-392O17.1	-3.73	0.000217	0.0265	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219467421	chr1:219409681~219411941:-
HNSC	cis	rs11148252	0.904	rs9526927	ENSG00000198384.8	TPTE2P3	3.73	0.000217	0.0265	0.21	0.17	Lewy body disease;	chr13:52477492	chr13:52522632~52586906:+
HNSC	cis	rs9788721	0.9	rs4243084	ENSG00000261762.1	RP11-650L12.2	-3.73	0.000217	0.0265	-0.2	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78619330	chr15:78589123~78591276:-
HNSC	cis	rs765751	0.775	rs1531093	ENSG00000228536.1	RP11-392O17.1	-3.73	0.000217	0.0265	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219482496	chr1:219409681~219411941:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000217	0.0265	-0.24	-0.17	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
HNSC	cis	rs116095464	0.558	rs6962	ENSG00000250848.1	CTD-2083E4.5	-3.73	0.000217	0.0265	-0.25	-0.17	Breast cancer;	chr5:256394	chr5:288833~290321:-
HNSC	cis	rs6460942	0.659	rs28366613	ENSG00000226690.5	AC005281.1	3.73	0.000217	0.0265	0.29	0.17	Coronary artery disease;	chr7:12472541	chr7:12496429~12541910:+
HNSC	cis	rs7829975	0.659	rs4382480	ENSG00000233609.3	RP11-62H7.2	3.73	0.000217	0.0265	0.16	0.17	Mood instability;	chr8:8863963	chr8:8961200~8979025:+
HNSC	cis	rs73201462	1	rs11706908	ENSG00000231305.3	RP11-723O4.2	-3.73	0.000217	0.0265	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314205	chr3:128861313~128871540:-
HNSC	cis	rs7520050	0.966	rs10789481	ENSG00000280836.1	AL355480.1	3.73	0.000217	0.0265	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45581219~45581321:-
HNSC	cis	rs3176789	0.914	rs4519176	ENSG00000256673.1	RP11-599J14.2	-3.73	0.000217	0.0265	-0.18	-0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772636	chr12:9398355~9414851:-
HNSC	cis	rs9650657	0.645	rs4841409	ENSG00000255310.2	AF131215.2	3.73	0.000217	0.0265	0.16	0.17	Neuroticism;	chr8:10658864	chr8:11107788~11109726:-
HNSC	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-3.73	0.000217	0.0265	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
HNSC	cis	rs35000415	1	rs35000415	ENSG00000275106.1	RP11-309L24.10	-3.73	0.000217	0.0265	-0.38	-0.17	Systemic lupus erythematosus;	chr7:128945562	chr7:128952527~128953316:-
HNSC	cis	rs3785574	0.962	rs9944483	ENSG00000266402.3	RP11-329L6.2	3.73	0.000217	0.0265	0.13	0.17	Height;	chr17:63706193	chr17:64145970~64146476:+
HNSC	cis	rs55975637	0.73	rs62283491	ENSG00000240476.1	LINC00973	3.73	0.000217	0.0265	0.32	0.17	Advanced age-related macular degeneration;	chr3:99747267	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs62283492	ENSG00000240476.1	LINC00973	3.73	0.000217	0.0265	0.32	0.17	Advanced age-related macular degeneration;	chr3:99748134	chr3:98981058~98983096:+
HNSC	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000217	0.0266	-0.21	-0.17	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
HNSC	cis	rs2486288	0.656	rs6493145	ENSG00000259479.5	SORD2P	-3.73	0.000217	0.0266	-0.19	-0.17	Glomerular filtration rate;	chr15:45281664	chr15:44826371~44884694:-
HNSC	cis	rs9487051	0.714	rs1546722	ENSG00000219700.1	PTCHD3P3	3.73	0.000217	0.0266	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109304594	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.698	rs35757653	ENSG00000243587.6	C6orf183	-3.73	0.000217	0.0266	-0.18	-0.17	Reticulocyte fraction of red cells;	chr6:109323396	chr6:109165833~109271014:+
HNSC	cis	rs1015213	1	rs6990124	ENSG00000272024.1	RP11-546K22.3	3.73	0.000217	0.0266	0.3	0.17	Glaucoma (primary angle closure);	chr8:51975588	chr8:51950284~51950690:+
HNSC	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-3.73	0.000217	0.0266	-0.18	-0.17	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
HNSC	cis	rs116095464	0.681	rs10060016	ENSG00000277812.1	AC021087.1	3.73	0.000217	0.0266	0.29	0.17	Breast cancer;	chr5:240985	chr5:262769~262881:+
HNSC	cis	rs860295	0.557	rs12035524	ENSG00000225855.5	RUSC1-AS1	3.73	0.000217	0.0266	0.12	0.17	Body mass index;	chr1:155697311	chr1:155316863~155324176:-
HNSC	cis	rs7937890	1	rs2970334	ENSG00000254418.1	RP11-21L19.1	-3.73	0.000217	0.0266	-0.2	-0.17	Mitochondrial DNA levels;	chr11:14307809	chr11:14262846~14273691:-
HNSC	cis	rs6012564	1	rs2426106	ENSG00000227431.4	CSE1L-AS1	-3.73	0.000218	0.0266	-0.19	-0.17	Anger;	chr20:49022927	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs3091866	ENSG00000227431.4	CSE1L-AS1	-3.73	0.000218	0.0266	-0.19	-0.17	Anger;	chr20:49031816	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs3818262	ENSG00000227431.4	CSE1L-AS1	3.73	0.000218	0.0266	0.19	0.17	Anger;	chr20:49125019	chr20:49040463~49046044:-
HNSC	cis	rs9863	0.828	rs7307277	ENSG00000270028.1	RP11-380L11.4	3.73	0.000218	0.0266	0.2	0.17	White blood cell count;	chr12:123990609	chr12:123925461~123926083:-
HNSC	cis	rs6430585	0.583	rs78364332	ENSG00000231890.6	DARS-AS1	-3.73	0.000218	0.0266	-0.3	-0.17	Corneal structure;	chr2:135882531	chr2:135985176~136022593:+
HNSC	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	3.73	0.000218	0.0266	0.2	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
HNSC	cis	rs2975734	0.676	rs4841299	ENSG00000269918.1	AF131215.9	-3.73	0.000218	0.0266	-0.18	-0.17	Chronotype;Morning vs. evening chronotype;	chr8:10255083	chr8:11104691~11106704:-
HNSC	cis	rs8031584	0.678	rs798086	ENSG00000270015.1	RP11-540B6.6	3.73	0.000218	0.0266	0.18	0.17	Huntington's disease progression;	chr15:30837008	chr15:30926514~30928407:+
HNSC	cis	rs9987353	0.83	rs4841114	ENSG00000254340.1	RP11-10A14.3	-3.73	0.000218	0.0266	-0.24	-0.17	Recombination measurement;	chr8:9272188	chr8:9141424~9145435:+
HNSC	cis	rs7688540	0.8	rs6837796	ENSG00000250892.1	RP11-1365D11.1	-3.73	0.000218	0.0266	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:201409~205009:-
HNSC	cis	rs3740713	1	rs16935424	ENSG00000256464.1	YWHABP2	3.73	0.000218	0.0266	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438674	ENSG00000256464.1	YWHABP2	3.73	0.000218	0.0266	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr11:18490243~18490955:-
HNSC	cis	rs10022260	1	rs10022260	ENSG00000251022.5	THAP9-AS1	-3.73	0.000218	0.0266	-0.19	-0.17	Adult asthma;	chr4:82872768	chr4:82893009~82900960:-
HNSC	cis	rs795484	0.78	rs795476	ENSG00000275409.1	RP11-131L12.4	-3.73	0.000218	0.0266	-0.21	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118184920	chr12:118430147~118430699:+
HNSC	cis	rs397969	0.646	rs203454	ENSG00000266126.1	RP11-209D14.4	3.73	0.000218	0.0266	0.21	0.17	Platelet count;	chr17:19918200	chr17:19929372~19929737:-
HNSC	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-3.73	0.000218	0.0266	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
HNSC	cis	rs12047808	0.512	rs60741626	ENSG00000227141.2	RP11-545A16.3	-3.73	0.000218	0.0266	-0.28	-0.17	Multiple sclerosis (age of onset);	chr1:179263894	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.512	rs60826716	ENSG00000227141.2	RP11-545A16.3	-3.73	0.000218	0.0266	-0.28	-0.17	Multiple sclerosis (age of onset);	chr1:179264079	chr1:179586705~179589175:+
HNSC	cis	rs11976020	1	rs11976020	ENSG00000205578.5	POM121B	-3.73	0.000218	0.0266	-0.21	-0.17	Educational attainment (years of education);	chr7:72782785	chr7:73293497~73301161:+
HNSC	cis	rs62025270	0.632	rs62022920	ENSG00000259762.1	RP11-158M2.4	-3.73	0.000218	0.0266	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85750336~85752901:-
HNSC	cis	rs72949976	0.864	rs13389834	ENSG00000270659.1	RP11-105N14.1	3.73	0.000218	0.0266	0.17	0.17	Squamous cell lung carcinoma;Lung cancer;	chr2:213160388	chr2:213152970~213153659:+
HNSC	cis	rs2865126	0.761	rs1881089	ENSG00000264714.1	RP11-21G15.1	-3.73	0.000218	0.0266	-0.21	-0.17	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10765808	chr18:10724619~10728539:+
HNSC	cis	rs4853525	0.522	rs1860167	ENSG00000228509.4	AC006460.2	3.73	0.000218	0.0266	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190717661	chr2:190676944~190708716:-
HNSC	cis	rs3743772	0.5	rs28671196	ENSG00000279344.1	RP11-44F14.7	3.73	0.000218	0.0266	0.23	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53478957~53481550:-
HNSC	cis	rs2554380	0.843	rs1426160	ENSG00000259570.1	RP11-671M22.4	3.73	0.000218	0.0266	0.22	0.17	Height;	chr15:83739882	chr15:84394512~84395514:+
HNSC	cis	rs6601327	0.586	rs6601340	ENSG00000233609.3	RP11-62H7.2	-3.73	0.000218	0.0266	-0.16	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9603805	chr8:8961200~8979025:+
HNSC	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	3.73	0.000218	0.0266	0.13	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
HNSC	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	3.73	0.000218	0.0266	0.33	0.17	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
HNSC	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	3.73	0.000218	0.0266	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
HNSC	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	3.73	0.000218	0.0266	0.17	0.17	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
HNSC	cis	rs875971	0.66	rs79009421	ENSG00000272831.1	RP11-792A8.4	-3.73	0.000218	0.0266	-0.14	-0.17	Aortic root size;	chr7:66603522	chr7:66739829~66740385:-
HNSC	cis	rs17772222	0.917	rs12588535	ENSG00000258789.1	RP11-507K2.3	-3.73	0.000218	0.0266	-0.21	-0.17	Coronary artery calcification;	chr14:88781900	chr14:88551597~88552493:+
HNSC	cis	rs9437689	0.966	rs4339907	ENSG00000237416.5	RP11-465K1.2	-3.73	0.000218	0.0266	-0.21	-0.17	Phospholipid levels (plasma);	chr1:95067910	chr1:94836748~94855426:-
HNSC	cis	rs12701220	0.894	rs12701406	ENSG00000224079.1	AC091729.7	3.73	0.000218	0.0266	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1074450~1078036:+
HNSC	cis	rs12701220	0.894	rs12539012	ENSG00000224079.1	AC091729.7	3.73	0.000218	0.0266	0.26	0.17	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1074450~1078036:+
HNSC	cis	rs12370275	0.58	rs35473666	ENSG00000257528.1	KRT8P19	-3.73	0.000218	0.0266	-0.23	-0.17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61357254	chr12:61879318~61880772:+
HNSC	cis	rs9573567	0.881	rs1570541	ENSG00000261553.4	RP11-29G8.3	3.73	0.000218	0.0266	0.33	0.17	Red blood cell count;Mean corpuscular volume;	chr13:75500729	chr13:75549773~75807120:+
HNSC	cis	rs4281086	0.544	rs6601476	ENSG00000255310.2	AF131215.2	3.73	0.000218	0.0267	0.17	0.17	Obesity-related traits;	chr8:10497669	chr8:11107788~11109726:-
HNSC	cis	rs67340775	0.834	rs13218875	ENSG00000219891.2	ZSCAN12P1	3.73	0.000218	0.0267	0.36	0.17	Lung cancer in ever smokers;	chr6:27916234	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs67040724	ENSG00000219891.2	ZSCAN12P1	3.73	0.000218	0.0267	0.36	0.17	Depression;	chr6:27937731	chr6:28091154~28093664:+
HNSC	cis	rs9303401	0.614	rs8081058	ENSG00000266701.1	AC005702.4	3.73	0.000218	0.0267	0.23	0.17	Cognitive test performance;	chr17:59083152	chr17:60042546~60042627:-
HNSC	cis	rs9303401	0.573	rs34097494	ENSG00000266701.1	AC005702.4	3.73	0.000218	0.0267	0.23	0.17	Cognitive test performance;	chr17:59094556	chr17:60042546~60042627:-
HNSC	cis	rs9303401	0.614	rs34678056	ENSG00000266701.1	AC005702.4	3.73	0.000218	0.0267	0.23	0.17	Cognitive test performance;	chr17:59100188	chr17:60042546~60042627:-
HNSC	cis	rs9303401	0.614	rs56284918	ENSG00000266701.1	AC005702.4	3.73	0.000218	0.0267	0.23	0.17	Cognitive test performance;	chr17:59101477	chr17:60042546~60042627:-
HNSC	cis	rs11626933	1	rs3742669	ENSG00000275198.1	RP11-471B22.3	3.73	0.000218	0.0267	0.18	0.17	Gut microbiota (bacterial taxa);	chr14:90301402	chr14:90383365~90387973:+
HNSC	cis	rs11250098	0.642	rs4841460	ENSG00000269918.1	AF131215.9	-3.73	0.000218	0.0267	-0.17	-0.17	Morning vs. evening chronotype;	chr8:10931983	chr8:11104691~11106704:-
HNSC	cis	rs11711311	0.911	rs28577577	ENSG00000241529.3	RN7SL767P	-3.73	0.000218	0.0267	-0.22	-0.17	IgG glycosylation;	chr3:113728429	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs13073843	ENSG00000241529.3	RN7SL767P	-3.73	0.000218	0.0267	-0.22	-0.17	IgG glycosylation;	chr3:113730303	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9865435	ENSG00000241529.3	RN7SL767P	-3.73	0.000218	0.0267	-0.22	-0.17	IgG glycosylation;	chr3:113731199	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9865965	ENSG00000241529.3	RN7SL767P	-3.73	0.000218	0.0267	-0.22	-0.17	IgG glycosylation;	chr3:113731648	chr3:113632704~113632998:+
HNSC	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-3.73	0.000218	0.0267	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
HNSC	cis	rs6674970	0.933	rs11204772	ENSG00000261168.1	RP11-68I18.10	-3.73	0.000218	0.0267	-0.21	-0.17	Childhood ear infection;	chr1:151083829	chr1:151130075~151131610:-
HNSC	cis	rs6674970	1	rs4970941	ENSG00000261168.1	RP11-68I18.10	-3.73	0.000218	0.0267	-0.21	-0.17	Childhood ear infection;	chr1:151096070	chr1:151130075~151131610:-
HNSC	cis	rs471144	0.881	rs12081541	ENSG00000237975.5	FLG-AS1	-3.73	0.000218	0.0267	-0.33	-0.17	Inflammatory skin disease;	chr1:152468890	chr1:152168125~152445456:+
HNSC	cis	rs3015497	0.637	rs12587877	ENSG00000277050.1	RP11-102G14.1	3.73	0.000218	0.0267	0.16	0.17	Mean platelet volume;	chr14:50710284	chr14:51637348~51637947:-
HNSC	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-3.73	0.000218	0.0267	-0.23	-0.17	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
HNSC	cis	rs10851478	0.872	rs10851479	ENSG00000259656.1	RP11-325E5.1	3.73	0.000218	0.0267	0.2	0.17	Oral cavity cancer;	chr15:49617544	chr15:49101791~49103264:+
HNSC	cis	rs12935418	0.672	rs11866803	ENSG00000278985.1	RP11-303E16.9	3.73	0.000218	0.0267	0.17	0.17	Mean corpuscular volume;	chr16:81017598	chr16:80982319~80984094:-
HNSC	cis	rs73607972	0.866	rs16952362	ENSG00000275191.1	RP11-36I17.2	-3.73	0.000218	0.0267	-0.25	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53603976	chr16:53628256~53628816:-
HNSC	cis	rs638893	0.528	rs521910	ENSG00000255422.1	AP002954.4	3.73	0.000219	0.0267	0.28	0.17	Vitiligo;	chr11:118739920	chr11:118704607~118750263:+
HNSC	cis	rs16977195	0.649	rs79727831	ENSG00000259416.2	RP11-158M2.5	3.73	0.000219	0.0267	0.33	0.17	Schizophrenia;	chr15:86409015	chr15:85754941~85756237:-
HNSC	cis	rs9896933	0.778	rs80112422	ENSG00000262663.1	RP11-497H17.1	3.73	0.000219	0.0267	0.23	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82869843	chr17:82918282~82918785:+
HNSC	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-3.73	0.000219	0.0267	-0.19	-0.17	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
HNSC	cis	rs73198271	0.653	rs10099808	ENSG00000173295.6	FAM86B3P	3.73	0.000219	0.0267	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8228595~8244865:+
HNSC	cis	rs7615952	0.551	rs6438945	ENSG00000241278.1	ENPP7P4	-3.73	0.000219	0.0267	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125915630	chr3:125848223~125909372:+
HNSC	cis	rs7615952	0.673	rs7632557	ENSG00000241278.1	ENPP7P4	-3.73	0.000219	0.0267	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:125916038	chr3:125848223~125909372:+
HNSC	cis	rs2483519	0.578	rs2780753	ENSG00000236799.1	RP11-383C6.2	-3.73	0.000219	0.0267	-0.18	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114707934	chr10:114994657~114996593:+
HNSC	cis	rs11976180	1	rs2961144	ENSG00000244479.5	OR2A1-AS1	-3.73	0.000219	0.0267	-0.2	-0.17	Obesity-related traits;	chr7:144050777	chr7:144251264~144356181:-
HNSC	cis	rs116095464	0.558	rs10057674	ENSG00000277812.1	AC021087.1	3.73	0.000219	0.0267	0.28	0.17	Breast cancer;	chr5:266698	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs1812843	ENSG00000277812.1	AC021087.1	3.73	0.000219	0.0267	0.28	0.17	Breast cancer;	chr5:267543	chr5:262769~262881:+
HNSC	cis	rs12999542	0.706	rs80321720	ENSG00000234389.1	AC007278.3	3.73	0.000219	0.0267	0.29	0.17	Serum protein levels (sST2);	chr2:102408209	chr2:102438713~102440475:+
HNSC	cis	rs12999542	0.706	rs62152712	ENSG00000234389.1	AC007278.3	3.73	0.000219	0.0267	0.29	0.17	Serum protein levels (sST2);	chr2:102408697	chr2:102438713~102440475:+
HNSC	cis	rs13178541	0.81	rs62365677	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000219	0.0267	-0.21	-0.17	IgG glycosylation;	chr5:135752861	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs7380576	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000219	0.0267	-0.21	-0.17	IgG glycosylation;	chr5:135752903	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs7380618	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000219	0.0267	-0.21	-0.17	IgG glycosylation;	chr5:135753120	chr5:135812667~135826582:+
HNSC	cis	rs865483	0.895	rs4795200	ENSG00000276054.1	RP11-378E13.3	3.73	0.000219	0.0267	0.2	0.17	Monocyte count;	chr17:37457003	chr17:37386886~37387926:+
HNSC	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	3.73	0.000219	0.0267	0.24	0.17	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
HNSC	cis	rs7771547	0.642	rs9470309	ENSG00000219023.1	RP3-340B19.2	3.73	0.000219	0.0267	0.15	0.17	Platelet distribution width;	chr6:36541974	chr6:35555873~35556264:+
HNSC	cis	rs7558911	0.769	rs2881930	ENSG00000183308.6	AC005037.3	3.73	0.000219	0.0267	0.2	0.17	Chronic lymphocytic leukemia;	chr2:201211029	chr2:200963263~201009102:+
HNSC	cis	rs6952407	1	rs6952407	ENSG00000272831.1	RP11-792A8.4	-3.73	0.000219	0.0267	-0.14	-0.17	Cotinine glucuronidation;	chr7:66580525	chr7:66739829~66740385:-
HNSC	cis	rs12664251	0.683	rs2066408	ENSG00000253194.1	RP11-351A11.1	-3.73	0.000219	0.0267	-0.2	-0.17	Schizophrenia;	chr6:119021069	chr6:118934785~119031541:+
HNSC	cis	rs7615952	0.688	rs12485622	ENSG00000241278.1	ENPP7P4	-3.73	0.000219	0.0267	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125991896	chr3:125848223~125909372:+
HNSC	cis	rs597539	0.616	rs631001	ENSG00000261625.1	RP11-554A11.4	-3.73	0.000219	0.0267	-0.19	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:69000765~69002048:-
HNSC	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	3.73	0.000219	0.0267	0.25	0.17	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
HNSC	cis	rs950027	0.62	rs1719245	ENSG00000259479.5	SORD2P	3.73	0.000219	0.0267	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:44826371~44884694:-
HNSC	cis	rs4838594	0.715	rs11101340	ENSG00000279822.1	RP11-541M12.6	3.73	0.000219	0.0267	0.22	0.17	Daytime sleep phenotypes;	chr10:48474359	chr10:48443836~48445820:-
HNSC	cis	rs2554380	0.628	rs2081541	ENSG00000259570.1	RP11-671M22.4	3.73	0.000219	0.0267	0.21	0.17	Height;	chr15:83774934	chr15:84394512~84395514:+
HNSC	cis	rs440932	1	rs378974	ENSG00000233609.3	RP11-62H7.2	3.73	0.000219	0.0267	0.17	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8961200~8979025:+
HNSC	cis	rs6570726	0.846	rs6899900	ENSG00000270638.1	RP3-466P17.1	3.73	0.000219	0.0267	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145735570~145737218:+
HNSC	cis	rs11231017	0.514	rs953169	ENSG00000250659.2	RP11-864I4.3	3.73	0.000219	0.0267	0.21	0.17	HIV-1 viral setpoint;	chr11:62316070	chr11:62537312~62542018:+
HNSC	cis	rs9467711	0.606	rs9393715	ENSG00000241549.7	GUSBP2	3.73	0.000219	0.0267	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26375417	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.72	rs9348716	ENSG00000241549.7	GUSBP2	3.73	0.000219	0.0267	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:26375430	chr6:26871484~26956554:-
HNSC	cis	rs17772222	0.958	rs17203789	ENSG00000258789.1	RP11-507K2.3	-3.72	0.000219	0.0268	-0.21	-0.17	Coronary artery calcification;	chr14:88541362	chr14:88551597~88552493:+
HNSC	cis	rs10073892	0.743	rs62372222	ENSG00000250682.4	LINC00491	-3.72	0.000219	0.0268	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315801	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.606	rs2736273	ENSG00000255495.1	AC145124.2	3.72	0.000219	0.0268	0.19	0.17	Retinal vascular caliber;	chr8:11342429	chr8:12194467~12196280:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000259429.4	UBE2Q2P2	-3.72	0.000219	0.0268	-0.15	-0.17	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82355142~82420075:+
HNSC	cis	rs7558911	0.802	rs11674246	ENSG00000183308.6	AC005037.3	3.72	0.000219	0.0268	0.2	0.17	Chronic lymphocytic leukemia;	chr2:201183400	chr2:200963263~201009102:+
HNSC	cis	rs7267979	0.789	rs6076347	ENSG00000204556.4	CTD-2514C3.1	3.72	0.000219	0.0268	0.21	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26018832~26020684:+
HNSC	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-3.72	0.000219	0.0268	-0.2	-0.17	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
HNSC	cis	rs28573326	0.962	rs10517845	ENSG00000121089.4	NACA3P	3.72	0.000219	0.0268	0.2	0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415983	chr4:164943290~164943937:+
HNSC	cis	rs427943	0.553	rs11701929	ENSG00000223768.1	LINC00205	-3.72	0.000219	0.0268	-0.18	-0.17	Body mass index;	chr21:45224820	chr21:45293285~45297354:+
HNSC	cis	rs9863	0.828	rs12303933	ENSG00000270028.1	RP11-380L11.4	3.72	0.000219	0.0268	0.2	0.17	White blood cell count;	chr12:123997709	chr12:123925461~123926083:-
HNSC	cis	rs3947	0.789	rs8005	ENSG00000269918.1	AF131215.9	3.72	0.000219	0.0268	0.18	0.17	Blood protein levels;	chr8:11843587	chr8:11104691~11106704:-
HNSC	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-3.72	0.000219	0.0268	-0.19	-0.17	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
HNSC	cis	rs2060793	0.741	rs2060794	ENSG00000254418.1	RP11-21L19.1	3.72	0.000219	0.0268	0.2	0.17	Vitamin D levels;	chr11:14791437	chr11:14262846~14273691:-
HNSC	cis	rs2060793	0.741	rs3740823	ENSG00000254418.1	RP11-21L19.1	3.72	0.000219	0.0268	0.2	0.17	Vitamin D levels;	chr11:14804158	chr11:14262846~14273691:-
HNSC	cis	rs6095360	0.727	rs6095391	ENSG00000222365.1	SNORD12B	-3.72	0.000219	0.0268	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:49002298	chr20:49280319~49280409:+
HNSC	cis	rs8072100	0.967	rs4580230	ENSG00000263293.2	RP11-290H9.4	3.72	0.00022	0.0268	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47303460~47323613:-
HNSC	cis	rs6012564	1	rs2869716	ENSG00000227431.4	CSE1L-AS1	3.72	0.00022	0.0268	0.2	0.17	Anger;	chr20:49162803	chr20:49040463~49046044:-
HNSC	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-3.72	0.00022	0.0268	-0.22	-0.17	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
HNSC	cis	rs4073405	1	rs4073405	ENSG00000254651.1	RP11-430H10.3	3.72	0.00022	0.0268	0.21	0.17	Schizophrenia;	chr11:45302302	chr11:45399448~45400528:+
HNSC	cis	rs9467711	0.606	rs72841536	ENSG00000241549.7	GUSBP2	3.72	0.00022	0.0268	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26378060	chr6:26871484~26956554:-
HNSC	cis	rs1003719	0.591	rs2018521	ENSG00000242553.1	AP001432.14	3.72	0.00022	0.0268	0.19	0.17	Eye color traits;	chr21:37144964	chr21:37221419~37237744:+
HNSC	cis	rs3736485	0.966	rs11070855	ENSG00000259438.1	CTD-2650P22.1	3.72	0.00022	0.0268	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51558086	chr15:52010999~52019095:-
HNSC	cis	rs28830936	0.966	rs8025714	ENSG00000250379.1	RP11-23P13.4	3.72	0.00022	0.0268	0.21	0.17	Diastolic blood pressure;	chr15:41827959	chr15:41825099~41827936:-
HNSC	cis	rs11603691	1	rs113309829	ENSG00000254662.1	RP11-872D17.4	-3.72	0.00022	0.0268	-0.36	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57239098	chr11:57325603~57327958:+
HNSC	cis	rs10484434	0.818	rs11756400	ENSG00000272810.1	U91328.22	3.72	0.00022	0.0268	0.2	0.17	HIV-1 viral setpoint;	chr6:26040625	chr6:26013241~26013757:+
HNSC	cis	rs6545883	0.929	rs7561229	ENSG00000271889.1	RP11-493E12.1	3.72	0.00022	0.0268	0.2	0.17	Tuberculosis;	chr2:61510855	chr2:61151433~61162105:-
HNSC	cis	rs919433	0.617	rs700643	ENSG00000231621.1	AC013264.2	-3.72	0.00022	0.0268	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736646	chr2:197197991~197199273:+
HNSC	cis	rs2016266	0.859	rs2886129	ENSG00000270175.1	RP11-793H13.11	-3.72	0.00022	0.0268	-0.17	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53338200	chr12:53500162~53500936:-
HNSC	cis	rs7688540	0.771	rs10005733	ENSG00000250892.1	RP11-1365D11.1	-3.72	0.00022	0.0268	-0.28	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:201409~205009:-
HNSC	cis	rs1865760	0.613	rs9379805	ENSG00000272810.1	U91328.22	-3.72	0.00022	0.0268	-0.15	-0.17	Height;	chr6:25938536	chr6:26013241~26013757:+
HNSC	cis	rs332034	0.546	rs28886957	ENSG00000253893.2	FAM85B	3.72	0.00022	0.0268	0.32	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8832983	chr8:8167819~8226614:-
HNSC	cis	rs332034	0.546	rs28823269	ENSG00000253893.2	FAM85B	3.72	0.00022	0.0268	0.32	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8833007	chr8:8167819~8226614:-
HNSC	cis	rs72827839	0.696	rs77556405	ENSG00000228782.6	CTD-2026D20.3	3.72	0.00022	0.0268	0.23	0.17	Ease of getting up in the morning;	chr17:48386547	chr17:47450568~47492492:-
HNSC	cis	rs9880211	0.8	rs35422852	ENSG00000239213.4	NCK1-AS1	3.72	0.00022	0.0268	0.18	0.17	Height;Body mass index;	chr3:136787073	chr3:136841726~136862054:-
HNSC	cis	rs9880211	0.8	rs35880395	ENSG00000239213.4	NCK1-AS1	3.72	0.00022	0.0268	0.18	0.17	Height;Body mass index;	chr3:136788248	chr3:136841726~136862054:-
HNSC	cis	rs8030379	1	rs1526080	ENSG00000230373.7	GOLGA6L5P	-3.72	0.00022	0.0268	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921168	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1852264	ENSG00000230373.7	GOLGA6L5P	-3.72	0.00022	0.0268	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921188	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1526081	ENSG00000230373.7	GOLGA6L5P	-3.72	0.00022	0.0268	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921314	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs8030379	ENSG00000230373.7	GOLGA6L5P	-3.72	0.00022	0.0268	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922158	chr15:84507885~84516814:-
HNSC	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	3.72	0.00022	0.0268	0.19	0.17	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
HNSC	cis	rs11951515	0.663	rs10039617	ENSG00000249286.1	CTD-2210P15.2	3.72	0.00022	0.0268	0.18	0.17	Metabolite levels  (X-11787);	chr5:43319250	chr5:43586918~43588223:-
HNSC	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	3.72	0.00022	0.0268	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
HNSC	cis	rs7927592	0.731	rs11228275	ENSG00000255031.4	RP11-802E16.3	-3.72	0.00022	0.0268	-0.14	-0.17	Total body bone mineral density;	chr11:68536512	chr11:68050740~68053762:+
HNSC	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	3.72	0.00022	0.0268	0.19	0.17	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
HNSC	cis	rs62229266	0.839	rs11088335	ENSG00000230212.5	AP000688.14	-3.72	0.00022	0.0268	-0.18	-0.17	Mitral valve prolapse;	chr21:36098037	chr21:36069642~36126640:-
HNSC	cis	rs686320	1	rs616599	ENSG00000245532.5	NEAT1	3.72	0.00022	0.0268	0.19	0.17	Hip circumference adjusted for BMI;	chr11:65486554	chr11:65422774~65445540:+
HNSC	cis	rs853679	0.599	rs13193295	ENSG00000219891.2	ZSCAN12P1	3.72	0.00022	0.0268	0.35	0.17	Depression;	chr6:28035450	chr6:28091154~28093664:+
HNSC	cis	rs4449834	0.816	rs1038351	ENSG00000254432.1	RP11-33I11.2	-3.72	0.00022	0.0268	-0.21	-0.17	Sum eosinophil basophil counts;	chr8:60757749	chr8:60808735~60809606:-
HNSC	cis	rs4449834	0.816	rs1038352	ENSG00000254432.1	RP11-33I11.2	-3.72	0.00022	0.0268	-0.21	-0.17	Sum eosinophil basophil counts;	chr8:60757754	chr8:60808735~60809606:-
HNSC	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-3.72	0.00022	0.0268	-0.17	-0.17	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
HNSC	cis	rs1316952	0.831	rs78985577	ENSG00000269938.1	RP11-214K3.20	-3.72	0.00022	0.0268	-0.3	-0.17	Visceral adipose tissue adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr12:123908570	chr12:123968023~123968579:-
HNSC	cis	rs2839186	0.771	rs2280957	ENSG00000239415.1	AP001469.9	-3.72	0.00022	0.0268	-0.15	-0.17	Testicular germ cell tumor;	chr21:46222358	chr21:46251549~46254133:-
HNSC	cis	rs795484	0.816	rs2650175	ENSG00000275409.1	RP11-131L12.4	-3.72	0.00022	0.0268	-0.21	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118229615	chr12:118430147~118430699:+
HNSC	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	3.72	0.00022	0.0268	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
HNSC	cis	rs73198271	1	rs11776513	ENSG00000253893.2	FAM85B	3.72	0.00022	0.0268	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8167819~8226614:-
HNSC	cis	rs67311347	0.544	rs13062243	ENSG00000280739.1	EIF1B-AS1	3.72	0.00022	0.0268	0.18	0.17	Renal cell carcinoma;	chr3:40295298	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs12054197	ENSG00000280739.1	EIF1B-AS1	3.72	0.00022	0.0268	0.18	0.17	Renal cell carcinoma;	chr3:40296071	chr3:40173145~40309698:-
HNSC	cis	rs2013441	1	rs2703801	ENSG00000261033.1	RP11-209D14.2	3.72	0.00022	0.0268	0.19	0.17	Obesity-related traits;	chr17:20197287	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703802	ENSG00000261033.1	RP11-209D14.2	3.72	0.00022	0.0268	0.19	0.17	Obesity-related traits;	chr17:20197726	chr17:20008051~20009234:-
HNSC	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	3.72	0.00022	0.0269	0.2	0.17	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
HNSC	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	3.72	0.00022	0.0269	0.2	0.17	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
HNSC	cis	rs6968419	1	rs12536669	ENSG00000237870.5	AC073130.1	3.72	0.00022	0.0269	0.19	0.17	Intraocular pressure;	chr7:116173624	chr7:116275606~116286734:-
HNSC	cis	rs6968419	1	rs6977233	ENSG00000237870.5	AC073130.1	3.72	0.00022	0.0269	0.19	0.17	Intraocular pressure;	chr7:116174688	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.962	rs6959449	ENSG00000237870.5	AC073130.1	3.72	0.00022	0.0269	0.19	0.17	Intraocular pressure;	chr7:116174738	chr7:116275606~116286734:-
HNSC	cis	rs73081554	0.611	rs4681852	ENSG00000273493.1	RP11-80H18.4	-3.72	0.00022	0.0269	-0.28	-0.17	Rheumatoid arthritis;	chr3:58423446	chr3:58329965~58330118:+
HNSC	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	3.72	0.00022	0.0269	0.14	0.17	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
HNSC	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	3.72	0.00022	0.0269	0.15	0.17	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
HNSC	cis	rs12931792	0.712	rs2887799	ENSG00000273724.1	RP11-347C12.12	3.72	0.00022	0.0269	0.19	0.17	Tonsillectomy;	chr16:30152512	chr16:30336400~30343336:+
HNSC	cis	rs4853525	0.522	rs62179717	ENSG00000228509.4	AC006460.2	3.72	0.00022	0.0269	0.22	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190726087	chr2:190676944~190708716:-
HNSC	cis	rs10995356	0.584	rs10822092	ENSG00000238280.1	RP11-436D10.3	-3.72	0.000221	0.0269	-0.2	-0.17	Temperament;	chr10:62944981	chr10:62793562~62805887:-
HNSC	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	3.72	0.000221	0.0269	0.21	0.17	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
HNSC	cis	rs853679	1	rs9986596	ENSG00000219891.2	ZSCAN12P1	3.72	0.000221	0.0269	0.27	0.17	Depression;	chr6:28251883	chr6:28091154~28093664:+
HNSC	cis	rs6545883	0.894	rs778158	ENSG00000271889.1	RP11-493E12.1	-3.72	0.000221	0.0269	-0.19	-0.17	Tuberculosis;	chr2:61328286	chr2:61151433~61162105:-
HNSC	cis	rs9487051	0.582	rs351716	ENSG00000243587.6	C6orf183	-3.72	0.000221	0.0269	-0.18	-0.17	Reticulocyte fraction of red cells;	chr6:109232561	chr6:109165833~109271014:+
HNSC	cis	rs544991	0.687	rs9943159	ENSG00000239670.1	RP4-803A2.2	3.72	0.000221	0.0269	0.21	0.17	Intelligence;	chr1:33747476	chr1:32986952~32988233:+
HNSC	cis	rs3857747	0.537	rs4421260	ENSG00000228554.1	AC004837.5	3.72	0.000221	0.0269	0.17	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40385309	chr7:39700341~39703296:-
HNSC	cis	rs250677	0.687	rs250671	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000221	0.0269	-0.22	-0.17	Breast cancer;	chr5:149066960	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.652	rs250670	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000221	0.0269	-0.22	-0.17	Breast cancer;	chr5:149067083	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs168750	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000221	0.0269	-0.22	-0.17	Breast cancer;	chr5:149067193	chr5:149063317~149109787:+
HNSC	cis	rs13325613	0.834	rs10510749	ENSG00000223552.1	RP11-24F11.2	3.72	0.000221	0.0269	0.26	0.17	Monocyte count;	chr3:46138924	chr3:46364955~46407059:-
HNSC	cis	rs1065852	0.906	rs9611734	ENSG00000227370.1	RP4-669P10.19	3.72	0.000221	0.0269	0.2	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42132543~42132998:+
HNSC	cis	rs8030379	1	rs1564472	ENSG00000230373.7	GOLGA6L5P	-3.72	0.000221	0.0269	-0.17	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84507885~84516814:-
HNSC	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.24	0.17	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
HNSC	cis	rs7568498	0.564	rs10490563	ENSG00000235724.7	AC009299.2	3.72	0.000221	0.0269	0.23	0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161222785~161308303:-
HNSC	cis	rs7568498	0.564	rs9287807	ENSG00000235724.7	AC009299.2	3.72	0.000221	0.0269	0.23	0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161222785~161308303:-
HNSC	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	3.72	0.000221	0.0269	0.19	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
HNSC	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	3.72	0.000221	0.0269	0.17	0.17	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	3.72	0.000221	0.0269	0.17	0.17	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
HNSC	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	3.72	0.000221	0.0269	0.18	0.17	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
HNSC	cis	rs11168618	0.904	rs7978948	ENSG00000240399.1	RP1-228P16.1	3.72	0.000221	0.0269	0.14	0.17	Adiponectin levels;	chr12:48536240	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.904	rs12366459	ENSG00000240399.1	RP1-228P16.1	3.72	0.000221	0.0269	0.14	0.17	Adiponectin levels;	chr12:48537117	chr12:48054813~48055591:-
HNSC	cis	rs17250963	0.645	rs696295	ENSG00000249485.1	RBBP4P1	-3.72	0.000221	0.0269	-0.17	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14746531	chr5:14797125~14798400:-
HNSC	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	3.72	0.000221	0.0269	0.17	0.17	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
HNSC	cis	rs10789207	0.531	rs57572851	ENSG00000248458.2	RP4-598P13.1	-3.72	0.000221	0.0269	-0.25	-0.17	Resting heart rate;	chr1:66630329	chr1:66665864~66677027:-
HNSC	cis	rs10789207	0.531	rs72669451	ENSG00000248458.2	RP4-598P13.1	-3.72	0.000221	0.0269	-0.25	-0.17	Resting heart rate;	chr1:66630507	chr1:66665864~66677027:-
HNSC	cis	rs3806843	0.576	rs155360	ENSG00000276545.1	PCDHGB9P	3.72	0.000221	0.0269	0.2	0.17	Depressive symptoms (multi-trait analysis);	chr5:140929431	chr5:141439853~141442449:+
HNSC	cis	rs11668609	0.935	rs7257096	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000221	0.0269	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24098965	chr19:24162370~24163425:-
HNSC	cis	rs11668609	0.872	rs11668697	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000221	0.0269	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24108247	chr19:24162370~24163425:-
HNSC	cis	rs11668609	1	rs3844579	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000221	0.0269	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24120337	chr19:24162370~24163425:-
HNSC	cis	rs300890	0.76	rs6537152	ENSG00000250326.1	RP11-284M14.1	-3.72	0.000221	0.0269	-0.19	-0.17	Nasopharyngeal carcinoma;	chr4:143280891	chr4:142933195~143184861:-
HNSC	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.26	0.17	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.26	0.17	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	3.72	0.000221	0.0269	0.26	0.17	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
HNSC	cis	rs929354	1	rs1182414	ENSG00000224629.1	RP5-1142J19.2	3.72	0.000221	0.0269	0.17	0.17	Body mass index;	chr7:157265669	chr7:157263022~157263229:-
HNSC	cis	rs13260300	0.645	rs2114056	ENSG00000254349.4	FLJ39080	3.72	0.000221	0.0269	0.2	0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74609384	chr8:74599775~74823313:+
HNSC	cis	rs13260300	0.572	rs7824069	ENSG00000254349.4	FLJ39080	3.72	0.000221	0.0269	0.2	0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74610367	chr8:74599775~74823313:+
HNSC	cis	rs6601327	0.678	rs10106040	ENSG00000233609.3	RP11-62H7.2	3.72	0.000221	0.0269	0.16	0.17	Multiple myeloma (hyperdiploidy);	chr8:9754903	chr8:8961200~8979025:+
HNSC	cis	rs6928977	0.863	rs2746430	ENSG00000217482.2	HMGB1P17	-3.72	0.000221	0.0269	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352154	chr6:135636086~135636713:-
HNSC	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.0269	0.33	0.17	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
HNSC	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-3.72	0.000221	0.0269	-0.18	-0.17	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
HNSC	cis	rs34792	0.688	rs153782	ENSG00000207425.1	Y_RNA	3.72	0.000221	0.0269	0.2	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14915457~14915556:-
HNSC	cis	rs7005380	0.556	rs62528692	ENSG00000279347.1	RP11-85I17.2	3.72	0.000221	0.0269	0.17	0.17	Interstitial lung disease;	chr8:119932967	chr8:119838736~119840385:-
HNSC	cis	rs6710503	0.926	rs6749833	ENSG00000271936.1	RP11-443B20.1	-3.72	0.000221	0.0269	-0.19	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24692473	chr2:24825610~24826717:+
HNSC	cis	rs10995356	0.565	rs7096063	ENSG00000238280.1	RP11-436D10.3	-3.72	0.000221	0.0269	-0.2	-0.17	Temperament;	chr10:62971134	chr10:62793562~62805887:-
HNSC	cis	rs988913	0.957	rs6908170	ENSG00000224984.1	RP11-524H19.2	3.72	0.000221	0.0269	0.2	0.17	Menarche (age at onset);	chr6:54956354	chr6:54840118~54840855:-
HNSC	cis	rs7948471	0.618	rs401507	ENSG00000254595.1	CTD-2010I16.1	-3.72	0.000221	0.0269	-0.18	-0.17	Sickle cell anemia (haemolysis);	chr11:5490667	chr11:6488186~6489377:-
HNSC	cis	rs7201929	0.801	rs9933198	ENSG00000251417.2	RP11-1348G14.4	3.72	0.000221	0.0269	0.22	0.17	QT interval;	chr16:28877088	chr16:28802743~28817828:+
HNSC	cis	rs7777677	0.925	rs4726546	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.925	rs6960743	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.925	rs6956756	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.889	rs6975391	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.925	rs9655661	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.888	rs9655574	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.963	rs4726550	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142492132~142492673:+
HNSC	cis	rs7777677	0.963	rs7796324	ENSG00000211727.3	TRBV7-6	3.72	0.000221	0.027	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142492132~142492673:+
HNSC	cis	rs300890	0.76	rs13118846	ENSG00000250326.1	RP11-284M14.1	3.72	0.000221	0.027	0.19	0.17	Nasopharyngeal carcinoma;	chr4:143289009	chr4:142933195~143184861:-
HNSC	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	3.72	0.000221	0.027	0.34	0.17	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
HNSC	cis	rs13113518	0.507	rs11943456	ENSG00000249700.7	SRD5A3-AS1	3.72	0.000221	0.027	0.19	0.17	Height;	chr4:55410167	chr4:55363971~55395847:-
HNSC	cis	rs2836974	0.899	rs2836957	ENSG00000255568.3	BRWD1-AS2	3.72	0.000221	0.027	0.16	0.17	Cognitive function;	chr21:39251208	chr21:39313935~39314962:+
HNSC	cis	rs250677	0.687	rs250673	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000221	0.027	-0.22	-0.17	Breast cancer;	chr5:149066235	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs250672	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000221	0.027	-0.22	-0.17	Breast cancer;	chr5:149066547	chr5:149063317~149109787:+
HNSC	cis	rs73198271	0.96	rs12155530	ENSG00000254340.1	RP11-10A14.3	-3.72	0.000221	0.027	-0.25	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8753454	chr8:9141424~9145435:+
HNSC	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-3.72	0.000221	0.027	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
HNSC	cis	rs7937890	0.559	rs1116739	ENSG00000254418.1	RP11-21L19.1	3.72	0.000221	0.027	0.2	0.17	Mitochondrial DNA levels;	chr11:14467636	chr11:14262846~14273691:-
HNSC	cis	rs10484434	0.901	rs2230654	ENSG00000272810.1	U91328.22	-3.72	0.000221	0.027	-0.2	-0.17	HIV-1 viral setpoint;	chr6:26033413	chr6:26013241~26013757:+
HNSC	cis	rs8044868	0.781	rs3852788	ENSG00000259209.3	RP5-991G20.2	3.72	0.000221	0.027	0.18	0.17	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72191887	chr16:72805998~72809872:+
HNSC	cis	rs2247572	0.778	rs2247672	ENSG00000250295.5	RP11-434I12.2	3.72	0.000221	0.027	0.21	0.17	Cognitive performance;	chr8:72719868	chr8:73297711~73356461:-
HNSC	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-3.72	0.000221	0.027	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
HNSC	cis	rs690037	0.78	rs690437	ENSG00000271964.1	RP11-415F23.2	-3.72	0.000221	0.027	-0.17	-0.17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr3:16314439~16314987:+
HNSC	cis	rs73198271	0.843	rs11775888	ENSG00000173295.6	FAM86B3P	-3.72	0.000222	0.027	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8228595~8244865:+
HNSC	cis	rs7688540	0.771	rs61794996	ENSG00000250892.1	RP11-1365D11.1	-3.72	0.000222	0.027	-0.3	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:201409~205009:-
HNSC	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	3.72	0.000222	0.027	0.24	0.17	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
HNSC	cis	rs6095360	0.727	rs71351953	ENSG00000222365.1	SNORD12B	-3.72	0.000222	0.027	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48958210	chr20:49280319~49280409:+
HNSC	cis	rs6095360	0.7	rs67623477	ENSG00000222365.1	SNORD12B	-3.72	0.000222	0.027	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:49052640	chr20:49280319~49280409:+
HNSC	cis	rs2179367	0.959	rs628488	ENSG00000216906.2	RP11-350J20.9	3.72	0.000222	0.027	0.21	0.17	Dupuytren's disease;	chr6:149398264	chr6:149904243~149906418:+
HNSC	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-3.72	0.000222	0.027	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
HNSC	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-3.72	0.000222	0.027	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
HNSC	cis	rs12047808	0.841	rs59949433	ENSG00000227141.2	RP11-545A16.3	-3.72	0.000222	0.027	-0.27	-0.17	Multiple sclerosis (age of onset);	chr1:179388351	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.841	rs78233610	ENSG00000227141.2	RP11-545A16.3	-3.72	0.000222	0.027	-0.27	-0.17	Multiple sclerosis (age of onset);	chr1:179400482	chr1:179586705~179589175:+
HNSC	cis	rs67311347	1	rs7612015	ENSG00000280739.1	EIF1B-AS1	3.72	0.000222	0.027	0.18	0.17	Renal cell carcinoma;	chr3:40358483	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs7644643	ENSG00000280739.1	EIF1B-AS1	-3.72	0.000222	0.027	-0.18	-0.17	Renal cell carcinoma;	chr3:40308718	chr3:40173145~40309698:-
HNSC	cis	rs988913	0.662	rs11754240	ENSG00000224984.1	RP11-524H19.2	3.72	0.000222	0.027	0.2	0.17	Menarche (age at onset);	chr6:55056701	chr6:54840118~54840855:-
HNSC	cis	rs988913	0.634	rs9464182	ENSG00000224984.1	RP11-524H19.2	3.72	0.000222	0.027	0.2	0.17	Menarche (age at onset);	chr6:55057140	chr6:54840118~54840855:-
HNSC	cis	rs300890	0.664	rs13137362	ENSG00000250326.1	RP11-284M14.1	-3.72	0.000222	0.027	-0.19	-0.17	Nasopharyngeal carcinoma;	chr4:143278821	chr4:142933195~143184861:-
HNSC	cis	rs686320	1	rs3132770	ENSG00000245532.5	NEAT1	3.72	0.000222	0.027	0.19	0.17	Hip circumference adjusted for BMI;	chr11:65483846	chr11:65422774~65445540:+
HNSC	cis	rs4853525	0.923	rs4853521	ENSG00000235852.1	AC005540.3	3.72	0.000222	0.027	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865458	chr2:190880797~190882059:-
HNSC	cis	rs8054556	0.751	rs11642430	ENSG00000250616.2	RP11-455F5.3	3.72	0.000222	0.027	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30096430~30104116:+
HNSC	cis	rs7324557	0.683	rs7327303	ENSG00000205861.10	C1QTNF9B-AS1	3.72	0.000222	0.027	0.23	0.17	Visceral adipose tissue adjusted for BMI;	chr13:23823175	chr13:23888889~23897263:+
HNSC	cis	rs7592578	0.825	rs12477369	ENSG00000228509.4	AC006460.2	-3.72	0.000222	0.027	-0.25	-0.17	Diastolic blood pressure;	chr2:190590898	chr2:190676944~190708716:-
HNSC	cis	rs28489187	0.706	rs4949890	ENSG00000223653.4	RP11-131L23.1	3.72	0.000222	0.027	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85364949	chr1:85276715~85448124:+
HNSC	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-3.72	0.000222	0.027	-0.2	-0.17	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-3.72	0.000222	0.027	-0.2	-0.17	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
HNSC	cis	rs3741151	0.686	rs12285885	ENSG00000256448.4	RP11-809N8.4	3.72	0.000222	0.027	0.24	0.17	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73583433	chr11:73405297~73410682:+
HNSC	cis	rs9649213	0.559	rs56997921	ENSG00000272950.1	RP11-307C18.1	3.72	0.000222	0.027	0.25	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98379912	chr7:98322853~98323430:+
HNSC	cis	rs9583531	0.689	rs9588247	ENSG00000259831.1	LINC00567	-3.72	0.000222	0.027	-0.2	-0.17	Coronary artery disease;	chr13:110723224	chr13:110809676~110813084:-
HNSC	cis	rs12745968	0.652	rs942753	ENSG00000223787.2	RP4-593M8.1	-3.72	0.000222	0.027	-0.21	-0.17	Bipolar disorder and schizophrenia;	chr1:92476909	chr1:92580476~92580821:-
HNSC	cis	rs55975637	0.73	rs34795953	ENSG00000240476.1	LINC00973	3.72	0.000222	0.027	0.32	0.17	Advanced age-related macular degeneration;	chr3:99746082	chr3:98981058~98983096:+
HNSC	cis	rs9487051	0.698	rs13202939	ENSG00000243587.6	C6orf183	-3.72	0.000222	0.027	-0.18	-0.17	Reticulocyte fraction of red cells;	chr6:109328452	chr6:109165833~109271014:+
HNSC	cis	rs67311347	1	rs11714032	ENSG00000280739.1	EIF1B-AS1	3.72	0.000222	0.027	0.2	0.17	Renal cell carcinoma;	chr3:40390114	chr3:40173145~40309698:-
HNSC	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	3.72	0.000222	0.027	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	3.72	0.000222	0.027	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	3.72	0.000222	0.027	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
HNSC	cis	rs6995541	0.647	rs7000939	ENSG00000269918.1	AF131215.9	-3.72	0.000222	0.027	-0.18	-0.17	Triglyceride levels;	chr8:10831364	chr8:11104691~11106704:-
HNSC	cis	rs3018712	0.532	rs2510397	ENSG00000255031.4	RP11-802E16.3	-3.72	0.000222	0.027	-0.19	-0.17	Total body bone mineral density;	chr11:68652091	chr11:68050740~68053762:+
HNSC	cis	rs1908814	0.516	rs10113062	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11935740	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs10113145	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11935786	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs4367597	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11936020	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.899	rs9329251	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.773	rs7842810	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs7812563	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11936979	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs13281077	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11937305	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs13281315	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11937346	chr8:12362019~12388296:+
HNSC	cis	rs1908814	0.516	rs4840597	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Neuroticism;	chr8:11938559	chr8:12362019~12388296:+
HNSC	cis	rs804280	0.509	rs4841639	ENSG00000227888.4	FAM66A	3.72	0.000222	0.027	0.17	0.17	Myopia (pathological);	chr8:11938584	chr8:12362019~12388296:+
HNSC	cis	rs865483	0.826	rs853198	ENSG00000276054.1	RP11-378E13.3	3.72	0.000222	0.027	0.21	0.17	Monocyte count;	chr17:37489236	chr17:37386886~37387926:+
HNSC	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	3.72	0.000222	0.027	0.17	0.17	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
HNSC	cis	rs2439831	0.717	rs2470132	ENSG00000275601.1	AC011330.13	-3.72	0.000222	0.0271	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43543283	chr15:43642389~43643023:-
HNSC	cis	rs447735	0.565	rs10852626	ENSG00000261172.1	RP11-356C4.5	-3.72	0.000222	0.0271	-0.2	-0.17	Hemoglobin concentration;	chr16:89848225	chr16:90110574~90168225:-
HNSC	cis	rs9768139	0.708	rs11771764	ENSG00000223872.1	AC006372.5	-3.72	0.000222	0.0271	-0.18	-0.17	Calcium levels;	chr7:158327179	chr7:157501322~157503577:+
HNSC	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	3.72	0.000222	0.0271	0.17	0.17	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
HNSC	cis	rs2153535	0.585	rs9406188	ENSG00000230939.1	RP11-314C16.1	-3.72	0.000222	0.0271	-0.2	-0.17	Motion sickness;	chr6:8667604	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9328501	ENSG00000230939.1	RP11-314C16.1	-3.72	0.000222	0.0271	-0.2	-0.17	Motion sickness;	chr6:8669287	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.56	rs9379239	ENSG00000230939.1	RP11-314C16.1	-3.72	0.000222	0.0271	-0.2	-0.17	Motion sickness;	chr6:8670263	chr6:8784178~8785445:+
HNSC	cis	rs11610143	0.53	rs10876221	ENSG00000135477.10	KRT87P	3.72	0.000222	0.0271	0.19	0.17	Lung cancer;Adenocarcinoma;	chr12:51936226	chr12:52250466~52258867:-
HNSC	cis	rs7746199	0.736	rs35848276	ENSG00000280107.1	AL022393.9	-3.72	0.000223	0.0271	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28170845~28172521:+
HNSC	cis	rs656319	0.629	rs10111315	ENSG00000254340.1	RP11-10A14.3	-3.72	0.000223	0.0271	-0.2	-0.17	Myopia (pathological);	chr8:10008078	chr8:9141424~9145435:+
HNSC	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	3.72	0.000223	0.0271	0.11	0.17	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
HNSC	cis	rs10507380	0.943	rs17085414	ENSG00000260704.1	LINC00543	3.72	0.000223	0.0271	0.3	0.17	Electrocardiographic traits;	chr13:27306709	chr13:27953526~27955370:+
HNSC	cis	rs11638815	0.626	rs4779039	ENSG00000259429.4	UBE2Q2P2	3.72	0.000223	0.0271	0.17	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:82355142~82420075:+
HNSC	cis	rs3213758	0.541	rs8056869	ENSG00000275191.1	RP11-36I17.2	-3.72	0.000223	0.0271	-0.27	-0.17	Vitiligo (non-segmental);	chr16:53653467	chr16:53628256~53628816:-
HNSC	cis	rs10938353	0.871	rs6820273	ENSG00000273369.1	RP11-700J17.1	-3.72	0.000223	0.0271	-0.21	-0.17	Body mass index;	chr4:44581490	chr4:44693946~44694386:-
HNSC	cis	rs2562784	0.638	rs2585044	ENSG00000225151.9	GOLGA2P7	-3.72	0.000223	0.0271	-0.32	-0.17	Height;	chr15:83637194	chr15:84199311~84230136:-
HNSC	cis	rs11703808	1	rs11703808	ENSG00000236132.1	CTA-440B3.1	3.72	0.000223	0.0271	0.19	0.17	Intelligence;	chr22:31628994	chr22:31816379~31817491:-
HNSC	cis	rs11649653	0.502	rs62057232	ENSG00000262766.1	RP11-196G11.4	-3.72	0.000223	0.0271	-0.14	-0.17	Triglycerides;	chr16:30809545	chr16:31118078~31118747:+
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	3.72	0.000223	0.0271	0.2	0.17	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
HNSC	cis	rs2307394	1	rs13017754	ENSG00000281469.1	RP11-567F11.1	3.72	0.000223	0.0271	0.19	0.17	Urate levels;	chr2:147837786	chr2:148044380~148044894:+
HNSC	cis	rs61160187	0.51	rs6876335	ENSG00000272308.1	RP11-231G3.1	-3.72	0.000223	0.0271	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60866457~60866935:-
HNSC	cis	rs2976388	1	rs2294010	ENSG00000253741.1	CTD-2292P10.4	3.72	0.000223	0.0271	0.16	0.17	Urinary tract infection frequency;	chr8:142681012	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2976392	ENSG00000253741.1	CTD-2292P10.4	3.72	0.000223	0.0271	0.16	0.17	Urinary tract infection frequency;	chr8:142681514	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2978982	ENSG00000253741.1	CTD-2292P10.4	3.72	0.000223	0.0271	0.16	0.17	Urinary tract infection frequency;	chr8:142682072	chr8:142702252~142726973:-
HNSC	cis	rs6088580	0.609	rs945674	ENSG00000276073.1	RP5-1125A11.7	3.72	0.000223	0.0271	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6088483	ENSG00000276073.1	RP5-1125A11.7	3.72	0.000223	0.0271	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6088484	ENSG00000276073.1	RP5-1125A11.7	3.72	0.000223	0.0271	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs4911423	ENSG00000276073.1	RP5-1125A11.7	3.72	0.000223	0.0271	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:33985617~33988989:-
HNSC	cis	rs2657294	0.62	rs4746261	ENSG00000226051.5	ZNF503-AS1	3.72	0.000223	0.0271	0.22	0.17	Pneumonia;	chr10:75085874	chr10:75269819~75373500:+
HNSC	cis	rs7777677	1	rs7777677	ENSG00000276557.1	TRBV18	3.72	0.000223	0.0271	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142615716~142616415:+
HNSC	cis	rs4835473	0.868	rs62337303	ENSG00000249741.2	RP11-673E1.3	3.72	0.000223	0.0271	0.19	0.17	Immature fraction of reticulocytes;	chr4:143824967	chr4:143911514~143912053:-
HNSC	cis	rs16852403	0.531	rs389563	ENSG00000273062.1	RP11-428K3.1	-3.72	0.000223	0.0271	-0.19	-0.17	Childhood ear infection;	chr1:178194009	chr1:178724306~178726285:-
HNSC	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-3.72	0.000223	0.0271	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
HNSC	cis	rs10056811	0.538	rs2035191	ENSG00000271815.1	CTD-2235C13.3	-3.72	0.000223	0.0271	-0.26	-0.17	Coronary artery disease;	chr5:75117888	chr5:75363760~75364242:+
HNSC	cis	rs62025270	0.547	rs338540	ENSG00000259295.5	CSPG4P12	3.72	0.000223	0.0271	0.21	0.17	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85191438~85213905:+
HNSC	cis	rs950027	0.62	rs1049518	ENSG00000259479.5	SORD2P	3.72	0.000223	0.0271	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:44826371~44884694:-
HNSC	cis	rs950027	0.584	rs1145086	ENSG00000259479.5	SORD2P	3.72	0.000223	0.0271	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:44826371~44884694:-
HNSC	cis	rs889398	0.738	rs7196842	ENSG00000196696.11	PDXDC2P	-3.72	0.000223	0.0271	-0.12	-0.17	Body mass index;	chr16:69889430	chr16:69976297~70065948:-
HNSC	cis	rs9652601	0.719	rs2867880	ENSG00000274038.1	RP11-66H6.4	-3.72	0.000223	0.0271	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11138000	chr16:11056556~11057034:+
HNSC	cis	rs546131	0.642	rs11605381	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000223	0.0271	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34825646	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.559	rs12803664	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000223	0.0271	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34830382	chr11:34709600~34710161:+
HNSC	cis	rs8072100	1	rs4375701	ENSG00000263293.2	RP11-290H9.4	3.72	0.000223	0.0271	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47303460~47323613:-
HNSC	cis	rs1440410	0.835	rs9790396	ENSG00000250326.1	RP11-284M14.1	-3.72	0.000223	0.0271	-0.19	-0.17	Ischemic stroke;	chr4:143130366	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs7693817	ENSG00000250326.1	RP11-284M14.1	-3.72	0.000223	0.0271	-0.19	-0.17	Ischemic stroke;	chr4:143130372	chr4:142933195~143184861:-
HNSC	cis	rs7937890	1	rs6486190	ENSG00000254418.1	RP11-21L19.1	3.72	0.000223	0.0271	0.2	0.17	Mitochondrial DNA levels;	chr11:14379670	chr11:14262846~14273691:-
HNSC	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-3.72	0.000223	0.0272	-0.2	-0.17	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
HNSC	cis	rs13179617	0.928	rs13172084	ENSG00000215032.2	GNL3LP1	-3.72	0.000223	0.0272	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61529317	chr5:60891935~60893577:-
HNSC	cis	rs13179617	0.928	rs1045352	ENSG00000215032.2	GNL3LP1	-3.72	0.000223	0.0272	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61537253	chr5:60891935~60893577:-
HNSC	cis	rs4936891	0.645	rs896891	ENSG00000200879.1	SNORD14E	-3.72	0.000223	0.0272	-0.2	-0.17	Male fertility;	chr11:124040033	chr11:123058077~123058161:-
HNSC	cis	rs4760636	1	rs7418	ENSG00000268069.2	RP5-1057I20.4	-3.72	0.000223	0.0272	-0.2	-0.17	Urate levels;	chr12:47783009	chr12:47784923~47786002:+
HNSC	cis	rs2439831	0.85	rs16977798	ENSG00000201136.1	RNU6-353P	-3.72	0.000224	0.0272	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43859750	chr15:43702363~43702470:+
HNSC	cis	rs886126	0.684	rs3858704	ENSG00000257595.2	RP3-473L9.4	3.72	0.000224	0.0272	0.2	0.17	Coronary heart disease;	chr12:111268089	chr12:111369282~111403310:+
HNSC	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-3.72	0.000224	0.0272	-0.21	-0.17	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
HNSC	cis	rs2179367	0.632	rs9485389	ENSG00000217733.2	CCT7P1	-3.72	0.000224	0.0272	-0.21	-0.17	Dupuytren's disease;	chr6:149420078	chr6:149879962~149881572:+
HNSC	cis	rs7246657	0.524	rs35080624	ENSG00000276846.1	CTD-3220F14.3	3.72	0.000224	0.0272	0.27	0.17	Coronary artery calcification;	chr19:36965680	chr19:37314868~37315620:-
HNSC	cis	rs6500395	1	rs7194570	ENSG00000261267.1	RP11-44I10.3	3.72	0.000224	0.0272	0.21	0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48639075	chr16:48559661~48587403:+
HNSC	cis	rs700651	0.789	rs2196176	ENSG00000231621.1	AC013264.2	-3.72	0.000224	0.0272	-0.16	-0.17	Intracranial aneurysm;	chr2:198040190	chr2:197197991~197199273:+
HNSC	cis	rs734999	0.566	rs6664969	ENSG00000238164.5	RP3-395M20.8	-3.72	0.000224	0.0272	-0.12	-0.17	Ulcerative colitis;	chr1:2603539	chr1:2549920~2557031:-
HNSC	cis	rs28573326	0.886	rs1866221	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165410900	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10030374	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165411220	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10008344	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165411449	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10011067	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165411970	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10011401	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412099	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs10011416	ENSG00000121089.4	NACA3P	-3.72	0.000224	0.0272	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412164	chr4:164943290~164943937:+
HNSC	cis	rs6095360	0.727	rs17448715	ENSG00000222365.1	SNORD12B	-3.72	0.000224	0.0272	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:49075206	chr20:49280319~49280409:+
HNSC	cis	rs4713118	0.628	rs12179134	ENSG00000219392.1	RP1-265C24.5	-3.72	0.000224	0.0272	-0.25	-0.17	Parkinson's disease;	chr6:27707690	chr6:28115628~28116551:+
HNSC	cis	rs2354432	0.607	rs4950310	ENSG00000274372.3	RP11-94I2.4	3.72	0.000224	0.0272	0.31	0.17	Mitochondrial DNA levels;	chr1:147188385	chr1:148021850~148025931:+
HNSC	cis	rs17666538	0.585	rs4735812	ENSG00000254207.1	RP11-43A14.1	3.72	0.000224	0.0272	0.37	0.17	IgG glycosylation;	chr8:657766	chr8:725188~725877:-
HNSC	cis	rs11668609	1	rs10414556	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000224	0.0272	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24186167	chr19:24162370~24163425:-
HNSC	cis	rs7189233	0.531	rs4783813	ENSG00000261056.2	RP11-454F8.2	-3.72	0.000224	0.0272	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53298224~53299792:+
HNSC	cis	rs7189233	0.531	rs8046307	ENSG00000261056.2	RP11-454F8.2	-3.72	0.000224	0.0272	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53298224~53299792:+
HNSC	cis	rs7189233	0.531	rs13337544	ENSG00000261056.2	RP11-454F8.2	-3.72	0.000224	0.0272	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53298224~53299792:+
HNSC	cis	rs7927592	0.913	rs4988291	ENSG00000255031.4	RP11-802E16.3	3.72	0.000224	0.0272	0.15	0.17	Total body bone mineral density;	chr11:68614139	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.871	rs12941	ENSG00000255031.4	RP11-802E16.3	3.72	0.000224	0.0272	0.15	0.17	Total body bone mineral density;	chr11:68614725	chr11:68050740~68053762:+
HNSC	cis	rs2554380	0.55	rs11853949	ENSG00000259570.1	RP11-671M22.4	3.72	0.000224	0.0272	0.22	0.17	Height;	chr15:83848152	chr15:84394512~84395514:+
HNSC	cis	rs72634501	0.716	rs2036465	ENSG00000228060.1	RP11-69E11.8	3.72	0.000224	0.0272	0.2	0.17	HDL cholesterol;	chr1:39110310	chr1:39565160~39573203:+
HNSC	cis	rs17373728	1	rs17373728	ENSG00000249395.2	CASC9	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr8:75313281	chr8:75223404~75324741:-
HNSC	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	3.72	0.000224	0.0272	0.25	0.17	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
HNSC	cis	rs62025270	0.593	rs62022926	ENSG00000259762.1	RP11-158M2.4	-3.72	0.000224	0.0272	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85750336~85752901:-
HNSC	cis	rs970821	1	rs1946584	ENSG00000253106.1	RP11-158K1.3	3.72	0.000224	0.0272	0.15	0.17	Breast cancer;	chr8:123738345	chr8:124488510~124491643:+
HNSC	cis	rs970821	0.966	rs1946585	ENSG00000253106.1	RP11-158K1.3	3.72	0.000224	0.0272	0.15	0.17	Breast cancer;	chr8:123738501	chr8:124488510~124491643:+
HNSC	cis	rs1642645	1	rs1642645	ENSG00000225099.1	ATP6V1E1P1	-3.72	0.000224	0.0272	-0.24	-0.17	Left ventricular obstructive tract defect (maternal effect);	chr1:42036610	chr1:42903232~42903912:+
HNSC	cis	rs62229266	0.659	rs2835258	ENSG00000230212.5	AP000688.14	-3.72	0.000224	0.0272	-0.18	-0.17	Mitral valve prolapse;	chr21:36052067	chr21:36069642~36126640:-
HNSC	cis	rs35306767	0.669	rs2101051	ENSG00000229869.1	RP11-363N22.2	-3.72	0.000224	0.0272	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:1112851	chr10:933026~942743:+
HNSC	cis	rs859767	0.709	rs4954154	ENSG00000224043.6	CCNT2-AS1	3.72	0.000224	0.0272	0.21	0.17	Neuroticism;	chr2:134613086	chr2:134735464~134918710:-
HNSC	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	3.72	0.000224	0.0272	0.25	0.17	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
HNSC	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0272	-0.24	-0.17	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
HNSC	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-3.72	0.000224	0.0272	-0.27	-0.17	QT interval;	chr4:75137695	chr4:75081702~75084717:-
HNSC	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-3.72	0.000224	0.0272	-0.27	-0.17	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
HNSC	cis	rs10504130	1	rs58583070	ENSG00000272024.1	RP11-546K22.3	-3.72	0.000224	0.0272	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51775492	chr8:51950284~51950690:+
HNSC	cis	rs9813712	0.953	rs12635811	ENSG00000228252.7	COL6A4P2	-3.72	0.000224	0.0272	-0.18	-0.17	Response to amphetamines;	chr3:130262534	chr3:130212823~130273806:+
HNSC	cis	rs12468226	0.808	rs73992849	ENSG00000226261.1	AC064836.3	3.72	0.000224	0.0272	0.25	0.17	Urate levels;	chr2:202152444	chr2:202336024~202336727:-
HNSC	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	3.72	0.000224	0.0272	0.21	0.17	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
HNSC	cis	rs1355223	0.623	rs286878	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000224	0.0272	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673309	chr11:34709600~34710161:+
HNSC	cis	rs8054556	0.787	rs3814877	ENSG00000250616.2	RP11-455F5.3	3.72	0.000224	0.0272	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30096430~30104116:+
HNSC	cis	rs17772222	0.876	rs12587598	ENSG00000258789.1	RP11-507K2.3	-3.72	0.000224	0.0273	-0.2	-0.17	Coronary artery calcification;	chr14:88729474	chr14:88551597~88552493:+
HNSC	cis	rs11633886	0.707	rs11070471	ENSG00000273972.1	CTD-2306A12.1	3.72	0.000224	0.0273	0.2	0.17	Diisocyanate-induced asthma;	chr15:45743923	chr15:45702640~45703183:+
HNSC	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000224	0.0273	0.24	0.17	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
HNSC	cis	rs2554380	0.628	rs919069	ENSG00000259570.1	RP11-671M22.4	3.72	0.000225	0.0273	0.21	0.17	Height;	chr15:83775776	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.628	rs4843156	ENSG00000259570.1	RP11-671M22.4	3.72	0.000225	0.0273	0.21	0.17	Height;	chr15:83788593	chr15:84394512~84395514:+
HNSC	cis	rs4819052	0.766	rs4819035	ENSG00000215447.6	BX322557.10	-3.72	0.000225	0.0273	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45288052~45291738:+
HNSC	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	3.72	0.000225	0.0273	0.19	0.17	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
HNSC	cis	rs137699	0.959	rs5757631	ENSG00000261202.1	RP3-496C20.1	-3.72	0.000225	0.0273	-0.19	-0.17	IgG glycosylation;	chr22:39359948	chr22:40043068~40044530:-
HNSC	cis	rs597539	0.617	rs672853	ENSG00000261625.1	RP11-554A11.4	-3.72	0.000225	0.0273	-0.19	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:69000765~69002048:-
HNSC	cis	rs6012564	1	rs3091529	ENSG00000227431.4	CSE1L-AS1	-3.72	0.000225	0.0273	-0.19	-0.17	Anger;	chr20:49030531	chr20:49040463~49046044:-
HNSC	cis	rs75422866	0.867	rs73104112	ENSG00000276691.1	RP5-1057I20.5	3.72	0.000225	0.0273	0.29	0.17	Pneumonia;	chr12:47680969	chr12:47788426~47788971:+
HNSC	cis	rs3785356	0.524	rs3024622	ENSG00000259940.2	CTD-3203P2.1	-3.72	0.000225	0.0273	-0.19	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr16:27354132	chr16:27213308~27214993:-
HNSC	cis	rs4434138	0.683	rs13063160	ENSG00000243224.1	RP5-1157M23.2	-3.72	0.000225	0.0273	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:52568258	chr3:52239258~52241097:+
HNSC	cis	rs9311474	0.508	rs6786043	ENSG00000243224.1	RP5-1157M23.2	-3.72	0.000225	0.0273	-0.16	-0.17	Electroencephalogram traits;	chr3:52570845	chr3:52239258~52241097:+
HNSC	cis	rs12410462	0.681	rs74582965	ENSG00000224834.1	BTF3P9	3.72	0.000225	0.0273	0.28	0.17	Major depressive disorder;	chr1:227422425	chr1:227434064~227434346:+
HNSC	cis	rs10090774	0.901	rs11166995	ENSG00000279766.1	RP11-642A1.2	3.72	0.000225	0.0273	0.17	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140709152	chr8:140572142~140572812:-
HNSC	cis	rs868153	0.662	rs1085381	ENSG00000275339.1	RP3-425C14.6	3.72	0.000225	0.0273	0.18	0.17	Vertical cup-disc ratio;	chr6:122244364	chr6:122454358~122454612:+
HNSC	cis	rs73198271	1	rs11774744	ENSG00000173295.6	FAM86B3P	-3.72	0.000225	0.0273	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8228595~8244865:+
HNSC	cis	rs1823874	0.581	rs9920347	ENSG00000259363.4	CTD-2054N24.2	3.72	0.000225	0.0273	0.19	0.17	IgG glycosylation;	chr15:99799126	chr15:99807023~99877148:+
HNSC	cis	rs7590368	0.6	rs72777393	ENSG00000272275.1	RP11-791G15.2	3.72	0.000225	0.0273	0.29	0.17	Educational attainment (years of education);	chr2:10777429	chr2:10767875~10770058:-
HNSC	cis	rs9487051	0.802	rs6910696	ENSG00000219700.1	PTCHD3P3	3.72	0.000225	0.0273	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109271126	chr6:109288571~109290503:-
HNSC	cis	rs2688482	0.557	rs3103952	ENSG00000185485.13	SDHAP1	3.72	0.000225	0.0273	0.19	0.17	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195959748~195990318:-
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	3.72	0.000225	0.0273	0.33	0.17	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
HNSC	cis	rs72827839	0.744	rs16956892	ENSG00000210741.1	MIR196A1	-3.72	0.000225	0.0273	-0.21	-0.17	Ease of getting up in the morning;	chr17:48446557	chr17:48632490~48632559:-
HNSC	cis	rs11096990	0.892	rs1473364	ENSG00000249685.1	RP11-360F5.3	3.72	0.000225	0.0273	0.21	0.17	Cognitive function;	chr4:39211259	chr4:39133913~39135608:+
HNSC	cis	rs950027	0.62	rs1346267	ENSG00000259479.5	SORD2P	3.72	0.000225	0.0273	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:44826371~44884694:-
HNSC	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	3.72	0.000225	0.0273	0.21	0.17	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
HNSC	cis	rs3740713	1	rs73436668	ENSG00000256464.1	YWHABP2	3.72	0.000225	0.0273	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr11:18490243~18490955:-
HNSC	cis	rs6840258	0.723	rs443459	ENSG00000251411.1	RP11-397E7.4	-3.72	0.000225	0.0273	-0.19	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87054903	chr4:86913266~86914817:-
HNSC	cis	rs72827839	0.779	rs58953228	ENSG00000210741.1	MIR196A1	-3.72	0.000225	0.0273	-0.21	-0.17	Ease of getting up in the morning;	chr17:48436452	chr17:48632490~48632559:-
HNSC	cis	rs656319	0.513	rs6985941	ENSG00000255310.2	AF131215.2	-3.72	0.000225	0.0273	-0.17	-0.17	Myopia (pathological);	chr8:10125669	chr8:11107788~11109726:-
HNSC	cis	rs9326246	0.598	rs480823	ENSG00000254851.1	RP11-109L13.1	3.72	0.000225	0.0273	0.38	0.17	Coronary artery disease;	chr11:116655013	chr11:117135528~117138582:+
HNSC	cis	rs2348418	0.681	rs10771435	ENSG00000257176.2	RP11-996F15.2	-3.72	0.000225	0.0273	-0.17	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28582769	chr12:29280418~29317848:-
HNSC	cis	rs1552244	1	rs66838678	ENSG00000180385.7	EMC3-AS1	3.72	0.000225	0.0273	0.19	0.17	Alzheimer's disease;	chr3:10108666	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.935	rs7618815	ENSG00000180385.7	EMC3-AS1	3.72	0.000225	0.0273	0.19	0.17	Alzheimer's disease;	chr3:10109361	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7652935	ENSG00000180385.7	EMC3-AS1	3.72	0.000225	0.0273	0.19	0.17	Alzheimer's disease;	chr3:10109454	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs67134728	ENSG00000180385.7	EMC3-AS1	3.72	0.000225	0.0273	0.19	0.17	Alzheimer's disease;	chr3:10109747	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs68045038	ENSG00000180385.7	EMC3-AS1	3.72	0.000225	0.0273	0.19	0.17	Alzheimer's disease;	chr3:10110144	chr3:9986893~10006990:+
HNSC	cis	rs7772486	0.754	rs702323	ENSG00000270638.1	RP3-466P17.1	-3.72	0.000225	0.0273	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145735570~145737218:+
HNSC	cis	rs853679	0.546	rs35017208	ENSG00000226314.6	ZNF192P1	-3.72	0.000225	0.0273	-0.33	-0.17	Depression;	chr6:28377505	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs36092177	ENSG00000226314.6	ZNF192P1	-3.72	0.000225	0.0273	-0.33	-0.17	Depression;	chr6:28390030	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs2232429	ENSG00000226314.6	ZNF192P1	-3.72	0.000225	0.0273	-0.33	-0.17	Depression;	chr6:28391855	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs2232426	ENSG00000226314.6	ZNF192P1	-3.72	0.000225	0.0273	-0.33	-0.17	Depression;	chr6:28392882	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs2232423	ENSG00000226314.6	ZNF192P1	-3.72	0.000225	0.0273	-0.33	-0.17	Depression;	chr6:28398374	chr6:28161781~28169594:+
HNSC	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000225	0.0273	-0.19	-0.17	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
HNSC	cis	rs2279168	1	rs4632086	ENSG00000259295.5	CSPG4P12	-3.72	0.000225	0.0273	-0.32	-0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85485591	chr15:85191438~85213905:+
HNSC	cis	rs10783487	0.749	rs3817606	ENSG00000257542.4	OR7E47P	-3.72	0.000225	0.0273	-0.2	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52091857	chr12:52079696~52108261:+
HNSC	cis	rs9863	0.827	rs4930724	ENSG00000269938.1	RP11-214K3.20	-3.72	0.000225	0.0273	-0.21	-0.17	White blood cell count;	chr12:123939270	chr12:123968023~123968579:-
HNSC	cis	rs56114371	0.568	rs200468	ENSG00000219392.1	RP1-265C24.5	-3.72	0.000225	0.0273	-0.23	-0.17	Breast cancer;	chr6:27790076	chr6:28115628~28116551:+
HNSC	cis	rs2919009	0.664	rs17591472	ENSG00000271670.1	RP11-95I16.4	3.72	0.000225	0.0273	0.21	0.17	Obesity-related traits;	chr10:120785735	chr10:120879256~120880667:-
HNSC	cis	rs2839186	0.77	rs2330353	ENSG00000239415.1	AP001469.9	3.72	0.000225	0.0273	0.15	0.17	Testicular germ cell tumor;	chr21:46249734	chr21:46251549~46254133:-
HNSC	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-3.72	0.000225	0.0273	-0.2	-0.17	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
HNSC	cis	rs250677	0.687	rs185155	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000225	0.0273	-0.22	-0.17	Breast cancer;	chr5:149076330	chr5:149063317~149109787:+
HNSC	cis	rs4841134	0.704	rs2169386	ENSG00000233609.3	RP11-62H7.2	-3.72	0.000225	0.0273	-0.16	-0.17	Age-related disease endophenotypes;	chr8:9340770	chr8:8961200~8979025:+
HNSC	cis	rs801193	0.935	rs11772264	ENSG00000273142.1	RP11-458F8.4	-3.72	0.000225	0.0273	-0.14	-0.17	Aortic root size;	chr7:66711400	chr7:66902857~66906297:+
HNSC	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	3.72	0.000225	0.0273	0.2	0.17	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
HNSC	cis	rs440932	0.747	rs330946	ENSG00000253981.4	ALG1L13P	3.72	0.000225	0.0273	0.19	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8236003~8244667:-
HNSC	cis	rs1595825	0.891	rs73061068	ENSG00000231621.1	AC013264.2	-3.72	0.000225	0.0274	-0.21	-0.17	Ulcerative colitis;	chr2:198043715	chr2:197197991~197199273:+
HNSC	cis	rs11893307	0.507	rs1465304	ENSG00000228509.4	AC006460.2	3.72	0.000225	0.0274	0.21	0.17	Mean platelet volume;	chr2:190720672	chr2:190676944~190708716:-
HNSC	cis	rs12701220	0.817	rs59471534	ENSG00000224079.1	AC091729.7	3.72	0.000226	0.0274	0.24	0.17	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1074450~1078036:+
HNSC	cis	rs10256972	0.721	rs2030959	ENSG00000225146.1	AC073957.15	3.72	0.000226	0.0274	0.2	0.17	Endometriosis;Longevity;	chr7:1036270	chr7:1029025~1043891:+
HNSC	cis	rs597539	0.652	rs636049	ENSG00000255741.1	RP11-757G1.5	-3.72	0.000226	0.0274	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68941503~68942852:-
HNSC	cis	rs9611565	0.512	rs8141103	ENSG00000235513.1	RP4-756G23.5	-3.72	0.000226	0.0274	-0.21	-0.17	Vitiligo;	chr22:41740926	chr22:41209122~41217627:-
HNSC	cis	rs7829975	0.688	rs13270194	ENSG00000233609.3	RP11-62H7.2	3.72	0.000226	0.0274	0.16	0.17	Mood instability;	chr8:8520592	chr8:8961200~8979025:+
HNSC	cis	rs3929778	0.883	rs6054334	ENSG00000278192.1	RP5-1056H1.2	-3.72	0.000226	0.0274	-0.23	-0.17	QRS complex (Cornell);	chr20:6537873	chr20:6065966~6067897:-
HNSC	cis	rs7735319	0.966	rs3860754	ENSG00000249572.1	CTD-2203K17.1	-3.72	0.000226	0.0274	-0.19	-0.17	Systolic blood pressure;	chr5:33149343	chr5:33424025~33440619:-
HNSC	cis	rs9768139	0.733	rs56205111	ENSG00000223872.1	AC006372.5	-3.72	0.000226	0.0274	-0.18	-0.17	Calcium levels;	chr7:158328363	chr7:157501322~157503577:+
HNSC	cis	rs683257	0.852	rs9495861	ENSG00000234147.1	RP3-460G2.2	3.72	0.000226	0.0274	0.37	0.17	Facial emotion recognition (angry faces);	chr6:140900922	chr6:140845958~140852924:-
HNSC	cis	rs10073892	0.619	rs1901515	ENSG00000175749.11	EIF3KP1	-3.72	0.000226	0.0274	-0.21	-0.17	Cognitive decline (age-related);	chr5:102375545	chr5:103032376~103033031:+
HNSC	cis	rs28489187	0.706	rs233067	ENSG00000223653.4	RP11-131L23.1	3.72	0.000226	0.0274	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339295	chr1:85276715~85448124:+
HNSC	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	3.72	0.000226	0.0274	0.25	0.17	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
HNSC	cis	rs9487051	0.735	rs396000	ENSG00000243587.6	C6orf183	3.72	0.000226	0.0274	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109198408	chr6:109165833~109271014:+
HNSC	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-3.72	0.000226	0.0274	-0.28	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
HNSC	cis	rs7824557	0.602	rs35807737	ENSG00000255495.1	AC145124.2	3.72	0.000226	0.0274	0.19	0.17	Retinal vascular caliber;	chr8:11346902	chr8:12194467~12196280:+
HNSC	cis	rs4266144	0.562	rs56357317	ENSG00000241770.1	RP11-555M1.3	-3.72	0.000226	0.0274	-0.23	-0.17	Coronary artery disease;	chr3:157117385	chr3:157163452~157169133:+
HNSC	cis	rs7572733	0.555	rs7600269	ENSG00000222017.1	AC011997.1	3.72	0.000226	0.0274	0.22	0.17	Dermatomyositis;	chr2:198058744	chr2:197693106~197774823:+
HNSC	cis	rs9487051	0.698	rs11153168	ENSG00000243587.6	C6orf183	-3.72	0.000226	0.0274	-0.17	-0.17	Reticulocyte fraction of red cells;	chr6:109308217	chr6:109165833~109271014:+
HNSC	cis	rs9467711	0.559	rs2295593	ENSG00000241549.7	GUSBP2	3.72	0.000226	0.0274	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:26501540	chr6:26871484~26956554:-
HNSC	cis	rs13178541	0.81	rs4452549	ENSG00000250378.1	RP11-119J18.1	-3.72	0.000226	0.0274	-0.22	-0.17	IgG glycosylation;	chr5:135762020	chr5:135812667~135826582:+
HNSC	cis	rs9880211	0.58	rs56308637	ENSG00000273486.1	RP11-731C17.2	3.72	0.000226	0.0274	0.16	0.17	Height;Body mass index;	chr3:135920806	chr3:136837338~136839021:-
HNSC	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-3.72	0.000226	0.0274	-0.21	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
HNSC	cis	rs8041447	0.896	rs11853366	ENSG00000259756.1	RP11-625H11.2	3.72	0.000226	0.0274	0.19	0.17	Immature fraction of reticulocytes;	chr15:62776189	chr15:62682916~62690448:-
HNSC	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	3.72	0.000226	0.0274	0.35	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
HNSC	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	3.72	0.000226	0.0274	0.35	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
HNSC	cis	rs12370275	0.58	rs2138421	ENSG00000257528.1	KRT8P19	-3.72	0.000226	0.0274	-0.23	-0.17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61360696	chr12:61879318~61880772:+
HNSC	cis	rs6430585	0.528	rs111682961	ENSG00000231890.6	DARS-AS1	-3.72	0.000226	0.0274	-0.3	-0.17	Corneal structure;	chr2:135896278	chr2:135985176~136022593:+
HNSC	cis	rs5758659	0.714	rs2413668	ENSG00000182057.4	OGFRP1	-3.72	0.000226	0.0274	-0.17	-0.17	Cognitive function;	chr22:42109837	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.657	rs5758587	ENSG00000182057.4	OGFRP1	-3.72	0.000226	0.0274	-0.17	-0.17	Cognitive function;	chr22:42121632	chr22:42269753~42275196:+
HNSC	cis	rs7429990	0.864	rs4858851	ENSG00000228638.1	FCF1P2	3.72	0.000226	0.0274	0.16	0.17	Educational attainment (years of education);	chr3:47724165	chr3:48290793~48291375:-
HNSC	cis	rs6012564	1	rs3092039	ENSG00000227431.4	CSE1L-AS1	-3.72	0.000226	0.0274	-0.19	-0.17	Anger;	chr20:49062233	chr20:49040463~49046044:-
HNSC	cis	rs792448	0.743	rs7519959	ENSG00000226251.4	RP11-15I11.3	-3.72	0.000226	0.0274	-0.21	-0.17	White blood cell count (basophil);	chr1:212325310	chr1:212225278~212238977:-
HNSC	cis	rs17772222	0.917	rs17188228	ENSG00000258789.1	RP11-507K2.3	-3.72	0.000226	0.0274	-0.2	-0.17	Coronary artery calcification;	chr14:88738921	chr14:88551597~88552493:+
HNSC	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	3.72	0.000226	0.0274	0.15	0.17	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	3.72	0.000226	0.0274	0.15	0.17	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
HNSC	cis	rs12410462	0.681	rs6681096	ENSG00000224834.1	BTF3P9	3.72	0.000226	0.0275	0.28	0.17	Major depressive disorder;	chr1:227422019	chr1:227434064~227434346:+
HNSC	cis	rs35146811	0.696	rs1727124	ENSG00000235077.1	AC073842.19	-3.72	0.000226	0.0275	-0.21	-0.17	Coronary artery disease;	chr7:100206481	chr7:100130964~100140439:+
HNSC	cis	rs1642645	0.872	rs10890170	ENSG00000228452.1	RP5-994D16.9	-3.72	0.000226	0.0275	-0.24	-0.17	Left ventricular obstructive tract defect (maternal effect);	chr1:41943851	chr1:42775813~42776790:-
HNSC	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	3.72	0.000226	0.0275	0.19	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
HNSC	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	3.72	0.000226	0.0275	0.19	0.17	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
HNSC	cis	rs1440410	0.83	rs1470130	ENSG00000250326.1	RP11-284M14.1	-3.72	0.000226	0.0275	-0.19	-0.17	Ischemic stroke;	chr4:143257749	chr4:142933195~143184861:-
HNSC	cis	rs896655	1	rs10811590	ENSG00000244230.3	RN7SL151P	3.72	0.000226	0.0275	0.18	0.17	Coronary artery disease;	chr9:21708884	chr9:21699314~21699596:+
HNSC	cis	rs6968419	1	rs6949241	ENSG00000237870.5	AC073130.1	3.72	0.000226	0.0275	0.19	0.17	Intraocular pressure;	chr7:116176318	chr7:116275606~116286734:-
HNSC	cis	rs911119	1	rs911119	ENSG00000270001.1	RP11-218C14.8	3.72	0.000226	0.0275	0.24	0.17	Chronic kidney disease;	chr20:23632100	chr20:23631826~23632316:-
HNSC	cis	rs13113518	0.545	rs6810483	ENSG00000249700.7	SRD5A3-AS1	3.72	0.000226	0.0275	0.19	0.17	Height;	chr4:55424406	chr4:55363971~55395847:-
HNSC	cis	rs2944755	0.686	rs7824304	ENSG00000279766.1	RP11-642A1.2	-3.72	0.000226	0.0275	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140573918	chr8:140572142~140572812:-
HNSC	cis	rs4704187	0.687	rs13360638	ENSG00000272040.1	CTC-366B18.4	-3.72	0.000227	0.0275	-0.16	-0.17	Response to amphetamines;	chr5:75137433	chr5:75608817~75609983:+
HNSC	cis	rs3736485	0.578	rs11638106	ENSG00000274528.1	CTD-2650P22.2	3.72	0.000227	0.0275	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677098	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.609	rs11631725	ENSG00000274528.1	CTD-2650P22.2	3.72	0.000227	0.0275	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677277	chr15:52017167~52018032:-
HNSC	cis	rs13179617	0.928	rs6878927	ENSG00000215032.2	GNL3LP1	3.72	0.000227	0.0275	0.2	0.17	Intelligence (multi-trait analysis);	chr5:61500464	chr5:60891935~60893577:-
HNSC	cis	rs11773103	0.786	rs6979269	ENSG00000224046.1	AC005076.5	3.72	0.000227	0.0275	0.24	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87125666	chr7:87151423~87152420:-
HNSC	cis	rs11773103	0.786	rs734607	ENSG00000224046.1	AC005076.5	3.72	0.000227	0.0275	0.24	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87125842	chr7:87151423~87152420:-
HNSC	cis	rs250677	0.652	rs168751	ENSG00000250072.4	CTC-529P8.1	-3.72	0.000227	0.0275	-0.23	-0.17	Breast cancer;	chr5:149058701	chr5:149063317~149109787:+
HNSC	cis	rs7989332	1	rs7320606	ENSG00000226633.2	PPIAP28	-3.72	0.000227	0.0275	-0.23	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20478382	chr13:20178978~20179462:-
HNSC	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-3.72	0.000227	0.0275	-0.13	-0.17	Breast size;	chr12:9209187	chr12:9277235~9313241:+
HNSC	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-3.72	0.000227	0.0275	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-3.72	0.000227	0.0275	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
HNSC	cis	rs1536827	0.698	rs10857736	ENSG00000278518.1	RP11-108K14.12	-3.72	0.000227	0.0275	-0.3	-0.17	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133523010	chr10:133526259~133527513:-
HNSC	cis	rs1790761	0.505	rs7106423	ENSG00000184224.3	C11orf72	-3.72	0.000227	0.0275	-0.21	-0.17	Mean corpuscular volume;	chr11:67546673	chr11:67602880~67606706:-
HNSC	cis	rs2836974	0.602	rs2836987	ENSG00000255568.3	BRWD1-AS2	-3.72	0.000227	0.0275	-0.15	-0.17	Cognitive function;	chr21:39334668	chr21:39313935~39314962:+
HNSC	cis	rs6787172	0.622	rs9867617	ENSG00000272087.1	RP11-379F4.7	3.72	0.000227	0.0275	0.17	0.17	Subjective well-being;	chr3:158359555	chr3:158693120~158693768:-
HNSC	cis	rs879620	0.929	rs2238435	ENSG00000262185.1	RP11-462G12.1	-3.72	0.000227	0.0275	-0.21	-0.17	Hip circumference;Body mass index;	chr16:3964281	chr16:3947609~3950444:-
HNSC	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-3.72	0.000227	0.0275	-0.2	-0.17	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
HNSC	cis	rs2055729	0.677	rs59880252	ENSG00000254340.1	RP11-10A14.3	3.72	0.000227	0.0275	0.24	0.17	Multiple myeloma (hyperdiploidy);	chr8:9883522	chr8:9141424~9145435:+
HNSC	cis	rs6088590	0.561	rs6087605	ENSG00000276073.1	RP5-1125A11.7	-3.72	0.000227	0.0275	-0.18	-0.17	Coronary artery disease;	chr20:34592820	chr20:33985617~33988989:-
HNSC	cis	rs2279168	0.737	rs74024844	ENSG00000259407.1	RP11-158M2.3	3.72	0.000227	0.0275	0.34	0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85440126	chr15:85744109~85750281:-
HNSC	cis	rs72627123	1	rs76553384	ENSG00000259065.1	RP5-1021I20.1	-3.72	0.000227	0.0275	-0.29	-0.17	Morning vs. evening chronotype;	chr14:73916976	chr14:73787360~73803270:+
HNSC	cis	rs3015497	0.741	rs7146084	ENSG00000277050.1	RP11-102G14.1	3.72	0.000227	0.0275	0.16	0.17	Mean platelet volume;	chr14:50696776	chr14:51637348~51637947:-
HNSC	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	3.72	0.000227	0.0275	0.34	0.17	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
HNSC	cis	rs35306767	0.903	rs10508208	ENSG00000229869.1	RP11-363N22.2	-3.72	0.000227	0.0275	-0.25	-0.17	Eosinophil percentage of granulocytes;	chr10:865043	chr10:933026~942743:+
HNSC	cis	rs6012564	1	rs6066982	ENSG00000227431.4	CSE1L-AS1	3.72	0.000227	0.0275	0.19	0.17	Anger;	chr20:49147021	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs7272164	ENSG00000227431.4	CSE1L-AS1	3.72	0.000227	0.0275	0.19	0.17	Anger;	chr20:49149660	chr20:49040463~49046044:-
HNSC	cis	rs3740713	1	rs73440604	ENSG00000256464.1	YWHABP2	3.72	0.000227	0.0275	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr11:18490243~18490955:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000233609.3	RP11-62H7.2	3.72	0.000227	0.0275	0.16	0.17	Mood instability;	chr8:8484905	chr8:8961200~8979025:+
HNSC	cis	rs7178375	1	rs11070678	ENSG00000215302.7	CTD-3092A11.1	-3.72	0.000227	0.0275	-0.26	-0.17	Hypertriglyceridemia;	chr15:30927561	chr15:30470779~30507623:+
HNSC	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	3.72	0.000227	0.0275	0.25	0.17	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
HNSC	cis	rs950027	0.62	rs1145093	ENSG00000259479.5	SORD2P	3.72	0.000227	0.0275	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:44826371~44884694:-
HNSC	cis	rs2554380	0.628	rs2401131	ENSG00000259570.1	RP11-671M22.4	3.72	0.000227	0.0275	0.21	0.17	Height;	chr15:83802144	chr15:84394512~84395514:+
HNSC	cis	rs28573326	0.886	rs13126229	ENSG00000121089.4	NACA3P	-3.72	0.000227	0.0275	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412740	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.886	rs13103782	ENSG00000121089.4	NACA3P	-3.72	0.000227	0.0275	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412794	chr4:164943290~164943937:+
HNSC	cis	rs832540	0.618	rs41106	ENSG00000225230.1	AC008937.3	3.72	0.000227	0.0275	0.18	0.17	Coronary artery disease;	chr5:56849230	chr5:56900041~56910714:-
HNSC	cis	rs832540	0.564	rs33329	ENSG00000225230.1	AC008937.3	3.72	0.000227	0.0275	0.18	0.17	Coronary artery disease;	chr5:56849241	chr5:56900041~56910714:-
HNSC	cis	rs832540	0.656	rs832567	ENSG00000225230.1	AC008937.3	3.72	0.000227	0.0275	0.18	0.17	Coronary artery disease;	chr5:56856589	chr5:56900041~56910714:-
HNSC	cis	rs853679	0.607	rs66868086	ENSG00000219891.2	ZSCAN12P1	3.72	0.000227	0.0275	0.35	0.17	Depression;	chr6:27898124	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs13199649	ENSG00000219891.2	ZSCAN12P1	3.72	0.000227	0.0275	0.35	0.17	Depression;	chr6:27901014	chr6:28091154~28093664:+
HNSC	cis	rs12047808	0.73	rs3818587	ENSG00000227141.2	RP11-545A16.3	3.72	0.000227	0.0275	0.26	0.17	Multiple sclerosis (age of onset);	chr1:179551287	chr1:179586705~179589175:+
HNSC	cis	rs793571	0.628	rs12917083	ENSG00000245975.2	RP11-30K9.6	3.72	0.000227	0.0275	0.29	0.17	Schizophrenia;	chr15:58752341	chr15:58768072~58770974:-
HNSC	cis	rs3750965	1	rs7937006	ENSG00000265539.1	MIR3164	-3.72	0.000227	0.0276	-0.18	-0.17	Hair color;	chr11:69076464	chr11:69083176~69083258:+
HNSC	cis	rs561341	1	rs501957	ENSG00000278867.1	RP11-640N20.4	-3.72	0.000227	0.0276	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31987485	chr17:32051030~32053208:+
HNSC	cis	rs700651	0.789	rs10190226	ENSG00000231621.1	AC013264.2	3.72	0.000227	0.0276	0.16	0.17	Intracranial aneurysm;	chr2:198036840	chr2:197197991~197199273:+
HNSC	cis	rs67981189	0.896	rs2158997	ENSG00000274818.1	RP1-292L20.3	-3.72	0.000228	0.0276	-0.2	-0.17	Schizophrenia;	chr14:71031077	chr14:70906657~70907111:-
HNSC	cis	rs2836974	0.931	rs12151994	ENSG00000255568.3	BRWD1-AS2	3.72	0.000228	0.0276	0.16	0.17	Cognitive function;	chr21:39318471	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.966	rs7283516	ENSG00000255568.3	BRWD1-AS2	3.72	0.000228	0.0276	0.16	0.17	Cognitive function;	chr21:39318611	chr21:39313935~39314962:+
HNSC	cis	rs1552244	1	rs7628448	ENSG00000180385.7	EMC3-AS1	3.72	0.000228	0.0276	0.2	0.17	Alzheimer's disease;	chr3:10105144	chr3:9986893~10006990:+
HNSC	cis	rs561341	0.769	rs12941700	ENSG00000278867.1	RP11-640N20.4	3.72	0.000228	0.0276	0.25	0.17	Hip circumference adjusted for BMI;	chr17:31858003	chr17:32051030~32053208:+
HNSC	cis	rs9531006	0.636	rs12876835	ENSG00000227676.3	LINC01068	-3.72	0.000228	0.0276	-0.26	-0.17	Sleep duration;	chr13:79903644	chr13:79566727~79571436:+
HNSC	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	3.72	0.000228	0.0276	0.15	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
HNSC	cis	rs7107174	1	rs1006441	ENSG00000251323.2	RP11-452H21.4	3.72	0.000228	0.0276	0.26	0.17	Testicular germ cell tumor;	chr11:78221080	chr11:78423982~78429836:-
HNSC	cis	rs9880211	0.613	rs28535121	ENSG00000239213.4	NCK1-AS1	3.72	0.000228	0.0276	0.16	0.17	Height;Body mass index;	chr3:136173956	chr3:136841726~136862054:-
HNSC	cis	rs2013441	1	rs2526484	ENSG00000261033.1	RP11-209D14.2	3.72	0.000228	0.0276	0.19	0.17	Obesity-related traits;	chr17:20200447	chr17:20008051~20009234:-
HNSC	cis	rs9302065	0.681	rs59108692	ENSG00000223298.1	RNY3P8	3.72	0.000228	0.0276	0.17	0.17	Blood metabolite levels;	chr13:95310170	chr13:95310830~95310955:-
HNSC	cis	rs6493858	0.809	rs2682054	ENSG00000277245.1	RP11-48G14.3	-3.72	0.000228	0.0276	-0.19	-0.17	Relative hand skill in reading disability;	chr15:56254950	chr15:56447120~56447697:+
HNSC	cis	rs4908769	0.66	rs13596	ENSG00000232912.4	RP5-1115A15.1	-3.72	0.000228	0.0276	-0.19	-0.17	Allergy;	chr1:8361143	chr1:8424645~8434838:+
HNSC	cis	rs748404	0.666	rs7177146	ENSG00000166763.7	STRCP1	3.72	0.000228	0.0276	0.24	0.17	Lung cancer;	chr15:43506110	chr15:43699488~43718184:-
HNSC	cis	rs4767841	0.775	rs203330	ENSG00000277283.1	RP1-267D11.6	3.72	0.000228	0.0276	0.16	0.17	Urgency urinary incontinence;	chr12:119771954	chr12:120116907~120119000:+
HNSC	cis	rs17253792	0.822	rs75999534	ENSG00000186615.9	KTN1-AS1	-3.72	0.000228	0.0276	-0.37	-0.17	Putamen volume;	chr14:55569695	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76612185	ENSG00000186615.9	KTN1-AS1	-3.72	0.000228	0.0276	-0.37	-0.17	Putamen volume;	chr14:55570988	chr14:55499278~55580110:-
HNSC	cis	rs6921919	0.583	rs9468367	ENSG00000227214.2	HCG15	3.72	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28986203~28987484:+
HNSC	cis	rs17666538	0.585	rs1669733	ENSG00000254207.1	RP11-43A14.1	-3.72	0.000228	0.0276	-0.37	-0.17	IgG glycosylation;	chr8:656696	chr8:725188~725877:-
HNSC	cis	rs67311347	1	rs7648952	ENSG00000280739.1	EIF1B-AS1	-3.72	0.000228	0.0276	-0.18	-0.17	Renal cell carcinoma;	chr3:40415547	chr3:40173145~40309698:-
HNSC	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	3.72	0.000228	0.0276	0.23	0.17	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
HNSC	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	3.71	0.000228	0.0276	0.2	0.17	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
HNSC	cis	rs919433	0.783	rs788011	ENSG00000231621.1	AC013264.2	-3.71	0.000228	0.0276	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366047	chr2:197197991~197199273:+
HNSC	cis	rs4906332	1	rs35366629	ENSG00000244691.1	RPL10AP1	-3.71	0.000228	0.0276	-0.2	-0.17	Coronary artery disease;	chr14:103436717	chr14:103412119~103412761:-
HNSC	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-3.71	0.000228	0.0276	-0.28	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
HNSC	cis	rs10129255	0.957	rs11847726	ENSG00000224373.3	IGHV4-59	3.71	0.000228	0.0276	0.11	0.17	Kawasaki disease;	chr14:106779116	chr14:106627249~106627825:-
HNSC	cis	rs6568686	0.627	rs174381	ENSG00000255389.1	C6orf3	3.71	0.000228	0.0276	0.22	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111592276	chr6:111599875~111602295:+
HNSC	cis	rs7674212	0.865	rs13149311	ENSG00000251288.2	RP11-10L12.2	-3.71	0.000228	0.0276	-0.19	-0.17	Type 2 diabetes;	chr4:103056543	chr4:102751401~102752641:+
HNSC	cis	rs9611565	0.802	rs9611571	ENSG00000235513.1	RP4-756G23.5	3.71	0.000228	0.0276	0.2	0.17	Vitiligo;	chr22:41388863	chr22:41209122~41217627:-
HNSC	cis	rs338389	0.542	rs7182139	ENSG00000260657.2	RP11-315D16.4	-3.71	0.000228	0.0276	-0.2	-0.17	Survival in rectal cancer;	chr15:67993116	chr15:68267792~68277994:-
HNSC	cis	rs61160187	0.582	rs4700407	ENSG00000272308.1	RP11-231G3.1	3.71	0.000228	0.0276	0.17	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60866457~60866935:-
HNSC	cis	rs150658949	1	rs150658949	ENSG00000258708.1	SLC25A21-AS1	-3.71	0.000228	0.0276	-0.17	-0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:37218926	chr14:37171888~37173811:+
HNSC	cis	rs6840360	0.901	rs1946999	ENSG00000251611.1	RP11-610P16.1	-3.71	0.000228	0.0276	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151534187	chr4:151407551~151408835:-
HNSC	cis	rs7777677	0.925	rs4726542	ENSG00000276557.1	TRBV18	3.71	0.000228	0.0276	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142615716~142616415:+
HNSC	cis	rs2235302	0.715	rs1569476	ENSG00000213063.3	RPL29P7	-3.71	0.000228	0.0276	-0.2	-0.17	Soluble levels of adhesion molecules;	chr1:169639679	chr1:168938467~168938923:+
HNSC	cis	rs8062405	1	rs2008514	ENSG00000261089.1	RP11-435I10.3	-3.71	0.000228	0.0276	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28413703~28415018:+
HNSC	cis	rs73198271	1	rs73198271	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000228	0.0276	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:8961200~8979025:+
HNSC	cis	rs73198271	1	rs73198272	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000228	0.0276	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:8961200~8979025:+
HNSC	cis	rs73198271	1	rs4841030	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000228	0.0276	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:8961200~8979025:+
HNSC	cis	rs78320035	1	rs7552213	ENSG00000250762.1	RP1-313L4.4	-3.71	0.000228	0.0276	-0.41	-0.17	Red cell distribution width;	chr1:168168487	chr1:167819898~167820248:-
HNSC	cis	rs7824557	0.583	rs2263511	ENSG00000255310.2	AF131215.2	-3.71	0.000228	0.0276	-0.16	-0.17	Retinal vascular caliber;	chr8:11375809	chr8:11107788~11109726:-
HNSC	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000228	0.0276	-0.25	-0.17	Gout;	chr7:66671562	chr7:66848496~66858136:+
HNSC	cis	rs1005277	0.563	rs2505215	ENSG00000099251.13	HSD17B7P2	3.71	0.000228	0.0276	0.17	0.17	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.563	rs2505216	ENSG00000099251.13	HSD17B7P2	3.71	0.000228	0.0276	0.17	0.17	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.563	rs2800550	ENSG00000099251.13	HSD17B7P2	3.71	0.000228	0.0276	0.17	0.17	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.579	rs2749612	ENSG00000099251.13	HSD17B7P2	3.71	0.000228	0.0276	0.17	0.17	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38356380~38378505:+
HNSC	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-3.71	0.000228	0.0276	-0.18	-0.17	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
HNSC	cis	rs897984	0.77	rs12930657	ENSG00000260911.2	RP11-196G11.2	-3.71	0.000228	0.0276	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30920647	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.77	rs3813020	ENSG00000260911.2	RP11-196G11.2	-3.71	0.000228	0.0276	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30922754	chr16:31043150~31049868:+
HNSC	cis	rs3741151	0.686	rs7941359	ENSG00000256448.4	RP11-809N8.4	3.71	0.000228	0.0276	0.24	0.17	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73447074	chr11:73405297~73410682:+
HNSC	cis	rs3764400	0.508	rs72823528	ENSG00000228782.6	CTD-2026D20.3	-3.71	0.000228	0.0276	-0.26	-0.17	Body mass index;	chr17:48021578	chr17:47450568~47492492:-
HNSC	cis	rs9911578	0.967	rs2333410	ENSG00000224738.1	AC099850.1	-3.71	0.000228	0.0276	-0.17	-0.17	Intelligence (multi-trait analysis);	chr17:59059768	chr17:59106598~59118267:+
HNSC	cis	rs9611565	0.649	rs6002480	ENSG00000233903.2	Z83851.4	-3.71	0.000228	0.0276	-0.24	-0.17	Vitiligo;	chr22:41780913	chr22:42276355~42277052:+
HNSC	cis	rs3213473	0.542	rs16967441	ENSG00000262171.1	CTA-972D3.2	-3.71	0.000228	0.0276	-0.23	-0.17	IgG glycosylation;	chr16:16163553	chr16:15885029~15886158:+
HNSC	cis	rs2976388	0.967	rs2976387	ENSG00000253741.1	CTD-2292P10.4	3.71	0.000228	0.0277	0.16	0.17	Urinary tract infection frequency;	chr8:142677946	chr8:142702252~142726973:-
HNSC	cis	rs6490294	0.851	rs1016079	ENSG00000234608.6	MAPKAPK5-AS1	-3.71	0.000228	0.0277	-0.12	-0.17	Mean platelet volume;	chr12:111972382	chr12:111839764~111842902:-
HNSC	cis	rs6723108	0.738	rs10928512	ENSG00000224043.6	CCNT2-AS1	-3.71	0.000228	0.0277	-0.2	-0.17	Type 2 diabetes;	chr2:134693732	chr2:134735464~134918710:-
HNSC	cis	rs11096990	0.892	rs1901404	ENSG00000249685.1	RP11-360F5.3	-3.71	0.000228	0.0277	-0.21	-0.17	Cognitive function;	chr4:39210990	chr4:39133913~39135608:+
HNSC	cis	rs2976388	0.935	rs2978980	ENSG00000253741.1	CTD-2292P10.4	3.71	0.000228	0.0277	0.16	0.17	Urinary tract infection frequency;	chr8:142676290	chr8:142702252~142726973:-
HNSC	cis	rs929354	1	rs1182378	ENSG00000224629.1	RP5-1142J19.2	3.71	0.000228	0.0277	0.17	0.17	Body mass index;	chr7:157255628	chr7:157263022~157263229:-
HNSC	cis	rs7927592	0.913	rs7106010	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68597744	chr11:68050740~68053762:+
HNSC	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-3.71	0.000229	0.0277	-0.17	-0.17	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
HNSC	cis	rs1665050	0.534	rs4465553	ENSG00000259732.1	RP11-59H7.3	-3.71	0.000229	0.0277	-0.22	-0.17	Atopic dermatitis;	chr15:58954621	chr15:59121034~59133250:+
HNSC	cis	rs11638815	0.626	rs11633829	ENSG00000259429.4	UBE2Q2P2	3.71	0.000229	0.0277	0.17	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:82355142~82420075:+
HNSC	cis	rs1185460	0.967	rs2509121	ENSG00000272186.1	RP11-110I1.13	-3.71	0.000229	0.0277	-0.19	-0.17	Coronary artery disease;	chr11:119057542	chr11:119067374~119067698:-
HNSC	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	3.71	0.000229	0.0277	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
HNSC	cis	rs11951515	0.714	rs12520895	ENSG00000249286.1	CTD-2210P15.2	3.71	0.000229	0.0277	0.18	0.17	Metabolite levels  (X-11787);	chr5:43369447	chr5:43586918~43588223:-
HNSC	cis	rs868153	0.557	rs2085401	ENSG00000275339.1	RP3-425C14.6	3.71	0.000229	0.0277	0.18	0.17	Vertical cup-disc ratio;	chr6:122248089	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs2770118	ENSG00000275339.1	RP3-425C14.6	3.71	0.000229	0.0277	0.18	0.17	Vertical cup-disc ratio;	chr6:122248578	chr6:122454358~122454612:+
HNSC	cis	rs13287066	0.669	rs10992728	ENSG00000227603.1	RP11-165J3.6	3.71	0.000229	0.0277	0.15	0.17	Intelligence (multi-trait analysis);	chr9:93416386	chr9:93435332~93437121:-
HNSC	cis	rs3740713	1	rs60376560	ENSG00000256464.1	YWHABP2	3.71	0.000229	0.0277	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr11:18490243~18490955:-
HNSC	cis	rs2247572	0.667	rs2196906	ENSG00000250295.5	RP11-434I12.2	3.71	0.000229	0.0277	0.22	0.17	Cognitive performance;	chr8:72696046	chr8:73297711~73356461:-
HNSC	cis	rs2247572	0.667	rs2264035	ENSG00000250295.5	RP11-434I12.2	3.71	0.000229	0.0277	0.22	0.17	Cognitive performance;	chr8:72699756	chr8:73297711~73356461:-
HNSC	cis	rs11098499	0.566	rs17051356	ENSG00000250412.1	KLHL2P1	3.71	0.000229	0.0277	0.23	0.17	Corneal astigmatism;	chr4:119664153	chr4:119334329~119378233:+
HNSC	cis	rs9863	0.804	rs80270210	ENSG00000270028.1	RP11-380L11.4	3.71	0.000229	0.0277	0.22	0.17	White blood cell count;	chr12:123962850	chr12:123925461~123926083:-
HNSC	cis	rs686320	1	rs679643	ENSG00000245532.5	NEAT1	3.71	0.000229	0.0277	0.19	0.17	Hip circumference adjusted for BMI;	chr11:65483119	chr11:65422774~65445540:+
HNSC	cis	rs11723261	0.582	rs7679573	ENSG00000211553.1	AC253576.2	-3.71	0.000229	0.0277	-0.25	-0.17	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:136461~136568:+
HNSC	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	3.71	0.000229	0.0277	0.18	0.17	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
HNSC	cis	rs9652601	0.748	rs12924112	ENSG00000274038.1	RP11-66H6.4	-3.71	0.000229	0.0277	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11125863	chr16:11056556~11057034:+
HNSC	cis	rs6012564	1	rs3092720	ENSG00000227431.4	CSE1L-AS1	-3.71	0.000229	0.0277	-0.19	-0.17	Anger;	chr20:49023929	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs2252259	ENSG00000227431.4	CSE1L-AS1	-3.71	0.000229	0.0277	-0.19	-0.17	Anger;	chr20:49046286	chr20:49040463~49046044:-
HNSC	cis	rs7189233	0.531	rs17801498	ENSG00000275191.1	RP11-36I17.2	-3.71	0.000229	0.0277	-0.19	-0.17	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53628256~53628816:-
HNSC	cis	rs6095360	0.727	rs7274612	ENSG00000222365.1	SNORD12B	3.71	0.000229	0.0277	0.21	0.17	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49280319~49280409:+
HNSC	cis	rs7621025	0.63	rs1681816	ENSG00000273486.1	RP11-731C17.2	-3.71	0.000229	0.0277	-0.16	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136837338~136839021:-
HNSC	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	3.71	0.000229	0.0277	0.21	0.17	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
HNSC	cis	rs11098499	0.874	rs7661020	ENSG00000250412.1	KLHL2P1	3.71	0.000229	0.0277	0.22	0.17	Corneal astigmatism;	chr4:119185827	chr4:119334329~119378233:+
HNSC	cis	rs73198271	0.562	rs17631052	ENSG00000253893.2	FAM85B	3.71	0.000229	0.0277	0.26	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8806277	chr8:8167819~8226614:-
HNSC	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	3.71	0.000229	0.0277	0.21	0.17	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
HNSC	cis	rs9923283	0.673	rs1050881	ENSG00000205534.6	SMG1P2	3.71	0.000229	0.0277	0.37	0.17	Plateletcrit;	chr16:29664607	chr16:29527568~29594966:-
HNSC	cis	rs8062405	1	rs12443881	ENSG00000261089.1	RP11-435I10.3	3.71	0.000229	0.0277	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28413703~28415018:+
HNSC	cis	rs7824557	0.564	rs55758514	ENSG00000255495.1	AC145124.2	-3.71	0.000229	0.0277	-0.19	-0.17	Retinal vascular caliber;	chr8:11372750	chr8:12194467~12196280:+
HNSC	cis	rs9914544	0.545	rs8078993	ENSG00000264885.1	RP11-815I9.4	-3.71	0.000229	0.0277	-0.17	-0.17	Educational attainment (years of education);	chr17:18893813	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs57035178	ENSG00000264885.1	RP11-815I9.4	-3.71	0.000229	0.0277	-0.17	-0.17	Educational attainment (years of education);	chr17:18894454	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.524	rs7209853	ENSG00000264885.1	RP11-815I9.4	-3.71	0.000229	0.0277	-0.17	-0.17	Educational attainment (years of education);	chr17:18895287	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs4924940	ENSG00000264885.1	RP11-815I9.4	-3.71	0.000229	0.0277	-0.17	-0.17	Educational attainment (years of education);	chr17:18896779	chr17:18667629~18669461:-
HNSC	cis	rs9863	0.861	rs4405410	ENSG00000270028.1	RP11-380L11.4	3.71	0.000229	0.0277	0.2	0.17	White blood cell count;	chr12:123951241	chr12:123925461~123926083:-
HNSC	cis	rs56804039	1	rs7017341	ENSG00000254153.1	CTA-398F10.2	-3.71	0.000229	0.0277	-0.22	-0.17	Cervical cancer;	chr8:8524154	chr8:8456909~8461337:-
HNSC	cis	rs9531006	0.603	rs9601288	ENSG00000227676.3	LINC01068	3.71	0.000229	0.0277	0.26	0.17	Sleep duration;	chr13:79893120	chr13:79566727~79571436:+
HNSC	cis	rs9531006	0.602	rs9601289	ENSG00000227676.3	LINC01068	3.71	0.000229	0.0277	0.26	0.17	Sleep duration;	chr13:79893972	chr13:79566727~79571436:+
HNSC	cis	rs9531006	0.636	rs9601290	ENSG00000227676.3	LINC01068	3.71	0.000229	0.0277	0.26	0.17	Sleep duration;	chr13:79895192	chr13:79566727~79571436:+
HNSC	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	3.71	0.000229	0.0277	0.17	0.17	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
HNSC	cis	rs10459221	1	rs10459221	ENSG00000258101.2	RP11-977B10.2	3.71	0.000229	0.0277	0.21	0.17	Bipolar disorder;	chr12:49073211	chr12:49232790~49264756:-
HNSC	cis	rs7927592	0.913	rs3740631	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68574254	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs3824850	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68574405	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs3740629	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68576125	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs11228287	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68582286	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs10896346	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68585203	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs10896347	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68585659	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs6591344	ENSG00000255031.4	RP11-802E16.3	3.71	0.000229	0.0277	0.15	0.17	Total body bone mineral density;	chr11:68593405	chr11:68050740~68053762:+
HNSC	cis	rs1941023	0.517	rs8181503	ENSG00000279632.1	RP11-286N22.6	-3.71	0.000229	0.0277	-0.18	-0.17	Congenital heart disease (maternal effect);	chr11:60496830	chr11:61426448~61427325:-
HNSC	cis	rs7781557	0.638	rs55781834	ENSG00000239969.4	RP11-163E9.2	-3.71	0.000229	0.0277	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102931986	chr7:102364162~102380633:+
HNSC	cis	rs2976388	0.762	rs34635647	ENSG00000253741.1	CTD-2292P10.4	3.71	0.000229	0.0277	0.16	0.17	Urinary tract infection frequency;	chr8:142675472	chr8:142702252~142726973:-
HNSC	cis	rs79220007	0.557	rs56329220	ENSG00000272462.2	U91328.19	-3.71	0.000229	0.0277	-0.31	-0.17	Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr6:25657617	chr6:25992662~26001775:+
HNSC	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	3.71	0.000229	0.0277	0.22	0.17	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
HNSC	cis	rs4906332	1	rs2065015	ENSG00000244691.1	RPL10AP1	3.71	0.000229	0.0277	0.2	0.17	Coronary artery disease;	chr14:103437724	chr14:103412119~103412761:-
HNSC	cis	rs10129255	0.5	rs9324092	ENSG00000211976.2	IGHV3-73	3.71	0.000229	0.0277	0.12	0.17	Kawasaki disease;	chr14:106683806	chr14:106802694~106803233:-
HNSC	cis	rs1865760	0.593	rs2097273	ENSG00000272810.1	U91328.22	-3.71	0.000229	0.0277	-0.15	-0.17	Height;	chr6:25941082	chr6:26013241~26013757:+
HNSC	cis	rs748404	0.666	rs36078097	ENSG00000166763.7	STRCP1	3.71	0.000229	0.0277	0.24	0.17	Lung cancer;	chr15:43466209	chr15:43699488~43718184:-
HNSC	cis	rs2446066	0.872	rs10876447	ENSG00000270175.1	RP11-793H13.11	-3.71	0.000229	0.0278	-0.21	-0.17	Red blood cell count;	chr12:53377157	chr12:53500162~53500936:-
HNSC	cis	rs4906332	0.966	rs7401563	ENSG00000244691.1	RPL10AP1	-3.71	0.00023	0.0278	-0.2	-0.17	Coronary artery disease;	chr14:103498088	chr14:103412119~103412761:-
HNSC	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	3.71	0.00023	0.0278	0.24	0.17	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
HNSC	cis	rs8002861	0.664	rs4941474	ENSG00000274001.1	RP11-5G9.5	3.71	0.00023	0.0278	0.17	0.17	Leprosy;	chr13:43876153	chr13:43877715~43878163:-
HNSC	cis	rs896655	0.599	rs10965143	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0278	0.19	0.17	Coronary artery disease;	chr9:21808753	chr9:21699314~21699596:+
HNSC	cis	rs970821	1	rs4617136	ENSG00000253106.1	RP11-158K1.3	3.71	0.00023	0.0278	0.15	0.17	Breast cancer;	chr8:123738211	chr8:124488510~124491643:+
HNSC	cis	rs2657294	0.929	rs6480771	ENSG00000233313.2	HMGA1P5	-3.71	0.00023	0.0278	-0.18	-0.17	Pneumonia;	chr10:75101922	chr10:75276376~75276646:-
HNSC	cis	rs4073405	0.691	rs7114339	ENSG00000254651.1	RP11-430H10.3	3.71	0.00023	0.0278	0.21	0.17	Schizophrenia;	chr11:45264926	chr11:45399448~45400528:+
HNSC	cis	rs4073405	0.691	rs11604409	ENSG00000254651.1	RP11-430H10.3	3.71	0.00023	0.0278	0.21	0.17	Schizophrenia;	chr11:45265411	chr11:45399448~45400528:+
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000273142.1	RP11-458F8.4	-3.71	0.00023	0.0278	-0.14	-0.17	Aortic root size;	chr7:66542376	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs801217	ENSG00000273142.1	RP11-458F8.4	3.71	0.00023	0.0278	0.14	0.17	Aortic root size;	chr7:66545590	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.638	rs801216	ENSG00000273142.1	RP11-458F8.4	3.71	0.00023	0.0278	0.14	0.17	Aortic root size;	chr7:66546680	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs801211	ENSG00000273142.1	RP11-458F8.4	3.71	0.00023	0.0278	0.14	0.17	Aortic root size;	chr7:66550702	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.638	rs801205	ENSG00000273142.1	RP11-458F8.4	3.71	0.00023	0.0278	0.14	0.17	Aortic root size;	chr7:66557157	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.617	rs810400	ENSG00000273142.1	RP11-458F8.4	3.71	0.00023	0.0278	0.14	0.17	Aortic root size;	chr7:66557902	chr7:66902857~66906297:+
HNSC	cis	rs12893668	0.637	rs12892038	ENSG00000269958.1	RP11-73M18.8	3.71	0.00023	0.0278	0.16	0.17	Reticulocyte count;	chr14:103602292	chr14:103696353~103697163:+
HNSC	cis	rs2548724	0.812	rs434771	ENSG00000250682.4	LINC00491	-3.71	0.00023	0.0278	-0.22	-0.17	Type 2 diabetes;	chr5:102261084	chr5:102609156~102671559:-
HNSC	cis	rs6517329	0.526	rs2835291	ENSG00000214867.3	SRSF9P1	-3.71	0.00023	0.0278	-0.21	-0.17	Schizophrenia;	chr21:36166622	chr21:36295173~36295702:-
HNSC	cis	rs6570726	1	rs951143	ENSG00000270638.1	RP3-466P17.1	3.71	0.00023	0.0278	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145735570~145737218:+
HNSC	cis	rs6545883	0.965	rs9989775	ENSG00000271889.1	RP11-493E12.1	3.71	0.00023	0.0278	0.19	0.17	Tuberculosis;	chr2:61534639	chr2:61151433~61162105:-
HNSC	cis	rs2836974	0.666	rs11910705	ENSG00000255568.3	BRWD1-AS2	-3.71	0.00023	0.0278	-0.14	-0.17	Cognitive function;	chr21:39313678	chr21:39313935~39314962:+
HNSC	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-3.71	0.00023	0.0278	-0.24	-0.17	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
HNSC	cis	rs13108904	0.901	rs6826029	ENSG00000272588.1	RP11-440L14.4	3.71	0.00023	0.0278	0.17	0.17	Obesity-related traits;	chr4:1313901	chr4:757022~757740:-
HNSC	cis	rs4834770	0.668	rs10007409	ENSG00000249244.1	RP11-548H18.2	-3.71	0.00023	0.0278	-0.19	-0.17	Blood protein levels;	chr4:119221151	chr4:119391831~119395335:-
HNSC	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	3.71	0.00023	0.0278	0.24	0.17	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.92	rs12915390	ENSG00000230373.7	GOLGA6L5P	-3.71	0.00023	0.0278	-0.19	-0.17	Schizophrenia;	chr15:84123317	chr15:84507885~84516814:-
HNSC	cis	rs8072100	0.934	rs9905583	ENSG00000263293.2	RP11-290H9.4	3.71	0.00023	0.0278	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47303460~47323613:-
HNSC	cis	rs2998286	0.678	rs332184	ENSG00000254635.4	WAC-AS1	-3.71	0.00023	0.0278	-0.26	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624042	chr10:28522652~28532743:-
HNSC	cis	rs1595825	0.891	rs75163179	ENSG00000231621.1	AC013264.2	-3.71	0.00023	0.0278	-0.2	-0.17	Ulcerative colitis;	chr2:198030678	chr2:197197991~197199273:+
HNSC	cis	rs2273156	0.929	rs12894820	ENSG00000258938.1	RP11-317N8.5	3.71	0.00023	0.0278	0.21	0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966319	chr14:35819224~35826765:-
HNSC	cis	rs5751168	0.605	rs5758503	ENSG00000274422.1	LL22NC03-2H8.5	3.71	0.00023	0.0278	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22498765	chr22:22283928~22287220:-
HNSC	cis	rs11668609	0.748	rs8112938	ENSG00000268442.1	CTD-2027I19.2	3.71	0.00023	0.0278	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:24162370~24163425:-
HNSC	cis	rs9813712	0.571	rs9855777	ENSG00000253540.4	FAM86HP	3.71	0.00023	0.0278	0.15	0.17	Response to amphetamines;	chr3:130214805	chr3:130099092~130111472:-
HNSC	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-3.71	0.00023	0.0278	-0.21	-0.17	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
HNSC	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	3.71	0.00023	0.0278	0.24	0.17	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
HNSC	cis	rs913655	0.819	rs2495832	ENSG00000225527.1	RP11-383B4.4	3.71	0.00023	0.0278	0.22	0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18785532	chr10:18531849~18533336:-
HNSC	cis	rs6545883	0.894	rs2694634	ENSG00000271889.1	RP11-493E12.1	-3.71	0.00023	0.0278	-0.19	-0.17	Tuberculosis;	chr2:61324300	chr2:61151433~61162105:-
HNSC	cis	rs597539	0.616	rs473997	ENSG00000255741.1	RP11-757G1.5	-3.71	0.00023	0.0278	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68941503~68942852:-
HNSC	cis	rs7615952	0.736	rs9862893	ENSG00000241439.1	RP11-666A20.3	3.71	0.00023	0.0278	0.23	0.17	Blood pressure (smoking interaction);	chr3:125968131	chr3:125958556~125958817:+
HNSC	cis	rs13108904	0.875	rs1732099	ENSG00000272588.1	RP11-440L14.4	-3.71	0.00023	0.0278	-0.17	-0.17	Obesity-related traits;	chr4:1288908	chr4:757022~757740:-
HNSC	cis	rs7023329	0.59	rs7858991	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0279	0.17	0.17	Melanoma;	chr9:21735857	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs7874319	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0279	0.17	0.17	Melanoma;	chr9:21735882	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.619	rs6475572	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0279	0.17	0.17	Melanoma;	chr9:21736021	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs4384075	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0279	0.17	0.17	Melanoma;	chr9:21736035	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.56	rs6475574	ENSG00000244230.3	RN7SL151P	3.71	0.00023	0.0279	0.17	0.17	Melanoma;	chr9:21736053	chr9:21699314~21699596:+
HNSC	cis	rs11846409	0.932	rs2015469	ENSG00000280411.1	IGHV1-69-2	-3.71	0.000231	0.0279	-0.15	-0.17	Rheumatic heart disease;	chr14:106631857	chr14:106762092~106762588:-
HNSC	cis	rs11846409	0.932	rs56167903	ENSG00000280411.1	IGHV1-69-2	-3.71	0.000231	0.0279	-0.15	-0.17	Rheumatic heart disease;	chr14:106632070	chr14:106762092~106762588:-
HNSC	cis	rs227275	0.556	rs7676765	ENSG00000248740.4	RP11-328K4.1	-3.71	0.000231	0.0279	-0.17	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:103256159~103453658:+
HNSC	cis	rs911555	0.755	rs2273702	ENSG00000244691.1	RPL10AP1	3.71	0.000231	0.0279	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103412119~103412761:-
HNSC	cis	rs656319	0.58	rs13279701	ENSG00000254340.1	RP11-10A14.3	-3.71	0.000231	0.0279	-0.21	-0.17	Myopia (pathological);	chr8:10111940	chr8:9141424~9145435:+
HNSC	cis	rs9813712	0.818	rs11718381	ENSG00000228252.7	COL6A4P2	3.71	0.000231	0.0279	0.18	0.17	Response to amphetamines;	chr3:130222660	chr3:130212823~130273806:+
HNSC	cis	rs2403083	0.626	rs4150867	ENSG00000253549.4	RP11-317J10.2	3.71	0.000231	0.0279	0.2	0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85187307	chr8:85441851~85464915:-
HNSC	cis	rs2403083	0.515	rs4150869	ENSG00000253549.4	RP11-317J10.2	3.71	0.000231	0.0279	0.2	0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85187466	chr8:85441851~85464915:-
HNSC	cis	rs544991	0.687	rs513049	ENSG00000239670.1	RP4-803A2.2	-3.71	0.000231	0.0279	-0.2	-0.17	Intelligence;	chr1:33741378	chr1:32986952~32988233:+
HNSC	cis	rs3176789	0.914	rs4519175	ENSG00000256673.1	RP11-599J14.2	3.71	0.000231	0.0279	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772568	chr12:9398355~9414851:-
HNSC	cis	rs1040393	0.953	rs989928	ENSG00000225171.2	DUTP6	3.71	0.000231	0.0279	0.21	0.17	Schizophrenia;	chr1:166898830	chr1:166868748~166869209:+
HNSC	cis	rs886774	0.899	rs757935	ENSG00000273055.1	CTB-13F3.1	-3.71	0.000231	0.0279	-0.17	-0.17	Ulcerative colitis;	chr7:107862017	chr7:107942116~107942740:+
HNSC	cis	rs870825	1	rs870821	ENSG00000254233.1	RP11-242J7.1	3.71	0.000231	0.0279	0.28	0.17	Blood protein levels;	chr4:184666223	chr4:184584093~184625030:-
HNSC	cis	rs12893668	0.637	rs12892038	ENSG00000269910.1	RP11-73M18.10	3.71	0.000231	0.0279	0.17	0.17	Reticulocyte count;	chr14:103602292	chr14:103694516~103695050:-
HNSC	cis	rs4834770	0.668	rs11737086	ENSG00000249244.1	RP11-548H18.2	-3.71	0.000231	0.0279	-0.2	-0.17	Blood protein levels;	chr4:119205962	chr4:119391831~119395335:-
HNSC	cis	rs4834770	0.668	rs1397610	ENSG00000249244.1	RP11-548H18.2	-3.71	0.000231	0.0279	-0.2	-0.17	Blood protein levels;	chr4:119206606	chr4:119391831~119395335:-
HNSC	cis	rs62025270	0.632	rs17637411	ENSG00000259762.1	RP11-158M2.4	-3.71	0.000231	0.0279	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85750336~85752901:-
HNSC	cis	rs2310173	0.612	rs3819369	ENSG00000281162.1	LINC01127	-3.71	0.000231	0.0279	-0.22	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102016120	chr2:101962056~101987167:+
HNSC	cis	rs9297145	0.724	rs6954584	ENSG00000272950.1	RP11-307C18.1	-3.71	0.000231	0.0279	-0.25	-0.17	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99169307	chr7:98322853~98323430:+
HNSC	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	3.71	0.000231	0.0279	0.15	0.17	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
HNSC	cis	rs1519814	0.616	rs28885745	ENSG00000254343.2	RP11-760H22.2	-3.71	0.000231	0.0279	-0.23	-0.17	Breast cancer;	chr8:120000219	chr8:120052180~120056201:+
HNSC	cis	rs6071166	0.935	rs6015693	ENSG00000224635.1	RP4-564F22.5	-3.71	0.000231	0.0279	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38702166	chr20:38406011~38416797:-
HNSC	cis	rs6787172	0.811	rs6441204	ENSG00000272087.1	RP11-379F4.7	3.71	0.000231	0.0279	0.18	0.17	Subjective well-being;	chr3:158482424	chr3:158693120~158693768:-
HNSC	cis	rs9650657	0.707	rs1115867	ENSG00000255310.2	AF131215.2	-3.71	0.000231	0.0279	-0.17	-0.17	Neuroticism;	chr8:10781240	chr8:11107788~11109726:-
HNSC	cis	rs7688540	0.8	rs73793597	ENSG00000250892.1	RP11-1365D11.1	-3.71	0.000231	0.0279	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:201409~205009:-
HNSC	cis	rs614226	1	rs563920	ENSG00000202538.1	RNU4-2	-3.71	0.000231	0.0279	-0.29	-0.17	Type 1 diabetes nephropathy;	chr12:120579636	chr12:120291763~120291903:-
HNSC	cis	rs7746199	0.736	rs13193542	ENSG00000226314.6	ZNF192P1	-3.71	0.000231	0.0279	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs13193480	ENSG00000226314.6	ZNF192P1	-3.71	0.000231	0.0279	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28161781~28169594:+
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-3.71	0.000231	0.0279	-0.21	-0.17	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
HNSC	cis	rs36093844	0.527	rs4944550	ENSG00000279742.1	RP11-700A24.1	-3.71	0.000231	0.0279	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85974531	chr11:85852557~85854943:-
HNSC	cis	rs10849893	0.576	rs7134248	ENSG00000258435.1	RP11-711D18.2	-3.71	0.000231	0.0279	-0.17	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121459249	chr12:121391962~121399859:+
HNSC	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000231	0.0279	-0.24	-0.17	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
HNSC	cis	rs3018712	0.59	rs4930236	ENSG00000212093.1	AP000807.1	-3.71	0.000231	0.0279	-0.24	-0.17	Total body bone mineral density;	chr11:68646532	chr11:68506083~68506166:-
HNSC	cis	rs73201462	1	rs13077913	ENSG00000231305.3	RP11-723O4.2	-3.71	0.000231	0.0279	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163761	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs13077790	ENSG00000231305.3	RP11-723O4.2	-3.71	0.000231	0.0279	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163815	chr3:128861313~128871540:-
HNSC	cis	rs10865541	0.869	rs13020433	ENSG00000234171.2	RNASEH1-AS1	3.71	0.000231	0.028	0.18	0.17	Obesity-related traits;	chr2:3413806	chr2:3558492~3561745:+
HNSC	cis	rs7246760	0.867	rs3859512	ENSG00000267289.1	CTD-2623N2.11	3.71	0.000232	0.028	0.3	0.17	Pursuit maintenance gain;	chr19:9822155	chr19:9834079~9835013:-
HNSC	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
HNSC	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
HNSC	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
HNSC	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
HNSC	cis	rs13178541	0.745	rs7379714	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000232	0.028	-0.22	-0.17	IgG glycosylation;	chr5:135757447	chr5:135812667~135826582:+
HNSC	cis	rs28489187	0.683	rs2177461	ENSG00000223653.4	RP11-131L23.1	-3.71	0.000232	0.028	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85396293	chr1:85276715~85448124:+
HNSC	cis	rs73201462	1	rs11706826	ENSG00000231305.3	RP11-723O4.2	-3.71	0.000232	0.028	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314148	chr3:128861313~128871540:-
HNSC	cis	rs801193	1	rs62466793	ENSG00000273142.1	RP11-458F8.4	-3.71	0.000232	0.028	-0.14	-0.17	Aortic root size;	chr7:66726530	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs62466794	ENSG00000273142.1	RP11-458F8.4	-3.71	0.000232	0.028	-0.14	-0.17	Aortic root size;	chr7:66726592	chr7:66902857~66906297:+
HNSC	cis	rs6840360	0.582	rs2724555	ENSG00000251611.1	RP11-610P16.1	-3.71	0.000232	0.028	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151407551~151408835:-
HNSC	cis	rs7824557	0.564	rs12550129	ENSG00000255495.1	AC145124.2	-3.71	0.000232	0.028	-0.19	-0.17	Retinal vascular caliber;	chr8:11376408	chr8:12194467~12196280:+
HNSC	cis	rs2236521	0.659	rs72487383	ENSG00000228812.6	LAMA5-AS1	-3.71	0.000232	0.028	-0.21	-0.17	Pelvic organ prolapse;	chr20:62314257	chr20:62352995~62356480:+
HNSC	cis	rs6545883	0.894	rs12620105	ENSG00000271889.1	RP11-493E12.1	-3.71	0.000232	0.028	-0.2	-0.17	Tuberculosis;	chr2:61285186	chr2:61151433~61162105:-
HNSC	cis	rs116095464	0.558	rs10079760	ENSG00000277812.1	AC021087.1	3.71	0.000232	0.028	0.28	0.17	Breast cancer;	chr5:230663	chr5:262769~262881:+
HNSC	cis	rs1553477	0.64	rs6866551	ENSG00000272123.1	CTD-2366F13.2	3.71	0.000232	0.028	0.2	0.17	Monobrow;	chr5:53824052	chr5:53089016~53089468:-
HNSC	cis	rs2280018	0.609	rs2941253	ENSG00000188599.16	NPIPP1	-3.71	0.000232	0.028	-0.14	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15104312~15123498:-
HNSC	cis	rs6499755	0.965	rs2042448	ENSG00000260135.5	RP11-212I21.2	-3.71	0.000232	0.028	-0.19	-0.17	Hypospadias;	chr16:55318151	chr16:55426797~55462297:-
HNSC	cis	rs6499755	0.965	rs9888978	ENSG00000260135.5	RP11-212I21.2	-3.71	0.000232	0.028	-0.19	-0.17	Hypospadias;	chr16:55319072	chr16:55426797~55462297:-
HNSC	cis	rs6499755	0.965	rs9889178	ENSG00000260135.5	RP11-212I21.2	-3.71	0.000232	0.028	-0.19	-0.17	Hypospadias;	chr16:55319198	chr16:55426797~55462297:-
HNSC	cis	rs1662342	1	rs73937040	ENSG00000272625.1	RP11-737O24.5	-3.71	0.000232	0.028	-0.29	-0.17	QRS duration;	chr18:3258735	chr18:2920966~2921685:+
HNSC	cis	rs10484434	1	rs11751732	ENSG00000272810.1	U91328.22	3.71	0.000232	0.028	0.2	0.17	HIV-1 viral setpoint;	chr6:26043836	chr6:26013241~26013757:+
HNSC	cis	rs7011507	0.582	rs56057107	ENSG00000253608.1	RP11-770E5.1	-3.71	0.000232	0.028	-0.35	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48303844	chr8:48551567~48698510:+
HNSC	cis	rs13256369	1	rs10088439	ENSG00000173295.6	FAM86B3P	3.71	0.000232	0.028	0.21	0.17	Obesity-related traits;	chr8:8719189	chr8:8228595~8244865:+
HNSC	cis	rs4648045	0.598	rs6833745	ENSG00000230069.3	LRRC37A15P	-3.71	0.000232	0.028	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102494665	chr4:102727274~102730721:-
HNSC	cis	rs72827839	0.779	rs72827858	ENSG00000272763.1	RP11-357H14.17	-3.71	0.000232	0.028	-0.24	-0.17	Ease of getting up in the morning;	chr17:48396999	chr17:48635923~48647023:-
HNSC	cis	rs36093844	0.527	rs72961110	ENSG00000279742.1	RP11-700A24.1	-3.71	0.000232	0.028	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86007976	chr11:85852557~85854943:-
HNSC	cis	rs5751168	0.652	rs4619723	ENSG00000274422.1	LL22NC03-2H8.5	3.71	0.000232	0.028	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22497909	chr22:22283928~22287220:-
HNSC	cis	rs853679	1	rs1679732	ENSG00000270326.1	RP5-874C20.6	3.71	0.000232	0.028	0.25	0.17	Depression;	chr6:28253486	chr6:28319660~28319852:-
HNSC	cis	rs988913	0.515	rs11756299	ENSG00000224984.1	RP11-524H19.2	3.71	0.000232	0.028	0.19	0.17	Menarche (age at onset);	chr6:55086218	chr6:54840118~54840855:-
HNSC	cis	rs9329221	0.509	rs3088186	ENSG00000269918.1	AF131215.9	3.71	0.000232	0.028	0.19	0.17	Neuroticism;	chr8:10368845	chr8:11104691~11106704:-
HNSC	cis	rs10995356	0.565	rs7076790	ENSG00000238280.1	RP11-436D10.3	-3.71	0.000232	0.028	-0.2	-0.17	Temperament;	chr10:62944273	chr10:62793562~62805887:-
HNSC	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
HNSC	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-3.71	0.000232	0.028	-0.2	-0.17	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
HNSC	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	3.71	0.000232	0.028	0.12	0.17	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
HNSC	cis	rs2013441	1	rs34712254	ENSG00000261033.1	RP11-209D14.2	-3.71	0.000232	0.028	-0.19	-0.17	Obesity-related traits;	chr17:20145995	chr17:20008051~20009234:-
HNSC	cis	rs6787172	0.811	rs6780896	ENSG00000272087.1	RP11-379F4.7	3.71	0.000232	0.028	0.18	0.17	Subjective well-being;	chr3:158477606	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.728	rs6783284	ENSG00000272087.1	RP11-379F4.7	3.71	0.000232	0.028	0.18	0.17	Subjective well-being;	chr3:158477761	chr3:158693120~158693768:-
HNSC	cis	rs2638953	0.893	rs7313862	ENSG00000257176.2	RP11-996F15.2	3.71	0.000232	0.028	0.19	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458846	chr12:29280418~29317848:-
HNSC	cis	rs13178541	0.689	rs12521005	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000232	0.028	-0.22	-0.17	IgG glycosylation;	chr5:135823313	chr5:135812667~135826582:+
HNSC	cis	rs860295	0.557	rs12037177	ENSG00000225855.5	RUSC1-AS1	-3.71	0.000232	0.028	-0.12	-0.17	Body mass index;	chr1:155907238	chr1:155316863~155324176:-
HNSC	cis	rs6088580	0.634	rs1205344	ENSG00000276073.1	RP5-1125A11.7	3.71	0.000232	0.028	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:33985617~33988989:-
HNSC	cis	rs12999542	0.706	rs11465711	ENSG00000234389.1	AC007278.3	3.71	0.000232	0.028	0.29	0.17	Serum protein levels (sST2);	chr2:102443632	chr2:102438713~102440475:+
HNSC	cis	rs6442522	0.573	rs9825720	ENSG00000224728.1	AC090945.1	3.71	0.000232	0.028	0.28	0.17	Uric acid levels;	chr3:15373742	chr3:15878047~15879571:+
HNSC	cis	rs7927592	0.956	rs55816191	ENSG00000239559.2	RPL37P2	3.71	0.000232	0.0281	0.17	0.17	Total body bone mineral density;	chr11:68495511	chr11:67682772~67683058:-
HNSC	cis	rs1580019	0.885	rs1610141	ENSG00000226468.2	AC018641.7	-3.71	0.000232	0.0281	-0.23	-0.17	Cognitive ability;	chr7:32458823	chr7:32456963~32457758:-
HNSC	cis	rs11668609	0.872	rs4416149	ENSG00000268442.1	CTD-2027I19.2	3.71	0.000232	0.0281	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24093551	chr19:24162370~24163425:-
HNSC	cis	rs950027	0.62	rs1153857	ENSG00000259479.5	SORD2P	3.71	0.000232	0.0281	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:44826371~44884694:-
HNSC	cis	rs950027	0.62	rs1153855	ENSG00000259479.5	SORD2P	3.71	0.000232	0.0281	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:44826371~44884694:-
HNSC	cis	rs7927592	0.913	rs7104345	ENSG00000255031.4	RP11-802E16.3	3.71	0.000233	0.0281	0.15	0.17	Total body bone mineral density;	chr11:68549304	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs12284933	ENSG00000255031.4	RP11-802E16.3	3.71	0.000233	0.0281	0.15	0.17	Total body bone mineral density;	chr11:68552021	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.871	rs11228284	ENSG00000255031.4	RP11-802E16.3	3.71	0.000233	0.0281	0.15	0.17	Total body bone mineral density;	chr11:68555299	chr11:68050740~68053762:+
HNSC	cis	rs853679	1	rs7740487	ENSG00000219891.2	ZSCAN12P1	3.71	0.000233	0.0281	0.27	0.17	Depression;	chr6:28248708	chr6:28091154~28093664:+
HNSC	cis	rs853679	1	rs68141011	ENSG00000219891.2	ZSCAN12P1	3.71	0.000233	0.0281	0.27	0.17	Depression;	chr6:28250019	chr6:28091154~28093664:+
HNSC	cis	rs853679	1	rs13200462	ENSG00000219891.2	ZSCAN12P1	3.71	0.000233	0.0281	0.27	0.17	Depression;	chr6:28250421	chr6:28091154~28093664:+
HNSC	cis	rs6964587	0.61	rs2888850	ENSG00000188693.7	CYP51A1-AS1	-3.71	0.000233	0.0281	-0.18	-0.17	Breast cancer;	chr7:91800713	chr7:92134604~92180725:+
HNSC	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-3.71	0.000233	0.0281	-0.21	-0.17	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
HNSC	cis	rs7581030	0.517	rs17743415	ENSG00000234896.1	OR7E62P	3.71	0.000233	0.0281	0.19	0.17	Testicular germ cell tumor;	chr2:71335373	chr2:71055527~71056003:+
HNSC	cis	rs4819052	0.788	rs35323494	ENSG00000223768.1	LINC00205	-3.71	0.000233	0.0281	-0.19	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45293285~45297354:+
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000269918.1	AF131215.9	3.71	0.000233	0.0281	0.17	0.17	Neuroticism;	chr8:11935465	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000269918.1	AF131215.9	3.71	0.000233	0.0281	0.17	0.17	Neuroticism;	chr8:11935469	chr8:11104691~11106704:-
HNSC	cis	rs12893668	0.581	rs34843146	ENSG00000269958.1	RP11-73M18.8	3.71	0.000233	0.0281	0.16	0.17	Reticulocyte count;	chr14:103613527	chr14:103696353~103697163:+
HNSC	cis	rs12817549	0.869	rs11107176	ENSG00000213250.5	RBMS2P1	3.71	0.000233	0.0281	0.15	0.17	Hip circumference adjusted for BMI;	chr12:93769687	chr12:94423744~94424969:-
HNSC	cis	rs300890	0.76	rs7655782	ENSG00000250326.1	RP11-284M14.1	-3.71	0.000233	0.0281	-0.19	-0.17	Nasopharyngeal carcinoma;	chr4:143285095	chr4:142933195~143184861:-
HNSC	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	3.71	0.000233	0.0281	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
HNSC	cis	rs62458065	0.713	rs1597560	ENSG00000226468.2	AC018641.7	3.71	0.000233	0.0281	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32454274	chr7:32456963~32457758:-
HNSC	cis	rs6840360	0.901	rs6826799	ENSG00000251611.1	RP11-610P16.1	-3.71	0.000233	0.0281	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151534548	chr4:151407551~151408835:-
HNSC	cis	rs9650657	0.769	rs1115866	ENSG00000255310.2	AF131215.2	-3.71	0.000233	0.0281	-0.17	-0.17	Neuroticism;	chr8:10780823	chr8:11107788~11109726:-
HNSC	cis	rs4767841	0.868	rs1318272	ENSG00000277283.1	RP1-267D11.6	3.71	0.000233	0.0281	0.17	0.17	Urgency urinary incontinence;	chr12:119751883	chr12:120116907~120119000:+
HNSC	cis	rs4767841	0.901	rs904654	ENSG00000277283.1	RP1-267D11.6	3.71	0.000233	0.0281	0.17	0.17	Urgency urinary incontinence;	chr12:119752083	chr12:120116907~120119000:+
HNSC	cis	rs11676676	1	rs737478	ENSG00000204588.5	LINC01123	-3.71	0.000233	0.0281	-0.26	-0.17	Pediatric bone mineral density (spine);	chr2:109152690	chr2:109987063~109996140:+
HNSC	cis	rs11676676	1	rs11681754	ENSG00000204588.5	LINC01123	-3.71	0.000233	0.0281	-0.26	-0.17	Pediatric bone mineral density (spine);	chr2:109154264	chr2:109987063~109996140:+
HNSC	cis	rs11676676	1	rs11681808	ENSG00000204588.5	LINC01123	-3.71	0.000233	0.0281	-0.26	-0.17	Pediatric bone mineral density (spine);	chr2:109154401	chr2:109987063~109996140:+
HNSC	cis	rs11676676	1	rs11692935	ENSG00000204588.5	LINC01123	-3.71	0.000233	0.0281	-0.26	-0.17	Pediatric bone mineral density (spine);	chr2:109154434	chr2:109987063~109996140:+
HNSC	cis	rs11676676	0.935	rs11689009	ENSG00000204588.5	LINC01123	-3.71	0.000233	0.0281	-0.26	-0.17	Pediatric bone mineral density (spine);	chr2:109154917	chr2:109987063~109996140:+
HNSC	cis	rs62025270	0.632	rs8029034	ENSG00000259762.1	RP11-158M2.4	-3.71	0.000233	0.0281	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85750336~85752901:-
HNSC	cis	rs12908161	1	rs58416181	ENSG00000229212.6	RP11-561C5.4	-3.71	0.000233	0.0281	-0.24	-0.17	Schizophrenia;	chr15:84721230	chr15:85205440~85234795:-
HNSC	cis	rs17253792	0.822	rs117050012	ENSG00000186615.9	KTN1-AS1	-3.71	0.000233	0.0281	-0.37	-0.17	Putamen volume;	chr14:55572011	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs118027213	ENSG00000186615.9	KTN1-AS1	-3.71	0.000233	0.0281	-0.37	-0.17	Putamen volume;	chr14:55572358	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs17683614	ENSG00000186615.9	KTN1-AS1	-3.71	0.000233	0.0281	-0.37	-0.17	Putamen volume;	chr14:55574340	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.555	rs17683626	ENSG00000186615.9	KTN1-AS1	-3.71	0.000233	0.0281	-0.37	-0.17	Putamen volume;	chr14:55574394	chr14:55499278~55580110:-
HNSC	cis	rs13438327	0.901	rs112830011	ENSG00000243554.1	AC004967.7	3.71	0.000233	0.0281	0.35	0.17	Sudden cardiac arrest;	chr7:97988216	chr7:97969005~97972254:-
HNSC	cis	rs2462686	1	rs788765	ENSG00000234536.1	AC096582.7	3.71	0.000233	0.0281	0.18	0.17	Major depressive disorder;	chr7:45957386	chr7:45773595~45783157:+
HNSC	cis	rs2462686	1	rs809298	ENSG00000234536.1	AC096582.7	3.71	0.000233	0.0281	0.18	0.17	Major depressive disorder;	chr7:45958745	chr7:45773595~45783157:+
HNSC	cis	rs2462686	0.932	rs2471557	ENSG00000234536.1	AC096582.7	3.71	0.000233	0.0281	0.18	0.17	Major depressive disorder;	chr7:45960996	chr7:45773595~45783157:+
HNSC	cis	rs2462686	1	rs1525828	ENSG00000234536.1	AC096582.7	3.71	0.000233	0.0281	0.18	0.17	Major depressive disorder;	chr7:45962479	chr7:45773595~45783157:+
HNSC	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	3.71	0.000233	0.0281	0.17	0.17	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
HNSC	cis	rs11846409	0.652	rs10143549	ENSG00000280411.1	IGHV1-69-2	-3.71	0.000233	0.0281	-0.15	-0.17	Rheumatic heart disease;	chr14:106644643	chr14:106762092~106762588:-
HNSC	cis	rs36093844	0.527	rs72951266	ENSG00000279742.1	RP11-700A24.1	-3.71	0.000233	0.0281	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85983565	chr11:85852557~85854943:-
HNSC	cis	rs62202398	0.618	rs6094993	ENSG00000276923.1	RP11-321P16.1	-3.71	0.000233	0.0281	-0.31	-0.17	Alcohol consumption;	chr20:48154371	chr20:48073869~48074188:+
HNSC	cis	rs7107174	1	rs1318241	ENSG00000251323.2	RP11-452H21.4	3.71	0.000233	0.0281	0.26	0.17	Testicular germ cell tumor;	chr11:78219746	chr11:78423982~78429836:-
HNSC	cis	rs3096299	0.933	rs2965938	ENSG00000261118.1	RP11-104N10.1	3.71	0.000233	0.0282	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89492017~89504460:-
HNSC	cis	rs9467711	0.559	rs3799383	ENSG00000241549.7	GUSBP2	3.71	0.000233	0.0282	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:26510520	chr6:26871484~26956554:-
HNSC	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-3.71	0.000234	0.0282	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
HNSC	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000234	0.0282	-0.22	-0.17	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
HNSC	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-3.71	0.000234	0.0282	-0.14	-0.17	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
HNSC	cis	rs73201462	1	rs2811534	ENSG00000231305.3	RP11-723O4.2	3.71	0.000234	0.0282	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272265	chr3:128861313~128871540:-
HNSC	cis	rs453301	0.658	rs12114954	ENSG00000253981.4	ALG1L13P	-3.71	0.000234	0.0282	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9047352	chr8:8236003~8244667:-
HNSC	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	3.71	0.000234	0.0282	0.17	0.17	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	3.71	0.000234	0.0282	0.17	0.17	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
HNSC	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	3.71	0.000234	0.0282	0.17	0.17	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
HNSC	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-3.71	0.000234	0.0282	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
HNSC	cis	rs12047808	0.908	rs59288190	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000234	0.0282	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179471008	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.908	rs60940069	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000234	0.0282	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179471316	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.908	rs59913185	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000234	0.0282	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179472685	chr1:179586705~179589175:+
HNSC	cis	rs13178541	0.748	rs13158124	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0282	-0.22	-0.17	IgG glycosylation;	chr5:135730290	chr5:135812667~135826582:+
HNSC	cis	rs853679	0.55	rs1225598	ENSG00000219891.2	ZSCAN12P1	3.71	0.000234	0.0282	0.23	0.17	Depression;	chr6:28193021	chr6:28091154~28093664:+
HNSC	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	3.71	0.000234	0.0282	0.25	0.17	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
HNSC	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	3.71	0.000234	0.0282	0.25	0.17	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
HNSC	cis	rs28489187	0.706	rs761601	ENSG00000223653.4	RP11-131L23.1	3.71	0.000234	0.0282	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85331615	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.73	rs12121675	ENSG00000223653.4	RP11-131L23.1	3.71	0.000234	0.0282	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85332801	chr1:85276715~85448124:+
HNSC	cis	rs10865541	0.902	rs6739163	ENSG00000234171.2	RNASEH1-AS1	3.71	0.000234	0.0282	0.18	0.17	Obesity-related traits;	chr2:3415240	chr2:3558492~3561745:+
HNSC	cis	rs6869502	0.554	rs1363477	ENSG00000214784.4	AC010468.1	3.71	0.000234	0.0282	0.18	0.17	Allergic disease (asthma, hay fever or eczema);	chr5:110638881	chr5:111192226~111193042:-
HNSC	cis	rs7824557	0.872	rs2572431	ENSG00000255310.2	AF131215.2	-3.71	0.000234	0.0282	-0.16	-0.17	Retinal vascular caliber;	chr8:11247568	chr8:11107788~11109726:-
HNSC	cis	rs28829049	0.597	rs12563386	ENSG00000270728.1	RP4-657E11.10	-3.71	0.000234	0.0282	-0.16	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19128711	chr1:19297080~19297903:+
HNSC	cis	rs964611	1	rs74011998	ENSG00000259488.2	RP11-154J22.1	-3.71	0.000234	0.0282	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48304516	chr15:48312353~48331856:-
HNSC	cis	rs7023329	0.59	rs6475562	ENSG00000244230.3	RN7SL151P	3.71	0.000234	0.0282	0.17	0.17	Melanoma;	chr9:21725766	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs1414235	ENSG00000244230.3	RN7SL151P	3.71	0.000234	0.0282	0.17	0.17	Melanoma;	chr9:21726307	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs1832075	ENSG00000244230.3	RN7SL151P	3.71	0.000234	0.0282	0.17	0.17	Melanoma;	chr9:21726491	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs1832076	ENSG00000244230.3	RN7SL151P	3.71	0.000234	0.0282	0.17	0.17	Melanoma;	chr9:21726665	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs6475563	ENSG00000244230.3	RN7SL151P	3.71	0.000234	0.0282	0.17	0.17	Melanoma;	chr9:21726779	chr9:21699314~21699596:+
HNSC	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-3.71	0.000234	0.0282	-0.18	-0.17	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
HNSC	cis	rs2562784	0.638	rs2585045	ENSG00000225151.9	GOLGA2P7	-3.71	0.000234	0.0282	-0.32	-0.17	Height;	chr15:83637562	chr15:84199311~84230136:-
HNSC	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	3.71	0.000234	0.0282	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
HNSC	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	3.71	0.000234	0.0282	0.19	0.17	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
HNSC	cis	rs28489187	0.706	rs66811655	ENSG00000223653.4	RP11-131L23.1	3.71	0.000234	0.0282	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85365861	chr1:85276715~85448124:+
HNSC	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	3.71	0.000234	0.0282	0.19	0.17	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
HNSC	cis	rs4356203	0.875	rs527810	ENSG00000272034.1	SNORD14A	-3.71	0.000234	0.0282	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17074654~17074744:-
HNSC	cis	rs4356203	0.905	rs589319	ENSG00000272034.1	SNORD14A	-3.71	0.000234	0.0282	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17074654~17074744:-
HNSC	cis	rs77140172	0.677	rs77860352	ENSG00000248019.2	FAM13A-AS1	-3.71	0.000234	0.0282	-0.29	-0.17	Post bronchodilator FEV1;	chr4:88706623	chr4:88709789~88730103:+
HNSC	cis	rs13179617	0.778	rs7734879	ENSG00000215032.2	GNL3LP1	3.71	0.000234	0.0282	0.2	0.17	Intelligence (multi-trait analysis);	chr5:61415805	chr5:60891935~60893577:-
HNSC	cis	rs7824557	0.564	rs6601584	ENSG00000255310.2	AF131215.2	-3.71	0.000234	0.0282	-0.16	-0.17	Retinal vascular caliber;	chr8:11374834	chr8:11107788~11109726:-
HNSC	cis	rs6545883	0.929	rs12617911	ENSG00000271889.1	RP11-493E12.1	3.71	0.000234	0.0282	0.19	0.17	Tuberculosis;	chr2:61513690	chr2:61151433~61162105:-
HNSC	cis	rs6587515	0.901	rs3738483	ENSG00000274963.1	Metazoa_SRP	-3.71	0.000234	0.0282	-0.28	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150828990	chr1:150568971~150569269:-
HNSC	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	3.71	0.000234	0.0283	0.19	0.17	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
HNSC	cis	rs11671005	0.735	rs34188294	ENSG00000269473.1	CTD-2619J13.19	3.71	0.000234	0.0283	0.27	0.17	Mean platelet volume;	chr19:58408190	chr19:58440448~58445849:+
HNSC	cis	rs6180	0.622	rs1423650	ENSG00000215068.6	AC025171.1	-3.71	0.000235	0.0283	-0.17	-0.17	Height;	chr5:42854626	chr5:43041575~43045390:+
HNSC	cis	rs970821	0.667	rs1030590	ENSG00000253106.1	RP11-158K1.3	3.71	0.000235	0.0283	0.15	0.17	Breast cancer;	chr8:123742170	chr8:124488510~124491643:+
HNSC	cis	rs3176789	0.914	rs4385980	ENSG00000256673.1	RP11-599J14.2	3.71	0.000235	0.0283	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772596	chr12:9398355~9414851:-
HNSC	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	3.71	0.000235	0.0283	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
HNSC	cis	rs4908760	0.832	rs11121209	ENSG00000232912.4	RP5-1115A15.1	3.71	0.000235	0.0283	0.18	0.17	Vitiligo;	chr1:8626803	chr1:8424645~8434838:+
HNSC	cis	rs950169	0.58	rs2271431	ENSG00000229212.6	RP11-561C5.4	-3.71	0.000235	0.0283	-0.24	-0.17	Schizophrenia;	chr15:84646233	chr15:85205440~85234795:-
HNSC	cis	rs2836974	0.897	rs8133146	ENSG00000255568.3	BRWD1-AS2	3.71	0.000235	0.0283	0.15	0.17	Cognitive function;	chr21:39242372	chr21:39313935~39314962:+
HNSC	cis	rs4073405	0.721	rs7483595	ENSG00000254651.1	RP11-430H10.3	-3.71	0.000235	0.0283	-0.2	-0.17	Schizophrenia;	chr11:45317267	chr11:45399448~45400528:+
HNSC	cis	rs2289700	0.561	rs16970223	ENSG00000252061.1	RNU6-415P	-3.71	0.000235	0.0283	-0.29	-0.17	Bipolar disorder;	chr15:78901944	chr15:78898840~78898936:-
HNSC	cis	rs3736485	0.641	rs979259	ENSG00000259438.1	CTD-2650P22.1	3.71	0.000235	0.0283	0.18	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51667233	chr15:52010999~52019095:-
HNSC	cis	rs73252553	0.548	rs4697564	ENSG00000281501.1	SEPSECS-AS1	3.71	0.000235	0.0283	0.26	0.17	Cannabis dependence symptom count;	chr4:25311514	chr4:25160641~25201440:+
HNSC	cis	rs35146811	0.735	rs1727139	ENSG00000235077.1	AC073842.19	-3.71	0.000235	0.0283	-0.2	-0.17	Coronary artery disease;	chr7:100217744	chr7:100130964~100140439:+
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-3.71	0.000235	0.0283	-0.18	-0.17	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
HNSC	cis	rs10256972	0.758	rs9801444	ENSG00000225146.1	AC073957.15	-3.71	0.000235	0.0283	-0.2	-0.17	Endometriosis;Longevity;	chr7:1040808	chr7:1029025~1043891:+
HNSC	cis	rs2562456	0.833	rs11669790	ENSG00000268119.4	CTD-2561J22.5	3.71	0.000235	0.0283	0.26	0.17	Pain;	chr19:21328980	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62107534	ENSG00000268119.4	CTD-2561J22.5	3.71	0.000235	0.0283	0.26	0.17	Pain;	chr19:21329389	chr19:21444241~21463908:-
HNSC	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	3.71	0.000235	0.0283	0.2	0.17	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
HNSC	cis	rs9487051	0.702	rs368467	ENSG00000243587.6	C6orf183	-3.71	0.000235	0.0283	-0.16	-0.17	Reticulocyte fraction of red cells;	chr6:109198248	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.735	rs380774	ENSG00000243587.6	C6orf183	-3.71	0.000235	0.0283	-0.16	-0.17	Reticulocyte fraction of red cells;	chr6:109198420	chr6:109165833~109271014:+
HNSC	cis	rs12682352	0.602	rs4841044	ENSG00000173295.6	FAM86B3P	-3.71	0.000235	0.0283	-0.19	-0.17	Neuroticism;	chr8:8807430	chr8:8228595~8244865:+
HNSC	cis	rs17594362	1	rs17594362	ENSG00000229473.2	RGS17P1	-3.71	0.000235	0.0283	-0.27	-0.17	Multiple sclerosis;	chr13:41565109	chr13:40992779~40993331:-
HNSC	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-3.71	0.000235	0.0283	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
HNSC	cis	rs2013441	0.866	rs2526470	ENSG00000261033.1	RP11-209D14.2	3.71	0.000235	0.0283	0.2	0.17	Obesity-related traits;	chr17:20256957	chr17:20008051~20009234:-
HNSC	cis	rs12047808	1	rs56392198	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000235	0.0283	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179481989	chr1:179586705~179589175:+
HNSC	cis	rs12047808	1	rs76901676	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000235	0.0283	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179483385	chr1:179586705~179589175:+
HNSC	cis	rs12047808	1	rs55998153	ENSG00000227141.2	RP11-545A16.3	-3.71	0.000235	0.0283	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179484689	chr1:179586705~179589175:+
HNSC	cis	rs4845570	0.85	rs11204892	ENSG00000203288.3	RP11-98D18.9	3.71	0.000235	0.0283	0.25	0.17	Coronary artery disease;	chr1:151795572	chr1:151790804~151794402:+
HNSC	cis	rs2554380	0.843	rs7182216	ENSG00000259570.1	RP11-671M22.4	-3.71	0.000235	0.0283	-0.23	-0.17	Height;	chr15:83753754	chr15:84394512~84395514:+
HNSC	cis	rs2836974	0.666	rs35182074	ENSG00000255568.3	BRWD1-AS2	-3.71	0.000235	0.0283	-0.14	-0.17	Cognitive function;	chr21:39313358	chr21:39313935~39314962:+
HNSC	cis	rs10216189	0.785	rs4623325	ENSG00000230733.2	AC092171.4	-3.71	0.000235	0.0283	-0.21	-0.17	Relative hand skill in reading disability;	chr7:5487176	chr7:5475804~5479811:+
HNSC	cis	rs1552244	1	rs7648104	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10031627	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs113771705	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10034299	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs111392584	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10034307	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs17032276	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10035291	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs17032277	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10035339	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs17032278	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10036271	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs66797209	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10036842	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7631678	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10037132	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7637888	ENSG00000180385.7	EMC3-AS1	3.71	0.000235	0.0283	0.19	0.17	Alzheimer's disease;	chr3:10039038	chr3:9986893~10006990:+
HNSC	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	3.71	0.000235	0.0283	0.24	0.17	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	3.71	0.000235	0.0283	0.24	0.17	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
HNSC	cis	rs11671005	0.735	rs11084544	ENSG00000269473.1	CTD-2619J13.19	3.71	0.000235	0.0283	0.27	0.17	Mean platelet volume;	chr19:58428760	chr19:58440448~58445849:+
HNSC	cis	rs2307394	1	rs13004041	ENSG00000281469.1	RP11-567F11.1	3.71	0.000235	0.0283	0.19	0.17	Urate levels;	chr2:147984052	chr2:148044380~148044894:+
HNSC	cis	rs9863	0.828	rs71458830	ENSG00000270028.1	RP11-380L11.4	3.71	0.000235	0.0283	0.2	0.17	White blood cell count;	chr12:123992014	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.828	rs12809473	ENSG00000270028.1	RP11-380L11.4	3.71	0.000235	0.0283	0.2	0.17	White blood cell count;	chr12:123992052	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.828	rs12827409	ENSG00000270028.1	RP11-380L11.4	3.71	0.000235	0.0283	0.2	0.17	White blood cell count;	chr12:123992159	chr12:123925461~123926083:-
HNSC	cis	rs4699052	0.537	rs1580278	ENSG00000251288.2	RP11-10L12.2	3.71	0.000235	0.0283	0.2	0.17	Testicular germ cell tumor;	chr4:103219691	chr4:102751401~102752641:+
HNSC	cis	rs1056107	0.572	rs10817334	ENSG00000225513.1	RP11-165N19.2	-3.71	0.000236	0.0284	-0.18	-0.17	Colorectal cancer;	chr9:112401777	chr9:112173522~112173971:-
HNSC	cis	rs6558174	0.965	rs2003908	ENSG00000253837.1	RP11-177H13.2	-3.71	0.000236	0.0284	-0.18	-0.17	Breast cancer;	chr8:22634005	chr8:23336171~23366125:+
HNSC	cis	rs868153	0.591	rs2078231	ENSG00000275339.1	RP3-425C14.6	3.71	0.000236	0.0284	0.18	0.17	Vertical cup-disc ratio;	chr6:122161570	chr6:122454358~122454612:+
HNSC	cis	rs7819412	0.521	rs10100660	ENSG00000255310.2	AF131215.2	-3.71	0.000236	0.0284	-0.17	-0.17	Triglycerides;	chr8:11181376	chr8:11107788~11109726:-
HNSC	cis	rs62292953	0.591	rs78117783	ENSG00000248724.5	NPHP3-AS1	-3.71	0.000236	0.0284	-0.4	-0.17	Red cell distribution width;	chr3:132495545	chr3:132721750~132874223:+
HNSC	cis	rs17412738	0.51	rs77436593	ENSG00000248724.5	NPHP3-AS1	-3.71	0.000236	0.0284	-0.4	-0.17	Blood protein levels;	chr3:132496927	chr3:132721750~132874223:+
HNSC	cis	rs62292953	0.591	rs76569928	ENSG00000248724.5	NPHP3-AS1	-3.71	0.000236	0.0284	-0.4	-0.17	Red cell distribution width;	chr3:132497763	chr3:132721750~132874223:+
HNSC	cis	rs62292953	0.591	rs78526588	ENSG00000248724.5	NPHP3-AS1	-3.71	0.000236	0.0284	-0.4	-0.17	Red cell distribution width;	chr3:132499113	chr3:132721750~132874223:+
HNSC	cis	rs17412738	0.51	rs78208917	ENSG00000248724.5	NPHP3-AS1	-3.71	0.000236	0.0284	-0.4	-0.17	Blood protein levels;	chr3:132510864	chr3:132721750~132874223:+
HNSC	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	3.71	0.000236	0.0284	0.16	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
HNSC	cis	rs7554547	0.667	rs7525521	ENSG00000242349.4	NPPA-AS1	-3.71	0.000236	0.0284	-0.17	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr1:11841017~11848079:+
HNSC	cis	rs1832007	0.554	rs7101071	ENSG00000224034.1	RP11-445P17.8	-3.71	0.000236	0.0284	-0.2	-0.17	Triglyceride levels;Triglycerides;	chr10:5200674	chr10:5266033~5271236:-
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000259570.1	RP11-671M22.4	3.71	0.000236	0.0284	0.23	0.17	Schizophrenia;	chr15:84400409	chr15:84394512~84395514:+
HNSC	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-3.71	0.000236	0.0284	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
HNSC	cis	rs7688540	0.771	rs7686546	ENSG00000211553.1	AC253576.2	-3.71	0.000236	0.0284	-0.26	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:136461~136568:+
HNSC	cis	rs6968419	0.755	rs6948556	ENSG00000237870.5	AC073130.1	3.71	0.000236	0.0284	0.21	0.17	Intraocular pressure;	chr7:116255379	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs6967695	ENSG00000237870.5	AC073130.1	3.71	0.000236	0.0284	0.21	0.17	Intraocular pressure;	chr7:116255995	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs3807981	ENSG00000237870.5	AC073130.1	3.71	0.000236	0.0284	0.21	0.17	Intraocular pressure;	chr7:116256662	chr7:116275606~116286734:-
HNSC	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-3.71	0.000236	0.0284	-0.25	-0.17	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
HNSC	cis	rs7674212	0.539	rs7676041	ENSG00000251288.2	RP11-10L12.2	-3.71	0.000236	0.0284	-0.19	-0.17	Type 2 diabetes;	chr4:103205264	chr4:102751401~102752641:+
HNSC	cis	rs16852403	0.531	rs494481	ENSG00000273062.1	RP11-428K3.1	-3.71	0.000236	0.0284	-0.19	-0.17	Childhood ear infection;	chr1:178249688	chr1:178724306~178726285:-
HNSC	cis	rs7283707	0.681	rs7281511	ENSG00000236471.1	AF127577.12	3.71	0.000236	0.0284	0.31	0.17	QRS complex (12-leadsum);	chr21:15845135	chr21:15067070~15067837:+
HNSC	cis	rs1937680	0.657	rs7921365	ENSG00000236671.6	PRKG1-AS1	3.71	0.000236	0.0284	0.24	0.17	Breast cancer;	chr10:51878478	chr10:52230742~52314128:-
HNSC	cis	rs6710503	0.632	rs17799110	ENSG00000271936.1	RP11-443B20.1	3.71	0.000236	0.0284	0.21	0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24773846	chr2:24825610~24826717:+
HNSC	cis	rs853679	1	rs1778511	ENSG00000219891.2	ZSCAN12P1	-3.71	0.000236	0.0284	-0.27	-0.17	Depression;	chr6:28261633	chr6:28091154~28093664:+
HNSC	cis	rs17164851	0.714	rs17133172	ENSG00000273329.1	RP11-448A19.1	-3.71	0.000236	0.0284	-0.2	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr7:130389019	chr7:129604548~129611630:-
HNSC	cis	rs12999542	0.706	rs11465689	ENSG00000234389.1	AC007278.3	3.71	0.000236	0.0284	0.29	0.17	Serum protein levels (sST2);	chr2:102423707	chr2:102438713~102440475:+
HNSC	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-3.71	0.000236	0.0284	-0.25	-0.17	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-3.71	0.000236	0.0284	-0.25	-0.17	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
HNSC	cis	rs78366141	0.649	rs77135481	ENSG00000248019.2	FAM13A-AS1	-3.71	0.000236	0.0284	-0.27	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88768529	chr4:88709789~88730103:+
HNSC	cis	rs9813712	0.595	rs1453240	ENSG00000253540.4	FAM86HP	-3.71	0.000236	0.0284	-0.16	-0.17	Response to amphetamines;	chr3:130282849	chr3:130099092~130111472:-
HNSC	cis	rs7023329	0.532	rs2027162	ENSG00000244230.3	RN7SL151P	3.71	0.000236	0.0284	0.17	0.17	Melanoma;	chr9:21737917	chr9:21699314~21699596:+
HNSC	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	3.71	0.000236	0.0284	0.19	0.17	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
HNSC	cis	rs12545912	0.525	rs597910	ENSG00000254340.1	RP11-10A14.3	-3.71	0.000236	0.0284	-0.28	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9937714	chr8:9141424~9145435:+
HNSC	cis	rs2055729	0.592	rs7462499	ENSG00000254340.1	RP11-10A14.3	-3.71	0.000236	0.0284	-0.28	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9937753	chr8:9141424~9145435:+
HNSC	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-3.71	0.000236	0.0284	-0.24	-0.17	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
HNSC	cis	rs12817549	0.791	rs10777536	ENSG00000213250.5	RBMS2P1	3.71	0.000236	0.0284	0.15	0.17	Hip circumference adjusted for BMI;	chr12:93726956	chr12:94423744~94424969:-
HNSC	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-3.71	0.000236	0.0284	-0.17	-0.17	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
HNSC	cis	rs1925953	0.711	rs12125272	ENSG00000233589.1	RP4-694A7.2	-3.71	0.000236	0.0284	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68362734	chr1:68479129~68483539:+
HNSC	cis	rs2562784	0.638	rs2585046	ENSG00000225151.9	GOLGA2P7	-3.71	0.000236	0.0284	-0.32	-0.17	Height;	chr15:83640221	chr15:84199311~84230136:-
HNSC	cis	rs453301	0.522	rs2929309	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000236	0.0284	-0.16	-0.17	Joint mobility (Beighton score);	chr8:9226261	chr8:8961200~8979025:+
HNSC	cis	rs4356203	0.905	rs6486354	ENSG00000272034.1	SNORD14A	-3.71	0.000236	0.0284	-0.13	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17074654~17074744:-
HNSC	cis	rs5751168	0.915	rs4822059	ENSG00000274422.1	LL22NC03-2H8.5	3.71	0.000236	0.0284	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22491354	chr22:22283928~22287220:-
HNSC	cis	rs5751168	0.765	rs2006783	ENSG00000274422.1	LL22NC03-2H8.5	3.71	0.000236	0.0284	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22495045	chr22:22283928~22287220:-
HNSC	cis	rs7267979	0.816	rs376742	ENSG00000231081.1	RP4-760C5.3	-3.71	0.000236	0.0284	-0.17	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26008791~26010531:-
HNSC	cis	rs8077577	0.747	rs7405677	ENSG00000273018.4	CTD-2303H24.2	3.71	0.000236	0.0284	0.25	0.17	Obesity-related traits;	chr17:18227922	chr17:18511221~18551705:-
HNSC	cis	rs35146811	0.735	rs7811662	ENSG00000235077.1	AC073842.19	3.71	0.000236	0.0284	0.2	0.17	Coronary artery disease;	chr7:100194985	chr7:100130964~100140439:+
HNSC	cis	rs7824557	0.564	rs2572400	ENSG00000255495.1	AC145124.2	-3.71	0.000236	0.0284	-0.19	-0.17	Retinal vascular caliber;	chr8:11376858	chr8:12194467~12196280:+
HNSC	cis	rs10504130	0.867	rs11786167	ENSG00000272024.1	RP11-546K22.3	-3.71	0.000236	0.0284	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51763097	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs75527521	ENSG00000272024.1	RP11-546K22.3	-3.71	0.000236	0.0284	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51769788	chr8:51950284~51950690:+
HNSC	cis	rs10504130	1	rs12675907	ENSG00000272024.1	RP11-546K22.3	-3.71	0.000236	0.0284	-0.29	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51773102	chr8:51950284~51950690:+
HNSC	cis	rs1015213	1	rs112333642	ENSG00000272024.1	RP11-546K22.3	-3.71	0.000236	0.0284	-0.3	-0.17	Glaucoma (primary angle closure);	chr8:51974568	chr8:51950284~51950690:+
HNSC	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	3.71	0.000237	0.0285	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	3.71	0.000237	0.0285	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	3.71	0.000237	0.0285	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
HNSC	cis	rs57221529	0.713	rs12521091	ENSG00000225138.6	CTD-2228K2.7	3.71	0.000237	0.0285	0.25	0.17	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:473236~480884:+
HNSC	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-3.71	0.000237	0.0285	-0.19	-0.17	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
HNSC	cis	rs6088580	0.634	rs1890000	ENSG00000276073.1	RP5-1125A11.7	3.71	0.000237	0.0285	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:33985617~33988989:-
HNSC	cis	rs12234571	1	rs11971380	ENSG00000214293.7	APTR	3.71	0.000237	0.0285	0.23	0.17	Obesity-related traits;	chr7:77887567	chr7:77657660~77696265:-
HNSC	cis	rs12234571	1	rs10953373	ENSG00000214293.7	APTR	3.71	0.000237	0.0285	0.23	0.17	Obesity-related traits;	chr7:77894387	chr7:77657660~77696265:-
HNSC	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000237	0.0285	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
HNSC	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	3.7	0.000237	0.0285	0.18	0.17	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
HNSC	cis	rs7824557	0.527	rs2736305	ENSG00000255495.1	AC145124.2	-3.7	0.000237	0.0285	-0.19	-0.17	Retinal vascular caliber;	chr8:11380264	chr8:12194467~12196280:+
HNSC	cis	rs7129556	0.52	rs7943055	ENSG00000219529.2	AP000580.1	3.7	0.000237	0.0285	0.2	0.17	Weight loss (gastric bypass surgery);	chr11:77550006	chr11:77813319~77813676:-
HNSC	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-3.7	0.000237	0.0285	-0.2	-0.17	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
HNSC	cis	rs35146811	0.66	rs3779046	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100181620	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.66	rs3779045	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100181636	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.7	rs4729579	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100182659	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.7	rs7788301	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100185130	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs6465766	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100188048	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs2272344	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100189196	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs11764176	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100189341	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs6948729	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100189749	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs11767968	ENSG00000235077.1	AC073842.19	3.7	0.000237	0.0285	0.2	0.17	Coronary artery disease;	chr7:100193348	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs2528900	ENSG00000235077.1	AC073842.19	-3.7	0.000237	0.0285	-0.2	-0.17	Coronary artery disease;	chr7:100207696	chr7:100130964~100140439:+
HNSC	cis	rs35146811	0.735	rs1061230	ENSG00000235077.1	AC073842.19	-3.7	0.000237	0.0285	-0.2	-0.17	Coronary artery disease;	chr7:100209642	chr7:100130964~100140439:+
HNSC	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-3.7	0.000237	0.0285	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
HNSC	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-3.7	0.000237	0.0285	-0.19	-0.17	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000269918.1	AF131215.9	3.7	0.000237	0.0285	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000269918.1	AF131215.9	3.7	0.000237	0.0285	0.17	0.17	Neuroticism;	chr8:11935587	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000269918.1	AF131215.9	3.7	0.000237	0.0285	0.17	0.17	Neuroticism;	chr8:11935631	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000269918.1	AF131215.9	3.7	0.000237	0.0285	0.17	0.17	Neuroticism;	chr8:11935669	chr8:11104691~11106704:-
HNSC	cis	rs4648045	0.796	rs4648058	ENSG00000230069.3	LRRC37A15P	-3.7	0.000237	0.0285	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102594434	chr4:102727274~102730721:-
HNSC	cis	rs62025270	0.632	rs80036674	ENSG00000259762.1	RP11-158M2.4	-3.7	0.000237	0.0285	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85750336~85752901:-
HNSC	cis	rs10484434	0.901	rs2230654	ENSG00000217159.2	LARP1P1	-3.7	0.000237	0.0285	-0.25	-0.17	HIV-1 viral setpoint;	chr6:26033413	chr6:26164072~26164363:+
HNSC	cis	rs2463822	0.669	rs72919480	ENSG00000250659.2	RP11-864I4.3	3.7	0.000237	0.0285	0.35	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62275661	chr11:62537312~62542018:+
HNSC	cis	rs2463822	0.669	rs72919484	ENSG00000250659.2	RP11-864I4.3	3.7	0.000237	0.0285	0.35	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62275958	chr11:62537312~62542018:+
HNSC	cis	rs2463822	0.592	rs72919486	ENSG00000250659.2	RP11-864I4.3	3.7	0.000237	0.0285	0.35	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62276029	chr11:62537312~62542018:+
HNSC	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-3.7	0.000237	0.0285	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
HNSC	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	3.7	0.000237	0.0285	0.17	0.17	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
HNSC	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-3.7	0.000237	0.0285	-0.17	-0.17	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
HNSC	cis	rs5758511	0.573	rs5996074	ENSG00000235513.1	RP4-756G23.5	3.7	0.000237	0.0285	0.18	0.17	Birth weight;	chr22:41840333	chr22:41209122~41217627:-
HNSC	cis	rs7429990	0.813	rs7637622	ENSG00000228638.1	FCF1P2	3.7	0.000237	0.0285	0.15	0.17	Educational attainment (years of education);	chr3:48051561	chr3:48290793~48291375:-
HNSC	cis	rs57561814	1	rs57561814	ENSG00000179428.2	AC073072.5	-3.7	0.000237	0.0285	-0.32	-0.17	Tonsillectomy;	chr7:22714056	chr7:22725395~22727620:-
HNSC	cis	rs792448	0.743	rs351377	ENSG00000226251.4	RP11-15I11.3	-3.7	0.000237	0.0285	-0.2	-0.17	White blood cell count (basophil);	chr1:212252429	chr1:212225278~212238977:-
HNSC	cis	rs7772486	0.686	rs9485019	ENSG00000270638.1	RP3-466P17.1	-3.7	0.000237	0.0285	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145735570~145737218:+
HNSC	cis	rs6071166	0.935	rs1358899	ENSG00000224635.1	RP4-564F22.5	-3.7	0.000237	0.0285	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38701050	chr20:38406011~38416797:-
HNSC	cis	rs7589342	0.509	rs10177819	ENSG00000272994.1	RP11-332H14.2	3.7	0.000237	0.0285	0.13	0.17	Addiction;	chr2:105770183	chr2:105334027~105337475:-
HNSC	cis	rs1595825	0.891	rs17520121	ENSG00000231621.1	AC013264.2	-3.7	0.000237	0.0285	-0.21	-0.17	Ulcerative colitis;	chr2:198033994	chr2:197197991~197199273:+
HNSC	cis	rs8077577	0.747	rs3829956	ENSG00000273018.4	CTD-2303H24.2	-3.7	0.000237	0.0285	-0.24	-0.17	Obesity-related traits;	chr17:18316521	chr17:18511221~18551705:-
HNSC	cis	rs683257	0.866	rs11758847	ENSG00000234147.1	RP3-460G2.2	-3.7	0.000237	0.0285	-0.34	-0.17	Facial emotion recognition (angry faces);	chr6:140693962	chr6:140845958~140852924:-
HNSC	cis	rs11992162	0.56	rs13256329	ENSG00000227888.4	FAM66A	-3.7	0.000237	0.0285	-0.17	-0.17	Monocyte count;	chr8:11924705	chr8:12362019~12388296:+
HNSC	cis	rs10435719	0.638	rs67146188	ENSG00000227888.4	FAM66A	-3.7	0.000237	0.0285	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12362019~12388296:+
HNSC	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	3.7	0.000237	0.0285	0.19	0.17	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
HNSC	cis	rs1881509	0.66	rs4963080	ENSG00000255153.1	TOLLIP-AS1	-3.7	0.000237	0.0285	-0.18	-0.17	Heroin dependence;	chr11:1414623	chr11:1309769~1310707:+
HNSC	cis	rs9298506	0.851	rs10283206	ENSG00000254142.2	RP11-53M11.3	3.7	0.000237	0.0285	0.25	0.17	Intracranial aneurysm;	chr8:54497832	chr8:54554361~54561927:+
HNSC	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000237	0.0285	-0.19	-0.17	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
HNSC	cis	rs7023329	0.59	rs7854990	ENSG00000244230.3	RN7SL151P	3.7	0.000237	0.0285	0.17	0.17	Melanoma;	chr9:21725963	chr9:21699314~21699596:+
HNSC	cis	rs6710503	0.603	rs1550383	ENSG00000271936.1	RP11-443B20.1	-3.7	0.000238	0.0285	-0.21	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24708419	chr2:24825610~24826717:+
HNSC	cis	rs2554380	0.628	rs11853983	ENSG00000259570.1	RP11-671M22.4	-3.7	0.000238	0.0285	-0.2	-0.17	Height;	chr15:83794058	chr15:84394512~84395514:+
HNSC	cis	rs5758659	0.652	rs133336	ENSG00000182057.4	OGFRP1	3.7	0.000238	0.0285	0.17	0.17	Cognitive function;	chr22:42020299	chr22:42269753~42275196:+
HNSC	cis	rs1867631	0.585	rs9787219	ENSG00000248458.2	RP4-598P13.1	3.7	0.000238	0.0285	0.16	0.17	Menopause (age at onset);	chr1:66614476	chr1:66665864~66677027:-
HNSC	cis	rs1867631	0.585	rs11208922	ENSG00000248458.2	RP4-598P13.1	3.7	0.000238	0.0285	0.16	0.17	Menopause (age at onset);	chr1:66614543	chr1:66665864~66677027:-
HNSC	cis	rs62027291	0.561	rs2469196	ENSG00000259422.1	RP11-593F23.1	3.7	0.000238	0.0286	0.21	0.17	Plateletcrit;	chr15:76974347	chr15:76174891~76181486:-
HNSC	cis	rs268134	0.53	rs17534034	ENSG00000235725.1	AC007389.3	-3.7	0.000238	0.0286	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65367062	chr2:65589566~65640177:-
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000255310.2	AF131215.2	-3.7	0.000238	0.0286	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11107788~11109726:-
HNSC	cis	rs11603691	1	rs11228973	ENSG00000254662.1	RP11-872D17.4	-3.7	0.000238	0.0286	-0.35	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57262770	chr11:57325603~57327958:+
HNSC	cis	rs939574	0.512	rs55908154	ENSG00000243910.6	TUBA4B	3.7	0.000238	0.0286	0.28	0.17	Platelet distribution width;	chr2:219281238	chr2:219253243~219272188:+
HNSC	cis	rs1028883	0.839	rs9543406	ENSG00000228295.1	LINC00392	-3.7	0.000238	0.0286	-0.17	-0.17	Lean body mass;	chr13:73590131	chr13:73564244~73588070:+
HNSC	cis	rs1665050	0.534	rs35124643	ENSG00000277144.1	RP11-59H7.4	-3.7	0.000238	0.0286	-0.21	-0.17	Atopic dermatitis;	chr15:58949802	chr15:59115547~59116089:-
HNSC	cis	rs1665050	0.534	rs11858479	ENSG00000277144.1	RP11-59H7.4	-3.7	0.000238	0.0286	-0.21	-0.17	Atopic dermatitis;	chr15:58950507	chr15:59115547~59116089:-
HNSC	cis	rs3736485	0.932	rs28795073	ENSG00000274528.1	CTD-2650P22.2	3.7	0.000238	0.0286	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51635365	chr15:52017167~52018032:-
HNSC	cis	rs801193	1	rs2420824	ENSG00000272831.1	RP11-792A8.4	-3.7	0.000238	0.0286	-0.14	-0.17	Aortic root size;	chr7:66666129	chr7:66739829~66740385:-
HNSC	cis	rs801193	1	rs2659909	ENSG00000272831.1	RP11-792A8.4	3.7	0.000238	0.0286	0.14	0.17	Aortic root size;	chr7:66695292	chr7:66739829~66740385:-
HNSC	cis	rs6439153	0.55	rs789223	ENSG00000261159.1	RP11-723O4.9	3.7	0.000238	0.0286	0.16	0.17	Pneumococcal bacteremia;	chr3:128952303	chr3:128859716~128860526:-
HNSC	cis	rs6939532	0.522	rs4712980	ENSG00000241549.7	GUSBP2	-3.7	0.000238	0.0286	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26355530	chr6:26871484~26956554:-
HNSC	cis	rs793571	0.822	rs28529423	ENSG00000245975.2	RP11-30K9.6	3.7	0.000238	0.0286	0.28	0.17	Schizophrenia;	chr15:58881183	chr15:58768072~58770974:-
HNSC	cis	rs793571	0.822	rs28709922	ENSG00000245975.2	RP11-30K9.6	3.7	0.000238	0.0286	0.28	0.17	Schizophrenia;	chr15:58881282	chr15:58768072~58770974:-
HNSC	cis	rs2645424	1	rs7009302	ENSG00000255046.1	RP11-297N6.4	3.7	0.000238	0.0286	0.17	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr8:11797928~11802568:-
HNSC	cis	rs2055729	0.677	rs6601389	ENSG00000254340.1	RP11-10A14.3	3.7	0.000238	0.0286	0.23	0.17	Multiple myeloma (hyperdiploidy);	chr8:9883126	chr8:9141424~9145435:+
HNSC	cis	rs853679	0.607	rs67998226	ENSG00000280107.1	AL022393.9	-3.7	0.000238	0.0286	-0.29	-0.17	Depression;	chr6:28270281	chr6:28170845~28172521:+
HNSC	cis	rs7819412	0.775	rs2001329	ENSG00000270076.1	AF131215.8	-3.7	0.000238	0.0286	-0.19	-0.17	Triglycerides;	chr8:11129349	chr8:11202965~11203671:+
HNSC	cis	rs868153	0.625	rs13197292	ENSG00000275339.1	RP3-425C14.6	-3.7	0.000238	0.0286	-0.18	-0.17	Vertical cup-disc ratio;	chr6:122205441	chr6:122454358~122454612:+
HNSC	cis	rs17014483	0.749	rs2972030	ENSG00000248019.2	FAM13A-AS1	-3.7	0.000238	0.0286	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88709878	chr4:88709789~88730103:+
HNSC	cis	rs7720894	0.935	rs1986252	ENSG00000215032.2	GNL3LP1	-3.7	0.000238	0.0286	-0.19	-0.17	Body mass index;	chr5:61458592	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs10057395	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000238	0.0286	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792967	chr5:60866457~60866935:-
HNSC	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000238	0.0286	-0.17	-0.17	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
HNSC	cis	rs7274811	0.625	rs169797	ENSG00000277301.1	RP5-1184F4.7	-3.7	0.000238	0.0286	-0.18	-0.17	Height;	chr20:33338684	chr20:32509959~32520285:+
HNSC	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	3.7	0.000238	0.0286	0.19	0.17	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
HNSC	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	3.7	0.000238	0.0286	0.19	0.17	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
HNSC	cis	rs28489187	0.629	rs2012683	ENSG00000223653.4	RP11-131L23.1	3.7	0.000238	0.0286	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85375802	chr1:85276715~85448124:+
HNSC	cis	rs2562456	0.755	rs11670868	ENSG00000268081.1	RP11-678G14.2	3.7	0.000238	0.0286	0.25	0.17	Pain;	chr19:21373613	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs2358993	ENSG00000268081.1	RP11-678G14.2	3.7	0.000238	0.0286	0.25	0.17	Pain;	chr19:21375367	chr19:21554640~21569237:-
HNSC	cis	rs28573326	0.962	rs34485171	ENSG00000121089.4	NACA3P	-3.7	0.000238	0.0286	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415775	chr4:164943290~164943937:+
HNSC	cis	rs1662342	1	rs1662340	ENSG00000272625.1	RP11-737O24.5	-3.7	0.000238	0.0286	-0.28	-0.17	QRS duration;	chr18:3257217	chr18:2920966~2921685:+
HNSC	cis	rs4873772	0.834	rs10094128	ENSG00000253330.1	RP11-697N18.3	-3.7	0.000238	0.0286	-0.22	-0.17	Lobe attachment (rater-scored or self-reported);	chr8:47646835	chr8:47511034~47512141:-
HNSC	cis	rs853679	0.607	rs34788973	ENSG00000219891.2	ZSCAN12P1	3.7	0.000238	0.0286	0.35	0.17	Depression;	chr6:27911422	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs61742093	ENSG00000219891.2	ZSCAN12P1	3.7	0.000238	0.0286	0.35	0.17	Depression;	chr6:27912204	chr6:28091154~28093664:+
HNSC	cis	rs12188164	0.686	rs72711367	ENSG00000215246.5	RP11-43F13.3	-3.7	0.000238	0.0286	-0.2	-0.17	Cystic fibrosis severity;	chr5:418379	chr5:987180~997308:-
HNSC	cis	rs3779195	0.585	rs7777991	ENSG00000183444.10	OR7E38P	-3.7	0.000238	0.0286	-0.25	-0.17	Sex hormone-binding globulin levels;	chr7:98236445	chr7:97966090~97967074:-
HNSC	cis	rs73198271	0.7	rs10090152	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000239	0.0286	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8456909~8461337:-
HNSC	cis	rs4704187	0.687	rs9654426	ENSG00000272040.1	CTC-366B18.4	-3.7	0.000239	0.0286	-0.16	-0.17	Response to amphetamines;	chr5:75170912	chr5:75608817~75609983:+
HNSC	cis	rs2919917	0.628	rs6990105	ENSG00000260398.1	RP11-594N15.3	3.7	0.000239	0.0287	0.23	0.17	Lymphocyte counts;	chr8:78689652	chr8:78605952~78609705:+
HNSC	cis	rs4900538	0.963	rs4906205	ENSG00000272533.1	SNORA28	-3.7	0.000239	0.0287	-0.18	-0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102466110	chr14:103337849~103337974:+
HNSC	cis	rs11157436	0.602	rs2331594	ENSG00000211814.1	TRAV35	-3.7	0.000239	0.0287	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22221896~22222475:+
HNSC	cis	rs11157436	0.602	rs12588757	ENSG00000211814.1	TRAV35	-3.7	0.000239	0.0287	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22221896~22222475:+
HNSC	cis	rs9925964	0.748	rs4889603	ENSG00000279196.1	RP11-1072A3.3	3.7	0.000239	0.0287	0.2	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:30984630~30988270:-
HNSC	cis	rs868153	0.625	rs1350228	ENSG00000275339.1	RP3-425C14.6	3.7	0.000239	0.0287	0.18	0.17	Vertical cup-disc ratio;	chr6:122225991	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs786101	ENSG00000275339.1	RP3-425C14.6	3.7	0.000239	0.0287	0.18	0.17	Vertical cup-disc ratio;	chr6:122231547	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs17084362	ENSG00000275339.1	RP3-425C14.6	3.7	0.000239	0.0287	0.18	0.17	Vertical cup-disc ratio;	chr6:122239030	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs786100	ENSG00000275339.1	RP3-425C14.6	3.7	0.000239	0.0287	0.18	0.17	Vertical cup-disc ratio;	chr6:122241607	chr6:122454358~122454612:+
HNSC	cis	rs74054849	0.85	rs76989769	ENSG00000215908.6	CROCCP2	3.7	0.000239	0.0287	0.23	0.17	Alcoholic chronic pancreatitis;	chr1:15710754	chr1:16618262~16644683:-
HNSC	cis	rs74054849	0.85	rs78749140	ENSG00000215908.6	CROCCP2	3.7	0.000239	0.0287	0.23	0.17	Alcoholic chronic pancreatitis;	chr1:15710768	chr1:16618262~16644683:-
HNSC	cis	rs831571	0.534	rs7621907	ENSG00000280620.1	SCAANT1	3.7	0.000239	0.0287	0.29	0.17	Type 2 diabetes;	chr3:64106541	chr3:63911518~63911772:-
HNSC	cis	rs34792	0.525	rs66651392	ENSG00000207425.1	Y_RNA	-3.7	0.000239	0.0287	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:14915457~14915556:-
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000227888.4	FAM66A	3.7	0.000239	0.0287	0.17	0.17	Neuroticism;	chr8:11936935	chr8:12362019~12388296:+
HNSC	cis	rs8091660	0.624	rs1028010	ENSG00000278983.1	RP11-426J5.3	3.7	0.000239	0.0287	0.24	0.17	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48559459	chr18:48564795~48568342:+
HNSC	cis	rs79220007	0.557	rs1321247	ENSG00000272462.2	U91328.19	-3.7	0.000239	0.0287	-0.31	-0.17	Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr6:25662645	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.599	rs202906	ENSG00000204709.4	LINC01556	-3.7	0.000239	0.0287	-0.27	-0.17	Depression;	chr6:28043874	chr6:28943877~28944537:+
HNSC	cis	rs6601327	0.736	rs4840426	ENSG00000233609.3	RP11-62H7.2	3.7	0.000239	0.0287	0.16	0.17	Multiple myeloma (hyperdiploidy);	chr8:9551468	chr8:8961200~8979025:+
HNSC	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	3.7	0.000239	0.0287	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
HNSC	cis	rs11711311	0.955	rs9851812	ENSG00000241529.3	RN7SL767P	-3.7	0.000239	0.0287	-0.22	-0.17	IgG glycosylation;	chr3:113693515	chr3:113632704~113632998:+
HNSC	cis	rs4704187	0.663	rs7735057	ENSG00000271815.1	CTD-2235C13.3	-3.7	0.000239	0.0287	-0.21	-0.17	Response to amphetamines;	chr5:75108032	chr5:75363760~75364242:+
HNSC	cis	rs875971	1	rs937495	ENSG00000272831.1	RP11-792A8.4	-3.7	0.000239	0.0287	-0.15	-0.17	Aortic root size;	chr7:66314811	chr7:66739829~66740385:-
HNSC	cis	rs875971	1	rs2036264	ENSG00000272831.1	RP11-792A8.4	-3.7	0.000239	0.0287	-0.15	-0.17	Aortic root size;	chr7:66334917	chr7:66739829~66740385:-
HNSC	cis	rs875971	1	rs7783613	ENSG00000272831.1	RP11-792A8.4	-3.7	0.000239	0.0287	-0.15	-0.17	Aortic root size;	chr7:66340274	chr7:66739829~66740385:-
HNSC	cis	rs1150668	0.768	rs1150716	ENSG00000217862.2	HIST1H4PS1	-3.7	0.000239	0.0287	-0.17	-0.17	Pubertal anthropometrics;	chr6:28294921	chr6:27807075~27807339:+
HNSC	cis	rs950169	1	rs1848093	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000239	0.0287	-0.18	-0.17	Schizophrenia;	chr15:84086775	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs12915234	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000239	0.0287	-0.18	-0.17	Schizophrenia;	chr15:84089549	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs34751999	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000239	0.0287	-0.18	-0.17	Schizophrenia;	chr15:84089667	chr15:84507885~84516814:-
HNSC	cis	rs16846053	0.515	rs1567981	ENSG00000227403.1	AC009299.3	-3.7	0.000239	0.0287	-0.31	-0.17	Blood osmolality (transformed sodium);	chr2:161692589	chr2:161244739~161249050:+
HNSC	cis	rs453301	0.658	rs6983877	ENSG00000253981.4	ALG1L13P	-3.7	0.000239	0.0287	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9047129	chr8:8236003~8244667:-
HNSC	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-3.7	0.000239	0.0287	-0.18	-0.17	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
HNSC	cis	rs17507216	0.628	rs4627310	ENSG00000252690.3	SCARNA15	3.7	0.000239	0.0287	0.17	0.17	Excessive daytime sleepiness;	chr15:82708330	chr15:82752884~82757208:+
HNSC	cis	rs12664251	0.666	rs1889561	ENSG00000253194.1	RP11-351A11.1	-3.7	0.000239	0.0287	-0.2	-0.17	Schizophrenia;	chr6:119014700	chr6:118934785~119031541:+
HNSC	cis	rs1832007	0.529	rs4880716	ENSG00000224034.1	RP11-445P17.8	3.7	0.000239	0.0287	0.2	0.17	Triglyceride levels;Triglycerides;	chr10:5196233	chr10:5266033~5271236:-
HNSC	cis	rs1440410	0.748	rs4690774	ENSG00000250326.1	RP11-284M14.1	-3.7	0.000239	0.0287	-0.2	-0.17	Ischemic stroke;	chr4:143164174	chr4:142933195~143184861:-
HNSC	cis	rs7720894	1	rs10939902	ENSG00000215032.2	GNL3LP1	-3.7	0.000239	0.0287	-0.19	-0.17	Body mass index;	chr5:61432163	chr5:60891935~60893577:-
HNSC	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	3.7	0.000239	0.0287	0.19	0.17	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
HNSC	cis	rs7824557	0.564	rs2736290	ENSG00000255310.2	AF131215.2	-3.7	0.000239	0.0287	-0.16	-0.17	Retinal vascular caliber;	chr8:11376789	chr8:11107788~11109726:-
HNSC	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-3.7	0.000239	0.0287	-0.27	-0.17	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
HNSC	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-3.7	0.000239	0.0287	-0.27	-0.17	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
HNSC	cis	rs6496044	1	rs6496044	ENSG00000259407.1	RP11-158M2.3	-3.7	0.000239	0.0287	-0.19	-0.17	Interstitial lung disease;	chr15:85524075	chr15:85744109~85750281:-
HNSC	cis	rs859767	1	rs842361	ENSG00000224043.6	CCNT2-AS1	-3.7	0.000239	0.0287	-0.2	-0.17	Neuroticism;	chr2:134583270	chr2:134735464~134918710:-
HNSC	cis	rs9611565	0.649	rs2413659	ENSG00000233903.2	Z83851.4	3.7	0.000239	0.0287	0.23	0.17	Vitiligo;	chr22:41768858	chr22:42276355~42277052:+
HNSC	cis	rs11250098	0.548	rs7843470	ENSG00000269918.1	AF131215.9	-3.7	0.000239	0.0287	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10926982	chr8:11104691~11106704:-
HNSC	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	3.7	0.000239	0.0287	0.21	0.17	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
HNSC	cis	rs2836974	0.644	rs9978775	ENSG00000255568.3	BRWD1-AS2	-3.7	0.000239	0.0287	-0.15	-0.17	Cognitive function;	chr21:39322600	chr21:39313935~39314962:+
HNSC	cis	rs989128	0.6	rs9913430	ENSG00000250286.1	RP11-94C24.8	-3.7	0.000239	0.0287	-0.18	-0.17	Type 2 diabetes;	chr17:50551109	chr17:50537294~50538754:-
HNSC	cis	rs67311347	1	rs4973878	ENSG00000280739.1	EIF1B-AS1	3.7	0.000239	0.0287	0.18	0.17	Renal cell carcinoma;	chr3:40366074	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs4246666	ENSG00000280739.1	EIF1B-AS1	3.7	0.000239	0.0287	0.18	0.17	Renal cell carcinoma;	chr3:40366179	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs2887995	ENSG00000280739.1	EIF1B-AS1	3.7	0.000239	0.0287	0.18	0.17	Renal cell carcinoma;	chr3:40367538	chr3:40173145~40309698:-
HNSC	cis	rs11951515	0.663	rs6451684	ENSG00000249286.1	CTD-2210P15.2	-3.7	0.00024	0.0287	-0.18	-0.17	Metabolite levels  (X-11787);	chr5:43319545	chr5:43586918~43588223:-
HNSC	cis	rs540254	0.504	rs11265492	ENSG00000244682.6	FCGR2C	3.7	0.00024	0.0287	0.17	0.17	Blood protein levels;	chr1:160829484	chr1:161581339~161605662:+
HNSC	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	3.7	0.00024	0.0287	0.24	0.17	Pain;	chr19:21331762	chr19:21554640~21569237:-
HNSC	cis	rs7107174	1	rs1017908	ENSG00000251323.2	RP11-452H21.4	3.7	0.00024	0.0287	0.25	0.17	Testicular germ cell tumor;	chr11:78237049	chr11:78423982~78429836:-
HNSC	cis	rs929354	1	rs1182452	ENSG00000224629.1	RP5-1142J19.2	3.7	0.00024	0.0288	0.17	0.17	Body mass index;	chr7:157260924	chr7:157263022~157263229:-
HNSC	cis	rs1519814	0.696	rs7012522	ENSG00000254343.2	RP11-760H22.2	-3.7	0.00024	0.0288	-0.22	-0.17	Breast cancer;	chr8:120025805	chr8:120052180~120056201:+
HNSC	cis	rs1519814	0.702	rs7846263	ENSG00000254343.2	RP11-760H22.2	-3.7	0.00024	0.0288	-0.22	-0.17	Breast cancer;	chr8:120026797	chr8:120052180~120056201:+
HNSC	cis	rs12370275	0.58	rs1033232	ENSG00000257528.1	KRT8P19	-3.7	0.00024	0.0288	-0.22	-0.17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61353594	chr12:61879318~61880772:+
HNSC	cis	rs3736485	0.932	rs2278989	ENSG00000274528.1	CTD-2650P22.2	3.7	0.00024	0.0288	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51622519	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.932	rs10519313	ENSG00000274528.1	CTD-2650P22.2	3.7	0.00024	0.0288	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51623615	chr15:52017167~52018032:-
HNSC	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	3.7	0.00024	0.0288	0.15	0.17	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	3.7	0.00024	0.0288	0.15	0.17	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
HNSC	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	3.7	0.00024	0.0288	0.15	0.17	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
HNSC	cis	rs17253792	0.915	rs28537145	ENSG00000186615.9	KTN1-AS1	-3.7	0.00024	0.0288	-0.34	-0.17	Putamen volume;	chr14:55712401	chr14:55499278~55580110:-
HNSC	cis	rs28573326	0.886	rs17624977	ENSG00000121089.4	NACA3P	-3.7	0.00024	0.0288	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165410983	chr4:164943290~164943937:+
HNSC	cis	rs10073892	0.591	rs1349589	ENSG00000250682.4	LINC00491	-3.7	0.00024	0.0288	-0.23	-0.17	Cognitive decline (age-related);	chr5:102311770	chr5:102609156~102671559:-
HNSC	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00024	0.0288	-0.22	-0.17	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
HNSC	cis	rs74997117	1	rs2581849	ENSG00000214106.6	PAXIP1-AS2	-3.7	0.00024	0.0288	-0.3	-0.17	Sulfasalazine-induced agranulocytosis;	chr7:155049862	chr7:154928498~154949908:+
HNSC	cis	rs7614311	0.594	rs2280162	ENSG00000271843.1	RP11-245J9.5	-3.7	0.00024	0.0288	-0.25	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:64011815	chr3:64008082~64008692:-
HNSC	cis	rs10789207	0.501	rs13376692	ENSG00000248458.2	RP4-598P13.1	-3.7	0.00024	0.0288	-0.26	-0.17	Resting heart rate;	chr1:66650360	chr1:66665864~66677027:-
HNSC	cis	rs1440410	0.835	rs7685075	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143133546	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10155324	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143135820	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs6537150	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143146716	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs4337690	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143148408	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs13139558	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143149410	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10011709	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143159347	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10015190	ENSG00000250326.1	RP11-284M14.1	-3.7	0.00024	0.0288	-0.19	-0.17	Ischemic stroke;	chr4:143160595	chr4:142933195~143184861:-
HNSC	cis	rs10875943	0.751	rs11168962	ENSG00000258017.1	RP11-386G11.10	-3.7	0.00024	0.0288	-0.22	-0.17	Prostate cancer;	chr12:49278956	chr12:49127782~49147869:+
HNSC	cis	rs75968099	0.731	rs55690320	ENSG00000236411.1	NDUFAF4P3	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:36880738	chr3:37789921~37790445:-
HNSC	cis	rs913655	0.785	rs2451510	ENSG00000225527.1	RP11-383B4.4	-3.7	0.00024	0.0288	-0.23	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18773293	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.785	rs2451511	ENSG00000225527.1	RP11-383B4.4	-3.7	0.00024	0.0288	-0.23	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18774489	chr10:18531849~18533336:-
HNSC	cis	rs913655	0.752	rs2493621	ENSG00000225527.1	RP11-383B4.4	-3.7	0.00024	0.0288	-0.23	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18777236	chr10:18531849~18533336:-
HNSC	cis	rs6723108	0.678	rs512375	ENSG00000224043.6	CCNT2-AS1	-3.7	0.00024	0.0288	-0.21	-0.17	Type 2 diabetes;	chr2:134527708	chr2:134735464~134918710:-
HNSC	cis	rs7302981	0.899	rs1862043	ENSG00000272368.2	RP4-605O3.4	-3.7	0.00024	0.0288	-0.18	-0.17	Systolic blood pressure;	chr12:50182533	chr12:50112197~50165618:+
HNSC	cis	rs889398	0.617	rs4985450	ENSG00000196696.11	PDXDC2P	3.7	0.00024	0.0288	0.12	0.17	Body mass index;	chr16:69867203	chr16:69976297~70065948:-
HNSC	cis	rs6921919	0.583	rs1054372	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs9468354	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs7773051	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs12697938	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs13437294	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.609	rs9468357	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs34513104	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs9461456	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.525	rs9468360	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs16894021	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs11751693	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs7749736	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.525	rs9468361	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs7775132	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs3734563	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs1591913	ENSG00000227214.2	HCG15	3.7	0.00024	0.0288	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28986203~28987484:+
HNSC	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	3.7	0.00024	0.0288	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
HNSC	cis	rs10504130	0.569	rs12681734	ENSG00000253844.1	RP11-546K22.1	-3.7	0.00024	0.0288	-0.24	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51961458~52022974:+
HNSC	cis	rs7267979	0.789	rs6050472	ENSG00000204556.4	CTD-2514C3.1	-3.7	0.00024	0.0288	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:26018832~26020684:+
HNSC	cis	rs870825	0.616	rs7660064	ENSG00000254233.1	RP11-242J7.1	3.7	0.00024	0.0288	0.25	0.17	Blood protein levels;	chr4:184696375	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.549	rs28542773	ENSG00000254233.1	RP11-242J7.1	3.7	0.00024	0.0288	0.25	0.17	Blood protein levels;	chr4:184696781	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28416641	ENSG00000254233.1	RP11-242J7.1	3.7	0.00024	0.0288	0.25	0.17	Blood protein levels;	chr4:184696845	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7683615	ENSG00000254233.1	RP11-242J7.1	3.7	0.00024	0.0288	0.25	0.17	Blood protein levels;	chr4:184697219	chr4:184584093~184625030:-
HNSC	cis	rs6493858	0.818	rs1477590	ENSG00000277245.1	RP11-48G14.3	-3.7	0.00024	0.0288	-0.19	-0.17	Relative hand skill in reading disability;	chr15:56453107	chr15:56447120~56447697:+
HNSC	cis	rs58873874	0.579	rs3815829	ENSG00000251405.2	CTB-109A12.1	3.7	0.00024	0.0288	0.33	0.17	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157362615~157460078:-
HNSC	cis	rs11633886	0.677	rs11633202	ENSG00000273972.1	CTD-2306A12.1	-3.7	0.00024	0.0288	-0.2	-0.17	Diisocyanate-induced asthma;	chr15:45760722	chr15:45702640~45703183:+
HNSC	cis	rs11711311	1	rs9826808	ENSG00000241529.3	RN7SL767P	-3.7	0.00024	0.0288	-0.22	-0.17	IgG glycosylation;	chr3:113736797	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9830978	ENSG00000241529.3	RN7SL767P	-3.7	0.00024	0.0288	-0.22	-0.17	IgG glycosylation;	chr3:113737093	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs9879760	ENSG00000241529.3	RN7SL767P	-3.7	0.00024	0.0288	-0.22	-0.17	IgG glycosylation;	chr3:113739101	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs34475696	ENSG00000241529.3	RN7SL767P	-3.7	0.00024	0.0288	-0.22	-0.17	IgG glycosylation;	chr3:113739446	chr3:113632704~113632998:+
HNSC	cis	rs6928977	0.863	rs2614277	ENSG00000217482.2	HMGB1P17	-3.7	0.00024	0.0288	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135333856	chr6:135636086~135636713:-
HNSC	cis	rs2836974	0.836	rs1041440	ENSG00000255568.3	BRWD1-AS2	3.7	0.00024	0.0288	0.15	0.17	Cognitive function;	chr21:39255399	chr21:39313935~39314962:+
HNSC	cis	rs8077577	0.731	rs11869952	ENSG00000273018.4	CTD-2303H24.2	-3.7	0.00024	0.0288	-0.24	-0.17	Obesity-related traits;	chr17:18318399	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.689	rs16961133	ENSG00000273018.4	CTD-2303H24.2	-3.7	0.00024	0.0288	-0.24	-0.17	Obesity-related traits;	chr17:18320234	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.747	rs57697650	ENSG00000273018.4	CTD-2303H24.2	-3.7	0.00024	0.0288	-0.24	-0.17	Obesity-related traits;	chr17:18321381	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.747	rs62072540	ENSG00000273018.4	CTD-2303H24.2	-3.7	0.00024	0.0288	-0.24	-0.17	Obesity-related traits;	chr17:18321914	chr17:18511221~18551705:-
HNSC	cis	rs10927875	0.518	rs732286	ENSG00000226029.1	RP4-798A10.2	-3.7	0.00024	0.0288	-0.16	-0.17	Dilated cardiomyopathy;	chr1:16017865	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.518	rs945416	ENSG00000226029.1	RP4-798A10.2	-3.7	0.00024	0.0288	-0.16	-0.17	Dilated cardiomyopathy;	chr1:16017907	chr1:16460948~16468481:+
HNSC	cis	rs614226	1	rs7174	ENSG00000202538.1	RNU4-2	-3.7	0.000241	0.0288	-0.29	-0.17	Type 1 diabetes nephropathy;	chr12:120579368	chr12:120291763~120291903:-
HNSC	cis	rs17253792	0.687	rs10137995	ENSG00000186615.9	KTN1-AS1	-3.7	0.000241	0.0288	-0.27	-0.17	Putamen volume;	chr14:55706969	chr14:55499278~55580110:-
HNSC	cis	rs4924935	0.851	rs12936834	ENSG00000264885.1	RP11-815I9.4	-3.7	0.000241	0.0288	-0.2	-0.17	Pancreatic cancer;	chr17:18903765	chr17:18667629~18669461:-
HNSC	cis	rs9914988	0.943	rs7224870	ENSG00000264577.1	AC010761.8	3.7	0.000241	0.0288	0.14	0.17	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28775602	chr17:28721487~28722877:-
HNSC	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	3.7	0.000241	0.0288	0.2	0.17	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
HNSC	cis	rs801193	1	rs13239306	ENSG00000273142.1	RP11-458F8.4	3.7	0.000241	0.0288	0.15	0.17	Aortic root size;	chr7:66671030	chr7:66902857~66906297:+
HNSC	cis	rs9583531	0.6	rs754599	ENSG00000259831.1	LINC00567	3.7	0.000241	0.0288	0.19	0.17	Coronary artery disease;	chr13:110702441	chr13:110809676~110813084:-
HNSC	cis	rs1443512	0.812	rs1867299	ENSG00000249641.2	HOXC13-AS	-3.7	0.000241	0.0288	-0.19	-0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53936191	chr12:53935328~53939643:-
HNSC	cis	rs9329221	0.662	rs34155841	ENSG00000255310.2	AF131215.2	3.7	0.000241	0.0288	0.17	0.17	Neuroticism;	chr8:10390019	chr8:11107788~11109726:-
HNSC	cis	rs7712401	0.511	rs30068	ENSG00000250539.1	KRT8P33	-3.7	0.000241	0.0288	-0.19	-0.17	Mean platelet volume;	chr5:122957914	chr5:123400922~123402344:-
HNSC	cis	rs546131	0.642	rs61881103	ENSG00000271369.1	RP11-350D17.3	-3.7	0.000241	0.0288	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34816717	chr11:34709600~34710161:+
HNSC	cis	rs6493858	0.837	rs2718934	ENSG00000277245.1	RP11-48G14.3	-3.7	0.000241	0.0288	-0.18	-0.17	Relative hand skill in reading disability;	chr15:56265220	chr15:56447120~56447697:+
HNSC	cis	rs1620921	0.598	rs12176297	ENSG00000231863.1	RP3-428L16.1	-3.7	0.000241	0.0289	-0.2	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160845385	chr6:160931080~160969771:+
HNSC	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-3.7	0.000241	0.0289	-0.21	-0.17	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
HNSC	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000241	0.0289	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000241	0.0289	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
HNSC	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000241	0.0289	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
HNSC	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000241	0.0289	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
HNSC	cis	rs34286592	0.929	rs8058824	ENSG00000214725.6	CDIPT-AS1	-3.7	0.000241	0.0289	-0.24	-0.17	Multiple sclerosis;	chr16:29817389	chr16:29863593~29868053:+
HNSC	cis	rs34286592	0.929	rs35901559	ENSG00000214725.6	CDIPT-AS1	-3.7	0.000241	0.0289	-0.24	-0.17	Multiple sclerosis;	chr16:29818294	chr16:29863593~29868053:+
HNSC	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	3.7	0.000241	0.0289	0.24	0.17	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
HNSC	cis	rs6493858	0.809	rs12911427	ENSG00000277245.1	RP11-48G14.3	-3.7	0.000241	0.0289	-0.2	-0.17	Relative hand skill in reading disability;	chr15:56165626	chr15:56447120~56447697:+
HNSC	cis	rs8014204	0.604	rs2159906	ENSG00000259138.1	RP11-950C14.7	3.7	0.000241	0.0289	0.19	0.17	Caffeine consumption;	chr14:74924209	chr14:75127153~75136930:+
HNSC	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	3.7	0.000241	0.0289	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	3.7	0.000241	0.0289	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	3.7	0.000241	0.0289	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
HNSC	cis	rs16852403	0.585	rs2815288	ENSG00000273062.1	RP11-428K3.1	-3.7	0.000241	0.0289	-0.19	-0.17	Childhood ear infection;	chr1:178250651	chr1:178724306~178726285:-
HNSC	cis	rs67311347	0.544	rs12633295	ENSG00000280739.1	EIF1B-AS1	-3.7	0.000241	0.0289	-0.17	-0.17	Renal cell carcinoma;	chr3:40293801	chr3:40173145~40309698:-
HNSC	cis	rs1659258	0.568	rs1258409	ENSG00000232508.1	MRPL45P1	3.7	0.000241	0.0289	0.29	0.17	Visceral fat;	chr2:88319719	chr2:88364695~88365608:-
HNSC	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	3.7	0.000241	0.0289	0.19	0.17	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
HNSC	cis	rs9829778	0.791	rs6583177	ENSG00000272359.1	U4	3.7	0.000241	0.0289	0.19	0.17	Sum eosinophil basophil counts;	chr3:196822871	chr3:196747192~196747324:-
HNSC	cis	rs4578769	0.55	rs11082225	ENSG00000265943.1	RP11-739L10.1	3.7	0.000241	0.0289	0.2	0.17	Eosinophil percentage of white cells;	chr18:22963794	chr18:22699481~22933764:-
HNSC	cis	rs859767	0.741	rs1104802	ENSG00000224043.6	CCNT2-AS1	3.7	0.000241	0.0289	0.2	0.17	Neuroticism;	chr2:134678796	chr2:134735464~134918710:-
HNSC	cis	rs3176789	0.914	rs10844750	ENSG00000256673.1	RP11-599J14.2	3.7	0.000241	0.0289	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774279	chr12:9398355~9414851:-
HNSC	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-3.7	0.000241	0.0289	-0.23	-0.17	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
HNSC	cis	rs2554380	0.628	rs7177929	ENSG00000259570.1	RP11-671M22.4	3.7	0.000241	0.0289	0.21	0.17	Height;	chr15:83809927	chr15:84394512~84395514:+
HNSC	cis	rs2562456	0.833	rs11666447	ENSG00000268119.4	CTD-2561J22.5	3.7	0.000241	0.0289	0.26	0.17	Pain;	chr19:21416270	chr19:21444241~21463908:-
HNSC	cis	rs7178375	1	rs12907055	ENSG00000215302.7	CTD-3092A11.1	-3.7	0.000241	0.0289	-0.26	-0.17	Hypertriglyceridemia;	chr15:30912091	chr15:30470779~30507623:+
HNSC	cis	rs793571	0.822	rs694918	ENSG00000245975.2	RP11-30K9.6	3.7	0.000241	0.0289	0.28	0.17	Schizophrenia;	chr15:58863941	chr15:58768072~58770974:-
HNSC	cis	rs597480	0.963	rs290195	ENSG00000279742.1	RP11-700A24.1	-3.7	0.000241	0.0289	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85721377	chr11:85852557~85854943:-
HNSC	cis	rs11168618	0.875	rs11458	ENSG00000240399.1	RP1-228P16.1	3.7	0.000241	0.0289	0.14	0.17	Adiponectin levels;	chr12:48494811	chr12:48054813~48055591:-
HNSC	cis	rs2505998	0.833	rs1864402	ENSG00000273008.1	RP11-351D16.3	-3.7	0.000241	0.0289	-0.21	-0.17	Hirschsprung disease;	chr10:43110412	chr10:43136824~43138334:-
HNSC	cis	rs2518049	0.51	rs1781938	ENSG00000224034.1	RP11-445P17.8	3.7	0.000241	0.0289	0.18	0.17	Metabolic traits;	chr10:5159246	chr10:5266033~5271236:-
HNSC	cis	rs919433	0.75	rs788012	ENSG00000231621.1	AC013264.2	-3.7	0.000241	0.0289	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197365132	chr2:197197991~197199273:+
HNSC	cis	rs6921919	0.562	rs13198809	ENSG00000226314.6	ZNF192P1	-3.7	0.000242	0.0289	-0.32	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28161781~28169594:+
HNSC	cis	rs944002	0.951	rs7150997	ENSG00000259444.1	RP11-736N17.8	3.7	0.000242	0.0289	0.21	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103105537	chr14:103094723~103098885:+
HNSC	cis	rs72634501	0.517	rs10788925	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000242	0.0289	-0.17	-0.17	HDL cholesterol;	chr1:39128430	chr1:39522280~39546187:-
HNSC	cis	rs2554380	0.55	rs62025822	ENSG00000259570.1	RP11-671M22.4	-3.7	0.000242	0.0289	-0.22	-0.17	Height;	chr15:83870162	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.55	rs56159777	ENSG00000259570.1	RP11-671M22.4	-3.7	0.000242	0.0289	-0.22	-0.17	Height;	chr15:83870527	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.55	rs4842919	ENSG00000259570.1	RP11-671M22.4	-3.7	0.000242	0.0289	-0.22	-0.17	Height;	chr15:83870668	chr15:84394512~84395514:+
HNSC	cis	rs4073405	0.691	rs7123765	ENSG00000254651.1	RP11-430H10.3	3.7	0.000242	0.0289	0.21	0.17	Schizophrenia;	chr11:45267842	chr11:45399448~45400528:+
HNSC	cis	rs7781557	0.64	rs73192025	ENSG00000239969.4	RP11-163E9.2	-3.7	0.000242	0.0289	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102951042	chr7:102364162~102380633:+
HNSC	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	3.7	0.000242	0.0289	0.19	0.17	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
HNSC	cis	rs7005380	0.62	rs13282901	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.0289	-0.14	-0.17	Interstitial lung disease;	chr8:119881561	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13260088	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.0289	-0.14	-0.17	Interstitial lung disease;	chr8:119886525	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs10955940	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.0289	-0.14	-0.17	Interstitial lung disease;	chr8:119890246	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10103058	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.0289	-0.14	-0.17	Interstitial lung disease;	chr8:119890830	chr8:119838736~119840385:-
HNSC	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	3.7	0.000242	0.0289	0.29	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
HNSC	cis	rs11711311	1	rs9851731	ENSG00000241529.3	RN7SL767P	3.7	0.000242	0.029	0.21	0.17	IgG glycosylation;	chr3:113783804	chr3:113632704~113632998:+
HNSC	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-3.7	0.000242	0.029	-0.15	-0.17	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
HNSC	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-3.7	0.000242	0.029	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
HNSC	cis	rs478304	0.651	rs11604462	ENSG00000255120.4	OVOL1-AS1	-3.7	0.000242	0.029	-0.18	-0.17	Acne (severe);	chr11:65784177	chr11:65789051~65790868:-
HNSC	cis	rs7267979	0.727	rs4815431	ENSG00000231081.1	RP4-760C5.3	3.7	0.000242	0.029	0.17	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26008791~26010531:-
HNSC	cis	rs10090774	0.87	rs6994744	ENSG00000279766.1	RP11-642A1.2	3.7	0.000242	0.029	0.17	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730769	chr8:140572142~140572812:-
HNSC	cis	rs9650657	0.707	rs7814757	ENSG00000255310.2	AF131215.2	-3.7	0.000242	0.029	-0.16	-0.17	Neuroticism;	chr8:10817678	chr8:11107788~11109726:-
HNSC	cis	rs1275468	1	rs1148004	ENSG00000257497.2	RP11-585P4.5	-3.7	0.000242	0.029	-0.25	-0.17	Polycystic ovary syndrome;	chr12:75584897	chr12:75483454~75489820:-
HNSC	cis	rs13434995	0.787	rs62303724	ENSG00000273257.1	RP11-177J6.1	-3.7	0.000242	0.029	-0.28	-0.17	Adiponectin levels;	chr4:55485114	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.842	rs62305269	ENSG00000273257.1	RP11-177J6.1	-3.7	0.000242	0.029	-0.28	-0.17	Adiponectin levels;	chr4:55507237	chr4:55387949~55388271:+
HNSC	cis	rs13434995	0.842	rs73236149	ENSG00000273257.1	RP11-177J6.1	-3.7	0.000242	0.029	-0.28	-0.17	Adiponectin levels;	chr4:55507307	chr4:55387949~55388271:+
HNSC	cis	rs4900538	0.928	rs1190551	ENSG00000272533.1	SNORA28	3.7	0.000242	0.029	0.18	0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102445171	chr14:103337849~103337974:+
HNSC	cis	rs561341	1	rs693116	ENSG00000278867.1	RP11-640N20.4	-3.7	0.000242	0.029	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31919105	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs55959993	ENSG00000278867.1	RP11-640N20.4	-3.7	0.000242	0.029	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31927752	chr17:32051030~32053208:+
HNSC	cis	rs2919009	0.62	rs17501806	ENSG00000271670.1	RP11-95I16.4	3.7	0.000242	0.029	0.2	0.17	Obesity-related traits;	chr10:120868905	chr10:120879256~120880667:-
HNSC	cis	rs7189233	0.531	rs8055279	ENSG00000261056.2	RP11-454F8.2	-3.7	0.000242	0.029	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53298224~53299792:+
HNSC	cis	rs73198271	1	rs11775821	ENSG00000253893.2	FAM85B	3.7	0.000242	0.029	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8167819~8226614:-
HNSC	cis	rs5770917	1	rs3213445	ENSG00000272821.1	CTA-384D8.36	-3.7	0.000242	0.029	-0.27	-0.17	Narcolepsy;	chr22:50577409	chr22:50523926~50524780:+
HNSC	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-3.7	0.000242	0.029	-0.17	-0.17	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
HNSC	cis	rs546131	0.642	rs10501136	ENSG00000271369.1	RP11-350D17.3	3.7	0.000242	0.029	0.23	0.17	Lung disease severity in cystic fibrosis;	chr11:34824969	chr11:34709600~34710161:+
HNSC	cis	rs2836974	0.568	rs11910906	ENSG00000255568.3	BRWD1-AS2	-3.7	0.000242	0.029	-0.14	-0.17	Cognitive function;	chr21:39313736	chr21:39313935~39314962:+
HNSC	cis	rs11951515	0.738	rs59814709	ENSG00000249286.1	CTD-2210P15.2	3.7	0.000242	0.029	0.18	0.17	Metabolite levels  (X-11787);	chr5:43359992	chr5:43586918~43588223:-
HNSC	cis	rs1990950	0.933	rs11747685	ENSG00000251405.2	CTB-109A12.1	-3.7	0.000242	0.029	-0.19	-0.17	Lung function (FEV1/FVC);	chr5:157476582	chr5:157362615~157460078:-
HNSC	cis	rs61629263	0.503	rs60210170	ENSG00000260793.2	RP5-882C2.2	3.7	0.000242	0.029	0.15	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43741772	chr17:44221401~44223710:+
HNSC	cis	rs516805	0.667	rs9490411	ENSG00000279453.1	RP3-425C14.4	3.7	0.000242	0.029	0.24	0.17	Lymphocyte counts;	chr6:122217270	chr6:122436789~122439223:-
HNSC	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	3.7	0.000242	0.029	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	3.7	0.000242	0.029	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
HNSC	cis	rs8091660	0.624	rs2175565	ENSG00000278983.1	RP11-426J5.3	-3.7	0.000242	0.029	-0.24	-0.17	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48553481	chr18:48564795~48568342:+
HNSC	cis	rs2310173	0.575	rs2071008	ENSG00000281162.1	LINC01127	-3.7	0.000242	0.029	-0.22	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101998817	chr2:101962056~101987167:+
HNSC	cis	rs7829975	0.714	rs59046059	ENSG00000233609.3	RP11-62H7.2	3.7	0.000242	0.029	0.16	0.17	Mood instability;	chr8:8813226	chr8:8961200~8979025:+
HNSC	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-3.7	0.000242	0.029	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
HNSC	cis	rs860295	0.627	rs11264410	ENSG00000225855.5	RUSC1-AS1	3.7	0.000242	0.029	0.12	0.17	Body mass index;	chr1:155775558	chr1:155316863~155324176:-
HNSC	cis	rs10143078	1	rs60005479	ENSG00000258689.1	LINC01269	3.7	0.000242	0.029	0.34	0.17	Blood pressure;	chr14:70493201	chr14:70698698~70712153:+
HNSC	cis	rs67311347	1	rs28434528	ENSG00000280739.1	EIF1B-AS1	3.7	0.000242	0.029	0.18	0.17	Renal cell carcinoma;	chr3:40443402	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs11716675	ENSG00000280739.1	EIF1B-AS1	3.7	0.000242	0.029	0.18	0.17	Renal cell carcinoma;	chr3:40443789	chr3:40173145~40309698:-
HNSC	cis	rs11951515	0.714	rs10512828	ENSG00000249286.1	CTD-2210P15.2	3.7	0.000242	0.029	0.18	0.17	Metabolite levels  (X-11787);	chr5:43368188	chr5:43586918~43588223:-
HNSC	cis	rs7005380	0.62	rs10955941	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891271	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.6	rs13257316	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891494	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.58	rs12681623	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891616	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs13265367	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891769	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10107251	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892108	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10094455	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892436	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10094458	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892448	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.62	rs10094587	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000242	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892560	chr8:119838736~119840385:-
HNSC	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-3.7	0.000242	0.029	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
HNSC	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	3.7	0.000242	0.029	0.21	0.17	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
HNSC	cis	rs9467711	0.606	rs1977	ENSG00000241549.7	GUSBP2	3.7	0.000243	0.029	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377318	chr6:26871484~26956554:-
HNSC	cis	rs116095464	0.51	rs7714944	ENSG00000277812.1	AC021087.1	3.7	0.000243	0.029	0.28	0.17	Breast cancer;	chr5:231650	chr5:262769~262881:+
HNSC	cis	rs3018712	0.532	rs2513289	ENSG00000212093.1	AP000807.1	-3.7	0.000243	0.029	-0.25	-0.17	Total body bone mineral density;	chr11:68652187	chr11:68506083~68506166:-
HNSC	cis	rs11651000	0.625	rs2074190	ENSG00000263412.1	RP5-890E16.2	3.7	0.000243	0.029	0.16	0.17	IgG glycosylation;	chr17:47733844	chr17:48045141~48048073:-
HNSC	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	3.7	0.000243	0.029	0.32	0.17	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
HNSC	cis	rs1028883	0.839	rs7338091	ENSG00000228295.1	LINC00392	-3.7	0.000243	0.029	-0.18	-0.17	Lean body mass;	chr13:73591287	chr13:73564244~73588070:+
HNSC	cis	rs8022179	0.566	rs959083	ENSG00000244691.1	RPL10AP1	-3.7	0.000243	0.029	-0.23	-0.17	Monocyte count;	chr14:103356350	chr14:103412119~103412761:-
HNSC	cis	rs11603691	1	rs117497302	ENSG00000254662.1	RP11-872D17.4	-3.7	0.000243	0.029	-0.36	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57242333	chr11:57325603~57327958:+
HNSC	cis	rs2439831	1	rs689754	ENSG00000275601.1	AC011330.13	-3.7	0.000243	0.029	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43483697	chr15:43642389~43643023:-
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000272831.1	RP11-792A8.4	3.7	0.000243	0.029	0.14	0.17	Aortic root size;	chr7:65967557	chr7:66739829~66740385:-
HNSC	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	3.7	0.000243	0.029	0.25	0.17	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
HNSC	cis	rs7868228	0.891	rs12342723	ENSG00000240498.5	CDKN2B-AS1	-3.7	0.000243	0.0291	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21670462	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.891	rs10124915	ENSG00000240498.5	CDKN2B-AS1	-3.7	0.000243	0.0291	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21670655	chr9:21994778~22121097:+
HNSC	cis	rs7868228	0.891	rs10124917	ENSG00000240498.5	CDKN2B-AS1	-3.7	0.000243	0.0291	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21670659	chr9:21994778~22121097:+
HNSC	cis	rs62025270	0.522	rs16943120	ENSG00000259762.1	RP11-158M2.4	-3.7	0.000243	0.0291	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85750336~85752901:-
HNSC	cis	rs481331	0.866	rs6593349	ENSG00000215146.4	RP11-313J2.1	3.7	0.000243	0.0291	0.28	0.17	Systemic juvenile idiopathic arthritis;	chr10:42489844	chr10:42331866~42367974:-
HNSC	cis	rs11603691	1	rs117981067	ENSG00000254662.1	RP11-872D17.4	-3.7	0.000243	0.0291	-0.35	-0.17	Low high density lipoprotein cholesterol levels;	chr11:57296638	chr11:57325603~57327958:+
HNSC	cis	rs12479254	0.701	rs6718026	ENSG00000273113.1	RP11-367H1.1	-3.7	0.000243	0.0291	-0.18	-0.17	Brain structure;	chr2:241555977	chr2:241581922~241582726:+
HNSC	cis	rs3733585	0.631	rs7699671	ENSG00000250413.1	RP11-448G15.1	3.7	0.000243	0.0291	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10124250	chr4:10006482~10009725:+
HNSC	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	3.7	0.000243	0.0291	0.17	0.17	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
HNSC	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	3.7	0.000243	0.0291	0.17	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	3.7	0.000243	0.0291	0.17	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
HNSC	cis	rs792448	0.743	rs11119904	ENSG00000226251.4	RP11-15I11.3	-3.7	0.000243	0.0291	-0.21	-0.17	White blood cell count (basophil);	chr1:212293262	chr1:212225278~212238977:-
HNSC	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	3.7	0.000243	0.0291	0.25	0.17	Pain;	chr19:21410849	chr19:21554640~21569237:-
HNSC	cis	rs11676676	1	rs6721559	ENSG00000204588.5	LINC01123	-3.7	0.000243	0.0291	-0.25	-0.17	Pediatric bone mineral density (spine);	chr2:109153451	chr2:109987063~109996140:+
HNSC	cis	rs1865760	0.593	rs3903852	ENSG00000272810.1	U91328.22	-3.7	0.000243	0.0291	-0.15	-0.17	Height;	chr6:25914919	chr6:26013241~26013757:+
HNSC	cis	rs10090774	0.769	rs56352956	ENSG00000279766.1	RP11-642A1.2	3.7	0.000243	0.0291	0.17	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730167	chr8:140572142~140572812:-
HNSC	cis	rs6095360	1	rs1885163	ENSG00000227431.4	CSE1L-AS1	-3.7	0.000243	0.0291	-0.21	-0.17	Intelligence (multi-trait analysis);	chr20:49085228	chr20:49040463~49046044:-
HNSC	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	3.7	0.000243	0.0291	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
HNSC	cis	rs300890	0.76	rs12643013	ENSG00000250326.1	RP11-284M14.1	-3.7	0.000243	0.0291	-0.19	-0.17	Nasopharyngeal carcinoma;	chr4:143285795	chr4:142933195~143184861:-
HNSC	cis	rs944002	0.857	rs77071436	ENSG00000259444.1	RP11-736N17.8	3.7	0.000243	0.0291	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102644	chr14:103094723~103098885:+
HNSC	cis	rs4700393	0.967	rs921897	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.51	rs10076679	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.527	rs10076742	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.527	rs6890201	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.51	rs6875456	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.51	rs6894750	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000243	0.0291	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60866457~60866935:-
HNSC	cis	rs11846409	0.872	rs2956482	ENSG00000280411.1	IGHV1-69-2	3.7	0.000243	0.0291	0.15	0.17	Rheumatic heart disease;	chr14:106630013	chr14:106762092~106762588:-
HNSC	cis	rs7615952	0.599	rs6803160	ENSG00000241278.1	ENPP7P4	-3.7	0.000243	0.0291	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125990711	chr3:125848223~125909372:+
HNSC	cis	rs2412819	0.571	rs4923964	ENSG00000166763.7	STRCP1	-3.7	0.000243	0.0291	-0.24	-0.17	Lung cancer;	chr15:43722882	chr15:43699488~43718184:-
HNSC	cis	rs62025270	0.547	rs386346	ENSG00000259295.5	CSPG4P12	-3.7	0.000243	0.0291	-0.22	-0.17	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85191438~85213905:+
HNSC	cis	rs7267979	0.789	rs6050472	ENSG00000231081.1	RP4-760C5.3	-3.7	0.000243	0.0291	-0.17	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:26008791~26010531:-
HNSC	cis	rs1009077	0.68	rs61747388	ENSG00000245958.5	RP11-33B1.1	3.7	0.000244	0.0291	0.18	0.17	Endometriosis;	chr4:119512860	chr4:119454791~119552025:+
HNSC	cis	rs11711311	0.747	rs7638378	ENSG00000241529.3	RN7SL767P	-3.7	0.000244	0.0291	-0.22	-0.17	IgG glycosylation;	chr3:113624783	chr3:113632704~113632998:+
HNSC	cis	rs853679	0.599	rs188015	ENSG00000219392.1	RP1-265C24.5	-3.7	0.000244	0.0291	-0.28	-0.17	Depression;	chr6:27909668	chr6:28115628~28116551:+
HNSC	cis	rs7005380	0.556	rs35362581	ENSG00000279347.1	RP11-85I17.2	3.7	0.000244	0.0291	0.17	0.17	Interstitial lung disease;	chr8:119921628	chr8:119838736~119840385:-
HNSC	cis	rs735129	1	rs735129	ENSG00000248846.2	CTD-2016O11.1	3.7	0.000244	0.0291	0.28	0.17	Colonoscopy-negative controls vs population controls;	chr5:66244501	chr5:66206212~66209447:-
HNSC	cis	rs34792	0.554	rs12929694	ENSG00000207425.1	Y_RNA	-3.7	0.000244	0.0291	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:14915457~14915556:-
HNSC	cis	rs7688540	0.771	rs11248009	ENSG00000211553.1	AC253576.2	-3.7	0.000244	0.0291	-0.26	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:136461~136568:+
HNSC	cis	rs12893668	0.638	rs11851616	ENSG00000269958.1	RP11-73M18.8	3.7	0.000244	0.0291	0.16	0.17	Reticulocyte count;	chr14:103599263	chr14:103696353~103697163:+
HNSC	cis	rs494453	0.922	rs486982	ENSG00000227811.2	FAM212B-AS1	-3.7	0.000244	0.0291	-0.2	-0.17	Osteoporosis-related phenotypes;	chr1:111710492	chr1:111739841~111747798:+
HNSC	cis	rs9926296	0.715	rs467035	ENSG00000274627.1	RP11-104N10.2	-3.7	0.000244	0.0291	-0.17	-0.17	Vitiligo;	chr16:89673877	chr16:89516797~89522217:+
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000272831.1	RP11-792A8.4	3.7	0.000244	0.0291	0.14	0.17	Aortic root size;	chr7:65930047	chr7:66739829~66740385:-
HNSC	cis	rs478304	0.651	rs11604451	ENSG00000255120.4	OVOL1-AS1	-3.7	0.000244	0.0291	-0.18	-0.17	Acne (severe);	chr11:65784239	chr11:65789051~65790868:-
HNSC	cis	rs1580019	0.922	rs1376289	ENSG00000226468.2	AC018641.7	3.7	0.000244	0.0291	0.24	0.17	Cognitive ability;	chr7:32447368	chr7:32456963~32457758:-
HNSC	cis	rs62025270	0.632	rs62022918	ENSG00000259762.1	RP11-158M2.4	-3.7	0.000244	0.0291	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85750336~85752901:-
HNSC	cis	rs56804039	1	rs6986470	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000244	0.0292	-0.22	-0.17	Cervical cancer;	chr8:8523920	chr8:8456909~8461337:-
HNSC	cis	rs12291225	0.679	rs11238	ENSG00000254418.1	RP11-21L19.1	-3.7	0.000244	0.0292	-0.2	-0.17	Sense of smell;	chr11:14266582	chr11:14262846~14273691:-
HNSC	cis	rs17253792	0.822	rs79483507	ENSG00000186615.9	KTN1-AS1	-3.7	0.000244	0.0292	-0.34	-0.17	Putamen volume;	chr14:55698000	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs76205307	ENSG00000186615.9	KTN1-AS1	-3.7	0.000244	0.0292	-0.34	-0.17	Putamen volume;	chr14:55699320	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs78615025	ENSG00000186615.9	KTN1-AS1	-3.7	0.000244	0.0292	-0.34	-0.17	Putamen volume;	chr14:55701294	chr14:55499278~55580110:-
HNSC	cis	rs17253792	0.822	rs79873916	ENSG00000186615.9	KTN1-AS1	-3.7	0.000244	0.0292	-0.34	-0.17	Putamen volume;	chr14:55705913	chr14:55499278~55580110:-
HNSC	cis	rs7824557	0.627	rs7838897	ENSG00000269918.1	AF131215.9	3.7	0.000244	0.0292	0.16	0.17	Retinal vascular caliber;	chr8:11349817	chr8:11104691~11106704:-
HNSC	cis	rs939574	0.512	rs10194278	ENSG00000243910.6	TUBA4B	3.7	0.000244	0.0292	0.26	0.17	Platelet distribution width;	chr2:219273686	chr2:219253243~219272188:+
HNSC	cis	rs3018712	0.532	rs2510399	ENSG00000212093.1	AP000807.1	-3.7	0.000244	0.0292	-0.25	-0.17	Total body bone mineral density;	chr11:68653990	chr11:68506083~68506166:-
HNSC	cis	rs4427176	0.507	rs4841212	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000244	0.0292	-0.23	-0.17	Mosquito bite size;	chr8:9743857	chr8:9141424~9145435:+
HNSC	cis	rs11773103	0.5	rs1636913	ENSG00000224046.1	AC005076.5	3.7	0.000244	0.0292	0.22	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87322760	chr7:87151423~87152420:-
HNSC	cis	rs7592578	0.599	rs62180992	ENSG00000228509.4	AC006460.2	3.7	0.000244	0.0292	0.25	0.17	Diastolic blood pressure;	chr2:190421006	chr2:190676944~190708716:-
HNSC	cis	rs2337406	1	rs11845269	ENSG00000211972.2	IGHV3-66	3.7	0.000244	0.0292	0.17	0.17	Alzheimer's disease (late onset);	chr14:106683851	chr14:106675017~106675544:-
HNSC	cis	rs4795519	0.614	rs2086266	ENSG00000265646.2	TUFMP1	-3.7	0.000244	0.0292	-0.21	-0.17	Chronic myeloid leukemia;	chr17:27153431	chr17:27082690~27084036:-
HNSC	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000244	0.0292	-0.24	-0.17	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
HNSC	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	3.7	0.000244	0.0292	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	3.7	0.000244	0.0292	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
HNSC	cis	rs12701220	0.568	rs7777700	ENSG00000224079.1	AC091729.7	3.7	0.000244	0.0292	0.25	0.17	Bronchopulmonary dysplasia;	chr7:963460	chr7:1074450~1078036:+
HNSC	cis	rs12893668	0.637	rs4525427	ENSG00000269910.1	RP11-73M18.10	3.7	0.000244	0.0292	0.16	0.17	Reticulocyte count;	chr14:103606456	chr14:103694516~103695050:-
HNSC	cis	rs10256972	0.758	rs4723649	ENSG00000225146.1	AC073957.15	3.7	0.000244	0.0292	0.2	0.17	Endometriosis;Longevity;	chr7:1032269	chr7:1029025~1043891:+
HNSC	cis	rs4378999	0.8	rs1996332	ENSG00000213587.3	RP11-646D13.1	-3.7	0.000244	0.0292	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51294957	chr3:50719482~50719951:-
HNSC	cis	rs4378999	0.748	rs1996331	ENSG00000213587.3	RP11-646D13.1	-3.7	0.000244	0.0292	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51295153	chr3:50719482~50719951:-
HNSC	cis	rs4378999	0.8	rs2219891	ENSG00000213587.3	RP11-646D13.1	-3.7	0.000244	0.0292	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51295635	chr3:50719482~50719951:-
HNSC	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-3.7	0.000244	0.0292	-0.25	-0.17	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
HNSC	cis	rs11098499	0.691	rs17009144	ENSG00000250412.1	KLHL2P1	-3.7	0.000244	0.0292	-0.21	-0.17	Corneal astigmatism;	chr4:119349640	chr4:119334329~119378233:+
HNSC	cis	rs28489187	0.66	rs3949301	ENSG00000223653.4	RP11-131L23.1	-3.7	0.000244	0.0292	-0.23	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85397700	chr1:85276715~85448124:+
HNSC	cis	rs3096299	0.967	rs2911253	ENSG00000261118.1	RP11-104N10.1	3.7	0.000244	0.0292	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89492017~89504460:-
HNSC	cis	rs1440410	0.798	rs11100772	ENSG00000250326.1	RP11-284M14.1	-3.7	0.000244	0.0292	-0.19	-0.17	Ischemic stroke;	chr4:143132935	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs11100773	ENSG00000250326.1	RP11-284M14.1	-3.7	0.000244	0.0292	-0.19	-0.17	Ischemic stroke;	chr4:143133075	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs7684430	ENSG00000250326.1	RP11-284M14.1	-3.7	0.000244	0.0292	-0.19	-0.17	Ischemic stroke;	chr4:143133191	chr4:142933195~143184861:-
HNSC	cis	rs1925953	0.683	rs12135857	ENSG00000233589.1	RP4-694A7.2	-3.7	0.000244	0.0292	-0.21	-0.17	Vertical cup-disc ratio;	chr1:68366116	chr1:68479129~68483539:+
HNSC	cis	rs7100689	0.826	rs7098414	ENSG00000226659.1	RP11-137H2.4	-3.7	0.000244	0.0292	-0.24	-0.17	Post bronchodilator FEV1;	chr10:80454830	chr10:80529597~80535942:-
HNSC	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-3.7	0.000244	0.0292	-0.17	-0.17	Height;	chr5:36848456	chr5:36666214~36725195:-
HNSC	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-3.7	0.000244	0.0292	-0.25	-0.17	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
HNSC	cis	rs330048	0.545	rs11249913	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000244	0.0292	-0.19	-0.17	Systemic lupus erythematosus;	chr8:9286011	chr8:8456909~8461337:-
HNSC	cis	rs9863	0.828	rs7135314	ENSG00000270028.1	RP11-380L11.4	3.7	0.000244	0.0292	0.2	0.17	White blood cell count;	chr12:123994019	chr12:123925461~123926083:-
HNSC	cis	rs5758659	0.714	rs5751216	ENSG00000182057.4	OGFRP1	-3.7	0.000244	0.0292	-0.17	-0.17	Cognitive function;	chr22:42112933	chr22:42269753~42275196:+
HNSC	cis	rs13178541	0.745	rs10900833	ENSG00000250378.1	RP11-119J18.1	-3.7	0.000245	0.0292	-0.22	-0.17	IgG glycosylation;	chr5:135765741	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs10900834	ENSG00000250378.1	RP11-119J18.1	-3.7	0.000245	0.0292	-0.22	-0.17	IgG glycosylation;	chr5:135765792	chr5:135812667~135826582:+
HNSC	cis	rs1881509	0.702	rs4963077	ENSG00000255153.1	TOLLIP-AS1	-3.7	0.000245	0.0292	-0.18	-0.17	Heroin dependence;	chr11:1402487	chr11:1309769~1310707:+
HNSC	cis	rs1881509	0.66	rs11025492	ENSG00000255153.1	TOLLIP-AS1	-3.7	0.000245	0.0292	-0.18	-0.17	Heroin dependence;	chr11:1403112	chr11:1309769~1310707:+
HNSC	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	3.7	0.000245	0.0292	0.2	0.17	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
HNSC	cis	rs224278	0.509	rs4147153	ENSG00000238280.1	RP11-436D10.3	3.7	0.000245	0.0292	0.24	0.17	Ewing sarcoma;	chr10:62959167	chr10:62793562~62805887:-
HNSC	cis	rs11992162	0.573	rs61468577	ENSG00000227888.4	FAM66A	-3.7	0.000245	0.0292	-0.17	-0.17	Monocyte count;	chr8:11927416	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.507	rs60902764	ENSG00000227888.4	FAM66A	-3.7	0.000245	0.0292	-0.17	-0.17	Monocyte count;	chr8:11927482	chr8:12362019~12388296:+
HNSC	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-3.7	0.000245	0.0292	-0.21	-0.17	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	3.7	0.000245	0.0292	0.34	0.17	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
HNSC	cis	rs62025270	0.631	rs55968154	ENSG00000259762.1	RP11-158M2.4	-3.7	0.000245	0.0292	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.688	rs55851385	ENSG00000259762.1	RP11-158M2.4	-3.7	0.000245	0.0292	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85750336~85752901:-
HNSC	cis	rs9880211	0.635	rs10049233	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0292	0.16	0.17	Height;Body mass index;	chr3:136066627	chr3:136837338~136839021:-
HNSC	cis	rs1075232	1	rs12437749	ENSG00000103832.10	GOLGA8UP	-3.7	0.000245	0.0292	-0.35	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30791573~30801859:+
HNSC	cis	rs2253762	0.68	rs2461212	ENSG00000276742.1	RP11-500G22.4	3.7	0.000245	0.0292	0.2	0.17	Breast cancer;	chr10:122033882	chr10:121956782~121957098:+
HNSC	cis	rs7927592	0.913	rs7123564	ENSG00000255031.4	RP11-802E16.3	3.7	0.000245	0.0292	0.15	0.17	Total body bone mineral density;	chr11:68594696	chr11:68050740~68053762:+
HNSC	cis	rs10435719	0.902	rs6601633	ENSG00000227888.4	FAM66A	-3.7	0.000245	0.0292	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:12362019~12388296:+
HNSC	cis	rs11098499	0.722	rs7673476	ENSG00000250412.1	KLHL2P1	3.7	0.000245	0.0292	0.21	0.17	Corneal astigmatism;	chr4:119327528	chr4:119334329~119378233:+
HNSC	cis	rs7927592	0.731	rs2840367	ENSG00000255031.4	RP11-802E16.3	-3.7	0.000245	0.0292	-0.14	-0.17	Total body bone mineral density;	chr11:68534633	chr11:68050740~68053762:+
HNSC	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	3.7	0.000245	0.0292	0.22	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
HNSC	cis	rs6545883	0.929	rs6545877	ENSG00000271889.1	RP11-493E12.1	3.7	0.000245	0.0292	0.19	0.17	Tuberculosis;	chr2:61514812	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.929	rs7606167	ENSG00000271889.1	RP11-493E12.1	3.7	0.000245	0.0292	0.19	0.17	Tuberculosis;	chr2:61515519	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.929	rs3732170	ENSG00000271889.1	RP11-493E12.1	3.7	0.000245	0.0292	0.19	0.17	Tuberculosis;	chr2:61522581	chr2:61151433~61162105:-
HNSC	cis	rs61160187	0.51	rs6449501	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000245	0.0292	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60866457~60866935:-
HNSC	cis	rs853679	0.607	rs67340775	ENSG00000280107.1	AL022393.9	-3.7	0.000245	0.0292	-0.29	-0.17	Depression;	chr6:28336607	chr6:28170845~28172521:+
HNSC	cis	rs8041447	0.864	rs937414	ENSG00000259756.1	RP11-625H11.2	3.7	0.000245	0.0292	0.19	0.17	Immature fraction of reticulocytes;	chr15:62771413	chr15:62682916~62690448:-
HNSC	cis	rs7246657	0.606	rs2972439	ENSG00000276846.1	CTD-3220F14.3	-3.7	0.000245	0.0292	-0.23	-0.17	Coronary artery calcification;	chr19:37721680	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs2909100	ENSG00000276846.1	CTD-3220F14.3	-3.7	0.000245	0.0292	-0.23	-0.17	Coronary artery calcification;	chr19:37721779	chr19:37314868~37315620:-
HNSC	cis	rs8062405	1	rs1987472	ENSG00000261089.1	RP11-435I10.3	3.7	0.000245	0.0293	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000261089.1	RP11-435I10.3	3.7	0.000245	0.0293	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28413703~28415018:+
HNSC	cis	rs12188164	1	rs34453673	ENSG00000215246.5	RP11-43F13.3	-3.7	0.000245	0.0293	-0.19	-0.17	Cystic fibrosis severity;	chr5:434607	chr5:987180~997308:-
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000245	0.0293	-0.19	-0.17	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
HNSC	cis	rs7927592	0.913	rs7116994	ENSG00000239559.2	RPL37P2	3.7	0.000245	0.0293	0.17	0.17	Total body bone mineral density;	chr11:68487159	chr11:67682772~67683058:-
HNSC	cis	rs11098499	0.821	rs56155624	ENSG00000249244.1	RP11-548H18.2	3.7	0.000245	0.0293	0.22	0.17	Corneal astigmatism;	chr4:119369871	chr4:119391831~119395335:-
HNSC	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	3.7	0.000245	0.0293	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
HNSC	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-3.7	0.000245	0.0293	-0.18	-0.17	Height;	chr5:36832039	chr5:36666214~36725195:-
HNSC	cis	rs7937890	0.9	rs7118682	ENSG00000251991.1	RNU7-49P	-3.7	0.000245	0.0293	-0.18	-0.17	Mitochondrial DNA levels;	chr11:14253004	chr11:14478892~14478953:+
HNSC	cis	rs830124	1	rs1154513	ENSG00000280138.1	RP11-463O12.5	-3.7	0.000245	0.0293	-0.21	-0.17	Urinary metabolites;	chr12:121954057	chr12:122870059~122888720:-
HNSC	cis	rs544991	0.687	rs1550545	ENSG00000239670.1	RP4-803A2.2	3.7	0.000245	0.0293	0.21	0.17	Intelligence;	chr1:33744486	chr1:32986952~32988233:+
HNSC	cis	rs544991	0.687	rs4578181	ENSG00000239670.1	RP4-803A2.2	3.7	0.000245	0.0293	0.21	0.17	Intelligence;	chr1:33744931	chr1:32986952~32988233:+
HNSC	cis	rs4636294	0.792	rs6475571	ENSG00000244230.3	RN7SL151P	3.7	0.000245	0.0293	0.17	0.17	Cutaneous nevi;	chr9:21736018	chr9:21699314~21699596:+
HNSC	cis	rs35306767	0.903	rs34847097	ENSG00000229869.1	RP11-363N22.2	-3.7	0.000245	0.0293	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:856312	chr10:933026~942743:+
HNSC	cis	rs35306767	0.671	rs11253473	ENSG00000229869.1	RP11-363N22.2	-3.7	0.000245	0.0293	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:860886	chr10:933026~942743:+
HNSC	cis	rs11638815	0.626	rs4779041	ENSG00000259429.4	UBE2Q2P2	3.7	0.000245	0.0293	0.17	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:82355142~82420075:+
HNSC	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-3.7	0.000245	0.0293	-0.19	-0.17	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
HNSC	cis	rs2836974	0.965	rs2836965	ENSG00000255568.3	BRWD1-AS2	-3.7	0.000245	0.0293	-0.15	-0.17	Cognitive function;	chr21:39261705	chr21:39313935~39314962:+
HNSC	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	3.7	0.000246	0.0293	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
HNSC	cis	rs12149695	0.872	rs4787415	ENSG00000259940.2	CTD-3203P2.1	3.7	0.000246	0.0293	0.19	0.17	Gut microbiota (bacterial taxa);	chr16:27239885	chr16:27213308~27214993:-
HNSC	cis	rs7824557	0.602	rs11784544	ENSG00000255495.1	AC145124.2	3.7	0.000246	0.0293	0.19	0.17	Retinal vascular caliber;	chr8:11346994	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.602	rs11781375	ENSG00000255495.1	AC145124.2	3.7	0.000246	0.0293	0.19	0.17	Retinal vascular caliber;	chr8:11347023	chr8:12194467~12196280:+
HNSC	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	3.7	0.000246	0.0293	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	3.7	0.000246	0.0293	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	3.7	0.000246	0.0293	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
HNSC	cis	rs1713985	1	rs1718828	ENSG00000269949.1	RP11-738E22.3	-3.7	0.000246	0.0293	-0.33	-0.17	Age-related macular degeneration;	chr4:56941319	chr4:56960927~56961373:-
HNSC	cis	rs6001482	0.702	rs5757586	ENSG00000253818.1	IGLV1-41	-3.7	0.000246	0.0293	-0.14	-0.17	Diastolic blood pressure;	chr22:22234458	chr22:22404207~22404721:+
HNSC	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	3.7	0.000246	0.0293	0.28	0.17	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
HNSC	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	3.7	0.000246	0.0293	0.28	0.17	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
HNSC	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	3.7	0.000246	0.0293	0.28	0.17	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
HNSC	cis	rs1595825	0.891	rs16826873	ENSG00000231621.1	AC013264.2	3.7	0.000246	0.0293	0.19	0.17	Ulcerative colitis;	chr2:198033498	chr2:197197991~197199273:+
HNSC	cis	rs526231	0.543	rs17154913	ENSG00000250682.4	LINC00491	3.7	0.000246	0.0293	0.21	0.17	Primary biliary cholangitis;	chr5:102992786	chr5:102609156~102671559:-
HNSC	cis	rs7005380	0.62	rs13249122	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000246	0.0293	-0.14	-0.17	Interstitial lung disease;	chr8:119893679	chr8:119838736~119840385:-
HNSC	cis	rs1865760	0.713	rs2013063	ENSG00000272810.1	U91328.22	-3.7	0.000246	0.0293	-0.15	-0.17	Height;	chr6:25993870	chr6:26013241~26013757:+
HNSC	cis	rs4947019	0.609	rs4946968	ENSG00000260273.1	RP11-425D10.10	3.7	0.000246	0.0293	0.44	0.17	Hematological parameters;	chr6:109357907	chr6:109382795~109383666:+
HNSC	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-3.7	0.000246	0.0293	-0.18	-0.17	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
HNSC	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-3.7	0.000246	0.0293	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
HNSC	cis	rs1552244	1	rs7615764	ENSG00000180385.7	EMC3-AS1	3.7	0.000246	0.0293	0.19	0.17	Alzheimer's disease;	chr3:10040908	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs35220123	ENSG00000180385.7	EMC3-AS1	3.7	0.000246	0.0293	0.19	0.17	Alzheimer's disease;	chr3:10041485	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.935	rs4441636	ENSG00000180385.7	EMC3-AS1	3.7	0.000246	0.0293	0.19	0.17	Alzheimer's disease;	chr3:10042192	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.748	rs113890152	ENSG00000180385.7	EMC3-AS1	3.7	0.000246	0.0293	0.19	0.17	Alzheimer's disease;	chr3:10044302	chr3:9986893~10006990:+
HNSC	cis	rs12047808	0.908	rs59377201	ENSG00000227141.2	RP11-545A16.3	-3.7	0.000246	0.0293	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179492840	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.73	rs73036768	ENSG00000227141.2	RP11-545A16.3	-3.7	0.000246	0.0293	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179493084	chr1:179586705~179589175:+
HNSC	cis	rs12047808	1	rs73036771	ENSG00000227141.2	RP11-545A16.3	-3.7	0.000246	0.0293	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179494790	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.908	rs61100999	ENSG00000227141.2	RP11-545A16.3	-3.7	0.000246	0.0293	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179496157	chr1:179586705~179589175:+
HNSC	cis	rs4648045	0.796	rs3774963	ENSG00000230069.3	LRRC37A15P	-3.69	0.000246	0.0294	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102598208	chr4:102727274~102730721:-
HNSC	cis	rs6545883	0.859	rs7561672	ENSG00000271889.1	RP11-493E12.1	-3.69	0.000246	0.0294	-0.19	-0.17	Tuberculosis;	chr2:61291959	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.894	rs4672431	ENSG00000271889.1	RP11-493E12.1	-3.69	0.000246	0.0294	-0.19	-0.17	Tuberculosis;	chr2:61292787	chr2:61151433~61162105:-
HNSC	cis	rs4787491	0.729	rs11544328	ENSG00000250616.2	RP11-455F5.3	3.69	0.000246	0.0294	0.17	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30096430~30104116:+
HNSC	cis	rs4578769	0.55	rs9951410	ENSG00000265943.1	RP11-739L10.1	3.69	0.000246	0.0294	0.2	0.17	Eosinophil percentage of white cells;	chr18:22964944	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.505	rs9951982	ENSG00000265943.1	RP11-739L10.1	3.69	0.000246	0.0294	0.2	0.17	Eosinophil percentage of white cells;	chr18:22965607	chr18:22699481~22933764:-
HNSC	cis	rs4950322	0.547	rs56864370	ENSG00000230832.3	RP11-325P15.2	-3.69	0.000246	0.0294	-0.22	-0.17	Protein quantitative trait loci;	chr1:147111847	chr1:147082338~147083578:-
HNSC	cis	rs11951515	0.663	rs10039048	ENSG00000249286.1	CTD-2210P15.2	3.69	0.000246	0.0294	0.18	0.17	Metabolite levels  (X-11787);	chr5:43313076	chr5:43586918~43588223:-
HNSC	cis	rs58123204	1	rs58123204	ENSG00000270175.1	RP11-793H13.11	-3.69	0.000246	0.0294	-0.22	-0.17	Mean corpuscular hemoglobin;	chr12:53366378	chr12:53500162~53500936:-
HNSC	cis	rs73252553	0.548	rs4697563	ENSG00000281501.1	SEPSECS-AS1	-3.69	0.000246	0.0294	-0.26	-0.17	Cannabis dependence symptom count;	chr4:25311495	chr4:25160641~25201440:+
HNSC	cis	rs73252553	0.548	rs4697566	ENSG00000281501.1	SEPSECS-AS1	-3.69	0.000246	0.0294	-0.26	-0.17	Cannabis dependence symptom count;	chr4:25311932	chr4:25160641~25201440:+
HNSC	cis	rs4908760	0.792	rs6577515	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000246	0.0294	0.17	0.17	Vitiligo;	chr1:8654143	chr1:8424645~8434838:+
HNSC	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	3.69	0.000246	0.0294	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	3.69	0.000246	0.0294	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
HNSC	cis	rs1585471	0.736	rs2597882	ENSG00000249532.3	RP11-148B6.1	3.69	0.000246	0.0294	0.2	0.17	Myopia (pathological);	chr4:111688599	chr4:112646476~112650051:-
HNSC	cis	rs1585471	0.736	rs2597883	ENSG00000249532.3	RP11-148B6.1	3.69	0.000246	0.0294	0.2	0.17	Myopia (pathological);	chr4:111688738	chr4:112646476~112650051:-
HNSC	cis	rs9987353	0.83	rs4841117	ENSG00000254340.1	RP11-10A14.3	-3.69	0.000246	0.0294	-0.24	-0.17	Recombination measurement;	chr8:9272622	chr8:9141424~9145435:+
HNSC	cis	rs7746199	0.736	rs17749927	ENSG00000226314.6	ZNF192P1	-3.69	0.000246	0.0294	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs13192965	ENSG00000226314.6	ZNF192P1	-3.69	0.000246	0.0294	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28161781~28169594:+
HNSC	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	3.69	0.000246	0.0294	0.2	0.17	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
HNSC	cis	rs6137473	0.966	rs6047663	ENSG00000227063.5	RPL41P1	3.69	0.000246	0.0294	0.18	0.17	Adolescent idiopathic scoliosis;	chr20:21841272	chr20:21755270~21755350:+
HNSC	cis	rs6787172	0.622	rs7610713	ENSG00000272087.1	RP11-379F4.7	3.69	0.000246	0.0294	0.17	0.17	Subjective well-being;	chr3:158354468	chr3:158693120~158693768:-
HNSC	cis	rs1440410	0.804	rs12647238	ENSG00000250326.1	RP11-284M14.1	-3.69	0.000246	0.0294	-0.2	-0.17	Ischemic stroke;	chr4:143141504	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.804	rs13146326	ENSG00000250326.1	RP11-284M14.1	-3.69	0.000246	0.0294	-0.2	-0.17	Ischemic stroke;	chr4:143155588	chr4:142933195~143184861:-
HNSC	cis	rs739496	0.653	rs11613713	ENSG00000226469.1	ADAM1B	3.69	0.000246	0.0294	0.2	0.17	Platelet count;	chr12:111779334	chr12:111927018~111929017:+
HNSC	cis	rs10090774	0.76	rs6993266	ENSG00000279766.1	RP11-642A1.2	3.69	0.000246	0.0294	0.18	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752560	chr8:140572142~140572812:-
HNSC	cis	rs2307394	0.714	rs13022125	ENSG00000281469.1	RP11-567F11.1	3.69	0.000246	0.0294	0.19	0.17	Urate levels;	chr2:147755522	chr2:148044380~148044894:+
HNSC	cis	rs889398	0.802	rs2937121	ENSG00000196696.11	PDXDC2P	3.69	0.000246	0.0294	0.12	0.17	Body mass index;	chr16:69836506	chr16:69976297~70065948:-
HNSC	cis	rs1538970	0.924	rs11211111	ENSG00000234329.1	RP11-767N6.2	3.69	0.000246	0.0294	0.2	0.17	Platelet count;	chr1:45443110	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.924	rs1006216	ENSG00000234329.1	RP11-767N6.2	3.69	0.000246	0.0294	0.2	0.17	Platelet count;	chr1:45444322	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.924	rs1007858	ENSG00000234329.1	RP11-767N6.2	3.69	0.000246	0.0294	0.2	0.17	Platelet count;	chr1:45446333	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.924	rs7528573	ENSG00000234329.1	RP11-767N6.2	3.69	0.000246	0.0294	0.2	0.17	Platelet count;	chr1:45448188	chr1:45651039~45651826:-
HNSC	cis	rs6787172	0.592	rs6788703	ENSG00000272087.1	RP11-379F4.7	3.69	0.000247	0.0294	0.17	0.17	Subjective well-being;	chr3:158349448	chr3:158693120~158693768:-
HNSC	cis	rs7765004	0.851	rs4496829	ENSG00000228624.6	RP3-399L15.3	3.69	0.000247	0.0294	0.17	0.17	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113758518	chr6:113969701~114471705:+
HNSC	cis	rs12234571	1	rs6953416	ENSG00000214293.7	APTR	3.69	0.000247	0.0294	0.23	0.17	Obesity-related traits;	chr7:77880608	chr7:77657660~77696265:-
HNSC	cis	rs950027	0.62	rs1145080	ENSG00000259479.5	SORD2P	3.69	0.000247	0.0294	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:44826371~44884694:-
HNSC	cis	rs7189233	0.955	rs7189726	ENSG00000279344.1	RP11-44F14.7	3.69	0.000247	0.0294	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53478957~53481550:-
HNSC	cis	rs860295	0.58	rs2282301	ENSG00000203761.5	MSTO2P	3.69	0.000247	0.0294	0.13	0.17	Body mass index;	chr1:155898834	chr1:155745829~155750137:+
HNSC	cis	rs755249	0.501	rs2455648	ENSG00000228060.1	RP11-69E11.8	-3.69	0.000247	0.0294	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39565160~39573203:+
HNSC	cis	rs8046011	0.537	rs1646066	ENSG00000280153.1	RP11-876N24.3	-3.69	0.000247	0.0294	-0.16	-0.17	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11224649	chr16:10933903~10936280:+
HNSC	cis	rs9894429	0.527	rs7405469	ENSG00000281517.1	Metazoa_SRP	-3.69	0.000247	0.0294	-0.19	-0.17	Eye color traits;	chr17:81599570	chr17:81718849~81719095:-
HNSC	cis	rs12049351	0.507	rs41271481	ENSG00000177788.5	RP5-1061H20.4	-3.69	0.000247	0.0294	-0.22	-0.17	Circulating myeloperoxidase levels (plasma);	chr1:229432890	chr1:229258281~229271028:-
HNSC	cis	rs897984	0.762	rs7206511	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000247	0.0294	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30939031	chr16:31043150~31049868:+
HNSC	cis	rs4073405	0.691	rs10769133	ENSG00000254651.1	RP11-430H10.3	3.69	0.000247	0.0294	0.21	0.17	Schizophrenia;	chr11:45268962	chr11:45399448~45400528:+
HNSC	cis	rs4073405	0.691	rs10769134	ENSG00000254651.1	RP11-430H10.3	3.69	0.000247	0.0294	0.21	0.17	Schizophrenia;	chr11:45269204	chr11:45399448~45400528:+
HNSC	cis	rs2136613	0.651	rs16917768	ENSG00000238280.1	RP11-436D10.3	-3.69	0.000247	0.0294	-0.2	-0.17	Selective IgA deficiency;	chr10:62864705	chr10:62793562~62805887:-
HNSC	cis	rs1962073	0.528	rs9329223	ENSG00000255310.2	AF131215.2	-3.69	0.000247	0.0294	-0.16	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10474244	chr8:11107788~11109726:-
HNSC	cis	rs9437689	0.966	rs11585462	ENSG00000237416.5	RP11-465K1.2	-3.69	0.000247	0.0294	-0.21	-0.17	Phospholipid levels (plasma);	chr1:95072236	chr1:94836748~94855426:-
HNSC	cis	rs597539	0.731	rs664229	ENSG00000255741.1	RP11-757G1.5	-3.69	0.000247	0.0294	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68941503~68942852:-
HNSC	cis	rs2468186	0.583	rs2450065	ENSG00000279347.1	RP11-85I17.2	-3.69	0.000247	0.0294	-0.15	-0.17	Osteoprotegerin levels;	chr8:119084575	chr8:119838736~119840385:-
HNSC	cis	rs860295	0.702	rs10908479	ENSG00000225855.5	RUSC1-AS1	3.69	0.000247	0.0294	0.11	0.17	Body mass index;	chr1:155673612	chr1:155316863~155324176:-
HNSC	cis	rs9863	0.827	rs7134121	ENSG00000270028.1	RP11-380L11.4	3.69	0.000247	0.0294	0.2	0.17	White blood cell count;	chr12:123962799	chr12:123925461~123926083:-
HNSC	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	3.69	0.000247	0.0294	0.12	0.17	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
HNSC	cis	rs9987353	0.784	rs4841116	ENSG00000254340.1	RP11-10A14.3	-3.69	0.000247	0.0294	-0.24	-0.17	Recombination measurement;	chr8:9272606	chr8:9141424~9145435:+
HNSC	cis	rs35740288	0.787	rs2291047	ENSG00000259407.1	RP11-158M2.3	-3.69	0.000247	0.0294	-0.23	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85744109~85750281:-
HNSC	cis	rs11846409	0.86	rs10150951	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000247	0.0294	-0.15	-0.17	Rheumatic heart disease;	chr14:106632988	chr14:106762092~106762588:-
HNSC	cis	rs11846409	0.86	rs17112419	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000247	0.0294	-0.15	-0.17	Rheumatic heart disease;	chr14:106633260	chr14:106762092~106762588:-
HNSC	cis	rs11846409	0.932	rs2583329	ENSG00000280411.1	IGHV1-69-2	3.69	0.000247	0.0294	0.15	0.17	Rheumatic heart disease;	chr14:106632971	chr14:106762092~106762588:-
HNSC	cis	rs6012564	1	rs56131635	ENSG00000227431.4	CSE1L-AS1	3.69	0.000247	0.0294	0.19	0.17	Anger;	chr20:49157806	chr20:49040463~49046044:-
HNSC	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-3.69	0.000247	0.0294	-0.2	-0.17	Height;	chr14:75203367	chr14:75011269~75012851:-
HNSC	cis	rs9467711	0.606	rs68072215	ENSG00000241549.7	GUSBP2	3.69	0.000247	0.0294	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377699	chr6:26871484~26956554:-
HNSC	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	3.69	0.000247	0.0294	0.24	0.17	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
HNSC	cis	rs9652601	0.748	rs9927527	ENSG00000274038.1	RP11-66H6.4	-3.69	0.000247	0.0295	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11118824	chr16:11056556~11057034:+
HNSC	cis	rs4908768	0.539	rs6675443	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000247	0.0295	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8424645~8434838:+
HNSC	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	3.69	0.000247	0.0295	0.19	0.17	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
HNSC	cis	rs1823874	0.584	rs9806196	ENSG00000182397.13	DNM1P46	-3.69	0.000247	0.0295	-0.17	-0.17	IgG glycosylation;	chr15:99842201	chr15:99790156~99806927:-
HNSC	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-3.69	0.000247	0.0295	-0.18	-0.17	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
HNSC	cis	rs7586673	0.725	rs6715870	ENSG00000235724.7	AC009299.2	-3.69	0.000247	0.0295	-0.22	-0.17	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161222785~161308303:-
HNSC	cis	rs970821	0.667	rs1985668	ENSG00000253106.1	RP11-158K1.3	3.69	0.000247	0.0295	0.15	0.17	Breast cancer;	chr8:123730712	chr8:124488510~124491643:+
HNSC	cis	rs7824557	0.564	rs7814131	ENSG00000269918.1	AF131215.9	-3.69	0.000247	0.0295	-0.17	-0.17	Retinal vascular caliber;	chr8:11241690	chr8:11104691~11106704:-
HNSC	cis	rs6940638	0.688	rs9393790	ENSG00000224843.5	LINC00240	-3.69	0.000247	0.0295	-0.17	-0.17	Intelligence (multi-trait analysis);	chr6:27146273	chr6:26956992~27023924:+
HNSC	cis	rs12997796	0.556	rs35594332	ENSG00000273080.1	RP11-301O19.1	3.69	0.000247	0.0295	0.25	0.17	Schizophrenia;	chr2:86755528	chr2:86195590~86196049:+
HNSC	cis	rs6095360	0.87	rs1569749	ENSG00000227431.4	CSE1L-AS1	-3.69	0.000247	0.0295	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48984972	chr20:49040463~49046044:-
HNSC	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-3.69	0.000247	0.0295	-0.17	-0.17	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
HNSC	cis	rs6787172	0.622	rs74808906	ENSG00000272087.1	RP11-379F4.7	3.69	0.000247	0.0295	0.17	0.17	Subjective well-being;	chr3:158349573	chr3:158693120~158693768:-
HNSC	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	3.69	0.000248	0.0295	0.21	0.17	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
HNSC	cis	rs7302981	0.899	rs4883481	ENSG00000272368.2	RP4-605O3.4	-3.69	0.000248	0.0295	-0.18	-0.17	Systolic blood pressure;	chr12:50180528	chr12:50112197~50165618:+
HNSC	cis	rs964184	0.564	rs2266788	ENSG00000280143.1	AP000892.6	3.69	0.000248	0.0295	0.34	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117204967~117210292:+
HNSC	cis	rs11638815	0.603	rs783520	ENSG00000259429.4	UBE2Q2P2	-3.69	0.000248	0.0295	-0.16	-0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:82355142~82420075:+
HNSC	cis	rs330048	0.545	rs11781008	ENSG00000254153.1	CTA-398F10.2	3.69	0.000248	0.0295	0.19	0.17	Systemic lupus erythematosus;	chr8:9295729	chr8:8456909~8461337:-
HNSC	cis	rs6710503	0.632	rs13416069	ENSG00000271936.1	RP11-443B20.1	-3.69	0.000248	0.0295	-0.22	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24785397	chr2:24825610~24826717:+
HNSC	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-3.69	0.000248	0.0295	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
HNSC	cis	rs453301	0.682	rs2929451	ENSG00000233609.3	RP11-62H7.2	3.69	0.000248	0.0295	0.15	0.17	Joint mobility (Beighton score);	chr8:9227785	chr8:8961200~8979025:+
HNSC	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	3.69	0.000248	0.0295	0.17	0.17	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
HNSC	cis	rs61160187	0.673	rs3958943	ENSG00000215032.2	GNL3LP1	-3.69	0.000248	0.0295	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60580922	chr5:60891935~60893577:-
HNSC	cis	rs2307394	0.896	rs6734998	ENSG00000281469.1	RP11-567F11.1	3.69	0.000248	0.0296	0.18	0.17	Urate levels;	chr2:147808752	chr2:148044380~148044894:+
HNSC	cis	rs9549328	0.756	rs2993291	ENSG00000276248.1	RP11-230F18.5	-3.69	0.000248	0.0296	-0.18	-0.17	Systolic blood pressure;	chr13:112999532	chr13:113527260~113530621:+
HNSC	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-3.69	0.000248	0.0296	-0.17	-0.17	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
HNSC	cis	rs2439831	0.85	rs3097773	ENSG00000201136.1	RNU6-353P	3.69	0.000248	0.0296	0.26	0.17	Lung cancer in ever smokers;	chr15:43600874	chr15:43702363~43702470:+
HNSC	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000248	0.0296	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
HNSC	cis	rs9467711	0.659	rs66757203	ENSG00000241549.7	GUSBP2	3.69	0.000248	0.0296	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:26871484~26956554:-
HNSC	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	3.69	0.000248	0.0296	0.23	0.17	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
HNSC	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000248	0.0296	0.17	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
HNSC	cis	rs6570726	0.846	rs6570698	ENSG00000270638.1	RP3-466P17.1	3.69	0.000248	0.0296	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145735570~145737218:+
HNSC	cis	rs1580019	0.961	rs1868777	ENSG00000231952.3	DPY19L1P2	-3.69	0.000248	0.0296	-0.23	-0.17	Cognitive ability;	chr7:32454464	chr7:32812757~32838570:+
HNSC	cis	rs7572733	0.773	rs970552	ENSG00000222017.1	AC011997.1	-3.69	0.000248	0.0296	-0.21	-0.17	Dermatomyositis;	chr2:197632788	chr2:197693106~197774823:+
HNSC	cis	rs9437689	0.966	rs6698046	ENSG00000237416.5	RP11-465K1.2	-3.69	0.000248	0.0296	-0.2	-0.17	Phospholipid levels (plasma);	chr1:94983726	chr1:94836748~94855426:-
HNSC	cis	rs2976388	0.935	rs2920285	ENSG00000253741.1	CTD-2292P10.4	3.69	0.000248	0.0296	0.16	0.17	Urinary tract infection frequency;	chr8:142674800	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.935	rs2978978	ENSG00000253741.1	CTD-2292P10.4	3.69	0.000248	0.0296	0.16	0.17	Urinary tract infection frequency;	chr8:142675112	chr8:142702252~142726973:-
HNSC	cis	rs2976388	0.935	rs2920284	ENSG00000253741.1	CTD-2292P10.4	3.69	0.000248	0.0296	0.16	0.17	Urinary tract infection frequency;	chr8:142675501	chr8:142702252~142726973:-
HNSC	cis	rs2976388	1	rs2920283	ENSG00000253741.1	CTD-2292P10.4	3.69	0.000248	0.0296	0.16	0.17	Urinary tract infection frequency;	chr8:142675619	chr8:142702252~142726973:-
HNSC	cis	rs859767	0.741	rs1467194	ENSG00000224043.6	CCNT2-AS1	3.69	0.000248	0.0296	0.2	0.17	Neuroticism;	chr2:134673051	chr2:134735464~134918710:-
HNSC	cis	rs202072	1	rs202072	ENSG00000215022.6	RP1-257A7.4	3.69	0.000248	0.0296	0.21	0.17	HIV-1 viral setpoint;	chr6:13267979	chr6:13264861~13295586:-
HNSC	cis	rs2005199	0.51	rs62115081	ENSG00000268520.1	CTD-2616J11.10	-3.69	0.000248	0.0296	-0.38	-0.17	Blood protein levels;Carotid intima media thickness;	chr19:51487548	chr19:51361712~51365544:-
HNSC	cis	rs7760535	0.794	rs463860	ENSG00000271789.1	RP5-1112D6.7	-3.69	0.000248	0.0296	-0.2	-0.17	Metabolic traits;	chr6:111370518	chr6:111297126~111298510:+
HNSC	cis	rs2554380	0.8	rs1544876	ENSG00000259570.1	RP11-671M22.4	3.69	0.000248	0.0296	0.23	0.17	Height;	chr15:83707049	chr15:84394512~84395514:+
HNSC	cis	rs3176789	0.872	rs7488011	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772740	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1029994	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772834	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.872	rs1029993	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772843	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1029992	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773162	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1029991	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773468	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1029990	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773801	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs10844749	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774028	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1540356	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774188	chr12:9398355~9414851:-
HNSC	cis	rs3176789	0.914	rs1540355	ENSG00000256673.1	RP11-599J14.2	3.69	0.000248	0.0296	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774272	chr12:9398355~9414851:-
HNSC	cis	rs10971721	0.584	rs10971935	ENSG00000260947.1	RP11-384P7.7	3.69	0.000248	0.0296	0.29	0.17	Body mass index;	chr9:34118147	chr9:33697459~33700986:+
HNSC	cis	rs999943	0.774	rs10947421	ENSG00000224557.6	HLA-DPB2	-3.69	0.000248	0.0296	-0.23	-0.17	Obesity (extreme);	chr6:33643501	chr6:33112451~33129084:+
HNSC	cis	rs999943	0.846	rs10947422	ENSG00000224557.6	HLA-DPB2	-3.69	0.000248	0.0296	-0.23	-0.17	Obesity (extreme);	chr6:33643574	chr6:33112451~33129084:+
HNSC	cis	rs9393777	0.92	rs13212562	ENSG00000216901.1	AL022393.7	3.69	0.000248	0.0296	0.29	0.17	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28176188~28176674:+
HNSC	cis	rs9505118	1	rs3799514	ENSG00000238221.1	RP11-69L16.4	3.69	0.000248	0.0296	0.21	0.17	Type 2 diabetes;	chr6:7290515	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs3799515	ENSG00000238221.1	RP11-69L16.4	3.69	0.000248	0.0296	0.21	0.17	Type 2 diabetes;	chr6:7290666	chr6:7276031~7298872:+
HNSC	cis	rs9505118	0.965	rs3799516	ENSG00000238221.1	RP11-69L16.4	3.69	0.000248	0.0296	0.21	0.17	Type 2 diabetes;	chr6:7290678	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs9505119	ENSG00000238221.1	RP11-69L16.4	3.69	0.000248	0.0296	0.21	0.17	Type 2 diabetes;	chr6:7290840	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs9505120	ENSG00000238221.1	RP11-69L16.4	3.69	0.000248	0.0296	0.21	0.17	Type 2 diabetes;	chr6:7290953	chr6:7276031~7298872:+
HNSC	cis	rs4853525	0.522	rs62179715	ENSG00000228509.4	AC006460.2	3.69	0.000248	0.0296	0.22	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190705346	chr2:190676944~190708716:-
HNSC	cis	rs3929778	0.883	rs2423166	ENSG00000275632.1	RP5-967N21.11	-3.69	0.000249	0.0296	-0.16	-0.17	QRS complex (Cornell);	chr20:6545478	chr20:6000418~6000941:+
HNSC	cis	rs3738443	0.951	rs55914345	ENSG00000259865.1	RP11-488L18.10	3.69	0.000249	0.0296	0.16	0.17	Alcohol dependence;	chr1:247216105	chr1:247187281~247188526:-
HNSC	cis	rs3738443	0.951	rs61840467	ENSG00000259865.1	RP11-488L18.10	3.69	0.000249	0.0296	0.16	0.17	Alcohol dependence;	chr1:247216936	chr1:247187281~247188526:-
HNSC	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	3.69	0.000249	0.0296	0.28	0.17	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
HNSC	cis	rs2836974	0.644	rs2410123	ENSG00000255568.3	BRWD1-AS2	-3.69	0.000249	0.0296	-0.15	-0.17	Cognitive function;	chr21:39328167	chr21:39313935~39314962:+
HNSC	cis	rs227275	0.554	rs6810668	ENSG00000248740.4	RP11-328K4.1	3.69	0.000249	0.0296	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:103256159~103453658:+
HNSC	cis	rs913655	0.508	rs10763624	ENSG00000225527.1	RP11-383B4.4	-3.69	0.000249	0.0296	-0.2	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18744832	chr10:18531849~18533336:-
HNSC	cis	rs919433	0.519	rs700658	ENSG00000231621.1	AC013264.2	-3.69	0.000249	0.0296	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197790283	chr2:197197991~197199273:+
HNSC	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	3.69	0.000249	0.0296	0.23	0.17	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
HNSC	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	3.69	0.000249	0.0296	0.23	0.17	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
HNSC	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	3.69	0.000249	0.0296	0.23	0.17	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
HNSC	cis	rs12893668	0.667	rs11844466	ENSG00000269910.1	RP11-73M18.10	3.69	0.000249	0.0296	0.17	0.17	Reticulocyte count;	chr14:103600085	chr14:103694516~103695050:-
HNSC	cis	rs394563	0.601	rs391875	ENSG00000216906.2	RP11-350J20.9	3.69	0.000249	0.0296	0.21	0.17	Dupuytren's disease;	chr6:149474000	chr6:149904243~149906418:+
HNSC	cis	rs7027203	0.576	rs7855940	ENSG00000227603.1	RP11-165J3.6	-3.69	0.000249	0.0296	-0.15	-0.17	DNA methylation (variation);	chr9:93773684	chr9:93435332~93437121:-
HNSC	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-3.69	0.000249	0.0296	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
HNSC	cis	rs7760535	0.764	rs240994	ENSG00000271789.1	RP5-1112D6.7	-3.69	0.000249	0.0297	-0.2	-0.17	Metabolic traits;	chr6:111354554	chr6:111297126~111298510:+
HNSC	cis	rs6545883	0.929	rs2600663	ENSG00000271889.1	RP11-493E12.1	-3.69	0.000249	0.0297	-0.19	-0.17	Tuberculosis;	chr2:61313552	chr2:61151433~61162105:-
HNSC	cis	rs35000415	0.938	rs13239597	ENSG00000275106.1	RP11-309L24.10	-3.69	0.000249	0.0297	-0.4	-0.17	Systemic lupus erythematosus;	chr7:129055929	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.745	rs117944677	ENSG00000275106.1	RP11-309L24.10	-3.69	0.000249	0.0297	-0.4	-0.17	Systemic lupus erythematosus;	chr7:129058131	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.745	rs117473643	ENSG00000275106.1	RP11-309L24.10	-3.69	0.000249	0.0297	-0.4	-0.17	Systemic lupus erythematosus;	chr7:129058132	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.873	rs34748780	ENSG00000275106.1	RP11-309L24.10	-3.69	0.000249	0.0297	-0.4	-0.17	Systemic lupus erythematosus;	chr7:129060099	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.873	rs13246321	ENSG00000275106.1	RP11-309L24.10	-3.69	0.000249	0.0297	-0.4	-0.17	Systemic lupus erythematosus;	chr7:129061277	chr7:128952527~128953316:-
HNSC	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	3.69	0.000249	0.0297	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	3.69	0.000249	0.0297	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
HNSC	cis	rs17772222	1	rs56987357	ENSG00000258789.1	RP11-507K2.3	-3.69	0.000249	0.0297	-0.21	-0.17	Coronary artery calcification;	chr14:88358019	chr14:88551597~88552493:+
HNSC	cis	rs328506	0.545	rs2865380	ENSG00000124224.15	PPP4R1L	3.69	0.000249	0.0297	0.16	0.17	Type 2 diabetes;	chr20:57468755	chr20:58228940~58309439:-
HNSC	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	3.69	0.000249	0.0297	0.24	0.17	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
HNSC	cis	rs28573326	0.962	rs4349560	ENSG00000121089.4	NACA3P	-3.69	0.000249	0.0297	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165414974	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs11732478	ENSG00000121089.4	NACA3P	-3.69	0.000249	0.0297	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165415028	chr4:164943290~164943937:+
HNSC	cis	rs7927592	0.913	rs7127948	ENSG00000255031.4	RP11-802E16.3	3.69	0.000249	0.0297	0.15	0.17	Total body bone mineral density;	chr11:68595594	chr11:68050740~68053762:+
HNSC	cis	rs4392868	0.514	rs4236831	ENSG00000245080.5	RP11-320N21.1	-3.69	0.000249	0.0297	-0.2	-0.17	Radiation response;	chr8:95093705	chr8:95066808~95073182:-
HNSC	cis	rs6500395	1	rs924476	ENSG00000261267.1	RP11-44I10.3	-3.69	0.000249	0.0297	-0.21	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48522936	chr16:48559661~48587403:+
HNSC	cis	rs11846409	0.932	rs28378201	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000249	0.0297	-0.15	-0.17	Rheumatic heart disease;	chr14:106637262	chr14:106762092~106762588:-
HNSC	cis	rs853679	0.882	rs2743555	ENSG00000270326.1	RP5-874C20.6	-3.69	0.00025	0.0297	-0.25	-0.17	Depression;	chr6:28273304	chr6:28319660~28319852:-
HNSC	cis	rs853679	1	rs1419183	ENSG00000270326.1	RP5-874C20.6	-3.69	0.00025	0.0297	-0.25	-0.17	Depression;	chr6:28275017	chr6:28319660~28319852:-
HNSC	cis	rs999943	0.846	rs9357162	ENSG00000224557.6	HLA-DPB2	-3.69	0.00025	0.0297	-0.23	-0.17	Obesity (extreme);	chr6:33645567	chr6:33112451~33129084:+
HNSC	cis	rs964611	1	rs7168752	ENSG00000259488.2	RP11-154J22.1	-3.69	0.00025	0.0297	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48308583	chr15:48312353~48331856:-
HNSC	cis	rs964611	1	rs79040993	ENSG00000259488.2	RP11-154J22.1	-3.69	0.00025	0.0297	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48309949	chr15:48312353~48331856:-
HNSC	cis	rs964611	0.935	rs76749119	ENSG00000259488.2	RP11-154J22.1	-3.69	0.00025	0.0297	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48312868	chr15:48312353~48331856:-
HNSC	cis	rs964611	1	rs74012001	ENSG00000259488.2	RP11-154J22.1	-3.69	0.00025	0.0297	-0.18	-0.17	Metabolite levels (Pyroglutamine);	chr15:48313011	chr15:48312353~48331856:-
HNSC	cis	rs9788333	0.792	rs34479949	ENSG00000236953.1	ZDHHC20-IT1	-3.69	0.00025	0.0297	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21321435	chr13:21376977~21377874:-
HNSC	cis	rs7429990	0.52	rs78838427	ENSG00000228638.1	FCF1P2	3.69	0.00025	0.0297	0.15	0.17	Educational attainment (years of education);	chr3:47595561	chr3:48290793~48291375:-
HNSC	cis	rs1008375	1	rs10939747	ENSG00000249502.1	AC006160.5	-3.69	0.00025	0.0297	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689543	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs10939748	ENSG00000249502.1	AC006160.5	-3.69	0.00025	0.0297	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689607	chr4:17587467~17614571:-
HNSC	cis	rs2153535	0.585	rs7765238	ENSG00000230939.1	RP11-314C16.1	3.69	0.00025	0.0297	0.19	0.17	Motion sickness;	chr6:8632560	chr6:8784178~8785445:+
HNSC	cis	rs10256972	0.721	rs10435145	ENSG00000225146.1	AC073957.15	3.69	0.00025	0.0297	0.2	0.17	Endometriosis;Longevity;	chr7:1026352	chr7:1029025~1043891:+
HNSC	cis	rs1008375	1	rs10939756	ENSG00000249502.1	AC006160.5	-3.69	0.00025	0.0297	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692244	chr4:17587467~17614571:-
HNSC	cis	rs28489187	0.617	rs233061	ENSG00000223653.4	RP11-131L23.1	3.69	0.00025	0.0297	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333599	chr1:85276715~85448124:+
HNSC	cis	rs3738000	0.576	rs9867591	ENSG00000248468.1	RP11-517B11.4	-3.69	0.00025	0.0297	-0.19	-0.17	Carotid intima media thickness;	chr3:131255896	chr3:131517831~131520880:+
HNSC	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	3.69	0.00025	0.0297	0.17	0.17	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
HNSC	cis	rs4489787	1	rs2705123	ENSG00000257763.1	OR5BK1P	3.69	0.00025	0.0297	0.26	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48485009	chr12:48355792~48356614:-
HNSC	cis	rs72843506	0.722	rs3764436	ENSG00000189423.10	USP32P3	3.69	0.00025	0.0297	0.28	0.17	Schizophrenia;	chr17:20110489	chr17:20415547~20431008:+
HNSC	cis	rs859767	0.774	rs6758396	ENSG00000224043.6	CCNT2-AS1	3.69	0.00025	0.0297	0.2	0.17	Neuroticism;	chr2:134659287	chr2:134735464~134918710:-
HNSC	cis	rs853679	0.607	rs35001169	ENSG00000226314.6	ZNF192P1	-3.69	0.00025	0.0297	-0.33	-0.17	Depression;	chr6:28219854	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.955	rs9393848	ENSG00000226314.6	ZNF192P1	-3.69	0.00025	0.0297	-0.2	-0.17	Parkinson's disease;	chr6:27720590	chr6:28161781~28169594:+
HNSC	cis	rs3018712	0.532	rs2513281	ENSG00000255031.4	RP11-802E16.3	-3.69	0.00025	0.0297	-0.19	-0.17	Total body bone mineral density;	chr11:68649626	chr11:68050740~68053762:+
HNSC	cis	rs7746199	0.736	rs35848276	ENSG00000241549.7	GUSBP2	3.69	0.00025	0.0297	0.29	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:26871484~26956554:-
HNSC	cis	rs1859596	1	rs1859598	ENSG00000234456.6	MAGI2-AS3	3.69	0.00025	0.0297	0.13	0.17	Reading or mathematical ability;	chr7:79484678	chr7:79452877~79471208:+
HNSC	cis	rs1859596	1	rs4727886	ENSG00000234456.6	MAGI2-AS3	3.69	0.00025	0.0297	0.13	0.17	Reading or mathematical ability;	chr7:79485656	chr7:79452877~79471208:+
HNSC	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-3.69	0.00025	0.0298	-0.19	-0.17	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
HNSC	cis	rs58873874	0.579	rs10037386	ENSG00000248544.2	CTB-47B11.3	3.69	0.00025	0.0298	0.29	0.17	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157375741~157384950:-
HNSC	cis	rs13434995	0.891	rs62309728	ENSG00000273257.1	RP11-177J6.1	-3.69	0.00025	0.0298	-0.28	-0.17	Adiponectin levels;	chr4:55530648	chr4:55387949~55388271:+
HNSC	cis	rs10435719	0.902	rs7459983	ENSG00000227888.4	FAM66A	3.69	0.00025	0.0298	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:12362019~12388296:+
HNSC	cis	rs6430585	0.528	rs309151	ENSG00000231890.6	DARS-AS1	-3.69	0.00025	0.0298	-0.29	-0.17	Corneal structure;	chr2:135903580	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs309167	ENSG00000231890.6	DARS-AS1	-3.69	0.00025	0.0298	-0.29	-0.17	Corneal structure;	chr2:135911694	chr2:135985176~136022593:+
HNSC	cis	rs7824557	0.602	rs7833966	ENSG00000255495.1	AC145124.2	3.69	0.00025	0.0298	0.19	0.17	Retinal vascular caliber;	chr8:11348711	chr8:12194467~12196280:+
HNSC	cis	rs4919694	1	rs17881215	ENSG00000236937.2	PTGES3P4	3.69	0.00025	0.0298	0.31	0.17	Arsenic metabolism;	chr10:102869479	chr10:102845595~102845950:+
HNSC	cis	rs67311347	1	rs2168111	ENSG00000280739.1	EIF1B-AS1	3.69	0.00025	0.0298	0.18	0.17	Renal cell carcinoma;	chr3:40353834	chr3:40173145~40309698:-
HNSC	cis	rs2307394	0.716	rs7560139	ENSG00000281469.1	RP11-567F11.1	3.69	0.00025	0.0298	0.19	0.17	Urate levels;	chr2:147767384	chr2:148044380~148044894:+
HNSC	cis	rs793571	0.826	rs637918	ENSG00000245975.2	RP11-30K9.6	3.69	0.00025	0.0298	0.3	0.17	Schizophrenia;	chr15:58846071	chr15:58768072~58770974:-
HNSC	cis	rs12817549	0.817	rs9971690	ENSG00000213250.5	RBMS2P1	-3.69	0.00025	0.0298	-0.15	-0.17	Hip circumference adjusted for BMI;	chr12:93710248	chr12:94423744~94424969:-
HNSC	cis	rs1075232	0.826	rs12437800	ENSG00000260382.1	RP11-540B6.2	-3.69	0.00025	0.0298	-0.37	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30882267~30883231:-
HNSC	cis	rs9487051	0.698	rs9374081	ENSG00000243587.6	C6orf183	-3.69	0.000251	0.0298	-0.18	-0.17	Reticulocyte fraction of red cells;	chr6:109310579	chr6:109165833~109271014:+
HNSC	cis	rs6840360	0.567	rs6844259	ENSG00000251611.1	RP11-610P16.1	-3.69	0.000251	0.0298	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151370032	chr4:151407551~151408835:-
HNSC	cis	rs9409565	0.787	rs11789704	ENSG00000231806.2	PCAT7	-3.69	0.000251	0.0298	-0.19	-0.17	Colorectal cancer (alcohol consumption interaction);	chr9:94471126	chr9:94555069~94568127:+
HNSC	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	3.69	0.000251	0.0298	0.17	0.17	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
HNSC	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	3.69	0.000251	0.0298	0.17	0.17	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
HNSC	cis	rs897984	0.806	rs9319588	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000251	0.0298	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30919662	chr16:31043150~31049868:+
HNSC	cis	rs919433	0.783	rs3097383	ENSG00000231621.1	AC013264.2	-3.69	0.000251	0.0298	-0.15	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372163	chr2:197197991~197199273:+
HNSC	cis	rs73173548	0.502	rs12659818	ENSG00000247828.6	TMEM161B-AS1	3.69	0.000251	0.0298	0.18	0.17	Macular telangiectasia type 2;	chr5:88451964	chr5:88268895~88436685:+
HNSC	cis	rs17742757	0.521	rs2736324	ENSG00000255495.1	AC145124.2	3.69	0.000251	0.0298	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11470673	chr8:12194467~12196280:+
HNSC	cis	rs988913	0.706	rs13192291	ENSG00000224984.1	RP11-524H19.2	3.69	0.000251	0.0298	0.2	0.17	Menarche (age at onset);	chr6:55099948	chr6:54840118~54840855:-
HNSC	cis	rs11157436	0.56	rs988997	ENSG00000211814.1	TRAV35	-3.69	0.000251	0.0298	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22221896~22222475:+
HNSC	cis	rs2836974	0.897	rs34599551	ENSG00000255568.3	BRWD1-AS2	3.69	0.000251	0.0298	0.15	0.17	Cognitive function;	chr21:39222972	chr21:39313935~39314962:+
HNSC	cis	rs6500395	0.708	rs9930644	ENSG00000261267.1	RP11-44I10.3	-3.69	0.000251	0.0298	-0.21	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48522018	chr16:48559661~48587403:+
HNSC	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	3.69	0.000251	0.0298	0.23	0.17	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
HNSC	cis	rs8007643	0.85	rs11845683	ENSG00000211778.2	TRAV4	3.69	0.000251	0.0298	0.2	0.17	Nose morphology;	chr14:20880251	chr14:21736152~21736982:+
HNSC	cis	rs34792	0.637	rs2450356	ENSG00000260872.1	RP11-680G24.5	3.69	0.000251	0.0298	0.16	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:15018106~15020488:-
HNSC	cis	rs17772222	0.511	rs12880017	ENSG00000258789.1	RP11-507K2.3	-3.69	0.000251	0.0298	-0.19	-0.17	Coronary artery calcification;	chr14:88840228	chr14:88551597~88552493:+
HNSC	cis	rs4862750	0.872	rs7664463	ENSG00000250971.1	RP11-696F12.1	3.69	0.000251	0.0298	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr4:186955532	chr4:187060099~187060930:+
HNSC	cis	rs910316	0.503	rs12894709	ENSG00000279594.1	RP11-950C14.10	3.69	0.000251	0.0298	0.2	0.17	Height;	chr14:74975031	chr14:75011269~75012851:-
HNSC	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-3.69	0.000251	0.0298	-0.18	-0.17	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
HNSC	cis	rs2337406	1	rs78631692	ENSG00000211972.2	IGHV3-66	3.69	0.000251	0.0298	0.18	0.17	Alzheimer's disease (late onset);	chr14:106709371	chr14:106675017~106675544:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000272831.1	RP11-792A8.4	-3.69	0.000251	0.0298	-0.14	-0.17	Aortic root size;	chr7:66586553	chr7:66739829~66740385:-
HNSC	cis	rs62005083	0.5	rs10135300	ENSG00000259065.1	RP5-1021I20.1	-3.69	0.000251	0.0298	-0.23	-0.17	Mean corpuscular volume;	chr14:74107858	chr14:73787360~73803270:+
HNSC	cis	rs6545883	0.894	rs7572603	ENSG00000271889.1	RP11-493E12.1	-3.69	0.000251	0.0298	-0.19	-0.17	Tuberculosis;	chr2:61325010	chr2:61151433~61162105:-
HNSC	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-3.69	0.000251	0.0298	-0.17	-0.17	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
HNSC	cis	rs7760535	0.764	rs2343614	ENSG00000271789.1	RP5-1112D6.7	-3.69	0.000251	0.0298	-0.2	-0.17	Metabolic traits;	chr6:111383955	chr6:111297126~111298510:+
HNSC	cis	rs1862618	0.641	rs2591954	ENSG00000248727.4	CTC-236F12.4	-3.69	0.000251	0.0298	-0.22	-0.17	Initial pursuit acceleration;	chr5:56949217	chr5:56457795~56481946:-
HNSC	cis	rs11047510	1	rs11047510	ENSG00000256673.1	RP11-599J14.2	3.69	0.000251	0.0298	0.22	0.17	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8837320	chr12:9398355~9414851:-
HNSC	cis	rs755249	0.727	rs2242500	ENSG00000182109.6	RP11-69E11.4	3.69	0.000251	0.0298	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39522280~39546187:-
HNSC	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	3.69	0.000251	0.0298	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
HNSC	cis	rs13434995	0.589	rs496055	ENSG00000249700.7	SRD5A3-AS1	-3.69	0.000251	0.0298	-0.22	-0.17	Adiponectin levels;	chr4:55383670	chr4:55363971~55395847:-
HNSC	cis	rs250677	0.687	rs41181	ENSG00000250072.4	CTC-529P8.1	3.69	0.000251	0.0299	0.22	0.17	Breast cancer;	chr5:149064694	chr5:149063317~149109787:+
HNSC	cis	rs868153	0.625	rs12664873	ENSG00000275339.1	RP3-425C14.6	3.69	0.000251	0.0299	0.18	0.17	Vertical cup-disc ratio;	chr6:122142045	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs6914962	ENSG00000275339.1	RP3-425C14.6	3.69	0.000251	0.0299	0.18	0.17	Vertical cup-disc ratio;	chr6:122151677	chr6:122454358~122454612:+
HNSC	cis	rs7688540	0.8	rs10023604	ENSG00000250892.1	RP11-1365D11.1	-3.69	0.000251	0.0299	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:201409~205009:-
HNSC	cis	rs1185460	1	rs1614264	ENSG00000272186.1	RP11-110I1.13	-3.69	0.000251	0.0299	-0.19	-0.17	Coronary artery disease;	chr11:119071928	chr11:119067374~119067698:-
HNSC	cis	rs2276314	0.512	rs17562898	ENSG00000278986.1	RP11-723J4.3	3.69	0.000251	0.0299	0.34	0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35997212	chr18:35972151~35973916:+
HNSC	cis	rs2048656	0.524	rs12543959	ENSG00000233609.3	RP11-62H7.2	-3.69	0.000251	0.0299	-0.17	-0.17	Schizophrenia;	chr8:9681490	chr8:8961200~8979025:+
HNSC	cis	rs12545912	0.739	rs12541617	ENSG00000233609.3	RP11-62H7.2	-3.69	0.000251	0.0299	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9681589	chr8:8961200~8979025:+
HNSC	cis	rs7778833	1	rs79335543	ENSG00000272537.1	GS1-166A23.1	3.69	0.000251	0.0299	0.42	0.17	Childhood ear infection;	chr7:15716127	chr7:16471184~16471373:+
HNSC	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	3.69	0.000251	0.0299	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
HNSC	cis	rs62025270	1	rs62025270	ENSG00000259762.1	RP11-158M2.4	-3.69	0.000251	0.0299	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85750336~85752901:-
HNSC	cis	rs45509595	0.841	rs9368531	ENSG00000219392.1	RP1-265C24.5	-3.69	0.000251	0.0299	-0.29	-0.17	Breast cancer;	chr6:27814094	chr6:28115628~28116551:+
HNSC	cis	rs45509595	0.749	rs401763	ENSG00000219392.1	RP1-265C24.5	-3.69	0.000251	0.0299	-0.29	-0.17	Breast cancer;	chr6:27814750	chr6:28115628~28116551:+
HNSC	cis	rs45509595	0.659	rs390764	ENSG00000219392.1	RP1-265C24.5	-3.69	0.000251	0.0299	-0.29	-0.17	Breast cancer;	chr6:27814757	chr6:28115628~28116551:+
HNSC	cis	rs45509595	0.841	rs401754	ENSG00000219392.1	RP1-265C24.5	-3.69	0.000251	0.0299	-0.29	-0.17	Breast cancer;	chr6:27814760	chr6:28115628~28116551:+
HNSC	cis	rs6570726	0.846	rs6914304	ENSG00000270638.1	RP3-466P17.1	3.69	0.000252	0.0299	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145735570~145737218:+
HNSC	cis	rs12047808	1	rs75408336	ENSG00000227141.2	RP11-545A16.3	-3.69	0.000252	0.0299	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179490350	chr1:179586705~179589175:+
HNSC	cis	rs7572733	0.555	rs11903129	ENSG00000231621.1	AC013264.2	-3.69	0.000252	0.0299	-0.16	-0.17	Dermatomyositis;	chr2:198053867	chr2:197197991~197199273:+
HNSC	cis	rs6504950	0.751	rs12937760	ENSG00000279059.1	RP11-257O5.2	-3.69	0.000252	0.0299	-0.14	-0.17	Breast cancer;	chr17:54938769	chr17:54956760~54958426:-
HNSC	cis	rs8010715	0.816	rs2332224	ENSG00000259321.1	RP11-468E2.5	3.69	0.000252	0.0299	0.14	0.17	IgG glycosylation;	chr14:24129335	chr14:24139445~24140444:+
HNSC	cis	rs4937076	1	rs4937076	ENSG00000254967.5	RP11-680F20.6	-3.69	0.000252	0.0299	-0.18	-0.17	Primary tooth development (time to first tooth eruption);	chr11:125956807	chr11:125950116~125956319:+
HNSC	cis	rs6651255	0.58	rs72718335	ENSG00000224110.3	MTRF1LP2	-3.69	0.000252	0.0299	-0.22	-0.17	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129777226	chr8:129728744~129730445:+
HNSC	cis	rs67311347	0.568	rs9864544	ENSG00000280739.1	EIF1B-AS1	3.69	0.000252	0.0299	0.18	0.17	Renal cell carcinoma;	chr3:40294713	chr3:40173145~40309698:-
HNSC	cis	rs9863	0.861	rs75321546	ENSG00000270028.1	RP11-380L11.4	3.69	0.000252	0.0299	0.2	0.17	White blood cell count;	chr12:123962918	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs55990776	ENSG00000270028.1	RP11-380L11.4	3.69	0.000252	0.0299	0.2	0.17	White blood cell count;	chr12:123962919	chr12:123925461~123926083:-
HNSC	cis	rs17095355	1	rs72828241	ENSG00000203876.8	ADD3-AS1	-3.69	0.000252	0.0299	-0.23	-0.17	Biliary atresia;	chr10:109984946	chr10:109940104~110008381:-
HNSC	cis	rs6587515	0.748	rs4970970	ENSG00000274963.1	Metazoa_SRP	-3.69	0.000252	0.0299	-0.27	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150665477	chr1:150568971~150569269:-
HNSC	cis	rs6587515	0.901	rs11204700	ENSG00000274963.1	Metazoa_SRP	-3.69	0.000252	0.0299	-0.27	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150688226	chr1:150568971~150569269:-
HNSC	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-3.69	0.000252	0.0299	-0.19	-0.17	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
HNSC	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	3.69	0.000252	0.0299	0.24	0.17	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	3.69	0.000252	0.0299	0.24	0.17	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	3.69	0.000252	0.0299	0.24	0.17	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	3.69	0.000252	0.0299	0.24	0.17	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
HNSC	cis	rs10484434	1	rs11751732	ENSG00000272462.2	U91328.19	3.69	0.000252	0.0299	0.21	0.17	HIV-1 viral setpoint;	chr6:26043836	chr6:25992662~26001775:+
HNSC	cis	rs1799955	0.935	rs3764791	ENSG00000215515.2	IFIT1P1	-3.69	0.000252	0.0299	-0.24	-0.17	LDL cholesterol levels;	chr13:32376974	chr13:32384660~32386108:+
HNSC	cis	rs28573326	0.886	rs13149691	ENSG00000121089.4	NACA3P	-3.69	0.000252	0.0299	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165412500	chr4:164943290~164943937:+
HNSC	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21416503	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21416835	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21419172	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21419192	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21420124	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	3.69	0.000252	0.03	0.25	0.17	Pain;	chr19:21422843	chr19:21554640~21569237:-
HNSC	cis	rs3764400	0.508	rs74412170	ENSG00000228782.6	CTD-2026D20.3	-3.69	0.000252	0.03	-0.25	-0.17	Body mass index;	chr17:48040147	chr17:47450568~47492492:-
HNSC	cis	rs3764400	0.508	rs12601350	ENSG00000228782.6	CTD-2026D20.3	-3.69	0.000252	0.03	-0.25	-0.17	Body mass index;	chr17:48043057	chr17:47450568~47492492:-
HNSC	cis	rs4844614	0.904	rs6686325	ENSG00000274245.1	RP11-357P18.2	-3.69	0.000252	0.03	-0.25	-0.17	LDL cholesterol;	chr1:207660012	chr1:207372559~207373252:+
HNSC	cis	rs7291412	0.684	rs6417773	ENSG00000273289.1	RP6-109B7.5	3.69	0.000252	0.03	0.2	0.17	Dupuytren's disease;Subjective well-being;	chr22:46062737	chr22:46053093~46053560:+
HNSC	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	3.69	0.000252	0.03	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
HNSC	cis	rs1075232	0.649	rs905436	ENSG00000260382.1	RP11-540B6.2	3.69	0.000252	0.03	0.34	0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31804319	chr15:30882267~30883231:-
HNSC	cis	rs2060793	0.741	rs10741656	ENSG00000254418.1	RP11-21L19.1	3.69	0.000252	0.03	0.19	0.17	Vitamin D levels;	chr11:14803699	chr11:14262846~14273691:-
HNSC	cis	rs875971	0.862	rs10274883	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66651104	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs881285	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66654433	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs3846973	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66655048	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs2013908	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66656082	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.569	rs13242290	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66656898	chr7:67302621~67321526:+
HNSC	cis	rs801193	0.548	rs2109297	ENSG00000106610.13	STAG3L4	3.69	0.000252	0.03	0.21	0.17	Aortic root size;	chr7:66657397	chr7:67302621~67321526:+
HNSC	cis	rs71520386	0.846	rs76474740	ENSG00000230658.1	KLHL7-AS1	3.69	0.000252	0.03	0.26	0.17	Fibrinogen levels;	chr7:22775741	chr7:23101228~23105703:-
HNSC	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-3.69	0.000252	0.03	-0.21	-0.17	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
HNSC	cis	rs7189233	0.55	rs3803657	ENSG00000261056.2	RP11-454F8.2	-3.69	0.000252	0.03	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53298224~53299792:+
HNSC	cis	rs897984	0.762	rs12930545	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000252	0.03	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30927490	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.806	rs10782001	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000252	0.03	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30931304	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.806	rs12928852	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000252	0.03	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30932667	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.806	rs4889571	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000252	0.03	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30937726	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.806	rs11640534	ENSG00000260911.2	RP11-196G11.2	-3.69	0.000252	0.03	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30938194	chr16:31043150~31049868:+
HNSC	cis	rs1859596	0.934	rs2365423	ENSG00000234456.6	MAGI2-AS3	3.69	0.000252	0.03	0.13	0.17	Reading or mathematical ability;	chr7:79485440	chr7:79452877~79471208:+
HNSC	cis	rs1859596	0.903	rs2365424	ENSG00000234456.6	MAGI2-AS3	3.69	0.000252	0.03	0.13	0.17	Reading or mathematical ability;	chr7:79485459	chr7:79452877~79471208:+
HNSC	cis	rs72827839	1	rs72827830	ENSG00000244649.3	CTD-2377D24.6	-3.69	0.000252	0.03	-0.25	-0.17	Ease of getting up in the morning;	chr17:48320140	chr17:48646923~48707346:+
HNSC	cis	rs448720	0.692	rs4777011	ENSG00000260657.2	RP11-315D16.4	-3.69	0.000253	0.03	-0.19	-0.17	Cognitive performance;	chr15:67928836	chr15:68267792~68277994:-
HNSC	cis	rs858239	0.539	rs4295546	ENSG00000226816.2	AC005082.12	3.69	0.000253	0.03	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23206013~23208045:+
HNSC	cis	rs7572733	0.967	rs1318867	ENSG00000222017.1	AC011997.1	-3.69	0.000253	0.03	-0.2	-0.17	Dermatomyositis;	chr2:198015757	chr2:197693106~197774823:+
HNSC	cis	rs10971721	0.584	rs10971933	ENSG00000260947.1	RP11-384P7.7	3.69	0.000253	0.03	0.29	0.17	Body mass index;	chr9:34117073	chr9:33697459~33700986:+
HNSC	cis	rs7246657	0.722	rs12979640	ENSG00000276846.1	CTD-3220F14.3	-3.69	0.000253	0.03	-0.23	-0.17	Coronary artery calcification;	chr19:37688255	chr19:37314868~37315620:-
HNSC	cis	rs6499755	0.712	rs31093	ENSG00000260135.5	RP11-212I21.2	-3.69	0.000253	0.03	-0.18	-0.17	Hypospadias;	chr16:55332264	chr16:55426797~55462297:-
HNSC	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	3.69	0.000253	0.03	0.18	0.17	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
HNSC	cis	rs3929778	0.816	rs6085604	ENSG00000275632.1	RP5-967N21.11	-3.69	0.000253	0.03	-0.17	-0.17	QRS complex (Cornell);	chr20:6569306	chr20:6000418~6000941:+
HNSC	cis	rs2337406	0.929	rs12050200	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000253	0.03	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106780983	chr14:106762092~106762588:-
HNSC	cis	rs62025270	0.576	rs55639123	ENSG00000259762.1	RP11-158M2.4	-3.69	0.000253	0.03	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85750336~85752901:-
HNSC	cis	rs7429990	0.864	rs3888	ENSG00000228638.1	FCF1P2	3.69	0.000253	0.03	0.15	0.17	Educational attainment (years of education);	chr3:47816085	chr3:48290793~48291375:-
HNSC	cis	rs1867631	0.959	rs11208914	ENSG00000248458.2	RP4-598P13.1	3.69	0.000253	0.03	0.17	0.17	Menopause (age at onset);	chr1:66584045	chr1:66665864~66677027:-
HNSC	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-3.69	0.000253	0.03	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-3.69	0.000253	0.03	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
HNSC	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-3.69	0.000253	0.03	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-3.69	0.000253	0.03	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
HNSC	cis	rs4845570	0.85	rs11204892	ENSG00000249602.1	RP11-98D18.3	3.69	0.000253	0.03	0.27	0.17	Coronary artery disease;	chr1:151795572	chr1:151763384~151769501:-
HNSC	cis	rs7714670	1	rs7714670	ENSG00000184084.7	CTD-2372A4.1	3.69	0.000253	0.03	0.18	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73776529	chr5:73803296~73803599:-
HNSC	cis	rs853679	0.505	rs200992	ENSG00000241549.7	GUSBP2	3.69	0.000253	0.03	0.25	0.17	Depression;	chr6:27846899	chr6:26871484~26956554:-
HNSC	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-3.69	0.000253	0.03	-0.21	-0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
HNSC	cis	rs2048656	0.605	rs34592740	ENSG00000233609.3	RP11-62H7.2	3.69	0.000253	0.03	0.17	0.17	Schizophrenia;	chr8:9793586	chr8:8961200~8979025:+
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000219891.2	ZSCAN12P1	3.69	0.000253	0.03	0.22	0.17	Parkinson's disease;	chr6:27910960	chr6:28091154~28093664:+
HNSC	cis	rs67311347	0.824	rs73073561	ENSG00000280739.1	EIF1B-AS1	3.69	0.000253	0.03	0.18	0.17	Renal cell carcinoma;	chr3:40315807	chr3:40173145~40309698:-
HNSC	cis	rs10754283	0.557	rs1215511	ENSG00000231613.1	RP5-943J3.1	3.69	0.000253	0.0301	0.19	0.17	Amyotrophic lateral sclerosis (sporadic);	chr1:89621984	chr1:89788914~89790492:+
HNSC	cis	rs9611565	0.512	rs1983576	ENSG00000235513.1	RP4-756G23.5	-3.69	0.000253	0.0301	-0.21	-0.17	Vitiligo;	chr22:41770482	chr22:41209122~41217627:-
HNSC	cis	rs12049351	0.665	rs970103	ENSG00000177788.5	RP5-1061H20.4	-3.69	0.000253	0.0301	-0.22	-0.17	Circulating myeloperoxidase levels (plasma);	chr1:229434388	chr1:229258281~229271028:-
HNSC	cis	rs7824557	0.583	rs2263512	ENSG00000255310.2	AF131215.2	-3.69	0.000253	0.0301	-0.16	-0.17	Retinal vascular caliber;	chr8:11375910	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.583	rs6601585	ENSG00000255310.2	AF131215.2	-3.69	0.000253	0.0301	-0.16	-0.17	Retinal vascular caliber;	chr8:11376150	chr8:11107788~11109726:-
HNSC	cis	rs11122895	0.716	rs11679110	ENSG00000278962.1	RP11-399B17.1	-3.69	0.000253	0.0301	-0.15	-0.17	Allergic sensitization;	chr2:111710778	chr2:112188364~112190635:+
HNSC	cis	rs1015213	0.737	rs76410510	ENSG00000272024.1	RP11-546K22.3	-3.69	0.000253	0.0301	-0.43	-0.17	Glaucoma (primary angle closure);	chr8:51987811	chr8:51950284~51950690:+
HNSC	cis	rs67311347	1	rs11707278	ENSG00000280739.1	EIF1B-AS1	3.69	0.000253	0.0301	0.19	0.17	Renal cell carcinoma;	chr3:40445584	chr3:40173145~40309698:-
HNSC	cis	rs5758511	0.68	rs5758667	ENSG00000233903.2	Z83851.4	3.69	0.000253	0.0301	0.25	0.17	Birth weight;	chr22:42237198	chr22:42276355~42277052:+
HNSC	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-3.69	0.000253	0.0301	-0.21	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
HNSC	cis	rs17666538	0.585	rs10090260	ENSG00000254207.1	RP11-43A14.1	3.69	0.000254	0.0301	0.36	0.17	IgG glycosylation;	chr8:658034	chr8:725188~725877:-
HNSC	cis	rs896655	0.622	rs7848524	ENSG00000229835.2	KHSRPP1	-3.69	0.000254	0.0301	-0.17	-0.17	Coronary artery disease;	chr9:21701433	chr9:21695176~21696943:+
HNSC	cis	rs7429990	0.833	rs4858801	ENSG00000228638.1	FCF1P2	3.69	0.000254	0.0301	0.15	0.17	Educational attainment (years of education);	chr3:47599432	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs61620099	ENSG00000228638.1	FCF1P2	3.69	0.000254	0.0301	0.15	0.17	Educational attainment (years of education);	chr3:47600755	chr3:48290793~48291375:-
HNSC	cis	rs2836974	0.931	rs13047663	ENSG00000255568.3	BRWD1-AS2	3.69	0.000254	0.0301	0.16	0.17	Cognitive function;	chr21:39336892	chr21:39313935~39314962:+
HNSC	cis	rs113835537	0.935	rs76228630	ENSG00000231793.4	DOC2GP	-3.69	0.000254	0.0301	-0.21	-0.17	Airway imaging phenotypes;	chr11:66691205	chr11:67612653~67616257:-
HNSC	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	3.69	0.000254	0.0301	0.25	0.17	Pain;	chr19:21430984	chr19:21554640~21569237:-
HNSC	cis	rs2919917	0.628	rs1905364	ENSG00000260398.1	RP11-594N15.3	3.69	0.000254	0.0301	0.22	0.17	Lymphocyte counts;	chr8:78660244	chr8:78605952~78609705:+
HNSC	cis	rs4718428	0.705	rs11028	ENSG00000179406.6	LINC00174	-3.69	0.000254	0.0301	-0.24	-0.17	Corneal structure;	chr7:66811230	chr7:66376044~66401338:-
HNSC	cis	rs2919917	0.628	rs2717540	ENSG00000260398.1	RP11-594N15.3	3.69	0.000254	0.0301	0.23	0.17	Lymphocyte counts;	chr8:78710128	chr8:78605952~78609705:+
HNSC	cis	rs7829975	0.711	rs4841051	ENSG00000254153.1	CTA-398F10.2	-3.69	0.000254	0.0301	-0.19	-0.17	Mood instability;	chr8:8828136	chr8:8456909~8461337:-
HNSC	cis	rs13256369	1	rs7004438	ENSG00000254153.1	CTA-398F10.2	3.69	0.000254	0.0301	0.21	0.17	Obesity-related traits;	chr8:8716869	chr8:8456909~8461337:-
HNSC	cis	rs12980942	0.591	rs2304231	ENSG00000233622.1	CYP2T1P	3.69	0.000254	0.0301	0.24	0.17	Coronary artery disease;	chr19:41256765	chr19:40808525~40811390:-
HNSC	cis	rs6674176	0.932	rs7412307	ENSG00000237950.1	RP11-7O11.3	-3.69	0.000254	0.0301	-0.21	-0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43968192	chr1:43944370~43946551:-
HNSC	cis	rs6090919	0.501	rs6019451	ENSG00000222365.1	SNORD12B	-3.69	0.000254	0.0301	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48843490	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs35269082	ENSG00000222365.1	SNORD12B	-3.69	0.000254	0.0301	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48843778	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs57438425	ENSG00000222365.1	SNORD12B	-3.69	0.000254	0.0301	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48844269	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs11907029	ENSG00000222365.1	SNORD12B	-3.69	0.000254	0.0301	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48844284	chr20:49280319~49280409:+
HNSC	cis	rs6090919	0.501	rs36034145	ENSG00000222365.1	SNORD12B	-3.69	0.000254	0.0301	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48845206	chr20:49280319~49280409:+
HNSC	cis	rs344364	0.511	rs1657144	ENSG00000277602.1	AC005363.11	-3.69	0.000254	0.0301	-0.25	-0.17	Glomerular filtration rate in chronic kidney disease;	chr16:1913988	chr16:1971655~1971896:-
HNSC	cis	rs2243480	0.666	rs1880311	ENSG00000229886.1	RP5-1132H15.3	-3.69	0.000254	0.0301	-0.3	-0.17	Diabetic kidney disease;	chr7:65811765	chr7:66025126~66031544:-
HNSC	cis	rs2179367	0.887	rs506268	ENSG00000216906.2	RP11-350J20.9	3.69	0.000254	0.0301	0.2	0.17	Dupuytren's disease;	chr6:149364481	chr6:149904243~149906418:+
HNSC	cis	rs7777677	0.925	rs6969951	ENSG00000211727.3	TRBV7-6	-3.69	0.000254	0.0301	-0.15	-0.17	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142492132~142492673:+
HNSC	cis	rs853679	0.607	rs35072899	ENSG00000226314.6	ZNF192P1	-3.69	0.000254	0.0301	-0.32	-0.17	Depression;	chr6:28313764	chr6:28161781~28169594:+
HNSC	cis	rs12073359	0.954	rs72692899	ENSG00000261716.1	RP11-196G18.22	-3.69	0.000254	0.0301	-0.21	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077980	chr1:149844498~149849024:-
HNSC	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-3.69	0.000254	0.0301	-0.26	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
HNSC	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-3.69	0.000254	0.0301	-0.18	-0.17	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
HNSC	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	3.69	0.000254	0.0301	0.21	0.17	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
HNSC	cis	rs1008375	1	rs10009541	ENSG00000249502.1	AC006160.5	3.69	0.000254	0.0301	0.18	0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680595	chr4:17587467~17614571:-
HNSC	cis	rs10771431	0.81	rs10771418	ENSG00000256427.1	RP11-118B22.4	3.69	0.000254	0.0302	0.18	0.17	Breast size;	chr12:9206399	chr12:9246497~9257960:+
HNSC	cis	rs1150668	0.796	rs2531832	ENSG00000217862.2	HIST1H4PS1	-3.69	0.000254	0.0302	-0.17	-0.17	Pubertal anthropometrics;	chr6:28421445	chr6:27807075~27807339:+
HNSC	cis	rs9400467	0.509	rs11153287	ENSG00000271789.1	RP5-1112D6.7	-3.69	0.000254	0.0302	-0.2	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111297126~111298510:+
HNSC	cis	rs28489187	0.597	rs6576765	ENSG00000223653.4	RP11-131L23.1	-3.69	0.000254	0.0302	-0.22	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85405329	chr1:85276715~85448124:+
HNSC	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-3.69	0.000254	0.0302	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
HNSC	cis	rs17739794	0.764	rs2336409	ENSG00000254207.1	RP11-43A14.1	3.69	0.000254	0.0302	0.2	0.17	Clozapine-induced cytotoxicity;	chr8:859079	chr8:725188~725877:-
HNSC	cis	rs7714670	0.736	rs1565005	ENSG00000184084.7	CTD-2372A4.1	-3.69	0.000254	0.0302	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73799810	chr5:73803296~73803599:-
HNSC	cis	rs9914988	0.887	rs62066838	ENSG00000264577.1	AC010761.8	-3.69	0.000254	0.0302	-0.14	-0.17	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28857515	chr17:28721487~28722877:-
HNSC	cis	rs17772222	0.92	rs61975260	ENSG00000258789.1	RP11-507K2.3	-3.69	0.000254	0.0302	-0.22	-0.17	Coronary artery calcification;	chr14:88429597	chr14:88551597~88552493:+
HNSC	cis	rs6122940	0.73	rs6126042	ENSG00000203999.7	LINC01270	3.69	0.000254	0.0302	0.3	0.17	Lymphocyte counts;	chr20:50545649	chr20:50292720~50314922:+
HNSC	cis	rs875971	0.522	rs9530	ENSG00000272831.1	RP11-792A8.4	3.69	0.000254	0.0302	0.14	0.17	Aortic root size;	chr7:65960907	chr7:66739829~66740385:-
HNSC	cis	rs7824557	0.51	rs4841524	ENSG00000255495.1	AC145124.2	-3.69	0.000254	0.0302	-0.19	-0.17	Retinal vascular caliber;	chr8:11385617	chr8:12194467~12196280:+
HNSC	cis	rs2179367	0.959	rs4895788	ENSG00000216906.2	RP11-350J20.9	3.69	0.000254	0.0302	0.21	0.17	Dupuytren's disease;	chr6:149426955	chr6:149904243~149906418:+
HNSC	cis	rs12586317	0.513	rs17102962	ENSG00000258704.4	SRP54-AS1	-3.69	0.000254	0.0302	-0.22	-0.17	Psoriasis;	chr14:35009576	chr14:34920858~34982532:-
HNSC	cis	rs153852	1	rs153852	ENSG00000243806.1	RPL7P18	3.69	0.000254	0.0302	0.2	0.17	Cancer;	chr5:94840876	chr5:94825961~94826694:-
HNSC	cis	rs7085104	0.552	rs11191414	ENSG00000213061.2	PFN1P11	3.69	0.000254	0.0302	0.21	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102838011~102845473:-
HNSC	cis	rs6952407	1	rs6952407	ENSG00000273142.1	RP11-458F8.4	3.69	0.000254	0.0302	0.14	0.17	Cotinine glucuronidation;	chr7:66580525	chr7:66902857~66906297:+
HNSC	cis	rs12234571	1	rs61283667	ENSG00000214293.7	APTR	3.69	0.000254	0.0302	0.23	0.17	Obesity-related traits;	chr7:77879771	chr7:77657660~77696265:-
HNSC	cis	rs9880211	0.898	rs9870825	ENSG00000239213.4	NCK1-AS1	3.69	0.000254	0.0302	0.17	0.17	Height;Body mass index;	chr3:136346878	chr3:136841726~136862054:-
HNSC	cis	rs7637230	0.945	rs6772005	ENSG00000244119.1	PDCL3P4	-3.69	0.000254	0.0302	-0.18	-0.17	Psoriasis vulgaris;Psoriasis;	chr3:101919648	chr3:101712472~101713191:+
HNSC	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-3.69	0.000254	0.0302	-0.17	-0.17	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
HNSC	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000255	0.0302	-0.21	-0.17	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000255	0.0302	-0.21	-0.17	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
HNSC	cis	rs6710503	0.662	rs11693308	ENSG00000271936.1	RP11-443B20.1	-3.69	0.000255	0.0302	-0.21	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24723319	chr2:24825610~24826717:+
HNSC	cis	rs3213758	0.541	rs9935278	ENSG00000275191.1	RP11-36I17.2	-3.69	0.000255	0.0302	-0.26	-0.17	Vitiligo (non-segmental);	chr16:53627670	chr16:53628256~53628816:-
HNSC	cis	rs3213758	0.541	rs1344504	ENSG00000275191.1	RP11-36I17.2	-3.69	0.000255	0.0302	-0.26	-0.17	Vitiligo (non-segmental);	chr16:53627958	chr16:53628256~53628816:-
HNSC	cis	rs7824557	0.564	rs55758514	ENSG00000255310.2	AF131215.2	-3.69	0.000255	0.0302	-0.16	-0.17	Retinal vascular caliber;	chr8:11372750	chr8:11107788~11109726:-
HNSC	cis	rs1519814	0.581	rs1879150	ENSG00000254343.2	RP11-760H22.2	-3.69	0.000255	0.0302	-0.23	-0.17	Breast cancer;	chr8:119998994	chr8:120052180~120056201:+
HNSC	cis	rs1519814	0.616	rs2326428	ENSG00000254343.2	RP11-760H22.2	-3.69	0.000255	0.0302	-0.23	-0.17	Breast cancer;	chr8:119999124	chr8:120052180~120056201:+
HNSC	cis	rs4699052	0.662	rs6533082	ENSG00000246560.2	RP11-10L12.4	3.69	0.000255	0.0302	0.19	0.17	Testicular germ cell tumor;	chr4:103320048	chr4:102828055~102844075:+
HNSC	cis	rs6012564	0.964	rs73266241	ENSG00000227431.4	CSE1L-AS1	3.69	0.000255	0.0302	0.19	0.17	Anger;	chr20:49043748	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs1022687	ENSG00000227431.4	CSE1L-AS1	-3.69	0.000255	0.0302	-0.19	-0.17	Anger;	chr20:49032317	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.964	rs3092302	ENSG00000227431.4	CSE1L-AS1	-3.69	0.000255	0.0302	-0.19	-0.17	Anger;	chr20:49037721	chr20:49040463~49046044:-
HNSC	cis	rs4713118	0.955	rs9468203	ENSG00000226314.6	ZNF192P1	-3.69	0.000255	0.0302	-0.2	-0.17	Parkinson's disease;	chr6:27720888	chr6:28161781~28169594:+
HNSC	cis	rs801193	1	rs2659906	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000255	0.0302	-0.14	-0.17	Aortic root size;	chr7:66700323	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.935	rs2659899	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000255	0.0302	-0.14	-0.17	Aortic root size;	chr7:66721734	chr7:66902857~66906297:+
HNSC	cis	rs2307394	1	rs2113793	ENSG00000281469.1	RP11-567F11.1	3.69	0.000255	0.0302	0.18	0.17	Urate levels;	chr2:147865884	chr2:148044380~148044894:+
HNSC	cis	rs9863	0.861	rs7312404	ENSG00000270028.1	RP11-380L11.4	3.69	0.000255	0.0302	0.2	0.17	White blood cell count;	chr12:123962181	chr12:123925461~123926083:-
HNSC	cis	rs10851478	0.872	rs12591659	ENSG00000259656.1	RP11-325E5.1	3.69	0.000255	0.0302	0.2	0.17	Oral cavity cancer;	chr15:49641626	chr15:49101791~49103264:+
HNSC	cis	rs853679	1	rs853679	ENSG00000270326.1	RP5-874C20.6	-3.69	0.000255	0.0302	-0.25	-0.17	Depression;	chr6:28329086	chr6:28319660~28319852:-
HNSC	cis	rs853679	1	rs853678	ENSG00000270326.1	RP5-874C20.6	-3.69	0.000255	0.0302	-0.25	-0.17	Depression;	chr6:28329536	chr6:28319660~28319852:-
HNSC	cis	rs12935418	0.83	rs7188549	ENSG00000278985.1	RP11-303E16.9	3.69	0.000255	0.0302	0.21	0.17	Mean corpuscular volume;	chr16:81016371	chr16:80982319~80984094:-
HNSC	cis	rs1881509	0.702	rs1554856	ENSG00000255153.1	TOLLIP-AS1	-3.69	0.000255	0.0302	-0.18	-0.17	Heroin dependence;	chr11:1412666	chr11:1309769~1310707:+
HNSC	cis	rs7520050	0.966	rs785492	ENSG00000280836.1	AL355480.1	3.69	0.000255	0.0302	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45581219~45581321:-
HNSC	cis	rs1830074	1	rs1830074	ENSG00000187953.9	PMS2CL	-3.69	0.000255	0.0302	-0.18	-0.17	Body mass index;	chr7:6679043	chr7:6710128~6753862:+
HNSC	cis	rs9313772	1	rs1952652	ENSG00000254350.1	RP11-542A14.1	-3.69	0.000255	0.0302	-0.19	-0.17	Blood pressure;	chr5:158384080	chr5:158424585~158452758:+
HNSC	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000255	0.0302	0.17	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
HNSC	cis	rs300890	0.76	rs10028909	ENSG00000250326.1	RP11-284M14.1	-3.69	0.000255	0.0302	-0.19	-0.17	Nasopharyngeal carcinoma;	chr4:143279439	chr4:142933195~143184861:-
HNSC	cis	rs1538970	0.924	rs12097497	ENSG00000234329.1	RP11-767N6.2	3.69	0.000255	0.0302	0.19	0.17	Platelet count;	chr1:45414997	chr1:45651039~45651826:-
HNSC	cis	rs72827839	0.802	rs4794321	ENSG00000228782.6	CTD-2026D20.3	-3.69	0.000255	0.0302	-0.2	-0.17	Ease of getting up in the morning;	chr17:47951478	chr17:47450568~47492492:-
HNSC	cis	rs2179367	1	rs2179367	ENSG00000216906.2	RP11-350J20.9	3.69	0.000255	0.0302	0.21	0.17	Dupuytren's disease;	chr6:149441401	chr6:149904243~149906418:+
HNSC	cis	rs137699	1	rs2049986	ENSG00000261202.1	RP3-496C20.1	3.69	0.000255	0.0302	0.19	0.17	IgG glycosylation;	chr22:39360849	chr22:40043068~40044530:-
HNSC	cis	rs3764021	0.84	rs10743823	ENSG00000256673.1	RP11-599J14.2	-3.69	0.000255	0.0303	-0.16	-0.17	Type 1 diabetes;	chr12:9728529	chr12:9398355~9414851:-
HNSC	cis	rs13178541	0.745	rs35767093	ENSG00000250378.1	RP11-119J18.1	-3.69	0.000255	0.0303	-0.22	-0.17	IgG glycosylation;	chr5:135765243	chr5:135812667~135826582:+
HNSC	cis	rs17508449	0.732	rs75746385	ENSG00000232450.1	RP4-730K3.3	-3.69	0.000255	0.0303	-0.27	-0.17	Leprosy;	chr1:113758270	chr1:113698884~113699631:-
HNSC	cis	rs2016266	0.785	rs10747660	ENSG00000270175.1	RP11-793H13.11	-3.69	0.000255	0.0303	-0.16	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53256090	chr12:53500162~53500936:-
HNSC	cis	rs1035144	0.583	rs35472552	ENSG00000258841.1	EEF1A1P2	3.69	0.000255	0.0303	0.18	0.17	Male sexual orientation;	chr14:81001906	chr14:81661428~81662874:+
HNSC	cis	rs4835473	0.808	rs6836630	ENSG00000249741.2	RP11-673E1.3	3.69	0.000255	0.0303	0.19	0.17	Immature fraction of reticulocytes;	chr4:143801068	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs13101541	ENSG00000249741.2	RP11-673E1.3	3.69	0.000255	0.0303	0.19	0.17	Immature fraction of reticulocytes;	chr4:143806590	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs17695238	ENSG00000249741.2	RP11-673E1.3	3.69	0.000255	0.0303	0.19	0.17	Immature fraction of reticulocytes;	chr4:143820720	chr4:143911514~143912053:-
HNSC	cis	rs597539	0.69	rs552517	ENSG00000255741.1	RP11-757G1.5	-3.69	0.000255	0.0303	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68941503~68942852:-
HNSC	cis	rs11951515	0.738	rs4866822	ENSG00000249286.1	CTD-2210P15.2	3.69	0.000255	0.0303	0.18	0.17	Metabolite levels  (X-11787);	chr5:43357992	chr5:43586918~43588223:-
HNSC	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	3.69	0.000255	0.0303	0.26	0.17	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
HNSC	cis	rs614226	0.935	rs2235222	ENSG00000202538.1	RNU4-2	3.69	0.000255	0.0303	0.27	0.17	Type 1 diabetes nephropathy;	chr12:120454390	chr12:120291763~120291903:-
HNSC	cis	rs45509595	0.822	rs200484	ENSG00000219392.1	RP1-265C24.5	-3.68	0.000256	0.0303	-0.29	-0.17	Breast cancer;	chr6:27807896	chr6:28115628~28116551:+
HNSC	cis	rs1519814	0.696	rs2326430	ENSG00000254343.2	RP11-760H22.2	-3.68	0.000256	0.0303	-0.23	-0.17	Breast cancer;	chr8:120024659	chr8:120052180~120056201:+
HNSC	cis	rs853679	0.546	rs200989	ENSG00000219392.1	RP1-265C24.5	-3.68	0.000256	0.0303	-0.29	-0.17	Depression;	chr6:27848664	chr6:28115628~28116551:+
HNSC	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	3.68	0.000256	0.0303	0.21	0.17	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
HNSC	cis	rs988913	0.706	rs9475130	ENSG00000224984.1	RP11-524H19.2	3.68	0.000256	0.0303	0.19	0.17	Menarche (age at onset);	chr6:55060668	chr6:54840118~54840855:-
HNSC	cis	rs9500256	0.655	rs12191043	ENSG00000225096.1	XXbac-BPG55C20.7	-3.68	0.000256	0.0303	-0.2	-0.17	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57965630~57972218:+
HNSC	cis	rs4388249	1	rs3753175	ENSG00000271849.1	CTC-332L22.1	-3.68	0.000256	0.0303	-0.26	-0.17	Schizophrenia;	chr5:109772237	chr5:109687802~109688329:-
HNSC	cis	rs1602565	1	rs7938219	ENSG00000255450.1	CTD-2063L20.1	-3.68	0.000256	0.0303	-0.3	-0.17	Schizophrenia;	chr11:29180893	chr11:29275655~29276565:+
HNSC	cis	rs793571	0.822	rs17302038	ENSG00000245975.2	RP11-30K9.6	3.68	0.000256	0.0303	0.28	0.17	Schizophrenia;	chr15:58876603	chr15:58768072~58770974:-
HNSC	cis	rs9611565	0.625	rs73178625	ENSG00000235513.1	RP4-756G23.5	3.68	0.000256	0.0303	0.2	0.17	Vitiligo;	chr22:41532316	chr22:41209122~41217627:-
HNSC	cis	rs2060793	0.712	rs6486202	ENSG00000254418.1	RP11-21L19.1	3.68	0.000256	0.0303	0.19	0.17	Vitamin D levels;	chr11:14777260	chr11:14262846~14273691:-
HNSC	cis	rs11773103	0.786	rs56365880	ENSG00000224046.1	AC005076.5	3.68	0.000256	0.0303	0.24	0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87126354	chr7:87151423~87152420:-
HNSC	cis	rs1298062	0.861	rs2431821	ENSG00000268047.1	AC018766.6	-3.68	0.000256	0.0303	-0.17	-0.17	Age of smoking initiation;	chr19:50491841	chr19:49852887~49854967:-
HNSC	cis	rs6430585	0.528	rs309123	ENSG00000231890.6	DARS-AS1	-3.68	0.000256	0.0303	-0.29	-0.17	Corneal structure;	chr2:136003605	chr2:135985176~136022593:+
HNSC	cis	rs868153	0.557	rs7757343	ENSG00000275339.1	RP3-425C14.6	3.68	0.000256	0.0303	0.18	0.17	Vertical cup-disc ratio;	chr6:122237159	chr6:122454358~122454612:+
HNSC	cis	rs10742752	0.676	rs12275086	ENSG00000254651.1	RP11-430H10.3	3.68	0.000256	0.0303	0.2	0.17	Body mass index;	chr11:45401189	chr11:45399448~45400528:+
HNSC	cis	rs792448	0.743	rs351398	ENSG00000226251.4	RP11-15I11.3	-3.68	0.000256	0.0303	-0.21	-0.17	White blood cell count (basophil);	chr1:212292897	chr1:212225278~212238977:-
HNSC	cis	rs6012564	0.826	rs2869715	ENSG00000227431.4	CSE1L-AS1	3.68	0.000256	0.0303	0.19	0.17	Anger;	chr20:49143463	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.793	rs6066979	ENSG00000227431.4	CSE1L-AS1	3.68	0.000256	0.0303	0.19	0.17	Anger;	chr20:49144319	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.762	rs6066980	ENSG00000227431.4	CSE1L-AS1	3.68	0.000256	0.0303	0.19	0.17	Anger;	chr20:49144320	chr20:49040463~49046044:-
HNSC	cis	rs2898290	0.622	rs13272061	ENSG00000269918.1	AF131215.9	-3.68	0.000256	0.0303	-0.16	-0.17	Systolic blood pressure;	chr8:11494752	chr8:11104691~11106704:-
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000272831.1	RP11-792A8.4	3.68	0.000256	0.0303	0.14	0.17	Aortic root size;	chr7:65871069	chr7:66739829~66740385:-
HNSC	cis	rs6088580	0.634	rs6059875	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000256	0.0303	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6088512	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000256	0.0303	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6058070	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000256	0.0303	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:33985617~33988989:-
HNSC	cis	rs4523957	0.533	rs9899330	ENSG00000262333.1	HNRNPA1P16	3.68	0.000256	0.0303	0.17	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2282533	chr17:2306761~2307715:+
HNSC	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-3.68	0.000256	0.0303	-0.2	-0.17	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
HNSC	cis	rs1298062	0.756	rs2463241	ENSG00000268047.1	AC018766.6	3.68	0.000256	0.0304	0.16	0.17	Age of smoking initiation;	chr19:50493704	chr19:49852887~49854967:-
HNSC	cis	rs7953528	1	rs7304170	ENSG00000245311.2	ARNTL2-AS1	-3.68	0.000256	0.0304	-0.28	-0.17	Bone mineral density;	chr12:27852908	chr12:27389789~27446625:-
HNSC	cis	rs7267979	0.745	rs6132845	ENSG00000231081.1	RP4-760C5.3	-3.68	0.000256	0.0304	-0.17	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26008791~26010531:-
HNSC	cis	rs73198271	0.694	rs73201840	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000256	0.0304	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.694	rs113694763	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000256	0.0304	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.694	rs115037021	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000256	0.0304	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.694	rs114184516	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000256	0.0304	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8456909~8461337:-
HNSC	cis	rs72843166	0.562	rs17760841	ENSG00000265971.1	RP11-269G24.6	-3.68	0.000256	0.0304	-0.21	-0.17	Intelligence (multi-trait analysis);	chr17:63395459	chr17:63454993~63455817:+
HNSC	cis	rs7572733	1	rs35062652	ENSG00000222017.1	AC011997.1	3.68	0.000256	0.0304	0.2	0.17	Dermatomyositis;	chr2:198063203	chr2:197693106~197774823:+
HNSC	cis	rs7771547	0.642	rs12214285	ENSG00000219023.1	RP3-340B19.2	-3.68	0.000256	0.0304	-0.15	-0.17	Platelet distribution width;	chr6:36466902	chr6:35555873~35556264:+
HNSC	cis	rs2625529	0.761	rs972029	ENSG00000260037.4	CTD-2524L6.3	-3.68	0.000256	0.0304	-0.24	-0.17	Red blood cell count;	chr15:71880645	chr15:71818396~71823384:+
HNSC	cis	rs5758659	1	rs5758677	ENSG00000270083.1	RP1-257I20.14	3.68	0.000257	0.0304	0.15	0.17	Cognitive function;	chr22:42247033	chr22:42089630~42090028:-
HNSC	cis	rs2048656	0.526	rs12545912	ENSG00000254340.1	RP11-10A14.3	3.68	0.000257	0.0304	0.24	0.17	Schizophrenia;	chr8:9744189	chr8:9141424~9145435:+
HNSC	cis	rs6012564	1	rs6063353	ENSG00000227431.4	CSE1L-AS1	3.68	0.000257	0.0304	0.19	0.17	Anger;	chr20:49103273	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs6063354	ENSG00000227431.4	CSE1L-AS1	3.68	0.000257	0.0304	0.19	0.17	Anger;	chr20:49103412	chr20:49040463~49046044:-
HNSC	cis	rs2016266	0.859	rs10876433	ENSG00000270175.1	RP11-793H13.11	3.68	0.000257	0.0304	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53340330	chr12:53500162~53500936:-
HNSC	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-3.68	0.000257	0.0304	-0.25	-0.17	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
HNSC	cis	rs12893668	0.637	rs4525427	ENSG00000269958.1	RP11-73M18.8	3.68	0.000257	0.0304	0.16	0.17	Reticulocyte count;	chr14:103606456	chr14:103696353~103697163:+
HNSC	cis	rs6710503	0.632	rs3769669	ENSG00000271936.1	RP11-443B20.1	-3.68	0.000257	0.0304	-0.21	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24726187	chr2:24825610~24826717:+
HNSC	cis	rs67311347	0.822	rs11709089	ENSG00000280739.1	EIF1B-AS1	3.68	0.000257	0.0304	0.18	0.17	Renal cell carcinoma;	chr3:40309993	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.866	rs9826419	ENSG00000280739.1	EIF1B-AS1	3.68	0.000257	0.0304	0.18	0.17	Renal cell carcinoma;	chr3:40310560	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.866	rs3214006	ENSG00000280739.1	EIF1B-AS1	3.68	0.000257	0.0304	0.18	0.17	Renal cell carcinoma;	chr3:40310643	chr3:40173145~40309698:-
HNSC	cis	rs10849893	0.538	rs10744762	ENSG00000258435.1	RP11-711D18.2	3.68	0.000257	0.0304	0.18	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121401898	chr12:121391962~121399859:+
HNSC	cis	rs7777677	0.925	rs4726542	ENSG00000211727.3	TRBV7-6	3.68	0.000257	0.0304	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142492132~142492673:+
HNSC	cis	rs11711311	1	rs16861312	ENSG00000241529.3	RN7SL767P	-3.68	0.000257	0.0304	-0.21	-0.17	IgG glycosylation;	chr3:113773555	chr3:113632704~113632998:+
HNSC	cis	rs579113	0.574	rs572845	ENSG00000222365.1	SNORD12B	3.68	0.000257	0.0304	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr20:49460077	chr20:49280319~49280409:+
HNSC	cis	rs160451	0.782	rs218892	ENSG00000251136.7	RP11-37B2.1	3.68	0.000257	0.0304	0.16	0.17	Leprosy;	chr8:89685582	chr8:89609409~89757727:-
HNSC	cis	rs7283707	0.581	rs9977069	ENSG00000236471.1	AF127577.12	3.68	0.000257	0.0304	0.3	0.17	QRS complex (12-leadsum);	chr21:15848298	chr21:15067070~15067837:+
HNSC	cis	rs7927592	0.956	rs7944870	ENSG00000255031.4	RP11-802E16.3	3.68	0.000257	0.0304	0.15	0.17	Total body bone mineral density;	chr11:68541640	chr11:68050740~68053762:+
HNSC	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	3.68	0.000257	0.0304	0.2	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
HNSC	cis	rs9393777	0.588	rs3799380	ENSG00000224843.5	LINC00240	-3.68	0.000257	0.0304	-0.2	-0.17	Intelligence (multi-trait analysis);	chr6:26466954	chr6:26956992~27023924:+
HNSC	cis	rs1865760	0.713	rs1130000	ENSG00000272810.1	U91328.22	-3.68	0.000257	0.0304	-0.15	-0.17	Height;	chr6:25985168	chr6:26013241~26013757:+
HNSC	cis	rs12693043	0.601	rs13407318	ENSG00000226853.2	AC010894.3	3.68	0.000257	0.0304	0.18	0.17	Urate levels (BMI interaction);	chr2:174528376	chr2:174487389~174488386:+
HNSC	cis	rs10075741	0.652	rs7721589	ENSG00000281357.1	ARRDC3-AS1	3.68	0.000257	0.0304	0.25	0.17	TRAIL levels;	chr5:92082012	chr5:91380349~91439085:+
HNSC	cis	rs2834288	0.7	rs11088263	ENSG00000273102.1	AP000569.9	-3.68	0.000257	0.0304	-0.2	-0.17	Gut microbiota (bacterial taxa);	chr21:33918486	chr21:33967101~33968573:-
HNSC	cis	rs2098713	0.537	rs36190855	ENSG00000250155.1	CTD-2353F22.1	3.68	0.000257	0.0304	0.17	0.17	Telomere length;	chr5:37528407	chr5:36666214~36725195:-
HNSC	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	3.68	0.000257	0.0304	0.21	0.17	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
HNSC	cis	rs720475	0.732	rs17172978	ENSG00000170356.8	OR2A20P	3.68	0.000257	0.0305	0.24	0.17	Breast cancer;	chr7:144429551	chr7:144250045~144252957:-
HNSC	cis	rs2117029	0.5	rs1054442	ENSG00000258017.1	RP11-386G11.10	-3.68	0.000257	0.0305	-0.2	-0.17	Intelligence (multi-trait analysis);	chr12:48995537	chr12:49127782~49147869:+
HNSC	cis	rs4873772	0.66	rs13269722	ENSG00000253330.1	RP11-697N18.3	3.68	0.000257	0.0305	0.24	0.17	Lobe attachment (rater-scored or self-reported);	chr8:47895977	chr8:47511034~47512141:-
HNSC	cis	rs8017423	0.605	rs3742673	ENSG00000275198.1	RP11-471B22.3	-3.68	0.000257	0.0305	-0.17	-0.17	Mortality in heart failure;	chr14:90269363	chr14:90383365~90387973:+
HNSC	cis	rs711830	0.965	rs2857532	ENSG00000226363.3	HAGLROS	-3.68	0.000257	0.0305	-0.23	-0.17	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176168555	chr2:176177717~176179008:+
HNSC	cis	rs9505118	0.965	rs9502585	ENSG00000238221.1	RP11-69L16.4	3.68	0.000257	0.0305	0.21	0.17	Type 2 diabetes;	chr6:7291275	chr6:7276031~7298872:+
HNSC	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	3.68	0.000257	0.0305	0.18	0.17	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
HNSC	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	3.68	0.000257	0.0305	0.29	0.17	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
HNSC	cis	rs853679	0.546	rs35656932	ENSG00000226314.6	ZNF192P1	-3.68	0.000257	0.0305	-0.33	-0.17	Depression;	chr6:28223510	chr6:28161781~28169594:+
HNSC	cis	rs332034	0.546	rs28581487	ENSG00000253893.2	FAM85B	3.68	0.000258	0.0305	0.31	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8838832	chr8:8167819~8226614:-
HNSC	cis	rs332034	0.546	rs28481744	ENSG00000253893.2	FAM85B	3.68	0.000258	0.0305	0.31	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8838836	chr8:8167819~8226614:-
HNSC	cis	rs7176527	1	rs3762168	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000258	0.0305	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84394512~84395514:+
HNSC	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	3.68	0.000258	0.0305	0.2	0.17	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000227888.4	FAM66A	-3.68	0.000258	0.0305	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12362019~12388296:+
HNSC	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-3.68	0.000258	0.0305	-0.15	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
HNSC	cis	rs17122278	1	rs11216891	ENSG00000255422.1	AP002954.4	3.68	0.000258	0.0305	0.3	0.17	Total cholesterol levels;	chr11:118551519	chr11:118704607~118750263:+
HNSC	cis	rs820077	0.61	rs2177382	ENSG00000272374.1	RP3-329A5.8	-3.68	0.000258	0.0305	-0.2	-0.17	Systemic lupus erythematosus;	chr6:35082729	chr6:35220370~35224630:-
HNSC	cis	rs3741151	0.686	rs11235809	ENSG00000256448.4	RP11-809N8.4	3.68	0.000258	0.0305	0.24	0.17	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73579118	chr11:73405297~73410682:+
HNSC	cis	rs727563	0.638	rs4820443	ENSG00000235513.1	RP4-756G23.5	3.68	0.000258	0.0305	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr22:41209122~41217627:-
HNSC	cis	rs7092929	0.574	rs7074352	ENSG00000237399.6	PITRM1-AS1	3.68	0.000258	0.0305	0.19	0.17	Coronary artery calcification;	chr10:3496557	chr10:3141632~3167972:+
HNSC	cis	rs6001482	0.647	rs8140302	ENSG00000253818.1	IGLV1-41	-3.68	0.000258	0.0305	-0.14	-0.17	Diastolic blood pressure;	chr22:22234843	chr22:22404207~22404721:+
HNSC	cis	rs298182	0.803	rs298196	ENSG00000254102.1	RP11-21C4.1	-3.68	0.000258	0.0305	-0.27	-0.17	Verbal declarative memory;	chr8:64384045	chr8:64574306~64581888:-
HNSC	cis	rs298182	0.73	rs298197	ENSG00000254102.1	RP11-21C4.1	-3.68	0.000258	0.0305	-0.27	-0.17	Verbal declarative memory;	chr8:64384407	chr8:64574306~64581888:-
HNSC	cis	rs298182	0.803	rs298198	ENSG00000254102.1	RP11-21C4.1	-3.68	0.000258	0.0305	-0.27	-0.17	Verbal declarative memory;	chr8:64384609	chr8:64574306~64581888:-
HNSC	cis	rs298182	1	rs298179	ENSG00000254102.1	RP11-21C4.1	-3.68	0.000258	0.0305	-0.27	-0.17	Verbal declarative memory;	chr8:64388316	chr8:64574306~64581888:-
HNSC	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	3.68	0.000258	0.0305	0.19	0.17	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
HNSC	cis	rs6587515	0.748	rs7520511	ENSG00000274963.1	Metazoa_SRP	-3.68	0.000258	0.0305	-0.27	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150687216	chr1:150568971~150569269:-
HNSC	cis	rs6587515	0.901	rs7520516	ENSG00000274963.1	Metazoa_SRP	-3.68	0.000258	0.0305	-0.27	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150687219	chr1:150568971~150569269:-
HNSC	cis	rs9467711	0.659	rs34605993	ENSG00000241549.7	GUSBP2	3.68	0.000258	0.0305	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.659	rs35680819	ENSG00000241549.7	GUSBP2	3.68	0.000258	0.0305	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.659	rs36033628	ENSG00000241549.7	GUSBP2	3.68	0.000258	0.0305	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:26871484~26956554:-
HNSC	cis	rs13438327	1	rs10251155	ENSG00000243554.1	AC004967.7	3.68	0.000258	0.0305	0.35	0.17	Sudden cardiac arrest;	chr7:97989224	chr7:97969005~97972254:-
HNSC	cis	rs9487051	0.837	rs932223	ENSG00000219700.1	PTCHD3P3	3.68	0.000258	0.0305	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109265453	chr6:109288571~109290503:-
HNSC	cis	rs859767	0.54	rs13424016	ENSG00000224043.6	CCNT2-AS1	3.68	0.000258	0.0305	0.2	0.17	Neuroticism;	chr2:134648825	chr2:134735464~134918710:-
HNSC	cis	rs561341	1	rs55962687	ENSG00000278867.1	RP11-640N20.4	-3.68	0.000258	0.0305	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31933350	chr17:32051030~32053208:+
HNSC	cis	rs7746199	0.736	rs17693963	ENSG00000226314.6	ZNF192P1	-3.68	0.000258	0.0305	-0.3	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28161781~28169594:+
HNSC	cis	rs79349575	0.721	rs4794004	ENSG00000270781.1	RP11-501C14.9	-3.68	0.000258	0.0305	-0.18	-0.17	Type 2 diabetes;	chr17:48961109	chr17:48899131~48899748:+
HNSC	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-3.68	0.000258	0.0305	-0.2	-0.17	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
HNSC	cis	rs3764400	0.564	rs12602670	ENSG00000228782.6	CTD-2026D20.3	-3.68	0.000258	0.0305	-0.25	-0.17	Body mass index;	chr17:48027514	chr17:47450568~47492492:-
HNSC	cis	rs365302	0.672	rs396364	ENSG00000235086.1	FNDC1-IT1	3.68	0.000258	0.0305	0.2	0.17	Coronary heart disease;	chr6:159190119	chr6:159240786~159243329:+
HNSC	cis	rs11711311	0.955	rs34048496	ENSG00000241529.3	RN7SL767P	-3.68	0.000258	0.0305	-0.22	-0.17	IgG glycosylation;	chr3:113695274	chr3:113632704~113632998:+
HNSC	cis	rs1595825	0.891	rs16826895	ENSG00000231621.1	AC013264.2	-3.68	0.000258	0.0305	-0.21	-0.17	Ulcerative colitis;	chr2:198036918	chr2:197197991~197199273:+
HNSC	cis	rs597480	0.713	rs1445497	ENSG00000279742.1	RP11-700A24.1	-3.68	0.000258	0.0305	-0.19	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85807542	chr11:85852557~85854943:-
HNSC	cis	rs35146811	0.735	rs1043915	ENSG00000235077.1	AC073842.19	3.68	0.000258	0.0305	0.2	0.17	Coronary artery disease;	chr7:100202222	chr7:100130964~100140439:+
HNSC	cis	rs950027	0.62	rs1719246	ENSG00000259479.5	SORD2P	3.68	0.000258	0.0305	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:44826371~44884694:-
HNSC	cis	rs11148252	1	rs4886018	ENSG00000198384.8	TPTE2P3	3.68	0.000258	0.0305	0.2	0.17	Lewy body disease;	chr13:52416582	chr13:52522632~52586906:+
HNSC	cis	rs10073892	0.743	rs62372215	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315092	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs62372216	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315178	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs62372217	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315214	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.704	rs62372218	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315282	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs62372219	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315447	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.701	rs62372220	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315707	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs62372221	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315762	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs13360644	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102315968	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs13358420	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102316242	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.661	rs13358421	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102316254	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.701	rs13358882	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102316324	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.701	rs28625937	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102316525	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.701	rs28421510	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102316548	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10077220	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102317153	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs1584714	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102317653	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs1584715	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102317658	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs2895807	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102317866	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10063002	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102319868	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10214232	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102320466	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10073051	ENSG00000250682.4	LINC00491	-3.68	0.000258	0.0305	-0.23	-0.17	Cognitive decline (age-related);	chr5:102321228	chr5:102609156~102671559:-
HNSC	cis	rs6840360	0.87	rs1372978	ENSG00000251611.1	RP11-610P16.1	-3.68	0.000258	0.0306	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151407551~151408835:-
HNSC	cis	rs11157436	0.602	rs11157439	ENSG00000211814.1	TRAV35	-3.68	0.000258	0.0306	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22221896~22222475:+
HNSC	cis	rs11157436	0.602	rs10872984	ENSG00000211814.1	TRAV35	-3.68	0.000258	0.0306	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22221896~22222475:+
HNSC	cis	rs6088590	0.561	rs2295444	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000258	0.0306	-0.17	-0.17	Coronary artery disease;	chr20:34586079	chr20:33985617~33988989:-
HNSC	cis	rs7781557	0.938	rs73192015	ENSG00000239969.4	RP11-163E9.2	-3.68	0.000258	0.0306	-0.23	-0.17	Colorectal adenoma (advanced);	chr7:102871285	chr7:102364162~102380633:+
HNSC	cis	rs7937890	0.559	rs2034480	ENSG00000254418.1	RP11-21L19.1	3.68	0.000258	0.0306	0.2	0.17	Mitochondrial DNA levels;	chr11:14445377	chr11:14262846~14273691:-
HNSC	cis	rs67311347	1	rs9874006	ENSG00000280739.1	EIF1B-AS1	3.68	0.000258	0.0306	0.18	0.17	Renal cell carcinoma;	chr3:40430105	chr3:40173145~40309698:-
HNSC	cis	rs2554380	0.943	rs2585049	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000258	0.0306	-0.24	-0.17	Height;	chr15:83684121	chr15:84394512~84395514:+
HNSC	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-3.68	0.000258	0.0306	-0.2	-0.17	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
HNSC	cis	rs2836974	0.897	rs2026265	ENSG00000255568.3	BRWD1-AS2	3.68	0.000258	0.0306	0.15	0.17	Cognitive function;	chr21:39223591	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.897	rs1984022	ENSG00000255568.3	BRWD1-AS2	3.68	0.000258	0.0306	0.15	0.17	Cognitive function;	chr21:39224159	chr21:39313935~39314962:+
HNSC	cis	rs6545883	1	rs778763	ENSG00000271889.1	RP11-493E12.1	3.68	0.000259	0.0306	0.19	0.17	Tuberculosis;	chr2:61558504	chr2:61151433~61162105:-
HNSC	cis	rs11621710	0.557	rs799474	ENSG00000258704.4	SRP54-AS1	-3.68	0.000259	0.0306	-0.17	-0.17	Granulocyte percentage of myeloid white cells;	chr14:35046893	chr14:34920858~34982532:-
HNSC	cis	rs6088580	0.634	rs6059896	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000259	0.0306	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:33985617~33988989:-
HNSC	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	3.68	0.000259	0.0306	0.22	0.17	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
HNSC	cis	rs7777677	0.925	rs73543808	ENSG00000211727.3	TRBV7-6	3.68	0.000259	0.0306	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142492132~142492673:+
HNSC	cis	rs11671005	0.735	rs11668420	ENSG00000269473.1	CTD-2619J13.19	3.68	0.000259	0.0306	0.27	0.17	Mean platelet volume;	chr19:58426469	chr19:58440448~58445849:+
HNSC	cis	rs10221833	1	rs441414	ENSG00000233255.1	AC019181.2	3.68	0.000259	0.0306	0.33	0.17	Response to statin therapy;	chr2:164819183	chr2:164840749~164849334:+
HNSC	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-3.68	0.000259	0.0306	-0.12	-0.17	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
HNSC	cis	rs868153	0.625	rs2606593	ENSG00000275339.1	RP3-425C14.6	3.68	0.000259	0.0306	0.18	0.17	Vertical cup-disc ratio;	chr6:122251977	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs2770119	ENSG00000275339.1	RP3-425C14.6	3.68	0.000259	0.0306	0.18	0.17	Vertical cup-disc ratio;	chr6:122252810	chr6:122454358~122454612:+
HNSC	cis	rs28489187	0.706	rs173026	ENSG00000223653.4	RP11-131L23.1	3.68	0.000259	0.0306	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85338566	chr1:85276715~85448124:+
HNSC	cis	rs79040073	0.607	rs73400205	ENSG00000259531.2	RP11-295H24.3	3.68	0.000259	0.0306	0.21	0.17	Lung cancer in ever smokers;	chr15:49442346	chr15:49365124~49366685:-
HNSC	cis	rs13256369	1	rs10110591	ENSG00000173295.6	FAM86B3P	-3.68	0.000259	0.0306	-0.21	-0.17	Obesity-related traits;	chr8:8719098	chr8:8228595~8244865:+
HNSC	cis	rs57675369	1	rs57675369	ENSG00000251000.1	AC008592.3	3.68	0.000259	0.0306	0.28	0.17	Immature fraction of reticulocytes;	chr5:95826714	chr5:95834424~95835046:-
HNSC	cis	rs13178541	0.81	rs9327728	ENSG00000250378.1	RP11-119J18.1	-3.68	0.000259	0.0306	-0.21	-0.17	IgG glycosylation;	chr5:135760318	chr5:135812667~135826582:+
HNSC	cis	rs7824557	0.591	rs2293859	ENSG00000255495.1	AC145124.2	3.68	0.000259	0.0306	0.19	0.17	Retinal vascular caliber;	chr8:11359252	chr8:12194467~12196280:+
HNSC	cis	rs9611565	0.649	rs9623450	ENSG00000233903.2	Z83851.4	3.68	0.000259	0.0306	0.23	0.17	Vitiligo;	chr22:41779227	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.568	rs5751159	ENSG00000233903.2	Z83851.4	3.68	0.000259	0.0306	0.23	0.17	Vitiligo;	chr22:41779361	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.649	rs5758466	ENSG00000233903.2	Z83851.4	3.68	0.000259	0.0306	0.23	0.17	Vitiligo;	chr22:41780055	chr22:42276355~42277052:+
HNSC	cis	rs11231017	0.507	rs11231027	ENSG00000250659.2	RP11-864I4.3	-3.68	0.000259	0.0306	-0.21	-0.17	HIV-1 viral setpoint;	chr11:62312570	chr11:62537312~62542018:+
HNSC	cis	rs3808502	0.527	rs2736389	ENSG00000255310.2	AF131215.2	3.68	0.000259	0.0306	0.18	0.17	Neuroticism;	chr8:11303801	chr8:11107788~11109726:-
HNSC	cis	rs7927592	0.913	rs948316	ENSG00000255031.4	RP11-802E16.3	3.68	0.000259	0.0306	0.15	0.17	Total body bone mineral density;	chr11:68542202	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.956	rs10896341	ENSG00000255031.4	RP11-802E16.3	3.68	0.000259	0.0306	0.15	0.17	Total body bone mineral density;	chr11:68545712	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs67947146	ENSG00000255031.4	RP11-802E16.3	3.68	0.000259	0.0306	0.15	0.17	Total body bone mineral density;	chr11:68547512	chr11:68050740~68053762:+
HNSC	cis	rs4948102	0.731	rs7800001	ENSG00000213650.3	RP11-760D2.7	3.68	0.000259	0.0306	0.19	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56004317	chr7:56567906~56568858:-
HNSC	cis	rs1937680	0.688	rs10762468	ENSG00000236671.6	PRKG1-AS1	-3.68	0.000259	0.0306	-0.24	-0.17	Breast cancer;	chr10:51887351	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.582	rs10762469	ENSG00000236671.6	PRKG1-AS1	-3.68	0.000259	0.0306	-0.24	-0.17	Breast cancer;	chr10:51887362	chr10:52230742~52314128:-
HNSC	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	3.68	0.000259	0.0306	0.21	0.17	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
HNSC	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	3.68	0.000259	0.0306	0.17	0.17	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
HNSC	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	3.68	0.000259	0.0306	0.17	0.17	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
HNSC	cis	rs7209700	0.547	rs8078614	ENSG00000262879.4	RP11-156P1.3	3.68	0.000259	0.0306	0.22	0.17	IgG glycosylation;	chr17:47274139	chr17:46984045~47100323:-
HNSC	cis	rs7824557	0.527	rs4634600	ENSG00000255495.1	AC145124.2	-3.68	0.000259	0.0306	-0.19	-0.17	Retinal vascular caliber;	chr8:11381508	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.527	rs4631425	ENSG00000255495.1	AC145124.2	-3.68	0.000259	0.0306	-0.19	-0.17	Retinal vascular caliber;	chr8:11381545	chr8:12194467~12196280:+
HNSC	cis	rs3808502	0.585	rs4549730	ENSG00000255495.1	AC145124.2	-3.68	0.000259	0.0306	-0.19	-0.17	Neuroticism;	chr8:11381569	chr8:12194467~12196280:+
HNSC	cis	rs868153	0.558	rs1870006	ENSG00000275339.1	RP3-425C14.6	3.68	0.000259	0.0306	0.18	0.17	Vertical cup-disc ratio;	chr6:122246832	chr6:122454358~122454612:+
HNSC	cis	rs10851478	0.872	rs8032688	ENSG00000259656.1	RP11-325E5.1	3.68	0.000259	0.0306	0.2	0.17	Oral cavity cancer;	chr15:49637467	chr15:49101791~49103264:+
HNSC	cis	rs9813712	0.596	rs2587988	ENSG00000253540.4	FAM86HP	-3.68	0.000259	0.0306	-0.15	-0.17	Response to amphetamines;	chr3:130201415	chr3:130099092~130111472:-
HNSC	cis	rs2115630	1	rs58581703	ENSG00000275120.1	RP11-182J1.17	-3.68	0.000259	0.0306	-0.18	-0.17	P wave terminal force;	chr15:84733704	chr15:84599434~84606463:-
HNSC	cis	rs2835345	1	rs4817797	ENSG00000230479.1	AP000695.6	-3.68	0.000259	0.0307	-0.19	-0.17	Pulmonary function;	chr21:36429098	chr21:36430360~36481070:+
HNSC	cis	rs12666612	0.516	rs80353572	ENSG00000237773.4	AC003075.4	3.68	0.000259	0.0307	0.39	0.17	Obesity-related traits;	chr7:18187177	chr7:17279834~17299357:-
HNSC	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	3.68	0.000259	0.0307	0.19	0.17	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
HNSC	cis	rs2307394	0.896	rs12475399	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147800129	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs12479193	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147800342	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs12472058	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147800472	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs4972326	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147801279	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.858	rs4972327	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147801624	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs13024558	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147802007	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.964	rs7605029	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147802352	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs4972331	ENSG00000281469.1	RP11-567F11.1	3.68	0.000259	0.0307	0.18	0.17	Urate levels;	chr2:147803737	chr2:148044380~148044894:+
HNSC	cis	rs11098499	0.874	rs9995277	ENSG00000250412.1	KLHL2P1	3.68	0.000259	0.0307	0.21	0.17	Corneal astigmatism;	chr4:119187448	chr4:119334329~119378233:+
HNSC	cis	rs73198271	0.92	rs11783112	ENSG00000253893.2	FAM85B	3.68	0.000259	0.0307	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:8167819~8226614:-
HNSC	cis	rs116139393	0.611	rs7792579	ENSG00000187953.9	PMS2CL	-3.68	0.000259	0.0307	-0.23	-0.17	Alzheimer's disease (APOE e4 interaction);	chr7:6725962	chr7:6710128~6753862:+
HNSC	cis	rs1979679	0.842	rs7316299	ENSG00000247934.4	RP11-967K21.1	-3.68	0.000259	0.0307	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28163298~28190738:-
HNSC	cis	rs6545883	0.894	rs12997538	ENSG00000271889.1	RP11-493E12.1	-3.68	0.000259	0.0307	-0.19	-0.17	Tuberculosis;	chr2:61337114	chr2:61151433~61162105:-
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000272831.1	RP11-792A8.4	3.68	0.000259	0.0307	0.14	0.17	Aortic root size;	chr7:66789659	chr7:66739829~66740385:-
HNSC	cis	rs9500256	0.903	rs726783	ENSG00000225096.1	XXbac-BPG55C20.7	-3.68	0.00026	0.0307	-0.19	-0.17	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57965630~57972218:+
HNSC	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-3.68	0.00026	0.0307	-0.27	-0.17	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-3.68	0.00026	0.0307	-0.27	-0.17	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
HNSC	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-3.68	0.00026	0.0307	-0.27	-0.17	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
HNSC	cis	rs2439831	0.867	rs2255042	ENSG00000275601.1	AC011330.13	3.68	0.00026	0.0307	0.26	0.17	Lung cancer in ever smokers;	chr15:43542120	chr15:43642389~43643023:-
HNSC	cis	rs17660992	0.716	rs8111426	ENSG00000273837.1	LLNLR-470E3.1	-3.68	0.00026	0.0307	-0.19	-0.17	Blood protein levels;	chr19:51662110	chr19:51639478~51639931:-
HNSC	cis	rs6988985	0.765	rs4379428	ENSG00000247317.3	RP11-273G15.2	-3.68	0.00026	0.0307	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906632	chr8:142981738~143018437:-
HNSC	cis	rs268134	0.53	rs62139125	ENSG00000235725.1	AC007389.3	-3.68	0.00026	0.0307	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65373188	chr2:65589566~65640177:-
HNSC	cis	rs13178541	0.81	rs11951836	ENSG00000250378.1	RP11-119J18.1	-3.68	0.00026	0.0307	-0.22	-0.17	IgG glycosylation;	chr5:135816068	chr5:135812667~135826582:+
HNSC	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	3.68	0.00026	0.0307	0.24	0.17	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	3.68	0.00026	0.0307	0.24	0.17	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	3.68	0.00026	0.0307	0.24	0.17	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	3.68	0.00026	0.0307	0.24	0.17	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
HNSC	cis	rs870825	0.616	rs56232457	ENSG00000254233.1	RP11-242J7.1	3.68	0.00026	0.0307	0.25	0.17	Blood protein levels;	chr4:184706999	chr4:184584093~184625030:-
HNSC	cis	rs61160187	0.582	rs1526896	ENSG00000272308.1	RP11-231G3.1	-3.68	0.00026	0.0307	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60866457~60866935:-
HNSC	cis	rs2337406	0.866	rs4583128	ENSG00000280411.1	IGHV1-69-2	-3.68	0.00026	0.0307	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106780669	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.929	rs59263250	ENSG00000280411.1	IGHV1-69-2	-3.68	0.00026	0.0307	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106781183	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs58083017	ENSG00000280411.1	IGHV1-69-2	-3.68	0.00026	0.0307	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106781256	chr14:106762092~106762588:-
HNSC	cis	rs13434995	0.589	rs499110	ENSG00000249700.7	SRD5A3-AS1	-3.68	0.00026	0.0307	-0.22	-0.17	Adiponectin levels;	chr4:55381628	chr4:55363971~55395847:-
HNSC	cis	rs67311347	1	rs4973997	ENSG00000280739.1	EIF1B-AS1	3.68	0.00026	0.0307	0.18	0.17	Renal cell carcinoma;	chr3:40418654	chr3:40173145~40309698:-
HNSC	cis	rs2239557	1	rs7157566	ENSG00000258769.1	RAP1AP	3.68	0.00026	0.0307	0.18	0.17	Common traits (Other);	chr14:74182426	chr14:74482985~74483435:+
HNSC	cis	rs4266144	0.544	rs6805781	ENSG00000241770.1	RP11-555M1.3	3.68	0.00026	0.0307	0.19	0.17	Coronary artery disease;	chr3:157112780	chr3:157163452~157169133:+
HNSC	cis	rs12149074	0.527	rs1115722	ENSG00000261061.1	RP11-303E16.2	-3.68	0.00026	0.0307	-0.2	-0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80095775	chr16:81030770~81031485:+
HNSC	cis	rs720475	0.732	rs73159066	ENSG00000170356.8	OR2A20P	3.68	0.00026	0.0307	0.24	0.17	Breast cancer;	chr7:144426495	chr7:144250045~144252957:-
HNSC	cis	rs7005380	0.556	rs4073559	ENSG00000279347.1	RP11-85I17.2	-3.68	0.00026	0.0307	-0.17	-0.17	Interstitial lung disease;	chr8:119905203	chr8:119838736~119840385:-
HNSC	cis	rs7005380	0.531	rs7388491	ENSG00000279347.1	RP11-85I17.2	-3.68	0.00026	0.0307	-0.17	-0.17	Interstitial lung disease;	chr8:119913637	chr8:119838736~119840385:-
HNSC	cis	rs765751	0.736	rs2605108	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219478667	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs2791552	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219478691	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs1563350	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219479347	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs1563351	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219479352	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs1563355	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219479759	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.665	rs2605109	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219480012	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.699	rs2791551	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219481689	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs2791550	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219482027	chr1:219409681~219411941:-
HNSC	cis	rs765751	0.775	rs1531094	ENSG00000228536.1	RP11-392O17.1	-3.68	0.00026	0.0307	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219482534	chr1:219409681~219411941:-
HNSC	cis	rs516805	0.748	rs12212981	ENSG00000279453.1	RP3-425C14.4	3.68	0.00026	0.0307	0.26	0.17	Lymphocyte counts;	chr6:122580854	chr6:122436789~122439223:-
HNSC	cis	rs7937890	0.706	rs7115393	ENSG00000251991.1	RNU7-49P	-3.68	0.00026	0.0307	-0.19	-0.17	Mitochondrial DNA levels;	chr11:14246832	chr11:14478892~14478953:+
HNSC	cis	rs10865541	0.902	rs10173635	ENSG00000234171.2	RNASEH1-AS1	3.68	0.00026	0.0307	0.17	0.17	Obesity-related traits;	chr2:3417442	chr2:3558492~3561745:+
HNSC	cis	rs546131	0.515	rs7128804	ENSG00000271369.1	RP11-350D17.3	-3.68	0.00026	0.0307	-0.22	-0.17	Lung disease severity in cystic fibrosis;	chr11:34836401	chr11:34709600~34710161:+
HNSC	cis	rs2921036	0.505	rs35190619	ENSG00000253981.4	ALG1L13P	-3.68	0.00026	0.0307	-0.2	-0.17	Neuroticism;	chr8:8504313	chr8:8236003~8244667:-
HNSC	cis	rs73201462	1	rs2955096	ENSG00000231305.3	RP11-723O4.2	-3.68	0.00026	0.0307	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259023	chr3:128861313~128871540:-
HNSC	cis	rs1420956	0.512	rs661433	ENSG00000263846.1	CIAPIN1P	-3.68	0.00026	0.0307	-0.21	-0.17	Obesity-related traits;	chr18:27589392	chr18:26599408~26600338:+
HNSC	cis	rs11089937	0.54	rs9622920	ENSG00000234630.1	LL22NC03-2H8.4	-3.68	0.00026	0.0307	-0.15	-0.17	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22293733~22294794:+
HNSC	cis	rs757081	0.658	rs214069	ENSG00000260196.1	RP1-239B22.5	-3.68	0.00026	0.0307	-0.18	-0.17	Systolic blood pressure;	chr11:17284053	chr11:17380649~17383531:+
HNSC	cis	rs73173548	0.502	rs4129235	ENSG00000247828.6	TMEM161B-AS1	3.68	0.00026	0.0307	0.18	0.17	Macular telangiectasia type 2;	chr5:88441465	chr5:88268895~88436685:+
HNSC	cis	rs1991601	1	rs1991601	ENSG00000236449.1	AC018890.6	3.68	0.00026	0.0308	0.25	0.17	QRS complex (12-leadsum);	chr2:174603041	chr2:174547141~174774827:+
HNSC	cis	rs28830936	1	rs17678767	ENSG00000250379.1	RP11-23P13.4	3.68	0.00026	0.0308	0.2	0.17	Diastolic blood pressure;	chr15:41804224	chr15:41825099~41827936:-
HNSC	cis	rs1023500	0.505	rs134891	ENSG00000182057.4	OGFRP1	3.68	0.00026	0.0308	0.18	0.17	Schizophrenia;	chr22:42279876	chr22:42269753~42275196:+
HNSC	cis	rs896655	0.63	rs3900787	ENSG00000244230.3	RN7SL151P	3.68	0.000261	0.0308	0.17	0.17	Coronary artery disease;	chr9:21828111	chr9:21699314~21699596:+
HNSC	cis	rs55975637	0.73	rs71313564	ENSG00000240476.1	LINC00973	3.68	0.000261	0.0308	0.32	0.17	Advanced age-related macular degeneration;	chr3:99710828	chr3:98981058~98983096:+
HNSC	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	3.68	0.000261	0.0308	0.24	0.17	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	3.68	0.000261	0.0308	0.24	0.17	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	3.68	0.000261	0.0308	0.24	0.17	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
HNSC	cis	rs6570726	0.846	rs426874	ENSG00000270638.1	RP3-466P17.1	3.68	0.000261	0.0308	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145735570~145737218:+
HNSC	cis	rs13325613	0.834	rs34340501	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46183724	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs71327038	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46184503	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs36010446	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46185233	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs17282797	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46191273	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13080979	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46192198	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13097666	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46192975	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs13098911	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46193709	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.834	rs34378541	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46198157	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs17282922	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000261	0.0308	-0.3	-0.17	Monocyte count;	chr3:46198680	chr3:46364955~46407059:-
HNSC	cis	rs35306767	0.761	rs11253557	ENSG00000229869.1	RP11-363N22.2	-3.68	0.000261	0.0308	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:997727	chr10:933026~942743:+
HNSC	cis	rs6928977	0.66	rs2757647	ENSG00000231028.7	LINC00271	3.68	0.000261	0.0308	0.19	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135497801~135716055:+
HNSC	cis	rs2016266	0.787	rs61928080	ENSG00000270175.1	RP11-793H13.11	3.68	0.000261	0.0308	0.18	0.17	Bone mineral density;Bone mineral density (spine);	chr12:53358420	chr12:53500162~53500936:-
HNSC	cis	rs449789	0.502	rs529281	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159287473	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.817	rs534519	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159290897	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs2501175	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159293380	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.779	rs553197	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159293593	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs578714	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159294086	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs579533	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159294171	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs687314	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159295230	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs606833	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000261	0.0308	-0.2	-0.17	Pulse pressure;	chr6:159296744	chr6:159240786~159243329:+
HNSC	cis	rs35306767	0.622	rs66462130	ENSG00000229869.1	RP11-363N22.2	-3.68	0.000261	0.0308	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:976168	chr10:933026~942743:+
HNSC	cis	rs17250963	0.562	rs697568	ENSG00000249485.1	RBBP4P1	-3.68	0.000261	0.0308	-0.16	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14746241	chr5:14797125~14798400:-
HNSC	cis	rs4713118	0.5	rs9461434	ENSG00000219891.2	ZSCAN12P1	3.68	0.000261	0.0308	0.25	0.17	Parkinson's disease;	chr6:28134687	chr6:28091154~28093664:+
HNSC	cis	rs12664251	0.66	rs794257	ENSG00000253194.1	RP11-351A11.1	-3.68	0.000261	0.0308	-0.19	-0.17	Schizophrenia;	chr6:119032047	chr6:118934785~119031541:+
HNSC	cis	rs6928977	0.66	rs2614263	ENSG00000231028.7	LINC00271	3.68	0.000261	0.0308	0.19	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135497801~135716055:+
HNSC	cis	rs1552244	1	rs6764068	ENSG00000180385.7	EMC3-AS1	3.68	0.000261	0.0308	0.19	0.17	Alzheimer's disease;	chr3:10112158	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs113522867	ENSG00000180385.7	EMC3-AS1	3.68	0.000261	0.0308	0.19	0.17	Alzheimer's disease;	chr3:10112819	chr3:9986893~10006990:+
HNSC	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
HNSC	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	3.68	0.000261	0.0308	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
HNSC	cis	rs10927875	0.894	rs10927878	ENSG00000226029.1	RP4-798A10.2	3.68	0.000261	0.0308	0.17	0.17	Dilated cardiomyopathy;	chr1:15993462	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.894	rs34957618	ENSG00000226029.1	RP4-798A10.2	3.68	0.000261	0.0308	0.17	0.17	Dilated cardiomyopathy;	chr1:15994004	chr1:16460948~16468481:+
HNSC	cis	rs6928977	0.66	rs2614267	ENSG00000231028.7	LINC00271	3.68	0.000261	0.0308	0.19	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135497801~135716055:+
HNSC	cis	rs2638953	0.924	rs11049606	ENSG00000257176.2	RP11-996F15.2	3.68	0.000261	0.0308	0.19	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444213	chr12:29280418~29317848:-
HNSC	cis	rs639012	0.636	rs7110631	ENSG00000279742.1	RP11-700A24.1	-3.68	0.000261	0.0308	-0.18	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr11:86145145	chr11:85852557~85854943:-
HNSC	cis	rs8089099	0.546	rs498017	ENSG00000273352.1	RP11-61L19.3	-3.68	0.000261	0.0308	-0.19	-0.17	Pulmonary function (smoking interaction);	chr18:10087531	chr18:9519449~9520199:+
HNSC	cis	rs853679	1	rs2799077	ENSG00000219891.2	ZSCAN12P1	3.68	0.000261	0.0308	0.27	0.17	Depression;	chr6:28266819	chr6:28091154~28093664:+
HNSC	cis	rs6460942	0.597	rs7798779	ENSG00000226690.5	AC005281.1	3.68	0.000261	0.0309	0.27	0.17	Coronary artery disease;	chr7:12503864	chr7:12496429~12541910:+
HNSC	cis	rs13178541	0.745	rs3963615	ENSG00000250378.1	RP11-119J18.1	-3.68	0.000261	0.0309	-0.21	-0.17	IgG glycosylation;	chr5:135750292	chr5:135812667~135826582:+
HNSC	cis	rs2734839	0.507	rs2002453	ENSG00000270179.1	RP11-159N11.4	-3.68	0.000261	0.0309	-0.24	-0.17	Information processing speed;	chr11:113418576	chr11:113368478~113369117:+
HNSC	cis	rs66887589	0.934	rs56843000	ENSG00000249244.1	RP11-548H18.2	-3.68	0.000261	0.0309	-0.18	-0.17	Diastolic blood pressure;	chr4:119595442	chr4:119391831~119395335:-
HNSC	cis	rs2179367	0.959	rs4897125	ENSG00000216906.2	RP11-350J20.9	3.68	0.000261	0.0309	0.21	0.17	Dupuytren's disease;	chr6:149445072	chr6:149904243~149906418:+
HNSC	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	3.68	0.000261	0.0309	0.17	0.17	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
HNSC	cis	rs4704187	0.687	rs922390	ENSG00000271815.1	CTD-2235C13.3	-3.68	0.000262	0.0309	-0.21	-0.17	Response to amphetamines;	chr5:75105444	chr5:75363760~75364242:+
HNSC	cis	rs36093924	0.646	rs5996092	ENSG00000207457.1	RNU6-476P	-3.68	0.000262	0.0309	-0.17	-0.17	Intelligence;	chr22:41948404	chr22:41679711~41679817:+
HNSC	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	3.68	0.000262	0.0309	0.17	0.17	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
HNSC	cis	rs11098499	0.604	rs12642411	ENSG00000250412.1	KLHL2P1	3.68	0.000262	0.0309	0.23	0.17	Corneal astigmatism;	chr4:119659370	chr4:119334329~119378233:+
HNSC	cis	rs66887589	0.967	rs56173225	ENSG00000249244.1	RP11-548H18.2	-3.68	0.000262	0.0309	-0.18	-0.17	Diastolic blood pressure;	chr4:119588817	chr4:119391831~119395335:-
HNSC	cis	rs66887589	0.967	rs7678973	ENSG00000249244.1	RP11-548H18.2	-3.68	0.000262	0.0309	-0.18	-0.17	Diastolic blood pressure;	chr4:119590662	chr4:119391831~119395335:-
HNSC	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	3.68	0.000262	0.0309	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
HNSC	cis	rs11083475	0.935	rs10416718	ENSG00000269486.2	CTC-360G5.9	3.68	0.000262	0.0309	0.19	0.17	Heart rate;	chr19:38756336	chr19:38935297~38938632:-
HNSC	cis	rs1023500	0.505	rs134886	ENSG00000182057.4	OGFRP1	-3.68	0.000262	0.0309	-0.18	-0.17	Schizophrenia;	chr22:42277850	chr22:42269753~42275196:+
HNSC	cis	rs7746199	0.736	rs58616630	ENSG00000226314.6	ZNF192P1	-3.68	0.000262	0.0309	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28161781~28169594:+
HNSC	cis	rs61160187	0.51	rs4235481	ENSG00000272308.1	RP11-231G3.1	-3.68	0.000262	0.0309	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60866457~60866935:-
HNSC	cis	rs72827839	1	rs72827834	ENSG00000244649.3	CTD-2377D24.6	-3.68	0.000262	0.0309	-0.25	-0.17	Ease of getting up in the morning;	chr17:48336457	chr17:48646923~48707346:+
HNSC	cis	rs11711311	1	rs9288982	ENSG00000241529.3	RN7SL767P	-3.68	0.000262	0.0309	-0.22	-0.17	IgG glycosylation;	chr3:113751302	chr3:113632704~113632998:+
HNSC	cis	rs6554196	0.932	rs34284864	ENSG00000272650.1	RP11-571I18.4	-3.68	0.000262	0.0309	-0.2	-0.17	Monocyte count;	chr4:54668767	chr4:53997415~53997712:-
HNSC	cis	rs6840258	0.689	rs6811587	ENSG00000251411.1	RP11-397E7.4	3.68	0.000262	0.0309	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000653	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.76	rs340637	ENSG00000251411.1	RP11-397E7.4	3.68	0.000262	0.0309	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87008040	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.723	rs340633	ENSG00000251411.1	RP11-397E7.4	3.68	0.000262	0.0309	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87010746	chr4:86913266~86914817:-
HNSC	cis	rs16852403	0.531	rs608656	ENSG00000273062.1	RP11-428K3.1	-3.68	0.000262	0.0309	-0.19	-0.17	Childhood ear infection;	chr1:178232012	chr1:178724306~178726285:-
HNSC	cis	rs34286592	0.929	rs9932653	ENSG00000196796.5	CTB-134H23.2	3.68	0.000262	0.0309	0.25	0.17	Multiple sclerosis;	chr16:29854352	chr16:29038655~29052726:+
HNSC	cis	rs1937680	0.613	rs7069974	ENSG00000236671.6	PRKG1-AS1	-3.68	0.000262	0.0309	-0.24	-0.17	Breast cancer;	chr10:51882410	chr10:52230742~52314128:-
HNSC	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-3.68	0.000262	0.0309	-0.18	-0.17	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
HNSC	cis	rs67311347	1	rs9822644	ENSG00000280739.1	EIF1B-AS1	3.68	0.000262	0.0309	0.2	0.17	Renal cell carcinoma;	chr3:40385118	chr3:40173145~40309698:-
HNSC	cis	rs2657294	0.965	rs2047951	ENSG00000233313.2	HMGA1P5	-3.68	0.000262	0.0309	-0.18	-0.17	Pneumonia;	chr10:75161310	chr10:75276376~75276646:-
HNSC	cis	rs2657294	0.965	rs2804523	ENSG00000233313.2	HMGA1P5	-3.68	0.000262	0.0309	-0.18	-0.17	Pneumonia;	chr10:75161584	chr10:75276376~75276646:-
HNSC	cis	rs2657294	0.965	rs2657285	ENSG00000233313.2	HMGA1P5	-3.68	0.000262	0.0309	-0.18	-0.17	Pneumonia;	chr10:75164166	chr10:75276376~75276646:-
HNSC	cis	rs8049634	0.798	rs11639837	ENSG00000250685.6	RP11-486L19.2	3.68	0.000262	0.0309	0.17	0.17	Small cell lung carcinoma;	chr16:84197435	chr16:84192558~84197053:-
HNSC	cis	rs4814920	0.818	rs4813376	ENSG00000233895.1	RP1-122P22.2	3.68	0.000262	0.0309	0.21	0.17	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19757708~19809675:+
HNSC	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-3.68	0.000262	0.0309	-0.21	-0.17	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
HNSC	cis	rs62458065	1	rs6462363	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32425147	chr7:32456963~32457758:-
HNSC	cis	rs62458065	1	rs6462364	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32425164	chr7:32456963~32457758:-
HNSC	cis	rs62458065	1	rs10246687	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32425571	chr7:32456963~32457758:-
HNSC	cis	rs62458065	1	rs10231294	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32425745	chr7:32456963~32457758:-
HNSC	cis	rs62458065	1	rs10250808	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32426541	chr7:32456963~32457758:-
HNSC	cis	rs62458065	1	rs10275978	ENSG00000226468.2	AC018641.7	3.68	0.000262	0.0309	0.27	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32427107	chr7:32456963~32457758:-
HNSC	cis	rs36093924	0.646	rs4822069	ENSG00000182057.4	OGFRP1	-3.68	0.000262	0.0309	-0.17	-0.17	Intelligence;	chr22:41955477	chr22:42269753~42275196:+
HNSC	cis	rs847649	1	rs9718453	ENSG00000239969.4	RP11-163E9.2	3.68	0.000262	0.0309	0.19	0.17	Morning vs. evening chronotype;	chr7:102954529	chr7:102364162~102380633:+
HNSC	cis	rs847649	0.961	rs7456502	ENSG00000239969.4	RP11-163E9.2	3.68	0.000262	0.0309	0.19	0.17	Morning vs. evening chronotype;	chr7:102955575	chr7:102364162~102380633:+
HNSC	cis	rs9813712	0.526	rs13065659	ENSG00000253540.4	FAM86HP	-3.68	0.000262	0.0309	-0.16	-0.17	Response to amphetamines;	chr3:130231945	chr3:130099092~130111472:-
HNSC	cis	rs7829975	0.582	rs11783950	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000262	0.0309	-0.19	-0.17	Mood instability;	chr8:8740321	chr8:8456909~8461337:-
HNSC	cis	rs694383	1	rs1148776	ENSG00000261504.1	RP11-317P15.4	3.68	0.000262	0.0309	0.34	0.17	Chronotype;Sleep traits (multi-trait analysis);	chr1:182595169	chr1:182615254~182616629:+
HNSC	cis	rs7826238	0.543	rs2976908	ENSG00000233609.3	RP11-62H7.2	3.68	0.000262	0.031	0.16	0.17	Systolic blood pressure;	chr8:8488264	chr8:8961200~8979025:+
HNSC	cis	rs765751	0.696	rs2486895	ENSG00000228536.1	RP11-392O17.1	-3.68	0.000263	0.031	-0.2	-0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219480362	chr1:219409681~219411941:-
HNSC	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	3.68	0.000263	0.031	0.2	0.17	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-3.68	0.000263	0.031	-0.25	-0.17	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
HNSC	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-3.68	0.000263	0.031	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
HNSC	cis	rs17214007	0.518	rs35694612	ENSG00000263065.1	AF001548.6	-3.68	0.000263	0.031	-0.23	-0.17	Cognitive function;	chr16:15674392	chr16:15741151~15741791:+
HNSC	cis	rs10742752	0.651	rs35072015	ENSG00000255267.3	RP11-430H10.2	3.68	0.000263	0.031	0.22	0.17	Body mass index;	chr11:45405378	chr11:45371397~45388508:+
HNSC	cis	rs7829975	0.617	rs4841072	ENSG00000253981.4	ALG1L13P	-3.68	0.000263	0.031	-0.18	-0.17	Mood instability;	chr8:8933743	chr8:8236003~8244667:-
HNSC	cis	rs6095360	0.615	rs17445665	ENSG00000222365.1	SNORD12B	3.68	0.000263	0.031	0.2	0.17	Intelligence (multi-trait analysis);	chr20:48893954	chr20:49280319~49280409:+
HNSC	cis	rs72683786	0.623	rs4246122	ENSG00000279766.1	RP11-642A1.2	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr8:140715701	chr8:140572142~140572812:-
HNSC	cis	rs4812973	0.744	rs4613344	ENSG00000213820.3	RPL13P2	-3.68	0.000263	0.031	-0.33	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr20:45848118	chr20:46099518~46100176:+
HNSC	cis	rs34286592	1	rs34286592	ENSG00000214725.6	CDIPT-AS1	-3.68	0.000263	0.031	-0.25	-0.17	Multiple sclerosis;	chr16:29809159	chr16:29863593~29868053:+
HNSC	cis	rs9650657	0.65	rs2898248	ENSG00000255310.2	AF131215.2	3.68	0.000263	0.031	0.16	0.17	Neuroticism;	chr8:10779240	chr8:11107788~11109726:-
HNSC	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	3.68	0.000263	0.031	0.15	0.17	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
HNSC	cis	rs57237364	1	rs57237364	ENSG00000239969.4	RP11-163E9.2	-3.68	0.000263	0.031	-0.19	-0.17	Breast cancer;	chr7:102824806	chr7:102364162~102380633:+
HNSC	cis	rs11782824	0.679	rs6474512	ENSG00000253356.1	RP11-90P5.2	3.68	0.000263	0.031	0.19	0.17	Neuroticism;	chr8:38923088	chr8:38148741~38163772:+
HNSC	cis	rs12653396	0.609	rs2194027	ENSG00000247828.6	TMEM161B-AS1	3.68	0.000263	0.031	0.15	0.17	Educational attainment (years of education);	chr5:88526854	chr5:88268895~88436685:+
HNSC	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	3.68	0.000263	0.031	0.17	0.17	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
HNSC	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-3.68	0.000263	0.031	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
HNSC	cis	rs8062405	0.698	rs7188071	ENSG00000261089.1	RP11-435I10.3	-3.68	0.000263	0.031	-0.2	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28413703~28415018:+
HNSC	cis	rs6968419	0.755	rs73452247	ENSG00000237870.5	AC073130.1	3.68	0.000263	0.031	0.2	0.17	Intraocular pressure;	chr7:116253843	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs17138486	ENSG00000237870.5	AC073130.1	3.68	0.000263	0.031	0.2	0.17	Intraocular pressure;	chr7:116254349	chr7:116275606~116286734:-
HNSC	cis	rs9633740	0.545	rs2343306	ENSG00000226659.1	RP11-137H2.4	3.68	0.000263	0.031	0.25	0.17	Post bronchodilator FEV1;	chr10:80470390	chr10:80529597~80535942:-
HNSC	cis	rs2337406	1	rs17113257	ENSG00000211972.2	IGHV3-66	3.68	0.000263	0.031	0.17	0.17	Alzheimer's disease (late onset);	chr14:106679574	chr14:106675017~106675544:-
HNSC	cis	rs67311347	0.524	rs7649168	ENSG00000280739.1	EIF1B-AS1	3.68	0.000263	0.031	0.18	0.17	Renal cell carcinoma;	chr3:40314667	chr3:40173145~40309698:-
HNSC	cis	rs4906332	1	rs12896612	ENSG00000244691.1	RPL10AP1	-3.68	0.000263	0.031	-0.19	-0.17	Coronary artery disease;	chr14:103411531	chr14:103412119~103412761:-
HNSC	cis	rs863750	0.687	rs825476	ENSG00000275389.1	RP11-214K3.24	3.68	0.000263	0.031	0.23	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124083909	chr12:124085761~124088598:+
HNSC	cis	rs7927592	0.763	rs7119422	ENSG00000255031.4	RP11-802E16.3	-3.68	0.000263	0.031	-0.14	-0.17	Total body bone mineral density;	chr11:68563686	chr11:68050740~68053762:+
HNSC	cis	rs868153	0.591	rs1870005	ENSG00000275339.1	RP3-425C14.6	3.68	0.000263	0.031	0.18	0.17	Vertical cup-disc ratio;	chr6:122246993	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.558	rs1870001	ENSG00000275339.1	RP3-425C14.6	3.68	0.000263	0.031	0.18	0.17	Vertical cup-disc ratio;	chr6:122247491	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs2085400	ENSG00000275339.1	RP3-425C14.6	3.68	0.000263	0.031	0.18	0.17	Vertical cup-disc ratio;	chr6:122248199	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs2770117	ENSG00000275339.1	RP3-425C14.6	3.68	0.000263	0.031	0.18	0.17	Vertical cup-disc ratio;	chr6:122248464	chr6:122454358~122454612:+
HNSC	cis	rs11098499	0.866	rs7665125	ENSG00000260091.1	RP11-33B1.4	3.68	0.000264	0.031	0.16	0.17	Corneal astigmatism;	chr4:119480924	chr4:119409333~119410233:+
HNSC	cis	rs11153306	1	rs17703931	ENSG00000255389.1	C6orf3	3.68	0.000264	0.0311	0.15	0.17	Tonsillectomy;	chr6:111629792	chr6:111599875~111602295:+
HNSC	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-3.68	0.000264	0.0311	-0.25	-0.17	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
HNSC	cis	rs720475	0.695	rs62483108	ENSG00000170356.8	OR2A20P	3.68	0.000264	0.0311	0.24	0.17	Breast cancer;	chr7:144442326	chr7:144250045~144252957:-
HNSC	cis	rs11098499	0.874	rs17839089	ENSG00000250412.1	KLHL2P1	3.68	0.000264	0.0311	0.21	0.17	Corneal astigmatism;	chr4:119189914	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.874	rs6826823	ENSG00000250412.1	KLHL2P1	3.68	0.000264	0.0311	0.21	0.17	Corneal astigmatism;	chr4:119190943	chr4:119334329~119378233:+
HNSC	cis	rs11168618	0.875	rs11168606	ENSG00000240399.1	RP1-228P16.1	3.68	0.000264	0.0311	0.14	0.17	Adiponectin levels;	chr12:48498906	chr12:48054813~48055591:-
HNSC	cis	rs11168618	0.87	rs7302209	ENSG00000240399.1	RP1-228P16.1	3.68	0.000264	0.0311	0.14	0.17	Adiponectin levels;	chr12:48501601	chr12:48054813~48055591:-
HNSC	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000264	0.0311	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
HNSC	cis	rs268134	0.53	rs34820212	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65350186	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs35315862	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65351913	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs13011574	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65354918	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs17704661	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65358683	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs62139122	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65360492	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs17534153	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65371088	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs34665164	ENSG00000235725.1	AC007389.3	-3.68	0.000264	0.0311	-0.31	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65372150	chr2:65589566~65640177:-
HNSC	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	3.68	0.000264	0.0311	0.17	0.17	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
HNSC	cis	rs6693388	0.789	rs3791153	ENSG00000229021.2	AL591893.1	-3.68	0.000264	0.0311	-0.19	-0.17	Blood metabolite ratios;	chr1:151985668	chr1:151994531~152042774:+
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000272831.1	RP11-792A8.4	3.68	0.000264	0.0311	0.14	0.17	Calcium levels;	chr7:65903721	chr7:66739829~66740385:-
HNSC	cis	rs2436845	1	rs2679754	ENSG00000253669.3	KB-1732A1.1	-3.68	0.000264	0.0311	-0.16	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855772	chr8:102805517~102809971:+
HNSC	cis	rs8077577	0.708	rs4925151	ENSG00000273018.4	CTD-2303H24.2	3.68	0.000264	0.0311	0.24	0.17	Obesity-related traits;	chr17:18226818	chr17:18511221~18551705:-
HNSC	cis	rs73198271	0.729	rs66564323	ENSG00000254340.1	RP11-10A14.3	-3.68	0.000264	0.0311	-0.26	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747486	chr8:9141424~9145435:+
HNSC	cis	rs73198271	0.729	rs67653033	ENSG00000254340.1	RP11-10A14.3	-3.68	0.000264	0.0311	-0.26	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747534	chr8:9141424~9145435:+
HNSC	cis	rs73198271	0.729	rs67000451	ENSG00000254340.1	RP11-10A14.3	-3.68	0.000264	0.0311	-0.26	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747573	chr8:9141424~9145435:+
HNSC	cis	rs7512898	0.545	rs12047681	ENSG00000260088.1	RP11-92G12.3	-3.68	0.000264	0.0311	-0.2	-0.17	Electrocardiographic conduction measures;	chr1:200727731	chr1:200669507~200694250:+
HNSC	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0311	-0.24	-0.17	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
HNSC	cis	rs7824557	0.603	rs6995404	ENSG00000255020.1	AF131216.5	3.68	0.000264	0.0311	0.17	0.17	Retinal vascular caliber;	chr8:11324639	chr8:11345748~11347502:-
HNSC	cis	rs1015213	1	rs7816406	ENSG00000253844.1	RP11-546K22.1	-3.68	0.000264	0.0311	-0.31	-0.17	Glaucoma (primary angle closure);	chr8:51978116	chr8:51961458~52022974:+
HNSC	cis	rs1015213	0.737	rs7817432	ENSG00000253844.1	RP11-546K22.1	-3.68	0.000264	0.0311	-0.31	-0.17	Glaucoma (primary angle closure);	chr8:51978123	chr8:51961458~52022974:+
HNSC	cis	rs28573326	0.706	rs17686882	ENSG00000121089.4	NACA3P	-3.68	0.000264	0.0311	-0.22	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165401246	chr4:164943290~164943937:+
HNSC	cis	rs4853525	0.59	rs3771308	ENSG00000228509.4	AC006460.2	3.68	0.000264	0.0311	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190936179	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.561	rs10931476	ENSG00000228509.4	AC006460.2	3.68	0.000264	0.0311	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190938082	chr2:190676944~190708716:-
HNSC	cis	rs4853525	0.504	rs2883582	ENSG00000228509.4	AC006460.2	3.68	0.000264	0.0311	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190939306	chr2:190676944~190708716:-
HNSC	cis	rs2898681	1	rs2046364	ENSG00000248375.1	RP11-177B4.1	-3.68	0.000264	0.0311	-0.25	-0.17	Optic nerve measurement (cup area);	chr4:52877051	chr4:52720081~52720831:-
HNSC	cis	rs6430585	0.583	rs79176913	ENSG00000231890.6	DARS-AS1	-3.68	0.000264	0.0311	-0.3	-0.17	Corneal structure;	chr2:135880543	chr2:135985176~136022593:+
HNSC	cis	rs453301	0.562	rs1038248	ENSG00000233609.3	RP11-62H7.2	-3.68	0.000264	0.0311	-0.15	-0.17	Joint mobility (Beighton score);	chr8:9183348	chr8:8961200~8979025:+
HNSC	cis	rs73198271	0.74	rs3827807	ENSG00000173295.6	FAM86B3P	-3.68	0.000264	0.0311	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8228595~8244865:+
HNSC	cis	rs6951245	0.554	rs75075857	ENSG00000225146.1	AC073957.15	-3.68	0.000264	0.0311	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1029025~1043891:+
HNSC	cis	rs45509595	0.841	rs200501	ENSG00000219392.1	RP1-265C24.5	-3.68	0.000264	0.0311	-0.29	-0.17	Breast cancer;	chr6:27821164	chr6:28115628~28116551:+
HNSC	cis	rs9813712	0.571	rs9824426	ENSG00000253540.4	FAM86HP	-3.68	0.000264	0.0311	-0.15	-0.17	Response to amphetamines;	chr3:130226115	chr3:130099092~130111472:-
HNSC	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-3.68	0.000264	0.0311	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
HNSC	cis	rs4906332	0.782	rs2236281	ENSG00000269940.1	RP11-73M18.7	3.68	0.000264	0.0311	0.19	0.17	Coronary artery disease;	chr14:103534181	chr14:103694560~103695170:+
HNSC	cis	rs6921919	0.673	rs13201681	ENSG00000204709.4	LINC01556	3.68	0.000264	0.0311	0.36	0.17	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28943877~28944537:+
HNSC	cis	rs67340775	0.541	rs200968	ENSG00000241549.7	GUSBP2	3.68	0.000264	0.0311	0.21	0.17	Lung cancer in ever smokers;	chr6:27891790	chr6:26871484~26956554:-
HNSC	cis	rs4908768	0.535	rs2784738	ENSG00000232912.4	RP5-1115A15.1	-3.68	0.000264	0.0311	-0.21	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406157	chr1:8424645~8434838:+
HNSC	cis	rs4908768	0.535	rs2748456	ENSG00000232912.4	RP5-1115A15.1	-3.68	0.000264	0.0311	-0.21	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406690	chr1:8424645~8434838:+
HNSC	cis	rs3738000	0.556	rs1991442	ENSG00000248468.1	RP11-517B11.4	-3.68	0.000264	0.0311	-0.18	-0.17	Carotid intima media thickness;	chr3:131249337	chr3:131517831~131520880:+
HNSC	cis	rs6088580	0.634	rs6059867	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000264	0.0311	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:33985617~33988989:-
HNSC	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	3.68	0.000264	0.0311	0.23	0.17	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	3.68	0.000264	0.0311	0.23	0.17	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	3.68	0.000264	0.0311	0.23	0.17	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
HNSC	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	3.68	0.000264	0.0311	0.23	0.17	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
HNSC	cis	rs9914544	0.545	rs2305064	ENSG00000264885.1	RP11-815I9.4	-3.68	0.000265	0.0311	-0.17	-0.17	Educational attainment (years of education);	chr17:18867420	chr17:18667629~18669461:-
HNSC	cis	rs7824557	0.606	rs1435277	ENSG00000255495.1	AC145124.2	3.68	0.000265	0.0312	0.19	0.17	Retinal vascular caliber;	chr8:11339461	chr8:12194467~12196280:+
HNSC	cis	rs28573326	0.962	rs2874700	ENSG00000121089.4	NACA3P	-3.68	0.000265	0.0312	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413664	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.924	rs1866225	ENSG00000121089.4	NACA3P	-3.68	0.000265	0.0312	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413805	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs13111798	ENSG00000121089.4	NACA3P	-3.68	0.000265	0.0312	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413883	chr4:164943290~164943937:+
HNSC	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-3.68	0.000265	0.0312	-0.21	-0.17	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
HNSC	cis	rs7937890	1	rs2970335	ENSG00000254418.1	RP11-21L19.1	3.68	0.000265	0.0312	0.19	0.17	Mitochondrial DNA levels;	chr11:14303855	chr11:14262846~14273691:-
HNSC	cis	rs6545883	0.931	rs778765	ENSG00000271889.1	RP11-493E12.1	3.68	0.000265	0.0312	0.19	0.17	Tuberculosis;	chr2:61559250	chr2:61151433~61162105:-
HNSC	cis	rs911555	0.755	rs4143998	ENSG00000244691.1	RPL10AP1	-3.68	0.000265	0.0312	-0.21	-0.17	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs1138400	ENSG00000244691.1	RPL10AP1	-3.68	0.000265	0.0312	-0.21	-0.17	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs7147664	ENSG00000244691.1	RPL10AP1	-3.68	0.000265	0.0312	-0.21	-0.17	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103412119~103412761:-
HNSC	cis	rs36715	1	rs40527	ENSG00000245937.6	LINC01184	3.68	0.000265	0.0312	0.22	0.17	Breast cancer;	chr5:128214560	chr5:127940426~128083172:-
HNSC	cis	rs12701220	0.5	rs6463224	ENSG00000224079.1	AC091729.7	3.68	0.000265	0.0312	0.25	0.17	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1074450~1078036:+
HNSC	cis	rs1167832	0.645	rs1167828	ENSG00000165178.9	NCF1C	3.68	0.000265	0.0312	0.19	0.17	Ankle injury;	chr7:75534076	chr7:75156639~75172044:-
HNSC	cis	rs1862618	0.671	rs252897	ENSG00000265665.1	AC008391.1	3.68	0.000265	0.0312	0.22	0.17	Initial pursuit acceleration;	chr5:56927173	chr5:56457038~56457138:-
HNSC	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	3.68	0.000265	0.0312	0.19	0.17	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
HNSC	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	3.68	0.000265	0.0312	0.19	0.17	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
HNSC	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	3.68	0.000265	0.0312	0.19	0.17	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
HNSC	cis	rs2337406	0.706	rs74090742	ENSG00000211972.2	IGHV3-66	3.68	0.000265	0.0312	0.17	0.17	Alzheimer's disease (late onset);	chr14:106696601	chr14:106675017~106675544:-
HNSC	cis	rs16858210	0.648	rs57604063	ENSG00000234371.6	RPSAP31	3.68	0.000265	0.0312	0.23	0.17	Menopause (age at onset);	chr3:183860901	chr3:183884924~183888449:+
HNSC	cis	rs1028883	0.571	rs4581593	ENSG00000228295.1	LINC00392	-3.68	0.000265	0.0312	-0.18	-0.17	Lean body mass;	chr13:73595690	chr13:73564244~73588070:+
HNSC	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-3.68	0.000265	0.0312	-0.19	-0.17	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
HNSC	cis	rs7824557	0.602	rs7839053	ENSG00000269918.1	AF131215.9	3.68	0.000265	0.0312	0.16	0.17	Retinal vascular caliber;	chr8:11349922	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.602	rs10110557	ENSG00000269918.1	AF131215.9	3.68	0.000265	0.0312	0.16	0.17	Retinal vascular caliber;	chr8:11349999	chr8:11104691~11106704:-
HNSC	cis	rs1028883	0.87	rs1034048	ENSG00000228295.1	LINC00392	-3.68	0.000265	0.0312	-0.17	-0.17	Lean body mass;	chr13:73552715	chr13:73564244~73588070:+
HNSC	cis	rs1979679	0.842	rs35098487	ENSG00000247934.4	RP11-967K21.1	-3.68	0.000265	0.0312	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28163298~28190738:-
HNSC	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-3.68	0.000265	0.0312	-0.17	-0.17	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
HNSC	cis	rs12893668	0.703	rs8017993	ENSG00000269958.1	RP11-73M18.8	3.68	0.000265	0.0312	0.16	0.17	Reticulocyte count;	chr14:103581397	chr14:103696353~103697163:+
HNSC	cis	rs1009077	0.61	rs2389864	ENSG00000245958.5	RP11-33B1.1	-3.68	0.000265	0.0312	-0.16	-0.17	Endometriosis;	chr4:119589595	chr4:119454791~119552025:+
HNSC	cis	rs12745968	0.586	rs2065915	ENSG00000223787.2	RP4-593M8.1	-3.68	0.000265	0.0312	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92735925	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.718	rs10782941	ENSG00000223787.2	RP4-593M8.1	-3.68	0.000265	0.0312	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92744283	chr1:92580476~92580821:-
HNSC	cis	rs17489649	1	rs2300989	ENSG00000271849.1	CTC-332L22.1	3.68	0.000265	0.0312	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109697123	chr5:109687802~109688329:-
HNSC	cis	rs2998286	1	rs2998286	ENSG00000254635.4	WAC-AS1	-3.68	0.000265	0.0312	-0.2	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491444	chr10:28522652~28532743:-
HNSC	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	3.68	0.000265	0.0312	0.18	0.17	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
HNSC	cis	rs16846053	0.515	rs1510084	ENSG00000227403.1	AC009299.3	-3.68	0.000265	0.0312	-0.3	-0.17	Blood osmolality (transformed sodium);	chr2:161647233	chr2:161244739~161249050:+
HNSC	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	3.68	0.000265	0.0312	0.25	0.17	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
HNSC	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	3.68	0.000265	0.0312	0.25	0.17	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
HNSC	cis	rs656319	0.625	rs34427895	ENSG00000254340.1	RP11-10A14.3	-3.68	0.000265	0.0312	-0.21	-0.17	Myopia (pathological);	chr8:10017711	chr8:9141424~9145435:+
HNSC	cis	rs240993	0.812	rs9487668	ENSG00000230177.1	RP5-1112D6.4	3.68	0.000265	0.0312	0.21	0.17	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111277932~111278742:+
HNSC	cis	rs2562456	0.793	rs7258473	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21331795	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs2219839	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21333520	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62107539	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21334910	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs76646508	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21335247	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs77576302	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21335385	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62107540	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21335693	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62107541	ENSG00000268081.1	RP11-678G14.2	3.68	0.000265	0.0312	0.24	0.17	Pain;	chr19:21335733	chr19:21554640~21569237:-
HNSC	cis	rs727563	0.636	rs2413653	ENSG00000235513.1	RP4-756G23.5	-3.68	0.000265	0.0312	-0.21	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr22:41209122~41217627:-
HNSC	cis	rs7085104	0.632	rs7097872	ENSG00000213061.2	PFN1P11	3.68	0.000265	0.0312	0.21	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102838011~102845473:-
HNSC	cis	rs7937890	1	rs2915401	ENSG00000251991.1	RNU7-49P	-3.68	0.000265	0.0312	-0.19	-0.17	Mitochondrial DNA levels;	chr11:14353467	chr11:14478892~14478953:+
HNSC	cis	rs4489787	0.892	rs2731101	ENSG00000257763.1	OR5BK1P	3.68	0.000265	0.0312	0.29	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48510456	chr12:48355792~48356614:-
HNSC	cis	rs4578769	0.55	rs930909	ENSG00000265943.1	RP11-739L10.1	3.68	0.000265	0.0312	0.2	0.17	Eosinophil percentage of white cells;	chr18:22976361	chr18:22699481~22933764:-
HNSC	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	3.68	0.000265	0.0312	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
HNSC	cis	rs34421088	0.548	rs2618443	ENSG00000206014.6	OR7E161P	3.67	0.000265	0.0312	0.18	0.17	Neuroticism;	chr8:11527047	chr8:11928597~11929563:-
HNSC	cis	rs859767	0.519	rs11688414	ENSG00000224043.6	CCNT2-AS1	3.67	0.000265	0.0312	0.2	0.17	Neuroticism;	chr2:134662667	chr2:134735464~134918710:-
HNSC	cis	rs6001482	0.533	rs5757621	ENSG00000274422.1	LL22NC03-2H8.5	3.67	0.000266	0.0312	0.17	0.17	Diastolic blood pressure;	chr22:22240976	chr22:22283928~22287220:-
HNSC	cis	rs4654783	0.505	rs4655025	ENSG00000218510.5	LINC00339	-3.67	0.000266	0.0312	-0.15	-0.17	Endometriosis;	chr1:22133261	chr1:22025188~22031223:+
HNSC	cis	rs8054556	0.787	rs35105141	ENSG00000250616.2	RP11-455F5.3	3.67	0.000266	0.0312	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30096430~30104116:+
HNSC	cis	rs4845570	0.92	rs1521185	ENSG00000249602.1	RP11-98D18.3	3.67	0.000266	0.0312	0.27	0.17	Coronary artery disease;	chr1:151791573	chr1:151763384~151769501:-
HNSC	cis	rs7178375	1	rs10163148	ENSG00000270055.1	CTD-3092A11.2	-3.67	0.000266	0.0312	-0.22	-0.17	Hypertriglyceridemia;	chr15:30920481	chr15:30487963~30490313:+
HNSC	cis	rs13178541	0.745	rs4605777	ENSG00000250378.1	RP11-119J18.1	-3.67	0.000266	0.0312	-0.21	-0.17	IgG glycosylation;	chr5:135760855	chr5:135812667~135826582:+
HNSC	cis	rs11668609	1	rs919813	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000266	0.0312	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:24162370~24163425:-
HNSC	cis	rs6088580	0.634	rs1890002	ENSG00000276073.1	RP5-1125A11.7	3.67	0.000266	0.0312	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:33985617~33988989:-
HNSC	cis	rs2270676	0.659	rs55940411	ENSG00000254974.1	RP11-702H23.2	-3.67	0.000266	0.0312	-0.28	-0.17	Corneal astigmatism;	chr11:74470263	chr11:74485580~74486051:-
HNSC	cis	rs12899811	0.53	rs11073967	ENSG00000213471.7	TTLL13P	-3.67	0.000266	0.0313	-0.21	-0.17	Type 2 diabetes;	chr15:91022574	chr15:90249530~90265482:+
HNSC	cis	rs4704187	0.663	rs965735	ENSG00000272040.1	CTC-366B18.4	-3.67	0.000266	0.0313	-0.16	-0.17	Response to amphetamines;	chr5:75163395	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6885071	ENSG00000272040.1	CTC-366B18.4	-3.67	0.000266	0.0313	-0.16	-0.17	Response to amphetamines;	chr5:75164220	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs7711762	ENSG00000272040.1	CTC-366B18.4	-3.67	0.000266	0.0313	-0.16	-0.17	Response to amphetamines;	chr5:75165850	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs1363577	ENSG00000272040.1	CTC-366B18.4	-3.67	0.000266	0.0313	-0.16	-0.17	Response to amphetamines;	chr5:75167360	chr5:75608817~75609983:+
HNSC	cis	rs11083475	1	rs883394	ENSG00000269486.2	CTC-360G5.9	3.67	0.000266	0.0313	0.19	0.17	Heart rate;	chr19:38714973	chr19:38935297~38938632:-
HNSC	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	3.67	0.000266	0.0313	0.13	0.17	Breast size;	chr12:9209471	chr12:9277235~9313241:+
HNSC	cis	rs17772222	0.917	rs61984737	ENSG00000258789.1	RP11-507K2.3	-3.67	0.000266	0.0313	-0.2	-0.17	Coronary artery calcification;	chr14:88637028	chr14:88551597~88552493:+
HNSC	cis	rs2908197	0.843	rs2961041	ENSG00000186704.9	DTX2P1	3.67	0.000266	0.0313	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316627	chr7:76978617~77004308:+
HNSC	cis	rs2908197	0.843	rs2908193	ENSG00000186704.9	DTX2P1	3.67	0.000266	0.0313	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316628	chr7:76978617~77004308:+
HNSC	cis	rs17014483	1	rs17014483	ENSG00000248019.2	FAM13A-AS1	-3.67	0.000266	0.0313	-0.21	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88746440	chr4:88709789~88730103:+
HNSC	cis	rs6840360	0.582	rs2709827	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000266	0.0313	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151407551~151408835:-
HNSC	cis	rs495337	0.965	rs4810999	ENSG00000229222.1	KRT18P4	-3.67	0.000266	0.0313	-0.19	-0.17	Psoriasis;	chr20:49964432	chr20:49956745~49958032:+
HNSC	cis	rs5770917	1	rs5770911	ENSG00000272821.1	CTA-384D8.36	-3.67	0.000266	0.0313	-0.31	-0.17	Narcolepsy;	chr22:50572812	chr22:50523926~50524780:+
HNSC	cis	rs853679	0.607	rs68188794	ENSG00000226314.6	ZNF192P1	-3.67	0.000266	0.0313	-0.33	-0.17	Depression;	chr6:28112999	chr6:28161781~28169594:+
HNSC	cis	rs897984	0.806	rs11150600	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000266	0.0313	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30929010	chr16:31043150~31049868:+
HNSC	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	3.67	0.000266	0.0313	0.19	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
HNSC	cis	rs2307394	0.749	rs13000231	ENSG00000281469.1	RP11-567F11.1	3.67	0.000266	0.0313	0.2	0.17	Urate levels;	chr2:147701838	chr2:148044380~148044894:+
HNSC	cis	rs9863	0.861	rs3802999	ENSG00000270028.1	RP11-380L11.4	3.67	0.000266	0.0313	0.2	0.17	White blood cell count;	chr12:123929551	chr12:123925461~123926083:-
HNSC	cis	rs3808502	0.527	rs4410870	ENSG00000255310.2	AF131215.2	-3.67	0.000266	0.0313	-0.17	-0.17	Neuroticism;	chr8:11298611	chr8:11107788~11109726:-
HNSC	cis	rs6095360	1	rs6019547	ENSG00000227431.4	CSE1L-AS1	-3.67	0.000266	0.0313	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48944554	chr20:49040463~49046044:-
HNSC	cis	rs526231	0.543	rs246906	ENSG00000250682.4	LINC00491	3.67	0.000266	0.0313	0.23	0.17	Primary biliary cholangitis;	chr5:103230770	chr5:102609156~102671559:-
HNSC	cis	rs57221529	0.713	rs56328416	ENSG00000225138.6	CTD-2228K2.7	3.67	0.000266	0.0313	0.25	0.17	Lung disease severity in cystic fibrosis;	chr5:591023	chr5:473236~480884:+
HNSC	cis	rs17489649	0.5	rs10045731	ENSG00000271849.1	CTC-332L22.1	3.67	0.000266	0.0313	0.22	0.17	Intelligence (multi-trait analysis);	chr5:109888396	chr5:109687802~109688329:-
HNSC	cis	rs7824557	0.564	rs2572394	ENSG00000255495.1	AC145124.2	-3.67	0.000266	0.0313	-0.19	-0.17	Retinal vascular caliber;	chr8:11377884	chr8:12194467~12196280:+
HNSC	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	3.67	0.000266	0.0313	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
HNSC	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-3.67	0.000267	0.0313	-0.17	-0.17	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
HNSC	cis	rs526231	0.543	rs34784	ENSG00000250682.4	LINC00491	3.67	0.000267	0.0313	0.22	0.17	Primary biliary cholangitis;	chr5:103121626	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs32849	ENSG00000250682.4	LINC00491	3.67	0.000267	0.0313	0.22	0.17	Primary biliary cholangitis;	chr5:103134339	chr5:102609156~102671559:-
HNSC	cis	rs8030379	1	rs1564472	ENSG00000225151.9	GOLGA2P7	-3.67	0.000267	0.0313	-0.21	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84199311~84230136:-
HNSC	cis	rs2736345	0.788	rs998683	ENSG00000255046.1	RP11-297N6.4	3.67	0.000267	0.0313	0.19	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:11797928~11802568:-
HNSC	cis	rs9457247	0.534	rs9347170	ENSG00000227598.1	RP1-167A14.2	3.67	0.000267	0.0313	0.19	0.17	Crohn's disease;	chr6:166991699	chr6:166969626~166999065:-
HNSC	cis	rs793571	0.826	rs1092172	ENSG00000245975.2	RP11-30K9.6	3.67	0.000267	0.0314	0.28	0.17	Schizophrenia;	chr15:58863341	chr15:58768072~58770974:-
HNSC	cis	rs4906332	1	rs1951389	ENSG00000244691.1	RPL10AP1	-3.67	0.000267	0.0314	-0.19	-0.17	Coronary artery disease;	chr14:103432188	chr14:103412119~103412761:-
HNSC	cis	rs4906332	0.901	rs4900575	ENSG00000244691.1	RPL10AP1	-3.67	0.000267	0.0314	-0.19	-0.17	Coronary artery disease;	chr14:103432832	chr14:103412119~103412761:-
HNSC	cis	rs6809854	0.545	rs404552	ENSG00000228956.7	SATB1-AS1	3.67	0.000267	0.0314	0.19	0.17	Psoriasis;Itch intensity from mosquito bite;	chr3:18611113	chr3:18445024~18920401:+
HNSC	cis	rs969413	0.624	rs7213540	ENSG00000262115.1	RP11-455O6.2	-3.67	0.000267	0.0314	-0.17	-0.17	Frontotemporal dementia;	chr17:81282112	chr17:81197393~81200288:+
HNSC	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-3.67	0.000267	0.0314	-0.14	-0.17	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
HNSC	cis	rs12893668	0.581	rs34843146	ENSG00000269910.1	RP11-73M18.10	3.67	0.000267	0.0314	0.16	0.17	Reticulocyte count;	chr14:103613527	chr14:103694516~103695050:-
HNSC	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	3.67	0.000267	0.0314	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
HNSC	cis	rs7829975	0.582	rs6982832	ENSG00000253981.4	ALG1L13P	-3.67	0.000267	0.0314	-0.18	-0.17	Mood instability;	chr8:8934707	chr8:8236003~8244667:-
HNSC	cis	rs7688540	0.665	rs11731933	ENSG00000250892.1	RP11-1365D11.1	-3.67	0.000267	0.0314	-0.29	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:201409~205009:-
HNSC	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	3.67	0.000267	0.0314	0.18	0.17	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
HNSC	cis	rs597539	0.654	rs655816	ENSG00000255741.1	RP11-757G1.5	-3.67	0.000267	0.0314	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.69	rs497149	ENSG00000255741.1	RP11-757G1.5	-3.67	0.000267	0.0314	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68941503~68942852:-
HNSC	cis	rs4660214	0.724	rs2484751	ENSG00000228060.1	RP11-69E11.8	3.67	0.000267	0.0314	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39565160~39573203:+
HNSC	cis	rs1979679	0.918	rs786707	ENSG00000247934.4	RP11-967K21.1	-3.67	0.000267	0.0314	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28163298~28190738:-
HNSC	cis	rs298182	1	rs298214	ENSG00000254102.1	RP11-21C4.1	-3.67	0.000267	0.0314	-0.27	-0.17	Verbal declarative memory;	chr8:64380224	chr8:64574306~64581888:-
HNSC	cis	rs2384207	0.584	rs2891437	ENSG00000201208.1	Y_RNA	-3.67	0.000267	0.0314	-0.25	-0.17	Response to fenofibrate (adiponectin levels);	chr12:113323574	chr12:113178423~113178519:-
HNSC	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-3.67	0.000267	0.0314	-0.21	-0.17	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
HNSC	cis	rs6964587	0.626	rs404	ENSG00000188693.7	CYP51A1-AS1	3.67	0.000267	0.0314	0.18	0.17	Breast cancer;	chr7:91915002	chr7:92134604~92180725:+
HNSC	cis	rs950027	0.62	rs1145076	ENSG00000259479.5	SORD2P	3.67	0.000267	0.0314	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:44826371~44884694:-
HNSC	cis	rs11649653	0.512	rs4889634	ENSG00000232748.3	RP11-196G11.6	3.67	0.000267	0.0314	0.23	0.17	Triglycerides;	chr16:30867542	chr16:31056460~31062803:+
HNSC	cis	rs11773103	0.708	rs55825235	ENSG00000182165.16	TP53TG1	-3.67	0.000267	0.0314	-0.25	-0.17	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87325225~87345515:-
HNSC	cis	rs4388249	1	rs13189822	ENSG00000271849.1	CTC-332L22.1	-3.67	0.000267	0.0314	-0.25	-0.17	Schizophrenia;	chr5:109781470	chr5:109687802~109688329:-
HNSC	cis	rs7107174	0.892	rs2512529	ENSG00000251323.2	RP11-452H21.4	3.67	0.000267	0.0314	0.27	0.17	Testicular germ cell tumor;	chr11:78266305	chr11:78423982~78429836:-
HNSC	cis	rs7577696	0.528	rs160801	ENSG00000272716.1	RP11-563N4.1	-3.67	0.000267	0.0314	-0.16	-0.17	Inflammatory biomarkers;	chr2:31879685	chr2:32165046~32165757:-
HNSC	cis	rs7189233	1	rs62048544	ENSG00000279344.1	RP11-44F14.7	3.67	0.000267	0.0314	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53503829	chr16:53478957~53481550:-
HNSC	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-3.67	0.000267	0.0314	-0.2	-0.17	Height;	chr14:75022929	chr14:75011269~75012851:-
HNSC	cis	rs1497406	0.744	rs12057175	ENSG00000227959.1	RP11-276H7.2	3.67	0.000267	0.0314	0.18	0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181880	chr1:16155211~16157329:+
HNSC	cis	rs1497406	0.744	rs12057222	ENSG00000227959.1	RP11-276H7.2	3.67	0.000267	0.0314	0.18	0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16182039	chr1:16155211~16157329:+
HNSC	cis	rs9926296	0.593	rs6500456	ENSG00000261812.4	TUBB8P7	-3.67	0.000267	0.0314	-0.18	-0.17	Vitiligo;	chr16:89821933	chr16:90093154~90096354:+
HNSC	cis	rs9961653	0.753	rs9944697	ENSG00000267677.1	RP11-27G24.1	-3.67	0.000267	0.0314	-0.16	-0.17	Morning vs. evening chronotype;Chronotype;	chr18:59092844	chr18:59360700~59386749:+
HNSC	cis	rs7772486	0.686	rs9497395	ENSG00000270638.1	RP3-466P17.1	-3.67	0.000267	0.0314	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145735570~145737218:+
HNSC	cis	rs1994321	0.609	rs4757149	ENSG00000254991.1	RP13-631K18.3	-3.67	0.000267	0.0314	-0.19	-0.17	Non-response to selective serotonin reuptake inhibitors and depression;	chr11:12066501	chr11:12066929~12073014:+
HNSC	cis	rs2307394	0.896	rs6430241	ENSG00000281469.1	RP11-567F11.1	3.67	0.000267	0.0314	0.18	0.17	Urate levels;	chr2:147793783	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs13005423	ENSG00000281469.1	RP11-567F11.1	3.67	0.000267	0.0314	0.18	0.17	Urate levels;	chr2:147795737	chr2:148044380~148044894:+
HNSC	cis	rs950027	0.787	rs1547487	ENSG00000259479.5	SORD2P	3.67	0.000267	0.0314	0.2	0.17	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:44826371~44884694:-
HNSC	cis	rs2919009	0.563	rs55761976	ENSG00000271670.1	RP11-95I16.4	3.67	0.000267	0.0314	0.21	0.17	Obesity-related traits;	chr10:120935030	chr10:120879256~120880667:-
HNSC	cis	rs2919009	0.607	rs56004902	ENSG00000271670.1	RP11-95I16.4	3.67	0.000267	0.0314	0.21	0.17	Obesity-related traits;	chr10:120938378	chr10:120879256~120880667:-
HNSC	cis	rs61160187	0.517	rs7709522	ENSG00000152931.7	PART1	-3.67	0.000267	0.0314	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60487713~60547657:+
HNSC	cis	rs2835345	0.962	rs2835344	ENSG00000230479.1	AP000695.6	3.67	0.000267	0.0314	0.19	0.17	Pulmonary function;	chr21:36429047	chr21:36430360~36481070:+
HNSC	cis	rs6840360	0.642	rs11099815	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000268	0.0314	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151407551~151408835:-
HNSC	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000268	0.0314	-0.24	-0.17	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
HNSC	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	3.67	0.000268	0.0314	0.2	0.17	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
HNSC	cis	rs4427176	0.507	rs10794712	ENSG00000254340.1	RP11-10A14.3	-3.67	0.000268	0.0314	-0.24	-0.17	Mosquito bite size;	chr8:9698809	chr8:9141424~9145435:+
HNSC	cis	rs886774	0.866	rs10267797	ENSG00000273055.1	CTB-13F3.1	-3.67	0.000268	0.0314	-0.16	-0.17	Ulcerative colitis;	chr7:107874855	chr7:107942116~107942740:+
HNSC	cis	rs656319	0.513	rs17746227	ENSG00000255310.2	AF131215.2	-3.67	0.000268	0.0314	-0.17	-0.17	Myopia (pathological);	chr8:10124144	chr8:11107788~11109726:-
HNSC	cis	rs711830	0.931	rs717852	ENSG00000226363.3	HAGLROS	-3.67	0.000268	0.0314	-0.23	-0.17	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166895	chr2:176177717~176179008:+
HNSC	cis	rs711830	1	rs2249131	ENSG00000226363.3	HAGLROS	-3.67	0.000268	0.0314	-0.23	-0.17	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176167367	chr2:176177717~176179008:+
HNSC	cis	rs62202398	0.529	rs6094994	ENSG00000276923.1	RP11-321P16.1	-3.67	0.000268	0.0314	-0.31	-0.17	Alcohol consumption;	chr20:48154593	chr20:48073869~48074188:+
HNSC	cis	rs8072100	0.967	rs2317826	ENSG00000263293.2	RP11-290H9.4	3.67	0.000268	0.0314	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47303460~47323613:-
HNSC	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	3.67	0.000268	0.0314	0.2	0.17	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
HNSC	cis	rs2245008	0.762	rs168800	ENSG00000261286.1	RP11-517C16.2	3.67	0.000268	0.0314	0.2	0.17	Pursuit maintenance gain;	chr16:83946786	chr16:84459259~84467361:-
HNSC	cis	rs4853525	0.62	rs1914408	ENSG00000228509.4	AC006460.2	-3.67	0.000268	0.0314	-0.23	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190975250	chr2:190676944~190708716:-
HNSC	cis	rs9467711	0.591	rs56195001	ENSG00000241549.7	GUSBP2	3.67	0.000268	0.0314	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:25975937	chr6:26871484~26956554:-
HNSC	cis	rs544991	0.687	rs6680356	ENSG00000239670.1	RP4-803A2.2	3.67	0.000268	0.0315	0.21	0.17	Intelligence;	chr1:33753073	chr1:32986952~32988233:+
HNSC	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-3.67	0.000268	0.0315	-0.19	-0.17	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
HNSC	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-3.67	0.000268	0.0315	-0.19	-0.17	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
HNSC	cis	rs1555322	0.929	rs2247828	ENSG00000279253.1	RP4-614O4.13	3.67	0.000268	0.0315	0.24	0.17	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35262727~35264187:-
HNSC	cis	rs7086627	0.515	rs6585994	ENSG00000226659.1	RP11-137H2.4	-3.67	0.000268	0.0315	-0.21	-0.17	Post bronchodilator FEV1;	chr10:80431887	chr10:80529597~80535942:-
HNSC	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000268	0.0315	-0.19	-0.17	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000268	0.0315	-0.2	-0.17	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
HNSC	cis	rs73201462	0.831	rs2811524	ENSG00000231305.3	RP11-723O4.2	3.67	0.000268	0.0315	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281112	chr3:128861313~128871540:-
HNSC	cis	rs8062405	0.755	rs1074631	ENSG00000261766.1	RP11-22P6.2	3.67	0.000268	0.0315	0.16	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28862166~28863340:-
HNSC	cis	rs897984	0.762	rs11150601	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000268	0.0315	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30966478	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.721	rs4889525	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000268	0.0315	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30978537	chr16:31043150~31049868:+
HNSC	cis	rs365302	0.628	rs409096	ENSG00000235086.1	FNDC1-IT1	3.67	0.000268	0.0315	0.2	0.17	Coronary heart disease;	chr6:159189872	chr6:159240786~159243329:+
HNSC	cis	rs656900	0.765	rs599842	ENSG00000261229.4	MTHFS	-3.67	0.000268	0.0315	-0.18	-0.17	Cerebrospinal P-tau181p levels;	chr15:79819549	chr15:79843547~79897285:-
HNSC	cis	rs7572733	0.555	rs2164071	ENSG00000231621.1	AC013264.2	-3.67	0.000268	0.0315	-0.16	-0.17	Dermatomyositis;	chr2:198050743	chr2:197197991~197199273:+
HNSC	cis	rs6973609	0.927	rs10238969	ENSG00000271122.1	RP11-379H18.1	3.67	0.000268	0.0315	0.15	0.17	Obesity-related traits;	chr7:35569730	chr7:35695214~35699413:+
HNSC	cis	rs853679	0.882	rs9461432	ENSG00000204709.4	LINC01556	3.67	0.000268	0.0315	0.29	0.17	Depression;	chr6:28119105	chr6:28943877~28944537:+
HNSC	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	3.67	0.000268	0.0315	0.21	0.17	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
HNSC	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	3.67	0.000268	0.0315	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
HNSC	cis	rs11992186	0.57	rs17628941	ENSG00000173295.6	FAM86B3P	-3.67	0.000268	0.0315	-0.2	-0.17	Neuroticism;	chr8:8730024	chr8:8228595~8244865:+
HNSC	cis	rs8063160	0.628	rs258322	ENSG00000260259.1	RP11-368I7.4	-3.67	0.000268	0.0315	-0.31	-0.17	Red vs non-red hair color;Brown vs. non-brown hair color;Light vs. dark hair color;	chr16:89689495	chr16:89682620~89686569:-
HNSC	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-3.67	0.000268	0.0315	-0.18	-0.17	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
HNSC	cis	rs875971	0.66	rs801192	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000268	0.0315	-0.14	-0.17	Aortic root size;	chr7:66566965	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs801190	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000268	0.0315	-0.14	-0.17	Aortic root size;	chr7:66568046	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000268	0.0315	-0.14	-0.17	Aortic root size;	chr7:66571204	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000268	0.0315	-0.14	-0.17	Aortic root size;	chr7:66571411	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000268	0.0315	-0.14	-0.17	Aortic root size;	chr7:66572000	chr7:66739829~66740385:-
HNSC	cis	rs2638953	0.893	rs10843192	ENSG00000257176.2	RP11-996F15.2	3.67	0.000269	0.0315	0.19	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508756	chr12:29280418~29317848:-
HNSC	cis	rs9435732	0.945	rs2311528	ENSG00000235241.1	RP11-108M9.5	3.67	0.000269	0.0315	0.23	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16983045	chr1:16889095~16889602:+
HNSC	cis	rs172166	0.61	rs276369	ENSG00000224843.5	LINC00240	3.67	0.000269	0.0315	0.17	0.17	Cardiac Troponin-T levels;	chr6:27951465	chr6:26956992~27023924:+
HNSC	cis	rs2762353	0.935	rs1165195	ENSG00000272462.2	U91328.19	-3.67	0.000269	0.0315	-0.16	-0.17	Blood metabolite levels;	chr6:25814852	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.935	rs1185567	ENSG00000272462.2	U91328.19	-3.67	0.000269	0.0315	-0.16	-0.17	Blood metabolite levels;	chr6:25818360	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.935	rs1183200	ENSG00000272462.2	U91328.19	-3.67	0.000269	0.0315	-0.16	-0.17	Blood metabolite levels;	chr6:25818418	chr6:25992662~26001775:+
HNSC	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	3.67	0.000269	0.0315	0.2	0.17	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
HNSC	cis	rs7829975	0.626	rs332040	ENSG00000233609.3	RP11-62H7.2	3.67	0.000269	0.0315	0.16	0.17	Mood instability;	chr8:8872978	chr8:8961200~8979025:+
HNSC	cis	rs17122278	1	rs11216887	ENSG00000255422.1	AP002954.4	3.67	0.000269	0.0315	0.3	0.17	Total cholesterol levels;	chr11:118550021	chr11:118704607~118750263:+
HNSC	cis	rs9531006	0.602	rs3898550	ENSG00000227676.3	LINC01068	3.67	0.000269	0.0315	0.26	0.17	Sleep duration;	chr13:79895562	chr13:79566727~79571436:+
HNSC	cis	rs1552244	0.572	rs41464050	ENSG00000180385.7	EMC3-AS1	3.67	0.000269	0.0316	0.2	0.17	Alzheimer's disease;	chr3:10116709	chr3:9986893~10006990:+
HNSC	cis	rs11098499	0.604	rs2389886	ENSG00000250412.1	KLHL2P1	3.67	0.000269	0.0316	0.23	0.17	Corneal astigmatism;	chr4:119649267	chr4:119334329~119378233:+
HNSC	cis	rs12034383	0.783	rs12036785	ENSG00000274245.1	RP11-357P18.2	-3.67	0.000269	0.0316	-0.21	-0.17	Erythrocyte sedimentation rate;	chr1:207619564	chr1:207372559~207373252:+
HNSC	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	3.67	0.000269	0.0316	0.16	0.17	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
HNSC	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	3.67	0.000269	0.0316	0.19	0.17	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
HNSC	cis	rs7581030	0.874	rs4852784	ENSG00000205847.5	OR7E91P	3.67	0.000269	0.0316	0.22	0.17	Testicular germ cell tumor;	chr2:71418760	chr2:71029028~71029893:+
HNSC	cis	rs10849893	0.557	rs7962143	ENSG00000258435.1	RP11-711D18.2	-3.67	0.000269	0.0316	-0.17	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121392230	chr12:121391962~121399859:+
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000255310.2	AF131215.2	3.67	0.000269	0.0316	0.16	0.17	Myopia (pathological);	chr8:11929423	chr8:11107788~11109726:-
HNSC	cis	rs6840360	0.642	rs2709819	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000269	0.0316	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151407551~151408835:-
HNSC	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-3.67	0.000269	0.0316	-0.17	-0.17	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-3.67	0.000269	0.0316	-0.17	-0.17	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
HNSC	cis	rs6142618	0.934	rs14316	ENSG00000275576.1	RP5-836N17.4	-3.67	0.000269	0.0316	-0.17	-0.17	Inflammatory bowel disease;	chr20:32165467	chr20:32116171~32116629:+
HNSC	cis	rs6723108	0.713	rs6728095	ENSG00000224043.6	CCNT2-AS1	3.67	0.000269	0.0316	0.2	0.17	Type 2 diabetes;	chr2:134618502	chr2:134735464~134918710:-
HNSC	cis	rs2243480	1	rs160655	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000269	0.0316	-0.24	-0.17	Diabetic kidney disease;	chr7:66068227	chr7:66848496~66858136:+
HNSC	cis	rs116095464	0.867	rs7726582	ENSG00000277812.1	AC021087.1	3.67	0.000269	0.0316	0.28	0.17	Breast cancer;	chr5:215234	chr5:262769~262881:+
HNSC	cis	rs9527	0.59	rs10883820	ENSG00000213277.3	MARCKSL1P1	3.67	0.000269	0.0316	0.19	0.17	Arsenic metabolism;	chr10:103004904	chr10:103175554~103176094:+
HNSC	cis	rs10789207	0.531	rs17129245	ENSG00000248458.2	RP4-598P13.1	-3.67	0.000269	0.0316	-0.25	-0.17	Resting heart rate;	chr1:66644105	chr1:66665864~66677027:-
HNSC	cis	rs10789207	0.531	rs61313508	ENSG00000248458.2	RP4-598P13.1	-3.67	0.000269	0.0316	-0.25	-0.17	Resting heart rate;	chr1:66644949	chr1:66665864~66677027:-
HNSC	cis	rs2279168	0.737	rs60345430	ENSG00000259407.1	RP11-158M2.3	3.67	0.000269	0.0316	0.35	0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85416871	chr15:85744109~85750281:-
HNSC	cis	rs6445975	0.726	rs4330265	ENSG00000273493.1	RP11-80H18.4	-3.67	0.000269	0.0316	-0.19	-0.17	Systemic lupus erythematosus;	chr3:58482301	chr3:58329965~58330118:+
HNSC	cis	rs7246657	0.722	rs2927746	ENSG00000276846.1	CTD-3220F14.3	-3.67	0.000269	0.0316	-0.23	-0.17	Coronary artery calcification;	chr19:37665669	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs2927747	ENSG00000276846.1	CTD-3220F14.3	-3.67	0.000269	0.0316	-0.23	-0.17	Coronary artery calcification;	chr19:37668629	chr19:37314868~37315620:-
HNSC	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	3.67	0.000269	0.0316	0.22	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
HNSC	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	3.67	0.000269	0.0316	0.22	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
HNSC	cis	rs2243480	1	rs34815098	ENSG00000226002.1	RP11-460N20.5	-3.67	0.000269	0.0316	-0.29	-0.17	Diabetic kidney disease;	chr7:65827267	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs7456042	ENSG00000226002.1	RP11-460N20.5	-3.67	0.000269	0.0316	-0.29	-0.17	Diabetic kidney disease;	chr7:65834791	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs35735127	ENSG00000226002.1	RP11-460N20.5	-3.67	0.000269	0.0316	-0.29	-0.17	Diabetic kidney disease;	chr7:65835436	chr7:65084103~65100232:+
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000226002.1	RP11-460N20.5	-3.67	0.000269	0.0316	-0.29	-0.17	Diabetic kidney disease;	chr7:65841418	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000269	0.0316	-0.24	-0.17	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
HNSC	cis	rs1536827	0.841	rs10857737	ENSG00000278518.1	RP11-108K14.12	-3.67	0.000269	0.0316	-0.3	-0.17	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133523212	chr10:133526259~133527513:-
HNSC	cis	rs8062405	1	rs72793811	ENSG00000261089.1	RP11-435I10.3	3.67	0.000269	0.0316	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28413703~28415018:+
HNSC	cis	rs4144743	0.938	rs55677902	ENSG00000228782.6	CTD-2026D20.3	-3.67	0.000269	0.0316	-0.19	-0.17	Body mass index;	chr17:47245206	chr17:47450568~47492492:-
HNSC	cis	rs61160187	0.577	rs34741733	ENSG00000272308.1	RP11-231G3.1	-3.67	0.000269	0.0316	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60866457~60866935:-
HNSC	cis	rs6928977	0.514	rs2757635	ENSG00000231028.7	LINC00271	3.67	0.000269	0.0316	0.19	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135497801~135716055:+
HNSC	cis	rs7429990	0.864	rs1464614	ENSG00000228638.1	FCF1P2	-3.67	0.000269	0.0316	-0.14	-0.17	Educational attainment (years of education);	chr3:47612885	chr3:48290793~48291375:-
HNSC	cis	rs12291225	0.839	rs4757244	ENSG00000251991.1	RNU7-49P	-3.67	0.000269	0.0316	-0.19	-0.17	Sense of smell;	chr11:14237109	chr11:14478892~14478953:+
HNSC	cis	rs7746199	0.736	rs34965299	ENSG00000226314.6	ZNF192P1	-3.67	0.000269	0.0316	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28161781~28169594:+
HNSC	cis	rs2908197	0.843	rs2961040	ENSG00000186704.9	DTX2P1	3.67	0.00027	0.0316	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76317446	chr7:76978617~77004308:+
HNSC	cis	rs11951515	0.738	rs6886499	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43362976	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs10941631	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43363907	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.714	rs10805675	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43363942	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.7	rs11956936	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43367247	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs11960415	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43367407	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs10512827	ENSG00000249286.1	CTD-2210P15.2	3.67	0.00027	0.0316	0.18	0.17	Metabolite levels  (X-11787);	chr5:43367964	chr5:43586918~43588223:-
HNSC	cis	rs6601327	0.736	rs4840426	ENSG00000254340.1	RP11-10A14.3	3.67	0.00027	0.0316	0.2	0.17	Multiple myeloma (hyperdiploidy);	chr8:9551468	chr8:9141424~9145435:+
HNSC	cis	rs4950322	0.547	rs61838945	ENSG00000230832.3	RP11-325P15.2	-3.67	0.00027	0.0316	-0.22	-0.17	Protein quantitative trait loci;	chr1:147111477	chr1:147082338~147083578:-
HNSC	cis	rs4950322	0.563	rs6686480	ENSG00000230832.3	RP11-325P15.2	-3.67	0.00027	0.0316	-0.22	-0.17	Protein quantitative trait loci;	chr1:147111986	chr1:147082338~147083578:-
HNSC	cis	rs4950322	0.563	rs6700783	ENSG00000230832.3	RP11-325P15.2	-3.67	0.00027	0.0316	-0.22	-0.17	Protein quantitative trait loci;	chr1:147111987	chr1:147082338~147083578:-
HNSC	cis	rs919433	0.653	rs700651	ENSG00000231621.1	AC013264.2	-3.67	0.00027	0.0316	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197766990	chr2:197197991~197199273:+
HNSC	cis	rs1519814	0.654	rs11986190	ENSG00000254343.2	RP11-760H22.2	-3.67	0.00027	0.0316	-0.23	-0.17	Breast cancer;	chr8:120001086	chr8:120052180~120056201:+
HNSC	cis	rs7688540	0.771	rs61792116	ENSG00000250892.1	RP11-1365D11.1	-3.67	0.00027	0.0316	-0.31	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:201409~205009:-
HNSC	cis	rs35000415	0.688	rs13232316	ENSG00000275106.1	RP11-309L24.10	-3.67	0.00027	0.0316	-0.34	-0.17	Systemic lupus erythematosus;	chr7:129075245	chr7:128952527~128953316:-
HNSC	cis	rs11676676	1	rs11676676	ENSG00000204588.5	LINC01123	3.67	0.00027	0.0316	0.25	0.17	Pediatric bone mineral density (spine);	chr2:109150717	chr2:109987063~109996140:+
HNSC	cis	rs10507380	0.891	rs73501714	ENSG00000260704.1	LINC00543	3.67	0.00027	0.0316	0.28	0.17	Electrocardiographic traits;	chr13:27293840	chr13:27953526~27955370:+
HNSC	cis	rs870825	0.616	rs36022027	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718038	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs2310108	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718321	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4416519	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718348	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs57086463	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718371	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.55	rs35981185	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718566	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.587	rs35377170	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718574	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.587	rs58332461	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718588	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.587	rs35845099	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718608	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs72705689	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718740	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6834156	ENSG00000254233.1	RP11-242J7.1	3.67	0.00027	0.0316	0.24	0.17	Blood protein levels;	chr4:184718749	chr4:184584093~184625030:-
HNSC	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-3.67	0.00027	0.0316	-0.21	-0.17	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
HNSC	cis	rs10256972	0.758	rs7799391	ENSG00000225146.1	AC073957.15	3.67	0.00027	0.0316	0.2	0.17	Endometriosis;Longevity;	chr7:1042930	chr7:1029025~1043891:+
HNSC	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	3.67	0.00027	0.0317	0.21	0.17	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
HNSC	cis	rs73201462	0.908	rs2811520	ENSG00000231305.3	RP11-723O4.2	3.67	0.00027	0.0317	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128293434	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811519	ENSG00000231305.3	RP11-723O4.2	3.67	0.00027	0.0317	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294033	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811518	ENSG00000231305.3	RP11-723O4.2	3.67	0.00027	0.0317	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294802	chr3:128861313~128871540:-
HNSC	cis	rs16846053	0.515	rs2892770	ENSG00000227403.1	AC009299.3	-3.67	0.00027	0.0317	-0.3	-0.17	Blood osmolality (transformed sodium);	chr2:161638321	chr2:161244739~161249050:+
HNSC	cis	rs2247572	0.667	rs2256816	ENSG00000250295.5	RP11-434I12.2	3.67	0.00027	0.0317	0.22	0.17	Cognitive performance;	chr8:72678761	chr8:73297711~73356461:-
HNSC	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-3.67	0.00027	0.0317	-0.24	-0.17	Gout;	chr7:66693028	chr7:66848496~66858136:+
HNSC	cis	rs1552244	1	rs67569278	ENSG00000180385.7	EMC3-AS1	3.67	0.00027	0.0317	0.19	0.17	Alzheimer's disease;	chr3:10108209	chr3:9986893~10006990:+
HNSC	cis	rs526231	0.543	rs27698	ENSG00000250682.4	LINC00491	-3.67	0.00027	0.0317	-0.22	-0.17	Primary biliary cholangitis;	chr5:103190474	chr5:102609156~102671559:-
HNSC	cis	rs6831352	0.589	rs2924584	ENSG00000263923.1	RP11-571L19.7	-3.67	0.00027	0.0317	-0.17	-0.17	Alcohol dependence;	chr4:99067057	chr4:98928897~98994994:+
HNSC	cis	rs7432375	0.641	rs835649	ENSG00000239213.4	NCK1-AS1	3.67	0.00027	0.0317	0.14	0.17	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136841726~136862054:-
HNSC	cis	rs9863	0.794	rs12310367	ENSG00000270028.1	RP11-380L11.4	3.67	0.00027	0.0317	0.2	0.17	White blood cell count;	chr12:124002131	chr12:123925461~123926083:-
HNSC	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-3.67	0.00027	0.0317	-0.24	-0.17	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
HNSC	cis	rs897984	0.881	rs12920259	ENSG00000279196.1	RP11-1072A3.3	-3.67	0.00027	0.0317	-0.19	-0.17	Dementia with Lewy bodies;	chr16:30869978	chr16:30984630~30988270:-
HNSC	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-3.67	0.00027	0.0317	-0.2	-0.17	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
HNSC	cis	rs17122278	1	rs7929887	ENSG00000255422.1	AP002954.4	3.67	0.00027	0.0317	0.3	0.17	Total cholesterol levels;	chr11:118558076	chr11:118704607~118750263:+
HNSC	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	3.67	0.00027	0.0317	0.19	0.17	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
HNSC	cis	rs6600671	1	rs1591882	ENSG00000272583.1	RP11-344P13.6	-3.67	0.00027	0.0317	-0.19	-0.17	Hip geometry;	chr1:121441455	chr1:121518366~121518829:-
HNSC	cis	rs3812049	0.532	rs251389	ENSG00000245937.6	LINC01184	3.67	0.00027	0.0317	0.22	0.17	Lymphocyte counts;Red cell distribution width;	chr5:128206185	chr5:127940426~128083172:-
HNSC	cis	rs10040610	0.524	rs271419	ENSG00000250490.1	FLJ33360	-3.67	0.00027	0.0317	-0.22	-0.17	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6353897	chr5:6310441~6339884:-
HNSC	cis	rs66486766	1	rs66486766	ENSG00000230373.7	GOLGA6L5P	-3.67	0.00027	0.0317	-0.19	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84507885~84516814:-
HNSC	cis	rs4814920	0.818	rs6035467	ENSG00000233895.1	RP1-122P22.2	-3.67	0.00027	0.0317	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19757708~19809675:+
HNSC	cis	rs7726839	0.54	rs4957080	ENSG00000225138.6	CTD-2228K2.7	-3.67	0.00027	0.0317	-0.25	-0.17	Obesity-related traits;	chr5:644437	chr5:473236~480884:+
HNSC	cis	rs7726839	0.574	rs12522955	ENSG00000225138.6	CTD-2228K2.7	3.67	0.00027	0.0317	0.25	0.17	Obesity-related traits;	chr5:639116	chr5:473236~480884:+
HNSC	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-3.67	0.000271	0.0317	-0.19	-0.17	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
HNSC	cis	rs2836974	0.897	rs4817996	ENSG00000255568.3	BRWD1-AS2	3.67	0.000271	0.0317	0.15	0.17	Cognitive function;	chr21:39153833	chr21:39313935~39314962:+
HNSC	cis	rs9652601	0.691	rs998592	ENSG00000274038.1	RP11-66H6.4	3.67	0.000271	0.0317	0.2	0.17	Systemic lupus erythematosus;	chr16:11105821	chr16:11056556~11057034:+
HNSC	cis	rs7777677	1	rs7777677	ENSG00000276953.1	TRBV12-4	3.67	0.000271	0.0317	0.15	0.17	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142563740~142564245:+
HNSC	cis	rs17203016	0.731	rs10932191	ENSG00000231908.1	IDH1-AS1	-3.67	0.000271	0.0317	-0.24	-0.17	Body mass index;	chr2:207371526	chr2:208255247~208256181:+
HNSC	cis	rs9303401	0.573	rs35104446	ENSG00000266701.1	AC005702.4	3.67	0.000271	0.0317	0.23	0.17	Cognitive test performance;	chr17:59102873	chr17:60042546~60042627:-
HNSC	cis	rs8030379	1	rs7496814	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000271	0.0317	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84507885~84516814:-
HNSC	cis	rs10875746	0.768	rs4760609	ENSG00000257763.1	OR5BK1P	3.67	0.000271	0.0317	0.2	0.17	Longevity (90 years and older);	chr12:48021974	chr12:48355792~48356614:-
HNSC	cis	rs10484434	0.818	rs11756400	ENSG00000272462.2	U91328.19	3.67	0.000271	0.0317	0.21	0.17	HIV-1 viral setpoint;	chr6:26040625	chr6:25992662~26001775:+
HNSC	cis	rs34787248	1	rs34787248	ENSG00000270326.1	RP5-874C20.6	-3.67	0.000271	0.0317	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28319660~28319852:-
HNSC	cis	rs6840360	0.667	rs2709832	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000271	0.0317	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709831	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000271	0.0317	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709816	ENSG00000251611.1	RP11-610P16.1	-3.67	0.000271	0.0317	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151407551~151408835:-
HNSC	cis	rs7927592	0.763	rs10791982	ENSG00000255031.4	RP11-802E16.3	-3.67	0.000271	0.0317	-0.14	-0.17	Total body bone mineral density;	chr11:68570196	chr11:68050740~68053762:+
HNSC	cis	rs847649	0.699	rs10241865	ENSG00000239969.4	RP11-163E9.2	-3.67	0.000271	0.0317	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102887070	chr7:102364162~102380633:+
HNSC	cis	rs868153	0.625	rs13204964	ENSG00000275339.1	RP3-425C14.6	3.67	0.000271	0.0317	0.18	0.17	Vertical cup-disc ratio;	chr6:122219967	chr6:122454358~122454612:+
HNSC	cis	rs12530134	0.519	rs3920484	ENSG00000225532.1	XX-C2158C6.3	3.67	0.000271	0.0317	0.32	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr6:170436993	chr6:170736173~170737777:-
HNSC	cis	rs9733	0.566	rs11204675	ENSG00000236713.1	RP11-363I22.3	3.67	0.000271	0.0317	0.18	0.17	Tonsillectomy;	chr1:150598509	chr1:150780272~150780644:+
HNSC	cis	rs11779988	0.528	rs376771	ENSG00000253671.1	RP11-806O11.1	-3.67	0.000271	0.0317	-0.19	-0.17	Breast cancer;	chr8:18007476	chr8:17808941~17820868:+
HNSC	cis	rs2834288	0.734	rs743336	ENSG00000273102.1	AP000569.9	-3.67	0.000271	0.0317	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr21:33893080	chr21:33967101~33968573:-
HNSC	cis	rs2834288	0.734	rs743337	ENSG00000273102.1	AP000569.9	-3.67	0.000271	0.0317	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr21:33893220	chr21:33967101~33968573:-
HNSC	cis	rs4578769	0.55	rs12971230	ENSG00000265943.1	RP11-739L10.1	3.67	0.000271	0.0317	0.2	0.17	Eosinophil percentage of white cells;	chr18:22962987	chr18:22699481~22933764:-
HNSC	cis	rs172166	0.61	rs156737	ENSG00000224843.5	LINC00240	3.67	0.000271	0.0318	0.17	0.17	Cardiac Troponin-T levels;	chr6:27927435	chr6:26956992~27023924:+
HNSC	cis	rs2307394	0.749	rs12691762	ENSG00000281469.1	RP11-567F11.1	3.67	0.000271	0.0318	0.2	0.17	Urate levels;	chr2:147734478	chr2:148044380~148044894:+
HNSC	cis	rs137699	1	rs137703	ENSG00000261202.1	RP3-496C20.1	-3.67	0.000271	0.0318	-0.2	-0.17	IgG glycosylation;	chr22:39354236	chr22:40043068~40044530:-
HNSC	cis	rs2243480	0.803	rs160649	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000271	0.0318	-0.24	-0.17	Diabetic kidney disease;	chr7:66078212	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160648	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000271	0.0318	-0.24	-0.17	Diabetic kidney disease;	chr7:66078397	chr7:66848496~66858136:+
HNSC	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000271	0.0318	-0.19	-0.17	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
HNSC	cis	rs1440410	0.798	rs11100783	ENSG00000250326.1	RP11-284M14.1	-3.67	0.000271	0.0318	-0.19	-0.17	Ischemic stroke;	chr4:143241047	chr4:142933195~143184861:-
HNSC	cis	rs36093844	0.626	rs12270433	ENSG00000279742.1	RP11-700A24.1	-3.67	0.000271	0.0318	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86052277	chr11:85852557~85854943:-
HNSC	cis	rs34286592	1	rs4787480	ENSG00000196796.5	CTB-134H23.2	3.67	0.000271	0.0318	0.25	0.17	Multiple sclerosis;	chr16:29845995	chr16:29038655~29052726:+
HNSC	cis	rs8030379	1	rs10906983	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000271	0.0318	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs922664	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000271	0.0318	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84507885~84516814:-
HNSC	cis	rs12681963	1	rs6468131	ENSG00000248159.1	HSPA8P11	-3.67	0.000271	0.0318	-0.26	-0.17	Migraine;	chr8:30123504	chr8:30237382~30240997:+
HNSC	cis	rs8062405	1	rs3088215	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs28403629	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs61737565	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs4788099	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs9972693	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.964	rs9972768	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.965	rs62037363	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs7205323	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs4788101	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.929	rs11150609	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.737	rs11861132	ENSG00000261089.1	RP11-435I10.3	3.67	0.000271	0.0318	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28413703~28415018:+
HNSC	cis	rs11002791	0.607	rs10824706	ENSG00000224596.6	ZMIZ1-AS1	3.67	0.000271	0.0318	0.2	0.17	Red blood cell count;	chr10:79032865	chr10:78943328~79067895:-
HNSC	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	3.67	0.000271	0.0318	0.19	0.17	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
HNSC	cis	rs17416285	0.537	rs61772594	ENSG00000260971.3	RP11-504A18.1	3.67	0.000271	0.0318	0.22	0.17	Coronary artery disease;	chr1:56517616	chr1:56248294~56258571:-
HNSC	cis	rs1552244	1	rs67006488	ENSG00000180385.7	EMC3-AS1	3.67	0.000272	0.0318	0.19	0.17	Alzheimer's disease;	chr3:10111309	chr3:9986893~10006990:+
HNSC	cis	rs4242434	0.819	rs1871902	ENSG00000253837.1	RP11-177H13.2	-3.67	0.000272	0.0318	-0.17	-0.17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22613197	chr8:23336171~23366125:+
HNSC	cis	rs12893668	0.703	rs4906335	ENSG00000269958.1	RP11-73M18.8	3.67	0.000272	0.0318	0.16	0.17	Reticulocyte count;	chr14:103554804	chr14:103696353~103697163:+
HNSC	cis	rs2070419	0.855	rs58111141	ENSG00000261610.1	AP000265.1	3.67	0.000272	0.0318	0.24	0.17	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31566765	chr21:32259804~32261585:-
HNSC	cis	rs11098499	0.722	rs10025925	ENSG00000250412.1	KLHL2P1	3.67	0.000272	0.0318	0.21	0.17	Corneal astigmatism;	chr4:119350589	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.731	rs10015579	ENSG00000250412.1	KLHL2P1	3.67	0.000272	0.0318	0.21	0.17	Corneal astigmatism;	chr4:119350647	chr4:119334329~119378233:+
HNSC	cis	rs860295	0.529	rs1475766	ENSG00000203761.5	MSTO2P	3.67	0.000272	0.0318	0.12	0.17	Body mass index;	chr1:156011698	chr1:155745829~155750137:+
HNSC	cis	rs189798	0.807	rs330912	ENSG00000233609.3	RP11-62H7.2	3.67	0.000272	0.0318	0.18	0.17	Myopia (pathological);	chr8:9138784	chr8:8961200~8979025:+
HNSC	cis	rs728616	0.51	rs34782759	ENSG00000225484.5	NUTM2B-AS1	-3.67	0.000272	0.0318	-0.31	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80435463	chr10:79663088~79826594:-
HNSC	cis	rs9402682	1	rs9402682	ENSG00000232876.1	CTA-212D2.2	-3.67	0.000272	0.0318	-0.22	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135085045	chr6:135055033~135060550:+
HNSC	cis	rs12893668	0.572	rs34000399	ENSG00000269958.1	RP11-73M18.8	3.67	0.000272	0.0318	0.15	0.17	Reticulocyte count;	chr14:103635080	chr14:103696353~103697163:+
HNSC	cis	rs7224668	0.647	rs9898133	ENSG00000280407.2	RP13-516M14.8	3.67	0.000272	0.0318	0.14	0.17	IgG glycosylation;	chr17:81276197	chr17:82249067~82251844:+
HNSC	cis	rs4473651	0.551	rs73226572	ENSG00000273133.1	RP11-799M12.2	-3.67	0.000272	0.0318	-0.42	-0.17	Blood protein levels;	chr4:15803052	chr4:15563698~15564253:-
HNSC	cis	rs2562456	0.833	rs17680605	ENSG00000268119.4	CTD-2561J22.5	3.67	0.000272	0.0318	0.25	0.17	Pain;	chr19:21379646	chr19:21444241~21463908:-
HNSC	cis	rs9926296	0.585	rs6500450	ENSG00000261812.4	TUBB8P7	-3.67	0.000272	0.0318	-0.18	-0.17	Vitiligo;	chr16:89791616	chr16:90093154~90096354:+
HNSC	cis	rs12887734	0.546	rs66676135	ENSG00000269910.1	RP11-73M18.10	3.67	0.000272	0.0318	0.16	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694516~103695050:-
HNSC	cis	rs62292953	0.719	rs62292467	ENSG00000248724.5	NPHP3-AS1	-3.67	0.000272	0.0318	-0.39	-0.17	Red cell distribution width;	chr3:132688302	chr3:132721750~132874223:+
HNSC	cis	rs62292953	0.719	rs2271491	ENSG00000248724.5	NPHP3-AS1	-3.67	0.000272	0.0318	-0.39	-0.17	Red cell distribution width;	chr3:132691358	chr3:132721750~132874223:+
HNSC	cis	rs62292953	0.719	rs2271490	ENSG00000248724.5	NPHP3-AS1	-3.67	0.000272	0.0318	-0.39	-0.17	Red cell distribution width;	chr3:132691370	chr3:132721750~132874223:+
HNSC	cis	rs36715	0.953	rs185177	ENSG00000245937.6	LINC01184	3.67	0.000272	0.0318	0.21	0.17	Breast cancer;	chr5:128212118	chr5:127940426~128083172:-
HNSC	cis	rs418053	0.935	rs204246	ENSG00000237786.1	GFOD1-AS1	3.67	0.000272	0.0318	0.2	0.17	Breast cancer;	chr6:13723142	chr6:13486294~13486852:+
HNSC	cis	rs3740713	1	rs74663287	ENSG00000256464.1	YWHABP2	3.67	0.000272	0.0318	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438697	ENSG00000256464.1	YWHABP2	3.67	0.000272	0.0318	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs114330751	ENSG00000256464.1	YWHABP2	3.67	0.000272	0.0318	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438699	ENSG00000256464.1	YWHABP2	3.67	0.000272	0.0318	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr11:18490243~18490955:-
HNSC	cis	rs4704187	0.687	rs1422696	ENSG00000272040.1	CTC-366B18.4	-3.67	0.000272	0.0318	-0.16	-0.17	Response to amphetamines;	chr5:75168590	chr5:75608817~75609983:+
HNSC	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	3.67	0.000272	0.0318	0.18	0.17	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
HNSC	cis	rs1979679	0.879	rs1581630	ENSG00000247934.4	RP11-967K21.1	3.67	0.000272	0.0318	0.18	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28163298~28190738:-
HNSC	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	3.67	0.000272	0.0318	0.29	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
HNSC	cis	rs728616	0.717	rs17098169	ENSG00000225484.5	NUTM2B-AS1	3.67	0.000272	0.0318	0.33	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79663088~79826594:-
HNSC	cis	rs16958440	0.867	rs79275306	ENSG00000267724.1	RP11-49K24.8	3.67	0.000272	0.0319	0.33	0.17	Sitting height ratio;	chr18:47185249	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.609	rs75911383	ENSG00000267724.1	RP11-49K24.8	3.67	0.000272	0.0319	0.33	0.17	Sitting height ratio;	chr18:47189640	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs75481537	ENSG00000267724.1	RP11-49K24.8	3.67	0.000272	0.0319	0.33	0.17	Sitting height ratio;	chr18:47193575	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs9304342	ENSG00000267724.1	RP11-49K24.8	3.67	0.000272	0.0319	0.33	0.17	Sitting height ratio;	chr18:47193828	chr18:47105946~47108062:+
HNSC	cis	rs1908814	0.504	rs7830734	ENSG00000227888.4	FAM66A	3.67	0.000272	0.0319	0.17	0.17	Neuroticism;	chr8:11938130	chr8:12362019~12388296:+
HNSC	cis	rs11711311	0.747	rs9882193	ENSG00000241529.3	RN7SL767P	3.67	0.000272	0.0319	0.21	0.17	IgG glycosylation;	chr3:113630604	chr3:113632704~113632998:+
HNSC	cis	rs34792	0.524	rs34629185	ENSG00000207425.1	Y_RNA	-3.67	0.000272	0.0319	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:14915457~14915556:-
HNSC	cis	rs12817549	0.817	rs2196424	ENSG00000213250.5	RBMS2P1	3.67	0.000272	0.0319	0.15	0.17	Hip circumference adjusted for BMI;	chr12:93710505	chr12:94423744~94424969:-
HNSC	cis	rs7772486	0.686	rs2179323	ENSG00000270638.1	RP3-466P17.1	-3.67	0.000272	0.0319	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145735570~145737218:+
HNSC	cis	rs853679	0.607	rs56189111	ENSG00000226314.6	ZNF192P1	-3.67	0.000272	0.0319	-0.32	-0.17	Depression;	chr6:28304196	chr6:28161781~28169594:+
HNSC	cis	rs6545883	0.899	rs1562309	ENSG00000271889.1	RP11-493E12.1	3.67	0.000272	0.0319	0.19	0.17	Tuberculosis;	chr2:61542991	chr2:61151433~61162105:-
HNSC	cis	rs10463554	0.853	rs458598	ENSG00000250682.4	LINC00491	3.67	0.000272	0.0319	0.22	0.17	Parkinson's disease;	chr5:103233677	chr5:102609156~102671559:-
HNSC	cis	rs1865760	0.568	rs2032450	ENSG00000272810.1	U91328.22	-3.67	0.000272	0.0319	-0.15	-0.17	Height;	chr6:25992886	chr6:26013241~26013757:+
HNSC	cis	rs8002861	0.641	rs4942252	ENSG00000274001.1	RP11-5G9.5	3.67	0.000272	0.0319	0.17	0.17	Leprosy;	chr13:43868903	chr13:43877715~43878163:-
HNSC	cis	rs8054556	0.787	rs1140239	ENSG00000250616.2	RP11-455F5.3	3.67	0.000272	0.0319	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30096430~30104116:+
HNSC	cis	rs16958440	0.867	rs117060920	ENSG00000267724.1	RP11-49K24.8	3.67	0.000272	0.0319	0.33	0.17	Sitting height ratio;	chr18:47182664	chr18:47105946~47108062:+
HNSC	cis	rs2115630	0.791	rs2008262	ENSG00000259295.5	CSPG4P12	-3.67	0.000272	0.0319	-0.2	-0.17	P wave terminal force;	chr15:84762039	chr15:85191438~85213905:+
HNSC	cis	rs3198697	1	rs3198697	ENSG00000263065.1	AF001548.6	-3.67	0.000272	0.0319	-0.2	-0.17	Triglycerides;	chr16:15036083	chr16:15741151~15741791:+
HNSC	cis	rs5758659	0.845	rs5758645	ENSG00000270083.1	RP1-257I20.14	3.67	0.000272	0.0319	0.15	0.17	Cognitive function;	chr22:42202945	chr22:42089630~42090028:-
HNSC	cis	rs28489187	0.706	rs18582	ENSG00000223653.4	RP11-131L23.1	3.67	0.000272	0.0319	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329136	chr1:85276715~85448124:+
HNSC	cis	rs9467711	0.606	rs9393718	ENSG00000241549.7	GUSBP2	3.67	0.000272	0.0319	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26407254	chr6:26871484~26956554:-
HNSC	cis	rs2439831	0.867	rs2447196	ENSG00000201136.1	RNU6-353P	3.67	0.000272	0.0319	0.25	0.17	Lung cancer in ever smokers;	chr15:43601620	chr15:43702363~43702470:+
HNSC	cis	rs6095360	0.7	rs4599176	ENSG00000222365.1	SNORD12B	-3.67	0.000272	0.0319	-0.21	-0.17	Intelligence (multi-trait analysis);	chr20:48903557	chr20:49280319~49280409:+
HNSC	cis	rs1620921	0.711	rs2565724	ENSG00000233342.1	RP11-235G24.3	-3.67	0.000272	0.0319	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160820857	chr6:160926369~160927162:+
HNSC	cis	rs897984	0.759	rs13708	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000272	0.0319	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30989488	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.762	rs4889599	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000272	0.0319	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30957268	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.721	rs2305884	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000272	0.0319	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30959420	chr16:31043150~31049868:+
HNSC	cis	rs354225	0.586	rs966003	ENSG00000237887.1	AC092839.1	-3.67	0.000272	0.0319	-0.19	-0.17	Schizophrenia;	chr2:54657733	chr2:54529343~54529801:+
HNSC	cis	rs2253762	0.645	rs11200366	ENSG00000226864.1	ATE1-AS1	-3.67	0.000272	0.0319	-0.26	-0.17	Breast cancer;	chr10:122044170	chr10:121928312~121951965:+
HNSC	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	3.67	0.000273	0.0319	0.21	0.17	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
HNSC	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	3.67	0.000273	0.0319	0.15	0.17	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
HNSC	cis	rs4906332	0.782	rs2236281	ENSG00000269910.1	RP11-73M18.10	3.67	0.000273	0.0319	0.18	0.17	Coronary artery disease;	chr14:103534181	chr14:103694516~103695050:-
HNSC	cis	rs1979679	0.659	rs11049461	ENSG00000247934.4	RP11-967K21.1	-3.67	0.000273	0.0319	-0.2	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28163298~28190738:-
HNSC	cis	rs7221109	0.711	rs11651694	ENSG00000278834.1	RP11-458J1.1	3.67	0.000273	0.0319	0.16	0.17	Type 1 diabetes;	chr17:40602009	chr17:40648300~40649718:+
HNSC	cis	rs7829975	0.623	rs7010753	ENSG00000233609.3	RP11-62H7.2	3.67	0.000273	0.0319	0.16	0.17	Mood instability;	chr8:8516446	chr8:8961200~8979025:+
HNSC	cis	rs2307394	0.749	rs10497018	ENSG00000281469.1	RP11-567F11.1	3.67	0.000273	0.0319	0.2	0.17	Urate levels;	chr2:147699743	chr2:148044380~148044894:+
HNSC	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-3.67	0.000273	0.0319	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
HNSC	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	3.67	0.000273	0.0319	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
HNSC	cis	rs7746199	0.736	rs35848276	ENSG00000226314.6	ZNF192P1	-3.67	0.000273	0.0319	-0.32	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28161781~28169594:+
HNSC	cis	rs1602565	1	rs72881814	ENSG00000255450.1	CTD-2063L20.1	-3.67	0.000273	0.0319	-0.29	-0.17	Schizophrenia;	chr11:29189168	chr11:29275655~29276565:+
HNSC	cis	rs6546886	0.625	rs12991192	ENSG00000217702.2	RP11-287D1.4	-3.67	0.000273	0.0319	-0.23	-0.17	Dialysis-related mortality;	chr2:74082539	chr2:74130583~74135395:+
HNSC	cis	rs7824557	0.614	rs2293858	ENSG00000255495.1	AC145124.2	3.67	0.000273	0.0319	0.18	0.17	Retinal vascular caliber;	chr8:11356372	chr8:12194467~12196280:+
HNSC	cis	rs2839186	0.585	rs2839154	ENSG00000239415.1	AP001469.9	-3.67	0.000273	0.0319	-0.15	-0.17	Testicular germ cell tumor;	chr21:46217846	chr21:46251549~46254133:-
HNSC	cis	rs4853525	0.59	rs2203715	ENSG00000228509.4	AC006460.2	3.67	0.000273	0.0319	0.23	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944157	chr2:190676944~190708716:-
HNSC	cis	rs58873874	0.737	rs12654973	ENSG00000248544.2	CTB-47B11.3	3.67	0.000273	0.0319	0.34	0.17	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.579	rs74804793	ENSG00000248544.2	CTB-47B11.3	3.67	0.000273	0.0319	0.34	0.17	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157375741~157384950:-
HNSC	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	3.67	0.000273	0.0319	0.18	0.17	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
HNSC	cis	rs72843506	0.722	rs12051550	ENSG00000189423.10	USP32P3	3.67	0.000273	0.0319	0.26	0.17	Schizophrenia;	chr17:20226233	chr17:20415547~20431008:+
HNSC	cis	rs72843506	0.722	rs9901484	ENSG00000189423.10	USP32P3	3.67	0.000273	0.0319	0.26	0.17	Schizophrenia;	chr17:20229581	chr17:20415547~20431008:+
HNSC	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-3.67	0.000273	0.0319	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
HNSC	cis	rs17594362	1	rs12429256	ENSG00000229473.2	RGS17P1	3.67	0.000273	0.0319	0.26	0.17	Multiple sclerosis;	chr13:41562247	chr13:40992779~40993331:-
HNSC	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	3.67	0.000273	0.0319	0.23	0.17	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
HNSC	cis	rs1595825	0.891	rs2164070	ENSG00000231621.1	AC013264.2	-3.67	0.000273	0.032	-0.21	-0.17	Ulcerative colitis;	chr2:198017006	chr2:197197991~197199273:+
HNSC	cis	rs1595825	0.838	rs73058854	ENSG00000231621.1	AC013264.2	-3.67	0.000273	0.032	-0.21	-0.17	Ulcerative colitis;	chr2:198020336	chr2:197197991~197199273:+
HNSC	cis	rs6494601	0.5	rs12050872	ENSG00000223509.7	RP11-632K20.7	3.67	0.000273	0.032	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr15:32761267	chr15:32519848~32536926:-
HNSC	cis	rs8014252	0.708	rs8010473	ENSG00000269927.1	RP6-91H8.3	-3.67	0.000273	0.032	-0.28	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70522276	chr14:71141125~71143253:-
HNSC	cis	rs2880765	0.546	rs11637726	ENSG00000259295.5	CSPG4P12	-3.67	0.000273	0.032	-0.22	-0.17	Coronary artery disease;	chr15:85516040	chr15:85191438~85213905:+
HNSC	cis	rs9914544	0.545	rs1037037	ENSG00000264885.1	RP11-815I9.4	-3.67	0.000273	0.032	-0.17	-0.17	Educational attainment (years of education);	chr17:18861708	chr17:18667629~18669461:-
HNSC	cis	rs34286592	1	rs7201519	ENSG00000196796.5	CTB-134H23.2	3.67	0.000273	0.032	0.25	0.17	Multiple sclerosis;	chr16:29848656	chr16:29038655~29052726:+
HNSC	cis	rs34286592	1	rs28599680	ENSG00000196796.5	CTB-134H23.2	3.67	0.000273	0.032	0.25	0.17	Multiple sclerosis;	chr16:29849364	chr16:29038655~29052726:+
HNSC	cis	rs1075265	0.509	rs10178643	ENSG00000233266.1	HMGB1P31	3.67	0.000273	0.032	0.21	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53728341	chr2:54051334~54051760:+
HNSC	cis	rs4713118	0.568	rs9468213	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000273	0.032	-0.19	-0.17	Parkinson's disease;	chr6:27738401	chr6:28115628~28116551:+
HNSC	cis	rs12893668	0.628	rs57072546	ENSG00000269910.1	RP11-73M18.10	3.67	0.000273	0.032	0.16	0.17	Reticulocyte count;	chr14:103597386	chr14:103694516~103695050:-
HNSC	cis	rs2554380	0.843	rs2562783	ENSG00000259570.1	RP11-671M22.4	3.67	0.000273	0.032	0.22	0.17	Height;	chr15:83719174	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.8	rs8032414	ENSG00000259570.1	RP11-671M22.4	3.67	0.000273	0.032	0.22	0.17	Height;	chr15:83727217	chr15:84394512~84395514:+
HNSC	cis	rs10129255	0.517	rs11625572	ENSG00000211974.3	IGHV2-70	3.67	0.000273	0.032	0.16	0.17	Kawasaki disease;	chr14:106656426	chr14:106723574~106724093:-
HNSC	cis	rs2548724	1	rs841934	ENSG00000175749.11	EIF3KP1	-3.67	0.000273	0.032	-0.24	-0.17	Type 2 diabetes;	chr5:102286496	chr5:103032376~103033031:+
HNSC	cis	rs4392868	0.514	rs4323439	ENSG00000245080.5	RP11-320N21.1	-3.67	0.000273	0.032	-0.2	-0.17	Radiation response;	chr8:95093533	chr8:95066808~95073182:-
HNSC	cis	rs7520050	0.966	rs10890363	ENSG00000280836.1	AL355480.1	-3.67	0.000273	0.032	-0.17	-0.17	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45581219~45581321:-
HNSC	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	3.67	0.000273	0.032	0.2	0.17	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
HNSC	cis	rs16977195	0.649	rs77308725	ENSG00000259416.2	RP11-158M2.5	3.67	0.000273	0.032	0.33	0.17	Schizophrenia;	chr15:86416126	chr15:85754941~85756237:-
HNSC	cis	rs2117029	0.521	rs12227610	ENSG00000258101.2	RP11-977B10.2	3.67	0.000273	0.032	0.22	0.17	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49232790~49264756:-
HNSC	cis	rs1656402	0.911	rs2880817	ENSG00000263941.2	RN7SL32P	3.67	0.000273	0.032	0.21	0.17	Non-small cell lung cancer (survival);	chr2:232588995	chr2:233205199~233205479:+
HNSC	cis	rs208623	0.911	rs208568	ENSG00000237296.8	SMG1P1	3.67	0.000273	0.032	0.2	0.17	CTACK levels;	chr16:22944655	chr16:22437008~22492220:+
HNSC	cis	rs7107174	0.892	rs1007837	ENSG00000251323.2	RP11-452H21.4	3.67	0.000273	0.032	0.24	0.17	Testicular germ cell tumor;	chr11:78230030	chr11:78423982~78429836:-
HNSC	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	3.67	0.000273	0.032	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
HNSC	cis	rs870825	0.655	rs67798981	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184698413	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs2310104	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184698813	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.746	rs1107908	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184698959	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552801	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184699469	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6552802	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184699597	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs877276	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184700095	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs79884757	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184700300	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28444118	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184700538	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7674952	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184701173	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4256263	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184701805	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28660669	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702158	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs67641203	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702691	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.698	rs66462315	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702763	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.698	rs72703549	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702809	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs67409049	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702835	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4615214	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184702975	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4263438	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184703084	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4386643	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184703127	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4264873	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184703182	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.698	rs7673203	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184704243	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs9631782	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184705225	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs9631783	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184705357	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs55674580	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184705451	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28620459	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184705978	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.549	rs28579266	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184706108	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28673855	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184706262	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28500698	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184706592	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28558715	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184706607	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28497285	ENSG00000254233.1	RP11-242J7.1	3.67	0.000273	0.032	0.25	0.17	Blood protein levels;	chr4:184708015	chr4:184584093~184625030:-
HNSC	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	3.67	0.000273	0.032	0.18	0.17	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
HNSC	cis	rs2337406	0.85	rs4774179	ENSG00000211972.2	IGHV3-66	3.67	0.000273	0.032	0.17	0.17	Alzheimer's disease (late onset);	chr14:106700837	chr14:106675017~106675544:-
HNSC	cis	rs1937680	0.924	rs7073470	ENSG00000236671.6	PRKG1-AS1	-3.67	0.000273	0.032	-0.22	-0.17	Breast cancer;	chr10:51913702	chr10:52230742~52314128:-
HNSC	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000273	0.032	-0.19	-0.17	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000273	0.032	-0.19	-0.17	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
HNSC	cis	rs1411478	1	rs3789362	ENSG00000243155.1	RP11-46A10.5	3.67	0.000274	0.032	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180982556	chr1:180944042~180976482:-
HNSC	cis	rs73198271	1	rs4840356	ENSG00000233609.3	RP11-62H7.2	-3.67	0.000274	0.032	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8961200~8979025:+
HNSC	cis	rs9531006	0.636	rs3898551	ENSG00000227676.3	LINC01068	3.67	0.000274	0.032	0.26	0.17	Sleep duration;	chr13:79895630	chr13:79566727~79571436:+
HNSC	cis	rs546131	0.642	rs12808574	ENSG00000271369.1	RP11-350D17.3	3.67	0.000274	0.032	0.22	0.17	Lung disease severity in cystic fibrosis;	chr11:34830573	chr11:34709600~34710161:+
HNSC	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	3.67	0.000274	0.032	0.2	0.17	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
HNSC	cis	rs4578769	0.55	rs8087501	ENSG00000265943.1	RP11-739L10.1	3.67	0.000274	0.032	0.2	0.17	Eosinophil percentage of white cells;	chr18:22970711	chr18:22699481~22933764:-
HNSC	cis	rs10875746	0.768	rs4760676	ENSG00000257763.1	OR5BK1P	-3.67	0.000274	0.032	-0.2	-0.17	Longevity (90 years and older);	chr12:48027880	chr12:48355792~48356614:-
HNSC	cis	rs7927592	0.871	rs55953412	ENSG00000255031.4	RP11-802E16.3	3.67	0.000274	0.032	0.15	0.17	Total body bone mineral density;	chr11:68560815	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs7102898	ENSG00000255031.4	RP11-802E16.3	3.67	0.000274	0.032	0.15	0.17	Total body bone mineral density;	chr11:68561402	chr11:68050740~68053762:+
HNSC	cis	rs67072384	1	rs2365442	ENSG00000213365.3	AP000593.6	3.67	0.000274	0.032	0.29	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739173	chr11:72280151~72281178:+
HNSC	cis	rs868153	0.591	rs1456692	ENSG00000275339.1	RP3-425C14.6	3.67	0.000274	0.032	0.18	0.17	Vertical cup-disc ratio;	chr6:122233537	chr6:122454358~122454612:+
HNSC	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	3.67	0.000274	0.032	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
HNSC	cis	rs13434995	0.842	rs62303716	ENSG00000273257.1	RP11-177J6.1	-3.67	0.000274	0.032	-0.27	-0.17	Adiponectin levels;	chr4:55468085	chr4:55387949~55388271:+
HNSC	cis	rs8058578	0.945	rs34480360	ENSG00000279196.1	RP11-1072A3.3	3.67	0.000274	0.032	0.21	0.17	Multiple myeloma;	chr16:30787368	chr16:30984630~30988270:-
HNSC	cis	rs67311347	0.544	rs9833640	ENSG00000280739.1	EIF1B-AS1	3.67	0.000274	0.032	0.18	0.17	Renal cell carcinoma;	chr3:40313450	chr3:40173145~40309698:-
HNSC	cis	rs7299940	1	rs6486613	ENSG00000256250.1	RP11-989F5.1	3.67	0.000274	0.032	0.18	0.17	Panic disorder;	chr12:130909133	chr12:130810606~130812438:+
HNSC	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	3.67	0.000274	0.032	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	3.67	0.000274	0.032	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
HNSC	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	3.67	0.000274	0.032	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
HNSC	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	3.67	0.000274	0.032	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
HNSC	cis	rs886774	0.866	rs12668766	ENSG00000273055.1	CTB-13F3.1	-3.67	0.000274	0.032	-0.17	-0.17	Ulcerative colitis;	chr7:107876264	chr7:107942116~107942740:+
HNSC	cis	rs6088580	0.634	rs4911152	ENSG00000276073.1	RP5-1125A11.7	3.67	0.000274	0.032	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:33985617~33988989:-
HNSC	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	3.67	0.000274	0.032	0.18	0.17	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	3.67	0.000274	0.032	0.18	0.17	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
HNSC	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	3.67	0.000274	0.032	0.18	0.17	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
HNSC	cis	rs4843747	0.671	rs13334603	ENSG00000260750.4	RP11-482M8.1	3.67	0.000274	0.032	0.21	0.17	Menopause (age at onset);	chr16:88082410	chr16:87492555~87515635:+
HNSC	cis	rs172166	0.694	rs536704	ENSG00000219891.2	ZSCAN12P1	3.67	0.000274	0.032	0.22	0.17	Cardiac Troponin-T levels;	chr6:28124825	chr6:28091154~28093664:+
HNSC	cis	rs597480	0.853	rs652615	ENSG00000279742.1	RP11-700A24.1	-3.67	0.000274	0.032	-0.18	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85774407	chr11:85852557~85854943:-
HNSC	cis	rs4899412	1	rs4899412	ENSG00000266869.1	RP6-114E22.1	3.67	0.000274	0.032	0.23	0.17	Heart rate variability traits (SDNN);	chr14:71997545	chr14:71848606~71908430:+
HNSC	cis	rs12545912	0.691	rs13250951	ENSG00000233609.3	RP11-62H7.2	-3.67	0.000274	0.032	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9683945	chr8:8961200~8979025:+
HNSC	cis	rs3096299	0.967	rs2911256	ENSG00000224888.4	RP5-1142A6.2	3.67	0.000274	0.032	0.16	0.17	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:88731180~88741425:+
HNSC	cis	rs4908760	0.792	rs10864361	ENSG00000232912.4	RP5-1115A15.1	-3.67	0.000274	0.032	-0.18	-0.17	Vitiligo;	chr1:8666662	chr1:8424645~8434838:+
HNSC	cis	rs2013441	1	rs1373147	ENSG00000261033.1	RP11-209D14.2	3.67	0.000274	0.032	0.19	0.17	Obesity-related traits;	chr17:20303332	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs11871945	ENSG00000261033.1	RP11-209D14.2	3.67	0.000274	0.032	0.19	0.17	Obesity-related traits;	chr17:20303570	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2120282	ENSG00000261033.1	RP11-209D14.2	3.67	0.000274	0.032	0.19	0.17	Obesity-related traits;	chr17:20306161	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2165897	ENSG00000261033.1	RP11-209D14.2	3.67	0.000274	0.032	0.19	0.17	Obesity-related traits;	chr17:20306408	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.965	rs8071665	ENSG00000261033.1	RP11-209D14.2	3.67	0.000274	0.032	0.19	0.17	Obesity-related traits;	chr17:20306630	chr17:20008051~20009234:-
HNSC	cis	rs58873874	0.649	rs75791619	ENSG00000251405.2	CTB-109A12.1	3.67	0.000274	0.032	0.32	0.17	Bipolar disorder (body mass index interaction);	chr5:157370204	chr5:157362615~157460078:-
HNSC	cis	rs9303280	0.587	rs35123741	ENSG00000266469.1	CTB-131K11.1	3.67	0.000274	0.032	0.14	0.17	Self-reported allergy;	chr17:39936677	chr17:39401793~39406233:+
HNSC	cis	rs8054556	0.787	rs12935701	ENSG00000250616.2	RP11-455F5.3	3.67	0.000274	0.0321	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30096430~30104116:+
HNSC	cis	rs2139634	0.965	rs2037391	ENSG00000227398.3	KIF9-AS1	-3.67	0.000274	0.0321	-0.17	-0.17	Cerebrospinal fluid biomarker levels;	chr3:46498033	chr3:47164497~47246601:+
HNSC	cis	rs9329221	0.537	rs6601414	ENSG00000255310.2	AF131215.2	3.67	0.000274	0.0321	0.16	0.17	Neuroticism;	chr8:10119238	chr8:11107788~11109726:-
HNSC	cis	rs853679	0.599	rs202906	ENSG00000219392.1	RP1-265C24.5	3.67	0.000274	0.0321	0.26	0.17	Depression;	chr6:28043874	chr6:28115628~28116551:+
HNSC	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-3.67	0.000274	0.0321	-0.16	-0.17	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
HNSC	cis	rs55702914	0.935	rs17405525	ENSG00000222017.1	AC011997.1	-3.67	0.000274	0.0321	-0.2	-0.17	Major depression and alcohol dependence;	chr2:197349459	chr2:197693106~197774823:+
HNSC	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-3.67	0.000274	0.0321	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
HNSC	cis	rs2337406	1	rs61268362	ENSG00000211972.2	IGHV3-66	3.67	0.000274	0.0321	0.17	0.17	Alzheimer's disease (late onset);	chr14:106697010	chr14:106675017~106675544:-
HNSC	cis	rs2337406	0.85	rs8014460	ENSG00000211972.2	IGHV3-66	3.67	0.000274	0.0321	0.17	0.17	Alzheimer's disease (late onset);	chr14:106697140	chr14:106675017~106675544:-
HNSC	cis	rs73201462	0.908	rs4593050	ENSG00000231305.3	RP11-723O4.2	3.67	0.000274	0.0321	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128285688	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6439124	ENSG00000231305.3	RP11-723O4.2	3.67	0.000274	0.0321	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128288623	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs7373998	ENSG00000231305.3	RP11-723O4.2	3.67	0.000274	0.0321	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128289380	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955101	ENSG00000231305.3	RP11-723O4.2	3.67	0.000274	0.0321	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128290769	chr3:128861313~128871540:-
HNSC	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	3.67	0.000274	0.0321	0.24	0.17	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	3.67	0.000274	0.0321	0.24	0.17	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
HNSC	cis	rs988913	0.706	rs4712087	ENSG00000224984.1	RP11-524H19.2	3.67	0.000274	0.0321	0.19	0.17	Menarche (age at onset);	chr6:55075305	chr6:54840118~54840855:-
HNSC	cis	rs7555523	0.887	rs12691499	ENSG00000224358.1	RP11-466F5.8	-3.67	0.000274	0.0321	-0.26	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718428	chr1:165768929~165775176:+
HNSC	cis	rs7555523	0.83	rs12691500	ENSG00000224358.1	RP11-466F5.8	-3.67	0.000274	0.0321	-0.26	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718524	chr1:165768929~165775176:+
HNSC	cis	rs1218582	0.741	rs10908447	ENSG00000270361.1	RP11-307C12.13	-3.67	0.000275	0.0321	-0.19	-0.17	Prostate cancer;	chr1:154897266	chr1:154937370~154938059:+
HNSC	cis	rs12986445	0.894	rs12713700	ENSG00000218682.1	AC010150.1	3.67	0.000275	0.0321	0.22	0.17	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25913127	chr2:25856461~25856966:-
HNSC	cis	rs35491132	1	rs35491132	ENSG00000226314.6	ZNF192P1	-3.67	0.000275	0.0321	-0.31	-0.17	Urinary tract infection frequency;	chr6:27559449	chr6:28161781~28169594:+
HNSC	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-3.67	0.000275	0.0321	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
HNSC	cis	rs2239557	0.961	rs8003212	ENSG00000258769.1	RAP1AP	3.67	0.000275	0.0321	0.18	0.17	Common traits (Other);	chr14:74158260	chr14:74482985~74483435:+
HNSC	cis	rs5758511	0.68	rs58654759	ENSG00000233903.2	Z83851.4	3.67	0.000275	0.0321	0.26	0.17	Birth weight;	chr22:42246570	chr22:42276355~42277052:+
HNSC	cis	rs73201462	0.901	rs56050323	ENSG00000231305.3	RP11-723O4.2	-3.67	0.000275	0.0321	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128455	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs35145572	ENSG00000231305.3	RP11-723O4.2	-3.67	0.000275	0.0321	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128575	chr3:128861313~128871540:-
HNSC	cis	rs793571	0.628	rs12437952	ENSG00000245975.2	RP11-30K9.6	3.67	0.000275	0.0321	0.3	0.17	Schizophrenia;	chr15:58757147	chr15:58768072~58770974:-
HNSC	cis	rs2944755	0.723	rs9694342	ENSG00000279766.1	RP11-642A1.2	-3.67	0.000275	0.0321	-0.19	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577305	chr8:140572142~140572812:-
HNSC	cis	rs2976388	1	rs2920280	ENSG00000253741.1	CTD-2292P10.4	3.67	0.000275	0.0321	0.16	0.17	Urinary tract infection frequency;	chr8:142679726	chr8:142702252~142726973:-
HNSC	cis	rs546131	0.642	rs1594425	ENSG00000271369.1	RP11-350D17.3	-3.67	0.000275	0.0321	-0.22	-0.17	Lung disease severity in cystic fibrosis;	chr11:34811775	chr11:34709600~34710161:+
HNSC	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	3.67	0.000275	0.0321	0.21	0.17	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
HNSC	cis	rs72827839	1	rs72827832	ENSG00000244649.3	CTD-2377D24.6	-3.67	0.000275	0.0321	-0.25	-0.17	Ease of getting up in the morning;	chr17:48329746	chr17:48646923~48707346:+
HNSC	cis	rs9813712	0.78	rs55929137	ENSG00000228252.7	COL6A4P2	3.67	0.000275	0.0321	0.18	0.17	Response to amphetamines;	chr3:130236002	chr3:130212823~130273806:+
HNSC	cis	rs9467711	0.606	rs9379851	ENSG00000241549.7	GUSBP2	3.67	0.000275	0.0321	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26354552	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9366655	ENSG00000241549.7	GUSBP2	3.67	0.000275	0.0321	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377157	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.79	rs1979	ENSG00000241549.7	GUSBP2	3.67	0.000275	0.0321	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377363	chr6:26871484~26956554:-
HNSC	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000275	0.0321	-0.21	-0.17	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
HNSC	cis	rs12047808	0.73	rs61373961	ENSG00000227141.2	RP11-545A16.3	-3.67	0.000275	0.0321	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179562767	chr1:179586705~179589175:+
HNSC	cis	rs1513670	1	rs1534402	ENSG00000260793.2	RP5-882C2.2	3.67	0.000275	0.0321	0.15	0.17	Bone mineral density (hip);	chr17:43732479	chr17:44221401~44223710:+
HNSC	cis	rs1563304	1	rs1563304	ENSG00000232300.1	FAM215B	3.67	0.000275	0.0321	0.26	0.17	Neuroticism;	chr17:46797087	chr17:46558830~46562795:-
HNSC	cis	rs4427176	0.507	rs4841212	ENSG00000233609.3	RP11-62H7.2	-3.67	0.000275	0.0321	-0.18	-0.17	Mosquito bite size;	chr8:9743857	chr8:8961200~8979025:+
HNSC	cis	rs875971	0.619	rs12533585	ENSG00000272831.1	RP11-792A8.4	3.67	0.000275	0.0321	0.14	0.17	Aortic root size;	chr7:66519618	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs12698534	ENSG00000272831.1	RP11-792A8.4	3.67	0.000275	0.0321	0.14	0.17	Aortic root size;	chr7:66521858	chr7:66739829~66740385:-
HNSC	cis	rs8049634	0.869	rs3759975	ENSG00000250685.6	RP11-486L19.2	3.67	0.000275	0.0321	0.16	0.17	Small cell lung carcinoma;	chr16:84187479	chr16:84192558~84197053:-
HNSC	cis	rs9650657	0.675	rs2409658	ENSG00000255310.2	AF131215.2	-3.67	0.000275	0.0322	-0.16	-0.17	Neuroticism;	chr8:10811455	chr8:11107788~11109726:-
HNSC	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-3.67	0.000275	0.0322	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
HNSC	cis	rs1990950	1	rs1990950	ENSG00000248544.2	CTB-47B11.3	-3.67	0.000275	0.0322	-0.18	-0.17	Lung function (FEV1/FVC);	chr5:157493748	chr5:157375741~157384950:-
HNSC	cis	rs9813712	0.953	rs9883455	ENSG00000228252.7	COL6A4P2	-3.67	0.000275	0.0322	-0.18	-0.17	Response to amphetamines;	chr3:130260088	chr3:130212823~130273806:+
HNSC	cis	rs6674970	0.748	rs56299877	ENSG00000228126.1	FALEC	3.67	0.000275	0.0322	0.25	0.17	Childhood ear infection;	chr1:151143169	chr1:150515757~150518032:+
HNSC	cis	rs2055729	0.736	rs11249965	ENSG00000254340.1	RP11-10A14.3	-3.67	0.000275	0.0322	-0.21	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9883353	chr8:9141424~9145435:+
HNSC	cis	rs2337406	0.852	rs12050239	ENSG00000280411.1	IGHV1-69-2	-3.67	0.000275	0.0322	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106781132	chr14:106762092~106762588:-
HNSC	cis	rs2153535	0.585	rs9393056	ENSG00000230939.1	RP11-314C16.1	-3.67	0.000276	0.0322	-0.19	-0.17	Motion sickness;	chr6:8667641	chr6:8784178~8785445:+
HNSC	cis	rs2439831	0.867	rs3213990	ENSG00000275601.1	AC011330.13	-3.67	0.000276	0.0322	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43378028	chr15:43642389~43643023:-
HNSC	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	3.67	0.000276	0.0322	0.19	0.17	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
HNSC	cis	rs2905347	0.56	rs2961291	ENSG00000179428.2	AC073072.5	3.67	0.000276	0.0322	0.2	0.17	Major depression and alcohol dependence;	chr7:22641885	chr7:22725395~22727620:-
HNSC	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	3.67	0.000276	0.0322	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
HNSC	cis	rs67311347	0.956	rs12633446	ENSG00000280739.1	EIF1B-AS1	-3.67	0.000276	0.0322	-0.18	-0.17	Renal cell carcinoma;	chr3:40464170	chr3:40173145~40309698:-
HNSC	cis	rs919433	0.617	rs700645	ENSG00000231621.1	AC013264.2	-3.67	0.000276	0.0322	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197740790	chr2:197197991~197199273:+
HNSC	cis	rs12544026	0.617	rs7828516	ENSG00000253633.1	KB-1980E6.3	3.67	0.000276	0.0322	0.2	0.17	Major depression and alcohol dependence;	chr8:101829488	chr8:102528740~102538668:+
HNSC	cis	rs35306767	0.903	rs12249828	ENSG00000229869.1	RP11-363N22.2	-3.66	0.000276	0.0322	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:848898	chr10:933026~942743:+
HNSC	cis	rs2239557	0.961	rs10133356	ENSG00000258769.1	RAP1AP	3.66	0.000276	0.0322	0.18	0.17	Common traits (Other);	chr14:74181056	chr14:74482985~74483435:+
HNSC	cis	rs2239557	1	rs10144220	ENSG00000258769.1	RAP1AP	3.66	0.000276	0.0322	0.18	0.17	Common traits (Other);	chr14:74181201	chr14:74482985~74483435:+
HNSC	cis	rs2239557	0.961	rs10135858	ENSG00000258769.1	RAP1AP	3.66	0.000276	0.0322	0.18	0.17	Common traits (Other);	chr14:74181259	chr14:74482985~74483435:+
HNSC	cis	rs6545883	0.895	rs2177961	ENSG00000271889.1	RP11-493E12.1	-3.66	0.000276	0.0322	-0.19	-0.17	Tuberculosis;	chr2:61333129	chr2:61151433~61162105:-
HNSC	cis	rs4427176	0.507	rs11785987	ENSG00000254340.1	RP11-10A14.3	-3.66	0.000276	0.0322	-0.23	-0.17	Mosquito bite size;	chr8:9730384	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.908	rs7016839	ENSG00000254340.1	RP11-10A14.3	-3.66	0.000276	0.0322	-0.23	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9730439	chr8:9141424~9145435:+
HNSC	cis	rs11157436	0.56	rs2242543	ENSG00000211814.1	TRAV35	-3.66	0.000276	0.0322	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22221896~22222475:+
HNSC	cis	rs853679	0.607	rs13207345	ENSG00000226314.6	ZNF192P1	-3.66	0.000276	0.0322	-0.32	-0.17	Depression;	chr6:28297795	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs72854513	ENSG00000226314.6	ZNF192P1	-3.66	0.000276	0.0322	-0.32	-0.17	Depression;	chr6:28298177	chr6:28161781~28169594:+
HNSC	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-3.66	0.000276	0.0322	-0.2	-0.17	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
HNSC	cis	rs9911578	0.967	rs8182277	ENSG00000224738.1	AC099850.1	3.66	0.000276	0.0322	0.17	0.17	Intelligence (multi-trait analysis);	chr17:59067006	chr17:59106598~59118267:+
HNSC	cis	rs8014252	0.803	rs7158201	ENSG00000269927.1	RP6-91H8.3	3.66	0.000276	0.0322	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543829	chr14:71141125~71143253:-
HNSC	cis	rs753307	0.676	rs753308	ENSG00000268655.1	CTB-60B18.10	-3.66	0.000276	0.0322	-0.19	-0.17	Blood protein levels;	chr19:49015318	chr19:49018247~49019484:-
HNSC	cis	rs16858210	0.874	rs6792309	ENSG00000234371.6	RPSAP31	3.66	0.000276	0.0322	0.2	0.17	Menopause (age at onset);	chr3:183889873	chr3:183884924~183888449:+
HNSC	cis	rs1008375	0.966	rs6449330	ENSG00000249502.1	AC006160.5	3.66	0.000276	0.0322	0.17	0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17702326	chr4:17587467~17614571:-
HNSC	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	3.66	0.000276	0.0322	0.21	0.17	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
HNSC	cis	rs1028883	0.805	rs7989486	ENSG00000228295.1	LINC00392	3.66	0.000276	0.0322	0.18	0.17	Lean body mass;	chr13:73568339	chr13:73564244~73588070:+
HNSC	cis	rs73198271	0.74	rs3827807	ENSG00000233609.3	RP11-62H7.2	-3.66	0.000276	0.0322	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8961200~8979025:+
HNSC	cis	rs17122278	0.929	rs113739713	ENSG00000255422.1	AP002954.4	3.66	0.000276	0.0322	0.3	0.17	Total cholesterol levels;	chr11:118549386	chr11:118704607~118750263:+
HNSC	cis	rs2013441	1	rs2703799	ENSG00000261033.1	RP11-209D14.2	3.66	0.000276	0.0322	0.19	0.17	Obesity-related traits;	chr17:20182455	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526460	ENSG00000261033.1	RP11-209D14.2	3.66	0.000276	0.0322	0.19	0.17	Obesity-related traits;	chr17:20183039	chr17:20008051~20009234:-
HNSC	cis	rs17076726	0.519	rs17076676	ENSG00000249031.1	SUMO2P6	-3.66	0.000276	0.0322	-0.21	-0.17	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173899577	chr5:174561776~174562063:+
HNSC	cis	rs9313772	0.928	rs7701003	ENSG00000254350.1	RP11-542A14.1	-3.66	0.000276	0.0322	-0.19	-0.17	Blood pressure;	chr5:158397473	chr5:158424585~158452758:+
HNSC	cis	rs7735319	0.704	rs1428216	ENSG00000250697.1	CTD-2066L21.3	3.66	0.000276	0.0322	0.2	0.17	Systolic blood pressure;	chr5:33056239	chr5:32925639~33297910:-
HNSC	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000276	0.0323	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
HNSC	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000276	0.0323	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
HNSC	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000276	0.0323	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
HNSC	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000276	0.0323	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
HNSC	cis	rs2919009	0.664	rs61872418	ENSG00000271670.1	RP11-95I16.4	3.66	0.000276	0.0323	0.2	0.17	Obesity-related traits;	chr10:120785859	chr10:120879256~120880667:-
HNSC	cis	rs988913	0.629	rs34685175	ENSG00000224984.1	RP11-524H19.2	3.66	0.000276	0.0323	0.19	0.17	Menarche (age at onset);	chr6:55001939	chr6:54840118~54840855:-
HNSC	cis	rs2463822	0.669	rs72919493	ENSG00000250659.2	RP11-864I4.3	3.66	0.000276	0.0323	0.36	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62282179	chr11:62537312~62542018:+
HNSC	cis	rs6088580	0.634	rs3746455	ENSG00000276073.1	RP5-1125A11.7	3.66	0.000276	0.0323	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:33985617~33988989:-
HNSC	cis	rs8062405	1	rs11861174	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs4788102	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs62037367	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs7198606	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.929	rs11864750	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.964	rs7193733	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs8055982	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28413703~28415018:+
HNSC	cis	rs8062405	1	rs7498665	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28413703~28415018:+
HNSC	cis	rs8062405	0.964	rs11864107	ENSG00000261089.1	RP11-435I10.3	3.66	0.000276	0.0323	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28413703~28415018:+
HNSC	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-3.66	0.000277	0.0323	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
HNSC	cis	rs61160187	0.582	rs2049579	ENSG00000272308.1	RP11-231G3.1	-3.66	0.000277	0.0323	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60866457~60866935:-
HNSC	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-3.66	0.000277	0.0323	-0.17	-0.17	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
HNSC	cis	rs9611565	0.694	rs5758389	ENSG00000233903.2	Z83851.4	-3.66	0.000277	0.0323	-0.23	-0.17	Vitiligo;	chr22:41545745	chr22:42276355~42277052:+
HNSC	cis	rs739496	0.843	rs10774631	ENSG00000226469.1	ADAM1B	-3.66	0.000277	0.0323	-0.18	-0.17	Platelet count;	chr12:111585197	chr12:111927018~111929017:+
HNSC	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	3.66	0.000277	0.0323	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
HNSC	cis	rs6921919	0.583	rs7759191	ENSG00000227214.2	HCG15	3.66	0.000277	0.0323	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28986203~28987484:+
HNSC	cis	rs4377367	0.653	rs35423307	ENSG00000273073.1	RP11-109E12.1	-3.66	0.000277	0.0323	-0.32	-0.17	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr2:130927968	chr2:131461821~131463615:-
HNSC	cis	rs4377367	0.653	rs34278111	ENSG00000273073.1	RP11-109E12.1	-3.66	0.000277	0.0323	-0.32	-0.17	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr2:130928132	chr2:131461821~131463615:-
HNSC	cis	rs886774	0.932	rs2007417	ENSG00000273055.1	CTB-13F3.1	-3.66	0.000277	0.0323	-0.17	-0.17	Ulcerative colitis;	chr7:107859802	chr7:107942116~107942740:+
HNSC	cis	rs10540	1	rs12794284	ENSG00000279672.1	CMB9-55F22.1	3.66	0.000277	0.0323	0.28	0.17	Body mass index;	chr11:477623	chr11:779617~780755:+
HNSC	cis	rs1552244	1	rs61077902	ENSG00000180385.7	EMC3-AS1	3.66	0.000277	0.0323	0.19	0.17	Alzheimer's disease;	chr3:10084469	chr3:9986893~10006990:+
HNSC	cis	rs6921919	0.848	rs9468350	ENSG00000227214.2	HCG15	3.66	0.000277	0.0323	0.21	0.17	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28986203~28987484:+
HNSC	cis	rs7937890	0.904	rs67623158	ENSG00000251991.1	RNU7-49P	-3.66	0.000277	0.0323	-0.18	-0.17	Mitochondrial DNA levels;	chr11:14273650	chr11:14478892~14478953:+
HNSC	cis	rs2905347	0.895	rs2961280	ENSG00000179428.2	AC073072.5	3.66	0.000277	0.0323	0.2	0.17	Major depression and alcohol dependence;	chr7:22600098	chr7:22725395~22727620:-
HNSC	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-3.66	0.000277	0.0323	-0.19	-0.17	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
HNSC	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	3.66	0.000277	0.0323	0.24	0.17	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
HNSC	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000277	0.0323	-0.24	-0.17	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000277	0.0323	-0.24	-0.17	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000277	0.0323	-0.24	-0.17	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
HNSC	cis	rs4803480	0.572	rs17710743	ENSG00000270164.1	LINC01480	3.66	0.000277	0.0323	0.22	0.17	Schizophrenia;	chr19:41569079	chr19:41535183~41536904:+
HNSC	cis	rs897984	0.609	rs72800847	ENSG00000275263.1	RP11-1072A3.4	-3.66	0.000277	0.0323	-0.19	-0.17	Dementia with Lewy bodies;	chr16:31011318	chr16:30956872~30957199:-
HNSC	cis	rs9368481	0.743	rs9368480	ENSG00000238621.1	TRI-TAT2-2	-3.66	0.000277	0.0323	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:27020335~27020447:+
HNSC	cis	rs4924935	1	rs35341640	ENSG00000264885.1	RP11-815I9.4	3.66	0.000277	0.0323	0.19	0.17	Pancreatic cancer;	chr17:18914915	chr17:18667629~18669461:-
HNSC	cis	rs9467711	0.606	rs9379875	ENSG00000241549.7	GUSBP2	3.66	0.000277	0.0323	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26444504	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.538	rs35942482	ENSG00000241549.7	GUSBP2	3.66	0.000277	0.0323	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26444710	chr6:26871484~26956554:-
HNSC	cis	rs78545713	0.649	rs79662647	ENSG00000241549.7	GUSBP2	-3.66	0.000277	0.0323	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26217617	chr6:26871484~26956554:-
HNSC	cis	rs78545713	0.649	rs114015443	ENSG00000241549.7	GUSBP2	-3.66	0.000277	0.0323	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26221751	chr6:26871484~26956554:-
HNSC	cis	rs78545713	0.649	rs77727979	ENSG00000241549.7	GUSBP2	-3.66	0.000277	0.0323	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26221798	chr6:26871484~26956554:-
HNSC	cis	rs78545713	0.541	rs111465843	ENSG00000241549.7	GUSBP2	-3.66	0.000277	0.0323	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26222595	chr6:26871484~26956554:-
HNSC	cis	rs78545713	0.649	rs113407109	ENSG00000241549.7	GUSBP2	-3.66	0.000277	0.0323	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26224175	chr6:26871484~26956554:-
HNSC	cis	rs35146811	0.657	rs36019559	ENSG00000235077.1	AC073842.19	-3.66	0.000277	0.0324	-0.2	-0.17	Coronary artery disease;	chr7:100216963	chr7:100130964~100140439:+
HNSC	cis	rs1665050	0.534	rs4600408	ENSG00000259732.1	RP11-59H7.3	-3.66	0.000277	0.0324	-0.22	-0.17	Atopic dermatitis;	chr15:58954601	chr15:59121034~59133250:+
HNSC	cis	rs758324	0.732	rs45511	ENSG00000279691.1	RP11-485M7.2	3.66	0.000277	0.0324	0.19	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132103468	chr5:133052769~133052971:+
HNSC	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	3.66	0.000277	0.0324	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
HNSC	cis	rs12911832	0.727	rs682619	ENSG00000259657.1	PIGHP1	3.66	0.000277	0.0324	0.17	0.17	Schizophrenia;	chr15:58806574	chr15:59676757~59677321:+
HNSC	cis	rs79040073	0.637	rs112792737	ENSG00000259531.2	RP11-295H24.3	3.66	0.000278	0.0324	0.21	0.17	Lung cancer in ever smokers;	chr15:49198849	chr15:49365124~49366685:-
HNSC	cis	rs9813712	1	rs57804141	ENSG00000228252.7	COL6A4P2	3.66	0.000278	0.0324	0.18	0.17	Response to amphetamines;	chr3:130243669	chr3:130212823~130273806:+
HNSC	cis	rs35740288	0.822	rs4843090	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000278	0.0324	-0.23	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85744109~85750281:-
HNSC	cis	rs3850699	0.886	rs12773600	ENSG00000236937.2	PTGES3P4	3.66	0.000278	0.0324	0.24	0.17	Prostate cancer;	chr10:102658471	chr10:102845595~102845950:+
HNSC	cis	rs2243480	0.522	rs431168	ENSG00000230295.1	RP11-458F8.2	-3.66	0.000278	0.0324	-0.28	-0.17	Diabetic kidney disease;	chr7:66046617	chr7:66880708~66882981:+
HNSC	cis	rs7178375	0.843	rs3794596	ENSG00000215302.7	CTD-3092A11.1	-3.66	0.000278	0.0324	-0.26	-0.17	Hypertriglyceridemia;	chr15:30930823	chr15:30470779~30507623:+
HNSC	cis	rs9940149	1	rs9940149	ENSG00000231439.4	WASIR2	-3.66	0.000278	0.0324	-0.18	-0.17	Type 2 diabetes;	chr16:250642	chr16:22910~25123:+
HNSC	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	3.66	0.000278	0.0324	0.2	0.17	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	3.66	0.000278	0.0324	0.2	0.17	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
HNSC	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	3.66	0.000278	0.0324	0.21	0.17	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
HNSC	cis	rs9863	0.828	rs952632	ENSG00000270028.1	RP11-380L11.4	3.66	0.000278	0.0324	0.2	0.17	White blood cell count;	chr12:123985191	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.694	rs11837287	ENSG00000270028.1	RP11-380L11.4	3.66	0.000278	0.0324	0.2	0.17	White blood cell count;	chr12:123985512	chr12:123925461~123926083:-
HNSC	cis	rs970821	0.966	rs4549748	ENSG00000253106.1	RP11-158K1.3	3.66	0.000278	0.0324	0.15	0.17	Breast cancer;	chr8:123731092	chr8:124488510~124491643:+
HNSC	cis	rs6964587	0.869	rs10276682	ENSG00000188693.7	CYP51A1-AS1	3.66	0.000278	0.0324	0.18	0.17	Breast cancer;	chr7:91856756	chr7:92134604~92180725:+
HNSC	cis	rs6964587	0.869	rs4729010	ENSG00000188693.7	CYP51A1-AS1	3.66	0.000278	0.0324	0.18	0.17	Breast cancer;	chr7:91857437	chr7:92134604~92180725:+
HNSC	cis	rs11098499	0.629	rs28369518	ENSG00000250412.1	KLHL2P1	3.66	0.000278	0.0324	0.21	0.17	Corneal astigmatism;	chr4:119350475	chr4:119334329~119378233:+
HNSC	cis	rs871012	0.502	rs56259240	ENSG00000251405.2	CTB-109A12.1	-3.66	0.000278	0.0324	-0.19	-0.17	IgG glycosylation;	chr5:157464523	chr5:157362615~157460078:-
HNSC	cis	rs4908768	0.52	rs6681362	ENSG00000232912.4	RP5-1115A15.1	3.66	0.000278	0.0324	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8424645~8434838:+
HNSC	cis	rs10742752	0.676	rs1873056	ENSG00000254651.1	RP11-430H10.3	3.66	0.000278	0.0324	0.2	0.17	Body mass index;	chr11:45426970	chr11:45399448~45400528:+
HNSC	cis	rs9611565	0.559	rs5758428	ENSG00000235513.1	RP4-756G23.5	-3.66	0.000278	0.0324	-0.21	-0.17	Vitiligo;	chr22:41710212	chr22:41209122~41217627:-
HNSC	cis	rs875971	0.564	rs313804	ENSG00000232559.3	GS1-124K5.12	3.66	0.000278	0.0324	0.19	0.17	Aortic root size;	chr7:66049635	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	3.66	0.000278	0.0324	0.19	0.17	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	3.66	0.000278	0.0324	0.19	0.17	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
HNSC	cis	rs9647570	0.557	rs12515610	ENSG00000253357.1	CTB-78F1.2	3.66	0.000278	0.0324	0.22	0.17	Menarche (age at onset);	chr5:167842152	chr5:167721363~167729124:+
HNSC	cis	rs614226	1	rs614226	ENSG00000202538.1	RNU4-2	3.66	0.000278	0.0324	0.28	0.17	Type 1 diabetes nephropathy;	chr12:120536707	chr12:120291763~120291903:-
HNSC	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	3.66	0.000278	0.0324	0.24	0.17	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
HNSC	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	3.66	0.000278	0.0324	0.17	0.17	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
HNSC	cis	rs853679	0.713	rs200991	ENSG00000219891.2	ZSCAN12P1	-3.66	0.000278	0.0324	-0.26	-0.17	Depression;	chr6:27847716	chr6:28091154~28093664:+
HNSC	cis	rs45509595	0.841	rs2747054	ENSG00000219392.1	RP1-265C24.5	-3.66	0.000278	0.0324	-0.29	-0.17	Breast cancer;	chr6:27815581	chr6:28115628~28116551:+
HNSC	cis	rs2439831	0.867	rs2251844	ENSG00000275601.1	AC011330.13	-3.66	0.000278	0.0324	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43544280	chr15:43642389~43643023:-
HNSC	cis	rs10849893	0.576	rs10774592	ENSG00000258435.1	RP11-711D18.2	-3.66	0.000278	0.0324	-0.17	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121387644	chr12:121391962~121399859:+
HNSC	cis	rs2347867	0.614	rs1514347	ENSG00000218996.1	RP1-99E18.2	3.66	0.000278	0.0324	0.23	0.17	Age at first birth;	chr6:151908310	chr6:150934968~150935566:+
HNSC	cis	rs1865760	0.713	rs6928951	ENSG00000272810.1	U91328.22	-3.66	0.000278	0.0324	-0.15	-0.17	Height;	chr6:25995326	chr6:26013241~26013757:+
HNSC	cis	rs6787172	0.622	rs6774676	ENSG00000272087.1	RP11-379F4.7	3.66	0.000278	0.0324	0.17	0.17	Subjective well-being;	chr3:158375252	chr3:158693120~158693768:-
HNSC	cis	rs8180991	0.744	rs7015677	ENSG00000254431.1	RP11-550A5.2	-3.66	0.000278	0.0324	-0.25	-0.17	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125466516	chr8:125348196~125351416:-
HNSC	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	3.66	0.000278	0.0324	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
HNSC	cis	rs853679	0.505	rs200992	ENSG00000219392.1	RP1-265C24.5	-3.66	0.000278	0.0324	-0.29	-0.17	Depression;	chr6:27846899	chr6:28115628~28116551:+
HNSC	cis	rs16935110	1	rs16935110	ENSG00000254337.1	RP11-865I6.2	-3.66	0.000278	0.0324	-0.25	-0.17	Obesity-related traits;	chr8:68818484	chr8:68848742~68852763:-
HNSC	cis	rs2562456	0.833	rs2650776	ENSG00000268119.4	CTD-2561J22.5	3.66	0.000278	0.0324	0.25	0.17	Pain;	chr19:21430595	chr19:21444241~21463908:-
HNSC	cis	rs13434995	0.589	rs62306207	ENSG00000249700.7	SRD5A3-AS1	-3.66	0.000278	0.0324	-0.22	-0.17	Adiponectin levels;	chr4:55384548	chr4:55363971~55395847:-
HNSC	cis	rs10090774	0.786	rs11780023	ENSG00000279766.1	RP11-642A1.2	-3.66	0.000278	0.0324	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140982679	chr8:140572142~140572812:-
HNSC	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-3.66	0.000278	0.0324	-0.16	-0.17	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
HNSC	cis	rs17772222	0.511	rs1013794	ENSG00000258789.1	RP11-507K2.3	-3.66	0.000278	0.0325	-0.18	-0.17	Coronary artery calcification;	chr14:88847401	chr14:88551597~88552493:+
HNSC	cis	rs17122278	1	rs7108845	ENSG00000255422.1	AP002954.4	3.66	0.000278	0.0325	0.3	0.17	Total cholesterol levels;	chr11:118536808	chr11:118704607~118750263:+
HNSC	cis	rs2919009	0.509	rs17100858	ENSG00000271670.1	RP11-95I16.4	3.66	0.000279	0.0325	0.2	0.17	Obesity-related traits;	chr10:120783858	chr10:120879256~120880667:-
HNSC	cis	rs4256159	0.696	rs11711604	ENSG00000228956.7	SATB1-AS1	3.66	0.000279	0.0325	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718624	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs11711641	ENSG00000228956.7	SATB1-AS1	3.66	0.000279	0.0325	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718752	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs11719571	ENSG00000228956.7	SATB1-AS1	3.66	0.000279	0.0325	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718942	chr3:18445024~18920401:+
HNSC	cis	rs6657613	0.68	rs7545499	ENSG00000186715.9	MST1L	3.66	0.000279	0.0325	0.14	0.17	Hip circumference adjusted for BMI;	chr1:17048193	chr1:16754910~16770237:-
HNSC	cis	rs886126	0.901	rs4766557	ENSG00000257595.2	RP3-473L9.4	3.66	0.000279	0.0325	0.22	0.17	Coronary heart disease;	chr12:111226240	chr12:111369282~111403310:+
HNSC	cis	rs546131	0.515	rs6484737	ENSG00000271369.1	RP11-350D17.3	-3.66	0.000279	0.0325	-0.22	-0.17	Lung disease severity in cystic fibrosis;	chr11:34836032	chr11:34709600~34710161:+
HNSC	cis	rs1580019	0.844	rs1037322	ENSG00000226468.2	AC018641.7	-3.66	0.000279	0.0325	-0.23	-0.17	Cognitive ability;	chr7:32462245	chr7:32456963~32457758:-
HNSC	cis	rs2436845	1	rs892484	ENSG00000253669.3	KB-1732A1.1	3.66	0.000279	0.0325	0.15	0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862333	chr8:102805517~102809971:+
HNSC	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-3.66	0.000279	0.0325	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-3.66	0.000279	0.0325	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-3.66	0.000279	0.0325	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
HNSC	cis	rs6088580	0.608	rs8114616	ENSG00000276073.1	RP5-1125A11.7	3.66	0.000279	0.0325	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:33985617~33988989:-
HNSC	cis	rs11782517	0.881	rs7845806	ENSG00000269918.1	AF131215.9	3.66	0.000279	0.0325	0.19	0.17	Nose size;	chr8:10252678	chr8:11104691~11106704:-
HNSC	cis	rs2919009	0.607	rs59153085	ENSG00000271670.1	RP11-95I16.4	3.66	0.000279	0.0325	0.21	0.17	Obesity-related traits;	chr10:120931782	chr10:120879256~120880667:-
HNSC	cis	rs6545883	0.965	rs3771258	ENSG00000271889.1	RP11-493E12.1	3.66	0.000279	0.0325	0.19	0.17	Tuberculosis;	chr2:61537005	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.965	rs1992765	ENSG00000271889.1	RP11-493E12.1	3.66	0.000279	0.0325	0.19	0.17	Tuberculosis;	chr2:61524198	chr2:61151433~61162105:-
HNSC	cis	rs17666538	0.792	rs1703912	ENSG00000254207.1	RP11-43A14.1	3.66	0.000279	0.0325	0.37	0.17	IgG glycosylation;	chr8:650643	chr8:725188~725877:-
HNSC	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	3.66	0.000279	0.0325	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
HNSC	cis	rs62229266	0.626	rs7280896	ENSG00000230212.5	AP000688.14	-3.66	0.000279	0.0325	-0.18	-0.17	Mitral valve prolapse;	chr21:36088608	chr21:36069642~36126640:-
HNSC	cis	rs73201462	1	rs2955091	ENSG00000231305.3	RP11-723O4.2	3.66	0.000279	0.0325	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252518	chr3:128861313~128871540:-
HNSC	cis	rs9652601	0.748	rs4322688	ENSG00000274038.1	RP11-66H6.4	-3.66	0.000279	0.0325	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11145134	chr16:11056556~11057034:+
HNSC	cis	rs11098499	0.738	rs72918577	ENSG00000250412.1	KLHL2P1	3.66	0.000279	0.0325	0.21	0.17	Corneal astigmatism;	chr4:119405546	chr4:119334329~119378233:+
HNSC	cis	rs950027	0.62	rs1145084	ENSG00000259479.5	SORD2P	3.66	0.000279	0.0325	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:44826371~44884694:-
HNSC	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	3.66	0.000279	0.0325	0.25	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
HNSC	cis	rs5758511	0.68	rs5758699	ENSG00000226450.2	CYP2D8P	3.66	0.000279	0.0325	0.16	0.17	Birth weight;	chr22:42292028	chr22:42149886~42155001:-
HNSC	cis	rs2948294	0.524	rs13270062	ENSG00000254153.1	CTA-398F10.2	3.66	0.000279	0.0325	0.19	0.17	Red cell distribution width;	chr8:8255128	chr8:8456909~8461337:-
HNSC	cis	rs6951245	0.572	rs73265911	ENSG00000224079.1	AC091729.7	-3.66	0.000279	0.0325	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1015727	chr7:1074450~1078036:+
HNSC	cis	rs116095464	0.51	rs60844864	ENSG00000277812.1	AC021087.1	3.66	0.000279	0.0325	0.28	0.17	Breast cancer;	chr5:266885	chr5:262769~262881:+
HNSC	cis	rs2548724	0.673	rs709370	ENSG00000250682.4	LINC00491	-3.66	0.000279	0.0325	-0.22	-0.17	Type 2 diabetes;	chr5:102288689	chr5:102609156~102671559:-
HNSC	cis	rs913655	0.819	rs2495825	ENSG00000225527.1	RP11-383B4.4	-3.66	0.000279	0.0325	-0.22	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18797219	chr10:18531849~18533336:-
HNSC	cis	rs7085104	0.632	rs4290163	ENSG00000213061.2	PFN1P11	3.66	0.000279	0.0325	0.21	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102838011~102845473:-
HNSC	cis	rs6001482	0.686	rs9623125	ENSG00000253818.1	IGLV1-41	-3.66	0.000279	0.0325	-0.14	-0.17	Diastolic blood pressure;	chr22:22234600	chr22:22404207~22404721:+
HNSC	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000279	0.0325	-0.23	-0.17	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
HNSC	cis	rs7674212	0.531	rs4698876	ENSG00000248740.4	RP11-328K4.1	3.66	0.000279	0.0325	0.17	0.17	Type 2 diabetes;	chr4:103012410	chr4:103256159~103453658:+
HNSC	cis	rs7674212	0.531	rs7665026	ENSG00000248740.4	RP11-328K4.1	3.66	0.000279	0.0325	0.17	0.17	Type 2 diabetes;	chr4:103015491	chr4:103256159~103453658:+
HNSC	cis	rs10073892	0.743	rs10076313	ENSG00000250682.4	LINC00491	-3.66	0.000279	0.0326	-0.23	-0.17	Cognitive decline (age-related);	chr5:102321649	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10076451	ENSG00000250682.4	LINC00491	-3.66	0.000279	0.0326	-0.23	-0.17	Cognitive decline (age-related);	chr5:102321818	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs10067263	ENSG00000250682.4	LINC00491	-3.66	0.000279	0.0326	-0.23	-0.17	Cognitive decline (age-related);	chr5:102321831	chr5:102609156~102671559:-
HNSC	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	3.66	0.00028	0.0326	0.17	0.17	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
HNSC	cis	rs6490294	0.571	rs58886972	ENSG00000226469.1	ADAM1B	3.66	0.00028	0.0326	0.26	0.17	Mean platelet volume;	chr12:112071477	chr12:111927018~111929017:+
HNSC	cis	rs7698623	0.85	rs13120034	ENSG00000248180.1	GAPDHP60	3.66	0.00028	0.0326	0.37	0.17	Cardiovascular disease risk factors;	chr4:87880750	chr4:87207092~87208086:+
HNSC	cis	rs7698623	0.85	rs13147372	ENSG00000248180.1	GAPDHP60	3.66	0.00028	0.0326	0.37	0.17	Cardiovascular disease risk factors;	chr4:87880754	chr4:87207092~87208086:+
HNSC	cis	rs7698623	0.717	rs2869724	ENSG00000248180.1	GAPDHP60	3.66	0.00028	0.0326	0.37	0.17	Cardiovascular disease risk factors;	chr4:87881647	chr4:87207092~87208086:+
HNSC	cis	rs7698623	0.717	rs1540584	ENSG00000248180.1	GAPDHP60	3.66	0.00028	0.0326	0.37	0.17	Cardiovascular disease risk factors;	chr4:87882761	chr4:87207092~87208086:+
HNSC	cis	rs7698623	0.85	rs1540585	ENSG00000248180.1	GAPDHP60	3.66	0.00028	0.0326	0.37	0.17	Cardiovascular disease risk factors;	chr4:87882832	chr4:87207092~87208086:+
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000270326.1	RP5-874C20.6	-3.66	0.00028	0.0326	-0.23	-0.17	Depression;	chr6:28237724	chr6:28319660~28319852:-
HNSC	cis	rs12545109	0.765	rs2576589	ENSG00000246430.5	LINC00968	-3.66	0.00028	0.0326	-0.23	-0.17	Obesity-related traits;	chr8:56513088	chr8:56496246~56559823:-
HNSC	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	3.66	0.00028	0.0326	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
HNSC	cis	rs7572733	0.773	rs13396312	ENSG00000222017.1	AC011997.1	-3.66	0.00028	0.0326	-0.2	-0.17	Dermatomyositis;	chr2:197628979	chr2:197693106~197774823:+
HNSC	cis	rs74024059	0.661	rs1503955	ENSG00000260269.4	CTD-2323K18.1	-3.66	0.00028	0.0326	-0.39	-0.17	Red blood cell count;Hematocrit;	chr15:75950277	chr15:75527150~75601205:-
HNSC	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	3.66	0.00028	0.0326	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	3.66	0.00028	0.0326	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
HNSC	cis	rs28830936	1	rs12440747	ENSG00000250379.1	RP11-23P13.4	3.66	0.00028	0.0326	0.2	0.17	Diastolic blood pressure;	chr15:41744492	chr15:41825099~41827936:-
HNSC	cis	rs7615952	0.688	rs17334074	ENSG00000241278.1	ENPP7P4	3.66	0.00028	0.0326	0.24	0.17	Blood pressure (smoking interaction);	chr3:125821617	chr3:125848223~125909372:+
HNSC	cis	rs11168618	0.715	rs35367885	ENSG00000240399.1	RP1-228P16.1	3.66	0.00028	0.0326	0.14	0.17	Adiponectin levels;	chr12:48525877	chr12:48054813~48055591:-
HNSC	cis	rs6968419	0.755	rs4730720	ENSG00000237870.5	AC073130.1	-3.66	0.00028	0.0326	-0.2	-0.17	Intraocular pressure;	chr7:116255181	chr7:116275606~116286734:-
HNSC	cis	rs5771040	0.56	rs4824152	ENSG00000273253.2	RP3-402G11.26	-3.66	0.00028	0.0326	-0.22	-0.17	IgG glycosylation;	chr22:50473447	chr22:50199090~50200837:-
HNSC	cis	rs4256159	1	rs4349516	ENSG00000228956.7	SATB1-AS1	3.66	0.00028	0.0326	0.27	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18725326	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs76233447	ENSG00000228956.7	SATB1-AS1	3.66	0.00028	0.0326	0.27	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18726087	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs79196759	ENSG00000228956.7	SATB1-AS1	3.66	0.00028	0.0326	0.27	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18726088	chr3:18445024~18920401:+
HNSC	cis	rs4256159	1	rs35885806	ENSG00000228956.7	SATB1-AS1	3.66	0.00028	0.0326	0.27	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18728915	chr3:18445024~18920401:+
HNSC	cis	rs6490294	0.528	rs12422941	ENSG00000226469.1	ADAM1B	-3.66	0.00028	0.0326	-0.26	-0.17	Mean platelet volume;	chr12:112099934	chr12:111927018~111929017:+
HNSC	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	3.66	0.00028	0.0326	0.17	0.17	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
HNSC	cis	rs41271951	0.518	rs11588221	ENSG00000261716.1	RP11-196G18.22	3.66	0.00028	0.0326	0.22	0.17	Blood protein levels;	chr1:150415394	chr1:149844498~149849024:-
HNSC	cis	rs10875746	0.517	rs12721420	ENSG00000257763.1	OR5BK1P	-3.66	0.00028	0.0326	-0.23	-0.17	Longevity (90 years and older);	chr12:47965011	chr12:48355792~48356614:-
HNSC	cis	rs7572733	0.555	rs6434953	ENSG00000222017.1	AC011997.1	3.66	0.00028	0.0326	0.22	0.17	Dermatomyositis;	chr2:198064969	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.555	rs6745726	ENSG00000222017.1	AC011997.1	3.66	0.00028	0.0326	0.22	0.17	Dermatomyositis;	chr2:198069356	chr2:197693106~197774823:+
HNSC	cis	rs8028182	0.501	rs7166281	ENSG00000275645.1	RP11-817O13.9	-3.66	0.00028	0.0326	-0.17	-0.17	Sudden cardiac arrest;	chr15:75635851	chr15:75346744~75347161:-
HNSC	cis	rs7772486	0.623	rs735535	ENSG00000270638.1	RP3-466P17.1	-3.66	0.00028	0.0326	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.566	rs735536	ENSG00000270638.1	RP3-466P17.1	-3.66	0.00028	0.0326	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145735570~145737218:+
HNSC	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	3.66	0.00028	0.0326	0.24	0.17	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
HNSC	cis	rs804280	0.662	rs11784764	ENSG00000255354.1	RP11-148O21.2	3.66	0.00028	0.0326	0.16	0.17	Myopia (pathological);	chr8:11753365	chr8:11558466~11560020:-
HNSC	cis	rs78545713	0.649	rs77362785	ENSG00000241549.7	GUSBP2	-3.66	0.00028	0.0326	-0.28	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26232123	chr6:26871484~26956554:-
HNSC	cis	rs2836974	0.965	rs6517538	ENSG00000255568.3	BRWD1-AS2	3.66	0.00028	0.0326	0.15	0.17	Cognitive function;	chr21:39284316	chr21:39313935~39314962:+
HNSC	cis	rs2247572	0.778	rs2253662	ENSG00000250295.5	RP11-434I12.2	3.66	0.00028	0.0326	0.22	0.17	Cognitive performance;	chr8:72740602	chr8:73297711~73356461:-
HNSC	cis	rs1161098	1	rs1161098	ENSG00000203585.3	RP11-542B15.1	3.66	0.00028	0.0326	0.23	0.17	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67453680	chr12:67519829~67567126:+
HNSC	cis	rs6852435	1	rs34400328	ENSG00000234801.3	MORF4	3.66	0.00028	0.0326	0.26	0.17	Response to acetaminophen (hepatotoxicity);	chr4:174377063	chr4:173615936~173616906:-
HNSC	cis	rs9982086	0.793	rs7278807	ENSG00000260583.1	AP000223.42	3.66	0.00028	0.0326	0.32	0.17	Carboplatin disposition in epthelial ovarian cancer;	chr21:25553754	chr21:25582770~25583326:-
HNSC	cis	rs2548724	0.617	rs3114659	ENSG00000250682.4	LINC00491	-3.66	0.000281	0.0326	-0.22	-0.17	Type 2 diabetes;	chr5:102295888	chr5:102609156~102671559:-
HNSC	cis	rs5758511	0.689	rs17002947	ENSG00000227370.1	RP4-669P10.19	-3.66	0.000281	0.0327	-0.2	-0.17	Birth weight;	chr22:42292526	chr22:42132543~42132998:+
HNSC	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	3.66	0.000281	0.0327	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000261089.1	RP11-435I10.3	3.66	0.000281	0.0327	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28413703~28415018:+
HNSC	cis	rs2337406	0.789	rs112027230	ENSG00000280411.1	IGHV1-69-2	-3.66	0.000281	0.0327	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106810329	chr14:106762092~106762588:-
HNSC	cis	rs2645424	1	rs2645424	ENSG00000255046.1	RP11-297N6.4	-3.66	0.000281	0.0327	-0.17	-0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr8:11797928~11802568:-
HNSC	cis	rs60617249	0.772	rs7800732	ENSG00000228204.2	RP4-724E13.2	3.66	0.000281	0.0327	0.18	0.17	Major depression and alcohol dependence;	chr7:50916540	chr7:50866747~51022990:+
HNSC	cis	rs35000415	0.938	rs10488631	ENSG00000244556.1	ODCP	3.66	0.000281	0.0327	0.33	0.17	Systemic lupus erythematosus;	chr7:128954129	chr7:129028889~129030527:+
HNSC	cis	rs886774	0.644	rs10953555	ENSG00000273055.1	CTB-13F3.1	-3.66	0.000281	0.0327	-0.17	-0.17	Ulcerative colitis;	chr7:107940901	chr7:107942116~107942740:+
HNSC	cis	rs793571	0.822	rs173214	ENSG00000245975.2	RP11-30K9.6	3.66	0.000281	0.0327	0.28	0.17	Schizophrenia;	chr15:58867989	chr15:58768072~58770974:-
HNSC	cis	rs853679	1	rs1936365	ENSG00000226314.6	ZNF192P1	3.66	0.000281	0.0327	0.23	0.17	Depression;	chr6:28300675	chr6:28161781~28169594:+
HNSC	cis	rs2976388	0.935	rs2978979	ENSG00000253741.1	CTD-2292P10.4	3.66	0.000281	0.0327	0.16	0.17	Urinary tract infection frequency;	chr8:142675868	chr8:142702252~142726973:-
HNSC	cis	rs67311347	0.911	rs6775936	ENSG00000280739.1	EIF1B-AS1	3.66	0.000281	0.0327	0.18	0.17	Renal cell carcinoma;	chr3:40335908	chr3:40173145~40309698:-
HNSC	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000281	0.0327	-0.24	-0.17	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
HNSC	cis	rs727563	0.593	rs132770	ENSG00000233903.2	Z83851.4	3.66	0.000281	0.0327	0.25	0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr22:42276355~42277052:+
HNSC	cis	rs6968419	0.547	rs72603593	ENSG00000237870.5	AC073130.1	3.66	0.000281	0.0327	0.2	0.17	Intraocular pressure;	chr7:116254322	chr7:116275606~116286734:-
HNSC	cis	rs2243480	1	rs12698509	ENSG00000164669.11	INTS4P1	3.66	0.000281	0.0327	0.32	0.17	Diabetic kidney disease;	chr7:65953889	chr7:65141225~65234216:+
HNSC	cis	rs67311347	1	rs12488805	ENSG00000280739.1	EIF1B-AS1	3.66	0.000281	0.0327	0.2	0.17	Renal cell carcinoma;	chr3:40381378	chr3:40173145~40309698:-
HNSC	cis	rs13325613	0.915	rs10510748	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000281	0.0327	-0.22	-0.17	Monocyte count;	chr3:46137046	chr3:46364955~46407059:-
HNSC	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-3.66	0.000281	0.0327	-0.22	-0.17	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
HNSC	cis	rs7246657	0.722	rs2972447	ENSG00000276846.1	CTD-3220F14.3	-3.66	0.000281	0.0327	-0.23	-0.17	Coronary artery calcification;	chr19:37638835	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.678	rs2972446	ENSG00000276846.1	CTD-3220F14.3	-3.66	0.000281	0.0327	-0.23	-0.17	Coronary artery calcification;	chr19:37638992	chr19:37314868~37315620:-
HNSC	cis	rs4924935	1	rs2158100	ENSG00000264885.1	RP11-815I9.4	3.66	0.000281	0.0327	0.19	0.17	Pancreatic cancer;	chr17:18908166	chr17:18667629~18669461:-
HNSC	cis	rs950169	0.96	rs35159785	ENSG00000230373.7	GOLGA6L5P	-3.66	0.000281	0.0327	-0.19	-0.17	Schizophrenia;	chr15:84135262	chr15:84507885~84516814:-
HNSC	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	3.66	0.000281	0.0327	0.22	0.17	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
HNSC	cis	rs3743772	0.5	rs2388117	ENSG00000279344.1	RP11-44F14.7	3.66	0.000281	0.0327	0.23	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53478957~53481550:-
HNSC	cis	rs3743772	0.5	rs28415605	ENSG00000279344.1	RP11-44F14.7	3.66	0.000281	0.0327	0.23	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53478957~53481550:-
HNSC	cis	rs3743772	0.5	rs2160290	ENSG00000279344.1	RP11-44F14.7	3.66	0.000281	0.0327	0.23	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53478957~53481550:-
HNSC	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-3.66	0.000281	0.0327	-0.19	-0.17	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
HNSC	cis	rs6968419	0.963	rs940471	ENSG00000237870.5	AC073130.1	3.66	0.000281	0.0327	0.19	0.17	Intraocular pressure;	chr7:116201154	chr7:116275606~116286734:-
HNSC	cis	rs10819861	0.621	rs7025349	ENSG00000175611.10	LINC00476	-3.66	0.000281	0.0327	-0.16	-0.17	Electrocardiographic traits;	chr9:96085409	chr9:95759231~95875977:-
HNSC	cis	rs10504130	0.502	rs10087958	ENSG00000228801.5	RP11-110G21.1	-3.66	0.000281	0.0327	-0.2	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51899325~51947173:+
HNSC	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-3.66	0.000282	0.0327	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.638	rs7793569	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66651646	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs6975195	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66659787	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs3857688	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66662819	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2286684	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66664843	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.935	rs2286683	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66664856	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs10274773	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66668591	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs7785213	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66673991	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs11773829	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66676087	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.935	rs3800820	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66682191	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2003301	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66682669	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs7788576	ENSG00000273142.1	RP11-458F8.4	3.66	0.000282	0.0327	0.14	0.17	Aortic root size;	chr7:66683315	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs6958520	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66686466	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.967	rs2707849	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66687725	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.967	rs2707841	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66692033	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2707836	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66695448	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs4717310	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66696020	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.844	rs7779971	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66696803	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs1553609	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66732152	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs1553610	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66732246	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2707845	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66733811	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2707850	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66738883	chr7:66902857~66906297:+
HNSC	cis	rs801193	0.967	rs1110414	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66740595	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs7783924	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66744070	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs7789184	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66745208	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2707854	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000282	0.0327	-0.14	-0.17	Aortic root size;	chr7:66747610	chr7:66902857~66906297:+
HNSC	cis	rs13434995	0.842	rs3792603	ENSG00000273257.1	RP11-177J6.1	-3.66	0.000282	0.0327	-0.28	-0.17	Adiponectin levels;	chr4:55435891	chr4:55387949~55388271:+
HNSC	cis	rs9313772	0.775	rs7724836	ENSG00000254350.1	RP11-542A14.1	-3.66	0.000282	0.0327	-0.18	-0.17	Blood pressure;	chr5:158399273	chr5:158424585~158452758:+
HNSC	cis	rs1440410	0.93	rs4618266	ENSG00000250326.1	RP11-284M14.1	-3.66	0.000282	0.0327	-0.19	-0.17	Ischemic stroke;	chr4:143114974	chr4:142933195~143184861:-
HNSC	cis	rs597480	1	rs641393	ENSG00000279742.1	RP11-700A24.1	-3.66	0.000282	0.0327	-0.18	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85725309	chr11:85852557~85854943:-
HNSC	cis	rs12745968	0.652	rs4970703	ENSG00000223787.2	RP4-593M8.1	-3.66	0.000282	0.0328	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92492298	chr1:92580476~92580821:-
HNSC	cis	rs12745968	0.62	rs7520630	ENSG00000223787.2	RP4-593M8.1	-3.66	0.000282	0.0328	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92493404	chr1:92580476~92580821:-
HNSC	cis	rs2436845	0.627	rs2570941	ENSG00000253320.4	KB-1507C5.2	-3.66	0.000282	0.0328	-0.19	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845253	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.627	rs2679747	ENSG00000253320.4	KB-1507C5.2	-3.66	0.000282	0.0328	-0.19	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845886	chr8:102864300~102977876:+
HNSC	cis	rs6601327	0.504	rs2048655	ENSG00000233609.3	RP11-62H7.2	3.66	0.000282	0.0328	0.17	0.17	Multiple myeloma (hyperdiploidy);	chr8:9788052	chr8:8961200~8979025:+
HNSC	cis	rs4578769	0.569	rs9951157	ENSG00000265943.1	RP11-739L10.1	3.66	0.000282	0.0328	0.19	0.17	Eosinophil percentage of white cells;	chr18:22974173	chr18:22699481~22933764:-
HNSC	cis	rs2919009	0.551	rs61872771	ENSG00000271670.1	RP11-95I16.4	3.66	0.000282	0.0328	0.21	0.17	Obesity-related traits;	chr10:120939465	chr10:120879256~120880667:-
HNSC	cis	rs929354	1	rs1182385	ENSG00000224629.1	RP5-1142J19.2	3.66	0.000282	0.0328	0.16	0.17	Body mass index;	chr7:157247889	chr7:157263022~157263229:-
HNSC	cis	rs7615952	0.515	rs7630575	ENSG00000241278.1	ENPP7P4	-3.66	0.000282	0.0328	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125963487	chr3:125848223~125909372:+
HNSC	cis	rs67311347	1	rs73078162	ENSG00000280739.1	EIF1B-AS1	3.66	0.000282	0.0328	0.2	0.17	Renal cell carcinoma;	chr3:40435618	chr3:40173145~40309698:-
HNSC	cis	rs7429990	0.965	rs7627645	ENSG00000228638.1	FCF1P2	3.66	0.000282	0.0328	0.15	0.17	Educational attainment (years of education);	chr3:48051643	chr3:48290793~48291375:-
HNSC	cis	rs11711441	0.519	rs7639990	ENSG00000233885.6	YEATS2-AS1	-3.66	0.000282	0.0328	-0.13	-0.17	Parkinson's disease;	chr3:183143386	chr3:183806457~183810783:-
HNSC	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	3.66	0.000282	0.0328	0.19	0.17	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
HNSC	cis	rs597539	0.689	rs596874	ENSG00000255741.1	RP11-757G1.5	3.66	0.000282	0.0328	0.22	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68941503~68942852:-
HNSC	cis	rs6570726	0.791	rs6570692	ENSG00000270638.1	RP3-466P17.1	3.66	0.000282	0.0328	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6902410	ENSG00000270638.1	RP3-466P17.1	3.66	0.000282	0.0328	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9322029	ENSG00000270638.1	RP3-466P17.1	3.66	0.000282	0.0328	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9373464	ENSG00000270638.1	RP3-466P17.1	3.66	0.000282	0.0328	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9403730	ENSG00000270638.1	RP3-466P17.1	3.66	0.000282	0.0328	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145735570~145737218:+
HNSC	cis	rs3736485	0.966	rs12440990	ENSG00000274528.1	CTD-2650P22.2	3.66	0.000282	0.0328	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51610062	chr15:52017167~52018032:-
HNSC	cis	rs9880211	0.948	rs9820621	ENSG00000239213.4	NCK1-AS1	3.66	0.000282	0.0328	0.17	0.17	Height;Body mass index;	chr3:136391671	chr3:136841726~136862054:-
HNSC	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	3.66	0.000282	0.0328	0.29	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
HNSC	cis	rs889398	0.935	rs1364063	ENSG00000196696.11	PDXDC2P	3.66	0.000282	0.0328	0.12	0.17	Body mass index;	chr16:69554669	chr16:69976297~70065948:-
HNSC	cis	rs853679	1	rs853685	ENSG00000270326.1	RP5-874C20.6	-3.66	0.000282	0.0328	-0.25	-0.17	Depression;	chr6:28321008	chr6:28319660~28319852:-
HNSC	cis	rs897984	0.762	rs7204459	ENSG00000260911.2	RP11-196G11.2	-3.66	0.000282	0.0328	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30972891	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.762	rs4889604	ENSG00000260911.2	RP11-196G11.2	-3.66	0.000282	0.0328	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30974673	chr16:31043150~31049868:+
HNSC	cis	rs6012564	0.826	rs34778847	ENSG00000227431.4	CSE1L-AS1	3.66	0.000282	0.0328	0.19	0.17	Anger;	chr20:49121421	chr20:49040463~49046044:-
HNSC	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-3.66	0.000282	0.0328	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
HNSC	cis	rs10435719	0.834	rs11250176	ENSG00000227888.4	FAM66A	3.66	0.000282	0.0328	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12362019~12388296:+
HNSC	cis	rs853679	1	rs853685	ENSG00000204709.4	LINC01556	3.66	0.000282	0.0328	0.26	0.17	Depression;	chr6:28321008	chr6:28943877~28944537:+
HNSC	cis	rs6545883	0.965	rs766447	ENSG00000271889.1	RP11-493E12.1	3.66	0.000282	0.0328	0.19	0.17	Tuberculosis;	chr2:61508434	chr2:61151433~61162105:-
HNSC	cis	rs1519814	0.696	rs7822000	ENSG00000254343.2	RP11-760H22.2	-3.66	0.000282	0.0328	-0.23	-0.17	Breast cancer;	chr8:120021873	chr8:120052180~120056201:+
HNSC	cis	rs481331	0.866	rs1813564	ENSG00000215146.4	RP11-313J2.1	3.66	0.000282	0.0328	0.27	0.17	Systemic juvenile idiopathic arthritis;	chr10:42503316	chr10:42331866~42367974:-
HNSC	cis	rs10129255	0.518	rs2006284	ENSG00000211976.2	IGHV3-73	-3.66	0.000282	0.0328	-0.12	-0.17	Kawasaki disease;	chr14:106676185	chr14:106802694~106803233:-
HNSC	cis	rs12291225	0.679	rs34238445	ENSG00000254418.1	RP11-21L19.1	3.66	0.000282	0.0328	0.2	0.17	Sense of smell;	chr11:14294369	chr11:14262846~14273691:-
HNSC	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	3.66	0.000282	0.0328	0.17	0.17	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
HNSC	cis	rs2439831	0.867	rs6493082	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43342610	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs8041132	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43342938	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs7170489	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43344453	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs16957627	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43350459	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs16957630	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43350582	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs16957632	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43350699	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.717	rs7165471	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43352590	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.867	rs6493085	ENSG00000275601.1	AC011330.13	-3.66	0.000282	0.0328	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43361984	chr15:43642389~43643023:-
HNSC	cis	rs561341	1	rs72821952	ENSG00000278867.1	RP11-640N20.4	-3.66	0.000282	0.0328	-0.24	-0.17	Hip circumference adjusted for BMI;	chr17:31921114	chr17:32051030~32053208:+
HNSC	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	3.66	0.000282	0.0328	0.19	0.17	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000282	0.0328	-0.19	-0.17	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000282	0.0328	-0.19	-0.17	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000282	0.0328	-0.19	-0.17	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
HNSC	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	3.66	0.000283	0.0328	0.24	0.17	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	3.66	0.000283	0.0328	0.24	0.17	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
HNSC	cis	rs7572733	0.846	rs1518359	ENSG00000222017.1	AC011997.1	3.66	0.000283	0.0328	0.2	0.17	Dermatomyositis;	chr2:197982659	chr2:197693106~197774823:+
HNSC	cis	rs8062405	0.755	rs17640009	ENSG00000260367.2	RP11-264B17.4	-3.66	0.000283	0.0328	-0.15	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28973962~28978824:-
HNSC	cis	rs34792	0.554	rs62039130	ENSG00000207425.1	Y_RNA	-3.66	0.000283	0.0328	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:14915457~14915556:-
HNSC	cis	rs6732189	1	rs6711368	ENSG00000279844.1	RP11-20F18.1	-3.66	0.000283	0.0328	-0.17	-0.17	Educational attainment;	chr2:160718408	chr2:160849313~160850676:-
HNSC	cis	rs72843506	0.722	rs9908032	ENSG00000189423.10	USP32P3	3.66	0.000283	0.0328	0.26	0.17	Schizophrenia;	chr17:20204871	chr17:20415547~20431008:+
HNSC	cis	rs12534093	0.67	rs11773147	ENSG00000234286.1	AC006026.13	-3.66	0.000283	0.0328	-0.19	-0.17	Infant length;Height;	chr7:23549567	chr7:23680195~23680786:-
HNSC	cis	rs10742752	0.676	rs12275086	ENSG00000255267.3	RP11-430H10.2	3.66	0.000283	0.0328	0.22	0.17	Body mass index;	chr11:45401189	chr11:45371397~45388508:+
HNSC	cis	rs57502260	0.704	rs60538784	ENSG00000255031.4	RP11-802E16.3	3.66	0.000283	0.0328	0.19	0.17	Total body bone mineral density (age 45-60);	chr11:68619267	chr11:68050740~68053762:+
HNSC	cis	rs28489187	0.706	rs233066	ENSG00000223653.4	RP11-131L23.1	3.66	0.000283	0.0328	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339247	chr1:85276715~85448124:+
HNSC	cis	rs6840360	0.642	rs4235219	ENSG00000251611.1	RP11-610P16.1	-3.66	0.000283	0.0328	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs6851814	ENSG00000251611.1	RP11-610P16.1	-3.66	0.000283	0.0328	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.606	rs10028035	ENSG00000251611.1	RP11-610P16.1	-3.66	0.000283	0.0328	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.667	rs4266275	ENSG00000251611.1	RP11-610P16.1	-3.66	0.000283	0.0328	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151407551~151408835:-
HNSC	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000283	0.0328	-0.21	-0.17	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
HNSC	cis	rs10888838	0.652	rs12410868	ENSG00000198711.5	SSBP3-AS1	3.66	0.000283	0.0328	0.23	0.17	Mitochondrial DNA levels;	chr1:54230646	chr1:54236440~54239063:+
HNSC	cis	rs526231	0.543	rs3776863	ENSG00000250682.4	LINC00491	3.66	0.000283	0.0329	0.21	0.17	Primary biliary cholangitis;	chr5:102992165	chr5:102609156~102671559:-
HNSC	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-3.66	0.000283	0.0329	-0.2	-0.17	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
HNSC	cis	rs2243480	1	rs73142121	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000283	0.0329	-0.29	-0.17	Diabetic kidney disease;	chr7:65846219	chr7:65084103~65100232:+
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000283	0.0329	-0.29	-0.17	Diabetic kidney disease;	chr7:65847191	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs35825738	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000283	0.0329	-0.29	-0.17	Diabetic kidney disease;	chr7:65853040	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs34702770	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000283	0.0329	-0.29	-0.17	Diabetic kidney disease;	chr7:65879836	chr7:65084103~65100232:+
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000283	0.0329	-0.29	-0.17	Diabetic kidney disease;	chr7:65892097	chr7:65084103~65100232:+
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000227888.4	FAM66A	3.66	0.000283	0.0329	0.17	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12362019~12388296:+
HNSC	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000283	0.0329	-0.19	-0.17	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
HNSC	cis	rs17818399	0.547	rs4953400	ENSG00000279254.1	RP11-536C12.1	-3.66	0.000283	0.0329	-0.21	-0.17	Height;	chr2:46550069	chr2:46668870~46670778:+
HNSC	cis	rs683257	0.81	rs72990178	ENSG00000234147.1	RP3-460G2.2	-3.66	0.000283	0.0329	-0.3	-0.17	Facial emotion recognition (angry faces);	chr6:140888076	chr6:140845958~140852924:-
HNSC	cis	rs442309	0.875	rs224062	ENSG00000238280.1	RP11-436D10.3	-3.66	0.000283	0.0329	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62743036	chr10:62793562~62805887:-
HNSC	cis	rs67072384	0.901	rs58076660	ENSG00000245148.2	ARAP1-AS2	3.66	0.000283	0.0329	0.22	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72730450	chr11:72700474~72705607:+
HNSC	cis	rs4725617	0.822	rs7792901	ENSG00000244479.5	OR2A1-AS1	-3.66	0.000283	0.0329	-0.33	-0.17	Blood protein levels;	chr7:143410226	chr7:144251264~144356181:-
HNSC	cis	rs2055729	0.614	rs17150693	ENSG00000254340.1	RP11-10A14.3	3.66	0.000283	0.0329	0.24	0.17	Multiple myeloma (hyperdiploidy);	chr8:9884142	chr8:9141424~9145435:+
HNSC	cis	rs7674212	0.541	rs4699051	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000283	0.0329	-0.19	-0.17	Type 2 diabetes;	chr4:103193237	chr4:102751401~102752641:+
HNSC	cis	rs34792	0.554	rs62039131	ENSG00000207425.1	Y_RNA	-3.66	0.000283	0.0329	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:14915457~14915556:-
HNSC	cis	rs4815191	0.755	rs6048656	ENSG00000279164.1	RP4-737E23.5	3.66	0.000283	0.0329	0.24	0.17	Obesity-related traits;	chr20:23267490	chr20:23148086~23149939:+
HNSC	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	3.66	0.000283	0.0329	0.24	0.17	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
HNSC	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000283	0.0329	-0.21	-0.17	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
HNSC	cis	rs9313772	0.775	rs1958604	ENSG00000254350.1	RP11-542A14.1	-3.66	0.000283	0.0329	-0.18	-0.17	Blood pressure;	chr5:158390600	chr5:158424585~158452758:+
HNSC	cis	rs28489187	0.617	rs233072	ENSG00000223653.4	RP11-131L23.1	3.66	0.000283	0.0329	0.22	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85342012	chr1:85276715~85448124:+
HNSC	cis	rs11098499	0.754	rs1814813	ENSG00000260091.1	RP11-33B1.4	-3.66	0.000283	0.0329	-0.16	-0.17	Corneal astigmatism;	chr4:119337052	chr4:119409333~119410233:+
HNSC	cis	rs73201462	1	rs6783253	ENSG00000231305.3	RP11-723O4.2	-3.66	0.000283	0.0329	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128132718	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6797834	ENSG00000231305.3	RP11-723O4.2	-3.66	0.000283	0.0329	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137557	chr3:128861313~128871540:-
HNSC	cis	rs6558530	0.64	rs4875889	ENSG00000253982.1	CTD-2336O2.1	3.66	0.000283	0.0329	0.21	0.17	Systolic blood pressure;	chr8:1747125	chr8:1761990~1764502:-
HNSC	cis	rs6496044	0.963	rs6496050	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000283	0.0329	-0.18	-0.17	Interstitial lung disease;	chr15:85526019	chr15:85744109~85750281:-
HNSC	cis	rs12291225	0.679	rs11605531	ENSG00000254418.1	RP11-21L19.1	3.66	0.000283	0.0329	0.2	0.17	Sense of smell;	chr11:14270048	chr11:14262846~14273691:-
HNSC	cis	rs9914544	0.545	rs8073436	ENSG00000264885.1	RP11-815I9.4	-3.66	0.000283	0.0329	-0.17	-0.17	Educational attainment (years of education);	chr17:18898528	chr17:18667629~18669461:-
HNSC	cis	rs2436845	0.627	rs974758	ENSG00000253320.4	KB-1507C5.2	-3.66	0.000283	0.0329	-0.19	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825263	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.627	rs1062048	ENSG00000253320.4	KB-1507C5.2	-3.66	0.000283	0.0329	-0.19	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838824	chr8:102864300~102977876:+
HNSC	cis	rs4648045	0.621	rs2903282	ENSG00000230069.3	LRRC37A15P	-3.66	0.000284	0.0329	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102492194	chr4:102727274~102730721:-
HNSC	cis	rs12188164	0.515	rs17562461	ENSG00000225138.6	CTD-2228K2.7	3.66	0.000284	0.0329	0.2	0.17	Cystic fibrosis severity;	chr5:411246	chr5:473236~480884:+
HNSC	cis	rs10073892	0.743	rs13359604	ENSG00000250682.4	LINC00491	-3.66	0.000284	0.0329	-0.23	-0.17	Cognitive decline (age-related);	chr5:102317896	chr5:102609156~102671559:-
HNSC	cis	rs9768139	0.733	rs13225172	ENSG00000223872.1	AC006372.5	-3.66	0.000284	0.0329	-0.18	-0.17	Calcium levels;	chr7:158327642	chr7:157501322~157503577:+
HNSC	cis	rs896655	0.629	rs10965145	ENSG00000244230.3	RN7SL151P	3.66	0.000284	0.0329	0.18	0.17	Coronary artery disease;	chr9:21809078	chr9:21699314~21699596:+
HNSC	cis	rs853679	0.55	rs1150692	ENSG00000219891.2	ZSCAN12P1	3.66	0.000284	0.0329	0.23	0.17	Depression;	chr6:28206179	chr6:28091154~28093664:+
HNSC	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	3.66	0.000284	0.0329	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
HNSC	cis	rs4256159	0.696	rs11711564	ENSG00000228956.7	SATB1-AS1	3.66	0.000284	0.0329	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718528	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs80043323	ENSG00000228956.7	SATB1-AS1	3.66	0.000284	0.0329	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718570	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs11707962	ENSG00000228956.7	SATB1-AS1	3.66	0.000284	0.0329	0.23	0.17	Crohn's disease;Inflammatory bowel disease;	chr3:18718602	chr3:18445024~18920401:+
HNSC	cis	rs73198271	1	rs4841031	ENSG00000173295.6	FAM86B3P	-3.66	0.000284	0.0329	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:8228595~8244865:+
HNSC	cis	rs73198271	1	rs11784958	ENSG00000173295.6	FAM86B3P	-3.66	0.000284	0.0329	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8228595~8244865:+
HNSC	cis	rs1560104	0.718	rs36003824	ENSG00000261216.1	RP11-166B2.5	-3.66	0.000284	0.0329	-0.2	-0.17	Obesity-related traits;	chr16:12611781	chr16:11908208~11908916:+
HNSC	cis	rs7178375	0.941	rs4779796	ENSG00000270015.1	RP11-540B6.6	3.66	0.000284	0.0329	0.21	0.17	Hypertriglyceridemia;	chr15:30915847	chr15:30926514~30928407:+
HNSC	cis	rs116095464	0.558	rs10057492	ENSG00000277812.1	AC021087.1	3.66	0.000284	0.0329	0.28	0.17	Breast cancer;	chr5:239388	chr5:262769~262881:+
HNSC	cis	rs5758659	0.714	rs2413668	ENSG00000270083.1	RP1-257I20.14	-3.66	0.000284	0.033	-0.15	-0.17	Cognitive function;	chr22:42109837	chr22:42089630~42090028:-
HNSC	cis	rs5758659	0.657	rs5758587	ENSG00000270083.1	RP1-257I20.14	-3.66	0.000284	0.033	-0.15	-0.17	Cognitive function;	chr22:42121632	chr22:42089630~42090028:-
HNSC	cis	rs4908768	0.535	rs2708628	ENSG00000232912.4	RP5-1115A15.1	-3.66	0.000284	0.033	-0.21	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8390388	chr1:8424645~8434838:+
HNSC	cis	rs2661868	0.788	rs2708631	ENSG00000232912.4	RP5-1115A15.1	-3.66	0.000284	0.033	-0.21	-0.17	Life satisfaction;	chr1:8403450	chr1:8424645~8434838:+
HNSC	cis	rs7927592	0.913	rs11228276	ENSG00000255031.4	RP11-802E16.3	3.66	0.000284	0.033	0.15	0.17	Total body bone mineral density;	chr11:68540057	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs67005337	ENSG00000255031.4	RP11-802E16.3	3.66	0.000284	0.033	0.15	0.17	Total body bone mineral density;	chr11:68540290	chr11:68050740~68053762:+
HNSC	cis	rs9314614	0.901	rs2978902	ENSG00000245857.2	GS1-24F4.2	-3.66	0.000284	0.033	-0.16	-0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6832651	chr8:6835554~6885276:+
HNSC	cis	rs8031584	1	rs1474380	ENSG00000270015.1	RP11-540B6.6	-3.66	0.000284	0.033	-0.17	-0.17	Huntington's disease progression;	chr15:30977032	chr15:30926514~30928407:+
HNSC	cis	rs9487051	0.604	rs9320282	ENSG00000219700.1	PTCHD3P3	3.66	0.000284	0.033	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109298174	chr6:109288571~109290503:-
HNSC	cis	rs10515750	0.656	rs112839393	ENSG00000248544.2	CTB-47B11.3	3.66	0.000284	0.033	0.34	0.17	Lung function (FEV1/FVC);	chr5:157282304	chr5:157375741~157384950:-
HNSC	cis	rs4908768	0.535	rs2661868	ENSG00000232912.4	RP5-1115A15.1	-3.66	0.000284	0.033	-0.21	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8409729	chr1:8424645~8434838:+
HNSC	cis	rs4938303	0.788	rs12799766	ENSG00000254851.1	RP11-109L13.1	-3.66	0.000284	0.033	-0.26	-0.17	Triglycerides;	chr11:116687711	chr11:117135528~117138582:+
HNSC	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	3.66	0.000284	0.033	0.21	0.17	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
HNSC	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	3.66	0.000284	0.033	0.21	0.17	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
HNSC	cis	rs1513670	1	rs1534401	ENSG00000260793.2	RP5-882C2.2	3.66	0.000284	0.033	0.15	0.17	Bone mineral density (hip);	chr17:43732756	chr17:44221401~44223710:+
HNSC	cis	rs7771547	0.642	rs1003250	ENSG00000219023.1	RP3-340B19.2	-3.66	0.000284	0.033	-0.15	-0.17	Platelet distribution width;	chr6:36469635	chr6:35555873~35556264:+
HNSC	cis	rs10028773	0.666	rs12498657	ENSG00000250412.1	KLHL2P1	3.66	0.000284	0.033	0.21	0.17	Educational attainment;	chr4:119341711	chr4:119334329~119378233:+
HNSC	cis	rs62229266	0.771	rs7280136	ENSG00000230212.5	AP000688.14	3.66	0.000284	0.033	0.18	0.17	Mitral valve prolapse;	chr21:36060612	chr21:36069642~36126640:-
HNSC	cis	rs12047808	0.73	rs745317	ENSG00000227141.2	RP11-545A16.3	-3.66	0.000284	0.033	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179556176	chr1:179586705~179589175:+
HNSC	cis	rs12047808	0.73	rs73051834	ENSG00000227141.2	RP11-545A16.3	-3.66	0.000284	0.033	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179556917	chr1:179586705~179589175:+
HNSC	cis	rs2991971	0.729	rs10890328	ENSG00000234329.1	RP11-767N6.2	3.66	0.000284	0.033	0.17	0.17	High light scatter reticulocyte count;	chr1:45439711	chr1:45651039~45651826:-
HNSC	cis	rs12534093	0.883	rs10950942	ENSG00000234286.1	AC006026.13	-3.66	0.000284	0.033	-0.2	-0.17	Infant length;Height;	chr7:23445083	chr7:23680195~23680786:-
HNSC	cis	rs12745968	0.653	rs6604008	ENSG00000223787.2	RP4-593M8.1	-3.66	0.000284	0.033	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92711884	chr1:92580476~92580821:-
HNSC	cis	rs875971	0.505	rs1723275	ENSG00000272831.1	RP11-792A8.4	-3.66	0.000284	0.033	-0.14	-0.17	Aortic root size;	chr7:66039646	chr7:66739829~66740385:-
HNSC	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-3.66	0.000284	0.033	-0.19	-0.17	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
HNSC	cis	rs74781061	0.932	rs7178568	ENSG00000260103.2	RP11-10O17.1	-3.66	0.000284	0.033	-0.2	-0.17	Endometriosis;	chr15:74559075	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs8023479	ENSG00000260103.2	RP11-10O17.1	-3.66	0.000284	0.033	-0.2	-0.17	Endometriosis;	chr15:74561337	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs12437519	ENSG00000260103.2	RP11-10O17.1	-3.66	0.000284	0.033	-0.2	-0.17	Endometriosis;	chr15:74562109	chr15:74478070~74490286:-
HNSC	cis	rs8062405	1	rs62036617	ENSG00000261766.1	RP11-22P6.2	-3.66	0.000285	0.033	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28862166~28863340:-
HNSC	cis	rs8062405	1	rs4788095	ENSG00000261766.1	RP11-22P6.2	-3.66	0.000285	0.033	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28862166~28863340:-
HNSC	cis	rs8062405	0.964	rs72793809	ENSG00000261766.1	RP11-22P6.2	-3.66	0.000285	0.033	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28862166~28863340:-
HNSC	cis	rs8062405	1	rs62036620	ENSG00000261766.1	RP11-22P6.2	-3.66	0.000285	0.033	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28862166~28863340:-
HNSC	cis	rs8062405	1	rs62036621	ENSG00000261766.1	RP11-22P6.2	-3.66	0.000285	0.033	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28862166~28863340:-
HNSC	cis	rs896655	0.598	rs2383185	ENSG00000244230.3	RN7SL151P	3.66	0.000285	0.033	0.17	0.17	Coronary artery disease;	chr9:21728391	chr9:21699314~21699596:+
HNSC	cis	rs10484434	0.818	rs11759668	ENSG00000272462.2	U91328.19	3.66	0.000285	0.033	0.21	0.17	HIV-1 viral setpoint;	chr6:26014261	chr6:25992662~26001775:+
HNSC	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-3.66	0.000285	0.033	-0.18	-0.17	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
HNSC	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000285	0.033	-0.19	-0.17	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000285	0.033	-0.19	-0.17	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
HNSC	cis	rs67478160	0.625	rs7141473	ENSG00000259515.1	RP11-365N19.2	-3.66	0.000285	0.033	-0.15	-0.17	Schizophrenia;	chr14:103849718	chr14:102933574~102937177:+
HNSC	cis	rs11083475	1	rs9304578	ENSG00000269486.2	CTC-360G5.9	-3.66	0.000285	0.033	-0.19	-0.17	Heart rate;	chr19:38759697	chr19:38935297~38938632:-
HNSC	cis	rs2280018	0.963	rs4985147	ENSG00000263335.1	AF001548.5	-3.66	0.000285	0.0331	-0.22	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15726674~15732993:+
HNSC	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	3.66	0.000285	0.0331	0.19	0.17	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
HNSC	cis	rs6001482	0.702	rs9623126	ENSG00000253818.1	IGLV1-41	-3.66	0.000285	0.0331	-0.14	-0.17	Diastolic blood pressure;	chr22:22234624	chr22:22404207~22404721:+
HNSC	cis	rs6088580	0.634	rs1205345	ENSG00000276073.1	RP5-1125A11.7	3.66	0.000285	0.0331	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:33985617~33988989:-
HNSC	cis	rs2836974	0.59	rs11911822	ENSG00000255568.3	BRWD1-AS2	-3.66	0.000285	0.0331	-0.14	-0.17	Cognitive function;	chr21:39235917	chr21:39313935~39314962:+
HNSC	cis	rs73198271	0.681	rs35457364	ENSG00000254153.1	CTA-398F10.2	-3.66	0.000285	0.0331	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.681	rs11987924	ENSG00000254153.1	CTA-398F10.2	-3.66	0.000285	0.0331	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8456909~8461337:-
HNSC	cis	rs748404	0.589	rs62020616	ENSG00000166763.7	STRCP1	3.66	0.000285	0.0331	0.23	0.17	Lung cancer;	chr15:43558554	chr15:43699488~43718184:-
HNSC	cis	rs11976180	1	rs13226728	ENSG00000244479.5	OR2A1-AS1	3.66	0.000285	0.0331	0.19	0.17	Obesity-related traits;	chr7:144049485	chr7:144251264~144356181:-
HNSC	cis	rs1440410	0.798	rs11727441	ENSG00000250326.1	RP11-284M14.1	-3.66	0.000285	0.0331	-0.19	-0.17	Ischemic stroke;	chr4:143242602	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs10010367	ENSG00000250326.1	RP11-284M14.1	-3.66	0.000285	0.0331	-0.19	-0.17	Ischemic stroke;	chr4:143243669	chr4:142933195~143184861:-
HNSC	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	3.66	0.000285	0.0331	0.25	0.17	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
HNSC	cis	rs58873874	0.579	rs3815829	ENSG00000248544.2	CTB-47B11.3	3.66	0.000285	0.0331	0.32	0.17	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157375741~157384950:-
HNSC	cis	rs6142618	0.935	rs4911554	ENSG00000275576.1	RP5-836N17.4	-3.66	0.000285	0.0331	-0.17	-0.17	Inflammatory bowel disease;	chr20:32164207	chr20:32116171~32116629:+
HNSC	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	3.66	0.000285	0.0331	0.24	0.17	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
HNSC	cis	rs61160187	0.51	rs10077663	ENSG00000215032.2	GNL3LP1	3.66	0.000285	0.0331	0.18	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60891935~60893577:-
HNSC	cis	rs2307394	0.929	rs11894371	ENSG00000281469.1	RP11-567F11.1	3.66	0.000285	0.0331	0.18	0.17	Urate levels;	chr2:147818303	chr2:148044380~148044894:+
HNSC	cis	rs2562456	0.833	rs62110428	ENSG00000268119.4	CTD-2561J22.5	3.66	0.000285	0.0331	0.25	0.17	Pain;	chr19:21430854	chr19:21444241~21463908:-
HNSC	cis	rs11783469	0.522	rs4872125	ENSG00000253390.1	CTC-756D1.2	-3.66	0.000285	0.0331	-0.26	-0.17	Reticulocyte count;	chr8:23410757	chr8:23458601~23484971:+
HNSC	cis	rs10791097	0.694	rs4436551	ENSG00000254842.5	RP11-890B15.2	3.66	0.000285	0.0331	0.14	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885844	chr11:130844191~130865561:-
HNSC	cis	rs8031584	0.918	rs34693097	ENSG00000270015.1	RP11-540B6.6	-3.66	0.000285	0.0331	-0.17	-0.17	Huntington's disease progression;	chr15:30961781	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.918	rs35784593	ENSG00000270015.1	RP11-540B6.6	-3.66	0.000285	0.0331	-0.17	-0.17	Huntington's disease progression;	chr15:30962385	chr15:30926514~30928407:+
HNSC	cis	rs28573326	0.886	rs1866223	ENSG00000121089.4	NACA3P	-3.66	0.000285	0.0331	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165413533	chr4:164943290~164943937:+
HNSC	cis	rs2153535	0.585	rs6915130	ENSG00000230939.1	RP11-314C16.1	-3.66	0.000285	0.0331	-0.2	-0.17	Motion sickness;	chr6:8661262	chr6:8784178~8785445:+
HNSC	cis	rs6026584	0.823	rs6026574	ENSG00000270951.1	RP1-309F20.4	-3.66	0.000285	0.0331	-0.17	-0.17	Renal function-related traits (BUN);	chr20:58881440	chr20:58876592~58876981:-
HNSC	cis	rs12997796	0.556	rs35129240	ENSG00000273080.1	RP11-301O19.1	3.66	0.000285	0.0331	0.24	0.17	Schizophrenia;	chr2:86702094	chr2:86195590~86196049:+
HNSC	cis	rs453301	0.571	rs2929454	ENSG00000253981.4	ALG1L13P	-3.66	0.000285	0.0331	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9226344	chr8:8236003~8244667:-
HNSC	cis	rs7746199	0.736	rs10484399	ENSG00000226314.6	ZNF192P1	-3.66	0.000285	0.0331	-0.3	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28161781~28169594:+
HNSC	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	3.66	0.000285	0.0331	0.18	0.17	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
HNSC	cis	rs35000415	0.938	rs12531711	ENSG00000244556.1	ODCP	3.66	0.000285	0.0331	0.32	0.17	Systemic lupus erythematosus;	chr7:128977412	chr7:129028889~129030527:+
HNSC	cis	rs1440410	1	rs1440410	ENSG00000250326.1	RP11-284M14.1	-3.66	0.000285	0.0331	-0.19	-0.17	Ischemic stroke;	chr4:143237156	chr4:142933195~143184861:-
HNSC	cis	rs58873874	0.737	rs80320835	ENSG00000248544.2	CTB-47B11.3	3.66	0.000286	0.0331	0.38	0.17	Bipolar disorder (body mass index interaction);	chr5:157389887	chr5:157375741~157384950:-
HNSC	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	3.66	0.000286	0.0331	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
HNSC	cis	rs1552244	1	rs61052895	ENSG00000180385.7	EMC3-AS1	3.66	0.000286	0.0331	0.19	0.17	Alzheimer's disease;	chr3:10105832	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs68067759	ENSG00000180385.7	EMC3-AS1	3.66	0.000286	0.0331	0.19	0.17	Alzheimer's disease;	chr3:10108851	chr3:9986893~10006990:+
HNSC	cis	rs17666538	0.535	rs1669658	ENSG00000254207.1	RP11-43A14.1	3.66	0.000286	0.0331	0.36	0.17	IgG glycosylation;	chr8:657380	chr8:725188~725877:-
HNSC	cis	rs10073892	0.743	rs9327834	ENSG00000250682.4	LINC00491	-3.66	0.000286	0.0331	-0.23	-0.17	Cognitive decline (age-related);	chr5:102322296	chr5:102609156~102671559:-
HNSC	cis	rs10073892	0.743	rs61566297	ENSG00000250682.4	LINC00491	-3.66	0.000286	0.0331	-0.23	-0.17	Cognitive decline (age-related);	chr5:102322707	chr5:102609156~102671559:-
HNSC	cis	rs7572733	0.555	rs6434953	ENSG00000231621.1	AC013264.2	-3.66	0.000286	0.0331	-0.16	-0.17	Dermatomyositis;	chr2:198064969	chr2:197197991~197199273:+
HNSC	cis	rs7572733	0.555	rs6745726	ENSG00000231621.1	AC013264.2	-3.66	0.000286	0.0331	-0.16	-0.17	Dermatomyositis;	chr2:198069356	chr2:197197991~197199273:+
HNSC	cis	rs7475343	0.538	rs4881404	ENSG00000224034.1	RP11-445P17.8	-3.66	0.000286	0.0331	-0.2	-0.17	Intelligence;	chr10:5131435	chr10:5266033~5271236:-
HNSC	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	3.66	0.000286	0.0331	0.2	0.17	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
HNSC	cis	rs2834288	0.734	rs9984662	ENSG00000273102.1	AP000569.9	3.66	0.000286	0.0331	0.19	0.17	Gut microbiota (bacterial taxa);	chr21:33892504	chr21:33967101~33968573:-
HNSC	cis	rs5758511	0.68	rs17002902	ENSG00000233903.2	Z83851.4	3.66	0.000286	0.0331	0.25	0.17	Birth weight;	chr22:42229503	chr22:42276355~42277052:+
HNSC	cis	rs5758511	0.68	rs5758662	ENSG00000233903.2	Z83851.4	3.66	0.000286	0.0331	0.25	0.17	Birth weight;	chr22:42232082	chr22:42276355~42277052:+
HNSC	cis	rs58873874	0.579	rs80253028	ENSG00000248544.2	CTB-47B11.3	3.66	0.000286	0.0331	0.3	0.17	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157375741~157384950:-
HNSC	cis	rs2908197	0.765	rs2098205	ENSG00000186704.9	DTX2P1	3.66	0.000286	0.0331	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76309571	chr7:76978617~77004308:+
HNSC	cis	rs73198271	1	rs11774744	ENSG00000233609.3	RP11-62H7.2	-3.66	0.000286	0.0331	-0.19	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8961200~8979025:+
HNSC	cis	rs35306767	0.807	rs1013505	ENSG00000229869.1	RP11-363N22.2	-3.66	0.000286	0.0332	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:907333	chr10:933026~942743:+
HNSC	cis	rs6088590	0.561	rs6087600	ENSG00000276073.1	RP5-1125A11.7	-3.66	0.000286	0.0332	-0.17	-0.17	Coronary artery disease;	chr20:34569413	chr20:33985617~33988989:-
HNSC	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	3.66	0.000286	0.0332	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
HNSC	cis	rs2439831	0.867	rs2242068	ENSG00000275601.1	AC011330.13	-3.66	0.000286	0.0332	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43407106	chr15:43642389~43643023:-
HNSC	cis	rs7824557	0.602	rs7834139	ENSG00000255495.1	AC145124.2	3.66	0.000286	0.0332	0.19	0.17	Retinal vascular caliber;	chr8:11348854	chr8:12194467~12196280:+
HNSC	cis	rs8031584	0.918	rs61997140	ENSG00000270015.1	RP11-540B6.6	-3.66	0.000286	0.0332	-0.17	-0.17	Huntington's disease progression;	chr15:30985109	chr15:30926514~30928407:+
HNSC	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	3.66	0.000286	0.0332	0.2	0.17	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	3.66	0.000286	0.0332	0.2	0.17	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	3.66	0.000286	0.0332	0.2	0.17	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
HNSC	cis	rs7189233	1	rs7189233	ENSG00000279344.1	RP11-44F14.7	3.66	0.000286	0.0332	0.16	0.17	Intelligence (multi-trait analysis);	chr16:53421471	chr16:53478957~53481550:-
HNSC	cis	rs8077577	0.747	rs12449313	ENSG00000273018.4	CTD-2303H24.2	-3.66	0.000286	0.0332	-0.24	-0.17	Obesity-related traits;	chr17:18317696	chr17:18511221~18551705:-
HNSC	cis	rs1538970	1	rs1417578	ENSG00000234329.1	RP11-767N6.2	3.66	0.000286	0.0332	0.18	0.17	Platelet count;	chr1:45384918	chr1:45651039~45651826:-
HNSC	cis	rs853679	1	rs6905391	ENSG00000204709.4	LINC01556	3.66	0.000286	0.0332	0.26	0.17	Depression;	chr6:28294909	chr6:28943877~28944537:+
HNSC	cis	rs224278	0.509	rs1509952	ENSG00000238280.1	RP11-436D10.3	-3.66	0.000286	0.0332	-0.24	-0.17	Ewing sarcoma;	chr10:62979908	chr10:62793562~62805887:-
HNSC	cis	rs12370275	0.58	rs66632726	ENSG00000257528.1	KRT8P19	-3.66	0.000286	0.0332	-0.22	-0.17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61357823	chr12:61879318~61880772:+
HNSC	cis	rs10995356	0.565	rs1397028	ENSG00000238280.1	RP11-436D10.3	-3.66	0.000286	0.0332	-0.2	-0.17	Temperament;	chr10:62968438	chr10:62793562~62805887:-
HNSC	cis	rs2836974	0.897	rs35391055	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39153590	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.897	rs2836924	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39153713	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.897	rs6517513	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39154952	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.899	rs6517514	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39155169	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.829	rs8128191	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39155385	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.897	rs8132419	ENSG00000255568.3	BRWD1-AS2	3.66	0.000286	0.0332	0.15	0.17	Cognitive function;	chr21:39155901	chr21:39313935~39314962:+
HNSC	cis	rs4704187	0.687	rs11950665	ENSG00000271815.1	CTD-2235C13.3	-3.66	0.000286	0.0332	-0.21	-0.17	Response to amphetamines;	chr5:75127514	chr5:75363760~75364242:+
HNSC	cis	rs7746199	0.736	rs34064842	ENSG00000226314.6	ZNF192P1	-3.66	0.000286	0.0332	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28161781~28169594:+
HNSC	cis	rs17407555	0.657	rs10489076	ENSG00000250413.1	RP11-448G15.1	-3.66	0.000286	0.0332	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10269224	chr4:10006482~10009725:+
HNSC	cis	rs17407555	0.657	rs12505144	ENSG00000250413.1	RP11-448G15.1	-3.66	0.000286	0.0332	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10269295	chr4:10006482~10009725:+
HNSC	cis	rs17407555	0.657	rs12508233	ENSG00000250413.1	RP11-448G15.1	-3.66	0.000286	0.0332	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10269413	chr4:10006482~10009725:+
HNSC	cis	rs17407555	0.632	rs12510726	ENSG00000250413.1	RP11-448G15.1	-3.66	0.000286	0.0332	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10269443	chr4:10006482~10009725:+
HNSC	cis	rs17407555	0.632	rs12510727	ENSG00000250413.1	RP11-448G15.1	-3.66	0.000286	0.0332	-0.22	-0.17	Schizophrenia (age at onset);	chr4:10269446	chr4:10006482~10009725:+
HNSC	cis	rs6142618	0.783	rs1737896	ENSG00000275576.1	RP5-836N17.4	-3.66	0.000286	0.0332	-0.17	-0.17	Inflammatory bowel disease;	chr20:32439711	chr20:32116171~32116629:+
HNSC	cis	rs711830	1	rs2857540	ENSG00000226363.3	HAGLROS	-3.66	0.000286	0.0332	-0.23	-0.17	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176161970	chr2:176177717~176179008:+
HNSC	cis	rs72634501	0.716	rs67637163	ENSG00000182109.6	RP11-69E11.4	3.66	0.000286	0.0332	0.2	0.17	HDL cholesterol;	chr1:39110949	chr1:39522280~39546187:-
HNSC	cis	rs6460942	0.915	rs7803051	ENSG00000226690.5	AC005281.1	3.65	0.000286	0.0332	0.22	0.17	Coronary artery disease;	chr7:12267278	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.915	rs7803056	ENSG00000226690.5	AC005281.1	3.65	0.000286	0.0332	0.22	0.17	Coronary artery disease;	chr7:12267287	chr7:12496429~12541910:+
HNSC	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-3.65	0.000286	0.0332	-0.14	-0.17	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
HNSC	cis	rs656900	0.647	rs668641	ENSG00000261229.4	MTHFS	3.65	0.000286	0.0332	0.18	0.17	Cerebrospinal P-tau181p levels;	chr15:79826282	chr15:79843547~79897285:-
HNSC	cis	rs656900	0.669	rs665629	ENSG00000261229.4	MTHFS	3.65	0.000286	0.0332	0.18	0.17	Cerebrospinal P-tau181p levels;	chr15:79826889	chr15:79843547~79897285:-
HNSC	cis	rs7246657	0.722	rs2909098	ENSG00000276846.1	CTD-3220F14.3	-3.65	0.000286	0.0332	-0.23	-0.17	Coronary artery calcification;	chr19:37713347	chr19:37314868~37315620:-
HNSC	cis	rs7306455	0.558	rs12371643	ENSG00000237774.3	RP11-129B9.1	-3.65	0.000287	0.0332	-0.4	-0.17	Coronary artery disease;	chr12:94931606	chr12:95125760~95126389:+
HNSC	cis	rs240993	0.812	rs9398272	ENSG00000230177.1	RP5-1112D6.4	3.65	0.000287	0.0332	0.21	0.17	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111277932~111278742:+
HNSC	cis	rs67311347	0.544	rs9814779	ENSG00000280739.1	EIF1B-AS1	3.65	0.000287	0.0332	0.18	0.17	Renal cell carcinoma;	chr3:40298940	chr3:40173145~40309698:-
HNSC	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-3.65	0.000287	0.0332	-0.17	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
HNSC	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	3.65	0.000287	0.0332	0.19	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000272831.1	RP11-792A8.4	-3.65	0.000287	0.0332	-0.14	-0.17	Aortic root size;	chr7:66577454	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000272831.1	RP11-792A8.4	-3.65	0.000287	0.0332	-0.14	-0.17	Aortic root size;	chr7:66577989	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000272831.1	RP11-792A8.4	-3.65	0.000287	0.0332	-0.14	-0.17	Aortic root size;	chr7:66591816	chr7:66739829~66740385:-
HNSC	cis	rs28830936	1	rs4924575	ENSG00000250379.1	RP11-23P13.4	3.65	0.000287	0.0332	0.2	0.17	Diastolic blood pressure;	chr15:41804728	chr15:41825099~41827936:-
HNSC	cis	rs1150668	0.796	rs1124132	ENSG00000217862.2	HIST1H4PS1	-3.65	0.000287	0.0332	-0.17	-0.17	Pubertal anthropometrics;	chr6:28412544	chr6:27807075~27807339:+
HNSC	cis	rs5758659	0.714	rs6002607	ENSG00000273366.1	CTA-989H11.1	3.65	0.000287	0.0332	0.2	0.17	Cognitive function;	chr22:42100502	chr22:42278188~42278846:+
HNSC	cis	rs495337	1	rs6067293	ENSG00000229222.1	KRT18P4	-3.65	0.000287	0.0332	-0.19	-0.17	Psoriasis;	chr20:49965204	chr20:49956745~49958032:+
HNSC	cis	rs2836974	0.932	rs11910151	ENSG00000255568.3	BRWD1-AS2	3.65	0.000287	0.0332	0.15	0.17	Cognitive function;	chr21:39188336	chr21:39313935~39314962:+
HNSC	cis	rs7100689	0.89	rs4934169	ENSG00000226659.1	RP11-137H2.4	-3.65	0.000287	0.0332	-0.23	-0.17	Post bronchodilator FEV1;	chr10:80443907	chr10:80529597~80535942:-
HNSC	cis	rs8062405	1	rs62037364	ENSG00000261089.1	RP11-435I10.3	3.65	0.000287	0.0332	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28413703~28415018:+
HNSC	cis	rs999943	0.846	rs9348923	ENSG00000224557.6	HLA-DPB2	-3.65	0.000287	0.0332	-0.23	-0.17	Obesity (extreme);	chr6:33650147	chr6:33112451~33129084:+
HNSC	cis	rs929354	1	rs1182384	ENSG00000224629.1	RP5-1142J19.2	3.65	0.000287	0.0332	0.16	0.17	Body mass index;	chr7:157247948	chr7:157263022~157263229:-
HNSC	cis	rs7824557	0.564	rs12547100	ENSG00000269918.1	AF131215.9	-3.65	0.000287	0.0332	-0.16	-0.17	Retinal vascular caliber;	chr8:11385123	chr8:11104691~11106704:-
HNSC	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	3.65	0.000287	0.0332	0.22	0.17	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
HNSC	cis	rs9467711	0.606	rs66823108	ENSG00000241549.7	GUSBP2	3.65	0.000287	0.0332	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26377711	chr6:26871484~26956554:-
HNSC	cis	rs5167	0.506	rs11669173	ENSG00000269148.1	AC092301.3	-3.65	0.000287	0.0332	-0.15	-0.17	Blood protein levels;	chr19:44989301	chr19:45830164~45831108:+
HNSC	cis	rs2048656	0.635	rs7830613	ENSG00000254340.1	RP11-10A14.3	-3.65	0.000287	0.0332	-0.22	-0.17	Schizophrenia;	chr8:9792259	chr8:9141424~9145435:+
HNSC	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-3.65	0.000287	0.0332	-0.25	-0.17	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-3.65	0.000287	0.0332	-0.25	-0.17	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-3.65	0.000287	0.0332	-0.25	-0.17	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-3.65	0.000287	0.0332	-0.25	-0.17	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
HNSC	cis	rs1005277	0.522	rs289648	ENSG00000263064.2	RP11-291L22.7	3.65	0.000287	0.0332	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38448689~38448949:+
HNSC	cis	rs7819412	0.775	rs6601564	ENSG00000270076.1	AF131215.8	-3.65	0.000287	0.0332	-0.19	-0.17	Triglycerides;	chr8:11124541	chr8:11202965~11203671:+
HNSC	cis	rs4578769	0.531	rs9951973	ENSG00000266850.1	RP11-370A5.1	-3.65	0.000287	0.0332	-0.23	-0.17	Eosinophil percentage of white cells;	chr18:22974353	chr18:22723491~22907721:-
HNSC	cis	rs6995541	0.647	rs6991499	ENSG00000269918.1	AF131215.9	3.65	0.000287	0.0332	0.18	0.17	Triglyceride levels;	chr8:10831487	chr8:11104691~11106704:-
HNSC	cis	rs4449834	0.634	rs11997122	ENSG00000254432.1	RP11-33I11.2	-3.65	0.000287	0.0332	-0.2	-0.17	Sum eosinophil basophil counts;	chr8:60693088	chr8:60808735~60809606:-
HNSC	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	3.65	0.000287	0.0333	0.18	0.17	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
HNSC	cis	rs793571	0.822	rs1078001	ENSG00000245975.2	RP11-30K9.6	-3.65	0.000287	0.0333	-0.27	-0.17	Schizophrenia;	chr15:58875666	chr15:58768072~58770974:-
HNSC	cis	rs2277027	1	rs4579242	ENSG00000251405.2	CTB-109A12.1	3.65	0.000287	0.0333	0.2	0.17	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512490	chr5:157362615~157460078:-
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	3.65	0.000287	0.0333	0.19	0.17	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
HNSC	cis	rs6547741	0.563	rs10196039	ENSG00000272148.1	RP11-195B17.1	-3.65	0.000287	0.0333	-0.17	-0.17	Oral cavity cancer;	chr2:27748328	chr2:27062428~27062907:-
HNSC	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	3.65	0.000287	0.0333	0.18	0.17	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
HNSC	cis	rs11992162	0.636	rs11250182	ENSG00000255046.1	RP11-297N6.4	3.65	0.000287	0.0333	0.17	0.17	Monocyte count;	chr8:11950067	chr8:11797928~11802568:-
HNSC	cis	rs67340775	0.541	rs169287	ENSG00000241549.7	GUSBP2	3.65	0.000287	0.0333	0.21	0.17	Lung cancer in ever smokers;	chr6:27886982	chr6:26871484~26956554:-
HNSC	cis	rs9329221	0.657	rs17694485	ENSG00000255310.2	AF131215.2	3.65	0.000287	0.0333	0.17	0.17	Neuroticism;	chr8:10256948	chr8:11107788~11109726:-
HNSC	cis	rs8054556	0.787	rs11649274	ENSG00000250616.2	RP11-455F5.3	3.65	0.000287	0.0333	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30096430~30104116:+
HNSC	cis	rs710865	0.519	rs10753518	ENSG00000270728.1	RP4-657E11.10	-3.65	0.000287	0.0333	-0.14	-0.17	Brain structure;	chr1:19157099	chr1:19297080~19297903:+
HNSC	cis	rs9921222	0.521	rs62032884	ENSG00000268836.1	LA16c-OS12.2	3.65	0.000287	0.0333	0.18	0.17	Bone mineral density (spine);Bone mineral density;	chr16:313415	chr16:185748~186294:-
HNSC	cis	rs875971	0.577	rs35072105	ENSG00000273142.1	RP11-458F8.4	3.65	0.000288	0.0333	0.14	0.17	Aortic root size;	chr7:66144830	chr7:66902857~66906297:+
HNSC	cis	rs2098713	0.569	rs35624889	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000288	0.0333	0.17	0.17	Telomere length;	chr5:37514162	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs36186847	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000288	0.0333	0.17	0.17	Telomere length;	chr5:37514268	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.534	rs12515702	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000288	0.0333	0.17	0.17	Telomere length;	chr5:37520773	chr5:36666214~36725195:-
HNSC	cis	rs9500256	0.625	rs1936228	ENSG00000266579.1	RP1-71H19.2	-3.65	0.000288	0.0333	-0.2	-0.17	Eosinophilic esophagitis (pediatric);	chr6:58018478	chr6:57493855~57497691:+
HNSC	cis	rs10789207	0.531	rs72669472	ENSG00000248458.2	RP4-598P13.1	-3.65	0.000288	0.0333	-0.25	-0.17	Resting heart rate;	chr1:66663774	chr1:66665864~66677027:-
HNSC	cis	rs338389	0.542	rs8036189	ENSG00000260657.2	RP11-315D16.4	-3.65	0.000288	0.0333	-0.2	-0.17	Survival in rectal cancer;	chr15:68000614	chr15:68267792~68277994:-
HNSC	cis	rs7772486	0.686	rs9399564	ENSG00000270638.1	RP3-466P17.1	-3.65	0.000288	0.0333	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145735570~145737218:+
HNSC	cis	rs16846053	0.515	rs7557876	ENSG00000227403.1	AC009299.3	-3.65	0.000288	0.0333	-0.3	-0.17	Blood osmolality (transformed sodium);	chr2:161633024	chr2:161244739~161249050:+
HNSC	cis	rs73173548	0.502	rs13165211	ENSG00000247828.6	TMEM161B-AS1	3.65	0.000288	0.0333	0.17	0.17	Macular telangiectasia type 2;	chr5:88443772	chr5:88268895~88436685:+
HNSC	cis	rs2028299	1	rs8031576	ENSG00000259677.1	RP11-493E3.1	3.65	0.000288	0.0333	0.2	0.17	Type 2 diabetes;	chr15:89836982	chr15:89876540~89877285:+
HNSC	cis	rs13108904	0.901	rs2293634	ENSG00000254094.1	AC078852.1	-3.65	0.000288	0.0333	-0.18	-0.17	Obesity-related traits;	chr4:1297923	chr4:1356581~1358075:+
HNSC	cis	rs8058578	1	rs3747481	ENSG00000279196.1	RP11-1072A3.3	3.65	0.000288	0.0333	0.2	0.17	Multiple myeloma;	chr16:30655046	chr16:30984630~30988270:-
HNSC	cis	rs6141600	0.574	rs7263536	ENSG00000232907.6	DLGAP4-AS1	3.65	0.000288	0.0333	0.22	0.17	Height;Hip circumference;	chr20:36059535	chr20:36507702~36573391:-
HNSC	cis	rs7475343	0.573	rs61854733	ENSG00000224034.1	RP11-445P17.8	-3.65	0.000288	0.0333	-0.24	-0.17	Intelligence;	chr10:5193570	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs61854734	ENSG00000224034.1	RP11-445P17.8	-3.65	0.000288	0.0333	-0.24	-0.17	Intelligence;	chr10:5193631	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs61854735	ENSG00000224034.1	RP11-445P17.8	-3.65	0.000288	0.0333	-0.24	-0.17	Intelligence;	chr10:5193799	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs61854736	ENSG00000224034.1	RP11-445P17.8	-3.65	0.000288	0.0333	-0.24	-0.17	Intelligence;	chr10:5193861	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.573	rs61854737	ENSG00000224034.1	RP11-445P17.8	-3.65	0.000288	0.0333	-0.24	-0.17	Intelligence;	chr10:5194167	chr10:5266033~5271236:-
HNSC	cis	rs2179367	0.959	rs514839	ENSG00000216906.2	RP11-350J20.9	3.65	0.000288	0.0333	0.21	0.17	Dupuytren's disease;	chr6:149327304	chr6:149904243~149906418:+
HNSC	cis	rs8067545	0.514	rs12449662	ENSG00000261033.1	RP11-209D14.2	-3.65	0.000288	0.0333	-0.19	-0.17	Schizophrenia;	chr17:19994532	chr17:20008051~20009234:-
HNSC	cis	rs3736485	0.609	rs11634955	ENSG00000259438.1	CTD-2650P22.1	-3.65	0.000288	0.0333	-0.17	-0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51671066	chr15:52010999~52019095:-
HNSC	cis	rs546131	0.642	rs12278295	ENSG00000271369.1	RP11-350D17.3	-3.65	0.000288	0.0333	-0.22	-0.17	Lung disease severity in cystic fibrosis;	chr11:34824707	chr11:34709600~34710161:+
HNSC	cis	rs10484434	0.901	rs62394550	ENSG00000272462.2	U91328.19	3.65	0.000288	0.0333	0.21	0.17	HIV-1 viral setpoint;	chr6:26034024	chr6:25992662~26001775:+
HNSC	cis	rs172166	0.543	rs1150691	ENSG00000226314.6	ZNF192P1	-3.65	0.000288	0.0333	-0.18	-0.17	Cardiac Troponin-T levels;	chr6:28200255	chr6:28161781~28169594:+
HNSC	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	3.65	0.000288	0.0333	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
HNSC	cis	rs71636778	0.509	rs6659176	ENSG00000260063.1	RP5-968P14.2	-3.65	0.000288	0.0333	-0.37	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26913429	chr1:26692132~26694131:-
HNSC	cis	rs4843185	0.731	rs10514608	ENSG00000268388.4	FENDRR	-3.65	0.000288	0.0333	-0.17	-0.17	Platelet distribution width;	chr16:85679567	chr16:86474529~86509099:-
HNSC	cis	rs2834288	0.734	rs8126669	ENSG00000273102.1	AP000569.9	-3.65	0.000288	0.0333	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr21:33895836	chr21:33967101~33968573:-
HNSC	cis	rs1015213	0.737	rs78423653	ENSG00000272024.1	RP11-546K22.3	-3.65	0.000288	0.0333	-0.44	-0.17	Glaucoma (primary angle closure);	chr8:51992158	chr8:51950284~51950690:+
HNSC	cis	rs7772486	0.686	rs4896827	ENSG00000270638.1	RP3-466P17.1	3.65	0.000288	0.0333	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145735570~145737218:+
HNSC	cis	rs4873772	0.744	rs2213178	ENSG00000253330.1	RP11-697N18.3	3.65	0.000288	0.0333	0.24	0.17	Lobe attachment (rater-scored or self-reported);	chr8:47904156	chr8:47511034~47512141:-
HNSC	cis	rs4948102	0.731	rs10229446	ENSG00000226278.1	PSPHP1	3.65	0.000288	0.0334	0.19	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr7:55764797~55773288:+
HNSC	cis	rs9611565	0.559	rs5758397	ENSG00000233903.2	Z83851.4	3.65	0.000288	0.0334	0.25	0.17	Vitiligo;	chr22:41623247	chr22:42276355~42277052:+
HNSC	cis	rs7246657	0.638	rs7246461	ENSG00000276846.1	CTD-3220F14.3	-3.65	0.000288	0.0334	-0.22	-0.17	Coronary artery calcification;	chr19:37705680	chr19:37314868~37315620:-
HNSC	cis	rs2657294	0.965	rs4746270	ENSG00000233313.2	HMGA1P5	-3.65	0.000288	0.0334	-0.18	-0.17	Pneumonia;	chr10:75185189	chr10:75276376~75276646:-
HNSC	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000288	0.0334	-0.2	-0.17	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000288	0.0334	-0.2	-0.17	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
HNSC	cis	rs2762353	0.806	rs6909187	ENSG00000272462.2	U91328.19	3.65	0.000288	0.0334	0.16	0.17	Blood metabolite levels;	chr6:25785697	chr6:25992662~26001775:+
HNSC	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	3.65	0.000288	0.0334	0.17	0.17	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
HNSC	cis	rs7824557	0.602	rs11784458	ENSG00000255495.1	AC145124.2	3.65	0.000288	0.0334	0.19	0.17	Retinal vascular caliber;	chr8:11346675	chr8:12194467~12196280:+
HNSC	cis	rs4835473	0.932	rs17763107	ENSG00000249741.2	RP11-673E1.3	3.65	0.000288	0.0334	0.19	0.17	Immature fraction of reticulocytes;	chr4:143828512	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs34917094	ENSG00000249741.2	RP11-673E1.3	3.65	0.000288	0.0334	0.19	0.17	Immature fraction of reticulocytes;	chr4:143832003	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs11736609	ENSG00000249741.2	RP11-673E1.3	3.65	0.000288	0.0334	0.19	0.17	Immature fraction of reticulocytes;	chr4:143832876	chr4:143911514~143912053:-
HNSC	cis	rs7772486	0.686	rs1337841	ENSG00000270638.1	RP3-466P17.1	-3.65	0.000288	0.0334	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145735570~145737218:+
HNSC	cis	rs11951515	0.646	rs58102827	ENSG00000249286.1	CTD-2210P15.2	3.65	0.000289	0.0334	0.17	0.17	Metabolite levels  (X-11787);	chr5:43331514	chr5:43586918~43588223:-
HNSC	cis	rs9923283	0.673	rs8062082	ENSG00000205534.6	SMG1P2	3.65	0.000289	0.0334	0.33	0.17	Plateletcrit;	chr16:29661261	chr16:29527568~29594966:-
HNSC	cis	rs7113211	0.817	rs2036934	ENSG00000176343.5	RPL37AP8	3.65	0.000289	0.0334	0.17	0.17	Expressive vocabulary in infants;	chr11:112768683	chr11:111889199~111889474:-
HNSC	cis	rs494453	0.807	rs1324889	ENSG00000227811.2	FAM212B-AS1	3.65	0.000289	0.0334	0.19	0.17	Osteoporosis-related phenotypes;	chr1:111641018	chr1:111739841~111747798:+
HNSC	cis	rs7577696	0.962	rs2365555	ENSG00000272716.1	RP11-563N4.1	3.65	0.000289	0.0334	0.16	0.17	Inflammatory biomarkers;	chr2:32055630	chr2:32165046~32165757:-
HNSC	cis	rs2117029	0.586	rs7954521	ENSG00000258101.2	RP11-977B10.2	3.65	0.000289	0.0334	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49232790~49264756:-
HNSC	cis	rs2117029	0.553	rs2162644	ENSG00000258101.2	RP11-977B10.2	3.65	0.000289	0.0334	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49232790~49264756:-
HNSC	cis	rs8067545	0.667	rs7222403	ENSG00000266126.1	RP11-209D14.4	3.65	0.000289	0.0334	0.19	0.17	Schizophrenia;	chr17:19975851	chr17:19929372~19929737:-
HNSC	cis	rs8067545	0.72	rs6587206	ENSG00000266126.1	RP11-209D14.4	3.65	0.000289	0.0334	0.19	0.17	Schizophrenia;	chr17:19978274	chr17:19929372~19929737:-
HNSC	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-3.65	0.000289	0.0334	-0.17	-0.17	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
HNSC	cis	rs6919854	0.682	rs163980	ENSG00000270362.1	HMGN3-AS1	3.65	0.000289	0.0334	0.21	0.17	Daytime sleep phenotypes;	chr6:79896105	chr6:79233718~79236797:+
HNSC	cis	rs6570726	0.791	rs418701	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs1280275	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6900040	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6923074	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.755	rs2092296	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.755	rs2092297	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.755	rs2103633	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9373463	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.764	rs9322028	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs12205752	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9390336	ENSG00000270638.1	RP3-466P17.1	3.65	0.000289	0.0334	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145735570~145737218:+
HNSC	cis	rs2153535	0.561	rs2181194	ENSG00000230939.1	RP11-314C16.1	-3.65	0.000289	0.0334	-0.19	-0.17	Motion sickness;	chr6:8667318	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.561	rs9505511	ENSG00000230939.1	RP11-314C16.1	-3.65	0.000289	0.0334	-0.19	-0.17	Motion sickness;	chr6:8667322	chr6:8784178~8785445:+
HNSC	cis	rs9863	0.861	rs12301673	ENSG00000270028.1	RP11-380L11.4	3.65	0.000289	0.0334	0.2	0.17	White blood cell count;	chr12:123971271	chr12:123925461~123926083:-
HNSC	cis	rs6690583	0.512	rs7547224	ENSG00000223653.4	RP11-131L23.1	3.65	0.000289	0.0334	0.31	0.17	Serum sulfate level;	chr1:84991219	chr1:85276715~85448124:+
HNSC	cis	rs6690583	0.573	rs7547317	ENSG00000223653.4	RP11-131L23.1	3.65	0.000289	0.0334	0.31	0.17	Serum sulfate level;	chr1:84991278	chr1:85276715~85448124:+
HNSC	cis	rs3738443	0.951	rs61840056	ENSG00000259865.1	RP11-488L18.10	3.65	0.000289	0.0334	0.16	0.17	Alcohol dependence;	chr1:247205930	chr1:247187281~247188526:-
HNSC	cis	rs2657294	0.931	rs2804522	ENSG00000233313.2	HMGA1P5	-3.65	0.000289	0.0334	-0.18	-0.17	Pneumonia;	chr10:75159132	chr10:75276376~75276646:-
HNSC	cis	rs4295623	0.816	rs35558975	ENSG00000255310.2	AF131215.2	-3.65	0.000289	0.0334	-0.17	-0.17	Morning vs. evening chronotype;	chr8:11726967	chr8:11107788~11109726:-
HNSC	cis	rs4760636	1	rs2525042	ENSG00000268069.2	RP5-1057I20.4	3.65	0.000289	0.0334	0.2	0.17	Urate levels;	chr12:47781310	chr12:47784923~47786002:+
HNSC	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	3.65	0.000289	0.0334	0.11	0.17	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
HNSC	cis	rs17489649	1	rs2269207	ENSG00000271849.1	CTC-332L22.1	3.65	0.000289	0.0334	0.21	0.17	Intelligence (multi-trait analysis);	chr5:109787042	chr5:109687802~109688329:-
HNSC	cis	rs12745968	0.718	rs911523	ENSG00000223787.2	RP4-593M8.1	-3.65	0.000289	0.0334	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92696163	chr1:92580476~92580821:-
HNSC	cis	rs853679	0.607	rs34661125	ENSG00000280107.1	AL022393.9	-3.65	0.000289	0.0334	-0.29	-0.17	Depression;	chr6:28314117	chr6:28170845~28172521:+
HNSC	cis	rs853679	0.607	rs13190888	ENSG00000280107.1	AL022393.9	-3.65	0.000289	0.0334	-0.29	-0.17	Depression;	chr6:28318208	chr6:28170845~28172521:+
HNSC	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	3.65	0.000289	0.0334	0.13	0.17	Breast size;	chr12:9209254	chr12:9277235~9313241:+
HNSC	cis	rs17250963	0.589	rs1679140	ENSG00000249485.1	RBBP4P1	-3.65	0.000289	0.0334	-0.16	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14746169	chr5:14797125~14798400:-
HNSC	cis	rs9313772	0.775	rs4704936	ENSG00000254350.1	RP11-542A14.1	-3.65	0.000289	0.0334	-0.18	-0.17	Blood pressure;	chr5:158389037	chr5:158424585~158452758:+
HNSC	cis	rs4704187	0.687	rs7735937	ENSG00000272040.1	CTC-366B18.4	-3.65	0.000289	0.0334	-0.16	-0.17	Response to amphetamines;	chr5:75145875	chr5:75608817~75609983:+
HNSC	cis	rs9467773	0.572	rs9467737	ENSG00000241549.7	GUSBP2	3.65	0.000289	0.0334	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26381402	chr6:26871484~26956554:-
HNSC	cis	rs9929215	1	rs9929215	ENSG00000270020.1	RP11-463O9.9	-3.65	0.000289	0.0334	-0.42	-0.17	Colorectal cancer;	chr16:86487884	chr16:86520383~86523897:-
HNSC	cis	rs987724	0.515	rs4315647	ENSG00000243926.1	TIPARP-AS1	3.65	0.000289	0.0334	0.19	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156941199	chr3:156671862~156674378:-
HNSC	cis	rs17772222	1	rs12589467	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000289	0.0334	-0.21	-0.17	Coronary artery calcification;	chr14:88357239	chr14:88551597~88552493:+
HNSC	cis	rs1580019	0.813	rs2044839	ENSG00000226468.2	AC018641.7	-3.65	0.000289	0.0334	-0.23	-0.17	Cognitive ability;	chr7:32461193	chr7:32456963~32457758:-
HNSC	cis	rs9952991	0.883	rs2542148	ENSG00000260302.1	RP11-973H7.1	-3.65	0.000289	0.0334	-0.27	-0.17	Inflammatory skin disease;	chr18:12777574	chr18:12774651~12775923:-
HNSC	cis	rs6142618	0.84	rs2424879	ENSG00000275576.1	RP5-836N17.4	3.65	0.000289	0.0334	0.17	0.17	Inflammatory bowel disease;	chr20:32371901	chr20:32116171~32116629:+
HNSC	cis	rs58873874	0.737	rs11134766	ENSG00000248544.2	CTB-47B11.3	3.65	0.000289	0.0335	0.41	0.17	Bipolar disorder (body mass index interaction);	chr5:157481309	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs11466807	ENSG00000248544.2	CTB-47B11.3	3.65	0.000289	0.0335	0.41	0.17	Bipolar disorder (body mass index interaction);	chr5:157487920	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs111759027	ENSG00000248544.2	CTB-47B11.3	3.65	0.000289	0.0335	0.41	0.17	Bipolar disorder (body mass index interaction);	chr5:157489628	chr5:157375741~157384950:-
HNSC	cis	rs2975734	0.709	rs4841298	ENSG00000269918.1	AF131215.9	-3.65	0.000289	0.0335	-0.18	-0.17	Chronotype;Morning vs. evening chronotype;	chr8:10254127	chr8:11104691~11106704:-
HNSC	cis	rs6538678	0.833	rs10859966	ENSG00000199172.2	MIR331	3.65	0.000289	0.0335	0.18	0.17	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95308410~95308520:+
HNSC	cis	rs853679	0.546	rs200948	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000289	0.0335	-0.29	-0.17	Depression;	chr6:27867494	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs200950	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000289	0.0335	-0.29	-0.17	Depression;	chr6:27867994	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs200952	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000289	0.0335	-0.29	-0.17	Depression;	chr6:27869198	chr6:28115628~28116551:+
HNSC	cis	rs853679	0.546	rs200954	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000289	0.0335	-0.29	-0.17	Depression;	chr6:27870986	chr6:28115628~28116551:+
HNSC	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-3.65	0.000289	0.0335	-0.15	-0.17	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
HNSC	cis	rs8030379	1	rs1564474	ENSG00000230373.7	GOLGA6L5P	-3.65	0.000289	0.0335	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84507885~84516814:-
HNSC	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000289	0.0335	-0.2	-0.17	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
HNSC	cis	rs9611565	0.512	rs6519289	ENSG00000235513.1	RP4-756G23.5	-3.65	0.000289	0.0335	-0.21	-0.17	Vitiligo;	chr22:41774428	chr22:41209122~41217627:-
HNSC	cis	rs11168618	0.904	rs4359253	ENSG00000240399.1	RP1-228P16.1	3.65	0.000289	0.0335	0.14	0.17	Adiponectin levels;	chr12:48533925	chr12:48054813~48055591:-
HNSC	cis	rs8072100	0.544	rs9284377	ENSG00000263293.2	RP11-290H9.4	3.65	0.000289	0.0335	0.18	0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47303460~47323613:-
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000260091.1	RP11-33B1.4	3.65	0.000289	0.0335	0.16	0.17	Corneal astigmatism;	chr4:119359886	chr4:119409333~119410233:+
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000260091.1	RP11-33B1.4	3.65	0.000289	0.0335	0.16	0.17	Corneal astigmatism;	chr4:119359887	chr4:119409333~119410233:+
HNSC	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000289	0.0335	-0.21	-0.17	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
HNSC	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-3.65	0.000289	0.0335	-0.17	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
HNSC	cis	rs8062405	1	rs62037365	ENSG00000261089.1	RP11-435I10.3	3.65	0.00029	0.0335	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28413703~28415018:+
HNSC	cis	rs17014483	0.749	rs3017899	ENSG00000248019.2	FAM13A-AS1	-3.65	0.00029	0.0335	-0.2	-0.17	Post bronchodilator FEV1/FVC ratio;	chr4:88722846	chr4:88709789~88730103:+
HNSC	cis	rs11157436	0.602	rs11157437	ENSG00000211814.1	TRAV35	-3.65	0.00029	0.0335	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22221896~22222475:+
HNSC	cis	rs4144743	1	rs4541130	ENSG00000228782.6	CTD-2026D20.3	-3.65	0.00029	0.0335	-0.19	-0.17	Body mass index;	chr17:47243671	chr17:47450568~47492492:-
HNSC	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	3.65	0.00029	0.0335	0.21	0.17	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
HNSC	cis	rs7824557	0.527	rs2572448	ENSG00000255495.1	AC145124.2	-3.65	0.00029	0.0335	-0.19	-0.17	Retinal vascular caliber;	chr8:11381843	chr8:12194467~12196280:+
HNSC	cis	rs67839313	0.748	rs961090	ENSG00000259330.1	INAFM2	3.65	0.00029	0.0335	0.24	0.17	Type 2 diabetes;	chr15:40325213	chr15:40325216~40326715:+
HNSC	cis	rs1908814	0.541	rs7824267	ENSG00000227888.4	FAM66A	3.65	0.00029	0.0335	0.17	0.17	Neuroticism;	chr8:11936770	chr8:12362019~12388296:+
HNSC	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-3.65	0.00029	0.0335	-0.21	-0.17	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
HNSC	cis	rs8058578	0.832	rs35969813	ENSG00000279196.1	RP11-1072A3.3	3.65	0.00029	0.0335	0.21	0.17	Multiple myeloma;	chr16:30703096	chr16:30984630~30988270:-
HNSC	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-3.65	0.00029	0.0335	-0.21	-0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
HNSC	cis	rs7824557	0.527	rs2572369	ENSG00000255495.1	AC145124.2	-3.65	0.00029	0.0335	-0.19	-0.17	Retinal vascular caliber;	chr8:11381088	chr8:12194467~12196280:+
HNSC	cis	rs9311474	0.508	rs7625743	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.16	-0.17	Electroencephalogram traits;	chr3:52572350	chr3:52239258~52241097:+
HNSC	cis	rs9311474	0.508	rs6805156	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.16	-0.17	Electroencephalogram traits;	chr3:52575346	chr3:52239258~52241097:+
HNSC	cis	rs9311474	0.508	rs7652191	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.16	-0.17	Electroencephalogram traits;	chr3:52576399	chr3:52239258~52241097:+
HNSC	cis	rs1008375	1	rs7654345	ENSG00000249502.1	AC006160.5	-3.65	0.00029	0.0335	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690173	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs10939749	ENSG00000249502.1	AC006160.5	-3.65	0.00029	0.0335	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690696	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698648	ENSG00000249502.1	AC006160.5	-3.65	0.00029	0.0335	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691092	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698649	ENSG00000249502.1	AC006160.5	-3.65	0.00029	0.0335	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691159	chr4:17587467~17614571:-
HNSC	cis	rs74781061	0.872	rs4886598	ENSG00000260103.2	RP11-10O17.1	-3.65	0.00029	0.0335	-0.19	-0.17	Endometriosis;	chr15:74484441	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.872	rs6495106	ENSG00000260103.2	RP11-10O17.1	-3.65	0.00029	0.0335	-0.19	-0.17	Endometriosis;	chr15:74487006	chr15:74478070~74490286:-
HNSC	cis	rs7572733	0.576	rs4850441	ENSG00000231621.1	AC013264.2	3.65	0.00029	0.0335	0.16	0.17	Dermatomyositis;	chr2:198048689	chr2:197197991~197199273:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000272831.1	RP11-792A8.4	-3.65	0.00029	0.0335	-0.14	-0.17	Aortic root size;	chr7:66595421	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000272831.1	RP11-792A8.4	-3.65	0.00029	0.0335	-0.14	-0.17	Aortic root size;	chr7:66598087	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs801192	ENSG00000273142.1	RP11-458F8.4	3.65	0.00029	0.0335	0.14	0.17	Aortic root size;	chr7:66566965	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs801190	ENSG00000273142.1	RP11-458F8.4	3.65	0.00029	0.0335	0.14	0.17	Aortic root size;	chr7:66568046	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs3857686	ENSG00000273142.1	RP11-458F8.4	3.65	0.00029	0.0335	0.14	0.17	Aortic root size;	chr7:66571204	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.638	rs3898855	ENSG00000273142.1	RP11-458F8.4	3.65	0.00029	0.0335	0.14	0.17	Aortic root size;	chr7:66571411	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.638	rs10278816	ENSG00000273142.1	RP11-458F8.4	3.65	0.00029	0.0335	0.14	0.17	Aortic root size;	chr7:66572000	chr7:66902857~66906297:+
HNSC	cis	rs7824557	0.527	rs2736298	ENSG00000255495.1	AC145124.2	-3.65	0.00029	0.0335	-0.18	-0.17	Retinal vascular caliber;	chr8:11377627	chr8:12194467~12196280:+
HNSC	cis	rs3771180	0.505	rs2160203	ENSG00000234389.1	AC007278.3	3.65	0.00029	0.0335	0.19	0.17	Asthma;	chr2:102344364	chr2:102438713~102440475:+
HNSC	cis	rs36715	1	rs181850	ENSG00000245937.6	LINC01184	3.65	0.00029	0.0335	0.21	0.17	Breast cancer;	chr5:128211795	chr5:127940426~128083172:-
HNSC	cis	rs490608	0.628	rs678157	ENSG00000225855.5	RUSC1-AS1	3.65	0.00029	0.0335	0.11	0.17	Inflammatory bowel disease;	chr1:155688550	chr1:155316863~155324176:-
HNSC	cis	rs868153	0.625	rs1379090	ENSG00000275339.1	RP3-425C14.6	3.65	0.00029	0.0335	0.18	0.17	Vertical cup-disc ratio;	chr6:122218236	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs12664221	ENSG00000275339.1	RP3-425C14.6	3.65	0.00029	0.0335	0.18	0.17	Vertical cup-disc ratio;	chr6:122225172	chr6:122454358~122454612:+
HNSC	cis	rs9487051	0.714	rs6902892	ENSG00000219700.1	PTCHD3P3	3.65	0.00029	0.0335	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109306398	chr6:109288571~109290503:-
HNSC	cis	rs28830936	1	rs12441300	ENSG00000250379.1	RP11-23P13.4	3.65	0.00029	0.0335	0.2	0.17	Diastolic blood pressure;	chr15:41810647	chr15:41825099~41827936:-
HNSC	cis	rs11651000	0.895	rs79065115	ENSG00000228782.6	CTD-2026D20.3	-3.65	0.00029	0.0335	-0.22	-0.17	IgG glycosylation;	chr17:47778563	chr17:47450568~47492492:-
HNSC	cis	rs6840360	0.642	rs2709817	ENSG00000251611.1	RP11-610P16.1	-3.65	0.00029	0.0335	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs2709818	ENSG00000251611.1	RP11-610P16.1	-3.65	0.00029	0.0335	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151407551~151408835:-
HNSC	cis	rs4841097	0.806	rs6992247	ENSG00000254340.1	RP11-10A14.3	3.65	0.00029	0.0335	0.2	0.17	Platelet distribution width;	chr8:9090959	chr8:9141424~9145435:+
HNSC	cis	rs2976388	0.967	rs2978981	ENSG00000253741.1	CTD-2292P10.4	3.65	0.00029	0.0335	0.16	0.17	Urinary tract infection frequency;	chr8:142677719	chr8:142702252~142726973:-
HNSC	cis	rs988913	0.678	rs4275060	ENSG00000224984.1	RP11-524H19.2	3.65	0.00029	0.0335	0.2	0.17	Menarche (age at onset);	chr6:55131783	chr6:54840118~54840855:-
HNSC	cis	rs4493873	0.812	rs10956792	ENSG00000253738.1	OTUD6B-AS1	-3.65	0.00029	0.0335	-0.17	-0.17	Migraine - clinic-based;	chr8:91097510	chr8:91059909~91070189:-
HNSC	cis	rs7224668	0.564	rs9894535	ENSG00000280407.2	RP13-516M14.8	3.65	0.00029	0.0335	0.14	0.17	IgG glycosylation;	chr17:81279117	chr17:82249067~82251844:+
HNSC	cis	rs860295	0.702	rs12067371	ENSG00000225855.5	RUSC1-AS1	3.65	0.00029	0.0335	0.11	0.17	Body mass index;	chr1:155467878	chr1:155316863~155324176:-
HNSC	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	3.65	0.00029	0.0335	0.2	0.17	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
HNSC	cis	rs11711311	0.955	rs1048892	ENSG00000241529.3	RN7SL767P	-3.65	0.00029	0.0335	-0.21	-0.17	IgG glycosylation;	chr3:113746012	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs3806641	ENSG00000241529.3	RN7SL767P	-3.65	0.00029	0.0335	-0.21	-0.17	IgG glycosylation;	chr3:113746914	chr3:113632704~113632998:+
HNSC	cis	rs11225055	0.588	rs11225085	ENSG00000254506.1	RP11-748H22.1	-3.65	0.00029	0.0335	-0.39	-0.17	Response to methotrexate in juvenile idiopathic arthritis;	chr11:101955231	chr11:101584295~101595156:+
HNSC	cis	rs6095360	1	rs6019600	ENSG00000227431.4	CSE1L-AS1	-3.65	0.00029	0.0336	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:49030395	chr20:49040463~49046044:-
HNSC	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-3.65	0.00029	0.0336	-0.26	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
HNSC	cis	rs599083	0.573	rs3018713	ENSG00000255031.4	RP11-802E16.3	3.65	0.00029	0.0336	0.14	0.17	Bone mineral density (spine);	chr11:68623518	chr11:68050740~68053762:+
HNSC	cis	rs2013441	1	rs2526462	ENSG00000261033.1	RP11-209D14.2	3.65	0.00029	0.0336	0.19	0.17	Obesity-related traits;	chr17:20176147	chr17:20008051~20009234:-
HNSC	cis	rs8030379	0.967	rs2401171	ENSG00000230373.7	GOLGA6L5P	-3.65	0.00029	0.0336	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83888924	chr15:84507885~84516814:-
HNSC	cis	rs17122278	1	rs73022058	ENSG00000255422.1	AP002954.4	3.65	0.00029	0.0336	0.3	0.17	Total cholesterol levels;	chr11:118552957	chr11:118704607~118750263:+
HNSC	cis	rs4578769	0.55	rs4517887	ENSG00000265943.1	RP11-739L10.1	-3.65	0.000291	0.0336	-0.2	-0.17	Eosinophil percentage of white cells;	chr18:22994715	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.55	rs4635434	ENSG00000265943.1	RP11-739L10.1	-3.65	0.000291	0.0336	-0.2	-0.17	Eosinophil percentage of white cells;	chr18:22996032	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.55	rs4471804	ENSG00000265943.1	RP11-739L10.1	-3.65	0.000291	0.0336	-0.2	-0.17	Eosinophil percentage of white cells;	chr18:22996218	chr18:22699481~22933764:-
HNSC	cis	rs394563	0.601	rs439495	ENSG00000216906.2	RP11-350J20.9	-3.65	0.000291	0.0336	-0.22	-0.17	Dupuytren's disease;	chr6:149472088	chr6:149904243~149906418:+
HNSC	cis	rs12234571	1	rs73375848	ENSG00000214293.7	APTR	3.65	0.000291	0.0336	0.24	0.17	Obesity-related traits;	chr7:77885873	chr7:77657660~77696265:-
HNSC	cis	rs8089099	0.546	rs529827	ENSG00000273352.1	RP11-61L19.3	-3.65	0.000291	0.0336	-0.19	-0.17	Pulmonary function (smoking interaction);	chr18:10086383	chr18:9519449~9520199:+
HNSC	cis	rs6693388	0.789	rs16833743	ENSG00000229021.2	AL591893.1	-3.65	0.000291	0.0336	-0.19	-0.17	Blood metabolite ratios;	chr1:151992403	chr1:151994531~152042774:+
HNSC	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	3.65	0.000291	0.0336	0.13	0.17	Breast size;	chr12:9232743	chr12:9277235~9313241:+
HNSC	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-3.65	0.000291	0.0336	-0.28	-0.17	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
HNSC	cis	rs9987353	0.544	rs2929469	ENSG00000254153.1	CTA-398F10.2	3.65	0.000291	0.0336	0.19	0.17	Recombination measurement;	chr8:9205146	chr8:8456909~8461337:-
HNSC	cis	rs896655	0.631	rs12555601	ENSG00000244230.3	RN7SL151P	3.65	0.000291	0.0336	0.18	0.17	Coronary artery disease;	chr9:21744790	chr9:21699314~21699596:+
HNSC	cis	rs801193	1	rs10234018	ENSG00000273142.1	RP11-458F8.4	3.65	0.000291	0.0336	0.14	0.17	Aortic root size;	chr7:66681297	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs3778909	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000291	0.0336	-0.14	-0.17	Aortic root size;	chr7:66790659	chr7:66902857~66906297:+
HNSC	cis	rs832540	0.629	rs10940512	ENSG00000225230.1	AC008937.3	3.65	0.000291	0.0336	0.18	0.17	Coronary artery disease;	chr5:56786267	chr5:56900041~56910714:-
HNSC	cis	rs5758511	0.773	rs12167978	ENSG00000226450.2	CYP2D8P	3.65	0.000291	0.0336	0.15	0.17	Birth weight;	chr22:41950471	chr22:42149886~42155001:-
HNSC	cis	rs10971721	0.584	rs56145814	ENSG00000260947.1	RP11-384P7.7	3.65	0.000291	0.0336	0.3	0.17	Body mass index;	chr9:34088953	chr9:33697459~33700986:+
HNSC	cis	rs12887734	0.524	rs12588797	ENSG00000269940.1	RP11-73M18.7	-3.65	0.000291	0.0336	-0.16	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103694560~103695170:+
HNSC	cis	rs74922337	0.772	rs4402447	ENSG00000231530.1	RP11-187A9.3	-3.65	0.000291	0.0336	-0.33	-0.17	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:41410606	chr13:42043727~42044247:-
HNSC	cis	rs870825	0.616	rs6843185	ENSG00000254233.1	RP11-242J7.1	3.65	0.000291	0.0336	0.24	0.17	Blood protein levels;	chr4:184728724	chr4:184584093~184625030:-
HNSC	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	3.65	0.000291	0.0336	0.2	0.17	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
HNSC	cis	rs7107174	0.711	rs66583694	ENSG00000251323.2	RP11-452H21.4	3.65	0.000291	0.0336	0.23	0.17	Testicular germ cell tumor;	chr11:78326727	chr11:78423982~78429836:-
HNSC	cis	rs9650657	0.812	rs11250074	ENSG00000255310.2	AF131215.2	-3.65	0.000291	0.0336	-0.16	-0.17	Neuroticism;	chr8:10774749	chr8:11107788~11109726:-
HNSC	cis	rs7772486	0.686	rs1292337	ENSG00000270638.1	RP3-466P17.1	-3.65	0.000291	0.0336	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs857879	ENSG00000270638.1	RP3-466P17.1	-3.65	0.000291	0.0336	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145735570~145737218:+
HNSC	cis	rs11509153	0.648	rs2160269	ENSG00000226690.5	AC005281.1	3.65	0.000291	0.0336	0.18	0.17	Residual cognition;	chr7:12208081	chr7:12496429~12541910:+
HNSC	cis	rs11168618	0.904	rs7137866	ENSG00000240399.1	RP1-228P16.1	3.65	0.000291	0.0336	0.14	0.17	Adiponectin levels;	chr12:48529019	chr12:48054813~48055591:-
HNSC	cis	rs9487051	0.698	rs59502176	ENSG00000243587.6	C6orf183	-3.65	0.000291	0.0336	-0.17	-0.17	Reticulocyte fraction of red cells;	chr6:109323516	chr6:109165833~109271014:+
HNSC	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21337882	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs4429400	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21338163	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs1932087	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21338625	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs11671609	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21342769	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.793	rs62109212	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21343716	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs57250002	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21344048	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62109218	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21346059	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62109223	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21349591	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62109225	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21353861	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.754	rs62109226	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21354111	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.754	rs62109227	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21354128	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.754	rs62109228	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21354129	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs8102783	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21355751	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs2061916	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21358906	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs4359573	ENSG00000268081.1	RP11-678G14.2	3.65	0.000291	0.0336	0.24	0.17	Pain;	chr19:21359494	chr19:21554640~21569237:-
HNSC	cis	rs7646881	0.544	rs16847135	ENSG00000272087.1	RP11-379F4.7	3.65	0.000291	0.0336	0.24	0.17	Tetralogy of Fallot;	chr3:158706064	chr3:158693120~158693768:-
HNSC	cis	rs3929778	0.816	rs6085604	ENSG00000278192.1	RP5-1056H1.2	-3.65	0.000291	0.0336	-0.23	-0.17	QRS complex (Cornell);	chr20:6569306	chr20:6065966~6067897:-
HNSC	cis	rs116095464	1	rs6879758	ENSG00000250848.1	CTD-2083E4.5	-3.65	0.000291	0.0336	-0.32	-0.17	Breast cancer;	chr5:350162	chr5:288833~290321:-
HNSC	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000291	0.0336	-0.24	-0.17	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000291	0.0336	-0.24	-0.17	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000291	0.0336	-0.24	-0.17	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
HNSC	cis	rs17711722	0.565	rs4717276	ENSG00000213640.3	EEF1DP4	-3.65	0.000291	0.0336	-0.21	-0.17	Calcium levels;	chr7:65829754	chr7:64862999~64864370:+
HNSC	cis	rs4704187	0.687	rs10050948	ENSG00000272040.1	CTC-366B18.4	-3.65	0.000291	0.0336	-0.15	-0.17	Response to amphetamines;	chr5:75188450	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs1345704	ENSG00000272040.1	CTC-366B18.4	-3.65	0.000291	0.0336	-0.15	-0.17	Response to amphetamines;	chr5:75194173	chr5:75608817~75609983:+
HNSC	cis	rs17253792	0.915	rs75296402	ENSG00000186615.9	KTN1-AS1	-3.65	0.000291	0.0336	-0.34	-0.17	Putamen volume;	chr14:55715773	chr14:55499278~55580110:-
HNSC	cis	rs71520386	0.796	rs71520381	ENSG00000230658.1	KLHL7-AS1	3.65	0.000291	0.0336	0.26	0.17	Fibrinogen levels;	chr7:22776388	chr7:23101228~23105703:-
HNSC	cis	rs36093844	0.527	rs111552865	ENSG00000279742.1	RP11-700A24.1	-3.65	0.000291	0.0336	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86049069	chr11:85852557~85854943:-
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000106610.13	STAG3L4	3.65	0.000291	0.0336	0.22	0.17	Aortic root size;	chr7:66325720	chr7:67302621~67321526:+
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000106610.13	STAG3L4	3.65	0.000291	0.0336	0.22	0.17	Aortic root size;	chr7:66330724	chr7:67302621~67321526:+
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000106610.13	STAG3L4	3.65	0.000291	0.0336	0.22	0.17	Aortic root size;	chr7:66331087	chr7:67302621~67321526:+
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000106610.13	STAG3L4	3.65	0.000291	0.0336	0.22	0.17	Aortic root size;	chr7:66343621	chr7:67302621~67321526:+
HNSC	cis	rs875971	0.862	rs778736	ENSG00000106610.13	STAG3L4	-3.65	0.000291	0.0336	-0.22	-0.17	Aortic root size;	chr7:66348861	chr7:67302621~67321526:+
HNSC	cis	rs9487051	0.714	rs9487058	ENSG00000219700.1	PTCHD3P3	3.65	0.000291	0.0337	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109309857	chr6:109288571~109290503:-
HNSC	cis	rs3771570	1	rs56383420	ENSG00000260942.1	CAPN10-AS1	-3.65	0.000291	0.0337	-0.19	-0.17	Prostate cancer;	chr2:241279866	chr2:240582700~240586699:-
HNSC	cis	rs3771570	0.786	rs62186396	ENSG00000260942.1	CAPN10-AS1	-3.65	0.000291	0.0337	-0.19	-0.17	Prostate cancer;	chr2:241281804	chr2:240582700~240586699:-
HNSC	cis	rs7703051	0.775	rs2335418	ENSG00000271815.1	CTD-2235C13.3	3.65	0.000291	0.0337	0.2	0.17	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75307654	chr5:75363760~75364242:+
HNSC	cis	rs868153	0.625	rs35735278	ENSG00000275339.1	RP3-425C14.6	3.65	0.000292	0.0337	0.18	0.17	Vertical cup-disc ratio;	chr6:122187551	chr6:122454358~122454612:+
HNSC	cis	rs2904524	1	rs58974570	ENSG00000257815.4	RP11-611E13.2	-3.65	0.000292	0.0337	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70363568	chr12:69904033~70243360:-
HNSC	cis	rs7674212	0.539	rs6815783	ENSG00000251288.2	RP11-10L12.2	-3.65	0.000292	0.0337	-0.19	-0.17	Type 2 diabetes;	chr4:103200989	chr4:102751401~102752641:+
HNSC	cis	rs871012	0.524	rs11952499	ENSG00000251405.2	CTB-109A12.1	-3.65	0.000292	0.0337	-0.2	-0.17	IgG glycosylation;	chr5:157455626	chr5:157362615~157460078:-
HNSC	cis	rs4372836	0.928	rs55836936	ENSG00000226833.4	AC097724.3	-3.65	0.000292	0.0337	-0.21	-0.17	Body mass index;	chr2:28699967	chr2:28708953~28736205:-
HNSC	cis	rs2300747	0.872	rs10754445	ENSG00000177173.5	NAP1L4P1	-3.65	0.000292	0.0337	-0.3	-0.17	Primary biliary cholangitis;Multiple sclerosis;	chr1:116534837	chr1:116532936~116534092:-
HNSC	cis	rs5758659	0.714	rs133376	ENSG00000273366.1	CTA-989H11.1	-3.65	0.000292	0.0337	-0.2	-0.17	Cognitive function;	chr22:42070901	chr22:42278188~42278846:+
HNSC	cis	rs5758659	0.653	rs133383	ENSG00000273366.1	CTA-989H11.1	-3.65	0.000292	0.0337	-0.2	-0.17	Cognitive function;	chr22:42077599	chr22:42278188~42278846:+
HNSC	cis	rs6071166	0.935	rs6071146	ENSG00000224635.1	RP4-564F22.5	3.65	0.000292	0.0337	0.2	0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38699962	chr20:38406011~38416797:-
HNSC	cis	rs4489787	0.892	rs2705161	ENSG00000257763.1	OR5BK1P	3.65	0.000292	0.0337	0.26	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48506683	chr12:48355792~48356614:-
HNSC	cis	rs170183	0.934	rs35734452	ENSG00000230479.1	AP000695.6	-3.65	0.000292	0.0337	-0.17	-0.17	Bone mineral density;	chr21:36483703	chr21:36430360~36481070:+
HNSC	cis	rs8181477	1	rs11014504	ENSG00000240291.1	RP11-499P20.2	-3.65	0.000292	0.0337	-0.14	-0.17	Obesity-related traits;	chr10:18495059	chr10:18513115~18545651:-
HNSC	cis	rs1218582	0.682	rs12144978	ENSG00000270361.1	RP11-307C12.13	-3.65	0.000292	0.0337	-0.19	-0.17	Prostate cancer;	chr1:154877969	chr1:154937370~154938059:+
HNSC	cis	rs7023329	0.59	rs2184551	ENSG00000229835.2	KHSRPP1	-3.65	0.000292	0.0337	-0.17	-0.17	Melanoma;	chr9:21773223	chr9:21695176~21696943:+
HNSC	cis	rs6430585	0.528	rs114760827	ENSG00000231890.6	DARS-AS1	-3.65	0.000292	0.0337	-0.29	-0.17	Corneal structure;	chr2:135903540	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs79826902	ENSG00000231890.6	DARS-AS1	-3.65	0.000292	0.0337	-0.29	-0.17	Corneal structure;	chr2:135912849	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs16832205	ENSG00000231890.6	DARS-AS1	-3.65	0.000292	0.0337	-0.29	-0.17	Corneal structure;	chr2:135927062	chr2:135985176~136022593:+
HNSC	cis	rs482329	0.719	rs534978	ENSG00000224939.1	LINC00184	3.65	0.000292	0.0337	0.21	0.17	Life threatening arrhythmia;	chr1:234672526	chr1:234629311~234634780:+
HNSC	cis	rs2115630	0.764	rs11073716	ENSG00000259295.5	CSPG4P12	-3.65	0.000292	0.0337	-0.2	-0.17	P wave terminal force;	chr15:84792543	chr15:85191438~85213905:+
HNSC	cis	rs10903027	0.727	rs12040971	ENSG00000261349.1	RP3-465N24.5	-3.65	0.000292	0.0337	-0.21	-0.17	IgG glycosylation;	chr1:25077618	chr1:25266102~25267136:-
HNSC	cis	rs11951515	0.638	rs10065852	ENSG00000249286.1	CTD-2210P15.2	3.65	0.000292	0.0337	0.18	0.17	Metabolite levels  (X-11787);	chr5:43342063	chr5:43586918~43588223:-
HNSC	cis	rs7189233	0.531	rs17801498	ENSG00000261056.2	RP11-454F8.2	-3.65	0.000292	0.0337	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53298224~53299792:+
HNSC	cis	rs9611565	0.503	rs5751156	ENSG00000235513.1	RP4-756G23.5	-3.65	0.000292	0.0337	-0.21	-0.17	Vitiligo;	chr22:41774021	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.571	rs2050032	ENSG00000235513.1	RP4-756G23.5	-3.65	0.000292	0.0337	-0.19	-0.17	Vitiligo;	chr22:41756425	chr22:41209122~41217627:-
HNSC	cis	rs5758659	1	rs134882	ENSG00000270083.1	RP1-257I20.14	3.65	0.000292	0.0337	0.15	0.17	Cognitive function;	chr22:42274959	chr22:42089630~42090028:-
HNSC	cis	rs6988985	0.765	rs28753687	ENSG00000247317.3	RP11-273G15.2	-3.65	0.000292	0.0337	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906961	chr8:142981738~143018437:-
HNSC	cis	rs1979679	0.744	rs2348236	ENSG00000247934.4	RP11-967K21.1	3.65	0.000292	0.0337	0.18	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28163298~28190738:-
HNSC	cis	rs8030379	1	rs1564473	ENSG00000230373.7	GOLGA6L5P	-3.65	0.000292	0.0338	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84507885~84516814:-
HNSC	cis	rs6095360	1	rs6019535	ENSG00000227431.4	CSE1L-AS1	-3.65	0.000292	0.0338	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48924980	chr20:49040463~49046044:-
HNSC	cis	rs7615952	0.599	rs16834938	ENSG00000241278.1	ENPP7P4	-3.65	0.000292	0.0338	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125987203	chr3:125848223~125909372:+
HNSC	cis	rs6430585	0.583	rs4594504	ENSG00000231890.6	DARS-AS1	-3.65	0.000293	0.0338	-0.29	-0.17	Corneal structure;	chr2:135867543	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.583	rs3769001	ENSG00000231890.6	DARS-AS1	-3.65	0.000293	0.0338	-0.29	-0.17	Corneal structure;	chr2:135868508	chr2:135985176~136022593:+
HNSC	cis	rs13385	0.553	rs13179861	ENSG00000254363.5	CTB-131B5.5	3.65	0.000293	0.0338	0.24	0.17	Atrial fibrillation;	chr5:140148136	chr5:140157319~140173051:+
HNSC	cis	rs17495987	0.63	rs17562406	ENSG00000219545.8	UMAD1	3.65	0.000293	0.0338	0.22	0.17	Tonsillectomy;	chr7:7868699	chr7:7640711~8004059:+
HNSC	cis	rs7824557	0.751	rs2099456	ENSG00000270076.1	AF131215.8	3.65	0.000293	0.0338	0.19	0.17	Retinal vascular caliber;	chr8:11269492	chr8:11202965~11203671:+
HNSC	cis	rs1155750	0.72	rs171226	ENSG00000224984.1	RP11-524H19.2	-3.65	0.000293	0.0338	-0.24	-0.17	Colorectal cancer;	chr6:54908276	chr6:54840118~54840855:-
HNSC	cis	rs890448	0.726	rs2850367	ENSG00000254531.1	FLJ20021	-3.65	0.000293	0.0338	-0.17	-0.17	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101310306	chr4:101347780~101348883:+
HNSC	cis	rs17772222	1	rs17698817	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000293	0.0338	-0.21	-0.17	Coronary artery calcification;	chr14:88356632	chr14:88551597~88552493:+
HNSC	cis	rs6964587	0.839	rs6949700	ENSG00000188693.7	CYP51A1-AS1	-3.65	0.000293	0.0338	-0.17	-0.17	Breast cancer;	chr7:91838121	chr7:92134604~92180725:+
HNSC	cis	rs34286592	0.929	rs11863748	ENSG00000214725.6	CDIPT-AS1	-3.65	0.000293	0.0338	-0.23	-0.17	Multiple sclerosis;	chr16:29824267	chr16:29863593~29868053:+
HNSC	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-3.65	0.000293	0.0338	-0.17	-0.17	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
HNSC	cis	rs4253772	0.591	rs6007732	ENSG00000277232.2	GTSE1-AS1	-3.65	0.000293	0.0338	-0.2	-0.17	Cholesterol, total;LDL cholesterol;	chr22:46256406	chr22:46295143~46296660:-
HNSC	cis	rs6988985	0.693	rs6395	ENSG00000247317.3	RP11-273G15.2	-3.65	0.000293	0.0338	-0.18	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142875392	chr8:142981738~143018437:-
HNSC	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-3.65	0.000293	0.0338	-0.2	-0.17	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
HNSC	cis	rs11846409	0.932	rs60659763	ENSG00000280411.1	IGHV1-69-2	-3.65	0.000293	0.0338	-0.15	-0.17	Rheumatic heart disease;	chr14:106634172	chr14:106762092~106762588:-
HNSC	cis	rs11846409	0.932	rs57080270	ENSG00000280411.1	IGHV1-69-2	-3.65	0.000293	0.0338	-0.15	-0.17	Rheumatic heart disease;	chr14:106634215	chr14:106762092~106762588:-
HNSC	cis	rs11846409	0.932	rs60917084	ENSG00000280411.1	IGHV1-69-2	-3.65	0.000293	0.0338	-0.15	-0.17	Rheumatic heart disease;	chr14:106634621	chr14:106762092~106762588:-
HNSC	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	3.65	0.000293	0.0338	0.2	0.17	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
HNSC	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	3.65	0.000293	0.0338	0.21	0.17	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
HNSC	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-3.65	0.000293	0.0338	-0.17	-0.17	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
HNSC	cis	rs6012564	0.928	rs1043357	ENSG00000227431.4	CSE1L-AS1	3.65	0.000293	0.0338	0.19	0.17	Anger;	chr20:49114691	chr20:49040463~49046044:-
HNSC	cis	rs6968419	1	rs4082046	ENSG00000237870.5	AC073130.1	3.65	0.000293	0.0338	0.19	0.17	Intraocular pressure;	chr7:116177133	chr7:116275606~116286734:-
HNSC	cis	rs9863	0.861	rs77020228	ENSG00000270028.1	RP11-380L11.4	3.65	0.000293	0.0339	0.2	0.17	White blood cell count;	chr12:123933925	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.861	rs11057396	ENSG00000270028.1	RP11-380L11.4	3.65	0.000293	0.0339	0.2	0.17	White blood cell count;	chr12:123934515	chr12:123925461~123926083:-
HNSC	cis	rs2253762	0.527	rs11200323	ENSG00000276742.1	RP11-500G22.4	-3.65	0.000293	0.0339	-0.21	-0.17	Breast cancer;	chr10:122008869	chr10:121956782~121957098:+
HNSC	cis	rs3736485	0.738	rs930920	ENSG00000274528.1	CTD-2650P22.2	3.65	0.000294	0.0339	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51457529	chr15:52017167~52018032:-
HNSC	cis	rs13434995	0.589	rs62305201	ENSG00000249700.7	SRD5A3-AS1	-3.65	0.000294	0.0339	-0.22	-0.17	Adiponectin levels;	chr4:55386778	chr4:55363971~55395847:-
HNSC	cis	rs13434995	0.589	rs62305202	ENSG00000249700.7	SRD5A3-AS1	-3.65	0.000294	0.0339	-0.22	-0.17	Adiponectin levels;	chr4:55386861	chr4:55363971~55395847:-
HNSC	cis	rs1440410	0.798	rs1605581	ENSG00000250326.1	RP11-284M14.1	-3.65	0.000294	0.0339	-0.19	-0.17	Ischemic stroke;	chr4:143245634	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs1039763	ENSG00000250326.1	RP11-284M14.1	-3.65	0.000294	0.0339	-0.19	-0.17	Ischemic stroke;	chr4:143246860	chr4:142933195~143184861:-
HNSC	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	3.65	0.000294	0.0339	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
HNSC	cis	rs11668609	1	rs12609544	ENSG00000268442.1	CTD-2027I19.2	3.65	0.000294	0.0339	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24142763	chr19:24162370~24163425:-
HNSC	cis	rs4843747	0.573	rs7499959	ENSG00000205037.2	RP11-863P13.4	3.65	0.000294	0.0339	0.19	0.17	Menopause (age at onset);	chr16:88076816	chr16:88088041~88100985:-
HNSC	cis	rs911555	0.755	rs11627446	ENSG00000244691.1	RPL10AP1	-3.65	0.000294	0.0339	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103412119~103412761:-
HNSC	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-3.65	0.000294	0.0339	-0.15	-0.17	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
HNSC	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-3.65	0.000294	0.0339	-0.17	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
HNSC	cis	rs12817549	0.817	rs7954185	ENSG00000213250.5	RBMS2P1	-3.65	0.000294	0.0339	-0.15	-0.17	Hip circumference adjusted for BMI;	chr12:93702397	chr12:94423744~94424969:-
HNSC	cis	rs686320	1	rs1787666	ENSG00000245532.5	NEAT1	3.65	0.000294	0.0339	0.18	0.17	Hip circumference adjusted for BMI;	chr11:65481618	chr11:65422774~65445540:+
HNSC	cis	rs7771547	0.573	rs546272	ENSG00000219023.1	RP3-340B19.2	3.65	0.000294	0.0339	0.15	0.17	Platelet distribution width;	chr6:36430785	chr6:35555873~35556264:+
HNSC	cis	rs875971	0.862	rs778720	ENSG00000229886.1	RP5-1132H15.3	-3.65	0.000294	0.0339	-0.18	-0.17	Aortic root size;	chr7:66381288	chr7:66025126~66031544:-
HNSC	cis	rs193541	0.509	rs7720862	ENSG00000260686.1	CTB-36H16.2	-3.65	0.000294	0.0339	-0.15	-0.17	Glucose homeostasis traits;	chr5:122832420	chr5:122832356~122834533:+
HNSC	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	3.65	0.000294	0.0339	0.17	0.17	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
HNSC	cis	rs6570726	0.738	rs6925594	ENSG00000270638.1	RP3-466P17.1	3.65	0.000294	0.0339	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs11155432	ENSG00000270638.1	RP3-466P17.1	3.65	0.000294	0.0339	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6913727	ENSG00000270638.1	RP3-466P17.1	3.65	0.000294	0.0339	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs10872577	ENSG00000270638.1	RP3-466P17.1	3.65	0.000294	0.0339	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145735570~145737218:+
HNSC	cis	rs73198271	1	rs4841031	ENSG00000253893.2	FAM85B	3.65	0.000294	0.0339	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:8167819~8226614:-
HNSC	cis	rs73198271	1	rs11784958	ENSG00000253893.2	FAM85B	3.65	0.000294	0.0339	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8167819~8226614:-
HNSC	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-3.65	0.000294	0.0339	-0.19	-0.17	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
HNSC	cis	rs886774	0.774	rs4730281	ENSG00000273055.1	CTB-13F3.1	3.65	0.000294	0.0339	0.17	0.17	Ulcerative colitis;	chr7:107941491	chr7:107942116~107942740:+
HNSC	cis	rs9611565	0.532	rs4401299	ENSG00000233903.2	Z83851.4	3.65	0.000294	0.0339	0.23	0.17	Vitiligo;	chr22:41760513	chr22:42276355~42277052:+
HNSC	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	3.65	0.000294	0.0339	0.17	0.17	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
HNSC	cis	rs17507216	0.56	rs28493687	ENSG00000252690.3	SCARNA15	3.65	0.000294	0.0339	0.13	0.17	Excessive daytime sleepiness;	chr15:82560062	chr15:82752884~82757208:+
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	3.65	0.000294	0.0339	0.2	0.17	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
HNSC	cis	rs3799379	0.55	rs2072804	ENSG00000241549.7	GUSBP2	3.65	0.000294	0.0339	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26390962	chr6:26871484~26956554:-
HNSC	cis	rs2055729	1	rs2055729	ENSG00000254340.1	RP11-10A14.3	-3.65	0.000294	0.0339	-0.21	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9935152	chr8:9141424~9145435:+
HNSC	cis	rs8077577	0.689	rs62072515	ENSG00000273018.4	CTD-2303H24.2	-3.65	0.000294	0.0339	-0.24	-0.17	Obesity-related traits;	chr17:18310121	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.689	rs16961114	ENSG00000273018.4	CTD-2303H24.2	-3.65	0.000294	0.0339	-0.24	-0.17	Obesity-related traits;	chr17:18312025	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.747	rs62072537	ENSG00000273018.4	CTD-2303H24.2	-3.65	0.000294	0.0339	-0.24	-0.17	Obesity-related traits;	chr17:18312786	chr17:18511221~18551705:-
HNSC	cis	rs2153535	0.585	rs9379238	ENSG00000230939.1	RP11-314C16.1	-3.65	0.000294	0.0339	-0.19	-0.17	Motion sickness;	chr6:8667806	chr6:8784178~8785445:+
HNSC	cis	rs4489787	0.892	rs2705159	ENSG00000257763.1	OR5BK1P	3.65	0.000294	0.0339	0.27	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48508409	chr12:48355792~48356614:-
HNSC	cis	rs4489787	0.803	rs2705158	ENSG00000257763.1	OR5BK1P	3.65	0.000294	0.0339	0.27	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48511092	chr12:48355792~48356614:-
HNSC	cis	rs683257	0.81	rs1879508	ENSG00000234147.1	RP3-460G2.2	-3.65	0.000294	0.0339	-0.3	-0.17	Facial emotion recognition (angry faces);	chr6:140879471	chr6:140845958~140852924:-
HNSC	cis	rs2098713	0.534	rs12188314	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000294	0.0339	0.18	0.17	Telomere length;	chr5:37578577	chr5:36666214~36725195:-
HNSC	cis	rs2013441	0.761	rs2526468	ENSG00000261033.1	RP11-209D14.2	3.65	0.000294	0.0339	0.19	0.17	Obesity-related traits;	chr17:20259759	chr17:20008051~20009234:-
HNSC	cis	rs6787172	0.622	rs9872089	ENSG00000272087.1	RP11-379F4.7	3.65	0.000294	0.0339	0.17	0.17	Subjective well-being;	chr3:158360206	chr3:158693120~158693768:-
HNSC	cis	rs1513670	1	rs955412	ENSG00000260793.2	RP5-882C2.2	3.65	0.000294	0.0339	0.15	0.17	Bone mineral density (hip);	chr17:43735193	chr17:44221401~44223710:+
HNSC	cis	rs2898681	1	rs2003198	ENSG00000248375.1	RP11-177B4.1	-3.65	0.000294	0.0339	-0.25	-0.17	Optic nerve measurement (cup area);	chr4:52882416	chr4:52720081~52720831:-
HNSC	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-3.65	0.000294	0.0339	-0.16	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
HNSC	cis	rs8054556	0.787	rs12325400	ENSG00000250616.2	RP11-455F5.3	3.65	0.000294	0.0339	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30096430~30104116:+
HNSC	cis	rs4489787	0.764	rs2705162	ENSG00000257763.1	OR5BK1P	3.65	0.000295	0.0339	0.28	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48504734	chr12:48355792~48356614:-
HNSC	cis	rs6840258	0.76	rs340638	ENSG00000251411.1	RP11-397E7.4	3.65	0.000295	0.0339	0.2	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87007052	chr4:86913266~86914817:-
HNSC	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-3.65	0.000295	0.034	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
HNSC	cis	rs526231	0.543	rs246900	ENSG00000250682.4	LINC00491	3.65	0.000295	0.034	0.23	0.17	Primary biliary cholangitis;	chr5:103198928	chr5:102609156~102671559:-
HNSC	cis	rs6968419	0.674	rs7459355	ENSG00000237870.5	AC073130.1	3.65	0.000295	0.034	0.2	0.17	Intraocular pressure;	chr7:116266721	chr7:116275606~116286734:-
HNSC	cis	rs6012564	1	rs755589	ENSG00000227431.4	CSE1L-AS1	3.65	0.000295	0.034	0.19	0.17	Anger;	chr20:49104848	chr20:49040463~49046044:-
HNSC	cis	rs643506	0.845	rs7114594	ENSG00000230911.1	PPIHP1	-3.65	0.000295	0.034	-0.22	-0.17	Breast cancer;	chr11:111897389	chr11:112029858~112030367:-
HNSC	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-3.65	0.000295	0.034	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
HNSC	cis	rs4713118	0.621	rs9295755	ENSG00000219891.2	ZSCAN12P1	-3.65	0.000295	0.034	-0.23	-0.17	Parkinson's disease;	chr6:28065396	chr6:28091154~28093664:+
HNSC	cis	rs4648045	0.565	rs11733749	ENSG00000246560.2	RP11-10L12.4	3.65	0.000295	0.034	0.2	0.17	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102828055~102844075:+
HNSC	cis	rs7911264	0.739	rs4933734	ENSG00000232709.1	MARK2P9	-3.65	0.000295	0.034	-0.19	-0.17	Inflammatory bowel disease;	chr10:92654810	chr10:92418667~92420875:+
HNSC	cis	rs62292953	0.79	rs11925382	ENSG00000248724.5	NPHP3-AS1	-3.65	0.000295	0.034	-0.34	-0.17	Red cell distribution width;	chr3:132500710	chr3:132721750~132874223:+
HNSC	cis	rs61160187	0.582	rs62372103	ENSG00000272308.1	RP11-231G3.1	-3.65	0.000295	0.034	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60866457~60866935:-
HNSC	cis	rs10484434	0.818	rs6935470	ENSG00000217159.2	LARP1P1	3.65	0.000295	0.034	0.25	0.17	HIV-1 viral setpoint;	chr6:25990590	chr6:26164072~26164363:+
HNSC	cis	rs10484434	0.818	rs2051538	ENSG00000217159.2	LARP1P1	3.65	0.000295	0.034	0.25	0.17	HIV-1 viral setpoint;	chr6:25991392	chr6:26164072~26164363:+
HNSC	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	3.65	0.000295	0.034	0.21	0.17	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
HNSC	cis	rs4938303	0.788	rs12799449	ENSG00000254851.1	RP11-109L13.1	3.65	0.000295	0.034	0.26	0.17	Triglycerides;	chr11:116687809	chr11:117135528~117138582:+
HNSC	cis	rs1445130	0.636	rs1373775	ENSG00000260331.1	RP11-111J6.2	3.65	0.000295	0.034	0.22	0.17	Bulimia nervosa;	chr2:18656664	chr2:18547386~18548204:-
HNSC	cis	rs1445130	0.636	rs13022166	ENSG00000260331.1	RP11-111J6.2	3.65	0.000295	0.034	0.22	0.17	Bulimia nervosa;	chr2:18658178	chr2:18547386~18548204:-
HNSC	cis	rs35824328	0.706	rs76663547	ENSG00000229267.2	AC072062.1	3.65	0.000295	0.034	0.27	0.17	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214235330	chr2:214810229~214963274:+
HNSC	cis	rs2762353	0.718	rs1747550	ENSG00000272462.2	U91328.19	-3.65	0.000295	0.034	-0.16	-0.17	Blood metabolite levels;	chr6:25851305	chr6:25992662~26001775:+
HNSC	cis	rs924607	0.583	rs12516251	ENSG00000188242.4	PP7080	-3.65	0.000295	0.034	-0.18	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:608824	chr5:466124~473098:-
HNSC	cis	rs4787951	0.754	rs2072130	ENSG00000259940.2	CTD-3203P2.1	-3.65	0.000295	0.034	-0.18	-0.17	Eosinophil percentage of white cells;	chr16:27345077	chr16:27213308~27214993:-
HNSC	cis	rs28489187	0.617	rs233068	ENSG00000223653.4	RP11-131L23.1	3.65	0.000295	0.034	0.22	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339672	chr1:85276715~85448124:+
HNSC	cis	rs2013441	1	rs2386429	ENSG00000261033.1	RP11-209D14.2	3.65	0.000295	0.034	0.19	0.17	Obesity-related traits;	chr17:20307496	chr17:20008051~20009234:-
HNSC	cis	rs4517514	0.509	rs11018869	ENSG00000280385.1	AP000648.5	3.65	0.000295	0.034	0.28	0.17	Trans fatty acid levels;	chr11:90132000	chr11:90193614~90198120:+
HNSC	cis	rs4517514	0.509	rs10830411	ENSG00000280385.1	AP000648.5	3.65	0.000295	0.034	0.28	0.17	Trans fatty acid levels;	chr11:90132364	chr11:90193614~90198120:+
HNSC	cis	rs4517514	0.509	rs11018875	ENSG00000280385.1	AP000648.5	3.65	0.000295	0.034	0.28	0.17	Trans fatty acid levels;	chr11:90143188	chr11:90193614~90198120:+
HNSC	cis	rs2836974	0.965	rs2836967	ENSG00000255568.3	BRWD1-AS2	3.65	0.000295	0.034	0.15	0.17	Cognitive function;	chr21:39267176	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.965	rs8130984	ENSG00000255568.3	BRWD1-AS2	3.65	0.000295	0.034	0.15	0.17	Cognitive function;	chr21:39268040	chr21:39313935~39314962:+
HNSC	cis	rs9652601	0.92	rs12923098	ENSG00000274038.1	RP11-66H6.4	-3.65	0.000295	0.034	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11083196	chr16:11056556~11057034:+
HNSC	cis	rs11671005	0.693	rs11668757	ENSG00000269473.1	CTD-2619J13.19	3.65	0.000295	0.034	0.27	0.17	Mean platelet volume;	chr19:58416932	chr19:58440448~58445849:+
HNSC	cis	rs643955	0.609	rs13259465	ENSG00000255310.2	AF131215.2	-3.65	0.000295	0.034	-0.16	-0.17	Systemic lupus erythematosus;	chr8:10125443	chr8:11107788~11109726:-
HNSC	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000295	0.034	-0.24	-0.17	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
HNSC	cis	rs6538678	0.963	rs11108310	ENSG00000199172.2	MIR331	-3.65	0.000295	0.034	-0.19	-0.17	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95308410~95308520:+
HNSC	cis	rs1015213	0.737	rs72639766	ENSG00000272024.1	RP11-546K22.3	-3.65	0.000296	0.0341	-0.43	-0.17	Glaucoma (primary angle closure);	chr8:51973680	chr8:51950284~51950690:+
HNSC	cis	rs1015213	0.737	rs74930917	ENSG00000272024.1	RP11-546K22.3	-3.65	0.000296	0.0341	-0.43	-0.17	Glaucoma (primary angle closure);	chr8:51973789	chr8:51950284~51950690:+
HNSC	cis	rs3018712	0.522	rs4930593	ENSG00000255031.4	RP11-802E16.3	-3.65	0.000296	0.0341	-0.14	-0.17	Total body bone mineral density;	chr11:68666713	chr11:68050740~68053762:+
HNSC	cis	rs2013441	1	rs2703772	ENSG00000261033.1	RP11-209D14.2	3.65	0.000296	0.0341	0.19	0.17	Obesity-related traits;	chr17:20228140	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526475	ENSG00000261033.1	RP11-209D14.2	3.65	0.000296	0.0341	0.19	0.17	Obesity-related traits;	chr17:20232903	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.901	rs2526474	ENSG00000261033.1	RP11-209D14.2	3.65	0.000296	0.0341	0.19	0.17	Obesity-related traits;	chr17:20233821	chr17:20008051~20009234:-
HNSC	cis	rs6088580	0.634	rs6087579	ENSG00000276073.1	RP5-1125A11.7	3.65	0.000296	0.0341	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:33985617~33988989:-
HNSC	cis	rs6919854	0.682	rs163982	ENSG00000270362.1	HMGN3-AS1	-3.65	0.000296	0.0341	-0.21	-0.17	Daytime sleep phenotypes;	chr6:79896927	chr6:79233718~79236797:+
HNSC	cis	rs7572733	0.935	rs2880389	ENSG00000222017.1	AC011997.1	3.65	0.000296	0.0341	0.2	0.17	Dermatomyositis;	chr2:197936983	chr2:197693106~197774823:+
HNSC	cis	rs4648045	0.598	rs6811263	ENSG00000230069.3	LRRC37A15P	-3.65	0.000296	0.0341	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102494656	chr4:102727274~102730721:-
HNSC	cis	rs9437689	0.531	rs859048	ENSG00000237416.5	RP11-465K1.2	-3.65	0.000296	0.0341	-0.22	-0.17	Phospholipid levels (plasma);	chr1:94911873	chr1:94836748~94855426:-
HNSC	cis	rs11168618	1	rs12815544	ENSG00000240399.1	RP1-228P16.1	3.65	0.000296	0.0341	0.14	0.17	Adiponectin levels;	chr12:48555825	chr12:48054813~48055591:-
HNSC	cis	rs9652601	0.748	rs8064154	ENSG00000274038.1	RP11-66H6.4	-3.65	0.000296	0.0341	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11125562	chr16:11056556~11057034:+
HNSC	cis	rs2117029	0.782	rs6580699	ENSG00000258101.2	RP11-977B10.2	-3.65	0.000296	0.0341	-0.21	-0.17	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49232790~49264756:-
HNSC	cis	rs7246657	0.722	rs2927739	ENSG00000276846.1	CTD-3220F14.3	-3.65	0.000296	0.0341	-0.23	-0.17	Coronary artery calcification;	chr19:37658429	chr19:37314868~37315620:-
HNSC	cis	rs2179367	0.959	rs9285519	ENSG00000216906.2	RP11-350J20.9	3.65	0.000296	0.0341	0.2	0.17	Dupuytren's disease;	chr6:149371799	chr6:149904243~149906418:+
HNSC	cis	rs2239557	0.961	rs11159061	ENSG00000258769.1	RAP1AP	-3.65	0.000296	0.0341	-0.18	-0.17	Common traits (Other);	chr14:74089560	chr14:74482985~74483435:+
HNSC	cis	rs2239557	1	rs17096228	ENSG00000258769.1	RAP1AP	-3.65	0.000296	0.0341	-0.18	-0.17	Common traits (Other);	chr14:74091966	chr14:74482985~74483435:+
HNSC	cis	rs6088580	0.634	rs1205338	ENSG00000276073.1	RP5-1125A11.7	3.65	0.000296	0.0341	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:33985617~33988989:-
HNSC	cis	rs9863	0.896	rs4930722	ENSG00000270028.1	RP11-380L11.4	3.65	0.000296	0.0341	0.21	0.17	White blood cell count;	chr12:123938728	chr12:123925461~123926083:-
HNSC	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	3.65	0.000296	0.0341	0.22	0.17	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
HNSC	cis	rs6142618	0.783	rs6058619	ENSG00000275576.1	RP5-836N17.4	-3.65	0.000296	0.0341	-0.17	-0.17	Inflammatory bowel disease;	chr20:32293549	chr20:32116171~32116629:+
HNSC	cis	rs9326246	0.598	rs481843	ENSG00000254851.1	RP11-109L13.1	3.65	0.000296	0.0341	0.37	0.17	Coronary artery disease;	chr11:116655150	chr11:117135528~117138582:+
HNSC	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	3.65	0.000296	0.0341	0.2	0.17	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
HNSC	cis	rs7927592	0.913	rs10896330	ENSG00000239559.2	RPL37P2	3.65	0.000296	0.0341	0.17	0.17	Total body bone mineral density;	chr11:68487530	chr11:67682772~67683058:-
HNSC	cis	rs4449834	0.816	rs4738821	ENSG00000254432.1	RP11-33I11.2	-3.65	0.000296	0.0341	-0.21	-0.17	Sum eosinophil basophil counts;	chr8:60763977	chr8:60808735~60809606:-
HNSC	cis	rs4449834	0.816	rs11991467	ENSG00000254432.1	RP11-33I11.2	-3.65	0.000296	0.0341	-0.21	-0.17	Sum eosinophil basophil counts;	chr8:60766815	chr8:60808735~60809606:-
HNSC	cis	rs9329221	0.506	rs17689674	ENSG00000255310.2	AF131215.2	3.65	0.000296	0.0341	0.16	0.17	Neuroticism;	chr8:10124344	chr8:11107788~11109726:-
HNSC	cis	rs5758659	0.652	rs133335	ENSG00000227370.1	RP4-669P10.19	3.65	0.000296	0.0341	0.16	0.17	Cognitive function;	chr22:42020052	chr22:42132543~42132998:+
HNSC	cis	rs3736485	0.966	rs8031903	ENSG00000259438.1	CTD-2650P22.1	3.65	0.000296	0.0341	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51545964	chr15:52010999~52019095:-
HNSC	cis	rs2030746	0.899	rs3843846	ENSG00000237614.1	AC073257.2	3.65	0.000296	0.0341	0.2	0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120554223	chr2:120542909~120544326:-
HNSC	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	3.65	0.000296	0.0341	0.23	0.17	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
HNSC	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	3.65	0.000296	0.0341	0.18	0.17	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
HNSC	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	3.65	0.000296	0.0341	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
HNSC	cis	rs16858210	0.874	rs1879256	ENSG00000234371.6	RPSAP31	3.65	0.000296	0.0341	0.19	0.17	Menopause (age at onset);	chr3:183891273	chr3:183884924~183888449:+
HNSC	cis	rs10484434	0.818	rs6935470	ENSG00000272462.2	U91328.19	3.65	0.000296	0.0341	0.21	0.17	HIV-1 viral setpoint;	chr6:25990590	chr6:25992662~26001775:+
HNSC	cis	rs10484434	0.818	rs2051538	ENSG00000272462.2	U91328.19	3.65	0.000296	0.0341	0.21	0.17	HIV-1 viral setpoint;	chr6:25991392	chr6:25992662~26001775:+
HNSC	cis	rs9368481	0.547	rs2093303	ENSG00000238621.1	TRI-TAT2-2	-3.65	0.000297	0.0341	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:27020335~27020447:+
HNSC	cis	rs4886920	0.714	rs6416511	ENSG00000260988.1	RP11-285A1.1	-3.65	0.000297	0.0341	-0.2	-0.17	Neuroticism;	chr15:77850052	chr15:78141243~78143173:+
HNSC	cis	rs6787172	0.622	rs6798940	ENSG00000272087.1	RP11-379F4.7	3.65	0.000297	0.0341	0.17	0.17	Subjective well-being;	chr3:158375232	chr3:158693120~158693768:-
HNSC	cis	rs7927592	0.956	rs12274114	ENSG00000239559.2	RPL37P2	3.65	0.000297	0.0341	0.17	0.17	Total body bone mineral density;	chr11:68488109	chr11:67682772~67683058:-
HNSC	cis	rs4908760	0.792	rs4908505	ENSG00000232912.4	RP5-1115A15.1	3.65	0.000297	0.0342	0.17	0.17	Vitiligo;	chr1:8668805	chr1:8424645~8434838:+
HNSC	cis	rs12817549	0.817	rs2033669	ENSG00000213250.5	RBMS2P1	3.65	0.000297	0.0342	0.15	0.17	Hip circumference adjusted for BMI;	chr12:93705713	chr12:94423744~94424969:-
HNSC	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-3.65	0.000297	0.0342	-0.19	-0.17	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
HNSC	cis	rs699371	0.525	rs1156021	ENSG00000270000.1	RP3-449M8.9	3.65	0.000297	0.0342	0.19	0.17	Height;	chr14:74432889	chr14:74471930~74472360:-
HNSC	cis	rs3736485	0.934	rs2414105	ENSG00000259438.1	CTD-2650P22.1	3.65	0.000297	0.0342	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51576176	chr15:52010999~52019095:-
HNSC	cis	rs3736485	0.934	rs4775952	ENSG00000259438.1	CTD-2650P22.1	3.65	0.000297	0.0342	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51576859	chr15:52010999~52019095:-
HNSC	cis	rs394563	0.601	rs376269	ENSG00000216906.2	RP11-350J20.9	3.65	0.000297	0.0342	0.21	0.17	Dupuytren's disease;	chr6:149474018	chr6:149904243~149906418:+
HNSC	cis	rs10090774	0.901	rs11986785	ENSG00000279766.1	RP11-642A1.2	-3.65	0.000297	0.0342	-0.17	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140701852	chr8:140572142~140572812:-
HNSC	cis	rs6001482	0.573	rs4990163	ENSG00000253818.1	IGLV1-41	-3.65	0.000297	0.0342	-0.13	-0.17	Diastolic blood pressure;	chr22:22233778	chr22:22404207~22404721:+
HNSC	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	3.65	0.000297	0.0342	0.21	0.17	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	3.65	0.000297	0.0342	0.21	0.17	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	3.65	0.000297	0.0342	0.21	0.17	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
HNSC	cis	rs6547741	0.844	rs9678851	ENSG00000272148.1	RP11-195B17.1	-3.65	0.000297	0.0342	-0.17	-0.17	Oral cavity cancer;	chr2:27664167	chr2:27062428~27062907:-
HNSC	cis	rs17772222	0.917	rs61986664	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88711251	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.876	rs61986665	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88711354	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs8018755	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88714249	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs8018630	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88714250	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs8020072	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88714332	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs12589982	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88716861	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs61986671	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000297	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88732917	chr14:88551597~88552493:+
HNSC	cis	rs6802315	0.604	rs4680467	ENSG00000272087.1	RP11-379F4.7	3.65	0.000297	0.0342	0.17	0.17	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158693120~158693768:-
HNSC	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000297	0.0342	-0.19	-0.17	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
HNSC	cis	rs8054556	1	rs4283241	ENSG00000261367.1	RP11-455F5.4	3.65	0.000297	0.0342	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30107675~30110541:+
HNSC	cis	rs7224668	0.647	rs9892688	ENSG00000280407.2	RP13-516M14.8	3.65	0.000297	0.0342	0.14	0.17	IgG glycosylation;	chr17:81278717	chr17:82249067~82251844:+
HNSC	cis	rs12410462	0.681	rs12401677	ENSG00000224834.1	BTF3P9	3.65	0.000297	0.0342	0.27	0.17	Major depressive disorder;	chr1:227420876	chr1:227434064~227434346:+
HNSC	cis	rs9611565	0.918	rs73176685	ENSG00000233903.2	Z83851.4	-3.65	0.000297	0.0342	-0.23	-0.17	Vitiligo;	chr22:41385090	chr22:42276355~42277052:+
HNSC	cis	rs4787491	0.679	rs7204852	ENSG00000250616.2	RP11-455F5.3	3.65	0.000297	0.0342	0.17	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30096430~30104116:+
HNSC	cis	rs6802315	0.604	rs2115941	ENSG00000272087.1	RP11-379F4.7	3.65	0.000297	0.0342	0.17	0.17	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158693120~158693768:-
HNSC	cis	rs2286492	1	rs75393023	ENSG00000228649.7	AC005682.5	-3.65	0.000297	0.0342	-0.32	-0.17	Bipolar disorder;	chr7:22942323	chr7:22854178~22861579:+
HNSC	cis	rs16958440	0.581	rs12386097	ENSG00000267724.1	RP11-49K24.8	3.65	0.000297	0.0342	0.26	0.17	Sitting height ratio;	chr18:47146897	chr18:47105946~47108062:+
HNSC	cis	rs4489787	0.892	rs2468353	ENSG00000257763.1	OR5BK1P	3.65	0.000297	0.0342	0.26	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48451803	chr12:48355792~48356614:-
HNSC	cis	rs4740619	0.556	rs2987011	ENSG00000215237.6	RP11-54D18.2	-3.65	0.000297	0.0342	-0.19	-0.17	Body mass index;	chr9:15966438	chr9:14993312~15019729:+
HNSC	cis	rs7735319	0.565	rs10079558	ENSG00000249102.1	CTD-2066L21.1	3.65	0.000297	0.0342	0.19	0.17	Systolic blood pressure;	chr5:33163419	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs7707319	ENSG00000249102.1	CTD-2066L21.1	3.65	0.000297	0.0342	0.19	0.17	Systolic blood pressure;	chr5:33164388	chr5:33008994~33025724:+
HNSC	cis	rs757081	0.669	rs542274	ENSG00000260196.1	RP1-239B22.5	-3.65	0.000297	0.0342	-0.18	-0.17	Systolic blood pressure;	chr11:17185886	chr11:17380649~17383531:+
HNSC	cis	rs17407555	1	rs6833988	ENSG00000250413.1	RP11-448G15.1	3.65	0.000297	0.0342	0.24	0.17	Schizophrenia (age at onset);	chr4:10293962	chr4:10006482~10009725:+
HNSC	cis	rs8028182	0.636	rs11637586	ENSG00000275645.1	RP11-817O13.9	3.65	0.000297	0.0342	0.18	0.17	Sudden cardiac arrest;	chr15:75498771	chr15:75346744~75347161:-
HNSC	cis	rs8031584	0.651	rs28664821	ENSG00000259845.1	HERC2P10	-3.65	0.000297	0.0342	-0.19	-0.17	Huntington's disease progression;	chr15:30880120	chr15:30815271~30844153:+
HNSC	cis	rs9402743	0.775	rs12196952	ENSG00000234084.1	RP3-388E23.2	-3.65	0.000297	0.0342	-0.17	-0.17	Systemic lupus erythematosus;	chr6:135662235	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9494323	ENSG00000234084.1	RP3-388E23.2	-3.65	0.000297	0.0342	-0.17	-0.17	Systemic lupus erythematosus;	chr6:135663249	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs6917604	ENSG00000234084.1	RP3-388E23.2	-3.65	0.000297	0.0342	-0.17	-0.17	Systemic lupus erythematosus;	chr6:135664161	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs7768645	ENSG00000234084.1	RP3-388E23.2	-3.65	0.000297	0.0342	-0.17	-0.17	Systemic lupus erythematosus;	chr6:135664656	chr6:135301568~135307158:+
HNSC	cis	rs2439831	0.867	rs2255051	ENSG00000201136.1	RNU6-353P	-3.65	0.000297	0.0342	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43553963	chr15:43702363~43702470:+
HNSC	cis	rs36423	0.841	rs17178946	ENSG00000266869.1	RP6-114E22.1	3.64	0.000297	0.0342	0.34	0.17	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71899050	chr14:71848606~71908430:+
HNSC	cis	rs1040393	0.953	rs6427042	ENSG00000225171.2	DUTP6	3.64	0.000298	0.0342	0.21	0.17	Schizophrenia;	chr1:166894319	chr1:166868748~166869209:+
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84390487	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84393989	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84396135	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84399732	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84400482	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84400554	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84400736	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84401537	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84401867	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000259570.1	RP11-671M22.4	3.64	0.000298	0.0342	0.22	0.17	Schizophrenia;	chr15:84402196	chr15:84394512~84395514:+
HNSC	cis	rs17772222	0.917	rs61986669	ENSG00000258789.1	RP11-507K2.3	-3.64	0.000298	0.0342	-0.2	-0.17	Coronary artery calcification;	chr14:88727121	chr14:88551597~88552493:+
HNSC	cis	rs7432375	0.609	rs835637	ENSG00000239213.4	NCK1-AS1	3.64	0.000298	0.0342	0.14	0.17	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136954315	chr3:136841726~136862054:-
HNSC	cis	rs1580019	0.844	rs1584615	ENSG00000226468.2	AC018641.7	-3.64	0.000298	0.0342	-0.23	-0.17	Cognitive ability;	chr7:32463646	chr7:32456963~32457758:-
HNSC	cis	rs61160187	0.673	rs55768631	ENSG00000215032.2	GNL3LP1	3.64	0.000298	0.0342	0.19	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60581364	chr5:60891935~60893577:-
HNSC	cis	rs6012564	1	rs2075678	ENSG00000227431.4	CSE1L-AS1	3.64	0.000298	0.0342	0.19	0.17	Anger;	chr20:49084802	chr20:49040463~49046044:-
HNSC	cis	rs17250963	0.589	rs697567	ENSG00000249485.1	RBBP4P1	-3.64	0.000298	0.0342	-0.16	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14746160	chr5:14797125~14798400:-
HNSC	cis	rs17250963	0.618	rs6895129	ENSG00000249485.1	RBBP4P1	-3.64	0.000298	0.0342	-0.16	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14746174	chr5:14797125~14798400:-
HNSC	cis	rs10865541	0.778	rs10779975	ENSG00000234171.2	RNASEH1-AS1	3.64	0.000298	0.0342	0.17	0.17	Obesity-related traits;	chr2:3416261	chr2:3558492~3561745:+
HNSC	cis	rs6840360	0.642	rs2709820	ENSG00000251611.1	RP11-610P16.1	-3.64	0.000298	0.0342	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151407551~151408835:-
HNSC	cis	rs9400467	0.528	rs240954	ENSG00000271789.1	RP5-1112D6.7	-3.64	0.000298	0.0342	-0.2	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111297126~111298510:+
HNSC	cis	rs8062405	0.965	rs56040780	ENSG00000261089.1	RP11-435I10.3	3.64	0.000298	0.0342	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28413703~28415018:+
HNSC	cis	rs6142618	0.583	rs2235904	ENSG00000260257.2	RP5-1085F17.3	-3.64	0.000298	0.0342	-0.16	-0.17	Inflammatory bowel disease;	chr20:32133909	chr20:32856621~32858751:+
HNSC	cis	rs950169	0.649	rs12911612	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000298	0.0343	-0.19	-0.17	Schizophrenia;	chr15:84022262	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.649	rs12905952	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000298	0.0343	-0.19	-0.17	Schizophrenia;	chr15:84022509	chr15:84507885~84516814:-
HNSC	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	3.64	0.000298	0.0343	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
HNSC	cis	rs8077577	0.747	rs62072541	ENSG00000273018.4	CTD-2303H24.2	-3.64	0.000298	0.0343	-0.24	-0.17	Obesity-related traits;	chr17:18323385	chr17:18511221~18551705:-
HNSC	cis	rs526231	0.543	rs7714539	ENSG00000250682.4	LINC00491	3.64	0.000298	0.0343	0.21	0.17	Primary biliary cholangitis;	chr5:102993174	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs60633061	ENSG00000250682.4	LINC00491	3.64	0.000298	0.0343	0.21	0.17	Primary biliary cholangitis;	chr5:102994345	chr5:102609156~102671559:-
HNSC	cis	rs6180	0.788	rs35293842	ENSG00000272144.1	CTD-2035E11.5	-3.64	0.000298	0.0343	-0.16	-0.17	Height;	chr5:42837608	chr5:43061395~43062441:+
HNSC	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	3.64	0.000298	0.0343	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
HNSC	cis	rs8062405	1	rs8062405	ENSG00000261766.1	RP11-22P6.2	3.64	0.000298	0.0343	0.16	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28862166~28863340:-
HNSC	cis	rs7735319	0.966	rs35317495	ENSG00000249572.1	CTD-2203K17.1	3.64	0.000298	0.0343	0.19	0.17	Systolic blood pressure;	chr5:33155097	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.901	rs7731489	ENSG00000249572.1	CTD-2203K17.1	3.64	0.000298	0.0343	0.19	0.17	Systolic blood pressure;	chr5:33156621	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.87	rs7735427	ENSG00000249572.1	CTD-2203K17.1	3.64	0.000298	0.0343	0.19	0.17	Systolic blood pressure;	chr5:33156782	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.966	rs62368014	ENSG00000249572.1	CTD-2203K17.1	3.64	0.000298	0.0343	0.19	0.17	Systolic blood pressure;	chr5:33157378	chr5:33424025~33440619:-
HNSC	cis	rs4934494	0.736	rs10881613	ENSG00000240996.1	RP11-80H5.7	-3.64	0.000298	0.0343	-0.21	-0.17	Red blood cell count;	chr10:89629468	chr10:89694295~89697928:-
HNSC	cis	rs6493858	0.839	rs2682051	ENSG00000277245.1	RP11-48G14.3	3.64	0.000298	0.0343	0.19	0.17	Relative hand skill in reading disability;	chr15:56251224	chr15:56447120~56447697:+
HNSC	cis	rs7829975	0.523	rs9644774	ENSG00000254153.1	CTA-398F10.2	-3.64	0.000298	0.0343	-0.2	-0.17	Mood instability;	chr8:8702322	chr8:8456909~8461337:-
HNSC	cis	rs9921222	1	rs9921222	ENSG00000268836.1	LA16c-OS12.2	-3.64	0.000298	0.0343	-0.16	-0.17	Bone mineral density (spine);Bone mineral density;	chr16:325782	chr16:185748~186294:-
HNSC	cis	rs7011507	0.582	rs72637696	ENSG00000253608.1	RP11-770E5.1	-3.64	0.000298	0.0343	-0.34	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48378366	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.582	rs72637697	ENSG00000253608.1	RP11-770E5.1	-3.64	0.000298	0.0343	-0.34	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48379025	chr8:48551567~48698510:+
HNSC	cis	rs7100689	0.542	rs7096715	ENSG00000226659.1	RP11-137H2.4	-3.64	0.000298	0.0343	-0.21	-0.17	Post bronchodilator FEV1;	chr10:80436193	chr10:80529597~80535942:-
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	3.64	0.000298	0.0343	0.24	0.17	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0343	-0.24	-0.17	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
HNSC	cis	rs2836974	0.644	rs719230	ENSG00000255568.3	BRWD1-AS2	-3.64	0.000298	0.0343	-0.14	-0.17	Cognitive function;	chr21:39304381	chr21:39313935~39314962:+
HNSC	cis	rs786425	0.899	rs1515814	ENSG00000278112.1	RP11-972P1.11	3.64	0.000298	0.0343	0.16	0.17	Pubertal anthropometrics;	chr12:123624152	chr12:123519390~123519856:-
HNSC	cis	rs10484434	0.792	rs66505449	ENSG00000272462.2	U91328.19	3.64	0.000298	0.0343	0.22	0.17	HIV-1 viral setpoint;	chr6:26031257	chr6:25992662~26001775:+
HNSC	cis	rs1979679	0.673	rs12229872	ENSG00000278733.1	RP11-425D17.1	3.64	0.000298	0.0343	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28185625~28186190:-
HNSC	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-3.64	0.000298	0.0343	-0.19	-0.17	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
HNSC	cis	rs4853525	0.961	rs11687659	ENSG00000228509.4	AC006460.2	-3.64	0.000298	0.0343	-0.2	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190876471	chr2:190676944~190708716:-
HNSC	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	3.64	0.000298	0.0343	0.19	0.17	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
HNSC	cis	rs9525638	0.875	rs9525644	ENSG00000231530.1	RP11-187A9.3	-3.64	0.000298	0.0343	-0.19	-0.17	Cortical thickness;TB-LM or TBLH-BMD (pleiotropy);Total body bone mineral density (age 0-15);Bone mineral density (paediatric, upper limb);Bone mineral density (paediatric, total body less head);	chr13:42585668	chr13:42043727~42044247:-
HNSC	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-3.64	0.000298	0.0343	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
HNSC	cis	rs9911578	1	rs12938772	ENSG00000224738.1	AC099850.1	3.64	0.000298	0.0343	0.17	0.17	Intelligence (multi-trait analysis);	chr17:58698959	chr17:59106598~59118267:+
HNSC	cis	rs6968419	1	rs10245914	ENSG00000237870.5	AC073130.1	-3.64	0.000298	0.0343	-0.19	-0.17	Intraocular pressure;	chr7:116177531	chr7:116275606~116286734:-
HNSC	cis	rs863750	0.721	rs851132	ENSG00000275389.1	RP11-214K3.24	3.64	0.000298	0.0343	0.23	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124050277	chr12:124085761~124088598:+
HNSC	cis	rs35146811	0.735	rs1727140	ENSG00000235077.1	AC073842.19	-3.64	0.000299	0.0343	-0.2	-0.17	Coronary artery disease;	chr7:100217776	chr7:100130964~100140439:+
HNSC	cis	rs700651	0.624	rs12105927	ENSG00000222017.1	AC011997.1	3.64	0.000299	0.0343	0.22	0.17	Intracranial aneurysm;	chr2:198072534	chr2:197693106~197774823:+
HNSC	cis	rs950169	0.96	rs12905475	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000299	0.0343	-0.19	-0.17	Schizophrenia;	chr15:84131743	chr15:84507885~84516814:-
HNSC	cis	rs4072980	0.545	rs10890285	ENSG00000212541.1	RNU6-510P	3.64	0.000299	0.0343	0.2	0.17	Coronary artery disease;	chr1:37987904	chr1:37991462~37991569:+
HNSC	cis	rs10819861	0.645	rs4743535	ENSG00000175611.10	LINC00476	3.64	0.000299	0.0344	0.16	0.17	Electrocardiographic traits;	chr9:96095671	chr9:95759231~95875977:-
HNSC	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-3.64	0.000299	0.0344	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
HNSC	cis	rs67311347	1	rs9829800	ENSG00000280739.1	EIF1B-AS1	3.64	0.000299	0.0344	0.18	0.17	Renal cell carcinoma;	chr3:40402436	chr3:40173145~40309698:-
HNSC	cis	rs4787491	0.704	rs35605010	ENSG00000250616.2	RP11-455F5.3	3.64	0.000299	0.0344	0.17	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30096430~30104116:+
HNSC	cis	rs4787491	0.729	rs4788213	ENSG00000250616.2	RP11-455F5.3	3.64	0.000299	0.0344	0.17	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30096430~30104116:+
HNSC	cis	rs11866815	0.739	rs35050910	ENSG00000226942.2	IL9RP3	-3.64	0.000299	0.0344	-0.21	-0.17	Body mass index;	chr16:344483	chr16:29336~38321:-
HNSC	cis	rs67311347	0.544	rs13098483	ENSG00000280739.1	EIF1B-AS1	3.64	0.000299	0.0344	0.18	0.17	Renal cell carcinoma;	chr3:40301252	chr3:40173145~40309698:-
HNSC	cis	rs12682352	0.602	rs6988939	ENSG00000254153.1	CTA-398F10.2	3.64	0.000299	0.0344	0.18	0.17	Neuroticism;	chr8:8809406	chr8:8456909~8461337:-
HNSC	cis	rs28829049	0.597	rs2313509	ENSG00000270728.1	RP4-657E11.10	-3.64	0.000299	0.0344	-0.15	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111366	chr1:19297080~19297903:+
HNSC	cis	rs7520050	0.966	rs11810993	ENSG00000280836.1	AL355480.1	3.64	0.000299	0.0344	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.898	rs34175029	ENSG00000280836.1	AL355480.1	3.64	0.000299	0.0344	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45581219~45581321:-
HNSC	cis	rs2554380	0.628	rs7175491	ENSG00000259570.1	RP11-671M22.4	3.64	0.000299	0.0344	0.21	0.17	Height;	chr15:83806187	chr15:84394512~84395514:+
HNSC	cis	rs1440410	0.897	rs9999826	ENSG00000250326.1	RP11-284M14.1	-3.64	0.000299	0.0344	-0.18	-0.17	Ischemic stroke;	chr4:143115304	chr4:142933195~143184861:-
HNSC	cis	rs11157436	0.602	rs17255447	ENSG00000211814.1	TRAV35	3.64	0.000299	0.0344	0.15	0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22221896~22222475:+
HNSC	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	3.64	0.000299	0.0344	0.2	0.17	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
HNSC	cis	rs721917	0.544	rs2243639	ENSG00000244733.5	RP11-506M13.3	-3.64	0.000299	0.0344	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79941966	chr10:79660891~79677996:+
HNSC	cis	rs7735319	0.604	rs9292485	ENSG00000249102.1	CTD-2066L21.1	3.64	0.000299	0.0344	0.19	0.17	Systolic blood pressure;	chr5:33154160	chr5:33008994~33025724:+
HNSC	cis	rs2243480	1	rs34703416	ENSG00000226002.1	RP11-460N20.5	-3.64	0.000299	0.0344	-0.29	-0.17	Diabetic kidney disease;	chr7:65835655	chr7:65084103~65100232:+
HNSC	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-3.64	0.000299	0.0344	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
HNSC	cis	rs481331	0.866	rs1831915	ENSG00000215146.4	RP11-313J2.1	3.64	0.000299	0.0344	0.27	0.17	Systemic juvenile idiopathic arthritis;	chr10:42494262	chr10:42331866~42367974:-
HNSC	cis	rs75504410	0.678	rs17428931	ENSG00000249207.1	RP11-360F5.1	-3.64	0.000299	0.0344	-0.37	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38687421	chr4:39112677~39126818:-
HNSC	cis	rs4660214	0.666	rs4660550	ENSG00000182109.6	RP11-69E11.4	-3.64	0.000299	0.0344	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39522280~39546187:-
HNSC	cis	rs988913	0.706	rs12523720	ENSG00000224984.1	RP11-524H19.2	3.64	3e-04	0.0344	0.2	0.17	Menarche (age at onset);	chr6:55078243	chr6:54840118~54840855:-
HNSC	cis	rs1908814	0.503	rs34657250	ENSG00000255495.1	AC145124.2	-3.64	3e-04	0.0344	-0.19	-0.17	Neuroticism;	chr8:11937864	chr8:12194467~12196280:+
HNSC	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	3.64	3e-04	0.0344	0.29	0.17	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
HNSC	cis	rs7726839	0.794	rs10053310	ENSG00000225138.6	CTD-2228K2.7	3.64	3e-04	0.0344	0.23	0.17	Obesity-related traits;	chr5:595546	chr5:473236~480884:+
HNSC	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-3.64	3e-04	0.0344	-0.12	-0.17	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
HNSC	cis	rs9402743	0.775	rs2179724	ENSG00000234084.1	RP3-388E23.2	-3.64	3e-04	0.0344	-0.17	-0.17	Systemic lupus erythematosus;	chr6:135647928	chr6:135301568~135307158:+
HNSC	cis	rs6921919	0.583	rs7764722	ENSG00000227214.2	HCG15	3.64	3e-04	0.0344	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28986203~28987484:+
HNSC	cis	rs2562456	0.754	rs112195516	ENSG00000268119.4	CTD-2561J22.5	3.64	3e-04	0.0344	0.25	0.17	Pain;	chr19:21410849	chr19:21444241~21463908:-
HNSC	cis	rs875971	0.628	rs6974355	ENSG00000273142.1	RP11-458F8.4	-3.64	3e-04	0.0344	-0.14	-0.17	Aortic root size;	chr7:66376994	chr7:66902857~66906297:+
HNSC	cis	rs2117029	0.586	rs2114846	ENSG00000258101.2	RP11-977B10.2	3.64	3e-04	0.0344	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49232790~49264756:-
HNSC	cis	rs9611565	0.546	rs5758426	ENSG00000233903.2	Z83851.4	3.64	3e-04	0.0344	0.24	0.17	Vitiligo;	chr22:41702759	chr22:42276355~42277052:+
HNSC	cis	rs28830936	0.966	rs17733613	ENSG00000250379.1	RP11-23P13.4	3.64	3e-04	0.0344	0.2	0.17	Diastolic blood pressure;	chr15:41625387	chr15:41825099~41827936:-
HNSC	cis	rs6095360	1	rs34984028	ENSG00000227431.4	CSE1L-AS1	-3.64	3e-04	0.0344	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48932510	chr20:49040463~49046044:-
HNSC	cis	rs2013441	1	rs34089239	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0344	-0.19	-0.17	Obesity-related traits;	chr17:20154646	chr17:20008051~20009234:-
HNSC	cis	rs4346053	0.702	rs1500053	ENSG00000274964.1	RP11-817I4.1	3.64	3e-04	0.0344	0.35	0.17	Body mass index (change over time) in lung cancer;	chr12:32992881	chr12:32339368~32340724:+
HNSC	cis	rs2292864	0.764	rs3892085	ENSG00000228782.6	CTD-2026D20.3	-3.64	3e-04	0.0344	-0.27	-0.17	Left atrial antero-posterior diameter;	chr17:47263114	chr17:47450568~47492492:-
HNSC	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	3.64	3e-04	0.0344	0.24	0.17	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000224843.5	LINC00240	3.64	3e-04	0.0344	0.18	0.17	Parkinson's disease;	chr6:27879739	chr6:26956992~27023924:+
HNSC	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-3.64	3e-04	0.0344	-0.17	-0.17	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
HNSC	cis	rs16853722	0.892	rs16853743	ENSG00000240373.1	SEC62-AS1	-3.64	3e-04	0.0344	-0.25	-0.17	Renal function-related traits (BUN);	chr3:169440977	chr3:169978536~169985715:-
HNSC	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-3.64	3e-04	0.0344	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
HNSC	cis	rs863750	0.687	rs825485	ENSG00000275389.1	RP11-214K3.24	3.64	3e-04	0.0345	0.24	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091865	chr12:124085761~124088598:+
HNSC	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	3.64	3e-04	0.0345	0.24	0.17	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
HNSC	cis	rs2179367	0.919	rs4897124	ENSG00000216906.2	RP11-350J20.9	3.64	3e-04	0.0345	0.21	0.17	Dupuytren's disease;	chr6:149442073	chr6:149904243~149906418:+
HNSC	cis	rs2013441	1	rs2080673	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0345	-0.19	-0.17	Obesity-related traits;	chr17:20159082	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs34644796	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0345	-0.19	-0.17	Obesity-related traits;	chr17:20160815	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.931	rs4925089	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0345	-0.19	-0.17	Obesity-related traits;	chr17:20161471	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs4924810	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0345	-0.19	-0.17	Obesity-related traits;	chr17:20168506	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703794	ENSG00000261033.1	RP11-209D14.2	-3.64	3e-04	0.0345	-0.19	-0.17	Obesity-related traits;	chr17:20170025	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2526464	ENSG00000261033.1	RP11-209D14.2	3.64	3e-04	0.0345	0.19	0.17	Obesity-related traits;	chr17:20171739	chr17:20008051~20009234:-
HNSC	cis	rs12893668	0.663	rs12889731	ENSG00000269958.1	RP11-73M18.8	3.64	3e-04	0.0345	0.16	0.17	Reticulocyte count;	chr14:103621145	chr14:103696353~103697163:+
HNSC	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-3.64	3e-04	0.0345	-0.2	-0.17	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
HNSC	cis	rs11951515	0.59	rs7722781	ENSG00000249286.1	CTD-2210P15.2	3.64	3e-04	0.0345	0.18	0.17	Metabolite levels  (X-11787);	chr5:43340913	chr5:43586918~43588223:-
HNSC	cis	rs7189233	1	rs7189819	ENSG00000279344.1	RP11-44F14.7	3.64	3e-04	0.0345	0.16	0.17	Intelligence (multi-trait analysis);	chr16:53502433	chr16:53478957~53481550:-
HNSC	cis	rs453301	0.571	rs330057	ENSG00000253981.4	ALG1L13P	-3.64	3e-04	0.0345	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9232283	chr8:8236003~8244667:-
HNSC	cis	rs2562456	0.55	rs4809143	ENSG00000268081.1	RP11-678G14.2	3.64	3e-04	0.0345	0.23	0.17	Pain;	chr19:21589926	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.583	rs4809144	ENSG00000268081.1	RP11-678G14.2	3.64	3e-04	0.0345	0.23	0.17	Pain;	chr19:21589928	chr19:21554640~21569237:-
HNSC	cis	rs2439831	0.867	rs2243434	ENSG00000275601.1	AC011330.13	-3.64	3e-04	0.0345	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43397669	chr15:43642389~43643023:-
HNSC	cis	rs950027	0.62	rs2467862	ENSG00000259479.5	SORD2P	3.64	3e-04	0.0345	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:44826371~44884694:-
HNSC	cis	rs875971	0.965	rs7794930	ENSG00000272831.1	RP11-792A8.4	-3.64	3e-04	0.0345	-0.14	-0.17	Aortic root size;	chr7:66313559	chr7:66739829~66740385:-
HNSC	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	3.64	3e-04	0.0345	0.22	0.17	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
HNSC	cis	rs72827839	0.569	rs117972490	ENSG00000228782.6	CTD-2026D20.3	3.64	3e-04	0.0345	0.18	0.17	Ease of getting up in the morning;	chr17:47969283	chr17:47450568~47492492:-
HNSC	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-3.64	3e-04	0.0345	-0.21	-0.17	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
HNSC	cis	rs6740322	0.748	rs6544636	ENSG00000234936.1	AC010883.5	3.64	3e-04	0.0345	0.18	0.17	Coronary artery disease;	chr2:43260347	chr2:43229573~43233394:+
HNSC	cis	rs6921919	0.583	rs7764737	ENSG00000227214.2	HCG15	3.64	3e-04	0.0345	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs9461458	ENSG00000227214.2	HCG15	3.64	3e-04	0.0345	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.609	rs9468365	ENSG00000227214.2	HCG15	3.64	3e-04	0.0345	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs1361385	ENSG00000227214.2	HCG15	3.64	3e-04	0.0345	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28986203~28987484:+
HNSC	cis	rs6921919	0.583	rs1416918	ENSG00000227214.2	HCG15	3.64	3e-04	0.0345	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28986203~28987484:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000259570.1	RP11-671M22.4	3.64	3e-04	0.0345	0.22	0.17	Schizophrenia;	chr15:84387263	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000259570.1	RP11-671M22.4	3.64	3e-04	0.0345	0.22	0.17	Schizophrenia;	chr15:84387606	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000259570.1	RP11-671M22.4	3.64	3e-04	0.0345	0.22	0.17	Schizophrenia;	chr15:84387633	chr15:84394512~84395514:+
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000259570.1	RP11-671M22.4	3.64	3e-04	0.0345	0.22	0.17	Schizophrenia;	chr15:84387641	chr15:84394512~84395514:+
HNSC	cis	rs35306767	0.855	rs11253468	ENSG00000229869.1	RP11-363N22.2	-3.64	3e-04	0.0345	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:857321	chr10:933026~942743:+
HNSC	cis	rs72843506	0.591	rs75334890	ENSG00000189423.10	USP32P3	3.64	3e-04	0.0345	0.26	0.17	Schizophrenia;	chr17:20318087	chr17:20415547~20431008:+
HNSC	cis	rs11157436	0.602	rs2032441	ENSG00000211812.1	TRAV26-2	-3.64	0.000301	0.0345	-0.15	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22202583~22203368:+
HNSC	cis	rs250677	0.687	rs10040624	ENSG00000250072.4	CTC-529P8.1	-3.64	0.000301	0.0345	-0.22	-0.17	Breast cancer;	chr5:149058016	chr5:149063317~149109787:+
HNSC	cis	rs11148252	0.904	rs7321964	ENSG00000198384.8	TPTE2P3	3.64	0.000301	0.0345	0.21	0.17	Lewy body disease;	chr13:52466687	chr13:52522632~52586906:+
HNSC	cis	rs7572733	0.765	rs2164068	ENSG00000222017.1	AC011997.1	3.64	0.000301	0.0345	0.2	0.17	Dermatomyositis;	chr2:198079128	chr2:197693106~197774823:+
HNSC	cis	rs2562456	0.833	rs2562416	ENSG00000268119.4	CTD-2561J22.5	3.64	0.000301	0.0345	0.25	0.17	Pain;	chr19:21430609	chr19:21444241~21463908:-
HNSC	cis	rs7590368	0.62	rs55675740	ENSG00000272275.1	RP11-791G15.2	3.64	0.000301	0.0345	0.28	0.17	Educational attainment (years of education);	chr2:10779962	chr2:10767875~10770058:-
HNSC	cis	rs911263	0.961	rs3784099	ENSG00000240210.3	RP11-204K16.1	3.64	0.000301	0.0345	0.2	0.17	Primary biliary cholangitis;	chr14:68283210	chr14:68338728~68339528:-
HNSC	cis	rs1853665	0.58	rs4242282	ENSG00000268592.3	RAET1E-AS1	3.64	0.000301	0.0345	0.26	0.17	Radiation response;	chr6:149952210	chr6:149863494~149919507:+
HNSC	cis	rs944002	1	rs62006947	ENSG00000259444.1	RP11-736N17.8	3.64	0.000301	0.0345	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099033	chr14:103094723~103098885:+
HNSC	cis	rs7674212	0.539	rs6850461	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000301	0.0345	-0.19	-0.17	Type 2 diabetes;	chr4:103198884	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.539	rs6533056	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000301	0.0345	-0.19	-0.17	Type 2 diabetes;	chr4:103199840	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.539	rs2866635	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000301	0.0345	-0.19	-0.17	Type 2 diabetes;	chr4:103200419	chr4:102751401~102752641:+
HNSC	cis	rs67311347	0.544	rs6762121	ENSG00000280739.1	EIF1B-AS1	3.64	0.000301	0.0345	0.18	0.17	Renal cell carcinoma;	chr3:40313822	chr3:40173145~40309698:-
HNSC	cis	rs67311347	0.544	rs6787516	ENSG00000280739.1	EIF1B-AS1	3.64	0.000301	0.0345	0.18	0.17	Renal cell carcinoma;	chr3:40314125	chr3:40173145~40309698:-
HNSC	cis	rs160451	0.782	rs2132348	ENSG00000251136.7	RP11-37B2.1	3.64	0.000301	0.0345	0.16	0.17	Leprosy;	chr8:89694545	chr8:89609409~89757727:-
HNSC	cis	rs7267979	0.604	rs242130	ENSG00000231081.1	RP4-760C5.3	3.64	0.000301	0.0345	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:26008791~26010531:-
HNSC	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	3.64	0.000301	0.0345	0.22	0.17	QT interval;	chr16:28857143	chr16:28802743~28817828:+
HNSC	cis	rs6995541	0.505	rs11250083	ENSG00000248896.2	CTD-2135J3.3	3.64	0.000301	0.0345	0.21	0.17	Triglyceride levels;	chr8:10848652	chr8:10729314~10771392:+
HNSC	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-3.64	0.000301	0.0345	-0.16	-0.17	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
HNSC	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	3.64	0.000301	0.0345	0.19	0.17	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
HNSC	cis	rs28489187	0.683	rs12047422	ENSG00000223653.4	RP11-131L23.1	3.64	0.000301	0.0345	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383147	chr1:85276715~85448124:+
HNSC	cis	rs801193	0.904	rs4718403	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000301	0.0345	-0.14	-0.17	Aortic root size;	chr7:66777742	chr7:66902857~66906297:+
HNSC	cis	rs4648045	0.929	rs230493	ENSG00000230069.3	LRRC37A15P	-3.64	0.000301	0.0345	-0.17	-0.17	Lymphocyte percentage of white cells;	chr4:102565059	chr4:102727274~102730721:-
HNSC	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	3.64	0.000301	0.0345	0.19	0.17	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
HNSC	cis	rs397969	0.646	rs403021	ENSG00000266126.1	RP11-209D14.4	3.64	0.000301	0.0345	0.21	0.17	Platelet count;	chr17:19903516	chr17:19929372~19929737:-
HNSC	cis	rs913655	0.508	rs1907042	ENSG00000225527.1	RP11-383B4.4	3.64	0.000301	0.0346	0.21	0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719329	chr10:18531849~18533336:-
HNSC	cis	rs7927592	0.956	rs12365160	ENSG00000239559.2	RPL37P2	3.64	0.000301	0.0346	0.17	0.17	Total body bone mineral density;	chr11:68482951	chr11:67682772~67683058:-
HNSC	cis	rs7927592	0.956	rs11228256	ENSG00000239559.2	RPL37P2	3.64	0.000301	0.0346	0.17	0.17	Total body bone mineral density;	chr11:68483992	chr11:67682772~67683058:-
HNSC	cis	rs2337406	0.866	rs112089985	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000301	0.0346	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106780074	chr14:106762092~106762588:-
HNSC	cis	rs35141484	1	rs35141484	ENSG00000249207.1	RP11-360F5.1	-3.64	0.000301	0.0346	-0.43	-0.17	Asthma (childhood onset);	chr4:39086721	chr4:39112677~39126818:-
HNSC	cis	rs6600671	1	rs2185281	ENSG00000272583.1	RP11-344P13.6	-3.64	0.000301	0.0346	-0.19	-0.17	Hip geometry;	chr1:121438132	chr1:121518366~121518829:-
HNSC	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-3.64	0.000301	0.0346	-0.18	-0.17	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-3.64	0.000301	0.0346	-0.18	-0.17	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-3.64	0.000301	0.0346	-0.18	-0.17	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
HNSC	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-3.64	0.000301	0.0346	-0.23	-0.17	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
HNSC	cis	rs1983891	0.874	rs2395779	ENSG00000261068.2	RP11-7K24.3	-3.64	0.000301	0.0346	-0.17	-0.17	Prostate cancer;	chr6:41544212	chr6:42092233~42094259:-
HNSC	cis	rs615134	0.52	rs11503171	ENSG00000234608.6	MAPKAPK5-AS1	3.64	0.000301	0.0346	0.17	0.17	Mean corpuscular volume;	chr12:111823543	chr12:111839764~111842902:-
HNSC	cis	rs728616	0.614	rs61859198	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000301	0.0346	-0.31	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79663088~79826594:-
HNSC	cis	rs7107174	0.892	rs2090095	ENSG00000251323.2	RP11-452H21.4	3.64	0.000301	0.0346	0.24	0.17	Testicular germ cell tumor;	chr11:78322974	chr11:78423982~78429836:-
HNSC	cis	rs56804039	0.524	rs58668637	ENSG00000173295.6	FAM86B3P	-3.64	0.000301	0.0346	-0.3	-0.17	Cervical cancer;	chr8:8519590	chr8:8228595~8244865:+
HNSC	cis	rs2562456	0.833	rs61035285	ENSG00000268081.1	RP11-678G14.2	3.64	0.000301	0.0346	0.24	0.17	Pain;	chr19:21329475	chr19:21554640~21569237:-
HNSC	cis	rs7572733	0.935	rs11679040	ENSG00000222017.1	AC011997.1	3.64	0.000301	0.0346	0.2	0.17	Dermatomyositis;	chr2:197942105	chr2:197693106~197774823:+
HNSC	cis	rs3929778	0.848	rs2326793	ENSG00000275632.1	RP5-967N21.11	-3.64	0.000301	0.0346	-0.16	-0.17	QRS complex (Cornell);	chr20:6560734	chr20:6000418~6000941:+
HNSC	cis	rs4924935	0.509	rs8074020	ENSG00000264885.1	RP11-815I9.4	-3.64	0.000301	0.0346	-0.17	-0.17	Pancreatic cancer;	chr17:18898067	chr17:18667629~18669461:-
HNSC	cis	rs7777677	0.925	rs4726544	ENSG00000276953.1	TRBV12-4	3.64	0.000301	0.0346	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142563740~142564245:+
HNSC	cis	rs1865760	0.613	rs9379801	ENSG00000272810.1	U91328.22	-3.64	0.000302	0.0346	-0.14	-0.17	Height;	chr6:25901483	chr6:26013241~26013757:+
HNSC	cis	rs2976388	0.935	rs2976386	ENSG00000253741.1	CTD-2292P10.4	3.64	0.000302	0.0346	0.16	0.17	Urinary tract infection frequency;	chr8:142675991	chr8:142702252~142726973:-
HNSC	cis	rs6088580	0.602	rs6058064	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000302	0.0346	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:33985617~33988989:-
HNSC	cis	rs782107	0.541	rs35831134	ENSG00000270039.1	RP11-571M6.17	-3.64	0.000302	0.0346	-0.21	-0.17	Interleukin-12p70 levels;	chr12:58417093	chr12:57803838~57804415:+
HNSC	cis	rs1538970	0.961	rs4660854	ENSG00000234329.1	RP11-767N6.2	3.64	0.000302	0.0346	0.19	0.17	Platelet count;	chr1:45388415	chr1:45651039~45651826:-
HNSC	cis	rs6995541	0.505	rs7013032	ENSG00000248896.2	CTD-2135J3.3	-3.64	0.000302	0.0346	-0.21	-0.17	Triglyceride levels;	chr8:10848849	chr8:10729314~10771392:+
HNSC	cis	rs7937890	0.532	rs2575827	ENSG00000254418.1	RP11-21L19.1	3.64	0.000302	0.0346	0.2	0.17	Mitochondrial DNA levels;	chr11:14453969	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.532	rs2256884	ENSG00000254418.1	RP11-21L19.1	3.64	0.000302	0.0346	0.2	0.17	Mitochondrial DNA levels;	chr11:14454856	chr11:14262846~14273691:-
HNSC	cis	rs6095360	1	rs6019573	ENSG00000227431.4	CSE1L-AS1	-3.64	0.000302	0.0346	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48986295	chr20:49040463~49046044:-
HNSC	cis	rs449789	0.857	rs9355713	ENSG00000235086.1	FNDC1-IT1	-3.64	0.000302	0.0346	-0.2	-0.17	Pulse pressure;	chr6:159301516	chr6:159240786~159243329:+
HNSC	cis	rs7246657	0.722	rs16958861	ENSG00000276846.1	CTD-3220F14.3	3.64	0.000302	0.0346	0.23	0.17	Coronary artery calcification;	chr19:37633278	chr19:37314868~37315620:-
HNSC	cis	rs1937680	0.657	rs7921498	ENSG00000236671.6	PRKG1-AS1	-3.64	0.000302	0.0346	-0.24	-0.17	Breast cancer;	chr10:51878546	chr10:52230742~52314128:-
HNSC	cis	rs2908197	0.806	rs12534035	ENSG00000186704.9	DTX2P1	3.64	0.000302	0.0346	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76351629	chr7:76978617~77004308:+
HNSC	cis	rs6723108	0.678	rs606101	ENSG00000224043.6	CCNT2-AS1	-3.64	0.000302	0.0346	-0.22	-0.17	Type 2 diabetes;	chr2:134526736	chr2:134735464~134918710:-
HNSC	cis	rs9437689	0.714	rs7533303	ENSG00000237416.5	RP11-465K1.2	3.64	0.000302	0.0346	0.2	0.17	Phospholipid levels (plasma);	chr1:94997415	chr1:94836748~94855426:-
HNSC	cis	rs801193	1	rs4717319	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000302	0.0346	-0.14	-0.17	Aortic root size;	chr7:66777606	chr7:66902857~66906297:+
HNSC	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-3.64	0.000302	0.0346	-0.22	-0.17	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
HNSC	cis	rs3018712	0.532	rs61889616	ENSG00000255031.4	RP11-802E16.3	-3.64	0.000302	0.0346	-0.19	-0.17	Total body bone mineral density;	chr11:68644538	chr11:68050740~68053762:+
HNSC	cis	rs11951515	0.546	rs13187876	ENSG00000249286.1	CTD-2210P15.2	3.64	0.000302	0.0346	0.18	0.17	Metabolite levels  (X-11787);	chr5:43367552	chr5:43586918~43588223:-
HNSC	cis	rs62184315	0.536	rs62185874	ENSG00000253559.1	OSGEPL1-AS1	-3.64	0.000302	0.0347	-0.27	-0.17	Alcohol dependence (age at onset);	chr2:189704288	chr2:189762704~189765556:+
HNSC	cis	rs6828666	1	rs6828666	ENSG00000271817.2	U3	-3.64	0.000302	0.0347	-0.19	-0.17	Depression;	chr4:158858089	chr4:158700691~158700909:+
HNSC	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	3.64	0.000302	0.0347	0.24	0.17	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000302	0.0347	-0.24	-0.17	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
HNSC	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	3.64	0.000302	0.0347	0.19	0.17	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	3.64	0.000302	0.0347	0.19	0.17	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
HNSC	cis	rs6968419	0.963	rs28710948	ENSG00000237870.5	AC073130.1	3.64	0.000302	0.0347	0.19	0.17	Intraocular pressure;	chr7:116176494	chr7:116275606~116286734:-
HNSC	cis	rs830124	0.852	rs693277	ENSG00000280138.1	RP11-463O12.5	-3.64	0.000302	0.0347	-0.2	-0.17	Urinary metabolites;	chr12:121949831	chr12:122870059~122888720:-
HNSC	cis	rs830124	0.85	rs1667584	ENSG00000280138.1	RP11-463O12.5	-3.64	0.000302	0.0347	-0.2	-0.17	Urinary metabolites;	chr12:121950490	chr12:122870059~122888720:-
HNSC	cis	rs2337406	0.85	rs11849578	ENSG00000211972.2	IGHV3-66	3.64	0.000302	0.0347	0.18	0.17	Alzheimer's disease (late onset);	chr14:106670302	chr14:106675017~106675544:-
HNSC	cis	rs34286592	1	rs13331733	ENSG00000214725.6	CDIPT-AS1	-3.64	0.000302	0.0347	-0.23	-0.17	Multiple sclerosis;	chr16:29837096	chr16:29863593~29868053:+
HNSC	cis	rs9834975	0.544	rs6805448	ENSG00000272758.4	RP11-299J3.8	3.64	0.000302	0.0347	0.15	0.17	Diastolic blood pressure;	chr3:122563636	chr3:122416207~122443180:+
HNSC	cis	rs7572733	0.875	rs7587043	ENSG00000222017.1	AC011997.1	3.64	0.000303	0.0347	0.2	0.17	Dermatomyositis;	chr2:197977005	chr2:197693106~197774823:+
HNSC	cis	rs7572733	0.935	rs7587598	ENSG00000222017.1	AC011997.1	3.64	0.000303	0.0347	0.2	0.17	Dermatomyositis;	chr2:197977520	chr2:197693106~197774823:+
HNSC	cis	rs6951245	0.554	rs4724294	ENSG00000225146.1	AC073957.15	-3.64	0.000303	0.0347	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1029025~1043891:+
HNSC	cis	rs28573326	0.962	rs4266249	ENSG00000121089.4	NACA3P	-3.64	0.000303	0.0347	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165414398	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs4299540	ENSG00000121089.4	NACA3P	-3.64	0.000303	0.0347	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165414649	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs4408916	ENSG00000121089.4	NACA3P	-3.64	0.000303	0.0347	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165414783	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.962	rs4293756	ENSG00000121089.4	NACA3P	-3.64	0.000303	0.0347	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr4:165414834	chr4:164943290~164943937:+
HNSC	cis	rs3018712	0.532	rs2513282	ENSG00000255031.4	RP11-802E16.3	-3.64	0.000303	0.0347	-0.19	-0.17	Total body bone mineral density;	chr11:68650843	chr11:68050740~68053762:+
HNSC	cis	rs1538970	0.962	rs2153608	ENSG00000234329.1	RP11-767N6.2	-3.64	0.000303	0.0347	-0.19	-0.17	Platelet count;	chr1:45348269	chr1:45651039~45651826:-
HNSC	cis	rs2898290	0.54	rs35005793	ENSG00000206014.6	OR7E161P	-3.64	0.000303	0.0347	-0.19	-0.17	Systolic blood pressure;	chr8:11592963	chr8:11928597~11929563:-
HNSC	cis	rs2554380	0.628	rs6602990	ENSG00000259570.1	RP11-671M22.4	3.64	0.000303	0.0347	0.21	0.17	Height;	chr15:83783470	chr15:84394512~84395514:+
HNSC	cis	rs35000415	0.872	rs2070197	ENSG00000244556.1	ODCP	3.64	0.000303	0.0347	0.33	0.17	Systemic lupus erythematosus;	chr7:128948946	chr7:129028889~129030527:+
HNSC	cis	rs4704187	0.64	rs7721018	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000303	0.0347	-0.15	-0.17	Response to amphetamines;	chr5:75197153	chr5:75608817~75609983:+
HNSC	cis	rs1155750	0.72	rs239852	ENSG00000224984.1	RP11-524H19.2	-3.64	0.000303	0.0347	-0.24	-0.17	Colorectal cancer;	chr6:54895469	chr6:54840118~54840855:-
HNSC	cis	rs5758659	0.652	rs133321	ENSG00000227370.1	RP4-669P10.19	-3.64	0.000303	0.0347	-0.15	-0.17	Cognitive function;	chr22:42009318	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.652	rs133324	ENSG00000227370.1	RP4-669P10.19	-3.64	0.000303	0.0347	-0.15	-0.17	Cognitive function;	chr22:42010367	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.652	rs133330	ENSG00000227370.1	RP4-669P10.19	-3.64	0.000303	0.0347	-0.15	-0.17	Cognitive function;	chr22:42013452	chr22:42132543~42132998:+
HNSC	cis	rs7772486	0.659	rs9376957	ENSG00000270638.1	RP3-466P17.1	-3.64	0.000303	0.0347	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145735570~145737218:+
HNSC	cis	rs748404	0.666	rs60018990	ENSG00000166763.7	STRCP1	3.64	0.000303	0.0347	0.23	0.17	Lung cancer;	chr15:43504606	chr15:43699488~43718184:-
HNSC	cis	rs2337406	0.929	rs11847182	ENSG00000211972.2	IGHV3-66	3.64	0.000303	0.0347	0.18	0.17	Alzheimer's disease (late onset);	chr14:106697724	chr14:106675017~106675544:-
HNSC	cis	rs7577696	0.924	rs6748621	ENSG00000272716.1	RP11-563N4.1	-3.64	0.000303	0.0347	-0.16	-0.17	Inflammatory biomarkers;	chr2:32037132	chr2:32165046~32165757:-
HNSC	cis	rs12541595	1	rs12541595	ENSG00000255491.1	RP11-1082L8.4	-3.64	0.000303	0.0347	-0.21	-0.17	Left ventricle diastolic internal dimension;	chr8:124845117	chr8:124811618~124815682:-
HNSC	cis	rs7688540	0.723	rs1986386	ENSG00000211553.1	AC253576.2	-3.64	0.000303	0.0347	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:136461~136568:+
HNSC	cis	rs4948102	0.731	rs4948099	ENSG00000226278.1	PSPHP1	3.64	0.000303	0.0347	0.18	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr7:55764797~55773288:+
HNSC	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	3.64	0.000303	0.0347	0.16	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
HNSC	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-3.64	0.000303	0.0347	-0.28	-0.17	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
HNSC	cis	rs782107	0.541	rs36116460	ENSG00000270039.1	RP11-571M6.17	-3.64	0.000303	0.0347	-0.21	-0.17	Interleukin-12p70 levels;	chr12:58417648	chr12:57803838~57804415:+
HNSC	cis	rs10435719	0.805	rs13269417	ENSG00000255046.1	RP11-297N6.4	-3.64	0.000303	0.0347	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11797928~11802568:-
HNSC	cis	rs11992162	0.548	rs4841631	ENSG00000227888.4	FAM66A	-3.64	0.000303	0.0347	-0.17	-0.17	Monocyte count;	chr8:11924159	chr8:12362019~12388296:+
HNSC	cis	rs889398	0.967	rs244415	ENSG00000226232.7	RP11-419C5.2	3.64	0.000303	0.0348	0.15	0.17	Body mass index;	chr16:69632780	chr16:69976388~69996188:-
HNSC	cis	rs938554	0.501	rs7671266	ENSG00000252002.1	RNA5SP154	3.64	0.000303	0.0348	0.22	0.17	Blood metabolite levels;	chr4:10054752	chr4:9792751~9792861:-
HNSC	cis	rs9435732	0.559	rs11203280	ENSG00000186715.9	MST1L	3.64	0.000303	0.0348	0.14	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016288	chr1:16754910~16770237:-
HNSC	cis	rs73201462	0.708	rs11709725	ENSG00000231305.3	RP11-723O4.2	-3.64	0.000303	0.0348	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128139090	chr3:128861313~128871540:-
HNSC	cis	rs4252134	0.959	rs28402939	ENSG00000231863.1	RP3-428L16.1	3.64	0.000303	0.0348	0.22	0.17	Giant cell arteritis;	chr6:160747917	chr6:160931080~160969771:+
HNSC	cis	rs7554547	0.905	rs4993564	ENSG00000242349.4	NPPA-AS1	-3.64	0.000303	0.0348	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr1:11841017~11848079:+
HNSC	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	3.64	0.000303	0.0348	0.16	0.17	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
HNSC	cis	rs988913	0.706	rs34563989	ENSG00000224984.1	RP11-524H19.2	3.64	0.000304	0.0348	0.19	0.17	Menarche (age at onset);	chr6:55080671	chr6:54840118~54840855:-
HNSC	cis	rs61160187	0.549	rs12518404	ENSG00000272308.1	RP11-231G3.1	-3.64	0.000304	0.0348	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60866457~60866935:-
HNSC	cis	rs36093924	0.646	rs7285557	ENSG00000182057.4	OGFRP1	-3.64	0.000304	0.0348	-0.17	-0.17	Intelligence;	chr22:41952786	chr22:42269753~42275196:+
HNSC	cis	rs700651	0.624	rs12105927	ENSG00000231621.1	AC013264.2	-3.64	0.000304	0.0348	-0.16	-0.17	Intracranial aneurysm;	chr2:198072534	chr2:197197991~197199273:+
HNSC	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-3.64	0.000304	0.0348	-0.23	-0.17	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
HNSC	cis	rs7189233	0.955	rs72801853	ENSG00000279344.1	RP11-44F14.7	3.64	0.000304	0.0348	0.16	0.17	Intelligence (multi-trait analysis);	chr16:53482912	chr16:53478957~53481550:-
HNSC	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	3.64	0.000304	0.0348	0.18	0.17	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
HNSC	cis	rs6012564	0.928	rs8118105	ENSG00000227431.4	CSE1L-AS1	3.64	0.000304	0.0348	0.19	0.17	Anger;	chr20:49182127	chr20:49040463~49046044:-
HNSC	cis	rs7023329	0.56	rs2027163	ENSG00000244230.3	RN7SL151P	3.64	0.000304	0.0348	0.17	0.17	Melanoma;	chr9:21738134	chr9:21699314~21699596:+
HNSC	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	3.64	0.000304	0.0348	0.16	0.17	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
HNSC	cis	rs524732	0.706	rs563440	ENSG00000218358.2	RAET1K	-3.64	0.000304	0.0348	-0.22	-0.17	Schizophrenia;	chr6:150967855	chr6:149998019~150005157:-
HNSC	cis	rs2645424	0.604	rs9644756	ENSG00000255046.1	RP11-297N6.4	3.64	0.000304	0.0348	0.19	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11857591	chr8:11797928~11802568:-
HNSC	cis	rs5758511	0.68	rs17002902	ENSG00000227370.1	RP4-669P10.19	3.64	0.000304	0.0348	0.2	0.17	Birth weight;	chr22:42229503	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	3.64	0.000304	0.0348	0.2	0.17	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
HNSC	cis	rs1866631	0.605	rs10930579	ENSG00000238133.5	MLK7-AS1	3.64	0.000304	0.0348	0.18	0.17	Lung cancer in ever smokers;	chr2:173210466	chr2:173166446~173282036:-
HNSC	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-3.64	0.000304	0.0348	-0.2	-0.17	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
HNSC	cis	rs7824557	0.564	rs34389419	ENSG00000255495.1	AC145124.2	-3.64	0.000304	0.0348	-0.19	-0.17	Retinal vascular caliber;	chr8:11371810	chr8:12194467~12196280:+
HNSC	cis	rs1023500	0.505	rs134885	ENSG00000182057.4	OGFRP1	3.64	0.000304	0.0348	0.17	0.17	Schizophrenia;	chr22:42277805	chr22:42269753~42275196:+
HNSC	cis	rs4535700	0.501	rs9642405	ENSG00000213650.3	RP11-760D2.7	-3.64	0.000304	0.0348	-0.19	-0.17	Macular telangiectasia type 2;	chr7:55910473	chr7:56567906~56568858:-
HNSC	cis	rs2084881	0.527	rs8073710	ENSG00000272763.1	RP11-357H14.17	-3.64	0.000304	0.0348	-0.2	-0.17	Ovarian cancer;	chr17:48282044	chr17:48635923~48647023:-
HNSC	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-3.64	0.000304	0.0348	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
HNSC	cis	rs9910055	0.529	rs368328	ENSG00000267080.4	ASB16-AS1	3.64	0.000304	0.0348	0.13	0.17	Total body bone mineral density;	chr17:44092921	chr17:44175973~44186717:-
HNSC	cis	rs7746199	0.736	rs13209332	ENSG00000226314.6	ZNF192P1	-3.64	0.000304	0.0348	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28161781~28169594:+
HNSC	cis	rs67072384	1	rs7128364	ENSG00000245148.2	ARAP1-AS2	3.64	0.000304	0.0348	0.23	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72740896	chr11:72700474~72705607:+
HNSC	cis	rs2384207	0.584	rs67388112	ENSG00000201208.1	Y_RNA	-3.64	0.000304	0.0348	-0.25	-0.17	Response to fenofibrate (adiponectin levels);	chr12:113320117	chr12:113178423~113178519:-
HNSC	cis	rs6570726	0.791	rs6918814	ENSG00000270638.1	RP3-466P17.1	3.64	0.000304	0.0348	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145735570~145737218:+
HNSC	cis	rs10470013	1	rs10470013	ENSG00000233077.1	LINC01271	3.64	0.000304	0.0348	0.28	0.17	Longitudinal change in brain amyloid plaque burden;	chr20:50993140	chr20:50310711~50321342:-
HNSC	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	3.64	0.000304	0.0348	0.13	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
HNSC	cis	rs2898290	0.54	rs12677146	ENSG00000206014.6	OR7E161P	3.64	0.000304	0.0348	0.19	0.17	Systolic blood pressure;	chr8:11593228	chr8:11928597~11929563:-
HNSC	cis	rs436483	1	rs436483	ENSG00000213385.3	RP11-577H5.1	-3.64	0.000304	0.0348	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr7:102056456	chr7:102755146~102755939:+
HNSC	cis	rs11992162	0.591	rs4240678	ENSG00000255495.1	AC145124.2	-3.64	0.000304	0.0348	-0.19	-0.17	Monocyte count;	chr8:11944917	chr8:12194467~12196280:+
HNSC	cis	rs4704187	0.687	rs1582504	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75183720	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs10036527	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75186012	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6889429	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75186358	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.64	rs4704188	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75186850	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6898116	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75190953	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.663	rs4704189	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000304	0.0349	-0.15	-0.17	Response to amphetamines;	chr5:75191550	chr5:75608817~75609983:+
HNSC	cis	rs9926296	0.632	rs72807526	ENSG00000260259.1	RP11-368I7.4	3.64	0.000304	0.0349	0.2	0.17	Vitiligo;	chr16:89709538	chr16:89682620~89686569:-
HNSC	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	3.64	0.000304	0.0349	0.19	0.17	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
HNSC	cis	rs7824557	0.638	rs4413734	ENSG00000255495.1	AC145124.2	3.64	0.000304	0.0349	0.19	0.17	Retinal vascular caliber;	chr8:11355269	chr8:12194467~12196280:+
HNSC	cis	rs9611565	0.694	rs19573	ENSG00000235513.1	RP4-756G23.5	-3.64	0.000304	0.0349	-0.2	-0.17	Vitiligo;	chr22:41469805	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.694	rs79011	ENSG00000235513.1	RP4-756G23.5	-3.64	0.000304	0.0349	-0.2	-0.17	Vitiligo;	chr22:41470934	chr22:41209122~41217627:-
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000204709.4	LINC01556	3.64	0.000304	0.0349	0.28	0.17	Depression;	chr6:28129415	chr6:28943877~28944537:+
HNSC	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	3.64	0.000305	0.0349	0.24	0.17	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
HNSC	cis	rs2836974	0.899	rs35774464	ENSG00000255568.3	BRWD1-AS2	3.64	0.000305	0.0349	0.15	0.17	Cognitive function;	chr21:39208243	chr21:39313935~39314962:+
HNSC	cis	rs12468579	0.524	rs1607187	ENSG00000235852.1	AC005540.3	3.64	0.000305	0.0349	0.19	0.17	JT interval (sulfonylurea treatment interaction);	chr2:190950312	chr2:190880797~190882059:-
HNSC	cis	rs7726839	0.54	rs72705030	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000305	0.0349	0.25	0.17	Obesity-related traits;	chr5:645447	chr5:473236~480884:+
HNSC	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
HNSC	cis	rs17489649	1	rs7710031	ENSG00000271849.1	CTC-332L22.1	3.64	0.000305	0.0349	0.21	0.17	Intelligence (multi-trait analysis);	chr5:109799144	chr5:109687802~109688329:-
HNSC	cis	rs2307394	0.749	rs12464985	ENSG00000281469.1	RP11-567F11.1	3.64	0.000305	0.0349	0.19	0.17	Urate levels;	chr2:147710066	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.749	rs13033070	ENSG00000281469.1	RP11-567F11.1	3.64	0.000305	0.0349	0.19	0.17	Urate levels;	chr2:147711560	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.749	rs35826590	ENSG00000281469.1	RP11-567F11.1	3.64	0.000305	0.0349	0.19	0.17	Urate levels;	chr2:147712421	chr2:148044380~148044894:+
HNSC	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-3.64	0.000305	0.0349	-0.21	-0.17	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
HNSC	cis	rs929354	1	rs1182381	ENSG00000224629.1	RP5-1142J19.2	3.64	0.000305	0.0349	0.16	0.17	Body mass index;	chr7:157250779	chr7:157263022~157263229:-
HNSC	cis	rs1513670	1	rs8071941	ENSG00000260793.2	RP5-882C2.2	-3.64	0.000305	0.0349	-0.15	-0.17	Bone mineral density (hip);	chr17:43732945	chr17:44221401~44223710:+
HNSC	cis	rs6493858	0.809	rs9672886	ENSG00000277245.1	RP11-48G14.3	-3.64	0.000305	0.0349	-0.19	-0.17	Relative hand skill in reading disability;	chr15:56117021	chr15:56447120~56447697:+
HNSC	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-3.64	0.000305	0.0349	-0.16	-0.17	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
HNSC	cis	rs1580019	0.885	rs4580942	ENSG00000229358.3	DPY19L1P1	-3.64	0.000305	0.0349	-0.19	-0.17	Cognitive ability;	chr7:32456823	chr7:32580949~32761787:-
HNSC	cis	rs2736345	0.788	rs2618476	ENSG00000255046.1	RP11-297N6.4	-3.64	0.000305	0.0349	-0.18	-0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11797928~11802568:-
HNSC	cis	rs17489649	1	rs1008661	ENSG00000271849.1	CTC-332L22.1	3.64	0.000305	0.0349	0.21	0.17	Intelligence (multi-trait analysis);	chr5:109799795	chr5:109687802~109688329:-
HNSC	cis	rs7942368	0.941	rs10899279	ENSG00000254632.1	RP11-21L23.4	3.64	0.000305	0.0349	0.2	0.17	Endometriosis;	chr11:76766200	chr11:76759916~76768223:-
HNSC	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs781156	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66014154	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs781150	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66015986	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs781149	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66016297	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs451396	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66019087	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1167613	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66022452	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1715235	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66023407	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313798	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66028044	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313799	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66029343	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35396113	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66030474	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313807	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66034494	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs313809	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000305	0.0349	-0.24	-0.17	Diabetic kidney disease;	chr7:66034996	chr7:66848496~66858136:+
HNSC	cis	rs2084898	0.882	rs7114201	ENSG00000176984.5	AP000679.2	3.64	0.000305	0.0349	0.27	0.17	Stroke (pediatric);	chr11:120179405	chr11:120168977~120171679:+
HNSC	cis	rs4281086	0.561	rs4997498	ENSG00000255310.2	AF131215.2	3.64	0.000305	0.0349	0.17	0.17	Obesity-related traits;	chr8:10495112	chr8:11107788~11109726:-
HNSC	cis	rs479844	0.617	rs12146493	ENSG00000255120.4	OVOL1-AS1	3.64	0.000305	0.0349	0.18	0.17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);Atopic march;	chr11:65779862	chr11:65789051~65790868:-
HNSC	cis	rs7735319	0.932	rs11532635	ENSG00000250697.1	CTD-2066L21.3	3.64	0.000305	0.0349	0.2	0.17	Systolic blood pressure;	chr5:33095140	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.933	rs7708185	ENSG00000250697.1	CTD-2066L21.3	3.64	0.000305	0.0349	0.2	0.17	Systolic blood pressure;	chr5:33104477	chr5:32925639~33297910:-
HNSC	cis	rs7735319	0.966	rs62367969	ENSG00000250697.1	CTD-2066L21.3	3.64	0.000305	0.0349	0.2	0.17	Systolic blood pressure;	chr5:33105461	chr5:32925639~33297910:-
HNSC	cis	rs1937680	0.657	rs2339888	ENSG00000236671.6	PRKG1-AS1	-3.64	0.000305	0.0349	-0.24	-0.17	Breast cancer;	chr10:51874597	chr10:52230742~52314128:-
HNSC	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	3.64	0.000305	0.0349	0.19	0.17	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
HNSC	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	3.64	0.000305	0.035	0.23	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
HNSC	cis	rs875971	0.558	rs4433015	ENSG00000273142.1	RP11-458F8.4	3.64	0.000305	0.035	0.14	0.17	Aortic root size;	chr7:66174736	chr7:66902857~66906297:+
HNSC	cis	rs13434995	0.842	rs62303685	ENSG00000273257.1	RP11-177J6.1	-3.64	0.000305	0.035	-0.28	-0.17	Adiponectin levels;	chr4:55418915	chr4:55387949~55388271:+
HNSC	cis	rs7100689	0.542	rs10887869	ENSG00000226659.1	RP11-137H2.4	-3.64	0.000305	0.035	-0.21	-0.17	Post bronchodilator FEV1;	chr10:80434933	chr10:80529597~80535942:-
HNSC	cis	rs9611565	0.592	rs9611613	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41565827	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.559	rs12483860	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41565912	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.559	rs7290990	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41568353	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.559	rs7290991	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41568357	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.592	rs5996037	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41569288	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.592	rs5996038	ENSG00000235513.1	RP4-756G23.5	3.64	0.000306	0.035	0.19	0.17	Vitiligo;	chr22:41569296	chr22:41209122~41217627:-
HNSC	cis	rs859767	0.709	rs7575742	ENSG00000224043.6	CCNT2-AS1	3.64	0.000306	0.035	0.2	0.17	Neuroticism;	chr2:134671432	chr2:134735464~134918710:-
HNSC	cis	rs9880211	0.613	rs13081671	ENSG00000239213.4	NCK1-AS1	3.64	0.000306	0.035	0.15	0.17	Height;Body mass index;	chr3:136157707	chr3:136841726~136862054:-
HNSC	cis	rs36715	0.951	rs36698	ENSG00000245937.6	LINC01184	3.64	0.000306	0.035	0.21	0.17	Breast cancer;	chr5:128214057	chr5:127940426~128083172:-
HNSC	cis	rs2061333	1	rs3746319	ENSG00000278492.1	RP11-15A1.9	-3.64	0.000306	0.035	-0.25	-0.17	Alzheimer's disease;	chr19:44108078	chr19:43978376~43978663:+
HNSC	cis	rs11951515	0.568	rs13354903	ENSG00000249286.1	CTD-2210P15.2	3.64	0.000306	0.035	0.18	0.17	Metabolite levels  (X-11787);	chr5:43331515	chr5:43586918~43588223:-
HNSC	cis	rs2048656	0.605	rs7837008	ENSG00000233609.3	RP11-62H7.2	3.64	0.000306	0.035	0.17	0.17	Schizophrenia;	chr8:9788996	chr8:8961200~8979025:+
HNSC	cis	rs2048656	0.605	rs7814507	ENSG00000233609.3	RP11-62H7.2	3.64	0.000306	0.035	0.17	0.17	Schizophrenia;	chr8:9789050	chr8:8961200~8979025:+
HNSC	cis	rs4704187	0.687	rs2335134	ENSG00000272040.1	CTC-366B18.4	-3.64	0.000306	0.035	-0.15	-0.17	Response to amphetamines;	chr5:75183018	chr5:75608817~75609983:+
HNSC	cis	rs2836974	0.899	rs34433511	ENSG00000255568.3	BRWD1-AS2	3.64	0.000306	0.035	0.15	0.17	Cognitive function;	chr21:39246957	chr21:39313935~39314962:+
HNSC	cis	rs4252134	0.881	rs4252181	ENSG00000231863.1	RP3-428L16.1	3.64	0.000306	0.035	0.22	0.17	Giant cell arteritis;	chr6:160753972	chr6:160931080~160969771:+
HNSC	cis	rs1440410	0.835	rs11100771	ENSG00000250326.1	RP11-284M14.1	3.64	0.000306	0.035	0.18	0.17	Ischemic stroke;	chr4:143132728	chr4:142933195~143184861:-
HNSC	cis	rs2115630	0.755	rs7169629	ENSG00000275120.1	RP11-182J1.17	3.64	0.000306	0.035	0.18	0.17	P wave terminal force;	chr15:84648043	chr15:84599434~84606463:-
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000204709.4	LINC01556	3.64	0.000306	0.035	0.29	0.17	Depression;	chr6:28111963	chr6:28943877~28944537:+
HNSC	cis	rs868153	0.591	rs12665385	ENSG00000275339.1	RP3-425C14.6	3.64	0.000306	0.035	0.19	0.17	Vertical cup-disc ratio;	chr6:122188462	chr6:122454358~122454612:+
HNSC	cis	rs853679	0.723	rs1736904	ENSG00000219891.2	ZSCAN12P1	3.64	0.000306	0.035	0.22	0.17	Depression;	chr6:28251492	chr6:28091154~28093664:+
HNSC	cis	rs853679	1	rs6901575	ENSG00000204709.4	LINC01556	3.64	0.000306	0.035	0.26	0.17	Depression;	chr6:28283207	chr6:28943877~28944537:+
HNSC	cis	rs8062405	1	rs4451951	ENSG00000261766.1	RP11-22P6.2	-3.64	0.000306	0.035	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28862166~28863340:-
HNSC	cis	rs2518049	1	rs12387	ENSG00000224034.1	RP11-445P17.8	-3.64	0.000306	0.035	-0.21	-0.17	Metabolic traits;	chr10:5097493	chr10:5266033~5271236:-
HNSC	cis	rs2976388	0.524	rs7012804	ENSG00000253741.1	CTD-2292P10.4	-3.64	0.000306	0.035	-0.15	-0.17	Urinary tract infection frequency;	chr8:142763232	chr8:142702252~142726973:-
HNSC	cis	rs8180991	0.744	rs34417638	ENSG00000254431.1	RP11-550A5.2	-3.64	0.000306	0.035	-0.25	-0.17	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125476332	chr8:125348196~125351416:-
HNSC	cis	rs6142618	0.846	rs11907716	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000306	0.035	-0.17	-0.17	Inflammatory bowel disease;	chr20:32189997	chr20:32116171~32116629:+
HNSC	cis	rs6142618	0.846	rs11907235	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000306	0.035	-0.17	-0.17	Inflammatory bowel disease;	chr20:32190057	chr20:32116171~32116629:+
HNSC	cis	rs683257	0.929	rs72990119	ENSG00000234147.1	RP3-460G2.2	-3.64	0.000306	0.035	-0.37	-0.17	Facial emotion recognition (angry faces);	chr6:140848009	chr6:140845958~140852924:-
HNSC	cis	rs7615952	0.641	rs6438951	ENSG00000241278.1	ENPP7P4	-3.64	0.000306	0.035	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:125978156	chr3:125848223~125909372:+
HNSC	cis	rs7092929	0.574	rs10795050	ENSG00000237399.6	PITRM1-AS1	3.64	0.000306	0.0351	0.18	0.17	Coronary artery calcification;	chr10:3496463	chr10:3141632~3167972:+
HNSC	cis	rs266719	0.509	rs1426810	ENSG00000223401.1	RP11-211G3.2	3.64	0.000306	0.0351	0.17	0.17	Adiponectin levels;	chr3:186785646	chr3:187743686~187745420:+
HNSC	cis	rs9287719	0.753	rs1990613	ENSG00000243819.4	RN7SL832P	-3.64	0.000306	0.0351	-0.15	-0.17	Prostate cancer;	chr2:10641849	chr2:10690344~10692099:+
HNSC	cis	rs859767	0.741	rs6713239	ENSG00000224043.6	CCNT2-AS1	3.64	0.000306	0.0351	0.2	0.17	Neuroticism;	chr2:134677279	chr2:134735464~134918710:-
HNSC	cis	rs6787172	0.644	rs55971926	ENSG00000272087.1	RP11-379F4.7	3.64	0.000306	0.0351	0.18	0.17	Subjective well-being;	chr3:158466856	chr3:158693120~158693768:-
HNSC	cis	rs9733	0.593	rs10888384	ENSG00000236713.1	RP11-363I22.3	3.64	0.000307	0.0351	0.18	0.17	Tonsillectomy;	chr1:150601780	chr1:150780272~150780644:+
HNSC	cis	rs7107174	0.901	rs11237459	ENSG00000251323.2	RP11-452H21.4	3.64	0.000307	0.0351	0.24	0.17	Testicular germ cell tumor;	chr11:78345227	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs11237460	ENSG00000251323.2	RP11-452H21.4	3.64	0.000307	0.0351	0.24	0.17	Testicular germ cell tumor;	chr11:78345228	chr11:78423982~78429836:-
HNSC	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	3.64	0.000307	0.0351	0.18	0.17	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
HNSC	cis	rs9583531	0.55	rs7985098	ENSG00000259831.1	LINC00567	3.64	0.000307	0.0351	0.19	0.17	Coronary artery disease;	chr13:110734069	chr13:110809676~110813084:-
HNSC	cis	rs73242632	0.737	rs4242005	ENSG00000245067.5	IGFBP7-AS1	3.64	0.000307	0.0351	0.34	0.17	Congenital heart disease (maternal effect);	chr4:57096301	chr4:57109762~57205510:+
HNSC	cis	rs17772222	0.511	rs12879875	ENSG00000258789.1	RP11-507K2.3	-3.64	0.000307	0.0351	-0.18	-0.17	Coronary artery calcification;	chr14:88840206	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.511	rs17124903	ENSG00000258789.1	RP11-507K2.3	-3.64	0.000307	0.0351	-0.18	-0.17	Coronary artery calcification;	chr14:88842934	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.511	rs10150833	ENSG00000258789.1	RP11-507K2.3	-3.64	0.000307	0.0351	-0.18	-0.17	Coronary artery calcification;	chr14:88843296	chr14:88551597~88552493:+
HNSC	cis	rs911555	0.706	rs10129426	ENSG00000269958.1	RP11-73M18.8	3.64	0.000307	0.0351	0.15	0.17	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103696353~103697163:+
HNSC	cis	rs56804039	1	rs11780966	ENSG00000254153.1	CTA-398F10.2	-3.64	0.000307	0.0351	-0.21	-0.17	Cervical cancer;	chr8:8525886	chr8:8456909~8461337:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	3.64	0.000307	0.0351	0.33	0.17	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
HNSC	cis	rs6460942	0.511	rs13245890	ENSG00000226690.5	AC005281.1	3.64	0.000307	0.0351	0.27	0.17	Coronary artery disease;	chr7:12503508	chr7:12496429~12541910:+
HNSC	cis	rs6460942	0.597	rs7778131	ENSG00000226690.5	AC005281.1	3.64	0.000307	0.0351	0.27	0.17	Coronary artery disease;	chr7:12503607	chr7:12496429~12541910:+
HNSC	cis	rs868153	0.591	rs1379088	ENSG00000275339.1	RP3-425C14.6	3.64	0.000307	0.0351	0.18	0.17	Vertical cup-disc ratio;	chr6:122223758	chr6:122454358~122454612:+
HNSC	cis	rs12893668	0.667	rs11844466	ENSG00000269958.1	RP11-73M18.8	3.64	0.000307	0.0351	0.16	0.17	Reticulocyte count;	chr14:103600085	chr14:103696353~103697163:+
HNSC	cis	rs10134944	1	rs34261212	ENSG00000258900.1	HNRNPCP1	3.64	0.000307	0.0351	0.31	0.17	Bipolar disorder;	chr14:57654453	chr14:58521223~58521988:+
HNSC	cis	rs6787172	0.667	rs10936142	ENSG00000272087.1	RP11-379F4.7	3.64	0.000307	0.0351	0.18	0.17	Subjective well-being;	chr3:158454616	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.667	rs4324501	ENSG00000272087.1	RP11-379F4.7	3.64	0.000307	0.0351	0.18	0.17	Subjective well-being;	chr3:158458200	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.667	rs12631628	ENSG00000272087.1	RP11-379F4.7	3.64	0.000307	0.0351	0.18	0.17	Subjective well-being;	chr3:158459634	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.652	rs12631675	ENSG00000272087.1	RP11-379F4.7	3.64	0.000307	0.0351	0.18	0.17	Subjective well-being;	chr3:158459793	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.644	rs55705928	ENSG00000272087.1	RP11-379F4.7	3.64	0.000307	0.0351	0.18	0.17	Subjective well-being;	chr3:158463730	chr3:158693120~158693768:-
HNSC	cis	rs1620921	0.774	rs2565721	ENSG00000233342.1	RP11-235G24.3	-3.64	0.000307	0.0351	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160814066	chr6:160926369~160927162:+
HNSC	cis	rs2708377	0.789	rs3911150	ENSG00000212125.2	TAS2R15P	-3.64	0.000307	0.0351	-0.24	-0.17	Bitter taste perception;	chr12:11049649	chr12:10964425~10965352:-
HNSC	cis	rs6088580	0.713	rs1884669	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000307	0.0351	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:33985617~33988989:-
HNSC	cis	rs3771570	1	rs62186400	ENSG00000260942.1	CAPN10-AS1	-3.64	0.000307	0.0351	-0.19	-0.17	Prostate cancer;	chr2:241287285	chr2:240582700~240586699:-
HNSC	cis	rs3771570	1	rs56363214	ENSG00000260942.1	CAPN10-AS1	-3.64	0.000307	0.0351	-0.19	-0.17	Prostate cancer;	chr2:241287742	chr2:240582700~240586699:-
HNSC	cis	rs6731420	0.519	rs12477570	ENSG00000234896.1	OR7E62P	3.64	0.000307	0.0351	0.19	0.17	Intelligence (multi-trait analysis);	chr2:71281055	chr2:71055527~71056003:+
HNSC	cis	rs12701220	0.553	rs13245507	ENSG00000224079.1	AC091729.7	3.64	0.000307	0.0351	0.25	0.17	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1074450~1078036:+
HNSC	cis	rs6587515	0.901	rs10788795	ENSG00000274963.1	Metazoa_SRP	-3.64	0.000307	0.0351	-0.27	-0.17	Pericardial adipose tissue adjusted for height and weight;	chr1:150785571	chr1:150568971~150569269:-
HNSC	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	3.64	0.000307	0.0351	0.2	0.17	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	3.64	0.000307	0.0351	0.2	0.17	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	3.64	0.000307	0.0351	0.2	0.17	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	3.64	0.000307	0.0351	0.2	0.17	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
HNSC	cis	rs7589342	0.566	rs11895542	ENSG00000272994.1	RP11-332H14.2	3.64	0.000307	0.0351	0.13	0.17	Addiction;	chr2:105773972	chr2:105334027~105337475:-
HNSC	cis	rs453301	0.686	rs7017868	ENSG00000253981.4	ALG1L13P	-3.64	0.000307	0.0351	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9015783	chr8:8236003~8244667:-
HNSC	cis	rs6840258	0.76	rs340626	ENSG00000251411.1	RP11-397E7.4	3.64	0.000307	0.0351	0.19	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87035287	chr4:86913266~86914817:-
HNSC	cis	rs1075232	1	rs9672214	ENSG00000103832.10	GOLGA8UP	-3.64	0.000307	0.0351	-0.34	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30791573~30801859:+
HNSC	cis	rs6545883	0.894	rs9677047	ENSG00000271889.1	RP11-493E12.1	-3.64	0.000307	0.0351	-0.19	-0.17	Tuberculosis;	chr2:61358160	chr2:61151433~61162105:-
HNSC	cis	rs2288884	0.579	rs6509603	ENSG00000275055.1	CTC-471J1.11	-3.64	0.000307	0.0351	-0.24	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52049007~52049754:+
HNSC	cis	rs1832007	0.554	rs11596429	ENSG00000224034.1	RP11-445P17.8	-3.64	0.000307	0.0351	-0.2	-0.17	Triglyceride levels;Triglycerides;	chr10:5203345	chr10:5266033~5271236:-
HNSC	cis	rs7819412	0.668	rs2409714	ENSG00000255310.2	AF131215.2	-3.64	0.000307	0.0351	-0.16	-0.17	Triglycerides;	chr8:11152608	chr8:11107788~11109726:-
HNSC	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-3.64	0.000307	0.0351	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
HNSC	cis	rs6088580	0.634	rs9789792	ENSG00000276073.1	RP5-1125A11.7	3.64	0.000307	0.0351	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:33985617~33988989:-
HNSC	cis	rs12410462	0.502	rs78101727	ENSG00000224834.1	BTF3P9	3.64	0.000307	0.0351	0.31	0.17	Major depressive disorder;	chr1:227544368	chr1:227434064~227434346:+
HNSC	cis	rs728616	0.681	rs56184245	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000307	0.0351	-0.32	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80258800	chr10:79663088~79826594:-
HNSC	cis	rs7572733	1	rs9973400	ENSG00000222017.1	AC011997.1	3.64	0.000307	0.0351	0.2	0.17	Dermatomyositis;	chr2:198076854	chr2:197693106~197774823:+
HNSC	cis	rs4704187	0.687	rs4340901	ENSG00000271815.1	CTD-2235C13.3	-3.64	0.000307	0.0351	-0.21	-0.17	Response to amphetamines;	chr5:75109080	chr5:75363760~75364242:+
HNSC	cis	rs4381823	1	rs17036971	ENSG00000235369.1	RPL36AP15	3.64	0.000307	0.0351	0.41	0.17	Schizophrenia;	chr2:47808854	chr2:47797826~47798091:-
HNSC	cis	rs9863	0.828	rs12311848	ENSG00000270028.1	RP11-380L11.4	3.64	0.000307	0.0351	0.2	0.17	White blood cell count;	chr12:124002304	chr12:123925461~123926083:-
HNSC	cis	rs5758511	0.514	rs5758637	ENSG00000205702.9	CYP2D7	3.64	0.000307	0.0351	0.14	0.17	Birth weight;	chr22:42184927	chr22:42140203~42144577:-
HNSC	cis	rs459482	0.508	rs461093	ENSG00000228318.3	AP001610.5	3.64	0.000307	0.0351	0.19	0.17	IgG glycosylation;	chr21:41428263	chr21:41441056~41445708:-
HNSC	cis	rs2243480	0.901	rs58207111	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000307	0.0351	-0.24	-0.17	Diabetic kidney disease;	chr7:66021736	chr7:66848496~66858136:+
HNSC	cis	rs4950322	0.542	rs115179956	ENSG00000278811.3	LINC00624	3.64	0.000307	0.0351	0.17	0.17	Protein quantitative trait loci;	chr1:147172620	chr1:147258885~147517875:-
HNSC	cis	rs950027	0.62	rs2461700	ENSG00000259479.5	SORD2P	3.64	0.000307	0.0351	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:44826371~44884694:-
HNSC	cis	rs10832963	1	rs7943121	ENSG00000256282.1	RP11-504G3.4	-3.64	0.000307	0.0351	-0.16	-0.17	Breast cancer;	chr11:18634515	chr11:18595459~18599683:-
HNSC	cis	rs10832963	1	rs10832962	ENSG00000256282.1	RP11-504G3.4	-3.64	0.000307	0.0351	-0.16	-0.17	Breast cancer;	chr11:18634724	chr11:18595459~18599683:-
HNSC	cis	rs1866631	0.565	rs3769161	ENSG00000238133.5	MLK7-AS1	3.64	0.000307	0.0351	0.18	0.17	Lung cancer in ever smokers;	chr2:173201747	chr2:173166446~173282036:-
HNSC	cis	rs7826238	0.601	rs2979206	ENSG00000254340.1	RP11-10A14.3	3.64	0.000307	0.0351	0.2	0.17	Systolic blood pressure;	chr8:8488071	chr8:9141424~9145435:+
HNSC	cis	rs11846409	0.86	rs59055020	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000307	0.0352	-0.14	-0.17	Rheumatic heart disease;	chr14:106631573	chr14:106762092~106762588:-
HNSC	cis	rs28489187	0.706	rs233074	ENSG00000223653.4	RP11-131L23.1	3.64	0.000308	0.0352	0.24	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85343382	chr1:85276715~85448124:+
HNSC	cis	rs7829975	0.582	rs6983150	ENSG00000253981.4	ALG1L13P	-3.64	0.000308	0.0352	-0.18	-0.17	Mood instability;	chr8:8934916	chr8:8236003~8244667:-
HNSC	cis	rs988913	0.874	rs4712084	ENSG00000224984.1	RP11-524H19.2	3.64	0.000308	0.0352	0.19	0.17	Menarche (age at onset);	chr6:54996486	chr6:54840118~54840855:-
HNSC	cis	rs643506	0.817	rs1940392	ENSG00000230911.1	PPIHP1	-3.64	0.000308	0.0352	-0.22	-0.17	Breast cancer;	chr11:111906122	chr11:112029858~112030367:-
HNSC	cis	rs860295	0.58	rs2016251	ENSG00000203761.5	MSTO2P	-3.64	0.000308	0.0352	-0.13	-0.17	Body mass index;	chr1:155945197	chr1:155745829~155750137:+
HNSC	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	3.64	0.000308	0.0352	0.24	0.17	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
HNSC	cis	rs748404	0.666	rs7181783	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43469723	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs34181131	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43478527	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs7173383	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43480838	chr15:43699488~43718184:-
HNSC	cis	rs748404	0.666	rs12911740	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43498254	chr15:43699488~43718184:-
HNSC	cis	rs73201462	0.908	rs2955098	ENSG00000231305.3	RP11-723O4.2	3.64	0.000308	0.0352	0.24	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260658	chr3:128861313~128871540:-
HNSC	cis	rs67478160	0.608	rs11628787	ENSG00000269940.1	RP11-73M18.7	-3.64	0.000308	0.0352	-0.16	-0.17	Schizophrenia;	chr14:103857647	chr14:103694560~103695170:+
HNSC	cis	rs913655	0.819	rs2495823	ENSG00000225527.1	RP11-383B4.4	-3.64	0.000308	0.0352	-0.22	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18801199	chr10:18531849~18533336:-
HNSC	cis	rs9287719	0.639	rs2357650	ENSG00000243819.4	RN7SL832P	3.64	0.000308	0.0352	0.17	0.17	Prostate cancer;	chr2:10556751	chr2:10690344~10692099:+
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000255310.2	AF131215.2	3.64	0.000308	0.0352	0.16	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11107788~11109726:-
HNSC	cis	rs6430585	0.583	rs6728946	ENSG00000231890.6	DARS-AS1	-3.64	0.000308	0.0352	-0.29	-0.17	Corneal structure;	chr2:135877773	chr2:135985176~136022593:+
HNSC	cis	rs2836974	0.931	rs2989330	ENSG00000255568.3	BRWD1-AS2	3.64	0.000308	0.0352	0.16	0.17	Cognitive function;	chr21:39344283	chr21:39313935~39314962:+
HNSC	cis	rs7246657	0.722	rs3101746	ENSG00000276846.1	CTD-3220F14.3	-3.64	0.000308	0.0352	-0.23	-0.17	Coronary artery calcification;	chr19:37655499	chr19:37314868~37315620:-
HNSC	cis	rs7405404	0.672	rs9940897	ENSG00000262454.1	RP11-65J21.3	-3.64	0.000308	0.0352	-0.15	-0.17	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13644805	chr16:14302288~14326353:+
HNSC	cis	rs734999	0.588	rs3748818	ENSG00000238164.5	RP3-395M20.8	-3.64	0.000308	0.0352	-0.12	-0.17	Ulcerative colitis;	chr1:2594221	chr1:2549920~2557031:-
HNSC	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	3.64	0.000308	0.0352	0.24	0.17	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
HNSC	cis	rs860295	0.812	rs12407800	ENSG00000225855.5	RUSC1-AS1	3.64	0.000308	0.0352	0.11	0.17	Body mass index;	chr1:155790951	chr1:155316863~155324176:-
HNSC	cis	rs748404	0.589	rs3862138	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43523801	chr15:43699488~43718184:-
HNSC	cis	rs868153	0.625	rs35099519	ENSG00000275339.1	RP3-425C14.6	3.64	0.000308	0.0352	0.18	0.17	Vertical cup-disc ratio;	chr6:122257125	chr6:122454358~122454612:+
HNSC	cis	rs6787172	0.72	rs1630524	ENSG00000272087.1	RP11-379F4.7	3.64	0.000308	0.0352	0.17	0.17	Subjective well-being;	chr3:158552510	chr3:158693120~158693768:-
HNSC	cis	rs4246076	0.804	rs10214456	ENSG00000215057.4	PKMP5	3.64	0.000308	0.0352	0.19	0.17	Urate levels in overweight individuals;	chr6:6591862	chr6:5972412~5974012:+
HNSC	cis	rs7011507	0.648	rs6471752	ENSG00000253608.1	RP11-770E5.1	-3.64	0.000308	0.0352	-0.27	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr8:48396607	chr8:48551567~48698510:+
HNSC	cis	rs853679	1	rs6901575	ENSG00000219891.2	ZSCAN12P1	3.64	0.000308	0.0352	0.27	0.17	Depression;	chr6:28283207	chr6:28091154~28093664:+
HNSC	cis	rs11168618	0.692	rs4760707	ENSG00000240399.1	RP1-228P16.1	3.64	0.000308	0.0352	0.14	0.17	Adiponectin levels;	chr12:48454857	chr12:48054813~48055591:-
HNSC	cis	rs3741151	0.686	rs7125598	ENSG00000256448.4	RP11-809N8.4	-3.64	0.000308	0.0352	-0.23	-0.17	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73449544	chr11:73405297~73410682:+
HNSC	cis	rs35306767	0.855	rs12781100	ENSG00000229869.1	RP11-363N22.2	-3.64	0.000308	0.0352	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:792696	chr10:933026~942743:+
HNSC	cis	rs67072384	1	rs67072384	ENSG00000213365.3	AP000593.6	3.64	0.000308	0.0352	0.28	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739679	chr11:72280151~72281178:+
HNSC	cis	rs67072384	1	rs67809272	ENSG00000213365.3	AP000593.6	3.64	0.000308	0.0352	0.28	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739896	chr11:72280151~72281178:+
HNSC	cis	rs748404	0.589	rs62020612	ENSG00000166763.7	STRCP1	3.64	0.000308	0.0352	0.23	0.17	Lung cancer;	chr15:43525881	chr15:43699488~43718184:-
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000254153.1	CTA-398F10.2	3.64	0.000308	0.0352	0.19	0.17	Recombination measurement;	chr8:9205517	chr8:8456909~8461337:-
HNSC	cis	rs2638953	0.962	rs11049621	ENSG00000257176.2	RP11-996F15.2	3.64	0.000308	0.0352	0.18	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:29280418~29317848:-
HNSC	cis	rs7824557	0.564	rs34964435	ENSG00000255495.1	AC145124.2	-3.64	0.000309	0.0352	-0.18	-0.17	Retinal vascular caliber;	chr8:11372697	chr8:12194467~12196280:+
HNSC	cis	rs7475343	0.538	rs2211630	ENSG00000224034.1	RP11-445P17.8	3.64	0.000309	0.0352	0.21	0.17	Intelligence;	chr10:5117604	chr10:5266033~5271236:-
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000309	0.0353	-0.24	-0.17	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000309	0.0353	-0.24	-0.17	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000309	0.0353	-0.24	-0.17	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000309	0.0353	-0.24	-0.17	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000309	0.0353	-0.24	-0.17	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
HNSC	cis	rs17122278	1	rs73022038	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118537756	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs73022041	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118538074	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs73022042	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118538178	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs7128587	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118538587	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs11216883	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118539753	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs11216884	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118539773	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs11216886	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118540709	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs61290697	ENSG00000255422.1	AP002954.4	3.64	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118541643	chr11:118704607~118750263:+
HNSC	cis	rs4873772	0.714	rs1231201	ENSG00000253330.1	RP11-697N18.3	3.64	0.000309	0.0353	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr8:47933603	chr8:47511034~47512141:-
HNSC	cis	rs62025270	0.688	rs17576534	ENSG00000259762.1	RP11-158M2.4	-3.64	0.000309	0.0353	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85750336~85752901:-
HNSC	cis	rs673253	0.597	rs58097944	ENSG00000234694.1	RP1-92O14.3	-3.64	0.000309	0.0353	-0.17	-0.17	Intelligence (multi-trait analysis);	chr1:43589323	chr1:43354684~43358658:-
HNSC	cis	rs4950322	0.58	rs17355419	ENSG00000230832.3	RP11-325P15.2	-3.64	0.000309	0.0353	-0.22	-0.17	Protein quantitative trait loci;	chr1:147110094	chr1:147082338~147083578:-
HNSC	cis	rs4950322	0.58	rs72706428	ENSG00000230832.3	RP11-325P15.2	-3.64	0.000309	0.0353	-0.22	-0.17	Protein quantitative trait loci;	chr1:147110219	chr1:147082338~147083578:-
HNSC	cis	rs4950322	0.563	rs61838944	ENSG00000230832.3	RP11-325P15.2	-3.64	0.000309	0.0353	-0.22	-0.17	Protein quantitative trait loci;	chr1:147110275	chr1:147082338~147083578:-
HNSC	cis	rs950169	0.92	rs2135551	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000309	0.0353	-0.18	-0.17	Schizophrenia;	chr15:84039099	chr15:84507885~84516814:-
HNSC	cis	rs526231	0.511	rs27896	ENSG00000250682.4	LINC00491	3.64	0.000309	0.0353	0.22	0.17	Primary biliary cholangitis;	chr5:103152867	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.543	rs246909	ENSG00000250682.4	LINC00491	3.64	0.000309	0.0353	0.22	0.17	Primary biliary cholangitis;	chr5:103227976	chr5:102609156~102671559:-
HNSC	cis	rs4388249	0.861	rs11956236	ENSG00000271849.1	CTC-332L22.1	-3.64	0.000309	0.0353	-0.27	-0.17	Schizophrenia;	chr5:109871780	chr5:109687802~109688329:-
HNSC	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	3.63	0.000309	0.0353	0.32	0.17	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
HNSC	cis	rs7246760	0.867	rs67539464	ENSG00000267289.1	CTD-2623N2.11	3.63	0.000309	0.0353	0.28	0.17	Pursuit maintenance gain;	chr19:9721748	chr19:9834079~9835013:-
HNSC	cis	rs7246760	0.867	rs57943754	ENSG00000267289.1	CTD-2623N2.11	3.63	0.000309	0.0353	0.28	0.17	Pursuit maintenance gain;	chr19:9730607	chr19:9834079~9835013:-
HNSC	cis	rs5758511	0.68	rs5758684	ENSG00000233903.2	Z83851.4	3.63	0.000309	0.0353	0.25	0.17	Birth weight;	chr22:42253503	chr22:42276355~42277052:+
HNSC	cis	rs11992162	0.508	rs7003792	ENSG00000227888.4	FAM66A	-3.63	0.000309	0.0353	-0.17	-0.17	Monocyte count;	chr8:11923955	chr8:12362019~12388296:+
HNSC	cis	rs2310173	0.575	rs2110563	ENSG00000281162.1	LINC01127	-3.63	0.000309	0.0353	-0.21	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102011971	chr2:101962056~101987167:+
HNSC	cis	rs3736485	0.932	rs11633395	ENSG00000274528.1	CTD-2650P22.2	3.63	0.000309	0.0353	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51625760	chr15:52017167~52018032:-
HNSC	cis	rs16958440	0.867	rs77348110	ENSG00000267724.1	RP11-49K24.8	3.63	0.000309	0.0353	0.32	0.17	Sitting height ratio;	chr18:47147796	chr18:47105946~47108062:+
HNSC	cis	rs17122278	1	rs3741324	ENSG00000255422.1	AP002954.4	3.63	0.000309	0.0353	0.29	0.17	Total cholesterol levels;	chr11:118535120	chr11:118704607~118750263:+
HNSC	cis	rs73198271	1	rs73198271	ENSG00000253893.2	FAM85B	3.63	0.000309	0.0353	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:8167819~8226614:-
HNSC	cis	rs73198271	1	rs73198272	ENSG00000253893.2	FAM85B	3.63	0.000309	0.0353	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:8167819~8226614:-
HNSC	cis	rs73198271	1	rs4841030	ENSG00000253893.2	FAM85B	3.63	0.000309	0.0353	0.24	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:8167819~8226614:-
HNSC	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-3.63	0.000309	0.0353	-0.17	-0.17	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
HNSC	cis	rs700651	0.752	rs7592556	ENSG00000222017.1	AC011997.1	3.63	0.000309	0.0353	0.21	0.17	Intracranial aneurysm;	chr2:198026297	chr2:197693106~197774823:+
HNSC	cis	rs709400	0.859	rs942863	ENSG00000270108.1	RP11-73M18.6	3.63	0.000309	0.0353	0.18	0.17	Body mass index;	chr14:103554931	chr14:103687576~103688127:+
HNSC	cis	rs6570726	1	rs386678	ENSG00000270638.1	RP3-466P17.1	3.63	0.000309	0.0353	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145735570~145737218:+
HNSC	cis	rs61990749	0.597	rs717683	ENSG00000239272.1	RPL21P10	3.63	0.000309	0.0353	0.24	0.17	Fibroblast growth factor basic levels;	chr14:77789110	chr14:77683202~77683989:-
HNSC	cis	rs61990749	0.544	rs1477259	ENSG00000239272.1	RPL21P10	3.63	0.000309	0.0353	0.24	0.17	Fibroblast growth factor basic levels;	chr14:77789795	chr14:77683202~77683989:-
HNSC	cis	rs9768139	0.683	rs72505558	ENSG00000223872.1	AC006372.5	-3.63	0.000309	0.0353	-0.18	-0.17	Calcium levels;	chr7:158320523	chr7:157501322~157503577:+
HNSC	cis	rs886774	0.774	rs2108224	ENSG00000273055.1	CTB-13F3.1	3.63	0.000309	0.0353	0.17	0.17	Ulcerative colitis;	chr7:107943181	chr7:107942116~107942740:+
HNSC	cis	rs8077577	0.895	rs11658477	ENSG00000273018.4	CTD-2303H24.2	-3.63	0.000309	0.0353	-0.26	-0.17	Obesity-related traits;	chr17:18141579	chr17:18511221~18551705:-
HNSC	cis	rs62025270	0.547	rs386346	ENSG00000259407.1	RP11-158M2.3	3.63	0.00031	0.0353	0.19	0.17	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85744109~85750281:-
HNSC	cis	rs8030379	1	rs6603003	ENSG00000230373.7	GOLGA6L5P	-3.63	0.00031	0.0353	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84507885~84516814:-
HNSC	cis	rs2070419	0.724	rs9974876	ENSG00000261610.1	AP000265.1	3.63	0.00031	0.0353	0.2	0.17	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31566905	chr21:32259804~32261585:-
HNSC	cis	rs950169	0.92	rs11637666	ENSG00000230373.7	GOLGA6L5P	-3.63	0.00031	0.0353	-0.19	-0.17	Schizophrenia;	chr15:84035122	chr15:84507885~84516814:-
HNSC	cis	rs9813712	0.818	rs16845853	ENSG00000228252.7	COL6A4P2	3.63	0.00031	0.0353	0.17	0.17	Response to amphetamines;	chr3:130229587	chr3:130212823~130273806:+
HNSC	cis	rs727563	0.635	rs5758444	ENSG00000233903.2	Z83851.4	3.63	0.00031	0.0353	0.25	0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr22:42276355~42277052:+
HNSC	cis	rs12586317	0.513	rs74564132	ENSG00000258704.4	SRP54-AS1	-3.63	0.00031	0.0353	-0.22	-0.17	Psoriasis;	chr14:35003676	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs28569331	ENSG00000258704.4	SRP54-AS1	-3.63	0.00031	0.0353	-0.22	-0.17	Psoriasis;	chr14:35004378	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs74243586	ENSG00000258704.4	SRP54-AS1	-3.63	0.00031	0.0353	-0.22	-0.17	Psoriasis;	chr14:35008119	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs28589276	ENSG00000258704.4	SRP54-AS1	-3.63	0.00031	0.0353	-0.22	-0.17	Psoriasis;	chr14:35009659	chr14:34920858~34982532:-
HNSC	cis	rs639012	0.636	rs7941541	ENSG00000279742.1	RP11-700A24.1	3.63	0.00031	0.0354	0.19	0.17	Alzheimer's disease in APOE e4+ carriers;	chr11:86147496	chr11:85852557~85854943:-
HNSC	cis	rs11846409	0.86	rs61686131	ENSG00000280411.1	IGHV1-69-2	-3.63	0.00031	0.0354	-0.15	-0.17	Rheumatic heart disease;	chr14:106631568	chr14:106762092~106762588:-
HNSC	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	3.63	0.00031	0.0354	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
HNSC	cis	rs3733585	0.605	rs7656624	ENSG00000250413.1	RP11-448G15.1	3.63	0.00031	0.0354	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10119473	chr4:10006482~10009725:+
HNSC	cis	rs7781557	0.646	rs12113759	ENSG00000239969.4	RP11-163E9.2	-3.63	0.00031	0.0354	-0.23	-0.17	Colorectal adenoma (advanced);	chr7:102800467	chr7:102364162~102380633:+
HNSC	cis	rs7781557	1	rs4610658	ENSG00000239969.4	RP11-163E9.2	-3.63	0.00031	0.0354	-0.23	-0.17	Colorectal adenoma (advanced);	chr7:102805448	chr7:102364162~102380633:+
HNSC	cis	rs9457247	1	rs386548	ENSG00000227598.1	RP1-167A14.2	3.63	0.00031	0.0354	0.17	0.17	Crohn's disease;	chr6:166972045	chr6:166969626~166999065:-
HNSC	cis	rs17250963	0.645	rs192218	ENSG00000249485.1	RBBP4P1	-3.63	0.00031	0.0354	-0.16	-0.17	Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr5:14741560	chr5:14797125~14798400:-
HNSC	cis	rs11633886	0.785	rs11637965	ENSG00000273972.1	CTD-2306A12.1	-3.63	0.00031	0.0354	-0.2	-0.17	Diisocyanate-induced asthma;	chr15:45772645	chr15:45702640~45703183:+
HNSC	cis	rs2836974	0.644	rs2836981	ENSG00000255568.3	BRWD1-AS2	-3.63	0.00031	0.0354	-0.14	-0.17	Cognitive function;	chr21:39316439	chr21:39313935~39314962:+
HNSC	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	3.63	0.00031	0.0354	0.19	0.17	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
HNSC	cis	rs7027203	0.576	rs11792101	ENSG00000227603.1	RP11-165J3.6	3.63	0.00031	0.0354	0.15	0.17	DNA methylation (variation);	chr9:93773188	chr9:93435332~93437121:-
HNSC	cis	rs62202398	0.618	rs73315407	ENSG00000276923.1	RP11-321P16.1	-3.63	0.00031	0.0354	-0.3	-0.17	Alcohol consumption;	chr20:48152920	chr20:48073869~48074188:+
HNSC	cis	rs1440410	0.835	rs11722027	ENSG00000250326.1	RP11-284M14.1	-3.63	0.00031	0.0354	-0.18	-0.17	Ischemic stroke;	chr4:143128864	chr4:142933195~143184861:-
HNSC	cis	rs12545109	0.765	rs2438063	ENSG00000246430.5	LINC00968	3.63	0.00031	0.0354	0.21	0.17	Obesity-related traits;	chr8:56471801	chr8:56496246~56559823:-
HNSC	cis	rs1075232	1	rs12437749	ENSG00000260382.1	RP11-540B6.2	-3.63	0.00031	0.0354	-0.37	-0.17	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30882267~30883231:-
HNSC	cis	rs3733585	0.579	rs4235356	ENSG00000250413.1	RP11-448G15.1	3.63	0.00031	0.0354	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10121482	chr4:10006482~10009725:+
HNSC	cis	rs5758659	1	rs5758659	ENSG00000270083.1	RP1-257I20.14	3.63	0.00031	0.0354	0.15	0.17	Cognitive function;	chr22:42225997	chr22:42089630~42090028:-
HNSC	cis	rs7023329	0.59	rs6475568	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21733707	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs6475569	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21733890	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.56	rs7854222	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734349	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs7854018	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734367	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs10757240	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734450	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs10757241	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734481	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs10811601	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734834	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.561	rs10811602	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21734837	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.505	rs1335502	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21736275	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs1414238	ENSG00000244230.3	RN7SL151P	3.63	0.00031	0.0354	0.17	0.17	Melanoma;	chr9:21737150	chr9:21699314~21699596:+
HNSC	cis	rs3736485	0.609	rs11638154	ENSG00000274528.1	CTD-2650P22.2	3.63	0.00031	0.0354	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51677219	chr15:52017167~52018032:-
HNSC	cis	rs2908197	0.843	rs1076437	ENSG00000186704.9	DTX2P1	3.63	0.00031	0.0354	0.16	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76310404	chr7:76978617~77004308:+
HNSC	cis	rs2337406	1	rs1961901	ENSG00000211972.2	IGHV3-66	3.63	0.00031	0.0354	0.17	0.17	Alzheimer's disease (late onset);	chr14:106680856	chr14:106675017~106675544:-
HNSC	cis	rs2337406	1	rs4774172	ENSG00000211972.2	IGHV3-66	3.63	0.00031	0.0354	0.17	0.17	Alzheimer's disease (late onset);	chr14:106681320	chr14:106675017~106675544:-
HNSC	cis	rs2337406	1	rs4774173	ENSG00000211972.2	IGHV3-66	3.63	0.00031	0.0354	0.17	0.17	Alzheimer's disease (late onset);	chr14:106682029	chr14:106675017~106675544:-
HNSC	cis	rs7637230	0.685	rs28609215	ENSG00000244119.1	PDCL3P4	-3.63	0.00031	0.0354	-0.18	-0.17	Psoriasis vulgaris;Psoriasis;	chr3:101926305	chr3:101712472~101713191:+
HNSC	cis	rs7216064	1	rs7221651	ENSG00000277476.1	RP11-147L13.13	3.63	0.00031	0.0354	0.18	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836274	chr17:68133201~68135935:+
HNSC	cis	rs1908814	0.516	rs11250178	ENSG00000269918.1	AF131215.9	3.63	0.00031	0.0354	0.16	0.17	Neuroticism;	chr8:11942725	chr8:11104691~11106704:-
HNSC	cis	rs870825	0.616	rs6814278	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184723263	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6844588	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184723363	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs28451943	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184724418	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6852082	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184724629	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.55	rs59051283	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184725322	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.55	rs57301026	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184725351	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28582728	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184725766	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28442259	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184725808	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs28555435	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726146	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28672716	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726191	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28375770	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726241	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28524599	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726260	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs2090589	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726577	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs2090590	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726696	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs2310110	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184726748	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7700216	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727356	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.549	rs7699919	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727456	chr4:184584093~184625030:-
HNSC	cis	rs7683537	0.887	rs7678412	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Systemic lupus erythematosus;	chr4:184727457	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7678616	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727560	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7678849	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727714	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7654208	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727723	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28445002	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727823	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28649620	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727843	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28618216	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184727844	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs10022834	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184728277	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.52	rs10022842	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184728305	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs10025167	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.24	0.17	Blood protein levels;	chr4:184728397	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.86	rs2696044	ENSG00000254233.1	RP11-242J7.1	3.63	0.00031	0.0354	0.25	0.17	Blood protein levels;	chr4:184674834	chr4:184584093~184625030:-
HNSC	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-3.63	0.00031	0.0354	-0.23	-0.17	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
HNSC	cis	rs860295	0.812	rs12081192	ENSG00000225855.5	RUSC1-AS1	3.63	0.00031	0.0354	0.11	0.17	Body mass index;	chr1:155768253	chr1:155316863~155324176:-
HNSC	cis	rs73198271	0.92	rs11783112	ENSG00000173295.6	FAM86B3P	-3.63	0.00031	0.0354	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:8228595~8244865:+
HNSC	cis	rs36715	1	rs36697	ENSG00000245937.6	LINC01184	3.63	0.00031	0.0354	0.21	0.17	Breast cancer;	chr5:128213921	chr5:127940426~128083172:-
HNSC	cis	rs7746199	0.736	rs35037868	ENSG00000241549.7	GUSBP2	3.63	0.00031	0.0354	0.29	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:26871484~26956554:-
HNSC	cis	rs9329221	0.512	rs7843924	ENSG00000255310.2	AF131215.2	3.63	0.00031	0.0354	0.16	0.17	Neuroticism;	chr8:10119030	chr8:11107788~11109726:-
HNSC	cis	rs2337406	0.866	rs74092512	ENSG00000280411.1	IGHV1-69-2	-3.63	0.000311	0.0354	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106779306	chr14:106762092~106762588:-
HNSC	cis	rs35306767	0.633	rs17221491	ENSG00000229869.1	RP11-363N22.2	-3.63	0.000311	0.0354	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:1019251	chr10:933026~942743:+
HNSC	cis	rs2013441	1	rs11870147	ENSG00000261033.1	RP11-209D14.2	3.63	0.000311	0.0354	0.19	0.17	Obesity-related traits;	chr17:20312782	chr17:20008051~20009234:-
HNSC	cis	rs9297145	0.724	rs6958790	ENSG00000272950.1	RP11-307C18.1	3.63	0.000311	0.0354	0.25	0.17	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99177115	chr7:98322853~98323430:+
HNSC	cis	rs614226	0.938	rs7972244	ENSG00000202538.1	RNU4-2	-3.63	0.000311	0.0354	-0.28	-0.17	Type 1 diabetes nephropathy;	chr12:120557069	chr12:120291763~120291903:-
HNSC	cis	rs614226	0.935	rs7956998	ENSG00000202538.1	RNU4-2	-3.63	0.000311	0.0354	-0.28	-0.17	Type 1 diabetes nephropathy;	chr12:120557129	chr12:120291763~120291903:-
HNSC	cis	rs11853189	1	rs2867933	ENSG00000259562.2	RP11-762H8.2	-3.63	0.000311	0.0354	-0.19	-0.17	Red cell distribution width;	chr15:78282445	chr15:78290527~78291221:-
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000233609.3	RP11-62H7.2	3.63	0.000311	0.0354	0.16	0.17	Mood instability;	chr8:8401202	chr8:8961200~8979025:+
HNSC	cis	rs10040610	0.822	rs62330543	ENSG00000250490.1	FLJ33360	-3.63	0.000311	0.0354	-0.28	-0.17	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6341769	chr5:6310441~6339884:-
HNSC	cis	rs6570726	0.846	rs6570700	ENSG00000270638.1	RP3-466P17.1	3.63	0.000311	0.0354	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.846	rs870491	ENSG00000270638.1	RP3-466P17.1	3.63	0.000311	0.0354	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs4332001	ENSG00000270638.1	RP3-466P17.1	3.63	0.000311	0.0354	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145735570~145737218:+
HNSC	cis	rs6928977	0.733	rs9321500	ENSG00000217482.2	HMGB1P17	-3.63	0.000311	0.0354	-0.18	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320231	chr6:135636086~135636713:-
HNSC	cis	rs11951515	0.738	rs56185290	ENSG00000249286.1	CTD-2210P15.2	3.63	0.000311	0.0355	0.18	0.17	Metabolite levels  (X-11787);	chr5:43356604	chr5:43586918~43588223:-
HNSC	cis	rs1662342	1	rs1662342	ENSG00000272625.1	RP11-737O24.5	-3.63	0.000311	0.0355	-0.27	-0.17	QRS duration;	chr18:3255303	chr18:2920966~2921685:+
HNSC	cis	rs3748656	0.945	rs34107138	ENSG00000273483.1	RP4-671G15.2	3.63	0.000311	0.0355	0.22	0.17	Hip circumference adjusted for BMI;	chr1:112594948	chr1:112517799~112518441:-
HNSC	cis	rs12600394	0.767	rs2323452	ENSG00000231595.1	AC005224.2	3.63	0.000311	0.0355	0.2	0.17	Response to platinum-based chemotherapy (cisplatin);	chr17:14628707	chr17:14210488~14217922:+
HNSC	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	3.63	0.000311	0.0355	0.24	0.17	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	3.63	0.000311	0.0355	0.24	0.17	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	3.63	0.000311	0.0355	0.24	0.17	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	3.63	0.000311	0.0355	0.24	0.17	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
HNSC	cis	rs911555	0.723	rs6575986	ENSG00000244691.1	RPL10AP1	-3.63	0.000311	0.0355	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103412119~103412761:-
HNSC	cis	rs11951515	0.663	rs11743622	ENSG00000249286.1	CTD-2210P15.2	3.63	0.000311	0.0355	0.18	0.17	Metabolite levels  (X-11787);	chr5:43351501	chr5:43586918~43588223:-
HNSC	cis	rs6095360	1	rs6019601	ENSG00000227431.4	CSE1L-AS1	-3.63	0.000311	0.0355	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:49031125	chr20:49040463~49046044:-
HNSC	cis	rs17057718	0.95	rs76645245	ENSG00000272146.4	RP11-755B10.4	-3.63	0.000311	0.0355	-0.26	-0.17	Cerebrospinal fluid biomarker levels;	chr3:57106766	chr3:57597715~57600927:+
HNSC	cis	rs2117029	0.554	rs12306494	ENSG00000258101.2	RP11-977B10.2	3.63	0.000311	0.0355	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49232790~49264756:-
HNSC	cis	rs12962334	0.518	rs4800141	ENSG00000265943.1	RP11-739L10.1	3.63	0.000311	0.0355	0.2	0.17	Breast cancer;	chr18:22984312	chr18:22699481~22933764:-
HNSC	cis	rs7568498	1	rs10164593	ENSG00000235724.7	AC009299.2	3.63	0.000311	0.0355	0.27	0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161125461	chr2:161222785~161308303:-
HNSC	cis	rs7674212	0.507	rs223331	ENSG00000248740.4	RP11-328K4.1	3.63	0.000311	0.0355	0.18	0.17	Type 2 diabetes;	chr4:102872408	chr4:103256159~103453658:+
HNSC	cis	rs16958440	0.867	rs76922914	ENSG00000267724.1	RP11-49K24.8	3.63	0.000311	0.0355	0.32	0.17	Sitting height ratio;	chr18:47162083	chr18:47105946~47108062:+
HNSC	cis	rs2562784	0.638	rs2099126	ENSG00000225151.9	GOLGA2P7	-3.63	0.000311	0.0355	-0.31	-0.17	Height;	chr15:83623472	chr15:84199311~84230136:-
HNSC	cis	rs4908768	0.539	rs7526171	ENSG00000232912.4	RP5-1115A15.1	3.63	0.000311	0.0355	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8424645~8434838:+
HNSC	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	3.63	0.000311	0.0355	0.24	0.17	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
HNSC	cis	rs6088590	0.561	rs6088527	ENSG00000276073.1	RP5-1125A11.7	-3.63	0.000311	0.0355	-0.17	-0.17	Coronary artery disease;	chr20:34568037	chr20:33985617~33988989:-
HNSC	cis	rs6088590	0.561	rs6059926	ENSG00000276073.1	RP5-1125A11.7	-3.63	0.000311	0.0355	-0.17	-0.17	Coronary artery disease;	chr20:34577000	chr20:33985617~33988989:-
HNSC	cis	rs17507216	0.588	rs28864981	ENSG00000252690.3	SCARNA15	3.63	0.000311	0.0355	0.16	0.17	Excessive daytime sleepiness;	chr15:82695420	chr15:82752884~82757208:+
HNSC	cis	rs67072384	1	rs7122017	ENSG00000245148.2	ARAP1-AS2	3.63	0.000311	0.0355	0.23	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737513	chr11:72700474~72705607:+
HNSC	cis	rs9467711	0.606	rs34273322	ENSG00000241549.7	GUSBP2	3.63	0.000311	0.0355	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26415181	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9358939	ENSG00000241549.7	GUSBP2	3.63	0.000311	0.0355	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26416559	chr6:26871484~26956554:-
HNSC	cis	rs2975734	0.68	rs1052453	ENSG00000269918.1	AF131215.9	-3.63	0.000311	0.0355	-0.18	-0.17	Chronotype;Morning vs. evening chronotype;	chr8:10250815	chr8:11104691~11106704:-
HNSC	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-3.63	0.000311	0.0355	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
HNSC	cis	rs8002861	0.664	rs9567292	ENSG00000274001.1	RP11-5G9.5	3.63	0.000311	0.0355	0.17	0.17	Leprosy;	chr13:43870680	chr13:43877715~43878163:-
HNSC	cis	rs1552244	1	rs6786638	ENSG00000180385.7	EMC3-AS1	3.63	0.000311	0.0355	0.19	0.17	Alzheimer's disease;	chr3:10076391	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs6442150	ENSG00000180385.7	EMC3-AS1	3.63	0.000311	0.0355	0.19	0.17	Alzheimer's disease;	chr3:10080891	chr3:9986893~10006990:+
HNSC	cis	rs7243790	0.837	rs1992129	ENSG00000277324.1	RP11-850A17.1	-3.63	0.000311	0.0355	-0.19	-0.17	Diastolic blood pressure;	chr18:54419723	chr18:54268346~54270028:-
HNSC	cis	rs12589282	0.505	rs11157596	ENSG00000270433.1	RP11-124D2.7	3.63	0.000311	0.0355	0.16	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);	chr14:22438076	chr14:23293852~23295798:+
HNSC	cis	rs9940149	1	rs9940149	ENSG00000226942.2	IL9RP3	-3.63	0.000312	0.0355	-0.2	-0.17	Type 2 diabetes;	chr16:250642	chr16:29336~38321:-
HNSC	cis	rs12047808	1	rs76475039	ENSG00000227141.2	RP11-545A16.3	-3.63	0.000312	0.0355	-0.25	-0.17	Multiple sclerosis (age of onset);	chr1:179507628	chr1:179586705~179589175:+
HNSC	cis	rs11671005	0.693	rs11084542	ENSG00000269473.1	CTD-2619J13.19	3.63	0.000312	0.0355	0.26	0.17	Mean platelet volume;	chr19:58420732	chr19:58440448~58445849:+
HNSC	cis	rs11668609	1	rs66972560	ENSG00000268442.1	CTD-2027I19.2	3.63	0.000312	0.0355	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:24162370~24163425:-
HNSC	cis	rs11711311	0.784	rs13081931	ENSG00000241529.3	RN7SL767P	-3.63	0.000312	0.0355	-0.22	-0.17	IgG glycosylation;	chr3:113631081	chr3:113632704~113632998:+
HNSC	cis	rs35306767	0.807	rs61831436	ENSG00000229869.1	RP11-363N22.2	-3.63	0.000312	0.0355	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:791942	chr10:933026~942743:+
HNSC	cis	rs758324	0.732	rs45512	ENSG00000279691.1	RP11-485M7.2	3.63	0.000312	0.0355	0.19	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132103643	chr5:133052769~133052971:+
HNSC	cis	rs3015497	0.528	rs3015467	ENSG00000269906.1	RP11-248J18.2	-3.63	0.000312	0.0355	-0.22	-0.17	Mean platelet volume;	chr14:50692130	chr14:50662511~50663178:-
HNSC	cis	rs3015497	0.561	rs4578563	ENSG00000269906.1	RP11-248J18.2	-3.63	0.000312	0.0355	-0.22	-0.17	Mean platelet volume;	chr14:50692867	chr14:50662511~50663178:-
HNSC	cis	rs6651255	0.618	rs72718337	ENSG00000224110.3	MTRF1LP2	-3.63	0.000312	0.0356	-0.21	-0.17	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);	chr8:129784769	chr8:129728744~129730445:+
HNSC	cis	rs10463554	0.759	rs461609	ENSG00000250682.4	LINC00491	3.63	0.000312	0.0356	0.22	0.17	Parkinson's disease;	chr5:103111601	chr5:102609156~102671559:-
HNSC	cis	rs4906332	1	rs28711288	ENSG00000244691.1	RPL10AP1	-3.63	0.000312	0.0356	-0.19	-0.17	Coronary artery disease;	chr14:103439789	chr14:103412119~103412761:-
HNSC	cis	rs116095464	0.614	rs10067482	ENSG00000277812.1	AC021087.1	3.63	0.000312	0.0356	0.28	0.17	Breast cancer;	chr5:219213	chr5:262769~262881:+
HNSC	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-3.63	0.000312	0.0356	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-3.63	0.000312	0.0356	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
HNSC	cis	rs2625529	0.73	rs2957737	ENSG00000260037.4	CTD-2524L6.3	3.63	0.000312	0.0356	0.23	0.17	Red blood cell count;	chr15:71973069	chr15:71818396~71823384:+
HNSC	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-3.63	0.000312	0.0356	-0.19	-0.17	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-3.63	0.000312	0.0356	-0.19	-0.17	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
HNSC	cis	rs6012564	1	rs6012564	ENSG00000227431.4	CSE1L-AS1	3.63	0.000312	0.0356	0.18	0.17	Anger;	chr20:48925063	chr20:49040463~49046044:-
HNSC	cis	rs2098713	0.569	rs62359006	ENSG00000250155.1	CTD-2353F22.1	3.63	0.000312	0.0356	0.17	0.17	Telomere length;	chr5:37510947	chr5:36666214~36725195:-
HNSC	cis	rs7688540	0.8	rs11723492	ENSG00000250892.1	RP11-1365D11.1	-3.63	0.000312	0.0356	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:201409~205009:-
HNSC	cis	rs4144743	0.759	rs67972765	ENSG00000228782.6	CTD-2026D20.3	-3.63	0.000312	0.0356	-0.22	-0.17	Body mass index;	chr17:47240960	chr17:47450568~47492492:-
HNSC	cis	rs9921222	0.502	rs28461430	ENSG00000268836.1	LA16c-OS12.2	3.63	0.000312	0.0356	0.18	0.17	Bone mineral density (spine);Bone mineral density;	chr16:319562	chr16:185748~186294:-
HNSC	cis	rs9611565	0.592	rs5751139	ENSG00000235513.1	RP4-756G23.5	-3.63	0.000312	0.0356	-0.2	-0.17	Vitiligo;	chr22:41703977	chr22:41209122~41217627:-
HNSC	cis	rs8030379	1	rs2030840	ENSG00000230373.7	GOLGA6L5P	-3.63	0.000312	0.0356	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1880730	ENSG00000230373.7	GOLGA6L5P	-3.63	0.000312	0.0356	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84507885~84516814:-
HNSC	cis	rs868153	0.591	rs1456693	ENSG00000275339.1	RP3-425C14.6	3.63	0.000312	0.0356	0.18	0.17	Vertical cup-disc ratio;	chr6:122233482	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs1585127	ENSG00000275339.1	RP3-425C14.6	3.63	0.000312	0.0356	0.18	0.17	Vertical cup-disc ratio;	chr6:122234097	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs12660649	ENSG00000275339.1	RP3-425C14.6	3.63	0.000312	0.0356	0.18	0.17	Vertical cup-disc ratio;	chr6:122235451	chr6:122454358~122454612:+
HNSC	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	3.63	0.000312	0.0356	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
HNSC	cis	rs6919534	0.667	rs17611877	ENSG00000272374.1	RP3-329A5.8	3.63	0.000312	0.0356	0.23	0.17	Height;	chr6:35151027	chr6:35220370~35224630:-
HNSC	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-3.63	0.000312	0.0356	-0.22	-0.17	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
HNSC	cis	rs6517329	0.565	rs73374920	ENSG00000214867.3	SRSF9P1	-3.63	0.000312	0.0356	-0.2	-0.17	Schizophrenia;	chr21:36170687	chr21:36295173~36295702:-
HNSC	cis	rs643506	0.874	rs582465	ENSG00000230911.1	PPIHP1	-3.63	0.000312	0.0356	-0.22	-0.17	Breast cancer;	chr11:111797861	chr11:112029858~112030367:-
HNSC	cis	rs643506	0.874	rs613292	ENSG00000230911.1	PPIHP1	-3.63	0.000312	0.0356	-0.22	-0.17	Breast cancer;	chr11:111798081	chr11:112029858~112030367:-
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000273142.1	RP11-458F8.4	-3.63	0.000312	0.0356	-0.14	-0.17	Aortic root size;	chr7:66540031	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000273142.1	RP11-458F8.4	-3.63	0.000312	0.0356	-0.14	-0.17	Aortic root size;	chr7:66540165	chr7:66902857~66906297:+
HNSC	cis	rs2638953	0.893	rs1464011	ENSG00000257176.2	RP11-996F15.2	3.63	0.000312	0.0356	0.18	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:29280418~29317848:-
HNSC	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	3.63	0.000313	0.0356	0.19	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
HNSC	cis	rs3764021	0.87	rs11052710	ENSG00000256673.1	RP11-599J14.2	-3.63	0.000313	0.0356	-0.16	-0.17	Type 1 diabetes;	chr12:9723754	chr12:9398355~9414851:-
HNSC	cis	rs4489787	1	rs2705154	ENSG00000257763.1	OR5BK1P	3.63	0.000313	0.0356	0.29	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48514010	chr12:48355792~48356614:-
HNSC	cis	rs9813712	0.672	rs73210789	ENSG00000228252.7	COL6A4P2	3.63	0.000313	0.0356	0.18	0.17	Response to amphetamines;	chr3:130243418	chr3:130212823~130273806:+
HNSC	cis	rs870825	0.549	rs10015956	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184693551	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6825561	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184694378	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs14969	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184694610	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs3184982	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184694614	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs1527870	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184695477	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs6810600	ENSG00000254233.1	RP11-242J7.1	3.63	0.000313	0.0356	0.24	0.17	Blood protein levels;	chr4:184695660	chr4:184584093~184625030:-
HNSC	cis	rs9992667	0.563	rs17500878	ENSG00000231160.8	KLF3-AS1	3.63	0.000313	0.0356	0.16	0.17	Eosinophil percentage of granulocytes;	chr4:38701308	chr4:38612701~38664883:-
HNSC	cis	rs73201462	1	rs2811387	ENSG00000231305.3	RP11-723O4.2	3.63	0.000313	0.0356	0.23	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128296335	chr3:128861313~128871540:-
HNSC	cis	rs6540234	0.701	rs4843877	ENSG00000270058.1	RP11-514D23.3	3.63	0.000313	0.0356	0.18	0.17	Monocyte count;Granulocyte percentage of myeloid white cells;	chr16:85959626	chr16:86221423~86222729:-
HNSC	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	3.63	0.000313	0.0356	0.22	0.17	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
HNSC	cis	rs36093924	0.646	rs5996094	ENSG00000207457.1	RNU6-476P	-3.63	0.000313	0.0356	-0.17	-0.17	Intelligence;	chr22:41951056	chr22:41679711~41679817:+
HNSC	cis	rs12545912	0.609	rs12549128	ENSG00000233609.3	RP11-62H7.2	3.63	0.000313	0.0357	0.2	0.17	Multiple myeloma (hyperdiploidy);	chr8:9942259	chr8:8961200~8979025:+
HNSC	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	3.63	0.000313	0.0357	0.24	0.17	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	3.63	0.000313	0.0357	0.24	0.17	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	3.63	0.000313	0.0357	0.24	0.17	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	3.63	0.000313	0.0357	0.24	0.17	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
HNSC	cis	rs860295	0.58	rs6672284	ENSG00000225855.5	RUSC1-AS1	3.63	0.000313	0.0357	0.12	0.17	Body mass index;	chr1:155308172	chr1:155316863~155324176:-
HNSC	cis	rs3018712	0.532	rs4930588	ENSG00000212093.1	AP000807.1	3.63	0.000313	0.0357	0.24	0.17	Total body bone mineral density;	chr11:68647767	chr11:68506083~68506166:-
HNSC	cis	rs8062405	1	rs62036622	ENSG00000261089.1	RP11-435I10.3	3.63	0.000313	0.0357	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28413703~28415018:+
HNSC	cis	rs3764021	0.87	rs10844597	ENSG00000256673.1	RP11-599J14.2	-3.63	0.000313	0.0357	-0.16	-0.17	Type 1 diabetes;	chr12:9722303	chr12:9398355~9414851:-
HNSC	cis	rs4846217	0.915	rs7525661	ENSG00000230337.1	RP4-635E18.6	-3.63	0.000313	0.0357	-0.29	-0.17	Platelet count;	chr1:10393235	chr1:11099675~11102100:+
HNSC	cis	rs71382995	0.764	rs75013658	ENSG00000267340.1	RP11-242D8.3	-3.63	0.000313	0.0357	-0.33	-0.17	Bone mineral density (spine);Bone mineral density (hip);	chr17:43747744	chr17:43169880~43170077:-
HNSC	cis	rs2337406	1	rs1858677	ENSG00000211972.2	IGHV3-66	3.63	0.000313	0.0357	0.16	0.17	Alzheimer's disease (late onset);	chr14:106706828	chr14:106675017~106675544:-
HNSC	cis	rs11711311	1	rs3732793	ENSG00000241529.3	RN7SL767P	-3.63	0.000313	0.0357	-0.21	-0.17	IgG glycosylation;	chr3:113723351	chr3:113632704~113632998:+
HNSC	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	3.63	0.000313	0.0357	0.19	0.17	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
HNSC	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-3.63	0.000313	0.0357	-0.16	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
HNSC	cis	rs28489187	0.683	rs6704103	ENSG00000223653.4	RP11-131L23.1	-3.63	0.000313	0.0357	-0.22	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85402974	chr1:85276715~85448124:+
HNSC	cis	rs28489187	0.683	rs11161611	ENSG00000223653.4	RP11-131L23.1	-3.63	0.000313	0.0357	-0.22	-0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85402996	chr1:85276715~85448124:+
HNSC	cis	rs11587682	0.806	rs71622690	ENSG00000236713.1	RP11-363I22.3	3.63	0.000313	0.0357	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150308908	chr1:150780272~150780644:+
HNSC	cis	rs9768139	0.708	rs921616	ENSG00000223872.1	AC006372.5	-3.63	0.000313	0.0357	-0.18	-0.17	Calcium levels;	chr7:158325268	chr7:157501322~157503577:+
HNSC	cis	rs9768139	0.733	rs921617	ENSG00000223872.1	AC006372.5	-3.63	0.000313	0.0357	-0.18	-0.17	Calcium levels;	chr7:158325506	chr7:157501322~157503577:+
HNSC	cis	rs9768139	0.733	rs13221388	ENSG00000223872.1	AC006372.5	-3.63	0.000313	0.0357	-0.18	-0.17	Calcium levels;	chr7:158326578	chr7:157501322~157503577:+
HNSC	cis	rs9768139	0.611	rs12698211	ENSG00000223872.1	AC006372.5	-3.63	0.000313	0.0357	-0.18	-0.17	Calcium levels;	chr7:158326931	chr7:157501322~157503577:+
HNSC	cis	rs36715	0.953	rs36700	ENSG00000245937.6	LINC01184	3.63	0.000313	0.0357	0.21	0.17	Breast cancer;	chr5:128215581	chr5:127940426~128083172:-
HNSC	cis	rs9847710	0.818	rs6445558	ENSG00000242142.1	SERBP1P3	-3.63	0.000314	0.0357	-0.18	-0.17	Ulcerative colitis;	chr3:53063644	chr3:53064283~53065091:-
HNSC	cis	rs12545912	0.77	rs12677313	ENSG00000233609.3	RP11-62H7.2	-3.63	0.000314	0.0357	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9685610	chr8:8961200~8979025:+
HNSC	cis	rs2048656	0.561	rs11776236	ENSG00000233609.3	RP11-62H7.2	-3.63	0.000314	0.0357	-0.17	-0.17	Schizophrenia;	chr8:9687657	chr8:8961200~8979025:+
HNSC	cis	rs67311347	0.824	rs59922539	ENSG00000280739.1	EIF1B-AS1	3.63	0.000314	0.0357	0.18	0.17	Renal cell carcinoma;	chr3:40295619	chr3:40173145~40309698:-
HNSC	cis	rs2307394	0.648	rs12467429	ENSG00000281469.1	RP11-567F11.1	3.63	0.000314	0.0357	0.19	0.17	Urate levels;	chr2:147708679	chr2:148044380~148044894:+
HNSC	cis	rs5758511	0.773	rs8140869	ENSG00000226450.2	CYP2D8P	-3.63	0.000314	0.0357	-0.15	-0.17	Birth weight;	chr22:41948293	chr22:42149886~42155001:-
HNSC	cis	rs8054556	0.708	rs2278557	ENSG00000250616.2	RP11-455F5.3	3.63	0.000314	0.0357	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30082458	chr16:30096430~30104116:+
HNSC	cis	rs28830936	0.966	rs890498	ENSG00000250379.1	RP11-23P13.4	3.63	0.000314	0.0357	0.2	0.17	Diastolic blood pressure;	chr15:41819100	chr15:41825099~41827936:-
HNSC	cis	rs5758659	0.652	rs5758537	ENSG00000227370.1	RP4-669P10.19	-3.63	0.000314	0.0357	-0.15	-0.17	Cognitive function;	chr22:42001038	chr22:42132543~42132998:+
HNSC	cis	rs6928289	0.693	rs7770185	ENSG00000234956.4	RP11-356I2.1	3.63	0.000314	0.0357	0.18	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137310512	chr6:137730170~137738983:-
HNSC	cis	rs6710503	0.546	rs2289392	ENSG00000271936.1	RP11-443B20.1	3.63	0.000314	0.0357	0.16	0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24705628	chr2:24825610~24826717:+
HNSC	cis	rs6710503	0.569	rs2289394	ENSG00000271936.1	RP11-443B20.1	3.63	0.000314	0.0357	0.16	0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24705805	chr2:24825610~24826717:+
HNSC	cis	rs597539	0.521	rs7943745	ENSG00000255741.1	RP11-757G1.5	3.63	0.000314	0.0357	0.21	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68838360	chr11:68941503~68942852:-
HNSC	cis	rs9400467	0.528	rs6568680	ENSG00000271789.1	RP5-1112D6.7	-3.63	0.000314	0.0357	-0.2	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111297126~111298510:+
HNSC	cis	rs2439831	0.85	rs28590651	ENSG00000201136.1	RNU6-353P	-3.63	0.000314	0.0357	-0.26	-0.17	Lung cancer in ever smokers;	chr15:43820818	chr15:43702363~43702470:+
HNSC	cis	rs61629263	0.503	rs35590725	ENSG00000260793.2	RP5-882C2.2	3.63	0.000314	0.0357	0.15	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43741585	chr17:44221401~44223710:+
HNSC	cis	rs9923283	0.673	rs1050881	ENSG00000183604.13	SMG1P5	3.63	0.000314	0.0357	0.3	0.17	Plateletcrit;	chr16:29664607	chr16:30267553~30335374:-
HNSC	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	3.63	0.000314	0.0357	0.18	0.17	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
HNSC	cis	rs6545883	0.894	rs2177962	ENSG00000271889.1	RP11-493E12.1	-3.63	0.000314	0.0357	-0.19	-0.17	Tuberculosis;	chr2:61360935	chr2:61151433~61162105:-
HNSC	cis	rs7868228	0.891	rs10120436	ENSG00000240498.5	CDKN2B-AS1	-3.63	0.000314	0.0357	-0.24	-0.17	Gut microbiome composition (winter);	chr9:21672011	chr9:21994778~22121097:+
HNSC	cis	rs10978777	1	rs12345455	ENSG00000226535.1	RP11-417L14.1	-3.63	0.000314	0.0357	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107270217	chr9:107169569~107171148:-
HNSC	cis	rs170183	0.934	rs35734452	ENSG00000279365.1	KB-176G8.1	-3.63	0.000314	0.0357	-0.19	-0.17	Bone mineral density;	chr21:36483703	chr21:36485867~36487760:+
HNSC	cis	rs2307394	1	rs13026220	ENSG00000281469.1	RP11-567F11.1	3.63	0.000314	0.0357	0.18	0.17	Urate levels;	chr2:147828890	chr2:148044380~148044894:+
HNSC	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	3.63	0.000314	0.0357	0.19	0.17	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
HNSC	cis	rs7771547	0.642	rs668499	ENSG00000219023.1	RP3-340B19.2	3.63	0.000314	0.0357	0.15	0.17	Platelet distribution width;	chr6:36528602	chr6:35555873~35556264:+
HNSC	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	3.63	0.000314	0.0357	0.2	0.17	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
HNSC	cis	rs2836974	0.932	rs35571600	ENSG00000255568.3	BRWD1-AS2	3.63	0.000314	0.0358	0.15	0.17	Cognitive function;	chr21:39218698	chr21:39313935~39314962:+
HNSC	cis	rs12545912	0.77	rs7822700	ENSG00000233609.3	RP11-62H7.2	-3.63	0.000314	0.0358	-0.16	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9683344	chr8:8961200~8979025:+
HNSC	cis	rs6430585	0.528	rs12464050	ENSG00000231890.6	DARS-AS1	-3.63	0.000314	0.0358	-0.29	-0.17	Corneal structure;	chr2:135905540	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.591	rs77096272	ENSG00000231890.6	DARS-AS1	-3.63	0.000314	0.0358	-0.29	-0.17	Corneal structure;	chr2:135906035	chr2:135985176~136022593:+
HNSC	cis	rs2446066	0.872	rs10876450	ENSG00000270175.1	RP11-793H13.11	3.63	0.000314	0.0358	0.2	0.17	Red blood cell count;	chr12:53417250	chr12:53500162~53500936:-
HNSC	cis	rs8031584	0.918	rs61997138	ENSG00000270015.1	RP11-540B6.6	-3.63	0.000314	0.0358	-0.17	-0.17	Huntington's disease progression;	chr15:30978573	chr15:30926514~30928407:+
HNSC	cis	rs3736485	0.652	rs2054166	ENSG00000274528.1	CTD-2650P22.2	3.63	0.000314	0.0358	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51682713	chr15:52017167~52018032:-
HNSC	cis	rs12745968	0.652	rs10782912	ENSG00000223787.2	RP4-593M8.1	-3.63	0.000314	0.0358	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92491355	chr1:92580476~92580821:-
HNSC	cis	rs9834975	0.544	rs10804557	ENSG00000272758.4	RP11-299J3.8	3.63	0.000314	0.0358	0.15	0.17	Diastolic blood pressure;	chr3:122553507	chr3:122416207~122443180:+
HNSC	cis	rs2153535	0.585	rs9505512	ENSG00000230939.1	RP11-314C16.1	-3.63	0.000314	0.0358	-0.19	-0.17	Motion sickness;	chr6:8667337	chr6:8784178~8785445:+
HNSC	cis	rs1501911	0.509	rs34487	ENSG00000246763.5	RGMB-AS1	3.63	0.000314	0.0358	0.19	0.17	Lung function (FEV1/FVC);	chr5:98872725	chr5:98769618~98773469:-
HNSC	cis	rs1501911	0.509	rs327786	ENSG00000246763.5	RGMB-AS1	3.63	0.000314	0.0358	0.19	0.17	Lung function (FEV1/FVC);	chr5:98878301	chr5:98769618~98773469:-
HNSC	cis	rs6088580	0.584	rs2378203	ENSG00000276073.1	RP5-1125A11.7	3.63	0.000314	0.0358	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:33985617~33988989:-
HNSC	cis	rs4578769	0.55	rs9953479	ENSG00000265943.1	RP11-739L10.1	3.63	0.000314	0.0358	0.2	0.17	Eosinophil percentage of white cells;	chr18:22962644	chr18:22699481~22933764:-
HNSC	cis	rs11168618	0.904	rs7136845	ENSG00000240399.1	RP1-228P16.1	3.63	0.000315	0.0358	0.14	0.17	Adiponectin levels;	chr12:48513246	chr12:48054813~48055591:-
HNSC	cis	rs9500256	0.625	rs1936228	ENSG00000225096.1	XXbac-BPG55C20.7	-3.63	0.000315	0.0358	-0.18	-0.17	Eosinophilic esophagitis (pediatric);	chr6:58018478	chr6:57965630~57972218:+
HNSC	cis	rs6142618	0.846	rs1407013	ENSG00000275576.1	RP5-836N17.4	-3.63	0.000315	0.0358	-0.17	-0.17	Inflammatory bowel disease;	chr20:32206982	chr20:32116171~32116629:+
HNSC	cis	rs6142618	0.74	rs1923095	ENSG00000275576.1	RP5-836N17.4	-3.63	0.000315	0.0358	-0.17	-0.17	Inflammatory bowel disease;	chr20:32208016	chr20:32116171~32116629:+
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000269918.1	AF131215.9	3.63	0.000315	0.0358	0.16	0.17	Neuroticism;	chr8:11939219	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000269918.1	AF131215.9	3.63	0.000315	0.0358	0.16	0.17	Neuroticism;	chr8:11939586	chr8:11104691~11106704:-
HNSC	cis	rs9400467	0.528	rs6913769	ENSG00000271789.1	RP5-1112D6.7	-3.63	0.000315	0.0358	-0.2	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111297126~111298510:+
HNSC	cis	rs12586317	0.547	rs2383693	ENSG00000258704.4	SRP54-AS1	-3.63	0.000315	0.0358	-0.22	-0.17	Psoriasis;	chr14:35030999	chr14:34920858~34982532:-
HNSC	cis	rs2307394	0.896	rs12989810	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147806307	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs1863153	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147806624	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs1863152	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147806836	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.858	rs4972272	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147807877	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs987122	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147808065	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.821	rs1991169	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147809350	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs12990959	ENSG00000281469.1	RP11-567F11.1	3.63	0.000315	0.0358	0.18	0.17	Urate levels;	chr2:147814591	chr2:148044380~148044894:+
HNSC	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	3.63	0.000315	0.0358	0.16	0.17	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	3.63	0.000315	0.0358	0.16	0.17	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	3.63	0.000315	0.0358	0.16	0.17	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
HNSC	cis	rs9863	0.861	rs4930725	ENSG00000270028.1	RP11-380L11.4	3.63	0.000315	0.0358	0.2	0.17	White blood cell count;	chr12:123943615	chr12:123925461~123926083:-
HNSC	cis	rs7615952	0.546	rs2979306	ENSG00000241288.6	RP11-379B18.5	-3.63	0.000315	0.0358	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125593286	chr3:125827238~125916384:-
HNSC	cis	rs7746199	0.736	rs13210634	ENSG00000226314.6	ZNF192P1	-3.63	0.000315	0.0358	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs13215275	ENSG00000226314.6	ZNF192P1	-3.63	0.000315	0.0358	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28161781~28169594:+
HNSC	cis	rs7824557	0.545	rs34482136	ENSG00000269918.1	AF131215.9	-3.63	0.000315	0.0358	-0.16	-0.17	Retinal vascular caliber;	chr8:11370376	chr8:11104691~11106704:-
HNSC	cis	rs2562456	0.793	rs61445561	ENSG00000268081.1	RP11-678G14.2	3.63	0.000315	0.0358	0.24	0.17	Pain;	chr19:21321230	chr19:21554640~21569237:-
HNSC	cis	rs10832963	1	rs2084220	ENSG00000256282.1	RP11-504G3.4	-3.63	0.000315	0.0358	-0.16	-0.17	Breast cancer;	chr11:18635385	chr11:18595459~18599683:-
HNSC	cis	rs6701713	1	rs3818361	ENSG00000274245.1	RP11-357P18.2	-3.63	0.000315	0.0358	-0.26	-0.17	Alzheimer's disease (late onset);	chr1:207611623	chr1:207372559~207373252:+
HNSC	cis	rs6701713	1	rs6701713	ENSG00000274245.1	RP11-357P18.2	-3.63	0.000315	0.0358	-0.26	-0.17	Alzheimer's disease (late onset);	chr1:207612944	chr1:207372559~207373252:+
HNSC	cis	rs6701713	0.96	rs2093760	ENSG00000274245.1	RP11-357P18.2	-3.63	0.000315	0.0358	-0.26	-0.17	Alzheimer's disease (late onset);	chr1:207613483	chr1:207372559~207373252:+
HNSC	cis	rs2839186	0.721	rs3788252	ENSG00000239415.1	AP001469.9	3.63	0.000315	0.0358	0.15	0.17	Testicular germ cell tumor;	chr21:46241321	chr21:46251549~46254133:-
HNSC	cis	rs2839186	0.814	rs2839167	ENSG00000239415.1	AP001469.9	3.63	0.000315	0.0358	0.15	0.17	Testicular germ cell tumor;	chr21:46241673	chr21:46251549~46254133:-
HNSC	cis	rs6787172	0.783	rs6441201	ENSG00000272087.1	RP11-379F4.7	3.63	0.000315	0.0358	0.17	0.17	Subjective well-being;	chr3:158460535	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.783	rs12496767	ENSG00000272087.1	RP11-379F4.7	3.63	0.000315	0.0358	0.17	0.17	Subjective well-being;	chr3:158461448	chr3:158693120~158693768:-
HNSC	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	3.63	0.000315	0.0358	0.24	0.17	Pain;	chr19:21283020	chr19:21554640~21569237:-
HNSC	cis	rs2048656	0.605	rs13273565	ENSG00000254340.1	RP11-10A14.3	3.63	0.000315	0.0358	0.22	0.17	Schizophrenia;	chr8:9791636	chr8:9141424~9145435:+
HNSC	cis	rs56804039	0.895	rs11776995	ENSG00000254153.1	CTA-398F10.2	-3.63	0.000315	0.0358	-0.21	-0.17	Cervical cancer;	chr8:8528037	chr8:8456909~8461337:-
HNSC	cis	rs1979679	0.918	rs10771427	ENSG00000247934.4	RP11-967K21.1	-3.63	0.000315	0.0358	-0.18	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28163298~28190738:-
HNSC	cis	rs210138	0.591	rs1408711	ENSG00000197251.3	LINC00336	-3.63	0.000315	0.0358	-0.22	-0.17	Testicular germ cell tumor;	chr6:33652231	chr6:33586106~33593338:-
HNSC	cis	rs3764021	0.87	rs10772085	ENSG00000256673.1	RP11-599J14.2	-3.63	0.000315	0.0358	-0.16	-0.17	Type 1 diabetes;	chr12:9724281	chr12:9398355~9414851:-
HNSC	cis	rs2554380	0.657	rs4530091	ENSG00000259570.1	RP11-671M22.4	3.63	0.000315	0.0358	0.21	0.17	Height;	chr15:83814026	chr15:84394512~84395514:+
HNSC	cis	rs2562784	0.638	rs2730075	ENSG00000225151.9	GOLGA2P7	-3.63	0.000315	0.0359	-0.32	-0.17	Height;	chr15:83645689	chr15:84199311~84230136:-
HNSC	cis	rs9611565	0.559	rs6002408	ENSG00000235513.1	RP4-756G23.5	3.63	0.000315	0.0359	0.19	0.17	Vitiligo;	chr22:41571866	chr22:41209122~41217627:-
HNSC	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-3.63	0.000315	0.0359	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
HNSC	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-3.63	0.000315	0.0359	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
HNSC	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-3.63	0.000315	0.0359	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
HNSC	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-3.63	0.000315	0.0359	-0.27	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
HNSC	cis	rs2337406	0.789	rs74092514	ENSG00000280411.1	IGHV1-69-2	-3.63	0.000315	0.0359	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106779385	chr14:106762092~106762588:-
HNSC	cis	rs3018712	0.532	rs2510398	ENSG00000255031.4	RP11-802E16.3	-3.63	0.000315	0.0359	-0.19	-0.17	Total body bone mineral density;	chr11:68653948	chr11:68050740~68053762:+
HNSC	cis	rs3740713	1	rs73440614	ENSG00000256464.1	YWHABP2	3.63	0.000315	0.0359	0.31	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18490243~18490955:-
HNSC	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-3.63	0.000315	0.0359	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
HNSC	cis	rs9926296	0.605	rs1800287	ENSG00000261812.4	TUBB8P7	-3.63	0.000316	0.0359	-0.18	-0.17	Vitiligo;	chr16:89792117	chr16:90093154~90096354:+
HNSC	cis	rs9926296	0.605	rs6500453	ENSG00000261812.4	TUBB8P7	-3.63	0.000316	0.0359	-0.18	-0.17	Vitiligo;	chr16:89792249	chr16:90093154~90096354:+
HNSC	cis	rs7107174	0.892	rs2512540	ENSG00000251323.2	RP11-452H21.4	3.63	0.000316	0.0359	0.26	0.17	Testicular germ cell tumor;	chr11:78268253	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs2510049	ENSG00000251323.2	RP11-452H21.4	3.63	0.000316	0.0359	0.26	0.17	Testicular germ cell tumor;	chr11:78274413	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs2510048	ENSG00000251323.2	RP11-452H21.4	3.63	0.000316	0.0359	0.26	0.17	Testicular germ cell tumor;	chr11:78276418	chr11:78423982~78429836:-
HNSC	cis	rs61776719	0.905	rs17465420	ENSG00000212541.1	RNU6-510P	-3.63	0.000316	0.0359	-0.19	-0.17	Coronary artery disease;	chr1:37932916	chr1:37991462~37991569:+
HNSC	cis	rs12188164	0.965	rs56146525	ENSG00000215246.5	RP11-43F13.3	-3.63	0.000316	0.0359	-0.18	-0.17	Cystic fibrosis severity;	chr5:442456	chr5:987180~997308:-
HNSC	cis	rs2919917	0.628	rs13251931	ENSG00000260398.1	RP11-594N15.3	3.63	0.000316	0.0359	0.22	0.17	Lymphocyte counts;	chr8:78653990	chr8:78605952~78609705:+
HNSC	cis	rs950027	0.62	rs2453533	ENSG00000259479.5	SORD2P	3.63	0.000316	0.0359	0.19	0.17	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:44826371~44884694:-
HNSC	cis	rs6558530	0.625	rs7459507	ENSG00000253982.1	CTD-2336O2.1	3.63	0.000316	0.0359	0.22	0.17	Systolic blood pressure;	chr8:1750026	chr8:1761990~1764502:-
HNSC	cis	rs7937890	0.56	rs2597194	ENSG00000254418.1	RP11-21L19.1	3.63	0.000316	0.0359	0.21	0.17	Mitochondrial DNA levels;	chr11:14475723	chr11:14262846~14273691:-
HNSC	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	3.63	0.000316	0.0359	0.34	0.17	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
HNSC	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	3.63	0.000316	0.0359	0.34	0.17	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
HNSC	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	3.63	0.000316	0.0359	0.34	0.17	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
HNSC	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	3.63	0.000316	0.0359	0.34	0.17	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
HNSC	cis	rs11809180	0.557	rs1591734	ENSG00000227777.1	RP4-738P11.3	3.63	0.000316	0.0359	0.27	0.17	Electrocardiographic traits;	chr1:169302664	chr1:168542737~168543354:+
HNSC	cis	rs2286492	0.655	rs2067983	ENSG00000221740.1	SNORD93	-3.63	0.000316	0.0359	-0.32	-0.17	Bipolar disorder;	chr7:23060159	chr7:22856613~22856686:+
HNSC	cis	rs9487051	0.735	rs351745	ENSG00000243587.6	C6orf183	3.63	0.000316	0.0359	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109207966	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.766	rs351748	ENSG00000243587.6	C6orf183	3.63	0.000316	0.0359	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109211093	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.735	rs351754	ENSG00000243587.6	C6orf183	3.63	0.000316	0.0359	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109216350	chr6:109165833~109271014:+
HNSC	cis	rs911555	0.723	rs11160751	ENSG00000244691.1	RPL10AP1	-3.63	0.000316	0.0359	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103412119~103412761:-
HNSC	cis	rs11668609	0.748	rs16982728	ENSG00000268442.1	CTD-2027I19.2	3.63	0.000316	0.0359	0.23	0.17	Response to taxane treatment (docetaxel);	chr19:24186760	chr19:24162370~24163425:-
HNSC	cis	rs786425	0.933	rs786423	ENSG00000278112.1	RP11-972P1.11	-3.63	0.000316	0.0359	-0.16	-0.17	Pubertal anthropometrics;	chr12:123599351	chr12:123519390~123519856:-
HNSC	cis	rs9880211	0.718	rs56398805	ENSG00000239213.4	NCK1-AS1	3.63	0.000316	0.0359	0.15	0.17	Height;Body mass index;	chr3:136213558	chr3:136841726~136862054:-
HNSC	cis	rs7572733	1	rs7587251	ENSG00000222017.1	AC011997.1	3.63	0.000316	0.0359	0.2	0.17	Dermatomyositis;	chr2:198065473	chr2:197693106~197774823:+
HNSC	cis	rs1853665	0.58	rs4242283	ENSG00000268592.3	RAET1E-AS1	-3.63	0.000316	0.0359	-0.26	-0.17	Radiation response;	chr6:149952270	chr6:149863494~149919507:+
HNSC	cis	rs250677	0.652	rs250680	ENSG00000250072.4	CTC-529P8.1	-3.63	0.000316	0.0359	-0.22	-0.17	Breast cancer;	chr5:149056461	chr5:149063317~149109787:+
HNSC	cis	rs250677	0.687	rs3095947	ENSG00000250072.4	CTC-529P8.1	-3.63	0.000316	0.0359	-0.22	-0.17	Breast cancer;	chr5:149057165	chr5:149063317~149109787:+
HNSC	cis	rs73607972	0.575	rs12926468	ENSG00000275191.1	RP11-36I17.2	-3.63	0.000316	0.036	-0.2	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53555488	chr16:53628256~53628816:-
HNSC	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	3.63	0.000316	0.036	0.17	0.17	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-3.63	0.000316	0.036	-0.24	-0.17	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-3.63	0.000316	0.036	-0.24	-0.17	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-3.63	0.000316	0.036	-0.24	-0.17	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-3.63	0.000316	0.036	-0.24	-0.17	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
HNSC	cis	rs13434995	0.842	rs62303715	ENSG00000273257.1	RP11-177J6.1	-3.63	0.000316	0.036	-0.27	-0.17	Adiponectin levels;	chr4:55466893	chr4:55387949~55388271:+
HNSC	cis	rs13113518	0.51	rs6828454	ENSG00000249700.7	SRD5A3-AS1	3.63	0.000316	0.036	0.19	0.17	Height;	chr4:55424329	chr4:55363971~55395847:-
HNSC	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	3.63	0.000316	0.036	0.18	0.17	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
HNSC	cis	rs793571	0.822	rs604057	ENSG00000245975.2	RP11-30K9.6	3.63	0.000316	0.036	0.28	0.17	Schizophrenia;	chr15:58865090	chr15:58768072~58770974:-
HNSC	cis	rs12893668	0.667	rs71417869	ENSG00000269958.1	RP11-73M18.8	3.63	0.000317	0.036	0.15	0.17	Reticulocyte count;	chr14:103611097	chr14:103696353~103697163:+
HNSC	cis	rs4934494	0.834	rs3740033	ENSG00000240996.1	RP11-80H5.7	3.63	0.000317	0.036	0.2	0.17	Red blood cell count;	chr10:89634639	chr10:89694295~89697928:-
HNSC	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	3.63	0.000317	0.036	0.19	0.17	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
HNSC	cis	rs643506	0.874	rs663511	ENSG00000230911.1	PPIHP1	-3.63	0.000317	0.036	-0.22	-0.17	Breast cancer;	chr11:111839311	chr11:112029858~112030367:-
HNSC	cis	rs7735319	0.966	rs7712171	ENSG00000249102.1	CTD-2066L21.1	3.63	0.000317	0.036	0.19	0.17	Systolic blood pressure;	chr5:33104850	chr5:33008994~33025724:+
HNSC	cis	rs9600832	0.505	rs9600885	ENSG00000120664.9	SPG20-AS1	-3.63	0.000317	0.036	-0.24	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr13:35508625	chr13:36346431~36369601:+
HNSC	cis	rs6995541	0.529	rs752446	ENSG00000269918.1	AF131215.9	-3.63	0.000317	0.036	-0.17	-0.17	Triglyceride levels;	chr8:10792257	chr8:11104691~11106704:-
HNSC	cis	rs4242434	0.819	rs7826059	ENSG00000253837.1	RP11-177H13.2	3.63	0.000317	0.036	0.17	0.17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22654555	chr8:23336171~23366125:+
HNSC	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	3.63	0.000317	0.036	0.26	0.17	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
HNSC	cis	rs7824557	0.628	rs7841394	ENSG00000255310.2	AF131215.2	3.63	0.000317	0.036	0.15	0.17	Retinal vascular caliber;	chr8:11328162	chr8:11107788~11109726:-
HNSC	cis	rs4767841	0.594	rs3847957	ENSG00000277423.1	RP11-173P15.9	-3.63	0.000317	0.036	-0.23	-0.17	Urgency urinary incontinence;	chr12:119797066	chr12:120703867~120704282:+
HNSC	cis	rs7688540	0.76	rs12506250	ENSG00000250892.1	RP11-1365D11.1	-3.63	0.000317	0.036	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:201409~205009:-
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000270326.1	RP5-874C20.6	-3.63	0.000317	0.036	-0.26	-0.17	Depression;	chr6:28235522	chr6:28319660~28319852:-
HNSC	cis	rs4840086	0.905	rs4840082	ENSG00000219755.1	RP1-199J3.5	3.63	0.000317	0.036	0.2	0.17	Menarche (age at onset);	chr6:99752021	chr6:99575712~99576456:+
HNSC	cis	rs268134	0.53	rs36188795	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391134	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs35312858	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391501	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs36044502	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391595	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs35162271	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65394623	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs17475676	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65395010	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs34073446	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65397338	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs62141062	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400703	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs35837416	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400957	chr2:65589566~65640177:-
HNSC	cis	rs268134	0.53	rs13029865	ENSG00000235725.1	AC007389.3	-3.63	0.000317	0.036	-0.3	-0.17	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65406771	chr2:65589566~65640177:-
HNSC	cis	rs1937680	0.613	rs4601716	ENSG00000236671.6	PRKG1-AS1	-3.63	0.000317	0.036	-0.22	-0.17	Breast cancer;	chr10:51890263	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs7916936	ENSG00000236671.6	PRKG1-AS1	-3.63	0.000317	0.036	-0.22	-0.17	Breast cancer;	chr10:51890571	chr10:52230742~52314128:-
HNSC	cis	rs859767	0.704	rs6750788	ENSG00000224043.6	CCNT2-AS1	3.63	0.000317	0.036	0.2	0.17	Neuroticism;	chr2:134605411	chr2:134735464~134918710:-
HNSC	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-3.63	0.000317	0.036	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-3.63	0.000317	0.036	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-3.63	0.000317	0.036	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
HNSC	cis	rs896655	0.598	rs10811597	ENSG00000244230.3	RN7SL151P	3.63	0.000317	0.036	0.17	0.17	Coronary artery disease;	chr9:21728451	chr9:21699314~21699596:+
HNSC	cis	rs6142618	0.783	rs6057548	ENSG00000260257.2	RP5-1085F17.3	3.63	0.000317	0.036	0.16	0.17	Inflammatory bowel disease;	chr20:32266575	chr20:32856621~32858751:+
HNSC	cis	rs1937680	0.613	rs1937726	ENSG00000236671.6	PRKG1-AS1	-3.63	0.000317	0.036	-0.24	-0.17	Breast cancer;	chr10:51878111	chr10:52230742~52314128:-
HNSC	cis	rs683257	1	rs11758974	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000317	0.036	-0.36	-0.17	Facial emotion recognition (angry faces);	chr6:140856333	chr6:140845958~140852924:-
HNSC	cis	rs683257	1	rs72988191	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000317	0.036	-0.37	-0.17	Facial emotion recognition (angry faces);	chr6:140838654	chr6:140845958~140852924:-
HNSC	cis	rs683257	1	rs11758771	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000317	0.036	-0.37	-0.17	Facial emotion recognition (angry faces);	chr6:140841644	chr6:140845958~140852924:-
HNSC	cis	rs683257	1	rs72988196	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000317	0.036	-0.37	-0.17	Facial emotion recognition (angry faces);	chr6:140841728	chr6:140845958~140852924:-
HNSC	cis	rs868153	0.557	rs35461771	ENSG00000275339.1	RP3-425C14.6	3.63	0.000317	0.036	0.18	0.17	Vertical cup-disc ratio;	chr6:122146701	chr6:122454358~122454612:+
HNSC	cis	rs656319	0.58	rs13252589	ENSG00000255310.2	AF131215.2	-3.63	0.000317	0.036	-0.16	-0.17	Myopia (pathological);	chr8:10148016	chr8:11107788~11109726:-
HNSC	cis	rs4906332	1	rs17617307	ENSG00000244691.1	RPL10AP1	-3.63	0.000317	0.036	-0.19	-0.17	Coronary artery disease;	chr14:103438628	chr14:103412119~103412761:-
HNSC	cis	rs5758511	0.514	rs9607885	ENSG00000227370.1	RP4-669P10.19	3.63	0.000317	0.0361	0.19	0.17	Birth weight;	chr22:42182590	chr22:42132543~42132998:+
HNSC	cis	rs58785573	0.57	rs4833078	ENSG00000231160.8	KLF3-AS1	-3.63	0.000317	0.0361	-0.15	-0.17	Lymphocyte percentage of white cells;	chr4:38644855	chr4:38612701~38664883:-
HNSC	cis	rs7937890	0.593	rs2597189	ENSG00000254418.1	RP11-21L19.1	3.63	0.000317	0.0361	0.21	0.17	Mitochondrial DNA levels;	chr11:14490514	chr11:14262846~14273691:-
HNSC	cis	rs867371	0.614	rs7183805	ENSG00000259429.4	UBE2Q2P2	-3.63	0.000318	0.0361	-0.17	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82355142~82420075:+
HNSC	cis	rs3799379	0.53	rs10456045	ENSG00000241549.7	GUSBP2	-3.63	0.000318	0.0361	-0.17	-0.17	Intelligence (multi-trait analysis);	chr6:26404730	chr6:26871484~26956554:-
HNSC	cis	rs871012	0.542	rs58995342	ENSG00000251405.2	CTB-109A12.1	-3.63	0.000318	0.0361	-0.19	-0.17	IgG glycosylation;	chr5:157401332	chr5:157362615~157460078:-
HNSC	cis	rs4934494	0.862	rs12246250	ENSG00000240996.1	RP11-80H5.7	-3.63	0.000318	0.0361	-0.21	-0.17	Red blood cell count;	chr10:89629540	chr10:89694295~89697928:-
HNSC	cis	rs2915864	0.784	rs2961694	ENSG00000280047.1	CTC-463A16.1	-3.63	0.000318	0.0361	-0.29	-0.17	Facial morphology (factor 20);	chr5:142163786	chr5:142165767~142168387:+
HNSC	cis	rs9321637	1	rs7769491	ENSG00000226004.1	RP11-10J5.1	3.63	0.000318	0.0361	0.2	0.17	Cardiac Troponin-T levels;	chr6:137942748	chr6:137943079~137945802:-
HNSC	cis	rs9321637	1	rs6570196	ENSG00000226004.1	RP11-10J5.1	3.63	0.000318	0.0361	0.2	0.17	Cardiac Troponin-T levels;	chr6:137943302	chr6:137943079~137945802:-
HNSC	cis	rs4713118	0.513	rs149878	ENSG00000224843.5	LINC00240	3.63	0.000318	0.0361	0.18	0.17	Parkinson's disease;	chr6:27910960	chr6:26956992~27023924:+
HNSC	cis	rs886126	0.853	rs4766558	ENSG00000257595.2	RP3-473L9.4	3.63	0.000318	0.0361	0.22	0.17	Coronary heart disease;	chr12:111226257	chr12:111369282~111403310:+
HNSC	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	3.63	0.000318	0.0361	0.25	0.17	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
HNSC	cis	rs847649	0.692	rs6969054	ENSG00000239969.4	RP11-163E9.2	-3.63	0.000318	0.0361	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102806122	chr7:102364162~102380633:+
HNSC	cis	rs847649	0.692	rs6949391	ENSG00000239969.4	RP11-163E9.2	-3.63	0.000318	0.0361	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102806416	chr7:102364162~102380633:+
HNSC	cis	rs847649	0.692	rs10257317	ENSG00000239969.4	RP11-163E9.2	-3.63	0.000318	0.0361	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102806609	chr7:102364162~102380633:+
HNSC	cis	rs1941023	0.739	rs4146870	ENSG00000279632.1	RP11-286N22.6	3.63	0.000318	0.0361	0.18	0.17	Congenital heart disease (maternal effect);	chr11:60464513	chr11:61426448~61427325:-
HNSC	cis	rs8059260	0.604	rs8052325	ENSG00000262488.1	RP11-876N24.1	3.63	0.000318	0.0361	0.24	0.17	Alcohol consumption over the past year;	chr16:11044121	chr16:10840384~10841544:-
HNSC	cis	rs17772222	0.917	rs61984683	ENSG00000258789.1	RP11-507K2.3	-3.63	0.000318	0.0361	-0.2	-0.17	Coronary artery calcification;	chr14:88553162	chr14:88551597~88552493:+
HNSC	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-3.63	0.000318	0.0361	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
HNSC	cis	rs74781061	0.932	rs11629946	ENSG00000260103.2	RP11-10O17.1	3.63	0.000318	0.0361	0.19	0.17	Endometriosis;	chr15:74579550	chr15:74478070~74490286:-
HNSC	cis	rs1023500	0.505	rs2143139	ENSG00000182057.4	OGFRP1	3.63	0.000318	0.0361	0.18	0.17	Schizophrenia;	chr22:42218395	chr22:42269753~42275196:+
HNSC	cis	rs870825	0.616	rs2130393	ENSG00000254233.1	RP11-242J7.1	3.63	0.000318	0.0361	0.24	0.17	Blood protein levels;	chr4:184721181	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs4623060	ENSG00000254233.1	RP11-242J7.1	3.63	0.000318	0.0361	0.24	0.17	Blood protein levels;	chr4:184721789	chr4:184584093~184625030:-
HNSC	cis	rs13178541	0.745	rs7380109	ENSG00000250378.1	RP11-119J18.1	-3.63	0.000318	0.0361	-0.2	-0.17	IgG glycosylation;	chr5:135751385	chr5:135812667~135826582:+
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000255046.1	RP11-297N6.4	-3.63	0.000318	0.0361	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11797928~11802568:-
HNSC	cis	rs12208357	1	rs12208357	ENSG00000213073.4	RP11-288H12.3	3.63	0.000318	0.0361	0.35	0.17	Cholesterol, total;	chr6:160122116	chr6:160093082~160096212:+
HNSC	cis	rs1020096	0.656	rs1020098	ENSG00000213771.3	KRT8P37	3.63	0.000318	0.0361	0.25	0.17	Obstetric antiphospholipid syndrome;	chr10:9234680	chr10:8513687~8515106:-
HNSC	cis	rs8062405	0.755	rs17707300	ENSG00000260367.2	RP11-264B17.4	-3.63	0.000318	0.0361	-0.15	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28973962~28978824:-
HNSC	cis	rs73201462	1	rs11710704	ENSG00000231305.3	RP11-723O4.2	-3.63	0.000318	0.0361	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328393	chr3:128861313~128871540:-
HNSC	cis	rs6142618	0.819	rs6141637	ENSG00000275576.1	RP5-836N17.4	-3.63	0.000318	0.0361	-0.17	-0.17	Inflammatory bowel disease;	chr20:32213213	chr20:32116171~32116629:+
HNSC	cis	rs10186029	0.582	rs2371795	ENSG00000270659.1	RP11-105N14.1	-3.63	0.000318	0.0361	-0.16	-0.17	Systemic sclerosis;	chr2:213130065	chr2:213152970~213153659:+
HNSC	cis	rs3736485	0.932	rs4774598	ENSG00000274528.1	CTD-2650P22.2	3.63	0.000318	0.0361	0.17	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51627470	chr15:52017167~52018032:-
HNSC	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	3.63	0.000318	0.0361	0.2	0.17	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
HNSC	cis	rs17203016	0.83	rs13426173	ENSG00000231908.1	IDH1-AS1	3.63	0.000318	0.0361	0.22	0.17	Body mass index;	chr2:207386719	chr2:208255247~208256181:+
HNSC	cis	rs8030379	1	rs10152119	ENSG00000230373.7	GOLGA6L5P	-3.63	0.000318	0.0362	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84507885~84516814:-
HNSC	cis	rs988913	0.678	rs9357840	ENSG00000224984.1	RP11-524H19.2	3.63	0.000319	0.0362	0.19	0.17	Menarche (age at onset);	chr6:55101784	chr6:54840118~54840855:-
HNSC	cis	rs11587682	0.612	rs12139488	ENSG00000236713.1	RP11-363I22.3	3.63	0.000319	0.0362	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150404625	chr1:150780272~150780644:+
HNSC	cis	rs7829975	0.54	rs2976909	ENSG00000233609.3	RP11-62H7.2	-3.63	0.000319	0.0362	-0.16	-0.17	Mood instability;	chr8:8489180	chr8:8961200~8979025:+
HNSC	cis	rs911555	0.539	rs4374097	ENSG00000269958.1	RP11-73M18.8	3.63	0.000319	0.0362	0.15	0.17	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103696353~103697163:+
HNSC	cis	rs7107174	1	rs10899455	ENSG00000251323.2	RP11-452H21.4	3.63	0.000319	0.0362	0.25	0.17	Testicular germ cell tumor;	chr11:78288117	chr11:78423982~78429836:-
HNSC	cis	rs1133146	1	rs12971799	ENSG00000269608.1	CTB-167G5.3	3.63	0.000319	0.0362	0.19	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr19:53163873	chr19:53616802~53617254:+
HNSC	cis	rs7662987	1	rs7683704	ENSG00000263923.1	RP11-571L19.7	3.63	0.000319	0.0362	0.24	0.17	Smoking initiation;	chr4:99083075	chr4:98928897~98994994:+
HNSC	cis	rs73198271	1	rs73198271	ENSG00000173295.6	FAM86B3P	-3.63	0.000319	0.0362	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:8228595~8244865:+
HNSC	cis	rs73198271	1	rs73198272	ENSG00000173295.6	FAM86B3P	-3.63	0.000319	0.0362	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:8228595~8244865:+
HNSC	cis	rs73198271	1	rs4841030	ENSG00000173295.6	FAM86B3P	-3.63	0.000319	0.0362	-0.23	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:8228595~8244865:+
HNSC	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	3.63	0.000319	0.0362	0.16	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
HNSC	cis	rs12562037	0.673	rs16851653	ENSG00000224321.1	RP11-169K16.6	-3.63	0.000319	0.0362	-0.29	-0.17	Alcoholic chronic pancreatitis;	chr1:15452618	chr1:15792796~15793285:+
HNSC	cis	rs28489187	0.706	rs233069	ENSG00000223653.4	RP11-131L23.1	3.63	0.000319	0.0362	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339783	chr1:85276715~85448124:+
HNSC	cis	rs9907295	0.591	rs3817655	ENSG00000271013.1	AC015849.15	3.63	0.000319	0.0362	0.19	0.17	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35912635~35918010:-
HNSC	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	3.63	0.000319	0.0362	0.22	0.17	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
HNSC	cis	rs1620921	0.622	rs60507137	ENSG00000233342.1	RP11-235G24.3	-3.63	0.000319	0.0362	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160852034	chr6:160926369~160927162:+
HNSC	cis	rs1620921	0.565	rs66542006	ENSG00000233342.1	RP11-235G24.3	-3.63	0.000319	0.0362	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160852220	chr6:160926369~160927162:+
HNSC	cis	rs16958440	0.867	rs12386076	ENSG00000267724.1	RP11-49K24.8	3.63	0.000319	0.0362	0.32	0.17	Sitting height ratio;	chr18:47146969	chr18:47105946~47108062:+
HNSC	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	3.63	0.000319	0.0362	0.17	0.17	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
HNSC	cis	rs1440410	0.835	rs7670439	ENSG00000250326.1	RP11-284M14.1	-3.63	0.000319	0.0362	-0.19	-0.17	Ischemic stroke;	chr4:143159114	chr4:142933195~143184861:-
HNSC	cis	rs8030379	1	rs117031571	ENSG00000230373.7	GOLGA6L5P	-3.63	0.000319	0.0362	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84507885~84516814:-
HNSC	cis	rs12664251	0.706	rs2357021	ENSG00000253194.1	RP11-351A11.1	-3.63	0.000319	0.0362	-0.19	-0.17	Schizophrenia;	chr6:119018949	chr6:118934785~119031541:+
HNSC	cis	rs12188164	1	rs56104584	ENSG00000215246.5	RP11-43F13.3	-3.63	0.000319	0.0362	-0.18	-0.17	Cystic fibrosis severity;	chr5:437427	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs55842567	ENSG00000215246.5	RP11-43F13.3	-3.63	0.000319	0.0362	-0.18	-0.17	Cystic fibrosis severity;	chr5:437471	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs56042615	ENSG00000215246.5	RP11-43F13.3	-3.63	0.000319	0.0362	-0.18	-0.17	Cystic fibrosis severity;	chr5:437552	chr5:987180~997308:-
HNSC	cis	rs12188164	1	rs34847072	ENSG00000215246.5	RP11-43F13.3	-3.63	0.000319	0.0362	-0.18	-0.17	Cystic fibrosis severity;	chr5:437747	chr5:987180~997308:-
HNSC	cis	rs6012564	0.927	rs932451	ENSG00000227431.4	CSE1L-AS1	-3.63	0.000319	0.0362	-0.19	-0.17	Anger;	chr20:48957061	chr20:49040463~49046044:-
HNSC	cis	rs4822044	0.617	rs13054514	ENSG00000235513.1	RP4-756G23.5	-3.63	0.000319	0.0362	-0.18	-0.17	Cannabis dependence symptom count;	chr22:41734379	chr22:41209122~41217627:-
HNSC	cis	rs12544026	0.515	rs513159	ENSG00000253633.1	KB-1980E6.3	-3.63	0.000319	0.0362	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101887248	chr8:102528740~102538668:+
HNSC	cis	rs9768139	0.708	rs921615	ENSG00000223872.1	AC006372.5	-3.63	0.000319	0.0362	-0.18	-0.17	Calcium levels;	chr7:158325243	chr7:157501322~157503577:+
HNSC	cis	rs7819412	0.691	rs73198970	ENSG00000269918.1	AF131215.9	-3.63	0.000319	0.0362	-0.17	-0.17	Triglycerides;	chr8:11182707	chr8:11104691~11106704:-
HNSC	cis	rs8010715	0.816	rs6573565	ENSG00000259321.1	RP11-468E2.5	-3.63	0.000319	0.0362	-0.14	-0.17	IgG glycosylation;	chr14:24125524	chr14:24139445~24140444:+
HNSC	cis	rs875971	0.66	rs28698552	ENSG00000272831.1	RP11-792A8.4	3.63	0.000319	0.0362	0.14	0.17	Aortic root size;	chr7:66540031	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs62465434	ENSG00000272831.1	RP11-792A8.4	3.63	0.000319	0.0362	0.14	0.17	Aortic root size;	chr7:66540165	chr7:66739829~66740385:-
HNSC	cis	rs28489187	0.706	rs233071	ENSG00000223653.4	RP11-131L23.1	3.63	0.000319	0.0362	0.23	0.17	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85340322	chr1:85276715~85448124:+
HNSC	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	3.63	0.000319	0.0362	0.19	0.17	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
HNSC	cis	rs11955398	0.585	rs12655977	ENSG00000215032.2	GNL3LP1	3.63	0.000319	0.0362	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60738648	chr5:60891935~60893577:-
HNSC	cis	rs8054556	0.787	rs11642612	ENSG00000250616.2	RP11-455F5.3	3.63	0.000319	0.0362	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30096430~30104116:+
HNSC	cis	rs8054556	0.787	rs11150581	ENSG00000250616.2	RP11-455F5.3	3.63	0.000319	0.0362	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30096430~30104116:+
HNSC	cis	rs4242434	0.819	rs55776566	ENSG00000253837.1	RP11-177H13.2	-3.63	0.000319	0.0362	-0.17	-0.17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22611979	chr8:23336171~23366125:+
HNSC	cis	rs36715	1	rs251213	ENSG00000245937.6	LINC01184	3.63	0.000319	0.0362	0.21	0.17	Breast cancer;	chr5:128209913	chr5:127940426~128083172:-
HNSC	cis	rs36715	1	rs251212	ENSG00000245937.6	LINC01184	3.63	0.000319	0.0362	0.21	0.17	Breast cancer;	chr5:128210218	chr5:127940426~128083172:-
HNSC	cis	rs36715	1	rs2617621	ENSG00000245937.6	LINC01184	3.63	0.000319	0.0362	0.21	0.17	Breast cancer;	chr5:128210574	chr5:127940426~128083172:-
HNSC	cis	rs6840258	1	rs6840258	ENSG00000251411.1	RP11-397E7.4	-3.63	0.00032	0.0362	-0.21	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87052516	chr4:86913266~86914817:-
HNSC	cis	rs7590368	0.6	rs3856466	ENSG00000272275.1	RP11-791G15.2	3.63	0.00032	0.0362	0.28	0.17	Educational attainment (years of education);	chr2:10776644	chr2:10767875~10770058:-
HNSC	cis	rs6088580	0.634	rs6059905	ENSG00000276073.1	RP5-1125A11.7	-3.63	0.00032	0.0362	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:33985617~33988989:-
HNSC	cis	rs6142618	0.811	rs6057547	ENSG00000275576.1	RP5-836N17.4	-3.63	0.00032	0.0362	-0.17	-0.17	Inflammatory bowel disease;	chr20:32257534	chr20:32116171~32116629:+
HNSC	cis	rs9926296	0.533	rs7190823	ENSG00000261812.4	TUBB8P7	-3.63	0.00032	0.0363	-0.18	-0.17	Vitiligo;	chr16:89799635	chr16:90093154~90096354:+
HNSC	cis	rs546131	0.642	rs35833762	ENSG00000271369.1	RP11-350D17.3	-3.63	0.00032	0.0363	-0.23	-0.17	Lung disease severity in cystic fibrosis;	chr11:34824311	chr11:34709600~34710161:+
HNSC	cis	rs2013441	1	rs2526472	ENSG00000261033.1	RP11-209D14.2	3.63	0.00032	0.0363	0.19	0.17	Obesity-related traits;	chr17:20234575	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703778	ENSG00000261033.1	RP11-209D14.2	3.63	0.00032	0.0363	0.19	0.17	Obesity-related traits;	chr17:20235587	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2158473	ENSG00000261033.1	RP11-209D14.2	3.63	0.00032	0.0363	0.19	0.17	Obesity-related traits;	chr17:20235777	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703780	ENSG00000261033.1	RP11-209D14.2	3.63	0.00032	0.0363	0.19	0.17	Obesity-related traits;	chr17:20240359	chr17:20008051~20009234:-
HNSC	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-3.63	0.00032	0.0363	-0.19	-0.17	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
HNSC	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.00032	0.0363	-0.2	-0.17	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
HNSC	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.00032	0.0363	-0.2	-0.17	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.00032	0.0363	-0.2	-0.17	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
HNSC	cis	rs8025790	0.508	rs12902812	ENSG00000270964.1	RP11-502I4.3	-3.63	0.00032	0.0363	-0.18	-0.17	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67616941	chr15:67541072~67542604:-
HNSC	cis	rs2280018	0.581	rs7404524	ENSG00000188599.16	NPIPP1	-3.63	0.00032	0.0363	-0.14	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15104312~15123498:-
HNSC	cis	rs67180937	0.553	rs3002148	ENSG00000200033.1	RNU6-403P	3.63	0.00032	0.0363	0.23	0.17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:221837334~221837437:-
HNSC	cis	rs870825	0.616	rs4610378	ENSG00000254233.1	RP11-242J7.1	-3.63	0.00032	0.0363	-0.24	-0.17	Blood protein levels;	chr4:184703066	chr4:184584093~184625030:-
HNSC	cis	rs172166	0.769	rs149965	ENSG00000219891.2	ZSCAN12P1	3.63	0.00032	0.0363	0.22	0.17	Cardiac Troponin-T levels;	chr6:28050911	chr6:28091154~28093664:+
HNSC	cis	rs7824557	0.564	rs13274106	ENSG00000255310.2	AF131215.2	-3.63	0.00032	0.0363	-0.15	-0.17	Retinal vascular caliber;	chr8:11376449	chr8:11107788~11109726:-
HNSC	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-3.63	0.00032	0.0363	-0.14	-0.17	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
HNSC	cis	rs9863	0.861	rs11057397	ENSG00000270028.1	RP11-380L11.4	3.63	0.00032	0.0363	0.2	0.17	White blood cell count;	chr12:123935181	chr12:123925461~123926083:-
HNSC	cis	rs5758659	1	rs134882	ENSG00000273366.1	CTA-989H11.1	-3.63	0.00032	0.0363	-0.19	-0.17	Cognitive function;	chr22:42274959	chr22:42278188~42278846:+
HNSC	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	3.63	0.00032	0.0363	0.2	0.17	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	3.63	0.00032	0.0363	0.2	0.17	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	3.63	0.00032	0.0363	0.2	0.17	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
HNSC	cis	rs544991	0.687	rs6425837	ENSG00000239670.1	RP4-803A2.2	3.63	0.00032	0.0363	0.21	0.17	Intelligence;	chr1:33748703	chr1:32986952~32988233:+
HNSC	cis	rs544991	0.687	rs6665517	ENSG00000239670.1	RP4-803A2.2	3.63	0.00032	0.0363	0.21	0.17	Intelligence;	chr1:33748898	chr1:32986952~32988233:+
HNSC	cis	rs2239557	1	rs2358628	ENSG00000279594.1	RP11-950C14.10	3.63	0.00032	0.0363	0.21	0.17	Common traits (Other);	chr14:74165054	chr14:75011269~75012851:-
HNSC	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-3.63	0.00032	0.0363	-0.27	-0.17	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
HNSC	cis	rs116095464	0.558	rs10036253	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:238404	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10075018	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:239060	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10076655	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:239349	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs28418643	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:240744	chr5:262769~262881:+
HNSC	cis	rs116095464	0.614	rs62344339	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:252880	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs9687898	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:253837	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs9688045	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:253920	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs112343653	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:257059	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs73024831	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:257077	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs62344345	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:257305	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs57335027	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:262792	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6869925	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:263921	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6875291	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:264077	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6866776	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:264380	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6874745	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:264412	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs7715108	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:264546	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs7730700	ENSG00000277812.1	AC021087.1	3.63	0.00032	0.0363	0.28	0.17	Breast cancer;	chr5:264598	chr5:262769~262881:+
HNSC	cis	rs896655	0.631	rs13298275	ENSG00000244230.3	RN7SL151P	3.63	0.00032	0.0363	0.17	0.17	Coronary artery disease;	chr9:21732360	chr9:21699314~21699596:+
HNSC	cis	rs3740713	1	rs75647856	ENSG00000256464.1	YWHABP2	3.63	0.00032	0.0363	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73438687	ENSG00000256464.1	YWHABP2	3.63	0.00032	0.0363	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr11:18490243~18490955:-
HNSC	cis	rs6688613	0.685	rs61815130	ENSG00000215834.7	FMO9P	3.63	0.00032	0.0363	0.23	0.17	Refractive astigmatism;	chr1:166941228	chr1:166603675~166631400:+
HNSC	cis	rs6095360	0.615	rs6019506	ENSG00000222365.1	SNORD12B	-3.63	0.00032	0.0363	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48899655	chr20:49280319~49280409:+
HNSC	cis	rs7824557	0.602	rs7817658	ENSG00000255495.1	AC145124.2	3.63	0.00032	0.0363	0.19	0.17	Retinal vascular caliber;	chr8:11349034	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.568	rs35747588	ENSG00000255495.1	AC145124.2	3.63	0.00032	0.0363	0.19	0.17	Retinal vascular caliber;	chr8:11349118	chr8:12194467~12196280:+
HNSC	cis	rs2253762	0.68	rs2461212	ENSG00000226864.1	ATE1-AS1	3.63	0.00032	0.0363	0.22	0.17	Breast cancer;	chr10:122033882	chr10:121928312~121951965:+
HNSC	cis	rs4705962	0.918	rs11242122	ENSG00000230612.2	AC004237.1	-3.63	0.00032	0.0363	-0.18	-0.17	Atopic dermatitis;	chr5:132689016	chr5:132688681~132723725:+
HNSC	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	3.63	0.00032	0.0363	0.15	0.17	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
HNSC	cis	rs6860540	0.796	rs3734029	ENSG00000251405.2	CTB-109A12.1	-3.63	0.000321	0.0363	-0.19	-0.17	Inflammatory skin disease;	chr5:157473742	chr5:157362615~157460078:-
HNSC	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	3.63	0.000321	0.0363	0.2	0.17	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
HNSC	cis	rs58521262	0.546	rs2927368	ENSG00000269837.1	IPO5P1	-3.63	0.000321	0.0363	-0.23	-0.17	Testicular germ cell tumor;	chr19:23049683	chr19:23255053~23257939:-
HNSC	cis	rs11846409	0.872	rs2516914	ENSG00000280411.1	IGHV1-69-2	3.63	0.000321	0.0363	0.15	0.17	Rheumatic heart disease;	chr14:106629835	chr14:106762092~106762588:-
HNSC	cis	rs17556665	0.741	rs17554294	ENSG00000254418.1	RP11-21L19.1	3.63	0.000321	0.0363	0.32	0.17	Inflammatory biomarkers;	chr11:13979988	chr11:14262846~14273691:-
HNSC	cis	rs17556665	0.741	rs72856939	ENSG00000254418.1	RP11-21L19.1	3.63	0.000321	0.0363	0.32	0.17	Inflammatory biomarkers;	chr11:13981279	chr11:14262846~14273691:-
HNSC	cis	rs526231	0.543	rs62362884	ENSG00000250682.4	LINC00491	3.63	0.000321	0.0363	0.22	0.17	Primary biliary cholangitis;	chr5:103231754	chr5:102609156~102671559:-
HNSC	cis	rs73242632	0.737	rs2899085	ENSG00000245067.5	IGFBP7-AS1	-3.63	0.000321	0.0363	-0.38	-0.17	Congenital heart disease (maternal effect);	chr4:57087045	chr4:57109762~57205510:+
HNSC	cis	rs73242632	0.619	rs2412787	ENSG00000245067.5	IGFBP7-AS1	-3.63	0.000321	0.0363	-0.38	-0.17	Congenital heart disease (maternal effect);	chr4:57087366	chr4:57109762~57205510:+
HNSC	cis	rs73242632	0.619	rs1111628	ENSG00000245067.5	IGFBP7-AS1	-3.63	0.000321	0.0363	-0.38	-0.17	Congenital heart disease (maternal effect);	chr4:57087521	chr4:57109762~57205510:+
HNSC	cis	rs73242632	0.737	rs1111629	ENSG00000245067.5	IGFBP7-AS1	-3.63	0.000321	0.0363	-0.38	-0.17	Congenital heart disease (maternal effect);	chr4:57087608	chr4:57109762~57205510:+
HNSC	cis	rs1411478	1	rs12744212	ENSG00000243155.1	RP11-46A10.5	3.63	0.000321	0.0363	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983380	chr1:180944042~180976482:-
HNSC	cis	rs7735319	0.899	rs13168108	ENSG00000249572.1	CTD-2203K17.1	3.62	0.000321	0.0363	0.19	0.17	Systolic blood pressure;	chr5:33119232	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.966	rs13169007	ENSG00000249572.1	CTD-2203K17.1	3.62	0.000321	0.0363	0.19	0.17	Systolic blood pressure;	chr5:33119553	chr5:33424025~33440619:-
HNSC	cis	rs7735319	0.966	rs13182741	ENSG00000249572.1	CTD-2203K17.1	3.62	0.000321	0.0363	0.19	0.17	Systolic blood pressure;	chr5:33134293	chr5:33424025~33440619:-
HNSC	cis	rs12911832	0.727	rs2604454	ENSG00000259657.1	PIGHP1	3.62	0.000321	0.0364	0.17	0.17	Schizophrenia;	chr15:58806533	chr15:59676757~59677321:+
HNSC	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	3.62	0.000321	0.0364	0.21	0.17	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
HNSC	cis	rs8024893	1	rs8038787	ENSG00000259448.2	RP11-16E12.1	-3.62	0.000321	0.0364	-0.23	-0.17	Red cell distribution width;	chr15:31246171	chr15:31216020~31224445:+
HNSC	cis	rs10927875	0.518	rs732286	ENSG00000226457.1	RP11-430L17.1	-3.62	0.000321	0.0364	-0.16	-0.17	Dilated cardiomyopathy;	chr1:16017865	chr1:16369150~16369530:-
HNSC	cis	rs10927875	0.518	rs945416	ENSG00000226457.1	RP11-430L17.1	-3.62	0.000321	0.0364	-0.16	-0.17	Dilated cardiomyopathy;	chr1:16017907	chr1:16369150~16369530:-
HNSC	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	3.62	0.000321	0.0364	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
HNSC	cis	rs9940149	1	rs6600208	ENSG00000226942.2	IL9RP3	-3.62	0.000321	0.0364	-0.21	-0.17	Type 2 diabetes;	chr16:255269	chr16:29336~38321:-
HNSC	cis	rs17489649	1	rs11747338	ENSG00000271849.1	CTC-332L22.1	3.62	0.000321	0.0364	0.21	0.17	Intelligence (multi-trait analysis);	chr5:109815030	chr5:109687802~109688329:-
HNSC	cis	rs7824557	0.628	rs11782706	ENSG00000269918.1	AF131215.9	3.62	0.000321	0.0364	0.16	0.17	Retinal vascular caliber;	chr8:11328706	chr8:11104691~11106704:-
HNSC	cis	rs703842	0.616	rs10783851	ENSG00000270039.1	RP11-571M6.17	3.62	0.000321	0.0364	0.2	0.17	Multiple sclerosis;	chr12:57837372	chr12:57803838~57804415:+
HNSC	cis	rs2505998	0.833	rs2251674	ENSG00000273008.1	RP11-351D16.3	3.62	0.000321	0.0364	0.2	0.17	Hirschsprung disease;	chr10:43109944	chr10:43136824~43138334:-
HNSC	cis	rs4381823	1	rs17036971	ENSG00000225187.1	AC073283.7	3.62	0.000321	0.0364	0.39	0.17	Schizophrenia;	chr2:47808854	chr2:47067822~47071204:+
HNSC	cis	rs3740713	1	rs75740864	ENSG00000256464.1	YWHABP2	3.62	0.000321	0.0364	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18490243~18490955:-
HNSC	cis	rs7189233	1	rs62048543	ENSG00000279344.1	RP11-44F14.7	3.62	0.000321	0.0364	0.16	0.17	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53478957~53481550:-
HNSC	cis	rs13325613	0.915	rs34005848	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46222254	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs34414382	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46223699	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs35613615	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46223752	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs34745455	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46225842	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs71327041	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46226091	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.748	rs114115904	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46227173	chr3:46364955~46407059:-
HNSC	cis	rs13325613	0.915	rs34677490	ENSG00000223552.1	RP11-24F11.2	-3.62	0.000321	0.0364	-0.31	-0.17	Monocyte count;	chr3:46229257	chr3:46364955~46407059:-
HNSC	cis	rs7189233	1	rs62048491	ENSG00000279344.1	RP11-44F14.7	3.62	0.000321	0.0364	0.16	0.17	Intelligence (multi-trait analysis);	chr16:53422479	chr16:53478957~53481550:-
HNSC	cis	rs11651000	0.625	rs58067360	ENSG00000263412.1	RP5-890E16.2	3.62	0.000321	0.0364	0.15	0.17	IgG glycosylation;	chr17:47742221	chr17:48045141~48048073:-
HNSC	cis	rs2762353	0.902	rs3799344	ENSG00000272462.2	U91328.19	3.62	0.000321	0.0364	0.16	0.17	Blood metabolite levels;	chr6:25786765	chr6:25992662~26001775:+
HNSC	cis	rs3736485	0.932	rs4775966	ENSG00000274528.1	CTD-2650P22.2	3.62	0.000321	0.0364	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51621591	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.932	rs2278988	ENSG00000274528.1	CTD-2650P22.2	3.62	0.000321	0.0364	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51623037	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.932	rs2124879	ENSG00000274528.1	CTD-2650P22.2	3.62	0.000321	0.0364	0.16	0.17	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51624636	chr15:52017167~52018032:-
HNSC	cis	rs55726902	0.553	rs2525052	ENSG00000276691.1	RP5-1057I20.5	3.62	0.000321	0.0364	0.16	0.17	Allergic disease (asthma, hay fever or eczema);	chr12:47801641	chr12:47788426~47788971:+
HNSC	cis	rs6499755	0.932	rs12928690	ENSG00000260135.5	RP11-212I21.2	-3.62	0.000321	0.0364	-0.19	-0.17	Hypospadias;	chr16:55309653	chr16:55426797~55462297:-
HNSC	cis	rs950169	0.84	rs62029595	ENSG00000259570.1	RP11-671M22.4	3.62	0.000321	0.0364	0.22	0.17	Schizophrenia;	chr15:84400603	chr15:84394512~84395514:+
HNSC	cis	rs7429990	0.965	rs7430913	ENSG00000228638.1	FCF1P2	3.62	0.000321	0.0364	0.15	0.17	Educational attainment (years of education);	chr3:47990867	chr3:48290793~48291375:-
HNSC	cis	rs1908814	0.516	rs35391955	ENSG00000255310.2	AF131215.2	3.62	0.000321	0.0364	0.16	0.17	Neuroticism;	chr8:11939219	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs58869268	ENSG00000255310.2	AF131215.2	3.62	0.000321	0.0364	0.16	0.17	Neuroticism;	chr8:11939586	chr8:11107788~11109726:-
HNSC	cis	rs12664251	0.706	rs2797356	ENSG00000253194.1	RP11-351A11.1	-3.62	0.000321	0.0364	-0.19	-0.17	Schizophrenia;	chr6:119014786	chr6:118934785~119031541:+
HNSC	cis	rs9652601	0.748	rs2903692	ENSG00000274038.1	RP11-66H6.4	-3.62	0.000321	0.0364	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11144926	chr16:11056556~11057034:+
HNSC	cis	rs7927592	0.913	rs12294029	ENSG00000239559.2	RPL37P2	3.62	0.000321	0.0364	0.17	0.17	Total body bone mineral density;	chr11:68489591	chr11:67682772~67683058:-
HNSC	cis	rs12047808	0.841	rs78940976	ENSG00000227141.2	RP11-545A16.3	-3.62	0.000321	0.0364	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179446916	chr1:179586705~179589175:+
HNSC	cis	rs765751	0.736	rs2605098	ENSG00000228536.1	RP11-392O17.1	3.62	0.000321	0.0364	0.19	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219470307	chr1:219409681~219411941:-
HNSC	cis	rs1113500	0.787	rs10881502	ENSG00000226822.1	RP11-356N1.2	-3.62	0.000322	0.0364	-0.18	-0.17	Growth-regulated protein alpha levels;	chr1:108099197	chr1:108071482~108074519:+
HNSC	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-3.62	0.000322	0.0364	-0.23	-0.17	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
HNSC	cis	rs9467711	0.651	rs35069699	ENSG00000241549.7	GUSBP2	3.62	0.000322	0.0364	0.27	0.17	Autism spectrum disorder or schizophrenia;	chr6:25957054	chr6:26871484~26956554:-
HNSC	cis	rs12030196	0.827	rs6699576	ENSG00000230812.4	LINC01358	3.62	0.000322	0.0364	0.18	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957154	chr1:59020387~59044614:+
HNSC	cis	rs2562784	0.597	rs2562785	ENSG00000225151.9	GOLGA2P7	-3.62	0.000322	0.0364	-0.31	-0.17	Height;	chr15:83617269	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.8	rs4842847	ENSG00000259570.1	RP11-671M22.4	3.62	0.000322	0.0364	0.22	0.17	Schizophrenia;	chr15:84262447	chr15:84394512~84395514:+
HNSC	cis	rs76455782	1	rs74904120	ENSG00000249465.1	RBMXP4	3.62	0.000322	0.0364	0.45	0.17	Common carotid intima-media thickness in HIV negative individuals;	chr4:109220044	chr4:109346326~109347459:-
HNSC	cis	rs76455782	1	rs7675810	ENSG00000249465.1	RBMXP4	-3.62	0.000322	0.0364	-0.45	-0.17	Common carotid intima-media thickness in HIV negative individuals;	chr4:109218055	chr4:109346326~109347459:-
HNSC	cis	rs4427176	0.507	rs6601348	ENSG00000254340.1	RP11-10A14.3	-3.62	0.000322	0.0364	-0.23	-0.17	Mosquito bite size;	chr8:9712984	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.71	rs10903317	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000322	0.0364	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9698397	chr8:8961200~8979025:+
HNSC	cis	rs7937890	0.681	rs4756784	ENSG00000251991.1	RNU7-49P	-3.62	0.000322	0.0364	-0.19	-0.17	Mitochondrial DNA levels;	chr11:14249358	chr11:14478892~14478953:+
HNSC	cis	rs12047808	0.73	rs73035925	ENSG00000227141.2	RP11-545A16.3	-3.62	0.000322	0.0364	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179562986	chr1:179586705~179589175:+
HNSC	cis	rs1937680	0.613	rs6480547	ENSG00000236671.6	PRKG1-AS1	-3.62	0.000322	0.0364	-0.22	-0.17	Breast cancer;	chr10:51890375	chr10:52230742~52314128:-
HNSC	cis	rs13178541	0.745	rs9986164	ENSG00000250378.1	RP11-119J18.1	-3.62	0.000322	0.0365	-0.21	-0.17	IgG glycosylation;	chr5:135827074	chr5:135812667~135826582:+
HNSC	cis	rs13178541	0.81	rs9986268	ENSG00000250378.1	RP11-119J18.1	-3.62	0.000322	0.0365	-0.21	-0.17	IgG glycosylation;	chr5:135827124	chr5:135812667~135826582:+
HNSC	cis	rs7572733	0.555	rs10202569	ENSG00000231621.1	AC013264.2	-3.62	0.000322	0.0365	-0.16	-0.17	Dermatomyositis;	chr2:198070002	chr2:197197991~197199273:+
HNSC	cis	rs847649	1	rs28856331	ENSG00000239969.4	RP11-163E9.2	-3.62	0.000322	0.0365	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102903316	chr7:102364162~102380633:+
HNSC	cis	rs5758659	0.967	rs5751250	ENSG00000270083.1	RP1-257I20.14	3.62	0.000322	0.0365	0.15	0.17	Cognitive function;	chr22:42243639	chr22:42089630~42090028:-
HNSC	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000322	0.0365	-0.24	-0.17	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
HNSC	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	3.62	0.000322	0.0365	0.25	0.17	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	3.62	0.000322	0.0365	0.25	0.17	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
HNSC	cis	rs7107174	0.901	rs2450137	ENSG00000251323.2	RP11-452H21.4	3.62	0.000322	0.0365	0.25	0.17	Testicular germ cell tumor;	chr11:78214187	chr11:78423982~78429836:-
HNSC	cis	rs2243480	1	rs313831	ENSG00000229886.1	RP5-1132H15.3	3.62	0.000322	0.0365	0.28	0.17	Diabetic kidney disease;	chr7:66086239	chr7:66025126~66031544:-
HNSC	cis	rs6012564	1	rs730543	ENSG00000227431.4	CSE1L-AS1	-3.62	0.000322	0.0365	-0.18	-0.17	Anger;	chr20:49019178	chr20:49040463~49046044:-
HNSC	cis	rs1595825	0.838	rs16826872	ENSG00000231621.1	AC013264.2	-3.62	0.000322	0.0365	-0.2	-0.17	Ulcerative colitis;	chr2:198033331	chr2:197197991~197199273:+
HNSC	cis	rs1440410	0.795	rs10461280	ENSG00000250326.1	RP11-284M14.1	-3.62	0.000322	0.0365	-0.18	-0.17	Ischemic stroke;	chr4:143263750	chr4:142933195~143184861:-
HNSC	cis	rs6928289	0.728	rs7747814	ENSG00000234956.4	RP11-356I2.1	3.62	0.000322	0.0365	0.17	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137310085	chr6:137730170~137738983:-
HNSC	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-3.62	0.000322	0.0365	-0.21	-0.17	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
HNSC	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-3.62	0.000322	0.0365	-0.17	-0.17	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
HNSC	cis	rs3733585	0.605	rs4235355	ENSG00000250413.1	RP11-448G15.1	3.62	0.000322	0.0365	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10121454	chr4:10006482~10009725:+
HNSC	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	3.62	0.000322	0.0365	0.17	0.17	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
HNSC	cis	rs11633958	1	rs11633958	ENSG00000261762.1	RP11-650L12.2	-3.62	0.000323	0.0365	-0.2	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78569722	chr15:78589123~78591276:-
HNSC	cis	rs45509595	0.556	rs34409918	ENSG00000226314.6	ZNF192P1	-3.62	0.000323	0.0365	-0.31	-0.17	Breast cancer;	chr6:27717569	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs13212318	ENSG00000226314.6	ZNF192P1	-3.62	0.000323	0.0365	-0.31	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28161781~28169594:+
HNSC	cis	rs2310173	0.575	rs4850993	ENSG00000281162.1	LINC01127	-3.62	0.000323	0.0365	-0.21	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102006004	chr2:101962056~101987167:+
HNSC	cis	rs2117029	0.586	rs10783308	ENSG00000258101.2	RP11-977B10.2	3.62	0.000323	0.0365	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49232790~49264756:-
HNSC	cis	rs2836974	0.681	rs8128827	ENSG00000255568.3	BRWD1-AS2	3.62	0.000323	0.0365	0.15	0.17	Cognitive function;	chr21:39338621	chr21:39313935~39314962:+
HNSC	cis	rs12234571	1	rs12667288	ENSG00000214293.7	APTR	3.62	0.000323	0.0365	0.21	0.17	Obesity-related traits;	chr7:77777224	chr7:77657660~77696265:-
HNSC	cis	rs6860540	0.796	rs10404	ENSG00000251405.2	CTB-109A12.1	-3.62	0.000323	0.0365	-0.19	-0.17	Inflammatory skin disease;	chr5:157477625	chr5:157362615~157460078:-
HNSC	cis	rs6499755	0.901	rs4784522	ENSG00000260135.5	RP11-212I21.2	-3.62	0.000323	0.0365	-0.19	-0.17	Hypospadias;	chr16:55314837	chr16:55426797~55462297:-
HNSC	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	3.62	0.000323	0.0365	0.23	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
HNSC	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	3.62	0.000323	0.0365	0.23	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
HNSC	cis	rs950169	0.919	rs12915589	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000323	0.0365	-0.18	-0.17	Schizophrenia;	chr15:84065712	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.959	rs66801143	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000323	0.0365	-0.18	-0.17	Schizophrenia;	chr15:84067905	chr15:84507885~84516814:-
HNSC	cis	rs950169	1	rs35648189	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000323	0.0365	-0.18	-0.17	Schizophrenia;	chr15:84071996	chr15:84507885~84516814:-
HNSC	cis	rs950169	0.92	rs17300048	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000323	0.0365	-0.18	-0.17	Schizophrenia;	chr15:84080725	chr15:84507885~84516814:-
HNSC	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-3.62	0.000323	0.0365	-0.22	-0.17	Pain;	chr19:21473244	chr19:21554640~21569237:-
HNSC	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-3.62	0.000323	0.0365	-0.19	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
HNSC	cis	rs5760092	0.572	rs738806	ENSG00000228039.3	KB-1125A3.10	3.62	0.000323	0.0365	0.24	0.17	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23963780~23964374:+
HNSC	cis	rs10435719	0.58	rs13260712	ENSG00000227888.4	FAM66A	-3.62	0.000323	0.0365	-0.17	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.551	rs13268217	ENSG00000227888.4	FAM66A	-3.62	0.000323	0.0365	-0.17	-0.17	Monocyte count;	chr8:11925100	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.573	rs13264994	ENSG00000227888.4	FAM66A	-3.62	0.000323	0.0365	-0.17	-0.17	Monocyte count;	chr8:11925250	chr8:12362019~12388296:+
HNSC	cis	rs11992162	0.573	rs13275808	ENSG00000227888.4	FAM66A	-3.62	0.000323	0.0365	-0.17	-0.17	Monocyte count;	chr8:11925306	chr8:12362019~12388296:+
HNSC	cis	rs12047808	1	rs16854186	ENSG00000227141.2	RP11-545A16.3	-3.62	0.000323	0.0365	-0.25	-0.17	Multiple sclerosis (age of onset);	chr1:179504569	chr1:179586705~179589175:+
HNSC	cis	rs4352251	0.778	rs7562234	ENSG00000205716.4	FAM183DP	-3.62	0.000323	0.0365	-0.27	-0.17	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101356469	chr2:102249857~102250255:-
HNSC	cis	rs6928977	0.802	rs2244745	ENSG00000217482.2	HMGB1P17	-3.62	0.000323	0.0365	-0.18	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341683	chr6:135636086~135636713:-
HNSC	cis	rs73607972	0.935	rs4783818	ENSG00000275191.1	RP11-36I17.2	-3.62	0.000323	0.0365	-0.25	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53704371	chr16:53628256~53628816:-
HNSC	cis	rs441460	0.502	rs3788991	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0365	-0.18	-0.17	Platelet count;	chr6:25599006	chr6:26523450~26526579:+
HNSC	cis	rs6545883	0.894	rs2121661	ENSG00000271889.1	RP11-493E12.1	-3.62	0.000323	0.0365	-0.19	-0.17	Tuberculosis;	chr2:61334523	chr2:61151433~61162105:-
HNSC	cis	rs116095464	0.51	rs10057501	ENSG00000277812.1	AC021087.1	3.62	0.000323	0.0365	0.28	0.17	Breast cancer;	chr5:239430	chr5:262769~262881:+
HNSC	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000323	0.0365	-0.24	-0.17	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
HNSC	cis	rs3771570	1	rs73018141	ENSG00000260942.1	CAPN10-AS1	-3.62	0.000323	0.0366	-0.18	-0.17	Prostate cancer;	chr2:241282155	chr2:240582700~240586699:-
HNSC	cis	rs3932549	1	rs3932549	ENSG00000231806.2	PCAT7	3.62	0.000323	0.0366	0.19	0.17	Body mass index;	chr9:94311306	chr9:94555069~94568127:+
HNSC	cis	rs10865541	0.967	rs6751808	ENSG00000234171.2	RNASEH1-AS1	3.62	0.000323	0.0366	0.17	0.17	Obesity-related traits;	chr2:3393606	chr2:3558492~3561745:+
HNSC	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	3.62	0.000323	0.0366	0.17	0.17	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
HNSC	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	3.62	0.000323	0.0366	0.23	0.17	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
HNSC	cis	rs13068223	1	rs13068223	ENSG00000240875.4	LINC00886	3.62	0.000323	0.0366	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156747346~156817062:-
HNSC	cis	rs1028883	0.571	rs9543411	ENSG00000228295.1	LINC00392	-3.62	0.000323	0.0366	-0.17	-0.17	Lean body mass;	chr13:73599288	chr13:73564244~73588070:+
HNSC	cis	rs1028883	0.554	rs9530209	ENSG00000228295.1	LINC00392	-3.62	0.000323	0.0366	-0.17	-0.17	Lean body mass;	chr13:73599398	chr13:73564244~73588070:+
HNSC	cis	rs853679	0.55	rs1233699	ENSG00000219891.2	ZSCAN12P1	3.62	0.000323	0.0366	0.23	0.17	Depression;	chr6:28201380	chr6:28091154~28093664:+
HNSC	cis	rs1659258	0.568	rs1258443	ENSG00000232508.1	MRPL45P1	3.62	0.000323	0.0366	0.28	0.17	Visceral fat;	chr2:88297724	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.667	rs1713943	ENSG00000232508.1	MRPL45P1	3.62	0.000323	0.0366	0.28	0.17	Visceral fat;	chr2:88300247	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.568	rs2579026	ENSG00000232508.1	MRPL45P1	3.62	0.000323	0.0366	0.28	0.17	Visceral fat;	chr2:88302036	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.568	rs1258437	ENSG00000232508.1	MRPL45P1	3.62	0.000323	0.0366	0.28	0.17	Visceral fat;	chr2:88309250	chr2:88364695~88365608:-
HNSC	cis	rs1659258	0.568	rs1258436	ENSG00000232508.1	MRPL45P1	3.62	0.000323	0.0366	0.28	0.17	Visceral fat;	chr2:88309443	chr2:88364695~88365608:-
HNSC	cis	rs9467711	0.606	rs34104395	ENSG00000241549.7	GUSBP2	3.62	0.000323	0.0366	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:26871484~26956554:-
HNSC	cis	rs919433	0.756	rs7575389	ENSG00000231621.1	AC013264.2	3.62	0.000323	0.0366	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197333765	chr2:197197991~197199273:+
HNSC	cis	rs614226	0.516	rs1794748	ENSG00000202538.1	RNU4-2	-3.62	0.000323	0.0366	-0.28	-0.17	Type 1 diabetes nephropathy;	chr12:120515955	chr12:120291763~120291903:-
HNSC	cis	rs614226	1	rs1614223	ENSG00000202538.1	RNU4-2	-3.62	0.000323	0.0366	-0.28	-0.17	Type 1 diabetes nephropathy;	chr12:120526240	chr12:120291763~120291903:-
HNSC	cis	rs614226	1	rs1167727	ENSG00000202538.1	RNU4-2	-3.62	0.000323	0.0366	-0.28	-0.17	Type 1 diabetes nephropathy;	chr12:120527705	chr12:120291763~120291903:-
HNSC	cis	rs61542988	0.797	rs4329182	ENSG00000226329.2	AC005682.6	3.62	0.000323	0.0366	0.23	0.17	Fibrinogen levels;	chr7:22843002	chr7:22863874~22881350:-
HNSC	cis	rs61542988	0.756	rs5013587	ENSG00000226329.2	AC005682.6	3.62	0.000323	0.0366	0.23	0.17	Fibrinogen levels;	chr7:22843041	chr7:22863874~22881350:-
HNSC	cis	rs10435719	0.902	rs11250179	ENSG00000269918.1	AF131215.9	3.62	0.000324	0.0366	0.16	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs464895	ENSG00000226002.1	RP11-460N20.5	-3.62	0.000324	0.0366	-0.29	-0.17	Diabetic kidney disease;	chr7:66062119	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000226002.1	RP11-460N20.5	-3.62	0.000324	0.0366	-0.29	-0.17	Diabetic kidney disease;	chr7:66063241	chr7:65084103~65100232:+
HNSC	cis	rs9595908	0.9	rs731413	ENSG00000215515.2	IFIT1P1	3.62	0.000324	0.0366	0.19	0.17	Body mass index;	chr13:32601519	chr13:32384660~32386108:+
HNSC	cis	rs2048656	0.605	rs13273565	ENSG00000233609.3	RP11-62H7.2	3.62	0.000324	0.0366	0.17	0.17	Schizophrenia;	chr8:9791636	chr8:8961200~8979025:+
HNSC	cis	rs7178375	1	rs1474382	ENSG00000270015.1	RP11-540B6.6	3.62	0.000324	0.0366	0.21	0.17	Hypertriglyceridemia;	chr15:30922446	chr15:30926514~30928407:+
HNSC	cis	rs60695258	0.529	rs340630	ENSG00000251411.1	RP11-397E7.4	3.62	0.000324	0.0366	0.17	0.17	Hematocrit;	chr4:87037243	chr4:86913266~86914817:-
HNSC	cis	rs6430585	0.528	rs115553816	ENSG00000231890.6	DARS-AS1	-3.62	0.000324	0.0366	-0.29	-0.17	Corneal structure;	chr2:135935323	chr2:135985176~136022593:+
HNSC	cis	rs2243480	1	rs313832	ENSG00000229886.1	RP5-1132H15.3	3.62	0.000324	0.0366	0.28	0.17	Diabetic kidney disease;	chr7:66085904	chr7:66025126~66031544:-
HNSC	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-3.62	0.000324	0.0366	-0.18	-0.17	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
HNSC	cis	rs6715284	0.786	rs61695176	ENSG00000183308.6	AC005037.3	3.62	0.000324	0.0366	0.38	0.17	Rheumatoid arthritis;	chr2:201468592	chr2:200963263~201009102:+
HNSC	cis	rs6715284	0.786	rs73988793	ENSG00000183308.6	AC005037.3	3.62	0.000324	0.0366	0.38	0.17	Rheumatoid arthritis;	chr2:201473570	chr2:200963263~201009102:+
HNSC	cis	rs828999	0.713	rs547364	ENSG00000280186.1	RP11-483I13.6	3.62	0.000324	0.0366	0.18	0.17	Monocyte percentage of white cells;	chr1:108199501	chr1:108200413~108202743:+
HNSC	cis	rs2016266	0.806	rs11170494	ENSG00000270175.1	RP11-793H13.11	-3.62	0.000324	0.0366	-0.15	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53271380	chr12:53500162~53500936:-
HNSC	cis	rs62229266	0.659	rs62230814	ENSG00000230212.5	AP000688.14	-3.62	0.000324	0.0366	-0.18	-0.17	Mitral valve prolapse;	chr21:36031248	chr21:36069642~36126640:-
HNSC	cis	rs9611565	0.649	rs126092	ENSG00000235513.1	RP4-756G23.5	-3.62	0.000324	0.0366	-0.2	-0.17	Vitiligo;	chr22:41782437	chr22:41209122~41217627:-
HNSC	cis	rs449789	0.524	rs4709299	ENSG00000235086.1	FNDC1-IT1	3.62	0.000324	0.0366	0.2	0.17	Pulse pressure;	chr6:159330001	chr6:159240786~159243329:+
HNSC	cis	rs2880765	0.546	rs36098649	ENSG00000259295.5	CSPG4P12	3.62	0.000324	0.0366	0.22	0.17	Coronary artery disease;	chr15:85513576	chr15:85191438~85213905:+
HNSC	cis	rs13256369	1	rs10110591	ENSG00000254153.1	CTA-398F10.2	-3.62	0.000324	0.0366	-0.2	-0.17	Obesity-related traits;	chr8:8719098	chr8:8456909~8461337:-
HNSC	cis	rs870825	0.872	rs12506750	ENSG00000254233.1	RP11-242J7.1	3.62	0.000324	0.0366	0.29	0.17	Blood protein levels;	chr4:184649969	chr4:184584093~184625030:-
HNSC	cis	rs6545883	0.772	rs1186709	ENSG00000271889.1	RP11-493E12.1	3.62	0.000324	0.0366	0.19	0.17	Tuberculosis;	chr2:61462245	chr2:61151433~61162105:-
HNSC	cis	rs7746199	0.736	rs17693963	ENSG00000280107.1	AL022393.9	-3.62	0.000324	0.0366	-0.28	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28170845~28172521:+
HNSC	cis	rs11098499	0.874	rs6851169	ENSG00000250412.1	KLHL2P1	3.62	0.000324	0.0366	0.21	0.17	Corneal astigmatism;	chr4:119196355	chr4:119334329~119378233:+
HNSC	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-3.62	0.000324	0.0366	-0.2	-0.17	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
HNSC	cis	rs6869502	0.554	rs244408	ENSG00000214784.4	AC010468.1	3.62	0.000324	0.0367	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr5:110686168	chr5:111192226~111193042:-
HNSC	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	3.62	0.000324	0.0367	0.15	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
HNSC	cis	rs9733	0.687	rs12410050	ENSG00000236713.1	RP11-363I22.3	3.62	0.000324	0.0367	0.18	0.17	Tonsillectomy;	chr1:150884665	chr1:150780272~150780644:+
HNSC	cis	rs6545883	0.894	rs2463102	ENSG00000271889.1	RP11-493E12.1	-3.62	0.000324	0.0367	-0.19	-0.17	Tuberculosis;	chr2:61344160	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.894	rs2593633	ENSG00000271889.1	RP11-493E12.1	-3.62	0.000324	0.0367	-0.19	-0.17	Tuberculosis;	chr2:61344378	chr2:61151433~61162105:-
HNSC	cis	rs4814920	0.756	rs6046400	ENSG00000233895.1	RP1-122P22.2	-3.62	0.000324	0.0367	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19757708~19809675:+
HNSC	cis	rs210152	0.588	rs210131	ENSG00000223534.1	HLA-DQB1-AS1	-3.62	0.000324	0.0367	-0.36	-0.17	Schizophrenia;	chr6:33567689	chr6:32659880~32660729:+
HNSC	cis	rs11231017	0.507	rs10897267	ENSG00000250659.2	RP11-864I4.3	-3.62	0.000324	0.0367	-0.21	-0.17	HIV-1 viral setpoint;	chr11:62389946	chr11:62537312~62542018:+
HNSC	cis	rs1445130	0.636	rs12989389	ENSG00000260331.1	RP11-111J6.2	-3.62	0.000324	0.0367	-0.22	-0.17	Bulimia nervosa;	chr2:18655563	chr2:18547386~18548204:-
HNSC	cis	rs9329221	0.648	rs4512422	ENSG00000269918.1	AF131215.9	-3.62	0.000325	0.0367	-0.16	-0.17	Neuroticism;	chr8:10401379	chr8:11104691~11106704:-
HNSC	cis	rs17489649	0.956	rs2301013	ENSG00000271849.1	CTC-332L22.1	3.62	0.000325	0.0367	0.21	0.17	Intelligence (multi-trait analysis);	chr5:109802219	chr5:109687802~109688329:-
HNSC	cis	rs16935110	1	rs77705633	ENSG00000254337.1	RP11-865I6.2	-3.62	0.000325	0.0367	-0.25	-0.17	Obesity-related traits;	chr8:68818562	chr8:68848742~68852763:-
HNSC	cis	rs7688540	0.771	rs12505835	ENSG00000250892.1	RP11-1365D11.1	-3.62	0.000325	0.0367	-0.31	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:201409~205009:-
HNSC	cis	rs7911264	0.739	rs10736069	ENSG00000232709.1	MARK2P9	-3.62	0.000325	0.0367	-0.19	-0.17	Inflammatory bowel disease;	chr10:92635636	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs7900689	ENSG00000232709.1	MARK2P9	-3.62	0.000325	0.0367	-0.19	-0.17	Inflammatory bowel disease;	chr10:92635991	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs6583830	ENSG00000232709.1	MARK2P9	-3.62	0.000325	0.0367	-0.19	-0.17	Inflammatory bowel disease;	chr10:92638361	chr10:92418667~92420875:+
HNSC	cis	rs67072384	1	rs67075228	ENSG00000213365.3	AP000593.6	3.62	0.000325	0.0367	0.28	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739730	chr11:72280151~72281178:+
HNSC	cis	rs2919917	0.628	rs6981103	ENSG00000260398.1	RP11-594N15.3	3.62	0.000325	0.0367	0.22	0.17	Lymphocyte counts;	chr8:78691702	chr8:78605952~78609705:+
HNSC	cis	rs6787172	0.622	rs73170348	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158369965	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs12494098	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158370807	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs4680430	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158371300	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs10936135	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158373985	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs11706187	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158375384	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs55964653	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158375877	chr3:158693120~158693768:-
HNSC	cis	rs6787172	0.622	rs12632998	ENSG00000272087.1	RP11-379F4.7	3.62	0.000325	0.0367	0.17	0.17	Subjective well-being;	chr3:158379024	chr3:158693120~158693768:-
HNSC	cis	rs9911578	0.967	rs8072712	ENSG00000224738.1	AC099850.1	3.62	0.000325	0.0367	0.17	0.17	Intelligence (multi-trait analysis);	chr17:59085103	chr17:59106598~59118267:+
HNSC	cis	rs7189233	0.55	rs17193176	ENSG00000261056.2	RP11-454F8.2	-3.62	0.000325	0.0367	-0.18	-0.17	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53298224~53299792:+
HNSC	cis	rs726288	1	rs12219080	ENSG00000280355.1	RP11-119F19.5	-3.62	0.000325	0.0367	-0.38	-0.17	Rheumatoid arthritis;	chr10:79949523	chr10:79681973~79684094:-
HNSC	cis	rs9329221	0.736	rs11250002	ENSG00000269918.1	AF131215.9	3.62	0.000325	0.0367	0.17	0.17	Neuroticism;	chr8:10399531	chr8:11104691~11106704:-
HNSC	cis	rs35306767	0.903	rs7074642	ENSG00000229869.1	RP11-363N22.2	-3.62	0.000325	0.0367	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr10:832419	chr10:933026~942743:+
HNSC	cis	rs911555	0.673	rs7144271	ENSG00000244691.1	RPL10AP1	-3.62	0.000325	0.0367	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs10148970	ENSG00000244691.1	RPL10AP1	-3.62	0.000325	0.0367	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103412119~103412761:-
HNSC	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	3.62	0.000325	0.0367	0.28	0.17	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
HNSC	cis	rs9487051	0.768	rs371960	ENSG00000243587.6	C6orf183	-3.62	0.000325	0.0367	-0.16	-0.17	Reticulocyte fraction of red cells;	chr6:109203879	chr6:109165833~109271014:+
HNSC	cis	rs16858210	0.618	rs12638094	ENSG00000234371.6	RPSAP31	3.62	0.000325	0.0367	0.25	0.17	Menopause (age at onset);	chr3:183847771	chr3:183884924~183888449:+
HNSC	cis	rs1620921	0.783	rs1782618	ENSG00000233342.1	RP11-235G24.3	-3.62	0.000325	0.0367	-0.19	-0.17	Lipoprotein (a) - cholesterol levels;	chr6:160809336	chr6:160926369~160927162:+
HNSC	cis	rs988913	0.918	rs7739399	ENSG00000224984.1	RP11-524H19.2	3.62	0.000325	0.0367	0.19	0.17	Menarche (age at onset);	chr6:54990740	chr6:54840118~54840855:-
HNSC	cis	rs10073892	0.62	rs7730106	ENSG00000250682.4	LINC00491	-3.62	0.000325	0.0367	-0.23	-0.17	Cognitive decline (age-related);	chr5:102629339	chr5:102609156~102671559:-
HNSC	cis	rs7781557	0.64	rs73714541	ENSG00000239969.4	RP11-163E9.2	-3.62	0.000325	0.0368	-0.25	-0.17	Colorectal adenoma (advanced);	chr7:102982217	chr7:102364162~102380633:+
HNSC	cis	rs11711311	0.955	rs7650764	ENSG00000241529.3	RN7SL767P	-3.62	0.000325	0.0368	-0.22	-0.17	IgG glycosylation;	chr3:113695592	chr3:113632704~113632998:+
HNSC	cis	rs9926296	0.542	rs12599531	ENSG00000261812.4	TUBB8P7	3.62	0.000325	0.0368	0.18	0.17	Vitiligo;	chr16:89842993	chr16:90093154~90096354:+
HNSC	cis	rs6493858	0.805	rs35972806	ENSG00000277245.1	RP11-48G14.3	-3.62	0.000325	0.0368	-0.19	-0.17	Relative hand skill in reading disability;	chr15:56131414	chr15:56447120~56447697:+
HNSC	cis	rs2253762	0.578	rs2459084	ENSG00000276742.1	RP11-500G22.4	-3.62	0.000325	0.0368	-0.19	-0.17	Breast cancer;	chr10:122024162	chr10:121956782~121957098:+
HNSC	cis	rs1003719	0.591	rs2835618	ENSG00000242553.1	AP001432.14	3.62	0.000326	0.0368	0.19	0.17	Eye color traits;	chr21:37130826	chr21:37221419~37237744:+
HNSC	cis	rs12047808	0.841	rs58340590	ENSG00000227141.2	RP11-545A16.3	-3.62	0.000326	0.0368	-0.24	-0.17	Multiple sclerosis (age of onset);	chr1:179447433	chr1:179586705~179589175:+
HNSC	cis	rs73191547	0.541	rs10097315	ENSG00000269918.1	AF131215.9	3.62	0.000326	0.0368	0.17	0.17	Schizophrenia;	chr8:10203128	chr8:11104691~11106704:-
HNSC	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	3.62	0.000326	0.0368	0.2	0.17	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
HNSC	cis	rs10895275	0.961	rs10895276	ENSG00000225678.2	AP000619.5	3.62	0.000326	0.0368	0.2	0.17	Migraine;	chr11:102212964	chr11:102751070~102754943:-
HNSC	cis	rs11098499	0.722	rs17595727	ENSG00000250412.1	KLHL2P1	-3.62	0.000326	0.0368	-0.21	-0.17	Corneal astigmatism;	chr4:119340919	chr4:119334329~119378233:+
HNSC	cis	rs11671005	0.693	rs11669665	ENSG00000269473.1	CTD-2619J13.19	3.62	0.000326	0.0368	0.26	0.17	Mean platelet volume;	chr19:58420518	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs11084543	ENSG00000269473.1	CTD-2619J13.19	3.62	0.000326	0.0368	0.26	0.17	Mean platelet volume;	chr19:58421334	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs11881000	ENSG00000269473.1	CTD-2619J13.19	3.62	0.000326	0.0368	0.26	0.17	Mean platelet volume;	chr19:58421421	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs12981875	ENSG00000269473.1	CTD-2619J13.19	3.62	0.000326	0.0368	0.26	0.17	Mean platelet volume;	chr19:58423763	chr19:58440448~58445849:+
HNSC	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	3.62	0.000326	0.0368	0.16	0.17	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
HNSC	cis	rs4938303	0.788	rs61906115	ENSG00000254851.1	RP11-109L13.1	3.62	0.000326	0.0368	0.26	0.17	Triglycerides;	chr11:116687529	chr11:117135528~117138582:+
HNSC	cis	rs9649213	0.614	rs3944111	ENSG00000272950.1	RP11-307C18.1	3.62	0.000326	0.0368	0.25	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98376454	chr7:98322853~98323430:+
HNSC	cis	rs2337406	1	rs11850709	ENSG00000211972.2	IGHV3-66	3.62	0.000326	0.0368	0.17	0.17	Alzheimer's disease (late onset);	chr14:106670844	chr14:106675017~106675544:-
HNSC	cis	rs2976388	1	rs2920282	ENSG00000253741.1	CTD-2292P10.4	3.62	0.000326	0.0368	0.16	0.17	Urinary tract infection frequency;	chr8:142676345	chr8:142702252~142726973:-
HNSC	cis	rs728616	0.558	rs2880599	ENSG00000225484.5	NUTM2B-AS1	-3.62	0.000326	0.0368	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79663088~79826594:-
HNSC	cis	rs73201462	1	rs67575175	ENSG00000231305.3	RP11-723O4.2	-3.62	0.000326	0.0368	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128161383	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs13071740	ENSG00000231305.3	RP11-723O4.2	-3.62	0.000326	0.0368	-0.24	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128162725	chr3:128861313~128871540:-
HNSC	cis	rs4578769	0.55	rs4800442	ENSG00000265943.1	RP11-739L10.1	3.62	0.000326	0.0368	0.2	0.17	Eosinophil percentage of white cells;	chr18:22958337	chr18:22699481~22933764:-
HNSC	cis	rs10829156	0.679	rs4748476	ENSG00000240291.1	RP11-499P20.2	3.62	0.000326	0.0368	0.18	0.17	Sudden cardiac arrest;	chr10:18503946	chr10:18513115~18545651:-
HNSC	cis	rs3748656	0.945	rs12137269	ENSG00000273483.1	RP4-671G15.2	3.62	0.000326	0.0368	0.22	0.17	Hip circumference adjusted for BMI;	chr1:112564011	chr1:112517799~112518441:-
HNSC	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-3.62	0.000326	0.0368	-0.23	-0.17	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
HNSC	cis	rs7948661	1	rs9332816	ENSG00000278376.1	RP11-158I9.8	3.62	0.000326	0.0368	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118493689	chr11:118791254~118793137:+
HNSC	cis	rs12745968	0.652	rs4970702	ENSG00000223787.2	RP4-593M8.1	-3.62	0.000326	0.0368	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr1:92479437	chr1:92580476~92580821:-
HNSC	cis	rs172166	0.516	rs1225710	ENSG00000217862.2	HIST1H4PS1	3.62	0.000326	0.0368	0.17	0.17	Cardiac Troponin-T levels;	chr6:28132862	chr6:27807075~27807339:+
HNSC	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	3.62	0.000326	0.0368	0.12	0.17	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
HNSC	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	3.62	0.000326	0.0368	0.2	0.17	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
HNSC	cis	rs17407555	0.779	rs57757169	ENSG00000250413.1	RP11-448G15.1	3.62	0.000326	0.0368	0.25	0.17	Schizophrenia (age at onset);	chr4:10114079	chr4:10006482~10009725:+
HNSC	cis	rs9487051	0.703	rs351755	ENSG00000243587.6	C6orf183	3.62	0.000326	0.0368	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109216870	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.735	rs351756	ENSG00000243587.6	C6orf183	3.62	0.000326	0.0368	0.16	0.17	Reticulocyte fraction of red cells;	chr6:109217570	chr6:109165833~109271014:+
HNSC	cis	rs3750965	0.959	rs4930264	ENSG00000265539.1	MIR3164	-3.62	0.000326	0.0368	-0.18	-0.17	Hair color;	chr11:69084713	chr11:69083176~69083258:+
HNSC	cis	rs6968419	0.714	rs3807980	ENSG00000237870.5	AC073130.1	3.62	0.000326	0.0369	0.2	0.17	Intraocular pressure;	chr7:116253593	chr7:116275606~116286734:-
HNSC	cis	rs2439831	0.867	rs2412778	ENSG00000275601.1	AC011330.13	-3.62	0.000326	0.0369	-0.25	-0.17	Lung cancer in ever smokers;	chr15:43368784	chr15:43642389~43643023:-
HNSC	cis	rs7246657	0.654	rs10407568	ENSG00000276846.1	CTD-3220F14.3	3.62	0.000326	0.0369	0.22	0.17	Coronary artery calcification;	chr19:37632108	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs10409605	ENSG00000276846.1	CTD-3220F14.3	3.62	0.000326	0.0369	0.22	0.17	Coronary artery calcification;	chr19:37632236	chr19:37314868~37315620:-
HNSC	cis	rs453301	0.652	rs2043129	ENSG00000253981.4	ALG1L13P	3.62	0.000327	0.0369	0.18	0.17	Joint mobility (Beighton score);	chr8:8967994	chr8:8236003~8244667:-
HNSC	cis	rs7829975	0.508	rs1594437	ENSG00000253981.4	ALG1L13P	3.62	0.000327	0.0369	0.18	0.17	Mood instability;	chr8:8968365	chr8:8236003~8244667:-
HNSC	cis	rs35000415	0.938	rs35234849	ENSG00000275106.1	RP11-309L24.10	-3.62	0.000327	0.0369	-0.37	-0.17	Systemic lupus erythematosus;	chr7:129008899	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs12539476	ENSG00000275106.1	RP11-309L24.10	-3.62	0.000327	0.0369	-0.37	-0.17	Systemic lupus erythematosus;	chr7:129017429	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs13236009	ENSG00000275106.1	RP11-309L24.10	-3.62	0.000327	0.0369	-0.37	-0.17	Systemic lupus erythematosus;	chr7:129023119	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs71581958	ENSG00000275106.1	RP11-309L24.10	-3.62	0.000327	0.0369	-0.37	-0.17	Systemic lupus erythematosus;	chr7:129025488	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs34381587	ENSG00000275106.1	RP11-309L24.10	-3.62	0.000327	0.0369	-0.37	-0.17	Systemic lupus erythematosus;	chr7:129026771	chr7:128952527~128953316:-
HNSC	cis	rs9611565	0.512	rs132767	ENSG00000213857.3	RP11-12M9.4	3.62	0.000327	0.0369	0.22	0.17	Vitiligo;	chr22:41613516	chr22:41074180~41075239:-
HNSC	cis	rs8077577	0.708	rs3829590	ENSG00000273018.4	CTD-2303H24.2	3.62	0.000327	0.0369	0.24	0.17	Obesity-related traits;	chr17:18230951	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.708	rs3829589	ENSG00000273018.4	CTD-2303H24.2	3.62	0.000327	0.0369	0.24	0.17	Obesity-related traits;	chr17:18230952	chr17:18511221~18551705:-
HNSC	cis	rs73201462	0.908	rs2811386	ENSG00000231305.3	RP11-723O4.2	3.62	0.000327	0.0369	0.23	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281172	chr3:128861313~128871540:-
HNSC	cis	rs6921919	0.789	rs13210258	ENSG00000227214.2	HCG15	3.62	0.000327	0.0369	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28986203~28987484:+
HNSC	cis	rs4845570	0.92	rs1196456	ENSG00000268288.1	RP11-98D18.16	3.62	0.000327	0.0369	0.26	0.17	Coronary artery disease;	chr1:151764873	chr1:151766486~151767000:-
HNSC	cis	rs442309	1	rs224139	ENSG00000238280.1	RP11-436D10.3	-3.62	0.000327	0.0369	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62713956	chr10:62793562~62805887:-
HNSC	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.898	rs785502	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785491	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785494	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785503	ENSG00000280836.1	AL355480.1	3.62	0.000327	0.0369	0.17	0.17	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45581219~45581321:-
HNSC	cis	rs526231	0.543	rs34783	ENSG00000250682.4	LINC00491	3.62	0.000327	0.0369	0.22	0.17	Primary biliary cholangitis;	chr5:103121337	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.512	rs28022	ENSG00000250682.4	LINC00491	3.62	0.000327	0.0369	0.22	0.17	Primary biliary cholangitis;	chr5:103128663	chr5:102609156~102671559:-
HNSC	cis	rs7587476	0.626	rs7593780	ENSG00000229267.2	AC072062.1	-3.62	0.000327	0.0369	-0.19	-0.17	Neuroblastoma;	chr2:214775672	chr2:214810229~214963274:+
HNSC	cis	rs853679	1	rs1679709	ENSG00000219891.2	ZSCAN12P1	-3.62	0.000327	0.0369	-0.26	-0.17	Depression;	chr6:28260564	chr6:28091154~28093664:+
HNSC	cis	rs1155750	0.72	rs378853	ENSG00000224984.1	RP11-524H19.2	-3.62	0.000327	0.0369	-0.24	-0.17	Colorectal cancer;	chr6:54931004	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239787	ENSG00000224984.1	RP11-524H19.2	-3.62	0.000327	0.0369	-0.24	-0.17	Colorectal cancer;	chr6:54934089	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239788	ENSG00000224984.1	RP11-524H19.2	-3.62	0.000327	0.0369	-0.24	-0.17	Colorectal cancer;	chr6:54935022	chr6:54840118~54840855:-
HNSC	cis	rs6095360	0.966	rs6090940	ENSG00000227431.4	CSE1L-AS1	-3.62	0.000327	0.0369	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:49049490	chr20:49040463~49046044:-
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-3.62	0.000327	0.0369	-0.19	-0.17	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
HNSC	cis	rs16958440	0.581	rs60726022	ENSG00000267724.1	RP11-49K24.8	3.62	0.000327	0.0369	0.26	0.17	Sitting height ratio;	chr18:47153442	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.581	rs72907280	ENSG00000267724.1	RP11-49K24.8	3.62	0.000327	0.0369	0.26	0.17	Sitting height ratio;	chr18:47154759	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.581	rs11872531	ENSG00000267724.1	RP11-49K24.8	3.62	0.000327	0.0369	0.26	0.17	Sitting height ratio;	chr18:47162863	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.581	rs11875768	ENSG00000267724.1	RP11-49K24.8	3.62	0.000327	0.0369	0.26	0.17	Sitting height ratio;	chr18:47162989	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.581	rs11873880	ENSG00000267724.1	RP11-49K24.8	3.62	0.000327	0.0369	0.26	0.17	Sitting height ratio;	chr18:47166094	chr18:47105946~47108062:+
HNSC	cis	rs1023500	1	rs1023498	ENSG00000205702.9	CYP2D7	-3.62	0.000327	0.0369	-0.14	-0.17	Schizophrenia;	chr22:41944565	chr22:42140203~42144577:-
HNSC	cis	rs74781061	1	rs74781061	ENSG00000260103.2	RP11-10O17.1	-3.62	0.000327	0.0369	-0.19	-0.17	Endometriosis;	chr15:74595855	chr15:74478070~74490286:-
HNSC	cis	rs11711311	0.747	rs2895415	ENSG00000241529.3	RN7SL767P	-3.62	0.000327	0.0369	-0.22	-0.17	IgG glycosylation;	chr3:113626718	chr3:113632704~113632998:+
HNSC	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	3.62	0.000327	0.0369	0.17	0.17	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
HNSC	cis	rs783147	0.652	rs1782629	ENSG00000231863.1	RP3-428L16.1	3.62	0.000327	0.0369	0.2	0.17	Lp (a) levels;	chr6:160774834	chr6:160931080~160969771:+
HNSC	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	3.62	0.000327	0.0369	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
HNSC	cis	rs67072384	0.786	rs58424437	ENSG00000245148.2	ARAP1-AS2	3.62	0.000327	0.0369	0.23	0.17	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737211	chr11:72700474~72705607:+
HNSC	cis	rs1642645	0.831	rs784103	ENSG00000228452.1	RP5-994D16.9	-3.62	0.000327	0.0369	-0.22	-0.17	Left ventricular obstructive tract defect (maternal effect);	chr1:42021388	chr1:42775813~42776790:-
HNSC	cis	rs10927875	0.541	rs1739841	ENSG00000226029.1	RP4-798A10.2	-3.62	0.000327	0.0369	-0.15	-0.17	Dilated cardiomyopathy;	chr1:16016232	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.541	rs1739842	ENSG00000226029.1	RP4-798A10.2	-3.62	0.000327	0.0369	-0.15	-0.17	Dilated cardiomyopathy;	chr1:16016353	chr1:16460948~16468481:+
HNSC	cis	rs12586317	0.545	rs58342373	ENSG00000258704.4	SRP54-AS1	-3.62	0.000327	0.0369	-0.2	-0.17	Psoriasis;	chr14:34926063	chr14:34920858~34982532:-
HNSC	cis	rs4938303	0.633	rs567209	ENSG00000280143.1	AP000892.6	-3.62	0.000327	0.0369	-0.23	-0.17	Triglycerides;	chr11:116664111	chr11:117204967~117210292:+
HNSC	cis	rs12701220	0.894	rs8591	ENSG00000224079.1	AC091729.7	3.62	0.000327	0.0369	0.25	0.17	Bronchopulmonary dysplasia;	chr7:997163	chr7:1074450~1078036:+
HNSC	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	3.62	0.000327	0.0369	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
HNSC	cis	rs2013441	1	rs2703782	ENSG00000261033.1	RP11-209D14.2	3.62	0.000327	0.0369	0.19	0.17	Obesity-related traits;	chr17:20241486	chr17:20008051~20009234:-
HNSC	cis	rs8077577	0.747	rs12451698	ENSG00000273018.4	CTD-2303H24.2	-3.62	0.000327	0.037	-0.24	-0.17	Obesity-related traits;	chr17:18333802	chr17:18511221~18551705:-
HNSC	cis	rs1131351	0.644	rs2348477	ENSG00000234378.1	AC098828.2	3.62	0.000327	0.037	0.19	0.17	Seasonality;	chr2:20200346	chr2:20063856~20106829:-
HNSC	cis	rs870825	0.587	rs6826883	ENSG00000254233.1	RP11-242J7.1	3.62	0.000327	0.037	0.24	0.17	Blood protein levels;	chr4:184695013	chr4:184584093~184625030:-
HNSC	cis	rs35306767	0.807	rs72778228	ENSG00000229869.1	RP11-363N22.2	-3.62	0.000327	0.037	-0.26	-0.17	Eosinophil percentage of granulocytes;	chr10:892495	chr10:933026~942743:+
HNSC	cis	rs1865760	0.713	rs7766342	ENSG00000272810.1	U91328.22	-3.62	0.000327	0.037	-0.15	-0.17	Height;	chr6:25990446	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.713	rs9461229	ENSG00000272810.1	U91328.22	-3.62	0.000327	0.037	-0.15	-0.17	Height;	chr6:25992051	chr6:26013241~26013757:+
HNSC	cis	rs2243480	0.666	rs1880311	ENSG00000226002.1	RP11-460N20.5	3.62	0.000327	0.037	0.3	0.17	Diabetic kidney disease;	chr7:65811765	chr7:65084103~65100232:+
HNSC	cis	rs9914544	0.545	rs9912713	ENSG00000264885.1	RP11-815I9.4	-3.62	0.000327	0.037	-0.17	-0.17	Educational attainment (years of education);	chr17:18867832	chr17:18667629~18669461:-
HNSC	cis	rs10134944	1	rs35253945	ENSG00000258900.1	HNRNPCP1	3.62	0.000327	0.037	0.3	0.17	Bipolar disorder;	chr14:57654670	chr14:58521223~58521988:+
HNSC	cis	rs10134944	1	rs12890746	ENSG00000258900.1	HNRNPCP1	3.62	0.000327	0.037	0.3	0.17	Bipolar disorder;	chr14:57654974	chr14:58521223~58521988:+
HNSC	cis	rs9487051	0.66	rs2884036	ENSG00000243587.6	C6orf183	3.62	0.000327	0.037	0.17	0.17	Reticulocyte fraction of red cells;	chr6:109321713	chr6:109165833~109271014:+
HNSC	cis	rs9494145	0.59	rs9376090	ENSG00000232876.1	CTA-212D2.2	-3.62	0.000328	0.037	-0.24	-0.17	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135090090	chr6:135055033~135060550:+
HNSC	cis	rs6690583	0.573	rs61768854	ENSG00000223653.4	RP11-131L23.1	3.62	0.000328	0.037	0.31	0.17	Serum sulfate level;	chr1:84994338	chr1:85276715~85448124:+
HNSC	cis	rs859767	1	rs859767	ENSG00000224043.6	CCNT2-AS1	-3.62	0.000328	0.037	-0.2	-0.17	Neuroticism;	chr2:134583630	chr2:134735464~134918710:-
HNSC	cis	rs8077577	0.708	rs7211573	ENSG00000273018.4	CTD-2303H24.2	3.62	0.000328	0.037	0.24	0.17	Obesity-related traits;	chr17:18228299	chr17:18511221~18551705:-
HNSC	cis	rs11668609	0.938	rs8110507	ENSG00000268442.1	CTD-2027I19.2	3.62	0.000328	0.037	0.22	0.17	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:24162370~24163425:-
HNSC	cis	rs968451	0.507	rs137618	ENSG00000273076.1	RP3-508I15.22	3.62	0.000328	0.037	0.16	0.17	Primary biliary cholangitis;	chr22:39309099	chr22:38743495~38743910:+
HNSC	cis	rs10888574	1	rs10888574	ENSG00000228126.1	FALEC	-3.62	0.000328	0.037	-0.22	-0.17	Pediatric bone mineral content (hip);	chr1:150191796	chr1:150515757~150518032:+
HNSC	cis	rs35000415	1	rs35000415	ENSG00000244556.1	ODCP	3.62	0.000328	0.037	0.33	0.17	Systemic lupus erythematosus;	chr7:128945562	chr7:129028889~129030527:+
HNSC	cis	rs2333194	1	rs2333194	ENSG00000258695.2	RP3-414A15.2	-3.62	0.000328	0.037	-0.17	-0.17	Bipolar disorder with mood-incongruent psychosis;	chr14:73300506	chr14:73522878~73530610:+
HNSC	cis	rs4648045	0.565	rs17033014	ENSG00000246560.2	RP11-10L12.4	3.62	0.000328	0.037	0.2	0.17	Lymphocyte percentage of white cells;	chr4:102625029	chr4:102828055~102844075:+
HNSC	cis	rs72949976	0.934	rs1922794	ENSG00000270659.1	RP11-105N14.1	3.62	0.000328	0.037	0.17	0.17	Squamous cell lung carcinoma;Lung cancer;	chr2:213161457	chr2:213152970~213153659:+
HNSC	cis	rs2337406	0.866	rs74092520	ENSG00000280411.1	IGHV1-69-2	-3.62	0.000328	0.037	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106779632	chr14:106762092~106762588:-
HNSC	cis	rs2013441	1	rs2189710	ENSG00000261033.1	RP11-209D14.2	3.62	0.000328	0.037	0.19	0.17	Obesity-related traits;	chr17:20175651	chr17:20008051~20009234:-
HNSC	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	3.62	0.000328	0.037	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
HNSC	cis	rs782107	0.541	rs17120781	ENSG00000270039.1	RP11-571M6.17	-3.62	0.000328	0.037	-0.2	-0.17	Interleukin-12p70 levels;	chr12:58418282	chr12:57803838~57804415:+
HNSC	cis	rs782107	0.541	rs17120783	ENSG00000270039.1	RP11-571M6.17	-3.62	0.000328	0.037	-0.2	-0.17	Interleukin-12p70 levels;	chr12:58418318	chr12:57803838~57804415:+
HNSC	cis	rs112521149	1	rs112521149	ENSG00000242349.4	NPPA-AS1	-3.62	0.000328	0.037	-0.26	-0.17	Mean corpuscular volume;	chr1:11829758	chr1:11841017~11848079:+
HNSC	cis	rs11992162	0.591	rs34123222	ENSG00000227888.4	FAM66A	-3.62	0.000328	0.037	-0.17	-0.17	Monocyte count;	chr8:11937840	chr8:12362019~12388296:+
HNSC	cis	rs253959	0.545	rs6896147	ENSG00000271918.1	CTD-2287O16.5	-3.62	0.000328	0.037	-0.15	-0.17	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116083807~116085416:-
HNSC	cis	rs890448	0.726	rs2044043	ENSG00000254531.1	FLJ20021	-3.62	0.000328	0.037	-0.16	-0.17	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101314983	chr4:101347780~101348883:+
HNSC	cis	rs4908760	0.864	rs12136766	ENSG00000232912.4	RP5-1115A15.1	3.62	0.000328	0.037	0.17	0.17	Vitiligo;	chr1:8603762	chr1:8424645~8434838:+
HNSC	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	3.62	0.000328	0.037	0.26	0.17	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
HNSC	cis	rs12545109	0.959	rs12546307	ENSG00000246430.5	LINC00968	-3.62	0.000328	0.037	-0.21	-0.17	Obesity-related traits;	chr8:56402231	chr8:56496246~56559823:-
HNSC	cis	rs516805	0.528	rs2684245	ENSG00000279453.1	RP3-425C14.4	-3.62	0.000328	0.037	-0.23	-0.17	Lymphocyte counts;	chr6:122092990	chr6:122436789~122439223:-
HNSC	cis	rs2439831	0.764	rs12324584	ENSG00000275601.1	AC011330.13	-3.62	0.000328	0.037	-0.24	-0.17	Lung cancer in ever smokers;	chr15:43391248	chr15:43642389~43643023:-
HNSC	cis	rs3929778	0.848	rs6054318	ENSG00000275632.1	RP5-967N21.11	3.62	0.000328	0.037	0.16	0.17	QRS complex (Cornell);	chr20:6508786	chr20:6000418~6000941:+
HNSC	cis	rs3929778	0.883	rs6054323	ENSG00000275632.1	RP5-967N21.11	3.62	0.000328	0.037	0.16	0.17	QRS complex (Cornell);	chr20:6513615	chr20:6000418~6000941:+
HNSC	cis	rs10875746	0.587	rs9788082	ENSG00000257763.1	OR5BK1P	-3.62	0.000328	0.037	-0.21	-0.17	Longevity (90 years and older);	chr12:48358273	chr12:48355792~48356614:-
HNSC	cis	rs2836974	0.899	rs68004583	ENSG00000255568.3	BRWD1-AS2	3.62	0.000328	0.037	0.15	0.17	Cognitive function;	chr21:39287661	chr21:39313935~39314962:+
HNSC	cis	rs8042680	0.688	rs11073964	ENSG00000213471.7	TTLL13P	-3.62	0.000328	0.037	-0.2	-0.17	Type 2 diabetes;	chr15:91000531	chr15:90249530~90265482:+
HNSC	cis	rs11671005	0.735	rs11667591	ENSG00000269473.1	CTD-2619J13.19	3.62	0.000328	0.037	0.26	0.17	Mean platelet volume;	chr19:58426270	chr19:58440448~58445849:+
HNSC	cis	rs7714670	1	rs11949860	ENSG00000184084.7	CTD-2372A4.1	-3.62	0.000328	0.037	-0.18	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:73780632	chr5:73803296~73803599:-
HNSC	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	3.62	0.000328	0.037	0.2	0.17	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
HNSC	cis	rs6951245	0.554	rs35126802	ENSG00000225146.1	AC073957.15	-3.62	0.000328	0.037	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1029025~1043891:+
HNSC	cis	rs9650657	0.707	rs4841452	ENSG00000255310.2	AF131215.2	-3.62	0.000329	0.0371	-0.16	-0.17	Neuroticism;	chr8:10829611	chr8:11107788~11109726:-
HNSC	cis	rs2439831	0.867	rs2278860	ENSG00000275601.1	AC011330.13	3.62	0.000329	0.0371	0.25	0.17	Lung cancer in ever smokers;	chr15:43366848	chr15:43642389~43643023:-
HNSC	cis	rs62025270	0.632	rs78572940	ENSG00000259762.1	RP11-158M2.4	-3.62	0.000329	0.0371	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85750336~85752901:-
HNSC	cis	rs897984	0.762	rs12931046	ENSG00000260911.2	RP11-196G11.2	-3.62	0.000329	0.0371	-0.15	-0.17	Dementia with Lewy bodies;	chr16:30975823	chr16:31043150~31049868:+
HNSC	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-3.62	0.000329	0.0371	-0.15	-0.17	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
HNSC	cis	rs5758659	0.652	rs133313	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000329	0.0371	-0.15	-0.17	Cognitive function;	chr22:42005745	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.652	rs133314	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000329	0.0371	-0.15	-0.17	Cognitive function;	chr22:42005837	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.652	rs133323	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000329	0.0371	-0.15	-0.17	Cognitive function;	chr22:42009918	chr22:42132543~42132998:+
HNSC	cis	rs5758659	0.652	rs133327	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000329	0.0371	-0.15	-0.17	Cognitive function;	chr22:42011685	chr22:42132543~42132998:+
HNSC	cis	rs7824557	0.602	rs7834139	ENSG00000269918.1	AF131215.9	3.62	0.000329	0.0371	0.16	0.17	Retinal vascular caliber;	chr8:11348854	chr8:11104691~11106704:-
HNSC	cis	rs8002861	0.664	rs4942247	ENSG00000274001.1	RP11-5G9.5	3.62	0.000329	0.0371	0.17	0.17	Leprosy;	chr13:43830971	chr13:43877715~43878163:-
HNSC	cis	rs1519814	0.624	rs2176749	ENSG00000254343.2	RP11-760H22.2	-3.62	0.000329	0.0371	-0.22	-0.17	Breast cancer;	chr8:120020195	chr8:120052180~120056201:+
HNSC	cis	rs6088580	0.66	rs6087592	ENSG00000276073.1	RP5-1125A11.7	-3.62	0.000329	0.0371	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:33985617~33988989:-
HNSC	cis	rs6545883	0.826	rs2694617	ENSG00000271889.1	RP11-493E12.1	-3.62	0.000329	0.0371	-0.19	-0.17	Tuberculosis;	chr2:61310079	chr2:61151433~61162105:-
HNSC	cis	rs8024893	1	rs6493544	ENSG00000259448.2	RP11-16E12.1	-3.62	0.000329	0.0371	-0.23	-0.17	Red cell distribution width;	chr15:31245356	chr15:31216020~31224445:+
HNSC	cis	rs7824557	0.591	rs2060457	ENSG00000255495.1	AC145124.2	3.62	0.000329	0.0371	0.18	0.17	Retinal vascular caliber;	chr8:11355741	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.614	rs2060456	ENSG00000255495.1	AC145124.2	3.62	0.000329	0.0371	0.18	0.17	Retinal vascular caliber;	chr8:11355854	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.614	rs5029571	ENSG00000255495.1	AC145124.2	3.62	0.000329	0.0371	0.18	0.17	Retinal vascular caliber;	chr8:11355880	chr8:12194467~12196280:+
HNSC	cis	rs8180040	0.62	rs6414435	ENSG00000276925.1	RP11-708J19.3	-3.62	0.000329	0.0371	-0.16	-0.17	Colorectal cancer;	chr3:47079650	chr3:47469777~47469987:+
HNSC	cis	rs6469606	0.598	rs2721943	ENSG00000249917.2	LINC00536	-3.62	0.000329	0.0371	-0.22	-0.17	Granulocyte percentage of myeloid white cells;	chr8:115625772	chr8:115950511~116325059:-
HNSC	cis	rs734999	0.588	rs2764848	ENSG00000238164.5	RP3-395M20.8	3.62	0.000329	0.0371	0.12	0.17	Ulcerative colitis;	chr1:2599255	chr1:2549920~2557031:-
HNSC	cis	rs9467711	0.517	rs16901784	ENSG00000241549.7	GUSBP2	3.62	0.000329	0.0371	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:26555205	chr6:26871484~26956554:-
HNSC	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-3.62	0.000329	0.0371	-0.18	-0.17	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
HNSC	cis	rs7646881	0.544	rs73030851	ENSG00000272087.1	RP11-379F4.7	3.62	0.000329	0.0371	0.24	0.17	Tetralogy of Fallot;	chr3:158699163	chr3:158693120~158693768:-
HNSC	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	3.62	0.000329	0.0371	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	3.62	0.000329	0.0371	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	3.62	0.000329	0.0371	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
HNSC	cis	rs2638953	0.886	rs11049572	ENSG00000257176.2	RP11-996F15.2	3.62	0.000329	0.0371	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:29280418~29317848:-
HNSC	cis	rs3748656	0.943	rs11102520	ENSG00000273483.1	RP4-671G15.2	3.62	0.000329	0.0371	0.22	0.17	Hip circumference adjusted for BMI;	chr1:112692264	chr1:112517799~112518441:-
HNSC	cis	rs2919917	0.628	rs13267679	ENSG00000260398.1	RP11-594N15.3	-3.62	0.000329	0.0371	-0.23	-0.17	Lymphocyte counts;	chr8:78711603	chr8:78605952~78609705:+
HNSC	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-3.62	0.000329	0.0371	-0.21	-0.17	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
HNSC	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	3.62	0.000329	0.0371	0.24	0.17	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
HNSC	cis	rs12545912	0.739	rs6601344	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000329	0.0371	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9690635	chr8:8961200~8979025:+
HNSC	cis	rs12545912	0.77	rs4313162	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000329	0.0371	-0.17	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9691082	chr8:8961200~8979025:+
HNSC	cis	rs61160187	0.582	rs12652878	ENSG00000272308.1	RP11-231G3.1	-3.62	0.000329	0.0371	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.548	rs17392014	ENSG00000272308.1	RP11-231G3.1	-3.62	0.000329	0.0371	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.582	rs4647150	ENSG00000272308.1	RP11-231G3.1	-3.62	0.000329	0.0371	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60866457~60866935:-
HNSC	cis	rs3857747	0.557	rs10951635	ENSG00000228554.1	AC004837.5	3.62	0.000329	0.0371	0.17	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40350492	chr7:39700341~39703296:-
HNSC	cis	rs4242434	0.819	rs2306518	ENSG00000253837.1	RP11-177H13.2	-3.62	0.000329	0.0371	-0.17	-0.17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22612795	chr8:23336171~23366125:+
HNSC	cis	rs2288884	0.505	rs12459170	ENSG00000267879.1	CTB-147C22.9	3.62	0.000329	0.0371	0.25	0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:50968210~51012129:+
HNSC	cis	rs2288884	0.505	rs8110213	ENSG00000267879.1	CTB-147C22.9	3.62	0.000329	0.0371	0.25	0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:50968210~51012129:+
HNSC	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-3.62	0.000329	0.0371	-0.22	-0.17	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
HNSC	cis	rs2483519	0.828	rs1333682	ENSG00000236799.1	RP11-383C6.2	-3.62	0.000329	0.0371	-0.17	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114657788	chr10:114994657~114996593:+
HNSC	cis	rs7364180	0.582	rs139568	ENSG00000235513.1	RP4-756G23.5	-3.62	0.000329	0.0371	-0.16	-0.17	Alzheimer's disease biomarkers;	chr22:41814981	chr22:41209122~41217627:-
HNSC	cis	rs62025270	0.547	rs338536	ENSG00000259295.5	CSPG4P12	-3.62	0.000329	0.0371	-0.21	-0.17	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85191438~85213905:+
HNSC	cis	rs969413	0.535	rs8077394	ENSG00000262115.1	RP11-455O6.2	-3.62	0.000329	0.0371	-0.17	-0.17	Frontotemporal dementia;	chr17:81284987	chr17:81197393~81200288:+
HNSC	cis	rs6001482	0.727	rs5757616	ENSG00000253818.1	IGLV1-41	-3.62	0.000329	0.0371	-0.14	-0.17	Diastolic blood pressure;	chr22:22240095	chr22:22404207~22404721:+
HNSC	cis	rs10263639	0.63	rs2215137	ENSG00000226824.5	RP4-756H11.3	-3.62	0.000329	0.0371	-0.3	-0.17	Breast cancer;	chr7:67586540	chr7:66654538~66669855:+
HNSC	cis	rs7824557	0.527	rs2736296	ENSG00000255495.1	AC145124.2	-3.62	0.000329	0.0371	-0.18	-0.17	Retinal vascular caliber;	chr8:11377335	chr8:12194467~12196280:+
HNSC	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	3.62	0.000329	0.0371	0.19	0.17	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
HNSC	cis	rs17253792	0.822	rs77250916	ENSG00000186615.9	KTN1-AS1	-3.62	0.000329	0.0371	-0.35	-0.17	Putamen volume;	chr14:55575490	chr14:55499278~55580110:-
HNSC	cis	rs9311474	0.508	rs11720243	ENSG00000243224.1	RP5-1157M23.2	-3.62	0.000329	0.0371	-0.16	-0.17	Electroencephalogram traits;	chr3:52584002	chr3:52239258~52241097:+
HNSC	cis	rs7824557	0.592	rs920044	ENSG00000255310.2	AF131215.2	3.62	0.00033	0.0371	0.15	0.17	Retinal vascular caliber;	chr8:11366804	chr8:11107788~11109726:-
HNSC	cis	rs643506	0.845	rs2850245	ENSG00000230911.1	PPIHP1	-3.62	0.00033	0.0371	-0.22	-0.17	Breast cancer;	chr11:111890014	chr11:112029858~112030367:-
HNSC	cis	rs6840360	0.901	rs1443094	ENSG00000251611.1	RP11-610P16.1	-3.62	0.00033	0.0371	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151407551~151408835:-
HNSC	cis	rs7637230	1	rs7637230	ENSG00000244119.1	PDCL3P4	-3.62	0.00033	0.0371	-0.17	-0.17	Psoriasis vulgaris;Psoriasis;	chr3:101944711	chr3:101712472~101713191:+
HNSC	cis	rs886126	1	rs876027	ENSG00000257595.2	RP3-473L9.4	3.62	0.00033	0.0371	0.21	0.17	Coronary heart disease;	chr12:111240654	chr12:111369282~111403310:+
HNSC	cis	rs911119	1	rs3088162	ENSG00000270001.1	RP11-218C14.8	-3.62	0.00033	0.0372	-0.24	-0.17	Chronic kidney disease;	chr20:23627115	chr20:23631826~23632316:-
HNSC	cis	rs875971	0.66	rs10281080	ENSG00000273142.1	RP11-458F8.4	3.62	0.00033	0.0372	0.14	0.17	Aortic root size;	chr7:66577454	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs10950044	ENSG00000273142.1	RP11-458F8.4	3.62	0.00033	0.0372	0.14	0.17	Aortic root size;	chr7:66577989	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.522	rs1968127	ENSG00000273142.1	RP11-458F8.4	3.62	0.00033	0.0372	0.14	0.17	Aortic root size;	chr7:66591816	chr7:66902857~66906297:+
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	3.62	0.00033	0.0372	0.2	0.17	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
HNSC	cis	rs9505118	0.931	rs9505121	ENSG00000238221.1	RP11-69L16.4	3.62	0.00033	0.0372	0.21	0.17	Type 2 diabetes;	chr6:7290957	chr6:7276031~7298872:+
HNSC	cis	rs2069426	0.591	rs17694493	ENSG00000266446.1	RP11-149I2.4	3.62	0.00033	0.0372	0.25	0.17	Acute lymphoblastic leukemia (childhood);	chr9:22041999	chr9:21995482~21996013:+
HNSC	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-3.62	0.00033	0.0372	-0.19	-0.17	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
HNSC	cis	rs9355610	0.727	rs2247315	ENSG00000227598.1	RP1-167A14.2	3.62	0.00033	0.0372	0.18	0.17	Graves' disease;	chr6:166956723	chr6:166969626~166999065:-
HNSC	cis	rs6499755	0.897	rs8046197	ENSG00000260135.5	RP11-212I21.2	-3.62	0.00033	0.0372	-0.19	-0.17	Hypospadias;	chr16:55312100	chr16:55426797~55462297:-
HNSC	cis	rs988913	0.957	rs9382396	ENSG00000224984.1	RP11-524H19.2	3.62	0.00033	0.0372	0.19	0.17	Menarche (age at onset);	chr6:54895888	chr6:54840118~54840855:-
HNSC	cis	rs11756659	0.653	rs199738	ENSG00000218690.1	HIST1H2APS4	3.62	0.00033	0.0372	0.22	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963228	chr6:26272193~26272540:-
HNSC	cis	rs73198271	1	rs73198279	ENSG00000233609.3	RP11-62H7.2	-3.62	0.00033	0.0372	-0.19	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8961200~8979025:+
HNSC	cis	rs7824557	0.603	rs7016671	ENSG00000255310.2	AF131215.2	3.62	0.00033	0.0372	0.16	0.17	Retinal vascular caliber;	chr8:11324946	chr8:11107788~11109726:-
HNSC	cis	rs870825	0.581	rs28602720	ENSG00000254233.1	RP11-242J7.1	3.62	0.00033	0.0372	0.24	0.17	Blood protein levels;	chr4:184709444	chr4:184584093~184625030:-
HNSC	cis	rs4252134	0.881	rs56262039	ENSG00000231863.1	RP3-428L16.1	3.62	0.00033	0.0372	0.21	0.17	Giant cell arteritis;	chr6:160762423	chr6:160931080~160969771:+
HNSC	cis	rs2760061	0.583	rs708118	ENSG00000270110.1	RP5-1139B12.4	3.62	0.00033	0.0372	0.17	0.17	Diastolic blood pressure;	chr1:228014100	chr1:228295911~228302998:-
HNSC	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-3.62	0.00033	0.0372	-0.21	-0.17	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
HNSC	cis	rs7646881	0.544	rs61107068	ENSG00000272087.1	RP11-379F4.7	3.62	0.00033	0.0372	0.23	0.17	Tetralogy of Fallot;	chr3:158665915	chr3:158693120~158693768:-
HNSC	cis	rs6499755	0.768	rs31095	ENSG00000260135.5	RP11-212I21.2	-3.62	0.00033	0.0372	-0.18	-0.17	Hypospadias;	chr16:55333318	chr16:55426797~55462297:-
HNSC	cis	rs2098713	0.534	rs6867424	ENSG00000250155.1	CTD-2353F22.1	3.62	0.00033	0.0372	0.17	0.17	Telomere length;	chr5:37534771	chr5:36666214~36725195:-
HNSC	cis	rs6690583	0.623	rs12033900	ENSG00000223653.4	RP11-131L23.1	3.62	0.00033	0.0372	0.32	0.17	Serum sulfate level;	chr1:85012876	chr1:85276715~85448124:+
HNSC	cis	rs9303280	0.617	rs6503525	ENSG00000266469.1	CTB-131K11.1	-3.62	0.00033	0.0372	-0.14	-0.17	Self-reported allergy;	chr17:39938921	chr17:39401793~39406233:+
HNSC	cis	rs9914544	0.545	rs9915343	ENSG00000264885.1	RP11-815I9.4	-3.62	0.00033	0.0372	-0.17	-0.17	Educational attainment (years of education);	chr17:18863181	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs12942794	ENSG00000264885.1	RP11-815I9.4	-3.62	0.00033	0.0372	-0.17	-0.17	Educational attainment (years of education);	chr17:18863904	chr17:18667629~18669461:-
HNSC	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	3.62	0.00033	0.0372	0.18	0.17	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
HNSC	cis	rs11098499	0.691	rs28396837	ENSG00000250412.1	KLHL2P1	3.62	0.00033	0.0372	0.21	0.17	Corneal astigmatism;	chr4:119350386	chr4:119334329~119378233:+
HNSC	cis	rs7824557	0.564	rs2736293	ENSG00000255495.1	AC145124.2	-3.62	0.00033	0.0372	-0.18	-0.17	Retinal vascular caliber;	chr8:11377104	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.564	rs2736294	ENSG00000255495.1	AC145124.2	-3.62	0.00033	0.0372	-0.18	-0.17	Retinal vascular caliber;	chr8:11377117	chr8:12194467~12196280:+
HNSC	cis	rs9297145	0.678	rs62473048	ENSG00000272950.1	RP11-307C18.1	-3.62	0.00033	0.0372	-0.25	-0.17	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99177888	chr7:98322853~98323430:+
HNSC	cis	rs2645424	0.55	rs12338	ENSG00000255046.1	RP11-297N6.4	3.62	0.00033	0.0372	0.18	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853379	chr8:11797928~11802568:-
HNSC	cis	rs9733	0.635	rs486836	ENSG00000236713.1	RP11-363I22.3	3.62	0.00033	0.0372	0.18	0.17	Tonsillectomy;	chr1:150903491	chr1:150780272~150780644:+
HNSC	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-3.62	0.00033	0.0372	-0.2	-0.17	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
HNSC	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	3.62	0.00033	0.0372	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
HNSC	cis	rs7113211	0.79	rs11214352	ENSG00000176343.5	RPL37AP8	3.62	0.00033	0.0372	0.17	0.17	Expressive vocabulary in infants;	chr11:112757764	chr11:111889199~111889474:-
HNSC	cis	rs2587695	1	rs2587653	ENSG00000223549.1	MTND5P28	3.62	0.00033	0.0372	0.18	0.17	Attention deficit hyperactivity disorder;	chr2:119540655	chr2:120215181~120217279:+
HNSC	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-3.62	0.00033	0.0372	-0.24	-0.17	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
HNSC	cis	rs7937890	0.732	rs7946902	ENSG00000251991.1	RNU7-49P	-3.62	0.00033	0.0372	-0.18	-0.17	Mitochondrial DNA levels;	chr11:14251762	chr11:14478892~14478953:+
HNSC	cis	rs6090919	0.501	rs13040284	ENSG00000222365.1	SNORD12B	3.62	0.00033	0.0372	0.23	0.17	Intelligence (multi-trait analysis);	chr20:48854681	chr20:49280319~49280409:+
HNSC	cis	rs859767	0.741	rs10803548	ENSG00000224043.6	CCNT2-AS1	3.62	0.00033	0.0372	0.2	0.17	Neuroticism;	chr2:134639168	chr2:134735464~134918710:-
HNSC	cis	rs2243480	1	rs466983	ENSG00000226002.1	RP11-460N20.5	-3.62	0.00033	0.0372	-0.29	-0.17	Diabetic kidney disease;	chr7:66055509	chr7:65084103~65100232:+
HNSC	cis	rs1131351	0.644	rs4350703	ENSG00000234378.1	AC098828.2	3.62	0.00033	0.0372	0.19	0.17	Seasonality;	chr2:20200508	chr2:20063856~20106829:-
HNSC	cis	rs9650657	0.524	rs2163379	ENSG00000255310.2	AF131215.2	3.62	0.00033	0.0372	0.17	0.17	Neuroticism;	chr8:10874540	chr8:11107788~11109726:-
HNSC	cis	rs865483	0.895	rs2522972	ENSG00000276054.1	RP11-378E13.3	3.62	0.000331	0.0372	0.2	0.17	Monocyte count;	chr17:37478916	chr17:37386886~37387926:+
HNSC	cis	rs3204270	0.53	rs57707013	ENSG00000262049.1	RP13-1032I1.7	3.62	0.000331	0.0372	0.17	0.17	Dental caries;	chr17:81668251	chr17:81701324~81703300:-
HNSC	cis	rs9357733	0.673	rs10484877	ENSG00000243236.5	GSTA9P	3.62	0.000331	0.0372	0.24	0.17	Atopic march;	chr6:52377904	chr6:52939726~52957521:-
HNSC	cis	rs7688540	0.76	rs2883229	ENSG00000250892.1	RP11-1365D11.1	-3.62	0.000331	0.0372	-0.25	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:201409~205009:-
HNSC	cis	rs16958440	0.867	rs80106524	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47150268	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs79712753	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47150356	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs3809965	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47150501	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs74411203	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47151095	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs74346439	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47151096	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs3809966	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47151256	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs12326457	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47152054	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs12326465	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47152274	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs75934126	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47153410	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs12326221	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47156522	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs12326412	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47157223	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs77615793	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47158093	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs58061761	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47159794	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs75287977	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47160452	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs28578518	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47161177	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs28587821	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47161535	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs77599321	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47163271	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs75901436	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47163273	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs74845165	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47164481	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs114475395	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47164639	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs16949157	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47164953	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs75808931	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47166671	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs59217333	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47168473	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs10083937	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47169231	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs79395141	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47169309	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs80006910	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47170011	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs77149690	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47170772	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs79285649	ENSG00000267724.1	RP11-49K24.8	3.62	0.000331	0.0372	0.32	0.17	Sitting height ratio;	chr18:47172648	chr18:47105946~47108062:+
HNSC	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-3.62	0.000331	0.0373	-0.17	-0.17	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
HNSC	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-3.62	0.000331	0.0373	-0.19	-0.17	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
HNSC	cis	rs801193	1	rs2659912	ENSG00000273142.1	RP11-458F8.4	-3.62	0.000331	0.0373	-0.14	-0.17	Aortic root size;	chr7:66693012	chr7:66902857~66906297:+
HNSC	cis	rs2548724	0.812	rs390614	ENSG00000250682.4	LINC00491	-3.62	0.000331	0.0373	-0.21	-0.17	Type 2 diabetes;	chr5:102260540	chr5:102609156~102671559:-
HNSC	cis	rs7937890	0.559	rs4369365	ENSG00000251991.1	RNU7-49P	3.62	0.000331	0.0373	0.18	0.17	Mitochondrial DNA levels;	chr11:14422969	chr11:14478892~14478953:+
HNSC	cis	rs3764021	0.87	rs10492166	ENSG00000256673.1	RP11-599J14.2	-3.62	0.000331	0.0373	-0.16	-0.17	Type 1 diabetes;	chr12:9733403	chr12:9398355~9414851:-
HNSC	cis	rs740160	0.618	rs680055	ENSG00000281555.1	AC005071.3	-3.62	0.000331	0.0373	-0.33	-0.17	Dehydroepiandrosterone sulphate levels;	chr7:99859982	chr7:100217065~100217165:-
HNSC	cis	rs2307394	1	rs12998729	ENSG00000281469.1	RP11-567F11.1	3.62	0.000331	0.0373	0.18	0.17	Urate levels;	chr2:147859723	chr2:148044380~148044894:+
HNSC	cis	rs67311347	1	rs12108041	ENSG00000280739.1	EIF1B-AS1	3.62	0.000331	0.0373	0.19	0.17	Renal cell carcinoma;	chr3:40446044	chr3:40173145~40309698:-
HNSC	cis	rs34792	0.554	rs12918517	ENSG00000207425.1	Y_RNA	-3.62	0.000331	0.0373	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:14915457~14915556:-
HNSC	cis	rs3750965	0.959	rs4930265	ENSG00000265539.1	MIR3164	-3.62	0.000331	0.0373	-0.18	-0.17	Hair color;	chr11:69088486	chr11:69083176~69083258:+
HNSC	cis	rs9300255	0.602	rs1569068	ENSG00000280120.1	RP11-546D6.3	-3.62	0.000331	0.0373	-0.16	-0.17	Neutrophil percentage of white cells;	chr12:123147729	chr12:123152324~123153377:-
HNSC	cis	rs6940638	0.744	rs858964	ENSG00000224843.5	LINC00240	-3.62	0.000331	0.0373	-0.17	-0.17	Intelligence (multi-trait analysis);	chr6:27174835	chr6:26956992~27023924:+
HNSC	cis	rs1008375	0.933	rs7689101	ENSG00000249502.1	AC006160.5	-3.62	0.000331	0.0373	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692411	chr4:17587467~17614571:-
HNSC	cis	rs1008375	0.933	rs10939757	ENSG00000249502.1	AC006160.5	-3.62	0.000331	0.0373	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692502	chr4:17587467~17614571:-
HNSC	cis	rs1008375	1	rs4698651	ENSG00000249502.1	AC006160.5	-3.62	0.000331	0.0373	-0.18	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692600	chr4:17587467~17614571:-
HNSC	cis	rs2117029	0.619	rs9325145	ENSG00000258101.2	RP11-977B10.2	3.62	0.000331	0.0373	0.21	0.17	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49232790~49264756:-
HNSC	cis	rs67311347	0.955	rs11711994	ENSG00000280739.1	EIF1B-AS1	3.62	0.000331	0.0373	0.19	0.17	Renal cell carcinoma;	chr3:40349595	chr3:40173145~40309698:-
HNSC	cis	rs6142618	0.811	rs4911207	ENSG00000275576.1	RP5-836N17.4	-3.62	0.000331	0.0373	-0.17	-0.17	Inflammatory bowel disease;	chr20:32258714	chr20:32116171~32116629:+
HNSC	cis	rs7735319	0.933	rs4030363	ENSG00000250697.1	CTD-2066L21.3	3.62	0.000331	0.0373	0.2	0.17	Systolic blood pressure;	chr5:33111244	chr5:32925639~33297910:-
HNSC	cis	rs4388249	1	rs12656720	ENSG00000271849.1	CTC-332L22.1	-3.62	0.000331	0.0373	-0.26	-0.17	Schizophrenia;	chr5:109771161	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs4141493	ENSG00000271849.1	CTC-332L22.1	-3.62	0.000331	0.0373	-0.26	-0.17	Schizophrenia;	chr5:109771388	chr5:109687802~109688329:-
HNSC	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-3.62	0.000331	0.0373	-0.11	-0.17	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
HNSC	cis	rs9863	0.828	rs7975482	ENSG00000270028.1	RP11-380L11.4	3.62	0.000331	0.0373	0.19	0.17	White blood cell count;	chr12:123997143	chr12:123925461~123926083:-
HNSC	cis	rs1552244	0.935	rs35148833	ENSG00000180385.7	EMC3-AS1	3.62	0.000331	0.0373	0.18	0.17	Alzheimer's disease;	chr3:10075253	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.81	rs35711405	ENSG00000180385.7	EMC3-AS1	3.62	0.000331	0.0373	0.18	0.17	Alzheimer's disease;	chr3:10075255	chr3:9986893~10006990:+
HNSC	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	3.62	0.000331	0.0373	0.2	0.17	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
HNSC	cis	rs67311347	0.822	rs9826847	ENSG00000280739.1	EIF1B-AS1	3.62	0.000331	0.0373	0.18	0.17	Renal cell carcinoma;	chr3:40303821	chr3:40173145~40309698:-
HNSC	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-3.62	0.000332	0.0373	-0.19	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
HNSC	cis	rs9652601	0.691	rs3862468	ENSG00000274038.1	RP11-66H6.4	3.62	0.000332	0.0373	0.19	0.17	Systemic lupus erythematosus;	chr16:11100161	chr16:11056556~11057034:+
HNSC	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	3.62	0.000332	0.0373	0.23	0.17	Pain;	chr19:21419181	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	3.62	0.000332	0.0373	0.23	0.17	Pain;	chr19:21420084	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	3.62	0.000332	0.0373	0.23	0.17	Pain;	chr19:21420337	chr19:21554640~21569237:-
HNSC	cis	rs2518049	1	rs4478887	ENSG00000224034.1	RP11-445P17.8	3.62	0.000332	0.0373	0.21	0.17	Metabolic traits;	chr10:5100605	chr10:5266033~5271236:-
HNSC	cis	rs1580019	0.885	rs3801331	ENSG00000226468.2	AC018641.7	3.62	0.000332	0.0373	0.22	0.17	Cognitive ability;	chr7:32457427	chr7:32456963~32457758:-
HNSC	cis	rs2048656	0.634	rs13259344	ENSG00000254340.1	RP11-10A14.3	3.62	0.000332	0.0373	0.21	0.17	Schizophrenia;	chr8:9794490	chr8:9141424~9145435:+
HNSC	cis	rs348196	0.672	rs670876	ENSG00000225855.5	RUSC1-AS1	3.62	0.000332	0.0373	0.11	0.17	Breast cancer;	chr1:155701887	chr1:155316863~155324176:-
HNSC	cis	rs35306767	0.623	rs56201968	ENSG00000229869.1	RP11-363N22.2	-3.62	0.000332	0.0373	-0.23	-0.17	Eosinophil percentage of granulocytes;	chr10:1095726	chr10:933026~942743:+
HNSC	cis	rs55823223	0.564	rs936391	ENSG00000267801.1	RP11-552F3.9	-3.62	0.000332	0.0373	-0.18	-0.17	Psoriasis;	chr17:75851718	chr17:75876372~75879546:+
HNSC	cis	rs7246657	0.722	rs11083432	ENSG00000276846.1	CTD-3220F14.3	-3.62	0.000332	0.0373	-0.22	-0.17	Coronary artery calcification;	chr19:37691732	chr19:37314868~37315620:-
HNSC	cis	rs656319	0.559	rs17689037	ENSG00000255310.2	AF131215.2	-3.62	0.000332	0.0373	-0.16	-0.17	Myopia (pathological);	chr8:10117348	chr8:11107788~11109726:-
HNSC	cis	rs2286492	1	rs75393023	ENSG00000221740.1	SNORD93	-3.62	0.000332	0.0373	-0.33	-0.17	Bipolar disorder;	chr7:22942323	chr7:22856613~22856686:+
HNSC	cis	rs193541	0.509	rs10054392	ENSG00000260686.1	CTB-36H16.2	-3.62	0.000332	0.0374	-0.16	-0.17	Glucose homeostasis traits;	chr5:122892871	chr5:122832356~122834533:+
HNSC	cis	rs2243480	1	rs464895	ENSG00000164669.11	INTS4P1	3.62	0.000332	0.0374	0.33	0.17	Diabetic kidney disease;	chr7:66062119	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	3.62	0.000332	0.0374	0.33	0.17	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
HNSC	cis	rs8062405	1	rs72793812	ENSG00000261089.1	RP11-435I10.3	3.62	0.000332	0.0374	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28413703~28415018:+
HNSC	cis	rs7824557	0.602	rs1435273	ENSG00000255495.1	AC145124.2	3.62	0.000332	0.0374	0.19	0.17	Retinal vascular caliber;	chr8:11351990	chr8:12194467~12196280:+
HNSC	cis	rs9652601	0.779	rs9929994	ENSG00000274038.1	RP11-66H6.4	-3.62	0.000332	0.0374	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11084388	chr16:11056556~11057034:+
HNSC	cis	rs875971	0.638	rs6460305	ENSG00000273142.1	RP11-458F8.4	3.62	0.000332	0.0374	0.14	0.17	Aortic root size;	chr7:66595421	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs10272357	ENSG00000273142.1	RP11-458F8.4	3.62	0.000332	0.0374	0.14	0.17	Aortic root size;	chr7:66598087	chr7:66902857~66906297:+
HNSC	cis	rs236373	0.522	rs236349	ENSG00000232598.2	RP1-90K10.4	-3.62	0.000332	0.0374	-0.18	-0.17	Heart rate;	chr6:36852789	chr6:36940071~36944675:-
HNSC	cis	rs7937890	0.505	rs4403769	ENSG00000251991.1	RNU7-49P	3.62	0.000332	0.0374	0.18	0.17	Mitochondrial DNA levels;	chr11:14428630	chr11:14478892~14478953:+
HNSC	cis	rs7735319	0.565	rs6883710	ENSG00000249102.1	CTD-2066L21.1	3.62	0.000332	0.0374	0.19	0.17	Systolic blood pressure;	chr5:33167192	chr5:33008994~33025724:+
HNSC	cis	rs1662342	1	rs1662347	ENSG00000272625.1	RP11-737O24.5	-3.62	0.000332	0.0374	-0.26	-0.17	QRS duration;	chr18:3250328	chr18:2920966~2921685:+
HNSC	cis	rs6012564	0.559	rs61418814	ENSG00000227431.4	CSE1L-AS1	3.62	0.000332	0.0374	0.19	0.17	Anger;	chr20:49153301	chr20:49040463~49046044:-
HNSC	cis	rs12887734	0.524	rs722637	ENSG00000269940.1	RP11-73M18.7	-3.62	0.000332	0.0374	-0.16	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103694560~103695170:+
HNSC	cis	rs1497406	0.744	rs4537547	ENSG00000227959.1	RP11-276H7.2	-3.62	0.000332	0.0374	-0.18	-0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16184303	chr1:16155211~16157329:+
HNSC	cis	rs216205	0.547	rs2641431	ENSG00000262333.1	HNRNPA1P16	3.62	0.000332	0.0374	0.17	0.17	Mitral valve prolapse;	chr17:2127213	chr17:2306761~2307715:+
HNSC	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-3.62	0.000332	0.0374	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-3.62	0.000332	0.0374	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
HNSC	cis	rs10995356	0.646	rs10761677	ENSG00000238280.1	RP11-436D10.3	-3.62	0.000332	0.0374	-0.19	-0.17	Temperament;	chr10:62892846	chr10:62793562~62805887:-
HNSC	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	3.62	0.000332	0.0374	0.2	0.17	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	3.62	0.000332	0.0374	0.2	0.17	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
HNSC	cis	rs8062405	0.964	rs11860513	ENSG00000261766.1	RP11-22P6.2	-3.62	0.000332	0.0374	-0.16	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28862166~28863340:-
HNSC	cis	rs1580019	0.844	rs1901202	ENSG00000226468.2	AC018641.7	-3.62	0.000332	0.0374	-0.23	-0.17	Cognitive ability;	chr7:32464112	chr7:32456963~32457758:-
HNSC	cis	rs9329221	0.662	rs9650650	ENSG00000255310.2	AF131215.2	3.62	0.000332	0.0374	0.17	0.17	Neuroticism;	chr8:10390466	chr8:11107788~11109726:-
HNSC	cis	rs7927592	0.913	rs7109294	ENSG00000255031.4	RP11-802E16.3	3.62	0.000333	0.0374	0.15	0.17	Total body bone mineral density;	chr11:68564625	chr11:68050740~68053762:+
HNSC	cis	rs4835473	0.932	rs4835013	ENSG00000249741.2	RP11-673E1.3	-3.62	0.000333	0.0374	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143748485	chr4:143911514~143912053:-
HNSC	cis	rs12534701	0.534	rs13235571	ENSG00000214106.6	PAXIP1-AS2	-3.62	0.000333	0.0374	-0.17	-0.17	Colorectal cancer (diet interaction);	chr7:154894821	chr7:154928498~154949908:+
HNSC	cis	rs12534701	0.596	rs940380	ENSG00000214106.6	PAXIP1-AS2	-3.62	0.000333	0.0374	-0.17	-0.17	Colorectal cancer (diet interaction);	chr7:154894947	chr7:154928498~154949908:+
HNSC	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-3.62	0.000333	0.0374	-0.27	-0.17	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
HNSC	cis	rs7688540	0.739	rs11729659	ENSG00000250892.1	RP11-1365D11.1	-3.62	0.000333	0.0374	-0.28	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:201409~205009:-
HNSC	cis	rs449789	0.619	rs2341553	ENSG00000216480.2	RP3-393E18.1	3.62	0.000333	0.0374	0.23	0.17	Pulse pressure;	chr6:159368176	chr6:159526062~159526527:-
HNSC	cis	rs6840360	0.642	rs1899550	ENSG00000251611.1	RP11-610P16.1	-3.62	0.000333	0.0374	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151407551~151408835:-
HNSC	cis	rs478304	0.654	rs7947604	ENSG00000255120.4	OVOL1-AS1	-3.62	0.000333	0.0374	-0.17	-0.17	Acne (severe);	chr11:65674588	chr11:65789051~65790868:-
HNSC	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-3.62	0.000333	0.0374	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
HNSC	cis	rs948562	0.744	rs11229449	ENSG00000280010.1	AP001350.4	3.62	0.000333	0.0374	0.26	0.16	Lymphoma;	chr11:58434155	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.744	rs111377246	ENSG00000280010.1	AP001350.4	3.62	0.000333	0.0374	0.26	0.16	Lymphoma;	chr11:58436505	chr11:58627435~58628528:+
HNSC	cis	rs73198271	0.562	rs75525911	ENSG00000253893.2	FAM85B	3.62	0.000333	0.0374	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801849	chr8:8167819~8226614:-
HNSC	cis	rs13108904	0.901	rs7673398	ENSG00000272588.1	RP11-440L14.4	3.62	0.000333	0.0374	0.17	0.16	Obesity-related traits;	chr4:1306289	chr4:757022~757740:-
HNSC	cis	rs12289961	0.526	rs11229362	ENSG00000280010.1	AP001350.4	-3.62	0.000333	0.0374	-0.29	-0.16	Lymphoma;	chr11:58323142	chr11:58627435~58628528:+
HNSC	cis	rs888468	0.752	rs11615716	ENSG00000256164.1	CCND2-AS1	-3.62	0.000333	0.0374	-0.23	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr12:4423135	chr12:4248765~4276184:-
HNSC	cis	rs888468	0.752	rs11609781	ENSG00000256164.1	CCND2-AS1	-3.62	0.000333	0.0374	-0.23	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr12:4423136	chr12:4248765~4276184:-
HNSC	cis	rs739496	0.615	rs7978737	ENSG00000234608.6	MAPKAPK5-AS1	3.62	0.000333	0.0374	0.12	0.16	Platelet count;	chr12:111758807	chr12:111839764~111842902:-
HNSC	cis	rs7621025	0.63	rs1681818	ENSG00000273486.1	RP11-731C17.2	-3.62	0.000333	0.0375	-0.15	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136754831	chr3:136837338~136839021:-
HNSC	cis	rs938554	0.501	rs7671266	ENSG00000250413.1	RP11-448G15.1	3.62	0.000333	0.0375	0.24	0.16	Blood metabolite levels;	chr4:10054752	chr4:10006482~10009725:+
HNSC	cis	rs12545109	0.836	rs2196586	ENSG00000246430.5	LINC00968	3.62	0.000333	0.0375	0.2	0.16	Obesity-related traits;	chr8:56434567	chr8:56496246~56559823:-
HNSC	cis	rs911555	0.755	rs10144051	ENSG00000244691.1	RPL10AP1	-3.62	0.000333	0.0375	-0.2	-0.16	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103412119~103412761:-
HNSC	cis	rs8077577	0.708	rs28364628	ENSG00000260647.1	RP1-178F10.1	3.62	0.000333	0.0375	0.24	0.16	Obesity-related traits;	chr17:18259948	chr17:18268080~18268828:+
HNSC	cis	rs10865541	0.902	rs7558487	ENSG00000234171.2	RNASEH1-AS1	3.61	0.000333	0.0375	0.17	0.16	Obesity-related traits;	chr2:3421743	chr2:3558492~3561745:+
HNSC	cis	rs2436845	1	rs2513935	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000333	0.0375	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832620	chr8:102805517~102809971:+
HNSC	cis	rs35306767	0.855	rs12774985	ENSG00000229869.1	RP11-363N22.2	-3.61	0.000333	0.0375	-0.26	-0.16	Eosinophil percentage of granulocytes;	chr10:858305	chr10:933026~942743:+
HNSC	cis	rs7824557	0.602	rs11784544	ENSG00000269918.1	AF131215.9	3.61	0.000333	0.0375	0.16	0.16	Retinal vascular caliber;	chr8:11346994	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.602	rs11781375	ENSG00000269918.1	AF131215.9	3.61	0.000333	0.0375	0.16	0.16	Retinal vascular caliber;	chr8:11347023	chr8:11104691~11106704:-
HNSC	cis	rs73198271	1	rs11776513	ENSG00000173295.6	FAM86B3P	-3.61	0.000333	0.0375	-0.23	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8228595~8244865:+
HNSC	cis	rs1395	0.744	rs1122227	ENSG00000231636.1	AGBL5-AS1	3.61	0.000333	0.0375	0.23	0.16	Blood metabolite levels;	chr2:27321418	chr2:27049683~27050264:-
HNSC	cis	rs1620921	0.564	rs28594774	ENSG00000233342.1	RP11-235G24.3	-3.61	0.000333	0.0375	-0.19	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160850634	chr6:160926369~160927162:+
HNSC	cis	rs10875746	0.551	rs2054904	ENSG00000257763.1	OR5BK1P	-3.61	0.000333	0.0375	-0.21	-0.16	Longevity (90 years and older);	chr12:48330571	chr12:48355792~48356614:-
HNSC	cis	rs11992162	1	rs11994417	ENSG00000269918.1	AF131215.9	3.61	0.000333	0.0375	0.16	0.16	Monocyte count;	chr8:11975753	chr8:11104691~11106704:-
HNSC	cis	rs9402743	0.775	rs9494322	ENSG00000234084.1	RP3-388E23.2	3.61	0.000333	0.0375	0.17	0.16	Systemic lupus erythematosus;	chr6:135660922	chr6:135301568~135307158:+
HNSC	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	3.61	0.000333	0.0375	0.17	0.16	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
HNSC	cis	rs683257	0.929	rs72990158	ENSG00000234147.1	RP3-460G2.2	-3.61	0.000333	0.0375	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140867736	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.706	rs72990167	ENSG00000234147.1	RP3-460G2.2	-3.61	0.000333	0.0375	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140874714	chr6:140845958~140852924:-
HNSC	cis	rs73607972	0.569	rs34115013	ENSG00000275191.1	RP11-36I17.2	-3.61	0.000333	0.0375	-0.21	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53534324	chr16:53628256~53628816:-
HNSC	cis	rs9859260	0.744	rs539816	ENSG00000273009.1	RP11-352G9.1	3.61	0.000333	0.0375	0.19	0.16	Mean corpuscular volume;	chr3:196057205	chr3:195913078~195913683:-
HNSC	cis	rs9859260	0.744	rs492349	ENSG00000273009.1	RP11-352G9.1	3.61	0.000333	0.0375	0.19	0.16	Mean corpuscular volume;	chr3:196057321	chr3:195913078~195913683:-
HNSC	cis	rs9859260	0.744	rs492288	ENSG00000273009.1	RP11-352G9.1	3.61	0.000333	0.0375	0.19	0.16	Mean corpuscular volume;	chr3:196057339	chr3:195913078~195913683:-
HNSC	cis	rs7520050	0.966	rs2486447	ENSG00000280836.1	AL355480.1	3.61	0.000333	0.0375	0.17	0.16	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs1085244	ENSG00000280836.1	AL355480.1	3.61	0.000333	0.0375	0.17	0.16	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6662641	ENSG00000280836.1	AL355480.1	3.61	0.000333	0.0375	0.17	0.16	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs1707335	ENSG00000280836.1	AL355480.1	3.61	0.000333	0.0375	0.17	0.16	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45581219~45581321:-
HNSC	cis	rs17122278	1	rs7932700	ENSG00000255422.1	AP002954.4	3.61	0.000333	0.0375	0.29	0.16	Total cholesterol levels;	chr11:118540998	chr11:118704607~118750263:+
HNSC	cis	rs683257	0.85	rs72988116	ENSG00000234147.1	RP3-460G2.2	-3.61	0.000333	0.0375	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140813529	chr6:140845958~140852924:-
HNSC	cis	rs2013441	1	rs4924808	ENSG00000261033.1	RP11-209D14.2	3.61	0.000333	0.0375	0.19	0.16	Obesity-related traits;	chr17:20123235	chr17:20008051~20009234:-
HNSC	cis	rs544991	0.652	rs10914770	ENSG00000239670.1	RP4-803A2.2	3.61	0.000333	0.0375	0.21	0.16	Intelligence;	chr1:33745279	chr1:32986952~32988233:+
HNSC	cis	rs4853525	0.859	rs6434424	ENSG00000235852.1	AC005540.3	3.61	0.000333	0.0375	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190857400	chr2:190880797~190882059:-
HNSC	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-3.61	0.000333	0.0375	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
HNSC	cis	rs11853189	0.938	rs77056929	ENSG00000259562.2	RP11-762H8.2	3.61	0.000334	0.0375	0.2	0.16	Red cell distribution width;	chr15:78296175	chr15:78290527~78291221:-
HNSC	cis	rs4242434	0.597	rs876714	ENSG00000253837.1	RP11-177H13.2	-3.61	0.000334	0.0375	-0.17	-0.16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22625286	chr8:23336171~23366125:+
HNSC	cis	rs7520050	0.902	rs9429088	ENSG00000280836.1	AL355480.1	3.61	0.000334	0.0375	0.17	0.16	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45581219~45581321:-
HNSC	cis	rs3096299	0.719	rs12934708	ENSG00000261118.1	RP11-104N10.1	3.61	0.000334	0.0375	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89492017~89504460:-
HNSC	cis	rs9611565	0.592	rs4822046	ENSG00000233903.2	Z83851.4	-3.61	0.000334	0.0375	-0.25	-0.16	Vitiligo;	chr22:41591539	chr22:42276355~42277052:+
HNSC	cis	rs12188164	0.502	rs55929184	ENSG00000225138.6	CTD-2228K2.7	3.61	0.000334	0.0375	0.2	0.16	Cystic fibrosis severity;	chr5:405461	chr5:473236~480884:+
HNSC	cis	rs4704187	0.687	rs4447963	ENSG00000271815.1	CTD-2235C13.3	-3.61	0.000334	0.0375	-0.21	-0.16	Response to amphetamines;	chr5:75080484	chr5:75363760~75364242:+
HNSC	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-3.61	0.000334	0.0375	-0.21	-0.16	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-3.61	0.000334	0.0375	-0.21	-0.16	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
HNSC	cis	rs72827839	0.947	rs72827814	ENSG00000244649.3	CTD-2377D24.6	-3.61	0.000334	0.0375	-0.24	-0.16	Ease of getting up in the morning;	chr17:48289598	chr17:48646923~48707346:+
HNSC	cis	rs72827839	1	rs17695373	ENSG00000244649.3	CTD-2377D24.6	-3.61	0.000334	0.0375	-0.24	-0.16	Ease of getting up in the morning;	chr17:48298105	chr17:48646923~48707346:+
HNSC	cis	rs6001482	0.656	rs1894237	ENSG00000253818.1	IGLV1-41	-3.61	0.000334	0.0375	-0.13	-0.16	Diastolic blood pressure;	chr22:22235546	chr22:22404207~22404721:+
HNSC	cis	rs868153	0.625	rs17084333	ENSG00000275339.1	RP3-425C14.6	3.61	0.000334	0.0375	0.18	0.16	Vertical cup-disc ratio;	chr6:122187264	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs34379825	ENSG00000275339.1	RP3-425C14.6	3.61	0.000334	0.0375	0.18	0.16	Vertical cup-disc ratio;	chr6:122187844	chr6:122454358~122454612:+
HNSC	cis	rs116095464	0.614	rs28736753	ENSG00000248925.1	CTD-2083E4.6	3.61	0.000334	0.0375	0.27	0.16	Breast cancer;	chr5:273966	chr5:269858~271516:-
HNSC	cis	rs2439831	0.867	rs933941	ENSG00000275601.1	AC011330.13	-3.61	0.000334	0.0376	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43340028	chr15:43642389~43643023:-
HNSC	cis	rs1389663	0.512	rs1491881	ENSG00000206728.1	Y_RNA	-3.61	0.000334	0.0376	-0.2	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr3:22292612	chr3:23273807~23273910:+
HNSC	cis	rs9650657	0.812	rs6993841	ENSG00000255310.2	AF131215.2	-3.61	0.000334	0.0376	-0.16	-0.16	Neuroticism;	chr8:10775174	chr8:11107788~11109726:-
HNSC	cis	rs8044868	0.502	rs9927526	ENSG00000259209.3	RP5-991G20.2	3.61	0.000334	0.0376	0.18	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72155285	chr16:72805998~72809872:+
HNSC	cis	rs11711311	1	rs11711311	ENSG00000241529.3	RN7SL767P	-3.61	0.000334	0.0376	-0.21	-0.16	IgG glycosylation;	chr3:113711752	chr3:113632704~113632998:+
HNSC	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	3.61	0.000334	0.0376	0.29	0.16	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
HNSC	cis	rs6951245	0.58	rs77101766	ENSG00000225146.1	AC073957.15	-3.61	0.000334	0.0376	-0.22	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1029025~1043891:+
HNSC	cis	rs28573326	0.962	rs11732583	ENSG00000121089.4	NACA3P	3.61	0.000334	0.0376	0.2	0.16	Pelvic organ prolapse (moderate/severe);	chr4:165415313	chr4:164943290~164943937:+
HNSC	cis	rs72634501	0.622	rs4660416	ENSG00000182109.6	RP11-69E11.4	3.61	0.000334	0.0376	0.19	0.16	HDL cholesterol;	chr1:39113314	chr1:39522280~39546187:-
HNSC	cis	rs1568657	1	rs1568657	ENSG00000278603.1	RP13-608F4.5	-3.61	0.000334	0.0376	-0.24	-0.16	Kawasaki disease;	chr15:83057427	chr15:82472203~82472426:+
HNSC	cis	rs4704187	0.687	rs6864485	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75202159	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6879894	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75202339	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs10051422	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75206748	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs10051572	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75206972	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.663	rs6889760	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75207879	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs10035303	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000334	0.0376	-0.15	-0.16	Response to amphetamines;	chr5:75209670	chr5:75608817~75609983:+
HNSC	cis	rs597539	0.69	rs647661	ENSG00000255741.1	RP11-757G1.5	-3.61	0.000334	0.0376	-0.23	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68941503~68942852:-
HNSC	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-3.61	0.000334	0.0376	-0.19	-0.16	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
HNSC	cis	rs597539	0.69	rs578791	ENSG00000255741.1	RP11-757G1.5	-3.61	0.000334	0.0376	-0.23	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68941503~68942852:-
HNSC	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	3.61	0.000334	0.0376	0.22	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
HNSC	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	3.61	0.000334	0.0376	0.21	0.16	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
HNSC	cis	rs643506	0.845	rs607327	ENSG00000230911.1	PPIHP1	-3.61	0.000334	0.0376	-0.22	-0.16	Breast cancer;	chr11:111824985	chr11:112029858~112030367:-
HNSC	cis	rs919433	0.679	rs9967823	ENSG00000231621.1	AC013264.2	-3.61	0.000334	0.0376	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197666805	chr2:197197991~197199273:+
HNSC	cis	rs2384207	0.584	rs111540683	ENSG00000201208.1	Y_RNA	-3.61	0.000334	0.0376	-0.25	-0.16	Response to fenofibrate (adiponectin levels);	chr12:113304680	chr12:113178423~113178519:-
HNSC	cis	rs4237845	0.591	rs4760344	ENSG00000257159.1	RP11-58A17.3	3.61	0.000334	0.0376	0.21	0.16	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57967058~57968399:+
HNSC	cis	rs73017364	1	rs73017364	ENSG00000206921.1	RNU6-481P	3.61	0.000334	0.0376	0.32	0.16	QT interval;	chr1:162214956	chr1:161401289~161401395:+
HNSC	cis	rs4622329	0.572	rs7956803	ENSG00000258033.1	RP11-350G24.2	3.61	0.000334	0.0376	0.18	0.16	Systemic lupus erythematosus;	chr12:101900084	chr12:101066734~101069232:+
HNSC	cis	rs35306767	0.903	rs12250937	ENSG00000229869.1	RP11-363N22.2	-3.61	0.000334	0.0376	-0.24	-0.16	Eosinophil percentage of granulocytes;	chr10:854269	chr10:933026~942743:+
HNSC	cis	rs2286313	0.51	rs12897490	ENSG00000266869.1	RP6-114E22.1	-3.61	0.000334	0.0376	-0.41	-0.16	Colorectal cancer;	chr14:71005802	chr14:71848606~71908430:+
HNSC	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	3.61	0.000334	0.0376	0.17	0.16	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
HNSC	cis	rs16935110	0.935	rs16935104	ENSG00000254337.1	RP11-865I6.2	-3.61	0.000335	0.0376	-0.25	-0.16	Obesity-related traits;	chr8:68818051	chr8:68848742~68852763:-
HNSC	cis	rs16935110	1	rs16935106	ENSG00000254337.1	RP11-865I6.2	-3.61	0.000335	0.0376	-0.25	-0.16	Obesity-related traits;	chr8:68818197	chr8:68848742~68852763:-
HNSC	cis	rs16935110	1	rs16935109	ENSG00000254337.1	RP11-865I6.2	-3.61	0.000335	0.0376	-0.25	-0.16	Obesity-related traits;	chr8:68818253	chr8:68848742~68852763:-
HNSC	cis	rs10186029	0.582	rs1992395	ENSG00000270659.1	RP11-105N14.1	3.61	0.000335	0.0376	0.16	0.16	Systemic sclerosis;	chr2:213139147	chr2:213152970~213153659:+
HNSC	cis	rs9611565	0.512	rs4820444	ENSG00000235513.1	RP4-756G23.5	-3.61	0.000335	0.0376	-0.2	-0.16	Vitiligo;	chr22:41806602	chr22:41209122~41217627:-
HNSC	cis	rs4948102	0.655	rs4947533	ENSG00000213650.3	RP11-760D2.7	3.61	0.000335	0.0376	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr7:56567906~56568858:-
HNSC	cis	rs7429990	0.803	rs13081356	ENSG00000228638.1	FCF1P2	3.61	0.000335	0.0376	0.15	0.16	Educational attainment (years of education);	chr3:47660067	chr3:48290793~48291375:-
HNSC	cis	rs2179367	0.959	rs9322178	ENSG00000216906.2	RP11-350J20.9	3.61	0.000335	0.0376	0.2	0.16	Dupuytren's disease;	chr6:149372131	chr6:149904243~149906418:+
HNSC	cis	rs9303401	0.614	rs35308719	ENSG00000266701.1	AC005702.4	3.61	0.000335	0.0376	0.23	0.16	Cognitive test performance;	chr17:59086140	chr17:60042546~60042627:-
HNSC	cis	rs7004769	0.518	rs10091555	ENSG00000254153.1	CTA-398F10.2	-3.61	0.000335	0.0376	-0.26	-0.16	Fibrinogen levels;	chr8:9326492	chr8:8456909~8461337:-
HNSC	cis	rs10504130	0.66	rs6473666	ENSG00000228801.5	RP11-110G21.1	-3.61	0.000335	0.0376	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51899325~51947173:+
HNSC	cis	rs6540234	0.701	rs925993	ENSG00000270058.1	RP11-514D23.3	-3.61	0.000335	0.0376	-0.19	-0.16	Monocyte count;Granulocyte percentage of myeloid white cells;	chr16:85956745	chr16:86221423~86222729:-
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-3.61	0.000335	0.0376	-0.19	-0.16	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
HNSC	cis	rs4301033	1	rs62269236	ENSG00000244265.1	SIAH2-AS1	-3.61	0.000335	0.0376	-0.29	-0.16	Adiponectin levels;	chr3:150326854	chr3:150761937~150762538:+
HNSC	cis	rs66887589	0.87	rs59590064	ENSG00000249244.1	RP11-548H18.2	-3.61	0.000335	0.0376	-0.18	-0.16	Diastolic blood pressure;	chr4:119618598	chr4:119391831~119395335:-
HNSC	cis	rs67311347	0.911	rs9849224	ENSG00000280739.1	EIF1B-AS1	3.61	0.000335	0.0376	0.18	0.16	Renal cell carcinoma;	chr3:40351071	chr3:40173145~40309698:-
HNSC	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	3.61	0.000335	0.0376	0.15	0.16	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
HNSC	cis	rs2074409	0.509	rs853193	ENSG00000276054.1	RP11-378E13.3	3.61	0.000335	0.0376	0.18	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37463009	chr17:37386886~37387926:+
HNSC	cis	rs2074409	0.509	rs853205	ENSG00000276054.1	RP11-378E13.3	3.61	0.000335	0.0376	0.18	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37464292	chr17:37386886~37387926:+
HNSC	cis	rs2014572	0.967	rs10418480	ENSG00000267454.4	ZNF582-AS1	3.61	0.000335	0.0376	0.16	0.16	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:56393656~56399172:+
HNSC	cis	rs597539	0.69	rs578791	ENSG00000261625.1	RP11-554A11.4	-3.61	0.000335	0.0377	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:69000765~69002048:-
HNSC	cis	rs7189233	0.513	rs8044091	ENSG00000261056.2	RP11-454F8.2	-3.61	0.000335	0.0377	-0.18	-0.16	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53298224~53299792:+
HNSC	cis	rs2436845	1	rs2513922	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000335	0.0377	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102817960	chr8:102805517~102809971:+
HNSC	cis	rs2760061	0.819	rs1745417	ENSG00000270110.1	RP5-1139B12.4	-3.61	0.000335	0.0377	-0.16	-0.16	Diastolic blood pressure;	chr1:228016578	chr1:228295911~228302998:-
HNSC	cis	rs2760061	0.819	rs1745416	ENSG00000270110.1	RP5-1139B12.4	-3.61	0.000335	0.0377	-0.16	-0.16	Diastolic blood pressure;	chr1:228016796	chr1:228295911~228302998:-
HNSC	cis	rs12600394	0.767	rs2159391	ENSG00000236088.8	COX10-AS1	3.61	0.000335	0.0377	0.2	0.16	Response to platinum-based chemotherapy (cisplatin);	chr17:14627598	chr17:13756478~14069495:-
HNSC	cis	rs12600394	0.767	rs2159392	ENSG00000236088.8	COX10-AS1	3.61	0.000335	0.0377	0.2	0.16	Response to platinum-based chemotherapy (cisplatin);	chr17:14627610	chr17:13756478~14069495:-
HNSC	cis	rs12600394	0.767	rs2109159	ENSG00000236088.8	COX10-AS1	3.61	0.000335	0.0377	0.2	0.16	Response to platinum-based chemotherapy (cisplatin);	chr17:14627694	chr17:13756478~14069495:-
HNSC	cis	rs7121616	0.92	rs7109445	ENSG00000200879.1	SNORD14E	3.61	0.000335	0.0377	0.2	0.16	Breast cancer;	chr11:123094779	chr11:123058077~123058161:-
HNSC	cis	rs911555	0.713	rs10162425	ENSG00000244691.1	RPL10AP1	-3.61	0.000335	0.0377	-0.2	-0.16	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103412119~103412761:-
HNSC	cis	rs8002861	0.664	rs4942246	ENSG00000274001.1	RP11-5G9.5	3.61	0.000335	0.0377	0.17	0.16	Leprosy;	chr13:43830717	chr13:43877715~43878163:-
HNSC	cis	rs2554380	0.628	rs7179507	ENSG00000259570.1	RP11-671M22.4	3.61	0.000335	0.0377	0.2	0.16	Height;	chr15:83804779	chr15:84394512~84395514:+
HNSC	cis	rs7927592	0.913	rs7115374	ENSG00000255031.4	RP11-802E16.3	3.61	0.000335	0.0377	0.15	0.16	Total body bone mineral density;	chr11:68532608	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs67605986	ENSG00000255031.4	RP11-802E16.3	3.61	0.000335	0.0377	0.15	0.16	Total body bone mineral density;	chr11:68533487	chr11:68050740~68053762:+
HNSC	cis	rs7927592	0.913	rs12285993	ENSG00000255031.4	RP11-802E16.3	3.61	0.000335	0.0377	0.15	0.16	Total body bone mineral density;	chr11:68535070	chr11:68050740~68053762:+
HNSC	cis	rs9467711	0.591	rs13203673	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0377	0.27	0.16	Autism spectrum disorder or schizophrenia;	chr6:25978894	chr6:26871484~26956554:-
HNSC	cis	rs4699052	0.537	rs1580278	ENSG00000230069.3	LRRC37A15P	3.61	0.000335	0.0377	0.17	0.16	Testicular germ cell tumor;	chr4:103219691	chr4:102727274~102730721:-
HNSC	cis	rs597539	0.652	rs544370	ENSG00000255741.1	RP11-757G1.5	-3.61	0.000336	0.0377	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68941503~68942852:-
HNSC	cis	rs2115630	0.905	rs1975277	ENSG00000275120.1	RP11-182J1.17	-3.61	0.000336	0.0377	-0.18	-0.16	P wave terminal force;	chr15:84786327	chr15:84599434~84606463:-
HNSC	cis	rs2279168	0.749	rs73450316	ENSG00000259295.5	CSPG4P12	-3.61	0.000336	0.0377	-0.31	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85473255	chr15:85191438~85213905:+
HNSC	cis	rs3733585	0.631	rs3822236	ENSG00000250413.1	RP11-448G15.1	3.61	0.000336	0.0377	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10118337	chr4:10006482~10009725:+
HNSC	cis	rs748404	0.666	rs72709871	ENSG00000166763.7	STRCP1	3.61	0.000336	0.0377	0.23	0.16	Lung cancer;	chr15:43499025	chr15:43699488~43718184:-
HNSC	cis	rs13438327	1	rs7789181	ENSG00000243554.1	AC004967.7	3.61	0.000336	0.0377	0.34	0.16	Sudden cardiac arrest;	chr7:97991951	chr7:97969005~97972254:-
HNSC	cis	rs7027203	0.576	rs7865043	ENSG00000227603.1	RP11-165J3.6	3.61	0.000336	0.0377	0.15	0.16	DNA methylation (variation);	chr9:93786722	chr9:93435332~93437121:-
HNSC	cis	rs734999	0.588	rs4648562	ENSG00000238164.5	RP3-395M20.8	-3.61	0.000336	0.0377	-0.12	-0.16	Ulcerative colitis;	chr1:2604174	chr1:2549920~2557031:-
HNSC	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	3.61	0.000336	0.0377	0.18	0.16	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
HNSC	cis	rs7824557	0.614	rs17741537	ENSG00000255495.1	AC145124.2	3.61	0.000336	0.0377	0.18	0.16	Retinal vascular caliber;	chr8:11355583	chr8:12194467~12196280:+
HNSC	cis	rs7927592	0.913	rs2282563	ENSG00000255031.4	RP11-802E16.3	3.61	0.000336	0.0377	0.15	0.16	Total body bone mineral density;	chr11:68565732	chr11:68050740~68053762:+
HNSC	cis	rs3929778	0.883	rs6054334	ENSG00000275632.1	RP5-967N21.11	-3.61	0.000336	0.0377	-0.16	-0.16	QRS complex (Cornell);	chr20:6537873	chr20:6000418~6000941:+
HNSC	cis	rs10040610	0.524	rs271414	ENSG00000250490.1	FLJ33360	-3.61	0.000336	0.0377	-0.22	-0.16	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6349022	chr5:6310441~6339884:-
HNSC	cis	rs11018874	0.709	rs10765241	ENSG00000280385.1	AP000648.5	3.61	0.000336	0.0377	0.28	0.16	White blood cell types;	chr11:90116148	chr11:90193614~90198120:+
HNSC	cis	rs7937890	0.904	rs11023169	ENSG00000251991.1	RNU7-49P	-3.61	0.000336	0.0377	-0.17	-0.16	Mitochondrial DNA levels;	chr11:14269439	chr11:14478892~14478953:+
HNSC	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	3.61	0.000336	0.0377	0.17	0.16	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
HNSC	cis	rs62025270	0.547	rs416916	ENSG00000259295.5	CSPG4P12	-3.61	0.000336	0.0377	-0.21	-0.16	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85191438~85213905:+
HNSC	cis	rs2518049	0.51	rs1781939	ENSG00000224034.1	RP11-445P17.8	3.61	0.000336	0.0377	0.18	0.16	Metabolic traits;	chr10:5159781	chr10:5266033~5271236:-
HNSC	cis	rs2357982	0.556	rs16845440	ENSG00000235724.7	AC009299.2	-3.61	0.000336	0.0377	-0.28	-0.16	Presence of antiphospholipid antibodies;	chr2:161029121	chr2:161222785~161308303:-
HNSC	cis	rs7824557	0.614	rs2736277	ENSG00000255495.1	AC145124.2	-3.61	0.000336	0.0378	-0.18	-0.16	Retinal vascular caliber;	chr8:11361384	chr8:12194467~12196280:+
HNSC	cis	rs6445975	1	rs4681681	ENSG00000273493.1	RP11-80H18.4	-3.61	0.000336	0.0378	-0.19	-0.16	Systemic lupus erythematosus;	chr3:58347185	chr3:58329965~58330118:+
HNSC	cis	rs3736485	0.716	rs1080394	ENSG00000259438.1	CTD-2650P22.1	3.61	0.000336	0.0378	0.17	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51465424	chr15:52010999~52019095:-
HNSC	cis	rs4819052	0.679	rs4819053	ENSG00000184274.3	LINC00315	3.61	0.000336	0.0378	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45300245~45305257:-
HNSC	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-3.61	0.000336	0.0378	-0.17	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
HNSC	cis	rs9914544	0.545	rs9903574	ENSG00000264885.1	RP11-815I9.4	-3.61	0.000336	0.0378	-0.17	-0.16	Educational attainment (years of education);	chr17:18865269	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs12937933	ENSG00000264885.1	RP11-815I9.4	-3.61	0.000336	0.0378	-0.17	-0.16	Educational attainment (years of education);	chr17:18866970	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.564	rs11868520	ENSG00000264885.1	RP11-815I9.4	-3.61	0.000336	0.0378	-0.17	-0.16	Educational attainment (years of education);	chr17:18867054	chr17:18667629~18669461:-
HNSC	cis	rs6095360	0.615	rs2869689	ENSG00000222365.1	SNORD12B	-3.61	0.000336	0.0378	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48898389	chr20:49280319~49280409:+
HNSC	cis	rs7246657	0.722	rs35863684	ENSG00000276846.1	CTD-3220F14.3	3.61	0.000336	0.0378	0.22	0.16	Coronary artery calcification;	chr19:37618876	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs10402671	ENSG00000276846.1	CTD-3220F14.3	3.61	0.000336	0.0378	0.22	0.16	Coronary artery calcification;	chr19:37626185	chr19:37314868~37315620:-
HNSC	cis	rs6107845	0.645	rs1998151	ENSG00000275632.1	RP5-967N21.11	-3.61	0.000336	0.0378	-0.14	-0.16	Vertical cup-disc ratio;	chr20:6566640	chr20:6000418~6000941:+
HNSC	cis	rs9911578	0.967	rs12603238	ENSG00000224738.1	AC099850.1	-3.61	0.000337	0.0378	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59053424	chr17:59106598~59118267:+
HNSC	cis	rs11509153	0.542	rs4721056	ENSG00000226690.5	AC005281.1	3.61	0.000337	0.0378	0.18	0.16	Residual cognition;	chr7:12211636	chr7:12496429~12541910:+
HNSC	cis	rs7094131	0.66	rs7917460	ENSG00000224215.1	RP11-371A19.2	3.61	0.000337	0.0378	0.22	0.16	Obesity-related traits;	chr10:22595719	chr10:23343957~23345181:+
HNSC	cis	rs12291225	0.679	rs1043237	ENSG00000254418.1	RP11-21L19.1	3.61	0.000337	0.0378	0.19	0.16	Sense of smell;	chr11:14267507	chr11:14262846~14273691:-
HNSC	cis	rs4252134	0.881	rs9456580	ENSG00000231863.1	RP3-428L16.1	3.61	0.000337	0.0378	0.21	0.16	Giant cell arteritis;	chr6:160764348	chr6:160931080~160969771:+
HNSC	cis	rs6430585	0.528	rs309154	ENSG00000231890.6	DARS-AS1	-3.61	0.000337	0.0378	-0.28	-0.16	Corneal structure;	chr2:135968997	chr2:135985176~136022593:+
HNSC	cis	rs7107174	1	rs948662	ENSG00000251323.2	RP11-452H21.4	3.61	0.000337	0.0378	0.25	0.16	Testicular germ cell tumor;	chr11:78268783	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs2510051	ENSG00000251323.2	RP11-452H21.4	3.61	0.000337	0.0378	0.25	0.16	Testicular germ cell tumor;	chr11:78270125	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs2512541	ENSG00000251323.2	RP11-452H21.4	3.61	0.000337	0.0378	0.25	0.16	Testicular germ cell tumor;	chr11:78270701	chr11:78423982~78429836:-
HNSC	cis	rs7107174	1	rs2511186	ENSG00000251323.2	RP11-452H21.4	3.61	0.000337	0.0378	0.25	0.16	Testicular germ cell tumor;	chr11:78273260	chr11:78423982~78429836:-
HNSC	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-3.61	0.000337	0.0378	-0.24	-0.16	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-3.61	0.000337	0.0378	-0.24	-0.16	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
HNSC	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-3.61	0.000337	0.0378	-0.24	-0.16	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
HNSC	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-3.61	0.000337	0.0378	-0.24	-0.16	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
HNSC	cis	rs875971	0.66	rs801193	ENSG00000272831.1	RP11-792A8.4	-3.61	0.000337	0.0378	-0.13	-0.16	Aortic root size;	chr7:66565625	chr7:66739829~66740385:-
HNSC	cis	rs1420956	0.553	rs582149	ENSG00000263846.1	CIAPIN1P	3.61	0.000337	0.0378	0.2	0.16	Obesity-related traits;	chr18:27598297	chr18:26599408~26600338:+
HNSC	cis	rs804280	0.509	rs35626932	ENSG00000269918.1	AF131215.9	3.61	0.000337	0.0378	0.16	0.16	Myopia (pathological);	chr8:11929423	chr8:11104691~11106704:-
HNSC	cis	rs711830	1	rs1318778	ENSG00000226363.3	HAGLROS	-3.61	0.000337	0.0378	-0.22	-0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176173103	chr2:176177717~176179008:+
HNSC	cis	rs427691	0.545	rs25914	ENSG00000271849.1	CTC-332L22.1	-3.61	0.000337	0.0378	-0.25	-0.16	Autism spectrum disorder or schizophrenia;	chr5:109657320	chr5:109687802~109688329:-
HNSC	cis	rs7824557	0.564	rs12547100	ENSG00000255495.1	AC145124.2	-3.61	0.000337	0.0378	-0.18	-0.16	Retinal vascular caliber;	chr8:11385123	chr8:12194467~12196280:+
HNSC	cis	rs10129255	0.5	rs4774008	ENSG00000211976.2	IGHV3-73	-3.61	0.000337	0.0378	-0.12	-0.16	Kawasaki disease;	chr14:106681273	chr14:106802694~106803233:-
HNSC	cis	rs6090919	0.501	rs13043461	ENSG00000222365.1	SNORD12B	-3.61	0.000337	0.0378	-0.23	-0.16	Intelligence (multi-trait analysis);	chr20:48841515	chr20:49280319~49280409:+
HNSC	cis	rs2638953	0.962	rs9300176	ENSG00000257176.2	RP11-996F15.2	-3.61	0.000337	0.0378	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:29280418~29317848:-
HNSC	cis	rs4072980	0.545	rs7519947	ENSG00000212541.1	RNU6-510P	3.61	0.000337	0.0378	0.21	0.16	Coronary artery disease;	chr1:37982053	chr1:37991462~37991569:+
HNSC	cis	rs1853665	0.58	rs6557200	ENSG00000231760.4	RP11-350J20.5	-3.61	0.000337	0.0378	-0.26	-0.16	Radiation response;	chr6:149951396	chr6:149796151~149826294:-
HNSC	cis	rs2271001	0.542	rs1503501	ENSG00000256282.1	RP11-504G3.4	-3.61	0.000337	0.0378	-0.15	-0.16	Gut microbiome composition (winter);	chr11:19176471	chr11:18595459~18599683:-
HNSC	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-3.61	0.000337	0.0378	-0.21	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
HNSC	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-3.61	0.000337	0.0378	-0.21	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
HNSC	cis	rs4578769	0.513	rs34623893	ENSG00000265943.1	RP11-739L10.1	3.61	0.000337	0.0378	0.19	0.16	Eosinophil percentage of white cells;	chr18:22967224	chr18:22699481~22933764:-
HNSC	cis	rs1019173	0.966	rs6971164	ENSG00000261455.1	LINC01003	3.61	0.000337	0.0378	0.18	0.16	Kidney function decline traits;	chr7:152011217	chr7:152463786~152465549:+
HNSC	cis	rs4356203	0.905	rs214940	ENSG00000272034.1	SNORD14A	-3.61	0.000337	0.0378	-0.12	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17074654~17074744:-
HNSC	cis	rs7429990	0.833	rs11716582	ENSG00000228638.1	FCF1P2	3.61	0.000337	0.0378	0.15	0.16	Educational attainment (years of education);	chr3:47592269	chr3:48290793~48291375:-
HNSC	cis	rs828999	0.586	rs7555404	ENSG00000280186.1	RP11-483I13.6	-3.61	0.000337	0.0378	-0.18	-0.16	Monocyte percentage of white cells;	chr1:108182936	chr1:108200413~108202743:+
HNSC	cis	rs1167832	0.645	rs1167829	ENSG00000165178.9	NCF1C	3.61	0.000337	0.0378	0.18	0.16	Ankle injury;	chr7:75535697	chr7:75156639~75172044:-
HNSC	cis	rs9611565	0.572	rs139569	ENSG00000233903.2	Z83851.4	-3.61	0.000337	0.0378	-0.23	-0.16	Vitiligo;	chr22:41815137	chr22:42276355~42277052:+
HNSC	cis	rs853679	0.506	rs1150693	ENSG00000219891.2	ZSCAN12P1	3.61	0.000337	0.0378	0.23	0.16	Depression;	chr6:28206812	chr6:28091154~28093664:+
HNSC	cis	rs6869502	0.554	rs9326806	ENSG00000214784.4	AC010468.1	3.61	0.000337	0.0378	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr5:110656566	chr5:111192226~111193042:-
HNSC	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	3.61	0.000337	0.0378	0.19	0.16	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
HNSC	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.803	rs36127118	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000337	0.0378	-0.23	-0.16	Diabetic kidney disease;	chr7:66100518	chr7:66848496~66858136:+
HNSC	cis	rs4835473	0.868	rs35809032	ENSG00000249741.2	RP11-673E1.3	3.61	0.000337	0.0378	0.18	0.16	Immature fraction of reticulocytes;	chr4:143824797	chr4:143911514~143912053:-
HNSC	cis	rs875971	0.862	rs6460293	ENSG00000106610.13	STAG3L4	3.61	0.000337	0.0378	0.21	0.16	Aortic root size;	chr7:66345205	chr7:67302621~67321526:+
HNSC	cis	rs11951515	0.7	rs11956988	ENSG00000249286.1	CTD-2210P15.2	3.61	0.000337	0.0378	0.17	0.16	Metabolite levels  (X-11787);	chr5:43367267	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs12517362	ENSG00000249286.1	CTD-2210P15.2	3.61	0.000337	0.0378	0.17	0.16	Metabolite levels  (X-11787);	chr5:43368060	chr5:43586918~43588223:-
HNSC	cis	rs7278690	1	rs7278690	ENSG00000235609.7	AF127936.9	3.61	0.000337	0.0379	0.38	0.16	Breast cancer;	chr21:14855305	chr21:14818843~15014430:-
HNSC	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	3.61	0.000337	0.0379	0.24	0.16	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
HNSC	cis	rs516805	0.781	rs560717	ENSG00000279453.1	RP3-425C14.4	-3.61	0.000337	0.0379	-0.23	-0.16	Lymphocyte counts;	chr6:122482909	chr6:122436789~122439223:-
HNSC	cis	rs4489787	1	rs11168576	ENSG00000257763.1	OR5BK1P	-3.61	0.000337	0.0379	-0.26	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48446635	chr12:48355792~48356614:-
HNSC	cis	rs11687659	0.515	rs6725611	ENSG00000228509.4	AC006460.2	3.61	0.000338	0.0379	0.21	0.16	Immature fraction of reticulocytes;	chr2:190714299	chr2:190676944~190708716:-
HNSC	cis	rs6095360	0.966	rs6019557	ENSG00000227431.4	CSE1L-AS1	-3.61	0.000338	0.0379	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48966835	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019558	ENSG00000227431.4	CSE1L-AS1	-3.61	0.000338	0.0379	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48966943	chr20:49040463~49046044:-
HNSC	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-3.61	0.000338	0.0379	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
HNSC	cis	rs7680126	0.596	rs4637402	ENSG00000252002.1	RNA5SP154	-3.61	0.000338	0.0379	-0.23	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10043806	chr4:9792751~9792861:-
HNSC	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-3.61	0.000338	0.0379	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
HNSC	cis	rs4622329	0.615	rs7136688	ENSG00000258033.1	RP11-350G24.2	3.61	0.000338	0.0379	0.18	0.16	Systemic lupus erythematosus;	chr12:101900716	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs7305951	ENSG00000258033.1	RP11-350G24.2	3.61	0.000338	0.0379	0.18	0.16	Systemic lupus erythematosus;	chr12:101900723	chr12:101066734~101069232:+
HNSC	cis	rs3026445	1	rs3026445	ENSG00000241413.3	RN7SL441P	-3.61	0.000338	0.0379	-0.17	-0.16	QT interval;	chr12:110285398	chr12:109866214~109866509:-
HNSC	cis	rs2836974	0.836	rs8129355	ENSG00000255568.3	BRWD1-AS2	3.61	0.000338	0.0379	0.15	0.16	Cognitive function;	chr21:39207943	chr21:39313935~39314962:+
HNSC	cis	rs4835473	0.932	rs17695782	ENSG00000249741.2	RP11-673E1.3	3.61	0.000338	0.0379	0.18	0.16	Immature fraction of reticulocytes;	chr4:143830311	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs11730929	ENSG00000249741.2	RP11-673E1.3	3.61	0.000338	0.0379	0.18	0.16	Immature fraction of reticulocytes;	chr4:143834795	chr4:143911514~143912053:-
HNSC	cis	rs4713118	0.513	rs149962	ENSG00000219891.2	ZSCAN12P1	3.61	0.000338	0.0379	0.22	0.16	Parkinson's disease;	chr6:28048140	chr6:28091154~28093664:+
HNSC	cis	rs11723261	0.546	rs57839456	ENSG00000211553.1	AC253576.2	-3.61	0.000338	0.0379	-0.24	-0.16	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:136461~136568:+
HNSC	cis	rs72827839	0.744	rs16955463	ENSG00000242207.1	HOXB-AS4	-3.61	0.000338	0.0379	-0.22	-0.16	Ease of getting up in the morning;	chr17:48322135	chr17:48628675~48634932:+
HNSC	cis	rs886126	1	rs10082818	ENSG00000257595.2	RP3-473L9.4	3.61	0.000338	0.0379	0.22	0.16	Coronary heart disease;	chr12:111225373	chr12:111369282~111403310:+
HNSC	cis	rs6570726	0.846	rs1935616	ENSG00000270638.1	RP3-466P17.1	3.61	0.000338	0.0379	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.846	rs9376954	ENSG00000270638.1	RP3-466P17.1	3.61	0.000338	0.0379	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.846	rs9399559	ENSG00000270638.1	RP3-466P17.1	3.61	0.000338	0.0379	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145735570~145737218:+
HNSC	cis	rs3929778	0.816	rs2876037	ENSG00000278192.1	RP5-1056H1.2	-3.61	0.000338	0.0379	-0.23	-0.16	QRS complex (Cornell);	chr20:6554912	chr20:6065966~6067897:-
HNSC	cis	rs3740713	1	rs73440636	ENSG00000256464.1	YWHABP2	3.61	0.000338	0.0379	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr11:18490243~18490955:-
HNSC	cis	rs7927592	0.956	rs55816191	ENSG00000255031.4	RP11-802E16.3	3.61	0.000338	0.0379	0.15	0.16	Total body bone mineral density;	chr11:68495511	chr11:68050740~68053762:+
HNSC	cis	rs6787172	0.622	rs12629587	ENSG00000272087.1	RP11-379F4.7	3.61	0.000338	0.0379	0.17	0.16	Subjective well-being;	chr3:158391143	chr3:158693120~158693768:-
HNSC	cis	rs13108904	0.901	rs7668661	ENSG00000272588.1	RP11-440L14.4	3.61	0.000338	0.0379	0.17	0.16	Obesity-related traits;	chr4:1306384	chr4:757022~757740:-
HNSC	cis	rs17489649	0.824	rs724783	ENSG00000271849.1	CTC-332L22.1	3.61	0.000338	0.0379	0.21	0.16	Intelligence (multi-trait analysis);	chr5:109717759	chr5:109687802~109688329:-
HNSC	cis	rs4948102	0.731	rs4689	ENSG00000213650.3	RP11-760D2.7	3.61	0.000338	0.0379	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr7:56567906~56568858:-
HNSC	cis	rs9914544	0.545	rs8069826	ENSG00000264885.1	RP11-815I9.4	-3.61	0.000338	0.0379	-0.17	-0.16	Educational attainment (years of education);	chr17:18862177	chr17:18667629~18669461:-
HNSC	cis	rs10865541	0.967	rs6755327	ENSG00000234171.2	RNASEH1-AS1	3.61	0.000338	0.0379	0.17	0.16	Obesity-related traits;	chr2:3393510	chr2:3558492~3561745:+
HNSC	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	3.61	0.000338	0.0379	0.15	0.16	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
HNSC	cis	rs7023329	0.562	rs10757242	ENSG00000244230.3	RN7SL151P	3.61	0.000338	0.0379	0.17	0.16	Melanoma;	chr9:21739593	chr9:21699314~21699596:+
HNSC	cis	rs7927592	0.956	rs7126340	ENSG00000239559.2	RPL37P2	3.61	0.000338	0.0379	0.17	0.16	Total body bone mineral density;	chr11:68489825	chr11:67682772~67683058:-
HNSC	cis	rs6951245	0.554	rs78999139	ENSG00000225146.1	AC073957.15	-3.61	0.000338	0.0379	-0.22	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1029025~1043891:+
HNSC	cis	rs1075232	1	rs56396205	ENSG00000103832.10	GOLGA8UP	-3.61	0.000338	0.0379	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30791573~30801859:+
HNSC	cis	rs1075232	1	rs12438318	ENSG00000103832.10	GOLGA8UP	-3.61	0.000338	0.0379	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30791573~30801859:+
HNSC	cis	rs3018712	0.59	rs2513304	ENSG00000255031.4	RP11-802E16.3	-3.61	0.000338	0.0379	-0.14	-0.16	Total body bone mineral density;	chr11:68693677	chr11:68050740~68053762:+
HNSC	cis	rs853679	0.628	rs9368560	ENSG00000219891.2	ZSCAN12P1	3.61	0.000338	0.0379	0.24	0.16	Depression;	chr6:28192182	chr6:28091154~28093664:+
HNSC	cis	rs8062405	1	rs8055138	ENSG00000261089.1	RP11-435I10.3	3.61	0.000338	0.0379	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28413703~28415018:+
HNSC	cis	rs72843506	0.656	rs16959946	ENSG00000189423.10	USP32P3	3.61	0.000338	0.0379	0.26	0.16	Schizophrenia;	chr17:20269134	chr17:20415547~20431008:+
HNSC	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-3.61	0.000338	0.0379	-0.16	-0.16	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
HNSC	cis	rs7781557	1	rs10487281	ENSG00000239969.4	RP11-163E9.2	-3.61	0.000338	0.0379	-0.24	-0.16	Colorectal adenoma (advanced);	chr7:102837134	chr7:102364162~102380633:+
HNSC	cis	rs2562456	0.755	rs11670868	ENSG00000268119.4	CTD-2561J22.5	3.61	0.000338	0.0379	0.25	0.16	Pain;	chr19:21373613	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs2358993	ENSG00000268119.4	CTD-2561J22.5	3.61	0.000338	0.0379	0.25	0.16	Pain;	chr19:21375367	chr19:21444241~21463908:-
HNSC	cis	rs890448	0.726	rs2583396	ENSG00000254531.1	FLJ20021	-3.61	0.000338	0.0379	-0.16	-0.16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308621	chr4:101347780~101348883:+
HNSC	cis	rs7686660	0.614	rs4266246	ENSG00000249806.1	RP11-223C24.1	-3.61	0.000338	0.0379	-0.2	-0.16	Asthma;	chr4:143050089	chr4:142566019~142660950:+
HNSC	cis	rs170183	0.934	rs13051987	ENSG00000279365.1	KB-176G8.1	-3.61	0.000338	0.0379	-0.19	-0.16	Bone mineral density;	chr21:36483676	chr21:36485867~36487760:+
HNSC	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	3.61	0.000339	0.038	0.21	0.16	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
HNSC	cis	rs6988985	0.693	rs4736357	ENSG00000247317.3	RP11-273G15.2	-3.61	0.000339	0.038	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905802	chr8:142981738~143018437:-
HNSC	cis	rs6988985	0.765	rs4736359	ENSG00000247317.3	RP11-273G15.2	-3.61	0.000339	0.038	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906011	chr8:142981738~143018437:-
HNSC	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-3.61	0.000339	0.038	-0.19	-0.16	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000272831.1	RP11-792A8.4	-3.61	0.000339	0.038	-0.14	-0.16	Aortic root size;	chr7:66589419	chr7:66739829~66740385:-
HNSC	cis	rs6088590	0.561	rs3891369	ENSG00000276073.1	RP5-1125A11.7	-3.61	0.000339	0.038	-0.17	-0.16	Coronary artery disease;	chr20:34573323	chr20:33985617~33988989:-
HNSC	cis	rs3018712	0.532	rs2513280	ENSG00000255031.4	RP11-802E16.3	-3.61	0.000339	0.038	-0.19	-0.16	Total body bone mineral density;	chr11:68649439	chr11:68050740~68053762:+
HNSC	cis	rs9311474	0.508	rs12637627	ENSG00000243224.1	RP5-1157M23.2	-3.61	0.000339	0.038	-0.16	-0.16	Electroencephalogram traits;	chr3:52585946	chr3:52239258~52241097:+
HNSC	cis	rs889398	0.56	rs8057620	ENSG00000226232.7	RP11-419C5.2	-3.61	0.000339	0.038	-0.14	-0.16	Body mass index;	chr16:69850716	chr16:69976388~69996188:-
HNSC	cis	rs8037818	1	rs4643284	ENSG00000223509.7	RP11-632K20.7	-3.61	0.000339	0.038	-0.16	-0.16	Obesity-related traits;	chr15:32639897	chr15:32519848~32536926:-
HNSC	cis	rs6493858	0.839	rs59432349	ENSG00000277245.1	RP11-48G14.3	-3.61	0.000339	0.038	-0.19	-0.16	Relative hand skill in reading disability;	chr15:56173246	chr15:56447120~56447697:+
HNSC	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	3.61	0.000339	0.038	0.2	0.16	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
HNSC	cis	rs2307394	0.896	rs1424949	ENSG00000281469.1	RP11-567F11.1	3.61	0.000339	0.038	0.18	0.16	Urate levels;	chr2:147785394	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs13032660	ENSG00000281469.1	RP11-567F11.1	3.61	0.000339	0.038	0.18	0.16	Urate levels;	chr2:147805340	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.896	rs11884013	ENSG00000281469.1	RP11-567F11.1	3.61	0.000339	0.038	0.18	0.16	Urate levels;	chr2:147805922	chr2:148044380~148044894:+
HNSC	cis	rs11638815	0.581	rs783537	ENSG00000259429.4	UBE2Q2P2	-3.61	0.000339	0.038	-0.16	-0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:82355142~82420075:+
HNSC	cis	rs10863681	0.875	rs1890759	ENSG00000238042.4	RP11-815M8.1	3.61	0.000339	0.038	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222081282	chr1:221880981~221978523:-
HNSC	cis	rs10863681	0.875	rs1591912	ENSG00000238042.4	RP11-815M8.1	3.61	0.000339	0.038	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222082798	chr1:221880981~221978523:-
HNSC	cis	rs1008375	0.966	rs4235389	ENSG00000249502.1	AC006160.5	-3.61	0.000339	0.038	-0.17	-0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694657	chr4:17587467~17614571:-
HNSC	cis	rs1799949	0.628	rs4474733	ENSG00000236383.6	LINC00854	-3.61	0.000339	0.038	-0.17	-0.16	Menopause (age at onset);	chr17:43356292	chr17:43216941~43305976:-
HNSC	cis	rs6095360	1	rs2426125	ENSG00000227431.4	CSE1L-AS1	-3.61	0.000339	0.038	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49084445	chr20:49040463~49046044:-
HNSC	cis	rs765751	0.775	rs1531095	ENSG00000228536.1	RP11-392O17.1	-3.61	0.000339	0.038	-0.19	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219482752	chr1:219409681~219411941:-
HNSC	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-3.61	0.000339	0.038	-0.23	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
HNSC	cis	rs2255336	0.808	rs59611026	ENSG00000245648.1	RP11-277P12.20	-3.61	0.000339	0.038	-0.24	-0.16	Blood protein levels;	chr12:10445387	chr12:10363769~10398506:+
HNSC	cis	rs13256369	1	rs10095733	ENSG00000173295.6	FAM86B3P	3.61	0.000339	0.038	0.21	0.16	Obesity-related traits;	chr8:8717136	chr8:8228595~8244865:+
HNSC	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	3.61	0.000339	0.038	0.27	0.16	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
HNSC	cis	rs8077577	0.638	rs4386179	ENSG00000273018.4	CTD-2303H24.2	3.61	0.000339	0.038	0.24	0.16	Obesity-related traits;	chr17:18231460	chr17:18511221~18551705:-
HNSC	cis	rs67311347	1	rs12492035	ENSG00000280739.1	EIF1B-AS1	3.61	0.000339	0.038	0.19	0.16	Renal cell carcinoma;	chr3:40425619	chr3:40173145~40309698:-
HNSC	cis	rs6499755	0.768	rs31096	ENSG00000260135.5	RP11-212I21.2	-3.61	0.000339	0.038	-0.18	-0.16	Hypospadias;	chr16:55333491	chr16:55426797~55462297:-
HNSC	cis	rs4523957	0.533	rs170043	ENSG00000262333.1	HNRNPA1P16	3.61	0.000339	0.038	0.16	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2297140	chr17:2306761~2307715:+
HNSC	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000339	0.038	-0.12	-0.16	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
HNSC	cis	rs4906332	0.811	rs2296487	ENSG00000269940.1	RP11-73M18.7	3.61	0.000339	0.038	0.18	0.16	Coronary artery disease;	chr14:103529868	chr14:103694560~103695170:+
HNSC	cis	rs7772486	0.651	rs1292338	ENSG00000270638.1	RP3-466P17.1	-3.61	0.000339	0.038	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145735570~145737218:+
HNSC	cis	rs6988985	0.667	rs7818953	ENSG00000247317.3	RP11-273G15.2	-3.61	0.000339	0.038	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142877873	chr8:142981738~143018437:-
HNSC	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-3.61	0.000339	0.038	-0.17	-0.16	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
HNSC	cis	rs9560113	0.509	rs4773390	ENSG00000229152.2	ANKRD10-IT1	3.61	0.00034	0.038	0.12	0.16	Menarche (age at onset);	chr13:111556557	chr13:110894639~110899172:-
HNSC	cis	rs2274273	0.805	rs8012156	ENSG00000233924.1	AL160471.6	-3.61	0.00034	0.038	-0.19	-0.16	Protein biomarker;	chr14:55085782	chr14:55004813~55005687:-
HNSC	cis	rs1440410	0.835	rs11100770	ENSG00000250326.1	RP11-284M14.1	-3.61	0.00034	0.038	-0.18	-0.16	Ischemic stroke;	chr4:143132629	chr4:142933195~143184861:-
HNSC	cis	rs2060793	0.519	rs1357332	ENSG00000251991.1	RNU7-49P	3.61	0.00034	0.038	0.17	0.16	Vitamin D levels;	chr11:14618570	chr11:14478892~14478953:+
HNSC	cis	rs1513670	1	rs6503475	ENSG00000260793.2	RP5-882C2.2	3.61	0.00034	0.0381	0.15	0.16	Bone mineral density (hip);	chr17:43733640	chr17:44221401~44223710:+
HNSC	cis	rs9611565	0.512	rs5751145	ENSG00000235513.1	RP4-756G23.5	-3.61	0.00034	0.0381	-0.2	-0.16	Vitiligo;	chr22:41737548	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs964899	ENSG00000235513.1	RP4-756G23.5	-3.61	0.00034	0.0381	-0.2	-0.16	Vitiligo;	chr22:41746382	chr22:41209122~41217627:-
HNSC	cis	rs17264034	0.95	rs55970326	ENSG00000250786.1	SNHG18	3.61	0.00034	0.0381	0.28	0.16	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557008	chr5:9546200~9550609:+
HNSC	cis	rs6840360	0.642	rs2724577	ENSG00000251611.1	RP11-610P16.1	-3.61	0.00034	0.0381	-0.19	-0.16	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151407551~151408835:-
HNSC	cis	rs7824557	0.51	rs2736297	ENSG00000255495.1	AC145124.2	-3.61	0.00034	0.0381	-0.18	-0.16	Retinal vascular caliber;	chr8:11377376	chr8:12194467~12196280:+
HNSC	cis	rs3771570	1	rs6752050	ENSG00000260942.1	CAPN10-AS1	-3.61	0.00034	0.0381	-0.19	-0.16	Prostate cancer;	chr2:241289365	chr2:240582700~240586699:-
HNSC	cis	rs71636778	0.509	rs17162339	ENSG00000260063.1	RP5-968P14.2	3.61	0.00034	0.0381	0.34	0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26926332	chr1:26692132~26694131:-
HNSC	cis	rs35306767	0.855	rs11253459	ENSG00000229869.1	RP11-363N22.2	-3.61	0.00034	0.0381	-0.24	-0.16	Eosinophil percentage of granulocytes;	chr10:840462	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs1341741	ENSG00000229869.1	RP11-363N22.2	-3.61	0.00034	0.0381	-0.24	-0.16	Eosinophil percentage of granulocytes;	chr10:842133	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs11253462	ENSG00000229869.1	RP11-363N22.2	-3.61	0.00034	0.0381	-0.24	-0.16	Eosinophil percentage of granulocytes;	chr10:843383	chr10:933026~942743:+
HNSC	cis	rs219780	0.679	rs219787	ENSG00000233818.1	AP000695.4	3.61	0.00034	0.0381	0.2	0.16	Kidney stones;	chr21:36457210	chr21:36445731~36532408:+
HNSC	cis	rs2439831	0.867	rs4075674	ENSG00000275601.1	AC011330.13	-3.61	0.00034	0.0381	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43358032	chr15:43642389~43643023:-
HNSC	cis	rs4819052	0.918	rs2330013	ENSG00000215447.6	BX322557.10	-3.61	0.00034	0.0381	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45288052~45291738:+
HNSC	cis	rs1028883	0.571	rs7324515	ENSG00000228295.1	LINC00392	-3.61	0.00034	0.0381	-0.17	-0.16	Lean body mass;	chr13:73597762	chr13:73564244~73588070:+
HNSC	cis	rs1028883	0.571	rs9543409	ENSG00000228295.1	LINC00392	-3.61	0.00034	0.0381	-0.17	-0.16	Lean body mass;	chr13:73597901	chr13:73564244~73588070:+
HNSC	cis	rs1028883	0.571	rs9543410	ENSG00000228295.1	LINC00392	-3.61	0.00034	0.0381	-0.17	-0.16	Lean body mass;	chr13:73598296	chr13:73564244~73588070:+
HNSC	cis	rs3771570	0.901	rs56129392	ENSG00000260942.1	CAPN10-AS1	-3.61	0.00034	0.0381	-0.18	-0.16	Prostate cancer;	chr2:241303024	chr2:240582700~240586699:-
HNSC	cis	rs3771570	1	rs56052835	ENSG00000260942.1	CAPN10-AS1	-3.61	0.00034	0.0381	-0.18	-0.16	Prostate cancer;	chr2:241303836	chr2:240582700~240586699:-
HNSC	cis	rs9611565	0.681	rs132918	ENSG00000235513.1	RP4-756G23.5	-3.61	0.00034	0.0381	-0.19	-0.16	Vitiligo;	chr22:41412346	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.765	rs132921	ENSG00000235513.1	RP4-756G23.5	-3.61	0.00034	0.0381	-0.19	-0.16	Vitiligo;	chr22:41416040	chr22:41209122~41217627:-
HNSC	cis	rs12073359	0.955	rs72694959	ENSG00000261716.1	RP11-196G18.22	-3.61	0.00034	0.0381	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150165955	chr1:149844498~149849024:-
HNSC	cis	rs2904967	0.929	rs2904980	ENSG00000254614.2	AP003068.23	-3.61	0.00034	0.0381	-0.28	-0.16	Mean corpuscular volume;	chr11:65234208	chr11:65177606~65181834:-
HNSC	cis	rs8062405	1	rs2008514	ENSG00000261766.1	RP11-22P6.2	3.61	0.00034	0.0381	0.16	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28862166~28863340:-
HNSC	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	3.61	0.00034	0.0381	0.2	0.16	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	3.61	0.00034	0.0381	0.2	0.16	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
HNSC	cis	rs8022179	0.58	rs58153827	ENSG00000244691.1	RPL10AP1	3.61	0.00034	0.0381	0.23	0.16	Monocyte count;	chr14:103378293	chr14:103412119~103412761:-
HNSC	cis	rs2836974	0.932	rs2836955	ENSG00000255568.3	BRWD1-AS2	3.61	0.00034	0.0381	0.15	0.16	Cognitive function;	chr21:39247961	chr21:39313935~39314962:+
HNSC	cis	rs60617249	0.735	rs7792463	ENSG00000228204.2	RP4-724E13.2	3.61	0.00034	0.0381	0.18	0.16	Major depression and alcohol dependence;	chr7:50879708	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.772	rs10249917	ENSG00000228204.2	RP4-724E13.2	3.61	0.00034	0.0381	0.18	0.16	Major depression and alcohol dependence;	chr7:50881203	chr7:50866747~51022990:+
HNSC	cis	rs60617249	0.772	rs6964994	ENSG00000228204.2	RP4-724E13.2	3.61	0.00034	0.0381	0.18	0.16	Major depression and alcohol dependence;	chr7:50881531	chr7:50866747~51022990:+
HNSC	cis	rs11587682	0.806	rs1050818	ENSG00000236713.1	RP11-363I22.3	3.61	0.000341	0.0381	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150294139	chr1:150780272~150780644:+
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000269918.1	AF131215.9	3.61	0.000341	0.0381	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11104691~11106704:-
HNSC	cis	rs1440410	0.835	rs7684481	ENSG00000250326.1	RP11-284M14.1	-3.61	0.000341	0.0381	-0.18	-0.16	Ischemic stroke;	chr4:143133252	chr4:142933195~143184861:-
HNSC	cis	rs10435719	0.902	rs7459983	ENSG00000269918.1	AF131215.9	3.61	0.000341	0.0381	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-3.61	0.000341	0.0381	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
HNSC	cis	rs2074409	0.509	rs11655957	ENSG00000276054.1	RP11-378E13.3	3.61	0.000341	0.0381	0.18	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37459133	chr17:37386886~37387926:+
HNSC	cis	rs5758511	0.773	rs10154700	ENSG00000273366.1	CTA-989H11.1	3.61	0.000341	0.0381	0.24	0.16	Birth weight;	chr22:41969069	chr22:42278188~42278846:+
HNSC	cis	rs6545883	0.894	rs2600660	ENSG00000271889.1	RP11-493E12.1	-3.61	0.000341	0.0381	-0.19	-0.16	Tuberculosis;	chr2:61322465	chr2:61151433~61162105:-
HNSC	cis	rs7726839	0.718	rs6887972	ENSG00000225138.6	CTD-2228K2.7	3.61	0.000341	0.0381	0.23	0.16	Obesity-related traits;	chr5:597159	chr5:473236~480884:+
HNSC	cis	rs62229266	0.609	rs12482541	ENSG00000230212.5	AP000688.14	-3.61	0.000341	0.0382	-0.18	-0.16	Mitral valve prolapse;	chr21:36047445	chr21:36069642~36126640:-
HNSC	cis	rs62229266	0.609	rs2835253	ENSG00000230212.5	AP000688.14	-3.61	0.000341	0.0382	-0.18	-0.16	Mitral valve prolapse;	chr21:36047447	chr21:36069642~36126640:-
HNSC	cis	rs12234571	1	rs7799614	ENSG00000214293.7	APTR	3.61	0.000341	0.0382	0.22	0.16	Obesity-related traits;	chr7:77740666	chr7:77657660~77696265:-
HNSC	cis	rs330048	0.545	rs11774353	ENSG00000233609.3	RP11-62H7.2	3.61	0.000341	0.0382	0.16	0.16	Systemic lupus erythematosus;	chr8:9295617	chr8:8961200~8979025:+
HNSC	cis	rs12546962	0.593	rs61198364	ENSG00000233609.3	RP11-62H7.2	3.61	0.000341	0.0382	0.2	0.16	Body mass index;	chr8:9334787	chr8:8961200~8979025:+
HNSC	cis	rs2836974	0.897	rs2836973	ENSG00000255568.3	BRWD1-AS2	3.61	0.000341	0.0382	0.15	0.16	Cognitive function;	chr21:39283002	chr21:39313935~39314962:+
HNSC	cis	rs2554380	0.76	rs1946367	ENSG00000259570.1	RP11-671M22.4	3.61	0.000341	0.0382	0.22	0.16	Height;	chr15:83756511	chr15:84394512~84395514:+
HNSC	cis	rs3736485	0.966	rs11070862	ENSG00000274528.1	CTD-2650P22.2	3.61	0.000341	0.0382	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51610030	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.934	rs2899476	ENSG00000274528.1	CTD-2650P22.2	3.61	0.000341	0.0382	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51611677	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.966	rs2414113	ENSG00000274528.1	CTD-2650P22.2	3.61	0.000341	0.0382	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51611699	chr15:52017167~52018032:-
HNSC	cis	rs870825	0.616	rs57316663	ENSG00000254233.1	RP11-242J7.1	3.61	0.000341	0.0382	0.24	0.16	Blood protein levels;	chr4:184708857	chr4:184584093~184625030:-
HNSC	cis	rs10761256	0.778	rs6479499	ENSG00000227603.1	RP11-165J3.6	3.61	0.000341	0.0382	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93643582	chr9:93435332~93437121:-
HNSC	cis	rs10040610	0.524	rs60844356	ENSG00000250490.1	FLJ33360	-3.61	0.000341	0.0382	-0.21	-0.16	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6354481	chr5:6310441~6339884:-
HNSC	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	3.61	0.000341	0.0382	0.2	0.16	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
HNSC	cis	rs853679	0.666	rs200956	ENSG00000241549.7	GUSBP2	3.61	0.000341	0.0382	0.19	0.16	Depression;	chr6:27871968	chr6:26871484~26956554:-
HNSC	cis	rs11976180	1	rs1320893	ENSG00000204959.4	ARHGEF34P	3.61	0.000341	0.0382	0.19	0.16	Obesity-related traits;	chr7:144055019	chr7:144272445~144286966:-
HNSC	cis	rs6568686	0.786	rs6910340	ENSG00000255389.1	C6orf3	-3.61	0.000341	0.0382	-0.21	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111541861	chr6:111599875~111602295:+
HNSC	cis	rs4704187	0.687	rs10462354	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000341	0.0382	-0.15	-0.16	Response to amphetamines;	chr5:75157202	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs28376290	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000341	0.0382	-0.15	-0.16	Response to amphetamines;	chr5:75158881	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs4703655	ENSG00000272040.1	CTC-366B18.4	-3.61	0.000341	0.0382	-0.15	-0.16	Response to amphetamines;	chr5:75159238	chr5:75608817~75609983:+
HNSC	cis	rs5758511	0.68	rs5758667	ENSG00000227370.1	RP4-669P10.19	3.61	0.000341	0.0382	0.2	0.16	Birth weight;	chr22:42237198	chr22:42132543~42132998:+
HNSC	cis	rs3929778	0.848	rs6085575	ENSG00000278192.1	RP5-1056H1.2	3.61	0.000341	0.0382	0.22	0.16	QRS complex (Cornell);	chr20:6486404	chr20:6065966~6067897:-
HNSC	cis	rs449789	0.857	rs4708817	ENSG00000235086.1	FNDC1-IT1	-3.61	0.000341	0.0382	-0.2	-0.16	Pulse pressure;	chr6:159299608	chr6:159240786~159243329:+
HNSC	cis	rs859767	0.741	rs7602801	ENSG00000224043.6	CCNT2-AS1	3.61	0.000342	0.0382	0.2	0.16	Neuroticism;	chr2:134606300	chr2:134735464~134918710:-
HNSC	cis	rs859767	0.741	rs2176341	ENSG00000224043.6	CCNT2-AS1	3.61	0.000342	0.0382	0.2	0.16	Neuroticism;	chr2:134613851	chr2:134735464~134918710:-
HNSC	cis	rs62025270	0.547	rs338536	ENSG00000259407.1	RP11-158M2.3	3.61	0.000342	0.0382	0.19	0.16	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85744109~85750281:-
HNSC	cis	rs4622329	0.636	rs7974969	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101894645	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.636	rs7975403	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101894749	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs7975321	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101894835	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.636	rs4764670	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101895089	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs4764672	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101895437	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs4764676	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101896179	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs7954630	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101896376	chr12:101066734~101069232:+
HNSC	cis	rs4622329	0.615	rs6539016	ENSG00000258033.1	RP11-350G24.2	3.61	0.000342	0.0382	0.18	0.16	Systemic lupus erythematosus;	chr12:101896459	chr12:101066734~101069232:+
HNSC	cis	rs11098499	0.691	rs10028773	ENSG00000250412.1	KLHL2P1	-3.61	0.000342	0.0382	-0.21	-0.16	Corneal astigmatism;	chr4:119344104	chr4:119334329~119378233:+
HNSC	cis	rs4083242	0.522	rs1623214	ENSG00000280278.1	FLJ30679	-3.61	0.000342	0.0382	-0.21	-0.16	Obesity-related traits;	chr16:86359258	chr16:86555320~86557299:+
HNSC	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	3.61	0.000342	0.0382	0.19	0.16	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
HNSC	cis	rs13178541	0.748	rs4976306	ENSG00000250378.1	RP11-119J18.1	3.61	0.000342	0.0382	0.21	0.16	IgG glycosylation;	chr5:135728489	chr5:135812667~135826582:+
HNSC	cis	rs1440410	0.835	rs4626148	ENSG00000250326.1	RP11-284M14.1	-3.61	0.000342	0.0382	-0.18	-0.16	Ischemic stroke;	chr4:143131307	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10034769	ENSG00000250326.1	RP11-284M14.1	-3.61	0.000342	0.0382	-0.18	-0.16	Ischemic stroke;	chr4:143131740	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs6829621	ENSG00000250326.1	RP11-284M14.1	-3.61	0.000342	0.0382	-0.18	-0.16	Ischemic stroke;	chr4:143131818	chr4:142933195~143184861:-
HNSC	cis	rs6489785	0.737	rs497273	ENSG00000256742.1	RP13-941N14.1	-3.61	0.000342	0.0382	-0.19	-0.16	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120766879	chr12:121580792~121593504:+
HNSC	cis	rs10865541	1	rs11684337	ENSG00000234171.2	RNASEH1-AS1	-3.61	0.000342	0.0382	-0.17	-0.16	Obesity-related traits;	chr2:3391516	chr2:3558492~3561745:+
HNSC	cis	rs7714670	1	rs2339608	ENSG00000184084.7	CTD-2372A4.1	-3.61	0.000342	0.0382	-0.19	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:73775725	chr5:73803296~73803599:-
HNSC	cis	rs643506	0.874	rs645411	ENSG00000230911.1	PPIHP1	-3.61	0.000342	0.0382	-0.22	-0.16	Breast cancer;	chr11:111823766	chr11:112029858~112030367:-
HNSC	cis	rs9926296	0.632	rs1800286	ENSG00000260528.3	FAM157C	-3.61	0.000342	0.0382	-0.15	-0.16	Vitiligo;	chr16:89803353	chr16:90102271~90186204:+
HNSC	cis	rs1552244	1	rs6764168	ENSG00000180385.7	EMC3-AS1	3.61	0.000342	0.0382	0.18	0.16	Alzheimer's disease;	chr3:10082121	chr3:9986893~10006990:+
HNSC	cis	rs2098713	0.534	rs11952015	ENSG00000250155.1	CTD-2353F22.1	3.61	0.000342	0.0382	0.17	0.16	Telomere length;	chr5:37539402	chr5:36666214~36725195:-
HNSC	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-3.61	0.000342	0.0382	-0.2	-0.16	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
HNSC	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-3.61	0.000342	0.0383	-0.18	-0.16	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
HNSC	cis	rs2486288	0.656	rs6493144	ENSG00000259479.5	SORD2P	3.61	0.000342	0.0383	0.19	0.16	Glomerular filtration rate;	chr15:45281291	chr15:44826371~44884694:-
HNSC	cis	rs34286592	1	rs9938630	ENSG00000214725.6	CDIPT-AS1	-3.61	0.000342	0.0383	-0.22	-0.16	Multiple sclerosis;	chr16:29825787	chr16:29863593~29868053:+
HNSC	cis	rs3740713	1	rs1848048	ENSG00000256464.1	YWHABP2	3.61	0.000342	0.0383	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs16935432	ENSG00000256464.1	YWHABP2	3.61	0.000342	0.0383	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs73440625	ENSG00000256464.1	YWHABP2	3.61	0.000342	0.0383	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18490243~18490955:-
HNSC	cis	rs3740713	1	rs76599129	ENSG00000256464.1	YWHABP2	3.61	0.000342	0.0383	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18490243~18490955:-
HNSC	cis	rs2277027	1	rs1422795	ENSG00000251405.2	CTB-109A12.1	-3.61	0.000342	0.0383	-0.19	-0.16	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509356	chr5:157362615~157460078:-
HNSC	cis	rs17837474	0.656	rs17273	ENSG00000211746.3	TRBV19	3.61	0.000342	0.0383	0.16	0.16	Cancer;	chr7:142407435	chr7:142618849~142619532:+
HNSC	cis	rs1322639	0.614	rs6940913	ENSG00000261039.2	RP11-417E7.2	-3.61	0.000342	0.0383	-0.27	-0.16	Pulse pressure;	chr6:169163571	chr6:169175304~169182740:-
HNSC	cis	rs9437689	1	rs35678413	ENSG00000237416.5	RP11-465K1.2	-3.61	0.000342	0.0383	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95073327	chr1:94836748~94855426:-
HNSC	cis	rs6878727	0.815	rs988409	ENSG00000253807.4	LINC01170	-3.61	0.000342	0.0383	-0.21	-0.16	Breast cancer;	chr5:124394790	chr5:124059794~124405079:-
HNSC	cis	rs4713118	0.955	rs9468201	ENSG00000217862.2	HIST1H4PS1	-3.61	0.000342	0.0383	-0.19	-0.16	Parkinson's disease;	chr6:27719256	chr6:27807075~27807339:+
HNSC	cis	rs7824557	0.602	rs7833966	ENSG00000269918.1	AF131215.9	3.61	0.000342	0.0383	0.16	0.16	Retinal vascular caliber;	chr8:11348711	chr8:11104691~11106704:-
HNSC	cis	rs9611565	0.512	rs139560	ENSG00000235513.1	RP4-756G23.5	3.61	0.000342	0.0383	0.2	0.16	Vitiligo;	chr22:41798958	chr22:41209122~41217627:-
HNSC	cis	rs5758511	0.68	rs58654759	ENSG00000227370.1	RP4-669P10.19	3.61	0.000342	0.0383	0.2	0.16	Birth weight;	chr22:42246570	chr22:42132543~42132998:+
HNSC	cis	rs9437689	1	rs4950058	ENSG00000237416.5	RP11-465K1.2	-3.61	0.000342	0.0383	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95082595	chr1:94836748~94855426:-
HNSC	cis	rs7107174	0.681	rs4340079	ENSG00000251323.2	RP11-452H21.4	3.61	0.000342	0.0383	0.25	0.16	Testicular germ cell tumor;	chr11:78296874	chr11:78423982~78429836:-
HNSC	cis	rs28573326	0.925	rs10018971	ENSG00000121089.4	NACA3P	-3.61	0.000342	0.0383	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165430582	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.853	rs10029342	ENSG00000121089.4	NACA3P	-3.61	0.000342	0.0383	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165430608	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.853	rs10019052	ENSG00000121089.4	NACA3P	-3.61	0.000342	0.0383	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165430616	chr4:164943290~164943937:+
HNSC	cis	rs8077577	0.708	rs2290502	ENSG00000273018.4	CTD-2303H24.2	3.61	0.000342	0.0383	0.24	0.16	Obesity-related traits;	chr17:18230181	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.708	rs3862147	ENSG00000273018.4	CTD-2303H24.2	3.61	0.000342	0.0383	0.24	0.16	Obesity-related traits;	chr17:18230399	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.708	rs3889544	ENSG00000273018.4	CTD-2303H24.2	3.61	0.000342	0.0383	0.24	0.16	Obesity-related traits;	chr17:18230474	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.708	rs4556848	ENSG00000273018.4	CTD-2303H24.2	3.61	0.000342	0.0383	0.24	0.16	Obesity-related traits;	chr17:18231553	chr17:18511221~18551705:-
HNSC	cis	rs11083475	0.686	rs73040728	ENSG00000207296.1	RNU6-140P	-3.61	0.000342	0.0383	-0.17	-0.16	Heart rate;	chr19:38766961	chr19:38797002~38797109:-
HNSC	cis	rs765751	0.775	rs2820427	ENSG00000228536.1	RP11-392O17.1	-3.61	0.000342	0.0383	-0.19	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219483782	chr1:219409681~219411941:-
HNSC	cis	rs3096299	0.667	rs2965947	ENSG00000261118.1	RP11-104N10.1	3.61	0.000342	0.0383	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89492017~89504460:-
HNSC	cis	rs2436845	1	rs1434235	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102830804	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs34655485	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832474	chr8:102805517~102809971:+
HNSC	cis	rs2436845	0.934	rs2256440	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102836035	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs2436844	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102837864	chr8:102805517~102809971:+
HNSC	cis	rs2436845	0.966	rs2513898	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838004	chr8:102805517~102809971:+
HNSC	cis	rs703842	0.616	rs10783850	ENSG00000270039.1	RP11-571M6.17	-3.61	0.000343	0.0383	-0.2	-0.16	Multiple sclerosis;	chr12:57835594	chr12:57803838~57804415:+
HNSC	cis	rs6964587	1	rs2075881	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000343	0.0383	-0.17	-0.16	Breast cancer;	chr7:92105238	chr7:92134604~92180725:+
HNSC	cis	rs6964587	1	rs7785971	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000343	0.0383	-0.17	-0.16	Breast cancer;	chr7:92107480	chr7:92134604~92180725:+
HNSC	cis	rs783147	0.5	rs4252150	ENSG00000231863.1	RP3-428L16.1	3.61	0.000343	0.0383	0.2	0.16	Lp (a) levels;	chr6:160737974	chr6:160931080~160969771:+
HNSC	cis	rs783147	0.5	rs4252151	ENSG00000231863.1	RP3-428L16.1	3.61	0.000343	0.0383	0.2	0.16	Lp (a) levels;	chr6:160737984	chr6:160931080~160969771:+
HNSC	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	3.61	0.000343	0.0383	0.22	0.16	QT interval;	chr16:28824579	chr16:28802743~28817828:+
HNSC	cis	rs6012564	1	rs6066975	ENSG00000227431.4	CSE1L-AS1	-3.61	0.000343	0.0383	-0.19	-0.16	Anger;	chr20:49133840	chr20:49040463~49046044:-
HNSC	cis	rs9467711	0.651	rs17587597	ENSG00000241549.7	GUSBP2	3.61	0.000343	0.0383	0.27	0.16	Autism spectrum disorder or schizophrenia;	chr6:25986223	chr6:26871484~26956554:-
HNSC	cis	rs2436845	1	rs974759	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000343	0.0383	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825684	chr8:102805517~102809971:+
HNSC	cis	rs4388249	1	rs67997427	ENSG00000271849.1	CTC-332L22.1	-3.61	0.000343	0.0383	-0.26	-0.16	Schizophrenia;	chr5:109826222	chr5:109687802~109688329:-
HNSC	cis	rs1553477	0.64	rs17248426	ENSG00000272123.1	CTD-2366F13.2	3.61	0.000343	0.0383	0.19	0.16	Monobrow;	chr5:53820323	chr5:53089016~53089468:-
HNSC	cis	rs250677	0.687	rs250678	ENSG00000250072.4	CTC-529P8.1	-3.61	0.000343	0.0383	-0.21	-0.16	Breast cancer;	chr5:149055267	chr5:149063317~149109787:+
HNSC	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	3.61	0.000343	0.0383	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
HNSC	cis	rs34792	0.528	rs153803	ENSG00000207425.1	Y_RNA	3.61	0.000343	0.0383	0.19	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15458303	chr16:14915457~14915556:-
HNSC	cis	rs6710503	0.561	rs62140561	ENSG00000271936.1	RP11-443B20.1	-3.61	0.000343	0.0383	-0.2	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24787549	chr2:24825610~24826717:+
HNSC	cis	rs1979679	0.842	rs11049373	ENSG00000247934.4	RP11-967K21.1	-3.61	0.000343	0.0383	-0.18	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28163298~28190738:-
HNSC	cis	rs11951515	0.579	rs58966636	ENSG00000249286.1	CTD-2210P15.2	3.61	0.000343	0.0384	0.18	0.16	Metabolite levels  (X-11787);	chr5:43355264	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.603	rs59625262	ENSG00000249286.1	CTD-2210P15.2	3.61	0.000343	0.0384	0.18	0.16	Metabolite levels  (X-11787);	chr5:43355270	chr5:43586918~43588223:-
HNSC	cis	rs9583531	0.689	rs2165418	ENSG00000259831.1	LINC00567	-3.61	0.000343	0.0384	-0.19	-0.16	Coronary artery disease;	chr13:110727018	chr13:110809676~110813084:-
HNSC	cis	rs10849893	0.595	rs6489811	ENSG00000258435.1	RP11-711D18.2	3.61	0.000343	0.0384	0.17	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121455823	chr12:121391962~121399859:+
HNSC	cis	rs72843166	0.898	rs17745579	ENSG00000265282.1	RP11-269G24.4	3.61	0.000343	0.0384	0.26	0.16	Intelligence (multi-trait analysis);	chr17:63150276	chr17:63430468~63432211:-
HNSC	cis	rs9368481	0.594	rs7768643	ENSG00000238621.1	TRI-TAT2-2	-3.61	0.000343	0.0384	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:27020335~27020447:+
HNSC	cis	rs9368481	0.594	rs7768814	ENSG00000238621.1	TRI-TAT2-2	-3.61	0.000343	0.0384	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:27020335~27020447:+
HNSC	cis	rs2836974	0.897	rs2026267	ENSG00000255568.3	BRWD1-AS2	3.61	0.000343	0.0384	0.15	0.16	Cognitive function;	chr21:39339551	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.897	rs35123057	ENSG00000255568.3	BRWD1-AS2	3.61	0.000343	0.0384	0.15	0.16	Cognitive function;	chr21:39339763	chr21:39313935~39314962:+
HNSC	cis	rs2548724	1	rs2600825	ENSG00000250682.4	LINC00491	-3.61	0.000343	0.0384	-0.22	-0.16	Type 2 diabetes;	chr5:102284760	chr5:102609156~102671559:-
HNSC	cis	rs2245368	0.523	rs67814714	ENSG00000233448.2	PMS2P9	-3.61	0.000343	0.0384	-0.25	-0.16	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr7:76888105	chr7:77039944~77043776:+
HNSC	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	3.61	0.000343	0.0384	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
HNSC	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-3.61	0.000343	0.0384	-0.16	-0.16	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
HNSC	cis	rs12745968	0.652	rs4565725	ENSG00000223787.2	RP4-593M8.1	-3.61	0.000343	0.0384	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92485380	chr1:92580476~92580821:-
HNSC	cis	rs2377058	0.924	rs7203947	ENSG00000274627.1	RP11-104N10.2	-3.61	0.000343	0.0384	-0.17	-0.16	Hip circumference adjusted for BMI;	chr16:89656103	chr16:89516797~89522217:+
HNSC	cis	rs9402743	0.67	rs7769840	ENSG00000231028.7	LINC00271	3.61	0.000343	0.0384	0.19	0.16	Systemic lupus erythematosus;	chr6:135605412	chr6:135497801~135716055:+
HNSC	cis	rs73201462	0.901	rs2811400	ENSG00000231305.3	RP11-723O4.2	3.61	0.000343	0.0384	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269024	chr3:128861313~128871540:-
HNSC	cis	rs6732189	0.54	rs13019912	ENSG00000279844.1	RP11-20F18.1	3.61	0.000344	0.0384	0.16	0.16	Educational attainment;	chr2:160763932	chr2:160849313~160850676:-
HNSC	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	3.61	0.000344	0.0384	0.17	0.16	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
HNSC	cis	rs494453	0.883	rs1099800	ENSG00000227811.2	FAM212B-AS1	-3.61	0.000344	0.0384	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111682961	chr1:111739841~111747798:+
HNSC	cis	rs11711311	1	rs4362695	ENSG00000241529.3	RN7SL767P	-3.61	0.000344	0.0384	-0.21	-0.16	IgG glycosylation;	chr3:113816009	chr3:113632704~113632998:+
HNSC	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	3.61	0.000344	0.0384	0.21	0.16	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
HNSC	cis	rs7772486	0.686	rs9376956	ENSG00000270638.1	RP3-466P17.1	3.61	0.000344	0.0384	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.658	rs6570706	ENSG00000270638.1	RP3-466P17.1	3.61	0.000344	0.0384	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145735570~145737218:+
HNSC	cis	rs10129255	0.5	rs1024350	ENSG00000211976.2	IGHV3-73	-3.61	0.000344	0.0384	-0.12	-0.16	Kawasaki disease;	chr14:106685105	chr14:106802694~106803233:-
HNSC	cis	rs8067354	0.789	rs1292068	ENSG00000266701.1	AC005702.4	3.61	0.000344	0.0384	0.2	0.16	Hemoglobin concentration;	chr17:59851958	chr17:60042546~60042627:-
HNSC	cis	rs734999	0.588	rs2843401	ENSG00000238164.5	RP3-395M20.8	3.61	0.000344	0.0384	0.12	0.16	Ulcerative colitis;	chr1:2596694	chr1:2549920~2557031:-
HNSC	cis	rs8062405	1	rs12446589	ENSG00000261089.1	RP11-435I10.3	3.61	0.000344	0.0384	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28413703~28415018:+
HNSC	cis	rs73198271	0.843	rs11775888	ENSG00000254153.1	CTA-398F10.2	-3.61	0.000344	0.0384	-0.22	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8456909~8461337:-
HNSC	cis	rs6001482	0.679	rs6001528	ENSG00000253818.1	IGLV1-41	-3.61	0.000344	0.0384	-0.13	-0.16	Diastolic blood pressure;	chr22:22236511	chr22:22404207~22404721:+
HNSC	cis	rs7824557	0.564	rs2572399	ENSG00000255495.1	AC145124.2	-3.61	0.000344	0.0384	-0.18	-0.16	Retinal vascular caliber;	chr8:11377011	chr8:12194467~12196280:+
HNSC	cis	rs12817549	0.791	rs10161389	ENSG00000213250.5	RBMS2P1	3.61	0.000344	0.0384	0.15	0.16	Hip circumference adjusted for BMI;	chr12:93747483	chr12:94423744~94424969:-
HNSC	cis	rs3017493	0.786	rs12295625	ENSG00000227726.1	AP001271.3	3.61	0.000344	0.0384	0.32	0.16	Renal transplant outcome;	chr11:70825755	chr11:70477277~70477592:-
HNSC	cis	rs7246657	0.722	rs2927742	ENSG00000276846.1	CTD-3220F14.3	-3.61	0.000344	0.0384	-0.22	-0.16	Coronary artery calcification;	chr19:37642717	chr19:37314868~37315620:-
HNSC	cis	rs7781557	1	rs7790451	ENSG00000239969.4	RP11-163E9.2	-3.61	0.000344	0.0384	-0.23	-0.16	Colorectal adenoma (advanced);	chr7:102825541	chr7:102364162~102380633:+
HNSC	cis	rs7824557	0.564	rs34964435	ENSG00000255310.2	AF131215.2	-3.61	0.000344	0.0384	-0.15	-0.16	Retinal vascular caliber;	chr8:11372697	chr8:11107788~11109726:-
HNSC	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-3.61	0.000344	0.0384	-0.2	-0.16	Height;	chr14:75040172	chr14:75011269~75012851:-
HNSC	cis	rs2562456	0.833	rs11672583	ENSG00000268081.1	RP11-678G14.2	3.61	0.000344	0.0384	0.24	0.16	Pain;	chr19:21379363	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.833	rs62110416	ENSG00000268081.1	RP11-678G14.2	3.61	0.000344	0.0384	0.24	0.16	Pain;	chr19:21401924	chr19:21554640~21569237:-
HNSC	cis	rs950169	0.922	rs17531523	ENSG00000230373.7	GOLGA6L5P	-3.61	0.000344	0.0384	-0.18	-0.16	Schizophrenia;	chr15:84589218	chr15:84507885~84516814:-
HNSC	cis	rs61160187	0.51	rs4482855	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000344	0.0384	-0.18	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:61162070~61232040:+
HNSC	cis	rs4713118	0.699	rs200969	ENSG00000217862.2	HIST1H4PS1	-3.61	0.000344	0.0384	-0.2	-0.16	Parkinson's disease;	chr6:27891675	chr6:27807075~27807339:+
HNSC	cis	rs863750	0.811	rs1716407	ENSG00000275389.1	RP11-214K3.24	3.61	0.000344	0.0384	0.23	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124030671	chr12:124085761~124088598:+
HNSC	cis	rs4924935	0.887	rs2428380	ENSG00000264885.1	RP11-815I9.4	3.61	0.000344	0.0384	0.2	0.16	Pancreatic cancer;	chr17:18939776	chr17:18667629~18669461:-
HNSC	cis	rs58873874	0.737	rs11749762	ENSG00000248544.2	CTB-47B11.3	3.61	0.000344	0.0385	0.36	0.16	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157375741~157384950:-
HNSC	cis	rs13276960	0.553	rs58867349	ENSG00000253320.4	KB-1507C5.2	3.61	0.000344	0.0385	0.16	0.16	Schizophrenia;	chr8:102915932	chr8:102864300~102977876:+
HNSC	cis	rs7824557	0.592	rs920044	ENSG00000255495.1	AC145124.2	3.61	0.000344	0.0385	0.18	0.16	Retinal vascular caliber;	chr8:11366804	chr8:12194467~12196280:+
HNSC	cis	rs12960472	0.524	rs12456854	ENSG00000277324.1	RP11-850A17.1	3.61	0.000344	0.0385	0.23	0.16	Positive affect;	chr18:54435946	chr18:54268346~54270028:-
HNSC	cis	rs7868228	0.838	rs10120643	ENSG00000240498.5	CDKN2B-AS1	-3.61	0.000344	0.0385	-0.23	-0.16	Gut microbiome composition (winter);	chr9:21672770	chr9:21994778~22121097:+
HNSC	cis	rs11853189	0.938	rs2280364	ENSG00000259562.2	RP11-762H8.2	3.61	0.000344	0.0385	0.2	0.16	Red cell distribution width;	chr15:78292764	chr15:78290527~78291221:-
HNSC	cis	rs11168618	0.567	rs56354789	ENSG00000240399.1	RP1-228P16.1	3.61	0.000344	0.0385	0.14	0.16	Adiponectin levels;	chr12:48410160	chr12:48054813~48055591:-
HNSC	cis	rs6903823	0.508	rs1778484	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000344	0.0385	-0.19	-0.16	Pulmonary function;	chr6:28273021	chr6:28115628~28116551:+
HNSC	cis	rs7246760	1	rs56357664	ENSG00000267289.1	CTD-2623N2.11	3.61	0.000344	0.0385	0.29	0.16	Pursuit maintenance gain;	chr19:9792723	chr19:9834079~9835013:-
HNSC	cis	rs964611	1	rs74012002	ENSG00000259488.2	RP11-154J22.1	-3.61	0.000344	0.0385	-0.17	-0.16	Metabolite levels (Pyroglutamine);	chr15:48313250	chr15:48312353~48331856:-
HNSC	cis	rs7722022	1	rs7722165	ENSG00000253768.1	CTB-33O18.1	-3.61	0.000344	0.0385	-0.18	-0.16	Adiponectin levels;	chr5:173507967	chr5:173562478~173573199:+
HNSC	cis	rs8040855	0.794	rs4843024	ENSG00000259774.1	RP11-182J1.13	-3.61	0.000344	0.0385	-0.21	-0.16	Bulimia nervosa;	chr15:85162669	chr15:84422618~84425882:+
HNSC	cis	rs7558911	0.801	rs13019444	ENSG00000183308.6	AC005037.3	3.61	0.000344	0.0385	0.2	0.16	Chronic lymphocytic leukemia;	chr2:201225893	chr2:200963263~201009102:+
HNSC	cis	rs1656402	0.953	rs1550099	ENSG00000263941.2	RN7SL32P	-3.61	0.000344	0.0385	-0.2	-0.16	Non-small cell lung cancer (survival);	chr2:232563437	chr2:233205199~233205479:+
HNSC	cis	rs6496044	0.963	rs11853972	ENSG00000259407.1	RP11-158M2.3	-3.61	0.000344	0.0385	-0.18	-0.16	Interstitial lung disease;	chr15:85519209	chr15:85744109~85750281:-
HNSC	cis	rs2013441	0.866	rs10438824	ENSG00000261033.1	RP11-209D14.2	-3.61	0.000345	0.0385	-0.19	-0.16	Obesity-related traits;	chr17:20155197	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.866	rs1009082	ENSG00000261033.1	RP11-209D14.2	-3.61	0.000345	0.0385	-0.19	-0.16	Obesity-related traits;	chr17:20159646	chr17:20008051~20009234:-
HNSC	cis	rs2013441	0.866	rs2703797	ENSG00000261033.1	RP11-209D14.2	3.61	0.000345	0.0385	0.19	0.16	Obesity-related traits;	chr17:20176988	chr17:20008051~20009234:-
HNSC	cis	rs2304003	0.528	rs7577371	ENSG00000235192.1	AC009495.2	3.61	0.000345	0.0385	0.22	0.16	Social communication problems;	chr2:165873172	chr2:165794851~165810010:+
HNSC	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-3.61	0.000345	0.0385	-0.2	-0.16	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
HNSC	cis	rs875971	1	rs3981131	ENSG00000232559.3	GS1-124K5.12	3.61	0.000345	0.0385	0.18	0.16	Aortic root size;	chr7:66486690	chr7:66554588~66576923:-
HNSC	cis	rs1513670	1	rs1969505	ENSG00000260793.2	RP5-882C2.2	3.61	0.000345	0.0385	0.15	0.16	Bone mineral density (hip);	chr17:43733206	chr17:44221401~44223710:+
HNSC	cis	rs8062405	1	rs62037371	ENSG00000261089.1	RP11-435I10.3	3.61	0.000345	0.0385	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28413703~28415018:+
HNSC	cis	rs911555	0.504	rs4444269	ENSG00000269940.1	RP11-73M18.7	3.61	0.000345	0.0385	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103694560~103695170:+
HNSC	cis	rs911555	0.504	rs8021368	ENSG00000269940.1	RP11-73M18.7	3.61	0.000345	0.0385	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103694560~103695170:+
HNSC	cis	rs793571	0.822	rs592407	ENSG00000245975.2	RP11-30K9.6	3.61	0.000345	0.0385	0.27	0.16	Schizophrenia;	chr15:58865341	chr15:58768072~58770974:-
HNSC	cis	rs1440410	0.83	rs1440411	ENSG00000250326.1	RP11-284M14.1	-3.61	0.000345	0.0385	-0.18	-0.16	Ischemic stroke;	chr4:143237132	chr4:142933195~143184861:-
HNSC	cis	rs9457247	1	rs408918	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000345	0.0385	-0.17	-0.16	Crohn's disease;	chr6:166985794	chr6:166969626~166999065:-
HNSC	cis	rs67311347	1	rs9854493	ENSG00000280739.1	EIF1B-AS1	3.61	0.000345	0.0385	0.2	0.16	Renal cell carcinoma;	chr3:40382131	chr3:40173145~40309698:-
HNSC	cis	rs750460	0.966	rs4243042	ENSG00000261801.4	LOXL1-AS1	3.61	0.000345	0.0385	0.15	0.16	Height;	chr15:73949283	chr15:73908071~73928248:-
HNSC	cis	rs3748656	1	rs12133583	ENSG00000273483.1	RP4-671G15.2	3.61	0.000345	0.0385	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112698168	chr1:112517799~112518441:-
HNSC	cis	rs13178541	0.81	rs11959218	ENSG00000250378.1	RP11-119J18.1	-3.61	0.000345	0.0385	-0.22	-0.16	IgG glycosylation;	chr5:135809526	chr5:135812667~135826582:+
HNSC	cis	rs875971	0.964	rs697969	ENSG00000272831.1	RP11-792A8.4	-3.61	0.000345	0.0385	-0.14	-0.16	Aortic root size;	chr7:66093491	chr7:66739829~66740385:-
HNSC	cis	rs875971	1	rs1182882	ENSG00000272831.1	RP11-792A8.4	-3.61	0.000345	0.0385	-0.14	-0.16	Aortic root size;	chr7:66097076	chr7:66739829~66740385:-
HNSC	cis	rs11756659	0.653	rs185635	ENSG00000272810.1	U91328.22	3.61	0.000345	0.0385	0.18	0.16	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:26013241~26013757:+
HNSC	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-3.61	0.000345	0.0385	-0.18	-0.16	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
HNSC	cis	rs734999	0.588	rs11585048	ENSG00000238164.5	RP3-395M20.8	-3.61	0.000345	0.0385	-0.12	-0.16	Ulcerative colitis;	chr1:2602648	chr1:2549920~2557031:-
HNSC	cis	rs225675	0.739	rs225606	ENSG00000229017.5	LINC01277	3.61	0.000345	0.0385	0.21	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142132770	chr6:142966421~143038077:-
HNSC	cis	rs2439831	0.85	rs3825783	ENSG00000201136.1	RNU6-353P	-3.61	0.000345	0.0385	-0.26	-0.16	Lung cancer in ever smokers;	chr15:43810111	chr15:43702363~43702470:+
HNSC	cis	rs225245	1	rs225245	ENSG00000270977.1	AC015849.16	3.61	0.000345	0.0385	0.16	0.16	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35619088	chr17:35893707~35911023:-
HNSC	cis	rs748404	0.666	rs72709879	ENSG00000166763.7	STRCP1	3.61	0.000345	0.0385	0.23	0.16	Lung cancer;	chr15:43507777	chr15:43699488~43718184:-
HNSC	cis	rs228614	0.51	rs223378	ENSG00000230069.3	LRRC37A15P	-3.61	0.000345	0.0385	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102727274~102730721:-
HNSC	cis	rs7772486	0.686	rs9497380	ENSG00000270638.1	RP3-466P17.1	3.61	0.000345	0.0385	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145735570~145737218:+
HNSC	cis	rs7107174	1	rs2450128	ENSG00000251323.2	RP11-452H21.4	3.61	0.000345	0.0385	0.25	0.16	Testicular germ cell tumor;	chr11:78229029	chr11:78423982~78429836:-
HNSC	cis	rs2337406	0.925	rs873533	ENSG00000211972.2	IGHV3-66	3.61	0.000345	0.0385	0.17	0.16	Alzheimer's disease (late onset);	chr14:106667442	chr14:106675017~106675544:-
HNSC	cis	rs13113518	0.51	rs10049561	ENSG00000249700.7	SRD5A3-AS1	3.61	0.000345	0.0386	0.19	0.16	Height;	chr4:55426623	chr4:55363971~55395847:-
HNSC	cis	rs6545883	0.894	rs7566035	ENSG00000271889.1	RP11-493E12.1	-3.61	0.000345	0.0386	-0.19	-0.16	Tuberculosis;	chr2:61293680	chr2:61151433~61162105:-
HNSC	cis	rs847649	1	rs1100046	ENSG00000239969.4	RP11-163E9.2	-3.61	0.000345	0.0386	-0.19	-0.16	Morning vs. evening chronotype;	chr7:102908848	chr7:102364162~102380633:+
HNSC	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	3.61	0.000345	0.0386	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
HNSC	cis	rs6554196	0.895	rs759083	ENSG00000272650.1	RP11-571I18.4	3.61	0.000345	0.0386	0.19	0.16	Monocyte count;	chr4:54671315	chr4:53997415~53997712:-
HNSC	cis	rs1008375	0.932	rs4698650	ENSG00000249502.1	AC006160.5	-3.61	0.000346	0.0386	-0.17	-0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691255	chr4:17587467~17614571:-
HNSC	cis	rs9505118	1	rs11071	ENSG00000238221.1	RP11-69L16.4	3.61	0.000346	0.0386	0.2	0.16	Type 2 diabetes;	chr6:7288311	chr6:7276031~7298872:+
HNSC	cis	rs8072100	0.811	rs1912483	ENSG00000263293.2	RP11-290H9.4	3.61	0.000346	0.0386	0.18	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47303460~47323613:-
HNSC	cis	rs11871801	0.517	rs34855406	ENSG00000267151.3	RP11-100E5.2	3.61	0.000346	0.0386	0.24	0.16	Crohn's disease;	chr17:42579393	chr17:43444707~43451200:+
HNSC	cis	rs11098499	0.874	rs6832670	ENSG00000250412.1	KLHL2P1	3.61	0.000346	0.0386	0.21	0.16	Corneal astigmatism;	chr4:119197637	chr4:119334329~119378233:+
HNSC	cis	rs1862618	0.641	rs2591954	ENSG00000265665.1	AC008391.1	-3.61	0.000346	0.0386	-0.21	-0.16	Initial pursuit acceleration;	chr5:56949217	chr5:56457038~56457138:-
HNSC	cis	rs728616	0.558	rs12414691	ENSG00000225484.5	NUTM2B-AS1	-3.61	0.000346	0.0386	-0.3	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.558	rs12767261	ENSG00000225484.5	NUTM2B-AS1	-3.61	0.000346	0.0386	-0.3	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.558	rs2343302	ENSG00000225484.5	NUTM2B-AS1	-3.61	0.000346	0.0386	-0.3	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79663088~79826594:-
HNSC	cis	rs683257	1	rs72990174	ENSG00000234147.1	RP3-460G2.2	-3.61	0.000346	0.0386	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140879827	chr6:140845958~140852924:-
HNSC	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-3.6	0.000346	0.0386	-0.2	-0.16	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
HNSC	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-3.6	0.000346	0.0386	-0.2	-0.16	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
HNSC	cis	rs5758511	0.689	rs45441993	ENSG00000227370.1	RP4-669P10.19	3.6	0.000346	0.0386	0.21	0.16	Birth weight;	chr22:42075734	chr22:42132543~42132998:+
HNSC	cis	rs870825	0.616	rs7659201	ENSG00000254233.1	RP11-242J7.1	3.6	0.000346	0.0386	0.24	0.16	Blood protein levels;	chr4:184710859	chr4:184584093~184625030:-
HNSC	cis	rs2919917	0.628	rs10111658	ENSG00000260398.1	RP11-594N15.3	3.6	0.000346	0.0386	0.22	0.16	Lymphocyte counts;	chr8:78652834	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.59	rs10098472	ENSG00000260398.1	RP11-594N15.3	3.6	0.000346	0.0386	0.22	0.16	Lymphocyte counts;	chr8:78652955	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.628	rs13265305	ENSG00000260398.1	RP11-594N15.3	3.6	0.000346	0.0386	0.22	0.16	Lymphocyte counts;	chr8:78656575	chr8:78605952~78609705:+
HNSC	cis	rs5758659	1	rs5751255	ENSG00000273366.1	CTA-989H11.1	-3.6	0.000346	0.0386	-0.19	-0.16	Cognitive function;	chr22:42252402	chr22:42278188~42278846:+
HNSC	cis	rs6088580	0.634	rs6059866	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000346	0.0386	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:33985617~33988989:-
HNSC	cis	rs6600671	1	rs6600669	ENSG00000272583.1	RP11-344P13.6	-3.6	0.000346	0.0386	-0.19	-0.16	Hip geometry;	chr1:121471785	chr1:121518366~121518829:-
HNSC	cis	rs72627123	0.5	rs67852564	ENSG00000258769.1	RAP1AP	-3.6	0.000346	0.0386	-0.21	-0.16	Morning vs. evening chronotype;	chr14:74093217	chr14:74482985~74483435:+
HNSC	cis	rs10504130	0.569	rs12678646	ENSG00000253844.1	RP11-546K22.1	-3.6	0.000346	0.0386	-0.24	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51961458~52022974:+
HNSC	cis	rs208623	1	rs208623	ENSG00000237296.8	SMG1P1	-3.6	0.000346	0.0386	-0.21	-0.16	CTACK levels;	chr16:22933272	chr16:22437008~22492220:+
HNSC	cis	rs6545883	0.859	rs13004855	ENSG00000271889.1	RP11-493E12.1	-3.6	0.000346	0.0386	-0.19	-0.16	Tuberculosis;	chr2:61277937	chr2:61151433~61162105:-
HNSC	cis	rs1155750	0.766	rs239793	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000346	0.0386	-0.23	-0.16	Colorectal cancer;	chr6:54937431	chr6:54840118~54840855:-
HNSC	cis	rs481331	0.799	rs210269	ENSG00000215146.4	RP11-313J2.1	-3.6	0.000346	0.0386	-0.31	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42505999	chr10:42331866~42367974:-
HNSC	cis	rs1881509	0.702	rs6578333	ENSG00000255153.1	TOLLIP-AS1	-3.6	0.000346	0.0386	-0.18	-0.16	Heroin dependence;	chr11:1415484	chr11:1309769~1310707:+
HNSC	cis	rs57221529	0.766	rs12519469	ENSG00000225138.6	CTD-2228K2.7	3.6	0.000346	0.0386	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:581657	chr5:473236~480884:+
HNSC	cis	rs3947	1	rs1736084	ENSG00000269918.1	AF131215.9	-3.6	0.000346	0.0386	-0.2	-0.16	Blood protein levels;	chr8:11846148	chr8:11104691~11106704:-
HNSC	cis	rs3947	1	rs1736085	ENSG00000269918.1	AF131215.9	-3.6	0.000346	0.0386	-0.2	-0.16	Blood protein levels;	chr8:11846150	chr8:11104691~11106704:-
HNSC	cis	rs11002791	0.579	rs11814929	ENSG00000224596.6	ZMIZ1-AS1	3.6	0.000346	0.0386	0.2	0.16	Red blood cell count;	chr10:79032176	chr10:78943328~79067895:-
HNSC	cis	rs7804306	0.522	rs34261596	ENSG00000233264.2	AC006042.8	3.6	0.000346	0.0386	0.26	0.16	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036054	chr7:7980312~7982228:+
HNSC	cis	rs8030379	1	rs8041056	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000346	0.0386	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs7162129	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000346	0.0386	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84507885~84516814:-
HNSC	cis	rs2337406	1	rs11849532	ENSG00000211972.2	IGHV3-66	3.6	0.000346	0.0386	0.17	0.16	Alzheimer's disease (late onset);	chr14:106669877	chr14:106675017~106675544:-
HNSC	cis	rs397969	0.646	rs1638528	ENSG00000266126.1	RP11-209D14.4	3.6	0.000346	0.0386	0.2	0.16	Platelet count;	chr17:19934616	chr17:19929372~19929737:-
HNSC	cis	rs436483	0.932	rs405779	ENSG00000213385.3	RP11-577H5.1	-3.6	0.000346	0.0386	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr7:102070952	chr7:102755146~102755939:+
HNSC	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-3.6	0.000346	0.0387	-0.24	-0.16	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
HNSC	cis	rs9505118	1	rs60066572	ENSG00000238221.1	RP11-69L16.4	3.6	0.000346	0.0387	0.21	0.16	Type 2 diabetes;	chr6:7292441	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs60562190	ENSG00000238221.1	RP11-69L16.4	3.6	0.000346	0.0387	0.21	0.16	Type 2 diabetes;	chr6:7292479	chr6:7276031~7298872:+
HNSC	cis	rs6715284	0.786	rs1009276	ENSG00000183308.6	AC005037.3	-3.6	0.000347	0.0387	-0.37	-0.16	Rheumatoid arthritis;	chr2:201458233	chr2:200963263~201009102:+
HNSC	cis	rs9922134	1	rs13332819	ENSG00000261235.1	RP11-510J16.5	-3.6	0.000347	0.0387	-0.32	-0.16	Maximal oxygen uptake response;	chr16:83108455	chr16:82044336~82139631:-
HNSC	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	3.6	0.000347	0.0387	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
HNSC	cis	rs924607	0.898	rs1697990	ENSG00000225138.6	CTD-2228K2.7	-3.6	0.000347	0.0387	-0.17	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:626163	chr5:473236~480884:+
HNSC	cis	rs9611565	0.513	rs739135	ENSG00000213857.3	RP11-12M9.4	-3.6	0.000347	0.0387	-0.22	-0.16	Vitiligo;	chr22:41694065	chr22:41074180~41075239:-
HNSC	cis	rs4822044	0.68	rs8138780	ENSG00000213857.3	RP11-12M9.4	-3.6	0.000347	0.0387	-0.22	-0.16	Cannabis dependence symptom count;	chr22:41701458	chr22:41074180~41075239:-
HNSC	cis	rs2048656	0.501	rs13276750	ENSG00000254340.1	RP11-10A14.3	-3.6	0.000347	0.0387	-0.23	-0.16	Schizophrenia;	chr8:9616699	chr8:9141424~9145435:+
HNSC	cis	rs6012564	0.964	rs2064853	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000347	0.0387	-0.18	-0.16	Anger;	chr20:49058639	chr20:49040463~49046044:-
HNSC	cis	rs7824557	0.602	rs7817658	ENSG00000269918.1	AF131215.9	3.6	0.000347	0.0387	0.16	0.16	Retinal vascular caliber;	chr8:11349034	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.568	rs35747588	ENSG00000269918.1	AF131215.9	3.6	0.000347	0.0387	0.16	0.16	Retinal vascular caliber;	chr8:11349118	chr8:11104691~11106704:-
HNSC	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-3.6	0.000347	0.0387	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
HNSC	cis	rs10463554	0.853	rs246903	ENSG00000250682.4	LINC00491	3.6	0.000347	0.0387	0.21	0.16	Parkinson's disease;	chr5:103253753	chr5:102609156~102671559:-
HNSC	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-3.6	0.000347	0.0387	-0.19	-0.16	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
HNSC	cis	rs62005083	0.5	rs10135300	ENSG00000258769.1	RAP1AP	-3.6	0.000347	0.0387	-0.21	-0.16	Mean corpuscular volume;	chr14:74107858	chr14:74482985~74483435:+
HNSC	cis	rs4704187	0.687	rs10058460	ENSG00000272040.1	CTC-366B18.4	-3.6	0.000347	0.0387	-0.15	-0.16	Response to amphetamines;	chr5:75202890	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6891023	ENSG00000272040.1	CTC-366B18.4	-3.6	0.000347	0.0387	-0.15	-0.16	Response to amphetamines;	chr5:75204930	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs10051040	ENSG00000272040.1	CTC-366B18.4	-3.6	0.000347	0.0387	-0.15	-0.16	Response to amphetamines;	chr5:75206151	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs1592948	ENSG00000272040.1	CTC-366B18.4	-3.6	0.000347	0.0387	-0.15	-0.16	Response to amphetamines;	chr5:75208327	chr5:75608817~75609983:+
HNSC	cis	rs748404	0.65	rs518234	ENSG00000224055.1	GAPDHP55	3.6	0.000347	0.0387	0.19	0.16	Lung cancer;	chr15:43281223	chr15:44063511~44064313:+
HNSC	cis	rs748404	0.65	rs518261	ENSG00000224055.1	GAPDHP55	3.6	0.000347	0.0387	0.19	0.16	Lung cancer;	chr15:43281231	chr15:44063511~44064313:+
HNSC	cis	rs8010715	1	rs3742500	ENSG00000259321.1	RP11-468E2.5	3.6	0.000347	0.0387	0.15	0.16	IgG glycosylation;	chr14:24142769	chr14:24139445~24140444:+
HNSC	cis	rs6860540	0.687	rs6871720	ENSG00000251405.2	CTB-109A12.1	-3.6	0.000347	0.0387	-0.19	-0.16	Inflammatory skin disease;	chr5:157447457	chr5:157362615~157460078:-
HNSC	cis	rs1065852	0.51	rs5751247	ENSG00000270083.1	RP1-257I20.14	-3.6	0.000347	0.0387	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42089630~42090028:-
HNSC	cis	rs7674212	0.507	rs223322	ENSG00000248740.4	RP11-328K4.1	3.6	0.000347	0.0387	0.18	0.16	Type 2 diabetes;	chr4:102879037	chr4:103256159~103453658:+
HNSC	cis	rs683257	1	rs117661682	ENSG00000234147.1	RP3-460G2.2	-3.6	0.000347	0.0387	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140832838	chr6:140845958~140852924:-
HNSC	cis	rs4776970	0.632	rs3784706	ENSG00000270964.1	RP11-502I4.3	-3.6	0.000347	0.0387	-0.17	-0.16	Body mass index;Waist circumference;	chr15:67737411	chr15:67541072~67542604:-
HNSC	cis	rs6142618	0.846	rs6061216	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000347	0.0387	-0.17	-0.16	Inflammatory bowel disease;	chr20:32194310	chr20:32116171~32116629:+
HNSC	cis	rs79349575	0.756	rs2291726	ENSG00000270781.1	RP11-501C14.9	3.6	0.000347	0.0387	0.17	0.16	Type 2 diabetes;	chr17:48961892	chr17:48899131~48899748:+
HNSC	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-3.6	0.000347	0.0387	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
HNSC	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	3.6	0.000347	0.0387	0.2	0.16	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	3.6	0.000347	0.0387	0.2	0.16	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
HNSC	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-3.6	0.000348	0.0388	-0.22	-0.16	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
HNSC	cis	rs2436845	1	rs2436845	ENSG00000253669.3	KB-1732A1.1	-3.6	0.000348	0.0388	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840179	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs2436846	ENSG00000253669.3	KB-1732A1.1	-3.6	0.000348	0.0388	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840181	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs2513913	ENSG00000253669.3	KB-1732A1.1	-3.6	0.000348	0.0388	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102842878	chr8:102805517~102809971:+
HNSC	cis	rs2554380	0.55	rs4842918	ENSG00000259570.1	RP11-671M22.4	-3.6	0.000348	0.0388	-0.21	-0.16	Height;	chr15:83868247	chr15:84394512~84395514:+
HNSC	cis	rs12545912	0.569	rs582027	ENSG00000254340.1	RP11-10A14.3	-3.6	0.000348	0.0388	-0.25	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9936525	chr8:9141424~9145435:+
HNSC	cis	rs224278	0.509	rs7073383	ENSG00000238280.1	RP11-436D10.3	-3.6	0.000348	0.0388	-0.24	-0.16	Ewing sarcoma;	chr10:62961149	chr10:62793562~62805887:-
HNSC	cis	rs55975637	0.73	rs13082798	ENSG00000240476.1	LINC00973	3.6	0.000348	0.0388	0.29	0.16	Advanced age-related macular degeneration;	chr3:99674707	chr3:98981058~98983096:+
HNSC	cis	rs13070279	0.655	rs11927001	ENSG00000241163.6	LINC00877	3.6	0.000348	0.0388	0.25	0.16	Monocyte count;	chr3:71746073	chr3:72035300~72279503:-
HNSC	cis	rs71636778	0.509	rs6656815	ENSG00000260063.1	RP5-968P14.2	-3.6	0.000348	0.0388	-0.33	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26965971	chr1:26692132~26694131:-
HNSC	cis	rs250677	0.687	rs250667	ENSG00000250072.4	CTC-529P8.1	3.6	0.000348	0.0388	0.21	0.16	Breast cancer;	chr5:149075571	chr5:149063317~149109787:+
HNSC	cis	rs2307394	0.716	rs13012344	ENSG00000281469.1	RP11-567F11.1	3.6	0.000348	0.0388	0.19	0.16	Urate levels;	chr2:147736470	chr2:148044380~148044894:+
HNSC	cis	rs3018712	0.532	rs2513294	ENSG00000255031.4	RP11-802E16.3	-3.6	0.000348	0.0388	-0.18	-0.16	Total body bone mineral density;	chr11:68653726	chr11:68050740~68053762:+
HNSC	cis	rs11098499	0.874	rs13139045	ENSG00000250412.1	KLHL2P1	3.6	0.000348	0.0388	0.21	0.16	Corneal astigmatism;	chr4:119247433	chr4:119334329~119378233:+
HNSC	cis	rs180730	0.861	rs4833694	ENSG00000251609.2	SETP12	3.6	0.000348	0.0388	0.23	0.16	Fasting plasma glucose;	chr4:120928563	chr4:120895494~120897083:-
HNSC	cis	rs73198271	1	rs11775821	ENSG00000173295.6	FAM86B3P	-3.6	0.000348	0.0388	-0.22	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8228595~8244865:+
HNSC	cis	rs2032366	1	rs1840047	ENSG00000267279.1	RP11-879F14.2	-3.6	0.000348	0.0388	-0.2	-0.16	Obesity-related traits;	chr18:61591312	chr18:61585746~61606916:-
HNSC	cis	rs804280	0.662	rs804283	ENSG00000255354.1	RP11-148O21.2	-3.6	0.000348	0.0388	-0.16	-0.16	Myopia (pathological);	chr8:11753534	chr8:11558466~11560020:-
HNSC	cis	rs9467711	0.606	rs13190739	ENSG00000241549.7	GUSBP2	3.6	0.000348	0.0388	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:26871484~26956554:-
HNSC	cis	rs9911578	0.933	rs74370218	ENSG00000224738.1	AC099850.1	-3.6	0.000348	0.0388	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59017851	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.803	rs8069033	ENSG00000224738.1	AC099850.1	-3.6	0.000348	0.0388	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59054220	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.967	rs6503893	ENSG00000224738.1	AC099850.1	3.6	0.000348	0.0388	0.17	0.16	Intelligence (multi-trait analysis);	chr17:59072334	chr17:59106598~59118267:+
HNSC	cis	rs6460942	0.597	rs13232817	ENSG00000226690.5	AC005281.1	3.6	0.000348	0.0388	0.27	0.16	Coronary artery disease;	chr7:12512283	chr7:12496429~12541910:+
HNSC	cis	rs7735319	0.546	rs10073673	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33120279	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.584	rs1979419	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33121553	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs1981968	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33121891	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs10058070	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33132706	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs10059641	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33132816	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.546	rs1834962	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33134513	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs4541672	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33135825	chr5:33008994~33025724:+
HNSC	cis	rs7735319	0.565	rs4478335	ENSG00000249102.1	CTD-2066L21.1	3.6	0.000348	0.0388	0.18	0.16	Systolic blood pressure;	chr5:33138242	chr5:33008994~33025724:+
HNSC	cis	rs4704846	0.646	rs6879197	ENSG00000253519.1	AC106801.1	-3.6	0.000348	0.0388	-0.23	-0.16	Blood protein levels;	chr5:157075867	chr5:157565964~157569098:+
HNSC	cis	rs6787172	0.72	rs1714509	ENSG00000272087.1	RP11-379F4.7	3.6	0.000348	0.0388	0.17	0.16	Subjective well-being;	chr3:158535169	chr3:158693120~158693768:-
HNSC	cis	rs544991	0.687	rs10914773	ENSG00000239670.1	RP4-803A2.2	3.6	0.000348	0.0388	0.2	0.16	Intelligence;	chr1:33749459	chr1:32986952~32988233:+
HNSC	cis	rs66887589	0.934	rs7681980	ENSG00000249244.1	RP11-548H18.2	-3.6	0.000348	0.0388	-0.18	-0.16	Diastolic blood pressure;	chr4:119612068	chr4:119391831~119395335:-
HNSC	cis	rs8030379	1	rs10152139	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000348	0.0388	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901510	chr15:84507885~84516814:-
HNSC	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	3.6	0.000348	0.0388	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
HNSC	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	3.6	0.000348	0.0388	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
HNSC	cis	rs449789	0.857	rs1553482	ENSG00000235086.1	FNDC1-IT1	-3.6	0.000348	0.0388	-0.2	-0.16	Pulse pressure;	chr6:159301115	chr6:159240786~159243329:+
HNSC	cis	rs546131	0.571	rs4351790	ENSG00000271369.1	RP11-350D17.3	-3.6	0.000348	0.0388	-0.21	-0.16	Lung disease severity in cystic fibrosis;	chr11:34835344	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.571	rs4593984	ENSG00000271369.1	RP11-350D17.3	-3.6	0.000348	0.0388	-0.21	-0.16	Lung disease severity in cystic fibrosis;	chr11:34835387	chr11:34709600~34710161:+
HNSC	cis	rs546131	0.571	rs2421741	ENSG00000271369.1	RP11-350D17.3	-3.6	0.000348	0.0388	-0.21	-0.16	Lung disease severity in cystic fibrosis;	chr11:34835429	chr11:34709600~34710161:+
HNSC	cis	rs72949976	0.678	rs7573232	ENSG00000270659.1	RP11-105N14.1	3.6	0.000348	0.0388	0.17	0.16	Squamous cell lung carcinoma;Lung cancer;	chr2:213175701	chr2:213152970~213153659:+
HNSC	cis	rs62458065	0.64	rs4141788	ENSG00000226468.2	AC018641.7	3.6	0.000349	0.0388	0.29	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32479652	chr7:32456963~32457758:-
HNSC	cis	rs988913	0.678	rs4428503	ENSG00000224984.1	RP11-524H19.2	3.6	0.000349	0.0388	0.19	0.16	Menarche (age at onset);	chr6:55133550	chr6:54840118~54840855:-
HNSC	cis	rs889398	0.802	rs12921407	ENSG00000196696.11	PDXDC2P	3.6	0.000349	0.0388	0.11	0.16	Body mass index;	chr16:69827030	chr16:69976297~70065948:-
HNSC	cis	rs4489787	1	rs2956716	ENSG00000257763.1	OR5BK1P	3.6	0.000349	0.0388	0.26	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48462400	chr12:48355792~48356614:-
HNSC	cis	rs6545883	1	rs778758	ENSG00000271889.1	RP11-493E12.1	3.6	0.000349	0.0389	0.19	0.16	Tuberculosis;	chr2:61555026	chr2:61151433~61162105:-
HNSC	cis	rs847649	0.692	rs7800548	ENSG00000239969.4	RP11-163E9.2	3.6	0.000349	0.0389	0.18	0.16	Morning vs. evening chronotype;	chr7:102841395	chr7:102364162~102380633:+
HNSC	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-3.6	0.000349	0.0389	-0.14	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
HNSC	cis	rs41369048	1	rs2738751	ENSG00000238078.1	LINC01352	-3.6	0.000349	0.0389	-0.22	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220878371	chr1:220829255~220832429:+
HNSC	cis	rs6988985	0.678	rs6651273	ENSG00000247317.3	RP11-273G15.2	-3.6	0.000349	0.0389	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905084	chr8:142981738~143018437:-
HNSC	cis	rs6988985	0.765	rs6471581	ENSG00000247317.3	RP11-273G15.2	-3.6	0.000349	0.0389	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905503	chr8:142981738~143018437:-
HNSC	cis	rs8072100	0.935	rs12150231	ENSG00000263293.2	RP11-290H9.4	-3.6	0.000349	0.0389	-0.18	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47303460~47323613:-
HNSC	cis	rs11711311	0.712	rs3773684	ENSG00000241529.3	RN7SL767P	3.6	0.000349	0.0389	0.22	0.16	IgG glycosylation;	chr3:113615641	chr3:113632704~113632998:+
HNSC	cis	rs6867032	0.527	rs4246752	ENSG00000248597.1	RP11-259O2.2	3.6	0.000349	0.0389	0.23	0.16	Gut microbiome composition (winter);	chr5:1975461	chr5:1963609~1967154:-
HNSC	cis	rs6995541	0.776	rs10105487	ENSG00000269918.1	AF131215.9	-3.6	0.000349	0.0389	-0.17	-0.16	Triglyceride levels;	chr8:10811241	chr8:11104691~11106704:-
HNSC	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	3.6	0.000349	0.0389	0.16	0.16	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
HNSC	cis	rs12817549	0.781	rs7969076	ENSG00000213250.5	RBMS2P1	3.6	0.000349	0.0389	0.15	0.16	Hip circumference adjusted for BMI;	chr12:93702266	chr12:94423744~94424969:-
HNSC	cis	rs67311347	0.866	rs2371183	ENSG00000280739.1	EIF1B-AS1	-3.6	0.000349	0.0389	-0.17	-0.16	Renal cell carcinoma;	chr3:40292756	chr3:40173145~40309698:-
HNSC	cis	rs1440410	0.798	rs10026015	ENSG00000250326.1	RP11-284M14.1	-3.6	0.000349	0.0389	-0.18	-0.16	Ischemic stroke;	chr4:143248486	chr4:142933195~143184861:-
HNSC	cis	rs4381823	1	rs74414802	ENSG00000230979.3	AC079250.1	-3.6	0.000349	0.0389	-0.27	-0.16	Schizophrenia;	chr2:47833737	chr2:47690716~47691246:-
HNSC	cis	rs7772486	0.625	rs9390355	ENSG00000270638.1	RP3-466P17.1	-3.6	0.000349	0.0389	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.658	rs4895683	ENSG00000270638.1	RP3-466P17.1	-3.6	0.000349	0.0389	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.625	rs2050027	ENSG00000270638.1	RP3-466P17.1	-3.6	0.000349	0.0389	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145735570~145737218:+
HNSC	cis	rs6088580	0.634	rs3736762	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000349	0.0389	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6120650	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000349	0.0389	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6058051	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000349	0.0389	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6059860	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000349	0.0389	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:33985617~33988989:-
HNSC	cis	rs10875746	0.951	rs10875756	ENSG00000257763.1	OR5BK1P	-3.6	0.000349	0.0389	-0.21	-0.16	Longevity (90 years and older);	chr12:48168521	chr12:48355792~48356614:-
HNSC	cis	rs17507216	0.628	rs17158396	ENSG00000276710.3	CSPG4P8	-3.6	0.00035	0.0389	-0.22	-0.16	Excessive daytime sleepiness;	chr15:82615688	chr15:82459472~82477258:+
HNSC	cis	rs6142618	0.846	rs6058569	ENSG00000275576.1	RP5-836N17.4	-3.6	0.00035	0.0389	-0.17	-0.16	Inflammatory bowel disease;	chr20:32230016	chr20:32116171~32116629:+
HNSC	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-3.6	0.00035	0.0389	-0.26	-0.16	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
HNSC	cis	rs2908197	0.806	rs2961047	ENSG00000186704.9	DTX2P1	3.6	0.00035	0.0389	0.16	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76305739	chr7:76978617~77004308:+
HNSC	cis	rs1008375	1	rs11947857	ENSG00000249502.1	AC006160.5	3.6	0.00035	0.0389	0.18	0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689424	chr4:17587467~17614571:-
HNSC	cis	rs1912483	0.505	rs11079772	ENSG00000263293.2	RP11-290H9.4	-3.6	0.00035	0.0389	-0.19	-0.16	Coronary artery disease;	chr17:47316373	chr17:47303460~47323613:-
HNSC	cis	rs3740713	1	rs12289603	ENSG00000256464.1	YWHABP2	3.6	0.00035	0.0389	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr11:18490243~18490955:-
HNSC	cis	rs7558911	0.801	rs13006529	ENSG00000183308.6	AC005037.3	3.6	0.00035	0.039	0.19	0.16	Chronic lymphocytic leukemia;	chr2:201217736	chr2:200963263~201009102:+
HNSC	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	3.6	0.00035	0.039	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
HNSC	cis	rs853679	0.607	rs34950484	ENSG00000280107.1	AL022393.9	-3.6	0.00035	0.039	-0.28	-0.16	Depression;	chr6:28310911	chr6:28170845~28172521:+
HNSC	cis	rs1387259	0.64	rs10783243	ENSG00000240399.1	RP1-228P16.1	-3.6	0.00035	0.039	-0.14	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48054813~48055591:-
HNSC	cis	rs6088580	0.634	rs6059779	ENSG00000276073.1	RP5-1125A11.7	3.6	0.00035	0.039	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:33985617~33988989:-
HNSC	cis	rs28830936	0.966	rs2303518	ENSG00000250379.1	RP11-23P13.4	3.6	0.00035	0.039	0.19	0.16	Diastolic blood pressure;	chr15:41817777	chr15:41825099~41827936:-
HNSC	cis	rs4906332	0.811	rs2296487	ENSG00000269910.1	RP11-73M18.10	3.6	0.00035	0.039	0.18	0.16	Coronary artery disease;	chr14:103529868	chr14:103694516~103695050:-
HNSC	cis	rs7630852	0.841	rs9325377	ENSG00000236833.1	AC024560.2	3.6	0.00035	0.039	0.17	0.16	Eosinophil counts;	chr3:196779282	chr3:197660565~197665757:-
HNSC	cis	rs300890	0.76	rs6823434	ENSG00000250326.1	RP11-284M14.1	-3.6	0.00035	0.039	-0.18	-0.16	Nasopharyngeal carcinoma;	chr4:143278700	chr4:142933195~143184861:-
HNSC	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	3.6	0.00035	0.039	0.17	0.16	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
HNSC	cis	rs9911578	0.933	rs11868348	ENSG00000224738.1	AC099850.1	3.6	0.00035	0.039	0.17	0.16	Intelligence (multi-trait analysis);	chr17:59101877	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.9	rs8067264	ENSG00000224738.1	AC099850.1	3.6	0.00035	0.039	0.17	0.16	Intelligence (multi-trait analysis);	chr17:59105432	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.967	rs7503190	ENSG00000224738.1	AC099850.1	3.6	0.00035	0.039	0.17	0.16	Intelligence (multi-trait analysis);	chr17:59106801	chr17:59106598~59118267:+
HNSC	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-3.6	0.00035	0.039	-0.17	-0.16	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
HNSC	cis	rs7224685	0.871	rs9892466	ENSG00000240898.1	RP11-48B14.1	3.6	0.00035	0.039	0.14	0.16	Type 2 diabetes;	chr17:4066233	chr17:3665220~3665702:+
HNSC	cis	rs74781061	0.932	rs6495121	ENSG00000260103.2	RP11-10O17.1	-3.6	0.00035	0.039	-0.19	-0.16	Endometriosis;	chr15:74711167	chr15:74478070~74490286:-
HNSC	cis	rs2980439	0.525	rs2945238	ENSG00000233609.3	RP11-62H7.2	3.6	0.00035	0.039	0.16	0.16	Neuroticism;	chr8:8312614	chr8:8961200~8979025:+
HNSC	cis	rs6840360	0.642	rs1596290	ENSG00000251611.1	RP11-610P16.1	-3.6	0.00035	0.039	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151407551~151408835:-
HNSC	cis	rs61776719	0.81	rs34655914	ENSG00000212541.1	RNU6-510P	-3.6	0.00035	0.039	-0.19	-0.16	Coronary artery disease;	chr1:37931669	chr1:37991462~37991569:+
HNSC	cis	rs61776719	0.84	rs35267671	ENSG00000212541.1	RNU6-510P	-3.6	0.00035	0.039	-0.19	-0.16	Coronary artery disease;	chr1:37931697	chr1:37991462~37991569:+
HNSC	cis	rs55702914	0.628	rs67657812	ENSG00000222017.1	AC011997.1	3.6	0.00035	0.039	0.2	0.16	Major depression and alcohol dependence;	chr2:197522677	chr2:197693106~197774823:+
HNSC	cis	rs295490	0.748	rs78681436	ENSG00000272656.1	RP11-219D15.3	3.6	0.00035	0.039	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139349024~139349371:-
HNSC	cis	rs295490	0.748	rs79854429	ENSG00000272656.1	RP11-219D15.3	3.6	0.00035	0.039	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139349024~139349371:-
HNSC	cis	rs804280	0.662	rs810738	ENSG00000255354.1	RP11-148O21.2	-3.6	0.00035	0.039	-0.16	-0.16	Myopia (pathological);	chr8:11753697	chr8:11558466~11560020:-
HNSC	cis	rs2762353	0.505	rs2096386	ENSG00000272462.2	U91328.19	3.6	0.00035	0.039	0.15	0.16	Blood metabolite levels;	chr6:25787589	chr6:25992662~26001775:+
HNSC	cis	rs6142618	0.819	rs6141641	ENSG00000275576.1	RP5-836N17.4	-3.6	0.00035	0.039	-0.17	-0.16	Inflammatory bowel disease;	chr20:32227947	chr20:32116171~32116629:+
HNSC	cis	rs73198271	0.583	rs11781985	ENSG00000173295.6	FAM86B3P	3.6	0.00035	0.039	0.22	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8228595~8244865:+
HNSC	cis	rs6918586	0.565	rs198855	ENSG00000272462.2	U91328.19	-3.6	0.00035	0.039	-0.17	-0.16	Schizophrenia;	chr6:26103170	chr6:25992662~26001775:+
HNSC	cis	rs860818	1	rs858303	ENSG00000226816.2	AC005082.12	3.6	0.00035	0.039	0.4	0.16	Initial pursuit acceleration;	chr7:23203879	chr7:23206013~23208045:+
HNSC	cis	rs9402743	0.775	rs4504492	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135648536	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs2876312	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135648714	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9483862	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135649541	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9494315	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135649778	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.816	rs9402738	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135652112	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.74	rs9494318	ENSG00000234084.1	RP3-388E23.2	-3.6	0.000351	0.039	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135653519	chr6:135301568~135307158:+
HNSC	cis	rs13179617	0.928	rs7719647	ENSG00000215032.2	GNL3LP1	-3.6	0.000351	0.039	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61478141	chr5:60891935~60893577:-
HNSC	cis	rs11951515	0.738	rs55759097	ENSG00000249286.1	CTD-2210P15.2	3.6	0.000351	0.039	0.17	0.16	Metabolite levels  (X-11787);	chr5:43371762	chr5:43586918~43588223:-
HNSC	cis	rs11951515	0.738	rs11950040	ENSG00000249286.1	CTD-2210P15.2	3.6	0.000351	0.039	0.17	0.16	Metabolite levels  (X-11787);	chr5:43372087	chr5:43586918~43588223:-
HNSC	cis	rs9487051	0.646	rs351736	ENSG00000203799.9	CCDC162P	3.6	0.000351	0.039	0.17	0.16	Reticulocyte fraction of red cells;	chr6:109184691	chr6:109285485~109355063:+
HNSC	cis	rs4281086	0.561	rs4997498	ENSG00000269918.1	AF131215.9	3.6	0.000351	0.039	0.17	0.16	Obesity-related traits;	chr8:10495112	chr8:11104691~11106704:-
HNSC	cis	rs8054556	0.787	rs12325539	ENSG00000261367.1	RP11-455F5.4	-3.6	0.000351	0.039	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30107675~30110541:+
HNSC	cis	rs2638953	0.924	rs10843169	ENSG00000257176.2	RP11-996F15.2	-3.6	0.000351	0.039	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:29280418~29317848:-
HNSC	cis	rs5758659	1	rs134869	ENSG00000270083.1	RP1-257I20.14	3.6	0.000351	0.039	0.15	0.16	Cognitive function;	chr22:42256068	chr22:42089630~42090028:-
HNSC	cis	rs2048656	0.561	rs9650639	ENSG00000233609.3	RP11-62H7.2	-3.6	0.000351	0.039	-0.16	-0.16	Schizophrenia;	chr8:9685091	chr8:8961200~8979025:+
HNSC	cis	rs12545912	0.77	rs7003791	ENSG00000233609.3	RP11-62H7.2	-3.6	0.000351	0.039	-0.16	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9687858	chr8:8961200~8979025:+
HNSC	cis	rs7615952	0.546	rs16836896	ENSG00000241288.6	RP11-379B18.5	-3.6	0.000351	0.039	-0.23	-0.16	Blood pressure (smoking interaction);	chr3:125592418	chr3:125827238~125916384:-
HNSC	cis	rs2518049	1	rs7091485	ENSG00000224034.1	RP11-445P17.8	3.6	0.000351	0.039	0.21	0.16	Metabolic traits;	chr10:5103257	chr10:5266033~5271236:-
HNSC	cis	rs17666538	0.71	rs11987001	ENSG00000254207.1	RP11-43A14.1	3.6	0.000351	0.039	0.38	0.16	IgG glycosylation;	chr8:680755	chr8:725188~725877:-
HNSC	cis	rs6095360	1	rs7270848	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49023200	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019591	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49023492	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs66970580	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49024802	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs7262379	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49026042	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.933	rs6019594	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49027017	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019595	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49027495	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6095400	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49029452	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.87	rs6095401	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49030084	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs13042947	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49031339	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019602	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49034955	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs707533	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49035717	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs707534	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49035801	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.901	rs16994347	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49036824	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019603	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49036869	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.966	rs927160	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49038027	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.933	rs3817652	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49046831	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6090939	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49049288	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6012590	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49050700	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.901	rs6012591	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49050805	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs7509369	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49051500	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs2869694	ENSG00000227431.4	CSE1L-AS1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49051846	chr20:49040463~49046044:-
HNSC	cis	rs11098499	0.569	rs10023641	ENSG00000250412.1	KLHL2P1	3.6	0.000351	0.039	0.21	0.16	Corneal astigmatism;	chr4:119337255	chr4:119334329~119378233:+
HNSC	cis	rs4713118	0.911	rs2394000	ENSG00000217862.2	HIST1H4PS1	-3.6	0.000351	0.039	-0.19	-0.16	Parkinson's disease;	chr6:27719212	chr6:27807075~27807339:+
HNSC	cis	rs4713118	0.955	rs9393847	ENSG00000217862.2	HIST1H4PS1	-3.6	0.000351	0.039	-0.19	-0.16	Parkinson's disease;	chr6:27720194	chr6:27807075~27807339:+
HNSC	cis	rs7688540	0.723	rs80316648	ENSG00000250892.1	RP11-1365D11.1	-3.6	0.000351	0.039	-0.28	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:201409~205009:-
HNSC	cis	rs2055729	0.961	rs9918834	ENSG00000254340.1	RP11-10A14.3	3.6	0.000351	0.039	0.21	0.16	Multiple myeloma (hyperdiploidy);	chr8:9933041	chr8:9141424~9145435:+
HNSC	cis	rs13434995	0.842	rs62303709	ENSG00000273257.1	RP11-177J6.1	-3.6	0.000351	0.0391	-0.27	-0.16	Adiponectin levels;	chr4:55449015	chr4:55387949~55388271:+
HNSC	cis	rs10742752	0.702	rs2046733	ENSG00000255267.3	RP11-430H10.2	3.6	0.000351	0.0391	0.22	0.16	Body mass index;	chr11:45426540	chr11:45371397~45388508:+
HNSC	cis	rs4242434	0.536	rs1871900	ENSG00000253837.1	RP11-177H13.2	-3.6	0.000351	0.0391	-0.16	-0.16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22623936	chr8:23336171~23366125:+
HNSC	cis	rs11722779	0.903	rs13130741	ENSG00000248740.4	RP11-328K4.1	3.6	0.000351	0.0391	0.17	0.16	Schizophrenia;	chr4:103035799	chr4:103256159~103453658:+
HNSC	cis	rs11603691	1	rs2155232	ENSG00000254662.1	RP11-872D17.4	-3.6	0.000351	0.0391	-0.33	-0.16	Low high density lipoprotein cholesterol levels;	chr11:57273904	chr11:57325603~57327958:+
HNSC	cis	rs8072100	0.811	rs9889709	ENSG00000263293.2	RP11-290H9.4	3.6	0.000351	0.0391	0.18	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47303460~47323613:-
HNSC	cis	rs12793173	0.711	rs17783405	ENSG00000271369.1	RP11-350D17.3	3.6	0.000351	0.0391	0.23	0.16	Cystic fibrosis severity;	chr11:34805770	chr11:34709600~34710161:+
HNSC	cis	rs9925964	0.9	rs9934438	ENSG00000232748.3	RP11-196G11.6	3.6	0.000351	0.0391	0.22	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:31056460~31062803:+
HNSC	cis	rs734999	0.566	rs4648563	ENSG00000238164.5	RP3-395M20.8	-3.6	0.000351	0.0391	-0.12	-0.16	Ulcerative colitis;	chr1:2604563	chr1:2549920~2557031:-
HNSC	cis	rs6995541	0.737	rs17152576	ENSG00000269918.1	AF131215.9	-3.6	0.000351	0.0391	-0.18	-0.16	Triglyceride levels;	chr8:10826478	chr8:11104691~11106704:-
HNSC	cis	rs643506	0.874	rs609007	ENSG00000230911.1	PPIHP1	3.6	0.000351	0.0391	0.22	0.16	Breast cancer;	chr11:111848870	chr11:112029858~112030367:-
HNSC	cis	rs6088580	0.634	rs1205334	ENSG00000276073.1	RP5-1125A11.7	3.6	0.000351	0.0391	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:33985617~33988989:-
HNSC	cis	rs7819412	0.502	rs11777918	ENSG00000255310.2	AF131215.2	3.6	0.000351	0.0391	0.17	0.16	Triglycerides;	chr8:11179410	chr8:11107788~11109726:-
HNSC	cis	rs67311347	1	rs7634375	ENSG00000280739.1	EIF1B-AS1	3.6	0.000351	0.0391	0.2	0.16	Renal cell carcinoma;	chr3:40390455	chr3:40173145~40309698:-
HNSC	cis	rs1440410	0.835	rs28649839	ENSG00000250326.1	RP11-284M14.1	-3.6	0.000351	0.0391	-0.18	-0.16	Ischemic stroke;	chr4:143225047	chr4:142933195~143184861:-
HNSC	cis	rs9813712	0.78	rs7625942	ENSG00000228252.7	COL6A4P2	3.6	0.000351	0.0391	0.18	0.16	Response to amphetamines;	chr3:130232611	chr3:130212823~130273806:+
HNSC	cis	rs55975637	0.73	rs34259523	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99709496	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs35492383	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99712049	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs62283465	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99714088	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs35170022	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99714937	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs79611082	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99721399	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs75422650	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99721498	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs62283470	ENSG00000240476.1	LINC00973	3.6	0.000351	0.0391	0.31	0.16	Advanced age-related macular degeneration;	chr3:99728928	chr3:98981058~98983096:+
HNSC	cis	rs6968419	0.755	rs3823977	ENSG00000237870.5	AC073130.1	3.6	0.000351	0.0391	0.2	0.16	Intraocular pressure;	chr7:116253353	chr7:116275606~116286734:-
HNSC	cis	rs10463554	0.526	rs114525197	ENSG00000250682.4	LINC00491	3.6	0.000352	0.0391	0.22	0.16	Parkinson's disease;	chr5:103107341	chr5:102609156~102671559:-
HNSC	cis	rs7824557	0.564	rs11782430	ENSG00000269918.1	AF131215.9	-3.6	0.000352	0.0391	-0.16	-0.16	Retinal vascular caliber;	chr8:11368562	chr8:11104691~11106704:-
HNSC	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	3.6	0.000352	0.0391	0.23	0.16	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
HNSC	cis	rs1538970	0.962	rs7532762	ENSG00000234329.1	RP11-767N6.2	3.6	0.000352	0.0391	0.19	0.16	Platelet count;	chr1:45399023	chr1:45651039~45651826:-
HNSC	cis	rs4908760	0.731	rs12075458	ENSG00000232912.4	RP5-1115A15.1	3.6	0.000352	0.0391	0.17	0.16	Vitiligo;	chr1:8698735	chr1:8424645~8434838:+
HNSC	cis	rs2898681	1	rs2411281	ENSG00000248375.1	RP11-177B4.1	-3.6	0.000352	0.0391	-0.25	-0.16	Optic nerve measurement (cup area);	chr4:52890890	chr4:52720081~52720831:-
HNSC	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-3.6	0.000352	0.0391	-0.15	-0.16	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
HNSC	cis	rs526231	0.543	rs34766	ENSG00000250682.4	LINC00491	3.6	0.000352	0.0391	0.22	0.16	Primary biliary cholangitis;	chr5:103175219	chr5:102609156~102671559:-
HNSC	cis	rs6088580	0.634	rs6087587	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000352	0.0391	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:33985617~33988989:-
HNSC	cis	rs116095464	0.558	rs9654453	ENSG00000250848.1	CTD-2083E4.5	-3.6	0.000352	0.0391	-0.24	-0.16	Breast cancer;	chr5:299506	chr5:288833~290321:-
HNSC	cis	rs7989524	0.708	rs11617984	ENSG00000227879.2	PSPC1P1	3.6	0.000352	0.0391	0.22	0.16	Schizophrenia;	chr13:19048003	chr13:19201637~19227432:-
HNSC	cis	rs9911578	0.967	rs57869245	ENSG00000224738.1	AC099850.1	-3.6	0.000352	0.0391	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59029269	chr17:59106598~59118267:+
HNSC	cis	rs4938303	0.788	rs12803249	ENSG00000254851.1	RP11-109L13.1	3.6	0.000352	0.0391	0.25	0.16	Triglycerides;	chr11:116665701	chr11:117135528~117138582:+
HNSC	cis	rs11846409	0.932	rs61233250	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000352	0.0391	-0.15	-0.16	Rheumatic heart disease;	chr14:106634072	chr14:106762092~106762588:-
HNSC	cis	rs79280654	0.52	rs111568541	ENSG00000175147.10	TMEM51-AS1	-3.6	0.000352	0.0391	-0.31	-0.16	Alcoholic chronic pancreatitis;	chr1:15385733	chr1:15111815~15152464:-
HNSC	cis	rs79280654	0.52	rs57862684	ENSG00000175147.10	TMEM51-AS1	-3.6	0.000352	0.0391	-0.31	-0.16	Alcoholic chronic pancreatitis;	chr1:15387422	chr1:15111815~15152464:-
HNSC	cis	rs79280654	0.581	rs72879964	ENSG00000175147.10	TMEM51-AS1	-3.6	0.000352	0.0391	-0.31	-0.16	Alcoholic chronic pancreatitis;	chr1:15389990	chr1:15111815~15152464:-
HNSC	cis	rs2762353	0.935	rs1165153	ENSG00000272462.2	U91328.19	-3.6	0.000352	0.0391	-0.16	-0.16	Blood metabolite levels;	chr6:25817561	chr6:25992662~26001775:+
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000270326.1	RP5-874C20.6	-3.6	0.000352	0.0391	-0.23	-0.16	Depression;	chr6:28231986	chr6:28319660~28319852:-
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000270326.1	RP5-874C20.6	-3.6	0.000352	0.0391	-0.23	-0.16	Depression;	chr6:28232159	chr6:28319660~28319852:-
HNSC	cis	rs683257	0.929	rs9495849	ENSG00000234147.1	RP3-460G2.2	-3.6	0.000352	0.0391	-0.3	-0.16	Facial emotion recognition (angry faces);	chr6:140867341	chr6:140845958~140852924:-
HNSC	cis	rs7178375	1	rs28693590	ENSG00000215302.7	CTD-3092A11.1	-3.6	0.000352	0.0391	-0.26	-0.16	Hypertriglyceridemia;	chr15:30902818	chr15:30470779~30507623:+
HNSC	cis	rs13178541	0.745	rs7379919	ENSG00000250378.1	RP11-119J18.1	-3.6	0.000352	0.0391	-0.21	-0.16	IgG glycosylation;	chr5:135767028	chr5:135812667~135826582:+
HNSC	cis	rs7475343	0.538	rs7917079	ENSG00000224034.1	RP11-445P17.8	3.6	0.000352	0.0391	0.21	0.16	Intelligence;	chr10:5116283	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.538	rs2398195	ENSG00000224034.1	RP11-445P17.8	3.6	0.000352	0.0391	0.21	0.16	Intelligence;	chr10:5116417	chr10:5266033~5271236:-
HNSC	cis	rs7475343	0.505	rs1892404	ENSG00000224034.1	RP11-445P17.8	3.6	0.000352	0.0391	0.21	0.16	Intelligence;	chr10:5116851	chr10:5266033~5271236:-
HNSC	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-3.6	0.000352	0.0391	-0.19	-0.16	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
HNSC	cis	rs7107174	1	rs4492844	ENSG00000251323.2	RP11-452H21.4	3.6	0.000352	0.0391	0.25	0.16	Testicular germ cell tumor;	chr11:78315470	chr11:78423982~78429836:-
HNSC	cis	rs2975734	0.68	rs10503406	ENSG00000255310.2	AF131215.2	-3.6	0.000352	0.0391	-0.17	-0.16	Chronotype;Morning vs. evening chronotype;	chr8:10251462	chr8:11107788~11109726:-
HNSC	cis	rs11190179	0.744	rs11190170	ENSG00000260475.1	RP11-85A1.3	3.6	0.000352	0.0391	0.3	0.16	&beta2-Glycoprotein I (β2-GPI) plasma levels;	chr10:99597960	chr10:99621055~99621918:+
HNSC	cis	rs11190179	1	rs11190172	ENSG00000260475.1	RP11-85A1.3	3.6	0.000352	0.0391	0.3	0.16	&beta2-Glycoprotein I (β2-GPI) plasma levels;	chr10:99598624	chr10:99621055~99621918:+
HNSC	cis	rs1218582	0.744	rs6674853	ENSG00000270361.1	RP11-307C12.13	-3.6	0.000352	0.0391	-0.18	-0.16	Prostate cancer;	chr1:154920277	chr1:154937370~154938059:+
HNSC	cis	rs739496	0.843	rs621899	ENSG00000226469.1	ADAM1B	3.6	0.000352	0.0391	0.18	0.16	Platelet count;	chr12:111547047	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.843	rs625093	ENSG00000226469.1	ADAM1B	3.6	0.000352	0.0391	0.18	0.16	Platelet count;	chr12:111550628	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.843	rs638791	ENSG00000226469.1	ADAM1B	3.6	0.000352	0.0391	0.18	0.16	Platelet count;	chr12:111551432	chr12:111927018~111929017:+
HNSC	cis	rs7267979	0.718	rs2983489	ENSG00000231081.1	RP4-760C5.3	-3.6	0.000352	0.0392	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26008791~26010531:-
HNSC	cis	rs7267979	0.727	rs2474765	ENSG00000231081.1	RP4-760C5.3	-3.6	0.000352	0.0392	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26008791~26010531:-
HNSC	cis	rs2518049	0.51	rs17134471	ENSG00000224034.1	RP11-445P17.8	-3.6	0.000352	0.0392	-0.18	-0.16	Metabolic traits;	chr10:5161386	chr10:5266033~5271236:-
HNSC	cis	rs2518049	0.51	rs3750573	ENSG00000224034.1	RP11-445P17.8	-3.6	0.000352	0.0392	-0.18	-0.16	Metabolic traits;	chr10:5161785	chr10:5266033~5271236:-
HNSC	cis	rs5758511	0.689	rs11913578	ENSG00000226450.2	CYP2D8P	3.6	0.000352	0.0392	0.15	0.16	Birth weight;	chr22:41951387	chr22:42149886~42155001:-
HNSC	cis	rs1553477	0.617	rs747671	ENSG00000272123.1	CTD-2366F13.2	3.6	0.000352	0.0392	0.19	0.16	Monobrow;	chr5:53817261	chr5:53089016~53089468:-
HNSC	cis	rs4950322	0.58	rs7515160	ENSG00000230832.3	RP11-325P15.2	-3.6	0.000352	0.0392	-0.22	-0.16	Protein quantitative trait loci;	chr1:147120714	chr1:147082338~147083578:-
HNSC	cis	rs1865760	0.613	rs9295674	ENSG00000272810.1	U91328.22	-3.6	0.000352	0.0392	-0.14	-0.16	Height;	chr6:25912114	chr6:26013241~26013757:+
HNSC	cis	rs7113211	0.817	rs7951615	ENSG00000176343.5	RPL37AP8	3.6	0.000352	0.0392	0.17	0.16	Expressive vocabulary in infants;	chr11:112768825	chr11:111889199~111889474:-
HNSC	cis	rs9487051	1	rs9374080	ENSG00000219700.1	PTCHD3P3	-3.6	0.000352	0.0392	-0.16	-0.16	Reticulocyte fraction of red cells;	chr6:109295217	chr6:109288571~109290503:-
HNSC	cis	rs1656402	0.834	rs11676437	ENSG00000263941.2	RN7SL32P	3.6	0.000352	0.0392	0.2	0.16	Non-small cell lung cancer (survival);	chr2:232588355	chr2:233205199~233205479:+
HNSC	cis	rs1028883	0.87	rs1887646	ENSG00000228295.1	LINC00392	-3.6	0.000352	0.0392	-0.17	-0.16	Lean body mass;	chr13:73551661	chr13:73564244~73588070:+
HNSC	cis	rs2153535	0.585	rs9378565	ENSG00000230939.1	RP11-314C16.1	-3.6	0.000352	0.0392	-0.19	-0.16	Motion sickness;	chr6:8664580	chr6:8784178~8785445:+
HNSC	cis	rs5758659	0.652	rs1063392	ENSG00000182057.4	OGFRP1	-3.6	0.000352	0.0392	-0.17	-0.16	Cognitive function;	chr22:42058946	chr22:42269753~42275196:+
HNSC	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	3.6	0.000353	0.0392	0.2	0.16	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
HNSC	cis	rs734999	0.588	rs876938	ENSG00000238164.5	RP3-395M20.8	-3.6	0.000353	0.0392	-0.12	-0.16	Ulcerative colitis;	chr1:2591773	chr1:2549920~2557031:-
HNSC	cis	rs2280018	0.963	rs11075255	ENSG00000263335.1	AF001548.5	-3.6	0.000353	0.0392	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15726674~15732993:+
HNSC	cis	rs11992162	0.967	rs4841661	ENSG00000269918.1	AF131215.9	3.6	0.000353	0.0392	0.16	0.16	Monocyte count;	chr8:11975260	chr8:11104691~11106704:-
HNSC	cis	rs7824557	0.836	rs1435278	ENSG00000270076.1	AF131215.8	-3.6	0.000353	0.0392	-0.19	-0.16	Retinal vascular caliber;	chr8:11265520	chr8:11202965~11203671:+
HNSC	cis	rs17221829	0.703	rs10047486	ENSG00000280385.1	AP000648.5	-3.6	0.000353	0.0392	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89672022	chr11:90193614~90198120:+
HNSC	cis	rs4578769	0.55	rs9945620	ENSG00000265943.1	RP11-739L10.1	3.6	0.000353	0.0392	0.19	0.16	Eosinophil percentage of white cells;	chr18:22997367	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.55	rs2305886	ENSG00000265943.1	RP11-739L10.1	3.6	0.000353	0.0392	0.19	0.16	Eosinophil percentage of white cells;	chr18:22997493	chr18:22699481~22933764:-
HNSC	cis	rs597539	0.652	rs579136	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000353	0.0392	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs10792001	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000353	0.0392	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68941503~68942852:-
HNSC	cis	rs597539	0.652	rs613128	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000353	0.0392	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68941503~68942852:-
HNSC	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	3.6	0.000353	0.0392	0.2	0.16	Height;	chr14:75012879	chr14:75011269~75012851:-
HNSC	cis	rs55665837	0.701	rs12787709	ENSG00000251991.1	RNU7-49P	3.6	0.000353	0.0392	0.19	0.16	Vitamin D levels;	chr11:14617711	chr11:14478892~14478953:+
HNSC	cis	rs6951245	0.529	rs10262070	ENSG00000225146.1	AC073957.15	-3.6	0.000353	0.0392	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1029025~1043891:+
HNSC	cis	rs8025790	0.508	rs4776370	ENSG00000270964.1	RP11-502I4.3	-3.6	0.000353	0.0392	-0.18	-0.16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67612173	chr15:67541072~67542604:-
HNSC	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-3.6	0.000353	0.0392	-0.22	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
HNSC	cis	rs4352251	0.841	rs4280474	ENSG00000205716.4	FAM183DP	-3.6	0.000353	0.0392	-0.27	-0.16	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101365332	chr2:102249857~102250255:-
HNSC	cis	rs6840360	0.642	rs7682837	ENSG00000251611.1	RP11-610P16.1	-3.6	0.000353	0.0392	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151407551~151408835:-
HNSC	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-3.6	0.000353	0.0392	-0.18	-0.16	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-3.6	0.000353	0.0392	-0.18	-0.16	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
HNSC	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	3.6	0.000353	0.0392	0.24	0.16	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
HNSC	cis	rs13434995	0.755	rs62303690	ENSG00000273257.1	RP11-177J6.1	-3.6	0.000353	0.0392	-0.27	-0.16	Adiponectin levels;	chr4:55439838	chr4:55387949~55388271:+
HNSC	cis	rs73201462	0.908	rs2999083	ENSG00000231305.3	RP11-723O4.2	3.6	0.000353	0.0392	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235591	chr3:128861313~128871540:-
HNSC	cis	rs73201462	0.901	rs2999080	ENSG00000231305.3	RP11-723O4.2	3.6	0.000353	0.0392	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237865	chr3:128861313~128871540:-
HNSC	cis	rs10027350	0.647	rs313548	ENSG00000281501.1	SEPSECS-AS1	3.6	0.000353	0.0393	0.22	0.16	Childhood ear infection;	chr4:25235769	chr4:25160641~25201440:+
HNSC	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000353	0.0393	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
HNSC	cis	rs73198271	0.531	rs17630714	ENSG00000253893.2	FAM85B	3.6	0.000353	0.0393	0.26	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8800171	chr8:8167819~8226614:-
HNSC	cis	rs9611565	0.559	rs5758397	ENSG00000213857.3	RP11-12M9.4	-3.6	0.000353	0.0393	-0.22	-0.16	Vitiligo;	chr22:41623247	chr22:41074180~41075239:-
HNSC	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-3.6	0.000353	0.0393	-0.18	-0.16	QT interval;	chr12:29306357	chr12:29280418~29317848:-
HNSC	cis	rs870825	0.929	rs2310102	ENSG00000254233.1	RP11-242J7.1	-3.6	0.000353	0.0393	-0.25	-0.16	Blood protein levels;	chr4:184673987	chr4:184584093~184625030:-
HNSC	cis	rs1075232	1	rs72722829	ENSG00000103832.10	GOLGA8UP	-3.6	0.000354	0.0393	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30791573~30801859:+
HNSC	cis	rs1075232	1	rs16956707	ENSG00000103832.10	GOLGA8UP	-3.6	0.000354	0.0393	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30791573~30801859:+
HNSC	cis	rs6715284	0.786	rs56360544	ENSG00000183308.6	AC005037.3	3.6	0.000354	0.0393	0.38	0.16	Rheumatoid arthritis;	chr2:201415911	chr2:200963263~201009102:+
HNSC	cis	rs6715284	0.786	rs78374785	ENSG00000183308.6	AC005037.3	3.6	0.000354	0.0393	0.38	0.16	Rheumatoid arthritis;	chr2:201418196	chr2:200963263~201009102:+
HNSC	cis	rs6715284	0.786	rs55724588	ENSG00000183308.6	AC005037.3	3.6	0.000354	0.0393	0.38	0.16	Rheumatoid arthritis;	chr2:201442897	chr2:200963263~201009102:+
HNSC	cis	rs6496044	0.568	rs12708554	ENSG00000259407.1	RP11-158M2.3	-3.6	0.000354	0.0393	-0.17	-0.16	Interstitial lung disease;	chr15:85531066	chr15:85744109~85750281:-
HNSC	cis	rs6878727	0.85	rs7712066	ENSG00000253807.4	LINC01170	-3.6	0.000354	0.0393	-0.2	-0.16	Breast cancer;	chr5:124382061	chr5:124059794~124405079:-
HNSC	cis	rs11633886	0.677	rs17630344	ENSG00000273972.1	CTD-2306A12.1	-3.6	0.000354	0.0393	-0.19	-0.16	Diisocyanate-induced asthma;	chr15:45759724	chr15:45702640~45703183:+
HNSC	cis	rs12908161	0.92	rs35738019	ENSG00000229212.6	RP11-561C5.4	-3.6	0.000354	0.0393	-0.23	-0.16	Schizophrenia;	chr15:84736979	chr15:85205440~85234795:-
HNSC	cis	rs12908161	1	rs34570071	ENSG00000229212.6	RP11-561C5.4	-3.6	0.000354	0.0393	-0.23	-0.16	Schizophrenia;	chr15:84736981	chr15:85205440~85234795:-
HNSC	cis	rs2337406	0.925	rs4774188	ENSG00000211972.2	IGHV3-66	3.6	0.000354	0.0393	0.18	0.16	Alzheimer's disease (late onset);	chr14:106767918	chr14:106675017~106675544:-
HNSC	cis	rs6710503	0.569	rs11682130	ENSG00000271936.1	RP11-443B20.1	3.6	0.000354	0.0393	0.15	0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24724181	chr2:24825610~24826717:+
HNSC	cis	rs495337	1	rs4810997	ENSG00000229222.1	KRT18P4	-3.6	0.000354	0.0393	-0.18	-0.16	Psoriasis;	chr20:49962811	chr20:49956745~49958032:+
HNSC	cis	rs11048434	0.761	rs2110192	ENSG00000233719.3	GOT2P3	-3.6	0.000354	0.0393	-0.21	-0.16	Sjögren's syndrome;	chr12:8983755	chr12:9641802~9643007:+
HNSC	cis	rs1155750	0.72	rs239838	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000354	0.0393	-0.24	-0.16	Colorectal cancer;	chr6:54902127	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs239833	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000354	0.0393	-0.24	-0.16	Colorectal cancer;	chr6:54904555	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs406149	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000354	0.0393	-0.24	-0.16	Colorectal cancer;	chr6:54914721	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.656	rs1028423	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000354	0.0393	-0.24	-0.16	Colorectal cancer;	chr6:54914905	chr6:54840118~54840855:-
HNSC	cis	rs1155750	0.72	rs183011	ENSG00000224984.1	RP11-524H19.2	-3.6	0.000354	0.0393	-0.24	-0.16	Colorectal cancer;	chr6:54915982	chr6:54840118~54840855:-
HNSC	cis	rs6490294	0.747	rs632650	ENSG00000226469.1	ADAM1B	3.6	0.000354	0.0393	0.2	0.16	Mean platelet volume;	chr12:111693894	chr12:111927018~111929017:+
HNSC	cis	rs2554380	0.55	rs62025825	ENSG00000259570.1	RP11-671M22.4	-3.6	0.000354	0.0393	-0.21	-0.16	Height;	chr15:83872285	chr15:84394512~84395514:+
HNSC	cis	rs7572733	0.555	rs10202569	ENSG00000222017.1	AC011997.1	3.6	0.000354	0.0393	0.21	0.16	Dermatomyositis;	chr2:198070002	chr2:197693106~197774823:+
HNSC	cis	rs7200543	0.89	rs4985155	ENSG00000207425.1	Y_RNA	-3.6	0.000354	0.0393	-0.2	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15035602	chr16:14915457~14915556:-
HNSC	cis	rs911555	0.755	rs7148567	ENSG00000244691.1	RPL10AP1	-3.6	0.000354	0.0393	-0.2	-0.16	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103412119~103412761:-
HNSC	cis	rs1937680	0.613	rs7082594	ENSG00000236671.6	PRKG1-AS1	-3.6	0.000354	0.0393	-0.22	-0.16	Breast cancer;	chr10:51891437	chr10:52230742~52314128:-
HNSC	cis	rs11148252	0.967	rs11620062	ENSG00000198384.8	TPTE2P3	3.6	0.000354	0.0393	0.2	0.16	Lewy body disease;	chr13:52419891	chr13:52522632~52586906:+
HNSC	cis	rs16858210	0.826	rs35494670	ENSG00000234371.6	RPSAP31	3.6	0.000354	0.0393	0.19	0.16	Menopause (age at onset);	chr3:183888569	chr3:183884924~183888449:+
HNSC	cis	rs4076943	0.513	rs4243925	ENSG00000255260.1	CTD-3224I3.3	-3.6	0.000354	0.0393	-0.2	-0.16	Post bronchodilator FEV1;	chr11:11261541	chr11:11243188~11243715:-
HNSC	cis	rs7824557	0.602	rs35807737	ENSG00000269918.1	AF131215.9	3.6	0.000354	0.0393	0.16	0.16	Retinal vascular caliber;	chr8:11346902	chr8:11104691~11106704:-
HNSC	cis	rs6088580	0.57	rs6058057	ENSG00000276073.1	RP5-1125A11.7	-3.6	0.000355	0.0394	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:33985617~33988989:-
HNSC	cis	rs11846409	0.789	rs34917868	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000355	0.0394	-0.15	-0.16	Rheumatic heart disease;	chr14:106618321	chr14:106762092~106762588:-
HNSC	cis	rs13178541	0.81	rs10070559	ENSG00000250378.1	RP11-119J18.1	-3.6	0.000355	0.0394	-0.22	-0.16	IgG glycosylation;	chr5:135822430	chr5:135812667~135826582:+
HNSC	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	3.6	0.000355	0.0394	0.15	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
HNSC	cis	rs7208859	0.562	rs216408	ENSG00000263603.1	CTD-2349P21.5	3.6	0.000355	0.0394	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30729469~30731202:+
HNSC	cis	rs1853665	0.895	rs9478311	ENSG00000231760.4	RP11-350J20.5	3.6	0.000355	0.0394	0.25	0.16	Radiation response;	chr6:149965999	chr6:149796151~149826294:-
HNSC	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	3.6	0.000355	0.0394	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
HNSC	cis	rs3947	1	rs1736082	ENSG00000269918.1	AF131215.9	-3.6	0.000355	0.0394	-0.2	-0.16	Blood protein levels;	chr8:11845911	chr8:11104691~11106704:-
HNSC	cis	rs1005277	0.579	rs1780116	ENSG00000099251.13	HSD17B7P2	3.6	0.000355	0.0394	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.579	rs1780121	ENSG00000099251.13	HSD17B7P2	3.6	0.000355	0.0394	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.579	rs1780122	ENSG00000099251.13	HSD17B7P2	3.6	0.000355	0.0394	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.579	rs1780145	ENSG00000099251.13	HSD17B7P2	3.6	0.000355	0.0394	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38356380~38378505:+
HNSC	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	3.6	0.000355	0.0394	0.2	0.16	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
HNSC	cis	rs603446	0.586	rs947986	ENSG00000254851.1	RP11-109L13.1	3.6	0.000355	0.0394	0.22	0.16	Triglycerides;	chr11:116698488	chr11:117135528~117138582:+
HNSC	cis	rs2760061	0.846	rs3094912	ENSG00000270110.1	RP5-1139B12.4	-3.6	0.000355	0.0394	-0.16	-0.16	Diastolic blood pressure;	chr1:228022114	chr1:228295911~228302998:-
HNSC	cis	rs7283707	0.786	rs2297247	ENSG00000236471.1	AF127577.12	3.6	0.000355	0.0394	0.27	0.16	QRS complex (12-leadsum);	chr21:15763053	chr21:15067070~15067837:+
HNSC	cis	rs7224685	0.859	rs34348519	ENSG00000240898.1	RP11-48B14.1	-3.6	0.000355	0.0394	-0.15	-0.16	Type 2 diabetes;	chr17:4190845	chr17:3665220~3665702:+
HNSC	cis	rs17221829	0.599	rs7112871	ENSG00000280385.1	AP000648.5	-3.6	0.000355	0.0394	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89671661	chr11:90193614~90198120:+
HNSC	cis	rs17221829	0.703	rs10830336	ENSG00000280385.1	AP000648.5	-3.6	0.000355	0.0394	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89673293	chr11:90193614~90198120:+
HNSC	cis	rs7246657	0.722	rs2972458	ENSG00000276846.1	CTD-3220F14.3	-3.6	0.000355	0.0394	-0.22	-0.16	Coronary artery calcification;	chr19:37644502	chr19:37314868~37315620:-
HNSC	cis	rs7824557	0.564	rs34389419	ENSG00000255310.2	AF131215.2	-3.6	0.000355	0.0394	-0.16	-0.16	Retinal vascular caliber;	chr8:11371810	chr8:11107788~11109726:-
HNSC	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	3.6	0.000355	0.0394	0.16	0.16	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
HNSC	cis	rs734999	0.588	rs2260976	ENSG00000238164.5	RP3-395M20.8	3.6	0.000355	0.0394	0.12	0.16	Ulcerative colitis;	chr1:2596239	chr1:2549920~2557031:-
HNSC	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-3.6	0.000355	0.0394	-0.17	-0.16	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
HNSC	cis	rs72827839	0.779	rs16955073	ENSG00000242207.1	HOXB-AS4	-3.6	0.000355	0.0394	-0.22	-0.16	Ease of getting up in the morning;	chr17:48304384	chr17:48628675~48634932:+
HNSC	cis	rs950169	0.922	rs12915832	ENSG00000259570.1	RP11-671M22.4	3.6	0.000355	0.0394	0.22	0.16	Schizophrenia;	chr15:84568226	chr15:84394512~84395514:+
HNSC	cis	rs3743266	1	rs3743266	ENSG00000245534.5	RORA-AS1	-3.6	0.000355	0.0394	-0.21	-0.16	Menarche (age at onset);	chr15:60489314	chr15:60479178~60630637:+
HNSC	cis	rs5758659	0.845	rs5758645	ENSG00000273366.1	CTA-989H11.1	-3.6	0.000355	0.0394	-0.19	-0.16	Cognitive function;	chr22:42202945	chr22:42278188~42278846:+
HNSC	cis	rs73173548	0.502	rs12516483	ENSG00000247828.6	TMEM161B-AS1	3.6	0.000355	0.0395	0.17	0.16	Macular telangiectasia type 2;	chr5:88454718	chr5:88268895~88436685:+
HNSC	cis	rs853679	0.55	rs6901017	ENSG00000219891.2	ZSCAN12P1	3.6	0.000356	0.0395	0.23	0.16	Depression;	chr6:28184805	chr6:28091154~28093664:+
HNSC	cis	rs7246657	0.722	rs2972437	ENSG00000276846.1	CTD-3220F14.3	3.6	0.000356	0.0395	0.22	0.16	Coronary artery calcification;	chr19:37719610	chr19:37314868~37315620:-
HNSC	cis	rs7757969	0.536	rs697642	ENSG00000215807.4	KRT18P65	-3.6	0.000356	0.0395	-0.28	-0.16	Schizophrenia;	chr6:111731902	chr6:112361437~112362722:-
HNSC	cis	rs7129556	0.539	rs6592728	ENSG00000219529.2	AP000580.1	3.6	0.000356	0.0395	0.19	0.16	Weight loss (gastric bypass surgery);	chr11:77536215	chr11:77813319~77813676:-
HNSC	cis	rs2179367	0.959	rs9390677	ENSG00000216906.2	RP11-350J20.9	3.6	0.000356	0.0395	0.2	0.16	Dupuytren's disease;	chr6:149389361	chr6:149904243~149906418:+
HNSC	cis	rs1497406	0.744	rs1007887	ENSG00000227959.1	RP11-276H7.2	3.6	0.000356	0.0395	0.18	0.16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16182534	chr1:16155211~16157329:+
HNSC	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-3.6	0.000356	0.0395	-0.19	-0.16	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
HNSC	cis	rs597539	0.652	rs592697	ENSG00000261625.1	RP11-554A11.4	-3.6	0.000356	0.0395	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.652	rs654071	ENSG00000261625.1	RP11-554A11.4	-3.6	0.000356	0.0395	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:69000765~69002048:-
HNSC	cis	rs2562456	0.652	rs62110214	ENSG00000268081.1	RP11-678G14.2	3.6	0.000356	0.0395	0.23	0.16	Pain;	chr19:21592406	chr19:21554640~21569237:-
HNSC	cis	rs2115630	1	rs6496452	ENSG00000259295.5	CSPG4P12	-3.6	0.000356	0.0395	-0.18	-0.16	P wave terminal force;	chr15:84829414	chr15:85191438~85213905:+
HNSC	cis	rs482329	0.719	rs605957	ENSG00000224939.1	LINC00184	3.6	0.000356	0.0395	0.2	0.16	Life threatening arrhythmia;	chr1:234672761	chr1:234629311~234634780:+
HNSC	cis	rs3740713	0.925	rs55727925	ENSG00000256464.1	YWHABP2	3.6	0.000356	0.0395	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr11:18490243~18490955:-
HNSC	cis	rs2408955	0.522	rs3997	ENSG00000257763.1	OR5BK1P	-3.6	0.000356	0.0395	-0.16	-0.16	Glycated hemoglobin levels;	chr12:48087804	chr12:48355792~48356614:-
HNSC	cis	rs293748	0.54	rs12655320	ENSG00000250155.1	CTD-2353F22.1	-3.6	0.000356	0.0395	-0.2	-0.16	Obesity-related traits;	chr5:37104756	chr5:36666214~36725195:-
HNSC	cis	rs2337406	1	rs75651733	ENSG00000211972.2	IGHV3-66	3.6	0.000356	0.0395	0.17	0.16	Alzheimer's disease (late onset);	chr14:106701309	chr14:106675017~106675544:-
HNSC	cis	rs7023329	0.561	rs10811600	ENSG00000244230.3	RN7SL151P	3.6	0.000356	0.0395	0.17	0.16	Melanoma;	chr9:21734803	chr9:21699314~21699596:+
HNSC	cis	rs3929778	0.848	rs2104012	ENSG00000278192.1	RP5-1056H1.2	-3.6	0.000356	0.0395	-0.23	-0.16	QRS complex (Cornell);	chr20:6570774	chr20:6065966~6067897:-
HNSC	cis	rs4253772	0.591	rs7291444	ENSG00000277232.2	GTSE1-AS1	-3.6	0.000356	0.0395	-0.21	-0.16	Cholesterol, total;LDL cholesterol;	chr22:46260349	chr22:46295143~46296660:-
HNSC	cis	rs36093844	0.527	rs72963092	ENSG00000279742.1	RP11-700A24.1	-3.6	0.000356	0.0395	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86033584	chr11:85852557~85854943:-
HNSC	cis	rs6968419	0.674	rs57756655	ENSG00000237870.5	AC073130.1	3.6	0.000356	0.0395	0.2	0.16	Intraocular pressure;	chr7:116287114	chr7:116275606~116286734:-
HNSC	cis	rs10865541	0.869	rs6711292	ENSG00000234171.2	RNASEH1-AS1	3.6	0.000356	0.0395	0.17	0.16	Obesity-related traits;	chr2:3418399	chr2:3558492~3561745:+
HNSC	cis	rs35851103	0.507	rs6601649	ENSG00000255046.1	RP11-297N6.4	3.6	0.000356	0.0395	0.17	0.16	Neuroticism;	chr8:11999808	chr8:11797928~11802568:-
HNSC	cis	rs67478160	0.643	rs8005594	ENSG00000269940.1	RP11-73M18.7	3.6	0.000356	0.0395	0.15	0.16	Schizophrenia;	chr14:103813552	chr14:103694560~103695170:+
HNSC	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	3.6	0.000356	0.0395	0.32	0.16	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
HNSC	cis	rs748404	0.666	rs55801120	ENSG00000166763.7	STRCP1	3.6	0.000356	0.0395	0.23	0.16	Lung cancer;	chr15:43495042	chr15:43699488~43718184:-
HNSC	cis	rs2976388	1	rs2294008	ENSG00000253741.1	CTD-2292P10.4	3.6	0.000356	0.0395	0.15	0.16	Urinary tract infection frequency;	chr8:142680513	chr8:142702252~142726973:-
HNSC	cis	rs711830	1	rs1051929	ENSG00000226363.3	HAGLROS	-3.6	0.000356	0.0395	-0.22	-0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172026	chr2:176177717~176179008:+
HNSC	cis	rs2919917	0.554	rs2086755	ENSG00000260398.1	RP11-594N15.3	3.6	0.000356	0.0395	0.22	0.16	Lymphocyte counts;	chr8:78701809	chr8:78605952~78609705:+
HNSC	cis	rs2921036	0.503	rs7817832	ENSG00000253893.2	FAM85B	-3.6	0.000356	0.0395	-0.24	-0.16	Neuroticism;	chr8:8523311	chr8:8167819~8226614:-
HNSC	cis	rs3771570	1	rs56156035	ENSG00000260942.1	CAPN10-AS1	-3.6	0.000356	0.0395	-0.18	-0.16	Prostate cancer;	chr2:241266540	chr2:240582700~240586699:-
HNSC	cis	rs3771570	1	rs7557535	ENSG00000260942.1	CAPN10-AS1	-3.6	0.000356	0.0395	-0.18	-0.16	Prostate cancer;	chr2:241267140	chr2:240582700~240586699:-
HNSC	cis	rs870825	0.616	rs72703531	ENSG00000254233.1	RP11-242J7.1	3.6	0.000356	0.0395	0.26	0.16	Blood protein levels;	chr4:184689938	chr4:184584093~184625030:-
HNSC	cis	rs10740039	0.768	rs920646	ENSG00000254271.1	RP11-131N11.4	3.6	0.000356	0.0395	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703767	chr10:60734342~60741828:+
HNSC	cis	rs10056811	0.538	rs3923323	ENSG00000271815.1	CTD-2235C13.3	3.6	0.000356	0.0395	0.27	0.16	Coronary artery disease;	chr5:75076316	chr5:75363760~75364242:+
HNSC	cis	rs7011507	0.582	rs56080763	ENSG00000253608.1	RP11-770E5.1	-3.6	0.000356	0.0395	-0.34	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48302389	chr8:48551567~48698510:+
HNSC	cis	rs2300747	0.872	rs11588376	ENSG00000177173.5	NAP1L4P1	-3.6	0.000356	0.0395	-0.29	-0.16	Primary biliary cholangitis;Multiple sclerosis;	chr1:116529902	chr1:116532936~116534092:-
HNSC	cis	rs2300747	0.872	rs1034919	ENSG00000177173.5	NAP1L4P1	-3.6	0.000356	0.0395	-0.29	-0.16	Primary biliary cholangitis;Multiple sclerosis;	chr1:116532883	chr1:116532936~116534092:-
HNSC	cis	rs12047808	0.558	rs115243371	ENSG00000261060.1	RP11-545A16.4	-3.6	0.000356	0.0395	-0.3	-0.16	Multiple sclerosis (age of onset);	chr1:179198168	chr1:179590372~179591305:+
HNSC	cis	rs526231	0.543	rs75913944	ENSG00000250682.4	LINC00491	3.6	0.000356	0.0395	0.22	0.16	Primary biliary cholangitis;	chr5:103143799	chr5:102609156~102671559:-
HNSC	cis	rs9513627	0.512	rs9517759	ENSG00000280710.1	RP11-214F16.8	3.6	0.000357	0.0395	0.21	0.16	Obesity-related traits;	chr13:99527854	chr13:99498524~99501315:+
HNSC	cis	rs8062405	1	rs8061590	ENSG00000261089.1	RP11-435I10.3	3.6	0.000357	0.0395	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28413703~28415018:+
HNSC	cis	rs4381823	1	rs17036971	ENSG00000230979.3	AC079250.1	-3.6	0.000357	0.0395	-0.28	-0.16	Schizophrenia;	chr2:47808854	chr2:47690716~47691246:-
HNSC	cis	rs11148252	1	rs11148252	ENSG00000198384.8	TPTE2P3	3.6	0.000357	0.0396	0.2	0.16	Lewy body disease;	chr13:52434913	chr13:52522632~52586906:+
HNSC	cis	rs853679	0.76	rs9393910	ENSG00000176933.5	TOB2P1	3.6	0.000357	0.0396	0.22	0.16	Depression;	chr6:28240414	chr6:28217643~28218634:-
HNSC	cis	rs853679	0.76	rs9368563	ENSG00000176933.5	TOB2P1	3.6	0.000357	0.0396	0.22	0.16	Depression;	chr6:28240780	chr6:28217643~28218634:-
HNSC	cis	rs26232	0.521	rs40508	ENSG00000250682.4	LINC00491	3.6	0.000357	0.0396	0.22	0.16	Rheumatoid arthritis;	chr5:103108234	chr5:102609156~102671559:-
HNSC	cis	rs1665050	0.901	rs1665051	ENSG00000277144.1	RP11-59H7.4	-3.6	0.000357	0.0396	-0.2	-0.16	Atopic dermatitis;	chr15:59003025	chr15:59115547~59116089:-
HNSC	cis	rs494453	0.922	rs2477428	ENSG00000227811.2	FAM212B-AS1	-3.6	0.000357	0.0396	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111671634	chr1:111739841~111747798:+
HNSC	cis	rs7772486	0.686	rs6933161	ENSG00000270638.1	RP3-466P17.1	-3.6	0.000357	0.0396	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs9399565	ENSG00000270638.1	RP3-466P17.1	-3.6	0.000357	0.0396	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145735570~145737218:+
HNSC	cis	rs2307394	0.68	rs12988144	ENSG00000281469.1	RP11-567F11.1	3.6	0.000357	0.0396	0.19	0.16	Urate levels;	chr2:147752540	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.68	rs13035656	ENSG00000281469.1	RP11-567F11.1	3.6	0.000357	0.0396	0.19	0.16	Urate levels;	chr2:147754236	chr2:148044380~148044894:+
HNSC	cis	rs73201462	1	rs7374952	ENSG00000231305.3	RP11-723O4.2	-3.6	0.000357	0.0396	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282524	chr3:128861313~128871540:-
HNSC	cis	rs2117029	0.523	rs12227296	ENSG00000258101.2	RP11-977B10.2	3.6	0.000357	0.0396	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49232790~49264756:-
HNSC	cis	rs2117029	0.521	rs10875925	ENSG00000258101.2	RP11-977B10.2	3.6	0.000357	0.0396	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49232790~49264756:-
HNSC	cis	rs2117029	0.586	rs11168882	ENSG00000258101.2	RP11-977B10.2	3.6	0.000357	0.0396	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49232790~49264756:-
HNSC	cis	rs8070740	0.559	rs1806263	ENSG00000234203.1	RP5-1050D4.2	-3.6	0.000357	0.0396	-0.18	-0.16	Menopause (age at onset);	chr17:5414172	chr17:4972851~4974681:+
HNSC	cis	rs9650657	0.812	rs11250072	ENSG00000255310.2	AF131215.2	-3.6	0.000357	0.0396	-0.16	-0.16	Neuroticism;	chr8:10774611	chr8:11107788~11109726:-
HNSC	cis	rs9650657	0.812	rs11250073	ENSG00000255310.2	AF131215.2	-3.6	0.000357	0.0396	-0.16	-0.16	Neuroticism;	chr8:10774726	chr8:11107788~11109726:-
HNSC	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	3.6	0.000357	0.0396	0.28	0.16	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
HNSC	cis	rs34286592	1	rs3815824	ENSG00000196796.5	CTB-134H23.2	3.6	0.000357	0.0396	0.24	0.16	Multiple sclerosis;	chr16:29841539	chr16:29038655~29052726:+
HNSC	cis	rs1862618	0.671	rs2591965	ENSG00000271828.1	CTD-2310F14.1	-3.6	0.000357	0.0396	-0.2	-0.16	Initial pursuit acceleration;	chr5:56940349	chr5:56927874~56929573:+
HNSC	cis	rs8177376	0.953	rs73017399	ENSG00000254759.1	NAP1L1P1	-3.6	0.000357	0.0396	-0.22	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126067539~126068601:+
HNSC	cis	rs4950322	0.58	rs4950308	ENSG00000230832.3	RP11-325P15.2	-3.6	0.000357	0.0396	-0.21	-0.16	Protein quantitative trait loci;	chr1:147120092	chr1:147082338~147083578:-
HNSC	cis	rs11951515	0.691	rs36050992	ENSG00000249286.1	CTD-2210P15.2	3.6	0.000357	0.0396	0.17	0.16	Metabolite levels  (X-11787);	chr5:43364305	chr5:43586918~43588223:-
HNSC	cis	rs9650657	0.775	rs10100265	ENSG00000255310.2	AF131215.2	-3.6	0.000357	0.0396	-0.16	-0.16	Neuroticism;	chr8:10775649	chr8:11107788~11109726:-
HNSC	cis	rs999943	0.846	rs9366826	ENSG00000224557.6	HLA-DPB2	-3.6	0.000357	0.0396	-0.22	-0.16	Obesity (extreme);	chr6:33651407	chr6:33112451~33129084:+
HNSC	cis	rs67311347	1	rs2276868	ENSG00000280739.1	EIF1B-AS1	-3.6	0.000357	0.0396	-0.17	-0.16	Renal cell carcinoma;	chr3:40457354	chr3:40173145~40309698:-
HNSC	cis	rs9650657	0.683	rs7005905	ENSG00000255310.2	AF131215.2	3.6	0.000357	0.0396	0.16	0.16	Neuroticism;	chr8:10727634	chr8:11107788~11109726:-
HNSC	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-3.6	0.000357	0.0396	-0.27	-0.16	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
HNSC	cis	rs11018874	0.808	rs71471032	ENSG00000280385.1	AP000648.5	3.6	0.000358	0.0396	0.28	0.16	White blood cell types;	chr11:90155753	chr11:90193614~90198120:+
HNSC	cis	rs1028883	0.773	rs12428715	ENSG00000228295.1	LINC00392	3.6	0.000358	0.0396	0.17	0.16	Lean body mass;	chr13:73585642	chr13:73564244~73588070:+
HNSC	cis	rs13385	0.769	rs13178142	ENSG00000254363.5	CTB-131B5.5	3.6	0.000358	0.0396	0.23	0.16	Atrial fibrillation;	chr5:140216967	chr5:140157319~140173051:+
HNSC	cis	rs2243480	0.522	rs1638736	ENSG00000229886.1	RP5-1132H15.3	3.6	0.000358	0.0396	0.34	0.16	Diabetic kidney disease;	chr7:66627321	chr7:66025126~66031544:-
HNSC	cis	rs2839186	0.708	rs17183123	ENSG00000239415.1	AP001469.9	3.6	0.000358	0.0396	0.14	0.16	Testicular germ cell tumor;	chr21:46252047	chr21:46251549~46254133:-
HNSC	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	3.6	0.000358	0.0397	0.2	0.16	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
HNSC	cis	rs4725617	0.584	rs7792781	ENSG00000204959.4	ARHGEF34P	3.6	0.000358	0.0397	0.32	0.16	Blood protein levels;	chr7:143409933	chr7:144272445~144286966:-
HNSC	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	3.6	0.000358	0.0397	0.19	0.16	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
HNSC	cis	rs11853189	0.938	rs2277551	ENSG00000259562.2	RP11-762H8.2	3.6	0.000358	0.0397	0.2	0.16	Red cell distribution width;	chr15:78288139	chr15:78290527~78291221:-
HNSC	cis	rs875971	0.66	rs7807930	ENSG00000273142.1	RP11-458F8.4	3.6	0.000358	0.0397	0.14	0.16	Aortic root size;	chr7:66622178	chr7:66902857~66906297:+
HNSC	cis	rs875971	0.66	rs7807944	ENSG00000273142.1	RP11-458F8.4	3.6	0.000358	0.0397	0.14	0.16	Aortic root size;	chr7:66622208	chr7:66902857~66906297:+
HNSC	cis	rs61160187	0.51	rs6872863	ENSG00000215032.2	GNL3LP1	3.6	0.000358	0.0397	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.527	rs6873181	ENSG00000215032.2	GNL3LP1	3.6	0.000358	0.0397	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.527	rs6894672	ENSG00000215032.2	GNL3LP1	3.6	0.000358	0.0397	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60891935~60893577:-
HNSC	cis	rs9311474	0.508	rs7614498	ENSG00000243224.1	RP5-1157M23.2	-3.6	0.000358	0.0397	-0.16	-0.16	Electroencephalogram traits;	chr3:52584925	chr3:52239258~52241097:+
HNSC	cis	rs10927875	0.541	rs1763596	ENSG00000226029.1	RP4-798A10.2	-3.6	0.000358	0.0397	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16017340	chr1:16460948~16468481:+
HNSC	cis	rs7015630	0.738	rs7013987	ENSG00000251136.7	RP11-37B2.1	-3.6	0.000358	0.0397	-0.18	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89860755	chr8:89609409~89757727:-
HNSC	cis	rs1908814	0.516	rs11250178	ENSG00000255310.2	AF131215.2	3.6	0.000358	0.0397	0.16	0.16	Neuroticism;	chr8:11942725	chr8:11107788~11109726:-
HNSC	cis	rs11866815	0.602	rs60907769	ENSG00000226942.2	IL9RP3	-3.6	0.000358	0.0397	-0.23	-0.16	Body mass index;	chr16:330547	chr16:29336~38321:-
HNSC	cis	rs7824557	0.628	rs11250129	ENSG00000255495.1	AC145124.2	3.6	0.000358	0.0397	0.18	0.16	Retinal vascular caliber;	chr8:11344645	chr8:12194467~12196280:+
HNSC	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-3.6	0.000358	0.0397	-0.19	-0.16	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
HNSC	cis	rs12745968	0.652	rs11164601	ENSG00000223787.2	RP4-593M8.1	-3.6	0.000358	0.0397	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92479950	chr1:92580476~92580821:-
HNSC	cis	rs875971	0.862	rs2909688	ENSG00000106610.13	STAG3L4	-3.6	0.000358	0.0397	-0.21	-0.16	Aortic root size;	chr7:66376625	chr7:67302621~67321526:+
HNSC	cis	rs7577696	0.671	rs72863940	ENSG00000272716.1	RP11-563N4.1	-3.6	0.000358	0.0397	-0.16	-0.16	Inflammatory biomarkers;	chr2:32169605	chr2:32165046~32165757:-
HNSC	cis	rs2749592	0.531	rs1208559	ENSG00000099251.13	HSD17B7P2	-3.6	0.000358	0.0397	-0.17	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38356380~38378505:+
HNSC	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	3.6	0.000358	0.0397	0.22	0.16	QT interval;	chr16:28845498	chr16:28802743~28817828:+
HNSC	cis	rs7781557	1	rs727175	ENSG00000239969.4	RP11-163E9.2	-3.6	0.000358	0.0397	-0.24	-0.16	Colorectal adenoma (advanced);	chr7:102831333	chr7:102364162~102380633:+
HNSC	cis	rs4936891	0.645	rs74858431	ENSG00000200879.1	SNORD14E	-3.6	0.000358	0.0397	-0.19	-0.16	Male fertility;	chr11:124032155	chr11:123058077~123058161:-
HNSC	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-3.6	0.000358	0.0397	-0.21	-0.16	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
HNSC	cis	rs2760061	0.784	rs1745414	ENSG00000270110.1	RP5-1139B12.4	-3.6	0.000358	0.0397	-0.16	-0.16	Diastolic blood pressure;	chr1:228024458	chr1:228295911~228302998:-
HNSC	cis	rs12682352	0.602	rs13260419	ENSG00000254153.1	CTA-398F10.2	3.6	0.000358	0.0397	0.18	0.16	Neuroticism;	chr8:8817666	chr8:8456909~8461337:-
HNSC	cis	rs4142110	0.658	rs1170098	ENSG00000237263.1	MAPK6PS3	-3.6	0.000358	0.0397	-0.22	-0.16	Nephrolithiasis;	chr13:42199089	chr13:42068932~42071093:-
HNSC	cis	rs7246657	0.722	rs8100646	ENSG00000276846.1	CTD-3220F14.3	3.6	0.000358	0.0397	0.22	0.16	Coronary artery calcification;	chr19:37617042	chr19:37314868~37315620:-
HNSC	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-3.6	0.000359	0.0397	-0.27	-0.16	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
HNSC	cis	rs7726839	0.794	rs6883536	ENSG00000225138.6	CTD-2228K2.7	3.6	0.000359	0.0397	0.23	0.16	Obesity-related traits;	chr5:599159	chr5:473236~480884:+
HNSC	cis	rs35740288	0.822	rs11638720	ENSG00000259407.1	RP11-158M2.3	-3.6	0.000359	0.0397	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85744109~85750281:-
HNSC	cis	rs35740288	0.822	rs2016517	ENSG00000259407.1	RP11-158M2.3	-3.6	0.000359	0.0397	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85744109~85750281:-
HNSC	cis	rs35740288	0.822	rs4843092	ENSG00000259407.1	RP11-158M2.3	-3.6	0.000359	0.0397	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85744109~85750281:-
HNSC	cis	rs853679	1	rs853694	ENSG00000226314.6	ZNF192P1	-3.6	0.000359	0.0397	-0.23	-0.16	Depression;	chr6:28311323	chr6:28161781~28169594:+
HNSC	cis	rs2762353	0.935	rs1165215	ENSG00000272462.2	U91328.19	-3.6	0.000359	0.0397	-0.16	-0.16	Blood metabolite levels;	chr6:25798704	chr6:25992662~26001775:+
HNSC	cis	rs12681963	1	rs10954872	ENSG00000248159.1	HSPA8P11	-3.6	0.000359	0.0397	-0.26	-0.16	Migraine;	chr8:30121096	chr8:30237382~30240997:+
HNSC	cis	rs9876781	1	rs9876781	ENSG00000229759.1	MRPS18AP1	3.6	0.000359	0.0397	0.15	0.16	Longevity;	chr3:48445934	chr3:48256350~48256938:-
HNSC	cis	rs988913	0.957	rs9475100	ENSG00000224984.1	RP11-524H19.2	3.6	0.000359	0.0397	0.19	0.16	Menarche (age at onset);	chr6:54975435	chr6:54840118~54840855:-
HNSC	cis	rs72843506	0.722	rs9908418	ENSG00000189423.10	USP32P3	3.6	0.000359	0.0397	0.24	0.16	Schizophrenia;	chr17:20311252	chr17:20415547~20431008:+
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	3.6	0.000359	0.0397	0.2	0.16	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
HNSC	cis	rs17373728	0.739	rs6472896	ENSG00000249395.2	CASC9	3.59	0.000359	0.0398	0.22	0.16	Diabetic kidney disease;	chr8:75278080	chr8:75223404~75324741:-
HNSC	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-3.59	0.000359	0.0398	-0.28	-0.16	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
HNSC	cis	rs801193	0.901	rs4273746	ENSG00000273142.1	RP11-458F8.4	3.59	0.000359	0.0398	0.14	0.16	Aortic root size;	chr7:66836124	chr7:66902857~66906297:+
HNSC	cis	rs7592578	0.766	rs62182885	ENSG00000228509.4	AC006460.2	3.59	0.000359	0.0398	0.26	0.16	Diastolic blood pressure;	chr2:190572298	chr2:190676944~190708716:-
HNSC	cis	rs2991971	0.782	rs10789463	ENSG00000234329.1	RP11-767N6.2	3.59	0.000359	0.0398	0.16	0.16	High light scatter reticulocyte count;	chr1:45462176	chr1:45651039~45651826:-
HNSC	cis	rs4388249	1	rs11241036	ENSG00000271849.1	CTC-332L22.1	-3.59	0.000359	0.0398	-0.26	-0.16	Schizophrenia;	chr5:109831140	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs11241037	ENSG00000271849.1	CTC-332L22.1	-3.59	0.000359	0.0398	-0.26	-0.16	Schizophrenia;	chr5:109831249	chr5:109687802~109688329:-
HNSC	cis	rs13256369	1	rs13256369	ENSG00000254153.1	CTA-398F10.2	3.59	0.000359	0.0398	0.2	0.16	Obesity-related traits;	chr8:8719869	chr8:8456909~8461337:-
HNSC	cis	rs8061903	0.613	rs1001890	ENSG00000260350.1	RP11-152P23.2	-3.59	0.000359	0.0398	-0.22	-0.16	HIV-1 viral setpoint;	chr16:9210442	chr16:8847650~8848724:-
HNSC	cis	rs889398	0.967	rs244417	ENSG00000196696.11	PDXDC2P	3.59	0.000359	0.0398	0.11	0.16	Body mass index;	chr16:69629616	chr16:69976297~70065948:-
HNSC	cis	rs8030605	0.543	rs1031077	ENSG00000261072.2	RP11-5N19.3	3.59	0.000359	0.0398	0.2	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56141852	chr15:56192353~56193262:-
HNSC	cis	rs79040073	0.637	rs78050772	ENSG00000259531.2	RP11-295H24.3	3.59	0.000359	0.0398	0.21	0.16	Lung cancer in ever smokers;	chr15:49286380	chr15:49365124~49366685:-
HNSC	cis	rs6545883	0.894	rs35292974	ENSG00000271889.1	RP11-493E12.1	-3.59	0.000359	0.0398	-0.19	-0.16	Tuberculosis;	chr2:61294912	chr2:61151433~61162105:-
HNSC	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-3.59	0.000359	0.0398	-0.18	-0.16	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-3.59	0.000359	0.0398	-0.18	-0.16	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-3.59	0.000359	0.0398	-0.18	-0.16	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
HNSC	cis	rs4381823	0.867	rs75240149	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47868036	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs76653170	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47868748	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs75129775	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47869386	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs74583969	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47870318	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs75988362	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47870406	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs77562694	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47871144	chr2:47690716~47691246:-
HNSC	cis	rs4381823	0.867	rs74706786	ENSG00000230979.3	AC079250.1	-3.59	0.000359	0.0398	-0.27	-0.16	Schizophrenia;	chr2:47871962	chr2:47690716~47691246:-
HNSC	cis	rs3736485	0.966	rs6493498	ENSG00000259438.1	CTD-2650P22.1	3.59	0.000359	0.0398	0.17	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51462254	chr15:52010999~52019095:-
HNSC	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	3.59	0.00036	0.0398	0.23	0.16	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	3.59	0.00036	0.0398	0.23	0.16	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
HNSC	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	3.59	0.00036	0.0398	0.23	0.16	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
HNSC	cis	rs67072384	0.892	rs7104664	ENSG00000245148.2	ARAP1-AS2	3.59	0.00036	0.0398	0.23	0.16	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733405	chr11:72700474~72705607:+
HNSC	cis	rs4578769	0.55	rs12954377	ENSG00000265943.1	RP11-739L10.1	3.59	0.00036	0.0398	0.19	0.16	Eosinophil percentage of white cells;	chr18:22940862	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.55	rs9957690	ENSG00000265943.1	RP11-739L10.1	3.59	0.00036	0.0398	0.19	0.16	Eosinophil percentage of white cells;	chr18:22942697	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.55	rs12956837	ENSG00000265943.1	RP11-739L10.1	3.59	0.00036	0.0398	0.19	0.16	Eosinophil percentage of white cells;	chr18:22946865	chr18:22699481~22933764:-
HNSC	cis	rs4578769	0.513	rs9953640	ENSG00000265943.1	RP11-739L10.1	3.59	0.00036	0.0398	0.19	0.16	Eosinophil percentage of white cells;	chr18:22947856	chr18:22699481~22933764:-
HNSC	cis	rs727563	0.594	rs5758408	ENSG00000213857.3	RP11-12M9.4	-3.59	0.00036	0.0398	-0.22	-0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr22:41074180~41075239:-
HNSC	cis	rs6558174	0.965	rs4872524	ENSG00000253986.1	CTC-756D1.3	-3.59	0.00036	0.0398	-0.18	-0.16	Breast cancer;	chr8:22632024	chr8:23493009~23494198:-
HNSC	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	3.59	0.00036	0.0398	0.17	0.16	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
HNSC	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	3.59	0.00036	0.0398	0.17	0.16	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
HNSC	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	3.59	0.00036	0.0398	0.18	0.16	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
HNSC	cis	rs9911578	0.967	rs7502208	ENSG00000224738.1	AC099850.1	3.59	0.00036	0.0398	0.17	0.16	Intelligence (multi-trait analysis);	chr17:59087736	chr17:59106598~59118267:+
HNSC	cis	rs11951515	0.738	rs7720681	ENSG00000249286.1	CTD-2210P15.2	-3.59	0.00036	0.0398	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43373205	chr5:43586918~43588223:-
HNSC	cis	rs17507216	0.628	rs8032321	ENSG00000252690.3	SCARNA15	3.59	0.00036	0.0398	0.16	0.16	Excessive daytime sleepiness;	chr15:82698956	chr15:82752884~82757208:+
HNSC	cis	rs17507216	0.628	rs8040488	ENSG00000252690.3	SCARNA15	3.59	0.00036	0.0398	0.16	0.16	Excessive daytime sleepiness;	chr15:82699081	chr15:82752884~82757208:+
HNSC	cis	rs6600671	1	rs10794671	ENSG00000272583.1	RP11-344P13.6	-3.59	0.00036	0.0398	-0.18	-0.16	Hip geometry;	chr1:121426382	chr1:121518366~121518829:-
HNSC	cis	rs6600671	1	rs1856572	ENSG00000272583.1	RP11-344P13.6	-3.59	0.00036	0.0398	-0.18	-0.16	Hip geometry;	chr1:121427719	chr1:121518366~121518829:-
HNSC	cis	rs10875746	0.951	rs4760690	ENSG00000257763.1	OR5BK1P	-3.59	0.00036	0.0398	-0.21	-0.16	Longevity (90 years and older);	chr12:48169870	chr12:48355792~48356614:-
HNSC	cis	rs2562456	0.834	rs13346641	ENSG00000268081.1	RP11-678G14.2	3.59	0.00036	0.0398	0.23	0.16	Pain;	chr19:21409481	chr19:21554640~21569237:-
HNSC	cis	rs4427176	0.507	rs13249683	ENSG00000254340.1	RP11-10A14.3	-3.59	0.00036	0.0399	-0.23	-0.16	Mosquito bite size;	chr8:9745028	chr8:9141424~9145435:+
HNSC	cis	rs6600671	1	rs4844381	ENSG00000272583.1	RP11-344P13.6	-3.59	0.00036	0.0399	-0.18	-0.16	Hip geometry;	chr1:121443040	chr1:121518366~121518829:-
HNSC	cis	rs801193	0.761	rs2659888	ENSG00000273142.1	RP11-458F8.4	-3.59	0.00036	0.0399	-0.14	-0.16	Aortic root size;	chr7:66765184	chr7:66902857~66906297:+
HNSC	cis	rs944002	1	rs2297067	ENSG00000259444.1	RP11-736N17.8	-3.59	0.00036	0.0399	-0.19	-0.16	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100448	chr14:103094723~103098885:+
HNSC	cis	rs1662342	1	rs7811	ENSG00000272625.1	RP11-737O24.5	-3.59	0.00036	0.0399	-0.28	-0.16	QRS duration;	chr18:3256114	chr18:2920966~2921685:+
HNSC	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-3.59	0.00036	0.0399	-0.27	-0.16	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
HNSC	cis	rs853679	0.723	rs9366718	ENSG00000176933.5	TOB2P1	3.59	0.00036	0.0399	0.22	0.16	Depression;	chr6:28237724	chr6:28217643~28218634:-
HNSC	cis	rs1937680	0.613	rs7069812	ENSG00000236671.6	PRKG1-AS1	-3.59	0.00036	0.0399	-0.23	-0.16	Breast cancer;	chr10:51882297	chr10:52230742~52314128:-
HNSC	cis	rs8054556	0.787	rs12444108	ENSG00000250616.2	RP11-455F5.3	3.59	0.00036	0.0399	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30096430~30104116:+
HNSC	cis	rs7735319	0.735	rs34458865	ENSG00000249572.1	CTD-2203K17.1	3.59	0.000361	0.0399	0.19	0.16	Systolic blood pressure;	chr5:33049683	chr5:33424025~33440619:-
HNSC	cis	rs8044868	0.53	rs8060770	ENSG00000259209.3	RP5-991G20.2	3.59	0.000361	0.0399	0.18	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72121795	chr16:72805998~72809872:+
HNSC	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-3.59	0.000361	0.0399	-0.18	-0.16	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
HNSC	cis	rs4648045	0.796	rs7683854	ENSG00000230069.3	LRRC37A15P	-3.59	0.000361	0.0399	-0.17	-0.16	Lymphocyte percentage of white cells;	chr4:102608899	chr4:102727274~102730721:-
HNSC	cis	rs2692194	0.522	rs2612183	ENSG00000278600.1	RP11-81A1.6	-3.59	0.000361	0.0399	-0.15	-0.16	IgG glycosylation;	chr15:79721190	chr15:79920195~79922455:-
HNSC	cis	rs2638953	0.815	rs11049669	ENSG00000257176.2	RP11-996F15.2	-3.59	0.000361	0.0399	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498982	chr12:29280418~29317848:-
HNSC	cis	rs4787951	0.754	rs3024560	ENSG00000259940.2	CTD-3203P2.1	3.59	0.000361	0.0399	0.17	0.16	Eosinophil percentage of white cells;	chr16:27345346	chr16:27213308~27214993:-
HNSC	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	3.59	0.000361	0.0399	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
HNSC	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000361	0.0399	-0.22	-0.16	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000361	0.0399	-0.22	-0.16	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000361	0.0399	-0.22	-0.16	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
HNSC	cis	rs526231	0.543	rs26523	ENSG00000250682.4	LINC00491	3.59	0.000361	0.0399	0.22	0.16	Primary biliary cholangitis;	chr5:103120550	chr5:102609156~102671559:-
HNSC	cis	rs9313772	1	rs7715501	ENSG00000254350.1	RP11-542A14.1	-3.59	0.000361	0.04	-0.19	-0.16	Blood pressure;	chr5:158375262	chr5:158424585~158452758:+
HNSC	cis	rs12030196	1	rs932770	ENSG00000230812.4	LINC01358	3.59	0.000361	0.04	0.19	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017934	chr1:59020387~59044614:+
HNSC	cis	rs6012564	1	rs911411	ENSG00000227431.4	CSE1L-AS1	3.59	0.000361	0.04	0.18	0.16	Anger;	chr20:49101894	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs6063352	ENSG00000227431.4	CSE1L-AS1	3.59	0.000361	0.04	0.18	0.16	Anger;	chr20:49102057	chr20:49040463~49046044:-
HNSC	cis	rs6968419	0.963	rs10953811	ENSG00000237870.5	AC073130.1	3.59	0.000361	0.04	0.18	0.16	Intraocular pressure;	chr7:116172451	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.815	rs6977380	ENSG00000237870.5	AC073130.1	3.59	0.000361	0.04	0.18	0.16	Intraocular pressure;	chr7:116174756	chr7:116275606~116286734:-
HNSC	cis	rs4252134	0.96	rs1897108	ENSG00000233342.1	RP11-235G24.3	3.59	0.000361	0.04	0.2	0.16	Giant cell arteritis;	chr6:160725672	chr6:160926369~160927162:+
HNSC	cis	rs2836974	0.666	rs12626405	ENSG00000255568.3	BRWD1-AS2	-3.59	0.000361	0.04	-0.14	-0.16	Cognitive function;	chr21:39291195	chr21:39313935~39314962:+
HNSC	cis	rs7688540	0.76	rs4510422	ENSG00000250892.1	RP11-1365D11.1	-3.59	0.000362	0.04	-0.25	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:201409~205009:-
HNSC	cis	rs9914544	0.545	rs4393623	ENSG00000264885.1	RP11-815I9.4	-3.59	0.000362	0.04	-0.16	-0.16	Educational attainment (years of education);	chr17:18872587	chr17:18667629~18669461:-
HNSC	cis	rs4664304	0.511	rs2303547	ENSG00000226266.5	AC009961.3	3.59	0.000362	0.04	0.18	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159835318	chr2:159670708~159712435:-
HNSC	cis	rs454217	0.521	rs11106512	ENSG00000277851.1	RP11-756G20.1	-3.59	0.000362	0.04	-0.18	-0.16	Smoking quantity;	chr12:92333017	chr12:92247756~92363832:-
HNSC	cis	rs7246760	0.5	rs7250760	ENSG00000267289.1	CTD-2623N2.11	3.59	0.000362	0.04	0.25	0.16	Pursuit maintenance gain;	chr19:9878622	chr19:9834079~9835013:-
HNSC	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-3.59	0.000362	0.04	-0.26	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
HNSC	cis	rs910316	0.726	rs12882664	ENSG00000279594.1	RP11-950C14.10	3.59	0.000362	0.04	0.2	0.16	Height;	chr14:74980075	chr14:75011269~75012851:-
HNSC	cis	rs1408799	0.598	rs13283345	ENSG00000235448.1	LURAP1L-AS1	3.59	0.000362	0.04	0.2	0.16	Eye color;Blue vs. green eyes;	chr9:12650198	chr9:12700100~12814345:-
HNSC	cis	rs9302065	1	rs2389236	ENSG00000223298.1	RNY3P8	3.59	0.000362	0.04	0.16	0.16	Blood metabolite levels;	chr13:95319223	chr13:95310830~95310955:-
HNSC	cis	rs72949976	0.734	rs62189579	ENSG00000270659.1	RP11-105N14.1	3.59	0.000362	0.04	0.17	0.16	Squamous cell lung carcinoma;Lung cancer;	chr2:213152260	chr2:213152970~213153659:+
HNSC	cis	rs7246657	0.722	rs16958863	ENSG00000276846.1	CTD-3220F14.3	3.59	0.000362	0.04	0.22	0.16	Coronary artery calcification;	chr19:37633334	chr19:37314868~37315620:-
HNSC	cis	rs3779195	0.524	rs80195155	ENSG00000183444.10	OR7E38P	-3.59	0.000362	0.04	-0.24	-0.16	Sex hormone-binding globulin levels;	chr7:98248841	chr7:97966090~97967074:-
HNSC	cis	rs3748656	0.887	rs11102496	ENSG00000273483.1	RP4-671G15.2	3.59	0.000362	0.04	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112565842	chr1:112517799~112518441:-
HNSC	cis	rs3748656	0.945	rs10857967	ENSG00000273483.1	RP4-671G15.2	3.59	0.000362	0.04	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112577971	chr1:112517799~112518441:-
HNSC	cis	rs2048656	0.605	rs13248108	ENSG00000233609.3	RP11-62H7.2	3.59	0.000362	0.04	0.17	0.16	Schizophrenia;	chr8:9793763	chr8:8961200~8979025:+
HNSC	cis	rs6568686	0.786	rs6911772	ENSG00000255389.1	C6orf3	-3.59	0.000362	0.04	-0.21	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111536435	chr6:111599875~111602295:+
HNSC	cis	rs9467711	0.606	rs9393708	ENSG00000241549.7	GUSBP2	-3.59	0.000362	0.04	-0.25	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26362415	chr6:26871484~26956554:-
HNSC	cis	rs1881509	0.623	rs7101802	ENSG00000255153.1	TOLLIP-AS1	-3.59	0.000362	0.04	-0.18	-0.16	Heroin dependence;	chr11:1416552	chr11:1309769~1310707:+
HNSC	cis	rs4713118	0.513	rs149954	ENSG00000219891.2	ZSCAN12P1	3.59	0.000362	0.04	0.22	0.16	Parkinson's disease;	chr6:28067468	chr6:28091154~28093664:+
HNSC	cis	rs8059260	0.604	rs741176	ENSG00000262488.1	RP11-876N24.1	-3.59	0.000362	0.04	-0.23	-0.16	Alcohol consumption over the past year;	chr16:11051953	chr16:10840384~10841544:-
HNSC	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-3.59	0.000362	0.04	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
HNSC	cis	rs12701220	0.901	rs12701713	ENSG00000224079.1	AC091729.7	3.59	0.000362	0.04	0.23	0.16	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1074450~1078036:+
HNSC	cis	rs6517329	0.564	rs2835287	ENSG00000214867.3	SRSF9P1	-3.59	0.000362	0.04	-0.2	-0.16	Schizophrenia;	chr21:36148980	chr21:36295173~36295702:-
HNSC	cis	rs73201462	1	rs6798749	ENSG00000231305.3	RP11-723O4.2	3.59	0.000362	0.04	0.21	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128338054	chr3:128861313~128871540:-
HNSC	cis	rs2839186	0.771	rs2839155	ENSG00000239415.1	AP001469.9	3.59	0.000362	0.04	0.15	0.16	Testicular germ cell tumor;	chr21:46220078	chr21:46251549~46254133:-
HNSC	cis	rs615632	0.53	rs10092464	ENSG00000233609.3	RP11-62H7.2	-3.59	0.000362	0.04	-0.16	-0.16	Neuroticism;	chr8:9946675	chr8:8961200~8979025:+
HNSC	cis	rs2439831	0.867	rs2447208	ENSG00000166763.7	STRCP1	-3.59	0.000362	0.04	-0.24	-0.16	Lung cancer in ever smokers;	chr15:43641697	chr15:43699488~43718184:-
HNSC	cis	rs11711311	1	rs10934243	ENSG00000241529.3	RN7SL767P	-3.59	0.000362	0.04	-0.21	-0.16	IgG glycosylation;	chr3:113711392	chr3:113632704~113632998:+
HNSC	cis	rs7085104	0.591	rs4919683	ENSG00000213061.2	PFN1P11	3.59	0.000362	0.04	0.2	0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102838011~102845473:-
HNSC	cis	rs2016266	0.819	rs4758965	ENSG00000270175.1	RP11-793H13.11	-3.59	0.000362	0.04	-0.15	-0.16	Bone mineral density;Bone mineral density (spine);	chr12:53268951	chr12:53500162~53500936:-
HNSC	cis	rs561341	0.709	rs8068049	ENSG00000278867.1	RP11-640N20.4	3.59	0.000362	0.04	0.25	0.16	Hip circumference adjusted for BMI;	chr17:31856838	chr17:32051030~32053208:+
HNSC	cis	rs12188164	0.515	rs11742006	ENSG00000225138.6	CTD-2228K2.7	3.59	0.000362	0.0401	0.2	0.16	Cystic fibrosis severity;	chr5:408414	chr5:473236~480884:+
HNSC	cis	rs2030746	0.521	rs6750309	ENSG00000227788.1	AC012363.8	3.59	0.000362	0.0401	0.16	0.16	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120574615	chr2:120211727~120212862:+
HNSC	cis	rs12908161	0.853	rs12912342	ENSG00000229212.6	RP11-561C5.4	-3.59	0.000362	0.0401	-0.21	-0.16	Schizophrenia;	chr15:84704985	chr15:85205440~85234795:-
HNSC	cis	rs7274811	0.625	rs293725	ENSG00000277301.1	RP5-1184F4.7	-3.59	0.000362	0.0401	-0.18	-0.16	Height;	chr20:33341837	chr20:32509959~32520285:+
HNSC	cis	rs2307394	0.928	rs72855232	ENSG00000281469.1	RP11-567F11.1	3.59	0.000362	0.0401	0.18	0.16	Urate levels;	chr2:147991398	chr2:148044380~148044894:+
HNSC	cis	rs10875746	0.551	rs2054903	ENSG00000257763.1	OR5BK1P	-3.59	0.000362	0.0401	-0.21	-0.16	Longevity (90 years and older);	chr12:48330710	chr12:48355792~48356614:-
HNSC	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	3.59	0.000362	0.0401	0.18	0.16	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
HNSC	cis	rs365302	0.767	rs413952	ENSG00000235086.1	FNDC1-IT1	3.59	0.000362	0.0401	0.19	0.16	Coronary heart disease;	chr6:159191629	chr6:159240786~159243329:+
HNSC	cis	rs67311347	1	rs73078163	ENSG00000280739.1	EIF1B-AS1	3.59	0.000362	0.0401	0.19	0.16	Renal cell carcinoma;	chr3:40438467	chr3:40173145~40309698:-
HNSC	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000362	0.0401	-0.22	-0.16	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
HNSC	cis	rs9646303	0.774	rs9936994	ENSG00000276337.1	RP11-106D4.2	3.59	0.000363	0.0401	0.21	0.16	Major depressive disorder;	chr16:87469209	chr16:87470370~87474370:-
HNSC	cis	rs73191547	0.519	rs7812517	ENSG00000255310.2	AF131215.2	-3.59	0.000363	0.0401	-0.16	-0.16	Schizophrenia;	chr8:10203793	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.874	rs12509054	ENSG00000250412.1	KLHL2P1	3.59	0.000363	0.0401	0.21	0.16	Corneal astigmatism;	chr4:119193920	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.874	rs10022508	ENSG00000250412.1	KLHL2P1	3.59	0.000363	0.0401	0.21	0.16	Corneal astigmatism;	chr4:119194073	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.874	rs12502503	ENSG00000250412.1	KLHL2P1	3.59	0.000363	0.0401	0.21	0.16	Corneal astigmatism;	chr4:119195100	chr4:119334329~119378233:+
HNSC	cis	rs7577696	0.752	rs212721	ENSG00000272716.1	RP11-563N4.1	3.59	0.000363	0.0401	0.17	0.16	Inflammatory biomarkers;	chr2:32240960	chr2:32165046~32165757:-
HNSC	cis	rs7927592	0.913	rs10896338	ENSG00000255031.4	RP11-802E16.3	3.59	0.000363	0.0401	0.15	0.16	Total body bone mineral density;	chr11:68531892	chr11:68050740~68053762:+
HNSC	cis	rs7688540	0.8	rs28531997	ENSG00000250892.1	RP11-1365D11.1	-3.59	0.000363	0.0401	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:201409~205009:-
HNSC	cis	rs858267	0.661	rs7786708	ENSG00000226816.2	AC005082.12	3.59	0.000363	0.0401	0.35	0.16	Blood protein levels;	chr7:23075797	chr7:23206013~23208045:+
HNSC	cis	rs6671200	0.748	rs12753842	ENSG00000226026.4	RP11-57H12.3	3.59	0.000363	0.0401	0.27	0.16	Stearic acid (18:0) levels;	chr1:95049769	chr1:95163219~95233982:-
HNSC	cis	rs7107174	1	rs2512549	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000363	0.0401	-0.23	-0.16	Testicular germ cell tumor;	chr11:78229117	chr11:78423982~78429836:-
HNSC	cis	rs3929778	0.883	rs6038521	ENSG00000278192.1	RP5-1056H1.2	3.59	0.000363	0.0401	0.22	0.16	QRS complex (Cornell);	chr20:6494587	chr20:6065966~6067897:-
HNSC	cis	rs7937890	0.504	rs2575847	ENSG00000254418.1	RP11-21L19.1	3.59	0.000363	0.0401	0.19	0.16	Mitochondrial DNA levels;	chr11:14449626	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.559	rs2575825	ENSG00000254418.1	RP11-21L19.1	3.59	0.000363	0.0401	0.19	0.16	Mitochondrial DNA levels;	chr11:14450550	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.559	rs2597206	ENSG00000254418.1	RP11-21L19.1	3.59	0.000363	0.0401	0.19	0.16	Mitochondrial DNA levels;	chr11:14455992	chr11:14262846~14273691:-
HNSC	cis	rs853679	0.599	rs13193295	ENSG00000226314.6	ZNF192P1	-3.59	0.000363	0.0401	-0.3	-0.16	Depression;	chr6:28035450	chr6:28161781~28169594:+
HNSC	cis	rs10078	0.559	rs2037077	ENSG00000225138.6	CTD-2228K2.7	3.59	0.000363	0.0401	0.28	0.16	Fat distribution (HIV);	chr5:447111	chr5:473236~480884:+
HNSC	cis	rs71520386	0.846	rs77741999	ENSG00000230658.1	KLHL7-AS1	3.59	0.000363	0.0401	0.25	0.16	Fibrinogen levels;	chr7:22775785	chr7:23101228~23105703:-
HNSC	cis	rs10158481	0.911	rs6600265	ENSG00000224183.1	SDHDP6	-3.59	0.000363	0.0401	-0.2	-0.16	Urate levels in obese individuals;	chr1:25168789	chr1:25294164~25294643:-
HNSC	cis	rs6095360	1	rs6019604	ENSG00000227431.4	CSE1L-AS1	-3.59	0.000363	0.0401	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49036961	chr20:49040463~49046044:-
HNSC	cis	rs6988985	0.791	rs13257680	ENSG00000253741.1	CTD-2292P10.4	3.59	0.000363	0.0401	0.16	0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142915893	chr8:142702252~142726973:-
HNSC	cis	rs9311474	0.508	rs11720159	ENSG00000243224.1	RP5-1157M23.2	-3.59	0.000363	0.0401	-0.16	-0.16	Electroencephalogram traits;	chr3:52583786	chr3:52239258~52241097:+
HNSC	cis	rs6543140	0.693	rs7579737	ENSG00000234389.1	AC007278.3	3.59	0.000363	0.0401	0.17	0.16	Blood protein levels;	chr2:102370901	chr2:102438713~102440475:+
HNSC	cis	rs853679	1	rs1778508	ENSG00000219891.2	ZSCAN12P1	-3.59	0.000363	0.0401	-0.26	-0.16	Depression;	chr6:28262103	chr6:28091154~28093664:+
HNSC	cis	rs801193	0.904	rs4718405	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000363	0.0401	-0.14	-0.16	Aortic root size;	chr7:66789659	chr7:66902857~66906297:+
HNSC	cis	rs911263	0.961	rs8008961	ENSG00000240210.3	RP11-204K16.1	3.59	0.000363	0.0401	0.19	0.16	Primary biliary cholangitis;	chr14:68285926	chr14:68338728~68339528:-
HNSC	cis	rs2084898	1	rs2084898	ENSG00000176984.5	AP000679.2	3.59	0.000363	0.0401	0.26	0.16	Stroke (pediatric);	chr11:120156040	chr11:120168977~120171679:+
HNSC	cis	rs2562456	0.833	rs55875743	ENSG00000268119.4	CTD-2561J22.5	3.59	0.000363	0.0401	0.25	0.16	Pain;	chr19:21383393	chr19:21444241~21463908:-
HNSC	cis	rs2518049	0.52	rs80177247	ENSG00000224034.1	RP11-445P17.8	-3.59	0.000363	0.0402	-0.24	-0.16	Metabolic traits;	chr10:5254280	chr10:5266033~5271236:-
HNSC	cis	rs9487051	0.714	rs6930733	ENSG00000219700.1	PTCHD3P3	3.59	0.000363	0.0402	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109310384	chr6:109288571~109290503:-
HNSC	cis	rs9487051	0.714	rs9386797	ENSG00000219700.1	PTCHD3P3	3.59	0.000363	0.0402	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109311317	chr6:109288571~109290503:-
HNSC	cis	rs6968419	0.755	rs4710	ENSG00000237870.5	AC073130.1	3.59	0.000364	0.0402	0.2	0.16	Intraocular pressure;	chr7:116257338	chr7:116275606~116286734:-
HNSC	cis	rs7572733	1	rs1579695	ENSG00000222017.1	AC011997.1	3.59	0.000364	0.0402	0.19	0.16	Dermatomyositis;	chr2:198035639	chr2:197693106~197774823:+
HNSC	cis	rs3764021	0.87	rs2401391	ENSG00000256673.1	RP11-599J14.2	-3.59	0.000364	0.0402	-0.15	-0.16	Type 1 diabetes;	chr12:9725987	chr12:9398355~9414851:-
HNSC	cis	rs804280	0.542	rs34117651	ENSG00000227888.4	FAM66A	3.59	0.000364	0.0402	0.17	0.16	Myopia (pathological);	chr8:11934108	chr8:12362019~12388296:+
HNSC	cis	rs13006863	1	rs13006863	ENSG00000257800.1	FNBP1P1	-3.59	0.000364	0.0402	-0.17	-0.16	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74236439	chr2:74120680~74123218:+
HNSC	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-3.59	0.000364	0.0402	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
HNSC	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	3.59	0.000364	0.0402	0.28	0.16	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
HNSC	cis	rs859767	0.741	rs4954156	ENSG00000224043.6	CCNT2-AS1	3.59	0.000364	0.0402	0.2	0.16	Neuroticism;	chr2:134638293	chr2:134735464~134918710:-
HNSC	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000364	0.0402	-0.2	-0.16	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
HNSC	cis	rs10895275	0.649	rs2846836	ENSG00000277459.1	RP11-732A21.3	-3.59	0.000364	0.0402	-0.18	-0.16	Migraine;	chr11:102234942	chr11:102109827~102110457:-
HNSC	cis	rs7011507	0.562	rs10092171	ENSG00000253608.1	RP11-770E5.1	-3.59	0.000364	0.0402	-0.25	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48514607	chr8:48551567~48698510:+
HNSC	cis	rs67072384	0.892	rs67034709	ENSG00000245148.2	ARAP1-AS2	3.59	0.000364	0.0402	0.23	0.16	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72739959	chr11:72700474~72705607:+
HNSC	cis	rs643506	0.817	rs658373	ENSG00000230911.1	PPIHP1	-3.59	0.000364	0.0402	-0.21	-0.16	Breast cancer;	chr11:111812267	chr11:112029858~112030367:-
HNSC	cis	rs4256159	0.696	rs11708105	ENSG00000228956.7	SATB1-AS1	3.59	0.000364	0.0402	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18718957	chr3:18445024~18920401:+
HNSC	cis	rs6142618	0.819	rs6057540	ENSG00000275576.1	RP5-836N17.4	-3.59	0.000364	0.0402	-0.17	-0.16	Inflammatory bowel disease;	chr20:32225342	chr20:32116171~32116629:+
HNSC	cis	rs801193	0.967	rs2707853	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000364	0.0402	-0.14	-0.16	Aortic root size;	chr7:66749023	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs2659889	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000364	0.0402	-0.14	-0.16	Aortic root size;	chr7:66752125	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs3800812	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000364	0.0402	-0.14	-0.16	Aortic root size;	chr7:66758474	chr7:66902857~66906297:+
HNSC	cis	rs801193	1	rs4279493	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000364	0.0402	-0.14	-0.16	Aortic root size;	chr7:66761633	chr7:66902857~66906297:+
HNSC	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	3.59	0.000364	0.0402	0.2	0.16	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	3.59	0.000364	0.0402	0.2	0.16	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
HNSC	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-3.59	0.000364	0.0402	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
HNSC	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-3.59	0.000364	0.0402	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
HNSC	cis	rs4295623	0.504	rs11250160	ENSG00000255052.4	FAM66D	3.59	0.000364	0.0402	0.17	0.16	Morning vs. evening chronotype;	chr8:11735208	chr8:12115782~12177550:+
HNSC	cis	rs10073892	0.789	rs62371036	ENSG00000250682.4	LINC00491	-3.59	0.000364	0.0402	-0.24	-0.16	Cognitive decline (age-related);	chr5:102504399	chr5:102609156~102671559:-
HNSC	cis	rs67311347	0.544	rs2887965	ENSG00000280739.1	EIF1B-AS1	-3.59	0.000364	0.0402	-0.17	-0.16	Renal cell carcinoma;	chr3:40292663	chr3:40173145~40309698:-
HNSC	cis	rs2253762	0.736	rs2459082	ENSG00000276742.1	RP11-500G22.4	3.59	0.000364	0.0402	0.19	0.16	Breast cancer;	chr10:122036570	chr10:121956782~121957098:+
HNSC	cis	rs4713118	0.539	rs200967	ENSG00000219891.2	ZSCAN12P1	3.59	0.000364	0.0402	0.22	0.16	Parkinson's disease;	chr6:27894349	chr6:28091154~28093664:+
HNSC	cis	rs1028883	0.839	rs9543400	ENSG00000228295.1	LINC00392	-3.59	0.000364	0.0402	-0.17	-0.16	Lean body mass;	chr13:73576261	chr13:73564244~73588070:+
HNSC	cis	rs3771570	1	rs62186411	ENSG00000260942.1	CAPN10-AS1	-3.59	0.000364	0.0402	-0.18	-0.16	Prostate cancer;	chr2:241297252	chr2:240582700~240586699:-
HNSC	cis	rs10484434	0.901	rs62394550	ENSG00000272810.1	U91328.22	3.59	0.000364	0.0402	0.19	0.16	HIV-1 viral setpoint;	chr6:26034024	chr6:26013241~26013757:+
HNSC	cis	rs6988985	0.589	rs13252628	ENSG00000247317.3	RP11-273G15.2	3.59	0.000364	0.0402	0.18	0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142913528	chr8:142981738~143018437:-
HNSC	cis	rs921874	0.673	rs7943346	ENSG00000246523.6	RP11-736K20.6	3.59	0.000364	0.0402	0.24	0.16	Total body bone mineral density;	chr11:87031327	chr11:86955619~87000959:+
HNSC	cis	rs10783487	0.803	rs2272484	ENSG00000257542.4	OR7E47P	-3.59	0.000364	0.0402	-0.2	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52087533	chr12:52079696~52108261:+
HNSC	cis	rs1538970	0.924	rs4660855	ENSG00000234329.1	RP11-767N6.2	3.59	0.000364	0.0402	0.19	0.16	Platelet count;	chr1:45434123	chr1:45651039~45651826:-
HNSC	cis	rs859767	0.741	rs35599954	ENSG00000224043.6	CCNT2-AS1	3.59	0.000365	0.0403	0.2	0.16	Neuroticism;	chr2:134634911	chr2:134735464~134918710:-
HNSC	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-3.59	0.000365	0.0403	-0.19	-0.16	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
HNSC	cis	rs853679	0.567	rs7740429	ENSG00000217862.2	HIST1H4PS1	-3.59	0.000365	0.0403	-0.18	-0.16	Depression;	chr6:28431469	chr6:27807075~27807339:+
HNSC	cis	rs71636778	0.509	rs35108146	ENSG00000260063.1	RP5-968P14.2	-3.59	0.000365	0.0403	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921949	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12752711	ENSG00000260063.1	RP5-968P14.2	-3.59	0.000365	0.0403	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26923767	chr1:26692132~26694131:-
HNSC	cis	rs9595908	1	rs9591165	ENSG00000215515.2	IFIT1P1	3.59	0.000365	0.0403	0.19	0.16	Body mass index;	chr13:32611016	chr13:32384660~32386108:+
HNSC	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-3.59	0.000365	0.0403	-0.18	-0.16	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
HNSC	cis	rs34792	0.528	rs153804	ENSG00000207425.1	Y_RNA	3.59	0.000365	0.0403	0.19	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15459197	chr16:14915457~14915556:-
HNSC	cis	rs763567	0.585	rs651386	ENSG00000271811.1	RP1-79C4.4	3.59	0.000365	0.0403	0.17	0.16	Tonsillectomy;	chr1:170622169	chr1:170667381~170669425:+
HNSC	cis	rs189798	0.807	rs330905	ENSG00000233609.3	RP11-62H7.2	3.59	0.000365	0.0403	0.16	0.16	Myopia (pathological);	chr8:9136041	chr8:8961200~8979025:+
HNSC	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	3.59	0.000365	0.0403	0.15	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
HNSC	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	3.59	0.000365	0.0403	0.15	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
HNSC	cis	rs2905347	1	rs2905347	ENSG00000232759.1	AC002480.3	-3.59	0.000365	0.0403	-0.18	-0.16	Major depression and alcohol dependence;	chr7:22580700	chr7:22563337~22573996:+
HNSC	cis	rs2919917	0.628	rs1351742	ENSG00000260398.1	RP11-594N15.3	3.59	0.000365	0.0403	0.22	0.16	Lymphocyte counts;	chr8:78655823	chr8:78605952~78609705:+
HNSC	cis	rs2919917	0.666	rs982032	ENSG00000260398.1	RP11-594N15.3	3.59	0.000365	0.0403	0.22	0.16	Lymphocyte counts;	chr8:78655825	chr8:78605952~78609705:+
HNSC	cis	rs8013055	0.796	rs4075104	ENSG00000258701.1	LINC00638	-3.59	0.000365	0.0403	-0.22	-0.16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);	chr14:105533877	chr14:104821201~104823718:+
HNSC	cis	rs16858210	0.542	rs12636826	ENSG00000234371.6	RPSAP31	3.59	0.000365	0.0403	0.21	0.16	Menopause (age at onset);	chr3:183840793	chr3:183884924~183888449:+
HNSC	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-3.59	0.000365	0.0403	-0.16	-0.16	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-3.59	0.000365	0.0403	-0.16	-0.16	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-3.59	0.000365	0.0403	-0.16	-0.16	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-3.59	0.000365	0.0403	-0.16	-0.16	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
HNSC	cis	rs4900538	0.892	rs4906208	ENSG00000272533.1	SNORA28	-3.59	0.000365	0.0403	-0.17	-0.16	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102490152	chr14:103337849~103337974:+
HNSC	cis	rs4900538	0.927	rs8005804	ENSG00000272533.1	SNORA28	-3.59	0.000365	0.0403	-0.17	-0.16	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:102491466	chr14:103337849~103337974:+
HNSC	cis	rs7824557	0.564	rs6601584	ENSG00000255495.1	AC145124.2	-3.59	0.000365	0.0403	-0.18	-0.16	Retinal vascular caliber;	chr8:11374834	chr8:12194467~12196280:+
HNSC	cis	rs12545912	0.865	rs4240632	ENSG00000254340.1	RP11-10A14.3	-3.59	0.000365	0.0403	-0.23	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9695481	chr8:9141424~9145435:+
HNSC	cis	rs3764021	0.87	rs10743819	ENSG00000256673.1	RP11-599J14.2	-3.59	0.000365	0.0403	-0.15	-0.16	Type 1 diabetes;	chr12:9724172	chr12:9398355~9414851:-
HNSC	cis	rs853679	0.607	rs34878803	ENSG00000280107.1	AL022393.9	-3.59	0.000365	0.0403	-0.29	-0.16	Depression;	chr6:28282402	chr6:28170845~28172521:+
HNSC	cis	rs62292953	0.719	rs62292465	ENSG00000248724.5	NPHP3-AS1	-3.59	0.000365	0.0403	-0.39	-0.16	Red cell distribution width;	chr3:132678948	chr3:132721750~132874223:+
HNSC	cis	rs6988985	0.589	rs6995989	ENSG00000247317.3	RP11-273G15.2	-3.59	0.000365	0.0403	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142904167	chr8:142981738~143018437:-
HNSC	cis	rs7246657	0.722	rs2972438	ENSG00000276846.1	CTD-3220F14.3	3.59	0.000365	0.0403	0.22	0.16	Coronary artery calcification;	chr19:37719946	chr19:37314868~37315620:-
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-3.59	0.000365	0.0403	-0.19	-0.16	Depression;	chr6:28229408	chr6:28170845~28172521:+
HNSC	cis	rs9633740	0.504	rs1993484	ENSG00000226659.1	RP11-137H2.4	-3.59	0.000365	0.0403	-0.25	-0.16	Post bronchodilator FEV1;	chr10:80462942	chr10:80529597~80535942:-
HNSC	cis	rs896655	0.631	rs7049092	ENSG00000244230.3	RN7SL151P	-3.59	0.000365	0.0403	-0.17	-0.16	Coronary artery disease;	chr9:21787263	chr9:21699314~21699596:+
HNSC	cis	rs71636778	0.509	rs12741472	ENSG00000260063.1	RP5-968P14.2	-3.59	0.000365	0.0403	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895118	chr1:26692132~26694131:-
HNSC	cis	rs750460	1	rs12441130	ENSG00000261801.4	LOXL1-AS1	-3.59	0.000365	0.0403	-0.15	-0.16	Height;	chr15:73942561	chr15:73908071~73928248:-
HNSC	cis	rs9880211	0.635	rs6775778	ENSG00000273486.1	RP11-731C17.2	-3.59	0.000366	0.0403	-0.15	-0.16	Height;Body mass index;	chr3:136007837	chr3:136837338~136839021:-
HNSC	cis	rs2638953	0.925	rs7967281	ENSG00000257176.2	RP11-996F15.2	3.59	0.000366	0.0403	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:29280418~29317848:-
HNSC	cis	rs6142618	0.777	rs6058635	ENSG00000275576.1	RP5-836N17.4	-3.59	0.000366	0.0403	-0.17	-0.16	Inflammatory bowel disease;	chr20:32304122	chr20:32116171~32116629:+
HNSC	cis	rs853679	0.825	rs8180562	ENSG00000219891.2	ZSCAN12P1	3.59	0.000366	0.0404	0.3	0.16	Depression;	chr6:28173682	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.882	rs9380064	ENSG00000219891.2	ZSCAN12P1	3.59	0.000366	0.0404	0.3	0.16	Depression;	chr6:28175340	chr6:28091154~28093664:+
HNSC	cis	rs10809307	1	rs10809307	ENSG00000270372.1	RP11-109M17.2	3.59	0.000366	0.0404	0.2	0.16	Interferon gamma-induced protein 10 levels;	chr9:11045908	chr9:10948372~10948481:-
HNSC	cis	rs10895275	1	rs10895275	ENSG00000225678.2	AP000619.5	3.59	0.000366	0.0404	0.2	0.16	Migraine;	chr11:102212877	chr11:102751070~102754943:-
HNSC	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-3.59	0.000366	0.0404	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
HNSC	cis	rs6860540	0.796	rs10475585	ENSG00000251405.2	CTB-109A12.1	-3.59	0.000366	0.0404	-0.19	-0.16	Inflammatory skin disease;	chr5:157488080	chr5:157362615~157460078:-
HNSC	cis	rs11700980	0.551	rs16983159	ENSG00000232855.5	AF131217.1	3.59	0.000366	0.0404	0.23	0.16	QRS complex (12-leadsum);	chr21:28746004	chr21:28439346~28674848:-
HNSC	cis	rs7124676	1	rs7124676	ENSG00000257086.1	RP11-783K16.13	-3.59	0.000366	0.0404	-0.17	-0.16	Obesity-related traits;	chr11:64545819	chr11:64246939~64249494:-
HNSC	cis	rs8031584	0.958	rs7176569	ENSG00000270015.1	RP11-540B6.6	3.59	0.000366	0.0404	0.17	0.16	Huntington's disease progression;	chr15:30952292	chr15:30926514~30928407:+
HNSC	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000366	0.0404	-0.24	-0.16	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
HNSC	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-3.59	0.000366	0.0404	-0.18	-0.16	QT interval;	chr12:29303562	chr12:29280418~29317848:-
HNSC	cis	rs11168618	0.846	rs7974213	ENSG00000240399.1	RP1-228P16.1	-3.59	0.000366	0.0404	-0.14	-0.16	Adiponectin levels;	chr12:48487709	chr12:48054813~48055591:-
HNSC	cis	rs773506	0.628	rs10991816	ENSG00000229694.5	RP11-305L7.6	3.59	0.000366	0.0404	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91188231	chr9:91119062~91182762:+
HNSC	cis	rs12623288	0.51	rs7577700	ENSG00000233845.1	AC093732.1	3.59	0.000366	0.0404	0.35	0.16	Hair morphology;	chr2:46383466	chr2:47035279~47040524:-
HNSC	cis	rs62034325	0.697	rs710410	ENSG00000261766.1	RP11-22P6.2	-3.59	0.000366	0.0404	-0.16	-0.16	Body mass index;	chr16:28592021	chr16:28862166~28863340:-
HNSC	cis	rs2243480	0.901	rs313808	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000366	0.0404	-0.24	-0.16	Diabetic kidney disease;	chr7:66034886	chr7:66848496~66858136:+
HNSC	cis	rs12534093	0.921	rs12700440	ENSG00000234286.1	AC006026.13	-3.59	0.000366	0.0404	-0.2	-0.16	Infant length;Height;	chr7:23453562	chr7:23680195~23680786:-
HNSC	cis	rs3748656	0.895	rs11102498	ENSG00000273483.1	RP4-671G15.2	3.59	0.000366	0.0404	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112576820	chr1:112517799~112518441:-
HNSC	cis	rs2967951	0.908	rs2934219	ENSG00000280369.1	CTD-2256P15.3	3.59	0.000366	0.0404	0.23	0.16	Body mass index;	chr5:10412415	chr5:10342813~10343131:+
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000269918.1	AF131215.9	3.59	0.000366	0.0404	0.16	0.16	Neuroticism;	chr8:11936935	chr8:11104691~11106704:-
HNSC	cis	rs11157436	0.602	rs11157438	ENSG00000211814.1	TRAV35	-3.59	0.000366	0.0404	-0.15	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22221896~22222475:+
HNSC	cis	rs891998	1	rs891998	ENSG00000253683.1	CTB-79E8.3	-3.59	0.000366	0.0404	-0.16	-0.16	Tonsillectomy;	chr5:172491770	chr5:172656522~172656713:-
HNSC	cis	rs2286492	0.881	rs118163088	ENSG00000221740.1	SNORD93	-3.59	0.000366	0.0404	-0.32	-0.16	Bipolar disorder;	chr7:23053830	chr7:22856613~22856686:+
HNSC	cis	rs72799341	0.706	rs1060506	ENSG00000279196.1	RP11-1072A3.3	3.59	0.000366	0.0404	0.19	0.16	Diastolic blood pressure;	chr16:31122128	chr16:30984630~30988270:-
HNSC	cis	rs9531006	0.636	rs7330635	ENSG00000227676.3	LINC01068	3.59	0.000366	0.0404	0.25	0.16	Sleep duration;	chr13:79895804	chr13:79566727~79571436:+
HNSC	cis	rs6587515	0.901	rs2134688	ENSG00000274963.1	Metazoa_SRP	-3.59	0.000366	0.0404	-0.27	-0.16	Pericardial adipose tissue adjusted for height and weight;	chr1:150844410	chr1:150568971~150569269:-
HNSC	cis	rs73017364	1	rs79460141	ENSG00000206921.1	RNU6-481P	3.59	0.000366	0.0404	0.31	0.16	QT interval;	chr1:162215059	chr1:161401289~161401395:+
HNSC	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	3.59	0.000367	0.0404	0.15	0.16	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
HNSC	cis	rs6951245	0.58	rs78894484	ENSG00000225146.1	AC073957.15	-3.59	0.000367	0.0404	-0.22	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1029025~1043891:+
HNSC	cis	rs12188164	0.762	rs11745923	ENSG00000215246.5	RP11-43F13.3	-3.59	0.000367	0.0404	-0.18	-0.16	Cystic fibrosis severity;	chr5:475293	chr5:987180~997308:-
HNSC	cis	rs13006863	0.509	rs1667605	ENSG00000257800.1	FNBP1P1	-3.59	0.000367	0.0404	-0.15	-0.16	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74147757	chr2:74120680~74123218:+
HNSC	cis	rs12541595	0.866	rs7003871	ENSG00000255491.1	RP11-1082L8.4	-3.59	0.000367	0.0404	-0.2	-0.16	Left ventricle diastolic internal dimension;	chr8:124839268	chr8:124811618~124815682:-
HNSC	cis	rs261902	1	rs261893	ENSG00000276136.1	RP11-50I19.2	-3.59	0.000367	0.0404	-0.21	-0.16	Normalized brain volume;	chr12:32326869	chr12:32000375~32001222:+
HNSC	cis	rs261902	1	rs261892	ENSG00000276136.1	RP11-50I19.2	-3.59	0.000367	0.0404	-0.21	-0.16	Normalized brain volume;	chr12:32326897	chr12:32000375~32001222:+
HNSC	cis	rs261902	1	rs187788	ENSG00000276136.1	RP11-50I19.2	-3.59	0.000367	0.0404	-0.21	-0.16	Normalized brain volume;	chr12:32327209	chr12:32000375~32001222:+
HNSC	cis	rs160451	0.84	rs216990	ENSG00000251136.7	RP11-37B2.1	3.59	0.000367	0.0404	0.15	0.16	Leprosy;	chr8:89664572	chr8:89609409~89757727:-
HNSC	cis	rs4713118	0.513	rs9368547	ENSG00000219891.2	ZSCAN12P1	3.59	0.000367	0.0404	0.22	0.16	Parkinson's disease;	chr6:28060289	chr6:28091154~28093664:+
HNSC	cis	rs4713118	0.513	rs183244	ENSG00000219891.2	ZSCAN12P1	3.59	0.000367	0.0404	0.22	0.16	Parkinson's disease;	chr6:28064060	chr6:28091154~28093664:+
HNSC	cis	rs2255336	0.938	rs61610254	ENSG00000245648.1	RP11-277P12.20	-3.59	0.000367	0.0404	-0.24	-0.16	Blood protein levels;	chr12:10446176	chr12:10363769~10398506:+
HNSC	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	3.59	0.000367	0.0404	0.19	0.16	Height;	chr4:55544621	chr4:55540502~55540835:-
HNSC	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000367	0.0405	-0.22	-0.16	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
HNSC	cis	rs2836974	0.666	rs1888487	ENSG00000255568.3	BRWD1-AS2	-3.59	0.000367	0.0405	-0.14	-0.16	Cognitive function;	chr21:39311333	chr21:39313935~39314962:+
HNSC	cis	rs17711722	0.51	rs11767457	ENSG00000179406.6	LINC00174	-3.59	0.000367	0.0405	-0.22	-0.16	Calcium levels;	chr7:65825628	chr7:66376044~66401338:-
HNSC	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	3.59	0.000367	0.0405	0.13	0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
HNSC	cis	rs2562456	0.833	rs55875743	ENSG00000268081.1	RP11-678G14.2	3.59	0.000367	0.0405	0.24	0.16	Pain;	chr19:21383393	chr19:21554640~21569237:-
HNSC	cis	rs4948102	0.731	rs6593292	ENSG00000213650.3	RP11-760D2.7	3.59	0.000367	0.0405	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr7:56567906~56568858:-
HNSC	cis	rs4948102	0.731	rs4535700	ENSG00000213650.3	RP11-760D2.7	3.59	0.000367	0.0405	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr7:56567906~56568858:-
HNSC	cis	rs4948102	0.731	rs4543497	ENSG00000213650.3	RP11-760D2.7	3.59	0.000367	0.0405	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr7:56567906~56568858:-
HNSC	cis	rs4948102	0.767	rs4948096	ENSG00000213650.3	RP11-760D2.7	3.59	0.000367	0.0405	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr7:56567906~56568858:-
HNSC	cis	rs4948102	0.727	rs4948097	ENSG00000213650.3	RP11-760D2.7	3.59	0.000367	0.0405	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr7:56567906~56568858:-
HNSC	cis	rs13434995	0.513	rs2171617	ENSG00000249700.7	SRD5A3-AS1	3.59	0.000367	0.0405	0.22	0.16	Adiponectin levels;	chr4:55591023	chr4:55363971~55395847:-
HNSC	cis	rs8030379	0.967	rs62027761	ENSG00000230373.7	GOLGA6L5P	-3.59	0.000367	0.0405	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84507885~84516814:-
HNSC	cis	rs7720894	0.935	rs1374043	ENSG00000215032.2	GNL3LP1	-3.59	0.000367	0.0405	-0.18	-0.16	Body mass index;	chr5:61478400	chr5:60891935~60893577:-
HNSC	cis	rs8030379	1	rs12914857	ENSG00000230373.7	GOLGA6L5P	-3.59	0.000367	0.0405	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2055712	ENSG00000230373.7	GOLGA6L5P	-3.59	0.000367	0.0405	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84507885~84516814:-
HNSC	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	3.59	0.000367	0.0405	0.15	0.16	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
HNSC	cis	rs9487051	1	rs11757567	ENSG00000219700.1	PTCHD3P3	3.59	0.000367	0.0405	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109293510	chr6:109288571~109290503:-
HNSC	cis	rs359027	0.957	rs1994266	ENSG00000206573.7	THUMPD3-AS1	-3.59	0.000367	0.0405	-0.13	-0.16	Low high density lipoprotein cholesterol levels;	chr3:8418237	chr3:9349689~9398579:-
HNSC	cis	rs359027	0.957	rs1018114	ENSG00000206573.7	THUMPD3-AS1	-3.59	0.000367	0.0405	-0.13	-0.16	Low high density lipoprotein cholesterol levels;	chr3:8418397	chr3:9349689~9398579:-
HNSC	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-3.59	0.000367	0.0405	-0.26	-0.16	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
HNSC	cis	rs1722133	1	rs1722133	ENSG00000221971.3	TTC4P1	3.59	0.000367	0.0405	0.17	0.16	Sitting height ratio;	chr7:46088511	chr7:45999621~46000778:-
HNSC	cis	rs6513791	0.851	rs6030240	ENSG00000273951.1	RP4-620E11.8	3.59	0.000367	0.0405	0.27	0.16	Microalbuminuria;	chr20:42438433	chr20:41485571~41486225:-
HNSC	cis	rs6513791	0.901	rs6016794	ENSG00000273951.1	RP4-620E11.8	3.59	0.000367	0.0405	0.27	0.16	Microalbuminuria;	chr20:42438434	chr20:41485571~41486225:-
HNSC	cis	rs73198271	0.562	rs17631022	ENSG00000253893.2	FAM85B	3.59	0.000368	0.0405	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8804687	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.562	rs112717383	ENSG00000253893.2	FAM85B	3.59	0.000368	0.0405	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8805706	chr8:8167819~8226614:-
HNSC	cis	rs6840360	0.642	rs2709842	ENSG00000251611.1	RP11-610P16.1	3.59	0.000368	0.0405	0.16	0.16	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151407551~151408835:-
HNSC	cis	rs2172873	0.609	rs10860908	ENSG00000257202.1	RP11-512N21.3	3.59	0.000368	0.0405	0.23	0.16	Uterine fibroids;	chr12:102741055	chr12:101923410~101924719:-
HNSC	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-3.59	0.000368	0.0405	-0.26	-0.16	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
HNSC	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-3.59	0.000368	0.0405	-0.26	-0.16	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
HNSC	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-3.59	0.000368	0.0405	-0.26	-0.16	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
HNSC	cis	rs8062405	1	rs80275162	ENSG00000261766.1	RP11-22P6.2	-3.59	0.000368	0.0405	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28862166~28863340:-
HNSC	cis	rs2919917	0.578	rs11783804	ENSG00000260398.1	RP11-594N15.3	3.59	0.000368	0.0405	0.21	0.16	Lymphocyte counts;	chr8:78652776	chr8:78605952~78609705:+
HNSC	cis	rs6869502	0.595	rs244410	ENSG00000214784.4	AC010468.1	-3.59	0.000368	0.0405	-0.17	-0.16	Allergic disease (asthma, hay fever or eczema);	chr5:110687631	chr5:111192226~111193042:-
HNSC	cis	rs8024893	1	rs8024893	ENSG00000259448.2	RP11-16E12.1	-3.59	0.000368	0.0406	-0.22	-0.16	Red cell distribution width;	chr15:31248786	chr15:31216020~31224445:+
HNSC	cis	rs9368481	0.761	rs9357030	ENSG00000238621.1	TRI-TAT2-2	3.59	0.000368	0.0406	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:27020335~27020447:+
HNSC	cis	rs597539	0.652	rs602805	ENSG00000261625.1	RP11-554A11.4	-3.59	0.000368	0.0406	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.652	rs602364	ENSG00000261625.1	RP11-554A11.4	-3.59	0.000368	0.0406	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:69000765~69002048:-
HNSC	cis	rs3736485	0.966	rs1031664	ENSG00000274528.1	CTD-2650P22.2	3.59	0.000368	0.0406	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51462700	chr15:52017167~52018032:-
HNSC	cis	rs9393777	0.778	rs77666565	ENSG00000241549.7	GUSBP2	3.59	0.000368	0.0406	0.27	0.16	Intelligence (multi-trait analysis);	chr6:26883636	chr6:26871484~26956554:-
HNSC	cis	rs889398	0.802	rs2291959	ENSG00000196696.11	PDXDC2P	-3.59	0.000368	0.0406	-0.11	-0.16	Body mass index;	chr16:69840089	chr16:69976297~70065948:-
HNSC	cis	rs9467711	0.659	rs36162392	ENSG00000241549.7	GUSBP2	3.59	0.000368	0.0406	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:26871484~26956554:-
HNSC	cis	rs12122100	0.651	rs12129691	ENSG00000230832.3	RP11-325P15.2	3.59	0.000368	0.0406	0.21	0.16	HIV-1 control;	chr1:147082598	chr1:147082338~147083578:-
HNSC	cis	rs1937680	0.613	rs7092679	ENSG00000236671.6	PRKG1-AS1	-3.59	0.000368	0.0406	-0.23	-0.16	Breast cancer;	chr10:51882878	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.613	rs6480538	ENSG00000236671.6	PRKG1-AS1	-3.59	0.000368	0.0406	-0.23	-0.16	Breast cancer;	chr10:51883895	chr10:52230742~52314128:-
HNSC	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-3.59	0.000368	0.0406	-0.18	-0.16	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
HNSC	cis	rs7772486	0.79	rs9497424	ENSG00000270638.1	RP3-466P17.1	-3.59	0.000368	0.0406	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145735570~145737218:+
HNSC	cis	rs1440410	0.835	rs7693583	ENSG00000250326.1	RP11-284M14.1	-3.59	0.000368	0.0406	-0.18	-0.16	Ischemic stroke;	chr4:143130189	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs9790822	ENSG00000250326.1	RP11-284M14.1	-3.59	0.000368	0.0406	-0.18	-0.16	Ischemic stroke;	chr4:143130748	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs4323054	ENSG00000250326.1	RP11-284M14.1	-3.59	0.000368	0.0406	-0.18	-0.16	Ischemic stroke;	chr4:143130970	chr4:142933195~143184861:-
HNSC	cis	rs9487051	1	rs9480924	ENSG00000219700.1	PTCHD3P3	3.59	0.000368	0.0406	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109295867	chr6:109288571~109290503:-
HNSC	cis	rs9487051	1	rs9487052	ENSG00000219700.1	PTCHD3P3	3.59	0.000368	0.0406	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109295883	chr6:109288571~109290503:-
HNSC	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-3.59	0.000368	0.0406	-0.24	-0.16	Depression;	chr6:28129415	chr6:28170845~28172521:+
HNSC	cis	rs7508	1	rs7508	ENSG00000253671.1	RP11-806O11.1	-3.59	0.000368	0.0406	-0.17	-0.16	Atrial fibrillation;	chr8:18056461	chr8:17808941~17820868:+
HNSC	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	3.59	0.000369	0.0406	0.18	0.16	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	3.59	0.000369	0.0406	0.18	0.16	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
HNSC	cis	rs7735319	0.546	rs10472219	ENSG00000249102.1	CTD-2066L21.1	-3.59	0.000369	0.0406	-0.18	-0.16	Systolic blood pressure;	chr5:33139667	chr5:33008994~33025724:+
HNSC	cis	rs3947	0.951	rs1692819	ENSG00000269918.1	AF131215.9	-3.59	0.000369	0.0406	-0.2	-0.16	Blood protein levels;	chr8:11847939	chr8:11104691~11106704:-
HNSC	cis	rs4073405	0.621	rs10838437	ENSG00000254651.1	RP11-430H10.3	3.59	0.000369	0.0406	0.2	0.16	Schizophrenia;	chr11:45258367	chr11:45399448~45400528:+
HNSC	cis	rs2286313	0.51	rs78724829	ENSG00000266869.1	RP6-114E22.1	-3.59	0.000369	0.0406	-0.41	-0.16	Colorectal cancer;	chr14:70908895	chr14:71848606~71908430:+
HNSC	cis	rs10871290	0.65	rs28484753	ENSG00000207525.1	Y_RNA	-3.59	0.000369	0.0406	-0.18	-0.16	Breast cancer;	chr16:74455497	chr16:74463888~74463988:-
HNSC	cis	rs12234571	1	rs73372301	ENSG00000214293.7	APTR	3.59	0.000369	0.0406	0.22	0.16	Obesity-related traits;	chr7:77723502	chr7:77657660~77696265:-
HNSC	cis	rs12234571	1	rs73374113	ENSG00000214293.7	APTR	3.59	0.000369	0.0406	0.22	0.16	Obesity-related traits;	chr7:77732629	chr7:77657660~77696265:-
HNSC	cis	rs12234571	1	rs12672657	ENSG00000214293.7	APTR	3.59	0.000369	0.0406	0.22	0.16	Obesity-related traits;	chr7:77733091	chr7:77657660~77696265:-
HNSC	cis	rs10129255	0.957	rs2007467	ENSG00000211974.3	IGHV2-70	-3.59	0.000369	0.0406	-0.15	-0.16	Kawasaki disease;	chr14:106771605	chr14:106723574~106724093:-
HNSC	cis	rs2483519	0.578	rs703348	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000369	0.0406	-0.18	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114708988	chr10:114994657~114996593:+
HNSC	cis	rs71520386	0.846	rs13243243	ENSG00000230658.1	KLHL7-AS1	-3.59	0.000369	0.0406	-0.25	-0.16	Fibrinogen levels;	chr7:22781400	chr7:23101228~23105703:-
HNSC	cis	rs9611565	0.559	rs132765	ENSG00000235513.1	RP4-756G23.5	-3.59	0.000369	0.0406	-0.2	-0.16	Vitiligo;	chr22:41612064	chr22:41209122~41217627:-
HNSC	cis	rs800888	0.706	rs1569364	ENSG00000249917.2	LINC00536	-3.59	0.000369	0.0406	-0.2	-0.16	Monocyte percentage of white cells;	chr8:115617505	chr8:115950511~116325059:-
HNSC	cis	rs10865541	0.902	rs13399186	ENSG00000234171.2	RNASEH1-AS1	3.59	0.000369	0.0406	0.17	0.16	Obesity-related traits;	chr2:3419430	chr2:3558492~3561745:+
HNSC	cis	rs1853665	0.58	rs6557200	ENSG00000268592.3	RAET1E-AS1	-3.59	0.000369	0.0406	-0.26	-0.16	Radiation response;	chr6:149951396	chr6:149863494~149919507:+
HNSC	cis	rs7746199	0.736	rs13202295	ENSG00000226314.6	ZNF192P1	-3.59	0.000369	0.0406	-0.31	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28161781~28169594:+
HNSC	cis	rs6964587	0.692	rs7807490	ENSG00000188693.7	CYP51A1-AS1	-3.59	0.000369	0.0406	-0.17	-0.16	Breast cancer;	chr7:92144045	chr7:92134604~92180725:+
HNSC	cis	rs494453	0.922	rs476515	ENSG00000227811.2	FAM212B-AS1	-3.59	0.000369	0.0406	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111672454	chr1:111739841~111747798:+
HNSC	cis	rs268134	0.53	rs35839181	ENSG00000235725.1	AC007389.3	-3.59	0.000369	0.0407	-0.3	-0.16	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400878	chr2:65589566~65640177:-
HNSC	cis	rs1937680	0.657	rs10762464	ENSG00000236671.6	PRKG1-AS1	-3.59	0.000369	0.0407	-0.23	-0.16	Breast cancer;	chr10:51884890	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.657	rs6480539	ENSG00000236671.6	PRKG1-AS1	-3.59	0.000369	0.0407	-0.23	-0.16	Breast cancer;	chr10:51885397	chr10:52230742~52314128:-
HNSC	cis	rs1937680	0.657	rs6480540	ENSG00000236671.6	PRKG1-AS1	-3.59	0.000369	0.0407	-0.23	-0.16	Breast cancer;	chr10:51885605	chr10:52230742~52314128:-
HNSC	cis	rs597480	0.747	rs630613	ENSG00000279742.1	RP11-700A24.1	-3.59	0.000369	0.0407	-0.18	-0.16	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85767954	chr11:85852557~85854943:-
HNSC	cis	rs6499755	0.901	rs2042447	ENSG00000260135.5	RP11-212I21.2	3.59	0.000369	0.0407	0.18	0.16	Hypospadias;	chr16:55318110	chr16:55426797~55462297:-
HNSC	cis	rs12365302	0.617	rs2666907	ENSG00000205106.4	DKFZp779M0652	3.59	0.000369	0.0407	0.22	0.16	Diastolic blood pressure;	chr11:45745913	chr11:45771432~45772358:+
HNSC	cis	rs28573326	0.924	rs28409044	ENSG00000121089.4	NACA3P	-3.59	0.000369	0.0407	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165416309	chr4:164943290~164943937:+
HNSC	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	3.59	0.000369	0.0407	0.18	0.16	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
HNSC	cis	rs494453	0.885	rs496296	ENSG00000227811.2	FAM212B-AS1	-3.59	0.000369	0.0407	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111682034	chr1:111739841~111747798:+
HNSC	cis	rs870825	0.616	rs61653735	ENSG00000254233.1	RP11-242J7.1	3.59	0.000369	0.0407	0.24	0.16	Blood protein levels;	chr4:184708871	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs10033035	ENSG00000254233.1	RP11-242J7.1	3.59	0.000369	0.0407	0.24	0.16	Blood protein levels;	chr4:184709726	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs72703561	ENSG00000254233.1	RP11-242J7.1	3.59	0.000369	0.0407	0.24	0.16	Blood protein levels;	chr4:184709736	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28666955	ENSG00000254233.1	RP11-242J7.1	3.59	0.000369	0.0407	0.24	0.16	Blood protein levels;	chr4:184710184	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.55	rs28525282	ENSG00000254233.1	RP11-242J7.1	3.59	0.000369	0.0407	0.24	0.16	Blood protein levels;	chr4:184710314	chr4:184584093~184625030:-
HNSC	cis	rs7429990	0.833	rs1486915	ENSG00000228638.1	FCF1P2	3.59	0.000369	0.0407	0.15	0.16	Educational attainment (years of education);	chr3:47781053	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.828	rs6792350	ENSG00000228638.1	FCF1P2	3.59	0.000369	0.0407	0.15	0.16	Educational attainment (years of education);	chr3:47797451	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs4858860	ENSG00000228638.1	FCF1P2	3.59	0.000369	0.0407	0.15	0.16	Educational attainment (years of education);	chr3:47817344	chr3:48290793~48291375:-
HNSC	cis	rs6982240	0.514	rs892362	ENSG00000253307.1	RP11-10J21.4	-3.59	0.000369	0.0407	-0.21	-0.16	Tonsillectomy;	chr8:141259115	chr8:141252286~141253292:-
HNSC	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	3.59	0.000369	0.0407	0.23	0.16	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	3.59	0.000369	0.0407	0.23	0.16	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	3.59	0.000369	0.0407	0.23	0.16	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
HNSC	cis	rs73198271	0.737	rs506960	ENSG00000233609.3	RP11-62H7.2	-3.59	0.00037	0.0407	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8961200~8979025:+
HNSC	cis	rs7822232	1	rs7822232	ENSG00000255224.1	CTD-3065J16.9	-3.59	0.00037	0.0407	-0.24	-0.16	Blood metabolite levels;	chr8:144090784	chr8:144078002~144079265:-
HNSC	cis	rs11722779	0.935	rs7681629	ENSG00000248740.4	RP11-328K4.1	3.59	0.00037	0.0407	0.17	0.16	Schizophrenia;	chr4:102974407	chr4:103256159~103453658:+
HNSC	cis	rs11722779	0.844	rs17033381	ENSG00000248740.4	RP11-328K4.1	3.59	0.00037	0.0407	0.17	0.16	Schizophrenia;	chr4:102974952	chr4:103256159~103453658:+
HNSC	cis	rs227275	0.556	rs4699044	ENSG00000248740.4	RP11-328K4.1	3.59	0.00037	0.0407	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:103256159~103453658:+
HNSC	cis	rs227275	0.556	rs4699045	ENSG00000248740.4	RP11-328K4.1	3.59	0.00037	0.0407	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:103256159~103453658:+
HNSC	cis	rs1185460	0.934	rs1006195	ENSG00000272186.1	RP11-110I1.13	3.59	0.00037	0.0407	0.19	0.16	Coronary artery disease;	chr11:119088159	chr11:119067374~119067698:-
HNSC	cis	rs782107	0.541	rs4760216	ENSG00000270039.1	RP11-571M6.17	3.59	0.00037	0.0407	0.2	0.16	Interleukin-12p70 levels;	chr12:58434955	chr12:57803838~57804415:+
HNSC	cis	rs2708377	0.656	rs116607079	ENSG00000212125.2	TAS2R15P	3.59	0.00037	0.0407	0.25	0.16	Bitter taste perception;	chr12:11109445	chr12:10964425~10965352:-
HNSC	cis	rs2708377	0.929	rs73066828	ENSG00000212125.2	TAS2R15P	3.59	0.00037	0.0407	0.25	0.16	Bitter taste perception;	chr12:11118055	chr12:10964425~10965352:-
HNSC	cis	rs2708377	0.656	rs73066852	ENSG00000212125.2	TAS2R15P	3.59	0.00037	0.0407	0.25	0.16	Bitter taste perception;	chr12:11123942	chr12:10964425~10965352:-
HNSC	cis	rs2708377	0.858	rs117212341	ENSG00000212125.2	TAS2R15P	3.59	0.00037	0.0407	0.25	0.16	Bitter taste perception;	chr12:11129957	chr12:10964425~10965352:-
HNSC	cis	rs12188164	0.812	rs10072668	ENSG00000215246.5	RP11-43F13.3	-3.59	0.00037	0.0407	-0.18	-0.16	Cystic fibrosis severity;	chr5:422637	chr5:987180~997308:-
HNSC	cis	rs12188164	0.812	rs9313065	ENSG00000215246.5	RP11-43F13.3	-3.59	0.00037	0.0407	-0.18	-0.16	Cystic fibrosis severity;	chr5:423311	chr5:987180~997308:-
HNSC	cis	rs67311347	0.955	rs6599100	ENSG00000280739.1	EIF1B-AS1	3.59	0.00037	0.0407	0.17	0.16	Renal cell carcinoma;	chr3:40405871	chr3:40173145~40309698:-
HNSC	cis	rs6787172	1	rs6787172	ENSG00000272087.1	RP11-379F4.7	3.59	0.00037	0.0407	0.17	0.16	Subjective well-being;	chr3:158470022	chr3:158693120~158693768:-
HNSC	cis	rs1008375	0.932	rs13134570	ENSG00000249502.1	AC006160.5	3.59	0.00037	0.0407	0.18	0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691240	chr4:17587467~17614571:-
HNSC	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	3.59	0.00037	0.0407	0.19	0.16	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
HNSC	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-3.59	0.00037	0.0407	-0.16	-0.16	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
HNSC	cis	rs3857747	0.578	rs10281352	ENSG00000228554.1	AC004837.5	3.59	0.00037	0.0407	0.16	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40344337	chr7:39700341~39703296:-
HNSC	cis	rs870825	0.655	rs7683556	ENSG00000254233.1	RP11-242J7.1	3.59	0.00037	0.0408	0.24	0.16	Blood protein levels;	chr4:184710865	chr4:184584093~184625030:-
HNSC	cis	rs820077	0.736	rs34715060	ENSG00000272374.1	RP3-329A5.8	3.59	0.00037	0.0408	0.19	0.16	Systemic lupus erythematosus;	chr6:35140004	chr6:35220370~35224630:-
HNSC	cis	rs889398	0.934	rs12923231	ENSG00000196696.11	PDXDC2P	3.59	0.00037	0.0408	0.12	0.16	Body mass index;	chr16:69538989	chr16:69976297~70065948:-
HNSC	cis	rs2163813	0.788	rs247774	ENSG00000275540.1	CTC-559E9.12	-3.59	0.00037	0.0408	-0.21	-0.16	Toenail selenium levels;	chr19:19732742	chr19:19740884~19750127:+
HNSC	cis	rs116095464	0.558	rs7708182	ENSG00000277812.1	AC021087.1	3.59	0.00037	0.0408	0.27	0.16	Breast cancer;	chr5:234673	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10058428	ENSG00000277812.1	AC021087.1	3.59	0.00037	0.0408	0.27	0.16	Breast cancer;	chr5:235493	chr5:262769~262881:+
HNSC	cis	rs1124609	1	rs1365506	ENSG00000244879.4	GABPB1-AS1	3.59	0.00037	0.0408	0.21	0.16	Subjective well-being;	chr15:50184942	chr15:50354959~50372202:+
HNSC	cis	rs67072384	1	rs61489692	ENSG00000245148.2	ARAP1-AS2	3.59	0.00037	0.0408	0.23	0.16	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734269	chr11:72700474~72705607:+
HNSC	cis	rs7015263	0.603	rs56102132	ENSG00000254231.1	CTD-2284J15.1	-3.59	0.00037	0.0408	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86425798	chr8:86333274~86343314:-
HNSC	cis	rs7015263	0.689	rs10093379	ENSG00000254231.1	CTD-2284J15.1	3.59	0.00037	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr8:86435831	chr8:86333274~86343314:-
HNSC	cis	rs7015263	0.714	rs6471345	ENSG00000254231.1	CTD-2284J15.1	3.59	0.00037	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr8:86445357	chr8:86333274~86343314:-
HNSC	cis	rs7015263	0.689	rs6988601	ENSG00000254231.1	CTD-2284J15.1	3.59	0.00037	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr8:86451366	chr8:86333274~86343314:-
HNSC	cis	rs7015263	0.689	rs10095129	ENSG00000254231.1	CTD-2284J15.1	3.59	0.00037	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr8:86454079	chr8:86333274~86343314:-
HNSC	cis	rs865483	0.861	rs1063215	ENSG00000276054.1	RP11-378E13.3	3.59	0.00037	0.0408	0.2	0.16	Monocyte count;	chr17:37514833	chr17:37386886~37387926:+
HNSC	cis	rs9393777	0.588	rs6456727	ENSG00000241549.7	GUSBP2	3.59	0.00037	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr6:26470927	chr6:26871484~26956554:-
HNSC	cis	rs8077577	0.747	rs2290505	ENSG00000260647.1	RP1-178F10.1	-3.59	0.00037	0.0408	-0.23	-0.16	Obesity-related traits;	chr17:18233827	chr17:18268080~18268828:+
HNSC	cis	rs5758511	0.68	rs5758657	ENSG00000227370.1	RP4-669P10.19	3.59	0.00037	0.0408	0.2	0.16	Birth weight;	chr22:42222663	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.68	rs1033459	ENSG00000227370.1	RP4-669P10.19	3.59	0.00037	0.0408	0.2	0.16	Birth weight;	chr22:42223061	chr22:42132543~42132998:+
HNSC	cis	rs11096990	0.819	rs4974991	ENSG00000249685.1	RP11-360F5.3	-3.59	0.000371	0.0408	-0.2	-0.16	Cognitive function;	chr4:39193147	chr4:39133913~39135608:+
HNSC	cis	rs11096990	0.892	rs6815686	ENSG00000249685.1	RP11-360F5.3	-3.59	0.000371	0.0408	-0.2	-0.16	Cognitive function;	chr4:39198171	chr4:39133913~39135608:+
HNSC	cis	rs7824557	0.527	rs2572376	ENSG00000255495.1	AC145124.2	-3.59	0.000371	0.0408	-0.18	-0.16	Retinal vascular caliber;	chr8:11380247	chr8:12194467~12196280:+
HNSC	cis	rs597539	0.552	rs10896384	ENSG00000261625.1	RP11-554A11.4	3.59	0.000371	0.0408	0.19	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:69000765~69002048:-
HNSC	cis	rs7829975	0.522	rs6601689	ENSG00000233609.3	RP11-62H7.2	3.59	0.000371	0.0408	0.16	0.16	Mood instability;	chr8:8314761	chr8:8961200~8979025:+
HNSC	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	3.59	0.000371	0.0408	0.2	0.16	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
HNSC	cis	rs17711722	0.565	rs4275112	ENSG00000213640.3	EEF1DP4	3.59	0.000371	0.0408	0.2	0.16	Calcium levels;	chr7:65733651	chr7:64862999~64864370:+
HNSC	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-3.59	0.000371	0.0408	-0.28	-0.16	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
HNSC	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	3.59	0.000371	0.0408	0.19	0.16	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
HNSC	cis	rs78487399	0.614	rs74907855	ENSG00000234936.1	AC010883.5	3.59	0.000371	0.0408	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43529062	chr2:43229573~43233394:+
HNSC	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	3.59	0.000371	0.0408	0.2	0.16	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	3.59	0.000371	0.0408	0.2	0.16	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	3.59	0.000371	0.0408	0.2	0.16	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	3.59	0.000371	0.0408	0.2	0.16	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
HNSC	cis	rs7474896	1	rs11011344	ENSG00000263064.2	RP11-291L22.7	3.59	0.000371	0.0408	0.26	0.16	Obesity (extreme);	chr10:37715918	chr10:38448689~38448949:+
HNSC	cis	rs7113211	0.539	rs10891434	ENSG00000176343.5	RPL37AP8	3.59	0.000371	0.0408	0.18	0.16	Expressive vocabulary in infants;	chr11:112780197	chr11:111889199~111889474:-
HNSC	cis	rs2013441	1	rs2703817	ENSG00000261033.1	RP11-209D14.2	3.59	0.000371	0.0408	0.19	0.16	Obesity-related traits;	chr17:20216364	chr17:20008051~20009234:-
HNSC	cis	rs614226	0.744	rs787832	ENSG00000202538.1	RNU4-2	-3.59	0.000371	0.0408	-0.27	-0.16	Type 1 diabetes nephropathy;	chr12:120548998	chr12:120291763~120291903:-
HNSC	cis	rs57221529	0.766	rs56278696	ENSG00000225138.6	CTD-2228K2.7	3.59	0.000371	0.0408	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:582554	chr5:473236~480884:+
HNSC	cis	rs11951515	0.663	rs4866820	ENSG00000249286.1	CTD-2210P15.2	3.59	0.000371	0.0408	0.17	0.16	Metabolite levels  (X-11787);	chr5:43353675	chr5:43586918~43588223:-
HNSC	cis	rs58873874	0.737	rs11134767	ENSG00000248544.2	CTB-47B11.3	3.59	0.000371	0.0408	0.41	0.16	Bipolar disorder (body mass index interaction);	chr5:157481645	chr5:157375741~157384950:-
HNSC	cis	rs58873874	0.737	rs77273565	ENSG00000248544.2	CTB-47B11.3	3.59	0.000371	0.0408	0.41	0.16	Bipolar disorder (body mass index interaction);	chr5:157489547	chr5:157375741~157384950:-
HNSC	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000371	0.0408	-0.24	-0.16	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
HNSC	cis	rs2760061	0.717	rs708117	ENSG00000270110.1	RP5-1139B12.4	-3.59	0.000371	0.0408	-0.16	-0.16	Diastolic blood pressure;	chr1:228012201	chr1:228295911~228302998:-
HNSC	cis	rs10510102	0.516	rs11200306	ENSG00000226864.1	ATE1-AS1	3.59	0.000371	0.0408	0.28	0.16	Breast cancer;	chr10:121980862	chr10:121928312~121951965:+
HNSC	cis	rs34792	0.554	rs2067063	ENSG00000207425.1	Y_RNA	-3.59	0.000371	0.0408	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:14915457~14915556:-
HNSC	cis	rs7824557	0.564	rs2736295	ENSG00000255495.1	AC145124.2	3.59	0.000371	0.0408	0.18	0.16	Retinal vascular caliber;	chr8:11377271	chr8:12194467~12196280:+
HNSC	cis	rs1003719	0.68	rs3737540	ENSG00000242553.1	AP001432.14	3.59	0.000371	0.0408	0.19	0.16	Eye color traits;	chr21:37150966	chr21:37221419~37237744:+
HNSC	cis	rs2980439	0.525	rs1850511	ENSG00000233609.3	RP11-62H7.2	3.59	0.000371	0.0408	0.15	0.16	Neuroticism;	chr8:8312807	chr8:8961200~8979025:+
HNSC	cis	rs6088580	0.634	rs6058073	ENSG00000276073.1	RP5-1125A11.7	-3.59	0.000371	0.0408	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:33985617~33988989:-
HNSC	cis	rs7937890	0.559	rs2597197	ENSG00000254418.1	RP11-21L19.1	3.59	0.000371	0.0408	0.19	0.16	Mitochondrial DNA levels;	chr11:14468286	chr11:14262846~14273691:-
HNSC	cis	rs728616	0.614	rs17678737	ENSG00000225484.5	NUTM2B-AS1	-3.59	0.000371	0.0408	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79663088~79826594:-
HNSC	cis	rs17772222	0.917	rs12431548	ENSG00000258789.1	RP11-507K2.3	-3.59	0.000371	0.0408	-0.2	-0.16	Coronary artery calcification;	chr14:88635826	chr14:88551597~88552493:+
HNSC	cis	rs734999	0.588	rs745368	ENSG00000238164.5	RP3-395M20.8	-3.59	0.000371	0.0408	-0.12	-0.16	Ulcerative colitis;	chr1:2592766	chr1:2549920~2557031:-
HNSC	cis	rs734999	0.566	rs10752747	ENSG00000238164.5	RP3-395M20.8	-3.59	0.000371	0.0408	-0.12	-0.16	Ulcerative colitis;	chr1:2593476	chr1:2549920~2557031:-
HNSC	cis	rs17076726	0.519	rs17076676	ENSG00000253785.1	CTC-308K20.3	3.59	0.000371	0.0409	0.17	0.16	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173899577	chr5:172975511~172976374:+
HNSC	cis	rs67311347	1	rs73078123	ENSG00000280739.1	EIF1B-AS1	3.59	0.000371	0.0409	0.2	0.16	Renal cell carcinoma;	chr3:40417472	chr3:40173145~40309698:-
HNSC	cis	rs1440410	0.835	rs11100780	ENSG00000250326.1	RP11-284M14.1	-3.59	0.000371	0.0409	-0.18	-0.16	Ischemic stroke;	chr4:143183753	chr4:142933195~143184861:-
HNSC	cis	rs9733	0.536	rs10888385	ENSG00000236713.1	RP11-363I22.3	3.59	0.000372	0.0409	0.18	0.16	Tonsillectomy;	chr1:150601826	chr1:150780272~150780644:+
HNSC	cis	rs6012564	0.793	rs1043361	ENSG00000227431.4	CSE1L-AS1	3.59	0.000372	0.0409	0.19	0.16	Anger;	chr20:49114621	chr20:49040463~49046044:-
HNSC	cis	rs896655	0.631	rs10757244	ENSG00000244230.3	RN7SL151P	3.59	0.000372	0.0409	0.17	0.16	Coronary artery disease;	chr9:21746420	chr9:21699314~21699596:+
HNSC	cis	rs1823874	0.542	rs1962946	ENSG00000182397.13	DNM1P46	-3.59	0.000372	0.0409	-0.17	-0.16	IgG glycosylation;	chr15:99834410	chr15:99790156~99806927:-
HNSC	cis	rs6710503	0.926	rs12618641	ENSG00000271936.1	RP11-443B20.1	-3.59	0.000372	0.0409	-0.18	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24701797	chr2:24825610~24826717:+
HNSC	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	3.59	0.000372	0.0409	0.16	0.16	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
HNSC	cis	rs11776767	0.538	rs12546026	ENSG00000269918.1	AF131215.9	3.59	0.000372	0.0409	0.17	0.16	Triglycerides;	chr8:10853205	chr8:11104691~11106704:-
HNSC	cis	rs1729407	0.814	rs2542051	ENSG00000280143.1	AP000892.6	-3.59	0.000372	0.0409	-0.16	-0.16	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117204967~117210292:+
HNSC	cis	rs2836974	0.897	rs3945	ENSG00000255568.3	BRWD1-AS2	3.59	0.000372	0.0409	0.15	0.16	Cognitive function;	chr21:39194141	chr21:39313935~39314962:+
HNSC	cis	rs1005277	0.505	rs7099777	ENSG00000263064.2	RP11-291L22.7	-3.59	0.000372	0.0409	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38448689~38448949:+
HNSC	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	3.59	0.000372	0.0409	0.2	0.16	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
HNSC	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	3.59	0.000372	0.0409	0.2	0.16	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
HNSC	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	3.59	0.000372	0.0409	0.19	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
HNSC	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	3.59	0.000372	0.0409	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	3.59	0.000372	0.0409	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	3.59	0.000372	0.0409	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
HNSC	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	3.59	0.000372	0.0409	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
HNSC	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-3.59	0.000372	0.0409	-0.2	-0.16	Height;	chr14:75036124	chr14:75011269~75012851:-
HNSC	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-3.59	0.000372	0.0409	-0.2	-0.16	Height;	chr14:75037751	chr14:75011269~75012851:-
HNSC	cis	rs1585471	0.931	rs11946643	ENSG00000249532.3	RP11-148B6.1	-3.59	0.000372	0.0409	-0.2	-0.16	Myopia (pathological);	chr4:111679621	chr4:112646476~112650051:-
HNSC	cis	rs7592578	0.766	rs62181052	ENSG00000228509.4	AC006460.2	3.59	0.000372	0.0409	0.26	0.16	Diastolic blood pressure;	chr2:190523132	chr2:190676944~190708716:-
HNSC	cis	rs6995541	0.744	rs10109416	ENSG00000269918.1	AF131215.9	-3.59	0.000372	0.0409	-0.17	-0.16	Triglyceride levels;	chr8:10827245	chr8:11104691~11106704:-
HNSC	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	3.59	0.000372	0.0409	0.24	0.16	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	3.59	0.000372	0.0409	0.24	0.16	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	3.59	0.000372	0.0409	0.24	0.16	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	3.59	0.000372	0.0409	0.24	0.16	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
HNSC	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	3.59	0.000372	0.0409	0.24	0.16	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
HNSC	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	3.59	0.000372	0.0409	0.17	0.16	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
HNSC	cis	rs2657294	0.965	rs2657291	ENSG00000233313.2	HMGA1P5	-3.59	0.000372	0.0409	-0.18	-0.16	Pneumonia;	chr10:75166945	chr10:75276376~75276646:-
HNSC	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-3.59	0.000372	0.0409	-0.19	-0.16	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-3.59	0.000372	0.0409	-0.19	-0.16	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-3.59	0.000372	0.0409	-0.19	-0.16	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
HNSC	cis	rs7083345	0.961	rs1538396	ENSG00000237943.5	PRKCQ-AS1	3.59	0.000372	0.0409	0.21	0.16	Gut microbiota (bacterial taxa);	chr10:7002342	chr10:6580419~6616452:+
HNSC	cis	rs7011507	0.562	rs2047787	ENSG00000253608.1	RP11-770E5.1	-3.59	0.000372	0.0409	-0.24	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48464449	chr8:48551567~48698510:+
HNSC	cis	rs6545883	0.894	rs778148	ENSG00000271889.1	RP11-493E12.1	-3.59	0.000372	0.041	-0.19	-0.16	Tuberculosis;	chr2:61379731	chr2:61151433~61162105:-
HNSC	cis	rs853679	0.76	rs967005	ENSG00000176933.5	TOB2P1	3.59	0.000373	0.041	0.22	0.16	Depression;	chr6:28242910	chr6:28217643~28218634:-
HNSC	cis	rs34286592	1	rs34286592	ENSG00000183604.13	SMG1P5	-3.58	0.000373	0.041	-0.23	-0.16	Multiple sclerosis;	chr16:29809159	chr16:30267553~30335374:-
HNSC	cis	rs4853525	0.923	rs7582941	ENSG00000235852.1	AC005540.3	3.58	0.000373	0.041	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190864174	chr2:190880797~190882059:-
HNSC	cis	rs1133146	1	rs10454108	ENSG00000269608.1	CTB-167G5.3	-3.58	0.000373	0.041	-0.19	-0.16	Yu-Zhi constitution type in type 2 diabetes;	chr19:53167297	chr19:53616802~53617254:+
HNSC	cis	rs13434995	0.513	rs6851971	ENSG00000249700.7	SRD5A3-AS1	3.58	0.000373	0.041	0.22	0.16	Adiponectin levels;	chr4:55561897	chr4:55363971~55395847:-
HNSC	cis	rs853679	0.567	rs2232427	ENSG00000227214.2	HCG15	3.58	0.000373	0.041	0.2	0.16	Depression;	chr6:28391932	chr6:28986203~28987484:+
HNSC	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	3.58	0.000373	0.041	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
HNSC	cis	rs6499755	0.965	rs9932163	ENSG00000260135.5	RP11-212I21.2	-3.58	0.000373	0.041	-0.19	-0.16	Hypospadias;	chr16:55316771	chr16:55426797~55462297:-
HNSC	cis	rs10761256	0.806	rs2398851	ENSG00000227603.1	RP11-165J3.6	3.58	0.000373	0.041	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93636226	chr9:93435332~93437121:-
HNSC	cis	rs11711311	0.822	rs9850256	ENSG00000241529.3	RN7SL767P	-3.58	0.000373	0.041	-0.22	-0.16	IgG glycosylation;	chr3:113689535	chr3:113632704~113632998:+
HNSC	cis	rs727563	0.593	rs132770	ENSG00000213857.3	RP11-12M9.4	-3.58	0.000373	0.041	-0.22	-0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr22:41074180~41075239:-
HNSC	cis	rs7121616	1	rs7121616	ENSG00000200879.1	SNORD14E	3.58	0.000373	0.041	0.2	0.16	Breast cancer;	chr11:123095918	chr11:123058077~123058161:-
HNSC	cis	rs7121616	0.96	rs7122306	ENSG00000200879.1	SNORD14E	3.58	0.000373	0.041	0.2	0.16	Breast cancer;	chr11:123096254	chr11:123058077~123058161:-
HNSC	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-3.58	0.000373	0.041	-0.27	-0.16	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
HNSC	cis	rs782107	0.518	rs73112211	ENSG00000270039.1	RP11-571M6.17	-3.58	0.000373	0.041	-0.2	-0.16	Interleukin-12p70 levels;	chr12:58418117	chr12:57803838~57804415:+
HNSC	cis	rs782107	0.541	rs66631297	ENSG00000270039.1	RP11-571M6.17	-3.58	0.000373	0.041	-0.2	-0.16	Interleukin-12p70 levels;	chr12:58418302	chr12:57803838~57804415:+
HNSC	cis	rs782107	0.541	rs11172595	ENSG00000270039.1	RP11-571M6.17	-3.58	0.000373	0.041	-0.2	-0.16	Interleukin-12p70 levels;	chr12:58419128	chr12:57803838~57804415:+
HNSC	cis	rs782107	0.541	rs11172596	ENSG00000270039.1	RP11-571M6.17	-3.58	0.000373	0.041	-0.2	-0.16	Interleukin-12p70 levels;	chr12:58419396	chr12:57803838~57804415:+
HNSC	cis	rs7674212	0.539	rs6821617	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000373	0.041	-0.19	-0.16	Type 2 diabetes;	chr4:103207253	chr4:102751401~102752641:+
HNSC	cis	rs8041447	0.864	rs938981	ENSG00000259756.1	RP11-625H11.2	3.58	0.000373	0.041	0.18	0.16	Immature fraction of reticulocytes;	chr15:62770703	chr15:62682916~62690448:-
HNSC	cis	rs7688540	0.771	rs11723615	ENSG00000250892.1	RP11-1365D11.1	-3.58	0.000373	0.041	-0.3	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:201409~205009:-
HNSC	cis	rs7246657	0.722	rs968073	ENSG00000276846.1	CTD-3220F14.3	-3.58	0.000373	0.041	-0.22	-0.16	Coronary artery calcification;	chr19:37701120	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs2909093	ENSG00000276846.1	CTD-3220F14.3	-3.58	0.000373	0.041	-0.22	-0.16	Coronary artery calcification;	chr19:37708561	chr19:37314868~37315620:-
HNSC	cis	rs12234571	1	rs4391357	ENSG00000214293.7	APTR	3.58	0.000373	0.041	0.21	0.16	Obesity-related traits;	chr7:77776304	chr7:77657660~77696265:-
HNSC	cis	rs2115630	0.691	rs2292462	ENSG00000259295.5	CSPG4P12	-3.58	0.000373	0.041	-0.18	-0.16	P wave terminal force;	chr15:84657523	chr15:85191438~85213905:+
HNSC	cis	rs2164068	0.57	rs700677	ENSG00000222017.1	AC011997.1	-3.58	0.000373	0.041	-0.2	-0.16	Allergy;	chr2:197837700	chr2:197693106~197774823:+
HNSC	cis	rs7189233	0.955	rs60420081	ENSG00000279344.1	RP11-44F14.7	3.58	0.000373	0.041	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53486892	chr16:53478957~53481550:-
HNSC	cis	rs2074409	0.509	rs2074412	ENSG00000276054.1	RP11-378E13.3	3.58	0.000373	0.041	0.18	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37478961	chr17:37386886~37387926:+
HNSC	cis	rs1440410	0.798	rs34664017	ENSG00000250326.1	RP11-284M14.1	-3.58	0.000373	0.041	-0.18	-0.16	Ischemic stroke;	chr4:143173191	chr4:142933195~143184861:-
HNSC	cis	rs950169	0.922	rs12906983	ENSG00000259570.1	RP11-671M22.4	3.58	0.000373	0.041	0.22	0.16	Schizophrenia;	chr15:84262270	chr15:84394512~84395514:+
HNSC	cis	rs4713118	0.513	rs156738	ENSG00000219891.2	ZSCAN12P1	3.58	0.000373	0.041	0.22	0.16	Parkinson's disease;	chr6:28046247	chr6:28091154~28093664:+
HNSC	cis	rs12188164	0.686	rs56279338	ENSG00000215246.5	RP11-43F13.3	-3.58	0.000373	0.041	-0.19	-0.16	Cystic fibrosis severity;	chr5:416003	chr5:987180~997308:-
HNSC	cis	rs12188164	0.686	rs72711365	ENSG00000215246.5	RP11-43F13.3	-3.58	0.000373	0.041	-0.19	-0.16	Cystic fibrosis severity;	chr5:416557	chr5:987180~997308:-
HNSC	cis	rs10789207	0.531	rs74087510	ENSG00000248458.2	RP4-598P13.1	-3.58	0.000373	0.041	-0.24	-0.16	Resting heart rate;	chr1:66643184	chr1:66665864~66677027:-
HNSC	cis	rs10789207	0.531	rs17129244	ENSG00000248458.2	RP4-598P13.1	-3.58	0.000373	0.041	-0.24	-0.16	Resting heart rate;	chr1:66643796	chr1:66665864~66677027:-
HNSC	cis	rs116095464	0.51	rs73016876	ENSG00000277812.1	AC021087.1	3.58	0.000373	0.041	0.28	0.16	Breast cancer;	chr5:244360	chr5:262769~262881:+
HNSC	cis	rs2692947	0.644	rs1030864	ENSG00000231584.7	FAHD2CP	-3.58	0.000373	0.041	-0.15	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96156634	chr2:96010551~96023380:+
HNSC	cis	rs9329221	0.651	rs2975648	ENSG00000255310.2	AF131215.2	-3.58	0.000373	0.041	-0.15	-0.16	Neuroticism;	chr8:10278466	chr8:11107788~11109726:-
HNSC	cis	rs9467711	0.606	rs35076545	ENSG00000241549.7	GUSBP2	3.58	0.000373	0.041	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs13212985	ENSG00000241549.7	GUSBP2	3.58	0.000373	0.041	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:26871484~26956554:-
HNSC	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	3.58	0.000374	0.041	0.19	0.16	Height;	chr4:55532542	chr4:55540502~55540835:-
HNSC	cis	rs7246657	0.678	rs2927740	ENSG00000276846.1	CTD-3220F14.3	-3.58	0.000374	0.041	-0.22	-0.16	Coronary artery calcification;	chr19:37650065	chr19:37314868~37315620:-
HNSC	cis	rs72675573	0.508	rs2404393	ENSG00000223956.1	RP4-710M16.2	3.58	0.000374	0.041	0.16	0.16	Monocyte count;	chr1:56039628	chr1:56414963~56415966:+
HNSC	cis	rs12122100	0.651	rs12127461	ENSG00000230832.3	RP11-325P15.2	3.58	0.000374	0.041	0.22	0.16	HIV-1 control;	chr1:147080339	chr1:147082338~147083578:-
HNSC	cis	rs2638953	0.962	rs11049539	ENSG00000257176.2	RP11-996F15.2	3.58	0.000374	0.041	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:29280418~29317848:-
HNSC	cis	rs6095360	0.546	rs6012562	ENSG00000227431.4	CSE1L-AS1	3.58	0.000374	0.0411	0.19	0.16	Intelligence (multi-trait analysis);	chr20:48918724	chr20:49040463~49046044:-
HNSC	cis	rs7036656	0.691	rs10757261	ENSG00000240498.5	CDKN2B-AS1	-3.58	0.000374	0.0411	-0.2	-0.16	White blood cell count;	chr9:21954954	chr9:21994778~22121097:+
HNSC	cis	rs2548724	0.741	rs11948335	ENSG00000175749.11	EIF3KP1	3.58	0.000374	0.0411	0.22	0.16	Type 2 diabetes;	chr5:102368475	chr5:103032376~103033031:+
HNSC	cis	rs2548724	0.796	rs58644688	ENSG00000175749.11	EIF3KP1	3.58	0.000374	0.0411	0.22	0.16	Type 2 diabetes;	chr5:102375793	chr5:103032376~103033031:+
HNSC	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	3.58	0.000374	0.0411	0.25	0.16	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
HNSC	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	3.58	0.000374	0.0411	0.21	0.16	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
HNSC	cis	rs4938303	0.633	rs528806	ENSG00000280143.1	AP000892.6	-3.58	0.000374	0.0411	-0.23	-0.16	Triglycerides;	chr11:116659197	chr11:117204967~117210292:+
HNSC	cis	rs10819861	0.679	rs4623574	ENSG00000175611.10	LINC00476	3.58	0.000374	0.0411	0.16	0.16	Electrocardiographic traits;	chr9:96087342	chr9:95759231~95875977:-
HNSC	cis	rs10819861	0.645	rs10819810	ENSG00000175611.10	LINC00476	3.58	0.000374	0.0411	0.16	0.16	Electrocardiographic traits;	chr9:96087629	chr9:95759231~95875977:-
HNSC	cis	rs9402743	0.634	rs9321512	ENSG00000231028.7	LINC00271	3.58	0.000374	0.0411	0.19	0.16	Systemic lupus erythematosus;	chr6:135603299	chr6:135497801~135716055:+
HNSC	cis	rs10242455	0.702	rs73397447	ENSG00000078319.8	PMS2P1	-3.58	0.000374	0.0411	-0.35	-0.16	Blood metabolite levels;	chr7:99413326	chr7:100320992~100341908:-
HNSC	cis	rs9925964	0.622	rs8046707	ENSG00000274678.1	RP11-2C24.7	-3.58	0.000374	0.0411	-0.18	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30904912	chr16:30821338~30821884:+
HNSC	cis	rs2179367	0.959	rs9373592	ENSG00000216906.2	RP11-350J20.9	3.58	0.000374	0.0411	0.2	0.16	Dupuytren's disease;	chr6:149412119	chr6:149904243~149906418:+
HNSC	cis	rs2286503	1	rs1029740	ENSG00000230042.1	AK3P3	3.58	0.000374	0.0411	0.17	0.16	Fibrinogen;	chr7:22833967	chr7:23129178~23129841:+
HNSC	cis	rs2074409	0.509	rs2680720	ENSG00000276054.1	RP11-378E13.3	3.58	0.000374	0.0411	0.18	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37458360	chr17:37386886~37387926:+
HNSC	cis	rs7646881	0.544	rs1038885	ENSG00000272087.1	RP11-379F4.7	3.58	0.000374	0.0411	0.25	0.16	Tetralogy of Fallot;	chr3:158629222	chr3:158693120~158693768:-
HNSC	cis	rs1005277	0.579	rs1740737	ENSG00000099251.13	HSD17B7P2	3.58	0.000374	0.0411	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38356380~38378505:+
HNSC	cis	rs6430585	0.646	rs1057031	ENSG00000231890.6	DARS-AS1	-3.58	0.000374	0.0411	-0.29	-0.16	Corneal structure;	chr2:135876392	chr2:135985176~136022593:+
HNSC	cis	rs61160187	0.636	rs153152	ENSG00000215032.2	GNL3LP1	3.58	0.000374	0.0411	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60547144	chr5:60891935~60893577:-
HNSC	cis	rs7927592	0.956	rs10896337	ENSG00000239559.2	RPL37P2	3.58	0.000374	0.0411	0.17	0.16	Total body bone mineral density;	chr11:68516768	chr11:67682772~67683058:-
HNSC	cis	rs2013441	0.965	rs8068720	ENSG00000261033.1	RP11-209D14.2	3.58	0.000374	0.0411	0.19	0.16	Obesity-related traits;	chr17:20310858	chr17:20008051~20009234:-
HNSC	cis	rs143811622	1	rs143811622	ENSG00000228217.1	AL390877.1	3.58	0.000374	0.0411	0.23	0.16	Platelet distribution width;	chr1:117612527	chr1:117778087~117778506:-
HNSC	cis	rs939574	0.512	rs6730612	ENSG00000243910.6	TUBA4B	3.58	0.000374	0.0411	0.27	0.16	Platelet distribution width;	chr2:219281474	chr2:219253243~219272188:+
HNSC	cis	rs3731896	1	rs3731896	ENSG00000243910.6	TUBA4B	3.58	0.000374	0.0411	0.27	0.16	Educational attainment;	chr2:219281680	chr2:219253243~219272188:+
HNSC	cis	rs9467711	0.559	rs12176129	ENSG00000241549.7	GUSBP2	3.58	0.000374	0.0411	0.24	0.16	Autism spectrum disorder or schizophrenia;	chr6:26514712	chr6:26871484~26956554:-
HNSC	cis	rs3018712	0.532	rs948861	ENSG00000255031.4	RP11-802E16.3	-3.58	0.000374	0.0411	-0.18	-0.16	Total body bone mineral density;	chr11:68653154	chr11:68050740~68053762:+
HNSC	cis	rs3018712	0.532	rs948863	ENSG00000255031.4	RP11-802E16.3	-3.58	0.000374	0.0411	-0.18	-0.16	Total body bone mineral density;	chr11:68653506	chr11:68050740~68053762:+
HNSC	cis	rs643955	0.611	rs35044612	ENSG00000254340.1	RP11-10A14.3	-3.58	0.000374	0.0411	-0.19	-0.16	Systemic lupus erythematosus;	chr8:10007470	chr8:9141424~9145435:+
HNSC	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	3.58	0.000374	0.0411	0.17	0.16	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
HNSC	cis	rs9487051	1	rs9386795	ENSG00000219700.1	PTCHD3P3	3.58	0.000374	0.0411	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109295325	chr6:109288571~109290503:-
HNSC	cis	rs494453	0.922	rs2473843	ENSG00000227811.2	FAM212B-AS1	-3.58	0.000374	0.0411	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111698035	chr1:111739841~111747798:+
HNSC	cis	rs494453	0.845	rs2477427	ENSG00000227811.2	FAM212B-AS1	-3.58	0.000374	0.0411	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111698072	chr1:111739841~111747798:+
HNSC	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	3.58	0.000374	0.0411	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	3.58	0.000374	0.0411	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	3.58	0.000374	0.0411	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	3.58	0.000374	0.0411	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	3.58	0.000374	0.0411	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
HNSC	cis	rs9595908	0.965	rs11840502	ENSG00000215515.2	IFIT1P1	3.58	0.000374	0.0411	0.19	0.16	Body mass index;	chr13:32624572	chr13:32384660~32386108:+
HNSC	cis	rs12545109	0.642	rs2055984	ENSG00000246430.5	LINC00968	-3.58	0.000374	0.0411	-0.23	-0.16	Obesity-related traits;	chr8:56505773	chr8:56496246~56559823:-
HNSC	cis	rs9929218	0.551	rs2296408	ENSG00000260459.2	FTLP14	-3.58	0.000374	0.0411	-0.21	-0.16	Colorectal cancer;	chr16:68679920	chr16:68822587~68823070:+
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000269918.1	AF131215.9	3.58	0.000374	0.0411	0.16	0.16	Neuroticism;	chr8:11939481	chr8:11104691~11106704:-
HNSC	cis	rs9304742	0.962	rs1044467	ENSG00000213793.4	ZNF888	3.58	0.000375	0.0411	0.19	0.16	Psoriasis;	chr19:52949516	chr19:52915196~52923470:-
HNSC	cis	rs10435719	0.902	rs4840599	ENSG00000255310.2	AF131215.2	-3.58	0.000375	0.0411	-0.15	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.527	rs11785394	ENSG00000255310.2	AF131215.2	-3.58	0.000375	0.0411	-0.15	-0.16	Retinal vascular caliber;	chr8:11380520	chr8:11107788~11109726:-
HNSC	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	3.58	0.000375	0.0411	0.15	0.16	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
HNSC	cis	rs2657294	0.965	rs4746264	ENSG00000233313.2	HMGA1P5	-3.58	0.000375	0.0411	-0.18	-0.16	Pneumonia;	chr10:75114194	chr10:75276376~75276646:-
HNSC	cis	rs6918586	0.565	rs198855	ENSG00000216331.1	HIST1H1PS1	-3.58	0.000375	0.0411	-0.22	-0.16	Schizophrenia;	chr6:26103170	chr6:26195566~26195771:+
HNSC	cis	rs13256369	0.76	rs7816171	ENSG00000254153.1	CTA-398F10.2	3.58	0.000375	0.0411	0.2	0.16	Obesity-related traits;	chr8:8718325	chr8:8456909~8461337:-
HNSC	cis	rs13256369	0.76	rs7839473	ENSG00000254153.1	CTA-398F10.2	3.58	0.000375	0.0411	0.2	0.16	Obesity-related traits;	chr8:8718326	chr8:8456909~8461337:-
HNSC	cis	rs13196561	0.826	rs74534871	ENSG00000213177.3	PRDX2P4	-3.58	0.000375	0.0412	-0.25	-0.16	Menarche (age at onset);	chr6:100340936	chr6:100136064~100136663:+
HNSC	cis	rs1964356	0.524	rs7839585	ENSG00000254153.1	CTA-398F10.2	-3.58	0.000375	0.0412	-0.18	-0.16	Mean corpuscular volume;	chr8:8996725	chr8:8456909~8461337:-
HNSC	cis	rs11633886	0.72	rs4408481	ENSG00000273972.1	CTD-2306A12.1	-3.58	0.000375	0.0412	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45768871	chr15:45702640~45703183:+
HNSC	cis	rs4948102	0.731	rs10229446	ENSG00000213650.3	RP11-760D2.7	-3.58	0.000375	0.0412	-0.18	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr7:56567906~56568858:-
HNSC	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-3.58	0.000375	0.0412	-0.19	-0.16	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
HNSC	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-3.58	0.000375	0.0412	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
HNSC	cis	rs2548724	0.812	rs2600828	ENSG00000175749.11	EIF3KP1	-3.58	0.000375	0.0412	-0.23	-0.16	Type 2 diabetes;	chr5:102271899	chr5:103032376~103033031:+
HNSC	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	3.58	0.000375	0.0412	0.22	0.16	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
HNSC	cis	rs13178541	0.81	rs4466158	ENSG00000250378.1	RP11-119J18.1	-3.58	0.000375	0.0412	-0.22	-0.16	IgG glycosylation;	chr5:135829468	chr5:135812667~135826582:+
HNSC	cis	rs6493858	0.775	rs9672928	ENSG00000277245.1	RP11-48G14.3	-3.58	0.000375	0.0412	-0.19	-0.16	Relative hand skill in reading disability;	chr15:56117007	chr15:56447120~56447697:+
HNSC	cis	rs11866815	0.857	rs2361988	ENSG00000219274.1	RPS20P2	-3.58	0.000375	0.0412	-0.2	-0.16	Body mass index;	chr16:348151	chr16:1329078~1329777:+
HNSC	cis	rs295490	0.831	rs57707457	ENSG00000272656.1	RP11-219D15.3	3.58	0.000375	0.0412	0.34	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520256	chr3:139349024~139349371:-
HNSC	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	3.58	0.000375	0.0412	0.21	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
HNSC	cis	rs9650657	0.769	rs2116094	ENSG00000255310.2	AF131215.2	-3.58	0.000375	0.0412	-0.16	-0.16	Neuroticism;	chr8:10741312	chr8:11107788~11109726:-
HNSC	cis	rs28489187	0.683	rs11161607	ENSG00000223653.4	RP11-131L23.1	3.58	0.000375	0.0412	0.23	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85390172	chr1:85276715~85448124:+
HNSC	cis	rs7189233	0.955	rs7184800	ENSG00000279344.1	RP11-44F14.7	3.58	0.000375	0.0412	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53475219	chr16:53478957~53481550:-
HNSC	cis	rs9583531	0.6	rs1441042	ENSG00000259831.1	LINC00567	3.58	0.000375	0.0412	0.19	0.16	Coronary artery disease;	chr13:110713242	chr13:110809676~110813084:-
HNSC	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-3.58	0.000375	0.0412	-0.22	-0.16	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
HNSC	cis	rs8042680	0.688	rs4244883	ENSG00000213471.7	TTLL13P	-3.58	0.000375	0.0412	-0.2	-0.16	Type 2 diabetes;	chr15:91003267	chr15:90249530~90265482:+
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000269918.1	AF131215.9	3.58	0.000375	0.0412	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11104691~11106704:-
HNSC	cis	rs11098499	0.863	rs1010739	ENSG00000250412.1	KLHL2P1	3.58	0.000375	0.0412	0.22	0.16	Corneal astigmatism;	chr4:119542316	chr4:119334329~119378233:+
HNSC	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-3.58	0.000375	0.0412	-0.24	-0.16	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
HNSC	cis	rs2554380	0.891	rs2562781	ENSG00000259570.1	RP11-671M22.4	3.58	0.000375	0.0412	0.23	0.16	Height;	chr15:83643816	chr15:84394512~84395514:+
HNSC	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-3.58	0.000376	0.0412	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
HNSC	cis	rs66887589	0.967	rs1155577	ENSG00000249244.1	RP11-548H18.2	-3.58	0.000376	0.0412	-0.18	-0.16	Diastolic blood pressure;	chr4:119528655	chr4:119391831~119395335:-
HNSC	cis	rs4578769	0.55	rs12966925	ENSG00000265943.1	RP11-739L10.1	3.58	0.000376	0.0412	0.19	0.16	Eosinophil percentage of white cells;	chr18:22953734	chr18:22699481~22933764:-
HNSC	cis	rs6090919	0.501	rs6019464	ENSG00000222365.1	SNORD12B	-3.58	0.000376	0.0412	-0.21	-0.16	Intelligence (multi-trait analysis);	chr20:48863239	chr20:49280319~49280409:+
HNSC	cis	rs1167827	1	rs1167827	ENSG00000165178.9	NCF1C	3.58	0.000376	0.0412	0.14	0.16	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75156639~75172044:-
HNSC	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	3.58	0.000376	0.0412	0.19	0.16	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
HNSC	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	3.58	0.000376	0.0412	0.19	0.16	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
HNSC	cis	rs11587682	0.785	rs72694993	ENSG00000261716.1	RP11-196G18.22	-3.58	0.000376	0.0412	-0.22	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150270203	chr1:149844498~149849024:-
HNSC	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-3.58	0.000376	0.0412	-0.16	-0.16	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
HNSC	cis	rs853679	0.546	rs175597	ENSG00000219392.1	RP1-265C24.5	-3.58	0.000376	0.0412	-0.28	-0.16	Depression;	chr6:27842848	chr6:28115628~28116551:+
HNSC	cis	rs758324	0.732	rs152198	ENSG00000279691.1	RP11-485M7.2	3.58	0.000376	0.0412	0.19	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132103117	chr5:133052769~133052971:+
HNSC	cis	rs6921919	0.778	rs67381177	ENSG00000204709.4	LINC01556	3.58	0.000376	0.0412	0.35	0.16	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28943877~28944537:+
HNSC	cis	rs6921919	1	rs35875412	ENSG00000217862.2	HIST1H4PS1	-3.58	0.000376	0.0412	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:27807075~27807339:+
HNSC	cis	rs6001482	0.507	rs62234784	ENSG00000253590.1	IGLV3-13	-3.58	0.000376	0.0412	-0.14	-0.16	Diastolic blood pressure;	chr22:22234610	chr22:22762294~22762516:+
HNSC	cis	rs4252134	0.687	rs3846778	ENSG00000233342.1	RP11-235G24.3	3.58	0.000376	0.0412	0.21	0.16	Giant cell arteritis;	chr6:160809769	chr6:160926369~160927162:+
HNSC	cis	rs7364180	0.883	rs2228314	ENSG00000205702.9	CYP2D7	-3.58	0.000376	0.0412	-0.13	-0.16	Alzheimer's disease biomarkers;	chr22:41880738	chr22:42140203~42144577:-
HNSC	cis	rs28489187	0.706	rs3768227	ENSG00000223653.4	RP11-131L23.1	3.58	0.000376	0.0412	0.23	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85338404	chr1:85276715~85448124:+
HNSC	cis	rs11587682	0.578	rs12121421	ENSG00000236713.1	RP11-363I22.3	3.58	0.000376	0.0412	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150432190	chr1:150780272~150780644:+
HNSC	cis	rs71636778	0.509	rs35969145	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26932901	chr1:26692132~26694131:-
HNSC	cis	rs41307935	0.818	rs35576939	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26947604	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs17340509	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26948209	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs17356923	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956185	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs12742376	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26958704	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs34514856	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961069	chr1:26692132~26694131:-
HNSC	cis	rs71636778	0.509	rs60340200	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0412	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961225	chr1:26692132~26694131:-
HNSC	cis	rs6142618	0.807	rs6057559	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000376	0.0413	-0.17	-0.16	Inflammatory bowel disease;	chr20:32304151	chr20:32116171~32116629:+
HNSC	cis	rs4704187	0.687	rs4340901	ENSG00000272040.1	CTC-366B18.4	-3.58	0.000376	0.0413	-0.15	-0.16	Response to amphetamines;	chr5:75109080	chr5:75608817~75609983:+
HNSC	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-3.58	0.000376	0.0413	-0.18	-0.16	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
HNSC	cis	rs1190596	0.666	rs12892927	ENSG00000272444.1	RP11-1017G21.6	3.58	0.000376	0.0413	0.22	0.16	Behavioural disinhibition (generation interaction);	chr14:102297705	chr14:101952416~101953063:+
HNSC	cis	rs8022179	0.566	rs62006258	ENSG00000244691.1	RPL10AP1	3.58	0.000376	0.0413	0.22	0.16	Monocyte count;	chr14:103372572	chr14:103412119~103412761:-
HNSC	cis	rs6545883	0.894	rs12622458	ENSG00000271889.1	RP11-493E12.1	-3.58	0.000376	0.0413	-0.19	-0.16	Tuberculosis;	chr2:61296419	chr2:61151433~61162105:-
HNSC	cis	rs5751168	0.834	rs11109	ENSG00000274422.1	LL22NC03-2H8.5	3.58	0.000376	0.0413	0.2	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22487881	chr22:22283928~22287220:-
HNSC	cis	rs3771570	1	rs57196672	ENSG00000260942.1	CAPN10-AS1	-3.58	0.000376	0.0413	-0.18	-0.16	Prostate cancer;	chr2:241295778	chr2:240582700~240586699:-
HNSC	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	3.58	0.000376	0.0413	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
HNSC	cis	rs344024	0.621	rs985856	ENSG00000240489.1	SETP14	3.58	0.000376	0.0413	0.15	0.16	Total body bone mineral density;	chr3:156645119	chr3:155987304~155988176:+
HNSC	cis	rs12701220	0.901	rs12701708	ENSG00000224079.1	AC091729.7	3.58	0.000377	0.0413	0.23	0.16	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1074450~1078036:+
HNSC	cis	rs10256972	0.758	rs11979275	ENSG00000225146.1	AC073957.15	3.58	0.000377	0.0413	0.19	0.16	Endometriosis;Longevity;	chr7:1029699	chr7:1029025~1043891:+
HNSC	cis	rs10256972	0.758	rs11980081	ENSG00000225146.1	AC073957.15	3.58	0.000377	0.0413	0.19	0.16	Endometriosis;Longevity;	chr7:1029736	chr7:1029025~1043891:+
HNSC	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-3.58	0.000377	0.0413	-0.2	-0.16	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
HNSC	cis	rs9768139	0.733	rs71545585	ENSG00000223872.1	AC006372.5	-3.58	0.000377	0.0413	-0.17	-0.16	Calcium levels;	chr7:158325980	chr7:157501322~157503577:+
HNSC	cis	rs890448	0.694	rs2583398	ENSG00000254531.1	FLJ20021	-3.58	0.000377	0.0413	-0.17	-0.16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101307539	chr4:101347780~101348883:+
HNSC	cis	rs11711311	1	rs12632983	ENSG00000241529.3	RN7SL767P	-3.58	0.000377	0.0413	-0.21	-0.16	IgG glycosylation;	chr3:113763066	chr3:113632704~113632998:+
HNSC	cis	rs11711311	0.868	rs13091621	ENSG00000241529.3	RN7SL767P	-3.58	0.000377	0.0413	-0.21	-0.16	IgG glycosylation;	chr3:113763130	chr3:113632704~113632998:+
HNSC	cis	rs3740713	1	rs75487138	ENSG00000256464.1	YWHABP2	3.58	0.000377	0.0413	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr11:18490243~18490955:-
HNSC	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-3.58	0.000377	0.0413	-0.18	-0.16	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
HNSC	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-3.58	0.000377	0.0413	-0.18	-0.16	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
HNSC	cis	rs7015263	0.689	rs62510798	ENSG00000254231.1	CTD-2284J15.1	-3.58	0.000377	0.0413	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86432337	chr8:86333274~86343314:-
HNSC	cis	rs7735319	0.533	rs2331146	ENSG00000251281.1	CTD-2066L21.2	-3.58	0.000377	0.0413	-0.19	-0.16	Systolic blood pressure;	chr5:33052415	chr5:33011322~33017607:-
HNSC	cis	rs11711311	0.955	rs10934247	ENSG00000241529.3	RN7SL767P	-3.58	0.000377	0.0413	-0.21	-0.16	IgG glycosylation;	chr3:113816094	chr3:113632704~113632998:+
HNSC	cis	rs2839186	0.967	rs17176131	ENSG00000239415.1	AP001469.9	3.58	0.000377	0.0413	0.14	0.16	Testicular germ cell tumor;	chr21:46285323	chr21:46251549~46254133:-
HNSC	cis	rs9393777	0.778	rs74689501	ENSG00000241549.7	GUSBP2	3.58	0.000377	0.0413	0.27	0.16	Intelligence (multi-trait analysis);	chr6:26920042	chr6:26871484~26956554:-
HNSC	cis	rs13178541	0.748	rs4317317	ENSG00000250378.1	RP11-119J18.1	-3.58	0.000377	0.0413	-0.21	-0.16	IgG glycosylation;	chr5:135740765	chr5:135812667~135826582:+
HNSC	cis	rs9652601	0.691	rs12922303	ENSG00000274038.1	RP11-66H6.4	-3.58	0.000377	0.0413	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11099608	chr16:11056556~11057034:+
HNSC	cis	rs1585471	0.931	rs6832873	ENSG00000249532.3	RP11-148B6.1	-3.58	0.000377	0.0413	-0.2	-0.16	Myopia (pathological);	chr4:111683227	chr4:112646476~112650051:-
HNSC	cis	rs7246657	0.722	rs1975937	ENSG00000276846.1	CTD-3220F14.3	3.58	0.000377	0.0413	0.22	0.16	Coronary artery calcification;	chr19:37601031	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs8103647	ENSG00000276846.1	CTD-3220F14.3	3.58	0.000377	0.0413	0.22	0.16	Coronary artery calcification;	chr19:37609551	chr19:37314868~37315620:-
HNSC	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	3.58	0.000377	0.0414	0.19	0.16	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
HNSC	cis	rs2247572	0.778	rs2253912	ENSG00000250295.5	RP11-434I12.2	3.58	0.000377	0.0414	0.21	0.16	Cognitive performance;	chr8:72738707	chr8:73297711~73356461:-
HNSC	cis	rs2300747	0.546	rs10924103	ENSG00000177173.5	NAP1L4P1	-3.58	0.000377	0.0414	-0.23	-0.16	Primary biliary cholangitis;Multiple sclerosis;	chr1:116493929	chr1:116532936~116534092:-
HNSC	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-3.58	0.000377	0.0414	-0.19	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
HNSC	cis	rs17772222	0.917	rs10143767	ENSG00000258789.1	RP11-507K2.3	-3.58	0.000377	0.0414	-0.2	-0.16	Coronary artery calcification;	chr14:88514867	chr14:88551597~88552493:+
HNSC	cis	rs7726839	0.561	rs72703050	ENSG00000225138.6	CTD-2228K2.7	3.58	0.000377	0.0414	0.23	0.16	Obesity-related traits;	chr5:582802	chr5:473236~480884:+
HNSC	cis	rs8062405	0.789	rs1968752	ENSG00000260367.2	RP11-264B17.4	-3.58	0.000377	0.0414	-0.15	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28973962~28978824:-
HNSC	cis	rs1005277	0.522	rs1208684	ENSG00000263064.2	RP11-291L22.7	3.58	0.000377	0.0414	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38448689~38448949:+
HNSC	cis	rs758117	0.696	rs12425203	ENSG00000246627.5	CACNA1C-AS1	3.58	0.000377	0.0414	0.17	0.16	Schizophrenia;	chr12:2365495	chr12:2676001~2691200:-
HNSC	cis	rs300890	0.536	rs10033104	ENSG00000250326.1	RP11-284M14.1	-3.58	0.000377	0.0414	-0.19	-0.16	Nasopharyngeal carcinoma;	chr4:143252330	chr4:142933195~143184861:-
HNSC	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-3.58	0.000377	0.0414	-0.24	-0.16	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-3.58	0.000377	0.0414	-0.24	-0.16	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
HNSC	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-3.58	0.000377	0.0414	-0.24	-0.16	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
HNSC	cis	rs7674212	0.51	rs55715738	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000377	0.0414	-0.19	-0.16	Type 2 diabetes;	chr4:103209032	chr4:102751401~102752641:+
HNSC	cis	rs7688540	0.771	rs2353605	ENSG00000250892.1	RP11-1365D11.1	-3.58	0.000377	0.0414	-0.28	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:201409~205009:-
HNSC	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	3.58	0.000377	0.0414	0.18	0.16	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	3.58	0.000377	0.0414	0.18	0.16	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
HNSC	cis	rs11672691	0.67	rs758643	ENSG00000269843.1	CTC-490E21.10	-3.58	0.000377	0.0414	-0.24	-0.16	Prostate cancer;	chr19:41485616	chr19:40831221~40837210:-
HNSC	cis	rs875971	0.522	rs781144	ENSG00000272831.1	RP11-792A8.4	3.58	0.000378	0.0414	0.14	0.16	Aortic root size;	chr7:65975357	chr7:66739829~66740385:-
HNSC	cis	rs36093844	0.527	rs17745105	ENSG00000279742.1	RP11-700A24.1	-3.58	0.000378	0.0414	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86001394	chr11:85852557~85854943:-
HNSC	cis	rs5758511	0.689	rs17002947	ENSG00000226450.2	CYP2D8P	-3.58	0.000378	0.0414	-0.16	-0.16	Birth weight;	chr22:42292526	chr22:42149886~42155001:-
HNSC	cis	rs1075232	1	rs4450360	ENSG00000103832.10	GOLGA8UP	-3.58	0.000378	0.0414	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30791573~30801859:+
HNSC	cis	rs1075232	1	rs72722847	ENSG00000103832.10	GOLGA8UP	-3.58	0.000378	0.0414	-0.34	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30791573~30801859:+
HNSC	cis	rs9611565	0.503	rs5996062	ENSG00000235513.1	RP4-756G23.5	-3.58	0.000378	0.0414	-0.21	-0.16	Vitiligo;	chr22:41771460	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs6002474	ENSG00000235513.1	RP4-756G23.5	-3.58	0.000378	0.0414	-0.21	-0.16	Vitiligo;	chr22:41772177	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs5996063	ENSG00000235513.1	RP4-756G23.5	-3.58	0.000378	0.0414	-0.21	-0.16	Vitiligo;	chr22:41772763	chr22:41209122~41217627:-
HNSC	cis	rs10129255	0.5	rs2105991	ENSG00000211976.2	IGHV3-73	-3.58	0.000378	0.0414	-0.11	-0.16	Kawasaki disease;	chr14:106682022	chr14:106802694~106803233:-
HNSC	cis	rs2081015	0.701	rs890793	ENSG00000277039.1	Metazoa_SRP	-3.58	0.000378	0.0414	-0.18	-0.16	Carotid artery intima media thickness (sex interaction);	chr5:154194378	chr5:154821943~154822258:+
HNSC	cis	rs16873450	0.507	rs2390825	ENSG00000234800.2	PCMTD1P3	3.58	0.000378	0.0414	0.16	0.16	Verbal memory performance (residualized delayed recall level);	chr7:23837194	chr7:23721311~23721782:-
HNSC	cis	rs853679	1	rs6905391	ENSG00000270326.1	RP5-874C20.6	-3.58	0.000378	0.0414	-0.24	-0.16	Depression;	chr6:28294909	chr6:28319660~28319852:-
HNSC	cis	rs35851103	0.6	rs4841662	ENSG00000206014.6	OR7E161P	3.58	0.000378	0.0414	0.17	0.16	Neuroticism;	chr8:11986249	chr8:11928597~11929563:-
HNSC	cis	rs6710503	0.632	rs893770	ENSG00000271936.1	RP11-443B20.1	-3.58	0.000378	0.0414	-0.21	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24732085	chr2:24825610~24826717:+
HNSC	cis	rs2562784	0.587	rs2554393	ENSG00000225151.9	GOLGA2P7	-3.58	0.000378	0.0414	-0.31	-0.16	Height;	chr15:83624348	chr15:84199311~84230136:-
HNSC	cis	rs8062405	1	rs1987472	ENSG00000261766.1	RP11-22P6.2	-3.58	0.000378	0.0414	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28862166~28863340:-
HNSC	cis	rs8062405	0.895	rs56186137	ENSG00000261766.1	RP11-22P6.2	-3.58	0.000378	0.0414	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28862166~28863340:-
HNSC	cis	rs13256369	1	rs13267501	ENSG00000254153.1	CTA-398F10.2	3.58	0.000378	0.0414	0.2	0.16	Obesity-related traits;	chr8:8716548	chr8:8456909~8461337:-
HNSC	cis	rs13256369	0.95	rs13270006	ENSG00000254153.1	CTA-398F10.2	3.58	0.000378	0.0414	0.2	0.16	Obesity-related traits;	chr8:8716687	chr8:8456909~8461337:-
HNSC	cis	rs4704187	0.687	rs4345300	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75080746	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.687	rs6869345	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75082917	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.687	rs6858969	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75083456	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.595	rs6859176	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75083600	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.663	rs12523187	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75083800	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.687	rs6453111	ENSG00000271815.1	CTD-2235C13.3	-3.58	0.000378	0.0414	-0.21	-0.16	Response to amphetamines;	chr5:75084101	chr5:75363760~75364242:+
HNSC	cis	rs6951245	0.554	rs11761322	ENSG00000225146.1	AC073957.15	-3.58	0.000378	0.0414	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1029025~1043891:+
HNSC	cis	rs7299940	0.967	rs9738957	ENSG00000256250.1	RP11-989F5.1	3.58	0.000378	0.0414	0.17	0.16	Panic disorder;	chr12:130904256	chr12:130810606~130812438:+
HNSC	cis	rs6570726	0.846	rs446031	ENSG00000270638.1	RP3-466P17.1	3.58	0.000378	0.0414	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145735570~145737218:+
HNSC	cis	rs4899412	0.695	rs12586968	ENSG00000266869.1	RP6-114E22.1	3.58	0.000378	0.0414	0.21	0.16	Heart rate variability traits (SDNN);	chr14:72001688	chr14:71848606~71908430:+
HNSC	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	3.58	0.000378	0.0414	0.19	0.16	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
HNSC	cis	rs9311474	0.508	rs4687629	ENSG00000243224.1	RP5-1157M23.2	-3.58	0.000378	0.0414	-0.16	-0.16	Electroencephalogram traits;	chr3:52581211	chr3:52239258~52241097:+
HNSC	cis	rs886774	0.932	rs6964972	ENSG00000273055.1	CTB-13F3.1	-3.58	0.000378	0.0414	-0.16	-0.16	Ulcerative colitis;	chr7:107859551	chr7:107942116~107942740:+
HNSC	cis	rs8077577	0.747	rs16961153	ENSG00000273018.4	CTD-2303H24.2	3.58	0.000378	0.0414	0.24	0.16	Obesity-related traits;	chr17:18323787	chr17:18511221~18551705:-
HNSC	cis	rs3779195	0.52	rs17169479	ENSG00000183444.10	OR7E38P	3.58	0.000378	0.0415	0.24	0.16	Sex hormone-binding globulin levels;	chr7:98238721	chr7:97966090~97967074:-
HNSC	cis	rs473651	0.935	rs483166	ENSG00000229915.1	AC016999.2	3.58	0.000378	0.0415	0.2	0.16	Multiple system atrophy;	chr2:238438000	chr2:238427077~238427729:-
HNSC	cis	rs2247572	0.887	rs2249770	ENSG00000250295.5	RP11-434I12.2	3.58	0.000378	0.0415	0.19	0.16	Cognitive performance;	chr8:72665319	chr8:73297711~73356461:-
HNSC	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-3.58	0.000378	0.0415	-0.17	-0.16	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
HNSC	cis	rs2562456	0.833	rs56179986	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21337882	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs4429400	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21338163	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs1932087	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21338625	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs11671609	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21342769	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.793	rs62109212	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21343716	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs57250002	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21344048	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62109218	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21346059	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62109223	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21349591	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62109225	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21353861	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.754	rs62109226	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21354111	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.754	rs62109227	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21354128	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.754	rs62109228	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21354129	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs8102783	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21355751	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs2061916	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21358906	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs4359573	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000378	0.0415	0.25	0.16	Pain;	chr19:21359494	chr19:21444241~21463908:-
HNSC	cis	rs9311676	0.609	rs12634722	ENSG00000273493.1	RP11-80H18.4	-3.58	0.000378	0.0415	-0.17	-0.16	Systemic lupus erythematosus;	chr3:58362430	chr3:58329965~58330118:+
HNSC	cis	rs61160187	0.667	rs7722373	ENSG00000272308.1	RP11-231G3.1	-3.58	0.000378	0.0415	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60866457~60866935:-
HNSC	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-3.58	0.000378	0.0415	-0.18	-0.16	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
HNSC	cis	rs432925	0.529	rs9925945	ENSG00000226942.2	IL9RP3	-3.58	0.000378	0.0415	-0.2	-0.16	Morning vs. evening chronotype;	chr16:343564	chr16:29336~38321:-
HNSC	cis	rs7771547	0.642	rs628213	ENSG00000219023.1	RP3-340B19.2	3.58	0.000379	0.0415	0.15	0.16	Platelet distribution width;	chr6:36540869	chr6:35555873~35556264:+
HNSC	cis	rs3738443	0.951	rs4582838	ENSG00000259865.1	RP11-488L18.10	3.58	0.000379	0.0415	0.16	0.16	Alcohol dependence;	chr1:247210269	chr1:247187281~247188526:-
HNSC	cis	rs449789	0.857	rs543547	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159281319	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs625687	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159282262	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs625284	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159282341	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs575681	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159282502	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.681	rs12529478	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159283690	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.711	rs7765794	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159283893	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs592212	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159290051	chr6:159240786~159243329:+
HNSC	cis	rs449789	0.857	rs2451988	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000379	0.0415	-0.19	-0.16	Pulse pressure;	chr6:159293358	chr6:159240786~159243329:+
HNSC	cis	rs2762353	0.935	rs3757130	ENSG00000272462.2	U91328.19	3.58	0.000379	0.0415	0.16	0.16	Blood metabolite levels;	chr6:25770638	chr6:25992662~26001775:+
HNSC	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	3.58	0.000379	0.0415	0.14	0.16	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
HNSC	cis	rs2307394	0.896	rs2382110	ENSG00000281469.1	RP11-567F11.1	3.58	0.000379	0.0415	0.18	0.16	Urate levels;	chr2:147817242	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.929	rs13012991	ENSG00000281469.1	RP11-567F11.1	3.58	0.000379	0.0415	0.18	0.16	Urate levels;	chr2:147817913	chr2:148044380~148044894:+
HNSC	cis	rs6544773	0.899	rs12465198	ENSG00000205054.5	LINC01121	3.58	0.000379	0.0415	0.18	0.16	Mosquito bite size;	chr2:44850269	chr2:45164870~45323295:-
HNSC	cis	rs509208	0.818	rs9809383	ENSG00000220343.5	RP11-440K22.1	3.58	0.000379	0.0415	0.23	0.16	Alzheimer's disease biomarkers;	chr3:166359198	chr3:167065831~167066320:+
HNSC	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-3.58	0.000379	0.0415	-0.21	-0.16	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
HNSC	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-3.58	0.000379	0.0415	-0.16	-0.16	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
HNSC	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-3.58	0.000379	0.0415	-0.19	-0.16	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
HNSC	cis	rs289997	0.502	rs1502943	ENSG00000232383.1	AC010677.5	-3.58	0.000379	0.0415	-0.23	-0.16	Breast cancer;	chr7:25538733	chr7:26276195~26276606:+
HNSC	cis	rs6001482	0.662	rs6001526	ENSG00000253818.1	IGLV1-41	-3.58	0.000379	0.0415	-0.13	-0.16	Diastolic blood pressure;	chr22:22234518	chr22:22404207~22404721:+
HNSC	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	3.58	0.000379	0.0415	0.27	0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
HNSC	cis	rs1519814	0.696	rs7386139	ENSG00000254343.2	RP11-760H22.2	-3.58	0.000379	0.0415	-0.22	-0.16	Breast cancer;	chr8:120015180	chr8:120052180~120056201:+
HNSC	cis	rs2638953	0.924	rs2272361	ENSG00000257176.2	RP11-996F15.2	3.58	0.000379	0.0415	0.18	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:29280418~29317848:-
HNSC	cis	rs11098499	0.644	rs3986377	ENSG00000250412.1	KLHL2P1	3.58	0.000379	0.0415	0.21	0.16	Corneal astigmatism;	chr4:119339115	chr4:119334329~119378233:+
HNSC	cis	rs10028773	0.556	rs4473640	ENSG00000250412.1	KLHL2P1	3.58	0.000379	0.0415	0.21	0.16	Educational attainment;	chr4:119339282	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.691	rs10010355	ENSG00000250412.1	KLHL2P1	3.58	0.000379	0.0415	0.21	0.16	Corneal astigmatism;	chr4:119339888	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.691	rs9307471	ENSG00000250412.1	KLHL2P1	3.58	0.000379	0.0415	0.21	0.16	Corneal astigmatism;	chr4:119340107	chr4:119334329~119378233:+
HNSC	cis	rs8044868	0.53	rs3890860	ENSG00000259209.3	RP5-991G20.2	3.58	0.000379	0.0415	0.17	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72069510	chr16:72805998~72809872:+
HNSC	cis	rs4699052	0.59	rs2138593	ENSG00000246560.2	RP11-10L12.4	3.58	0.000379	0.0415	0.18	0.16	Testicular germ cell tumor;	chr4:103317564	chr4:102828055~102844075:+
HNSC	cis	rs4699052	0.662	rs2866645	ENSG00000246560.2	RP11-10L12.4	3.58	0.000379	0.0415	0.18	0.16	Testicular germ cell tumor;	chr4:103318044	chr4:102828055~102844075:+
HNSC	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0415	0.23	0.16	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
HNSC	cis	rs17772222	0.917	rs17260408	ENSG00000258789.1	RP11-507K2.3	-3.58	0.000379	0.0415	-0.19	-0.16	Coronary artery calcification;	chr14:88715464	chr14:88551597~88552493:+
HNSC	cis	rs17772222	0.917	rs8021690	ENSG00000258789.1	RP11-507K2.3	-3.58	0.000379	0.0415	-0.19	-0.16	Coronary artery calcification;	chr14:88717806	chr14:88551597~88552493:+
HNSC	cis	rs55726902	0.553	rs2525053	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000379	0.0415	0.16	0.16	Allergic disease (asthma, hay fever or eczema);	chr12:47801565	chr12:47788426~47788971:+
HNSC	cis	rs6840360	0.608	rs6831644	ENSG00000251611.1	RP11-610P16.1	-3.58	0.000379	0.0415	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151362594	chr4:151407551~151408835:-
HNSC	cis	rs10851478	0.872	rs12591317	ENSG00000259656.1	RP11-325E5.1	3.58	0.000379	0.0416	0.19	0.16	Oral cavity cancer;	chr15:49653478	chr15:49101791~49103264:+
HNSC	cis	rs10851478	0.872	rs11852336	ENSG00000259656.1	RP11-325E5.1	3.58	0.000379	0.0416	0.19	0.16	Oral cavity cancer;	chr15:49656627	chr15:49101791~49103264:+
HNSC	cis	rs11871801	0.915	rs3785897	ENSG00000267151.3	RP11-100E5.2	-3.58	0.00038	0.0416	-0.24	-0.16	Crohn's disease;	chr17:42518212	chr17:43444707~43451200:+
HNSC	cis	rs11168618	1	rs3961921	ENSG00000240399.1	RP1-228P16.1	3.58	0.00038	0.0416	0.14	0.16	Adiponectin levels;	chr12:48549716	chr12:48054813~48055591:-
HNSC	cis	rs6012564	1	rs2426112	ENSG00000227431.4	CSE1L-AS1	-3.58	0.00038	0.0416	-0.18	-0.16	Anger;	chr20:49073602	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs2426113	ENSG00000227431.4	CSE1L-AS1	-3.58	0.00038	0.0416	-0.18	-0.16	Anger;	chr20:49073652	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs3092411	ENSG00000227431.4	CSE1L-AS1	-3.58	0.00038	0.0416	-0.18	-0.16	Anger;	chr20:49074054	chr20:49040463~49046044:-
HNSC	cis	rs6012564	0.929	rs2426114	ENSG00000227431.4	CSE1L-AS1	-3.58	0.00038	0.0416	-0.18	-0.16	Anger;	chr20:49075855	chr20:49040463~49046044:-
HNSC	cis	rs6012564	1	rs2426116	ENSG00000227431.4	CSE1L-AS1	-3.58	0.00038	0.0416	-0.18	-0.16	Anger;	chr20:49076510	chr20:49040463~49046044:-
HNSC	cis	rs9487051	0.621	rs351735	ENSG00000203799.9	CCDC162P	3.58	0.00038	0.0416	0.17	0.16	Reticulocyte fraction of red cells;	chr6:109184737	chr6:109285485~109355063:+
HNSC	cis	rs73198271	0.737	rs506960	ENSG00000173295.6	FAM86B3P	-3.58	0.00038	0.0416	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8228595~8244865:+
HNSC	cis	rs3002142	0.731	rs3008620	ENSG00000272750.1	RP11-378J18.8	-3.58	0.00038	0.0416	-0.24	-0.16	LDL peak particle diameter (total fat intake interaction);	chr1:222629584	chr1:222658867~222661512:-
HNSC	cis	rs10754283	0.967	rs1934044	ENSG00000231999.5	FLJ27354	-3.58	0.00038	0.0416	-0.17	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89583241~89632894:-
HNSC	cis	rs10819861	0.645	rs7862829	ENSG00000175611.10	LINC00476	3.58	0.00038	0.0416	0.16	0.16	Electrocardiographic traits;	chr9:96094462	chr9:95759231~95875977:-
HNSC	cis	rs8028182	0.636	rs8034317	ENSG00000275645.1	RP11-817O13.9	3.58	0.00038	0.0416	0.17	0.16	Sudden cardiac arrest;	chr15:75472002	chr15:75346744~75347161:-
HNSC	cis	rs8028182	0.636	rs28737338	ENSG00000275645.1	RP11-817O13.9	3.58	0.00038	0.0416	0.17	0.16	Sudden cardiac arrest;	chr15:75476338	chr15:75346744~75347161:-
HNSC	cis	rs7246657	0.722	rs10417576	ENSG00000276846.1	CTD-3220F14.3	3.58	0.00038	0.0416	0.22	0.16	Coronary artery calcification;	chr19:37628311	chr19:37314868~37315620:-
HNSC	cis	rs11587682	0.806	rs7542510	ENSG00000236713.1	RP11-363I22.3	3.58	0.00038	0.0416	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150306392	chr1:150780272~150780644:+
HNSC	cis	rs7299940	0.967	rs10848243	ENSG00000256250.1	RP11-989F5.1	-3.58	0.00038	0.0416	-0.17	-0.16	Panic disorder;	chr12:130894769	chr12:130810606~130812438:+
HNSC	cis	rs9911578	0.967	rs4932693	ENSG00000224738.1	AC099850.1	-3.58	0.00038	0.0416	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59032966	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.934	rs58092632	ENSG00000224738.1	AC099850.1	-3.58	0.00038	0.0416	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59033740	chr17:59106598~59118267:+
HNSC	cis	rs7772486	0.624	rs9485018	ENSG00000270638.1	RP3-466P17.1	-3.58	0.00038	0.0416	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs2092263	ENSG00000270638.1	RP3-466P17.1	-3.58	0.00038	0.0416	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145735570~145737218:+
HNSC	cis	rs4713118	0.955	rs9380010	ENSG00000226314.6	ZNF192P1	-3.58	0.00038	0.0416	-0.2	-0.16	Parkinson's disease;	chr6:27715793	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.955	rs9368528	ENSG00000226314.6	ZNF192P1	-3.58	0.00038	0.0416	-0.2	-0.16	Parkinson's disease;	chr6:27716019	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.955	rs9380011	ENSG00000226314.6	ZNF192P1	-3.58	0.00038	0.0416	-0.2	-0.16	Parkinson's disease;	chr6:27716145	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.955	rs9368529	ENSG00000226314.6	ZNF192P1	-3.58	0.00038	0.0416	-0.2	-0.16	Parkinson's disease;	chr6:27716852	chr6:28161781~28169594:+
HNSC	cis	rs4713118	0.955	rs9380012	ENSG00000226314.6	ZNF192P1	-3.58	0.00038	0.0416	-0.2	-0.16	Parkinson's disease;	chr6:27716875	chr6:28161781~28169594:+
HNSC	cis	rs804280	1	rs804280	ENSG00000255310.2	AF131215.2	3.58	0.00038	0.0416	0.15	0.16	Myopia (pathological);	chr8:11755189	chr8:11107788~11109726:-
HNSC	cis	rs36093844	0.626	rs41381550	ENSG00000279742.1	RP11-700A24.1	3.58	0.00038	0.0416	0.22	0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85956045	chr11:85852557~85854943:-
HNSC	cis	rs2179367	0.586	rs62426088	ENSG00000217733.2	CCT7P1	3.58	0.00038	0.0416	0.21	0.16	Dupuytren's disease;	chr6:149339301	chr6:149879962~149881572:+
HNSC	cis	rs1962636	1	rs1962636	ENSG00000237296.8	SMG1P1	-3.58	0.00038	0.0416	-0.16	-0.16	Schizophrenia;	chr16:22053074	chr16:22437008~22492220:+
HNSC	cis	rs6493858	0.935	rs7170307	ENSG00000277245.1	RP11-48G14.3	-3.58	0.00038	0.0416	-0.18	-0.16	Relative hand skill in reading disability;	chr15:56445099	chr15:56447120~56447697:+
HNSC	cis	rs7772486	0.686	rs9497396	ENSG00000270638.1	RP3-466P17.1	-3.58	0.00038	0.0416	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145735570~145737218:+
HNSC	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	3.58	0.00038	0.0416	0.2	0.16	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
HNSC	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	3.58	0.00038	0.0416	0.17	0.16	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
HNSC	cis	rs6545883	0.895	rs6545871	ENSG00000271889.1	RP11-493E12.1	3.58	0.000381	0.0416	0.19	0.16	Tuberculosis;	chr2:61465068	chr2:61151433~61162105:-
HNSC	cis	rs17221829	0.733	rs10830337	ENSG00000280385.1	AP000648.5	-3.58	0.000381	0.0416	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89673881	chr11:90193614~90198120:+
HNSC	cis	rs61160187	0.582	rs7713481	ENSG00000272308.1	RP11-231G3.1	-3.58	0.000381	0.0416	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.582	rs7737276	ENSG00000272308.1	RP11-231G3.1	-3.58	0.000381	0.0416	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60866457~60866935:-
HNSC	cis	rs2333194	0.772	rs12589739	ENSG00000258695.2	RP3-414A15.2	-3.58	0.000381	0.0417	-0.17	-0.16	Bipolar disorder with mood-incongruent psychosis;	chr14:73436348	chr14:73522878~73530610:+
HNSC	cis	rs2307394	0.786	rs12464921	ENSG00000281469.1	RP11-567F11.1	3.58	0.000381	0.0417	0.19	0.16	Urate levels;	chr2:147718927	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.749	rs12467064	ENSG00000281469.1	RP11-567F11.1	3.58	0.000381	0.0417	0.19	0.16	Urate levels;	chr2:147720808	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.749	rs1113958	ENSG00000281469.1	RP11-567F11.1	3.58	0.000381	0.0417	0.19	0.16	Urate levels;	chr2:147723410	chr2:148044380~148044894:+
HNSC	cis	rs2307394	0.749	rs12464481	ENSG00000281469.1	RP11-567F11.1	3.58	0.000381	0.0417	0.19	0.16	Urate levels;	chr2:147723592	chr2:148044380~148044894:+
HNSC	cis	rs943437	0.604	rs9487769	ENSG00000230177.1	RP5-1112D6.4	3.58	0.000381	0.0417	0.23	0.16	Parkinson's disease;	chr6:111956878	chr6:111277932~111278742:+
HNSC	cis	rs228614	0.502	rs4648004	ENSG00000246560.2	RP11-10L12.4	-3.58	0.000381	0.0417	-0.2	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102539950	chr4:102828055~102844075:+
HNSC	cis	rs1620921	0.711	rs2489942	ENSG00000231863.1	RP3-428L16.1	-3.58	0.000381	0.0417	-0.2	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160836929	chr6:160931080~160969771:+
HNSC	cis	rs1620921	0.711	rs2465846	ENSG00000231863.1	RP3-428L16.1	-3.58	0.000381	0.0417	-0.2	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160836995	chr6:160931080~160969771:+
HNSC	cis	rs12545912	0.77	rs12679180	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000381	0.0417	-0.16	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9685570	chr8:8961200~8979025:+
HNSC	cis	rs4787951	0.826	rs2074572	ENSG00000259940.2	CTD-3203P2.1	-3.58	0.000381	0.0417	-0.18	-0.16	Eosinophil percentage of white cells;	chr16:27345038	chr16:27213308~27214993:-
HNSC	cis	rs1862618	0.641	rs252893	ENSG00000265665.1	AC008391.1	3.58	0.000381	0.0417	0.21	0.16	Initial pursuit acceleration;	chr5:56928887	chr5:56457038~56457138:-
HNSC	cis	rs11098499	0.687	rs71610270	ENSG00000260091.1	RP11-33B1.4	3.58	0.000381	0.0417	0.16	0.16	Corneal astigmatism;	chr4:119366281	chr4:119409333~119410233:+
HNSC	cis	rs8062405	0.69	rs762634	ENSG00000261766.1	RP11-22P6.2	-3.58	0.000381	0.0417	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28862166~28863340:-
HNSC	cis	rs16958440	0.867	rs76558586	ENSG00000267724.1	RP11-49K24.8	3.58	0.000381	0.0417	0.32	0.16	Sitting height ratio;	chr18:47211242	chr18:47105946~47108062:+
HNSC	cis	rs6545883	0.965	rs1562308	ENSG00000271889.1	RP11-493E12.1	3.58	0.000381	0.0417	0.19	0.16	Tuberculosis;	chr2:61541286	chr2:61151433~61162105:-
HNSC	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	3.58	0.000381	0.0417	0.17	0.16	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
HNSC	cis	rs4427176	0.507	rs7462054	ENSG00000254340.1	RP11-10A14.3	-3.58	0.000381	0.0417	-0.23	-0.16	Mosquito bite size;	chr8:9721003	chr8:9141424~9145435:+
HNSC	cis	rs10742752	0.702	rs10838467	ENSG00000255267.3	RP11-430H10.2	3.58	0.000381	0.0417	0.21	0.16	Body mass index;	chr11:45419703	chr11:45371397~45388508:+
HNSC	cis	rs3096299	0.9	rs4785663	ENSG00000261118.1	RP11-104N10.1	3.58	0.000381	0.0417	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89492017~89504460:-
HNSC	cis	rs73198271	0.96	rs10503392	ENSG00000254340.1	RP11-10A14.3	-3.58	0.000381	0.0417	-0.24	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:9141424~9145435:+
HNSC	cis	rs3740713	1	rs78549183	ENSG00000256464.1	YWHABP2	3.58	0.000381	0.0417	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr11:18490243~18490955:-
HNSC	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	3.58	0.000381	0.0417	0.21	0.16	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
HNSC	cis	rs7824557	0.564	rs7814131	ENSG00000255310.2	AF131215.2	-3.58	0.000382	0.0417	-0.16	-0.16	Retinal vascular caliber;	chr8:11241690	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs13275143	ENSG00000255310.2	AF131215.2	3.58	0.000382	0.0417	0.15	0.16	Neuroticism;	chr8:11939481	chr8:11107788~11109726:-
HNSC	cis	rs7176527	0.519	rs12148368	ENSG00000225151.9	GOLGA2P7	3.58	0.000382	0.0417	0.23	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84199311~84230136:-
HNSC	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	3.58	0.000382	0.0417	0.2	0.16	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
HNSC	cis	rs12908161	0.96	rs34452033	ENSG00000229212.6	RP11-561C5.4	-3.58	0.000382	0.0417	-0.23	-0.16	Schizophrenia;	chr15:84678762	chr15:85205440~85234795:-
HNSC	cis	rs13260300	0.657	rs4302822	ENSG00000254349.4	FLJ39080	3.58	0.000382	0.0418	0.2	0.16	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74572798	chr8:74599775~74823313:+
HNSC	cis	rs71636778	0.509	rs11555809	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000382	0.0418	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26890178	chr1:26692132~26694131:-
HNSC	cis	rs17122278	1	rs3741320	ENSG00000255422.1	AP002954.4	3.58	0.000382	0.0418	0.29	0.16	Total cholesterol levels;	chr11:118545132	chr11:118704607~118750263:+
HNSC	cis	rs17122278	1	rs3741319	ENSG00000255422.1	AP002954.4	3.58	0.000382	0.0418	0.29	0.16	Total cholesterol levels;	chr11:118545133	chr11:118704607~118750263:+
HNSC	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	3.58	0.000382	0.0418	0.2	0.16	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
HNSC	cis	rs7829975	0.502	rs7820738	ENSG00000254340.1	RP11-10A14.3	-3.58	0.000382	0.0418	-0.2	-0.16	Mood instability;	chr8:8845097	chr8:9141424~9145435:+
HNSC	cis	rs344024	0.664	rs28493995	ENSG00000240489.1	SETP14	3.58	0.000382	0.0418	0.15	0.16	Total body bone mineral density;	chr3:156646225	chr3:155987304~155988176:+
HNSC	cis	rs853679	0.567	rs13209596	ENSG00000217862.2	HIST1H4PS1	-3.58	0.000382	0.0418	-0.18	-0.16	Depression;	chr6:28428413	chr6:27807075~27807339:+
HNSC	cis	rs482329	0.773	rs656521	ENSG00000224939.1	LINC00184	3.58	0.000382	0.0418	0.21	0.16	Life threatening arrhythmia;	chr1:234663402	chr1:234629311~234634780:+
HNSC	cis	rs9437689	1	rs9437689	ENSG00000237416.5	RP11-465K1.2	-3.58	0.000382	0.0418	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95083980	chr1:94836748~94855426:-
HNSC	cis	rs8040855	0.825	rs4843021	ENSG00000259774.1	RP11-182J1.13	-3.58	0.000382	0.0418	-0.21	-0.16	Bulimia nervosa;	chr15:85151317	chr15:84422618~84425882:+
HNSC	cis	rs7429990	0.864	rs7631950	ENSG00000228638.1	FCF1P2	3.58	0.000382	0.0418	0.15	0.16	Educational attainment (years of education);	chr3:47591865	chr3:48290793~48291375:-
HNSC	cis	rs1440410	0.835	rs4582112	ENSG00000250326.1	RP11-284M14.1	-3.58	0.000382	0.0418	-0.18	-0.16	Ischemic stroke;	chr4:143190579	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs13106497	ENSG00000250326.1	RP11-284M14.1	-3.58	0.000382	0.0418	-0.18	-0.16	Ischemic stroke;	chr4:143199527	chr4:142933195~143184861:-
HNSC	cis	rs7586673	1	rs7586673	ENSG00000235724.7	AC009299.2	-3.58	0.000382	0.0418	-0.21	-0.16	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161222785~161308303:-
HNSC	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	3.58	0.000382	0.0418	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	3.58	0.000382	0.0418	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	3.58	0.000382	0.0418	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	3.58	0.000382	0.0418	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
HNSC	cis	rs73198271	0.843	rs11775888	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000382	0.0418	-0.19	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8961200~8979025:+
HNSC	cis	rs7771547	0.605	rs659726	ENSG00000219023.1	RP3-340B19.2	3.58	0.000382	0.0418	0.15	0.16	Platelet distribution width;	chr6:36500014	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.607	rs632943	ENSG00000219023.1	RP3-340B19.2	3.58	0.000382	0.0418	0.15	0.16	Platelet distribution width;	chr6:36501344	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.573	rs621796	ENSG00000219023.1	RP3-340B19.2	3.58	0.000382	0.0418	0.15	0.16	Platelet distribution width;	chr6:36504482	chr6:35555873~35556264:+
HNSC	cis	rs7771547	0.607	rs614028	ENSG00000219023.1	RP3-340B19.2	3.58	0.000382	0.0418	0.15	0.16	Platelet distribution width;	chr6:36516475	chr6:35555873~35556264:+
HNSC	cis	rs6988985	0.728	rs10105643	ENSG00000247317.3	RP11-273G15.2	-3.58	0.000383	0.0418	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142876470	chr8:142981738~143018437:-
HNSC	cis	rs6504108	0.624	rs3792694	ENSG00000264920.1	RP11-6N17.4	3.58	0.000383	0.0418	0.19	0.16	Body mass index;	chr17:48183080	chr17:47891255~47895812:-
HNSC	cis	rs3736485	0.903	rs8039835	ENSG00000259438.1	CTD-2650P22.1	3.58	0.000383	0.0418	0.17	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51573667	chr15:52010999~52019095:-
HNSC	cis	rs13434995	0.635	rs1818461	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000383	0.0418	-0.22	-0.16	Adiponectin levels;	chr4:55379156	chr4:55363971~55395847:-
HNSC	cis	rs1150668	0.796	rs2247002	ENSG00000217862.2	HIST1H4PS1	-3.58	0.000383	0.0418	-0.16	-0.16	Pubertal anthropometrics;	chr6:28430174	chr6:27807075~27807339:+
HNSC	cis	rs853679	0.713	rs200991	ENSG00000241549.7	GUSBP2	-3.58	0.000383	0.0418	-0.2	-0.16	Depression;	chr6:27847716	chr6:26871484~26956554:-
HNSC	cis	rs9650657	0.801	rs4841437	ENSG00000255310.2	AF131215.2	-3.58	0.000383	0.0418	-0.16	-0.16	Neuroticism;	chr8:10739285	chr8:11107788~11109726:-
HNSC	cis	rs5758659	1	rs134902	ENSG00000273366.1	CTA-989H11.1	-3.58	0.000383	0.0418	-0.19	-0.16	Cognitive function;	chr22:42287991	chr22:42278188~42278846:+
HNSC	cis	rs9329221	0.736	rs34381075	ENSG00000269918.1	AF131215.9	3.58	0.000383	0.0419	0.17	0.16	Neuroticism;	chr8:10386275	chr8:11104691~11106704:-
HNSC	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	3.58	0.000383	0.0419	0.27	0.16	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
HNSC	cis	rs397969	0.646	rs1638526	ENSG00000266126.1	RP11-209D14.4	3.58	0.000383	0.0419	0.2	0.16	Platelet count;	chr17:19945137	chr17:19929372~19929737:-
HNSC	cis	rs4449834	0.816	rs7000766	ENSG00000254432.1	RP11-33I11.2	-3.58	0.000383	0.0419	-0.2	-0.16	Sum eosinophil basophil counts;	chr8:60745274	chr8:60808735~60809606:-
HNSC	cis	rs1799949	0.965	rs8176198	ENSG00000236383.6	LINC00854	-3.58	0.000383	0.0419	-0.15	-0.16	Menopause (age at onset);	chr17:43078520	chr17:43216941~43305976:-
HNSC	cis	rs79040073	0.637	rs17476361	ENSG00000259531.2	RP11-295H24.3	3.58	0.000383	0.0419	0.21	0.16	Lung cancer in ever smokers;	chr15:49302255	chr15:49365124~49366685:-
HNSC	cis	rs7412746	0.622	rs11552229	ENSG00000236713.1	RP11-363I22.3	-3.58	0.000383	0.0419	-0.18	-0.16	Melanoma;	chr1:150811509	chr1:150780272~150780644:+
HNSC	cis	rs55975637	0.73	rs13100157	ENSG00000240476.1	LINC00973	3.58	0.000383	0.0419	0.29	0.16	Advanced age-related macular degeneration;	chr3:99670684	chr3:98981058~98983096:+
HNSC	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-3.58	0.000383	0.0419	-0.18	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
HNSC	cis	rs7927592	0.83	rs7120635	ENSG00000239559.2	RPL37P2	3.58	0.000383	0.0419	0.16	0.16	Total body bone mineral density;	chr11:68493825	chr11:67682772~67683058:-
HNSC	cis	rs67478160	0.572	rs8015603	ENSG00000259515.1	RP11-365N19.2	3.58	0.000383	0.0419	0.14	0.16	Schizophrenia;	chr14:103827341	chr14:102933574~102937177:+
HNSC	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	3.58	0.000383	0.0419	0.17	0.16	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
HNSC	cis	rs2657294	0.965	rs9299525	ENSG00000233313.2	HMGA1P5	-3.58	0.000383	0.0419	-0.18	-0.16	Pneumonia;	chr10:75118267	chr10:75276376~75276646:-
HNSC	cis	rs2657294	0.965	rs10762658	ENSG00000233313.2	HMGA1P5	-3.58	0.000383	0.0419	-0.18	-0.16	Pneumonia;	chr10:75119804	chr10:75276376~75276646:-
HNSC	cis	rs10484434	0.792	rs11961143	ENSG00000272810.1	U91328.22	3.58	0.000383	0.0419	0.19	0.16	HIV-1 viral setpoint;	chr6:26032645	chr6:26013241~26013757:+
HNSC	cis	rs4388249	0.904	rs3797670	ENSG00000271849.1	CTC-332L22.1	-3.58	0.000383	0.0419	-0.26	-0.16	Schizophrenia;	chr5:109866331	chr5:109687802~109688329:-
HNSC	cis	rs4266144	1	rs4266144	ENSG00000241770.1	RP11-555M1.3	-3.58	0.000383	0.0419	-0.19	-0.16	Coronary artery disease;	chr3:157134803	chr3:157163452~157169133:+
HNSC	cis	rs7824557	0.579	rs10098322	ENSG00000255020.1	AF131216.5	3.58	0.000383	0.0419	0.17	0.16	Retinal vascular caliber;	chr8:11338786	chr8:11345748~11347502:-
HNSC	cis	rs1023500	1	rs1023499	ENSG00000205702.9	CYP2D7	-3.58	0.000384	0.0419	-0.14	-0.16	Schizophrenia;	chr22:41944578	chr22:42140203~42144577:-
HNSC	cis	rs2055729	0.677	rs6601393	ENSG00000254340.1	RP11-10A14.3	-3.58	0.000384	0.0419	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9883525	chr8:9141424~9145435:+
HNSC	cis	rs6088590	0.561	rs764597	ENSG00000276073.1	RP5-1125A11.7	-3.58	0.000384	0.0419	-0.17	-0.16	Coronary artery disease;	chr20:34573421	chr20:33985617~33988989:-
HNSC	cis	rs71636778	0.57	rs34026565	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000384	0.0419	-0.36	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903485	chr1:26692132~26694131:-
HNSC	cis	rs875971	0.862	rs778724	ENSG00000106610.13	STAG3L4	-3.58	0.000384	0.0419	-0.21	-0.16	Aortic root size;	chr7:66364304	chr7:67302621~67321526:+
HNSC	cis	rs5758511	0.689	rs17478227	ENSG00000233903.2	Z83851.4	-3.58	0.000384	0.0419	-0.27	-0.16	Birth weight;	chr22:42258321	chr22:42276355~42277052:+
HNSC	cis	rs12745968	0.652	rs11164608	ENSG00000223787.2	RP4-593M8.1	-3.58	0.000384	0.0419	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92481870	chr1:92580476~92580821:-
HNSC	cis	rs4654783	1	rs4654783	ENSG00000228397.1	RP1-224A6.3	3.58	0.000384	0.0419	0.21	0.16	Endometriosis;	chr1:22113027	chr1:22023994~22024968:-
HNSC	cis	rs997295	0.504	rs12905397	ENSG00000270964.1	RP11-502I4.3	-3.58	0.000384	0.0419	-0.17	-0.16	Motion sickness;	chr15:67741812	chr15:67541072~67542604:-
HNSC	cis	rs6095360	0.644	rs35269800	ENSG00000222365.1	SNORD12B	-3.58	0.000384	0.042	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48896484	chr20:49280319~49280409:+
HNSC	cis	rs2439831	0.85	rs8032649	ENSG00000201136.1	RNU6-353P	3.58	0.000384	0.042	0.26	0.16	Lung cancer in ever smokers;	chr15:43842724	chr15:43702363~43702470:+
HNSC	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	3.58	0.000384	0.042	0.2	0.16	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	3.58	0.000384	0.042	0.2	0.16	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	3.58	0.000384	0.042	0.2	0.16	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	3.58	0.000384	0.042	0.2	0.16	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
HNSC	cis	rs1937680	0.657	rs6480545	ENSG00000236671.6	PRKG1-AS1	-3.58	0.000384	0.042	-0.22	-0.16	Breast cancer;	chr10:51888590	chr10:52230742~52314128:-
HNSC	cis	rs875971	0.638	rs10249404	ENSG00000272831.1	RP11-792A8.4	-3.58	0.000384	0.042	-0.14	-0.16	Aortic root size;	chr7:66581737	chr7:66739829~66740385:-
HNSC	cis	rs9467711	0.659	rs72844462	ENSG00000241549.7	GUSBP2	3.58	0.000384	0.042	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:26871484~26956554:-
HNSC	cis	rs9876781	1	rs7635522	ENSG00000229759.1	MRPS18AP1	3.58	0.000384	0.042	0.16	0.16	Longevity;	chr3:48382166	chr3:48256350~48256938:-
HNSC	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-3.58	0.000384	0.042	-0.2	-0.16	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
HNSC	cis	rs328506	0.545	rs4810077	ENSG00000124224.15	PPP4R1L	3.58	0.000384	0.042	0.16	0.16	Type 2 diabetes;	chr20:57469047	chr20:58228940~58309439:-
HNSC	cis	rs544991	0.652	rs9943133	ENSG00000239670.1	RP4-803A2.2	3.58	0.000384	0.042	0.2	0.16	Intelligence;	chr1:33749981	chr1:32986952~32988233:+
HNSC	cis	rs4906332	1	rs3783400	ENSG00000244691.1	RPL10AP1	-3.58	0.000384	0.042	-0.19	-0.16	Coronary artery disease;	chr14:103500708	chr14:103412119~103412761:-
HNSC	cis	rs7824557	0.614	rs4394351	ENSG00000255495.1	AC145124.2	3.58	0.000384	0.042	0.18	0.16	Retinal vascular caliber;	chr8:11355366	chr8:12194467~12196280:+
HNSC	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	3.58	0.000384	0.042	0.19	0.16	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
HNSC	cis	rs12440869	0.649	rs4776929	ENSG00000270964.1	RP11-502I4.3	3.58	0.000384	0.042	0.2	0.16	Peak velocity of the mitral A-wave;	chr15:67414796	chr15:67541072~67542604:-
HNSC	cis	rs4703129	0.934	rs1978419	ENSG00000246763.5	RGMB-AS1	-3.58	0.000384	0.042	-0.18	-0.16	Asperger disorder;	chr5:98532166	chr5:98769618~98773469:-
HNSC	cis	rs4703129	1	rs6865579	ENSG00000246763.5	RGMB-AS1	-3.58	0.000384	0.042	-0.18	-0.16	Asperger disorder;	chr5:98532425	chr5:98769618~98773469:-
HNSC	cis	rs7246657	0.722	rs2075284	ENSG00000276846.1	CTD-3220F14.3	-3.58	0.000384	0.042	-0.22	-0.16	Coronary artery calcification;	chr19:37698715	chr19:37314868~37315620:-
HNSC	cis	rs7937890	0.559	rs2575829	ENSG00000254418.1	RP11-21L19.1	3.58	0.000384	0.042	0.19	0.16	Mitochondrial DNA levels;	chr11:14463475	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.559	rs2597200	ENSG00000254418.1	RP11-21L19.1	3.58	0.000384	0.042	0.19	0.16	Mitochondrial DNA levels;	chr11:14464054	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.559	rs2575830	ENSG00000254418.1	RP11-21L19.1	3.58	0.000384	0.042	0.19	0.16	Mitochondrial DNA levels;	chr11:14464056	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.559	rs2575831	ENSG00000254418.1	RP11-21L19.1	3.58	0.000384	0.042	0.19	0.16	Mitochondrial DNA levels;	chr11:14464648	chr11:14262846~14273691:-
HNSC	cis	rs11711311	0.869	rs1026364	ENSG00000241529.3	RN7SL767P	-3.58	0.000384	0.042	-0.22	-0.16	IgG glycosylation;	chr3:113651163	chr3:113632704~113632998:+
HNSC	cis	rs12234571	1	rs35462861	ENSG00000214293.7	APTR	3.58	0.000384	0.042	0.21	0.16	Obesity-related traits;	chr7:77941441	chr7:77657660~77696265:-
HNSC	cis	rs12492269	0.702	rs41381644	ENSG00000260743.1	RP11-255C15.3	3.58	0.000384	0.042	0.39	0.16	Plasma clusterin levels;	chr3:178443826	chr3:179340322~179341887:+
HNSC	cis	rs189798	0.807	rs330909	ENSG00000253981.4	ALG1L13P	3.58	0.000385	0.042	0.19	0.16	Myopia (pathological);	chr8:9137877	chr8:8236003~8244667:-
HNSC	cis	rs4906332	0.754	rs34235720	ENSG00000269940.1	RP11-73M18.7	3.58	0.000385	0.042	0.18	0.16	Coronary artery disease;	chr14:103538631	chr14:103694560~103695170:+
HNSC	cis	rs2436845	1	rs2570942	ENSG00000253669.3	KB-1732A1.1	-3.58	0.000385	0.042	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848812	chr8:102805517~102809971:+
HNSC	cis	rs17407555	0.738	rs73212870	ENSG00000250413.1	RP11-448G15.1	3.58	0.000385	0.042	0.25	0.16	Schizophrenia (age at onset);	chr4:10110174	chr4:10006482~10009725:+
HNSC	cis	rs11722779	0.935	rs11938650	ENSG00000248740.4	RP11-328K4.1	3.58	0.000385	0.042	0.17	0.16	Schizophrenia;	chr4:103021639	chr4:103256159~103453658:+
HNSC	cis	rs9611565	0.659	rs17367716	ENSG00000235513.1	RP4-756G23.5	3.58	0.000385	0.042	0.2	0.16	Vitiligo;	chr22:41517840	chr22:41209122~41217627:-
HNSC	cis	rs9402743	0.634	rs2327647	ENSG00000231028.7	LINC00271	3.58	0.000385	0.042	0.19	0.16	Systemic lupus erythematosus;	chr6:135597296	chr6:135497801~135716055:+
HNSC	cis	rs5758659	1	rs134873	ENSG00000270083.1	RP1-257I20.14	3.58	0.000385	0.042	0.15	0.16	Cognitive function;	chr22:42261560	chr22:42089630~42090028:-
HNSC	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000385	0.042	-0.24	-0.16	Gout;	chr7:66654674	chr7:66848496~66858136:+
HNSC	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000385	0.042	-0.24	-0.16	Gout;	chr7:66661502	chr7:66848496~66858136:+
HNSC	cis	rs75920871	0.66	rs4938330	ENSG00000254851.1	RP11-109L13.1	3.58	0.000385	0.042	0.23	0.16	Subjective well-being;	chr11:117057798	chr11:117135528~117138582:+
HNSC	cis	rs6012564	0.964	rs6125547	ENSG00000227431.4	CSE1L-AS1	3.58	0.000385	0.042	0.19	0.16	Anger;	chr20:49100868	chr20:49040463~49046044:-
HNSC	cis	rs964184	0.63	rs2075290	ENSG00000280143.1	AP000892.6	3.58	0.000385	0.042	0.32	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117204967~117210292:+
HNSC	cis	rs7429990	0.864	rs7637950	ENSG00000228638.1	FCF1P2	3.58	0.000385	0.042	0.15	0.16	Educational attainment (years of education);	chr3:47758204	chr3:48290793~48291375:-
HNSC	cis	rs8022179	0.58	rs6575977	ENSG00000244691.1	RPL10AP1	3.58	0.000385	0.042	0.23	0.16	Monocyte count;	chr14:103357011	chr14:103412119~103412761:-
HNSC	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-3.58	0.000385	0.042	-0.24	-0.16	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
HNSC	cis	rs12545109	0.879	rs7845180	ENSG00000246430.5	LINC00968	3.58	0.000385	0.042	0.2	0.16	Obesity-related traits;	chr8:56411872	chr8:56496246~56559823:-
HNSC	cis	rs739496	0.843	rs688812	ENSG00000226469.1	ADAM1B	3.58	0.000385	0.042	0.18	0.16	Platelet count;	chr12:111524777	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.793	rs76604970	ENSG00000226469.1	ADAM1B	3.58	0.000385	0.042	0.18	0.16	Platelet count;	chr12:111529351	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.602	rs79209359	ENSG00000226469.1	ADAM1B	3.58	0.000385	0.042	0.18	0.16	Platelet count;	chr12:111529357	chr12:111927018~111929017:+
HNSC	cis	rs17404153	0.599	rs6792616	ENSG00000248724.5	NPHP3-AS1	-3.58	0.000385	0.0421	-0.28	-0.16	LDL cholesterol;HDL cholesterol;	chr3:132430707	chr3:132721750~132874223:+
HNSC	cis	rs6545883	0.525	rs1621048	ENSG00000271889.1	RP11-493E12.1	-3.58	0.000385	0.0421	-0.18	-0.16	Tuberculosis;	chr2:61137081	chr2:61151433~61162105:-
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000269918.1	AF131215.9	3.58	0.000385	0.0421	0.16	0.16	Neuroticism;	chr8:11942522	chr8:11104691~11106704:-
HNSC	cis	rs643506	0.874	rs4245045	ENSG00000230911.1	PPIHP1	-3.58	0.000385	0.0421	-0.21	-0.16	Breast cancer;	chr11:111789200	chr11:112029858~112030367:-
HNSC	cis	rs6604026	0.503	rs4847311	ENSG00000223787.2	RP4-593M8.1	-3.58	0.000385	0.0421	-0.2	-0.16	Multiple sclerosis;	chr1:92758297	chr1:92580476~92580821:-
HNSC	cis	rs1865760	0.964	rs9379802	ENSG00000272810.1	U91328.22	-3.58	0.000385	0.0421	-0.15	-0.16	Height;	chr6:25933670	chr6:26013241~26013757:+
HNSC	cis	rs17221829	0.733	rs11600011	ENSG00000280385.1	AP000648.5	-3.58	0.000386	0.0421	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89674812	chr11:90193614~90198120:+
HNSC	cis	rs870825	0.616	rs1401358	ENSG00000254233.1	RP11-242J7.1	3.58	0.000386	0.0421	0.23	0.16	Blood protein levels;	chr4:184718903	chr4:184584093~184625030:-
HNSC	cis	rs7554547	0.667	rs2336377	ENSG00000242349.4	NPPA-AS1	3.58	0.000386	0.0421	0.16	0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr1:11841017~11848079:+
HNSC	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	3.58	0.000386	0.0421	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
HNSC	cis	rs9545047	0.567	rs7321186	ENSG00000227354.5	RBM26-AS1	3.58	0.000386	0.0421	0.17	0.16	Schizophrenia;	chr13:79383403	chr13:79406309~79424328:+
HNSC	cis	rs73201462	1	rs11712798	ENSG00000231305.3	RP11-723O4.2	-3.58	0.000386	0.0421	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128175451	chr3:128861313~128871540:-
HNSC	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-3.58	0.000386	0.0421	-0.19	-0.16	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	3.58	0.000386	0.0421	0.19	0.16	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
HNSC	cis	rs10851478	0.515	rs28375625	ENSG00000259531.2	RP11-295H24.3	3.58	0.000386	0.0421	0.18	0.16	Oral cavity cancer;	chr15:49450297	chr15:49365124~49366685:-
HNSC	cis	rs17594362	1	rs12867333	ENSG00000229473.2	RGS17P1	-3.58	0.000386	0.0421	-0.26	-0.16	Multiple sclerosis;	chr13:41564029	chr13:40992779~40993331:-
HNSC	cis	rs1553477	0.617	rs1994870	ENSG00000272123.1	CTD-2366F13.2	3.58	0.000386	0.0421	0.19	0.16	Monobrow;	chr5:53819433	chr5:53089016~53089468:-
HNSC	cis	rs12745968	0.652	rs4970714	ENSG00000223787.2	RP4-593M8.1	-3.58	0.000386	0.0421	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92475800	chr1:92580476~92580821:-
HNSC	cis	rs2562456	0.652	rs4809145	ENSG00000268081.1	RP11-678G14.2	3.58	0.000386	0.0421	0.23	0.16	Pain;	chr19:21597907	chr19:21554640~21569237:-
HNSC	cis	rs683257	1	rs72984130	ENSG00000234147.1	RP3-460G2.2	-3.58	0.000386	0.0421	-0.36	-0.16	Facial emotion recognition (angry faces);	chr6:140707447	chr6:140845958~140852924:-
HNSC	cis	rs35740288	0.857	rs3803506	ENSG00000259407.1	RP11-158M2.3	-3.58	0.000386	0.0421	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85744109~85750281:-
HNSC	cis	rs116139393	0.611	rs62439722	ENSG00000187953.9	PMS2CL	-3.58	0.000386	0.0421	-0.22	-0.16	Alzheimer's disease (APOE e4 interaction);	chr7:6725309	chr7:6710128~6753862:+
HNSC	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-3.58	0.000386	0.0421	-0.28	-0.16	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
HNSC	cis	rs757081	0.671	rs214091	ENSG00000260196.1	RP1-239B22.5	-3.58	0.000386	0.0421	-0.21	-0.16	Systolic blood pressure;	chr11:17274916	chr11:17380649~17383531:+
HNSC	cis	rs10073892	0.62	rs13163706	ENSG00000250682.4	LINC00491	-3.58	0.000386	0.0421	-0.24	-0.16	Cognitive decline (age-related);	chr5:102667073	chr5:102609156~102671559:-
HNSC	cis	rs2307394	0.716	rs7605932	ENSG00000281469.1	RP11-567F11.1	3.58	0.000386	0.0421	0.19	0.16	Urate levels;	chr2:147759732	chr2:148044380~148044894:+
HNSC	cis	rs7674212	0.865	rs1481279	ENSG00000251288.2	RP11-10L12.2	3.58	0.000386	0.0422	0.18	0.16	Type 2 diabetes;	chr4:103056781	chr4:102751401~102752641:+
HNSC	cis	rs868153	0.625	rs12661247	ENSG00000275339.1	RP3-425C14.6	3.58	0.000386	0.0422	0.18	0.16	Vertical cup-disc ratio;	chr6:122166817	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.662	rs12662551	ENSG00000275339.1	RP3-425C14.6	3.58	0.000386	0.0422	0.18	0.16	Vertical cup-disc ratio;	chr6:122170376	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs12662023	ENSG00000275339.1	RP3-425C14.6	3.58	0.000386	0.0422	0.18	0.16	Vertical cup-disc ratio;	chr6:122179257	chr6:122454358~122454612:+
HNSC	cis	rs12586317	0.513	rs11156871	ENSG00000258704.4	SRP54-AS1	-3.58	0.000386	0.0422	-0.22	-0.16	Psoriasis;	chr14:35011990	chr14:34920858~34982532:-
HNSC	cis	rs1538970	0.884	rs61788261	ENSG00000234329.1	RP11-767N6.2	3.58	0.000386	0.0422	0.19	0.16	Platelet count;	chr1:45433442	chr1:45651039~45651826:-
HNSC	cis	rs2857078	0.654	rs4793083	ENSG00000267080.4	ASB16-AS1	3.58	0.000386	0.0422	0.13	0.16	Red cell distribution width;Reticulocyte count;	chr17:44235605	chr17:44175973~44186717:-
HNSC	cis	rs4919687	0.55	rs12259058	ENSG00000236937.2	PTGES3P4	3.58	0.000386	0.0422	0.21	0.16	Colorectal cancer;	chr10:102725042	chr10:102845595~102845950:+
HNSC	cis	rs4919687	0.55	rs12775883	ENSG00000236937.2	PTGES3P4	3.58	0.000386	0.0422	0.21	0.16	Colorectal cancer;	chr10:102725544	chr10:102845595~102845950:+
HNSC	cis	rs1005277	0.522	rs289649	ENSG00000263064.2	RP11-291L22.7	3.58	0.000387	0.0422	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38448689~38448949:+
HNSC	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	3.58	0.000387	0.0422	0.19	0.16	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
HNSC	cis	rs2446066	0.728	rs10876444	ENSG00000270175.1	RP11-793H13.11	-3.58	0.000387	0.0422	-0.21	-0.16	Red blood cell count;	chr12:53358697	chr12:53500162~53500936:-
HNSC	cis	rs12541595	0.79	rs28455756	ENSG00000255491.1	RP11-1082L8.4	3.58	0.000387	0.0422	0.21	0.16	Left ventricle diastolic internal dimension;	chr8:124881909	chr8:124811618~124815682:-
HNSC	cis	rs72827839	1	rs1472966	ENSG00000244649.3	CTD-2377D24.6	-3.57	0.000387	0.0422	-0.24	-0.16	Ease of getting up in the morning;	chr17:48352783	chr17:48646923~48707346:+
HNSC	cis	rs12047808	0.73	rs12021876	ENSG00000227141.2	RP11-545A16.3	-3.57	0.000387	0.0422	-0.23	-0.16	Multiple sclerosis (age of onset);	chr1:179572606	chr1:179586705~179589175:+
HNSC	cis	rs853679	0.567	rs7774981	ENSG00000227214.2	HCG15	3.57	0.000387	0.0422	0.2	0.16	Depression;	chr6:28379133	chr6:28986203~28987484:+
HNSC	cis	rs853679	0.567	rs7754960	ENSG00000227214.2	HCG15	3.57	0.000387	0.0422	0.2	0.16	Depression;	chr6:28379168	chr6:28986203~28987484:+
HNSC	cis	rs7283707	0.786	rs6517613	ENSG00000236471.1	AF127577.12	3.57	0.000387	0.0422	0.27	0.16	QRS complex (12-leadsum);	chr21:15746069	chr21:15067070~15067837:+
HNSC	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	3.57	0.000387	0.0422	0.15	0.16	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
HNSC	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	3.57	0.000387	0.0422	0.19	0.16	Height;	chr4:55489895	chr4:55540502~55540835:-
HNSC	cis	rs36093844	1	rs11234452	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000387	0.0422	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865758	chr11:85852557~85854943:-
HNSC	cis	rs2762353	0.935	rs1165152	ENSG00000272462.2	U91328.19	-3.57	0.000387	0.0422	-0.16	-0.16	Blood metabolite levels;	chr6:25818538	chr6:25992662~26001775:+
HNSC	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-3.57	0.000387	0.0422	-0.18	-0.16	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
HNSC	cis	rs7520050	0.966	rs1707304	ENSG00000280836.1	AL355480.1	3.57	0.000387	0.0422	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45581219~45581321:-
HNSC	cis	rs12234571	1	rs6980016	ENSG00000214293.7	APTR	3.57	0.000387	0.0423	0.21	0.16	Obesity-related traits;	chr7:77751448	chr7:77657660~77696265:-
HNSC	cis	rs10851478	0.872	rs62022665	ENSG00000259656.1	RP11-325E5.1	3.57	0.000387	0.0423	0.19	0.16	Oral cavity cancer;	chr15:49581614	chr15:49101791~49103264:+
HNSC	cis	rs6095360	1	rs1538482	ENSG00000227431.4	CSE1L-AS1	-3.57	0.000387	0.0423	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49088959	chr20:49040463~49046044:-
HNSC	cis	rs10819861	0.575	rs10760780	ENSG00000175611.10	LINC00476	-3.57	0.000388	0.0423	-0.16	-0.16	Electrocardiographic traits;	chr9:96110509	chr9:95759231~95875977:-
HNSC	cis	rs2001970	0.586	rs7206391	ENSG00000259711.1	CTD-3032H12.2	-3.57	0.000388	0.0423	-0.18	-0.16	Visceral fat;	chr16:55210810	chr16:54934913~54954665:+
HNSC	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-3.57	0.000388	0.0423	-0.24	-0.16	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
HNSC	cis	rs1387259	0.619	rs2130095	ENSG00000240399.1	RP1-228P16.1	-3.57	0.000388	0.0423	-0.14	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48054813~48055591:-
HNSC	cis	rs453301	0.686	rs7814328	ENSG00000253981.4	ALG1L13P	-3.57	0.000388	0.0423	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9018719	chr8:8236003~8244667:-
HNSC	cis	rs2944755	0.959	rs2977491	ENSG00000279766.1	RP11-642A1.2	-3.57	0.000388	0.0423	-0.19	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564178	chr8:140572142~140572812:-
HNSC	cis	rs853679	0.538	rs13199081	ENSG00000217862.2	HIST1H4PS1	-3.57	0.000388	0.0423	-0.18	-0.16	Depression;	chr6:28364057	chr6:27807075~27807339:+
HNSC	cis	rs944801	0.678	rs518394	ENSG00000266446.1	RP11-149I2.4	3.57	0.000388	0.0423	0.18	0.16	Type 2 diabetes;	chr9:22019674	chr9:21995482~21996013:+
HNSC	cis	rs61990749	0.597	rs4903643	ENSG00000239272.1	RPL21P10	3.57	0.000388	0.0423	0.25	0.16	Fibroblast growth factor basic levels;	chr14:77788448	chr14:77683202~77683989:-
HNSC	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-3.57	0.000388	0.0423	-0.15	-0.16	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
HNSC	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	3.57	0.000388	0.0423	0.28	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
HNSC	cis	rs9611565	0.802	rs4822028	ENSG00000235513.1	RP4-756G23.5	3.57	0.000388	0.0423	0.19	0.16	Vitiligo;	chr22:41393404	chr22:41209122~41217627:-
HNSC	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-3.57	0.000388	0.0423	-0.15	-0.16	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
HNSC	cis	rs210152	0.531	rs4713634	ENSG00000223534.1	HLA-DQB1-AS1	-3.57	0.000388	0.0423	-0.35	-0.16	Schizophrenia;	chr6:33546931	chr6:32659880~32660729:+
HNSC	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	3.57	0.000388	0.0423	0.19	0.16	Height;	chr4:55542243	chr4:55540502~55540835:-
HNSC	cis	rs71636778	0.509	rs17360994	ENSG00000260063.1	RP5-968P14.2	-3.57	0.000388	0.0423	-0.35	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26952082	chr1:26692132~26694131:-
HNSC	cis	rs950169	0.61	rs34529571	ENSG00000230373.7	GOLGA6L5P	-3.57	0.000388	0.0423	-0.19	-0.16	Schizophrenia;	chr15:84023055	chr15:84507885~84516814:-
HNSC	cis	rs4704187	0.687	rs10462512	ENSG00000271815.1	CTD-2235C13.3	-3.57	0.000388	0.0423	-0.21	-0.16	Response to amphetamines;	chr5:75091492	chr5:75363760~75364242:+
HNSC	cis	rs728616	0.614	rs56147535	ENSG00000225484.5	NUTM2B-AS1	-3.57	0.000388	0.0423	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80267869	chr10:79663088~79826594:-
HNSC	cis	rs2294015	1	rs2294015	ENSG00000207704.2	MIR548AA1	-3.57	0.000388	0.0423	-0.16	-0.16	Event-related brain oscillations;	chr8:123684627	chr8:123348034~123348130:+
HNSC	cis	rs7937682	0.921	rs11213945	ENSG00000230911.1	PPIHP1	3.57	0.000388	0.0423	0.24	0.16	Primary sclerosing cholangitis;	chr11:111590279	chr11:112029858~112030367:-
HNSC	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-3.57	0.000388	0.0423	-0.11	-0.16	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
HNSC	cis	rs11157436	0.509	rs12589104	ENSG00000211814.1	TRAV35	-3.57	0.000388	0.0423	-0.15	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22221896~22222475:+
HNSC	cis	rs3018712	0.532	rs7116363	ENSG00000212093.1	AP000807.1	-3.57	0.000388	0.0423	-0.23	-0.16	Total body bone mineral density;	chr11:68645330	chr11:68506083~68506166:-
HNSC	cis	rs10865541	0.806	rs10187625	ENSG00000234171.2	RNASEH1-AS1	3.57	0.000388	0.0423	0.17	0.16	Obesity-related traits;	chr2:3417397	chr2:3558492~3561745:+
HNSC	cis	rs2919917	0.628	rs10109359	ENSG00000260398.1	RP11-594N15.3	3.57	0.000388	0.0423	0.22	0.16	Lymphocyte counts;	chr8:78694369	chr8:78605952~78609705:+
HNSC	cis	rs2436845	1	rs2679755	ENSG00000253669.3	KB-1732A1.1	-3.57	0.000388	0.0423	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102856682	chr8:102805517~102809971:+
HNSC	cis	rs4256159	1	rs35143588	ENSG00000228956.7	SATB1-AS1	3.57	0.000388	0.0423	0.26	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18727679	chr3:18445024~18920401:+
HNSC	cis	rs7011507	0.563	rs10094801	ENSG00000253608.1	RP11-770E5.1	-3.57	0.000388	0.0423	-0.26	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48548032	chr8:48551567~48698510:+
HNSC	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	3.57	0.000388	0.0423	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
HNSC	cis	rs875971	0.862	rs709596	ENSG00000106610.13	STAG3L4	-3.57	0.000388	0.0423	-0.21	-0.16	Aortic root size;	chr7:66360926	chr7:67302621~67321526:+
HNSC	cis	rs6964587	0.692	rs2374550	ENSG00000188693.7	CYP51A1-AS1	-3.57	0.000388	0.0423	-0.17	-0.16	Breast cancer;	chr7:92191673	chr7:92134604~92180725:+
HNSC	cis	rs17533156	0.525	rs77932036	ENSG00000163597.13	SNHG16	-3.57	0.000388	0.0423	-0.22	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:77211504	chr17:76557766~76565348:+
HNSC	cis	rs7942368	1	rs1440978	ENSG00000254632.1	RP11-21L23.4	3.57	0.000388	0.0423	0.2	0.16	Endometriosis;	chr11:76765236	chr11:76759916~76768223:-
HNSC	cis	rs17772222	0.958	rs17798341	ENSG00000258789.1	RP11-507K2.3	-3.57	0.000388	0.0423	-0.2	-0.16	Coronary artery calcification;	chr14:88548201	chr14:88551597~88552493:+
HNSC	cis	rs12073359	0.955	rs72694960	ENSG00000261716.1	RP11-196G18.22	-3.57	0.000388	0.0423	-0.21	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150174687	chr1:149844498~149849024:-
HNSC	cis	rs9611565	0.592	rs9611613	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41565827	chr22:41074180~41075239:-
HNSC	cis	rs9611565	0.559	rs12483860	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41565912	chr22:41074180~41075239:-
HNSC	cis	rs9611565	0.559	rs7290990	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41568353	chr22:41074180~41075239:-
HNSC	cis	rs9611565	0.559	rs7290991	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41568357	chr22:41074180~41075239:-
HNSC	cis	rs9611565	0.592	rs5996037	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41569288	chr22:41074180~41075239:-
HNSC	cis	rs9611565	0.592	rs5996038	ENSG00000213857.3	RP11-12M9.4	3.57	0.000388	0.0423	0.2	0.16	Vitiligo;	chr22:41569296	chr22:41074180~41075239:-
HNSC	cis	rs67311347	1	rs13324109	ENSG00000280739.1	EIF1B-AS1	3.57	0.000389	0.0423	0.18	0.16	Renal cell carcinoma;	chr3:40419276	chr3:40173145~40309698:-
HNSC	cis	rs73191547	0.519	rs57515357	ENSG00000255310.2	AF131215.2	3.57	0.000389	0.0423	0.16	0.16	Schizophrenia;	chr8:10203585	chr8:11107788~11109726:-
HNSC	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	3.57	0.000389	0.0423	0.2	0.16	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	3.57	0.000389	0.0423	0.2	0.16	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	3.57	0.000389	0.0423	0.2	0.16	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	3.57	0.000389	0.0423	0.2	0.16	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
HNSC	cis	rs2048656	0.57	rs7814635	ENSG00000233609.3	RP11-62H7.2	3.57	0.000389	0.0423	0.17	0.16	Schizophrenia;	chr8:9789110	chr8:8961200~8979025:+
HNSC	cis	rs7777677	1	rs7777677	ENSG00000211727.3	TRBV7-6	3.57	0.000389	0.0423	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142492132~142492673:+
HNSC	cis	rs9652601	0.779	rs11648679	ENSG00000274038.1	RP11-66H6.4	-3.57	0.000389	0.0423	-0.2	-0.16	Systemic lupus erythematosus;	chr16:11082127	chr16:11056556~11057034:+
HNSC	cis	rs7646881	0.544	rs16829283	ENSG00000272087.1	RP11-379F4.7	3.57	0.000389	0.0424	0.23	0.16	Tetralogy of Fallot;	chr3:158671339	chr3:158693120~158693768:-
HNSC	cis	rs61990749	0.597	rs176952	ENSG00000239272.1	RPL21P10	3.57	0.000389	0.0424	0.24	0.16	Fibroblast growth factor basic levels;	chr14:77714393	chr14:77683202~77683989:-
HNSC	cis	rs61990749	0.544	rs2544566	ENSG00000239272.1	RPL21P10	3.57	0.000389	0.0424	0.24	0.16	Fibroblast growth factor basic levels;	chr14:77715395	chr14:77683202~77683989:-
HNSC	cis	rs61990749	0.544	rs2544567	ENSG00000239272.1	RPL21P10	3.57	0.000389	0.0424	0.24	0.16	Fibroblast growth factor basic levels;	chr14:77715396	chr14:77683202~77683989:-
HNSC	cis	rs1865760	0.613	rs9358894	ENSG00000272810.1	U91328.22	-3.57	0.000389	0.0424	-0.14	-0.16	Height;	chr6:25923087	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs2858993	ENSG00000272810.1	U91328.22	-3.57	0.000389	0.0424	-0.15	-0.16	Height;	chr6:26087628	chr6:26013241~26013757:+
HNSC	cis	rs897984	0.76	rs11076	ENSG00000260911.2	RP11-196G11.2	-3.57	0.000389	0.0424	-0.15	-0.16	Dementia with Lewy bodies;	chr16:30984207	chr16:31043150~31049868:+
HNSC	cis	rs9880211	0.606	rs9852406	ENSG00000273486.1	RP11-731C17.2	3.57	0.000389	0.0424	0.15	0.16	Height;Body mass index;	chr3:135906656	chr3:136837338~136839021:-
HNSC	cis	rs6058526	0.631	rs3813922	ENSG00000224628.2	RP5-854E16.2	-3.57	0.000389	0.0424	-0.23	-0.16	Chronic obstructive pulmonary disease;	chr20:32189533	chr20:31285317~31286835:-
HNSC	cis	rs2179367	0.632	rs9498325	ENSG00000217733.2	CCT7P1	3.57	0.000389	0.0424	0.21	0.16	Dupuytren's disease;	chr6:149345993	chr6:149879962~149881572:+
HNSC	cis	rs2179367	0.632	rs9498326	ENSG00000217733.2	CCT7P1	3.57	0.000389	0.0424	0.21	0.16	Dupuytren's disease;	chr6:149346112	chr6:149879962~149881572:+
HNSC	cis	rs6545883	0.826	rs2694651	ENSG00000271889.1	RP11-493E12.1	-3.57	0.000389	0.0424	-0.19	-0.16	Tuberculosis;	chr2:61361507	chr2:61151433~61162105:-
HNSC	cis	rs16935110	1	rs11985332	ENSG00000254337.1	RP11-865I6.2	-3.57	0.000389	0.0424	-0.25	-0.16	Obesity-related traits;	chr8:68819683	chr8:68848742~68852763:-
HNSC	cis	rs17711722	0.701	rs55773927	ENSG00000272831.1	RP11-792A8.4	3.57	0.000389	0.0424	0.14	0.16	Calcium levels;	chr7:65872915	chr7:66739829~66740385:-
HNSC	cis	rs1190596	0.562	rs1307671	ENSG00000271780.1	RP11-1017G21.5	-3.57	0.000389	0.0424	-0.19	-0.16	Behavioural disinhibition (generation interaction);	chr14:102176116	chr14:101948347~101949425:+
HNSC	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-3.57	0.000389	0.0424	-0.28	-0.16	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
HNSC	cis	rs7714670	0.736	rs2962278	ENSG00000184084.7	CTD-2372A4.1	-3.57	0.000389	0.0424	-0.18	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:73798133	chr5:73803296~73803599:-
HNSC	cis	rs7830057	0.829	rs2000479	ENSG00000253395.1	KB-1460A1.1	3.57	0.000389	0.0424	0.16	0.16	Asthma;	chr8:100436188	chr8:101122145~101126158:-
HNSC	cis	rs36093844	0.898	rs80079882	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000389	0.0424	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879912	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.898	rs11234457	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000389	0.0424	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879998	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.898	rs11512932	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000389	0.0424	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85880087	chr11:85852557~85854943:-
HNSC	cis	rs36093844	0.898	rs11234458	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000389	0.0424	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85880327	chr11:85852557~85854943:-
HNSC	cis	rs78487399	0.808	rs77787499	ENSG00000234936.1	AC010883.5	3.57	0.00039	0.0424	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536670	chr2:43229573~43233394:+
HNSC	cis	rs4803480	0.786	rs4803479	ENSG00000270164.1	LINC01480	-3.57	0.00039	0.0424	-0.13	-0.16	Schizophrenia;	chr19:41551234	chr19:41535183~41536904:+
HNSC	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-3.57	0.00039	0.0424	-0.11	-0.16	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
HNSC	cis	rs2430307	0.518	rs67763033	ENSG00000242435.1	UPK3BP1	3.57	0.00039	0.0425	0.24	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76888360	chr7:77004662~77005774:+
HNSC	cis	rs7246760	0.867	rs889177	ENSG00000267289.1	CTD-2623N2.11	3.57	0.00039	0.0425	0.28	0.16	Pursuit maintenance gain;	chr19:9735549	chr19:9834079~9835013:-
HNSC	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	3.57	0.00039	0.0425	0.23	0.16	Pain;	chr19:21406377	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	3.57	0.00039	0.0425	0.23	0.16	Pain;	chr19:21407834	chr19:21554640~21569237:-
HNSC	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	3.57	0.00039	0.0425	0.23	0.16	Pain;	chr19:21409710	chr19:21554640~21569237:-
HNSC	cis	rs2907092	0.662	rs2907113	ENSG00000259802.1	CTD-2256P15.2	-3.57	0.00039	0.0425	-0.16	-0.16	Common carotid intima-media thickness in HIV infection;	chr5:11091398	chr5:10352701~10353601:-
HNSC	cis	rs9836270	1	rs6770783	ENSG00000242899.1	RPL7P16	3.57	0.00039	0.0425	0.18	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:132214767	chr3:132243528~132244265:-
HNSC	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	3.57	0.00039	0.0425	0.2	0.16	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
HNSC	cis	rs3204270	0.639	rs7215738	ENSG00000262049.1	RP13-1032I1.7	3.57	0.00039	0.0425	0.18	0.16	Dental caries;	chr17:81692817	chr17:81701324~81703300:-
HNSC	cis	rs12370275	0.58	rs12815776	ENSG00000257528.1	KRT8P19	-3.57	0.00039	0.0425	-0.22	-0.16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61348916	chr12:61879318~61880772:+
HNSC	cis	rs6519955	0.796	rs4072455	ENSG00000231711.2	LINC00899	3.57	0.00039	0.0425	0.16	0.16	Dupuytren's disease;	chr22:46027058	chr22:46039907~46044853:-
HNSC	cis	rs9527	0.615	rs17725614	ENSG00000213277.3	MARCKSL1P1	-3.57	0.00039	0.0425	-0.19	-0.16	Arsenic metabolism;	chr10:102925736	chr10:103175554~103176094:+
HNSC	cis	rs11711311	1	rs2566970	ENSG00000241529.3	RN7SL767P	3.57	0.00039	0.0425	0.21	0.16	IgG glycosylation;	chr3:113743276	chr3:113632704~113632998:+
HNSC	cis	rs73201462	1	rs2955095	ENSG00000231305.3	RP11-723O4.2	-3.57	0.00039	0.0425	-0.22	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258822	chr3:128861313~128871540:-
HNSC	cis	rs4427176	0.507	rs7462055	ENSG00000254340.1	RP11-10A14.3	-3.57	0.00039	0.0425	-0.22	-0.16	Mosquito bite size;	chr8:9721021	chr8:9141424~9145435:+
HNSC	cis	rs6449502	0.925	rs35006499	ENSG00000251279.1	CTC-436P18.1	-3.57	0.00039	0.0425	-0.25	-0.16	Mean platelet volume;	chr5:60816122	chr5:61162070~61232040:+
HNSC	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-3.57	0.00039	0.0425	-0.19	-0.16	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-3.57	0.00039	0.0425	-0.19	-0.16	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-3.57	0.00039	0.0425	-0.19	-0.16	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
HNSC	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-3.57	0.00039	0.0425	-0.18	-0.16	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
HNSC	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	3.57	0.00039	0.0425	0.2	0.16	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
HNSC	cis	rs988913	0.957	rs4141552	ENSG00000224984.1	RP11-524H19.2	3.57	0.00039	0.0425	0.19	0.16	Menarche (age at onset);	chr6:54895131	chr6:54840118~54840855:-
HNSC	cis	rs73201462	1	rs2811396	ENSG00000231305.3	RP11-723O4.2	3.57	0.00039	0.0425	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128268513	chr3:128861313~128871540:-
HNSC	cis	rs7296418	0.961	rs4148862	ENSG00000280120.1	RP11-546D6.3	3.57	0.00039	0.0425	0.14	0.16	Platelet count;	chr12:123084072	chr12:123152324~123153377:-
HNSC	cis	rs73198271	1	rs11775821	ENSG00000233609.3	RP11-62H7.2	-3.57	0.000391	0.0425	-0.19	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8961200~8979025:+
HNSC	cis	rs10851478	0.872	rs12901680	ENSG00000259656.1	RP11-325E5.1	3.57	0.000391	0.0425	0.19	0.16	Oral cavity cancer;	chr15:49588708	chr15:49101791~49103264:+
HNSC	cis	rs870825	0.616	rs4444872	ENSG00000254233.1	RP11-242J7.1	3.57	0.000391	0.0425	0.24	0.16	Blood protein levels;	chr4:184707251	chr4:184584093~184625030:-
HNSC	cis	rs11722779	0.815	rs223347	ENSG00000248740.4	RP11-328K4.1	3.57	0.000391	0.0425	0.17	0.16	Schizophrenia;	chr4:102858815	chr4:103256159~103453658:+
HNSC	cis	rs11722779	0.873	rs223346	ENSG00000248740.4	RP11-328K4.1	3.57	0.000391	0.0425	0.17	0.16	Schizophrenia;	chr4:102859339	chr4:103256159~103453658:+
HNSC	cis	rs5758659	0.569	rs133294	ENSG00000270083.1	RP1-257I20.14	3.57	0.000391	0.0425	0.15	0.16	Cognitive function;	chr22:41986801	chr22:42089630~42090028:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000269918.1	AF131215.9	3.57	0.000391	0.0425	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11104691~11106704:-
HNSC	cis	rs8177876	0.658	rs11150337	ENSG00000261838.4	RP11-303E16.6	3.57	0.000391	0.0425	0.3	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81069854~81076598:+
HNSC	cis	rs7615952	0.599	rs6438953	ENSG00000241278.1	ENPP7P4	-3.57	0.000391	0.0425	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:126006108	chr3:125848223~125909372:+
HNSC	cis	rs7615952	0.599	rs1044215	ENSG00000241278.1	ENPP7P4	-3.57	0.000391	0.0425	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:126006716	chr3:125848223~125909372:+
HNSC	cis	rs11866815	0.901	rs758033	ENSG00000226942.2	IL9RP3	-3.57	0.000391	0.0426	-0.2	-0.16	Body mass index;	chr16:347044	chr16:29336~38321:-
HNSC	cis	rs2403083	0.505	rs11261471	ENSG00000253549.4	RP11-317J10.2	-3.57	0.000391	0.0426	-0.18	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85288750	chr8:85441851~85464915:-
HNSC	cis	rs11992162	0.967	rs10112888	ENSG00000255310.2	AF131215.2	3.57	0.000391	0.0426	0.15	0.16	Monocyte count;	chr8:11972699	chr8:11107788~11109726:-
HNSC	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	3.57	0.000391	0.0426	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
HNSC	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	3.57	0.000391	0.0426	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
HNSC	cis	rs7826238	0.72	rs12546760	ENSG00000254153.1	CTA-398F10.2	-3.57	0.000391	0.0426	-0.18	-0.16	Systolic blood pressure;	chr8:8517326	chr8:8456909~8461337:-
HNSC	cis	rs7005380	0.62	rs28669275	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000391	0.0426	-0.13	-0.16	Interstitial lung disease;	chr8:119889713	chr8:119838736~119840385:-
HNSC	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-3.57	0.000391	0.0426	-0.22	-0.16	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
HNSC	cis	rs7819412	0.521	rs11777887	ENSG00000255310.2	AF131215.2	3.57	0.000391	0.0426	0.16	0.16	Triglycerides;	chr8:11179290	chr8:11107788~11109726:-
HNSC	cis	rs11098499	0.874	rs6822498	ENSG00000250412.1	KLHL2P1	3.57	0.000391	0.0426	0.21	0.16	Corneal astigmatism;	chr4:119199028	chr4:119334329~119378233:+
HNSC	cis	rs6710503	0.632	rs13401689	ENSG00000271936.1	RP11-443B20.1	-3.57	0.000391	0.0426	-0.2	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24748469	chr2:24825610~24826717:+
HNSC	cis	rs11638815	0.626	rs1313492	ENSG00000259429.4	UBE2Q2P2	-3.57	0.000391	0.0426	-0.16	-0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:82355142~82420075:+
HNSC	cis	rs11098499	0.954	rs11098524	ENSG00000250412.1	KLHL2P1	3.57	0.000391	0.0426	0.22	0.16	Corneal astigmatism;	chr4:119468877	chr4:119334329~119378233:+
HNSC	cis	rs750460	0.899	rs8023330	ENSG00000261801.4	LOXL1-AS1	-3.57	0.000391	0.0426	-0.15	-0.16	Height;	chr15:73928258	chr15:73908071~73928248:-
HNSC	cis	rs750460	0.932	rs1550436	ENSG00000261801.4	LOXL1-AS1	-3.57	0.000391	0.0426	-0.15	-0.16	Height;	chr15:73928816	chr15:73908071~73928248:-
HNSC	cis	rs10875746	0.669	rs11168499	ENSG00000257763.1	OR5BK1P	-3.57	0.000391	0.0426	-0.21	-0.16	Longevity (90 years and older);	chr12:48268887	chr12:48355792~48356614:-
HNSC	cis	rs16958440	0.581	rs56395942	ENSG00000267724.1	RP11-49K24.8	3.57	0.000391	0.0426	0.25	0.16	Sitting height ratio;	chr18:47145928	chr18:47105946~47108062:+
HNSC	cis	rs10129255	0.518	rs7143784	ENSG00000211976.2	IGHV3-73	-3.57	0.000391	0.0426	-0.11	-0.16	Kawasaki disease;	chr14:106687277	chr14:106802694~106803233:-
HNSC	cis	rs6095360	1	rs1997854	ENSG00000227431.4	CSE1L-AS1	3.57	0.000391	0.0426	0.19	0.16	Intelligence (multi-trait analysis);	chr20:48985802	chr20:49040463~49046044:-
HNSC	cis	rs13113518	0.51	rs11732723	ENSG00000249700.7	SRD5A3-AS1	-3.57	0.000391	0.0426	-0.19	-0.16	Height;	chr4:55424391	chr4:55363971~55395847:-
HNSC	cis	rs919433	0.963	rs10153881	ENSG00000231621.1	AC013264.2	3.57	0.000391	0.0426	0.15	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306374	chr2:197197991~197199273:+
HNSC	cis	rs614226	0.872	rs12307148	ENSG00000202538.1	RNU4-2	3.57	0.000391	0.0426	0.26	0.16	Type 1 diabetes nephropathy;	chr12:120465376	chr12:120291763~120291903:-
HNSC	cis	rs12545912	0.909	rs4841182	ENSG00000254340.1	RP11-10A14.3	3.57	0.000392	0.0426	0.23	0.16	Multiple myeloma (hyperdiploidy);	chr8:9613204	chr8:9141424~9145435:+
HNSC	cis	rs858239	0.669	rs1990365	ENSG00000230042.1	AK3P3	-3.57	0.000392	0.0426	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23129178~23129841:+
HNSC	cis	rs7189233	0.531	rs3929	ENSG00000261056.2	RP11-454F8.2	3.57	0.000392	0.0426	0.18	0.16	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53298224~53299792:+
HNSC	cis	rs868153	0.662	rs225072	ENSG00000275339.1	RP3-425C14.6	3.57	0.000392	0.0426	0.18	0.16	Vertical cup-disc ratio;	chr6:122264990	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.625	rs225073	ENSG00000275339.1	RP3-425C14.6	3.57	0.000392	0.0426	0.18	0.16	Vertical cup-disc ratio;	chr6:122265092	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.662	rs225075	ENSG00000275339.1	RP3-425C14.6	3.57	0.000392	0.0426	0.18	0.16	Vertical cup-disc ratio;	chr6:122268734	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.662	rs225076	ENSG00000275339.1	RP3-425C14.6	3.57	0.000392	0.0426	0.18	0.16	Vertical cup-disc ratio;	chr6:122269225	chr6:122454358~122454612:+
HNSC	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-3.57	0.000392	0.0426	-0.18	-0.16	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
HNSC	cis	rs67311347	1	rs977652	ENSG00000280739.1	EIF1B-AS1	3.57	0.000392	0.0426	0.17	0.16	Renal cell carcinoma;	chr3:40437678	chr3:40173145~40309698:-
HNSC	cis	rs4664293	0.967	rs12611922	ENSG00000213189.5	BTF3L4P2	-3.57	0.000392	0.0426	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159606238	chr2:159003975~159004320:+
HNSC	cis	rs2212361	0.558	rs16924599	ENSG00000255893.1	RP11-685N10.1	-3.57	0.000392	0.0426	-0.24	-0.16	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94523265	chr11:94472908~94473570:-
HNSC	cis	rs9611565	0.512	rs45500192	ENSG00000235513.1	RP4-756G23.5	3.57	0.000392	0.0426	0.21	0.16	Vitiligo;	chr22:41781895	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs5758465	ENSG00000235513.1	RP4-756G23.5	-3.57	0.000392	0.0426	-0.21	-0.16	Vitiligo;	chr22:41779310	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.559	rs5751160	ENSG00000235513.1	RP4-756G23.5	-3.57	0.000392	0.0426	-0.21	-0.16	Vitiligo;	chr22:41779691	chr22:41209122~41217627:-
HNSC	cis	rs10895275	0.961	rs2282652	ENSG00000277459.1	RP11-732A21.3	3.57	0.000392	0.0426	0.19	0.16	Migraine;	chr11:102226584	chr11:102109827~102110457:-
HNSC	cis	rs7071247	0.915	rs10883875	ENSG00000266852.2	MIR4482	3.57	0.000392	0.0426	0.25	0.16	Platelet aggregation;	chr10:103500160	chr10:104268336~104268405:-
HNSC	cis	rs17594362	0.731	rs9594576	ENSG00000229473.2	RGS17P1	-3.57	0.000392	0.0426	-0.23	-0.16	Multiple sclerosis;	chr13:41568456	chr13:40992779~40993331:-
HNSC	cis	rs911555	0.655	rs10149470	ENSG00000269958.1	RP11-73M18.8	3.57	0.000392	0.0426	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103551616	chr14:103696353~103697163:+
HNSC	cis	rs1832007	0.58	rs72772226	ENSG00000224034.1	RP11-445P17.8	-3.57	0.000392	0.0426	-0.2	-0.16	Triglyceride levels;Triglycerides;	chr10:5203048	chr10:5266033~5271236:-
HNSC	cis	rs12600121	0.579	rs7184140	ENSG00000261008.5	LINC01572	-3.57	0.000392	0.0427	-0.19	-0.16	Intelligence (multi-trait analysis);	chr16:71992000	chr16:72283301~72665009:-
HNSC	cis	rs8030379	0.967	rs8028359	ENSG00000230373.7	GOLGA6L5P	-3.57	0.000392	0.0427	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84507885~84516814:-
HNSC	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	3.57	0.000392	0.0427	0.23	0.16	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
HNSC	cis	rs597480	0.864	rs2374683	ENSG00000279742.1	RP11-700A24.1	-3.57	0.000392	0.0427	-0.17	-0.16	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85801114	chr11:85852557~85854943:-
HNSC	cis	rs35000415	0.873	rs12539741	ENSG00000244556.1	ODCP	3.57	0.000392	0.0427	0.32	0.16	Systemic lupus erythematosus;	chr7:128956751	chr7:129028889~129030527:+
HNSC	cis	rs5758511	0.68	rs5758682	ENSG00000233903.2	Z83851.4	3.57	0.000392	0.0427	0.25	0.16	Birth weight;	chr22:42249196	chr22:42276355~42277052:+
HNSC	cis	rs5758511	0.68	rs34107327	ENSG00000233903.2	Z83851.4	3.57	0.000392	0.0427	0.25	0.16	Birth weight;	chr22:42252347	chr22:42276355~42277052:+
HNSC	cis	rs2286313	0.51	rs34761065	ENSG00000266869.1	RP6-114E22.1	-3.57	0.000392	0.0427	-0.41	-0.16	Colorectal cancer;	chr14:70911517	chr14:71848606~71908430:+
HNSC	cis	rs6430585	0.528	rs12474975	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135944548	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs895285	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135952984	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs75524146	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135967889	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs78274583	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135976999	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs16832417	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135987108	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs721765	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135991209	chr2:135985176~136022593:+
HNSC	cis	rs6430585	0.528	rs10496738	ENSG00000231890.6	DARS-AS1	-3.57	0.000392	0.0427	-0.28	-0.16	Corneal structure;	chr2:135993918	chr2:135985176~136022593:+
HNSC	cis	rs1008375	1	rs7661631	ENSG00000249502.1	AC006160.5	3.57	0.000392	0.0427	0.17	0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678128	chr4:17587467~17614571:-
HNSC	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-3.57	0.000392	0.0427	-0.16	-0.16	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-3.57	0.000392	0.0427	-0.16	-0.16	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-3.57	0.000392	0.0427	-0.16	-0.16	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-3.57	0.000392	0.0427	-0.16	-0.16	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
HNSC	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-3.57	0.000392	0.0427	-0.16	-0.16	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
HNSC	cis	rs1620921	0.657	rs7383738	ENSG00000233342.1	RP11-235G24.3	-3.57	0.000392	0.0427	-0.19	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160855015	chr6:160926369~160927162:+
HNSC	cis	rs2573652	1	rs2573652	ENSG00000254744.3	CTD-3076O17.1	-3.57	0.000392	0.0427	-0.19	-0.16	Height;	chr15:99974409	chr15:99970215~99974010:+
HNSC	cis	rs6001482	0.638	rs5757574	ENSG00000253818.1	IGLV1-41	-3.57	0.000392	0.0427	-0.13	-0.16	Diastolic blood pressure;	chr22:22231597	chr22:22404207~22404721:+
HNSC	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	3.57	0.000392	0.0427	0.18	0.16	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
HNSC	cis	rs710865	0.519	rs3748759	ENSG00000270728.1	RP4-657E11.10	3.57	0.000392	0.0427	0.14	0.16	Brain structure;	chr1:19161162	chr1:19297080~19297903:+
HNSC	cis	rs728616	0.681	rs12413174	ENSG00000225484.5	NUTM2B-AS1	-3.57	0.000392	0.0427	-0.32	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79663088~79826594:-
HNSC	cis	rs4713118	0.513	rs200971	ENSG00000219891.2	ZSCAN12P1	3.57	0.000392	0.0427	0.21	0.16	Parkinson's disease;	chr6:27891126	chr6:28091154~28093664:+
HNSC	cis	rs7535099	0.563	rs12069188	ENSG00000224570.1	RP11-430H12.2	-3.57	0.000392	0.0427	-0.22	-0.16	Blood protein levels;	chr1:65593340	chr1:65576129~65578380:-
HNSC	cis	rs2307394	0.896	rs7600869	ENSG00000281469.1	RP11-567F11.1	3.57	0.000392	0.0427	0.18	0.16	Urate levels;	chr2:147793663	chr2:148044380~148044894:+
HNSC	cis	rs9487051	0.708	rs378447	ENSG00000243587.6	C6orf183	-3.57	0.000392	0.0427	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109205620	chr6:109165833~109271014:+
HNSC	cis	rs198813	0.611	rs198823	ENSG00000272810.1	U91328.22	-3.57	0.000392	0.0427	-0.15	-0.16	Intelligence (multi-trait analysis);	chr6:26122705	chr6:26013241~26013757:+
HNSC	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	3.57	0.000393	0.0427	0.2	0.16	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	3.57	0.000393	0.0427	0.2	0.16	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
HNSC	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	3.57	0.000393	0.0427	0.2	0.16	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
HNSC	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	3.57	0.000393	0.0427	0.2	0.16	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
HNSC	cis	rs2098713	0.569	rs7700431	ENSG00000250155.1	CTD-2353F22.1	3.57	0.000393	0.0427	0.17	0.16	Telomere length;	chr5:37552750	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs16903666	ENSG00000250155.1	CTD-2353F22.1	3.57	0.000393	0.0427	0.17	0.16	Telomere length;	chr5:37557648	chr5:36666214~36725195:-
HNSC	cis	rs17221829	0.673	rs4491227	ENSG00000280385.1	AP000648.5	-3.57	0.000393	0.0427	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89670591	chr11:90193614~90198120:+
HNSC	cis	rs7824557	0.614	rs2736286	ENSG00000255310.2	AF131215.2	-3.57	0.000393	0.0427	-0.15	-0.16	Retinal vascular caliber;	chr8:11369595	chr8:11107788~11109726:-
HNSC	cis	rs886774	0.717	rs6964905	ENSG00000273055.1	CTB-13F3.1	3.57	0.000393	0.0427	0.16	0.16	Ulcerative colitis;	chr7:107859316	chr7:107942116~107942740:+
HNSC	cis	rs9329221	0.686	rs35840352	ENSG00000269918.1	AF131215.9	3.57	0.000393	0.0427	0.17	0.16	Neuroticism;	chr8:10382297	chr8:11104691~11106704:-
HNSC	cis	rs1008375	0.932	rs11934968	ENSG00000249502.1	AC006160.5	-3.57	0.000393	0.0427	-0.18	-0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666143	chr4:17587467~17614571:-
HNSC	cis	rs7777677	0.925	rs4726544	ENSG00000211727.3	TRBV7-6	3.57	0.000393	0.0427	0.15	0.16	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142492132~142492673:+
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000269918.1	AF131215.9	3.57	0.000393	0.0427	0.16	0.16	Neuroticism;	chr8:11939165	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000269918.1	AF131215.9	3.57	0.000393	0.0427	0.16	0.16	Neuroticism;	chr8:11939166	chr8:11104691~11106704:-
HNSC	cis	rs6723108	0.626	rs1530559	ENSG00000224043.6	CCNT2-AS1	3.57	0.000393	0.0427	0.2	0.16	Type 2 diabetes;	chr2:134998059	chr2:134735464~134918710:-
HNSC	cis	rs948562	0.69	rs734777	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.0427	0.26	0.16	Lymphoma;	chr11:58343636	chr11:58627435~58628528:+
HNSC	cis	rs863750	0.777	rs825456	ENSG00000275389.1	RP11-214K3.24	3.57	0.000393	0.0427	0.22	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124053028	chr12:124085761~124088598:+
HNSC	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-3.57	0.000393	0.0427	-0.19	-0.16	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
HNSC	cis	rs890448	0.726	rs1031035	ENSG00000254531.1	FLJ20021	-3.57	0.000393	0.0427	-0.16	-0.16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101301927	chr4:101347780~101348883:+
HNSC	cis	rs11098499	0.698	rs4422403	ENSG00000250412.1	KLHL2P1	3.57	0.000393	0.0427	0.21	0.16	Corneal astigmatism;	chr4:119337039	chr4:119334329~119378233:+
HNSC	cis	rs66887589	0.934	rs12648182	ENSG00000249244.1	RP11-548H18.2	-3.57	0.000393	0.0427	-0.18	-0.16	Diastolic blood pressure;	chr4:119582736	chr4:119391831~119395335:-
HNSC	cis	rs2572431	0.543	rs2256016	ENSG00000269918.1	AF131215.9	3.57	0.000393	0.0427	0.17	0.16	Neuroticism;	chr8:11305093	chr8:11104691~11106704:-
HNSC	cis	rs449789	0.857	rs9346784	ENSG00000235086.1	FNDC1-IT1	-3.57	0.000393	0.0427	-0.19	-0.16	Pulse pressure;	chr6:159282725	chr6:159240786~159243329:+
HNSC	cis	rs870825	0.929	rs72689269	ENSG00000254233.1	RP11-242J7.1	3.57	0.000393	0.0427	0.27	0.16	Blood protein levels;	chr4:184670931	chr4:184584093~184625030:-
HNSC	cis	rs3748656	1	rs1110042	ENSG00000273483.1	RP4-671G15.2	3.57	0.000393	0.0427	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112693912	chr1:112517799~112518441:-
HNSC	cis	rs3748656	1	rs3748656	ENSG00000273483.1	RP4-671G15.2	3.57	0.000393	0.0427	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112694059	chr1:112517799~112518441:-
HNSC	cis	rs3748656	0.832	rs883593	ENSG00000273483.1	RP4-671G15.2	3.57	0.000393	0.0427	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112694549	chr1:112517799~112518441:-
HNSC	cis	rs7189233	0.531	rs8043918	ENSG00000261056.2	RP11-454F8.2	-3.57	0.000393	0.0427	-0.18	-0.16	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53298224~53299792:+
HNSC	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-3.57	0.000393	0.0427	-0.18	-0.16	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
HNSC	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-3.57	0.000393	0.0427	-0.18	-0.16	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
HNSC	cis	rs875971	0.577	rs34888281	ENSG00000273142.1	RP11-458F8.4	3.57	0.000393	0.0428	0.14	0.16	Aortic root size;	chr7:66120784	chr7:66902857~66906297:+
HNSC	cis	rs10186029	0.623	rs10497996	ENSG00000270659.1	RP11-105N14.1	-3.57	0.000393	0.0428	-0.16	-0.16	Systemic sclerosis;	chr2:213133141	chr2:213152970~213153659:+
HNSC	cis	rs1040393	0.953	rs2223222	ENSG00000225171.2	DUTP6	3.57	0.000393	0.0428	0.2	0.16	Schizophrenia;	chr1:166911293	chr1:166868748~166869209:+
HNSC	cis	rs74781061	0.932	rs7176491	ENSG00000260103.2	RP11-10O17.1	-3.57	0.000393	0.0428	-0.19	-0.16	Endometriosis;	chr15:74514875	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.932	rs61168092	ENSG00000260103.2	RP11-10O17.1	-3.57	0.000393	0.0428	-0.19	-0.16	Endometriosis;	chr15:74517619	chr15:74478070~74490286:-
HNSC	cis	rs74781061	1	rs8040745	ENSG00000260103.2	RP11-10O17.1	-3.57	0.000393	0.0428	-0.19	-0.16	Endometriosis;	chr15:74525791	chr15:74478070~74490286:-
HNSC	cis	rs74781061	0.929	rs11072493	ENSG00000260103.2	RP11-10O17.1	-3.57	0.000393	0.0428	-0.19	-0.16	Endometriosis;	chr15:74536881	chr15:74478070~74490286:-
HNSC	cis	rs950169	0.922	rs12910334	ENSG00000259570.1	RP11-671M22.4	3.57	0.000394	0.0428	0.22	0.16	Schizophrenia;	chr15:84403620	chr15:84394512~84395514:+
HNSC	cis	rs2638953	0.853	rs3926041	ENSG00000257176.2	RP11-996F15.2	3.57	0.000394	0.0428	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:29280418~29317848:-
HNSC	cis	rs8031584	0.958	rs34909055	ENSG00000270015.1	RP11-540B6.6	-3.57	0.000394	0.0428	-0.16	-0.16	Huntington's disease progression;	chr15:30991967	chr15:30926514~30928407:+
HNSC	cis	rs482329	0.93	rs636705	ENSG00000224939.1	LINC00184	3.57	0.000394	0.0428	0.2	0.16	Life threatening arrhythmia;	chr1:234667873	chr1:234629311~234634780:+
HNSC	cis	rs155076	0.938	rs261375	ENSG00000233325.3	MIPEPP3	-3.57	0.000394	0.0428	-0.29	-0.16	White matter hyperintensity burden;	chr13:21297743	chr13:21298139~21306373:+
HNSC	cis	rs7178375	1	rs1474381	ENSG00000270015.1	RP11-540B6.6	3.57	0.000394	0.0428	0.2	0.16	Hypertriglyceridemia;	chr15:30922788	chr15:30926514~30928407:+
HNSC	cis	rs853679	1	rs1778508	ENSG00000270326.1	RP5-874C20.6	3.57	0.000394	0.0428	0.24	0.16	Depression;	chr6:28262103	chr6:28319660~28319852:-
HNSC	cis	rs6988985	0.594	rs12543598	ENSG00000247317.3	RP11-273G15.2	-3.57	0.000394	0.0428	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873902	chr8:142981738~143018437:-
HNSC	cis	rs7646881	0.544	rs6792976	ENSG00000272087.1	RP11-379F4.7	3.57	0.000394	0.0428	0.22	0.16	Tetralogy of Fallot;	chr3:158608781	chr3:158693120~158693768:-
HNSC	cis	rs950027	0.62	rs1153860	ENSG00000259479.5	SORD2P	-3.57	0.000394	0.0428	-0.19	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:44826371~44884694:-
HNSC	cis	rs2307394	0.624	rs7595433	ENSG00000281469.1	RP11-567F11.1	3.57	0.000394	0.0428	0.18	0.16	Urate levels;	chr2:147748275	chr2:148044380~148044894:+
HNSC	cis	rs2013441	0.866	rs12947950	ENSG00000261033.1	RP11-209D14.2	-3.57	0.000394	0.0428	-0.19	-0.16	Obesity-related traits;	chr17:20141863	chr17:20008051~20009234:-
HNSC	cis	rs1440410	0.866	rs13139457	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000394	0.0428	-0.18	-0.16	Ischemic stroke;	chr4:143192647	chr4:142933195~143184861:-
HNSC	cis	rs7267979	0.816	rs6037158	ENSG00000231081.1	RP4-760C5.3	-3.57	0.000394	0.0428	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26008791~26010531:-
HNSC	cis	rs240993	0.715	rs240995	ENSG00000230177.1	RP5-1112D6.4	-3.57	0.000394	0.0428	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111355310	chr6:111277932~111278742:+
HNSC	cis	rs9299	0.502	rs4793944	ENSG00000233101.9	HOXB-AS3	3.57	0.000394	0.0428	0.19	0.16	Obesity;	chr17:48589942	chr17:48549630~48606414:+
HNSC	cis	rs4713118	0.513	rs149958	ENSG00000219891.2	ZSCAN12P1	3.57	0.000394	0.0428	0.22	0.16	Parkinson's disease;	chr6:28045839	chr6:28091154~28093664:+
HNSC	cis	rs11722779	0.844	rs7694724	ENSG00000248740.4	RP11-328K4.1	3.57	0.000394	0.0428	0.17	0.16	Schizophrenia;	chr4:103041375	chr4:103256159~103453658:+
HNSC	cis	rs987710	0.568	rs738885	ENSG00000211639.2	IGLV4-60	-3.57	0.000394	0.0428	-0.21	-0.16	Iron status biomarkers;Iron deficiency;	chr22:22162633	chr22:22162199~22162681:+
HNSC	cis	rs67478160	0.704	rs12894254	ENSG00000269940.1	RP11-73M18.7	3.57	0.000394	0.0428	0.15	0.16	Schizophrenia;	chr14:103824612	chr14:103694560~103695170:+
HNSC	cis	rs2337406	1	rs17095456	ENSG00000211972.2	IGHV3-66	3.57	0.000394	0.0428	0.17	0.16	Alzheimer's disease (late onset);	chr14:106676559	chr14:106675017~106675544:-
HNSC	cis	rs7937890	0.904	rs7484197	ENSG00000251991.1	RNU7-49P	3.57	0.000394	0.0428	0.17	0.16	Mitochondrial DNA levels;	chr11:14262108	chr11:14478892~14478953:+
HNSC	cis	rs3204270	0.639	rs62077183	ENSG00000262049.1	RP13-1032I1.7	3.57	0.000394	0.0428	0.18	0.16	Dental caries;	chr17:81691910	chr17:81701324~81703300:-
HNSC	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-3.57	0.000394	0.0428	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-3.57	0.000394	0.0428	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
HNSC	cis	rs4256159	0.696	rs13086597	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18714738	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs4269103	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18714877	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs73170251	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18715239	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs73170252	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18715250	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs34420486	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18715850	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs34587988	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18716020	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs67385647	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18716191	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs35614865	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18716711	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs13098781	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18716927	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.66	rs34776738	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18717154	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.735	rs11714078	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18717627	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs11706286	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18717721	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs34852778	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18717938	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs58146266	ENSG00000228956.7	SATB1-AS1	3.57	0.000394	0.0428	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18718272	chr3:18445024~18920401:+
HNSC	cis	rs5758659	0.652	rs6519301	ENSG00000270083.1	RP1-257I20.14	3.57	0.000394	0.0429	0.14	0.16	Cognitive function;	chr22:41989963	chr22:42089630~42090028:-
HNSC	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	3.57	0.000394	0.0429	0.27	0.16	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
HNSC	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-3.57	0.000394	0.0429	-0.18	-0.16	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
HNSC	cis	rs4776970	0.632	rs55993790	ENSG00000270964.1	RP11-502I4.3	-3.57	0.000394	0.0429	-0.17	-0.16	Body mass index;Waist circumference;	chr15:67734184	chr15:67541072~67542604:-
HNSC	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000394	0.0429	0.17	0.16	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
HNSC	cis	rs7015263	0.643	rs17608598	ENSG00000254231.1	CTD-2284J15.1	-3.57	0.000395	0.0429	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86375035	chr8:86333274~86343314:-
HNSC	cis	rs1411478	1	rs6425658	ENSG00000243155.1	RP11-46A10.5	3.57	0.000395	0.0429	0.18	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180987849	chr1:180944042~180976482:-
HNSC	cis	rs3736485	0.966	rs28376817	ENSG00000274528.1	CTD-2650P22.2	3.57	0.000395	0.0429	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51597083	chr15:52017167~52018032:-
HNSC	cis	rs227275	0.525	rs7660298	ENSG00000248740.4	RP11-328K4.1	3.57	0.000395	0.0429	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:103256159~103453658:+
HNSC	cis	rs9467711	0.606	rs34781270	ENSG00000241549.7	GUSBP2	3.57	0.000395	0.0429	0.28	0.16	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:26871484~26956554:-
HNSC	cis	rs62229266	0.633	rs34259635	ENSG00000230212.5	AP000688.14	-3.57	0.000395	0.0429	-0.17	-0.16	Mitral valve prolapse;	chr21:36031272	chr21:36069642~36126640:-
HNSC	cis	rs853679	0.546	rs13213152	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0429	-0.31	-0.16	Depression;	chr6:28381921	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs13213986	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0429	-0.31	-0.16	Depression;	chr6:28390232	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs34546986	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0429	-0.31	-0.16	Depression;	chr6:28394532	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs34871267	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0429	-0.31	-0.16	Depression;	chr6:28396455	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.546	rs35883476	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0429	-0.31	-0.16	Depression;	chr6:28400731	chr6:28161781~28169594:+
HNSC	cis	rs4256159	0.696	rs4279124	ENSG00000228956.7	SATB1-AS1	3.57	0.000395	0.0429	0.25	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18722782	chr3:18445024~18920401:+
HNSC	cis	rs78487399	0.71	rs76215753	ENSG00000234936.1	AC010883.5	3.57	0.000395	0.0429	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43370003	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs79629200	ENSG00000234936.1	AC010883.5	3.57	0.000395	0.0429	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43375793	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs74469180	ENSG00000234936.1	AC010883.5	3.57	0.000395	0.0429	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43376228	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs78314405	ENSG00000234936.1	AC010883.5	3.57	0.000395	0.0429	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43377602	chr2:43229573~43233394:+
HNSC	cis	rs7824557	0.564	rs2437152	ENSG00000255495.1	AC145124.2	-3.57	0.000395	0.0429	-0.18	-0.16	Retinal vascular caliber;	chr8:11377988	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.564	rs2736300	ENSG00000255495.1	AC145124.2	-3.57	0.000395	0.0429	-0.18	-0.16	Retinal vascular caliber;	chr8:11378070	chr8:12194467~12196280:+
HNSC	cis	rs7246760	1	rs59867671	ENSG00000267289.1	CTD-2623N2.11	3.57	0.000395	0.0429	0.29	0.16	Pursuit maintenance gain;	chr19:9822882	chr19:9834079~9835013:-
HNSC	cis	rs7772486	0.686	rs1569540	ENSG00000270638.1	RP3-466P17.1	-3.57	0.000395	0.0429	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs2142983	ENSG00000270638.1	RP3-466P17.1	-3.57	0.000395	0.0429	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145735570~145737218:+
HNSC	cis	rs482329	0.93	rs572408	ENSG00000224939.1	LINC00184	-3.57	0.000395	0.0429	-0.2	-0.16	Life threatening arrhythmia;	chr1:234666347	chr1:234629311~234634780:+
HNSC	cis	rs8077577	0.747	rs62072509	ENSG00000273018.4	CTD-2303H24.2	-3.57	0.000395	0.0429	-0.24	-0.16	Obesity-related traits;	chr17:18279079	chr17:18511221~18551705:-
HNSC	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-3.57	0.000395	0.0429	-0.23	-0.16	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
HNSC	cis	rs2098713	0.569	rs55822509	ENSG00000250155.1	CTD-2353F22.1	3.57	0.000395	0.0429	0.17	0.16	Telomere length;	chr5:37571908	chr5:36666214~36725195:-
HNSC	cis	rs830124	0.759	rs2688412	ENSG00000280138.1	RP11-463O12.5	-3.57	0.000395	0.0429	-0.21	-0.16	Urinary metabolites;	chr12:121911152	chr12:122870059~122888720:-
HNSC	cis	rs1941184	0.759	rs10048329	ENSG00000266521.1	RP11-650P15.1	3.57	0.000395	0.0429	0.21	0.16	Parkinson's disease (age of onset);	chr18:31443662	chr18:31496645~31497195:-
HNSC	cis	rs2991971	0.81	rs2356413	ENSG00000234329.1	RP11-767N6.2	3.57	0.000395	0.0429	0.17	0.16	High light scatter reticulocyte count;	chr1:45448376	chr1:45651039~45651826:-
HNSC	cis	rs73198271	0.562	rs79296712	ENSG00000253893.2	FAM85B	3.57	0.000395	0.0429	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802468	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.562	rs76702427	ENSG00000253893.2	FAM85B	3.57	0.000395	0.0429	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802631	chr8:8167819~8226614:-
HNSC	cis	rs11002791	0.607	rs1595608	ENSG00000224596.6	ZMIZ1-AS1	3.57	0.000395	0.0429	0.2	0.16	Red blood cell count;	chr10:79041650	chr10:78943328~79067895:-
HNSC	cis	rs1862618	0.671	rs2591956	ENSG00000248727.4	CTC-236F12.4	-3.57	0.000395	0.0429	-0.21	-0.16	Initial pursuit acceleration;	chr5:56948777	chr5:56457795~56481946:-
HNSC	cis	rs1862618	0.671	rs2591955	ENSG00000248727.4	CTC-236F12.4	-3.57	0.000395	0.0429	-0.21	-0.16	Initial pursuit acceleration;	chr5:56949121	chr5:56457795~56481946:-
HNSC	cis	rs1862618	0.671	rs906631	ENSG00000248727.4	CTC-236F12.4	-3.57	0.000395	0.0429	-0.21	-0.16	Initial pursuit acceleration;	chr5:56949976	chr5:56457795~56481946:-
HNSC	cis	rs7927592	0.956	rs7124078	ENSG00000239559.2	RPL37P2	3.57	0.000395	0.0429	0.17	0.16	Total body bone mineral density;	chr11:68531165	chr11:67682772~67683058:-
HNSC	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	3.57	0.000395	0.0429	0.23	0.16	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
HNSC	cis	rs225675	0.721	rs225637	ENSG00000229017.5	LINC01277	3.57	0.000395	0.0429	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142157432	chr6:142966421~143038077:-
HNSC	cis	rs6988985	0.728	rs5303	ENSG00000247317.3	RP11-273G15.2	-3.57	0.000395	0.0429	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873679	chr8:142981738~143018437:-
HNSC	cis	rs6840360	0.642	rs7682770	ENSG00000251611.1	RP11-610P16.1	-3.57	0.000395	0.0429	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.667	rs9994482	ENSG00000251611.1	RP11-610P16.1	-3.57	0.000395	0.0429	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs11729923	ENSG00000251611.1	RP11-610P16.1	-3.57	0.000395	0.0429	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs7657747	ENSG00000251611.1	RP11-610P16.1	-3.57	0.000395	0.0429	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151407551~151408835:-
HNSC	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-3.57	0.000395	0.0429	-0.19	-0.16	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
HNSC	cis	rs4535700	0.501	rs6943341	ENSG00000213650.3	RP11-760D2.7	-3.57	0.000395	0.0429	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55907489	chr7:56567906~56568858:-
HNSC	cis	rs3770081	1	rs17027011	ENSG00000273080.1	RP11-301O19.1	-3.57	0.000395	0.0429	-0.37	-0.16	Facial emotion recognition (sad faces);	chr2:86179433	chr2:86195590~86196049:+
HNSC	cis	rs2436845	0.934	rs2916564	ENSG00000253669.3	KB-1732A1.1	-3.57	0.000395	0.0429	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102811112	chr8:102805517~102809971:+
HNSC	cis	rs442309	0.551	rs10822056	ENSG00000238280.1	RP11-436D10.3	-3.57	0.000395	0.0429	-0.19	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62754351	chr10:62793562~62805887:-
HNSC	cis	rs6587515	1	rs12034302	ENSG00000203804.4	ADAMTSL4-AS1	3.57	0.000395	0.0429	0.3	0.16	Pericardial adipose tissue adjusted for height and weight;	chr1:150582400	chr1:150560202~150574552:-
HNSC	cis	rs16873450	1	rs16873450	ENSG00000234800.2	PCMTD1P3	-3.57	0.000395	0.0429	-0.16	-0.16	Verbal memory performance (residualized delayed recall level);	chr7:23767021	chr7:23721311~23721782:-
HNSC	cis	rs4888378	0.535	rs9319483	ENSG00000280152.1	RP11-331F4.5	3.57	0.000395	0.0429	0.21	0.16	Coronary artery disease;	chr16:75311893	chr16:75245994~75250077:-
HNSC	cis	rs6095298	0.595	rs11905558	ENSG00000222365.1	SNORD12B	-3.57	0.000395	0.0429	-0.18	-0.16	Intelligence (multi-trait analysis);	chr20:48836040	chr20:49280319~49280409:+
HNSC	cis	rs6095298	0.595	rs35567324	ENSG00000222365.1	SNORD12B	-3.57	0.000395	0.0429	-0.18	-0.16	Intelligence (multi-trait analysis);	chr20:48836517	chr20:49280319~49280409:+
HNSC	cis	rs7586673	0.93	rs6432667	ENSG00000235724.7	AC009299.2	-3.57	0.000395	0.0429	-0.21	-0.16	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161222785~161308303:-
HNSC	cis	rs9650657	0.585	rs7830317	ENSG00000269918.1	AF131215.9	-3.57	0.000395	0.0429	-0.16	-0.16	Neuroticism;	chr8:10842744	chr8:11104691~11106704:-
HNSC	cis	rs9650657	0.683	rs7830431	ENSG00000269918.1	AF131215.9	-3.57	0.000395	0.0429	-0.16	-0.16	Neuroticism;	chr8:10842807	chr8:11104691~11106704:-
HNSC	cis	rs8114671	0.967	rs2069945	ENSG00000269202.1	RP4-614O4.12	-3.57	0.000396	0.0429	-0.18	-0.16	Height;	chr20:35174034	chr20:35201747~35203288:-
HNSC	cis	rs17407555	0.779	rs17475461	ENSG00000250413.1	RP11-448G15.1	3.57	0.000396	0.043	0.23	0.16	Schizophrenia (age at onset);	chr4:10286053	chr4:10006482~10009725:+
HNSC	cis	rs7824557	0.564	rs2572392	ENSG00000255495.1	AC145124.2	-3.57	0.000396	0.043	-0.18	-0.16	Retinal vascular caliber;	chr8:11378096	chr8:12194467~12196280:+
HNSC	cis	rs61160187	0.582	rs55814394	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000396	0.043	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60866457~60866935:-
HNSC	cis	rs950027	0.787	rs2433616	ENSG00000259479.5	SORD2P	3.57	0.000396	0.043	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:44826371~44884694:-
HNSC	cis	rs559928	0.642	rs2286615	ENSG00000236935.1	AP003774.1	3.57	0.000396	0.043	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64271703	chr11:64325050~64329504:-
HNSC	cis	rs67311347	0.911	rs6773917	ENSG00000280739.1	EIF1B-AS1	3.57	0.000396	0.043	0.18	0.16	Renal cell carcinoma;	chr3:40427763	chr3:40173145~40309698:-
HNSC	cis	rs544991	0.643	rs9943211	ENSG00000239670.1	RP4-803A2.2	3.57	0.000396	0.043	0.2	0.16	Intelligence;	chr1:33750306	chr1:32986952~32988233:+
HNSC	cis	rs9926296	0.542	rs12599531	ENSG00000261172.1	RP11-356C4.5	3.57	0.000396	0.043	0.19	0.16	Vitiligo;	chr16:89842993	chr16:90110574~90168225:-
HNSC	cis	rs9876781	1	rs13314659	ENSG00000229759.1	MRPS18AP1	-3.57	0.000396	0.043	-0.15	-0.16	Longevity;	chr3:48407742	chr3:48256350~48256938:-
HNSC	cis	rs1865760	1	rs2071299	ENSG00000272810.1	U91328.22	-3.57	0.000396	0.043	-0.15	-0.16	Height;	chr6:25914573	chr6:26013241~26013757:+
HNSC	cis	rs1865760	1	rs2071298	ENSG00000272810.1	U91328.22	-3.57	0.000396	0.043	-0.15	-0.16	Height;	chr6:25914673	chr6:26013241~26013757:+
HNSC	cis	rs6095360	1	rs2295027	ENSG00000227431.4	CSE1L-AS1	-3.57	0.000396	0.043	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48966347	chr20:49040463~49046044:-
HNSC	cis	rs7142881	0.873	rs8009647	ENSG00000257636.5	RP11-1103G16.1	-3.57	0.000396	0.043	-0.16	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31571806	chr14:30437992~30573629:-
HNSC	cis	rs5758659	0.622	rs129856	ENSG00000182057.4	OGFRP1	3.57	0.000396	0.043	0.16	0.16	Cognitive function;	chr22:42003392	chr22:42269753~42275196:+
HNSC	cis	rs7837791	0.652	rs10755941	ENSG00000167912.5	RP11-25K19.1	-3.57	0.000396	0.043	-0.18	-0.16	Refractive error;	chr8:59242755	chr8:59119040~59121346:+
HNSC	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	3.57	0.000396	0.043	0.19	0.16	Height;	chr4:55540928	chr4:55540502~55540835:-
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000269918.1	AF131215.9	3.57	0.000396	0.043	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11104691~11106704:-
HNSC	cis	rs2243480	1	rs6460260	ENSG00000226002.1	RP11-460N20.5	3.57	0.000396	0.043	0.28	0.16	Diabetic kidney disease;	chr7:65750468	chr7:65084103~65100232:+
HNSC	cis	rs2243480	1	rs6460261	ENSG00000226002.1	RP11-460N20.5	3.57	0.000396	0.043	0.28	0.16	Diabetic kidney disease;	chr7:65750593	chr7:65084103~65100232:+
HNSC	cis	rs2243480	0.908	rs4718273	ENSG00000226002.1	RP11-460N20.5	3.57	0.000396	0.043	0.28	0.16	Diabetic kidney disease;	chr7:65751112	chr7:65084103~65100232:+
HNSC	cis	rs2436845	1	rs2513921	ENSG00000253669.3	KB-1732A1.1	-3.57	0.000396	0.043	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818167	chr8:102805517~102809971:+
HNSC	cis	rs57221529	0.766	rs12522140	ENSG00000225138.6	CTD-2228K2.7	3.57	0.000396	0.043	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:587146	chr5:473236~480884:+
HNSC	cis	rs57221529	0.766	rs72703064	ENSG00000225138.6	CTD-2228K2.7	3.57	0.000396	0.043	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:587710	chr5:473236~480884:+
HNSC	cis	rs57221529	0.766	rs72703065	ENSG00000225138.6	CTD-2228K2.7	3.57	0.000396	0.043	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:588008	chr5:473236~480884:+
HNSC	cis	rs57221529	0.766	rs1399381	ENSG00000225138.6	CTD-2228K2.7	3.57	0.000396	0.043	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:589738	chr5:473236~480884:+
HNSC	cis	rs17772222	1	rs1955599	ENSG00000258789.1	RP11-507K2.3	-3.57	0.000396	0.043	-0.2	-0.16	Coronary artery calcification;	chr14:88358788	chr14:88551597~88552493:+
HNSC	cis	rs17772222	1	rs1955600	ENSG00000258789.1	RP11-507K2.3	-3.57	0.000396	0.043	-0.2	-0.16	Coronary artery calcification;	chr14:88359040	chr14:88551597~88552493:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000260091.1	RP11-33B1.4	3.57	0.000396	0.043	0.16	0.16	Corneal astigmatism;	chr4:119480680	chr4:119409333~119410233:+
HNSC	cis	rs2236521	0.714	rs6062210	ENSG00000228812.6	LAMA5-AS1	-3.57	0.000396	0.043	-0.19	-0.16	Pelvic organ prolapse;	chr20:62315319	chr20:62352995~62356480:+
HNSC	cis	rs35146811	0.735	rs1727138	ENSG00000235077.1	AC073842.19	-3.57	0.000396	0.043	-0.2	-0.16	Coronary artery disease;	chr7:100217624	chr7:100130964~100140439:+
HNSC	cis	rs2625529	0.73	rs12912771	ENSG00000260037.4	CTD-2524L6.3	-3.57	0.000396	0.043	-0.2	-0.16	Red blood cell count;	chr15:71870587	chr15:71818396~71823384:+
HNSC	cis	rs5758659	1	rs5758660	ENSG00000270083.1	RP1-257I20.14	3.57	0.000396	0.043	0.15	0.16	Cognitive function;	chr22:42227712	chr22:42089630~42090028:-
HNSC	cis	rs73201462	0.901	rs34749881	ENSG00000231305.3	RP11-723O4.2	-3.57	0.000396	0.043	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128151426	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs11711710	ENSG00000231305.3	RP11-723O4.2	-3.57	0.000396	0.043	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128153663	chr3:128861313~128871540:-
HNSC	cis	rs9505118	1	rs3799512	ENSG00000238221.1	RP11-69L16.4	3.57	0.000396	0.043	0.2	0.16	Type 2 diabetes;	chr6:7290113	chr6:7276031~7298872:+
HNSC	cis	rs7829975	0.714	rs11777085	ENSG00000233609.3	RP11-62H7.2	3.57	0.000396	0.043	0.15	0.16	Mood instability;	chr8:8814919	chr8:8961200~8979025:+
HNSC	cis	rs867371	0.82	rs12443224	ENSG00000276710.3	CSPG4P8	-3.57	0.000396	0.043	-0.18	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82459472~82477258:+
HNSC	cis	rs9467711	0.606	rs9357006	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26364400	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs28362606	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26365358	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs66827971	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26365538	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs71557334	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26365685	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9348712	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26366283	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9379856	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26366608	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9379857	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26367426	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9379858	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26367461	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs9393710	ENSG00000241549.7	GUSBP2	3.57	0.000397	0.043	0.26	0.16	Autism spectrum disorder or schizophrenia;	chr6:26367605	chr6:26871484~26956554:-
HNSC	cis	rs2625529	0.73	rs2957725	ENSG00000260037.4	CTD-2524L6.3	3.57	0.000397	0.043	0.22	0.16	Red blood cell count;	chr15:71955864	chr15:71818396~71823384:+
HNSC	cis	rs9650657	0.77	rs6601529	ENSG00000255310.2	AF131215.2	-3.57	0.000397	0.043	-0.15	-0.16	Neuroticism;	chr8:10813040	chr8:11107788~11109726:-
HNSC	cis	rs7688540	0.771	rs4582105	ENSG00000250892.1	RP11-1365D11.1	-3.57	0.000397	0.043	-0.3	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:201409~205009:-
HNSC	cis	rs13260300	0.533	rs890219	ENSG00000254349.4	FLJ39080	-3.57	0.000397	0.043	-0.19	-0.16	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581235	chr8:74599775~74823313:+
HNSC	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	3.57	0.000397	0.043	0.32	0.16	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
HNSC	cis	rs476633	0.595	rs11857726	ENSG00000247556.5	OIP5-AS1	3.57	0.000397	0.043	0.15	0.16	Glomerular filtration rate (creatinine);	chr15:41238161	chr15:41283990~41309737:+
HNSC	cis	rs6142618	0.846	rs911129	ENSG00000275576.1	RP5-836N17.4	-3.57	0.000397	0.043	-0.17	-0.16	Inflammatory bowel disease;	chr20:32201385	chr20:32116171~32116629:+
HNSC	cis	rs4853525	0.923	rs4853523	ENSG00000235852.1	AC005540.3	3.57	0.000397	0.043	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868053	chr2:190880797~190882059:-
HNSC	cis	rs6142618	0.783	rs4911090	ENSG00000275576.1	RP5-836N17.4	-3.57	0.000397	0.0431	-0.16	-0.16	Inflammatory bowel disease;	chr20:32299103	chr20:32116171~32116629:+
HNSC	cis	rs6142618	0.74	rs4911214	ENSG00000275576.1	RP5-836N17.4	-3.57	0.000397	0.0431	-0.16	-0.16	Inflammatory bowel disease;	chr20:32299661	chr20:32116171~32116629:+
HNSC	cis	rs12449568	0.874	rs11657999	ENSG00000263120.1	RP5-1107A17.4	-3.57	0.000397	0.0431	-0.15	-0.16	Height;	chr17:56334147	chr17:56982749~56985104:+
HNSC	cis	rs16944687	1	rs75953930	ENSG00000261567.1	RP11-680G10.1	-3.57	0.000397	0.0431	-0.41	-0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr16:86105021	chr16:85357463~85359449:+
HNSC	cis	rs9304742	0.962	rs1808106	ENSG00000213793.4	ZNF888	3.57	0.000397	0.0431	0.19	0.16	Psoriasis;	chr19:52949691	chr19:52915196~52923470:-
HNSC	cis	rs2084898	1	rs7119954	ENSG00000176984.5	AP000679.2	3.57	0.000397	0.0431	0.26	0.16	Stroke (pediatric);	chr11:120175516	chr11:120168977~120171679:+
HNSC	cis	rs2048656	0.523	rs6990300	ENSG00000233609.3	RP11-62H7.2	-3.57	0.000397	0.0431	-0.16	-0.16	Schizophrenia;	chr8:9690351	chr8:8961200~8979025:+
HNSC	cis	rs859767	0.741	rs4954155	ENSG00000224043.6	CCNT2-AS1	3.57	0.000397	0.0431	0.2	0.16	Neuroticism;	chr2:134625934	chr2:134735464~134918710:-
HNSC	cis	rs9487051	1	rs9386796	ENSG00000219700.1	PTCHD3P3	3.57	0.000397	0.0431	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109297501	chr6:109288571~109290503:-
HNSC	cis	rs7829975	0.686	rs907180	ENSG00000254340.1	RP11-10A14.3	3.57	0.000397	0.0431	0.19	0.16	Mood instability;	chr8:8845317	chr8:9141424~9145435:+
HNSC	cis	rs11853189	0.938	rs1879152	ENSG00000259562.2	RP11-762H8.2	3.57	0.000397	0.0431	0.2	0.16	Red cell distribution width;	chr15:78289498	chr15:78290527~78291221:-
HNSC	cis	rs2305707	0.544	rs2470153	ENSG00000259306.2	RP11-108K3.2	-3.57	0.000397	0.0431	-0.33	-0.16	Height;	chr15:51300720	chr15:51315841~51321996:+
HNSC	cis	rs889398	0.904	rs6499244	ENSG00000226232.7	RP11-419C5.2	-3.57	0.000397	0.0431	-0.14	-0.16	Body mass index;	chr16:69701368	chr16:69976388~69996188:-
HNSC	cis	rs6012564	1	rs2024959	ENSG00000227431.4	CSE1L-AS1	3.57	0.000397	0.0431	0.18	0.16	Anger;	chr20:49078854	chr20:49040463~49046044:-
HNSC	cis	rs6504108	0.624	rs3897986	ENSG00000264920.1	RP11-6N17.4	3.57	0.000397	0.0431	0.19	0.16	Body mass index;	chr17:48184177	chr17:47891255~47895812:-
HNSC	cis	rs10186029	0.539	rs4672676	ENSG00000270659.1	RP11-105N14.1	-3.57	0.000397	0.0431	-0.16	-0.16	Systemic sclerosis;	chr2:213137224	chr2:213152970~213153659:+
HNSC	cis	rs10186029	0.548	rs4673728	ENSG00000270659.1	RP11-105N14.1	-3.57	0.000397	0.0431	-0.16	-0.16	Systemic sclerosis;	chr2:213137273	chr2:213152970~213153659:+
HNSC	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	3.57	0.000397	0.0431	0.16	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
HNSC	cis	rs853679	0.882	rs9468300	ENSG00000204709.4	LINC01556	3.57	0.000397	0.0431	0.28	0.16	Depression;	chr6:28159062	chr6:28943877~28944537:+
HNSC	cis	rs7429990	0.864	rs2140335	ENSG00000228638.1	FCF1P2	3.57	0.000397	0.0431	0.15	0.16	Educational attainment (years of education);	chr3:47663625	chr3:48290793~48291375:-
HNSC	cis	rs5758659	0.967	rs5758670	ENSG00000270083.1	RP1-257I20.14	3.57	0.000397	0.0431	0.15	0.16	Cognitive function;	chr22:42240681	chr22:42089630~42090028:-
HNSC	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-3.57	0.000397	0.0431	-0.22	-0.16	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
HNSC	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-3.57	0.000397	0.0431	-0.18	-0.16	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
HNSC	cis	rs6445975	0.726	rs7616659	ENSG00000273493.1	RP11-80H18.4	-3.57	0.000397	0.0431	-0.18	-0.16	Systemic lupus erythematosus;	chr3:58481860	chr3:58329965~58330118:+
HNSC	cis	rs911119	1	rs13041070	ENSG00000270001.1	RP11-218C14.8	-3.57	0.000397	0.0431	-0.24	-0.16	Chronic kidney disease;	chr20:23633624	chr20:23631826~23632316:-
HNSC	cis	rs911119	1	rs3787498	ENSG00000270001.1	RP11-218C14.8	-3.57	0.000397	0.0431	-0.24	-0.16	Chronic kidney disease;	chr20:23636144	chr20:23631826~23632316:-
HNSC	cis	rs28489187	0.643	rs1884139	ENSG00000223653.4	RP11-131L23.1	3.57	0.000397	0.0431	0.22	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85380315	chr1:85276715~85448124:+
HNSC	cis	rs3748656	0.945	rs12724928	ENSG00000273483.1	RP4-671G15.2	3.57	0.000397	0.0431	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112586309	chr1:112517799~112518441:-
HNSC	cis	rs11756659	0.653	rs185635	ENSG00000216331.1	HIST1H1PS1	3.57	0.000398	0.0431	0.24	0.16	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:26195566~26195771:+
HNSC	cis	rs9303401	0.614	rs12947982	ENSG00000266701.1	AC005702.4	3.57	0.000398	0.0431	0.22	0.16	Cognitive test performance;	chr17:59062940	chr17:60042546~60042627:-
HNSC	cis	rs853679	0.556	rs45509595	ENSG00000241549.7	GUSBP2	3.57	0.000398	0.0431	0.28	0.16	Depression;	chr6:27873148	chr6:26871484~26956554:-
HNSC	cis	rs514406	0.76	rs1242198	ENSG00000225675.2	RP4-784A16.5	3.57	0.000398	0.0431	0.17	0.16	Monocyte count;	chr1:52886344	chr1:53328233~53336509:+
HNSC	cis	rs10463554	1	rs3776864	ENSG00000250682.4	LINC00491	3.57	0.000398	0.0431	0.21	0.16	Parkinson's disease;	chr5:102992164	chr5:102609156~102671559:-
HNSC	cis	rs9329221	0.505	rs7840347	ENSG00000255310.2	AF131215.2	-3.57	0.000398	0.0431	-0.16	-0.16	Neuroticism;	chr8:10214840	chr8:11107788~11109726:-
HNSC	cis	rs10435719	0.899	rs11250177	ENSG00000255310.2	AF131215.2	3.57	0.000398	0.0431	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11107788~11109726:-
HNSC	cis	rs3758785	0.537	rs622647	ENSG00000255893.1	RP11-685N10.1	3.57	0.000398	0.0431	0.19	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94336553	chr11:94472908~94473570:-
HNSC	cis	rs3758785	0.51	rs483476	ENSG00000255893.1	RP11-685N10.1	3.57	0.000398	0.0431	0.19	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94336649	chr11:94472908~94473570:-
HNSC	cis	rs820077	0.736	rs34989337	ENSG00000272374.1	RP3-329A5.8	3.57	0.000398	0.0431	0.18	0.16	Systemic lupus erythematosus;	chr6:35096913	chr6:35220370~35224630:-
HNSC	cis	rs6095360	0.934	rs6019581	ENSG00000222365.1	SNORD12B	3.57	0.000398	0.0431	0.17	0.16	Intelligence (multi-trait analysis);	chr20:49011035	chr20:49280319~49280409:+
HNSC	cis	rs1440410	0.835	rs7685461	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143133730	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10857405	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143134361	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs7666785	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143139311	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10004598	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143141264	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.763	rs9631769	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143144588	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs6537151	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143146753	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs13107465	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143147664	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs4511955	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143149081	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs13140643	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143149221	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs6817849	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143154848	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs10012434	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143156365	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs7687417	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000398	0.0432	-0.18	-0.16	Ischemic stroke;	chr4:143158848	chr4:142933195~143184861:-
HNSC	cis	rs546131	0.642	rs61881097	ENSG00000271369.1	RP11-350D17.3	-3.57	0.000398	0.0432	-0.22	-0.16	Lung disease severity in cystic fibrosis;	chr11:34800051	chr11:34709600~34710161:+
HNSC	cis	rs5758511	0.773	rs11913631	ENSG00000226450.2	CYP2D8P	3.57	0.000398	0.0432	0.15	0.16	Birth weight;	chr22:41951367	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.773	rs1894714	ENSG00000226450.2	CYP2D8P	-3.57	0.000398	0.0432	-0.15	-0.16	Birth weight;	chr22:41953130	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.731	rs5751186	ENSG00000226450.2	CYP2D8P	-3.57	0.000398	0.0432	-0.15	-0.16	Birth weight;	chr22:41953706	chr22:42149886~42155001:-
HNSC	cis	rs2408955	0.561	rs11168365	ENSG00000257763.1	OR5BK1P	-3.57	0.000398	0.0432	-0.16	-0.16	Glycated hemoglobin levels;	chr12:48027989	chr12:48355792~48356614:-
HNSC	cis	rs1055129	0.516	rs7218498	ENSG00000274051.1	uc_338	3.57	0.000398	0.0432	0.14	0.16	White matter hyperintensity burden;	chr17:75935766	chr17:76721216~76721396:-
HNSC	cis	rs9487051	0.714	rs6903695	ENSG00000219700.1	PTCHD3P3	-3.57	0.000398	0.0432	-0.16	-0.16	Reticulocyte fraction of red cells;	chr6:109310219	chr6:109288571~109290503:-
HNSC	cis	rs61160187	0.51	rs6449501	ENSG00000215032.2	GNL3LP1	3.57	0.000398	0.0432	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60891935~60893577:-
HNSC	cis	rs2898681	1	rs6833096	ENSG00000248375.1	RP11-177B4.1	-3.57	0.000398	0.0432	-0.25	-0.16	Optic nerve measurement (cup area);	chr4:52878108	chr4:52720081~52720831:-
HNSC	cis	rs4713118	0.591	rs2056924	ENSG00000219392.1	RP1-265C24.5	-3.57	0.000398	0.0432	-0.19	-0.16	Parkinson's disease;	chr6:27722395	chr6:28115628~28116551:+
HNSC	cis	rs1476670	0.545	rs11210947	ENSG00000230615.5	RP5-1198O20.4	-3.57	0.000398	0.0432	-0.19	-0.16	Eotaxin levels;	chr1:44054398	chr1:44030443~44115913:+
HNSC	cis	rs9487051	0.735	rs1260595	ENSG00000243587.6	C6orf183	-3.57	0.000398	0.0432	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109198670	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.735	rs1260594	ENSG00000243587.6	C6orf183	-3.57	0.000398	0.0432	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109198688	chr6:109165833~109271014:+
HNSC	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	3.57	0.000398	0.0432	0.16	0.16	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
HNSC	cis	rs853679	1	rs6901575	ENSG00000270326.1	RP5-874C20.6	-3.57	0.000398	0.0432	-0.25	-0.16	Depression;	chr6:28283207	chr6:28319660~28319852:-
HNSC	cis	rs2468186	0.583	rs2450067	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000398	0.0432	-0.14	-0.16	Osteoprotegerin levels;	chr8:119084294	chr8:119838736~119840385:-
HNSC	cis	rs2468186	0.554	rs2450066	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000398	0.0432	-0.14	-0.16	Osteoprotegerin levels;	chr8:119084568	chr8:119838736~119840385:-
HNSC	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	3.57	0.000399	0.0432	0.19	0.16	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
HNSC	cis	rs7107174	1	rs2511178	ENSG00000251323.2	RP11-452H21.4	3.57	0.000399	0.0432	0.25	0.16	Testicular germ cell tumor;	chr11:78212174	chr11:78423982~78429836:-
HNSC	cis	rs7107174	0.892	rs2510042	ENSG00000251323.2	RP11-452H21.4	3.57	0.000399	0.0432	0.25	0.16	Testicular germ cell tumor;	chr11:78212619	chr11:78423982~78429836:-
HNSC	cis	rs17407555	0.697	rs73212840	ENSG00000250413.1	RP11-448G15.1	3.57	0.000399	0.0432	0.26	0.16	Schizophrenia (age at onset);	chr4:10085834	chr4:10006482~10009725:+
HNSC	cis	rs11700980	0.551	rs2832015	ENSG00000232855.5	AF131217.1	3.57	0.000399	0.0432	0.23	0.16	QRS complex (12-leadsum);	chr21:28738870	chr21:28439346~28674848:-
HNSC	cis	rs7015263	0.689	rs10956803	ENSG00000254231.1	CTD-2284J15.1	-3.57	0.000399	0.0432	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86350845	chr8:86333274~86343314:-
HNSC	cis	rs2041895	0.509	rs2024518	ENSG00000260329.1	RP11-412D9.4	-3.57	0.000399	0.0432	-0.15	-0.16	Glaucoma (low intraocular pressure);	chr12:106903124	chr12:106954029~106955497:-
HNSC	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	3.57	0.000399	0.0432	0.19	0.16	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	3.57	0.000399	0.0432	0.19	0.16	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.66	rs6460308	ENSG00000273142.1	RP11-458F8.4	3.57	0.000399	0.0432	0.14	0.16	Aortic root size;	chr7:66619753	chr7:66902857~66906297:+
HNSC	cis	rs859767	0.741	rs6430529	ENSG00000224043.6	CCNT2-AS1	3.57	0.000399	0.0432	0.2	0.16	Neuroticism;	chr2:134675453	chr2:134735464~134918710:-
HNSC	cis	rs1979679	0.76	rs16932640	ENSG00000278733.1	RP11-425D17.1	3.57	0.000399	0.0432	0.18	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28185625~28186190:-
HNSC	cis	rs10844154	0.638	rs179104	ENSG00000274105.1	RP11-278C7.3	3.57	0.000399	0.0432	0.17	0.16	Emphysema-related traits;Weight;	chr12:32249463	chr12:32728169~32729024:-
HNSC	cis	rs495337	1	rs4810998	ENSG00000229222.1	KRT18P4	-3.57	0.000399	0.0432	-0.18	-0.16	Psoriasis;	chr20:49963473	chr20:49956745~49958032:+
HNSC	cis	rs1832007	0.529	rs4612705	ENSG00000224034.1	RP11-445P17.8	-3.57	0.000399	0.0433	-0.19	-0.16	Triglyceride levels;Triglycerides;	chr10:5201635	chr10:5266033~5271236:-
HNSC	cis	rs8054556	0.539	rs12596543	ENSG00000250616.2	RP11-455F5.3	3.57	0.000399	0.0433	0.16	0.16	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30096430~30104116:+
HNSC	cis	rs1862618	0.671	rs2591964	ENSG00000265665.1	AC008391.1	-3.57	0.000399	0.0433	-0.21	-0.16	Initial pursuit acceleration;	chr5:56941073	chr5:56457038~56457138:-
HNSC	cis	rs12534093	0.921	rs11763760	ENSG00000234286.1	AC006026.13	-3.57	0.000399	0.0433	-0.2	-0.16	Infant length;Height;	chr7:23440848	chr7:23680195~23680786:-
HNSC	cis	rs62229266	0.659	rs7275820	ENSG00000230212.5	AP000688.14	-3.57	0.000399	0.0433	-0.17	-0.16	Mitral valve prolapse;	chr21:36037116	chr21:36069642~36126640:-
HNSC	cis	rs62229266	0.652	rs7280551	ENSG00000230212.5	AP000688.14	-3.57	0.000399	0.0433	-0.17	-0.16	Mitral valve prolapse;	chr21:36037311	chr21:36069642~36126640:-
HNSC	cis	rs6928977	0.863	rs2614277	ENSG00000231028.7	LINC00271	3.57	0.000399	0.0433	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135333856	chr6:135497801~135716055:+
HNSC	cis	rs929354	1	rs1182377	ENSG00000224629.1	RP5-1142J19.2	3.57	0.000399	0.0433	0.16	0.16	Body mass index;	chr7:157255709	chr7:157263022~157263229:-
HNSC	cis	rs8062405	0.755	rs7193402	ENSG00000261766.1	RP11-22P6.2	-3.57	0.000399	0.0433	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28862166~28863340:-
HNSC	cis	rs13178541	0.748	rs4976308	ENSG00000250378.1	RP11-119J18.1	-3.57	4e-04	0.0433	-0.21	-0.16	IgG glycosylation;	chr5:135729915	chr5:135812667~135826582:+
HNSC	cis	rs1846899	1	rs1846899	ENSG00000226652.2	PSMD10P2	3.57	4e-04	0.0433	0.26	0.16	Blood protein levels;	chr3:186755027	chr3:186760693~186762050:+
HNSC	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-3.57	4e-04	0.0433	-0.24	-0.16	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
HNSC	cis	rs9437689	1	rs4390223	ENSG00000237416.5	RP11-465K1.2	-3.57	4e-04	0.0433	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95091073	chr1:94836748~94855426:-
HNSC	cis	rs9437689	1	rs4309032	ENSG00000237416.5	RP11-465K1.2	-3.57	4e-04	0.0433	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95091212	chr1:94836748~94855426:-
HNSC	cis	rs17772222	0.917	rs61977053	ENSG00000258789.1	RP11-507K2.3	-3.57	4e-04	0.0433	-0.2	-0.16	Coronary artery calcification;	chr14:88380876	chr14:88551597~88552493:+
HNSC	cis	rs864537	0.618	rs1214595	ENSG00000233411.1	RP11-104L21.2	3.57	4e-04	0.0433	0.19	0.16	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167458320	chr1:167457383~167458661:-
HNSC	cis	rs1440410	0.763	rs1039762	ENSG00000250326.1	RP11-284M14.1	-3.57	4e-04	0.0433	-0.18	-0.16	Ischemic stroke;	chr4:143246893	chr4:142933195~143184861:-
HNSC	cis	rs7726839	0.574	rs11134148	ENSG00000225138.6	CTD-2228K2.7	3.57	4e-04	0.0433	0.25	0.16	Obesity-related traits;	chr5:636992	chr5:473236~480884:+
HNSC	cis	rs79478560	0.502	rs10846562	ENSG00000269938.1	RP11-214K3.20	-3.57	4e-04	0.0433	-0.18	-0.16	Lymphocyte counts;	chr12:123855779	chr12:123968023~123968579:-
HNSC	cis	rs10783487	0.895	rs1317275	ENSG00000257542.4	OR7E47P	3.57	4e-04	0.0433	0.2	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52088803	chr12:52079696~52108261:+
HNSC	cis	rs7937890	0.532	rs2575833	ENSG00000254418.1	RP11-21L19.1	3.57	4e-04	0.0433	0.19	0.16	Mitochondrial DNA levels;	chr11:14470959	chr11:14262846~14273691:-
HNSC	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	3.57	4e-04	0.0433	0.32	0.16	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
HNSC	cis	rs870825	0.616	rs28563856	ENSG00000254233.1	RP11-242J7.1	3.57	4e-04	0.0433	0.24	0.16	Blood protein levels;	chr4:184714427	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs12502771	ENSG00000254233.1	RP11-242J7.1	3.57	4e-04	0.0433	0.24	0.16	Blood protein levels;	chr4:184714680	chr4:184584093~184625030:-
HNSC	cis	rs4073405	0.889	rs7131174	ENSG00000254651.1	RP11-430H10.3	3.57	4e-04	0.0433	0.2	0.16	Schizophrenia;	chr11:45300640	chr11:45399448~45400528:+
HNSC	cis	rs4377367	0.653	rs11685644	ENSG00000273073.1	RP11-109E12.1	-3.57	4e-04	0.0433	-0.32	-0.16	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr2:130922373	chr2:131461821~131463615:-
HNSC	cis	rs12545109	0.959	rs12547974	ENSG00000246430.5	LINC00968	-3.57	4e-04	0.0433	-0.21	-0.16	Obesity-related traits;	chr8:56402226	chr8:56496246~56559823:-
HNSC	cis	rs2445762	0.659	rs17524318	ENSG00000259438.1	CTD-2650P22.1	3.57	4e-04	0.0433	0.2	0.16	Hormone measurements;	chr15:51371189	chr15:52010999~52019095:-
HNSC	cis	rs2445762	0.659	rs55810637	ENSG00000259438.1	CTD-2650P22.1	3.57	4e-04	0.0433	0.2	0.16	Hormone measurements;	chr15:51372706	chr15:52010999~52019095:-
HNSC	cis	rs4648045	0.822	rs72696109	ENSG00000230069.3	LRRC37A15P	-3.57	4e-04	0.0433	-0.17	-0.16	Lymphocyte percentage of white cells;	chr4:102491188	chr4:102727274~102730721:-
HNSC	cis	rs36715	0.953	rs42916	ENSG00000245937.6	LINC01184	3.57	4e-04	0.0434	0.21	0.16	Breast cancer;	chr5:128224967	chr5:127940426~128083172:-
HNSC	cis	rs1008375	0.932	rs7677212	ENSG00000249502.1	AC006160.5	3.57	4e-04	0.0434	0.18	0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674309	chr4:17587467~17614571:-
HNSC	cis	rs6968419	0.714	rs1048508	ENSG00000237870.5	AC073130.1	-3.57	4e-04	0.0434	-0.2	-0.16	Intraocular pressure;	chr7:116252596	chr7:116275606~116286734:-
HNSC	cis	rs250677	0.652	rs250675	ENSG00000250072.4	CTC-529P8.1	3.57	4e-04	0.0434	0.22	0.16	Breast cancer;	chr5:149059002	chr5:149063317~149109787:+
HNSC	cis	rs236373	0.522	rs236352	ENSG00000232598.2	RP1-90K10.4	3.57	4e-04	0.0434	0.18	0.16	Heart rate;	chr6:36849337	chr6:36940071~36944675:-
HNSC	cis	rs6594357	0.588	rs10900654	ENSG00000271849.1	CTC-332L22.1	-3.57	4e-04	0.0434	-0.19	-0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr5:109206825	chr5:109687802~109688329:-
HNSC	cis	rs28830936	0.966	rs3179542	ENSG00000250379.1	RP11-23P13.4	3.57	0.000401	0.0434	0.2	0.16	Diastolic blood pressure;	chr15:41825925	chr15:41825099~41827936:-
HNSC	cis	rs758970	0.571	rs16929088	ENSG00000200788.1	Y_RNA	3.57	0.000401	0.0434	0.18	0.16	Obesity-related traits;	chr9:126507567	chr9:127470875~127470987:+
HNSC	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-3.57	0.000401	0.0434	-0.16	-0.16	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
HNSC	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-3.57	0.000401	0.0434	-0.17	-0.16	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
HNSC	cis	rs9313772	0.926	rs7712354	ENSG00000254350.1	RP11-542A14.1	-3.57	0.000401	0.0434	-0.19	-0.16	Blood pressure;	chr5:158379242	chr5:158424585~158452758:+
HNSC	cis	rs793571	0.58	rs12913383	ENSG00000245975.2	RP11-30K9.6	-3.57	0.000401	0.0434	-0.26	-0.16	Schizophrenia;	chr15:58751587	chr15:58768072~58770974:-
HNSC	cis	rs28489187	0.706	rs233099	ENSG00000223653.4	RP11-131L23.1	3.57	0.000401	0.0434	0.23	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85360511	chr1:85276715~85448124:+
HNSC	cis	rs870825	0.655	rs28661636	ENSG00000254233.1	RP11-242J7.1	3.57	0.000401	0.0434	0.24	0.16	Blood protein levels;	chr4:184713064	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7678949	ENSG00000254233.1	RP11-242J7.1	3.57	0.000401	0.0434	0.24	0.16	Blood protein levels;	chr4:184713864	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7678864	ENSG00000254233.1	RP11-242J7.1	3.57	0.000401	0.0434	0.24	0.16	Blood protein levels;	chr4:184714004	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.549	rs7656993	ENSG00000254233.1	RP11-242J7.1	3.57	0.000401	0.0434	0.24	0.16	Blood protein levels;	chr4:184714005	chr4:184584093~184625030:-
HNSC	cis	rs1602565	0.92	rs2467589	ENSG00000255450.1	CTD-2063L20.1	-3.57	0.000401	0.0434	-0.28	-0.16	Schizophrenia;	chr11:29184150	chr11:29275655~29276565:+
HNSC	cis	rs1867631	0.585	rs6694782	ENSG00000248458.2	RP4-598P13.1	-3.57	0.000401	0.0434	-0.15	-0.16	Menopause (age at onset);	chr1:66661079	chr1:66665864~66677027:-
HNSC	cis	rs4252134	0.959	rs1972748	ENSG00000231863.1	RP3-428L16.1	3.57	0.000401	0.0434	0.2	0.16	Giant cell arteritis;	chr6:160733685	chr6:160931080~160969771:+
HNSC	cis	rs58785573	0.504	rs9522	ENSG00000231160.8	KLF3-AS1	-3.57	0.000401	0.0434	-0.14	-0.16	Lymphocyte percentage of white cells;	chr4:38665351	chr4:38612701~38664883:-
HNSC	cis	rs7772486	0.686	rs1011596	ENSG00000270638.1	RP3-466P17.1	3.57	0.000401	0.0434	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145735570~145737218:+
HNSC	cis	rs9467711	0.606	rs67234939	ENSG00000241549.7	GUSBP2	3.57	0.000401	0.0434	0.24	0.16	Autism spectrum disorder or schizophrenia;	chr6:26530191	chr6:26871484~26956554:-
HNSC	cis	rs4704187	0.687	rs1363579	ENSG00000272040.1	CTC-366B18.4	-3.57	0.000401	0.0434	-0.15	-0.16	Response to amphetamines;	chr5:75214528	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs2216638	ENSG00000272040.1	CTC-366B18.4	-3.57	0.000401	0.0434	-0.15	-0.16	Response to amphetamines;	chr5:75217162	chr5:75608817~75609983:+
HNSC	cis	rs860295	0.812	rs3820594	ENSG00000225855.5	RUSC1-AS1	3.57	0.000401	0.0435	0.11	0.16	Body mass index;	chr1:155859720	chr1:155316863~155324176:-
HNSC	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	3.56	0.000401	0.0435	0.23	0.16	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
HNSC	cis	rs1538970	0.924	rs3790582	ENSG00000234329.1	RP11-767N6.2	3.56	0.000401	0.0435	0.19	0.16	Platelet count;	chr1:45421616	chr1:45651039~45651826:-
HNSC	cis	rs62202398	0.618	rs73315404	ENSG00000276923.1	RP11-321P16.1	-3.56	0.000401	0.0435	-0.29	-0.16	Alcohol consumption;	chr20:48152719	chr20:48073869~48074188:+
HNSC	cis	rs62202398	0.618	rs73315405	ENSG00000276923.1	RP11-321P16.1	-3.56	0.000401	0.0435	-0.29	-0.16	Alcohol consumption;	chr20:48152855	chr20:48073869~48074188:+
HNSC	cis	rs10819861	0.645	rs4743535	ENSG00000271384.1	RP11-435O5.7	3.56	0.000401	0.0435	0.16	0.16	Electrocardiographic traits;	chr9:96095671	chr9:95406990~95407662:-
HNSC	cis	rs2998286	0.723	rs332190	ENSG00000254635.4	WAC-AS1	-3.56	0.000402	0.0435	-0.25	-0.16	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28630899	chr10:28522652~28532743:-
HNSC	cis	rs7178375	1	rs9806159	ENSG00000270055.1	CTD-3092A11.2	-3.56	0.000402	0.0435	-0.21	-0.16	Hypertriglyceridemia;	chr15:30917451	chr15:30487963~30490313:+
HNSC	cis	rs2377058	0.924	rs76762453	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000402	0.0435	-0.16	-0.16	Hip circumference adjusted for BMI;	chr16:89657194	chr16:89516797~89522217:+
HNSC	cis	rs17711722	0.727	rs35850374	ENSG00000272831.1	RP11-792A8.4	3.56	0.000402	0.0435	0.14	0.16	Calcium levels;	chr7:65892789	chr7:66739829~66740385:-
HNSC	cis	rs11700980	0.551	rs909329	ENSG00000232855.5	AF131217.1	3.56	0.000402	0.0435	0.23	0.16	QRS complex (12-leadsum);	chr21:28735940	chr21:28439346~28674848:-
HNSC	cis	rs28573326	0.962	rs11736871	ENSG00000121089.4	NACA3P	3.56	0.000402	0.0435	0.2	0.16	Pelvic organ prolapse (moderate/severe);	chr4:165415230	chr4:164943290~164943937:+
HNSC	cis	rs7824557	0.579	rs10098322	ENSG00000269918.1	AF131215.9	3.56	0.000402	0.0435	0.16	0.16	Retinal vascular caliber;	chr8:11338786	chr8:11104691~11106704:-
HNSC	cis	rs1048238	0.506	rs7552077	ENSG00000226029.1	RP4-798A10.2	-3.56	0.000402	0.0435	-0.15	-0.16	Systolic blood pressure;	chr1:15870264	chr1:16460948~16468481:+
HNSC	cis	rs7258015	1	rs3176767	ENSG00000273733.1	CTC-510F12.7	-3.56	0.000402	0.0435	-0.21	-0.16	Systemic lupus erythematosus or rheumatoid arthritis;	chr19:10339075	chr19:11221083~11221573:+
HNSC	cis	rs2243480	1	rs410128	ENSG00000164669.11	INTS4P1	3.56	0.000402	0.0435	0.34	0.16	Diabetic kidney disease;	chr7:66138186	chr7:65141225~65234216:+
HNSC	cis	rs6723108	0.619	rs1942041	ENSG00000224043.6	CCNT2-AS1	-3.56	0.000402	0.0435	-0.2	-0.16	Type 2 diabetes;	chr2:134757922	chr2:134735464~134918710:-
HNSC	cis	rs9863	0.898	rs11057400	ENSG00000270028.1	RP11-380L11.4	3.56	0.000402	0.0435	0.2	0.16	White blood cell count;	chr12:123940602	chr12:123925461~123926083:-
HNSC	cis	rs2408955	0.521	rs1476607	ENSG00000257763.1	OR5BK1P	-3.56	0.000402	0.0435	-0.16	-0.16	Glycated hemoglobin levels;	chr12:48131021	chr12:48355792~48356614:-
HNSC	cis	rs9402743	0.775	rs7742843	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135654681	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9494319	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135655122	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs6916924	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135656563	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs6916825	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135656739	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs6917005	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135656842	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9494320	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135657576	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs2068394	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135658279	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.775	rs9494321	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135658892	chr6:135301568~135307158:+
HNSC	cis	rs9402743	0.781	rs6935190	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000402	0.0435	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135659553	chr6:135301568~135307158:+
HNSC	cis	rs4535700	0.501	rs2135116	ENSG00000213650.3	RP11-760D2.7	-3.56	0.000402	0.0435	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55923451	chr7:56567906~56568858:-
HNSC	cis	rs4535700	0.543	rs2174459	ENSG00000213650.3	RP11-760D2.7	-3.56	0.000402	0.0435	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55923600	chr7:56567906~56568858:-
HNSC	cis	rs4535700	0.504	rs66528253	ENSG00000213650.3	RP11-760D2.7	-3.56	0.000402	0.0435	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55929070	chr7:56567906~56568858:-
HNSC	cis	rs4535700	0.501	rs11765577	ENSG00000213650.3	RP11-760D2.7	-3.56	0.000402	0.0435	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55930245	chr7:56567906~56568858:-
HNSC	cis	rs6089584	0.546	rs6061978	ENSG00000229873.1	OGFR-AS1	3.56	0.000402	0.0435	0.16	0.16	Body mass index;	chr20:62040548	chr20:62800627~62805587:-
HNSC	cis	rs8013055	0.796	rs4075105	ENSG00000258701.1	LINC00638	-3.56	0.000402	0.0435	-0.21	-0.16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);	chr14:105533894	chr14:104821201~104823718:+
HNSC	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-3.56	0.000402	0.0435	-0.22	-0.16	Depression;	chr6:28235522	chr6:28170845~28172521:+
HNSC	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-3.56	0.000402	0.0435	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
HNSC	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-3.56	0.000402	0.0435	-0.27	-0.16	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
HNSC	cis	rs7246657	0.722	rs1531549	ENSG00000276846.1	CTD-3220F14.3	3.56	0.000402	0.0435	0.22	0.16	Coronary artery calcification;	chr19:37597108	chr19:37314868~37315620:-
HNSC	cis	rs4853525	0.961	rs11687659	ENSG00000235852.1	AC005540.3	-3.56	0.000402	0.0435	-0.19	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190876471	chr2:190880797~190882059:-
HNSC	cis	rs2836974	0.627	rs9981301	ENSG00000255568.3	BRWD1-AS2	-3.56	0.000402	0.0435	-0.14	-0.16	Cognitive function;	chr21:39314152	chr21:39313935~39314962:+
HNSC	cis	rs3736485	0.578	rs2305716	ENSG00000274528.1	CTD-2650P22.2	3.56	0.000402	0.0435	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689094	chr15:52017167~52018032:-
HNSC	cis	rs3736485	0.578	rs1456300	ENSG00000274528.1	CTD-2650P22.2	3.56	0.000402	0.0435	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689819	chr15:52017167~52018032:-
HNSC	cis	rs526231	0.575	rs62362524	ENSG00000250682.4	LINC00491	3.56	0.000402	0.0435	0.21	0.16	Primary biliary cholangitis;	chr5:102978523	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.511	rs10515341	ENSG00000250682.4	LINC00491	3.56	0.000402	0.0435	0.21	0.16	Primary biliary cholangitis;	chr5:102981413	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.575	rs10463990	ENSG00000250682.4	LINC00491	3.56	0.000402	0.0435	0.21	0.16	Primary biliary cholangitis;	chr5:102981714	chr5:102609156~102671559:-
HNSC	cis	rs1667255	0.505	rs9963959	ENSG00000266521.1	RP11-650P15.1	3.56	0.000402	0.0435	0.19	0.16	Retinol levels;	chr18:31566987	chr18:31496645~31497195:-
HNSC	cis	rs911119	0.954	rs2254635	ENSG00000270001.1	RP11-218C14.8	-3.56	0.000402	0.0435	-0.23	-0.16	Chronic kidney disease;	chr20:23642121	chr20:23631826~23632316:-
HNSC	cis	rs76025697	1	rs76025697	ENSG00000278965.1	RP11-39H3.2	3.56	0.000402	0.0435	0.2	0.16	Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Granulocyte count;	chr5:179757487	chr5:180078357~180081691:-
HNSC	cis	rs950027	0.596	rs2467865	ENSG00000259479.5	SORD2P	3.56	0.000402	0.0435	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:44826371~44884694:-
HNSC	cis	rs1519814	0.696	rs7821842	ENSG00000254343.2	RP11-760H22.2	-3.56	0.000403	0.0436	-0.21	-0.16	Breast cancer;	chr8:120021743	chr8:120052180~120056201:+
HNSC	cis	rs7586673	1	rs16845584	ENSG00000235724.7	AC009299.2	3.56	0.000403	0.0436	0.21	0.16	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161222785~161308303:-
HNSC	cis	rs2337406	1	rs3858878	ENSG00000211972.2	IGHV3-66	3.56	0.000403	0.0436	0.16	0.16	Alzheimer's disease (late onset);	chr14:106688061	chr14:106675017~106675544:-
HNSC	cis	rs10435719	0.902	rs7459545	ENSG00000255310.2	AF131215.2	3.56	0.000403	0.0436	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11107788~11109726:-
HNSC	cis	rs793571	0.779	rs62002476	ENSG00000245975.2	RP11-30K9.6	3.56	0.000403	0.0436	0.28	0.16	Schizophrenia;	chr15:58970501	chr15:58768072~58770974:-
HNSC	cis	rs73607972	1	rs73607972	ENSG00000275191.1	RP11-36I17.2	-3.56	0.000403	0.0436	-0.26	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53634741	chr16:53628256~53628816:-
HNSC	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-3.56	0.000403	0.0436	-0.18	-0.16	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
HNSC	cis	rs17772222	1	rs55722539	ENSG00000258789.1	RP11-507K2.3	-3.56	0.000403	0.0436	-0.2	-0.16	Coronary artery calcification;	chr14:88411691	chr14:88551597~88552493:+
HNSC	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	3.56	0.000403	0.0436	0.2	0.16	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
HNSC	cis	rs7824557	0.527	rs2572447	ENSG00000255495.1	AC145124.2	-3.56	0.000403	0.0436	-0.18	-0.16	Retinal vascular caliber;	chr8:11382001	chr8:12194467~12196280:+
HNSC	cis	rs5758511	0.68	rs1033460	ENSG00000227370.1	RP4-669P10.19	3.56	0.000403	0.0436	0.2	0.16	Birth weight;	chr22:42223302	chr22:42132543~42132998:+
HNSC	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	3.56	0.000403	0.0436	0.25	0.16	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
HNSC	cis	rs9505118	0.965	rs2326899	ENSG00000238221.1	RP11-69L16.4	3.56	0.000403	0.0436	0.21	0.16	Type 2 diabetes;	chr6:7296479	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs2326900	ENSG00000238221.1	RP11-69L16.4	3.56	0.000403	0.0436	0.21	0.16	Type 2 diabetes;	chr6:7296514	chr6:7276031~7298872:+
HNSC	cis	rs72759215	1	rs72759215	ENSG00000251279.1	CTC-436P18.1	-3.56	0.000403	0.0436	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61056756	chr5:61162070~61232040:+
HNSC	cis	rs6732189	0.54	rs11682960	ENSG00000279844.1	RP11-20F18.1	3.56	0.000403	0.0436	0.16	0.16	Educational attainment;	chr2:160752165	chr2:160849313~160850676:-
HNSC	cis	rs17507216	0.628	rs28737193	ENSG00000252690.3	SCARNA15	3.56	0.000403	0.0436	0.16	0.16	Excessive daytime sleepiness;	chr15:82701318	chr15:82752884~82757208:+
HNSC	cis	rs4347184	1	rs6684621	ENSG00000248458.2	RP4-598P13.1	3.56	0.000403	0.0436	0.15	0.16	Schizophrenia;	chr1:65849767	chr1:66665864~66677027:-
HNSC	cis	rs7027203	0.595	rs4308796	ENSG00000227603.1	RP11-165J3.6	3.56	0.000403	0.0436	0.15	0.16	DNA methylation (variation);	chr9:93807883	chr9:93435332~93437121:-
HNSC	cis	rs1941184	0.759	rs7240892	ENSG00000266521.1	RP11-650P15.1	-3.56	0.000403	0.0436	-0.2	-0.16	Parkinson's disease (age of onset);	chr18:31449511	chr18:31496645~31497195:-
HNSC	cis	rs170183	0.934	rs13051987	ENSG00000230479.1	AP000695.6	-3.56	0.000403	0.0436	-0.17	-0.16	Bone mineral density;	chr21:36483676	chr21:36430360~36481070:+
HNSC	cis	rs801193	0.66	rs10950049	ENSG00000106610.13	STAG3L4	-3.56	0.000403	0.0436	-0.2	-0.16	Aortic root size;	chr7:66765873	chr7:67302621~67321526:+
HNSC	cis	rs6921919	0.789	rs6456814	ENSG00000227214.2	HCG15	3.56	0.000403	0.0436	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28986203~28987484:+
HNSC	cis	rs7015263	0.689	rs56039487	ENSG00000254231.1	CTD-2284J15.1	-3.56	0.000403	0.0436	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86347208	chr8:86333274~86343314:-
HNSC	cis	rs7015263	0.666	rs10956802	ENSG00000254231.1	CTD-2284J15.1	-3.56	0.000403	0.0436	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86350477	chr8:86333274~86343314:-
HNSC	cis	rs8030379	1	rs1564475	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs7183263	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs7178962	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs899926	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs8029387	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs940934	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.935	rs1815172	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1810049	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11853052	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000403	0.0436	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84507885~84516814:-
HNSC	cis	rs12047808	0.841	rs73036715	ENSG00000227141.2	RP11-545A16.3	-3.56	0.000403	0.0436	-0.24	-0.16	Multiple sclerosis (age of onset);	chr1:179448600	chr1:179586705~179589175:+
HNSC	cis	rs7824557	0.547	rs2409749	ENSG00000255495.1	AC145124.2	-3.56	0.000403	0.0436	-0.19	-0.16	Retinal vascular caliber;	chr8:11221440	chr8:12194467~12196280:+
HNSC	cis	rs7520050	0.966	rs12021587	ENSG00000280836.1	AL355480.1	3.56	0.000403	0.0436	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45581219~45581321:-
HNSC	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-3.56	0.000404	0.0436	-0.17	-0.16	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
HNSC	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-3.56	0.000404	0.0436	-0.17	-0.16	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
HNSC	cis	rs11168618	1	rs10875830	ENSG00000240399.1	RP1-228P16.1	3.56	0.000404	0.0436	0.14	0.16	Adiponectin levels;	chr12:48543727	chr12:48054813~48055591:-
HNSC	cis	rs10789207	0.531	rs72669475	ENSG00000248458.2	RP4-598P13.1	-3.56	0.000404	0.0436	-0.25	-0.16	Resting heart rate;	chr1:66664893	chr1:66665864~66677027:-
HNSC	cis	rs9859260	0.555	rs9877493	ENSG00000273013.1	CTD-2002J20.1	-3.56	0.000404	0.0436	-0.18	-0.16	Mean corpuscular volume;	chr3:196105276	chr3:196474801~196475394:+
HNSC	cis	rs7189233	0.911	rs72801854	ENSG00000279344.1	RP11-44F14.7	3.56	0.000404	0.0436	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53483330	chr16:53478957~53481550:-
HNSC	cis	rs4388249	1	rs2301005	ENSG00000271849.1	CTC-332L22.1	-3.56	0.000404	0.0436	-0.25	-0.16	Schizophrenia;	chr5:109786027	chr5:109687802~109688329:-
HNSC	cis	rs61160187	0.673	rs248912	ENSG00000215032.2	GNL3LP1	3.56	0.000404	0.0437	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60548252	chr5:60891935~60893577:-
HNSC	cis	rs2117029	0.555	rs9788139	ENSG00000258101.2	RP11-977B10.2	3.56	0.000404	0.0437	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49232790~49264756:-
HNSC	cis	rs2117029	0.619	rs2241727	ENSG00000258101.2	RP11-977B10.2	3.56	0.000404	0.0437	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49232790~49264756:-
HNSC	cis	rs6787172	0.622	rs2362965	ENSG00000272087.1	RP11-379F4.7	-3.56	0.000404	0.0437	-0.17	-0.16	Subjective well-being;	chr3:158391590	chr3:158693120~158693768:-
HNSC	cis	rs9911578	0.867	rs72628394	ENSG00000224738.1	AC099850.1	-3.56	0.000404	0.0437	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:59043952	chr17:59106598~59118267:+
HNSC	cis	rs7746199	0.736	rs13202291	ENSG00000226314.6	ZNF192P1	-3.56	0.000404	0.0437	-0.3	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28161781~28169594:+
HNSC	cis	rs7746199	0.736	rs17750424	ENSG00000226314.6	ZNF192P1	-3.56	0.000404	0.0437	-0.3	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28161781~28169594:+
HNSC	cis	rs2905347	0.965	rs2961272	ENSG00000232759.1	AC002480.3	3.56	0.000404	0.0437	0.18	0.16	Major depression and alcohol dependence;	chr7:22585117	chr7:22563337~22573996:+
HNSC	cis	rs7911264	0.739	rs6583827	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92598266	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs7096101	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92603171	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs10786050	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92607473	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs10882091	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92614620	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.703	rs7894183	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92622283	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs7071905	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92626365	chr10:92418667~92420875:+
HNSC	cis	rs7911264	0.739	rs10882094	ENSG00000232709.1	MARK2P9	-3.56	0.000404	0.0437	-0.18	-0.16	Inflammatory bowel disease;	chr10:92627919	chr10:92418667~92420875:+
HNSC	cis	rs6095360	0.565	rs6019518	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000404	0.0437	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:48914708	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.546	rs6019525	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000404	0.0437	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:48917419	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.546	rs8119308	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000404	0.0437	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:48918572	chr20:49040463~49046044:-
HNSC	cis	rs10073892	0.66	rs9327869	ENSG00000250682.4	LINC00491	-3.56	0.000404	0.0437	-0.23	-0.16	Cognitive decline (age-related);	chr5:102638877	chr5:102609156~102671559:-
HNSC	cis	rs870825	0.616	rs7681824	ENSG00000254233.1	RP11-242J7.1	3.56	0.000404	0.0437	0.24	0.16	Blood protein levels;	chr4:184696371	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs10013685	ENSG00000254233.1	RP11-242J7.1	3.56	0.000404	0.0437	0.24	0.16	Blood protein levels;	chr4:184696631	chr4:184584093~184625030:-
HNSC	cis	rs7221595	0.778	rs62072386	ENSG00000240898.1	RP11-48B14.1	-3.56	0.000404	0.0437	-0.18	-0.16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;	chr17:3992874	chr17:3665220~3665702:+
HNSC	cis	rs7592578	0.766	rs62182865	ENSG00000228509.4	AC006460.2	3.56	0.000404	0.0437	0.26	0.16	Diastolic blood pressure;	chr2:190569454	chr2:190676944~190708716:-
HNSC	cis	rs9297145	0.761	rs62473005	ENSG00000272950.1	RP11-307C18.1	-3.56	0.000404	0.0437	-0.25	-0.16	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99144887	chr7:98322853~98323430:+
HNSC	cis	rs7937890	0.531	rs2575828	ENSG00000254418.1	RP11-21L19.1	3.56	0.000404	0.0437	0.19	0.16	Mitochondrial DNA levels;	chr11:14462646	chr11:14262846~14273691:-
HNSC	cis	rs2403083	0.578	rs7823218	ENSG00000253549.4	RP11-317J10.2	3.56	0.000404	0.0437	0.19	0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85173662	chr8:85441851~85464915:-
HNSC	cis	rs2898681	1	rs4864690	ENSG00000248375.1	RP11-177B4.1	-3.56	0.000404	0.0437	-0.25	-0.16	Optic nerve measurement (cup area);	chr4:52884604	chr4:52720081~52720831:-
HNSC	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	3.56	0.000404	0.0437	0.21	0.16	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
HNSC	cis	rs113401313	0.529	rs4461968	ENSG00000213539.4	YBX1P6	3.56	0.000404	0.0437	0.28	0.16	CTACK levels;	chr9:109603952	chr9:109532830~109534332:-
HNSC	cis	rs2462686	0.93	rs2462687	ENSG00000234536.1	AC096582.7	3.56	0.000404	0.0437	0.17	0.16	Major depressive disorder;	chr7:45942707	chr7:45773595~45783157:+
HNSC	cis	rs6600671	1	rs4844380	ENSG00000272583.1	RP11-344P13.6	-3.56	0.000404	0.0437	-0.18	-0.16	Hip geometry;	chr1:121451764	chr1:121518366~121518829:-
HNSC	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	3.56	0.000405	0.0437	0.21	0.16	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
HNSC	cis	rs4648045	0.765	rs4699031	ENSG00000230069.3	LRRC37A15P	-3.56	0.000405	0.0437	-0.17	-0.16	Lymphocyte percentage of white cells;	chr4:102605271	chr4:102727274~102730721:-
HNSC	cis	rs4648045	0.796	rs3755867	ENSG00000230069.3	LRRC37A15P	-3.56	0.000405	0.0437	-0.17	-0.16	Lymphocyte percentage of white cells;	chr4:102605517	chr4:102727274~102730721:-
HNSC	cis	rs4388249	0.904	rs3776932	ENSG00000271849.1	CTC-332L22.1	-3.56	0.000405	0.0437	-0.25	-0.16	Schizophrenia;	chr5:109850287	chr5:109687802~109688329:-
HNSC	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-3.56	0.000405	0.0437	-0.19	-0.16	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
HNSC	cis	rs4906332	1	rs7155822	ENSG00000244691.1	RPL10AP1	-3.56	0.000405	0.0438	-0.19	-0.16	Coronary artery disease;	chr14:103456053	chr14:103412119~103412761:-
HNSC	cis	rs9910055	0.529	rs228764	ENSG00000267080.4	ASB16-AS1	3.56	0.000405	0.0438	0.13	0.16	Total body bone mineral density;	chr17:44108101	chr17:44175973~44186717:-
HNSC	cis	rs10129255	0.576	rs2157616	ENSG00000224373.3	IGHV4-59	3.56	0.000405	0.0438	0.09	0.16	Kawasaki disease;	chr14:106767802	chr14:106627249~106627825:-
HNSC	cis	rs853679	0.607	rs34396849	ENSG00000280107.1	AL022393.9	-3.56	0.000405	0.0438	-0.29	-0.16	Depression;	chr6:28283178	chr6:28170845~28172521:+
HNSC	cis	rs227275	0.556	rs10015289	ENSG00000248740.4	RP11-328K4.1	3.56	0.000405	0.0438	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:103256159~103453658:+
HNSC	cis	rs227275	0.556	rs6852141	ENSG00000248740.4	RP11-328K4.1	3.56	0.000405	0.0438	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:103256159~103453658:+
HNSC	cis	rs228614	0.509	rs4455415	ENSG00000248740.4	RP11-328K4.1	3.56	0.000405	0.0438	0.17	0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:103256159~103453658:+
HNSC	cis	rs227275	0.525	rs6853193	ENSG00000248740.4	RP11-328K4.1	3.56	0.000405	0.0438	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:103256159~103453658:+
HNSC	cis	rs12935418	0.83	rs7195459	ENSG00000278985.1	RP11-303E16.9	3.56	0.000405	0.0438	0.2	0.16	Mean corpuscular volume;	chr16:81016376	chr16:80982319~80984094:-
HNSC	cis	rs2436845	1	rs2679756	ENSG00000253669.3	KB-1732A1.1	-3.56	0.000405	0.0438	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858241	chr8:102805517~102809971:+
HNSC	cis	rs2436845	1	rs2679757	ENSG00000253669.3	KB-1732A1.1	-3.56	0.000405	0.0438	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858590	chr8:102805517~102809971:+
HNSC	cis	rs7475343	0.573	rs2226260	ENSG00000224034.1	RP11-445P17.8	3.56	0.000405	0.0438	0.21	0.16	Intelligence;	chr10:5117405	chr10:5266033~5271236:-
HNSC	cis	rs728616	0.51	rs7074356	ENSG00000225484.5	NUTM2B-AS1	-3.56	0.000405	0.0438	-0.26	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:79663088~79826594:-
HNSC	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-3.56	0.000405	0.0438	-0.17	-0.16	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
HNSC	cis	rs35740288	0.822	rs1961601	ENSG00000259407.1	RP11-158M2.3	-3.56	0.000405	0.0438	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85744109~85750281:-
HNSC	cis	rs35740288	0.787	rs727379	ENSG00000259407.1	RP11-158M2.3	-3.56	0.000405	0.0438	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85744109~85750281:-
HNSC	cis	rs34286592	1	rs34127220	ENSG00000214725.6	CDIPT-AS1	-3.56	0.000405	0.0438	-0.23	-0.16	Multiple sclerosis;	chr16:29831570	chr16:29863593~29868053:+
HNSC	cis	rs66887589	0.934	rs6817317	ENSG00000249244.1	RP11-548H18.2	-3.56	0.000405	0.0438	-0.18	-0.16	Diastolic blood pressure;	chr4:119621672	chr4:119391831~119395335:-
HNSC	cis	rs66887589	0.934	rs7672519	ENSG00000249244.1	RP11-548H18.2	-3.56	0.000405	0.0438	-0.18	-0.16	Diastolic blood pressure;	chr4:119622957	chr4:119391831~119395335:-
HNSC	cis	rs240993	0.81	rs466765	ENSG00000230177.1	RP5-1112D6.4	-3.56	0.000405	0.0438	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111347291	chr6:111277932~111278742:+
HNSC	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000405	0.0438	-0.19	-0.16	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
HNSC	cis	rs6995541	0.505	rs7013032	ENSG00000269918.1	AF131215.9	-3.56	0.000405	0.0438	-0.17	-0.16	Triglyceride levels;	chr8:10848849	chr8:11104691~11106704:-
HNSC	cis	rs2153535	0.561	rs9405407	ENSG00000230939.1	RP11-314C16.1	-3.56	0.000406	0.0438	-0.19	-0.16	Motion sickness;	chr6:8665199	chr6:8784178~8785445:+
HNSC	cis	rs2153535	0.585	rs9378566	ENSG00000230939.1	RP11-314C16.1	-3.56	0.000406	0.0438	-0.19	-0.16	Motion sickness;	chr6:8665203	chr6:8784178~8785445:+
HNSC	cis	rs2919009	0.664	rs7906521	ENSG00000271670.1	RP11-95I16.4	3.56	0.000406	0.0438	0.2	0.16	Obesity-related traits;	chr10:120927034	chr10:120879256~120880667:-
HNSC	cis	rs4835473	0.831	rs1579816	ENSG00000249741.2	RP11-673E1.3	-3.56	0.000406	0.0438	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143866772	chr4:143911514~143912053:-
HNSC	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	3.56	0.000406	0.0438	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	3.56	0.000406	0.0438	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	3.56	0.000406	0.0438	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
HNSC	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	3.56	0.000406	0.0438	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
HNSC	cis	rs853679	0.607	rs66868086	ENSG00000241549.7	GUSBP2	3.56	0.000406	0.0438	0.27	0.16	Depression;	chr6:27898124	chr6:26871484~26956554:-
HNSC	cis	rs853679	0.607	rs13199649	ENSG00000241549.7	GUSBP2	3.56	0.000406	0.0438	0.27	0.16	Depression;	chr6:27901014	chr6:26871484~26956554:-
HNSC	cis	rs7726839	0.794	rs11739663	ENSG00000225138.6	CTD-2228K2.7	3.56	0.000406	0.0438	0.22	0.16	Obesity-related traits;	chr5:593968	chr5:473236~480884:+
HNSC	cis	rs11722779	0.935	rs3857200	ENSG00000248740.4	RP11-328K4.1	3.56	0.000406	0.0438	0.17	0.16	Schizophrenia;	chr4:103001864	chr4:103256159~103453658:+
HNSC	cis	rs11098499	0.866	rs10518329	ENSG00000250412.1	KLHL2P1	3.56	0.000406	0.0438	0.2	0.16	Corneal astigmatism;	chr4:119480680	chr4:119334329~119378233:+
HNSC	cis	rs11587682	0.714	rs35699789	ENSG00000236713.1	RP11-363I22.3	3.56	0.000406	0.0438	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150469624	chr1:150780272~150780644:+
HNSC	cis	rs7274811	0.681	rs293733	ENSG00000277301.1	RP5-1184F4.7	-3.56	0.000406	0.0438	-0.16	-0.16	Height;	chr20:33388170	chr20:32509959~32520285:+
HNSC	cis	rs6088580	0.634	rs11700221	ENSG00000276073.1	RP5-1125A11.7	3.56	0.000406	0.0438	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:33985617~33988989:-
HNSC	cis	rs62025270	0.632	rs62023935	ENSG00000259762.1	RP11-158M2.4	-3.56	0.000406	0.0439	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85750336~85752901:-
HNSC	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000406	0.0439	-0.21	-0.16	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
HNSC	cis	rs7674212	0.531	rs4699048	ENSG00000248740.4	RP11-328K4.1	3.56	0.000406	0.0439	0.17	0.16	Type 2 diabetes;	chr4:103005570	chr4:103256159~103453658:+
HNSC	cis	rs6088580	0.634	rs2378134	ENSG00000276073.1	RP5-1125A11.7	3.56	0.000406	0.0439	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:33985617~33988989:-
HNSC	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000406	0.0439	-0.2	-0.16	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
HNSC	cis	rs28472312	0.823	rs62037373	ENSG00000259982.1	CDC37P1	3.56	0.000406	0.0439	0.19	0.16	Intelligence (multi-trait analysis);	chr16:28881974	chr16:28700294~28701540:-
HNSC	cis	rs860295	0.58	rs10908483	ENSG00000203761.5	MSTO2P	-3.56	0.000406	0.0439	-0.13	-0.16	Body mass index;	chr1:155897043	chr1:155745829~155750137:+
HNSC	cis	rs16935110	1	rs4737917	ENSG00000254337.1	RP11-865I6.2	3.56	0.000406	0.0439	0.23	0.16	Obesity-related traits;	chr8:68823812	chr8:68848742~68852763:-
HNSC	cis	rs1155750	0.72	rs9475077	ENSG00000224984.1	RP11-524H19.2	3.56	0.000406	0.0439	0.23	0.16	Colorectal cancer;	chr6:54941691	chr6:54840118~54840855:-
HNSC	cis	rs9487051	0.768	rs9398188	ENSG00000243587.6	C6orf183	-3.56	0.000406	0.0439	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109205412	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.768	rs1766814	ENSG00000243587.6	C6orf183	-3.56	0.000406	0.0439	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109205493	chr6:109165833~109271014:+
HNSC	cis	rs227275	0.556	rs11731885	ENSG00000248740.4	RP11-328K4.1	3.56	0.000406	0.0439	0.17	0.16	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:103256159~103453658:+
HNSC	cis	rs7429990	0.833	rs883661	ENSG00000228638.1	FCF1P2	3.56	0.000406	0.0439	0.15	0.16	Educational attainment (years of education);	chr3:47618611	chr3:48290793~48291375:-
HNSC	cis	rs1440410	0.798	rs13128884	ENSG00000250326.1	RP11-284M14.1	-3.56	0.000406	0.0439	-0.18	-0.16	Ischemic stroke;	chr4:143186669	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs10029373	ENSG00000250326.1	RP11-284M14.1	-3.56	0.000406	0.0439	-0.18	-0.16	Ischemic stroke;	chr4:143208965	chr4:142933195~143184861:-
HNSC	cis	rs2439831	0.702	rs495175	ENSG00000275601.1	AC011330.13	-3.56	0.000406	0.0439	-0.26	-0.16	Lung cancer in ever smokers;	chr15:43506486	chr15:43642389~43643023:-
HNSC	cis	rs2243480	0.522	rs778717	ENSG00000229886.1	RP5-1132H15.3	3.56	0.000407	0.0439	0.34	0.16	Diabetic kidney disease;	chr7:66383164	chr7:66025126~66031544:-
HNSC	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	3.56	0.000407	0.0439	0.25	0.16	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
HNSC	cis	rs17321999	0.909	rs17009315	ENSG00000235997.2	AC109642.1	-3.56	0.000407	0.0439	-0.21	-0.16	Systemic lupus erythematosus;	chr2:30268526	chr2:30346659~30352431:+
HNSC	cis	rs860295	0.529	rs1475766	ENSG00000246203.2	RP11-29H23.5	3.56	0.000407	0.0439	0.18	0.16	Body mass index;	chr1:156011698	chr1:155614726~155660245:-
HNSC	cis	rs6918586	0.658	rs198844	ENSG00000272810.1	U91328.22	-3.56	0.000407	0.0439	-0.14	-0.16	Schizophrenia;	chr6:26108054	chr6:26013241~26013757:+
HNSC	cis	rs11250098	0.548	rs7837038	ENSG00000255310.2	AF131215.2	-3.56	0.000407	0.0439	-0.15	-0.16	Morning vs. evening chronotype;	chr8:10925564	chr8:11107788~11109726:-
HNSC	cis	rs2762353	0.935	rs2817188	ENSG00000272462.2	U91328.19	-3.56	0.000407	0.0439	-0.16	-0.16	Blood metabolite levels;	chr6:25807375	chr6:25992662~26001775:+
HNSC	cis	rs9934948	1	rs12597270	ENSG00000197445.2	C16orf47	3.56	0.000407	0.0439	0.29	0.16	Breast cancer (survival);	chr16:73406042	chr16:73126637~73144447:-
HNSC	cis	rs916888	0.61	rs199529	ENSG00000260075.1	NSFP1	-3.56	0.000407	0.0439	-0.22	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46372855~46487141:+
HNSC	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-3.56	0.000407	0.0439	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
HNSC	cis	rs13098911	0.54	rs17215981	ENSG00000223552.1	RP11-24F11.2	3.56	0.000407	0.0439	0.25	0.16	Celiac disease;	chr3:46082926	chr3:46364955~46407059:-
HNSC	cis	rs6558174	0.93	rs1038311	ENSG00000253837.1	RP11-177H13.2	-3.56	0.000407	0.0439	-0.17	-0.16	Breast cancer;	chr8:22631734	chr8:23336171~23366125:+
HNSC	cis	rs7837791	0.62	rs4237030	ENSG00000167912.5	RP11-25K19.1	-3.56	0.000407	0.0439	-0.18	-0.16	Refractive error;	chr8:59239001	chr8:59119040~59121346:+
HNSC	cis	rs62025270	0.632	rs55981798	ENSG00000259762.1	RP11-158M2.4	-3.56	0.000407	0.0439	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.576	rs17633959	ENSG00000259762.1	RP11-158M2.4	-3.56	0.000407	0.0439	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85750336~85752901:-
HNSC	cis	rs62025270	0.688	rs7182210	ENSG00000259762.1	RP11-158M2.4	-3.56	0.000407	0.0439	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85750336~85752901:-
HNSC	cis	rs853679	0.55	rs34477097	ENSG00000226314.6	ZNF192P1	-3.56	0.000407	0.0439	-0.2	-0.16	Depression;	chr6:28229408	chr6:28161781~28169594:+
HNSC	cis	rs1662342	1	rs12606445	ENSG00000272625.1	RP11-737O24.5	-3.56	0.000407	0.0439	-0.27	-0.16	QRS duration;	chr18:3255702	chr18:2920966~2921685:+
HNSC	cis	rs4948102	0.691	rs10435504	ENSG00000213650.3	RP11-760D2.7	3.56	0.000407	0.0439	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr7:56567906~56568858:-
HNSC	cis	rs4948102	0.653	rs6593294	ENSG00000213650.3	RP11-760D2.7	3.56	0.000407	0.0439	0.18	0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr7:56567906~56568858:-
HNSC	cis	rs11671005	0.735	rs3088284	ENSG00000269473.1	CTD-2619J13.19	3.56	0.000407	0.0439	0.26	0.16	Mean platelet volume;	chr19:58418060	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs12981649	ENSG00000269473.1	CTD-2619J13.19	3.56	0.000407	0.0439	0.26	0.16	Mean platelet volume;	chr19:58418676	chr19:58440448~58445849:+
HNSC	cis	rs12234571	1	rs11971037	ENSG00000214293.7	APTR	3.56	0.000407	0.0439	0.21	0.16	Obesity-related traits;	chr7:77948368	chr7:77657660~77696265:-
HNSC	cis	rs9393777	0.588	rs6456728	ENSG00000241549.7	GUSBP2	3.56	0.000407	0.0439	0.19	0.16	Intelligence (multi-trait analysis);	chr6:26477551	chr6:26871484~26956554:-
HNSC	cis	rs4704187	0.649	rs1422701	ENSG00000272040.1	CTC-366B18.4	-3.56	0.000407	0.0439	-0.15	-0.16	Response to amphetamines;	chr5:75214692	chr5:75608817~75609983:+
HNSC	cis	rs7200786	0.565	rs10852330	ENSG00000274038.1	RP11-66H6.4	-3.56	0.000407	0.044	-0.21	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11122201	chr16:11056556~11057034:+
HNSC	cis	rs2307394	1	rs13033664	ENSG00000281469.1	RP11-567F11.1	3.56	0.000407	0.044	0.18	0.16	Urate levels;	chr2:148012705	chr2:148044380~148044894:+
HNSC	cis	rs6869502	0.505	rs2443511	ENSG00000214784.4	AC010468.1	-3.56	0.000407	0.044	-0.17	-0.16	Allergic disease (asthma, hay fever or eczema);	chr5:110706424	chr5:111192226~111193042:-
HNSC	cis	rs7520050	0.966	rs785471	ENSG00000280836.1	AL355480.1	3.56	0.000407	0.044	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs1707321	ENSG00000280836.1	AL355480.1	3.56	0.000407	0.044	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45581219~45581321:-
HNSC	cis	rs2310173	0.69	rs11888059	ENSG00000281162.1	LINC01127	-3.56	0.000407	0.044	-0.21	-0.16	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102048625	chr2:101962056~101987167:+
HNSC	cis	rs13256369	0.802	rs34762800	ENSG00000254153.1	CTA-398F10.2	3.56	0.000407	0.044	0.21	0.16	Obesity-related traits;	chr8:8701784	chr8:8456909~8461337:-
HNSC	cis	rs2834512	0.673	rs60084578	ENSG00000214955.5	AP000318.2	3.56	0.000407	0.044	0.28	0.16	Cancer;	chr21:34534391	chr21:34205055~34325034:+
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000226314.6	ZNF192P1	-3.56	0.000407	0.044	-0.18	-0.16	Depression;	chr6:28430971	chr6:28161781~28169594:+
HNSC	cis	rs72827839	1	rs17696392	ENSG00000244649.3	CTD-2377D24.6	3.56	0.000407	0.044	0.24	0.16	Ease of getting up in the morning;	chr17:48349798	chr17:48646923~48707346:+
HNSC	cis	rs3771570	1	rs62186422	ENSG00000260942.1	CAPN10-AS1	-3.56	0.000407	0.044	-0.18	-0.16	Prostate cancer;	chr2:241310084	chr2:240582700~240586699:-
HNSC	cis	rs34421088	0.532	rs2736385	ENSG00000269918.1	AF131215.9	3.56	0.000408	0.044	0.17	0.16	Neuroticism;	chr8:11291104	chr8:11104691~11106704:-
HNSC	cis	rs2310173	0.898	rs4851533	ENSG00000281162.1	LINC01127	-3.56	0.000408	0.044	-0.21	-0.16	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102035208	chr2:101962056~101987167:+
HNSC	cis	rs58785573	0.513	rs6531651	ENSG00000231160.8	KLF3-AS1	3.56	0.000408	0.044	0.15	0.16	Lymphocyte percentage of white cells;	chr4:38590803	chr4:38612701~38664883:-
HNSC	cis	rs9487051	0.837	rs2356817	ENSG00000219700.1	PTCHD3P3	3.56	0.000408	0.044	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109321472	chr6:109288571~109290503:-
HNSC	cis	rs870825	0.616	rs7682677	ENSG00000254233.1	RP11-242J7.1	3.56	0.000408	0.044	0.24	0.16	Blood protein levels;	chr4:184719563	chr4:184584093~184625030:-
HNSC	cis	rs12234571	1	rs78163487	ENSG00000214293.7	APTR	3.56	0.000408	0.044	0.21	0.16	Obesity-related traits;	chr7:77901796	chr7:77657660~77696265:-
HNSC	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-3.56	0.000408	0.044	-0.18	-0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
HNSC	cis	rs11247230	0.901	rs2411841	ENSG00000270127.2	RP11-526I2.5	3.56	0.000408	0.044	0.17	0.16	Optic cup area;	chr15:100652046	chr15:100547765~100550153:-
HNSC	cis	rs28830936	1	rs2577960	ENSG00000250379.1	RP11-23P13.4	-3.56	0.000408	0.044	-0.2	-0.16	Diastolic blood pressure;	chr15:41736156	chr15:41825099~41827936:-
HNSC	cis	rs6968419	0.755	rs2402057	ENSG00000237870.5	AC073130.1	-3.56	0.000408	0.044	-0.2	-0.16	Intraocular pressure;	chr7:116257042	chr7:116275606~116286734:-
HNSC	cis	rs1298062	0.535	rs2463240	ENSG00000269495.1	CTB-147C22.8	3.56	0.000408	0.044	0.15	0.16	Age of smoking initiation;	chr19:50438648	chr19:50950185~50963649:+
HNSC	cis	rs6141600	0.627	rs6142512	ENSG00000199676.1	Y_RNA	3.56	0.000408	0.044	0.26	0.16	Height;Hip circumference;	chr20:36127515	chr20:35853252~35853364:-
HNSC	cis	rs6570726	0.791	rs1509214	ENSG00000270638.1	RP3-466P17.1	-3.56	0.000408	0.044	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145735570~145737218:+
HNSC	cis	rs17221829	0.702	rs12360859	ENSG00000280385.1	AP000648.5	-3.56	0.000408	0.044	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89626719	chr11:90193614~90198120:+
HNSC	cis	rs1485395	0.836	rs10444558	ENSG00000270175.1	RP11-793H13.11	-3.56	0.000408	0.044	-0.2	-0.16	Migraine without aura;	chr12:53661701	chr12:53500162~53500936:-
HNSC	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	3.56	0.000408	0.044	0.14	0.16	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
HNSC	cis	rs7615952	0.515	rs4267608	ENSG00000248787.1	RP11-666A20.4	-3.56	0.000408	0.044	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:125961657	chr3:125908005~125910272:-
HNSC	cis	rs734999	0.545	rs28568531	ENSG00000238164.5	RP3-395M20.8	-3.56	0.000408	0.044	-0.12	-0.16	Ulcerative colitis;	chr1:2624201	chr1:2549920~2557031:-
HNSC	cis	rs2468186	0.524	rs2450064	ENSG00000279347.1	RP11-85I17.2	-3.56	0.000408	0.044	-0.14	-0.16	Osteoprotegerin levels;	chr8:119084905	chr8:119838736~119840385:-
HNSC	cis	rs4787491	0.729	rs4238960	ENSG00000250616.2	RP11-455F5.3	3.56	0.000408	0.044	0.16	0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30096430~30104116:+
HNSC	cis	rs7572733	0.555	rs6434954	ENSG00000231621.1	AC013264.2	-3.56	0.000408	0.044	-0.16	-0.16	Dermatomyositis;	chr2:198064992	chr2:197197991~197199273:+
HNSC	cis	rs6493858	0.572	rs7183363	ENSG00000277245.1	RP11-48G14.3	-3.56	0.000408	0.044	-0.18	-0.16	Relative hand skill in reading disability;	chr15:56075298	chr15:56447120~56447697:+
HNSC	cis	rs72772090	0.634	rs12186366	ENSG00000249180.1	CTC-506B8.1	-3.56	0.000408	0.044	-0.24	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96741079~96742698:-
HNSC	cis	rs7429990	1	rs7429990	ENSG00000228638.1	FCF1P2	-3.56	0.000408	0.044	-0.16	-0.16	Educational attainment (years of education);	chr3:47860313	chr3:48290793~48291375:-
HNSC	cis	rs2877187	0.576	rs887060	ENSG00000232006.7	AC005537.2	-3.56	0.000408	0.044	-0.18	-0.16	Lung cancer in ever smokers;	chr7:43017799	chr7:42954135~43113931:-
HNSC	cis	rs2638953	0.85	rs10843167	ENSG00000257176.2	RP11-996F15.2	3.56	0.000408	0.0441	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:29280418~29317848:-
HNSC	cis	rs853679	0.599	rs156743	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000408	0.0441	-0.27	-0.16	Depression;	chr6:27999311	chr6:28115628~28116551:+
HNSC	cis	rs4256159	0.696	rs6808463	ENSG00000228956.7	SATB1-AS1	3.56	0.000408	0.0441	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18713853	chr3:18445024~18920401:+
HNSC	cis	rs4256159	0.696	rs6767892	ENSG00000228956.7	SATB1-AS1	3.56	0.000408	0.0441	0.23	0.16	Crohn's disease;Inflammatory bowel disease;	chr3:18713856	chr3:18445024~18920401:+
HNSC	cis	rs3805389	0.504	rs17725163	ENSG00000249700.7	SRD5A3-AS1	3.56	0.000409	0.0441	0.24	0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55363971~55395847:-
HNSC	cis	rs2991971	0.81	rs998199	ENSG00000234329.1	RP11-767N6.2	3.56	0.000409	0.0441	0.17	0.16	High light scatter reticulocyte count;	chr1:45447226	chr1:45651039~45651826:-
HNSC	cis	rs6449502	0.748	rs10062839	ENSG00000251279.1	CTC-436P18.1	-3.56	0.000409	0.0441	-0.23	-0.16	Mean platelet volume;	chr5:60807625	chr5:61162070~61232040:+
HNSC	cis	rs6088580	0.634	rs6059851	ENSG00000276073.1	RP5-1125A11.7	-3.56	0.000409	0.0441	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:33985617~33988989:-
HNSC	cis	rs594074	0.951	rs581403	ENSG00000225092.2	RP11-405O10.2	3.56	0.000409	0.0441	0.22	0.16	Diabetic kidney disease;	chr6:6555887	chr6:7183083~7185287:+
HNSC	cis	rs860295	0.812	rs2297775	ENSG00000225855.5	RUSC1-AS1	-3.56	0.000409	0.0441	-0.11	-0.16	Body mass index;	chr1:155765221	chr1:155316863~155324176:-
HNSC	cis	rs61160187	0.582	rs2049579	ENSG00000251279.1	CTC-436P18.1	-3.56	0.000409	0.0441	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:61162070~61232040:+
HNSC	cis	rs6710503	0.632	rs28744588	ENSG00000271936.1	RP11-443B20.1	-3.56	0.000409	0.0441	-0.2	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24735344	chr2:24825610~24826717:+
HNSC	cis	rs6095360	1	rs3092427	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000409	0.0441	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49158244	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.933	rs348267	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000409	0.0441	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49159384	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs2426139	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000409	0.0441	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49163568	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs348276	ENSG00000227431.4	CSE1L-AS1	-3.56	0.000409	0.0441	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49169653	chr20:49040463~49046044:-
HNSC	cis	rs4517514	0.509	rs4385851	ENSG00000280385.1	AP000648.5	3.56	0.000409	0.0441	0.28	0.16	Trans fatty acid levels;	chr11:90137582	chr11:90193614~90198120:+
HNSC	cis	rs4517514	0.509	rs10830417	ENSG00000280385.1	AP000648.5	3.56	0.000409	0.0441	0.28	0.16	Trans fatty acid levels;	chr11:90138772	chr11:90193614~90198120:+
HNSC	cis	rs8028182	0.636	rs4299117	ENSG00000275645.1	RP11-817O13.9	3.56	0.000409	0.0441	0.17	0.16	Sudden cardiac arrest;	chr15:75497103	chr15:75346744~75347161:-
HNSC	cis	rs948562	0.744	rs11229468	ENSG00000280010.1	AP001350.4	3.56	0.000409	0.0441	0.26	0.16	Lymphoma;	chr11:58451300	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.744	rs113392266	ENSG00000280010.1	AP001350.4	3.56	0.000409	0.0441	0.26	0.16	Lymphoma;	chr11:58452278	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.744	rs74406537	ENSG00000280010.1	AP001350.4	3.56	0.000409	0.0441	0.26	0.16	Lymphoma;	chr11:58452887	chr11:58627435~58628528:+
HNSC	cis	rs9914544	0.545	rs12452289	ENSG00000264885.1	RP11-815I9.4	-3.56	0.000409	0.0441	-0.17	-0.16	Educational attainment (years of education);	chr17:18878496	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs35911764	ENSG00000264885.1	RP11-815I9.4	-3.56	0.000409	0.0441	-0.17	-0.16	Educational attainment (years of education);	chr17:18879269	chr17:18667629~18669461:-
HNSC	cis	rs12545912	0.909	rs10903315	ENSG00000233609.3	RP11-62H7.2	-3.56	0.000409	0.0441	-0.18	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9626411	chr8:8961200~8979025:+
HNSC	cis	rs12699921	0.599	rs6973480	ENSG00000279048.1	RP11-511H23.2	3.56	0.000409	0.0441	0.13	0.16	Fibrinogen levels;	chr7:17938506	chr7:17940503~17942922:+
HNSC	cis	rs268134	0.53	rs874952	ENSG00000235725.1	AC007389.3	-3.56	0.000409	0.0441	-0.29	-0.16	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65381391	chr2:65589566~65640177:-
HNSC	cis	rs11846409	0.587	rs1806881	ENSG00000280411.1	IGHV1-69-2	3.56	0.000409	0.0441	0.15	0.16	Rheumatic heart disease;	chr14:106650770	chr14:106762092~106762588:-
HNSC	cis	rs526231	0.511	rs158402	ENSG00000250682.4	LINC00491	3.56	0.000409	0.0441	0.21	0.16	Primary biliary cholangitis;	chr5:103079821	chr5:102609156~102671559:-
HNSC	cis	rs2299587	0.585	rs379167	ENSG00000253671.1	RP11-806O11.1	-3.56	0.000409	0.0441	-0.18	-0.16	Economic and political preferences;	chr8:17921415	chr8:17808941~17820868:+
HNSC	cis	rs3812049	0.506	rs36694	ENSG00000245937.6	LINC01184	3.56	0.000409	0.0441	0.21	0.16	Lymphocyte counts;Red cell distribution width;	chr5:128213263	chr5:127940426~128083172:-
HNSC	cis	rs73201462	0.808	rs34689870	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141636	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs34817706	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128142215	chr3:128861313~128871540:-
HNSC	cis	rs6800225	1	rs6800225	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128143335	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2687723	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128146716	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs73192978	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149432	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs73192979	ENSG00000231305.3	RP11-723O4.2	-3.56	0.00041	0.0441	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149478	chr3:128861313~128871540:-
HNSC	cis	rs8077577	0.562	rs8081042	ENSG00000273018.4	CTD-2303H24.2	-3.56	0.00041	0.0441	-0.24	-0.16	Obesity-related traits;	chr17:18295753	chr17:18511221~18551705:-
HNSC	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	3.56	0.00041	0.0441	0.19	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
HNSC	cis	rs6554196	0.932	rs2282780	ENSG00000272650.1	RP11-571I18.4	-3.56	0.00041	0.0442	-0.2	-0.16	Monocyte count;	chr4:54667385	chr4:53997415~53997712:-
HNSC	cis	rs6554196	0.932	rs2282779	ENSG00000272650.1	RP11-571I18.4	-3.56	0.00041	0.0442	-0.2	-0.16	Monocyte count;	chr4:54667417	chr4:53997415~53997712:-
HNSC	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	3.56	0.00041	0.0442	0.16	0.16	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
HNSC	cis	rs189798	0.738	rs330908	ENSG00000253981.4	ALG1L13P	3.56	0.00041	0.0442	0.19	0.16	Myopia (pathological);	chr8:9137656	chr8:8236003~8244667:-
HNSC	cis	rs116095464	0.558	rs6555055	ENSG00000277812.1	AC021087.1	3.56	0.00041	0.0442	0.27	0.16	Breast cancer;	chr5:226045	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6555056	ENSG00000277812.1	AC021087.1	3.56	0.00041	0.0442	0.27	0.16	Breast cancer;	chr5:226107	chr5:262769~262881:+
HNSC	cis	rs734999	0.566	rs10797435	ENSG00000238164.5	RP3-395M20.8	-3.56	0.00041	0.0442	-0.12	-0.16	Ulcerative colitis;	chr1:2603362	chr1:2549920~2557031:-
HNSC	cis	rs11853189	0.938	rs75281351	ENSG00000259562.2	RP11-762H8.2	3.56	0.00041	0.0442	0.2	0.16	Red cell distribution width;	chr15:78287308	chr15:78290527~78291221:-
HNSC	cis	rs13108904	0.935	rs6853002	ENSG00000272588.1	RP11-440L14.4	3.56	0.00041	0.0442	0.17	0.16	Obesity-related traits;	chr4:1302203	chr4:757022~757740:-
HNSC	cis	rs72827839	1	rs72827839	ENSG00000244649.3	CTD-2377D24.6	-3.56	0.00041	0.0442	-0.25	-0.16	Ease of getting up in the morning;	chr17:48343634	chr17:48646923~48707346:+
HNSC	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	3.56	0.00041	0.0442	0.16	0.16	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
HNSC	cis	rs6499755	0.712	rs31087	ENSG00000260135.5	RP11-212I21.2	-3.56	0.00041	0.0442	-0.18	-0.16	Hypospadias;	chr16:55329326	chr16:55426797~55462297:-
HNSC	cis	rs7011507	0.617	rs7816648	ENSG00000253608.1	RP11-770E5.1	-3.56	0.00041	0.0442	-0.24	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48406643	chr8:48551567~48698510:+
HNSC	cis	rs2243480	1	rs1723267	ENSG00000226002.1	RP11-460N20.5	-3.56	0.00041	0.0442	-0.28	-0.16	Diabetic kidney disease;	chr7:66008327	chr7:65084103~65100232:+
HNSC	cis	rs57221529	0.766	rs72703070	ENSG00000225138.6	CTD-2228K2.7	3.56	0.00041	0.0442	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:473236~480884:+
HNSC	cis	rs57221529	0.713	rs72703072	ENSG00000225138.6	CTD-2228K2.7	3.56	0.00041	0.0442	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:473236~480884:+
HNSC	cis	rs57221529	0.713	rs12522724	ENSG00000225138.6	CTD-2228K2.7	3.56	0.00041	0.0442	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:473236~480884:+
HNSC	cis	rs7189233	0.955	rs8044205	ENSG00000279344.1	RP11-44F14.7	3.56	0.00041	0.0442	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53481181	chr16:53478957~53481550:-
HNSC	cis	rs7189233	0.955	rs8058684	ENSG00000279344.1	RP11-44F14.7	3.56	0.00041	0.0442	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53481206	chr16:53478957~53481550:-
HNSC	cis	rs3929778	0.883	rs6054337	ENSG00000278192.1	RP5-1056H1.2	-3.56	0.00041	0.0442	-0.22	-0.16	QRS complex (Cornell);	chr20:6553992	chr20:6065966~6067897:-
HNSC	cis	rs3735485	0.738	rs10280402	ENSG00000232956.7	SNHG15	-3.56	0.00041	0.0442	-0.19	-0.16	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45049419	chr7:44983023~44986961:-
HNSC	cis	rs2842169	0.908	rs1025642	ENSG00000224023.9	FLJ37035	3.56	0.00041	0.0442	0.26	0.16	Response to radiotherapy in prostate cancer (overall toxicity);	chr10:126618531	chr10:125700436~125719566:-
HNSC	cis	rs1440410	0.798	rs10002867	ENSG00000250326.1	RP11-284M14.1	-3.56	0.00041	0.0442	-0.18	-0.16	Ischemic stroke;	chr4:143248497	chr4:142933195~143184861:-
HNSC	cis	rs870825	0.616	rs1401359	ENSG00000254233.1	RP11-242J7.1	3.56	0.00041	0.0442	0.24	0.16	Blood protein levels;	chr4:184719062	chr4:184584093~184625030:-
HNSC	cis	rs9297145	0.761	rs12534399	ENSG00000272950.1	RP11-307C18.1	-3.56	0.00041	0.0442	-0.25	-0.16	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99148778	chr7:98322853~98323430:+
HNSC	cis	rs5758659	0.714	rs133373	ENSG00000270083.1	RP1-257I20.14	3.56	0.00041	0.0442	0.15	0.16	Cognitive function;	chr22:42069784	chr22:42089630~42090028:-
HNSC	cis	rs6499755	0.712	rs31090	ENSG00000260135.5	RP11-212I21.2	-3.56	0.00041	0.0442	-0.18	-0.16	Hypospadias;	chr16:55329716	chr16:55426797~55462297:-
HNSC	cis	rs6499755	0.712	rs31091	ENSG00000260135.5	RP11-212I21.2	-3.56	0.00041	0.0442	-0.18	-0.16	Hypospadias;	chr16:55329906	chr16:55426797~55462297:-
HNSC	cis	rs13179617	0.928	rs1348716	ENSG00000215032.2	GNL3LP1	-3.56	0.00041	0.0442	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61451158	chr5:60891935~60893577:-
HNSC	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-3.56	0.00041	0.0442	-0.17	-0.16	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-3.56	0.00041	0.0442	-0.17	-0.16	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
HNSC	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-3.56	0.00041	0.0442	-0.17	-0.16	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
HNSC	cis	rs9329221	0.508	rs6601455	ENSG00000255310.2	AF131215.2	3.56	0.00041	0.0442	0.16	0.16	Neuroticism;	chr8:10415916	chr8:11107788~11109726:-
HNSC	cis	rs17489649	0.915	rs759809	ENSG00000271849.1	CTC-332L22.1	3.56	0.00041	0.0442	0.21	0.16	Intelligence (multi-trait analysis);	chr5:109830083	chr5:109687802~109688329:-
HNSC	cis	rs1832007	0.529	rs7085249	ENSG00000224034.1	RP11-445P17.8	-3.56	0.00041	0.0442	-0.19	-0.16	Triglyceride levels;Triglycerides;	chr10:5201054	chr10:5266033~5271236:-
HNSC	cis	rs73191547	0.501	rs6986885	ENSG00000255310.2	AF131215.2	3.56	0.000411	0.0442	0.15	0.16	Schizophrenia;	chr8:10120961	chr8:11107788~11109726:-
HNSC	cis	rs6840258	0.8	rs6839933	ENSG00000251411.1	RP11-397E7.4	-3.56	0.000411	0.0442	-0.19	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043211	chr4:86913266~86914817:-
HNSC	cis	rs5758511	0.679	rs55867855	ENSG00000227370.1	RP4-669P10.19	3.56	0.000411	0.0442	0.2	0.16	Birth weight;	chr22:42227252	chr22:42132543~42132998:+
HNSC	cis	rs2562456	0.752	rs279809	ENSG00000268081.1	RP11-678G14.2	3.56	0.000411	0.0442	0.24	0.16	Pain;	chr19:21284729	chr19:21554640~21569237:-
HNSC	cis	rs9302065	1	rs9302065	ENSG00000223298.1	RNY3P8	-3.56	0.000411	0.0442	-0.16	-0.16	Blood metabolite levels;	chr13:95318762	chr13:95310830~95310955:-
HNSC	cis	rs9437689	1	rs9437813	ENSG00000237416.5	RP11-465K1.2	-3.56	0.000411	0.0443	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95084357	chr1:94836748~94855426:-
HNSC	cis	rs9437689	1	rs4949965	ENSG00000237416.5	RP11-465K1.2	-3.56	0.000411	0.0443	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95085681	chr1:94836748~94855426:-
HNSC	cis	rs1552244	0.515	rs111560858	ENSG00000180385.7	EMC3-AS1	3.56	0.000411	0.0443	0.2	0.16	Alzheimer's disease;	chr3:10125161	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.572	rs17032426	ENSG00000180385.7	EMC3-AS1	3.56	0.000411	0.0443	0.2	0.16	Alzheimer's disease;	chr3:10125428	chr3:9986893~10006990:+
HNSC	cis	rs2016266	0.859	rs11170506	ENSG00000270175.1	RP11-793H13.11	3.56	0.000411	0.0443	0.17	0.16	Bone mineral density;Bone mineral density (spine);	chr12:53336975	chr12:53500162~53500936:-
HNSC	cis	rs61160187	0.518	rs62372133	ENSG00000272308.1	RP11-231G3.1	-3.56	0.000411	0.0443	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.582	rs62372134	ENSG00000272308.1	RP11-231G3.1	-3.56	0.000411	0.0443	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60866457~60866935:-
HNSC	cis	rs61160187	0.582	rs12655603	ENSG00000272308.1	RP11-231G3.1	-3.56	0.000411	0.0443	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60866457~60866935:-
HNSC	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	3.56	0.000411	0.0443	0.18	0.16	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
HNSC	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-3.56	0.000411	0.0443	-0.18	-0.16	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
HNSC	cis	rs2307394	1	rs13013743	ENSG00000281469.1	RP11-567F11.1	3.56	0.000411	0.0443	0.18	0.16	Urate levels;	chr2:147827374	chr2:148044380~148044894:+
HNSC	cis	rs8044868	0.586	rs3844425	ENSG00000259209.3	RP5-991G20.2	3.56	0.000411	0.0443	0.17	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72160426	chr16:72805998~72809872:+
HNSC	cis	rs4664293	0.867	rs3771719	ENSG00000226266.5	AC009961.3	3.56	0.000411	0.0443	0.17	0.16	Monocyte percentage of white cells;	chr2:159774453	chr2:159670708~159712435:-
HNSC	cis	rs12539814	1	rs12539814	ENSG00000244198.4	RP4-545C24.1	3.56	0.000411	0.0443	0.28	0.16	Diastolic blood pressure;	chr7:144433417	chr7:144194858~144280547:+
HNSC	cis	rs739496	0.793	rs73199895	ENSG00000226469.1	ADAM1B	3.56	0.000411	0.0443	0.17	0.16	Platelet count;	chr12:111428283	chr12:111927018~111929017:+
HNSC	cis	rs36093844	0.527	rs72949443	ENSG00000279742.1	RP11-700A24.1	-3.56	0.000411	0.0443	-0.23	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85944402	chr11:85852557~85854943:-
HNSC	cis	rs728616	0.614	rs61859196	ENSG00000225484.5	NUTM2B-AS1	-3.56	0.000411	0.0443	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79663088~79826594:-
HNSC	cis	rs828999	0.713	rs476386	ENSG00000280186.1	RP11-483I13.6	3.56	0.000411	0.0443	0.18	0.16	Monocyte percentage of white cells;	chr1:108194964	chr1:108200413~108202743:+
HNSC	cis	rs2657294	0.62	rs7475340	ENSG00000226051.5	ZNF503-AS1	-3.56	0.000411	0.0443	-0.21	-0.16	Pneumonia;	chr10:75079597	chr10:75269819~75373500:+
HNSC	cis	rs3929778	0.883	rs2423166	ENSG00000278192.1	RP5-1056H1.2	-3.56	0.000411	0.0443	-0.22	-0.16	QRS complex (Cornell);	chr20:6545478	chr20:6065966~6067897:-
HNSC	cis	rs62025270	0.688	rs62022941	ENSG00000259762.1	RP11-158M2.4	-3.56	0.000412	0.0443	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85750336~85752901:-
HNSC	cis	rs73198271	1	rs73198279	ENSG00000173295.6	FAM86B3P	-3.56	0.000412	0.0443	-0.22	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8228595~8244865:+
HNSC	cis	rs1865760	0.892	rs9379806	ENSG00000272810.1	U91328.22	-3.56	0.000412	0.0443	-0.15	-0.16	Height;	chr6:25940730	chr6:26013241~26013757:+
HNSC	cis	rs4555772	0.573	rs7714420	ENSG00000272040.1	CTC-366B18.4	-3.56	0.000412	0.0443	-0.15	-0.16	Stearic acid (18:0) levels;	chr5:75044502	chr5:75608817~75609983:+
HNSC	cis	rs61160187	0.505	rs4235482	ENSG00000215032.2	GNL3LP1	3.56	0.000412	0.0443	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60891935~60893577:-
HNSC	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	3.56	0.000412	0.0443	0.19	0.16	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
HNSC	cis	rs987710	0.568	rs4821790	ENSG00000211639.2	IGLV4-60	-3.56	0.000412	0.0444	-0.2	-0.16	Iron status biomarkers;Iron deficiency;	chr22:22156977	chr22:22162199~22162681:+
HNSC	cis	rs987710	0.568	rs987708	ENSG00000211639.2	IGLV4-60	-3.56	0.000412	0.0444	-0.2	-0.16	Iron status biomarkers;Iron deficiency;	chr22:22157688	chr22:22162199~22162681:+
HNSC	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-3.56	0.000412	0.0444	-0.2	-0.16	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
HNSC	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-3.56	0.000412	0.0444	-0.2	-0.16	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
HNSC	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-3.56	0.000412	0.0444	-0.2	-0.16	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
HNSC	cis	rs302668	0.862	rs302669	ENSG00000255241.1	RP11-164N3.3	3.56	0.000412	0.0444	0.18	0.16	Frontotemporal dementia;	chr11:88143644	chr11:88098591~88115835:+
HNSC	cis	rs6545883	0.894	rs2600672	ENSG00000271889.1	RP11-493E12.1	3.56	0.000412	0.0444	0.19	0.16	Tuberculosis;	chr2:61309605	chr2:61151433~61162105:-
HNSC	cis	rs35000415	0.938	rs17339836	ENSG00000275106.1	RP11-309L24.10	-3.56	0.000412	0.0444	-0.37	-0.16	Systemic lupus erythematosus;	chr7:129041008	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.938	rs35188261	ENSG00000275106.1	RP11-309L24.10	-3.56	0.000412	0.0444	-0.37	-0.16	Systemic lupus erythematosus;	chr7:129043485	chr7:128952527~128953316:-
HNSC	cis	rs35000415	0.873	rs62478615	ENSG00000275106.1	RP11-309L24.10	-3.56	0.000412	0.0444	-0.37	-0.16	Systemic lupus erythematosus;	chr7:129044262	chr7:128952527~128953316:-
HNSC	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000412	0.0444	-0.22	-0.16	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000412	0.0444	-0.22	-0.16	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000412	0.0444	-0.22	-0.16	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
HNSC	cis	rs4819052	1	rs733739	ENSG00000215447.6	BX322557.10	-3.56	0.000412	0.0444	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45288052~45291738:+
HNSC	cis	rs4459386	0.509	rs10876020	ENSG00000272368.2	RP4-605O3.4	3.56	0.000412	0.0444	0.16	0.16	Schizophrenia;	chr12:50342482	chr12:50112197~50165618:+
HNSC	cis	rs13256369	1	rs10095733	ENSG00000254153.1	CTA-398F10.2	3.56	0.000412	0.0444	0.2	0.16	Obesity-related traits;	chr8:8717136	chr8:8456909~8461337:-
HNSC	cis	rs801193	0.569	rs10950050	ENSG00000106610.13	STAG3L4	-3.56	0.000412	0.0444	-0.21	-0.16	Aortic root size;	chr7:66774601	chr7:67302621~67321526:+
HNSC	cis	rs739496	0.947	rs2283358	ENSG00000226469.1	ADAM1B	3.56	0.000412	0.0444	0.17	0.16	Platelet count;	chr12:111427761	chr12:111927018~111929017:+
HNSC	cis	rs9595908	0.9	rs7981943	ENSG00000215515.2	IFIT1P1	3.56	0.000412	0.0444	0.18	0.16	Body mass index;	chr13:32593754	chr13:32384660~32386108:+
HNSC	cis	rs9595908	0.9	rs7327429	ENSG00000215515.2	IFIT1P1	3.56	0.000412	0.0444	0.18	0.16	Body mass index;	chr13:32595259	chr13:32384660~32386108:+
HNSC	cis	rs739496	0.615	rs77684561	ENSG00000226469.1	ADAM1B	3.56	0.000412	0.0444	0.19	0.16	Platelet count;	chr12:111623919	chr12:111927018~111929017:+
HNSC	cis	rs4287000	0.508	rs62573991	ENSG00000227603.1	RP11-165J3.6	-3.56	0.000412	0.0444	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93615453	chr9:93435332~93437121:-
HNSC	cis	rs4287000	0.508	rs2989756	ENSG00000227603.1	RP11-165J3.6	-3.56	0.000412	0.0444	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93616328	chr9:93435332~93437121:-
HNSC	cis	rs7429990	0.864	rs12492915	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47636545	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs12636863	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47638629	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7613934	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47640681	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7621236	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47646677	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7624474	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47647786	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs4858846	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47654591	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.803	rs11130145	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47661780	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs11130146	ENSG00000228638.1	FCF1P2	3.56	0.000413	0.0444	0.15	0.16	Educational attainment (years of education);	chr3:47666322	chr3:48290793~48291375:-
HNSC	cis	rs9611565	0.659	rs9611602	ENSG00000235513.1	RP4-756G23.5	3.56	0.000413	0.0444	0.2	0.16	Vitiligo;	chr22:41512401	chr22:41209122~41217627:-
HNSC	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	3.56	0.000413	0.0444	0.15	0.16	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
HNSC	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	3.56	0.000413	0.0444	0.22	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
HNSC	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-3.56	0.000413	0.0444	-0.23	-0.16	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
HNSC	cis	rs597539	0.654	rs619727	ENSG00000261625.1	RP11-554A11.4	-3.56	0.000413	0.0444	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:69000765~69002048:-
HNSC	cis	rs4578769	0.55	rs12958492	ENSG00000265943.1	RP11-739L10.1	3.56	0.000413	0.0444	0.19	0.16	Eosinophil percentage of white cells;	chr18:22988974	chr18:22699481~22933764:-
HNSC	cis	rs453301	0.686	rs3895823	ENSG00000253981.4	ALG1L13P	-3.56	0.000413	0.0444	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9016136	chr8:8236003~8244667:-
HNSC	cis	rs9303029	1	rs72859120	ENSG00000265458.1	RP13-20L14.6	3.56	0.000413	0.0444	0.28	0.16	Protein quantitative trait loci;	chr17:82463234	chr17:82454273~82458521:-
HNSC	cis	rs11846409	0.86	rs73378154	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0444	-0.15	-0.16	Rheumatic heart disease;	chr14:106637687	chr14:106762092~106762588:-
HNSC	cis	rs11700980	0.551	rs2832045	ENSG00000232855.5	AF131217.1	3.56	0.000413	0.0445	0.23	0.16	QRS complex (12-leadsum);	chr21:28744431	chr21:28439346~28674848:-
HNSC	cis	rs34526934	0.619	rs17336374	ENSG00000226363.3	HAGLROS	3.56	0.000413	0.0445	0.22	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176203910	chr2:176177717~176179008:+
HNSC	cis	rs3096299	0.504	rs4785574	ENSG00000261118.1	RP11-104N10.1	3.56	0.000413	0.0445	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89492017~89504460:-
HNSC	cis	rs2836974	0.653	rs8130556	ENSG00000255568.3	BRWD1-AS2	3.56	0.000413	0.0445	0.15	0.16	Cognitive function;	chr21:39144946	chr21:39313935~39314962:+
HNSC	cis	rs11902236	0.667	rs6741117	ENSG00000261104.1	RP11-734K21.5	3.56	0.000413	0.0445	0.27	0.16	Prostate cancer;	chr2:9968385	chr2:9106593~9109865:+
HNSC	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-3.56	0.000413	0.0445	-0.23	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
HNSC	cis	rs11587682	0.76	rs10888582	ENSG00000236713.1	RP11-363I22.3	3.56	0.000413	0.0445	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150456343	chr1:150780272~150780644:+
HNSC	cis	rs12030196	1	rs12023539	ENSG00000230812.4	LINC01358	-3.56	0.000413	0.0445	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59005959	chr1:59020387~59044614:+
HNSC	cis	rs2239557	1	rs7153587	ENSG00000258769.1	RAP1AP	-3.56	0.000413	0.0445	-0.18	-0.16	Common traits (Other);	chr14:74042957	chr14:74482985~74483435:+
HNSC	cis	rs9402743	0.775	rs12210389	ENSG00000234084.1	RP3-388E23.2	-3.56	0.000413	0.0445	-0.17	-0.16	Systemic lupus erythematosus;	chr6:135661977	chr6:135301568~135307158:+
HNSC	cis	rs2834512	0.673	rs2834524	ENSG00000214955.5	AP000318.2	-3.56	0.000413	0.0445	-0.25	-0.16	Cancer;	chr21:34547455	chr21:34205055~34325034:+
HNSC	cis	rs2115630	0.967	rs12595786	ENSG00000259295.5	CSPG4P12	-3.56	0.000413	0.0445	-0.18	-0.16	P wave terminal force;	chr15:84793439	chr15:85191438~85213905:+
HNSC	cis	rs9889296	0.621	rs3091328	ENSG00000267457.1	RP5-837J1.4	3.56	0.000413	0.0445	0.16	0.16	Inflammatory bowel disease;	chr17:34276702	chr17:35073831~35074374:-
HNSC	cis	rs116095464	0.558	rs6866632	ENSG00000277812.1	AC021087.1	3.56	0.000413	0.0445	0.27	0.16	Breast cancer;	chr5:264314	chr5:262769~262881:+
HNSC	cis	rs950169	0.763	rs35372971	ENSG00000259570.1	RP11-671M22.4	3.56	0.000413	0.0445	0.22	0.16	Schizophrenia;	chr15:84387097	chr15:84394512~84395514:+
HNSC	cis	rs4604234	0.901	rs6907326	ENSG00000272129.1	RP11-250B2.6	-3.56	0.000413	0.0445	-0.39	-0.16	Cancer;	chr6:80395748	chr6:80355424~80356859:+
HNSC	cis	rs1440410	0.835	rs13150694	ENSG00000250326.1	RP11-284M14.1	-3.56	0.000413	0.0445	-0.18	-0.16	Ischemic stroke;	chr4:143155900	chr4:142933195~143184861:-
HNSC	cis	rs3748656	1	rs2306940	ENSG00000273483.1	RP4-671G15.2	3.56	0.000413	0.0445	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112698430	chr1:112517799~112518441:-
HNSC	cis	rs9940149	1	rs9934398	ENSG00000226942.2	IL9RP3	-3.56	0.000413	0.0445	-0.21	-0.16	Type 2 diabetes;	chr16:250697	chr16:29336~38321:-
HNSC	cis	rs2337406	0.866	rs8003852	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0445	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106776648	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs988131	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0445	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106776833	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs8005518	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0445	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777009	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs988130	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0445	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777154	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs57684263	ENSG00000280411.1	IGHV1-69-2	-3.56	0.000413	0.0445	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777263	chr14:106762092~106762588:-
HNSC	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	3.56	0.000414	0.0445	0.19	0.16	Height;	chr4:55587104	chr4:55540502~55540835:-
HNSC	cis	rs948562	0.744	rs11229444	ENSG00000280010.1	AP001350.4	3.56	0.000414	0.0445	0.26	0.16	Lymphoma;	chr11:58430400	chr11:58627435~58628528:+
HNSC	cis	rs2548724	1	rs841932	ENSG00000175749.11	EIF3KP1	-3.56	0.000414	0.0445	-0.23	-0.16	Type 2 diabetes;	chr5:102287324	chr5:103032376~103033031:+
HNSC	cis	rs17507216	0.628	rs8028130	ENSG00000252690.3	SCARNA15	3.56	0.000414	0.0445	0.16	0.16	Excessive daytime sleepiness;	chr15:82734974	chr15:82752884~82757208:+
HNSC	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	3.56	0.000414	0.0445	0.21	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
HNSC	cis	rs1440410	0.835	rs9992189	ENSG00000250326.1	RP11-284M14.1	-3.56	0.000414	0.0445	-0.18	-0.16	Ischemic stroke;	chr4:143139575	chr4:142933195~143184861:-
HNSC	cis	rs3736485	0.966	rs2124876	ENSG00000274528.1	CTD-2650P22.2	3.56	0.000414	0.0445	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51613965	chr15:52017167~52018032:-
HNSC	cis	rs62229266	0.659	rs2255734	ENSG00000230212.5	AP000688.14	-3.56	0.000414	0.0445	-0.17	-0.16	Mitral valve prolapse;	chr21:36039611	chr21:36069642~36126640:-
HNSC	cis	rs62229266	0.659	rs2835242	ENSG00000230212.5	AP000688.14	-3.56	0.000414	0.0445	-0.17	-0.16	Mitral valve prolapse;	chr21:36041234	chr21:36069642~36126640:-
HNSC	cis	rs62229266	0.659	rs2835243	ENSG00000230212.5	AP000688.14	-3.56	0.000414	0.0445	-0.17	-0.16	Mitral valve prolapse;	chr21:36041648	chr21:36069642~36126640:-
HNSC	cis	rs72843506	0.586	rs74433421	ENSG00000270091.1	RP11-78O7.2	-3.56	0.000414	0.0445	-0.23	-0.16	Schizophrenia;	chr17:19914774	chr17:19896590~19897287:-
HNSC	cis	rs9928842	0.664	rs8053265	ENSG00000261783.1	RP11-252K23.2	3.56	0.000414	0.0445	0.26	0.16	Alcoholic chronic pancreatitis;	chr16:75187953	chr16:75379818~75381260:-
HNSC	cis	rs11098499	0.691	rs12510133	ENSG00000250412.1	KLHL2P1	3.56	0.000414	0.0445	0.21	0.16	Corneal astigmatism;	chr4:119350189	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.754	rs12506487	ENSG00000250412.1	KLHL2P1	3.56	0.000414	0.0445	0.21	0.16	Corneal astigmatism;	chr4:119350206	chr4:119334329~119378233:+
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000261089.1	RP11-435I10.3	3.56	0.000414	0.0445	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28413703~28415018:+
HNSC	cis	rs911119	0.657	rs2104005	ENSG00000270001.1	RP11-218C14.8	-3.56	0.000414	0.0445	-0.26	-0.16	Chronic kidney disease;	chr20:23650124	chr20:23631826~23632316:-
HNSC	cis	rs4664293	1	rs6753181	ENSG00000213189.5	BTF3L4P2	-3.56	0.000414	0.0445	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159635927	chr2:159003975~159004320:+
HNSC	cis	rs783147	0.5	rs1321197	ENSG00000233342.1	RP11-235G24.3	3.56	0.000414	0.0445	0.19	0.16	Lp (a) levels;	chr6:160724144	chr6:160926369~160927162:+
HNSC	cis	rs494453	1	rs494453	ENSG00000227811.2	FAM212B-AS1	-3.56	0.000414	0.0445	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111649500	chr1:111739841~111747798:+
HNSC	cis	rs225675	0.729	rs225621	ENSG00000229017.5	LINC01277	3.56	0.000414	0.0446	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142144848	chr6:142966421~143038077:-
HNSC	cis	rs225675	0.729	rs225623	ENSG00000229017.5	LINC01277	3.56	0.000414	0.0446	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142146437	chr6:142966421~143038077:-
HNSC	cis	rs344024	0.628	rs4679782	ENSG00000240489.1	SETP14	3.56	0.000414	0.0446	0.15	0.16	Total body bone mineral density;	chr3:156651220	chr3:155987304~155988176:+
HNSC	cis	rs6088590	0.502	rs6059861	ENSG00000276073.1	RP5-1125A11.7	-3.56	0.000414	0.0446	-0.17	-0.16	Coronary artery disease;	chr20:34480758	chr20:33985617~33988989:-
HNSC	cis	rs2277027	1	rs3734030	ENSG00000251405.2	CTB-109A12.1	3.56	0.000414	0.0446	0.19	0.16	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512872	chr5:157362615~157460078:-
HNSC	cis	rs6568686	0.577	rs174400	ENSG00000255389.1	C6orf3	3.56	0.000414	0.0446	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111601776	chr6:111599875~111602295:+
HNSC	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-3.56	0.000414	0.0446	-0.25	-0.16	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
HNSC	cis	rs73201462	1	rs55762931	ENSG00000231305.3	RP11-723O4.2	-3.56	0.000414	0.0446	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128832	chr3:128861313~128871540:-
HNSC	cis	rs1445130	0.688	rs1445124	ENSG00000260331.1	RP11-111J6.2	-3.56	0.000414	0.0446	-0.23	-0.16	Bulimia nervosa;	chr2:18667587	chr2:18547386~18548204:-
HNSC	cis	rs12234571	1	rs60293809	ENSG00000214293.7	APTR	3.56	0.000414	0.0446	0.22	0.16	Obesity-related traits;	chr7:77700879	chr7:77657660~77696265:-
HNSC	cis	rs76280858	1	rs76395821	ENSG00000215196.4	AC091878.1	3.56	0.000415	0.0446	0.4	0.16	Cannabis use (age at onset);	chr5:17877953	chr5:17130028~17217047:-
HNSC	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-3.56	0.000415	0.0446	-0.18	-0.16	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
HNSC	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-3.56	0.000415	0.0446	-0.18	-0.16	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
HNSC	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-3.56	0.000415	0.0446	-0.24	-0.16	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
HNSC	cis	rs1865760	0.532	rs2794719	ENSG00000272810.1	U91328.22	-3.56	0.000415	0.0446	-0.15	-0.16	Height;	chr6:26088662	chr6:26013241~26013757:+
HNSC	cis	rs9926296	0.568	rs1230	ENSG00000261812.4	TUBB8P7	3.56	0.000415	0.0446	0.18	0.16	Vitiligo;	chr16:89738447	chr16:90093154~90096354:+
HNSC	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000415	0.0446	-0.23	-0.16	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
HNSC	cis	rs6968419	0.755	rs3173919	ENSG00000237870.5	AC073130.1	3.56	0.000415	0.0446	0.2	0.16	Intraocular pressure;	chr7:116258123	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs1141470	ENSG00000237870.5	AC073130.1	3.56	0.000415	0.0446	0.2	0.16	Intraocular pressure;	chr7:116258388	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs3807982	ENSG00000237870.5	AC073130.1	3.56	0.000415	0.0446	0.2	0.16	Intraocular pressure;	chr7:116258831	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.755	rs3807983	ENSG00000237870.5	AC073130.1	3.56	0.000415	0.0446	0.2	0.16	Intraocular pressure;	chr7:116258937	chr7:116275606~116286734:-
HNSC	cis	rs11997175	0.625	rs953617	ENSG00000272338.2	RP11-722E23.2	3.56	0.000415	0.0446	0.16	0.16	Body mass index;	chr8:33741640	chr8:33360839~33361415:-
HNSC	cis	rs801193	0.569	rs6978178	ENSG00000106610.13	STAG3L4	3.56	0.000415	0.0446	0.21	0.16	Aortic root size;	chr7:66658097	chr7:67302621~67321526:+
HNSC	cis	rs34421088	0.532	rs3808515	ENSG00000269918.1	AF131215.9	3.56	0.000415	0.0446	0.17	0.16	Neuroticism;	chr8:11298532	chr8:11104691~11106704:-
HNSC	cis	rs3096299	0.9	rs2911258	ENSG00000261118.1	RP11-104N10.1	3.56	0.000415	0.0446	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89492017~89504460:-
HNSC	cis	rs11651000	0.894	rs66490177	ENSG00000228782.6	CTD-2026D20.3	-3.56	0.000415	0.0446	-0.2	-0.16	IgG glycosylation;	chr17:47740357	chr17:47450568~47492492:-
HNSC	cis	rs2408955	0.542	rs7975632	ENSG00000257763.1	OR5BK1P	3.56	0.000415	0.0446	0.15	0.16	Glycated hemoglobin levels;	chr12:48049265	chr12:48355792~48356614:-
HNSC	cis	rs7246657	0.722	rs2909102	ENSG00000276846.1	CTD-3220F14.3	-3.56	0.000415	0.0446	-0.22	-0.16	Coronary artery calcification;	chr19:37676463	chr19:37314868~37315620:-
HNSC	cis	rs9914544	0.545	rs2386404	ENSG00000264885.1	RP11-815I9.4	-3.56	0.000415	0.0446	-0.16	-0.16	Educational attainment (years of education);	chr17:18866036	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs2386403	ENSG00000264885.1	RP11-815I9.4	-3.56	0.000415	0.0446	-0.16	-0.16	Educational attainment (years of education);	chr17:18866287	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.564	rs11868500	ENSG00000264885.1	RP11-815I9.4	-3.56	0.000415	0.0446	-0.16	-0.16	Educational attainment (years of education);	chr17:18866941	chr17:18667629~18669461:-
HNSC	cis	rs79040073	0.599	rs17396536	ENSG00000259531.2	RP11-295H24.3	3.56	0.000415	0.0446	0.21	0.16	Lung cancer in ever smokers;	chr15:49256871	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.637	rs78881953	ENSG00000259531.2	RP11-295H24.3	3.56	0.000415	0.0446	0.21	0.16	Lung cancer in ever smokers;	chr15:49269019	chr15:49365124~49366685:-
HNSC	cis	rs347412	0.867	rs369829	ENSG00000237263.1	MAPK6PS3	-3.56	0.000415	0.0446	-0.2	-0.16	Pulmonary function in asthmatics;	chr13:42228994	chr13:42068932~42071093:-
HNSC	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-3.56	0.000415	0.0446	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
HNSC	cis	rs2239557	1	rs2072293	ENSG00000258769.1	RAP1AP	-3.56	0.000415	0.0446	-0.17	-0.16	Common traits (Other);	chr14:74071182	chr14:74482985~74483435:+
HNSC	cis	rs4622329	0.553	rs12305145	ENSG00000258033.1	RP11-350G24.2	3.56	0.000415	0.0446	0.18	0.16	Systemic lupus erythematosus;	chr12:101918748	chr12:101066734~101069232:+
HNSC	cis	rs8062405	0.964	rs62036614	ENSG00000261089.1	RP11-435I10.3	3.56	0.000415	0.0446	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28413703~28415018:+
HNSC	cis	rs1429606	1	rs3910021	ENSG00000247828.6	TMEM161B-AS1	-3.56	0.000415	0.0446	-0.3	-0.16	Number of children (6+ vs. 0 or 1);	chr5:87982927	chr5:88268895~88436685:+
HNSC	cis	rs1865760	0.928	rs9295673	ENSG00000272810.1	U91328.22	-3.56	0.000415	0.0446	-0.15	-0.16	Height;	chr6:25911866	chr6:26013241~26013757:+
HNSC	cis	rs4535700	0.501	rs57251705	ENSG00000213650.3	RP11-760D2.7	-3.56	0.000415	0.0446	-0.18	-0.16	Macular telangiectasia type 2;	chr7:55913390	chr7:56567906~56568858:-
HNSC	cis	rs225675	0.729	rs225607	ENSG00000229017.5	LINC01277	3.56	0.000415	0.0446	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142133993	chr6:142966421~143038077:-
HNSC	cis	rs7829975	0.533	rs1039917	ENSG00000254340.1	RP11-10A14.3	3.56	0.000415	0.0446	0.2	0.16	Mood instability;	chr8:8861340	chr8:9141424~9145435:+
HNSC	cis	rs9487051	0.552	rs59272337	ENSG00000243587.6	C6orf183	-3.56	0.000415	0.0446	-0.16	-0.16	Reticulocyte fraction of red cells;	chr6:109317692	chr6:109165833~109271014:+
HNSC	cis	rs2554380	0.628	rs963690	ENSG00000259570.1	RP11-671M22.4	3.56	0.000415	0.0446	0.2	0.16	Height;	chr15:83771068	chr15:84394512~84395514:+
HNSC	cis	rs73201462	1	rs11706455	ENSG00000231305.3	RP11-723O4.2	-3.56	0.000415	0.0446	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128173148	chr3:128861313~128871540:-
HNSC	cis	rs9876781	1	rs2362452	ENSG00000229759.1	MRPS18AP1	-3.56	0.000415	0.0446	-0.15	-0.16	Longevity;	chr3:48376724	chr3:48256350~48256938:-
HNSC	cis	rs9914988	1	rs9914988	ENSG00000264577.1	AC010761.8	-3.56	0.000415	0.0447	-0.13	-0.16	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28856086	chr17:28721487~28722877:-
HNSC	cis	rs9914988	1	rs9916866	ENSG00000264577.1	AC010761.8	-3.56	0.000415	0.0447	-0.13	-0.16	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28856137	chr17:28721487~28722877:-
HNSC	cis	rs9467711	0.606	rs9366656	ENSG00000241549.7	GUSBP2	3.56	0.000415	0.0447	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26434402	chr6:26871484~26956554:-
HNSC	cis	rs6001482	0.679	rs1475928	ENSG00000253818.1	IGLV1-41	-3.56	0.000415	0.0447	-0.13	-0.16	Diastolic blood pressure;	chr22:22236137	chr22:22404207~22404721:+
HNSC	cis	rs7824557	0.527	rs57629785	ENSG00000255495.1	AC145124.2	-3.56	0.000416	0.0447	-0.18	-0.16	Retinal vascular caliber;	chr8:11377641	chr8:12194467~12196280:+
HNSC	cis	rs7824557	0.564	rs2572395	ENSG00000255495.1	AC145124.2	-3.56	0.000416	0.0447	-0.18	-0.16	Retinal vascular caliber;	chr8:11377851	chr8:12194467~12196280:+
HNSC	cis	rs643506	0.874	rs618421	ENSG00000230911.1	PPIHP1	-3.56	0.000416	0.0447	-0.21	-0.16	Breast cancer;	chr11:111778085	chr11:112029858~112030367:-
HNSC	cis	rs8077577	0.708	rs2290503	ENSG00000273018.4	CTD-2303H24.2	3.56	0.000416	0.0447	0.23	0.16	Obesity-related traits;	chr17:18232439	chr17:18511221~18551705:-
HNSC	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-3.56	0.000416	0.0447	-0.32	-0.16	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	3.56	0.000416	0.0447	0.32	0.16	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
HNSC	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-3.56	0.000416	0.0447	-0.26	-0.16	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
HNSC	cis	rs1440410	0.795	rs13119330	ENSG00000250326.1	RP11-284M14.1	-3.56	0.000416	0.0447	-0.18	-0.16	Ischemic stroke;	chr4:143264416	chr4:142933195~143184861:-
HNSC	cis	rs4622329	0.636	rs7976056	ENSG00000258033.1	RP11-350G24.2	3.56	0.000416	0.0447	0.18	0.16	Systemic lupus erythematosus;	chr12:101919728	chr12:101066734~101069232:+
HNSC	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-3.56	0.000416	0.0447	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
HNSC	cis	rs7937890	0.506	rs10741655	ENSG00000254418.1	RP11-21L19.1	3.56	0.000416	0.0447	0.19	0.16	Mitochondrial DNA levels;	chr11:14746838	chr11:14262846~14273691:-
HNSC	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000416	0.0447	-0.21	-0.16	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000416	0.0447	-0.21	-0.16	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000416	0.0447	-0.21	-0.16	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
HNSC	cis	rs4646450	0.838	rs10257758	ENSG00000244219.5	GS1-259H13.2	-3.56	0.000416	0.0447	-0.25	-0.16	Blood metabolite levels;	chr7:99591365	chr7:99598066~99610813:+
HNSC	cis	rs7412746	0.658	rs10305714	ENSG00000236713.1	RP11-363I22.3	3.56	0.000416	0.0447	0.18	0.16	Melanoma;	chr1:150828179	chr1:150780272~150780644:+
HNSC	cis	rs9911578	0.902	rs12948746	ENSG00000224738.1	AC099850.1	3.56	0.000416	0.0447	0.17	0.16	Intelligence (multi-trait analysis);	chr17:58994531	chr17:59106598~59118267:+
HNSC	cis	rs9911578	0.934	rs8081967	ENSG00000224738.1	AC099850.1	3.56	0.000416	0.0447	0.17	0.16	Intelligence (multi-trait analysis);	chr17:58995340	chr17:59106598~59118267:+
HNSC	cis	rs656900	0.692	rs7171819	ENSG00000261229.4	MTHFS	-3.56	0.000416	0.0447	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr15:79815677	chr15:79843547~79897285:-
HNSC	cis	rs2055729	0.677	rs10104353	ENSG00000254340.1	RP11-10A14.3	-3.56	0.000416	0.0447	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9882848	chr8:9141424~9145435:+
HNSC	cis	rs1015213	0.737	rs114431757	ENSG00000272024.1	RP11-546K22.3	-3.56	0.000416	0.0447	-0.43	-0.16	Glaucoma (primary angle closure);	chr8:51972689	chr8:51950284~51950690:+
HNSC	cis	rs9611565	0.512	rs964898	ENSG00000235513.1	RP4-756G23.5	3.56	0.000416	0.0447	0.2	0.16	Vitiligo;	chr22:41746302	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs5758439	ENSG00000235513.1	RP4-756G23.5	-3.56	0.000416	0.0447	-0.2	-0.16	Vitiligo;	chr22:41735758	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs768414	ENSG00000235513.1	RP4-756G23.5	-3.56	0.000416	0.0447	-0.2	-0.16	Vitiligo;	chr22:41739747	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs5751148	ENSG00000235513.1	RP4-756G23.5	-3.56	0.000416	0.0447	-0.2	-0.16	Vitiligo;	chr22:41743074	chr22:41209122~41217627:-
HNSC	cis	rs727563	0.635	rs5751149	ENSG00000235513.1	RP4-756G23.5	-3.56	0.000416	0.0447	-0.2	-0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr22:41209122~41217627:-
HNSC	cis	rs727563	0.638	rs5996058	ENSG00000235513.1	RP4-756G23.5	-3.56	0.000416	0.0447	-0.2	-0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr22:41209122~41217627:-
HNSC	cis	rs709400	0.93	rs2274268	ENSG00000270108.1	RP11-73M18.6	3.56	0.000416	0.0447	0.18	0.16	Body mass index;	chr14:103563041	chr14:103687576~103688127:+
HNSC	cis	rs12745968	0.652	rs6603986	ENSG00000223787.2	RP4-593M8.1	-3.56	0.000416	0.0447	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92551664	chr1:92580476~92580821:-
HNSC	cis	rs4819052	1	rs733738	ENSG00000215447.6	BX322557.10	3.56	0.000416	0.0447	0.17	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45288052~45291738:+
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000255310.2	AF131215.2	3.56	0.000416	0.0447	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11107788~11109726:-
HNSC	cis	rs2179367	0.632	rs9498324	ENSG00000217733.2	CCT7P1	3.56	0.000416	0.0447	0.21	0.16	Dupuytren's disease;	chr6:149338973	chr6:149879962~149881572:+
HNSC	cis	rs2179367	0.632	rs55826712	ENSG00000217733.2	CCT7P1	3.56	0.000416	0.0447	0.21	0.16	Dupuytren's disease;	chr6:149344716	chr6:149879962~149881572:+
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000226314.6	ZNF192P1	-3.56	0.000416	0.0447	-0.18	-0.16	Depression;	chr6:28432562	chr6:28161781~28169594:+
HNSC	cis	rs2436845	0.934	rs2436865	ENSG00000253669.3	KB-1732A1.1	-3.56	0.000416	0.0447	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102806542	chr8:102805517~102809971:+
HNSC	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	3.56	0.000416	0.0447	0.15	0.16	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
HNSC	cis	rs2562456	0.793	rs7258473	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21331795	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.793	rs2219839	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21333520	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62107539	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21334910	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs76646508	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21335247	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs77576302	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21335385	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62107540	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21335693	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62107541	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000416	0.0447	0.25	0.16	Pain;	chr19:21335733	chr19:21444241~21463908:-
HNSC	cis	rs9475752	0.688	rs6941401	ENSG00000220666.2	RCC2P7	3.55	0.000417	0.0447	0.21	0.16	Menarche (age at onset);	chr6:56919898	chr6:56431950~56433213:-
HNSC	cis	rs6545883	0.602	rs11125871	ENSG00000271889.1	RP11-493E12.1	-3.55	0.000417	0.0447	-0.19	-0.16	Tuberculosis;	chr2:61242991	chr2:61151433~61162105:-
HNSC	cis	rs4648045	0.621	rs980455	ENSG00000230069.3	LRRC37A15P	-3.55	0.000417	0.0447	-0.16	-0.16	Lymphocyte percentage of white cells;	chr4:102497800	chr4:102727274~102730721:-
HNSC	cis	rs3026445	0.926	rs12300631	ENSG00000241413.3	RN7SL441P	-3.55	0.000417	0.0448	-0.17	-0.16	QT interval;	chr12:110111979	chr12:109866214~109866509:-
HNSC	cis	rs4704187	0.687	rs6862740	ENSG00000271815.1	CTD-2235C13.3	-3.55	0.000417	0.0448	-0.2	-0.16	Response to amphetamines;	chr5:75109924	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.687	rs9763362	ENSG00000271815.1	CTD-2235C13.3	-3.55	0.000417	0.0448	-0.2	-0.16	Response to amphetamines;	chr5:75110491	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.617	rs2035192	ENSG00000271815.1	CTD-2235C13.3	-3.55	0.000417	0.0448	-0.2	-0.16	Response to amphetamines;	chr5:75111406	chr5:75363760~75364242:+
HNSC	cis	rs4704187	0.687	rs2335136	ENSG00000271815.1	CTD-2235C13.3	-3.55	0.000417	0.0448	-0.2	-0.16	Response to amphetamines;	chr5:75112169	chr5:75363760~75364242:+
HNSC	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	3.55	0.000417	0.0448	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
HNSC	cis	rs950027	0.62	rs35861938	ENSG00000259479.5	SORD2P	3.55	0.000417	0.0448	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:44826371~44884694:-
HNSC	cis	rs2243480	0.901	rs35087093	ENSG00000164669.11	INTS4P1	3.55	0.000417	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65940221	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35046236	ENSG00000164669.11	INTS4P1	3.55	0.000417	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65943626	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs36068983	ENSG00000164669.11	INTS4P1	3.55	0.000417	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65944004	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs68189316	ENSG00000164669.11	INTS4P1	3.55	0.000417	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65944182	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs34804747	ENSG00000164669.11	INTS4P1	3.55	0.000417	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65947955	chr7:65141225~65234216:+
HNSC	cis	rs71636778	0.509	rs34667713	ENSG00000260063.1	RP5-968P14.2	-3.55	0.000417	0.0448	-0.35	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966187	chr1:26692132~26694131:-
HNSC	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000417	0.0448	-0.23	-0.16	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
HNSC	cis	rs2436845	0.966	rs3018956	ENSG00000253669.3	KB-1732A1.1	-3.55	0.000417	0.0448	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102835367	chr8:102805517~102809971:+
HNSC	cis	rs1440410	0.835	rs11737209	ENSG00000250326.1	RP11-284M14.1	-3.55	0.000417	0.0448	-0.18	-0.16	Ischemic stroke;	chr4:143211519	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.835	rs11933603	ENSG00000250326.1	RP11-284M14.1	-3.55	0.000417	0.0448	-0.18	-0.16	Ischemic stroke;	chr4:143212704	chr4:142933195~143184861:-
HNSC	cis	rs1440410	0.798	rs10001113	ENSG00000250326.1	RP11-284M14.1	-3.55	0.000417	0.0448	-0.18	-0.16	Ischemic stroke;	chr4:143215252	chr4:142933195~143184861:-
HNSC	cis	rs10073892	0.62	rs10068654	ENSG00000250682.4	LINC00491	-3.55	0.000417	0.0448	-0.23	-0.16	Cognitive decline (age-related);	chr5:102643593	chr5:102609156~102671559:-
HNSC	cis	rs6988985	0.618	rs62525983	ENSG00000247317.3	RP11-273G15.2	-3.55	0.000417	0.0448	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142907570	chr8:142981738~143018437:-
HNSC	cis	rs3018712	0.532	rs61889616	ENSG00000212093.1	AP000807.1	-3.55	0.000417	0.0448	-0.25	-0.16	Total body bone mineral density;	chr11:68644538	chr11:68506083~68506166:-
HNSC	cis	rs9400467	0.528	rs445349	ENSG00000271789.1	RP5-1112D6.7	3.55	0.000417	0.0448	0.19	0.16	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111297126~111298510:+
HNSC	cis	rs2070419	0.724	rs2833447	ENSG00000261610.1	AP000265.1	3.55	0.000417	0.0448	0.2	0.16	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks);	chr21:31568156	chr21:32259804~32261585:-
HNSC	cis	rs2439831	1	rs690002	ENSG00000275601.1	AC011330.13	-3.55	0.000417	0.0448	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43437151	chr15:43642389~43643023:-
HNSC	cis	rs61160187	0.51	rs4235481	ENSG00000215032.2	GNL3LP1	3.55	0.000417	0.0448	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60891935~60893577:-
HNSC	cis	rs9437689	0.966	rs12751774	ENSG00000237416.5	RP11-465K1.2	-3.55	0.000417	0.0448	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95082137	chr1:94836748~94855426:-
HNSC	cis	rs12664251	0.706	rs1775620	ENSG00000253194.1	RP11-351A11.1	-3.55	0.000417	0.0448	-0.19	-0.16	Schizophrenia;	chr6:119012273	chr6:118934785~119031541:+
HNSC	cis	rs2565722	0.622	rs1937480	ENSG00000233342.1	RP11-235G24.3	-3.55	0.000417	0.0448	-0.25	-0.16	Blood protein levels;	chr6:160883291	chr6:160926369~160927162:+
HNSC	cis	rs6558174	0.965	rs2404655	ENSG00000253986.1	CTC-756D1.3	-3.55	0.000417	0.0448	-0.18	-0.16	Breast cancer;	chr8:22632696	chr8:23493009~23494198:-
HNSC	cis	rs2243480	0.522	rs73150635	ENSG00000179342.4	GS1-124K5.9	-3.55	0.000417	0.0448	-0.36	-0.16	Diabetic kidney disease;	chr7:66507503	chr7:66505155~66506223:-
HNSC	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	3.55	0.000418	0.0448	0.32	0.16	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
HNSC	cis	rs73201462	1	rs6810006	ENSG00000231305.3	RP11-723O4.2	-3.55	0.000418	0.0448	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137215	chr3:128861313~128871540:-
HNSC	cis	rs2307394	0.896	rs986508	ENSG00000281469.1	RP11-567F11.1	3.55	0.000418	0.0448	0.18	0.16	Urate levels;	chr2:147804462	chr2:148044380~148044894:+
HNSC	cis	rs2212361	0.6	rs34185869	ENSG00000255893.1	RP11-685N10.1	-3.55	0.000418	0.0448	-0.23	-0.16	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535430	chr11:94472908~94473570:-
HNSC	cis	rs2212361	0.593	rs34288874	ENSG00000255893.1	RP11-685N10.1	-3.55	0.000418	0.0448	-0.23	-0.16	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535484	chr11:94472908~94473570:-
HNSC	cis	rs34286592	1	rs3815824	ENSG00000183604.13	SMG1P5	-3.55	0.000418	0.0449	-0.22	-0.16	Multiple sclerosis;	chr16:29841539	chr16:30267553~30335374:-
HNSC	cis	rs62560775	0.688	rs3217986	ENSG00000224854.3	CDKN2A-AS1	3.55	0.000418	0.0449	0.28	0.16	Lung cancer;Lung adenocarcinoma;	chr9:22005331	chr9:21966929~21967751:+
HNSC	cis	rs7023329	0.59	rs7866540	ENSG00000244230.3	RN7SL151P	-3.55	0.000418	0.0449	-0.16	-0.16	Melanoma;	chr9:21760397	chr9:21699314~21699596:+
HNSC	cis	rs12701220	0.895	rs12534778	ENSG00000224079.1	AC091729.7	-3.55	0.000418	0.0449	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1074450~1078036:+
HNSC	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-3.55	0.000418	0.0449	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-3.55	0.000418	0.0449	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
HNSC	cis	rs9329221	0.71	rs11249995	ENSG00000269918.1	AF131215.9	3.55	0.000418	0.0449	0.17	0.16	Neuroticism;	chr8:10381412	chr8:11104691~11106704:-
HNSC	cis	rs4819052	1	rs4819052	ENSG00000215447.6	BX322557.10	-3.55	0.000418	0.0449	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45288052~45291738:+
HNSC	cis	rs17221829	0.673	rs10830335	ENSG00000280385.1	AP000648.5	-3.55	0.000418	0.0449	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89670766	chr11:90193614~90198120:+
HNSC	cis	rs3018712	0.532	rs4930587	ENSG00000255031.4	RP11-802E16.3	-3.55	0.000418	0.0449	-0.18	-0.16	Total body bone mineral density;	chr11:68647667	chr11:68050740~68053762:+
HNSC	cis	rs3018712	0.532	rs4930589	ENSG00000255031.4	RP11-802E16.3	-3.55	0.000418	0.0449	-0.18	-0.16	Total body bone mineral density;	chr11:68647789	chr11:68050740~68053762:+
HNSC	cis	rs3018712	0.532	rs11228312	ENSG00000255031.4	RP11-802E16.3	-3.55	0.000418	0.0449	-0.18	-0.16	Total body bone mineral density;	chr11:68648049	chr11:68050740~68053762:+
HNSC	cis	rs3018712	0.532	rs10791988	ENSG00000255031.4	RP11-802E16.3	-3.55	0.000418	0.0449	-0.18	-0.16	Total body bone mineral density;	chr11:68648583	chr11:68050740~68053762:+
HNSC	cis	rs61160187	0.582	rs10939879	ENSG00000272308.1	RP11-231G3.1	-3.55	0.000418	0.0449	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60866457~60866935:-
HNSC	cis	rs782107	0.565	rs4760128	ENSG00000270039.1	RP11-571M6.17	3.55	0.000418	0.0449	0.2	0.16	Interleukin-12p70 levels;	chr12:58432649	chr12:57803838~57804415:+
HNSC	cis	rs36093924	0.646	rs5996094	ENSG00000270083.1	RP1-257I20.14	-3.55	0.000418	0.0449	-0.14	-0.16	Intelligence;	chr22:41951056	chr22:42089630~42090028:-
HNSC	cis	rs773506	0.72	rs12236714	ENSG00000229694.5	RP11-305L7.6	-3.55	0.000418	0.0449	-0.19	-0.16	Type 2 diabetes nephropathy;	chr9:91199045	chr9:91119062~91182762:+
HNSC	cis	rs9650657	0.596	rs2409674	ENSG00000269918.1	AF131215.9	-3.55	0.000418	0.0449	-0.16	-0.16	Neuroticism;	chr8:10738368	chr8:11104691~11106704:-
HNSC	cis	rs4287000	0.508	rs928368	ENSG00000227603.1	RP11-165J3.6	-3.55	0.000418	0.0449	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93610202	chr9:93435332~93437121:-
HNSC	cis	rs9863	0.828	rs75989601	ENSG00000270028.1	RP11-380L11.4	3.55	0.000418	0.0449	0.19	0.16	White blood cell count;	chr12:123982176	chr12:123925461~123926083:-
HNSC	cis	rs9863	0.828	rs35099862	ENSG00000270028.1	RP11-380L11.4	3.55	0.000418	0.0449	0.19	0.16	White blood cell count;	chr12:123982657	chr12:123925461~123926083:-
HNSC	cis	rs17772222	1	rs11159856	ENSG00000258789.1	RP11-507K2.3	-3.55	0.000418	0.0449	-0.2	-0.16	Coronary artery calcification;	chr14:88417585	chr14:88551597~88552493:+
HNSC	cis	rs853679	0.76	rs9295768	ENSG00000176933.5	TOB2P1	3.55	0.000419	0.0449	0.21	0.16	Depression;	chr6:28241324	chr6:28217643~28218634:-
HNSC	cis	rs853679	0.699	rs9468318	ENSG00000176933.5	TOB2P1	3.55	0.000419	0.0449	0.21	0.16	Depression;	chr6:28241753	chr6:28217643~28218634:-
HNSC	cis	rs853679	0.76	rs9357067	ENSG00000176933.5	TOB2P1	3.55	0.000419	0.0449	0.21	0.16	Depression;	chr6:28242515	chr6:28217643~28218634:-
HNSC	cis	rs11846409	0.86	rs74091720	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000419	0.0449	-0.14	-0.16	Rheumatic heart disease;	chr14:106638192	chr14:106762092~106762588:-
HNSC	cis	rs10875746	0.551	rs1471998	ENSG00000257763.1	OR5BK1P	-3.55	0.000419	0.0449	-0.2	-0.16	Longevity (90 years and older);	chr12:48318219	chr12:48355792~48356614:-
HNSC	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-3.55	0.000419	0.0449	-0.18	-0.16	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
HNSC	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-3.55	0.000419	0.0449	-0.19	-0.16	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
HNSC	cis	rs17416285	0.537	rs2798153	ENSG00000260971.3	RP11-504A18.1	3.55	0.000419	0.0449	0.21	0.16	Coronary artery disease;	chr1:56523547	chr1:56248294~56258571:-
HNSC	cis	rs1941184	0.667	rs28698782	ENSG00000266521.1	RP11-650P15.1	3.55	0.000419	0.0449	0.21	0.16	Parkinson's disease (age of onset);	chr18:31446383	chr18:31496645~31497195:-
HNSC	cis	rs783147	0.5	rs4252135	ENSG00000231863.1	RP3-428L16.1	3.55	0.000419	0.0449	0.21	0.16	Lp (a) levels;	chr6:160733200	chr6:160931080~160969771:+
HNSC	cis	rs9768139	0.634	rs11762383	ENSG00000223872.1	AC006372.5	-3.55	0.000419	0.0449	-0.18	-0.16	Calcium levels;	chr7:158321197	chr7:157501322~157503577:+
HNSC	cis	rs4535700	0.501	rs28828764	ENSG00000213650.3	RP11-760D2.7	-3.55	0.000419	0.0449	-0.18	-0.16	Macular telangiectasia type 2;	chr7:55920986	chr7:56567906~56568858:-
HNSC	cis	rs800888	0.518	rs2737226	ENSG00000249917.2	LINC00536	-3.55	0.000419	0.0449	-0.22	-0.16	Monocyte percentage of white cells;	chr8:115627247	chr8:115950511~116325059:-
HNSC	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-3.55	0.000419	0.0449	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
HNSC	cis	rs4835473	0.897	rs6537170	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000419	0.045	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143691747	chr4:143911514~143912053:-
HNSC	cis	rs7246657	0.722	rs2972430	ENSG00000276846.1	CTD-3220F14.3	-3.55	0.000419	0.045	-0.22	-0.16	Coronary artery calcification;	chr19:37691210	chr19:37314868~37315620:-
HNSC	cis	rs7246657	0.722	rs2287229	ENSG00000276846.1	CTD-3220F14.3	-3.55	0.000419	0.045	-0.22	-0.16	Coronary artery calcification;	chr19:37697751	chr19:37314868~37315620:-
HNSC	cis	rs2048656	0.605	rs13249234	ENSG00000254340.1	RP11-10A14.3	3.55	0.000419	0.045	0.21	0.16	Schizophrenia;	chr8:9792891	chr8:9141424~9145435:+
HNSC	cis	rs9650657	0.655	rs1991651	ENSG00000255310.2	AF131215.2	3.55	0.000419	0.045	0.16	0.16	Neuroticism;	chr8:10848901	chr8:11107788~11109726:-
HNSC	cis	rs7572733	0.555	rs7600269	ENSG00000231621.1	AC013264.2	-3.55	0.000419	0.045	-0.16	-0.16	Dermatomyositis;	chr2:198058744	chr2:197197991~197199273:+
HNSC	cis	rs72843506	0.722	rs9902683	ENSG00000189423.10	USP32P3	3.55	0.000419	0.045	0.27	0.16	Schizophrenia;	chr17:20112115	chr17:20415547~20431008:+
HNSC	cis	rs9611565	0.592	rs8779	ENSG00000233903.2	Z83851.4	3.55	0.000419	0.045	0.25	0.16	Vitiligo;	chr22:41674272	chr22:42276355~42277052:+
HNSC	cis	rs727563	0.594	rs132807	ENSG00000233903.2	Z83851.4	3.55	0.000419	0.045	0.25	0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.592	rs1811113	ENSG00000233903.2	Z83851.4	3.55	0.000419	0.045	0.25	0.16	Vitiligo;	chr22:41677130	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.559	rs5758412	ENSG00000233903.2	Z83851.4	3.55	0.000419	0.045	0.25	0.16	Vitiligo;	chr22:41684799	chr22:42276355~42277052:+
HNSC	cis	rs9611565	0.559	rs13056262	ENSG00000233903.2	Z83851.4	3.55	0.000419	0.045	0.25	0.16	Vitiligo;	chr22:41685917	chr22:42276355~42277052:+
HNSC	cis	rs1908814	0.516	rs4841641	ENSG00000269918.1	AF131215.9	3.55	0.000419	0.045	0.16	0.16	Neuroticism;	chr8:11940718	chr8:11104691~11106704:-
HNSC	cis	rs62202398	0.618	rs73315410	ENSG00000276923.1	RP11-321P16.1	-3.55	0.000419	0.045	-0.3	-0.16	Alcohol consumption;	chr20:48153330	chr20:48073869~48074188:+
HNSC	cis	rs2625529	0.73	rs2929528	ENSG00000260037.4	CTD-2524L6.3	3.55	0.000419	0.045	0.22	0.16	Red blood cell count;	chr15:71976996	chr15:71818396~71823384:+
HNSC	cis	rs950027	0.62	rs1617984	ENSG00000259479.5	SORD2P	3.55	0.000419	0.045	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:44826371~44884694:-
HNSC	cis	rs7568069	0.897	rs3771382	ENSG00000234896.1	OR7E62P	3.55	0.000419	0.045	0.18	0.16	Height;	chr2:71332315	chr2:71055527~71056003:+
HNSC	cis	rs7129556	0.52	rs4945178	ENSG00000219529.2	AP000580.1	3.55	0.000419	0.045	0.19	0.16	Weight loss (gastric bypass surgery);	chr11:77537866	chr11:77813319~77813676:-
HNSC	cis	rs3851050	0.684	rs11201697	ENSG00000230091.5	TMEM254-AS1	3.55	0.000419	0.045	0.19	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80104428	chr10:80046860~80078912:-
HNSC	cis	rs10435719	0.718	rs7813935	ENSG00000255310.2	AF131215.2	3.55	0.00042	0.045	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11107788~11109726:-
HNSC	cis	rs6499755	0.712	rs22747	ENSG00000260135.5	RP11-212I21.2	-3.55	0.00042	0.045	-0.18	-0.16	Hypospadias;	chr16:55331996	chr16:55426797~55462297:-
HNSC	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	3.55	0.00042	0.045	0.24	0.16	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
HNSC	cis	rs6840360	0.642	rs12647555	ENSG00000251611.1	RP11-610P16.1	-3.55	0.00042	0.045	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151407551~151408835:-
HNSC	cis	rs988913	1	rs9475099	ENSG00000224984.1	RP11-524H19.2	3.55	0.00042	0.045	0.19	0.16	Menarche (age at onset);	chr6:54974272	chr6:54840118~54840855:-
HNSC	cis	rs78487399	0.71	rs57696714	ENSG00000234936.1	AC010883.5	3.55	0.00042	0.045	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399382	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs57381820	ENSG00000234936.1	AC010883.5	3.55	0.00042	0.045	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399529	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs72879276	ENSG00000234936.1	AC010883.5	3.55	0.00042	0.045	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399962	chr2:43229573~43233394:+
HNSC	cis	rs78487399	0.71	rs7607777	ENSG00000234936.1	AC010883.5	3.55	0.00042	0.045	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43402792	chr2:43229573~43233394:+
HNSC	cis	rs7189233	0.531	rs56126229	ENSG00000261056.2	RP11-454F8.2	-3.55	0.00042	0.045	-0.17	-0.16	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53298224~53299792:+
HNSC	cis	rs7169223	0.653	rs2904228	ENSG00000261762.1	RP11-650L12.2	3.55	0.00042	0.045	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78793757	chr15:78589123~78591276:-
HNSC	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
HNSC	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	3.55	0.00042	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
HNSC	cis	rs2337406	0.5	rs7152934	ENSG00000280411.1	IGHV1-69-2	-3.55	0.00042	0.045	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106778702	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.789	rs12050392	ENSG00000280411.1	IGHV1-69-2	-3.55	0.00042	0.045	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106779073	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs74092505	ENSG00000280411.1	IGHV1-69-2	-3.55	0.00042	0.045	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106779163	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.789	rs74092507	ENSG00000280411.1	IGHV1-69-2	-3.55	0.00042	0.045	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106779174	chr14:106762092~106762588:-
HNSC	cis	rs9393777	0.513	rs7740197	ENSG00000224843.5	LINC00240	-3.55	0.00042	0.0451	-0.2	-0.16	Intelligence (multi-trait analysis);	chr6:26663250	chr6:26956992~27023924:+
HNSC	cis	rs727563	0.593	rs5758461	ENSG00000235513.1	RP4-756G23.5	-3.55	0.00042	0.0451	-0.2	-0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.512	rs2899349	ENSG00000235513.1	RP4-756G23.5	-3.55	0.00042	0.0451	-0.2	-0.16	Vitiligo;	chr22:41768656	chr22:41209122~41217627:-
HNSC	cis	rs4427176	0.507	rs7465249	ENSG00000254340.1	RP11-10A14.3	-3.55	0.00042	0.0451	-0.22	-0.16	Mosquito bite size;	chr8:9720883	chr8:9141424~9145435:+
HNSC	cis	rs9611565	0.512	rs139566	ENSG00000235513.1	RP4-756G23.5	3.55	0.00042	0.0451	0.2	0.16	Vitiligo;	chr22:41803273	chr22:41209122~41217627:-
HNSC	cis	rs180730	1	rs343197	ENSG00000251609.2	SETP12	3.55	0.00042	0.0451	0.23	0.16	Fasting plasma glucose;	chr4:120877330	chr4:120895494~120897083:-
HNSC	cis	rs66887589	0.967	rs6844263	ENSG00000249244.1	RP11-548H18.2	3.55	0.00042	0.0451	0.18	0.16	Diastolic blood pressure;	chr4:119512652	chr4:119391831~119395335:-
HNSC	cis	rs6787172	0.811	rs827102	ENSG00000272087.1	RP11-379F4.7	-3.55	0.00042	0.0451	-0.17	-0.16	Subjective well-being;	chr3:158222327	chr3:158693120~158693768:-
HNSC	cis	rs911555	0.504	rs4906340	ENSG00000269910.1	RP11-73M18.10	-3.55	0.00042	0.0451	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103694516~103695050:-
HNSC	cis	rs3736485	0.609	rs1456299	ENSG00000274528.1	CTD-2650P22.2	3.55	0.00042	0.0451	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51689868	chr15:52017167~52018032:-
HNSC	cis	rs987724	0.515	rs344079	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837783	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs344080	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837996	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs344082	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838290	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs344084	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838591	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs344087	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156842608	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs4680309	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs2874488	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs6765353	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:156671862~156674378:-
HNSC	cis	rs987724	0.515	rs7638330	ENSG00000243926.1	TIPARP-AS1	3.55	0.00042	0.0451	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:156671862~156674378:-
HNSC	cis	rs7615952	0.604	rs9837847	ENSG00000241278.1	ENPP7P4	-3.55	0.00042	0.0451	-0.28	-0.16	Blood pressure (smoking interaction);	chr3:125905076	chr3:125848223~125909372:+
HNSC	cis	rs9400467	0.508	rs11153294	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.00042	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs7451051	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.00042	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111297126~111298510:+
HNSC	cis	rs871012	0.502	rs17599812	ENSG00000251405.2	CTB-109A12.1	-3.55	0.00042	0.0451	-0.19	-0.16	IgG glycosylation;	chr5:157450982	chr5:157362615~157460078:-
HNSC	cis	rs11700980	0.551	rs12481736	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741335	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832024	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741370	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.515	rs12481795	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741408	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs34161405	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741518	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs12481819	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741579	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs56165045	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741705	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs56852856	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28741855	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.591	rs2832025	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742000	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832027	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742043	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832028	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742109	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832030	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742298	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832031	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742358	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832032	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742468	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832033	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742519	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832034	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742605	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832035	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742710	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832036	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742848	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832037	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28742924	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs11701759	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28743249	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs11701783	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28743307	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832040	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28743518	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832041	ENSG00000232855.5	AF131217.1	3.55	0.000421	0.0451	0.23	0.16	QRS complex (12-leadsum);	chr21:28743696	chr21:28439346~28674848:-
HNSC	cis	rs9649213	0.614	rs1006169	ENSG00000272950.1	RP11-307C18.1	-3.55	0.000421	0.0451	-0.24	-0.16	Prostate cancer (SNP x SNP interaction);	chr7:98309131	chr7:98322853~98323430:+
HNSC	cis	rs1005277	0.579	rs1780146	ENSG00000099251.13	HSD17B7P2	3.55	0.000421	0.0451	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38356380~38378505:+
HNSC	cis	rs7927592	0.731	rs643609	ENSG00000255031.4	RP11-802E16.3	3.55	0.000421	0.0451	0.13	0.16	Total body bone mineral density;	chr11:68474365	chr11:68050740~68053762:+
HNSC	cis	rs78579285	0.584	rs34908386	ENSG00000278341.1	RP5-1142A6.10	-3.55	0.000421	0.0451	-0.28	-0.16	Joint mobility (Beighton score);	chr16:88734505	chr16:88708956~88710437:-
HNSC	cis	rs225675	0.765	rs2842761	ENSG00000229017.5	LINC01277	3.55	0.000421	0.0451	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142120313	chr6:142966421~143038077:-
HNSC	cis	rs17203016	0.811	rs72951688	ENSG00000231908.1	IDH1-AS1	-3.55	0.000421	0.0451	-0.24	-0.16	Body mass index;	chr2:207363632	chr2:208255247~208256181:+
HNSC	cis	rs2904967	0.929	rs10750761	ENSG00000254614.2	AP003068.23	-3.55	0.000421	0.0451	-0.28	-0.16	Mean corpuscular volume;	chr11:65234620	chr11:65177606~65181834:-
HNSC	cis	rs7274811	0.681	rs210074	ENSG00000277301.1	RP5-1184F4.7	-3.55	0.000421	0.0451	-0.16	-0.16	Height;	chr20:33361950	chr20:32509959~32520285:+
HNSC	cis	rs7274811	0.681	rs186026	ENSG00000277301.1	RP5-1184F4.7	-3.55	0.000421	0.0451	-0.16	-0.16	Height;	chr20:33364187	chr20:32509959~32520285:+
HNSC	cis	rs1275468	0.731	rs1480001	ENSG00000257497.2	RP11-585P4.5	-3.55	0.000421	0.0451	-0.25	-0.16	Polycystic ovary syndrome;	chr12:75586939	chr12:75483454~75489820:-
HNSC	cis	rs1008375	1	rs7436403	ENSG00000249502.1	AC006160.5	3.55	0.000421	0.0451	0.17	0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691062	chr4:17587467~17614571:-
HNSC	cis	rs6012564	0.928	rs2038509	ENSG00000227431.4	CSE1L-AS1	3.55	0.000421	0.0451	0.19	0.16	Anger;	chr20:49191533	chr20:49040463~49046044:-
HNSC	cis	rs1538970	0.924	rs11211108	ENSG00000234329.1	RP11-767N6.2	3.55	0.000421	0.0451	0.19	0.16	Platelet count;	chr1:45425480	chr1:45651039~45651826:-
HNSC	cis	rs1538970	0.924	rs10890327	ENSG00000234329.1	RP11-767N6.2	3.55	0.000421	0.0451	0.19	0.16	Platelet count;	chr1:45425786	chr1:45651039~45651826:-
HNSC	cis	rs7823467	0.851	rs7838118	ENSG00000167912.5	RP11-25K19.1	-3.55	0.000421	0.0451	-0.18	-0.16	Refractive astigmatism;	chr8:59148244	chr8:59119040~59121346:+
HNSC	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	3.55	0.000421	0.0451	0.19	0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
HNSC	cis	rs750460	1	rs750460	ENSG00000261801.4	LOXL1-AS1	-3.55	0.000421	0.0451	-0.15	-0.16	Height;	chr15:73949165	chr15:73908071~73928248:-
HNSC	cis	rs7208859	0.623	rs11658022	ENSG00000264538.5	SUZ12P1	-3.55	0.000421	0.0451	-0.16	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30709299~30790908:+
HNSC	cis	rs10131894	0.575	rs2159904	ENSG00000279594.1	RP11-950C14.10	3.55	0.000421	0.0451	0.2	0.16	Coronary artery disease;	chr14:74965476	chr14:75011269~75012851:-
HNSC	cis	rs41369048	0.8	rs2784252	ENSG00000238078.1	LINC01352	-3.55	0.000421	0.0451	-0.21	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220889342	chr1:220829255~220832429:+
HNSC	cis	rs7688540	0.8	rs1578898	ENSG00000250892.1	RP11-1365D11.1	-3.55	0.000421	0.0451	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:201409~205009:-
HNSC	cis	rs56346965	0.506	rs929566	ENSG00000228509.4	AC006460.2	3.55	0.000421	0.0451	0.2	0.16	Bone mineral density (Ward's triangle area);	chr2:190656715	chr2:190676944~190708716:-
HNSC	cis	rs2468186	0.583	rs2450069	ENSG00000279347.1	RP11-85I17.2	-3.55	0.000421	0.0451	-0.14	-0.16	Osteoprotegerin levels;	chr8:119083589	chr8:119838736~119840385:-
HNSC	cis	rs2468186	0.583	rs2450068	ENSG00000279347.1	RP11-85I17.2	-3.55	0.000421	0.0451	-0.14	-0.16	Osteoprotegerin levels;	chr8:119083620	chr8:119838736~119840385:-
HNSC	cis	rs62070183	0.766	rs10512441	ENSG00000226377.1	AC084809.2	-3.55	0.000421	0.0451	-0.24	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32876759~32878637:+
HNSC	cis	rs7760535	0.811	rs1002475	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Metabolic traits;	chr6:111388386	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs11153288	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs11153290	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs11153291	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs11153292	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs12190634	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0451	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111297126~111298510:+
HNSC	cis	rs6496044	0.963	rs7165300	ENSG00000259407.1	RP11-158M2.3	-3.55	0.000421	0.0451	-0.18	-0.16	Interstitial lung disease;	chr15:85526838	chr15:85744109~85750281:-
HNSC	cis	rs1867631	0.958	rs7520226	ENSG00000248458.2	RP4-598P13.1	3.55	0.000421	0.0452	0.16	0.16	Menopause (age at onset);	chr1:66615312	chr1:66665864~66677027:-
HNSC	cis	rs9400467	0.508	rs11153293	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0452	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.508	rs11756643	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000421	0.0452	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111297126~111298510:+
HNSC	cis	rs160451	0.782	rs10956226	ENSG00000251136.7	RP11-37B2.1	3.55	0.000422	0.0452	0.15	0.16	Leprosy;	chr8:89687131	chr8:89609409~89757727:-
HNSC	cis	rs2032447	0.898	rs807205	ENSG00000272462.2	U91328.19	-3.55	0.000422	0.0452	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26074807	chr6:25992662~26001775:+
HNSC	cis	rs868153	0.591	rs12661260	ENSG00000275339.1	RP3-425C14.6	3.55	0.000422	0.0452	0.17	0.16	Vertical cup-disc ratio;	chr6:122254940	chr6:122454358~122454612:+
HNSC	cis	rs7824557	0.815	rs2572430	ENSG00000255310.2	AF131215.2	3.55	0.000422	0.0452	0.16	0.16	Retinal vascular caliber;	chr8:11247795	chr8:11107788~11109726:-
HNSC	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-3.55	0.000422	0.0452	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
HNSC	cis	rs7735319	0.565	rs9292482	ENSG00000249102.1	CTD-2066L21.1	-3.55	0.000422	0.0452	-0.18	-0.16	Systolic blood pressure;	chr5:33140561	chr5:33008994~33025724:+
HNSC	cis	rs4713118	0.513	rs149955	ENSG00000219891.2	ZSCAN12P1	3.55	0.000422	0.0452	0.22	0.16	Parkinson's disease;	chr6:28068447	chr6:28091154~28093664:+
HNSC	cis	rs7429990	0.895	rs35790549	ENSG00000228638.1	FCF1P2	-3.55	0.000422	0.0452	-0.16	-0.16	Educational attainment (years of education);	chr3:48029998	chr3:48290793~48291375:-
HNSC	cis	rs17489649	0.956	rs2269210	ENSG00000271849.1	CTC-332L22.1	3.55	0.000422	0.0452	0.21	0.16	Intelligence (multi-trait analysis);	chr5:109793064	chr5:109687802~109688329:-
HNSC	cis	rs6095360	1	rs1569750	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000422	0.0452	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48986704	chr20:49040463~49046044:-
HNSC	cis	rs3096299	0.658	rs12443705	ENSG00000261118.1	RP11-104N10.1	3.55	0.000422	0.0452	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89492017~89504460:-
HNSC	cis	rs34286592	0.929	rs9939514	ENSG00000196796.5	CTB-134H23.2	3.55	0.000422	0.0452	0.24	0.16	Multiple sclerosis;	chr16:29844410	chr16:29038655~29052726:+
HNSC	cis	rs2347867	0.614	rs1913474	ENSG00000218996.1	RP1-99E18.2	3.55	0.000422	0.0452	0.22	0.16	Age at first birth;	chr6:151887587	chr6:150934968~150935566:+
HNSC	cis	rs6088580	0.619	rs1205335	ENSG00000276073.1	RP5-1125A11.7	3.55	0.000422	0.0452	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:33985617~33988989:-
HNSC	cis	rs8014204	0.604	rs11159109	ENSG00000259138.1	RP11-950C14.7	3.55	0.000422	0.0452	0.18	0.16	Caffeine consumption;	chr14:74922371	chr14:75127153~75136930:+
HNSC	cis	rs4853525	0.617	rs3771313	ENSG00000235852.1	AC005540.3	-3.55	0.000422	0.0452	-0.19	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190900480	chr2:190880797~190882059:-
HNSC	cis	rs189798	0.738	rs330908	ENSG00000253893.2	FAM85B	-3.55	0.000422	0.0452	-0.2	-0.16	Myopia (pathological);	chr8:9137656	chr8:8167819~8226614:-
HNSC	cis	rs4835473	0.897	rs4054616	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000422	0.0452	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143837472	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.897	rs2323325	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000422	0.0452	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143837561	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.8	rs4835330	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000422	0.0452	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143846303	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.736	rs6851661	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000422	0.0452	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143850587	chr4:143911514~143912053:-
HNSC	cis	rs875971	0.54	rs35510581	ENSG00000273142.1	RP11-458F8.4	3.55	0.000422	0.0452	0.14	0.16	Aortic root size;	chr7:66113790	chr7:66902857~66906297:+
HNSC	cis	rs12701220	0.655	rs11489405	ENSG00000224079.1	AC091729.7	3.55	0.000422	0.0452	0.23	0.16	Bronchopulmonary dysplasia;	chr7:1100256	chr7:1074450~1078036:+
HNSC	cis	rs333332	0.961	rs333333	ENSG00000240622.1	RPL7P15	3.55	0.000422	0.0452	0.17	0.16	Heschl's gyrus morphology;	chr3:124609541	chr3:124151960~124153063:-
HNSC	cis	rs7746199	0.736	rs72845070	ENSG00000226314.6	ZNF192P1	-3.55	0.000422	0.0452	-0.31	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28161781~28169594:+
HNSC	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-3.55	0.000422	0.0452	-0.16	-0.16	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
HNSC	cis	rs2518049	0.51	rs7090038	ENSG00000224034.1	RP11-445P17.8	-3.55	0.000422	0.0453	-0.18	-0.16	Metabolic traits;	chr10:5161118	chr10:5266033~5271236:-
HNSC	cis	rs988913	0.957	rs10485136	ENSG00000224984.1	RP11-524H19.2	-3.55	0.000423	0.0453	-0.18	-0.16	Menarche (age at onset);	chr6:54891697	chr6:54840118~54840855:-
HNSC	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-3.55	0.000423	0.0453	-0.16	-0.16	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
HNSC	cis	rs1722133	0.869	rs2690720	ENSG00000221971.3	TTC4P1	3.55	0.000423	0.0453	0.17	0.16	Sitting height ratio;	chr7:46086197	chr7:45999621~46000778:-
HNSC	cis	rs911119	1	rs6036478	ENSG00000270001.1	RP11-218C14.8	-3.55	0.000423	0.0453	-0.24	-0.16	Chronic kidney disease;	chr20:23630722	chr20:23631826~23632316:-
HNSC	cis	rs2307394	1	rs12473564	ENSG00000281469.1	RP11-567F11.1	3.55	0.000423	0.0453	0.18	0.16	Urate levels;	chr2:148036161	chr2:148044380~148044894:+
HNSC	cis	rs6787172	0.582	rs1656377	ENSG00000272087.1	RP11-379F4.7	-3.55	0.000423	0.0453	-0.18	-0.16	Subjective well-being;	chr3:158567491	chr3:158693120~158693768:-
HNSC	cis	rs2439831	0.717	rs2447198	ENSG00000166763.7	STRCP1	-3.55	0.000423	0.0453	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43602920	chr15:43699488~43718184:-
HNSC	cis	rs8074700	0.648	rs62064612	ENSG00000239552.2	HOXB-AS2	-3.55	0.000423	0.0453	-0.23	-0.16	Body mass index in non-asthmatics;	chr17:48667259	chr17:48557262~48560333:+
HNSC	cis	rs10851478	0.872	rs12906134	ENSG00000259656.1	RP11-325E5.1	3.55	0.000423	0.0453	0.19	0.16	Oral cavity cancer;	chr15:49677423	chr15:49101791~49103264:+
HNSC	cis	rs4535700	0.501	rs28678267	ENSG00000213650.3	RP11-760D2.7	-3.55	0.000423	0.0453	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55941797	chr7:56567906~56568858:-
HNSC	cis	rs4535700	0.501	rs11765531	ENSG00000213650.3	RP11-760D2.7	-3.55	0.000423	0.0453	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55942594	chr7:56567906~56568858:-
HNSC	cis	rs4535700	0.501	rs10227764	ENSG00000213650.3	RP11-760D2.7	-3.55	0.000423	0.0453	-0.19	-0.16	Macular telangiectasia type 2;	chr7:55944729	chr7:56567906~56568858:-
HNSC	cis	rs3096299	0.967	rs2911255	ENSG00000261118.1	RP11-104N10.1	3.55	0.000423	0.0453	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89492017~89504460:-
HNSC	cis	rs859767	0.812	rs842357	ENSG00000224043.6	CCNT2-AS1	-3.55	0.000423	0.0453	-0.19	-0.16	Neuroticism;	chr2:134587489	chr2:134735464~134918710:-
HNSC	cis	rs2337406	0.714	rs117798641	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000423	0.0453	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777984	chr14:106762092~106762588:-
HNSC	cis	rs2991971	0.81	rs12119202	ENSG00000234329.1	RP11-767N6.2	3.55	0.000423	0.0453	0.16	0.16	High light scatter reticulocyte count;	chr1:45460259	chr1:45651039~45651826:-
HNSC	cis	rs6545883	0.791	rs2600665	ENSG00000271889.1	RP11-493E12.1	3.55	0.000423	0.0453	0.19	0.16	Tuberculosis;	chr2:61178660	chr2:61151433~61162105:-
HNSC	cis	rs2762353	1	rs2762353	ENSG00000272462.2	U91328.19	-3.55	0.000423	0.0453	-0.16	-0.16	Blood metabolite levels;	chr6:25794203	chr6:25992662~26001775:+
HNSC	cis	rs3748656	1	rs1106287	ENSG00000273483.1	RP4-671G15.2	3.55	0.000423	0.0453	0.22	0.16	Hip circumference adjusted for BMI;	chr1:112699500	chr1:112517799~112518441:-
HNSC	cis	rs9437689	0.69	rs7547662	ENSG00000237416.5	RP11-465K1.2	3.55	0.000423	0.0453	0.2	0.16	Phospholipid levels (plasma);	chr1:94991680	chr1:94836748~94855426:-
HNSC	cis	rs8077577	0.747	rs7215678	ENSG00000260647.1	RP1-178F10.1	-3.55	0.000423	0.0453	-0.23	-0.16	Obesity-related traits;	chr17:18236479	chr17:18268080~18268828:+
HNSC	cis	rs10134944	1	rs12890287	ENSG00000258900.1	HNRNPCP1	3.55	0.000423	0.0453	0.3	0.16	Bipolar disorder;	chr14:57654927	chr14:58521223~58521988:+
HNSC	cis	rs875971	0.66	rs801217	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000423	0.0453	-0.13	-0.16	Aortic root size;	chr7:66545590	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.638	rs801216	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000423	0.0453	-0.13	-0.16	Aortic root size;	chr7:66546680	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs801211	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000423	0.0453	-0.13	-0.16	Aortic root size;	chr7:66550702	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.638	rs801205	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000423	0.0453	-0.13	-0.16	Aortic root size;	chr7:66557157	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.617	rs810400	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000423	0.0453	-0.13	-0.16	Aortic root size;	chr7:66557902	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.66	rs13224319	ENSG00000272831.1	RP11-792A8.4	3.55	0.000423	0.0453	0.13	0.16	Aortic root size;	chr7:66542376	chr7:66739829~66740385:-
HNSC	cis	rs656319	0.559	rs60384372	ENSG00000254340.1	RP11-10A14.3	-3.55	0.000423	0.0453	-0.2	-0.16	Myopia (pathological);	chr8:10117074	chr8:9141424~9145435:+
HNSC	cis	rs853679	1	rs7740487	ENSG00000270326.1	RP5-874C20.6	-3.55	0.000423	0.0453	-0.24	-0.16	Depression;	chr6:28248708	chr6:28319660~28319852:-
HNSC	cis	rs853679	1	rs68141011	ENSG00000270326.1	RP5-874C20.6	-3.55	0.000423	0.0453	-0.24	-0.16	Depression;	chr6:28250019	chr6:28319660~28319852:-
HNSC	cis	rs853679	1	rs13200462	ENSG00000270326.1	RP5-874C20.6	-3.55	0.000423	0.0453	-0.24	-0.16	Depression;	chr6:28250421	chr6:28319660~28319852:-
HNSC	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	3.55	0.000423	0.0453	0.19	0.16	Height;	chr14:75198236	chr14:75011269~75012851:-
HNSC	cis	rs6988985	0.678	rs10110732	ENSG00000247317.3	RP11-273G15.2	3.55	0.000424	0.0453	0.18	0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142914578	chr8:142981738~143018437:-
HNSC	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	3.55	0.000424	0.0453	0.19	0.16	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
HNSC	cis	rs6545883	0.86	rs6749226	ENSG00000271889.1	RP11-493E12.1	-3.55	0.000424	0.0453	-0.19	-0.16	Tuberculosis;	chr2:61282648	chr2:61151433~61162105:-
HNSC	cis	rs67478160	0.643	rs12434686	ENSG00000259515.1	RP11-365N19.2	-3.55	0.000424	0.0453	-0.14	-0.16	Schizophrenia;	chr14:103849696	chr14:102933574~102937177:+
HNSC	cis	rs950169	0.84	rs62019457	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000424	0.0454	-0.18	-0.16	Schizophrenia;	chr15:84558911	chr15:84507885~84516814:-
HNSC	cis	rs7824557	0.527	rs10109537	ENSG00000255495.1	AC145124.2	-3.55	0.000424	0.0454	-0.18	-0.16	Retinal vascular caliber;	chr8:11382131	chr8:12194467~12196280:+
HNSC	cis	rs4555082	0.794	rs2735827	ENSG00000253701.2	AL928768.3	3.55	0.000424	0.0454	0.13	0.16	Platelet distribution width;Mean platelet volume;	chr14:105244263	chr14:105703961~105704602:-
HNSC	cis	rs4704846	0.66	rs246878	ENSG00000253519.1	AC106801.1	3.55	0.000424	0.0454	0.27	0.16	Blood protein levels;	chr5:157129663	chr5:157565964~157569098:+
HNSC	cis	rs4704846	0.66	rs246879	ENSG00000253519.1	AC106801.1	3.55	0.000424	0.0454	0.27	0.16	Blood protein levels;	chr5:157129835	chr5:157565964~157569098:+
HNSC	cis	rs736408	0.546	rs3733046	ENSG00000243224.1	RP5-1157M23.2	-3.55	0.000424	0.0454	-0.16	-0.16	Bipolar disorder;	chr3:52587611	chr3:52239258~52241097:+
HNSC	cis	rs6088580	0.634	rs4911151	ENSG00000276073.1	RP5-1125A11.7	3.55	0.000424	0.0454	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:33985617~33988989:-
HNSC	cis	rs6088580	0.634	rs6088471	ENSG00000276073.1	RP5-1125A11.7	3.55	0.000424	0.0454	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:33985617~33988989:-
HNSC	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-3.55	0.000424	0.0454	-0.19	-0.16	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
HNSC	cis	rs7726839	0.54	rs74553517	ENSG00000225138.6	CTD-2228K2.7	3.55	0.000424	0.0454	0.24	0.16	Obesity-related traits;	chr5:665556	chr5:473236~480884:+
HNSC	cis	rs12030196	0.778	rs12748496	ENSG00000230812.4	LINC01358	3.55	0.000424	0.0454	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59020879	chr1:59020387~59044614:+
HNSC	cis	rs10435719	0.867	rs6999030	ENSG00000269918.1	AF131215.9	3.55	0.000424	0.0454	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11104691~11106704:-
HNSC	cis	rs10435719	0.834	rs6985792	ENSG00000269918.1	AF131215.9	3.55	0.000424	0.0454	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11104691~11106704:-
HNSC	cis	rs911555	0.655	rs10141157	ENSG00000269910.1	RP11-73M18.10	3.55	0.000424	0.0454	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103694516~103695050:-
HNSC	cis	rs11603023	0.625	rs633683	ENSG00000278376.1	RP11-158I9.8	-3.55	0.000424	0.0454	-0.13	-0.16	Cholesterol, total;	chr11:118634025	chr11:118791254~118793137:+
HNSC	cis	rs73201462	1	rs2999068	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259135	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999067	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259688	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2955099	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260811	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999066	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128261443	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2999065	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128262595	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811545	ENSG00000231305.3	RP11-723O4.2	3.55	0.000424	0.0454	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264305	chr3:128861313~128871540:-
HNSC	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-3.55	0.000424	0.0454	-0.19	-0.16	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
HNSC	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-3.55	0.000424	0.0454	-0.19	-0.16	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
HNSC	cis	rs5751168	0.85	rs5758478	ENSG00000274422.1	LL22NC03-2H8.5	3.55	0.000424	0.0454	0.2	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22487516	chr22:22283928~22287220:-
HNSC	cis	rs7824557	0.578	rs2060458	ENSG00000255495.1	AC145124.2	3.55	0.000424	0.0454	0.18	0.16	Retinal vascular caliber;	chr8:11355302	chr8:12194467~12196280:+
HNSC	cis	rs9863	0.794	rs7978610	ENSG00000270028.1	RP11-380L11.4	-3.55	0.000424	0.0454	-0.19	-0.16	White blood cell count;	chr12:123984025	chr12:123925461~123926083:-
HNSC	cis	rs7572733	0.515	rs13382697	ENSG00000231621.1	AC013264.2	-3.55	0.000424	0.0454	-0.16	-0.16	Dermatomyositis;	chr2:198055836	chr2:197197991~197199273:+
HNSC	cis	rs2904524	1	rs17107924	ENSG00000257815.4	RP11-611E13.2	3.55	0.000424	0.0454	0.21	0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70280875	chr12:69904033~70243360:-
HNSC	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000424	0.0454	-0.22	-0.16	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
HNSC	cis	rs7772486	0.714	rs1883365	ENSG00000270638.1	RP3-466P17.1	-3.55	0.000424	0.0454	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145735570~145737218:+
HNSC	cis	rs4974559	0.947	rs28711287	ENSG00000254094.1	AC078852.1	3.55	0.000424	0.0454	0.27	0.16	Systolic blood pressure;	chr4:1352894	chr4:1356581~1358075:+
HNSC	cis	rs2084898	1	rs2084899	ENSG00000176984.5	AP000679.2	3.55	0.000425	0.0454	0.26	0.16	Stroke (pediatric);	chr11:120156102	chr11:120168977~120171679:+
HNSC	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-3.55	0.000425	0.0454	-0.26	-0.16	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
HNSC	cis	rs1387259	0.619	rs7134565	ENSG00000240399.1	RP1-228P16.1	-3.55	0.000425	0.0454	-0.13	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48054813~48055591:-
HNSC	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-3.55	0.000425	0.0454	-0.15	-0.16	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
HNSC	cis	rs3176789	0.914	rs10772132	ENSG00000256673.1	RP11-599J14.2	-3.55	0.000425	0.0454	-0.17	-0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772316	chr12:9398355~9414851:-
HNSC	cis	rs12701220	0.817	rs7798459	ENSG00000224079.1	AC091729.7	3.55	0.000425	0.0454	0.23	0.16	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1074450~1078036:+
HNSC	cis	rs6787172	0.748	rs7630443	ENSG00000272440.1	RP11-379F4.6	-3.55	0.000425	0.0454	-0.17	-0.16	Subjective well-being;	chr3:158406115	chr3:158695367~158695581:+
HNSC	cis	rs6988985	0.678	rs28710914	ENSG00000247317.3	RP11-273G15.2	-3.55	0.000425	0.0454	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921874	chr8:142981738~143018437:-
HNSC	cis	rs2905347	0.696	rs2905319	ENSG00000179428.2	AC073072.5	3.55	0.000425	0.0454	0.19	0.16	Major depression and alcohol dependence;	chr7:22657522	chr7:22725395~22727620:-
HNSC	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	3.55	0.000425	0.0454	0.19	0.16	Height;	chr4:55528801	chr4:55540502~55540835:-
HNSC	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	3.55	0.000425	0.0454	0.19	0.16	Height;	chr4:55529387	chr4:55540502~55540835:-
HNSC	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	3.55	0.000425	0.0454	0.19	0.16	Height;	chr4:55529786	chr4:55540502~55540835:-
HNSC	cis	rs9400467	0.528	rs9689727	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000425	0.0454	-0.2	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs12214380	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000425	0.0454	-0.2	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111297126~111298510:+
HNSC	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
HNSC	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0454	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
HNSC	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	3.55	0.000425	0.0454	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
HNSC	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	3.55	0.000425	0.0454	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
HNSC	cis	rs12410462	0.502	rs77615958	ENSG00000224834.1	BTF3P9	3.55	0.000425	0.0454	0.3	0.16	Major depressive disorder;	chr1:227618382	chr1:227434064~227434346:+
HNSC	cis	rs2279168	0.737	rs7178054	ENSG00000259295.5	CSPG4P12	3.55	0.000425	0.0454	0.35	0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85440272	chr15:85191438~85213905:+
HNSC	cis	rs875971	0.66	rs10215132	ENSG00000273142.1	RP11-458F8.4	3.55	0.000425	0.0454	0.14	0.16	Aortic root size;	chr7:66589419	chr7:66902857~66906297:+
HNSC	cis	rs73198271	0.74	rs10113326	ENSG00000254153.1	CTA-398F10.2	-3.55	0.000425	0.0454	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8456909~8461337:-
HNSC	cis	rs16828019	0.777	rs34502739	ENSG00000281207.1	SLFNL1-AS1	3.55	0.000425	0.0455	0.2	0.16	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41014590~41043890:+
HNSC	cis	rs16828019	0.777	rs67450703	ENSG00000281207.1	SLFNL1-AS1	3.55	0.000425	0.0455	0.2	0.16	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41014590~41043890:+
HNSC	cis	rs6058526	0.631	rs1884865	ENSG00000224628.2	RP5-854E16.2	-3.55	0.000425	0.0455	-0.22	-0.16	Chronic obstructive pulmonary disease;	chr20:32234059	chr20:31285317~31286835:-
HNSC	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	3.55	0.000425	0.0455	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
HNSC	cis	rs1832007	0.554	rs75353459	ENSG00000224034.1	RP11-445P17.8	-3.55	0.000425	0.0455	-0.2	-0.16	Triglyceride levels;Triglycerides;	chr10:5202899	chr10:5266033~5271236:-
HNSC	cis	rs1832007	0.554	rs77506074	ENSG00000224034.1	RP11-445P17.8	-3.55	0.000425	0.0455	-0.2	-0.16	Triglyceride levels;Triglycerides;	chr10:5202905	chr10:5266033~5271236:-
HNSC	cis	rs1832007	0.554	rs11594428	ENSG00000224034.1	RP11-445P17.8	-3.55	0.000425	0.0455	-0.2	-0.16	Triglyceride levels;Triglycerides;	chr10:5203006	chr10:5266033~5271236:-
HNSC	cis	rs868153	0.591	rs7450267	ENSG00000275339.1	RP3-425C14.6	3.55	0.000425	0.0455	0.17	0.16	Vertical cup-disc ratio;	chr6:122167888	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs1456699	ENSG00000275339.1	RP3-425C14.6	3.55	0.000425	0.0455	0.17	0.16	Vertical cup-disc ratio;	chr6:122168800	chr6:122454358~122454612:+
HNSC	cis	rs868153	0.591	rs2316266	ENSG00000275339.1	RP3-425C14.6	3.55	0.000425	0.0455	0.17	0.16	Vertical cup-disc ratio;	chr6:122175481	chr6:122454358~122454612:+
HNSC	cis	rs9914544	0.564	rs9906799	ENSG00000264885.1	RP11-815I9.4	-3.55	0.000425	0.0455	-0.16	-0.16	Educational attainment (years of education);	chr17:18892004	chr17:18667629~18669461:-
HNSC	cis	rs1028883	0.87	rs9530201	ENSG00000228295.1	LINC00392	-3.55	0.000425	0.0455	-0.17	-0.16	Lean body mass;	chr13:73542254	chr13:73564244~73588070:+
HNSC	cis	rs860295	0.535	rs2297649	ENSG00000225855.5	RUSC1-AS1	-3.55	0.000425	0.0455	-0.11	-0.16	Body mass index;	chr1:155965453	chr1:155316863~155324176:-
HNSC	cis	rs10927875	0.541	rs1739843	ENSG00000226457.1	RP11-430L17.1	-3.55	0.000425	0.0455	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016759	chr1:16369150~16369530:-
HNSC	cis	rs10927875	0.518	rs1763597	ENSG00000226457.1	RP11-430L17.1	-3.55	0.000425	0.0455	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016802	chr1:16369150~16369530:-
HNSC	cis	rs10927875	0.541	rs1739844	ENSG00000226457.1	RP11-430L17.1	-3.55	0.000425	0.0455	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016827	chr1:16369150~16369530:-
HNSC	cis	rs4295623	0.556	rs10903343	ENSG00000255310.2	AF131215.2	3.55	0.000425	0.0455	0.16	0.16	Morning vs. evening chronotype;	chr8:11838363	chr8:11107788~11109726:-
HNSC	cis	rs7071247	0.915	rs3740474	ENSG00000266852.2	MIR4482	3.55	0.000425	0.0455	0.24	0.16	Platelet aggregation;	chr10:103515184	chr10:104268336~104268405:-
HNSC	cis	rs7772486	0.875	rs2748497	ENSG00000270638.1	RP3-466P17.1	3.55	0.000425	0.0455	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145735570~145737218:+
HNSC	cis	rs6088580	0.634	rs6059868	ENSG00000276073.1	RP5-1125A11.7	-3.55	0.000425	0.0455	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:33985617~33988989:-
HNSC	cis	rs17221829	0.673	rs10830334	ENSG00000280385.1	AP000648.5	-3.55	0.000426	0.0455	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89670753	chr11:90193614~90198120:+
HNSC	cis	rs2243480	1	rs160655	ENSG00000226002.1	RP11-460N20.5	-3.55	0.000426	0.0455	-0.27	-0.16	Diabetic kidney disease;	chr7:66068227	chr7:65084103~65100232:+
HNSC	cis	rs60695258	0.594	rs6531946	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000426	0.0455	-0.17	-0.16	Hematocrit;	chr4:87044239	chr4:86913266~86914817:-
HNSC	cis	rs728616	0.614	rs61859199	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000426	0.0455	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs1538818	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000426	0.0455	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61859209	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000426	0.0455	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79663088~79826594:-
HNSC	cis	rs728616	0.614	rs61859210	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000426	0.0455	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79663088~79826594:-
HNSC	cis	rs73173548	0.528	rs12189274	ENSG00000247828.6	TMEM161B-AS1	-3.55	0.000426	0.0455	-0.17	-0.16	Macular telangiectasia type 2;	chr5:88468669	chr5:88268895~88436685:+
HNSC	cis	rs561341	0.709	rs11542477	ENSG00000278867.1	RP11-640N20.4	3.55	0.000426	0.0455	0.24	0.16	Hip circumference adjusted for BMI;	chr17:31858873	chr17:32051030~32053208:+
HNSC	cis	rs4711350	0.723	rs6915136	ENSG00000224557.6	HLA-DPB2	-3.55	0.000426	0.0455	-0.26	-0.16	Schizophrenia;	chr6:33683545	chr6:33112451~33129084:+
HNSC	cis	rs2337406	0.866	rs7152809	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0455	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106778385	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs7152832	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0455	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106778427	chr14:106762092~106762588:-
HNSC	cis	rs2976388	1	rs2920295	ENSG00000253741.1	CTD-2292P10.4	3.55	0.000426	0.0455	0.15	0.16	Urinary tract infection frequency;	chr8:142683519	chr8:142702252~142726973:-
HNSC	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	3.55	0.000426	0.0455	0.16	0.16	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
HNSC	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	3.55	0.000426	0.0455	0.16	0.16	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
HNSC	cis	rs2991971	0.716	rs7532573	ENSG00000234329.1	RP11-767N6.2	3.55	0.000426	0.0455	0.17	0.16	High light scatter reticulocyte count;	chr1:45450220	chr1:45651039~45651826:-
HNSC	cis	rs801193	1	rs13239306	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000426	0.0455	-0.14	-0.16	Aortic root size;	chr7:66671030	chr7:66739829~66740385:-
HNSC	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000426	0.0455	-0.21	-0.16	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000426	0.0455	-0.21	-0.16	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000426	0.0455	-0.21	-0.16	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
HNSC	cis	rs11756659	0.653	rs199729	ENSG00000216331.1	HIST1H1PS1	3.55	0.000426	0.0455	0.24	0.16	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:26195566~26195771:+
HNSC	cis	rs911555	0.706	rs10129426	ENSG00000269910.1	RP11-73M18.10	3.55	0.000426	0.0455	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694516~103695050:-
HNSC	cis	rs4144743	1	rs72823473	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.000426	0.0455	-0.19	-0.16	Body mass index;	chr17:47244409	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs72823474	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.000426	0.0455	-0.19	-0.16	Body mass index;	chr17:47244410	chr17:47450568~47492492:-
HNSC	cis	rs8030379	0.967	rs6603000	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000426	0.0455	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883142	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs12916223	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000426	0.0455	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883742	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.875	rs28801104	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000426	0.0455	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884091	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs12900412	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000426	0.0455	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884314	chr15:84507885~84516814:-
HNSC	cis	rs73201462	0.803	rs2811478	ENSG00000231305.3	RP11-723O4.2	-3.55	0.000426	0.0455	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128180781	chr3:128861313~128871540:-
HNSC	cis	rs17489649	1	rs3776933	ENSG00000271849.1	CTC-332L22.1	3.55	0.000426	0.0456	0.21	0.16	Intelligence (multi-trait analysis);	chr5:109805922	chr5:109687802~109688329:-
HNSC	cis	rs35740288	0.822	rs2306225	ENSG00000259407.1	RP11-158M2.3	-3.55	0.000426	0.0456	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85744109~85750281:-
HNSC	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000426	0.0456	-0.22	-0.16	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
HNSC	cis	rs6964587	0.869	rs10250014	ENSG00000188693.7	CYP51A1-AS1	3.55	0.000426	0.0456	0.17	0.16	Breast cancer;	chr7:91860894	chr7:92134604~92180725:+
HNSC	cis	rs765751	0.775	rs1531097	ENSG00000228536.1	RP11-392O17.1	-3.55	0.000426	0.0456	-0.19	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219483418	chr1:219409681~219411941:-
HNSC	cis	rs7429990	0.833	rs6777632	ENSG00000228638.1	FCF1P2	3.55	0.000426	0.0456	0.15	0.16	Educational attainment (years of education);	chr3:47748775	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs13098128	ENSG00000228638.1	FCF1P2	3.55	0.000426	0.0456	0.15	0.16	Educational attainment (years of education);	chr3:47756066	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs6442085	ENSG00000228638.1	FCF1P2	3.55	0.000426	0.0456	0.15	0.16	Educational attainment (years of education);	chr3:47760080	chr3:48290793~48291375:-
HNSC	cis	rs5754249	0.805	rs5754248	ENSG00000128254.12	C22orf24	3.55	0.000426	0.0456	0.19	0.16	Blood protein levels;	chr22:32751497	chr22:31933521~31945518:-
HNSC	cis	rs2243480	0.522	rs431168	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000426	0.0456	0.35	0.16	Diabetic kidney disease;	chr7:66046617	chr7:66025126~66031544:-
HNSC	cis	rs6430585	0.583	rs4988145	ENSG00000231890.6	DARS-AS1	-3.55	0.000427	0.0456	-0.29	-0.16	Corneal structure;	chr2:135874730	chr2:135985176~136022593:+
HNSC	cis	rs875971	0.83	rs427973	ENSG00000232559.3	GS1-124K5.12	3.55	0.000427	0.0456	0.18	0.16	Aortic root size;	chr7:66061661	chr7:66554588~66576923:-
HNSC	cis	rs6142618	0.555	rs242602	ENSG00000275576.1	RP5-836N17.4	3.55	0.000427	0.0456	0.16	0.16	Inflammatory bowel disease;	chr20:32079145	chr20:32116171~32116629:+
HNSC	cis	rs9297145	0.715	rs62473008	ENSG00000272950.1	RP11-307C18.1	-3.55	0.000427	0.0456	-0.25	-0.16	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99153918	chr7:98322853~98323430:+
HNSC	cis	rs2179367	0.92	rs638407	ENSG00000216906.2	RP11-350J20.9	3.55	0.000427	0.0456	0.2	0.16	Dupuytren's disease;	chr6:149417214	chr6:149904243~149906418:+
HNSC	cis	rs1585471	0.965	rs4134086	ENSG00000249532.3	RP11-148B6.1	-3.55	0.000427	0.0456	-0.2	-0.16	Myopia (pathological);	chr4:111712885	chr4:112646476~112650051:-
HNSC	cis	rs1552244	0.935	rs41520445	ENSG00000180385.7	EMC3-AS1	-3.55	0.000427	0.0456	-0.18	-0.16	Alzheimer's disease;	chr3:10111457	chr3:9986893~10006990:+
HNSC	cis	rs9527	0.59	rs10883843	ENSG00000213277.3	MARCKSL1P1	-3.55	0.000427	0.0456	-0.18	-0.16	Arsenic metabolism;	chr10:103187736	chr10:103175554~103176094:+
HNSC	cis	rs28573326	0.646	rs35355030	ENSG00000121089.4	NACA3P	-3.55	0.000427	0.0456	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165394348	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.607	rs11724810	ENSG00000121089.4	NACA3P	-3.55	0.000427	0.0456	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165394537	chr4:164943290~164943937:+
HNSC	cis	rs12047808	1	rs74403477	ENSG00000227141.2	RP11-545A16.3	-3.55	0.000427	0.0456	-0.24	-0.16	Multiple sclerosis (age of onset);	chr1:179455245	chr1:179586705~179589175:+
HNSC	cis	rs4835473	0.932	rs1849113	ENSG00000249741.2	RP11-673E1.3	3.55	0.000427	0.0456	0.18	0.16	Immature fraction of reticulocytes;	chr4:143962512	chr4:143911514~143912053:-
HNSC	cis	rs58688157	0.705	rs7122021	ENSG00000255158.1	RP11-754B17.1	-3.55	0.000427	0.0456	-0.2	-0.16	Systemic lupus erythematosus;	chr11:595810	chr11:665910~678391:+
HNSC	cis	rs58688157	0.705	rs12419720	ENSG00000255158.1	RP11-754B17.1	-3.55	0.000427	0.0456	-0.2	-0.16	Systemic lupus erythematosus;	chr11:598205	chr11:665910~678391:+
HNSC	cis	rs58688157	0.705	rs36060383	ENSG00000255158.1	RP11-754B17.1	-3.55	0.000427	0.0456	-0.2	-0.16	Systemic lupus erythematosus;	chr11:598723	chr11:665910~678391:+
HNSC	cis	rs10506328	0.509	rs4759073	ENSG00000248265.1	FLJ12825	3.55	0.000427	0.0456	0.19	0.16	Mean platelet volume;	chr12:54259474	chr12:54058254~54122234:+
HNSC	cis	rs2153535	0.585	rs11243268	ENSG00000230939.1	RP11-314C16.1	-3.55	0.000427	0.0456	-0.19	-0.16	Motion sickness;	chr6:8662375	chr6:8784178~8785445:+
HNSC	cis	rs526231	0.543	rs26819	ENSG00000250682.4	LINC00491	3.55	0.000427	0.0456	0.22	0.16	Primary biliary cholangitis;	chr5:103193700	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.615	rs26818	ENSG00000250682.4	LINC00491	3.55	0.000427	0.0456	0.22	0.16	Primary biliary cholangitis;	chr5:103194018	chr5:102609156~102671559:-
HNSC	cis	rs988913	0.541	rs9464196	ENSG00000224984.1	RP11-524H19.2	-3.55	0.000427	0.0456	-0.18	-0.16	Menarche (age at onset);	chr6:55132851	chr6:54840118~54840855:-
HNSC	cis	rs3015469	0.517	rs11625096	ENSG00000214900.7	LINC01588	-3.55	0.000427	0.0456	-0.18	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50480660	chr14:49981712~50007520:-
HNSC	cis	rs9487051	0.735	rs1146246	ENSG00000243587.6	C6orf183	-3.55	0.000427	0.0456	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109198538	chr6:109165833~109271014:+
HNSC	cis	rs1190596	0.567	rs36060205	ENSG00000272444.1	RP11-1017G21.6	3.55	0.000427	0.0456	0.19	0.16	Behavioural disinhibition (generation interaction);	chr14:102253360	chr14:101952416~101953063:+
HNSC	cis	rs1832007	0.529	rs72772224	ENSG00000224034.1	RP11-445P17.8	-3.55	0.000427	0.0456	-0.2	-0.16	Triglyceride levels;Triglycerides;	chr10:5202739	chr10:5266033~5271236:-
HNSC	cis	rs60695258	0.517	rs867196	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000427	0.0456	-0.17	-0.16	Hematocrit;	chr4:87050448	chr4:86913266~86914817:-
HNSC	cis	rs60695258	0.572	rs375795	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000427	0.0456	-0.17	-0.16	Hematocrit;	chr4:87051313	chr4:86913266~86914817:-
HNSC	cis	rs60695258	0.55	rs2007132	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000427	0.0456	-0.17	-0.16	Hematocrit;	chr4:87051433	chr4:86913266~86914817:-
HNSC	cis	rs7646881	0.544	rs12637589	ENSG00000272087.1	RP11-379F4.7	3.55	0.000427	0.0456	0.25	0.16	Tetralogy of Fallot;	chr3:158625546	chr3:158693120~158693768:-
HNSC	cis	rs9505118	0.733	rs3778331	ENSG00000238221.1	RP11-69L16.4	3.55	0.000427	0.0456	0.2	0.16	Type 2 diabetes;	chr6:7305499	chr6:7276031~7298872:+
HNSC	cis	rs2245368	0.523	rs67814714	ENSG00000242435.1	UPK3BP1	3.55	0.000427	0.0456	0.24	0.16	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr7:76888105	chr7:77004662~77005774:+
HNSC	cis	rs9863	0.861	rs4765219	ENSG00000270028.1	RP11-380L11.4	3.55	0.000427	0.0456	0.19	0.16	White blood cell count;	chr12:123955563	chr12:123925461~123926083:-
HNSC	cis	rs853679	0.607	rs200489	ENSG00000219392.1	RP1-265C24.5	-3.55	0.000427	0.0456	-0.28	-0.16	Depression;	chr6:27830479	chr6:28115628~28116551:+
HNSC	cis	rs453301	0.658	rs6986044	ENSG00000253981.4	ALG1L13P	-3.55	0.000427	0.0457	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9017276	chr8:8236003~8244667:-
HNSC	cis	rs28489187	0.683	rs6576764	ENSG00000223653.4	RP11-131L23.1	-3.55	0.000428	0.0457	-0.22	-0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85400728	chr1:85276715~85448124:+
HNSC	cis	rs9409565	1	rs9409565	ENSG00000231806.2	PCAT7	-3.55	0.000428	0.0457	-0.19	-0.16	Colorectal cancer (alcohol consumption interaction);	chr9:94488752	chr9:94555069~94568127:+
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000428	0.0457	-0.23	-0.16	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
HNSC	cis	rs868153	0.625	rs13195388	ENSG00000275339.1	RP3-425C14.6	3.55	0.000428	0.0457	0.17	0.16	Vertical cup-disc ratio;	chr6:122165346	chr6:122454358~122454612:+
HNSC	cis	rs17508449	0.732	rs74533448	ENSG00000232450.1	RP4-730K3.3	-3.55	0.000428	0.0457	-0.27	-0.16	Leprosy;	chr1:113750266	chr1:113698884~113699631:-
HNSC	cis	rs1008375	0.966	rs7666888	ENSG00000249502.1	AC006160.5	-3.55	0.000428	0.0457	-0.17	-0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694099	chr4:17587467~17614571:-
HNSC	cis	rs77437330	0.667	rs12524058	ENSG00000215807.4	KRT18P65	-3.55	0.000428	0.0457	-0.38	-0.16	Skin pigmentation;	chr6:111751127	chr6:112361437~112362722:-
HNSC	cis	rs11711311	0.747	rs11928590	ENSG00000241529.3	RN7SL767P	-3.55	0.000428	0.0457	-0.21	-0.16	IgG glycosylation;	chr3:113624631	chr3:113632704~113632998:+
HNSC	cis	rs9467711	0.606	rs9379854	ENSG00000241549.7	GUSBP2	3.55	0.000428	0.0457	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26362626	chr6:26871484~26956554:-
HNSC	cis	rs60695258	0.55	rs6531948	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000428	0.0457	-0.17	-0.16	Hematocrit;	chr4:87051816	chr4:86913266~86914817:-
HNSC	cis	rs2562456	0.833	rs11666525	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21416503	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.793	rs62110424	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21416835	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.793	rs3853837	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21419172	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.793	rs3853838	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21419192	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62110426	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21420124	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.754	rs11666213	ENSG00000268119.4	CTD-2561J22.5	3.55	0.000428	0.0457	0.25	0.16	Pain;	chr19:21422843	chr19:21444241~21463908:-
HNSC	cis	rs9652601	0.691	rs12708717	ENSG00000274038.1	RP11-66H6.4	-3.55	0.000428	0.0457	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11098522	chr16:11056556~11057034:+
HNSC	cis	rs832540	0.618	rs2548663	ENSG00000225230.1	AC008937.3	3.55	0.000428	0.0457	0.18	0.16	Coronary artery disease;	chr5:56876951	chr5:56900041~56910714:-
HNSC	cis	rs875971	0.619	rs10278371	ENSG00000273142.1	RP11-458F8.4	3.55	0.000428	0.0457	0.14	0.16	Aortic root size;	chr7:66586553	chr7:66902857~66906297:+
HNSC	cis	rs2518049	1	rs2154309	ENSG00000224034.1	RP11-445P17.8	3.55	0.000428	0.0457	0.21	0.16	Metabolic traits;	chr10:5104985	chr10:5266033~5271236:-
HNSC	cis	rs9982086	0.793	rs2226328	ENSG00000260583.1	AP000223.42	3.55	0.000428	0.0457	0.31	0.16	Carboplatin disposition in epthelial ovarian cancer;	chr21:25614096	chr21:25582770~25583326:-
HNSC	cis	rs9925964	0.591	rs11649653	ENSG00000274678.1	RP11-2C24.7	-3.55	0.000428	0.0457	-0.17	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30907166	chr16:30821338~30821884:+
HNSC	cis	rs853679	0.607	rs34661125	ENSG00000219891.2	ZSCAN12P1	3.55	0.000428	0.0457	0.33	0.16	Depression;	chr6:28314117	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs13190888	ENSG00000219891.2	ZSCAN12P1	3.55	0.000428	0.0457	0.33	0.16	Depression;	chr6:28318208	chr6:28091154~28093664:+
HNSC	cis	rs17221829	0.703	rs75183199	ENSG00000280385.1	AP000648.5	-3.55	0.000428	0.0457	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89623819	chr11:90193614~90198120:+
HNSC	cis	rs17221829	0.769	rs11018674	ENSG00000280385.1	AP000648.5	-3.55	0.000428	0.0457	-0.19	-0.16	Anxiety in major depressive disorder;	chr11:89623945	chr11:90193614~90198120:+
HNSC	cis	rs7937890	1	rs2915401	ENSG00000254418.1	RP11-21L19.1	-3.55	0.000428	0.0457	-0.19	-0.16	Mitochondrial DNA levels;	chr11:14353467	chr11:14262846~14273691:-
HNSC	cis	rs7726839	0.54	rs61731455	ENSG00000225138.6	CTD-2228K2.7	3.55	0.000428	0.0457	0.24	0.16	Obesity-related traits;	chr5:665180	chr5:473236~480884:+
HNSC	cis	rs7824557	0.564	rs1435275	ENSG00000255495.1	AC145124.2	-3.55	0.000429	0.0457	-0.18	-0.16	Retinal vascular caliber;	chr8:11378226	chr8:12194467~12196280:+
HNSC	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	3.55	0.000429	0.0457	0.23	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
HNSC	cis	rs4919687	0.55	rs7904252	ENSG00000236937.2	PTGES3P4	-3.55	0.000429	0.0457	-0.21	-0.16	Colorectal cancer;	chr10:102696968	chr10:102845595~102845950:+
HNSC	cis	rs12893668	0.663	rs12889731	ENSG00000269910.1	RP11-73M18.10	3.55	0.000429	0.0457	0.16	0.16	Reticulocyte count;	chr14:103621145	chr14:103694516~103695050:-
HNSC	cis	rs853679	0.882	rs4713139	ENSG00000204709.4	LINC01556	3.55	0.000429	0.0457	0.28	0.16	Depression;	chr6:28124907	chr6:28943877~28944537:+
HNSC	cis	rs5758659	0.652	rs133326	ENSG00000227370.1	RP4-669P10.19	-3.55	0.000429	0.0458	-0.15	-0.16	Cognitive function;	chr22:42010881	chr22:42132543~42132998:+
HNSC	cis	rs13070279	0.582	rs67109126	ENSG00000241163.6	LINC00877	3.55	0.000429	0.0458	0.25	0.16	Monocyte count;	chr3:71750657	chr3:72035300~72279503:-
HNSC	cis	rs13070279	0.582	rs34586454	ENSG00000241163.6	LINC00877	3.55	0.000429	0.0458	0.25	0.16	Monocyte count;	chr3:71750746	chr3:72035300~72279503:-
HNSC	cis	rs3736485	0.966	rs2414111	ENSG00000274528.1	CTD-2650P22.2	-3.55	0.000429	0.0458	-0.16	-0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51609160	chr15:52017167~52018032:-
HNSC	cis	rs4704187	0.687	rs4389672	ENSG00000271815.1	CTD-2235C13.3	-3.55	0.000429	0.0458	-0.21	-0.16	Response to amphetamines;	chr5:75072817	chr5:75363760~75364242:+
HNSC	cis	rs10435719	0.834	rs11250176	ENSG00000269918.1	AF131215.9	3.55	0.000429	0.0458	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11104691~11106704:-
HNSC	cis	rs2565722	0.665	rs2465854	ENSG00000233342.1	RP11-235G24.3	3.55	0.000429	0.0458	0.25	0.16	Blood protein levels;	chr6:160889878	chr6:160926369~160927162:+
HNSC	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-3.55	0.000429	0.0458	-0.2	-0.16	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
HNSC	cis	rs10256972	0.567	rs2960850	ENSG00000225146.1	AC073957.15	3.55	0.000429	0.0458	0.2	0.16	Endometriosis;Longevity;	chr7:1172013	chr7:1029025~1043891:+
HNSC	cis	rs3018712	0.564	rs3136547	ENSG00000255031.4	RP11-802E16.3	-3.55	0.000429	0.0458	-0.14	-0.16	Total body bone mineral density;	chr11:68694191	chr11:68050740~68053762:+
HNSC	cis	rs7735319	0.966	rs6895701	ENSG00000249572.1	CTD-2203K17.1	3.55	0.000429	0.0458	0.18	0.16	Systolic blood pressure;	chr5:33130367	chr5:33424025~33440619:-
HNSC	cis	rs6558174	0.93	rs1038311	ENSG00000253986.1	CTC-756D1.3	-3.55	0.000429	0.0458	-0.18	-0.16	Breast cancer;	chr8:22631734	chr8:23493009~23494198:-
HNSC	cis	rs1585471	0.863	rs13110448	ENSG00000249532.3	RP11-148B6.1	-3.55	0.000429	0.0458	-0.2	-0.16	Myopia (pathological);	chr4:111706142	chr4:112646476~112650051:-
HNSC	cis	rs2337406	0.636	rs74090069	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000429	0.0458	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777532	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.866	rs74090071	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000429	0.0458	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777533	chr14:106762092~106762588:-
HNSC	cis	rs703842	0.616	rs4760171	ENSG00000270039.1	RP11-571M6.17	-3.55	0.000429	0.0458	-0.19	-0.16	Multiple sclerosis;	chr12:57832121	chr12:57803838~57804415:+
HNSC	cis	rs7615952	0.932	rs6438948	ENSG00000241278.1	ENPP7P4	3.55	0.000429	0.0458	0.22	0.16	Blood pressure (smoking interaction);	chr3:125931202	chr3:125848223~125909372:+
HNSC	cis	rs2013441	1	rs11871827	ENSG00000261033.1	RP11-209D14.2	3.55	0.000429	0.0458	0.18	0.16	Obesity-related traits;	chr17:20312592	chr17:20008051~20009234:-
HNSC	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000429	0.0458	-0.23	-0.16	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
HNSC	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-3.55	0.000429	0.0458	-0.2	-0.16	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
HNSC	cis	rs4835473	0.932	rs13134808	ENSG00000249741.2	RP11-673E1.3	3.55	0.000429	0.0458	0.18	0.16	Immature fraction of reticulocytes;	chr4:143798339	chr4:143911514~143912053:-
HNSC	cis	rs71007656	1	rs71007656	ENSG00000263064.2	RP11-291L22.7	3.55	0.000429	0.0458	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38448689~38448949:+
HNSC	cis	rs4899412	0.695	rs2239268	ENSG00000266869.1	RP6-114E22.1	-3.55	0.000429	0.0458	-0.2	-0.16	Heart rate variability traits (SDNN);	chr14:72002874	chr14:71848606~71908430:+
HNSC	cis	rs875971	1	rs10215948	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000429	0.0458	-0.14	-0.16	Aortic root size;	chr7:66282799	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.965	rs9969301	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000429	0.0458	-0.14	-0.16	Aortic root size;	chr7:66316668	chr7:66739829~66740385:-
HNSC	cis	rs2408955	0.504	rs11168441	ENSG00000257763.1	OR5BK1P	3.55	0.000429	0.0458	0.15	0.16	Glycated hemoglobin levels;	chr12:48182271	chr12:48355792~48356614:-
HNSC	cis	rs8024893	0.764	rs7182545	ENSG00000215302.7	CTD-3092A11.1	-3.55	0.000429	0.0458	-0.26	-0.16	Red cell distribution width;	chr15:31239638	chr15:30470779~30507623:+
HNSC	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	3.55	0.000429	0.0458	0.14	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
HNSC	cis	rs3015497	0.637	rs6572692	ENSG00000277050.1	RP11-102G14.1	3.55	0.00043	0.0458	0.15	0.16	Mean platelet volume;	chr14:50710021	chr14:51637348~51637947:-
HNSC	cis	rs1908814	0.516	rs60176945	ENSG00000255310.2	AF131215.2	3.55	0.00043	0.0458	0.15	0.16	Neuroticism;	chr8:11939165	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs56102998	ENSG00000255310.2	AF131215.2	3.55	0.00043	0.0458	0.15	0.16	Neuroticism;	chr8:11939166	chr8:11107788~11109726:-
HNSC	cis	rs7903456	0.512	rs9420426	ENSG00000200253.1	RNU6-529P	3.55	0.00043	0.0458	0.21	0.16	Gout;Renal underexcretion gout;	chr10:87046781	chr10:87041238~87041341:-
HNSC	cis	rs10927875	0.541	rs1763599	ENSG00000226029.1	RP4-798A10.2	-3.55	0.00043	0.0458	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016107	chr1:16460948~16468481:+
HNSC	cis	rs6538678	0.895	rs7137751	ENSG00000199172.2	MIR331	-3.55	0.00043	0.0458	-0.19	-0.16	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95308410~95308520:+
HNSC	cis	rs1908814	0.516	rs11996277	ENSG00000255310.2	AF131215.2	3.55	0.00043	0.0458	0.15	0.16	Neuroticism;	chr8:11942522	chr8:11107788~11109726:-
HNSC	cis	rs12745968	0.652	rs7546197	ENSG00000223787.2	RP4-593M8.1	-3.55	0.00043	0.0458	-0.2	-0.16	Bipolar disorder and schizophrenia;	chr1:92690382	chr1:92580476~92580821:-
HNSC	cis	rs1142	0.507	rs2428161	ENSG00000237513.1	RP11-325F22.2	3.55	0.00043	0.0458	0.15	0.16	Advanced age-related macular degeneration;	chr7:104952120	chr7:104941063~104962334:+
HNSC	cis	rs896655	0.631	rs10811598	ENSG00000244230.3	RN7SL151P	3.55	0.00043	0.0458	0.17	0.16	Coronary artery disease;	chr9:21729853	chr9:21699314~21699596:+
HNSC	cis	rs865483	0.86	rs12603185	ENSG00000276054.1	RP11-378E13.3	3.55	0.00043	0.0458	0.2	0.16	Monocyte count;	chr17:37508198	chr17:37386886~37387926:+
HNSC	cis	rs4253772	0.513	rs6008700	ENSG00000277232.2	GTSE1-AS1	-3.55	0.00043	0.0458	-0.2	-0.16	Cholesterol, total;LDL cholesterol;	chr22:46326663	chr22:46295143~46296660:-
HNSC	cis	rs17095355	1	rs752584	ENSG00000203876.8	ADD3-AS1	-3.55	0.00043	0.0458	-0.22	-0.16	Biliary atresia;	chr10:109923176	chr10:109940104~110008381:-
HNSC	cis	rs440932	1	rs378974	ENSG00000253981.4	ALG1L13P	3.55	0.00043	0.0458	0.19	0.16	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8236003~8244667:-
HNSC	cis	rs11509153	0.672	rs4719302	ENSG00000226690.5	AC005281.1	3.55	0.00043	0.0459	0.17	0.16	Residual cognition;	chr7:12205994	chr7:12496429~12541910:+
HNSC	cis	rs2657294	0.704	rs10824266	ENSG00000233313.2	HMGA1P5	-3.55	0.00043	0.0459	-0.18	-0.16	Pneumonia;	chr10:75083476	chr10:75276376~75276646:-
HNSC	cis	rs4144743	1	rs4144744	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.00043	0.0459	-0.18	-0.16	Body mass index;	chr17:47245896	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs4144745	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.00043	0.0459	-0.18	-0.16	Body mass index;	chr17:47245983	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs4144746	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.00043	0.0459	-0.18	-0.16	Body mass index;	chr17:47245989	chr17:47450568~47492492:-
HNSC	cis	rs4144743	1	rs10438781	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.00043	0.0459	-0.18	-0.16	Body mass index;	chr17:47246453	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.941	rs10438782	ENSG00000228782.6	CTD-2026D20.3	-3.55	0.00043	0.0459	-0.18	-0.16	Body mass index;	chr17:47246526	chr17:47450568~47492492:-
HNSC	cis	rs10107145	0.509	rs4310166	ENSG00000269918.1	AF131215.9	-3.55	0.00043	0.0459	-0.17	-0.16	Systolic blood pressure;	chr8:10906226	chr8:11104691~11106704:-
HNSC	cis	rs2337406	0.866	rs79901786	ENSG00000280411.1	IGHV1-69-2	-3.55	0.00043	0.0459	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106777623	chr14:106762092~106762588:-
HNSC	cis	rs4796354	0.604	rs4796560	ENSG00000261996.1	CTC-281F24.1	-3.55	0.00043	0.0459	-0.17	-0.16	Colonoscopy-negative controls vs population controls;	chr17:6812359	chr17:6653464~6655009:-
HNSC	cis	rs2341917	0.818	rs7580435	ENSG00000227992.1	AC108463.2	-3.55	0.00043	0.0459	-0.26	-0.16	Attention function in attention deficit hyperactive disorder;	chr2:110911164	chr2:111203964~111206215:-
HNSC	cis	rs13201294	1	rs13201294	ENSG00000226314.6	ZNF192P1	-3.55	0.00043	0.0459	-0.27	-0.16	Squamous cell lung carcinoma;	chr6:27588362	chr6:28161781~28169594:+
HNSC	cis	rs4936891	0.601	rs7929503	ENSG00000200879.1	SNORD14E	-3.55	0.00043	0.0459	-0.19	-0.16	Male fertility;	chr11:124045453	chr11:123058077~123058161:-
HNSC	cis	rs2436845	0.627	rs34352733	ENSG00000253320.4	KB-1507C5.2	-3.55	0.00043	0.0459	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819280	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.627	rs3018954	ENSG00000253320.4	KB-1507C5.2	-3.55	0.00043	0.0459	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102821343	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.627	rs2513915	ENSG00000253320.4	KB-1507C5.2	-3.55	0.00043	0.0459	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102822312	chr8:102864300~102977876:+
HNSC	cis	rs6787172	0.622	rs939114	ENSG00000272087.1	RP11-379F4.7	3.55	0.000431	0.0459	0.17	0.16	Subjective well-being;	chr3:158397464	chr3:158693120~158693768:-
HNSC	cis	rs17407555	0.683	rs4698000	ENSG00000250413.1	RP11-448G15.1	3.55	0.000431	0.0459	0.21	0.16	Schizophrenia (age at onset);	chr4:10275843	chr4:10006482~10009725:+
HNSC	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	3.55	0.000431	0.0459	0.16	0.16	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	3.55	0.000431	0.0459	0.16	0.16	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	3.55	0.000431	0.0459	0.16	0.16	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
HNSC	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	3.55	0.000431	0.0459	0.16	0.16	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
HNSC	cis	rs6545883	0.894	rs10177303	ENSG00000271889.1	RP11-493E12.1	-3.55	0.000431	0.0459	-0.19	-0.16	Tuberculosis;	chr2:61367324	chr2:61151433~61162105:-
HNSC	cis	rs6545883	0.894	rs2694639	ENSG00000271889.1	RP11-493E12.1	-3.55	0.000431	0.0459	-0.19	-0.16	Tuberculosis;	chr2:61368156	chr2:61151433~61162105:-
HNSC	cis	rs12908161	0.96	rs62019463	ENSG00000229212.6	RP11-561C5.4	-3.55	0.000431	0.0459	-0.23	-0.16	Schizophrenia;	chr15:84744856	chr15:85205440~85234795:-
HNSC	cis	rs853679	0.567	rs13196606	ENSG00000219392.1	RP1-265C24.5	-3.55	0.000431	0.0459	-0.19	-0.16	Depression;	chr6:28402301	chr6:28115628~28116551:+
HNSC	cis	rs3096299	0.503	rs9940093	ENSG00000261118.1	RP11-104N10.1	3.55	0.000431	0.0459	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89492017~89504460:-
HNSC	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	3.55	0.000431	0.0459	0.2	0.16	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
HNSC	cis	rs10435719	0.902	rs12681142	ENSG00000255310.2	AF131215.2	3.55	0.000431	0.0459	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11107788~11109726:-
HNSC	cis	rs10028773	0.546	rs13117947	ENSG00000249244.1	RP11-548H18.2	3.55	0.000431	0.0459	0.19	0.16	Educational attainment;	chr4:119335905	chr4:119391831~119395335:-
HNSC	cis	rs9914544	0.505	rs7503678	ENSG00000264885.1	RP11-815I9.4	-3.55	0.000431	0.0459	-0.16	-0.16	Educational attainment (years of education);	chr17:18872707	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.564	rs12451220	ENSG00000264885.1	RP11-815I9.4	-3.55	0.000431	0.0459	-0.16	-0.16	Educational attainment (years of education);	chr17:18875108	chr17:18667629~18669461:-
HNSC	cis	rs9914544	0.545	rs12451200	ENSG00000264885.1	RP11-815I9.4	-3.55	0.000431	0.0459	-0.16	-0.16	Educational attainment (years of education);	chr17:18875180	chr17:18667629~18669461:-
HNSC	cis	rs9402743	1	rs7739635	ENSG00000234084.1	RP3-388E23.2	-3.55	0.000431	0.0459	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135676640	chr6:135301568~135307158:+
HNSC	cis	rs17416285	0.537	rs1777276	ENSG00000260971.3	RP11-504A18.1	3.55	0.000431	0.0459	0.21	0.16	Coronary artery disease;	chr1:56522805	chr1:56248294~56258571:-
HNSC	cis	rs28573326	0.607	rs9997245	ENSG00000121089.4	NACA3P	-3.55	0.000431	0.0459	-0.21	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165388061	chr4:164943290~164943937:+
HNSC	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	3.55	0.000431	0.0459	0.18	0.16	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
HNSC	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-3.55	0.000431	0.046	-0.19	-0.16	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
HNSC	cis	rs62344088	1	rs7715867	ENSG00000250848.1	CTD-2083E4.5	-3.55	0.000431	0.046	-0.37	-0.16	Asthma (childhood onset);	chr5:128944	chr5:288833~290321:-
HNSC	cis	rs62344088	1	rs73022563	ENSG00000250848.1	CTD-2083E4.5	-3.55	0.000431	0.046	-0.37	-0.16	Asthma (childhood onset);	chr5:140698	chr5:288833~290321:-
HNSC	cis	rs5758659	0.652	rs133358	ENSG00000182057.4	OGFRP1	3.55	0.000431	0.046	0.16	0.16	Cognitive function;	chr22:42046535	chr22:42269753~42275196:+
HNSC	cis	rs3748656	0.945	rs12140506	ENSG00000273483.1	RP4-671G15.2	3.55	0.000431	0.046	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112584808	chr1:112517799~112518441:-
HNSC	cis	rs116095464	0.558	rs3213838	ENSG00000277812.1	AC021087.1	3.55	0.000431	0.046	0.27	0.16	Breast cancer;	chr5:223775	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6555052	ENSG00000277812.1	AC021087.1	3.55	0.000431	0.046	0.27	0.16	Breast cancer;	chr5:224153	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs61689490	ENSG00000277812.1	AC021087.1	3.55	0.000431	0.046	0.27	0.16	Breast cancer;	chr5:224789	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs61492827	ENSG00000277812.1	AC021087.1	3.55	0.000431	0.046	0.27	0.16	Breast cancer;	chr5:225659	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs56342538	ENSG00000277812.1	AC021087.1	3.55	0.000431	0.046	0.27	0.16	Breast cancer;	chr5:225681	chr5:262769~262881:+
HNSC	cis	rs7124676	1	rs3759053	ENSG00000257086.1	RP11-783K16.13	3.55	0.000431	0.046	0.17	0.16	Obesity-related traits;	chr11:64555608	chr11:64246939~64249494:-
HNSC	cis	rs2898290	0.578	rs34163377	ENSG00000206014.6	OR7E161P	-3.55	0.000431	0.046	-0.18	-0.16	Systolic blood pressure;	chr8:11592704	chr8:11928597~11929563:-
HNSC	cis	rs4700393	0.967	rs921897	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs10076679	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.527	rs10076742	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.527	rs6890201	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs6875456	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs6894750	ENSG00000215032.2	GNL3LP1	3.55	0.000431	0.046	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60891935~60893577:-
HNSC	cis	rs6095360	0.933	rs6019620	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49062763	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019621	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49063426	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs2075675	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49068956	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6019624	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49069278	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs6512567	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49072083	chr20:49040463~49046044:-
HNSC	cis	rs6095360	1	rs2075676	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49074674	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.901	rs2426120	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49080716	chr20:49040463~49046044:-
HNSC	cis	rs6095360	0.933	rs2426122	ENSG00000227431.4	CSE1L-AS1	-3.55	0.000431	0.046	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49081402	chr20:49040463~49046044:-
HNSC	cis	rs9788721	0.967	rs2036527	ENSG00000261762.1	RP11-650L12.2	-3.55	0.000431	0.046	-0.19	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78559273	chr15:78589123~78591276:-
HNSC	cis	rs17122278	1	rs3741325	ENSG00000255422.1	AP002954.4	3.55	0.000431	0.046	0.29	0.16	Total cholesterol levels;	chr11:118535274	chr11:118704607~118750263:+
HNSC	cis	rs11951515	0.7	rs7714027	ENSG00000249286.1	CTD-2210P15.2	3.55	0.000431	0.046	0.17	0.16	Metabolite levels  (X-11787);	chr5:43373116	chr5:43586918~43588223:-
HNSC	cis	rs11098499	0.691	rs12502524	ENSG00000250412.1	KLHL2P1	3.55	0.000431	0.046	0.21	0.16	Corneal astigmatism;	chr4:119350259	chr4:119334329~119378233:+
HNSC	cis	rs9923283	1	rs9888858	ENSG00000260517.2	RP11-426C22.5	-3.55	0.000431	0.046	-0.23	-0.16	Plateletcrit;	chr16:29645556	chr16:29116127~29217860:+
HNSC	cis	rs5167	0.645	rs1130742	ENSG00000214855.8	APOC1P1	3.55	0.000432	0.046	0.18	0.16	Blood protein levels;	chr19:44949555	chr19:44926804~44931386:+
HNSC	cis	rs9500256	0.655	rs12208465	ENSG00000225096.1	XXbac-BPG55C20.7	-3.55	0.000432	0.046	-0.19	-0.16	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57965630~57972218:+
HNSC	cis	rs9500256	0.655	rs12210275	ENSG00000225096.1	XXbac-BPG55C20.7	-3.55	0.000432	0.046	-0.19	-0.16	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57965630~57972218:+
HNSC	cis	rs2839186	0.934	rs17182538	ENSG00000239415.1	AP001469.9	3.55	0.000432	0.046	0.14	0.16	Testicular germ cell tumor;	chr21:46285759	chr21:46251549~46254133:-
HNSC	cis	rs10927875	0.557	rs1572381	ENSG00000226457.1	RP11-430L17.1	-3.55	0.000432	0.046	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16017999	chr1:16369150~16369530:-
HNSC	cis	rs7688540	0.8	rs12506277	ENSG00000250892.1	RP11-1365D11.1	-3.55	0.000432	0.046	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:201409~205009:-
HNSC	cis	rs7688540	0.8	rs12501727	ENSG00000250892.1	RP11-1365D11.1	-3.55	0.000432	0.046	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:201409~205009:-
HNSC	cis	rs4787491	0.729	rs11150584	ENSG00000250616.2	RP11-455F5.3	3.55	0.000432	0.046	0.16	0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30096430~30104116:+
HNSC	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	3.55	0.000432	0.046	0.32	0.16	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
HNSC	cis	rs2252521	0.643	rs4141275	ENSG00000225264.3	ZNRF2P2	-3.55	0.000432	0.046	-0.15	-0.16	Cognitive performance;	chr7:29040254	chr7:29598795~29685255:-
HNSC	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-3.55	0.000432	0.046	-0.16	-0.16	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
HNSC	cis	rs12546962	0.739	rs1461727	ENSG00000233609.3	RP11-62H7.2	3.55	0.000432	0.046	0.17	0.16	Body mass index;	chr8:9342840	chr8:8961200~8979025:+
HNSC	cis	rs2412819	0.571	rs6493090	ENSG00000166763.7	STRCP1	-3.55	0.000432	0.046	-0.23	-0.16	Lung cancer;	chr15:43792084	chr15:43699488~43718184:-
HNSC	cis	rs73198271	0.74	rs1039911	ENSG00000254153.1	CTA-398F10.2	-3.55	0.000432	0.046	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8456909~8461337:-
HNSC	cis	rs333332	1	rs333332	ENSG00000240622.1	RPL7P15	3.55	0.000432	0.046	0.17	0.16	Heschl's gyrus morphology;	chr3:124609647	chr3:124151960~124153063:-
HNSC	cis	rs10992797	0.523	rs4744258	ENSG00000227603.1	RP11-165J3.6	-3.55	0.000432	0.046	-0.14	-0.16	Intelligence (multi-trait analysis);	chr9:93599287	chr9:93435332~93437121:-
HNSC	cis	rs2288884	0.505	rs2278414	ENSG00000267879.1	CTB-147C22.9	3.55	0.000432	0.046	0.26	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964569	chr19:50968210~51012129:+
HNSC	cis	rs1445130	0.892	rs55645309	ENSG00000260331.1	RP11-111J6.2	3.55	0.000432	0.046	0.33	0.16	Bulimia nervosa;	chr2:18666719	chr2:18547386~18548204:-
HNSC	cis	rs7572733	0.576	rs1368989	ENSG00000231621.1	AC013264.2	-3.55	0.000432	0.046	-0.16	-0.16	Dermatomyositis;	chr2:198072358	chr2:197197991~197199273:+
HNSC	cis	rs116095464	0.558	rs6872854	ENSG00000277812.1	AC021087.1	3.55	0.000432	0.046	0.27	0.16	Breast cancer;	chr5:208923	chr5:262769~262881:+
HNSC	cis	rs9505118	0.931	rs6597262	ENSG00000238221.1	RP11-69L16.4	3.55	0.000432	0.046	0.2	0.16	Type 2 diabetes;	chr6:7293583	chr6:7276031~7298872:+
HNSC	cis	rs9505118	0.965	rs9505127	ENSG00000238221.1	RP11-69L16.4	3.55	0.000432	0.046	0.2	0.16	Type 2 diabetes;	chr6:7294385	chr6:7276031~7298872:+
HNSC	cis	rs8030379	0.967	rs7182563	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000432	0.046	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83879994	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs11629657	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000432	0.046	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880228	chr15:84507885~84516814:-
HNSC	cis	rs8030379	0.967	rs7181926	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000432	0.046	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880676	chr15:84507885~84516814:-
HNSC	cis	rs9467711	0.606	rs2073527	ENSG00000241549.7	GUSBP2	3.55	0.000432	0.046	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26374750	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs2073530	ENSG00000241549.7	GUSBP2	3.55	0.000432	0.046	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26375015	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs2073531	ENSG00000241549.7	GUSBP2	3.55	0.000432	0.046	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26375028	chr6:26871484~26956554:-
HNSC	cis	rs4927850	1	rs10881563	ENSG00000278820.1	AC024937.1	3.55	0.000432	0.046	0.15	0.16	Pancreatic cancer;	chr3:196023354	chr3:195960500~195960612:-
HNSC	cis	rs561341	0.941	rs550213	ENSG00000278867.1	RP11-640N20.4	-3.55	0.000432	0.046	-0.21	-0.16	Hip circumference adjusted for BMI;	chr17:31990499	chr17:32051030~32053208:+
HNSC	cis	rs561341	1	rs530715	ENSG00000278867.1	RP11-640N20.4	-3.55	0.000432	0.046	-0.21	-0.16	Hip circumference adjusted for BMI;	chr17:31993525	chr17:32051030~32053208:+
HNSC	cis	rs7937890	0.81	rs10734224	ENSG00000254418.1	RP11-21L19.1	3.54	0.000432	0.0461	0.19	0.16	Mitochondrial DNA levels;	chr11:14402578	chr11:14262846~14273691:-
HNSC	cis	rs10073892	0.789	rs10044449	ENSG00000250682.4	LINC00491	-3.54	0.000432	0.0461	-0.24	-0.16	Cognitive decline (age-related);	chr5:102516737	chr5:102609156~102671559:-
HNSC	cis	rs10992797	0.504	rs2989755	ENSG00000227603.1	RP11-165J3.6	-3.54	0.000432	0.0461	-0.14	-0.16	Intelligence (multi-trait analysis);	chr9:93613971	chr9:93435332~93437121:-
HNSC	cis	rs8072100	1	rs11870935	ENSG00000263293.2	RP11-290H9.4	-3.54	0.000432	0.0461	-0.17	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47303460~47323613:-
HNSC	cis	rs35306767	0.903	rs12762228	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000432	0.0461	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:834914	chr10:933026~942743:+
HNSC	cis	rs35306767	0.903	rs7914758	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000432	0.0461	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:845762	chr10:933026~942743:+
HNSC	cis	rs494453	0.883	rs474722	ENSG00000227811.2	FAM212B-AS1	-3.54	0.000432	0.0461	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111674356	chr1:111739841~111747798:+
HNSC	cis	rs8077577	0.708	rs9913139	ENSG00000273018.4	CTD-2303H24.2	-3.54	0.000432	0.0461	-0.23	-0.16	Obesity-related traits;	chr17:18250501	chr17:18511221~18551705:-
HNSC	cis	rs17122278	0.613	rs477106	ENSG00000255422.1	AP002954.4	-3.54	0.000433	0.0461	-0.24	-0.16	Total cholesterol levels;	chr11:118492709	chr11:118704607~118750263:+
HNSC	cis	rs6545883	0.794	rs778152	ENSG00000271889.1	RP11-493E12.1	-3.54	0.000433	0.0461	-0.18	-0.16	Tuberculosis;	chr2:61381405	chr2:61151433~61162105:-
HNSC	cis	rs800888	0.518	rs2737227	ENSG00000249917.2	LINC00536	-3.54	0.000433	0.0461	-0.21	-0.16	Monocyte percentage of white cells;	chr8:115631894	chr8:115950511~116325059:-
HNSC	cis	rs9505118	1	rs9505118	ENSG00000238221.1	RP11-69L16.4	-3.54	0.000433	0.0461	-0.2	-0.16	Type 2 diabetes;	chr6:7290204	chr6:7276031~7298872:+
HNSC	cis	rs2013441	0.866	rs62067558	ENSG00000261033.1	RP11-209D14.2	-3.54	0.000433	0.0461	-0.19	-0.16	Obesity-related traits;	chr17:20122393	chr17:20008051~20009234:-
HNSC	cis	rs1862618	0.671	rs2255726	ENSG00000248727.4	CTC-236F12.4	-3.54	0.000433	0.0461	-0.21	-0.16	Initial pursuit acceleration;	chr5:56947301	chr5:56457795~56481946:-
HNSC	cis	rs853679	0.546	rs483143	ENSG00000241549.7	GUSBP2	3.54	0.000433	0.0461	0.24	0.16	Depression;	chr6:27878966	chr6:26871484~26956554:-
HNSC	cis	rs2836974	0.8	rs73221174	ENSG00000255568.3	BRWD1-AS2	3.54	0.000433	0.0461	0.14	0.16	Cognitive function;	chr21:39169013	chr21:39313935~39314962:+
HNSC	cis	rs8062405	0.679	rs72793818	ENSG00000261766.1	RP11-22P6.2	-3.54	0.000433	0.0461	-0.16	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28862166~28863340:-
HNSC	cis	rs4906172	0.838	rs2619092	ENSG00000272444.1	RP11-1017G21.6	-3.54	0.000433	0.0461	-0.18	-0.16	Menopause (age at onset);	chr14:101959638	chr14:101952416~101953063:+
HNSC	cis	rs11951515	0.714	rs11956635	ENSG00000249286.1	CTD-2210P15.2	3.54	0.000433	0.0461	0.17	0.16	Metabolite levels  (X-11787);	chr5:43371926	chr5:43586918~43588223:-
HNSC	cis	rs4704187	0.687	rs4361493	ENSG00000272040.1	CTC-366B18.4	-3.54	0.000433	0.0461	-0.15	-0.16	Response to amphetamines;	chr5:75109272	chr5:75608817~75609983:+
HNSC	cis	rs3733829	0.732	rs41530251	ENSG00000233622.1	CYP2T1P	3.54	0.000433	0.0461	0.16	0.16	Smoking behavior;	chr19:40810450	chr19:40808525~40811390:-
HNSC	cis	rs10514995	0.964	rs6449809	ENSG00000248846.2	CTD-2016O11.1	3.54	0.000433	0.0461	0.17	0.16	RR interval (heart rate);	chr5:66441462	chr5:66206212~66209447:-
HNSC	cis	rs1552244	1	rs2272123	ENSG00000180385.7	EMC3-AS1	3.54	0.000433	0.0461	0.18	0.16	Alzheimer's disease;	chr3:10098431	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs58275763	ENSG00000180385.7	EMC3-AS1	3.54	0.000433	0.0461	0.18	0.16	Alzheimer's disease;	chr3:10101590	chr3:9986893~10006990:+
HNSC	cis	rs10819861	0.645	rs4443780	ENSG00000271384.1	RP11-435O5.7	3.54	0.000433	0.0461	0.16	0.16	Electrocardiographic traits;	chr9:96089485	chr9:95406990~95407662:-
HNSC	cis	rs8077577	0.747	rs8081155	ENSG00000273018.4	CTD-2303H24.2	-3.54	0.000433	0.0461	-0.24	-0.16	Obesity-related traits;	chr17:18288634	chr17:18511221~18551705:-
HNSC	cis	rs8077577	0.747	rs3817992	ENSG00000273018.4	CTD-2303H24.2	-3.54	0.000433	0.0461	-0.24	-0.16	Obesity-related traits;	chr17:18290697	chr17:18511221~18551705:-
HNSC	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-3.54	0.000433	0.0461	-0.23	-0.16	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
HNSC	cis	rs8077577	0.747	rs7215678	ENSG00000273018.4	CTD-2303H24.2	3.54	0.000433	0.0461	0.24	0.16	Obesity-related traits;	chr17:18236479	chr17:18511221~18551705:-
HNSC	cis	rs7023329	0.59	rs6475566	ENSG00000229835.2	KHSRPP1	-3.54	0.000433	0.0461	-0.17	-0.16	Melanoma;	chr9:21733501	chr9:21695176~21696943:+
HNSC	cis	rs55975637	0.73	rs35340549	ENSG00000240476.1	LINC00973	3.54	0.000433	0.0461	0.28	0.16	Advanced age-related macular degeneration;	chr3:99669415	chr3:98981058~98983096:+
HNSC	cis	rs7772486	0.686	rs9390349	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000433	0.0461	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs2072911	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000433	0.0461	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145735570~145737218:+
HNSC	cis	rs5758511	0.68	rs5758651	ENSG00000227370.1	RP4-669P10.19	3.54	0.000433	0.0461	0.2	0.16	Birth weight;	chr22:42213142	chr22:42132543~42132998:+
HNSC	cis	rs5758511	0.68	rs5758652	ENSG00000227370.1	RP4-669P10.19	3.54	0.000433	0.0461	0.2	0.16	Birth weight;	chr22:42216402	chr22:42132543~42132998:+
HNSC	cis	rs6928977	0.826	rs9321502	ENSG00000217482.2	HMGB1P17	-3.54	0.000433	0.0461	-0.18	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135335114	chr6:135636086~135636713:-
HNSC	cis	rs6009527	1	rs4315635	ENSG00000273192.1	CITF22-1A6.3	3.54	0.000433	0.0461	0.18	0.16	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);	chr22:49175604	chr22:49902228~49904576:+
HNSC	cis	rs9834975	0.565	rs4485669	ENSG00000272758.4	RP11-299J3.8	3.54	0.000433	0.0461	0.15	0.16	Diastolic blood pressure;	chr3:122515768	chr3:122416207~122443180:+
HNSC	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-3.54	0.000433	0.0461	-0.27	-0.16	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
HNSC	cis	rs5758659	0.622	rs129856	ENSG00000227370.1	RP4-669P10.19	-3.54	0.000433	0.0461	-0.15	-0.16	Cognitive function;	chr22:42003392	chr22:42132543~42132998:+
HNSC	cis	rs948562	0.69	rs11229391	ENSG00000280010.1	AP001350.4	3.54	0.000433	0.0461	0.26	0.16	Lymphoma;	chr11:58382503	chr11:58627435~58628528:+
HNSC	cis	rs948562	0.69	rs17473544	ENSG00000280010.1	AP001350.4	3.54	0.000433	0.0461	0.26	0.16	Lymphoma;	chr11:58388994	chr11:58627435~58628528:+
HNSC	cis	rs3748656	0.945	rs56135413	ENSG00000273483.1	RP4-671G15.2	3.54	0.000433	0.0462	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112550284	chr1:112517799~112518441:-
HNSC	cis	rs10742752	0.702	rs59678781	ENSG00000255267.3	RP11-430H10.2	3.54	0.000433	0.0462	0.21	0.16	Body mass index;	chr11:45413276	chr11:45371397~45388508:+
HNSC	cis	rs62025270	0.688	rs17577869	ENSG00000259416.2	RP11-158M2.5	-3.54	0.000434	0.0462	-0.2	-0.16	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85754941~85756237:-
HNSC	cis	rs6928977	0.66	rs12214269	ENSG00000231028.7	LINC00271	3.54	0.000434	0.0462	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135525380	chr6:135497801~135716055:+
HNSC	cis	rs7429990	0.864	rs2047559	ENSG00000228638.1	FCF1P2	3.54	0.000434	0.0462	0.15	0.16	Educational attainment (years of education);	chr3:47704695	chr3:48290793~48291375:-
HNSC	cis	rs7107174	1	rs2510037	ENSG00000251323.2	RP11-452H21.4	3.54	0.000434	0.0462	0.24	0.16	Testicular germ cell tumor;	chr11:78255053	chr11:78423982~78429836:-
HNSC	cis	rs4924935	0.851	rs966811	ENSG00000264885.1	RP11-815I9.4	3.54	0.000434	0.0462	0.19	0.16	Pancreatic cancer;	chr17:18926974	chr17:18667629~18669461:-
HNSC	cis	rs870825	0.616	rs4519838	ENSG00000254233.1	RP11-242J7.1	3.54	0.000434	0.0462	0.24	0.16	Blood protein levels;	chr4:184707303	chr4:184584093~184625030:-
HNSC	cis	rs67311347	1	rs1466237	ENSG00000280739.1	EIF1B-AS1	3.54	0.000434	0.0462	0.18	0.16	Renal cell carcinoma;	chr3:40420535	chr3:40173145~40309698:-
HNSC	cis	rs6058526	0.631	rs6119776	ENSG00000224628.2	RP5-854E16.2	-3.54	0.000434	0.0462	-0.22	-0.16	Chronic obstructive pulmonary disease;	chr20:32222297	chr20:31285317~31286835:-
HNSC	cis	rs6058526	0.631	rs6087839	ENSG00000224628.2	RP5-854E16.2	-3.54	0.000434	0.0462	-0.22	-0.16	Chronic obstructive pulmonary disease;	chr20:32224976	chr20:31285317~31286835:-
HNSC	cis	rs6058526	0.631	rs6119784	ENSG00000224628.2	RP5-854E16.2	-3.54	0.000434	0.0462	-0.22	-0.16	Chronic obstructive pulmonary disease;	chr20:32229979	chr20:31285317~31286835:-
HNSC	cis	rs10754283	0.967	rs2390763	ENSG00000231999.5	FLJ27354	3.54	0.000434	0.0462	0.18	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89583241~89632894:-
HNSC	cis	rs8072100	0.744	rs34537623	ENSG00000263293.2	RP11-290H9.4	3.54	0.000434	0.0462	0.17	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47303460~47323613:-
HNSC	cis	rs10897167	1	rs7943167	ENSG00000279491.1	RP11-810P12.7	3.54	0.000434	0.0462	0.3	0.16	Intelligence (multi-trait analysis);	chr11:61520885	chr11:61967794~61969490:+
HNSC	cis	rs5758659	0.714	rs6002626	ENSG00000270083.1	RP1-257I20.14	-3.54	0.000434	0.0462	-0.15	-0.16	Cognitive function;	chr22:42121985	chr22:42089630~42090028:-
HNSC	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	3.54	0.000434	0.0462	0.19	0.16	Height;	chr14:74990535	chr14:75011269~75012851:-
HNSC	cis	rs11158609	1	rs12879736	ENSG00000278784.1	RP11-468E2.11	3.54	0.000434	0.0462	0.22	0.16	Systolic blood pressure (cigarette smoking interaction);	chr14:24205587	chr14:24201612~24202811:-
HNSC	cis	rs77505915	0.512	rs12921808	ENSG00000280152.1	RP11-331F4.5	3.54	0.000434	0.0462	0.21	0.16	Migraine;	chr16:75350086	chr16:75245994~75250077:-
HNSC	cis	rs62025270	0.632	rs7163838	ENSG00000259762.1	RP11-158M2.4	-3.54	0.000434	0.0462	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85750336~85752901:-
HNSC	cis	rs7274811	0.681	rs291674	ENSG00000277301.1	RP5-1184F4.7	-3.54	0.000434	0.0462	-0.17	-0.16	Height;	chr20:33367084	chr20:32509959~32520285:+
HNSC	cis	rs2836974	0.897	rs34035316	ENSG00000255568.3	BRWD1-AS2	3.54	0.000434	0.0462	0.15	0.16	Cognitive function;	chr21:39222097	chr21:39313935~39314962:+
HNSC	cis	rs35740288	0.822	rs11630179	ENSG00000259407.1	RP11-158M2.3	-3.54	0.000434	0.0462	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85744109~85750281:-
HNSC	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-3.54	0.000434	0.0462	-0.15	-0.16	Longevity;	chr3:48464565	chr3:48256350~48256938:-
HNSC	cis	rs61160187	0.698	rs12517174	ENSG00000251279.1	CTC-436P18.1	3.54	0.000434	0.0462	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60673188	chr5:61162070~61232040:+
HNSC	cis	rs2657294	0.965	rs2395140	ENSG00000233313.2	HMGA1P5	-3.54	0.000434	0.0462	-0.18	-0.16	Pneumonia;	chr10:75139253	chr10:75276376~75276646:-
HNSC	cis	rs2657294	0.965	rs2997754	ENSG00000233313.2	HMGA1P5	-3.54	0.000434	0.0462	-0.18	-0.16	Pneumonia;	chr10:75144379	chr10:75276376~75276646:-
HNSC	cis	rs860295	0.702	rs11264375	ENSG00000225855.5	RUSC1-AS1	-3.54	0.000434	0.0462	-0.11	-0.16	Body mass index;	chr1:155454274	chr1:155316863~155324176:-
HNSC	cis	rs875971	1	rs6946143	ENSG00000272831.1	RP11-792A8.4	3.54	0.000434	0.0462	0.14	0.16	Aortic root size;	chr7:66114735	chr7:66739829~66740385:-
HNSC	cis	rs721917	0.811	rs2256462	ENSG00000225484.5	NUTM2B-AS1	-3.54	0.000434	0.0462	-0.2	-0.16	Chronic obstructive pulmonary disease;	chr10:79925837	chr10:79663088~79826594:-
HNSC	cis	rs7107174	1	rs729354	ENSG00000251323.2	RP11-452H21.4	3.54	0.000434	0.0462	0.25	0.16	Testicular germ cell tumor;	chr11:78251407	chr11:78423982~78429836:-
HNSC	cis	rs7572733	0.905	rs6434945	ENSG00000222017.1	AC011997.1	3.54	0.000435	0.0462	0.19	0.16	Dermatomyositis;	chr2:197933236	chr2:197693106~197774823:+
HNSC	cis	rs73198271	1	rs4840356	ENSG00000173295.6	FAM86B3P	-3.54	0.000435	0.0463	-0.22	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8228595~8244865:+
HNSC	cis	rs7674212	0.57	rs2711898	ENSG00000251288.2	RP11-10L12.2	-3.54	0.000435	0.0463	-0.18	-0.16	Type 2 diabetes;	chr4:103141914	chr4:102751401~102752641:+
HNSC	cis	rs9583531	0.657	rs7337126	ENSG00000259831.1	LINC00567	3.54	0.000435	0.0463	0.19	0.16	Coronary artery disease;	chr13:110724441	chr13:110809676~110813084:-
HNSC	cis	rs7015630	0.648	rs16901016	ENSG00000251136.7	RP11-37B2.1	-3.54	0.000435	0.0463	-0.18	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89839916	chr8:89609409~89757727:-
HNSC	cis	rs800888	0.518	rs2721948	ENSG00000249917.2	LINC00536	-3.54	0.000435	0.0463	-0.22	-0.16	Monocyte percentage of white cells;	chr8:115631111	chr8:115950511~116325059:-
HNSC	cis	rs4927850	0.529	rs6800500	ENSG00000273013.1	CTD-2002J20.1	-3.54	0.000435	0.0463	-0.18	-0.16	Pancreatic cancer;	chr3:196106636	chr3:196474801~196475394:+
HNSC	cis	rs1559040	0.86	rs7586592	ENSG00000272156.1	RP11-477N3.1	-3.54	0.000435	0.0463	-0.3	-0.16	Sudden cardiac arrest;	chr2:54145060	chr2:54082554~54085066:+
HNSC	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	3.54	0.000435	0.0463	0.17	0.16	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
HNSC	cis	rs10005067	0.792	rs10029763	ENSG00000248180.1	GAPDHP60	3.54	0.000435	0.0463	0.15	0.16	Total body bone mineral density (age 30-45);	chr4:87946844	chr4:87207092~87208086:+
HNSC	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	3.54	0.000435	0.0463	0.18	0.16	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	3.54	0.000435	0.0463	0.18	0.16	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	3.54	0.000435	0.0463	0.18	0.16	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
HNSC	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	3.54	0.000435	0.0463	0.18	0.16	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
HNSC	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	3.54	0.000435	0.0463	0.18	0.16	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
HNSC	cis	rs1374313	0.571	rs2422464	ENSG00000223549.1	MTND5P28	3.54	0.000435	0.0463	0.16	0.16	Obesity-related traits;	chr2:119400431	chr2:120215181~120217279:+
HNSC	cis	rs56114371	0.777	rs200481	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000435	0.0463	-0.26	-0.16	Breast cancer;	chr6:27806054	chr6:28115628~28116551:+
HNSC	cis	rs9368481	0.678	rs62402024	ENSG00000238621.1	TRI-TAT2-2	-3.54	0.000435	0.0463	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:27020335~27020447:+
HNSC	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	3.54	0.000435	0.0463	0.18	0.16	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
HNSC	cis	rs8030379	1	rs1471552	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000435	0.0463	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1471553	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000435	0.0463	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84507885~84516814:-
HNSC	cis	rs3096299	0.503	rs4785677	ENSG00000261118.1	RP11-104N10.1	3.54	0.000435	0.0463	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89492017~89504460:-
HNSC	cis	rs6693567	0.545	rs4451552	ENSG00000228126.1	FALEC	3.54	0.000435	0.0463	0.2	0.16	Migraine;	chr1:150483378	chr1:150515757~150518032:+
HNSC	cis	rs9354951	0.55	rs6455394	ENSG00000232295.6	RP11-154D6.1	3.54	0.000435	0.0463	0.16	0.16	Daytime sleep phenotypes;	chr6:70974192	chr6:71221457~71328228:-
HNSC	cis	rs6125597	0.516	rs6019537	ENSG00000227431.4	CSE1L-AS1	-3.54	0.000435	0.0463	-0.18	-0.16	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49040463~49046044:-
HNSC	cis	rs73201462	1	rs2811522	ENSG00000231305.3	RP11-723O4.2	3.54	0.000435	0.0463	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292580	chr3:128861313~128871540:-
HNSC	cis	rs9693857	1	rs9693857	ENSG00000233609.3	RP11-62H7.2	-3.54	0.000435	0.0463	-0.16	-0.16	Systolic blood pressure;	chr8:9409607	chr8:8961200~8979025:+
HNSC	cis	rs7778833	1	rs11768344	ENSG00000272537.1	GS1-166A23.1	3.54	0.000435	0.0463	0.41	0.16	Childhood ear infection;	chr7:15702390	chr7:16471184~16471373:+
HNSC	cis	rs2361718	0.603	rs12951255	ENSG00000275479.1	RP11-334C17.6	3.54	0.000436	0.0463	0.17	0.16	Yeast infection;	chr17:80111798	chr17:80149627~80149798:+
HNSC	cis	rs9611565	0.559	rs132761	ENSG00000235513.1	RP4-756G23.5	-3.54	0.000436	0.0463	-0.2	-0.16	Vitiligo;	chr22:41608367	chr22:41209122~41217627:-
HNSC	cis	rs875971	0.638	rs35986979	ENSG00000273142.1	RP11-458F8.4	3.54	0.000436	0.0463	0.14	0.16	Aortic root size;	chr7:66624003	chr7:66902857~66906297:+
HNSC	cis	rs2554380	0.943	rs2401128	ENSG00000259570.1	RP11-671M22.4	3.54	0.000436	0.0463	0.23	0.16	Height;	chr15:83678426	chr15:84394512~84395514:+
HNSC	cis	rs2554380	0.943	rs2585061	ENSG00000259570.1	RP11-671M22.4	3.54	0.000436	0.0463	0.23	0.16	Height;	chr15:83678999	chr15:84394512~84395514:+
HNSC	cis	rs11671005	0.735	rs34873624	ENSG00000269473.1	CTD-2619J13.19	3.54	0.000436	0.0463	0.26	0.16	Mean platelet volume;	chr19:58432035	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.693	rs34230465	ENSG00000269473.1	CTD-2619J13.19	3.54	0.000436	0.0463	0.26	0.16	Mean platelet volume;	chr19:58432209	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs3764529	ENSG00000269473.1	CTD-2619J13.19	3.54	0.000436	0.0463	0.26	0.16	Mean platelet volume;	chr19:58433722	chr19:58440448~58445849:+
HNSC	cis	rs9650657	0.623	rs6601517	ENSG00000269918.1	AF131215.9	-3.54	0.000436	0.0463	-0.16	-0.16	Neuroticism;	chr8:10746283	chr8:11104691~11106704:-
HNSC	cis	rs739496	0.843	rs10774629	ENSG00000226469.1	ADAM1B	-3.54	0.000436	0.0463	-0.17	-0.16	Platelet count;	chr12:111582410	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.843	rs610769	ENSG00000226469.1	ADAM1B	3.54	0.000436	0.0463	0.17	0.16	Platelet count;	chr12:111561766	chr12:111927018~111929017:+
HNSC	cis	rs739496	0.843	rs595529	ENSG00000226469.1	ADAM1B	3.54	0.000436	0.0463	0.17	0.16	Platelet count;	chr12:111562844	chr12:111927018~111929017:+
HNSC	cis	rs711830	1	rs711830	ENSG00000226363.3	HAGLROS	3.54	0.000436	0.0463	0.21	0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172583	chr2:176177717~176179008:+
HNSC	cis	rs2337406	0.866	rs7152038	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000436	0.0463	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106778230	chr14:106762092~106762588:-
HNSC	cis	rs948562	0.744	rs12363774	ENSG00000280010.1	AP001350.4	3.54	0.000436	0.0463	0.26	0.16	Lymphoma;	chr11:58457562	chr11:58627435~58628528:+
HNSC	cis	rs911555	0.706	rs10129426	ENSG00000269940.1	RP11-73M18.7	3.54	0.000436	0.0464	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694560~103695170:+
HNSC	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	3.54	0.000436	0.0464	0.32	0.16	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	3.54	0.000436	0.0464	0.32	0.16	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	3.54	0.000436	0.0464	0.32	0.16	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	3.54	0.000436	0.0464	0.32	0.16	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
HNSC	cis	rs7914558	1	rs4917994	ENSG00000236937.2	PTGES3P4	3.54	0.000436	0.0464	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102845595~102845950:+
HNSC	cis	rs7914558	1	rs2275271	ENSG00000236937.2	PTGES3P4	3.54	0.000436	0.0464	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102845595~102845950:+
HNSC	cis	rs7914558	1	rs11191539	ENSG00000236937.2	PTGES3P4	3.54	0.000436	0.0464	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102845595~102845950:+
HNSC	cis	rs7914558	1	rs11191541	ENSG00000236937.2	PTGES3P4	3.54	0.000436	0.0464	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102845595~102845950:+
HNSC	cis	rs11893307	0.536	rs6719798	ENSG00000228509.4	AC006460.2	3.54	0.000436	0.0464	0.23	0.16	Mean platelet volume;	chr2:190812938	chr2:190676944~190708716:-
HNSC	cis	rs1937680	0.573	rs7096128	ENSG00000236671.6	PRKG1-AS1	-3.54	0.000436	0.0464	-0.24	-0.16	Breast cancer;	chr10:51866046	chr10:52230742~52314128:-
HNSC	cis	rs10510102	0.516	rs2420976	ENSG00000226864.1	ATE1-AS1	-3.54	0.000436	0.0464	-0.3	-0.16	Breast cancer;	chr10:121986932	chr10:121928312~121951965:+
HNSC	cis	rs886126	1	rs7969686	ENSG00000257595.2	RP3-473L9.4	3.54	0.000436	0.0464	0.21	0.16	Coronary heart disease;	chr12:111227584	chr12:111369282~111403310:+
HNSC	cis	rs2283792	0.765	rs5999749	ENSG00000211666.2	IGLV2-14	3.54	0.000436	0.0464	0.1	0.16	Multiple sclerosis;	chr22:21833371	chr22:22758700~22759218:+
HNSC	cis	rs853679	0.76	rs9468317	ENSG00000270326.1	RP5-874C20.6	-3.54	0.000436	0.0464	-0.22	-0.16	Depression;	chr6:28230678	chr6:28319660~28319852:-
HNSC	cis	rs4819052	1	rs13052356	ENSG00000215447.6	BX322557.10	-3.54	0.000436	0.0464	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45288052~45291738:+
HNSC	cis	rs4819052	1	rs28628220	ENSG00000215447.6	BX322557.10	-3.54	0.000436	0.0464	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45288052~45291738:+
HNSC	cis	rs9652601	0.748	rs12930373	ENSG00000274038.1	RP11-66H6.4	-3.54	0.000436	0.0464	-0.2	-0.16	Systemic lupus erythematosus;	chr16:11145742	chr16:11056556~11057034:+
HNSC	cis	rs2307394	1	rs1364658	ENSG00000281469.1	RP11-567F11.1	3.54	0.000436	0.0464	0.18	0.16	Urate levels;	chr2:147850239	chr2:148044380~148044894:+
HNSC	cis	rs67478160	0.619	rs1040813	ENSG00000259515.1	RP11-365N19.2	3.54	0.000436	0.0464	0.14	0.16	Schizophrenia;	chr14:103840359	chr14:102933574~102937177:+
HNSC	cis	rs67478160	0.619	rs1187416	ENSG00000259515.1	RP11-365N19.2	3.54	0.000436	0.0464	0.14	0.16	Schizophrenia;	chr14:103845128	chr14:102933574~102937177:+
HNSC	cis	rs8077577	0.747	rs2290505	ENSG00000273018.4	CTD-2303H24.2	3.54	0.000436	0.0464	0.24	0.16	Obesity-related traits;	chr17:18233827	chr17:18511221~18551705:-
HNSC	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	3.54	0.000436	0.0464	0.19	0.16	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
HNSC	cis	rs4388249	0.948	rs17162298	ENSG00000271849.1	CTC-332L22.1	-3.54	0.000436	0.0464	-0.26	-0.16	Schizophrenia;	chr5:109815485	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs3797685	ENSG00000271849.1	CTC-332L22.1	-3.54	0.000436	0.0464	-0.26	-0.16	Schizophrenia;	chr5:109815737	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs3797684	ENSG00000271849.1	CTC-332L22.1	-3.54	0.000436	0.0464	-0.26	-0.16	Schizophrenia;	chr5:109815955	chr5:109687802~109688329:-
HNSC	cis	rs1055129	0.655	rs8067076	ENSG00000267342.1	RP11-552F3.10	3.54	0.000436	0.0464	0.13	0.16	White matter hyperintensity burden;	chr17:75841061	chr17:75897060~75900148:+
HNSC	cis	rs2439831	1	rs471229	ENSG00000275601.1	AC011330.13	-3.54	0.000437	0.0464	-0.24	-0.16	Lung cancer in ever smokers;	chr15:43441796	chr15:43642389~43643023:-
HNSC	cis	rs2439831	1	rs2439841	ENSG00000275601.1	AC011330.13	-3.54	0.000437	0.0464	-0.24	-0.16	Lung cancer in ever smokers;	chr15:43442551	chr15:43642389~43643023:-
HNSC	cis	rs7927592	0.913	rs7106339	ENSG00000239559.2	RPL37P2	3.54	0.000437	0.0464	0.17	0.16	Total body bone mineral density;	chr11:68472773	chr11:67682772~67683058:-
HNSC	cis	rs72827839	0.625	rs61454280	ENSG00000228782.6	CTD-2026D20.3	3.54	0.000437	0.0464	0.17	0.16	Ease of getting up in the morning;	chr17:47972759	chr17:47450568~47492492:-
HNSC	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	3.54	0.000437	0.0464	0.16	0.16	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
HNSC	cis	rs2657294	0.965	rs7079694	ENSG00000233313.2	HMGA1P5	-3.54	0.000437	0.0464	-0.18	-0.16	Pneumonia;	chr10:75136804	chr10:75276376~75276646:-
HNSC	cis	rs17772222	0.636	rs10484010	ENSG00000258752.1	RP11-356K23.1	3.54	0.000437	0.0464	0.19	0.16	Coronary artery calcification;	chr14:88831944	chr14:89350285~89364699:+
HNSC	cis	rs4287000	0.508	rs2265576	ENSG00000227603.1	RP11-165J3.6	-3.54	0.000437	0.0464	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93609519	chr9:93435332~93437121:-
HNSC	cis	rs4853525	0.561	rs12693589	ENSG00000228509.4	AC006460.2	3.54	0.000437	0.0464	0.22	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190967936	chr2:190676944~190708716:-
HNSC	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	3.54	0.000437	0.0464	0.19	0.16	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	3.54	0.000437	0.0464	0.19	0.16	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
HNSC	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	3.54	0.000437	0.0464	0.19	0.16	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
HNSC	cis	rs4950322	0.542	rs17159914	ENSG00000278811.3	LINC00624	-3.54	0.000437	0.0464	-0.17	-0.16	Protein quantitative trait loci;	chr1:147183226	chr1:147258885~147517875:-
HNSC	cis	rs6988985	0.626	rs6392	ENSG00000247317.3	RP11-273G15.2	-3.54	0.000437	0.0464	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142875509	chr8:142981738~143018437:-
HNSC	cis	rs6988985	0.533	rs6391	ENSG00000247317.3	RP11-273G15.2	-3.54	0.000437	0.0464	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142875549	chr8:142981738~143018437:-
HNSC	cis	rs4427176	0.507	rs13269437	ENSG00000233609.3	RP11-62H7.2	-3.54	0.000437	0.0464	-0.17	-0.16	Mosquito bite size;	chr8:9721780	chr8:8961200~8979025:+
HNSC	cis	rs2439831	1	rs2584726	ENSG00000275601.1	AC011330.13	-3.54	0.000437	0.0464	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43423184	chr15:43642389~43643023:-
HNSC	cis	rs7824557	0.564	rs35009431	ENSG00000255310.2	AF131215.2	-3.54	0.000437	0.0465	-0.15	-0.16	Retinal vascular caliber;	chr8:11375279	chr8:11107788~11109726:-
HNSC	cis	rs2439831	0.681	rs498837	ENSG00000275601.1	AC011330.13	-3.54	0.000437	0.0465	-0.24	-0.16	Lung cancer in ever smokers;	chr15:43315826	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.681	rs1095386	ENSG00000275601.1	AC011330.13	-3.54	0.000437	0.0465	-0.24	-0.16	Lung cancer in ever smokers;	chr15:43317311	chr15:43642389~43643023:-
HNSC	cis	rs2692947	0.644	rs1724125	ENSG00000231584.7	FAHD2CP	-3.54	0.000437	0.0465	-0.15	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96165617	chr2:96010551~96023380:+
HNSC	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-3.54	0.000437	0.0465	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-3.54	0.000437	0.0465	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
HNSC	cis	rs6964587	0.655	rs6465351	ENSG00000188693.7	CYP51A1-AS1	-3.54	0.000437	0.0465	-0.17	-0.16	Breast cancer;	chr7:92143899	chr7:92134604~92180725:+
HNSC	cis	rs10040610	0.822	rs10035149	ENSG00000250490.1	FLJ33360	3.54	0.000437	0.0465	0.26	0.16	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6363613	chr5:6310441~6339884:-
HNSC	cis	rs12047808	0.512	rs12080991	ENSG00000227141.2	RP11-545A16.3	-3.54	0.000437	0.0465	-0.25	-0.16	Multiple sclerosis (age of onset);	chr1:179273005	chr1:179586705~179589175:+
HNSC	cis	rs2115630	1	rs6496452	ENSG00000275120.1	RP11-182J1.17	-3.54	0.000437	0.0465	-0.17	-0.16	P wave terminal force;	chr15:84829414	chr15:84599434~84606463:-
HNSC	cis	rs2098713	0.569	rs56264101	ENSG00000250155.1	CTD-2353F22.1	3.54	0.000437	0.0465	0.17	0.16	Telomere length;	chr5:37540792	chr5:36666214~36725195:-
HNSC	cis	rs2098713	0.569	rs55716037	ENSG00000250155.1	CTD-2353F22.1	3.54	0.000437	0.0465	0.17	0.16	Telomere length;	chr5:37540805	chr5:36666214~36725195:-
HNSC	cis	rs875971	0.505	rs2462573	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000437	0.0465	-0.13	-0.16	Aortic root size;	chr7:66042405	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.505	rs1167386	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000437	0.0465	-0.13	-0.16	Aortic root size;	chr7:66048109	chr7:66739829~66740385:-
HNSC	cis	rs875971	0.505	rs1167385	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000437	0.0465	-0.13	-0.16	Aortic root size;	chr7:66048321	chr7:66739829~66740385:-
HNSC	cis	rs859767	0.704	rs9287437	ENSG00000224043.6	CCNT2-AS1	3.54	0.000437	0.0465	0.19	0.16	Neuroticism;	chr2:134599932	chr2:134735464~134918710:-
HNSC	cis	rs36715	1	rs251386	ENSG00000245937.6	LINC01184	3.54	0.000437	0.0465	0.21	0.16	Breast cancer;	chr5:128211606	chr5:127940426~128083172:-
HNSC	cis	rs3805389	0.924	rs2412665	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000437	0.0465	-0.21	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55606812	chr4:55363971~55395847:-
HNSC	cis	rs2692947	0.637	rs1168967	ENSG00000231584.7	FAHD2CP	-3.54	0.000438	0.0465	-0.15	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96160278	chr2:96010551~96023380:+
HNSC	cis	rs2016266	0.929	rs7399003	ENSG00000270175.1	RP11-793H13.11	-3.54	0.000438	0.0465	-0.15	-0.16	Bone mineral density;Bone mineral density (spine);	chr12:53265752	chr12:53500162~53500936:-
HNSC	cis	rs9437689	1	rs12569207	ENSG00000237416.5	RP11-465K1.2	-3.54	0.000438	0.0465	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95093446	chr1:94836748~94855426:-
HNSC	cis	rs7520050	0.966	rs785479	ENSG00000280836.1	AL355480.1	3.54	0.000438	0.0465	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45581219~45581321:-
HNSC	cis	rs526231	0.543	rs62362541	ENSG00000250682.4	LINC00491	3.54	0.000438	0.0465	0.21	0.16	Primary biliary cholangitis;	chr5:102986744	chr5:102609156~102671559:-
HNSC	cis	rs2408955	0.522	rs11168408	ENSG00000257763.1	OR5BK1P	-3.54	0.000438	0.0465	-0.15	-0.16	Glycated hemoglobin levels;	chr12:48104544	chr12:48355792~48356614:-
HNSC	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-3.54	0.000438	0.0465	-0.18	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
HNSC	cis	rs860295	0.557	rs6696019	ENSG00000203761.5	MSTO2P	-3.54	0.000438	0.0465	-0.13	-0.16	Body mass index;	chr1:155895186	chr1:155745829~155750137:+
HNSC	cis	rs2247572	0.667	rs1489222	ENSG00000250295.5	RP11-434I12.2	3.54	0.000438	0.0465	0.21	0.16	Cognitive performance;	chr8:72639066	chr8:73297711~73356461:-
HNSC	cis	rs61160187	0.582	rs56025209	ENSG00000272308.1	RP11-231G3.1	-3.54	0.000438	0.0465	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60866457~60866935:-
HNSC	cis	rs10484434	0.901	rs1800758	ENSG00000217159.2	LARP1P1	3.54	0.000438	0.0465	0.27	0.16	HIV-1 viral setpoint;	chr6:26093008	chr6:26164072~26164363:+
HNSC	cis	rs8044188	1	rs8044188	ENSG00000280039.1	CTD-2270L9.3	-3.54	0.000438	0.0465	-0.17	-0.16	Multiple system atrophy;	chr16:23019939	chr16:23412380~23416680:+
HNSC	cis	rs4713118	0.513	rs1225591	ENSG00000219891.2	ZSCAN12P1	3.54	0.000438	0.0465	0.22	0.16	Parkinson's disease;	chr6:28180974	chr6:28091154~28093664:+
HNSC	cis	rs1908814	0.504	rs7830734	ENSG00000255046.1	RP11-297N6.4	-3.54	0.000438	0.0465	-0.17	-0.16	Neuroticism;	chr8:11938130	chr8:11797928~11802568:-
HNSC	cis	rs7429990	0.864	rs12633604	ENSG00000228638.1	FCF1P2	3.54	0.000438	0.0465	0.15	0.16	Educational attainment (years of education);	chr3:47673308	chr3:48290793~48291375:-
HNSC	cis	rs10875746	0.669	rs2279464	ENSG00000257763.1	OR5BK1P	-3.54	0.000438	0.0465	-0.2	-0.16	Longevity (90 years and older);	chr12:48296626	chr12:48355792~48356614:-
HNSC	cis	rs5758511	0.679	rs55867855	ENSG00000233903.2	Z83851.4	3.54	0.000438	0.0465	0.25	0.16	Birth weight;	chr22:42227252	chr22:42276355~42277052:+
HNSC	cis	rs55661361	0.651	rs12293621	ENSG00000254941.1	RP11-677M14.5	3.54	0.000438	0.0465	0.18	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742932	chr11:124807822~124808269:-
HNSC	cis	rs7581030	0.517	rs2287326	ENSG00000234896.1	OR7E62P	3.54	0.000438	0.0465	0.18	0.16	Testicular germ cell tumor;	chr2:71331977	chr2:71055527~71056003:+
HNSC	cis	rs10504130	1	rs10504130	ENSG00000272024.1	RP11-546K22.3	-3.54	0.000438	0.0465	-0.26	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51844533	chr8:51950284~51950690:+
HNSC	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-3.54	0.000438	0.0465	-0.24	-0.16	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
HNSC	cis	rs6840360	0.642	rs6843639	ENSG00000251611.1	RP11-610P16.1	-3.54	0.000438	0.0465	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs28666858	ENSG00000251611.1	RP11-610P16.1	-3.54	0.000438	0.0465	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151407551~151408835:-
HNSC	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000438	0.0465	-0.22	-0.16	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000438	0.0465	-0.22	-0.16	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
HNSC	cis	rs4287000	0.508	rs10821177	ENSG00000227603.1	RP11-165J3.6	-3.54	0.000438	0.0466	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93605304	chr9:93435332~93437121:-
HNSC	cis	rs62344088	1	rs10037843	ENSG00000250848.1	CTD-2083E4.5	-3.54	0.000438	0.0466	-0.37	-0.16	Asthma (childhood onset);	chr5:119963	chr5:288833~290321:-
HNSC	cis	rs62344088	1	rs13436694	ENSG00000250848.1	CTD-2083E4.5	-3.54	0.000438	0.0466	-0.37	-0.16	Asthma (childhood onset);	chr5:122767	chr5:288833~290321:-
HNSC	cis	rs54211	0.536	rs470081	ENSG00000261202.1	RP3-496C20.1	-3.54	0.000438	0.0466	-0.24	-0.16	Sudden cardiac arrest;	chr22:39317100	chr22:40043068~40044530:-
HNSC	cis	rs9633740	0.842	rs1870140	ENSG00000226659.1	RP11-137H2.4	-3.54	0.000438	0.0466	-0.27	-0.16	Post bronchodilator FEV1;	chr10:80486993	chr10:80529597~80535942:-
HNSC	cis	rs7772486	0.686	rs1004752	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000438	0.0466	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs9390347	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000438	0.0466	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.686	rs9390348	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000438	0.0466	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145735570~145737218:+
HNSC	cis	rs7772486	0.632	rs9386128	ENSG00000270638.1	RP3-466P17.1	-3.54	0.000438	0.0466	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145735570~145737218:+
HNSC	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	3.54	0.000439	0.0466	0.2	0.16	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
HNSC	cis	rs6547741	0.844	rs55826602	ENSG00000272148.1	RP11-195B17.1	-3.54	0.000439	0.0466	-0.16	-0.16	Oral cavity cancer;	chr2:27640585	chr2:27062428~27062907:-
HNSC	cis	rs67340775	0.541	rs200975	ENSG00000241549.7	GUSBP2	3.54	0.000439	0.0466	0.21	0.16	Lung cancer in ever smokers;	chr6:27887847	chr6:26871484~26956554:-
HNSC	cis	rs67340775	0.541	rs200974	ENSG00000241549.7	GUSBP2	3.54	0.000439	0.0466	0.21	0.16	Lung cancer in ever smokers;	chr6:27888067	chr6:26871484~26956554:-
HNSC	cis	rs11552145	0.953	rs67465929	ENSG00000124224.15	PPP4R1L	3.54	0.000439	0.0466	0.21	0.16	Prudent dietary pattern;	chr20:57541118	chr20:58228940~58309439:-
HNSC	cis	rs2062225	0.696	rs10200225	ENSG00000233370.1	AC092664.1	3.54	0.000439	0.0466	0.23	0.16	Monocyte count;	chr2:111020987	chr2:110184054~110185179:+
HNSC	cis	rs10484434	0.818	rs11759668	ENSG00000272810.1	U91328.22	3.54	0.000439	0.0466	0.18	0.16	HIV-1 viral setpoint;	chr6:26014261	chr6:26013241~26013757:+
HNSC	cis	rs9329221	0.543	rs2952205	ENSG00000255310.2	AF131215.2	3.54	0.000439	0.0466	0.16	0.16	Neuroticism;	chr8:10282355	chr8:11107788~11109726:-
HNSC	cis	rs643506	0.774	rs11214033	ENSG00000230911.1	PPIHP1	3.54	0.000439	0.0466	0.21	0.16	Breast cancer;	chr11:111898978	chr11:112029858~112030367:-
HNSC	cis	rs753307	0.512	rs749776	ENSG00000268655.1	CTB-60B18.10	3.54	0.000439	0.0466	0.19	0.16	Blood protein levels;	chr19:49015801	chr19:49018247~49019484:-
HNSC	cis	rs9321659	0.614	rs10457669	ENSG00000272017.1	RP1-199J3.7	3.54	0.000439	0.0466	0.27	0.16	Menarche (age at onset);	chr6:99668120	chr6:99568097~99569096:+
HNSC	cis	rs2013441	0.866	rs12949485	ENSG00000261033.1	RP11-209D14.2	-3.54	0.000439	0.0466	-0.19	-0.16	Obesity-related traits;	chr17:20118348	chr17:20008051~20009234:-
HNSC	cis	rs9650657	0.74	rs12676417	ENSG00000255310.2	AF131215.2	3.54	0.000439	0.0466	0.15	0.16	Neuroticism;	chr8:10811124	chr8:11107788~11109726:-
HNSC	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	3.54	0.000439	0.0466	0.17	0.16	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
HNSC	cis	rs8077577	0.747	rs35738574	ENSG00000273018.4	CTD-2303H24.2	-3.54	0.000439	0.0466	-0.24	-0.16	Obesity-related traits;	chr17:18248110	chr17:18511221~18551705:-
HNSC	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-3.54	0.000439	0.0466	-0.19	-0.16	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
HNSC	cis	rs1028883	0.837	rs9318191	ENSG00000228295.1	LINC00392	-3.54	0.000439	0.0466	-0.17	-0.16	Lean body mass;	chr13:73561861	chr13:73564244~73588070:+
HNSC	cis	rs853679	0.76	rs11967137	ENSG00000176933.5	TOB2P1	3.54	0.000439	0.0466	0.22	0.16	Depression;	chr6:28231986	chr6:28217643~28218634:-
HNSC	cis	rs853679	0.76	rs11962305	ENSG00000176933.5	TOB2P1	3.54	0.000439	0.0466	0.22	0.16	Depression;	chr6:28232159	chr6:28217643~28218634:-
HNSC	cis	rs6951245	0.638	rs4720486	ENSG00000225146.1	AC073957.15	-3.54	0.000439	0.0466	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1029025~1043891:+
HNSC	cis	rs8031584	0.736	rs11635775	ENSG00000270015.1	RP11-540B6.6	-3.54	0.000439	0.0466	-0.17	-0.16	Huntington's disease progression;	chr15:30868437	chr15:30926514~30928407:+
HNSC	cis	rs4287000	0.508	rs2254712	ENSG00000227603.1	RP11-165J3.6	-3.54	0.000439	0.0466	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93601577	chr9:93435332~93437121:-
HNSC	cis	rs6517329	0.526	rs35433179	ENSG00000214867.3	SRSF9P1	3.54	0.000439	0.0466	0.2	0.16	Schizophrenia;	chr21:36167162	chr21:36295173~36295702:-
HNSC	cis	rs2172873	0.536	rs7312593	ENSG00000257202.1	RP11-512N21.3	-3.54	0.000439	0.0466	-0.23	-0.16	Uterine fibroids;	chr12:102741234	chr12:101923410~101924719:-
HNSC	cis	rs5758659	0.652	rs5758553	ENSG00000273366.1	CTA-989H11.1	-3.54	0.000439	0.0466	-0.19	-0.16	Cognitive function;	chr22:42035425	chr22:42278188~42278846:+
HNSC	cis	rs896655	0.596	rs10757257	ENSG00000244230.3	RN7SL151P	-3.54	0.000439	0.0466	-0.18	-0.16	Coronary artery disease;	chr9:21806565	chr9:21699314~21699596:+
HNSC	cis	rs7592578	0.766	rs12472081	ENSG00000228509.4	AC006460.2	3.54	0.00044	0.0467	0.26	0.16	Diastolic blood pressure;	chr2:190533819	chr2:190676944~190708716:-
HNSC	cis	rs4704187	0.663	rs7735057	ENSG00000272040.1	CTC-366B18.4	-3.54	0.00044	0.0467	-0.15	-0.16	Response to amphetamines;	chr5:75108032	chr5:75608817~75609983:+
HNSC	cis	rs797680	0.576	rs55838267	ENSG00000229635.1	RP4-713B5.2	3.54	0.00044	0.0467	0.25	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93384487~93384998:-
HNSC	cis	rs9889296	0.598	rs2887258	ENSG00000267457.1	RP5-837J1.4	-3.54	0.00044	0.0467	-0.16	-0.16	Inflammatory bowel disease;	chr17:34274716	chr17:35073831~35074374:-
HNSC	cis	rs10242455	0.702	rs73401510	ENSG00000078319.8	PMS2P1	-3.54	0.00044	0.0467	-0.33	-0.16	Blood metabolite levels;	chr7:99468189	chr7:100320992~100341908:-
HNSC	cis	rs10242455	0.557	rs73401516	ENSG00000078319.8	PMS2P1	-3.54	0.00044	0.0467	-0.33	-0.16	Blood metabolite levels;	chr7:99470728	chr7:100320992~100341908:-
HNSC	cis	rs10242455	0.557	rs77997620	ENSG00000078319.8	PMS2P1	-3.54	0.00044	0.0467	-0.33	-0.16	Blood metabolite levels;	chr7:99472792	chr7:100320992~100341908:-
HNSC	cis	rs10242455	0.702	rs59240302	ENSG00000078319.8	PMS2P1	-3.54	0.00044	0.0467	-0.33	-0.16	Blood metabolite levels;	chr7:99475368	chr7:100320992~100341908:-
HNSC	cis	rs1003719	0.591	rs13046303	ENSG00000242553.1	AP001432.14	3.54	0.00044	0.0467	0.19	0.16	Eye color traits;	chr21:37179674	chr21:37221419~37237744:+
HNSC	cis	rs721917	0.506	rs2758538	ENSG00000244733.5	RP11-506M13.3	-3.54	0.00044	0.0467	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79660891~79677996:+
HNSC	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	3.54	0.00044	0.0467	0.19	0.16	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
HNSC	cis	rs9611565	0.592	rs4822038	ENSG00000235513.1	RP4-756G23.5	3.54	0.00044	0.0467	0.19	0.16	Vitiligo;	chr22:41562491	chr22:41209122~41217627:-
HNSC	cis	rs12935418	0.616	rs13332890	ENSG00000278985.1	RP11-303E16.9	3.54	0.00044	0.0467	0.17	0.16	Mean corpuscular volume;	chr16:80971836	chr16:80982319~80984094:-
HNSC	cis	rs9903692	0.505	rs208008	ENSG00000278765.1	RP5-890E16.5	-3.54	0.00044	0.0467	-0.3	-0.16	Pulse pressure;	chr17:48153476	chr17:48066704~48067293:-
HNSC	cis	rs656900	0.74	rs644315	ENSG00000261229.4	MTHFS	3.54	0.00044	0.0467	0.18	0.16	Cerebrospinal P-tau181p levels;	chr15:79821207	chr15:79843547~79897285:-
HNSC	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-3.54	0.00044	0.0467	-0.18	-0.16	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
HNSC	cis	rs67478160	0.609	rs6576003	ENSG00000269940.1	RP11-73M18.7	3.54	0.00044	0.0467	0.15	0.16	Schizophrenia;	chr14:103824993	chr14:103694560~103695170:+
HNSC	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	3.54	0.00044	0.0467	0.17	0.16	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
HNSC	cis	rs1859596	1	rs4560732	ENSG00000234456.6	MAGI2-AS3	3.54	0.00044	0.0467	0.13	0.16	Reading or mathematical ability;	chr7:79486307	chr7:79452877~79471208:+
HNSC	cis	rs987724	0.515	rs6441101	ENSG00000243926.1	TIPARP-AS1	3.54	0.00044	0.0467	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156875409	chr3:156671862~156674378:-
HNSC	cis	rs8077577	0.708	rs4450455	ENSG00000260647.1	RP1-178F10.1	-3.54	0.00044	0.0467	-0.23	-0.16	Obesity-related traits;	chr17:18237133	chr17:18268080~18268828:+
HNSC	cis	rs12545912	0.77	rs4841196	ENSG00000254340.1	RP11-10A14.3	-3.54	0.00044	0.0467	-0.2	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9697582	chr8:9141424~9145435:+
HNSC	cis	rs8072100	0.84	rs9900360	ENSG00000263293.2	RP11-290H9.4	3.54	0.00044	0.0467	0.17	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47303460~47323613:-
HNSC	cis	rs8072100	0.84	rs56952963	ENSG00000263293.2	RP11-290H9.4	3.54	0.00044	0.0467	0.17	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47303460~47323613:-
HNSC	cis	rs8072100	0.84	rs9893901	ENSG00000263293.2	RP11-290H9.4	3.54	0.00044	0.0467	0.17	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47303460~47323613:-
HNSC	cis	rs9527	0.545	rs7894588	ENSG00000213277.3	MARCKSL1P1	-3.54	0.00044	0.0467	-0.18	-0.16	Arsenic metabolism;	chr10:102996273	chr10:103175554~103176094:+
HNSC	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-3.54	0.00044	0.0467	-0.23	-0.16	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-3.54	0.00044	0.0467	-0.23	-0.16	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-3.54	0.00044	0.0467	-0.23	-0.16	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-3.54	0.00044	0.0467	-0.23	-0.16	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
HNSC	cis	rs10073892	0.701	rs62372298	ENSG00000250682.4	LINC00491	-3.54	0.000441	0.0467	-0.22	-0.16	Cognitive decline (age-related);	chr5:102339880	chr5:102609156~102671559:-
HNSC	cis	rs9487051	1	rs6568570	ENSG00000219700.1	PTCHD3P3	3.54	0.000441	0.0468	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109292038	chr6:109288571~109290503:-
HNSC	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-3.54	0.000441	0.0468	-0.24	-0.16	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
HNSC	cis	rs643506	0.874	rs625477	ENSG00000230911.1	PPIHP1	-3.54	0.000441	0.0468	-0.21	-0.16	Breast cancer;	chr11:111790962	chr11:112029858~112030367:-
HNSC	cis	rs2463822	0.669	rs72919496	ENSG00000250659.2	RP11-864I4.3	3.54	0.000441	0.0468	0.33	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62285258	chr11:62537312~62542018:+
HNSC	cis	rs8044868	0.512	rs10048144	ENSG00000259209.3	RP5-991G20.2	3.54	0.000441	0.0468	0.17	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72018992	chr16:72805998~72809872:+
HNSC	cis	rs2657294	0.965	rs10824285	ENSG00000233313.2	HMGA1P5	-3.54	0.000441	0.0468	-0.17	-0.16	Pneumonia;	chr10:75153271	chr10:75276376~75276646:-
HNSC	cis	rs3748656	0.945	rs11102501	ENSG00000273483.1	RP4-671G15.2	3.54	0.000441	0.0468	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112585332	chr1:112517799~112518441:-
HNSC	cis	rs72843166	0.898	rs17760257	ENSG00000265282.1	RP11-269G24.4	3.54	0.000441	0.0468	0.26	0.16	Intelligence (multi-trait analysis);	chr17:63330719	chr17:63430468~63432211:-
HNSC	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	3.54	0.000441	0.0468	0.2	0.16	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
HNSC	cis	rs74394007	1	rs6802511	ENSG00000243176.4	RP11-550I24.2	3.54	0.000441	0.0468	0.24	0.16	Total body bone mineral density;	chr3:156936133	chr3:157175223~157381265:+
HNSC	cis	rs1008375	0.902	rs7654332	ENSG00000249502.1	AC006160.5	-3.54	0.000441	0.0468	-0.17	-0.16	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690155	chr4:17587467~17614571:-
HNSC	cis	rs9733	0.744	rs12126004	ENSG00000236713.1	RP11-363I22.3	3.54	0.000441	0.0468	0.17	0.16	Tonsillectomy;	chr1:150917401	chr1:150780272~150780644:+
HNSC	cis	rs1062753	0.771	rs932376	ENSG00000227370.1	RP4-669P10.19	3.54	0.000441	0.0468	0.17	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42218356	chr22:42132543~42132998:+
HNSC	cis	rs5167	0.677	rs73047643	ENSG00000214855.8	APOC1P1	3.54	0.000441	0.0468	0.18	0.16	Blood protein levels;	chr19:44954136	chr19:44926804~44931386:+
HNSC	cis	rs2798269	0.528	rs9509802	ENSG00000235438.6	ESRRAP2	3.54	0.000441	0.0468	0.19	0.16	PR segment;	chr13:21574559	chr13:21260015~21295003:+
HNSC	cis	rs7189233	0.531	rs7204496	ENSG00000261056.2	RP11-454F8.2	3.54	0.000441	0.0468	0.17	0.16	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53298224~53299792:+
HNSC	cis	rs1555322	0.932	rs6119593	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000441	0.0468	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35245926	chr20:35262727~35264187:-
HNSC	cis	rs62025270	0.688	rs17575870	ENSG00000259762.1	RP11-158M2.4	-3.54	0.000441	0.0468	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85750336~85752901:-
HNSC	cis	rs11992162	0.529	rs6995037	ENSG00000255495.1	AC145124.2	-3.54	0.000441	0.0468	-0.18	-0.16	Monocyte count;	chr8:11923378	chr8:12194467~12196280:+
HNSC	cis	rs10242455	0.702	rs73403247	ENSG00000078319.8	PMS2P1	-3.54	0.000441	0.0468	-0.33	-0.16	Blood metabolite levels;	chr7:99491107	chr7:100320992~100341908:-
HNSC	cis	rs9402743	0.634	rs6570018	ENSG00000231028.7	LINC00271	-3.54	0.000441	0.0468	-0.19	-0.16	Systemic lupus erythematosus;	chr6:135602218	chr6:135497801~135716055:+
HNSC	cis	rs9402743	0.634	rs9494294	ENSG00000231028.7	LINC00271	-3.54	0.000441	0.0468	-0.19	-0.16	Systemic lupus erythematosus;	chr6:135603460	chr6:135497801~135716055:+
HNSC	cis	rs12545912	0.908	rs6994557	ENSG00000233609.3	RP11-62H7.2	-3.54	0.000441	0.0468	-0.17	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9720720	chr8:8961200~8979025:+
HNSC	cis	rs7429990	0.965	rs5012971	ENSG00000228638.1	FCF1P2	3.54	0.000441	0.0468	0.14	0.16	Educational attainment (years of education);	chr3:48033057	chr3:48290793~48291375:-
HNSC	cis	rs10134944	1	rs17093508	ENSG00000258900.1	HNRNPCP1	3.54	0.000441	0.0468	0.3	0.16	Bipolar disorder;	chr14:57655054	chr14:58521223~58521988:+
HNSC	cis	rs8030379	1	rs8041056	ENSG00000225151.9	GOLGA2P7	-3.54	0.000441	0.0468	-0.2	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84199311~84230136:-
HNSC	cis	rs8030379	1	rs7162129	ENSG00000225151.9	GOLGA2P7	-3.54	0.000441	0.0468	-0.2	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84199311~84230136:-
HNSC	cis	rs4713118	0.539	rs510987	ENSG00000219891.2	ZSCAN12P1	3.54	0.000441	0.0468	0.21	0.16	Parkinson's disease;	chr6:27879739	chr6:28091154~28093664:+
HNSC	cis	rs149866169	1	rs149866169	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000441	0.0468	-0.29	-0.16	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28115628~28116551:+
HNSC	cis	rs7746199	0.668	rs34864796	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000441	0.0468	-0.29	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28115628~28116551:+
HNSC	cis	rs9652601	0.648	rs7197422	ENSG00000274038.1	RP11-66H6.4	-3.54	0.000442	0.0468	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11027214	chr16:11056556~11057034:+
HNSC	cis	rs4578769	0.55	rs9953702	ENSG00000265943.1	RP11-739L10.1	3.54	0.000442	0.0468	0.19	0.16	Eosinophil percentage of white cells;	chr18:22971001	chr18:22699481~22933764:-
HNSC	cis	rs12682352	0.602	rs4841044	ENSG00000254153.1	CTA-398F10.2	-3.54	0.000442	0.0468	-0.18	-0.16	Neuroticism;	chr8:8807430	chr8:8456909~8461337:-
HNSC	cis	rs12030196	1	rs11207369	ENSG00000230812.4	LINC01358	3.54	0.000442	0.0468	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59019419	chr1:59020387~59044614:+
HNSC	cis	rs875971	0.862	rs6944374	ENSG00000229886.1	RP5-1132H15.3	-3.54	0.000442	0.0468	-0.17	-0.16	Aortic root size;	chr7:66221942	chr7:66025126~66031544:-
HNSC	cis	rs4427176	0.507	rs7462115	ENSG00000254340.1	RP11-10A14.3	-3.54	0.000442	0.0468	-0.22	-0.16	Mosquito bite size;	chr8:9721165	chr8:9141424~9145435:+
HNSC	cis	rs870825	0.616	rs7659101	ENSG00000254233.1	RP11-242J7.1	3.54	0.000442	0.0468	0.24	0.16	Blood protein levels;	chr4:184711004	chr4:184584093~184625030:-
HNSC	cis	rs1056107	0.572	rs10981396	ENSG00000225513.1	RP11-165N19.2	3.54	0.000442	0.0469	0.17	0.16	Colorectal cancer;	chr9:112407993	chr9:112173522~112173971:-
HNSC	cis	rs4833079	0.562	rs11944291	ENSG00000231160.8	KLF3-AS1	-3.54	0.000442	0.0469	-0.15	-0.16	Body mass index;	chr4:38629999	chr4:38612701~38664883:-
HNSC	cis	rs7989332	1	rs4769117	ENSG00000226633.2	PPIAP28	-3.54	0.000442	0.0469	-0.22	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20480585	chr13:20178978~20179462:-
HNSC	cis	rs36093844	0.626	rs12281958	ENSG00000279742.1	RP11-700A24.1	-3.54	0.000442	0.0469	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85998907	chr11:85852557~85854943:-
HNSC	cis	rs3738443	0.904	rs10924968	ENSG00000259865.1	RP11-488L18.10	3.54	0.000442	0.0469	0.15	0.16	Alcohol dependence;	chr1:247236957	chr1:247187281~247188526:-
HNSC	cis	rs12370275	0.58	rs12822251	ENSG00000257528.1	KRT8P19	3.54	0.000442	0.0469	0.22	0.16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr12:61355891	chr12:61879318~61880772:+
HNSC	cis	rs2638953	0.962	rs10843171	ENSG00000257176.2	RP11-996F15.2	3.54	0.000442	0.0469	0.19	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28435583	chr12:29280418~29317848:-
HNSC	cis	rs597539	0.652	rs513359	ENSG00000261625.1	RP11-554A11.4	3.54	0.000442	0.0469	0.17	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:69000765~69002048:-
HNSC	cis	rs6504950	1	rs7221223	ENSG00000279059.1	RP11-257O5.2	-3.54	0.000442	0.0469	-0.14	-0.16	Breast cancer;	chr17:54981646	chr17:54956760~54958426:-
HNSC	cis	rs2436845	0.627	rs2513920	ENSG00000253320.4	KB-1507C5.2	-3.54	0.000442	0.0469	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818464	chr8:102864300~102977876:+
HNSC	cis	rs3176789	0.957	rs3136559	ENSG00000256673.1	RP11-599J14.2	3.54	0.000442	0.0469	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764044	chr12:9398355~9414851:-
HNSC	cis	rs783540	0.874	rs10468217	ENSG00000237550.5	UBE2Q2P6	-3.54	0.000442	0.0469	-0.19	-0.16	Schizophrenia;	chr15:82579329	chr15:82372196~82372912:-
HNSC	cis	rs9437689	0.833	rs1146461	ENSG00000237416.5	RP11-465K1.2	3.54	0.000442	0.0469	0.2	0.16	Phospholipid levels (plasma);	chr1:94942936	chr1:94836748~94855426:-
HNSC	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	3.54	0.000442	0.0469	0.19	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
HNSC	cis	rs853679	0.607	rs67662114	ENSG00000219891.2	ZSCAN12P1	3.54	0.000442	0.0469	0.34	0.16	Depression;	chr6:27964523	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs13216117	ENSG00000219891.2	ZSCAN12P1	3.54	0.000442	0.0469	0.34	0.16	Depression;	chr6:27970706	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs36101351	ENSG00000219891.2	ZSCAN12P1	3.54	0.000442	0.0469	0.34	0.16	Depression;	chr6:27975591	chr6:28091154~28093664:+
HNSC	cis	rs853679	0.607	rs28360499	ENSG00000219891.2	ZSCAN12P1	3.54	0.000442	0.0469	0.34	0.16	Depression;	chr6:27977618	chr6:28091154~28093664:+
HNSC	cis	rs7927592	0.871	rs12360903	ENSG00000239559.2	RPL37P2	3.54	0.000442	0.0469	0.17	0.16	Total body bone mineral density;	chr11:68468846	chr11:67682772~67683058:-
HNSC	cis	rs4835473	0.932	rs4240334	ENSG00000249741.2	RP11-673E1.3	-3.54	0.000443	0.0469	-0.18	-0.16	Immature fraction of reticulocytes;	chr4:143871352	chr4:143911514~143912053:-
HNSC	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	3.54	0.000443	0.0469	0.22	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
HNSC	cis	rs355838	0.898	rs355900	ENSG00000233255.1	AC019181.2	3.54	0.000443	0.0469	0.2	0.16	Hip circumference;	chr2:164781560	chr2:164840749~164849334:+
HNSC	cis	rs1322639	0.614	rs9364356	ENSG00000261039.2	RP11-417E7.2	-3.54	0.000443	0.0469	-0.27	-0.16	Pulse pressure;	chr6:169167013	chr6:169175304~169182740:-
HNSC	cis	rs2638953	0.853	rs10843191	ENSG00000257176.2	RP11-996F15.2	3.54	0.000443	0.0469	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:29280418~29317848:-
HNSC	cis	rs1190596	0.525	rs6575901	ENSG00000271780.1	RP11-1017G21.5	3.54	0.000443	0.0469	0.16	0.16	Behavioural disinhibition (generation interaction);	chr14:102225517	chr14:101948347~101949425:+
HNSC	cis	rs60733400	0.5	rs72644697	ENSG00000238164.5	RP3-395M20.8	-3.54	0.000443	0.0469	-0.12	-0.16	Multiple sclerosis;	chr1:2602166	chr1:2549920~2557031:-
HNSC	cis	rs6988985	0.791	rs11779229	ENSG00000253741.1	CTD-2292P10.4	3.54	0.000443	0.0469	0.16	0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142916791	chr8:142702252~142726973:-
HNSC	cis	rs870825	0.616	rs55685500	ENSG00000254233.1	RP11-242J7.1	3.54	0.000443	0.0469	0.25	0.16	Blood protein levels;	chr4:184693656	chr4:184584093~184625030:-
HNSC	cis	rs494453	0.845	rs523650	ENSG00000227811.2	FAM212B-AS1	-3.54	0.000443	0.0469	-0.19	-0.16	Osteoporosis-related phenotypes;	chr1:111699642	chr1:111739841~111747798:+
HNSC	cis	rs7224668	0.564	rs7223939	ENSG00000280407.2	RP13-516M14.8	3.54	0.000443	0.0469	0.13	0.16	IgG glycosylation;	chr17:81267721	chr17:82249067~82251844:+
HNSC	cis	rs73173548	0.528	rs68019847	ENSG00000247828.6	TMEM161B-AS1	3.54	0.000443	0.0469	0.17	0.16	Macular telangiectasia type 2;	chr5:88446795	chr5:88268895~88436685:+
HNSC	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	3.54	0.000443	0.0469	0.16	0.16	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
HNSC	cis	rs1908814	0.516	rs7825529	ENSG00000255310.2	AF131215.2	3.54	0.000443	0.047	0.15	0.16	Neuroticism;	chr8:11936935	chr8:11107788~11109726:-
HNSC	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000443	0.047	-0.23	-0.16	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
HNSC	cis	rs67478160	0.619	rs28698555	ENSG00000259515.1	RP11-365N19.2	-3.54	0.000443	0.047	-0.14	-0.16	Schizophrenia;	chr14:103850149	chr14:102933574~102937177:+
HNSC	cis	rs6600671	1	rs11249350	ENSG00000272583.1	RP11-344P13.6	-3.54	0.000443	0.047	-0.18	-0.16	Hip geometry;	chr1:121436587	chr1:121518366~121518829:-
HNSC	cis	rs55975637	0.73	rs13079203	ENSG00000240476.1	LINC00973	3.54	0.000443	0.047	0.28	0.16	Advanced age-related macular degeneration;	chr3:99669671	chr3:98981058~98983096:+
HNSC	cis	rs55975637	0.73	rs13081022	ENSG00000240476.1	LINC00973	3.54	0.000443	0.047	0.28	0.16	Advanced age-related macular degeneration;	chr3:99670838	chr3:98981058~98983096:+
HNSC	cis	rs2307394	0.896	rs9679427	ENSG00000281469.1	RP11-567F11.1	3.54	0.000443	0.047	0.17	0.16	Urate levels;	chr2:147786399	chr2:148044380~148044894:+
HNSC	cis	rs7726839	0.54	rs56325086	ENSG00000225138.6	CTD-2228K2.7	3.54	0.000443	0.047	0.24	0.16	Obesity-related traits;	chr5:640613	chr5:473236~480884:+
HNSC	cis	rs1005277	0.579	rs1614236	ENSG00000099251.13	HSD17B7P2	3.54	0.000443	0.047	0.16	0.16	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38356380~38378505:+
HNSC	cis	rs1005277	0.579	rs2749616	ENSG00000099251.13	HSD17B7P2	3.54	0.000443	0.047	0.16	0.16	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38356380~38378505:+
HNSC	cis	rs7757969	0.536	rs706911	ENSG00000215807.4	KRT18P65	3.54	0.000444	0.047	0.28	0.16	Schizophrenia;	chr6:111728849	chr6:112361437~112362722:-
HNSC	cis	rs12188164	0.965	rs41282625	ENSG00000215246.5	RP11-43F13.3	-3.54	0.000444	0.047	-0.18	-0.16	Cystic fibrosis severity;	chr5:475511	chr5:987180~997308:-
HNSC	cis	rs10519937	0.935	rs3756721	ENSG00000230929.5	RP11-395C3.1	-3.54	0.000444	0.047	-0.23	-0.16	IgG glycosylation;	chr5:127459467	chr5:126628019~126628319:-
HNSC	cis	rs2625529	0.73	rs8182011	ENSG00000260037.4	CTD-2524L6.3	3.54	0.000444	0.047	0.23	0.16	Red blood cell count;	chr15:72097607	chr15:71818396~71823384:+
HNSC	cis	rs10519937	1	rs6595767	ENSG00000230929.5	RP11-395C3.1	-3.54	0.000444	0.047	-0.26	-0.16	IgG glycosylation;	chr5:127398575	chr5:126628019~126628319:-
HNSC	cis	rs911555	0.655	rs10141157	ENSG00000269958.1	RP11-73M18.8	3.54	0.000444	0.047	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103696353~103697163:+
HNSC	cis	rs5758659	0.714	rs5751220	ENSG00000270083.1	RP1-257I20.14	-3.54	0.000444	0.047	-0.15	-0.16	Cognitive function;	chr22:42120201	chr22:42089630~42090028:-
HNSC	cis	rs9304742	0.683	rs10402714	ENSG00000242779.5	ZNF702P	3.54	0.000444	0.047	0.19	0.16	Psoriasis;	chr19:52960427	chr19:52968251~53037898:-
HNSC	cis	rs643506	0.715	rs11214031	ENSG00000230911.1	PPIHP1	-3.54	0.000444	0.047	-0.21	-0.16	Breast cancer;	chr11:111895315	chr11:112029858~112030367:-
HNSC	cis	rs7615952	0.546	rs2979307	ENSG00000241288.6	RP11-379B18.5	3.54	0.000444	0.047	0.23	0.16	Blood pressure (smoking interaction);	chr3:125590730	chr3:125827238~125916384:-
HNSC	cis	rs1005277	0.579	rs1780137	ENSG00000099251.13	HSD17B7P2	3.54	0.000444	0.047	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38356380~38378505:+
HNSC	cis	rs11711311	1	rs9811200	ENSG00000241529.3	RN7SL767P	-3.54	0.000444	0.047	-0.21	-0.16	IgG glycosylation;	chr3:113812333	chr3:113632704~113632998:+
HNSC	cis	rs9611565	0.546	rs132793	ENSG00000213857.3	RP11-12M9.4	-3.54	0.000444	0.047	-0.22	-0.16	Vitiligo;	chr22:41667677	chr22:41074180~41075239:-
HNSC	cis	rs7011507	0.562	rs10113165	ENSG00000253608.1	RP11-770E5.1	-3.54	0.000444	0.0471	-0.24	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48452590	chr8:48551567~48698510:+
HNSC	cis	rs7011507	0.562	rs11985893	ENSG00000253608.1	RP11-770E5.1	-3.54	0.000444	0.0471	-0.24	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48453953	chr8:48551567~48698510:+
HNSC	cis	rs9652601	0.843	rs7204643	ENSG00000274038.1	RP11-66H6.4	3.54	0.000444	0.0471	0.2	0.16	Systemic lupus erythematosus;	chr16:11073746	chr16:11056556~11057034:+
HNSC	cis	rs11648785	0.59	rs3743827	ENSG00000221819.5	GAS8-AS1	3.54	0.000444	0.0471	0.17	0.16	Tanning;	chr16:90027787	chr16:90028908~90029367:-
HNSC	cis	rs868153	0.625	rs13216068	ENSG00000275339.1	RP3-425C14.6	3.54	0.000444	0.0471	0.17	0.16	Vertical cup-disc ratio;	chr6:122169922	chr6:122454358~122454612:+
HNSC	cis	rs7172689	0.908	rs11638043	ENSG00000271725.1	RP11-761I4.4	3.54	0.000444	0.0471	0.23	0.16	Inattentive symptoms;	chr15:81277598	chr15:81303215~81309391:-
HNSC	cis	rs7824557	0.767	rs6985460	ENSG00000255495.1	AC145124.2	3.54	0.000444	0.0471	0.19	0.16	Retinal vascular caliber;	chr8:11313578	chr8:12194467~12196280:+
HNSC	cis	rs6600671	1	rs10903159	ENSG00000272583.1	RP11-344P13.6	-3.54	0.000445	0.0471	-0.18	-0.16	Hip geometry;	chr1:121440138	chr1:121518366~121518829:-
HNSC	cis	rs73198271	0.74	rs10094270	ENSG00000254153.1	CTA-398F10.2	-3.54	0.000445	0.0471	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8456909~8461337:-
HNSC	cis	rs73198271	0.74	rs28521727	ENSG00000254153.1	CTA-398F10.2	-3.54	0.000445	0.0471	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8456909~8461337:-
HNSC	cis	rs12410462	0.681	rs76705164	ENSG00000224834.1	BTF3P9	3.54	0.000445	0.0471	0.26	0.16	Major depressive disorder;	chr1:227427869	chr1:227434064~227434346:+
HNSC	cis	rs7306455	0.558	rs35249403	ENSG00000237774.3	RP11-129B9.1	-3.54	0.000445	0.0471	-0.39	-0.16	Coronary artery disease;	chr12:94932967	chr12:95125760~95126389:+
HNSC	cis	rs8077577	0.747	rs2071242	ENSG00000260647.1	RP1-178F10.1	3.54	0.000445	0.0471	0.23	0.16	Obesity-related traits;	chr17:18251196	chr17:18268080~18268828:+
HNSC	cis	rs12073359	1	rs11577346	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150094433	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs112521467	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150101194	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs112245786	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102532	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs112814713	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102647	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694914	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102833	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694915	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102876	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694923	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150105152	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694926	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150107999	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694928	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150109454	chr1:149844498~149849024:-
HNSC	cis	rs12073359	0.954	rs113082139	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150117796	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694933	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150122414	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs55840680	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125477	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72694936	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125986	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs11584091	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000445	0.0471	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150129018	chr1:149844498~149849024:-
HNSC	cis	rs61160187	0.51	rs6893642	ENSG00000215032.2	GNL3LP1	3.54	0.000445	0.0471	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs3936423	ENSG00000215032.2	GNL3LP1	3.54	0.000445	0.0471	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.51	rs1445293	ENSG00000215032.2	GNL3LP1	3.54	0.000445	0.0471	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60891935~60893577:-
HNSC	cis	rs79040073	0.679	rs76231511	ENSG00000259531.2	RP11-295H24.3	3.54	0.000445	0.0471	0.21	0.16	Lung cancer in ever smokers;	chr15:49222243	chr15:49365124~49366685:-
HNSC	cis	rs1580019	0.844	rs4723159	ENSG00000226468.2	AC018641.7	-3.54	0.000445	0.0471	-0.22	-0.16	Cognitive ability;	chr7:32473192	chr7:32456963~32457758:-
HNSC	cis	rs12234571	1	rs73372287	ENSG00000214293.7	APTR	3.54	0.000445	0.0471	0.22	0.16	Obesity-related traits;	chr7:77713268	chr7:77657660~77696265:-
HNSC	cis	rs74781061	0.932	rs74025818	ENSG00000260103.2	RP11-10O17.1	-3.54	0.000445	0.0471	-0.19	-0.16	Endometriosis;	chr15:74618287	chr15:74478070~74490286:-
HNSC	cis	rs4713118	0.955	rs9468206	ENSG00000217862.2	HIST1H4PS1	-3.54	0.000445	0.0471	-0.19	-0.16	Parkinson's disease;	chr6:27722674	chr6:27807075~27807339:+
HNSC	cis	rs853679	0.666	rs200956	ENSG00000219891.2	ZSCAN12P1	3.54	0.000445	0.0471	0.24	0.16	Depression;	chr6:27871968	chr6:28091154~28093664:+
HNSC	cis	rs6988985	0.678	rs9643358	ENSG00000247317.3	RP11-273G15.2	-3.54	0.000445	0.0471	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921722	chr8:142981738~143018437:-
HNSC	cis	rs6545883	0.86	rs6545848	ENSG00000271889.1	RP11-493E12.1	-3.54	0.000445	0.0471	-0.18	-0.16	Tuberculosis;	chr2:61234048	chr2:61151433~61162105:-
HNSC	cis	rs6997458	0.742	rs3758076	ENSG00000253549.4	RP11-317J10.2	3.54	0.000445	0.0471	0.18	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463306	chr8:85441851~85464915:-
HNSC	cis	rs61160187	0.582	rs12516995	ENSG00000272308.1	RP11-231G3.1	-3.54	0.000445	0.0471	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60866457~60866935:-
HNSC	cis	rs4704187	0.687	rs10942729	ENSG00000271815.1	CTD-2235C13.3	-3.54	0.000445	0.0471	-0.2	-0.16	Response to amphetamines;	chr5:75068475	chr5:75363760~75364242:+
HNSC	cis	rs1005277	0.505	rs13503	ENSG00000263064.2	RP11-291L22.7	-3.54	0.000445	0.0471	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38448689~38448949:+
HNSC	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	3.54	0.000445	0.0471	0.18	0.16	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
HNSC	cis	rs6925255	1	rs7768071	ENSG00000270362.1	HMGN3-AS1	3.54	0.000445	0.0472	0.2	0.16	Aging;	chr6:79757937	chr6:79233718~79236797:+
HNSC	cis	rs5758511	0.68	rs5758657	ENSG00000233903.2	Z83851.4	3.54	0.000445	0.0472	0.25	0.16	Birth weight;	chr22:42222663	chr22:42276355~42277052:+
HNSC	cis	rs5758511	0.68	rs1033459	ENSG00000233903.2	Z83851.4	3.54	0.000445	0.0472	0.25	0.16	Birth weight;	chr22:42223061	chr22:42276355~42277052:+
HNSC	cis	rs72843506	0.652	rs28550747	ENSG00000189423.10	USP32P3	3.54	0.000445	0.0472	0.25	0.16	Schizophrenia;	chr17:20274999	chr17:20415547~20431008:+
HNSC	cis	rs10832963	1	rs11024739	ENSG00000256282.1	RP11-504G3.4	3.54	0.000445	0.0472	0.16	0.16	Breast cancer;	chr11:18624296	chr11:18595459~18599683:-
HNSC	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	3.54	0.000446	0.0472	0.23	0.16	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
HNSC	cis	rs4713118	0.628	rs9295740	ENSG00000217862.2	HIST1H4PS1	-3.54	0.000446	0.0472	-0.2	-0.16	Parkinson's disease;	chr6:27721723	chr6:27807075~27807339:+
HNSC	cis	rs561341	1	rs4795670	ENSG00000265798.5	RP11-271K11.5	3.54	0.000446	0.0472	0.24	0.16	Hip circumference adjusted for BMI;	chr17:31917820	chr17:31038575~31059121:-
HNSC	cis	rs561341	1	rs8073186	ENSG00000265798.5	RP11-271K11.5	3.54	0.000446	0.0472	0.24	0.16	Hip circumference adjusted for BMI;	chr17:31917937	chr17:31038575~31059121:-
HNSC	cis	rs12049351	0.665	rs6690907	ENSG00000177788.5	RP5-1061H20.4	-3.54	0.000446	0.0472	-0.21	-0.16	Circulating myeloperoxidase levels (plasma);	chr1:229457643	chr1:229258281~229271028:-
HNSC	cis	rs2032447	0.899	rs1090947	ENSG00000272462.2	U91328.19	-3.54	0.000446	0.0472	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26076414	chr6:25992662~26001775:+
HNSC	cis	rs7209700	0.889	rs11079769	ENSG00000262879.4	RP11-156P1.3	3.54	0.000446	0.0472	0.18	0.16	IgG glycosylation;	chr17:47272365	chr17:46984045~47100323:-
HNSC	cis	rs786425	0.966	rs4456350	ENSG00000278112.1	RP11-972P1.11	3.54	0.000446	0.0472	0.15	0.16	Pubertal anthropometrics;	chr12:123573942	chr12:123519390~123519856:-
HNSC	cis	rs5758659	0.904	rs134877	ENSG00000270083.1	RP1-257I20.14	3.54	0.000446	0.0472	0.15	0.16	Cognitive function;	chr22:42266365	chr22:42089630~42090028:-
HNSC	cis	rs36715	1	rs36693	ENSG00000245937.6	LINC01184	3.54	0.000446	0.0472	0.21	0.16	Breast cancer;	chr5:128213008	chr5:127940426~128083172:-
HNSC	cis	rs7405404	0.672	rs8060141	ENSG00000262454.1	RP11-65J21.3	-3.54	0.000446	0.0472	-0.14	-0.16	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13642055	chr16:14302288~14326353:+
HNSC	cis	rs6587515	0.901	rs10888396	ENSG00000274963.1	Metazoa_SRP	-3.54	0.000446	0.0472	-0.26	-0.16	Pericardial adipose tissue adjusted for height and weight;	chr1:150805038	chr1:150568971~150569269:-
HNSC	cis	rs7187365	0.938	rs1169634	ENSG00000270006.2	RP11-178L8.7	-3.54	0.000446	0.0472	-0.19	-0.16	Obesity (early onset extreme);	chr16:86492149	chr16:87317509~87318043:+
HNSC	cis	rs8072100	1	rs7210738	ENSG00000263293.2	RP11-290H9.4	-3.54	0.000446	0.0472	-0.17	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47303460~47323613:-
HNSC	cis	rs7015630	0.779	rs13260987	ENSG00000251136.7	RP11-37B2.1	-3.54	0.000446	0.0472	-0.18	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89854126	chr8:89609409~89757727:-
HNSC	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	3.54	0.000446	0.0472	0.25	0.16	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
HNSC	cis	rs2098713	0.569	rs55758014	ENSG00000250155.1	CTD-2353F22.1	3.54	0.000446	0.0472	0.17	0.16	Telomere length;	chr5:37565674	chr5:36666214~36725195:-
HNSC	cis	rs1867631	0.876	rs10889637	ENSG00000248458.2	RP4-598P13.1	3.54	0.000446	0.0472	0.16	0.16	Menopause (age at onset);	chr1:66631782	chr1:66665864~66677027:-
HNSC	cis	rs13178541	0.81	rs7378848	ENSG00000250378.1	RP11-119J18.1	3.54	0.000446	0.0472	0.19	0.16	IgG glycosylation;	chr5:135751336	chr5:135812667~135826582:+
HNSC	cis	rs9952991	0.883	rs11663253	ENSG00000260302.1	RP11-973H7.1	3.54	0.000446	0.0472	0.28	0.16	Inflammatory skin disease;	chr18:12789557	chr18:12774651~12775923:-
HNSC	cis	rs2337406	0.929	rs12050233	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000446	0.0472	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106781123	chr14:106762092~106762588:-
HNSC	cis	rs2337406	0.852	rs12050466	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000446	0.0472	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106781131	chr14:106762092~106762588:-
HNSC	cis	rs73201462	1	rs6784159	ENSG00000231305.3	RP11-723O4.2	-3.54	0.000446	0.0472	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128124535	chr3:128861313~128871540:-
HNSC	cis	rs73198271	0.531	rs17154756	ENSG00000253893.2	FAM85B	3.54	0.000446	0.0472	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794884	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.531	rs11985640	ENSG00000253893.2	FAM85B	3.54	0.000446	0.0472	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794994	chr8:8167819~8226614:-
HNSC	cis	rs73198271	0.531	rs56100346	ENSG00000253893.2	FAM85B	3.54	0.000446	0.0472	0.25	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795334	chr8:8167819~8226614:-
HNSC	cis	rs2436845	0.783	rs1062315	ENSG00000253320.4	KB-1507C5.2	-3.54	0.000446	0.0472	-0.17	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102826936	chr8:102864300~102977876:+
HNSC	cis	rs35824328	0.831	rs17766460	ENSG00000229267.2	AC072062.1	-3.54	0.000446	0.0472	-0.26	-0.16	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214244083	chr2:214810229~214963274:+
HNSC	cis	rs1832007	0.529	rs7100517	ENSG00000224034.1	RP11-445P17.8	-3.54	0.000446	0.0472	-0.19	-0.16	Triglyceride levels;Triglycerides;	chr10:5201007	chr10:5266033~5271236:-
HNSC	cis	rs1832007	0.529	rs7088788	ENSG00000224034.1	RP11-445P17.8	-3.54	0.000446	0.0472	-0.19	-0.16	Triglyceride levels;Triglycerides;	chr10:5201130	chr10:5266033~5271236:-
HNSC	cis	rs2762353	0.718	rs1165207	ENSG00000272462.2	U91328.19	-3.54	0.000446	0.0472	-0.16	-0.16	Blood metabolite levels;	chr6:25865038	chr6:25992662~26001775:+
HNSC	cis	rs12887734	0.524	rs4906363	ENSG00000269910.1	RP11-73M18.10	3.54	0.000446	0.0472	0.16	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694516~103695050:-
HNSC	cis	rs7937890	0.532	rs2575832	ENSG00000254418.1	RP11-21L19.1	3.54	0.000446	0.0472	0.19	0.16	Mitochondrial DNA levels;	chr11:14467264	chr11:14262846~14273691:-
HNSC	cis	rs67311347	1	rs1119179	ENSG00000280739.1	EIF1B-AS1	-3.54	0.000446	0.0472	-0.19	-0.16	Renal cell carcinoma;	chr3:40383438	chr3:40173145~40309698:-
HNSC	cis	rs57221529	0.766	rs4081847	ENSG00000225138.6	CTD-2228K2.7	3.54	0.000447	0.0473	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:473236~480884:+
HNSC	cis	rs6541297	0.703	rs621328	ENSG00000237481.1	RP4-803J11.2	-3.54	0.000447	0.0473	-0.26	-0.16	Coronary artery disease;	chr1:230174668	chr1:229319403~229323087:+
HNSC	cis	rs2836974	0.897	rs2836944	ENSG00000255568.3	BRWD1-AS2	3.54	0.000447	0.0473	0.15	0.16	Cognitive function;	chr21:39221613	chr21:39313935~39314962:+
HNSC	cis	rs1867631	1	rs6665859	ENSG00000248458.2	RP4-598P13.1	3.54	0.000447	0.0473	0.16	0.16	Menopause (age at onset);	chr1:66611872	chr1:66665864~66677027:-
HNSC	cis	rs11866815	0.739	rs35050910	ENSG00000219274.1	RPS20P2	-3.54	0.000447	0.0473	-0.2	-0.16	Body mass index;	chr16:344483	chr16:1329078~1329777:+
HNSC	cis	rs7616559	1	rs7616559	ENSG00000240875.4	LINC00886	3.54	0.000447	0.0473	0.2	0.16	Carotid artery intima media thickness (sex interaction);	chr3:157010821	chr3:156747346~156817062:-
HNSC	cis	rs73173548	0.528	rs80083342	ENSG00000247828.6	TMEM161B-AS1	3.54	0.000447	0.0473	0.17	0.16	Macular telangiectasia type 2;	chr5:88476921	chr5:88268895~88436685:+
HNSC	cis	rs7809950	0.637	rs3801964	ENSG00000238832.1	snoU109	-3.54	0.000447	0.0473	-0.24	-0.16	Coronary artery disease;	chr7:107195797	chr7:107603363~107603507:+
HNSC	cis	rs61160187	0.582	rs55814394	ENSG00000152931.7	PART1	-3.54	0.000447	0.0473	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60487713~60547657:+
HNSC	cis	rs10863681	0.875	rs10863685	ENSG00000238042.4	RP11-815M8.1	3.54	0.000447	0.0473	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222082581	chr1:221880981~221978523:-
HNSC	cis	rs6493858	0.809	rs11631191	ENSG00000277245.1	RP11-48G14.3	-3.54	0.000447	0.0473	-0.18	-0.16	Relative hand skill in reading disability;	chr15:56155802	chr15:56447120~56447697:+
HNSC	cis	rs35000415	0.938	rs12531711	ENSG00000275106.1	RP11-309L24.10	-3.54	0.000447	0.0473	-0.36	-0.16	Systemic lupus erythematosus;	chr7:128977412	chr7:128952527~128953316:-
HNSC	cis	rs964184	0.63	rs10750096	ENSG00000280143.1	AP000892.6	3.54	0.000447	0.0473	0.3	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117204967~117210292:+
HNSC	cis	rs1440410	0.735	rs893929	ENSG00000250326.1	RP11-284M14.1	-3.54	0.000447	0.0473	-0.18	-0.16	Ischemic stroke;	chr4:143266227	chr4:142933195~143184861:-
HNSC	cis	rs344024	0.621	rs1510280	ENSG00000240489.1	SETP14	3.54	0.000447	0.0473	0.15	0.16	Total body bone mineral density;	chr3:156648824	chr3:155987304~155988176:+
HNSC	cis	rs344024	0.659	rs9835981	ENSG00000240489.1	SETP14	3.54	0.000447	0.0473	0.15	0.16	Total body bone mineral density;	chr3:156649625	chr3:155987304~155988176:+
HNSC	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	3.54	0.000447	0.0473	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
HNSC	cis	rs16846053	0.515	rs918964	ENSG00000227403.1	AC009299.3	-3.54	0.000447	0.0473	-0.28	-0.16	Blood osmolality (transformed sodium);	chr2:161440405	chr2:161244739~161249050:+
HNSC	cis	rs10507380	0.891	rs9512603	ENSG00000260704.1	LINC00543	3.54	0.000447	0.0473	0.27	0.16	Electrocardiographic traits;	chr13:27290531	chr13:27953526~27955370:+
HNSC	cis	rs4073405	0.584	rs7396488	ENSG00000254651.1	RP11-430H10.3	-3.54	0.000447	0.0473	-0.19	-0.16	Schizophrenia;	chr11:45290422	chr11:45399448~45400528:+
HNSC	cis	rs1005277	0.505	rs7069702	ENSG00000263064.2	RP11-291L22.7	-3.54	0.000448	0.0473	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38448689~38448949:+
HNSC	cis	rs7772486	0.712	rs1292335	ENSG00000270638.1	RP3-466P17.1	3.54	0.000448	0.0473	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145735570~145737218:+
HNSC	cis	rs9650657	0.801	rs718741	ENSG00000255310.2	AF131215.2	-3.54	0.000448	0.0473	-0.16	-0.16	Neuroticism;	chr8:10756874	chr8:11107788~11109726:-
HNSC	cis	rs870825	0.616	rs56844261	ENSG00000254233.1	RP11-242J7.1	3.54	0.000448	0.0473	0.24	0.16	Blood protein levels;	chr4:184711324	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.587	rs28454955	ENSG00000254233.1	RP11-242J7.1	3.54	0.000448	0.0473	0.24	0.16	Blood protein levels;	chr4:184711547	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs9715644	ENSG00000254233.1	RP11-242J7.1	3.54	0.000448	0.0473	0.24	0.16	Blood protein levels;	chr4:184711811	chr4:184584093~184625030:-
HNSC	cis	rs7683537	0.887	rs4540092	ENSG00000254233.1	RP11-242J7.1	3.54	0.000448	0.0473	0.24	0.16	Systemic lupus erythematosus;	chr4:184712392	chr4:184584093~184625030:-
HNSC	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	3.54	0.000448	0.0473	0.22	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
HNSC	cis	rs12073359	0.908	rs11589801	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000448	0.0473	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150168635	chr1:149844498~149849024:-
HNSC	cis	rs12073359	0.955	rs78676616	ENSG00000261716.1	RP11-196G18.22	-3.54	0.000448	0.0473	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150171103	chr1:149844498~149849024:-
HNSC	cis	rs6928977	0.802	rs2244745	ENSG00000231028.7	LINC00271	3.54	0.000448	0.0473	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341683	chr6:135497801~135716055:+
HNSC	cis	rs1445130	0.892	rs56407213	ENSG00000260331.1	RP11-111J6.2	3.54	0.000448	0.0473	0.34	0.16	Bulimia nervosa;	chr2:18666832	chr2:18547386~18548204:-
HNSC	cis	rs6674970	0.518	rs15740	ENSG00000261168.1	RP11-68I18.10	-3.54	0.000448	0.0474	-0.21	-0.16	Childhood ear infection;	chr1:151067959	chr1:151130075~151131610:-
HNSC	cis	rs73201462	1	rs10934850	ENSG00000231305.3	RP11-723O4.2	-3.54	0.000448	0.0474	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128168114	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs13067650	ENSG00000231305.3	RP11-723O4.2	-3.54	0.000448	0.0474	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128170699	chr3:128861313~128871540:-
HNSC	cis	rs2013441	0.866	rs17686622	ENSG00000261033.1	RP11-209D14.2	3.54	0.000448	0.0474	0.19	0.16	Obesity-related traits;	chr17:20117051	chr17:20008051~20009234:-
HNSC	cis	rs6449502	0.748	rs6449504	ENSG00000251279.1	CTC-436P18.1	-3.54	0.000448	0.0474	-0.23	-0.16	Mean platelet volume;	chr5:60809409	chr5:61162070~61232040:+
HNSC	cis	rs6449502	0.748	rs36111624	ENSG00000251279.1	CTC-436P18.1	-3.54	0.000448	0.0474	-0.23	-0.16	Mean platelet volume;	chr5:60810179	chr5:61162070~61232040:+
HNSC	cis	rs35306767	0.855	rs35666723	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000448	0.0474	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:821406	chr10:933026~942743:+
HNSC	cis	rs35306767	0.855	rs56222464	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000448	0.0474	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:821595	chr10:933026~942743:+
HNSC	cis	rs35306767	0.855	rs61830900	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000448	0.0474	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:825541	chr10:933026~942743:+
HNSC	cis	rs35306767	0.855	rs12771179	ENSG00000229869.1	RP11-363N22.2	-3.54	0.000448	0.0474	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:826407	chr10:933026~942743:+
HNSC	cis	rs9400467	0.528	rs456569	ENSG00000271789.1	RP5-1112D6.7	-3.54	0.000448	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111297126~111298510:+
HNSC	cis	rs1881509	0.748	rs1574179	ENSG00000255153.1	TOLLIP-AS1	-3.54	0.000448	0.0474	-0.18	-0.16	Heroin dependence;	chr11:1399839	chr11:1309769~1310707:+
HNSC	cis	rs72627123	0.582	rs62005101	ENSG00000259065.1	RP5-1021I20.1	-3.54	0.000448	0.0474	-0.23	-0.16	Morning vs. evening chronotype;	chr14:74033882	chr14:73787360~73803270:+
HNSC	cis	rs72627123	0.582	rs62005102	ENSG00000259065.1	RP5-1021I20.1	-3.54	0.000448	0.0474	-0.23	-0.16	Morning vs. evening chronotype;	chr14:74033883	chr14:73787360~73803270:+
HNSC	cis	rs9611565	0.559	rs132771	ENSG00000233903.2	Z83851.4	3.54	0.000448	0.0474	0.24	0.16	Vitiligo;	chr22:41629346	chr22:42276355~42277052:+
HNSC	cis	rs727563	0.52	rs132773	ENSG00000233903.2	Z83851.4	3.54	0.000448	0.0474	0.24	0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr22:42276355~42277052:+
HNSC	cis	rs34286592	1	rs34127220	ENSG00000183604.13	SMG1P5	-3.54	0.000448	0.0474	-0.22	-0.16	Multiple sclerosis;	chr16:29831570	chr16:30267553~30335374:-
HNSC	cis	rs481331	0.741	rs3740329	ENSG00000215146.4	RP11-313J2.1	3.54	0.000448	0.0474	0.25	0.16	Systemic juvenile idiopathic arthritis;	chr10:42638638	chr10:42331866~42367974:-
HNSC	cis	rs9487051	0.704	rs1741930	ENSG00000243587.6	C6orf183	-3.54	0.000448	0.0474	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109198594	chr6:109165833~109271014:+
HNSC	cis	rs9487051	0.735	rs1260596	ENSG00000243587.6	C6orf183	-3.54	0.000448	0.0474	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109198644	chr6:109165833~109271014:+
HNSC	cis	rs6732426	0.721	rs35491011	ENSG00000279873.2	LINC01126	3.54	0.000448	0.0474	0.15	0.16	Hair morphology;	chr2:43386851	chr2:43227210~43228855:+
HNSC	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	3.54	0.000448	0.0474	0.18	0.16	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
HNSC	cis	rs793571	0.779	rs8035628	ENSG00000245975.2	RP11-30K9.6	-3.54	0.000448	0.0474	-0.25	-0.16	Schizophrenia;	chr15:58885201	chr15:58768072~58770974:-
HNSC	cis	rs13113518	0.51	rs3749473	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000448	0.0474	0.18	0.16	Height;	chr4:55428461	chr4:55363971~55395847:-
HNSC	cis	rs3176789	0.914	rs12582052	ENSG00000256673.1	RP11-599J14.2	-3.54	0.000448	0.0474	-0.17	-0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774974	chr12:9398355~9414851:-
HNSC	cis	rs5756813	0.668	rs5756805	ENSG00000225867.1	RP5-1177I5.3	-3.53	0.000448	0.0474	-0.19	-0.16	Optic cup area;Vertical cup-disc ratio;	chr22:37748611	chr22:37550026~37551735:+
HNSC	cis	rs58688157	0.705	rs2396545	ENSG00000255158.1	RP11-754B17.1	-3.53	0.000448	0.0474	-0.2	-0.16	Systemic lupus erythematosus;	chr11:601785	chr11:665910~678391:+
HNSC	cis	rs10805346	0.558	rs12506562	ENSG00000261490.1	RP11-448G15.3	3.53	0.000449	0.0474	0.13	0.16	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10105330	chr4:10068089~10073019:-
HNSC	cis	rs1185460	0.967	rs11217133	ENSG00000272186.1	RP11-110I1.13	-3.53	0.000449	0.0474	-0.19	-0.16	Coronary artery disease;	chr11:119057538	chr11:119067374~119067698:-
HNSC	cis	rs6831352	0.851	rs1230164	ENSG00000263923.1	RP11-571L19.7	-3.53	0.000449	0.0474	-0.17	-0.16	Alcohol dependence;	chr4:99064872	chr4:98928897~98994994:+
HNSC	cis	rs4144743	1	rs34492688	ENSG00000228782.6	CTD-2026D20.3	-3.53	0.000449	0.0474	-0.18	-0.16	Body mass index;	chr17:47244256	chr17:47450568~47492492:-
HNSC	cis	rs4144743	0.938	rs35439279	ENSG00000228782.6	CTD-2026D20.3	-3.53	0.000449	0.0474	-0.18	-0.16	Body mass index;	chr17:47244328	chr17:47450568~47492492:-
HNSC	cis	rs11225055	0.588	rs4754822	ENSG00000254506.1	RP11-748H22.1	3.53	0.000449	0.0474	0.37	0.16	Response to methotrexate in juvenile idiopathic arthritis;	chr11:101960232	chr11:101584295~101595156:+
HNSC	cis	rs6973609	0.671	rs889935	ENSG00000271122.1	RP11-379H18.1	3.53	0.000449	0.0474	0.15	0.16	Obesity-related traits;	chr7:35569538	chr7:35695214~35699413:+
HNSC	cis	rs5758659	0.652	rs133349	ENSG00000273366.1	CTA-989H11.1	-3.53	0.000449	0.0474	-0.19	-0.16	Cognitive function;	chr22:42032723	chr22:42278188~42278846:+
HNSC	cis	rs7405404	0.672	rs6498447	ENSG00000262454.1	RP11-65J21.3	-3.53	0.000449	0.0474	-0.14	-0.16	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13642837	chr16:14302288~14326353:+
HNSC	cis	rs7405404	0.672	rs4781519	ENSG00000262454.1	RP11-65J21.3	-3.53	0.000449	0.0474	-0.14	-0.16	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13644176	chr16:14302288~14326353:+
HNSC	cis	rs7615952	0.611	rs7632305	ENSG00000241439.1	RP11-666A20.3	3.53	0.000449	0.0474	0.24	0.16	Blood pressure (smoking interaction);	chr3:125915924	chr3:125958556~125958817:+
HNSC	cis	rs9611565	0.513	rs739135	ENSG00000235513.1	RP4-756G23.5	-3.53	0.000449	0.0474	-0.2	-0.16	Vitiligo;	chr22:41694065	chr22:41209122~41217627:-
HNSC	cis	rs4822044	0.68	rs8138780	ENSG00000235513.1	RP4-756G23.5	-3.53	0.000449	0.0474	-0.2	-0.16	Cannabis dependence symptom count;	chr22:41701458	chr22:41209122~41217627:-
HNSC	cis	rs2834288	0.734	rs1557269	ENSG00000273102.1	AP000569.9	-3.53	0.000449	0.0474	-0.19	-0.16	Gut microbiota (bacterial taxa);	chr21:33894091	chr21:33967101~33968573:-
HNSC	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-3.53	0.000449	0.0474	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
HNSC	cis	rs875971	0.66	rs10263935	ENSG00000273142.1	RP11-458F8.4	-3.53	0.000449	0.0474	-0.14	-0.16	Aortic root size;	chr7:66631041	chr7:66902857~66906297:+
HNSC	cis	rs683257	0.81	rs9484446	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000449	0.0474	-0.29	-0.16	Facial emotion recognition (angry faces);	chr6:140861432	chr6:140845958~140852924:-
HNSC	cis	rs683257	0.659	rs9495848	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000449	0.0474	-0.29	-0.16	Facial emotion recognition (angry faces);	chr6:140863462	chr6:140845958~140852924:-
HNSC	cis	rs9400467	0.528	rs455247	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111297126~111298510:+
HNSC	cis	rs7760535	0.811	rs464401	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Metabolic traits;	chr6:111347804	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.509	rs463854	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.509	rs463853	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs455335	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs465795	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs110732	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000449	0.0474	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111297126~111298510:+
HNSC	cis	rs1005277	0.522	rs9417256	ENSG00000263064.2	RP11-291L22.7	3.53	0.000449	0.0474	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38448689~38448949:+
HNSC	cis	rs12817549	0.781	rs10859561	ENSG00000213250.5	RBMS2P1	3.53	0.000449	0.0474	0.14	0.16	Hip circumference adjusted for BMI;	chr12:93713936	chr12:94423744~94424969:-
HNSC	cis	rs394563	0.517	rs385303	ENSG00000217733.2	CCT7P1	3.53	0.000449	0.0474	0.18	0.16	Dupuytren's disease;	chr6:149457928	chr6:149879962~149881572:+
HNSC	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	3.53	0.000449	0.0475	0.18	0.16	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
HNSC	cis	rs7927592	0.913	rs10047412	ENSG00000239559.2	RPL37P2	3.53	0.000449	0.0475	0.17	0.16	Total body bone mineral density;	chr11:68465444	chr11:67682772~67683058:-
HNSC	cis	rs16858210	0.874	rs7618182	ENSG00000234371.6	RPSAP31	3.53	0.000449	0.0475	0.19	0.16	Menopause (age at onset);	chr3:183889215	chr3:183884924~183888449:+
HNSC	cis	rs853679	0.527	rs213228	ENSG00000219392.1	RP1-265C24.5	-3.53	0.000449	0.0475	-0.18	-0.16	Depression;	chr6:28363475	chr6:28115628~28116551:+
HNSC	cis	rs2439831	1	rs101094	ENSG00000275601.1	AC011330.13	-3.53	0.000449	0.0475	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43495124	chr15:43642389~43643023:-
HNSC	cis	rs2439831	1	rs2584725	ENSG00000275601.1	AC011330.13	-3.53	0.000449	0.0475	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43500937	chr15:43642389~43643023:-
HNSC	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	3.53	0.000449	0.0475	0.23	0.16	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
HNSC	cis	rs9400467	0.592	rs462493	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00045	0.0475	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.508	rs456871	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00045	0.0475	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111297126~111298510:+
HNSC	cis	rs7760535	0.811	rs455732	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00045	0.0475	-0.19	-0.16	Metabolic traits;	chr6:111374065	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs458486	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00045	0.0475	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111297126~111298510:+
HNSC	cis	rs9400467	0.528	rs455726	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00045	0.0475	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111297126~111298510:+
HNSC	cis	rs853679	1	rs853694	ENSG00000204709.4	LINC01556	3.53	0.00045	0.0475	0.25	0.16	Depression;	chr6:28311323	chr6:28943877~28944537:+
HNSC	cis	rs332034	0.507	rs13259619	ENSG00000253893.2	FAM85B	-3.53	0.00045	0.0475	-0.26	-0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8832916	chr8:8167819~8226614:-
HNSC	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-3.53	0.00045	0.0475	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
HNSC	cis	rs12234571	1	rs4729710	ENSG00000214293.7	APTR	3.53	0.00045	0.0475	0.23	0.16	Obesity-related traits;	chr7:77764422	chr7:77657660~77696265:-
HNSC	cis	rs2299587	0.607	rs2237848	ENSG00000253671.1	RP11-806O11.1	-3.53	0.00045	0.0475	-0.17	-0.16	Economic and political preferences;	chr8:18017095	chr8:17808941~17820868:+
HNSC	cis	rs7221109	0.711	rs9889953	ENSG00000278834.1	RP11-458J1.1	3.53	0.00045	0.0475	0.15	0.16	Type 1 diabetes;	chr17:40598548	chr17:40648300~40649718:+
HNSC	cis	rs3747869	1	rs3747869	ENSG00000279406.1	RP11-327E2.5	3.53	0.00045	0.0475	0.26	0.16	Myeloid white cell count;White blood cell count;	chr10:71760875	chr10:71364243~71366374:+
HNSC	cis	rs73198271	0.53	rs113160067	ENSG00000253893.2	FAM85B	3.53	0.00045	0.0475	0.24	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797011	chr8:8167819~8226614:-
HNSC	cis	rs6545883	0.929	rs12612982	ENSG00000271889.1	RP11-493E12.1	3.53	0.00045	0.0475	0.18	0.16	Tuberculosis;	chr2:61520220	chr2:61151433~61162105:-
HNSC	cis	rs116095464	0.619	rs2303741	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:218241	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs56043030	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:220802	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs10067021	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:221375	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs9312977	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:221801	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6881920	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:222296	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6878061	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:222957	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs6882584	ENSG00000277812.1	AC021087.1	3.53	0.00045	0.0475	0.27	0.16	Breast cancer;	chr5:223296	chr5:262769~262881:+
HNSC	cis	rs2762353	0.935	rs2328895	ENSG00000272462.2	U91328.19	-3.53	0.00045	0.0475	-0.16	-0.16	Blood metabolite levels;	chr6:25801855	chr6:25992662~26001775:+
HNSC	cis	rs7688540	0.76	rs7687833	ENSG00000250892.1	RP11-1365D11.1	-3.53	0.00045	0.0475	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:201409~205009:-
HNSC	cis	rs7824557	0.564	rs2736295	ENSG00000269918.1	AF131215.9	3.53	0.00045	0.0476	0.16	0.16	Retinal vascular caliber;	chr8:11377271	chr8:11104691~11106704:-
HNSC	cis	rs11853542	0.59	rs2584162	ENSG00000273540.1	RP11-133L19.3	3.53	0.00045	0.0476	0.19	0.16	Colorectal cancer;	chr15:87493543	chr15:86914443~86916155:+
HNSC	cis	rs6832769	0.767	rs11133394	ENSG00000249700.7	SRD5A3-AS1	3.53	0.00045	0.0476	0.19	0.16	Personality dimensions;	chr4:55517071	chr4:55363971~55395847:-
HNSC	cis	rs9611565	0.659	rs9611603	ENSG00000235513.1	RP4-756G23.5	3.53	0.00045	0.0476	0.19	0.16	Vitiligo;	chr22:41516746	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.659	rs12484694	ENSG00000235513.1	RP4-756G23.5	3.53	0.00045	0.0476	0.19	0.16	Vitiligo;	chr22:41523326	chr22:41209122~41217627:-
HNSC	cis	rs651907	0.64	rs771575	ENSG00000244119.1	PDCL3P4	3.53	0.00045	0.0476	0.16	0.16	Colorectal cancer;	chr3:101900515	chr3:101712472~101713191:+
HNSC	cis	rs870825	0.616	rs7682505	ENSG00000254233.1	RP11-242J7.1	3.53	0.00045	0.0476	0.24	0.16	Blood protein levels;	chr4:184719494	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.587	rs7682995	ENSG00000254233.1	RP11-242J7.1	3.53	0.00045	0.0476	0.24	0.16	Blood protein levels;	chr4:184719530	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7682557	ENSG00000254233.1	RP11-242J7.1	3.53	0.00045	0.0476	0.24	0.16	Blood protein levels;	chr4:184719619	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs7660939	ENSG00000254233.1	RP11-242J7.1	3.53	0.00045	0.0476	0.24	0.16	Blood protein levels;	chr4:184719638	chr4:184584093~184625030:-
HNSC	cis	rs7683537	0.725	rs28837443	ENSG00000254233.1	RP11-242J7.1	3.53	0.00045	0.0476	0.24	0.16	Systemic lupus erythematosus;	chr4:184720343	chr4:184584093~184625030:-
HNSC	cis	rs13256369	1	rs9329165	ENSG00000173295.6	FAM86B3P	-3.53	0.00045	0.0476	-0.2	-0.16	Obesity-related traits;	chr8:8719132	chr8:8228595~8244865:+
HNSC	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-3.53	0.00045	0.0476	-0.26	-0.16	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
HNSC	cis	rs11992162	0.591	rs35657308	ENSG00000255495.1	AC145124.2	-3.53	0.00045	0.0476	-0.18	-0.16	Monocyte count;	chr8:11946893	chr8:12194467~12196280:+
HNSC	cis	rs71520386	0.861	rs35841035	ENSG00000228649.7	AC005682.5	-3.53	0.00045	0.0476	-0.22	-0.16	Fibrinogen levels;	chr7:22822987	chr7:22854178~22861579:+
HNSC	cis	rs6568686	0.73	rs4526232	ENSG00000255389.1	C6orf3	-3.53	0.000451	0.0476	-0.2	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111535842	chr6:111599875~111602295:+
HNSC	cis	rs868153	0.625	rs2315817	ENSG00000275339.1	RP3-425C14.6	3.53	0.000451	0.0476	0.17	0.16	Vertical cup-disc ratio;	chr6:122117894	chr6:122454358~122454612:+
HNSC	cis	rs4822044	0.56	rs7284839	ENSG00000235513.1	RP4-756G23.5	-3.53	0.000451	0.0476	-0.2	-0.16	Cannabis dependence symptom count;	chr22:41614898	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.559	rs132768	ENSG00000235513.1	RP4-756G23.5	-3.53	0.000451	0.0476	-0.2	-0.16	Vitiligo;	chr22:41617519	chr22:41209122~41217627:-
HNSC	cis	rs6095298	0.595	rs34280360	ENSG00000222365.1	SNORD12B	-3.53	0.000451	0.0476	-0.18	-0.16	Intelligence (multi-trait analysis);	chr20:48837634	chr20:49280319~49280409:+
HNSC	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	3.53	0.000451	0.0476	0.14	0.16	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
HNSC	cis	rs7781557	0.582	rs2411061	ENSG00000239969.4	RP11-163E9.2	-3.53	0.000451	0.0476	-0.23	-0.16	Colorectal adenoma (advanced);	chr7:102973043	chr7:102364162~102380633:+
HNSC	cis	rs7023329	0.56	rs7853131	ENSG00000244230.3	RN7SL151P	3.53	0.000451	0.0476	0.17	0.16	Melanoma;	chr9:21746977	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs1372058	ENSG00000244230.3	RN7SL151P	3.53	0.000451	0.0476	0.17	0.16	Melanoma;	chr9:21747312	chr9:21699314~21699596:+
HNSC	cis	rs7023329	0.59	rs1372059	ENSG00000244230.3	RN7SL151P	3.53	0.000451	0.0476	0.17	0.16	Melanoma;	chr9:21747421	chr9:21699314~21699596:+
HNSC	cis	rs10927875	0.541	rs1763601	ENSG00000226029.1	RP4-798A10.2	-3.53	0.000451	0.0476	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16013965	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.541	rs1048237	ENSG00000226029.1	RP4-798A10.2	-3.53	0.000451	0.0476	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16015238	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.541	rs1739840	ENSG00000226029.1	RP4-798A10.2	-3.53	0.000451	0.0476	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16015742	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.541	rs761759	ENSG00000226029.1	RP4-798A10.2	-3.53	0.000451	0.0476	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16015855	chr1:16460948~16468481:+
HNSC	cis	rs1048238	0.935	rs761760	ENSG00000226029.1	RP4-798A10.2	-3.53	0.000451	0.0476	-0.15	-0.16	Systolic blood pressure;	chr1:16015924	chr1:16460948~16468481:+
HNSC	cis	rs6071524	0.517	rs6071589	ENSG00000224635.1	RP4-564F22.5	-3.53	0.000451	0.0476	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr20:38815578	chr20:38406011~38416797:-
HNSC	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	3.53	0.000451	0.0476	0.2	0.16	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	3.53	0.000451	0.0476	0.2	0.16	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
HNSC	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	3.53	0.000451	0.0476	0.2	0.16	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
HNSC	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	3.53	0.000451	0.0476	0.32	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
HNSC	cis	rs1005277	0.522	rs7090858	ENSG00000263064.2	RP11-291L22.7	-3.53	0.000451	0.0476	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38448689~38448949:+
HNSC	cis	rs870825	0.616	rs6810635	ENSG00000254233.1	RP11-242J7.1	3.53	0.000451	0.0476	0.24	0.16	Blood protein levels;	chr4:184695705	chr4:184584093~184625030:-
HNSC	cis	rs10992797	0.504	rs2994369	ENSG00000227603.1	RP11-165J3.6	-3.53	0.000451	0.0476	-0.14	-0.16	Intelligence (multi-trait analysis);	chr9:93604231	chr9:93435332~93437121:-
HNSC	cis	rs987724	0.515	rs9870137	ENSG00000243926.1	TIPARP-AS1	3.53	0.000451	0.0476	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:156671862~156674378:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	3.53	0.000451	0.0476	0.18	0.16	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
HNSC	cis	rs8030379	1	rs2401172	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2401174	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259929	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259930	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs1480827	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2401176	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2401179	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2401180	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259932	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259934	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs11259935	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000451	0.0476	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84507885~84516814:-
HNSC	cis	rs853679	1	rs853694	ENSG00000270326.1	RP5-874C20.6	-3.53	0.000452	0.0477	-0.24	-0.16	Depression;	chr6:28311323	chr6:28319660~28319852:-
HNSC	cis	rs4493873	0.869	rs7815938	ENSG00000253738.1	OTUD6B-AS1	3.53	0.000452	0.0477	0.17	0.16	Migraine - clinic-based;	chr8:91097445	chr8:91059909~91070189:-
HNSC	cis	rs8062405	0.755	rs62034325	ENSG00000260367.2	RP11-264B17.4	-3.53	0.000452	0.0477	-0.15	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28973962~28978824:-
HNSC	cis	rs7107174	1	rs2511175	ENSG00000251323.2	RP11-452H21.4	3.53	0.000452	0.0477	0.25	0.16	Testicular germ cell tumor;	chr11:78264035	chr11:78423982~78429836:-
HNSC	cis	rs4834770	0.668	rs6833072	ENSG00000245958.5	RP11-33B1.1	3.53	0.000452	0.0477	0.14	0.16	Blood protein levels;	chr4:119212737	chr4:119454791~119552025:+
HNSC	cis	rs6430585	0.528	rs12476127	ENSG00000231890.6	DARS-AS1	-3.53	0.000452	0.0477	-0.28	-0.16	Corneal structure;	chr2:136005672	chr2:135985176~136022593:+
HNSC	cis	rs4843747	0.749	rs12102841	ENSG00000260750.4	RP11-482M8.1	-3.53	0.000452	0.0477	-0.21	-0.16	Menopause (age at onset);	chr16:88038968	chr16:87492555~87515635:+
HNSC	cis	rs9402743	0.962	rs11967412	ENSG00000234084.1	RP3-388E23.2	-3.53	0.000452	0.0477	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135648288	chr6:135301568~135307158:+
HNSC	cis	rs868153	0.591	rs6916464	ENSG00000275339.1	RP3-425C14.6	3.53	0.000452	0.0477	0.17	0.16	Vertical cup-disc ratio;	chr6:122145080	chr6:122454358~122454612:+
HNSC	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	3.53	0.000452	0.0477	0.18	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
HNSC	cis	rs597480	0.765	rs2008890	ENSG00000279742.1	RP11-700A24.1	3.53	0.000452	0.0477	0.17	0.16	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85802427	chr11:85852557~85854943:-
HNSC	cis	rs7746199	0.736	rs13202295	ENSG00000241549.7	GUSBP2	3.53	0.000452	0.0477	0.28	0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:26871484~26956554:-
HNSC	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-3.53	0.000452	0.0477	-0.25	-0.16	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
HNSC	cis	rs61160187	0.582	rs1479645	ENSG00000152931.7	PART1	-3.53	0.000452	0.0477	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60487713~60547657:+
HNSC	cis	rs12545912	0.909	rs10088037	ENSG00000254340.1	RP11-10A14.3	3.53	0.000452	0.0477	0.22	0.16	Multiple myeloma (hyperdiploidy);	chr8:9610689	chr8:9141424~9145435:+
HNSC	cis	rs12545912	0.909	rs10088039	ENSG00000254340.1	RP11-10A14.3	3.53	0.000452	0.0477	0.22	0.16	Multiple myeloma (hyperdiploidy);	chr8:9610694	chr8:9141424~9145435:+
HNSC	cis	rs35740288	0.857	rs11632034	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000452	0.0477	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85744109~85750281:-
HNSC	cis	rs6968419	0.755	rs10500059	ENSG00000237870.5	AC073130.1	3.53	0.000452	0.0477	0.2	0.16	Intraocular pressure;	chr7:116260340	chr7:116275606~116286734:-
HNSC	cis	rs6968419	0.692	rs10500060	ENSG00000237870.5	AC073130.1	3.53	0.000452	0.0477	0.2	0.16	Intraocular pressure;	chr7:116260632	chr7:116275606~116286734:-
HNSC	cis	rs710865	0.627	rs10799710	ENSG00000270728.1	RP4-657E11.10	-3.53	0.000452	0.0477	-0.14	-0.16	Brain structure;	chr1:19156715	chr1:19297080~19297903:+
HNSC	cis	rs2013441	1	rs4924809	ENSG00000261033.1	RP11-209D14.2	-3.53	0.000452	0.0477	-0.18	-0.16	Obesity-related traits;	chr17:20141360	chr17:20008051~20009234:-
HNSC	cis	rs12908161	0.96	rs17599989	ENSG00000229212.6	RP11-561C5.4	-3.53	0.000452	0.0477	-0.23	-0.16	Schizophrenia;	chr15:84742305	chr15:85205440~85234795:-
HNSC	cis	rs8031584	0.918	rs3817498	ENSG00000260382.1	RP11-540B6.2	3.53	0.000452	0.0477	0.2	0.16	Huntington's disease progression;	chr15:30976578	chr15:30882267~30883231:-
HNSC	cis	rs61160187	0.51	rs10072745	ENSG00000215032.2	GNL3LP1	3.53	0.000452	0.0477	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60891935~60893577:-
HNSC	cis	rs61160187	0.527	rs6449500	ENSG00000215032.2	GNL3LP1	3.53	0.000452	0.0477	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60891935~60893577:-
HNSC	cis	rs34792	0.637	rs34793	ENSG00000260872.1	RP11-680G24.5	3.53	0.000452	0.0477	0.15	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:15018106~15020488:-
HNSC	cis	rs1979679	0.842	rs2127315	ENSG00000247934.4	RP11-967K21.1	-3.53	0.000452	0.0477	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28163298~28190738:-
HNSC	cis	rs793571	0.554	rs12441912	ENSG00000245975.2	RP11-30K9.6	3.53	0.000452	0.0477	0.3	0.16	Schizophrenia;	chr15:58701495	chr15:58768072~58770974:-
HNSC	cis	rs793571	0.554	rs12908261	ENSG00000245975.2	RP11-30K9.6	3.53	0.000452	0.0477	0.3	0.16	Schizophrenia;	chr15:58701582	chr15:58768072~58770974:-
HNSC	cis	rs793571	0.554	rs17301954	ENSG00000245975.2	RP11-30K9.6	3.53	0.000452	0.0477	0.3	0.16	Schizophrenia;	chr15:58708232	chr15:58768072~58770974:-
HNSC	cis	rs2117029	0.586	rs6580701	ENSG00000258101.2	RP11-977B10.2	3.53	0.000453	0.0477	0.2	0.16	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49232790~49264756:-
HNSC	cis	rs2505998	0.833	rs1864405	ENSG00000273008.1	RP11-351D16.3	-3.53	0.000453	0.0477	-0.2	-0.16	Hirschsprung disease;	chr10:43108700	chr10:43136824~43138334:-
HNSC	cis	rs2505998	0.833	rs1864404	ENSG00000273008.1	RP11-351D16.3	-3.53	0.000453	0.0477	-0.2	-0.16	Hirschsprung disease;	chr10:43108942	chr10:43136824~43138334:-
HNSC	cis	rs72843506	0.722	rs74255392	ENSG00000189423.10	USP32P3	3.53	0.000453	0.0477	0.25	0.16	Schizophrenia;	chr17:20425739	chr17:20415547~20431008:+
HNSC	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	3.53	0.000453	0.0477	0.32	0.16	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
HNSC	cis	rs4704187	0.663	rs28448485	ENSG00000272040.1	CTC-366B18.4	-3.53	0.000453	0.0477	-0.15	-0.16	Response to amphetamines;	chr5:75129950	chr5:75608817~75609983:+
HNSC	cis	rs2836974	1	rs2836974	ENSG00000255568.3	BRWD1-AS2	-3.53	0.000453	0.0478	-0.14	-0.16	Cognitive function;	chr21:39291255	chr21:39313935~39314962:+
HNSC	cis	rs6928977	0.66	rs2757643	ENSG00000231028.7	LINC00271	-3.53	0.000453	0.0478	-0.18	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135497801~135716055:+
HNSC	cis	rs9910055	0.529	rs400460	ENSG00000267080.4	ASB16-AS1	3.53	0.000453	0.0478	0.13	0.16	Total body bone mineral density;	chr17:44105402	chr17:44175973~44186717:-
HNSC	cis	rs4845570	0.85	rs4504897	ENSG00000203288.3	RP11-98D18.9	3.53	0.000453	0.0478	0.24	0.16	Coronary artery disease;	chr1:151794375	chr1:151790804~151794402:+
HNSC	cis	rs865483	0.929	rs9906140	ENSG00000276054.1	RP11-378E13.3	-3.53	0.000453	0.0478	-0.19	-0.16	Monocyte count;	chr17:37497045	chr17:37386886~37387926:+
HNSC	cis	rs12537284	0.542	rs17340646	ENSG00000275106.1	RP11-309L24.10	-3.53	0.000453	0.0478	-0.26	-0.16	Systemic lupus erythematosus;	chr7:129082460	chr7:128952527~128953316:-
HNSC	cis	rs11711311	1	rs7622515	ENSG00000241529.3	RN7SL767P	-3.53	0.000453	0.0478	-0.2	-0.16	IgG glycosylation;	chr3:113753691	chr3:113632704~113632998:+
HNSC	cis	rs17095355	1	rs17126883	ENSG00000203876.8	ADD3-AS1	-3.53	0.000453	0.0478	-0.21	-0.16	Biliary atresia;	chr10:109934938	chr10:109940104~110008381:-
HNSC	cis	rs10075741	1	rs67448050	ENSG00000234292.3	RP11-213H15.1	3.53	0.000453	0.0478	0.24	0.16	TRAIL levels;	chr5:92083613	chr5:91280097~91281142:-
HNSC	cis	rs8031584	0.918	rs61997139	ENSG00000270015.1	RP11-540B6.6	-3.53	0.000453	0.0478	-0.16	-0.16	Huntington's disease progression;	chr15:30981399	chr15:30926514~30928407:+
HNSC	cis	rs3105593	0.933	rs3105598	ENSG00000244879.4	GABPB1-AS1	3.53	0.000453	0.0478	0.14	0.16	QT interval;	chr15:50533069	chr15:50354959~50372202:+
HNSC	cis	rs9329221	0.935	rs6601450	ENSG00000269918.1	AF131215.9	3.53	0.000453	0.0478	0.16	0.16	Neuroticism;	chr8:10385591	chr8:11104691~11106704:-
HNSC	cis	rs860295	0.58	rs2016251	ENSG00000225855.5	RUSC1-AS1	3.53	0.000454	0.0478	0.11	0.16	Body mass index;	chr1:155945197	chr1:155316863~155324176:-
HNSC	cis	rs8181477	1	rs8181477	ENSG00000240291.1	RP11-499P20.2	3.53	0.000454	0.0478	0.13	0.16	Obesity-related traits;	chr10:18493951	chr10:18513115~18545651:-
HNSC	cis	rs67311347	0.956	rs9817233	ENSG00000280739.1	EIF1B-AS1	3.53	0.000454	0.0478	0.19	0.16	Renal cell carcinoma;	chr3:40384127	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs9817142	ENSG00000280739.1	EIF1B-AS1	3.53	0.000454	0.0478	0.19	0.16	Renal cell carcinoma;	chr3:40384283	chr3:40173145~40309698:-
HNSC	cis	rs7267979	0.816	rs422148	ENSG00000231081.1	RP4-760C5.3	-3.53	0.000454	0.0478	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26008791~26010531:-
HNSC	cis	rs853679	0.546	rs71537572	ENSG00000219891.2	ZSCAN12P1	3.53	0.000454	0.0478	0.34	0.16	Depression;	chr6:28002937	chr6:28091154~28093664:+
HNSC	cis	rs9400467	0.528	rs459403	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000454	0.0478	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111297126~111298510:+
HNSC	cis	rs5757676	0.858	rs6001585	ENSG00000261202.1	RP3-496C20.1	-3.53	0.000454	0.0478	-0.23	-0.16	IgG glycosylation;	chr22:39416981	chr22:40043068~40044530:-
HNSC	cis	rs2131877	0.83	rs62290330	ENSG00000230266.1	XXYLT1-AS2	-3.53	0.000454	0.0478	-0.24	-0.16	Non-small cell lung cancer;	chr3:195123026	chr3:195147871~195152790:+
HNSC	cis	rs11809443	0.569	rs11800309	ENSG00000269934.1	RP5-1139B12.3	3.53	0.000454	0.0478	0.18	0.16	Coronary artery disease;	chr1:228204107	chr1:228274584~228276066:-
HNSC	cis	rs7927592	0.956	rs7104877	ENSG00000255031.4	RP11-802E16.3	-3.53	0.000454	0.0478	-0.14	-0.16	Total body bone mineral density;	chr11:68610134	chr11:68050740~68053762:+
HNSC	cis	rs4489787	1	rs2468942	ENSG00000257763.1	OR5BK1P	-3.53	0.000454	0.0478	-0.25	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48446708	chr12:48355792~48356614:-
HNSC	cis	rs2548724	0.812	rs452857	ENSG00000175749.11	EIF3KP1	3.53	0.000454	0.0478	0.22	0.16	Type 2 diabetes;	chr5:102260929	chr5:103032376~103033031:+
HNSC	cis	rs17495987	0.626	rs17494629	ENSG00000227719.1	AC006042.6	3.53	0.000454	0.0479	0.19	0.16	Tonsillectomy;	chr7:7831900	chr7:8114025~8116561:+
HNSC	cis	rs2024125	0.736	rs4612244	ENSG00000228903.5	RASA4CP	3.53	0.000454	0.0479	0.16	0.16	Obesity-related traits;	chr7:43119026	chr7:44026951~44041892:-
HNSC	cis	rs762679	1	rs762679	ENSG00000253330.1	RP11-697N18.3	-3.53	0.000454	0.0479	-0.3	-0.16	Red blood cell count;Mean corpuscular volume;	chr8:47972876	chr8:47511034~47512141:-
HNSC	cis	rs4449834	0.816	rs4738820	ENSG00000254432.1	RP11-33I11.2	-3.53	0.000454	0.0479	-0.2	-0.16	Sum eosinophil basophil counts;	chr8:60758416	chr8:60808735~60809606:-
HNSC	cis	rs823156	0.598	rs823072	ENSG00000206762.1	RNU6-418P	-3.53	0.000454	0.0479	-0.18	-0.16	Parkinson's disease;	chr1:205804524	chr1:205595041~205595147:+
HNSC	cis	rs8180991	0.744	rs12679184	ENSG00000254431.1	RP11-550A5.2	-3.53	0.000454	0.0479	-0.24	-0.16	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr8:125475269	chr8:125348196~125351416:-
HNSC	cis	rs801193	1	rs17566701	ENSG00000273142.1	RP11-458F8.4	-3.53	0.000454	0.0479	-0.14	-0.16	Aortic root size;	chr7:66728196	chr7:66902857~66906297:+
HNSC	cis	rs67478160	0.644	rs7159810	ENSG00000259515.1	RP11-365N19.2	3.53	0.000454	0.0479	0.14	0.16	Schizophrenia;	chr14:103827780	chr14:102933574~102937177:+
HNSC	cis	rs656319	0.702	rs477860	ENSG00000233609.3	RP11-62H7.2	-3.53	0.000454	0.0479	-0.17	-0.16	Myopia (pathological);	chr8:9954255	chr8:8961200~8979025:+
HNSC	cis	rs7651778	0.588	rs7638936	ENSG00000243926.1	TIPARP-AS1	-3.53	0.000454	0.0479	-0.14	-0.16	Corneal astigmatism;	chr3:156621843	chr3:156671862~156674378:-
HNSC	cis	rs28573326	0.785	rs78409537	ENSG00000121089.4	NACA3P	-3.53	0.000454	0.0479	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165430463	chr4:164943290~164943937:+
HNSC	cis	rs28573326	0.752	rs80030753	ENSG00000121089.4	NACA3P	-3.53	0.000454	0.0479	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr4:165430464	chr4:164943290~164943937:+
HNSC	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-3.53	0.000454	0.0479	-0.28	-0.16	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
HNSC	cis	rs11295209	1	rs11295209	ENSG00000249244.1	RP11-548H18.2	-3.53	0.000454	0.0479	-0.18	-0.16	Plateletcrit;	chr4:119559079	chr4:119391831~119395335:-
HNSC	cis	rs6430585	0.583	rs1435577	ENSG00000231890.6	DARS-AS1	-3.53	0.000454	0.0479	-0.28	-0.16	Corneal structure;	chr2:135867377	chr2:135985176~136022593:+
HNSC	cis	rs6545883	0.965	rs2305156	ENSG00000271889.1	RP11-493E12.1	3.53	0.000455	0.0479	0.18	0.16	Tuberculosis;	chr2:61502133	chr2:61151433~61162105:-
HNSC	cis	rs2243480	1	rs313813	ENSG00000226002.1	RP11-460N20.5	-3.53	0.000455	0.0479	-0.28	-0.16	Diabetic kidney disease;	chr7:66038513	chr7:65084103~65100232:+
HNSC	cis	rs3617	0.573	rs6795646	ENSG00000222345.1	SNORD19	-3.53	0.000455	0.0479	-0.14	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52888605	chr3:52691378~52691453:+
HNSC	cis	rs755249	0.501	rs2484749	ENSG00000228060.1	RP11-69E11.8	3.53	0.000455	0.0479	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39565160~39573203:+
HNSC	cis	rs66887589	0.967	rs13104219	ENSG00000249244.1	RP11-548H18.2	3.53	0.000455	0.0479	0.18	0.16	Diastolic blood pressure;	chr4:119517019	chr4:119391831~119395335:-
HNSC	cis	rs12817549	0.817	rs9308296	ENSG00000213250.5	RBMS2P1	3.53	0.000455	0.0479	0.15	0.16	Hip circumference adjusted for BMI;	chr12:93708678	chr12:94423744~94424969:-
HNSC	cis	rs219780	0.784	rs219779	ENSG00000233818.1	AP000695.4	3.53	0.000455	0.0479	0.19	0.16	Kidney stones;	chr21:36461453	chr21:36445731~36532408:+
HNSC	cis	rs4388249	0.948	rs34364676	ENSG00000271849.1	CTC-332L22.1	-3.53	0.000455	0.0479	-0.26	-0.16	Schizophrenia;	chr5:109760822	chr5:109687802~109688329:-
HNSC	cis	rs4388249	1	rs34961375	ENSG00000271849.1	CTC-332L22.1	-3.53	0.000455	0.0479	-0.26	-0.16	Schizophrenia;	chr5:109761009	chr5:109687802~109688329:-
HNSC	cis	rs4845570	0.92	rs1521185	ENSG00000203288.3	RP11-98D18.9	3.53	0.000455	0.0479	0.24	0.16	Coronary artery disease;	chr1:151791573	chr1:151790804~151794402:+
HNSC	cis	rs12545912	0.821	rs4841183	ENSG00000254340.1	RP11-10A14.3	3.53	0.000455	0.0479	0.22	0.16	Multiple myeloma (hyperdiploidy);	chr8:9613352	chr8:9141424~9145435:+
HNSC	cis	rs10938353	0.515	rs10009336	ENSG00000273369.1	RP11-700J17.1	-3.53	0.000455	0.0479	-0.19	-0.16	Body mass index;	chr4:44478766	chr4:44693946~44694386:-
HNSC	cis	rs982100	0.722	rs918862	ENSG00000226856.4	AC093901.1	3.53	0.000455	0.0479	0.23	0.16	Alzheimer disease and age of onset;	chr2:117694501	chr2:118132128~118186386:-
HNSC	cis	rs62344088	1	rs6872393	ENSG00000250848.1	CTD-2083E4.5	3.53	0.000455	0.0479	0.35	0.16	Asthma (childhood onset);	chr5:155739	chr5:288833~290321:-
HNSC	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	3.53	0.000455	0.0479	0.32	0.16	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	3.53	0.000455	0.0479	0.32	0.16	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	3.53	0.000455	0.0479	0.32	0.16	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	3.53	0.000455	0.0479	0.32	0.16	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	3.53	0.000455	0.0479	0.32	0.16	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
HNSC	cis	rs7023329	0.59	rs1414236	ENSG00000244230.3	RN7SL151P	3.53	0.000455	0.0479	0.16	0.16	Melanoma;	chr9:21732545	chr9:21699314~21699596:+
HNSC	cis	rs4805834	0.843	rs2287880	ENSG00000201388.1	SNORA68	3.53	0.000455	0.0479	0.25	0.16	Creatinine levels;	chr19:32858389	chr19:32608337~32608469:-
HNSC	cis	rs67311347	1	rs7617989	ENSG00000280739.1	EIF1B-AS1	-3.53	0.000455	0.0479	-0.18	-0.16	Renal cell carcinoma;	chr3:40470972	chr3:40173145~40309698:-
HNSC	cis	rs9768139	0.683	rs4909178	ENSG00000223872.1	AC006372.5	-3.53	0.000455	0.0479	-0.17	-0.16	Calcium levels;	chr7:158325060	chr7:157501322~157503577:+
HNSC	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	3.53	0.000455	0.0479	0.18	0.16	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
HNSC	cis	rs473651	0.935	rs477041	ENSG00000229915.1	AC016999.2	3.53	0.000455	0.0479	0.19	0.16	Multiple system atrophy;	chr2:238447354	chr2:238427077~238427729:-
HNSC	cis	rs875971	1	rs6979382	ENSG00000272831.1	RP11-792A8.4	3.53	0.000455	0.0479	0.14	0.16	Aortic root size;	chr7:66421388	chr7:66739829~66740385:-
HNSC	cis	rs875971	1	rs6961990	ENSG00000272831.1	RP11-792A8.4	3.53	0.000455	0.0479	0.14	0.16	Aortic root size;	chr7:66423583	chr7:66739829~66740385:-
HNSC	cis	rs11711311	1	rs10212375	ENSG00000241529.3	RN7SL767P	-3.53	0.000455	0.0479	-0.2	-0.16	IgG glycosylation;	chr3:113752489	chr3:113632704~113632998:+
HNSC	cis	rs11711311	1	rs13070720	ENSG00000241529.3	RN7SL767P	-3.53	0.000455	0.0479	-0.2	-0.16	IgG glycosylation;	chr3:113754907	chr3:113632704~113632998:+
HNSC	cis	rs1015213	1	rs1015213	ENSG00000253844.1	RP11-546K22.1	3.53	0.000455	0.048	0.3	0.16	Glaucoma (primary angle closure);	chr8:51974981	chr8:51961458~52022974:+
HNSC	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-3.53	0.000455	0.048	-0.18	-0.16	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
HNSC	cis	rs1908814	0.516	rs13252853	ENSG00000255310.2	AF131215.2	3.53	0.000455	0.048	0.15	0.16	Neuroticism;	chr8:11935465	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs13252854	ENSG00000255310.2	AF131215.2	3.53	0.000455	0.048	0.15	0.16	Neuroticism;	chr8:11935469	chr8:11107788~11109726:-
HNSC	cis	rs17772222	0.917	rs61984684	ENSG00000258789.1	RP11-507K2.3	-3.53	0.000456	0.048	-0.2	-0.16	Coronary artery calcification;	chr14:88559104	chr14:88551597~88552493:+
HNSC	cis	rs614226	1	rs1167725	ENSG00000202538.1	RNU4-2	-3.53	0.000456	0.048	-0.27	-0.16	Type 1 diabetes nephropathy;	chr12:120530756	chr12:120291763~120291903:-
HNSC	cis	rs1867631	1	rs7546090	ENSG00000248458.2	RP4-598P13.1	3.53	0.000456	0.048	0.16	0.16	Menopause (age at onset);	chr1:66618298	chr1:66665864~66677027:-
HNSC	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	3.53	0.000456	0.048	0.18	0.16	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
HNSC	cis	rs116095464	0.558	rs7713524	ENSG00000277812.1	AC021087.1	-3.53	0.000456	0.048	-0.27	-0.16	Breast cancer;	chr5:276085	chr5:262769~262881:+
HNSC	cis	rs1991651	0.507	rs17778581	ENSG00000255310.2	AF131215.2	-3.53	0.000456	0.048	-0.15	-0.16	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:11107788~11109726:-
HNSC	cis	rs6981523	0.553	rs11783045	ENSG00000255310.2	AF131215.2	-3.53	0.000456	0.048	-0.16	-0.16	Neuroticism;	chr8:11198666	chr8:11107788~11109726:-
HNSC	cis	rs365302	0.716	rs452441	ENSG00000235086.1	FNDC1-IT1	3.53	0.000456	0.048	0.19	0.16	Coronary heart disease;	chr6:159189590	chr6:159240786~159243329:+
HNSC	cis	rs853679	0.607	rs34243448	ENSG00000226314.6	ZNF192P1	-3.53	0.000456	0.048	-0.31	-0.16	Depression;	chr6:28225324	chr6:28161781~28169594:+
HNSC	cis	rs67311347	1	rs9842564	ENSG00000280739.1	EIF1B-AS1	-3.53	0.000456	0.048	-0.16	-0.16	Renal cell carcinoma;	chr3:40364319	chr3:40173145~40309698:-
HNSC	cis	rs12188164	0.965	rs1056465	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:442323	chr5:987180~997308:-
HNSC	cis	rs12188164	0.931	rs115554641	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:443121	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs11739543	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:443561	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs72717430	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:444387	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs72717435	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:448087	chr5:987180~997308:-
HNSC	cis	rs12188164	0.93	rs72717436	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:448176	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs72717438	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:448548	chr5:987180~997308:-
HNSC	cis	rs12188164	0.93	rs72717440	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:449586	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs11743639	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:450595	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs11745789	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:450662	chr5:987180~997308:-
HNSC	cis	rs12188164	0.965	rs11744539	ENSG00000215246.5	RP11-43F13.3	-3.53	0.000456	0.048	-0.18	-0.16	Cystic fibrosis severity;	chr5:451310	chr5:987180~997308:-
HNSC	cis	rs913655	0.819	rs2493618	ENSG00000225527.1	RP11-383B4.4	-3.53	0.000456	0.048	-0.21	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18778360	chr10:18531849~18533336:-
HNSC	cis	rs10875746	0.951	rs10875747	ENSG00000257763.1	OR5BK1P	-3.53	0.000456	0.048	-0.2	-0.16	Longevity (90 years and older);	chr12:48132078	chr12:48355792~48356614:-
HNSC	cis	rs10875746	0.951	rs10875748	ENSG00000257763.1	OR5BK1P	-3.53	0.000456	0.048	-0.2	-0.16	Longevity (90 years and older);	chr12:48132577	chr12:48355792~48356614:-
HNSC	cis	rs10507380	0.891	rs79061620	ENSG00000260704.1	LINC00543	3.53	0.000456	0.048	0.31	0.16	Electrocardiographic traits;	chr13:27307377	chr13:27953526~27955370:+
HNSC	cis	rs10507380	0.943	rs117220255	ENSG00000260704.1	LINC00543	3.53	0.000456	0.048	0.31	0.16	Electrocardiographic traits;	chr13:27307396	chr13:27953526~27955370:+
HNSC	cis	rs4538475	1	rs4538475	ENSG00000214846.4	RP11-115L11.1	3.53	0.000456	0.048	0.26	0.16	Parkinson's disease;	chr4:15736314	chr4:15730962~15731627:-
HNSC	cis	rs61990749	0.597	rs759808	ENSG00000239272.1	RPL21P10	3.53	0.000456	0.048	0.24	0.16	Fibroblast growth factor basic levels;	chr14:77784502	chr14:77683202~77683989:-
HNSC	cis	rs2898290	0.506	rs2736311	ENSG00000269918.1	AF131215.9	-3.53	0.000456	0.048	-0.15	-0.16	Systolic blood pressure;	chr8:11394661	chr8:11104691~11106704:-
HNSC	cis	rs2115630	1	rs8037423	ENSG00000259295.5	CSPG4P12	-3.53	0.000456	0.048	-0.18	-0.16	P wave terminal force;	chr15:84812263	chr15:85191438~85213905:+
HNSC	cis	rs17772222	0.958	rs60213984	ENSG00000258789.1	RP11-507K2.3	-3.53	0.000456	0.048	-0.2	-0.16	Coronary artery calcification;	chr14:88401473	chr14:88551597~88552493:+
HNSC	cis	rs12435908	1	rs17826448	ENSG00000276116.2	FUT8-AS1	3.53	0.000456	0.048	0.22	0.16	Ischemic stroke;	chr14:65385299	chr14:65411170~65412690:-
HNSC	cis	rs1862618	0.671	rs173763	ENSG00000265665.1	AC008391.1	3.53	0.000456	0.048	0.21	0.16	Initial pursuit acceleration;	chr5:56929591	chr5:56457038~56457138:-
HNSC	cis	rs1862618	0.62	rs189695	ENSG00000265665.1	AC008391.1	3.53	0.000456	0.048	0.21	0.16	Initial pursuit acceleration;	chr5:56929942	chr5:56457038~56457138:-
HNSC	cis	rs1862618	0.613	rs252889	ENSG00000265665.1	AC008391.1	3.53	0.000456	0.048	0.21	0.16	Initial pursuit acceleration;	chr5:56931242	chr5:56457038~56457138:-
HNSC	cis	rs2337406	0.587	rs11624678	ENSG00000280411.1	IGHV1-69-2	3.53	0.000456	0.048	0.15	0.16	Alzheimer's disease (late onset);	chr14:106650408	chr14:106762092~106762588:-
HNSC	cis	rs13434995	0.589	rs861029	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.000456	0.048	-0.22	-0.16	Adiponectin levels;	chr4:55379470	chr4:55363971~55395847:-
HNSC	cis	rs45509595	0.841	rs200485	ENSG00000219392.1	RP1-265C24.5	-3.53	0.000456	0.048	-0.27	-0.16	Breast cancer;	chr6:27807919	chr6:28115628~28116551:+
HNSC	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	3.53	0.000456	0.048	0.19	0.16	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
HNSC	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-3.53	0.000456	0.048	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
HNSC	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-3.53	0.000456	0.048	-0.16	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
HNSC	cis	rs73198271	0.96	rs11778970	ENSG00000254340.1	RP11-10A14.3	-3.53	0.000456	0.048	-0.24	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:9141424~9145435:+
HNSC	cis	rs7937890	0.684	rs12799007	ENSG00000254418.1	RP11-21L19.1	3.53	0.000456	0.048	0.19	0.16	Mitochondrial DNA levels;	chr11:14404938	chr11:14262846~14273691:-
HNSC	cis	rs1440410	0.835	rs4513514	ENSG00000250326.1	RP11-284M14.1	-3.53	0.000456	0.048	-0.18	-0.16	Ischemic stroke;	chr4:143218559	chr4:142933195~143184861:-
HNSC	cis	rs6558174	0.965	rs6558172	ENSG00000253837.1	RP11-177H13.2	-3.53	0.000456	0.048	-0.17	-0.16	Breast cancer;	chr8:22634539	chr8:23336171~23366125:+
HNSC	cis	rs6685187	0.797	rs4845713	ENSG00000229021.2	AL591893.1	3.53	0.000456	0.048	0.18	0.16	Blood metabolite levels;	chr1:151922411	chr1:151994531~152042774:+
HNSC	cis	rs7914558	1	rs943038	ENSG00000236937.2	PTGES3P4	3.53	0.000456	0.048	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102845595~102845950:+
HNSC	cis	rs919433	0.963	rs4850786	ENSG00000231621.1	AC013264.2	-3.53	0.000456	0.048	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313884	chr2:197197991~197199273:+
HNSC	cis	rs365302	0.716	rs452651	ENSG00000235086.1	FNDC1-IT1	3.53	0.000456	0.048	0.19	0.16	Coronary heart disease;	chr6:159189914	chr6:159240786~159243329:+
HNSC	cis	rs711830	0.576	rs72916141	ENSG00000226363.3	HAGLROS	3.53	0.000456	0.048	0.24	0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176204636	chr2:176177717~176179008:+
HNSC	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-3.53	0.000456	0.048	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-3.53	0.000456	0.048	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-3.53	0.000456	0.048	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
HNSC	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-3.53	0.000456	0.048	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
HNSC	cis	rs2337406	0.925	rs76288499	ENSG00000211972.2	IGHV3-66	3.53	0.000456	0.048	0.17	0.16	Alzheimer's disease (late onset);	chr14:106686309	chr14:106675017~106675544:-
HNSC	cis	rs853679	0.567	rs9969098	ENSG00000217862.2	HIST1H4PS1	-3.53	0.000457	0.048	-0.18	-0.16	Depression;	chr6:28430971	chr6:27807075~27807339:+
HNSC	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-3.53	0.000457	0.048	-0.25	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
HNSC	cis	rs7581030	0.958	rs6725892	ENSG00000205847.5	OR7E91P	3.53	0.000457	0.0481	0.22	0.16	Testicular germ cell tumor;	chr2:71289061	chr2:71029028~71029893:+
HNSC	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-3.53	0.000457	0.0481	-0.15	-0.16	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
HNSC	cis	rs4281086	0.648	rs7834351	ENSG00000269918.1	AF131215.9	3.53	0.000457	0.0481	0.16	0.16	Obesity-related traits;	chr8:10520895	chr8:11104691~11106704:-
HNSC	cis	rs17122278	1	rs3741323	ENSG00000255422.1	AP002954.4	3.53	0.000457	0.0481	0.28	0.16	Total cholesterol levels;	chr11:118534926	chr11:118704607~118750263:+
HNSC	cis	rs12546962	0.731	rs9650630	ENSG00000233609.3	RP11-62H7.2	-3.53	0.000457	0.0481	-0.17	-0.16	Body mass index;	chr8:9347057	chr8:8961200~8979025:+
HNSC	cis	rs7581030	0.958	rs2058898	ENSG00000205847.5	OR7E91P	3.53	0.000457	0.0481	0.22	0.16	Testicular germ cell tumor;	chr2:71297627	chr2:71029028~71029893:+
HNSC	cis	rs4845570	0.85	rs4504897	ENSG00000249602.1	RP11-98D18.3	3.53	0.000457	0.0481	0.26	0.16	Coronary artery disease;	chr1:151794375	chr1:151763384~151769501:-
HNSC	cis	rs35934224	0.831	rs1044732	ENSG00000281530.1	DGCR12	-3.53	0.000457	0.0481	-0.21	-0.16	Glaucoma (primary open-angle);	chr22:19875619	chr22:19061041~19061843:-
HNSC	cis	rs78366141	0.649	rs7666372	ENSG00000248019.2	FAM13A-AS1	-3.53	0.000457	0.0481	-0.25	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88766380	chr4:88709789~88730103:+
HNSC	cis	rs2865126	0.818	rs7242408	ENSG00000264714.1	RP11-21G15.1	-3.53	0.000457	0.0481	-0.19	-0.16	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10757870	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.818	rs7407105	ENSG00000264714.1	RP11-21G15.1	-3.53	0.000457	0.0481	-0.19	-0.16	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10758025	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.779	rs7228152	ENSG00000264714.1	RP11-21G15.1	-3.53	0.000457	0.0481	-0.19	-0.16	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10758386	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.818	rs4432309	ENSG00000264714.1	RP11-21G15.1	-3.53	0.000457	0.0481	-0.19	-0.16	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10758976	chr18:10724619~10728539:+
HNSC	cis	rs2865126	0.779	rs4516291	ENSG00000264714.1	RP11-21G15.1	-3.53	0.000457	0.0481	-0.19	-0.16	Metabolite levels (5-HIAA/ MHPG Ratio);	chr18:10758990	chr18:10724619~10728539:+
HNSC	cis	rs870825	0.616	rs7658186	ENSG00000254233.1	RP11-242J7.1	3.53	0.000457	0.0481	0.24	0.16	Blood protein levels;	chr4:184701355	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.655	rs67380800	ENSG00000254233.1	RP11-242J7.1	3.53	0.000457	0.0481	0.24	0.16	Blood protein levels;	chr4:184702634	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.616	rs28636679	ENSG00000254233.1	RP11-242J7.1	3.53	0.000457	0.0481	0.24	0.16	Blood protein levels;	chr4:184706327	chr4:184584093~184625030:-
HNSC	cis	rs853679	0.546	rs35016036	ENSG00000280107.1	AL022393.9	-3.53	0.000457	0.0481	-0.29	-0.16	Depression;	chr6:28347103	chr6:28170845~28172521:+
HNSC	cis	rs6860540	0.796	rs6879450	ENSG00000251405.2	CTB-109A12.1	-3.53	0.000457	0.0481	-0.18	-0.16	Inflammatory skin disease;	chr5:157471959	chr5:157362615~157460078:-
HNSC	cis	rs116095464	0.558	rs62347678	ENSG00000277812.1	AC021087.1	3.53	0.000457	0.0481	0.27	0.16	Breast cancer;	chr5:227381	chr5:262769~262881:+
HNSC	cis	rs116095464	0.558	rs73031482	ENSG00000277812.1	AC021087.1	3.53	0.000457	0.0481	0.27	0.16	Breast cancer;	chr5:227479	chr5:262769~262881:+
HNSC	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	3.53	0.000457	0.0481	0.19	0.16	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
HNSC	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
HNSC	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000457	0.0481	-0.24	-0.16	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
HNSC	cis	rs4381823	1	rs113797613	ENSG00000230979.3	AC079250.1	-3.53	0.000457	0.0481	-0.25	-0.16	Schizophrenia;	chr2:47842306	chr2:47690716~47691246:-
HNSC	cis	rs654351	0.572	rs556578	ENSG00000216368.2	RP3-486D24.1	3.53	0.000457	0.0481	0.16	0.16	Squamous cell lung carcinoma;	chr6:10388522	chr6:10118452~10119253:+
HNSC	cis	rs3018712	0.532	rs4930588	ENSG00000255031.4	RP11-802E16.3	3.53	0.000457	0.0481	0.18	0.16	Total body bone mineral density;	chr11:68647767	chr11:68050740~68053762:+
HNSC	cis	rs138249	0.867	rs715616	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000457	0.0481	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50120076	chr22:50199090~50200837:-
HNSC	cis	rs138249	0.898	rs84504	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000457	0.0481	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50120818	chr22:50199090~50200837:-
HNSC	cis	rs138249	0.898	rs138232	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000457	0.0481	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50121409	chr22:50199090~50200837:-
HNSC	cis	rs138249	0.934	rs138234	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000457	0.0481	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50121943	chr22:50199090~50200837:-
HNSC	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	3.53	0.000457	0.0481	0.14	0.16	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
HNSC	cis	rs1941184	0.759	rs10048348	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31443980	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs12185410	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444193	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs12185303	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444366	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs12185412	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444389	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs958961	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444504	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs724481	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444603	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs724482	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31444774	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs7237765	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31445105	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs7236759	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31445267	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs7236769	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31445294	chr18:31496645~31497195:-
HNSC	cis	rs1941184	0.759	rs10048282	ENSG00000266521.1	RP11-650P15.1	3.53	0.000457	0.0481	0.21	0.16	Parkinson's disease (age of onset);	chr18:31445681	chr18:31496645~31497195:-
HNSC	cis	rs7200786	0.528	rs8050875	ENSG00000274038.1	RP11-66H6.4	-3.53	0.000457	0.0481	-0.22	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11129680	chr16:11056556~11057034:+
HNSC	cis	rs478304	0.654	rs11227260	ENSG00000255120.4	OVOL1-AS1	-3.53	0.000457	0.0481	-0.17	-0.16	Acne (severe);	chr11:65693687	chr11:65789051~65790868:-
HNSC	cis	rs73198271	0.773	rs66618176	ENSG00000254153.1	CTA-398F10.2	-3.53	0.000457	0.0481	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8456909~8461337:-
HNSC	cis	rs2762353	0.904	rs13197601	ENSG00000272462.2	U91328.19	3.53	0.000457	0.0481	0.16	0.16	Blood metabolite levels;	chr6:25785707	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.904	rs13197514	ENSG00000272462.2	U91328.19	3.53	0.000457	0.0481	0.16	0.16	Blood metabolite levels;	chr6:25785763	chr6:25992662~26001775:+
HNSC	cis	rs11657639	0.616	rs7211780	ENSG00000272763.1	RP11-357H14.17	3.53	0.000457	0.0481	0.21	0.16	Red blood cell count;	chr17:48442561	chr17:48635923~48647023:-
HNSC	cis	rs950169	1	rs12903820	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000457	0.0481	-0.18	-0.16	Schizophrenia;	chr15:84055068	chr15:84507885~84516814:-
HNSC	cis	rs16873450	0.527	rs10234251	ENSG00000234800.2	PCMTD1P3	3.53	0.000457	0.0481	0.16	0.16	Verbal memory performance (residualized delayed recall level);	chr7:23741022	chr7:23721311~23721782:-
HNSC	cis	rs16873450	0.527	rs11982084	ENSG00000234800.2	PCMTD1P3	3.53	0.000457	0.0481	0.16	0.16	Verbal memory performance (residualized delayed recall level);	chr7:23743097	chr7:23721311~23721782:-
HNSC	cis	rs5758511	0.731	rs58302269	ENSG00000226450.2	CYP2D8P	3.53	0.000457	0.0481	0.15	0.16	Birth weight;	chr22:41955305	chr22:42149886~42155001:-
HNSC	cis	rs5758511	0.773	rs62240999	ENSG00000226450.2	CYP2D8P	3.53	0.000457	0.0481	0.15	0.16	Birth weight;	chr22:41959559	chr22:42149886~42155001:-
HNSC	cis	rs643506	0.874	rs648544	ENSG00000230911.1	PPIHP1	-3.53	0.000457	0.0481	-0.21	-0.16	Breast cancer;	chr11:111795404	chr11:112029858~112030367:-
HNSC	cis	rs67311347	1	rs73078164	ENSG00000280739.1	EIF1B-AS1	3.53	0.000457	0.0481	0.19	0.16	Renal cell carcinoma;	chr3:40438798	chr3:40173145~40309698:-
HNSC	cis	rs67311347	1	rs1123019	ENSG00000280739.1	EIF1B-AS1	3.53	0.000457	0.0481	0.19	0.16	Renal cell carcinoma;	chr3:40446789	chr3:40173145~40309698:-
HNSC	cis	rs3785356	0.524	rs3024619	ENSG00000259940.2	CTD-3203P2.1	3.53	0.000458	0.0481	0.18	0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr16:27353485	chr16:27213308~27214993:-
HNSC	cis	rs12935418	0.504	rs1549288	ENSG00000278985.1	RP11-303E16.9	3.53	0.000458	0.0481	0.15	0.16	Mean corpuscular volume;	chr16:81027156	chr16:80982319~80984094:-
HNSC	cis	rs7686660	0.614	rs13126430	ENSG00000249806.1	RP11-223C24.1	-3.53	0.000458	0.0481	-0.19	-0.16	Asthma;	chr4:143077129	chr4:142566019~142660950:+
HNSC	cis	rs11429307	1	rs11429307	ENSG00000265665.1	AC008391.1	3.53	0.000458	0.0481	0.23	0.16	High light scatter reticulocyte percentage of red cells;	chr5:56561198	chr5:56457038~56457138:-
HNSC	cis	rs8044188	1	rs8047304	ENSG00000280039.1	CTD-2270L9.3	3.53	0.000458	0.0481	0.17	0.16	Multiple system atrophy;	chr16:23029284	chr16:23412380~23416680:+
HNSC	cis	rs859767	0.812	rs842355	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000458	0.0481	-0.19	-0.16	Neuroticism;	chr2:134587311	chr2:134735464~134918710:-
HNSC	cis	rs1908814	0.516	rs10113062	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11935740	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs10113145	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11935786	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs4367597	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11936020	chr8:11104691~11106704:-
HNSC	cis	rs10435719	0.899	rs9329251	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11104691~11106704:-
HNSC	cis	rs10435719	0.773	rs7842810	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs7812563	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11936979	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs13281077	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11937305	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs13281315	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11937346	chr8:11104691~11106704:-
HNSC	cis	rs1908814	0.516	rs4840597	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Neuroticism;	chr8:11938559	chr8:11104691~11106704:-
HNSC	cis	rs804280	0.509	rs4841639	ENSG00000269918.1	AF131215.9	3.53	0.000458	0.0481	0.16	0.16	Myopia (pathological);	chr8:11938584	chr8:11104691~11106704:-
HNSC	cis	rs2657294	0.796	rs6480770	ENSG00000233313.2	HMGA1P5	-3.53	0.000458	0.0481	-0.18	-0.16	Pneumonia;	chr10:75098799	chr10:75276376~75276646:-
HNSC	cis	rs10506328	0.509	rs2293602	ENSG00000248265.1	FLJ12825	3.53	0.000458	0.0481	0.19	0.16	Mean platelet volume;	chr12:54242062	chr12:54058254~54122234:+
HNSC	cis	rs225675	0.629	rs4637658	ENSG00000229017.5	LINC01277	-3.53	0.000458	0.0482	-0.2	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142069995	chr6:142966421~143038077:-
HNSC	cis	rs3764400	0.567	rs8071879	ENSG00000278765.1	RP5-890E16.5	-3.53	0.000458	0.0482	-0.3	-0.16	Body mass index;	chr17:48140095	chr17:48066704~48067293:-
HNSC	cis	rs597480	0.509	rs290185	ENSG00000279742.1	RP11-700A24.1	3.53	0.000458	0.0482	0.17	0.16	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr11:85684675	chr11:85852557~85854943:-
HNSC	cis	rs1853665	0.58	rs4242282	ENSG00000231760.4	RP11-350J20.5	3.53	0.000458	0.0482	0.25	0.16	Radiation response;	chr6:149952210	chr6:149796151~149826294:-
HNSC	cis	rs6840360	0.642	rs2034061	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000458	0.0482	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151407551~151408835:-
HNSC	cis	rs6545883	0.894	rs2694643	ENSG00000271889.1	RP11-493E12.1	3.53	0.000458	0.0482	0.19	0.16	Tuberculosis;	chr2:61377248	chr2:61151433~61162105:-
HNSC	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000458	0.0482	-0.2	-0.16	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
HNSC	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	3.53	0.000458	0.0482	0.11	0.16	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
HNSC	cis	rs7124676	0.966	rs4930426	ENSG00000257086.1	RP11-783K16.13	3.53	0.000458	0.0482	0.17	0.16	Obesity-related traits;	chr11:64548442	chr11:64246939~64249494:-
HNSC	cis	rs2257011	0.967	rs2585058	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000458	0.0482	-0.16	-0.16	Height;	chr15:83615800	chr15:84507885~84516814:-
HNSC	cis	rs4787491	0.679	rs12933575	ENSG00000250616.2	RP11-455F5.3	3.53	0.000458	0.0482	0.16	0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30096430~30104116:+
HNSC	cis	rs690037	0.673	rs690573	ENSG00000271964.1	RP11-415F23.2	-3.53	0.000458	0.0482	-0.16	-0.16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16314439~16314987:+
HNSC	cis	rs6840360	0.642	rs7680013	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000458	0.0482	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs7680236	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000458	0.0482	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151407551~151408835:-
HNSC	cis	rs6840360	0.642	rs4696092	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000458	0.0482	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151407551~151408835:-
HNSC	cis	rs2055729	0.813	rs55999429	ENSG00000254340.1	RP11-10A14.3	-3.53	0.000458	0.0482	-0.21	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9883675	chr8:9141424~9145435:+
HNSC	cis	rs911119	1	rs6048956	ENSG00000270001.1	RP11-218C14.8	-3.53	0.000458	0.0482	-0.24	-0.16	Chronic kidney disease;	chr20:23628664	chr20:23631826~23632316:-
HNSC	cis	rs683257	1	rs72986118	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000458	0.0482	-0.34	-0.16	Facial emotion recognition (angry faces);	chr6:140745861	chr6:140845958~140852924:-
HNSC	cis	rs1560104	0.709	rs9806858	ENSG00000261216.1	RP11-166B2.5	-3.53	0.000458	0.0482	-0.19	-0.16	Obesity-related traits;	chr16:12610564	chr16:11908208~11908916:+
HNSC	cis	rs9907295	0.584	rs7215845	ENSG00000271013.1	AC015849.15	-3.53	0.000459	0.0482	-0.18	-0.16	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35912635~35918010:-
HNSC	cis	rs9907295	0.591	rs4796128	ENSG00000271013.1	AC015849.15	-3.53	0.000459	0.0482	-0.18	-0.16	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35912635~35918010:-
HNSC	cis	rs9987353	0.519	rs11779181	ENSG00000233609.3	RP11-62H7.2	3.53	0.000459	0.0482	0.16	0.16	Recombination measurement;	chr8:9205517	chr8:8961200~8979025:+
HNSC	cis	rs2762353	0.935	rs1165209	ENSG00000272462.2	U91328.19	-3.53	0.000459	0.0482	-0.16	-0.16	Blood metabolite levels;	chr6:25801091	chr6:25992662~26001775:+
HNSC	cis	rs12701220	0.948	rs10275712	ENSG00000224079.1	AC091729.7	3.53	0.000459	0.0482	0.24	0.16	Bronchopulmonary dysplasia;	chr7:1043282	chr7:1074450~1078036:+
HNSC	cis	rs2117029	0.586	rs11168884	ENSG00000258101.2	RP11-977B10.2	3.53	0.000459	0.0482	0.2	0.16	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49232790~49264756:-
HNSC	cis	rs11168854	0.719	rs11168890	ENSG00000258101.2	RP11-977B10.2	3.53	0.000459	0.0482	0.2	0.16	Body mass index;	chr12:49150130	chr12:49232790~49264756:-
HNSC	cis	rs16873450	0.527	rs10950958	ENSG00000234800.2	PCMTD1P3	3.53	0.000459	0.0482	0.16	0.16	Verbal memory performance (residualized delayed recall level);	chr7:23748650	chr7:23721311~23721782:-
HNSC	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	3.53	0.000459	0.0482	0.25	0.16	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
HNSC	cis	rs853679	0.546	rs13214023	ENSG00000280107.1	AL022393.9	3.53	0.000459	0.0482	0.27	0.16	Depression;	chr6:28364364	chr6:28170845~28172521:+
HNSC	cis	rs526231	0.543	rs62362521	ENSG00000250682.4	LINC00491	3.53	0.000459	0.0482	0.21	0.16	Primary biliary cholangitis;	chr5:102970357	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.575	rs12652973	ENSG00000250682.4	LINC00491	3.53	0.000459	0.0482	0.21	0.16	Primary biliary cholangitis;	chr5:102970618	chr5:102609156~102671559:-
HNSC	cis	rs526231	0.575	rs66730942	ENSG00000250682.4	LINC00491	3.53	0.000459	0.0482	0.21	0.16	Primary biliary cholangitis;	chr5:102971075	chr5:102609156~102671559:-
HNSC	cis	rs2361701	0.636	rs1982244	ENSG00000279259.1	RP11-334C17.3	3.53	0.000459	0.0482	0.21	0.16	IgG glycosylation;	chr17:80095149	chr17:80147250~80148596:+
HNSC	cis	rs16958440	0.867	rs78585258	ENSG00000267724.1	RP11-49K24.8	3.53	0.000459	0.0482	0.32	0.16	Sitting height ratio;	chr18:47151358	chr18:47105946~47108062:+
HNSC	cis	rs10158481	0.911	rs1883466	ENSG00000224183.1	SDHDP6	-3.53	0.000459	0.0483	-0.19	-0.16	Urate levels in obese individuals;	chr1:25167604	chr1:25294164~25294643:-
HNSC	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	3.53	0.000459	0.0483	0.24	0.16	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
HNSC	cis	rs6568686	0.553	rs9372301	ENSG00000255389.1	C6orf3	-3.53	0.000459	0.0483	-0.21	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111582126	chr6:111599875~111602295:+
HNSC	cis	rs4648045	0.647	rs1585213	ENSG00000230069.3	LRRC37A15P	-3.53	0.000459	0.0483	-0.16	-0.16	Lymphocyte percentage of white cells;	chr4:102523541	chr4:102727274~102730721:-
HNSC	cis	rs6547741	0.816	rs7560847	ENSG00000272148.1	RP11-195B17.1	-3.53	0.000459	0.0483	-0.16	-0.16	Oral cavity cancer;	chr2:27659833	chr2:27062428~27062907:-
HNSC	cis	rs11096990	0.892	rs11932351	ENSG00000249685.1	RP11-360F5.3	-3.53	0.000459	0.0483	-0.19	-0.16	Cognitive function;	chr4:39229837	chr4:39133913~39135608:+
HNSC	cis	rs7011507	0.582	rs72635700	ENSG00000253608.1	RP11-770E5.1	-3.53	0.000459	0.0483	-0.32	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48308740	chr8:48551567~48698510:+
HNSC	cis	rs1620921	0.563	rs13217026	ENSG00000233342.1	RP11-235G24.3	-3.53	0.000459	0.0483	-0.18	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160848919	chr6:160926369~160927162:+
HNSC	cis	rs1620921	0.594	rs13220254	ENSG00000233342.1	RP11-235G24.3	-3.53	0.000459	0.0483	-0.18	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160848926	chr6:160926369~160927162:+
HNSC	cis	rs1620921	0.506	rs13201433	ENSG00000233342.1	RP11-235G24.3	-3.53	0.000459	0.0483	-0.18	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160848927	chr6:160926369~160927162:+
HNSC	cis	rs1538970	0.924	rs7531253	ENSG00000234329.1	RP11-767N6.2	3.53	0.000459	0.0483	0.19	0.16	Platelet count;	chr1:45424511	chr1:45651039~45651826:-
HNSC	cis	rs9896933	0.832	rs79103992	ENSG00000262663.1	RP11-497H17.1	3.53	0.000459	0.0483	0.21	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82897607	chr17:82918282~82918785:+
HNSC	cis	rs7824557	0.564	rs13268126	ENSG00000255310.2	AF131215.2	-3.53	0.000459	0.0483	-0.15	-0.16	Retinal vascular caliber;	chr8:11373065	chr8:11107788~11109726:-
HNSC	cis	rs7824557	0.564	rs13268126	ENSG00000255495.1	AC145124.2	-3.53	0.000459	0.0483	-0.18	-0.16	Retinal vascular caliber;	chr8:11373065	chr8:12194467~12196280:+
HNSC	cis	rs7927592	0.672	rs10501398	ENSG00000255031.4	RP11-802E16.3	-3.53	0.00046	0.0483	-0.13	-0.16	Total body bone mineral density;	chr11:68564247	chr11:68050740~68053762:+
HNSC	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-3.53	0.00046	0.0483	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
HNSC	cis	rs12725198	1	rs12725198	ENSG00000224459.1	RP11-169K16.4	-3.53	0.00046	0.0483	-0.22	-0.16	Cardiac Troponin-T levels;	chr1:15753676	chr1:15740051~15749896:-
HNSC	cis	rs7027203	0.828	rs10761288	ENSG00000227603.1	RP11-165J3.6	-3.53	0.00046	0.0483	-0.15	-0.16	DNA methylation (variation);	chr9:93847081	chr9:93435332~93437121:-
HNSC	cis	rs11190179	0.744	rs11190181	ENSG00000260475.1	RP11-85A1.3	3.53	0.00046	0.0483	0.28	0.16	&beta2-Glycoprotein I (β2-GPI) plasma levels;	chr10:99606268	chr10:99621055~99621918:+
HNSC	cis	rs6089584	0.526	rs6061965	ENSG00000229873.1	OGFR-AS1	3.53	0.00046	0.0483	0.16	0.16	Body mass index;	chr20:62032802	chr20:62800627~62805587:-
HNSC	cis	rs853679	0.607	rs34218844	ENSG00000280107.1	AL022393.9	-3.53	0.00046	0.0483	-0.28	-0.16	Depression;	chr6:28322870	chr6:28170845~28172521:+
HNSC	cis	rs9290366	0.604	rs1918969	ENSG00000241479.1	RP11-641D5.2	3.53	0.00046	0.0483	0.18	0.16	Red blood cell count;	chr3:169422102	chr3:169447867~169477052:+
HNSC	cis	rs432925	0.529	rs2885415	ENSG00000226942.2	IL9RP3	3.53	0.00046	0.0483	0.2	0.16	Morning vs. evening chronotype;	chr16:345396	chr16:29336~38321:-
HNSC	cis	rs6554196	0.832	rs6851498	ENSG00000272650.1	RP11-571I18.4	-3.53	0.00046	0.0483	-0.2	-0.16	Monocyte count;	chr4:54628165	chr4:53997415~53997712:-
HNSC	cis	rs7819412	0.521	rs4451268	ENSG00000255310.2	AF131215.2	-3.53	0.00046	0.0483	-0.16	-0.16	Triglycerides;	chr8:11177350	chr8:11107788~11109726:-
HNSC	cis	rs1805008	0.535	rs7196459	ENSG00000260259.1	RP11-368I7.4	3.53	0.00046	0.0483	0.37	0.16	Skin colour saturation;	chr16:90075069	chr16:89682620~89686569:-
HNSC	cis	rs6558174	0.965	rs2009212	ENSG00000253837.1	RP11-177H13.2	-3.53	0.00046	0.0483	-0.17	-0.16	Breast cancer;	chr8:22633983	chr8:23336171~23366125:+
HNSC	cis	rs2274459	0.722	rs2296328	ENSG00000224557.6	HLA-DPB2	3.53	0.00046	0.0484	0.21	0.16	Obesity (extreme);	chr6:33683500	chr6:33112451~33129084:+
HNSC	cis	rs1005277	0.505	rs7917943	ENSG00000263064.2	RP11-291L22.7	-3.53	0.00046	0.0484	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38448689~38448949:+
HNSC	cis	rs2762353	0.935	rs1892249	ENSG00000272462.2	U91328.19	3.53	0.00046	0.0484	0.16	0.16	Blood metabolite levels;	chr6:25768764	chr6:25992662~26001775:+
HNSC	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	3.53	0.00046	0.0484	0.32	0.16	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
HNSC	cis	rs603446	0.586	rs1787690	ENSG00000254851.1	RP11-109L13.1	3.53	0.00046	0.0484	0.22	0.16	Triglycerides;	chr11:116697800	chr11:117135528~117138582:+
HNSC	cis	rs8041447	0.896	rs8033211	ENSG00000259756.1	RP11-625H11.2	3.53	0.00046	0.0484	0.18	0.16	Immature fraction of reticulocytes;	chr15:62769688	chr15:62682916~62690448:-
HNSC	cis	rs79040073	0.637	rs117582142	ENSG00000259531.2	RP11-295H24.3	3.53	0.00046	0.0484	0.2	0.16	Lung cancer in ever smokers;	chr15:49228624	chr15:49365124~49366685:-
HNSC	cis	rs79040073	0.565	rs11638515	ENSG00000259531.2	RP11-295H24.3	3.53	0.00046	0.0484	0.2	0.16	Lung cancer in ever smokers;	chr15:49233530	chr15:49365124~49366685:-
HNSC	cis	rs7688540	0.8	rs61792060	ENSG00000250892.1	RP11-1365D11.1	-3.53	0.00046	0.0484	-0.24	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:201409~205009:-
HNSC	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-3.53	0.00046	0.0484	-0.23	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
HNSC	cis	rs3015469	0.584	rs1950730	ENSG00000214900.7	LINC01588	-3.53	0.000461	0.0484	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50409110	chr14:49981712~50007520:-
HNSC	cis	rs7162943	1	rs7162943	ENSG00000260123.1	RP11-326A19.4	3.53	0.000461	0.0484	0.19	0.16	Mean platelet volume;	chr15:89072044	chr15:89041223~89082819:+
HNSC	cis	rs6600671	0.934	rs11249348	ENSG00000272583.1	RP11-344P13.6	-3.53	0.000461	0.0484	-0.18	-0.16	Hip geometry;	chr1:121446444	chr1:121518366~121518829:-
HNSC	cis	rs10256972	0.786	rs3735686	ENSG00000225146.1	AC073957.15	3.53	0.000461	0.0484	0.19	0.16	Endometriosis;Longevity;	chr7:1022891	chr7:1029025~1043891:+
HNSC	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-3.53	0.000461	0.0484	-0.15	-0.16	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
HNSC	cis	rs4815191	0.788	rs1114220	ENSG00000279164.1	RP4-737E23.5	3.53	0.000461	0.0484	0.24	0.16	Obesity-related traits;	chr20:23269569	chr20:23148086~23149939:+
HNSC	cis	rs832540	0.898	rs170732	ENSG00000265665.1	AC008391.1	3.53	0.000461	0.0484	0.18	0.16	Coronary artery disease;	chr5:56955950	chr5:56457038~56457138:-
HNSC	cis	rs12549025	0.516	rs13257250	ENSG00000253390.1	CTC-756D1.2	-3.53	0.000461	0.0484	-0.24	-0.16	Reticulocyte fraction of red cells;	chr8:23485446	chr8:23458601~23484971:+
HNSC	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-3.53	0.000461	0.0484	-0.17	-0.16	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
HNSC	cis	rs4835473	0.932	rs1849136	ENSG00000249741.2	RP11-673E1.3	3.53	0.000461	0.0484	0.18	0.16	Immature fraction of reticulocytes;	chr4:143912380	chr4:143911514~143912053:-
HNSC	cis	rs7824557	0.545	rs2572450	ENSG00000269918.1	AF131215.9	-3.53	0.000461	0.0484	-0.16	-0.16	Retinal vascular caliber;	chr8:11372129	chr8:11104691~11106704:-
HNSC	cis	rs7107174	1	rs7941617	ENSG00000251323.2	RP11-452H21.4	3.53	0.000461	0.0484	0.23	0.16	Testicular germ cell tumor;	chr11:78310100	chr11:78423982~78429836:-
HNSC	cis	rs896655	0.622	rs1452658	ENSG00000244230.3	RN7SL151P	-3.53	0.000461	0.0484	-0.16	-0.16	Coronary artery disease;	chr9:21700796	chr9:21699314~21699596:+
HNSC	cis	rs7267979	0.903	rs6050482	ENSG00000231081.1	RP4-760C5.3	-3.53	0.000461	0.0484	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26008791~26010531:-
HNSC	cis	rs919433	0.648	rs787975	ENSG00000231621.1	AC013264.2	-3.53	0.000461	0.0484	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197383404	chr2:197197991~197199273:+
HNSC	cis	rs7712401	0.537	rs60418991	ENSG00000260686.1	CTB-36H16.2	-3.53	0.000461	0.0484	-0.15	-0.16	Mean platelet volume;	chr5:123020132	chr5:122832356~122834533:+
HNSC	cis	rs4835473	0.932	rs6849896	ENSG00000249741.2	RP11-673E1.3	3.53	0.000461	0.0484	0.17	0.16	Immature fraction of reticulocytes;	chr4:143794927	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.932	rs6826665	ENSG00000249741.2	RP11-673E1.3	3.53	0.000461	0.0484	0.17	0.16	Immature fraction of reticulocytes;	chr4:143795140	chr4:143911514~143912053:-
HNSC	cis	rs4835473	0.838	rs35998817	ENSG00000249741.2	RP11-673E1.3	3.53	0.000461	0.0484	0.17	0.16	Immature fraction of reticulocytes;	chr4:143795355	chr4:143911514~143912053:-
HNSC	cis	rs8077577	0.747	rs1925	ENSG00000273018.4	CTD-2303H24.2	-3.53	0.000461	0.0484	-0.23	-0.16	Obesity-related traits;	chr17:18274401	chr17:18511221~18551705:-
HNSC	cis	rs4704187	0.663	rs17738989	ENSG00000272040.1	CTC-366B18.4	-3.53	0.000461	0.0484	-0.15	-0.16	Response to amphetamines;	chr5:75237905	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.663	rs28539749	ENSG00000272040.1	CTC-366B18.4	-3.53	0.000461	0.0484	-0.15	-0.16	Response to amphetamines;	chr5:75238077	chr5:75608817~75609983:+
HNSC	cis	rs4704187	0.687	rs6866661	ENSG00000272040.1	CTC-366B18.4	-3.53	0.000461	0.0484	-0.15	-0.16	Response to amphetamines;	chr5:75238547	chr5:75608817~75609983:+
HNSC	cis	rs12701220	0.817	rs1058727	ENSG00000224079.1	AC091729.7	3.53	0.000461	0.0484	0.22	0.16	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1074450~1078036:+
HNSC	cis	rs13160562	0.623	rs26509	ENSG00000249180.1	CTC-506B8.1	-3.53	0.000461	0.0484	-0.16	-0.16	Alcohol dependence;	chr5:96746976	chr5:96741079~96742698:-
HNSC	cis	rs73201462	1	rs2811541	ENSG00000231305.3	RP11-723O4.2	3.53	0.000461	0.0484	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128265951	chr3:128861313~128871540:-
HNSC	cis	rs7688540	0.771	rs11722197	ENSG00000250892.1	RP11-1365D11.1	-3.53	0.000461	0.0485	-0.3	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:201409~205009:-
HNSC	cis	rs7688540	0.771	rs11723261	ENSG00000250892.1	RP11-1365D11.1	-3.53	0.000461	0.0485	-0.3	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:201409~205009:-
HNSC	cis	rs5758511	0.773	rs7288749	ENSG00000226450.2	CYP2D8P	3.53	0.000461	0.0485	0.15	0.16	Birth weight;	chr22:41960426	chr22:42149886~42155001:-
HNSC	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	3.53	0.000462	0.0485	0.17	0.16	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
HNSC	cis	rs853679	0.546	rs34295134	ENSG00000219392.1	RP1-265C24.5	-3.53	0.000462	0.0485	-0.28	-0.16	Depression;	chr6:27860373	chr6:28115628~28116551:+
HNSC	cis	rs4555082	0.834	rs2975217	ENSG00000253701.2	AL928768.3	3.53	0.000462	0.0485	0.13	0.16	Platelet distribution width;Mean platelet volume;	chr14:105243901	chr14:105703961~105704602:-
HNSC	cis	rs7937890	0.559	rs2597201	ENSG00000254418.1	RP11-21L19.1	3.53	0.000462	0.0485	0.19	0.16	Mitochondrial DNA levels;	chr11:14463858	chr11:14262846~14273691:-
HNSC	cis	rs6840360	0.582	rs2709826	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000462	0.0485	-0.16	-0.16	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151407551~151408835:-
HNSC	cis	rs7720894	0.935	rs2053694	ENSG00000215032.2	GNL3LP1	-3.53	0.000462	0.0485	-0.17	-0.16	Body mass index;	chr5:61512059	chr5:60891935~60893577:-
HNSC	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000462	0.0485	-0.24	-0.16	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
HNSC	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000462	0.0485	-0.24	-0.16	Gout;	chr7:66642037	chr7:66848496~66858136:+
HNSC	cis	rs12817549	0.817	rs3741675	ENSG00000213250.5	RBMS2P1	3.53	0.000462	0.0485	0.14	0.16	Hip circumference adjusted for BMI;	chr12:93714753	chr12:94423744~94424969:-
HNSC	cis	rs8077577	0.708	rs4925151	ENSG00000260647.1	RP1-178F10.1	-3.53	0.000462	0.0485	-0.23	-0.16	Obesity-related traits;	chr17:18226818	chr17:18268080~18268828:+
HNSC	cis	rs4934494	0.871	rs927907	ENSG00000240996.1	RP11-80H5.7	-3.53	0.000462	0.0485	-0.21	-0.16	Red blood cell count;	chr10:89629981	chr10:89694295~89697928:-
HNSC	cis	rs12073359	0.955	rs11584354	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000462	0.0485	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150066990	chr1:149844498~149849024:-
HNSC	cis	rs853679	1	rs9986596	ENSG00000270326.1	RP5-874C20.6	-3.53	0.000462	0.0485	-0.24	-0.16	Depression;	chr6:28251883	chr6:28319660~28319852:-
HNSC	cis	rs453301	0.571	rs2929305	ENSG00000253981.4	ALG1L13P	-3.53	0.000462	0.0485	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9227707	chr8:8236003~8244667:-
HNSC	cis	rs9487051	0.676	rs13195816	ENSG00000219700.1	PTCHD3P3	3.53	0.000462	0.0485	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109277421	chr6:109288571~109290503:-
HNSC	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-3.53	0.000462	0.0485	-0.24	-0.16	Depression;	chr6:28111963	chr6:28170845~28172521:+
HNSC	cis	rs6088580	0.634	rs13041646	ENSG00000276073.1	RP5-1125A11.7	-3.53	0.000462	0.0485	-0.16	-0.16	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:33985617~33988989:-
HNSC	cis	rs1979679	0.801	rs7977538	ENSG00000247934.4	RP11-967K21.1	-3.53	0.000462	0.0485	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28163298~28190738:-
HNSC	cis	rs1979679	0.801	rs1965280	ENSG00000247934.4	RP11-967K21.1	-3.53	0.000462	0.0485	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28163298~28190738:-
HNSC	cis	rs1538138	1	rs1538138	ENSG00000226453.1	RP11-379B8.1	-3.53	0.000462	0.0485	-0.21	-0.16	Corneal structure;	chr6:82084877	chr6:81845185~81933480:-
HNSC	cis	rs10865541	0.902	rs7593978	ENSG00000234171.2	RNASEH1-AS1	3.53	0.000462	0.0485	0.17	0.16	Obesity-related traits;	chr2:3411773	chr2:3558492~3561745:+
HNSC	cis	rs9611565	0.592	rs12484254	ENSG00000235513.1	RP4-756G23.5	3.53	0.000462	0.0485	0.18	0.16	Vitiligo;	chr22:41565999	chr22:41209122~41217627:-
HNSC	cis	rs225675	0.729	rs225601	ENSG00000229017.5	LINC01277	3.53	0.000462	0.0485	0.2	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142129140	chr6:142966421~143038077:-
HNSC	cis	rs11723261	0.582	rs6814287	ENSG00000211553.1	AC253576.2	-3.53	0.000462	0.0485	-0.24	-0.16	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:136461~136568:+
HNSC	cis	rs9402743	0.597	rs9385729	ENSG00000231028.7	LINC00271	-3.53	0.000462	0.0485	-0.19	-0.16	Systemic lupus erythematosus;	chr6:135600001	chr6:135497801~135716055:+
HNSC	cis	rs11700980	0.551	rs2832016	ENSG00000232855.5	AF131217.1	3.53	0.000462	0.0485	0.23	0.16	QRS complex (12-leadsum);	chr21:28739075	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832018	ENSG00000232855.5	AF131217.1	3.53	0.000462	0.0485	0.23	0.16	QRS complex (12-leadsum);	chr21:28739317	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832019	ENSG00000232855.5	AF131217.1	3.53	0.000462	0.0485	0.23	0.16	QRS complex (12-leadsum);	chr21:28739885	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832020	ENSG00000232855.5	AF131217.1	3.53	0.000462	0.0485	0.23	0.16	QRS complex (12-leadsum);	chr21:28739909	chr21:28439346~28674848:-
HNSC	cis	rs11700980	0.551	rs2832022	ENSG00000232855.5	AF131217.1	3.53	0.000462	0.0485	0.23	0.16	QRS complex (12-leadsum);	chr21:28740396	chr21:28439346~28674848:-
HNSC	cis	rs720475	0.732	rs62483107	ENSG00000170356.8	OR2A20P	3.53	0.000462	0.0485	0.22	0.16	Breast cancer;	chr7:144442144	chr7:144250045~144252957:-
HNSC	cis	rs2243480	1	rs160652	ENSG00000226002.1	RP11-460N20.5	-3.53	0.000463	0.0485	-0.28	-0.16	Diabetic kidney disease;	chr7:66073444	chr7:65084103~65100232:+
HNSC	cis	rs7429990	0.864	rs13063042	ENSG00000228638.1	FCF1P2	3.53	0.000463	0.0485	0.15	0.16	Educational attainment (years of education);	chr3:47683825	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs2133601	ENSG00000228638.1	FCF1P2	3.53	0.000463	0.0485	0.15	0.16	Educational attainment (years of education);	chr3:47692525	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs6792497	ENSG00000228638.1	FCF1P2	3.53	0.000463	0.0485	0.15	0.16	Educational attainment (years of education);	chr3:47693684	chr3:48290793~48291375:-
HNSC	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-3.53	0.000463	0.0486	-0.18	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
HNSC	cis	rs12073359	0.955	rs112287706	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000463	0.0486	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150074061	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72692893	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000463	0.0486	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150075047	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72692898	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000463	0.0486	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077904	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs72692900	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000463	0.0486	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150078190	chr1:149844498~149849024:-
HNSC	cis	rs12073359	1	rs56212907	ENSG00000261716.1	RP11-196G18.22	-3.53	0.000463	0.0486	-0.2	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086719	chr1:149844498~149849024:-
HNSC	cis	rs67311347	1	rs4973998	ENSG00000280739.1	EIF1B-AS1	3.53	0.000463	0.0486	0.19	0.16	Renal cell carcinoma;	chr3:40418861	chr3:40173145~40309698:-
HNSC	cis	rs4648045	0.796	rs3817685	ENSG00000230069.3	LRRC37A15P	-3.53	0.000463	0.0486	-0.16	-0.16	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102727274~102730721:-
HNSC	cis	rs138249	0.867	rs138226	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000463	0.0486	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118358	chr22:50199090~50200837:-
HNSC	cis	rs138249	0.898	rs138227	ENSG00000273253.2	RP3-402G11.26	-3.53	0.000463	0.0486	-0.16	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118386	chr22:50199090~50200837:-
HNSC	cis	rs4787951	0.505	rs3024575	ENSG00000259940.2	CTD-3203P2.1	-3.53	0.000463	0.0486	-0.17	-0.16	Eosinophil percentage of white cells;	chr16:27346811	chr16:27213308~27214993:-
HNSC	cis	rs10819861	0.679	rs4623574	ENSG00000271384.1	RP11-435O5.7	3.53	0.000463	0.0486	0.16	0.16	Electrocardiographic traits;	chr9:96087342	chr9:95406990~95407662:-
HNSC	cis	rs10819861	0.645	rs10819810	ENSG00000271384.1	RP11-435O5.7	3.53	0.000463	0.0486	0.16	0.16	Electrocardiographic traits;	chr9:96087629	chr9:95406990~95407662:-
HNSC	cis	rs8062405	1	rs3888190	ENSG00000261089.1	RP11-435I10.3	3.53	0.000463	0.0486	0.18	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28413703~28415018:+
HNSC	cis	rs11157436	0.602	rs4982569	ENSG00000211814.1	TRAV35	-3.53	0.000463	0.0486	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22221896~22222475:+
HNSC	cis	rs7845219	0.544	rs34208552	ENSG00000245080.5	RP11-320N21.1	-3.53	0.000463	0.0486	-0.2	-0.16	Type 2 diabetes;	chr8:94895839	chr8:95066808~95073182:-
HNSC	cis	rs11671005	0.735	rs3826684	ENSG00000269473.1	CTD-2619J13.19	3.53	0.000463	0.0486	0.25	0.16	Mean platelet volume;	chr19:58407338	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs3826683	ENSG00000269473.1	CTD-2619J13.19	3.53	0.000463	0.0486	0.25	0.16	Mean platelet volume;	chr19:58407366	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs3826682	ENSG00000269473.1	CTD-2619J13.19	3.53	0.000463	0.0486	0.25	0.16	Mean platelet volume;	chr19:58407381	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs3826681	ENSG00000269473.1	CTD-2619J13.19	3.53	0.000463	0.0486	0.25	0.16	Mean platelet volume;	chr19:58407397	chr19:58440448~58445849:+
HNSC	cis	rs2117029	0.521	rs12229524	ENSG00000258101.2	RP11-977B10.2	3.53	0.000463	0.0486	0.21	0.16	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49232790~49264756:-
HNSC	cis	rs7515577	0.797	rs2391140	ENSG00000223787.2	RP4-593M8.1	-3.53	0.000463	0.0486	-0.27	-0.16	Cholesterol, total;	chr1:92296097	chr1:92580476~92580821:-
HNSC	cis	rs9437689	0.966	rs11165299	ENSG00000237416.5	RP11-465K1.2	-3.53	0.000463	0.0486	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95079300	chr1:94836748~94855426:-
HNSC	cis	rs9437689	1	rs9437812	ENSG00000237416.5	RP11-465K1.2	-3.53	0.000463	0.0486	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95081509	chr1:94836748~94855426:-
HNSC	cis	rs597539	0.652	rs660614	ENSG00000261625.1	RP11-554A11.4	-3.53	0.000463	0.0486	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:69000765~69002048:-
HNSC	cis	rs34286592	0.929	rs9932653	ENSG00000214725.6	CDIPT-AS1	-3.53	0.000463	0.0486	-0.23	-0.16	Multiple sclerosis;	chr16:29854352	chr16:29863593~29868053:+
HNSC	cis	rs35740288	0.752	rs11635956	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000463	0.0486	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85744109~85750281:-
HNSC	cis	rs1709393	1	rs1709393	ENSG00000256628.3	ZBTB11-AS1	-3.53	0.000463	0.0486	-0.18	-0.16	Anxiety disorder;	chr3:101980310	chr3:101676475~101679217:+
HNSC	cis	rs2139634	0.864	rs885485	ENSG00000227398.3	KIF9-AS1	-3.53	0.000463	0.0486	-0.16	-0.16	Cerebrospinal fluid biomarker levels;	chr3:46469678	chr3:47164497~47246601:+
HNSC	cis	rs2139634	0.896	rs885486	ENSG00000227398.3	KIF9-AS1	-3.53	0.000463	0.0486	-0.16	-0.16	Cerebrospinal fluid biomarker levels;	chr3:46469736	chr3:47164497~47246601:+
HNSC	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000463	0.0486	-0.22	-0.16	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
HNSC	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000463	0.0486	-0.22	-0.16	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
HNSC	cis	rs950169	0.922	rs11631096	ENSG00000230373.7	GOLGA6L5P	-3.53	0.000463	0.0486	-0.18	-0.16	Schizophrenia;	chr15:84557698	chr15:84507885~84516814:-
HNSC	cis	rs3748656	0.887	rs35147679	ENSG00000273483.1	RP4-671G15.2	3.53	0.000463	0.0486	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112525955	chr1:112517799~112518441:-
HNSC	cis	rs6802315	0.575	rs1864508	ENSG00000272087.1	RP11-379F4.7	3.53	0.000463	0.0486	0.17	0.16	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158693120~158693768:-
HNSC	cis	rs10754283	0.905	rs7519969	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs7519971	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs7546410	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs7515375	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.901	rs6663526	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.934	rs6428563	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.934	rs7529653	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.87	rs2390764	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.901	rs4520403	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs4658130	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.934	rs10754284	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs10801759	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs10801760	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89583241~89632894:-
HNSC	cis	rs10754283	0.967	rs7528433	ENSG00000231999.5	FLJ27354	3.53	0.000463	0.0486	0.17	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89583241~89632894:-
HNSC	cis	rs17076726	0.519	rs6875393	ENSG00000253785.1	CTC-308K20.3	-3.53	0.000463	0.0486	-0.17	-0.16	Red cell distribution width;Mean corpuscular hemoglobin;	chr5:173932998	chr5:172975511~172976374:+
HNSC	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	3.53	0.000463	0.0486	0.15	0.16	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
HNSC	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	3.53	0.000463	0.0486	0.15	0.16	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
HNSC	cis	rs911555	0.546	rs28798508	ENSG00000269940.1	RP11-73M18.7	3.53	0.000464	0.0486	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103694560~103695170:+
HNSC	cis	rs36093844	0.948	rs56271770	ENSG00000279742.1	RP11-700A24.1	-3.53	0.000464	0.0486	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837357	chr11:85852557~85854943:-
HNSC	cis	rs6141600	0.627	rs6142510	ENSG00000199676.1	Y_RNA	3.53	0.000464	0.0486	0.26	0.16	Height;Hip circumference;	chr20:36121094	chr20:35853252~35853364:-
HNSC	cis	rs6141600	0.627	rs2235799	ENSG00000199676.1	Y_RNA	3.53	0.000464	0.0486	0.26	0.16	Height;Hip circumference;	chr20:36122582	chr20:35853252~35853364:-
HNSC	cis	rs6968419	0.963	rs2896175	ENSG00000237870.5	AC073130.1	3.53	0.000464	0.0486	0.18	0.16	Intraocular pressure;	chr7:116171382	chr7:116275606~116286734:-
HNSC	cis	rs4073405	0.621	rs4992029	ENSG00000254651.1	RP11-430H10.3	3.53	0.000464	0.0486	0.19	0.16	Schizophrenia;	chr11:45258127	chr11:45399448~45400528:+
HNSC	cis	rs2348418	0.515	rs17434556	ENSG00000257042.1	RP11-993B23.3	-3.53	0.000464	0.0486	-0.17	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28442760	chr12:27958517~27969813:+
HNSC	cis	rs9527	0.59	rs7898770	ENSG00000213277.3	MARCKSL1P1	3.53	0.000464	0.0486	0.18	0.16	Arsenic metabolism;	chr10:102996879	chr10:103175554~103176094:+
HNSC	cis	rs7674212	0.833	rs61075040	ENSG00000230069.3	LRRC37A15P	-3.53	0.000464	0.0486	-0.16	-0.16	Type 2 diabetes;	chr4:103052804	chr4:102727274~102730721:-
HNSC	cis	rs3929778	0.883	rs9679882	ENSG00000278192.1	RP5-1056H1.2	3.53	0.000464	0.0486	0.22	0.16	QRS complex (Cornell);	chr20:6488562	chr20:6065966~6067897:-
HNSC	cis	rs10789207	0.563	rs58418199	ENSG00000248458.2	RP4-598P13.1	-3.53	0.000464	0.0487	-0.24	-0.16	Resting heart rate;	chr1:66641592	chr1:66665864~66677027:-
HNSC	cis	rs1519814	0.696	rs7813264	ENSG00000254343.2	RP11-760H22.2	-3.53	0.000464	0.0487	-0.21	-0.16	Breast cancer;	chr8:120020514	chr8:120052180~120056201:+
HNSC	cis	rs1519814	0.659	rs7817075	ENSG00000254343.2	RP11-760H22.2	-3.53	0.000464	0.0487	-0.21	-0.16	Breast cancer;	chr8:120020607	chr8:120052180~120056201:+
HNSC	cis	rs950027	0.62	rs1617634	ENSG00000259479.5	SORD2P	3.53	0.000464	0.0487	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:44826371~44884694:-
HNSC	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-3.53	0.000464	0.0487	-0.18	-0.16	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
HNSC	cis	rs7914558	0.966	rs7908280	ENSG00000236937.2	PTGES3P4	3.53	0.000464	0.0487	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102845595~102845950:+
HNSC	cis	rs1795708	0.65	rs61921688	ENSG00000270039.1	RP11-571M6.17	3.53	0.000464	0.0487	0.19	0.16	Obesity-related traits;	chr12:58433493	chr12:57803838~57804415:+
HNSC	cis	rs4295623	0.585	rs34421088	ENSG00000255052.4	FAM66D	3.53	0.000464	0.0487	0.17	0.16	Morning vs. evening chronotype;	chr8:11731533	chr8:12115782~12177550:+
HNSC	cis	rs10435719	0.902	rs7006538	ENSG00000255046.1	RP11-297N6.4	-3.53	0.000464	0.0487	-0.16	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11797928~11802568:-
HNSC	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	3.53	0.000464	0.0487	0.2	0.16	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
HNSC	cis	rs344364	0.636	rs344363	ENSG00000277602.1	AC005363.11	-3.53	0.000464	0.0487	-0.26	-0.16	Glomerular filtration rate in chronic kidney disease;	chr16:1922547	chr16:1971655~1971896:-
HNSC	cis	rs10540	1	rs71487292	ENSG00000279672.1	CMB9-55F22.1	3.53	0.000464	0.0487	0.28	0.16	Body mass index;	chr11:486076	chr11:779617~780755:+
HNSC	cis	rs10540	1	rs61876333	ENSG00000279672.1	CMB9-55F22.1	3.53	0.000464	0.0487	0.28	0.16	Body mass index;	chr11:487136	chr11:779617~780755:+
HNSC	cis	rs61160187	0.582	rs4700404	ENSG00000251279.1	CTC-436P18.1	-3.53	0.000464	0.0487	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:61162070~61232040:+
HNSC	cis	rs4512344	0.509	rs2409784	ENSG00000269918.1	AF131215.9	-3.53	0.000464	0.0487	-0.15	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11104691~11106704:-
HNSC	cis	rs28489187	0.643	rs997251	ENSG00000223653.4	RP11-131L23.1	3.53	0.000465	0.0487	0.22	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85379684	chr1:85276715~85448124:+
HNSC	cis	rs10992797	0.527	rs10821172	ENSG00000227603.1	RP11-165J3.6	-3.53	0.000465	0.0487	-0.14	-0.16	Intelligence (multi-trait analysis);	chr9:93599969	chr9:93435332~93437121:-
HNSC	cis	rs4287000	0.508	rs62574558	ENSG00000227603.1	RP11-165J3.6	-3.53	0.000465	0.0487	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600380	chr9:93435332~93437121:-
HNSC	cis	rs4287000	0.508	rs4744259	ENSG00000227603.1	RP11-165J3.6	-3.53	0.000465	0.0487	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600636	chr9:93435332~93437121:-
HNSC	cis	rs35740288	0.822	rs2241268	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000465	0.0487	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85744109~85750281:-
HNSC	cis	rs11098499	0.644	rs17517414	ENSG00000250412.1	KLHL2P1	3.53	0.000465	0.0487	0.2	0.16	Corneal astigmatism;	chr4:119340946	chr4:119334329~119378233:+
HNSC	cis	rs7178375	1	rs35162264	ENSG00000215302.7	CTD-3092A11.1	-3.53	0.000465	0.0487	-0.25	-0.16	Hypertriglyceridemia;	chr15:30908480	chr15:30470779~30507623:+
HNSC	cis	rs782107	0.565	rs4760214	ENSG00000270039.1	RP11-571M6.17	3.53	0.000465	0.0487	0.19	0.16	Interleukin-12p70 levels;	chr12:58432459	chr12:57803838~57804415:+
HNSC	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	3.53	0.000465	0.0487	0.16	0.16	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
HNSC	cis	rs7726839	0.54	rs72707016	ENSG00000225138.6	CTD-2228K2.7	3.53	0.000465	0.0487	0.24	0.16	Obesity-related traits;	chr5:665033	chr5:473236~480884:+
HNSC	cis	rs911119	1	rs2016161	ENSG00000270001.1	RP11-218C14.8	3.53	0.000465	0.0487	0.23	0.16	Chronic kidney disease;	chr20:23640537	chr20:23631826~23632316:-
HNSC	cis	rs5758659	0.714	rs5758589	ENSG00000270083.1	RP1-257I20.14	-3.53	0.000465	0.0487	-0.15	-0.16	Cognitive function;	chr22:42122378	chr22:42089630~42090028:-
HNSC	cis	rs2836974	0.897	rs13049280	ENSG00000255568.3	BRWD1-AS2	3.53	0.000465	0.0487	0.15	0.16	Cognitive function;	chr21:39222730	chr21:39313935~39314962:+
HNSC	cis	rs875971	0.54	rs781152	ENSG00000273142.1	RP11-458F8.4	-3.53	0.000465	0.0488	-0.14	-0.16	Aortic root size;	chr7:66014585	chr7:66902857~66906297:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000273142.1	RP11-458F8.4	-3.53	0.000465	0.0488	-0.14	-0.16	Calcium levels;	chr7:66014891	chr7:66902857~66906297:+
HNSC	cis	rs17772222	0.917	rs17124652	ENSG00000258789.1	RP11-507K2.3	-3.53	0.000465	0.0488	-0.2	-0.16	Coronary artery calcification;	chr14:88424384	chr14:88551597~88552493:+
HNSC	cis	rs8077577	0.708	rs2290504	ENSG00000273018.4	CTD-2303H24.2	3.52	0.000465	0.0488	0.23	0.16	Obesity-related traits;	chr17:18233674	chr17:18511221~18551705:-
HNSC	cis	rs72827839	1	rs72827830	ENSG00000272763.1	RP11-357H14.17	-3.52	0.000465	0.0488	-0.26	-0.16	Ease of getting up in the morning;	chr17:48320140	chr17:48635923~48647023:-
HNSC	cis	rs61160187	0.582	rs726824	ENSG00000152931.7	PART1	-3.52	0.000465	0.0488	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60487713~60547657:+
HNSC	cis	rs3096299	0.719	rs2353581	ENSG00000261118.1	RP11-104N10.1	3.52	0.000465	0.0488	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89492017~89504460:-
HNSC	cis	rs988913	0.678	rs11756900	ENSG00000224984.1	RP11-524H19.2	3.52	0.000465	0.0488	0.19	0.16	Menarche (age at onset);	chr6:55141340	chr6:54840118~54840855:-
HNSC	cis	rs783147	0.5	rs4252114	ENSG00000233342.1	RP11-235G24.3	3.52	0.000465	0.0488	0.19	0.16	Lp (a) levels;	chr6:160722158	chr6:160926369~160927162:+
HNSC	cis	rs651907	0.64	rs771574	ENSG00000244119.1	PDCL3P4	3.52	0.000465	0.0488	0.16	0.16	Colorectal cancer;	chr3:101901838	chr3:101712472~101713191:+
HNSC	cis	rs28829049	0.597	rs12745238	ENSG00000270728.1	RP4-657E11.10	-3.52	0.000465	0.0488	-0.15	-0.16	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19067216	chr1:19297080~19297903:+
HNSC	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-3.52	0.000466	0.0488	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
HNSC	cis	rs13325613	0.834	rs33998492	ENSG00000223552.1	RP11-24F11.2	-3.52	0.000466	0.0488	-0.31	-0.16	Monocyte count;	chr3:46232107	chr3:46364955~46407059:-
HNSC	cis	rs7826238	0.653	rs2979202	ENSG00000254340.1	RP11-10A14.3	3.52	0.000466	0.0488	0.2	0.16	Systolic blood pressure;	chr8:8486617	chr8:9141424~9145435:+
HNSC	cis	rs13260300	0.533	rs12548780	ENSG00000254349.4	FLJ39080	3.52	0.000466	0.0488	0.19	0.16	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582379	chr8:74599775~74823313:+
HNSC	cis	rs2565722	0.583	rs2489945	ENSG00000231863.1	RP3-428L16.1	3.52	0.000466	0.0488	0.24	0.16	Blood protein levels;	chr6:160876692	chr6:160931080~160969771:+
HNSC	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	3.52	0.000466	0.0488	0.2	0.16	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
HNSC	cis	rs7824557	0.806	rs34171564	ENSG00000255310.2	AF131215.2	-3.52	0.000466	0.0488	-0.15	-0.16	Retinal vascular caliber;	chr8:11237837	chr8:11107788~11109726:-
HNSC	cis	rs591584	0.59	rs7120587	ENSG00000255893.1	RP11-685N10.1	-3.52	0.000466	0.0488	-0.22	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94586307	chr11:94472908~94473570:-
HNSC	cis	rs73201462	1	rs13095660	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129313	chr3:128861313~128871540:-
HNSC	cis	rs73201462	0.708	rs6788497	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129545	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs6439116	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130224	chr3:128861313~128871540:-
HNSC	cis	rs13059975	1	rs13059975	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130841	chr3:128861313~128871540:-
HNSC	cis	rs34174370	1	rs34174370	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130901	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs11714619	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000466	0.0488	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131233	chr3:128861313~128871540:-
HNSC	cis	rs7551222	0.681	rs4245739	ENSG00000280924.1	LINC00628	-3.52	0.000466	0.0488	-0.2	-0.16	Schizophrenia;	chr1:204549714	chr1:204368431~204369719:-
HNSC	cis	rs3929778	0.816	rs1119779	ENSG00000278192.1	RP5-1056H1.2	-3.52	0.000466	0.0488	-0.22	-0.16	QRS complex (Cornell);	chr20:6554946	chr20:6065966~6067897:-
HNSC	cis	rs3929778	0.816	rs1581712	ENSG00000278192.1	RP5-1056H1.2	-3.52	0.000466	0.0488	-0.22	-0.16	QRS complex (Cornell);	chr20:6554952	chr20:6065966~6067897:-
HNSC	cis	rs3929778	0.848	rs1321438	ENSG00000278192.1	RP5-1056H1.2	-3.52	0.000466	0.0488	-0.22	-0.16	QRS complex (Cornell);	chr20:6555680	chr20:6065966~6067897:-
HNSC	cis	rs3929778	0.848	rs967797	ENSG00000278192.1	RP5-1056H1.2	-3.52	0.000466	0.0488	-0.22	-0.16	QRS complex (Cornell);	chr20:6566444	chr20:6065966~6067897:-
HNSC	cis	rs9329221	0.698	rs12547997	ENSG00000269918.1	AF131215.9	3.52	0.000466	0.0488	0.16	0.16	Neuroticism;	chr8:10403327	chr8:11104691~11106704:-
HNSC	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	3.52	0.000466	0.0488	0.2	0.16	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
HNSC	cis	rs683257	0.759	rs6937932	ENSG00000234147.1	RP3-460G2.2	-3.52	0.000466	0.0488	-0.29	-0.16	Facial emotion recognition (angry faces);	chr6:140884616	chr6:140845958~140852924:-
HNSC	cis	rs67311347	1	rs2371186	ENSG00000280739.1	EIF1B-AS1	3.52	0.000466	0.0488	0.19	0.16	Renal cell carcinoma;	chr3:40447222	chr3:40173145~40309698:-
HNSC	cis	rs4853525	0.561	rs7597768	ENSG00000228509.4	AC006460.2	3.52	0.000466	0.0488	0.22	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977153	chr2:190676944~190708716:-
HNSC	cis	rs5758659	0.652	rs133347	ENSG00000273366.1	CTA-989H11.1	-3.52	0.000466	0.0488	-0.19	-0.16	Cognitive function;	chr22:42027641	chr22:42278188~42278846:+
HNSC	cis	rs1476029	0.8	rs105161	ENSG00000279805.1	CTA-212A2.1	-3.52	0.000466	0.0488	-0.26	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr22:36134380	chr22:36137430~36139350:-
HNSC	cis	rs2253762	0.577	rs2461201	ENSG00000226864.1	ATE1-AS1	3.52	0.000466	0.0488	0.21	0.16	Breast cancer;	chr10:122039699	chr10:121928312~121951965:+
HNSC	cis	rs7746199	0.668	rs7749305	ENSG00000219392.1	RP1-265C24.5	-3.52	0.000466	0.0488	-0.29	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28115628~28116551:+
HNSC	cis	rs982100	0.778	rs1477451	ENSG00000226856.4	AC093901.1	-3.52	0.000466	0.0488	-0.23	-0.16	Alzheimer disease and age of onset;	chr2:117690798	chr2:118132128~118186386:-
HNSC	cis	rs6554196	0.869	rs11733357	ENSG00000272650.1	RP11-571I18.4	-3.52	0.000466	0.0488	-0.2	-0.16	Monocyte count;	chr4:54664715	chr4:53997415~53997712:-
HNSC	cis	rs6554196	0.932	rs4864915	ENSG00000272650.1	RP11-571I18.4	-3.52	0.000466	0.0488	-0.2	-0.16	Monocyte count;	chr4:54665514	chr4:53997415~53997712:-
HNSC	cis	rs250677	0.522	rs10038913	ENSG00000250072.4	CTC-529P8.1	3.52	0.000466	0.0488	0.2	0.16	Breast cancer;	chr5:148974661	chr5:149063317~149109787:+
HNSC	cis	rs7098414	0.53	rs10749572	ENSG00000226659.1	RP11-137H2.4	-3.52	0.000466	0.0488	-0.2	-0.16	Post bronchodilator FEV1;	chr10:80376908	chr10:80529597~80535942:-
HNSC	cis	rs7086627	0.506	rs10749575	ENSG00000226659.1	RP11-137H2.4	-3.52	0.000466	0.0488	-0.2	-0.16	Post bronchodilator FEV1;	chr10:80377165	chr10:80529597~80535942:-
HNSC	cis	rs10090774	0.687	rs9644447	ENSG00000279766.1	RP11-642A1.2	-3.52	0.000466	0.0488	-0.17	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682695	chr8:140572142~140572812:-
HNSC	cis	rs28489187	0.643	rs233054	ENSG00000223653.4	RP11-131L23.1	3.52	0.000466	0.0488	0.22	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85374508	chr1:85276715~85448124:+
HNSC	cis	rs12537284	0.518	rs12540468	ENSG00000275106.1	RP11-309L24.10	-3.52	0.000466	0.0488	-0.26	-0.16	Systemic lupus erythematosus;	chr7:129082746	chr7:128952527~128953316:-
HNSC	cis	rs116095464	0.558	rs6555058	ENSG00000277812.1	AC021087.1	-3.52	0.000466	0.0488	-0.27	-0.16	Breast cancer;	chr5:226261	chr5:262769~262881:+
HNSC	cis	rs73198271	0.74	rs1039910	ENSG00000254153.1	CTA-398F10.2	-3.52	0.000466	0.0488	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8456909~8461337:-
HNSC	cis	rs10435719	0.744	rs11250175	ENSG00000255310.2	AF131215.2	3.52	0.000466	0.0488	0.15	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs13279577	ENSG00000255310.2	AF131215.2	3.52	0.000466	0.0488	0.15	0.16	Neuroticism;	chr8:11935587	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs10112958	ENSG00000255310.2	AF131215.2	3.52	0.000466	0.0488	0.15	0.16	Neuroticism;	chr8:11935631	chr8:11107788~11109726:-
HNSC	cis	rs1908814	0.516	rs10113042	ENSG00000255310.2	AF131215.2	3.52	0.000466	0.0488	0.15	0.16	Neuroticism;	chr8:11935669	chr8:11107788~11109726:-
HNSC	cis	rs481331	0.741	rs17158044	ENSG00000215146.4	RP11-313J2.1	3.52	0.000466	0.0489	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42689688	chr10:42331866~42367974:-
HNSC	cis	rs897984	0.683	rs8050330	ENSG00000279196.1	RP11-1072A3.3	3.52	0.000466	0.0489	0.18	0.16	Dementia with Lewy bodies;	chr16:30813649	chr16:30984630~30988270:-
HNSC	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	3.52	0.000466	0.0489	0.32	0.16	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
HNSC	cis	rs17711722	1	rs17711722	ENSG00000272831.1	RP11-792A8.4	-3.52	0.000467	0.0489	-0.14	-0.16	Calcium levels;	chr7:65806210	chr7:66739829~66740385:-
HNSC	cis	rs10761256	0.752	rs6479500	ENSG00000227603.1	RP11-165J3.6	3.52	0.000467	0.0489	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93645540	chr9:93435332~93437121:-
HNSC	cis	rs10761256	0.806	rs6479501	ENSG00000227603.1	RP11-165J3.6	3.52	0.000467	0.0489	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93646621	chr9:93435332~93437121:-
HNSC	cis	rs7686660	0.614	rs13125763	ENSG00000249806.1	RP11-223C24.1	-3.52	0.000467	0.0489	-0.19	-0.16	Asthma;	chr4:143080545	chr4:142566019~142660950:+
HNSC	cis	rs7686660	0.614	rs4374584	ENSG00000249806.1	RP11-223C24.1	-3.52	0.000467	0.0489	-0.19	-0.16	Asthma;	chr4:143086425	chr4:142566019~142660950:+
HNSC	cis	rs9467711	0.606	rs2393667	ENSG00000241549.7	GUSBP2	3.52	0.000467	0.0489	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26421117	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs2076030	ENSG00000241549.7	GUSBP2	3.52	0.000467	0.0489	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26426628	chr6:26871484~26956554:-
HNSC	cis	rs9467711	0.606	rs2235251	ENSG00000241549.7	GUSBP2	3.52	0.000467	0.0489	0.25	0.16	Autism spectrum disorder or schizophrenia;	chr6:26431754	chr6:26871484~26956554:-
HNSC	cis	rs11002791	0.607	rs34483750	ENSG00000224596.6	ZMIZ1-AS1	3.52	0.000467	0.0489	0.19	0.16	Red blood cell count;	chr10:79037430	chr10:78943328~79067895:-
HNSC	cis	rs8031584	0.918	rs34095794	ENSG00000270015.1	RP11-540B6.6	-3.52	0.000467	0.0489	-0.16	-0.16	Huntington's disease progression;	chr15:30977488	chr15:30926514~30928407:+
HNSC	cis	rs4703129	1	rs2052519	ENSG00000246763.5	RGMB-AS1	-3.52	0.000467	0.0489	-0.18	-0.16	Asperger disorder;	chr5:98535314	chr5:98769618~98773469:-
HNSC	cis	rs4704846	0.66	rs173505	ENSG00000253519.1	AC106801.1	3.52	0.000467	0.0489	0.27	0.16	Blood protein levels;	chr5:157124079	chr5:157565964~157569098:+
HNSC	cis	rs4704846	0.66	rs185029	ENSG00000253519.1	AC106801.1	3.52	0.000467	0.0489	0.27	0.16	Blood protein levels;	chr5:157124219	chr5:157565964~157569098:+
HNSC	cis	rs4704846	0.66	rs246863	ENSG00000253519.1	AC106801.1	3.52	0.000467	0.0489	0.27	0.16	Blood protein levels;	chr5:157124860	chr5:157565964~157569098:+
HNSC	cis	rs4704846	0.66	rs165989	ENSG00000253519.1	AC106801.1	3.52	0.000467	0.0489	0.27	0.16	Blood protein levels;	chr5:157125416	chr5:157565964~157569098:+
HNSC	cis	rs2565722	0.622	rs10945704	ENSG00000233342.1	RP11-235G24.3	-3.52	0.000467	0.0489	-0.26	-0.16	Blood protein levels;	chr6:160869894	chr6:160926369~160927162:+
HNSC	cis	rs711830	1	rs6433571	ENSG00000226363.3	HAGLROS	-3.52	0.000467	0.0489	-0.22	-0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174850	chr2:176177717~176179008:+
HNSC	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-3.52	0.000467	0.0489	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
HNSC	cis	rs6095360	1	rs6019618	ENSG00000227431.4	CSE1L-AS1	-3.52	0.000467	0.0489	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:49055001	chr20:49040463~49046044:-
HNSC	cis	rs597539	0.654	rs655816	ENSG00000261625.1	RP11-554A11.4	-3.52	0.000467	0.0489	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:69000765~69002048:-
HNSC	cis	rs597539	0.69	rs497149	ENSG00000261625.1	RP11-554A11.4	-3.52	0.000467	0.0489	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:69000765~69002048:-
HNSC	cis	rs7209700	0.692	rs11652097	ENSG00000228782.6	CTD-2026D20.3	-3.52	0.000467	0.0489	-0.16	-0.16	IgG glycosylation;	chr17:47239351	chr17:47450568~47492492:-
HNSC	cis	rs4073405	0.691	rs1075778	ENSG00000254651.1	RP11-430H10.3	3.52	0.000467	0.0489	0.2	0.16	Schizophrenia;	chr11:45271839	chr11:45399448~45400528:+
HNSC	cis	rs36093844	0.626	rs72959177	ENSG00000279742.1	RP11-700A24.1	-3.52	0.000467	0.0489	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85988019	chr11:85852557~85854943:-
HNSC	cis	rs6568686	0.577	rs174391	ENSG00000255389.1	C6orf3	3.52	0.000467	0.0489	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111596745	chr6:111599875~111602295:+
HNSC	cis	rs1150668	0.796	rs728122	ENSG00000217862.2	HIST1H4PS1	-3.52	0.000467	0.0489	-0.16	-0.16	Pubertal anthropometrics;	chr6:28431347	chr6:27807075~27807339:+
HNSC	cis	rs17095355	1	rs17126931	ENSG00000203876.8	ADD3-AS1	-3.52	0.000467	0.0489	-0.22	-0.16	Biliary atresia;	chr10:109994875	chr10:109940104~110008381:-
HNSC	cis	rs300890	0.76	rs1532981	ENSG00000250326.1	RP11-284M14.1	-3.52	0.000467	0.0489	-0.18	-0.16	Nasopharyngeal carcinoma;	chr4:143294193	chr4:142933195~143184861:-
HNSC	cis	rs2115630	0.967	rs11073702	ENSG00000259295.5	CSPG4P12	-3.52	0.000467	0.0489	-0.18	-0.16	P wave terminal force;	chr15:84766840	chr15:85191438~85213905:+
HNSC	cis	rs4660214	0.627	rs61779282	ENSG00000182109.6	RP11-69E11.4	3.52	0.000467	0.0489	0.21	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39522280~39546187:-
HNSC	cis	rs12600394	0.767	rs2323452	ENSG00000236088.8	COX10-AS1	3.52	0.000467	0.0489	0.2	0.16	Response to platinum-based chemotherapy (cisplatin);	chr17:14628707	chr17:13756478~14069495:-
HNSC	cis	rs843532	0.925	rs1718416	ENSG00000236833.1	AC024560.2	3.52	0.000467	0.0489	0.26	0.16	Glucose homeostasis traits;	chr3:196792362	chr3:197660565~197665757:-
HNSC	cis	rs2836974	0.897	rs1541102	ENSG00000255568.3	BRWD1-AS2	3.52	0.000467	0.0489	0.15	0.16	Cognitive function;	chr21:39256839	chr21:39313935~39314962:+
HNSC	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-3.52	0.000467	0.0489	-0.19	-0.16	Height;	chr14:75031474	chr14:75011269~75012851:-
HNSC	cis	rs5769765	0.542	rs5769751	ENSG00000229409.1	RP11-494O16.3	-3.52	0.000467	0.0489	-0.31	-0.16	Schizophrenia;	chr22:49849085	chr22:49845929~49846090:+
HNSC	cis	rs7688540	0.8	rs11731285	ENSG00000275426.1	CH17-262A2.1	3.52	0.000467	0.0489	0.21	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:149738~150317:+
HNSC	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-3.52	0.000468	0.0489	-0.18	-0.16	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
HNSC	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-3.52	0.000468	0.0489	-0.18	-0.16	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
HNSC	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	3.52	0.000468	0.049	0.18	0.16	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
HNSC	cis	rs34421088	0.532	rs2736388	ENSG00000269918.1	AF131215.9	3.52	0.000468	0.049	0.17	0.16	Neuroticism;	chr8:11302079	chr8:11104691~11106704:-
HNSC	cis	rs7023329	0.59	rs2891159	ENSG00000244230.3	RN7SL151P	3.52	0.000468	0.049	0.16	0.16	Melanoma;	chr9:21747673	chr9:21699314~21699596:+
HNSC	cis	rs2839186	0.77	rs2839984	ENSG00000239415.1	AP001469.9	3.52	0.000468	0.049	0.14	0.16	Testicular germ cell tumor;	chr21:46251776	chr21:46251549~46254133:-
HNSC	cis	rs35306767	0.623	rs72760943	ENSG00000229869.1	RP11-363N22.2	-3.52	0.000468	0.049	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:1097164	chr10:933026~942743:+
HNSC	cis	rs35306767	0.623	rs34034003	ENSG00000229869.1	RP11-363N22.2	-3.52	0.000468	0.049	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:1097495	chr10:933026~942743:+
HNSC	cis	rs6545883	1	rs778762	ENSG00000271889.1	RP11-493E12.1	3.52	0.000468	0.049	0.18	0.16	Tuberculosis;	chr2:61555786	chr2:61151433~61162105:-
HNSC	cis	rs6544773	0.726	rs1878511	ENSG00000205054.5	LINC01121	3.52	0.000468	0.049	0.18	0.16	Mosquito bite size;	chr2:44827406	chr2:45164870~45323295:-
HNSC	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-3.52	0.000468	0.049	-0.19	-0.16	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
HNSC	cis	rs17057718	1	rs79932559	ENSG00000272146.4	RP11-755B10.4	-3.52	0.000468	0.049	-0.25	-0.16	Cerebrospinal fluid biomarker levels;	chr3:57111698	chr3:57597715~57600927:+
HNSC	cis	rs57221529	0.766	rs56350081	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000468	0.049	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:583083	chr5:473236~480884:+
HNSC	cis	rs57221529	0.766	rs12518859	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000468	0.049	0.24	0.16	Lung disease severity in cystic fibrosis;	chr5:587317	chr5:473236~480884:+
HNSC	cis	rs1867631	0.958	rs7536188	ENSG00000248458.2	RP4-598P13.1	-3.52	0.000468	0.049	-0.16	-0.16	Menopause (age at onset);	chr1:66622243	chr1:66665864~66677027:-
HNSC	cis	rs3096299	0.685	rs4785568	ENSG00000261118.1	RP11-104N10.1	3.52	0.000468	0.049	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89492017~89504460:-
HNSC	cis	rs12701220	0.762	rs7777565	ENSG00000224079.1	AC091729.7	3.52	0.000468	0.049	0.24	0.16	Bronchopulmonary dysplasia;	chr7:963375	chr7:1074450~1078036:+
HNSC	cis	rs1546924	0.692	rs197379	ENSG00000227811.2	FAM212B-AS1	-3.52	0.000468	0.049	-0.18	-0.16	Body mass index;	chr1:111749681	chr1:111739841~111747798:+
HNSC	cis	rs72932726	0.524	rs1851065	ENSG00000249274.1	PDLIM1P4	-3.52	0.000468	0.049	-0.3	-0.16	Heschl's gyrus morphology;	chr3:99252837	chr3:98782188~98783193:+
HNSC	cis	rs10504130	0.666	rs7833668	ENSG00000228801.5	RP11-110G21.1	3.52	0.000468	0.049	0.2	0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51941326	chr8:51899325~51947173:+
HNSC	cis	rs977987	0.528	rs9926933	ENSG00000280152.1	RP11-331F4.5	3.52	0.000468	0.049	0.22	0.16	Dupuytren's disease;	chr16:75467669	chr16:75245994~75250077:-
HNSC	cis	rs10927875	0.541	rs1739843	ENSG00000226029.1	RP4-798A10.2	-3.52	0.000468	0.049	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016759	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.518	rs1763597	ENSG00000226029.1	RP4-798A10.2	-3.52	0.000468	0.049	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016802	chr1:16460948~16468481:+
HNSC	cis	rs10927875	0.541	rs1739844	ENSG00000226029.1	RP4-798A10.2	-3.52	0.000468	0.049	-0.15	-0.16	Dilated cardiomyopathy;	chr1:16016827	chr1:16460948~16468481:+
HNSC	cis	rs11711311	1	rs2603789	ENSG00000241529.3	RN7SL767P	-3.52	0.000468	0.049	-0.2	-0.16	IgG glycosylation;	chr3:113751632	chr3:113632704~113632998:+
HNSC	cis	rs7429990	0.864	rs1403578	ENSG00000228638.1	FCF1P2	3.52	0.000468	0.049	0.14	0.16	Educational attainment (years of education);	chr3:47617997	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.833	rs870622	ENSG00000228638.1	FCF1P2	3.52	0.000468	0.049	0.14	0.16	Educational attainment (years of education);	chr3:47618683	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs868255	ENSG00000228638.1	FCF1P2	3.52	0.000468	0.049	0.14	0.16	Educational attainment (years of education);	chr3:47619074	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs4858842	ENSG00000228638.1	FCF1P2	3.52	0.000468	0.049	0.14	0.16	Educational attainment (years of education);	chr3:47619574	chr3:48290793~48291375:-
HNSC	cis	rs7674212	0.539	rs6854709	ENSG00000251288.2	RP11-10L12.2	-3.52	0.000468	0.049	-0.18	-0.16	Type 2 diabetes;	chr4:103208629	chr4:102751401~102752641:+
HNSC	cis	rs11992162	0.636	rs11250182	ENSG00000227888.4	FAM66A	-3.52	0.000468	0.049	-0.16	-0.16	Monocyte count;	chr8:11950067	chr8:12362019~12388296:+
HNSC	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	3.52	0.000468	0.049	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
HNSC	cis	rs61990749	0.597	rs176944	ENSG00000239272.1	RPL21P10	-3.52	0.000468	0.049	-0.24	-0.16	Fibroblast growth factor basic levels;	chr14:77709868	chr14:77683202~77683989:-
HNSC	cis	rs61160187	0.582	rs12516995	ENSG00000152931.7	PART1	-3.52	0.000468	0.049	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60487713~60547657:+
HNSC	cis	rs7267979	0.706	rs6037069	ENSG00000231081.1	RP4-760C5.3	-3.52	0.000469	0.049	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26008791~26010531:-
HNSC	cis	rs11098499	0.73	rs78971550	ENSG00000250412.1	KLHL2P1	3.52	0.000469	0.049	0.21	0.16	Corneal astigmatism;	chr4:119359886	chr4:119334329~119378233:+
HNSC	cis	rs11098499	0.645	rs78422072	ENSG00000250412.1	KLHL2P1	3.52	0.000469	0.049	0.21	0.16	Corneal astigmatism;	chr4:119359887	chr4:119334329~119378233:+
HNSC	cis	rs67311347	1	rs73078158	ENSG00000280739.1	EIF1B-AS1	3.52	0.000469	0.049	0.18	0.16	Renal cell carcinoma;	chr3:40431076	chr3:40173145~40309698:-
HNSC	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	3.52	0.000469	0.049	0.32	0.16	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	3.52	0.000469	0.049	0.32	0.16	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
HNSC	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	3.52	0.000469	0.049	0.32	0.16	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	3.52	0.000469	0.049	0.32	0.16	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
HNSC	cis	rs9611565	0.546	rs5758430	ENSG00000235513.1	RP4-756G23.5	-3.52	0.000469	0.049	-0.2	-0.16	Vitiligo;	chr22:41713840	chr22:41209122~41217627:-
HNSC	cis	rs9611565	0.546	rs5758431	ENSG00000235513.1	RP4-756G23.5	-3.52	0.000469	0.049	-0.2	-0.16	Vitiligo;	chr22:41713913	chr22:41209122~41217627:-
HNSC	cis	rs4761669	0.876	rs12368595	ENSG00000241556.1	RP11-490G8.1	-3.52	0.000469	0.049	-0.17	-0.16	Common carotid intima-media thickness in HIV infection;	chr12:94821281	chr12:95467397~95467861:-
HNSC	cis	rs9525638	1	rs67629713	ENSG00000231530.1	RP11-187A9.3	-3.52	0.000469	0.049	-0.19	-0.16	Cortical thickness;TB-LM or TBLH-BMD (pleiotropy);Total body bone mineral density (age 0-15);Bone mineral density (paediatric, upper limb);Bone mineral density (paediatric, total body less head);	chr13:42591246	chr13:42043727~42044247:-
HNSC	cis	rs9487051	1	rs6568569	ENSG00000219700.1	PTCHD3P3	3.52	0.000469	0.049	0.16	0.16	Reticulocyte fraction of red cells;	chr6:109291993	chr6:109288571~109290503:-
HNSC	cis	rs1538970	0.924	rs1826691	ENSG00000234329.1	RP11-767N6.2	-3.52	0.000469	0.0491	-0.19	-0.16	Platelet count;	chr1:45415590	chr1:45651039~45651826:-
HNSC	cis	rs863750	0.721	rs844085	ENSG00000275389.1	RP11-214K3.24	3.52	0.000469	0.0491	0.22	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124080711	chr12:124085761~124088598:+
HNSC	cis	rs11270836	1	rs11270836	ENSG00000231160.8	KLF3-AS1	-3.52	0.000469	0.0491	-0.15	-0.16	Mumps;	chr4:38624294	chr4:38612701~38664883:-
HNSC	cis	rs11671005	0.735	rs12986387	ENSG00000269473.1	CTD-2619J13.19	3.52	0.000469	0.0491	0.25	0.16	Mean platelet volume;	chr19:58415848	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs11667723	ENSG00000269473.1	CTD-2619J13.19	3.52	0.000469	0.0491	0.25	0.16	Mean platelet volume;	chr19:58416122	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs11668789	ENSG00000269473.1	CTD-2619J13.19	3.52	0.000469	0.0491	0.25	0.16	Mean platelet volume;	chr19:58416942	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs35652377	ENSG00000269473.1	CTD-2619J13.19	3.52	0.000469	0.0491	0.25	0.16	Mean platelet volume;	chr19:58417833	chr19:58440448~58445849:+
HNSC	cis	rs11671005	0.735	rs3764532	ENSG00000269473.1	CTD-2619J13.19	3.52	0.000469	0.0491	0.25	0.16	Mean platelet volume;	chr19:58417855	chr19:58440448~58445849:+
HNSC	cis	rs2638953	0.853	rs10843178	ENSG00000257176.2	RP11-996F15.2	3.52	0.000469	0.0491	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:29280418~29317848:-
HNSC	cis	rs853679	0.607	rs56075693	ENSG00000280107.1	AL022393.9	-3.52	0.000469	0.0491	-0.29	-0.16	Depression;	chr6:28322551	chr6:28170845~28172521:+
HNSC	cis	rs7429990	0.864	rs6772301	ENSG00000228638.1	FCF1P2	3.52	0.000469	0.0491	0.14	0.16	Educational attainment (years of education);	chr3:47682366	chr3:48290793~48291375:-
HNSC	cis	rs1519814	0.654	rs1401810	ENSG00000254343.2	RP11-760H22.2	-3.52	0.000469	0.0491	-0.23	-0.16	Breast cancer;	chr8:120003581	chr8:120052180~120056201:+
HNSC	cis	rs6685187	0.8	rs4845409	ENSG00000229021.2	AL591893.1	3.52	0.000469	0.0491	0.18	0.16	Blood metabolite levels;	chr1:151921903	chr1:151994531~152042774:+
HNSC	cis	rs12586317	0.547	rs10146699	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35014371	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs13379372	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35014676	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs45531432	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35015217	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs76770287	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35018004	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.514	rs74590021	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35020907	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs112510746	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35022627	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs77262907	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35026528	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs28577270	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35029237	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.511	rs11540758	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35029279	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs10134907	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35030005	chr14:34920858~34982532:-
HNSC	cis	rs12586317	0.547	rs74462850	ENSG00000258704.4	SRP54-AS1	-3.52	0.000469	0.0491	-0.21	-0.16	Psoriasis;	chr14:35030887	chr14:34920858~34982532:-
HNSC	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-3.52	0.000469	0.0491	-0.23	-0.16	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
HNSC	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-3.52	0.000469	0.0491	-0.23	-0.16	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
HNSC	cis	rs931127	0.554	rs11227261	ENSG00000255120.4	OVOL1-AS1	-3.52	0.000469	0.0491	-0.16	-0.16	Systemic lupus erythematosus;	chr11:65695372	chr11:65789051~65790868:-
HNSC	cis	rs11231017	0.507	rs11231025	ENSG00000250659.2	RP11-864I4.3	-3.52	0.000469	0.0491	-0.2	-0.16	HIV-1 viral setpoint;	chr11:62305833	chr11:62537312~62542018:+
HNSC	cis	rs6988985	0.678	rs28571827	ENSG00000247317.3	RP11-273G15.2	-3.52	0.000469	0.0491	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921791	chr8:142981738~143018437:-
HNSC	cis	rs2638953	0.962	rs11049558	ENSG00000257176.2	RP11-996F15.2	3.52	0.000469	0.0491	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:29280418~29317848:-
HNSC	cis	rs853679	0.567	rs16894106	ENSG00000217862.2	HIST1H4PS1	-3.52	0.000469	0.0491	-0.18	-0.16	Depression;	chr6:28432562	chr6:27807075~27807339:+
HNSC	cis	rs4648045	0.565	rs4698860	ENSG00000230069.3	LRRC37A15P	-3.52	0.000469	0.0491	-0.16	-0.16	Lymphocyte percentage of white cells;	chr4:102624170	chr4:102727274~102730721:-
HNSC	cis	rs332034	0.546	rs10099757	ENSG00000253893.2	FAM85B	3.52	0.000469	0.0491	0.3	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8837732	chr8:8167819~8226614:-
HNSC	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000469	0.0491	-0.21	-0.16	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
HNSC	cis	rs734999	0.588	rs6689711	ENSG00000238164.5	RP3-395M20.8	3.52	0.000469	0.0491	0.12	0.16	Ulcerative colitis;	chr1:2600028	chr1:2549920~2557031:-
HNSC	cis	rs644587	0.571	rs692890	ENSG00000244040.4	IL12A-AS1	-3.52	0.00047	0.0491	-0.2	-0.16	Primary biliary cholangitis;	chr3:159981785	chr3:159913400~160225299:-
HNSC	cis	rs2436845	0.627	rs2916559	ENSG00000253320.4	KB-1507C5.2	-3.52	0.00047	0.0491	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102814856	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.627	rs2436849	ENSG00000253320.4	KB-1507C5.2	-3.52	0.00047	0.0491	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102815320	chr8:102864300~102977876:+
HNSC	cis	rs7845219	0.544	rs34293080	ENSG00000245080.5	RP11-320N21.1	-3.52	0.00047	0.0491	-0.19	-0.16	Type 2 diabetes;	chr8:94895850	chr8:95066808~95073182:-
HNSC	cis	rs6968419	0.755	rs4730719	ENSG00000237870.5	AC073130.1	-3.52	0.00047	0.0491	-0.19	-0.16	Intraocular pressure;	chr7:116254956	chr7:116275606~116286734:-
HNSC	cis	rs1560104	0.675	rs9927256	ENSG00000261216.1	RP11-166B2.5	-3.52	0.00047	0.0491	-0.19	-0.16	Obesity-related traits;	chr16:12611158	chr16:11908208~11908916:+
HNSC	cis	rs7014346	0.683	rs10956368	ENSG00000207110.1	RNU1-106P	-3.52	0.00047	0.0491	-0.17	-0.16	Colorectal cancer;	chr8:127411405	chr8:127999131~127999294:+
HNSC	cis	rs17404153	0.599	rs11706084	ENSG00000248724.5	NPHP3-AS1	3.52	0.00047	0.0491	0.28	0.16	LDL cholesterol;HDL cholesterol;	chr3:132413855	chr3:132721750~132874223:+
HNSC	cis	rs9527	0.59	rs11191513	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103013227	chr10:103175554~103176094:+
HNSC	cis	rs9527	0.59	rs10509764	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103016718	chr10:103175554~103176094:+
HNSC	cis	rs9527	0.59	rs6584537	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103018510	chr10:103175554~103176094:+
HNSC	cis	rs9527	0.569	rs78193706	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103020807	chr10:103175554~103176094:+
HNSC	cis	rs9527	0.59	rs7906754	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103022800	chr10:103175554~103176094:+
HNSC	cis	rs9527	0.615	rs4917991	ENSG00000213277.3	MARCKSL1P1	-3.52	0.00047	0.0491	-0.18	-0.16	Arsenic metabolism;	chr10:103024076	chr10:103175554~103176094:+
HNSC	cis	rs9487051	0.837	rs2356817	ENSG00000243587.6	C6orf183	-3.52	0.00047	0.0491	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109321472	chr6:109165833~109271014:+
HNSC	cis	rs2436845	0.9	rs2436857	ENSG00000253669.3	KB-1732A1.1	-3.52	0.00047	0.0491	-0.15	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813236	chr8:102805517~102809971:+
HNSC	cis	rs16944687	1	rs75034192	ENSG00000261567.1	RP11-680G10.1	-3.52	0.00047	0.0491	-0.41	-0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr16:86104883	chr16:85357463~85359449:+
HNSC	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-3.52	0.00047	0.0491	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
HNSC	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-3.52	0.00047	0.0491	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
HNSC	cis	rs1555322	0.932	rs6060321	ENSG00000279253.1	RP4-614O4.13	-3.52	0.00047	0.0492	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35262727~35264187:-
HNSC	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	3.52	0.00047	0.0492	0.2	0.16	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
HNSC	cis	rs2292096	0.636	rs7511678	ENSG00000260088.1	RP11-92G12.3	3.52	0.00047	0.0492	0.23	0.16	Epilepsy;	chr1:200863729	chr1:200669507~200694250:+
HNSC	cis	rs2289700	0.518	rs77362013	ENSG00000252061.1	RNU6-415P	-3.52	0.00047	0.0492	-0.29	-0.16	Bipolar disorder;	chr15:78874918	chr15:78898840~78898936:-
HNSC	cis	rs989128	0.517	rs1809284	ENSG00000250286.1	RP11-94C24.8	-3.52	0.00047	0.0492	-0.17	-0.16	Type 2 diabetes;	chr17:50554949	chr17:50537294~50538754:-
HNSC	cis	rs10178094	0.716	rs7424771	ENSG00000279844.1	RP11-20F18.1	3.52	0.00047	0.0492	0.16	0.16	White blood cell count;	chr2:160419867	chr2:160849313~160850676:-
HNSC	cis	rs78487399	0.71	rs79165612	ENSG00000234936.1	AC010883.5	3.52	0.00047	0.0492	0.28	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43397113	chr2:43229573~43233394:+
HNSC	cis	rs4761669	0.876	rs10777624	ENSG00000241556.1	RP11-490G8.1	-3.52	0.00047	0.0492	-0.17	-0.16	Common carotid intima-media thickness in HIV infection;	chr12:94805239	chr12:95467397~95467861:-
HNSC	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	3.52	0.00047	0.0492	0.22	0.16	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
HNSC	cis	rs3748656	1	rs34848593	ENSG00000273483.1	RP4-671G15.2	3.52	0.00047	0.0492	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112697484	chr1:112517799~112518441:-
HNSC	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	3.52	0.00047	0.0492	0.17	0.16	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
HNSC	cis	rs6693388	0.749	rs7554859	ENSG00000229021.2	AL591893.1	-3.52	0.00047	0.0492	-0.18	-0.16	Blood metabolite ratios;	chr1:151965462	chr1:151994531~152042774:+
HNSC	cis	rs2013441	1	rs9325894	ENSG00000261033.1	RP11-209D14.2	3.52	0.00047	0.0492	0.18	0.16	Obesity-related traits;	chr17:20293788	chr17:20008051~20009234:-
HNSC	cis	rs1865760	0.566	rs9379825	ENSG00000272810.1	U91328.22	-3.52	0.00047	0.0492	-0.15	-0.16	Height;	chr6:26083643	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs9467672	ENSG00000272810.1	U91328.22	-3.52	0.00047	0.0492	-0.15	-0.16	Height;	chr6:26083676	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs9295688	ENSG00000272810.1	U91328.22	-3.52	0.00047	0.0492	-0.15	-0.16	Height;	chr6:26083989	chr6:26013241~26013757:+
HNSC	cis	rs11587682	0.806	rs34247601	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150407066	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.806	rs36029278	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150409359	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.84	rs12741448	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150410545	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.84	rs9651184	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150410805	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.84	rs11205368	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150412038	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.76	rs36122812	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150412419	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.806	rs11808242	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150412806	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.806	rs11589873	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150413955	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.774	rs11588184	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150415239	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.806	rs11589632	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150415310	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.714	rs57565292	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150415535	chr1:150780272~150780644:+
HNSC	cis	rs11587682	0.806	rs56321241	ENSG00000236713.1	RP11-363I22.3	3.52	0.000471	0.0492	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150416553	chr1:150780272~150780644:+
HNSC	cis	rs6604026	0.74	rs10782945	ENSG00000223787.2	RP4-593M8.1	-3.52	0.000471	0.0492	-0.2	-0.16	Multiple sclerosis;	chr1:92838715	chr1:92580476~92580821:-
HNSC	cis	rs10256972	0.758	rs2280724	ENSG00000225146.1	AC073957.15	3.52	0.000471	0.0492	0.19	0.16	Endometriosis;Longevity;	chr7:1025084	chr7:1029025~1043891:+
HNSC	cis	rs67311347	1	rs6793596	ENSG00000280739.1	EIF1B-AS1	3.52	0.000471	0.0492	0.2	0.16	Renal cell carcinoma;	chr3:40416304	chr3:40173145~40309698:-
HNSC	cis	rs2967951	1	rs814597	ENSG00000271980.1	CTD-2256P15.4	3.52	0.000471	0.0492	0.23	0.16	Body mass index;	chr5:10468817	chr5:10264597~10267146:-
HNSC	cis	rs17221829	0.733	rs10765227	ENSG00000280385.1	AP000648.5	-3.52	0.000471	0.0492	-0.18	-0.16	Anxiety in major depressive disorder;	chr11:89651948	chr11:90193614~90198120:+
HNSC	cis	rs17221829	0.733	rs10765228	ENSG00000280385.1	AP000648.5	-3.52	0.000471	0.0492	-0.18	-0.16	Anxiety in major depressive disorder;	chr11:89651964	chr11:90193614~90198120:+
HNSC	cis	rs5758659	0.714	rs2284087	ENSG00000270083.1	RP1-257I20.14	-3.52	0.000471	0.0492	-0.15	-0.16	Cognitive function;	chr22:42089667	chr22:42089630~42090028:-
HNSC	cis	rs9925964	0.933	rs8050894	ENSG00000232748.3	RP11-196G11.6	3.52	0.000471	0.0492	0.21	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31056460~31062803:+
HNSC	cis	rs5758511	0.68	rs5758699	ENSG00000205702.9	CYP2D7	3.52	0.000471	0.0492	0.14	0.16	Birth weight;	chr22:42292028	chr22:42140203~42144577:-
HNSC	cis	rs9303542	0.504	rs1973577	ENSG00000210741.1	MIR196A1	3.52	0.000471	0.0492	0.18	0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48432437	chr17:48632490~48632559:-
HNSC	cis	rs793571	0.554	rs12442451	ENSG00000245975.2	RP11-30K9.6	3.52	0.000471	0.0492	0.28	0.16	Schizophrenia;	chr15:58630196	chr15:58768072~58770974:-
HNSC	cis	rs2505998	0.833	rs2565204	ENSG00000273008.1	RP11-351D16.3	-3.52	0.000471	0.0492	-0.2	-0.16	Hirschsprung disease;	chr10:43107725	chr10:43136824~43138334:-
HNSC	cis	rs2505998	0.833	rs2742244	ENSG00000273008.1	RP11-351D16.3	-3.52	0.000471	0.0492	-0.2	-0.16	Hirschsprung disease;	chr10:43108144	chr10:43136824~43138334:-
HNSC	cis	rs801193	1	rs10252765	ENSG00000273142.1	RP11-458F8.4	-3.52	0.000471	0.0492	-0.14	-0.16	Aortic root size;	chr7:66763745	chr7:66902857~66906297:+
HNSC	cis	rs2333194	1	rs177377	ENSG00000258695.2	RP3-414A15.2	-3.52	0.000471	0.0492	-0.17	-0.16	Bipolar disorder with mood-incongruent psychosis;	chr14:73286811	chr14:73522878~73530610:+
HNSC	cis	rs10938353	0.911	rs1866511	ENSG00000273369.1	RP11-700J17.1	3.52	0.000471	0.0492	0.2	0.16	Body mass index;	chr4:44590153	chr4:44693946~44694386:-
HNSC	cis	rs28489187	0.683	rs2892888	ENSG00000223653.4	RP11-131L23.1	-3.52	0.000471	0.0492	-0.22	-0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85400464	chr1:85276715~85448124:+
HNSC	cis	rs2908197	0.788	rs6465111	ENSG00000186704.9	DTX2P1	3.52	0.000471	0.0492	0.16	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76362061	chr7:76978617~77004308:+
HNSC	cis	rs172166	0.694	rs1150666	ENSG00000219891.2	ZSCAN12P1	3.52	0.000471	0.0492	0.21	0.16	Cardiac Troponin-T levels;	chr6:28156150	chr6:28091154~28093664:+
HNSC	cis	rs2117029	0.782	rs6580698	ENSG00000258101.2	RP11-977B10.2	3.52	0.000471	0.0492	0.2	0.16	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49232790~49264756:-
HNSC	cis	rs344024	0.621	rs7628802	ENSG00000240489.1	SETP14	-3.52	0.000471	0.0492	-0.14	-0.16	Total body bone mineral density;	chr3:156652144	chr3:155987304~155988176:+
HNSC	cis	rs509208	0.818	rs35386726	ENSG00000220343.5	RP11-440K22.1	3.52	0.000471	0.0493	0.23	0.16	Alzheimer's disease biomarkers;	chr3:166360582	chr3:167065831~167066320:+
HNSC	cis	rs11648785	0.747	rs3743826	ENSG00000274627.1	RP11-104N10.2	3.52	0.000471	0.0493	0.18	0.16	Tanning;	chr16:90027806	chr16:89516797~89522217:+
HNSC	cis	rs2060793	0.712	rs10741654	ENSG00000254418.1	RP11-21L19.1	3.52	0.000471	0.0493	0.19	0.16	Vitamin D levels;	chr11:14726506	chr11:14262846~14273691:-
HNSC	cis	rs7937890	0.505	rs9971395	ENSG00000254418.1	RP11-21L19.1	3.52	0.000471	0.0493	0.19	0.16	Mitochondrial DNA levels;	chr11:14745580	chr11:14262846~14273691:-
HNSC	cis	rs2016266	0.82	rs11170496	ENSG00000270175.1	RP11-793H13.11	-3.52	0.000471	0.0493	-0.15	-0.16	Bone mineral density;Bone mineral density (spine);	chr12:53272411	chr12:53500162~53500936:-
HNSC	cis	rs28489187	0.683	rs233050	ENSG00000223653.4	RP11-131L23.1	3.52	0.000471	0.0493	0.22	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85372110	chr1:85276715~85448124:+
HNSC	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-3.52	0.000471	0.0493	-0.19	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
HNSC	cis	rs7429990	0.965	rs7430879	ENSG00000228638.1	FCF1P2	3.52	0.000471	0.0493	0.14	0.16	Educational attainment (years of education);	chr3:47997224	chr3:48290793~48291375:-
HNSC	cis	rs870825	0.929	rs72689272	ENSG00000254233.1	RP11-242J7.1	3.52	0.000472	0.0493	0.27	0.16	Blood protein levels;	chr4:184671361	chr4:184584093~184625030:-
HNSC	cis	rs870825	0.929	rs72689273	ENSG00000254233.1	RP11-242J7.1	3.52	0.000472	0.0493	0.27	0.16	Blood protein levels;	chr4:184671596	chr4:184584093~184625030:-
HNSC	cis	rs12047808	0.841	rs56253737	ENSG00000227141.2	RP11-545A16.3	-3.52	0.000472	0.0493	-0.24	-0.16	Multiple sclerosis (age of onset);	chr1:179373499	chr1:179586705~179589175:+
HNSC	cis	rs700651	0.753	rs10207232	ENSG00000222017.1	AC011997.1	3.52	0.000472	0.0493	0.2	0.16	Intracranial aneurysm;	chr2:198029089	chr2:197693106~197774823:+
HNSC	cis	rs3736485	0.966	rs11070854	ENSG00000274528.1	CTD-2650P22.2	3.52	0.000472	0.0493	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51516168	chr15:52017167~52018032:-
HNSC	cis	rs58873874	0.579	rs10040318	ENSG00000248544.2	CTB-47B11.3	3.52	0.000472	0.0493	0.29	0.16	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157375741~157384950:-
HNSC	cis	rs2645424	0.519	rs17154027	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000472	0.0493	-0.17	-0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856343	chr8:11797928~11802568:-
HNSC	cis	rs1155750	0.72	rs239810	ENSG00000224984.1	RP11-524H19.2	-3.52	0.000472	0.0493	-0.23	-0.16	Colorectal cancer;	chr6:54944304	chr6:54840118~54840855:-
HNSC	cis	rs7429990	0.864	rs11130144	ENSG00000228638.1	FCF1P2	3.52	0.000472	0.0493	0.14	0.16	Educational attainment (years of education);	chr3:47626444	chr3:48290793~48291375:-
HNSC	cis	rs3748656	0.945	rs10857964	ENSG00000273483.1	RP4-671G15.2	3.52	0.000472	0.0493	0.21	0.16	Hip circumference adjusted for BMI;	chr1:112555011	chr1:112517799~112518441:-
HNSC	cis	rs10789207	0.531	rs55817355	ENSG00000248458.2	RP4-598P13.1	-3.52	0.000472	0.0493	-0.24	-0.16	Resting heart rate;	chr1:66641431	chr1:66665864~66677027:-
HNSC	cis	rs9568867	1	rs1927861	ENSG00000273784.3	RP11-78J21.7	-3.52	0.000472	0.0493	-0.26	-0.16	Obesity;Body mass index;	chr13:53517624	chr13:52600042~52642542:+
HNSC	cis	rs2354432	0.607	rs4950385	ENSG00000274372.3	RP11-94I2.4	3.52	0.000472	0.0493	0.27	0.16	Mitochondrial DNA levels;	chr1:147184713	chr1:148021850~148025931:+
HNSC	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	3.52	0.000472	0.0493	0.23	0.16	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
HNSC	cis	rs2071303	0.502	rs9393686	ENSG00000272462.2	U91328.19	3.52	0.000472	0.0493	0.19	0.16	Intelligence (multi-trait analysis);	chr6:26106373	chr6:25992662~26001775:+
HNSC	cis	rs13178541	0.873	rs11749405	ENSG00000250378.1	RP11-119J18.1	-3.52	0.000472	0.0493	-0.22	-0.16	IgG glycosylation;	chr5:135804386	chr5:135812667~135826582:+
HNSC	cis	rs3805389	1	rs3805383	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000472	0.0493	-0.21	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55609171	chr4:55363971~55395847:-
HNSC	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-3.52	0.000472	0.0493	-0.23	-0.16	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
HNSC	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-3.52	0.000472	0.0493	-0.23	-0.16	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
HNSC	cis	rs11122895	0.716	rs3952774	ENSG00000278962.1	RP11-399B17.1	-3.52	0.000472	0.0493	-0.14	-0.16	Allergic sensitization;	chr2:111711830	chr2:112188364~112190635:+
HNSC	cis	rs11122895	0.716	rs7580929	ENSG00000278962.1	RP11-399B17.1	-3.52	0.000472	0.0493	-0.14	-0.16	Allergic sensitization;	chr2:111713904	chr2:112188364~112190635:+
HNSC	cis	rs6496044	0.568	rs2344436	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000472	0.0493	-0.17	-0.16	Interstitial lung disease;	chr15:85531675	chr15:85744109~85750281:-
HNSC	cis	rs6496044	0.568	rs6496065	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000472	0.0493	-0.17	-0.16	Interstitial lung disease;	chr15:85532141	chr15:85744109~85750281:-
HNSC	cis	rs6496044	0.568	rs6496066	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000472	0.0493	-0.17	-0.16	Interstitial lung disease;	chr15:85532231	chr15:85744109~85750281:-
HNSC	cis	rs4347184	1	rs4609402	ENSG00000248458.2	RP4-598P13.1	3.52	0.000472	0.0494	0.15	0.16	Schizophrenia;	chr1:65852945	chr1:66665864~66677027:-
HNSC	cis	rs721917	0.525	rs2758545	ENSG00000244733.5	RP11-506M13.3	-3.52	0.000473	0.0494	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79660891~79677996:+
HNSC	cis	rs35934224	0.891	rs73148965	ENSG00000281530.1	DGCR12	-3.52	0.000473	0.0494	-0.22	-0.16	Glaucoma (primary open-angle);	chr22:19885412	chr22:19061041~19061843:-
HNSC	cis	rs709400	0.93	rs57447494	ENSG00000270108.1	RP11-73M18.6	3.52	0.000473	0.0494	0.18	0.16	Body mass index;	chr14:103568232	chr14:103687576~103688127:+
HNSC	cis	rs4845875	0.626	rs11121827	ENSG00000242349.4	NPPA-AS1	3.52	0.000473	0.0494	0.16	0.16	Midregional pro atrial natriuretic peptide levels;	chr1:11772043	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.626	rs10779764	ENSG00000242349.4	NPPA-AS1	3.52	0.000473	0.0494	0.16	0.16	Midregional pro atrial natriuretic peptide levels;	chr1:11772254	chr1:11841017~11848079:+
HNSC	cis	rs7246657	0.722	rs3095726	ENSG00000276846.1	CTD-3220F14.3	-3.52	0.000473	0.0494	-0.24	-0.16	Coronary artery calcification;	chr19:37738923	chr19:37314868~37315620:-
HNSC	cis	rs12216125	0.554	rs6942196	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Iron status biomarkers;	chr6:26072576	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs1539183	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26074823	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs9295686	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26081755	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.532	rs9295687	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26082482	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs4529296	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26082907	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs1971509	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26085549	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.532	rs2006736	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26085789	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs1800702	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26086235	chr6:26013241~26013757:+
HNSC	cis	rs1865760	0.566	rs2794720	ENSG00000272810.1	U91328.22	-3.52	0.000473	0.0494	-0.15	-0.16	Height;	chr6:26086974	chr6:26013241~26013757:+
HNSC	cis	rs950169	0.881	rs150965	ENSG00000275120.1	RP11-182J1.17	3.52	0.000473	0.0494	0.22	0.16	Schizophrenia;	chr15:84537296	chr15:84599434~84606463:-
HNSC	cis	rs853679	0.769	rs17720293	ENSG00000204709.4	LINC01556	3.52	0.000473	0.0494	0.29	0.16	Depression;	chr6:28246920	chr6:28943877~28944537:+
HNSC	cis	rs8042680	0.688	rs2386584	ENSG00000213471.7	TTLL13P	-3.52	0.000473	0.0494	-0.2	-0.16	Type 2 diabetes;	chr15:90996342	chr15:90249530~90265482:+
HNSC	cis	rs67072384	1	rs12292781	ENSG00000245148.2	ARAP1-AS2	3.52	0.000473	0.0494	0.22	0.16	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72737340	chr11:72700474~72705607:+
HNSC	cis	rs73201462	1	rs2955097	ENSG00000231305.3	RP11-723O4.2	3.52	0.000473	0.0494	0.23	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259662	chr3:128861313~128871540:-
HNSC	cis	rs2307394	1	rs13029038	ENSG00000281469.1	RP11-567F11.1	3.52	0.000473	0.0494	0.18	0.16	Urate levels;	chr2:148029739	chr2:148044380~148044894:+
HNSC	cis	rs9911578	0.967	rs4598970	ENSG00000224738.1	AC099850.1	-3.52	0.000473	0.0494	-0.17	-0.16	Intelligence (multi-trait analysis);	chr17:58999532	chr17:59106598~59118267:+
HNSC	cis	rs3018712	0.532	rs2510399	ENSG00000255031.4	RP11-802E16.3	-3.52	0.000473	0.0494	-0.18	-0.16	Total body bone mineral density;	chr11:68653990	chr11:68050740~68053762:+
HNSC	cis	rs60733400	0.817	rs4648657	ENSG00000238164.5	RP3-395M20.8	3.52	0.000473	0.0494	0.12	0.16	Multiple sclerosis;	chr1:2629296	chr1:2549920~2557031:-
HNSC	cis	rs561341	1	rs113676348	ENSG00000278867.1	RP11-640N20.4	-3.52	0.000473	0.0494	-0.21	-0.16	Hip circumference adjusted for BMI;	chr17:31917308	chr17:32051030~32053208:+
HNSC	cis	rs4924935	1	rs1737947	ENSG00000264885.1	RP11-815I9.4	3.52	0.000473	0.0494	0.18	0.16	Pancreatic cancer;	chr17:18928119	chr17:18667629~18669461:-
HNSC	cis	rs9880211	0.606	rs28576629	ENSG00000273486.1	RP11-731C17.2	3.52	0.000473	0.0494	0.15	0.16	Height;Body mass index;	chr3:136054819	chr3:136837338~136839021:-
HNSC	cis	rs9652601	0.748	rs12917893	ENSG00000274038.1	RP11-66H6.4	-3.52	0.000473	0.0494	-0.2	-0.16	Systemic lupus erythematosus;	chr16:11146121	chr16:11056556~11057034:+
HNSC	cis	rs2439831	0.681	rs2278859	ENSG00000275601.1	AC011330.13	-3.52	0.000473	0.0494	-0.23	-0.16	Lung cancer in ever smokers;	chr15:43340762	chr15:43642389~43643023:-
HNSC	cis	rs2439831	0.681	rs7168940	ENSG00000275601.1	AC011330.13	-3.52	0.000473	0.0494	-0.23	-0.16	Lung cancer in ever smokers;	chr15:43341136	chr15:43642389~43643023:-
HNSC	cis	rs6558174	0.93	rs12676084	ENSG00000253986.1	CTC-756D1.3	-3.52	0.000473	0.0494	-0.18	-0.16	Breast cancer;	chr8:22635837	chr8:23493009~23494198:-
HNSC	cis	rs17407555	0.657	rs4698001	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000473	0.0494	-0.22	-0.16	Schizophrenia (age at onset);	chr4:10277789	chr4:10006482~10009725:+
HNSC	cis	rs7246657	0.722	rs1564206	ENSG00000276846.1	CTD-3220F14.3	3.52	0.000473	0.0494	0.22	0.16	Coronary artery calcification;	chr19:37549174	chr19:37314868~37315620:-
HNSC	cis	rs4704187	0.617	rs6898134	ENSG00000272040.1	CTC-366B18.4	-3.52	0.000473	0.0494	-0.15	-0.16	Response to amphetamines;	chr5:75160906	chr5:75608817~75609983:+
HNSC	cis	rs5758659	0.594	rs739292	ENSG00000270083.1	RP1-257I20.14	3.52	0.000473	0.0494	0.15	0.16	Cognitive function;	chr22:41972853	chr22:42089630~42090028:-
HNSC	cis	rs1411478	1	rs3747957	ENSG00000243155.1	RP11-46A10.5	3.52	0.000473	0.0494	0.17	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984717	chr1:180944042~180976482:-
HNSC	cis	rs1411478	1	rs4652547	ENSG00000243155.1	RP11-46A10.5	3.52	0.000473	0.0494	0.17	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984953	chr1:180944042~180976482:-
HNSC	cis	rs1411478	1	rs4652548	ENSG00000243155.1	RP11-46A10.5	3.52	0.000473	0.0494	0.17	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984994	chr1:180944042~180976482:-
HNSC	cis	rs853679	0.607	rs66886492	ENSG00000226314.6	ZNF192P1	-3.52	0.000473	0.0494	-0.31	-0.16	Depression;	chr6:28121953	chr6:28161781~28169594:+
HNSC	cis	rs853679	0.607	rs35345226	ENSG00000226314.6	ZNF192P1	-3.52	0.000473	0.0494	-0.31	-0.16	Depression;	chr6:28123802	chr6:28161781~28169594:+
HNSC	cis	rs8023445	0.607	rs9302146	ENSG00000259216.2	RP11-227D13.2	-3.52	0.000473	0.0494	-0.24	-0.16	Major depressive disorder;	chr15:48901678	chr15:48725338~48725827:+
HNSC	cis	rs16958440	0.867	rs78854354	ENSG00000267724.1	RP11-49K24.8	3.52	0.000473	0.0494	0.31	0.16	Sitting height ratio;	chr18:47140553	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs79078752	ENSG00000267724.1	RP11-49K24.8	3.52	0.000473	0.0494	0.31	0.16	Sitting height ratio;	chr18:47141091	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs61689863	ENSG00000267724.1	RP11-49K24.8	3.52	0.000473	0.0494	0.31	0.16	Sitting height ratio;	chr18:47142786	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs80064497	ENSG00000267724.1	RP11-49K24.8	3.52	0.000473	0.0494	0.31	0.16	Sitting height ratio;	chr18:47143282	chr18:47105946~47108062:+
HNSC	cis	rs16958440	0.867	rs78547658	ENSG00000267724.1	RP11-49K24.8	3.52	0.000473	0.0494	0.31	0.16	Sitting height ratio;	chr18:47143481	chr18:47105946~47108062:+
HNSC	cis	rs3105593	0.545	rs3131605	ENSG00000244879.4	GABPB1-AS1	3.52	0.000474	0.0494	0.14	0.16	QT interval;	chr15:50519979	chr15:50354959~50372202:+
HNSC	cis	rs3929778	0.848	rs35625351	ENSG00000275632.1	RP5-967N21.11	3.52	0.000474	0.0494	0.16	0.16	QRS complex (Cornell);	chr20:6525903	chr20:6000418~6000941:+
HNSC	cis	rs2016266	0.896	rs3741663	ENSG00000270175.1	RP11-793H13.11	-3.52	0.000474	0.0494	-0.15	-0.16	Bone mineral density;Bone mineral density (spine);	chr12:53270231	chr12:53500162~53500936:-
HNSC	cis	rs4948102	0.924	rs13240915	ENSG00000226278.1	PSPHP1	-3.52	0.000474	0.0494	-0.18	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56023059	chr7:55764797~55773288:+
HNSC	cis	rs7914558	0.966	rs2065977	ENSG00000236937.2	PTGES3P4	3.52	0.000474	0.0494	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102845595~102845950:+
HNSC	cis	rs7914558	0.933	rs1538204	ENSG00000236937.2	PTGES3P4	3.52	0.000474	0.0494	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102845595~102845950:+
HNSC	cis	rs7824557	0.564	rs35009431	ENSG00000255495.1	AC145124.2	-3.52	0.000474	0.0494	-0.18	-0.16	Retinal vascular caliber;	chr8:11375279	chr8:12194467~12196280:+
HNSC	cis	rs6997458	0.742	rs10095352	ENSG00000253549.4	RP11-317J10.2	3.52	0.000474	0.0494	0.18	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85460203	chr8:85441851~85464915:-
HNSC	cis	rs6997458	0.742	rs3758077	ENSG00000253549.4	RP11-317J10.2	3.52	0.000474	0.0494	0.18	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463274	chr8:85441851~85464915:-
HNSC	cis	rs889398	0.967	rs12599391	ENSG00000196696.11	PDXDC2P	-3.52	0.000474	0.0494	-0.11	-0.16	Body mass index;	chr16:69571446	chr16:69976297~70065948:-
HNSC	cis	rs9813712	0.595	rs1993217	ENSG00000253540.4	FAM86HP	-3.52	0.000474	0.0494	-0.15	-0.16	Response to amphetamines;	chr3:130284832	chr3:130099092~130111472:-
HNSC	cis	rs6710503	0.59	rs7945	ENSG00000271936.1	RP11-443B20.1	-3.52	0.000474	0.0494	-0.2	-0.16	Lung cancer in ever smokers;Breast cancer;	chr2:24819753	chr2:24825610~24826717:+
HNSC	cis	rs67478160	0.679	rs8011109	ENSG00000269940.1	RP11-73M18.7	3.52	0.000474	0.0494	0.15	0.16	Schizophrenia;	chr14:103813637	chr14:103694560~103695170:+
HNSC	cis	rs67478160	0.655	rs4900598	ENSG00000269940.1	RP11-73M18.7	3.52	0.000474	0.0494	0.15	0.16	Schizophrenia;	chr14:103815204	chr14:103694560~103695170:+
HNSC	cis	rs67478160	0.619	rs8018062	ENSG00000269940.1	RP11-73M18.7	3.52	0.000474	0.0494	0.15	0.16	Schizophrenia;	chr14:103815617	chr14:103694560~103695170:+
HNSC	cis	rs6832769	0.767	rs6850524	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000474	0.0495	0.18	0.16	Personality dimensions;	chr4:55515830	chr4:55363971~55395847:-
HNSC	cis	rs2286503	0.65	rs1990279	ENSG00000230042.1	AK3P3	3.52	0.000474	0.0495	0.18	0.16	Fibrinogen;	chr7:22851123	chr7:23129178~23129841:+
HNSC	cis	rs6107845	0.645	rs1407035	ENSG00000275632.1	RP5-967N21.11	-3.52	0.000474	0.0495	-0.13	-0.16	Vertical cup-disc ratio;	chr20:6567190	chr20:6000418~6000941:+
HNSC	cis	rs6107845	0.667	rs1321443	ENSG00000275632.1	RP5-967N21.11	-3.52	0.000474	0.0495	-0.13	-0.16	Vertical cup-disc ratio;	chr20:6568216	chr20:6000418~6000941:+
HNSC	cis	rs4704846	0.66	rs72805202	ENSG00000253519.1	AC106801.1	3.52	0.000474	0.0495	0.27	0.16	Blood protein levels;	chr5:157126379	chr5:157565964~157569098:+
HNSC	cis	rs3806843	0.576	rs251370	ENSG00000202515.1	VTRNA1-3	3.52	0.000474	0.0495	0.17	0.16	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr5:140726158~140726246:+
HNSC	cis	rs10788575	0.568	rs11202622	ENSG00000271573.1	RP11-96C23.12	3.52	0.000474	0.0495	0.16	0.16	Type 2 diabetes;	chr10:88005180	chr10:87027184~87027477:+
HNSC	cis	rs228769	0.653	rs2523162	ENSG00000267080.4	ASB16-AS1	3.52	0.000474	0.0495	0.15	0.16	Bone mineral density (hip);Bone mineral density (spine);	chr17:44101913	chr17:44175973~44186717:-
HNSC	cis	rs4704187	0.687	rs9293643	ENSG00000272040.1	CTC-366B18.4	3.52	0.000474	0.0495	0.15	0.16	Response to amphetamines;	chr5:75069228	chr5:75608817~75609983:+
HNSC	cis	rs6988985	0.765	rs62525057	ENSG00000247317.3	RP11-273G15.2	-3.52	0.000474	0.0495	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142894607	chr8:142981738~143018437:-
HNSC	cis	rs6012564	1	rs2273653	ENSG00000227431.4	CSE1L-AS1	3.52	0.000474	0.0495	0.19	0.16	Anger;	chr20:49154219	chr20:49040463~49046044:-
HNSC	cis	rs2403083	0.556	rs4150884	ENSG00000253549.4	RP11-317J10.2	3.52	0.000474	0.0495	0.19	0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85189544	chr8:85441851~85464915:-
HNSC	cis	rs875971	0.964	rs778735	ENSG00000272831.1	RP11-792A8.4	3.52	0.000474	0.0495	0.14	0.16	Aortic root size;	chr7:66349822	chr7:66739829~66740385:-
HNSC	cis	rs6601327	0.602	rs7829463	ENSG00000254340.1	RP11-10A14.3	-3.52	0.000474	0.0495	-0.2	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9792181	chr8:9141424~9145435:+
HNSC	cis	rs7412746	0.658	rs11589458	ENSG00000236713.1	RP11-363I22.3	-3.52	0.000474	0.0495	-0.18	-0.16	Melanoma;	chr1:150820140	chr1:150780272~150780644:+
HNSC	cis	rs9505118	1	rs9505123	ENSG00000238221.1	RP11-69L16.4	3.52	0.000474	0.0495	0.2	0.16	Type 2 diabetes;	chr6:7291533	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs7452992	ENSG00000238221.1	RP11-69L16.4	3.52	0.000474	0.0495	0.2	0.16	Type 2 diabetes;	chr6:7291908	chr6:7276031~7298872:+
HNSC	cis	rs9505118	1	rs9505125	ENSG00000238221.1	RP11-69L16.4	3.52	0.000474	0.0495	0.2	0.16	Type 2 diabetes;	chr6:7292019	chr6:7276031~7298872:+
HNSC	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-3.52	0.000474	0.0495	-0.21	-0.16	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
HNSC	cis	rs2377058	0.882	rs11646741	ENSG00000274627.1	RP11-104N10.2	-3.52	0.000474	0.0495	-0.16	-0.16	Hip circumference adjusted for BMI;	chr16:89663676	chr16:89516797~89522217:+
HNSC	cis	rs2377058	0.803	rs13332439	ENSG00000274627.1	RP11-104N10.2	-3.52	0.000474	0.0495	-0.16	-0.16	Hip circumference adjusted for BMI;	chr16:89664071	chr16:89516797~89522217:+
HNSC	cis	rs2657294	0.674	rs10824268	ENSG00000233313.2	HMGA1P5	-3.52	0.000474	0.0495	-0.18	-0.16	Pneumonia;	chr10:75085937	chr10:75276376~75276646:-
HNSC	cis	rs12541595	0.754	rs3935882	ENSG00000255491.1	RP11-1082L8.4	-3.52	0.000474	0.0495	-0.2	-0.16	Left ventricle diastolic internal dimension;	chr8:124886015	chr8:124811618~124815682:-
HNSC	cis	rs7208859	0.673	rs1347359	ENSG00000263603.1	CTD-2349P21.5	-3.52	0.000474	0.0495	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30729469~30731202:+
HNSC	cis	rs2836974	0.568	rs2836969	ENSG00000255568.3	BRWD1-AS2	-3.52	0.000474	0.0495	-0.14	-0.16	Cognitive function;	chr21:39276339	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.584	rs6517535	ENSG00000255568.3	BRWD1-AS2	-3.52	0.000474	0.0495	-0.14	-0.16	Cognitive function;	chr21:39281426	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.627	rs7278985	ENSG00000255568.3	BRWD1-AS2	-3.52	0.000474	0.0495	-0.14	-0.16	Cognitive function;	chr21:39281841	chr21:39313935~39314962:+
HNSC	cis	rs67340775	0.541	rs200979	ENSG00000241549.7	GUSBP2	3.52	0.000474	0.0495	0.21	0.16	Lung cancer in ever smokers;	chr6:27884579	chr6:26871484~26956554:-
HNSC	cis	rs17373728	0.71	rs2221810	ENSG00000249395.2	CASC9	3.52	0.000474	0.0495	0.22	0.16	Diabetic kidney disease;	chr8:75309233	chr8:75223404~75324741:-
HNSC	cis	rs526231	0.575	rs62362523	ENSG00000250682.4	LINC00491	3.52	0.000475	0.0495	0.21	0.16	Primary biliary cholangitis;	chr5:102977979	chr5:102609156~102671559:-
HNSC	cis	rs2857078	0.654	rs4793083	ENSG00000267691.1	SHC1P2	3.52	0.000475	0.0495	0.19	0.16	Red cell distribution width;Reticulocyte count;	chr17:44235605	chr17:44228760~44230228:-
HNSC	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	3.52	0.000475	0.0495	0.32	0.16	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	3.52	0.000475	0.0495	0.32	0.16	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	3.52	0.000475	0.0495	0.32	0.16	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
HNSC	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	3.52	0.000475	0.0495	0.32	0.16	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
HNSC	cis	rs782107	0.541	rs11172597	ENSG00000270039.1	RP11-571M6.17	-3.52	0.000475	0.0495	-0.2	-0.16	Interleukin-12p70 levels;	chr12:58420499	chr12:57803838~57804415:+
HNSC	cis	rs3849811	0.504	rs6473685	ENSG00000253844.1	RP11-546K22.1	-3.52	0.000475	0.0495	-0.26	-0.16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr8:52093743	chr8:51961458~52022974:+
HNSC	cis	rs9303542	0.55	rs7211636	ENSG00000272763.1	RP11-357H14.17	3.52	0.000475	0.0495	0.2	0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48435326	chr17:48635923~48647023:-
HNSC	cis	rs1580019	0.961	rs2392056	ENSG00000229358.3	DPY19L1P1	-3.52	0.000475	0.0495	-0.18	-0.16	Cognitive ability;	chr7:32459341	chr7:32580949~32761787:-
HNSC	cis	rs7927592	0.956	rs10896334	ENSG00000239559.2	RPL37P2	3.52	0.000475	0.0495	0.16	0.16	Total body bone mineral density;	chr11:68514026	chr11:67682772~67683058:-
HNSC	cis	rs7927592	0.956	rs11228269	ENSG00000239559.2	RPL37P2	3.52	0.000475	0.0495	0.16	0.16	Total body bone mineral density;	chr11:68522328	chr11:67682772~67683058:-
HNSC	cis	rs7927592	0.956	rs7106259	ENSG00000239559.2	RPL37P2	3.52	0.000475	0.0495	0.16	0.16	Total body bone mineral density;	chr11:68531044	chr11:67682772~67683058:-
HNSC	cis	rs8062405	1	rs62036616	ENSG00000261089.1	RP11-435I10.3	3.52	0.000475	0.0495	0.18	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28413703~28415018:+
HNSC	cis	rs11509153	0.5	rs4721055	ENSG00000226690.5	AC005281.1	3.52	0.000475	0.0495	0.17	0.16	Residual cognition;	chr7:12202737	chr7:12496429~12541910:+
HNSC	cis	rs9611565	0.512	rs9607841	ENSG00000235513.1	RP4-756G23.5	3.52	0.000475	0.0495	0.2	0.16	Vitiligo;	chr22:41790834	chr22:41209122~41217627:-
HNSC	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000475	0.0495	-0.22	-0.16	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
HNSC	cis	rs11098499	0.588	rs2389874	ENSG00000250412.1	KLHL2P1	-3.52	0.000475	0.0495	-0.2	-0.16	Corneal astigmatism;	chr4:119633836	chr4:119334329~119378233:+
HNSC	cis	rs6570726	0.764	rs9403731	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.818	rs9390338	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6570693	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6570694	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs6570695	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.764	rs9386125	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145735570~145737218:+
HNSC	cis	rs6570726	0.791	rs9373466	ENSG00000270638.1	RP3-466P17.1	3.52	0.000475	0.0495	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145735570~145737218:+
HNSC	cis	rs950169	1	rs12902672	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000475	0.0495	-0.17	-0.16	Schizophrenia;	chr15:84048234	chr15:84507885~84516814:-
HNSC	cis	rs7648466	0.592	rs4683184	ENSG00000223552.1	RP11-24F11.2	3.52	0.000475	0.0495	0.14	0.16	Eotaxin levels;	chr3:46146215	chr3:46364955~46407059:-
HNSC	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000475	0.0495	-0.23	-0.16	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
HNSC	cis	rs8072100	1	rs8072100	ENSG00000263293.2	RP11-290H9.4	-3.52	0.000475	0.0495	-0.17	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47303460~47323613:-
HNSC	cis	rs7725337	0.899	rs1427970	ENSG00000247828.6	TMEM161B-AS1	-3.52	0.000475	0.0495	-0.15	-0.16	Total body bone mineral density;	chr5:88984608	chr5:88268895~88436685:+
HNSC	cis	rs11672691	0.519	rs10407939	ENSG00000269843.1	CTC-490E21.10	3.52	0.000475	0.0495	0.21	0.16	Prostate cancer;	chr19:41502561	chr19:40831221~40837210:-
HNSC	cis	rs6001482	0.679	rs5757568	ENSG00000253818.1	IGLV1-41	-3.52	0.000475	0.0495	-0.13	-0.16	Diastolic blood pressure;	chr22:22229175	chr22:22404207~22404721:+
HNSC	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	3.52	0.000475	0.0496	0.19	0.16	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
HNSC	cis	rs13179617	0.928	rs13160801	ENSG00000215032.2	GNL3LP1	-3.52	0.000475	0.0496	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61475861	chr5:60891935~60893577:-
HNSC	cis	rs786425	0.966	rs3748269	ENSG00000278112.1	RP11-972P1.11	3.52	0.000475	0.0496	0.16	0.16	Pubertal anthropometrics;	chr12:123615378	chr12:123519390~123519856:-
HNSC	cis	rs7011507	0.535	rs970214	ENSG00000253608.1	RP11-770E5.1	-3.52	0.000475	0.0496	-0.25	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48534838	chr8:48551567~48698510:+
HNSC	cis	rs67311347	0.544	rs7652439	ENSG00000280739.1	EIF1B-AS1	3.52	0.000475	0.0496	0.19	0.16	Renal cell carcinoma;	chr3:40308457	chr3:40173145~40309698:-
HNSC	cis	rs2337406	0.925	rs2011167	ENSG00000211972.2	IGHV3-66	3.52	0.000475	0.0496	0.17	0.16	Alzheimer's disease (late onset);	chr14:106680831	chr14:106675017~106675544:-
HNSC	cis	rs57561814	1	rs6949149	ENSG00000179428.2	AC073072.5	-3.52	0.000475	0.0496	-0.31	-0.16	Tonsillectomy;	chr7:22709538	chr7:22725395~22727620:-
HNSC	cis	rs868153	0.523	rs1456698	ENSG00000275339.1	RP3-425C14.6	3.52	0.000475	0.0496	0.17	0.16	Vertical cup-disc ratio;	chr6:122172618	chr6:122454358~122454612:+
HNSC	cis	rs62185668	0.693	rs6077967	ENSG00000230750.1	SDAD1P2	-3.52	0.000475	0.0496	-0.22	-0.16	Urinary bladder cancer;	chr20:10939126	chr20:10385779~10387806:+
HNSC	cis	rs1155750	0.72	rs2746440	ENSG00000224984.1	RP11-524H19.2	-3.52	0.000476	0.0496	-0.23	-0.16	Colorectal cancer;	chr6:54927438	chr6:54840118~54840855:-
HNSC	cis	rs7211079	0.843	rs73438138	ENSG00000275479.1	RP11-334C17.6	3.52	0.000476	0.0496	0.19	0.16	Myocardial infarction;	chr17:80148608	chr17:80149627~80149798:+
HNSC	cis	rs9889296	0.621	rs3091330	ENSG00000267457.1	RP5-837J1.4	-3.52	0.000476	0.0496	-0.16	-0.16	Inflammatory bowel disease;	chr17:34276488	chr17:35073831~35074374:-
HNSC	cis	rs6787172	0.667	rs2885663	ENSG00000272087.1	RP11-379F4.7	3.52	0.000476	0.0496	0.17	0.16	Subjective well-being;	chr3:158466474	chr3:158693120~158693768:-
HNSC	cis	rs453301	0.571	rs2929452	ENSG00000253981.4	ALG1L13P	-3.52	0.000476	0.0496	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9226955	chr8:8236003~8244667:-
HNSC	cis	rs9923283	0.932	rs1364184	ENSG00000260517.2	RP11-426C22.5	3.52	0.000476	0.0496	0.23	0.16	Plateletcrit;	chr16:29644889	chr16:29116127~29217860:+
HNSC	cis	rs546131	0.642	rs568529	ENSG00000271369.1	RP11-350D17.3	3.52	0.000476	0.0496	0.2	0.16	Lung disease severity in cystic fibrosis;	chr11:34820959	chr11:34709600~34710161:+
HNSC	cis	rs6496044	0.548	rs7163032	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000476	0.0496	-0.17	-0.16	Interstitial lung disease;	chr15:85529188	chr15:85744109~85750281:-
HNSC	cis	rs6496044	0.527	rs7163068	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000476	0.0496	-0.17	-0.16	Interstitial lung disease;	chr15:85529235	chr15:85744109~85750281:-
HNSC	cis	rs6496044	0.568	rs10468112	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000476	0.0496	-0.17	-0.16	Interstitial lung disease;	chr15:85530193	chr15:85744109~85750281:-
HNSC	cis	rs36093844	0.527	rs4944554	ENSG00000279742.1	RP11-700A24.1	-3.52	0.000476	0.0496	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86046850	chr11:85852557~85854943:-
HNSC	cis	rs1620921	0.711	rs2802354	ENSG00000231863.1	RP3-428L16.1	-3.52	0.000476	0.0496	-0.19	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:160824720	chr6:160931080~160969771:+
HNSC	cis	rs734999	0.588	rs2764842	ENSG00000238164.5	RP3-395M20.8	3.52	0.000476	0.0496	0.12	0.16	Ulcerative colitis;	chr1:2597753	chr1:2549920~2557031:-
HNSC	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-3.52	0.000476	0.0496	-0.17	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
HNSC	cis	rs35740288	0.822	rs17574774	ENSG00000259407.1	RP11-158M2.3	3.52	0.000476	0.0496	0.22	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85744109~85750281:-
HNSC	cis	rs1028883	0.615	rs9592925	ENSG00000228295.1	LINC00392	-3.52	0.000476	0.0496	-0.17	-0.16	Lean body mass;	chr13:73595125	chr13:73564244~73588070:+
HNSC	cis	rs853679	0.527	rs1997660	ENSG00000217862.2	HIST1H4PS1	-3.52	0.000476	0.0496	-0.17	-0.16	Depression;	chr6:28301886	chr6:27807075~27807339:+
HNSC	cis	rs3857747	0.557	rs11770113	ENSG00000228554.1	AC004837.5	3.52	0.000476	0.0497	0.16	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40344895	chr7:39700341~39703296:-
HNSC	cis	rs10519937	0.866	rs61175766	ENSG00000230929.5	RP11-395C3.1	-3.52	0.000476	0.0497	-0.23	-0.16	IgG glycosylation;	chr5:127464636	chr5:126628019~126628319:-
HNSC	cis	rs9402743	0.634	rs7767072	ENSG00000231028.7	LINC00271	-3.52	0.000477	0.0497	-0.19	-0.16	Systemic lupus erythematosus;	chr6:135593899	chr6:135497801~135716055:+
HNSC	cis	rs2436845	0.627	rs2436861	ENSG00000253320.4	KB-1507C5.2	-3.52	0.000477	0.0497	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102812625	chr8:102864300~102977876:+
HNSC	cis	rs2436845	0.603	rs2513923	ENSG00000253320.4	KB-1507C5.2	-3.52	0.000477	0.0497	-0.18	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813207	chr8:102864300~102977876:+
HNSC	cis	rs8077577	0.671	rs6502641	ENSG00000273018.4	CTD-2303H24.2	3.52	0.000477	0.0497	0.23	0.16	Obesity-related traits;	chr17:18229665	chr17:18511221~18551705:-
HNSC	cis	rs8023445	0.607	rs4775785	ENSG00000259216.2	RP11-227D13.2	3.52	0.000477	0.0497	0.23	0.16	Major depressive disorder;	chr15:48900129	chr15:48725338~48725827:+
HNSC	cis	rs7720894	0.967	rs7701440	ENSG00000215032.2	GNL3LP1	-3.52	0.000477	0.0497	-0.18	-0.16	Body mass index;	chr5:61325153	chr5:60891935~60893577:-
HNSC	cis	rs853679	0.657	rs1778483	ENSG00000217862.2	HIST1H4PS1	-3.52	0.000477	0.0497	-0.17	-0.16	Depression;	chr6:28273214	chr6:27807075~27807339:+
HNSC	cis	rs853679	0.657	rs1778482	ENSG00000217862.2	HIST1H4PS1	-3.52	0.000477	0.0497	-0.17	-0.16	Depression;	chr6:28273215	chr6:27807075~27807339:+
HNSC	cis	rs4937076	0.69	rs635798	ENSG00000254967.5	RP11-680F20.6	-3.52	0.000477	0.0497	-0.18	-0.16	Primary tooth development (time to first tooth eruption);	chr11:125948402	chr11:125950116~125956319:+
HNSC	cis	rs73201462	1	rs2811544	ENSG00000231305.3	RP11-723O4.2	3.52	0.000477	0.0497	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264652	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811543	ENSG00000231305.3	RP11-723O4.2	3.52	0.000477	0.0497	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264953	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811542	ENSG00000231305.3	RP11-723O4.2	3.52	0.000477	0.0497	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264957	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811540	ENSG00000231305.3	RP11-723O4.2	3.52	0.000477	0.0497	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128266726	chr3:128861313~128871540:-
HNSC	cis	rs73201462	1	rs2811538	ENSG00000231305.3	RP11-723O4.2	3.52	0.000477	0.0497	0.22	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128267788	chr3:128861313~128871540:-
HNSC	cis	rs73198271	1	rs11775476	ENSG00000173295.6	FAM86B3P	-3.52	0.000477	0.0497	-0.22	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8228595~8244865:+
HNSC	cis	rs2115630	1	rs11854313	ENSG00000259295.5	CSPG4P12	-3.52	0.000477	0.0497	-0.18	-0.16	P wave terminal force;	chr15:84760817	chr15:85191438~85213905:+
HNSC	cis	rs7520050	0.966	rs1707336	ENSG00000280836.1	AL355480.1	3.52	0.000477	0.0497	0.16	0.16	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45581219~45581321:-
HNSC	cis	rs73222236	0.787	rs6806795	ENSG00000239213.4	NCK1-AS1	3.52	0.000477	0.0497	0.14	0.16	Coronary artery disease;	chr3:136587297	chr3:136841726~136862054:-
HNSC	cis	rs3018712	0.59	rs6591350	ENSG00000255031.4	RP11-802E16.3	-3.52	0.000477	0.0497	-0.14	-0.16	Total body bone mineral density;	chr11:68701202	chr11:68050740~68053762:+
HNSC	cis	rs8030379	1	rs2061999	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000477	0.0497	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs3934135	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000477	0.0497	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84507885~84516814:-
HNSC	cis	rs8030379	1	rs2030838	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000477	0.0497	-0.16	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84507885~84516814:-
HNSC	cis	rs3736485	0.966	rs4775960	ENSG00000259438.1	CTD-2650P22.1	3.52	0.000477	0.0497	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51599501	chr15:52010999~52019095:-
HNSC	cis	rs2351088	0.52	rs9626448	ENSG00000231711.2	LINC00899	3.52	0.000477	0.0497	0.23	0.16	Tonsillectomy;	chr22:45802756	chr22:46039907~46044853:-
HNSC	cis	rs2307394	0.749	rs12474024	ENSG00000281469.1	RP11-567F11.1	-3.52	0.000477	0.0497	-0.19	-0.16	Urate levels;	chr2:147703431	chr2:148044380~148044894:+
HNSC	cis	rs2307394	1	rs13003171	ENSG00000281469.1	RP11-567F11.1	3.52	0.000477	0.0497	0.18	0.16	Urate levels;	chr2:147991008	chr2:148044380~148044894:+
HNSC	cis	rs2307394	1	rs12463554	ENSG00000281469.1	RP11-567F11.1	3.52	0.000477	0.0497	0.18	0.16	Urate levels;	chr2:147994043	chr2:148044380~148044894:+
HNSC	cis	rs3736485	0.578	rs4775968	ENSG00000274528.1	CTD-2650P22.2	-3.52	0.000477	0.0497	-0.16	-0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51688624	chr15:52017167~52018032:-
HNSC	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	3.52	0.000477	0.0497	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
HNSC	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	3.52	0.000477	0.0497	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
HNSC	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	3.52	0.000477	0.0497	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
HNSC	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	3.52	0.000477	0.0497	0.16	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
HNSC	cis	rs7107174	1	rs1399196	ENSG00000251323.2	RP11-452H21.4	3.52	0.000477	0.0497	0.23	0.16	Testicular germ cell tumor;	chr11:78360830	chr11:78423982~78429836:-
HNSC	cis	rs1807837	0.585	rs6692353	ENSG00000203307.2	RP11-375H19.2	3.52	0.000477	0.0497	0.23	0.16	Pursuit maintenance gain;	chr1:165293237	chr1:166081183~166087483:+
HNSC	cis	rs2985334	0.796	rs150082	ENSG00000270605.1	RP5-1092A3.4	3.52	0.000477	0.0497	0.14	0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:28917939	chr1:28239509~28241453:-
HNSC	cis	rs56322409	0.686	rs1409709	ENSG00000226688.5	ENTPD1-AS1	3.52	0.000477	0.0497	0.14	0.16	Blood metabolite levels;	chr10:95612802	chr10:95753206~96090238:-
HNSC	cis	rs7726839	0.561	rs56410216	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000477	0.0497	0.23	0.16	Obesity-related traits;	chr5:583101	chr5:473236~480884:+
HNSC	cis	rs7726839	0.561	rs4957048	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000477	0.0497	0.23	0.16	Obesity-related traits;	chr5:583327	chr5:473236~480884:+
HNSC	cis	rs7726839	0.561	rs72703058	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000477	0.0497	0.23	0.16	Obesity-related traits;	chr5:584404	chr5:473236~480884:+
HNSC	cis	rs73201462	1	rs34409786	ENSG00000231305.3	RP11-723O4.2	-3.52	0.000477	0.0497	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128169332	chr3:128861313~128871540:-
HNSC	cis	rs72799341	1	rs35675346	ENSG00000279196.1	RP11-1072A3.3	3.52	0.000477	0.0497	0.21	0.16	Diastolic blood pressure;	chr16:30924760	chr16:30984630~30988270:-
HNSC	cis	rs783540	0.967	rs1259183	ENSG00000237550.5	UBE2Q2P6	-3.52	0.000477	0.0497	-0.19	-0.16	Schizophrenia;	chr15:82610683	chr15:82372196~82372912:-
HNSC	cis	rs17767294	1	rs17767294	ENSG00000219392.1	RP1-265C24.5	-3.52	0.000477	0.0497	-0.34	-0.16	Parkinson's disease;	chr6:28086420	chr6:28115628~28116551:+
HNSC	cis	rs61160187	0.582	rs7713481	ENSG00000251279.1	CTC-436P18.1	-3.52	0.000477	0.0497	-0.18	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:61162070~61232040:+
HNSC	cis	rs61160187	0.582	rs7737276	ENSG00000251279.1	CTC-436P18.1	-3.52	0.000477	0.0497	-0.18	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:61162070~61232040:+
HNSC	cis	rs10864907	0.614	rs10199311	ENSG00000146556.13	WASH2P	3.52	0.000477	0.0497	0.11	0.16	Pulmonary function;	chr2:112940384	chr2:113588550~113599043:+
HNSC	cis	rs372883	0.648	rs1153291	ENSG00000273464.1	RP11-313P22.1	-3.52	0.000477	0.0497	-0.19	-0.16	Pancreatic cancer;	chr21:29316749	chr21:29657406~29657831:+
HNSC	cis	rs875971	0.54	rs781152	ENSG00000234585.5	CCT6P3	3.52	0.000478	0.0497	0.14	0.16	Aortic root size;	chr7:66014585	chr7:65038354~65074713:+
HNSC	cis	rs17711722	0.727	rs781151	ENSG00000234585.5	CCT6P3	3.52	0.000478	0.0497	0.14	0.16	Calcium levels;	chr7:66014891	chr7:65038354~65074713:+
HNSC	cis	rs62025270	0.688	rs55738258	ENSG00000259416.2	RP11-158M2.5	-3.52	0.000478	0.0497	-0.19	-0.16	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85754941~85756237:-
HNSC	cis	rs225675	0.729	rs225620	ENSG00000229017.5	LINC01277	-3.52	0.000478	0.0497	-0.2	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:142143751	chr6:142966421~143038077:-
HNSC	cis	rs34754277	0.636	rs3767809	ENSG00000228217.1	AL390877.1	3.52	0.000478	0.0498	0.23	0.16	Immature fraction of reticulocytes;	chr1:117612209	chr1:117778087~117778506:-
HNSC	cis	rs34754277	0.636	rs3767810	ENSG00000228217.1	AL390877.1	3.52	0.000478	0.0498	0.23	0.16	Immature fraction of reticulocytes;	chr1:117612316	chr1:117778087~117778506:-
HNSC	cis	rs4704187	0.687	rs10462513	ENSG00000272040.1	CTC-366B18.4	-3.52	0.000478	0.0498	-0.15	-0.16	Response to amphetamines;	chr5:75126782	chr5:75608817~75609983:+
HNSC	cis	rs948562	0.69	rs75365860	ENSG00000280010.1	AP001350.4	3.52	0.000478	0.0498	0.26	0.16	Lymphoma;	chr11:58402023	chr11:58627435~58628528:+
HNSC	cis	rs1862618	0.671	rs2255726	ENSG00000265665.1	AC008391.1	-3.52	0.000478	0.0498	-0.21	-0.16	Initial pursuit acceleration;	chr5:56947301	chr5:56457038~56457138:-
HNSC	cis	rs2836974	0.932	rs6517523	ENSG00000255568.3	BRWD1-AS2	3.52	0.000478	0.0498	0.15	0.16	Cognitive function;	chr21:39185406	chr21:39313935~39314962:+
HNSC	cis	rs2836974	0.932	rs13048178	ENSG00000255568.3	BRWD1-AS2	3.52	0.000478	0.0498	0.15	0.16	Cognitive function;	chr21:39189086	chr21:39313935~39314962:+
HNSC	cis	rs2625529	0.652	rs2415128	ENSG00000260037.4	CTD-2524L6.3	3.52	0.000478	0.0498	0.21	0.16	Red blood cell count;	chr15:71898732	chr15:71818396~71823384:+
HNSC	cis	rs3213473	0.5	rs11862458	ENSG00000262171.1	CTA-972D3.2	-3.52	0.000478	0.0498	-0.21	-0.16	IgG glycosylation;	chr16:16166796	chr16:15885029~15886158:+
HNSC	cis	rs7911264	0.905	rs7918084	ENSG00000232709.1	MARK2P9	-3.52	0.000478	0.0498	-0.18	-0.16	Inflammatory bowel disease;	chr10:92669710	chr10:92418667~92420875:+
HNSC	cis	rs7429990	0.864	rs6786001	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47718500	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs12495204	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47720540	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7612219	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47739676	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs35148469	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47739873	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.694	rs7645846	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47740829	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs6442082	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47743991	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.747	rs6442083	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47744305	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.786	rs13064183	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47745405	chr3:48290793~48291375:-
HNSC	cis	rs7429990	0.864	rs7637372	ENSG00000228638.1	FCF1P2	3.52	0.000478	0.0498	0.15	0.16	Educational attainment (years of education);	chr3:47750385	chr3:48290793~48291375:-
HNSC	cis	rs9487051	0.768	rs427960	ENSG00000243587.6	C6orf183	-3.52	0.000478	0.0498	-0.15	-0.16	Reticulocyte fraction of red cells;	chr6:109203736	chr6:109165833~109271014:+
HNSC	cis	rs2439831	1	rs550239	ENSG00000275601.1	AC011330.13	-3.52	0.000479	0.0498	-0.25	-0.16	Lung cancer in ever smokers;	chr15:43427999	chr15:43642389~43643023:-
HNSC	cis	rs9583531	0.574	rs7319459	ENSG00000259831.1	LINC00567	-3.52	0.000479	0.0498	-0.19	-0.16	Coronary artery disease;	chr13:110700061	chr13:110809676~110813084:-
HNSC	cis	rs9583531	0.574	rs61971615	ENSG00000259831.1	LINC00567	-3.52	0.000479	0.0498	-0.19	-0.16	Coronary artery disease;	chr13:110700764	chr13:110809676~110813084:-
HNSC	cis	rs859767	0.741	rs6729090	ENSG00000224043.6	CCNT2-AS1	3.52	0.000479	0.0498	0.19	0.16	Neuroticism;	chr2:134644308	chr2:134735464~134918710:-
HNSC	cis	rs11711311	1	rs2566968	ENSG00000241529.3	RN7SL767P	-3.52	0.000479	0.0498	-0.2	-0.16	IgG glycosylation;	chr3:113755307	chr3:113632704~113632998:+
HNSC	cis	rs11877825	1	rs11877825	ENSG00000265728.1	RP11-883A18.3	-3.52	0.000479	0.0498	-0.2	-0.16	Gut microbiota (bacterial taxa);	chr18:10566407	chr18:10594590~10604798:+
HNSC	cis	rs11877825	1	rs11877777	ENSG00000265728.1	RP11-883A18.3	-3.52	0.000479	0.0498	-0.2	-0.16	Gut microbiota (bacterial taxa);	chr18:10566408	chr18:10594590~10604798:+
HNSC	cis	rs4242434	0.672	rs4615566	ENSG00000253837.1	RP11-177H13.2	3.52	0.000479	0.0498	0.16	0.16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22663169	chr8:23336171~23366125:+
HNSC	cis	rs898123	0.583	rs4852762	ENSG00000234896.1	OR7E62P	3.52	0.000479	0.0498	0.18	0.16	Coronary artery disease;	chr2:71145906	chr2:71055527~71056003:+
HNSC	cis	rs7015263	0.579	rs34895735	ENSG00000254231.1	CTD-2284J15.1	-3.52	0.000479	0.0498	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:86393165	chr8:86333274~86343314:-
HNSC	cis	rs2638953	0.924	rs11049600	ENSG00000257176.2	RP11-996F15.2	3.52	0.000479	0.0498	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28439061	chr12:29280418~29317848:-
HNSC	cis	rs2562456	0.833	rs11672583	ENSG00000268119.4	CTD-2561J22.5	3.52	0.000479	0.0498	0.24	0.16	Pain;	chr19:21379363	chr19:21444241~21463908:-
HNSC	cis	rs2562456	0.833	rs62110416	ENSG00000268119.4	CTD-2561J22.5	3.52	0.000479	0.0498	0.24	0.16	Pain;	chr19:21401924	chr19:21444241~21463908:-
HNSC	cis	rs5743077	1	rs5743077	ENSG00000253559.1	OSGEPL1-AS1	-3.52	0.000479	0.0498	-0.26	-0.16	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189762704~189765556:+
HNSC	cis	rs35306767	0.623	rs12354710	ENSG00000229869.1	RP11-363N22.2	-3.52	0.000479	0.0498	-0.26	-0.16	Eosinophil percentage of granulocytes;	chr10:1068080	chr10:933026~942743:+
HNSC	cis	rs734999	0.505	rs4648659	ENSG00000238164.5	RP3-395M20.8	3.52	0.000479	0.0499	0.12	0.16	Ulcerative colitis;	chr1:2629464	chr1:2549920~2557031:-
HNSC	cis	rs734999	0.545	rs28532547	ENSG00000238164.5	RP3-395M20.8	3.52	0.000479	0.0499	0.12	0.16	Ulcerative colitis;	chr1:2629847	chr1:2549920~2557031:-
HNSC	cis	rs734999	0.545	rs6698817	ENSG00000238164.5	RP3-395M20.8	3.52	0.000479	0.0499	0.12	0.16	Ulcerative colitis;	chr1:2632744	chr1:2549920~2557031:-
HNSC	cis	rs734999	0.545	rs12752515	ENSG00000238164.5	RP3-395M20.8	3.52	0.000479	0.0499	0.12	0.16	Ulcerative colitis;	chr1:2633026	chr1:2549920~2557031:-
HNSC	cis	rs4664293	1	rs10204535	ENSG00000213189.5	BTF3L4P2	-3.52	0.000479	0.0499	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159607181	chr2:159003975~159004320:+
HNSC	cis	rs8135828	0.739	rs1049534	ENSG00000226471.5	CTA-292E10.6	3.52	0.000479	0.0499	0.21	0.16	Lipid traits;	chr22:29512083	chr22:28800683~28848559:+
HNSC	cis	rs9926296	0.605	rs12709094	ENSG00000261812.4	TUBB8P7	-3.52	0.000479	0.0499	-0.18	-0.16	Vitiligo;	chr16:89786609	chr16:90093154~90096354:+
HNSC	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000479	0.0499	-0.22	-0.16	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
HNSC	cis	rs2341917	0.818	rs35461378	ENSG00000227992.1	AC108463.2	-3.52	0.000479	0.0499	-0.27	-0.16	Attention function in attention deficit hyperactive disorder;	chr2:110890655	chr2:111203964~111206215:-
HNSC	cis	rs2348418	0.864	rs7957495	ENSG00000257042.1	RP11-993B23.3	3.52	0.000479	0.0499	0.15	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:27958517~27969813:+
HNSC	cis	rs10971721	0.584	rs12375716	ENSG00000260947.1	RP11-384P7.7	3.52	0.000479	0.0499	0.28	0.16	Body mass index;	chr9:34100034	chr9:33697459~33700986:+
HNSC	cis	rs10971721	0.584	rs12379730	ENSG00000260947.1	RP11-384P7.7	3.52	0.000479	0.0499	0.28	0.16	Body mass index;	chr9:34100072	chr9:33697459~33700986:+
HNSC	cis	rs10971721	0.584	rs55672700	ENSG00000260947.1	RP11-384P7.7	3.52	0.000479	0.0499	0.28	0.16	Body mass index;	chr9:34102723	chr9:33697459~33700986:+
HNSC	cis	rs2565722	0.583	rs2489945	ENSG00000233342.1	RP11-235G24.3	3.52	0.000479	0.0499	0.23	0.16	Blood protein levels;	chr6:160876692	chr6:160926369~160927162:+
HNSC	cis	rs2554380	0.943	rs2585042	ENSG00000259570.1	RP11-671M22.4	3.52	0.000479	0.0499	0.23	0.16	Height;	chr15:83672996	chr15:84394512~84395514:+
HNSC	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000479	0.0499	-0.2	-0.16	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
HNSC	cis	rs7520050	0.553	rs2993263	ENSG00000280836.1	AL355480.1	-3.52	0.000479	0.0499	-0.16	-0.16	Reticulocyte count;Red blood cell count;	chr1:45555958	chr1:45581219~45581321:-
HNSC	cis	rs11779988	0.545	rs208759	ENSG00000253671.1	RP11-806O11.1	-3.52	0.000479	0.0499	-0.18	-0.16	Breast cancer;	chr8:17950420	chr8:17808941~17820868:+
HNSC	cis	rs17270561	0.779	rs1165200	ENSG00000272810.1	U91328.22	3.52	0.00048	0.0499	0.17	0.16	Iron status biomarkers;	chr6:25874984	chr6:26013241~26013757:+
HNSC	cis	rs2013441	0.866	rs7207817	ENSG00000261033.1	RP11-209D14.2	3.52	0.00048	0.0499	0.19	0.16	Obesity-related traits;	chr17:20318015	chr17:20008051~20009234:-
HNSC	cis	rs4713118	0.738	rs200465	ENSG00000216901.1	AL022393.7	3.52	0.00048	0.0499	0.21	0.16	Parkinson's disease;	chr6:27789875	chr6:28176188~28176674:+
HNSC	cis	rs6142618	0.806	rs2424878	ENSG00000275576.1	RP5-836N17.4	3.52	0.00048	0.0499	0.16	0.16	Inflammatory bowel disease;	chr20:32368305	chr20:32116171~32116629:+
HNSC	cis	rs3805389	0.961	rs9996936	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.00048	0.0499	-0.21	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55601472	chr4:55363971~55395847:-
HNSC	cis	rs2062225	1	rs6542248	ENSG00000233370.1	AC092664.1	-3.52	0.00048	0.0499	-0.29	-0.16	Monocyte count;	chr2:110995651	chr2:110184054~110185179:+
HNSC	cis	rs2554380	0.55	rs62025831	ENSG00000259570.1	RP11-671M22.4	-3.52	0.00048	0.0499	-0.21	-0.16	Height;	chr15:83876933	chr15:84394512~84395514:+
HNSC	cis	rs1048238	0.846	rs945419	ENSG00000226457.1	RP11-430L17.1	-3.52	0.00048	0.0499	-0.15	-0.16	Systolic blood pressure;	chr1:16018363	chr1:16369150~16369530:-
HNSC	cis	rs1552244	1	rs35198334	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10062869	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.935	rs7652190	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10063466	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs7619340	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10066494	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs6793396	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10069243	chr3:9986893~10006990:+
HNSC	cis	rs1552244	1	rs6772315	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10071960	chr3:9986893~10006990:+
HNSC	cis	rs1552244	0.935	rs7621551	ENSG00000180385.7	EMC3-AS1	3.52	0.00048	0.0499	0.18	0.16	Alzheimer's disease;	chr3:10072521	chr3:9986893~10006990:+
HNSC	cis	rs12968116	0.607	rs12717119	ENSG00000267787.4	RP11-35G9.5	-3.52	0.00048	0.0499	-0.23	-0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr18:57668715	chr18:57639455~57738044:+
HNSC	cis	rs3849811	0.504	rs10090913	ENSG00000253844.1	RP11-546K22.1	-3.52	0.00048	0.0499	-0.26	-0.16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr8:52094206	chr8:51961458~52022974:+
HNSC	cis	rs9611565	0.592	rs5758406	ENSG00000233903.2	Z83851.4	3.52	0.00048	0.0499	0.24	0.16	Vitiligo;	chr22:41680637	chr22:42276355~42277052:+
HNSC	cis	rs868153	0.625	rs34247913	ENSG00000275339.1	RP3-425C14.6	3.52	0.00048	0.0499	0.17	0.16	Vertical cup-disc ratio;	chr6:122177358	chr6:122454358~122454612:+
HNSC	cis	rs1862618	0.671	rs2591957	ENSG00000248727.4	CTC-236F12.4	-3.52	0.00048	0.0499	-0.21	-0.16	Initial pursuit acceleration;	chr5:56947319	chr5:56457795~56481946:-
HNSC	cis	rs9859260	0.744	rs3933	ENSG00000273009.1	RP11-352G9.1	3.52	0.00048	0.0499	0.18	0.16	Mean corpuscular volume;	chr3:196058126	chr3:195913078~195913683:-
HNSC	cis	rs6545883	0.525	rs1729658	ENSG00000271889.1	RP11-493E12.1	3.52	0.00048	0.0499	0.18	0.16	Tuberculosis;	chr2:61146385	chr2:61151433~61162105:-
HNSC	cis	rs2013441	1	rs2703785	ENSG00000261033.1	RP11-209D14.2	3.52	0.00048	0.0499	0.18	0.16	Obesity-related traits;	chr17:20249105	chr17:20008051~20009234:-
HNSC	cis	rs2013441	1	rs2703787	ENSG00000261033.1	RP11-209D14.2	3.52	0.00048	0.0499	0.18	0.16	Obesity-related traits;	chr17:20255352	chr17:20008051~20009234:-
HNSC	cis	rs2762353	0.935	rs1177442	ENSG00000272462.2	U91328.19	-3.52	0.00048	0.05	-0.16	-0.16	Blood metabolite levels;	chr6:25808841	chr6:25992662~26001775:+
HNSC	cis	rs2762353	0.902	rs1165199	ENSG00000272462.2	U91328.19	-3.52	0.00048	0.05	-0.16	-0.16	Blood metabolite levels;	chr6:25808859	chr6:25992662~26001775:+
HNSC	cis	rs4906332	1	rs12879663	ENSG00000244691.1	RPL10AP1	-3.52	0.00048	0.05	-0.18	-0.16	Coronary artery disease;	chr14:103407878	chr14:103412119~103412761:-
HNSC	cis	rs17014483	1	rs3017914	ENSG00000248019.2	FAM13A-AS1	-3.52	0.00048	0.05	-0.2	-0.16	Post bronchodilator FEV1/FVC ratio;	chr4:88733014	chr4:88709789~88730103:+
HNSC	cis	rs6493858	0.572	rs7179706	ENSG00000277245.1	RP11-48G14.3	-3.52	0.00048	0.05	-0.17	-0.16	Relative hand skill in reading disability;	chr15:56075138	chr15:56447120~56447697:+
HNSC	cis	rs7405404	0.672	rs12149863	ENSG00000262454.1	RP11-65J21.3	3.52	0.000481	0.05	0.14	0.16	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13640938	chr16:14302288~14326353:+
HNSC	cis	rs6545883	0.718	rs2694624	ENSG00000271889.1	RP11-493E12.1	3.52	0.000481	0.05	0.18	0.16	Tuberculosis;	chr2:61445178	chr2:61151433~61162105:-
HNSC	cis	rs870825	0.616	rs10013562	ENSG00000254233.1	RP11-242J7.1	3.52	0.000481	0.05	0.23	0.16	Blood protein levels;	chr4:184689332	chr4:184584093~184625030:-
HNSC	cis	rs3764400	0.567	rs741058	ENSG00000278765.1	RP5-890E16.5	-3.52	0.000481	0.05	-0.3	-0.16	Body mass index;	chr17:48127991	chr17:48066704~48067293:-
HNSC	cis	rs9304742	0.646	rs10408610	ENSG00000242779.5	ZNF702P	3.52	0.000481	0.05	0.19	0.16	Psoriasis;	chr19:52960660	chr19:52968251~53037898:-
HNSC	cis	rs11700980	0.551	rs56263139	ENSG00000232855.5	AF131217.1	3.52	0.000481	0.05	0.23	0.16	QRS complex (12-leadsum);	chr21:28737129	chr21:28439346~28674848:-
HNSC	cis	rs4845875	0.557	rs6659541	ENSG00000242349.4	NPPA-AS1	3.52	0.000481	0.05	0.16	0.16	Midregional pro atrial natriuretic peptide levels;	chr1:11776385	chr1:11841017~11848079:+
HNSC	cis	rs4845875	0.626	rs7538516	ENSG00000242349.4	NPPA-AS1	3.52	0.000481	0.05	0.16	0.16	Midregional pro atrial natriuretic peptide levels;	chr1:11776625	chr1:11841017~11848079:+
HNSC	cis	rs9611565	0.729	rs203319	ENSG00000235513.1	RP4-756G23.5	3.52	0.000481	0.05	0.18	0.16	Vitiligo;	chr22:41518589	chr22:41209122~41217627:-
HNSC	cis	rs4246076	0.804	rs3804464	ENSG00000215057.4	PKMP5	-3.52	0.000481	0.05	-0.18	-0.16	Urate levels in overweight individuals;	chr6:6591050	chr6:5972412~5974012:+
HNSC	cis	rs3764021	0.87	rs7307111	ENSG00000256673.1	RP11-599J14.2	-3.52	0.000481	0.05	-0.15	-0.16	Type 1 diabetes;	chr12:9725227	chr12:9398355~9414851:-
HNSC	cis	rs559928	0.692	rs876064	ENSG00000236935.1	AP003774.1	3.52	0.000481	0.05	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64269561	chr11:64325050~64329504:-
HNSC	cis	rs9475752	0.744	rs6459174	ENSG00000220666.2	RCC2P7	3.52	0.000481	0.05	0.2	0.16	Menarche (age at onset);	chr6:56921257	chr6:56431950~56433213:-
HNSC	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	35.52	7.94e-135	3.97e-124	1.22	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	35.19	1.93e-133	2.61e-123	1.21	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	35.17	2.38e-133	2.61e-123	1.2	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	35.16	2.61e-133	2.61e-123	1.21	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	34.23	2.27e-129	1.42e-119	1.22	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	34.01	1.82e-128	1.01e-118	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	34	2.04e-128	1.02e-118	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	33.97	2.74e-128	1.25e-118	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	33.71	3.6e-127	1.5e-117	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	33.53	2.01e-126	5.91e-117	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	33.32	1.6e-125	4.43e-116	1.22	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	33.27	2.74e-125	7.21e-116	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	33.07	2e-124	4.99e-115	1.21	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	32.9	1.07e-123	2.33e-114	1.18	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	32.82	2.36e-123	4.73e-114	1.22	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
HNSC	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	32.73	5.91e-123	1.09e-113	1.14	0.83	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
HNSC	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	32.72	6.14e-123	1.1e-113	1.21	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
HNSC	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	32.39	1.78e-121	2.78e-112	1.15	0.83	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
HNSC	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	32.35	2.45e-121	3.61e-112	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	32.35	2.45e-121	3.61e-112	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
HNSC	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	32.31	3.87e-121	5.53e-112	1.15	0.83	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
HNSC	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	32.27	5.6e-121	7.37e-112	1.2	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
HNSC	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	32.04	5.44e-120	6.33e-111	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
HNSC	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	32.03	6.04e-120	6.82e-111	1.15	0.83	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
HNSC	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	32.03	6.27e-120	6.82e-111	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	32.03	6.27e-120	6.82e-111	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-32.01	7.31e-120	7.78e-111	-1.23	-0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
HNSC	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	32	8.24e-120	8.4e-111	1.14	0.83	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
HNSC	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	32	8.24e-120	8.4e-111	1.14	0.83	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
HNSC	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	31.93	1.77e-119	1.67e-110	1.14	0.83	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	31.88	2.93e-119	2.53e-110	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	31.88	2.93e-119	2.53e-110	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	31.79	7.06e-119	5.79e-110	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	31.79	7.06e-119	5.79e-110	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	31.79	7.06e-119	5.79e-110	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	31.77	8.32e-119	6.5e-110	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	31.77	8.32e-119	6.5e-110	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
HNSC	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	31.76	9.86e-119	7.58e-110	1.21	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
HNSC	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	31.75	1.03e-118	7.77e-110	1.15	0.83	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	31.75	1.06e-118	7.77e-110	1.18	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	31.75	1.06e-118	7.77e-110	1.18	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	31.66	2.61e-118	1.83e-109	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	31.66	2.61e-118	1.83e-109	1.2	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	31.55	8.11e-118	5.4e-109	1.21	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	31.55	8.11e-118	5.4e-109	1.21	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	31.55	8.11e-118	5.4e-109	1.21	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
HNSC	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	31.49	1.45e-117	9.43e-109	1.17	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
HNSC	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	31.47	1.76e-117	1.13e-108	1.21	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
HNSC	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-31.39	3.97e-117	2.51e-108	-0.96	-0.82	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	31.34	6.63e-117	3.9e-108	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	31.34	6.63e-117	3.9e-108	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	31.26	1.54e-116	8.72e-108	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	31.26	1.54e-116	8.72e-108	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-31.21	2.44e-116	1.36e-107	-1.19	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	31.19	3.03e-116	1.58e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	31.19	3.03e-116	1.58e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	31.19	3.03e-116	1.58e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
HNSC	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	31.17	3.47e-116	1.68e-107	1.25	0.82	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	31.17	3.47e-116	1.68e-107	1.25	0.82	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	31.17	3.47e-116	1.68e-107	1.25	0.82	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	31.17	3.47e-116	1.68e-107	1.25	0.82	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	31.13	5.47e-116	2.6e-107	1.23	0.82	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	31.08	9.28e-116	4.28e-107	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
HNSC	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	31.08	9.33e-116	4.28e-107	1.09	0.82	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
HNSC	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	31.08	9.42e-116	4.28e-107	1.26	0.82	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	31.07	9.84e-116	4.39e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	31.07	9.84e-116	4.39e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	31.04	1.34e-115	5.76e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	31.04	1.34e-115	5.76e-107	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	30.91	4.86e-115	2.03e-106	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	30.91	4.86e-115	2.03e-106	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	30.9	5.7e-115	2.26e-106	0.97	0.82	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	30.9	5.7e-115	2.26e-106	0.97	0.82	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	30.9	5.7e-115	2.26e-106	0.97	0.82	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	30.9	5.7e-115	2.26e-106	0.97	0.82	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	30.85	9.2e-115	3.59e-106	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
HNSC	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	30.83	1.16e-114	4.42e-106	1.14	0.82	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	30.83	1.16e-114	4.42e-106	1.14	0.82	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
HNSC	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	30.8	1.54e-114	4.8e-106	0.96	0.82	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	30.8	1.54e-114	4.8e-106	0.96	0.82	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	30.78	1.96e-114	5.77e-106	0.97	0.82	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	30.76	2.29e-114	6.65e-106	0.96	0.82	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	30.74	2.73e-114	7.72e-106	0.97	0.82	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	30.71	3.93e-114	1.09e-105	0.96	0.82	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	30.69	4.64e-114	1.27e-105	0.98	0.82	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	30.69	4.78e-114	1.29e-105	0.97	0.82	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	30.67	5.74e-114	1.52e-105	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	30.67	6.08e-114	1.6e-105	0.97	0.82	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	30.65	7.03e-114	1.84e-105	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
HNSC	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	30.65	7.09e-114	1.85e-105	1.09	0.82	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
HNSC	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	30.63	8.43e-114	2.14e-105	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	30.63	8.43e-114	2.14e-105	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	30.63	8.43e-114	2.14e-105	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	30.63	9.21e-114	2.17e-105	0.97	0.82	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
HNSC	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	30.61	1.04e-113	2.39e-105	1.09	0.82	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	30.61	1.04e-113	2.39e-105	1.09	0.82	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
HNSC	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	30.59	1.29e-113	2.93e-105	0.96	0.82	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	30.59	1.29e-113	2.93e-105	0.96	0.82	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	30.56	1.8e-113	4.08e-105	0.97	0.82	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	30.56	1.8e-113	4.08e-105	0.97	0.82	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	30.53	2.36e-113	5.32e-105	0.96	0.82	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	30.53	2.42e-113	5.33e-105	0.97	0.82	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	30.53	2.42e-113	5.33e-105	0.97	0.82	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	30.53	2.42e-113	5.33e-105	0.97	0.82	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	30.53	2.42e-113	5.33e-105	0.97	0.82	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
HNSC	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	30.51	2.95e-113	6.45e-105	1.09	0.82	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
HNSC	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	30.51	3.02e-113	6.53e-105	1.14	0.82	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
HNSC	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	30.51	3.02e-113	6.53e-105	1.14	0.82	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
HNSC	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	30.46	5.05e-113	1.06e-104	1.08	0.82	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	30.46	5.05e-113	1.06e-104	1.08	0.82	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	30.46	5.05e-113	1.06e-104	1.08	0.82	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
HNSC	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	30.44	5.88e-113	1.19e-104	1.13	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
HNSC	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	30.43	6.58e-113	1.32e-104	0.96	0.82	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	30.43	6.58e-113	1.32e-104	0.96	0.82	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	30.41	8.28e-113	1.65e-104	0.97	0.82	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	30.4	8.93e-113	1.77e-104	0.96	0.82	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
HNSC	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	30.36	1.38e-112	2.59e-104	1.13	0.81	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
HNSC	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	30.34	1.7e-112	3.1e-104	1.08	0.81	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
HNSC	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	30.33	1.91e-112	3.4e-104	1.24	0.81	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	30.33	1.91e-112	3.4e-104	1.24	0.81	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
HNSC	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	30.28	2.98e-112	5.16e-104	1.09	0.81	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-30.23	5.01e-112	8.57e-104	-1.07	-0.81	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
HNSC	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	30.22	5.83e-112	9.77e-104	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
HNSC	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-30.21	6.26e-112	1.05e-103	-1.12	-0.81	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
HNSC	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	30.21	6.43e-112	1.07e-103	1.08	0.81	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
HNSC	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-30.15	1.19e-111	1.96e-103	-1.14	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
HNSC	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	30.15	1.22e-111	2e-103	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	30.15	1.22e-111	2e-103	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
HNSC	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	30.1	1.9e-111	3.08e-103	1.08	0.81	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
HNSC	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	30.1	1.93e-111	3.12e-103	1.25	0.81	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
HNSC	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	30.02	4.49e-111	7.22e-103	1.08	0.81	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	29.98	7.04e-111	1.11e-102	1.07	0.81	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
HNSC	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	29.86	2.23e-110	3.38e-102	1.25	0.81	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	29.83	3.01e-110	4.49e-102	1.25	0.81	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
HNSC	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-29.75	7.44e-110	1.1e-101	-1.14	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
HNSC	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-29.75	7.44e-110	1.1e-101	-1.14	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
HNSC	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	29.7	1.24e-109	1.81e-101	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	29.62	2.72e-109	3.93e-101	1.14	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	29.58	3.94e-109	5.67e-101	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	29.52	7.82e-109	1.12e-100	1.14	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
HNSC	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	29.49	1.01e-108	1.45e-100	1.24	0.81	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	29.46	1.49e-108	2.13e-100	1.12	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	29.44	1.71e-108	2.44e-100	0.97	0.81	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	29.38	3.34e-108	4.69e-100	1.15	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	29.38	3.34e-108	4.69e-100	1.15	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
HNSC	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-29.35	4.56e-108	6.37e-100	-1.09	-0.81	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
HNSC	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	29.25	1.25e-107	1.74e-99	1.25	0.8	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	29.16	3.06e-107	3.93e-99	0.95	0.8	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
HNSC	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	29.15	3.51e-107	4.48e-99	1.24	0.8	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	29.15	3.57e-107	4.55e-99	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
HNSC	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	29.08	7.14e-107	9.04e-99	1.25	0.8	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	29.03	1.26e-106	1.57e-98	0.94	0.8	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	29.03	1.26e-106	1.57e-98	0.94	0.8	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	29.03	1.26e-106	1.57e-98	0.94	0.8	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	29.03	1.26e-106	1.57e-98	0.94	0.8	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	29.03	1.26e-106	1.57e-98	0.94	0.8	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	29	1.62e-106	1.99e-98	0.95	0.8	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	29	1.67e-106	2.05e-98	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
HNSC	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	28.99	1.85e-106	2.26e-98	1.09	0.8	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	28.96	2.48e-106	2.99e-98	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	28.96	2.48e-106	2.99e-98	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
HNSC	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	28.94	3.2e-106	3.84e-98	0.94	0.8	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	28.93	3.38e-106	4.04e-98	0.94	0.8	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	28.93	3.42e-106	4.06e-98	0.95	0.8	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	28.93	3.42e-106	4.06e-98	0.95	0.8	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	28.89	5.07e-106	5.98e-98	0.95	0.8	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	28.86	7.16e-106	8.38e-98	0.93	0.8	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-28.82	1.07e-105	1.25e-97	-1.16	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
HNSC	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	28.81	1.14e-105	1.33e-97	0.95	0.8	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	28.8	1.36e-105	1.57e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	28.8	1.36e-105	1.57e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	28.8	1.36e-105	1.57e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
HNSC	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	28.77	1.76e-105	2.03e-97	1.13	0.8	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
HNSC	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	28.74	2.37e-105	2.71e-97	1.24	0.8	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
HNSC	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-28.74	2.42e-105	2.76e-97	-1.09	-0.8	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	28.71	3.25e-105	3.68e-97	1.16	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	28.71	3.25e-105	3.68e-97	1.16	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	28.69	3.99e-105	4.49e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	28.69	3.99e-105	4.49e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
HNSC	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-28.68	4.65e-105	5.2e-97	-1.09	-0.8	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-28.68	4.65e-105	5.2e-97	-1.09	-0.8	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	28.67	5.01e-105	5.57e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	28.67	5.01e-105	5.57e-97	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	28.64	6.84e-105	7.58e-97	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
HNSC	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-28.55	1.81e-104	1.96e-96	-1.09	-0.8	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
HNSC	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	28.52	2.4e-104	2.6e-96	1.26	0.8	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	28.49	3.46e-104	3.72e-96	1.17	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	28.45	5.04e-104	5.36e-96	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	28.45	5.04e-104	5.36e-96	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	28.45	5.1e-104	5.38e-96	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	28.45	5.1e-104	5.38e-96	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	28.45	5.1e-104	5.38e-96	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	28.44	5.76e-104	6.08e-96	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	28.43	6.16e-104	6.44e-96	0.94	0.8	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	28.43	6.16e-104	6.44e-96	0.94	0.8	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	28.37	1.12e-103	1.16e-95	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	28.35	1.48e-103	1.53e-95	1.14	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
HNSC	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	28.33	1.76e-103	1.81e-95	0.94	0.8	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
HNSC	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	28.32	1.88e-103	1.94e-95	1.25	0.8	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	28.24	4.39e-103	4.46e-95	0.93	0.79	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	28.23	4.87e-103	4.94e-95	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
HNSC	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	28.22	5.35e-103	5.4e-95	0.94	0.79	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	28.08	2.44e-102	2.44e-94	0.95	0.79	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
HNSC	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	28.07	2.6e-102	2.59e-94	0.96	0.79	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
HNSC	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-28.02	4.7e-102	4.67e-94	-1.09	-0.79	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
HNSC	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	27.99	6.22e-102	6.11e-94	0.95	0.79	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	27.99	6.43e-102	6.3e-94	0.95	0.79	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
HNSC	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	27.98	6.77e-102	6.61e-94	0.94	0.79	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	27.94	1.02e-101	9.91e-94	1.05	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
HNSC	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	27.93	1.2e-101	1.16e-93	1.21	0.79	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	27.92	1.24e-101	1.2e-93	0.93	0.79	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
HNSC	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-27.91	1.42e-101	1.37e-93	-1.09	-0.79	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
HNSC	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	27.9	1.64e-101	1.57e-93	0.94	0.79	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
HNSC	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	27.87	2.22e-101	2.12e-93	1.04	0.79	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	27.76	6.52e-101	6.11e-93	1.07	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	27.76	6.52e-101	6.11e-93	1.07	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
HNSC	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-27.72	1.08e-100	1.02e-92	-1.09	-0.79	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
HNSC	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	27.71	1.21e-100	1.13e-92	0.95	0.79	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	27.7	1.32e-100	1.23e-92	0.93	0.79	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	27.65	2.11e-100	1.95e-92	1.12	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
HNSC	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	27.63	2.8e-100	2.58e-92	0.95	0.79	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	27.54	7.02e-100	6.43e-92	1.12	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
HNSC	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	27.45	1.74e-99	1.58e-91	1.08	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
HNSC	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	27.4	2.92e-99	2.65e-91	1.22	0.79	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
HNSC	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-27.39	3.46e-99	3.14e-91	-0.93	-0.79	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	27.38	3.59e-99	3.25e-91	1.08	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	27.36	4.79e-99	4.32e-91	1.08	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	27.36	4.79e-99	4.32e-91	1.08	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	27.32	7.14e-99	6.43e-91	1.08	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	27.26	1.36e-98	1.22e-90	1.08	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	27.24	1.64e-98	1.47e-90	0.93	0.78	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	27.21	2.31e-98	2.06e-90	0.93	0.78	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
HNSC	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-27.2	2.39e-98	2.13e-90	-1.09	-0.78	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	27.13	5.04e-98	4.46e-90	1.06	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	26.93	4.39e-97	3.83e-89	0.92	0.78	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
HNSC	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-26.84	1.09e-96	9.46e-89	-1.11	-0.78	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
HNSC	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	26.82	1.3e-96	1.12e-88	0.94	0.78	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	26.8	1.72e-96	1.49e-88	0.92	0.78	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
HNSC	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	26.78	2e-96	1.72e-88	1.22	0.78	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	26.78	2e-96	1.72e-88	1.22	0.78	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	26.68	6.26e-96	5.33e-88	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	26.56	2.09e-95	1.76e-87	1.1	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
HNSC	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	26.5	3.9e-95	3.26e-87	1.07	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
HNSC	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	26.48	4.96e-95	4.14e-87	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
HNSC	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	26.42	9.55e-95	7.94e-87	1.22	0.77	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	26.36	1.85e-94	1.53e-86	1.12	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	26.34	2.29e-94	1.88e-86	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
HNSC	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	26.3	3.42e-94	2.81e-86	1.07	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
HNSC	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	26.28	4.24e-94	3.47e-86	1.12	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
HNSC	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-26.23	7.03e-94	5.74e-86	-0.91	-0.77	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	26.07	3.7e-93	3e-85	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
HNSC	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	26.01	7.7e-93	6.22e-85	0.98	0.77	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
HNSC	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	25.87	3.28e-92	2.64e-84	1.03	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	25.87	3.28e-92	2.64e-84	1.03	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	25.75	1.17e-91	9.34e-84	1.03	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
HNSC	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	25.74	1.35e-91	1.08e-83	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
HNSC	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-25.67	2.8e-91	2.23e-83	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
HNSC	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	25.51	1.54e-90	1.21e-82	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	25.5	1.61e-90	1.26e-82	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
HNSC	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	25.45	2.84e-90	2.22e-82	1.17	0.76	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
HNSC	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-25.34	9.38e-90	7.26e-82	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-25.34	9.38e-90	7.26e-82	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-25.29	1.56e-89	1.2e-81	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	25.28	1.69e-89	1.3e-81	0.88	0.76	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
HNSC	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	25.28	1.69e-89	1.3e-81	1	0.76	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
HNSC	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	25.27	2e-89	1.53e-81	1.21	0.76	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	25.27	2.03e-89	1.55e-81	1.2	0.76	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
HNSC	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-25.27	2.05e-89	1.57e-81	-1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-25.24	2.73e-89	2.08e-81	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	25.23	2.88e-89	2.18e-81	1.03	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-25.22	3.52e-89	2.66e-81	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-25.22	3.52e-89	2.66e-81	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	25.21	3.79e-89	2.85e-81	0.88	0.76	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-25.14	8.09e-89	6.06e-81	-1.02	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	25.14	8.32e-89	6.19e-81	0.87	0.76	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	25.14	8.32e-89	6.19e-81	0.87	0.76	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	25.14	8.32e-89	6.19e-81	0.87	0.76	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-25.13	8.92e-89	6.63e-81	-0.98	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	25.09	1.33e-88	9.82e-81	0.88	0.76	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	25.06	1.84e-88	1.36e-80	1.03	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
HNSC	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	25.03	2.65e-88	1.94e-80	1.01	0.76	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	24.96	5.68e-88	4.15e-80	1.01	0.76	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-24.75	4.95e-87	3.54e-79	-0.98	-0.75	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
HNSC	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-24.67	1.23e-86	8.71e-79	-1.02	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	24.63	1.87e-86	1.32e-78	0.88	0.75	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
HNSC	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	24.63	1.95e-86	1.37e-78	1.27	0.75	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
HNSC	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	24.59	2.92e-86	2.05e-78	1.2	0.75	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
HNSC	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-24.55	4.2e-86	2.93e-78	-1.02	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-24.55	4.2e-86	2.93e-78	-1.02	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	24.45	1.32e-85	9.15e-78	0.87	0.75	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	24.39	2.44e-85	1.69e-77	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
HNSC	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-24.39	2.53e-85	1.75e-77	-1.05	-0.75	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
HNSC	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	24.38	2.61e-85	1.8e-77	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	24.25	1.11e-84	7.62e-77	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	24.16	2.88e-84	1.95e-76	0.87	0.75	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	24.16	2.88e-84	1.95e-76	0.87	0.75	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	24.09	6.04e-84	4.07e-76	0.86	0.74	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	24.06	8.34e-84	5.61e-76	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	24	1.63e-83	1.07e-75	0.86	0.74	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	23.9	4.55e-83	2.98e-75	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
HNSC	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	23.87	6.55e-83	4.27e-75	1.2	0.74	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	23.86	7.03e-83	4.57e-75	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	23.85	7.79e-83	5.06e-75	0.86	0.74	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	23.85	7.79e-83	5.06e-75	0.86	0.74	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	23.84	8.99e-83	5.83e-75	0.86	0.74	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	23.84	9.55e-83	6.18e-75	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
HNSC	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	23.77	1.97e-82	1.27e-74	0.97	0.74	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
HNSC	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	23.77	1.99e-82	1.28e-74	0.97	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
HNSC	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	23.77	2.03e-82	1.3e-74	0.86	0.74	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
HNSC	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	23.76	2.1e-82	1.35e-74	1.06	0.74	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	23.76	2.24e-82	1.43e-74	0.86	0.74	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	23.75	2.5e-82	1.59e-74	0.86	0.74	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	23.75	2.5e-82	1.59e-74	0.86	0.74	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	23.75	2.5e-82	1.59e-74	0.86	0.74	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	23.74	2.65e-82	1.68e-74	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	23.74	2.65e-82	1.68e-74	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
HNSC	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	23.72	3.47e-82	2.2e-74	1.22	0.74	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	23.58	1.57e-81	9.74e-74	0.85	0.74	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	23.58	1.57e-81	9.74e-74	0.85	0.74	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	23.58	1.57e-81	9.74e-74	0.85	0.74	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	23.55	2.15e-81	1.33e-73	0.86	0.74	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
HNSC	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	23.33	2.3e-80	1.4e-72	0.96	0.73	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
HNSC	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	23.26	4.81e-80	2.92e-72	1	0.73	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
HNSC	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	23.24	6.14e-80	3.72e-72	1.2	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
HNSC	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	23.23	6.47e-80	3.92e-72	1.17	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
HNSC	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	23.18	1.09e-79	6.57e-72	1.01	0.73	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
HNSC	trans	rs2657294	0.603	rs11543	ENSG00000172974.11	AC007318.5	23.16	1.32e-79	7.99e-72	0.93	0.73	Pneumonia;	chr10:75210855	chr2:65205108~65205988:+
HNSC	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	23.13	1.89e-79	1.14e-71	1.17	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	23.13	1.94e-79	1.17e-71	1.2	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
HNSC	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	23.12	2.17e-79	1.3e-71	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	23.1	2.67e-79	1.59e-71	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
HNSC	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	23.09	3.1e-79	1.84e-71	1	0.73	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	23.09	3.1e-79	1.84e-71	1	0.73	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	23.06	4.28e-79	2.54e-71	0.98	0.73	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
HNSC	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	23.05	4.65e-79	2.76e-71	1.01	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
HNSC	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	22.98	9.62e-79	5.65e-71	0.97	0.73	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	22.98	9.62e-79	5.65e-71	0.97	0.73	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	22.98	9.62e-79	5.65e-71	0.97	0.73	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	22.98	1.01e-78	5.9e-71	0.99	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
HNSC	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	22.97	1.1e-78	6.42e-71	1.2	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
HNSC	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-22.95	1.29e-78	7.55e-71	-0.97	-0.73	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
HNSC	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	22.91	2.09e-78	1.21e-70	1	0.73	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
HNSC	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	22.91	2.15e-78	1.25e-70	1.2	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
HNSC	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-22.87	3.13e-78	1.82e-70	-1.04	-0.73	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
HNSC	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	22.85	4.17e-78	2.41e-70	1.17	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
HNSC	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-22.75	1.19e-77	6.83e-70	-1.03	-0.73	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
HNSC	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	22.75	1.24e-77	7.07e-70	1.17	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	22.73	1.51e-77	8.61e-70	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	22.72	1.57e-77	8.92e-70	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
HNSC	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	22.63	4.17e-77	2.34e-69	1.06	0.72	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
HNSC	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	22.62	4.82e-77	2.7e-69	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	22.58	7.42e-77	4.14e-69	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
HNSC	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	22.57	8.38e-77	4.67e-69	1.06	0.72	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
HNSC	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	22.56	9.63e-77	5.34e-69	1.13	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
HNSC	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	22.54	1.14e-76	6.29e-69	1.06	0.72	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
HNSC	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	22.52	1.37e-76	7.57e-69	1.06	0.72	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
HNSC	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	22.52	1.37e-76	7.57e-69	1.06	0.72	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
HNSC	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	22.52	1.37e-76	7.57e-69	1.06	0.72	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
HNSC	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	22.36	8.18e-76	4.46e-68	1.04	0.72	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	22.34	1.03e-75	5.59e-68	1.05	0.72	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
HNSC	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	22.3	1.59e-75	8.6e-68	1.12	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
HNSC	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	22.27	2.01e-75	1.08e-67	0.97	0.72	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
HNSC	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	22.25	2.5e-75	1.34e-67	1.12	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
HNSC	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-22.22	3.61e-75	1.94e-67	-1.11	-0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
HNSC	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	22.21	4.12e-75	2.2e-67	0.96	0.72	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
HNSC	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	22.21	4.25e-75	2.27e-67	1.04	0.72	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-22.12	1.12e-74	5.95e-67	-0.81	-0.72	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
HNSC	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	22.04	2.41e-74	1.27e-66	1.07	0.71	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
HNSC	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	21.97	5.61e-74	2.94e-66	1.15	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
HNSC	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	21.94	7.59e-74	3.95e-66	1.06	0.71	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
HNSC	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	21.94	7.69e-74	4e-66	0.94	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
HNSC	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	21.94	7.69e-74	4e-66	0.94	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
HNSC	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	21.93	8.11e-74	4.2e-66	1.02	0.71	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
HNSC	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	21.85	1.9e-73	9.81e-66	1.15	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
HNSC	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	21.84	2.11e-73	1.08e-65	0.96	0.71	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
HNSC	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	21.83	2.41e-73	1.23e-65	1.06	0.71	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
HNSC	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-21.79	3.63e-73	1.85e-65	-1.02	-0.71	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-21.75	5.77e-73	2.91e-65	-0.81	-0.71	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
HNSC	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	21.73	7.4e-73	3.73e-65	1.12	0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
HNSC	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	21.66	1.57e-72	7.86e-65	0.9	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
HNSC	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	21.63	2.2e-72	1.09e-64	1.03	0.71	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	21.63	2.2e-72	1.09e-64	1.03	0.71	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
HNSC	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	21.61	2.79e-72	1.39e-64	1.14	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
HNSC	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	21.54	5.76e-72	2.78e-64	1.14	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
HNSC	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	21.5	9.2e-72	4.41e-64	1.11	0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
HNSC	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	21.49	9.85e-72	4.72e-64	0.81	0.71	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
HNSC	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	21.46	1.34e-71	6.34e-64	1.03	0.7	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	21.44	1.75e-71	8.26e-64	1.03	0.7	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	21.39	2.79e-71	1.31e-63	1.03	0.7	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	21.39	2.79e-71	1.31e-63	1.03	0.7	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	21.35	4.66e-71	2.16e-63	1.02	0.7	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	21.33	5.75e-71	2.64e-63	1.03	0.7	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	21.33	5.75e-71	2.64e-63	1.03	0.7	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	21.33	5.75e-71	2.64e-63	1.03	0.7	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	21.33	5.75e-71	2.64e-63	1.03	0.7	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	21.33	5.75e-71	2.64e-63	1.03	0.7	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	21.31	6.59e-71	3.03e-63	1.02	0.7	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	21.31	6.95e-71	3.19e-63	1.03	0.7	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	21.3	7.72e-71	3.53e-63	1.03	0.7	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	21.29	8.66e-71	3.95e-63	1.02	0.7	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
HNSC	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	21.29	9e-71	4.09e-63	1.03	0.7	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	21.29	9e-71	4.09e-63	1.03	0.7	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-21.28	9.44e-71	4.28e-63	-1.01	-0.7	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
HNSC	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	21.28	9.46e-71	4.28e-63	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
HNSC	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	21.28	9.46e-71	4.28e-63	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
HNSC	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-21.28	9.51e-71	4.3e-63	-1.01	-0.7	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
HNSC	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	21.26	1.24e-70	5.6e-63	1.06	0.7	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
HNSC	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	21.19	2.4e-70	1.07e-62	0.92	0.7	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	21.18	2.77e-70	1.24e-62	0.89	0.7	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	21.16	3.38e-70	1.51e-62	0.95	0.7	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-21.16	3.65e-70	1.62e-62	-0.98	-0.7	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
HNSC	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	21.14	4.26e-70	1.89e-62	0.9	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
HNSC	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-21.1	6.39e-70	2.82e-62	-1	-0.7	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-21.1	6.65e-70	2.93e-62	-0.82	-0.7	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
HNSC	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	21.09	7.32e-70	3.22e-62	1.02	0.7	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	21.04	1.27e-69	5.52e-62	0.98	0.7	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
HNSC	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	21.03	1.39e-69	6.03e-62	1.09	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
HNSC	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	21.03	1.42e-69	6.16e-62	1.03	0.7	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-21	2.05e-69	8.89e-62	-0.92	-0.7	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
HNSC	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	20.99	2.12e-69	9.19e-62	1.03	0.7	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
HNSC	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-20.99	2.3e-69	9.9e-62	-0.99	-0.7	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-20.99	2.3e-69	9.9e-62	-0.99	-0.7	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	20.99	2.3e-69	9.9e-62	0.93	0.7	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	20.98	2.48e-69	1.07e-61	0.94	0.7	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-20.98	2.49e-69	1.07e-61	-0.99	-0.7	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-20.92	4.47e-69	1.9e-61	-1	-0.7	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-20.92	4.66e-69	1.98e-61	-1	-0.7	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.61	rs199529	ENSG00000263503.1	RP11-707O23.5	20.9	5.68e-69	2.41e-61	0.89	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45600869~45602340:-
HNSC	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-20.9	5.85e-69	2.48e-61	-1.01	-0.7	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.779	rs199526	ENSG00000263503.1	RP11-707O23.5	-20.86	8.72e-69	3.66e-61	-0.92	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45600869~45602340:-
HNSC	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-20.85	1.04e-68	4.35e-61	-1	-0.69	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	20.85	1.04e-68	4.36e-61	0.91	0.69	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
HNSC	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-20.84	1.07e-68	4.48e-61	-0.8	-0.69	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
HNSC	trans	rs7949030	0.523	rs67308910	ENSG00000186676.3	EEF1GP1	20.83	1.2e-68	5.02e-61	1.11	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62609887	chr7:125033453~125035301:+
HNSC	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-20.82	1.32e-68	5.49e-61	-1	-0.69	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	20.79	1.83e-68	7.58e-61	0.8	0.69	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
HNSC	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	20.75	2.83e-68	1.17e-60	0.94	0.69	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-20.74	3.42e-68	1.4e-60	-1	-0.69	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	20.67	6.86e-68	2.77e-60	1.16	0.69	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-20.62	1.18e-67	4.77e-60	-0.98	-0.69	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	20.6	1.57e-67	6.33e-60	0.79	0.69	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
HNSC	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	20.58	1.96e-67	7.86e-60	0.93	0.69	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	20.56	2.24e-67	8.97e-60	0.87	0.69	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	20.56	2.24e-67	8.97e-60	0.87	0.69	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	20.56	2.24e-67	8.97e-60	0.87	0.69	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.51	rs7714944	ENSG00000185986.11	SDHAP3	20.56	2.25e-67	8.97e-60	0.99	0.69	Breast cancer;	chr5:231650	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	20.54	2.98e-67	1.19e-59	1.05	0.69	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	20.53	3.25e-67	1.29e-59	1.17	0.69	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-20.46	6.67e-67	2.6e-59	-0.99	-0.69	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
HNSC	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	20.46	6.94e-67	2.7e-59	1.01	0.69	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
HNSC	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	20.45	7.34e-67	2.86e-59	1.01	0.69	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
HNSC	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	20.42	1.07e-66	4.14e-59	0.87	0.69	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	20.4	1.36e-66	5.24e-59	0.94	0.69	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-20.38	1.7e-66	6.53e-59	-0.96	-0.69	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-20.38	1.7e-66	6.53e-59	-0.96	-0.69	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	20.36	2.01e-66	7.72e-59	1.19	0.69	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-20.35	2.25e-66	8.62e-59	-0.94	-0.69	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
HNSC	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	20.33	2.69e-66	1.03e-58	1.14	0.69	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
HNSC	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	20.32	2.99e-66	1.14e-58	0.94	0.69	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
HNSC	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	20.3	3.68e-66	1.39e-58	0.93	0.68	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-20.3	3.87e-66	1.46e-58	-0.95	-0.68	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	20.27	5.31e-66	1.99e-58	0.99	0.68	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	20.27	5.31e-66	1.99e-58	0.99	0.68	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	20.27	5.31e-66	1.99e-58	0.99	0.68	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
HNSC	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	20.26	5.74e-66	2.14e-58	0.97	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
HNSC	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-20.26	6.08e-66	2.27e-58	-0.95	-0.68	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	20.24	7.19e-66	2.68e-58	1.19	0.68	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
HNSC	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-20.24	7.21e-66	2.68e-58	-0.88	-0.68	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	20.23	7.76e-66	2.88e-58	0.97	0.68	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	20.23	7.76e-66	2.88e-58	0.97	0.68	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-20.22	8.64e-66	3.2e-58	-0.92	-0.68	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
HNSC	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	20.22	8.83e-66	3.26e-58	1.18	0.68	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
HNSC	trans	rs116095464	0.558	rs12173244	ENSG00000185986.11	SDHAP3	20.18	1.44e-65	5.32e-58	1.01	0.68	Breast cancer;	chr5:269409	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-20.17	1.53e-65	5.64e-58	-0.95	-0.68	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	20.16	1.77e-65	6.5e-58	1.18	0.68	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	20.16	1.79e-65	6.57e-58	0.95	0.68	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	20.15	1.95e-65	7.14e-58	0.89	0.68	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-20.15	1.98e-65	7.23e-58	-0.97	-0.68	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	20.15	1.98e-65	7.23e-58	0.99	0.68	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
HNSC	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	20.15	2.04e-65	7.43e-58	1.15	0.68	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
HNSC	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	20.14	2.06e-65	7.51e-58	0.87	0.68	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-20.12	2.7e-65	9.82e-58	-0.95	-0.68	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-20.12	2.7e-65	9.82e-58	-0.95	-0.68	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-20.1	3.44e-65	1.24e-57	-0.97	-0.68	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-20.08	4.1e-65	1.48e-57	-0.92	-0.68	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-20.08	4.34e-65	1.55e-57	-0.97	-0.68	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-20.08	4.34e-65	1.55e-57	-0.97	-0.68	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-20.08	4.34e-65	1.55e-57	-0.97	-0.68	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs56127718	ENSG00000185986.11	SDHAP3	20.08	4.35e-65	1.56e-57	1.01	0.68	Breast cancer;	chr5:270158	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.614	rs10061564	ENSG00000185986.11	SDHAP3	20.08	4.35e-65	1.56e-57	1.01	0.68	Breast cancer;	chr5:271214	chr5:1572222~1594620:-
HNSC	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	20.07	4.51e-65	1.61e-57	0.91	0.68	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
HNSC	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-20.07	4.6e-65	1.64e-57	-0.88	-0.68	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.558	rs10057674	ENSG00000185986.11	SDHAP3	20.06	4.89e-65	1.74e-57	1	0.68	Breast cancer;	chr5:266698	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs1812843	ENSG00000185986.11	SDHAP3	20.06	4.89e-65	1.74e-57	1	0.68	Breast cancer;	chr5:267543	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs1971229	ENSG00000185986.11	SDHAP3	20.05	5.43e-65	1.93e-57	1.01	0.68	Breast cancer;	chr5:268072	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	20.04	6.17e-65	2.18e-57	0.96	0.68	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs2288459	ENSG00000185986.11	SDHAP3	20.01	8.7e-65	3.03e-57	0.99	0.68	Breast cancer;	chr5:231028	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs2288458	ENSG00000185986.11	SDHAP3	20.01	8.7e-65	3.03e-57	0.99	0.68	Breast cancer;	chr5:231145	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs2288457	ENSG00000185986.11	SDHAP3	20.01	8.7e-65	3.03e-57	0.99	0.68	Breast cancer;	chr5:231155	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7713524	ENSG00000185986.11	SDHAP3	-20.01	8.8e-65	3.06e-57	-0.99	-0.68	Breast cancer;	chr5:276085	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-20	9.69e-65	3.36e-57	-0.94	-0.68	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-20	9.69e-65	3.36e-57	-0.94	-0.68	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
HNSC	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-20	1.03e-64	3.56e-57	-1.04	-0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
HNSC	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-19.98	1.22e-64	4.2e-57	-0.92	-0.68	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-19.98	1.25e-64	4.29e-57	-0.91	-0.68	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-19.98	1.25e-64	4.29e-57	-0.91	-0.68	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
HNSC	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-19.98	1.25e-64	4.29e-57	-0.91	-0.68	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-19.98	1.25e-64	4.29e-57	-0.91	-0.68	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-19.98	1.25e-64	4.29e-57	-0.91	-0.68	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.558	rs55776650	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:273711	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs59113266	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:279850	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs11959126	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:283765	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7356696	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:284136	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7356561	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:284266	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs59284383	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:284410	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7731089	ENSG00000185986.11	SDHAP3	19.96	1.44e-64	4.83e-57	1	0.68	Breast cancer;	chr5:290307	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7708182	ENSG00000185986.11	SDHAP3	19.96	1.48e-64	4.96e-57	0.99	0.68	Breast cancer;	chr5:234673	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10058428	ENSG00000185986.11	SDHAP3	19.96	1.48e-64	4.96e-57	0.99	0.68	Breast cancer;	chr5:235493	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs28729548	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:228910	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9688136	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:229233	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs62347683	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:230216	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.51	rs55750776	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:230352	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.764	rs10069197	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:230707	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.867	rs10074958	ENSG00000185986.11	SDHAP3	19.91	2.55e-64	8.33e-57	0.99	0.68	Breast cancer;	chr5:230713	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.681	rs9687745	ENSG00000185986.11	SDHAP3	19.9	2.78e-64	9.01e-57	0.99	0.68	Breast cancer;	chr5:229194	chr5:1572222~1594620:-
HNSC	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-19.9	3.05e-64	9.85e-57	-0.91	-0.68	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	19.89	3.08e-64	9.94e-57	0.92	0.68	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
HNSC	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-19.89	3.31e-64	1.07e-56	-0.91	-0.68	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-19.89	3.31e-64	1.07e-56	-0.91	-0.68	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	19.87	3.94e-64	1.26e-56	0.87	0.68	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
HNSC	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-19.86	4.46e-64	1.43e-56	-0.95	-0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
HNSC	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-19.84	5.27e-64	1.68e-56	-0.94	-0.68	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs10057492	ENSG00000185986.11	SDHAP3	19.84	5.3e-64	1.69e-56	1.01	0.68	Breast cancer;	chr5:239388	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-19.84	5.76e-64	1.83e-56	-0.78	-0.68	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
HNSC	trans	rs116095464	0.558	rs7708515	ENSG00000185986.11	SDHAP3	19.81	7.73e-64	2.44e-56	0.96	0.68	Breast cancer;	chr5:234874	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs2162870	ENSG00000185986.11	SDHAP3	19.81	7.96e-64	2.51e-56	0.99	0.68	Breast cancer;	chr5:228014	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10043002	ENSG00000185986.11	SDHAP3	19.8	8.69e-64	2.73e-56	0.99	0.68	Breast cancer;	chr5:226638	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs28635197	ENSG00000185986.11	SDHAP3	19.79	9.42e-64	2.96e-56	0.99	0.68	Breast cancer;	chr5:278956	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7736600	ENSG00000185986.11	SDHAP3	19.78	1.01e-63	3.17e-56	0.99	0.68	Breast cancer;	chr5:231222	chr5:1572222~1594620:-
HNSC	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-19.78	1.06e-63	3.31e-56	-0.87	-0.68	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
HNSC	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-19.77	1.12e-63	3.52e-56	-0.96	-0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
HNSC	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	19.76	1.33e-63	4.15e-56	0.98	0.67	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
HNSC	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	19.76	1.33e-63	4.15e-56	0.98	0.67	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.542	rs28650039	ENSG00000185986.11	SDHAP3	19.76	1.37e-63	4.26e-56	1	0.67	Breast cancer;	chr5:273839	chr5:1572222~1594620:-
HNSC	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	19.75	1.48e-63	4.6e-56	0.98	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-19.74	1.61e-63	5e-56	-0.87	-0.67	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-19.74	1.64e-63	5.07e-56	-0.94	-0.67	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs10036253	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:238404	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10075018	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:239060	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10076655	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:239349	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs28418643	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:240744	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.614	rs62344339	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:252880	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9687898	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:253837	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9688045	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:253920	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs112343653	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:257059	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs73024831	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:257077	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs62344345	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:257305	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs57335027	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:262792	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6869925	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:263921	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6875291	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:264077	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6866776	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:264380	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6874745	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:264412	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7715108	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:264546	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7730700	ENSG00000185986.11	SDHAP3	19.73	1.73e-63	5.19e-56	1	0.67	Breast cancer;	chr5:264598	chr5:1572222~1594620:-
HNSC	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	19.71	2.21e-63	6.6e-56	1.18	0.67	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
HNSC	trans	rs116095464	0.558	rs1541822	ENSG00000185986.11	SDHAP3	-19.7	2.43e-63	7.25e-56	-0.98	-0.67	Breast cancer;	chr5:269119	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.681	rs10060016	ENSG00000185986.11	SDHAP3	19.7	2.46e-63	7.35e-56	1	0.67	Breast cancer;	chr5:240985	chr5:1572222~1594620:-
HNSC	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	19.67	3.62e-63	1.08e-55	1.09	0.67	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
HNSC	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	19.66	3.69e-63	1.09e-55	0.98	0.67	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	19.66	3.69e-63	1.09e-55	0.98	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	19.66	3.69e-63	1.09e-55	0.98	0.67	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	19.66	3.69e-63	1.09e-55	0.98	0.67	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	19.66	3.69e-63	1.09e-55	0.98	0.67	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-19.66	3.8e-63	1.12e-55	-0.97	-0.67	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	19.65	4.15e-63	1.22e-55	0.92	0.67	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	19.65	4.15e-63	1.22e-55	0.92	0.67	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	19.65	4.19e-63	1.23e-55	0.98	0.67	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	19.65	4.28e-63	1.26e-55	0.87	0.67	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
HNSC	trans	rs116095464	0.558	rs10077076	ENSG00000185986.11	SDHAP3	19.65	4.3e-63	1.26e-55	0.99	0.67	Breast cancer;	chr5:231825	chr5:1572222~1594620:-
HNSC	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	19.65	4.37e-63	1.28e-55	0.92	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	19.65	4.37e-63	1.28e-55	0.92	0.67	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
HNSC	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	19.65	4.37e-63	1.28e-55	0.92	0.67	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	19.64	4.54e-63	1.33e-55	0.96	0.67	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	19.64	4.93e-63	1.43e-55	0.97	0.67	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	19.64	4.93e-63	1.43e-55	0.97	0.67	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	19.64	4.93e-63	1.43e-55	0.97	0.67	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	19.64	4.93e-63	1.43e-55	0.97	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	19.64	4.93e-63	1.43e-55	0.97	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-19.64	4.93e-63	1.43e-55	-0.97	-0.67	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs10052012	ENSG00000185986.11	SDHAP3	19.63	5.22e-63	1.51e-55	0.99	0.67	Breast cancer;	chr5:231793	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10080225	ENSG00000185986.11	SDHAP3	19.63	5.22e-63	1.51e-55	0.99	0.67	Breast cancer;	chr5:232060	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	19.62	6e-63	1.73e-55	0.98	0.67	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	19.62	6e-63	1.73e-55	0.98	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	19.61	6.51e-63	1.88e-55	0.97	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	19.6	7.03e-63	2.02e-55	0.97	0.67	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
HNSC	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	19.6	7.1e-63	2.04e-55	0.97	0.67	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	19.6	7.1e-63	2.04e-55	0.97	0.67	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-19.6	7.66e-63	2.19e-55	-0.97	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-19.6	7.66e-63	2.19e-55	-0.97	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-19.6	7.66e-63	2.19e-55	-0.97	-0.67	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-19.6	7.66e-63	2.19e-55	-0.97	-0.67	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-19.6	7.66e-63	2.19e-55	-0.97	-0.67	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	19.6	7.68e-63	2.19e-55	0.96	0.67	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	19.59	8.24e-63	2.34e-55	0.92	0.67	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-19.58	8.68e-63	2.46e-55	-0.93	-0.67	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-19.58	8.68e-63	2.46e-55	-0.93	-0.67	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
HNSC	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	19.58	9.3e-63	2.63e-55	0.93	0.67	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
HNSC	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	19.57	1.04e-62	2.94e-55	0.97	0.67	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	19.57	1.04e-62	2.94e-55	0.97	0.67	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	19.57	1.07e-62	3.02e-55	0.97	0.67	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-19.56	1.14e-62	3.21e-55	-0.91	-0.67	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	19.55	1.2e-62	3.37e-55	0.97	0.67	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	19.54	1.37e-62	3.84e-55	0.97	0.67	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	19.54	1.47e-62	4.13e-55	0.96	0.67	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.51	rs60844864	ENSG00000185986.11	SDHAP3	19.52	1.83e-62	5.11e-55	0.99	0.67	Breast cancer;	chr5:266885	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs62347677	ENSG00000185986.11	SDHAP3	19.51	1.88e-62	5.24e-55	0.98	0.67	Breast cancer;	chr5:227338	chr5:1572222~1594620:-
HNSC	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-19.5	2.09e-62	5.8e-55	-0.91	-0.67	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.51	rs10057501	ENSG00000185986.11	SDHAP3	19.5	2.11e-62	5.85e-55	0.99	0.67	Breast cancer;	chr5:239430	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-19.5	2.2e-62	6.1e-55	-0.92	-0.67	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-19.48	2.63e-62	7.24e-55	-0.93	-0.67	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-19.48	2.63e-62	7.24e-55	-0.93	-0.67	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-19.48	2.63e-62	7.24e-55	-0.93	-0.67	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-19.47	2.94e-62	8.07e-55	-0.9	-0.67	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
HNSC	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-19.47	3.04e-62	8.35e-55	-1.16	-0.67	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-19.45	3.75e-62	1.03e-54	-0.97	-0.67	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-19.44	3.92e-62	1.07e-54	-0.94	-0.67	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs10057299	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:242020	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs13354585	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:242148	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs13356367	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:242280	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.85	rs10055295	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:243634	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs60251075	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:245177	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs62344300	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:246221	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10462754	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:246554	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10462755	ENSG00000185986.11	SDHAP3	19.44	4.14e-62	1.12e-54	0.99	0.67	Breast cancer;	chr5:246633	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-19.44	4.19e-62	1.13e-54	-0.97	-0.67	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-19.43	4.65e-62	1.25e-54	-0.91	-0.67	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
HNSC	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-19.42	5.02e-62	1.34e-54	-0.93	-0.67	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
HNSC	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	19.41	5.95e-62	1.59e-54	0.87	0.67	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	19.4	6.07e-62	1.62e-54	0.97	0.67	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	19.39	7.39e-62	1.96e-54	0.94	0.67	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	19.36	1e-61	2.65e-54	0.93	0.67	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-19.35	1.1e-61	2.91e-54	-0.92	-0.67	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	19.34	1.25e-61	3.29e-54	0.88	0.67	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-19.33	1.28e-61	3.38e-54	-0.91	-0.67	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-19.32	1.48e-61	3.9e-54	-0.9	-0.67	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-19.31	1.7e-61	4.45e-54	-0.93	-0.67	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-19.27	2.52e-61	6.54e-54	-0.95	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-19.27	2.52e-61	6.54e-54	-0.95	-0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-19.25	3.07e-61	7.95e-54	-0.93	-0.67	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
HNSC	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	19.24	3.53e-61	9.14e-54	0.93	0.66	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
HNSC	trans	rs116095464	0.614	rs28736753	ENSG00000185986.11	SDHAP3	19.23	3.84e-61	9.91e-54	1	0.66	Breast cancer;	chr5:273966	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-19.22	4.4e-61	1.13e-53	-0.93	-0.66	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-19.22	4.47e-61	1.15e-53	-0.93	-0.66	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	19.21	4.76e-61	1.22e-53	0.96	0.66	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	19.21	4.76e-61	1.22e-53	0.96	0.66	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-19.2	5.58e-61	1.42e-53	-0.93	-0.66	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	19.18	6.98e-61	1.77e-53	0.96	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-19.17	7.21e-61	1.83e-53	-0.92	-0.66	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-19.15	9.24e-61	2.33e-53	-0.92	-0.66	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-19.15	9.24e-61	2.33e-53	-0.92	-0.66	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-19.15	9.24e-61	2.33e-53	-0.92	-0.66	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	19.15	9.75e-61	2.46e-53	0.98	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	19.15	9.75e-61	2.46e-53	0.98	0.66	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	19.14	1.05e-60	2.63e-53	0.93	0.66	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	19.14	1.07e-60	2.7e-53	0.96	0.66	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-19.13	1.14e-60	2.86e-53	-0.93	-0.66	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	19.11	1.4e-60	3.5e-53	0.98	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	19.11	1.4e-60	3.5e-53	0.98	0.66	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	19.11	1.43e-60	3.57e-53	0.96	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-19.11	1.48e-60	3.69e-53	-0.98	-0.66	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	19.09	1.8e-60	4.48e-53	0.95	0.66	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	19.09	1.85e-60	4.58e-53	0.95	0.66	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	19.09	1.85e-60	4.58e-53	0.95	0.66	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	19.08	1.93e-60	4.78e-53	0.98	0.66	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	19.07	2.14e-60	5.29e-53	1	0.66	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.51	rs73016876	ENSG00000185986.11	SDHAP3	19.06	2.5e-60	6.15e-53	0.98	0.66	Breast cancer;	chr5:244360	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	19.06	2.59e-60	6.37e-53	0.98	0.66	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	19.05	2.62e-60	6.42e-53	0.95	0.66	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	19.05	2.62e-60	6.42e-53	0.95	0.66	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	19.05	2.62e-60	6.42e-53	0.95	0.66	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs6555055	ENSG00000185986.11	SDHAP3	19.05	2.71e-60	6.63e-53	0.97	0.66	Breast cancer;	chr5:226045	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6555056	ENSG00000185986.11	SDHAP3	19.05	2.71e-60	6.63e-53	0.97	0.66	Breast cancer;	chr5:226107	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-19.04	2.92e-60	7.13e-53	-0.98	-0.66	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-19.03	3.34e-60	8.14e-53	-0.97	-0.66	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	19.02	3.68e-60	8.95e-53	0.95	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	19.01	4.01e-60	9.75e-53	0.9	0.66	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	19.01	4.15e-60	1.01e-52	0.95	0.66	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	19.01	4.39e-60	1.06e-52	0.91	0.66	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs55664502	ENSG00000185986.11	SDHAP3	18.99	5.02e-60	1.21e-52	0.97	0.66	Breast cancer;	chr5:270370	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.51	rs7723883	ENSG00000185986.11	SDHAP3	18.99	5.02e-60	1.21e-52	0.97	0.66	Breast cancer;	chr5:270683	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.614	rs4371799	ENSG00000185986.11	SDHAP3	18.98	5.58e-60	1.35e-52	0.97	0.66	Breast cancer;	chr5:268077	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	18.97	6.43e-60	1.55e-52	0.95	0.66	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs7725227	ENSG00000185986.11	SDHAP3	18.97	6.59e-60	1.58e-52	0.97	0.66	Breast cancer;	chr5:233402	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7710005	ENSG00000185986.11	SDHAP3	18.97	6.59e-60	1.58e-52	0.97	0.66	Breast cancer;	chr5:233457	chr5:1572222~1594620:-
HNSC	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-18.96	7.45e-60	1.78e-52	-0.83	-0.66	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
HNSC	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	18.95	7.91e-60	1.89e-52	0.94	0.66	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
HNSC	trans	rs116095464	0.558	rs3213838	ENSG00000185986.11	SDHAP3	18.94	9.3e-60	2.2e-52	0.97	0.66	Breast cancer;	chr5:223775	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6555052	ENSG00000185986.11	SDHAP3	18.94	9.3e-60	2.2e-52	0.97	0.66	Breast cancer;	chr5:224153	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs61689490	ENSG00000185986.11	SDHAP3	18.94	9.3e-60	2.2e-52	0.97	0.66	Breast cancer;	chr5:224789	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs61492827	ENSG00000185986.11	SDHAP3	18.94	9.3e-60	2.2e-52	0.97	0.66	Breast cancer;	chr5:225659	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs56342538	ENSG00000185986.11	SDHAP3	18.94	9.3e-60	2.2e-52	0.97	0.66	Breast cancer;	chr5:225681	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.614	rs62344292	ENSG00000185986.11	SDHAP3	18.92	1.09e-59	2.58e-52	0.98	0.66	Breast cancer;	chr5:244515	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs28558836	ENSG00000185986.11	SDHAP3	18.92	1.11e-59	2.62e-52	0.97	0.66	Breast cancer;	chr5:285633	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	18.91	1.26e-59	2.95e-52	0.98	0.66	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	18.88	1.67e-59	3.89e-52	0.92	0.66	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-18.88	1.78e-59	4.13e-52	-0.88	-0.66	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	18.85	2.37e-59	5.5e-52	0.98	0.66	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	18.85	2.42e-59	5.61e-52	0.95	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-18.85	2.46e-59	5.69e-52	-0.96	-0.66	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-18.85	2.46e-59	5.69e-52	-0.96	-0.66	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-18.85	2.47e-59	5.71e-52	-0.97	-0.66	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.619	rs2303741	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:218241	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs56043030	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:220802	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10067021	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:221375	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9312977	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:221801	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6881920	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:222296	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6878061	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:222957	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6882584	ENSG00000185986.11	SDHAP3	18.84	2.7e-59	6.19e-52	0.96	0.66	Breast cancer;	chr5:223296	chr5:1572222~1594620:-
HNSC	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	18.83	2.97e-59	6.82e-52	1.16	0.66	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	18.82	3.28e-59	7.5e-52	0.92	0.66	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	18.81	3.69e-59	8.43e-52	0.88	0.66	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	18.81	3.72e-59	8.5e-52	0.87	0.66	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-18.81	3.74e-59	8.55e-52	-0.96	-0.66	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-18.8	3.88e-59	8.85e-52	-0.87	-0.66	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.558	rs10475136	ENSG00000185986.11	SDHAP3	18.79	4.49e-59	1.02e-51	0.97	0.66	Breast cancer;	chr5:232681	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-18.79	4.53e-59	1.03e-51	-0.92	-0.66	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
HNSC	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-18.79	4.63e-59	1.05e-51	-0.89	-0.66	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
HNSC	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-18.78	4.87e-59	1.11e-51	-0.93	-0.66	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
HNSC	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	18.76	5.96e-59	1.35e-51	0.94	0.66	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	18.75	7.24e-59	1.63e-51	0.95	0.66	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	18.74	7.76e-59	1.75e-51	0.98	0.66	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
HNSC	trans	rs116095464	0.558	rs62347678	ENSG00000185986.11	SDHAP3	18.72	9.11e-59	2.04e-51	0.95	0.65	Breast cancer;	chr5:227381	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs73031482	ENSG00000185986.11	SDHAP3	18.72	9.11e-59	2.04e-51	0.95	0.65	Breast cancer;	chr5:227479	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-18.71	1.1e-58	2.47e-51	-0.93	-0.65	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.614	rs10067482	ENSG00000185986.11	SDHAP3	18.71	1.11e-58	2.47e-51	0.96	0.65	Breast cancer;	chr5:219213	chr5:1572222~1594620:-
HNSC	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	18.7	1.13e-58	2.52e-51	0.81	0.65	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
HNSC	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-18.7	1.21e-58	2.69e-51	-0.9	-0.65	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-18.7	1.21e-58	2.69e-51	-0.9	-0.65	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	18.7	1.24e-58	2.76e-51	0.97	0.65	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	18.7	1.24e-58	2.76e-51	0.97	0.65	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	18.7	1.24e-58	2.76e-51	0.97	0.65	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-18.69	1.27e-58	2.82e-51	-1.02	-0.65	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
HNSC	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	18.69	1.36e-58	3.02e-51	0.94	0.65	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
HNSC	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	18.68	1.45e-58	3.21e-51	0.81	0.65	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
HNSC	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-18.68	1.49e-58	3.29e-51	-0.91	-0.65	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	18.68	1.52e-58	3.36e-51	0.95	0.65	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	18.65	1.93e-58	4.23e-51	0.92	0.65	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
HNSC	trans	rs116095464	0.558	rs113796397	ENSG00000185986.11	SDHAP3	18.64	2.15e-58	4.71e-51	0.97	0.65	Breast cancer;	chr5:246388	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-18.64	2.32e-58	5.06e-51	-0.89	-0.65	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-18.64	2.32e-58	5.06e-51	-0.89	-0.65	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.614	rs56299325	ENSG00000185986.11	SDHAP3	18.62	2.82e-58	6.13e-51	0.95	0.65	Breast cancer;	chr5:220479	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs62346526	ENSG00000185986.11	SDHAP3	18.62	2.82e-58	6.13e-51	0.95	0.65	Breast cancer;	chr5:220499	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-18.61	3.2e-58	6.96e-51	-0.91	-0.65	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs7703803	ENSG00000185986.11	SDHAP3	18.6	3.39e-58	7.37e-51	0.98	0.65	Breast cancer;	chr5:292196	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.614	rs78905930	ENSG00000185986.11	SDHAP3	18.58	4.03e-58	8.74e-51	0.97	0.65	Breast cancer;	chr5:246445	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	18.58	4.36e-58	9.43e-51	0.97	0.65	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	18.58	4.36e-58	9.43e-51	0.97	0.65	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-18.58	4.36e-58	9.43e-51	-0.97	-0.65	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	18.56	5.09e-58	1.09e-50	0.75	0.65	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
HNSC	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	18.56	5.54e-58	1.19e-50	0.96	0.65	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	18.56	5.54e-58	1.19e-50	0.96	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	18.56	5.54e-58	1.19e-50	0.96	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-18.55	6.1e-58	1.3e-50	-1.02	-0.65	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
HNSC	trans	rs116095464	0.558	rs6866632	ENSG00000185986.11	SDHAP3	18.55	6.13e-58	1.31e-50	0.96	0.65	Breast cancer;	chr5:264314	chr5:1572222~1594620:-
HNSC	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	18.55	6.17e-58	1.31e-50	0.8	0.65	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	18.55	6.17e-58	1.31e-50	0.8	0.65	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	18.55	6.17e-58	1.31e-50	0.8	0.65	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	18.55	6.17e-58	1.31e-50	0.8	0.65	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
HNSC	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	18.54	6.22e-58	1.32e-50	0.8	0.65	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
HNSC	trans	rs116095464	0.558	rs10079760	ENSG00000185986.11	SDHAP3	18.53	7.12e-58	1.51e-50	0.93	0.65	Breast cancer;	chr5:230663	chr5:1572222~1594620:-
HNSC	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-18.53	7.15e-58	1.52e-50	-1.15	-0.65	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
HNSC	trans	rs116095464	0.558	rs13357299	ENSG00000185986.11	SDHAP3	18.53	7.32e-58	1.55e-50	0.96	0.65	Breast cancer;	chr5:242096	chr5:1572222~1594620:-
HNSC	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-18.53	7.48e-58	1.59e-50	-0.83	-0.65	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
HNSC	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	18.52	7.68e-58	1.62e-50	0.8	0.65	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
HNSC	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	18.52	7.68e-58	1.62e-50	0.8	0.65	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
HNSC	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	18.52	7.68e-58	1.62e-50	0.8	0.65	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
HNSC	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-18.52	7.94e-58	1.68e-50	-0.9	-0.65	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	18.52	8.5e-58	1.79e-50	0.8	0.65	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	18.51	8.63e-58	1.81e-50	0.91	0.65	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	18.51	8.63e-58	1.81e-50	0.91	0.65	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	18.51	9.02e-58	1.89e-50	0.93	0.65	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	18.49	1.1e-57	2.3e-50	0.8	0.65	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	18.49	1.11e-57	2.32e-50	0.8	0.65	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-18.49	1.18e-57	2.45e-50	-0.89	-0.65	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-18.48	1.18e-57	2.47e-50	-0.97	-0.65	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-18.46	1.47e-57	3.05e-50	-1.01	-0.65	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
HNSC	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-18.46	1.49e-57	3.1e-50	-0.89	-0.65	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	18.46	1.5e-57	3.12e-50	0.99	0.65	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	18.46	1.5e-57	3.12e-50	0.99	0.65	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
HNSC	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	18.46	1.53e-57	3.18e-50	0.8	0.65	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
HNSC	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-18.46	1.58e-57	3.28e-50	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-18.46	1.58e-57	3.28e-50	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
HNSC	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-18.46	1.62e-57	3.35e-50	-0.87	-0.65	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
HNSC	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	18.45	1.69e-57	3.48e-50	1.15	0.65	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	18.44	1.96e-57	4.03e-50	0.94	0.65	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
HNSC	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-18.42	2.26e-57	4.65e-50	-0.81	-0.65	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
HNSC	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-18.42	2.45e-57	5.01e-50	-1.02	-0.65	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-18.41	2.74e-57	5.61e-50	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
HNSC	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	18.41	2.75e-57	5.63e-50	0.92	0.65	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.867	rs7726582	ENSG00000185986.11	SDHAP3	18.4	3.01e-57	6.13e-50	0.95	0.65	Breast cancer;	chr5:215234	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	18.39	3.26e-57	6.65e-50	0.87	0.65	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	18.37	3.91e-57	7.95e-50	1	0.65	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
HNSC	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	18.37	4e-57	8.12e-50	0.8	0.65	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
HNSC	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-18.36	4.39e-57	8.9e-50	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-18.36	4.68e-57	9.5e-50	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
HNSC	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-18.35	4.98e-57	1.01e-49	-0.9	-0.65	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	18.35	5.23e-57	1.06e-49	0.8	0.65	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-18.34	5.61e-57	1.13e-49	-0.94	-0.65	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-18.34	5.64e-57	1.14e-49	-0.76	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
HNSC	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	18.33	6.45e-57	1.3e-49	0.84	0.65	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
HNSC	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	18.32	6.55e-57	1.32e-49	0.84	0.65	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-18.32	6.65e-57	1.34e-49	-0.73	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
HNSC	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	18.31	7.4e-57	1.49e-49	0.79	0.65	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-18.31	7.66e-57	1.54e-49	-0.89	-0.65	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	18.31	7.99e-57	1.6e-49	0.97	0.65	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	18.3	8.27e-57	1.66e-49	0.8	0.65	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-18.3	8.77e-57	1.76e-49	-0.87	-0.65	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-18.29	9.09e-57	1.82e-49	-0.73	-0.65	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
HNSC	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-18.29	9.27e-57	1.85e-49	-0.88	-0.65	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-18.29	9.32e-57	1.86e-49	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-18.29	9.32e-57	1.86e-49	-0.75	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
HNSC	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	18.27	1.16e-56	2.32e-49	0.79	0.65	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	18.27	1.17e-56	2.33e-49	0.8	0.65	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
HNSC	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	18.27	1.18e-56	2.35e-49	0.8	0.65	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
HNSC	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	18.27	1.19e-56	2.37e-49	0.8	0.65	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	18.27	1.19e-56	2.37e-49	0.8	0.65	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	18.27	1.22e-56	2.43e-49	0.8	0.65	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	18.27	1.23e-56	2.44e-49	0.8	0.65	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	18.27	1.23e-56	2.45e-49	0.8	0.65	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	18.24	1.58e-56	3.14e-49	0.8	0.65	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
HNSC	trans	rs116095464	0.558	rs6555058	ENSG00000185986.11	SDHAP3	-18.24	1.63e-56	3.23e-49	-0.95	-0.64	Breast cancer;	chr5:226261	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-18.23	1.78e-56	3.52e-49	-0.89	-0.64	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-18.23	1.85e-56	3.64e-49	-0.75	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
HNSC	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	18.2	2.53e-56	4.93e-49	0.79	0.64	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	18.2	2.53e-56	4.93e-49	0.79	0.64	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-18.17	3.45e-56	6.69e-49	-0.9	-0.64	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	18.15	4.04e-56	7.84e-49	0.8	0.64	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
HNSC	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-18.14	4.53e-56	8.75e-49	-1	-0.64	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
HNSC	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	18.13	5.09e-56	9.81e-49	0.87	0.64	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	18.12	5.84e-56	1.12e-48	1.55	0.64	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
HNSC	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	18.11	6.75e-56	1.29e-48	1	0.64	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
HNSC	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-18.1	7.01e-56	1.34e-48	-0.71	-0.64	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-18.1	7.57e-56	1.45e-48	-0.72	-0.64	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
HNSC	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	18.09	7.82e-56	1.49e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	18.09	7.82e-56	1.49e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	18.09	7.82e-56	1.49e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	18.09	7.82e-56	1.49e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	18.08	8.58e-56	1.63e-48	0.87	0.64	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
HNSC	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	18.08	8.86e-56	1.68e-48	0.79	0.64	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	18.08	8.97e-56	1.7e-48	0.82	0.64	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	18.08	8.97e-56	1.7e-48	0.82	0.64	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	18.08	8.97e-56	1.7e-48	0.82	0.64	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
HNSC	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	18.07	1.02e-55	1.93e-48	0.8	0.64	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
HNSC	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-18.06	1.07e-55	2.03e-48	-1	-0.64	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-18.06	1.07e-55	2.03e-48	-1	-0.64	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
HNSC	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-18.04	1.32e-55	2.5e-48	-0.82	-0.64	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
HNSC	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-18.04	1.43e-55	2.69e-48	-1.01	-0.64	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
HNSC	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	18.02	1.7e-55	3.19e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	18.02	1.7e-55	3.19e-48	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
HNSC	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	18.02	1.72e-55	3.22e-48	0.79	0.64	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
HNSC	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	18.02	1.73e-55	3.23e-48	0.91	0.64	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
HNSC	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	18.01	1.79e-55	3.35e-48	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-18.01	1.88e-55	3.49e-48	-0.73	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-18.01	1.88e-55	3.49e-48	-0.73	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
HNSC	trans	rs116095464	0.558	rs6872854	ENSG00000185986.11	SDHAP3	18	2e-55	3.71e-48	0.93	0.64	Breast cancer;	chr5:208923	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-18	2.08e-55	3.87e-48	-0.72	-0.64	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-18	2.17e-55	4.02e-48	-0.72	-0.64	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
HNSC	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-17.99	2.35e-55	4.35e-48	-0.98	-0.64	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
HNSC	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	17.99	2.36e-55	4.37e-48	0.79	0.64	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
HNSC	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-17.97	3.01e-55	5.54e-48	-0.7	-0.64	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-17.96	3.19e-55	5.86e-48	-0.72	-0.64	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
HNSC	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	17.96	3.28e-55	6.01e-48	0.82	0.64	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	17.96	3.28e-55	6.01e-48	0.82	0.64	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
HNSC	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-17.95	3.5e-55	6.41e-48	-0.85	-0.64	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	17.94	4.04e-55	7.37e-48	0.82	0.64	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-17.93	4.42e-55	8.03e-48	-0.75	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-17.92	5.09e-55	9.21e-48	-0.75	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
HNSC	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-17.91	5.69e-55	1.02e-47	-0.86	-0.64	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
HNSC	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	17.89	6.55e-55	1.17e-47	0.7	0.64	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
HNSC	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	17.89	6.62e-55	1.18e-47	1.15	0.64	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-17.89	6.76e-55	1.21e-47	-0.71	-0.64	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
HNSC	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	17.89	6.93e-55	1.24e-47	0.86	0.64	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
HNSC	trans	rs6708331	0.752	rs6721306	ENSG00000232654.1	FAM136BP	17.89	7.04e-55	1.26e-47	0.86	0.64	Obesity-related traits;	chr2:70190013	chr6:3045384~3045800:+
HNSC	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-17.89	7.09e-55	1.26e-47	-0.99	-0.64	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-17.89	7.09e-55	1.26e-47	-0.99	-0.64	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	17.88	7.58e-55	1.35e-47	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-17.87	8.14e-55	1.44e-47	-0.74	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	17.87	8.15e-55	1.44e-47	0.86	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
HNSC	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	17.87	8.54e-55	1.51e-47	0.77	0.64	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
HNSC	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-17.87	8.64e-55	1.53e-47	-0.94	-0.64	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	17.87	8.78e-55	1.55e-47	1.54	0.64	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	17.87	8.78e-55	1.55e-47	1.54	0.64	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	17.87	8.78e-55	1.55e-47	1.54	0.64	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
HNSC	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	17.86	8.95e-55	1.58e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
HNSC	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-17.86	9.49e-55	1.67e-47	-0.71	-0.64	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
HNSC	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	17.86	9.78e-55	1.72e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
HNSC	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-17.85	9.89e-55	1.73e-47	-0.71	-0.64	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
HNSC	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-17.85	1.04e-54	1.81e-47	-0.85	-0.64	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
HNSC	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	17.84	1.1e-54	1.93e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	17.84	1.1e-54	1.93e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
HNSC	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	17.84	1.13e-54	1.97e-47	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	17.84	1.13e-54	1.97e-47	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	17.84	1.13e-54	1.97e-47	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	17.84	1.13e-54	1.97e-47	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
HNSC	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-17.84	1.14e-54	2e-47	-0.8	-0.64	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
HNSC	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	17.83	1.23e-54	2.14e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	17.83	1.23e-54	2.14e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	17.83	1.29e-54	2.24e-47	0.84	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	17.83	1.29e-54	2.24e-47	0.84	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
HNSC	trans	rs6708331	0.54	rs28623550	ENSG00000232654.1	FAM136BP	17.83	1.34e-54	2.32e-47	0.79	0.64	Obesity-related traits;	chr2:70139260	chr6:3045384~3045800:+
HNSC	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	17.83	1.34e-54	2.32e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	17.83	1.35e-54	2.33e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	17.82	1.46e-54	2.53e-47	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
HNSC	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-17.81	1.5e-54	2.57e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
HNSC	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	17.8	1.71e-54	2.88e-47	0.99	0.64	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
HNSC	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-17.79	1.92e-54	3.23e-47	-0.71	-0.64	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
HNSC	trans	rs6708331	0.517	rs12617812	ENSG00000232654.1	FAM136BP	17.79	2e-54	3.35e-47	0.79	0.64	Obesity-related traits;	chr2:70132339	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.517	rs7599072	ENSG00000232654.1	FAM136BP	17.79	2e-54	3.35e-47	0.79	0.64	Obesity-related traits;	chr2:70132874	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.517	rs12992553	ENSG00000232654.1	FAM136BP	17.79	2e-54	3.35e-47	0.79	0.64	Obesity-related traits;	chr2:70133130	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.54	rs11890701	ENSG00000232654.1	FAM136BP	17.79	2e-54	3.35e-47	0.79	0.64	Obesity-related traits;	chr2:70133325	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.517	rs11890741	ENSG00000232654.1	FAM136BP	17.79	2e-54	3.35e-47	0.79	0.64	Obesity-related traits;	chr2:70133374	chr6:3045384~3045800:+
HNSC	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-17.77	2.34e-54	3.91e-47	-0.71	-0.64	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
HNSC	trans	rs941207	0.542	rs11171986	ENSG00000121089.4	NACA3P	-17.77	2.48e-54	4.14e-47	-0.9	-0.64	Platelet count;	chr12:56819043	chr4:164943290~164943937:+
HNSC	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	17.76	2.73e-54	4.54e-47	0.82	0.63	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	17.76	2.75e-54	4.58e-47	0.75	0.63	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
HNSC	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	17.75	2.84e-54	4.73e-47	1.15	0.63	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
HNSC	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-17.75	3.07e-54	5.09e-47	-0.8	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
HNSC	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-17.75	3.12e-54	5.17e-47	-0.97	-0.63	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-17.75	3.14e-54	5.21e-47	-0.99	-0.63	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
HNSC	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-17.74	3.32e-54	5.48e-47	-0.71	-0.63	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-17.74	3.32e-54	5.48e-47	-0.71	-0.63	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-17.74	3.32e-54	5.48e-47	-0.71	-0.63	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-17.74	3.32e-54	5.48e-47	-0.71	-0.63	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-17.74	3.37e-54	5.54e-47	-0.71	-0.63	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
HNSC	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	17.74	3.39e-54	5.57e-47	1.63	0.63	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
HNSC	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-17.74	3.42e-54	5.61e-47	-0.72	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
HNSC	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	17.74	3.48e-54	5.72e-47	1.65	0.63	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	17.74	3.48e-54	5.72e-47	1.65	0.63	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	17.73	3.74e-54	6.14e-47	0.87	0.63	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	17.73	3.86e-54	6.33e-47	0.99	0.63	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
HNSC	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-17.72	3.93e-54	6.45e-47	-0.87	-0.63	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-17.72	4.24e-54	6.95e-47	-0.84	-0.63	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
HNSC	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	17.72	4.29e-54	7.02e-47	0.94	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
HNSC	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-17.71	4.36e-54	7.12e-47	-0.8	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
HNSC	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	17.71	4.56e-54	7.46e-47	0.87	0.63	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
HNSC	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-17.7	5.28e-54	8.61e-47	-0.71	-0.63	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-17.69	5.54e-54	9.02e-47	-0.71	-0.63	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-17.69	5.58e-54	9.08e-47	-0.71	-0.63	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
HNSC	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	17.69	5.9e-54	9.59e-47	1.65	0.63	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
HNSC	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-17.68	6.14e-54	9.97e-47	-0.73	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
HNSC	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	17.67	7.22e-54	1.17e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	17.67	7.22e-54	1.17e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	17.67	7.22e-54	1.17e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	17.67	7.22e-54	1.17e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
HNSC	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-17.66	7.61e-54	1.23e-46	-0.85	-0.63	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-17.66	7.8e-54	1.26e-46	-0.71	-0.63	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
HNSC	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-17.65	8.87e-54	1.43e-46	-0.9	-0.63	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
HNSC	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	17.65	9.06e-54	1.46e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	17.65	9.06e-54	1.46e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
HNSC	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-17.63	1.07e-53	1.72e-46	-0.92	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-17.63	1.1e-53	1.77e-46	-0.71	-0.63	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	17.62	1.18e-53	1.9e-46	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
HNSC	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	17.62	1.21e-53	1.93e-46	1.12	0.63	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
HNSC	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-17.62	1.21e-53	1.94e-46	-0.7	-0.63	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-17.62	1.21e-53	1.94e-46	-0.7	-0.63	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-17.62	1.21e-53	1.94e-46	-0.7	-0.63	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-17.62	1.21e-53	1.94e-46	-0.7	-0.63	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
HNSC	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	17.61	1.3e-53	2.08e-46	0.95	0.63	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-17.61	1.34e-53	2.13e-46	-0.92	-0.63	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
HNSC	trans	rs6708331	0.517	rs12999042	ENSG00000232654.1	FAM136BP	17.61	1.39e-53	2.21e-46	0.78	0.63	Obesity-related traits;	chr2:70139679	chr6:3045384~3045800:+
HNSC	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	17.6	1.54e-53	2.45e-46	0.79	0.63	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
HNSC	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	17.6	1.54e-53	2.45e-46	0.97	0.63	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	17.59	1.58e-53	2.51e-46	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
HNSC	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	17.59	1.58e-53	2.51e-46	0.82	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
HNSC	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	17.59	1.59e-53	2.52e-46	0.79	0.63	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	17.59	1.59e-53	2.52e-46	0.79	0.63	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	17.59	1.59e-53	2.52e-46	0.79	0.63	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	17.59	1.59e-53	2.52e-46	0.79	0.63	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	17.59	1.59e-53	2.52e-46	0.79	0.63	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
HNSC	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	17.59	1.64e-53	2.59e-46	0.79	0.63	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	17.59	1.64e-53	2.6e-46	0.79	0.63	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-17.59	1.65e-53	2.61e-46	-0.71	-0.63	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-17.59	1.65e-53	2.61e-46	-0.71	-0.63	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-17.59	1.65e-53	2.61e-46	-0.71	-0.63	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
HNSC	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	17.59	1.73e-53	2.73e-46	0.79	0.63	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
HNSC	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-17.58	1.78e-53	2.81e-46	-0.89	-0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
HNSC	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-17.58	1.89e-53	2.98e-46	-0.71	-0.63	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
HNSC	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	17.57	1.93e-53	3.04e-46	0.97	0.63	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	17.57	1.99e-53	3.14e-46	0.79	0.63	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	17.57	2.05e-53	3.23e-46	0.79	0.63	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
HNSC	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	17.57	2.07e-53	3.26e-46	0.93	0.63	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
HNSC	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	17.57	2.08e-53	3.28e-46	0.79	0.63	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
HNSC	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	17.56	2.19e-53	3.43e-46	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	17.54	2.66e-53	4.15e-46	0.81	0.63	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	17.54	2.66e-53	4.15e-46	0.81	0.63	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
HNSC	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-17.54	2.66e-53	4.16e-46	-0.82	-0.63	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-17.54	2.85e-53	4.45e-46	-0.71	-0.63	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
HNSC	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	17.53	2.98e-53	4.64e-46	1.62	0.63	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
HNSC	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	17.53	3.07e-53	4.77e-46	0.8	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
HNSC	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	17.53	3.07e-53	4.77e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	17.53	3.07e-53	4.77e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	17.53	3.07e-53	4.77e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	17.53	3.07e-53	4.77e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	17.53	3.07e-53	4.77e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
HNSC	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-17.53	3.1e-53	4.81e-46	-0.71	-0.63	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
HNSC	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	17.53	3.1e-53	4.82e-46	0.91	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
HNSC	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	17.53	3.26e-53	5.06e-46	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
HNSC	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	17.52	3.27e-53	5.06e-46	0.94	0.63	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	17.52	3.27e-53	5.06e-46	0.94	0.63	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	17.52	3.27e-53	5.06e-46	0.94	0.63	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	17.52	3.27e-53	5.06e-46	0.94	0.63	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-17.52	3.29e-53	5.09e-46	-0.7	-0.63	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	17.52	3.29e-53	5.09e-46	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
HNSC	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	17.52	3.35e-53	5.17e-46	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	17.52	3.43e-53	5.3e-46	0.8	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	17.52	3.49e-53	5.39e-46	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	17.52	3.49e-53	5.39e-46	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	17.51	3.68e-53	5.69e-46	0.82	0.63	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
HNSC	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-17.51	3.85e-53	5.93e-46	-0.84	-0.63	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
HNSC	trans	rs6708331	0.517	rs9989836	ENSG00000232654.1	FAM136BP	17.51	3.93e-53	6.06e-46	0.77	0.63	Obesity-related traits;	chr2:70115595	chr6:3045384~3045800:+
HNSC	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	17.5	4.07e-53	6.25e-46	1.6	0.63	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	17.5	4.07e-53	6.25e-46	1.6	0.63	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	17.5	4.07e-53	6.25e-46	1.6	0.63	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	17.5	4.07e-53	6.25e-46	1.6	0.63	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
HNSC	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-17.5	4.2e-53	6.45e-46	-0.7	-0.63	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
HNSC	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	17.5	4.37e-53	6.7e-46	0.86	0.63	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
HNSC	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	17.49	4.51e-53	6.9e-46	0.91	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
HNSC	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	17.49	4.63e-53	7.08e-46	1.59	0.63	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
HNSC	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-17.49	4.84e-53	7.4e-46	-0.7	-0.63	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
HNSC	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	17.48	5.27e-53	8.03e-46	0.97	0.63	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	17.48	5.54e-53	8.44e-46	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
HNSC	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-17.47	5.99e-53	9.1e-46	-0.78	-0.63	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	17.46	6.62e-53	1e-45	0.8	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	17.46	6.62e-53	1e-45	0.8	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
HNSC	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	17.45	7.08e-53	1.07e-45	0.79	0.63	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	17.45	7.15e-53	1.08e-45	0.82	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
HNSC	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	17.45	7.18e-53	1.09e-45	1.6	0.63	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
HNSC	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	17.45	7.47e-53	1.13e-45	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	17.45	7.47e-53	1.13e-45	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
HNSC	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-17.43	8.57e-53	1.29e-45	-0.7	-0.63	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
HNSC	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	17.43	9.28e-53	1.39e-45	0.77	0.63	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
HNSC	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	17.42	9.45e-53	1.42e-45	0.77	0.63	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
HNSC	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-17.42	9.6e-53	1.44e-45	-0.81	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	17.42	9.64e-53	1.44e-45	0.84	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
HNSC	trans	rs6708331	0.517	rs6743372	ENSG00000232654.1	FAM136BP	17.42	1.01e-52	1.52e-45	0.78	0.63	Obesity-related traits;	chr2:70125508	chr6:3045384~3045800:+
HNSC	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	17.41	1.06e-52	1.58e-45	0.77	0.63	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
HNSC	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	17.41	1.1e-52	1.64e-45	0.85	0.63	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
HNSC	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-17.41	1.12e-52	1.67e-45	-0.7	-0.63	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
HNSC	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	17.41	1.13e-52	1.68e-45	0.77	0.63	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
HNSC	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	17.41	1.13e-52	1.68e-45	0.77	0.63	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
HNSC	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	17.4	1.2e-52	1.79e-45	0.81	0.63	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
HNSC	trans	rs116095464	0.558	rs7714335	ENSG00000185986.11	SDHAP3	17.4	1.27e-52	1.89e-45	0.94	0.63	Breast cancer;	chr5:263398	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-17.39	1.38e-52	2.05e-45	-0.7	-0.63	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
HNSC	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	17.38	1.48e-52	2.2e-45	0.78	0.63	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	17.38	1.49e-52	2.22e-45	0.81	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	17.38	1.51e-52	2.24e-45	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	17.38	1.51e-52	2.24e-45	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
HNSC	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	17.36	1.88e-52	2.77e-45	0.77	0.63	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
HNSC	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	17.36	1.9e-52	2.8e-45	0.8	0.63	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
HNSC	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-17.35	2.02e-52	2.98e-45	-0.9	-0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
HNSC	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	17.34	2.21e-52	3.25e-45	0.76	0.63	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
HNSC	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	17.34	2.33e-52	3.42e-45	0.82	0.63	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
HNSC	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-17.34	2.37e-52	3.49e-45	-0.7	-0.63	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	17.34	2.41e-52	3.54e-45	0.72	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
HNSC	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-17.33	2.57e-52	3.76e-45	-0.7	-0.63	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-17.33	2.63e-52	3.84e-45	-0.7	-0.63	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	17.33	2.7e-52	3.94e-45	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	17.33	2.7e-52	3.94e-45	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-17.33	2.71e-52	3.95e-45	-0.79	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
HNSC	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	17.32	2.81e-52	4.1e-45	0.8	0.63	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
HNSC	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-17.32	2.83e-52	4.13e-45	-0.85	-0.63	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs10068203	ENSG00000185986.11	SDHAP3	17.32	2.88e-52	4.2e-45	0.93	0.63	Breast cancer;	chr5:206503	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs73029475	ENSG00000185986.11	SDHAP3	17.32	2.88e-52	4.2e-45	0.93	0.63	Breast cancer;	chr5:206854	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-17.32	2.9e-52	4.22e-45	-0.71	-0.63	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-17.31	3.19e-52	4.64e-45	-0.81	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
HNSC	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-17.31	3.21e-52	4.66e-45	-0.88	-0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
HNSC	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	17.3	3.37e-52	4.89e-45	0.78	0.63	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	17.3	3.38e-52	4.89e-45	0.71	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
HNSC	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	17.3	3.39e-52	4.91e-45	0.8	0.63	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-17.3	3.47e-52	5.03e-45	-0.7	-0.63	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
HNSC	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	17.3	3.59e-52	5.2e-45	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
HNSC	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	17.28	4.23e-52	6.11e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
HNSC	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-17.27	5.11e-52	7.37e-45	-0.83	-0.62	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-17.26	5.42e-52	7.82e-45	-0.81	-0.62	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
HNSC	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	17.25	5.7e-52	8.21e-45	0.93	0.62	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	17.25	5.7e-52	8.21e-45	0.93	0.62	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
HNSC	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-17.25	6.09e-52	8.76e-45	-0.7	-0.62	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-17.25	6.09e-52	8.76e-45	-0.7	-0.62	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
HNSC	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-17.25	6.09e-52	8.76e-45	-0.7	-0.62	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	17.24	6.65e-52	9.54e-45	0.71	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
HNSC	trans	rs6708331	0.517	rs11692018	ENSG00000232654.1	FAM136BP	17.23	7.31e-52	1.05e-44	0.78	0.62	Obesity-related traits;	chr2:70142022	chr6:3045384~3045800:+
HNSC	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	17.23	7.32e-52	1.05e-44	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
HNSC	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-17.23	7.42e-52	1.06e-44	-0.77	-0.62	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	17.23	7.45e-52	1.07e-44	0.68	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
HNSC	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-17.23	7.46e-52	1.07e-44	-0.8	-0.62	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	17.22	8.11e-52	1.16e-44	0.8	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
HNSC	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	17.22	8.24e-52	1.18e-44	0.83	0.62	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
HNSC	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	17.21	9.17e-52	1.31e-44	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	17.2	9.78e-52	1.39e-44	0.7	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-17.2	9.83e-52	1.4e-44	-0.79	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
HNSC	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-17.2	1.02e-51	1.45e-44	-0.7	-0.62	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
HNSC	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	17.2	1.02e-51	1.45e-44	0.79	0.62	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
HNSC	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-17.2	1.03e-51	1.46e-44	-0.7	-0.62	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
HNSC	trans	rs116095464	0.558	rs10059907	ENSG00000185986.11	SDHAP3	17.2	1.03e-51	1.47e-44	0.93	0.62	Breast cancer;	chr5:205245	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs10060089	ENSG00000185986.11	SDHAP3	17.2	1.03e-51	1.47e-44	0.93	0.62	Breast cancer;	chr5:205450	chr5:1572222~1594620:-
HNSC	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	17.19	1.09e-51	1.54e-44	0.77	0.62	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
HNSC	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	17.19	1.1e-51	1.56e-44	1.01	0.62	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	17.19	1.16e-51	1.65e-44	0.71	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
HNSC	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-17.18	1.24e-51	1.76e-44	-0.7	-0.62	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-17.17	1.46e-51	2.07e-44	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
HNSC	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-17.16	1.58e-51	2.23e-44	-0.84	-0.62	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-17.11	2.56e-51	3.6e-44	-0.7	-0.62	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
HNSC	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	17.1	2.82e-51	3.95e-44	0.96	0.62	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
HNSC	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-17.09	3.09e-51	4.32e-44	-0.76	-0.62	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
HNSC	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-17.09	3.14e-51	4.39e-44	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
HNSC	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	17.09	3.24e-51	4.53e-44	0.95	0.62	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	17.09	3.32e-51	4.64e-44	0.79	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-17.09	3.34e-51	4.67e-44	-0.79	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
HNSC	trans	rs116095464	0.614	rs10059220	ENSG00000185986.11	SDHAP3	17.08	3.59e-51	5.02e-44	0.93	0.62	Breast cancer;	chr5:242698	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs6962	ENSG00000185986.11	SDHAP3	17.08	3.72e-51	5.19e-44	0.98	0.62	Breast cancer;	chr5:256394	chr5:1572222~1594620:-
HNSC	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-17.07	3.91e-51	5.45e-44	-0.76	-0.62	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
HNSC	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	17.07	4.12e-51	5.74e-44	1.12	0.62	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
HNSC	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-17.07	4.16e-51	5.79e-44	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
HNSC	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	17.06	4.26e-51	5.93e-44	0.9	0.62	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	17.06	4.26e-51	5.93e-44	0.9	0.62	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	17.06	4.47e-51	6.21e-44	0.78	0.62	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-17.05	4.92e-51	6.83e-44	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
HNSC	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-17.04	5.66e-51	7.83e-44	-0.76	-0.62	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
HNSC	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-17.03	5.97e-51	8.25e-44	-0.83	-0.62	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	17.03	5.98e-51	8.26e-44	0.79	0.62	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
HNSC	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	17.02	6.72e-51	9.28e-44	0.86	0.62	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
HNSC	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	17.02	6.81e-51	9.41e-44	0.75	0.62	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
HNSC	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-17.01	7.42e-51	1.02e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
HNSC	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-17.01	7.72e-51	1.06e-43	-0.84	-0.62	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	17.01	7.73e-51	1.06e-43	0.8	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
HNSC	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	17.01	7.83e-51	1.08e-43	0.87	0.62	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
HNSC	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	17	8.44e-51	1.16e-43	0.74	0.62	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
HNSC	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-16.99	8.96e-51	1.23e-43	-0.69	-0.62	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
HNSC	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-16.99	9.11e-51	1.25e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-16.99	9.11e-51	1.25e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
HNSC	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	16.99	9.6e-51	1.32e-43	0.92	0.62	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	16.99	9.6e-51	1.32e-43	0.92	0.62	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
HNSC	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	16.98	1e-50	1.37e-43	0.96	0.62	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	16.98	1.01e-50	1.39e-43	0.83	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	16.98	1.09e-50	1.5e-43	0.84	0.62	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
HNSC	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-16.96	1.26e-50	1.72e-43	-0.79	-0.62	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
HNSC	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-16.96	1.27e-50	1.74e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-16.96	1.27e-50	1.74e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
HNSC	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	16.96	1.35e-50	1.84e-43	0.76	0.62	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
HNSC	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	16.96	1.35e-50	1.85e-43	0.87	0.62	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
HNSC	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-16.95	1.38e-50	1.89e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
HNSC	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	16.95	1.44e-50	1.96e-43	0.75	0.62	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
HNSC	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-16.94	1.58e-50	2.16e-43	-0.69	-0.62	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
HNSC	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	16.94	1.66e-50	2.27e-43	0.79	0.62	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
HNSC	trans	rs116095464	1	rs28416084	ENSG00000185986.11	SDHAP3	16.93	1.7e-50	2.32e-43	0.92	0.62	Breast cancer;	chr5:217525	chr5:1572222~1594620:-
HNSC	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-16.93	1.81e-50	2.46e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	16.92	1.91e-50	2.6e-43	0.79	0.62	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	16.92	1.91e-50	2.6e-43	0.79	0.62	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
HNSC	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	16.92	1.92e-50	2.61e-43	0.77	0.62	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
HNSC	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	16.92	1.99e-50	2.7e-43	0.79	0.62	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-16.92	2.04e-50	2.77e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-16.92	2.04e-50	2.77e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-16.92	2.04e-50	2.77e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
HNSC	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	16.91	2.25e-50	3.04e-43	0.76	0.62	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
HNSC	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	16.9	2.36e-50	3.19e-43	0.76	0.62	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
HNSC	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	16.9	2.36e-50	3.2e-43	0.79	0.62	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
HNSC	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	16.9	2.39e-50	3.23e-43	0.77	0.62	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
HNSC	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	16.9	2.43e-50	3.29e-43	0.78	0.62	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	16.9	2.46e-50	3.32e-43	0.92	0.62	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-16.89	2.57e-50	3.47e-43	-0.91	-0.62	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	16.89	2.65e-50	3.57e-43	0.78	0.62	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	16.89	2.65e-50	3.57e-43	0.78	0.62	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-16.89	2.7e-50	3.63e-43	-0.94	-0.62	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
HNSC	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-16.89	2.72e-50	3.66e-43	-0.78	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
HNSC	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-16.89	2.78e-50	3.74e-43	-0.69	-0.62	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
HNSC	trans	rs116095464	0.558	rs62346506	ENSG00000185986.11	SDHAP3	16.88	2.97e-50	3.99e-43	0.92	0.62	Breast cancer;	chr5:201479	chr5:1572222~1594620:-
HNSC	trans	rs116095464	0.558	rs9312956	ENSG00000185986.11	SDHAP3	16.88	2.97e-50	3.99e-43	0.92	0.62	Breast cancer;	chr5:201697	chr5:1572222~1594620:-
HNSC	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-16.87	3.42e-50	4.59e-43	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
HNSC	trans	rs9607805	1	rs9607805	ENSG00000268568.1	AC007228.9	16.87	3.45e-50	4.62e-43	0.81	0.62	Neuroticism;	chr22:41458442	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	16.86	3.59e-50	4.81e-43	0.78	0.62	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	16.86	3.59e-50	4.81e-43	0.78	0.62	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	16.86	3.59e-50	4.81e-43	0.78	0.62	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
HNSC	trans	rs116095464	0.558	rs34629844	ENSG00000185986.11	SDHAP3	16.85	3.96e-50	5.3e-43	0.91	0.61	Breast cancer;	chr5:200714	chr5:1572222~1594620:-
HNSC	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	16.85	4.03e-50	5.39e-43	0.78	0.61	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
HNSC	trans	rs116095464	0.558	rs62346508	ENSG00000185986.11	SDHAP3	16.85	4.23e-50	5.65e-43	0.91	0.61	Breast cancer;	chr5:203553	chr5:1572222~1594620:-
HNSC	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	16.83	4.87e-50	6.51e-43	0.78	0.61	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
HNSC	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	16.83	5.06e-50	6.75e-43	0.85	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	16.83	5.1e-50	6.81e-43	0.95	0.61	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	16.83	5.29e-50	7.06e-43	0.78	0.61	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	16.83	5.3e-50	7.07e-43	0.75	0.61	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
HNSC	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	16.82	5.31e-50	7.08e-43	0.78	0.61	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	16.82	5.32e-50	7.09e-43	0.93	0.61	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	16.82	5.32e-50	7.09e-43	0.93	0.61	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	16.82	5.32e-50	7.09e-43	0.93	0.61	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	16.82	5.55e-50	7.38e-43	0.78	0.61	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	16.82	5.55e-50	7.38e-43	0.78	0.61	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	16.81	6.2e-50	8.24e-43	0.78	0.61	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	16.81	6.27e-50	8.33e-43	0.74	0.61	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
HNSC	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-16.81	6.37e-50	8.47e-43	-0.77	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
HNSC	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	16.81	6.42e-50	8.53e-43	0.86	0.61	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
HNSC	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	16.8	7e-50	9.28e-43	0.75	0.61	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
HNSC	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	16.8	7.11e-50	9.43e-43	0.75	0.61	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
HNSC	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	16.8	7.27e-50	9.64e-43	0.82	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	16.78	8.11e-50	1.07e-42	0.78	0.61	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	16.78	8.53e-50	1.13e-42	0.78	0.61	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	16.78	8.53e-50	1.13e-42	0.78	0.61	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-16.78	8.53e-50	1.13e-42	-0.78	-0.61	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	16.78	8.67e-50	1.15e-42	0.8	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	16.78	8.67e-50	1.15e-42	0.8	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
HNSC	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	16.77	9.21e-50	1.21e-42	1.53	0.61	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
HNSC	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-16.77	9.44e-50	1.24e-42	-0.81	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-16.77	9.44e-50	1.24e-42	-0.81	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-16.77	9.93e-50	1.31e-42	-0.8	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	16.76	1.04e-49	1.37e-42	0.78	0.61	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	16.76	1.05e-49	1.38e-42	0.78	0.61	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	16.76	1.05e-49	1.38e-42	0.78	0.61	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	16.76	1.05e-49	1.38e-42	0.78	0.61	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-16.76	1.06e-49	1.39e-42	-0.79	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
HNSC	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	16.76	1.09e-49	1.42e-42	0.84	0.61	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	16.75	1.13e-49	1.48e-42	0.78	0.61	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	16.75	1.21e-49	1.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	16.72	1.55e-49	2.01e-42	0.78	0.61	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	16.72	1.56e-49	2.03e-42	0.78	0.61	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
HNSC	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	16.72	1.58e-49	2.05e-42	1.47	0.61	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
HNSC	trans	rs116095464	0.558	rs6878087	ENSG00000185986.11	SDHAP3	-16.71	1.71e-49	2.22e-42	-0.89	-0.61	Breast cancer;	chr5:223002	chr5:1572222~1594620:-
HNSC	trans	rs5022636	0.821	rs4246525	ENSG00000180764.13	PIPSL	16.71	1.71e-49	2.22e-42	0.77	0.61	Gut microbiota (functional units);	chr1:151285263	chr10:93958191~93961540:-
HNSC	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	16.7	1.92e-49	2.49e-42	0.74	0.61	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
HNSC	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	16.7	1.98e-49	2.57e-42	0.78	0.61	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
HNSC	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	16.7	2.02e-49	2.62e-42	1.11	0.61	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
HNSC	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	16.68	2.46e-49	3.18e-42	0.77	0.61	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	16.68	2.47e-49	3.19e-42	0.8	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
HNSC	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	16.65	3.29e-49	4.24e-42	0.74	0.61	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
HNSC	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	16.65	3.4e-49	4.39e-42	0.74	0.61	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
HNSC	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	16.63	4.17e-49	5.36e-42	0.78	0.61	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	16.6	5.84e-49	7.49e-42	0.75	0.61	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
HNSC	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-16.59	5.97e-49	7.67e-42	-0.78	-0.61	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	16.58	6.99e-49	8.96e-42	0.7	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	16.58	6.99e-49	8.96e-42	0.7	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
HNSC	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-16.57	7.82e-49	1e-41	-0.72	-0.61	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
HNSC	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	16.56	8.41e-49	1.08e-41	0.8	0.61	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
HNSC	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	16.55	9.15e-49	1.17e-41	0.96	0.61	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
HNSC	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	16.54	1.08e-48	1.38e-41	0.73	0.61	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
HNSC	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	16.54	1.11e-48	1.42e-41	0.75	0.61	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
HNSC	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	16.53	1.22e-48	1.56e-41	0.74	0.61	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
HNSC	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-16.52	1.36e-48	1.73e-41	-0.8	-0.61	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
HNSC	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	16.51	1.38e-48	1.76e-41	0.74	0.61	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
HNSC	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	16.51	1.48e-48	1.88e-41	0.77	0.61	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
HNSC	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-16.5	1.53e-48	1.95e-41	-0.68	-0.61	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
HNSC	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	16.5	1.54e-48	1.95e-41	0.76	0.61	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
HNSC	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	16.5	1.64e-48	2.08e-41	0.93	0.61	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.591	rs149479	ENSG00000230849.2	GOT2P2	-16.5	1.67e-48	2.11e-41	-0.84	-0.61	Blood metabolite ratios;	chr16:58703171	chr1:173141100~173142350:-
HNSC	trans	rs6708331	0.54	rs6546576	ENSG00000232654.1	FAM136BP	16.49	1.76e-48	2.23e-41	0.76	0.61	Obesity-related traits;	chr2:70174356	chr6:3045384~3045800:+
HNSC	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-16.47	2.16e-48	2.73e-41	-0.85	-0.61	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
HNSC	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	16.46	2.51e-48	3.17e-41	0.73	0.61	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
HNSC	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-16.44	2.95e-48	3.71e-41	-0.74	-0.61	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
HNSC	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	16.44	3.13e-48	3.92e-41	0.77	0.61	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	16.44	3.13e-48	3.92e-41	0.77	0.61	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
HNSC	trans	rs6708331	0.517	rs6546572	ENSG00000232654.1	FAM136BP	16.44	3.13e-48	3.93e-41	0.75	0.61	Obesity-related traits;	chr2:70146510	chr6:3045384~3045800:+
HNSC	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	16.44	3.15e-48	3.95e-41	0.73	0.61	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
HNSC	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-16.42	3.64e-48	4.56e-41	-0.84	-0.61	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
HNSC	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-16.39	4.82e-48	6e-41	-0.72	-0.6	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
HNSC	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	16.39	4.83e-48	6.01e-41	0.8	0.6	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
HNSC	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	16.39	4.97e-48	6.19e-41	0.83	0.6	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
HNSC	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	16.39	5.15e-48	6.4e-41	0.73	0.6	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
HNSC	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-16.36	6.77e-48	8.38e-41	-0.84	-0.6	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
HNSC	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-16.34	8.35e-48	1.03e-40	-0.73	-0.6	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
HNSC	trans	rs6708331	0.517	rs13017427	ENSG00000232654.1	FAM136BP	16.33	9.43e-48	1.16e-40	0.75	0.6	Obesity-related traits;	chr2:70154399	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.54	rs9677885	ENSG00000232654.1	FAM136BP	16.33	9.43e-48	1.16e-40	0.75	0.6	Obesity-related traits;	chr2:70154687	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.54	rs9679269	ENSG00000232654.1	FAM136BP	16.33	9.43e-48	1.16e-40	0.75	0.6	Obesity-related traits;	chr2:70154696	chr6:3045384~3045800:+
HNSC	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	16.31	1.12e-47	1.38e-40	0.72	0.6	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
HNSC	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	16.31	1.13e-47	1.39e-40	0.79	0.6	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
HNSC	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	16.31	1.2e-47	1.48e-40	0.72	0.6	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-16.29	1.41e-47	1.72e-40	-0.73	-0.6	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	16.29	1.43e-47	1.75e-40	0.79	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
HNSC	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-16.29	1.44e-47	1.76e-40	-0.72	-0.6	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	16.26	1.97e-47	2.39e-40	0.79	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
HNSC	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	16.26	1.98e-47	2.41e-40	0.82	0.6	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
HNSC	trans	rs4240897	0.544	rs7542773	ENSG00000261819.1	RP11-680G24.4	16.26	2.06e-47	2.51e-40	0.8	0.6	Tuberculosis;	chr1:11901073	chr16:14988259~14990160:-
HNSC	trans	rs6708331	0.564	rs4632370	ENSG00000232654.1	FAM136BP	16.25	2.08e-47	2.53e-40	0.75	0.6	Obesity-related traits;	chr2:70149693	chr6:3045384~3045800:+
HNSC	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	16.25	2.25e-47	2.73e-40	0.8	0.6	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
HNSC	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	16.24	2.5e-47	3.03e-40	0.67	0.6	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
HNSC	trans	rs116095464	0.558	rs9312957	ENSG00000185986.11	SDHAP3	16.22	2.86e-47	3.46e-40	0.89	0.6	Breast cancer;	chr5:202079	chr5:1572222~1594620:-
HNSC	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-16.22	3.04e-47	3.67e-40	-0.72	-0.6	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
HNSC	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	16.21	3.25e-47	3.91e-40	0.83	0.6	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
HNSC	trans	rs6708331	0.517	rs6546570	ENSG00000232654.1	FAM136BP	16.21	3.25e-47	3.91e-40	0.74	0.6	Obesity-related traits;	chr2:70122901	chr6:3045384~3045800:+
HNSC	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-16.2	3.49e-47	4.2e-40	-0.67	-0.6	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
HNSC	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	16.2	3.76e-47	4.52e-40	0.72	0.6	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
HNSC	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	16.2	3.87e-47	4.64e-40	0.66	0.6	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
HNSC	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-16.19	3.96e-47	4.75e-40	-0.75	-0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
HNSC	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	16.18	4.4e-47	5.27e-40	0.79	0.6	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	16.18	4.4e-47	5.27e-40	0.79	0.6	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
HNSC	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	16.18	4.64e-47	5.54e-40	0.89	0.6	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	16.18	4.64e-47	5.54e-40	0.89	0.6	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
HNSC	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	16.15	5.92e-47	7.01e-40	0.73	0.6	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
HNSC	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	16.15	6.24e-47	7.39e-40	0.79	0.6	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	16.14	6.77e-47	8.01e-40	0.73	0.6	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
HNSC	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	16.14	6.94e-47	8.2e-40	0.72	0.6	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	16.13	7.64e-47	9.02e-40	0.8	0.6	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
HNSC	trans	rs4240897	0.561	rs12043045	ENSG00000261819.1	RP11-680G24.4	16.13	7.89e-47	9.32e-40	0.79	0.6	Tuberculosis;	chr1:11900294	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.508	rs7520898	ENSG00000261819.1	RP11-680G24.4	16.13	7.89e-47	9.32e-40	0.79	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11901078	chr16:14988259~14990160:-
HNSC	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-16.13	8e-47	9.44e-40	-0.71	-0.6	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
HNSC	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-16.12	8.6e-47	1.01e-39	-0.88	-0.6	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
HNSC	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	16.11	9.55e-47	1.12e-39	0.72	0.6	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
HNSC	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	16.1	1.08e-46	1.27e-39	0.72	0.6	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
HNSC	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	16.08	1.29e-46	1.51e-39	0.66	0.6	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
HNSC	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	16.08	1.33e-46	1.56e-39	0.79	0.6	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-16.07	1.36e-46	1.59e-39	-0.72	-0.6	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
HNSC	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	16.07	1.37e-46	1.6e-39	0.78	0.6	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	16.07	1.41e-46	1.64e-39	0.79	0.6	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
HNSC	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	16.07	1.41e-46	1.65e-39	0.72	0.6	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
HNSC	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	16.07	1.43e-46	1.67e-39	1.46	0.6	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	16.07	1.43e-46	1.67e-39	1.46	0.6	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
HNSC	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	16.07	1.48e-46	1.73e-39	0.71	0.6	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	16.07	1.48e-46	1.73e-39	0.71	0.6	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
HNSC	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	16.06	1.52e-46	1.77e-39	1.46	0.6	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
HNSC	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	16.06	1.54e-46	1.79e-39	0.71	0.6	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	16.06	1.54e-46	1.79e-39	0.71	0.6	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
HNSC	trans	rs6708331	0.517	rs7579922	ENSG00000232654.1	FAM136BP	16.06	1.64e-46	1.91e-39	0.74	0.6	Obesity-related traits;	chr2:70134781	chr6:3045384~3045800:+
HNSC	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	16.05	1.67e-46	1.94e-39	0.72	0.6	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
HNSC	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	16.04	1.89e-46	2.2e-39	0.79	0.6	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
HNSC	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	16.04	1.9e-46	2.2e-39	0.87	0.6	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
HNSC	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	16.04	1.9e-46	2.21e-39	0.66	0.6	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
HNSC	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	16.04	1.9e-46	2.21e-39	0.66	0.6	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
HNSC	trans	rs116095464	0.558	rs9654453	ENSG00000185986.11	SDHAP3	16.03	2.24e-46	2.6e-39	0.95	0.6	Breast cancer;	chr5:299506	chr5:1572222~1594620:-
HNSC	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-16.01	2.52e-46	2.91e-39	-0.74	-0.6	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-16.01	2.55e-46	2.95e-39	-0.76	-0.6	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
HNSC	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	16.01	2.64e-46	3.05e-39	0.72	0.6	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	16.01	2.64e-46	3.05e-39	0.72	0.6	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	16	2.97e-46	3.44e-39	0.86	0.6	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	15.99	3.11e-46	3.59e-39	0.79	0.59	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
HNSC	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	15.99	3.23e-46	3.72e-39	1.45	0.59	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
HNSC	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-15.99	3.34e-46	3.85e-39	-0.76	-0.59	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
HNSC	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	15.99	3.35e-46	3.86e-39	0.65	0.59	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
HNSC	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-15.98	3.69e-46	4.25e-39	-0.72	-0.59	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	15.98	3.74e-46	4.3e-39	0.87	0.59	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	15.97	4.07e-46	4.68e-39	0.85	0.59	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	15.96	4.29e-46	4.91e-39	0.78	0.59	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	15.96	4.29e-46	4.91e-39	0.78	0.59	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
HNSC	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	15.95	4.7e-46	5.37e-39	0.72	0.59	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	15.95	4.7e-46	5.37e-39	0.72	0.59	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
HNSC	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-15.95	4.81e-46	5.5e-39	-0.77	-0.59	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
HNSC	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	15.94	5.55e-46	6.3e-39	0.72	0.59	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
HNSC	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-15.94	5.57e-46	6.32e-39	-0.89	-0.59	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
HNSC	trans	rs7554547	0.838	rs885770	ENSG00000261819.1	RP11-680G24.4	15.93	5.83e-46	6.62e-39	0.76	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr16:14988259~14990160:-
HNSC	trans	rs6708331	0.517	rs2028879	ENSG00000232654.1	FAM136BP	15.93	6.04e-46	6.85e-39	0.74	0.59	Obesity-related traits;	chr2:70127505	chr6:3045384~3045800:+
HNSC	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	15.93	6.09e-46	6.9e-39	1.57	0.59	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
HNSC	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-15.92	6.7e-46	7.58e-39	-0.92	-0.59	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
HNSC	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	15.92	6.88e-46	7.79e-39	0.88	0.59	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	15.92	6.88e-46	7.79e-39	0.88	0.59	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	15.91	7.11e-46	8.04e-39	0.87	0.59	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	15.91	7.24e-46	8.18e-39	0.74	0.59	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-15.9	8.27e-46	9.34e-39	-0.72	-0.59	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-15.88	1.05e-45	1.19e-38	-0.65	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
HNSC	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-15.87	1.07e-45	1.21e-38	-0.68	-0.59	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
HNSC	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-15.87	1.07e-45	1.21e-38	-0.74	-0.59	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-15.87	1.07e-45	1.21e-38	-0.74	-0.59	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-15.87	1.07e-45	1.21e-38	-0.74	-0.59	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
HNSC	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	15.87	1.16e-45	1.3e-38	0.77	0.59	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
HNSC	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	15.86	1.24e-45	1.39e-38	0.88	0.59	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	15.86	1.24e-45	1.39e-38	0.88	0.59	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
HNSC	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	15.85	1.43e-45	1.59e-38	0.66	0.59	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
HNSC	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	15.85	1.43e-45	1.59e-38	0.66	0.59	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
HNSC	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	15.84	1.55e-45	1.73e-38	0.85	0.59	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
HNSC	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	15.84	1.61e-45	1.79e-38	0.77	0.59	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
HNSC	trans	rs928391	0.689	rs2644600	ENSG00000227183.3	HDGFP1	15.83	1.68e-45	1.87e-38	0.91	0.59	Platelet count;	chr1:156820891	chrX:131646639~131646890:+
HNSC	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	15.82	1.88e-45	2.08e-38	0.78	0.59	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
HNSC	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	15.82	1.92e-45	2.13e-38	0.87	0.59	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	15.82	1.92e-45	2.13e-38	0.87	0.59	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	15.82	1.92e-45	2.13e-38	0.87	0.59	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
HNSC	trans	rs916888	0.779	rs199526	ENSG00000214425.5	LRRC37A4P	15.81	2.16e-45	2.39e-38	0.66	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45506741~45550335:-
HNSC	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	15.8	2.32e-45	2.57e-38	0.87	0.59	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	15.8	2.36e-45	2.61e-38	0.86	0.59	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	15.79	2.49e-45	2.75e-38	0.87	0.59	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
HNSC	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	15.79	2.59e-45	2.85e-38	0.65	0.59	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
HNSC	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	15.79	2.62e-45	2.89e-38	0.7	0.59	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-15.78	2.91e-45	3.2e-38	-0.68	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
HNSC	trans	rs6708331	0.517	rs9989876	ENSG00000232654.1	FAM136BP	15.78	2.95e-45	3.25e-38	0.72	0.59	Obesity-related traits;	chr2:70115578	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.517	rs10496178	ENSG00000232654.1	FAM136BP	15.78	2.95e-45	3.25e-38	0.72	0.59	Obesity-related traits;	chr2:70115683	chr6:3045384~3045800:+
HNSC	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	15.77	3.15e-45	3.46e-38	0.66	0.59	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
HNSC	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	15.76	3.34e-45	3.67e-38	0.87	0.59	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	15.76	3.49e-45	3.83e-38	0.78	0.59	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	15.76	3.54e-45	3.89e-38	0.78	0.59	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
HNSC	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	15.75	3.71e-45	4.07e-38	0.87	0.59	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	15.75	3.86e-45	4.23e-38	0.97	0.59	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	15.75	4.01e-45	4.39e-38	0.78	0.59	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
HNSC	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-15.74	4.2e-45	4.6e-38	-0.78	-0.59	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
HNSC	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	15.74	4.44e-45	4.86e-38	0.89	0.59	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	15.73	4.79e-45	5.23e-38	0.77	0.59	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	15.73	4.96e-45	5.41e-38	0.78	0.59	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
HNSC	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	15.72	5.23e-45	5.7e-38	0.71	0.59	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	15.71	5.77e-45	6.28e-38	0.72	0.59	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	15.71	6.08e-45	6.61e-38	0.71	0.59	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	15.71	6.14e-45	6.67e-38	0.78	0.59	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
HNSC	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	15.7	6.66e-45	7.23e-38	0.7	0.59	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
HNSC	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	15.69	7.42e-45	8.04e-38	0.89	0.59	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	15.69	7.42e-45	8.04e-38	0.89	0.59	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
HNSC	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	15.66	9.5e-45	1.03e-37	0.87	0.59	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	15.65	1.06e-44	1.14e-37	0.78	0.59	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
HNSC	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	15.63	1.36e-44	1.47e-37	0.87	0.59	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
HNSC	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	15.63	1.38e-44	1.49e-37	0.71	0.59	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
HNSC	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-15.62	1.53e-44	1.65e-37	-0.72	-0.59	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
HNSC	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	15.61	1.7e-44	1.83e-37	0.77	0.59	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	15.61	1.7e-44	1.83e-37	0.77	0.59	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.689	rs2768764	ENSG00000227183.3	HDGFP1	15.6	1.76e-44	1.9e-37	0.91	0.59	Platelet count;	chr1:156817136	chrX:131646639~131646890:+
HNSC	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-15.59	2.03e-44	2.18e-37	-0.75	-0.59	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
HNSC	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	15.58	2.18e-44	2.34e-37	0.85	0.58	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
HNSC	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	15.56	2.65e-44	2.84e-37	0.77	0.58	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.689	rs2644599	ENSG00000227183.3	HDGFP1	15.56	2.7e-44	2.89e-37	0.9	0.58	Platelet count;	chr1:156821114	chrX:131646639~131646890:+
HNSC	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	15.56	2.85e-44	3.05e-37	0.77	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
HNSC	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-15.52	4.31e-44	4.59e-37	-0.72	-0.58	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
HNSC	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	15.5	5.35e-44	5.69e-37	0.86	0.58	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	15.49	5.92e-44	6.28e-37	0.77	0.58	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
HNSC	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	15.48	6.04e-44	6.41e-37	0.71	0.58	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	15.48	6.04e-44	6.41e-37	0.71	0.58	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	15.47	6.84e-44	7.24e-37	0.71	0.58	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
HNSC	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	15.46	8.1e-44	8.57e-37	0.77	0.58	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
HNSC	trans	rs2950393	0.726	rs10459246	ENSG00000121089.4	NACA3P	-15.46	8.14e-44	8.61e-37	-0.71	-0.58	Platelet distribution width;	chr12:56776034	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-15.43	1.02e-43	1.08e-36	-0.72	-0.58	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
HNSC	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	15.42	1.13e-43	1.19e-36	0.7	0.58	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
HNSC	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	15.41	1.36e-43	1.43e-36	0.65	0.58	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
HNSC	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	15.4	1.47e-43	1.55e-36	0.76	0.58	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
HNSC	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	15.38	1.81e-43	1.9e-36	0.65	0.58	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
HNSC	trans	rs5022636	0.929	rs7552906	ENSG00000180764.13	PIPSL	15.36	2.1e-43	2.2e-36	0.72	0.58	Gut microbiota (functional units);	chr1:151341298	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	15.36	2.16e-43	2.26e-36	0.76	0.58	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	15.36	2.16e-43	2.26e-36	0.76	0.58	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	15.34	2.66e-43	2.77e-36	1.53	0.58	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
HNSC	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	15.33	2.88e-43	3e-36	0.73	0.58	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
HNSC	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-15.33	2.97e-43	3.1e-36	-0.77	-0.58	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-15.32	3.19e-43	3.33e-36	-0.93	-0.58	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.689	rs2234883	ENSG00000227183.3	HDGFP1	15.3	3.93e-43	4.09e-36	0.91	0.58	Platelet count;	chr1:156817318	chrX:131646639~131646890:+
HNSC	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	15.29	4.37e-43	4.53e-36	0.86	0.58	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
HNSC	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	15.27	5.49e-43	5.69e-36	0.76	0.58	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
HNSC	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-15.26	6.22e-43	6.45e-36	-0.69	-0.58	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
HNSC	trans	rs116095464	0.558	rs12173015	ENSG00000185986.11	SDHAP3	-15.25	6.4e-43	6.62e-36	-0.85	-0.58	Breast cancer;	chr5:269852	chr5:1572222~1594620:-
HNSC	trans	rs5022636	0.964	rs7545392	ENSG00000180764.13	PIPSL	15.25	6.54e-43	6.76e-36	0.71	0.58	Gut microbiota (functional units);	chr1:151337779	chr10:93958191~93961540:-
HNSC	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	15.24	7.41e-43	7.66e-36	0.72	0.58	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
HNSC	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	15.23	7.89e-43	8.14e-36	0.72	0.58	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
HNSC	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	15.23	7.89e-43	8.14e-36	0.72	0.58	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
HNSC	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	15.22	8.73e-43	9e-36	0.75	0.58	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.603	rs9551099	ENSG00000237917.1	PARP4P1	-15.2	1.07e-42	1.1e-35	-0.68	-0.58	Obesity-related traits;	chr13:24410978	chrY:26594851~26634652:-
HNSC	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	15.15	1.79e-42	1.83e-35	0.76	0.57	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
HNSC	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	15.15	1.88e-42	1.92e-35	0.63	0.57	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
HNSC	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	15.15	1.91e-42	1.95e-35	0.72	0.57	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
HNSC	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	15.15	1.91e-42	1.95e-35	0.72	0.57	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
HNSC	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	15.14	2.04e-42	2.08e-35	0.77	0.57	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	15.14	2.06e-42	2.1e-35	0.76	0.57	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.964	rs1056847	ENSG00000180764.13	PIPSL	15.11	2.65e-42	2.69e-35	0.71	0.57	Gut microbiota (functional units);	chr1:151315696	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	15.07	4.28e-42	4.32e-35	0.77	0.57	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.779	rs199526	ENSG00000264070.1	DND1P1	-15.06	4.48e-42	4.53e-35	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	15.06	4.68e-42	4.73e-35	0.73	0.57	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
HNSC	trans	rs5022636	0.927	rs10888410	ENSG00000180764.13	PIPSL	15.06	4.76e-42	4.8e-35	0.71	0.57	Gut microbiota (functional units);	chr1:151299975	chr10:93958191~93961540:-
HNSC	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	15.05	4.99e-42	5.03e-35	0.75	0.57	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	15.03	6.55e-42	6.59e-35	0.75	0.57	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
HNSC	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	15.02	6.92e-42	6.96e-35	0.64	0.57	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
HNSC	trans	rs116095464	0.558	rs28636067	ENSG00000185986.11	SDHAP3	15.01	7.78e-42	7.8e-35	0.9	0.57	Breast cancer;	chr5:199300	chr5:1572222~1594620:-
HNSC	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-14.97	1.12e-41	1.12e-34	-0.88	-0.57	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
HNSC	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-14.93	1.66e-41	1.62e-34	-0.71	-0.57	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
HNSC	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	14.92	1.88e-41	1.83e-34	0.71	0.57	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
HNSC	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	14.92	1.98e-41	1.93e-34	0.75	0.57	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
HNSC	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	14.9	2.26e-41	2.19e-34	0.62	0.57	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
HNSC	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	14.9	2.26e-41	2.19e-34	0.62	0.57	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
HNSC	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	14.89	2.64e-41	2.55e-34	0.73	0.57	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	14.87	3.26e-41	3.15e-34	0.75	0.57	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
HNSC	trans	rs5022636	0.927	rs4971030	ENSG00000180764.13	PIPSL	-14.84	4.19e-41	4.04e-34	-0.7	-0.57	Gut microbiota (functional units);	chr1:151308519	chr10:93958191~93961540:-
HNSC	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	14.78	7.99e-41	7.61e-34	0.71	0.56	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	14.78	7.99e-41	7.61e-34	0.71	0.56	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
HNSC	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-14.74	1.23e-40	1.16e-33	-0.61	-0.56	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
HNSC	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	14.73	1.37e-40	1.29e-33	0.74	0.56	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
HNSC	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	14.72	1.49e-40	1.4e-33	0.64	0.56	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
HNSC	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-14.71	1.55e-40	1.45e-33	-0.91	-0.56	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
HNSC	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-14.69	2.01e-40	1.88e-33	-0.68	-0.56	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
HNSC	trans	rs959695	1	rs959695	ENSG00000260318.1	COX6CP1	14.69	2.01e-40	1.88e-33	0.74	0.56	Hippocampal atrophy;	chr8:99822954	chr16:11903923~11904137:-
HNSC	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	14.67	2.49e-40	2.32e-33	0.75	0.56	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	14.67	2.49e-40	2.32e-33	0.75	0.56	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	14.67	2.49e-40	2.32e-33	0.75	0.56	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
HNSC	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-14.65	3.09e-40	2.88e-33	-0.68	-0.56	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	14.6	4.69e-40	4.35e-33	0.74	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
HNSC	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	14.6	4.91e-40	4.55e-33	1.5	0.56	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
HNSC	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	14.58	5.99e-40	5.54e-33	0.7	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
HNSC	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-14.58	6e-40	5.55e-33	-0.69	-0.56	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
HNSC	trans	rs959695	0.864	rs7844422	ENSG00000260318.1	COX6CP1	14.51	1.16e-39	1.06e-32	0.72	0.56	Hippocampal atrophy;	chr8:99837782	chr16:11903923~11904137:-
HNSC	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	14.51	1.18e-39	1.08e-32	0.71	0.56	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
HNSC	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-14.51	1.22e-39	1.12e-32	-0.88	-0.56	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
HNSC	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	14.5	1.38e-39	1.26e-32	0.95	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	14.49	1.5e-39	1.37e-32	0.71	0.56	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	14.49	1.5e-39	1.37e-32	0.71	0.56	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	14.47	1.77e-39	1.61e-32	0.7	0.56	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	14.47	1.77e-39	1.61e-32	0.7	0.56	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	14.47	1.77e-39	1.61e-32	0.7	0.56	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
HNSC	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	14.47	1.89e-39	1.72e-32	0.68	0.56	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
HNSC	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	14.46	1.97e-39	1.79e-32	0.96	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
HNSC	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-14.45	2.1e-39	1.91e-32	-0.75	-0.56	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.569	rs6002328	ENSG00000268568.1	AC007228.9	-14.45	2.23e-39	2.02e-32	-0.69	-0.56	Vitiligo;	chr22:41314030	chr19:56672574~56673901:-
HNSC	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	14.44	2.5e-39	2.27e-32	0.93	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
HNSC	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	14.43	2.81e-39	2.54e-32	0.74	0.56	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
HNSC	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	14.39	3.94e-39	3.55e-32	0.7	0.55	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
HNSC	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-14.38	4.51e-39	4.06e-32	-0.75	-0.55	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
HNSC	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	14.36	5.32e-39	4.79e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
HNSC	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	14.36	5.35e-39	4.82e-32	0.63	0.55	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
HNSC	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-14.36	5.68e-39	5.11e-32	-0.73	-0.55	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
HNSC	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	14.35	5.75e-39	5.17e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	14.35	5.75e-39	5.17e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	14.35	5.76e-39	5.17e-32	0.69	0.55	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	14.35	5.76e-39	5.17e-32	0.69	0.55	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	14.35	5.76e-39	5.17e-32	0.69	0.55	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	14.35	5.87e-39	5.27e-32	0.68	0.55	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
HNSC	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	14.33	7.08e-39	6.34e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	14.33	7.08e-39	6.34e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	14.33	7.08e-39	6.34e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	14.31	8.55e-39	7.65e-32	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
HNSC	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	14.31	9.16e-39	8.19e-32	1.07	0.55	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
HNSC	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	14.31	9.34e-39	8.34e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	14.3	1.02e-38	9.14e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	14.3	1.02e-38	9.14e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	14.3	1.04e-38	9.24e-32	0.69	0.55	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
HNSC	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	14.29	1.1e-38	9.84e-32	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
HNSC	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	14.29	1.13e-38	1e-31	0.67	0.55	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
HNSC	trans	rs9611565	0.506	rs1883825	ENSG00000268568.1	AC007228.9	-14.28	1.21e-38	1.08e-31	-0.69	-0.55	Vitiligo;	chr22:41307404	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.525	rs1883827	ENSG00000268568.1	AC007228.9	-14.28	1.21e-38	1.08e-31	-0.69	-0.55	Vitiligo;	chr22:41307575	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	14.28	1.24e-38	1.11e-31	0.68	0.55	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
HNSC	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-14.28	1.26e-38	1.12e-31	-0.71	-0.55	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
HNSC	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	14.28	1.26e-38	1.12e-31	0.68	0.55	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	14.27	1.32e-38	1.17e-31	0.68	0.55	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	14.27	1.4e-38	1.24e-31	0.68	0.55	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
HNSC	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	14.26	1.41e-38	1.25e-31	0.68	0.55	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
HNSC	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-14.25	1.56e-38	1.38e-31	-0.63	-0.55	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
HNSC	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	14.25	1.65e-38	1.47e-31	0.69	0.55	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	14.25	1.65e-38	1.47e-31	0.69	0.55	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
HNSC	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	14.24	1.84e-38	1.63e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	14.24	1.84e-38	1.63e-31	0.74	0.55	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
HNSC	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	14.24	1.85e-38	1.63e-31	0.98	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
HNSC	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	14.23	1.98e-38	1.75e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
HNSC	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	14.22	2.1e-38	1.85e-31	1.05	0.55	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	14.22	2.24e-38	1.97e-31	0.69	0.55	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	14.22	2.24e-38	1.97e-31	0.69	0.55	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	14.22	2.27e-38	1.99e-31	0.6	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
HNSC	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	14.21	2.31e-38	2.03e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	14.21	2.35e-38	2.07e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
HNSC	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-14.21	2.35e-38	2.07e-31	-0.75	-0.55	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
HNSC	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	14.2	2.65e-38	2.33e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	14.2	2.66e-38	2.33e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	14.2	2.66e-38	2.34e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	14.2	2.66e-38	2.34e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
HNSC	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-14.2	2.78e-38	2.44e-31	-0.62	-0.55	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
HNSC	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-14.2	2.78e-38	2.44e-31	-0.62	-0.55	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
HNSC	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-14.19	2.84e-38	2.49e-31	-0.59	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
HNSC	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	14.19	2.86e-38	2.51e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	14.19	2.87e-38	2.52e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	14.19	2.89e-38	2.53e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	14.19	2.89e-38	2.53e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	14.19	2.93e-38	2.57e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	14.19	2.93e-38	2.57e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-14.19	2.99e-38	2.62e-31	-0.73	-0.55	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
HNSC	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	14.19	3.06e-38	2.67e-31	1.08	0.55	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	14.19	3.09e-38	2.7e-31	0.69	0.55	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
HNSC	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	14.18	3.35e-38	2.92e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	14.18	3.35e-38	2.92e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	14.18	3.35e-38	2.92e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	14.18	3.38e-38	2.96e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	14.18	3.39e-38	2.96e-31	0.72	0.55	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	14.17	3.52e-38	3.08e-31	0.74	0.55	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
HNSC	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	14.17	3.56e-38	3.11e-31	1.06	0.55	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	14.17	3.56e-38	3.11e-31	1.06	0.55	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
HNSC	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-14.16	3.8e-38	3.32e-31	-0.68	-0.55	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
HNSC	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	14.16	3.95e-38	3.45e-31	0.71	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
HNSC	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	14.16	3.96e-38	3.45e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	14.16	3.96e-38	3.45e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	14.16	3.96e-38	3.45e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	14.16	3.96e-38	3.45e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
HNSC	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-14.16	4.02e-38	3.5e-31	-0.64	-0.55	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
HNSC	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	14.16	4.08e-38	3.55e-31	0.69	0.55	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
HNSC	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	14.15	4.29e-38	3.73e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
HNSC	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	14.15	4.32e-38	3.76e-31	0.65	0.55	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
HNSC	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	14.15	4.33e-38	3.77e-31	0.73	0.55	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
HNSC	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	14.14	4.87e-38	4.23e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	14.14	4.87e-38	4.23e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	14.14	4.87e-38	4.23e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	14.14	4.87e-38	4.23e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	14.14	4.89e-38	4.24e-31	0.69	0.55	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-14.14	5e-38	4.34e-31	-0.59	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
HNSC	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-14.14	5e-38	4.34e-31	-0.59	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
HNSC	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-14.13	5.13e-38	4.45e-31	-0.64	-0.55	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
HNSC	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	14.13	5.25e-38	4.55e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	14.13	5.25e-38	4.55e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	14.13	5.25e-38	4.55e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	14.13	5.25e-38	4.55e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
HNSC	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-14.12	5.71e-38	4.94e-31	-0.6	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
HNSC	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-14.12	5.72e-38	4.95e-31	-0.97	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	14.12	5.73e-38	4.96e-31	0.67	0.55	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	14.12	5.73e-38	4.96e-31	0.67	0.55	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	14.12	5.8e-38	5.02e-31	0.69	0.55	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
HNSC	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	14.12	5.82e-38	5.03e-31	1.04	0.55	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	14.12	5.9e-38	5.1e-31	0.69	0.55	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-14.12	5.92e-38	5.12e-31	-0.59	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
HNSC	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	14.12	6.23e-38	5.38e-31	0.69	0.55	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
HNSC	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	14.11	6.34e-38	5.47e-31	0.68	0.55	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
HNSC	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-14.11	6.6e-38	5.7e-31	-0.62	-0.55	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
HNSC	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	14.1	7.08e-38	6.11e-31	0.7	0.55	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	14.1	7.08e-38	6.11e-31	0.7	0.55	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	14.1	7.08e-38	6.11e-31	0.7	0.55	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	14.1	7.12e-38	6.13e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	14.1	7.48e-38	6.44e-31	0.68	0.55	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
HNSC	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	14.09	7.66e-38	6.6e-31	1.06	0.55	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
HNSC	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	14.09	7.94e-38	6.84e-31	0.59	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
HNSC	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-14.09	7.95e-38	6.85e-31	-0.75	-0.55	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
HNSC	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	14.08	8.74e-38	7.52e-31	0.59	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
HNSC	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-14.06	1.07e-37	9.19e-31	-0.69	-0.55	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
HNSC	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-14.06	1.11e-37	9.53e-31	-0.62	-0.55	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
HNSC	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	14.05	1.15e-37	9.82e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	14.05	1.15e-37	9.82e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	14.05	1.15e-37	9.82e-31	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
HNSC	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	14.05	1.15e-37	9.88e-31	0.69	0.55	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
HNSC	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-14.05	1.16e-37	9.92e-31	-0.62	-0.55	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
HNSC	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-14.05	1.18e-37	1.01e-30	-1.19	-0.55	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-14.05	1.2e-37	1.02e-30	-0.68	-0.55	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	14.05	1.2e-37	1.02e-30	0.68	0.55	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	14.05	1.2e-37	1.02e-30	0.68	0.55	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
HNSC	trans	rs5022636	0.865	rs12069445	ENSG00000180764.13	PIPSL	14.04	1.28e-37	1.1e-30	0.66	0.54	Gut microbiota (functional units);	chr1:151362964	chr10:93958191~93961540:-
HNSC	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-14.04	1.33e-37	1.13e-30	-0.62	-0.54	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
HNSC	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	14.03	1.39e-37	1.19e-30	0.96	0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	14.03	1.43e-37	1.22e-30	0.73	0.54	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	14.03	1.46e-37	1.24e-30	0.68	0.54	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	14.03	1.46e-37	1.24e-30	0.68	0.54	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	14.03	1.46e-37	1.24e-30	0.68	0.54	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
HNSC	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	14.03	1.52e-37	1.3e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
HNSC	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	14.03	1.52e-37	1.3e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	14.02	1.58e-37	1.34e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
HNSC	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-14.02	1.62e-37	1.38e-30	-1.03	-0.54	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
HNSC	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	14.02	1.63e-37	1.39e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
HNSC	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	14.02	1.64e-37	1.4e-30	0.73	0.54	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
HNSC	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	14.01	1.75e-37	1.49e-30	0.67	0.54	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
HNSC	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-14.01	1.79e-37	1.52e-30	-0.99	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
HNSC	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	14.01	1.81e-37	1.54e-30	1.08	0.54	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
HNSC	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	14.01	1.81e-37	1.54e-30	1.08	0.54	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	14	1.87e-37	1.58e-30	1.07	0.54	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	14	1.98e-37	1.68e-30	0.68	0.54	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
HNSC	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	14	1.99e-37	1.69e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	14	1.99e-37	1.69e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
HNSC	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-13.99	2.11e-37	1.79e-30	-0.62	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
HNSC	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	13.99	2.11e-37	1.79e-30	0.67	0.54	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	13.99	2.23e-37	1.88e-30	0.67	0.54	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	13.98	2.37e-37	2e-30	0.68	0.54	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
HNSC	trans	rs6708331	0.941	rs6749886	ENSG00000232654.1	FAM136BP	13.98	2.45e-37	2.07e-30	0.75	0.54	Obesity-related traits;	chr2:70062968	chr6:3045384~3045800:+
HNSC	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-13.97	2.53e-37	2.13e-30	-0.75	-0.54	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
HNSC	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-13.97	2.53e-37	2.13e-30	-0.75	-0.54	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
HNSC	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	13.97	2.66e-37	2.24e-30	1.06	0.54	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
HNSC	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-13.97	2.67e-37	2.25e-30	-0.59	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
HNSC	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	13.96	2.78e-37	2.34e-30	0.66	0.54	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-13.96	2.92e-37	2.46e-30	-0.66	-0.54	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
HNSC	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-13.96	2.96e-37	2.49e-30	-0.69	-0.54	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-13.96	2.96e-37	2.49e-30	-0.69	-0.54	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-13.96	2.96e-37	2.49e-30	-0.69	-0.54	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-13.96	2.96e-37	2.49e-30	-0.69	-0.54	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-13.96	2.96e-37	2.49e-30	-0.69	-0.54	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
HNSC	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	13.96	2.98e-37	2.51e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
HNSC	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	13.96	3.03e-37	2.55e-30	0.68	0.54	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	13.95	3.23e-37	2.71e-30	0.59	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
HNSC	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	13.94	3.71e-37	3.12e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
HNSC	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-13.93	3.75e-37	3.15e-30	-0.73	-0.54	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
HNSC	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-13.93	3.93e-37	3.3e-30	-0.61	-0.54	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
HNSC	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	13.93	3.97e-37	3.33e-30	0.66	0.54	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	13.93	3.97e-37	3.33e-30	0.66	0.54	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
HNSC	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	13.93	3.97e-37	3.33e-30	0.66	0.54	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	13.92	4.18e-37	3.51e-30	0.68	0.54	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
HNSC	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-13.92	4.2e-37	3.52e-30	-0.67	-0.54	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
HNSC	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	13.92	4.24e-37	3.56e-30	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
HNSC	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	13.91	4.74e-37	3.97e-30	0.68	0.54	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
HNSC	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-13.91	4.74e-37	3.97e-30	-0.99	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
HNSC	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-13.91	4.74e-37	3.97e-30	-0.99	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	13.91	4.84e-37	4.05e-30	0.68	0.54	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
HNSC	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-13.91	4.85e-37	4.06e-30	-0.61	-0.54	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
HNSC	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-13.9	5.05e-37	4.22e-30	-0.99	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	13.9	5.09e-37	4.25e-30	0.68	0.54	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
HNSC	trans	rs7554511	1	rs55838263	ENSG00000244144.1	RP11-757F18.3	-13.9	5.28e-37	4.41e-30	-0.74	-0.54	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905600	chr3:112185480~112185998:-
HNSC	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-13.9	5.39e-37	4.5e-30	-0.74	-0.54	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
HNSC	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-13.9	5.4e-37	4.5e-30	-0.66	-0.54	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
HNSC	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	13.9	5.45e-37	4.55e-30	0.69	0.54	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
HNSC	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-13.89	5.64e-37	4.7e-30	-0.98	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	13.89	5.74e-37	4.79e-30	0.68	0.54	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	13.89	5.74e-37	4.79e-30	0.68	0.54	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
HNSC	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	13.89	5.8e-37	4.83e-30	1.04	0.54	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	13.89	5.8e-37	4.83e-30	1.04	0.54	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	13.89	5.8e-37	4.83e-30	1.04	0.54	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	13.89	5.8e-37	4.83e-30	1.04	0.54	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	13.89	5.95e-37	4.95e-30	0.67	0.54	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
HNSC	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	13.89	6.08e-37	5.06e-30	0.67	0.54	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-13.88	6.11e-37	5.08e-30	-0.68	-0.54	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
HNSC	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	13.88	6.64e-37	5.51e-30	0.61	0.54	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
HNSC	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	13.88	6.7e-37	5.56e-30	0.67	0.54	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
HNSC	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	13.87	6.77e-37	5.62e-30	0.68	0.54	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
HNSC	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-13.87	6.92e-37	5.74e-30	-0.68	-0.54	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
HNSC	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-13.87	6.98e-37	5.79e-30	-0.98	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
HNSC	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-13.87	6.98e-37	5.79e-30	-0.98	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
HNSC	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	13.87	7.03e-37	5.83e-30	0.68	0.54	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	13.87	7.03e-37	5.83e-30	0.68	0.54	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	13.87	7.03e-37	5.83e-30	0.68	0.54	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-13.87	7.14e-37	5.91e-30	-0.59	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
HNSC	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	13.87	7.26e-37	6e-30	0.68	0.54	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
HNSC	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	13.87	7.39e-37	6.1e-30	0.67	0.54	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
HNSC	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-13.86	7.52e-37	6.21e-30	-0.71	-0.54	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	13.86	7.57e-37	6.25e-30	0.68	0.54	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	13.86	8.12e-37	6.7e-30	0.68	0.54	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
HNSC	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	13.85	8.28e-37	6.83e-30	1.36	0.54	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
HNSC	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-13.85	8.43e-37	6.95e-30	-0.96	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
HNSC	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	13.85	8.95e-37	7.37e-30	1.04	0.54	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	13.85	8.95e-37	7.37e-30	1.04	0.54	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	13.85	8.95e-37	7.37e-30	1.04	0.54	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	13.85	8.95e-37	7.37e-30	1.04	0.54	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	13.84	9.55e-37	7.86e-30	0.68	0.54	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
HNSC	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	13.84	9.68e-37	7.97e-30	1.4	0.54	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	13.84	9.68e-37	7.97e-30	1.4	0.54	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
HNSC	trans	rs5022636	0.896	rs744536	ENSG00000180764.13	PIPSL	13.82	1.22e-36	9.99e-30	0.65	0.54	Gut microbiota (functional units);	chr1:151356318	chr10:93958191~93961540:-
HNSC	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-13.82	1.22e-36	1e-29	-0.74	-0.54	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
HNSC	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	13.81	1.22e-36	1e-29	0.67	0.54	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	13.81	1.25e-36	1.03e-29	0.66	0.54	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
HNSC	trans	rs10242455	0.702	rs10251282	ENSG00000228834.1	RP11-249L21.4	13.81	1.27e-36	1.04e-29	1.4	0.54	Blood metabolite levels;	chr7:99392613	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	13.81	1.27e-36	1.04e-29	1.4	0.54	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
HNSC	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-13.8	1.38e-36	1.13e-29	-0.67	-0.54	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
HNSC	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	13.79	1.49e-36	1.22e-29	1.06	0.54	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	13.79	1.49e-36	1.22e-29	1.06	0.54	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	13.79	1.49e-36	1.22e-29	1.06	0.54	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	13.79	1.49e-36	1.22e-29	1.06	0.54	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
HNSC	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	13.79	1.49e-36	1.22e-29	1.06	0.54	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
HNSC	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	13.79	1.49e-36	1.22e-29	0.66	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	13.78	1.76e-36	1.43e-29	0.7	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
HNSC	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	13.78	1.79e-36	1.46e-29	0.67	0.54	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
HNSC	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-13.77	1.86e-36	1.51e-29	-0.65	-0.54	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
HNSC	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	13.77	1.91e-36	1.55e-29	1.05	0.54	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
HNSC	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-13.76	2.11e-36	1.72e-29	-0.97	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
HNSC	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	13.75	2.27e-36	1.84e-29	0.66	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	13.75	2.4e-36	1.95e-29	0.57	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
HNSC	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-13.74	2.48e-36	2.01e-29	-0.61	-0.54	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
HNSC	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	13.72	3.08e-36	2.49e-29	0.66	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	13.72	3.08e-36	2.49e-29	0.66	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
HNSC	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-13.72	3.25e-36	2.62e-29	-0.66	-0.54	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
HNSC	trans	rs55665837	0.778	rs11023212	ENSG00000236360.2	RP11-334A14.2	13.7	3.62e-36	2.92e-29	0.74	0.54	Vitamin D levels;	chr11:14410163	chr1:52993201~52993702:-
HNSC	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	13.69	4.16e-36	3.34e-29	0.68	0.54	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
HNSC	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	13.69	4.36e-36	3.5e-29	1.01	0.54	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
HNSC	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-13.68	4.48e-36	3.6e-29	-0.68	-0.53	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.702	rs1045012	ENSG00000228834.1	RP11-249L21.4	13.67	4.95e-36	3.97e-29	1.4	0.53	Blood metabolite levels;	chr7:99386731	chr6:108907615~108907873:-
HNSC	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	13.67	4.99e-36	4e-29	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
HNSC	trans	rs5022636	0.896	rs10788804	ENSG00000180764.13	PIPSL	13.66	5.68e-36	4.54e-29	0.65	0.53	Gut microbiota (functional units);	chr1:151365312	chr10:93958191~93961540:-
HNSC	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-13.65	6.37e-36	5.08e-29	-0.95	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
HNSC	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	13.65	6.46e-36	5.15e-29	0.57	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
HNSC	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	13.64	6.67e-36	5.32e-29	1.03	0.53	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
HNSC	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-13.63	7.18e-36	5.71e-29	-0.66	-0.53	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
HNSC	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	13.63	7.29e-36	5.8e-29	0.66	0.53	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
HNSC	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	13.62	8.17e-36	6.48e-29	0.57	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
HNSC	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	13.62	8.19e-36	6.48e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
HNSC	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	13.6	9.86e-36	7.78e-29	0.93	0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
HNSC	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	13.6	9.98e-36	7.88e-29	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	13.6	9.98e-36	7.88e-29	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	13.6	9.98e-36	7.88e-29	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	13.6	9.98e-36	7.88e-29	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
HNSC	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	13.6	1e-35	7.88e-29	0.74	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
HNSC	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	13.6	1.05e-35	8.27e-29	0.67	0.53	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-13.59	1.07e-35	8.41e-29	-0.65	-0.53	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
HNSC	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	13.58	1.2e-35	9.41e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	13.57	1.34e-35	1.05e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
HNSC	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	13.56	1.49e-35	1.17e-28	0.66	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
HNSC	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	13.55	1.61e-35	1.27e-28	0.66	0.53	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	13.53	1.98e-35	1.54e-28	0.66	0.53	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
HNSC	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-13.53	2.05e-35	1.6e-28	-0.95	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
HNSC	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	13.53	2.09e-35	1.63e-28	1.05	0.53	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
HNSC	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	13.52	2.21e-35	1.72e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
HNSC	trans	rs12709013	0.597	rs1657171	ENSG00000233719.3	GOT2P3	13.51	2.35e-35	1.83e-28	0.67	0.53	Blood metabolite ratios;	chr16:58752083	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.636	rs1646285	ENSG00000233719.3	GOT2P3	13.51	2.35e-35	1.83e-28	0.67	0.53	Blood metabolite ratios;	chr16:58752102	chr12:9641802~9643007:+
HNSC	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	13.51	2.38e-35	1.85e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	13.51	2.49e-35	1.93e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	13.51	2.49e-35	1.93e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	13.51	2.49e-35	1.93e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	13.51	2.49e-35	1.93e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
HNSC	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-13.51	2.5e-35	1.94e-28	-0.65	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
HNSC	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-13.51	2.54e-35	1.97e-28	-0.67	-0.53	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	13.5	2.55e-35	1.98e-28	0.66	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
HNSC	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	13.49	2.94e-35	2.28e-28	1.38	0.53	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
HNSC	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-13.49	2.98e-35	2.31e-28	-0.66	-0.53	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
HNSC	trans	rs9611565	0.571	rs7364123	ENSG00000268568.1	AC007228.9	-13.46	3.84e-35	2.97e-28	-0.68	-0.53	Vitiligo;	chr22:41820322	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	13.46	4.04e-35	3.12e-28	1.28	0.53	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	13.45	4.33e-35	3.34e-28	0.69	0.53	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
HNSC	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-13.45	4.5e-35	3.47e-28	-0.94	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
HNSC	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	13.44	4.59e-35	3.53e-28	0.74	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
HNSC	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	13.44	4.66e-35	3.58e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.703	rs7543258	ENSG00000261819.1	RP11-680G24.4	13.43	5.33e-35	4.09e-28	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11901599	chr16:14988259~14990160:-
HNSC	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-13.43	5.34e-35	4.1e-28	-0.66	-0.53	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
HNSC	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	13.43	5.55e-35	4.26e-28	0.93	0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
HNSC	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	13.4	7.05e-35	5.38e-28	0.69	0.53	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
HNSC	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	13.39	7.68e-35	5.85e-28	0.73	0.53	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
HNSC	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	13.39	7.87e-35	5.99e-28	0.65	0.53	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
HNSC	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	13.38	8.25e-35	6.27e-28	0.65	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
HNSC	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	13.38	8.38e-35	6.37e-28	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
HNSC	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-13.38	8.48e-35	6.44e-28	-0.65	-0.53	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
HNSC	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	13.38	8.91e-35	6.76e-28	0.65	0.53	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
HNSC	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	13.38	9.03e-35	6.84e-28	0.65	0.53	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	13.38	9.03e-35	6.84e-28	0.65	0.53	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	13.38	9.03e-35	6.84e-28	0.65	0.53	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
HNSC	trans	rs6708331	0.878	rs12994100	ENSG00000232654.1	FAM136BP	13.37	9.35e-35	7.08e-28	0.71	0.53	Obesity-related traits;	chr2:70133785	chr6:3045384~3045800:+
HNSC	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-13.35	1.17e-34	8.84e-28	-0.65	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
HNSC	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	13.34	1.24e-34	9.37e-28	0.57	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
HNSC	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	13.34	1.28e-34	9.66e-28	0.68	0.53	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
HNSC	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	13.34	1.28e-34	9.66e-28	0.68	0.53	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
HNSC	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-13.33	1.36e-34	1.02e-27	-0.65	-0.53	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	13.33	1.41e-34	1.06e-27	0.71	0.52	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
HNSC	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	13.32	1.48e-34	1.11e-27	0.65	0.52	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
HNSC	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-13.31	1.68e-34	1.26e-27	-0.65	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
HNSC	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-13.31	1.72e-34	1.29e-27	-0.69	-0.52	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-13.3	1.87e-34	1.4e-27	-0.64	-0.52	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
HNSC	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-13.29	2e-34	1.5e-27	-0.95	-0.52	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
HNSC	trans	rs6708331	1	rs7578027	ENSG00000232654.1	FAM136BP	13.27	2.41e-34	1.79e-27	0.71	0.52	Obesity-related traits;	chr2:70173976	chr6:3045384~3045800:+
HNSC	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-13.26	2.87e-34	2.12e-27	-0.67	-0.52	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
HNSC	trans	rs6708331	0.816	rs10196979	ENSG00000232654.1	FAM136BP	13.25	2.92e-34	2.16e-27	0.7	0.52	Obesity-related traits;	chr2:70140265	chr6:3045384~3045800:+
HNSC	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	13.22	3.96e-34	2.87e-27	0.65	0.52	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
HNSC	trans	rs6708331	0.938	rs13000514	ENSG00000232654.1	FAM136BP	13.22	4.27e-34	3.09e-27	0.71	0.52	Obesity-related traits;	chr2:70167884	chr6:3045384~3045800:+
HNSC	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	13.2	4.83e-34	3.45e-27	0.68	0.52	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
HNSC	trans	rs6708331	1	rs13429940	ENSG00000232654.1	FAM136BP	13.2	4.96e-34	3.55e-27	0.7	0.52	Obesity-related traits;	chr2:70152736	chr6:3045384~3045800:+
HNSC	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-13.19	5.49e-34	3.92e-27	-0.62	-0.52	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
HNSC	trans	rs6708331	0.938	rs13389246	ENSG00000232654.1	FAM136BP	13.19	5.68e-34	4.05e-27	0.71	0.52	Obesity-related traits;	chr2:70127099	chr6:3045384~3045800:+
HNSC	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	13.18	6.1e-34	4.34e-27	0.64	0.52	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	13.18	6.1e-34	4.34e-27	0.64	0.52	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	13.17	6.31e-34	4.48e-27	0.64	0.52	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
HNSC	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-13.17	6.32e-34	4.49e-27	-0.62	-0.52	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
HNSC	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-13.17	6.53e-34	4.63e-27	-0.7	-0.52	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
HNSC	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-13.17	6.59e-34	4.68e-27	-0.67	-0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
HNSC	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	13.16	7.4e-34	5.23e-27	0.68	0.52	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
HNSC	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	13.15	7.96e-34	5.62e-27	0.64	0.52	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
HNSC	trans	rs12709013	0.591	rs149479	ENSG00000233719.3	GOT2P3	-13.14	8.48e-34	5.98e-27	-0.71	-0.52	Blood metabolite ratios;	chr16:58703171	chr12:9641802~9643007:+
HNSC	trans	rs6708331	1	rs35734267	ENSG00000232654.1	FAM136BP	13.14	8.89e-34	6.26e-27	0.69	0.52	Obesity-related traits;	chr2:70054058	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.941	rs6720799	ENSG00000232654.1	FAM136BP	-13.14	9.08e-34	6.4e-27	-0.71	-0.52	Obesity-related traits;	chr2:70144897	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.941	rs11903933	ENSG00000232654.1	FAM136BP	13.12	1.04e-33	7.3e-27	0.7	0.52	Obesity-related traits;	chr2:70149812	chr6:3045384~3045800:+
HNSC	trans	rs6708331	1	rs13000817	ENSG00000232654.1	FAM136BP	13.12	1.05e-33	7.37e-27	0.69	0.52	Obesity-related traits;	chr2:70046575	chr6:3045384~3045800:+
HNSC	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	13.12	1.12e-33	7.87e-27	0.68	0.52	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
HNSC	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	13.11	1.17e-33	8.22e-27	0.64	0.52	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	13.11	1.17e-33	8.22e-27	0.64	0.52	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
HNSC	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	13.1	1.24e-33	8.67e-27	0.68	0.52	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
HNSC	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	13.1	1.33e-33	9.32e-27	1.16	0.52	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	13.1	1.34e-33	9.35e-27	0.67	0.52	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	13.1	1.34e-33	9.35e-27	0.67	0.52	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
HNSC	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-13.09	1.45e-33	1.02e-26	-0.69	-0.52	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
HNSC	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-13.09	1.46e-33	1.02e-26	-0.64	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
HNSC	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	13.09	1.49e-33	1.04e-26	0.65	0.52	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
HNSC	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	13.08	1.51e-33	1.05e-26	0.67	0.52	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
HNSC	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-13.07	1.71e-33	1.19e-26	-0.69	-0.52	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
HNSC	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-13.07	1.74e-33	1.21e-26	-0.63	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
HNSC	trans	rs2657294	0.965	rs7088974	ENSG00000172974.11	AC007318.5	13.06	1.87e-33	1.3e-26	0.64	0.52	Pneumonia;	chr10:75131338	chr2:65205108~65205988:+
HNSC	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	13.06	1.91e-33	1.32e-26	0.64	0.52	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
HNSC	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	13.06	1.94e-33	1.35e-26	0.64	0.52	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
HNSC	trans	rs867371	0.722	rs8033050	ENSG00000235370.6	DNM1P51	-13.06	1.99e-33	1.38e-26	-0.67	-0.52	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:84398316~84411701:-
HNSC	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-13.05	2.01e-33	1.39e-26	-0.63	-0.52	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
HNSC	trans	rs6708331	0.646	rs12713688	ENSG00000232654.1	FAM136BP	13.05	2.11e-33	1.46e-26	0.7	0.52	Obesity-related traits;	chr2:70142371	chr6:3045384~3045800:+
HNSC	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-13.04	2.23e-33	1.54e-26	-0.64	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.716	rs6416775	ENSG00000230849.2	GOT2P2	13.04	2.29e-33	1.58e-26	0.63	0.52	Blood metabolite ratios;	chr16:58830410	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-13.03	2.44e-33	1.69e-26	-0.63	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	13.03	2.55e-33	1.76e-26	0.67	0.52	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
HNSC	trans	rs959695	0.834	rs6468693	ENSG00000260318.1	COX6CP1	-13.02	2.72e-33	1.87e-26	-0.63	-0.52	Hippocampal atrophy;	chr8:99839040	chr16:11903923~11904137:-
HNSC	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-13.02	2.76e-33	1.9e-26	-0.63	-0.52	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	13.02	2.79e-33	1.92e-26	0.67	0.52	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
HNSC	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	13.02	2.81e-33	1.94e-26	1.34	0.52	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
HNSC	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-13.02	2.87e-33	1.98e-26	-0.69	-0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
HNSC	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	13.02	2.88e-33	1.98e-26	0.64	0.52	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
HNSC	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-13.01	3.12e-33	2.14e-26	-0.63	-0.52	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
HNSC	trans	rs6708331	1	rs12999430	ENSG00000232654.1	FAM136BP	12.99	3.59e-33	2.44e-26	0.68	0.52	Obesity-related traits;	chr2:70079653	chr6:3045384~3045800:+
HNSC	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	12.97	4.32e-33	2.93e-26	0.7	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
HNSC	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	12.96	5.12e-33	3.48e-26	0.72	0.51	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
HNSC	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	12.95	5.26e-33	3.57e-26	0.7	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
HNSC	trans	rs6708331	0.941	rs12989076	ENSG00000232654.1	FAM136BP	12.95	5.7e-33	3.86e-26	0.69	0.51	Obesity-related traits;	chr2:70176275	chr6:3045384~3045800:+
HNSC	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-12.94	5.81e-33	3.94e-26	-0.63	-0.51	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
HNSC	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-12.94	5.83e-33	3.95e-26	-0.64	-0.51	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
HNSC	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-12.94	6e-33	4.06e-26	-0.67	-0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
HNSC	trans	rs6708331	0.938	rs36025045	ENSG00000232654.1	FAM136BP	12.93	6.86e-33	4.64e-26	0.68	0.51	Obesity-related traits;	chr2:70121829	chr6:3045384~3045800:+
HNSC	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-12.92	7.1e-33	4.8e-26	-0.69	-0.51	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
HNSC	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	12.92	7.26e-33	4.9e-26	0.67	0.51	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
HNSC	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	12.92	7.26e-33	4.91e-26	0.7	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
HNSC	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	12.92	7.63e-33	5.15e-26	0.67	0.51	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
HNSC	trans	rs9611519	0.857	rs4820434	ENSG00000268568.1	AC007228.9	-12.91	8.04e-33	5.43e-26	-0.68	-0.51	Neuroticism;	chr22:41241115	chr19:56672574~56673901:-
HNSC	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	12.89	9.65e-33	6.49e-26	0.81	0.51	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	12.89	9.65e-33	6.49e-26	0.81	0.51	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
HNSC	trans	rs7554547	0.739	rs2050269	ENSG00000261819.1	RP11-680G24.4	12.89	9.74e-33	6.55e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.765	rs2050268	ENSG00000261819.1	RP11-680G24.4	12.89	9.74e-33	6.55e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.765	rs2050267	ENSG00000261819.1	RP11-680G24.4	12.89	9.74e-33	6.55e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr16:14988259~14990160:-
HNSC	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	12.88	1.07e-32	7.17e-26	0.65	0.51	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
HNSC	trans	rs867371	0.762	rs12905578	ENSG00000235370.6	DNM1P51	12.87	1.22e-32	8.16e-26	0.67	0.51	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:84398316~84411701:-
HNSC	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	12.85	1.4e-32	9.4e-26	0.7	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
HNSC	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	12.85	1.42e-32	9.5e-26	0.78	0.51	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	12.85	1.46e-32	9.76e-26	0.67	0.51	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
HNSC	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	12.83	1.7e-32	1.13e-25	0.66	0.51	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
HNSC	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	12.83	1.76e-32	1.17e-25	0.67	0.51	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
HNSC	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	12.82	1.86e-32	1.24e-25	1.32	0.51	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	12.82	1.86e-32	1.24e-25	1.32	0.51	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	12.82	1.86e-32	1.24e-25	1.32	0.51	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
HNSC	trans	rs7554511	0.894	rs11589638	ENSG00000244144.1	RP11-757F18.3	-12.81	2.1e-32	1.4e-25	-0.69	-0.51	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200925807	chr3:112185480~112185998:-
HNSC	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	12.81	2.11e-32	1.41e-25	0.65	0.51	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
HNSC	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-12.81	2.12e-32	1.41e-25	-0.62	-0.51	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
HNSC	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	12.8	2.27e-32	1.51e-25	0.8	0.51	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
HNSC	trans	rs867371	0.762	rs1846910	ENSG00000235370.6	DNM1P51	-12.79	2.44e-32	1.62e-25	-0.66	-0.51	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:84398316~84411701:-
HNSC	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-12.79	2.58e-32	1.71e-25	-0.93	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
HNSC	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	12.78	2.84e-32	1.89e-25	0.64	0.51	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
HNSC	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	12.77	3.14e-32	2.08e-25	0.8	0.51	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
HNSC	trans	rs7554547	0.765	rs2050270	ENSG00000261819.1	RP11-680G24.4	12.76	3.23e-32	2.14e-25	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886399	chr16:14988259~14990160:-
HNSC	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	12.76	3.28e-32	2.18e-25	0.79	0.51	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.894	rs404339	ENSG00000244144.1	RP11-757F18.3	-12.76	3.33e-32	2.21e-25	-0.66	-0.51	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917763	chr3:112185480~112185998:-
HNSC	trans	rs867371	0.717	rs3858954	ENSG00000235370.6	DNM1P51	-12.75	3.56e-32	2.36e-25	-0.66	-0.51	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:84398316~84411701:-
HNSC	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	12.75	3.58e-32	2.37e-25	0.79	0.51	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	12.73	4.69e-32	3.08e-25	0.8	0.51	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
HNSC	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-12.73	4.69e-32	3.08e-25	-0.93	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
HNSC	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-12.69	6.4e-32	4.19e-25	-0.81	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
HNSC	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-12.69	6.4e-32	4.19e-25	-0.81	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
HNSC	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	12.68	7.12e-32	4.66e-25	0.82	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
HNSC	trans	rs6708331	0.941	rs7609359	ENSG00000232654.1	FAM136BP	12.68	7.24e-32	4.74e-25	0.66	0.51	Obesity-related traits;	chr2:70131844	chr6:3045384~3045800:+
HNSC	trans	rs6708331	0.941	rs7595262	ENSG00000232654.1	FAM136BP	12.68	7.24e-32	4.74e-25	0.66	0.51	Obesity-related traits;	chr2:70131865	chr6:3045384~3045800:+
HNSC	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	12.67	7.58e-32	4.96e-25	0.64	0.51	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
HNSC	trans	rs6708331	1	rs62151174	ENSG00000232654.1	FAM136BP	12.67	7.65e-32	5e-25	0.66	0.51	Obesity-related traits;	chr2:70136836	chr6:3045384~3045800:+
HNSC	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	12.67	7.76e-32	5.07e-25	0.8	0.51	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
HNSC	trans	rs6708331	1	rs7597199	ENSG00000232654.1	FAM136BP	12.67	7.91e-32	5.17e-25	0.66	0.51	Obesity-related traits;	chr2:70114443	chr6:3045384~3045800:+
HNSC	trans	rs7399018	0.739	rs7953955	ENSG00000223825.5	DAZAP2P1	12.66	8.65e-32	5.65e-25	0.62	0.51	Cisplatin-induced ototoxicity;	chr12:51214683	chr2:202201384~202201886:-
HNSC	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-12.65	9.13e-32	5.95e-25	-1.18	-0.51	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
HNSC	trans	rs6708331	1	rs6708331	ENSG00000232654.1	FAM136BP	12.65	9.24e-32	6.02e-25	0.65	0.51	Obesity-related traits;	chr2:70141791	chr6:3045384~3045800:+
HNSC	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	12.64	1.05e-31	6.84e-25	0.83	0.5	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
HNSC	trans	rs7399018	0.739	rs7399073	ENSG00000223825.5	DAZAP2P1	12.63	1.11e-31	7.22e-25	0.61	0.5	Cisplatin-induced ototoxicity;	chr12:51220266	chr2:202201384~202201886:-
HNSC	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-12.63	1.18e-31	7.67e-25	-0.68	-0.5	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
HNSC	trans	rs6708331	0.941	rs10173330	ENSG00000232654.1	FAM136BP	12.62	1.27e-31	8.26e-25	0.66	0.5	Obesity-related traits;	chr2:70139981	chr6:3045384~3045800:+
HNSC	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-12.62	1.3e-31	8.47e-25	-0.66	-0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
HNSC	trans	rs7554511	0.893	rs6427868	ENSG00000244144.1	RP11-757F18.3	-12.61	1.42e-31	9.21e-25	-0.68	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960354	chr3:112185480~112185998:-
HNSC	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-12.61	1.44e-31	9.34e-25	-0.8	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
HNSC	trans	rs6708331	0.941	rs10173259	ENSG00000232654.1	FAM136BP	12.58	1.83e-31	1.19e-24	0.66	0.5	Obesity-related traits;	chr2:70140078	chr6:3045384~3045800:+
HNSC	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	12.58	1.91e-31	1.24e-24	0.65	0.5	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
HNSC	trans	rs116095464	1	rs2015774	ENSG00000185986.11	SDHAP3	12.58	1.92e-31	1.24e-24	0.9	0.5	Breast cancer;	chr5:312843	chr5:1572222~1594620:-
HNSC	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	12.56	2.16e-31	1.4e-24	0.82	0.5	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	12.56	2.16e-31	1.4e-24	0.82	0.5	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
HNSC	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	12.55	2.4e-31	1.55e-24	0.63	0.5	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
HNSC	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	12.55	2.56e-31	1.65e-24	0.57	0.5	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
HNSC	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	12.54	2.59e-31	1.67e-24	0.96	0.5	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
HNSC	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	12.54	2.69e-31	1.73e-24	0.62	0.5	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	12.53	3.12e-31	2.01e-24	0.62	0.5	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
HNSC	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	12.52	3.22e-31	2.07e-24	0.85	0.5	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	12.52	3.39e-31	2.18e-24	0.84	0.5	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
HNSC	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-12.51	3.58e-31	2.3e-24	-0.64	-0.5	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
HNSC	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	12.49	4.18e-31	2.67e-24	0.81	0.5	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
HNSC	trans	rs2950393	0.611	rs7138821	ENSG00000121089.4	NACA3P	-12.49	4.18e-31	2.68e-24	-0.6	-0.5	Platelet distribution width;	chr12:56796206	chr4:164943290~164943937:+
HNSC	trans	rs6708331	0.941	rs12989257	ENSG00000232654.1	FAM136BP	12.48	4.72e-31	3.01e-24	0.65	0.5	Obesity-related traits;	chr2:70141466	chr6:3045384~3045800:+
HNSC	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	12.47	5.38e-31	3.44e-24	0.87	0.5	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	12.47	5.38e-31	3.44e-24	0.62	0.5	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	12.47	5.38e-31	3.44e-24	0.62	0.5	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	12.47	5.46e-31	3.49e-24	0.62	0.5	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
HNSC	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	12.46	5.7e-31	3.64e-24	0.8	0.5	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
HNSC	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	12.46	6e-31	3.83e-24	0.62	0.5	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
HNSC	trans	rs7554511	0.894	rs296543	ENSG00000244144.1	RP11-757F18.3	12.45	6.17e-31	3.93e-24	0.66	0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200920705	chr3:112185480~112185998:-
HNSC	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	12.44	6.91e-31	4.4e-24	0.65	0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
HNSC	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	12.43	7.31e-31	4.65e-24	0.67	0.5	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
HNSC	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-12.43	7.51e-31	4.77e-24	-0.86	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
HNSC	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	12.43	7.66e-31	4.87e-24	0.67	0.5	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	12.43	7.66e-31	4.87e-24	0.67	0.5	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	12.43	7.69e-31	4.89e-24	0.67	0.5	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
HNSC	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	12.43	7.89e-31	5.01e-24	0.82	0.5	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	12.43	7.89e-31	5.01e-24	0.82	0.5	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	12.43	7.97e-31	5.06e-24	0.62	0.5	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	12.42	8.02e-31	5.09e-24	0.62	0.5	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	12.42	8.02e-31	5.09e-24	0.62	0.5	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
HNSC	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	12.42	8.22e-31	5.22e-24	0.67	0.5	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	12.42	8.22e-31	5.22e-24	0.67	0.5	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
HNSC	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	12.41	9.26e-31	5.87e-24	0.61	0.5	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
HNSC	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	12.41	9.36e-31	5.93e-24	0.62	0.5	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
HNSC	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	12.4	1e-30	6.33e-24	0.67	0.5	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
HNSC	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	12.38	1.2e-30	7.58e-24	0.81	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
HNSC	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	12.38	1.21e-30	7.66e-24	0.78	0.5	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	12.36	1.47e-30	9.28e-24	0.63	0.5	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
HNSC	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	12.35	1.57e-30	9.92e-24	0.65	0.5	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
HNSC	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	12.35	1.58e-30	9.95e-24	0.61	0.5	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	12.35	1.58e-30	9.95e-24	0.61	0.5	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	12.35	1.58e-30	9.95e-24	0.61	0.5	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	12.35	1.58e-30	9.95e-24	0.61	0.5	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
HNSC	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	12.35	1.62e-30	1.02e-23	0.81	0.5	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
HNSC	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	12.34	1.74e-30	1.1e-23	0.56	0.5	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
HNSC	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-12.33	1.86e-30	1.17e-23	-0.61	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
HNSC	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	12.33	1.87e-30	1.18e-23	0.61	0.5	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
HNSC	trans	rs5877	0.568	rs1951627	ENSG00000213331.4	RP11-713C19.2	12.33	1.88e-30	1.18e-23	0.61	0.5	Subjective well-being (multi-trait analysis);	chr1:173922679	chr4:187970273~187971284:+
HNSC	trans	rs7554511	0.858	rs12142704	ENSG00000244144.1	RP11-757F18.3	-12.32	2.11e-30	1.32e-23	-0.68	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200988569	chr3:112185480~112185998:-
HNSC	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	12.32	2.18e-30	1.37e-23	0.56	0.5	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
HNSC	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	12.31	2.36e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	12.31	2.36e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	12.31	2.36e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
HNSC	trans	rs7554511	0.861	rs11583546	ENSG00000244144.1	RP11-757F18.3	-12.31	2.37e-30	1.48e-23	-0.69	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr3:112185480~112185998:-
HNSC	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	12.31	2.37e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	12.31	2.37e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	12.31	2.37e-30	1.48e-23	0.61	0.49	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	12.3	2.53e-30	1.58e-23	0.61	0.49	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
HNSC	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	12.3	2.57e-30	1.6e-23	0.8	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
HNSC	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	12.28	3.05e-30	1.9e-23	0.81	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
HNSC	trans	rs7554511	0.858	rs3208703	ENSG00000244144.1	RP11-757F18.3	-12.28	3.16e-30	1.97e-23	-0.66	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200970514	chr3:112185480~112185998:-
HNSC	trans	rs7554511	0.858	rs7539693	ENSG00000244144.1	RP11-757F18.3	-12.27	3.39e-30	2.12e-23	-0.67	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200986438	chr3:112185480~112185998:-
HNSC	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-12.26	3.78e-30	2.35e-23	-0.82	-0.49	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
HNSC	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	12.26	3.85e-30	2.4e-23	1.29	0.49	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	12.26	3.93e-30	2.44e-23	0.61	0.49	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
HNSC	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	12.23	5.01e-30	3.11e-23	0.8	0.49	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.858	rs12118735	ENSG00000244144.1	RP11-757F18.3	-12.23	5.17e-30	3.22e-23	-0.66	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200981832	chr3:112185480~112185998:-
HNSC	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	12.22	5.25e-30	3.26e-23	0.67	0.49	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	12.22	5.5e-30	3.41e-23	0.65	0.49	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
HNSC	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	12.21	5.85e-30	3.63e-23	0.62	0.49	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
HNSC	trans	rs2657294	0.796	rs6480770	ENSG00000172974.11	AC007318.5	12.2	6.48e-30	4.02e-23	0.62	0.49	Pneumonia;	chr10:75098799	chr2:65205108~65205988:+
HNSC	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	12.19	6.95e-30	4.31e-23	0.66	0.49	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
HNSC	trans	rs4240897	0.935	rs2236055	ENSG00000261819.1	RP11-680G24.4	12.18	7.82e-30	4.84e-23	0.66	0.49	Tuberculosis;	chr1:11982204	chr16:14988259~14990160:-
HNSC	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	12.18	8.1e-30	5.01e-23	0.79	0.49	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	12.18	8.1e-30	5.01e-23	0.79	0.49	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	12.18	8.1e-30	5.01e-23	0.79	0.49	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
HNSC	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	12.18	8.12e-30	5.01e-23	0.65	0.49	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	12.18	8.12e-30	5.01e-23	0.65	0.49	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	12.18	8.12e-30	5.01e-23	0.65	0.49	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	12.18	8.12e-30	5.01e-23	0.65	0.49	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	12.18	8.12e-30	5.01e-23	0.65	0.49	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
HNSC	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-12.18	8.18e-30	5.05e-23	-0.65	-0.49	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
HNSC	trans	rs9899728	0.539	rs56267297	ENSG00000234925.2	ATP5HP4	12.17	8.3e-30	5.12e-23	0.92	0.49	Alzheimer's disease or small vessel stroke;	chr17:75050901	chr12:68642519~68642993:-
HNSC	trans	rs6708331	0.517	rs12614547	ENSG00000232654.1	FAM136BP	12.17	8.32e-30	5.14e-23	0.6	0.49	Obesity-related traits;	chr2:70056839	chr6:3045384~3045800:+
HNSC	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	12.17	8.59e-30	5.3e-23	0.64	0.49	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
HNSC	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	12.17	9.09e-30	5.6e-23	0.65	0.49	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	12.16	9.34e-30	5.76e-23	0.65	0.49	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	12.16	9.36e-30	5.77e-23	0.66	0.49	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	12.16	9.44e-30	5.81e-23	0.65	0.49	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	12.16	9.58e-30	5.9e-23	0.66	0.49	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
HNSC	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	12.14	1.1e-29	6.75e-23	0.61	0.49	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
HNSC	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	12.14	1.12e-29	6.86e-23	0.65	0.49	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	12.14	1.12e-29	6.86e-23	0.65	0.49	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	12.14	1.15e-29	7.04e-23	0.66	0.49	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
HNSC	trans	rs7554511	0.893	rs10494828	ENSG00000244144.1	RP11-757F18.3	-12.13	1.26e-29	7.75e-23	-0.66	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200987904	chr3:112185480~112185998:-
HNSC	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	12.13	1.29e-29	7.87e-23	0.65	0.49	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	12.12	1.4e-29	8.56e-23	0.65	0.49	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
HNSC	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	12.1	1.71e-29	1.04e-22	0.81	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
HNSC	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	12.09	1.8e-29	1.1e-22	0.61	0.49	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
HNSC	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	12.08	1.96e-29	1.2e-22	0.62	0.49	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
HNSC	trans	rs74781061	0.86	rs6495102	ENSG00000227288.3	RP5-837I24.1	12.07	2.14e-29	1.3e-22	0.68	0.49	Endometriosis;	chr15:74470337	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	12.07	2.26e-29	1.37e-22	0.6	0.49	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
HNSC	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	12.04	2.91e-29	1.76e-22	0.81	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
HNSC	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	12.03	3.16e-29	1.91e-22	0.8	0.49	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.861	rs10920074	ENSG00000244144.1	RP11-757F18.3	-12.03	3.24e-29	1.96e-22	-0.67	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200943599	chr3:112185480~112185998:-
HNSC	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	12.03	3.29e-29	1.99e-22	0.82	0.49	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.792	rs12126806	ENSG00000244144.1	RP11-757F18.3	-12.02	3.36e-29	2.03e-22	-0.63	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200994697	chr3:112185480~112185998:-
HNSC	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	12.02	3.59e-29	2.17e-22	0.61	0.49	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
HNSC	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	12.01	3.7e-29	2.23e-22	0.82	0.49	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
HNSC	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	12.01	3.88e-29	2.34e-22	0.61	0.49	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
HNSC	trans	rs74781061	0.799	rs4372642	ENSG00000227288.3	RP5-837I24.1	12.01	3.95e-29	2.38e-22	0.68	0.49	Endometriosis;	chr15:74460095	chr1:81501794~81503468:+
HNSC	trans	rs3740713	0.669	rs78098319	ENSG00000235847.2	LDHAP7	12	4.23e-29	2.55e-22	0.83	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:84777259~84778223:-
HNSC	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	12	4.37e-29	2.63e-22	0.81	0.49	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	12	4.37e-29	2.63e-22	0.81	0.49	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
HNSC	trans	rs6708331	0.941	rs13028968	ENSG00000232654.1	FAM136BP	11.99	4.62e-29	2.78e-22	0.63	0.49	Obesity-related traits;	chr2:70179991	chr6:3045384~3045800:+
HNSC	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	11.99	4.66e-29	2.8e-22	0.54	0.49	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
HNSC	trans	rs2657294	0.895	rs2002023	ENSG00000172974.11	AC007318.5	11.96	5.91e-29	3.54e-22	0.61	0.48	Pneumonia;	chr10:75088766	chr2:65205108~65205988:+
HNSC	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	11.96	5.95e-29	3.57e-22	0.81	0.48	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
HNSC	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	11.96	6.1e-29	3.66e-22	1.05	0.48	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
HNSC	trans	rs7554511	0.858	rs12140420	ENSG00000244144.1	RP11-757F18.3	-11.96	6.14e-29	3.68e-22	-0.65	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993159	chr3:112185480~112185998:-
HNSC	trans	rs74781061	0.932	rs2012008	ENSG00000227288.3	RP5-837I24.1	11.95	6.39e-29	3.83e-22	0.68	0.48	Endometriosis;	chr15:74441827	chr1:81501794~81503468:+
HNSC	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	11.95	6.73e-29	4.03e-22	0.82	0.48	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	11.94	7.26e-29	4.34e-22	0.83	0.48	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
HNSC	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	11.93	7.73e-29	4.61e-22	0.56	0.48	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
HNSC	trans	rs74781061	0.932	rs7176491	ENSG00000227288.3	RP5-837I24.1	11.93	8.07e-29	4.81e-22	0.68	0.48	Endometriosis;	chr15:74514875	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs61168092	ENSG00000227288.3	RP5-837I24.1	11.93	8.07e-29	4.81e-22	0.68	0.48	Endometriosis;	chr15:74517619	chr1:81501794~81503468:+
HNSC	trans	rs74781061	1	rs8040745	ENSG00000227288.3	RP5-837I24.1	11.93	8.07e-29	4.81e-22	0.68	0.48	Endometriosis;	chr15:74525791	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs11072493	ENSG00000227288.3	RP5-837I24.1	11.93	8.07e-29	4.81e-22	0.68	0.48	Endometriosis;	chr15:74536881	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	11.92	8.46e-29	5.03e-22	0.59	0.48	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
HNSC	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	11.92	8.54e-29	5.08e-22	0.61	0.48	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
HNSC	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	11.92	8.81e-29	5.24e-22	0.6	0.48	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
HNSC	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.36e-22	0.75	0.48	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.36e-22	0.75	0.48	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.36e-22	0.75	0.48	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.36e-22	0.75	0.48	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.36e-22	0.75	0.48	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	11.92	9.03e-29	5.37e-22	0.81	0.48	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	11.92	9.06e-29	5.38e-22	0.6	0.48	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
HNSC	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	11.91	9.47e-29	5.62e-22	0.75	0.48	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
HNSC	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	11.91	9.56e-29	5.67e-22	0.77	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
HNSC	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	11.9	1.08e-28	6.38e-22	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
HNSC	trans	rs12709013	0.792	rs1473206	ENSG00000233719.3	GOT2P3	11.89	1.14e-28	6.72e-22	0.58	0.48	Blood metabolite ratios;	chr16:58737529	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1473205	ENSG00000233719.3	GOT2P3	11.89	1.14e-28	6.72e-22	0.58	0.48	Blood metabolite ratios;	chr16:58737547	chr12:9641802~9643007:+
HNSC	trans	rs7554511	0.929	rs55757739	ENSG00000244144.1	RP11-757F18.3	-11.89	1.21e-28	7.11e-22	-0.65	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200997848	chr3:112185480~112185998:-
HNSC	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	11.88	1.23e-28	7.27e-22	0.78	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
HNSC	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	11.88	1.24e-28	7.29e-22	0.81	0.48	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	11.88	1.25e-28	7.35e-22	0.61	0.48	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
HNSC	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	11.88	1.27e-28	7.46e-22	0.93	0.48	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
HNSC	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	11.88	1.3e-28	7.67e-22	0.55	0.48	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
HNSC	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-11.88	1.3e-28	7.67e-22	-0.61	-0.48	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
HNSC	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	11.87	1.44e-28	8.47e-22	1.13	0.48	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
HNSC	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	11.86	1.58e-28	9.27e-22	0.75	0.48	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	11.86	1.58e-28	9.27e-22	0.75	0.48	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	11.85	1.63e-28	9.54e-22	0.75	0.48	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
HNSC	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	11.85	1.69e-28	9.89e-22	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
HNSC	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	11.85	1.72e-28	1.01e-21	0.75	0.48	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
HNSC	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	11.84	1.78e-28	1.04e-21	0.55	0.48	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
HNSC	trans	rs12709013	0.694	rs1616798	ENSG00000233719.3	GOT2P3	11.84	1.86e-28	1.08e-21	0.58	0.48	Blood metabolite ratios;	chr16:58739433	chr12:9641802~9643007:+
HNSC	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	11.83	1.98e-28	1.16e-21	0.75	0.48	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	11.83	1.98e-28	1.16e-21	0.75	0.48	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	11.83	1.98e-28	1.16e-21	0.75	0.48	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-11.83	1.99e-28	1.16e-21	-0.59	-0.48	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-11.83	1.99e-28	1.16e-21	-0.59	-0.48	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
HNSC	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-11.83	2.01e-28	1.17e-21	-0.79	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
HNSC	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	11.83	2.02e-28	1.18e-21	0.6	0.48	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
HNSC	trans	rs3740713	0.719	rs78515595	ENSG00000235847.2	LDHAP7	11.82	2.2e-28	1.28e-21	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr2:84777259~84778223:-
HNSC	trans	rs7554511	0.893	rs17419032	ENSG00000244144.1	RP11-757F18.3	11.82	2.21e-28	1.28e-21	0.66	0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201029403	chr3:112185480~112185998:-
HNSC	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	11.82	2.29e-28	1.33e-21	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
HNSC	trans	rs12709013	0.729	rs1657179	ENSG00000233719.3	GOT2P3	11.82	2.29e-28	1.33e-21	0.58	0.48	Blood metabolite ratios;	chr16:58735115	chr12:9641802~9643007:+
HNSC	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-11.81	2.35e-28	1.37e-21	-0.46	-0.48	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
HNSC	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	11.81	2.39e-28	1.39e-21	0.6	0.48	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
HNSC	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	11.81	2.4e-28	1.4e-21	0.74	0.48	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
HNSC	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	11.81	2.51e-28	1.46e-21	1.12	0.48	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
HNSC	trans	rs7554511	0.893	rs55862304	ENSG00000244144.1	RP11-757F18.3	-11.8	2.71e-28	1.57e-21	-0.66	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020647	chr3:112185480~112185998:-
HNSC	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	11.8	2.75e-28	1.59e-21	0.61	0.48	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
HNSC	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	11.79	2.82e-28	1.64e-21	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
HNSC	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	11.79	2.87e-28	1.66e-21	0.65	0.48	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
HNSC	trans	rs74781061	0.872	rs4886598	ENSG00000227288.3	RP5-837I24.1	11.78	3.22e-28	1.86e-21	0.68	0.48	Endometriosis;	chr15:74484441	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.872	rs6495106	ENSG00000227288.3	RP5-837I24.1	11.78	3.22e-28	1.86e-21	0.68	0.48	Endometriosis;	chr15:74487006	chr1:81501794~81503468:+
HNSC	trans	rs9467773	0.933	rs2024970	ENSG00000242375.1	RP11-498P14.3	11.78	3.26e-28	1.89e-21	0.6	0.48	Intelligence (multi-trait analysis);	chr6:26497292	chr9:97195351~97197687:-
HNSC	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-11.78	3.26e-28	1.89e-21	-0.63	-0.48	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
HNSC	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	11.77	3.5e-28	2.02e-21	0.46	0.48	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
HNSC	trans	rs7554511	0.893	rs11586763	ENSG00000244144.1	RP11-757F18.3	-11.76	3.68e-28	2.12e-21	-0.66	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020316	chr3:112185480~112185998:-
HNSC	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	11.76	3.73e-28	2.15e-21	0.78	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
HNSC	trans	rs8010715	0.816	rs2332224	ENSG00000238000.1	RP11-274E7.2	11.76	3.9e-28	2.25e-21	0.46	0.48	IgG glycosylation;	chr14:24129335	chr5:98213402~98214121:+
HNSC	trans	rs7554511	0.894	rs296545	ENSG00000244144.1	RP11-757F18.3	11.75	4.06e-28	2.34e-21	0.62	0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921564	chr3:112185480~112185998:-
HNSC	trans	rs7554511	0.894	rs296546	ENSG00000244144.1	RP11-757F18.3	11.75	4.06e-28	2.34e-21	0.62	0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921963	chr3:112185480~112185998:-
HNSC	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	11.75	4.1e-28	2.36e-21	0.66	0.48	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
HNSC	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	11.75	4.15e-28	2.39e-21	0.74	0.48	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.893	rs11580823	ENSG00000244144.1	RP11-757F18.3	-11.75	4.29e-28	2.47e-21	-0.66	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201014361	chr3:112185480~112185998:-
HNSC	trans	rs8010715	0.816	rs7153156	ENSG00000238000.1	RP11-274E7.2	11.74	4.56e-28	2.62e-21	0.46	0.48	IgG glycosylation;	chr14:24129637	chr5:98213402~98214121:+
HNSC	trans	rs8010715	0.816	rs6573572	ENSG00000238000.1	RP11-274E7.2	11.74	4.56e-28	2.62e-21	0.46	0.48	IgG glycosylation;	chr14:24130021	chr5:98213402~98214121:+
HNSC	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	11.73	4.8e-28	2.76e-21	0.55	0.48	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
HNSC	trans	rs867371	1	rs13380317	ENSG00000235370.6	DNM1P51	11.72	5.24e-28	3e-21	0.58	0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:84398316~84411701:-
HNSC	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-11.72	5.38e-28	3.08e-21	-0.67	-0.48	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
HNSC	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	11.72	5.58e-28	3.19e-21	0.46	0.48	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
HNSC	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-11.72	5.6e-28	3.2e-21	-0.8	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
HNSC	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	11.71	5.95e-28	3.4e-21	0.46	0.48	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
HNSC	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	11.71	5.97e-28	3.41e-21	1.25	0.48	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	11.69	6.98e-28	3.98e-21	0.6	0.48	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
HNSC	trans	rs9899728	0.539	rs12938889	ENSG00000234925.2	ATP5HP4	-11.68	7.56e-28	4.29e-21	-0.88	-0.48	Alzheimer's disease or small vessel stroke;	chr17:75043834	chr12:68642519~68642993:-
HNSC	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-11.68	8.1e-28	4.59e-21	-0.6	-0.48	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
HNSC	trans	rs2896526	0.736	rs78950598	ENSG00000235847.2	LDHAP7	11.68	8.13e-28	4.6e-21	0.85	0.48	Amyloid A serum levels;	chr11:18375599	chr2:84777259~84778223:-
HNSC	trans	rs7554511	0.893	rs11589573	ENSG00000244144.1	RP11-757F18.3	-11.67	8.29e-28	4.69e-21	-0.66	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005987	chr3:112185480~112185998:-
HNSC	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	11.67	8.6e-28	4.86e-21	0.59	0.48	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
HNSC	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-11.66	9.7e-28	5.48e-21	-0.63	-0.47	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
HNSC	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	11.66	9.76e-28	5.51e-21	0.46	0.47	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
HNSC	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	11.65	1.05e-27	5.9e-21	0.64	0.47	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
HNSC	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	11.64	1.12e-27	6.3e-21	0.46	0.47	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
HNSC	trans	rs7554511	0.861	rs296563	ENSG00000244144.1	RP11-757F18.3	11.63	1.29e-27	7.27e-21	0.61	0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200975712	chr3:112185480~112185998:-
HNSC	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	11.62	1.35e-27	7.58e-21	0.63	0.47	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-11.61	1.54e-27	8.66e-21	-0.6	-0.47	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
HNSC	trans	rs1816752	0.646	rs1361578	ENSG00000224976.2	PARP4P2	11.6	1.57e-27	8.81e-21	0.53	0.47	Obesity-related traits;	chr13:24491117	chr13:19349137~19407962:+
HNSC	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	11.6	1.7e-27	9.54e-21	0.59	0.47	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
HNSC	trans	rs13253073	0.556	rs13279371	ENSG00000260318.1	COX6CP1	11.59	1.74e-27	9.76e-21	0.99	0.47	Glucose homeostasis traits;	chr8:99407006	chr16:11903923~11904137:-
HNSC	trans	rs2665103	0.715	rs16973457	ENSG00000235370.6	DNM1P51	-11.59	1.8e-27	1.01e-20	-0.54	-0.47	Intelligence (multi-trait analysis);	chr15:82271650	chr15:84398316~84411701:-
HNSC	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	11.59	1.87e-27	1.05e-20	0.75	0.47	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
HNSC	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	11.58	1.9e-27	1.07e-20	0.62	0.47	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
HNSC	trans	rs7554511	0.893	rs72749166	ENSG00000244144.1	RP11-757F18.3	-11.57	2.23e-27	1.25e-20	-0.66	-0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031177	chr3:112185480~112185998:-
HNSC	trans	rs13253073	0.556	rs35194538	ENSG00000260318.1	COX6CP1	11.56	2.25e-27	1.26e-20	0.98	0.47	Glucose homeostasis traits;	chr8:99397627	chr16:11903923~11904137:-
HNSC	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	11.56	2.28e-27	1.27e-20	0.62	0.47	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	11.56	2.28e-27	1.27e-20	0.62	0.47	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	11.56	2.35e-27	1.31e-20	0.63	0.47	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	11.56	2.35e-27	1.31e-20	0.63	0.47	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
HNSC	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	11.56	2.35e-27	1.31e-20	0.63	0.47	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
HNSC	trans	rs74781061	0.932	rs7178568	ENSG00000227288.3	RP5-837I24.1	11.56	2.4e-27	1.34e-20	0.68	0.47	Endometriosis;	chr15:74559075	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs8023479	ENSG00000227288.3	RP5-837I24.1	11.56	2.4e-27	1.34e-20	0.68	0.47	Endometriosis;	chr15:74561337	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs12437519	ENSG00000227288.3	RP5-837I24.1	11.56	2.4e-27	1.34e-20	0.68	0.47	Endometriosis;	chr15:74562109	chr1:81501794~81503468:+
HNSC	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	11.55	2.6e-27	1.45e-20	0.63	0.47	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
HNSC	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	11.53	2.96e-27	1.65e-20	0.8	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
HNSC	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	11.53	2.98e-27	1.66e-20	0.58	0.47	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
HNSC	trans	rs2665103	0.715	rs7403041	ENSG00000235370.6	DNM1P51	11.53	3.12e-27	1.74e-20	0.54	0.47	Intelligence (multi-trait analysis);	chr15:82287841	chr15:84398316~84411701:-
HNSC	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	11.53	3.19e-27	1.78e-20	0.75	0.47	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	11.53	3.19e-27	1.78e-20	0.75	0.47	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	11.53	3.19e-27	1.78e-20	0.75	0.47	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	11.53	3.19e-27	1.78e-20	0.75	0.47	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
HNSC	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	11.52	3.36e-27	1.87e-20	0.8	0.47	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
HNSC	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-11.51	3.77e-27	2.09e-20	-0.61	-0.47	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
HNSC	trans	rs7554511	0.894	rs2297909	ENSG00000244144.1	RP11-757F18.3	-11.51	3.81e-27	2.12e-20	-0.61	-0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200991179	chr3:112185480~112185998:-
HNSC	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	11.51	3.82e-27	2.12e-20	0.92	0.47	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
HNSC	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	11.51	3.85e-27	2.14e-20	0.58	0.47	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
HNSC	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	11.5	3.89e-27	2.16e-20	0.63	0.47	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
HNSC	trans	rs7811142	0.887	rs111972532	ENSG00000228546.2	CTA-313A17.3	11.5	3.96e-27	2.2e-20	0.76	0.47	Platelet count;	chr7:100471465	chr7:102337316~102339115:+
HNSC	trans	rs74781061	0.932	rs11072496	ENSG00000227288.3	RP5-837I24.1	11.5	3.97e-27	2.2e-20	0.67	0.47	Endometriosis;	chr15:74628191	chr1:81501794~81503468:+
HNSC	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	11.5	4.03e-27	2.24e-20	0.79	0.47	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
HNSC	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	11.5	4.2e-27	2.33e-20	1.04	0.47	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	11.49	4.26e-27	2.36e-20	0.58	0.47	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	11.49	4.26e-27	2.36e-20	0.58	0.47	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
HNSC	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-11.49	4.3e-27	2.38e-20	-0.61	-0.47	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
HNSC	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-11.48	4.78e-27	2.65e-20	-0.6	-0.47	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
HNSC	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	11.46	5.58e-27	3.08e-20	0.75	0.47	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
HNSC	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	11.46	5.72e-27	3.16e-20	0.55	0.47	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
HNSC	trans	rs867371	1	rs7173339	ENSG00000235370.6	DNM1P51	-11.45	6.3e-27	3.48e-20	-0.6	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:84398316~84411701:-
HNSC	trans	rs7554511	0.858	rs11584383	ENSG00000244144.1	RP11-757F18.3	11.44	6.64e-27	3.66e-20	0.61	0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200966738	chr3:112185480~112185998:-
HNSC	trans	rs1816752	0.669	rs3783072	ENSG00000224976.2	PARP4P2	11.44	6.74e-27	3.72e-20	0.52	0.47	Obesity-related traits;	chr13:24493258	chr13:19349137~19407962:+
HNSC	trans	rs2665103	0.687	rs11633000	ENSG00000235370.6	DNM1P51	-11.44	6.75e-27	3.72e-20	-0.54	-0.47	Intelligence (multi-trait analysis);	chr15:82269320	chr15:84398316~84411701:-
HNSC	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-11.44	7.13e-27	3.93e-20	-0.62	-0.47	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-11.44	7.13e-27	3.93e-20	-0.62	-0.47	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
HNSC	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	11.43	7.39e-27	4.07e-20	0.58	0.47	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	11.43	7.39e-27	4.07e-20	0.58	0.47	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
HNSC	trans	rs116095464	1	rs6555160	ENSG00000185986.11	SDHAP3	-11.43	7.46e-27	4.11e-20	-0.81	-0.47	Breast cancer;	chr5:311554	chr5:1572222~1594620:-
HNSC	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	11.43	7.46e-27	4.11e-20	0.58	0.47	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
HNSC	trans	rs7554511	0.928	rs905634	ENSG00000244144.1	RP11-757F18.3	-11.42	8.01e-27	4.41e-20	-0.61	-0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200915857	chr3:112185480~112185998:-
HNSC	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-11.4	1.02e-26	5.59e-20	-0.61	-0.47	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
HNSC	trans	rs74781061	1	rs74781061	ENSG00000227288.3	RP5-837I24.1	11.39	1.13e-26	6.19e-20	0.67	0.47	Endometriosis;	chr15:74595855	chr1:81501794~81503468:+
HNSC	trans	rs9899728	0.539	rs11077772	ENSG00000234925.2	ATP5HP4	11.38	1.2e-26	6.56e-20	0.92	0.47	Alzheimer's disease or small vessel stroke;	chr17:75039603	chr12:68642519~68642993:-
HNSC	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	11.37	1.24e-26	6.81e-20	0.58	0.47	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	11.37	1.24e-26	6.81e-20	0.58	0.47	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
HNSC	trans	rs9630182	0.602	rs1502243	ENSG00000257675.1	RP11-641A6.9	11.37	1.33e-26	7.25e-20	0.64	0.47	Bone mineral density;	chr11:13603892	chr12:52748776~52750127:+
HNSC	trans	rs74781061	0.932	rs11629946	ENSG00000227288.3	RP5-837I24.1	-11.37	1.36e-26	7.42e-20	-0.67	-0.47	Endometriosis;	chr15:74579550	chr1:81501794~81503468:+
HNSC	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-11.36	1.38e-26	7.51e-20	-0.61	-0.47	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-11.36	1.38e-26	7.51e-20	-0.61	-0.47	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-11.36	1.38e-26	7.51e-20	-0.61	-0.47	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-11.36	1.38e-26	7.51e-20	-0.61	-0.47	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
HNSC	trans	rs867371	0.929	rs7176075	ENSG00000235370.6	DNM1P51	-11.36	1.4e-26	7.64e-20	-0.59	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs8041868	ENSG00000235370.6	DNM1P51	-11.36	1.4e-26	7.64e-20	-0.59	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:84398316~84411701:-
HNSC	trans	rs1816752	0.624	rs4770701	ENSG00000224976.2	PARP4P2	11.36	1.44e-26	7.85e-20	0.52	0.47	Obesity-related traits;	chr13:24508806	chr13:19349137~19407962:+
HNSC	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	11.35	1.51e-26	8.24e-20	0.75	0.47	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	11.35	1.51e-26	8.24e-20	0.75	0.47	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
HNSC	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-11.35	1.52e-26	8.29e-20	-0.61	-0.47	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
HNSC	trans	rs867371	1	rs8041924	ENSG00000235370.6	DNM1P51	-11.35	1.55e-26	8.45e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs2088858	ENSG00000235370.6	DNM1P51	-11.35	1.55e-26	8.45e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs4778982	ENSG00000235370.6	DNM1P51	-11.35	1.55e-26	8.45e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs2867579	ENSG00000235370.6	DNM1P51	-11.35	1.55e-26	8.45e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs881308	ENSG00000235370.6	DNM1P51	-11.35	1.55e-26	8.45e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:84398316~84411701:-
HNSC	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-11.35	1.57e-26	8.56e-20	-0.61	-0.46	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
HNSC	trans	rs7554511	0.825	rs11576681	ENSG00000244144.1	RP11-757F18.3	-11.35	1.59e-26	8.63e-20	-0.64	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201034923	chr3:112185480~112185998:-
HNSC	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	11.34	1.67e-26	9.06e-20	0.75	0.46	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	11.34	1.67e-26	9.06e-20	0.75	0.46	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	11.34	1.67e-26	9.06e-20	0.75	0.46	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
HNSC	trans	rs867371	1	rs1501372	ENSG00000235370.6	DNM1P51	-11.34	1.73e-26	9.38e-20	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:84398316~84411701:-
HNSC	trans	rs1816752	0.603	rs7984094	ENSG00000224976.2	PARP4P2	11.33	1.78e-26	9.67e-20	0.52	0.46	Obesity-related traits;	chr13:24496212	chr13:19349137~19407962:+
HNSC	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	11.33	1.83e-26	9.94e-20	0.58	0.46	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	11.33	1.87e-26	1.01e-19	0.58	0.46	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	11.33	1.88e-26	1.02e-19	0.58	0.46	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
HNSC	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-11.33	1.89e-26	1.03e-19	-0.61	-0.46	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs3783073	ENSG00000224976.2	PARP4P2	11.33	1.92e-26	1.04e-19	0.52	0.46	Obesity-related traits;	chr13:24493222	chr13:19349137~19407962:+
HNSC	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	11.32	2.01e-26	1.09e-19	0.75	0.46	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	11.32	2.01e-26	1.09e-19	0.75	0.46	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
HNSC	trans	rs867371	1	rs1846911	ENSG00000235370.6	DNM1P51	-11.32	2.03e-26	1.1e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:84398316~84411701:-
HNSC	trans	rs1816752	0.624	rs9553312	ENSG00000224976.2	PARP4P2	11.31	2.17e-26	1.17e-19	0.52	0.46	Obesity-related traits;	chr13:24474055	chr13:19349137~19407962:+
HNSC	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	11.31	2.2e-26	1.19e-19	0.58	0.46	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	11.31	2.2e-26	1.19e-19	0.58	0.46	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
HNSC	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	11.31	2.22e-26	1.2e-19	0.74	0.46	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	11.31	2.22e-26	1.2e-19	0.74	0.46	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
HNSC	trans	rs7554547	0.714	rs926269	ENSG00000261819.1	RP11-680G24.4	11.31	2.32e-26	1.26e-19	0.64	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr16:14988259~14990160:-
HNSC	trans	rs7554511	0.858	rs6701496	ENSG00000244144.1	RP11-757F18.3	-11.3	2.37e-26	1.28e-19	-0.64	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201038700	chr3:112185480~112185998:-
HNSC	trans	rs7554547	0.714	rs2878679	ENSG00000261819.1	RP11-680G24.4	11.3	2.37e-26	1.28e-19	0.64	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr16:14988259~14990160:-
HNSC	trans	rs867371	1	rs7166570	ENSG00000235370.6	DNM1P51	-11.3	2.4e-26	1.3e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs8037224	ENSG00000235370.6	DNM1P51	-11.3	2.47e-26	1.33e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:84398316~84411701:-
HNSC	trans	rs9467773	0.869	rs9295689	ENSG00000242375.1	RP11-498P14.3	11.3	2.54e-26	1.37e-19	0.58	0.46	Intelligence (multi-trait analysis);	chr6:26455583	chr9:97195351~97197687:-
HNSC	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	11.29	2.58e-26	1.39e-19	0.74	0.46	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	11.29	2.58e-26	1.39e-19	0.74	0.46	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	11.29	2.58e-26	1.39e-19	0.74	0.46	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	11.29	2.58e-26	1.39e-19	0.74	0.46	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
HNSC	trans	rs1816752	0.624	rs7330766	ENSG00000224976.2	PARP4P2	11.29	2.58e-26	1.39e-19	0.52	0.46	Obesity-related traits;	chr13:24495579	chr13:19349137~19407962:+
HNSC	trans	rs867371	1	rs1392976	ENSG00000235370.6	DNM1P51	11.29	2.69e-26	1.45e-19	0.59	0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:84398316~84411701:-
HNSC	trans	rs7554511	0.858	rs10920084	ENSG00000244144.1	RP11-757F18.3	-11.29	2.73e-26	1.47e-19	-0.58	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993667	chr3:112185480~112185998:-
HNSC	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	11.29	2.76e-26	1.49e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
HNSC	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	11.27	3.07e-26	1.65e-19	0.74	0.46	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
HNSC	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	11.27	3.18e-26	1.71e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-11.27	3.26e-26	1.75e-19	-0.57	-0.46	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
HNSC	trans	rs867371	1	rs1174543	ENSG00000235370.6	DNM1P51	11.27	3.3e-26	1.77e-19	0.59	0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs11855089	ENSG00000235370.6	DNM1P51	-11.27	3.3e-26	1.77e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:84398316~84411701:-
HNSC	trans	rs74781061	0.932	rs74025818	ENSG00000227288.3	RP5-837I24.1	11.26	3.47e-26	1.87e-19	0.66	0.46	Endometriosis;	chr15:74618287	chr1:81501794~81503468:+
HNSC	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	11.26	3.5e-26	1.88e-19	1.03	0.46	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
HNSC	trans	rs867371	0.964	rs7169961	ENSG00000235370.6	DNM1P51	-11.26	3.62e-26	1.94e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs6495643	ENSG00000235370.6	DNM1P51	-11.26	3.62e-26	1.94e-19	-0.59	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:84398316~84411701:-
HNSC	trans	rs12709013	0.635	rs6993	ENSG00000233719.3	GOT2P3	11.25	3.73e-26	2e-19	0.6	0.46	Blood metabolite ratios;	chr16:58707463	chr12:9641802~9643007:+
HNSC	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	11.25	3.73e-26	2e-19	0.74	0.46	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	11.25	3.73e-26	2e-19	0.74	0.46	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
HNSC	trans	rs867371	1	rs9944197	ENSG00000235370.6	DNM1P51	-11.25	3.86e-26	2.07e-19	-0.58	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:84398316~84411701:-
HNSC	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	11.23	4.61e-26	2.47e-19	0.58	0.46	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
HNSC	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	11.23	4.69e-26	2.51e-19	0.74	0.46	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
HNSC	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-11.23	4.7e-26	2.52e-19	-0.44	-0.46	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
HNSC	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	11.22	4.85e-26	2.6e-19	0.58	0.46	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
HNSC	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-11.22	4.9e-26	2.62e-19	-0.61	-0.46	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
HNSC	trans	rs10242455	0.571	rs45593341	ENSG00000228834.1	RP11-249L21.4	11.21	5.24e-26	2.8e-19	1.03	0.46	Blood metabolite levels;	chr7:99707288	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	11.21	5.24e-26	2.8e-19	1.03	0.46	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
HNSC	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	11.21	5.27e-26	2.82e-19	0.8	0.46	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
HNSC	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	11.21	5.34e-26	2.85e-19	0.74	0.46	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
HNSC	trans	rs7554511	0.858	rs11583328	ENSG00000244144.1	RP11-757F18.3	11.2	6.16e-26	3.29e-19	0.63	0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr3:112185480~112185998:-
HNSC	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	11.2	6.18e-26	3.3e-19	0.81	0.46	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
HNSC	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	11.19	6.49e-26	3.46e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
HNSC	trans	rs2665103	0.715	rs11639440	ENSG00000235370.6	DNM1P51	-11.18	6.82e-26	3.63e-19	-0.53	-0.46	Intelligence (multi-trait analysis);	chr15:82278705	chr15:84398316~84411701:-
HNSC	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	11.18	6.83e-26	3.64e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
HNSC	trans	rs867371	1	rs13380319	ENSG00000235370.6	DNM1P51	-11.18	6.84e-26	3.65e-19	-0.58	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:84398316~84411701:-
HNSC	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-11.18	7.17e-26	3.82e-19	-0.6	-0.46	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs7995190	ENSG00000224976.2	PARP4P2	11.18	7.21e-26	3.84e-19	0.51	0.46	Obesity-related traits;	chr13:24475709	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.608	rs7326664	ENSG00000224976.2	PARP4P2	11.18	7.28e-26	3.88e-19	0.51	0.46	Obesity-related traits;	chr13:24475868	chr13:19349137~19407962:+
HNSC	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	11.18	7.32e-26	3.9e-19	0.73	0.46	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
HNSC	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-11.17	7.71e-26	4.1e-19	-0.6	-0.46	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-11.17	7.71e-26	4.1e-19	-0.6	-0.46	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-11.17	7.71e-26	4.1e-19	-0.6	-0.46	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
HNSC	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	11.16	8.37e-26	4.44e-19	0.53	0.46	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
HNSC	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	11.16	8.69e-26	4.61e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
HNSC	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	11.16	8.77e-26	4.65e-19	0.73	0.46	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
HNSC	trans	rs1816752	0.646	rs9511301	ENSG00000224976.2	PARP4P2	11.15	9.29e-26	4.92e-19	0.51	0.46	Obesity-related traits;	chr13:24477034	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs7332220	ENSG00000224976.2	PARP4P2	11.15	9.29e-26	4.92e-19	0.51	0.46	Obesity-related traits;	chr13:24477081	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.624	rs11149109	ENSG00000224976.2	PARP4P2	11.15	9.29e-26	4.92e-19	0.51	0.46	Obesity-related traits;	chr13:24477290	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511302	ENSG00000224976.2	PARP4P2	11.15	9.29e-26	4.92e-19	0.51	0.46	Obesity-related traits;	chr13:24477580	chr13:19349137~19407962:+
HNSC	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	11.15	9.31e-26	4.93e-19	0.73	0.46	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
HNSC	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	11.14	1.04e-25	5.52e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
HNSC	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	11.13	1.09e-25	5.74e-19	0.63	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
HNSC	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	11.13	1.09e-25	5.77e-19	0.73	0.46	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	11.13	1.13e-25	5.96e-19	0.57	0.46	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	11.13	1.13e-25	5.96e-19	0.57	0.46	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
HNSC	trans	rs1816752	0.646	rs9507355	ENSG00000224976.2	PARP4P2	-11.12	1.19e-25	6.27e-19	-0.5	-0.46	Obesity-related traits;	chr13:24476819	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs4770692	ENSG00000224976.2	PARP4P2	11.12	1.2e-25	6.32e-19	0.51	0.46	Obesity-related traits;	chr13:24468689	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs4770694	ENSG00000224976.2	PARP4P2	11.12	1.2e-25	6.32e-19	0.51	0.46	Obesity-related traits;	chr13:24468891	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.624	rs9507354	ENSG00000224976.2	PARP4P2	11.12	1.2e-25	6.32e-19	0.51	0.46	Obesity-related traits;	chr13:24469227	chr13:19349137~19407962:+
HNSC	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-11.12	1.23e-25	6.48e-19	-0.6	-0.46	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
HNSC	trans	rs867371	0.896	rs6495647	ENSG00000235370.6	DNM1P51	-11.12	1.24e-25	6.53e-19	-0.57	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:84398316~84411701:-
HNSC	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	11.11	1.27e-25	6.67e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	11.11	1.3e-25	6.83e-19	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
HNSC	trans	rs1816752	0.583	rs9553311	ENSG00000224976.2	PARP4P2	11.1	1.42e-25	7.44e-19	0.51	0.46	Obesity-related traits;	chr13:24474016	chr13:19349137~19407962:+
HNSC	trans	rs7554511	0.894	rs11579874	ENSG00000244144.1	RP11-757F18.3	11.1	1.43e-25	7.49e-19	0.63	0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200951234	chr3:112185480~112185998:-
HNSC	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	11.1	1.45e-25	7.57e-19	0.57	0.46	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
HNSC	trans	rs8010715	0.771	rs2277481	ENSG00000238000.1	RP11-274E7.2	11.1	1.48e-25	7.75e-19	0.43	0.46	IgG glycosylation;	chr14:24118336	chr5:98213402~98214121:+
HNSC	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-11.09	1.58e-25	8.24e-19	-0.61	-0.46	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
HNSC	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	11.09	1.59e-25	8.31e-19	0.7	0.46	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
HNSC	trans	rs1816752	0.646	rs7319207	ENSG00000224976.2	PARP4P2	11.08	1.69e-25	8.78e-19	0.51	0.46	Obesity-related traits;	chr13:24473220	chr13:19349137~19407962:+
HNSC	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-11.08	1.72e-25	8.94e-19	-0.6	-0.46	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
HNSC	trans	rs9611519	1	rs2273085	ENSG00000268568.1	AC007228.9	-11.07	1.82e-25	9.43e-19	-0.57	-0.46	Neuroticism;	chr22:41219372	chr19:56672574~56673901:-
HNSC	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	11.06	1.99e-25	1.03e-18	0.57	0.46	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
HNSC	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-11.06	2.06e-25	1.06e-18	-0.6	-0.46	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs4770700	ENSG00000224976.2	PARP4P2	11.06	2.1e-25	1.08e-18	0.51	0.46	Obesity-related traits;	chr13:24494796	chr13:19349137~19407962:+
HNSC	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-11.06	2.12e-25	1.1e-18	-0.6	-0.46	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
HNSC	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	11.05	2.16e-25	1.12e-18	0.47	0.46	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
HNSC	trans	rs1816752	0.524	rs7996445	ENSG00000224976.2	PARP4P2	11.05	2.23e-25	1.15e-18	0.5	0.46	Obesity-related traits;	chr13:24475329	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs6490937	ENSG00000224976.2	PARP4P2	11.05	2.25e-25	1.16e-18	0.5	0.46	Obesity-related traits;	chr13:24475834	chr13:19349137~19407962:+
HNSC	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-11.05	2.32e-25	1.2e-18	-0.78	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
HNSC	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-11.04	2.37e-25	1.22e-18	-0.56	-0.46	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
HNSC	trans	rs1816752	0.646	rs7997248	ENSG00000224976.2	PARP4P2	11.04	2.38e-25	1.22e-18	0.51	0.46	Obesity-related traits;	chr13:24507050	chr13:19349137~19407962:+
HNSC	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	11.03	2.72e-25	1.4e-18	0.72	0.45	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
HNSC	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-11.02	2.82e-25	1.45e-18	-0.61	-0.45	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
HNSC	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	11.02	2.85e-25	1.46e-18	0.57	0.45	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	11.02	2.89e-25	1.48e-18	0.46	0.45	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
HNSC	trans	rs7554511	0.861	rs965321	ENSG00000244144.1	RP11-757F18.3	11.01	3.22e-25	1.65e-18	0.61	0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036374	chr3:112185480~112185998:-
HNSC	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	11.01	3.27e-25	1.67e-18	1.05	0.45	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
HNSC	trans	rs1816752	0.646	rs7322323	ENSG00000224976.2	PARP4P2	11.01	3.29e-25	1.68e-18	0.5	0.45	Obesity-related traits;	chr13:24479189	chr13:19349137~19407962:+
HNSC	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	11	3.55e-25	1.81e-18	0.46	0.45	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
HNSC	trans	rs7554511	0.823	rs67602696	ENSG00000244144.1	RP11-757F18.3	-11	3.57e-25	1.82e-18	-0.63	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201043809	chr3:112185480~112185998:-
HNSC	trans	rs74781061	0.86	rs2289187	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74452058	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs7163775	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74452760	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs7166701	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74456674	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs77655065	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74462699	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs12592493	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74466999	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs6495103	ENSG00000227288.3	RP5-837I24.1	11	3.6e-25	1.84e-18	0.68	0.45	Endometriosis;	chr15:74470507	chr1:81501794~81503468:+
HNSC	trans	rs1816752	0.646	rs9634403	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24468211	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9581064	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24468251	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs4769361	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24468834	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs4770693	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24468835	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs4770695	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24468895	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs7337981	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24469245	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs7328391	ENSG00000224976.2	PARP4P2	10.99	3.77e-25	1.92e-18	0.5	0.45	Obesity-related traits;	chr13:24470325	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs4480642	ENSG00000224976.2	PARP4P2	10.99	3.8e-25	1.93e-18	0.5	0.45	Obesity-related traits;	chr13:24471358	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9551108	ENSG00000224976.2	PARP4P2	10.99	3.8e-25	1.93e-18	0.5	0.45	Obesity-related traits;	chr13:24471434	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.603	rs4238178	ENSG00000224976.2	PARP4P2	10.99	3.8e-25	1.93e-18	0.5	0.45	Obesity-related traits;	chr13:24472344	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs2862903	ENSG00000224976.2	PARP4P2	10.99	3.8e-25	1.93e-18	0.5	0.45	Obesity-related traits;	chr13:24473169	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511295	ENSG00000224976.2	PARP4P2	10.99	3.85e-25	1.96e-18	0.5	0.45	Obesity-related traits;	chr13:24467794	chr13:19349137~19407962:+
HNSC	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	10.98	4.05e-25	2.06e-18	0.56	0.45	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	10.98	4.11e-25	2.09e-18	0.56	0.45	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
HNSC	trans	rs116095464	1	rs7723693	ENSG00000185986.11	SDHAP3	10.98	4.21e-25	2.14e-18	0.84	0.45	Breast cancer;	chr5:305917	chr5:1572222~1594620:-
HNSC	trans	rs5022636	0.507	rs2031797	ENSG00000180764.13	PIPSL	10.97	4.38e-25	2.22e-18	0.63	0.45	Gut microbiota (functional units);	chr1:151306029	chr10:93958191~93961540:-
HNSC	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	10.97	4.39e-25	2.23e-18	0.78	0.45	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
HNSC	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-10.97	4.39e-25	2.23e-18	-0.57	-0.45	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
HNSC	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-10.97	4.39e-25	2.23e-18	-0.57	-0.45	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
HNSC	trans	rs867371	0.892	rs4344697	ENSG00000235370.6	DNM1P51	-10.97	4.52e-25	2.29e-18	-0.58	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:84398316~84411701:-
HNSC	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-10.97	4.66e-25	2.36e-18	-0.51	-0.45	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
HNSC	trans	rs5758265	1	rs5758265	ENSG00000268568.1	AC007228.9	-10.97	4.68e-25	2.37e-18	-0.57	-0.45	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr19:56672574~56673901:-
HNSC	trans	rs9611519	1	rs5751069	ENSG00000268568.1	AC007228.9	-10.96	4.81e-25	2.44e-18	-0.58	-0.45	Neuroticism;	chr22:41231771	chr19:56672574~56673901:-
HNSC	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	10.95	5.21e-25	2.63e-18	0.61	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
HNSC	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	10.95	5.21e-25	2.63e-18	0.61	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
HNSC	trans	rs74781061	0.86	rs4077703	ENSG00000227288.3	RP5-837I24.1	10.95	5.28e-25	2.67e-18	0.67	0.45	Endometriosis;	chr15:74469821	chr1:81501794~81503468:+
HNSC	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-10.95	5.38e-25	2.72e-18	-0.62	-0.45	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
HNSC	trans	rs7554547	0.69	rs57044570	ENSG00000261819.1	RP11-680G24.4	10.95	5.5e-25	2.78e-18	0.64	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11899181	chr16:14988259~14990160:-
HNSC	trans	rs12709013	0.792	rs11646756	ENSG00000233719.3	GOT2P3	10.95	5.56e-25	2.81e-18	0.55	0.45	Blood metabolite ratios;	chr16:58773598	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1657165	ENSG00000233719.3	GOT2P3	10.95	5.66e-25	2.86e-18	0.55	0.45	Blood metabolite ratios;	chr16:58747980	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.818	rs1646273	ENSG00000233719.3	GOT2P3	10.95	5.66e-25	2.86e-18	0.55	0.45	Blood metabolite ratios;	chr16:58748318	chr12:9641802~9643007:+
HNSC	trans	rs1816752	0.624	rs2096093	ENSG00000224976.2	PARP4P2	10.94	5.76e-25	2.91e-18	0.5	0.45	Obesity-related traits;	chr13:24472753	chr13:19349137~19407962:+
HNSC	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-10.94	5.81e-25	2.93e-18	-0.58	-0.45	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
HNSC	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	10.94	5.9e-25	2.97e-18	0.61	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
HNSC	trans	rs116095464	1	rs3777237	ENSG00000185986.11	SDHAP3	10.94	5.93e-25	2.99e-18	0.94	0.45	Breast cancer;	chr5:307526	chr5:1572222~1594620:-
HNSC	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	10.94	6.04e-25	3.05e-18	0.7	0.45	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
HNSC	trans	rs12709013	0.792	rs1646270	ENSG00000233719.3	GOT2P3	10.94	6.15e-25	3.1e-18	0.55	0.45	Blood metabolite ratios;	chr16:58745823	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.932	rs7161903	ENSG00000227288.3	RP5-837I24.1	10.93	6.39e-25	3.22e-18	0.64	0.45	Endometriosis;	chr15:74647929	chr1:81501794~81503468:+
HNSC	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	10.93	6.45e-25	3.25e-18	0.56	0.45	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
HNSC	trans	rs12709013	0.792	rs12598527	ENSG00000233719.3	GOT2P3	10.93	6.58e-25	3.32e-18	0.55	0.45	Blood metabolite ratios;	chr16:58772987	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs12600201	ENSG00000233719.3	GOT2P3	10.93	6.58e-25	3.32e-18	0.55	0.45	Blood metabolite ratios;	chr16:58773132	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs12600206	ENSG00000233719.3	GOT2P3	10.93	6.58e-25	3.32e-18	0.55	0.45	Blood metabolite ratios;	chr16:58773169	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs11076263	ENSG00000233719.3	GOT2P3	10.93	6.58e-25	3.32e-18	0.55	0.45	Blood metabolite ratios;	chr16:58773295	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.932	rs4886605	ENSG00000227288.3	RP5-837I24.1	10.93	6.63e-25	3.34e-18	0.62	0.45	Endometriosis;	chr15:74733647	chr1:81501794~81503468:+
HNSC	trans	rs7121616	0.531	rs10892958	ENSG00000229091.2	HSPA8P8	10.92	6.77e-25	3.41e-18	0.57	0.45	Breast cancer;	chr11:123061415	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.531	rs11218941	ENSG00000229091.2	HSPA8P8	10.92	6.77e-25	3.41e-18	0.57	0.45	Breast cancer;	chr11:123061701	chr7:10451311~10452526:+
HNSC	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	10.92	6.89e-25	3.47e-18	0.56	0.45	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
HNSC	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	10.92	7.2e-25	3.62e-18	0.62	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
HNSC	trans	rs1816752	0.646	rs8002599	ENSG00000224976.2	PARP4P2	10.91	7.64e-25	3.83e-18	0.5	0.45	Obesity-related traits;	chr13:24478486	chr13:19349137~19407962:+
HNSC	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	10.91	7.66e-25	3.84e-18	0.56	0.45	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	10.91	7.66e-25	3.84e-18	0.56	0.45	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	10.91	7.66e-25	3.84e-18	0.56	0.45	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
HNSC	trans	rs12709013	0.792	rs1646276	ENSG00000233719.3	GOT2P3	10.91	7.94e-25	3.98e-18	0.55	0.45	Blood metabolite ratios;	chr16:58749654	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1646277	ENSG00000233719.3	GOT2P3	10.91	7.94e-25	3.98e-18	0.55	0.45	Blood metabolite ratios;	chr16:58750037	chr12:9641802~9643007:+
HNSC	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	10.9	8.44e-25	4.23e-18	0.78	0.45	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
HNSC	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	10.9	8.44e-25	4.23e-18	0.78	0.45	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
HNSC	trans	rs12709013	0.792	rs12325510	ENSG00000233719.3	GOT2P3	10.9	8.49e-25	4.25e-18	0.55	0.45	Blood metabolite ratios;	chr16:58749707	chr12:9641802~9643007:+
HNSC	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-10.9	8.52e-25	4.26e-18	-0.59	-0.45	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
HNSC	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	10.9	8.52e-25	4.26e-18	0.56	0.45	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
HNSC	trans	rs8010715	0.848	rs2277483	ENSG00000238000.1	RP11-274E7.2	10.9	8.71e-25	4.35e-18	0.45	0.45	IgG glycosylation;	chr14:24122683	chr5:98213402~98214121:+
HNSC	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	10.9	8.76e-25	4.38e-18	0.62	0.45	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
HNSC	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-10.89	8.8e-25	4.4e-18	-0.6	-0.45	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
HNSC	trans	rs6708331	1	rs10195155	ENSG00000232654.1	FAM136BP	10.89	8.81e-25	4.4e-18	0.58	0.45	Obesity-related traits;	chr2:70127343	chr6:3045384~3045800:+
HNSC	trans	rs867371	1	rs8042464	ENSG00000235370.6	DNM1P51	-10.89	8.94e-25	4.47e-18	-0.57	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:84398316~84411701:-
HNSC	trans	rs1816752	0.583	rs9511284	ENSG00000224976.2	PARP4P2	10.89	9.29e-25	4.64e-18	0.5	0.45	Obesity-related traits;	chr13:24463660	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.716	rs1441058	ENSG00000224976.2	PARP4P2	10.89	9.49e-25	4.74e-18	0.5	0.45	Obesity-related traits;	chr13:24516275	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs7322329	ENSG00000224976.2	PARP4P2	10.88	9.67e-25	4.83e-18	0.5	0.45	Obesity-related traits;	chr13:24479193	chr13:19349137~19407962:+
HNSC	trans	rs8010715	0.848	rs8009511	ENSG00000238000.1	RP11-274E7.2	10.88	9.91e-25	4.94e-18	0.45	0.45	IgG glycosylation;	chr14:24124771	chr5:98213402~98214121:+
HNSC	trans	rs8010715	0.804	rs1134334	ENSG00000238000.1	RP11-274E7.2	10.88	9.91e-25	4.94e-18	0.45	0.45	IgG glycosylation;	chr14:24124905	chr5:98213402~98214121:+
HNSC	trans	rs1816752	0.716	rs9553330	ENSG00000224976.2	PARP4P2	10.87	1.11e-24	5.5e-18	0.49	0.45	Obesity-related traits;	chr13:24516018	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.608	rs9511290	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467189	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511291	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467609	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511292	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467623	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511293	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467747	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511294	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467773	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511296	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24467962	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9634401	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24468072	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.624	rs9634402	ENSG00000224976.2	PARP4P2	10.86	1.18e-24	5.88e-18	0.5	0.45	Obesity-related traits;	chr13:24468119	chr13:19349137~19407962:+
HNSC	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	10.86	1.19e-24	5.93e-18	0.71	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
HNSC	trans	rs5022636	0.533	rs4971029	ENSG00000180764.13	PIPSL	10.86	1.2e-24	5.94e-18	0.62	0.45	Gut microbiota (functional units);	chr1:151304783	chr10:93958191~93961540:-
HNSC	trans	rs7032940	0.626	rs4314718	ENSG00000228236.2	TXNP5	10.86	1.21e-24	6e-18	0.5	0.45	Height;	chr9:110211368	chr2:149068596~149068910:-
HNSC	trans	rs12709013	0.792	rs12325054	ENSG00000233719.3	GOT2P3	10.86	1.22e-24	6.04e-18	0.55	0.45	Blood metabolite ratios;	chr16:58749804	chr12:9641802~9643007:+
HNSC	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-10.86	1.23e-24	6.09e-18	-0.94	-0.45	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
HNSC	trans	rs12709013	0.66	rs30839	ENSG00000233719.3	GOT2P3	10.85	1.25e-24	6.22e-18	0.56	0.45	Blood metabolite ratios;	chr16:58711437	chr12:9641802~9643007:+
HNSC	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	10.84	1.38e-24	6.84e-18	0.56	0.45	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	10.84	1.4e-24	6.96e-18	0.56	0.45	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
HNSC	trans	rs74781061	0.789	rs1078011	ENSG00000227288.3	RP5-837I24.1	10.84	1.44e-24	7.14e-18	0.65	0.45	Endometriosis;	chr15:74442521	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs11854461	ENSG00000227288.3	RP5-837I24.1	10.84	1.45e-24	7.2e-18	0.64	0.45	Endometriosis;	chr15:74447400	chr1:81501794~81503468:+
HNSC	trans	rs7554511	0.861	rs10753888	ENSG00000244144.1	RP11-757F18.3	-10.83	1.49e-24	7.36e-18	-0.6	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201037057	chr3:112185480~112185998:-
HNSC	trans	rs867371	1	rs7181655	ENSG00000235370.6	DNM1P51	-10.83	1.5e-24	7.42e-18	-0.58	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:84398316~84411701:-
HNSC	trans	rs867371	1	rs7180584	ENSG00000235370.6	DNM1P51	-10.83	1.5e-24	7.42e-18	-0.58	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:84398316~84411701:-
HNSC	trans	rs74781061	0.86	rs6495101	ENSG00000227288.3	RP5-837I24.1	10.83	1.57e-24	7.75e-18	0.65	0.45	Endometriosis;	chr15:74450411	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.792	rs12926512	ENSG00000233719.3	GOT2P3	10.83	1.57e-24	7.78e-18	0.55	0.45	Blood metabolite ratios;	chr16:58768317	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs12595974	ENSG00000233719.3	GOT2P3	10.83	1.57e-24	7.78e-18	0.55	0.45	Blood metabolite ratios;	chr16:58769132	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1836877	ENSG00000233719.3	GOT2P3	10.83	1.57e-24	7.78e-18	0.55	0.45	Blood metabolite ratios;	chr16:58769821	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs62066815	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58751577	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.766	rs1657175	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58755527	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1646290	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58755807	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1364346	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58756420	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs257626	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58759574	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs257625	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58759978	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs1646262	ENSG00000233719.3	GOT2P3	10.83	1.6e-24	7.89e-18	0.55	0.45	Blood metabolite ratios;	chr16:58760593	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	10.83	1.6e-24	7.91e-18	0.65	0.45	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.792	rs257623	ENSG00000233719.3	GOT2P3	10.82	1.62e-24	8e-18	0.55	0.45	Blood metabolite ratios;	chr16:58761247	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.693	rs1627257	ENSG00000233719.3	GOT2P3	10.82	1.62e-24	8e-18	0.55	0.45	Blood metabolite ratios;	chr16:58763764	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs12935488	ENSG00000233719.3	GOT2P3	10.82	1.62e-24	8e-18	0.55	0.45	Blood metabolite ratios;	chr16:58766320	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	10.82	1.62e-24	8.01e-18	0.64	0.45	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
HNSC	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	10.82	1.67e-24	8.23e-18	0.75	0.45	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
HNSC	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	10.82	1.67e-24	8.23e-18	0.75	0.45	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
HNSC	trans	rs7258465	1	rs10413237	ENSG00000267533.1	RP11-815J4.7	10.82	1.7e-24	8.35e-18	0.56	0.45	Breast cancer;	chr19:18437439	chr18:12067173~12068417:-
HNSC	trans	rs12709013	0.792	rs1615326	ENSG00000233719.3	GOT2P3	10.82	1.7e-24	8.36e-18	0.55	0.45	Blood metabolite ratios;	chr16:58747148	chr12:9641802~9643007:+
HNSC	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	10.82	1.73e-24	8.53e-18	0.7	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
HNSC	trans	rs4925166	1	rs4925166	ENSG00000263946.1	RP11-434D2.11	10.81	1.79e-24	8.79e-18	0.52	0.45	Multiple sclerosis;	chr17:18307496	chr17:20554971~20559410:-
HNSC	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-10.81	1.81e-24	8.92e-18	-0.59	-0.45	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
HNSC	trans	rs9611519	1	rs5758264	ENSG00000268568.1	AC007228.9	-10.81	1.81e-24	8.92e-18	-0.56	-0.45	Neuroticism;	chr22:41220280	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-10.81	1.88e-24	9.25e-18	-0.59	-0.45	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
HNSC	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-10.81	1.9e-24	9.35e-18	-0.66	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
HNSC	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-10.8	1.94e-24	9.5e-18	-0.66	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
HNSC	trans	rs74781061	0.86	rs4887147	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74443863	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs4887151	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74445126	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.789	rs2289188	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74450127	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.789	rs12440654	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74453008	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs7169985	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74453437	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs8037211	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74455061	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.789	rs11852291	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74457624	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs4887152	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74464013	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs4544202	ENSG00000227288.3	RP5-837I24.1	10.8	1.99e-24	9.76e-18	0.65	0.45	Endometriosis;	chr15:74468654	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	10.8	2.05e-24	1.01e-17	0.64	0.45	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
HNSC	trans	rs12138950	0.681	rs10917472	ENSG00000224237.1	MINOS1P3	10.79	2.1e-24	1.03e-17	0.62	0.45	Hypothyroidism;Thyroid volume;	chr1:19524218	chr3:27214816~27215018:-
HNSC	trans	rs7032940	0.626	rs4314718	ENSG00000262519.1	TXNP4	10.79	2.13e-24	1.04e-17	0.56	0.45	Height;	chr9:110211368	chr17:4572206~4572515:+
HNSC	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-10.79	2.14e-24	1.04e-17	-0.57	-0.45	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
HNSC	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	10.79	2.16e-24	1.06e-17	0.58	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
HNSC	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-10.79	2.19e-24	1.07e-17	-0.69	-0.45	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
HNSC	trans	rs867371	1	rs6495642	ENSG00000235370.6	DNM1P51	-10.79	2.22e-24	1.08e-17	-0.58	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:84398316~84411701:-
HNSC	trans	rs74781061	0.86	rs8033841	ENSG00000227288.3	RP5-837I24.1	10.78	2.29e-24	1.12e-17	0.65	0.45	Endometriosis;	chr15:74471540	chr1:81501794~81503468:+
HNSC	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-10.78	2.35e-24	1.15e-17	-0.55	-0.45	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
HNSC	trans	rs8010715	0.52	rs12435994	ENSG00000238000.1	RP11-274E7.2	10.78	2.39e-24	1.17e-17	0.44	0.45	IgG glycosylation;	chr14:24120252	chr5:98213402~98214121:+
HNSC	trans	rs8010715	0.596	rs12435995	ENSG00000238000.1	RP11-274E7.2	10.78	2.39e-24	1.17e-17	0.44	0.45	IgG glycosylation;	chr14:24120255	chr5:98213402~98214121:+
HNSC	trans	rs867371	0.929	rs1045508	ENSG00000235370.6	DNM1P51	10.78	2.45e-24	1.19e-17	0.54	0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:84398316~84411701:-
HNSC	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-10.78	2.5e-24	1.22e-17	-0.59	-0.45	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
HNSC	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	10.77	2.59e-24	1.26e-17	0.71	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
HNSC	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-10.77	2.69e-24	1.31e-17	-0.59	-0.45	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
HNSC	trans	rs1816752	0.646	rs2862902	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24461965	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs734715	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462041	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs730030	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462509	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs7992667	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462821	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs7995958	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462895	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs8002741	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462918	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs7998198	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462979	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.609	rs7998203	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24462989	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs7998600	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24463222	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.624	rs9511282	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24463597	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.583	rs9511283	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24463656	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9507351	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24465118	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs4770688	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466007	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs4770689	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466008	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs12431171	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466380	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs12854523	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466460	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9578740	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466692	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.631	rs4769358	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466940	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.608	rs4769359	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24466966	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.608	rs4769360	ENSG00000224976.2	PARP4P2	10.76	2.87e-24	1.39e-17	0.49	0.45	Obesity-related traits;	chr13:24467016	chr13:19349137~19407962:+
HNSC	trans	rs74781061	0.86	rs4887150	ENSG00000227288.3	RP5-837I24.1	10.76	2.88e-24	1.39e-17	0.65	0.45	Endometriosis;	chr15:74444683	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.755	rs1628029	ENSG00000233719.3	GOT2P3	10.75	3.09e-24	1.49e-17	0.55	0.45	Blood metabolite ratios;	chr16:58763846	chr12:9641802~9643007:+
HNSC	trans	rs1816752	0.646	rs750390	ENSG00000224976.2	PARP4P2	10.75	3.1e-24	1.5e-17	0.5	0.45	Obesity-related traits;	chr13:24461603	chr13:19349137~19407962:+
HNSC	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-10.75	3.2e-24	1.55e-17	-0.59	-0.45	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
HNSC	trans	rs7554511	0.825	rs12122809	ENSG00000244144.1	RP11-757F18.3	-10.75	3.21e-24	1.55e-17	-0.62	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201045838	chr3:112185480~112185998:-
HNSC	trans	rs12709013	0.792	rs1646289	ENSG00000233719.3	GOT2P3	10.75	3.22e-24	1.56e-17	0.54	0.45	Blood metabolite ratios;	chr16:58755689	chr12:9641802~9643007:+
HNSC	trans	rs1816752	0.646	rs2902359	ENSG00000224976.2	PARP4P2	10.75	3.23e-24	1.56e-17	0.5	0.45	Obesity-related traits;	chr13:24461783	chr13:19349137~19407962:+
HNSC	trans	rs1039766	0.778	rs13399786	ENSG00000224334.1	AP000357.4	-10.74	3.25e-24	1.57e-17	-0.78	-0.45	Lung adenocarcinoma;Lung cancer;	chr2:65283571	chr22:24686923~24688087:+
HNSC	trans	rs1816752	0.646	rs750389	ENSG00000224976.2	PARP4P2	10.74	3.47e-24	1.67e-17	0.49	0.44	Obesity-related traits;	chr13:24461677	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs750388	ENSG00000224976.2	PARP4P2	10.74	3.52e-24	1.7e-17	0.49	0.44	Obesity-related traits;	chr13:24461690	chr13:19349137~19407962:+
HNSC	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-10.73	3.8e-24	1.83e-17	-0.59	-0.44	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-10.72	3.99e-24	1.92e-17	-0.46	-0.44	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
HNSC	trans	rs74781061	0.932	rs7497342	ENSG00000227288.3	RP5-837I24.1	10.72	4.09e-24	1.97e-17	0.64	0.44	Endometriosis;	chr15:74655722	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs11072497	ENSG00000227288.3	RP5-837I24.1	10.72	4.09e-24	1.97e-17	0.64	0.44	Endometriosis;	chr15:74659016	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs11072498	ENSG00000227288.3	RP5-837I24.1	10.72	4.09e-24	1.97e-17	0.64	0.44	Endometriosis;	chr15:74661846	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.932	rs2415245	ENSG00000227288.3	RP5-837I24.1	10.72	4.09e-24	1.97e-17	0.64	0.44	Endometriosis;	chr15:74678091	chr1:81501794~81503468:+
HNSC	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	10.71	4.34e-24	2.08e-17	0.6	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
HNSC	trans	rs8010715	0.848	rs927494	ENSG00000238000.1	RP11-274E7.2	10.71	4.36e-24	2.1e-17	0.44	0.44	IgG glycosylation;	chr14:24131181	chr5:98213402~98214121:+
HNSC	trans	rs74781061	0.932	rs11857328	ENSG00000227288.3	RP5-837I24.1	10.7	4.65e-24	2.23e-17	0.65	0.44	Endometriosis;	chr15:74510550	chr1:81501794~81503468:+
HNSC	trans	rs1816752	0.716	rs7995304	ENSG00000224976.2	PARP4P2	10.7	4.81e-24	2.31e-17	0.49	0.44	Obesity-related traits;	chr13:24514284	chr13:19349137~19407962:+
HNSC	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	10.7	4.84e-24	2.32e-17	0.74	0.44	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
HNSC	trans	rs12138950	0.681	rs28630511	ENSG00000224237.1	MINOS1P3	10.69	5.11e-24	2.45e-17	0.61	0.44	Hypothyroidism;Thyroid volume;	chr1:19516538	chr3:27214816~27215018:-
HNSC	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-10.69	5.23e-24	2.51e-17	-0.56	-0.44	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
HNSC	trans	rs74781061	0.929	rs8029116	ENSG00000227288.3	RP5-837I24.1	10.69	5.23e-24	2.51e-17	0.66	0.44	Endometriosis;	chr15:74530753	chr1:81501794~81503468:+
HNSC	trans	rs12138950	0.681	rs4362008	ENSG00000224237.1	MINOS1P3	10.68	5.69e-24	2.72e-17	0.62	0.44	Hypothyroidism;Thyroid volume;	chr1:19511064	chr3:27214816~27215018:-
HNSC	trans	rs12138950	0.711	rs10799821	ENSG00000224237.1	MINOS1P3	10.68	5.69e-24	2.72e-17	0.62	0.44	Hypothyroidism;Thyroid volume;	chr1:19511475	chr3:27214816~27215018:-
HNSC	trans	rs74781061	0.929	rs59946128	ENSG00000227288.3	RP5-837I24.1	10.68	5.9e-24	2.82e-17	0.66	0.44	Endometriosis;	chr15:74493006	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs60777494	ENSG00000227288.3	RP5-837I24.1	10.68	5.9e-24	2.82e-17	0.66	0.44	Endometriosis;	chr15:74493007	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs57271230	ENSG00000227288.3	RP5-837I24.1	10.68	5.9e-24	2.82e-17	0.66	0.44	Endometriosis;	chr15:74493018	chr1:81501794~81503468:+
HNSC	trans	rs12138950	0.681	rs9783019	ENSG00000224237.1	MINOS1P3	10.67	6.37e-24	3.04e-17	0.61	0.44	Hypothyroidism;Thyroid volume;	chr1:19523162	chr3:27214816~27215018:-
HNSC	trans	rs12138950	0.681	rs10799822	ENSG00000224237.1	MINOS1P3	10.67	6.45e-24	3.08e-17	0.61	0.44	Hypothyroidism;Thyroid volume;	chr1:19513327	chr3:27214816~27215018:-
HNSC	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	10.66	6.55e-24	3.13e-17	0.55	0.44	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
HNSC	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	10.66	6.74e-24	3.21e-17	0.55	0.44	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
HNSC	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	10.66	6.89e-24	3.29e-17	0.61	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
HNSC	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	10.65	7.58e-24	3.61e-17	0.7	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
HNSC	trans	rs1816752	0.669	rs2862906	ENSG00000224976.2	PARP4P2	10.65	7.58e-24	3.61e-17	0.49	0.44	Obesity-related traits;	chr13:24494482	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511279	ENSG00000224976.2	PARP4P2	10.64	7.79e-24	3.7e-17	0.49	0.44	Obesity-related traits;	chr13:24463348	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511280	ENSG00000224976.2	PARP4P2	10.64	7.79e-24	3.7e-17	0.49	0.44	Obesity-related traits;	chr13:24463364	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.646	rs9511281	ENSG00000224976.2	PARP4P2	10.64	7.79e-24	3.7e-17	0.49	0.44	Obesity-related traits;	chr13:24463441	chr13:19349137~19407962:+
HNSC	trans	rs12709013	0.716	rs6416775	ENSG00000233719.3	GOT2P3	10.64	8.08e-24	3.84e-17	0.53	0.44	Blood metabolite ratios;	chr16:58830410	chr12:9641802~9643007:+
HNSC	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	10.64	8.28e-24	3.92e-17	0.55	0.44	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
HNSC	trans	rs7121616	0.96	rs12361252	ENSG00000234176.1	HSPA8P1	10.64	8.3e-24	3.93e-17	0.6	0.44	Breast cancer;	chr11:123091564	chrX:121203182~121205014:-
HNSC	trans	rs1816752	0.646	rs2862905	ENSG00000224976.2	PARP4P2	10.64	8.32e-24	3.94e-17	0.49	0.44	Obesity-related traits;	chr13:24485142	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.716	rs1539096	ENSG00000224976.2	PARP4P2	10.63	8.43e-24	3.99e-17	0.49	0.44	Obesity-related traits;	chr13:24501721	chr13:19349137~19407962:+
HNSC	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-10.63	8.43e-24	4e-17	-0.55	-0.44	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
HNSC	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-10.63	8.43e-24	4e-17	-0.55	-0.44	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
HNSC	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	10.63	8.49e-24	4.02e-17	0.71	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
HNSC	trans	rs1816752	0.692	rs2282409	ENSG00000224976.2	PARP4P2	10.63	8.6e-24	4.07e-17	0.49	0.44	Obesity-related traits;	chr13:24512388	chr13:19349137~19407962:+
HNSC	trans	rs12138950	0.681	rs60066365	ENSG00000224237.1	MINOS1P3	10.63	8.99e-24	4.26e-17	0.62	0.44	Hypothyroidism;Thyroid volume;	chr1:19512191	chr3:27214816~27215018:-
HNSC	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	10.62	9.24e-24	4.37e-17	0.55	0.44	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	10.62	9.75e-24	4.61e-17	0.55	0.44	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	10.62	9.75e-24	4.61e-17	0.55	0.44	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs11673604	ENSG00000267533.1	RP11-815J4.7	10.62	9.98e-24	4.72e-17	0.55	0.44	Breast cancer;	chr19:18430178	chr18:12067173~12068417:-
HNSC	trans	rs1816752	0.646	rs9511309	ENSG00000224976.2	PARP4P2	10.61	1.03e-23	4.87e-17	0.49	0.44	Obesity-related traits;	chr13:24515435	chr13:19349137~19407962:+
HNSC	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	10.61	1.03e-23	4.88e-17	0.55	0.44	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
HNSC	trans	rs74781061	0.86	rs4887149	ENSG00000227288.3	RP5-837I24.1	10.61	1.05e-23	4.94e-17	0.65	0.44	Endometriosis;	chr15:74444108	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.86	rs1866113	ENSG00000227288.3	RP5-837I24.1	10.61	1.05e-23	4.94e-17	0.64	0.44	Endometriosis;	chr15:74437262	chr1:81501794~81503468:+
HNSC	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	10.61	1.09e-23	5.14e-17	0.55	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
HNSC	trans	rs12138950	0.625	rs12041608	ENSG00000224237.1	MINOS1P3	-10.6	1.16e-23	5.46e-17	-0.6	-0.44	Hypothyroidism;Thyroid volume;	chr1:19515431	chr3:27214816~27215018:-
HNSC	trans	rs1816752	0.608	rs4770690	ENSG00000224976.2	PARP4P2	10.59	1.25e-23	5.87e-17	0.48	0.44	Obesity-related traits;	chr13:24467049	chr13:19349137~19407962:+
HNSC	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-10.59	1.25e-23	5.87e-17	-0.63	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
HNSC	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-10.59	1.27e-23	5.98e-17	-0.56	-0.44	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
HNSC	trans	rs74781061	0.929	rs8043032	ENSG00000227288.3	RP5-837I24.1	10.59	1.27e-23	5.99e-17	0.66	0.44	Endometriosis;	chr15:74543975	chr1:81501794~81503468:+
HNSC	trans	rs5022636	0.533	rs1752387	ENSG00000180764.13	PIPSL	-10.59	1.28e-23	6.04e-17	-0.6	-0.44	Gut microbiota (functional units);	chr1:151341903	chr10:93958191~93961540:-
HNSC	trans	rs74781061	0.858	rs4278699	ENSG00000227288.3	RP5-837I24.1	10.59	1.28e-23	6.04e-17	0.66	0.44	Endometriosis;	chr15:74500057	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8038730	ENSG00000227288.3	RP5-837I24.1	10.59	1.28e-23	6.04e-17	0.66	0.44	Endometriosis;	chr15:74501003	chr1:81501794~81503468:+
HNSC	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	10.59	1.3e-23	6.1e-17	0.55	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
HNSC	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-10.58	1.31e-23	6.16e-17	-0.54	-0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
HNSC	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	10.58	1.38e-23	6.48e-17	0.55	0.44	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
HNSC	trans	rs7554511	0.666	rs2221581	ENSG00000244144.1	RP11-757F18.3	-10.58	1.38e-23	6.5e-17	-0.56	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201012797	chr3:112185480~112185998:-
HNSC	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	10.58	1.39e-23	6.51e-17	0.61	0.44	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
HNSC	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	10.58	1.39e-23	6.53e-17	1.09	0.44	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	10.58	1.39e-23	6.53e-17	1.09	0.44	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.571	rs80045298	ENSG00000228834.1	RP11-249L21.4	10.58	1.39e-23	6.53e-17	1.09	0.44	Blood metabolite levels;	chr7:99709830	chr6:108907615~108907873:-
HNSC	trans	rs10242455	0.571	rs41279866	ENSG00000228834.1	RP11-249L21.4	10.58	1.39e-23	6.53e-17	1.09	0.44	Blood metabolite levels;	chr7:99717653	chr6:108907615~108907873:-
HNSC	trans	rs74781061	0.929	rs7178219	ENSG00000227288.3	RP5-837I24.1	10.56	1.54e-23	7.24e-17	0.66	0.44	Endometriosis;	chr15:74502552	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs12442097	ENSG00000227288.3	RP5-837I24.1	10.56	1.54e-23	7.24e-17	0.66	0.44	Endometriosis;	chr15:74554792	chr1:81501794~81503468:+
HNSC	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	10.56	1.57e-23	7.37e-17	0.95	0.44	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
HNSC	trans	rs1816752	0.716	rs9553331	ENSG00000224976.2	PARP4P2	10.56	1.6e-23	7.49e-17	0.49	0.44	Obesity-related traits;	chr13:24516030	chr13:19349137~19407962:+
HNSC	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	10.55	1.69e-23	7.9e-17	0.64	0.44	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8037436	ENSG00000227288.3	RP5-837I24.1	10.55	1.72e-23	8.05e-17	0.66	0.44	Endometriosis;	chr15:74506167	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs4887155	ENSG00000227288.3	RP5-837I24.1	10.55	1.72e-23	8.05e-17	0.66	0.44	Endometriosis;	chr15:74512119	chr1:81501794~81503468:+
HNSC	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	10.55	1.77e-23	8.26e-17	0.61	0.44	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.692	rs6490944	ENSG00000224976.2	PARP4P2	10.54	1.85e-23	8.65e-17	0.49	0.44	Obesity-related traits;	chr13:24513866	chr13:19349137~19407962:+
HNSC	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	10.54	1.86e-23	8.67e-17	0.54	0.44	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
HNSC	trans	rs7554511	0.893	rs12122721	ENSG00000244144.1	RP11-757F18.3	10.53	2.01e-23	9.4e-17	0.59	0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201015352	chr3:112185480~112185998:-
HNSC	trans	rs74781061	0.929	rs11072490	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74515169	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs1821847	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74516873	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs7173006	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74517792	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs78796673	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74520186	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs4261483	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74520993	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8041030	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74525726	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8028163	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74530360	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs11072492	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74531782	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8041807	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74534590	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8027066	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74535682	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs12594447	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74536392	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs1821848	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74541443	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs2415242	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74546765	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs7177407	ENSG00000227288.3	RP5-837I24.1	10.53	2.04e-23	9.49e-17	0.66	0.44	Endometriosis;	chr15:74551444	chr1:81501794~81503468:+
HNSC	trans	rs7554547	0.667	rs4304595	ENSG00000261819.1	RP11-680G24.4	10.53	2.09e-23	9.73e-17	0.61	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11886332	chr16:14988259~14990160:-
HNSC	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	10.53	2.1e-23	9.79e-17	0.54	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
HNSC	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	10.53	2.1e-23	9.79e-17	0.54	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
HNSC	trans	rs74781061	1	rs11072488	ENSG00000227288.3	RP5-837I24.1	10.53	2.14e-23	9.96e-17	0.64	0.44	Endometriosis;	chr15:74494017	chr1:81501794~81503468:+
HNSC	trans	rs7554511	0.624	rs5010839	ENSG00000244144.1	RP11-757F18.3	-10.53	2.17e-23	1.01e-16	-0.61	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042916	chr3:112185480~112185998:-
HNSC	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	10.52	2.18e-23	1.01e-16	0.54	0.44	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-10.52	2.22e-23	1.03e-16	-0.54	-0.44	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
HNSC	trans	rs867371	0.929	rs7173852	ENSG00000235370.6	DNM1P51	-10.52	2.25e-23	1.05e-16	-0.53	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:84398316~84411701:-
HNSC	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	10.52	2.28e-23	1.06e-16	0.61	0.44	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
HNSC	trans	rs6732160	0.741	rs10203600	ENSG00000236165.1	PRADC1P1	10.52	2.34e-23	1.09e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73134270	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.845	rs9989755	ENSG00000236165.1	PRADC1P1	10.52	2.34e-23	1.09e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73134820	chr3:36976316~36976840:+
HNSC	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	10.52	2.35e-23	1.09e-16	0.54	0.44	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	10.52	2.35e-23	1.09e-16	0.54	0.44	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	10.52	2.35e-23	1.09e-16	0.55	0.44	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
HNSC	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-10.52	2.36e-23	1.1e-16	-0.73	-0.44	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
HNSC	trans	rs6732160	0.809	rs4299358	ENSG00000236165.1	PRADC1P1	10.51	2.41e-23	1.12e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73132213	chr3:36976316~36976840:+
HNSC	trans	rs1816752	0.669	rs9553309	ENSG00000224976.2	PARP4P2	10.51	2.46e-23	1.14e-16	0.49	0.44	Obesity-related traits;	chr13:24471476	chr13:19349137~19407962:+
HNSC	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	10.5	2.6e-23	1.2e-16	0.54	0.44	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
HNSC	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	10.5	2.61e-23	1.21e-16	0.6	0.44	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-10.5	2.65e-23	1.23e-16	-0.65	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
HNSC	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	10.5	2.65e-23	1.23e-16	0.54	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
HNSC	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	10.5	2.69e-23	1.25e-16	0.52	0.44	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
HNSC	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	10.49	2.9e-23	1.34e-16	0.54	0.44	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	10.49	2.9e-23	1.34e-16	0.54	0.44	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
HNSC	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	10.49	2.92e-23	1.35e-16	0.6	0.44	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
HNSC	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	10.49	2.92e-23	1.35e-16	0.6	0.44	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
HNSC	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-10.49	3.01e-23	1.39e-16	-0.58	-0.44	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-10.49	3.01e-23	1.39e-16	-0.58	-0.44	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
HNSC	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	10.48	3.11e-23	1.44e-16	0.6	0.44	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
HNSC	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	10.48	3.18e-23	1.47e-16	0.54	0.44	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
HNSC	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	10.48	3.22e-23	1.48e-16	0.61	0.44	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
HNSC	trans	rs5022636	0.507	rs4971035	ENSG00000180764.13	PIPSL	10.47	3.45e-23	1.59e-16	0.61	0.44	Gut microbiota (functional units);	chr1:151351582	chr10:93958191~93961540:-
HNSC	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	10.47	3.55e-23	1.63e-16	0.56	0.44	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
HNSC	trans	rs74781061	0.79	rs6495105	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74480512	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs12592906	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74481811	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs4886599	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74484442	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs11855521	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74488038	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs55662551	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74488745	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs79923136	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74492219	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	10.47	3.57e-23	1.64e-16	0.65	0.44	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
HNSC	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	10.47	3.58e-23	1.65e-16	0.54	0.44	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
HNSC	trans	rs12709013	0.636	rs30835	ENSG00000233719.3	GOT2P3	10.46	3.79e-23	1.74e-16	0.54	0.44	Blood metabolite ratios;	chr16:58714117	chr12:9641802~9643007:+
HNSC	trans	rs6732160	0.706	rs1430347	ENSG00000236165.1	PRADC1P1	10.46	3.81e-23	1.75e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73139931	chr3:36976316~36976840:+
HNSC	trans	rs74781061	0.929	rs4324083	ENSG00000227288.3	RP5-837I24.1	10.46	3.83e-23	1.76e-16	0.64	0.44	Endometriosis;	chr15:74479139	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs117379081	ENSG00000227288.3	RP5-837I24.1	10.46	3.83e-23	1.76e-16	0.64	0.44	Endometriosis;	chr15:74480106	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs79600239	ENSG00000227288.3	RP5-837I24.1	10.46	3.83e-23	1.76e-16	0.64	0.44	Endometriosis;	chr15:74481987	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs16969247	ENSG00000227288.3	RP5-837I24.1	10.46	3.83e-23	1.76e-16	0.64	0.44	Endometriosis;	chr15:74486541	chr1:81501794~81503468:+
HNSC	trans	rs6732160	0.845	rs2901420	ENSG00000236165.1	PRADC1P1	10.46	3.91e-23	1.79e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73138873	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.706	rs1430348	ENSG00000236165.1	PRADC1P1	10.46	3.91e-23	1.79e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73139930	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.774	rs7606271	ENSG00000236165.1	PRADC1P1	10.46	3.91e-23	1.79e-16	0.55	0.44	Intelligence (multi-trait analysis);	chr2:73140570	chr3:36976316~36976840:+
HNSC	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	10.46	3.94e-23	1.81e-16	0.53	0.44	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
HNSC	trans	rs7554511	0.691	rs10920091	ENSG00000244144.1	RP11-757F18.3	-10.45	3.96e-23	1.81e-16	-0.56	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005936	chr3:112185480~112185998:-
HNSC	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	10.45	4.05e-23	1.85e-16	0.54	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
HNSC	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	10.45	4.05e-23	1.85e-16	0.54	0.44	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
HNSC	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	10.44	4.61e-23	2.11e-16	0.54	0.43	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
HNSC	trans	rs74781061	0.929	rs4887153	ENSG00000227288.3	RP5-837I24.1	10.44	4.63e-23	2.11e-16	0.65	0.43	Endometriosis;	chr15:74484701	chr1:81501794~81503468:+
HNSC	trans	rs12138950	0.596	rs10917471	ENSG00000224237.1	MINOS1P3	10.43	4.84e-23	2.21e-16	0.6	0.43	Hypothyroidism;Thyroid volume;	chr1:19521118	chr3:27214816~27215018:-
HNSC	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	10.43	4.9e-23	2.24e-16	0.68	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
HNSC	trans	rs10037055	1	rs10037055	ENSG00000217325.2	PRELID1P1	-10.43	4.97e-23	2.27e-16	-0.58	-0.43	Migraine without aura;	chr5:177264278	chr6:126643488~126644390:+
HNSC	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	10.43	4.97e-23	2.27e-16	0.6	0.43	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-10.43	5.07e-23	2.31e-16	-0.65	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
HNSC	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	10.42	5.28e-23	2.41e-16	0.54	0.43	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	10.42	5.4e-23	2.46e-16	0.54	0.43	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	10.42	5.44e-23	2.48e-16	0.54	0.43	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
HNSC	trans	rs11023332	0.832	rs10832289	ENSG00000236360.2	RP11-334A14.2	-10.41	5.59e-23	2.55e-16	-0.58	-0.43	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr1:52993201~52993702:-
HNSC	trans	rs9899728	0.614	rs12949451	ENSG00000234925.2	ATP5HP4	-10.41	5.6e-23	2.55e-16	-0.89	-0.43	Alzheimer's disease or small vessel stroke;	chr17:75036224	chr12:68642519~68642993:-
HNSC	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	10.41	5.68e-23	2.58e-16	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
HNSC	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	10.41	6.05e-23	2.75e-16	0.6	0.43	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
HNSC	trans	rs10917477	0.653	rs1770480	ENSG00000224237.1	MINOS1P3	10.4	6.21e-23	2.82e-16	0.52	0.43	Thyroid function;	chr1:19590290	chr3:27214816~27215018:-
HNSC	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	10.4	6.24e-23	2.83e-16	0.54	0.43	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
HNSC	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	10.4	6.28e-23	2.85e-16	0.67	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
HNSC	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	10.4	6.3e-23	2.86e-16	0.54	0.43	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
HNSC	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-10.4	6.39e-23	2.9e-16	-0.62	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
HNSC	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-10.4	6.39e-23	2.9e-16	-0.62	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
HNSC	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	10.39	6.6e-23	2.99e-16	0.54	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
HNSC	trans	rs10037055	1	rs6886255	ENSG00000217325.2	PRELID1P1	10.39	6.91e-23	3.12e-16	0.59	0.43	Migraine without aura;	chr5:177291360	chr6:126643488~126644390:+
HNSC	trans	rs74781061	0.929	rs6495109	ENSG00000227288.3	RP5-837I24.1	10.39	7e-23	3.17e-16	0.65	0.43	Endometriosis;	chr15:74504720	chr1:81501794~81503468:+
HNSC	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	10.39	7.02e-23	3.17e-16	0.54	0.43	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
HNSC	trans	rs867371	0.896	rs8033831	ENSG00000235370.6	DNM1P51	-10.39	7.03e-23	3.18e-16	-0.53	-0.43	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:84398316~84411701:-
HNSC	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	10.38	7.24e-23	3.27e-16	0.6	0.43	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	10.38	7.27e-23	3.28e-16	0.7	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
HNSC	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	10.38	7.31e-23	3.3e-16	0.6	0.43	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-10.38	7.48e-23	3.38e-16	-0.45	-0.43	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-10.38	7.48e-23	3.38e-16	-0.45	-0.43	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
HNSC	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	10.38	7.63e-23	3.44e-16	0.55	0.43	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
HNSC	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	10.38	7.75e-23	3.5e-16	0.54	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
HNSC	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-10.38	7.8e-23	3.52e-16	-0.62	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
HNSC	trans	rs10037055	0.853	rs10476219	ENSG00000217325.2	PRELID1P1	-10.37	7.9e-23	3.56e-16	-0.58	-0.43	Migraine without aura;	chr5:177201547	chr6:126643488~126644390:+
HNSC	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-10.37	8.25e-23	3.72e-16	-0.65	-0.43	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
HNSC	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	10.36	8.64e-23	3.89e-16	0.55	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
HNSC	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	10.36	8.71e-23	3.92e-16	0.54	0.43	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	10.36	8.95e-23	4.03e-16	0.54	0.43	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	10.36	8.95e-23	4.03e-16	0.54	0.43	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
HNSC	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	10.35	9.4e-23	4.23e-16	0.59	0.43	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.792	rs62064901	ENSG00000233719.3	GOT2P3	10.35	9.61e-23	4.32e-16	0.54	0.43	Blood metabolite ratios;	chr16:58776758	chr12:9641802~9643007:+
HNSC	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-10.35	9.69e-23	4.35e-16	-0.65	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
HNSC	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	10.35	9.74e-23	4.38e-16	0.72	0.43	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
HNSC	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	10.34	1.02e-22	4.57e-16	0.54	0.43	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
HNSC	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	10.34	1.04e-22	4.68e-16	0.6	0.43	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
HNSC	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-10.34	1.06e-22	4.74e-16	-0.5	-0.43	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
HNSC	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	10.34	1.07e-22	4.8e-16	0.53	0.43	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	10.34	1.07e-22	4.8e-16	0.53	0.43	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
HNSC	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	10.33	1.11e-22	4.98e-16	0.57	0.43	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
HNSC	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	10.33	1.13e-22	5.07e-16	0.53	0.43	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
HNSC	trans	rs12709013	0.792	rs1657170	ENSG00000233719.3	GOT2P3	10.33	1.13e-22	5.08e-16	0.53	0.43	Blood metabolite ratios;	chr16:58752082	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs7185513	ENSG00000233719.3	GOT2P3	10.33	1.15e-22	5.13e-16	0.53	0.43	Blood metabolite ratios;	chr16:58794889	chr12:9641802~9643007:+
HNSC	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	10.33	1.17e-22	5.22e-16	0.57	0.43	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
HNSC	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	10.32	1.28e-22	5.73e-16	0.54	0.43	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	10.32	1.28e-22	5.73e-16	0.54	0.43	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
HNSC	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	10.31	1.33e-22	5.96e-16	0.57	0.43	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
HNSC	trans	rs74781061	0.929	rs7171838	ENSG00000227288.3	RP5-837I24.1	10.31	1.34e-22	5.97e-16	0.65	0.43	Endometriosis;	chr15:74571778	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8029099	ENSG00000227288.3	RP5-837I24.1	10.3	1.53e-22	6.8e-16	0.64	0.43	Endometriosis;	chr15:74474429	chr1:81501794~81503468:+
HNSC	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	10.29	1.57e-22	6.99e-16	0.53	0.43	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
HNSC	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	10.29	1.61e-22	7.14e-16	0.52	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
HNSC	trans	rs74781061	0.929	rs16969612	ENSG00000227288.3	RP5-837I24.1	-10.29	1.62e-22	7.2e-16	-0.64	-0.43	Endometriosis;	chr15:74514096	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs8023865	ENSG00000227288.3	RP5-837I24.1	10.28	1.72e-22	7.64e-16	0.64	0.43	Endometriosis;	chr15:74561263	chr1:81501794~81503468:+
HNSC	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	10.28	1.73e-22	7.69e-16	0.53	0.43	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
HNSC	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	10.28	1.75e-22	7.78e-16	0.6	0.43	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
HNSC	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	10.26	2.02e-22	8.95e-16	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
HNSC	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	10.25	2.23e-22	9.87e-16	0.56	0.43	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
HNSC	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	10.25	2.24e-22	9.9e-16	0.53	0.43	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	10.25	2.24e-22	9.9e-16	0.53	0.43	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
HNSC	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	10.25	2.27e-22	1.01e-15	0.7	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
HNSC	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	10.25	2.28e-22	1.01e-15	0.54	0.43	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
HNSC	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	10.25	2.28e-22	1.01e-15	0.53	0.43	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
HNSC	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-10.25	2.3e-22	1.02e-15	-0.65	-0.43	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
HNSC	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	10.25	2.32e-22	1.02e-15	0.58	0.43	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
HNSC	trans	rs10037055	0.687	rs6556308	ENSG00000217325.2	PRELID1P1	-10.25	2.34e-22	1.04e-15	-0.57	-0.43	Migraine without aura;	chr5:177219700	chr6:126643488~126644390:+
HNSC	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	10.24	2.41e-22	1.06e-15	0.53	0.43	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
HNSC	trans	rs2657294	0.704	rs10824266	ENSG00000172974.11	AC007318.5	10.24	2.44e-22	1.08e-15	0.54	0.43	Pneumonia;	chr10:75083476	chr2:65205108~65205988:+
HNSC	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	10.24	2.45e-22	1.08e-15	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
HNSC	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	10.24	2.49e-22	1.1e-15	0.53	0.43	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
HNSC	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	10.23	2.6e-22	1.15e-15	0.52	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
HNSC	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	10.23	2.6e-22	1.15e-15	0.57	0.43	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
HNSC	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-10.22	2.88e-22	1.27e-15	-0.65	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
HNSC	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	10.22	2.99e-22	1.31e-15	0.57	0.43	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
HNSC	trans	rs10037055	0.853	rs10056008	ENSG00000217325.2	PRELID1P1	-10.21	3.07e-22	1.35e-15	-0.57	-0.43	Migraine without aura;	chr5:177194147	chr6:126643488~126644390:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	10.21	3.07e-22	1.35e-15	0.49	0.43	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
HNSC	trans	rs10037055	0.853	rs6890580	ENSG00000217325.2	PRELID1P1	-10.21	3.1e-22	1.37e-15	-0.57	-0.43	Migraine without aura;	chr5:177226519	chr6:126643488~126644390:+
HNSC	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	10.21	3.13e-22	1.38e-15	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-10.21	3.25e-22	1.43e-15	-0.44	-0.43	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
HNSC	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	10.21	3.26e-22	1.44e-15	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
HNSC	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	10.2	3.3e-22	1.45e-15	0.52	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
HNSC	trans	rs2657294	0.734	rs10740449	ENSG00000172974.11	AC007318.5	10.2	3.36e-22	1.48e-15	0.54	0.43	Pneumonia;	chr10:75086620	chr2:65205108~65205988:+
HNSC	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-10.19	3.74e-22	1.64e-15	-0.52	-0.43	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
HNSC	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	10.18	4.13e-22	1.81e-15	0.65	0.43	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
HNSC	trans	rs7554547	0.667	rs2050266	ENSG00000261819.1	RP11-680G24.4	10.17	4.25e-22	1.86e-15	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr16:14988259~14990160:-
HNSC	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-10.17	4.3e-22	1.88e-15	-0.59	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
HNSC	trans	rs12709013	0.59	rs982848	ENSG00000233719.3	GOT2P3	10.17	4.32e-22	1.89e-15	0.51	0.43	Blood metabolite ratios;	chr16:58704294	chr12:9641802~9643007:+
HNSC	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	10.17	4.48e-22	1.96e-15	0.52	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
HNSC	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	10.17	4.54e-22	1.99e-15	0.59	0.43	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
HNSC	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	10.17	4.57e-22	2e-15	0.52	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
HNSC	trans	rs10037055	0.741	rs2336405	ENSG00000217325.2	PRELID1P1	-10.17	4.57e-22	2e-15	-0.56	-0.43	Migraine without aura;	chr5:177230288	chr6:126643488~126644390:+
HNSC	trans	rs55665837	0.54	rs10832294	ENSG00000236360.2	RP11-334A14.2	10.16	4.63e-22	2.03e-15	0.57	0.43	Vitamin D levels;	chr11:14725881	chr1:52993201~52993702:-
HNSC	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	10.16	4.67e-22	2.04e-15	0.6	0.43	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
HNSC	trans	rs7554511	0.763	rs55734382	ENSG00000244144.1	RP11-757F18.3	-10.16	4.68e-22	2.05e-15	-0.57	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201049931	chr3:112185480~112185998:-
HNSC	trans	rs55665837	0.54	rs10832299	ENSG00000236360.2	RP11-334A14.2	10.16	4.7e-22	2.06e-15	0.57	0.43	Vitamin D levels;	chr11:14747846	chr1:52993201~52993702:-
HNSC	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	10.15	5.08e-22	2.22e-15	0.53	0.43	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
HNSC	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	10.15	5.13e-22	2.24e-15	0.64	0.43	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
HNSC	trans	rs55665837	0.54	rs4144487	ENSG00000236360.2	RP11-334A14.2	10.15	5.46e-22	2.38e-15	0.57	0.42	Vitamin D levels;	chr11:14728905	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.54	rs12788030	ENSG00000236360.2	RP11-334A14.2	10.15	5.46e-22	2.38e-15	0.57	0.42	Vitamin D levels;	chr11:14743138	chr1:52993201~52993702:-
HNSC	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	10.14	5.46e-22	2.38e-15	0.6	0.42	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
HNSC	trans	rs74781061	0.929	rs4887159	ENSG00000227288.3	RP5-837I24.1	10.14	5.52e-22	2.4e-15	0.64	0.42	Endometriosis;	chr15:74573541	chr1:81501794~81503468:+
HNSC	trans	rs55665837	0.54	rs10219313	ENSG00000236360.2	RP11-334A14.2	10.14	5.57e-22	2.42e-15	0.57	0.42	Vitamin D levels;	chr11:14728303	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.519	rs10832297	ENSG00000236360.2	RP11-334A14.2	10.14	5.57e-22	2.42e-15	0.57	0.42	Vitamin D levels;	chr11:14736191	chr1:52993201~52993702:-
HNSC	trans	rs74781061	0.929	rs8029215	ENSG00000227288.3	RP5-837I24.1	10.14	5.58e-22	2.43e-15	0.65	0.42	Endometriosis;	chr15:74561147	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8043082	ENSG00000227288.3	RP5-837I24.1	10.14	5.58e-22	2.43e-15	0.65	0.42	Endometriosis;	chr15:74564896	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs8026923	ENSG00000227288.3	RP5-837I24.1	10.14	5.58e-22	2.43e-15	0.65	0.42	Endometriosis;	chr15:74565721	chr1:81501794~81503468:+
HNSC	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	10.14	5.84e-22	2.54e-15	0.6	0.42	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
HNSC	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	10.14	5.84e-22	2.54e-15	0.6	0.42	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
HNSC	trans	rs13190036	1	rs17078781	ENSG00000226986.4	RP11-543B16.2	-10.14	5.91e-22	2.57e-15	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr1:211207239~211207897:+
HNSC	trans	rs12709013	0.792	rs62064940	ENSG00000233719.3	GOT2P3	10.13	6.01e-22	2.61e-15	0.52	0.42	Blood metabolite ratios;	chr16:58796560	chr12:9641802~9643007:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	10.13	6.05e-22	2.63e-15	0.46	0.42	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
HNSC	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	10.13	6.11e-22	2.65e-15	0.56	0.42	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.892	rs71601339	ENSG00000228305.2	AC016734.2	-10.13	6.22e-22	2.7e-15	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr2:63622178~63622831:-
HNSC	trans	rs12709013	0.792	rs12596434	ENSG00000233719.3	GOT2P3	10.13	6.25e-22	2.71e-15	0.52	0.42	Blood metabolite ratios;	chr16:58792309	chr12:9641802~9643007:+
HNSC	trans	rs6708331	0.887	rs6546567	ENSG00000232654.1	FAM136BP	10.13	6.4e-22	2.77e-15	0.54	0.42	Obesity-related traits;	chr2:70081390	chr6:3045384~3045800:+
HNSC	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-10.12	6.52e-22	2.83e-15	-0.62	-0.42	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
HNSC	trans	rs12709013	0.729	rs34324769	ENSG00000233719.3	GOT2P3	10.12	6.66e-22	2.88e-15	0.53	0.42	Blood metabolite ratios;	chr16:58778131	chr12:9641802~9643007:+
HNSC	trans	rs55665837	0.519	rs1451677	ENSG00000236360.2	RP11-334A14.2	10.12	7.01e-22	3.03e-15	0.57	0.42	Vitamin D levels;	chr11:14724466	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	10.11	7.06e-22	3.05e-15	0.57	0.42	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
HNSC	trans	rs7554511	0.861	rs378672	ENSG00000244144.1	RP11-757F18.3	10.11	7.23e-22	3.13e-15	0.54	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917205	chr3:112185480~112185998:-
HNSC	trans	rs1039766	1	rs268870	ENSG00000224334.1	AP000357.4	10.11	7.36e-22	3.18e-15	0.71	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr22:24686923~24688087:+
HNSC	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	10.1	7.84e-22	3.38e-15	0.53	0.42	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
HNSC	trans	rs5022636	0.507	rs4579761	ENSG00000180764.13	PIPSL	10.1	8e-22	3.45e-15	0.59	0.42	Gut microbiota (functional units);	chr1:151363433	chr10:93958191~93961540:-
HNSC	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	10.09	8.51e-22	3.67e-15	0.56	0.42	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.54	rs1007392	ENSG00000236360.2	RP11-334A14.2	10.09	8.67e-22	3.73e-15	0.57	0.42	Vitamin D levels;	chr11:14753045	chr1:52993201~52993702:-
HNSC	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	10.09	8.92e-22	3.84e-15	0.72	0.42	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
HNSC	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	10.09	8.92e-22	3.84e-15	0.72	0.42	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
HNSC	trans	rs10037055	0.853	rs1546363	ENSG00000217325.2	PRELID1P1	-10.08	9.07e-22	3.9e-15	-0.56	-0.42	Migraine without aura;	chr5:177174030	chr6:126643488~126644390:+
HNSC	trans	rs13190036	0.892	rs71601339	ENSG00000226986.4	RP11-543B16.2	-10.08	9.08e-22	3.91e-15	-0.69	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr1:211207239~211207897:+
HNSC	trans	rs3740713	1	rs35593189	ENSG00000235847.2	LDHAP7	10.08	9.13e-22	3.93e-15	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:84777259~84778223:-
HNSC	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	10.08	9.15e-22	3.93e-15	0.56	0.42	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	10.08	9.15e-22	3.93e-15	0.56	0.42	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
HNSC	trans	rs9425766	0.85	rs9425755	ENSG00000213331.4	RP11-713C19.2	10.08	9.39e-22	4.03e-15	0.48	0.42	Life satisfaction;	chr1:173843501	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.927	rs9425757	ENSG00000213331.4	RP11-713C19.2	10.08	9.39e-22	4.03e-15	0.48	0.42	Life satisfaction;	chr1:173855675	chr4:187970273~187971284:+
HNSC	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	10.08	9.42e-22	4.05e-15	0.69	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
HNSC	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	10.07	1.01e-21	4.32e-15	0.57	0.42	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
HNSC	trans	rs7121616	0.563	rs4936770	ENSG00000229091.2	HSPA8P8	10.07	1.01e-21	4.33e-15	0.49	0.42	Breast cancer;	chr11:123058167	chr7:10451311~10452526:+
HNSC	trans	rs3740713	1	rs79199586	ENSG00000235847.2	LDHAP7	10.07	1.03e-21	4.42e-15	0.77	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:84777259~84778223:-
HNSC	trans	rs2657294	0.646	rs10762656	ENSG00000172974.11	AC007318.5	10.07	1.06e-21	4.52e-15	0.54	0.42	Pneumonia;	chr10:75085706	chr2:65205108~65205988:+
HNSC	trans	rs2134046	0.587	rs11854289	ENSG00000235370.6	DNM1P51	10.06	1.07e-21	4.58e-15	0.49	0.42	Cognitive ability;	chr15:82266461	chr15:84398316~84411701:-
HNSC	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	10.06	1.11e-21	4.75e-15	0.55	0.42	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
HNSC	trans	rs9425766	0.85	rs1322770	ENSG00000213331.4	RP11-713C19.2	10.06	1.13e-21	4.83e-15	0.48	0.42	Life satisfaction;	chr1:173863198	chr4:187970273~187971284:+
HNSC	trans	rs867371	0.929	rs1501371	ENSG00000235370.6	DNM1P51	-10.05	1.18e-21	5.05e-15	-0.53	-0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:84398316~84411701:-
HNSC	trans	rs13190036	0.901	rs55741473	ENSG00000226986.4	RP11-543B16.2	-10.05	1.19e-21	5.1e-15	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr1:211207239~211207897:+
HNSC	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	10.05	1.2e-21	5.12e-15	0.7	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
HNSC	trans	rs55665837	0.52	rs10766189	ENSG00000236360.2	RP11-334A14.2	10.05	1.22e-21	5.22e-15	0.57	0.42	Vitamin D levels;	chr11:14712377	chr1:52993201~52993702:-
HNSC	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	10.05	1.22e-21	5.22e-15	0.52	0.42	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
HNSC	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	10.05	1.22e-21	5.22e-15	0.52	0.42	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
HNSC	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	10.05	1.22e-21	5.22e-15	0.51	0.42	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
HNSC	trans	rs12138950	0.681	rs10917468	ENSG00000224237.1	MINOS1P3	-10.04	1.3e-21	5.55e-15	-0.58	-0.42	Hypothyroidism;Thyroid volume;	chr1:19516860	chr3:27214816~27215018:-
HNSC	trans	rs12709013	0.766	rs12599331	ENSG00000233719.3	GOT2P3	10.04	1.31e-21	5.6e-15	0.52	0.42	Blood metabolite ratios;	chr16:58805307	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs12928733	ENSG00000233719.3	GOT2P3	10.04	1.31e-21	5.6e-15	0.52	0.42	Blood metabolite ratios;	chr16:58807216	chr12:9641802~9643007:+
HNSC	trans	rs116095464	1	rs6879758	ENSG00000185986.11	SDHAP3	10.04	1.32e-21	5.64e-15	0.86	0.42	Breast cancer;	chr5:350162	chr5:1572222~1594620:-
HNSC	trans	rs74781061	1	rs4887166	ENSG00000227288.3	RP5-837I24.1	10.04	1.34e-21	5.72e-15	0.63	0.42	Endometriosis;	chr15:74605257	chr1:81501794~81503468:+
HNSC	trans	rs74781061	1	rs6495117	ENSG00000227288.3	RP5-837I24.1	10.04	1.34e-21	5.72e-15	0.63	0.42	Endometriosis;	chr15:74607159	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	10.03	1.39e-21	5.91e-15	0.64	0.42	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	10.03	1.39e-21	5.91e-15	0.64	0.42	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
HNSC	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-10.03	1.42e-21	6.06e-15	-0.69	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
HNSC	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-10.02	1.52e-21	6.47e-15	-0.58	-0.42	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
HNSC	trans	rs12709013	0.686	rs151817	ENSG00000233719.3	GOT2P3	-10.02	1.56e-21	6.64e-15	-0.51	-0.42	Blood metabolite ratios;	chr16:58704014	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.686	rs244919	ENSG00000233719.3	GOT2P3	-10.02	1.56e-21	6.64e-15	-0.51	-0.42	Blood metabolite ratios;	chr16:58704146	chr12:9641802~9643007:+
HNSC	trans	rs62344088	0.59	rs62346174	ENSG00000185986.11	SDHAP3	10.02	1.56e-21	6.64e-15	0.96	0.42	Asthma (childhood onset);	chr5:296193	chr5:1572222~1594620:-
HNSC	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	10.02	1.6e-21	6.79e-15	0.5	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
HNSC	trans	rs1039766	1	rs268861	ENSG00000224334.1	AP000357.4	10.02	1.62e-21	6.86e-15	0.7	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr22:24686923~24688087:+
HNSC	trans	rs1039766	1	rs268862	ENSG00000224334.1	AP000357.4	10.02	1.62e-21	6.86e-15	0.7	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr22:24686923~24688087:+
HNSC	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-10.01	1.62e-21	6.89e-15	-0.51	-0.42	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
HNSC	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-10.01	1.62e-21	6.89e-15	-0.49	-0.42	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
HNSC	trans	rs2657294	0.734	rs2894244	ENSG00000172974.11	AC007318.5	10.01	1.66e-21	7.03e-15	0.53	0.42	Pneumonia;	chr10:75087112	chr2:65205108~65205988:+
HNSC	trans	rs6708331	0.887	rs13016716	ENSG00000232654.1	FAM136BP	10.01	1.67e-21	7.1e-15	0.53	0.42	Obesity-related traits;	chr2:70036128	chr6:3045384~3045800:+
HNSC	trans	rs9611519	0.58	rs7286603	ENSG00000268568.1	AC007228.9	-10.01	1.67e-21	7.1e-15	-0.49	-0.42	Neuroticism;	chr22:41044057	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.558	rs8137906	ENSG00000268568.1	AC007228.9	-10.01	1.67e-21	7.1e-15	-0.49	-0.42	Neuroticism;	chr22:41046562	chr19:56672574~56673901:-
HNSC	trans	rs3740713	1	rs73438686	ENSG00000235847.2	LDHAP7	10.01	1.71e-21	7.24e-15	0.74	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr2:84777259~84778223:-
HNSC	trans	rs9611519	0.929	rs71327107	ENSG00000268568.1	AC007228.9	-10.01	1.71e-21	7.24e-15	-0.58	-0.42	Neuroticism;	chr22:41022225	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.828	rs9611460	ENSG00000268568.1	AC007228.9	-10	1.77e-21	7.52e-15	-0.58	-0.42	Neuroticism;	chr22:41022293	chr19:56672574~56673901:-
HNSC	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	10	1.82e-21	7.71e-15	0.55	0.42	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
HNSC	trans	rs3740713	1	rs73438690	ENSG00000235847.2	LDHAP7	10	1.82e-21	7.71e-15	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr2:84777259~84778223:-
HNSC	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	9.99	1.93e-21	8.19e-15	0.52	0.42	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
HNSC	trans	rs9611519	0.565	rs8135524	ENSG00000268568.1	AC007228.9	-9.99	1.96e-21	8.3e-15	-0.49	-0.42	Neuroticism;	chr22:41040438	chr19:56672574~56673901:-
HNSC	trans	rs3740713	1	rs73436638	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436642	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436666	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438611	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs2643872	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs75381502	ENSG00000235847.2	LDHAP7	9.99	1.99e-21	8.41e-15	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr2:84777259~84778223:-
HNSC	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	9.98	2.11e-21	8.92e-15	0.72	0.42	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
HNSC	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	9.98	2.15e-21	9.05e-15	0.56	0.42	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
HNSC	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-9.97	2.29e-21	9.66e-15	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
HNSC	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-9.97	2.29e-21	9.66e-15	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
HNSC	trans	rs12709013	0.792	rs11644344	ENSG00000233719.3	GOT2P3	9.97	2.39e-21	1.01e-14	0.51	0.42	Blood metabolite ratios;	chr16:58803080	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.875	rs9924389	ENSG00000230849.2	GOT2P2	9.97	2.41e-21	1.01e-14	0.52	0.42	Blood metabolite ratios;	chr16:58779849	chr1:173141100~173142350:-
HNSC	trans	rs3740713	1	rs76586692	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs57311859	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.92	rs112973292	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.92	rs73438656	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.92	rs73438659	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438666	ENSG00000235847.2	LDHAP7	9.97	2.42e-21	1.02e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr2:84777259~84778223:-
HNSC	trans	rs12709013	0.792	rs11649133	ENSG00000233719.3	GOT2P3	9.97	2.45e-21	1.03e-14	0.51	0.42	Blood metabolite ratios;	chr16:58803275	chr12:9641802~9643007:+
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-9.96	2.57e-21	1.08e-14	-0.49	-0.42	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-9.96	2.57e-21	1.08e-14	-0.49	-0.42	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
HNSC	trans	rs10917477	0.624	rs1320978	ENSG00000224237.1	MINOS1P3	9.96	2.61e-21	1.1e-14	0.5	0.42	Thyroid function;	chr1:19621479	chr3:27214816~27215018:-
HNSC	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-9.96	2.62e-21	1.1e-14	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
HNSC	trans	rs74781061	1	rs6495116	ENSG00000227288.3	RP5-837I24.1	9.96	2.66e-21	1.12e-14	0.63	0.42	Endometriosis;	chr15:74593607	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.766	rs11648511	ENSG00000233719.3	GOT2P3	9.95	2.69e-21	1.13e-14	0.51	0.42	Blood metabolite ratios;	chr16:58798171	chr12:9641802~9643007:+
HNSC	trans	rs2134046	0.555	rs11854483	ENSG00000235370.6	DNM1P51	-9.95	2.81e-21	1.18e-14	-0.49	-0.42	Cognitive ability;	chr15:82267217	chr15:84398316~84411701:-
HNSC	trans	rs6708331	0.793	rs6546566	ENSG00000232654.1	FAM136BP	9.94	3.01e-21	1.26e-14	0.53	0.42	Obesity-related traits;	chr2:70070865	chr6:3045384~3045800:+
HNSC	trans	rs1039766	1	rs10116	ENSG00000224334.1	AP000357.4	9.94	3.07e-21	1.29e-14	0.69	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr22:24686923~24688087:+
HNSC	trans	rs1039766	1	rs268878	ENSG00000224334.1	AP000357.4	9.94	3.07e-21	1.29e-14	0.69	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr22:24686923~24688087:+
HNSC	trans	rs1039766	0.929	rs268881	ENSG00000224334.1	AP000357.4	9.94	3.07e-21	1.29e-14	0.69	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr22:24686923~24688087:+
HNSC	trans	rs12709013	0.792	rs8049572	ENSG00000233719.3	GOT2P3	9.94	3.12e-21	1.3e-14	0.51	0.42	Blood metabolite ratios;	chr16:58809672	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.766	rs34438483	ENSG00000233719.3	GOT2P3	9.94	3.12e-21	1.3e-14	0.51	0.42	Blood metabolite ratios;	chr16:58810530	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.929	rs6495108	ENSG00000227288.3	RP5-837I24.1	9.93	3.19e-21	1.33e-14	0.6	0.42	Endometriosis;	chr15:74502186	chr1:81501794~81503468:+
HNSC	trans	rs3740713	1	rs73438695	ENSG00000235847.2	LDHAP7	9.93	3.24e-21	1.35e-14	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs76062966	ENSG00000235847.2	LDHAP7	9.93	3.24e-21	1.35e-14	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr2:84777259~84778223:-
HNSC	trans	rs116095464	1	rs62331562	ENSG00000185986.11	SDHAP3	9.93	3.29e-21	1.37e-14	0.91	0.42	Breast cancer;	chr5:349183	chr5:1572222~1594620:-
HNSC	trans	rs7662987	1	rs28730640	ENSG00000233859.2	ADH5P4	9.93	3.3e-21	1.38e-14	0.67	0.42	Smoking initiation;	chr4:99072902	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs7658118	ENSG00000233859.2	ADH5P4	9.93	3.3e-21	1.38e-14	0.67	0.42	Smoking initiation;	chr4:99073457	chr6:65836930~65838039:-
HNSC	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	9.93	3.33e-21	1.39e-14	0.54	0.42	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
HNSC	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	9.93	3.34e-21	1.39e-14	0.61	0.42	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	9.93	3.34e-21	1.39e-14	0.61	0.42	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	9.93	3.34e-21	1.39e-14	0.61	0.42	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
HNSC	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	9.93	3.39e-21	1.41e-14	0.69	0.42	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
HNSC	trans	rs10037055	0.853	rs2336237	ENSG00000217325.2	PRELID1P1	9.93	3.42e-21	1.42e-14	0.56	0.42	Migraine without aura;	chr5:177238878	chr6:126643488~126644390:+
HNSC	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	9.92	3.43e-21	1.43e-14	0.51	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
HNSC	trans	rs6732160	0.809	rs13416592	ENSG00000236165.1	PRADC1P1	9.92	3.6e-21	1.5e-14	0.52	0.42	Intelligence (multi-trait analysis);	chr2:73137928	chr3:36976316~36976840:+
HNSC	trans	rs9425766	0.962	rs6663875	ENSG00000213331.4	RP11-713C19.2	9.92	3.62e-21	1.51e-14	0.48	0.42	Life satisfaction;	chr1:173894071	chr4:187970273~187971284:+
HNSC	trans	rs3740713	1	rs73436645	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.925	rs73436650	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436655	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.92	rs80254575	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436662	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs113725670	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436682	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436685	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs2056781	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73436701	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438604	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438607	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs75010364	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438627	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438634	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs113036885	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs112410494	ENSG00000235847.2	LDHAP7	9.92	3.63e-21	1.51e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr2:84777259~84778223:-
HNSC	trans	rs62344088	0.744	rs76038312	ENSG00000185986.11	SDHAP3	9.92	3.66e-21	1.52e-14	0.92	0.42	Asthma (childhood onset);	chr5:228890	chr5:1572222~1594620:-
HNSC	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	9.91	3.77e-21	1.56e-14	0.51	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
HNSC	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	9.91	3.77e-21	1.56e-14	0.68	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
HNSC	trans	rs12709013	0.716	rs11647582	ENSG00000233719.3	GOT2P3	9.91	3.84e-21	1.59e-14	0.51	0.42	Blood metabolite ratios;	chr16:58801474	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs35684307	ENSG00000233719.3	GOT2P3	9.91	3.84e-21	1.59e-14	0.51	0.42	Blood metabolite ratios;	chr16:58801651	chr12:9641802~9643007:+
HNSC	trans	rs867371	0.656	rs2665103	ENSG00000235370.6	DNM1P51	9.91	3.96e-21	1.64e-14	0.49	0.42	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:84398316~84411701:-
HNSC	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	9.9	4.08e-21	1.69e-14	0.58	0.42	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
HNSC	trans	rs3740713	1	rs73440606	ENSG00000235847.2	LDHAP7	9.9	4.15e-21	1.72e-14	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73440615	ENSG00000235847.2	LDHAP7	9.9	4.15e-21	1.72e-14	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:84777259~84778223:-
HNSC	trans	rs6732160	0.834	rs57456443	ENSG00000236165.1	PRADC1P1	9.9	4.19e-21	1.73e-14	0.51	0.42	Intelligence (multi-trait analysis);	chr2:73139313	chr3:36976316~36976840:+
HNSC	trans	rs7554511	0.707	rs10800756	ENSG00000244144.1	RP11-757F18.3	9.9	4.29e-21	1.78e-14	0.55	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054931	chr3:112185480~112185998:-
HNSC	trans	rs13190036	1	rs17078781	ENSG00000228305.2	AC016734.2	-9.9	4.32e-21	1.79e-14	-0.69	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr2:63622178~63622831:-
HNSC	trans	rs3740713	1	rs74741949	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs113497813	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs61081934	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr2:84777259~84778223:-
HNSC	trans	rs3740713	0.92	rs112818034	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs76708296	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438668	ENSG00000235847.2	LDHAP7	9.89	4.39e-21	1.81e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr2:84777259~84778223:-
HNSC	trans	rs9425766	1	rs9425766	ENSG00000213331.4	RP11-713C19.2	9.89	4.4e-21	1.82e-14	0.48	0.42	Life satisfaction;	chr1:173883989	chr4:187970273~187971284:+
HNSC	trans	rs3740713	1	rs60376560	ENSG00000235847.2	LDHAP7	9.89	4.4e-21	1.82e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:84777259~84778223:-
HNSC	trans	rs7554511	0.763	rs3913893	ENSG00000244144.1	RP11-757F18.3	-9.89	4.65e-21	1.92e-14	-0.56	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201046655	chr3:112185480~112185998:-
HNSC	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-9.89	4.65e-21	1.92e-14	-0.68	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
HNSC	trans	rs1039766	0.925	rs268863	ENSG00000224334.1	AP000357.4	9.89	4.71e-21	1.94e-14	0.69	0.42	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr22:24686923~24688087:+
HNSC	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-9.89	4.72e-21	1.95e-14	-0.7	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
HNSC	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	9.89	4.75e-21	1.96e-14	0.61	0.42	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
HNSC	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	9.88	4.76e-21	1.96e-14	0.68	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
HNSC	trans	rs12709013	0.792	rs62066381	ENSG00000233719.3	GOT2P3	9.88	4.83e-21	1.99e-14	0.51	0.42	Blood metabolite ratios;	chr16:58807981	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.792	rs36098613	ENSG00000233719.3	GOT2P3	9.88	4.83e-21	1.99e-14	0.51	0.42	Blood metabolite ratios;	chr16:58810562	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.929	rs6495115	ENSG00000227288.3	RP5-837I24.1	9.88	4.86e-21	2e-14	0.64	0.42	Endometriosis;	chr15:74578122	chr1:81501794~81503468:+
HNSC	trans	rs7662987	1	rs7683704	ENSG00000233859.2	ADH5P4	9.88	4.91e-21	2.02e-14	0.67	0.42	Smoking initiation;	chr4:99083075	chr6:65836930~65838039:-
HNSC	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	9.88	5.03e-21	2.07e-14	0.52	0.42	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
HNSC	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	9.88	5.05e-21	2.08e-14	0.55	0.42	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
HNSC	trans	rs6708331	0.887	rs6546565	ENSG00000232654.1	FAM136BP	9.87	5.23e-21	2.15e-14	0.53	0.42	Obesity-related traits;	chr2:70070173	chr6:3045384~3045800:+
HNSC	trans	rs3740713	1	rs73436668	ENSG00000235847.2	LDHAP7	9.87	5.23e-21	2.15e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:84777259~84778223:-
HNSC	trans	rs116095464	1	rs2721025	ENSG00000185986.11	SDHAP3	9.87	5.27e-21	2.17e-14	0.84	0.42	Breast cancer;	chr5:347329	chr5:1572222~1594620:-
HNSC	trans	rs74781061	0.872	rs3826041	ENSG00000227288.3	RP5-837I24.1	9.87	5.35e-21	2.2e-14	0.61	0.42	Endometriosis;	chr15:74726549	chr1:81501794~81503468:+
HNSC	trans	rs12709013	0.792	rs11649387	ENSG00000233719.3	GOT2P3	9.87	5.48e-21	2.25e-14	0.51	0.42	Blood metabolite ratios;	chr16:58803176	chr12:9641802~9643007:+
HNSC	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	9.87	5.56e-21	2.28e-14	0.5	0.42	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
HNSC	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	9.86	5.64e-21	2.32e-14	0.53	0.42	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	9.86	5.79e-21	2.38e-14	0.54	0.42	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
HNSC	trans	rs3740713	1	rs16935424	ENSG00000235847.2	LDHAP7	9.86	5.81e-21	2.38e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438674	ENSG00000235847.2	LDHAP7	9.86	5.81e-21	2.38e-14	0.71	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs74663287	ENSG00000235847.2	LDHAP7	9.86	5.88e-21	2.41e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438697	ENSG00000235847.2	LDHAP7	9.86	5.88e-21	2.41e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs114330751	ENSG00000235847.2	LDHAP7	9.86	5.88e-21	2.41e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438699	ENSG00000235847.2	LDHAP7	9.86	5.88e-21	2.41e-14	0.72	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs75487138	ENSG00000235847.2	LDHAP7	9.86	5.96e-21	2.44e-14	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438631	ENSG00000235847.2	LDHAP7	9.86	6.07e-21	2.49e-14	0.72	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs1848048	ENSG00000235847.2	LDHAP7	9.85	6.31e-21	2.59e-14	0.73	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs16935432	ENSG00000235847.2	LDHAP7	9.85	6.31e-21	2.59e-14	0.73	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73440625	ENSG00000235847.2	LDHAP7	9.85	6.31e-21	2.59e-14	0.73	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs76599129	ENSG00000235847.2	LDHAP7	9.85	6.31e-21	2.59e-14	0.73	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:84777259~84778223:-
HNSC	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	9.85	6.36e-21	2.6e-14	0.63	0.41	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-9.85	6.39e-21	2.62e-14	-0.48	-0.41	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
HNSC	trans	rs3740713	1	rs75740864	ENSG00000235847.2	LDHAP7	9.85	6.46e-21	2.65e-14	0.72	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:84777259~84778223:-
HNSC	trans	rs6732160	0.845	rs10203125	ENSG00000236165.1	PRADC1P1	9.84	6.66e-21	2.73e-14	0.52	0.41	Intelligence (multi-trait analysis);	chr2:73134023	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.845	rs10203718	ENSG00000236165.1	PRADC1P1	9.84	6.66e-21	2.73e-14	0.52	0.41	Intelligence (multi-trait analysis);	chr2:73134387	chr3:36976316~36976840:+
HNSC	trans	rs74781061	0.929	rs6495118	ENSG00000227288.3	RP5-837I24.1	9.84	6.71e-21	2.74e-14	0.63	0.41	Endometriosis;	chr15:74619671	chr1:81501794~81503468:+
HNSC	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-9.84	7.02e-21	2.87e-14	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
HNSC	trans	rs11023332	1	rs11023332	ENSG00000236360.2	RP11-334A14.2	9.84	7.08e-21	2.89e-14	0.55	0.41	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr1:52993201~52993702:-
HNSC	trans	rs7554547	0.622	rs2179110	ENSG00000261819.1	RP11-680G24.4	9.84	7.1e-21	2.9e-14	0.6	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11912754	chr16:14988259~14990160:-
HNSC	trans	rs1039766	0.929	rs55843720	ENSG00000224334.1	AP000357.4	9.83	7.41e-21	3.03e-14	0.69	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr22:24686923~24688087:+
HNSC	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	9.83	7.44e-21	3.04e-14	0.54	0.41	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
HNSC	trans	rs3740713	1	rs73440604	ENSG00000235847.2	LDHAP7	9.83	7.51e-21	3.06e-14	0.72	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr2:84777259~84778223:-
HNSC	trans	rs4240897	1	rs4240897	ENSG00000261819.1	RP11-680G24.4	-9.83	7.72e-21	3.15e-14	-0.56	-0.41	Tuberculosis;	chr1:11982698	chr16:14988259~14990160:-
HNSC	trans	rs3740713	1	rs73440614	ENSG00000235847.2	LDHAP7	9.83	7.73e-21	3.15e-14	0.73	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:84777259~84778223:-
HNSC	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	9.82	7.81e-21	3.18e-14	0.61	0.41	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	9.82	7.81e-21	3.18e-14	0.61	0.41	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
HNSC	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	9.82	7.94e-21	3.24e-14	0.63	0.41	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
HNSC	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-9.82	8.04e-21	3.27e-14	-0.68	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
HNSC	trans	rs7554547	0.622	rs72864769	ENSG00000261819.1	RP11-680G24.4	9.82	8.14e-21	3.32e-14	0.57	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11881264	chr16:14988259~14990160:-
HNSC	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	9.82	8.28e-21	3.37e-14	0.5	0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	9.82	8.33e-21	3.39e-14	0.43	0.41	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
HNSC	trans	rs9425766	0.85	rs7349095	ENSG00000213331.4	RP11-713C19.2	9.81	8.67e-21	3.52e-14	0.48	0.41	Life satisfaction;	chr1:173887899	chr4:187970273~187971284:+
HNSC	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	9.81	8.82e-21	3.58e-14	0.63	0.41	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	9.81	8.82e-21	3.58e-14	0.63	0.41	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	9.81	8.82e-21	3.58e-14	0.63	0.41	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
HNSC	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	9.81	8.83e-21	3.58e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	9.81	8.83e-21	3.58e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
HNSC	trans	rs9425766	0.886	rs1322775	ENSG00000213331.4	RP11-713C19.2	9.81	9.15e-21	3.71e-14	0.47	0.41	Life satisfaction;	chr1:173886160	chr4:187970273~187971284:+
HNSC	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	9.8	9.36e-21	3.8e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
HNSC	trans	rs74781061	0.929	rs8025915	ENSG00000227288.3	RP5-837I24.1	9.8	9.49e-21	3.85e-14	0.64	0.41	Endometriosis;	chr15:74578188	chr1:81501794~81503468:+
HNSC	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	9.8	9.83e-21	3.98e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
HNSC	trans	rs7662987	1	rs11547772	ENSG00000233859.2	ADH5P4	9.79	1.03e-20	4.18e-14	0.66	0.41	Smoking initiation;	chr4:99071642	chr6:65836930~65838039:-
HNSC	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	9.79	1.04e-20	4.22e-14	0.64	0.41	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
HNSC	trans	rs3740713	1	rs75647856	ENSG00000235847.2	LDHAP7	9.79	1.05e-20	4.24e-14	0.71	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr2:84777259~84778223:-
HNSC	trans	rs3740713	1	rs73438687	ENSG00000235847.2	LDHAP7	9.79	1.05e-20	4.24e-14	0.71	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr2:84777259~84778223:-
HNSC	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-9.79	1.05e-20	4.26e-14	-0.68	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
HNSC	trans	rs3740713	1	rs73440610	ENSG00000235847.2	LDHAP7	9.79	1.06e-20	4.27e-14	0.72	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr2:84777259~84778223:-
HNSC	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	9.79	1.06e-20	4.31e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	9.79	1.06e-20	4.31e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	9.79	1.06e-20	4.31e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	9.79	1.06e-20	4.31e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-9.78	1.12e-20	4.52e-14	-0.48	-0.41	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
HNSC	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	9.78	1.15e-20	4.63e-14	0.6	0.41	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	9.77	1.18e-20	4.78e-14	0.54	0.41	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	9.77	1.26e-20	5.08e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	9.77	1.26e-20	5.08e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
HNSC	trans	rs7554511	0.707	rs6702590	ENSG00000244144.1	RP11-757F18.3	9.76	1.28e-20	5.15e-14	0.54	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201050977	chr3:112185480~112185998:-
HNSC	trans	rs13190036	1	rs351862	ENSG00000228305.2	AC016734.2	-9.76	1.3e-20	5.23e-14	-0.68	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr2:63622178~63622831:-
HNSC	trans	rs9425766	0.962	rs2065171	ENSG00000213331.4	RP11-713C19.2	9.76	1.33e-20	5.37e-14	0.47	0.41	Life satisfaction;	chr1:173876972	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.962	rs4652229	ENSG00000213331.4	RP11-713C19.2	9.76	1.33e-20	5.37e-14	0.47	0.41	Life satisfaction;	chr1:173877452	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.927	rs9425765	ENSG00000213331.4	RP11-713C19.2	9.76	1.33e-20	5.37e-14	0.47	0.41	Life satisfaction;	chr1:173878871	chr4:187970273~187971284:+
HNSC	trans	rs1563304	1	rs1563304	ENSG00000263503.1	RP11-707O23.5	9.76	1.35e-20	5.45e-14	0.63	0.41	Neuroticism;	chr17:46797087	chr17:45600869~45602340:-
HNSC	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	9.76	1.36e-20	5.47e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
HNSC	trans	rs12709013	0.935	rs8046667	ENSG00000230849.2	GOT2P2	9.76	1.36e-20	5.47e-14	0.51	0.41	Blood metabolite ratios;	chr16:58790935	chr1:173141100~173142350:-
HNSC	trans	rs12709013	1	rs8046998	ENSG00000230849.2	GOT2P2	9.76	1.36e-20	5.47e-14	0.51	0.41	Blood metabolite ratios;	chr16:58791109	chr1:173141100~173142350:-
HNSC	trans	rs13190036	1	rs59737888	ENSG00000226986.4	RP11-543B16.2	-9.75	1.42e-20	5.7e-14	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr1:211207239~211207897:+
HNSC	trans	rs3740713	1	rs78549183	ENSG00000235847.2	LDHAP7	9.75	1.42e-20	5.71e-14	0.71	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr2:84777259~84778223:-
HNSC	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	9.75	1.44e-20	5.81e-14	0.47	0.41	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
HNSC	trans	rs13190036	1	rs7714695	ENSG00000226986.4	RP11-543B16.2	-9.75	1.47e-20	5.9e-14	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr1:211207239~211207897:+
HNSC	trans	rs2456568	0.778	rs2456563	ENSG00000276509.1	CH17-353B19.1	9.75	1.47e-20	5.93e-14	0.45	0.41	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93945509	chr1:146235806~146237807:+
HNSC	trans	rs7121616	0.576	rs4802	ENSG00000229091.2	HSPA8P8	9.74	1.51e-20	6.05e-14	0.48	0.41	Breast cancer;	chr11:123057914	chr7:10451311~10452526:+
HNSC	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	9.74	1.55e-20	6.23e-14	0.53	0.41	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
HNSC	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	9.74	1.57e-20	6.31e-14	0.66	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
HNSC	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-9.74	1.61e-20	6.45e-14	-0.54	-0.41	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
HNSC	trans	rs74781061	0.929	rs8025976	ENSG00000227288.3	RP5-837I24.1	9.74	1.63e-20	6.54e-14	0.63	0.41	Endometriosis;	chr15:74577697	chr1:81501794~81503468:+
HNSC	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	9.73	1.67e-20	6.71e-14	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
HNSC	trans	rs55665837	0.539	rs10766196	ENSG00000236360.2	RP11-334A14.2	9.73	1.7e-20	6.81e-14	0.57	0.41	Vitamin D levels;	chr11:14891585	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.539	rs12794714	ENSG00000236360.2	RP11-334A14.2	9.73	1.7e-20	6.81e-14	0.57	0.41	Vitamin D levels;	chr11:14892029	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	9.73	1.72e-20	6.88e-14	0.54	0.41	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
HNSC	trans	rs3740713	1	rs12289603	ENSG00000235847.2	LDHAP7	9.73	1.72e-20	6.91e-14	0.71	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr2:84777259~84778223:-
HNSC	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	9.73	1.74e-20	6.97e-14	0.7	0.41	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
HNSC	trans	rs1039766	0.706	rs72822420	ENSG00000224334.1	AP000357.4	-9.72	1.85e-20	7.39e-14	-0.8	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr22:24686923~24688087:+
HNSC	trans	rs77688320	0.517	rs12991600	ENSG00000235105.1	RP11-329A14.1	9.72	1.87e-20	7.5e-14	0.51	0.41	Breast cancer;	chr2:201472513	chr1:48435967~48437223:+
HNSC	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-9.72	1.88e-20	7.51e-14	-0.68	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
HNSC	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-9.72	1.88e-20	7.51e-14	-0.68	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
HNSC	trans	rs13190036	1	rs351862	ENSG00000226986.4	RP11-543B16.2	-9.71	1.96e-20	7.84e-14	-0.67	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr1:211207239~211207897:+
HNSC	trans	rs9425766	0.886	rs9661233	ENSG00000213331.4	RP11-713C19.2	9.71	1.97e-20	7.88e-14	0.47	0.41	Life satisfaction;	chr1:173874913	chr4:187970273~187971284:+
HNSC	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	9.71	1.98e-20	7.94e-14	0.6	0.41	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
HNSC	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-9.71	2.04e-20	8.17e-14	-0.52	-0.41	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
HNSC	trans	rs7121616	1	rs79401687	ENSG00000234176.1	HSPA8P1	9.71	2.06e-20	8.23e-14	0.56	0.41	Breast cancer;	chr11:123096264	chrX:121203182~121205014:-
HNSC	trans	rs1039766	1	rs12104748	ENSG00000224334.1	AP000357.4	-9.71	2.08e-20	8.31e-14	-0.69	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr22:24686923~24688087:+
HNSC	trans	rs9425766	0.924	rs9286895	ENSG00000213331.4	RP11-713C19.2	9.7	2.13e-20	8.53e-14	0.47	0.41	Life satisfaction;	chr1:173873329	chr4:187970273~187971284:+
HNSC	trans	rs1039766	1	rs268864	ENSG00000224334.1	AP000357.4	-9.7	2.15e-20	8.59e-14	-0.66	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr22:24686923~24688087:+
HNSC	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	9.7	2.15e-20	8.6e-14	0.5	0.41	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
HNSC	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-9.7	2.17e-20	8.65e-14	-0.63	-0.41	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
HNSC	trans	rs7121616	1	rs75228513	ENSG00000234176.1	HSPA8P1	9.7	2.18e-20	8.69e-14	0.56	0.41	Breast cancer;	chr11:123096160	chrX:121203182~121205014:-
HNSC	trans	rs10037055	0.853	rs9313749	ENSG00000217325.2	PRELID1P1	-9.7	2.25e-20	9e-14	-0.54	-0.41	Migraine without aura;	chr5:177170693	chr6:126643488~126644390:+
HNSC	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-9.69	2.31e-20	9.21e-14	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
HNSC	trans	rs13190036	1	rs13185316	ENSG00000228305.2	AC016734.2	-9.69	2.31e-20	9.21e-14	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr2:63622178~63622831:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-9.69	2.33e-20	9.29e-14	-0.44	-0.41	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
HNSC	trans	rs7554511	0.707	rs3767501	ENSG00000244144.1	RP11-757F18.3	9.69	2.36e-20	9.41e-14	0.53	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053951	chr3:112185480~112185998:-
HNSC	trans	rs7554511	0.707	rs10800755	ENSG00000244144.1	RP11-757F18.3	9.69	2.37e-20	9.44e-14	0.54	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054852	chr3:112185480~112185998:-
HNSC	trans	rs3740713	0.925	rs55727925	ENSG00000235847.2	LDHAP7	9.68	2.52e-20	1e-13	0.7	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:84777259~84778223:-
HNSC	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	9.68	2.52e-20	1.01e-13	0.47	0.41	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
HNSC	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-9.67	2.67e-20	1.07e-13	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
HNSC	trans	rs1079467	1	rs1079467	ENSG00000233426.3	EIF3FP3	-9.67	2.68e-20	1.07e-13	-0.62	-0.41	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7948164	chr2:58251440~58252525:+
HNSC	trans	rs7662987	1	rs6852848	ENSG00000233859.2	ADH5P4	-9.67	2.8e-20	1.11e-13	-0.65	-0.41	Smoking initiation;	chr4:99080781	chr6:65836930~65838039:-
HNSC	trans	rs74781061	0.929	rs12439113	ENSG00000227288.3	RP5-837I24.1	9.66	3.01e-20	1.2e-13	0.63	0.41	Endometriosis;	chr15:74563806	chr1:81501794~81503468:+
HNSC	trans	rs12709013	1	rs12709013	ENSG00000230849.2	GOT2P2	-9.65	3.15e-20	1.25e-13	-0.5	-0.41	Blood metabolite ratios;	chr16:58795886	chr1:173141100~173142350:-
HNSC	trans	rs7399018	1	rs7399018	ENSG00000223825.5	DAZAP2P1	-9.65	3.18e-20	1.27e-13	-0.53	-0.41	Cisplatin-induced ototoxicity;	chr12:51216581	chr2:202201384~202201886:-
HNSC	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-9.65	3.27e-20	1.3e-13	-0.54	-0.41	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
HNSC	trans	rs3740713	1	rs73440636	ENSG00000235847.2	LDHAP7	9.65	3.38e-20	1.34e-13	0.7	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr2:84777259~84778223:-
HNSC	trans	rs12709013	1	rs34319345	ENSG00000230849.2	GOT2P2	9.64	3.45e-20	1.37e-13	0.51	0.41	Blood metabolite ratios;	chr16:58786688	chr1:173141100~173142350:-
HNSC	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-9.63	3.87e-20	1.53e-13	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
HNSC	trans	rs62344088	0.59	rs62345236	ENSG00000185986.11	SDHAP3	9.63	3.91e-20	1.55e-13	0.81	0.41	Asthma (childhood onset);	chr5:283404	chr5:1572222~1594620:-
HNSC	trans	rs1039766	1	rs1039766	ENSG00000224334.1	AP000357.4	-9.62	4.16e-20	1.65e-13	-0.68	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr22:24686923~24688087:+
HNSC	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	9.62	4.29e-20	1.7e-13	0.5	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
HNSC	trans	rs2456568	0.778	rs7940973	ENSG00000276509.1	CH17-353B19.1	-9.62	4.32e-20	1.71e-13	-0.44	-0.41	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93948879	chr1:146235806~146237807:+
HNSC	trans	rs10037055	0.853	rs10036193	ENSG00000217325.2	PRELID1P1	-9.61	4.6e-20	1.82e-13	-0.55	-0.41	Migraine without aura;	chr5:177141519	chr6:126643488~126644390:+
HNSC	trans	rs10037055	0.853	rs9885210	ENSG00000217325.2	PRELID1P1	-9.61	4.6e-20	1.82e-13	-0.55	-0.41	Migraine without aura;	chr5:177142187	chr6:126643488~126644390:+
HNSC	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	9.61	4.7e-20	1.86e-13	0.49	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
HNSC	trans	rs7121616	0.576	rs4936767	ENSG00000229091.2	HSPA8P8	9.6	4.72e-20	1.86e-13	0.48	0.41	Breast cancer;	chr11:123047451	chr7:10451311~10452526:+
HNSC	trans	rs7662987	1	rs1803037	ENSG00000233859.2	ADH5P4	9.6	4.76e-20	1.88e-13	0.62	0.41	Smoking initiation;	chr4:99072000	chr6:65836930~65838039:-
HNSC	trans	rs9425766	0.962	rs1322780	ENSG00000213331.4	RP11-713C19.2	9.6	4.94e-20	1.95e-13	0.47	0.41	Life satisfaction;	chr1:173896448	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.962	rs9425435	ENSG00000213331.4	RP11-713C19.2	9.6	4.94e-20	1.95e-13	0.47	0.41	Life satisfaction;	chr1:173896936	chr4:187970273~187971284:+
HNSC	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-9.6	5.06e-20	1.99e-13	-0.69	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
HNSC	trans	rs12709013	0.967	rs11643969	ENSG00000230849.2	GOT2P2	9.59	5.19e-20	2.04e-13	0.51	0.41	Blood metabolite ratios;	chr16:58785354	chr1:173141100~173142350:-
HNSC	trans	rs74781061	0.929	rs76160708	ENSG00000227288.3	RP5-837I24.1	9.59	5.26e-20	2.07e-13	0.62	0.41	Endometriosis;	chr15:74636901	chr1:81501794~81503468:+
HNSC	trans	rs74781061	0.929	rs79600165	ENSG00000227288.3	RP5-837I24.1	9.59	5.49e-20	2.16e-13	0.63	0.41	Endometriosis;	chr15:74648650	chr1:81501794~81503468:+
HNSC	trans	rs7662987	1	rs13125919	ENSG00000233859.2	ADH5P4	9.58	5.63e-20	2.21e-13	0.66	0.41	Smoking initiation;	chr4:99078697	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs7658127	ENSG00000233859.2	ADH5P4	9.58	5.85e-20	2.3e-13	0.66	0.41	Smoking initiation;	chr4:99073471	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs4699699	ENSG00000233859.2	ADH5P4	9.58	5.85e-20	2.3e-13	0.66	0.41	Smoking initiation;	chr4:99076028	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.938	rs13118409	ENSG00000233859.2	ADH5P4	9.58	5.85e-20	2.3e-13	0.66	0.41	Smoking initiation;	chr4:99077585	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs13145727	ENSG00000233859.2	ADH5P4	9.58	5.85e-20	2.3e-13	0.66	0.41	Smoking initiation;	chr4:99077715	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs13119035	ENSG00000233859.2	ADH5P4	9.58	5.85e-20	2.3e-13	0.66	0.41	Smoking initiation;	chr4:99077979	chr6:65836930~65838039:-
HNSC	trans	rs74781061	0.858	rs58473469	ENSG00000227288.3	RP5-837I24.1	9.58	5.85e-20	2.3e-13	0.63	0.41	Endometriosis;	chr15:74592722	chr1:81501794~81503468:+
HNSC	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-9.58	5.97e-20	2.34e-13	-0.51	-0.41	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-9.57	6.07e-20	2.38e-13	-0.44	-0.41	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
HNSC	trans	rs3740713	1	rs73440634	ENSG00000235847.2	LDHAP7	9.57	6.1e-20	2.39e-13	0.7	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr2:84777259~84778223:-
HNSC	trans	rs9611519	0.507	rs12484525	ENSG00000268568.1	AC007228.9	-9.57	6.18e-20	2.43e-13	-0.47	-0.4	Neuroticism;	chr22:41047873	chr19:56672574~56673901:-
HNSC	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	9.57	6.19e-20	2.43e-13	0.59	0.4	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
HNSC	trans	rs1039766	0.925	rs268850	ENSG00000224334.1	AP000357.4	9.56	6.75e-20	2.65e-13	0.69	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr22:24686923~24688087:+
HNSC	trans	rs1039766	1	rs268871	ENSG00000224334.1	AP000357.4	9.56	6.79e-20	2.66e-13	0.67	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr22:24686923~24688087:+
HNSC	trans	rs7121616	0.563	rs1461494	ENSG00000229091.2	HSPA8P8	9.56	6.95e-20	2.72e-13	0.48	0.4	Breast cancer;	chr11:123055777	chr7:10451311~10452526:+
HNSC	trans	rs7032940	0.651	rs7873398	ENSG00000228236.2	TXNP5	9.56	6.97e-20	2.73e-13	0.44	0.4	Height;	chr9:110194413	chr2:149068596~149068910:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-9.55	7.18e-20	2.81e-13	-0.44	-0.4	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-9.55	7.18e-20	2.81e-13	-0.44	-0.4	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
HNSC	trans	rs9611519	0.531	rs1967708	ENSG00000268568.1	AC007228.9	-9.55	7.2e-20	2.82e-13	-0.47	-0.4	Neuroticism;	chr22:41048440	chr19:56672574~56673901:-
HNSC	trans	rs7662987	1	rs7683802	ENSG00000233859.2	ADH5P4	9.55	7.27e-20	2.84e-13	0.65	0.4	Smoking initiation;	chr4:99073987	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.818	rs4699701	ENSG00000233859.2	ADH5P4	9.55	7.27e-20	2.84e-13	0.65	0.4	Smoking initiation;	chr4:99077296	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs13146416	ENSG00000233859.2	ADH5P4	9.55	7.27e-20	2.84e-13	0.65	0.4	Smoking initiation;	chr4:99078009	chr6:65836930~65838039:-
HNSC	trans	rs12709013	1	rs12599931	ENSG00000230849.2	GOT2P2	9.55	7.64e-20	2.98e-13	0.5	0.4	Blood metabolite ratios;	chr16:58792627	chr1:173141100~173142350:-
HNSC	trans	rs7554547	0.667	rs6666533	ENSG00000261819.1	RP11-680G24.4	9.54	8.01e-20	3.13e-13	0.57	0.4	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr16:14988259~14990160:-
HNSC	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-9.54	8.14e-20	3.18e-13	-0.55	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
HNSC	trans	rs11650106	0.529	rs35391268	ENSG00000187870.7	RNFT1P3	-9.53	8.36e-20	3.26e-13	-0.49	-0.4	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:20743333~20754501:-
HNSC	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	9.53	8.48e-20	3.3e-13	0.62	0.4	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
HNSC	trans	rs12709013	0.935	rs11648634	ENSG00000230849.2	GOT2P2	9.53	8.67e-20	3.38e-13	0.51	0.4	Blood metabolite ratios;	chr16:58785256	chr1:173141100~173142350:-
HNSC	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	9.53	8.86e-20	3.45e-13	0.52	0.4	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
HNSC	trans	rs13190036	1	rs7714695	ENSG00000228305.2	AC016734.2	-9.52	9.08e-20	3.53e-13	-0.68	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr2:63622178~63622831:-
HNSC	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-9.52	9.11e-20	3.54e-13	-0.5	-0.4	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
HNSC	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	9.52	9.12e-20	3.54e-13	0.54	0.4	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
HNSC	trans	rs3740713	1	rs73440637	ENSG00000235847.2	LDHAP7	9.52	9.36e-20	3.64e-13	0.74	0.4	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr2:84777259~84778223:-
HNSC	trans	rs7200543	0.89	rs4985155	ENSG00000250569.1	NTAN1P2	9.52	9.42e-20	3.66e-13	0.48	0.4	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15035602	chr8:86481754~86483002:-
HNSC	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	9.52	9.66e-20	3.75e-13	0.5	0.4	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
HNSC	trans	rs13190036	0.901	rs55741473	ENSG00000228305.2	AC016734.2	-9.51	1.01e-19	3.93e-13	-0.67	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr2:63622178~63622831:-
HNSC	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	9.51	1.02e-19	3.97e-13	0.52	0.4	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.935	rs34657766	ENSG00000230849.2	GOT2P2	9.5	1.06e-19	4.12e-13	0.5	0.4	Blood metabolite ratios;	chr16:58779468	chr1:173141100~173142350:-
HNSC	trans	rs7121616	0.562	rs2061602	ENSG00000229091.2	HSPA8P8	9.5	1.08e-19	4.2e-13	0.48	0.4	Breast cancer;	chr11:123065079	chr7:10451311~10452526:+
HNSC	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-9.49	1.15e-19	4.45e-13	-0.54	-0.4	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
HNSC	trans	rs9611519	0.589	rs8138917	ENSG00000268568.1	AC007228.9	-9.49	1.16e-19	4.49e-13	-0.47	-0.4	Neuroticism;	chr22:41016421	chr19:56672574~56673901:-
HNSC	trans	rs3779195	0.591	rs77968419	ENSG00000225169.1	BRI3P1	-9.49	1.19e-19	4.61e-13	-0.63	-0.4	Sex hormone-binding globulin levels;	chr7:98237168	chr1:100213293~100213670:+
HNSC	trans	rs7662987	1	rs28730587	ENSG00000233859.2	ADH5P4	9.49	1.21e-19	4.67e-13	0.67	0.4	Smoking initiation;	chr4:99083190	chr6:65836930~65838039:-
HNSC	trans	rs12709013	0.804	rs8051459	ENSG00000233719.3	GOT2P3	9.49	1.21e-19	4.68e-13	0.49	0.4	Blood metabolite ratios;	chr16:58783436	chr12:9641802~9643007:+
HNSC	trans	rs74781061	0.929	rs2068982	ENSG00000227288.3	RP5-837I24.1	-9.48	1.27e-19	4.9e-13	-0.61	-0.4	Endometriosis;	chr15:74623547	chr1:81501794~81503468:+
HNSC	trans	rs7554511	0.8	rs296539	ENSG00000244144.1	RP11-757F18.3	9.48	1.28e-19	4.93e-13	0.49	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200918529	chr3:112185480~112185998:-
HNSC	trans	rs7554511	0.655	rs3767502	ENSG00000244144.1	RP11-757F18.3	9.48	1.28e-19	4.95e-13	0.53	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053970	chr3:112185480~112185998:-
HNSC	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	9.48	1.3e-19	5.01e-13	0.52	0.4	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
HNSC	trans	rs7662987	1	rs28730595	ENSG00000233859.2	ADH5P4	9.48	1.3e-19	5.04e-13	0.67	0.4	Smoking initiation;	chr4:99082182	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.938	rs28730592	ENSG00000233859.2	ADH5P4	9.48	1.3e-19	5.04e-13	0.67	0.4	Smoking initiation;	chr4:99082592	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs28730591	ENSG00000233859.2	ADH5P4	9.48	1.3e-19	5.04e-13	0.67	0.4	Smoking initiation;	chr4:99082596	chr6:65836930~65838039:-
HNSC	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-9.47	1.35e-19	5.22e-13	-0.54	-0.4	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
HNSC	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-9.47	1.36e-19	5.25e-13	-0.54	-0.4	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
HNSC	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-9.47	1.37e-19	5.28e-13	-0.67	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
HNSC	trans	rs116095464	1	rs55671190	ENSG00000185986.11	SDHAP3	9.47	1.37e-19	5.29e-13	0.8	0.4	Breast cancer;	chr5:287307	chr5:1572222~1594620:-
HNSC	trans	rs7554511	0.643	rs1507147	ENSG00000244144.1	RP11-757F18.3	-9.47	1.42e-19	5.48e-13	-0.51	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042696	chr3:112185480~112185998:-
HNSC	trans	rs12709013	0.729	rs71400031	ENSG00000230849.2	GOT2P2	9.46	1.46e-19	5.63e-13	0.5	0.4	Blood metabolite ratios;	chr16:58779554	chr1:173141100~173142350:-
HNSC	trans	rs10037055	0.853	rs1363405	ENSG00000217325.2	PRELID1P1	9.46	1.52e-19	5.86e-13	0.51	0.4	Migraine without aura;	chr5:177209881	chr6:126643488~126644390:+
HNSC	trans	rs7121616	0.562	rs7131452	ENSG00000229091.2	HSPA8P8	9.45	1.58e-19	6.07e-13	0.47	0.4	Breast cancer;	chr11:123065314	chr7:10451311~10452526:+
HNSC	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	9.45	1.61e-19	6.2e-13	0.52	0.4	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	9.45	1.61e-19	6.2e-13	0.52	0.4	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	9.45	1.62e-19	6.25e-13	0.51	0.4	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
HNSC	trans	rs9611519	0.542	rs8139770	ENSG00000268568.1	AC007228.9	-9.45	1.63e-19	6.26e-13	-0.46	-0.4	Neuroticism;	chr22:41020177	chr19:56672574~56673901:-
HNSC	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	9.45	1.69e-19	6.51e-13	0.5	0.4	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
HNSC	trans	rs1039766	1	rs268882	ENSG00000224334.1	AP000357.4	-9.44	1.74e-19	6.69e-13	-0.65	-0.4	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr22:24686923~24688087:+
HNSC	trans	rs7200543	0.884	rs72789542	ENSG00000250569.1	NTAN1P2	9.44	1.76e-19	6.77e-13	0.51	0.4	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15033678	chr8:86481754~86483002:-
HNSC	trans	rs7662987	1	rs7662987	ENSG00000233859.2	ADH5P4	9.44	1.81e-19	6.93e-13	0.65	0.4	Smoking initiation;	chr4:99070491	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs7684986	ENSG00000233859.2	ADH5P4	9.44	1.81e-19	6.93e-13	0.65	0.4	Smoking initiation;	chr4:99070525	chr6:65836930~65838039:-
HNSC	trans	rs7662987	1	rs1061187	ENSG00000233859.2	ADH5P4	9.44	1.81e-19	6.93e-13	0.65	0.4	Smoking initiation;	chr4:99071702	chr6:65836930~65838039:-
HNSC	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-9.44	1.83e-19	7e-13	-0.54	-0.4	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
HNSC	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	9.44	1.83e-19	7.04e-13	0.52	0.4	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
HNSC	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-9.43	1.87e-19	7.16e-13	-0.52	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
HNSC	trans	rs13190036	1	rs59737888	ENSG00000228305.2	AC016734.2	-9.43	1.89e-19	7.23e-13	-0.68	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr2:63622178~63622831:-
HNSC	trans	rs7032940	0.651	rs7873398	ENSG00000262519.1	TXNP4	9.43	1.93e-19	7.41e-13	0.49	0.4	Height;	chr9:110194413	chr17:4572206~4572515:+
HNSC	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	9.43	1.95e-19	7.46e-13	0.46	0.4	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
HNSC	trans	rs8010715	0.636	rs2277482	ENSG00000238000.1	RP11-274E7.2	9.43	1.95e-19	7.48e-13	0.4	0.4	IgG glycosylation;	chr14:24118586	chr5:98213402~98214121:+
HNSC	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-9.42	2.14e-19	8.21e-13	-0.67	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
HNSC	trans	rs1039766	1	rs7558347	ENSG00000224334.1	AP000357.4	9.41	2.18e-19	8.34e-13	0.68	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr22:24686923~24688087:+
HNSC	trans	rs10037055	0.812	rs11949435	ENSG00000217325.2	PRELID1P1	9.41	2.23e-19	8.51e-13	0.53	0.4	Migraine without aura;	chr5:177287931	chr6:126643488~126644390:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	9.41	2.31e-19	8.81e-13	0.41	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
HNSC	trans	rs7554511	0.8	rs296547	ENSG00000244144.1	RP11-757F18.3	9.4	2.36e-19	9.02e-13	0.49	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923009	chr3:112185480~112185998:-
HNSC	trans	rs7554511	0.8	rs370411	ENSG00000244144.1	RP11-757F18.3	9.4	2.36e-19	9.02e-13	0.49	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923135	chr3:112185480~112185998:-
HNSC	trans	rs9611519	0.579	rs8136274	ENSG00000268568.1	AC007228.9	-9.4	2.38e-19	9.08e-13	-0.46	-0.4	Neuroticism;	chr22:41019307	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.59	rs4821980	ENSG00000268568.1	AC007228.9	-9.4	2.38e-19	9.08e-13	-0.46	-0.4	Neuroticism;	chr22:41019475	chr19:56672574~56673901:-
HNSC	trans	rs1039766	1	rs72822431	ENSG00000224334.1	AP000357.4	-9.4	2.44e-19	9.3e-13	-0.67	-0.4	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr22:24686923~24688087:+
HNSC	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-9.39	2.68e-19	1.02e-12	-0.51	-0.4	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
HNSC	trans	rs1039766	0.866	rs2160263	ENSG00000224334.1	AP000357.4	9.39	2.68e-19	1.02e-12	0.68	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65282104	chr22:24686923~24688087:+
HNSC	trans	rs7554547	0.622	rs28455075	ENSG00000261819.1	RP11-680G24.4	9.38	2.82e-19	1.07e-12	0.55	0.4	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr16:14988259~14990160:-
HNSC	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	9.37	3.03e-19	1.15e-12	0.51	0.4	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
HNSC	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-9.37	3.09e-19	1.17e-12	-0.67	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
HNSC	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-9.37	3.09e-19	1.17e-12	-0.67	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	9.37	3.21e-19	1.22e-12	0.44	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
HNSC	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	9.36	3.28e-19	1.24e-12	0.51	0.4	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
HNSC	trans	rs1039766	1	rs268853	ENSG00000224334.1	AP000357.4	9.36	3.31e-19	1.26e-12	0.67	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr22:24686923~24688087:+
HNSC	trans	rs7662987	1	rs17595424	ENSG00000233859.2	ADH5P4	9.36	3.34e-19	1.27e-12	0.63	0.4	Smoking initiation;	chr4:99072718	chr6:65836930~65838039:-
HNSC	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	9.36	3.42e-19	1.29e-12	0.53	0.4	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
HNSC	trans	rs10037055	0.853	rs4976681	ENSG00000217325.2	PRELID1P1	9.36	3.45e-19	1.31e-12	0.52	0.4	Migraine without aura;	chr5:177277662	chr6:126643488~126644390:+
HNSC	trans	rs12709013	1	rs11641836	ENSG00000230849.2	GOT2P2	9.36	3.49e-19	1.32e-12	0.49	0.4	Blood metabolite ratios;	chr16:58798143	chr1:173141100~173142350:-
HNSC	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	9.35	3.56e-19	1.35e-12	0.54	0.4	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.967	rs62064905	ENSG00000230849.2	GOT2P2	9.35	3.66e-19	1.38e-12	0.5	0.4	Blood metabolite ratios;	chr16:58778839	chr1:173141100~173142350:-
HNSC	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	9.34	3.95e-19	1.49e-12	0.53	0.4	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
HNSC	trans	rs10037055	0.853	rs4976680	ENSG00000217325.2	PRELID1P1	9.33	4.13e-19	1.56e-12	0.52	0.4	Migraine without aura;	chr5:177275745	chr6:126643488~126644390:+
HNSC	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-9.33	4.14e-19	1.56e-12	-0.51	-0.4	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	9.33	4.25e-19	1.61e-12	0.47	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	9.33	4.25e-19	1.61e-12	0.47	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
HNSC	trans	rs8010715	0.636	rs2277480	ENSG00000238000.1	RP11-274E7.2	9.33	4.41e-19	1.66e-12	0.4	0.4	IgG glycosylation;	chr14:24118306	chr5:98213402~98214121:+
HNSC	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	9.32	4.56e-19	1.72e-12	0.54	0.4	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
HNSC	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-9.32	4.58e-19	1.73e-12	-0.51	-0.4	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
HNSC	trans	rs2456568	0.778	rs7944194	ENSG00000276509.1	CH17-353B19.1	-9.32	4.72e-19	1.78e-12	-0.42	-0.4	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93949247	chr1:146235806~146237807:+
HNSC	trans	rs9611519	0.58	rs8138349	ENSG00000268568.1	AC007228.9	-9.31	4.95e-19	1.86e-12	-0.46	-0.4	Neuroticism;	chr22:41016719	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.602	rs8138520	ENSG00000268568.1	AC007228.9	-9.31	4.95e-19	1.86e-12	-0.46	-0.4	Neuroticism;	chr22:41016924	chr19:56672574~56673901:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-9.31	5.1e-19	1.92e-12	-0.42	-0.4	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-9.31	5.1e-19	1.92e-12	-0.42	-0.4	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
HNSC	trans	rs7662987	0.938	rs28730605	ENSG00000233859.2	ADH5P4	9.3	5.35e-19	2.01e-12	0.65	0.4	Smoking initiation;	chr4:99080389	chr6:65836930~65838039:-
HNSC	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-9.3	5.43e-19	2.04e-12	-0.56	-0.4	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-9.3	5.47e-19	2.05e-12	-0.63	-0.4	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
HNSC	trans	rs5022636	0.507	rs2800953	ENSG00000180764.13	PIPSL	-9.3	5.48e-19	2.06e-12	-0.55	-0.4	Gut microbiota (functional units);	chr1:151366094	chr10:93958191~93961540:-
HNSC	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-9.3	5.52e-19	2.07e-12	-0.53	-0.4	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
HNSC	trans	rs12709013	0.967	rs2118019	ENSG00000230849.2	GOT2P2	-9.29	5.87e-19	2.2e-12	-0.49	-0.39	Blood metabolite ratios;	chr16:58797825	chr1:173141100~173142350:-
HNSC	trans	rs7503168	1	rs10512472	ENSG00000234130.2	RP13-88F20.1	9.29	5.87e-19	2.2e-12	0.53	0.39	Plateletcrit;	chr17:35557785	chrX:93222220~93225015:-
HNSC	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	9.28	6.5e-19	2.43e-12	0.59	0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	9.27	6.91e-19	2.58e-12	0.48	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
HNSC	trans	rs9611519	0.603	rs9607764	ENSG00000268568.1	AC007228.9	-9.27	6.95e-19	2.6e-12	-0.45	-0.39	Neuroticism;	chr22:41015800	chr19:56672574~56673901:-
HNSC	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	9.27	7.09e-19	2.65e-12	0.52	0.39	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	9.27	7.09e-19	2.65e-12	0.52	0.39	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-9.26	7.32e-19	2.73e-12	-0.41	-0.39	Longevity;	chr3:48431794	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-9.26	7.32e-19	2.73e-12	-0.41	-0.39	Longevity;	chr3:48437629	chr1:27649419~27649610:+
HNSC	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	9.26	7.4e-19	2.76e-12	0.51	0.39	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
HNSC	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-9.25	7.84e-19	2.92e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-9.25	7.84e-19	2.92e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	9.25	7.86e-19	2.93e-12	0.42	0.39	Longevity;	chr3:48407507	chr1:27649419~27649610:+
HNSC	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-9.25	7.95e-19	2.96e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-9.25	7.95e-19	2.96e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-9.25	7.95e-19	2.96e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-9.25	7.95e-19	2.96e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-9.25	7.95e-19	2.96e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
HNSC	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-9.25	7.97e-19	2.97e-12	-0.56	-0.39	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.524	rs76976120	ENSG00000225169.1	BRI3P1	-9.25	7.97e-19	2.97e-12	-0.64	-0.39	Sex hormone-binding globulin levels;	chr7:98264860	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.585	rs73709460	ENSG00000225169.1	BRI3P1	-9.25	7.97e-19	2.97e-12	-0.64	-0.39	Sex hormone-binding globulin levels;	chr7:98265942	chr1:100213293~100213670:+
HNSC	trans	rs3779195	0.585	rs56694862	ENSG00000225169.1	BRI3P1	-9.25	7.97e-19	2.97e-12	-0.64	-0.39	Sex hormone-binding globulin levels;	chr7:98267808	chr1:100213293~100213670:+
HNSC	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	9.25	8.17e-19	3.04e-12	0.47	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
HNSC	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	9.25	8.19e-19	3.05e-12	0.53	0.39	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
HNSC	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	9.25	8.29e-19	3.09e-12	0.64	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
HNSC	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-9.24	8.44e-19	3.14e-12	-0.41	-0.39	Longevity;	chr3:48421052	chr1:27649419~27649610:+
HNSC	trans	rs116095464	0.718	rs62331563	ENSG00000185986.11	SDHAP3	9.24	8.52e-19	3.17e-12	0.85	0.39	Breast cancer;	chr5:355171	chr5:1572222~1594620:-
HNSC	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-9.24	8.58e-19	3.19e-12	-0.41	-0.39	Longevity;	chr3:48422302	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-9.24	8.58e-19	3.19e-12	-0.41	-0.39	Longevity;	chr3:48429347	chr1:27649419~27649610:+
HNSC	trans	rs7121616	0.576	rs11218967	ENSG00000229091.2	HSPA8P8	9.24	8.59e-19	3.19e-12	0.47	0.39	Breast cancer;	chr11:123087551	chr7:10451311~10452526:+
HNSC	trans	rs7554511	0.707	rs3767498	ENSG00000244144.1	RP11-757F18.3	-9.24	8.61e-19	3.2e-12	-0.51	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051599	chr3:112185480~112185998:-
HNSC	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	9.24	8.65e-19	3.21e-12	0.51	0.39	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	9.24	8.65e-19	3.21e-12	0.51	0.39	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
HNSC	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	9.24	8.8e-19	3.27e-12	0.53	0.39	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	9.24	8.8e-19	3.27e-12	0.53	0.39	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
HNSC	trans	rs10037055	0.853	rs12660023	ENSG00000217325.2	PRELID1P1	9.24	8.8e-19	3.27e-12	0.51	0.39	Migraine without aura;	chr5:177273884	chr6:126643488~126644390:+
HNSC	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	9.24	8.97e-19	3.33e-12	0.51	0.39	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	9.23	9.32e-19	3.46e-12	0.52	0.39	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	9.23	9.45e-19	3.48e-12	0.52	0.39	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
HNSC	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-9.23	9.47e-19	3.49e-12	-0.56	-0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
HNSC	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	9.23	9.8e-19	3.61e-12	0.52	0.39	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	9.22	1.02e-18	3.75e-12	0.53	0.39	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-9.22	1.02e-18	3.75e-12	-0.53	-0.39	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	9.22	1.02e-18	3.76e-12	0.52	0.39	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	9.22	1.03e-18	3.8e-12	0.52	0.39	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
HNSC	trans	rs3779195	0.585	rs7777991	ENSG00000225169.1	BRI3P1	-9.22	1.06e-18	3.9e-12	-0.63	-0.39	Sex hormone-binding globulin levels;	chr7:98236445	chr1:100213293~100213670:+
HNSC	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	9.21	1.07e-18	3.92e-12	0.52	0.39	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	9.21	1.07e-18	3.92e-12	0.52	0.39	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	9.21	1.07e-18	3.92e-12	0.52	0.39	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
HNSC	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	9.21	1.12e-18	4.09e-12	0.47	0.39	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
HNSC	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	9.21	1.15e-18	4.2e-12	0.53	0.39	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
HNSC	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	9.2	1.18e-18	4.31e-12	0.61	0.39	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
HNSC	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	9.2	1.2e-18	4.4e-12	0.51	0.39	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
HNSC	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-9.2	1.22e-18	4.47e-12	-0.57	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
HNSC	trans	rs13190036	1	rs13175695	ENSG00000228305.2	AC016734.2	9.2	1.23e-18	4.49e-12	0.59	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr2:63622178~63622831:-
HNSC	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-9.2	1.24e-18	4.55e-12	-0.42	-0.39	Longevity;	chr3:48393284	chr1:27649419~27649610:+
HNSC	trans	rs9581094	0.505	rs6490945	ENSG00000237917.1	PARP4P1	9.19	1.26e-18	4.61e-12	0.5	0.39	Sudden cardiac arrest;	chr13:24514056	chrY:26594851~26634652:-
HNSC	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	9.19	1.28e-18	4.69e-12	0.52	0.39	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	9.19	1.28e-18	4.69e-12	0.52	0.39	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	9.19	1.29e-18	4.7e-12	0.52	0.39	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	9.19	1.34e-18	4.91e-12	0.52	0.39	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
HNSC	trans	rs8010715	0.636	rs3825584	ENSG00000238000.1	RP11-274E7.2	9.18	1.36e-18	4.97e-12	0.39	0.39	IgG glycosylation;	chr14:24118430	chr5:98213402~98214121:+
HNSC	trans	rs7554511	0.643	rs1546416	ENSG00000244144.1	RP11-757F18.3	-9.18	1.39e-18	5.07e-12	-0.5	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201040428	chr3:112185480~112185998:-
HNSC	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-9.18	1.4e-18	5.11e-12	-0.56	-0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
HNSC	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	9.18	1.4e-18	5.11e-12	0.52	0.39	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	9.18	1.41e-18	5.13e-12	0.53	0.39	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	9.18	1.43e-18	5.23e-12	0.47	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	9.18	1.45e-18	5.27e-12	0.42	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
HNSC	trans	rs12709013	1	rs12926993	ENSG00000230849.2	GOT2P2	9.18	1.45e-18	5.27e-12	0.48	0.39	Blood metabolite ratios;	chr16:58789218	chr1:173141100~173142350:-
HNSC	trans	rs7937890	1	rs2915401	ENSG00000236360.2	RP11-334A14.2	-9.16	1.58e-18	5.75e-12	-0.52	-0.39	Mitochondrial DNA levels;	chr11:14353467	chr1:52993201~52993702:-
HNSC	trans	rs7554511	0.707	rs3861928	ENSG00000244144.1	RP11-757F18.3	-9.16	1.65e-18	5.98e-12	-0.52	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051446	chr3:112185480~112185998:-
HNSC	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-9.16	1.67e-18	6.07e-12	-0.5	-0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
HNSC	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-9.15	1.71e-18	6.21e-12	-0.51	-0.39	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-9.15	1.72e-18	6.23e-12	-0.5	-0.39	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	9.15	1.74e-18	6.3e-12	0.41	0.39	Longevity;	chr3:48376724	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	9.15	1.75e-18	6.33e-12	0.52	0.39	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-9.15	1.8e-18	6.54e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	9.15	1.82e-18	6.59e-12	0.52	0.39	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	9.15	1.82e-18	6.59e-12	0.52	0.39	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-9.15	1.82e-18	6.6e-12	-0.42	-0.39	Longevity;	chr3:48393659	chr1:27649419~27649610:+
HNSC	trans	rs9630182	0.641	rs730414	ENSG00000257675.1	RP11-641A6.9	-9.15	1.84e-18	6.65e-12	-0.47	-0.39	Bone mineral density;	chr11:13437307	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.683	rs730413	ENSG00000257675.1	RP11-641A6.9	-9.15	1.84e-18	6.65e-12	-0.47	-0.39	Bone mineral density;	chr11:13437447	chr12:52748776~52750127:+
HNSC	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-9.15	1.84e-18	6.65e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-9.15	1.84e-18	6.65e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-9.15	1.84e-18	6.65e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-9.15	1.84e-18	6.65e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-9.14	1.89e-18	6.83e-12	-0.56	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	9.13	2.13e-18	7.69e-12	0.52	0.39	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	9.13	2.15e-18	7.76e-12	0.52	0.39	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	9.13	2.15e-18	7.76e-12	0.52	0.39	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-9.12	2.2e-18	7.92e-12	-0.41	-0.39	Longevity;	chr3:48414217	chr1:27649419~27649610:+
HNSC	trans	rs10908521	0.685	rs7534418	ENSG00000227183.3	HDGFP1	-9.12	2.2e-18	7.94e-12	-0.52	-0.39	Uric acid clearance;	chr1:156836011	chrX:131646639~131646890:+
HNSC	trans	rs7554511	0.5	rs296548	ENSG00000244144.1	RP11-757F18.3	9.12	2.24e-18	8.06e-12	0.48	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923715	chr3:112185480~112185998:-
HNSC	trans	rs1816752	0.669	rs7984513	ENSG00000224976.2	PARP4P2	9.12	2.29e-18	8.22e-12	0.45	0.39	Obesity-related traits;	chr13:24445117	chr13:19349137~19407962:+
HNSC	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	9.12	2.3e-18	8.28e-12	0.63	0.39	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
HNSC	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	9.12	2.31e-18	8.31e-12	0.5	0.39	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
HNSC	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-9.11	2.5e-18	8.98e-12	-0.41	-0.39	Longevity;	chr3:48438208	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	9.1	2.55e-18	9.13e-12	0.52	0.39	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	9.1	2.55e-18	9.13e-12	0.52	0.39	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	9.1	2.55e-18	9.13e-12	0.52	0.39	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
HNSC	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	9.1	2.65e-18	9.48e-12	0.52	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	9.1	2.66e-18	9.5e-12	0.52	0.39	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	9.1	2.66e-18	9.5e-12	0.52	0.39	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
HNSC	trans	rs867371	0.82	rs7164362	ENSG00000235370.6	DNM1P51	-9.1	2.66e-18	9.52e-12	-0.5	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:84398316~84411701:-
HNSC	trans	rs12709013	0.967	rs56107162	ENSG00000230849.2	GOT2P2	9.1	2.73e-18	9.75e-12	0.48	0.39	Blood metabolite ratios;	chr16:58804358	chr1:173141100~173142350:-
HNSC	trans	rs9876781	1	rs7636782	ENSG00000235912.1	RP1-159A19.3	-9.09	2.8e-18	1e-11	-0.41	-0.39	Longevity;	chr3:48379897	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-9.09	2.81e-18	1e-11	-0.41	-0.39	Longevity;	chr3:48442021	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-9.09	2.81e-18	1e-11	-0.41	-0.39	Longevity;	chr3:48442035	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-9.09	2.81e-18	1e-11	-0.41	-0.39	Longevity;	chr3:48443151	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-9.09	2.81e-18	1e-11	-0.41	-0.39	Longevity;	chr3:48443275	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	9.09	2.81e-18	1e-11	0.52	0.39	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	1.02e-11	0.52	0.39	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-9.09	2.86e-18	1.02e-11	-0.41	-0.39	Longevity;	chr3:48419904	chr1:27649419~27649610:+
HNSC	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-9.09	2.87e-18	1.02e-11	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
HNSC	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-9.09	2.87e-18	1.02e-11	-0.55	-0.39	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-9.09	2.87e-18	1.02e-11	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-9.09	2.88e-18	1.03e-11	-0.41	-0.39	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
HNSC	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	9.08	2.96e-18	1.05e-11	0.52	0.39	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	9.08	3.03e-18	1.08e-11	0.52	0.39	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	9.08	3.08e-18	1.1e-11	0.55	0.39	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-9.07	3.22e-18	1.15e-11	-0.41	-0.39	Longevity;	chr3:48436629	chr1:27649419~27649610:+
HNSC	trans	rs9611519	0.566	rs4821981	ENSG00000268568.1	AC007228.9	9.07	3.23e-18	1.15e-11	0.45	0.39	Neuroticism;	chr22:41019640	chr19:56672574~56673901:-
HNSC	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	9.07	3.24e-18	1.15e-11	0.51	0.39	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	9.06	3.56e-18	1.27e-11	0.51	0.39	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-9.06	3.63e-18	1.29e-11	-0.44	-0.39	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
HNSC	trans	rs1079467	0.735	rs75941265	ENSG00000233426.3	EIF3FP3	-9.06	3.64e-18	1.3e-11	-0.67	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949542	chr2:58251440~58252525:+
HNSC	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	9.06	3.68e-18	1.31e-11	0.49	0.39	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
HNSC	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	9.05	3.79e-18	1.35e-11	0.51	0.39	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-9.05	3.81e-18	1.36e-11	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
HNSC	trans	rs7503168	1	rs7503168	ENSG00000234130.2	RP13-88F20.1	9.05	3.91e-18	1.39e-11	0.52	0.39	Plateletcrit;	chr17:35558885	chrX:93222220~93225015:-
HNSC	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-9.05	3.94e-18	1.4e-11	-0.49	-0.39	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
HNSC	trans	rs867371	0.826	rs2047678	ENSG00000235370.6	DNM1P51	-9.04	4.22e-18	1.5e-11	-0.49	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:84398316~84411701:-
HNSC	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	9.03	4.38e-18	1.55e-11	0.5	0.39	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
HNSC	trans	rs7503168	1	rs9894057	ENSG00000234130.2	RP13-88F20.1	9.03	4.46e-18	1.58e-11	0.52	0.39	Plateletcrit;	chr17:35562904	chrX:93222220~93225015:-
HNSC	trans	rs9630182	0.693	rs988617	ENSG00000257675.1	RP11-641A6.9	-9.03	4.51e-18	1.6e-11	-0.46	-0.39	Bone mineral density;	chr11:13449458	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	9.03	4.54e-18	1.61e-11	0.51	0.39	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-9.02	4.71e-18	1.67e-11	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	9.02	4.89e-18	1.73e-11	0.51	0.39	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
HNSC	trans	rs1079467	0.73	rs74933956	ENSG00000233426.3	EIF3FP3	-9.02	4.94e-18	1.75e-11	-0.67	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950507	chr2:58251440~58252525:+
HNSC	trans	rs1079467	0.73	rs77880011	ENSG00000233426.3	EIF3FP3	-9.02	4.94e-18	1.75e-11	-0.67	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950656	chr2:58251440~58252525:+
HNSC	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-9.01	5.22e-18	1.85e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.875	rs9924389	ENSG00000233719.3	GOT2P3	9.01	5.27e-18	1.86e-11	0.47	0.38	Blood metabolite ratios;	chr16:58779849	chr12:9641802~9643007:+
HNSC	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-9.01	5.38e-18	1.9e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-9.01	5.38e-18	1.9e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-9.01	5.42e-18	1.92e-11	-0.56	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-9.01	5.44e-18	1.92e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
HNSC	trans	rs12709013	1	rs6499983	ENSG00000230849.2	GOT2P2	9.01	5.44e-18	1.92e-11	0.48	0.38	Blood metabolite ratios;	chr16:58810005	chr1:173141100~173142350:-
HNSC	trans	rs12709013	0.967	rs8054482	ENSG00000230849.2	GOT2P2	9.01	5.44e-18	1.92e-11	0.48	0.38	Blood metabolite ratios;	chr16:58810532	chr1:173141100~173142350:-
HNSC	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-9.01	5.44e-18	1.92e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-9.01	5.44e-18	1.92e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-9.01	5.44e-18	1.92e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
HNSC	trans	rs867371	0.82	rs12443224	ENSG00000235370.6	DNM1P51	-9	5.52e-18	1.95e-11	-0.47	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:84398316~84411701:-
HNSC	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-9	5.52e-18	1.95e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-9	5.56e-18	1.96e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-9	5.56e-18	1.96e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-9	5.76e-18	2.03e-11	-0.5	-0.38	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-9	5.87e-18	2.07e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	9	5.92e-18	2.09e-11	0.51	0.38	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	9	5.93e-18	2.09e-11	0.51	0.38	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	8.99	6.06e-18	2.13e-11	0.51	0.38	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
HNSC	trans	rs13190036	0.792	rs6874206	ENSG00000228305.2	AC016734.2	-8.99	6.08e-18	2.14e-11	-0.57	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr2:63622178~63622831:-
HNSC	trans	rs13190036	0.901	rs10072499	ENSG00000228305.2	AC016734.2	-8.99	6.08e-18	2.14e-11	-0.57	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr2:63622178~63622831:-
HNSC	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	8.99	6.15e-18	2.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	8.99	6.15e-18	2.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-8.99	6.18e-18	2.17e-11	-0.41	-0.38	Longevity;	chr3:48378233	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	8.99	6.19e-18	2.18e-11	0.51	0.38	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	8.99	6.31e-18	2.22e-11	0.51	0.38	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
HNSC	trans	rs13190036	1	rs625882	ENSG00000226986.4	RP11-543B16.2	-8.99	6.41e-18	2.25e-11	-0.61	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr1:211207239~211207897:+
HNSC	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-8.98	6.52e-18	2.29e-11	-0.43	-0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
HNSC	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-8.98	6.63e-18	2.33e-11	-0.4	-0.38	Longevity;	chr3:48445934	chr1:27649419~27649610:+
HNSC	trans	rs74781061	0.929	rs9672559	ENSG00000227288.3	RP5-837I24.1	8.98	6.74e-18	2.36e-11	0.61	0.38	Endometriosis;	chr15:74698995	chr1:81501794~81503468:+
HNSC	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-8.97	7.02e-18	2.46e-11	-0.41	-0.38	Longevity;	chr3:48437797	chr1:27649419~27649610:+
HNSC	trans	rs7258465	1	rs4808804	ENSG00000267533.1	RP11-815J4.7	8.97	7.43e-18	2.6e-11	0.49	0.38	Breast cancer;	chr19:18474515	chr18:12067173~12068417:-
HNSC	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-8.97	7.44e-18	2.61e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-8.96	7.62e-18	2.67e-11	-0.52	-0.38	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-8.96	7.62e-18	2.67e-11	-0.52	-0.38	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-8.96	7.71e-18	2.7e-11	-0.51	-0.38	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-8.96	7.76e-18	2.72e-11	-0.43	-0.38	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-8.96	7.76e-18	2.72e-11	-0.43	-0.38	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
HNSC	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-8.96	7.79e-18	2.73e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-8.96	7.79e-18	2.73e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-8.96	7.81e-18	2.73e-11	-0.51	-0.38	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
HNSC	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-8.96	7.82e-18	2.74e-11	-0.5	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
HNSC	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-8.96	7.9e-18	2.76e-11	-0.41	-0.38	Longevity;	chr3:48422209	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-8.96	7.9e-18	2.76e-11	-0.41	-0.38	Longevity;	chr3:48423094	chr1:27649419~27649610:+
HNSC	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-8.96	7.9e-18	2.76e-11	-0.41	-0.38	Longevity;	chr3:48426493	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-8.96	7.9e-18	2.76e-11	-0.41	-0.38	Longevity;	chr3:48432839	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-8.96	7.9e-18	2.76e-11	-0.41	-0.38	Longevity;	chr3:48440237	chr1:27649419~27649610:+
HNSC	trans	rs7554547	0.6	rs2180180	ENSG00000261819.1	RP11-680G24.4	-8.96	7.93e-18	2.77e-11	-0.53	-0.38	Nonsyndromic cleft lip with cleft palate;	chr1:11959312	chr16:14988259~14990160:-
HNSC	trans	rs12709013	1	rs11641566	ENSG00000230849.2	GOT2P2	8.96	8.01e-18	2.8e-11	0.47	0.38	Blood metabolite ratios;	chr16:58801276	chr1:173141100~173142350:-
HNSC	trans	rs10908521	1	rs10908521	ENSG00000227183.3	HDGFP1	8.95	8.12e-18	2.84e-11	0.52	0.38	Uric acid clearance;	chr1:156843858	chrX:131646639~131646890:+
HNSC	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-8.95	8.42e-18	2.94e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	8.95	8.42e-18	2.94e-11	0.4	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
HNSC	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-8.95	8.66e-18	3.02e-11	-0.51	-0.38	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-8.95	8.7e-18	3.04e-11	-0.52	-0.38	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
HNSC	trans	rs7937890	1	rs6486190	ENSG00000236360.2	RP11-334A14.2	8.94	8.78e-18	3.06e-11	0.5	0.38	Mitochondrial DNA levels;	chr11:14379670	chr1:52993201~52993702:-
HNSC	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-8.94	9.05e-18	3.15e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-8.94	9.05e-18	3.15e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-8.94	9.05e-18	3.15e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.641	rs10766082	ENSG00000257675.1	RP11-641A6.9	-8.94	9.17e-18	3.2e-11	-0.46	-0.38	Bone mineral density;	chr11:13425751	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	8.94	9.23e-18	3.22e-11	0.51	0.38	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
HNSC	trans	rs12709013	1	rs11644891	ENSG00000230849.2	GOT2P2	8.94	9.23e-18	3.22e-11	0.47	0.38	Blood metabolite ratios;	chr16:58799921	chr1:173141100~173142350:-
HNSC	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-8.94	9.27e-18	3.23e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-8.94	9.27e-18	3.23e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-8.94	9.27e-18	3.23e-11	-0.55	-0.38	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-8.94	9.36e-18	3.26e-11	-0.51	-0.38	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-8.94	9.36e-18	3.26e-11	-0.51	-0.38	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-8.94	9.36e-18	3.26e-11	-0.51	-0.38	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-8.94	9.36e-18	3.26e-11	-0.51	-0.38	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
HNSC	trans	rs5877	0.512	rs56753505	ENSG00000213331.4	RP11-713C19.2	8.94	9.39e-18	3.27e-11	0.51	0.38	Subjective well-being (multi-trait analysis);	chr1:173898114	chr4:187970273~187971284:+
HNSC	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	8.94	9.42e-18	3.27e-11	0.51	0.38	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
HNSC	trans	rs12709013	1	rs11648514	ENSG00000230849.2	GOT2P2	8.93	9.59e-18	3.33e-11	0.47	0.38	Blood metabolite ratios;	chr16:58798176	chr1:173141100~173142350:-
HNSC	trans	rs12709013	1	rs8057892	ENSG00000230849.2	GOT2P2	8.93	9.59e-18	3.33e-11	0.47	0.38	Blood metabolite ratios;	chr16:58798855	chr1:173141100~173142350:-
HNSC	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-8.93	9.95e-18	3.45e-11	-0.41	-0.38	Longevity;	chr3:48408490	chr1:27649419~27649610:+
HNSC	trans	rs2657294	0.606	rs10824290	ENSG00000172974.11	AC007318.5	8.93	9.96e-18	3.46e-11	0.51	0.38	Pneumonia;	chr10:75204210	chr2:65205108~65205988:+
HNSC	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	8.93	9.97e-18	3.46e-11	0.51	0.38	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	8.93	9.97e-18	3.46e-11	0.51	0.38	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	8.93	9.97e-18	3.46e-11	0.51	0.38	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	8.93	9.97e-18	3.46e-11	0.51	0.38	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	8.93	9.97e-18	3.46e-11	0.51	0.38	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-8.92	1.02e-17	3.55e-11	-0.41	-0.38	Longevity;	chr3:48445949	chr1:27649419~27649610:+
HNSC	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	8.92	1.03e-17	3.58e-11	0.54	0.38	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
HNSC	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-8.92	1.03e-17	3.58e-11	-0.51	-0.38	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
HNSC	trans	rs3740713	1	rs3740713	ENSG00000235847.2	LDHAP7	8.92	1.08e-17	3.75e-11	0.69	0.38	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:84777259~84778223:-
HNSC	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	8.92	1.1e-17	3.82e-11	0.5	0.38	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-8.91	1.12e-17	3.86e-11	-0.49	-0.38	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	8.9	1.21e-17	4.18e-11	0.51	0.38	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	8.9	1.21e-17	4.18e-11	0.51	0.38	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	8.9	1.21e-17	4.19e-11	0.44	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
HNSC	trans	rs2657294	0.632	rs2657289	ENSG00000172974.11	AC007318.5	8.9	1.21e-17	4.2e-11	0.51	0.38	Pneumonia;	chr10:75206705	chr2:65205108~65205988:+
HNSC	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	8.9	1.23e-17	4.26e-11	0.5	0.38	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-8.9	1.23e-17	4.27e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
HNSC	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	8.9	1.24e-17	4.28e-11	0.51	0.38	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-8.9	1.24e-17	4.28e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
HNSC	trans	rs1079467	0.73	rs72846600	ENSG00000233426.3	EIF3FP3	-8.9	1.25e-17	4.32e-11	-0.65	-0.38	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7952994	chr2:58251440~58252525:+
HNSC	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-8.9	1.26e-17	4.33e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
HNSC	trans	rs11653357	1	rs11653357	ENSG00000234130.2	RP13-88F20.1	8.89	1.29e-17	4.45e-11	0.52	0.38	Platelet count;Platelet distribution width;	chr17:35596588	chrX:93222220~93225015:-
HNSC	trans	rs62079673	0.527	rs9788998	ENSG00000265574.1	WDR45BP1	8.89	1.3e-17	4.48e-11	0.44	0.38	Breast cancer;	chr17:82647768	chr17:32111562~32112590:-
HNSC	trans	rs4911253	0.527	rs853859	ENSG00000253915.1	MAPRE1P1	8.89	1.31e-17	4.51e-11	0.48	0.38	Lymphocyte counts;	chr20:32814463	chr8:135625185~135625981:-
HNSC	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	8.89	1.37e-17	4.71e-11	0.5	0.38	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.75e-11	0.5	0.38	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	8.89	1.39e-17	4.76e-11	0.5	0.38	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
HNSC	trans	rs7121616	0.595	rs7949414	ENSG00000229091.2	HSPA8P8	8.88	1.4e-17	4.82e-11	0.45	0.38	Breast cancer;	chr11:123072787	chr7:10451311~10452526:+
HNSC	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	8.88	1.43e-17	4.92e-11	0.54	0.38	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	8.88	1.43e-17	4.92e-11	0.54	0.38	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	8.88	1.46e-17	5.01e-11	0.51	0.38	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	8.88	1.46e-17	5.01e-11	0.51	0.38	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	8.88	1.49e-17	5.09e-11	0.49	0.38	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	8.88	1.49e-17	5.11e-11	0.51	0.38	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	8.88	1.49e-17	5.11e-11	0.51	0.38	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
HNSC	trans	rs7503168	1	rs16971217	ENSG00000234130.2	RP13-88F20.1	8.88	1.5e-17	5.13e-11	0.52	0.38	Plateletcrit;	chr17:35617036	chrX:93222220~93225015:-
HNSC	trans	rs77688320	0.5	rs6755428	ENSG00000235105.1	RP11-329A14.1	8.87	1.52e-17	5.19e-11	0.48	0.38	Breast cancer;	chr2:201431043	chr1:48435967~48437223:+
HNSC	trans	rs7503168	1	rs1037590	ENSG00000234130.2	RP13-88F20.1	8.87	1.52e-17	5.2e-11	0.52	0.38	Plateletcrit;	chr17:35575616	chrX:93222220~93225015:-
HNSC	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-8.87	1.53e-17	5.24e-11	-0.5	-0.38	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	8.87	1.56e-17	5.33e-11	0.5	0.38	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	8.87	1.56e-17	5.33e-11	0.5	0.38	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	8.87	1.56e-17	5.33e-11	0.5	0.38	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	8.87	1.61e-17	5.52e-11	0.5	0.38	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
HNSC	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-8.87	1.61e-17	5.52e-11	-0.4	-0.38	Longevity;	chr3:48445369	chr1:27649419~27649610:+
HNSC	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-8.86	1.65e-17	5.65e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	8.86	1.69e-17	5.77e-11	0.5	0.38	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
HNSC	trans	rs7121616	0.576	rs1461495	ENSG00000229091.2	HSPA8P8	-8.86	1.7e-17	5.79e-11	-0.48	-0.38	Breast cancer;	chr11:123056136	chr7:10451311~10452526:+
HNSC	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	-8.86	1.73e-17	5.91e-11	-0.43	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
HNSC	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-8.86	1.75e-17	5.95e-11	-0.41	-0.38	Longevity;	chr3:48440024	chr1:27649419~27649610:+
HNSC	trans	rs7662987	0.793	rs78790289	ENSG00000233859.2	ADH5P4	8.85	1.77e-17	6.03e-11	0.58	0.38	Smoking initiation;	chr4:99066736	chr6:65836930~65838039:-
HNSC	trans	rs1040555	0.516	rs242547	ENSG00000253915.1	MAPRE1P1	8.85	1.87e-17	6.38e-11	0.48	0.38	Lymphocyte percentage of white cells;	chr20:32830775	chr8:135625185~135625981:-
HNSC	trans	rs13190036	0.901	rs6898107	ENSG00000228305.2	AC016734.2	8.85	1.89e-17	6.42e-11	0.57	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr2:63622178~63622831:-
HNSC	trans	rs58106596	0.66	rs62197212	ENSG00000259020.3	RP11-529H20.3	8.84	1.89e-17	6.44e-11	0.61	0.38	Lymphocyte counts;White blood cell count;	chr2:231698017	chr14:92026566~92026887:+
HNSC	trans	rs77688320	0.5	rs7603584	ENSG00000235105.1	RP11-329A14.1	8.84	1.9e-17	6.46e-11	0.48	0.38	Breast cancer;	chr2:201440422	chr1:48435967~48437223:+
HNSC	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	8.84	1.92e-17	6.52e-11	0.61	0.38	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
HNSC	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-8.84	1.96e-17	6.66e-11	-0.5	-0.38	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	8.84	1.97e-17	6.68e-11	0.54	0.38	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-8.84	1.98e-17	6.72e-11	-0.54	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-8.84	1.98e-17	6.72e-11	-0.54	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	8.84	1.98e-17	6.73e-11	0.51	0.38	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-8.84	1.99e-17	6.75e-11	-0.49	-0.38	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	8.84	2.01e-17	6.83e-11	0.41	0.38	Longevity;	chr3:48453142	chr1:27649419~27649610:+
HNSC	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-8.84	2.01e-17	6.84e-11	-0.56	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	8.84	2.02e-17	6.86e-11	0.51	0.38	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs7635522	ENSG00000235912.1	RP1-159A19.3	-8.83	2.04e-17	6.94e-11	-0.4	-0.38	Longevity;	chr3:48382166	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	8.83	2.06e-17	7e-11	0.49	0.38	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
HNSC	trans	rs77688320	0.5	rs4129010	ENSG00000235105.1	RP11-329A14.1	8.83	2.07e-17	7.02e-11	0.48	0.38	Breast cancer;	chr2:201443602	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.5	rs4129011	ENSG00000235105.1	RP11-329A14.1	8.83	2.07e-17	7.02e-11	0.48	0.38	Breast cancer;	chr2:201443863	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.517	rs6717641	ENSG00000235105.1	RP11-329A14.1	8.83	2.07e-17	7.02e-11	0.48	0.38	Breast cancer;	chr2:201450484	chr1:48435967~48437223:+
HNSC	trans	rs7503168	0.818	rs9902765	ENSG00000234130.2	RP13-88F20.1	8.83	2.11e-17	7.17e-11	0.51	0.38	Plateletcrit;	chr17:35586124	chrX:93222220~93225015:-
HNSC	trans	rs7647973	1	rs11130189	ENSG00000197582.5	GPX1P1	8.83	2.12e-17	7.19e-11	0.54	0.38	Menarche (age at onset);	chr3:49309924	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	8.83	2.14e-17	7.26e-11	0.51	0.38	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	-8.82	2.23e-17	7.55e-11	-0.44	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
HNSC	trans	rs12709013	0.935	rs8046667	ENSG00000233719.3	GOT2P3	8.82	2.24e-17	7.59e-11	0.46	0.38	Blood metabolite ratios;	chr16:58790935	chr12:9641802~9643007:+
HNSC	trans	rs12709013	1	rs8046998	ENSG00000233719.3	GOT2P3	8.82	2.24e-17	7.59e-11	0.46	0.38	Blood metabolite ratios;	chr16:58791109	chr12:9641802~9643007:+
HNSC	trans	rs7121616	0.595	rs7941144	ENSG00000229091.2	HSPA8P8	8.82	2.26e-17	7.65e-11	0.44	0.38	Breast cancer;	chr11:123079805	chr7:10451311~10452526:+
HNSC	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-8.81	2.41e-17	8.16e-11	-0.5	-0.38	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-8.81	2.41e-17	8.16e-11	-0.5	-0.38	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
HNSC	trans	rs13190036	1	rs625882	ENSG00000228305.2	AC016734.2	-8.81	2.49e-17	8.42e-11	-0.6	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr2:63622178~63622831:-
HNSC	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	8.81	2.51e-17	8.48e-11	0.54	0.38	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	8.81	2.53e-17	8.53e-11	0.5	0.38	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	8.81	2.53e-17	8.53e-11	0.5	0.38	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	8.81	2.53e-17	8.55e-11	0.51	0.38	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
HNSC	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	8.8	2.57e-17	8.67e-11	0.57	0.38	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	8.8	2.57e-17	8.67e-11	0.57	0.38	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
HNSC	trans	rs77688320	0.535	rs10460403	ENSG00000235105.1	RP11-329A14.1	8.8	2.58e-17	8.72e-11	0.47	0.38	Breast cancer;	chr2:201478014	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	8.8	2.61e-17	8.8e-11	0.5	0.38	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-8.8	2.65e-17	8.94e-11	-0.45	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
HNSC	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	8.8	2.7e-17	9.09e-11	0.4	0.38	Longevity;	chr3:48447994	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	8.8	2.75e-17	9.26e-11	0.5	0.38	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-8.79	2.78e-17	9.38e-11	-0.51	-0.38	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.867	rs10501810	ENSG00000276509.1	CH17-353B19.1	8.79	2.79e-17	9.38e-11	0.41	0.38	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93933423	chr1:146235806~146237807:+
HNSC	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-8.79	2.83e-17	9.52e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-8.79	2.83e-17	9.52e-11	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	8.79	2.84e-17	9.55e-11	0.51	0.38	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	8.79	2.85e-17	9.6e-11	0.5	0.38	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	8.79	2.87e-17	9.65e-11	0.5	0.38	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	8.79	2.87e-17	9.65e-11	0.5	0.38	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	8.79	2.94e-17	9.88e-11	0.5	0.38	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	8.79	2.94e-17	9.88e-11	0.5	0.38	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	8.79	2.95e-17	9.93e-11	0.5	0.38	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	8.78	3.19e-17	1.07e-10	0.49	0.38	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
HNSC	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-8.78	3.2e-17	1.07e-10	-0.55	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.901	rs10056655	ENSG00000228305.2	AC016734.2	8.77	3.29e-17	1.1e-10	0.57	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr2:63622178~63622831:-
HNSC	trans	rs2657294	0.659	rs1259500	ENSG00000172974.11	AC007318.5	8.77	3.34e-17	1.12e-10	0.5	0.38	Pneumonia;	chr10:75230355	chr2:65205108~65205988:+
HNSC	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	-8.77	3.35e-17	1.12e-10	-0.45	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	8.77	3.42e-17	1.15e-10	0.42	0.38	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
HNSC	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-8.77	3.48e-17	1.17e-10	-0.57	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
HNSC	trans	rs9425766	0.888	rs1799876	ENSG00000213331.4	RP11-713C19.2	8.76	3.62e-17	1.21e-10	0.44	0.38	Life satisfaction;	chr1:173909333	chr4:187970273~187971284:+
HNSC	trans	rs12709013	0.935	rs34657766	ENSG00000233719.3	GOT2P3	8.76	3.63e-17	1.21e-10	0.46	0.38	Blood metabolite ratios;	chr16:58779468	chr12:9641802~9643007:+
HNSC	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	8.76	3.69e-17	1.23e-10	0.49	0.38	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	8.75	3.86e-17	1.29e-10	0.51	0.38	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-8.75	3.86e-17	1.29e-10	-0.41	-0.38	Longevity;	chr3:48402409	chr1:27649419~27649610:+
HNSC	trans	rs77688320	0.517	rs7573536	ENSG00000235105.1	RP11-329A14.1	8.75	3.86e-17	1.29e-10	0.47	0.38	Breast cancer;	chr2:201469676	chr1:48435967~48437223:+
HNSC	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	8.75	3.98e-17	1.33e-10	0.56	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
HNSC	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	8.75	3.99e-17	1.33e-10	0.57	0.38	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
HNSC	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	8.75	4e-17	1.34e-10	0.51	0.38	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	8.74	4.06e-17	1.35e-10	0.51	0.38	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	8.74	4.21e-17	1.4e-10	0.5	0.37	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
HNSC	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	8.74	4.24e-17	1.41e-10	0.57	0.37	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
HNSC	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	8.74	4.25e-17	1.42e-10	0.5	0.37	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	8.74	4.25e-17	1.42e-10	0.5	0.37	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
HNSC	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-8.74	4.26e-17	1.42e-10	-0.55	-0.37	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	8.74	4.29e-17	1.43e-10	0.5	0.37	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-8.74	4.29e-17	1.43e-10	-0.41	-0.37	Longevity;	chr3:48385276	chr1:27649419~27649610:+
HNSC	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	8.73	4.56e-17	1.51e-10	0.5	0.37	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	8.73	4.59e-17	1.52e-10	0.5	0.37	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
HNSC	trans	rs2657294	0.632	rs1259503	ENSG00000172974.11	AC007318.5	8.73	4.63e-17	1.54e-10	0.5	0.37	Pneumonia;	chr10:75232686	chr2:65205108~65205988:+
HNSC	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	8.72	4.74e-17	1.57e-10	0.61	0.37	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
HNSC	trans	rs7503168	1	rs35237539	ENSG00000234130.2	RP13-88F20.1	8.72	4.74e-17	1.57e-10	0.51	0.37	Plateletcrit;	chr17:35602563	chrX:93222220~93225015:-
HNSC	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	-8.72	4.83e-17	1.6e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	-8.72	4.83e-17	1.6e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
HNSC	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-8.72	4.85e-17	1.61e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-8.72	4.85e-17	1.61e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	8.72	4.85e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	-8.72	4.9e-17	1.62e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	-8.72	4.9e-17	1.62e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
HNSC	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	8.72	5.07e-17	1.68e-10	0.4	0.37	Longevity;	chr3:48464565	chr1:27649419~27649610:+
HNSC	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-8.72	5.07e-17	1.68e-10	-0.59	-0.37	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	8.71	5.12e-17	1.7e-10	0.44	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
HNSC	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	8.71	5.23e-17	1.73e-10	0.5	0.37	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
HNSC	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	8.71	5.29e-17	1.75e-10	0.56	0.37	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
HNSC	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	8.71	5.34e-17	1.77e-10	0.5	0.37	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
HNSC	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	-8.71	5.35e-17	1.77e-10	-0.45	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
HNSC	trans	rs7503168	0.908	rs9897552	ENSG00000234130.2	RP13-88F20.1	8.71	5.36e-17	1.77e-10	0.5	0.37	Plateletcrit;	chr17:35647462	chrX:93222220~93225015:-
HNSC	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	8.71	5.39e-17	1.78e-10	0.5	0.37	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	8.71	5.43e-17	1.8e-10	0.5	0.37	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-8.7	5.65e-17	1.87e-10	-0.4	-0.37	Longevity;	chr3:48393807	chr1:27649419~27649610:+
HNSC	trans	rs9425766	0.927	rs5878	ENSG00000213331.4	RP11-713C19.2	8.7	5.68e-17	1.88e-10	0.43	0.37	Life satisfaction;	chr1:173909694	chr4:187970273~187971284:+
HNSC	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	8.7	5.84e-17	1.92e-10	0.5	0.37	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	8.7	5.84e-17	1.92e-10	0.5	0.37	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-8.7	5.88e-17	1.94e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
HNSC	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-8.7	5.89e-17	1.94e-10	-0.57	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
HNSC	trans	rs11023332	0.706	rs11023379	ENSG00000236360.2	RP11-334A14.2	8.7	5.9e-17	1.95e-10	0.48	0.37	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr1:52993201~52993702:-
HNSC	trans	rs7554547	0.6	rs2273290	ENSG00000261819.1	RP11-680G24.4	8.69	6.01e-17	1.98e-10	0.53	0.37	Nonsyndromic cleft lip with cleft palate;	chr1:11958321	chr16:14988259~14990160:-
HNSC	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	8.69	6.03e-17	1.99e-10	0.51	0.37	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-8.69	6.07e-17	2e-10	-0.5	-0.37	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	8.69	6.14e-17	2.02e-10	0.5	0.37	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
HNSC	trans	rs11023332	0.706	rs11023380	ENSG00000236360.2	RP11-334A14.2	8.69	6.19e-17	2.04e-10	0.49	0.37	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr1:52993201~52993702:-
HNSC	trans	rs11023332	0.8	rs12271890	ENSG00000236360.2	RP11-334A14.2	8.69	6.19e-17	2.04e-10	0.49	0.37	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr1:52993201~52993702:-
HNSC	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	8.69	6.27e-17	2.06e-10	0.5	0.37	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	8.69	6.27e-17	2.06e-10	0.5	0.37	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	8.69	6.35e-17	2.09e-10	0.5	0.37	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
HNSC	trans	rs11638815	0.52	rs4779032	ENSG00000235370.6	DNM1P51	-8.69	6.36e-17	2.09e-10	-0.45	-0.37	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82576576	chr15:84398316~84411701:-
HNSC	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	8.68	6.48e-17	2.13e-10	0.5	0.37	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	8.68	6.49e-17	2.13e-10	0.5	0.37	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
HNSC	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-8.68	6.51e-17	2.14e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.729	rs71400031	ENSG00000233719.3	GOT2P3	8.68	6.7e-17	2.2e-10	0.46	0.37	Blood metabolite ratios;	chr16:58779554	chr12:9641802~9643007:+
HNSC	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	8.68	6.71e-17	2.2e-10	0.5	0.37	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	8.68	6.72e-17	2.2e-10	0.5	0.37	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	8.68	6.72e-17	2.2e-10	0.5	0.37	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	8.68	6.72e-17	2.2e-10	0.5	0.37	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	8.68	6.72e-17	2.2e-10	0.5	0.37	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.77	rs2018354	ENSG00000257675.1	RP11-641A6.9	-8.68	6.77e-17	2.22e-10	-0.44	-0.37	Bone mineral density;	chr11:13562319	chr12:52748776~52750127:+
HNSC	trans	rs7662987	0.793	rs28730602	ENSG00000233859.2	ADH5P4	8.68	6.82e-17	2.24e-10	0.57	0.37	Smoking initiation;	chr4:99080531	chr6:65836930~65838039:-
HNSC	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	8.68	6.86e-17	2.25e-10	0.54	0.37	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
HNSC	trans	rs7503168	1	rs16971227	ENSG00000234130.2	RP13-88F20.1	8.68	6.87e-17	2.25e-10	0.5	0.37	Plateletcrit;	chr17:35622203	chrX:93222220~93225015:-
HNSC	trans	rs7503168	1	rs12604067	ENSG00000234130.2	RP13-88F20.1	8.68	6.87e-17	2.25e-10	0.5	0.37	Plateletcrit;	chr17:35625084	chrX:93222220~93225015:-
HNSC	trans	rs7503168	0.73	rs11655803	ENSG00000234130.2	RP13-88F20.1	8.68	6.87e-17	2.25e-10	0.5	0.37	Plateletcrit;	chr17:35625677	chrX:93222220~93225015:-
HNSC	trans	rs11868206	1	rs11868206	ENSG00000234130.2	RP13-88F20.1	8.68	6.9e-17	2.26e-10	0.5	0.37	Mean platelet volume;	chr17:35632228	chrX:93222220~93225015:-
HNSC	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	8.68	6.9e-17	2.26e-10	0.5	0.37	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	8.67	6.96e-17	2.28e-10	0.5	0.37	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	8.67	6.96e-17	2.28e-10	0.5	0.37	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
HNSC	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	8.67	7.06e-17	2.31e-10	0.58	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
HNSC	trans	rs9876781	1	rs4858793	ENSG00000235912.1	RP1-159A19.3	8.67	7.16e-17	2.35e-10	0.41	0.37	Longevity;	chr3:48373517	chr1:27649419~27649610:+
HNSC	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	8.67	7.2e-17	2.36e-10	0.54	0.37	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	8.67	7.27e-17	2.38e-10	0.5	0.37	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	8.67	7.33e-17	2.4e-10	0.5	0.37	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
HNSC	trans	rs11023332	0.706	rs10766197	ENSG00000236360.2	RP11-334A14.2	8.67	7.34e-17	2.4e-10	0.49	0.37	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr1:52993201~52993702:-
HNSC	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	8.67	7.39e-17	2.42e-10	0.51	0.37	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-8.66	7.69e-17	2.51e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-8.66	7.85e-17	2.57e-10	-0.49	-0.37	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
HNSC	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-8.66	7.91e-17	2.58e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
HNSC	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-8.66	7.95e-17	2.6e-10	-0.56	-0.37	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
HNSC	trans	rs9898641	1	rs9898641	ENSG00000187870.7	RNFT1P3	8.65	8.04e-17	2.62e-10	0.44	0.37	Interleukin-1-beta levels;	chr17:59493672	chr17:20743333~20754501:-
HNSC	trans	rs2456568	0.835	rs7936182	ENSG00000276509.1	CH17-353B19.1	8.65	8.1e-17	2.65e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93932366	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	8.65	8.15e-17	2.66e-10	0.49	0.37	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
HNSC	trans	rs12709013	1	rs12709013	ENSG00000233719.3	GOT2P3	-8.65	8.17e-17	2.66e-10	-0.45	-0.37	Blood metabolite ratios;	chr16:58795886	chr12:9641802~9643007:+
HNSC	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	8.65	8.19e-17	2.67e-10	0.5	0.37	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	8.65	8.3e-17	2.71e-10	0.5	0.37	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	8.65	8.3e-17	2.71e-10	0.5	0.37	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	8.65	8.33e-17	2.72e-10	0.39	0.37	Longevity;	chr3:48378199	chr1:27649419~27649610:+
HNSC	trans	rs697003	1	rs697003	ENSG00000230450.1	NEK2P4	8.65	8.43e-17	2.75e-10	0.37	0.37	Red cell distribution width;	chr1:211669734	chr2:131177618~131178946:-
HNSC	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	8.65	8.44e-17	2.75e-10	0.5	0.37	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	8.65	8.44e-17	2.75e-10	0.5	0.37	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	8.65	8.44e-17	2.75e-10	0.5	0.37	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	8.65	8.44e-17	2.75e-10	0.5	0.37	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	8.65	8.44e-17	2.75e-10	0.5	0.37	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
HNSC	trans	rs12709013	0.967	rs62064905	ENSG00000233719.3	GOT2P3	8.65	8.47e-17	2.76e-10	0.46	0.37	Blood metabolite ratios;	chr16:58778839	chr12:9641802~9643007:+
HNSC	trans	rs6915893	0.967	rs12199316	ENSG00000267156.1	TPMTP1	8.65	8.47e-17	2.76e-10	0.44	0.37	Intrinsic epigenetic age acceleration;	chr6:18123271	chr18:47630112~47630848:+
HNSC	trans	rs12709013	0.935	rs11648634	ENSG00000233719.3	GOT2P3	8.65	8.52e-17	2.77e-10	0.46	0.37	Blood metabolite ratios;	chr16:58785256	chr12:9641802~9643007:+
HNSC	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-8.65	8.54e-17	2.78e-10	-0.4	-0.37	Longevity;	chr3:48458887	chr1:27649419~27649610:+
HNSC	trans	rs12709013	1	rs12599931	ENSG00000233719.3	GOT2P3	8.65	8.59e-17	2.8e-10	0.45	0.37	Blood metabolite ratios;	chr16:58792627	chr12:9641802~9643007:+
HNSC	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-8.65	8.64e-17	2.81e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	8.65	8.66e-17	2.82e-10	0.5	0.37	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	8.65	8.66e-17	2.82e-10	0.5	0.37	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	8.65	8.66e-17	2.82e-10	0.5	0.37	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	8.65	8.66e-17	2.82e-10	0.5	0.37	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
HNSC	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	8.64	8.73e-17	2.84e-10	0.57	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
HNSC	trans	rs12709013	1	rs34319345	ENSG00000233719.3	GOT2P3	8.64	8.82e-17	2.87e-10	0.46	0.37	Blood metabolite ratios;	chr16:58786688	chr12:9641802~9643007:+
HNSC	trans	rs13190036	0.901	rs6556309	ENSG00000228305.2	AC016734.2	8.64	8.9e-17	2.89e-10	0.56	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr2:63622178~63622831:-
HNSC	trans	rs2456568	0.867	rs1827931	ENSG00000276509.1	CH17-353B19.1	8.64	8.91e-17	2.89e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930004	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	8.64	8.94e-17	2.9e-10	0.5	0.37	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	8.64	8.94e-17	2.9e-10	0.5	0.37	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	8.64	8.94e-17	2.9e-10	0.5	0.37	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-8.64	9.12e-17	2.96e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
HNSC	trans	rs2288327	0.557	rs60488846	ENSG00000269800.1	PLEKHA3P1	8.64	9.17e-17	2.98e-10	0.52	0.37	Atrial fibrillation;	chr2:178493115	chr19:41521043~41521989:-
HNSC	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	8.64	9.21e-17	2.99e-10	0.5	0.37	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	8.64	9.21e-17	2.99e-10	0.5	0.37	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	8.64	9.21e-17	2.99e-10	0.5	0.37	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	8.64	9.21e-17	2.99e-10	0.5	0.37	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	8.64	9.27e-17	3.01e-10	0.5	0.37	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	8.64	9.27e-17	3.01e-10	0.5	0.37	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	8.64	9.27e-17	3.01e-10	0.5	0.37	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	8.64	9.27e-17	3.01e-10	0.5	0.37	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	8.64	9.29e-17	3.01e-10	0.48	0.37	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	8.63	9.37e-17	3.04e-10	0.49	0.37	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	8.63	9.38e-17	3.04e-10	0.5	0.37	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-8.63	9.51e-17	3.08e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-8.63	9.51e-17	3.08e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-8.63	9.56e-17	3.09e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-8.63	9.56e-17	3.09e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	8.63	9.87e-17	3.19e-10	0.56	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
HNSC	trans	rs2456568	0.867	rs4753111	ENSG00000276509.1	CH17-353B19.1	8.63	9.94e-17	3.21e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93925244	chr1:146235806~146237807:+
HNSC	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	8.63	9.99e-17	3.22e-10	0.5	0.37	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
HNSC	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-8.63	9.99e-17	3.22e-10	-0.54	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
HNSC	trans	rs77688320	0.517	rs10931949	ENSG00000235105.1	RP11-329A14.1	8.62	1.03e-16	3.3e-10	0.46	0.37	Breast cancer;	chr2:201459730	chr1:48435967~48437223:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-8.62	1.03e-16	3.3e-10	-0.39	-0.37	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
HNSC	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	8.62	1.03e-16	3.33e-10	0.49	0.37	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	8.62	1.05e-16	3.37e-10	0.54	0.37	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-8.62	1.05e-16	3.37e-10	-0.4	-0.37	Longevity;	chr3:48446507	chr1:27649419~27649610:+
HNSC	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	8.62	1.05e-16	3.38e-10	0.5	0.37	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.641	rs2896633	ENSG00000257675.1	RP11-641A6.9	-8.62	1.05e-16	3.39e-10	-0.44	-0.37	Bone mineral density;	chr11:13400727	chr12:52748776~52750127:+
HNSC	trans	rs2456568	0.695	rs877341	ENSG00000276509.1	CH17-353B19.1	-8.62	1.06e-16	3.41e-10	-0.42	-0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93956127	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.695	rs55756119	ENSG00000276509.1	CH17-353B19.1	-8.62	1.06e-16	3.41e-10	-0.42	-0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93956743	chr1:146235806~146237807:+
HNSC	trans	rs7032940	0.677	rs1331310	ENSG00000228236.2	TXNP5	8.62	1.07e-16	3.44e-10	0.42	0.37	Height;	chr9:110179601	chr2:149068596~149068910:-
HNSC	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	8.62	1.07e-16	3.45e-10	0.48	0.37	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.683	rs7103068	ENSG00000257675.1	RP11-641A6.9	8.62	1.07e-16	3.46e-10	0.44	0.37	Bone mineral density;	chr11:13408414	chr12:52748776~52750127:+
HNSC	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	8.62	1.08e-16	3.47e-10	0.5	0.37	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-8.61	1.1e-16	3.53e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
HNSC	trans	rs10908521	0.685	rs12746582	ENSG00000227183.3	HDGFP1	-8.61	1.1e-16	3.54e-10	-0.49	-0.37	Uric acid clearance;	chr1:156836231	chrX:131646639~131646890:+
HNSC	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	8.61	1.11e-16	3.56e-10	0.47	0.37	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
HNSC	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	8.61	1.11e-16	3.56e-10	0.57	0.37	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
HNSC	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	8.61	1.11e-16	3.56e-10	0.57	0.37	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
HNSC	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	8.61	1.13e-16	3.64e-10	0.55	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
HNSC	trans	rs2456568	0.695	rs7942055	ENSG00000276509.1	CH17-353B19.1	-8.61	1.14e-16	3.65e-10	-0.41	-0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93957897	chr1:146235806~146237807:+
HNSC	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	8.61	1.16e-16	3.73e-10	0.48	0.37	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	8.61	1.16e-16	3.73e-10	0.49	0.37	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	8.6	1.2e-16	3.84e-10	0.5	0.37	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	8.6	1.2e-16	3.84e-10	0.5	0.37	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
HNSC	trans	rs7121616	0.576	rs60405069	ENSG00000229091.2	HSPA8P8	8.6	1.21e-16	3.88e-10	0.47	0.37	Breast cancer;	chr11:123043616	chr7:10451311~10452526:+
HNSC	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	8.6	1.21e-16	3.89e-10	0.49	0.37	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
HNSC	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	8.6	1.24e-16	3.97e-10	0.44	0.37	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
HNSC	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	8.59	1.27e-16	4.07e-10	0.48	0.37	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.695	rs908748	ENSG00000276509.1	CH17-353B19.1	-8.59	1.27e-16	4.08e-10	-0.41	-0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93956982	chr1:146235806~146237807:+
HNSC	trans	rs12439619	0.693	rs9944185	ENSG00000259295.5	CSPG4P12	-8.59	1.29e-16	4.14e-10	-0.49	-0.37	Intelligence (multi-trait analysis);	chr15:82157927	chr15:85191438~85213905:+
HNSC	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	8.59	1.31e-16	4.2e-10	0.39	0.37	Longevity;	chr3:48376736	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-8.59	1.33e-16	4.25e-10	-0.4	-0.37	Longevity;	chr3:48452692	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	8.59	1.36e-16	4.34e-10	0.39	0.37	Longevity;	chr3:48377218	chr1:27649419~27649610:+
HNSC	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	8.58	1.39e-16	4.44e-10	0.45	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
HNSC	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-8.58	1.46e-16	4.66e-10	-0.49	-0.37	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-8.57	1.48e-16	4.71e-10	-0.49	-0.37	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
HNSC	trans	rs1816752	0.875	rs59531061	ENSG00000224976.2	PARP4P2	-8.57	1.49e-16	4.74e-10	-0.42	-0.37	Obesity-related traits;	chr13:24507297	chr13:19349137~19407962:+
HNSC	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	8.57	1.49e-16	4.76e-10	0.5	0.37	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-8.57	1.5e-16	4.77e-10	-0.51	-0.37	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	8.57	1.52e-16	4.85e-10	0.51	0.37	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
HNSC	trans	rs12709013	0.967	rs11643969	ENSG00000233719.3	GOT2P3	8.57	1.53e-16	4.86e-10	0.45	0.37	Blood metabolite ratios;	chr16:58785354	chr12:9641802~9643007:+
HNSC	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-8.57	1.54e-16	4.89e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
HNSC	trans	rs2456568	0.867	rs2462750	ENSG00000276509.1	CH17-353B19.1	8.57	1.55e-16	4.94e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93935424	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.9	rs2456559	ENSG00000276509.1	CH17-353B19.1	8.57	1.55e-16	4.94e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93935692	chr1:146235806~146237807:+
HNSC	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	8.57	1.56e-16	4.96e-10	0.48	0.37	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	8.57	1.57e-16	4.99e-10	0.49	0.37	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
HNSC	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	8.56	1.63e-16	5.18e-10	0.56	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
HNSC	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	8.56	1.66e-16	5.28e-10	0.49	0.37	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.545	rs11600517	ENSG00000229091.2	HSPA8P8	8.55	1.74e-16	5.51e-10	0.47	0.37	Breast cancer;	chr11:123047247	chr7:10451311~10452526:+
HNSC	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-8.55	1.77e-16	5.6e-10	-0.39	-0.37	Longevity;	chr3:48398713	chr1:27649419~27649610:+
HNSC	trans	rs7032940	0.677	rs4279674	ENSG00000228236.2	TXNP5	8.55	1.78e-16	5.65e-10	0.41	0.37	Height;	chr9:110179726	chr2:149068596~149068910:-
HNSC	trans	rs1816752	0.875	rs3783076	ENSG00000224976.2	PARP4P2	-8.55	1.79e-16	5.67e-10	-0.42	-0.37	Obesity-related traits;	chr13:24490319	chr13:19349137~19407962:+
HNSC	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-8.55	1.8e-16	5.71e-10	-0.55	-0.37	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	8.55	1.81e-16	5.75e-10	0.49	0.37	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
HNSC	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	8.55	1.82e-16	5.77e-10	0.49	0.37	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
HNSC	trans	rs2456568	0.867	rs1395384	ENSG00000276509.1	CH17-353B19.1	-8.55	1.83e-16	5.81e-10	-0.4	-0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930084	chr1:146235806~146237807:+
HNSC	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-8.54	1.87e-16	5.92e-10	-0.54	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
HNSC	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	8.54	1.87e-16	5.92e-10	0.49	0.37	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
HNSC	trans	rs2288327	0.557	rs7588593	ENSG00000269800.1	PLEKHA3P1	8.54	1.9e-16	6.03e-10	0.52	0.37	Atrial fibrillation;	chr2:178487723	chr19:41521043~41521989:-
HNSC	trans	rs2288327	0.557	rs7577862	ENSG00000269800.1	PLEKHA3P1	8.54	1.9e-16	6.03e-10	0.52	0.37	Atrial fibrillation;	chr2:178488130	chr19:41521043~41521989:-
HNSC	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-8.54	1.91e-16	6.04e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-8.54	1.91e-16	6.04e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-8.54	1.91e-16	6.04e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-8.54	1.91e-16	6.04e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-8.54	1.92e-16	6.09e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-8.54	1.92e-16	6.09e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-8.54	1.92e-16	6.09e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-8.54	1.92e-16	6.09e-10	-0.54	-0.37	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
HNSC	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	8.54	1.94e-16	6.14e-10	0.39	0.37	Longevity;	chr3:48375266	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	8.54	1.95e-16	6.16e-10	0.38	0.37	Longevity;	chr3:48377081	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	8.54	1.96e-16	6.2e-10	0.49	0.37	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	8.54	1.96e-16	6.2e-10	0.49	0.37	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
HNSC	trans	rs72615157	0.561	rs113401658	ENSG00000228546.2	CTA-313A17.3	8.54	1.97e-16	6.24e-10	0.62	0.37	Lung function (FEV1/FVC);	chr7:100260882	chr7:102337316~102339115:+
HNSC	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-8.54	1.97e-16	6.25e-10	-0.49	-0.37	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
HNSC	trans	rs9858542	1	rs9836291	ENSG00000197582.5	GPX1P1	-8.54	1.98e-16	6.26e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49660026	chrX:13378735~13379340:-
HNSC	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-8.53	1.99e-16	6.29e-10	-0.47	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
HNSC	trans	rs7121616	0.576	rs1841580	ENSG00000229091.2	HSPA8P8	8.53	1.99e-16	6.29e-10	0.47	0.37	Breast cancer;	chr11:123055956	chr7:10451311~10452526:+
HNSC	trans	rs6708331	0.752	rs7558246	ENSG00000232654.1	FAM136BP	8.53	2.05e-16	6.47e-10	0.45	0.37	Obesity-related traits;	chr2:69975481	chr6:3045384~3045800:+
HNSC	trans	rs7833986	0.501	rs72653921	ENSG00000244245.1	RP11-120B7.1	8.53	2.1e-16	6.63e-10	0.43	0.37	Height;	chr8:55984598	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.534	rs2458083	ENSG00000244245.1	RP11-120B7.1	8.53	2.1e-16	6.63e-10	0.43	0.37	Height;	chr8:55986226	chr5:108593609~108593967:+
HNSC	trans	rs9876781	0.874	rs56298324	ENSG00000235912.1	RP1-159A19.3	8.53	2.11e-16	6.66e-10	0.39	0.37	Longevity;	chr3:48393626	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-8.53	2.11e-16	6.67e-10	-0.39	-0.37	Longevity;	chr3:48408549	chr1:27649419~27649610:+
HNSC	trans	rs72615157	0.561	rs113844570	ENSG00000228546.2	CTA-313A17.3	8.53	2.12e-16	6.68e-10	0.62	0.37	Lung function (FEV1/FVC);	chr7:100276155	chr7:102337316~102339115:+
HNSC	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	8.53	2.12e-16	6.7e-10	0.49	0.37	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.69	rs7674713	ENSG00000275858.1	RP11-291L22.8	8.52	2.18e-16	6.87e-10	0.49	0.37	Corneal astigmatism;	chr4:119401102	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	-8.52	2.23e-16	7.03e-10	-0.44	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
HNSC	trans	rs7200543	0.666	rs34955778	ENSG00000250569.1	NTAN1P2	8.52	2.24e-16	7.05e-10	0.42	0.37	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr8:86481754~86483002:-
HNSC	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-8.52	2.25e-16	7.08e-10	-0.39	-0.37	Longevity;	chr3:48463903	chr1:27649419~27649610:+
HNSC	trans	rs2456568	0.835	rs1518578	ENSG00000276509.1	CH17-353B19.1	8.52	2.26e-16	7.11e-10	0.39	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93923688	chr1:146235806~146237807:+
HNSC	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	8.52	2.28e-16	7.17e-10	0.49	0.37	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-8.52	2.28e-16	7.18e-10	-0.47	-0.37	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	8.51	2.32e-16	7.32e-10	0.49	0.37	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.576	rs7942164	ENSG00000229091.2	HSPA8P8	8.51	2.33e-16	7.34e-10	0.47	0.37	Breast cancer;	chr11:123050459	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.576	rs56131320	ENSG00000229091.2	HSPA8P8	8.51	2.33e-16	7.34e-10	0.47	0.37	Breast cancer;	chr11:123053058	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.576	rs7929869	ENSG00000229091.2	HSPA8P8	8.51	2.33e-16	7.34e-10	0.47	0.37	Breast cancer;	chr11:123054435	chr7:10451311~10452526:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-8.51	2.34e-16	7.36e-10	-0.41	-0.37	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
HNSC	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	8.51	2.36e-16	7.41e-10	0.56	0.37	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
HNSC	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-8.51	2.39e-16	7.53e-10	-0.54	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
HNSC	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-8.51	2.39e-16	7.53e-10	-0.54	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
HNSC	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	8.51	2.4e-16	7.55e-10	0.55	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
HNSC	trans	rs2456568	0.867	rs7935801	ENSG00000276509.1	CH17-353B19.1	8.51	2.41e-16	7.57e-10	0.4	0.37	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93924834	chr1:146235806~146237807:+
HNSC	trans	rs7833986	0.534	rs2667980	ENSG00000244245.1	RP11-120B7.1	8.51	2.46e-16	7.74e-10	0.43	0.37	Height;	chr8:55983982	chr5:108593609~108593967:+
HNSC	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-8.5	2.48e-16	7.8e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-8.5	2.49e-16	7.82e-10	-0.53	-0.37	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
HNSC	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-8.5	2.49e-16	7.82e-10	-0.49	-0.37	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
HNSC	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	8.5	2.53e-16	7.95e-10	0.49	0.37	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	8.5	2.59e-16	8.14e-10	0.51	0.37	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
HNSC	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-8.5	2.6e-16	8.16e-10	-0.39	-0.37	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
HNSC	trans	rs7121616	0.576	rs1064585	ENSG00000229091.2	HSPA8P8	8.5	2.62e-16	8.21e-10	0.47	0.37	Breast cancer;	chr11:123058699	chr7:10451311~10452526:+
HNSC	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-8.5	2.66e-16	8.35e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-8.49	2.73e-16	8.55e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
HNSC	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-8.49	2.73e-16	8.55e-10	-0.54	-0.37	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-8.49	2.76e-16	8.64e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-8.49	2.77e-16	8.68e-10	-0.55	-0.37	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	8.49	2.84e-16	8.89e-10	0.49	0.37	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	8.48	2.88e-16	9e-10	0.53	0.37	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
HNSC	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-8.48	2.88e-16	9.01e-10	-0.56	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
HNSC	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	8.48	2.89e-16	9.05e-10	0.49	0.37	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-8.48	2.89e-16	9.05e-10	-0.39	-0.37	Longevity;	chr3:48372725	chr1:27649419~27649610:+
HNSC	trans	rs6915893	0.967	rs9477631	ENSG00000267156.1	TPMTP1	8.48	2.91e-16	9.09e-10	0.44	0.37	Intrinsic epigenetic age acceleration;	chr6:18123541	chr18:47630112~47630848:+
HNSC	trans	rs12709013	1	rs11641836	ENSG00000233719.3	GOT2P3	8.48	2.97e-16	9.3e-10	0.44	0.37	Blood metabolite ratios;	chr16:58798143	chr12:9641802~9643007:+
HNSC	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-8.48	2.99e-16	9.34e-10	-0.39	-0.37	Longevity;	chr3:48413059	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	8.48	2.99e-16	9.34e-10	0.48	0.37	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	8.48	2.99e-16	9.34e-10	0.48	0.37	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-8.48	3.02e-16	9.44e-10	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.531	rs1461497	ENSG00000229091.2	HSPA8P8	8.48	3.05e-16	9.53e-10	0.47	0.37	Breast cancer;	chr11:123060505	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.531	rs41361350	ENSG00000229091.2	HSPA8P8	8.48	3.05e-16	9.53e-10	0.47	0.37	Breast cancer;	chr11:123060917	chr7:10451311~10452526:+
HNSC	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	8.47	3.15e-16	9.83e-10	0.49	0.37	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-8.47	3.18e-16	9.93e-10	-0.54	-0.36	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-8.47	3.22e-16	1e-09	-0.44	-0.36	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
HNSC	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	8.47	3.28e-16	1.02e-09	0.48	0.36	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	8.47	3.3e-16	1.03e-09	0.48	0.36	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	8.47	3.33e-16	1.04e-09	0.41	0.36	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
HNSC	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-8.46	3.34e-16	1.04e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.576	rs7111590	ENSG00000229091.2	HSPA8P8	8.46	3.36e-16	1.05e-09	0.46	0.36	Breast cancer;	chr11:123055419	chr7:10451311~10452526:+
HNSC	trans	rs77688320	0.535	rs12468504	ENSG00000235105.1	RP11-329A14.1	-8.46	3.39e-16	1.06e-09	-0.46	-0.36	Breast cancer;	chr2:201393746	chr1:48435967~48437223:+
HNSC	trans	rs916888	0.779	rs199528	ENSG00000204650.12	CRHR1-IT1	8.46	3.45e-16	1.07e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.821	rs199525	ENSG00000204650.12	CRHR1-IT1	8.46	3.45e-16	1.07e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	8.46	3.45e-16	1.07e-09	0.49	0.36	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-8.46	3.48e-16	1.08e-09	-0.4	-0.36	Longevity;	chr3:48455358	chr1:27649419~27649610:+
HNSC	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-8.46	3.57e-16	1.11e-09	-0.46	-0.36	Mumps;	chr20:2665687	chr6:28783633~28784004:-
HNSC	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	8.46	3.59e-16	1.12e-09	0.49	0.36	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	8.45	3.69e-16	1.15e-09	0.48	0.36	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	8.45	3.74e-16	1.16e-09	0.48	0.36	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	8.45	3.74e-16	1.16e-09	0.48	0.36	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	8.45	3.74e-16	1.16e-09	0.48	0.36	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.73	rs307216	ENSG00000257675.1	RP11-641A6.9	8.45	3.86e-16	1.2e-09	0.43	0.36	Bone mineral density;	chr11:13477966	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	8.45	3.86e-16	1.2e-09	0.48	0.36	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-8.44	3.88e-16	1.2e-09	-0.48	-0.36	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
HNSC	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	8.44	3.91e-16	1.21e-09	0.39	0.36	Longevity;	chr3:48376729	chr1:27649419~27649610:+
HNSC	trans	rs7121616	0.576	rs73610509	ENSG00000229091.2	HSPA8P8	8.44	3.94e-16	1.22e-09	0.46	0.36	Breast cancer;	chr11:123048564	chr7:10451311~10452526:+
HNSC	trans	rs9630182	0.77	rs307223	ENSG00000257675.1	RP11-641A6.9	8.44	3.96e-16	1.23e-09	0.43	0.36	Bone mineral density;	chr11:13512803	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	8.44	3.98e-16	1.24e-09	0.48	0.36	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
HNSC	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	8.44	4.01e-16	1.24e-09	0.48	0.36	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
HNSC	trans	rs7503168	0.908	rs9907772	ENSG00000234130.2	RP13-88F20.1	8.44	4.03e-16	1.25e-09	0.48	0.36	Plateletcrit;	chr17:35673609	chrX:93222220~93225015:-
HNSC	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	8.44	4.09e-16	1.27e-09	0.38	0.36	Longevity;	chr3:48378407	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	8.44	4.12e-16	1.28e-09	0.48	0.36	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	8.44	4.15e-16	1.29e-09	0.48	0.36	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.74	rs6490924	ENSG00000224976.2	PARP4P2	8.43	4.19e-16	1.3e-09	0.41	0.36	Obesity-related traits;	chr13:24432914	chr13:19349137~19407962:+
HNSC	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-8.43	4.21e-16	1.3e-09	-0.39	-0.36	Longevity;	chr3:48389129	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	8.43	4.32e-16	1.34e-09	0.48	0.36	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	8.43	4.32e-16	1.34e-09	0.48	0.36	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
HNSC	trans	rs1816752	0.875	rs17384871	ENSG00000224976.2	PARP4P2	-8.43	4.45e-16	1.38e-09	-0.42	-0.36	Obesity-related traits;	chr13:24484959	chr13:19349137~19407962:+
HNSC	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	8.42	4.54e-16	1.4e-09	0.47	0.36	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
HNSC	trans	rs11023332	0.617	rs1879888	ENSG00000236360.2	RP11-334A14.2	8.42	4.59e-16	1.42e-09	0.47	0.36	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr1:52993201~52993702:-
HNSC	trans	rs77688320	0.535	rs11691118	ENSG00000235105.1	RP11-329A14.1	8.42	4.6e-16	1.42e-09	0.46	0.36	Breast cancer;	chr2:201405121	chr1:48435967~48437223:+
HNSC	trans	rs12709013	1	rs12926993	ENSG00000233719.3	GOT2P3	8.42	4.63e-16	1.43e-09	0.44	0.36	Blood metabolite ratios;	chr16:58789218	chr12:9641802~9643007:+
HNSC	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	8.42	4.65e-16	1.43e-09	0.48	0.36	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-8.42	4.69e-16	1.45e-09	-0.54	-0.36	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	8.42	4.75e-16	1.47e-09	0.48	0.36	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	8.42	4.8e-16	1.48e-09	0.54	0.36	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	8.42	4.82e-16	1.49e-09	0.49	0.36	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	8.42	4.83e-16	1.49e-09	0.48	0.36	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	8.41	4.86e-16	1.5e-09	0.47	0.36	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.773	rs199457	ENSG00000204650.12	CRHR1-IT1	8.41	4.86e-16	1.5e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	8.41	5e-16	1.54e-09	0.5	0.36	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-8.41	5.02e-16	1.55e-09	-0.53	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.545	rs7109336	ENSG00000229091.2	HSPA8P8	8.41	5.05e-16	1.55e-09	0.47	0.36	Breast cancer;	chr11:123056530	chr7:10451311~10452526:+
HNSC	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	8.41	5.06e-16	1.56e-09	0.47	0.36	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-8.41	5.06e-16	1.56e-09	-0.49	-0.36	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	8.41	5.07e-16	1.56e-09	0.48	0.36	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	8.41	5.07e-16	1.56e-09	0.48	0.36	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs2953911	ENSG00000244245.1	RP11-120B7.1	8.41	5.07e-16	1.56e-09	0.43	0.36	Height;	chr8:56035450	chr5:108593609~108593967:+
HNSC	trans	rs9630182	0.77	rs2403667	ENSG00000257675.1	RP11-641A6.9	8.41	5.13e-16	1.58e-09	0.43	0.36	Bone mineral density;	chr11:13540517	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	8.41	5.14e-16	1.58e-09	0.47	0.36	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	8.41	5.14e-16	1.58e-09	0.47	0.36	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.711	rs7941196	ENSG00000257675.1	RP11-641A6.9	8.41	5.16e-16	1.59e-09	0.43	0.36	Bone mineral density;	chr11:13591942	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs7123290	ENSG00000257675.1	RP11-641A6.9	8.41	5.16e-16	1.59e-09	0.43	0.36	Bone mineral density;	chr11:13592611	chr12:52748776~52750127:+
HNSC	trans	rs1190596	0.526	rs1190572	ENSG00000181359.5	HSP90AA6P	8.4	5.22e-16	1.61e-09	0.47	0.36	Behavioural disinhibition (generation interaction);	chr14:102168252	chr4:170581470~170605450:-
HNSC	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	8.4	5.27e-16	1.62e-09	0.48	0.36	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	8.4	5.27e-16	1.62e-09	0.48	0.36	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	8.4	5.27e-16	1.62e-09	0.48	0.36	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	8.4	5.27e-16	1.62e-09	0.48	0.36	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-8.4	5.28e-16	1.62e-09	-0.43	-0.36	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-8.4	5.28e-16	1.62e-09	-0.43	-0.36	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
HNSC	trans	rs12145833	0.538	rs4658547	ENSG00000154608.12	CEP170P1	8.4	5.38e-16	1.65e-09	0.53	0.36	Obesity (early onset extreme);	chr1:243227829	chr4:118467590~118554204:+
HNSC	trans	rs12145833	0.538	rs9803701	ENSG00000154608.12	CEP170P1	8.4	5.38e-16	1.65e-09	0.53	0.36	Obesity (early onset extreme);	chr1:243228332	chr4:118467590~118554204:+
HNSC	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	8.4	5.41e-16	1.66e-09	0.48	0.36	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	8.4	5.42e-16	1.67e-09	0.48	0.36	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	8.4	5.42e-16	1.67e-09	0.48	0.36	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.564	rs730415	ENSG00000257675.1	RP11-641A6.9	8.4	5.42e-16	1.67e-09	0.43	0.36	Bone mineral density;	chr11:13437198	chr12:52748776~52750127:+
HNSC	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	8.4	5.42e-16	1.67e-09	0.51	0.36	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	8.4	5.43e-16	1.67e-09	0.48	0.36	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	8.4	5.43e-16	1.67e-09	0.48	0.36	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	8.4	5.46e-16	1.68e-09	0.48	0.36	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	8.4	5.51e-16	1.69e-09	0.48	0.36	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.9	rs2511399	ENSG00000276509.1	CH17-353B19.1	-8.4	5.53e-16	1.7e-09	-0.39	-0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93948990	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	8.4	5.58e-16	1.71e-09	0.48	0.36	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	8.4	5.58e-16	1.71e-09	0.48	0.36	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	8.4	5.58e-16	1.71e-09	0.48	0.36	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-8.39	5.64e-16	1.73e-09	-0.53	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs6446268	ENSG00000197582.5	GPX1P1	-8.39	5.65e-16	1.73e-09	-0.53	-0.36	Menarche (age at onset);	chr3:49408262	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs898148	ENSG00000257675.1	RP11-641A6.9	-8.39	5.71e-16	1.75e-09	-0.43	-0.36	Bone mineral density;	chr11:13576869	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-8.39	5.72e-16	1.75e-09	-0.48	-0.36	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	8.39	5.8e-16	1.78e-09	0.48	0.36	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	8.39	5.83e-16	1.78e-09	0.48	0.36	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	8.39	5.87e-16	1.8e-09	0.49	0.36	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-8.39	5.97e-16	1.83e-09	-0.38	-0.36	Longevity;	chr3:48378818	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-8.39	5.97e-16	1.83e-09	-0.38	-0.36	Longevity;	chr3:48379768	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	8.39	5.99e-16	1.84e-09	0.48	0.36	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs2976012	ENSG00000244245.1	RP11-120B7.1	8.38	6.21e-16	1.9e-09	0.42	0.36	Height;	chr8:56061784	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2953922	ENSG00000244245.1	RP11-120B7.1	8.38	6.21e-16	1.9e-09	0.42	0.36	Height;	chr8:56064926	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2953897	ENSG00000244245.1	RP11-120B7.1	8.38	6.21e-16	1.9e-09	0.42	0.36	Height;	chr8:56068010	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2953898	ENSG00000244245.1	RP11-120B7.1	8.38	6.21e-16	1.9e-09	0.42	0.36	Height;	chr8:56068244	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2953901	ENSG00000244245.1	RP11-120B7.1	8.38	6.21e-16	1.9e-09	0.42	0.36	Height;	chr8:56069265	chr5:108593609~108593967:+
HNSC	trans	rs7121616	0.576	rs7948948	ENSG00000229091.2	HSPA8P8	8.38	6.23e-16	1.91e-09	0.47	0.36	Breast cancer;	chr11:123057467	chr7:10451311~10452526:+
HNSC	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	8.38	6.32e-16	1.93e-09	0.53	0.36	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
HNSC	trans	rs7833986	0.501	rs17814658	ENSG00000244245.1	RP11-120B7.1	8.38	6.34e-16	1.94e-09	0.42	0.36	Height;	chr8:56076571	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs72653957	ENSG00000244245.1	RP11-120B7.1	8.38	6.34e-16	1.94e-09	0.42	0.36	Height;	chr8:56077489	chr5:108593609~108593967:+
HNSC	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	8.38	6.41e-16	1.96e-09	0.48	0.36	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
HNSC	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	8.38	6.41e-16	1.96e-09	0.53	0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	8.37	6.53e-16	1.99e-09	0.47	0.36	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	8.37	6.53e-16	1.99e-09	0.47	0.36	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	8.37	6.53e-16	1.99e-09	0.47	0.36	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	8.37	6.53e-16	1.99e-09	0.47	0.36	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
HNSC	trans	rs77688320	0.535	rs11680694	ENSG00000235105.1	RP11-329A14.1	8.37	6.57e-16	2.01e-09	0.46	0.36	Breast cancer;	chr2:201393498	chr1:48435967~48437223:+
HNSC	trans	rs916888	0.773	rs199451	ENSG00000204650.12	CRHR1-IT1	8.37	6.64e-16	2.03e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45620328~45648216:+
HNSC	trans	rs9630182	0.793	rs307252	ENSG00000257675.1	RP11-641A6.9	8.37	6.66e-16	2.03e-09	0.43	0.36	Bone mineral density;	chr11:13488927	chr12:52748776~52750127:+
HNSC	trans	rs7121616	0.576	rs73610510	ENSG00000229091.2	HSPA8P8	8.37	6.83e-16	2.08e-09	0.46	0.36	Breast cancer;	chr11:123049365	chr7:10451311~10452526:+
HNSC	trans	rs77688320	0.535	rs7561048	ENSG00000235105.1	RP11-329A14.1	8.37	6.85e-16	2.09e-09	0.46	0.36	Breast cancer;	chr2:201388316	chr1:48435967~48437223:+
HNSC	trans	rs13014235	0.592	rs55860809	ENSG00000235105.1	RP11-329A14.1	8.37	6.85e-16	2.09e-09	0.46	0.36	Basal cell carcinoma;	chr2:201394347	chr1:48435967~48437223:+
HNSC	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	8.37	6.9e-16	2.1e-09	0.48	0.36	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	8.37	6.95e-16	2.12e-09	0.49	0.36	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
HNSC	trans	rs1816752	0.716	rs9553289	ENSG00000224976.2	PARP4P2	8.37	6.98e-16	2.13e-09	0.42	0.36	Obesity-related traits;	chr13:24400640	chr13:19349137~19407962:+
HNSC	trans	rs2456568	0.867	rs72962810	ENSG00000276509.1	CH17-353B19.1	8.36	7.04e-16	2.14e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930453	chr1:146235806~146237807:+
HNSC	trans	rs916888	0.687	rs199456	ENSG00000204650.12	CRHR1-IT1	8.36	7.08e-16	2.16e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45620328~45648216:+
HNSC	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	8.36	7.1e-16	2.16e-09	0.49	0.36	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	8.36	7.14e-16	2.17e-09	0.48	0.36	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	8.36	7.14e-16	2.17e-09	0.48	0.36	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	8.36	7.14e-16	2.17e-09	0.48	0.36	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs7129905	ENSG00000257675.1	RP11-641A6.9	8.36	7.17e-16	2.18e-09	0.43	0.36	Bone mineral density;	chr11:13591038	chr12:52748776~52750127:+
HNSC	trans	rs11023332	0.617	rs1451678	ENSG00000236360.2	RP11-334A14.2	8.36	7.2e-16	2.19e-09	0.47	0.36	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr1:52993201~52993702:-
HNSC	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	8.36	7.21e-16	2.19e-09	0.53	0.36	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.553	rs3795966	ENSG00000235105.1	RP11-329A14.1	8.36	7.32e-16	2.23e-09	0.46	0.36	Breast cancer;	chr2:201380521	chr1:48435967~48437223:+
HNSC	trans	rs7662987	0.818	rs35123946	ENSG00000233859.2	ADH5P4	8.36	7.39e-16	2.25e-09	0.64	0.36	Smoking initiation;	chr4:99079760	chr6:65836930~65838039:-
HNSC	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	8.36	7.53e-16	2.29e-09	0.47	0.36	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	8.36	7.54e-16	2.29e-09	0.48	0.36	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	8.35	7.71e-16	2.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.821	rs70600	ENSG00000204650.12	CRHR1-IT1	8.35	7.73e-16	2.35e-09	0.43	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45620328~45648216:+
HNSC	trans	rs11023332	0.65	rs2122942	ENSG00000236360.2	RP11-334A14.2	8.35	7.75e-16	2.35e-09	0.47	0.36	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr1:52993201~52993702:-
HNSC	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48384185	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48384586	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48385757	chr1:27649419~27649610:+
HNSC	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48386489	chr1:27649419~27649610:+
HNSC	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48387420	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48388977	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48392157	chr1:27649419~27649610:+
HNSC	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48392588	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-8.35	7.8e-16	2.36e-09	-0.38	-0.36	Longevity;	chr3:48392923	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	8.35	7.91e-16	2.4e-09	0.45	0.36	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
HNSC	trans	rs11023332	0.641	rs4281505	ENSG00000236360.2	RP11-334A14.2	8.35	7.92e-16	2.4e-09	0.47	0.36	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr1:52993201~52993702:-
HNSC	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	8.35	7.92e-16	2.4e-09	0.5	0.36	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs10832064	ENSG00000257675.1	RP11-641A6.9	8.35	7.93e-16	2.4e-09	0.43	0.36	Bone mineral density;	chr11:13554655	chr12:52748776~52750127:+
HNSC	trans	rs7121616	0.576	rs7111598	ENSG00000229091.2	HSPA8P8	8.35	7.95e-16	2.41e-09	0.45	0.36	Breast cancer;	chr11:123055438	chr7:10451311~10452526:+
HNSC	trans	rs77688320	0.535	rs7579853	ENSG00000235105.1	RP11-329A14.1	8.35	7.99e-16	2.42e-09	0.46	0.36	Breast cancer;	chr2:201384256	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	8.35	8e-16	2.42e-09	0.48	0.36	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
HNSC	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-8.35	8.05e-16	2.44e-09	-0.53	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	8.34	8.14e-16	2.46e-09	0.48	0.36	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.517	rs12623282	ENSG00000235105.1	RP11-329A14.1	8.34	8.2e-16	2.48e-09	0.46	0.36	Breast cancer;	chr2:201382734	chr1:48435967~48437223:+
HNSC	trans	rs7833986	0.501	rs72653959	ENSG00000244245.1	RP11-120B7.1	8.34	8.21e-16	2.48e-09	0.42	0.36	Height;	chr8:56083957	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs72653962	ENSG00000244245.1	RP11-120B7.1	8.34	8.21e-16	2.48e-09	0.42	0.36	Height;	chr8:56084946	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs72653967	ENSG00000244245.1	RP11-120B7.1	8.34	8.21e-16	2.48e-09	0.42	0.36	Height;	chr8:56086873	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs72653978	ENSG00000244245.1	RP11-120B7.1	8.34	8.21e-16	2.48e-09	0.42	0.36	Height;	chr8:56105834	chr5:108593609~108593967:+
HNSC	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-8.34	8.33e-16	2.52e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	8.34	8.35e-16	2.52e-09	0.48	0.36	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
HNSC	trans	rs55665837	0.539	rs10500804	ENSG00000236360.2	RP11-334A14.2	8.34	8.58e-16	2.59e-09	0.51	0.36	Vitamin D levels;	chr11:14888727	chr1:52993201~52993702:-
HNSC	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	8.34	8.61e-16	2.6e-09	0.48	0.36	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
HNSC	trans	rs12145833	0.538	rs10754798	ENSG00000154608.12	CEP170P1	8.34	8.62e-16	2.6e-09	0.49	0.36	Obesity (early onset extreme);	chr1:243146656	chr4:118467590~118554204:+
HNSC	trans	rs2456568	0.775	rs1607404	ENSG00000276509.1	CH17-353B19.1	8.34	8.65e-16	2.61e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93927283	chr1:146235806~146237807:+
HNSC	trans	rs9630182	0.77	rs1870413	ENSG00000257675.1	RP11-641A6.9	8.33	8.79e-16	2.65e-09	0.42	0.36	Bone mineral density;	chr11:13567608	chr12:52748776~52750127:+
HNSC	trans	rs697003	0.966	rs701929	ENSG00000230450.1	NEK2P4	-8.33	8.82e-16	2.66e-09	-0.36	-0.36	Red cell distribution width;	chr1:211673534	chr2:131177618~131178946:-
HNSC	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	8.33	8.84e-16	2.67e-09	0.5	0.36	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	8.33	8.89e-16	2.68e-09	0.5	0.36	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	8.33	8.98e-16	2.71e-09	0.48	0.36	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	8.33	9.03e-16	2.72e-09	0.48	0.36	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.576	rs7949127	ENSG00000229091.2	HSPA8P8	8.33	9.09e-16	2.74e-09	0.46	0.36	Breast cancer;	chr11:123057408	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.576	rs7949220	ENSG00000229091.2	HSPA8P8	8.33	9.09e-16	2.74e-09	0.46	0.36	Breast cancer;	chr11:123057418	chr7:10451311~10452526:+
HNSC	trans	rs916888	0.773	rs169201	ENSG00000204650.12	CRHR1-IT1	8.33	9.13e-16	2.75e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	8.33	9.23e-16	2.78e-09	0.47	0.36	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	8.33	9.24e-16	2.78e-09	0.48	0.36	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	8.33	9.27e-16	2.79e-09	0.48	0.36	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
HNSC	trans	rs6708331	0.715	rs11899723	ENSG00000232654.1	FAM136BP	8.33	9.29e-16	2.8e-09	0.45	0.36	Obesity-related traits;	chr2:69968887	chr6:3045384~3045800:+
HNSC	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	8.33	9.29e-16	2.8e-09	0.48	0.36	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	8.33	9.36e-16	2.82e-09	0.47	0.36	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs2667999	ENSG00000244245.1	RP11-120B7.1	8.33	9.39e-16	2.82e-09	0.42	0.36	Height;	chr8:56037915	chr5:108593609~108593967:+
HNSC	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-8.32	9.53e-16	2.87e-09	-0.38	-0.36	Longevity;	chr3:48396724	chr1:27649419~27649610:+
HNSC	trans	rs9630182	0.73	rs3099598	ENSG00000257675.1	RP11-641A6.9	8.32	9.56e-16	2.87e-09	0.43	0.36	Bone mineral density;	chr11:13481336	chr12:52748776~52750127:+
HNSC	trans	rs7930295	0.505	rs34303332	ENSG00000236257.1	EI24P2	8.32	9.56e-16	2.88e-09	0.5	0.36	Schizophrenia;	chr11:125544288	chr1:158454198~158455273:+
HNSC	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	8.32	9.58e-16	2.88e-09	0.48	0.36	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	8.32	9.7e-16	2.91e-09	0.49	0.36	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.9	rs2511376	ENSG00000276509.1	CH17-353B19.1	8.32	9.72e-16	2.92e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93937222	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.867	rs2511375	ENSG00000276509.1	CH17-353B19.1	8.32	9.72e-16	2.92e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93937951	chr1:146235806~146237807:+
HNSC	trans	rs12145833	0.538	rs61833885	ENSG00000154608.12	CEP170P1	-8.32	9.87e-16	2.97e-09	-0.54	-0.36	Obesity (early onset extreme);	chr1:243233886	chr4:118467590~118554204:+
HNSC	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	8.32	9.97e-16	2.99e-09	0.49	0.36	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	8.32	1e-15	3e-09	0.49	0.36	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	8.32	1e-15	3.01e-09	0.48	0.36	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs72653917	ENSG00000244245.1	RP11-120B7.1	8.31	1.01e-15	3.04e-09	0.42	0.36	Height;	chr8:55980285	chr5:108593609~108593967:+
HNSC	trans	rs916888	0.773	rs1378358	ENSG00000204650.12	CRHR1-IT1	8.31	1.02e-15	3.07e-09	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	8.31	1.07e-15	3.19e-09	0.47	0.36	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	8.31	1.07e-15	3.2e-09	0.48	0.36	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	8.31	1.07e-15	3.2e-09	0.48	0.36	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	8.31	1.07e-15	3.2e-09	0.48	0.36	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	8.31	1.07e-15	3.2e-09	0.48	0.36	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
HNSC	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-8.31	1.08e-15	3.22e-09	-0.53	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs307248	ENSG00000257675.1	RP11-641A6.9	8.31	1.08e-15	3.23e-09	0.43	0.36	Bone mineral density;	chr11:13491818	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs307247	ENSG00000257675.1	RP11-641A6.9	8.31	1.08e-15	3.23e-09	0.43	0.36	Bone mineral density;	chr11:13491931	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs192802	ENSG00000257675.1	RP11-641A6.9	8.31	1.08e-15	3.23e-09	0.43	0.36	Bone mineral density;	chr11:13494647	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs3099597	ENSG00000257675.1	RP11-641A6.9	8.31	1.08e-15	3.23e-09	0.43	0.36	Bone mineral density;	chr11:13495857	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs11022887	ENSG00000257675.1	RP11-641A6.9	8.31	1.08e-15	3.23e-09	0.43	0.36	Bone mineral density;	chr11:13563229	chr12:52748776~52750127:+
HNSC	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	8.31	1.08e-15	3.23e-09	0.37	0.36	Longevity;	chr3:48407742	chr1:27649419~27649610:+
HNSC	trans	rs7833986	0.534	rs10504198	ENSG00000244245.1	RP11-120B7.1	8.31	1.09e-15	3.26e-09	0.42	0.36	Height;	chr8:56093695	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.534	rs2976022	ENSG00000244245.1	RP11-120B7.1	8.31	1.09e-15	3.26e-09	0.42	0.36	Height;	chr8:56095284	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2976018	ENSG00000244245.1	RP11-120B7.1	8.31	1.09e-15	3.26e-09	0.42	0.36	Height;	chr8:56102193	chr5:108593609~108593967:+
HNSC	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-8.3	1.11e-15	3.33e-09	-0.38	-0.36	Longevity;	chr3:48395329	chr1:27649419~27649610:+
HNSC	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-8.3	1.11e-15	3.33e-09	-0.38	-0.36	Longevity;	chr3:48398582	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	8.3	1.12e-15	3.34e-09	0.47	0.36	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
HNSC	trans	rs3849046	0.846	rs462783	ENSG00000226666.1	HSPA9P1	-8.3	1.13e-15	3.38e-09	-0.36	-0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536427	chr2:221961737~221963765:+
HNSC	trans	rs7121616	0.545	rs7109348	ENSG00000229091.2	HSPA8P8	8.3	1.13e-15	3.39e-09	0.46	0.36	Breast cancer;	chr11:123056555	chr7:10451311~10452526:+
HNSC	trans	rs7032940	0.677	rs4279674	ENSG00000262519.1	TXNP4	8.3	1.14e-15	3.4e-09	0.45	0.36	Height;	chr9:110179726	chr17:4572206~4572515:+
HNSC	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	8.3	1.16e-15	3.46e-09	0.47	0.36	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-8.3	1.16e-15	3.47e-09	-0.53	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	8.3	1.16e-15	3.48e-09	0.47	0.36	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-8.3	1.17e-15	3.49e-09	-0.4	-0.36	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-8.3	1.17e-15	3.49e-09	-0.4	-0.36	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
HNSC	trans	rs77688320	0.535	rs34625194	ENSG00000235105.1	RP11-329A14.1	8.29	1.17e-15	3.5e-09	0.46	0.36	Breast cancer;	chr2:201406815	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs11691859	ENSG00000235105.1	RP11-329A14.1	8.29	1.17e-15	3.5e-09	0.46	0.36	Breast cancer;	chr2:201407268	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.517	rs11691865	ENSG00000235105.1	RP11-329A14.1	8.29	1.17e-15	3.5e-09	0.46	0.36	Breast cancer;	chr2:201407309	chr1:48435967~48437223:+
HNSC	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	8.29	1.17e-15	3.51e-09	0.48	0.36	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	8.29	1.17e-15	3.51e-09	0.48	0.36	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-8.29	1.18e-15	3.52e-09	-0.46	-0.36	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-8.29	1.18e-15	3.52e-09	-0.46	-0.36	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	8.29	1.2e-15	3.57e-09	0.49	0.36	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
HNSC	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	8.29	1.2e-15	3.57e-09	0.45	0.36	Mumps;	chr20:2666724	chr6:28783633~28784004:-
HNSC	trans	rs9630182	0.73	rs2593570	ENSG00000257675.1	RP11-641A6.9	8.29	1.2e-15	3.59e-09	0.43	0.36	Bone mineral density;	chr11:13497045	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	8.29	1.21e-15	3.61e-09	0.48	0.36	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	8.29	1.21e-15	3.61e-09	0.48	0.36	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	8.29	1.24e-15	3.7e-09	0.48	0.36	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	8.29	1.25e-15	3.72e-09	0.42	0.36	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
HNSC	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	8.29	1.25e-15	3.73e-09	0.48	0.36	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	8.28	1.26e-15	3.76e-09	0.47	0.36	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	8.28	1.26e-15	3.76e-09	0.47	0.36	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.686	rs2050376	ENSG00000255397.1	AC022182.2	-8.28	1.3e-15	3.87e-09	-0.46	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	8.28	1.32e-15	3.91e-09	0.46	0.36	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
HNSC	trans	rs9611519	0.639	rs7290458	ENSG00000268568.1	AC007228.9	8.28	1.32e-15	3.93e-09	0.43	0.36	Neuroticism;	chr22:41080333	chr19:56672574~56673901:-
HNSC	trans	rs1079467	0.73	rs4259814	ENSG00000233426.3	EIF3FP3	-8.28	1.34e-15	3.99e-09	-0.6	-0.36	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950941	chr2:58251440~58252525:+
HNSC	trans	rs9611519	0.639	rs7289989	ENSG00000268568.1	AC007228.9	-8.28	1.35e-15	4.01e-09	-0.42	-0.36	Neuroticism;	chr22:41080795	chr19:56672574~56673901:-
HNSC	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	8.28	1.36e-15	4.02e-09	0.46	0.36	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs2719257	ENSG00000244245.1	RP11-120B7.1	8.27	1.36e-15	4.03e-09	0.41	0.36	Height;	chr8:56027614	chr5:108593609~108593967:+
HNSC	trans	rs9630182	0.77	rs4757178	ENSG00000257675.1	RP11-641A6.9	8.27	1.37e-15	4.06e-09	0.43	0.36	Bone mineral density;	chr11:13561201	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs2006692	ENSG00000257675.1	RP11-641A6.9	8.27	1.37e-15	4.06e-09	0.43	0.36	Bone mineral density;	chr11:13561301	chr12:52748776~52750127:+
HNSC	trans	rs12709013	0.967	rs2118019	ENSG00000233719.3	GOT2P3	-8.27	1.37e-15	4.07e-09	-0.44	-0.36	Blood metabolite ratios;	chr16:58797825	chr12:9641802~9643007:+
HNSC	trans	rs7833986	0.501	rs2667983	ENSG00000244245.1	RP11-120B7.1	8.27	1.38e-15	4.09e-09	0.42	0.36	Height;	chr8:55981528	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2667981	ENSG00000244245.1	RP11-120B7.1	8.27	1.38e-15	4.09e-09	0.42	0.36	Height;	chr8:55981744	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2719245	ENSG00000244245.1	RP11-120B7.1	8.27	1.38e-15	4.09e-09	0.42	0.36	Height;	chr8:55981800	chr5:108593609~108593967:+
HNSC	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	8.27	1.39e-15	4.11e-09	0.5	0.36	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
HNSC	trans	rs12709013	0.967	rs56107162	ENSG00000233719.3	GOT2P3	8.27	1.39e-15	4.13e-09	0.44	0.36	Blood metabolite ratios;	chr16:58804358	chr12:9641802~9643007:+
HNSC	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	8.27	1.4e-15	4.14e-09	0.47	0.36	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	8.27	1.4e-15	4.15e-09	0.48	0.36	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
HNSC	trans	rs7833986	0.501	rs72653953	ENSG00000244245.1	RP11-120B7.1	8.27	1.4e-15	4.16e-09	0.42	0.36	Height;	chr8:56058236	chr5:108593609~108593967:+
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-8.27	1.41e-15	4.16e-09	-0.4	-0.36	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
HNSC	trans	rs9630182	0.77	rs307220	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.43	0.36	Bone mineral density;	chr11:13511363	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs7924884	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13568710	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757182	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13574450	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10430832	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13576244	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.73	rs898147	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13576797	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs1459018	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13577376	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757184	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13580135	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757185	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13580883	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs2896638	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13581545	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs2403673	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13581555	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs12278533	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13582232	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs11493157	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13583685	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs77921823	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13584238	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs11512032	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13585270	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs2125557	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13589402	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10766099	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13590132	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10160224	ENSG00000257675.1	RP11-641A6.9	8.27	1.41e-15	4.17e-09	0.42	0.36	Bone mineral density;	chr11:13590304	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-8.27	1.41e-15	4.17e-09	-0.48	-0.36	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.9	rs2511373	ENSG00000276509.1	CH17-353B19.1	8.27	1.42e-15	4.2e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93938248	chr1:146235806~146237807:+
HNSC	trans	rs12439619	0.693	rs7165536	ENSG00000259295.5	CSPG4P12	-8.27	1.42e-15	4.21e-09	-0.49	-0.36	Intelligence (multi-trait analysis);	chr15:82273743	chr15:85191438~85213905:+
HNSC	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	8.27	1.43e-15	4.22e-09	0.47	0.36	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	8.27	1.43e-15	4.22e-09	0.47	0.36	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-8.27	1.43e-15	4.23e-09	-0.46	-0.36	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
HNSC	trans	rs28647808	0.881	rs4962139	ENSG00000234981.1	RP11-534L20.4	-8.27	1.44e-15	4.25e-09	-0.57	-0.36	Blood protein levels;	chr9:133402740	chr1:206528915~206529706:+
HNSC	trans	rs9630182	0.693	rs307210	ENSG00000257675.1	RP11-641A6.9	8.27	1.45e-15	4.28e-09	0.42	0.36	Bone mineral density;	chr11:13501327	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs307208	ENSG00000257675.1	RP11-641A6.9	8.27	1.45e-15	4.28e-09	0.42	0.36	Bone mineral density;	chr11:13501947	chr12:52748776~52750127:+
HNSC	trans	rs2456568	0.805	rs55784864	ENSG00000276509.1	CH17-353B19.1	8.26	1.48e-15	4.36e-09	0.38	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93949721	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.805	rs55649862	ENSG00000276509.1	CH17-353B19.1	8.26	1.48e-15	4.36e-09	0.38	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93949722	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.867	rs2462744	ENSG00000276509.1	CH17-353B19.1	8.26	1.48e-15	4.36e-09	0.38	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93949747	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.933	rs1518577	ENSG00000276509.1	CH17-353B19.1	8.26	1.48e-15	4.38e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93941741	chr1:146235806~146237807:+
HNSC	trans	rs77688320	0.535	rs10804115	ENSG00000235105.1	RP11-329A14.1	8.26	1.49e-15	4.39e-09	0.46	0.36	Breast cancer;	chr2:201415510	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	8.26	1.49e-15	4.39e-09	0.47	0.36	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.805	rs2032400	ENSG00000276509.1	CH17-353B19.1	8.26	1.49e-15	4.39e-09	0.39	0.36	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93943771	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	8.26	1.49e-15	4.39e-09	0.47	0.36	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
HNSC	trans	rs1816752	0.875	rs59686377	ENSG00000224976.2	PARP4P2	-8.26	1.51e-15	4.46e-09	-0.41	-0.36	Obesity-related traits;	chr13:24475869	chr13:19349137~19407962:+
HNSC	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	8.26	1.53e-15	4.52e-09	0.48	0.36	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
HNSC	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	8.26	1.53e-15	4.52e-09	0.48	0.36	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	8.26	1.56e-15	4.6e-09	0.48	0.36	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	8.26	1.56e-15	4.6e-09	0.47	0.36	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	8.25	1.58e-15	4.66e-09	0.47	0.36	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	8.25	1.58e-15	4.66e-09	0.47	0.36	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
HNSC	trans	rs77688320	0.535	rs7575721	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201392055	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs3815515	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201393207	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs13001194	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201396452	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs7597850	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201396679	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs7571761	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201396837	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs10931944	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201398875	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs11681526	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201399037	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs13022344	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201399433	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs6732993	ENSG00000235105.1	RP11-329A14.1	8.25	1.59e-15	4.68e-09	0.46	0.36	Breast cancer;	chr2:201399593	chr1:48435967~48437223:+
HNSC	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	8.25	1.59e-15	4.68e-09	0.47	0.36	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	8.25	1.59e-15	4.68e-09	0.47	0.36	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	8.25	1.59e-15	4.68e-09	0.47	0.36	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	8.25	1.59e-15	4.68e-09	0.47	0.36	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-8.25	1.59e-15	4.69e-09	-0.53	-0.36	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
HNSC	trans	rs3849046	0.817	rs154069	ENSG00000226666.1	HSPA9P1	8.25	1.6e-15	4.71e-09	0.36	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138541231	chr2:221961737~221963765:+
HNSC	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	8.25	1.62e-15	4.75e-09	0.48	0.36	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	8.25	1.62e-15	4.76e-09	0.48	0.36	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	8.25	1.65e-15	4.84e-09	0.47	0.36	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	8.25	1.65e-15	4.84e-09	0.47	0.36	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.77	rs2403671	ENSG00000257675.1	RP11-641A6.9	8.25	1.65e-15	4.85e-09	0.42	0.36	Bone mineral density;	chr11:13581427	chr12:52748776~52750127:+
HNSC	trans	rs7121616	0.576	rs7123232	ENSG00000229091.2	HSPA8P8	8.25	1.67e-15	4.89e-09	0.44	0.36	Breast cancer;	chr11:123056237	chr7:10451311~10452526:+
HNSC	trans	rs9630182	0.77	rs2609802	ENSG00000257675.1	RP11-641A6.9	8.25	1.67e-15	4.9e-09	0.43	0.36	Bone mineral density;	chr11:13506970	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.74	rs2609803	ENSG00000257675.1	RP11-641A6.9	8.25	1.67e-15	4.9e-09	0.43	0.36	Bone mineral density;	chr11:13507078	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs307221	ENSG00000257675.1	RP11-641A6.9	8.25	1.67e-15	4.9e-09	0.43	0.36	Bone mineral density;	chr11:13511791	chr12:52748776~52750127:+
HNSC	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-8.24	1.69e-15	4.96e-09	-0.55	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
HNSC	trans	rs7833986	0.501	rs72653948	ENSG00000244245.1	RP11-120B7.1	8.24	1.69e-15	4.97e-09	0.4	0.36	Height;	chr8:56043130	chr5:108593609~108593967:+
HNSC	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	8.24	1.71e-15	5.01e-09	0.48	0.36	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs1870411	ENSG00000257675.1	RP11-641A6.9	8.24	1.72e-15	5.05e-09	0.42	0.36	Bone mineral density;	chr11:13567396	chr12:52748776~52750127:+
HNSC	trans	rs55665837	0.701	rs10766188	ENSG00000236360.2	RP11-334A14.2	8.24	1.73e-15	5.06e-09	0.48	0.36	Vitamin D levels;	chr11:14639280	chr1:52993201~52993702:-
HNSC	trans	rs12439619	0.693	rs4778989	ENSG00000259295.5	CSPG4P12	-8.24	1.73e-15	5.08e-09	-0.48	-0.36	Intelligence (multi-trait analysis);	chr15:82276963	chr15:85191438~85213905:+
HNSC	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	8.24	1.74e-15	5.1e-09	0.46	0.36	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
HNSC	trans	rs12145833	0.538	rs10926977	ENSG00000154608.12	CEP170P1	-8.24	1.75e-15	5.12e-09	-0.54	-0.36	Obesity (early onset extreme);	chr1:243248065	chr4:118467590~118554204:+
HNSC	trans	rs7833986	0.534	rs72653928	ENSG00000244245.1	RP11-120B7.1	8.24	1.75e-15	5.12e-09	0.41	0.36	Height;	chr8:55995176	chr5:108593609~108593967:+
HNSC	trans	rs3849046	0.846	rs10117	ENSG00000226666.1	HSPA9P1	8.24	1.76e-15	5.15e-09	0.36	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138556481	chr2:221961737~221963765:+
HNSC	trans	rs77688320	0.535	rs7579617	ENSG00000235105.1	RP11-329A14.1	8.24	1.77e-15	5.18e-09	0.45	0.36	Breast cancer;	chr2:201384065	chr1:48435967~48437223:+
HNSC	trans	rs9630182	0.77	rs4756766	ENSG00000257675.1	RP11-641A6.9	8.24	1.77e-15	5.19e-09	0.42	0.36	Bone mineral density;	chr11:13552026	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757169	ENSG00000257675.1	RP11-641A6.9	8.24	1.77e-15	5.19e-09	0.42	0.36	Bone mineral density;	chr11:13552175	chr12:52748776~52750127:+
HNSC	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-8.24	1.8e-15	5.27e-09	-0.5	-0.36	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
HNSC	trans	rs3849046	0.79	rs188731	ENSG00000226666.1	HSPA9P1	8.24	1.81e-15	5.28e-09	0.36	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545415	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.619	rs181919	ENSG00000226666.1	HSPA9P1	8.24	1.81e-15	5.28e-09	0.36	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138546923	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.875	rs255999	ENSG00000226666.1	HSPA9P1	8.24	1.81e-15	5.28e-09	0.36	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138554110	chr2:221961737~221963765:+
HNSC	trans	rs9630182	0.77	rs1011923	ENSG00000257675.1	RP11-641A6.9	8.24	1.81e-15	5.28e-09	0.42	0.36	Bone mineral density;	chr11:13569225	chr12:52748776~52750127:+
HNSC	trans	rs77688320	0.535	rs2241118	ENSG00000235105.1	RP11-329A14.1	8.24	1.81e-15	5.29e-09	0.45	0.36	Breast cancer;	chr2:201388993	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs6761777	ENSG00000235105.1	RP11-329A14.1	8.23	1.84e-15	5.38e-09	0.46	0.36	Breast cancer;	chr2:201399879	chr1:48435967~48437223:+
HNSC	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	8.23	1.85e-15	5.4e-09	0.5	0.36	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
HNSC	trans	rs7833986	0.501	rs9650314	ENSG00000244245.1	RP11-120B7.1	8.23	1.86e-15	5.42e-09	0.41	0.36	Height;	chr8:55991051	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.534	rs72653924	ENSG00000244245.1	RP11-120B7.1	8.23	1.86e-15	5.42e-09	0.41	0.36	Height;	chr8:55993529	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.534	rs2667972	ENSG00000244245.1	RP11-120B7.1	8.23	1.86e-15	5.42e-09	0.41	0.36	Height;	chr8:55994102	chr5:108593609~108593967:+
HNSC	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	8.23	1.88e-15	5.49e-09	0.48	0.36	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	8.23	1.89e-15	5.51e-09	0.48	0.36	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
HNSC	trans	rs55665837	0.701	rs11023265	ENSG00000236360.2	RP11-334A14.2	8.23	1.93e-15	5.63e-09	0.48	0.36	Vitamin D levels;	chr11:14594492	chr1:52993201~52993702:-
HNSC	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-8.22	2.01e-15	5.86e-09	-0.48	-0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
HNSC	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-8.22	2.01e-15	5.86e-09	-0.48	-0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
HNSC	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	8.22	2.03e-15	5.92e-09	0.47	0.36	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	8.22	2.03e-15	5.92e-09	0.47	0.36	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	8.22	2.03e-15	5.92e-09	0.47	0.36	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
HNSC	trans	rs55665837	0.701	rs10160597	ENSG00000236360.2	RP11-334A14.2	8.22	2.06e-15	5.99e-09	0.48	0.36	Vitamin D levels;	chr11:14582446	chr1:52993201~52993702:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-8.22	2.07e-15	6.03e-09	-0.4	-0.36	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
HNSC	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	8.22	2.08e-15	6.05e-09	0.47	0.36	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	8.22	2.08e-15	6.05e-09	0.47	0.36	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
HNSC	trans	rs77688320	0.535	rs6751543	ENSG00000235105.1	RP11-329A14.1	8.22	2.08e-15	6.05e-09	0.45	0.36	Breast cancer;	chr2:201400210	chr1:48435967~48437223:+
HNSC	trans	rs12709013	1	rs11644891	ENSG00000233719.3	GOT2P3	8.22	2.09e-15	6.07e-09	0.43	0.36	Blood metabolite ratios;	chr16:58799921	chr12:9641802~9643007:+
HNSC	trans	rs12439619	0.693	rs28689861	ENSG00000259295.5	CSPG4P12	-8.22	2.09e-15	6.09e-09	-0.49	-0.36	Intelligence (multi-trait analysis);	chr15:82206369	chr15:85191438~85213905:+
HNSC	trans	rs1816752	0.583	rs6490918	ENSG00000224976.2	PARP4P2	8.21	2.14e-15	6.23e-09	0.41	0.36	Obesity-related traits;	chr13:24427977	chr13:19349137~19407962:+
HNSC	trans	rs7833986	0.501	rs72653951	ENSG00000244245.1	RP11-120B7.1	8.21	2.15e-15	6.25e-09	0.4	0.36	Height;	chr8:56049278	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2719261	ENSG00000244245.1	RP11-120B7.1	8.21	2.15e-15	6.26e-09	0.4	0.36	Height;	chr8:56029423	chr5:108593609~108593967:+
HNSC	trans	rs12709013	1	rs11648514	ENSG00000233719.3	GOT2P3	8.21	2.16e-15	6.28e-09	0.43	0.36	Blood metabolite ratios;	chr16:58798176	chr12:9641802~9643007:+
HNSC	trans	rs12709013	1	rs8057892	ENSG00000233719.3	GOT2P3	8.21	2.16e-15	6.28e-09	0.43	0.36	Blood metabolite ratios;	chr16:58798855	chr12:9641802~9643007:+
HNSC	trans	rs9611519	0.603	rs4821999	ENSG00000268568.1	AC007228.9	-8.21	2.16e-15	6.28e-09	-0.42	-0.36	Neuroticism;	chr22:41073997	chr19:56672574~56673901:-
HNSC	trans	rs916888	0.773	rs199534	ENSG00000204650.12	CRHR1-IT1	8.21	2.18e-15	6.34e-09	0.43	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.773	rs199533	ENSG00000204650.12	CRHR1-IT1	8.21	2.18e-15	6.34e-09	0.43	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45620328~45648216:+
HNSC	trans	rs9611519	0.603	rs8142276	ENSG00000268568.1	AC007228.9	-8.21	2.2e-15	6.4e-09	-0.42	-0.36	Neuroticism;	chr22:41075443	chr19:56672574~56673901:-
HNSC	trans	rs9611519	0.567	rs8141730	ENSG00000268568.1	AC007228.9	-8.21	2.2e-15	6.4e-09	-0.42	-0.36	Neuroticism;	chr22:41077057	chr19:56672574~56673901:-
HNSC	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-8.21	2.21e-15	6.42e-09	-0.54	-0.36	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-8.21	2.21e-15	6.42e-09	-0.54	-0.36	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	8.21	2.24e-15	6.51e-09	0.46	0.35	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
HNSC	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-8.21	2.26e-15	6.55e-09	-0.53	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
HNSC	trans	rs7833986	0.501	rs2719258	ENSG00000244245.1	RP11-120B7.1	8.2	2.29e-15	6.63e-09	0.4	0.35	Height;	chr8:56028830	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2719259	ENSG00000244245.1	RP11-120B7.1	8.2	2.29e-15	6.63e-09	0.4	0.35	Height;	chr8:56029071	chr5:108593609~108593967:+
HNSC	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	8.2	2.3e-15	6.66e-09	0.48	0.35	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	8.2	2.3e-15	6.67e-09	0.47	0.35	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	8.2	2.32e-15	6.7e-09	0.48	0.35	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	8.2	2.35e-15	6.79e-09	0.47	0.35	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	6.82e-09	0.47	0.35	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	6.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	6.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	6.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	6.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.752	rs28550303	ENSG00000255397.1	AC022182.2	-8.2	2.37e-15	6.86e-09	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	8.2	2.39e-15	6.9e-09	0.47	0.35	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	8.2	2.39e-15	6.9e-09	0.47	0.35	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	8.2	2.39e-15	6.9e-09	0.47	0.35	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	8.2	2.39e-15	6.9e-09	0.47	0.35	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs72653941	ENSG00000244245.1	RP11-120B7.1	8.19	2.43e-15	7.03e-09	0.4	0.35	Height;	chr8:56029688	chr5:108593609~108593967:+
HNSC	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	8.19	2.45e-15	7.06e-09	0.47	0.35	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	8.19	2.45e-15	7.06e-09	0.47	0.35	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
HNSC	trans	rs6673267	0.874	rs10753887	ENSG00000244144.1	RP11-757F18.3	-8.19	2.45e-15	7.06e-09	-0.41	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201020313	chr3:112185480~112185998:-
HNSC	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	8.19	2.49e-15	7.18e-09	0.47	0.35	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	8.19	2.5e-15	7.2e-09	0.47	0.35	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	8.19	2.51e-15	7.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
HNSC	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-8.19	2.52e-15	7.25e-09	-0.49	-0.35	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.752	rs11211168	ENSG00000255397.1	AC022182.2	-8.19	2.54e-15	7.31e-09	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.773	rs199447	ENSG00000204650.12	CRHR1-IT1	8.19	2.54e-15	7.32e-09	0.43	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45620328~45648216:+
HNSC	trans	rs7833986	0.501	rs2953909	ENSG00000244245.1	RP11-120B7.1	8.19	2.54e-15	7.32e-09	0.41	0.35	Height;	chr8:56055641	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2953910	ENSG00000244245.1	RP11-120B7.1	8.19	2.54e-15	7.32e-09	0.41	0.35	Height;	chr8:56056202	chr5:108593609~108593967:+
HNSC	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	8.19	2.55e-15	7.33e-09	0.47	0.35	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	8.19	2.58e-15	7.42e-09	0.48	0.35	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
HNSC	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	8.18	2.66e-15	7.65e-09	0.38	0.35	Longevity;	chr3:48372047	chr1:27649419~27649610:+
HNSC	trans	rs12497850	0.931	rs7616815	ENSG00000197582.5	GPX1P1	8.18	2.68e-15	7.7e-09	0.47	0.35	Parkinson's disease;	chr3:48742282	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	8.18	2.72e-15	7.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	8.18	2.72e-15	7.82e-09	0.47	0.35	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
HNSC	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	8.18	2.74e-15	7.88e-09	0.47	0.35	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
HNSC	trans	rs12709013	1	rs11641566	ENSG00000233719.3	GOT2P3	8.17	2.82e-15	8.11e-09	0.43	0.35	Blood metabolite ratios;	chr16:58801276	chr12:9641802~9643007:+
HNSC	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	-8.17	2.82e-15	8.11e-09	-0.43	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	-8.17	2.82e-15	8.11e-09	-0.43	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
HNSC	trans	rs9630182	0.77	rs3101175	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13515843	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10766087	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13516013	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757159	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13516279	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs1459016	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13517987	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10832049	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13519604	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10444247	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13521285	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10444248	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13523570	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs1870414	ENSG00000257675.1	RP11-641A6.9	8.17	2.86e-15	8.19e-09	0.42	0.35	Bone mineral density;	chr11:13524437	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	8.17	2.87e-15	8.22e-09	0.47	0.35	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.9	rs1518571	ENSG00000276509.1	CH17-353B19.1	8.17	2.89e-15	8.28e-09	0.39	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93934254	chr1:146235806~146237807:+
HNSC	trans	rs616147	0.616	rs1768234	ENSG00000214263.2	RPSAP53	-8.17	2.93e-15	8.39e-09	-0.48	-0.35	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr13:67266845~67267706:-
HNSC	trans	rs7032940	0.677	rs1331310	ENSG00000262519.1	TXNP4	8.17	2.95e-15	8.44e-09	0.45	0.35	Height;	chr9:110179601	chr17:4572206~4572515:+
HNSC	trans	rs55665837	0.701	rs11023272	ENSG00000236360.2	RP11-334A14.2	8.17	2.97e-15	8.5e-09	0.48	0.35	Vitamin D levels;	chr11:14608824	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.665	rs11023273	ENSG00000236360.2	RP11-334A14.2	8.17	2.97e-15	8.5e-09	0.48	0.35	Vitamin D levels;	chr11:14609273	chr1:52993201~52993702:-
HNSC	trans	rs12709013	1	rs6499983	ENSG00000233719.3	GOT2P3	8.17	2.99e-15	8.55e-09	0.43	0.35	Blood metabolite ratios;	chr16:58810005	chr12:9641802~9643007:+
HNSC	trans	rs12709013	0.967	rs8054482	ENSG00000233719.3	GOT2P3	8.17	2.99e-15	8.55e-09	0.43	0.35	Blood metabolite ratios;	chr16:58810532	chr12:9641802~9643007:+
HNSC	trans	rs7937890	0.681	rs4756784	ENSG00000236360.2	RP11-334A14.2	-8.17	3e-15	8.58e-09	-0.47	-0.35	Mitochondrial DNA levels;	chr11:14249358	chr1:52993201~52993702:-
HNSC	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-8.17	3.01e-15	8.61e-09	-0.47	-0.35	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
HNSC	trans	rs6132905	0.52	rs2422823	ENSG00000257956.1	NOP56P3	-8.16	3.06e-15	8.74e-09	-0.46	-0.35	Mumps;	chr20:2665687	chr12:79558782~79559166:+
HNSC	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-8.16	3.06e-15	8.75e-09	-0.52	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
HNSC	trans	rs7937890	0.732	rs7946902	ENSG00000236360.2	RP11-334A14.2	-8.16	3.07e-15	8.78e-09	-0.47	-0.35	Mitochondrial DNA levels;	chr11:14251762	chr1:52993201~52993702:-
HNSC	trans	rs12439619	0.693	rs17269819	ENSG00000259295.5	CSPG4P12	-8.16	3.11e-15	8.88e-09	-0.48	-0.35	Intelligence (multi-trait analysis);	chr15:82174660	chr15:85191438~85213905:+
HNSC	trans	rs2456568	1	rs2456568	ENSG00000276509.1	CH17-353B19.1	8.16	3.12e-15	8.91e-09	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93958166	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	8.16	3.12e-15	8.92e-09	0.45	0.35	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.691	rs61784799	ENSG00000255397.1	AC022182.2	8.16	3.12e-15	8.92e-09	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr8:60937705~60939871:-
HNSC	trans	rs12145833	0.538	rs12026408	ENSG00000154608.12	CEP170P1	-8.16	3.15e-15	8.98e-09	-0.55	-0.35	Obesity (early onset extreme);	chr1:243203503	chr4:118467590~118554204:+
HNSC	trans	rs55665837	0.701	rs12286408	ENSG00000236360.2	RP11-334A14.2	8.16	3.19e-15	9.1e-09	0.48	0.35	Vitamin D levels;	chr11:14557830	chr1:52993201~52993702:-
HNSC	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	8.16	3.22e-15	9.2e-09	0.46	0.35	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.77	rs307230	ENSG00000257675.1	RP11-641A6.9	8.15	3.26e-15	9.29e-09	0.42	0.35	Bone mineral density;	chr11:13470334	chr12:52748776~52750127:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	8.15	3.26e-15	9.3e-09	0.4	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
HNSC	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	8.15	3.28e-15	9.36e-09	0.47	0.35	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.711	rs307240	ENSG00000257675.1	RP11-641A6.9	8.15	3.32e-15	9.47e-09	0.42	0.35	Bone mineral density;	chr11:13473536	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs307241	ENSG00000257675.1	RP11-641A6.9	8.15	3.32e-15	9.47e-09	0.42	0.35	Bone mineral density;	chr11:13473878	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	8.15	3.38e-15	9.63e-09	0.47	0.35	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.656	rs9429172	ENSG00000255397.1	AC022182.2	8.15	3.4e-15	9.67e-09	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr8:60937705~60939871:-
HNSC	trans	rs7554511	0.555	rs11807626	ENSG00000244144.1	RP11-757F18.3	8.15	3.41e-15	9.7e-09	0.42	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031226	chr3:112185480~112185998:-
HNSC	trans	rs1079467	0.679	rs12286813	ENSG00000233426.3	EIF3FP3	-8.15	3.46e-15	9.86e-09	-0.58	-0.35	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949826	chr2:58251440~58252525:+
HNSC	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	8.14	3.58e-15	1.02e-08	0.49	0.35	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
HNSC	trans	rs2456568	0.867	rs7114457	ENSG00000276509.1	CH17-353B19.1	8.14	3.59e-15	1.02e-08	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93924651	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	8.14	3.7e-15	1.05e-08	0.48	0.35	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	8.13	3.83e-15	1.09e-08	0.46	0.35	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
HNSC	trans	rs7032940	0.784	rs10980253	ENSG00000262519.1	TXNP4	8.13	3.96e-15	1.12e-08	0.48	0.35	Height;	chr9:110205555	chr17:4572206~4572515:+
HNSC	trans	rs1707322	0.752	rs28890893	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.716	rs28375469	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28545085	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28812624	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28507722	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28568986	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs28396194	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs28752166	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs10890345	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10789471	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211173	ENSG00000255397.1	AC022182.2	-8.12	4.09e-15	1.16e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr8:60937705~60939871:-
HNSC	trans	rs6673267	0.504	rs296553	ENSG00000244144.1	RP11-757F18.3	8.12	4.16e-15	1.17e-08	0.41	0.35	Lobe attachment (rater-scored or self-reported);	chr1:200959647	chr3:112185480~112185998:-
HNSC	trans	rs1707322	0.752	rs12047629	ENSG00000255397.1	AC022182.2	-8.12	4.16e-15	1.17e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211169	ENSG00000255397.1	AC022182.2	-8.12	4.16e-15	1.17e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211171	ENSG00000255397.1	AC022182.2	-8.12	4.16e-15	1.17e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28623463	ENSG00000255397.1	AC022182.2	-8.12	4.16e-15	1.17e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.716	rs28370457	ENSG00000255397.1	AC022182.2	-8.12	4.16e-15	1.17e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr8:60937705~60939871:-
HNSC	trans	rs2456568	0.867	rs2456569	ENSG00000276509.1	CH17-353B19.1	8.12	4.16e-15	1.17e-08	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93958227	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	8.12	4.17e-15	1.17e-08	0.47	0.35	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.9	rs877340	ENSG00000276509.1	CH17-353B19.1	8.12	4.24e-15	1.19e-08	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93956126	chr1:146235806~146237807:+
HNSC	trans	rs7833986	0.534	rs17814089	ENSG00000244245.1	RP11-120B7.1	-8.12	4.26e-15	1.2e-08	-0.4	-0.35	Height;	chr8:56053004	chr5:108593609~108593967:+
HNSC	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	8.11	4.35e-15	1.22e-08	0.46	0.35	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	8.11	4.35e-15	1.22e-08	0.46	0.35	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	8.11	4.43e-15	1.24e-08	0.46	0.35	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
HNSC	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-8.11	4.46e-15	1.25e-08	-0.55	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
HNSC	trans	rs9630182	0.77	rs307250	ENSG00000257675.1	RP11-641A6.9	8.11	4.49e-15	1.26e-08	0.42	0.35	Bone mineral density;	chr11:13490401	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.752	rs12062535	ENSG00000255397.1	AC022182.2	-8.11	4.5e-15	1.26e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr8:60937705~60939871:-
HNSC	trans	rs8067354	0.831	rs2333617	ENSG00000187870.7	RNFT1P3	-8.11	4.5e-15	1.26e-08	-0.42	-0.35	Hemoglobin concentration;	chr17:59818859	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.872	rs7224006	ENSG00000187870.7	RNFT1P3	-8.11	4.5e-15	1.26e-08	-0.42	-0.35	Hemoglobin concentration;	chr17:59818977	chr17:20743333~20754501:-
HNSC	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-8.11	4.52e-15	1.27e-08	-0.53	-0.35	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.682	rs3014241	ENSG00000255397.1	AC022182.2	8.11	4.6e-15	1.29e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr8:60937705~60939871:-
HNSC	trans	rs8067354	0.872	rs1295925	ENSG00000187870.7	RNFT1P3	-8.1	4.7e-15	1.32e-08	-0.42	-0.35	Hemoglobin concentration;	chr17:59832902	chr17:20743333~20754501:-
HNSC	trans	rs1707322	0.627	rs3014213	ENSG00000255397.1	AC022182.2	8.1	4.73e-15	1.33e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2152078	ENSG00000255397.1	AC022182.2	8.1	4.73e-15	1.33e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2991979	ENSG00000255397.1	AC022182.2	8.1	4.73e-15	1.33e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-8.1	4.81e-15	1.35e-08	-0.45	-0.35	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
HNSC	trans	rs3849046	0.846	rs256007	ENSG00000226666.1	HSPA9P1	8.1	4.82e-15	1.35e-08	0.36	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561900	chr2:221961737~221963765:+
HNSC	trans	rs8067354	0.872	rs1292060	ENSG00000187870.7	RNFT1P3	8.1	4.83e-15	1.35e-08	0.42	0.35	Hemoglobin concentration;	chr17:59836488	chr17:20743333~20754501:-
HNSC	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	8.1	4.86e-15	1.36e-08	0.37	0.35	Longevity;	chr3:48371689	chr1:27649419~27649610:+
HNSC	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	8.1	4.87e-15	1.36e-08	0.46	0.35	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-8.1	4.95e-15	1.38e-08	-0.53	-0.35	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
HNSC	trans	rs7554511	0.535	rs10920090	ENSG00000244144.1	RP11-757F18.3	-8.1	4.98e-15	1.39e-08	-0.41	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201003326	chr3:112185480~112185998:-
HNSC	trans	rs2456568	0.9	rs2000960	ENSG00000276509.1	CH17-353B19.1	8.09	5.04e-15	1.41e-08	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93949182	chr1:146235806~146237807:+
HNSC	trans	rs55665837	0.701	rs2007361	ENSG00000236360.2	RP11-334A14.2	8.09	5.1e-15	1.42e-08	0.48	0.35	Vitamin D levels;	chr11:14641176	chr1:52993201~52993702:-
HNSC	trans	rs1707322	0.716	rs10890342	ENSG00000255397.1	AC022182.2	-8.09	5.14e-15	1.43e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs6658700	ENSG00000255397.1	AC022182.2	-8.09	5.14e-15	1.43e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs4660313	ENSG00000255397.1	AC022182.2	8.09	5.15e-15	1.44e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	8.09	5.21e-15	1.45e-08	0.47	0.35	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	8.09	5.21e-15	1.45e-08	0.5	0.35	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
HNSC	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	8.09	5.22e-15	1.45e-08	0.46	0.35	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
HNSC	trans	rs12439619	0.693	rs8034801	ENSG00000259295.5	CSPG4P12	-8.09	5.22e-15	1.46e-08	-0.48	-0.35	Intelligence (multi-trait analysis);	chr15:82183996	chr15:85191438~85213905:+
HNSC	trans	rs1707322	0.721	rs10430124	ENSG00000255397.1	AC022182.2	-8.09	5.32e-15	1.48e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr8:60937705~60939871:-
HNSC	trans	rs3849046	0.846	rs256014	ENSG00000226666.1	HSPA9P1	8.09	5.33e-15	1.49e-08	0.35	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138567395	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.81	rs11957778	ENSG00000226666.1	HSPA9P1	-8.09	5.33e-15	1.49e-08	-0.35	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138582137	chr2:221961737~221963765:+
HNSC	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	8.09	5.34e-15	1.49e-08	0.46	0.35	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	8.09	5.34e-15	1.49e-08	0.46	0.35	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs72653981	ENSG00000244245.1	RP11-120B7.1	8.08	5.39e-15	1.5e-08	0.41	0.35	Height;	chr8:56115255	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2976038	ENSG00000244245.1	RP11-120B7.1	8.08	5.39e-15	1.5e-08	0.41	0.35	Height;	chr8:56116305	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs2976036	ENSG00000244245.1	RP11-120B7.1	8.08	5.39e-15	1.5e-08	0.41	0.35	Height;	chr8:56119162	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.534	rs17759244	ENSG00000244245.1	RP11-120B7.1	8.08	5.39e-15	1.5e-08	0.41	0.35	Height;	chr8:56121209	chr5:108593609~108593967:+
HNSC	trans	rs1707322	0.662	rs11211160	ENSG00000255397.1	AC022182.2	-8.08	5.39e-15	1.5e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr8:60937705~60939871:-
HNSC	trans	rs61041336	1	rs61041336	ENSG00000230849.2	GOT2P2	-8.08	5.4e-15	1.5e-08	-0.61	-0.35	Neuritic plaque;	chr16:58699258	chr1:173141100~173142350:-
HNSC	trans	rs916888	0.773	rs538628	ENSG00000204650.12	CRHR1-IT1	8.08	5.41e-15	1.5e-08	0.42	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	8.08	5.45e-15	1.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
HNSC	trans	rs697003	0.705	rs701926	ENSG00000230450.1	NEK2P4	8.08	5.45e-15	1.52e-08	0.36	0.35	Red cell distribution width;	chr1:211678277	chr2:131177618~131178946:-
HNSC	trans	rs1707322	0.686	rs2275085	ENSG00000255397.1	AC022182.2	8.08	5.53e-15	1.54e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr8:60937705~60939871:-
HNSC	trans	rs3849046	0.817	rs68128065	ENSG00000226666.1	HSPA9P1	-8.08	5.54e-15	1.54e-08	-0.35	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138590778	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.846	rs11738995	ENSG00000226666.1	HSPA9P1	-8.08	5.54e-15	1.54e-08	-0.35	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138591930	chr2:221961737~221963765:+
HNSC	trans	rs12145833	0.85	rs2490392	ENSG00000154608.12	CEP170P1	8.08	5.69e-15	1.58e-08	0.4	0.35	Obesity (early onset extreme);	chr1:243299221	chr4:118467590~118554204:+
HNSC	trans	rs9630182	0.77	rs4756765	ENSG00000257675.1	RP11-641A6.9	8.08	5.69e-15	1.58e-08	0.42	0.35	Bone mineral density;	chr11:13550302	chr12:52748776~52750127:+
HNSC	trans	rs11098499	0.821	rs56155624	ENSG00000275858.1	RP11-291L22.8	8.08	5.7e-15	1.58e-08	0.48	0.35	Corneal astigmatism;	chr4:119369871	chr10:38450738~38451069:-
HNSC	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	8.07	5.92e-15	1.64e-08	0.5	0.35	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
HNSC	trans	rs9630182	0.77	rs177706	ENSG00000257675.1	RP11-641A6.9	8.07	6.06e-15	1.68e-08	0.42	0.35	Bone mineral density;	chr11:13492958	chr12:52748776~52750127:+
HNSC	trans	rs916888	0.773	rs199439	ENSG00000204650.12	CRHR1-IT1	8.07	6.1e-15	1.69e-08	0.42	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45620328~45648216:+
HNSC	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-8.07	6.21e-15	1.72e-08	-0.47	-0.35	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.534	rs17813240	ENSG00000244245.1	RP11-120B7.1	8.06	6.22e-15	1.72e-08	0.41	0.35	Height;	chr8:56013232	chr5:108593609~108593967:+
HNSC	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	8.06	6.22e-15	1.72e-08	0.54	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
HNSC	trans	rs6673267	0.869	rs11583140	ENSG00000244144.1	RP11-757F18.3	-8.06	6.28e-15	1.74e-08	-0.41	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201007970	chr3:112185480~112185998:-
HNSC	trans	rs6673267	0.869	rs6700264	ENSG00000244144.1	RP11-757F18.3	-8.06	6.3e-15	1.75e-08	-0.4	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201014894	chr3:112185480~112185998:-
HNSC	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	8.06	6.44e-15	1.78e-08	0.46	0.35	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	8.06	6.44e-15	1.78e-08	0.46	0.35	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	8.06	6.47e-15	1.79e-08	0.46	0.35	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
HNSC	trans	rs6673267	0.869	rs957957	ENSG00000244144.1	RP11-757F18.3	-8.06	6.48e-15	1.79e-08	-0.4	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201018670	chr3:112185480~112185998:-
HNSC	trans	rs3849046	0.817	rs409273	ENSG00000226666.1	HSPA9P1	-8.06	6.49e-15	1.8e-08	-0.35	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138578193	chr2:221961737~221963765:+
HNSC	trans	rs6673267	0.904	rs6701469	ENSG00000244144.1	RP11-757F18.3	-8.06	6.63e-15	1.83e-08	-0.4	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201029691	chr3:112185480~112185998:-
HNSC	trans	rs1707322	0.717	rs1972410	ENSG00000255397.1	AC022182.2	-8.06	6.68e-15	1.85e-08	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.77	rs2403669	ENSG00000257675.1	RP11-641A6.9	8.05	6.76e-15	1.87e-08	0.43	0.35	Bone mineral density;	chr11:13565939	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.685	rs11211177	ENSG00000255397.1	AC022182.2	-8.05	6.78e-15	1.88e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs3014237	ENSG00000255397.1	AC022182.2	8.05	6.84e-15	1.89e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr8:60937705~60939871:-
HNSC	trans	rs941207	0.756	rs2926743	ENSG00000257210.1	NACAP3	8.05	6.89e-15	1.9e-08	0.45	0.35	Platelet count;	chr12:56720316	chr12:93124063~93124543:-
HNSC	trans	rs1707322	0.717	rs1547925	ENSG00000255397.1	AC022182.2	8.05	6.89e-15	1.9e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr8:60937705~60939871:-
HNSC	trans	rs11638815	0.626	rs11635624	ENSG00000235370.6	DNM1P51	-8.05	6.91e-15	1.91e-08	-0.44	-0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:84398316~84411701:-
HNSC	trans	rs1190596	0.581	rs1190571	ENSG00000181359.5	HSP90AA6P	8.05	7e-15	1.93e-08	0.45	0.35	Behavioural disinhibition (generation interaction);	chr14:102168564	chr4:170581470~170605450:-
HNSC	trans	rs1707322	0.717	rs1135850	ENSG00000255397.1	AC022182.2	-8.05	7.16e-15	1.97e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.655	rs3014240	ENSG00000255397.1	AC022182.2	8.05	7.16e-15	1.97e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs3014235	ENSG00000255397.1	AC022182.2	8.05	7.16e-15	1.97e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr8:60937705~60939871:-
HNSC	trans	rs12145833	0.596	rs61833906	ENSG00000154608.12	CEP170P1	-8.04	7.34e-15	2.02e-08	-0.53	-0.35	Obesity (early onset extreme);	chr1:243256404	chr4:118467590~118554204:+
HNSC	trans	rs12145833	0.665	rs78871868	ENSG00000154608.12	CEP170P1	-8.04	7.34e-15	2.02e-08	-0.53	-0.35	Obesity (early onset extreme);	chr1:243259020	chr4:118467590~118554204:+
HNSC	trans	rs12145833	0.596	rs12134228	ENSG00000154608.12	CEP170P1	-8.04	7.47e-15	2.05e-08	-0.52	-0.35	Obesity (early onset extreme);	chr1:243284316	chr4:118467590~118554204:+
HNSC	trans	rs6673267	0.904	rs6427870	ENSG00000244144.1	RP11-757F18.3	-8.04	7.64e-15	2.1e-08	-0.4	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201027061	chr3:112185480~112185998:-
HNSC	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-8.03	7.77e-15	2.13e-08	-0.38	-0.35	Longevity;	chr3:48457056	chr1:27649419~27649610:+
HNSC	trans	rs916888	0.773	rs199448	ENSG00000204650.12	CRHR1-IT1	8.03	7.88e-15	2.16e-08	0.41	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45620328~45648216:+
HNSC	trans	rs1707322	0.686	rs1084086	ENSG00000255397.1	AC022182.2	8.03	7.96e-15	2.18e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs10890358	ENSG00000255397.1	AC022182.2	-8.03	8.1e-15	2.22e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.77	rs7927571	ENSG00000257675.1	RP11-641A6.9	8.03	8.2e-15	2.25e-08	0.42	0.35	Bone mineral density;	chr11:13525305	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs7930499	ENSG00000257675.1	RP11-641A6.9	8.03	8.2e-15	2.25e-08	0.42	0.35	Bone mineral density;	chr11:13525437	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.717	rs3014245	ENSG00000255397.1	AC022182.2	8.03	8.25e-15	2.26e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.821	rs199513	ENSG00000204650.12	CRHR1-IT1	-8.02	8.38e-15	2.29e-08	-0.4	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45620328~45648216:+
HNSC	trans	rs673253	0.557	rs34898652	ENSG00000231007.5	CDC20P1	8.02	8.56e-15	2.34e-08	0.49	0.35	Intelligence (multi-trait analysis);	chr1:43508420	chr9:87011652~87013151:+
HNSC	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	8.02	8.58e-15	2.35e-08	0.46	0.35	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
HNSC	trans	rs7121616	0.576	rs73608699	ENSG00000229091.2	HSPA8P8	8.02	8.89e-15	2.43e-08	0.45	0.35	Breast cancer;	chr11:123044718	chr7:10451311~10452526:+
HNSC	trans	rs6673267	0.869	rs10920094	ENSG00000244144.1	RP11-757F18.3	-8.01	8.93e-15	2.44e-08	-0.4	-0.35	Lobe attachment (rater-scored or self-reported);	chr1:201011868	chr3:112185480~112185998:-
HNSC	trans	rs1707322	1	rs946527	ENSG00000255397.1	AC022182.2	-8.01	9.18e-15	2.51e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.77	rs4757166	ENSG00000257675.1	RP11-641A6.9	8.01	9.29e-15	2.53e-08	0.42	0.35	Bone mineral density;	chr11:13549566	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757167	ENSG00000257675.1	RP11-641A6.9	8.01	9.29e-15	2.53e-08	0.42	0.35	Bone mineral density;	chr11:13549664	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10832062	ENSG00000257675.1	RP11-641A6.9	8.01	9.29e-15	2.53e-08	0.42	0.35	Bone mineral density;	chr11:13550173	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.721	rs12418886	ENSG00000257675.1	RP11-641A6.9	-8.01	9.31e-15	2.54e-08	-0.41	-0.35	Bone mineral density;	chr11:13479231	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.752	rs11488313	ENSG00000255397.1	AC022182.2	-8.01	9.34e-15	2.55e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr8:60937705~60939871:-
HNSC	trans	rs2456568	0.835	rs8181533	ENSG00000276509.1	CH17-353B19.1	8	9.67e-15	2.64e-08	0.38	0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93905448	chr1:146235806~146237807:+
HNSC	trans	rs1707322	0.721	rs11211181	ENSG00000255397.1	AC022182.2	-8	9.72e-15	2.65e-08	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	8	9.86e-15	2.69e-08	0.47	0.35	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.691	rs61784803	ENSG00000255397.1	AC022182.2	8	9.92e-15	2.7e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.663	rs3935296	ENSG00000255397.1	AC022182.2	8	9.92e-15	2.7e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs28817701	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.691	rs28495425	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.685	rs28617418	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.682	rs28490344	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs28501477	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs28641748	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs6697821	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs4330955	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.691	rs12031182	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10430123	ENSG00000255397.1	AC022182.2	-8	9.92e-15	2.7e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr8:60937705~60939871:-
HNSC	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-8	1e-14	2.73e-08	-0.47	-0.35	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.752	rs6678444	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.73e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs61784796	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10749856	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890344	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs4564187	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs28438704	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs28442079	ENSG00000255397.1	AC022182.2	-8	1.01e-14	2.74e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr8:60937705~60939871:-
HNSC	trans	rs296547	0.602	rs296544	ENSG00000244144.1	RP11-757F18.3	7.99	1.09e-14	2.96e-08	0.41	0.35	Celiac disease;	chr1:200921225	chr3:112185480~112185998:-
HNSC	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	7.99	1.1e-14	2.98e-08	0.5	0.35	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
HNSC	trans	rs12145833	0.596	rs12026068	ENSG00000154608.12	CEP170P1	-7.98	1.1e-14	2.99e-08	-0.52	-0.35	Obesity (early onset extreme);	chr1:243277050	chr4:118467590~118554204:+
HNSC	trans	rs1707322	0.752	rs28719889	ENSG00000255397.1	AC022182.2	-7.98	1.1e-14	3e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs3014246	ENSG00000255397.1	AC022182.2	7.98	1.13e-14	3.06e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr8:60937705~60939871:-
HNSC	trans	rs6683419	0.729	rs10917477	ENSG00000224237.1	MINOS1P3	-7.98	1.14e-14	3.08e-08	-0.41	-0.35	Serum thyroid-stimulating hormone levels;	chr1:19534612	chr3:27214816~27215018:-
HNSC	trans	rs1707322	0.686	rs3014242	ENSG00000255397.1	AC022182.2	7.98	1.14e-14	3.08e-08	0.45	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.77	rs11022870	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13536715	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.628	rs10766092	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13538882	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.74	rs10832058	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13539435	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs10832059	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13539749	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.74	rs4757164	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13542846	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.711	rs1841149	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13543080	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.683	rs1841148	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13543097	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs7123535	ENSG00000257675.1	RP11-641A6.9	7.98	1.14e-14	3.08e-08	0.41	0.35	Bone mineral density;	chr11:13543746	chr12:52748776~52750127:+
HNSC	trans	rs6132905	0.52	rs2422824	ENSG00000257956.1	NOP56P3	7.98	1.15e-14	3.11e-08	0.45	0.35	Mumps;	chr20:2666724	chr12:79558782~79559166:+
HNSC	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	7.98	1.16e-14	3.13e-08	0.46	0.35	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	7.98	1.17e-14	3.16e-08	0.47	0.35	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.691	rs11211174	ENSG00000255397.1	AC022182.2	-7.97	1.19e-14	3.22e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr8:60937705~60939871:-
HNSC	trans	rs12145833	0.596	rs12043646	ENSG00000154608.12	CEP170P1	-7.97	1.23e-14	3.32e-08	-0.52	-0.35	Obesity (early onset extreme);	chr1:243118690	chr4:118467590~118554204:+
HNSC	trans	rs12145833	0.596	rs12123491	ENSG00000154608.12	CEP170P1	-7.97	1.25e-14	3.36e-08	-0.52	-0.35	Obesity (early onset extreme);	chr1:243134622	chr4:118467590~118554204:+
HNSC	trans	rs1707322	0.721	rs11211163	ENSG00000255397.1	AC022182.2	-7.97	1.25e-14	3.38e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12037803	ENSG00000255397.1	AC022182.2	-7.97	1.25e-14	3.38e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10789470	ENSG00000255397.1	AC022182.2	-7.97	1.25e-14	3.38e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	7.97	1.27e-14	3.42e-08	0.47	0.35	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	7.97	1.27e-14	3.42e-08	0.47	0.35	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
HNSC	trans	rs941207	0.724	rs4788	ENSG00000257210.1	NACAP3	7.96	1.28e-14	3.45e-08	0.44	0.35	Platelet count;	chr12:56712876	chr12:93124063~93124543:-
HNSC	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-7.96	1.28e-14	3.46e-08	-0.45	-0.35	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.721	rs4559551	ENSG00000255397.1	AC022182.2	-7.96	1.28e-14	3.46e-08	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	7.96	1.29e-14	3.48e-08	0.47	0.35	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
HNSC	trans	rs9425766	0.64	rs9425756	ENSG00000213331.4	RP11-713C19.2	7.96	1.31e-14	3.52e-08	0.43	0.35	Life satisfaction;	chr1:173847448	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.546	rs6691001	ENSG00000213331.4	RP11-713C19.2	7.96	1.31e-14	3.52e-08	0.43	0.35	Life satisfaction;	chr1:173849938	chr4:187970273~187971284:+
HNSC	trans	rs9630182	0.77	rs10766091	ENSG00000257675.1	RP11-641A6.9	7.96	1.31e-14	3.54e-08	0.41	0.35	Bone mineral density;	chr11:13530660	chr12:52748776~52750127:+
HNSC	trans	rs12145833	0.596	rs1060643	ENSG00000154608.12	CEP170P1	-7.96	1.32e-14	3.55e-08	-0.52	-0.35	Obesity (early onset extreme);	chr1:243266674	chr4:118467590~118554204:+
HNSC	trans	rs77688320	0.535	rs13027669	ENSG00000235105.1	RP11-329A14.1	7.96	1.34e-14	3.61e-08	0.43	0.35	Breast cancer;	chr2:201382596	chr1:48435967~48437223:+
HNSC	trans	rs12439619	0.53	rs28883606	ENSG00000259295.5	CSPG4P12	-7.96	1.36e-14	3.66e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr15:82216713	chr15:85191438~85213905:+
HNSC	trans	rs1707322	1	rs7531911	ENSG00000255397.1	AC022182.2	-7.96	1.36e-14	3.67e-08	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890359	ENSG00000255397.1	AC022182.2	-7.96	1.36e-14	3.67e-08	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr8:60937705~60939871:-
HNSC	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	7.95	1.38e-14	3.71e-08	0.5	0.35	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
HNSC	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	7.95	1.41e-14	3.8e-08	0.46	0.35	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
HNSC	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-7.95	1.42e-14	3.81e-08	-0.37	-0.35	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
HNSC	trans	rs1707322	0.682	rs28508523	ENSG00000255397.1	AC022182.2	-7.95	1.43e-14	3.85e-08	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.691	rs11211175	ENSG00000255397.1	AC022182.2	-7.95	1.43e-14	3.85e-08	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs61784800	ENSG00000255397.1	AC022182.2	7.95	1.43e-14	3.85e-08	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	7.95	1.46e-14	3.93e-08	0.47	0.35	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
HNSC	trans	rs8067354	0.872	rs2645488	ENSG00000187870.7	RNFT1P3	7.94	1.48e-14	3.97e-08	0.41	0.35	Hemoglobin concentration;	chr17:59812044	chr17:20743333~20754501:-
HNSC	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	7.94	1.49e-14	3.99e-08	0.49	0.34	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	7.94	1.49e-14	3.99e-08	0.49	0.34	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	7.94	1.49e-14	3.99e-08	0.49	0.34	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
HNSC	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	7.94	1.49e-14	3.99e-08	0.49	0.34	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
HNSC	trans	rs1190596	0.525	rs35350456	ENSG00000181359.5	HSP90AA6P	-7.94	1.49e-14	4e-08	-0.45	-0.34	Behavioural disinhibition (generation interaction);	chr14:102238414	chr4:170581470~170605450:-
HNSC	trans	rs3849046	0.846	rs256002	ENSG00000226666.1	HSPA9P1	7.94	1.49e-14	4.01e-08	0.35	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138559529	chr2:221961737~221963765:+
HNSC	trans	rs1707322	0.752	rs7541962	ENSG00000255397.1	AC022182.2	-7.94	1.5e-14	4.03e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.74	rs7115889	ENSG00000257675.1	RP11-641A6.9	7.94	1.5e-14	4.03e-08	0.41	0.34	Bone mineral density;	chr11:13526729	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.74	rs10766088	ENSG00000257675.1	RP11-641A6.9	7.94	1.5e-14	4.03e-08	0.41	0.34	Bone mineral density;	chr11:13527603	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757160	ENSG00000257675.1	RP11-641A6.9	7.94	1.5e-14	4.03e-08	0.41	0.34	Bone mineral density;	chr11:13528325	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.77	rs4757161	ENSG00000257675.1	RP11-641A6.9	7.94	1.5e-14	4.03e-08	0.41	0.34	Bone mineral density;	chr11:13528657	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.74	rs4757162	ENSG00000257675.1	RP11-641A6.9	7.94	1.5e-14	4.03e-08	0.41	0.34	Bone mineral density;	chr11:13529511	chr12:52748776~52750127:+
HNSC	trans	rs7824557	0.564	rs2043508	ENSG00000173295.6	FAM86B3P	-7.94	1.51e-14	4.05e-08	-0.38	-0.34	Retinal vascular caliber;	chr8:11369897	chr8:8228595~8244865:+
HNSC	trans	rs2456568	0.803	rs10765642	ENSG00000276509.1	CH17-353B19.1	-7.94	1.52e-14	4.07e-08	-0.37	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907189	chr1:146235806~146237807:+
HNSC	trans	rs8067354	0.872	rs2645466	ENSG00000187870.7	RNFT1P3	7.94	1.54e-14	4.13e-08	0.41	0.34	Hemoglobin concentration;	chr17:59775853	chr17:20743333~20754501:-
HNSC	trans	rs2456568	0.803	rs10831138	ENSG00000276509.1	CH17-353B19.1	7.94	1.56e-14	4.19e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907302	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs10831139	ENSG00000276509.1	CH17-353B19.1	7.93	1.58e-14	4.24e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907371	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.803	rs10831140	ENSG00000276509.1	CH17-353B19.1	7.93	1.59e-14	4.26e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907523	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.803	rs10831141	ENSG00000276509.1	CH17-353B19.1	7.93	1.59e-14	4.26e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907562	chr1:146235806~146237807:+
HNSC	trans	rs9630182	0.77	rs7942695	ENSG00000257675.1	RP11-641A6.9	7.93	1.62e-14	4.32e-08	0.41	0.34	Bone mineral density;	chr11:13560971	chr12:52748776~52750127:+
HNSC	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	7.93	1.62e-14	4.33e-08	0.49	0.34	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
HNSC	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-7.93	1.62e-14	4.34e-08	-0.5	-0.34	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.721	rs11211165	ENSG00000255397.1	AC022182.2	-7.93	1.64e-14	4.38e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs11211166	ENSG00000255397.1	AC022182.2	-7.93	1.64e-14	4.38e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs3014251	ENSG00000255397.1	AC022182.2	7.93	1.64e-14	4.38e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr8:60937705~60939871:-
HNSC	trans	rs511515	1	rs511515	ENSG00000175730.8	BAK1P1	7.93	1.65e-14	4.41e-08	0.45	0.34	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr6:33573730	chr20:32690180~32690815:-
HNSC	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-7.93	1.65e-14	4.42e-08	-0.36	-0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
HNSC	trans	rs74781061	0.929	rs10459648	ENSG00000227288.3	RP5-837I24.1	-7.93	1.68e-14	4.5e-08	-0.5	-0.34	Endometriosis;	chr15:74573099	chr1:81501794~81503468:+
HNSC	trans	rs1707322	1	rs34694458	ENSG00000255397.1	AC022182.2	-7.92	1.69e-14	4.52e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs6665808	ENSG00000255397.1	AC022182.2	-7.92	1.71e-14	4.56e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr8:60937705~60939871:-
HNSC	trans	rs6087990	0.568	rs853854	ENSG00000253915.1	MAPRE1P1	7.92	1.72e-14	4.59e-08	0.41	0.34	Ulcerative colitis;	chr20:32832951	chr8:135625185~135625981:-
HNSC	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-7.92	1.72e-14	4.6e-08	-0.46	-0.34	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
HNSC	trans	rs7824557	0.545	rs2572450	ENSG00000173295.6	FAM86B3P	-7.92	1.72e-14	4.6e-08	-0.39	-0.34	Retinal vascular caliber;	chr8:11372129	chr8:8228595~8244865:+
HNSC	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	7.92	1.72e-14	4.6e-08	0.39	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
HNSC	trans	rs1707322	0.686	rs3014239	ENSG00000255397.1	AC022182.2	7.92	1.75e-14	4.67e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs3014236	ENSG00000255397.1	AC022182.2	7.92	1.75e-14	4.67e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr8:60937705~60939871:-
HNSC	trans	rs7833986	0.501	rs2719233	ENSG00000244245.1	RP11-120B7.1	7.92	1.77e-14	4.73e-08	0.41	0.34	Height;	chr8:55973597	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs17812659	ENSG00000244245.1	RP11-120B7.1	7.92	1.77e-14	4.73e-08	0.41	0.34	Height;	chr8:55977303	chr5:108593609~108593967:+
HNSC	trans	rs9630182	0.793	rs10832046	ENSG00000257675.1	RP11-641A6.9	-7.92	1.79e-14	4.77e-08	-0.41	-0.34	Bone mineral density;	chr11:13485114	chr12:52748776~52750127:+
HNSC	trans	rs7121616	0.576	rs11600486	ENSG00000229091.2	HSPA8P8	7.91	1.85e-14	4.92e-08	0.44	0.34	Breast cancer;	chr11:123047060	chr7:10451311~10452526:+
HNSC	trans	rs7937890	0.587	rs11023204	ENSG00000236360.2	RP11-334A14.2	7.91	1.88e-14	5.01e-08	0.46	0.34	Mitochondrial DNA levels;	chr11:14389677	chr1:52993201~52993702:-
HNSC	trans	rs1707322	1	rs6661500	ENSG00000255397.1	AC022182.2	-7.91	1.91e-14	5.07e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs4660880	ENSG00000255397.1	AC022182.2	-7.91	1.94e-14	5.14e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs1547924	ENSG00000255397.1	AC022182.2	-7.9	1.97e-14	5.23e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.583	rs2263511	ENSG00000173295.6	FAM86B3P	-7.9	2e-14	5.31e-08	-0.38	-0.34	Retinal vascular caliber;	chr8:11375809	chr8:8228595~8244865:+
HNSC	trans	rs6673267	0.874	rs6427871	ENSG00000244144.1	RP11-757F18.3	-7.9	2.02e-14	5.37e-08	-0.39	-0.34	Lobe attachment (rater-scored or self-reported);	chr1:201028188	chr3:112185480~112185998:-
HNSC	trans	rs1707322	0.717	rs2275086	ENSG00000255397.1	AC022182.2	7.9	2.03e-14	5.37e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.564	rs2736288	ENSG00000173295.6	FAM86B3P	-7.9	2.07e-14	5.48e-08	-0.38	-0.34	Retinal vascular caliber;	chr8:11370591	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.752	rs3811436	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs12024590	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs12027622	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs7529699	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.716	rs6699444	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs10430105	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890341	ENSG00000255397.1	AC022182.2	-7.89	2.1e-14	5.56e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.682	rs12037459	ENSG00000255397.1	AC022182.2	-7.89	2.13e-14	5.64e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211145	ENSG00000255397.1	AC022182.2	-7.89	2.21e-14	5.85e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr8:60937705~60939871:-
HNSC	trans	rs12439619	0.846	rs28470877	ENSG00000259295.5	CSPG4P12	-7.89	2.22e-14	5.86e-08	-0.49	-0.34	Intelligence (multi-trait analysis);	chr15:82245797	chr15:85191438~85213905:+
HNSC	trans	rs7824557	0.564	rs13260727	ENSG00000173295.6	FAM86B3P	7.89	2.24e-14	5.92e-08	0.38	0.34	Retinal vascular caliber;	chr8:11375351	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.583	rs4448232	ENSG00000173295.6	FAM86B3P	7.88	2.29e-14	6.05e-08	0.38	0.34	Retinal vascular caliber;	chr8:11373845	chr8:8228595~8244865:+
HNSC	trans	rs1707322	1	rs4073847	ENSG00000255397.1	AC022182.2	7.88	2.3e-14	6.09e-08	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.697	rs199516	ENSG00000204650.12	CRHR1-IT1	-7.88	2.35e-14	6.2e-08	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45620328~45648216:+
HNSC	trans	rs1707322	1	rs34444543	ENSG00000255397.1	AC022182.2	-7.88	2.38e-14	6.28e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs4660314	ENSG00000255397.1	AC022182.2	-7.87	2.41e-14	6.36e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12069121	ENSG00000255397.1	AC022182.2	-7.87	2.41e-14	6.36e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs61784833	ENSG00000255397.1	AC022182.2	-7.87	2.41e-14	6.36e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr8:60937705~60939871:-
HNSC	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-7.87	2.47e-14	6.52e-08	-0.46	-0.34	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-7.87	2.47e-14	6.52e-08	-0.46	-0.34	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-7.87	2.47e-14	6.52e-08	-0.46	-0.34	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-7.87	2.47e-14	6.52e-08	-0.46	-0.34	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
HNSC	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-7.87	2.47e-14	6.52e-08	-0.46	-0.34	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
HNSC	trans	rs6673267	0.904	rs10800751	ENSG00000244144.1	RP11-757F18.3	-7.87	2.48e-14	6.54e-08	-0.4	-0.34	Lobe attachment (rater-scored or self-reported);	chr1:201030798	chr3:112185480~112185998:-
HNSC	trans	rs1707322	0.717	rs2253862	ENSG00000255397.1	AC022182.2	7.87	2.53e-14	6.65e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs2991988	ENSG00000255397.1	AC022182.2	7.87	2.53e-14	6.65e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs2991989	ENSG00000255397.1	AC022182.2	7.87	2.53e-14	6.65e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs6429588	ENSG00000255397.1	AC022182.2	-7.87	2.57e-14	6.77e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12097799	ENSG00000255397.1	AC022182.2	-7.87	2.57e-14	6.77e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr8:60937705~60939871:-
HNSC	trans	rs7769051	1	rs9493454	ENSG00000227615.1	RP11-864N7.2	-7.86	2.59e-14	6.81e-08	-0.53	-0.34	Type 2 diabetes nephropathy;	chr6:132823490	chr11:74745716~74746114:-
HNSC	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	7.86	2.6e-14	6.84e-08	0.45	0.34	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
HNSC	trans	rs2456568	0.802	rs11020586	ENSG00000276509.1	CH17-353B19.1	7.86	2.6e-14	6.84e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93905381	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.771	rs8181530	ENSG00000276509.1	CH17-353B19.1	7.86	2.6e-14	6.84e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93905512	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs7101791	ENSG00000276509.1	CH17-353B19.1	7.86	2.6e-14	6.84e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93905832	chr1:146235806~146237807:+
HNSC	trans	rs11638815	0.626	rs11633829	ENSG00000235370.6	DNM1P51	7.86	2.63e-14	6.91e-08	0.44	0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:84398316~84411701:-
HNSC	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-7.86	2.7e-14	7.1e-08	-0.46	-0.34	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
HNSC	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-7.86	2.71e-14	7.12e-08	-0.41	-0.34	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
HNSC	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-7.86	2.71e-14	7.13e-08	-0.45	-0.34	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
HNSC	trans	rs916888	0.821	rs199512	ENSG00000204650.12	CRHR1-IT1	-7.86	2.75e-14	7.24e-08	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45620328~45648216:+
HNSC	trans	rs1707322	0.721	rs4415615	ENSG00000255397.1	AC022182.2	-7.86	2.76e-14	7.26e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr8:60937705~60939871:-
HNSC	trans	rs55665837	0.701	rs11023278	ENSG00000236360.2	RP11-334A14.2	7.86	2.76e-14	7.26e-08	0.46	0.34	Vitamin D levels;	chr11:14619638	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.773	rs199445	ENSG00000204650.12	CRHR1-IT1	7.86	2.77e-14	7.28e-08	0.41	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.773	rs199443	ENSG00000204650.12	CRHR1-IT1	7.86	2.77e-14	7.28e-08	0.41	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45620328~45648216:+
HNSC	trans	rs1079467	0.786	rs2136907	ENSG00000233426.3	EIF3FP3	-7.85	2.78e-14	7.31e-08	-0.57	-0.34	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7951686	chr2:58251440~58252525:+
HNSC	trans	rs2456568	0.771	rs2102333	ENSG00000276509.1	CH17-353B19.1	7.85	2.79e-14	7.32e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93901583	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.741	rs2102332	ENSG00000276509.1	CH17-353B19.1	7.85	2.79e-14	7.32e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93902115	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs7115629	ENSG00000276509.1	CH17-353B19.1	7.85	2.79e-14	7.32e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93902311	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs10765639	ENSG00000276509.1	CH17-353B19.1	7.85	2.79e-14	7.32e-08	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903028	chr1:146235806~146237807:+
HNSC	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	7.85	2.82e-14	7.41e-08	0.38	0.34	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	7.85	2.93e-14	7.68e-08	0.36	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
HNSC	trans	rs8067354	0.789	rs4622571	ENSG00000187870.7	RNFT1P3	7.85	2.97e-14	7.76e-08	0.4	0.34	Hemoglobin concentration;	chr17:59807036	chr17:20743333~20754501:-
HNSC	trans	rs7833986	0.501	rs2667978	ENSG00000244245.1	RP11-120B7.1	7.85	2.97e-14	7.77e-08	0.39	0.34	Height;	chr8:55985392	chr5:108593609~108593967:+
HNSC	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-7.84	3e-14	7.84e-08	-0.51	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.656	rs3014210	ENSG00000255397.1	AC022182.2	7.84	3.02e-14	7.89e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.821	rs199509	ENSG00000204650.12	CRHR1-IT1	-7.84	3.04e-14	7.93e-08	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.821	rs199507	ENSG00000204650.12	CRHR1-IT1	-7.84	3.04e-14	7.93e-08	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45620328~45648216:+
HNSC	trans	rs12439619	0.508	rs8023960	ENSG00000259295.5	CSPG4P12	-7.84	3.05e-14	7.96e-08	-0.42	-0.34	Intelligence (multi-trait analysis);	chr15:82206704	chr15:85191438~85213905:+
HNSC	trans	rs9630182	0.74	rs7931255	ENSG00000257675.1	RP11-641A6.9	7.84	3.06e-14	7.98e-08	0.41	0.34	Bone mineral density;	chr11:13526070	chr12:52748776~52750127:+
HNSC	trans	rs1707322	1	rs10789486	ENSG00000255397.1	AC022182.2	-7.84	3.16e-14	8.23e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr8:60937705~60939871:-
HNSC	trans	rs12145833	0.596	rs61833913	ENSG00000154608.12	CEP170P1	-7.84	3.17e-14	8.25e-08	-0.51	-0.34	Obesity (early onset extreme);	chr1:243276726	chr4:118467590~118554204:+
HNSC	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-7.83	3.19e-14	8.31e-08	-0.5	-0.34	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
HNSC	trans	rs7824557	0.583	rs2263512	ENSG00000173295.6	FAM86B3P	-7.83	3.26e-14	8.47e-08	-0.37	-0.34	Retinal vascular caliber;	chr8:11375910	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.583	rs6601585	ENSG00000173295.6	FAM86B3P	-7.83	3.26e-14	8.47e-08	-0.37	-0.34	Retinal vascular caliber;	chr8:11376150	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.686	rs1541131	ENSG00000255397.1	AC022182.2	7.83	3.26e-14	8.47e-08	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs12023439	ENSG00000255397.1	AC022182.2	-7.82	3.46e-14	8.97e-08	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr8:60937705~60939871:-
HNSC	trans	rs9425766	0.64	rs2295366	ENSG00000213331.4	RP11-713C19.2	7.82	3.5e-14	9.08e-08	0.42	0.34	Life satisfaction;	chr1:173856554	chr4:187970273~187971284:+
HNSC	trans	rs1707322	0.685	rs56177313	ENSG00000255397.1	AC022182.2	-7.82	3.52e-14	9.11e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs11211178	ENSG00000255397.1	AC022182.2	-7.82	3.52e-14	9.11e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.506	rs2991983	ENSG00000255397.1	AC022182.2	7.82	3.55e-14	9.21e-08	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs12022335	ENSG00000255397.1	AC022182.2	-7.82	3.56e-14	9.21e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs2572369	ENSG00000173295.6	FAM86B3P	-7.82	3.57e-14	9.24e-08	-0.38	-0.34	Retinal vascular caliber;	chr8:11381088	chr8:8228595~8244865:+
HNSC	trans	rs1190596	0.558	rs10047840	ENSG00000181359.5	HSP90AA6P	-7.82	3.57e-14	9.24e-08	-0.45	-0.34	Behavioural disinhibition (generation interaction);	chr14:102236864	chr4:170581470~170605450:-
HNSC	trans	rs7824557	0.564	rs55758514	ENSG00000173295.6	FAM86B3P	-7.82	3.59e-14	9.29e-08	-0.37	-0.34	Retinal vascular caliber;	chr8:11372750	chr8:8228595~8244865:+
HNSC	trans	rs916888	0.821	rs199506	ENSG00000204650.12	CRHR1-IT1	-7.82	3.6e-14	9.31e-08	-0.41	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45620328~45648216:+
HNSC	trans	rs1707322	0.721	rs7519900	ENSG00000255397.1	AC022182.2	-7.82	3.63e-14	9.4e-08	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr8:60937705~60939871:-
HNSC	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-7.82	3.64e-14	9.41e-08	-0.36	-0.34	Longevity;	chr3:48380745	chr1:27649419~27649610:+
HNSC	trans	rs9630182	0.761	rs7950339	ENSG00000257675.1	RP11-641A6.9	-7.82	3.67e-14	9.49e-08	-0.41	-0.34	Bone mineral density;	chr11:13474797	chr12:52748776~52750127:+
HNSC	trans	rs7824557	0.564	rs34389419	ENSG00000173295.6	FAM86B3P	-7.81	3.68e-14	9.53e-08	-0.38	-0.34	Retinal vascular caliber;	chr8:11371810	chr8:8228595~8244865:+
HNSC	trans	rs6673267	0.869	rs6687260	ENSG00000244144.1	RP11-757F18.3	-7.81	3.74e-14	9.66e-08	-0.39	-0.34	Lobe attachment (rater-scored or self-reported);	chr1:201011570	chr3:112185480~112185998:-
HNSC	trans	rs12439619	0.693	rs28665836	ENSG00000259295.5	CSPG4P12	-7.81	3.78e-14	9.78e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr15:82218955	chr15:85191438~85213905:+
HNSC	trans	rs9630182	0.793	rs10766086	ENSG00000257675.1	RP11-641A6.9	-7.81	3.86e-14	9.96e-08	-0.41	-0.34	Bone mineral density;	chr11:13501904	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.717	rs1135812	ENSG00000255397.1	AC022182.2	-7.81	3.88e-14	1e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs6703748	ENSG00000255397.1	AC022182.2	-7.81	3.88e-14	1e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2991987	ENSG00000255397.1	AC022182.2	7.81	3.88e-14	1e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7547189	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7547284	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211205	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660895	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660318	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890360	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs6682683	ENSG00000255397.1	AC022182.2	-7.8	3.95e-14	1.02e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr8:60937705~60939871:-
HNSC	trans	rs7833986	0.501	rs2719226	ENSG00000244245.1	RP11-120B7.1	7.8	4.01e-14	1.03e-07	0.4	0.34	Height;	chr8:56131507	chr5:108593609~108593967:+
HNSC	trans	rs916888	0.779	rs199526	ENSG00000280022.1	RP11-707O23.1	-7.8	4.01e-14	1.04e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45592621~45593369:+
HNSC	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-7.8	4.1e-14	1.06e-07	-0.45	-0.34	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
HNSC	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	7.8	4.15e-14	1.07e-07	0.45	0.34	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.721	rs11211149	ENSG00000255397.1	AC022182.2	-7.8	4.21e-14	1.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890346	ENSG00000255397.1	AC022182.2	7.79	4.25e-14	1.09e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr8:60937705~60939871:-
HNSC	trans	rs11638815	0.603	rs10162807	ENSG00000235370.6	DNM1P51	-7.79	4.25e-14	1.09e-07	-0.43	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:84398316~84411701:-
HNSC	trans	rs1707322	1	rs4660331	ENSG00000255397.1	AC022182.2	-7.79	4.28e-14	1.1e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.821	rs199505	ENSG00000204650.12	CRHR1-IT1	-7.79	4.34e-14	1.12e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.821	rs70602	ENSG00000204650.12	CRHR1-IT1	-7.79	4.34e-14	1.12e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45620328~45648216:+
HNSC	trans	rs697003	0.672	rs701917	ENSG00000230450.1	NEK2P4	7.79	4.39e-14	1.13e-07	0.35	0.34	Red cell distribution width;	chr1:211688456	chr2:131177618~131178946:-
HNSC	trans	rs2456568	0.802	rs1395386	ENSG00000276509.1	CH17-353B19.1	-7.79	4.44e-14	1.14e-07	-0.37	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93906165	chr1:146235806~146237807:+
HNSC	trans	rs1707322	1	rs785478	ENSG00000255397.1	AC022182.2	7.79	4.47e-14	1.15e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr8:60937705~60939871:-
HNSC	trans	rs7647973	1	rs6774724	ENSG00000197582.5	GPX1P1	7.79	4.5e-14	1.16e-07	0.5	0.34	Menarche (age at onset);	chr3:49344478	chrX:13378735~13379340:-
HNSC	trans	rs1707322	1	rs3922887	ENSG00000255397.1	AC022182.2	-7.79	4.52e-14	1.16e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs3922886	ENSG00000255397.1	AC022182.2	-7.79	4.52e-14	1.16e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.656	rs2991981	ENSG00000255397.1	AC022182.2	7.78	4.53e-14	1.16e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890343	ENSG00000255397.1	AC022182.2	-7.78	4.56e-14	1.17e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs11211179	ENSG00000255397.1	AC022182.2	-7.78	4.57e-14	1.17e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10157795	ENSG00000255397.1	AC022182.2	-7.78	4.57e-14	1.17e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs12145287	ENSG00000255397.1	AC022182.2	-7.78	4.61e-14	1.18e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10789479	ENSG00000255397.1	AC022182.2	-7.78	4.61e-14	1.18e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr8:60937705~60939871:-
HNSC	trans	rs941207	0.756	rs2958149	ENSG00000257210.1	NACAP3	7.78	4.61e-14	1.18e-07	0.44	0.34	Platelet count;	chr12:56716008	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.724	rs1979325	ENSG00000257210.1	NACAP3	7.78	4.61e-14	1.18e-07	0.44	0.34	Platelet count;	chr12:56728152	chr12:93124063~93124543:-
HNSC	trans	rs11638815	0.581	rs2870965	ENSG00000235370.6	DNM1P51	-7.78	4.62e-14	1.19e-07	-0.43	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:84398316~84411701:-
HNSC	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	7.78	4.69e-14	1.2e-07	0.45	0.34	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.721	rs4660883	ENSG00000255397.1	AC022182.2	-7.78	4.71e-14	1.21e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.738	rs199515	ENSG00000204650.12	CRHR1-IT1	-7.78	4.75e-14	1.22e-07	-0.39	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45620328~45648216:+
HNSC	trans	rs2456568	0.802	rs10765638	ENSG00000276509.1	CH17-353B19.1	7.78	4.8e-14	1.23e-07	0.36	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903005	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs10765640	ENSG00000276509.1	CH17-353B19.1	7.78	4.8e-14	1.23e-07	0.36	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903296	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs10831136	ENSG00000276509.1	CH17-353B19.1	7.78	4.8e-14	1.23e-07	0.36	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903694	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs8181567	ENSG00000276509.1	CH17-353B19.1	7.78	4.8e-14	1.23e-07	0.36	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93904043	chr1:146235806~146237807:+
HNSC	trans	rs72615157	0.634	rs11762932	ENSG00000228546.2	CTA-313A17.3	-7.78	4.84e-14	1.24e-07	-0.52	-0.34	Lung function (FEV1/FVC);	chr7:100195043	chr7:102337316~102339115:+
HNSC	trans	rs1707322	1	rs6675222	ENSG00000255397.1	AC022182.2	-7.77	4.88e-14	1.25e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr8:60937705~60939871:-
HNSC	trans	rs2456568	0.802	rs8181578	ENSG00000276509.1	CH17-353B19.1	7.77	4.89e-14	1.25e-07	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93904276	chr1:146235806~146237807:+
HNSC	trans	rs1707322	0.963	rs10789484	ENSG00000255397.1	AC022182.2	-7.77	4.9e-14	1.25e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10158032	ENSG00000255397.1	AC022182.2	-7.77	4.93e-14	1.26e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs4634600	ENSG00000173295.6	FAM86B3P	-7.77	4.95e-14	1.27e-07	-0.37	-0.34	Retinal vascular caliber;	chr8:11381508	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.527	rs4631425	ENSG00000173295.6	FAM86B3P	-7.77	4.95e-14	1.27e-07	-0.37	-0.34	Retinal vascular caliber;	chr8:11381545	chr8:8228595~8244865:+
HNSC	trans	rs3808502	0.585	rs4549730	ENSG00000173295.6	FAM86B3P	-7.77	4.95e-14	1.27e-07	-0.37	-0.34	Neuroticism;	chr8:11381569	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.752	rs10789467	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890337	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs3811435	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs9793568	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.685	rs6690926	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs8179402	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs8179296	ENSG00000255397.1	AC022182.2	-7.77	4.96e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785465	ENSG00000255397.1	AC022182.2	-7.77	4.98e-14	1.27e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211223	ENSG00000255397.1	AC022182.2	-7.77	4.99e-14	1.28e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211217	ENSG00000255397.1	AC022182.2	-7.77	5.01e-14	1.28e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7553924	ENSG00000255397.1	AC022182.2	-7.77	5.01e-14	1.28e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4641257	ENSG00000255397.1	AC022182.2	-7.77	5.01e-14	1.28e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs6693336	ENSG00000255397.1	AC022182.2	-7.77	5.01e-14	1.28e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr8:60937705~60939871:-
HNSC	trans	rs210142	1	rs210142	ENSG00000175730.8	BAK1P1	7.77	5.02e-14	1.28e-07	0.44	0.34	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;	chr6:33579060	chr20:32690180~32690815:-
HNSC	trans	rs210143	1	rs210143	ENSG00000175730.8	BAK1P1	7.77	5.02e-14	1.28e-07	0.44	0.34	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;Neutrophil percentage of granulocytes;	chr6:33579153	chr20:32690180~32690815:-
HNSC	trans	rs9630182	0.793	rs11022858	ENSG00000257675.1	RP11-641A6.9	7.77	5.11e-14	1.31e-07	0.41	0.34	Bone mineral density;	chr11:13505086	chr12:52748776~52750127:+
HNSC	trans	rs7824557	0.527	rs2736305	ENSG00000173295.6	FAM86B3P	-7.77	5.19e-14	1.32e-07	-0.37	-0.34	Retinal vascular caliber;	chr8:11380264	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.905	rs3818938	ENSG00000224976.2	PARP4P2	-7.77	5.21e-14	1.33e-07	-0.39	-0.34	Obesity-related traits;	chr13:24454945	chr13:19349137~19407962:+
HNSC	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-7.76	5.21e-14	1.33e-07	-0.44	-0.34	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
HNSC	trans	rs7833986	0.501	rs2976044	ENSG00000244245.1	RP11-120B7.1	7.76	5.27e-14	1.34e-07	0.37	0.34	Height;	chr8:56074178	chr5:108593609~108593967:+
HNSC	trans	rs1707322	0.928	rs7527244	ENSG00000255397.1	AC022182.2	-7.76	5.28e-14	1.35e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211146	ENSG00000255397.1	AC022182.2	-7.76	5.37e-14	1.37e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211147	ENSG00000255397.1	AC022182.2	-7.76	5.37e-14	1.37e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs56255771	ENSG00000255397.1	AC022182.2	-7.76	5.45e-14	1.39e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2991986	ENSG00000255397.1	AC022182.2	7.76	5.52e-14	1.41e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr8:60937705~60939871:-
HNSC	trans	rs2456568	0.741	rs10831137	ENSG00000276509.1	CH17-353B19.1	7.76	5.54e-14	1.41e-07	0.37	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903746	chr1:146235806~146237807:+
HNSC	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	7.75	5.67e-14	1.44e-07	0.44	0.34	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.721	rs7520123	ENSG00000255397.1	AC022182.2	-7.75	5.67e-14	1.44e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-7.75	5.67e-14	1.44e-07	-0.43	-0.34	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-7.75	5.69e-14	1.45e-07	-0.37	-0.34	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
HNSC	trans	rs916888	0.773	rs199535	ENSG00000204650.12	CRHR1-IT1	7.75	5.72e-14	1.46e-07	0.4	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45620328~45648216:+
HNSC	trans	rs12145833	1	rs10926986	ENSG00000154608.12	CEP170P1	7.75	5.77e-14	1.47e-07	0.45	0.34	Obesity (early onset extreme);	chr1:243304309	chr4:118467590~118554204:+
HNSC	trans	rs9630182	0.624	rs10766083	ENSG00000257675.1	RP11-641A6.9	-7.75	5.85e-14	1.49e-07	-0.41	-0.34	Bone mineral density;	chr11:13475184	chr12:52748776~52750127:+
HNSC	trans	rs2456568	0.803	rs10765641	ENSG00000276509.1	CH17-353B19.1	7.75	5.89e-14	1.5e-07	0.36	0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907146	chr1:146235806~146237807:+
HNSC	trans	rs9630182	0.793	rs898146	ENSG00000257675.1	RP11-641A6.9	-7.75	5.89e-14	1.5e-07	-0.41	-0.34	Bone mineral density;	chr11:13471935	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.752	rs6662164	ENSG00000255397.1	AC022182.2	-7.75	5.91e-14	1.5e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.544	rs1865521	ENSG00000173295.6	FAM86B3P	7.75	5.98e-14	1.52e-07	0.37	0.34	Retinal vascular caliber;	chr8:11373740	chr8:8228595~8244865:+
HNSC	trans	rs1190596	0.594	rs33997362	ENSG00000181359.5	HSP90AA6P	-7.75	5.99e-14	1.52e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102253553	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.525	rs8013308	ENSG00000181359.5	HSP90AA6P	-7.75	5.99e-14	1.52e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102267188	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.525	rs7157909	ENSG00000181359.5	HSP90AA6P	-7.75	5.99e-14	1.52e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102267874	chr4:170581470~170605450:-
HNSC	trans	rs916888	0.821	rs199514	ENSG00000204650.12	CRHR1-IT1	-7.74	6.01e-14	1.53e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45620328~45648216:+
HNSC	trans	rs7833986	0.501	rs2719255	ENSG00000244245.1	RP11-120B7.1	7.74	6.02e-14	1.53e-07	0.4	0.34	Height;	chr8:56124099	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs72653990	ENSG00000244245.1	RP11-120B7.1	7.74	6.02e-14	1.53e-07	0.4	0.34	Height;	chr8:56124556	chr5:108593609~108593967:+
HNSC	trans	rs7833986	0.501	rs17815934	ENSG00000244245.1	RP11-120B7.1	7.74	6.02e-14	1.53e-07	0.4	0.34	Height;	chr8:56125836	chr5:108593609~108593967:+
HNSC	trans	rs3849046	0.817	rs13160755	ENSG00000226666.1	HSPA9P1	7.74	6.05e-14	1.54e-07	0.36	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138549942	chr2:221961737~221963765:+
HNSC	trans	rs172166	0.61	rs156737	ENSG00000204709.4	LINC01556	7.74	6.05e-14	1.54e-07	0.4	0.34	Cardiac Troponin-T levels;	chr6:27927435	chr6:28943877~28944537:+
HNSC	trans	rs1707322	0.928	rs6681068	ENSG00000255397.1	AC022182.2	-7.74	6.16e-14	1.56e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211228	ENSG00000255397.1	AC022182.2	-7.74	6.16e-14	1.56e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs11211229	ENSG00000255397.1	AC022182.2	-7.74	6.16e-14	1.56e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs9803784	ENSG00000255397.1	AC022182.2	-7.74	6.16e-14	1.56e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-7.74	6.23e-14	1.58e-07	-0.41	-0.34	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
HNSC	trans	rs1707322	0.964	rs6697830	ENSG00000255397.1	AC022182.2	-7.74	6.27e-14	1.59e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12060274	ENSG00000255397.1	AC022182.2	-7.74	6.27e-14	1.59e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4539075	ENSG00000255397.1	AC022182.2	-7.74	6.29e-14	1.59e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr8:60937705~60939871:-
HNSC	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	7.74	6.29e-14	1.59e-07	0.44	0.34	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
HNSC	trans	rs1190596	0.578	rs35601191	ENSG00000181359.5	HSP90AA6P	-7.74	6.3e-14	1.6e-07	-0.45	-0.34	Behavioural disinhibition (generation interaction);	chr14:102276489	chr4:170581470~170605450:-
HNSC	trans	rs9630182	0.793	rs2219487	ENSG00000257675.1	RP11-641A6.9	-7.74	6.31e-14	1.6e-07	-0.41	-0.34	Bone mineral density;	chr11:13593294	chr12:52748776~52750127:+
HNSC	trans	rs1190596	0.525	rs34440178	ENSG00000181359.5	HSP90AA6P	-7.74	6.35e-14	1.61e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102244864	chr4:170581470~170605450:-
HNSC	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-7.73	6.47e-14	1.64e-07	-0.38	-0.34	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
HNSC	trans	rs1707322	1	rs11211243	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211244	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660903	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs11211157	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs11211158	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs6429575	ENSG00000255397.1	AC022182.2	-7.73	6.47e-14	1.64e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs1250	ENSG00000255397.1	AC022182.2	-7.73	6.62e-14	1.67e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr8:60937705~60939871:-
HNSC	trans	rs7833986	0.501	rs72651502	ENSG00000244245.1	RP11-120B7.1	7.73	6.76e-14	1.71e-07	0.39	0.34	Height;	chr8:55962974	chr5:108593609~108593967:+
HNSC	trans	rs1707322	0.963	rs6429581	ENSG00000255397.1	AC022182.2	-7.73	6.77e-14	1.71e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	7.73	6.78e-14	1.71e-07	0.44	0.34	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	7.73	6.78e-14	1.71e-07	0.44	0.34	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	7.73	6.78e-14	1.71e-07	0.44	0.34	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
HNSC	trans	rs12439619	0.81	rs28876157	ENSG00000259295.5	CSPG4P12	-7.73	6.78e-14	1.71e-07	-0.48	-0.34	Intelligence (multi-trait analysis);	chr15:82216708	chr15:85191438~85213905:+
HNSC	trans	rs7032940	0.784	rs10980253	ENSG00000228236.2	TXNP5	7.73	6.79e-14	1.72e-07	0.41	0.34	Height;	chr9:110205555	chr2:149068596~149068910:-
HNSC	trans	rs1707322	0.682	rs10890334	ENSG00000255397.1	AC022182.2	-7.73	6.79e-14	1.72e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.682	rs10890335	ENSG00000255397.1	AC022182.2	-7.73	6.79e-14	1.72e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890380	ENSG00000255397.1	AC022182.2	-7.73	6.86e-14	1.73e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr8:60937705~60939871:-
HNSC	trans	rs1816752	0.603	rs9511278	ENSG00000224976.2	PARP4P2	7.73	6.87e-14	1.74e-07	0.39	0.34	Obesity-related traits;	chr13:24455766	chr13:19349137~19407962:+
HNSC	trans	rs72615157	0.716	rs75779608	ENSG00000228546.2	CTA-313A17.3	7.73	6.88e-14	1.74e-07	0.56	0.34	Lung function (FEV1/FVC);	chr7:100171334	chr7:102337316~102339115:+
HNSC	trans	rs1707322	1	rs4660334	ENSG00000255397.1	AC022182.2	-7.72	6.91e-14	1.74e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-7.72	6.95e-14	1.75e-07	-0.36	-0.34	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
HNSC	trans	rs1707322	1	rs10890375	ENSG00000255397.1	AC022182.2	-7.72	7.01e-14	1.77e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890377	ENSG00000255397.1	AC022182.2	-7.72	7.01e-14	1.77e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.716	rs6694889	ENSG00000255397.1	AC022182.2	-7.72	7.04e-14	1.78e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.682	rs12041197	ENSG00000255397.1	AC022182.2	-7.72	7.04e-14	1.78e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr8:60937705~60939871:-
HNSC	trans	rs2950393	0.509	rs10459247	ENSG00000257210.1	NACAP3	-7.72	7.07e-14	1.78e-07	-0.45	-0.34	Platelet distribution width;	chr12:56777732	chr12:93124063~93124543:-
HNSC	trans	rs1045902	0.574	rs1474298	ENSG00000236165.1	PRADC1P1	7.72	7.1e-14	1.79e-07	0.44	0.34	Intelligence (multi-trait analysis);	chr2:73239464	chr3:36976316~36976840:+
HNSC	trans	rs7647973	1	rs6805609	ENSG00000197582.5	GPX1P1	-7.72	7.12e-14	1.79e-07	-0.51	-0.34	Menarche (age at onset);	chr3:49434089	chrX:13378735~13379340:-
HNSC	trans	rs6673267	0.967	rs10920099	ENSG00000244144.1	RP11-757F18.3	-7.72	7.12e-14	1.79e-07	-0.39	-0.34	Lobe attachment (rater-scored or self-reported);	chr1:201034478	chr3:112185480~112185998:-
HNSC	trans	rs9630182	0.8	rs11602760	ENSG00000257675.1	RP11-641A6.9	-7.72	7.14e-14	1.8e-07	-0.41	-0.34	Bone mineral density;	chr11:13502836	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.964	rs7512395	ENSG00000255397.1	AC022182.2	-7.72	7.17e-14	1.81e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.793	rs694	ENSG00000257675.1	RP11-641A6.9	-7.72	7.18e-14	1.81e-07	-0.41	-0.34	Bone mineral density;	chr11:13492870	chr12:52748776~52750127:+
HNSC	trans	rs1190596	0.525	rs12896377	ENSG00000181359.5	HSP90AA6P	-7.72	7.27e-14	1.83e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102247244	chr4:170581470~170605450:-
HNSC	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	7.72	7.33e-14	1.84e-07	0.42	0.34	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
HNSC	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	7.71	7.39e-14	1.86e-07	0.45	0.34	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs10789485	ENSG00000255397.1	AC022182.2	-7.71	7.42e-14	1.87e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.793	rs2121633	ENSG00000257675.1	RP11-641A6.9	-7.71	7.7e-14	1.93e-07	-0.4	-0.34	Bone mineral density;	chr11:13499922	chr12:52748776~52750127:+
HNSC	trans	rs916888	0.821	rs199504	ENSG00000204650.12	CRHR1-IT1	-7.71	7.78e-14	1.96e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45620328~45648216:+
HNSC	trans	rs1707322	1	rs4660905	ENSG00000255397.1	AC022182.2	7.71	7.88e-14	1.98e-07	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs10890373	ENSG00000255397.1	AC022182.2	-7.71	7.88e-14	1.98e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs2572376	ENSG00000173295.6	FAM86B3P	-7.71	7.89e-14	1.98e-07	-0.37	-0.34	Retinal vascular caliber;	chr8:11380247	chr8:8228595~8244865:+
HNSC	trans	rs1707322	1	rs11211219	ENSG00000255397.1	AC022182.2	-7.7	8.03e-14	2.02e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.756	rs10832072	ENSG00000257675.1	RP11-641A6.9	-7.7	8.06e-14	2.02e-07	-0.4	-0.34	Bone mineral density;	chr11:13588009	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.793	rs10832076	ENSG00000257675.1	RP11-641A6.9	-7.7	8.06e-14	2.02e-07	-0.4	-0.34	Bone mineral density;	chr11:13589590	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.793	rs10832077	ENSG00000257675.1	RP11-641A6.9	-7.7	8.06e-14	2.02e-07	-0.4	-0.34	Bone mineral density;	chr11:13590416	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.789	rs12286864	ENSG00000257675.1	RP11-641A6.9	-7.7	8.18e-14	2.05e-07	-0.4	-0.34	Bone mineral density;	chr11:13487569	chr12:52748776~52750127:+
HNSC	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-7.7	8.24e-14	2.07e-07	-0.45	-0.34	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
HNSC	trans	rs7833986	0.501	rs2668007	ENSG00000244245.1	RP11-120B7.1	7.7	8.26e-14	2.07e-07	0.4	0.34	Height;	chr8:56031552	chr5:108593609~108593967:+
HNSC	trans	rs2456568	0.802	rs1108910	ENSG00000276509.1	CH17-353B19.1	-7.7	8.33e-14	2.09e-07	-0.36	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93896511	chr1:146235806~146237807:+
HNSC	trans	rs1707322	1	rs785480	ENSG00000255397.1	AC022182.2	-7.7	8.37e-14	2.1e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr8:60937705~60939871:-
HNSC	trans	rs1190596	0.525	rs3783372	ENSG00000181359.5	HSP90AA6P	-7.7	8.38e-14	2.1e-07	-0.44	-0.34	Behavioural disinhibition (generation interaction);	chr14:102253283	chr4:170581470~170605450:-
HNSC	trans	rs1707322	0.686	rs2230658	ENSG00000255397.1	AC022182.2	7.7	8.39e-14	2.1e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2230659	ENSG00000255397.1	AC022182.2	7.7	8.39e-14	2.1e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs11211152	ENSG00000255397.1	AC022182.2	-7.7	8.46e-14	2.12e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs4607935	ENSG00000255397.1	AC022182.2	-7.7	8.46e-14	2.12e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.681	rs12048866	ENSG00000255397.1	AC022182.2	-7.7	8.46e-14	2.12e-07	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.793	rs4757171	ENSG00000257675.1	RP11-641A6.9	7.69	8.5e-14	2.13e-07	0.4	0.34	Bone mineral density;	chr11:13553368	chr12:52748776~52750127:+
HNSC	trans	rs72615157	0.629	rs55839153	ENSG00000228546.2	CTA-313A17.3	7.69	8.52e-14	2.13e-07	0.56	0.34	Lung function (FEV1/FVC);	chr7:100154943	chr7:102337316~102339115:+
HNSC	trans	rs1707322	1	rs10890355	ENSG00000255397.1	AC022182.2	-7.69	8.62e-14	2.16e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211204	ENSG00000255397.1	AC022182.2	-7.69	8.62e-14	2.16e-07	-0.43	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr8:60937705~60939871:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	7.69	8.72e-14	2.18e-07	0.38	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
HNSC	trans	rs7032940	0.954	rs9722603	ENSG00000262519.1	TXNP4	7.69	8.77e-14	2.19e-07	0.48	0.34	Height;	chr9:110191400	chr17:4572206~4572515:+
HNSC	trans	rs9630182	0.77	rs307253	ENSG00000257675.1	RP11-641A6.9	7.69	8.79e-14	2.2e-07	0.4	0.34	Bone mineral density;	chr11:13488070	chr12:52748776~52750127:+
HNSC	trans	rs8067354	0.83	rs2453913	ENSG00000187870.7	RNFT1P3	7.69	8.97e-14	2.24e-07	0.4	0.34	Hemoglobin concentration;	chr17:59782789	chr17:20743333~20754501:-
HNSC	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	7.69	8.99e-14	2.25e-07	0.42	0.34	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
HNSC	trans	rs916888	0.821	rs415430	ENSG00000204650.12	CRHR1-IT1	-7.69	9.04e-14	2.26e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.779	rs430685	ENSG00000204650.12	CRHR1-IT1	-7.69	9.04e-14	2.26e-07	-0.4	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45620328~45648216:+
HNSC	trans	rs9630182	0.793	rs1875562	ENSG00000257675.1	RP11-641A6.9	-7.69	9.06e-14	2.26e-07	-0.4	-0.34	Bone mineral density;	chr11:13567545	chr12:52748776~52750127:+
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	7.68	9.1e-14	2.27e-07	0.38	0.34	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
HNSC	trans	rs7121616	0.576	rs7102045	ENSG00000229091.2	HSPA8P8	7.68	9.17e-14	2.29e-07	0.43	0.34	Breast cancer;	chr11:123052713	chr7:10451311~10452526:+
HNSC	trans	rs55665837	0.701	rs12787709	ENSG00000236360.2	RP11-334A14.2	7.68	9.19e-14	2.29e-07	0.46	0.34	Vitamin D levels;	chr11:14617711	chr1:52993201~52993702:-
HNSC	trans	rs55665837	0.701	rs1522633	ENSG00000236360.2	RP11-334A14.2	7.68	9.25e-14	2.31e-07	0.46	0.33	Vitamin D levels;	chr11:14623692	chr1:52993201~52993702:-
HNSC	trans	rs2456568	0.802	rs1506656	ENSG00000276509.1	CH17-353B19.1	7.68	9.47e-14	2.36e-07	0.36	0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93906647	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.802	rs11020585	ENSG00000276509.1	CH17-353B19.1	-7.68	9.57e-14	2.39e-07	-0.36	-0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93905327	chr1:146235806~146237807:+
HNSC	trans	rs1707322	0.821	rs11211182	ENSG00000255397.1	AC022182.2	-7.67	9.83e-14	2.45e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	7.67	1e-13	2.49e-07	0.44	0.33	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
HNSC	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	7.67	1e-13	2.49e-07	0.44	0.33	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs6657720	ENSG00000255397.1	AC022182.2	-7.67	1e-13	2.49e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7519181	ENSG00000255397.1	AC022182.2	-7.67	1e-13	2.49e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7526369	ENSG00000255397.1	AC022182.2	-7.67	1e-13	2.49e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs10890371	ENSG00000255397.1	AC022182.2	-7.67	1e-13	2.49e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890372	ENSG00000255397.1	AC022182.2	-7.67	1e-13	2.49e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.793	rs11022888	ENSG00000257675.1	RP11-641A6.9	-7.67	1.03e-13	2.55e-07	-0.4	-0.33	Bone mineral density;	chr11:13564833	chr12:52748776~52750127:+
HNSC	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	7.67	1.04e-13	2.58e-07	0.51	0.33	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
HNSC	trans	rs1707322	0.647	rs6686944	ENSG00000255397.1	AC022182.2	-7.67	1.04e-13	2.59e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs11211161	ENSG00000255397.1	AC022182.2	-7.66	1.05e-13	2.6e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs61784793	ENSG00000255397.1	AC022182.2	-7.66	1.05e-13	2.6e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.752	rs4586014	ENSG00000255397.1	AC022182.2	-7.66	1.05e-13	2.6e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.648	rs4439382	ENSG00000255397.1	AC022182.2	-7.66	1.05e-13	2.6e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr8:60937705~60939871:-
HNSC	trans	rs7833986	0.501	rs72653986	ENSG00000244245.1	RP11-120B7.1	7.66	1.05e-13	2.62e-07	0.4	0.33	Height;	chr8:56122489	chr5:108593609~108593967:+
HNSC	trans	rs7032940	0.859	rs11793349	ENSG00000262519.1	TXNP4	7.66	1.06e-13	2.62e-07	0.48	0.33	Height;	chr9:110191406	chr17:4572206~4572515:+
HNSC	trans	rs1707322	1	rs6687301	ENSG00000255397.1	AC022182.2	-7.66	1.06e-13	2.63e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.686	rs2991977	ENSG00000255397.1	AC022182.2	7.66	1.06e-13	2.63e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211190	ENSG00000255397.1	AC022182.2	-7.66	1.07e-13	2.67e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs6429580	ENSG00000255397.1	AC022182.2	-7.66	1.07e-13	2.67e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890376	ENSG00000255397.1	AC022182.2	-7.66	1.09e-13	2.7e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr8:60937705~60939871:-
HNSC	trans	rs12439619	0.508	rs8032033	ENSG00000259295.5	CSPG4P12	-7.66	1.09e-13	2.71e-07	-0.41	-0.33	Intelligence (multi-trait analysis);	chr15:82165555	chr15:85191438~85213905:+
HNSC	trans	rs10028773	0.632	rs34481394	ENSG00000275858.1	RP11-291L22.8	7.66	1.1e-13	2.73e-07	0.46	0.33	Educational attainment;	chr4:119327219	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.666	rs35231872	ENSG00000275858.1	RP11-291L22.8	7.66	1.1e-13	2.73e-07	0.46	0.33	Educational attainment;	chr4:119327221	chr10:38450738~38451069:-
HNSC	trans	rs10028773	0.7	rs35653026	ENSG00000275858.1	RP11-291L22.8	7.66	1.1e-13	2.73e-07	0.46	0.33	Educational attainment;	chr4:119327223	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs6695421	ENSG00000255397.1	AC022182.2	-7.66	1.1e-13	2.73e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr8:60937705~60939871:-
HNSC	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	7.66	1.1e-13	2.73e-07	0.44	0.33	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.827	rs10890347	ENSG00000255397.1	AC022182.2	7.66	1.1e-13	2.74e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs11785394	ENSG00000173295.6	FAM86B3P	-7.65	1.12e-13	2.77e-07	-0.37	-0.33	Retinal vascular caliber;	chr8:11380520	chr8:8228595~8244865:+
HNSC	trans	rs12145833	1	rs2802727	ENSG00000154608.12	CEP170P1	7.65	1.12e-13	2.78e-07	0.42	0.33	Obesity (early onset extreme);	chr1:243320024	chr4:118467590~118554204:+
HNSC	trans	rs867371	0.614	rs1814739	ENSG00000235370.6	DNM1P51	-7.65	1.13e-13	2.79e-07	-0.46	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:84398316~84411701:-
HNSC	trans	rs1707322	0.963	rs10789478	ENSG00000255397.1	AC022182.2	-7.65	1.13e-13	2.79e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.51	rs4841524	ENSG00000173295.6	FAM86B3P	-7.65	1.14e-13	2.81e-07	-0.37	-0.33	Retinal vascular caliber;	chr8:11385617	chr8:8228595~8244865:+
HNSC	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	7.65	1.14e-13	2.82e-07	0.43	0.33	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs11211222	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs9787412	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660896	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.928	rs10732844	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12133129	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs4553121	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs6690652	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.82e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660332	ENSG00000255397.1	AC022182.2	-7.65	1.14e-13	2.83e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.717	rs3014249	ENSG00000255397.1	AC022182.2	7.65	1.15e-13	2.84e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890353	ENSG00000255397.1	AC022182.2	-7.65	1.16e-13	2.87e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr8:60937705~60939871:-
HNSC	trans	rs7937890	0.874	rs6486191	ENSG00000236360.2	RP11-334A14.2	7.65	1.17e-13	2.89e-07	0.44	0.33	Mitochondrial DNA levels;	chr11:14382193	chr1:52993201~52993702:-
HNSC	trans	rs1707322	0.927	rs11211194	ENSG00000255397.1	AC022182.2	-7.65	1.17e-13	2.9e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.583	rs2736306	ENSG00000173295.6	FAM86B3P	7.65	1.18e-13	2.91e-07	0.37	0.33	Retinal vascular caliber;	chr8:11382253	chr8:8228595~8244865:+
HNSC	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	7.65	1.19e-13	2.93e-07	0.44	0.33	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
HNSC	trans	rs9733	0.744	rs12126004	ENSG00000180764.13	PIPSL	7.65	1.2e-13	2.95e-07	0.4	0.33	Tonsillectomy;	chr1:150917401	chr10:93958191~93961540:-
HNSC	trans	rs1707322	1	rs12403666	ENSG00000255397.1	AC022182.2	-7.64	1.21e-13	2.98e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr8:60937705~60939871:-
HNSC	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	7.64	1.21e-13	2.98e-07	0.42	0.33	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
HNSC	trans	rs12439619	0.508	rs8042665	ENSG00000259295.5	CSPG4P12	-7.64	1.22e-13	3e-07	-0.41	-0.33	Intelligence (multi-trait analysis);	chr15:82189008	chr15:85191438~85213905:+
HNSC	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	7.64	1.22e-13	3e-07	0.43	0.33	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	7.64	1.22e-13	3.01e-07	0.36	0.33	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
HNSC	trans	rs12145833	1	rs76473275	ENSG00000154608.12	CEP170P1	-7.64	1.22e-13	3.02e-07	-0.44	-0.33	Obesity (early onset extreme);	chr1:243297253	chr4:118467590~118554204:+
HNSC	trans	rs12145833	1	rs10926984	ENSG00000154608.12	CEP170P1	-7.64	1.22e-13	3.02e-07	-0.44	-0.33	Obesity (early onset extreme);	chr1:243298851	chr4:118467590~118554204:+
HNSC	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-7.64	1.23e-13	3.02e-07	-0.52	-0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
HNSC	trans	rs12439619	0.768	rs28694364	ENSG00000259295.5	CSPG4P12	-7.64	1.24e-13	3.06e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82208119	chr15:85191438~85213905:+
HNSC	trans	rs1707322	0.721	rs10890336	ENSG00000255397.1	AC022182.2	-7.64	1.25e-13	3.08e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr8:60937705~60939871:-
HNSC	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	7.64	1.26e-13	3.09e-07	0.4	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
HNSC	trans	rs1707322	0.721	rs10789468	ENSG00000255397.1	AC022182.2	-7.64	1.27e-13	3.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr8:60937705~60939871:-
HNSC	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	7.64	1.28e-13	3.15e-07	0.42	0.33	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
HNSC	trans	rs12439619	0.53	rs7162177	ENSG00000259295.5	CSPG4P12	-7.63	1.29e-13	3.17e-07	-0.41	-0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:85191438~85213905:+
HNSC	trans	rs2456568	0.606	rs11020616	ENSG00000276509.1	CH17-353B19.1	-7.63	1.3e-13	3.2e-07	-0.38	-0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93958428	chr1:146235806~146237807:+
HNSC	trans	rs12145833	0.92	rs12354170	ENSG00000154608.12	CEP170P1	-7.63	1.31e-13	3.22e-07	-0.44	-0.33	Obesity (early onset extreme);	chr1:243294474	chr4:118467590~118554204:+
HNSC	trans	rs7824557	0.564	rs35009431	ENSG00000173295.6	FAM86B3P	-7.63	1.32e-13	3.23e-07	-0.37	-0.33	Retinal vascular caliber;	chr8:11375279	chr8:8228595~8244865:+
HNSC	trans	rs2456568	0.802	rs1574515	ENSG00000276509.1	CH17-353B19.1	7.63	1.32e-13	3.23e-07	0.36	0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93896477	chr1:146235806~146237807:+
HNSC	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	7.63	1.32e-13	3.24e-07	0.39	0.33	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
HNSC	trans	rs7819412	0.539	rs11250131	ENSG00000173295.6	FAM86B3P	-7.63	1.34e-13	3.28e-07	-0.37	-0.33	Triglycerides;	chr8:11393666	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.793	rs11022841	ENSG00000257675.1	RP11-641A6.9	-7.63	1.34e-13	3.28e-07	-0.4	-0.33	Bone mineral density;	chr11:13469783	chr12:52748776~52750127:+
HNSC	trans	rs673253	0.581	rs11210860	ENSG00000231007.5	CDC20P1	-7.63	1.35e-13	3.3e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr1:43516856	chr9:87011652~87013151:+
HNSC	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	7.63	1.36e-13	3.33e-07	0.44	0.33	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs6677777	ENSG00000255397.1	AC022182.2	-7.63	1.37e-13	3.36e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.546	rs10832032	ENSG00000257675.1	RP11-641A6.9	-7.63	1.37e-13	3.37e-07	-0.38	-0.33	Bone mineral density;	chr11:13389797	chr12:52748776~52750127:+
HNSC	trans	rs7824557	0.564	rs34964435	ENSG00000173295.6	FAM86B3P	-7.62	1.38e-13	3.38e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11372697	chr8:8228595~8244865:+
HNSC	trans	rs1190596	0.525	rs28607975	ENSG00000181359.5	HSP90AA6P	-7.62	1.41e-13	3.46e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102252082	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.525	rs10145478	ENSG00000181359.5	HSP90AA6P	-7.62	1.41e-13	3.46e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102254559	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.525	rs10134693	ENSG00000181359.5	HSP90AA6P	-7.62	1.41e-13	3.46e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102266987	chr4:170581470~170605450:-
HNSC	trans	rs7032940	0.953	rs7036157	ENSG00000262519.1	TXNP4	7.62	1.41e-13	3.46e-07	0.48	0.33	Height;	chr9:110183494	chr17:4572206~4572515:+
HNSC	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	7.62	1.42e-13	3.48e-07	0.42	0.33	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
HNSC	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	7.62	1.43e-13	3.5e-07	0.44	0.33	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
HNSC	trans	rs9733	0.635	rs486836	ENSG00000180764.13	PIPSL	7.62	1.45e-13	3.55e-07	0.4	0.33	Tonsillectomy;	chr1:150903491	chr10:93958191~93961540:-
HNSC	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	7.62	1.47e-13	3.59e-07	0.44	0.33	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
HNSC	trans	rs1190596	0.525	rs7152627	ENSG00000181359.5	HSP90AA6P	7.62	1.47e-13	3.6e-07	0.45	0.33	Behavioural disinhibition (generation interaction);	chr14:102232062	chr4:170581470~170605450:-
HNSC	trans	rs10242455	0.681	rs59836234	ENSG00000228834.1	RP11-249L21.4	7.61	1.48e-13	3.62e-07	0.63	0.33	Blood metabolite levels;	chr7:99755926	chr6:108907615~108907873:-
HNSC	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	7.61	1.48e-13	3.63e-07	0.47	0.33	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs4074225	ENSG00000255397.1	AC022182.2	-7.61	1.49e-13	3.64e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4134387	ENSG00000255397.1	AC022182.2	-7.61	1.49e-13	3.64e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr8:60937705~60939871:-
HNSC	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	7.61	1.51e-13	3.7e-07	0.44	0.33	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
HNSC	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	7.61	1.53e-13	3.72e-07	0.48	0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
HNSC	trans	rs12439619	0.846	rs7496227	ENSG00000259295.5	CSPG4P12	-7.61	1.53e-13	3.72e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82275241	chr15:85191438~85213905:+
HNSC	trans	rs1707322	0.896	rs785512	ENSG00000255397.1	AC022182.2	7.61	1.55e-13	3.77e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr8:60937705~60939871:-
HNSC	trans	rs3849046	1	rs13155345	ENSG00000226666.1	HSPA9P1	-7.61	1.58e-13	3.85e-07	-0.34	-0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138519235	chr2:221961737~221963765:+
HNSC	trans	rs1707322	0.827	rs6694302	ENSG00000255397.1	AC022182.2	-7.6	1.59e-13	3.86e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs796773	ENSG00000255397.1	AC022182.2	7.6	1.59e-13	3.87e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.896	rs785518	ENSG00000255397.1	AC022182.2	7.6	1.59e-13	3.87e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785519	ENSG00000255397.1	AC022182.2	7.6	1.59e-13	3.87e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs2572449	ENSG00000173295.6	FAM86B3P	7.6	1.59e-13	3.88e-07	0.36	0.33	Retinal vascular caliber;	chr8:11381628	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.785	rs10890348	ENSG00000255397.1	AC022182.2	-7.6	1.59e-13	3.88e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr8:60937705~60939871:-
HNSC	trans	rs4713118	0.505	rs276371	ENSG00000204709.4	LINC01556	7.6	1.6e-13	3.9e-07	0.39	0.33	Parkinson's disease;	chr6:27942930	chr6:28943877~28944537:+
HNSC	trans	rs1707322	0.721	rs6429574	ENSG00000255397.1	AC022182.2	-7.6	1.61e-13	3.93e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs10890333	ENSG00000255397.1	AC022182.2	-7.6	1.62e-13	3.95e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12043945	ENSG00000255397.1	AC022182.2	-7.6	1.62e-13	3.95e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12091503	ENSG00000255397.1	AC022182.2	-7.6	1.62e-13	3.95e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr8:60937705~60939871:-
HNSC	trans	rs7554511	0.535	rs1995681	ENSG00000244144.1	RP11-757F18.3	7.6	1.63e-13	3.97e-07	0.39	0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036678	chr3:112185480~112185998:-
HNSC	trans	rs1190596	0.525	rs8004474	ENSG00000181359.5	HSP90AA6P	-7.6	1.63e-13	3.97e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102290161	chr4:170581470~170605450:-
HNSC	trans	rs1707322	0.789	rs7540578	ENSG00000255397.1	AC022182.2	-7.6	1.63e-13	3.98e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12124847	ENSG00000255397.1	AC022182.2	-7.6	1.65e-13	4.01e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	7.6	1.66e-13	4.03e-07	0.38	0.33	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
HNSC	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	7.6	1.66e-13	4.03e-07	0.44	0.33	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	7.6	1.66e-13	4.03e-07	0.38	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
HNSC	trans	rs1707322	1	rs9429186	ENSG00000255397.1	AC022182.2	7.6	1.67e-13	4.05e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785506	ENSG00000255397.1	AC022182.2	7.6	1.67e-13	4.05e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4489497	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211235	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.893	rs9919275	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211236	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660328	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.928	rs61785614	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs9793167	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211237	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs11211238	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4460583	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs4459051	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211239	ENSG00000255397.1	AC022182.2	-7.59	1.69e-13	4.11e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.527	rs2736298	ENSG00000173295.6	FAM86B3P	-7.59	1.7e-13	4.12e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11377627	chr8:8228595~8244865:+
HNSC	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	7.59	1.71e-13	4.15e-07	0.42	0.33	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
HNSC	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	7.59	1.72e-13	4.17e-07	0.44	0.33	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs4524994	ENSG00000255397.1	AC022182.2	-7.59	1.75e-13	4.23e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr8:60937705~60939871:-
HNSC	trans	rs1190596	0.525	rs6575901	ENSG00000181359.5	HSP90AA6P	-7.59	1.75e-13	4.23e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102225517	chr4:170581470~170605450:-
HNSC	trans	rs9630182	0.722	rs12294009	ENSG00000257675.1	RP11-641A6.9	-7.59	1.78e-13	4.31e-07	-0.4	-0.33	Bone mineral density;	chr11:13506121	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.964	rs7546237	ENSG00000255397.1	AC022182.2	-7.59	1.8e-13	4.37e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr8:60937705~60939871:-
HNSC	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-7.58	1.83e-13	4.43e-07	-0.4	-0.33	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
HNSC	trans	rs11638815	0.581	rs783537	ENSG00000235370.6	DNM1P51	-7.58	1.84e-13	4.46e-07	-0.42	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:84398316~84411701:-
HNSC	trans	rs1707322	1	rs10890350	ENSG00000255397.1	AC022182.2	-7.58	1.87e-13	4.53e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr8:60937705~60939871:-
HNSC	trans	rs12145833	1	rs12145833	ENSG00000154608.12	CEP170P1	7.58	1.88e-13	4.54e-07	0.44	0.33	Obesity (early onset extreme);	chr1:243320452	chr4:118467590~118554204:+
HNSC	trans	rs7824557	0.564	rs6601584	ENSG00000173295.6	FAM86B3P	-7.58	1.89e-13	4.56e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11374834	chr8:8228595~8244865:+
HNSC	trans	rs1707322	1	rs4298677	ENSG00000255397.1	AC022182.2	-7.58	1.9e-13	4.58e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr8:60937705~60939871:-
HNSC	trans	rs12439619	0.508	rs11856561	ENSG00000259295.5	CSPG4P12	-7.58	1.9e-13	4.59e-07	-0.41	-0.33	Intelligence (multi-trait analysis);	chr15:82161415	chr15:85191438~85213905:+
HNSC	trans	rs1707322	1	rs4660906	ENSG00000255397.1	AC022182.2	-7.58	1.91e-13	4.61e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr8:60937705~60939871:-
HNSC	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	7.58	1.92e-13	4.64e-07	0.43	0.33	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
HNSC	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	7.58	1.92e-13	4.64e-07	0.43	0.33	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
HNSC	trans	rs1707322	0.835	rs946525	ENSG00000255397.1	AC022182.2	7.58	1.93e-13	4.67e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs946524	ENSG00000255397.1	AC022182.2	7.58	1.93e-13	4.67e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660336	ENSG00000255397.1	AC022182.2	7.58	1.93e-13	4.67e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr8:60937705~60939871:-
HNSC	trans	rs1190596	0.578	rs12887161	ENSG00000181359.5	HSP90AA6P	-7.58	1.94e-13	4.68e-07	-0.43	-0.33	Behavioural disinhibition (generation interaction);	chr14:102240581	chr4:170581470~170605450:-
HNSC	trans	rs1707322	0.721	rs11211151	ENSG00000255397.1	AC022182.2	-7.58	1.94e-13	4.68e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12045096	ENSG00000255397.1	AC022182.2	-7.58	1.94e-13	4.68e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs4609469	ENSG00000255397.1	AC022182.2	-7.58	1.94e-13	4.68e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs12049027	ENSG00000255397.1	AC022182.2	-7.58	1.94e-13	4.68e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4390216	ENSG00000255397.1	AC022182.2	-7.57	1.94e-13	4.69e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs10437063	ENSG00000255397.1	AC022182.2	-7.57	1.94e-13	4.69e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs6676982	ENSG00000255397.1	AC022182.2	-7.57	1.94e-13	4.69e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs34907901	ENSG00000255397.1	AC022182.2	-7.57	1.97e-13	4.76e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	7.57	2.03e-13	4.9e-07	0.46	0.33	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	7.57	2.03e-13	4.9e-07	0.46	0.33	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	7.57	2.03e-13	4.9e-07	0.46	0.33	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-7.57	2.07e-13	4.98e-07	-0.4	-0.33	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
HNSC	trans	rs2456568	0.571	rs1105113	ENSG00000276509.1	CH17-353B19.1	-7.57	2.07e-13	4.99e-07	-0.38	-0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93960157	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.571	rs1105114	ENSG00000276509.1	CH17-353B19.1	-7.57	2.07e-13	4.99e-07	-0.38	-0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93960345	chr1:146235806~146237807:+
HNSC	trans	rs12439619	0.774	rs2867649	ENSG00000259295.5	CSPG4P12	-7.56	2.12e-13	5.1e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82262331	chr15:85191438~85213905:+
HNSC	trans	rs12439619	0.846	rs28697264	ENSG00000259295.5	CSPG4P12	-7.56	2.12e-13	5.1e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82265559	chr15:85191438~85213905:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	7.56	2.12e-13	5.11e-07	0.37	0.33	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
HNSC	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-7.56	2.12e-13	5.11e-07	-0.46	-0.33	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
HNSC	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-7.56	2.14e-13	5.15e-07	-0.43	-0.33	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-7.56	2.15e-13	5.16e-07	-0.37	-0.33	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
HNSC	trans	rs11638815	0.603	rs2678448	ENSG00000235370.6	DNM1P51	-7.56	2.2e-13	5.28e-07	-0.42	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:84398316~84411701:-
HNSC	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-7.55	2.24e-13	5.38e-07	-0.37	-0.33	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
HNSC	trans	rs7930295	0.556	rs9704355	ENSG00000236257.1	EI24P2	7.55	2.28e-13	5.47e-07	0.44	0.33	Schizophrenia;	chr11:125478435	chr1:158454198~158455273:+
HNSC	trans	rs6915893	1	rs9477630	ENSG00000267156.1	TPMTP1	7.55	2.3e-13	5.5e-07	0.39	0.33	Intrinsic epigenetic age acceleration;	chr6:18117867	chr18:47630112~47630848:+
HNSC	trans	rs2456568	0.571	rs12807496	ENSG00000276509.1	CH17-353B19.1	-7.55	2.3e-13	5.52e-07	-0.38	-0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93959898	chr1:146235806~146237807:+
HNSC	trans	rs1190596	0.525	rs4601978	ENSG00000181359.5	HSP90AA6P	-7.55	2.3e-13	5.52e-07	-0.44	-0.33	Behavioural disinhibition (generation interaction);	chr14:102284740	chr4:170581470~170605450:-
HNSC	trans	rs1707322	1	rs10890382	ENSG00000255397.1	AC022182.2	-7.55	2.35e-13	5.63e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr8:60937705~60939871:-
HNSC	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	7.55	2.36e-13	5.65e-07	0.5	0.33	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
HNSC	trans	rs7032940	0.954	rs10980249	ENSG00000262519.1	TXNP4	7.55	2.38e-13	5.71e-07	0.47	0.33	Height;	chr9:110190494	chr17:4572206~4572515:+
HNSC	trans	rs1707322	0.65	rs4553239	ENSG00000255397.1	AC022182.2	-7.54	2.4e-13	5.75e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr8:60937705~60939871:-
HNSC	trans	rs72615157	0.634	rs74742883	ENSG00000228546.2	CTA-313A17.3	7.54	2.42e-13	5.79e-07	0.52	0.33	Lung function (FEV1/FVC);	chr7:100188142	chr7:102337316~102339115:+
HNSC	trans	rs12145833	1	rs61833916	ENSG00000154608.12	CEP170P1	-7.54	2.44e-13	5.83e-07	-0.44	-0.33	Obesity (early onset extreme);	chr1:243306644	chr4:118467590~118554204:+
HNSC	trans	rs1190596	0.525	rs10133613	ENSG00000181359.5	HSP90AA6P	-7.54	2.48e-13	5.92e-07	-0.43	-0.33	Behavioural disinhibition (generation interaction);	chr14:102269846	chr4:170581470~170605450:-
HNSC	trans	rs1707322	1	rs6671754	ENSG00000255397.1	AC022182.2	-7.54	2.49e-13	5.94e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs6666763	ENSG00000255397.1	AC022182.2	-7.54	2.49e-13	5.94e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs2458400	ENSG00000255397.1	AC022182.2	7.54	2.54e-13	6.07e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	7.54	2.55e-13	6.08e-07	0.37	0.33	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
HNSC	trans	rs1707322	0.827	rs12125508	ENSG00000255397.1	AC022182.2	-7.54	2.55e-13	6.08e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs1768802	ENSG00000255397.1	AC022182.2	7.53	2.56e-13	6.1e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1588663	ENSG00000255397.1	AC022182.2	7.53	2.56e-13	6.1e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1768801	ENSG00000255397.1	AC022182.2	7.53	2.56e-13	6.1e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1768800	ENSG00000255397.1	AC022182.2	7.53	2.56e-13	6.1e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs785483	ENSG00000255397.1	AC022182.2	7.53	2.56e-13	6.1e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr8:60937705~60939871:-
HNSC	trans	rs1563304	1	rs1563304	ENSG00000214425.5	LRRC37A4P	-7.53	2.57e-13	6.14e-07	-0.43	-0.33	Neuroticism;	chr17:46797087	chr17:45506741~45550335:-
HNSC	trans	rs673253	0.556	rs11577403	ENSG00000231007.5	CDC20P1	7.53	2.59e-13	6.18e-07	0.47	0.33	Intelligence (multi-trait analysis);	chr1:43524102	chr9:87011652~87013151:+
HNSC	trans	rs1707322	0.964	rs785516	ENSG00000255397.1	AC022182.2	7.53	2.65e-13	6.31e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785517	ENSG00000255397.1	AC022182.2	7.53	2.65e-13	6.31e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785484	ENSG00000255397.1	AC022182.2	7.53	2.65e-13	6.31e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr8:60937705~60939871:-
HNSC	trans	rs12439619	0.846	rs62013464	ENSG00000259295.5	CSPG4P12	-7.53	2.68e-13	6.38e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82288250	chr15:85191438~85213905:+
HNSC	trans	rs7824557	0.524	rs7835318	ENSG00000173295.6	FAM86B3P	-7.52	2.74e-13	6.52e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11096364	chr8:8228595~8244865:+
HNSC	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	7.52	2.75e-13	6.54e-07	0.43	0.33	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs785507	ENSG00000255397.1	AC022182.2	7.52	2.76e-13	6.56e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs1768815	ENSG00000255397.1	AC022182.2	7.52	2.78e-13	6.61e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7527079	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs34446427	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs4660900	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4454479	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7517560	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12077546	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12124291	ENSG00000255397.1	AC022182.2	-7.52	2.8e-13	6.66e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr8:60937705~60939871:-
HNSC	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	7.52	2.82e-13	6.7e-07	0.41	0.33	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
HNSC	trans	rs3849046	0.817	rs2268439	ENSG00000226666.1	HSPA9P1	7.52	2.85e-13	6.76e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545103	chr2:221961737~221963765:+
HNSC	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-7.52	2.88e-13	6.84e-07	-0.37	-0.33	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
HNSC	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	7.52	2.89e-13	6.86e-07	0.36	0.33	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
HNSC	trans	rs6673267	1	rs6673267	ENSG00000244144.1	RP11-757F18.3	-7.52	2.9e-13	6.89e-07	-0.38	-0.33	Lobe attachment (rater-scored or self-reported);	chr1:201037533	chr3:112185480~112185998:-
HNSC	trans	rs1707322	0.89	rs2297883	ENSG00000255397.1	AC022182.2	7.52	2.91e-13	6.9e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1707338	ENSG00000255397.1	AC022182.2	7.52	2.91e-13	6.9e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs1707339	ENSG00000255397.1	AC022182.2	7.52	2.91e-13	6.9e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660335	ENSG00000255397.1	AC022182.2	-7.52	2.92e-13	6.92e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr8:60937705~60939871:-
HNSC	trans	rs2456568	0.802	rs1395387	ENSG00000276509.1	CH17-353B19.1	7.52	2.92e-13	6.93e-07	0.35	0.33	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93906141	chr1:146235806~146237807:+
HNSC	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	7.51	2.94e-13	6.97e-07	0.43	0.33	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
HNSC	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	7.51	2.96e-13	7.02e-07	0.37	0.33	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
HNSC	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	7.51	2.97e-13	7.04e-07	0.48	0.33	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
HNSC	trans	rs72615157	0.634	rs79986079	ENSG00000228546.2	CTA-313A17.3	7.51	3e-13	7.1e-07	0.52	0.33	Lung function (FEV1/FVC);	chr7:100204421	chr7:102337316~102339115:+
HNSC	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	7.51	3.03e-13	7.17e-07	0.43	0.33	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	7.51	3.03e-13	7.17e-07	0.43	0.33	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	7.51	3.03e-13	7.17e-07	0.43	0.33	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	7.51	3.03e-13	7.17e-07	0.43	0.33	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs7532204	ENSG00000255397.1	AC022182.2	7.51	3.12e-13	7.38e-07	0.42	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.545	rs34482136	ENSG00000173295.6	FAM86B3P	-7.51	3.12e-13	7.38e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11370376	chr8:8228595~8244865:+
HNSC	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	7.51	3.12e-13	7.39e-07	0.39	0.33	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
HNSC	trans	rs1707322	1	rs10890381	ENSG00000255397.1	AC022182.2	-7.5	3.16e-13	7.46e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	7.5	3.17e-13	7.49e-07	0.44	0.33	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	7.5	3.22e-13	7.61e-07	0.42	0.33	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
HNSC	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	7.5	3.24e-13	7.64e-07	0.35	0.33	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
HNSC	trans	rs1707322	0.963	rs11211202	ENSG00000255397.1	AC022182.2	-7.5	3.26e-13	7.7e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs4660889	ENSG00000255397.1	AC022182.2	-7.5	3.26e-13	7.7e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.667	rs11211176	ENSG00000255397.1	AC022182.2	7.5	3.29e-13	7.78e-07	0.41	0.33	Reticulocyte count;Red blood cell count;	chr1:45757414	chr8:60937705~60939871:-
HNSC	trans	rs3849046	0.934	rs7714751	ENSG00000226666.1	HSPA9P1	-7.5	3.34e-13	7.88e-07	-0.33	-0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513377	chr2:221961737~221963765:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	7.5	3.35e-13	7.92e-07	0.36	0.33	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
HNSC	trans	rs61826828	1	rs61826828	ENSG00000213331.4	RP11-713C19.2	7.49	3.35e-13	7.92e-07	0.47	0.33	Schizophrenia;	chr1:174046123	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.564	rs13274106	ENSG00000173295.6	FAM86B3P	-7.49	3.39e-13	7.99e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11376449	chr8:8228595~8244865:+
HNSC	trans	rs35486314	1	rs35486314	ENSG00000180764.13	PIPSL	7.49	3.4e-13	8.01e-07	0.4	0.33	Monocyte chemoattractant protein-1 levels;	chr1:150929385	chr10:93958191~93961540:-
HNSC	trans	rs6743068	0.541	rs12052257	ENSG00000235105.1	RP11-329A14.1	-7.49	3.42e-13	8.06e-07	-0.4	-0.33	Lymphocyte percentage of white cells;	chr2:201376871	chr1:48435967~48437223:+
HNSC	trans	rs12439619	0.846	rs62012003	ENSG00000259295.5	CSPG4P12	-7.49	3.44e-13	8.11e-07	-0.47	-0.33	Intelligence (multi-trait analysis);	chr15:82183236	chr15:85191438~85213905:+
HNSC	trans	rs58106596	0.747	rs72994902	ENSG00000259020.3	RP11-529H20.3	7.49	3.46e-13	8.15e-07	0.47	0.33	Lymphocyte counts;White blood cell count;	chr2:231720407	chr14:92026566~92026887:+
HNSC	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-7.49	3.47e-13	8.18e-07	-0.33	-0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
HNSC	trans	rs74781061	0.585	rs4646421	ENSG00000227288.3	RP5-837I24.1	7.49	3.53e-13	8.32e-07	0.6	0.33	Endometriosis;	chr15:74723851	chr1:81501794~81503468:+
HNSC	trans	rs9630182	0.793	rs4757165	ENSG00000257675.1	RP11-641A6.9	7.49	3.53e-13	8.32e-07	0.4	0.33	Bone mineral density;	chr11:13549503	chr12:52748776~52750127:+
HNSC	trans	rs1707322	1	rs1768818	ENSG00000255397.1	AC022182.2	7.49	3.54e-13	8.33e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1768817	ENSG00000255397.1	AC022182.2	7.49	3.54e-13	8.33e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785470	ENSG00000255397.1	AC022182.2	7.49	3.54e-13	8.33e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785469	ENSG00000255397.1	AC022182.2	7.49	3.56e-13	8.37e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785468	ENSG00000255397.1	AC022182.2	7.49	3.56e-13	8.37e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	7.49	3.57e-13	8.39e-07	0.46	0.33	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
HNSC	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	7.48	3.59e-13	8.45e-07	0.42	0.33	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
HNSC	trans	rs7412746	0.658	rs4970988	ENSG00000180764.13	PIPSL	7.48	3.63e-13	8.55e-07	0.4	0.33	Melanoma;	chr1:150977586	chr10:93958191~93961540:-
HNSC	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	7.48	3.63e-13	8.55e-07	0.43	0.33	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs10890378	ENSG00000255397.1	AC022182.2	7.48	3.65e-13	8.57e-07	0.42	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	7.48	3.65e-13	8.58e-07	0.37	0.33	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
HNSC	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	7.48	3.65e-13	8.58e-07	0.37	0.33	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
HNSC	trans	rs1707322	1	rs11211248	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	8.78e-07	-0.42	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	7.48	3.77e-13	8.85e-07	0.35	0.33	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	7.48	3.79e-13	8.91e-07	0.35	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
HNSC	trans	rs11638815	0.626	rs4779039	ENSG00000235370.6	DNM1P51	7.47	3.84e-13	9.02e-07	0.42	0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:84398316~84411701:-
HNSC	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	7.47	3.86e-13	9.07e-07	0.47	0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
HNSC	trans	rs7824557	0.564	rs2572400	ENSG00000173295.6	FAM86B3P	-7.47	3.89e-13	9.14e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11376858	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	7.47	3.91e-13	9.16e-07	0.35	0.33	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
HNSC	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	7.47	3.91e-13	9.16e-07	0.35	0.33	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
HNSC	trans	rs1707322	0.821	rs10749857	ENSG00000255397.1	AC022182.2	-7.47	3.91e-13	9.16e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr8:60937705~60939871:-
HNSC	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	7.47	3.93e-13	9.22e-07	0.43	0.33	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
HNSC	trans	rs7824557	0.527	rs2572448	ENSG00000173295.6	FAM86B3P	-7.47	3.96e-13	9.29e-07	-0.36	-0.33	Retinal vascular caliber;	chr8:11381843	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.721	rs6699418	ENSG00000255397.1	AC022182.2	-7.47	3.98e-13	9.32e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.721	rs4431884	ENSG00000255397.1	AC022182.2	-7.47	3.98e-13	9.32e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.65	rs4660879	ENSG00000255397.1	AC022182.2	-7.47	3.98e-13	9.32e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr8:60937705~60939871:-
HNSC	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	7.47	3.98e-13	9.34e-07	0.48	0.33	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	7.47	3.98e-13	9.34e-07	0.48	0.33	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	7.47	4.04e-13	9.45e-07	0.48	0.33	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
HNSC	trans	rs1707322	1	rs1612419	ENSG00000255397.1	AC022182.2	7.47	4.09e-13	9.58e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs10890370	ENSG00000255397.1	AC022182.2	-7.47	4.1e-13	9.59e-07	-0.42	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs11211232	ENSG00000255397.1	AC022182.2	-7.47	4.11e-13	9.62e-07	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	7.46	4.25e-13	9.95e-07	0.45	0.33	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
HNSC	trans	rs7824557	0.51	rs1435274	ENSG00000173295.6	FAM86B3P	-7.46	4.29e-13	1e-06	-0.36	-0.33	Retinal vascular caliber;	chr8:11378401	chr8:8228595~8244865:+
HNSC	trans	rs296547	0.583	rs296557	ENSG00000244144.1	RP11-757F18.3	7.46	4.33e-13	1.01e-06	0.38	0.33	Celiac disease;	chr1:200984435	chr3:112185480~112185998:-
HNSC	trans	rs3849046	0.781	rs4835691	ENSG00000226666.1	HSPA9P1	-7.46	4.34e-13	1.01e-06	-0.34	-0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138602884	chr2:221961737~221963765:+
HNSC	trans	rs9630182	0.93	rs7125774	ENSG00000257675.1	RP11-641A6.9	-7.46	4.34e-13	1.01e-06	-0.39	-0.33	Bone mineral density;	chr11:13597257	chr12:52748776~52750127:+
HNSC	trans	rs6915893	0.692	rs4074443	ENSG00000267156.1	TPMTP1	7.46	4.36e-13	1.02e-06	0.39	0.33	Intrinsic epigenetic age acceleration;	chr6:18106371	chr18:47630112~47630848:+
HNSC	trans	rs7824557	0.564	rs12547100	ENSG00000173295.6	FAM86B3P	-7.46	4.39e-13	1.03e-06	-0.36	-0.33	Retinal vascular caliber;	chr8:11385123	chr8:8228595~8244865:+
HNSC	trans	rs7937890	0.684	rs12799007	ENSG00000236360.2	RP11-334A14.2	7.45	4.4e-13	1.03e-06	0.43	0.33	Mitochondrial DNA levels;	chr11:14404938	chr1:52993201~52993702:-
HNSC	trans	rs10242455	0.614	rs2014764	ENSG00000228834.1	RP11-249L21.4	-7.45	4.41e-13	1.03e-06	-0.54	-0.33	Blood metabolite levels;	chr7:99749883	chr6:108907615~108907873:-
HNSC	trans	rs1707322	1	rs1707322	ENSG00000255397.1	AC022182.2	-7.45	4.42e-13	1.03e-06	-0.42	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.564	rs2437152	ENSG00000173295.6	FAM86B3P	-7.45	4.45e-13	1.04e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11377988	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2736300	ENSG00000173295.6	FAM86B3P	-7.45	4.45e-13	1.04e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11378070	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.859	rs7105697	ENSG00000257675.1	RP11-641A6.9	-7.45	4.53e-13	1.06e-06	-0.39	-0.33	Bone mineral density;	chr11:13597807	chr12:52748776~52750127:+
HNSC	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	7.45	4.54e-13	1.06e-06	0.37	0.33	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
HNSC	trans	rs7824557	0.564	rs2572392	ENSG00000173295.6	FAM86B3P	-7.45	4.54e-13	1.06e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11378096	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.756	rs2958153	ENSG00000257210.1	NACAP3	7.45	4.54e-13	1.06e-06	0.41	0.33	Platelet count;	chr12:56687733	chr12:93124063~93124543:-
HNSC	trans	rs6424115	0.8	rs2229583	ENSG00000228217.1	AL390877.1	-7.45	4.54e-13	1.06e-06	-0.4	-0.33	Immature fraction of reticulocytes;	chr1:23874493	chr1:117778087~117778506:-
HNSC	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	7.45	4.55e-13	1.06e-06	0.43	0.33	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	7.45	4.55e-13	1.06e-06	0.43	0.33	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
HNSC	trans	rs673253	0.581	rs2152113	ENSG00000231007.5	CDC20P1	-7.45	4.59e-13	1.07e-06	-0.46	-0.33	Intelligence (multi-trait analysis);	chr1:43517898	chr9:87011652~87013151:+
HNSC	trans	rs74781061	0.585	rs4646903	ENSG00000227288.3	RP5-837I24.1	7.45	4.63e-13	1.08e-06	0.59	0.33	Endometriosis;	chr15:74719300	chr1:81501794~81503468:+
HNSC	trans	rs453301	0.571	rs330048	ENSG00000173295.6	FAM86B3P	-7.45	4.64e-13	1.08e-06	-0.36	-0.33	Joint mobility (Beighton score);	chr8:9229768	chr8:8228595~8244865:+
HNSC	trans	rs1190596	0.525	rs72698572	ENSG00000181359.5	HSP90AA6P	-7.44	4.72e-13	1.1e-06	-0.43	-0.33	Behavioural disinhibition (generation interaction);	chr14:102289870	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.525	rs8010950	ENSG00000181359.5	HSP90AA6P	-7.44	4.72e-13	1.1e-06	-0.43	-0.33	Behavioural disinhibition (generation interaction);	chr14:102291520	chr4:170581470~170605450:-
HNSC	trans	rs7824557	0.527	rs57629785	ENSG00000173295.6	FAM86B3P	-7.44	4.73e-13	1.1e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11377641	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2572395	ENSG00000173295.6	FAM86B3P	-7.44	4.73e-13	1.1e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11377851	chr8:8228595~8244865:+
HNSC	trans	rs3849046	0.79	rs13187637	ENSG00000226666.1	HSPA9P1	7.44	4.74e-13	1.1e-06	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138540962	chr2:221961737~221963765:+
HNSC	trans	rs1707322	1	rs10890365	ENSG00000255397.1	AC022182.2	-7.44	4.78e-13	1.11e-06	-0.42	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr8:60937705~60939871:-
HNSC	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	7.44	4.9e-13	1.14e-06	0.43	0.33	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
HNSC	trans	rs7824557	0.564	rs1435275	ENSG00000173295.6	FAM86B3P	-7.44	4.91e-13	1.14e-06	-0.35	-0.33	Retinal vascular caliber;	chr8:11378226	chr8:8228595~8244865:+
HNSC	trans	rs1707322	1	rs785510	ENSG00000255397.1	AC022182.2	7.44	4.97e-13	1.16e-06	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr8:60937705~60939871:-
HNSC	trans	rs72615157	0.634	rs2272343	ENSG00000228546.2	CTA-313A17.3	7.44	5.01e-13	1.16e-06	0.51	0.33	Lung function (FEV1/FVC);	chr7:100180662	chr7:102337316~102339115:+
HNSC	trans	rs296547	0.602	rs296551	ENSG00000244144.1	RP11-757F18.3	7.44	5.02e-13	1.17e-06	0.38	0.33	Celiac disease;	chr1:200926330	chr3:112185480~112185998:-
HNSC	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	7.43	5.18e-13	1.2e-06	0.43	0.33	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs1707337	ENSG00000255397.1	AC022182.2	7.43	5.22e-13	1.21e-06	0.42	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1768807	ENSG00000255397.1	AC022182.2	7.43	5.22e-13	1.21e-06	0.42	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs12067716	ENSG00000255397.1	AC022182.2	-7.43	5.32e-13	1.23e-06	-0.43	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr8:60937705~60939871:-
HNSC	trans	rs1190596	0.525	rs2236493	ENSG00000181359.5	HSP90AA6P	-7.43	5.35e-13	1.24e-06	-0.42	-0.32	Behavioural disinhibition (generation interaction);	chr14:102229356	chr4:170581470~170605450:-
HNSC	trans	rs7824557	0.51	rs2736297	ENSG00000173295.6	FAM86B3P	-7.42	5.48e-13	1.27e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377376	chr8:8228595~8244865:+
HNSC	trans	rs740160	0.558	rs17161662	ENSG00000228834.1	RP11-249L21.4	7.42	5.57e-13	1.29e-06	0.58	0.32	Dehydroepiandrosterone sulphate levels;	chr7:99309773	chr6:108907615~108907873:-
HNSC	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	7.42	5.62e-13	1.3e-06	0.47	0.32	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
HNSC	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	7.42	5.66e-13	1.31e-06	0.46	0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
HNSC	trans	rs1707322	1	rs11211200	ENSG00000255397.1	AC022182.2	-7.42	5.68e-13	1.31e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785486	ENSG00000255397.1	AC022182.2	7.42	5.74e-13	1.33e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.865	rs785501	ENSG00000255397.1	AC022182.2	7.42	5.74e-13	1.33e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.929	rs785500	ENSG00000255397.1	AC022182.2	7.42	5.74e-13	1.33e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785504	ENSG00000255397.1	AC022182.2	7.42	5.74e-13	1.33e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs7539800	ENSG00000255397.1	AC022182.2	7.41	5.8e-13	1.34e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	7.41	5.86e-13	1.35e-06	0.45	0.32	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.896	rs809774	ENSG00000255397.1	AC022182.2	7.41	5.92e-13	1.37e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr8:60937705~60939871:-
HNSC	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-7.41	6.08e-13	1.4e-06	-0.35	-0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
HNSC	trans	rs9425766	0.64	rs2208850	ENSG00000213331.4	RP11-713C19.2	7.41	6.09e-13	1.41e-06	0.41	0.32	Life satisfaction;	chr1:173862569	chr4:187970273~187971284:+
HNSC	trans	rs1707322	1	rs785467	ENSG00000255397.1	AC022182.2	7.41	6.1e-13	1.41e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr8:60937705~60939871:-
HNSC	trans	rs9733	0.744	rs11204737	ENSG00000180764.13	PIPSL	7.41	6.12e-13	1.41e-06	0.39	0.32	Tonsillectomy;	chr1:150875171	chr10:93958191~93961540:-
HNSC	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	7.41	6.13e-13	1.41e-06	0.42	0.32	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
HNSC	trans	rs3849046	0.817	rs9327813	ENSG00000226666.1	HSPA9P1	7.41	6.16e-13	1.42e-06	0.35	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138528732	chr2:221961737~221963765:+
HNSC	trans	rs1707322	0.929	rs785513	ENSG00000255397.1	AC022182.2	7.41	6.17e-13	1.42e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs1707303	ENSG00000255397.1	AC022182.2	7.4	6.2e-13	1.43e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr8:60937705~60939871:-
HNSC	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	7.4	6.23e-13	1.44e-06	0.42	0.32	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
HNSC	trans	rs72615157	0.634	rs7789890	ENSG00000228546.2	CTA-313A17.3	7.4	6.24e-13	1.44e-06	0.51	0.32	Lung function (FEV1/FVC);	chr7:100202936	chr7:102337316~102339115:+
HNSC	trans	rs1707322	1	rs7538978	ENSG00000255397.1	AC022182.2	7.4	6.25e-13	1.44e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr8:60937705~60939871:-
HNSC	trans	rs3849046	0.817	rs4835687	ENSG00000226666.1	HSPA9P1	-7.4	6.29e-13	1.45e-06	-0.35	-0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536367	chr2:221961737~221963765:+
HNSC	trans	rs11638815	0.626	rs1313492	ENSG00000235370.6	DNM1P51	-7.4	6.32e-13	1.46e-06	-0.41	-0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:84398316~84411701:-
HNSC	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-7.4	6.38e-13	1.47e-06	-0.35	-0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
HNSC	trans	rs17301013	0.932	rs12077622	ENSG00000213331.4	RP11-713C19.2	7.4	6.42e-13	1.48e-06	0.39	0.32	Systemic lupus erythematosus;	chr1:174442507	chr4:187970273~187971284:+
HNSC	trans	rs3849046	0.817	rs6596438	ENSG00000226666.1	HSPA9P1	7.4	6.42e-13	1.48e-06	0.34	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138569759	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.817	rs6874487	ENSG00000226666.1	HSPA9P1	7.4	6.42e-13	1.48e-06	0.34	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138571317	chr2:221961737~221963765:+
HNSC	trans	rs941207	0.756	rs7315472	ENSG00000257210.1	NACAP3	-7.4	6.45e-13	1.49e-06	-0.41	-0.32	Platelet count;	chr12:56648276	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.756	rs67046307	ENSG00000257210.1	NACAP3	-7.4	6.45e-13	1.49e-06	-0.41	-0.32	Platelet count;	chr12:56651152	chr12:93124063~93124543:-
HNSC	trans	rs1707322	1	rs12097761	ENSG00000255397.1	AC022182.2	-7.4	6.45e-13	1.49e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr8:60937705~60939871:-
HNSC	trans	rs72615157	0.634	rs74774557	ENSG00000228546.2	CTA-313A17.3	7.4	6.47e-13	1.49e-06	0.51	0.32	Lung function (FEV1/FVC);	chr7:100212802	chr7:102337316~102339115:+
HNSC	trans	rs6915893	0.967	rs10949483	ENSG00000267156.1	TPMTP1	7.4	6.49e-13	1.49e-06	0.39	0.32	Intrinsic epigenetic age acceleration;	chr6:18122275	chr18:47630112~47630848:+
HNSC	trans	rs7824557	0.564	rs12550129	ENSG00000173295.6	FAM86B3P	-7.4	6.5e-13	1.5e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11376408	chr8:8228595~8244865:+
HNSC	trans	rs2456568	0.803	rs10831142	ENSG00000276509.1	CH17-353B19.1	-7.4	6.52e-13	1.5e-06	-0.35	-0.32	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93907615	chr1:146235806~146237807:+
HNSC	trans	rs11638815	0.603	rs783520	ENSG00000235370.6	DNM1P51	-7.39	6.61e-13	1.52e-06	-0.41	-0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:84398316~84411701:-
HNSC	trans	rs1707322	0.964	rs785508	ENSG00000255397.1	AC022182.2	7.39	6.73e-13	1.55e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs785509	ENSG00000255397.1	AC022182.2	7.39	6.73e-13	1.55e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.927	rs6690386	ENSG00000255397.1	AC022182.2	-7.39	6.73e-13	1.55e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs12077974	ENSG00000255397.1	AC022182.2	-7.39	6.82e-13	1.57e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr8:60937705~60939871:-
HNSC	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	7.39	6.83e-13	1.57e-06	0.36	0.32	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
HNSC	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	7.39	6.87e-13	1.58e-06	0.47	0.32	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
HNSC	trans	rs4948102	0.642	rs6593297	ENSG00000186940.6	CHCHD2P9	7.39	6.99e-13	1.61e-06	0.42	0.32	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr9:79391304~79391759:+
HNSC	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	7.39	7e-13	1.61e-06	0.42	0.32	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
HNSC	trans	rs7824557	0.564	rs2736290	ENSG00000173295.6	FAM86B3P	-7.38	7.2e-13	1.65e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11376789	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.658	rs12405726	ENSG00000180764.13	PIPSL	-7.38	7.21e-13	1.65e-06	-0.41	-0.32	Melanoma;	chr1:150983652	chr10:93958191~93961540:-
HNSC	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	7.38	7.24e-13	1.66e-06	0.39	0.32	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
HNSC	trans	rs9733	0.744	rs2039590	ENSG00000180764.13	PIPSL	7.38	7.28e-13	1.67e-06	0.39	0.32	Tonsillectomy;	chr1:150840839	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.807	rs10105315	ENSG00000173295.6	FAM86B3P	-7.38	7.35e-13	1.68e-06	-0.36	-0.32	Triglycerides;	chr8:11074693	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.658	rs12090215	ENSG00000180764.13	PIPSL	-7.38	7.41e-13	1.7e-06	-0.39	-0.32	Melanoma;	chr1:150921184	chr10:93958191~93961540:-
HNSC	trans	rs2456568	0.557	rs2456567	ENSG00000276509.1	CH17-353B19.1	7.38	7.44e-13	1.7e-06	0.35	0.32	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93965243	chr1:146235806~146237807:+
HNSC	trans	rs3849046	1	rs13164092	ENSG00000226666.1	HSPA9P1	-7.38	7.44e-13	1.7e-06	-0.33	-0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505171	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.967	rs55985421	ENSG00000226666.1	HSPA9P1	-7.38	7.44e-13	1.7e-06	-0.33	-0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505574	chr2:221961737~221963765:+
HNSC	trans	rs941207	0.756	rs2950394	ENSG00000257210.1	NACAP3	-7.38	7.48e-13	1.71e-06	-0.41	-0.32	Platelet count;	chr12:56644548	chr12:93124063~93124543:-
HNSC	trans	rs7824557	0.564	rs2736304	ENSG00000173295.6	FAM86B3P	-7.38	7.49e-13	1.72e-06	-0.36	-0.32	Retinal vascular caliber;	chr8:11379455	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.678	rs1951625	ENSG00000213331.4	RP11-713C19.2	7.38	7.5e-13	1.72e-06	0.41	0.32	Life satisfaction;	chr1:173867464	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs1322774	ENSG00000213331.4	RP11-713C19.2	7.38	7.5e-13	1.72e-06	0.41	0.32	Life satisfaction;	chr1:173870102	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.564	rs13268126	ENSG00000173295.6	FAM86B3P	-7.37	7.56e-13	1.73e-06	-0.36	-0.32	Retinal vascular caliber;	chr8:11373065	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.756	rs7313074	ENSG00000257210.1	NACAP3	-7.37	7.61e-13	1.74e-06	-0.42	-0.32	Platelet count;	chr12:56760705	chr12:93124063~93124543:-
HNSC	trans	rs1707322	0.896	rs946528	ENSG00000255397.1	AC022182.2	7.37	7.62e-13	1.74e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr8:60937705~60939871:-
HNSC	trans	rs17301013	0.932	rs1653632	ENSG00000213331.4	RP11-713C19.2	-7.37	7.68e-13	1.76e-06	-0.39	-0.32	Systemic lupus erythematosus;	chr1:174786459	chr4:187970273~187971284:+
HNSC	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-7.37	7.75e-13	1.77e-06	-0.38	-0.32	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
HNSC	trans	rs1816752	0.679	rs8181826	ENSG00000224976.2	PARP4P2	7.37	7.77e-13	1.78e-06	0.38	0.32	Obesity-related traits;	chr13:24396570	chr13:19349137~19407962:+
HNSC	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	7.37	7.83e-13	1.79e-06	0.43	0.32	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
HNSC	trans	rs7824557	0.527	rs2736296	ENSG00000173295.6	FAM86B3P	-7.37	7.85e-13	1.79e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377335	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	7.37	7.87e-13	1.8e-06	0.37	0.32	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
HNSC	trans	rs11638815	0.626	rs1367841	ENSG00000235370.6	DNM1P51	7.37	7.93e-13	1.81e-06	0.41	0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:84398316~84411701:-
HNSC	trans	rs17301013	0.896	rs6425287	ENSG00000213331.4	RP11-713C19.2	7.37	7.96e-13	1.82e-06	0.39	0.32	Systemic lupus erythematosus;	chr1:174566264	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.564	rs2736293	ENSG00000173295.6	FAM86B3P	-7.37	8e-13	1.83e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377104	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2736294	ENSG00000173295.6	FAM86B3P	-7.37	8e-13	1.83e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377117	chr8:8228595~8244865:+
HNSC	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	7.37	8.01e-13	1.83e-06	0.42	0.32	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	7.37	8.01e-13	1.83e-06	0.42	0.32	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	7.37	8.01e-13	1.83e-06	0.42	0.32	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
HNSC	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	7.36	8.09e-13	1.85e-06	0.47	0.32	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
HNSC	trans	rs7412746	0.658	rs4970987	ENSG00000180764.13	PIPSL	-7.36	8.15e-13	1.86e-06	-0.4	-0.32	Melanoma;	chr1:150977206	chr10:93958191~93961540:-
HNSC	trans	rs1707322	1	rs6672115	ENSG00000255397.1	AC022182.2	-7.36	8.21e-13	1.87e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr8:60937705~60939871:-
HNSC	trans	rs9733	0.681	rs7412746	ENSG00000180764.13	PIPSL	7.36	8.26e-13	1.88e-06	0.39	0.32	Tonsillectomy;	chr1:150887995	chr10:93958191~93961540:-
HNSC	trans	rs1707322	1	rs785493	ENSG00000255397.1	AC022182.2	7.36	8.28e-13	1.89e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.964	rs785496	ENSG00000255397.1	AC022182.2	7.36	8.28e-13	1.89e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr8:60937705~60939871:-
HNSC	trans	rs1707322	1	rs785497	ENSG00000255397.1	AC022182.2	7.36	8.28e-13	1.89e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr8:60937705~60939871:-
HNSC	trans	rs3849046	0.817	rs34629616	ENSG00000226666.1	HSPA9P1	7.36	8.33e-13	1.9e-06	0.34	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138532917	chr2:221961737~221963765:+
HNSC	trans	rs941207	0.756	rs10876915	ENSG00000257210.1	NACAP3	-7.36	8.48e-13	1.93e-06	-0.41	-0.32	Platelet count;	chr12:56655280	chr12:93124063~93124543:-
HNSC	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	7.36	8.58e-13	1.95e-06	0.42	0.32	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
HNSC	trans	rs1707322	1	rs785490	ENSG00000255397.1	AC022182.2	7.36	8.6e-13	1.96e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr8:60937705~60939871:-
HNSC	trans	rs11638815	0.626	rs4779041	ENSG00000235370.6	DNM1P51	7.35	8.65e-13	1.97e-06	0.41	0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:84398316~84411701:-
HNSC	trans	rs1707322	1	rs1707317	ENSG00000255397.1	AC022182.2	7.35	8.66e-13	1.97e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr8:60937705~60939871:-
HNSC	trans	rs4925166	1	rs4925166	ENSG00000188933.13	USP32P1	7.35	8.7e-13	1.98e-06	0.4	0.32	Multiple sclerosis;	chr17:18307496	chr17:16786489~16804455:+
HNSC	trans	rs13190036	0.551	rs1052432	ENSG00000228305.2	AC016734.2	-7.35	8.73e-13	1.98e-06	-0.51	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr2:63622178~63622831:-
HNSC	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	7.35	8.73e-13	1.99e-06	0.42	0.32	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
HNSC	trans	rs1707322	0.826	rs10890349	ENSG00000255397.1	AC022182.2	-7.35	8.79e-13	2e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.758	rs10789474	ENSG00000255397.1	AC022182.2	-7.35	8.79e-13	2e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr8:60937705~60939871:-
HNSC	trans	rs941207	0.789	rs2958145	ENSG00000257210.1	NACAP3	-7.35	8.81e-13	2e-06	-0.41	-0.32	Platelet count;	chr12:56662290	chr12:93124063~93124543:-
HNSC	trans	rs296547	0.563	rs7536000	ENSG00000244144.1	RP11-757F18.3	-7.35	8.81e-13	2e-06	-0.38	-0.32	Celiac disease;	chr1:200997855	chr3:112185480~112185998:-
HNSC	trans	rs7824557	0.564	rs2572389	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11378883	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2736301	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11378904	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2736302	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11378910	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs7821459	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379172	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs7834572	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379176	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs4631424	ENSG00000173295.6	FAM86B3P	-7.35	9.1e-13	2.07e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379300	chr8:8228595~8244865:+
HNSC	trans	rs7937890	0.598	rs10734225	ENSG00000236360.2	RP11-334A14.2	7.35	9.16e-13	2.08e-06	0.46	0.32	Mitochondrial DNA levels;	chr11:14421448	chr1:52993201~52993702:-
HNSC	trans	rs1707322	0.789	rs10789473	ENSG00000255397.1	AC022182.2	-7.35	9.23e-13	2.09e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr8:60937705~60939871:-
HNSC	trans	rs7819412	0.806	rs6980856	ENSG00000173295.6	FAM86B3P	7.34	9.42e-13	2.13e-06	0.36	0.32	Triglycerides;	chr8:11080750	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.932	rs6425282	ENSG00000213331.4	RP11-713C19.2	7.34	9.49e-13	2.15e-06	0.39	0.32	Systemic lupus erythematosus;	chr1:174493387	chr4:187970273~187971284:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	7.34	9.5e-13	2.15e-06	0.36	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
HNSC	trans	rs1707322	0.963	rs4630155	ENSG00000255397.1	AC022182.2	-7.34	9.51e-13	2.15e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs4508055	ENSG00000255397.1	AC022182.2	-7.34	9.51e-13	2.15e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr8:60937705~60939871:-
HNSC	trans	rs1707322	0.963	rs12076580	ENSG00000255397.1	AC022182.2	-7.34	9.51e-13	2.15e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr8:60937705~60939871:-
HNSC	trans	rs7032940	0.953	rs10816934	ENSG00000262519.1	TXNP4	7.34	9.57e-13	2.17e-06	0.46	0.32	Height;	chr9:110180540	chr17:4572206~4572515:+
HNSC	trans	rs9733	0.687	rs12410050	ENSG00000180764.13	PIPSL	7.34	9.67e-13	2.19e-06	0.38	0.32	Tonsillectomy;	chr1:150884665	chr10:93958191~93961540:-
HNSC	trans	rs296547	0.563	rs296558	ENSG00000244144.1	RP11-757F18.3	7.34	9.69e-13	2.19e-06	0.37	0.32	Celiac disease;	chr1:200983687	chr3:112185480~112185998:-
HNSC	trans	rs7819412	0.775	rs4545055	ENSG00000173295.6	FAM86B3P	-7.34	9.76e-13	2.21e-06	-0.36	-0.32	Triglycerides;	chr8:11077856	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.775	rs2898257	ENSG00000173295.6	FAM86B3P	-7.34	9.76e-13	2.21e-06	-0.36	-0.32	Triglycerides;	chr8:11077858	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.775	rs11773990	ENSG00000173295.6	FAM86B3P	-7.34	9.79e-13	2.21e-06	-0.36	-0.32	Triglycerides;	chr8:11077572	chr8:8228595~8244865:+
HNSC	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	7.34	9.83e-13	2.22e-06	0.4	0.32	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
HNSC	trans	rs7824557	0.527	rs2572447	ENSG00000173295.6	FAM86B3P	-7.34	9.87e-13	2.23e-06	-0.36	-0.32	Retinal vascular caliber;	chr8:11382001	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.744	rs2089081	ENSG00000180764.13	PIPSL	7.33	1.02e-12	2.3e-06	0.38	0.32	Tonsillectomy;	chr1:150827641	chr10:93958191~93961540:-
HNSC	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	7.33	1.03e-12	2.33e-06	0.42	0.32	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
HNSC	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	7.33	1.04e-12	2.36e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
HNSC	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	7.33	1.05e-12	2.36e-06	0.42	0.32	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	7.33	1.05e-12	2.36e-06	0.42	0.32	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	7.33	1.05e-12	2.36e-06	0.42	0.32	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	7.33	1.05e-12	2.36e-06	0.42	0.32	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	7.33	1.05e-12	2.36e-06	0.42	0.32	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
HNSC	trans	rs72615157	0.697	rs2056726	ENSG00000228546.2	CTA-313A17.3	7.33	1.05e-12	2.37e-06	0.5	0.32	Lung function (FEV1/FVC);	chr7:100182660	chr7:102337316~102339115:+
HNSC	trans	rs9630182	0.793	rs11603943	ENSG00000257675.1	RP11-641A6.9	-7.33	1.05e-12	2.38e-06	-0.39	-0.32	Bone mineral density;	chr11:13525567	chr12:52748776~52750127:+
HNSC	trans	rs6424115	0.83	rs2501423	ENSG00000228217.1	AL390877.1	-7.33	1.06e-12	2.38e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23872536	chr1:117778087~117778506:-
HNSC	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	7.32	1.06e-12	2.39e-06	0.35	0.32	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
HNSC	trans	rs1707322	1	rs4606257	ENSG00000255397.1	AC022182.2	-7.32	1.08e-12	2.44e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr8:60937705~60939871:-
HNSC	trans	rs7412746	0.658	rs72704682	ENSG00000180764.13	PIPSL	-7.32	1.1e-12	2.47e-06	-0.39	-0.32	Melanoma;	chr1:150925201	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs72704685	ENSG00000180764.13	PIPSL	-7.32	1.1e-12	2.47e-06	-0.39	-0.32	Melanoma;	chr1:150925211	chr10:93958191~93961540:-
HNSC	trans	rs7824557	0.564	rs2572379	ENSG00000173295.6	FAM86B3P	-7.32	1.1e-12	2.49e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379971	chr8:8228595~8244865:+
HNSC	trans	rs9467773	0.804	rs2073526	ENSG00000242375.1	RP11-498P14.3	-7.32	1.11e-12	2.5e-06	-0.41	-0.32	Intelligence (multi-trait analysis);	chr6:26374430	chr9:97195351~97197687:-
HNSC	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	7.32	1.11e-12	2.5e-06	0.42	0.32	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
HNSC	trans	rs11638815	0.581	rs783535	ENSG00000235370.6	DNM1P51	-7.32	1.12e-12	2.52e-06	-0.4	-0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:84398316~84411701:-
HNSC	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	7.32	1.13e-12	2.53e-06	0.42	0.32	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
HNSC	trans	rs9630182	0.793	rs11022868	ENSG00000257675.1	RP11-641A6.9	-7.32	1.13e-12	2.54e-06	-0.39	-0.32	Bone mineral density;	chr11:13527115	chr12:52748776~52750127:+
HNSC	trans	rs1707322	0.964	rs785499	ENSG00000255397.1	AC022182.2	7.31	1.13e-12	2.55e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr8:60937705~60939871:-
HNSC	trans	rs941207	0.756	rs2950388	ENSG00000257210.1	NACAP3	-7.31	1.15e-12	2.58e-06	-0.41	-0.32	Platelet count;	chr12:56639569	chr12:93124063~93124543:-
HNSC	trans	rs740160	0.558	rs12538893	ENSG00000228834.1	RP11-249L21.4	7.31	1.15e-12	2.58e-06	0.57	0.32	Dehydroepiandrosterone sulphate levels;	chr7:99310874	chr6:108907615~108907873:-
HNSC	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	7.31	1.16e-12	2.6e-06	0.45	0.32	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
HNSC	trans	rs9650657	0.644	rs4395858	ENSG00000173295.6	FAM86B3P	7.31	1.16e-12	2.61e-06	0.35	0.32	Neuroticism;	chr8:10663511	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.775	rs34094119	ENSG00000173295.6	FAM86B3P	-7.31	1.19e-12	2.67e-06	-0.35	-0.32	Triglycerides;	chr8:11078388	chr8:8228595~8244865:+
HNSC	trans	rs6915893	0.903	rs6921836	ENSG00000267156.1	TPMTP1	7.31	1.19e-12	2.67e-06	0.38	0.32	Intrinsic epigenetic age acceleration;	chr6:18104045	chr18:47630112~47630848:+
HNSC	trans	rs3806843	0.766	rs801399	ENSG00000231043.3	AC007238.1	7.31	1.19e-12	2.68e-06	0.32	0.32	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr2:58460292~58462032:-
HNSC	trans	rs7819412	0.775	rs4841489	ENSG00000173295.6	FAM86B3P	-7.31	1.2e-12	2.69e-06	-0.35	-0.32	Triglycerides;	chr8:11079301	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.775	rs4841490	ENSG00000173295.6	FAM86B3P	-7.31	1.2e-12	2.69e-06	-0.35	-0.32	Triglycerides;	chr8:11079381	chr8:8228595~8244865:+
HNSC	trans	rs296547	0.563	rs10920088	ENSG00000244144.1	RP11-757F18.3	-7.3	1.21e-12	2.71e-06	-0.37	-0.32	Celiac disease;	chr1:200996473	chr3:112185480~112185998:-
HNSC	trans	rs7824557	0.564	rs2572394	ENSG00000173295.6	FAM86B3P	-7.3	1.21e-12	2.71e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377884	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.634	rs12562939	ENSG00000180764.13	PIPSL	-7.3	1.21e-12	2.72e-06	-0.4	-0.32	Melanoma;	chr1:150978976	chr10:93958191~93961540:-
HNSC	trans	rs6673267	0.504	rs11810823	ENSG00000244144.1	RP11-757F18.3	-7.3	1.21e-12	2.72e-06	-0.37	-0.32	Lobe attachment (rater-scored or self-reported);	chr1:200997842	chr3:112185480~112185998:-
HNSC	trans	rs296547	0.524	rs10800749	ENSG00000244144.1	RP11-757F18.3	-7.3	1.23e-12	2.76e-06	-0.37	-0.32	Celiac disease;	chr1:200995209	chr3:112185480~112185998:-
HNSC	trans	rs296547	0.563	rs10800750	ENSG00000244144.1	RP11-757F18.3	-7.3	1.23e-12	2.76e-06	-0.37	-0.32	Celiac disease;	chr1:200995450	chr3:112185480~112185998:-
HNSC	trans	rs296547	0.524	rs10920086	ENSG00000244144.1	RP11-757F18.3	-7.3	1.23e-12	2.76e-06	-0.37	-0.32	Celiac disease;	chr1:200995588	chr3:112185480~112185998:-
HNSC	trans	rs296547	0.563	rs7531978	ENSG00000244144.1	RP11-757F18.3	-7.3	1.23e-12	2.76e-06	-0.37	-0.32	Celiac disease;	chr1:200996002	chr3:112185480~112185998:-
HNSC	trans	rs616147	0.816	rs1768190	ENSG00000214263.2	RPSAP53	7.3	1.24e-12	2.78e-06	0.42	0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr13:67266845~67267706:-
HNSC	trans	rs7824557	0.564	rs7828263	ENSG00000173295.6	FAM86B3P	-7.3	1.27e-12	2.85e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11374377	chr8:8228595~8244865:+
HNSC	trans	rs2456568	0.557	rs2456566	ENSG00000276509.1	CH17-353B19.1	7.29	1.29e-12	2.89e-06	0.35	0.32	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93965106	chr1:146235806~146237807:+
HNSC	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	7.29	1.3e-12	2.92e-06	0.42	0.32	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
HNSC	trans	rs62344088	1	rs56315075	ENSG00000185986.11	SDHAP3	7.29	1.31e-12	2.93e-06	0.7	0.32	Asthma (childhood onset);	chr5:103789	chr5:1572222~1594620:-
HNSC	trans	rs7937890	0.599	rs2597204	ENSG00000236360.2	RP11-334A14.2	7.29	1.31e-12	2.94e-06	0.45	0.32	Mitochondrial DNA levels;	chr11:14459471	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.779	rs199526	ENSG00000204650.12	CRHR1-IT1	-7.29	1.31e-12	2.94e-06	-0.37	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45620328~45648216:+
HNSC	trans	rs7819412	0.807	rs4840542	ENSG00000173295.6	FAM86B3P	-7.29	1.33e-12	2.98e-06	-0.36	-0.32	Triglycerides;	chr8:11087299	chr8:8228595~8244865:+
HNSC	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	7.29	1.34e-12	3e-06	0.43	0.32	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
HNSC	trans	rs9733	0.744	rs12568757	ENSG00000180764.13	PIPSL	7.29	1.35e-12	3.01e-06	0.38	0.32	Tonsillectomy;	chr1:150757317	chr10:93958191~93961540:-
HNSC	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	7.29	1.35e-12	3.01e-06	0.42	0.32	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	7.29	1.35e-12	3.01e-06	0.42	0.32	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	7.28	1.39e-12	3.1e-06	0.44	0.32	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
HNSC	trans	rs9733	0.687	rs11204735	ENSG00000180764.13	PIPSL	7.28	1.39e-12	3.11e-06	0.38	0.32	Tonsillectomy;	chr1:150869191	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.744	rs12758227	ENSG00000180764.13	PIPSL	7.28	1.39e-12	3.11e-06	0.38	0.32	Tonsillectomy;	chr1:150872107	chr10:93958191~93961540:-
HNSC	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	7.28	1.42e-12	3.17e-06	0.42	0.32	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
HNSC	trans	rs3019286	0.573	rs4292660	ENSG00000260318.1	COX6CP1	7.28	1.44e-12	3.2e-06	0.42	0.32	Suicide behavior;	chr8:98784068	chr16:11903923~11904137:-
HNSC	trans	rs6498068	0.594	rs3087620	ENSG00000278702.1	Metazoa_SRP	7.28	1.45e-12	3.24e-06	0.4	0.32	Metabolite levels (MHPG);	chr16:10529475	chr1:35399997~35400319:+
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-7.28	1.46e-12	3.25e-06	-0.38	-0.32	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
HNSC	trans	rs7819412	0.502	rs11777918	ENSG00000173295.6	FAM86B3P	7.28	1.46e-12	3.26e-06	0.38	0.32	Triglycerides;	chr8:11179410	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2572386	ENSG00000173295.6	FAM86B3P	-7.27	1.49e-12	3.32e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379466	chr8:8228595~8244865:+
HNSC	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	7.27	1.49e-12	3.32e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
HNSC	trans	rs7930295	0.556	rs6590146	ENSG00000236257.1	EI24P2	7.27	1.51e-12	3.35e-06	0.43	0.32	Schizophrenia;	chr11:125479933	chr1:158454198~158455273:+
HNSC	trans	rs7032940	0.954	rs10816936	ENSG00000262519.1	TXNP4	7.27	1.52e-12	3.38e-06	0.46	0.32	Height;	chr9:110189687	chr17:4572206~4572515:+
HNSC	trans	rs7824557	0.564	rs2572399	ENSG00000173295.6	FAM86B3P	-7.27	1.54e-12	3.42e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11377011	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.658	rs3843843	ENSG00000180764.13	PIPSL	-7.27	1.55e-12	3.45e-06	-0.39	-0.32	Melanoma;	chr1:150945608	chr10:93958191~93961540:-
HNSC	trans	rs17301013	0.9	rs56347239	ENSG00000213331.4	RP11-713C19.2	7.27	1.55e-12	3.45e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174564476	chr4:187970273~187971284:+
HNSC	trans	rs7412746	0.658	rs10888397	ENSG00000180764.13	PIPSL	7.27	1.56e-12	3.46e-06	0.39	0.32	Melanoma;	chr1:150914276	chr10:93958191~93961540:-
HNSC	trans	rs7937890	0.81	rs10734224	ENSG00000236360.2	RP11-334A14.2	7.26	1.6e-12	3.54e-06	0.42	0.32	Mitochondrial DNA levels;	chr11:14402578	chr1:52993201~52993702:-
HNSC	trans	rs7412746	0.611	rs7556661	ENSG00000180764.13	PIPSL	-7.26	1.6e-12	3.56e-06	-0.39	-0.32	Melanoma;	chr1:150919533	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs7521719	ENSG00000180764.13	PIPSL	-7.26	1.6e-12	3.56e-06	-0.39	-0.32	Melanoma;	chr1:150940658	chr10:93958191~93961540:-
HNSC	trans	rs7769051	1	rs9493454	ENSG00000213303.3	CTC-398G3.2	-7.26	1.63e-12	3.62e-06	-0.51	-0.32	Type 2 diabetes nephropathy;	chr6:132823490	chr19:11523436~11523831:+
HNSC	trans	rs11122895	0.61	rs13397902	ENSG00000233673.5	ANAPC1P1	7.26	1.63e-12	3.63e-06	0.39	0.32	Allergic sensitization;	chr2:111849928	chr2:86861825~86922693:+
HNSC	trans	rs11638815	0.581	rs28808991	ENSG00000235370.6	DNM1P51	-7.26	1.64e-12	3.65e-06	-0.4	-0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:84398316~84411701:-
HNSC	trans	rs74781061	0.585	rs17861109	ENSG00000227288.3	RP5-837I24.1	7.26	1.66e-12	3.68e-06	0.59	0.32	Endometriosis;	chr15:74727909	chr1:81501794~81503468:+
HNSC	trans	rs12439619	0.81	rs28876157	ENSG00000235370.6	DNM1P51	-7.26	1.66e-12	3.68e-06	-0.45	-0.32	Intelligence (multi-trait analysis);	chr15:82216708	chr15:84398316~84411701:-
HNSC	trans	rs17301013	0.932	rs6689170	ENSG00000213331.4	RP11-713C19.2	7.26	1.66e-12	3.69e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174639596	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.896	rs6425292	ENSG00000213331.4	RP11-713C19.2	7.26	1.66e-12	3.69e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174618364	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.655	rs6666767	ENSG00000213331.4	RP11-713C19.2	7.26	1.67e-12	3.7e-06	0.38	0.32	Life satisfaction;	chr1:174357564	chr4:187970273~187971284:+
HNSC	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	7.26	1.68e-12	3.73e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	7.26	1.68e-12	3.73e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
HNSC	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-7.25	1.7e-12	3.77e-06	-0.44	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
HNSC	trans	rs17301013	0.932	rs6425281	ENSG00000213331.4	RP11-713C19.2	7.25	1.71e-12	3.78e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174449784	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.527	rs2572446	ENSG00000173295.6	FAM86B3P	-7.25	1.71e-12	3.79e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11382056	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.658	rs1546376	ENSG00000180764.13	PIPSL	-7.25	1.72e-12	3.81e-06	-0.39	-0.32	Melanoma;	chr1:150965185	chr10:93958191~93961540:-
HNSC	trans	rs11583546	0.502	rs1572789	ENSG00000244144.1	RP11-757F18.3	7.25	1.73e-12	3.83e-06	0.37	0.32	Lymphocyte percentage of white cells;	chr1:200963177	chr3:112185480~112185998:-
HNSC	trans	rs3808502	0.647	rs7821302	ENSG00000173295.6	FAM86B3P	-7.25	1.73e-12	3.84e-06	-0.35	-0.32	Neuroticism;	chr8:11379063	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.715	rs7534124	ENSG00000180764.13	PIPSL	7.25	1.74e-12	3.86e-06	0.38	0.32	Tonsillectomy;	chr1:150766597	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs897815	ENSG00000180764.13	PIPSL	7.25	1.75e-12	3.87e-06	0.38	0.32	Melanoma;	chr1:150906625	chr10:93958191~93961540:-
HNSC	trans	rs6831352	0.879	rs1230154	ENSG00000233859.2	ADH5P4	-7.25	1.76e-12	3.89e-06	-0.36	-0.32	Alcohol dependence;	chr4:99067508	chr6:65836930~65838039:-
HNSC	trans	rs7930295	0.556	rs35904963	ENSG00000236257.1	EI24P2	7.25	1.77e-12	3.92e-06	0.43	0.32	Schizophrenia;	chr11:125476956	chr1:158454198~158455273:+
HNSC	trans	rs11951515	0.508	rs11958046	ENSG00000174977.8	AC026271.5	-7.25	1.79e-12	3.95e-06	-0.3	-0.32	Metabolite levels  (X-11787);	chr5:43583287	chr17:18650195~18651542:+
HNSC	trans	rs3019286	0.573	rs7845271	ENSG00000260318.1	COX6CP1	-7.25	1.79e-12	3.96e-06	-0.42	-0.32	Suicide behavior;	chr8:98786873	chr16:11903923~11904137:-
HNSC	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-7.25	1.8e-12	3.98e-06	-0.47	-0.32	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
HNSC	trans	rs6424115	0.83	rs6673210	ENSG00000228217.1	AL390877.1	-7.24	1.83e-12	4.05e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23877044	chr1:117778087~117778506:-
HNSC	trans	rs1707322	0.827	rs6683274	ENSG00000255397.1	AC022182.2	-7.24	1.85e-12	4.09e-06	-0.41	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr8:60937705~60939871:-
HNSC	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	7.24	1.85e-12	4.09e-06	0.45	0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
HNSC	trans	rs7937890	0.572	rs2597202	ENSG00000236360.2	RP11-334A14.2	7.24	1.88e-12	4.15e-06	0.45	0.32	Mitochondrial DNA levels;	chr11:14463099	chr1:52993201~52993702:-
HNSC	trans	rs941207	0.756	rs1465081	ENSG00000257210.1	NACAP3	-7.24	1.92e-12	4.23e-06	-0.41	-0.32	Platelet count;	chr12:56656390	chr12:93124063~93124543:-
HNSC	trans	rs1707322	1	rs1622208	ENSG00000255397.1	AC022182.2	7.23	1.93e-12	4.25e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr8:60937705~60939871:-
HNSC	trans	rs6732160	0.613	rs57208378	ENSG00000236165.1	PRADC1P1	7.23	1.94e-12	4.28e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr2:73162871	chr3:36976316~36976840:+
HNSC	trans	rs941207	0.756	rs7978685	ENSG00000257210.1	NACAP3	7.23	1.95e-12	4.3e-06	0.42	0.32	Platelet count;	chr12:56709370	chr12:93124063~93124543:-
HNSC	trans	rs12439619	0.768	rs28694364	ENSG00000235370.6	DNM1P51	-7.23	1.95e-12	4.31e-06	-0.45	-0.32	Intelligence (multi-trait analysis);	chr15:82208119	chr15:84398316~84411701:-
HNSC	trans	rs616147	0.85	rs631312	ENSG00000214263.2	RPSAP53	-7.23	1.98e-12	4.36e-06	-0.43	-0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr13:67266845~67267706:-
HNSC	trans	rs17301013	0.932	rs727279	ENSG00000213331.4	RP11-713C19.2	7.23	2.05e-12	4.52e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174496026	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.794	rs6425283	ENSG00000213331.4	RP11-713C19.2	7.23	2.05e-12	4.52e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174499853	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs2072760	ENSG00000213331.4	RP11-713C19.2	7.23	2.05e-12	4.52e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174510186	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs6668053	ENSG00000213331.4	RP11-713C19.2	7.23	2.05e-12	4.52e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174515139	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs10912804	ENSG00000213331.4	RP11-713C19.2	7.22	2.06e-12	4.53e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174527412	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.9	rs12088073	ENSG00000213331.4	RP11-713C19.2	7.22	2.06e-12	4.53e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174528504	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs10912797	ENSG00000213331.4	RP11-713C19.2	7.22	2.06e-12	4.53e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174511225	chr4:187970273~187971284:+
HNSC	trans	rs13177918	0.677	rs13171800	ENSG00000226396.1	RP5-1056L3.3	7.22	2.07e-12	4.56e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs2070841	ENSG00000226396.1	RP5-1056L3.3	7.22	2.07e-12	4.56e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:19608114~19608568:+
HNSC	trans	rs6498068	0.564	rs4780938	ENSG00000278702.1	Metazoa_SRP	7.22	2.08e-12	4.57e-06	0.41	0.32	Metabolite levels (MHPG);	chr16:10527228	chr1:35399997~35400319:+
HNSC	trans	rs7824557	0.545	rs2572380	ENSG00000173295.6	FAM86B3P	-7.22	2.09e-12	4.59e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11379968	chr8:8228595~8244865:+
HNSC	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	7.22	2.1e-12	4.61e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	7.22	2.1e-12	4.61e-06	0.26	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
HNSC	trans	rs2060793	0.506	rs10741658	ENSG00000236360.2	RP11-334A14.2	7.22	2.11e-12	4.63e-06	0.41	0.32	Vitamin D levels;	chr11:14903190	chr1:52993201~52993702:-
HNSC	trans	rs17301013	0.932	rs6664764	ENSG00000213331.4	RP11-713C19.2	7.22	2.11e-12	4.64e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174443402	chr4:187970273~187971284:+
HNSC	trans	rs7819412	0.745	rs2898260	ENSG00000173295.6	FAM86B3P	-7.22	2.14e-12	4.7e-06	-0.35	-0.32	Triglycerides;	chr8:11081980	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.679	rs2049992	ENSG00000213331.4	RP11-713C19.2	7.22	2.15e-12	4.72e-06	0.38	0.32	Life satisfaction;	chr1:174356554	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.771	rs801174	ENSG00000231043.3	AC007238.1	7.22	2.16e-12	4.73e-06	0.33	0.32	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr2:58460292~58462032:-
HNSC	trans	rs7819412	0.745	rs7017567	ENSG00000173295.6	FAM86B3P	-7.22	2.17e-12	4.75e-06	-0.36	-0.32	Triglycerides;	chr8:11076189	chr8:8228595~8244865:+
HNSC	trans	rs3806843	0.741	rs2563293	ENSG00000231043.3	AC007238.1	7.21	2.2e-12	4.82e-06	0.33	0.32	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr2:58460292~58462032:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-7.21	2.24e-12	4.91e-06	-0.35	-0.32	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-7.21	2.24e-12	4.91e-06	-0.35	-0.32	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
HNSC	trans	rs2898290	0.506	rs2736311	ENSG00000173295.6	FAM86B3P	-7.21	2.26e-12	4.95e-06	-0.34	-0.32	Systolic blood pressure;	chr8:11394661	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.744	rs11204725	ENSG00000180764.13	PIPSL	7.21	2.3e-12	5.02e-06	0.38	0.32	Tonsillectomy;	chr1:150770224	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.744	rs12125650	ENSG00000180764.13	PIPSL	7.21	2.3e-12	5.02e-06	0.38	0.32	Tonsillectomy;	chr1:150787698	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.688	rs12725667	ENSG00000180764.13	PIPSL	7.21	2.3e-12	5.02e-06	0.38	0.32	Tonsillectomy;	chr1:150793594	chr10:93958191~93961540:-
HNSC	trans	rs7824557	0.564	rs11782430	ENSG00000173295.6	FAM86B3P	-7.21	2.3e-12	5.03e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11368562	chr8:8228595~8244865:+
HNSC	trans	rs3849046	0.817	rs2304057	ENSG00000226666.1	HSPA9P1	7.21	2.3e-12	5.04e-06	0.33	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561485	chr2:221961737~221963765:+
HNSC	trans	rs6424115	0.691	rs4341315	ENSG00000228217.1	AL390877.1	-7.21	2.34e-12	5.12e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23878193	chr1:117778087~117778506:-
HNSC	trans	rs7833986	0.501	rs2719227	ENSG00000244245.1	RP11-120B7.1	-7.2	2.36e-12	5.16e-06	-0.36	-0.32	Height;	chr8:56131235	chr5:108593609~108593967:+
HNSC	trans	rs3806843	0.735	rs2563335	ENSG00000231043.3	AC007238.1	-7.2	2.37e-12	5.17e-06	-0.33	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr2:58460292~58462032:-
HNSC	trans	rs7412746	0.658	rs4970982	ENSG00000180764.13	PIPSL	-7.2	2.38e-12	5.2e-06	-0.38	-0.32	Melanoma;	chr1:150892608	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs12097963	ENSG00000180764.13	PIPSL	-7.2	2.38e-12	5.2e-06	-0.38	-0.32	Melanoma;	chr1:150897974	chr10:93958191~93961540:-
HNSC	trans	rs3849046	0.817	rs11953219	ENSG00000226666.1	HSPA9P1	7.2	2.43e-12	5.31e-06	0.33	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138592481	chr2:221961737~221963765:+
HNSC	trans	rs9733	0.744	rs4970976	ENSG00000180764.13	PIPSL	7.2	2.47e-12	5.39e-06	0.38	0.32	Tonsillectomy;	chr1:150807048	chr10:93958191~93961540:-
HNSC	trans	rs1190596	0.558	rs3087686	ENSG00000181359.5	HSP90AA6P	-7.2	2.48e-12	5.41e-06	-0.42	-0.32	Behavioural disinhibition (generation interaction);	chr14:102229226	chr4:170581470~170605450:-
HNSC	trans	rs7032940	1	rs7032940	ENSG00000262519.1	TXNP4	-7.2	2.49e-12	5.42e-06	-0.45	-0.32	Height;	chr9:110183125	chr17:4572206~4572515:+
HNSC	trans	rs7824557	0.527	rs10109537	ENSG00000173295.6	FAM86B3P	-7.19	2.53e-12	5.52e-06	-0.35	-0.32	Retinal vascular caliber;	chr8:11382131	chr8:8228595~8244865:+
HNSC	trans	rs6424115	0.83	rs6424119	ENSG00000228217.1	AL390877.1	-7.19	2.54e-12	5.53e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23877653	chr1:117778087~117778506:-
HNSC	trans	rs13190036	0.551	rs11957608	ENSG00000228305.2	AC016734.2	-7.19	2.56e-12	5.58e-06	-0.43	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr2:63622178~63622831:-
HNSC	trans	rs6498068	0.594	rs1875928	ENSG00000278702.1	Metazoa_SRP	7.19	2.57e-12	5.59e-06	0.4	0.32	Metabolite levels (MHPG);	chr16:10528028	chr1:35399997~35400319:+
HNSC	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-7.19	2.58e-12	5.61e-06	-0.39	-0.32	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	7.19	2.58e-12	5.61e-06	0.37	0.32	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
HNSC	trans	rs9425766	0.692	rs4652294	ENSG00000213331.4	RP11-713C19.2	7.19	2.59e-12	5.64e-06	0.38	0.32	Life satisfaction;	chr1:174272027	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs7542389	ENSG00000213331.4	RP11-713C19.2	7.19	2.6e-12	5.67e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174565104	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs12074753	ENSG00000213331.4	RP11-713C19.2	7.19	2.6e-12	5.67e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174565768	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs1016466	ENSG00000213331.4	RP11-713C19.2	7.19	2.6e-12	5.67e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174570652	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs10753086	ENSG00000213331.4	RP11-713C19.2	7.19	2.6e-12	5.67e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174580802	chr4:187970273~187971284:+
HNSC	trans	rs7412746	0.658	rs4970986	ENSG00000180764.13	PIPSL	-7.19	2.61e-12	5.67e-06	-0.38	-0.32	Melanoma;	chr1:150935479	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs59024312	ENSG00000180764.13	PIPSL	-7.19	2.61e-12	5.67e-06	-0.38	-0.32	Melanoma;	chr1:150936529	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs7528773	ENSG00000180764.13	PIPSL	-7.19	2.61e-12	5.67e-06	-0.38	-0.32	Melanoma;	chr1:150943399	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.634	rs2124952	ENSG00000180764.13	PIPSL	-7.19	2.61e-12	5.67e-06	-0.38	-0.32	Melanoma;	chr1:150951298	chr10:93958191~93961540:-
HNSC	trans	rs13190036	0.551	rs9313751	ENSG00000228305.2	AC016734.2	-7.19	2.61e-12	5.68e-06	-0.43	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr2:63622178~63622831:-
HNSC	trans	rs6498068	0.594	rs12996	ENSG00000278702.1	Metazoa_SRP	7.19	2.63e-12	5.71e-06	0.4	0.32	Metabolite levels (MHPG);	chr16:10529447	chr1:35399997~35400319:+
HNSC	trans	rs7937890	0.631	rs7118886	ENSG00000236360.2	RP11-334A14.2	7.19	2.66e-12	5.79e-06	0.42	0.32	Mitochondrial DNA levels;	chr11:14405971	chr1:52993201~52993702:-
HNSC	trans	rs941207	0.756	rs9634246	ENSG00000257210.1	NACAP3	-7.19	2.66e-12	5.79e-06	-0.41	-0.32	Platelet count;	chr12:56640604	chr12:93124063~93124543:-
HNSC	trans	rs4948102	0.642	rs766333	ENSG00000186940.6	CHCHD2P9	-7.19	2.67e-12	5.8e-06	-0.42	-0.32	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr9:79391304~79391759:+
HNSC	trans	rs6498068	0.594	rs1875929	ENSG00000278702.1	Metazoa_SRP	7.18	2.69e-12	5.84e-06	0.4	0.32	Metabolite levels (MHPG);	chr16:10528202	chr1:35399997~35400319:+
HNSC	trans	rs7032940	0.954	rs12553530	ENSG00000262519.1	TXNP4	7.18	2.7e-12	5.86e-06	0.46	0.32	Height;	chr9:110188455	chr17:4572206~4572515:+
HNSC	trans	rs17301013	0.932	rs10912807	ENSG00000213331.4	RP11-713C19.2	7.18	2.72e-12	5.91e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174547228	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.505	rs2572440	ENSG00000173295.6	FAM86B3P	7.18	2.78e-12	6.04e-06	0.34	0.32	Retinal vascular caliber;	chr8:11391501	chr8:8228595~8244865:+
HNSC	trans	rs3849046	1	rs3849046	ENSG00000226666.1	HSPA9P1	7.18	2.79e-12	6.06e-06	0.31	0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138515503	chr2:221961737~221963765:+
HNSC	trans	rs7412746	0.658	rs12067685	ENSG00000180764.13	PIPSL	-7.18	2.82e-12	6.11e-06	-0.39	-0.32	Melanoma;	chr1:150980441	chr10:93958191~93961540:-
HNSC	trans	rs6915893	1	rs4294009	ENSG00000267156.1	TPMTP1	7.18	2.84e-12	6.17e-06	0.38	0.32	Intrinsic epigenetic age acceleration;	chr6:18105845	chr18:47630112~47630848:+
HNSC	trans	rs17301013	0.861	rs332789	ENSG00000213331.4	RP11-713C19.2	7.17	2.87e-12	6.23e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174735754	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs461910	ENSG00000213331.4	RP11-713C19.2	7.17	2.87e-12	6.23e-06	0.38	0.32	Systemic lupus erythematosus;	chr1:174736351	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.735	rs801183	ENSG00000231043.3	AC007238.1	-7.17	2.88e-12	6.24e-06	-0.32	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr2:58460292~58462032:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-7.17	2.89e-12	6.26e-06	-0.35	-0.32	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
HNSC	trans	rs7809615	0.551	rs952319	ENSG00000228834.1	RP11-249L21.4	7.17	2.9e-12	6.28e-06	0.49	0.32	Blood metabolite ratios;	chr7:99573826	chr6:108907615~108907873:-
HNSC	trans	rs3806843	0.705	rs2530230	ENSG00000231043.3	AC007238.1	7.17	2.92e-12	6.33e-06	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr2:58460292~58462032:-
HNSC	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	7.17	2.93e-12	6.34e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	7.17	2.93e-12	6.34e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
HNSC	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-7.17	2.94e-12	6.36e-06	-0.42	-0.31	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
HNSC	trans	rs616147	0.962	rs1708104	ENSG00000214263.2	RPSAP53	-7.17	2.96e-12	6.4e-06	-0.42	-0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr13:67266845~67267706:-
HNSC	trans	rs76228276	0.737	rs4735642	ENSG00000260318.1	COX6CP1	7.17	2.96e-12	6.41e-06	0.85	0.31	Childhood ear infection;	chr8:99746260	chr16:11903923~11904137:-
HNSC	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	7.17	2.98e-12	6.44e-06	0.42	0.31	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
HNSC	trans	rs17301013	0.932	rs3737651	ENSG00000213331.4	RP11-713C19.2	-7.17	3e-12	6.48e-06	-0.38	-0.31	Systemic lupus erythematosus;	chr1:174475414	chr4:187970273~187971284:+
HNSC	trans	rs1707322	1	rs785498	ENSG00000255397.1	AC022182.2	7.17	3.02e-12	6.53e-06	0.43	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr8:60937705~60939871:-
HNSC	trans	rs13177918	0.677	rs4841	ENSG00000226396.1	RP5-1056L3.3	7.17	3.03e-12	6.56e-06	0.26	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13183077	ENSG00000226396.1	RP5-1056L3.3	7.17	3.03e-12	6.56e-06	0.26	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:19608114~19608568:+
HNSC	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	7.17	3.04e-12	6.56e-06	0.39	0.31	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
HNSC	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	7.16	3.06e-12	6.61e-06	0.42	0.31	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
HNSC	trans	rs7121616	0.576	rs7111598	ENSG00000256356.1	HSPA8P5	7.16	3.07e-12	6.63e-06	0.4	0.31	Breast cancer;	chr11:123055438	chr12:4097451~4099519:+
HNSC	trans	rs6673267	0.967	rs6675915	ENSG00000244144.1	RP11-757F18.3	-7.16	3.07e-12	6.63e-06	-0.37	-0.31	Lobe attachment (rater-scored or self-reported);	chr1:201041734	chr3:112185480~112185998:-
HNSC	trans	rs7412746	0.634	rs12096831	ENSG00000180764.13	PIPSL	-7.16	3.08e-12	6.66e-06	-0.38	-0.31	Melanoma;	chr1:150891637	chr10:93958191~93961540:-
HNSC	trans	rs3849046	0.817	rs11959184	ENSG00000226666.1	HSPA9P1	7.16	3.09e-12	6.67e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138596189	chr2:221961737~221963765:+
HNSC	trans	rs61041336	0.534	rs59234479	ENSG00000230849.2	GOT2P2	-7.16	3.1e-12	6.7e-06	-0.64	-0.31	Neuritic plaque;	chr16:58673724	chr1:173141100~173142350:-
HNSC	trans	rs7412746	0.658	rs11204750	ENSG00000180764.13	PIPSL	-7.16	3.1e-12	6.7e-06	-0.38	-0.31	Melanoma;	chr1:150967268	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs6656535	ENSG00000180764.13	PIPSL	-7.16	3.1e-12	6.7e-06	-0.38	-0.31	Melanoma;	chr1:150967881	chr10:93958191~93961540:-
HNSC	trans	rs9650657	0.547	rs11250099	ENSG00000173295.6	FAM86B3P	7.16	3.14e-12	6.78e-06	0.34	0.31	Neuroticism;	chr8:10961147	chr8:8228595~8244865:+
HNSC	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	7.16	3.14e-12	6.78e-06	0.46	0.31	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
HNSC	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	7.16	3.15e-12	6.79e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	7.16	3.15e-12	6.79e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	7.16	3.17e-12	6.83e-06	0.34	0.31	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
HNSC	trans	rs6732160	0.613	rs62151837	ENSG00000236165.1	PRADC1P1	7.16	3.19e-12	6.88e-06	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73163268	chr3:36976316~36976840:+
HNSC	trans	rs6424115	0.83	rs6658703	ENSG00000228217.1	AL390877.1	-7.16	3.2e-12	6.89e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23876926	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2501434	ENSG00000228217.1	AL390877.1	-7.16	3.2e-12	6.89e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23876935	chr1:117778087~117778506:-
HNSC	trans	rs9650657	0.529	rs10108618	ENSG00000173295.6	FAM86B3P	-7.16	3.2e-12	6.89e-06	-0.35	-0.31	Neuroticism;	chr8:11095582	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.589	rs10107145	ENSG00000173295.6	FAM86B3P	-7.15	3.26e-12	7.03e-06	-0.35	-0.31	Neuroticism;	chr8:10900703	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.715	rs12402006	ENSG00000180764.13	PIPSL	7.15	3.3e-12	7.11e-06	0.37	0.31	Tonsillectomy;	chr1:150897353	chr10:93958191~93961540:-
HNSC	trans	rs9581094	0.591	rs9553318	ENSG00000237917.1	PARP4P1	-7.15	3.33e-12	7.17e-06	-0.47	-0.31	Sudden cardiac arrest;	chr13:24477107	chrY:26594851~26634652:-
HNSC	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-7.15	3.35e-12	7.21e-06	-0.37	-0.31	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
HNSC	trans	rs7412746	0.658	rs11204739	ENSG00000180764.13	PIPSL	-7.15	3.37e-12	7.26e-06	-0.38	-0.31	Melanoma;	chr1:150893284	chr10:93958191~93961540:-
HNSC	trans	rs6424115	0.83	rs1106	ENSG00000228217.1	AL390877.1	-7.15	3.43e-12	7.37e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874282	chr1:117778087~117778506:-
HNSC	trans	rs17301013	0.932	rs6425280	ENSG00000213331.4	RP11-713C19.2	7.15	3.44e-12	7.41e-06	0.38	0.31	Systemic lupus erythematosus;	chr1:174422186	chr4:187970273~187971284:+
HNSC	trans	rs7032940	0.954	rs10816937	ENSG00000262519.1	TXNP4	-7.15	3.46e-12	7.43e-06	-0.45	-0.31	Height;	chr9:110189709	chr17:4572206~4572515:+
HNSC	trans	rs740160	0.558	rs17161669	ENSG00000228834.1	RP11-249L21.4	7.15	3.47e-12	7.45e-06	0.57	0.31	Dehydroepiandrosterone sulphate levels;	chr7:99311040	chr6:108907615~108907873:-
HNSC	trans	rs1063857	0.656	rs216291	ENSG00000241717.1	VWFP1	7.15	3.48e-12	7.47e-06	0.31	0.31	vWF levels;Coagulation factor levels;	chr12:6042707	chr22:16690103~16704477:-
HNSC	trans	rs74781061	0.722	rs77102700	ENSG00000227288.3	RP5-837I24.1	7.14	3.49e-12	7.5e-06	0.53	0.31	Endometriosis;	chr15:74604600	chr1:81501794~81503468:+
HNSC	trans	rs9425766	0.679	rs10912761	ENSG00000213331.4	RP11-713C19.2	7.14	3.5e-12	7.52e-06	0.38	0.31	Life satisfaction;	chr1:174312466	chr4:187970273~187971284:+
HNSC	trans	rs6600671	0.719	rs9728991	ENSG00000270231.3	NBPF8P	7.14	3.55e-12	7.62e-06	0.27	0.31	Hip geometry;	chr1:121522281	chr1:120436353~120467739:+
HNSC	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	7.14	3.55e-12	7.63e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
HNSC	trans	rs3806843	0.741	rs4912597	ENSG00000231043.3	AC007238.1	7.14	3.56e-12	7.64e-06	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.771	rs2563334	ENSG00000231043.3	AC007238.1	7.14	3.56e-12	7.64e-06	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr2:58460292~58462032:-
HNSC	trans	rs867371	0.614	rs7183805	ENSG00000235370.6	DNM1P51	-7.14	3.57e-12	7.66e-06	-0.43	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:84398316~84411701:-
HNSC	trans	rs6424115	0.83	rs1105	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874310	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2229585	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874431	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2229584	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874479	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.8	rs2229581	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874604	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.743	rs2229580	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874619	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2502993	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874772	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs4649124	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874867	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs3003336	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874958	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2501431	ENSG00000228217.1	AL390877.1	-7.14	3.59e-12	7.7e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23875153	chr1:117778087~117778506:-
HNSC	trans	rs6732160	0.613	rs10179063	ENSG00000236165.1	PRADC1P1	7.14	3.65e-12	7.82e-06	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73157983	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs62151795	ENSG00000236165.1	PRADC1P1	7.14	3.66e-12	7.85e-06	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73149712	chr3:36976316~36976840:+
HNSC	trans	rs7937890	0.869	rs2915404	ENSG00000236360.2	RP11-334A14.2	7.14	3.68e-12	7.89e-06	0.42	0.31	Mitochondrial DNA levels;	chr11:14383279	chr1:52993201~52993702:-
HNSC	trans	rs3806843	0.735	rs778596	ENSG00000231043.3	AC007238.1	7.14	3.68e-12	7.9e-06	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr2:58460292~58462032:-
HNSC	trans	rs6732160	0.613	rs59979991	ENSG00000236165.1	PRADC1P1	7.14	3.69e-12	7.91e-06	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73157294	chr3:36976316~36976840:+
HNSC	trans	rs7412746	0.658	rs11581757	ENSG00000180764.13	PIPSL	-7.14	3.69e-12	7.91e-06	-0.38	-0.31	Melanoma;	chr1:150919768	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	7.14	3.69e-12	7.92e-06	0.38	0.31	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
HNSC	trans	rs17301013	0.932	rs6664864	ENSG00000213331.4	RP11-713C19.2	7.13	3.73e-12	7.99e-06	0.38	0.31	Systemic lupus erythematosus;	chr1:174622912	chr4:187970273~187971284:+
HNSC	trans	rs7121616	0.531	rs10892958	ENSG00000256356.1	HSPA8P5	7.13	3.76e-12	8.05e-06	0.4	0.31	Breast cancer;	chr11:123061415	chr12:4097451~4099519:+
HNSC	trans	rs7121616	0.531	rs11218941	ENSG00000256356.1	HSPA8P5	7.13	3.76e-12	8.05e-06	0.4	0.31	Breast cancer;	chr11:123061701	chr12:4097451~4099519:+
HNSC	trans	rs2524276	1	rs2524276	ENSG00000230521.1	HCG4P7	7.13	3.77e-12	8.07e-06	0.73	0.31	Capecitabine sensitivity;	chr6:31440488	chr6:29887294~29888268:-
HNSC	trans	rs6424115	0.83	rs2502991	ENSG00000228217.1	AL390877.1	-7.13	3.82e-12	8.17e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23875828	chr1:117778087~117778506:-
HNSC	trans	rs9650657	0.562	rs10090444	ENSG00000173295.6	FAM86B3P	7.13	3.84e-12	8.23e-06	0.35	0.31	Neuroticism;	chr8:10887959	chr8:8228595~8244865:+
HNSC	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-7.13	3.86e-12	8.25e-06	-0.43	-0.31	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
HNSC	trans	rs6424115	0.867	rs2501432	ENSG00000228217.1	AL390877.1	-7.13	3.87e-12	8.28e-06	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23875430	chr1:117778087~117778506:-
HNSC	trans	rs6915893	1	rs12189658	ENSG00000267156.1	TPMTP1	7.13	3.96e-12	8.47e-06	0.37	0.31	Intrinsic epigenetic age acceleration;	chr6:18103106	chr18:47630112~47630848:+
HNSC	trans	rs916888	0.779	rs199498	ENSG00000280022.1	RP11-707O23.1	7.12	3.97e-12	8.49e-06	0.37	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45592621~45593369:+
HNSC	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	7.12	4.02e-12	8.6e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
HNSC	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	7.12	4.09e-12	8.73e-06	0.41	0.31	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
HNSC	trans	rs6915893	0.844	rs6910196	ENSG00000267156.1	TPMTP1	-7.12	4.17e-12	8.9e-06	-0.4	-0.31	Intrinsic epigenetic age acceleration;	chr6:18102276	chr18:47630112~47630848:+
HNSC	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	7.12	4.19e-12	8.95e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	7.12	4.19e-12	8.95e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	7.12	4.19e-12	8.95e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
HNSC	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-7.12	4.23e-12	9.03e-06	-0.38	-0.31	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
HNSC	trans	rs3806843	0.735	rs778595	ENSG00000231043.3	AC007238.1	7.11	4.25e-12	9.07e-06	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr2:58460292~58462032:-
HNSC	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	7.11	4.26e-12	9.08e-06	0.45	0.31	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
HNSC	trans	rs12439619	0.846	rs28470877	ENSG00000235370.6	DNM1P51	-7.11	4.28e-12	9.11e-06	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82245797	chr15:84398316~84411701:-
HNSC	trans	rs3849046	0.817	rs7711958	ENSG00000226666.1	HSPA9P1	7.11	4.3e-12	9.16e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138565812	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.817	rs4835689	ENSG00000226666.1	HSPA9P1	7.11	4.3e-12	9.16e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138580078	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.781	rs10070909	ENSG00000226666.1	HSPA9P1	7.11	4.3e-12	9.16e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138581104	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.817	rs9968657	ENSG00000226666.1	HSPA9P1	7.11	4.3e-12	9.16e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138584741	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.738	rs57958956	ENSG00000226666.1	HSPA9P1	7.11	4.32e-12	9.2e-06	0.33	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138590952	chr2:221961737~221963765:+
HNSC	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	7.11	4.33e-12	9.22e-06	0.39	0.31	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
HNSC	trans	rs12145833	0.748	rs11807162	ENSG00000154608.12	CEP170P1	-7.11	4.38e-12	9.31e-06	-0.41	-0.31	Obesity (early onset extreme);	chr1:243291378	chr4:118467590~118554204:+
HNSC	trans	rs10037055	0.685	rs10039241	ENSG00000226986.4	RP11-543B16.2	-7.11	4.4e-12	9.37e-06	-0.43	-0.31	Migraine without aura;	chr5:177151071	chr1:211207239~211207897:+
HNSC	trans	rs6732160	0.613	rs58317144	ENSG00000236165.1	PRADC1P1	7.11	4.47e-12	9.5e-06	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73161025	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs13394018	ENSG00000236165.1	PRADC1P1	7.11	4.48e-12	9.54e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73145477	chr3:36976316~36976840:+
HNSC	trans	rs9308062	1	rs9308062	ENSG00000232467.2	TMA16P2	7.11	4.49e-12	9.56e-06	0.38	0.31	Small cell lung carcinoma;	chr4:163517048	chr1:45846994~45847594:-
HNSC	trans	rs76228276	0.737	rs16897726	ENSG00000260318.1	COX6CP1	7.11	4.5e-12	9.56e-06	0.86	0.31	Childhood ear infection;	chr8:99808566	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs76397965	ENSG00000260318.1	COX6CP1	7.11	4.5e-12	9.56e-06	0.86	0.31	Childhood ear infection;	chr8:99811418	chr16:11903923~11904137:-
HNSC	trans	rs13177918	0.677	rs13177951	ENSG00000226396.1	RP5-1056L3.3	7.11	4.51e-12	9.58e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13177970	ENSG00000226396.1	RP5-1056L3.3	7.11	4.51e-12	9.58e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.677	rs13164105	ENSG00000226396.1	RP5-1056L3.3	7.11	4.51e-12	9.58e-06	0.25	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:19608114~19608568:+
HNSC	trans	rs76228276	0.737	rs1349244	ENSG00000260318.1	COX6CP1	7.11	4.52e-12	9.6e-06	0.82	0.31	Childhood ear infection;	chr8:99745774	chr16:11903923~11904137:-
HNSC	trans	rs6743068	0.541	rs6761514	ENSG00000235105.1	RP11-329A14.1	7.1	4.59e-12	9.76e-06	0.37	0.31	Lymphocyte percentage of white cells;	chr2:201362826	chr1:48435967~48437223:+
HNSC	trans	rs6831352	0.842	rs1230156	ENSG00000233859.2	ADH5P4	-7.1	4.61e-12	9.8e-06	-0.36	-0.31	Alcohol dependence;	chr4:99068475	chr6:65836930~65838039:-
HNSC	trans	rs17301013	0.932	rs332771	ENSG00000213331.4	RP11-713C19.2	7.1	4.67e-12	9.91e-06	0.37	0.31	Systemic lupus erythematosus;	chr1:174704141	chr4:187970273~187971284:+
HNSC	trans	rs7412746	0.634	rs4451553	ENSG00000180764.13	PIPSL	-7.1	4.68e-12	9.94e-06	-0.38	-0.31	Melanoma;	chr1:150964853	chr10:93958191~93961540:-
HNSC	trans	rs6424115	0.83	rs3003335	ENSG00000228217.1	AL390877.1	-7.1	4.72e-12	1e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23873562	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.8	rs6665733	ENSG00000228217.1	AL390877.1	-7.1	4.72e-12	1e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23873668	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2502992	ENSG00000228217.1	AL390877.1	-7.1	4.73e-12	1e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23875429	chr1:117778087~117778506:-
HNSC	trans	rs6732160	0.613	rs6546804	ENSG00000236165.1	PRADC1P1	7.1	4.74e-12	1.01e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73158791	chr3:36976316~36976840:+
HNSC	trans	rs12439619	0.846	rs62010071	ENSG00000259295.5	CSPG4P12	-7.1	4.79e-12	1.02e-05	-0.46	-0.31	Intelligence (multi-trait analysis);	chr15:82289442	chr15:85191438~85213905:+
HNSC	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-7.09	4.84e-12	1.03e-05	-0.43	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
HNSC	trans	rs6424115	0.83	rs1130321	ENSG00000228217.1	AL390877.1	-7.09	4.94e-12	1.05e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874034	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs1130320	ENSG00000228217.1	AL390877.1	-7.09	4.94e-12	1.05e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23874116	chr1:117778087~117778506:-
HNSC	trans	rs6743068	0.521	rs1406122	ENSG00000235105.1	RP11-329A14.1	-7.09	4.96e-12	1.05e-05	-0.37	-0.31	Lymphocyte percentage of white cells;	chr2:201346720	chr1:48435967~48437223:+
HNSC	trans	rs6915893	0.74	rs6910353	ENSG00000267156.1	TPMTP1	-7.09	4.97e-12	1.05e-05	-0.37	-0.31	Intrinsic epigenetic age acceleration;	chr6:18102327	chr18:47630112~47630848:+
HNSC	trans	rs61041336	0.534	rs2280399	ENSG00000230849.2	GOT2P2	-7.09	4.99e-12	1.06e-05	-0.63	-0.31	Neuritic plaque;	chr16:58677628	chr1:173141100~173142350:-
HNSC	trans	rs9733	0.744	rs3754211	ENSG00000180764.13	PIPSL	-7.09	5.02e-12	1.06e-05	-0.37	-0.31	Tonsillectomy;	chr1:150979381	chr10:93958191~93961540:-
HNSC	trans	rs6732160	0.588	rs13403748	ENSG00000236165.1	PRADC1P1	7.09	5.03e-12	1.06e-05	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73144347	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs13390460	ENSG00000236165.1	PRADC1P1	7.09	5.03e-12	1.06e-05	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73144348	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs72841902	ENSG00000236165.1	PRADC1P1	7.09	5.03e-12	1.06e-05	0.41	0.31	Intelligence (multi-trait analysis);	chr2:73145084	chr3:36976316~36976840:+
HNSC	trans	rs76228276	0.609	rs78437785	ENSG00000260318.1	COX6CP1	7.09	5.04e-12	1.07e-05	0.87	0.31	Childhood ear infection;	chr8:99790937	chr16:11903923~11904137:-
HNSC	trans	rs6831352	0.959	rs6532796	ENSG00000233859.2	ADH5P4	7.08	5.16e-12	1.09e-05	0.35	0.31	Alcohol dependence;	chr4:99121091	chr6:65836930~65838039:-
HNSC	trans	rs12439619	0.774	rs2867649	ENSG00000235370.6	DNM1P51	-7.08	5.19e-12	1.1e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82262331	chr15:84398316~84411701:-
HNSC	trans	rs12439619	0.846	rs28697264	ENSG00000235370.6	DNM1P51	-7.08	5.19e-12	1.1e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82265559	chr15:84398316~84411701:-
HNSC	trans	rs9425766	0.679	rs6681390	ENSG00000213331.4	RP11-713C19.2	7.08	5.2e-12	1.1e-05	0.38	0.31	Life satisfaction;	chr1:174261331	chr4:187970273~187971284:+
HNSC	trans	rs12439619	0.846	rs62012003	ENSG00000235370.6	DNM1P51	-7.08	5.2e-12	1.1e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82183236	chr15:84398316~84411701:-
HNSC	trans	rs867371	0.571	rs2654222	ENSG00000235370.6	DNM1P51	7.08	5.24e-12	1.11e-05	0.43	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82137496	chr15:84398316~84411701:-
HNSC	trans	rs7819412	0.838	rs3021494	ENSG00000173295.6	FAM86B3P	-7.08	5.28e-12	1.12e-05	-0.36	-0.31	Triglycerides;	chr8:11126024	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.896	rs13375788	ENSG00000213331.4	RP11-713C19.2	7.08	5.31e-12	1.12e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174524207	chr4:187970273~187971284:+
HNSC	trans	rs1063857	0.656	rs216292	ENSG00000241717.1	VWFP1	7.08	5.32e-12	1.12e-05	0.32	0.31	vWF levels;Coagulation factor levels;	chr12:6043810	chr22:16690103~16704477:-
HNSC	trans	rs12439619	0.846	rs62012056	ENSG00000259295.5	CSPG4P12	-7.08	5.33e-12	1.12e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82247278	chr15:85191438~85213905:+
HNSC	trans	rs7819412	0.715	rs35223712	ENSG00000173295.6	FAM86B3P	-7.08	5.39e-12	1.14e-05	-0.36	-0.31	Triglycerides;	chr8:11186417	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.64	rs6693423	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Life satisfaction;	chr1:174364680	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs60363188	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Life satisfaction;	chr1:174375959	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs12084119	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Life satisfaction;	chr1:174377138	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.965	rs7548540	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174411672	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.965	rs2179214	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174413954	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.93	rs7523263	ENSG00000213331.4	RP11-713C19.2	7.08	5.4e-12	1.14e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174414542	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs17301013	ENSG00000213331.4	RP11-713C19.2	7.08	5.41e-12	1.14e-05	0.37	0.31	Life satisfaction;	chr1:174343675	chr4:187970273~187971284:+
HNSC	trans	rs12439619	0.739	rs62012046	ENSG00000259295.5	CSPG4P12	-7.08	5.42e-12	1.14e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82236824	chr15:85191438~85213905:+
HNSC	trans	rs12439619	0.774	rs62012047	ENSG00000259295.5	CSPG4P12	-7.08	5.42e-12	1.14e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82236852	chr15:85191438~85213905:+
HNSC	trans	rs12439619	0.81	rs62012049	ENSG00000259295.5	CSPG4P12	-7.08	5.42e-12	1.14e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82237722	chr15:85191438~85213905:+
HNSC	trans	rs3806843	0.735	rs801168	ENSG00000231043.3	AC007238.1	7.08	5.44e-12	1.15e-05	0.31	0.31	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr2:58460292~58462032:-
HNSC	trans	rs17507216	0.718	rs4779034	ENSG00000259295.5	CSPG4P12	-7.07	5.61e-12	1.18e-05	-0.47	-0.31	Excessive daytime sleepiness;	chr15:82576799	chr15:85191438~85213905:+
HNSC	trans	rs12439619	0.846	rs62012059	ENSG00000259295.5	CSPG4P12	-7.07	5.69e-12	1.2e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82251669	chr15:85191438~85213905:+
HNSC	trans	rs867371	0.519	rs1566560	ENSG00000235370.6	DNM1P51	-7.07	5.7e-12	1.2e-05	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:84398316~84411701:-
HNSC	trans	rs867371	0.519	rs1566559	ENSG00000235370.6	DNM1P51	-7.07	5.7e-12	1.2e-05	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:84398316~84411701:-
HNSC	trans	rs4948102	0.595	rs7793921	ENSG00000186940.6	CHCHD2P9	-7.07	5.75e-12	1.21e-05	-0.4	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.595	rs10255049	ENSG00000186940.6	CHCHD2P9	-7.07	5.75e-12	1.21e-05	-0.4	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr9:79391304~79391759:+
HNSC	trans	rs6424115	1	rs6424115	ENSG00000228217.1	AL390877.1	7.07	5.82e-12	1.23e-05	0.39	0.31	Immature fraction of reticulocytes;	chr1:23826741	chr1:117778087~117778506:-
HNSC	trans	rs6498068	0.564	rs6498062	ENSG00000278702.1	Metazoa_SRP	7.07	5.84e-12	1.23e-05	0.4	0.31	Metabolite levels (MHPG);	chr16:10526021	chr1:35399997~35400319:+
HNSC	trans	rs3806843	0.735	rs778597	ENSG00000231043.3	AC007238.1	-7.06	5.88e-12	1.24e-05	-0.32	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr2:58460292~58462032:-
HNSC	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-7.06	5.94e-12	1.25e-05	-0.36	-0.31	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
HNSC	trans	rs2456568	0.709	rs1546400	ENSG00000276509.1	CH17-353B19.1	-7.06	5.98e-12	1.26e-05	-0.34	-0.31	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93906037	chr1:146235806~146237807:+
HNSC	trans	rs35851103	0.6	rs4841662	ENSG00000173295.6	FAM86B3P	-7.06	5.99e-12	1.26e-05	-0.34	-0.31	Neuroticism;	chr8:11986249	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.679	rs4650990	ENSG00000213331.4	RP11-713C19.2	7.06	6e-12	1.26e-05	0.38	0.31	Life satisfaction;	chr1:174289943	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.735	rs6849	ENSG00000231043.3	AC007238.1	7.06	6.06e-12	1.27e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr2:58460292~58462032:-
HNSC	trans	rs616147	0.962	rs1513219	ENSG00000214263.2	RPSAP53	7.06	6.1e-12	1.28e-05	0.41	0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr13:67266845~67267706:-
HNSC	trans	rs6732160	0.588	rs2043101	ENSG00000236165.1	PRADC1P1	7.06	6.1e-12	1.28e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73146922	chr3:36976316~36976840:+
HNSC	trans	rs6673267	0.967	rs2297906	ENSG00000244144.1	RP11-757F18.3	-7.06	6.11e-12	1.28e-05	-0.36	-0.31	Lobe attachment (rater-scored or self-reported);	chr1:201044208	chr3:112185480~112185998:-
HNSC	trans	rs3105169	0.733	rs1667633	ENSG00000260318.1	COX6CP1	7.06	6.12e-12	1.29e-05	0.84	0.31	Smoking initiation;	chr8:99777587	chr16:11903923~11904137:-
HNSC	trans	rs17301013	0.932	rs67967476	ENSG00000213331.4	RP11-713C19.2	7.05	6.3e-12	1.32e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174616119	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs6671824	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174603721	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.861	rs6672148	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174604016	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs10912813	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174607342	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs6683602	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174617615	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs6696197	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174617860	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.73	rs12060177	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174618545	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.612	rs56199565	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174640992	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.761	rs332805	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174652487	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.861	rs34819375	ENSG00000213331.4	RP11-713C19.2	7.05	6.32e-12	1.33e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174654958	chr4:187970273~187971284:+
HNSC	trans	rs11638815	0.603	rs7171180	ENSG00000235370.6	DNM1P51	7.05	6.48e-12	1.36e-05	0.38	0.31	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:84398316~84411701:-
HNSC	trans	rs12439619	0.846	rs62011975	ENSG00000259295.5	CSPG4P12	-7.05	6.52e-12	1.37e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82159213	chr15:85191438~85213905:+
HNSC	trans	rs11951515	0.509	rs12521249	ENSG00000174977.8	AC026271.5	7.05	6.54e-12	1.37e-05	0.3	0.31	Metabolite levels  (X-11787);	chr5:43558527	chr17:18650195~18651542:+
HNSC	trans	rs3806843	0.735	rs702394	ENSG00000231043.3	AC007238.1	7.05	6.57e-12	1.38e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr2:58460292~58462032:-
HNSC	trans	rs6424115	0.8	rs4649123	ENSG00000228217.1	AL390877.1	-7.05	6.58e-12	1.38e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr1:23871206	chr1:117778087~117778506:-
HNSC	trans	rs17301013	0.932	rs1754349	ENSG00000213331.4	RP11-713C19.2	-7.05	6.59e-12	1.38e-05	-0.37	-0.31	Systemic lupus erythematosus;	chr1:174837663	chr4:187970273~187971284:+
HNSC	trans	rs7662987	0.793	rs12697	ENSG00000228407.2	RP4-800M22.1	-7.05	6.64e-12	1.39e-05	-0.49	-0.31	Smoking initiation;	chr4:99072225	chr1:52160261~52160600:-
HNSC	trans	rs616147	1	rs616147	ENSG00000214263.2	RPSAP53	-7.05	6.66e-12	1.39e-05	-0.41	-0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr13:67266845~67267706:-
HNSC	trans	rs76228276	0.737	rs77547719	ENSG00000260318.1	COX6CP1	7.05	6.66e-12	1.39e-05	0.87	0.31	Childhood ear infection;	chr8:99583331	chr16:11903923~11904137:-
HNSC	trans	rs12439619	0.508	rs17354842	ENSG00000259295.5	CSPG4P12	7.05	6.68e-12	1.4e-05	0.37	0.31	Intelligence (multi-trait analysis);	chr15:82177259	chr15:85191438~85213905:+
HNSC	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-7.04	6.72e-12	1.41e-05	-0.38	-0.31	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
HNSC	trans	rs4930561	0.765	rs7931502	ENSG00000155070.8	UNC93B2	7.04	6.74e-12	1.41e-05	0.36	0.31	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr7:6855485~6859830:-
HNSC	trans	rs6732160	0.588	rs28626211	ENSG00000236165.1	PRADC1P1	7.04	6.8e-12	1.42e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73151394	chr3:36976316~36976840:+
HNSC	trans	rs3019286	0.573	rs7827435	ENSG00000260318.1	COX6CP1	-7.04	6.84e-12	1.43e-05	-0.41	-0.31	Suicide behavior;	chr8:98770798	chr16:11903923~11904137:-
HNSC	trans	rs6732160	0.588	rs3891890	ENSG00000236165.1	PRADC1P1	7.04	6.85e-12	1.43e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73150921	chr3:36976316~36976840:+
HNSC	trans	rs7412746	0.658	rs6669855	ENSG00000180764.13	PIPSL	-7.04	6.87e-12	1.44e-05	-0.38	-0.31	Melanoma;	chr1:150888753	chr10:93958191~93961540:-
HNSC	trans	rs7937890	0.506	rs10741655	ENSG00000236360.2	RP11-334A14.2	7.04	6.91e-12	1.44e-05	0.4	0.31	Mitochondrial DNA levels;	chr11:14746838	chr1:52993201~52993702:-
HNSC	trans	rs2060793	0.712	rs6486202	ENSG00000236360.2	RP11-334A14.2	7.04	6.94e-12	1.45e-05	0.4	0.31	Vitamin D levels;	chr11:14777260	chr1:52993201~52993702:-
HNSC	trans	rs17301013	0.932	rs7555533	ENSG00000213331.4	RP11-713C19.2	7.04	6.94e-12	1.45e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174589983	chr4:187970273~187971284:+
HNSC	trans	rs2456568	0.709	rs1354765	ENSG00000276509.1	CH17-353B19.1	-7.04	6.95e-12	1.45e-05	-0.34	-0.31	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93904610	chr1:146235806~146237807:+
HNSC	trans	rs6424115	0.83	rs6663474	ENSG00000228217.1	AL390877.1	-7.04	7.05e-12	1.47e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23873152	chr1:117778087~117778506:-
HNSC	trans	rs3003334	1	rs3003334	ENSG00000228217.1	AL390877.1	-7.04	7.05e-12	1.47e-05	-0.37	-0.31	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr1:23873379	chr1:117778087~117778506:-
HNSC	trans	rs58106596	0.95	rs11695646	ENSG00000259020.3	RP11-529H20.3	-7.04	7.05e-12	1.47e-05	-0.38	-0.31	Lymphocyte counts;White blood cell count;	chr2:231720097	chr14:92026566~92026887:+
HNSC	trans	rs12439619	0.846	rs7496227	ENSG00000235370.6	DNM1P51	-7.04	7.09e-12	1.48e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82275241	chr15:84398316~84411701:-
HNSC	trans	rs9425766	0.679	rs7552830	ENSG00000213331.4	RP11-713C19.2	7.04	7.11e-12	1.48e-05	0.37	0.31	Life satisfaction;	chr1:174321643	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs7523938	ENSG00000213331.4	RP11-713C19.2	7.04	7.11e-12	1.48e-05	0.37	0.31	Life satisfaction;	chr1:174327373	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs6681780	ENSG00000213331.4	RP11-713C19.2	7.04	7.11e-12	1.48e-05	0.37	0.31	Life satisfaction;	chr1:174328980	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.55	rs57366619	ENSG00000213331.4	RP11-713C19.2	7.04	7.11e-12	1.48e-05	0.37	0.31	Life satisfaction;	chr1:174334929	chr4:187970273~187971284:+
HNSC	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	7.04	7.11e-12	1.48e-05	0.42	0.31	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
HNSC	trans	rs3806843	0.735	rs2530235	ENSG00000231043.3	AC007238.1	7.03	7.18e-12	1.5e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr2:58460292~58462032:-
HNSC	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-7.03	7.23e-12	1.51e-05	-0.38	-0.31	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
HNSC	trans	rs2060793	0.741	rs10741656	ENSG00000236360.2	RP11-334A14.2	7.03	7.29e-12	1.52e-05	0.4	0.31	Vitamin D levels;	chr11:14803699	chr1:52993201~52993702:-
HNSC	trans	rs7121616	0.576	rs7102045	ENSG00000241478.1	HSPA8P9	7.03	7.37e-12	1.53e-05	0.41	0.31	Breast cancer;	chr11:123052713	chr3:137880295~137882237:+
HNSC	trans	rs6673267	0.967	rs10494827	ENSG00000244144.1	RP11-757F18.3	-7.03	7.49e-12	1.56e-05	-0.36	-0.31	Lobe attachment (rater-scored or self-reported);	chr1:201044819	chr3:112185480~112185998:-
HNSC	trans	rs6732160	0.564	rs60796597	ENSG00000236165.1	PRADC1P1	7.03	7.5e-12	1.56e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73155786	chr3:36976316~36976840:+
HNSC	trans	rs7647973	0.961	rs56324858	ENSG00000197582.5	GPX1P1	-7.03	7.53e-12	1.57e-05	-0.52	-0.31	Menarche (age at onset);	chr3:49506796	chrX:13378735~13379340:-
HNSC	trans	rs9650657	0.538	rs11250093	ENSG00000173295.6	FAM86B3P	7.03	7.54e-12	1.57e-05	0.35	0.31	Neuroticism;	chr8:10941318	chr8:8228595~8244865:+
HNSC	trans	rs7121616	0.576	rs1461495	ENSG00000256356.1	HSPA8P5	-7.03	7.55e-12	1.57e-05	-0.4	-0.31	Breast cancer;	chr11:123056136	chr12:4097451~4099519:+
HNSC	trans	rs12439619	0.846	rs62011975	ENSG00000235370.6	DNM1P51	-7.03	7.58e-12	1.58e-05	-0.45	-0.31	Intelligence (multi-trait analysis);	chr15:82159213	chr15:84398316~84411701:-
HNSC	trans	rs7412746	0.587	rs11204722	ENSG00000180764.13	PIPSL	7.02	7.7e-12	1.6e-05	0.38	0.31	Melanoma;	chr1:150757708	chr10:93958191~93961540:-
HNSC	trans	rs9650657	0.645	rs4841409	ENSG00000173295.6	FAM86B3P	7.02	7.74e-12	1.61e-05	0.34	0.31	Neuroticism;	chr8:10658864	chr8:8228595~8244865:+
HNSC	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	7.02	7.74e-12	1.61e-05	0.45	0.31	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	7.02	7.74e-12	1.61e-05	0.45	0.31	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
HNSC	trans	rs7412746	0.658	rs6657388	ENSG00000180764.13	PIPSL	-7.02	7.77e-12	1.62e-05	-0.38	-0.31	Melanoma;	chr1:150776310	chr10:93958191~93961540:-
HNSC	trans	rs9425766	0.64	rs7512930	ENSG00000213331.4	RP11-713C19.2	7.02	7.87e-12	1.64e-05	0.37	0.31	Life satisfaction;	chr1:174319464	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs7523460	ENSG00000213331.4	RP11-713C19.2	7.02	7.87e-12	1.64e-05	0.37	0.31	Life satisfaction;	chr1:174319664	chr4:187970273~187971284:+
HNSC	trans	rs74781061	0.722	rs4073149	ENSG00000227288.3	RP5-837I24.1	-7.02	7.94e-12	1.65e-05	-0.52	-0.31	Endometriosis;	chr15:74606078	chr1:81501794~81503468:+
HNSC	trans	rs3806843	0.735	rs801180	ENSG00000231043.3	AC007238.1	7.02	7.98e-12	1.66e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr2:58460292~58462032:-
HNSC	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-7.02	8.02e-12	1.67e-05	-0.41	-0.31	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
HNSC	trans	rs6424115	0.83	rs6680132	ENSG00000228217.1	AL390877.1	-7.02	8.05e-12	1.67e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872314	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs6672157	ENSG00000228217.1	AL390877.1	-7.02	8.05e-12	1.67e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872350	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.733	rs2502996	ENSG00000228217.1	AL390877.1	-7.02	8.05e-12	1.67e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872551	chr1:117778087~117778506:-
HNSC	trans	rs9630182	1	rs2036417	ENSG00000257675.1	RP11-641A6.9	-7.01	8.18e-12	1.7e-05	-0.37	-0.31	Bone mineral density;	chr11:13596061	chr12:52748776~52750127:+
HNSC	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	7.01	8.2e-12	1.7e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
HNSC	trans	rs9650657	0.53	rs6982381	ENSG00000173295.6	FAM86B3P	-7.01	8.22e-12	1.71e-05	-0.35	-0.31	Neuroticism;	chr8:11094990	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	7.01	8.23e-12	1.71e-05	0.36	0.31	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
HNSC	trans	rs4948102	0.599	rs2230197	ENSG00000186940.6	CHCHD2P9	-7.01	8.26e-12	1.71e-05	-0.41	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr9:79391304~79391759:+
HNSC	trans	rs2665103	0.589	rs2134046	ENSG00000235370.6	DNM1P51	-7.01	8.38e-12	1.74e-05	-0.37	-0.31	Intelligence (multi-trait analysis);	chr15:82232203	chr15:84398316~84411701:-
HNSC	trans	rs2456568	0.741	rs9633811	ENSG00000276509.1	CH17-353B19.1	-7.01	8.42e-12	1.75e-05	-0.34	-0.31	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93895161	chr1:146235806~146237807:+
HNSC	trans	rs7412746	0.658	rs6677420	ENSG00000180764.13	PIPSL	-7.01	8.48e-12	1.76e-05	-0.38	-0.31	Melanoma;	chr1:150974014	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-7.01	8.55e-12	1.77e-05	-0.35	-0.31	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
HNSC	trans	rs4930561	0.714	rs7950451	ENSG00000155070.8	UNC93B2	-7.01	8.56e-12	1.77e-05	-0.35	-0.31	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr7:6855485~6859830:-
HNSC	trans	rs4930561	0.714	rs7950452	ENSG00000155070.8	UNC93B2	-7.01	8.56e-12	1.77e-05	-0.35	-0.31	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr7:6855485~6859830:-
HNSC	trans	rs6732160	0.588	rs10192654	ENSG00000236165.1	PRADC1P1	-7.01	8.65e-12	1.79e-05	-0.4	-0.31	Intelligence (multi-trait analysis);	chr2:73143754	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs1430345	ENSG00000236165.1	PRADC1P1	7.01	8.65e-12	1.79e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73143554	chr3:36976316~36976840:+
HNSC	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	7	8.66e-12	1.79e-05	0.38	0.31	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
HNSC	trans	rs9630182	0.93	rs1502239	ENSG00000257675.1	RP11-641A6.9	-7	8.76e-12	1.81e-05	-0.37	-0.31	Bone mineral density;	chr11:13598755	chr12:52748776~52750127:+
HNSC	trans	rs7412746	0.658	rs72704652	ENSG00000180764.13	PIPSL	-7	8.78e-12	1.82e-05	-0.38	-0.31	Melanoma;	chr1:150846994	chr10:93958191~93961540:-
HNSC	trans	rs3806843	0.705	rs35614340	ENSG00000231043.3	AC007238.1	7	8.8e-12	1.82e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr2:58460292~58462032:-
HNSC	trans	rs17507216	0.718	rs4779033	ENSG00000259295.5	CSPG4P12	7	8.81e-12	1.82e-05	0.47	0.31	Excessive daytime sleepiness;	chr15:82576634	chr15:85191438~85213905:+
HNSC	trans	rs7412746	0.658	rs1027699	ENSG00000180764.13	PIPSL	-7	8.83e-12	1.83e-05	-0.38	-0.31	Melanoma;	chr1:150839236	chr10:93958191~93961540:-
HNSC	trans	rs4948102	0.731	rs4948099	ENSG00000186940.6	CHCHD2P9	7	8.89e-12	1.84e-05	0.41	0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr9:79391304~79391759:+
HNSC	trans	rs2060793	0.712	rs10832290	ENSG00000236360.2	RP11-334A14.2	7	8.93e-12	1.85e-05	0.4	0.31	Vitamin D levels;	chr11:14650684	chr1:52993201~52993702:-
HNSC	trans	rs2060793	0.774	rs1403249	ENSG00000236360.2	RP11-334A14.2	7	8.93e-12	1.85e-05	0.4	0.31	Vitamin D levels;	chr11:14651438	chr1:52993201~52993702:-
HNSC	trans	rs112158604	1	rs112158604	ENSG00000180764.13	PIPSL	7	8.97e-12	1.85e-05	0.37	0.31	Lymphocyte counts;	chr1:150724325	chr10:93958191~93961540:-
HNSC	trans	rs6915893	1	rs6915893	ENSG00000267156.1	TPMTP1	7	9.07e-12	1.87e-05	0.36	0.31	Intrinsic epigenetic age acceleration;	chr6:18110325	chr18:47630112~47630848:+
HNSC	trans	rs17301013	0.932	rs332795	ENSG00000213331.4	RP11-713C19.2	7	9.09e-12	1.88e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174726785	chr4:187970273~187971284:+
HNSC	trans	rs12439619	0.846	rs62012004	ENSG00000235370.6	DNM1P51	-7	9.09e-12	1.88e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82183924	chr15:84398316~84411701:-
HNSC	trans	rs6732160	0.588	rs1430344	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73146216	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs2043100	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73146968	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs2043099	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73147028	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs11126392	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73147326	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.588	rs7578991	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73149043	chr3:36976316~36976840:+
HNSC	trans	rs6732160	0.564	rs7605716	ENSG00000236165.1	PRADC1P1	7	9.11e-12	1.88e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73149122	chr3:36976316~36976840:+
HNSC	trans	rs10037055	0.947	rs10063803	ENSG00000228305.2	AC016734.2	7	9.2e-12	1.9e-05	0.4	0.31	Migraine without aura;	chr5:177240326	chr2:63622178~63622831:-
HNSC	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	7	9.21e-12	1.9e-05	0.34	0.31	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
HNSC	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	7	9.21e-12	1.9e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	7	9.23e-12	1.91e-05	0.37	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
HNSC	trans	rs941207	0.756	rs7313074	ENSG00000228224.3	NACAP1	-6.99	9.28e-12	1.91e-05	-0.38	-0.31	Platelet count;	chr12:56760705	chr8:101361794~101372707:+
HNSC	trans	rs7662987	0.508	rs13133908	ENSG00000233859.2	ADH5P4	-6.99	9.32e-12	1.92e-05	-0.47	-0.31	Smoking initiation;	chr4:99311467	chr6:65836930~65838039:-
HNSC	trans	rs1707322	0.964	rs6675259	ENSG00000255397.1	AC022182.2	6.99	9.43e-12	1.95e-05	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr8:60937705~60939871:-
HNSC	trans	rs2060793	0.741	rs1542291	ENSG00000236360.2	RP11-334A14.2	6.99	9.47e-12	1.95e-05	0.4	0.31	Vitamin D levels;	chr11:14784720	chr1:52993201~52993702:-
HNSC	trans	rs13190036	0.551	rs7732930	ENSG00000228305.2	AC016734.2	-6.99	9.48e-12	1.96e-05	-0.43	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr2:63622178~63622831:-
HNSC	trans	rs7412746	0.658	rs7526489	ENSG00000180764.13	PIPSL	-6.99	9.54e-12	1.97e-05	-0.38	-0.31	Melanoma;	chr1:150753762	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs12068264	ENSG00000180764.13	PIPSL	-6.99	9.54e-12	1.97e-05	-0.38	-0.31	Melanoma;	chr1:150754853	chr10:93958191~93961540:-
HNSC	trans	rs9425766	0.679	rs6670617	ENSG00000213331.4	RP11-713C19.2	6.99	9.55e-12	1.97e-05	0.37	0.31	Life satisfaction;	chr1:174277574	chr4:187970273~187971284:+
HNSC	trans	rs8067354	0.574	rs2531899	ENSG00000187870.7	RNFT1P3	-6.99	9.59e-12	1.97e-05	-0.43	-0.31	Hemoglobin concentration;	chr17:59929832	chr17:20743333~20754501:-
HNSC	trans	rs17301013	0.932	rs11804941	ENSG00000213331.4	RP11-713C19.2	-6.99	9.6e-12	1.98e-05	-0.37	-0.31	Systemic lupus erythematosus;	chr1:174624074	chr4:187970273~187971284:+
HNSC	trans	rs6424115	0.83	rs2501425	ENSG00000228217.1	AL390877.1	-6.99	9.64e-12	1.99e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872849	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2502994	ENSG00000228217.1	AL390877.1	-6.99	9.64e-12	1.99e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872873	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.83	rs2501426	ENSG00000228217.1	AL390877.1	-6.99	9.64e-12	1.99e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872874	chr1:117778087~117778506:-
HNSC	trans	rs7412746	0.658	rs8444	ENSG00000180764.13	PIPSL	-6.99	9.77e-12	2.01e-05	-0.38	-0.31	Melanoma;	chr1:150966095	chr10:93958191~93961540:-
HNSC	trans	rs2060793	0.712	rs10741654	ENSG00000236360.2	RP11-334A14.2	6.99	9.85e-12	2.03e-05	0.4	0.31	Vitamin D levels;	chr11:14726506	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.505	rs9971395	ENSG00000236360.2	RP11-334A14.2	6.99	9.85e-12	2.03e-05	0.4	0.31	Mitochondrial DNA levels;	chr11:14745580	chr1:52993201~52993702:-
HNSC	trans	rs2237234	0.542	rs7755997	ENSG00000242375.1	RP11-498P14.3	6.98	9.95e-12	2.05e-05	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:26482820	chr9:97195351~97197687:-
HNSC	trans	rs12439619	0.705	rs4778665	ENSG00000259295.5	CSPG4P12	-6.98	1e-11	2.06e-05	-0.46	-0.31	Intelligence (multi-trait analysis);	chr15:82144163	chr15:85191438~85213905:+
HNSC	trans	rs7412746	0.658	rs10305711	ENSG00000180764.13	PIPSL	-6.98	1e-11	2.06e-05	-0.38	-0.31	Melanoma;	chr1:150830520	chr10:93958191~93961540:-
HNSC	trans	rs2060793	0.741	rs7119073	ENSG00000236360.2	RP11-334A14.2	6.98	1.01e-11	2.07e-05	0.4	0.31	Vitamin D levels;	chr11:14669416	chr1:52993201~52993702:-
HNSC	trans	rs2060793	0.741	rs10741653	ENSG00000236360.2	RP11-334A14.2	6.98	1.01e-11	2.07e-05	0.4	0.31	Vitamin D levels;	chr11:14683294	chr1:52993201~52993702:-
HNSC	trans	rs2060793	0.741	rs4344519	ENSG00000236360.2	RP11-334A14.2	6.98	1.01e-11	2.07e-05	0.4	0.31	Vitamin D levels;	chr11:14701347	chr1:52993201~52993702:-
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	6.98	1.01e-11	2.08e-05	0.36	0.31	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
HNSC	trans	rs3806843	0.735	rs2530242	ENSG00000231043.3	AC007238.1	6.98	1.01e-11	2.08e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.735	rs2530241	ENSG00000231043.3	AC007238.1	6.98	1.01e-11	2.08e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr2:58460292~58462032:-
HNSC	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	6.98	1.03e-11	2.11e-05	0.38	0.31	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
HNSC	trans	rs7412746	0.658	rs2089082	ENSG00000180764.13	PIPSL	-6.98	1.03e-11	2.11e-05	-0.38	-0.31	Melanoma;	chr1:150827614	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs10305704	ENSG00000180764.13	PIPSL	-6.98	1.03e-11	2.11e-05	-0.38	-0.31	Melanoma;	chr1:150831953	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.855	rs2256341	ENSG00000257210.1	NACAP3	-6.98	1.03e-11	2.12e-05	-0.41	-0.31	Platelet count;	chr12:56599930	chr12:93124063~93124543:-
HNSC	trans	rs7412746	0.658	rs17660092	ENSG00000180764.13	PIPSL	-6.98	1.04e-11	2.13e-05	-0.38	-0.31	Melanoma;	chr1:150825272	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-6.98	1.04e-11	2.14e-05	-0.35	-0.31	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-6.98	1.04e-11	2.14e-05	-0.35	-0.31	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
HNSC	trans	rs941207	0.805	rs2958139	ENSG00000257210.1	NACAP3	-6.98	1.04e-11	2.14e-05	-0.41	-0.31	Platelet count;	chr12:56610884	chr12:93124063~93124543:-
HNSC	trans	rs7412746	0.658	rs3768016	ENSG00000180764.13	PIPSL	-6.98	1.04e-11	2.14e-05	-0.38	-0.31	Melanoma;	chr1:150837443	chr10:93958191~93961540:-
HNSC	trans	rs17507216	0.671	rs28582623	ENSG00000259295.5	CSPG4P12	-6.98	1.04e-11	2.14e-05	-0.46	-0.31	Excessive daytime sleepiness;	chr15:82577381	chr15:85191438~85213905:+
HNSC	trans	rs9733	0.791	rs11204693	ENSG00000180764.13	PIPSL	6.97	1.05e-11	2.16e-05	0.37	0.31	Tonsillectomy;	chr1:150675511	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.756	rs7978685	ENSG00000228224.3	NACAP1	6.97	1.05e-11	2.16e-05	0.39	0.31	Platelet count;	chr12:56709370	chr8:101361794~101372707:+
HNSC	trans	rs7412746	0.611	rs6660084	ENSG00000180764.13	PIPSL	-6.97	1.06e-11	2.16e-05	-0.38	-0.31	Melanoma;	chr1:150776327	chr10:93958191~93961540:-
HNSC	trans	rs17301013	0.932	rs1653627	ENSG00000213331.4	RP11-713C19.2	-6.97	1.06e-11	2.17e-05	-0.37	-0.31	Systemic lupus erythematosus;	chr1:174771879	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs1793297	ENSG00000213331.4	RP11-713C19.2	-6.97	1.06e-11	2.18e-05	-0.37	-0.31	Systemic lupus erythematosus;	chr1:174784411	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.676	rs1583005	ENSG00000231043.3	AC007238.1	6.97	1.06e-11	2.18e-05	0.32	0.31	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr2:58460292~58462032:-
HNSC	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	6.97	1.07e-11	2.19e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
HNSC	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	6.97	1.07e-11	2.19e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
HNSC	trans	rs13190036	0.515	rs2878686	ENSG00000228305.2	AC016734.2	-6.97	1.07e-11	2.2e-05	-0.43	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr2:63622178~63622831:-
HNSC	trans	rs9733	0.818	rs4970924	ENSG00000180764.13	PIPSL	6.97	1.07e-11	2.2e-05	0.37	0.31	Tonsillectomy;	chr1:150660603	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.791	rs11800059	ENSG00000180764.13	PIPSL	6.97	1.07e-11	2.2e-05	0.37	0.31	Tonsillectomy;	chr1:150678699	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs11204695	ENSG00000180764.13	PIPSL	6.97	1.07e-11	2.2e-05	0.37	0.31	Tonsillectomy;	chr1:150684535	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs11204702	ENSG00000180764.13	PIPSL	6.97	1.07e-11	2.2e-05	0.37	0.31	Tonsillectomy;	chr1:150691031	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	6.97	1.07e-11	2.2e-05	0.36	0.31	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
HNSC	trans	rs6498068	0.633	rs7194566	ENSG00000278702.1	Metazoa_SRP	6.97	1.08e-11	2.2e-05	0.39	0.31	Metabolite levels (MHPG);	chr16:10532140	chr1:35399997~35400319:+
HNSC	trans	rs7412746	0.658	rs2230061	ENSG00000180764.13	PIPSL	-6.97	1.08e-11	2.21e-05	-0.38	-0.31	Melanoma;	chr1:150755063	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.756	rs1465081	ENSG00000228224.3	NACAP1	-6.97	1.08e-11	2.22e-05	-0.38	-0.31	Platelet count;	chr12:56656390	chr8:101361794~101372707:+
HNSC	trans	rs7819412	0.806	rs2409689	ENSG00000173295.6	FAM86B3P	-6.97	1.09e-11	2.23e-05	-0.34	-0.31	Triglycerides;	chr8:11075358	chr8:8228595~8244865:+
HNSC	trans	rs6424115	0.83	rs2502995	ENSG00000228217.1	AL390877.1	-6.97	1.09e-11	2.24e-05	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23872800	chr1:117778087~117778506:-
HNSC	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	6.97	1.1e-11	2.25e-05	0.36	0.31	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
HNSC	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	6.97	1.1e-11	2.25e-05	0.36	0.31	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
HNSC	trans	rs2060793	0.741	rs10734227	ENSG00000236360.2	RP11-334A14.2	6.97	1.1e-11	2.25e-05	0.4	0.31	Vitamin D levels;	chr11:14767471	chr1:52993201~52993702:-
HNSC	trans	rs7873102	0.967	rs7025303	ENSG00000229007.1	EXOSC3P1	6.97	1.12e-11	2.29e-05	0.38	0.31	Brain structure;	chr9:38040098	chr21:32496812~32497311:+
HNSC	trans	rs7121616	0.576	rs7123232	ENSG00000256356.1	HSPA8P5	6.96	1.12e-11	2.3e-05	0.38	0.31	Breast cancer;	chr11:123056237	chr12:4097451~4099519:+
HNSC	trans	rs17301013	0.861	rs332770	ENSG00000213331.4	RP11-713C19.2	6.96	1.14e-11	2.34e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174681511	chr4:187970273~187971284:+
HNSC	trans	rs616147	0.962	rs545397	ENSG00000214263.2	RPSAP53	6.96	1.15e-11	2.34e-05	0.41	0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr13:67266845~67267706:-
HNSC	trans	rs7121616	0.595	rs7941144	ENSG00000256356.1	HSPA8P5	6.96	1.16e-11	2.37e-05	0.36	0.31	Breast cancer;	chr11:123079805	chr12:4097451~4099519:+
HNSC	trans	rs941207	1	rs941207	ENSG00000257210.1	NACAP3	-6.96	1.16e-11	2.37e-05	-0.4	-0.31	Platelet count;	chr12:56629500	chr12:93124063~93124543:-
HNSC	trans	rs916888	0.531	rs183211	ENSG00000280022.1	RP11-707O23.1	6.96	1.17e-11	2.38e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45592621~45593369:+
HNSC	trans	rs393155	0.517	rs330050	ENSG00000173295.6	FAM86B3P	-6.96	1.19e-11	2.43e-05	-0.33	-0.31	Neuroticism;	chr8:9230169	chr8:8228595~8244865:+
HNSC	trans	rs453301	0.571	rs330054	ENSG00000173295.6	FAM86B3P	-6.96	1.19e-11	2.43e-05	-0.33	-0.31	Joint mobility (Beighton score);	chr8:9230781	chr8:8228595~8244865:+
HNSC	trans	rs4930561	0.765	rs34493482	ENSG00000155070.8	UNC93B2	-6.95	1.2e-11	2.45e-05	-0.35	-0.31	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr7:6855485~6859830:-
HNSC	trans	rs7937890	0.505	rs1403248	ENSG00000236360.2	RP11-334A14.2	6.95	1.2e-11	2.45e-05	0.4	0.31	Mitochondrial DNA levels;	chr11:14657471	chr1:52993201~52993702:-
HNSC	trans	rs853679	0.556	rs13200214	ENSG00000253570.1	RNF5P1	6.95	1.21e-11	2.47e-05	0.72	0.31	Depression;	chr6:28049472	chr8:38600661~38601200:-
HNSC	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-6.95	1.22e-11	2.48e-05	-0.38	-0.31	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
HNSC	trans	rs7819412	0.811	rs2409691	ENSG00000173295.6	FAM86B3P	-6.95	1.23e-11	2.5e-05	-0.34	-0.31	Triglycerides;	chr8:11085766	chr8:8228595~8244865:+
HNSC	trans	rs3806843	0.648	rs2530233	ENSG00000231043.3	AC007238.1	6.95	1.23e-11	2.51e-05	0.31	0.31	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr2:58460292~58462032:-
HNSC	trans	rs6743068	0.521	rs12472273	ENSG00000235105.1	RP11-329A14.1	6.95	1.24e-11	2.53e-05	0.36	0.31	Lymphocyte percentage of white cells;	chr2:201346972	chr1:48435967~48437223:+
HNSC	trans	rs3806843	0.735	rs801167	ENSG00000231043.3	AC007238.1	-6.95	1.24e-11	2.53e-05	-0.32	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr2:58460292~58462032:-
HNSC	trans	rs12439619	0.846	rs62012059	ENSG00000235370.6	DNM1P51	-6.95	1.24e-11	2.53e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82251669	chr15:84398316~84411701:-
HNSC	trans	rs6498068	0.564	rs2062893	ENSG00000278702.1	Metazoa_SRP	6.95	1.25e-11	2.55e-05	0.39	0.31	Metabolite levels (MHPG);	chr16:10525460	chr1:35399997~35400319:+
HNSC	trans	rs6732160	0.564	rs1430346	ENSG00000236165.1	PRADC1P1	6.95	1.27e-11	2.58e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr2:73140117	chr3:36976316~36976840:+
HNSC	trans	rs916888	0.61	rs199438	ENSG00000280022.1	RP11-707O23.1	6.94	1.28e-11	2.6e-05	0.35	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45592621~45593369:+
HNSC	trans	rs4948102	0.597	rs12669623	ENSG00000186940.6	CHCHD2P9	-6.94	1.28e-11	2.6e-05	-0.41	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr9:79391304~79391759:+
HNSC	trans	rs7412746	0.658	rs2272214	ENSG00000180764.13	PIPSL	-6.94	1.28e-11	2.6e-05	-0.37	-0.31	Melanoma;	chr1:150958986	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs10788794	ENSG00000180764.13	PIPSL	-6.94	1.29e-11	2.62e-05	-0.37	-0.31	Melanoma;	chr1:150756200	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs10888391	ENSG00000180764.13	PIPSL	-6.94	1.29e-11	2.62e-05	-0.37	-0.31	Melanoma;	chr1:150757507	chr10:93958191~93961540:-
HNSC	trans	rs12439619	0.846	rs62012056	ENSG00000235370.6	DNM1P51	-6.94	1.3e-11	2.63e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82247278	chr15:84398316~84411701:-
HNSC	trans	rs12439619	0.846	rs62012004	ENSG00000259295.5	CSPG4P12	-6.94	1.3e-11	2.65e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82183924	chr15:85191438~85213905:+
HNSC	trans	rs7412746	0.524	rs58304714	ENSG00000180764.13	PIPSL	-6.94	1.31e-11	2.67e-05	-0.37	-0.31	Melanoma;	chr1:150859085	chr10:93958191~93961540:-
HNSC	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-6.94	1.31e-11	2.67e-05	-0.38	-0.31	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-6.94	1.31e-11	2.67e-05	-0.38	-0.31	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
HNSC	trans	rs7647973	0.731	rs7617480	ENSG00000197582.5	GPX1P1	-6.94	1.32e-11	2.67e-05	-0.45	-0.31	Menarche (age at onset);	chr3:49173299	chrX:13378735~13379340:-
HNSC	trans	rs877636	0.702	rs773108	ENSG00000242970.2	AC068522.4	6.94	1.32e-11	2.68e-05	0.37	0.31	Cognitive function;	chr12:55976127	chr8:58588420~58588764:-
HNSC	trans	rs12439619	0.739	rs62012046	ENSG00000235370.6	DNM1P51	-6.94	1.32e-11	2.69e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82236824	chr15:84398316~84411701:-
HNSC	trans	rs12439619	0.774	rs62012047	ENSG00000235370.6	DNM1P51	-6.94	1.32e-11	2.69e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82236852	chr15:84398316~84411701:-
HNSC	trans	rs12439619	0.81	rs62012049	ENSG00000235370.6	DNM1P51	-6.94	1.32e-11	2.69e-05	-0.44	-0.31	Intelligence (multi-trait analysis);	chr15:82237722	chr15:84398316~84411701:-
HNSC	trans	rs6424115	0.83	rs3123554	ENSG00000228217.1	AL390877.1	6.94	1.33e-11	2.71e-05	0.37	0.31	Immature fraction of reticulocytes;	chr1:23869911	chr1:117778087~117778506:-
HNSC	trans	rs8177876	0.822	rs10514514	ENSG00000224837.1	GCSHP5	6.94	1.33e-11	2.71e-05	0.5	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr1:168055901~168056422:-
HNSC	trans	rs6424115	0.83	rs2503002	ENSG00000228217.1	AL390877.1	-6.94	1.34e-11	2.71e-05	-0.36	-0.31	Immature fraction of reticulocytes;	chr1:23870467	chr1:117778087~117778506:-
HNSC	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
HNSC	trans	rs7412746	0.658	rs2275235	ENSG00000180764.13	PIPSL	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Melanoma;	chr1:150757803	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs11204723	ENSG00000180764.13	PIPSL	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Melanoma;	chr1:150759142	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs4537557	ENSG00000180764.13	PIPSL	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Melanoma;	chr1:150761960	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs2864869	ENSG00000180764.13	PIPSL	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Melanoma;	chr1:150762179	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.634	rs3754212	ENSG00000180764.13	PIPSL	-6.94	1.34e-11	2.71e-05	-0.38	-0.31	Melanoma;	chr1:150765724	chr10:93958191~93961540:-
HNSC	trans	rs3806843	0.735	rs809635	ENSG00000231043.3	AC007238.1	6.94	1.35e-11	2.73e-05	0.31	0.31	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr2:58460292~58462032:-
HNSC	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	6.94	1.35e-11	2.73e-05	0.24	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
HNSC	trans	rs1039766	0.925	rs268850	ENSG00000213985.4	AC078899.1	6.94	1.35e-11	2.74e-05	0.4	0.31	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr19:20257720~20259418:+
HNSC	trans	rs3806843	0.676	rs2569159	ENSG00000231043.3	AC007238.1	6.94	1.35e-11	2.75e-05	0.31	0.31	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr2:58460292~58462032:-
HNSC	trans	rs7121616	0.576	rs7102045	ENSG00000256356.1	HSPA8P5	6.94	1.36e-11	2.75e-05	0.39	0.31	Breast cancer;	chr11:123052713	chr12:4097451~4099519:+
HNSC	trans	rs2456568	0.548	rs1607402	ENSG00000276509.1	CH17-353B19.1	6.93	1.36e-11	2.76e-05	0.34	0.31	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93927566	chr1:146235806~146237807:+
HNSC	trans	rs7662987	0.517	rs2851286	ENSG00000233859.2	ADH5P4	6.93	1.36e-11	2.76e-05	0.37	0.31	Smoking initiation;	chr4:99093825	chr6:65836930~65838039:-
HNSC	trans	rs7412746	0.611	rs10888395	ENSG00000180764.13	PIPSL	-6.93	1.37e-11	2.77e-05	-0.38	-0.31	Melanoma;	chr1:150789695	chr10:93958191~93961540:-
HNSC	trans	rs2456568	0.709	rs7942444	ENSG00000276509.1	CH17-353B19.1	-6.93	1.37e-11	2.77e-05	-0.33	-0.31	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93903994	chr1:146235806~146237807:+
HNSC	trans	rs722599	0.748	rs731952	ENSG00000181227.3	RP4-682C21.2	-6.93	1.37e-11	2.77e-05	-0.32	-0.31	IgG glycosylation;	chr14:74899744	chr1:75743423~75744776:-
HNSC	trans	rs7937890	0.593	rs2597189	ENSG00000236360.2	RP11-334A14.2	6.93	1.38e-11	2.79e-05	0.43	0.31	Mitochondrial DNA levels;	chr11:14490514	chr1:52993201~52993702:-
HNSC	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-6.93	1.38e-11	2.79e-05	-0.38	-0.31	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
HNSC	trans	rs7121616	0.576	rs73610509	ENSG00000256356.1	HSPA8P5	6.93	1.4e-11	2.83e-05	0.39	0.31	Breast cancer;	chr11:123048564	chr12:4097451~4099519:+
HNSC	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-6.93	1.4e-11	2.83e-05	-0.38	-0.31	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-6.93	1.4e-11	2.83e-05	-0.38	-0.31	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
HNSC	trans	rs2060793	0.741	rs2060794	ENSG00000236360.2	RP11-334A14.2	6.93	1.4e-11	2.84e-05	0.39	0.31	Vitamin D levels;	chr11:14791437	chr1:52993201~52993702:-
HNSC	trans	rs2060793	0.741	rs3740823	ENSG00000236360.2	RP11-334A14.2	6.93	1.4e-11	2.84e-05	0.39	0.31	Vitamin D levels;	chr11:14804158	chr1:52993201~52993702:-
HNSC	trans	rs941207	0.756	rs2958149	ENSG00000228224.3	NACAP1	6.93	1.4e-11	2.84e-05	0.38	0.31	Platelet count;	chr12:56716008	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.724	rs1979325	ENSG00000228224.3	NACAP1	6.93	1.4e-11	2.84e-05	0.38	0.31	Platelet count;	chr12:56728152	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.756	rs7315472	ENSG00000228224.3	NACAP1	-6.93	1.43e-11	2.9e-05	-0.38	-0.31	Platelet count;	chr12:56648276	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.756	rs67046307	ENSG00000228224.3	NACAP1	-6.93	1.43e-11	2.9e-05	-0.38	-0.31	Platelet count;	chr12:56651152	chr8:101361794~101372707:+
HNSC	trans	rs17301013	0.896	rs332773	ENSG00000213331.4	RP11-713C19.2	6.93	1.44e-11	2.92e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174695711	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.932	rs444678	ENSG00000213331.4	RP11-713C19.2	6.93	1.44e-11	2.92e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174706080	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.896	rs332791	ENSG00000213331.4	RP11-713C19.2	6.93	1.44e-11	2.92e-05	0.37	0.31	Systemic lupus erythematosus;	chr1:174709784	chr4:187970273~187971284:+
HNSC	trans	rs1816752	0.935	rs3816219	ENSG00000224976.2	PARP4P2	-6.93	1.44e-11	2.92e-05	-0.37	-0.31	Obesity-related traits;	chr13:24442995	chr13:19349137~19407962:+
HNSC	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-6.93	1.45e-11	2.93e-05	-0.25	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
HNSC	trans	rs4930561	0.765	rs10896304	ENSG00000155070.8	UNC93B2	-6.93	1.45e-11	2.93e-05	-0.36	-0.31	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr7:6855485~6859830:-
HNSC	trans	rs3849046	0.901	rs11956240	ENSG00000226666.1	HSPA9P1	6.92	1.48e-11	2.98e-05	0.31	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138504604	chr2:221961737~221963765:+
HNSC	trans	rs7503168	0.558	rs11870472	ENSG00000234130.2	RP13-88F20.1	6.92	1.49e-11	3.01e-05	0.53	0.3	Plateletcrit;	chr17:35545630	chrX:93222220~93225015:-
HNSC	trans	rs11951515	0.508	rs7706431	ENSG00000174977.8	AC026271.5	-6.92	1.51e-11	3.04e-05	-0.29	-0.3	Metabolite levels  (X-11787);	chr5:43582321	chr17:18650195~18651542:+
HNSC	trans	rs11951515	0.508	rs6898866	ENSG00000174977.8	AC026271.5	-6.92	1.51e-11	3.04e-05	-0.29	-0.3	Metabolite levels  (X-11787);	chr5:43586273	chr17:18650195~18651542:+
HNSC	trans	rs941207	0.756	rs2950394	ENSG00000228224.3	NACAP1	-6.92	1.52e-11	3.07e-05	-0.38	-0.3	Platelet count;	chr12:56644548	chr8:101361794~101372707:+
HNSC	trans	rs9650657	0.506	rs7823296	ENSG00000173295.6	FAM86B3P	-6.92	1.52e-11	3.08e-05	-0.34	-0.3	Neuroticism;	chr8:10921036	chr8:8228595~8244865:+
HNSC	trans	rs1039766	0.866	rs2160263	ENSG00000213985.4	AC078899.1	6.92	1.53e-11	3.09e-05	0.4	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65282104	chr19:20257720~20259418:+
HNSC	trans	rs4730250	0.707	rs1981696	ENSG00000263266.2	RPS7P1	-6.91	1.57e-11	3.16e-05	-0.3	-0.3	Osteoarthritis;	chr7:107153655	chr17:28467822~28468406:+
HNSC	trans	rs7412746	0.622	rs72704654	ENSG00000180764.13	PIPSL	-6.91	1.57e-11	3.17e-05	-0.37	-0.3	Melanoma;	chr1:150853934	chr10:93958191~93961540:-
HNSC	trans	rs7662987	0.793	rs28730632	ENSG00000228407.2	RP4-800M22.1	6.91	1.59e-11	3.21e-05	0.48	0.3	Smoking initiation;	chr4:99074552	chr1:52160261~52160600:-
HNSC	trans	rs7662987	0.793	rs4699700	ENSG00000228407.2	RP4-800M22.1	6.91	1.59e-11	3.21e-05	0.48	0.3	Smoking initiation;	chr4:99077184	chr1:52160261~52160600:-
HNSC	trans	rs7412746	0.611	rs2864873	ENSG00000180764.13	PIPSL	-6.91	1.59e-11	3.21e-05	-0.37	-0.3	Melanoma;	chr1:150841698	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.546	rs35017208	ENSG00000253570.1	RNF5P1	6.91	1.6e-11	3.22e-05	0.71	0.3	Depression;	chr6:28377505	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs36092177	ENSG00000253570.1	RNF5P1	6.91	1.6e-11	3.22e-05	0.71	0.3	Depression;	chr6:28390030	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs2232429	ENSG00000253570.1	RNF5P1	6.91	1.6e-11	3.22e-05	0.71	0.3	Depression;	chr6:28391855	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs2232426	ENSG00000253570.1	RNF5P1	6.91	1.6e-11	3.22e-05	0.71	0.3	Depression;	chr6:28392882	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs2232423	ENSG00000253570.1	RNF5P1	6.91	1.6e-11	3.22e-05	0.71	0.3	Depression;	chr6:28398374	chr8:38600661~38601200:-
HNSC	trans	rs9425766	0.679	rs9787001	ENSG00000213331.4	RP11-713C19.2	6.91	1.61e-11	3.24e-05	0.37	0.3	Life satisfaction;	chr1:174222556	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs972361	ENSG00000213331.4	RP11-713C19.2	6.91	1.61e-11	3.24e-05	0.37	0.3	Life satisfaction;	chr1:174228270	chr4:187970273~187971284:+
HNSC	trans	rs4948102	0.551	rs4275190	ENSG00000186940.6	CHCHD2P9	-6.91	1.61e-11	3.24e-05	-0.41	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr9:79391304~79391759:+
HNSC	trans	rs12439619	0.693	rs9944185	ENSG00000235370.6	DNM1P51	-6.91	1.62e-11	3.26e-05	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82157927	chr15:84398316~84411701:-
HNSC	trans	rs10037055	0.853	rs10036193	ENSG00000226986.4	RP11-543B16.2	-6.91	1.62e-11	3.26e-05	-0.38	-0.3	Migraine without aura;	chr5:177141519	chr1:211207239~211207897:+
HNSC	trans	rs10037055	0.853	rs9885210	ENSG00000226986.4	RP11-543B16.2	-6.91	1.62e-11	3.26e-05	-0.38	-0.3	Migraine without aura;	chr5:177142187	chr1:211207239~211207897:+
HNSC	trans	rs6921919	0.832	rs17312661	ENSG00000228078.1	HLA-U	-6.91	1.63e-11	3.27e-05	-0.5	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:29934101~29934286:+
HNSC	trans	rs7520050	0.778	rs3014218	ENSG00000255397.1	AC022182.2	6.91	1.63e-11	3.29e-05	0.37	0.3	Reticulocyte count;Red blood cell count;	chr1:45560656	chr8:60937705~60939871:-
HNSC	trans	rs9425766	0.679	rs6667267	ENSG00000213331.4	RP11-713C19.2	6.91	1.64e-11	3.29e-05	0.37	0.3	Life satisfaction;	chr1:174243623	chr4:187970273~187971284:+
HNSC	trans	rs62344088	1	rs6872393	ENSG00000185986.11	SDHAP3	-6.9	1.65e-11	3.33e-05	-0.71	-0.3	Asthma (childhood onset);	chr5:155739	chr5:1572222~1594620:-
HNSC	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-6.9	1.66e-11	3.35e-05	-0.34	-0.3	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
HNSC	trans	rs941207	0.756	rs2926743	ENSG00000228224.3	NACAP1	6.9	1.67e-11	3.36e-05	0.38	0.3	Platelet count;	chr12:56720316	chr8:101361794~101372707:+
HNSC	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-6.9	1.68e-11	3.38e-05	-0.38	-0.3	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
HNSC	trans	rs4970988	0.787	rs1532770	ENSG00000180764.13	PIPSL	-6.9	1.68e-11	3.38e-05	-0.37	-0.3	Urate levels;	chr1:150752859	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs11582281	ENSG00000180764.13	PIPSL	-6.9	1.69e-11	3.41e-05	-0.37	-0.3	Melanoma;	chr1:150854355	chr10:93958191~93961540:-
HNSC	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-6.9	1.7e-11	3.41e-05	-0.38	-0.3	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
HNSC	trans	rs4930561	0.765	rs4930229	ENSG00000155070.8	UNC93B2	-6.9	1.7e-11	3.42e-05	-0.35	-0.3	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr7:6855485~6859830:-
HNSC	trans	rs9650657	0.504	rs10093053	ENSG00000173295.6	FAM86B3P	-6.9	1.7e-11	3.42e-05	-0.35	-0.3	Neuroticism;	chr8:11179678	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.932	rs1653626	ENSG00000213331.4	RP11-713C19.2	-6.9	1.7e-11	3.43e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174770348	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.676	rs2245640	ENSG00000231043.3	AC007238.1	6.9	1.73e-11	3.48e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr2:58460292~58462032:-
HNSC	trans	rs7412746	0.658	rs57818453	ENSG00000180764.13	PIPSL	-6.9	1.75e-11	3.51e-05	-0.37	-0.3	Melanoma;	chr1:150790663	chr10:93958191~93961540:-
HNSC	trans	rs3806843	0.676	rs778593	ENSG00000231043.3	AC007238.1	6.9	1.75e-11	3.52e-05	0.32	0.3	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.676	rs778594	ENSG00000231043.3	AC007238.1	6.9	1.75e-11	3.52e-05	0.32	0.3	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr2:58460292~58462032:-
HNSC	trans	rs17301013	0.93	rs6425279	ENSG00000213331.4	RP11-713C19.2	-6.89	1.78e-11	3.57e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174418717	chr4:187970273~187971284:+
HNSC	trans	rs3849046	0.718	rs28587037	ENSG00000226666.1	HSPA9P1	6.89	1.78e-11	3.58e-05	0.32	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138599355	chr2:221961737~221963765:+
HNSC	trans	rs7121616	0.576	rs73610510	ENSG00000241478.1	HSPA8P9	6.89	1.8e-11	3.61e-05	0.4	0.3	Breast cancer;	chr11:123049365	chr3:137880295~137882237:+
HNSC	trans	rs7412746	0.611	rs11204726	ENSG00000180764.13	PIPSL	-6.89	1.81e-11	3.62e-05	-0.37	-0.3	Melanoma;	chr1:150771016	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.553	rs59337856	ENSG00000180764.13	PIPSL	-6.89	1.81e-11	3.62e-05	-0.37	-0.3	Melanoma;	chr1:150773930	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs10888394	ENSG00000180764.13	PIPSL	-6.89	1.81e-11	3.62e-05	-0.37	-0.3	Melanoma;	chr1:150777437	chr10:93958191~93961540:-
HNSC	trans	rs3806843	0.619	rs2569160	ENSG00000231043.3	AC007238.1	6.89	1.81e-11	3.63e-05	0.32	0.3	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr2:58460292~58462032:-
HNSC	trans	rs1816752	0.905	rs7995492	ENSG00000224976.2	PARP4P2	-6.89	1.81e-11	3.63e-05	-0.35	-0.3	Obesity-related traits;	chr13:24438885	chr13:19349137~19407962:+
HNSC	trans	rs7647973	0.667	rs4241405	ENSG00000197582.5	GPX1P1	6.89	1.82e-11	3.64e-05	0.52	0.3	Menarche (age at onset);	chr3:49604594	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs12637313	ENSG00000197582.5	GPX1P1	6.89	1.82e-11	3.64e-05	0.52	0.3	Menarche (age at onset);	chr3:49608025	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.576	rs11600486	ENSG00000256356.1	HSPA8P5	6.89	1.82e-11	3.65e-05	0.39	0.3	Breast cancer;	chr11:123047060	chr12:4097451~4099519:+
HNSC	trans	rs7412746	0.566	rs2864871	ENSG00000180764.13	PIPSL	-6.89	1.82e-11	3.65e-05	-0.37	-0.3	Melanoma;	chr1:150794488	chr10:93958191~93961540:-
HNSC	trans	rs9425766	0.679	rs4650989	ENSG00000213331.4	RP11-713C19.2	6.89	1.82e-11	3.65e-05	0.37	0.3	Life satisfaction;	chr1:174289739	chr4:187970273~187971284:+
HNSC	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	6.89	1.82e-11	3.66e-05	0.37	0.3	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
HNSC	trans	rs7121616	0.531	rs1461497	ENSG00000256356.1	HSPA8P5	6.89	1.83e-11	3.66e-05	0.39	0.3	Breast cancer;	chr11:123060505	chr12:4097451~4099519:+
HNSC	trans	rs7121616	0.531	rs41361350	ENSG00000256356.1	HSPA8P5	6.89	1.83e-11	3.66e-05	0.39	0.3	Breast cancer;	chr11:123060917	chr12:4097451~4099519:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	6.89	1.83e-11	3.67e-05	0.33	0.3	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
HNSC	trans	rs13190036	0.551	rs11955537	ENSG00000228305.2	AC016734.2	-6.89	1.84e-11	3.7e-05	-0.42	-0.3	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr2:63622178~63622831:-
HNSC	trans	rs10037055	0.685	rs10039241	ENSG00000228305.2	AC016734.2	-6.89	1.86e-11	3.73e-05	-0.43	-0.3	Migraine without aura;	chr5:177151071	chr2:63622178~63622831:-
HNSC	trans	rs7824557	0.547	rs4512344	ENSG00000173295.6	FAM86B3P	-6.89	1.87e-11	3.74e-05	-0.34	-0.3	Retinal vascular caliber;	chr8:11221272	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	6.88	1.88e-11	3.77e-05	0.38	0.3	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
HNSC	trans	rs17301013	0.932	rs4233195	ENSG00000213331.4	RP11-713C19.2	-6.88	1.88e-11	3.77e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174806736	chr4:187970273~187971284:+
HNSC	trans	rs6424115	1	rs2179395	ENSG00000228217.1	AL390877.1	-6.88	1.88e-11	3.77e-05	-0.37	-0.3	Immature fraction of reticulocytes;	chr1:23821875	chr1:117778087~117778506:-
HNSC	trans	rs17507216	0.718	rs7165690	ENSG00000259295.5	CSPG4P12	-6.88	1.9e-11	3.81e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82654804	chr15:85191438~85213905:+
HNSC	trans	rs9425766	0.631	rs10158289	ENSG00000213331.4	RP11-713C19.2	6.88	1.9e-11	3.81e-05	0.37	0.3	Life satisfaction;	chr1:174081529	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs6685314	ENSG00000213331.4	RP11-713C19.2	6.88	1.9e-11	3.81e-05	0.37	0.3	Life satisfaction;	chr1:174089905	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.655	rs4652169	ENSG00000213331.4	RP11-713C19.2	6.88	1.9e-11	3.81e-05	0.37	0.3	Life satisfaction;	chr1:174095343	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs6691711	ENSG00000213331.4	RP11-713C19.2	6.88	1.9e-11	3.81e-05	0.37	0.3	Life satisfaction;	chr1:174100283	chr4:187970273~187971284:+
HNSC	trans	rs9733	0.818	rs4970926	ENSG00000180764.13	PIPSL	6.88	1.92e-11	3.85e-05	0.36	0.3	Tonsillectomy;	chr1:150701208	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs12403609	ENSG00000180764.13	PIPSL	6.88	1.92e-11	3.85e-05	0.36	0.3	Tonsillectomy;	chr1:150704009	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs6694531	ENSG00000180764.13	PIPSL	6.88	1.92e-11	3.85e-05	0.36	0.3	Tonsillectomy;	chr1:150711036	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs10888388	ENSG00000180764.13	PIPSL	6.88	1.92e-11	3.85e-05	0.36	0.3	Tonsillectomy;	chr1:150714820	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.818	rs12130363	ENSG00000180764.13	PIPSL	6.88	1.92e-11	3.85e-05	0.36	0.3	Tonsillectomy;	chr1:150716120	chr10:93958191~93961540:-
HNSC	trans	rs17507216	0.628	rs28371837	ENSG00000259295.5	CSPG4P12	-6.88	1.93e-11	3.85e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82714435	chr15:85191438~85213905:+
HNSC	trans	rs7937890	0.56	rs2597194	ENSG00000236360.2	RP11-334A14.2	6.88	1.93e-11	3.87e-05	0.42	0.3	Mitochondrial DNA levels;	chr11:14475723	chr1:52993201~52993702:-
HNSC	trans	rs13177918	0.626	rs13175436	ENSG00000226396.1	RP5-1056L3.3	6.88	1.95e-11	3.89e-05	0.24	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:19608114~19608568:+
HNSC	trans	rs13014235	0.846	rs10454127	ENSG00000235105.1	RP11-329A14.1	6.88	1.96e-11	3.91e-05	0.36	0.3	Basal cell carcinoma;	chr2:201347651	chr1:48435967~48437223:+
HNSC	trans	rs9425766	0.679	rs7555067	ENSG00000213331.4	RP11-713C19.2	6.88	1.96e-11	3.93e-05	0.36	0.3	Life satisfaction;	chr1:174297504	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs6695636	ENSG00000213331.4	RP11-713C19.2	6.88	1.97e-11	3.93e-05	0.36	0.3	Life satisfaction;	chr1:174303087	chr4:187970273~187971284:+
HNSC	trans	rs7930295	0.687	rs7117500	ENSG00000236257.1	EI24P2	6.88	1.97e-11	3.94e-05	0.44	0.3	Schizophrenia;	chr11:125504232	chr1:158454198~158455273:+
HNSC	trans	rs10037055	0.636	rs13166688	ENSG00000228305.2	AC016734.2	-6.88	1.97e-11	3.94e-05	-0.42	-0.3	Migraine without aura;	chr5:177156965	chr2:63622178~63622831:-
HNSC	trans	rs7121616	0.576	rs73610509	ENSG00000241478.1	HSPA8P9	6.88	1.98e-11	3.95e-05	0.4	0.3	Breast cancer;	chr11:123048564	chr3:137880295~137882237:+
HNSC	trans	rs7824557	0.527	rs2409756	ENSG00000173295.6	FAM86B3P	-6.88	1.98e-11	3.96e-05	-0.34	-0.3	Retinal vascular caliber;	chr8:11384516	chr8:8228595~8244865:+
HNSC	trans	rs7121616	0.545	rs11600517	ENSG00000256356.1	HSPA8P5	6.87	2e-11	4e-05	0.39	0.3	Breast cancer;	chr11:123047247	chr12:4097451~4099519:+
HNSC	trans	rs3806843	0.735	rs801188	ENSG00000231043.3	AC007238.1	6.87	2.01e-11	4.01e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr2:58460292~58462032:-
HNSC	trans	rs17507216	0.681	rs28877110	ENSG00000259295.5	CSPG4P12	-6.87	2.02e-11	4.03e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82672111	chr15:85191438~85213905:+
HNSC	trans	rs6743068	0.541	rs10206231	ENSG00000235105.1	RP11-329A14.1	6.87	2.02e-11	4.03e-05	0.37	0.3	Lymphocyte percentage of white cells;	chr2:201364502	chr1:48435967~48437223:+
HNSC	trans	rs2060793	0.659	rs1839834	ENSG00000236360.2	RP11-334A14.2	6.87	2.02e-11	4.03e-05	0.39	0.3	Vitamin D levels;	chr11:14807914	chr1:52993201~52993702:-
HNSC	trans	rs76228276	0.737	rs61753724	ENSG00000260318.1	COX6CP1	6.87	2.02e-11	4.03e-05	0.81	0.3	Childhood ear infection;	chr8:99720960	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs76975870	ENSG00000260318.1	COX6CP1	6.87	2.02e-11	4.03e-05	0.81	0.3	Childhood ear infection;	chr8:99724094	chr16:11903923~11904137:-
HNSC	trans	rs7662987	0.793	rs7684735	ENSG00000228407.2	RP4-800M22.1	6.87	2.04e-11	4.07e-05	0.47	0.3	Smoking initiation;	chr4:99070355	chr1:52160261~52160600:-
HNSC	trans	rs7121616	0.576	rs7111598	ENSG00000241478.1	HSPA8P9	6.87	2.04e-11	4.07e-05	0.4	0.3	Breast cancer;	chr11:123055438	chr3:137880295~137882237:+
HNSC	trans	rs7412746	0.588	rs10305664	ENSG00000180764.13	PIPSL	-6.87	2.05e-11	4.09e-05	-0.37	-0.3	Melanoma;	chr1:150867210	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.756	rs9634246	ENSG00000228224.3	NACAP1	-6.87	2.05e-11	4.09e-05	-0.38	-0.3	Platelet count;	chr12:56640604	chr8:101361794~101372707:+
HNSC	trans	rs12439619	0.693	rs28689861	ENSG00000235370.6	DNM1P51	-6.87	2.05e-11	4.1e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82206369	chr15:84398316~84411701:-
HNSC	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-6.87	2.06e-11	4.11e-05	-0.42	-0.3	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
HNSC	trans	rs7937890	0.572	rs2597218	ENSG00000236360.2	RP11-334A14.2	6.87	2.07e-11	4.13e-05	0.43	0.3	Mitochondrial DNA levels;	chr11:14510792	chr1:52993201~52993702:-
HNSC	trans	rs8067354	0.574	rs2526354	ENSG00000187870.7	RNFT1P3	6.87	2.08e-11	4.15e-05	0.41	0.3	Hemoglobin concentration;	chr17:59899297	chr17:20743333~20754501:-
HNSC	trans	rs6743068	0.521	rs6705845	ENSG00000235105.1	RP11-329A14.1	6.87	2.09e-11	4.17e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201354316	chr1:48435967~48437223:+
HNSC	trans	rs941207	0.724	rs4788	ENSG00000228224.3	NACAP1	6.87	2.1e-11	4.18e-05	0.38	0.3	Platelet count;	chr12:56712876	chr8:101361794~101372707:+
HNSC	trans	rs6732160	0.588	rs13407363	ENSG00000236165.1	PRADC1P1	6.87	2.1e-11	4.18e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr2:73145430	chr3:36976316~36976840:+
HNSC	trans	rs6743068	0.521	rs2349074	ENSG00000235105.1	RP11-329A14.1	6.87	2.11e-11	4.2e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201357784	chr1:48435967~48437223:+
HNSC	trans	rs2060793	0.712	rs11023310	ENSG00000236360.2	RP11-334A14.2	6.87	2.11e-11	4.2e-05	0.39	0.3	Vitamin D levels;	chr11:14703717	chr1:52993201~52993702:-
HNSC	trans	rs7412746	0.621	rs72704656	ENSG00000180764.13	PIPSL	-6.87	2.12e-11	4.23e-05	-0.37	-0.3	Melanoma;	chr1:150855831	chr10:93958191~93961540:-
HNSC	trans	rs9425766	0.679	rs12085290	ENSG00000213331.4	RP11-713C19.2	-6.86	2.14e-11	4.27e-05	-0.36	-0.3	Life satisfaction;	chr1:174124699	chr4:187970273~187971284:+
HNSC	trans	rs7819412	0.936	rs7814499	ENSG00000173295.6	FAM86B3P	-6.86	2.15e-11	4.28e-05	-0.35	-0.3	Triglycerides;	chr8:11183138	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.679	rs4652237	ENSG00000213331.4	RP11-713C19.2	6.86	2.15e-11	4.29e-05	0.37	0.3	Life satisfaction;	chr1:174189718	chr4:187970273~187971284:+
HNSC	trans	rs9650657	0.589	rs12542037	ENSG00000173295.6	FAM86B3P	6.86	2.16e-11	4.3e-05	0.34	0.3	Neuroticism;	chr8:10900986	chr8:8228595~8244865:+
HNSC	trans	rs3806843	0.801	rs2531358	ENSG00000231043.3	AC007238.1	6.86	2.17e-11	4.31e-05	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr2:58460292~58462032:-
HNSC	trans	rs3849046	0.68	rs13165665	ENSG00000226666.1	HSPA9P1	-6.86	2.17e-11	4.31e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610811	chr2:221961737~221963765:+
HNSC	trans	rs7819412	0.521	rs4451268	ENSG00000173295.6	FAM86B3P	-6.86	2.17e-11	4.32e-05	-0.35	-0.3	Triglycerides;	chr8:11177350	chr8:8228595~8244865:+
HNSC	trans	rs7647973	0.961	rs4955417	ENSG00000197582.5	GPX1P1	6.86	2.17e-11	4.33e-05	0.43	0.3	Menarche (age at onset);	chr3:49260772	chrX:13378735~13379340:-
HNSC	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-6.86	2.19e-11	4.36e-05	-0.39	-0.3	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-6.86	2.2e-11	4.38e-05	-0.36	-0.3	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
HNSC	trans	rs7412746	0.634	rs7521592	ENSG00000180764.13	PIPSL	-6.86	2.22e-11	4.42e-05	-0.37	-0.3	Melanoma;	chr1:150849215	chr10:93958191~93961540:-
HNSC	trans	rs79149102	0.522	rs12441794	ENSG00000227288.3	RP5-837I24.1	6.86	2.22e-11	4.42e-05	0.55	0.3	Lung cancer;	chr15:74471808	chr1:81501794~81503468:+
HNSC	trans	rs7412746	0.658	rs10305714	ENSG00000180764.13	PIPSL	6.86	2.22e-11	4.42e-05	0.37	0.3	Melanoma;	chr1:150828179	chr10:93958191~93961540:-
HNSC	trans	rs941207	0.756	rs10876915	ENSG00000228224.3	NACAP1	-6.86	2.23e-11	4.44e-05	-0.37	-0.3	Platelet count;	chr12:56655280	chr8:101361794~101372707:+
HNSC	trans	rs296547	0.563	rs10920085	ENSG00000244144.1	RP11-757F18.3	-6.86	2.24e-11	4.45e-05	-0.35	-0.3	Celiac disease;	chr1:200995154	chr3:112185480~112185998:-
HNSC	trans	rs4970988	0.556	rs6681426	ENSG00000180764.13	PIPSL	6.86	2.24e-11	4.45e-05	0.39	0.3	Urate levels;	chr1:150614495	chr10:93958191~93961540:-
HNSC	trans	rs3849046	0.68	rs11746692	ENSG00000226666.1	HSPA9P1	-6.86	2.24e-11	4.45e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610666	chr2:221961737~221963765:+
HNSC	trans	rs9650657	0.504	rs2409724	ENSG00000173295.6	FAM86B3P	-6.86	2.26e-11	4.5e-05	-0.35	-0.3	Neuroticism;	chr8:11184133	chr8:8228595~8244865:+
HNSC	trans	rs3806843	0.657	rs2563283	ENSG00000231043.3	AC007238.1	6.86	2.26e-11	4.5e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.771	rs2563336	ENSG00000231043.3	AC007238.1	6.86	2.26e-11	4.5e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr2:58460292~58462032:-
HNSC	trans	rs2456568	0.709	rs12806128	ENSG00000276509.1	CH17-353B19.1	-6.85	2.27e-11	4.5e-05	-0.33	-0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93901806	chr1:146235806~146237807:+
HNSC	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	6.85	2.29e-11	4.54e-05	0.46	0.3	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
HNSC	trans	rs941207	0.756	rs2958153	ENSG00000228224.3	NACAP1	6.85	2.29e-11	4.55e-05	0.37	0.3	Platelet count;	chr12:56687733	chr8:101361794~101372707:+
HNSC	trans	rs79149102	0.522	rs28854237	ENSG00000227288.3	RP5-837I24.1	6.85	2.3e-11	4.56e-05	0.57	0.3	Lung cancer;	chr15:74511279	chr1:81501794~81503468:+
HNSC	trans	rs79149102	0.522	rs11857192	ENSG00000227288.3	RP5-837I24.1	6.85	2.3e-11	4.56e-05	0.57	0.3	Lung cancer;	chr15:74530103	chr1:81501794~81503468:+
HNSC	trans	rs7647973	0.848	rs4955426	ENSG00000197582.5	GPX1P1	6.85	2.3e-11	4.57e-05	0.5	0.3	Menarche (age at onset);	chr3:49106005	chrX:13378735~13379340:-
HNSC	trans	rs17507216	0.718	rs72751675	ENSG00000259295.5	CSPG4P12	-6.85	2.32e-11	4.61e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82630452	chr15:85191438~85213905:+
HNSC	trans	rs7121616	0.576	rs73610510	ENSG00000256356.1	HSPA8P5	6.85	2.33e-11	4.62e-05	0.39	0.3	Breast cancer;	chr11:123049365	chr12:4097451~4099519:+
HNSC	trans	rs9630182	0.761	rs12365099	ENSG00000257675.1	RP11-641A6.9	-6.85	2.33e-11	4.63e-05	-0.37	-0.3	Bone mineral density;	chr11:13526553	chr12:52748776~52750127:+
HNSC	trans	rs8067354	0.574	rs1292035	ENSG00000187870.7	RNFT1P3	6.85	2.34e-11	4.65e-05	0.43	0.3	Hemoglobin concentration;	chr17:59912196	chr17:20743333~20754501:-
HNSC	trans	rs13177918	0.626	rs67026795	ENSG00000226396.1	RP5-1056L3.3	6.85	2.35e-11	4.66e-05	0.24	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:19608114~19608568:+
HNSC	trans	rs7819412	0.715	rs2409727	ENSG00000173295.6	FAM86B3P	-6.85	2.36e-11	4.68e-05	-0.35	-0.3	Triglycerides;	chr8:11185727	chr8:8228595~8244865:+
HNSC	trans	rs4970988	0.526	rs6655975	ENSG00000180764.13	PIPSL	6.85	2.36e-11	4.69e-05	0.39	0.3	Urate levels;	chr1:150569652	chr10:93958191~93961540:-
HNSC	trans	rs79149102	0.522	rs59665282	ENSG00000227288.3	RP5-837I24.1	6.85	2.37e-11	4.7e-05	0.57	0.3	Lung cancer;	chr15:74572227	chr1:81501794~81503468:+
HNSC	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	6.85	2.38e-11	4.73e-05	0.34	0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
HNSC	trans	rs7412746	0.611	rs4509581	ENSG00000180764.13	PIPSL	-6.85	2.39e-11	4.75e-05	-0.37	-0.3	Melanoma;	chr1:150801989	chr10:93958191~93961540:-
HNSC	trans	rs6915893	0.74	rs9477622	ENSG00000267156.1	TPMTP1	-6.85	2.41e-11	4.78e-05	-0.35	-0.3	Intrinsic epigenetic age acceleration;	chr6:18103430	chr18:47630112~47630848:+
HNSC	trans	rs17301013	0.932	rs1754355	ENSG00000213331.4	RP11-713C19.2	-6.84	2.42e-11	4.8e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174807407	chr4:187970273~187971284:+
HNSC	trans	rs11951515	0.508	rs7705166	ENSG00000174977.8	AC026271.5	-6.84	2.43e-11	4.82e-05	-0.29	-0.3	Metabolite levels  (X-11787);	chr5:43587346	chr17:18650195~18651542:+
HNSC	trans	rs17507216	0.628	rs28607761	ENSG00000259295.5	CSPG4P12	-6.84	2.44e-11	4.83e-05	-0.46	-0.3	Excessive daytime sleepiness;	chr15:82715317	chr15:85191438~85213905:+
HNSC	trans	rs6743068	0.541	rs1966423	ENSG00000235105.1	RP11-329A14.1	6.84	2.44e-11	4.83e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201351938	chr1:48435967~48437223:+
HNSC	trans	rs1039766	1	rs268853	ENSG00000213985.4	AC078899.1	6.84	2.44e-11	4.84e-05	0.39	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr19:20257720~20259418:+
HNSC	trans	rs13177918	0.603	rs10447222	ENSG00000226396.1	RP5-1056L3.3	6.84	2.46e-11	4.88e-05	0.24	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:19608114~19608568:+
HNSC	trans	rs3806843	0.676	rs2245643	ENSG00000231043.3	AC007238.1	6.84	2.47e-11	4.89e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr2:58460292~58462032:-
HNSC	trans	rs1816752	1	rs7988810	ENSG00000224976.2	PARP4P2	-6.84	2.52e-11	4.99e-05	-0.36	-0.3	Obesity-related traits;	chr13:24444958	chr13:19349137~19407962:+
HNSC	trans	rs3806843	0.735	rs801185	ENSG00000231043.3	AC007238.1	6.84	2.54e-11	5.02e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr2:58460292~58462032:-
HNSC	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	6.84	2.57e-11	5.09e-05	0.37	0.3	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
HNSC	trans	rs6831352	0.959	rs6532795	ENSG00000233859.2	ADH5P4	6.83	2.58e-11	5.1e-05	0.34	0.3	Alcohol dependence;	chr4:99121070	chr6:65836930~65838039:-
HNSC	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-6.83	2.58e-11	5.11e-05	-0.35	-0.3	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
HNSC	trans	rs6743068	0.541	rs6714736	ENSG00000235105.1	RP11-329A14.1	-6.83	2.59e-11	5.12e-05	-0.37	-0.3	Lymphocyte percentage of white cells;	chr2:201349425	chr1:48435967~48437223:+
HNSC	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-6.83	2.6e-11	5.14e-05	-0.38	-0.3	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
HNSC	trans	rs2456568	0.548	rs4402256	ENSG00000276509.1	CH17-353B19.1	6.83	2.61e-11	5.16e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93927637	chr1:146235806~146237807:+
HNSC	trans	rs7412746	0.622	rs11552229	ENSG00000180764.13	PIPSL	-6.83	2.61e-11	5.16e-05	-0.37	-0.3	Melanoma;	chr1:150811509	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.634	rs72704658	ENSG00000180764.13	PIPSL	-6.83	2.62e-11	5.17e-05	-0.37	-0.3	Melanoma;	chr1:150860534	chr10:93958191~93961540:-
HNSC	trans	rs11638815	0.639	rs6603030	ENSG00000235370.6	DNM1P51	-6.83	2.62e-11	5.18e-05	-0.46	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82561353	chr15:84398316~84411701:-
HNSC	trans	rs7121616	0.576	rs1461495	ENSG00000241478.1	HSPA8P9	-6.83	2.63e-11	5.2e-05	-0.4	-0.3	Breast cancer;	chr11:123056136	chr3:137880295~137882237:+
HNSC	trans	rs12439619	0.846	rs62013464	ENSG00000235370.6	DNM1P51	-6.83	2.64e-11	5.22e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr15:82288250	chr15:84398316~84411701:-
HNSC	trans	rs7662987	0.793	rs12106	ENSG00000228407.2	RP4-800M22.1	6.83	2.65e-11	5.23e-05	0.47	0.3	Smoking initiation;	chr4:99072199	chr1:52160261~52160600:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-6.83	2.65e-11	5.24e-05	-0.37	-0.3	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
HNSC	trans	rs1039766	1	rs72822431	ENSG00000213985.4	AC078899.1	-6.83	2.65e-11	5.24e-05	-0.39	-0.3	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr19:20257720~20259418:+
HNSC	trans	rs2456568	0.548	rs6483280	ENSG00000276509.1	CH17-353B19.1	6.83	2.67e-11	5.28e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93928426	chr1:146235806~146237807:+
HNSC	trans	rs3806843	0.735	rs3776129	ENSG00000231043.3	AC007238.1	6.83	2.7e-11	5.33e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr2:58460292~58462032:-
HNSC	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	6.83	2.72e-11	5.37e-05	0.45	0.3	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.545	rs11600517	ENSG00000241478.1	HSPA8P9	6.83	2.72e-11	5.37e-05	0.4	0.3	Breast cancer;	chr11:123047247	chr3:137880295~137882237:+
HNSC	trans	rs6732160	0.564	rs2043096	ENSG00000236165.1	PRADC1P1	6.83	2.73e-11	5.39e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr2:73148595	chr3:36976316~36976840:+
HNSC	trans	rs17507216	0.718	rs7161977	ENSG00000259295.5	CSPG4P12	-6.83	2.74e-11	5.4e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82646782	chr15:85191438~85213905:+
HNSC	trans	rs2456568	0.548	rs10466334	ENSG00000276509.1	CH17-353B19.1	6.83	2.74e-11	5.41e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930346	chr1:146235806~146237807:+
HNSC	trans	rs7819412	0.749	rs11991118	ENSG00000173295.6	FAM86B3P	6.82	2.75e-11	5.43e-05	0.34	0.3	Triglycerides;	chr8:11081763	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.611	rs16827671	ENSG00000180764.13	PIPSL	-6.82	2.78e-11	5.48e-05	-0.37	-0.3	Melanoma;	chr1:150766283	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.505	rs17782554	ENSG00000173295.6	FAM86B3P	-6.82	2.78e-11	5.49e-05	-0.34	-0.3	Triglycerides;	chr8:11164596	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-6.82	2.8e-11	5.52e-05	-0.33	-0.3	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
HNSC	trans	rs76228276	0.737	rs2084554	ENSG00000260318.1	COX6CP1	6.82	2.8e-11	5.53e-05	0.83	0.3	Childhood ear infection;	chr8:99685142	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs2100220	ENSG00000260318.1	COX6CP1	6.82	2.8e-11	5.53e-05	0.83	0.3	Childhood ear infection;	chr8:99685234	chr16:11903923~11904137:-
HNSC	trans	rs877636	0.74	rs705698	ENSG00000234513.1	AC073072.7	6.82	2.81e-11	5.54e-05	0.36	0.3	Cognitive function;	chr12:55990903	chr7:22773646~22773993:-
HNSC	trans	rs6915893	0.74	rs12189652	ENSG00000267156.1	TPMTP1	6.82	2.82e-11	5.56e-05	0.35	0.3	Intrinsic epigenetic age acceleration;	chr6:18103080	chr18:47630112~47630848:+
HNSC	trans	rs7121616	0.576	rs60405069	ENSG00000241478.1	HSPA8P9	6.82	2.83e-11	5.57e-05	0.4	0.3	Breast cancer;	chr11:123043616	chr3:137880295~137882237:+
HNSC	trans	rs3806843	0.735	rs2563306	ENSG00000231043.3	AC007238.1	6.82	2.83e-11	5.58e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.735	rs813897	ENSG00000231043.3	AC007238.1	6.82	2.83e-11	5.58e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.676	rs2563304	ENSG00000231043.3	AC007238.1	6.82	2.83e-11	5.58e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr2:58460292~58462032:-
HNSC	trans	rs7412746	0.658	rs3768015	ENSG00000180764.13	PIPSL	-6.82	2.84e-11	5.59e-05	-0.37	-0.3	Melanoma;	chr1:150840478	chr10:93958191~93961540:-
HNSC	trans	rs9425766	0.64	rs10912734	ENSG00000213331.4	RP11-713C19.2	6.82	2.84e-11	5.59e-05	0.36	0.3	Life satisfaction;	chr1:174141977	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs57919173	ENSG00000213331.4	RP11-713C19.2	6.82	2.84e-11	5.59e-05	0.36	0.3	Life satisfaction;	chr1:174159856	chr4:187970273~187971284:+
HNSC	trans	rs941207	0.789	rs2958145	ENSG00000228224.3	NACAP1	-6.82	2.88e-11	5.67e-05	-0.37	-0.3	Platelet count;	chr12:56662290	chr8:101361794~101372707:+
HNSC	trans	rs8067354	0.574	rs2526353	ENSG00000187870.7	RNFT1P3	6.82	2.88e-11	5.67e-05	0.43	0.3	Hemoglobin concentration;	chr17:59911246	chr17:20743333~20754501:-
HNSC	trans	rs7121616	0.576	rs7949127	ENSG00000241478.1	HSPA8P9	6.81	2.95e-11	5.8e-05	0.4	0.3	Breast cancer;	chr11:123057408	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.576	rs7949220	ENSG00000241478.1	HSPA8P9	6.81	2.95e-11	5.8e-05	0.4	0.3	Breast cancer;	chr11:123057418	chr3:137880295~137882237:+
HNSC	trans	rs6743068	0.521	rs6710974	ENSG00000235105.1	RP11-329A14.1	6.81	2.97e-11	5.84e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201348659	chr1:48435967~48437223:+
HNSC	trans	rs1563304	1	rs1563304	ENSG00000264070.1	DND1P1	6.81	2.97e-11	5.85e-05	0.45	0.3	Neuroticism;	chr17:46797087	chr17:45585871~45586929:+
HNSC	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-6.81	2.98e-11	5.86e-05	-0.38	-0.3	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
HNSC	trans	rs8177876	0.749	rs11537	ENSG00000224837.1	GCSHP5	6.81	3e-11	5.89e-05	0.56	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr1:168055901~168056422:-
HNSC	trans	rs1039766	0.778	rs13399786	ENSG00000213985.4	AC078899.1	-6.81	3e-11	5.9e-05	-0.41	-0.3	Lung adenocarcinoma;Lung cancer;	chr2:65283571	chr19:20257720~20259418:+
HNSC	trans	rs11220082	0.644	rs12577961	ENSG00000236257.1	EI24P2	-6.81	3e-11	5.9e-05	-0.37	-0.3	Schizophrenia;	chr11:125438943	chr1:158454198~158455273:+
HNSC	trans	rs7121616	0.576	rs1841580	ENSG00000256356.1	HSPA8P5	6.81	3.01e-11	5.91e-05	0.38	0.3	Breast cancer;	chr11:123055956	chr12:4097451~4099519:+
HNSC	trans	rs9650657	0.617	rs7814795	ENSG00000173295.6	FAM86B3P	-6.81	3.02e-11	5.94e-05	-0.33	-0.3	Neuroticism;	chr8:10661775	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.628	rs4513065	ENSG00000259295.5	CSPG4P12	-6.81	3.05e-11	6e-05	-0.46	-0.3	Excessive daytime sleepiness;	chr15:82712096	chr15:85191438~85213905:+
HNSC	trans	rs10037055	0.853	rs10476219	ENSG00000228305.2	AC016734.2	-6.81	3.08e-11	6.05e-05	-0.37	-0.3	Migraine without aura;	chr5:177201547	chr2:63622178~63622831:-
HNSC	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	6.81	3.09e-11	6.07e-05	0.37	0.3	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
HNSC	trans	rs7824557	0.843	rs2572418	ENSG00000173295.6	FAM86B3P	-6.81	3.09e-11	6.07e-05	-0.33	-0.3	Retinal vascular caliber;	chr8:11255580	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.546	rs13214023	ENSG00000253570.1	RNF5P1	-6.81	3.1e-11	6.09e-05	-0.64	-0.3	Depression;	chr6:28364364	chr8:38600661~38601200:-
HNSC	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	6.81	3.11e-11	6.1e-05	0.38	0.3	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
HNSC	trans	rs9630182	0.965	rs10766102	ENSG00000257675.1	RP11-641A6.9	-6.8	3.11e-11	6.11e-05	-0.36	-0.3	Bone mineral density;	chr11:13595819	chr12:52748776~52750127:+
HNSC	trans	rs7412746	0.658	rs6660845	ENSG00000180764.13	PIPSL	-6.8	3.13e-11	6.15e-05	-0.37	-0.3	Melanoma;	chr1:150868590	chr10:93958191~93961540:-
HNSC	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	6.8	3.14e-11	6.16e-05	0.37	0.3	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	6.8	3.14e-11	6.16e-05	0.37	0.3	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
HNSC	trans	rs2288327	0.915	rs12614435	ENSG00000269800.1	PLEKHA3P1	6.8	3.14e-11	6.17e-05	0.39	0.3	Atrial fibrillation;	chr2:178624999	chr19:41521043~41521989:-
HNSC	trans	rs3806843	0.868	rs2531349	ENSG00000231043.3	AC007238.1	6.8	3.15e-11	6.18e-05	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr2:58460292~58462032:-
HNSC	trans	rs1039766	1	rs268861	ENSG00000213985.4	AC078899.1	6.8	3.15e-11	6.19e-05	0.39	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr19:20257720~20259418:+
HNSC	trans	rs1039766	1	rs268862	ENSG00000213985.4	AC078899.1	6.8	3.15e-11	6.19e-05	0.39	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr19:20257720~20259418:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-6.8	3.16e-11	6.2e-05	-0.33	-0.3	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
HNSC	trans	rs7647973	0.848	rs4955411	ENSG00000197582.5	GPX1P1	6.8	3.17e-11	6.22e-05	0.46	0.3	Menarche (age at onset);	chr3:49107871	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.848	rs4292260	ENSG00000197582.5	GPX1P1	6.8	3.17e-11	6.22e-05	0.46	0.3	Menarche (age at onset);	chr3:49111457	chrX:13378735~13379340:-
HNSC	trans	rs9425766	0.679	rs6681618	ENSG00000213331.4	RP11-713C19.2	-6.8	3.18e-11	6.24e-05	-0.36	-0.3	Life satisfaction;	chr1:174201203	chr4:187970273~187971284:+
HNSC	trans	rs7647973	0.71	rs2029591	ENSG00000197582.5	GPX1P1	-6.8	3.19e-11	6.25e-05	-0.5	-0.3	Menarche (age at onset);	chr3:49609548	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.712	rs6490932	ENSG00000224976.2	PARP4P2	-6.8	3.19e-11	6.26e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443313	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.713	rs7336357	ENSG00000224976.2	PARP4P2	-6.8	3.19e-11	6.26e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443452	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.683	rs7330532	ENSG00000224976.2	PARP4P2	-6.8	3.19e-11	6.26e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443453	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.59	rs61947036	ENSG00000224976.2	PARP4P2	-6.8	3.19e-11	6.26e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443544	chr13:19349137~19407962:+
HNSC	trans	rs1933488	0.898	rs11155895	ENSG00000278974.1	RP11-756P10.6	-6.8	3.2e-11	6.28e-05	-0.4	-0.3	Prostate cancer;	chr6:153100410	chr4:188740507~188741281:-
HNSC	trans	rs4930561	0.765	rs1894204	ENSG00000155070.8	UNC93B2	-6.8	3.2e-11	6.28e-05	-0.35	-0.3	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr7:6855485~6859830:-
HNSC	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	6.8	3.2e-11	6.28e-05	0.37	0.3	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	6.8	3.2e-11	6.28e-05	0.37	0.3	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
HNSC	trans	rs916888	0.61	rs142167	ENSG00000280022.1	RP11-707O23.1	-6.8	3.23e-11	6.33e-05	-0.33	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45592621~45593369:+
HNSC	trans	rs3779195	0.584	rs1688605	ENSG00000225169.1	BRI3P1	-6.8	3.26e-11	6.39e-05	-0.5	-0.3	Sex hormone-binding globulin levels;	chr7:98410534	chr1:100213293~100213670:+
HNSC	trans	rs7121616	0.576	rs7942164	ENSG00000256356.1	HSPA8P5	6.8	3.27e-11	6.4e-05	0.39	0.3	Breast cancer;	chr11:123050459	chr12:4097451~4099519:+
HNSC	trans	rs7121616	0.576	rs56131320	ENSG00000256356.1	HSPA8P5	6.8	3.27e-11	6.4e-05	0.39	0.3	Breast cancer;	chr11:123053058	chr12:4097451~4099519:+
HNSC	trans	rs7121616	0.576	rs7929869	ENSG00000256356.1	HSPA8P5	6.8	3.27e-11	6.4e-05	0.39	0.3	Breast cancer;	chr11:123054435	chr12:4097451~4099519:+
HNSC	trans	rs7824557	0.564	rs2736295	ENSG00000173295.6	FAM86B3P	6.8	3.27e-11	6.4e-05	0.33	0.3	Retinal vascular caliber;	chr8:11377271	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-6.8	3.27e-11	6.41e-05	-0.37	-0.3	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-6.8	3.27e-11	6.41e-05	-0.37	-0.3	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
HNSC	trans	rs7819412	0.745	rs6601569	ENSG00000173295.6	FAM86B3P	-6.8	3.28e-11	6.42e-05	-0.35	-0.3	Triglycerides;	chr8:11216069	chr8:8228595~8244865:+
HNSC	trans	rs9425766	0.679	rs2064149	ENSG00000213331.4	RP11-713C19.2	6.8	3.29e-11	6.43e-05	0.36	0.3	Life satisfaction;	chr1:174255856	chr4:187970273~187971284:+
HNSC	trans	rs673253	0.686	rs596522	ENSG00000231007.5	CDC20P1	6.8	3.29e-11	6.44e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr1:43600753	chr9:87011652~87013151:+
HNSC	trans	rs7121616	0.576	rs7948948	ENSG00000241478.1	HSPA8P9	6.79	3.33e-11	6.51e-05	0.4	0.3	Breast cancer;	chr11:123057467	chr3:137880295~137882237:+
HNSC	trans	rs6743068	0.541	rs6435081	ENSG00000235105.1	RP11-329A14.1	6.79	3.34e-11	6.54e-05	0.37	0.3	Lymphocyte percentage of white cells;	chr2:201355900	chr1:48435967~48437223:+
HNSC	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-6.79	3.37e-11	6.59e-05	-0.37	-0.3	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
HNSC	trans	rs7412746	0.611	rs111905669	ENSG00000180764.13	PIPSL	-6.79	3.38e-11	6.6e-05	-0.37	-0.3	Melanoma;	chr1:150805089	chr10:93958191~93961540:-
HNSC	trans	rs1816752	0.774	rs55888616	ENSG00000224976.2	PARP4P2	-6.79	3.38e-11	6.62e-05	-0.35	-0.3	Obesity-related traits;	chr13:24441954	chr13:19349137~19407962:+
HNSC	trans	rs11951515	0.508	rs1366410	ENSG00000174977.8	AC026271.5	-6.79	3.4e-11	6.65e-05	-0.28	-0.3	Metabolite levels  (X-11787);	chr5:43601508	chr17:18650195~18651542:+
HNSC	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-6.79	3.41e-11	6.67e-05	-0.37	-0.3	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-6.79	3.41e-11	6.67e-05	-0.37	-0.3	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-6.79	3.41e-11	6.67e-05	-0.37	-0.3	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-6.79	3.41e-11	6.67e-05	-0.37	-0.3	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-6.79	3.41e-11	6.67e-05	-0.37	-0.3	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
HNSC	trans	rs2456568	0.508	rs1607403	ENSG00000276509.1	CH17-353B19.1	6.79	3.45e-11	6.75e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93927348	chr1:146235806~146237807:+
HNSC	trans	rs3808502	0.527	rs2736374	ENSG00000173295.6	FAM86B3P	-6.79	3.47e-11	6.78e-05	-0.36	-0.3	Neuroticism;	chr8:11256319	chr8:8228595~8244865:+
HNSC	trans	rs7121616	0.576	rs11600486	ENSG00000241478.1	HSPA8P9	6.79	3.47e-11	6.78e-05	0.4	0.3	Breast cancer;	chr11:123047060	chr3:137880295~137882237:+
HNSC	trans	rs1933488	0.804	rs9397586	ENSG00000278974.1	RP11-756P10.6	-6.79	3.48e-11	6.78e-05	-0.4	-0.3	Prostate cancer;	chr6:153093152	chr4:188740507~188741281:-
HNSC	trans	rs714543	0.811	rs13238404	ENSG00000226038.5	PPIAP21	6.79	3.48e-11	6.78e-05	0.36	0.3	Plateletcrit;	chr7:44811812	chr20:43230760~43231260:+
HNSC	trans	rs8067354	0.527	rs1292039	ENSG00000187870.7	RNFT1P3	6.79	3.48e-11	6.79e-05	0.42	0.3	Hemoglobin concentration;	chr17:59897552	chr17:20743333~20754501:-
HNSC	trans	rs13177918	0.603	rs13175992	ENSG00000226396.1	RP5-1056L3.3	6.79	3.51e-11	6.84e-05	0.23	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:19608114~19608568:+
HNSC	trans	rs7819412	1	rs2409722	ENSG00000173295.6	FAM86B3P	-6.79	3.51e-11	6.85e-05	-0.35	-0.3	Triglycerides;	chr8:11182307	chr8:8228595~8244865:+
HNSC	trans	rs1039766	1	rs12104748	ENSG00000213985.4	AC078899.1	-6.78	3.53e-11	6.88e-05	-0.39	-0.3	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr19:20257720~20259418:+
HNSC	trans	rs2456568	0.548	rs7105031	ENSG00000276509.1	CH17-353B19.1	6.78	3.54e-11	6.89e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93928041	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.531	rs7105060	ENSG00000276509.1	CH17-353B19.1	6.78	3.54e-11	6.89e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93928102	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.548	rs6483281	ENSG00000276509.1	CH17-353B19.1	6.78	3.54e-11	6.89e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93928674	chr1:146235806~146237807:+
HNSC	trans	rs13177918	0.626	rs13170300	ENSG00000226396.1	RP5-1056L3.3	6.78	3.55e-11	6.93e-05	0.23	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:19608114~19608568:+
HNSC	trans	rs6743068	0.541	rs6737085	ENSG00000235105.1	RP11-329A14.1	6.78	3.56e-11	6.93e-05	0.37	0.3	Lymphocyte percentage of white cells;	chr2:201356718	chr1:48435967~48437223:+
HNSC	trans	rs3849046	0.967	rs154073	ENSG00000226666.1	HSPA9P1	6.78	3.58e-11	6.98e-05	0.31	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138522378	chr2:221961737~221963765:+
HNSC	trans	rs7121616	0.576	rs60405069	ENSG00000256356.1	HSPA8P5	6.78	3.59e-11	7e-05	0.39	0.3	Breast cancer;	chr11:123043616	chr12:4097451~4099519:+
HNSC	trans	rs1816752	0.806	rs3816218	ENSG00000224976.2	PARP4P2	-6.78	3.59e-11	7e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443033	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.666	rs7994022	ENSG00000224976.2	PARP4P2	-6.78	3.59e-11	7e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443092	chr13:19349137~19407962:+
HNSC	trans	rs6743068	0.541	rs10178982	ENSG00000235105.1	RP11-329A14.1	6.78	3.6e-11	7.01e-05	0.37	0.3	Lymphocyte percentage of white cells;	chr2:201362917	chr1:48435967~48437223:+
HNSC	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-6.78	3.64e-11	7.08e-05	-0.35	-0.3	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
HNSC	trans	rs6981523	0.5	rs4412337	ENSG00000173295.6	FAM86B3P	6.78	3.65e-11	7.1e-05	0.36	0.3	Neuroticism;	chr8:11214511	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.731	rs7800001	ENSG00000186940.6	CHCHD2P9	-6.78	3.65e-11	7.11e-05	-0.41	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56004317	chr9:79391304~79391759:+
HNSC	trans	rs2456568	0.548	rs4753113	ENSG00000276509.1	CH17-353B19.1	6.78	3.66e-11	7.13e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93927808	chr1:146235806~146237807:+
HNSC	trans	rs4948102	0.731	rs4689	ENSG00000186940.6	CHCHD2P9	-6.78	3.67e-11	7.15e-05	-0.42	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr9:79391304~79391759:+
HNSC	trans	rs3806843	0.735	rs2530240	ENSG00000231043.3	AC007238.1	6.78	3.7e-11	7.2e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.735	rs801189	ENSG00000231043.3	AC007238.1	6.78	3.7e-11	7.2e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.706	rs1089305	ENSG00000231043.3	AC007238.1	6.78	3.7e-11	7.2e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr2:58460292~58462032:-
HNSC	trans	rs8177876	0.642	rs10514513	ENSG00000224837.1	GCSHP5	6.78	3.72e-11	7.24e-05	0.5	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr1:168055901~168056422:-
HNSC	trans	rs17507216	0.609	rs1431716	ENSG00000259295.5	CSPG4P12	-6.78	3.72e-11	7.24e-05	-0.47	-0.3	Excessive daytime sleepiness;	chr15:82676180	chr15:85191438~85213905:+
HNSC	trans	rs1933488	0.931	rs3870364	ENSG00000278974.1	RP11-756P10.6	-6.78	3.73e-11	7.25e-05	-0.4	-0.3	Prostate cancer;	chr6:153105544	chr4:188740507~188741281:-
HNSC	trans	rs1816752	0.805	rs61614647	ENSG00000224976.2	PARP4P2	-6.78	3.74e-11	7.27e-05	-0.35	-0.3	Obesity-related traits;	chr13:24441829	chr13:19349137~19407962:+
HNSC	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-6.78	3.74e-11	7.27e-05	-0.35	-0.3	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
HNSC	trans	rs3806843	0.706	rs2563302	ENSG00000231043.3	AC007238.1	6.78	3.74e-11	7.27e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr2:58460292~58462032:-
HNSC	trans	rs11638815	0.689	rs1267656	ENSG00000235370.6	DNM1P51	-6.78	3.75e-11	7.3e-05	-0.46	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82551349	chr15:84398316~84411701:-
HNSC	trans	rs2456568	0.548	rs10765647	ENSG00000276509.1	CH17-353B19.1	6.77	3.76e-11	7.31e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93929293	chr1:146235806~146237807:+
HNSC	trans	rs2456568	0.57	rs1827932	ENSG00000276509.1	CH17-353B19.1	6.77	3.76e-11	7.31e-05	0.34	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930153	chr1:146235806~146237807:+
HNSC	trans	rs12439619	0.846	rs62010071	ENSG00000235370.6	DNM1P51	-6.77	3.78e-11	7.35e-05	-0.43	-0.3	Intelligence (multi-trait analysis);	chr15:82289442	chr15:84398316~84411701:-
HNSC	trans	rs3806843	0.735	rs2563314	ENSG00000231043.3	AC007238.1	6.77	3.82e-11	7.41e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr2:58460292~58462032:-
HNSC	trans	rs7121616	0.576	rs7949127	ENSG00000256356.1	HSPA8P5	6.77	3.82e-11	7.43e-05	0.39	0.3	Breast cancer;	chr11:123057408	chr12:4097451~4099519:+
HNSC	trans	rs7121616	0.576	rs7949220	ENSG00000256356.1	HSPA8P5	6.77	3.82e-11	7.43e-05	0.39	0.3	Breast cancer;	chr11:123057418	chr12:4097451~4099519:+
HNSC	trans	rs8067354	0.574	rs1296279	ENSG00000187870.7	RNFT1P3	6.77	3.87e-11	7.51e-05	0.42	0.3	Hemoglobin concentration;	chr17:59888370	chr17:20743333~20754501:-
HNSC	trans	rs12439619	0.693	rs8034801	ENSG00000235370.6	DNM1P51	-6.77	3.9e-11	7.57e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82183996	chr15:84398316~84411701:-
HNSC	trans	rs13177918	0.626	rs3819332	ENSG00000226396.1	RP5-1056L3.3	6.77	3.94e-11	7.65e-05	0.23	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:19608114~19608568:+
HNSC	trans	rs9650657	0.538	rs6984496	ENSG00000173295.6	FAM86B3P	-6.77	3.97e-11	7.7e-05	-0.32	-0.3	Neuroticism;	chr8:10938583	chr8:8228595~8244865:+
HNSC	trans	rs10037055	0.812	rs11949435	ENSG00000228305.2	AC016734.2	6.77	4e-11	7.75e-05	0.37	0.3	Migraine without aura;	chr5:177287931	chr2:63622178~63622831:-
HNSC	trans	rs11220082	0.666	rs12789687	ENSG00000236257.1	EI24P2	-6.76	4.04e-11	7.83e-05	-0.35	-0.3	Schizophrenia;	chr11:125461254	chr1:158454198~158455273:+
HNSC	trans	rs864643	0.678	rs1768206	ENSG00000183298.5	RP11-556K13.1	6.76	4.04e-11	7.83e-05	0.48	0.3	Attention deficit hyperactivity disorder;	chr3:39480342	chr1:101786340~101787219:-
HNSC	trans	rs8067354	0.574	rs1292033	ENSG00000187870.7	RNFT1P3	6.76	4.06e-11	7.88e-05	0.42	0.3	Hemoglobin concentration;	chr17:59913236	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.574	rs1291947	ENSG00000187870.7	RNFT1P3	6.76	4.06e-11	7.88e-05	0.42	0.3	Hemoglobin concentration;	chr17:59918975	chr17:20743333~20754501:-
HNSC	trans	rs4276421	0.688	rs13436334	ENSG00000231752.4	EMBP1	6.76	4.09e-11	7.92e-05	0.38	0.3	P wave duration;	chr5:46243759	chr1:121519112~121571892:+
HNSC	trans	rs941207	0.756	rs2950388	ENSG00000228224.3	NACAP1	-6.76	4.11e-11	7.97e-05	-0.37	-0.3	Platelet count;	chr12:56639569	chr8:101361794~101372707:+
HNSC	trans	rs1933488	0.931	rs3870365	ENSG00000278974.1	RP11-756P10.6	-6.76	4.12e-11	7.98e-05	-0.4	-0.3	Prostate cancer;	chr6:153105797	chr4:188740507~188741281:-
HNSC	trans	rs4276421	0.688	rs4975961	ENSG00000231752.4	EMBP1	6.76	4.13e-11	8e-05	0.38	0.3	P wave duration;	chr5:46247615	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-6.76	4.18e-11	8.09e-05	-0.37	-0.3	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-6.76	4.18e-11	8.09e-05	-0.37	-0.3	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-6.76	4.18e-11	8.09e-05	-0.37	-0.3	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
HNSC	trans	rs7121616	0.576	rs1064585	ENSG00000241478.1	HSPA8P9	6.76	4.21e-11	8.15e-05	0.4	0.3	Breast cancer;	chr11:123058699	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.576	rs11218967	ENSG00000256356.1	HSPA8P5	6.75	4.27e-11	8.26e-05	0.36	0.3	Breast cancer;	chr11:123087551	chr12:4097451~4099519:+
HNSC	trans	rs17301013	0.932	rs2987869	ENSG00000213331.4	RP11-713C19.2	-6.75	4.28e-11	8.27e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174820269	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.827	rs1793309	ENSG00000213331.4	RP11-713C19.2	-6.75	4.28e-11	8.27e-05	-0.36	-0.3	Systemic lupus erythematosus;	chr1:174826199	chr4:187970273~187971284:+
HNSC	trans	rs1039766	0.929	rs55843720	ENSG00000213985.4	AC078899.1	6.75	4.28e-11	8.28e-05	0.39	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr19:20257720~20259418:+
HNSC	trans	rs1816752	0.819	rs7400583	ENSG00000224976.2	PARP4P2	-6.75	4.31e-11	8.33e-05	-0.35	-0.3	Obesity-related traits;	chr13:24415916	chr13:19349137~19407962:+
HNSC	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	-6.75	4.31e-11	8.34e-05	-0.34	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
HNSC	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-6.75	4.33e-11	8.37e-05	-0.37	-0.3	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
HNSC	trans	rs3849046	0.967	rs154072	ENSG00000226666.1	HSPA9P1	6.75	4.36e-11	8.42e-05	0.31	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138520684	chr2:221961737~221963765:+
HNSC	trans	rs7412746	0.658	rs11589458	ENSG00000180764.13	PIPSL	-6.75	4.36e-11	8.43e-05	-0.37	-0.3	Melanoma;	chr1:150820140	chr10:93958191~93961540:-
HNSC	trans	rs17301013	0.9	rs1754351	ENSG00000213331.4	RP11-713C19.2	-6.75	4.4e-11	8.49e-05	-0.35	-0.3	Systemic lupus erythematosus;	chr1:174762458	chr4:187970273~187971284:+
HNSC	trans	rs7121616	0.545	rs7109348	ENSG00000241478.1	HSPA8P9	6.75	4.4e-11	8.51e-05	0.4	0.3	Breast cancer;	chr11:123056555	chr3:137880295~137882237:+
HNSC	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	6.75	4.41e-11	8.52e-05	0.36	0.3	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
HNSC	trans	rs7824557	0.547	rs2409745	ENSG00000173295.6	FAM86B3P	6.75	4.42e-11	8.53e-05	0.34	0.3	Retinal vascular caliber;	chr8:11219126	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-6.75	4.42e-11	8.54e-05	-0.32	-0.3	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-6.75	4.42e-11	8.54e-05	-0.32	-0.3	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
HNSC	trans	rs7647973	0.71	rs1491983	ENSG00000197582.5	GPX1P1	6.75	4.44e-11	8.58e-05	0.5	0.3	Menarche (age at onset);	chr3:49602370	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.677	rs11130211	ENSG00000197582.5	GPX1P1	6.75	4.44e-11	8.58e-05	0.5	0.3	Menarche (age at onset);	chr3:49607776	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.667	rs11721148	ENSG00000197582.5	GPX1P1	6.75	4.44e-11	8.58e-05	0.5	0.3	Menarche (age at onset);	chr3:49609236	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.905	rs7995909	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24439159	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs6490927	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24439802	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs6490928	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24439921	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs6490929	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24440114	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs3825449	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24440303	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs7998797	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24440850	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs7981337	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24440915	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs7981480	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24440966	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.837	rs4769355	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24441059	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs4770680	ENSG00000224976.2	PARP4P2	-6.75	4.45e-11	8.58e-05	-0.35	-0.3	Obesity-related traits;	chr13:24441110	chr13:19349137~19407962:+
HNSC	trans	rs9425766	0.523	rs6668959	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174088488	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs12563301	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174090924	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.665	rs7553788	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174093773	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs6682017	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174097809	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.655	rs2145376	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174098911	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs6663794	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174099791	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs6658769	ENSG00000213331.4	RP11-713C19.2	6.75	4.47e-11	8.62e-05	0.36	0.3	Life satisfaction;	chr1:174100843	chr4:187970273~187971284:+
HNSC	trans	rs1816752	0.776	rs7998843	ENSG00000224976.2	PARP4P2	-6.75	4.47e-11	8.63e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443147	chr13:19349137~19407962:+
HNSC	trans	rs6831352	0.734	rs1154400	ENSG00000233859.2	ADH5P4	-6.75	4.48e-11	8.64e-05	-0.35	-0.3	Alcohol dependence;	chr4:99088859	chr6:65836930~65838039:-
HNSC	trans	rs7873102	0.967	rs943941	ENSG00000229007.1	EXOSC3P1	-6.75	4.51e-11	8.7e-05	-0.36	-0.3	Brain structure;	chr9:38058305	chr21:32496812~32497311:+
HNSC	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	6.75	4.52e-11	8.72e-05	0.35	0.3	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
HNSC	trans	rs9733	0.519	rs11587444	ENSG00000180764.13	PIPSL	-6.74	4.56e-11	8.78e-05	-0.36	-0.3	Tonsillectomy;	chr1:150750368	chr10:93958191~93961540:-
HNSC	trans	rs6743068	0.522	rs6757783	ENSG00000235105.1	RP11-329A14.1	6.74	4.57e-11	8.81e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201335101	chr1:48435967~48437223:+
HNSC	trans	rs6424115	0.83	rs2502999	ENSG00000228217.1	AL390877.1	-6.74	4.59e-11	8.85e-05	-0.36	-0.3	Immature fraction of reticulocytes;	chr1:23871831	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.793	rs2502998	ENSG00000228217.1	AL390877.1	-6.74	4.59e-11	8.85e-05	-0.36	-0.3	Immature fraction of reticulocytes;	chr1:23871837	chr1:117778087~117778506:-
HNSC	trans	rs7412746	0.634	rs12409208	ENSG00000180764.13	PIPSL	-6.74	4.6e-11	8.85e-05	-0.36	-0.3	Melanoma;	chr1:150887579	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.658	rs12410394	ENSG00000180764.13	PIPSL	-6.74	4.6e-11	8.85e-05	-0.36	-0.3	Melanoma;	chr1:150887710	chr10:93958191~93961540:-
HNSC	trans	rs2288327	0.915	rs35112591	ENSG00000269800.1	PLEKHA3P1	6.74	4.6e-11	8.87e-05	0.4	0.3	Atrial fibrillation;	chr2:178678490	chr19:41521043~41521989:-
HNSC	trans	rs1039766	1	rs10116	ENSG00000213985.4	AC078899.1	6.74	4.62e-11	8.9e-05	0.38	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr19:20257720~20259418:+
HNSC	trans	rs1039766	1	rs268878	ENSG00000213985.4	AC078899.1	6.74	4.62e-11	8.9e-05	0.38	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr19:20257720~20259418:+
HNSC	trans	rs1039766	0.929	rs268881	ENSG00000213985.4	AC078899.1	6.74	4.62e-11	8.9e-05	0.38	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr19:20257720~20259418:+
HNSC	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-6.74	4.65e-11	8.95e-05	-0.37	-0.3	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-6.74	4.65e-11	8.95e-05	-0.37	-0.3	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
HNSC	trans	rs4948102	0.655	rs4947533	ENSG00000186940.6	CHCHD2P9	-6.74	4.66e-11	8.97e-05	-0.42	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr9:79391304~79391759:+
HNSC	trans	rs8067354	0.574	rs1292050	ENSG00000187870.7	RNFT1P3	6.74	4.69e-11	9.01e-05	0.41	0.3	Hemoglobin concentration;	chr17:59887808	chr17:20743333~20754501:-
HNSC	trans	rs453301	0.571	rs330057	ENSG00000173295.6	FAM86B3P	-6.74	4.69e-11	9.01e-05	-0.33	-0.3	Joint mobility (Beighton score);	chr8:9232283	chr8:8228595~8244865:+
HNSC	trans	rs9329221	0.905	rs10283145	ENSG00000173295.6	FAM86B3P	-6.74	4.76e-11	9.14e-05	-0.33	-0.3	Neuroticism;	chr8:10383901	chr8:8228595~8244865:+
HNSC	trans	rs11638815	0.668	rs1877242	ENSG00000235370.6	DNM1P51	6.74	4.76e-11	9.15e-05	0.38	0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82728706	chr15:84398316~84411701:-
HNSC	trans	rs9630182	1	rs9630182	ENSG00000257675.1	RP11-641A6.9	6.74	4.76e-11	9.15e-05	0.36	0.3	Bone mineral density;	chr11:13598625	chr12:52748776~52750127:+
HNSC	trans	rs12439619	0.693	rs17269819	ENSG00000235370.6	DNM1P51	-6.74	4.77e-11	9.17e-05	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82174660	chr15:84398316~84411701:-
HNSC	trans	rs17507216	1	rs17356118	ENSG00000235370.6	DNM1P51	-6.74	4.79e-11	9.19e-05	-0.42	-0.3	Excessive daytime sleepiness;	chr15:82569149	chr15:84398316~84411701:-
HNSC	trans	rs11220082	0.666	rs12223186	ENSG00000236257.1	EI24P2	-6.74	4.82e-11	9.26e-05	-0.35	-0.3	Schizophrenia;	chr11:125461743	chr1:158454198~158455273:+
HNSC	trans	rs4930561	0.739	rs10896303	ENSG00000155070.8	UNC93B2	-6.74	4.82e-11	9.26e-05	-0.34	-0.3	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr7:6855485~6859830:-
HNSC	trans	rs4930561	0.739	rs12225316	ENSG00000155070.8	UNC93B2	-6.74	4.82e-11	9.26e-05	-0.34	-0.3	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr7:6855485~6859830:-
HNSC	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-6.74	4.82e-11	9.26e-05	-0.37	-0.3	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
HNSC	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-6.73	4.84e-11	9.3e-05	-0.37	-0.3	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
HNSC	trans	rs17507216	0.628	rs4627310	ENSG00000259295.5	CSPG4P12	-6.73	4.85e-11	9.32e-05	-0.46	-0.3	Excessive daytime sleepiness;	chr15:82708330	chr15:85191438~85213905:+
HNSC	trans	rs3849046	0.817	rs4835690	ENSG00000226666.1	HSPA9P1	6.73	4.86e-11	9.32e-05	0.32	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138594081	chr2:221961737~221963765:+
HNSC	trans	rs7121616	0.576	rs1841580	ENSG00000241478.1	HSPA8P9	6.73	4.86e-11	9.33e-05	0.4	0.3	Breast cancer;	chr11:123055956	chr3:137880295~137882237:+
HNSC	trans	rs10037055	0.853	rs10056008	ENSG00000228305.2	AC016734.2	-6.73	4.89e-11	9.38e-05	-0.37	-0.3	Migraine without aura;	chr5:177194147	chr2:63622178~63622831:-
HNSC	trans	rs6424115	0.83	rs2503000	ENSG00000228217.1	AL390877.1	-6.73	4.91e-11	9.41e-05	-0.36	-0.3	Immature fraction of reticulocytes;	chr1:23871408	chr1:117778087~117778506:-
HNSC	trans	rs714543	0.61	rs4724320	ENSG00000226038.5	PPIAP21	-6.73	4.95e-11	9.5e-05	-0.36	-0.3	Plateletcrit;	chr7:44775735	chr20:43230760~43231260:+
HNSC	trans	rs7647973	0.71	rs1532204	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49572044	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs6797299	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49572361	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs11130207	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49574233	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs11130208	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49578191	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs6446284	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49579564	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs9869120	ENSG00000197582.5	GPX1P1	6.73	4.98e-11	9.54e-05	0.5	0.3	Menarche (age at onset);	chr3:49586632	chrX:13378735~13379340:-
HNSC	trans	rs2288327	0.915	rs62178972	ENSG00000269800.1	PLEKHA3P1	6.73	5.01e-11	9.59e-05	0.41	0.3	Atrial fibrillation;	chr2:178676885	chr19:41521043~41521989:-
HNSC	trans	rs7662987	0.517	rs1133485	ENSG00000233859.2	ADH5P4	-6.73	5.05e-11	9.67e-05	-0.36	-0.3	Smoking initiation;	chr4:99102660	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602845	ENSG00000233859.2	ADH5P4	-6.73	5.05e-11	9.67e-05	-0.36	-0.3	Smoking initiation;	chr4:99102793	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2034696	ENSG00000233859.2	ADH5P4	-6.73	5.05e-11	9.67e-05	-0.36	-0.3	Smoking initiation;	chr4:99103171	chr6:65836930~65838039:-
HNSC	trans	rs7121616	0.545	rs7109348	ENSG00000256356.1	HSPA8P5	6.73	5.06e-11	9.69e-05	0.38	0.3	Breast cancer;	chr11:123056555	chr12:4097451~4099519:+
HNSC	trans	rs1816752	0.746	rs9511270	ENSG00000224976.2	PARP4P2	-6.73	5.07e-11	9.7e-05	-0.35	-0.3	Obesity-related traits;	chr13:24444542	chr13:19349137~19407962:+
HNSC	trans	rs7647973	0.731	rs9831648	ENSG00000197582.5	GPX1P1	6.73	5.08e-11	9.72e-05	0.45	0.3	Menarche (age at onset);	chr3:49176870	chrX:13378735~13379340:-
HNSC	trans	rs7662987	0.517	rs1377689	ENSG00000233859.2	ADH5P4	-6.73	5.08e-11	9.72e-05	-0.36	-0.3	Smoking initiation;	chr4:99100636	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs1453873	ENSG00000233859.2	ADH5P4	-6.73	5.08e-11	9.72e-05	-0.36	-0.3	Smoking initiation;	chr4:99101420	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs1453874	ENSG00000233859.2	ADH5P4	-6.73	5.08e-11	9.72e-05	-0.36	-0.3	Smoking initiation;	chr4:99101573	chr6:65836930~65838039:-
HNSC	trans	rs6743068	0.522	rs7597617	ENSG00000235105.1	RP11-329A14.1	6.73	5.09e-11	9.74e-05	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201338512	chr1:48435967~48437223:+
HNSC	trans	rs9425766	0.679	rs12079062	ENSG00000213331.4	RP11-713C19.2	6.73	5.1e-11	9.76e-05	0.36	0.3	Life satisfaction;	chr1:174110446	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.9	rs1793300	ENSG00000213331.4	RP11-713C19.2	-6.73	5.1e-11	9.76e-05	-0.35	-0.3	Systemic lupus erythematosus;	chr1:174768559	chr4:187970273~187971284:+
HNSC	trans	rs2899832	0.568	rs8017676	ENSG00000229083.1	PSMA6P2	6.73	5.11e-11	9.77e-05	0.49	0.3	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293460	chrX:12825840~12826833:+
HNSC	trans	rs10037055	0.853	rs4976681	ENSG00000228305.2	AC016734.2	6.73	5.11e-11	9.78e-05	0.36	0.3	Migraine without aura;	chr5:177277662	chr2:63622178~63622831:-
HNSC	trans	rs1933488	0.931	rs9479510	ENSG00000278974.1	RP11-756P10.6	6.73	5.12e-11	9.8e-05	0.4	0.3	Prostate cancer;	chr6:153106382	chr4:188740507~188741281:-
HNSC	trans	rs1039766	0.925	rs268863	ENSG00000213985.4	AC078899.1	6.73	5.12e-11	9.8e-05	0.38	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr19:20257720~20259418:+
HNSC	trans	rs7032940	0.626	rs10816929	ENSG00000262519.1	TXNP4	6.73	5.13e-11	9.81e-05	0.38	0.3	Height;	chr9:110173466	chr17:4572206~4572515:+
HNSC	trans	rs2456568	0.548	rs10466335	ENSG00000276509.1	CH17-353B19.1	6.72	5.15e-11	9.84e-05	0.33	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93930654	chr1:146235806~146237807:+
HNSC	trans	rs9650657	0.571	rs4240673	ENSG00000173295.6	FAM86B3P	-6.72	5.16e-11	9.87e-05	-0.32	-0.3	Neuroticism;	chr8:10930102	chr8:8228595~8244865:+
HNSC	trans	rs10037055	0.853	rs1546363	ENSG00000226986.4	RP11-543B16.2	-6.72	5.17e-11	9.88e-05	-0.36	-0.3	Migraine without aura;	chr5:177174030	chr1:211207239~211207897:+
HNSC	trans	rs8067354	0.574	rs2531898	ENSG00000187870.7	RNFT1P3	6.72	5.17e-11	9.88e-05	0.42	0.3	Hemoglobin concentration;	chr17:59934990	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.574	rs9789060	ENSG00000187870.7	RNFT1P3	6.72	5.17e-11	9.88e-05	0.42	0.3	Hemoglobin concentration;	chr17:59941209	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.574	rs7219089	ENSG00000187870.7	RNFT1P3	6.72	5.17e-11	9.88e-05	0.42	0.3	Hemoglobin concentration;	chr17:59955504	chr17:20743333~20754501:-
HNSC	trans	rs3806843	0.648	rs702399	ENSG00000231043.3	AC007238.1	6.72	5.19e-11	9.91e-05	0.31	0.3	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr2:58460292~58462032:-
HNSC	trans	rs12439619	0.705	rs4778665	ENSG00000235370.6	DNM1P51	-6.72	5.19e-11	9.92e-05	-0.44	-0.3	Intelligence (multi-trait analysis);	chr15:82144163	chr15:84398316~84411701:-
HNSC	trans	rs17507216	0.718	rs28587782	ENSG00000259295.5	CSPG4P12	-6.72	5.21e-11	9.96e-05	-0.45	-0.3	Excessive daytime sleepiness;	chr15:82576881	chr15:85191438~85213905:+
HNSC	trans	rs2950393	0.726	rs10459246	ENSG00000257210.1	NACAP3	-6.72	5.22e-11	9.98e-05	-0.34	-0.3	Platelet distribution width;	chr12:56776034	chr12:93124063~93124543:-
HNSC	trans	rs9733	0.65	rs11204680	ENSG00000180764.13	PIPSL	6.72	5.25e-11	1e-04	0.36	0.3	Tonsillectomy;	chr1:150614664	chr10:93958191~93961540:-
HNSC	trans	rs7121616	0.576	rs7942164	ENSG00000241478.1	HSPA8P9	6.72	5.31e-11	0.000101	0.4	0.3	Breast cancer;	chr11:123050459	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.576	rs56131320	ENSG00000241478.1	HSPA8P9	6.72	5.31e-11	0.000101	0.4	0.3	Breast cancer;	chr11:123053058	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.576	rs7929869	ENSG00000241478.1	HSPA8P9	6.72	5.31e-11	0.000101	0.4	0.3	Breast cancer;	chr11:123054435	chr3:137880295~137882237:+
HNSC	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-6.72	5.32e-11	0.000102	-0.37	-0.3	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-6.72	5.33e-11	0.000102	-0.36	-0.3	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
HNSC	trans	rs4263408	0.654	rs305827	ENSG00000237550.5	UBE2Q2P6	6.72	5.33e-11	0.000102	0.37	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39758369	chr15:82372196~82372912:-
HNSC	trans	rs7873102	0.967	rs7044992	ENSG00000229007.1	EXOSC3P1	-6.72	5.37e-11	0.000102	-0.37	-0.3	Brain structure;	chr9:38039928	chr21:32496812~32497311:+
HNSC	trans	rs1336900	0.641	rs6587756	ENSG00000180764.13	PIPSL	6.72	5.37e-11	0.000103	0.38	0.3	Blood protein levels;	chr1:150574389	chr10:93958191~93961540:-
HNSC	trans	rs2456568	0.57	rs1518579	ENSG00000276509.1	CH17-353B19.1	6.72	5.39e-11	0.000103	0.33	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93923655	chr1:146235806~146237807:+
HNSC	trans	rs11951515	0.508	rs10065689	ENSG00000174977.8	AC026271.5	-6.72	5.41e-11	0.000103	-0.28	-0.3	Metabolite levels  (X-11787);	chr5:43604156	chr17:18650195~18651542:+
HNSC	trans	rs7662987	0.517	rs1154406	ENSG00000233859.2	ADH5P4	-6.72	5.44e-11	0.000104	-0.36	-0.3	Smoking initiation;	chr4:99087343	chr6:65836930~65838039:-
HNSC	trans	rs1816752	0.774	rs2862895	ENSG00000224976.2	PARP4P2	-6.72	5.47e-11	0.000104	-0.34	-0.3	Obesity-related traits;	chr13:24410328	chr13:19349137~19407962:+
HNSC	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	6.72	5.47e-11	0.000104	0.36	0.3	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	6.71	5.51e-11	0.000105	0.37	0.3	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs71559070	ENSG00000253570.1	RNF5P1	6.71	5.51e-11	0.000105	0.69	0.3	Depression;	chr6:28071151	chr8:38600661~38601200:-
HNSC	trans	rs10037055	0.853	rs4976680	ENSG00000228305.2	AC016734.2	6.71	5.51e-11	0.000105	0.36	0.3	Migraine without aura;	chr5:177275745	chr2:63622178~63622831:-
HNSC	trans	rs8067354	0.54	rs7221472	ENSG00000187870.7	RNFT1P3	6.71	5.52e-11	0.000105	0.42	0.3	Hemoglobin concentration;	chr17:59959376	chr17:20743333~20754501:-
HNSC	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	6.71	5.53e-11	0.000105	0.37	0.3	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
HNSC	trans	rs2456568	0.548	rs7113080	ENSG00000276509.1	CH17-353B19.1	6.71	5.54e-11	0.000105	0.33	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93924354	chr1:146235806~146237807:+
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-6.71	5.61e-11	0.000107	-0.32	-0.3	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-6.71	5.61e-11	0.000107	-0.32	-0.3	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
HNSC	trans	rs7121616	0.576	rs73608699	ENSG00000256356.1	HSPA8P5	6.71	5.66e-11	0.000108	0.39	0.3	Breast cancer;	chr11:123044718	chr12:4097451~4099519:+
HNSC	trans	rs9733	0.65	rs2048558	ENSG00000180764.13	PIPSL	6.71	5.67e-11	0.000108	0.36	0.3	Tonsillectomy;	chr1:150599254	chr10:93958191~93961540:-
HNSC	trans	rs6831352	0.76	rs1311616	ENSG00000233859.2	ADH5P4	-6.71	5.68e-11	0.000108	-0.36	-0.3	Alcohol dependence;	chr4:99091152	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs1311617	ENSG00000233859.2	ADH5P4	-6.71	5.68e-11	0.000108	-0.36	-0.3	Smoking initiation;	chr4:99091274	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs1311618	ENSG00000233859.2	ADH5P4	-6.71	5.68e-11	0.000108	-0.36	-0.3	Smoking initiation;	chr4:99091461	chr6:65836930~65838039:-
HNSC	trans	rs8067354	0.54	rs12600680	ENSG00000187870.7	RNFT1P3	6.71	5.7e-11	0.000108	0.42	0.3	Hemoglobin concentration;	chr17:59960013	chr17:20743333~20754501:-
HNSC	trans	rs6743068	0.541	rs2349075	ENSG00000235105.1	RP11-329A14.1	6.71	5.71e-11	0.000109	0.36	0.3	Lymphocyte percentage of white cells;	chr2:201358843	chr1:48435967~48437223:+
HNSC	trans	rs17507216	0.628	rs8028130	ENSG00000235370.6	DNM1P51	-6.71	5.71e-11	0.000109	-0.45	-0.3	Excessive daytime sleepiness;	chr15:82734974	chr15:84398316~84411701:-
HNSC	trans	rs7824557	0.505	rs2736313	ENSG00000173295.6	FAM86B3P	6.71	5.72e-11	0.000109	0.33	0.3	Retinal vascular caliber;	chr8:11229433	chr8:8228595~8244865:+
HNSC	trans	rs3849046	0.967	rs10077407	ENSG00000226666.1	HSPA9P1	6.71	5.72e-11	0.000109	0.31	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513837	chr2:221961737~221963765:+
HNSC	trans	rs3849046	0.967	rs154067	ENSG00000226666.1	HSPA9P1	6.71	5.72e-11	0.000109	0.31	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138514370	chr2:221961737~221963765:+
HNSC	trans	rs9425766	0.64	rs3791020	ENSG00000213331.4	RP11-713C19.2	-6.71	5.72e-11	0.000109	-0.39	-0.3	Life satisfaction;	chr1:173844059	chr4:187970273~187971284:+
HNSC	trans	rs1023500	0.956	rs1894713	ENSG00000268568.1	AC007228.9	-6.71	5.75e-11	0.000109	-0.4	-0.3	Schizophrenia;	chr22:41939617	chr19:56672574~56673901:-
HNSC	trans	rs6424115	0.867	rs10917431	ENSG00000228217.1	AL390877.1	6.71	5.75e-11	0.000109	0.37	0.3	Immature fraction of reticulocytes;	chr1:23847603	chr1:117778087~117778506:-
HNSC	trans	rs7662987	0.517	rs1154405	ENSG00000233859.2	ADH5P4	-6.71	5.76e-11	0.00011	-0.36	-0.3	Smoking initiation;	chr4:99087599	chr6:65836930~65838039:-
HNSC	trans	rs7121616	0.531	rs10892958	ENSG00000241478.1	HSPA8P9	6.71	5.76e-11	0.00011	0.39	0.3	Breast cancer;	chr11:123061415	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.531	rs11218941	ENSG00000241478.1	HSPA8P9	6.71	5.76e-11	0.00011	0.39	0.3	Breast cancer;	chr11:123061701	chr3:137880295~137882237:+
HNSC	trans	rs864643	0.947	rs1708040	ENSG00000183298.5	RP11-556K13.1	6.71	5.79e-11	0.00011	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39523258	chr1:101786340~101787219:-
HNSC	trans	rs8177876	0.749	rs11865207	ENSG00000224837.1	GCSHP5	6.71	5.81e-11	0.00011	0.47	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr1:168055901~168056422:-
HNSC	trans	rs9329221	0.741	rs534523	ENSG00000173295.6	FAM86B3P	-6.7	5.84e-11	0.000111	-0.32	-0.3	Neuroticism;	chr8:10027489	chr8:8228595~8244865:+
HNSC	trans	rs1039766	1	rs268870	ENSG00000213985.4	AC078899.1	6.7	5.86e-11	0.000111	0.39	0.3	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr19:20257720~20259418:+
HNSC	trans	rs804280	0.509	rs12719915	ENSG00000173295.6	FAM86B3P	-6.7	5.93e-11	0.000113	-0.33	-0.3	Myopia (pathological);	chr8:11928746	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-6.7	5.94e-11	0.000113	-0.37	-0.3	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
HNSC	trans	rs7121616	0.92	rs7109445	ENSG00000229091.2	HSPA8P8	6.7	5.97e-11	0.000113	0.34	0.3	Breast cancer;	chr11:123094779	chr7:10451311~10452526:+
HNSC	trans	rs17507216	1	rs17507216	ENSG00000235370.6	DNM1P51	6.7	5.99e-11	0.000114	0.42	0.3	Excessive daytime sleepiness;	chr15:82558175	chr15:84398316~84411701:-
HNSC	trans	rs10037055	0.853	rs1546363	ENSG00000228305.2	AC016734.2	-6.7	6e-11	0.000114	-0.37	-0.3	Migraine without aura;	chr5:177174030	chr2:63622178~63622831:-
HNSC	trans	rs7121616	0.545	rs7109336	ENSG00000241478.1	HSPA8P9	6.7	6.09e-11	0.000116	0.4	0.3	Breast cancer;	chr11:123056530	chr3:137880295~137882237:+
HNSC	trans	rs2060793	0.741	rs4757268	ENSG00000236360.2	RP11-334A14.2	6.7	6.11e-11	0.000116	0.37	0.3	Vitamin D levels;	chr11:14789216	chr1:52993201~52993702:-
HNSC	trans	rs2237234	0.58	rs7763910	ENSG00000242375.1	RP11-498P14.3	-6.7	6.11e-11	0.000116	-0.36	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26472427	chr9:97195351~97197687:-
HNSC	trans	rs11638815	0.639	rs783542	ENSG00000235370.6	DNM1P51	-6.7	6.14e-11	0.000116	-0.45	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82567264	chr15:84398316~84411701:-
HNSC	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	6.7	6.16e-11	0.000117	0.36	0.3	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	6.7	6.17e-11	0.000117	0.36	0.3	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	6.7	6.17e-11	0.000117	0.36	0.3	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	6.7	6.17e-11	0.000117	0.36	0.3	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	6.7	6.17e-11	0.000117	0.36	0.3	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	6.7	6.17e-11	0.000117	0.36	0.3	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
HNSC	trans	rs11992162	0.967	rs4841661	ENSG00000173295.6	FAM86B3P	6.7	6.17e-11	0.000117	0.33	0.3	Monocyte count;	chr8:11975260	chr8:8228595~8244865:+
HNSC	trans	rs7121616	0.531	rs1461497	ENSG00000241478.1	HSPA8P9	6.7	6.18e-11	0.000117	0.4	0.3	Breast cancer;	chr11:123060505	chr3:137880295~137882237:+
HNSC	trans	rs7121616	0.531	rs41361350	ENSG00000241478.1	HSPA8P9	6.7	6.18e-11	0.000117	0.4	0.3	Breast cancer;	chr11:123060917	chr3:137880295~137882237:+
HNSC	trans	rs1933488	0.931	rs7740777	ENSG00000278974.1	RP11-756P10.6	6.7	6.19e-11	0.000117	0.39	0.3	Prostate cancer;	chr6:153092174	chr4:188740507~188741281:-
HNSC	trans	rs10037055	0.853	rs10476219	ENSG00000226986.4	RP11-543B16.2	-6.69	6.24e-11	0.000118	-0.36	-0.3	Migraine without aura;	chr5:177201547	chr1:211207239~211207897:+
HNSC	trans	rs17507216	0.718	rs4779033	ENSG00000235370.6	DNM1P51	6.69	6.25e-11	0.000118	0.45	0.3	Excessive daytime sleepiness;	chr15:82576634	chr15:84398316~84411701:-
HNSC	trans	rs11204677	1	rs11204677	ENSG00000180764.13	PIPSL	6.69	6.28e-11	0.000119	0.36	0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150602219	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs12085336	ENSG00000180764.13	PIPSL	-6.69	6.29e-11	0.000119	-0.36	-0.3	Melanoma;	chr1:150803304	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-6.69	6.32e-11	0.00012	-0.35	-0.3	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
HNSC	trans	rs6600671	0.691	rs6600662	ENSG00000270231.3	NBPF8P	6.69	6.33e-11	0.00012	0.25	0.3	Hip geometry;	chr1:121488992	chr1:120436353~120467739:+
HNSC	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	6.69	6.33e-11	0.00012	0.37	0.3	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
HNSC	trans	rs7662987	0.517	rs2851277	ENSG00000233859.2	ADH5P4	-6.69	6.33e-11	0.00012	-0.36	-0.3	Smoking initiation;	chr4:99101759	chr6:65836930~65838039:-
HNSC	trans	rs7121616	0.576	rs73608699	ENSG00000241478.1	HSPA8P9	6.69	6.34e-11	0.00012	0.4	0.3	Breast cancer;	chr11:123044718	chr3:137880295~137882237:+
HNSC	trans	rs1039766	1	rs268882	ENSG00000213985.4	AC078899.1	-6.69	6.35e-11	0.00012	-0.37	-0.3	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr19:20257720~20259418:+
HNSC	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-6.69	6.36e-11	0.00012	-0.36	-0.3	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
HNSC	trans	rs11220082	0.602	rs10893383	ENSG00000236257.1	EI24P2	-6.69	6.36e-11	0.00012	-0.35	-0.3	Schizophrenia;	chr11:125466237	chr1:158454198~158455273:+
HNSC	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	6.69	6.41e-11	0.000121	0.36	0.3	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	6.69	6.42e-11	0.000121	0.36	0.3	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
HNSC	trans	rs11172055	0.902	rs10783807	ENSG00000121089.4	NACA3P	-6.69	6.43e-11	0.000121	-0.34	-0.3	Migraine;	chr12:56872529	chr4:164943290~164943937:+
HNSC	trans	rs916888	0.779	rs199498	ENSG00000204650.12	CRHR1-IT1	6.69	6.46e-11	0.000122	0.35	0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45620328~45648216:+
HNSC	trans	rs9733	0.593	rs10888384	ENSG00000180764.13	PIPSL	6.69	6.49e-11	0.000122	0.36	0.3	Tonsillectomy;	chr1:150601780	chr10:93958191~93961540:-
HNSC	trans	rs7121616	0.576	rs7123232	ENSG00000241478.1	HSPA8P9	6.69	6.51e-11	0.000123	0.38	0.3	Breast cancer;	chr11:123056237	chr3:137880295~137882237:+
HNSC	trans	rs8067354	0.507	rs2645478	ENSG00000187870.7	RNFT1P3	6.69	6.55e-11	0.000124	0.41	0.3	Hemoglobin concentration;	chr17:59937351	chr17:20743333~20754501:-
HNSC	trans	rs1816752	1	rs9511265	ENSG00000224976.2	PARP4P2	-6.69	6.55e-11	0.000124	-0.35	-0.3	Obesity-related traits;	chr13:24438221	chr13:19349137~19407962:+
HNSC	trans	rs853679	0.546	rs13213152	ENSG00000253570.1	RNF5P1	6.69	6.58e-11	0.000124	0.7	0.3	Depression;	chr6:28381921	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs13213986	ENSG00000253570.1	RNF5P1	6.69	6.58e-11	0.000124	0.7	0.3	Depression;	chr6:28390232	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs34546986	ENSG00000253570.1	RNF5P1	6.69	6.58e-11	0.000124	0.7	0.3	Depression;	chr6:28394532	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs34871267	ENSG00000253570.1	RNF5P1	6.69	6.58e-11	0.000124	0.7	0.3	Depression;	chr6:28396455	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs35883476	ENSG00000253570.1	RNF5P1	6.69	6.58e-11	0.000124	0.7	0.3	Depression;	chr6:28400731	chr8:38600661~38601200:-
HNSC	trans	rs9425766	0.679	rs12087441	ENSG00000213331.4	RP11-713C19.2	6.68	6.6e-11	0.000125	0.36	0.3	Life satisfaction;	chr1:174188696	chr4:187970273~187971284:+
HNSC	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	6.68	6.62e-11	0.000125	0.36	0.3	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
HNSC	trans	rs9425766	0.628	rs6425274	ENSG00000213331.4	RP11-713C19.2	6.68	6.64e-11	0.000125	0.36	0.3	Life satisfaction;	chr1:174144270	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.566	rs6696076	ENSG00000213331.4	RP11-713C19.2	6.68	6.64e-11	0.000125	0.36	0.3	Life satisfaction;	chr1:174149900	chr4:187970273~187971284:+
HNSC	trans	rs17507216	0.958	rs28648832	ENSG00000235370.6	DNM1P51	-6.68	6.65e-11	0.000125	-0.42	-0.3	Excessive daytime sleepiness;	chr15:82567642	chr15:84398316~84411701:-
HNSC	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-6.68	6.66e-11	0.000126	-0.37	-0.3	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
HNSC	trans	rs9425766	0.679	rs6656188	ENSG00000213331.4	RP11-713C19.2	6.68	6.66e-11	0.000126	0.36	0.3	Life satisfaction;	chr1:174183550	chr4:187970273~187971284:+
HNSC	trans	rs74781061	0.79	rs74788606	ENSG00000227288.3	RP5-837I24.1	6.68	6.67e-11	0.000126	0.55	0.3	Endometriosis;	chr15:74532649	chr1:81501794~81503468:+
HNSC	trans	rs79149102	0.522	rs4887156	ENSG00000227288.3	RP5-837I24.1	6.68	6.67e-11	0.000126	0.55	0.3	Lung cancer;	chr15:74538844	chr1:81501794~81503468:+
HNSC	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	6.68	6.67e-11	0.000126	0.37	0.3	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
HNSC	trans	rs9425766	0.679	rs2143114	ENSG00000213331.4	RP11-713C19.2	6.68	6.75e-11	0.000127	0.36	0.3	Life satisfaction;	chr1:174192292	chr4:187970273~187971284:+
HNSC	trans	rs3808502	0.563	rs12549144	ENSG00000173295.6	FAM86B3P	6.68	6.78e-11	0.000128	0.33	0.3	Neuroticism;	chr8:11565352	chr8:8228595~8244865:+
HNSC	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	6.68	6.78e-11	0.000128	0.37	0.3	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
HNSC	trans	rs616147	1	rs1768208	ENSG00000214263.2	RPSAP53	-6.68	6.82e-11	0.000129	-0.43	-0.3	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr13:67266845~67267706:-
HNSC	trans	rs7662987	0.54	rs2851278	ENSG00000233859.2	ADH5P4	-6.68	6.85e-11	0.000129	-0.36	-0.3	Smoking initiation;	chr4:99100102	chr6:65836930~65838039:-
HNSC	trans	rs2456568	0.548	rs10501809	ENSG00000276509.1	CH17-353B19.1	6.68	6.86e-11	0.000129	0.33	0.3	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93933097	chr1:146235806~146237807:+
HNSC	trans	rs1023500	1	rs3752591	ENSG00000268568.1	AC007228.9	-6.68	6.86e-11	0.000129	-0.4	-0.3	Schizophrenia;	chr22:41943512	chr19:56672574~56673901:-
HNSC	trans	rs7819412	1	rs7819412	ENSG00000173295.6	FAM86B3P	6.68	6.88e-11	0.00013	0.33	0.3	Triglycerides;	chr8:11187652	chr8:8228595~8244865:+
HNSC	trans	rs6831352	0.725	rs2602846	ENSG00000233859.2	ADH5P4	-6.68	6.89e-11	0.00013	-0.36	-0.3	Alcohol dependence;	chr4:99104000	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.744	rs2602847	ENSG00000233859.2	ADH5P4	-6.68	6.89e-11	0.00013	-0.36	-0.3	Alcohol dependence;	chr4:99104812	chr6:65836930~65838039:-
HNSC	trans	rs7819412	0.521	rs9329238	ENSG00000173295.6	FAM86B3P	-6.68	6.93e-11	0.00013	-0.35	-0.3	Triglycerides;	chr8:11176228	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-6.68	6.94e-11	0.000131	-0.32	-0.3	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
HNSC	trans	rs6921919	0.562	rs13198809	ENSG00000243753.4	HLA-L	-6.68	6.95e-11	0.000131	-0.65	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:30259584~30293014:+
HNSC	trans	rs10037055	0.687	rs6556308	ENSG00000228305.2	AC016734.2	-6.68	6.96e-11	0.000131	-0.36	-0.3	Migraine without aura;	chr5:177219700	chr2:63622178~63622831:-
HNSC	trans	rs26067	0.74	rs27683	ENSG00000231752.4	EMBP1	6.68	6.97e-11	0.000131	0.39	0.3	Breast cancer;	chr5:50865708	chr1:121519112~121571892:+
HNSC	trans	rs1933488	0.898	rs1971152	ENSG00000278974.1	RP11-756P10.6	-6.68	7e-11	0.000132	-0.39	-0.3	Prostate cancer;	chr6:153104109	chr4:188740507~188741281:-
HNSC	trans	rs7662987	0.517	rs2851268	ENSG00000233859.2	ADH5P4	-6.68	7e-11	0.000132	-0.35	-0.3	Smoking initiation;	chr4:99106727	chr6:65836930~65838039:-
HNSC	trans	rs17507216	1	rs17158413	ENSG00000235370.6	DNM1P51	-6.68	7.01e-11	0.000132	-0.42	-0.3	Excessive daytime sleepiness;	chr15:82566658	chr15:84398316~84411701:-
HNSC	trans	rs79149102	0.522	rs10459601	ENSG00000227288.3	RP5-837I24.1	6.67	7.03e-11	0.000132	0.54	0.3	Lung cancer;	chr15:74573068	chr1:81501794~81503468:+
HNSC	trans	rs9733	0.621	rs12746899	ENSG00000180764.13	PIPSL	6.67	7.13e-11	0.000134	0.36	0.3	Tonsillectomy;	chr1:150607202	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.65	rs4970923	ENSG00000180764.13	PIPSL	6.67	7.13e-11	0.000134	0.36	0.3	Tonsillectomy;	chr1:150635824	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.65	rs11204684	ENSG00000180764.13	PIPSL	6.67	7.13e-11	0.000134	0.36	0.3	Tonsillectomy;	chr1:150636418	chr10:93958191~93961540:-
HNSC	trans	rs9650657	0.589	rs6985109	ENSG00000173295.6	FAM86B3P	6.67	7.15e-11	0.000134	0.33	0.3	Neuroticism;	chr8:10904075	chr8:8228595~8244865:+
HNSC	trans	rs3849046	0.781	rs11242436	ENSG00000226666.1	HSPA9P1	6.67	7.17e-11	0.000135	0.32	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138601629	chr2:221961737~221963765:+
HNSC	trans	rs9733	0.536	rs10888385	ENSG00000180764.13	PIPSL	6.67	7.17e-11	0.000135	0.36	0.29	Tonsillectomy;	chr1:150601826	chr10:93958191~93961540:-
HNSC	trans	rs7520050	0.778	rs2934857	ENSG00000255397.1	AC022182.2	-6.67	7.18e-11	0.000135	-0.35	-0.29	Reticulocyte count;Red blood cell count;	chr1:45573940	chr8:60937705~60939871:-
HNSC	trans	rs9630182	0.793	rs1459011	ENSG00000257675.1	RP11-641A6.9	-6.67	7.25e-11	0.000136	-0.36	-0.29	Bone mineral density;	chr11:13552007	chr12:52748776~52750127:+
HNSC	trans	rs7121616	0.545	rs7109336	ENSG00000256356.1	HSPA8P5	6.67	7.26e-11	0.000136	0.38	0.29	Breast cancer;	chr11:123056530	chr12:4097451~4099519:+
HNSC	trans	rs76228276	0.737	rs4735632	ENSG00000260318.1	COX6CP1	6.67	7.31e-11	0.000137	0.82	0.29	Childhood ear infection;	chr8:99686271	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs76599759	ENSG00000260318.1	COX6CP1	6.67	7.31e-11	0.000137	0.82	0.29	Childhood ear infection;	chr8:99687826	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs76126670	ENSG00000260318.1	COX6CP1	6.67	7.31e-11	0.000137	0.82	0.29	Childhood ear infection;	chr8:99690249	chr16:11903923~11904137:-
HNSC	trans	rs76228276	0.737	rs80337710	ENSG00000260318.1	COX6CP1	6.67	7.31e-11	0.000137	0.82	0.29	Childhood ear infection;	chr8:99690946	chr16:11903923~11904137:-
HNSC	trans	rs9425766	0.54	rs2294492	ENSG00000213331.4	RP11-713C19.2	6.67	7.33e-11	0.000138	0.35	0.29	Life satisfaction;	chr1:174157884	chr4:187970273~187971284:+
HNSC	trans	rs17507216	0.671	rs4779035	ENSG00000259295.5	CSPG4P12	-6.67	7.33e-11	0.000138	-0.46	-0.29	Excessive daytime sleepiness;	chr15:82591686	chr15:85191438~85213905:+
HNSC	trans	rs7647973	0.771	rs9865051	ENSG00000197582.5	GPX1P1	6.67	7.34e-11	0.000138	0.48	0.29	Menarche (age at onset);	chr3:49128636	chrX:13378735~13379340:-
HNSC	trans	rs7769051	1	rs6910639	ENSG00000227615.1	RP11-864N7.2	6.67	7.35e-11	0.000138	0.47	0.29	Type 2 diabetes nephropathy;	chr6:132799414	chr11:74745716~74746114:-
HNSC	trans	rs7769051	1	rs12204027	ENSG00000227615.1	RP11-864N7.2	6.67	7.35e-11	0.000138	0.47	0.29	Type 2 diabetes nephropathy;	chr6:132801692	chr11:74745716~74746114:-
HNSC	trans	rs7769051	1	rs9493444	ENSG00000227615.1	RP11-864N7.2	6.67	7.35e-11	0.000138	0.47	0.29	Type 2 diabetes nephropathy;	chr6:132804181	chr11:74745716~74746114:-
HNSC	trans	rs722599	0.748	rs2537824	ENSG00000181227.3	RP4-682C21.2	6.67	7.36e-11	0.000138	0.31	0.29	IgG glycosylation;	chr14:74900646	chr1:75743423~75744776:-
HNSC	trans	rs722599	0.748	rs20578	ENSG00000181227.3	RP4-682C21.2	6.67	7.36e-11	0.000138	0.31	0.29	IgG glycosylation;	chr14:74901104	chr1:75743423~75744776:-
HNSC	trans	rs722599	0.748	rs1059326	ENSG00000181227.3	RP4-682C21.2	6.67	7.36e-11	0.000138	0.31	0.29	IgG glycosylation;	chr14:74902682	chr1:75743423~75744776:-
HNSC	trans	rs7520050	0.751	rs2230657	ENSG00000255397.1	AC022182.2	6.67	7.37e-11	0.000138	0.36	0.29	Reticulocyte count;Red blood cell count;	chr1:45607817	chr8:60937705~60939871:-
HNSC	trans	rs7412746	0.611	rs3768018	ENSG00000180764.13	PIPSL	-6.67	7.42e-11	0.000139	-0.36	-0.29	Melanoma;	chr1:150751271	chr10:93958191~93961540:-
HNSC	trans	rs7121616	0.576	rs4802	ENSG00000241478.1	HSPA8P9	6.67	7.44e-11	0.00014	0.36	0.29	Breast cancer;	chr11:123057914	chr3:137880295~137882237:+
HNSC	trans	rs11220082	0.627	rs34912904	ENSG00000236257.1	EI24P2	-6.66	7.49e-11	0.00014	-0.35	-0.29	Schizophrenia;	chr11:125475460	chr1:158454198~158455273:+
HNSC	trans	rs2950393	0.804	rs7295862	ENSG00000257210.1	NACAP3	-6.66	7.51e-11	0.000141	-0.34	-0.29	Platelet distribution width;	chr12:56775374	chr12:93124063~93124543:-
HNSC	trans	rs7662987	0.517	rs3018048	ENSG00000233859.2	ADH5P4	-6.66	7.52e-11	0.000141	-0.36	-0.29	Smoking initiation;	chr4:99084387	chr6:65836930~65838039:-
HNSC	trans	rs853679	0.546	rs35744819	ENSG00000243753.4	HLA-L	-6.66	7.55e-11	0.000142	-0.64	-0.29	Depression;	chr6:28350554	chr6:30259584~30293014:+
HNSC	trans	rs138024639	1	rs138024639	ENSG00000253570.1	RNF5P1	6.66	7.59e-11	0.000142	0.73	0.29	Breast cancer;	chr6:28468244	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs55690788	ENSG00000253570.1	RNF5P1	6.66	7.59e-11	0.000142	0.73	0.29	Depression;	chr6:28468368	chr8:38600661~38601200:-
HNSC	trans	rs1816752	0.776	rs9511268	ENSG00000224976.2	PARP4P2	-6.66	7.6e-11	0.000142	-0.35	-0.29	Obesity-related traits;	chr13:24444182	chr13:19349137~19407962:+
HNSC	trans	rs10037055	0.741	rs2336405	ENSG00000228305.2	AC016734.2	-6.66	7.63e-11	0.000143	-0.36	-0.29	Migraine without aura;	chr5:177230288	chr2:63622178~63622831:-
HNSC	trans	rs7662987	0.517	rs2924580	ENSG00000233859.2	ADH5P4	-6.66	7.65e-11	0.000143	-0.35	-0.29	Smoking initiation;	chr4:99111017	chr6:65836930~65838039:-
HNSC	trans	rs10037055	0.853	rs6890580	ENSG00000228305.2	AC016734.2	-6.66	7.66e-11	0.000143	-0.36	-0.29	Migraine without aura;	chr5:177226519	chr2:63622178~63622831:-
HNSC	trans	rs7662987	0.517	rs1311615	ENSG00000233859.2	ADH5P4	-6.66	7.66e-11	0.000144	-0.36	-0.29	Smoking initiation;	chr4:99091110	chr6:65836930~65838039:-
HNSC	trans	rs7824557	0.872	rs2572417	ENSG00000173295.6	FAM86B3P	-6.66	7.68e-11	0.000144	-0.32	-0.29	Retinal vascular caliber;	chr8:11253953	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.561	rs2403664	ENSG00000257675.1	RP11-641A6.9	-6.66	7.74e-11	0.000145	-0.34	-0.29	Bone mineral density;	chr11:13420194	chr12:52748776~52750127:+
HNSC	trans	rs6424115	0.931	rs2473377	ENSG00000228217.1	AL390877.1	-6.66	7.77e-11	0.000145	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23821770	chr1:117778087~117778506:-
HNSC	trans	rs4930561	0.765	rs4930564	ENSG00000155070.8	UNC93B2	6.66	7.8e-11	0.000146	0.34	0.29	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr7:6855485~6859830:-
HNSC	trans	rs9329221	0.683	rs3105738	ENSG00000173295.6	FAM86B3P	-6.66	7.81e-11	0.000146	-0.32	-0.29	Neuroticism;	chr8:10032404	chr8:8228595~8244865:+
HNSC	trans	rs79149102	0.522	rs4887158	ENSG00000227288.3	RP5-837I24.1	6.66	7.85e-11	0.000147	0.55	0.29	Lung cancer;	chr15:74555473	chr1:81501794~81503468:+
HNSC	trans	rs17507216	1	rs3850610	ENSG00000259295.5	CSPG4P12	6.66	7.86e-11	0.000147	0.4	0.29	Excessive daytime sleepiness;	chr15:82552642	chr15:85191438~85213905:+
HNSC	trans	rs3849046	0.79	rs10793825	ENSG00000226666.1	HSPA9P1	6.66	7.92e-11	0.000148	0.32	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138598882	chr2:221961737~221963765:+
HNSC	trans	rs9393777	0.92	rs72839445	ENSG00000253570.1	RNF5P1	6.66	7.93e-11	0.000148	0.72	0.29	Intelligence (multi-trait analysis);	chr6:27281907	chr8:38600661~38601200:-
HNSC	trans	rs7647973	0.559	rs9586	ENSG00000197582.5	GPX1P1	6.66	7.94e-11	0.000148	0.44	0.29	Menarche (age at onset);	chr3:49176204	chrX:13378735~13379340:-
HNSC	trans	rs722599	0.748	rs61978948	ENSG00000181227.3	RP4-682C21.2	6.65	8.03e-11	0.00015	0.31	0.29	IgG glycosylation;	chr14:74896666	chr1:75743423~75744776:-
HNSC	trans	rs6424115	0.83	rs2501424	ENSG00000228217.1	AL390877.1	-6.65	8.04e-11	0.00015	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23872692	chr1:117778087~117778506:-
HNSC	trans	rs9650657	0.537	rs4841457	ENSG00000173295.6	FAM86B3P	-6.65	8.11e-11	0.000151	-0.33	-0.29	Neuroticism;	chr8:10916001	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.633	rs8002387	ENSG00000224976.2	PARP4P2	-6.65	8.12e-11	0.000152	-0.34	-0.29	Obesity-related traits;	chr13:24416306	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.819	rs4770664	ENSG00000224976.2	PARP4P2	-6.65	8.16e-11	0.000152	-0.34	-0.29	Obesity-related traits;	chr13:24414695	chr13:19349137~19407962:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-6.65	8.16e-11	0.000152	-0.32	-0.29	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
HNSC	trans	rs853679	0.607	rs68188794	ENSG00000253570.1	RNF5P1	6.65	8.18e-11	0.000153	0.7	0.29	Depression;	chr6:28112999	chr8:38600661~38601200:-
HNSC	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-6.65	8.2e-11	0.000153	-0.4	-0.29	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
HNSC	trans	rs11992162	1	rs11994417	ENSG00000173295.6	FAM86B3P	6.65	8.3e-11	0.000155	0.33	0.29	Monocyte count;	chr8:11975753	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.513	rs4841459	ENSG00000173295.6	FAM86B3P	-6.65	8.4e-11	0.000157	-0.32	-0.29	Neuroticism;	chr8:10924932	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-6.65	8.44e-11	0.000157	-0.37	-0.29	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
HNSC	trans	rs6981523	0.517	rs13251510	ENSG00000173295.6	FAM86B3P	-6.64	8.49e-11	0.000158	-0.34	-0.29	Neuroticism;	chr8:11059464	chr8:8228595~8244865:+
HNSC	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-6.64	8.51e-11	0.000158	-0.34	-0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
HNSC	trans	rs11935423	0.735	rs7693979	ENSG00000269888.1	RP11-3P17.5	-6.64	8.51e-11	0.000159	-0.39	-0.29	Gut microbiome composition (summer);	chr4:99543408	chr3:161429112~161429613:+
HNSC	trans	rs7121616	0.576	rs1064585	ENSG00000256356.1	HSPA8P5	6.64	8.58e-11	0.00016	0.38	0.29	Breast cancer;	chr11:123058699	chr12:4097451~4099519:+
HNSC	trans	rs17507216	0.588	rs28864981	ENSG00000259295.5	CSPG4P12	-6.64	8.73e-11	0.000162	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82695420	chr15:85191438~85213905:+
HNSC	trans	rs79149102	0.522	rs117774781	ENSG00000227288.3	RP5-837I24.1	6.64	8.76e-11	0.000163	0.54	0.29	Lung cancer;	chr15:74480109	chr1:81501794~81503468:+
HNSC	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-6.64	8.76e-11	0.000163	-0.37	-0.29	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
HNSC	trans	rs1816752	0.819	rs4770665	ENSG00000224976.2	PARP4P2	-6.64	8.79e-11	0.000163	-0.34	-0.29	Obesity-related traits;	chr13:24414810	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.721	rs7399656	ENSG00000224976.2	PARP4P2	-6.64	8.79e-11	0.000163	-0.34	-0.29	Obesity-related traits;	chr13:24415708	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.749	rs77832754	ENSG00000224976.2	PARP4P2	-6.64	8.79e-11	0.000163	-0.34	-0.29	Obesity-related traits;	chr13:24416016	chr13:19349137~19407962:+
HNSC	trans	rs7819412	0.505	rs17782536	ENSG00000173295.6	FAM86B3P	-6.64	8.85e-11	0.000165	-0.35	-0.29	Triglycerides;	chr8:11164172	chr8:8228595~8244865:+
HNSC	trans	rs9329221	0.683	rs688491	ENSG00000173295.6	FAM86B3P	-6.64	8.85e-11	0.000165	-0.32	-0.29	Neuroticism;	chr8:10027313	chr8:8228595~8244865:+
HNSC	trans	rs8067354	0.54	rs72840315	ENSG00000187870.7	RNFT1P3	6.64	8.91e-11	0.000166	0.41	0.29	Hemoglobin concentration;	chr17:59940781	chr17:20743333~20754501:-
HNSC	trans	rs7258465	0.563	rs10854166	ENSG00000267533.1	RP11-815J4.7	-6.64	8.92e-11	0.000166	-0.38	-0.29	Breast cancer;	chr19:18542034	chr18:12067173~12068417:-
HNSC	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-6.64	8.92e-11	0.000166	-0.37	-0.29	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
HNSC	trans	rs7769051	1	rs3813347	ENSG00000227615.1	RP11-864N7.2	6.63	9.06e-11	0.000168	0.47	0.29	Type 2 diabetes nephropathy;	chr6:132798639	chr11:74745716~74746114:-
HNSC	trans	rs9467711	0.79	rs66488313	ENSG00000253570.1	RNF5P1	6.63	9.07e-11	0.000168	0.71	0.29	Autism spectrum disorder or schizophrenia;	chr6:26631340	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-6.63	9.11e-11	0.000169	-0.36	-0.29	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
HNSC	trans	rs3808502	0.563	rs12549150	ENSG00000173295.6	FAM86B3P	6.63	9.11e-11	0.000169	0.33	0.29	Neuroticism;	chr8:11565427	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.804	rs1026565	ENSG00000257210.1	NACAP3	6.63	9.27e-11	0.000172	0.33	0.29	Platelet distribution width;	chr12:56744044	chr12:93124063~93124543:-
HNSC	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	6.63	9.28e-11	0.000172	0.46	0.29	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
HNSC	trans	rs7819412	0.74	rs11250119	ENSG00000173295.6	FAM86B3P	-6.63	9.31e-11	0.000173	-0.34	-0.29	Triglycerides;	chr8:11179525	chr8:8228595~8244865:+
HNSC	trans	rs1933488	0.835	rs9371280	ENSG00000278974.1	RP11-756P10.6	-6.63	9.34e-11	0.000173	-0.39	-0.29	Prostate cancer;	chr6:153093138	chr4:188740507~188741281:-
HNSC	trans	rs1933488	0.898	rs6557261	ENSG00000278974.1	RP11-756P10.6	-6.63	9.34e-11	0.000173	-0.39	-0.29	Prostate cancer;	chr6:153094233	chr4:188740507~188741281:-
HNSC	trans	rs1933488	0.898	rs9479505	ENSG00000278974.1	RP11-756P10.6	-6.63	9.34e-11	0.000173	-0.39	-0.29	Prostate cancer;	chr6:153094516	chr4:188740507~188741281:-
HNSC	trans	rs1933488	0.866	rs7756810	ENSG00000278974.1	RP11-756P10.6	-6.63	9.34e-11	0.000173	-0.39	-0.29	Prostate cancer;	chr6:153094998	chr4:188740507~188741281:-
HNSC	trans	rs1816752	0.748	rs6490912	ENSG00000224976.2	PARP4P2	-6.63	9.41e-11	0.000174	-0.34	-0.29	Obesity-related traits;	chr13:24408941	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.819	rs1981276	ENSG00000224976.2	PARP4P2	-6.63	9.41e-11	0.000174	-0.34	-0.29	Obesity-related traits;	chr13:24409361	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.837	rs57052031	ENSG00000224976.2	PARP4P2	-6.63	9.41e-11	0.000174	-0.34	-0.29	Obesity-related traits;	chr13:24409730	chr13:19349137~19407962:+
HNSC	trans	rs7819412	0.659	rs4073948	ENSG00000173295.6	FAM86B3P	-6.63	9.48e-11	0.000176	-0.33	-0.29	Triglycerides;	chr8:10915134	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.65	rs6698495	ENSG00000180764.13	PIPSL	6.62	9.6e-11	0.000178	0.36	0.29	Tonsillectomy;	chr1:150592000	chr10:93958191~93961540:-
HNSC	trans	rs26067	0.643	rs693082	ENSG00000231752.4	EMBP1	6.62	9.67e-11	0.000179	0.38	0.29	Breast cancer;	chr5:50808537	chr1:121519112~121571892:+
HNSC	trans	rs9425766	0.679	rs2860846	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174106786	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs2860847	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174106787	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs6672986	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174107726	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs7526024	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174109722	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs12079063	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174110447	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs12094341	ENSG00000213331.4	RP11-713C19.2	6.62	9.74e-11	0.00018	0.35	0.29	Life satisfaction;	chr1:174110562	chr4:187970273~187971284:+
HNSC	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	6.62	9.75e-11	0.00018	0.37	0.29	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	6.62	9.75e-11	0.00018	0.37	0.29	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
HNSC	trans	rs6831352	0.734	rs12502237	ENSG00000233859.2	ADH5P4	-6.62	9.76e-11	0.00018	-0.35	-0.29	Alcohol dependence;	chr4:99094524	chr6:65836930~65838039:-
HNSC	trans	rs4948102	0.731	rs6593292	ENSG00000186940.6	CHCHD2P9	-6.62	9.77e-11	0.000181	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.731	rs4535700	ENSG00000186940.6	CHCHD2P9	-6.62	9.77e-11	0.000181	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.731	rs4543497	ENSG00000186940.6	CHCHD2P9	-6.62	9.77e-11	0.000181	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.767	rs4948096	ENSG00000186940.6	CHCHD2P9	-6.62	9.77e-11	0.000181	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.727	rs4948097	ENSG00000186940.6	CHCHD2P9	-6.62	9.77e-11	0.000181	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr9:79391304~79391759:+
HNSC	trans	rs7819412	0.645	rs4841508	ENSG00000173295.6	FAM86B3P	-6.62	9.77e-11	0.000181	-0.35	-0.29	Triglycerides;	chr8:11207494	chr8:8228595~8244865:+
HNSC	trans	rs1933488	0.931	rs9397587	ENSG00000278974.1	RP11-756P10.6	-6.62	9.77e-11	0.000181	-0.39	-0.29	Prostate cancer;	chr6:153095777	chr4:188740507~188741281:-
HNSC	trans	rs9425766	0.679	rs4650945	ENSG00000213331.4	RP11-713C19.2	-6.62	9.78e-11	0.000181	-0.36	-0.29	Life satisfaction;	chr1:174114966	chr4:187970273~187971284:+
HNSC	trans	rs9630182	0.561	rs876226	ENSG00000257675.1	RP11-641A6.9	-6.62	9.85e-11	0.000182	-0.34	-0.29	Bone mineral density;	chr11:13419897	chr12:52748776~52750127:+
HNSC	trans	rs9329221	0.592	rs7832708	ENSG00000173295.6	FAM86B3P	6.62	9.91e-11	0.000183	0.32	0.29	Neuroticism;	chr8:10332530	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.755	rs1981277	ENSG00000224976.2	PARP4P2	-6.62	9.94e-11	0.000184	-0.34	-0.29	Obesity-related traits;	chr13:24409375	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.712	rs9507335	ENSG00000224976.2	PARP4P2	-6.62	9.94e-11	0.000184	-0.34	-0.29	Obesity-related traits;	chr13:24409766	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.811	rs9507337	ENSG00000224976.2	PARP4P2	-6.62	9.94e-11	0.000184	-0.34	-0.29	Obesity-related traits;	chr13:24410807	chr13:19349137~19407962:+
HNSC	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	6.62	9.96e-11	0.000184	0.36	0.29	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	6.62	9.96e-11	0.000184	0.36	0.29	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	6.62	9.96e-11	0.000184	0.36	0.29	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
HNSC	trans	rs13177918	0.578	rs35919198	ENSG00000226396.1	RP5-1056L3.3	6.62	1e-10	0.000185	0.23	0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:19608114~19608568:+
HNSC	trans	rs6756513	1	rs6756513	ENSG00000232654.1	FAM136BP	6.62	1e-10	0.000185	0.37	0.29	Breast cancer;Platelet count;	chr2:69945455	chr6:3045384~3045800:+
HNSC	trans	rs9650657	0.601	rs10903330	ENSG00000253893.2	FAM85B	-6.62	1e-10	0.000185	-0.35	-0.29	Neuroticism;	chr8:10815594	chr8:8167819~8226614:-
HNSC	trans	rs9329221	0.682	rs11786677	ENSG00000173295.6	FAM86B3P	6.62	1.01e-10	0.000186	0.32	0.29	Neuroticism;	chr8:10406750	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.628	rs8032321	ENSG00000259295.5	CSPG4P12	-6.62	1.01e-10	0.000186	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82698956	chr15:85191438~85213905:+
HNSC	trans	rs17507216	0.628	rs8040488	ENSG00000259295.5	CSPG4P12	-6.62	1.01e-10	0.000186	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82699081	chr15:85191438~85213905:+
HNSC	trans	rs9467711	0.79	rs72843784	ENSG00000253570.1	RNF5P1	6.62	1.01e-10	0.000187	0.71	0.29	Autism spectrum disorder or schizophrenia;	chr6:26498530	chr8:38600661~38601200:-
HNSC	trans	rs453301	0.624	rs330049	ENSG00000173295.6	FAM86B3P	6.62	1.02e-10	0.000187	0.32	0.29	Joint mobility (Beighton score);	chr8:9229789	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.69	rs35844144	ENSG00000186940.6	CHCHD2P9	-6.61	1.02e-10	0.000189	-0.41	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr9:79391304~79391759:+
HNSC	trans	rs7121616	0.576	rs7111590	ENSG00000241478.1	HSPA8P9	6.61	1.02e-10	0.000189	0.39	0.29	Breast cancer;	chr11:123055419	chr3:137880295~137882237:+
HNSC	trans	rs6424115	1	rs4237	ENSG00000228217.1	AL390877.1	-6.61	1.03e-10	0.000191	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23787639	chr1:117778087~117778506:-
HNSC	trans	rs7412746	0.621	rs7518156	ENSG00000180764.13	PIPSL	-6.61	1.04e-10	0.000193	-0.35	-0.29	Melanoma;	chr1:150973318	chr10:93958191~93961540:-
HNSC	trans	rs853679	1	rs10456362	ENSG00000253570.1	RNF5P1	-6.61	1.04e-10	0.000193	-0.49	-0.29	Depression;	chr6:28254038	chr8:38600661~38601200:-
HNSC	trans	rs9650657	0.537	rs11250092	ENSG00000173295.6	FAM86B3P	6.61	1.05e-10	0.000194	0.32	0.29	Neuroticism;	chr8:10929033	chr8:8228595~8244865:+
HNSC	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-6.61	1.05e-10	0.000194	-0.36	-0.29	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
HNSC	trans	rs7617480	0.648	rs6806356	ENSG00000197582.5	GPX1P1	6.61	1.06e-10	0.000195	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chrX:13378735~13379340:-
HNSC	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	6.61	1.06e-10	0.000195	0.36	0.29	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
HNSC	trans	rs1190596	0.558	rs7154553	ENSG00000181359.5	HSP90AA6P	-6.61	1.06e-10	0.000196	-0.4	-0.29	Behavioural disinhibition (generation interaction);	chr14:102219846	chr4:170581470~170605450:-
HNSC	trans	rs17507216	0.958	rs72751643	ENSG00000235370.6	DNM1P51	-6.61	1.06e-10	0.000196	-0.42	-0.29	Excessive daytime sleepiness;	chr15:82559444	chr15:84398316~84411701:-
HNSC	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	6.61	1.07e-10	0.000196	0.36	0.29	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	6.61	1.08e-10	0.000198	0.36	0.29	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
HNSC	trans	rs10037055	0.853	rs6890580	ENSG00000226986.4	RP11-543B16.2	-6.61	1.08e-10	0.000199	-0.36	-0.29	Migraine without aura;	chr5:177226519	chr1:211207239~211207897:+
HNSC	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	6.6	1.09e-10	0.000201	0.23	0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
HNSC	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	6.6	1.09e-10	0.000201	0.36	0.29	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
HNSC	trans	rs10037055	0.853	rs10056008	ENSG00000226986.4	RP11-543B16.2	-6.6	1.09e-10	0.000201	-0.36	-0.29	Migraine without aura;	chr5:177194147	chr1:211207239~211207897:+
HNSC	trans	rs867371	0.502	rs8025964	ENSG00000235370.6	DNM1P51	-6.6	1.1e-10	0.000202	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:84398316~84411701:-
HNSC	trans	rs6087990	0.584	rs6058897	ENSG00000253915.1	MAPRE1P1	-6.6	1.1e-10	0.000202	-0.35	-0.29	Ulcerative colitis;	chr20:32810299	chr8:135625185~135625981:-
HNSC	trans	rs1816752	0.783	rs7317439	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24410939	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.819	rs7316961	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24411039	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.783	rs7139527	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24411374	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.819	rs9511240	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24411768	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.819	rs7988388	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24412675	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.875	rs7993132	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24412903	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.792	rs7330956	ENSG00000224976.2	PARP4P2	-6.6	1.1e-10	0.000203	-0.34	-0.29	Obesity-related traits;	chr13:24413174	chr13:19349137~19407962:+
HNSC	trans	rs8177876	0.822	rs9923732	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9925940	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9925943	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9933184	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9926174	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.642	rs8052490	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs8056972	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs74437879	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs76948085	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs80315956	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.642	rs16954572	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9929586	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs9938965	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs7204040	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.731	rs7188508	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs28672349	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.818	rs59177227	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs59685942	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs10514515	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs1410	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs1412	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs1414	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs8177950	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.731	rs8177948	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs8177940	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.73	rs76656387	ENSG00000224837.1	GCSHP5	6.6	1.11e-10	0.000203	0.5	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr1:168055901~168056422:-
HNSC	trans	rs4948102	0.667	rs7811270	ENSG00000186940.6	CHCHD2P9	-6.6	1.11e-10	0.000203	-0.39	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr9:79391304~79391759:+
HNSC	trans	rs7032940	0.954	rs12553530	ENSG00000228236.2	TXNP5	6.6	1.11e-10	0.000204	0.38	0.29	Height;	chr9:110188455	chr2:149068596~149068910:-
HNSC	trans	rs6831352	0.819	rs1154401	ENSG00000233859.2	ADH5P4	-6.6	1.11e-10	0.000204	-0.33	-0.29	Alcohol dependence;	chr4:99088587	chr6:65836930~65838039:-
HNSC	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-6.6	1.12e-10	0.000205	-0.36	-0.29	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
HNSC	trans	rs6756513	0.5	rs17037193	ENSG00000232654.1	FAM136BP	6.6	1.12e-10	0.000205	0.39	0.29	Breast cancer;Platelet count;	chr2:69876372	chr6:3045384~3045800:+
HNSC	trans	rs17507216	0.628	rs28737193	ENSG00000259295.5	CSPG4P12	-6.6	1.12e-10	0.000205	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82701318	chr15:85191438~85213905:+
HNSC	trans	rs7824557	0.547	rs6601570	ENSG00000173295.6	FAM86B3P	-6.6	1.12e-10	0.000206	-0.33	-0.29	Retinal vascular caliber;	chr8:11221858	chr8:8228595~8244865:+
HNSC	trans	rs7121616	0.576	rs7948948	ENSG00000256356.1	HSPA8P5	6.6	1.12e-10	0.000206	0.38	0.29	Breast cancer;	chr11:123057467	chr12:4097451~4099519:+
HNSC	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-6.6	1.13e-10	0.000206	-0.37	-0.29	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-6.6	1.13e-10	0.000206	-0.37	-0.29	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs34166054	ENSG00000253570.1	RNF5P1	6.6	1.13e-10	0.000206	0.69	0.29	Depression;	chr6:28098023	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13203816	ENSG00000253570.1	RNF5P1	6.6	1.13e-10	0.000206	0.69	0.29	Depression;	chr6:28111820	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.556	rs34588114	ENSG00000253570.1	RNF5P1	6.6	1.13e-10	0.000206	0.69	0.29	Depression;	chr6:28112850	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs34371502	ENSG00000253570.1	RNF5P1	6.6	1.13e-10	0.000206	0.69	0.29	Depression;	chr6:28113980	chr8:38600661~38601200:-
HNSC	trans	rs7647973	0.626	rs1463728	ENSG00000197582.5	GPX1P1	6.6	1.13e-10	0.000207	0.5	0.29	Menarche (age at onset);	chr3:49609971	chrX:13378735~13379340:-
HNSC	trans	rs9425766	0.679	rs7533430	ENSG00000213331.4	RP11-713C19.2	6.6	1.13e-10	0.000207	0.35	0.29	Life satisfaction;	chr1:174109279	chr4:187970273~187971284:+
HNSC	trans	rs6424115	0.867	rs34902309	ENSG00000228217.1	AL390877.1	6.6	1.13e-10	0.000207	0.36	0.29	Immature fraction of reticulocytes;	chr1:23865710	chr1:117778087~117778506:-
HNSC	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-6.6	1.13e-10	0.000208	-0.4	-0.29	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
HNSC	trans	rs4948102	0.924	rs13240915	ENSG00000186940.6	CHCHD2P9	-6.6	1.14e-10	0.000208	-0.4	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56023059	chr9:79391304~79391759:+
HNSC	trans	rs1816752	0.905	rs9511266	ENSG00000224976.2	PARP4P2	-6.6	1.14e-10	0.000209	-0.34	-0.29	Obesity-related traits;	chr13:24438366	chr13:19349137~19407962:+
HNSC	trans	rs7819412	0.668	rs2409721	ENSG00000173295.6	FAM86B3P	-6.6	1.15e-10	0.00021	-0.34	-0.29	Triglycerides;	chr8:11180735	chr8:8228595~8244865:+
HNSC	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-6.6	1.15e-10	0.00021	-0.36	-0.29	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-6.6	1.15e-10	0.00021	-0.36	-0.29	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.546	rs35353359	ENSG00000253570.1	RNF5P1	6.6	1.15e-10	0.00021	0.68	0.29	Depression;	chr6:28356601	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	6.6	1.15e-10	0.00021	0.36	0.29	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
HNSC	trans	rs61041336	0.583	rs11647748	ENSG00000230849.2	GOT2P2	-6.6	1.15e-10	0.000211	-0.56	-0.29	Neuritic plaque;	chr16:58697980	chr1:173141100~173142350:-
HNSC	trans	rs9733	0.519	rs1134067	ENSG00000180764.13	PIPSL	-6.59	1.15e-10	0.000211	-0.35	-0.29	Tonsillectomy;	chr1:150748699	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs4970985	ENSG00000180764.13	PIPSL	6.59	1.15e-10	0.000211	0.35	0.29	Melanoma;	chr1:150914966	chr10:93958191~93961540:-
HNSC	trans	rs4295623	0.559	rs4841600	ENSG00000173295.6	FAM86B3P	6.59	1.16e-10	0.000212	0.32	0.29	Morning vs. evening chronotype;	chr8:11830639	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	6.59	1.16e-10	0.000212	0.33	0.29	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
HNSC	trans	rs10037055	0.687	rs6556308	ENSG00000226986.4	RP11-543B16.2	-6.59	1.16e-10	0.000212	-0.36	-0.29	Migraine without aura;	chr5:177219700	chr1:211207239~211207897:+
HNSC	trans	rs4970988	0.556	rs6695123	ENSG00000180764.13	PIPSL	6.59	1.16e-10	0.000212	0.38	0.29	Urate levels;	chr1:150591007	chr10:93958191~93961540:-
HNSC	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	6.59	1.16e-10	0.000213	0.36	0.29	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
HNSC	trans	rs867371	0.502	rs3759800	ENSG00000235370.6	DNM1P51	6.59	1.18e-10	0.000215	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:84398316~84411701:-
HNSC	trans	rs916888	0.61	rs199529	ENSG00000204650.12	CRHR1-IT1	6.59	1.18e-10	0.000215	0.33	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45620328~45648216:+
HNSC	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	6.59	1.18e-10	0.000216	0.36	0.29	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	6.59	1.18e-10	0.000216	0.36	0.29	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
HNSC	trans	rs9393777	0.777	rs35984974	ENSG00000176998.4	HCG4	-6.59	1.19e-10	0.000217	-0.52	-0.29	Intelligence (multi-trait analysis);	chr6:27442643	chr6:29791753~29792750:-
HNSC	trans	rs2899832	0.568	rs10144186	ENSG00000229083.1	PSMA6P2	6.59	1.19e-10	0.000218	0.49	0.29	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295199	chrX:12825840~12826833:+
HNSC	trans	rs1816752	0.603	rs9551099	ENSG00000224976.2	PARP4P2	6.59	1.2e-10	0.000219	0.34	0.29	Obesity-related traits;	chr13:24410978	chr13:19349137~19407962:+
HNSC	trans	rs34816374	1	rs34816374	ENSG00000253570.1	RNF5P1	6.59	1.2e-10	0.00022	0.68	0.29	Lung cancer in ever smokers;	chr6:26981893	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.79	rs13195401	ENSG00000253570.1	RNF5P1	6.59	1.21e-10	0.00022	0.7	0.29	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.79	rs13195402	ENSG00000253570.1	RNF5P1	6.59	1.21e-10	0.00022	0.7	0.29	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	6.59	1.21e-10	0.000221	0.36	0.29	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	6.59	1.21e-10	0.000221	0.36	0.29	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
HNSC	trans	rs9630182	0.561	rs11022810	ENSG00000257675.1	RP11-641A6.9	-6.59	1.22e-10	0.000222	-0.34	-0.29	Bone mineral density;	chr11:13416698	chr12:52748776~52750127:+
HNSC	trans	rs1816752	0.817	rs7985394	ENSG00000224976.2	PARP4P2	-6.59	1.22e-10	0.000222	-0.34	-0.29	Obesity-related traits;	chr13:24438714	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.789	rs7986037	ENSG00000224976.2	PARP4P2	-6.59	1.22e-10	0.000222	-0.34	-0.29	Obesity-related traits;	chr13:24438715	chr13:19349137~19407962:+
HNSC	trans	rs7929679	0.602	rs10501135	ENSG00000225531.1	RP11-196I18.3	6.59	1.22e-10	0.000223	0.35	0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34789633	chr9:107116829~107117557:+
HNSC	trans	rs11951515	0.508	rs67261887	ENSG00000174977.8	AC026271.5	-6.59	1.22e-10	0.000224	-0.28	-0.29	Metabolite levels  (X-11787);	chr5:43612339	chr17:18650195~18651542:+
HNSC	trans	rs2899832	0.568	rs17597281	ENSG00000229083.1	PSMA6P2	-6.58	1.23e-10	0.000224	-0.5	-0.29	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35313094	chrX:12825840~12826833:+
HNSC	trans	rs853679	0.607	rs35749575	ENSG00000253570.1	RNF5P1	6.58	1.23e-10	0.000225	0.69	0.29	Depression;	chr6:28147040	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13205911	ENSG00000253570.1	RNF5P1	6.58	1.23e-10	0.000225	0.69	0.29	Depression;	chr6:28156336	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13197176	ENSG00000253570.1	RNF5P1	6.58	1.23e-10	0.000225	0.69	0.29	Depression;	chr6:28161454	chr8:38600661~38601200:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-6.58	1.23e-10	0.000225	-0.34	-0.29	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-6.58	1.23e-10	0.000225	-0.34	-0.29	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
HNSC	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	6.58	1.23e-10	0.000225	0.36	0.29	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	6.58	1.23e-10	0.000225	0.36	0.29	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
HNSC	trans	rs9733	0.65	rs1971378	ENSG00000180764.13	PIPSL	6.58	1.24e-10	0.000225	0.35	0.29	Tonsillectomy;	chr1:150624785	chr10:93958191~93961540:-
HNSC	trans	rs79149102	0.522	rs8028893	ENSG00000227288.3	RP5-837I24.1	6.58	1.24e-10	0.000226	0.56	0.29	Lung cancer;	chr15:74553582	chr1:81501794~81503468:+
HNSC	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	6.58	1.24e-10	0.000226	0.37	0.29	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	6.58	1.25e-10	0.000228	0.36	0.29	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-6.58	1.26e-10	0.000229	-0.36	-0.29	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
HNSC	trans	rs1039766	1	rs268864	ENSG00000213985.4	AC078899.1	-6.58	1.26e-10	0.000229	-0.36	-0.29	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr19:20257720~20259418:+
HNSC	trans	rs7121616	0.576	rs7111590	ENSG00000256356.1	HSPA8P5	6.58	1.26e-10	0.00023	0.37	0.29	Breast cancer;	chr11:123055419	chr12:4097451~4099519:+
HNSC	trans	rs7032940	0.954	rs10980249	ENSG00000228236.2	TXNP5	6.58	1.26e-10	0.00023	0.37	0.29	Height;	chr9:110190494	chr2:149068596~149068910:-
HNSC	trans	rs722599	0.748	rs3742783	ENSG00000181227.3	RP4-682C21.2	6.58	1.26e-10	0.00023	0.31	0.29	IgG glycosylation;	chr14:74910305	chr1:75743423~75744776:-
HNSC	trans	rs697003	0.52	rs7553718	ENSG00000230450.1	NEK2P4	-6.58	1.26e-10	0.00023	-0.31	-0.29	Red cell distribution width;	chr1:211651455	chr2:131177618~131178946:-
HNSC	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	6.58	1.27e-10	0.000231	0.36	0.29	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	6.58	1.27e-10	0.000231	0.36	0.29	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
HNSC	trans	rs17507216	1	rs17507216	ENSG00000259295.5	CSPG4P12	6.58	1.27e-10	0.000232	0.42	0.29	Excessive daytime sleepiness;	chr15:82558175	chr15:85191438~85213905:+
HNSC	trans	rs9733	0.621	rs6669122	ENSG00000180764.13	PIPSL	6.58	1.28e-10	0.000232	0.35	0.29	Tonsillectomy;	chr1:150619256	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.654	rs34741518	ENSG00000173295.6	FAM86B3P	-6.58	1.28e-10	0.000234	-0.32	-0.29	Triglycerides;	chr8:10919350	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.504	rs6601566	ENSG00000173295.6	FAM86B3P	-6.58	1.29e-10	0.000235	-0.33	-0.29	Neuroticism;	chr8:11185465	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.595	rs10503416	ENSG00000173295.6	FAM86B3P	6.58	1.29e-10	0.000235	0.32	0.29	Triglycerides;	chr8:11130043	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.778	rs3014216	ENSG00000255397.1	AC022182.2	-6.58	1.29e-10	0.000235	-0.35	-0.29	Reticulocyte count;Red blood cell count;	chr1:45570088	chr8:60937705~60939871:-
HNSC	trans	rs7662987	0.517	rs1154410	ENSG00000233859.2	ADH5P4	-6.58	1.29e-10	0.000236	-0.35	-0.29	Smoking initiation;	chr4:99085494	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs3018047	ENSG00000233859.2	ADH5P4	6.57	1.31e-10	0.000238	0.35	0.29	Smoking initiation;	chr4:99093359	chr6:65836930~65838039:-
HNSC	trans	rs6981523	0.553	rs11783890	ENSG00000173295.6	FAM86B3P	-6.57	1.31e-10	0.000238	-0.35	-0.29	Neuroticism;	chr8:11198879	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.546	rs35353359	ENSG00000243753.4	HLA-L	-6.57	1.33e-10	0.000242	-0.64	-0.29	Depression;	chr6:28356601	chr6:30259584~30293014:+
HNSC	trans	rs2950393	0.804	rs898611	ENSG00000257210.1	NACAP3	-6.57	1.34e-10	0.000243	-0.32	-0.29	Platelet distribution width;	chr12:56769532	chr12:93124063~93124543:-
HNSC	trans	rs6756513	0.5	rs56222989	ENSG00000232654.1	FAM136BP	6.57	1.35e-10	0.000245	0.39	0.29	Breast cancer;Platelet count;	chr2:69861998	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs60248458	ENSG00000232654.1	FAM136BP	6.57	1.35e-10	0.000245	0.39	0.29	Breast cancer;Platelet count;	chr2:69866766	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs1013083	ENSG00000232654.1	FAM136BP	6.57	1.35e-10	0.000245	0.39	0.29	Breast cancer;Platelet count;	chr2:69872292	chr6:3045384~3045800:+
HNSC	trans	rs7412746	0.611	rs72704679	ENSG00000180764.13	PIPSL	-6.57	1.35e-10	0.000246	-0.35	-0.29	Melanoma;	chr1:150925001	chr10:93958191~93961540:-
HNSC	trans	rs6424115	0.964	rs2473375	ENSG00000228217.1	AL390877.1	-6.57	1.35e-10	0.000246	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23810055	chr1:117778087~117778506:-
HNSC	trans	rs6981523	0.553	rs11783045	ENSG00000173295.6	FAM86B3P	-6.57	1.36e-10	0.000247	-0.35	-0.29	Neuroticism;	chr8:11198666	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.607	rs13208096	ENSG00000243753.4	HLA-L	-6.57	1.36e-10	0.000247	-0.61	-0.29	Depression;	chr6:28257533	chr6:30259584~30293014:+
HNSC	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	6.57	1.36e-10	0.000248	0.36	0.29	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
HNSC	trans	rs941207	0.526	rs11171916	ENSG00000228224.3	NACAP1	-6.57	1.37e-10	0.000248	-0.34	-0.29	Platelet count;	chr12:56653236	chr8:101361794~101372707:+
HNSC	trans	rs7873102	0.967	rs4878742	ENSG00000229007.1	EXOSC3P1	-6.57	1.37e-10	0.000249	-0.36	-0.29	Brain structure;	chr9:38034184	chr21:32496812~32497311:+
HNSC	trans	rs7662987	0.793	rs7669660	ENSG00000228407.2	RP4-800M22.1	6.57	1.37e-10	0.000249	0.46	0.29	Smoking initiation;	chr4:99071451	chr1:52160261~52160600:-
HNSC	trans	rs6831352	0.819	rs1230158	ENSG00000233859.2	ADH5P4	-6.57	1.37e-10	0.000249	-0.33	-0.29	Alcohol dependence;	chr4:99069035	chr6:65836930~65838039:-
HNSC	trans	rs853679	0.607	rs72846780	ENSG00000253570.1	RNF5P1	6.57	1.38e-10	0.00025	0.69	0.29	Depression;	chr6:28151277	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	6.57	1.39e-10	0.000251	0.36	0.29	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	6.56	1.39e-10	0.000252	0.36	0.29	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	6.56	1.4e-10	0.000254	0.36	0.29	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
HNSC	trans	rs10917477	0.576	rs10917476	ENSG00000224237.1	MINOS1P3	-6.56	1.4e-10	0.000255	-0.36	-0.29	Thyroid function;	chr1:19534346	chr3:27214816~27215018:-
HNSC	trans	rs4948102	0.691	rs10435504	ENSG00000186940.6	CHCHD2P9	-6.56	1.41e-10	0.000255	-0.4	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.653	rs6593294	ENSG00000186940.6	CHCHD2P9	-6.56	1.41e-10	0.000255	-0.4	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr9:79391304~79391759:+
HNSC	trans	rs4276421	0.656	rs10473416	ENSG00000231752.4	EMBP1	6.56	1.41e-10	0.000256	0.36	0.29	P wave duration;	chr5:46246868	chr1:121519112~121571892:+
HNSC	trans	rs7617480	0.648	rs4858800	ENSG00000197582.5	GPX1P1	6.56	1.42e-10	0.000258	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chrX:13378735~13379340:-
HNSC	trans	rs7819412	0.745	rs4841498	ENSG00000173295.6	FAM86B3P	-6.56	1.43e-10	0.000258	-0.32	-0.29	Triglycerides;	chr8:11127922	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.566	rs11204743	ENSG00000180764.13	PIPSL	-6.56	1.43e-10	0.000259	-0.36	-0.29	Melanoma;	chr1:150917930	chr10:93958191~93961540:-
HNSC	trans	rs17783634	0.509	rs11775489	ENSG00000173295.6	FAM86B3P	-6.56	1.43e-10	0.000259	-0.34	-0.29	Subjective well-being;	chr8:11179334	chr8:8228595~8244865:+
HNSC	trans	rs1391708	1	rs7957145	ENSG00000121089.4	NACA3P	-6.56	1.43e-10	0.000259	-0.52	-0.29	Airway wall thickness;	chr12:56908336	chr4:164943290~164943937:+
HNSC	trans	rs8177876	0.822	rs1563077	ENSG00000224837.1	GCSHP5	6.56	1.44e-10	0.00026	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr1:168055901~168056422:-
HNSC	trans	rs3806843	0.832	rs2531360	ENSG00000231043.3	AC007238.1	6.56	1.44e-10	0.00026	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr2:58460292~58462032:-
HNSC	trans	rs9467711	0.79	rs45527431	ENSG00000253570.1	RNF5P1	6.56	1.44e-10	0.000261	0.71	0.29	Autism spectrum disorder or schizophrenia;	chr6:26599281	chr8:38600661~38601200:-
HNSC	trans	rs2950393	0.895	rs2958154	ENSG00000257210.1	NACAP3	-6.56	1.45e-10	0.000262	-0.34	-0.29	Platelet distribution width;	chr12:56671929	chr12:93124063~93124543:-
HNSC	trans	rs1816752	0.777	rs6490915	ENSG00000224976.2	PARP4P2	-6.56	1.45e-10	0.000262	-0.34	-0.29	Obesity-related traits;	chr13:24413724	chr13:19349137~19407962:+
HNSC	trans	rs61041336	0.534	rs2280398	ENSG00000230849.2	GOT2P2	-6.56	1.45e-10	0.000263	-0.57	-0.29	Neuritic plaque;	chr16:58678226	chr1:173141100~173142350:-
HNSC	trans	rs11951515	0.508	rs6860493	ENSG00000174977.8	AC026271.5	-6.56	1.46e-10	0.000264	-0.28	-0.29	Metabolite levels  (X-11787);	chr5:43602611	chr17:18650195~18651542:+
HNSC	trans	rs351855	0.642	rs2546095	ENSG00000217325.2	PRELID1P1	6.56	1.46e-10	0.000265	0.32	0.29	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr6:126643488~126644390:+
HNSC	trans	rs1023500	1	rs10154646	ENSG00000268568.1	AC007228.9	-6.56	1.47e-10	0.000266	-0.39	-0.29	Schizophrenia;	chr22:41935405	chr19:56672574~56673901:-
HNSC	trans	rs7617480	0.617	rs7610519	ENSG00000197582.5	GPX1P1	6.56	1.47e-10	0.000266	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48708994	chrX:13378735~13379340:-
HNSC	trans	rs17301013	0.932	rs2987874	ENSG00000213331.4	RP11-713C19.2	-6.56	1.47e-10	0.000266	-0.34	-0.29	Systemic lupus erythematosus;	chr1:174801053	chr4:187970273~187971284:+
HNSC	trans	rs17507216	0.718	rs17158403	ENSG00000259295.5	CSPG4P12	-6.55	1.48e-10	0.000267	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82572478	chr15:85191438~85213905:+
HNSC	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	6.55	1.48e-10	0.000268	0.36	0.29	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
HNSC	trans	rs1023500	1	rs6002548	ENSG00000268568.1	AC007228.9	-6.55	1.48e-10	0.000268	-0.39	-0.29	Schizophrenia;	chr22:41941036	chr19:56672574~56673901:-
HNSC	trans	rs7824557	0.628	rs7820301	ENSG00000173295.6	FAM86B3P	6.55	1.49e-10	0.00027	0.31	0.29	Retinal vascular caliber;	chr8:11371163	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.896	rs3118980	ENSG00000213331.4	RP11-713C19.2	-6.55	1.5e-10	0.000271	-0.34	-0.29	Systemic lupus erythematosus;	chr1:174793701	chr4:187970273~187971284:+
HNSC	trans	rs7819412	0.561	rs2001328	ENSG00000173295.6	FAM86B3P	-6.55	1.5e-10	0.000271	-0.33	-0.29	Triglycerides;	chr8:11129689	chr8:8228595~8244865:+
HNSC	trans	rs4713118	0.539	rs510987	ENSG00000204709.4	LINC01556	6.55	1.51e-10	0.000274	0.37	0.29	Parkinson's disease;	chr6:27879739	chr6:28943877~28944537:+
HNSC	trans	rs7819412	0.805	rs2409710	ENSG00000173295.6	FAM86B3P	-6.55	1.52e-10	0.000274	-0.33	-0.29	Triglycerides;	chr8:11122311	chr8:8228595~8244865:+
HNSC	trans	rs1039766	1	rs1039766	ENSG00000213985.4	AC078899.1	-6.55	1.52e-10	0.000274	-0.37	-0.29	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr19:20257720~20259418:+
HNSC	trans	rs1336900	0.637	rs35967040	ENSG00000180764.13	PIPSL	6.55	1.52e-10	0.000275	0.37	0.29	Blood protein levels;	chr1:150583112	chr10:93958191~93961540:-
HNSC	trans	rs17507216	0.628	rs8028130	ENSG00000259295.5	CSPG4P12	-6.55	1.54e-10	0.000279	-0.45	-0.29	Excessive daytime sleepiness;	chr15:82734974	chr15:85191438~85213905:+
HNSC	trans	rs200972	1	rs200972	ENSG00000204709.4	LINC01556	6.55	1.55e-10	0.00028	0.35	0.29	Urinary tract infection frequency;	chr6:27891059	chr6:28943877~28944537:+
HNSC	trans	rs1816752	0.905	rs9511264	ENSG00000224976.2	PARP4P2	6.55	1.56e-10	0.000281	0.34	0.29	Obesity-related traits;	chr13:24438079	chr13:19349137~19407962:+
HNSC	trans	rs12439619	0.705	rs17354185	ENSG00000235370.6	DNM1P51	6.55	1.57e-10	0.000283	0.42	0.29	Intelligence (multi-trait analysis);	chr15:82133829	chr15:84398316~84411701:-
HNSC	trans	rs877636	0.702	rs773108	ENSG00000212994.5	RPS26P6	6.54	1.58e-10	0.000284	0.36	0.29	Cognitive function;	chr12:55976127	chr8:100895771~100896118:+
HNSC	trans	rs722599	0.748	rs17102884	ENSG00000181227.3	RP4-682C21.2	6.54	1.58e-10	0.000285	0.3	0.29	IgG glycosylation;	chr14:74908196	chr1:75743423~75744776:-
HNSC	trans	rs13091206	1	rs13091206	ENSG00000197582.5	GPX1P1	6.54	1.59e-10	0.000286	0.47	0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chrX:13378735~13379340:-
HNSC	trans	rs1816752	0.819	rs7985478	ENSG00000224976.2	PARP4P2	-6.54	1.59e-10	0.000286	-0.33	-0.29	Obesity-related traits;	chr13:24417135	chr13:19349137~19407962:+
HNSC	trans	rs4295623	0.559	rs2409836	ENSG00000173295.6	FAM86B3P	6.54	1.59e-10	0.000287	0.32	0.29	Morning vs. evening chronotype;	chr8:11831719	chr8:8228595~8244865:+
HNSC	trans	rs867371	0.502	rs1846908	ENSG00000235370.6	DNM1P51	-6.54	1.6e-10	0.000288	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:84398316~84411701:-
HNSC	trans	rs2665103	0.655	rs1501367	ENSG00000235370.6	DNM1P51	-6.54	1.6e-10	0.000288	-0.34	-0.29	Intelligence (multi-trait analysis);	chr15:82230475	chr15:84398316~84411701:-
HNSC	trans	rs10037055	0.853	rs2336237	ENSG00000228305.2	AC016734.2	6.54	1.61e-10	0.00029	0.36	0.29	Migraine without aura;	chr5:177238878	chr2:63622178~63622831:-
HNSC	trans	rs453301	0.624	rs330056	ENSG00000173295.6	FAM86B3P	-6.54	1.61e-10	0.00029	-0.31	-0.29	Joint mobility (Beighton score);	chr8:9232185	chr8:8228595~8244865:+
HNSC	trans	rs453301	0.624	rs330058	ENSG00000173295.6	FAM86B3P	-6.54	1.61e-10	0.00029	-0.31	-0.29	Joint mobility (Beighton score);	chr8:9232299	chr8:8228595~8244865:+
HNSC	trans	rs11638815	0.724	rs2379997	ENSG00000235370.6	DNM1P51	6.54	1.62e-10	0.000292	0.37	0.29	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82734081	chr15:84398316~84411701:-
HNSC	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-6.54	1.62e-10	0.000292	-0.36	-0.29	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-6.54	1.62e-10	0.000293	-0.36	-0.29	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-6.54	1.62e-10	0.000293	-0.36	-0.29	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
HNSC	trans	rs6756513	0.5	rs2124007	ENSG00000232654.1	FAM136BP	6.54	1.63e-10	0.000293	0.39	0.29	Breast cancer;Platelet count;	chr2:69880277	chr6:3045384~3045800:+
HNSC	trans	rs6743068	0.541	rs6435079	ENSG00000235105.1	RP11-329A14.1	6.54	1.63e-10	0.000293	0.35	0.29	Lymphocyte percentage of white cells;	chr2:201335608	chr1:48435967~48437223:+
HNSC	trans	rs1039766	1	rs7558347	ENSG00000213985.4	AC078899.1	6.54	1.63e-10	0.000294	0.38	0.29	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr19:20257720~20259418:+
HNSC	trans	rs453301	0.624	rs330060	ENSG00000173295.6	FAM86B3P	-6.54	1.63e-10	0.000294	-0.31	-0.29	Joint mobility (Beighton score);	chr8:9233392	chr8:8228595~8244865:+
HNSC	trans	rs7032940	0.626	rs10816929	ENSG00000228236.2	TXNP5	6.54	1.63e-10	0.000294	0.33	0.29	Height;	chr9:110173466	chr2:149068596~149068910:-
HNSC	trans	rs6921919	0.778	rs67381177	ENSG00000253570.1	RNF5P1	6.54	1.64e-10	0.000295	0.7	0.29	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr8:38600661~38601200:-
HNSC	trans	rs10037055	0.741	rs2336405	ENSG00000226986.4	RP11-543B16.2	-6.54	1.64e-10	0.000295	-0.35	-0.29	Migraine without aura;	chr5:177230288	chr1:211207239~211207897:+
HNSC	trans	rs6921919	0.673	rs13201681	ENSG00000253570.1	RNF5P1	6.54	1.64e-10	0.000296	0.69	0.29	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr8:38600661~38601200:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-6.54	1.64e-10	0.000296	-0.33	-0.29	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
HNSC	trans	rs8067354	0.574	rs1295923	ENSG00000187870.7	RNFT1P3	6.54	1.65e-10	0.000296	0.41	0.29	Hemoglobin concentration;	chr17:59883075	chr17:20743333~20754501:-
HNSC	trans	rs9650657	0.59	rs10096777	ENSG00000173295.6	FAM86B3P	-6.54	1.65e-10	0.000297	-0.32	-0.29	Neuroticism;	chr8:10660990	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	6.54	1.66e-10	0.000298	0.36	0.29	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-6.54	1.66e-10	0.000299	-0.31	-0.29	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
HNSC	trans	rs9650657	0.571	rs11783247	ENSG00000173295.6	FAM86B3P	-6.53	1.67e-10	3e-04	-0.31	-0.29	Neuroticism;	chr8:10931365	chr8:8228595~8244865:+
HNSC	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	6.53	1.68e-10	0.000302	0.36	0.29	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
HNSC	trans	rs2665103	0.632	rs3902959	ENSG00000235370.6	DNM1P51	-6.53	1.68e-10	0.000303	-0.34	-0.29	Intelligence (multi-trait analysis);	chr15:82252586	chr15:84398316~84411701:-
HNSC	trans	rs7819412	0.54	rs2409726	ENSG00000173295.6	FAM86B3P	-6.53	1.69e-10	0.000305	-0.35	-0.29	Triglycerides;	chr8:11185629	chr8:8228595~8244865:+
HNSC	trans	rs3806843	0.766	rs2530239	ENSG00000231043.3	AC007238.1	6.53	1.7e-10	0.000305	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr2:58460292~58462032:-
HNSC	trans	rs722599	0.715	rs2300598	ENSG00000181227.3	RP4-682C21.2	6.53	1.7e-10	0.000306	0.31	0.29	IgG glycosylation;	chr14:74892526	chr1:75743423~75744776:-
HNSC	trans	rs12439619	0.693	rs7165536	ENSG00000235370.6	DNM1P51	-6.53	1.71e-10	0.000307	-0.39	-0.29	Intelligence (multi-trait analysis);	chr15:82273743	chr15:84398316~84411701:-
HNSC	trans	rs6831352	0.734	rs1311620	ENSG00000233859.2	ADH5P4	-6.53	1.71e-10	0.000307	-0.34	-0.29	Alcohol dependence;	chr4:99091940	chr6:65836930~65838039:-
HNSC	trans	rs7617480	0.648	rs9882443	ENSG00000197582.5	GPX1P1	6.53	1.71e-10	0.000307	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chrX:13378735~13379340:-
HNSC	trans	rs2456568	0.501	rs2511392	ENSG00000276509.1	CH17-353B19.1	6.53	1.71e-10	0.000308	0.32	0.29	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93969269	chr1:146235806~146237807:+
HNSC	trans	rs7662987	0.517	rs2602872	ENSG00000233859.2	ADH5P4	-6.53	1.71e-10	0.000308	-0.34	-0.29	Smoking initiation;	chr4:99117845	chr6:65836930~65838039:-
HNSC	trans	rs2250402	0.51	rs2291621	ENSG00000234106.3	RP11-288E14.2	6.53	1.71e-10	0.000308	0.62	0.29	Corneal curvature;	chr15:40032636	chr11:93535468~93535816:+
HNSC	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	6.53	1.74e-10	0.000312	0.36	0.29	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
HNSC	trans	rs7121616	0.563	rs1461494	ENSG00000241478.1	HSPA8P9	6.53	1.75e-10	0.000315	0.36	0.29	Breast cancer;	chr11:123055777	chr3:137880295~137882237:+
HNSC	trans	rs867371	0.502	rs28610286	ENSG00000235370.6	DNM1P51	-6.53	1.76e-10	0.000315	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:84398316~84411701:-
HNSC	trans	rs7824557	0.547	rs2736287	ENSG00000173295.6	FAM86B3P	-6.53	1.76e-10	0.000316	-0.31	-0.29	Retinal vascular caliber;	chr8:11370497	chr8:8228595~8244865:+
HNSC	trans	rs7930295	0.632	rs35245130	ENSG00000236257.1	EI24P2	6.53	1.76e-10	0.000316	0.42	0.29	Schizophrenia;	chr11:125771018	chr1:158454198~158455273:+
HNSC	trans	rs7930295	0.632	rs11220215	ENSG00000236257.1	EI24P2	6.53	1.76e-10	0.000316	0.42	0.29	Schizophrenia;	chr11:125771766	chr1:158454198~158455273:+
HNSC	trans	rs1816752	1	rs7999554	ENSG00000224976.2	PARP4P2	-6.53	1.76e-10	0.000316	-0.34	-0.29	Obesity-related traits;	chr13:24435631	chr13:19349137~19407962:+
HNSC	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	6.53	1.77e-10	0.000317	0.36	0.29	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
HNSC	trans	rs11220082	0.666	rs7103665	ENSG00000236257.1	EI24P2	-6.52	1.77e-10	0.000319	-0.35	-0.29	Schizophrenia;	chr11:125472998	chr1:158454198~158455273:+
HNSC	trans	rs11220082	0.644	rs61917855	ENSG00000236257.1	EI24P2	-6.52	1.77e-10	0.000319	-0.35	-0.29	Schizophrenia;	chr11:125473652	chr1:158454198~158455273:+
HNSC	trans	rs1391708	1	rs1391708	ENSG00000121089.4	NACA3P	-6.52	1.78e-10	0.00032	-0.51	-0.29	Airway wall thickness;	chr12:56911796	chr4:164943290~164943937:+
HNSC	trans	rs7930295	0.841	rs58929810	ENSG00000236257.1	EI24P2	6.52	1.79e-10	0.00032	0.44	0.29	Schizophrenia;	chr11:125460892	chr1:158454198~158455273:+
HNSC	trans	rs6831352	0.734	rs1453872	ENSG00000233859.2	ADH5P4	-6.52	1.79e-10	0.000322	-0.34	-0.29	Alcohol dependence;	chr4:99101331	chr6:65836930~65838039:-
HNSC	trans	rs7412746	0.658	rs6658066	ENSG00000180764.13	PIPSL	-6.52	1.8e-10	0.000323	-0.35	-0.29	Melanoma;	chr1:150946461	chr10:93958191~93961540:-
HNSC	trans	rs9393777	0.72	rs56401801	ENSG00000253570.1	RNF5P1	6.52	1.82e-10	0.000327	0.68	0.29	Intelligence (multi-trait analysis);	chr6:27333733	chr8:38600661~38601200:-
HNSC	trans	rs1336900	0.544	rs10888386	ENSG00000180764.13	PIPSL	6.52	1.83e-10	0.000329	0.36	0.29	Blood protein levels;	chr1:150639481	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.521	rs11777887	ENSG00000173295.6	FAM86B3P	6.52	1.85e-10	0.000331	0.33	0.29	Triglycerides;	chr8:11179290	chr8:8228595~8244865:+
HNSC	trans	rs58106596	0.747	rs10166046	ENSG00000259020.3	RP11-529H20.3	-6.52	1.86e-10	0.000333	-0.37	-0.29	Lymphocyte counts;White blood cell count;	chr2:231696274	chr14:92026566~92026887:+
HNSC	trans	rs1190596	1	rs1190596	ENSG00000181359.5	HSP90AA6P	6.52	1.86e-10	0.000334	0.43	0.29	Behavioural disinhibition (generation interaction);	chr14:102129288	chr4:170581470~170605450:-
HNSC	trans	rs79149102	0.522	rs8023786	ENSG00000227288.3	RP5-837I24.1	6.52	1.87e-10	0.000335	0.53	0.29	Lung cancer;	chr15:74530155	chr1:81501794~81503468:+
HNSC	trans	rs79149102	0.522	rs6495112	ENSG00000227288.3	RP5-837I24.1	6.52	1.87e-10	0.000335	0.53	0.29	Lung cancer;	chr15:74540457	chr1:81501794~81503468:+
HNSC	trans	rs79149102	0.522	rs7175512	ENSG00000227288.3	RP5-837I24.1	6.52	1.87e-10	0.000335	0.53	0.29	Lung cancer;	chr15:74540640	chr1:81501794~81503468:+
HNSC	trans	rs867371	0.502	rs7176926	ENSG00000235370.6	DNM1P51	-6.51	1.89e-10	0.000338	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:84398316~84411701:-
HNSC	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-6.51	1.89e-10	0.000338	-0.32	-0.29	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
HNSC	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-6.51	1.89e-10	0.000338	-0.32	-0.29	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
HNSC	trans	rs2336384	1	rs2103876	ENSG00000261819.1	RP11-680G24.4	6.51	1.91e-10	0.000343	0.41	0.29	Platelet count;	chr1:11993043	chr16:14988259~14990160:-
HNSC	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	6.51	1.92e-10	0.000343	0.36	0.29	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	6.51	1.92e-10	0.000343	0.36	0.29	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	6.51	1.92e-10	0.000343	0.36	0.29	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	6.51	1.93e-10	0.000346	0.35	0.29	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
HNSC	trans	rs6743068	0.521	rs7578970	ENSG00000235105.1	RP11-329A14.1	6.51	1.95e-10	0.000348	0.35	0.29	Lymphocyte percentage of white cells;	chr2:201365061	chr1:48435967~48437223:+
HNSC	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	6.51	1.95e-10	0.000348	0.36	0.29	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-6.51	1.95e-10	0.000348	-0.36	-0.29	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-6.51	1.95e-10	0.000348	-0.36	-0.29	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
HNSC	trans	rs453301	0.571	rs330048	ENSG00000253893.2	FAM85B	6.51	1.95e-10	0.000348	0.33	0.29	Joint mobility (Beighton score);	chr8:9229768	chr8:8167819~8226614:-
HNSC	trans	rs1023500	1	rs1047997	ENSG00000268568.1	AC007228.9	-6.51	1.95e-10	0.000349	-0.38	-0.29	Schizophrenia;	chr22:41938949	chr19:56672574~56673901:-
HNSC	trans	rs7617480	0.648	rs4858830	ENSG00000197582.5	GPX1P1	6.51	1.96e-10	0.00035	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chrX:13378735~13379340:-
HNSC	trans	rs7617480	0.544	rs6442129	ENSG00000197582.5	GPX1P1	6.51	1.96e-10	0.00035	0.46	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chrX:13378735~13379340:-
HNSC	trans	rs17301013	0.869	rs3133270	ENSG00000213331.4	RP11-713C19.2	-6.51	1.96e-10	0.000351	-0.34	-0.29	Systemic lupus erythematosus;	chr1:174819547	chr4:187970273~187971284:+
HNSC	trans	rs10037055	0.853	rs9313749	ENSG00000228305.2	AC016734.2	-6.51	1.98e-10	0.000353	-0.35	-0.29	Migraine without aura;	chr5:177170693	chr2:63622178~63622831:-
HNSC	trans	rs79149102	0.522	rs79811537	ENSG00000227288.3	RP5-837I24.1	6.51	1.98e-10	0.000354	0.53	0.29	Lung cancer;	chr15:74579474	chr1:81501794~81503468:+
HNSC	trans	rs79149102	0.649	rs9788672	ENSG00000227288.3	RP5-837I24.1	6.51	1.98e-10	0.000354	0.53	0.29	Lung cancer;	chr15:74584012	chr1:81501794~81503468:+
HNSC	trans	rs8177876	0.822	rs4324141	ENSG00000224837.1	GCSHP5	-6.5	2.01e-10	0.000358	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr1:168055901~168056422:-
HNSC	trans	rs8067354	0.54	rs1051424	ENSG00000187870.7	RNFT1P3	6.5	2.04e-10	0.000364	0.42	0.29	Hemoglobin concentration;	chr17:59946963	chr17:20743333~20754501:-
HNSC	trans	rs1816752	0.875	rs8001187	ENSG00000224976.2	PARP4P2	-6.5	2.04e-10	0.000364	-0.33	-0.29	Obesity-related traits;	chr13:24402276	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.783	rs9507333	ENSG00000224976.2	PARP4P2	-6.5	2.05e-10	0.000366	-0.33	-0.29	Obesity-related traits;	chr13:24404172	chr13:19349137~19407962:+
HNSC	trans	rs74781061	0.585	rs11072484	ENSG00000227288.3	RP5-837I24.1	6.5	2.06e-10	0.000367	0.59	0.29	Endometriosis;	chr15:74438407	chr1:81501794~81503468:+
HNSC	trans	rs11638815	0.668	rs11635460	ENSG00000235370.6	DNM1P51	-6.5	2.06e-10	0.000368	-0.36	-0.29	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725801	chr15:84398316~84411701:-
HNSC	trans	rs7819412	0.634	rs4841485	ENSG00000173295.6	FAM86B3P	6.5	2.07e-10	0.00037	0.33	0.29	Triglycerides;	chr8:11052426	chr8:8228595~8244865:+
HNSC	trans	rs697003	0.52	rs7551341	ENSG00000230450.1	NEK2P4	6.5	2.08e-10	0.000371	0.3	0.29	Red cell distribution width;	chr1:211651551	chr2:131177618~131178946:-
HNSC	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-6.5	2.08e-10	0.000371	-0.33	-0.29	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
HNSC	trans	rs1816752	0.819	rs6490917	ENSG00000224976.2	PARP4P2	-6.5	2.1e-10	0.000374	-0.33	-0.29	Obesity-related traits;	chr13:24423119	chr13:19349137~19407962:+
HNSC	trans	rs9630182	0.561	rs10832038	ENSG00000257675.1	RP11-641A6.9	-6.5	2.1e-10	0.000375	-0.33	-0.29	Bone mineral density;	chr11:13450707	chr12:52748776~52750127:+
HNSC	trans	rs13177918	0.559	rs12109637	ENSG00000226396.1	RP5-1056L3.3	6.5	2.1e-10	0.000375	0.21	0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:19608114~19608568:+
HNSC	trans	rs7412746	0.646	rs1972060	ENSG00000180764.13	PIPSL	-6.5	2.11e-10	0.000376	-0.35	-0.29	Melanoma;	chr1:150965118	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs752376	ENSG00000180764.13	PIPSL	-6.5	2.11e-10	0.000376	-0.35	-0.29	Melanoma;	chr1:150968905	chr10:93958191~93961540:-
HNSC	trans	rs7824557	0.547	rs2409749	ENSG00000173295.6	FAM86B3P	-6.49	2.13e-10	0.00038	-0.33	-0.29	Retinal vascular caliber;	chr8:11221440	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-6.49	2.15e-10	0.000382	-0.36	-0.29	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
HNSC	trans	rs8076336	1	rs8076336	ENSG00000263946.1	RP11-434D2.11	-6.49	2.15e-10	0.000383	-0.32	-0.29	Parental longevity (combined parental age at death);	chr17:18309300	chr17:20554971~20559410:-
HNSC	trans	rs2950393	0.895	rs2958123	ENSG00000257210.1	NACAP3	6.49	2.16e-10	0.000385	0.32	0.29	Platelet distribution width;	chr12:56668441	chr12:93124063~93124543:-
HNSC	trans	rs4730250	0.707	rs1981696	ENSG00000213326.4	RPS7P11	-6.49	2.16e-10	0.000385	-0.27	-0.29	Osteoarthritis;	chr7:107153655	chr17:46721582~46722167:-
HNSC	trans	rs9630182	0.561	rs1562436	ENSG00000257675.1	RP11-641A6.9	-6.49	2.17e-10	0.000387	-0.33	-0.29	Bone mineral density;	chr11:13440509	chr12:52748776~52750127:+
HNSC	trans	rs9733	0.596	rs17658705	ENSG00000180764.13	PIPSL	6.49	2.19e-10	0.00039	0.34	0.29	Tonsillectomy;	chr1:150705595	chr10:93958191~93961540:-
HNSC	trans	rs17507216	1	rs17158413	ENSG00000259295.5	CSPG4P12	-6.49	2.2e-10	0.000391	-0.41	-0.29	Excessive daytime sleepiness;	chr15:82566658	chr15:85191438~85213905:+
HNSC	trans	rs7412746	0.587	rs3849279	ENSG00000180764.13	PIPSL	-6.49	2.2e-10	0.000391	-0.35	-0.29	Melanoma;	chr1:150972231	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.634	rs6987767	ENSG00000173295.6	FAM86B3P	6.49	2.21e-10	0.000392	0.33	0.29	Triglycerides;	chr8:11052556	chr8:8228595~8244865:+
HNSC	trans	rs7112043	0.838	rs11032839	ENSG00000225531.1	RP11-196I18.3	6.49	2.21e-10	0.000393	0.36	0.29	Lung disease severity in cystic fibrosis;	chr11:34756178	chr9:107116829~107117557:+
HNSC	trans	rs1039766	1	rs268871	ENSG00000213985.4	AC078899.1	6.49	2.22e-10	0.000394	0.37	0.29	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr19:20257720~20259418:+
HNSC	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	6.49	2.22e-10	0.000395	0.34	0.29	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
HNSC	trans	rs7412746	0.646	rs10399947	ENSG00000180764.13	PIPSL	-6.49	2.23e-10	0.000396	-0.35	-0.29	Melanoma;	chr1:150889484	chr10:93958191~93961540:-
HNSC	trans	rs7873102	1	rs7850311	ENSG00000229007.1	EXOSC3P1	-6.49	2.23e-10	0.000397	-0.35	-0.29	Brain structure;	chr9:38060971	chr21:32496812~32497311:+
HNSC	trans	rs9393777	0.841	rs13207082	ENSG00000253570.1	RNF5P1	6.49	2.23e-10	0.000397	0.61	0.29	Intelligence (multi-trait analysis);	chr6:27283600	chr8:38600661~38601200:-
HNSC	trans	rs9733	0.526	rs6587542	ENSG00000180764.13	PIPSL	-6.49	2.24e-10	0.000398	-0.35	-0.29	Tonsillectomy;	chr1:150935225	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs4970931	ENSG00000180764.13	PIPSL	-6.49	2.24e-10	0.000398	-0.35	-0.29	Melanoma;	chr1:150938251	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs9661876	ENSG00000180764.13	PIPSL	-6.49	2.24e-10	0.000398	-0.35	-0.29	Melanoma;	chr1:150938435	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs2271076	ENSG00000180764.13	PIPSL	-6.49	2.24e-10	0.000398	-0.35	-0.29	Melanoma;	chr1:150944181	chr10:93958191~93961540:-
HNSC	trans	rs2950393	0.804	rs2958127	ENSG00000257210.1	NACAP3	6.48	2.26e-10	0.000402	0.32	0.29	Platelet distribution width;	chr12:56720523	chr12:93124063~93124543:-
HNSC	trans	rs6831352	0.703	rs2602854	ENSG00000233859.2	ADH5P4	-6.48	2.27e-10	0.000402	-0.34	-0.29	Alcohol dependence;	chr4:99107500	chr6:65836930~65838039:-
HNSC	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	6.48	2.27e-10	0.000403	0.35	0.29	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
HNSC	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	6.48	2.27e-10	0.000403	0.35	0.29	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
HNSC	trans	rs1355223	0.506	rs7130678	ENSG00000225531.1	RP11-196I18.3	6.48	2.27e-10	0.000403	0.36	0.29	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847634	chr9:107116829~107117557:+
HNSC	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	6.48	2.27e-10	0.000403	0.36	0.29	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	6.48	2.27e-10	0.000403	0.36	0.29	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
HNSC	trans	rs7412746	0.611	rs4970984	ENSG00000180764.13	PIPSL	-6.48	2.28e-10	0.000404	-0.35	-0.29	Melanoma;	chr1:150914901	chr10:93958191~93961540:-
HNSC	trans	rs864643	0.773	rs13064980	ENSG00000183298.5	RP11-556K13.1	-6.48	2.28e-10	0.000404	-0.43	-0.29	Attention deficit hyperactivity disorder;	chr3:39503973	chr1:101786340~101787219:-
HNSC	trans	rs4730250	0.707	rs1981696	ENSG00000239559.2	RPL37P2	-6.48	2.28e-10	0.000405	-0.28	-0.29	Osteoarthritis;	chr7:107153655	chr11:67682772~67683058:-
HNSC	trans	rs6600671	0.693	rs1853731	ENSG00000270231.3	NBPF8P	6.48	2.28e-10	0.000405	0.24	0.29	Hip geometry;	chr1:121510262	chr1:120436353~120467739:+
HNSC	trans	rs7647973	0.71	rs6446285	ENSG00000197582.5	GPX1P1	6.48	2.29e-10	0.000406	0.51	0.29	Menarche (age at onset);	chr3:49588873	chrX:13378735~13379340:-
HNSC	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	6.48	2.29e-10	0.000406	0.36	0.29	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
HNSC	trans	rs9329221	0.683	rs525726	ENSG00000173295.6	FAM86B3P	-6.48	2.29e-10	0.000406	-0.32	-0.29	Neuroticism;	chr8:10030287	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.542	rs11171978	ENSG00000257210.1	NACAP3	6.48	2.3e-10	0.000408	0.36	0.29	Platelet count;	chr12:56800015	chr12:93124063~93124543:-
HNSC	trans	rs26067	0.689	rs285529	ENSG00000231752.4	EMBP1	-6.48	2.3e-10	0.000408	-0.38	-0.29	Breast cancer;	chr5:50843452	chr1:121519112~121571892:+
HNSC	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-6.48	2.3e-10	0.000408	-0.31	-0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
HNSC	trans	rs7937890	0.559	rs1116739	ENSG00000236360.2	RP11-334A14.2	6.48	2.3e-10	0.000408	0.38	0.29	Mitochondrial DNA levels;	chr11:14467636	chr1:52993201~52993702:-
HNSC	trans	rs10037055	0.853	rs12660023	ENSG00000228305.2	AC016734.2	6.48	2.3e-10	0.000409	0.35	0.29	Migraine without aura;	chr5:177273884	chr2:63622178~63622831:-
HNSC	trans	rs7412746	0.611	rs1889741	ENSG00000180764.13	PIPSL	-6.48	2.31e-10	0.000409	-0.35	-0.29	Melanoma;	chr1:150896569	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs66847267	ENSG00000180764.13	PIPSL	-6.48	2.31e-10	0.000409	-0.35	-0.29	Melanoma;	chr1:150902697	chr10:93958191~93961540:-
HNSC	trans	rs2950393	0.804	rs7967600	ENSG00000257210.1	NACAP3	6.48	2.31e-10	0.00041	0.32	0.29	Platelet distribution width;	chr12:56768208	chr12:93124063~93124543:-
HNSC	trans	rs7662987	0.517	rs2851263	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99109203	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602858	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99109310	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.76	rs2602859	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Alcohol dependence;	chr4:99109432	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2851260	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99112423	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602865	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99113690	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602866	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99113846	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602873	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99117881	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2851256	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99118398	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs4235436	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99118469	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602881	ENSG00000233859.2	ADH5P4	-6.48	2.31e-10	0.00041	-0.34	-0.29	Smoking initiation;	chr4:99119544	chr6:65836930~65838039:-
HNSC	trans	rs853679	0.607	rs34662244	ENSG00000253570.1	RNF5P1	6.48	2.32e-10	0.000412	0.69	0.29	Depression;	chr6:28106103	chr8:38600661~38601200:-
HNSC	trans	rs35952432	1	rs35952432	ENSG00000253570.1	RNF5P1	6.48	2.32e-10	0.000412	0.69	0.29	Lung cancer;	chr6:28107123	chr8:38600661~38601200:-
HNSC	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	6.48	2.33e-10	0.000413	0.35	0.29	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
HNSC	trans	rs7412746	0.586	rs2864882	ENSG00000180764.13	PIPSL	-6.48	2.33e-10	0.000413	-0.35	-0.29	Melanoma;	chr1:150910561	chr10:93958191~93961540:-
HNSC	trans	rs7662987	0.517	rs2602876	ENSG00000233859.2	ADH5P4	-6.48	2.33e-10	0.000414	-0.34	-0.29	Smoking initiation;	chr4:99118384	chr6:65836930~65838039:-
HNSC	trans	rs6600671	0.692	rs11249430	ENSG00000270231.3	NBPF8P	6.48	2.35e-10	0.000417	0.24	0.29	Hip geometry;	chr1:121547115	chr1:120436353~120467739:+
HNSC	trans	rs853679	0.546	rs71537572	ENSG00000253570.1	RNF5P1	6.48	2.37e-10	0.000419	0.65	0.29	Depression;	chr6:28002937	chr8:38600661~38601200:-
HNSC	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-6.48	2.4e-10	0.000425	-0.39	-0.29	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
HNSC	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	6.47	2.42e-10	0.000428	0.35	0.29	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
HNSC	trans	rs11951515	0.508	rs10059993	ENSG00000174977.8	AC026271.5	-6.47	2.43e-10	0.000429	-0.27	-0.29	Metabolite levels  (X-11787);	chr5:43598250	chr17:18650195~18651542:+
HNSC	trans	rs6424115	1	rs58035855	ENSG00000228217.1	AL390877.1	6.47	2.44e-10	0.000431	0.36	0.29	Immature fraction of reticulocytes;	chr1:23838758	chr1:117778087~117778506:-
HNSC	trans	rs9329221	0.905	rs6601451	ENSG00000173295.6	FAM86B3P	-6.47	2.44e-10	0.000432	-0.32	-0.29	Neuroticism;	chr8:10386171	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.804	rs2035081	ENSG00000257210.1	NACAP3	6.47	2.44e-10	0.000432	0.32	0.29	Platelet distribution width;	chr12:56732095	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.804	rs10783796	ENSG00000257210.1	NACAP3	6.47	2.44e-10	0.000432	0.32	0.29	Platelet distribution width;	chr12:56733387	chr12:93124063~93124543:-
HNSC	trans	rs6831352	0.819	rs1230155	ENSG00000233859.2	ADH5P4	-6.47	2.45e-10	0.000433	-0.32	-0.29	Alcohol dependence;	chr4:99068108	chr6:65836930~65838039:-
HNSC	trans	rs853679	0.607	rs67662114	ENSG00000253570.1	RNF5P1	6.47	2.47e-10	0.000437	0.65	0.29	Depression;	chr6:27964523	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13216117	ENSG00000253570.1	RNF5P1	6.47	2.47e-10	0.000437	0.65	0.29	Depression;	chr6:27970706	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs36101351	ENSG00000253570.1	RNF5P1	6.47	2.47e-10	0.000437	0.65	0.29	Depression;	chr6:27975591	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs28360499	ENSG00000253570.1	RNF5P1	6.47	2.47e-10	0.000437	0.65	0.29	Depression;	chr6:27977618	chr8:38600661~38601200:-
HNSC	trans	rs8177876	0.57	rs11863158	ENSG00000224837.1	GCSHP5	6.47	2.47e-10	0.000437	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr1:168055901~168056422:-
HNSC	trans	rs11220082	0.666	rs2241514	ENSG00000236257.1	EI24P2	-6.47	2.49e-10	0.00044	-0.35	-0.29	Schizophrenia;	chr11:125456130	chr1:158454198~158455273:+
HNSC	trans	rs9733	0.503	rs7556451	ENSG00000180764.13	PIPSL	-6.47	2.49e-10	0.000441	-0.34	-0.29	Tonsillectomy;	chr1:150940666	chr10:93958191~93961540:-
HNSC	trans	rs9329221	0.772	rs7824675	ENSG00000173295.6	FAM86B3P	-6.47	2.5e-10	0.000442	-0.32	-0.29	Neuroticism;	chr8:10385908	chr8:8228595~8244865:+
HNSC	trans	rs7930295	0.632	rs2081502	ENSG00000236257.1	EI24P2	6.47	2.53e-10	0.000447	0.42	0.29	Schizophrenia;	chr11:125773374	chr1:158454198~158455273:+
HNSC	trans	rs7412746	0.611	rs10888398	ENSG00000180764.13	PIPSL	6.46	2.56e-10	0.000452	0.34	0.29	Melanoma;	chr1:150914306	chr10:93958191~93961540:-
HNSC	trans	rs1023500	1	rs9620001	ENSG00000268568.1	AC007228.9	-6.46	2.57e-10	0.000453	-0.38	-0.29	Schizophrenia;	chr22:41934225	chr19:56672574~56673901:-
HNSC	trans	rs9329221	0.683	rs4598253	ENSG00000173295.6	FAM86B3P	-6.46	2.57e-10	0.000454	-0.31	-0.29	Neuroticism;	chr8:10032794	chr8:8228595~8244865:+
HNSC	trans	rs7873102	0.967	rs10814646	ENSG00000229007.1	EXOSC3P1	-6.46	2.61e-10	0.00046	-0.36	-0.29	Brain structure;	chr9:38031033	chr21:32496812~32497311:+
HNSC	trans	rs7819412	0.54	rs11777355	ENSG00000173295.6	FAM86B3P	-6.46	2.61e-10	0.000461	-0.34	-0.29	Triglycerides;	chr8:11187180	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.526	rs2950393	ENSG00000228224.3	NACAP1	-6.46	2.63e-10	0.000463	-0.33	-0.29	Platelet count;	chr12:56642239	chr8:101361794~101372707:+
HNSC	trans	rs7121616	0.576	rs4936767	ENSG00000241478.1	HSPA8P9	6.46	2.65e-10	0.000467	0.36	0.29	Breast cancer;	chr11:123047451	chr3:137880295~137882237:+
HNSC	trans	rs853679	0.556	rs13197633	ENSG00000253570.1	RNF5P1	6.46	2.66e-10	0.000469	0.71	0.29	Depression;	chr6:28206979	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.79	rs67777156	ENSG00000253570.1	RNF5P1	6.46	2.66e-10	0.000469	0.69	0.29	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.722	rs13201782	ENSG00000253570.1	RNF5P1	6.46	2.66e-10	0.000469	0.69	0.29	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr8:38600661~38601200:-
HNSC	trans	rs26067	0.689	rs27266	ENSG00000231752.4	EMBP1	-6.46	2.67e-10	0.00047	-0.38	-0.29	Breast cancer;	chr5:50865793	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs35030260	ENSG00000243753.4	HLA-L	-6.46	2.67e-10	0.000471	-0.62	-0.29	Depression;	chr6:28337731	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13217619	ENSG00000243753.4	HLA-L	-6.46	2.67e-10	0.000471	-0.62	-0.29	Depression;	chr6:28338894	chr6:30259584~30293014:+
HNSC	trans	rs916888	0.647	rs199523	ENSG00000280022.1	RP11-707O23.1	-6.46	2.7e-10	0.000475	-0.32	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45592621~45593369:+
HNSC	trans	rs7412746	0.621	rs11204749	ENSG00000180764.13	PIPSL	-6.45	2.72e-10	0.000479	-0.34	-0.29	Melanoma;	chr1:150957087	chr10:93958191~93961540:-
HNSC	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-6.45	2.73e-10	0.00048	-0.36	-0.29	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-6.45	2.73e-10	0.00048	-0.36	-0.29	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-6.45	2.73e-10	0.00048	-0.36	-0.29	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
HNSC	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-6.45	2.73e-10	0.00048	-0.36	-0.29	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
HNSC	trans	rs9630182	0.519	rs12417641	ENSG00000257675.1	RP11-641A6.9	-6.45	2.73e-10	0.000481	-0.33	-0.29	Bone mineral density;	chr11:13373760	chr12:52748776~52750127:+
HNSC	trans	rs853679	0.546	rs13195291	ENSG00000253570.1	RNF5P1	6.45	2.73e-10	0.000481	0.7	0.29	Depression;	chr6:28201463	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-6.45	2.77e-10	0.000487	-0.35	-0.29	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-6.45	2.77e-10	0.000487	-0.35	-0.29	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
HNSC	trans	rs12145833	0.79	rs74666281	ENSG00000154608.12	CEP170P1	-6.45	2.77e-10	0.000488	-0.37	-0.29	Obesity (early onset extreme);	chr1:243352678	chr4:118467590~118554204:+
HNSC	trans	rs1816752	0.819	rs7317504	ENSG00000224976.2	PARP4P2	-6.45	2.78e-10	0.000488	-0.33	-0.29	Obesity-related traits;	chr13:24411287	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.783	rs7317712	ENSG00000224976.2	PARP4P2	-6.45	2.78e-10	0.000488	-0.33	-0.29	Obesity-related traits;	chr13:24411365	chr13:19349137~19407962:+
HNSC	trans	rs7937890	0.559	rs2575829	ENSG00000236360.2	RP11-334A14.2	6.45	2.79e-10	0.00049	0.38	0.29	Mitochondrial DNA levels;	chr11:14463475	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597200	ENSG00000236360.2	RP11-334A14.2	6.45	2.79e-10	0.00049	0.38	0.29	Mitochondrial DNA levels;	chr11:14464054	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2575830	ENSG00000236360.2	RP11-334A14.2	6.45	2.79e-10	0.00049	0.38	0.29	Mitochondrial DNA levels;	chr11:14464056	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2575831	ENSG00000236360.2	RP11-334A14.2	6.45	2.79e-10	0.00049	0.38	0.29	Mitochondrial DNA levels;	chr11:14464648	chr1:52993201~52993702:-
HNSC	trans	rs26067	0.74	rs26079	ENSG00000231752.4	EMBP1	-6.45	2.79e-10	0.00049	-0.38	-0.29	Breast cancer;	chr5:50863180	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	6.45	2.79e-10	0.00049	0.34	0.29	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
HNSC	trans	rs9650657	0.513	rs7005884	ENSG00000173295.6	FAM86B3P	-6.45	2.8e-10	0.000491	-0.31	-0.29	Neuroticism;	chr8:10938962	chr8:8228595~8244865:+
HNSC	trans	rs12439619	0.693	rs4778989	ENSG00000235370.6	DNM1P51	-6.45	2.8e-10	0.000491	-0.39	-0.29	Intelligence (multi-trait analysis);	chr15:82276963	chr15:84398316~84411701:-
HNSC	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-6.45	2.8e-10	0.000492	-0.36	-0.29	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-6.45	2.8e-10	0.000492	-0.36	-0.29	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
HNSC	trans	rs916888	0.647	rs199524	ENSG00000280022.1	RP11-707O23.1	-6.45	2.81e-10	0.000493	-0.32	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45592621~45593369:+
HNSC	trans	rs7824557	0.603	rs2736278	ENSG00000173295.6	FAM86B3P	6.45	2.82e-10	0.000494	0.32	0.29	Retinal vascular caliber;	chr8:11362272	chr8:8228595~8244865:+
HNSC	trans	rs7937890	0.531	rs2575828	ENSG00000236360.2	RP11-334A14.2	6.45	2.82e-10	0.000495	0.38	0.29	Mitochondrial DNA levels;	chr11:14462646	chr1:52993201~52993702:-
HNSC	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	6.45	2.82e-10	0.000495	0.36	0.29	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
HNSC	trans	rs62344088	1	rs62344088	ENSG00000185986.11	SDHAP3	6.45	2.83e-10	0.000496	0.69	0.29	Asthma (childhood onset);	chr5:95949	chr5:1572222~1594620:-
HNSC	trans	rs62344088	1	rs7727872	ENSG00000185986.11	SDHAP3	6.45	2.83e-10	0.000496	0.69	0.29	Asthma (childhood onset);	chr5:97818	chr5:1572222~1594620:-
HNSC	trans	rs62344088	1	rs9986162	ENSG00000185986.11	SDHAP3	6.45	2.83e-10	0.000496	0.69	0.29	Asthma (childhood onset);	chr5:107396	chr5:1572222~1594620:-
HNSC	trans	rs3849046	0.967	rs2242599	ENSG00000226666.1	HSPA9P1	6.45	2.85e-10	5e-04	0.29	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138508585	chr2:221961737~221963765:+
HNSC	trans	rs9393777	0.92	rs55834529	ENSG00000253570.1	RNF5P1	6.45	2.85e-10	5e-04	0.69	0.29	Intelligence (multi-trait analysis);	chr6:27104763	chr8:38600661~38601200:-
HNSC	trans	rs8177876	0.642	rs56032321	ENSG00000224837.1	GCSHP5	6.45	2.86e-10	0.000501	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs56119129	ENSG00000224837.1	GCSHP5	6.45	2.86e-10	0.000501	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.731	rs77145371	ENSG00000224837.1	GCSHP5	6.45	2.86e-10	0.000501	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.908	rs80187824	ENSG00000224837.1	GCSHP5	6.45	2.86e-10	0.000501	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr1:168055901~168056422:-
HNSC	trans	rs2898290	0.592	rs2736342	ENSG00000173295.6	FAM86B3P	-6.45	2.87e-10	0.000503	-0.31	-0.29	Systolic blood pressure;	chr8:11489780	chr8:8228595~8244865:+
HNSC	trans	rs8177876	0.822	rs8177959	ENSG00000224837.1	GCSHP5	6.45	2.87e-10	0.000504	0.48	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr1:168055901~168056422:-
HNSC	trans	rs7121616	0.961	rs11218976	ENSG00000229091.2	HSPA8P8	6.45	2.88e-10	0.000505	0.32	0.29	Breast cancer;	chr11:123090950	chr7:10451311~10452526:+
HNSC	trans	rs1816752	0.905	rs11839006	ENSG00000224976.2	PARP4P2	-6.44	2.89e-10	0.000506	-0.33	-0.29	Obesity-related traits;	chr13:24435893	chr13:19349137~19407962:+
HNSC	trans	rs7520050	0.778	rs3014238	ENSG00000255397.1	AC022182.2	6.44	2.92e-10	0.000511	0.34	0.29	Reticulocyte count;Red blood cell count;	chr1:45624542	chr8:60937705~60939871:-
HNSC	trans	rs2950393	0.804	rs1466382	ENSG00000257210.1	NACAP3	-6.44	2.92e-10	0.000512	-0.33	-0.29	Platelet distribution width;	chr12:56723050	chr12:93124063~93124543:-
HNSC	trans	rs9393777	0.92	rs35768595	ENSG00000253570.1	RNF5P1	6.44	2.92e-10	0.000512	0.69	0.29	Intelligence (multi-trait analysis);	chr6:27174125	chr8:38600661~38601200:-
HNSC	trans	rs1391708	0.834	rs4612852	ENSG00000121089.4	NACA3P	-6.44	2.94e-10	0.000514	-0.53	-0.29	Airway wall thickness;	chr12:56902257	chr4:164943290~164943937:+
HNSC	trans	rs6915893	0.74	rs12194394	ENSG00000267156.1	TPMTP1	-6.44	2.94e-10	0.000515	-0.35	-0.29	Intrinsic epigenetic age acceleration;	chr6:18103050	chr18:47630112~47630848:+
HNSC	trans	rs816535	1	rs816535	ENSG00000279352.1	RP11-411B10.7	6.44	2.94e-10	0.000515	0.43	0.29	Parkinson disease and lewy body pathology;	chr20:26275360	chr18:14010054~14010917:+
HNSC	trans	rs9393777	0.92	rs66462181	ENSG00000253570.1	RNF5P1	6.44	2.94e-10	0.000515	0.69	0.29	Intelligence (multi-trait analysis);	chr6:27123882	chr8:38600661~38601200:-
HNSC	trans	rs7929679	0.551	rs906902	ENSG00000225531.1	RP11-196I18.3	-6.44	2.99e-10	0.000523	-0.34	-0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34758731	chr9:107116829~107117557:+
HNSC	trans	rs4948102	0.731	rs10229446	ENSG00000186940.6	CHCHD2P9	6.44	3e-10	0.000525	0.4	0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr9:79391304~79391759:+
HNSC	trans	rs7930295	1	rs34880099	ENSG00000236257.1	EI24P2	6.44	3.02e-10	0.000529	0.43	0.29	Schizophrenia;	chr11:125442413	chr1:158454198~158455273:+
HNSC	trans	rs7824557	0.527	rs2572449	ENSG00000254340.1	RP11-10A14.3	6.44	3.02e-10	0.000529	0.33	0.29	Retinal vascular caliber;	chr8:11381628	chr8:9141424~9145435:+
HNSC	trans	rs1816752	0.712	rs2862898	ENSG00000224976.2	PARP4P2	-6.44	3.03e-10	0.00053	-0.33	-0.29	Obesity-related traits;	chr13:24414323	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.652	rs2902356	ENSG00000224976.2	PARP4P2	-6.44	3.03e-10	0.00053	-0.33	-0.29	Obesity-related traits;	chr13:24414333	chr13:19349137~19407962:+
HNSC	trans	rs4948102	0.731	rs4689	ENSG00000215006.4	CHCHD2P2	-6.44	3.03e-10	0.00053	-0.39	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr5:69333929~69334249:+
HNSC	trans	rs9733	0.65	rs12125672	ENSG00000180764.13	PIPSL	6.44	3.04e-10	0.000531	0.35	0.29	Tonsillectomy;	chr1:150581994	chr10:93958191~93961540:-
HNSC	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	6.44	3.04e-10	0.000531	0.35	0.29	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
HNSC	trans	rs9329221	0.683	rs555200	ENSG00000173295.6	FAM86B3P	-6.44	3.04e-10	0.000532	-0.31	-0.29	Neuroticism;	chr8:10031219	chr8:8228595~8244865:+
HNSC	trans	rs8177876	0.749	rs2278025	ENSG00000224837.1	GCSHP5	-6.44	3.04e-10	0.000532	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr1:168055901~168056422:-
HNSC	trans	rs941207	0.762	rs10450	ENSG00000257210.1	NACAP3	6.44	3.04e-10	0.000532	0.33	0.29	Platelet count;	chr12:56590822	chr12:93124063~93124543:-
HNSC	trans	rs6831352	0.819	rs13832	ENSG00000233859.2	ADH5P4	-6.44	3.05e-10	0.000534	-0.33	-0.29	Alcohol dependence;	chr4:99071924	chr6:65836930~65838039:-
HNSC	trans	rs1816752	0.875	rs1050110	ENSG00000224976.2	PARP4P2	-6.44	3.06e-10	0.000534	-0.33	-0.29	Obesity-related traits;	chr13:24435347	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs7320102	ENSG00000224976.2	PARP4P2	-6.44	3.06e-10	0.000535	-0.33	-0.29	Obesity-related traits;	chr13:24437435	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs7339140	ENSG00000224976.2	PARP4P2	-6.44	3.06e-10	0.000535	-0.33	-0.29	Obesity-related traits;	chr13:24437764	chr13:19349137~19407962:+
HNSC	trans	rs7824557	0.507	rs7010590	ENSG00000173295.6	FAM86B3P	6.43	3.1e-10	0.000542	0.32	0.29	Retinal vascular caliber;	chr8:11205373	chr8:8228595~8244865:+
HNSC	trans	rs7662987	0.517	rs2851265	ENSG00000233859.2	ADH5P4	-6.43	3.11e-10	0.000542	-0.34	-0.29	Smoking initiation;	chr4:99108533	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602877	ENSG00000233859.2	ADH5P4	-6.43	3.11e-10	0.000542	-0.34	-0.29	Smoking initiation;	chr4:99118696	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602878	ENSG00000233859.2	ADH5P4	-6.43	3.11e-10	0.000542	-0.34	-0.29	Smoking initiation;	chr4:99118802	chr6:65836930~65838039:-
HNSC	trans	rs7937890	0.559	rs2597197	ENSG00000236360.2	RP11-334A14.2	6.43	3.12e-10	0.000545	0.38	0.29	Mitochondrial DNA levels;	chr11:14468286	chr1:52993201~52993702:-
HNSC	trans	rs453301	0.624	rs330060	ENSG00000253893.2	FAM85B	6.43	3.12e-10	0.000545	0.33	0.29	Joint mobility (Beighton score);	chr8:9233392	chr8:8167819~8226614:-
HNSC	trans	rs941207	0.526	rs12229457	ENSG00000228224.3	NACAP1	-6.43	3.14e-10	0.000547	-0.33	-0.29	Platelet count;	chr12:56639896	chr8:101361794~101372707:+
HNSC	trans	rs453301	0.624	rs330056	ENSG00000253893.2	FAM85B	6.43	3.14e-10	0.000547	0.33	0.29	Joint mobility (Beighton score);	chr8:9232185	chr8:8167819~8226614:-
HNSC	trans	rs453301	0.624	rs330058	ENSG00000253893.2	FAM85B	6.43	3.14e-10	0.000547	0.33	0.29	Joint mobility (Beighton score);	chr8:9232299	chr8:8167819~8226614:-
HNSC	trans	rs864643	0.812	rs1513218	ENSG00000183298.5	RP11-556K13.1	6.43	3.14e-10	0.000548	0.43	0.29	Attention deficit hyperactivity disorder;	chr3:39504097	chr1:101786340~101787219:-
HNSC	trans	rs7412746	0.611	rs2280627	ENSG00000180764.13	PIPSL	-6.43	3.16e-10	0.000551	-0.34	-0.29	Melanoma;	chr1:150963396	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.607	rs35902873	ENSG00000253570.1	RNF5P1	6.43	3.16e-10	0.000552	0.68	0.29	Depression;	chr6:28091171	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13197574	ENSG00000253570.1	RNF5P1	6.43	3.16e-10	0.000552	0.68	0.29	Depression;	chr6:28092461	chr8:38600661~38601200:-
HNSC	trans	rs2950393	0.927	rs11171914	ENSG00000228224.3	NACAP1	-6.43	3.18e-10	0.000554	-0.33	-0.29	Platelet distribution width;	chr12:56649462	chr8:101361794~101372707:+
HNSC	trans	rs2336384	1	rs61776516	ENSG00000261819.1	RP11-680G24.4	6.43	3.18e-10	0.000555	0.4	0.29	Platelet count;	chr1:11986971	chr16:14988259~14990160:-
HNSC	trans	rs2336384	1	rs6668386	ENSG00000261819.1	RP11-680G24.4	6.43	3.18e-10	0.000555	0.4	0.29	Platelet count;	chr1:11987176	chr16:14988259~14990160:-
HNSC	trans	rs2336384	1	rs7551874	ENSG00000261819.1	RP11-680G24.4	6.43	3.18e-10	0.000555	0.4	0.29	Platelet count;	chr1:11988073	chr16:14988259~14990160:-
HNSC	trans	rs2336384	1	rs4846085	ENSG00000261819.1	RP11-680G24.4	6.43	3.18e-10	0.000555	0.4	0.29	Platelet count;	chr1:11990577	chr16:14988259~14990160:-
HNSC	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	6.43	3.18e-10	0.000555	0.35	0.29	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
HNSC	trans	rs6756513	0.5	rs12613917	ENSG00000232654.1	FAM136BP	6.43	3.19e-10	0.000557	0.38	0.29	Breast cancer;Platelet count;	chr2:69838970	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs11888098	ENSG00000232654.1	FAM136BP	6.43	3.19e-10	0.000557	0.38	0.29	Breast cancer;Platelet count;	chr2:69839759	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs11888102	ENSG00000232654.1	FAM136BP	6.43	3.19e-10	0.000557	0.38	0.29	Breast cancer;Platelet count;	chr2:69839790	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs3771533	ENSG00000232654.1	FAM136BP	6.43	3.19e-10	0.000557	0.38	0.29	Breast cancer;Platelet count;	chr2:69840925	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs2872076	ENSG00000232654.1	FAM136BP	6.43	3.19e-10	0.000557	0.38	0.29	Breast cancer;Platelet count;	chr2:69841623	chr6:3045384~3045800:+
HNSC	trans	rs8177876	0.731	rs74882687	ENSG00000224837.1	GCSHP5	6.43	3.21e-10	0.000559	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.642	rs76909932	ENSG00000224837.1	GCSHP5	6.43	3.21e-10	0.000559	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs8177939	ENSG00000224837.1	GCSHP5	6.43	3.21e-10	0.000559	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr1:168055901~168056422:-
HNSC	trans	rs11172055	0.807	rs7314567	ENSG00000121089.4	NACA3P	6.43	3.22e-10	0.000562	0.33	0.29	Migraine;	chr12:56864231	chr4:164943290~164943937:+
HNSC	trans	rs11220082	0.542	rs11220079	ENSG00000236257.1	EI24P2	-6.43	3.23e-10	0.000562	-0.35	-0.29	Schizophrenia;	chr11:125450033	chr1:158454198~158455273:+
HNSC	trans	rs7937890	0.532	rs2575827	ENSG00000236360.2	RP11-334A14.2	6.43	3.23e-10	0.000562	0.38	0.29	Mitochondrial DNA levels;	chr11:14453969	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.532	rs2256884	ENSG00000236360.2	RP11-334A14.2	6.43	3.23e-10	0.000562	0.38	0.29	Mitochondrial DNA levels;	chr11:14454856	chr1:52993201~52993702:-
HNSC	trans	rs546131	0.82	rs744841	ENSG00000225531.1	RP11-196I18.3	6.43	3.24e-10	0.000564	0.35	0.29	Lung disease severity in cystic fibrosis;	chr11:34836120	chr9:107116829~107117557:+
HNSC	trans	rs7412746	0.552	rs4970980	ENSG00000180764.13	PIPSL	-6.43	3.24e-10	0.000565	-0.34	-0.29	Melanoma;	chr1:150892516	chr10:93958191~93961540:-
HNSC	trans	rs10037055	0.853	rs1363405	ENSG00000228305.2	AC016734.2	6.43	3.25e-10	0.000565	0.34	0.29	Migraine without aura;	chr5:177209881	chr2:63622178~63622831:-
HNSC	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	6.43	3.25e-10	0.000566	0.3	0.28	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
HNSC	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	6.42	3.26e-10	0.000568	0.36	0.28	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
HNSC	trans	rs6756513	0.5	rs56168154	ENSG00000232654.1	FAM136BP	6.42	3.26e-10	0.000568	0.38	0.28	Breast cancer;Platelet count;	chr2:69863781	chr6:3045384~3045800:+
HNSC	trans	rs4948102	0.924	rs13241866	ENSG00000186940.6	CHCHD2P9	-6.42	3.27e-10	0.00057	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56023185	chr9:79391304~79391759:+
HNSC	trans	rs9630182	0.54	rs11022780	ENSG00000257675.1	RP11-641A6.9	-6.42	3.29e-10	0.000572	-0.33	-0.28	Bone mineral density;	chr11:13375362	chr12:52748776~52750127:+
HNSC	trans	rs6424115	0.83	rs3003333	ENSG00000228217.1	AL390877.1	6.42	3.31e-10	0.000575	0.35	0.28	Immature fraction of reticulocytes;	chr1:23867524	chr1:117778087~117778506:-
HNSC	trans	rs4879656	0.525	rs7852206	ENSG00000215007.3	DNAJA1P3	6.42	3.31e-10	0.000576	0.33	0.28	Menopause (age at onset);	chr9:33017383	chrX:107351650~107352843:-
HNSC	trans	rs864643	0.678	rs1768198	ENSG00000183298.5	RP11-556K13.1	6.42	3.35e-10	0.000583	0.45	0.28	Attention deficit hyperactivity disorder;	chr3:39474994	chr1:101786340~101787219:-
HNSC	trans	rs673253	0.686	rs3791136	ENSG00000231007.5	CDC20P1	6.42	3.35e-10	0.000583	0.41	0.28	Intelligence (multi-trait analysis);	chr1:43584276	chr9:87011652~87013151:+
HNSC	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	6.42	3.37e-10	0.000585	0.35	0.28	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
HNSC	trans	rs1816752	0.905	rs1050112	ENSG00000224976.2	PARP4P2	-6.42	3.38e-10	0.000587	-0.33	-0.28	Obesity-related traits;	chr13:24435159	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs13428	ENSG00000224976.2	PARP4P2	-6.42	3.38e-10	0.000587	-0.33	-0.28	Obesity-related traits;	chr13:24435303	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs2033955	ENSG00000224976.2	PARP4P2	-6.42	3.38e-10	0.000587	-0.33	-0.28	Obesity-related traits;	chr13:24436406	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs2033954	ENSG00000224976.2	PARP4P2	-6.42	3.38e-10	0.000587	-0.33	-0.28	Obesity-related traits;	chr13:24436429	chr13:19349137~19407962:+
HNSC	trans	rs453301	0.507	rs2929306	ENSG00000253893.2	FAM85B	6.42	3.39e-10	0.000589	0.33	0.28	Joint mobility (Beighton score);	chr8:9227399	chr8:8167819~8226614:-
HNSC	trans	rs673253	0.593	rs3791134	ENSG00000231007.5	CDC20P1	6.42	3.39e-10	0.000589	0.4	0.28	Intelligence (multi-trait analysis);	chr1:43583485	chr9:87011652~87013151:+
HNSC	trans	rs673253	0.686	rs3791139	ENSG00000231007.5	CDC20P1	6.42	3.39e-10	0.000589	0.4	0.28	Intelligence (multi-trait analysis);	chr1:43586100	chr9:87011652~87013151:+
HNSC	trans	rs4948102	0.691	rs4470984	ENSG00000186940.6	CHCHD2P9	-6.42	3.42e-10	0.000594	-0.4	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55965865	chr9:79391304~79391759:+
HNSC	trans	rs7412746	0.611	rs11204748	ENSG00000180764.13	PIPSL	-6.42	3.42e-10	0.000595	-0.34	-0.28	Melanoma;	chr1:150954893	chr10:93958191~93961540:-
HNSC	trans	rs7937890	0.559	rs2034480	ENSG00000236360.2	RP11-334A14.2	6.42	3.44e-10	0.000597	0.38	0.28	Mitochondrial DNA levels;	chr11:14445377	chr1:52993201~52993702:-
HNSC	trans	rs9329221	0.678	rs560638	ENSG00000173295.6	FAM86B3P	-6.42	3.44e-10	0.000598	-0.32	-0.28	Neuroticism;	chr8:10025257	chr8:8228595~8244865:+
HNSC	trans	rs6756513	0.5	rs6546552	ENSG00000232654.1	FAM136BP	6.42	3.44e-10	0.000598	0.38	0.28	Breast cancer;Platelet count;	chr2:69849518	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs7577662	ENSG00000232654.1	FAM136BP	6.42	3.44e-10	0.000598	0.38	0.28	Breast cancer;Platelet count;	chr2:69850290	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs7565230	ENSG00000232654.1	FAM136BP	6.42	3.44e-10	0.000598	0.38	0.28	Breast cancer;Platelet count;	chr2:69850301	chr6:3045384~3045800:+
HNSC	trans	rs7809615	0.515	rs11772470	ENSG00000228834.1	RP11-249L21.4	6.42	3.45e-10	0.000599	0.43	0.28	Blood metabolite ratios;	chr7:99583473	chr6:108907615~108907873:-
HNSC	trans	rs1063857	0.656	rs216293	ENSG00000241717.1	VWFP1	6.41	3.47e-10	0.000603	0.29	0.28	vWF levels;Coagulation factor levels;	chr12:6044493	chr22:16690103~16704477:-
HNSC	trans	rs79149102	0.522	rs6495104	ENSG00000227288.3	RP5-837I24.1	6.41	3.47e-10	0.000603	0.52	0.28	Lung cancer;	chr15:74475760	chr1:81501794~81503468:+
HNSC	trans	rs2288327	0.822	rs1429094	ENSG00000269800.1	PLEKHA3P1	6.41	3.47e-10	0.000603	0.38	0.28	Atrial fibrillation;	chr2:178651047	chr19:41521043~41521989:-
HNSC	trans	rs10716881	1	rs10716881	ENSG00000257210.1	NACAP3	-6.41	3.47e-10	0.000603	-0.32	-0.28	High light scatter reticulocyte count;	chr12:56644387	chr12:93124063~93124543:-
HNSC	trans	rs3806843	0.801	rs801170	ENSG00000231043.3	AC007238.1	6.41	3.48e-10	0.000604	0.29	0.28	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr2:58460292~58462032:-
HNSC	trans	rs17507216	1	rs17356118	ENSG00000259295.5	CSPG4P12	-6.41	3.49e-10	0.000606	-0.4	-0.28	Excessive daytime sleepiness;	chr15:82569149	chr15:85191438~85213905:+
HNSC	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-6.41	3.53e-10	0.000612	-0.36	-0.28	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs67340775	ENSG00000243753.4	HLA-L	-6.41	3.53e-10	0.000613	-0.6	-0.28	Depression;	chr6:28336607	chr6:30259584~30293014:+
HNSC	trans	rs6756513	0.5	rs3771535	ENSG00000232654.1	FAM136BP	6.41	3.54e-10	0.000615	0.38	0.28	Breast cancer;Platelet count;	chr2:69816643	chr6:3045384~3045800:+
HNSC	trans	rs1816752	0.905	rs9511260	ENSG00000224976.2	PARP4P2	-6.41	3.6e-10	0.000624	-0.33	-0.28	Obesity-related traits;	chr13:24437038	chr13:19349137~19407962:+
HNSC	trans	rs7662987	0.54	rs2851257	ENSG00000233859.2	ADH5P4	-6.41	3.64e-10	0.00063	-0.34	-0.28	Smoking initiation;	chr4:99118348	chr6:65836930~65838039:-
HNSC	trans	rs6756513	0.5	rs2290452	ENSG00000232654.1	FAM136BP	6.41	3.64e-10	0.00063	0.38	0.28	Breast cancer;Platelet count;	chr2:69820512	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs58819073	ENSG00000232654.1	FAM136BP	6.41	3.64e-10	0.00063	0.38	0.28	Breast cancer;Platelet count;	chr2:69822090	chr6:3045384~3045800:+
HNSC	trans	rs7819412	0.505	rs17726209	ENSG00000173295.6	FAM86B3P	6.41	3.64e-10	0.000631	0.33	0.28	Triglycerides;	chr8:11164675	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.54	rs2409725	ENSG00000173295.6	FAM86B3P	-6.4	3.68e-10	0.000638	-0.34	-0.28	Triglycerides;	chr8:11184152	chr8:8228595~8244865:+
HNSC	trans	rs13416322	0.699	rs57152574	ENSG00000214286.2	PDCL3P3	6.4	3.7e-10	0.000641	0.42	0.28	Intelligence (multi-trait analysis);	chr2:100563529	chr3:17877455~17878169:-
HNSC	trans	rs2950393	0.804	rs3214051	ENSG00000257210.1	NACAP3	6.4	3.7e-10	0.000641	0.32	0.28	Platelet distribution width;	chr12:56725452	chr12:93124063~93124543:-
HNSC	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-6.4	3.71e-10	0.000643	-0.35	-0.28	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
HNSC	trans	rs453301	0.682	rs2929451	ENSG00000253893.2	FAM85B	-6.4	3.71e-10	0.000643	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9227785	chr8:8167819~8226614:-
HNSC	trans	rs6831352	0.819	rs2851274	ENSG00000233859.2	ADH5P4	-6.4	3.71e-10	0.000643	-0.32	-0.28	Alcohol dependence;	chr4:99104715	chr6:65836930~65838039:-
HNSC	trans	rs7121616	0.563	rs4936770	ENSG00000256356.1	HSPA8P5	6.4	3.73e-10	0.000646	0.34	0.28	Breast cancer;	chr11:123058167	chr12:4097451~4099519:+
HNSC	trans	rs9650657	0.537	rs7016385	ENSG00000173295.6	FAM86B3P	6.4	3.78e-10	0.000654	0.31	0.28	Neuroticism;	chr8:10921962	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.857	rs9989034	ENSG00000257210.1	NACAP3	6.4	3.79e-10	0.000655	0.32	0.28	Platelet distribution width;	chr12:56674508	chr12:93124063~93124543:-
HNSC	trans	rs9467711	0.606	rs2393667	ENSG00000253570.1	RNF5P1	6.4	3.8e-10	0.000657	0.61	0.28	Autism spectrum disorder or schizophrenia;	chr6:26421117	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.606	rs2076030	ENSG00000253570.1	RNF5P1	6.4	3.8e-10	0.000657	0.61	0.28	Autism spectrum disorder or schizophrenia;	chr6:26426628	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.606	rs2235251	ENSG00000253570.1	RNF5P1	6.4	3.8e-10	0.000657	0.61	0.28	Autism spectrum disorder or schizophrenia;	chr6:26431754	chr8:38600661~38601200:-
HNSC	trans	rs7819412	0.595	rs4841500	ENSG00000173295.6	FAM86B3P	-6.4	3.82e-10	0.00066	-0.32	-0.28	Triglycerides;	chr8:11130765	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.52	rs2290035	ENSG00000257675.1	RP11-641A6.9	-6.4	3.83e-10	0.000662	-0.32	-0.28	Bone mineral density;	chr11:13386224	chr12:52748776~52750127:+
HNSC	trans	rs6831352	0.879	rs2602879	ENSG00000233859.2	ADH5P4	-6.4	3.85e-10	0.000665	-0.34	-0.28	Alcohol dependence;	chr4:99119501	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602880	ENSG00000233859.2	ADH5P4	-6.4	3.85e-10	0.000665	-0.34	-0.28	Smoking initiation;	chr4:99119502	chr6:65836930~65838039:-
HNSC	trans	rs17301013	0.803	rs2187562	ENSG00000213331.4	RP11-713C19.2	6.4	3.86e-10	0.000667	0.34	0.28	Systemic lupus erythematosus;	chr1:174842513	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.732	rs6658543	ENSG00000213331.4	RP11-713C19.2	6.4	3.86e-10	0.000668	0.34	0.28	Life satisfaction;	chr1:174183338	chr4:187970273~187971284:+
HNSC	trans	rs9733	0.65	rs3738485	ENSG00000180764.13	PIPSL	6.4	3.87e-10	0.000669	0.35	0.28	Tonsillectomy;	chr1:150579916	chr10:93958191~93961540:-
HNSC	trans	rs8177876	0.749	rs2278024	ENSG00000224837.1	GCSHP5	6.4	3.88e-10	0.00067	0.51	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr1:168055901~168056422:-
HNSC	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	6.4	3.88e-10	0.00067	0.35	0.28	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
HNSC	trans	rs12145833	0.679	rs12048498	ENSG00000154608.12	CEP170P1	-6.4	3.88e-10	0.000671	-0.39	-0.28	Obesity (early onset extreme);	chr1:243387345	chr4:118467590~118554204:+
HNSC	trans	rs7647973	0.667	rs9869256	ENSG00000197582.5	GPX1P1	6.4	3.89e-10	0.000672	0.5	0.28	Menarche (age at onset);	chr3:49586662	chrX:13378735~13379340:-
HNSC	trans	rs9393777	0.92	rs35869525	ENSG00000253570.1	RNF5P1	6.39	3.91e-10	0.000674	0.66	0.28	Intelligence (multi-trait analysis);	chr6:26978908	chr8:38600661~38601200:-
HNSC	trans	rs867371	0.502	rs2047679	ENSG00000235370.6	DNM1P51	-6.39	3.91e-10	0.000674	-0.33	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:84398316~84411701:-
HNSC	trans	rs2899832	0.5	rs10151128	ENSG00000229083.1	PSMA6P2	6.39	3.91e-10	0.000675	0.48	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35306578	chrX:12825840~12826833:+
HNSC	trans	rs9425766	0.679	rs7537517	ENSG00000213331.4	RP11-713C19.2	6.39	3.93e-10	0.000679	0.34	0.28	Life satisfaction;	chr1:174207225	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.679	rs4652234	ENSG00000213331.4	RP11-713C19.2	6.39	3.94e-10	0.00068	0.34	0.28	Life satisfaction;	chr1:174181712	chr4:187970273~187971284:+
HNSC	trans	rs11220082	0.666	rs35203305	ENSG00000236257.1	EI24P2	-6.39	3.95e-10	0.000681	-0.34	-0.28	Schizophrenia;	chr11:125468987	chr1:158454198~158455273:+
HNSC	trans	rs6424115	0.79	rs72874118	ENSG00000228217.1	AL390877.1	6.39	3.96e-10	0.000682	0.35	0.28	Immature fraction of reticulocytes;	chr1:23851310	chr1:117778087~117778506:-
HNSC	trans	rs722599	0.748	rs2300599	ENSG00000181227.3	RP4-682C21.2	6.39	3.96e-10	0.000683	0.3	0.28	IgG glycosylation;	chr14:74892738	chr1:75743423~75744776:-
HNSC	trans	rs4948102	0.69	rs35844144	ENSG00000215006.4	CHCHD2P2	-6.39	3.97e-10	0.000685	-0.39	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr5:69333929~69334249:+
HNSC	trans	rs2898290	0.622	rs1382567	ENSG00000173295.6	FAM86B3P	-6.39	3.98e-10	0.000687	-0.31	-0.28	Systolic blood pressure;	chr8:11493390	chr8:8228595~8244865:+
HNSC	trans	rs62344088	1	rs10037843	ENSG00000185986.11	SDHAP3	6.39	4e-10	0.000689	0.69	0.28	Asthma (childhood onset);	chr5:119963	chr5:1572222~1594620:-
HNSC	trans	rs62344088	1	rs13436694	ENSG00000185986.11	SDHAP3	6.39	4e-10	0.000689	0.69	0.28	Asthma (childhood onset);	chr5:122767	chr5:1572222~1594620:-
HNSC	trans	rs10037055	0.812	rs11949435	ENSG00000226986.4	RP11-543B16.2	6.39	4e-10	0.00069	0.34	0.28	Migraine without aura;	chr5:177287931	chr1:211207239~211207897:+
HNSC	trans	rs62344088	1	rs7715867	ENSG00000185986.11	SDHAP3	6.39	4.01e-10	0.000692	0.69	0.28	Asthma (childhood onset);	chr5:128944	chr5:1572222~1594620:-
HNSC	trans	rs62344088	1	rs73022563	ENSG00000185986.11	SDHAP3	6.39	4.01e-10	0.000692	0.69	0.28	Asthma (childhood onset);	chr5:140698	chr5:1572222~1594620:-
HNSC	trans	rs11220082	0.644	rs34435097	ENSG00000236257.1	EI24P2	-6.39	4.01e-10	0.000692	-0.34	-0.28	Schizophrenia;	chr11:125469075	chr1:158454198~158455273:+
HNSC	trans	rs9467711	0.606	rs34273322	ENSG00000253570.1	RNF5P1	6.39	4.02e-10	0.000694	0.61	0.28	Autism spectrum disorder or schizophrenia;	chr6:26415181	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.606	rs9358939	ENSG00000253570.1	RNF5P1	6.39	4.02e-10	0.000694	0.61	0.28	Autism spectrum disorder or schizophrenia;	chr6:26416559	chr8:38600661~38601200:-
HNSC	trans	rs6756513	0.5	rs36081078	ENSG00000232654.1	FAM136BP	6.39	4.03e-10	0.000695	0.38	0.28	Breast cancer;Platelet count;	chr2:69859231	chr6:3045384~3045800:+
HNSC	trans	rs877636	0.74	rs705698	ENSG00000242970.2	AC068522.4	6.39	4.04e-10	0.000697	0.34	0.28	Cognitive function;	chr12:55990903	chr8:58588420~58588764:-
HNSC	trans	rs9467711	0.79	rs35400317	ENSG00000253570.1	RNF5P1	6.39	4.04e-10	0.000697	0.69	0.28	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr8:38600661~38601200:-
HNSC	trans	rs941207	1	rs941207	ENSG00000228224.3	NACAP1	-6.39	4.08e-10	0.000703	-0.36	-0.28	Platelet count;	chr12:56629500	chr8:101361794~101372707:+
HNSC	trans	rs7647973	0.71	rs34890793	ENSG00000197582.5	GPX1P1	6.39	4.09e-10	0.000704	0.46	0.28	Menarche (age at onset);	chr3:49582060	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.71	rs7629322	ENSG00000197582.5	GPX1P1	6.39	4.09e-10	0.000704	0.46	0.28	Menarche (age at onset);	chr3:49584561	chrX:13378735~13379340:-
HNSC	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-6.39	4.1e-10	0.000705	-0.35	-0.28	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
HNSC	trans	rs13014235	0.532	rs3731709	ENSG00000235105.1	RP11-329A14.1	6.39	4.11e-10	0.000707	0.35	0.28	Basal cell carcinoma;	chr2:201381311	chr1:48435967~48437223:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	6.39	4.11e-10	0.000708	0.33	0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
HNSC	trans	rs9425766	0.64	rs2281486	ENSG00000213331.4	RP11-713C19.2	6.39	4.14e-10	0.000713	0.38	0.28	Life satisfaction;	chr1:173853083	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.64	rs16846439	ENSG00000213331.4	RP11-713C19.2	6.39	4.14e-10	0.000713	0.38	0.28	Life satisfaction;	chr1:173854900	chr4:187970273~187971284:+
HNSC	trans	rs3806843	0.801	rs801171	ENSG00000231043.3	AC007238.1	6.38	4.14e-10	0.000713	0.29	0.28	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr2:58460292~58462032:-
HNSC	trans	rs7520050	0.778	rs2088102	ENSG00000255397.1	AC022182.2	6.38	4.15e-10	0.000714	0.34	0.28	Reticulocyte count;Red blood cell count;	chr1:45567302	chr8:60937705~60939871:-
HNSC	trans	rs9733	0.68	rs3738484	ENSG00000180764.13	PIPSL	6.38	4.17e-10	0.000718	0.34	0.28	Tonsillectomy;	chr1:150579854	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.65	rs9803935	ENSG00000180764.13	PIPSL	6.38	4.17e-10	0.000718	0.34	0.28	Tonsillectomy;	chr1:150580146	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.65	rs61820165	ENSG00000180764.13	PIPSL	6.38	4.17e-10	0.000718	0.34	0.28	Tonsillectomy;	chr1:150583511	chr10:93958191~93961540:-
HNSC	trans	rs2950393	0.929	rs2958155	ENSG00000257210.1	NACAP3	6.38	4.18e-10	0.00072	0.31	0.28	Platelet distribution width;	chr12:56670761	chr12:93124063~93124543:-
HNSC	trans	rs7121616	0.562	rs2061602	ENSG00000256356.1	HSPA8P5	6.38	4.19e-10	0.00072	0.34	0.28	Breast cancer;	chr11:123065079	chr12:4097451~4099519:+
HNSC	trans	rs11220082	0.644	rs36143594	ENSG00000236257.1	EI24P2	-6.38	4.19e-10	0.000721	-0.34	-0.28	Schizophrenia;	chr11:125457076	chr1:158454198~158455273:+
HNSC	trans	rs12439619	0.705	rs17354185	ENSG00000259295.5	CSPG4P12	6.38	4.21e-10	0.000724	0.42	0.28	Intelligence (multi-trait analysis);	chr15:82133829	chr15:85191438~85213905:+
HNSC	trans	rs8067354	0.574	rs2250526	ENSG00000187870.7	RNFT1P3	6.38	4.22e-10	0.000726	0.39	0.28	Hemoglobin concentration;	chr17:59874612	chr17:20743333~20754501:-
HNSC	trans	rs673253	0.686	rs2782641	ENSG00000231007.5	CDC20P1	6.38	4.22e-10	0.000726	0.39	0.28	Intelligence (multi-trait analysis);	chr1:43547684	chr9:87011652~87013151:+
HNSC	trans	rs853679	0.607	rs35030260	ENSG00000253570.1	RNF5P1	6.38	4.23e-10	0.000727	0.65	0.28	Depression;	chr6:28337731	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13217619	ENSG00000253570.1	RNF5P1	6.38	4.23e-10	0.000727	0.65	0.28	Depression;	chr6:28338894	chr8:38600661~38601200:-
HNSC	trans	rs13014235	0.532	rs11681592	ENSG00000235105.1	RP11-329A14.1	6.38	4.23e-10	0.000727	0.35	0.28	Basal cell carcinoma;	chr2:201399178	chr1:48435967~48437223:+
HNSC	trans	rs10037055	0.853	rs4976681	ENSG00000226986.4	RP11-543B16.2	6.38	4.23e-10	0.000727	0.34	0.28	Migraine without aura;	chr5:177277662	chr1:211207239~211207897:+
HNSC	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	-6.38	4.23e-10	0.000728	-0.32	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
HNSC	trans	rs7873102	0.872	rs7044173	ENSG00000229007.1	EXOSC3P1	6.38	4.24e-10	0.000729	0.34	0.28	Brain structure;	chr9:37956355	chr21:32496812~32497311:+
HNSC	trans	rs2950393	0.929	rs2290893	ENSG00000257210.1	NACAP3	6.38	4.29e-10	0.000737	0.32	0.28	Platelet distribution width;	chr12:56684836	chr12:93124063~93124543:-
HNSC	trans	rs1023500	1	rs6002554	ENSG00000268568.1	AC007228.9	-6.38	4.35e-10	0.000746	-0.38	-0.28	Schizophrenia;	chr22:41943091	chr19:56672574~56673901:-
HNSC	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-6.38	4.38e-10	0.000751	-0.36	-0.28	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
HNSC	trans	rs10037055	0.947	rs10063803	ENSG00000226986.4	RP11-543B16.2	6.38	4.39e-10	0.000754	0.37	0.28	Migraine without aura;	chr5:177240326	chr1:211207239~211207897:+
HNSC	trans	rs453301	0.571	rs2929452	ENSG00000253893.2	FAM85B	6.38	4.4e-10	0.000755	0.33	0.28	Joint mobility (Beighton score);	chr8:9226955	chr8:8167819~8226614:-
HNSC	trans	rs80264589	1	rs80264589	ENSG00000253570.1	RNF5P1	6.37	4.42e-10	0.000758	0.66	0.28	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr8:38600661~38601200:-
HNSC	trans	rs7819412	0.875	rs6981523	ENSG00000173295.6	FAM86B3P	-6.37	4.44e-10	0.000762	-0.32	-0.28	Triglycerides;	chr8:11204283	chr8:8228595~8244865:+
HNSC	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-6.37	4.46e-10	0.000764	-0.35	-0.28	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
HNSC	trans	rs853679	0.607	rs13201308	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28162311	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs34505829	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28165461	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs35098436	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28166443	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs72846794	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28169721	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13217984	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28171932	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.505	rs35781323	ENSG00000253570.1	RNF5P1	6.37	4.46e-10	0.000764	0.69	0.28	Depression;	chr6:28177054	chr8:38600661~38601200:-
HNSC	trans	rs6921919	0.778	rs67381177	ENSG00000243753.4	HLA-L	-6.37	4.5e-10	0.000772	-0.64	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:30259584~30293014:+
HNSC	trans	rs740160	0.558	rs68164591	ENSG00000228834.1	RP11-249L21.4	6.37	4.53e-10	0.000776	0.53	0.28	Dehydroepiandrosterone sulphate levels;	chr7:99306817	chr6:108907615~108907873:-
HNSC	trans	rs7937890	0.559	rs2597196	ENSG00000236360.2	RP11-334A14.2	-6.37	4.55e-10	0.00078	-0.37	-0.28	Mitochondrial DNA levels;	chr11:14470055	chr1:52993201~52993702:-
HNSC	trans	rs853679	0.607	rs13205211	ENSG00000243753.4	HLA-L	-6.37	4.55e-10	0.00078	-0.62	-0.28	Depression;	chr6:28235278	chr6:30259584~30293014:+
HNSC	trans	rs9393777	0.841	rs67092078	ENSG00000253570.1	RNF5P1	6.37	4.56e-10	0.000782	0.68	0.28	Intelligence (multi-trait analysis);	chr6:27086993	chr8:38600661~38601200:-
HNSC	trans	rs6743068	0.521	rs9288318	ENSG00000235105.1	RP11-329A14.1	6.37	4.56e-10	0.000782	0.35	0.28	Lymphocyte percentage of white cells;	chr2:201331340	chr1:48435967~48437223:+
HNSC	trans	rs6921919	0.562	rs13198809	ENSG00000253570.1	RNF5P1	6.37	4.57e-10	0.000783	0.66	0.28	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr8:38600661~38601200:-
HNSC	trans	rs4948102	0.655	rs4947533	ENSG00000215006.4	CHCHD2P2	-6.37	4.6e-10	0.000788	-0.39	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr5:69333929~69334249:+
HNSC	trans	rs6921919	0.673	rs13201681	ENSG00000243753.4	HLA-L	-6.37	4.61e-10	0.000789	-0.63	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:30259584~30293014:+
HNSC	trans	rs453301	0.571	rs2929305	ENSG00000253893.2	FAM85B	6.37	4.65e-10	0.000795	0.32	0.28	Joint mobility (Beighton score);	chr8:9227707	chr8:8167819~8226614:-
HNSC	trans	rs4879656	0.564	rs2183870	ENSG00000215007.3	DNAJA1P3	-6.36	4.67e-10	0.000799	-0.33	-0.28	Menopause (age at onset);	chr9:32994502	chrX:107351650~107352843:-
HNSC	trans	rs13014235	0.532	rs6729982	ENSG00000235105.1	RP11-329A14.1	6.36	4.67e-10	8e-04	0.35	0.28	Basal cell carcinoma;	chr2:201416413	chr1:48435967~48437223:+
HNSC	trans	rs13014235	0.532	rs10497867	ENSG00000235105.1	RP11-329A14.1	6.36	4.67e-10	8e-04	0.35	0.28	Basal cell carcinoma;	chr2:201420144	chr1:48435967~48437223:+
HNSC	trans	rs9393777	0.764	rs35565446	ENSG00000253570.1	RNF5P1	6.36	4.68e-10	0.000801	0.68	0.28	Intelligence (multi-trait analysis);	chr6:27177562	chr8:38600661~38601200:-
HNSC	trans	rs7819412	0.521	rs10110684	ENSG00000173295.6	FAM86B3P	-6.36	4.72e-10	0.000808	-0.33	-0.28	Triglycerides;	chr8:11181650	chr8:8228595~8244865:+
HNSC	trans	rs4512344	0.514	rs13255193	ENSG00000173295.6	FAM86B3P	-6.36	4.73e-10	0.000809	-0.31	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.526	rs2950390	ENSG00000228224.3	NACAP1	6.36	4.77e-10	0.000815	0.32	0.28	Platelet count;	chr12:56661507	chr8:101361794~101372707:+
HNSC	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-6.36	4.8e-10	0.00082	-0.35	-0.28	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
HNSC	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-6.36	4.8e-10	0.00082	-0.35	-0.28	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
HNSC	trans	rs9393777	0.844	rs72839477	ENSG00000253570.1	RNF5P1	6.36	4.83e-10	0.000826	0.67	0.28	Intelligence (multi-trait analysis);	chr6:27359221	chr8:38600661~38601200:-
HNSC	trans	rs7937890	0.559	rs4369365	ENSG00000236360.2	RP11-334A14.2	6.36	4.83e-10	0.000826	0.37	0.28	Mitochondrial DNA levels;	chr11:14422969	chr1:52993201~52993702:-
HNSC	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-6.36	4.85e-10	0.000829	-0.35	-0.28	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
HNSC	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-6.36	4.85e-10	0.000829	-0.35	-0.28	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
HNSC	trans	rs7819412	0.595	rs10106914	ENSG00000173295.6	FAM86B3P	-6.36	4.87e-10	0.000833	-0.32	-0.28	Triglycerides;	chr8:11130141	chr8:8228595~8244865:+
HNSC	trans	rs7937890	0.559	rs2597201	ENSG00000236360.2	RP11-334A14.2	6.36	4.88e-10	0.000833	0.37	0.28	Mitochondrial DNA levels;	chr11:14463858	chr1:52993201~52993702:-
HNSC	trans	rs1023500	1	rs6002552	ENSG00000268568.1	AC007228.9	-6.36	4.89e-10	0.000836	-0.38	-0.28	Schizophrenia;	chr22:41942347	chr19:56672574~56673901:-
HNSC	trans	rs9630182	0.54	rs10832029	ENSG00000257675.1	RP11-641A6.9	-6.36	4.9e-10	0.000836	-0.33	-0.28	Bone mineral density;	chr11:13377533	chr12:52748776~52750127:+
HNSC	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	-6.36	4.94e-10	0.000843	-0.32	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
HNSC	trans	rs74781061	0.585	rs4887146	ENSG00000227288.3	RP5-837I24.1	6.35	4.97e-10	0.000849	0.58	0.28	Endometriosis;	chr15:74439725	chr1:81501794~81503468:+
HNSC	trans	rs4276421	0.594	rs7293434	ENSG00000231752.4	EMBP1	6.35	4.98e-10	0.00085	0.35	0.28	P wave duration;	chr5:46257587	chr1:121519112~121571892:+
HNSC	trans	rs7824557	0.872	rs1347410	ENSG00000173295.6	FAM86B3P	-6.35	4.98e-10	0.00085	-0.31	-0.28	Retinal vascular caliber;	chr8:11253733	chr8:8228595~8244865:+
HNSC	trans	rs7937890	0.559	rs2597208	ENSG00000236360.2	RP11-334A14.2	6.35	4.98e-10	0.00085	0.37	0.28	Mitochondrial DNA levels;	chr11:14450783	chr1:52993201~52993702:-
HNSC	trans	rs7819412	0.522	rs10088853	ENSG00000173295.6	FAM86B3P	-6.35	4.98e-10	0.00085	-0.33	-0.28	Triglycerides;	chr8:11130457	chr8:8228595~8244865:+
HNSC	trans	rs6424115	1	rs2256179	ENSG00000228217.1	AL390877.1	6.35	4.98e-10	0.000851	0.34	0.28	Immature fraction of reticulocytes;	chr1:23805815	chr1:117778087~117778506:-
HNSC	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-6.35	4.99e-10	0.000852	-0.39	-0.28	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
HNSC	trans	rs9467711	0.79	rs13198716	ENSG00000253570.1	RNF5P1	-6.35	5e-10	0.000854	-0.68	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr8:38600661~38601200:-
HNSC	trans	rs941207	0.526	rs7303216	ENSG00000257210.1	NACAP3	6.35	5e-10	0.000854	0.33	0.28	Platelet count;	chr12:56680909	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.507	rs7297289	ENSG00000257210.1	NACAP3	6.35	5e-10	0.000854	0.33	0.28	Platelet count;	chr12:56682703	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.526	rs4759028	ENSG00000257210.1	NACAP3	6.35	5e-10	0.000854	0.33	0.28	Platelet count;	chr12:56686399	chr12:93124063~93124543:-
HNSC	trans	rs7819412	0.805	rs4333549	ENSG00000173295.6	FAM86B3P	-6.35	5.02e-10	0.000856	-0.32	-0.28	Triglycerides;	chr8:11122051	chr8:8228595~8244865:+
HNSC	trans	rs4879656	0.564	rs4879657	ENSG00000215007.3	DNAJA1P3	6.35	5.02e-10	0.000857	0.33	0.28	Menopause (age at onset);	chr9:33012467	chrX:107351650~107352843:-
HNSC	trans	rs4948102	0.642	rs6593297	ENSG00000215006.4	CHCHD2P2	6.35	5.03e-10	0.000859	0.36	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr5:69333929~69334249:+
HNSC	trans	rs1933488	0.931	rs7750498	ENSG00000278974.1	RP11-756P10.6	-6.35	5.05e-10	0.000862	-0.37	-0.28	Prostate cancer;	chr6:153102920	chr4:188740507~188741281:-
HNSC	trans	rs1816752	0.87	rs8000215	ENSG00000224976.2	PARP4P2	-6.35	5.06e-10	0.000863	-0.33	-0.28	Obesity-related traits;	chr13:24435648	chr13:19349137~19407962:+
HNSC	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-6.35	5.18e-10	0.000882	-0.35	-0.28	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
HNSC	trans	rs7819412	0.538	rs4523214	ENSG00000173295.6	FAM86B3P	-6.35	5.22e-10	0.000888	-0.31	-0.28	Triglycerides;	chr8:11113263	chr8:8228595~8244865:+
HNSC	trans	rs13416322	0.699	rs61387584	ENSG00000214286.2	PDCL3P3	6.35	5.26e-10	0.000895	0.42	0.28	Intelligence (multi-trait analysis);	chr2:100559686	chr3:17877455~17878169:-
HNSC	trans	rs941207	0.526	rs2950390	ENSG00000257210.1	NACAP3	6.35	5.26e-10	0.000895	0.33	0.28	Platelet count;	chr12:56661507	chr12:93124063~93124543:-
HNSC	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	6.35	5.26e-10	0.000896	0.31	0.28	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
HNSC	trans	rs9329221	0.65	rs657913	ENSG00000173295.6	FAM86B3P	-6.34	5.28e-10	0.000899	-0.31	-0.28	Neuroticism;	chr8:10025065	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.804	rs2926748	ENSG00000257210.1	NACAP3	6.34	5.35e-10	0.00091	0.31	0.28	Platelet distribution width;	chr12:56715628	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.526	rs11171916	ENSG00000257210.1	NACAP3	-6.34	5.36e-10	0.000911	-0.34	-0.28	Platelet count;	chr12:56653236	chr12:93124063~93124543:-
HNSC	trans	rs7819412	0.66	rs7462931	ENSG00000173295.6	FAM86B3P	-6.34	5.38e-10	0.000914	-0.32	-0.28	Triglycerides;	chr8:11052833	chr8:8228595~8244865:+
HNSC	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-6.34	5.42e-10	0.000922	-0.29	-0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
HNSC	trans	rs7662987	0.793	rs28730602	ENSG00000228407.2	RP4-800M22.1	6.34	5.42e-10	0.000922	0.45	0.28	Smoking initiation;	chr4:99080531	chr1:52160261~52160600:-
HNSC	trans	rs7937890	0.532	rs2575832	ENSG00000236360.2	RP11-334A14.2	6.34	5.44e-10	0.000925	0.37	0.28	Mitochondrial DNA levels;	chr11:14467264	chr1:52993201~52993702:-
HNSC	trans	rs7520050	0.807	rs5021934	ENSG00000255397.1	AC022182.2	6.34	5.45e-10	0.000926	0.34	0.28	Reticulocyte count;Red blood cell count;	chr1:45643632	chr8:60937705~60939871:-
HNSC	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	6.34	5.45e-10	0.000927	0.35	0.28	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
HNSC	trans	rs546131	0.928	rs553789	ENSG00000225531.1	RP11-196I18.3	6.34	5.47e-10	0.000929	0.35	0.28	Lung disease severity in cystic fibrosis;	chr11:34806032	chr9:107116829~107117557:+
HNSC	trans	rs7617480	0.648	rs10865953	ENSG00000197582.5	GPX1P1	6.34	5.52e-10	0.000938	0.45	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48722129	chrX:13378735~13379340:-
HNSC	trans	rs9733	0.566	rs11204675	ENSG00000180764.13	PIPSL	6.34	5.52e-10	0.000938	0.34	0.28	Tonsillectomy;	chr1:150598509	chr10:93958191~93961540:-
HNSC	trans	rs13014235	0.532	rs13029007	ENSG00000235105.1	RP11-329A14.1	6.34	5.57e-10	0.000945	0.35	0.28	Basal cell carcinoma;	chr2:201400154	chr1:48435967~48437223:+
HNSC	trans	rs673253	0.686	rs6698389	ENSG00000231007.5	CDC20P1	6.34	5.57e-10	0.000946	0.4	0.28	Intelligence (multi-trait analysis);	chr1:43585903	chr9:87011652~87013151:+
HNSC	trans	rs673253	0.638	rs3791140	ENSG00000231007.5	CDC20P1	6.34	5.57e-10	0.000946	0.4	0.28	Intelligence (multi-trait analysis);	chr1:43586107	chr9:87011652~87013151:+
HNSC	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-6.34	5.58e-10	0.000947	-0.32	-0.28	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
HNSC	trans	rs2950393	0.804	rs898609	ENSG00000257210.1	NACAP3	6.33	5.62e-10	0.000953	0.31	0.28	Platelet distribution width;	chr12:56713026	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.804	rs4902	ENSG00000257210.1	NACAP3	6.33	5.62e-10	0.000953	0.31	0.28	Platelet distribution width;	chr12:56714419	chr12:93124063~93124543:-
HNSC	trans	rs7819412	0.775	rs2001329	ENSG00000173295.6	FAM86B3P	-6.33	5.62e-10	0.000955	-0.32	-0.28	Triglycerides;	chr8:11129349	chr8:8228595~8244865:+
HNSC	trans	rs2899832	0.568	rs2277460	ENSG00000229083.1	PSMA6P2	6.33	5.64e-10	0.000957	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292367	chrX:12825840~12826833:+
HNSC	trans	rs2899832	0.568	rs17458583	ENSG00000229083.1	PSMA6P2	6.33	5.64e-10	0.000957	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293295	chrX:12825840~12826833:+
HNSC	trans	rs10037055	0.853	rs4976680	ENSG00000226986.4	RP11-543B16.2	6.33	5.65e-10	0.000958	0.34	0.28	Migraine without aura;	chr5:177275745	chr1:211207239~211207897:+
HNSC	trans	rs7930295	0.632	rs12287044	ENSG00000236257.1	EI24P2	6.33	5.65e-10	0.000958	0.41	0.28	Schizophrenia;	chr11:125772649	chr1:158454198~158455273:+
HNSC	trans	rs7937890	0.504	rs2575847	ENSG00000236360.2	RP11-334A14.2	6.33	5.65e-10	0.000958	0.37	0.28	Mitochondrial DNA levels;	chr11:14449626	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2575825	ENSG00000236360.2	RP11-334A14.2	6.33	5.65e-10	0.000958	0.37	0.28	Mitochondrial DNA levels;	chr11:14450550	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597206	ENSG00000236360.2	RP11-334A14.2	6.33	5.65e-10	0.000958	0.37	0.28	Mitochondrial DNA levels;	chr11:14455992	chr1:52993201~52993702:-
HNSC	trans	rs2665103	0.61	rs56398167	ENSG00000235370.6	DNM1P51	-6.33	5.67e-10	0.000962	-0.33	-0.28	Intelligence (multi-trait analysis);	chr15:82237482	chr15:84398316~84411701:-
HNSC	trans	rs546131	0.928	rs535719	ENSG00000225531.1	RP11-196I18.3	6.33	5.7e-10	0.000968	0.34	0.28	Lung disease severity in cystic fibrosis;	chr11:34831835	chr9:107116829~107117557:+
HNSC	trans	rs853679	0.607	rs13208096	ENSG00000253570.1	RNF5P1	6.33	5.71e-10	0.000969	0.63	0.28	Depression;	chr6:28257533	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-6.33	5.72e-10	0.00097	-0.35	-0.28	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
HNSC	trans	rs7824557	0.592	rs2572371	ENSG00000254340.1	RP11-10A14.3	6.33	5.74e-10	0.000973	0.32	0.28	Retinal vascular caliber;	chr8:11366284	chr8:9141424~9145435:+
HNSC	trans	rs941207	0.542	rs11171979	ENSG00000257210.1	NACAP3	-6.33	5.76e-10	0.000976	-0.35	-0.28	Platelet count;	chr12:56802199	chr12:93124063~93124543:-
HNSC	trans	rs7824557	0.603	rs2246606	ENSG00000173295.6	FAM86B3P	6.33	5.79e-10	0.000981	0.31	0.28	Retinal vascular caliber;	chr8:11361825	chr8:8228595~8244865:+
HNSC	trans	rs11220082	0.627	rs35102191	ENSG00000236257.1	EI24P2	-6.33	5.8e-10	0.000983	-0.34	-0.28	Schizophrenia;	chr11:125455250	chr1:158454198~158455273:+
HNSC	trans	rs17507216	0.718	rs72751662	ENSG00000259295.5	CSPG4P12	-6.33	5.81e-10	0.000984	-0.45	-0.28	Excessive daytime sleepiness;	chr15:82594705	chr15:85191438~85213905:+
HNSC	trans	rs941207	0.542	rs6581107	ENSG00000257210.1	NACAP3	-6.33	5.81e-10	0.000984	-0.35	-0.28	Platelet count;	chr12:56801197	chr12:93124063~93124543:-
HNSC	trans	rs7121616	0.563	rs4936770	ENSG00000241478.1	HSPA8P9	6.33	5.81e-10	0.000985	0.34	0.28	Breast cancer;	chr11:123058167	chr3:137880295~137882237:+
HNSC	trans	rs9630182	0.561	rs11022781	ENSG00000257675.1	RP11-641A6.9	6.33	5.82e-10	0.000985	0.31	0.28	Bone mineral density;	chr11:13380862	chr12:52748776~52750127:+
HNSC	trans	rs62344088	1	rs10042022	ENSG00000185986.11	SDHAP3	6.33	5.83e-10	0.000987	0.71	0.28	Asthma (childhood onset);	chr5:113956	chr5:1572222~1594620:-
HNSC	trans	rs62344088	1	rs76792440	ENSG00000185986.11	SDHAP3	6.33	5.83e-10	0.000987	0.71	0.28	Asthma (childhood onset);	chr5:114459	chr5:1572222~1594620:-
HNSC	trans	rs2336384	1	rs4846083	ENSG00000261819.1	RP11-680G24.4	6.33	5.85e-10	0.000991	0.4	0.28	Platelet count;	chr1:11985498	chr16:14988259~14990160:-
HNSC	trans	rs7819412	0.521	rs2409720	ENSG00000173295.6	FAM86B3P	-6.33	5.88e-10	0.000996	-0.33	-0.28	Triglycerides;	chr8:11180394	chr8:8228595~8244865:+
HNSC	trans	rs393155	0.517	rs330050	ENSG00000253893.2	FAM85B	6.33	5.92e-10	0.001	0.32	0.28	Neuroticism;	chr8:9230169	chr8:8167819~8226614:-
HNSC	trans	rs453301	0.571	rs330054	ENSG00000253893.2	FAM85B	6.33	5.92e-10	0.001	0.32	0.28	Joint mobility (Beighton score);	chr8:9230781	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.607	rs34662244	ENSG00000243753.4	HLA-L	-6.32	5.94e-10	0.00101	-0.63	-0.28	Depression;	chr6:28106103	chr6:30259584~30293014:+
HNSC	trans	rs35952432	1	rs35952432	ENSG00000243753.4	HLA-L	-6.32	5.94e-10	0.00101	-0.63	-0.28	Lung cancer;	chr6:28107123	chr6:30259584~30293014:+
HNSC	trans	rs9733	0.519	rs11204717	ENSG00000180764.13	PIPSL	-6.32	6e-10	0.00102	-0.33	-0.28	Tonsillectomy;	chr1:150736653	chr10:93958191~93961540:-
HNSC	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-6.32	6e-10	0.00102	-0.35	-0.28	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
HNSC	trans	rs6756513	0.506	rs7575111	ENSG00000232654.1	FAM136BP	6.32	6.02e-10	0.00102	0.4	0.28	Breast cancer;Platelet count;	chr2:69844397	chr6:3045384~3045800:+
HNSC	trans	rs7819412	0.502	rs4841499	ENSG00000173295.6	FAM86B3P	-6.32	6.04e-10	0.00102	-0.34	-0.28	Triglycerides;	chr8:11130628	chr8:8228595~8244865:+
HNSC	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-6.32	6.11e-10	0.00103	-0.35	-0.28	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
HNSC	trans	rs17507216	0.718	rs4779034	ENSG00000235370.6	DNM1P51	-6.32	6.12e-10	0.00103	-0.42	-0.28	Excessive daytime sleepiness;	chr15:82576799	chr15:84398316~84411701:-
HNSC	trans	rs2950393	0.804	rs11171951	ENSG00000257210.1	NACAP3	6.32	6.13e-10	0.00104	0.31	0.28	Platelet distribution width;	chr12:56718853	chr12:93124063~93124543:-
HNSC	trans	rs853679	0.599	rs13193295	ENSG00000253570.1	RNF5P1	6.32	6.13e-10	0.00104	0.63	0.28	Depression;	chr6:28035450	chr8:38600661~38601200:-
HNSC	trans	rs1075232	0.649	rs7177058	ENSG00000270055.1	CTD-3092A11.2	6.32	6.17e-10	0.00104	0.43	0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31938737	chr15:30487963~30490313:+
HNSC	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	-6.32	6.18e-10	0.00104	-0.32	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
HNSC	trans	rs2288327	0.841	rs16866418	ENSG00000269800.1	PLEKHA3P1	6.32	6.2e-10	0.00105	0.35	0.28	Atrial fibrillation;	chr2:178626227	chr19:41521043~41521989:-
HNSC	trans	rs17507216	0.958	rs28648832	ENSG00000259295.5	CSPG4P12	-6.32	6.23e-10	0.00105	-0.4	-0.28	Excessive daytime sleepiness;	chr15:82567642	chr15:85191438~85213905:+
HNSC	trans	rs7127307	0.74	rs4144896	ENSG00000261620.1	HMGN2P41	6.32	6.23e-10	0.00105	0.48	0.28	Atopic dermatitis;	chr11:128312131	chr16:35802869~35803280:-
HNSC	trans	rs1707322	0.638	rs1707302	ENSG00000255397.1	AC022182.2	6.32	6.25e-10	0.00106	0.38	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs34218844	ENSG00000253570.1	RNF5P1	6.32	6.25e-10	0.00106	0.64	0.28	Depression;	chr6:28322870	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs35016036	ENSG00000253570.1	RNF5P1	6.32	6.28e-10	0.00106	0.64	0.28	Depression;	chr6:28347103	chr8:38600661~38601200:-
HNSC	trans	rs9733	0.519	rs7521898	ENSG00000180764.13	PIPSL	-6.32	6.28e-10	0.00106	-0.33	-0.28	Tonsillectomy;	chr1:150735120	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.519	rs7511673	ENSG00000180764.13	PIPSL	-6.32	6.28e-10	0.00106	-0.33	-0.28	Tonsillectomy;	chr1:150735160	chr10:93958191~93961540:-
HNSC	trans	rs2950393	0.804	rs7980317	ENSG00000257210.1	NACAP3	6.31	6.31e-10	0.00107	0.32	0.28	Platelet distribution width;	chr12:56764399	chr12:93124063~93124543:-
HNSC	trans	rs62344088	1	rs6880143	ENSG00000185986.11	SDHAP3	6.31	6.33e-10	0.00107	0.62	0.28	Asthma (childhood onset);	chr5:137401	chr5:1572222~1594620:-
HNSC	trans	rs7824557	0.527	rs11785394	ENSG00000254340.1	RP11-10A14.3	-6.31	6.34e-10	0.00107	-0.33	-0.28	Retinal vascular caliber;	chr8:11380520	chr8:9141424~9145435:+
HNSC	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-6.31	6.34e-10	0.00107	-0.35	-0.28	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
HNSC	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	6.31	6.35e-10	0.00107	0.31	0.28	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
HNSC	trans	rs9393777	0.92	rs67859638	ENSG00000253570.1	RNF5P1	6.31	6.38e-10	0.00108	0.67	0.28	Intelligence (multi-trait analysis);	chr6:27390199	chr8:38600661~38601200:-
HNSC	trans	rs2950393	0.895	rs2926740	ENSG00000257210.1	NACAP3	6.31	6.4e-10	0.00108	0.33	0.28	Platelet distribution width;	chr12:56666751	chr12:93124063~93124543:-
HNSC	trans	rs4713118	0.614	rs9468209	ENSG00000204709.4	LINC01556	6.31	6.4e-10	0.00108	0.33	0.28	Parkinson's disease;	chr6:27726642	chr6:28943877~28944537:+
HNSC	trans	rs7662987	0.793	rs78790289	ENSG00000228407.2	RP4-800M22.1	6.31	6.47e-10	0.00109	0.45	0.28	Smoking initiation;	chr4:99066736	chr1:52160261~52160600:-
HNSC	trans	rs7503168	0.558	rs1071965	ENSG00000234130.2	RP13-88F20.1	6.31	6.5e-10	0.0011	0.48	0.28	Plateletcrit;	chr17:35541737	chrX:93222220~93225015:-
HNSC	trans	rs9650657	0.504	rs10109167	ENSG00000173295.6	FAM86B3P	-6.31	6.5e-10	0.0011	-0.32	-0.28	Neuroticism;	chr8:11176016	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.87	rs9511261	ENSG00000224976.2	PARP4P2	-6.31	6.51e-10	0.0011	-0.33	-0.28	Obesity-related traits;	chr13:24437880	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs9511262	ENSG00000224976.2	PARP4P2	-6.31	6.51e-10	0.0011	-0.33	-0.28	Obesity-related traits;	chr13:24437885	chr13:19349137~19407962:+
HNSC	trans	rs6756513	0.5	rs2278932	ENSG00000232654.1	FAM136BP	6.31	6.59e-10	0.00111	0.37	0.28	Breast cancer;Platelet count;	chr2:69828984	chr6:3045384~3045800:+
HNSC	trans	rs1816752	0.819	rs4769349	ENSG00000224976.2	PARP4P2	6.31	6.62e-10	0.00111	0.32	0.28	Obesity-related traits;	chr13:24408694	chr13:19349137~19407962:+
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-6.31	6.64e-10	0.00112	-0.31	-0.28	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
HNSC	trans	rs7112043	0.868	rs10768093	ENSG00000225531.1	RP11-196I18.3	6.31	6.67e-10	0.00112	0.34	0.28	Lung disease severity in cystic fibrosis;	chr11:34756012	chr9:107116829~107117557:+
HNSC	trans	rs1991651	0.578	rs13259086	ENSG00000173295.6	FAM86B3P	6.31	6.68e-10	0.00112	0.32	0.28	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.504	rs10108347	ENSG00000173295.6	FAM86B3P	-6.3	6.69e-10	0.00113	-0.31	-0.28	Neuroticism;	chr8:11176008	chr8:8228595~8244865:+
HNSC	trans	rs7647973	0.769	rs4974081	ENSG00000197582.5	GPX1P1	-6.3	6.71e-10	0.00113	-0.41	-0.28	Menarche (age at onset);	chr3:49033066	chrX:13378735~13379340:-
HNSC	trans	rs13416322	0.699	rs2309849	ENSG00000214286.2	PDCL3P3	6.3	6.71e-10	0.00113	0.42	0.28	Intelligence (multi-trait analysis);	chr2:100557847	chr3:17877455~17878169:-
HNSC	trans	rs10037055	0.853	rs2336237	ENSG00000226986.4	RP11-543B16.2	6.3	6.71e-10	0.00113	0.34	0.28	Migraine without aura;	chr5:177238878	chr1:211207239~211207897:+
HNSC	trans	rs7032940	0.954	rs9722603	ENSG00000228236.2	TXNP5	6.3	6.75e-10	0.00113	0.36	0.28	Height;	chr9:110191400	chr2:149068596~149068910:-
HNSC	trans	rs9329221	0.683	rs814359	ENSG00000173295.6	FAM86B3P	-6.3	6.77e-10	0.00114	-0.31	-0.28	Neuroticism;	chr8:10025622	chr8:8228595~8244865:+
HNSC	trans	rs11992162	1	rs11784499	ENSG00000173295.6	FAM86B3P	6.3	6.77e-10	0.00114	0.32	0.28	Monocyte count;	chr8:11977030	chr8:8228595~8244865:+
HNSC	trans	rs6756513	0.5	rs33992437	ENSG00000232654.1	FAM136BP	6.3	6.78e-10	0.00114	0.37	0.28	Breast cancer;Platelet count;	chr2:69828039	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs2278933	ENSG00000232654.1	FAM136BP	6.3	6.78e-10	0.00114	0.37	0.28	Breast cancer;Platelet count;	chr2:69829233	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs72839877	ENSG00000232654.1	FAM136BP	6.3	6.78e-10	0.00114	0.37	0.28	Breast cancer;Platelet count;	chr2:69832475	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs72839879	ENSG00000232654.1	FAM136BP	6.3	6.78e-10	0.00114	0.37	0.28	Breast cancer;Platelet count;	chr2:69835144	chr6:3045384~3045800:+
HNSC	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-6.3	6.79e-10	0.00114	-0.35	-0.28	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-6.3	6.79e-10	0.00114	-0.35	-0.28	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-6.3	6.79e-10	0.00114	-0.35	-0.28	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
HNSC	trans	rs6831352	0.918	rs29001203	ENSG00000233859.2	ADH5P4	6.3	6.79e-10	0.00114	0.34	0.28	Alcohol dependence;	chr4:99131940	chr6:65836930~65838039:-
HNSC	trans	rs3806843	0.518	rs2563310	ENSG00000231043.3	AC007238.1	6.3	6.81e-10	0.00114	0.29	0.28	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr2:58460292~58462032:-
HNSC	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-6.3	6.81e-10	0.00115	-0.36	-0.28	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	6.3	6.82e-10	0.00115	0.31	0.28	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
HNSC	trans	rs6424115	0.965	rs2502986	ENSG00000228217.1	AL390877.1	-6.3	6.82e-10	0.00115	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23808802	chr1:117778087~117778506:-
HNSC	trans	rs7617480	0.648	rs9848268	ENSG00000197582.5	GPX1P1	6.3	6.85e-10	0.00115	0.46	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48724838	chrX:13378735~13379340:-
HNSC	trans	rs6831352	0.734	rs3100630	ENSG00000233859.2	ADH5P4	-6.3	6.9e-10	0.00116	-0.33	-0.28	Alcohol dependence;	chr4:99110564	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.703	rs3133152	ENSG00000233859.2	ADH5P4	-6.3	6.9e-10	0.00116	-0.33	-0.28	Alcohol dependence;	chr4:99110570	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.703	rs2602862	ENSG00000233859.2	ADH5P4	-6.3	6.9e-10	0.00116	-0.33	-0.28	Alcohol dependence;	chr4:99112070	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.734	rs2851259	ENSG00000233859.2	ADH5P4	-6.3	6.9e-10	0.00116	-0.33	-0.28	Alcohol dependence;	chr4:99112835	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.703	rs4235435	ENSG00000233859.2	ADH5P4	-6.3	6.9e-10	0.00116	-0.33	-0.28	Alcohol dependence;	chr4:99118427	chr6:65836930~65838039:-
HNSC	trans	rs7032940	0.954	rs10816936	ENSG00000228236.2	TXNP5	6.3	6.91e-10	0.00116	0.36	0.28	Height;	chr9:110189687	chr2:149068596~149068910:-
HNSC	trans	rs453301	0.571	rs330057	ENSG00000253893.2	FAM85B	6.3	6.94e-10	0.00116	0.32	0.28	Joint mobility (Beighton score);	chr8:9232283	chr8:8167819~8226614:-
HNSC	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	6.3	6.98e-10	0.00117	0.35	0.28	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs56075693	ENSG00000253570.1	RNF5P1	6.3	7.01e-10	0.00118	0.64	0.28	Depression;	chr6:28322551	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs67998226	ENSG00000243753.4	HLA-L	-6.3	7.02e-10	0.00118	-0.59	-0.28	Depression;	chr6:28270281	chr6:30259584~30293014:+
HNSC	trans	rs11172055	0.775	rs10876940	ENSG00000121089.4	NACA3P	6.3	7.04e-10	0.00118	0.33	0.28	Migraine;	chr12:56871233	chr4:164943290~164943937:+
HNSC	trans	rs7412746	0.611	rs111842513	ENSG00000180764.13	PIPSL	-6.3	7.08e-10	0.00119	-0.33	-0.28	Melanoma;	chr1:150740450	chr10:93958191~93961540:-
HNSC	trans	rs2950393	0.895	rs2926740	ENSG00000228224.3	NACAP1	6.29	7.18e-10	0.0012	0.32	0.28	Platelet distribution width;	chr12:56666751	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.804	rs2958127	ENSG00000228224.3	NACAP1	6.29	7.19e-10	0.0012	0.3	0.28	Platelet distribution width;	chr12:56720523	chr8:101361794~101372707:+
HNSC	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-6.29	7.22e-10	0.00121	-0.34	-0.28	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
HNSC	trans	rs9733	0.519	rs2184833	ENSG00000180764.13	PIPSL	-6.29	7.24e-10	0.00121	-0.33	-0.28	Tonsillectomy;	chr1:150703007	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.519	rs1336899	ENSG00000180764.13	PIPSL	-6.29	7.24e-10	0.00121	-0.33	-0.28	Tonsillectomy;	chr1:150706434	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs11803940	ENSG00000180764.13	PIPSL	-6.29	7.24e-10	0.00121	-0.33	-0.28	Melanoma;	chr1:150713359	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.775	rs6601564	ENSG00000173295.6	FAM86B3P	-6.29	7.25e-10	0.00121	-0.32	-0.28	Triglycerides;	chr8:11124541	chr8:8228595~8244865:+
HNSC	trans	rs6831352	0.918	rs2851247	ENSG00000233859.2	ADH5P4	6.29	7.28e-10	0.00122	0.35	0.28	Alcohol dependence;	chr4:99124940	chr6:65836930~65838039:-
HNSC	trans	rs9630182	0.599	rs11600996	ENSG00000257675.1	RP11-641A6.9	-6.29	7.33e-10	0.00123	-0.33	-0.28	Bone mineral density;	chr11:13374619	chr12:52748776~52750127:+
HNSC	trans	rs9425766	0.679	rs2901785	ENSG00000213331.4	RP11-713C19.2	6.29	7.34e-10	0.00123	0.33	0.28	Life satisfaction;	chr1:174135605	chr4:187970273~187971284:+
HNSC	trans	rs7121616	0.595	rs7949414	ENSG00000241478.1	HSPA8P9	6.29	7.35e-10	0.00123	0.35	0.28	Breast cancer;	chr11:123072787	chr3:137880295~137882237:+
HNSC	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	6.29	7.37e-10	0.00123	0.32	0.28	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
HNSC	trans	rs2288327	0.818	rs744426	ENSG00000269800.1	PLEKHA3P1	6.29	7.43e-10	0.00124	0.41	0.28	Atrial fibrillation;	chr2:178571293	chr19:41521043~41521989:-
HNSC	trans	rs6683419	0.967	rs6426808	ENSG00000224237.1	MINOS1P3	-6.29	7.43e-10	0.00124	-0.34	-0.28	Serum thyroid-stimulating hormone levels;	chr1:19508921	chr3:27214816~27215018:-
HNSC	trans	rs7937890	0.532	rs2575833	ENSG00000236360.2	RP11-334A14.2	6.29	7.5e-10	0.00126	0.37	0.28	Mitochondrial DNA levels;	chr11:14470959	chr1:52993201~52993702:-
HNSC	trans	rs2336384	1	rs6672267	ENSG00000261819.1	RP11-680G24.4	6.29	7.52e-10	0.00126	0.39	0.28	Platelet count;	chr1:11994854	chr16:14988259~14990160:-
HNSC	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	6.28	7.53e-10	0.00126	0.35	0.28	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs66886492	ENSG00000253570.1	RNF5P1	6.28	7.55e-10	0.00126	0.65	0.28	Depression;	chr6:28121953	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs35345226	ENSG00000253570.1	RNF5P1	6.28	7.55e-10	0.00126	0.65	0.28	Depression;	chr6:28123802	chr8:38600661~38601200:-
HNSC	trans	rs1816752	1	rs7326932	ENSG00000224976.2	PARP4P2	-6.28	7.56e-10	0.00126	-0.33	-0.28	Obesity-related traits;	chr13:24430355	chr13:19349137~19407962:+
HNSC	trans	rs8067354	0.574	rs2526358	ENSG00000187870.7	RNFT1P3	6.28	7.56e-10	0.00127	0.4	0.28	Hemoglobin concentration;	chr17:59865224	chr17:20743333~20754501:-
HNSC	trans	rs61041336	0.534	rs11641633	ENSG00000230849.2	GOT2P2	6.28	7.59e-10	0.00127	0.55	0.28	Neuritic plaque;	chr16:58679717	chr1:173141100~173142350:-
HNSC	trans	rs9733	0.525	rs11584184	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150723213	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6669369	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150723416	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6681990	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150723453	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6692960	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150723489	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702585	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150723951	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs12086472	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150725234	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.628	rs7540874	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150730187	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs1136808	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150730241	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs1415148	ENSG00000180764.13	PIPSL	-6.28	7.61e-10	0.00127	-0.33	-0.28	Tonsillectomy;	chr1:150733279	chr10:93958191~93961540:-
HNSC	trans	rs9650657	0.683	rs7836366	ENSG00000253893.2	FAM85B	6.28	7.64e-10	0.00128	0.34	0.28	Neuroticism;	chr8:10728173	chr8:8167819~8226614:-
HNSC	trans	rs941207	0.542	rs7311381	ENSG00000257210.1	NACAP3	-6.28	7.66e-10	0.00128	-0.35	-0.28	Platelet count;	chr12:56800286	chr12:93124063~93124543:-
HNSC	trans	rs7412746	0.571	rs12402939	ENSG00000180764.13	PIPSL	-6.28	7.68e-10	0.00128	-0.34	-0.28	Melanoma;	chr1:150642618	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs11204747	ENSG00000180764.13	PIPSL	6.28	7.69e-10	0.00128	0.33	0.28	Melanoma;	chr1:150954676	chr10:93958191~93961540:-
HNSC	trans	rs7647973	0.696	rs3087866	ENSG00000197582.5	GPX1P1	6.28	7.7e-10	0.00129	0.43	0.28	Menarche (age at onset);	chr3:49017259	chrX:13378735~13379340:-
HNSC	trans	rs7617480	0.648	rs6801211	ENSG00000197582.5	GPX1P1	6.28	7.7e-10	0.00129	0.41	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.595	rs7941144	ENSG00000241478.1	HSPA8P9	6.28	7.7e-10	0.00129	0.34	0.28	Breast cancer;	chr11:123079805	chr3:137880295~137882237:+
HNSC	trans	rs9650657	0.645	rs11774552	ENSG00000173295.6	FAM86B3P	-6.28	7.73e-10	0.00129	-0.3	-0.28	Neuroticism;	chr8:10658169	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	6.28	7.73e-10	0.00129	0.31	0.28	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
HNSC	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	6.28	7.73e-10	0.00129	0.31	0.28	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
HNSC	trans	rs10716881	1	rs10716881	ENSG00000228224.3	NACAP1	-6.28	7.74e-10	0.00129	-0.31	-0.28	High light scatter reticulocyte count;	chr12:56644387	chr8:101361794~101372707:+
HNSC	trans	rs7032940	0.954	rs10816937	ENSG00000228236.2	TXNP5	-6.28	7.74e-10	0.00129	-0.35	-0.28	Height;	chr9:110189709	chr2:149068596~149068910:-
HNSC	trans	rs7647973	0.769	rs6446204	ENSG00000197582.5	GPX1P1	6.28	7.75e-10	0.00129	0.44	0.28	Menarche (age at onset);	chr3:48997446	chrX:13378735~13379340:-
HNSC	trans	rs7824557	0.527	rs2572369	ENSG00000254340.1	RP11-10A14.3	-6.28	7.75e-10	0.00129	-0.33	-0.28	Retinal vascular caliber;	chr8:11381088	chr8:9141424~9145435:+
HNSC	trans	rs9650657	0.524	rs2163379	ENSG00000173295.6	FAM86B3P	6.28	7.78e-10	0.0013	0.34	0.28	Neuroticism;	chr8:10874540	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.718	rs7165690	ENSG00000235370.6	DNM1P51	-6.28	7.78e-10	0.0013	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82654804	chr15:84398316~84411701:-
HNSC	trans	rs941207	0.542	rs6581106	ENSG00000257210.1	NACAP3	-6.28	7.79e-10	0.0013	-0.35	-0.28	Platelet count;	chr12:56796759	chr12:93124063~93124543:-
HNSC	trans	rs1391708	1	rs34285886	ENSG00000121089.4	NACA3P	-6.28	7.8e-10	0.0013	-0.48	-0.28	Airway wall thickness;	chr12:56908736	chr4:164943290~164943937:+
HNSC	trans	rs9650657	0.645	rs4841408	ENSG00000173295.6	FAM86B3P	-6.28	7.82e-10	0.0013	-0.3	-0.28	Neuroticism;	chr8:10658826	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.607	rs34243448	ENSG00000253570.1	RNF5P1	6.28	7.82e-10	0.00131	0.65	0.28	Depression;	chr6:28225324	chr8:38600661~38601200:-
HNSC	trans	rs2899832	0.568	rs77796720	ENSG00000229083.1	PSMA6P2	6.28	7.84e-10	0.00131	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35314500	chrX:12825840~12826833:+
HNSC	trans	rs6831352	0.879	rs2851255	ENSG00000233859.2	ADH5P4	-6.28	7.86e-10	0.00131	-0.33	-0.28	Alcohol dependence;	chr4:99120952	chr6:65836930~65838039:-
HNSC	trans	rs7937890	0.505	rs4403769	ENSG00000236360.2	RP11-334A14.2	6.28	7.87e-10	0.00131	0.37	0.28	Mitochondrial DNA levels;	chr11:14428630	chr1:52993201~52993702:-
HNSC	trans	rs941207	0.542	rs4277148	ENSG00000257210.1	NACAP3	-6.28	7.88e-10	0.00131	-0.35	-0.28	Platelet count;	chr12:56787071	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs12370142	ENSG00000257210.1	NACAP3	-6.28	7.88e-10	0.00131	-0.35	-0.28	Platelet count;	chr12:56790801	chr12:93124063~93124543:-
HNSC	trans	rs12367822	0.956	rs9706160	ENSG00000257210.1	NACAP3	-6.28	7.88e-10	0.00131	-0.35	-0.28	Platelet aggregation;	chr12:56791119	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs2888095	ENSG00000257210.1	NACAP3	-6.28	7.88e-10	0.00131	-0.35	-0.28	Platelet count;	chr12:56793689	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs2888096	ENSG00000257210.1	NACAP3	-6.28	7.88e-10	0.00131	-0.35	-0.28	Platelet count;	chr12:56793851	chr12:93124063~93124543:-
HNSC	trans	rs853679	1	rs10456362	ENSG00000204622.9	HLA-J	6.28	7.89e-10	0.00132	0.45	0.28	Depression;	chr6:28254038	chr6:30006583~30009956:+
HNSC	trans	rs9329221	0.716	rs11989640	ENSG00000173295.6	FAM86B3P	-6.28	7.89e-10	0.00132	-0.34	-0.28	Neuroticism;	chr8:10398544	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.642	rs4948104	ENSG00000186940.6	CHCHD2P9	-6.28	7.9e-10	0.00132	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr9:79391304~79391759:+
HNSC	trans	rs7647973	0.696	rs7100	ENSG00000197582.5	GPX1P1	6.28	7.92e-10	0.00132	0.44	0.28	Menarche (age at onset);	chr3:49015786	chrX:13378735~13379340:-
HNSC	trans	rs7617480	0.648	rs6796790	ENSG00000197582.5	GPX1P1	6.28	7.94e-10	0.00132	0.41	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chrX:13378735~13379340:-
HNSC	trans	rs853679	0.607	rs71559070	ENSG00000243753.4	HLA-L	-6.28	7.96e-10	0.00133	-0.62	-0.28	Depression;	chr6:28071151	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.527	rs2572448	ENSG00000254340.1	RP11-10A14.3	-6.28	7.96e-10	0.00133	-0.33	-0.28	Retinal vascular caliber;	chr8:11381843	chr8:9141424~9145435:+
HNSC	trans	rs9733	0.596	rs12403255	ENSG00000180764.13	PIPSL	-6.28	7.97e-10	0.00133	-0.33	-0.28	Tonsillectomy;	chr1:150687936	chr10:93958191~93961540:-
HNSC	trans	rs11172055	1	rs11172055	ENSG00000121089.4	NACA3P	6.27	8e-10	0.00133	0.33	0.28	Migraine;	chr12:56914476	chr4:164943290~164943937:+
HNSC	trans	rs1355223	0.506	rs7130774	ENSG00000225531.1	RP11-196I18.3	6.27	8.04e-10	0.00134	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847720	chr9:107116829~107117557:+
HNSC	trans	rs2899832	0.568	rs28461608	ENSG00000229083.1	PSMA6P2	6.27	8.09e-10	0.00135	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258767	chrX:12825840~12826833:+
HNSC	trans	rs2899832	0.568	rs7140912	ENSG00000229083.1	PSMA6P2	6.27	8.09e-10	0.00135	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258823	chrX:12825840~12826833:+
HNSC	trans	rs9733	0.544	rs72700902	ENSG00000180764.13	PIPSL	-6.27	8.15e-10	0.00136	-0.33	-0.28	Tonsillectomy;	chr1:150660871	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.519	rs10788792	ENSG00000180764.13	PIPSL	-6.27	8.15e-10	0.00136	-0.33	-0.28	Tonsillectomy;	chr1:150666096	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.526	rs11204696	ENSG00000180764.13	PIPSL	-6.27	8.15e-10	0.00136	-0.33	-0.28	Tonsillectomy;	chr1:150686245	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.526	rs11204698	ENSG00000180764.13	PIPSL	-6.27	8.15e-10	0.00136	-0.33	-0.28	Tonsillectomy;	chr1:150687069	chr10:93958191~93961540:-
HNSC	trans	rs7819412	0.521	rs10100660	ENSG00000173295.6	FAM86B3P	-6.27	8.16e-10	0.00136	-0.33	-0.28	Triglycerides;	chr8:11181376	chr8:8228595~8244865:+
HNSC	trans	rs673253	0.662	rs61769642	ENSG00000231007.5	CDC20P1	6.27	8.17e-10	0.00136	0.39	0.28	Intelligence (multi-trait analysis);	chr1:43585959	chr9:87011652~87013151:+
HNSC	trans	rs7824557	0.603	rs2249804	ENSG00000173295.6	FAM86B3P	6.27	8.22e-10	0.00137	0.31	0.28	Retinal vascular caliber;	chr8:11358108	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.691	rs10435504	ENSG00000215006.4	CHCHD2P2	-6.27	8.24e-10	0.00137	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.653	rs6593294	ENSG00000215006.4	CHCHD2P2	-6.27	8.24e-10	0.00137	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr5:69333929~69334249:+
HNSC	trans	rs722599	0.748	rs55707505	ENSG00000181227.3	RP4-682C21.2	6.27	8.25e-10	0.00137	0.29	0.28	IgG glycosylation;	chr14:74895849	chr1:75743423~75744776:-
HNSC	trans	rs2950393	0.804	rs2958130	ENSG00000257210.1	NACAP3	6.27	8.26e-10	0.00137	0.31	0.28	Platelet distribution width;	chr12:56746722	chr12:93124063~93124543:-
HNSC	trans	rs853679	0.607	rs34788973	ENSG00000253570.1	RNF5P1	6.27	8.28e-10	0.00138	0.63	0.28	Depression;	chr6:27911422	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs61742093	ENSG00000253570.1	RNF5P1	6.27	8.28e-10	0.00138	0.63	0.28	Depression;	chr6:27912204	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs66868086	ENSG00000253570.1	RNF5P1	6.27	8.29e-10	0.00138	0.63	0.28	Depression;	chr6:27898124	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13199649	ENSG00000253570.1	RNF5P1	6.27	8.29e-10	0.00138	0.63	0.28	Depression;	chr6:27901014	chr8:38600661~38601200:-
HNSC	trans	rs9467773	0.595	rs3799379	ENSG00000242375.1	RP11-498P14.3	-6.27	8.29e-10	0.00138	-0.35	-0.28	Intelligence (multi-trait analysis);	chr6:26404466	chr9:97195351~97197687:-
HNSC	trans	rs1355223	0.545	rs7106831	ENSG00000225531.1	RP11-196I18.3	6.27	8.29e-10	0.00138	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr9:107116829~107117557:+
HNSC	trans	rs546131	0.928	rs552868	ENSG00000225531.1	RP11-196I18.3	6.27	8.32e-10	0.00138	0.34	0.28	Lung disease severity in cystic fibrosis;	chr11:34809147	chr9:107116829~107117557:+
HNSC	trans	rs853679	0.546	rs35016036	ENSG00000243753.4	HLA-L	-6.27	8.32e-10	0.00138	-0.6	-0.28	Depression;	chr6:28347103	chr6:30259584~30293014:+
HNSC	trans	rs6683419	0.967	rs10917470	ENSG00000224237.1	MINOS1P3	-6.27	8.35e-10	0.00139	-0.33	-0.28	Serum thyroid-stimulating hormone levels;	chr1:19518712	chr3:27214816~27215018:-
HNSC	trans	rs941207	0.507	rs73337030	ENSG00000257210.1	NACAP3	-6.27	8.35e-10	0.00139	-0.31	-0.28	Platelet count;	chr12:56652410	chr12:93124063~93124543:-
HNSC	trans	rs8177876	0.658	rs11150337	ENSG00000224837.1	GCSHP5	6.27	8.44e-10	0.0014	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr1:168055901~168056422:-
HNSC	trans	rs4970988	0.556	rs2280078	ENSG00000180764.13	PIPSL	6.27	8.46e-10	0.0014	0.35	0.28	Urate levels;	chr1:150627705	chr10:93958191~93961540:-
HNSC	trans	rs2336384	1	rs2336384	ENSG00000261819.1	RP11-680G24.4	-6.27	8.46e-10	0.0014	-0.39	-0.28	Platelet count;	chr1:11986006	chr16:14988259~14990160:-
HNSC	trans	rs8067354	0.609	rs1292066	ENSG00000187870.7	RNFT1P3	6.26	8.49e-10	0.00141	0.37	0.28	Hemoglobin concentration;	chr17:59854953	chr17:20743333~20754501:-
HNSC	trans	rs7031417	1	rs7031417	ENSG00000276529.1	AP001505.10	-6.26	8.52e-10	0.00141	-0.52	-0.28	Longitudinal alcohol consumption;	chr9:88211338	chr21:44978832~44979274:+
HNSC	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-6.26	8.54e-10	0.00142	-0.35	-0.28	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-6.26	8.54e-10	0.00142	-0.35	-0.28	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
HNSC	trans	rs9733	0.519	rs6700022	ENSG00000180764.13	PIPSL	6.26	8.56e-10	0.00142	0.33	0.28	Tonsillectomy;	chr1:150698008	chr10:93958191~93961540:-
HNSC	trans	rs7829975	0.54	rs2976909	ENSG00000255310.2	AF131215.2	-6.26	8.59e-10	0.00142	-0.28	-0.28	Mood instability;	chr8:8489180	chr8:11107788~11109726:-
HNSC	trans	rs9733	0.565	rs11804276	ENSG00000180764.13	PIPSL	-6.26	8.61e-10	0.00143	-0.33	-0.28	Tonsillectomy;	chr1:150713285	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.546	rs35744819	ENSG00000253570.1	RNF5P1	6.26	8.67e-10	0.00144	0.64	0.28	Depression;	chr6:28350554	chr8:38600661~38601200:-
HNSC	trans	rs6831352	0.734	rs2602857	ENSG00000233859.2	ADH5P4	-6.26	8.68e-10	0.00144	-0.33	-0.28	Alcohol dependence;	chr4:99109167	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.734	rs3018046	ENSG00000233859.2	ADH5P4	-6.26	8.68e-10	0.00144	-0.33	-0.28	Alcohol dependence;	chr4:99109237	chr6:65836930~65838039:-
HNSC	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	6.26	8.72e-10	0.00145	0.35	0.28	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
HNSC	trans	rs9733	0.596	rs11204704	ENSG00000180764.13	PIPSL	-6.26	8.73e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150699154	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.607	rs34218844	ENSG00000243753.4	HLA-L	-6.26	8.75e-10	0.00145	-0.6	-0.28	Depression;	chr6:28322870	chr6:30259584~30293014:+
HNSC	trans	rs9733	0.596	rs12077833	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150701857	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.566	rs112967224	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150704787	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702552	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150704986	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.566	rs72702554	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150705758	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11586422	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150706882	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702557	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150707654	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs17606613	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150710539	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.543	rs72702558	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150710775	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.628	rs11807409	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150710947	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs12072339	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150713623	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs34600506	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150715332	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702570	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150715720	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11582840	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150716011	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.569	rs11588404	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150716053	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702573	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150716574	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702580	ENSG00000180764.13	PIPSL	-6.26	8.77e-10	0.00145	-0.33	-0.28	Tonsillectomy;	chr1:150718809	chr10:93958191~93961540:-
HNSC	trans	rs7032940	0.859	rs11793349	ENSG00000228236.2	TXNP5	6.26	8.77e-10	0.00145	0.36	0.28	Height;	chr9:110191406	chr2:149068596~149068910:-
HNSC	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-6.26	8.82e-10	0.00146	-0.3	-0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
HNSC	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-6.26	8.83e-10	0.00146	-0.34	-0.28	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
HNSC	trans	rs67340775	0.834	rs13218875	ENSG00000253570.1	RNF5P1	6.26	8.91e-10	0.00147	0.63	0.28	Lung cancer in ever smokers;	chr6:27916234	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs67040724	ENSG00000253570.1	RNF5P1	6.26	8.91e-10	0.00147	0.63	0.28	Depression;	chr6:27937731	chr8:38600661~38601200:-
HNSC	trans	rs4713118	0.539	rs200967	ENSG00000204709.4	LINC01556	6.26	8.91e-10	0.00147	0.35	0.28	Parkinson's disease;	chr6:27894349	chr6:28943877~28944537:+
HNSC	trans	rs216303	0.841	rs2239160	ENSG00000241717.1	VWFP1	6.26	8.96e-10	0.00148	0.43	0.28	Low vWF levels;	chr12:6053588	chr22:16690103~16704477:-
HNSC	trans	rs7032940	0.953	rs7036157	ENSG00000228236.2	TXNP5	6.25	9e-10	0.00149	0.35	0.28	Height;	chr9:110183494	chr2:149068596~149068910:-
HNSC	trans	rs26067	0.689	rs152839	ENSG00000231752.4	EMBP1	-6.25	9e-10	0.00149	-0.37	-0.28	Breast cancer;	chr5:50849432	chr1:121519112~121571892:+
HNSC	trans	rs546131	0.928	rs516228	ENSG00000225531.1	RP11-196I18.3	6.25	9.04e-10	0.00149	0.34	0.28	Lung disease severity in cystic fibrosis;	chr11:34817276	chr9:107116829~107117557:+
HNSC	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-6.25	9.06e-10	0.0015	-0.34	-0.28	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
HNSC	trans	rs941207	0.526	rs7303216	ENSG00000228224.3	NACAP1	6.25	9.08e-10	0.0015	0.32	0.28	Platelet count;	chr12:56680909	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.507	rs7297289	ENSG00000228224.3	NACAP1	6.25	9.08e-10	0.0015	0.32	0.28	Platelet count;	chr12:56682703	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.526	rs4759028	ENSG00000228224.3	NACAP1	6.25	9.08e-10	0.0015	0.32	0.28	Platelet count;	chr12:56686399	chr8:101361794~101372707:+
HNSC	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	6.25	9.08e-10	0.0015	0.35	0.28	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
HNSC	trans	rs11638815	0.668	rs7182320	ENSG00000235370.6	DNM1P51	6.25	9.09e-10	0.0015	0.36	0.28	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719000	chr15:84398316~84411701:-
HNSC	trans	rs2665103	0.589	rs3858953	ENSG00000235370.6	DNM1P51	-6.25	9.13e-10	0.00151	-0.32	-0.28	Intelligence (multi-trait analysis);	chr15:82238049	chr15:84398316~84411701:-
HNSC	trans	rs2456568	0.501	rs2174638	ENSG00000276509.1	CH17-353B19.1	6.25	9.16e-10	0.00151	0.3	0.28	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93976049	chr1:146235806~146237807:+
HNSC	trans	rs853679	0.607	rs34765154	ENSG00000253570.1	RNF5P1	6.25	9.25e-10	0.00153	0.68	0.28	Depression;	chr6:28162672	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.556	rs67297533	ENSG00000253570.1	RNF5P1	6.25	9.25e-10	0.00153	0.68	0.28	Depression;	chr6:28173475	chr8:38600661~38601200:-
HNSC	trans	rs7647973	0.769	rs7434187	ENSG00000197582.5	GPX1P1	6.25	9.28e-10	0.00153	0.43	0.28	Menarche (age at onset);	chr3:48995534	chrX:13378735~13379340:-
HNSC	trans	rs7824557	0.603	rs2250028	ENSG00000173295.6	FAM86B3P	6.25	9.29e-10	0.00153	0.31	0.28	Retinal vascular caliber;	chr8:11356080	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.561	rs307246	ENSG00000257675.1	RP11-641A6.9	-6.25	9.32e-10	0.00154	-0.32	-0.28	Bone mineral density;	chr11:13461680	chr12:52748776~52750127:+
HNSC	trans	rs7617480	0.648	rs4974083	ENSG00000197582.5	GPX1P1	6.25	9.35e-10	0.00154	0.44	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48963193	chrX:13378735~13379340:-
HNSC	trans	rs2288327	0.841	rs2303828	ENSG00000269800.1	PLEKHA3P1	6.25	9.4e-10	0.00155	0.36	0.28	Atrial fibrillation;	chr2:178683133	chr19:41521043~41521989:-
HNSC	trans	rs7824557	0.527	rs2572376	ENSG00000254340.1	RP11-10A14.3	-6.25	9.42e-10	0.00155	-0.33	-0.28	Retinal vascular caliber;	chr8:11380247	chr8:9141424~9145435:+
HNSC	trans	rs10037055	0.853	rs1363405	ENSG00000226986.4	RP11-543B16.2	6.25	9.42e-10	0.00155	0.33	0.28	Migraine without aura;	chr5:177209881	chr1:211207239~211207897:+
HNSC	trans	rs9467711	0.659	rs35433030	ENSG00000253570.1	RNF5P1	6.25	9.43e-10	0.00156	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs66941101	ENSG00000253570.1	RNF5P1	6.25	9.43e-10	0.00156	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr8:38600661~38601200:-
HNSC	trans	rs7824557	0.778	rs3808502	ENSG00000173295.6	FAM86B3P	6.25	9.5e-10	0.00157	0.31	0.28	Retinal vascular caliber;	chr8:11321949	chr8:8228595~8244865:+
HNSC	trans	rs11220237	1	rs10893444	ENSG00000236257.1	EI24P2	6.25	9.51e-10	0.00157	0.41	0.28	Itch intensity from mosquito bite adjusted by bite size;	chr11:125875652	chr1:158454198~158455273:+
HNSC	trans	rs7617480	0.648	rs14018	ENSG00000197582.5	GPX1P1	6.24	9.56e-10	0.00158	0.44	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chrX:13378735~13379340:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	6.24	9.6e-10	0.00158	0.34	0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
HNSC	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	6.24	9.61e-10	0.00158	0.33	0.28	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
HNSC	trans	rs7121616	0.562	rs2061602	ENSG00000241478.1	HSPA8P9	6.24	9.61e-10	0.00158	0.34	0.28	Breast cancer;	chr11:123065079	chr3:137880295~137882237:+
HNSC	trans	rs4948102	0.732	rs6951810	ENSG00000186940.6	CHCHD2P9	-6.24	9.64e-10	0.00159	-0.4	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56008905	chr9:79391304~79391759:+
HNSC	trans	rs4948102	0.731	rs4948099	ENSG00000215006.4	CHCHD2P2	6.24	9.64e-10	0.00159	0.36	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr5:69333929~69334249:+
HNSC	trans	rs6831352	0.693	rs2602875	ENSG00000233859.2	ADH5P4	-6.24	9.67e-10	0.00159	-0.33	-0.28	Alcohol dependence;	chr4:99118344	chr6:65836930~65838039:-
HNSC	trans	rs3808502	0.527	rs4410870	ENSG00000173295.6	FAM86B3P	-6.24	9.73e-10	0.0016	-0.33	-0.28	Neuroticism;	chr8:11298611	chr8:8228595~8244865:+
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	6.24	9.77e-10	0.00161	0.31	0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
HNSC	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	6.24	9.78e-10	0.00161	0.33	0.28	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
HNSC	trans	rs9733	0.596	rs72702523	ENSG00000180764.13	PIPSL	-6.24	9.79e-10	0.00161	-0.33	-0.28	Tonsillectomy;	chr1:150677949	chr10:93958191~93961540:-
HNSC	trans	rs9650657	0.645	rs4841407	ENSG00000173295.6	FAM86B3P	-6.24	9.79e-10	0.00161	-0.3	-0.28	Neuroticism;	chr8:10658675	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.905	rs8002215	ENSG00000224976.2	PARP4P2	-6.24	9.81e-10	0.00162	-0.32	-0.28	Obesity-related traits;	chr13:24416229	chr13:19349137~19407962:+
HNSC	trans	rs7112043	0.778	rs1472975	ENSG00000225531.1	RP11-196I18.3	6.24	9.82e-10	0.00162	0.34	0.28	Lung disease severity in cystic fibrosis;	chr11:34755096	chr9:107116829~107117557:+
HNSC	trans	rs673253	0.686	rs501299	ENSG00000231007.5	CDC20P1	6.24	9.9e-10	0.00163	0.39	0.28	Intelligence (multi-trait analysis);	chr1:43586163	chr9:87011652~87013151:+
HNSC	trans	rs9329221	0.741	rs9650622	ENSG00000173295.6	FAM86B3P	-6.24	9.93e-10	0.00163	-0.31	-0.28	Neuroticism;	chr8:9946782	chr8:8228595~8244865:+
HNSC	trans	rs9467711	0.659	rs34246779	ENSG00000253570.1	RNF5P1	6.24	9.94e-10	0.00163	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs72845428	ENSG00000253570.1	RNF5P1	6.24	9.94e-10	0.00163	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs35277236	ENSG00000253570.1	RNF5P1	6.24	9.94e-10	0.00163	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr8:38600661~38601200:-
HNSC	trans	rs13177918	0.651	rs13184111	ENSG00000226396.1	RP5-1056L3.3	6.24	9.96e-10	0.00164	0.23	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:19608114~19608568:+
HNSC	trans	rs7824557	0.591	rs2572452	ENSG00000173295.6	FAM86B3P	-6.24	9.96e-10	0.00164	-0.3	-0.28	Retinal vascular caliber;	chr8:11370745	chr8:8228595~8244865:+
HNSC	trans	rs17507216	1	rs3850610	ENSG00000235370.6	DNM1P51	6.24	9.98e-10	0.00164	0.38	0.28	Excessive daytime sleepiness;	chr15:82552642	chr15:84398316~84411701:-
HNSC	trans	rs9329221	0.741	rs13264066	ENSG00000173295.6	FAM86B3P	-6.24	1e-09	0.00164	-0.31	-0.28	Neuroticism;	chr8:9946565	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.596	rs6587516	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150650745	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6678013	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150650809	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs2175615	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150651625	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.628	rs72700895	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150653553	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72700897	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150653562	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6661872	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150655881	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11204687	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150657404	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs2867304	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150658519	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6690725	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150659846	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702504	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150662898	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6686525	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150663335	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.536	rs6661415	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150663393	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11807058	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150667999	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs34140753	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150670107	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.569	rs11204691	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150671863	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs12089731	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150675322	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.519	rs12095002	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150676773	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs12085275	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150677789	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs12086630	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150678479	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs2065900	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150679726	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs2867301	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150681319	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs7538493	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150682945	chr10:93958191~93961540:-
HNSC	trans	rs4970988	0.64	rs7524734	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Urate levels;	chr1:150683210	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs6685702	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150683831	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs7549795	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150684397	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11204697	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150686495	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs7529998	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150690055	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs11803569	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150691601	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs1336898	ENSG00000180764.13	PIPSL	-6.24	1e-09	0.00164	-0.33	-0.28	Tonsillectomy;	chr1:150692574	chr10:93958191~93961540:-
HNSC	trans	rs4948102	0.642	rs766333	ENSG00000215006.4	CHCHD2P2	-6.24	1e-09	0.00165	-0.36	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr5:69333929~69334249:+
HNSC	trans	rs853679	0.607	rs56075693	ENSG00000243753.4	HLA-L	-6.24	1e-09	0.00165	-0.6	-0.28	Depression;	chr6:28322551	chr6:30259584~30293014:+
HNSC	trans	rs7520050	0.807	rs3013594	ENSG00000255397.1	AC022182.2	-6.24	1.01e-09	0.00165	-0.34	-0.28	Reticulocyte count;Red blood cell count;	chr1:45672328	chr8:60937705~60939871:-
HNSC	trans	rs6981523	0.553	rs2409730	ENSG00000173295.6	FAM86B3P	-6.24	1.01e-09	0.00165	-0.33	-0.28	Neuroticism;	chr8:11203129	chr8:8228595~8244865:+
HNSC	trans	rs9733	0.596	rs72702556	ENSG00000180764.13	PIPSL	-6.24	1.01e-09	0.00166	-0.33	-0.28	Tonsillectomy;	chr1:150707639	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.657	rs1778483	ENSG00000227766.1	HCG4P5	-6.23	1.02e-09	0.00168	-0.37	-0.28	Depression;	chr6:28273214	chr6:29942075~29943067:-
HNSC	trans	rs853679	0.657	rs1778482	ENSG00000227766.1	HCG4P5	-6.23	1.02e-09	0.00168	-0.37	-0.28	Depression;	chr6:28273215	chr6:29942075~29943067:-
HNSC	trans	rs7121616	1	rs7121616	ENSG00000229091.2	HSPA8P8	6.23	1.02e-09	0.00168	0.31	0.28	Breast cancer;	chr11:123095918	chr7:10451311~10452526:+
HNSC	trans	rs7121616	0.96	rs7122306	ENSG00000229091.2	HSPA8P8	6.23	1.02e-09	0.00168	0.31	0.28	Breast cancer;	chr11:123096254	chr7:10451311~10452526:+
HNSC	trans	rs7032940	0.953	rs10816934	ENSG00000228236.2	TXNP5	6.23	1.03e-09	0.00168	0.35	0.28	Height;	chr9:110180540	chr2:149068596~149068910:-
HNSC	trans	rs2950393	0.927	rs11171914	ENSG00000257210.1	NACAP3	-6.23	1.03e-09	0.00168	-0.33	-0.28	Platelet distribution width;	chr12:56649462	chr12:93124063~93124543:-
HNSC	trans	rs853679	0.607	rs35072899	ENSG00000243753.4	HLA-L	-6.23	1.03e-09	0.00168	-0.61	-0.28	Depression;	chr6:28313764	chr6:30259584~30293014:+
HNSC	trans	rs3806843	0.712	rs2530244	ENSG00000231043.3	AC007238.1	6.23	1.03e-09	0.00169	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr2:58460292~58462032:-
HNSC	trans	rs7662987	0.517	rs2602882	ENSG00000233859.2	ADH5P4	-6.23	1.03e-09	0.00169	-0.33	-0.28	Smoking initiation;	chr4:99119614	chr6:65836930~65838039:-
HNSC	trans	rs7662987	0.517	rs2602883	ENSG00000233859.2	ADH5P4	-6.23	1.03e-09	0.00169	-0.33	-0.28	Smoking initiation;	chr4:99119763	chr6:65836930~65838039:-
HNSC	trans	rs9733	0.596	rs56058687	ENSG00000180764.13	PIPSL	-6.23	1.04e-09	0.0017	-0.33	-0.28	Tonsillectomy;	chr1:150662590	chr10:93958191~93961540:-
HNSC	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	6.23	1.04e-09	0.0017	0.31	0.28	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
HNSC	trans	rs9733	0.596	rs2275236	ENSG00000180764.13	PIPSL	6.23	1.04e-09	0.0017	0.33	0.28	Tonsillectomy;	chr1:150697476	chr10:93958191~93961540:-
HNSC	trans	rs8067354	0.574	rs1292042	ENSG00000187870.7	RNFT1P3	6.23	1.04e-09	0.0017	0.4	0.28	Hemoglobin concentration;	chr17:59857634	chr17:20743333~20754501:-
HNSC	trans	rs4948102	0.731	rs6593292	ENSG00000215006.4	CHCHD2P2	-6.23	1.04e-09	0.0017	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.731	rs4535700	ENSG00000215006.4	CHCHD2P2	-6.23	1.04e-09	0.0017	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.731	rs4543497	ENSG00000215006.4	CHCHD2P2	-6.23	1.04e-09	0.0017	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.767	rs4948096	ENSG00000215006.4	CHCHD2P2	-6.23	1.04e-09	0.0017	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.727	rs4948097	ENSG00000215006.4	CHCHD2P2	-6.23	1.04e-09	0.0017	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr5:69333929~69334249:+
HNSC	trans	rs1816752	0.905	rs7400631	ENSG00000224976.2	PARP4P2	-6.23	1.04e-09	0.0017	-0.32	-0.28	Obesity-related traits;	chr13:24415927	chr13:19349137~19407962:+
HNSC	trans	rs941207	0.526	rs2950393	ENSG00000257210.1	NACAP3	-6.23	1.04e-09	0.00171	-0.33	-0.28	Platelet count;	chr12:56642239	chr12:93124063~93124543:-
HNSC	trans	rs9467711	0.606	rs9366656	ENSG00000253570.1	RNF5P1	6.23	1.04e-09	0.00171	0.59	0.28	Autism spectrum disorder or schizophrenia;	chr6:26434402	chr8:38600661~38601200:-
HNSC	trans	rs6087990	0.735	rs910083	ENSG00000253915.1	MAPRE1P1	6.23	1.05e-09	0.00172	0.33	0.28	Ulcerative colitis;	chr20:32790884	chr8:135625185~135625981:-
HNSC	trans	rs2553218	0.69	rs8032415	ENSG00000234742.1	AC144530.1	6.23	1.06e-09	0.00173	0.32	0.28	Immune response to smallpox vaccine (IL-6);	chr15:54559747	chr3:197850400~197850954:-
HNSC	trans	rs13177918	0.626	rs12186649	ENSG00000226396.1	RP5-1056L3.3	6.23	1.06e-09	0.00174	0.22	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:19608114~19608568:+
HNSC	trans	rs34546498	1	rs34546498	ENSG00000253570.1	RNF5P1	6.23	1.06e-09	0.00174	0.71	0.28	Breast cancer;	chr6:26993501	chr8:38600661~38601200:-
HNSC	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-6.23	1.06e-09	0.00174	-0.36	-0.28	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
HNSC	trans	rs2898290	0.622	rs978803	ENSG00000173295.6	FAM86B3P	6.23	1.07e-09	0.00174	0.3	0.28	Systolic blood pressure;	chr8:11485966	chr8:8228595~8244865:+
HNSC	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	6.22	1.08e-09	0.00176	0.34	0.28	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
HNSC	trans	rs9630182	0.561	rs11022817	ENSG00000257675.1	RP11-641A6.9	-6.22	1.08e-09	0.00176	-0.32	-0.28	Bone mineral density;	chr11:13424748	chr12:52748776~52750127:+
HNSC	trans	rs17507216	0.718	rs72753931	ENSG00000259295.5	CSPG4P12	-6.22	1.08e-09	0.00177	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82721485	chr15:85191438~85213905:+
HNSC	trans	rs3806843	0.733	rs801181	ENSG00000231043.3	AC007238.1	6.22	1.08e-09	0.00177	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr2:58460292~58462032:-
HNSC	trans	rs17507216	0.671	rs28582623	ENSG00000235370.6	DNM1P51	-6.22	1.08e-09	0.00177	-0.41	-0.28	Excessive daytime sleepiness;	chr15:82577381	chr15:84398316~84411701:-
HNSC	trans	rs2950393	0.857	rs1563896	ENSG00000228224.3	NACAP1	6.22	1.09e-09	0.00177	0.32	0.28	Platelet distribution width;	chr12:56699312	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.929	rs7973157	ENSG00000257210.1	NACAP3	-6.22	1.09e-09	0.00177	-0.31	-0.28	Platelet distribution width;	chr12:56655409	chr12:93124063~93124543:-
HNSC	trans	rs1355223	0.545	rs7123029	ENSG00000225531.1	RP11-196I18.3	6.22	1.09e-09	0.00178	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853268	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.545	rs7111695	ENSG00000225531.1	RP11-196I18.3	6.22	1.09e-09	0.00178	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853359	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.507	rs11032903	ENSG00000225531.1	RP11-196I18.3	6.22	1.09e-09	0.00178	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854629	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.545	rs12278318	ENSG00000225531.1	RP11-196I18.3	6.22	1.09e-09	0.00178	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854960	chr9:107116829~107117557:+
HNSC	trans	rs9329221	0.905	rs17765901	ENSG00000173295.6	FAM86B3P	-6.22	1.09e-09	0.00178	-0.31	-0.28	Neuroticism;	chr8:10391970	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.905	rs8002309	ENSG00000224976.2	PARP4P2	-6.22	1.09e-09	0.00178	-0.33	-0.28	Obesity-related traits;	chr13:24402217	chr13:19349137~19407962:+
HNSC	trans	rs9467711	0.79	rs13220495	ENSG00000253570.1	RNF5P1	6.22	1.09e-09	0.00178	0.67	0.28	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr8:38600661~38601200:-
HNSC	trans	rs7032940	1	rs7032940	ENSG00000228236.2	TXNP5	-6.22	1.09e-09	0.00178	-0.35	-0.28	Height;	chr9:110183125	chr2:149068596~149068910:-
HNSC	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-6.22	1.11e-09	0.0018	-0.35	-0.28	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
HNSC	trans	rs7121616	0.576	rs4802	ENSG00000256356.1	HSPA8P5	6.22	1.11e-09	0.00181	0.33	0.28	Breast cancer;	chr11:123057914	chr12:4097451~4099519:+
HNSC	trans	rs1568889	0.838	rs1483858	ENSG00000174912.7	METTL15P1	6.22	1.11e-09	0.00181	0.29	0.28	Bipolar disorder;	chr11:28168092	chr3:156713884~156714928:-
HNSC	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	6.22	1.11e-09	0.00181	0.35	0.28	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	6.22	1.12e-09	0.00182	0.31	0.28	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
HNSC	trans	rs9650657	0.613	rs877116	ENSG00000173295.6	FAM86B3P	-6.22	1.12e-09	0.00182	-0.32	-0.28	Neuroticism;	chr8:10855435	chr8:8228595~8244865:+
HNSC	trans	rs864643	0.625	rs1707958	ENSG00000183298.5	RP11-556K13.1	6.22	1.12e-09	0.00183	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39481931	chr1:101786340~101787219:-
HNSC	trans	rs6831352	1	rs1126670	ENSG00000233859.2	ADH5P4	-6.22	1.13e-09	0.00184	-0.31	-0.28	Alcohol dependence;	chr4:99131582	chr6:65836930~65838039:-
HNSC	trans	rs8014204	0.869	rs2070599	ENSG00000181227.3	RP4-682C21.2	6.22	1.13e-09	0.00185	0.27	0.28	Caffeine consumption;	chr14:74894474	chr1:75743423~75744776:-
HNSC	trans	rs6424115	0.931	rs2982390	ENSG00000228217.1	AL390877.1	-6.22	1.14e-09	0.00185	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23821340	chr1:117778087~117778506:-
HNSC	trans	rs2950393	0.804	rs2035081	ENSG00000228224.3	NACAP1	6.21	1.14e-09	0.00186	0.3	0.28	Platelet distribution width;	chr12:56732095	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.804	rs10783796	ENSG00000228224.3	NACAP1	6.21	1.14e-09	0.00186	0.3	0.28	Platelet distribution width;	chr12:56733387	chr8:101361794~101372707:+
HNSC	trans	rs7930295	1	rs11220081	ENSG00000236257.1	EI24P2	6.21	1.14e-09	0.00186	0.42	0.28	Schizophrenia;	chr11:125453646	chr1:158454198~158455273:+
HNSC	trans	rs9467773	0.595	rs4320356	ENSG00000242375.1	RP11-498P14.3	-6.21	1.14e-09	0.00186	-0.35	-0.28	Intelligence (multi-trait analysis);	chr6:26423332	chr9:97195351~97197687:-
HNSC	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-6.21	1.14e-09	0.00186	-0.35	-0.28	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
HNSC	trans	rs17507216	0.718	rs7161977	ENSG00000235370.6	DNM1P51	-6.21	1.15e-09	0.00187	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82646782	chr15:84398316~84411701:-
HNSC	trans	rs9329221	0.682	rs6982308	ENSG00000173295.6	FAM86B3P	-6.21	1.15e-09	0.00188	-0.31	-0.28	Neuroticism;	chr8:10336262	chr8:8228595~8244865:+
HNSC	trans	rs7617480	0.648	rs9864243	ENSG00000197582.5	GPX1P1	6.21	1.16e-09	0.00188	0.42	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chrX:13378735~13379340:-
HNSC	trans	rs7873102	0.967	rs1105774	ENSG00000229007.1	EXOSC3P1	6.21	1.16e-09	0.00188	0.34	0.28	Brain structure;	chr9:37979381	chr21:32496812~32497311:+
HNSC	trans	rs2899832	0.568	rs8014594	ENSG00000229083.1	PSMA6P2	6.21	1.16e-09	0.00189	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296623	chrX:12825840~12826833:+
HNSC	trans	rs2899832	0.568	rs7158019	ENSG00000229083.1	PSMA6P2	6.21	1.16e-09	0.00189	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35305912	chrX:12825840~12826833:+
HNSC	trans	rs10037055	0.853	rs10036193	ENSG00000228305.2	AC016734.2	-6.21	1.16e-09	0.00189	-0.34	-0.28	Migraine without aura;	chr5:177141519	chr2:63622178~63622831:-
HNSC	trans	rs10037055	0.853	rs9885210	ENSG00000228305.2	AC016734.2	-6.21	1.16e-09	0.00189	-0.34	-0.28	Migraine without aura;	chr5:177142187	chr2:63622178~63622831:-
HNSC	trans	rs8067354	0.574	rs1292043	ENSG00000187870.7	RNFT1P3	6.21	1.17e-09	0.00189	0.39	0.28	Hemoglobin concentration;	chr17:59856808	chr17:20743333~20754501:-
HNSC	trans	rs7121616	0.563	rs1461494	ENSG00000256356.1	HSPA8P5	6.21	1.17e-09	0.0019	0.33	0.28	Breast cancer;	chr11:123055777	chr12:4097451~4099519:+
HNSC	trans	rs67340775	0.541	rs200964	ENSG00000204709.4	LINC01556	6.21	1.17e-09	0.0019	0.43	0.28	Lung cancer in ever smokers;	chr6:27899165	chr6:28943877~28944537:+
HNSC	trans	rs941207	0.542	rs6581102	ENSG00000257210.1	NACAP3	-6.21	1.17e-09	0.0019	-0.34	-0.28	Platelet count;	chr12:56790632	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs6581103	ENSG00000257210.1	NACAP3	-6.21	1.17e-09	0.0019	-0.34	-0.28	Platelet count;	chr12:56790641	chr12:93124063~93124543:-
HNSC	trans	rs722599	0.748	rs17093914	ENSG00000181227.3	RP4-682C21.2	-6.21	1.18e-09	0.00192	-0.29	-0.28	IgG glycosylation;	chr14:74896938	chr1:75743423~75744776:-
HNSC	trans	rs7824557	0.564	rs34389419	ENSG00000254340.1	RP11-10A14.3	-6.21	1.18e-09	0.00192	-0.33	-0.28	Retinal vascular caliber;	chr8:11371810	chr8:9141424~9145435:+
HNSC	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-6.21	1.18e-09	0.00192	-0.34	-0.28	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
HNSC	trans	rs7412746	0.611	rs2228099	ENSG00000180764.13	PIPSL	-6.21	1.19e-09	0.00193	-0.33	-0.28	Melanoma;	chr1:150836413	chr10:93958191~93961540:-
HNSC	trans	rs7824557	0.527	rs2736305	ENSG00000254340.1	RP11-10A14.3	-6.21	1.19e-09	0.00193	-0.33	-0.28	Retinal vascular caliber;	chr8:11380264	chr8:9141424~9145435:+
HNSC	trans	rs2899832	0.568	rs8017330	ENSG00000229083.1	PSMA6P2	6.21	1.19e-09	0.00194	0.47	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35263163	chrX:12825840~12826833:+
HNSC	trans	rs4713118	0.869	rs9468214	ENSG00000204709.4	LINC01556	6.21	1.2e-09	0.00195	0.36	0.28	Parkinson's disease;	chr6:27745520	chr6:28943877~28944537:+
HNSC	trans	rs853679	0.769	rs7752608	ENSG00000253570.1	RNF5P1	6.21	1.2e-09	0.00195	0.57	0.28	Depression;	chr6:28333418	chr8:38600661~38601200:-
HNSC	trans	rs941207	0.507	rs2958124	ENSG00000257210.1	NACAP3	-6.2	1.21e-09	0.00196	-0.31	-0.28	Platelet count;	chr12:56633837	chr12:93124063~93124543:-
HNSC	trans	rs9467711	0.606	rs9379875	ENSG00000253570.1	RNF5P1	6.2	1.21e-09	0.00197	0.59	0.28	Autism spectrum disorder or schizophrenia;	chr6:26444504	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.538	rs35942482	ENSG00000253570.1	RNF5P1	6.2	1.21e-09	0.00197	0.59	0.28	Autism spectrum disorder or schizophrenia;	chr6:26444710	chr8:38600661~38601200:-
HNSC	trans	rs1707322	0.638	rs1416706	ENSG00000255397.1	AC022182.2	6.2	1.22e-09	0.00197	0.37	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr8:60937705~60939871:-
HNSC	trans	rs17507216	0.591	rs7163848	ENSG00000235370.6	DNM1P51	-6.2	1.22e-09	0.00198	-0.42	-0.28	Excessive daytime sleepiness;	chr15:82729563	chr15:84398316~84411701:-
HNSC	trans	rs11992162	0.967	rs11250185	ENSG00000173295.6	FAM86B3P	6.2	1.22e-09	0.00198	0.31	0.28	Monocyte count;	chr8:11975614	chr8:8228595~8244865:+
HNSC	trans	rs11992162	1	rs12334769	ENSG00000173295.6	FAM86B3P	6.2	1.22e-09	0.00198	0.31	0.28	Monocyte count;	chr8:11975652	chr8:8228595~8244865:+
HNSC	trans	rs8177876	0.822	rs4306521	ENSG00000224837.1	GCSHP5	6.2	1.22e-09	0.00199	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.822	rs4324142	ENSG00000224837.1	GCSHP5	6.2	1.22e-09	0.00199	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr1:168055901~168056422:-
HNSC	trans	rs8177876	0.642	rs4324143	ENSG00000224837.1	GCSHP5	6.2	1.22e-09	0.00199	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr1:168055901~168056422:-
HNSC	trans	rs7824557	0.724	rs2572398	ENSG00000254340.1	RP11-10A14.3	6.2	1.22e-09	0.00199	0.33	0.28	Retinal vascular caliber;	chr8:11320584	chr8:9141424~9145435:+
HNSC	trans	rs673253	0.71	rs56175694	ENSG00000231007.5	CDC20P1	6.2	1.22e-09	0.00199	0.39	0.28	Intelligence (multi-trait analysis);	chr1:43599477	chr9:87011652~87013151:+
HNSC	trans	rs4948102	0.731	rs7800001	ENSG00000215006.4	CHCHD2P2	-6.2	1.23e-09	0.00199	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56004317	chr5:69333929~69334249:+
HNSC	trans	rs71537559	1	rs71537559	ENSG00000253570.1	RNF5P1	6.2	1.23e-09	0.00199	0.63	0.28	Squamous cell lung carcinoma;	chr6:27342000	chr8:38600661~38601200:-
HNSC	trans	rs6831352	0.734	rs2602856	ENSG00000233859.2	ADH5P4	-6.2	1.23e-09	0.002	-0.31	-0.28	Alcohol dependence;	chr4:99107994	chr6:65836930~65838039:-
HNSC	trans	rs13177918	0.559	rs10447224	ENSG00000226396.1	RP5-1056L3.3	6.2	1.24e-09	0.00201	0.21	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:19608114~19608568:+
HNSC	trans	rs13177918	0.559	rs10447225	ENSG00000226396.1	RP5-1056L3.3	6.2	1.24e-09	0.00201	0.21	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:19608114~19608568:+
HNSC	trans	rs7412746	0.503	rs72704639	ENSG00000180764.13	PIPSL	-6.2	1.24e-09	0.00201	-0.34	-0.28	Melanoma;	chr1:150825859	chr10:93958191~93961540:-
HNSC	trans	rs6831352	1	rs6822348	ENSG00000233859.2	ADH5P4	-6.2	1.24e-09	0.00202	-0.31	-0.28	Alcohol dependence;	chr4:99132743	chr6:65836930~65838039:-
HNSC	trans	rs7930295	1	rs10893380	ENSG00000236257.1	EI24P2	-6.2	1.24e-09	0.00202	-0.39	-0.28	Schizophrenia;	chr11:125441778	chr1:158454198~158455273:+
HNSC	trans	rs9467711	0.659	rs72844462	ENSG00000253570.1	RNF5P1	6.2	1.25e-09	0.00202	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr8:38600661~38601200:-
HNSC	trans	rs673253	0.686	rs17371903	ENSG00000231007.5	CDC20P1	6.2	1.25e-09	0.00202	0.4	0.28	Intelligence (multi-trait analysis);	chr1:43605020	chr9:87011652~87013151:+
HNSC	trans	rs7412746	0.563	rs3768013	ENSG00000180764.13	PIPSL	-6.2	1.25e-09	0.00202	-0.34	-0.28	Melanoma;	chr1:150842935	chr10:93958191~93961540:-
HNSC	trans	rs10435719	0.647	rs10092605	ENSG00000173295.6	FAM86B3P	6.2	1.25e-09	0.00203	0.3	0.28	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	6.2	1.25e-09	0.00203	0.35	0.28	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
HNSC	trans	rs1355223	0.506	rs1509660	ENSG00000225531.1	RP11-196I18.3	6.2	1.26e-09	0.00204	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843470	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.506	rs1509659	ENSG00000225531.1	RP11-196I18.3	6.2	1.26e-09	0.00204	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843586	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.506	rs11032894	ENSG00000225531.1	RP11-196I18.3	6.2	1.26e-09	0.00204	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843997	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.506	rs7947848	ENSG00000225531.1	RP11-196I18.3	6.2	1.26e-09	0.00204	0.35	0.28	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34844673	chr9:107116829~107117557:+
HNSC	trans	rs7824557	0.527	rs4634600	ENSG00000254340.1	RP11-10A14.3	-6.2	1.26e-09	0.00204	-0.33	-0.28	Retinal vascular caliber;	chr8:11381508	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.527	rs4631425	ENSG00000254340.1	RP11-10A14.3	-6.2	1.26e-09	0.00204	-0.33	-0.28	Retinal vascular caliber;	chr8:11381545	chr8:9141424~9145435:+
HNSC	trans	rs3808502	0.585	rs4549730	ENSG00000254340.1	RP11-10A14.3	-6.2	1.26e-09	0.00204	-0.33	-0.28	Neuroticism;	chr8:11381569	chr8:9141424~9145435:+
HNSC	trans	rs2950393	0.804	rs2958132	ENSG00000257210.1	NACAP3	6.2	1.27e-09	0.00205	0.31	0.28	Platelet distribution width;	chr12:56750749	chr12:93124063~93124543:-
HNSC	trans	rs7929679	0.551	rs11032840	ENSG00000225531.1	RP11-196I18.3	6.2	1.27e-09	0.00205	0.33	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34757917	chr9:107116829~107117557:+
HNSC	trans	rs6756513	0.5	rs72839869	ENSG00000232654.1	FAM136BP	6.2	1.27e-09	0.00206	0.37	0.28	Breast cancer;Platelet count;	chr2:69814049	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs60168146	ENSG00000232654.1	FAM136BP	6.2	1.27e-09	0.00206	0.37	0.28	Breast cancer;Platelet count;	chr2:69815200	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs72839870	ENSG00000232654.1	FAM136BP	6.2	1.27e-09	0.00206	0.37	0.28	Breast cancer;Platelet count;	chr2:69815783	chr6:3045384~3045800:+
HNSC	trans	rs6756513	0.5	rs17037194	ENSG00000232654.1	FAM136BP	-6.2	1.27e-09	0.00206	-0.37	-0.28	Breast cancer;Platelet count;	chr2:69876670	chr6:3045384~3045800:+
HNSC	trans	rs1816752	1	rs1816752	ENSG00000224976.2	PARP4P2	-6.2	1.27e-09	0.00206	-0.33	-0.28	Obesity-related traits;	chr13:24406811	chr13:19349137~19407962:+
HNSC	trans	rs7647973	0.769	rs11130181	ENSG00000197582.5	GPX1P1	6.2	1.27e-09	0.00206	0.41	0.28	Menarche (age at onset);	chr3:49072486	chrX:13378735~13379340:-
HNSC	trans	rs7520050	0.778	rs12404197	ENSG00000255397.1	AC022182.2	6.2	1.28e-09	0.00207	0.33	0.28	Reticulocyte count;Red blood cell count;	chr1:45766748	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.801	rs6703960	ENSG00000255397.1	AC022182.2	6.2	1.28e-09	0.00207	0.33	0.28	Reticulocyte count;Red blood cell count;	chr1:45767051	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs12025621	ENSG00000255397.1	AC022182.2	6.19	1.28e-09	0.00207	0.33	0.28	Reticulocyte count;Red blood cell count;	chr1:45762719	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.724	rs2251473	ENSG00000254340.1	RP11-10A14.3	6.19	1.28e-09	0.00208	0.33	0.28	Retinal vascular caliber;	chr8:11319617	chr8:9141424~9145435:+
HNSC	trans	rs1292059	1	rs1292059	ENSG00000187870.7	RNFT1P3	6.19	1.28e-09	0.00208	0.37	0.28	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:20743333~20754501:-
HNSC	trans	rs4948102	0.551	rs4275190	ENSG00000215006.4	CHCHD2P2	-6.19	1.28e-09	0.00208	-0.37	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr5:69333929~69334249:+
HNSC	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-6.19	1.29e-09	0.00208	-0.34	-0.28	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
HNSC	trans	rs1816752	0.905	rs7571	ENSG00000224976.2	PARP4P2	-6.19	1.29e-09	0.00209	-0.32	-0.28	Obesity-related traits;	chr13:24426479	chr13:19349137~19407962:+
HNSC	trans	rs853679	0.546	rs13213152	ENSG00000243753.4	HLA-L	-6.19	1.29e-09	0.00209	-0.61	-0.28	Depression;	chr6:28381921	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs13213986	ENSG00000243753.4	HLA-L	-6.19	1.29e-09	0.00209	-0.61	-0.28	Depression;	chr6:28390232	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs34546986	ENSG00000243753.4	HLA-L	-6.19	1.29e-09	0.00209	-0.61	-0.28	Depression;	chr6:28394532	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs34871267	ENSG00000243753.4	HLA-L	-6.19	1.29e-09	0.00209	-0.61	-0.28	Depression;	chr6:28396455	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs35883476	ENSG00000243753.4	HLA-L	-6.19	1.29e-09	0.00209	-0.61	-0.28	Depression;	chr6:28400731	chr6:30259584~30293014:+
HNSC	trans	rs4713118	0.869	rs9283883	ENSG00000204709.4	LINC01556	6.19	1.29e-09	0.00209	0.36	0.28	Parkinson's disease;	chr6:27747691	chr6:28943877~28944537:+
HNSC	trans	rs2950393	0.929	rs7980835	ENSG00000257210.1	NACAP3	6.19	1.3e-09	0.0021	0.31	0.28	Platelet distribution width;	chr12:56676847	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.929	rs10747769	ENSG00000257210.1	NACAP3	6.19	1.3e-09	0.0021	0.31	0.28	Platelet distribution width;	chr12:56677056	chr12:93124063~93124543:-
HNSC	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	6.19	1.3e-09	0.0021	0.34	0.28	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
HNSC	trans	rs3806843	0.766	rs6848	ENSG00000231043.3	AC007238.1	6.19	1.31e-09	0.00212	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr2:58460292~58462032:-
HNSC	trans	rs7824557	0.591	rs2736283	ENSG00000173295.6	FAM86B3P	-6.19	1.31e-09	0.00212	-0.3	-0.28	Retinal vascular caliber;	chr8:11368401	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.771	rs4660882	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00212	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45650620	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs4660312	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00212	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45644900	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs4468203	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00212	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45647600	chr8:60937705~60939871:-
HNSC	trans	rs11220237	1	rs3824921	ENSG00000236257.1	EI24P2	6.19	1.32e-09	0.00213	0.42	0.28	Itch intensity from mosquito bite adjusted by bite size;	chr11:125891563	chr1:158454198~158455273:+
HNSC	trans	rs7520050	0.778	rs3013597	ENSG00000255397.1	AC022182.2	-6.19	1.32e-09	0.00213	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45662684	chr8:60937705~60939871:-
HNSC	trans	rs7819412	0.502	rs4840548	ENSG00000173295.6	FAM86B3P	-6.19	1.32e-09	0.00213	-0.33	-0.28	Triglycerides;	chr8:11135373	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.807	rs6656279	ENSG00000255397.1	AC022182.2	-6.19	1.32e-09	0.00213	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45658416	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs6671802	ENSG00000255397.1	AC022182.2	-6.19	1.32e-09	0.00213	-0.33	-0.28	Reticulocyte count;Red blood cell count;	chr1:45658991	chr8:60937705~60939871:-
HNSC	trans	rs864643	0.524	rs9822783	ENSG00000183298.5	RP11-556K13.1	6.19	1.32e-09	0.00214	0.5	0.28	Attention deficit hyperactivity disorder;	chr3:39463311	chr1:101786340~101787219:-
HNSC	trans	rs9467773	0.595	rs6907924	ENSG00000242375.1	RP11-498P14.3	-6.19	1.33e-09	0.00215	-0.35	-0.28	Intelligence (multi-trait analysis);	chr6:26438589	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.55	rs9379874	ENSG00000242375.1	RP11-498P14.3	-6.19	1.33e-09	0.00215	-0.35	-0.28	Intelligence (multi-trait analysis);	chr6:26440201	chr9:97195351~97197687:-
HNSC	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	6.19	1.33e-09	0.00215	0.32	0.28	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
HNSC	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	6.19	1.33e-09	0.00215	0.32	0.28	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
HNSC	trans	rs8177876	0.822	rs8043855	ENSG00000224837.1	GCSHP5	6.19	1.33e-09	0.00215	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089256	chr1:168055901~168056422:-
HNSC	trans	rs7819412	0.522	rs3021495	ENSG00000173295.6	FAM86B3P	-6.19	1.34e-09	0.00216	-0.33	-0.28	Triglycerides;	chr8:11137233	chr8:8228595~8244865:+
HNSC	trans	rs6831352	0.959	rs6848050	ENSG00000233859.2	ADH5P4	-6.19	1.34e-09	0.00216	-0.31	-0.28	Alcohol dependence;	chr4:99132582	chr6:65836930~65838039:-
HNSC	trans	rs6831352	1	rs6532798	ENSG00000233859.2	ADH5P4	-6.19	1.34e-09	0.00216	-0.31	-0.28	Alcohol dependence;	chr4:99133676	chr6:65836930~65838039:-
HNSC	trans	rs7617480	0.648	rs7653408	ENSG00000197582.5	GPX1P1	6.19	1.34e-09	0.00216	0.41	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chrX:13378735~13379340:-
HNSC	trans	rs9467711	0.72	rs75782365	ENSG00000253570.1	RNF5P1	6.19	1.34e-09	0.00217	0.67	0.28	Autism spectrum disorder or schizophrenia;	chr6:26408323	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.79	rs41266839	ENSG00000253570.1	RNF5P1	6.19	1.34e-09	0.00217	0.67	0.28	Autism spectrum disorder or schizophrenia;	chr6:26409662	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs36162392	ENSG00000253570.1	RNF5P1	6.19	1.35e-09	0.00217	0.64	0.28	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr8:38600661~38601200:-
HNSC	trans	rs17507216	0.718	rs72753931	ENSG00000235370.6	DNM1P51	-6.19	1.35e-09	0.00218	-0.44	-0.28	Excessive daytime sleepiness;	chr15:82721485	chr15:84398316~84411701:-
HNSC	trans	rs2950393	0.804	rs2290894	ENSG00000257210.1	NACAP3	6.19	1.36e-09	0.00219	0.31	0.28	Platelet distribution width;	chr12:56714911	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.777	rs2926747	ENSG00000257210.1	NACAP3	6.19	1.36e-09	0.00219	0.31	0.28	Platelet distribution width;	chr12:56716147	chr12:93124063~93124543:-
HNSC	trans	rs6756513	0.5	rs4420721	ENSG00000232654.1	FAM136BP	-6.19	1.36e-09	0.00219	-0.37	-0.28	Breast cancer;Platelet count;	chr2:69836395	chr6:3045384~3045800:+
HNSC	trans	rs7829975	0.54	rs2976909	ENSG00000269918.1	AF131215.9	-6.18	1.37e-09	0.0022	-0.28	-0.28	Mood instability;	chr8:8489180	chr8:11104691~11106704:-
HNSC	trans	rs17507216	0.681	rs28877110	ENSG00000235370.6	DNM1P51	-6.18	1.37e-09	0.00221	-0.43	-0.28	Excessive daytime sleepiness;	chr15:82672111	chr15:84398316~84411701:-
HNSC	trans	rs17507216	0.718	rs28587782	ENSG00000235370.6	DNM1P51	-6.18	1.38e-09	0.00223	-0.42	-0.28	Excessive daytime sleepiness;	chr15:82576881	chr15:84398316~84411701:-
HNSC	trans	rs9733	0.519	rs72704603	ENSG00000180764.13	PIPSL	-6.18	1.39e-09	0.00224	-0.33	-0.28	Tonsillectomy;	chr1:150735516	chr10:93958191~93961540:-
HNSC	trans	rs864643	0.947	rs704962	ENSG00000183298.5	RP11-556K13.1	-6.18	1.39e-09	0.00224	-0.44	-0.27	Attention deficit hyperactivity disorder;	chr3:39515629	chr1:101786340~101787219:-
HNSC	trans	rs6424115	0.867	rs11588187	ENSG00000228217.1	AL390877.1	-6.18	1.39e-09	0.00224	-0.34	-0.27	Immature fraction of reticulocytes;	chr1:23818557	chr1:117778087~117778506:-
HNSC	trans	rs9733	0.544	rs2867302	ENSG00000180764.13	PIPSL	-6.18	1.39e-09	0.00224	-0.33	-0.27	Tonsillectomy;	chr1:150681174	chr10:93958191~93961540:-
HNSC	trans	rs1707322	0.613	rs1473840	ENSG00000255397.1	AC022182.2	6.18	1.39e-09	0.00224	0.37	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr8:60937705~60939871:-
HNSC	trans	rs7929679	0.551	rs11032849	ENSG00000225531.1	RP11-196I18.3	6.18	1.39e-09	0.00225	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34764193	chr9:107116829~107117557:+
HNSC	trans	rs7121616	0.576	rs4936767	ENSG00000256356.1	HSPA8P5	6.18	1.4e-09	0.00225	0.33	0.27	Breast cancer;	chr11:123047451	chr12:4097451~4099519:+
HNSC	trans	rs9397240	0.545	rs9384296	ENSG00000221990.4	EXOC3-AS1	6.18	1.4e-09	0.00225	0.37	0.27	Life satisfaction;	chr6:155209710	chr5:441498~443160:-
HNSC	trans	rs1933488	1	rs4083914	ENSG00000278974.1	RP11-756P10.6	6.18	1.4e-09	0.00225	0.36	0.27	Prostate cancer;	chr6:153106571	chr4:188740507~188741281:-
HNSC	trans	rs3806843	0.766	rs2251860	ENSG00000231043.3	AC007238.1	6.18	1.4e-09	0.00225	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.766	rs702397	ENSG00000231043.3	AC007238.1	6.18	1.4e-09	0.00225	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr2:58460292~58462032:-
HNSC	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	6.18	1.4e-09	0.00226	0.31	0.27	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
HNSC	trans	rs1023500	1	rs1023500	ENSG00000268568.1	AC007228.9	6.18	1.4e-09	0.00226	0.37	0.27	Schizophrenia;	chr22:41944840	chr19:56672574~56673901:-
HNSC	trans	rs9650657	0.585	rs4841401	ENSG00000173295.6	FAM86B3P	-6.18	1.41e-09	0.00227	-0.31	-0.27	Neuroticism;	chr8:10632082	chr8:8228595~8244865:+
HNSC	trans	rs6831352	0.918	rs13110764	ENSG00000233859.2	ADH5P4	6.18	1.41e-09	0.00228	0.33	0.27	Alcohol dependence;	chr4:99141315	chr6:65836930~65838039:-
HNSC	trans	rs673253	0.686	rs72673082	ENSG00000231007.5	CDC20P1	6.18	1.42e-09	0.00228	0.39	0.27	Intelligence (multi-trait analysis);	chr1:43593571	chr9:87011652~87013151:+
HNSC	trans	rs9630182	0.619	rs12282416	ENSG00000257675.1	RP11-641A6.9	-6.18	1.42e-09	0.00229	-0.32	-0.27	Bone mineral density;	chr11:13420370	chr12:52748776~52750127:+
HNSC	trans	rs11220237	1	rs12273204	ENSG00000236257.1	EI24P2	6.17	1.44e-09	0.00232	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125784704	chr1:158454198~158455273:+
HNSC	trans	rs1816752	0.837	rs9318530	ENSG00000224976.2	PARP4P2	6.17	1.45e-09	0.00232	0.32	0.27	Obesity-related traits;	chr13:24424419	chr13:19349137~19407962:+
HNSC	trans	rs7121616	0.595	rs7949414	ENSG00000256356.1	HSPA8P5	6.17	1.45e-09	0.00234	0.33	0.27	Breast cancer;	chr11:123072787	chr12:4097451~4099519:+
HNSC	trans	rs853679	0.607	rs34166054	ENSG00000243753.4	HLA-L	-6.17	1.46e-09	0.00234	-0.62	-0.27	Depression;	chr6:28098023	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13203816	ENSG00000243753.4	HLA-L	-6.17	1.46e-09	0.00234	-0.62	-0.27	Depression;	chr6:28111820	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.556	rs34588114	ENSG00000243753.4	HLA-L	-6.17	1.46e-09	0.00234	-0.62	-0.27	Depression;	chr6:28112850	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs34371502	ENSG00000243753.4	HLA-L	-6.17	1.46e-09	0.00234	-0.62	-0.27	Depression;	chr6:28113980	chr6:30259584~30293014:+
HNSC	trans	rs9467711	0.659	rs13220261	ENSG00000253570.1	RNF5P1	6.17	1.46e-09	0.00234	0.63	0.27	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs35555795	ENSG00000253570.1	RNF5P1	6.17	1.46e-09	0.00234	0.63	0.27	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr8:38600661~38601200:-
HNSC	trans	rs7819412	0.595	rs2409712	ENSG00000173295.6	FAM86B3P	-6.17	1.46e-09	0.00235	-0.31	-0.27	Triglycerides;	chr8:11129327	chr8:8228595~8244865:+
HNSC	trans	rs7930295	1	rs34504992	ENSG00000236257.1	EI24P2	6.17	1.46e-09	0.00235	0.42	0.27	Schizophrenia;	chr11:125446177	chr1:158454198~158455273:+
HNSC	trans	rs7930295	1	rs28593289	ENSG00000236257.1	EI24P2	6.17	1.46e-09	0.00235	0.42	0.27	Schizophrenia;	chr11:125446628	chr1:158454198~158455273:+
HNSC	trans	rs7930295	1	rs6590145	ENSG00000236257.1	EI24P2	6.17	1.46e-09	0.00235	0.42	0.27	Schizophrenia;	chr11:125448020	chr1:158454198~158455273:+
HNSC	trans	rs804280	0.509	rs9886639	ENSG00000173295.6	FAM86B3P	6.17	1.47e-09	0.00235	0.3	0.27	Myopia (pathological);	chr8:11927020	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.526	rs12229457	ENSG00000257210.1	NACAP3	-6.17	1.47e-09	0.00236	-0.33	-0.27	Platelet count;	chr12:56639896	chr12:93124063~93124543:-
HNSC	trans	rs2898290	0.5	rs11998678	ENSG00000253893.2	FAM85B	6.17	1.47e-09	0.00236	0.32	0.27	Systolic blood pressure;	chr8:11972641	chr8:8167819~8226614:-
HNSC	trans	rs10435719	0.867	rs6999030	ENSG00000173295.6	FAM86B3P	6.17	1.48e-09	0.00237	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.834	rs6985792	ENSG00000173295.6	FAM86B3P	6.17	1.48e-09	0.00237	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:8228595~8244865:+
HNSC	trans	rs804280	0.509	rs10109241	ENSG00000173295.6	FAM86B3P	6.17	1.48e-09	0.00238	0.3	0.27	Myopia (pathological);	chr8:11927476	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.611	rs1889740	ENSG00000180764.13	PIPSL	-6.17	1.48e-09	0.00238	-0.34	-0.27	Melanoma;	chr1:150827279	chr10:93958191~93961540:-
HNSC	trans	rs3779195	1	rs3779195	ENSG00000230273.1	AC087163.3	-6.17	1.49e-09	0.00239	-0.38	-0.27	Sex hormone-binding globulin levels;	chr7:98364050	chr17:17981192~17981572:-
HNSC	trans	rs1355223	0.506	rs7131229	ENSG00000225531.1	RP11-196I18.3	-6.17	1.49e-09	0.0024	-0.34	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847781	chr9:107116829~107117557:+
HNSC	trans	rs853679	0.607	rs13205211	ENSG00000253570.1	RNF5P1	6.17	1.49e-09	0.0024	0.63	0.27	Depression;	chr6:28235278	chr8:38600661~38601200:-
HNSC	trans	rs17507216	0.718	rs17158403	ENSG00000235370.6	DNM1P51	-6.17	1.5e-09	0.0024	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82572478	chr15:84398316~84411701:-
HNSC	trans	rs61041336	1	rs61041336	ENSG00000233719.3	GOT2P3	-6.17	1.5e-09	0.00241	-0.47	-0.27	Neuritic plaque;	chr16:58699258	chr12:9641802~9643007:+
HNSC	trans	rs6498068	0.522	rs10775284	ENSG00000278702.1	Metazoa_SRP	6.17	1.5e-09	0.00241	0.35	0.27	Metabolite levels (MHPG);	chr16:10535402	chr1:35399997~35400319:+
HNSC	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-6.17	1.5e-09	0.00241	-0.34	-0.27	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-6.17	1.5e-09	0.00241	-0.34	-0.27	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-6.17	1.5e-09	0.00241	-0.34	-0.27	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-6.17	1.5e-09	0.00241	-0.34	-0.27	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
HNSC	trans	rs7520050	0.807	rs72688483	ENSG00000255397.1	AC022182.2	-6.17	1.52e-09	0.00244	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45683537	chr8:60937705~60939871:-
HNSC	trans	rs4713118	0.662	rs4713120	ENSG00000204709.4	LINC01556	6.17	1.53e-09	0.00244	0.33	0.27	Parkinson's disease;	chr6:27754056	chr6:28943877~28944537:+
HNSC	trans	rs9329221	0.683	rs658385	ENSG00000173295.6	FAM86B3P	-6.16	1.53e-09	0.00245	-0.3	-0.27	Neuroticism;	chr8:10034667	chr8:8228595~8244865:+
HNSC	trans	rs9630182	0.561	rs10832040	ENSG00000257675.1	RP11-641A6.9	-6.16	1.53e-09	0.00245	-0.32	-0.27	Bone mineral density;	chr11:13451660	chr12:52748776~52750127:+
HNSC	trans	rs13010713	0.84	rs4666716	ENSG00000224040.1	HMGN1P4	-6.16	1.53e-09	0.00246	-0.29	-0.27	Celiac disease;	chr2:181197269	chr1:182942115~182942404:-
HNSC	trans	rs7520050	0.743	rs61789988	ENSG00000255397.1	AC022182.2	6.16	1.54e-09	0.00247	0.33	0.27	Reticulocyte count;Red blood cell count;	chr1:45619570	chr8:60937705~60939871:-
HNSC	trans	rs1568889	0.838	rs7121937	ENSG00000174912.7	METTL15P1	6.16	1.54e-09	0.00247	0.28	0.27	Bipolar disorder;	chr11:28338311	chr3:156713884~156714928:-
HNSC	trans	rs7824557	0.527	rs2409756	ENSG00000254340.1	RP11-10A14.3	-6.16	1.55e-09	0.00248	-0.33	-0.27	Retinal vascular caliber;	chr8:11384516	chr8:9141424~9145435:+
HNSC	trans	rs453301	0.571	rs2929453	ENSG00000253893.2	FAM85B	6.16	1.55e-09	0.00248	0.31	0.27	Joint mobility (Beighton score);	chr8:9226831	chr8:8167819~8226614:-
HNSC	trans	rs4713118	0.869	rs10214440	ENSG00000204709.4	LINC01556	6.16	1.55e-09	0.00248	0.36	0.27	Parkinson's disease;	chr6:27734661	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs6902689	ENSG00000204709.4	LINC01556	6.16	1.55e-09	0.00248	0.36	0.27	Parkinson's disease;	chr6:27741662	chr6:28943877~28944537:+
HNSC	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-6.16	1.55e-09	0.00249	-0.34	-0.27	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
HNSC	trans	rs941207	0.526	rs2255074	ENSG00000257210.1	NACAP3	-6.16	1.55e-09	0.00249	-0.31	-0.27	Platelet count;	chr12:56636242	chr12:93124063~93124543:-
HNSC	trans	rs4713118	0.513	rs200971	ENSG00000204709.4	LINC01556	6.16	1.57e-09	0.00251	0.35	0.27	Parkinson's disease;	chr6:27891126	chr6:28943877~28944537:+
HNSC	trans	rs2243480	0.706	rs6460257	ENSG00000273142.1	RP11-458F8.4	-6.16	1.57e-09	0.00251	-0.33	-0.27	Diabetic kidney disease;	chr7:65731813	chr7:66902857~66906297:+
HNSC	trans	rs1568889	0.838	rs7943538	ENSG00000174912.7	METTL15P1	6.16	1.57e-09	0.00252	0.29	0.27	Bipolar disorder;	chr11:28267408	chr3:156713884~156714928:-
HNSC	trans	rs7819412	0.691	rs73198970	ENSG00000173295.6	FAM86B3P	-6.16	1.57e-09	0.00252	-0.31	-0.27	Triglycerides;	chr8:11182707	chr8:8228595~8244865:+
HNSC	trans	rs6424115	1	rs12031592	ENSG00000228217.1	AL390877.1	-6.16	1.57e-09	0.00252	-0.34	-0.27	Immature fraction of reticulocytes;	chr1:23801374	chr1:117778087~117778506:-
HNSC	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-6.16	1.58e-09	0.00252	-0.35	-0.27	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
HNSC	trans	rs2950393	0.895	rs2958123	ENSG00000228224.3	NACAP1	6.16	1.58e-09	0.00253	0.3	0.27	Platelet distribution width;	chr12:56668441	chr8:101361794~101372707:+
HNSC	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	6.16	1.58e-09	0.00253	0.34	0.27	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
HNSC	trans	rs77686669	1	rs77686669	ENSG00000228546.2	CTA-313A17.3	6.16	1.58e-09	0.00253	0.4	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:102337316~102339115:+
HNSC	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	-6.16	1.59e-09	0.00254	-0.31	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
HNSC	trans	rs13014235	0.579	rs6745435	ENSG00000235105.1	RP11-329A14.1	6.16	1.59e-09	0.00254	0.33	0.27	Basal cell carcinoma;	chr2:201337840	chr1:48435967~48437223:+
HNSC	trans	rs13014235	0.644	rs10201587	ENSG00000235105.1	RP11-329A14.1	6.16	1.59e-09	0.00254	0.33	0.27	Basal cell carcinoma;	chr2:201338068	chr1:48435967~48437223:+
HNSC	trans	rs7647973	0.577	rs6446247	ENSG00000197582.5	GPX1P1	6.16	1.59e-09	0.00255	0.42	0.27	Menarche (age at onset);	chr3:49064568	chrX:13378735~13379340:-
HNSC	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	6.16	1.6e-09	0.00256	0.34	0.27	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
HNSC	trans	rs853679	0.607	rs68188794	ENSG00000243753.4	HLA-L	-6.16	1.61e-09	0.00257	-0.62	-0.27	Depression;	chr6:28112999	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.778	rs3808502	ENSG00000254340.1	RP11-10A14.3	6.16	1.62e-09	0.00258	0.33	0.27	Retinal vascular caliber;	chr8:11321949	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.807	rs3013595	ENSG00000255397.1	AC022182.2	-6.15	1.62e-09	0.00259	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45687531	chr8:60937705~60939871:-
HNSC	trans	rs546131	0.963	rs539044	ENSG00000225531.1	RP11-196I18.3	6.15	1.62e-09	0.00259	0.34	0.27	Lung disease severity in cystic fibrosis;	chr11:34819995	chr9:107116829~107117557:+
HNSC	trans	rs7520050	0.807	rs28844317	ENSG00000255397.1	AC022182.2	-6.15	1.63e-09	0.0026	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45743535	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs6429576	ENSG00000255397.1	AC022182.2	-6.15	1.63e-09	0.0026	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45750903	chr8:60937705~60939871:-
HNSC	trans	rs941207	0.526	rs2255074	ENSG00000228224.3	NACAP1	-6.15	1.63e-09	0.0026	-0.3	-0.27	Platelet count;	chr12:56636242	chr8:101361794~101372707:+
HNSC	trans	rs9393777	0.92	rs13207689	ENSG00000253570.1	RNF5P1	6.15	1.63e-09	0.00261	0.65	0.27	Intelligence (multi-trait analysis);	chr6:27401925	chr8:38600661~38601200:-
HNSC	trans	rs9733	0.519	rs11807450	ENSG00000180764.13	PIPSL	-6.15	1.63e-09	0.00261	-0.33	-0.27	Tonsillectomy;	chr1:150705243	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.519	rs3768005	ENSG00000180764.13	PIPSL	-6.15	1.63e-09	0.00261	-0.33	-0.27	Tonsillectomy;	chr1:150708512	chr10:93958191~93961540:-
HNSC	trans	rs11172055	0.967	rs10876953	ENSG00000121089.4	NACA3P	6.15	1.63e-09	0.00261	0.32	0.27	Migraine;	chr12:56916418	chr4:164943290~164943937:+
HNSC	trans	rs7824557	0.527	rs2572447	ENSG00000254340.1	RP11-10A14.3	-6.15	1.65e-09	0.00264	-0.33	-0.27	Retinal vascular caliber;	chr8:11382001	chr8:9141424~9145435:+
HNSC	trans	rs9393777	0.777	rs56114371	ENSG00000253570.1	RNF5P1	6.15	1.65e-09	0.00264	0.64	0.27	Intelligence (multi-trait analysis);	chr6:27307055	chr8:38600661~38601200:-
HNSC	trans	rs6743068	0.541	rs13014235	ENSG00000235105.1	RP11-329A14.1	6.15	1.66e-09	0.00265	0.34	0.27	Lymphocyte percentage of white cells;	chr2:201350769	chr1:48435967~48437223:+
HNSC	trans	rs2950393	0.777	rs7966391	ENSG00000257210.1	NACAP3	6.15	1.66e-09	0.00265	0.31	0.27	Platelet distribution width;	chr12:56745272	chr12:93124063~93124543:-
HNSC	trans	rs7520050	0.807	rs28647556	ENSG00000255397.1	AC022182.2	-6.15	1.66e-09	0.00265	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45740727	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.807	rs4274104	ENSG00000255397.1	AC022182.2	-6.15	1.66e-09	0.00265	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45752269	chr8:60937705~60939871:-
HNSC	trans	rs7929679	0.602	rs11032870	ENSG00000225531.1	RP11-196I18.3	6.15	1.66e-09	0.00266	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34783977	chr9:107116829~107117557:+
HNSC	trans	rs1816752	0.905	rs1348110	ENSG00000224976.2	PARP4P2	-6.15	1.68e-09	0.00267	-0.32	-0.27	Obesity-related traits;	chr13:24406537	chr13:19349137~19407962:+
HNSC	trans	rs6424115	1	rs974698	ENSG00000228217.1	AL390877.1	-6.15	1.68e-09	0.00268	-0.34	-0.27	Immature fraction of reticulocytes;	chr1:23806295	chr1:117778087~117778506:-
HNSC	trans	rs740363	0.561	rs7097645	ENSG00000211820.1	TRAV41	-6.15	1.68e-09	0.00268	-0.23	-0.27	Heart failure;	chr10:116800966	chr14:22320188~22320691:+
HNSC	trans	rs7520050	0.807	rs28378621	ENSG00000255397.1	AC022182.2	-6.15	1.68e-09	0.00269	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45723882	chr8:60937705~60939871:-
HNSC	trans	rs10037055	0.853	rs12660023	ENSG00000226986.4	RP11-543B16.2	6.15	1.69e-09	0.00269	0.33	0.27	Migraine without aura;	chr5:177273884	chr1:211207239~211207897:+
HNSC	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-6.15	1.69e-09	0.0027	-0.34	-0.27	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
HNSC	trans	rs1816752	0.935	rs4770676	ENSG00000224976.2	PARP4P2	-6.15	1.7e-09	0.00271	-0.32	-0.27	Obesity-related traits;	chr13:24429745	chr13:19349137~19407962:+
HNSC	trans	rs7824557	0.724	rs2572398	ENSG00000173295.6	FAM86B3P	6.15	1.7e-09	0.00271	0.3	0.27	Retinal vascular caliber;	chr8:11320584	chr8:8228595~8244865:+
HNSC	trans	rs62344088	1	rs10065373	ENSG00000185986.11	SDHAP3	6.15	1.7e-09	0.00271	0.64	0.27	Asthma (childhood onset);	chr5:106704	chr5:1572222~1594620:-
HNSC	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-6.15	1.71e-09	0.00272	-0.3	-0.27	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-6.15	1.71e-09	0.00272	-0.3	-0.27	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
HNSC	trans	rs9467773	0.595	rs3846845	ENSG00000242375.1	RP11-498P14.3	-6.14	1.72e-09	0.00274	-0.35	-0.27	Intelligence (multi-trait analysis);	chr6:26444687	chr9:97195351~97197687:-
HNSC	trans	rs9467773	0.572	rs3846846	ENSG00000242375.1	RP11-498P14.3	-6.14	1.72e-09	0.00274	-0.35	-0.27	Intelligence (multi-trait analysis);	chr6:26444811	chr9:97195351~97197687:-
HNSC	trans	rs941207	0.507	rs2958124	ENSG00000228224.3	NACAP1	-6.14	1.72e-09	0.00274	-0.3	-0.27	Platelet count;	chr12:56633837	chr8:101361794~101372707:+
HNSC	trans	rs9733	0.519	rs11800855	ENSG00000180764.13	PIPSL	-6.14	1.74e-09	0.00276	-0.33	-0.27	Tonsillectomy;	chr1:150828519	chr10:93958191~93961540:-
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	6.14	1.74e-09	0.00277	0.3	0.27	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
HNSC	trans	rs7819412	0.875	rs11250121	ENSG00000173295.6	FAM86B3P	-6.14	1.75e-09	0.00279	-0.31	-0.27	Triglycerides;	chr8:11202802	chr8:8228595~8244865:+
HNSC	trans	rs6087990	0.735	rs6087420	ENSG00000253915.1	MAPRE1P1	6.14	1.75e-09	0.00279	0.32	0.27	Ulcerative colitis;	chr20:32771585	chr8:135625185~135625981:-
HNSC	trans	rs1075232	0.649	rs9635352	ENSG00000270055.1	CTD-3092A11.2	-6.14	1.76e-09	0.0028	-0.42	-0.27	Survival in colorectal cancer (non-distant metastatic);	chr15:31942591	chr15:30487963~30490313:+
HNSC	trans	rs2950393	0.929	rs7973157	ENSG00000228224.3	NACAP1	-6.14	1.76e-09	0.0028	-0.3	-0.27	Platelet distribution width;	chr12:56655409	chr8:101361794~101372707:+
HNSC	trans	rs7824557	0.614	rs2736286	ENSG00000173295.6	FAM86B3P	-6.14	1.76e-09	0.00281	-0.29	-0.27	Retinal vascular caliber;	chr8:11369595	chr8:8228595~8244865:+
HNSC	trans	rs13416322	0.591	rs3748929	ENSG00000214286.2	PDCL3P3	6.14	1.76e-09	0.00281	0.4	0.27	Intelligence (multi-trait analysis);	chr2:100556794	chr3:17877455~17878169:-
HNSC	trans	rs1816752	0.805	rs4769353	ENSG00000224976.2	PARP4P2	-6.14	1.77e-09	0.00281	-0.32	-0.27	Obesity-related traits;	chr13:24426318	chr13:19349137~19407962:+
HNSC	trans	rs9650657	0.655	rs1991651	ENSG00000173295.6	FAM86B3P	6.14	1.77e-09	0.00282	0.31	0.27	Neuroticism;	chr8:10848901	chr8:8228595~8244865:+
HNSC	trans	rs7929679	0.521	rs11032852	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34766761	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.521	rs11499809	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769196	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.521	rs1509667	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769756	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.551	rs10836302	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770350	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.521	rs10768094	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770642	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.551	rs10836303	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771155	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.521	rs10768097	ENSG00000225531.1	RP11-196I18.3	6.14	1.78e-09	0.00283	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771355	chr9:107116829~107117557:+
HNSC	trans	rs9733	0.596	rs6587518	ENSG00000180764.13	PIPSL	-6.14	1.79e-09	0.00285	-0.33	-0.27	Tonsillectomy;	chr1:150689311	chr10:93958191~93961540:-
HNSC	trans	rs1568889	0.838	rs11030220	ENSG00000174912.7	METTL15P1	6.14	1.79e-09	0.00285	0.29	0.27	Bipolar disorder;	chr11:28124222	chr3:156713884~156714928:-
HNSC	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	6.14	1.79e-09	0.00285	0.33	0.27	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
HNSC	trans	rs17507216	0.718	rs72751675	ENSG00000235370.6	DNM1P51	-6.14	1.8e-09	0.00286	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82630452	chr15:84398316~84411701:-
HNSC	trans	rs860295	0.529	rs1475766	ENSG00000241627.3	UBQLN4P1	6.14	1.81e-09	0.00287	0.29	0.27	Body mass index;	chr1:156011698	chr3:148985868~148987668:-
HNSC	trans	rs853679	0.766	rs9368561	ENSG00000253570.1	RNF5P1	6.14	1.81e-09	0.00287	0.54	0.27	Depression;	chr6:28200565	chr8:38600661~38601200:-
HNSC	trans	rs9733	0.596	rs3087960	ENSG00000180764.13	PIPSL	-6.14	1.81e-09	0.00287	-0.32	-0.27	Tonsillectomy;	chr1:150648093	chr10:93958191~93961540:-
HNSC	trans	rs9733	0.596	rs72702536	ENSG00000180764.13	PIPSL	-6.14	1.81e-09	0.00287	-0.33	-0.27	Tonsillectomy;	chr1:150690098	chr10:93958191~93961540:-
HNSC	trans	rs7121616	0.576	rs11218967	ENSG00000241478.1	HSPA8P9	6.14	1.81e-09	0.00288	0.34	0.27	Breast cancer;	chr11:123087551	chr3:137880295~137882237:+
HNSC	trans	rs9733	0.527	rs11204694	ENSG00000180764.13	PIPSL	-6.14	1.82e-09	0.00288	-0.33	-0.27	Tonsillectomy;	chr1:150680915	chr10:93958191~93961540:-
HNSC	trans	rs7824557	0.527	rs2572446	ENSG00000254340.1	RP11-10A14.3	-6.14	1.82e-09	0.00288	-0.33	-0.27	Retinal vascular caliber;	chr8:11382056	chr8:9141424~9145435:+
HNSC	trans	rs7873102	0.967	rs943940	ENSG00000229007.1	EXOSC3P1	6.13	1.82e-09	0.00289	0.34	0.27	Brain structure;	chr9:37986805	chr21:32496812~32497311:+
HNSC	trans	rs6087990	0.735	rs2424907	ENSG00000253915.1	MAPRE1P1	6.13	1.82e-09	0.0029	0.32	0.27	Ulcerative colitis;	chr20:32772013	chr8:135625185~135625981:-
HNSC	trans	rs864643	0.678	rs1768201	ENSG00000183298.5	RP11-556K13.1	6.13	1.82e-09	0.0029	0.44	0.27	Attention deficit hyperactivity disorder;	chr3:39476050	chr1:101786340~101787219:-
HNSC	trans	rs513349	1	rs210145	ENSG00000175730.8	BAK1P1	6.13	1.83e-09	0.0029	0.32	0.27	Platelet count;	chr6:33579663	chr20:32690180~32690815:-
HNSC	trans	rs4879656	0.564	rs20583	ENSG00000215007.3	DNAJA1P3	6.13	1.84e-09	0.00292	0.32	0.27	Menopause (age at onset);	chr9:33026574	chrX:107351650~107352843:-
HNSC	trans	rs8177876	0.749	rs12927828	ENSG00000224837.1	GCSHP5	6.13	1.84e-09	0.00292	0.44	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr1:168055901~168056422:-
HNSC	trans	rs73110464	0.505	rs2638503	ENSG00000254285.3	KRT8P3	-6.13	1.85e-09	0.00293	-0.32	-0.27	Cancer (pleiotropy);	chr12:52913585	chr8:61578220~61579668:+
HNSC	trans	rs10037055	0.853	rs9313749	ENSG00000226986.4	RP11-543B16.2	-6.13	1.85e-09	0.00294	-0.33	-0.27	Migraine without aura;	chr5:177170693	chr1:211207239~211207897:+
HNSC	trans	rs9467773	0.587	rs3208733	ENSG00000242375.1	RP11-498P14.3	-6.13	1.85e-09	0.00294	-0.35	-0.27	Intelligence (multi-trait analysis);	chr6:26414197	chr9:97195351~97197687:-
HNSC	trans	rs7412746	0.611	rs2256355	ENSG00000180764.13	PIPSL	-6.13	1.86e-09	0.00295	-0.33	-0.27	Melanoma;	chr1:150839318	chr10:93958191~93961540:-
HNSC	trans	rs722599	0.748	rs61978932	ENSG00000181227.3	RP4-682C21.2	6.13	1.87e-09	0.00296	0.28	0.27	IgG glycosylation;	chr14:74876251	chr1:75743423~75744776:-
HNSC	trans	rs7617480	0.648	rs9284885	ENSG00000197582.5	GPX1P1	6.13	1.87e-09	0.00297	0.4	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chrX:13378735~13379340:-
HNSC	trans	rs4948102	0.595	rs7793921	ENSG00000215006.4	CHCHD2P2	-6.13	1.89e-09	0.003	-0.35	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr5:69333929~69334249:+
HNSC	trans	rs4948102	0.595	rs10255049	ENSG00000215006.4	CHCHD2P2	-6.13	1.89e-09	0.003	-0.35	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr5:69333929~69334249:+
HNSC	trans	rs941207	0.542	rs10876928	ENSG00000257210.1	NACAP3	-6.13	1.91e-09	0.00302	-0.34	-0.27	Platelet count;	chr12:56813646	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs11171983	ENSG00000257210.1	NACAP3	-6.13	1.91e-09	0.00302	-0.34	-0.27	Platelet count;	chr12:56814461	chr12:93124063~93124543:-
HNSC	trans	rs6087990	0.735	rs4911260	ENSG00000253915.1	MAPRE1P1	6.13	1.91e-09	0.00303	0.32	0.27	Ulcerative colitis;	chr20:32788684	chr8:135625185~135625981:-
HNSC	trans	rs9467711	0.606	rs13190739	ENSG00000253570.1	RNF5P1	6.13	1.91e-09	0.00303	0.63	0.27	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr8:38600661~38601200:-
HNSC	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-6.13	1.92e-09	0.00304	-0.35	-0.27	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
HNSC	trans	rs17301013	0.861	rs1894200	ENSG00000213331.4	RP11-713C19.2	-6.13	1.92e-09	0.00304	-0.33	-0.27	Systemic lupus erythematosus;	chr1:174842039	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.861	rs1793319	ENSG00000213331.4	RP11-713C19.2	6.13	1.92e-09	0.00305	0.33	0.27	Systemic lupus erythematosus;	chr1:174795470	chr4:187970273~187971284:+
HNSC	trans	rs1568889	0.838	rs7131053	ENSG00000174912.7	METTL15P1	6.13	1.92e-09	0.00305	0.28	0.27	Bipolar disorder;	chr11:28121765	chr3:156713884~156714928:-
HNSC	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-6.12	1.93e-09	0.00306	-0.35	-0.27	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
HNSC	trans	rs6831352	1	rs6831352	ENSG00000233859.2	ADH5P4	-6.12	1.94e-09	0.00307	-0.31	-0.27	Alcohol dependence;	chr4:99142374	chr6:65836930~65838039:-
HNSC	trans	rs9733	0.565	rs7524620	ENSG00000180764.13	PIPSL	6.12	1.94e-09	0.00307	0.32	0.27	Tonsillectomy;	chr1:150644223	chr10:93958191~93961540:-
HNSC	trans	rs853679	0.607	rs56189111	ENSG00000253570.1	RNF5P1	6.12	1.94e-09	0.00307	0.63	0.27	Depression;	chr6:28304196	chr8:38600661~38601200:-
HNSC	trans	rs673253	0.608	rs605709	ENSG00000231007.5	CDC20P1	6.12	1.95e-09	0.00309	0.39	0.27	Intelligence (multi-trait analysis);	chr1:43592796	chr9:87011652~87013151:+
HNSC	trans	rs673253	0.71	rs583040	ENSG00000231007.5	CDC20P1	6.12	1.95e-09	0.00309	0.39	0.27	Intelligence (multi-trait analysis);	chr1:43594812	chr9:87011652~87013151:+
HNSC	trans	rs673253	0.71	rs673242	ENSG00000231007.5	CDC20P1	6.12	1.95e-09	0.00309	0.39	0.27	Intelligence (multi-trait analysis);	chr1:43596488	chr9:87011652~87013151:+
HNSC	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-6.12	1.95e-09	0.00309	-0.34	-0.27	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
HNSC	trans	rs1023500	1	rs7293091	ENSG00000268568.1	AC007228.9	-6.12	1.96e-09	0.0031	-0.37	-0.27	Schizophrenia;	chr22:41945304	chr19:56672574~56673901:-
HNSC	trans	rs1075232	0.649	rs56336240	ENSG00000270055.1	CTD-3092A11.2	-6.12	1.96e-09	0.00311	-0.42	-0.27	Survival in colorectal cancer (non-distant metastatic);	chr15:31938056	chr15:30487963~30490313:+
HNSC	trans	rs546131	0.928	rs572690	ENSG00000225531.1	RP11-196I18.3	6.12	1.97e-09	0.00311	0.33	0.27	Lung disease severity in cystic fibrosis;	chr11:34812067	chr9:107116829~107117557:+
HNSC	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-6.12	1.97e-09	0.00312	-0.34	-0.27	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
HNSC	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	6.12	1.98e-09	0.00313	0.34	0.27	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	6.12	1.98e-09	0.00313	0.34	0.27	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-6.12	1.98e-09	0.00314	-0.31	-0.27	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	6.12	1.98e-09	0.00314	0.32	0.27	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
HNSC	trans	rs6756513	0.5	rs2054046	ENSG00000232654.1	FAM136BP	-6.12	1.99e-09	0.00314	-0.37	-0.27	Breast cancer;Platelet count;	chr2:69889942	chr6:3045384~3045800:+
HNSC	trans	rs941207	0.542	rs1870674	ENSG00000257210.1	NACAP3	-6.12	1.99e-09	0.00315	-0.35	-0.27	Platelet count;	chr12:56805721	chr12:93124063~93124543:-
HNSC	trans	rs11220237	1	rs11220218	ENSG00000236257.1	EI24P2	6.12	1.99e-09	0.00315	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125793961	chr1:158454198~158455273:+
HNSC	trans	rs7930295	1	rs34238592	ENSG00000236257.1	EI24P2	6.12	1.99e-09	0.00315	0.42	0.27	Schizophrenia;	chr11:125445059	chr1:158454198~158455273:+
HNSC	trans	rs17507216	0.718	rs72751657	ENSG00000235370.6	DNM1P51	-6.12	1.99e-09	0.00315	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82581259	chr15:84398316~84411701:-
HNSC	trans	rs853679	0.556	rs13200214	ENSG00000243753.4	HLA-L	-6.12	2e-09	0.00316	-0.61	-0.27	Depression;	chr6:28049472	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.688	rs2572397	ENSG00000173295.6	FAM86B3P	6.12	2e-09	0.00316	0.3	0.27	Retinal vascular caliber;	chr8:11318894	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.592	rs920044	ENSG00000254340.1	RP11-10A14.3	6.12	2.01e-09	0.00317	0.31	0.27	Retinal vascular caliber;	chr8:11366804	chr8:9141424~9145435:+
HNSC	trans	rs1933488	0.866	rs63739861	ENSG00000278974.1	RP11-756P10.6	-6.12	2.01e-09	0.00318	-0.36	-0.27	Prostate cancer;	chr6:153109733	chr4:188740507~188741281:-
HNSC	trans	rs10435719	0.867	rs62493601	ENSG00000173295.6	FAM86B3P	6.12	2.01e-09	0.00318	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.753	rs9694940	ENSG00000173295.6	FAM86B3P	6.12	2.01e-09	0.00318	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.78	rs9692662	ENSG00000173295.6	FAM86B3P	6.12	2.01e-09	0.00318	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.899	rs9693925	ENSG00000173295.6	FAM86B3P	6.12	2.01e-09	0.00318	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.607	rs67340775	ENSG00000253570.1	RNF5P1	6.12	2.02e-09	0.00319	0.6	0.27	Depression;	chr6:28336607	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs35656932	ENSG00000253570.1	RNF5P1	6.12	2.02e-09	0.00319	0.65	0.27	Depression;	chr6:28223510	chr8:38600661~38601200:-
HNSC	trans	rs2950393	0.777	rs12828563	ENSG00000228224.3	NACAP1	6.12	2.02e-09	0.0032	0.3	0.27	Platelet distribution width;	chr12:56709378	chr8:101361794~101372707:+
HNSC	trans	rs2899832	0.568	rs17597267	ENSG00000229083.1	PSMA6P2	6.12	2.03e-09	0.0032	0.46	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312698	chrX:12825840~12826833:+
HNSC	trans	rs73110464	0.505	rs2682296	ENSG00000254285.3	KRT8P3	-6.12	2.03e-09	0.0032	-0.32	-0.27	Cancer (pleiotropy);	chr12:52914481	chr8:61578220~61579668:+
HNSC	trans	rs7873102	0.967	rs10814648	ENSG00000229007.1	EXOSC3P1	-6.12	2.03e-09	0.00321	-0.34	-0.27	Brain structure;	chr9:38038434	chr21:32496812~32497311:+
HNSC	trans	rs7647973	0.626	rs4855849	ENSG00000197582.5	GPX1P1	6.12	2.04e-09	0.00322	0.46	0.27	Menarche (age at onset);	chr3:49615945	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.588	rs4855848	ENSG00000197582.5	GPX1P1	6.12	2.04e-09	0.00322	0.46	0.27	Menarche (age at onset);	chr3:49616024	chrX:13378735~13379340:-
HNSC	trans	rs9467711	0.606	rs34781270	ENSG00000253570.1	RNF5P1	6.12	2.04e-09	0.00322	0.63	0.27	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr8:38600661~38601200:-
HNSC	trans	rs804280	0.542	rs34117651	ENSG00000173295.6	FAM86B3P	6.11	2.04e-09	0.00323	0.3	0.27	Myopia (pathological);	chr8:11934108	chr8:8228595~8244865:+
HNSC	trans	rs79149102	0.522	rs74925675	ENSG00000227288.3	RP5-837I24.1	6.11	2.05e-09	0.00324	0.52	0.27	Lung cancer;	chr15:74613415	chr1:81501794~81503468:+
HNSC	trans	rs7873102	0.967	rs1105773	ENSG00000229007.1	EXOSC3P1	6.11	2.05e-09	0.00324	0.33	0.27	Brain structure;	chr9:37979223	chr21:32496812~32497311:+
HNSC	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	6.11	2.06e-09	0.00325	0.39	0.27	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
HNSC	trans	rs722599	0.748	rs59112602	ENSG00000181227.3	RP4-682C21.2	6.11	2.07e-09	0.00327	0.29	0.27	IgG glycosylation;	chr14:74892114	chr1:75743423~75744776:-
HNSC	trans	rs8177876	0.822	rs1563075	ENSG00000224837.1	GCSHP5	6.11	2.08e-09	0.00328	0.47	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr1:168055901~168056422:-
HNSC	trans	rs1816752	0.905	rs4769352	ENSG00000224976.2	PARP4P2	-6.11	2.08e-09	0.00328	-0.32	-0.27	Obesity-related traits;	chr13:24426237	chr13:19349137~19407962:+
HNSC	trans	rs10435719	0.764	rs10103485	ENSG00000173295.6	FAM86B3P	6.11	2.09e-09	0.00329	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.804	rs898609	ENSG00000228224.3	NACAP1	6.11	2.09e-09	0.0033	0.29	0.27	Platelet distribution width;	chr12:56713026	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.804	rs4902	ENSG00000228224.3	NACAP1	6.11	2.09e-09	0.0033	0.29	0.27	Platelet distribution width;	chr12:56714419	chr8:101361794~101372707:+
HNSC	trans	rs7520050	0.553	rs2993263	ENSG00000255397.1	AC022182.2	-6.11	2.1e-09	0.00331	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45555958	chr8:60937705~60939871:-
HNSC	trans	rs6831352	0.918	rs17817958	ENSG00000233859.2	ADH5P4	-6.11	2.11e-09	0.00332	-0.36	-0.27	Alcohol dependence;	chr4:99140094	chr6:65836930~65838039:-
HNSC	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-6.11	2.12e-09	0.00334	-0.34	-0.27	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
HNSC	trans	rs13016963	0.604	rs12612166	ENSG00000235105.1	RP11-329A14.1	6.11	2.12e-09	0.00335	0.36	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201314035	chr1:48435967~48437223:+
HNSC	trans	rs9467711	0.606	rs34104395	ENSG00000253570.1	RNF5P1	6.11	2.12e-09	0.00335	0.63	0.27	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr8:38600661~38601200:-
HNSC	trans	rs7520050	0.778	rs2991985	ENSG00000255397.1	AC022182.2	6.11	2.13e-09	0.00336	0.33	0.27	Reticulocyte count;Red blood cell count;	chr1:45614858	chr8:60937705~60939871:-
HNSC	trans	rs1568889	0.838	rs3812738	ENSG00000174912.7	METTL15P1	6.11	2.14e-09	0.00338	0.29	0.27	Bipolar disorder;	chr11:28108435	chr3:156713884~156714928:-
HNSC	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-6.11	2.15e-09	0.00339	-0.3	-0.27	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
HNSC	trans	rs1933488	1	rs2119992	ENSG00000278974.1	RP11-756P10.6	-6.11	2.16e-09	0.0034	-0.36	-0.27	Prostate cancer;	chr6:153128535	chr4:188740507~188741281:-
HNSC	trans	rs1816752	0.905	rs4770666	ENSG00000224976.2	PARP4P2	-6.1	2.17e-09	0.00342	-0.32	-0.27	Obesity-related traits;	chr13:24414891	chr13:19349137~19407962:+
HNSC	trans	rs2950393	0.857	rs1563896	ENSG00000257210.1	NACAP3	6.1	2.18e-09	0.00343	0.33	0.27	Platelet distribution width;	chr12:56699312	chr12:93124063~93124543:-
HNSC	trans	rs722599	0.748	rs731165	ENSG00000181227.3	RP4-682C21.2	6.1	2.19e-09	0.00344	0.29	0.27	IgG glycosylation;	chr14:74885852	chr1:75743423~75744776:-
HNSC	trans	rs546131	0.89	rs496558	ENSG00000225531.1	RP11-196I18.3	6.1	2.19e-09	0.00346	0.33	0.27	Lung disease severity in cystic fibrosis;	chr11:34804878	chr9:107116829~107117557:+
HNSC	trans	rs902774	0.818	rs55958994	ENSG00000224520.2	KRT8P45	-6.1	2.2e-09	0.00346	-0.48	-0.27	Prostate cancer;	chr12:52907235	chr1:157073257~157074703:+
HNSC	trans	rs4865169	0.791	rs11731868	ENSG00000263812.4	LINC00908	-6.1	2.22e-09	0.00349	-0.31	-0.27	Breast cancer;	chr4:57029048	chr18:76528655~76610968:+
HNSC	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	6.1	2.22e-09	0.0035	0.34	0.27	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
HNSC	trans	rs941207	0.542	rs7315786	ENSG00000257210.1	NACAP3	-6.1	2.23e-09	0.0035	-0.34	-0.27	Platelet count;	chr12:56801595	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.804	rs2958130	ENSG00000228224.3	NACAP1	6.1	2.23e-09	0.00351	0.3	0.27	Platelet distribution width;	chr12:56746722	chr8:101361794~101372707:+
HNSC	trans	rs7824557	0.688	rs2572397	ENSG00000254340.1	RP11-10A14.3	6.1	2.23e-09	0.00352	0.33	0.27	Retinal vascular caliber;	chr8:11318894	chr8:9141424~9145435:+
HNSC	trans	rs2950393	0.804	rs2958132	ENSG00000228224.3	NACAP1	6.1	2.24e-09	0.00352	0.3	0.27	Platelet distribution width;	chr12:56750749	chr8:101361794~101372707:+
HNSC	trans	rs722599	0.748	rs741096	ENSG00000181227.3	RP4-682C21.2	6.1	2.24e-09	0.00352	0.29	0.27	IgG glycosylation;	chr14:74884784	chr1:75743423~75744776:-
HNSC	trans	rs722599	0.748	rs7145173	ENSG00000181227.3	RP4-682C21.2	6.1	2.24e-09	0.00352	0.29	0.27	IgG glycosylation;	chr14:74884944	chr1:75743423~75744776:-
HNSC	trans	rs4970988	0.527	rs12067556	ENSG00000180764.13	PIPSL	-6.1	2.26e-09	0.00355	-0.34	-0.27	Urate levels;	chr1:150642059	chr10:93958191~93961540:-
HNSC	trans	rs864643	0.678	rs1707960	ENSG00000183298.5	RP11-556K13.1	-6.1	2.26e-09	0.00355	-0.42	-0.27	Attention deficit hyperactivity disorder;	chr3:39481761	chr1:101786340~101787219:-
HNSC	trans	rs941207	0.542	rs1813109	ENSG00000257210.1	NACAP3	-6.1	2.26e-09	0.00356	-0.34	-0.27	Platelet count;	chr12:56798079	chr12:93124063~93124543:-
HNSC	trans	rs17507216	0.609	rs1431716	ENSG00000235370.6	DNM1P51	-6.1	2.28e-09	0.00358	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82676180	chr15:84398316~84411701:-
HNSC	trans	rs6424115	1	rs6697805	ENSG00000228217.1	AL390877.1	6.1	2.28e-09	0.00358	0.34	0.27	Immature fraction of reticulocytes;	chr1:23825506	chr1:117778087~117778506:-
HNSC	trans	rs7617480	0.585	rs7373072	ENSG00000197582.5	GPX1P1	6.1	2.29e-09	0.00359	0.4	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chrX:13378735~13379340:-
HNSC	trans	rs1933488	0.965	rs28642896	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153106933	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs9383649	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153106967	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs7747003	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153107847	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs17083581	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153108312	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs6931160	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153109316	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs12055786	ENSG00000278974.1	RP11-756P10.6	-6.1	2.29e-09	0.0036	-0.36	-0.27	Prostate cancer;	chr6:153109990	chr4:188740507~188741281:-
HNSC	trans	rs2899832	0.568	rs10467708	ENSG00000229083.1	PSMA6P2	6.1	2.29e-09	0.0036	0.46	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35317808	chrX:12825840~12826833:+
HNSC	trans	rs11992162	1	rs7460395	ENSG00000173295.6	FAM86B3P	6.09	2.3e-09	0.00361	0.31	0.27	Monocyte count;	chr8:11977866	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.855	rs2256341	ENSG00000228224.3	NACAP1	-6.09	2.3e-09	0.00362	-0.35	-0.27	Platelet count;	chr12:56599930	chr8:101361794~101372707:+
HNSC	trans	rs1190596	0.567	rs36060205	ENSG00000181359.5	HSP90AA6P	-6.09	2.31e-09	0.00362	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102253360	chr4:170581470~170605450:-
HNSC	trans	rs4948102	0.732	rs6951810	ENSG00000215006.4	CHCHD2P2	-6.09	2.32e-09	0.00364	-0.38	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56008905	chr5:69333929~69334249:+
HNSC	trans	rs11098499	0.739	rs10031033	ENSG00000275858.1	RP11-291L22.8	6.09	2.32e-09	0.00365	0.33	0.27	Corneal astigmatism;	chr4:119230297	chr10:38450738~38451069:-
HNSC	trans	rs6087990	0.735	rs1003522	ENSG00000253915.1	MAPRE1P1	6.09	2.33e-09	0.00365	0.32	0.27	Ulcerative colitis;	chr20:32780754	chr8:135625185~135625981:-
HNSC	trans	rs9393777	0.844	rs28360634	ENSG00000253570.1	RNF5P1	6.09	2.33e-09	0.00365	0.62	0.27	Intelligence (multi-trait analysis);	chr6:27365112	chr8:38600661~38601200:-
HNSC	trans	rs1991651	0.507	rs17778581	ENSG00000173295.6	FAM86B3P	-6.09	2.33e-09	0.00366	-0.3	-0.27	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:8228595~8244865:+
HNSC	trans	rs513349	1	rs210146	ENSG00000175730.8	BAK1P1	6.09	2.34e-09	0.00368	0.32	0.27	Platelet count;	chr6:33581321	chr20:32690180~32690815:-
HNSC	trans	rs8177876	0.822	rs16954582	ENSG00000224837.1	GCSHP5	6.09	2.35e-09	0.00368	0.46	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr1:168055901~168056422:-
HNSC	trans	rs9733	0.596	rs2867300	ENSG00000180764.13	PIPSL	-6.09	2.35e-09	0.00369	-0.32	-0.27	Tonsillectomy;	chr1:150694514	chr10:93958191~93961540:-
HNSC	trans	rs17507216	0.628	rs28607761	ENSG00000235370.6	DNM1P51	-6.09	2.36e-09	0.00371	-0.41	-0.27	Excessive daytime sleepiness;	chr15:82715317	chr15:84398316~84411701:-
HNSC	trans	rs853679	0.607	rs13204012	ENSG00000253570.1	RNF5P1	6.09	2.37e-09	0.00372	0.64	0.27	Depression;	chr6:28233753	chr8:38600661~38601200:-
HNSC	trans	rs6424115	0.965	rs2502979	ENSG00000228217.1	AL390877.1	-6.09	2.38e-09	0.00373	-0.34	-0.27	Immature fraction of reticulocytes;	chr1:23822825	chr1:117778087~117778506:-
HNSC	trans	rs1933488	1	rs6557266	ENSG00000278974.1	RP11-756P10.6	-6.09	2.38e-09	0.00373	-0.36	-0.27	Prostate cancer;	chr6:153112399	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs6907823	ENSG00000278974.1	RP11-756P10.6	-6.09	2.38e-09	0.00373	-0.36	-0.27	Prostate cancer;	chr6:153112407	chr4:188740507~188741281:-
HNSC	trans	rs7617480	0.549	rs9879978	ENSG00000197582.5	GPX1P1	6.09	2.39e-09	0.00374	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chrX:13378735~13379340:-
HNSC	trans	rs2950393	0.804	rs7967600	ENSG00000228224.3	NACAP1	6.09	2.39e-09	0.00375	0.3	0.27	Platelet distribution width;	chr12:56768208	chr8:101361794~101372707:+
HNSC	trans	rs1933488	1	rs7743683	ENSG00000278974.1	RP11-756P10.6	-6.09	2.39e-09	0.00375	-0.36	-0.27	Prostate cancer;	chr6:153111850	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs6557265	ENSG00000278974.1	RP11-756P10.6	-6.09	2.39e-09	0.00375	-0.36	-0.27	Prostate cancer;	chr6:153112267	chr4:188740507~188741281:-
HNSC	trans	rs2336384	1	rs873457	ENSG00000261819.1	RP11-680G24.4	6.09	2.4e-09	0.00375	0.38	0.27	Platelet count;	chr1:11986277	chr16:14988259~14990160:-
HNSC	trans	rs9733	0.519	rs1336900	ENSG00000180764.13	PIPSL	-6.09	2.4e-09	0.00376	-0.32	-0.27	Tonsillectomy;	chr1:150706557	chr10:93958191~93961540:-
HNSC	trans	rs9630182	0.619	rs10832039	ENSG00000257675.1	RP11-641A6.9	-6.09	2.4e-09	0.00376	-0.32	-0.27	Bone mineral density;	chr11:13450913	chr12:52748776~52750127:+
HNSC	trans	rs2899832	0.5	rs28522717	ENSG00000229083.1	PSMA6P2	6.09	2.4e-09	0.00376	0.46	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35266346	chrX:12825840~12826833:+
HNSC	trans	rs4713118	0.513	rs149878	ENSG00000204709.4	LINC01556	6.09	2.4e-09	0.00376	0.34	0.27	Parkinson's disease;	chr6:27910960	chr6:28943877~28944537:+
HNSC	trans	rs7873102	0.933	rs7019689	ENSG00000229007.1	EXOSC3P1	-6.09	2.41e-09	0.00377	-0.34	-0.27	Brain structure;	chr9:38028429	chr21:32496812~32497311:+
HNSC	trans	rs804280	0.543	rs13261205	ENSG00000173295.6	FAM86B3P	6.09	2.41e-09	0.00377	0.3	0.27	Myopia (pathological);	chr8:11933707	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.867	rs34465618	ENSG00000173295.6	FAM86B3P	6.09	2.41e-09	0.00377	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.867	rs34583868	ENSG00000173295.6	FAM86B3P	6.09	2.41e-09	0.00377	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:8228595~8244865:+
HNSC	trans	rs804280	0.518	rs34266352	ENSG00000173295.6	FAM86B3P	6.09	2.41e-09	0.00377	0.3	0.27	Myopia (pathological);	chr8:11933953	chr8:8228595~8244865:+
HNSC	trans	rs804280	0.542	rs36100659	ENSG00000173295.6	FAM86B3P	6.09	2.41e-09	0.00377	0.3	0.27	Myopia (pathological);	chr8:11934144	chr8:8228595~8244865:+
HNSC	trans	rs853679	1	rs11965538	ENSG00000204622.9	HLA-J	-6.09	2.41e-09	0.00378	-0.45	-0.27	Depression;	chr6:28272137	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs34243448	ENSG00000243753.4	HLA-L	-6.09	2.41e-09	0.00378	-0.6	-0.27	Depression;	chr6:28225324	chr6:30259584~30293014:+
HNSC	trans	rs941207	0.762	rs10450	ENSG00000228224.3	NACAP1	6.09	2.42e-09	0.00379	0.3	0.27	Platelet count;	chr12:56590822	chr8:101361794~101372707:+
HNSC	trans	rs1816752	0.905	rs7991450	ENSG00000224976.2	PARP4P2	-6.09	2.42e-09	0.00379	-0.32	-0.27	Obesity-related traits;	chr13:24425898	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.774	rs7986162	ENSG00000224976.2	PARP4P2	-6.09	2.42e-09	0.00379	-0.32	-0.27	Obesity-related traits;	chr13:24425941	chr13:19349137~19407962:+
HNSC	trans	rs9650657	0.645	rs9969657	ENSG00000173295.6	FAM86B3P	6.08	2.43e-09	0.0038	0.29	0.27	Neuroticism;	chr8:10657768	chr8:8228595~8244865:+
HNSC	trans	rs1336900	0.513	rs56253522	ENSG00000180764.13	PIPSL	-6.08	2.43e-09	0.00381	-0.33	-0.27	Blood protein levels;	chr1:150642393	chr10:93958191~93961540:-
HNSC	trans	rs7769051	0.803	rs12193474	ENSG00000227615.1	RP11-864N7.2	6.08	2.44e-09	0.00381	0.47	0.27	Type 2 diabetes nephropathy;	chr6:132865029	chr11:74745716~74746114:-
HNSC	trans	rs9630182	0.561	rs12802900	ENSG00000257675.1	RP11-641A6.9	-6.08	2.44e-09	0.00382	-0.31	-0.27	Bone mineral density;	chr11:13416376	chr12:52748776~52750127:+
HNSC	trans	rs864643	0.678	rs7631217	ENSG00000183298.5	RP11-556K13.1	-6.08	2.44e-09	0.00382	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr3:39478568	chr1:101786340~101787219:-
HNSC	trans	rs6424115	1	rs1018396	ENSG00000228217.1	AL390877.1	-6.08	2.45e-09	0.00383	-0.33	-0.27	Immature fraction of reticulocytes;	chr1:23807122	chr1:117778087~117778506:-
HNSC	trans	rs9650657	0.801	rs7018334	ENSG00000173295.6	FAM86B3P	-6.08	2.45e-09	0.00383	-0.31	-0.27	Neuroticism;	chr8:10754565	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.611	rs7532045	ENSG00000180764.13	PIPSL	-6.08	2.46e-09	0.00384	-0.33	-0.27	Melanoma;	chr1:150849371	chr10:93958191~93961540:-
HNSC	trans	rs4295623	0.504	rs11250160	ENSG00000173295.6	FAM86B3P	-6.08	2.46e-09	0.00385	-0.3	-0.27	Morning vs. evening chronotype;	chr8:11735208	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.718	rs72751657	ENSG00000259295.5	CSPG4P12	-6.08	2.47e-09	0.00387	-0.43	-0.27	Excessive daytime sleepiness;	chr15:82581259	chr15:85191438~85213905:+
HNSC	trans	rs9329221	0.935	rs3750311	ENSG00000173295.6	FAM86B3P	-6.08	2.49e-09	0.00389	-0.3	-0.27	Neuroticism;	chr8:10426092	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.51	rs1435274	ENSG00000254340.1	RP11-10A14.3	-6.08	2.5e-09	0.00391	-0.32	-0.27	Retinal vascular caliber;	chr8:11378401	chr8:9141424~9145435:+
HNSC	trans	rs853679	0.607	rs35072899	ENSG00000253570.1	RNF5P1	6.08	2.5e-09	0.00391	0.63	0.27	Depression;	chr6:28313764	chr8:38600661~38601200:-
HNSC	trans	rs9650657	0.683	rs7005905	ENSG00000253893.2	FAM85B	-6.08	2.51e-09	0.00392	-0.33	-0.27	Neuroticism;	chr8:10727634	chr8:8167819~8226614:-
HNSC	trans	rs1355223	0.506	rs11032898	ENSG00000225531.1	RP11-196I18.3	6.08	2.53e-09	0.00395	0.34	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848564	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.506	rs11032899	ENSG00000225531.1	RP11-196I18.3	6.08	2.53e-09	0.00395	0.34	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848687	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.506	rs1828299	ENSG00000225531.1	RP11-196I18.3	6.08	2.53e-09	0.00395	0.34	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848871	chr9:107116829~107117557:+
HNSC	trans	rs9650657	0.655	rs4841434	ENSG00000253893.2	FAM85B	6.08	2.53e-09	0.00396	0.33	0.27	Neuroticism;	chr8:10728613	chr8:8167819~8226614:-
HNSC	trans	rs7520050	0.807	rs4353138	ENSG00000255397.1	AC022182.2	6.08	2.55e-09	0.00398	0.34	0.27	Reticulocyte count;Red blood cell count;	chr1:45754131	chr8:60937705~60939871:-
HNSC	trans	rs2950393	0.804	rs2926748	ENSG00000228224.3	NACAP1	6.08	2.56e-09	0.00399	0.29	0.27	Platelet distribution width;	chr12:56715628	chr8:101361794~101372707:+
HNSC	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-6.08	2.56e-09	0.004	-0.31	-0.27	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
HNSC	trans	rs4948102	0.599	rs2230197	ENSG00000215006.4	CHCHD2P2	-6.08	2.56e-09	0.004	-0.35	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr5:69333929~69334249:+
HNSC	trans	rs1933488	0.931	rs6934121	ENSG00000278974.1	RP11-756P10.6	-6.08	2.57e-09	0.00401	-0.36	-0.27	Prostate cancer;	chr6:153127117	chr4:188740507~188741281:-
HNSC	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	6.07	2.58e-09	0.00403	0.34	0.27	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
HNSC	trans	rs9630182	0.561	rs10832036	ENSG00000257675.1	RP11-641A6.9	-6.07	2.6e-09	0.00405	-0.31	-0.27	Bone mineral density;	chr11:13441306	chr12:52748776~52750127:+
HNSC	trans	rs6831352	0.879	rs2602888	ENSG00000233859.2	ADH5P4	-6.07	2.61e-09	0.00407	-0.33	-0.27	Alcohol dependence;	chr4:99120555	chr6:65836930~65838039:-
HNSC	trans	rs2336384	0.929	rs2236056	ENSG00000261819.1	RP11-680G24.4	6.07	2.61e-09	0.00407	0.39	0.27	Platelet count;	chr1:11996383	chr16:14988259~14990160:-
HNSC	trans	rs853679	0.824	rs34712084	ENSG00000253570.1	RNF5P1	6.07	2.61e-09	0.00407	0.53	0.27	Depression;	chr6:28076050	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.824	rs1321505	ENSG00000253570.1	RNF5P1	6.07	2.61e-09	0.00407	0.53	0.27	Depression;	chr6:28085045	chr8:38600661~38601200:-
HNSC	trans	rs941207	0.542	rs2126068	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56804716	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs67808059	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56805228	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs11171980	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56806397	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs12366897	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56808329	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs12367312	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56809369	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs12367339	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56809521	chr12:93124063~93124543:-
HNSC	trans	rs941207	0.542	rs12367822	ENSG00000257210.1	NACAP3	-6.07	2.61e-09	0.00407	-0.34	-0.27	Platelet count;	chr12:56810376	chr12:93124063~93124543:-
HNSC	trans	rs11220237	0.925	rs9651705	ENSG00000236257.1	EI24P2	6.07	2.62e-09	0.00408	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125798921	chr1:158454198~158455273:+
HNSC	trans	rs7647973	0.807	rs4955416	ENSG00000197582.5	GPX1P1	6.07	2.62e-09	0.00409	0.4	0.27	Menarche (age at onset);	chr3:49070995	chrX:13378735~13379340:-
HNSC	trans	rs2950393	0.804	rs1131514	ENSG00000257210.1	NACAP3	-6.07	2.63e-09	0.0041	-0.3	-0.27	Platelet distribution width;	chr12:56739356	chr12:93124063~93124543:-
HNSC	trans	rs6756513	0.5	rs60515724	ENSG00000232654.1	FAM136BP	6.07	2.63e-09	0.0041	0.37	0.27	Breast cancer;Platelet count;	chr2:69889316	chr6:3045384~3045800:+
HNSC	trans	rs853679	0.607	rs66886492	ENSG00000243753.4	HLA-L	-6.07	2.64e-09	0.00411	-0.6	-0.27	Depression;	chr6:28121953	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs35345226	ENSG00000243753.4	HLA-L	-6.07	2.64e-09	0.00411	-0.6	-0.27	Depression;	chr6:28123802	chr6:30259584~30293014:+
HNSC	trans	rs7809615	0.515	rs6961634	ENSG00000228834.1	RP11-249L21.4	6.07	2.64e-09	0.00411	0.41	0.27	Blood metabolite ratios;	chr7:99584216	chr6:108907615~108907873:-
HNSC	trans	rs6831352	0.918	rs13110176	ENSG00000233859.2	ADH5P4	-6.07	2.64e-09	0.00412	-0.33	-0.27	Alcohol dependence;	chr4:99141279	chr6:65836930~65838039:-
HNSC	trans	rs2288327	1	rs2288327	ENSG00000269800.1	PLEKHA3P1	6.07	2.65e-09	0.00413	0.35	0.27	Atrial fibrillation;	chr2:178546938	chr19:41521043~41521989:-
HNSC	trans	rs8177876	0.658	rs889516	ENSG00000224837.1	GCSHP5	-6.07	2.65e-09	0.00413	-0.47	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr1:168055901~168056422:-
HNSC	trans	rs1568889	0.838	rs11030229	ENSG00000174912.7	METTL15P1	6.07	2.65e-09	0.00413	0.28	0.27	Bipolar disorder;	chr11:28152087	chr3:156713884~156714928:-
HNSC	trans	rs67340775	0.541	rs200966	ENSG00000204709.4	LINC01556	6.07	2.65e-09	0.00413	0.42	0.27	Lung cancer in ever smokers;	chr6:27894374	chr6:28943877~28944537:+
HNSC	trans	rs6921919	0.887	rs7766356	ENSG00000228078.1	HLA-U	-6.07	2.65e-09	0.00414	-0.45	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:29934101~29934286:+
HNSC	trans	rs7412746	0.597	rs868751	ENSG00000180764.13	PIPSL	-6.07	2.66e-09	0.00414	-0.32	-0.27	Melanoma;	chr1:150696938	chr10:93958191~93961540:-
HNSC	trans	rs9467773	0.595	rs9366657	ENSG00000242375.1	RP11-498P14.3	6.07	2.66e-09	0.00415	0.35	0.27	Intelligence (multi-trait analysis);	chr6:26434686	chr9:97195351~97197687:-
HNSC	trans	rs867371	1	rs13380317	ENSG00000259295.5	CSPG4P12	6.07	2.67e-09	0.00416	0.33	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:85191438~85213905:+
HNSC	trans	rs1816752	1	rs9507341	ENSG00000224976.2	PARP4P2	6.07	2.68e-09	0.00417	0.32	0.27	Obesity-related traits;	chr13:24432440	chr13:19349137~19407962:+
HNSC	trans	rs3956705	0.933	rs13311772	ENSG00000176826.14	FKBP9P1	-6.07	2.68e-09	0.00418	-0.29	-0.27	Red cell distribution width;	chr7:32960198	chr7:55681074~55713252:-
HNSC	trans	rs7617480	0.558	rs12715430	ENSG00000197582.5	GPX1P1	6.07	2.68e-09	0.00418	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chrX:13378735~13379340:-
HNSC	trans	rs853679	0.607	rs13204012	ENSG00000243753.4	HLA-L	-6.07	2.69e-09	0.00419	-0.6	-0.27	Depression;	chr6:28233753	chr6:30259584~30293014:+
HNSC	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	6.07	2.7e-09	0.00421	0.34	0.27	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
HNSC	trans	rs7819412	0.74	rs7844536	ENSG00000173295.6	FAM86B3P	-6.07	2.71e-09	0.00422	-0.31	-0.27	Triglycerides;	chr8:11176519	chr8:8228595~8244865:+
HNSC	trans	rs7769051	0.615	rs12209144	ENSG00000227615.1	RP11-864N7.2	6.07	2.72e-09	0.00423	0.46	0.27	Type 2 diabetes nephropathy;	chr6:132869925	chr11:74745716~74746114:-
HNSC	trans	rs853679	0.607	rs35001169	ENSG00000253570.1	RNF5P1	6.07	2.73e-09	0.00424	0.65	0.27	Depression;	chr6:28219854	chr8:38600661~38601200:-
HNSC	trans	rs3956705	1	rs35500246	ENSG00000176826.14	FKBP9P1	-6.06	2.73e-09	0.00426	-0.29	-0.27	Red cell distribution width;	chr7:32932161	chr7:55681074~55713252:-
HNSC	trans	rs73108077	0.764	rs75475053	ENSG00000279352.1	RP11-411B10.7	6.06	2.75e-09	0.00428	0.55	0.27	Red blood cell density in sickle cell anemia;	chr20:31217143	chr18:14010054~14010917:+
HNSC	trans	rs6424115	1	rs7519554	ENSG00000228217.1	AL390877.1	6.06	2.76e-09	0.00429	0.34	0.27	Immature fraction of reticulocytes;	chr1:23828076	chr1:117778087~117778506:-
HNSC	trans	rs1816752	0.719	rs11841989	ENSG00000224976.2	PARP4P2	-6.06	2.76e-09	0.00429	-0.31	-0.27	Obesity-related traits;	chr13:24423560	chr13:19349137~19407962:+
HNSC	trans	rs6087990	0.735	rs6057647	ENSG00000253915.1	MAPRE1P1	6.06	2.8e-09	0.00435	0.32	0.27	Ulcerative colitis;	chr20:32793884	chr8:135625185~135625981:-
HNSC	trans	rs1933488	0.965	rs7742238	ENSG00000278974.1	RP11-756P10.6	-6.06	2.81e-09	0.00436	-0.36	-0.27	Prostate cancer;	chr6:153107476	chr4:188740507~188741281:-
HNSC	trans	rs7824557	0.591	rs2736282	ENSG00000173295.6	FAM86B3P	6.06	2.82e-09	0.00438	0.29	0.27	Retinal vascular caliber;	chr8:11367971	chr8:8228595~8244865:+
HNSC	trans	rs7412746	0.611	rs12410869	ENSG00000180764.13	PIPSL	-6.06	2.82e-09	0.00438	-0.33	-0.27	Melanoma;	chr1:150883677	chr10:93958191~93961540:-
HNSC	trans	rs7412746	0.611	rs36008098	ENSG00000180764.13	PIPSL	-6.06	2.82e-09	0.00438	-0.33	-0.27	Melanoma;	chr1:150884330	chr10:93958191~93961540:-
HNSC	trans	rs6424115	1	rs34477640	ENSG00000228217.1	AL390877.1	6.06	2.82e-09	0.00439	0.34	0.27	Immature fraction of reticulocytes;	chr1:23827577	chr1:117778087~117778506:-
HNSC	trans	rs853679	0.607	rs72846780	ENSG00000243753.4	HLA-L	-6.06	2.82e-09	0.00439	-0.61	-0.27	Depression;	chr6:28151277	chr6:30259584~30293014:+
HNSC	trans	rs7412746	0.611	rs4319334	ENSG00000180764.13	PIPSL	-6.06	2.83e-09	0.0044	-0.33	-0.27	Melanoma;	chr1:150794346	chr10:93958191~93961540:-
HNSC	trans	rs1933488	1	rs1442744	ENSG00000278974.1	RP11-756P10.6	-6.06	2.84e-09	0.00441	-0.36	-0.27	Prostate cancer;	chr6:153120598	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs6927516	ENSG00000278974.1	RP11-756P10.6	-6.06	2.84e-09	0.00441	-0.36	-0.27	Prostate cancer;	chr6:153120696	chr4:188740507~188741281:-
HNSC	trans	rs513349	1	rs513349	ENSG00000175730.8	BAK1P1	6.06	2.84e-09	0.00442	0.31	0.27	Platelet count;	chr6:33573942	chr20:32690180~32690815:-
HNSC	trans	rs853679	0.607	rs35749575	ENSG00000243753.4	HLA-L	-6.06	2.85e-09	0.00442	-0.61	-0.27	Depression;	chr6:28147040	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13205911	ENSG00000243753.4	HLA-L	-6.06	2.85e-09	0.00442	-0.61	-0.27	Depression;	chr6:28156336	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13197176	ENSG00000243753.4	HLA-L	-6.06	2.85e-09	0.00442	-0.61	-0.27	Depression;	chr6:28161454	chr6:30259584~30293014:+
HNSC	trans	rs9467773	0.595	rs2237236	ENSG00000242375.1	RP11-498P14.3	-6.06	2.85e-09	0.00443	-0.35	-0.27	Intelligence (multi-trait analysis);	chr6:26451325	chr9:97195351~97197687:-
HNSC	trans	rs10435719	0.902	rs4840599	ENSG00000173295.6	FAM86B3P	-6.06	2.85e-09	0.00443	-0.3	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8228595~8244865:+
HNSC	trans	rs8014204	0.901	rs6574200	ENSG00000181227.3	RP4-682C21.2	6.06	2.85e-09	0.00443	0.26	0.27	Caffeine consumption;	chr14:74897748	chr1:75743423~75744776:-
HNSC	trans	rs9329221	0.905	rs13254263	ENSG00000173295.6	FAM86B3P	-6.06	2.86e-09	0.00444	-0.3	-0.27	Neuroticism;	chr8:10397671	chr8:8228595~8244865:+
HNSC	trans	rs2336384	1	rs2878677	ENSG00000261819.1	RP11-680G24.4	-6.06	2.87e-09	0.00445	-0.38	-0.27	Platelet count;	chr1:11993207	chr16:14988259~14990160:-
HNSC	trans	rs853679	0.882	rs4713140	ENSG00000204622.9	HLA-J	-6.06	2.87e-09	0.00445	-0.48	-0.27	Depression;	chr6:28129415	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs67998226	ENSG00000253570.1	RNF5P1	6.06	2.87e-09	0.00445	0.6	0.27	Depression;	chr6:28270281	chr8:38600661~38601200:-
HNSC	trans	rs804280	0.509	rs13276433	ENSG00000173295.6	FAM86B3P	6.06	2.88e-09	0.00447	0.3	0.27	Myopia (pathological);	chr8:11925527	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.774	rs11030235	ENSG00000174912.7	METTL15P1	6.06	2.89e-09	0.00448	0.28	0.27	Bipolar disorder;	chr11:28190828	chr3:156713884~156714928:-
HNSC	trans	rs7824557	0.527	rs10109537	ENSG00000254340.1	RP11-10A14.3	-6.05	2.9e-09	0.0045	-0.32	-0.27	Retinal vascular caliber;	chr8:11382131	chr8:9141424~9145435:+
HNSC	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	6.05	2.91e-09	0.00451	0.47	0.27	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
HNSC	trans	rs864643	0.524	rs72869131	ENSG00000183298.5	RP11-556K13.1	6.05	2.92e-09	0.00452	0.5	0.27	Attention deficit hyperactivity disorder;	chr3:39472959	chr1:101786340~101787219:-
HNSC	trans	rs6831352	1	rs1126671	ENSG00000233859.2	ADH5P4	-6.05	2.92e-09	0.00453	-0.31	-0.27	Alcohol dependence;	chr4:99127263	chr6:65836930~65838039:-
HNSC	trans	rs6831352	1	rs6837685	ENSG00000233859.2	ADH5P4	-6.05	2.92e-09	0.00453	-0.31	-0.27	Alcohol dependence;	chr4:99127994	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.959	rs4699710	ENSG00000233859.2	ADH5P4	-6.05	2.92e-09	0.00453	-0.31	-0.27	Alcohol dependence;	chr4:99130668	chr6:65836930~65838039:-
HNSC	trans	rs1933488	1	rs9479517	ENSG00000278974.1	RP11-756P10.6	-6.05	2.93e-09	0.00454	-0.36	-0.27	Prostate cancer;	chr6:153121654	chr4:188740507~188741281:-
HNSC	trans	rs3771529	1	rs3771529	ENSG00000232654.1	FAM136BP	6.05	2.95e-09	0.00457	0.38	0.27	Mean platelet volume;	chr2:69937708	chr6:3045384~3045800:+
HNSC	trans	rs2950393	0.509	rs10459247	ENSG00000228224.3	NACAP1	-6.05	2.95e-09	0.00457	-0.35	-0.27	Platelet distribution width;	chr12:56777732	chr8:101361794~101372707:+
HNSC	trans	rs804280	0.509	rs35626932	ENSG00000173295.6	FAM86B3P	6.05	2.96e-09	0.00458	0.3	0.27	Myopia (pathological);	chr8:11929423	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	6.05	2.96e-09	0.00459	0.34	0.27	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
HNSC	trans	rs1038094	1	rs1038094	ENSG00000236540.6	AC006547.13	-6.05	2.96e-09	0.00459	-0.38	-0.27	Bipolar disorder;	chr15:73720096	chr22:20058030~20070569:-
HNSC	trans	rs2950393	0.929	rs2290893	ENSG00000228224.3	NACAP1	6.05	2.98e-09	0.00461	0.29	0.27	Platelet distribution width;	chr12:56684836	chr8:101361794~101372707:+
HNSC	trans	rs7819412	0.745	rs28464654	ENSG00000173295.6	FAM86B3P	-6.05	2.98e-09	0.00462	-0.31	-0.27	Triglycerides;	chr8:11223156	chr8:8228595~8244865:+
HNSC	trans	rs7819412	0.745	rs28591576	ENSG00000173295.6	FAM86B3P	-6.05	2.98e-09	0.00462	-0.31	-0.27	Triglycerides;	chr8:11223166	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.887	rs7102237	ENSG00000174912.7	METTL15P1	6.05	2.99e-09	0.00463	0.28	0.27	Bipolar disorder;	chr11:28322749	chr3:156713884~156714928:-
HNSC	trans	rs10435719	0.867	rs35778860	ENSG00000173295.6	FAM86B3P	6.05	3e-09	0.00464	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:8228595~8244865:+
HNSC	trans	rs7617480	0.587	rs9311431	ENSG00000197582.5	GPX1P1	6.05	3e-09	0.00464	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chrX:13378735~13379340:-
HNSC	trans	rs7617480	0.648	rs4974088	ENSG00000197582.5	GPX1P1	6.05	3e-09	0.00464	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chrX:13378735~13379340:-
HNSC	trans	rs11220237	1	rs3862623	ENSG00000236257.1	EI24P2	6.05	3.01e-09	0.00466	0.41	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850351	chr1:158454198~158455273:+
HNSC	trans	rs6921919	1	rs35875412	ENSG00000228078.1	HLA-U	-6.05	3.01e-09	0.00466	-0.41	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:29934101~29934286:+
HNSC	trans	rs62344088	1	rs7710931	ENSG00000185986.11	SDHAP3	6.05	3.02e-09	0.00467	0.66	0.27	Asthma (childhood onset);	chr5:152171	chr5:1572222~1594620:-
HNSC	trans	rs1355223	0.506	rs6484738	ENSG00000225531.1	RP11-196I18.3	6.05	3.02e-09	0.00468	0.33	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34839311	chr9:107116829~107117557:+
HNSC	trans	rs6756513	0.505	rs2228203	ENSG00000232654.1	FAM136BP	6.05	3.02e-09	0.00468	0.36	0.27	Breast cancer;Platelet count;	chr2:69806452	chr6:3045384~3045800:+
HNSC	trans	rs11992162	0.967	rs7461062	ENSG00000173295.6	FAM86B3P	6.05	3.03e-09	0.00468	0.3	0.27	Monocyte count;	chr8:11974439	chr8:8228595~8244865:+
HNSC	trans	rs8067354	0.645	rs2102507	ENSG00000187870.7	RNFT1P3	6.05	3.03e-09	0.00468	0.35	0.27	Hemoglobin concentration;	chr17:59798546	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.645	rs2645491	ENSG00000187870.7	RNFT1P3	6.05	3.03e-09	0.00468	0.35	0.27	Hemoglobin concentration;	chr17:59799688	chr17:20743333~20754501:-
HNSC	trans	rs2950393	0.929	rs10876916	ENSG00000257210.1	NACAP3	6.05	3.04e-09	0.0047	0.3	0.27	Platelet distribution width;	chr12:56692728	chr12:93124063~93124543:-
HNSC	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-6.05	3.04e-09	0.0047	-0.34	-0.27	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
HNSC	trans	rs9467711	0.606	rs35076545	ENSG00000253570.1	RNF5P1	6.05	3.04e-09	0.0047	0.62	0.27	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.606	rs13212985	ENSG00000253570.1	RNF5P1	6.05	3.04e-09	0.0047	0.62	0.27	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr8:38600661~38601200:-
HNSC	trans	rs7520050	0.966	rs7556436	ENSG00000255397.1	AC022182.2	-6.05	3.04e-09	0.00471	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45898208	chr8:60937705~60939871:-
HNSC	trans	rs4713118	0.869	rs6922574	ENSG00000204709.4	LINC01556	6.04	3.07e-09	0.00474	0.35	0.27	Parkinson's disease;	chr6:27725224	chr6:28943877~28944537:+
HNSC	trans	rs7824557	0.564	rs7839307	ENSG00000254340.1	RP11-10A14.3	6.04	3.08e-09	0.00476	0.32	0.27	Retinal vascular caliber;	chr8:11341283	chr8:9141424~9145435:+
HNSC	trans	rs877636	0.702	rs773108	ENSG00000234513.1	AC073072.7	6.04	3.1e-09	0.00479	0.33	0.27	Cognitive function;	chr12:55976127	chr7:22773646~22773993:-
HNSC	trans	rs6424115	1	rs12116511	ENSG00000228217.1	AL390877.1	6.04	3.11e-09	0.00481	0.34	0.27	Immature fraction of reticulocytes;	chr1:23836172	chr1:117778087~117778506:-
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-6.04	3.12e-09	0.00481	-0.29	-0.27	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
HNSC	trans	rs902774	0.818	rs17120257	ENSG00000224520.2	KRT8P45	-6.04	3.12e-09	0.00483	-0.48	-0.27	Prostate cancer;	chr12:52909547	chr1:157073257~157074703:+
HNSC	trans	rs79149102	0.522	rs950323	ENSG00000227288.3	RP5-837I24.1	6.04	3.13e-09	0.00484	0.52	0.27	Lung cancer;	chr15:74674188	chr1:81501794~81503468:+
HNSC	trans	rs9393777	0.92	rs34196306	ENSG00000253570.1	RNF5P1	6.04	3.14e-09	0.00484	0.71	0.27	Intelligence (multi-trait analysis);	chr6:27457865	chr8:38600661~38601200:-
HNSC	trans	rs6087990	0.735	rs2424928	ENSG00000253915.1	MAPRE1P1	6.04	3.14e-09	0.00485	0.32	0.27	Ulcerative colitis;	chr20:32800830	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.735	rs2065576	ENSG00000253915.1	MAPRE1P1	6.04	3.14e-09	0.00485	0.32	0.27	Ulcerative colitis;	chr20:32801203	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.669	rs2424929	ENSG00000253915.1	MAPRE1P1	6.04	3.14e-09	0.00485	0.32	0.27	Ulcerative colitis;	chr20:32801712	chr8:135625185~135625981:-
HNSC	trans	rs67340775	0.541	rs200975	ENSG00000204709.4	LINC01556	6.04	3.15e-09	0.00486	0.42	0.27	Lung cancer in ever smokers;	chr6:27887847	chr6:28943877~28944537:+
HNSC	trans	rs67340775	0.541	rs200974	ENSG00000204709.4	LINC01556	6.04	3.15e-09	0.00486	0.42	0.27	Lung cancer in ever smokers;	chr6:27888067	chr6:28943877~28944537:+
HNSC	trans	rs2286492	1	rs75393023	ENSG00000273391.1	RP11-634H22.1	-6.04	3.15e-09	0.00487	-0.5	-0.27	Bipolar disorder;	chr7:22942323	chr7:139359032~139359566:-
HNSC	trans	rs4713118	0.614	rs9380007	ENSG00000204709.4	LINC01556	6.04	3.16e-09	0.00487	0.32	0.27	Parkinson's disease;	chr6:27692729	chr6:28943877~28944537:+
HNSC	trans	rs17607347	0.779	rs2860346	ENSG00000265201.1	MIR4677	6.04	3.16e-09	0.00488	0.35	0.27	Intelligence (multi-trait analysis);	chr16:72558410	chr1:243346176~243346255:+
HNSC	trans	rs7617480	0.616	rs7429596	ENSG00000197582.5	GPX1P1	6.04	3.17e-09	0.00489	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chrX:13378735~13379340:-
HNSC	trans	rs2250402	0.51	rs7535	ENSG00000234106.3	RP11-288E14.2	6.04	3.18e-09	0.00491	0.59	0.27	Corneal curvature;	chr15:40036374	chr11:93535468~93535816:+
HNSC	trans	rs1908814	0.504	rs7830734	ENSG00000173295.6	FAM86B3P	6.04	3.19e-09	0.00492	0.3	0.27	Neuroticism;	chr8:11938130	chr8:8228595~8244865:+
HNSC	trans	rs6087990	0.735	rs2424914	ENSG00000253915.1	MAPRE1P1	6.04	3.19e-09	0.00492	0.32	0.27	Ulcerative colitis;	chr20:32786714	chr8:135625185~135625981:-
HNSC	trans	rs56176327	0.583	rs7613603	ENSG00000197582.5	GPX1P1	-6.04	3.19e-09	0.00493	-0.44	-0.27	Intelligence (multi-trait analysis);	chr3:49775433	chrX:13378735~13379340:-
HNSC	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-6.04	3.2e-09	0.00494	-0.32	-0.27	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
HNSC	trans	rs1039766	0.706	rs72822420	ENSG00000213985.4	AC078899.1	-6.04	3.2e-09	0.00494	-0.41	-0.27	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr19:20257720~20259418:+
HNSC	trans	rs1568889	0.838	rs11030230	ENSG00000174912.7	METTL15P1	6.04	3.21e-09	0.00495	0.28	0.27	Bipolar disorder;	chr11:28153084	chr3:156713884~156714928:-
HNSC	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	6.04	3.22e-09	0.00496	0.34	0.27	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
HNSC	trans	rs1355223	0.506	rs12294339	ENSG00000225531.1	RP11-196I18.3	6.04	3.22e-09	0.00497	0.34	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34838652	chr9:107116829~107117557:+
HNSC	trans	rs17301013	0.897	rs1793291	ENSG00000213331.4	RP11-713C19.2	-6.04	3.23e-09	0.00498	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174822675	chr4:187970273~187971284:+
HNSC	trans	rs79149102	0.522	rs1030888	ENSG00000227288.3	RP5-837I24.1	6.04	3.23e-09	0.00498	0.56	0.27	Lung cancer;	chr15:74550982	chr1:81501794~81503468:+
HNSC	trans	rs73108077	0.621	rs7261582	ENSG00000279352.1	RP11-411B10.7	6.03	3.25e-09	0.00501	0.55	0.27	Red blood cell density in sickle cell anemia;	chr20:31226977	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.57	rs73119526	ENSG00000279352.1	RP11-411B10.7	6.03	3.25e-09	0.00501	0.55	0.27	Red blood cell density in sickle cell anemia;	chr20:31252117	chr18:14010054~14010917:+
HNSC	trans	rs11220237	1	rs11220261	ENSG00000236257.1	EI24P2	6.03	3.27e-09	0.00503	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125877574	chr1:158454198~158455273:+
HNSC	trans	rs9329221	0.905	rs17709397	ENSG00000173295.6	FAM86B3P	-6.03	3.28e-09	0.00505	-0.3	-0.27	Neuroticism;	chr8:10392351	chr8:8228595~8244865:+
HNSC	trans	rs7929679	0.551	rs10466455	ENSG00000225531.1	RP11-196I18.3	-6.03	3.29e-09	0.00506	-0.32	-0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34759389	chr9:107116829~107117557:+
HNSC	trans	rs7617480	0.616	rs9873227	ENSG00000197582.5	GPX1P1	6.03	3.29e-09	0.00507	0.42	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48735675	chrX:13378735~13379340:-
HNSC	trans	rs1075232	1	rs16956838	ENSG00000270055.1	CTD-3092A11.2	-6.03	3.31e-09	0.00509	-0.49	-0.27	Survival in colorectal cancer (non-distant metastatic);	chr15:31527492	chr15:30487963~30490313:+
HNSC	trans	rs11220237	1	rs12288151	ENSG00000236257.1	EI24P2	6.03	3.31e-09	0.0051	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125873344	chr1:158454198~158455273:+
HNSC	trans	rs3956705	1	rs12701265	ENSG00000176826.14	FKBP9P1	-6.03	3.32e-09	0.00511	-0.29	-0.27	Red cell distribution width;	chr7:32931624	chr7:55681074~55713252:-
HNSC	trans	rs1391708	0.504	rs11832720	ENSG00000121089.4	NACA3P	-6.03	3.32e-09	0.00511	-0.53	-0.27	Airway wall thickness;	chr12:56863460	chr4:164943290~164943937:+
HNSC	trans	rs7121616	0.563	rs4936770	ENSG00000214144.3	RP11-488L18.1	6.03	3.33e-09	0.00513	0.33	0.27	Breast cancer;	chr11:123058167	chr1:247229940~247231880:+
HNSC	trans	rs7824557	0.545	rs34482136	ENSG00000254340.1	RP11-10A14.3	-6.03	3.34e-09	0.00514	-0.32	-0.27	Retinal vascular caliber;	chr8:11370376	chr8:9141424~9145435:+
HNSC	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	6.03	3.34e-09	0.00514	0.34	0.27	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	6.03	3.34e-09	0.00514	0.34	0.27	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
HNSC	trans	rs11992162	0.967	rs10088415	ENSG00000173295.6	FAM86B3P	-6.03	3.35e-09	0.00516	-0.29	-0.27	Monocyte count;	chr8:11973316	chr8:8228595~8244865:+
HNSC	trans	rs7829975	0.659	rs4382480	ENSG00000269918.1	AF131215.9	6.03	3.36e-09	0.00517	0.26	0.27	Mood instability;	chr8:8863963	chr8:11104691~11106704:-
HNSC	trans	rs9733	0.596	rs12063547	ENSG00000180764.13	PIPSL	6.03	3.36e-09	0.00517	0.32	0.27	Tonsillectomy;	chr1:150701577	chr10:93958191~93961540:-
HNSC	trans	rs8067354	0.645	rs2665400	ENSG00000187870.7	RNFT1P3	6.03	3.36e-09	0.00517	0.35	0.27	Hemoglobin concentration;	chr17:59802840	chr17:20743333~20754501:-
HNSC	trans	rs7647973	0.626	rs9870858	ENSG00000197582.5	GPX1P1	6.03	3.37e-09	0.00518	0.44	0.27	Menarche (age at onset);	chr3:49731638	chrX:13378735~13379340:-
HNSC	trans	rs56176327	0.532	rs9849038	ENSG00000197582.5	GPX1P1	6.03	3.37e-09	0.00518	0.44	0.27	Intelligence (multi-trait analysis);	chr3:49734557	chrX:13378735~13379340:-
HNSC	trans	rs3806843	0.735	rs2563333	ENSG00000231043.3	AC007238.1	6.03	3.38e-09	0.0052	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr2:58460292~58462032:-
HNSC	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	6.03	3.39e-09	0.0052	0.34	0.27	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs68188794	ENSG00000204622.9	HLA-J	-6.03	3.41e-09	0.00524	-0.62	-0.27	Depression;	chr6:28112999	chr6:30006583~30009956:+
HNSC	trans	rs7647973	0.554	rs13096480	ENSG00000197582.5	GPX1P1	6.03	3.42e-09	0.00525	0.45	0.27	Menarche (age at onset);	chr3:49620651	chrX:13378735~13379340:-
HNSC	trans	rs1023500	1	rs1023498	ENSG00000268568.1	AC007228.9	-6.02	3.44e-09	0.00528	-0.36	-0.27	Schizophrenia;	chr22:41944565	chr19:56672574~56673901:-
HNSC	trans	rs7873102	0.901	rs776015	ENSG00000229007.1	EXOSC3P1	-6.02	3.44e-09	0.00529	-0.33	-0.27	Brain structure;	chr9:37942155	chr21:32496812~32497311:+
HNSC	trans	rs7930295	0.632	rs12099165	ENSG00000236257.1	EI24P2	6.02	3.44e-09	0.00529	0.38	0.27	Schizophrenia;	chr11:125770546	chr1:158454198~158455273:+
HNSC	trans	rs853679	0.546	rs71537572	ENSG00000243753.4	HLA-L	-6.02	3.46e-09	0.00531	-0.58	-0.27	Depression;	chr6:28002937	chr6:30259584~30293014:+
HNSC	trans	rs2456568	0.503	rs4254038	ENSG00000276509.1	CH17-353B19.1	6.02	3.47e-09	0.00533	0.31	0.27	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93933812	chr1:146235806~146237807:+
HNSC	trans	rs4713118	0.869	rs9348775	ENSG00000204709.4	LINC01556	6.02	3.48e-09	0.00534	0.35	0.27	Parkinson's disease;	chr6:27727550	chr6:28943877~28944537:+
HNSC	trans	rs9630182	0.54	rs11022834	ENSG00000257675.1	RP11-641A6.9	-6.02	3.49e-09	0.00536	-0.31	-0.27	Bone mineral density;	chr11:13457817	chr12:52748776~52750127:+
HNSC	trans	rs9630182	0.561	rs10832042	ENSG00000257675.1	RP11-641A6.9	-6.02	3.49e-09	0.00536	-0.31	-0.27	Bone mineral density;	chr11:13459877	chr12:52748776~52750127:+
HNSC	trans	rs6831352	1	rs10017466	ENSG00000233859.2	ADH5P4	-6.02	3.52e-09	0.0054	-0.3	-0.27	Alcohol dependence;	chr4:99134649	chr6:65836930~65838039:-
HNSC	trans	rs2898290	0.622	rs11250140	ENSG00000173295.6	FAM86B3P	-6.02	3.52e-09	0.0054	-0.29	-0.27	Systolic blood pressure;	chr8:11489083	chr8:8228595~8244865:+
HNSC	trans	rs902774	0.818	rs73110464	ENSG00000224520.2	KRT8P45	-6.02	3.53e-09	0.00542	-0.47	-0.27	Prostate cancer;	chr12:52918828	chr1:157073257~157074703:+
HNSC	trans	rs864643	0.588	rs604869	ENSG00000183298.5	RP11-556K13.1	6.02	3.54e-09	0.00543	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39486307	chr1:101786340~101787219:-
HNSC	trans	rs853679	0.607	rs35902873	ENSG00000243753.4	HLA-L	-6.02	3.54e-09	0.00543	-0.6	-0.27	Depression;	chr6:28091171	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13197574	ENSG00000243753.4	HLA-L	-6.02	3.54e-09	0.00543	-0.6	-0.27	Depression;	chr6:28092461	chr6:30259584~30293014:+
HNSC	trans	rs11220237	1	rs11220221	ENSG00000236257.1	EI24P2	6.02	3.55e-09	0.00544	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125796232	chr1:158454198~158455273:+
HNSC	trans	rs9630182	0.619	rs10832041	ENSG00000257675.1	RP11-641A6.9	-6.02	3.56e-09	0.00545	-0.31	-0.27	Bone mineral density;	chr11:13452426	chr12:52748776~52750127:+
HNSC	trans	rs2898290	0.622	rs1600250	ENSG00000173295.6	FAM86B3P	-6.02	3.56e-09	0.00545	-0.29	-0.27	Systolic blood pressure;	chr8:11487916	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.718	rs72751662	ENSG00000235370.6	DNM1P51	-6.02	3.56e-09	0.00546	-0.42	-0.27	Excessive daytime sleepiness;	chr15:82594705	chr15:84398316~84411701:-
HNSC	trans	rs1568889	0.838	rs10835276	ENSG00000174912.7	METTL15P1	6.02	3.57e-09	0.00547	0.28	0.27	Bipolar disorder;	chr11:28145600	chr3:156713884~156714928:-
HNSC	trans	rs13416322	0.699	rs6716167	ENSG00000214286.2	PDCL3P3	6.02	3.59e-09	0.0055	0.4	0.27	Intelligence (multi-trait analysis);	chr2:100550092	chr3:17877455~17878169:-
HNSC	trans	rs17301013	0.861	rs2038025	ENSG00000213331.4	RP11-713C19.2	6.02	3.59e-09	0.0055	0.32	0.27	Systemic lupus erythematosus;	chr1:174574712	chr4:187970273~187971284:+
HNSC	trans	rs1816752	0.837	rs7324645	ENSG00000224976.2	PARP4P2	-6.02	3.59e-09	0.0055	-0.32	-0.27	Obesity-related traits;	chr13:24426717	chr13:19349137~19407962:+
HNSC	trans	rs9393777	0.778	rs4452638	ENSG00000253570.1	RNF5P1	-6.02	3.6e-09	0.00552	-0.54	-0.27	Intelligence (multi-trait analysis);	chr6:27261486	chr8:38600661~38601200:-
HNSC	trans	rs67340775	0.834	rs13218875	ENSG00000243753.4	HLA-L	-6.01	3.65e-09	0.00558	-0.57	-0.27	Lung cancer in ever smokers;	chr6:27916234	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs67040724	ENSG00000243753.4	HLA-L	-6.01	3.65e-09	0.00558	-0.57	-0.27	Depression;	chr6:27937731	chr6:30259584~30293014:+
HNSC	trans	rs11220237	1	rs11220237	ENSG00000236257.1	EI24P2	6.01	3.65e-09	0.00558	0.41	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838942	chr1:158454198~158455273:+
HNSC	trans	rs3806843	0.868	rs2262574	ENSG00000231043.3	AC007238.1	6.01	3.65e-09	0.00558	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr2:58460292~58462032:-
HNSC	trans	rs714543	0.967	rs12536807	ENSG00000226038.5	PPIAP21	-6.01	3.66e-09	0.0056	-0.32	-0.27	Plateletcrit;	chr7:44838675	chr20:43230760~43231260:+
HNSC	trans	rs714543	0.967	rs10951776	ENSG00000226038.5	PPIAP21	-6.01	3.66e-09	0.0056	-0.32	-0.27	Plateletcrit;	chr7:44858152	chr20:43230760~43231260:+
HNSC	trans	rs1908814	0.51	rs57655799	ENSG00000173295.6	FAM86B3P	6.01	3.67e-09	0.00561	0.29	0.27	Neuroticism;	chr8:11924908	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.74	rs7002282	ENSG00000253893.2	FAM85B	6.01	3.68e-09	0.00563	0.32	0.27	Neuroticism;	chr8:10809483	chr8:8167819~8226614:-
HNSC	trans	rs7617480	0.648	rs6766238	ENSG00000197582.5	GPX1P1	6.01	3.69e-09	0.00564	0.41	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chrX:13378735~13379340:-
HNSC	trans	rs2967605	1	rs2967605	ENSG00000227097.5	RPS28P7	6.01	3.69e-09	0.00565	0.39	0.27	HDL cholesterol;	chr19:8404854	chr11:82689559~82689768:+
HNSC	trans	rs17301013	0.861	rs332796	ENSG00000213331.4	RP11-713C19.2	6.01	3.7e-09	0.00566	0.32	0.27	Systemic lupus erythematosus;	chr1:174727142	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.861	rs332799	ENSG00000213331.4	RP11-713C19.2	6.01	3.7e-09	0.00566	0.32	0.27	Systemic lupus erythematosus;	chr1:174731110	chr4:187970273~187971284:+
HNSC	trans	rs10435719	0.746	rs58007588	ENSG00000173295.6	FAM86B3P	6.01	3.7e-09	0.00566	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:8228595~8244865:+
HNSC	trans	rs4879656	0.564	rs1537253	ENSG00000215007.3	DNAJA1P3	-6.01	3.71e-09	0.00567	-0.32	-0.27	Menopause (age at onset);	chr9:32983373	chrX:107351650~107352843:-
HNSC	trans	rs941207	0.514	rs6581105	ENSG00000257210.1	NACAP3	-6.01	3.71e-09	0.00567	-0.34	-0.27	Platelet count;	chr12:56792184	chr12:93124063~93124543:-
HNSC	trans	rs722599	1	rs722599	ENSG00000181227.3	RP4-682C21.2	6.01	3.72e-09	0.00568	0.27	0.27	IgG glycosylation;	chr14:74860740	chr1:75743423~75744776:-
HNSC	trans	rs9393777	0.622	rs13191326	ENSG00000253570.1	RNF5P1	6.01	3.73e-09	0.0057	0.56	0.27	Intelligence (multi-trait analysis);	chr6:27063250	chr8:38600661~38601200:-
HNSC	trans	rs9733	0.621	rs932054	ENSG00000180764.13	PIPSL	6.01	3.73e-09	0.0057	0.33	0.27	Tonsillectomy;	chr1:150567391	chr10:93958191~93961540:-
HNSC	trans	rs12439619	0.508	rs11856561	ENSG00000235370.6	DNM1P51	-6.01	3.73e-09	0.0057	-0.33	-0.27	Intelligence (multi-trait analysis);	chr15:82161415	chr15:84398316~84411701:-
HNSC	trans	rs1355223	0.525	rs10836316	ENSG00000225531.1	RP11-196I18.3	6.01	3.75e-09	0.00573	0.34	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852748	chr9:107116829~107117557:+
HNSC	trans	rs6424115	1	rs35385477	ENSG00000228217.1	AL390877.1	-6.01	3.77e-09	0.00575	-0.33	-0.27	Immature fraction of reticulocytes;	chr1:23829434	chr1:117778087~117778506:-
HNSC	trans	rs9650657	0.711	rs10100209	ENSG00000253893.2	FAM85B	6.01	3.78e-09	0.00576	0.34	0.27	Neuroticism;	chr8:10726702	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.546	rs35017208	ENSG00000243753.4	HLA-L	-6.01	3.78e-09	0.00577	-0.59	-0.27	Depression;	chr6:28377505	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs36092177	ENSG00000243753.4	HLA-L	-6.01	3.78e-09	0.00577	-0.59	-0.27	Depression;	chr6:28390030	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs2232429	ENSG00000243753.4	HLA-L	-6.01	3.78e-09	0.00577	-0.59	-0.27	Depression;	chr6:28391855	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs2232426	ENSG00000243753.4	HLA-L	-6.01	3.78e-09	0.00577	-0.59	-0.27	Depression;	chr6:28392882	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs2232423	ENSG00000243753.4	HLA-L	-6.01	3.78e-09	0.00577	-0.59	-0.27	Depression;	chr6:28398374	chr6:30259584~30293014:+
HNSC	trans	rs67340775	0.541	rs200965	ENSG00000204709.4	LINC01556	6.01	3.78e-09	0.00577	0.42	0.27	Lung cancer in ever smokers;	chr6:27898606	chr6:28943877~28944537:+
HNSC	trans	rs2898290	0.593	rs1600252	ENSG00000173295.6	FAM86B3P	-6.01	3.79e-09	0.00579	-0.29	-0.27	Systolic blood pressure;	chr8:11488135	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.542	rs1903370	ENSG00000257210.1	NACAP3	-6.01	3.79e-09	0.00579	-0.33	-0.27	Platelet count;	chr12:56812900	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.804	rs7980317	ENSG00000228224.3	NACAP1	6.01	3.8e-09	0.00579	0.29	0.27	Platelet distribution width;	chr12:56764399	chr8:101361794~101372707:+
HNSC	trans	rs4948102	0.731	rs10229446	ENSG00000215006.4	CHCHD2P2	6.01	3.83e-09	0.00584	0.37	0.27	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr5:69333929~69334249:+
HNSC	trans	rs853679	0.607	rs34661125	ENSG00000243753.4	HLA-L	-6.01	3.85e-09	0.00586	-0.56	-0.27	Depression;	chr6:28314117	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13190888	ENSG00000243753.4	HLA-L	-6.01	3.85e-09	0.00586	-0.56	-0.27	Depression;	chr6:28318208	chr6:30259584~30293014:+
HNSC	trans	rs1816752	0.87	rs9581025	ENSG00000224976.2	PARP4P2	-6	3.87e-09	0.0059	-0.31	-0.27	Obesity-related traits;	chr13:24423687	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs9581026	ENSG00000224976.2	PARP4P2	-6	3.87e-09	0.0059	-0.31	-0.27	Obesity-related traits;	chr13:24423788	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs9581027	ENSG00000224976.2	PARP4P2	-6	3.87e-09	0.0059	-0.31	-0.27	Obesity-related traits;	chr13:24423790	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.87	rs9318529	ENSG00000224976.2	PARP4P2	-6	3.87e-09	0.0059	-0.31	-0.27	Obesity-related traits;	chr13:24424190	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs9511249	ENSG00000224976.2	PARP4P2	-6	3.87e-09	0.0059	-0.31	-0.27	Obesity-related traits;	chr13:24425457	chr13:19349137~19407962:+
HNSC	trans	rs8067354	0.645	rs2645489	ENSG00000187870.7	RNFT1P3	6	3.88e-09	0.00592	0.35	0.27	Hemoglobin concentration;	chr17:59806010	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.645	rs2645486	ENSG00000187870.7	RNFT1P3	6	3.88e-09	0.00592	0.35	0.27	Hemoglobin concentration;	chr17:59808540	chr17:20743333~20754501:-
HNSC	trans	rs8067354	0.645	rs2645487	ENSG00000187870.7	RNFT1P3	6	3.88e-09	0.00592	0.35	0.27	Hemoglobin concentration;	chr17:59808764	chr17:20743333~20754501:-
HNSC	trans	rs1051424	0.642	rs115869798	ENSG00000187870.7	RNFT1P3	6	3.88e-09	0.00592	0.35	0.27	Obesity-related traits;	chr17:59815468	chr17:20743333~20754501:-
HNSC	trans	rs9467711	0.524	rs13216484	ENSG00000253570.1	RNF5P1	6	3.89e-09	0.00593	0.6	0.27	Autism spectrum disorder or schizophrenia;	chr6:26739799	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.584	rs34244947	ENSG00000253570.1	RNF5P1	6	3.89e-09	0.00593	0.6	0.27	Autism spectrum disorder or schizophrenia;	chr6:26740141	chr8:38600661~38601200:-
HNSC	trans	rs11220237	1	rs10893434	ENSG00000236257.1	EI24P2	6	3.89e-09	0.00593	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125836029	chr1:158454198~158455273:+
HNSC	trans	rs1568889	0.838	rs7125749	ENSG00000174912.7	METTL15P1	6	3.9e-09	0.00594	0.28	0.27	Bipolar disorder;	chr11:28133145	chr3:156713884~156714928:-
HNSC	trans	rs1568889	0.838	rs10835273	ENSG00000174912.7	METTL15P1	6	3.9e-09	0.00594	0.28	0.27	Bipolar disorder;	chr11:28135051	chr3:156713884~156714928:-
HNSC	trans	rs7647973	0.593	rs7620848	ENSG00000197582.5	GPX1P1	-6	3.9e-09	0.00594	-0.44	-0.27	Menarche (age at onset);	chr3:49790588	chrX:13378735~13379340:-
HNSC	trans	rs17301013	0.861	rs333418	ENSG00000213331.4	RP11-713C19.2	6	3.9e-09	0.00594	0.32	0.27	Systemic lupus erythematosus;	chr1:174707294	chr4:187970273~187971284:+
HNSC	trans	rs7647973	0.566	rs57630346	ENSG00000197582.5	GPX1P1	6	3.91e-09	0.00596	0.42	0.27	Menarche (age at onset);	chr3:49048782	chrX:13378735~13379340:-
HNSC	trans	rs941207	0.526	rs2242497	ENSG00000257210.1	NACAP3	-6	3.92e-09	0.00596	-0.31	-0.27	Platelet count;	chr12:56598846	chr12:93124063~93124543:-
HNSC	trans	rs8177876	0.642	rs12445303	ENSG00000224837.1	GCSHP5	-6	3.93e-09	0.00598	-0.45	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr1:168055901~168056422:-
HNSC	trans	rs853679	0.607	rs13208096	ENSG00000176998.4	HCG4	-6	3.93e-09	0.00598	-0.51	-0.27	Depression;	chr6:28257533	chr6:29791753~29792750:-
HNSC	trans	rs941207	0.805	rs2958139	ENSG00000228224.3	NACAP1	-6	3.93e-09	0.00599	-0.34	-0.27	Platelet count;	chr12:56610884	chr8:101361794~101372707:+
HNSC	trans	rs11250098	0.516	rs7843666	ENSG00000173295.6	FAM86B3P	-6	3.94e-09	0.00599	-0.3	-0.27	Morning vs. evening chronotype;	chr8:10884549	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.614	rs2736286	ENSG00000254340.1	RP11-10A14.3	-6	3.94e-09	0.006	-0.31	-0.27	Retinal vascular caliber;	chr8:11369595	chr8:9141424~9145435:+
HNSC	trans	rs7121616	0.562	rs7131452	ENSG00000256356.1	HSPA8P5	6	3.94e-09	0.006	0.32	0.27	Breast cancer;	chr11:123065314	chr12:4097451~4099519:+
HNSC	trans	rs1355223	0.506	rs7131272	ENSG00000225531.1	RP11-196I18.3	-6	3.94e-09	0.006	-0.34	-0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848001	chr9:107116829~107117557:+
HNSC	trans	rs10435719	0.744	rs11250175	ENSG00000173295.6	FAM86B3P	6	3.95e-09	0.00601	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs13279577	ENSG00000173295.6	FAM86B3P	6	3.95e-09	0.00601	0.3	0.27	Neuroticism;	chr8:11935587	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs10112958	ENSG00000173295.6	FAM86B3P	6	3.95e-09	0.00601	0.3	0.27	Neuroticism;	chr8:11935631	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs10113042	ENSG00000173295.6	FAM86B3P	6	3.95e-09	0.00601	0.3	0.27	Neuroticism;	chr8:11935669	chr8:8228595~8244865:+
HNSC	trans	rs138024639	1	rs138024639	ENSG00000243753.4	HLA-L	-6	3.95e-09	0.00602	-0.63	-0.27	Breast cancer;	chr6:28468244	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.546	rs55690788	ENSG00000243753.4	HLA-L	-6	3.95e-09	0.00602	-0.63	-0.27	Depression;	chr6:28468368	chr6:30259584~30293014:+
HNSC	trans	rs1816752	0.905	rs9511242	ENSG00000224976.2	PARP4P2	-6	3.96e-09	0.00603	-0.31	-0.27	Obesity-related traits;	chr13:24419261	chr13:19349137~19407962:+
HNSC	trans	rs1816752	0.905	rs7317850	ENSG00000224976.2	PARP4P2	-6	3.96e-09	0.00603	-0.31	-0.27	Obesity-related traits;	chr13:24419899	chr13:19349137~19407962:+
HNSC	trans	rs853679	0.607	rs67662114	ENSG00000243753.4	HLA-L	-6	3.97e-09	0.00603	-0.57	-0.27	Depression;	chr6:27964523	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13216117	ENSG00000243753.4	HLA-L	-6	3.97e-09	0.00603	-0.57	-0.27	Depression;	chr6:27970706	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs36101351	ENSG00000243753.4	HLA-L	-6	3.97e-09	0.00603	-0.57	-0.27	Depression;	chr6:27975591	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs28360499	ENSG00000243753.4	HLA-L	-6	3.97e-09	0.00603	-0.57	-0.27	Depression;	chr6:27977618	chr6:30259584~30293014:+
HNSC	trans	rs1908814	0.516	rs13252853	ENSG00000173295.6	FAM86B3P	6	3.99e-09	0.00607	0.3	0.27	Neuroticism;	chr8:11935465	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs13252854	ENSG00000173295.6	FAM86B3P	6	3.99e-09	0.00607	0.3	0.27	Neuroticism;	chr8:11935469	chr8:8228595~8244865:+
HNSC	trans	rs17507216	0.628	rs28371837	ENSG00000235370.6	DNM1P51	-6	4e-09	0.00608	-0.41	-0.27	Excessive daytime sleepiness;	chr15:82714435	chr15:84398316~84411701:-
HNSC	trans	rs17301013	0.794	rs1793293	ENSG00000213331.4	RP11-713C19.2	-6	4e-09	0.00609	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174774451	chr4:187970273~187971284:+
HNSC	trans	rs7819412	0.775	rs2001329	ENSG00000254340.1	RP11-10A14.3	-6	4.02e-09	0.00611	-0.32	-0.27	Triglycerides;	chr8:11129349	chr8:9141424~9145435:+
HNSC	trans	rs7647973	0.626	rs12715437	ENSG00000197582.5	GPX1P1	6	4.02e-09	0.00611	0.44	0.27	Menarche (age at onset);	chr3:49714423	chrX:13378735~13379340:-
HNSC	trans	rs2898290	0.622	rs7829381	ENSG00000173295.6	FAM86B3P	-6	4.02e-09	0.00612	-0.29	-0.27	Systolic blood pressure;	chr8:11487064	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs10113062	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11935740	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs10113145	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11935786	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs4367597	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11936020	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.899	rs9329251	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.773	rs7842810	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs7812563	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11936979	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs13281077	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11937305	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs13281315	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11937346	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs4840597	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Neuroticism;	chr8:11938559	chr8:8228595~8244865:+
HNSC	trans	rs804280	0.509	rs4841639	ENSG00000173295.6	FAM86B3P	6	4.03e-09	0.00612	0.3	0.27	Myopia (pathological);	chr8:11938584	chr8:8228595~8244865:+
HNSC	trans	rs2280018	0.963	rs11075255	ENSG00000250569.1	NTAN1P2	6	4.03e-09	0.00612	0.32	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr8:86481754~86483002:-
HNSC	trans	rs11220237	0.841	rs7118459	ENSG00000236257.1	EI24P2	6	4.03e-09	0.00612	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125867837	chr1:158454198~158455273:+
HNSC	trans	rs7647973	0.626	rs1352889	ENSG00000197582.5	GPX1P1	6	4.03e-09	0.00613	0.44	0.27	Menarche (age at onset);	chr3:49614715	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs4855833	ENSG00000197582.5	GPX1P1	6	4.03e-09	0.00613	0.44	0.27	Menarche (age at onset);	chr3:49620008	chrX:13378735~13379340:-
HNSC	trans	rs867371	0.929	rs1045508	ENSG00000259295.5	CSPG4P12	5.99	4.08e-09	0.00619	0.33	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:85191438~85213905:+
HNSC	trans	rs853679	0.769	rs7752608	ENSG00000243753.4	HLA-L	-5.99	4.08e-09	0.0062	-0.52	-0.27	Depression;	chr6:28333418	chr6:30259584~30293014:+
HNSC	trans	rs1908814	0.516	rs7825529	ENSG00000173295.6	FAM86B3P	5.99	4.09e-09	0.0062	0.3	0.27	Neuroticism;	chr8:11936935	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.905	rs2000153	ENSG00000224976.2	PARP4P2	-5.99	4.09e-09	0.0062	-0.32	-0.27	Obesity-related traits;	chr13:24405752	chr13:19349137~19407962:+
HNSC	trans	rs7824557	0.564	rs7839307	ENSG00000173295.6	FAM86B3P	5.99	4.1e-09	0.00623	0.3	0.27	Retinal vascular caliber;	chr8:11341283	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.929	rs2958155	ENSG00000228224.3	NACAP1	5.99	4.11e-09	0.00623	0.29	0.27	Platelet distribution width;	chr12:56670761	chr8:101361794~101372707:+
HNSC	trans	rs853679	0.607	rs33932084	ENSG00000243753.4	HLA-L	-5.99	4.14e-09	0.00628	-0.58	-0.27	Depression;	chr6:28301047	chr6:30259584~30293014:+
HNSC	trans	rs4970988	0.501	rs11204713	ENSG00000180764.13	PIPSL	-5.99	4.15e-09	0.00629	-0.32	-0.27	Urate levels;	chr1:150722147	chr10:93958191~93961540:-
HNSC	trans	rs6087990	0.731	rs2424897	ENSG00000253915.1	MAPRE1P1	5.99	4.15e-09	0.0063	0.31	0.27	Ulcerative colitis;	chr20:32750292	chr8:135625185~135625981:-
HNSC	trans	rs911186	0.509	rs6934329	ENSG00000253570.1	RNF5P1	5.99	4.16e-09	0.00631	0.43	0.27	Autism spectrum disorder or schizophrenia;	chr6:27190254	chr8:38600661~38601200:-
HNSC	trans	rs7937890	0.559	rs2575838	ENSG00000236360.2	RP11-334A14.2	5.99	4.18e-09	0.00634	0.35	0.27	Mitochondrial DNA levels;	chr11:14476675	chr1:52993201~52993702:-
HNSC	trans	rs34421088	0.559	rs12386974	ENSG00000253893.2	FAM85B	-5.99	4.19e-09	0.00635	-0.31	-0.27	Neuroticism;	chr8:11543119	chr8:8167819~8226614:-
HNSC	trans	rs13016963	0.546	rs11691602	ENSG00000235105.1	RP11-329A14.1	5.99	4.19e-09	0.00635	0.32	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201362976	chr1:48435967~48437223:+
HNSC	trans	rs6831352	0.918	rs13138294	ENSG00000233859.2	ADH5P4	5.99	4.19e-09	0.00635	0.32	0.27	Alcohol dependence;	chr4:99141524	chr6:65836930~65838039:-
HNSC	trans	rs7647973	0.626	rs11709734	ENSG00000197582.5	GPX1P1	5.99	4.2e-09	0.00637	0.43	0.27	Menarche (age at onset);	chr3:49707802	chrX:13378735~13379340:-
HNSC	trans	rs56176327	0.6	rs7628207	ENSG00000197582.5	GPX1P1	5.99	4.2e-09	0.00637	0.43	0.27	Intelligence (multi-trait analysis);	chr3:49717537	chrX:13378735~13379340:-
HNSC	trans	rs1355223	0.525	rs7129533	ENSG00000225531.1	RP11-196I18.3	5.99	4.21e-09	0.00639	0.33	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850745	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.525	rs55796371	ENSG00000225531.1	RP11-196I18.3	5.99	4.21e-09	0.00639	0.33	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851222	chr9:107116829~107117557:+
HNSC	trans	rs1355223	0.525	rs12280958	ENSG00000225531.1	RP11-196I18.3	5.99	4.21e-09	0.00639	0.33	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851252	chr9:107116829~107117557:+
HNSC	trans	rs9393777	0.92	rs13196692	ENSG00000253570.1	RNF5P1	5.99	4.22e-09	0.0064	0.63	0.27	Intelligence (multi-trait analysis);	chr6:27411340	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	5.99	4.23e-09	0.0064	0.33	0.27	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-5.99	4.24e-09	0.00642	-0.34	-0.27	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
HNSC	trans	rs7520050	0.966	rs12409773	ENSG00000255397.1	AC022182.2	5.99	4.24e-09	0.00642	0.32	0.27	Reticulocyte count;Red blood cell count;	chr1:45893159	chr8:60937705~60939871:-
HNSC	trans	rs7520050	1	rs12410070	ENSG00000255397.1	AC022182.2	5.99	4.24e-09	0.00642	0.32	0.27	Reticulocyte count;Red blood cell count;	chr1:45893210	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs12410071	ENSG00000255397.1	AC022182.2	5.99	4.24e-09	0.00642	0.32	0.27	Reticulocyte count;Red blood cell count;	chr1:45893214	chr8:60937705~60939871:-
HNSC	trans	rs11220237	0.92	rs10893426	ENSG00000236257.1	EI24P2	5.99	4.24e-09	0.00642	0.38	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778426	chr1:158454198~158455273:+
HNSC	trans	rs7930295	0.632	rs12271647	ENSG00000236257.1	EI24P2	5.99	4.24e-09	0.00642	0.4	0.27	Schizophrenia;	chr11:125754161	chr1:158454198~158455273:+
HNSC	trans	rs1568889	0.838	rs4572130	ENSG00000174912.7	METTL15P1	5.99	4.25e-09	0.00643	0.28	0.27	Bipolar disorder;	chr11:28350247	chr3:156713884~156714928:-
HNSC	trans	rs7647973	0.626	rs1078341	ENSG00000197582.5	GPX1P1	5.98	4.33e-09	0.00654	0.43	0.27	Menarche (age at onset);	chr3:49648159	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs7637711	ENSG00000197582.5	GPX1P1	-5.98	4.34e-09	0.00656	-0.44	-0.27	Menarche (age at onset);	chr3:49792220	chrX:13378735~13379340:-
HNSC	trans	rs2950393	0.895	rs2958154	ENSG00000228224.3	NACAP1	-5.98	4.34e-09	0.00656	-0.3	-0.27	Platelet distribution width;	chr12:56671929	chr8:101361794~101372707:+
HNSC	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	5.98	4.34e-09	0.00656	0.34	0.27	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
HNSC	trans	rs10435719	0.902	rs7459983	ENSG00000173295.6	FAM86B3P	5.98	4.34e-09	0.00657	0.3	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.607	rs56189111	ENSG00000243753.4	HLA-L	-5.98	4.34e-09	0.00657	-0.59	-0.27	Depression;	chr6:28304196	chr6:30259584~30293014:+
HNSC	trans	rs9467711	0.606	rs9379855	ENSG00000176998.4	HCG4	5.98	4.35e-09	0.00658	0.48	0.27	Autism spectrum disorder or schizophrenia;	chr6:26364702	chr6:29791753~29792750:-
HNSC	trans	rs864643	1	rs1708002	ENSG00000183298.5	RP11-556K13.1	5.98	4.37e-09	0.0066	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39511185	chr1:101786340~101787219:-
HNSC	trans	rs13416322	0.699	rs6730933	ENSG00000214286.2	PDCL3P3	5.98	4.37e-09	0.00661	0.4	0.27	Intelligence (multi-trait analysis);	chr2:100545642	chr3:17877455~17878169:-
HNSC	trans	rs6756513	0.505	rs17037076	ENSG00000232654.1	FAM136BP	5.98	4.4e-09	0.00665	0.35	0.27	Breast cancer;Platelet count;	chr2:69806517	chr6:3045384~3045800:+
HNSC	trans	rs673253	0.662	rs61769611	ENSG00000231007.5	CDC20P1	5.98	4.4e-09	0.00666	0.39	0.27	Intelligence (multi-trait analysis);	chr1:43563242	chr9:87011652~87013151:+
HNSC	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-5.98	4.41e-09	0.00666	-0.34	-0.27	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
HNSC	trans	rs1816752	0.905	rs4769348	ENSG00000224976.2	PARP4P2	-5.98	4.41e-09	0.00667	-0.32	-0.27	Obesity-related traits;	chr13:24400975	chr13:19349137~19407962:+
HNSC	trans	rs17073641	0.534	rs12953568	ENSG00000214846.4	RP11-115L11.1	-5.98	4.41e-09	0.00667	-0.32	-0.27	Age-related macular degeneration (smoking status interaction);	chr18:64722914	chr4:15730962~15731627:-
HNSC	trans	rs7937890	0.559	rs2167160	ENSG00000236360.2	RP11-334A14.2	5.98	4.42e-09	0.00667	0.35	0.27	Mitochondrial DNA levels;	chr11:14485903	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597217	ENSG00000236360.2	RP11-334A14.2	5.98	4.42e-09	0.00667	0.35	0.27	Mitochondrial DNA levels;	chr11:14511337	chr1:52993201~52993702:-
HNSC	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-5.98	4.45e-09	0.00672	-0.34	-0.27	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
HNSC	trans	rs7746199	0.736	rs72845070	ENSG00000228078.1	HLA-U	-5.98	4.49e-09	0.00678	-0.61	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:29934101~29934286:+
HNSC	trans	rs2950393	0.804	rs3214051	ENSG00000228224.3	NACAP1	5.98	4.5e-09	0.00679	0.29	0.27	Platelet distribution width;	chr12:56725452	chr8:101361794~101372707:+
HNSC	trans	rs513349	0.964	rs210139	ENSG00000175730.8	BAK1P1	5.98	4.5e-09	0.00679	0.3	0.27	Platelet count;	chr6:33575632	chr20:32690180~32690815:-
HNSC	trans	rs804280	0.542	rs35647515	ENSG00000173295.6	FAM86B3P	5.98	4.51e-09	0.00681	0.3	0.27	Myopia (pathological);	chr8:11934120	chr8:8228595~8244865:+
HNSC	trans	rs714543	1	rs1990053	ENSG00000226038.5	PPIAP21	-5.98	4.51e-09	0.00681	-0.32	-0.27	Plateletcrit;	chr7:44886297	chr20:43230760~43231260:+
HNSC	trans	rs714543	0.935	rs2331174	ENSG00000226038.5	PPIAP21	-5.98	4.51e-09	0.00681	-0.32	-0.27	Plateletcrit;	chr7:44887228	chr20:43230760~43231260:+
HNSC	trans	rs7929679	0.521	rs7122506	ENSG00000225531.1	RP11-196I18.3	5.98	4.53e-09	0.00684	0.32	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34765306	chr9:107116829~107117557:+
HNSC	trans	rs11220237	0.92	rs1365081	ENSG00000236257.1	EI24P2	-5.98	4.54e-09	0.00685	-0.38	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778087	chr1:158454198~158455273:+
HNSC	trans	rs14057	0.86	rs731024	ENSG00000215869.3	RP11-364B6.1	-5.98	4.55e-09	0.00686	-0.32	-0.27	Systolic blood pressure;	chr1:6584663	chr1:104073023~104077087:+
HNSC	trans	rs2950393	0.804	rs898611	ENSG00000228224.3	NACAP1	-5.98	4.56e-09	0.00688	-0.29	-0.27	Platelet distribution width;	chr12:56769532	chr8:101361794~101372707:+
HNSC	trans	rs7769051	1	rs3813347	ENSG00000213303.3	CTC-398G3.2	5.98	4.57e-09	0.00689	0.45	0.27	Type 2 diabetes nephropathy;	chr6:132798639	chr19:11523436~11523831:+
HNSC	trans	rs853679	0.607	rs13211507	ENSG00000253570.1	RNF5P1	5.97	4.59e-09	0.00692	0.61	0.27	Depression;	chr6:28289600	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs34691223	ENSG00000253570.1	RNF5P1	5.97	4.59e-09	0.00692	0.61	0.27	Depression;	chr6:28290431	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs66868086	ENSG00000243753.4	HLA-L	-5.97	4.61e-09	0.00694	-0.57	-0.27	Depression;	chr6:27898124	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13199649	ENSG00000243753.4	HLA-L	-5.97	4.61e-09	0.00694	-0.57	-0.27	Depression;	chr6:27901014	chr6:30259584~30293014:+
HNSC	trans	rs7647973	0.626	rs11130217	ENSG00000197582.5	GPX1P1	5.97	4.61e-09	0.00694	0.43	0.27	Menarche (age at onset);	chr3:49699890	chrX:13378735~13379340:-
HNSC	trans	rs7937890	0.559	rs2575837	ENSG00000236360.2	RP11-334A14.2	5.97	4.62e-09	0.00696	0.35	0.27	Mitochondrial DNA levels;	chr11:14476455	chr1:52993201~52993702:-
HNSC	trans	rs67340775	0.541	rs169287	ENSG00000204709.4	LINC01556	5.97	4.63e-09	0.00698	0.42	0.27	Lung cancer in ever smokers;	chr6:27886982	chr6:28943877~28944537:+
HNSC	trans	rs11992162	0.933	rs10108075	ENSG00000173295.6	FAM86B3P	5.97	4.64e-09	0.00699	0.3	0.27	Monocyte count;	chr8:11974570	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.92	rs13195040	ENSG00000176998.4	HCG4	5.97	4.64e-09	0.00699	0.52	0.27	Intelligence (multi-trait analysis);	chr6:27446145	chr6:29791753~29792750:-
HNSC	trans	rs11220237	1	rs11220238	ENSG00000236257.1	EI24P2	5.97	4.64e-09	0.00699	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125839807	chr1:158454198~158455273:+
HNSC	trans	rs11220237	1	rs11220239	ENSG00000236257.1	EI24P2	5.97	4.64e-09	0.00699	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125840630	chr1:158454198~158455273:+
HNSC	trans	rs13016963	0.526	rs2110684	ENSG00000235105.1	RP11-329A14.1	5.97	4.66e-09	0.00701	0.32	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201357198	chr1:48435967~48437223:+
HNSC	trans	rs9393777	0.841	rs13207082	ENSG00000176998.4	HCG4	-5.97	4.66e-09	0.00702	-0.48	-0.27	Intelligence (multi-trait analysis);	chr6:27283600	chr6:29791753~29792750:-
HNSC	trans	rs2302190	0.882	rs7209650	ENSG00000273445.1	RP11-1399P15.1	5.97	4.67e-09	0.00704	0.31	0.27	Vitamin D levels;	chr17:58597544	chr2:87477495~87478034:-
HNSC	trans	rs34421088	0.548	rs2618443	ENSG00000253893.2	FAM85B	5.97	4.68e-09	0.00705	0.31	0.27	Neuroticism;	chr8:11527047	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.882	rs9393908	ENSG00000253570.1	RNF5P1	5.97	4.69e-09	0.00706	0.52	0.27	Depression;	chr6:28223052	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.882	rs9366717	ENSG00000253570.1	RNF5P1	5.97	4.69e-09	0.00706	0.52	0.27	Depression;	chr6:28223279	chr8:38600661~38601200:-
HNSC	trans	rs3806843	0.568	rs2530232	ENSG00000231043.3	AC007238.1	5.97	4.69e-09	0.00707	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr2:58460292~58462032:-
HNSC	trans	rs1355223	0.525	rs7129517	ENSG00000225531.1	RP11-196I18.3	5.97	4.72e-09	0.00711	0.33	0.27	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850689	chr9:107116829~107117557:+
HNSC	trans	rs7647973	0.626	rs1491985	ENSG00000197582.5	GPX1P1	5.97	4.8e-09	0.00722	0.43	0.27	Menarche (age at onset);	chr3:49702074	chrX:13378735~13379340:-
HNSC	trans	rs11220237	1	rs7124578	ENSG00000236257.1	EI24P2	5.97	4.81e-09	0.00723	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850600	chr1:158454198~158455273:+
HNSC	trans	rs853679	1	rs2799079	ENSG00000271581.1	XXbac-BPG248L24.12	-5.97	4.81e-09	0.00724	-0.39	-0.27	Depression;	chr6:28267398	chr6:31356647~31357637:+
HNSC	trans	rs7824557	0.606	rs1435277	ENSG00000254340.1	RP11-10A14.3	5.97	4.83e-09	0.00725	0.32	0.27	Retinal vascular caliber;	chr8:11339461	chr8:9141424~9145435:+
HNSC	trans	rs853679	0.607	rs34788973	ENSG00000243753.4	HLA-L	-5.97	4.83e-09	0.00726	-0.57	-0.27	Depression;	chr6:27911422	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs61742093	ENSG00000243753.4	HLA-L	-5.97	4.83e-09	0.00726	-0.57	-0.27	Depression;	chr6:27912204	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.724	rs2251473	ENSG00000173295.6	FAM86B3P	5.97	4.84e-09	0.00727	0.3	0.27	Retinal vascular caliber;	chr8:11319617	chr8:8228595~8244865:+
HNSC	trans	rs7113874	0.578	rs1026021	ENSG00000266891.1	RP11-692N5.2	-5.96	4.84e-09	0.00728	-0.41	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8543231	chr18:9734882~9735602:-
HNSC	trans	rs7824557	0.606	rs2736273	ENSG00000254340.1	RP11-10A14.3	5.96	4.84e-09	0.00728	0.32	0.27	Retinal vascular caliber;	chr8:11342429	chr8:9141424~9145435:+
HNSC	trans	rs702485	0.933	rs836559	ENSG00000249936.3	RAC1P2	5.96	4.86e-09	0.00731	0.31	0.27	HDL cholesterol levels;HDL cholesterol;	chr7:6409132	chr4:46723830~46724408:-
HNSC	trans	rs7824557	0.606	rs1047950	ENSG00000173295.6	FAM86B3P	5.96	4.86e-09	0.00731	0.3	0.27	Retinal vascular caliber;	chr8:11327587	chr8:8228595~8244865:+
HNSC	trans	rs2288327	1	rs3731746	ENSG00000269800.1	PLEKHA3P1	5.96	4.88e-09	0.00734	0.34	0.27	Atrial fibrillation;	chr2:178566270	chr19:41521043~41521989:-
HNSC	trans	rs17507216	0.628	rs4513065	ENSG00000235370.6	DNM1P51	-5.96	4.91e-09	0.00738	-0.41	-0.27	Excessive daytime sleepiness;	chr15:82712096	chr15:84398316~84411701:-
HNSC	trans	rs2274459	0.749	rs2281831	ENSG00000225246.1	RPS2P1	5.96	4.91e-09	0.00738	0.34	0.27	Obesity (extreme);	chr6:33728038	chr20:34122470~34123290:+
HNSC	trans	rs853679	0.607	rs34661125	ENSG00000253570.1	RNF5P1	5.96	4.92e-09	0.00739	0.59	0.27	Depression;	chr6:28314117	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13190888	ENSG00000253570.1	RNF5P1	5.96	4.92e-09	0.00739	0.59	0.27	Depression;	chr6:28318208	chr8:38600661~38601200:-
HNSC	trans	rs7824557	0.564	rs7828263	ENSG00000254340.1	RP11-10A14.3	-5.96	4.93e-09	0.0074	-0.32	-0.27	Retinal vascular caliber;	chr8:11374377	chr8:9141424~9145435:+
HNSC	trans	rs200986	1	rs200986	ENSG00000204709.4	LINC01556	5.96	4.94e-09	0.00742	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.539	rs200951	ENSG00000204709.4	LINC01556	5.96	4.94e-09	0.00742	0.34	0.27	Parkinson's disease;	chr6:27868152	chr6:28943877~28944537:+
HNSC	trans	rs6831352	0.918	rs34936974	ENSG00000233859.2	ADH5P4	-5.96	4.95e-09	0.00743	-0.32	-0.27	Alcohol dependence;	chr4:99131233	chr6:65836930~65838039:-
HNSC	trans	rs1991651	0.578	rs11778453	ENSG00000173295.6	FAM86B3P	-5.96	4.95e-09	0.00743	-0.3	-0.27	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:8228595~8244865:+
HNSC	trans	rs9467773	0.511	rs11755443	ENSG00000242375.1	RP11-498P14.3	5.96	4.96e-09	0.00744	0.34	0.27	Intelligence (multi-trait analysis);	chr6:26923824	chr9:97195351~97197687:-
HNSC	trans	rs9393777	0.92	rs34150729	ENSG00000253570.1	RNF5P1	5.96	4.96e-09	0.00744	0.64	0.27	Intelligence (multi-trait analysis);	chr6:27420975	chr8:38600661~38601200:-
HNSC	trans	rs9393777	0.92	rs13191227	ENSG00000253570.1	RNF5P1	5.96	4.96e-09	0.00744	0.64	0.27	Intelligence (multi-trait analysis);	chr6:27422336	chr8:38600661~38601200:-
HNSC	trans	rs11220237	1	rs7121477	ENSG00000236257.1	EI24P2	5.96	4.97e-09	0.00746	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853528	chr1:158454198~158455273:+
HNSC	trans	rs11220237	0.925	rs6590178	ENSG00000236257.1	EI24P2	5.96	4.97e-09	0.00746	0.4	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853735	chr1:158454198~158455273:+
HNSC	trans	rs7112043	1	rs7112043	ENSG00000225531.1	RP11-196I18.3	5.96	4.97e-09	0.00746	0.32	0.27	Lung disease severity in cystic fibrosis;	chr11:34767839	chr9:107116829~107117557:+
HNSC	trans	rs7647973	0.626	rs9829155	ENSG00000197582.5	GPX1P1	-5.96	4.97e-09	0.00746	-0.44	-0.27	Menarche (age at onset);	chr3:49780017	chrX:13378735~13379340:-
HNSC	trans	rs853679	0.607	rs33932084	ENSG00000253570.1	RNF5P1	5.96	4.97e-09	0.00746	0.61	0.27	Depression;	chr6:28301047	chr8:38600661~38601200:-
HNSC	trans	rs864643	0.678	rs568085	ENSG00000183298.5	RP11-556K13.1	5.96	4.98e-09	0.00747	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39472661	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.625	rs628725	ENSG00000183298.5	RP11-556K13.1	5.96	4.98e-09	0.00747	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39472887	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.625	rs570136	ENSG00000183298.5	RP11-556K13.1	5.96	4.98e-09	0.00747	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39472922	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.678	rs7615732	ENSG00000183298.5	RP11-556K13.1	5.96	4.98e-09	0.00747	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39473732	chr1:101786340~101787219:-
HNSC	trans	rs3806843	0.9	rs2563287	ENSG00000231043.3	AC007238.1	-5.96	4.99e-09	0.00748	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr2:58460292~58462032:-
HNSC	trans	rs9650657	0.648	rs6601512	ENSG00000253893.2	FAM85B	5.96	4.99e-09	0.00749	0.32	0.27	Neuroticism;	chr8:10728086	chr8:8167819~8226614:-
HNSC	trans	rs7819412	0.505	rs67849263	ENSG00000173295.6	FAM86B3P	-5.96	5.01e-09	0.00752	-0.32	-0.27	Triglycerides;	chr8:11150034	chr8:8228595~8244865:+
HNSC	trans	rs11098499	0.71	rs4145952	ENSG00000275858.1	RP11-291L22.8	5.96	5.02e-09	0.00753	0.34	0.27	Corneal astigmatism;	chr4:119234651	chr10:38450738~38451069:-
HNSC	trans	rs860295	0.65	rs2993207	ENSG00000241627.3	UBQLN4P1	5.96	5.05e-09	0.00756	0.29	0.27	Body mass index;	chr1:155903523	chr3:148985868~148987668:-
HNSC	trans	rs2950393	0.804	rs1131514	ENSG00000228224.3	NACAP1	-5.96	5.06e-09	0.00758	-0.29	-0.27	Platelet distribution width;	chr12:56739356	chr8:101361794~101372707:+
HNSC	trans	rs941207	0.507	rs1107479	ENSG00000257210.1	NACAP3	-5.96	5.07e-09	0.0076	-0.3	-0.27	Platelet count;	chr12:56636902	chr12:93124063~93124543:-
HNSC	trans	rs7769051	1	rs6910639	ENSG00000213303.3	CTC-398G3.2	5.96	5.08e-09	0.00761	0.44	0.27	Type 2 diabetes nephropathy;	chr6:132799414	chr19:11523436~11523831:+
HNSC	trans	rs7769051	1	rs12204027	ENSG00000213303.3	CTC-398G3.2	5.96	5.08e-09	0.00761	0.44	0.27	Type 2 diabetes nephropathy;	chr6:132801692	chr19:11523436~11523831:+
HNSC	trans	rs7769051	1	rs9493444	ENSG00000213303.3	CTC-398G3.2	5.96	5.08e-09	0.00761	0.44	0.27	Type 2 diabetes nephropathy;	chr6:132804181	chr19:11523436~11523831:+
HNSC	trans	rs1908814	0.516	rs60176945	ENSG00000173295.6	FAM86B3P	5.96	5.09e-09	0.00763	0.29	0.27	Neuroticism;	chr8:11939165	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs56102998	ENSG00000173295.6	FAM86B3P	5.96	5.09e-09	0.00763	0.29	0.27	Neuroticism;	chr8:11939166	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.794	rs1563897	ENSG00000257210.1	NACAP3	5.96	5.1e-09	0.00764	0.3	0.27	Platelet distribution width;	chr12:56699316	chr12:93124063~93124543:-
HNSC	trans	rs10435719	0.902	rs6601633	ENSG00000173295.6	FAM86B3P	-5.96	5.1e-09	0.00764	-0.29	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.556	rs45509595	ENSG00000253570.1	RNF5P1	5.96	5.11e-09	0.00765	0.62	0.27	Depression;	chr6:27873148	chr8:38600661~38601200:-
HNSC	trans	rs3806843	0.518	rs2569191	ENSG00000231043.3	AC007238.1	5.96	5.11e-09	0.00765	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140634318	chr2:58460292~58462032:-
HNSC	trans	rs11220237	1	rs12795730	ENSG00000236257.1	EI24P2	5.96	5.12e-09	0.00766	0.42	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125846182	chr1:158454198~158455273:+
HNSC	trans	rs7121616	0.562	rs7131452	ENSG00000241478.1	HSPA8P9	5.95	5.12e-09	0.00766	0.33	0.27	Breast cancer;	chr11:123065314	chr3:137880295~137882237:+
HNSC	trans	rs9425766	0.64	rs61827925	ENSG00000213331.4	RP11-713C19.2	5.95	5.12e-09	0.00767	0.37	0.27	Life satisfaction;	chr1:173862619	chr4:187970273~187971284:+
HNSC	trans	rs2302190	0.882	rs7210714	ENSG00000273445.1	RP11-1399P15.1	5.95	5.13e-09	0.00768	0.31	0.27	Vitamin D levels;	chr17:58598305	chr2:87477495~87478034:-
HNSC	trans	rs1568889	0.838	rs11030265	ENSG00000174912.7	METTL15P1	5.95	5.14e-09	0.00769	0.28	0.27	Bipolar disorder;	chr11:28274621	chr3:156713884~156714928:-
HNSC	trans	rs702485	0.933	rs836558	ENSG00000249936.3	RAC1P2	5.95	5.15e-09	0.0077	0.31	0.27	HDL cholesterol levels;HDL cholesterol;	chr7:6408360	chr4:46723830~46724408:-
HNSC	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	5.95	5.16e-09	0.00772	0.33	0.27	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
HNSC	trans	rs9467711	0.606	rs16891727	ENSG00000253570.1	RNF5P1	5.95	5.18e-09	0.00775	0.56	0.27	Autism spectrum disorder or schizophrenia;	chr6:26488632	chr8:38600661~38601200:-
HNSC	trans	rs1908814	0.516	rs35391955	ENSG00000173295.6	FAM86B3P	5.95	5.21e-09	0.00779	0.29	0.27	Neuroticism;	chr8:11939219	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs58869268	ENSG00000173295.6	FAM86B3P	5.95	5.21e-09	0.00779	0.29	0.27	Neuroticism;	chr8:11939586	chr8:8228595~8244865:+
HNSC	trans	rs2280018	0.963	rs4985147	ENSG00000250569.1	NTAN1P2	5.95	5.25e-09	0.00785	0.32	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr8:86481754~86483002:-
HNSC	trans	rs62158211	0.955	rs7556815	ENSG00000203709.8	C1orf132	5.95	5.27e-09	0.00787	0.34	0.27	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr1:207801518~207869150:-
HNSC	trans	rs11220237	1	rs7934485	ENSG00000236257.1	EI24P2	5.95	5.29e-09	0.0079	0.39	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804339	chr1:158454198~158455273:+
HNSC	trans	rs17507216	0.671	rs4779035	ENSG00000235370.6	DNM1P51	-5.95	5.3e-09	0.00791	-0.41	-0.27	Excessive daytime sleepiness;	chr15:82591686	chr15:84398316~84411701:-
HNSC	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	5.95	5.32e-09	0.00794	0.33	0.27	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
HNSC	trans	rs3956705	1	rs2392158	ENSG00000176826.14	FKBP9P1	-5.95	5.32e-09	0.00794	-0.28	-0.27	Red cell distribution width;	chr7:32940591	chr7:55681074~55713252:-
HNSC	trans	rs3956705	0.966	rs1037324	ENSG00000176826.14	FKBP9P1	-5.95	5.32e-09	0.00794	-0.28	-0.27	Red cell distribution width;	chr7:32941549	chr7:55681074~55713252:-
HNSC	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-5.95	5.32e-09	0.00794	-0.34	-0.27	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	5.95	5.33e-09	0.00795	0.33	0.27	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
HNSC	trans	rs6087990	0.871	rs1007122	ENSG00000253915.1	MAPRE1P1	5.95	5.34e-09	0.00796	0.32	0.27	Ulcerative colitis;	chr20:32758195	chr8:135625185~135625981:-
HNSC	trans	rs6831352	0.918	rs29001199	ENSG00000233859.2	ADH5P4	5.95	5.35e-09	0.00799	0.32	0.27	Alcohol dependence;	chr4:99132740	chr6:65836930~65838039:-
HNSC	trans	rs7929679	0.602	rs10836310	ENSG00000225531.1	RP11-196I18.3	5.95	5.39e-09	0.00804	0.32	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34787373	chr9:107116829~107117557:+
HNSC	trans	rs9650657	0.707	rs4841452	ENSG00000173295.6	FAM86B3P	-5.95	5.39e-09	0.00805	-0.3	-0.27	Neuroticism;	chr8:10829611	chr8:8228595~8244865:+
HNSC	trans	rs7873102	0.967	rs943937	ENSG00000229007.1	EXOSC3P1	-5.95	5.4e-09	0.00805	-0.32	-0.27	Brain structure;	chr9:37983660	chr21:32496812~32497311:+
HNSC	trans	rs853679	0.607	rs35902873	ENSG00000204622.9	HLA-J	-5.95	5.41e-09	0.00807	-0.61	-0.27	Depression;	chr6:28091171	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13197574	ENSG00000204622.9	HLA-J	-5.95	5.41e-09	0.00807	-0.61	-0.27	Depression;	chr6:28092461	chr6:30006583~30009956:+
HNSC	trans	rs702485	1	rs702485	ENSG00000249936.3	RAC1P2	5.95	5.41e-09	0.00807	0.31	0.27	HDL cholesterol levels;HDL cholesterol;	chr7:6409641	chr4:46723830~46724408:-
HNSC	trans	rs864643	0.678	rs610006	ENSG00000183298.5	RP11-556K13.1	5.94	5.43e-09	0.00809	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39481104	chr1:101786340~101787219:-
HNSC	trans	rs6087990	0.735	rs2424920	ENSG00000253915.1	MAPRE1P1	5.94	5.43e-09	0.0081	0.32	0.27	Ulcerative colitis;	chr20:32797646	chr8:135625185~135625981:-
HNSC	trans	rs17507216	0.628	rs4627310	ENSG00000235370.6	DNM1P51	-5.94	5.44e-09	0.00811	-0.41	-0.27	Excessive daytime sleepiness;	chr15:82708330	chr15:84398316~84411701:-
HNSC	trans	rs330048	0.545	rs11774353	ENSG00000173295.6	FAM86B3P	5.94	5.45e-09	0.00812	0.3	0.27	Systemic lupus erythematosus;	chr8:9295617	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.838	rs10835283	ENSG00000174912.7	METTL15P1	5.94	5.45e-09	0.00813	0.28	0.27	Bipolar disorder;	chr11:28193438	chr3:156713884~156714928:-
HNSC	trans	rs2950393	0.857	rs9989034	ENSG00000228224.3	NACAP1	5.94	5.46e-09	0.00814	0.29	0.27	Platelet distribution width;	chr12:56674508	chr8:101361794~101372707:+
HNSC	trans	rs9650657	0.741	rs10100333	ENSG00000253893.2	FAM85B	5.94	5.47e-09	0.00815	0.32	0.27	Neuroticism;	chr8:10726778	chr8:8167819~8226614:-
HNSC	trans	rs7520050	0.966	rs7515491	ENSG00000255397.1	AC022182.2	5.94	5.48e-09	0.00817	0.32	0.27	Reticulocyte count;Red blood cell count;	chr1:45889407	chr8:60937705~60939871:-
HNSC	trans	rs7929679	0.521	rs10836304	ENSG00000225531.1	RP11-196I18.3	-5.94	5.49e-09	0.00817	-0.32	-0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772477	chr9:107116829~107117557:+
HNSC	trans	rs6087990	0.701	rs1997797	ENSG00000253915.1	MAPRE1P1	5.94	5.49e-09	0.00818	0.32	0.27	Ulcerative colitis;	chr20:32800148	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.735	rs6058892	ENSG00000253915.1	MAPRE1P1	5.94	5.49e-09	0.00818	0.32	0.27	Ulcerative colitis;	chr20:32800655	chr8:135625185~135625981:-
HNSC	trans	rs17022021	0.553	rs17021907	ENSG00000230839.1	RP5-968J1.1	5.94	5.49e-09	0.00818	0.44	0.27	Late-onset Alzheimer's disease;	chr3:28758185	chr20:1804016~1817606:-
HNSC	trans	rs2302190	0.882	rs11658998	ENSG00000273445.1	RP11-1399P15.1	5.94	5.49e-09	0.00818	0.32	0.27	Vitamin D levels;	chr17:58578425	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.769	rs7218778	ENSG00000273445.1	RP11-1399P15.1	5.94	5.49e-09	0.00818	0.32	0.27	Vitamin D levels;	chr17:58586887	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs8072873	ENSG00000273445.1	RP11-1399P15.1	5.94	5.49e-09	0.00818	0.32	0.27	Vitamin D levels;	chr17:58591688	chr2:87477495~87478034:-
HNSC	trans	rs2280018	1	rs2280018	ENSG00000250569.1	NTAN1P2	5.94	5.5e-09	0.0082	0.31	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr8:86481754~86483002:-
HNSC	trans	rs2899832	0.5	rs112106731	ENSG00000229083.1	PSMA6P2	5.94	5.51e-09	0.0082	0.45	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298279	chrX:12825840~12826833:+
HNSC	trans	rs2899832	0.568	rs10142113	ENSG00000229083.1	PSMA6P2	5.94	5.51e-09	0.0082	0.45	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298623	chrX:12825840~12826833:+
HNSC	trans	rs1464321	0.851	rs10860978	ENSG00000258199.1	RP11-977G19.5	-5.94	5.51e-09	0.00821	-0.22	-0.27	Body mass index;	chr12:103290507	chr12:56162359~56190284:-
HNSC	trans	rs4733789	1	rs4733789	ENSG00000239830.1	RPS4XP22	-5.94	5.52e-09	0.00822	-0.29	-0.27	Height;	chr8:127822157	chr19:9683294~9684073:-
HNSC	trans	rs11220237	0.544	rs12361784	ENSG00000236257.1	EI24P2	-5.94	5.56e-09	0.00827	-0.42	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr11:125685531	chr1:158454198~158455273:+
HNSC	trans	rs941207	0.507	rs73337030	ENSG00000228224.3	NACAP1	-5.94	5.57e-09	0.00829	-0.29	-0.27	Platelet count;	chr12:56652410	chr8:101361794~101372707:+
HNSC	trans	rs3806843	0.518	rs2569188	ENSG00000231043.3	AC007238.1	5.94	5.59e-09	0.00832	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140628834	chr2:58460292~58462032:-
HNSC	trans	rs9329221	0.935	rs3750310	ENSG00000173295.6	FAM86B3P	-5.94	5.65e-09	0.0084	-0.29	-0.26	Neuroticism;	chr8:10425916	chr8:8228595~8244865:+
HNSC	trans	rs7647973	0.626	rs9835157	ENSG00000197582.5	GPX1P1	-5.94	5.68e-09	0.00844	-0.44	-0.26	Menarche (age at onset);	chr3:49760336	chrX:13378735~13379340:-
HNSC	trans	rs17073641	0.571	rs12455781	ENSG00000214846.4	RP11-115L11.1	-5.94	5.71e-09	0.00848	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64728527	chr4:15730962~15731627:-
HNSC	trans	rs7929679	0.602	rs10836311	ENSG00000225531.1	RP11-196I18.3	5.94	5.71e-09	0.00849	0.32	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34787619	chr9:107116829~107117557:+
HNSC	trans	rs4713118	0.568	rs9468213	ENSG00000204709.4	LINC01556	5.94	5.71e-09	0.00849	0.32	0.26	Parkinson's disease;	chr6:27738401	chr6:28943877~28944537:+
HNSC	trans	rs10435719	0.718	rs7813935	ENSG00000173295.6	FAM86B3P	5.94	5.72e-09	0.00849	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.597	rs12669623	ENSG00000215006.4	CHCHD2P2	-5.94	5.72e-09	0.00849	-0.35	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr5:69333929~69334249:+
HNSC	trans	rs34421088	0.56	rs2245250	ENSG00000253893.2	FAM85B	5.94	5.72e-09	0.0085	0.31	0.26	Neuroticism;	chr8:11543171	chr8:8167819~8226614:-
HNSC	trans	rs7929679	0.602	rs11032866	ENSG00000225531.1	RP11-196I18.3	5.94	5.72e-09	0.0085	0.32	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34781885	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.602	rs1396885	ENSG00000225531.1	RP11-196I18.3	5.94	5.72e-09	0.0085	0.32	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34783663	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.602	rs11032872	ENSG00000225531.1	RP11-196I18.3	5.94	5.72e-09	0.0085	0.32	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34784645	chr9:107116829~107117557:+
HNSC	trans	rs2950393	0.804	rs1026565	ENSG00000228224.3	NACAP1	5.93	5.75e-09	0.00855	0.29	0.26	Platelet distribution width;	chr12:56744044	chr8:101361794~101372707:+
HNSC	trans	rs10435719	0.805	rs13269417	ENSG00000173295.6	FAM86B3P	5.93	5.76e-09	0.00855	0.3	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.828	rs332783	ENSG00000213331.4	RP11-713C19.2	5.93	5.76e-09	0.00856	0.32	0.26	Systemic lupus erythematosus;	chr1:174719260	chr4:187970273~187971284:+
HNSC	trans	rs17301013	0.861	rs170768	ENSG00000213331.4	RP11-713C19.2	5.93	5.76e-09	0.00856	0.32	0.26	Systemic lupus erythematosus;	chr1:174720787	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.564	rs2736290	ENSG00000254340.1	RP11-10A14.3	-5.93	5.8e-09	0.0086	-0.31	-0.26	Retinal vascular caliber;	chr8:11376789	chr8:9141424~9145435:+
HNSC	trans	rs1908814	0.516	rs11250178	ENSG00000173295.6	FAM86B3P	5.93	5.8e-09	0.0086	0.29	0.26	Neuroticism;	chr8:11942725	chr8:8228595~8244865:+
HNSC	trans	rs17301013	0.861	rs7538650	ENSG00000213331.4	RP11-713C19.2	-5.93	5.8e-09	0.00861	-0.32	-0.26	Systemic lupus erythematosus;	chr1:174788821	chr4:187970273~187971284:+
HNSC	trans	rs1816752	0.719	rs11843470	ENSG00000224976.2	PARP4P2	-5.93	5.8e-09	0.00861	-0.32	-0.26	Obesity-related traits;	chr13:24423561	chr13:19349137~19407962:+
HNSC	trans	rs7647973	0.626	rs11720705	ENSG00000197582.5	GPX1P1	5.93	5.87e-09	0.00871	0.43	0.26	Menarche (age at onset);	chr3:49716355	chrX:13378735~13379340:-
HNSC	trans	rs853679	0.607	rs34662244	ENSG00000204622.9	HLA-J	-5.93	5.9e-09	0.00875	-0.61	-0.26	Depression;	chr6:28106103	chr6:30006583~30009956:+
HNSC	trans	rs35952432	1	rs35952432	ENSG00000204622.9	HLA-J	-5.93	5.9e-09	0.00875	-0.61	-0.26	Lung cancer;	chr6:28107123	chr6:30006583~30009956:+
HNSC	trans	rs864643	0.678	rs512923	ENSG00000183298.5	RP11-556K13.1	5.93	5.91e-09	0.00877	0.42	0.26	Attention deficit hyperactivity disorder;	chr3:39480472	chr1:101786340~101787219:-
HNSC	trans	rs11220237	1	rs59868022	ENSG00000236257.1	EI24P2	5.93	5.92e-09	0.00877	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850985	chr1:158454198~158455273:+
HNSC	trans	rs853679	0.546	rs35744819	ENSG00000176998.4	HCG4	-5.93	5.93e-09	0.00879	-0.52	-0.26	Depression;	chr6:28350554	chr6:29791753~29792750:-
HNSC	trans	rs853679	0.607	rs13207345	ENSG00000253570.1	RNF5P1	5.93	5.94e-09	0.0088	0.62	0.26	Depression;	chr6:28297795	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs72854513	ENSG00000253570.1	RNF5P1	5.93	5.94e-09	0.0088	0.62	0.26	Depression;	chr6:28298177	chr8:38600661~38601200:-
HNSC	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-5.93	6e-09	0.00888	-0.33	-0.26	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
HNSC	trans	rs17073641	0.553	rs12605461	ENSG00000214846.4	RP11-115L11.1	5.93	6.01e-09	0.0089	0.32	0.26	Age-related macular degeneration (smoking status interaction);	chr18:64712342	chr4:15730962~15731627:-
HNSC	trans	rs6831352	0.918	rs29001201	ENSG00000233859.2	ADH5P4	5.93	6.03e-09	0.00893	0.32	0.26	Alcohol dependence;	chr4:99132710	chr6:65836930~65838039:-
HNSC	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	5.93	6.03e-09	0.00893	0.33	0.26	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
HNSC	trans	rs2288327	1	rs890578	ENSG00000269800.1	PLEKHA3P1	5.93	6.05e-09	0.00896	0.34	0.26	Atrial fibrillation;	chr2:178549906	chr19:41521043~41521989:-
HNSC	trans	rs1051424	0.651	rs1292063	ENSG00000187870.7	RNFT1P3	-5.93	6.06e-09	0.00896	-0.34	-0.26	Obesity-related traits;	chr17:59830407	chr17:20743333~20754501:-
HNSC	trans	rs6831352	0.879	rs29001208	ENSG00000233859.2	ADH5P4	5.93	6.06e-09	0.00897	0.32	0.26	Alcohol dependence;	chr4:99131388	chr6:65836930~65838039:-
HNSC	trans	rs1568889	0.838	rs10835304	ENSG00000174912.7	METTL15P1	5.93	6.06e-09	0.00897	0.28	0.26	Bipolar disorder;	chr11:28274982	chr3:156713884~156714928:-
HNSC	trans	rs2302190	0.882	rs3803751	ENSG00000273445.1	RP11-1399P15.1	5.93	6.07e-09	0.00898	0.31	0.26	Vitamin D levels;	chr17:58572995	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs8068135	ENSG00000273445.1	RP11-1399P15.1	5.93	6.07e-09	0.00898	0.31	0.26	Vitamin D levels;	chr17:58576849	chr2:87477495~87478034:-
HNSC	trans	rs9650657	0.655	rs10093774	ENSG00000173295.6	FAM86B3P	5.92	6.08e-09	0.00899	0.29	0.26	Neuroticism;	chr8:10845783	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.838	rs10458896	ENSG00000174912.7	METTL15P1	5.92	6.08e-09	0.00899	0.28	0.26	Bipolar disorder;	chr11:28036410	chr3:156713884~156714928:-
HNSC	trans	rs13016963	0.526	rs11681616	ENSG00000235105.1	RP11-329A14.1	5.92	6.09e-09	0.009	0.31	0.26	Esophageal squamous cell carcinoma;Melanoma;	chr2:201360013	chr1:48435967~48437223:+
HNSC	trans	rs2665103	0.61	rs1972460	ENSG00000235370.6	DNM1P51	-5.92	6.09e-09	0.009	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82238289	chr15:84398316~84411701:-
HNSC	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	5.92	6.1e-09	0.00902	0.33	0.26	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
HNSC	trans	rs7809615	0.515	rs3843540	ENSG00000228834.1	RP11-249L21.4	5.92	6.11e-09	0.00904	0.39	0.26	Blood metabolite ratios;	chr7:99529017	chr6:108907615~108907873:-
HNSC	trans	rs2236178	0.579	rs6035868	ENSG00000177640.14	CASC2	-5.92	6.12e-09	0.00904	-0.28	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr20:21395188	chr10:118046279~118210153:+
HNSC	trans	rs13016963	0.526	rs11687854	ENSG00000235105.1	RP11-329A14.1	5.92	6.13e-09	0.00906	0.32	0.26	Esophageal squamous cell carcinoma;Melanoma;	chr2:201363879	chr1:48435967~48437223:+
HNSC	trans	rs6831352	0.959	rs1139490	ENSG00000233859.2	ADH5P4	-5.92	6.18e-09	0.00913	-0.3	-0.26	Alcohol dependence;	chr4:99123990	chr6:65836930~65838039:-
HNSC	trans	rs17301013	0.829	rs2006197	ENSG00000213331.4	RP11-713C19.2	5.92	6.25e-09	0.00922	0.31	0.26	Systemic lupus erythematosus;	chr1:174432825	chr4:187970273~187971284:+
HNSC	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-5.92	6.29e-09	0.00928	-0.31	-0.26	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
HNSC	trans	rs7824557	0.51	rs4841524	ENSG00000254340.1	RP11-10A14.3	-5.92	6.3e-09	0.0093	-0.32	-0.26	Retinal vascular caliber;	chr8:11385617	chr8:9141424~9145435:+
HNSC	trans	rs6831352	0.918	rs13129488	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99131874	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.84	rs35073321	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99132125	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001202	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99132631	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs29001196	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99132965	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17817359	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133046	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001195	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133093	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17217949	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133161	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs17218003	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133572	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001194	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133693	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13143133	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99133819	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs7672728	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134022	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs7689753	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134424	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218073	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134588	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218108	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134604	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13112176	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134674	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218141	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134757	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218162	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99134909	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.877	rs29001183	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99135388	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218239	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99135869	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13127153	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99136970	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13127582	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99137043	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13133633	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99137546	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13133647	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99137576	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs28987088	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99137988	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs7669636	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99138161	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs7670060	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99138417	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs7670241	ENSG00000233859.2	ADH5P4	5.92	6.32e-09	0.00931	0.32	0.26	Alcohol dependence;	chr4:99138468	chr6:65836930~65838039:-
HNSC	trans	rs546131	0.928	rs558967	ENSG00000225531.1	RP11-196I18.3	5.92	6.33e-09	0.00932	0.32	0.26	Lung disease severity in cystic fibrosis;	chr11:34805621	chr9:107116829~107117557:+
HNSC	trans	rs864643	0.678	rs621842	ENSG00000183298.5	RP11-556K13.1	5.92	6.33e-09	0.00932	0.42	0.26	Attention deficit hyperactivity disorder;	chr3:39480785	chr1:101786340~101787219:-
HNSC	trans	rs11220237	1	rs7938074	ENSG00000236257.1	EI24P2	5.92	6.33e-09	0.00933	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804743	chr1:158454198~158455273:+
HNSC	trans	rs7824557	0.564	rs2572400	ENSG00000254340.1	RP11-10A14.3	-5.92	6.38e-09	0.0094	-0.31	-0.26	Retinal vascular caliber;	chr8:11376858	chr8:9141424~9145435:+
HNSC	trans	rs867371	0.896	rs8033831	ENSG00000259295.5	CSPG4P12	-5.92	6.42e-09	0.00945	-0.32	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:85191438~85213905:+
HNSC	trans	rs1568889	1	rs10767693	ENSG00000174912.7	METTL15P1	5.92	6.42e-09	0.00945	0.28	0.26	Bipolar disorder;	chr11:28072379	chr3:156713884~156714928:-
HNSC	trans	rs3826795	0.569	rs3810300	ENSG00000269463.1	RP11-727F15.13	-5.91	6.42e-09	0.00945	-0.41	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46296940	chr11:62807682~62808063:-
HNSC	trans	rs6831352	0.851	rs1230164	ENSG00000233859.2	ADH5P4	-5.91	6.42e-09	0.00945	-0.3	-0.26	Alcohol dependence;	chr4:99064872	chr6:65836930~65838039:-
HNSC	trans	rs804280	0.517	rs7815179	ENSG00000173295.6	FAM86B3P	5.91	6.43e-09	0.00946	0.29	0.26	Myopia (pathological);	chr8:11934539	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.871	rs7815186	ENSG00000173295.6	FAM86B3P	5.91	6.43e-09	0.00946	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:8228595~8244865:+
HNSC	trans	rs1908814	0.516	rs7833079	ENSG00000173295.6	FAM86B3P	5.91	6.43e-09	0.00946	0.29	0.26	Neuroticism;	chr8:11934620	chr8:8228595~8244865:+
HNSC	trans	rs10435719	0.899	rs7815595	ENSG00000173295.6	FAM86B3P	5.91	6.43e-09	0.00946	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:8228595~8244865:+
HNSC	trans	rs9876781	0.624	rs12491849	ENSG00000235912.1	RP1-159A19.3	-5.91	6.46e-09	0.00951	-0.3	-0.26	Longevity;	chr3:48489975	chr1:27649419~27649610:+
HNSC	trans	rs2302190	0.882	rs9903050	ENSG00000273445.1	RP11-1399P15.1	5.91	6.46e-09	0.00951	0.31	0.26	Vitamin D levels;	chr17:58559547	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs6503869	ENSG00000273445.1	RP11-1399P15.1	5.91	6.46e-09	0.00951	0.31	0.26	Vitamin D levels;	chr17:58560100	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs1974586	ENSG00000273445.1	RP11-1399P15.1	5.91	6.46e-09	0.00951	0.31	0.26	Vitamin D levels;	chr17:58563370	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs7226008	ENSG00000273445.1	RP11-1399P15.1	5.91	6.46e-09	0.00951	0.31	0.26	Vitamin D levels;	chr17:58567272	chr2:87477495~87478034:-
HNSC	trans	rs3808502	0.574	rs4841559	ENSG00000173295.6	FAM86B3P	-5.91	6.48e-09	0.00953	-0.29	-0.26	Neuroticism;	chr8:11559376	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.882	rs2743555	ENSG00000204622.9	HLA-J	-5.91	6.51e-09	0.00957	-0.44	-0.26	Depression;	chr6:28273304	chr6:30006583~30009956:+
HNSC	trans	rs853679	1	rs1419183	ENSG00000204622.9	HLA-J	-5.91	6.51e-09	0.00957	-0.44	-0.26	Depression;	chr6:28275017	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.546	rs35016036	ENSG00000176998.4	HCG4	-5.91	6.51e-09	0.00958	-0.52	-0.26	Depression;	chr6:28347103	chr6:29791753~29792750:-
HNSC	trans	rs2250402	0.51	rs2898984	ENSG00000234106.3	RP11-288E14.2	5.91	6.52e-09	0.00959	0.57	0.26	Corneal curvature;	chr15:40031874	chr11:93535468~93535816:+
HNSC	trans	rs7824557	0.606	rs2736270	ENSG00000254340.1	RP11-10A14.3	5.91	6.52e-09	0.00959	0.31	0.26	Retinal vascular caliber;	chr8:11335084	chr8:9141424~9145435:+
HNSC	trans	rs9467711	0.559	rs9348721	ENSG00000253570.1	RNF5P1	5.91	6.53e-09	0.0096	0.56	0.26	Autism spectrum disorder or schizophrenia;	chr6:26485345	chr8:38600661~38601200:-
HNSC	trans	rs7937890	0.559	rs2575853	ENSG00000236360.2	RP11-334A14.2	5.91	6.54e-09	0.00961	0.35	0.26	Mitochondrial DNA levels;	chr11:14512417	chr1:52993201~52993702:-
HNSC	trans	rs853679	1	rs735765	ENSG00000204622.9	HLA-J	-5.91	6.57e-09	0.00965	-0.47	-0.26	Depression;	chr6:28202519	chr6:30006583~30009956:+
HNSC	trans	rs1568889	0.838	rs12273631	ENSG00000174912.7	METTL15P1	5.91	6.57e-09	0.00966	0.28	0.26	Bipolar disorder;	chr11:28020588	chr3:156713884~156714928:-
HNSC	trans	rs1568889	0.838	rs7127069	ENSG00000174912.7	METTL15P1	5.91	6.6e-09	0.0097	0.28	0.26	Bipolar disorder;	chr11:28303865	chr3:156713884~156714928:-
HNSC	trans	rs7746199	0.736	rs13202295	ENSG00000253570.1	RNF5P1	5.91	6.61e-09	0.00971	0.62	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr8:38600661~38601200:-
HNSC	trans	rs11220237	0.92	rs12272767	ENSG00000236257.1	EI24P2	5.91	6.64e-09	0.00975	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125824748	chr1:158454198~158455273:+
HNSC	trans	rs4948102	0.691	rs4470984	ENSG00000215006.4	CHCHD2P2	-5.91	6.64e-09	0.00975	-0.37	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:55965865	chr5:69333929~69334249:+
HNSC	trans	rs7873102	1	rs7026073	ENSG00000229007.1	EXOSC3P1	-5.91	6.67e-09	0.00979	-0.33	-0.26	Brain structure;	chr9:38040675	chr21:32496812~32497311:+
HNSC	trans	rs7873102	1	rs7042681	ENSG00000229007.1	EXOSC3P1	-5.91	6.67e-09	0.00979	-0.33	-0.26	Brain structure;	chr9:38040831	chr21:32496812~32497311:+
HNSC	trans	rs7829975	0.511	rs2976906	ENSG00000269918.1	AF131215.9	5.91	6.69e-09	0.00982	0.26	0.26	Mood instability;	chr8:8484905	chr8:11104691~11106704:-
HNSC	trans	rs17073641	0.553	rs10871577	ENSG00000214846.4	RP11-115L11.1	-5.91	6.7e-09	0.00984	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64721770	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12454585	ENSG00000214846.4	RP11-115L11.1	-5.91	6.7e-09	0.00984	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64723456	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs34619359	ENSG00000214846.4	RP11-115L11.1	-5.91	6.7e-09	0.00984	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64723473	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12962077	ENSG00000214846.4	RP11-115L11.1	-5.91	6.7e-09	0.00984	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64723963	chr4:15730962~15731627:-
HNSC	trans	rs9733	0.54	rs4971041	ENSG00000180764.13	PIPSL	5.91	6.71e-09	0.00984	0.32	0.26	Tonsillectomy;	chr1:150564881	chr10:93958191~93961540:-
HNSC	trans	rs6011368	0.84	rs6062361	ENSG00000226210.3	WASH7P	-5.91	6.78e-09	0.00994	-0.29	-0.26	Clozapine-induced cytotoxicity;	chr20:64273189	chr12:14522~32015:-
HNSC	trans	rs7824557	0.592	rs920044	ENSG00000173295.6	FAM86B3P	5.9	6.8e-09	0.00997	0.28	0.26	Retinal vascular caliber;	chr8:11366804	chr8:8228595~8244865:+
HNSC	trans	rs2736337	0.53	rs11782375	ENSG00000173295.6	FAM86B3P	5.9	6.81e-09	0.00998	0.32	0.26	Rheumatoid arthritis;	chr8:11437425	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.51	rs2736297	ENSG00000254340.1	RP11-10A14.3	-5.9	6.81e-09	0.00999	-0.31	-0.26	Retinal vascular caliber;	chr8:11377376	chr8:9141424~9145435:+
HNSC	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-5.9	6.83e-09	0.01	-0.33	-0.26	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
HNSC	trans	rs7929679	0.571	rs10768100	ENSG00000225531.1	RP11-196I18.3	5.9	6.84e-09	0.01	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777388	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.571	rs11032860	ENSG00000225531.1	RP11-196I18.3	5.9	6.84e-09	0.01	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777798	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.521	rs10836307	ENSG00000225531.1	RP11-196I18.3	5.9	6.84e-09	0.01	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34778681	chr9:107116829~107117557:+
HNSC	trans	rs9329221	0.87	rs11777976	ENSG00000173295.6	FAM86B3P	-5.9	6.84e-09	0.01	-0.3	-0.26	Neuroticism;	chr8:10397892	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.838	rs11030185	ENSG00000174912.7	METTL15P1	5.9	6.84e-09	0.01	0.28	0.26	Bipolar disorder;	chr11:28020357	chr3:156713884~156714928:-
HNSC	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	5.9	6.86e-09	0.01	0.33	0.26	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
HNSC	trans	rs7937890	0.535	rs2575857	ENSG00000236360.2	RP11-334A14.2	5.9	6.87e-09	0.0101	0.35	0.26	Mitochondrial DNA levels;	chr11:14479750	chr1:52993201~52993702:-
HNSC	trans	rs853679	0.607	rs13208096	ENSG00000228078.1	HLA-U	-5.9	6.89e-09	0.0101	-0.58	-0.26	Depression;	chr6:28257533	chr6:29934101~29934286:+
HNSC	trans	rs1432133	0.844	rs12899579	ENSG00000214182.5	PTMAP5	-5.9	6.89e-09	0.0101	-0.24	-0.26	Hepatitis;	chr15:26979174	chr13:81689911~81691072:+
HNSC	trans	rs7824557	0.933	rs6601576	ENSG00000254340.1	RP11-10A14.3	-5.9	6.89e-09	0.0101	-0.32	-0.26	Retinal vascular caliber;	chr8:11242766	chr8:9141424~9145435:+
HNSC	trans	rs1023500	1	rs1023499	ENSG00000268568.1	AC007228.9	-5.9	6.91e-09	0.0101	-0.36	-0.26	Schizophrenia;	chr22:41944578	chr19:56672574~56673901:-
HNSC	trans	rs6928289	0.81	rs12525010	ENSG00000237032.1	RP11-398C13.2	5.9	6.92e-09	0.0101	0.31	0.26	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:137334711	chr10:14723171~14724055:-
HNSC	trans	rs853679	0.607	rs13207345	ENSG00000243753.4	HLA-L	-5.9	6.95e-09	0.0102	-0.58	-0.26	Depression;	chr6:28297795	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs72854513	ENSG00000243753.4	HLA-L	-5.9	6.95e-09	0.0102	-0.58	-0.26	Depression;	chr6:28298177	chr6:30259584~30293014:+
HNSC	trans	rs9650657	0.74	rs6980805	ENSG00000173295.6	FAM86B3P	-5.9	6.96e-09	0.0102	-0.3	-0.26	Neuroticism;	chr8:10822332	chr8:8228595~8244865:+
HNSC	trans	rs8067354	0.645	rs2645467	ENSG00000187870.7	RNFT1P3	5.9	6.97e-09	0.0102	0.35	0.26	Hemoglobin concentration;	chr17:59777422	chr17:20743333~20754501:-
HNSC	trans	rs6087990	0.735	rs1855350	ENSG00000253915.1	MAPRE1P1	5.9	6.97e-09	0.0102	0.32	0.26	Ulcerative colitis;	chr20:32799719	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.735	rs2064350	ENSG00000253915.1	MAPRE1P1	5.9	6.97e-09	0.0102	0.32	0.26	Ulcerative colitis;	chr20:32802727	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.735	rs4911261	ENSG00000253915.1	MAPRE1P1	5.9	6.97e-09	0.0102	0.32	0.26	Ulcerative colitis;	chr20:32803554	chr8:135625185~135625981:-
HNSC	trans	rs7829975	0.633	rs2979181	ENSG00000269918.1	AF131215.9	5.9	7.01e-09	0.0103	0.26	0.26	Mood instability;	chr8:8465578	chr8:11104691~11106704:-
HNSC	trans	rs2950393	0.777	rs12828563	ENSG00000257210.1	NACAP3	5.9	7.04e-09	0.0103	0.3	0.26	Platelet distribution width;	chr12:56709378	chr12:93124063~93124543:-
HNSC	trans	rs6087990	0.735	rs2424921	ENSG00000253915.1	MAPRE1P1	5.9	7.05e-09	0.0103	0.31	0.26	Ulcerative colitis;	chr20:32798008	chr8:135625185~135625981:-
HNSC	trans	rs6921919	0.562	rs13198809	ENSG00000176998.4	HCG4	-5.9	7.05e-09	0.0103	-0.52	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:29791753~29792750:-
HNSC	trans	rs7873102	0.967	rs10973646	ENSG00000229007.1	EXOSC3P1	5.9	7.06e-09	0.0103	0.32	0.26	Brain structure;	chr9:38032377	chr21:32496812~32497311:+
HNSC	trans	rs12339966	0.689	rs1816823	ENSG00000263126.1	CTC-479C5.10	-5.9	7.07e-09	0.0103	-0.24	-0.26	Systolic blood pressure;	chr9:11676909	chr16:67882461~67886367:+
HNSC	trans	rs804280	0.509	rs13268030	ENSG00000173295.6	FAM86B3P	5.9	7.1e-09	0.0104	0.29	0.26	Myopia (pathological);	chr8:11925564	chr8:8228595~8244865:+
HNSC	trans	rs74902201	0.685	rs10491201	ENSG00000280434.1	RP4-671O14.6	-5.9	7.11e-09	0.0104	-0.43	-0.26	Food addiction;	chr17:66707045	chr22:44139365~44153626:+
HNSC	trans	rs7929679	0.577	rs10836306	ENSG00000225531.1	RP11-196I18.3	5.9	7.12e-09	0.0104	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34776415	chr9:107116829~107117557:+
HNSC	trans	rs4512344	0.509	rs2409784	ENSG00000173295.6	FAM86B3P	-5.9	7.14e-09	0.0104	-0.28	-0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8228595~8244865:+
HNSC	trans	rs1707322	0.638	rs9429095	ENSG00000255397.1	AC022182.2	5.9	7.14e-09	0.0104	0.36	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr8:60937705~60939871:-
HNSC	trans	rs7647973	0.626	rs1586827	ENSG00000197582.5	GPX1P1	5.9	7.18e-09	0.0105	0.44	0.26	Menarche (age at onset);	chr3:49633791	chrX:13378735~13379340:-
HNSC	trans	rs7824557	0.564	rs2736293	ENSG00000254340.1	RP11-10A14.3	-5.9	7.19e-09	0.0105	-0.31	-0.26	Retinal vascular caliber;	chr8:11377104	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs2736294	ENSG00000254340.1	RP11-10A14.3	-5.9	7.19e-09	0.0105	-0.31	-0.26	Retinal vascular caliber;	chr8:11377117	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs35009431	ENSG00000254340.1	RP11-10A14.3	-5.89	7.19e-09	0.0105	-0.31	-0.26	Retinal vascular caliber;	chr8:11375279	chr8:9141424~9145435:+
HNSC	trans	rs7819412	0.668	rs920047	ENSG00000173295.6	FAM86B3P	-5.89	7.22e-09	0.0105	-0.3	-0.26	Triglycerides;	chr8:11229966	chr8:8228595~8244865:+
HNSC	trans	rs941207	0.507	rs1107479	ENSG00000228224.3	NACAP1	-5.89	7.25e-09	0.0106	-0.29	-0.26	Platelet count;	chr12:56636902	chr8:101361794~101372707:+
HNSC	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-5.89	7.25e-09	0.0106	-0.33	-0.26	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs34878803	ENSG00000243753.4	HLA-L	-5.89	7.3e-09	0.0106	-0.57	-0.26	Depression;	chr6:28282402	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.527	rs2736296	ENSG00000254340.1	RP11-10A14.3	-5.89	7.3e-09	0.0107	-0.31	-0.26	Retinal vascular caliber;	chr8:11377335	chr8:9141424~9145435:+
HNSC	trans	rs74902201	1	rs715219	ENSG00000280434.1	RP4-671O14.6	-5.89	7.31e-09	0.0107	-0.49	-0.26	Food addiction;	chr17:66695548	chr22:44139365~44153626:+
HNSC	trans	rs4713118	0.869	rs2056925	ENSG00000204709.4	LINC01556	5.89	7.31e-09	0.0107	0.34	0.26	Parkinson's disease;	chr6:27723126	chr6:28943877~28944537:+
HNSC	trans	rs7113874	0.802	rs10769938	ENSG00000266891.1	RP11-692N5.2	5.89	7.32e-09	0.0107	0.35	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8650000	chr18:9734882~9735602:-
HNSC	trans	rs7647973	0.593	rs28535523	ENSG00000197582.5	GPX1P1	-5.89	7.34e-09	0.0107	-0.43	-0.26	Menarche (age at onset);	chr3:49810981	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs62260720	ENSG00000197582.5	GPX1P1	-5.89	7.34e-09	0.0107	-0.43	-0.26	Menarche (age at onset);	chr3:49816363	chrX:13378735~13379340:-
HNSC	trans	rs10100465	0.855	rs1396351	ENSG00000224861.1	YBX1P1	-5.89	7.35e-09	0.0107	-0.28	-0.26	Leprosy;	chr8:117677489	chr14:66012830~66013789:-
HNSC	trans	rs62158211	0.955	rs1823125	ENSG00000203709.8	C1orf132	-5.89	7.4e-09	0.0108	-0.32	-0.26	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr1:207801518~207869150:-
HNSC	trans	rs950169	1	rs12903820	ENSG00000229212.6	RP11-561C5.4	-5.89	7.41e-09	0.0108	-0.36	-0.26	Schizophrenia;	chr15:84055068	chr15:85205440~85234795:-
HNSC	trans	rs7937890	0.531	rs2575859	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14489190	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597188	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14495360	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597187	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14495473	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.504	rs2575822	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14498305	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2575823	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14499808	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597221	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14505529	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs6486197	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14508328	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2597219	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14509320	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs2575852	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14511822	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.531	rs2597216	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14512370	chr1:52993201~52993702:-
HNSC	trans	rs7937890	0.559	rs1548074	ENSG00000236360.2	RP11-334A14.2	5.89	7.41e-09	0.0108	0.35	0.26	Mitochondrial DNA levels;	chr11:14513279	chr1:52993201~52993702:-
HNSC	trans	rs864643	0.524	rs6810264	ENSG00000183298.5	RP11-556K13.1	5.89	7.43e-09	0.0108	0.49	0.26	Attention deficit hyperactivity disorder;	chr3:39471605	chr1:101786340~101787219:-
HNSC	trans	rs2302190	0.882	rs7213415	ENSG00000273445.1	RP11-1399P15.1	5.89	7.43e-09	0.0108	0.31	0.26	Vitamin D levels;	chr17:58595072	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs9911609	ENSG00000273445.1	RP11-1399P15.1	5.89	7.43e-09	0.0108	0.31	0.26	Vitamin D levels;	chr17:58595726	chr2:87477495~87478034:-
HNSC	trans	rs853679	0.882	rs9461432	ENSG00000204622.9	HLA-J	-5.89	7.47e-09	0.0109	-0.49	-0.26	Depression;	chr6:28119105	chr6:30006583~30009956:+
HNSC	trans	rs11220237	1	rs10893435	ENSG00000236257.1	EI24P2	5.89	7.47e-09	0.0109	0.38	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838890	chr1:158454198~158455273:+
HNSC	trans	rs864643	0.678	rs1707957	ENSG00000183298.5	RP11-556K13.1	5.89	7.48e-09	0.0109	0.42	0.26	Attention deficit hyperactivity disorder;	chr3:39482000	chr1:101786340~101787219:-
HNSC	trans	rs9393777	0.778	rs74689501	ENSG00000176998.4	HCG4	-5.89	7.49e-09	0.0109	-0.5	-0.26	Intelligence (multi-trait analysis);	chr6:26920042	chr6:29791753~29792750:-
HNSC	trans	rs7824557	0.603	rs2736278	ENSG00000254340.1	RP11-10A14.3	5.89	7.49e-09	0.0109	0.32	0.26	Retinal vascular caliber;	chr8:11362272	chr8:9141424~9145435:+
HNSC	trans	rs6087990	0.865	rs6058859	ENSG00000253915.1	MAPRE1P1	5.89	7.53e-09	0.011	0.31	0.26	Ulcerative colitis;	chr20:32747351	chr8:135625185~135625981:-
HNSC	trans	rs2400954	0.611	rs2178685	ENSG00000270083.1	RP1-257I20.14	5.89	7.54e-09	0.011	0.25	0.26	Alcohol dependence;	chr12:81598222	chr22:42089630~42090028:-
HNSC	trans	rs513349	0.964	rs210141	ENSG00000175730.8	BAK1P1	5.89	7.55e-09	0.011	0.31	0.26	Platelet count;	chr6:33579048	chr20:32690180~32690815:-
HNSC	trans	rs7824557	0.872	rs6601577	ENSG00000254340.1	RP11-10A14.3	5.89	7.59e-09	0.011	0.31	0.26	Retinal vascular caliber;	chr8:11245173	chr8:9141424~9145435:+
HNSC	trans	rs17073641	0.534	rs12954677	ENSG00000214846.4	RP11-115L11.1	-5.89	7.6e-09	0.0111	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726235	chr4:15730962~15731627:-
HNSC	trans	rs4713118	0.591	rs2056924	ENSG00000204709.4	LINC01556	5.88	7.61e-09	0.0111	0.32	0.26	Parkinson's disease;	chr6:27722395	chr6:28943877~28944537:+
HNSC	trans	rs1908814	0.516	rs11996277	ENSG00000173295.6	FAM86B3P	5.88	7.61e-09	0.0111	0.29	0.26	Neuroticism;	chr8:11942522	chr8:8228595~8244865:+
HNSC	trans	rs7746199	0.736	rs35037868	ENSG00000253570.1	RNF5P1	5.88	7.64e-09	0.0111	0.62	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr8:38600661~38601200:-
HNSC	trans	rs9329221	0.905	rs4841329	ENSG00000173295.6	FAM86B3P	-5.88	7.67e-09	0.0111	-0.29	-0.26	Neuroticism;	chr8:10395588	chr8:8228595~8244865:+
HNSC	trans	rs1816752	0.87	rs9581029	ENSG00000224976.2	PARP4P2	-5.88	7.69e-09	0.0112	-0.31	-0.26	Obesity-related traits;	chr13:24425147	chr13:19349137~19407962:+
HNSC	trans	rs7824557	0.606	rs1435277	ENSG00000173295.6	FAM86B3P	5.88	7.7e-09	0.0112	0.29	0.26	Retinal vascular caliber;	chr8:11339461	chr8:8228595~8244865:+
HNSC	trans	rs6831352	0.918	rs29001211	ENSG00000233859.2	ADH5P4	5.88	7.72e-09	0.0112	0.32	0.26	Alcohol dependence;	chr4:99130790	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001209	ENSG00000233859.2	ADH5P4	5.88	7.72e-09	0.0112	0.32	0.26	Alcohol dependence;	chr4:99131189	chr6:65836930~65838039:-
HNSC	trans	rs2400954	0.611	rs1317208	ENSG00000270083.1	RP1-257I20.14	5.88	7.72e-09	0.0112	0.25	0.26	Alcohol dependence;	chr12:81594064	chr22:42089630~42090028:-
HNSC	trans	rs2400954	0.607	rs10746193	ENSG00000270083.1	RP1-257I20.14	5.88	7.72e-09	0.0112	0.25	0.26	Alcohol dependence;	chr12:81596523	chr22:42089630~42090028:-
HNSC	trans	rs6831352	0.918	rs17218288	ENSG00000233859.2	ADH5P4	5.88	7.72e-09	0.0112	0.32	0.26	Alcohol dependence;	chr4:99136879	chr6:65836930~65838039:-
HNSC	trans	rs853679	0.607	rs35030260	ENSG00000176998.4	HCG4	-5.88	7.75e-09	0.0113	-0.52	-0.26	Depression;	chr6:28337731	chr6:29791753~29792750:-
HNSC	trans	rs853679	0.607	rs13217619	ENSG00000176998.4	HCG4	-5.88	7.75e-09	0.0113	-0.52	-0.26	Depression;	chr6:28338894	chr6:29791753~29792750:-
HNSC	trans	rs7937890	0.559	rs2575836	ENSG00000236360.2	RP11-334A14.2	5.88	7.76e-09	0.0113	0.35	0.26	Mitochondrial DNA levels;	chr11:14476318	chr1:52993201~52993702:-
HNSC	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	5.88	7.77e-09	0.0113	0.34	0.26	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
HNSC	trans	rs589756	0.924	rs681608	ENSG00000227260.1	AC116035.1	5.88	7.78e-09	0.0113	0.4	0.26	Obesity-related traits;	chr6:132309444	chr3:30524745~30527185:+
HNSC	trans	rs7819412	0.539	rs11250131	ENSG00000253981.4	ALG1L13P	-5.88	7.79e-09	0.0113	-0.28	-0.26	Triglycerides;	chr8:11393666	chr8:8236003~8244667:-
HNSC	trans	rs853679	0.546	rs200949	ENSG00000227766.1	HCG4P5	-5.88	7.84e-09	0.0114	-0.49	-0.26	Depression;	chr6:27867657	chr6:29942075~29943067:-
HNSC	trans	rs2243480	1	rs6460260	ENSG00000273142.1	RP11-458F8.4	5.88	7.85e-09	0.0114	0.38	0.26	Diabetic kidney disease;	chr7:65750468	chr7:66902857~66906297:+
HNSC	trans	rs2243480	1	rs6460261	ENSG00000273142.1	RP11-458F8.4	5.88	7.85e-09	0.0114	0.38	0.26	Diabetic kidney disease;	chr7:65750593	chr7:66902857~66906297:+
HNSC	trans	rs2243480	0.908	rs4718273	ENSG00000273142.1	RP11-458F8.4	5.88	7.85e-09	0.0114	0.38	0.26	Diabetic kidney disease;	chr7:65751112	chr7:66902857~66906297:+
HNSC	trans	rs1933488	0.931	rs6557272	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153116979	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs3870366	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153118632	chr4:188740507~188741281:-
HNSC	trans	rs1933488	0.898	rs6939447	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153118864	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs6917538	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153119062	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs9384082	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153119380	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs7740380	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153119576	chr4:188740507~188741281:-
HNSC	trans	rs1933488	1	rs1933488	ENSG00000278974.1	RP11-756P10.6	-5.88	7.85e-09	0.0114	-0.35	-0.26	Prostate cancer;	chr6:153119944	chr4:188740507~188741281:-
HNSC	trans	rs79149102	0.522	rs6495119	ENSG00000227288.3	RP5-837I24.1	5.88	7.86e-09	0.0114	0.5	0.26	Lung cancer;	chr15:74642099	chr1:81501794~81503468:+
HNSC	trans	rs3956705	0.866	rs71532543	ENSG00000176826.14	FKBP9P1	-5.88	7.87e-09	0.0114	-0.27	-0.26	Red cell distribution width;	chr7:32959298	chr7:55681074~55713252:-
HNSC	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-5.88	7.9e-09	0.0114	-0.33	-0.26	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
HNSC	trans	rs17301013	0.861	rs61826916	ENSG00000213331.4	RP11-713C19.2	5.88	7.94e-09	0.0115	0.32	0.26	Systemic lupus erythematosus;	chr1:174616048	chr4:187970273~187971284:+
HNSC	trans	rs860295	0.775	rs822508	ENSG00000241627.3	UBQLN4P1	-5.88	7.94e-09	0.0115	-0.28	-0.26	Body mass index;	chr1:155880767	chr3:148985868~148987668:-
HNSC	trans	rs7746199	0.736	rs35848276	ENSG00000253570.1	RNF5P1	5.88	7.96e-09	0.0115	0.61	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr8:38600661~38601200:-
HNSC	trans	rs2250402	0.51	rs2291619	ENSG00000234106.3	RP11-288E14.2	-5.88	7.97e-09	0.0116	-0.57	-0.26	Corneal curvature;	chr15:40036832	chr11:93535468~93535816:+
HNSC	trans	rs6087990	0.735	rs6058891	ENSG00000253915.1	MAPRE1P1	5.88	7.99e-09	0.0116	0.32	0.26	Ulcerative colitis;	chr20:32798541	chr8:135625185~135625981:-
HNSC	trans	rs6087990	0.735	rs2424922	ENSG00000253915.1	MAPRE1P1	5.88	7.99e-09	0.0116	0.32	0.26	Ulcerative colitis;	chr20:32798643	chr8:135625185~135625981:-
HNSC	trans	rs9650657	0.836	rs3905581	ENSG00000253893.2	FAM85B	5.88	7.99e-09	0.0116	0.31	0.26	Neuroticism;	chr8:10746195	chr8:8167819~8226614:-
HNSC	trans	rs6756513	0.5	rs11126249	ENSG00000232654.1	FAM136BP	5.88	8.01e-09	0.0116	0.36	0.26	Breast cancer;Platelet count;	chr2:69909485	chr6:3045384~3045800:+
HNSC	trans	rs902774	0.818	rs55958994	ENSG00000255815.3	KRT8P11	-5.87	8.05e-09	0.0117	-0.48	-0.26	Prostate cancer;	chr12:52907235	chr9:99305176~99306611:+
HNSC	trans	rs9650657	0.836	rs2898252	ENSG00000253893.2	FAM85B	5.87	8.09e-09	0.0117	0.31	0.26	Neuroticism;	chr8:10746654	chr8:8167819~8226614:-
HNSC	trans	rs2286492	0.748	rs75064321	ENSG00000273391.1	RP11-634H22.1	-5.87	8.1e-09	0.0117	-0.46	-0.26	Bipolar disorder;	chr7:22920672	chr7:139359032~139359566:-
HNSC	trans	rs7929679	0.545	rs2421740	ENSG00000225531.1	RP11-196I18.3	5.87	8.11e-09	0.0117	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775207	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.571	rs2136508	ENSG00000225531.1	RP11-196I18.3	5.87	8.11e-09	0.0117	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775299	chr9:107116829~107117557:+
HNSC	trans	rs7929679	0.571	rs10768099	ENSG00000225531.1	RP11-196I18.3	5.87	8.11e-09	0.0117	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775787	chr9:107116829~107117557:+
HNSC	trans	rs9650657	0.645	rs56057779	ENSG00000173295.6	FAM86B3P	-5.87	8.13e-09	0.0118	-0.29	-0.26	Neuroticism;	chr8:10659370	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.778	rs77666565	ENSG00000176998.4	HCG4	-5.87	8.16e-09	0.0118	-0.5	-0.26	Intelligence (multi-trait analysis);	chr6:26883636	chr6:29791753~29792750:-
HNSC	trans	rs9393777	0.778	rs13212921	ENSG00000253570.1	RNF5P1	5.87	8.17e-09	0.0118	0.53	0.26	Intelligence (multi-trait analysis);	chr6:27237643	chr8:38600661~38601200:-
HNSC	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	5.87	8.18e-09	0.0118	0.34	0.26	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
HNSC	trans	rs7937890	0.561	rs2575849	ENSG00000236360.2	RP11-334A14.2	5.87	8.21e-09	0.0119	0.35	0.26	Mitochondrial DNA levels;	chr11:14518093	chr1:52993201~52993702:-
HNSC	trans	rs67340775	0.541	rs200968	ENSG00000204709.4	LINC01556	5.87	8.25e-09	0.0119	0.41	0.26	Lung cancer in ever smokers;	chr6:27891790	chr6:28943877~28944537:+
HNSC	trans	rs2456568	0.564	rs7119708	ENSG00000276509.1	CH17-353B19.1	-5.87	8.27e-09	0.0119	-0.29	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93893475	chr1:146235806~146237807:+
HNSC	trans	rs7520050	0.966	rs12139630	ENSG00000255397.1	AC022182.2	5.87	8.27e-09	0.012	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45885263	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs12144263	ENSG00000255397.1	AC022182.2	5.87	8.27e-09	0.012	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45886774	chr8:60937705~60939871:-
HNSC	trans	rs6087990	0.835	rs4911106	ENSG00000253915.1	MAPRE1P1	5.87	8.28e-09	0.012	0.31	0.26	Ulcerative colitis;	chr20:32743524	chr8:135625185~135625981:-
HNSC	trans	rs9393777	0.92	rs35120058	ENSG00000253570.1	RNF5P1	5.87	8.3e-09	0.012	0.59	0.26	Intelligence (multi-trait analysis);	chr6:27390387	chr8:38600661~38601200:-
HNSC	trans	rs1933488	0.965	rs13215402	ENSG00000278974.1	RP11-756P10.6	-5.87	8.34e-09	0.012	-0.35	-0.26	Prostate cancer;	chr6:153126415	chr4:188740507~188741281:-
HNSC	trans	rs1568889	0.838	rs7933991	ENSG00000174912.7	METTL15P1	5.87	8.37e-09	0.0121	0.27	0.26	Bipolar disorder;	chr11:28038214	chr3:156713884~156714928:-
HNSC	trans	rs7520050	0.966	rs12760175	ENSG00000255397.1	AC022182.2	5.87	8.37e-09	0.0121	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:45982168	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.564	rs2736304	ENSG00000254340.1	RP11-10A14.3	-5.87	8.37e-09	0.0121	-0.31	-0.26	Retinal vascular caliber;	chr8:11379455	chr8:9141424~9145435:+
HNSC	trans	rs11220237	1	rs34506449	ENSG00000236257.1	EI24P2	5.87	8.37e-09	0.0121	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125833712	chr1:158454198~158455273:+
HNSC	trans	rs11220237	1	rs7937508	ENSG00000236257.1	EI24P2	5.87	8.37e-09	0.0121	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125834587	chr1:158454198~158455273:+
HNSC	trans	rs34421088	0.576	rs2572436	ENSG00000173295.6	FAM86B3P	-5.87	8.39e-09	0.0121	-0.33	-0.26	Neuroticism;	chr8:11241700	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	5.87	8.45e-09	0.0122	0.33	0.26	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
HNSC	trans	rs11992162	0.967	rs10112888	ENSG00000173295.6	FAM86B3P	5.87	8.46e-09	0.0122	0.29	0.26	Monocyte count;	chr8:11972699	chr8:8228595~8244865:+
HNSC	trans	rs7769051	0.522	rs62424539	ENSG00000227615.1	RP11-864N7.2	5.87	8.46e-09	0.0122	0.49	0.26	Type 2 diabetes nephropathy;	chr6:132852133	chr11:74745716~74746114:-
HNSC	trans	rs11835157	1	rs11835157	ENSG00000245954.5	RP11-18H21.1	-5.86	8.53e-09	0.0123	-0.51	-0.26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr12:96240427	chr4:152100754~152104720:+
HNSC	trans	rs2336384	1	rs1810563	ENSG00000261819.1	RP11-680G24.4	-5.86	8.57e-09	0.0124	-0.36	-0.26	Platelet count;	chr1:11993973	chr16:14988259~14990160:-
HNSC	trans	rs867371	1	rs13380319	ENSG00000259295.5	CSPG4P12	-5.86	8.61e-09	0.0124	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:85191438~85213905:+
HNSC	trans	rs7647973	0.626	rs9830730	ENSG00000197582.5	GPX1P1	5.86	8.63e-09	0.0124	0.44	0.26	Menarche (age at onset);	chr3:49638442	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs2329021	ENSG00000197582.5	GPX1P1	5.86	8.63e-09	0.0124	0.44	0.26	Menarche (age at onset);	chr3:49641639	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.587	rs10452032	ENSG00000197582.5	GPX1P1	5.86	8.63e-09	0.0124	0.44	0.26	Menarche (age at onset);	chr3:49643540	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.667	rs6446286	ENSG00000197582.5	GPX1P1	5.86	8.63e-09	0.0124	0.44	0.26	Menarche (age at onset);	chr3:49644271	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs4855846	ENSG00000197582.5	GPX1P1	5.86	8.63e-09	0.0124	0.44	0.26	Menarche (age at onset);	chr3:49646093	chrX:13378735~13379340:-
HNSC	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-5.86	8.63e-09	0.0124	-0.29	-0.26	Asthma;	chr12:55970537	chr15:64592979~64593326:+
HNSC	trans	rs853679	0.607	rs34950484	ENSG00000243753.4	HLA-L	-5.86	8.64e-09	0.0124	-0.55	-0.26	Depression;	chr6:28310911	chr6:30259584~30293014:+
HNSC	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	5.86	8.65e-09	0.0125	0.36	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
HNSC	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-5.86	8.66e-09	0.0125	-0.33	-0.26	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
HNSC	trans	rs7746199	0.736	rs35848276	ENSG00000243753.4	HLA-L	-5.86	8.66e-09	0.0125	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:30259584~30293014:+
HNSC	trans	rs11220237	0.62	rs60531419	ENSG00000236257.1	EI24P2	5.86	8.7e-09	0.0125	0.44	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125692958	chr1:158454198~158455273:+
HNSC	trans	rs9650657	0.74	rs10481451	ENSG00000253893.2	FAM85B	5.86	8.7e-09	0.0125	0.31	0.26	Neuroticism;	chr8:10791818	chr8:8167819~8226614:-
HNSC	trans	rs9425766	0.64	rs9660881	ENSG00000213331.4	RP11-713C19.2	5.86	8.74e-09	0.0126	0.36	0.26	Life satisfaction;	chr1:173867378	chr4:187970273~187971284:+
HNSC	trans	rs9425766	0.678	rs55829688	ENSG00000213331.4	RP11-713C19.2	5.86	8.74e-09	0.0126	0.36	0.26	Life satisfaction;	chr1:173868168	chr4:187970273~187971284:+
HNSC	trans	rs12295638	0.571	rs11029655	ENSG00000269846.1	RP4-621N11.2	-5.86	8.85e-09	0.0127	-0.4	-0.26	Obesity (extreme);	chr11:26629569	chr20:37095785~37097178:+
HNSC	trans	rs7824557	0.564	rs2572394	ENSG00000254340.1	RP11-10A14.3	-5.86	8.85e-09	0.0127	-0.31	-0.26	Retinal vascular caliber;	chr8:11377884	chr8:9141424~9145435:+
HNSC	trans	rs10435719	0.902	rs7459545	ENSG00000173295.6	FAM86B3P	5.86	8.86e-09	0.0127	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.569	rs35418978	ENSG00000254340.1	RP11-10A14.3	5.86	8.86e-09	0.0127	0.31	0.26	Retinal vascular caliber;	chr8:11328944	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.606	rs2736264	ENSG00000254340.1	RP11-10A14.3	5.86	8.86e-09	0.0127	0.31	0.26	Retinal vascular caliber;	chr8:11329130	chr8:9141424~9145435:+
HNSC	trans	rs950169	1	rs12902672	ENSG00000229212.6	RP11-561C5.4	-5.86	8.92e-09	0.0128	-0.36	-0.26	Schizophrenia;	chr15:84048234	chr15:85205440~85234795:-
HNSC	trans	rs2840044	0.711	rs225301	ENSG00000234130.2	RP13-88F20.1	-5.86	8.93e-09	0.0128	-0.34	-0.26	Response to radiotherapy in cancer (late toxicity);	chr17:35595392	chrX:93222220~93225015:-
HNSC	trans	rs6831352	0.879	rs36034266	ENSG00000233859.2	ADH5P4	5.86	8.96e-09	0.0129	0.32	0.26	Alcohol dependence;	chr4:99140237	chr6:65836930~65838039:-
HNSC	trans	rs2950393	0.804	rs2926752	ENSG00000228224.3	NACAP1	5.86	8.98e-09	0.0129	0.29	0.26	Platelet distribution width;	chr12:56710144	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.777	rs2958148	ENSG00000228224.3	NACAP1	5.86	8.98e-09	0.0129	0.29	0.26	Platelet distribution width;	chr12:56710153	chr8:101361794~101372707:+
HNSC	trans	rs10435719	0.902	rs11250179	ENSG00000173295.6	FAM86B3P	5.86	8.99e-09	0.0129	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:8228595~8244865:+
HNSC	trans	rs9467711	0.659	rs3734542	ENSG00000176998.4	HCG4	-5.86	8.99e-09	0.0129	-0.51	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs3734542	ENSG00000253570.1	RNF5P1	5.85	9.05e-09	0.013	0.59	0.26	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs34166054	ENSG00000204622.9	HLA-J	-5.85	9.1e-09	0.0131	-0.6	-0.26	Depression;	chr6:28098023	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13203816	ENSG00000204622.9	HLA-J	-5.85	9.1e-09	0.0131	-0.6	-0.26	Depression;	chr6:28111820	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.556	rs34588114	ENSG00000204622.9	HLA-J	-5.85	9.1e-09	0.0131	-0.6	-0.26	Depression;	chr6:28112850	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.546	rs34371502	ENSG00000204622.9	HLA-J	-5.85	9.1e-09	0.0131	-0.6	-0.26	Depression;	chr6:28113980	chr6:30006583~30009956:+
HNSC	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	5.85	9.12e-09	0.0131	0.34	0.26	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
HNSC	trans	rs1568889	0.887	rs2062269	ENSG00000174912.7	METTL15P1	5.85	9.13e-09	0.0131	0.28	0.26	Bipolar disorder;	chr11:28094990	chr3:156713884~156714928:-
HNSC	trans	rs17073641	0.553	rs7407204	ENSG00000214846.4	RP11-115L11.1	-5.85	9.13e-09	0.0131	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64721330	chr4:15730962~15731627:-
HNSC	trans	rs6087990	0.735	rs6058883	ENSG00000253915.1	MAPRE1P1	-5.85	9.14e-09	0.0131	-0.31	-0.26	Ulcerative colitis;	chr20:32777913	chr8:135625185~135625981:-
HNSC	trans	rs7520050	0.966	rs4660317	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45860554	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs10749860	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45862538	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs6688365	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45864212	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6656992	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45867396	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs61783220	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45869640	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs7540325	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45872545	chr8:60937705~60939871:-
HNSC	trans	rs7520050	1	rs7540699	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45872913	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs4660319	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45875951	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs11211213	ENSG00000255397.1	AC022182.2	5.85	9.15e-09	0.0131	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45876845	chr8:60937705~60939871:-
HNSC	trans	rs34421088	0.623	rs2572433	ENSG00000173295.6	FAM86B3P	5.85	9.24e-09	0.0132	0.32	0.26	Neuroticism;	chr8:11243532	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.838	rs716366	ENSG00000174912.7	METTL15P1	5.85	9.27e-09	0.0133	0.28	0.26	Bipolar disorder;	chr11:28099989	chr3:156713884~156714928:-
HNSC	trans	rs6831352	0.819	rs896992	ENSG00000233859.2	ADH5P4	-5.85	9.29e-09	0.0133	-0.3	-0.26	Alcohol dependence;	chr4:99081221	chr6:65836930~65838039:-
HNSC	trans	rs864643	0.513	rs1707944	ENSG00000183298.5	RP11-556K13.1	5.85	9.3e-09	0.0133	0.41	0.26	Attention deficit hyperactivity disorder;	chr3:39487141	chr1:101786340~101787219:-
HNSC	trans	rs7113874	0.592	rs34009921	ENSG00000266891.1	RP11-692N5.2	5.85	9.31e-09	0.0133	0.42	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8597314	chr18:9734882~9735602:-
HNSC	trans	rs1908814	0.516	rs13275143	ENSG00000173295.6	FAM86B3P	5.85	9.35e-09	0.0134	0.29	0.26	Neuroticism;	chr8:11939481	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.606	rs1047950	ENSG00000254340.1	RP11-10A14.3	5.85	9.37e-09	0.0134	0.31	0.26	Retinal vascular caliber;	chr8:11327587	chr8:9141424~9145435:+
HNSC	trans	rs7873102	1	rs7873102	ENSG00000229007.1	EXOSC3P1	-5.85	9.38e-09	0.0134	-0.32	-0.26	Brain structure;	chr9:38041145	chr21:32496812~32497311:+
HNSC	trans	rs1568889	0.838	rs10767708	ENSG00000174912.7	METTL15P1	5.85	9.38e-09	0.0134	0.27	0.26	Bipolar disorder;	chr11:28273300	chr3:156713884~156714928:-
HNSC	trans	rs9329221	0.537	rs1351876	ENSG00000173295.6	FAM86B3P	-5.85	9.39e-09	0.0134	-0.28	-0.26	Neuroticism;	chr8:10127267	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.527	rs2736298	ENSG00000254340.1	RP11-10A14.3	-5.85	9.42e-09	0.0135	-0.31	-0.26	Retinal vascular caliber;	chr8:11377627	chr8:9141424~9145435:+
HNSC	trans	rs2052923	1	rs12620289	ENSG00000177350.6	RPL13AP3	5.85	9.43e-09	0.0135	0.25	0.26	Coronary artery disease;	chr2:43184894	chr14:55766177~55767717:+
HNSC	trans	rs9393777	0.778	rs67457459	ENSG00000253570.1	RNF5P1	5.85	9.43e-09	0.0135	0.52	0.26	Intelligence (multi-trait analysis);	chr6:27230564	chr8:38600661~38601200:-
HNSC	trans	rs6756513	0.5	rs1048130	ENSG00000232654.1	FAM136BP	5.85	9.43e-09	0.0135	0.36	0.26	Breast cancer;Platelet count;	chr2:69904452	chr6:3045384~3045800:+
HNSC	trans	rs7121616	0.576	rs4802	ENSG00000214144.3	RP11-488L18.1	5.85	9.47e-09	0.0135	0.33	0.26	Breast cancer;	chr11:123057914	chr1:247229940~247231880:+
HNSC	trans	rs1568889	0.838	rs1525717	ENSG00000174912.7	METTL15P1	5.84	9.53e-09	0.0136	0.27	0.26	Bipolar disorder;	chr11:28059658	chr3:156713884~156714928:-
HNSC	trans	rs1568889	0.838	rs7131379	ENSG00000174912.7	METTL15P1	5.84	9.53e-09	0.0136	0.27	0.26	Bipolar disorder;	chr11:28064242	chr3:156713884~156714928:-
HNSC	trans	rs34421088	0.56	rs11780851	ENSG00000253893.2	FAM85B	5.84	9.55e-09	0.0136	0.31	0.26	Neuroticism;	chr8:11543607	chr8:8167819~8226614:-
HNSC	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	5.84	9.55e-09	0.0136	0.38	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
HNSC	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	5.84	9.56e-09	0.0137	0.33	0.26	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs34396849	ENSG00000243753.4	HLA-L	-5.84	9.56e-09	0.0137	-0.57	-0.26	Depression;	chr6:28283178	chr6:30259584~30293014:+
HNSC	trans	rs7520050	0.966	rs4076006	ENSG00000255397.1	AC022182.2	5.84	9.58e-09	0.0137	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45972404	chr8:60937705~60939871:-
HNSC	trans	rs216303	0.841	rs2239161	ENSG00000241717.1	VWFP1	5.84	9.59e-09	0.0137	0.44	0.26	Low vWF levels;	chr12:6053495	chr22:16690103~16704477:-
HNSC	trans	rs7520050	0.966	rs11211234	ENSG00000255397.1	AC022182.2	5.84	9.59e-09	0.0137	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45973115	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs11211241	ENSG00000255397.1	AC022182.2	5.84	9.59e-09	0.0137	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45987011	chr8:60937705~60939871:-
HNSC	trans	rs1816752	0.837	rs7139748	ENSG00000224976.2	PARP4P2	-5.84	9.6e-09	0.0137	-0.31	-0.26	Obesity-related traits;	chr13:24411531	chr13:19349137~19407962:+
HNSC	trans	rs3808502	0.516	rs6983727	ENSG00000173295.6	FAM86B3P	5.84	9.61e-09	0.0137	0.29	0.26	Neuroticism;	chr8:11558303	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.841	rs34332556	ENSG00000253570.1	RNF5P1	5.84	9.62e-09	0.0137	0.59	0.26	Intelligence (multi-trait analysis);	chr6:27389635	chr8:38600661~38601200:-
HNSC	trans	rs1023500	1	rs1023497	ENSG00000268568.1	AC007228.9	-5.84	9.63e-09	0.0137	-0.35	-0.26	Schizophrenia;	chr22:41944504	chr19:56672574~56673901:-
HNSC	trans	rs6831352	0.918	rs2851253	ENSG00000233859.2	ADH5P4	5.84	9.63e-09	0.0137	0.31	0.26	Alcohol dependence;	chr4:99122354	chr6:65836930~65838039:-
HNSC	trans	rs9650657	0.737	rs2116095	ENSG00000173295.6	FAM86B3P	-5.84	9.65e-09	0.0138	-0.29	-0.26	Neuroticism;	chr8:10777787	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.778	rs13219354	ENSG00000253570.1	RNF5P1	5.84	9.68e-09	0.0138	0.52	0.26	Intelligence (multi-trait analysis);	chr6:27217885	chr8:38600661~38601200:-
HNSC	trans	rs10989824	0.85	rs10820084	ENSG00000236901.4	MIR600HG	-5.84	9.7e-09	0.0138	-0.39	-0.26	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr9:102178547	chr9:123109494~123115477:-
HNSC	trans	rs7520050	0.966	rs6669522	ENSG00000255397.1	AC022182.2	5.84	9.71e-09	0.0138	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45932269	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6677007	ENSG00000255397.1	AC022182.2	5.84	9.71e-09	0.0138	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45934918	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs4660898	ENSG00000255397.1	AC022182.2	5.84	9.71e-09	0.0138	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45936499	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs11211230	ENSG00000255397.1	AC022182.2	5.84	9.71e-09	0.0138	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45941095	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs67340775	ENSG00000228078.1	HLA-U	-5.84	9.74e-09	0.0139	-0.57	-0.26	Depression;	chr6:28336607	chr6:29934101~29934286:+
HNSC	trans	rs7662987	1	rs28730640	ENSG00000228407.2	RP4-800M22.1	5.84	9.75e-09	0.0139	0.44	0.26	Smoking initiation;	chr4:99072902	chr1:52160261~52160600:-
HNSC	trans	rs7662987	1	rs7658118	ENSG00000228407.2	RP4-800M22.1	5.84	9.75e-09	0.0139	0.44	0.26	Smoking initiation;	chr4:99073457	chr1:52160261~52160600:-
HNSC	trans	rs4879656	0.564	rs1888869	ENSG00000215007.3	DNAJA1P3	-5.84	9.76e-09	0.0139	-0.31	-0.26	Menopause (age at onset);	chr9:32998239	chrX:107351650~107352843:-
HNSC	trans	rs17102884	0.506	rs887746	ENSG00000181227.3	RP4-682C21.2	5.84	9.76e-09	0.0139	0.26	0.26	Neuroticism;	chr14:74937114	chr1:75743423~75744776:-
HNSC	trans	rs3806843	0.868	rs2531352	ENSG00000231043.3	AC007238.1	5.84	9.78e-09	0.0139	0.26	0.26	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr2:58460292~58462032:-
HNSC	trans	rs7520050	0.966	rs11211208	ENSG00000255397.1	AC022182.2	5.84	9.79e-09	0.014	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45868584	chr8:60937705~60939871:-
HNSC	trans	rs722599	0.961	rs2359239	ENSG00000181227.3	RP4-682C21.2	5.84	9.84e-09	0.014	0.26	0.26	IgG glycosylation;	chr14:74860068	chr1:75743423~75744776:-
HNSC	trans	rs7930295	1	rs7930295	ENSG00000236257.1	EI24P2	5.84	9.85e-09	0.014	0.4	0.26	Schizophrenia;	chr11:125443703	chr1:158454198~158455273:+
HNSC	trans	rs9650657	0.711	rs7007318	ENSG00000253893.2	FAM85B	5.84	9.85e-09	0.014	0.32	0.26	Neuroticism;	chr8:10734768	chr8:8167819~8226614:-
HNSC	trans	rs11220237	1	rs11518432	ENSG00000236257.1	EI24P2	5.84	9.88e-09	0.0141	0.38	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125814838	chr1:158454198~158455273:+
HNSC	trans	rs864643	0.524	rs11706953	ENSG00000183298.5	RP11-556K13.1	5.84	9.89e-09	0.0141	0.49	0.26	Attention deficit hyperactivity disorder;	chr3:39472119	chr1:101786340~101787219:-
HNSC	trans	rs902774	0.818	rs73110464	ENSG00000255815.3	KRT8P11	-5.84	9.93e-09	0.0141	-0.48	-0.26	Prostate cancer;	chr12:52918828	chr9:99305176~99306611:+
HNSC	trans	rs6087990	0.765	rs6058900	ENSG00000253915.1	MAPRE1P1	5.84	9.94e-09	0.0142	0.31	0.26	Ulcerative colitis;	chr20:32812867	chr8:135625185~135625981:-
HNSC	trans	rs7520050	0.966	rs7524495	ENSG00000255397.1	AC022182.2	5.84	9.95e-09	0.0142	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45801260	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs12411269	ENSG00000255397.1	AC022182.2	5.84	9.95e-09	0.0142	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45805380	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs11211198	ENSG00000255397.1	AC022182.2	5.84	9.95e-09	0.0142	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45817001	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs10890352	ENSG00000255397.1	AC022182.2	5.84	9.95e-09	0.0142	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45817956	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6700597	ENSG00000255397.1	AC022182.2	5.84	9.95e-09	0.0142	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45818574	chr8:60937705~60939871:-
HNSC	trans	rs9650657	0.801	rs718741	ENSG00000173295.6	FAM86B3P	-5.84	9.95e-09	0.0142	-0.3	-0.26	Neuroticism;	chr8:10756874	chr8:8228595~8244865:+
HNSC	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-5.84	9.96e-09	0.0142	-0.33	-0.26	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-5.84	9.96e-09	0.0142	-0.33	-0.26	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs34396849	ENSG00000253570.1	RNF5P1	5.84	9.96e-09	0.0142	0.6	0.26	Depression;	chr6:28283178	chr8:38600661~38601200:-
HNSC	trans	rs6087990	0.842	rs6119279	ENSG00000253915.1	MAPRE1P1	5.84	9.98e-09	0.0142	0.3	0.26	Ulcerative colitis;	chr20:32742806	chr8:135625185~135625981:-
HNSC	trans	rs6831352	1	rs1126673	ENSG00000233859.2	ADH5P4	-5.84	1e-08	0.0142	-0.3	-0.26	Alcohol dependence;	chr4:99124465	chr6:65836930~65838039:-
HNSC	trans	rs17073641	0.534	rs35617612	ENSG00000214846.4	RP11-115L11.1	-5.84	1e-08	0.0143	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64729256	chr4:15730962~15731627:-
HNSC	trans	rs2950393	0.804	rs2290894	ENSG00000228224.3	NACAP1	5.84	1.01e-08	0.0143	0.28	0.26	Platelet distribution width;	chr12:56714911	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.777	rs2926747	ENSG00000228224.3	NACAP1	5.84	1.01e-08	0.0143	0.28	0.26	Platelet distribution width;	chr12:56716147	chr8:101361794~101372707:+
HNSC	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	5.83	1.01e-08	0.0143	0.33	0.26	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
HNSC	trans	rs7647973	0.588	rs9883000	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0144	0.42	0.26	Menarche (age at onset);	chr3:49630258	chrX:13378735~13379340:-
HNSC	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	5.83	1.01e-08	0.0144	0.33	0.26	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	5.83	1.01e-08	0.0144	0.33	0.26	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
HNSC	trans	rs10435719	0.902	rs7006538	ENSG00000173295.6	FAM86B3P	5.83	1.01e-08	0.0144	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:8228595~8244865:+
HNSC	trans	rs2950393	0.804	rs11171951	ENSG00000228224.3	NACAP1	5.83	1.02e-08	0.0144	0.28	0.26	Platelet distribution width;	chr12:56718853	chr8:101361794~101372707:+
HNSC	trans	rs853679	0.882	rs9468300	ENSG00000204622.9	HLA-J	-5.83	1.02e-08	0.0145	-0.49	-0.26	Depression;	chr6:28159062	chr6:30006583~30009956:+
HNSC	trans	rs9650657	0.836	rs891556	ENSG00000173295.6	FAM86B3P	-5.83	1.02e-08	0.0145	-0.3	-0.26	Neuroticism;	chr8:10766123	chr8:8228595~8244865:+
HNSC	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-5.83	1.02e-08	0.0145	-0.34	-0.26	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
HNSC	trans	rs9393777	0.777	rs56114371	ENSG00000243753.4	HLA-L	-5.83	1.03e-08	0.0146	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27307055	chr6:30259584~30293014:+
HNSC	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-5.83	1.03e-08	0.0146	-0.33	-0.26	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-5.83	1.03e-08	0.0146	-0.33	-0.26	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
HNSC	trans	rs73108077	0.736	rs6060993	ENSG00000279352.1	RP11-411B10.7	5.83	1.03e-08	0.0146	0.46	0.26	Red blood cell density in sickle cell anemia;	chr20:31278917	chr18:14010054~14010917:+
HNSC	trans	rs6087990	0.871	rs4911252	ENSG00000253915.1	MAPRE1P1	-5.83	1.03e-08	0.0147	-0.3	-0.26	Ulcerative colitis;	chr20:32742309	chr8:135625185~135625981:-
HNSC	trans	rs7520050	0.808	rs11211195	ENSG00000255397.1	AC022182.2	5.83	1.03e-08	0.0147	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45816623	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.808	rs11211196	ENSG00000255397.1	AC022182.2	5.83	1.03e-08	0.0147	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45816624	chr8:60937705~60939871:-
HNSC	trans	rs4713118	0.628	rs12179134	ENSG00000253570.1	RNF5P1	5.83	1.03e-08	0.0147	0.44	0.26	Parkinson's disease;	chr6:27707690	chr8:38600661~38601200:-
HNSC	trans	rs7520050	0.931	rs35743647	ENSG00000255397.1	AC022182.2	5.83	1.04e-08	0.0147	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45941580	chr8:60937705~60939871:-
HNSC	trans	rs2950393	0.777	rs7966391	ENSG00000228224.3	NACAP1	5.83	1.04e-08	0.0147	0.29	0.26	Platelet distribution width;	chr12:56745272	chr8:101361794~101372707:+
HNSC	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	5.83	1.04e-08	0.0148	0.33	0.26	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
HNSC	trans	rs7829975	0.511	rs2976902	ENSG00000269918.1	AF131215.9	5.83	1.04e-08	0.0148	0.26	0.26	Mood instability;	chr8:8483595	chr8:11104691~11106704:-
HNSC	trans	rs9650657	0.617	rs28680211	ENSG00000173295.6	FAM86B3P	-5.83	1.05e-08	0.0149	-0.29	-0.26	Neuroticism;	chr8:10661935	chr8:8228595~8244865:+
HNSC	trans	rs4713118	0.539	rs200988	ENSG00000204709.4	LINC01556	5.83	1.05e-08	0.0149	0.33	0.26	Parkinson's disease;	chr6:27851575	chr6:28943877~28944537:+
HNSC	trans	rs225245	0.541	rs321613	ENSG00000234130.2	RP13-88F20.1	5.83	1.05e-08	0.0149	0.3	0.26	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35554699	chrX:93222220~93225015:-
HNSC	trans	rs864643	0.574	rs1768192	ENSG00000183298.5	RP11-556K13.1	5.83	1.05e-08	0.0149	0.41	0.26	Attention deficit hyperactivity disorder;	chr3:39470669	chr1:101786340~101787219:-
HNSC	trans	rs7929679	0.602	rs1588354	ENSG00000225531.1	RP11-196I18.3	5.83	1.05e-08	0.0149	0.31	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34786939	chr9:107116829~107117557:+
HNSC	trans	rs2302190	0.769	rs8082396	ENSG00000273445.1	RP11-1399P15.1	5.83	1.05e-08	0.0149	0.31	0.26	Vitamin D levels;	chr17:58554832	chr2:87477495~87478034:-
HNSC	trans	rs7824557	0.527	rs57629785	ENSG00000254340.1	RP11-10A14.3	-5.83	1.06e-08	0.015	-0.31	-0.26	Retinal vascular caliber;	chr8:11377641	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs2572395	ENSG00000254340.1	RP11-10A14.3	-5.83	1.06e-08	0.015	-0.31	-0.26	Retinal vascular caliber;	chr8:11377851	chr8:9141424~9145435:+
HNSC	trans	rs4879656	0.564	rs1197774	ENSG00000215007.3	DNAJA1P3	5.83	1.06e-08	0.015	0.31	0.26	Menopause (age at onset);	chr9:33001451	chrX:107351650~107352843:-
HNSC	trans	rs7824557	0.564	rs2572392	ENSG00000254340.1	RP11-10A14.3	-5.83	1.06e-08	0.015	-0.31	-0.26	Retinal vascular caliber;	chr8:11378096	chr8:9141424~9145435:+
HNSC	trans	rs4343996	0.902	rs4349886	ENSG00000224750.5	RP11-94M14.2	5.83	1.06e-08	0.015	0.27	0.26	Motion sickness;	chr7:3330406	chr10:90454170~90502968:+
HNSC	trans	rs2950393	0.804	rs2926752	ENSG00000257210.1	NACAP3	5.83	1.06e-08	0.015	0.29	0.26	Platelet distribution width;	chr12:56710144	chr12:93124063~93124543:-
HNSC	trans	rs2950393	0.777	rs2958148	ENSG00000257210.1	NACAP3	5.83	1.06e-08	0.015	0.29	0.26	Platelet distribution width;	chr12:56710153	chr12:93124063~93124543:-
HNSC	trans	rs74902201	1	rs16960045	ENSG00000280434.1	RP4-671O14.6	-5.83	1.06e-08	0.0151	-0.5	-0.26	Food addiction;	chr17:66692790	chr22:44139365~44153626:+
HNSC	trans	rs2950393	0.929	rs10876916	ENSG00000228224.3	NACAP1	5.83	1.06e-08	0.0151	0.28	0.26	Platelet distribution width;	chr12:56692728	chr8:101361794~101372707:+
HNSC	trans	rs722599	0.683	rs8014695	ENSG00000181227.3	RP4-682C21.2	-5.82	1.06e-08	0.0151	-0.27	-0.26	IgG glycosylation;	chr14:74834914	chr1:75743423~75744776:-
HNSC	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	5.82	1.07e-08	0.0151	0.33	0.26	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
HNSC	trans	rs10435719	0.902	rs12681142	ENSG00000173295.6	FAM86B3P	5.82	1.07e-08	0.0151	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:8228595~8244865:+
HNSC	trans	rs2274223	0.62	rs35658839	ENSG00000264070.1	DND1P1	5.82	1.07e-08	0.0151	0.38	0.26	Esophageal cancer;Esophageal squamous cell carcinoma;	chr10:94302642	chr17:45585871~45586929:+
HNSC	trans	rs7520050	0.933	rs6694340	ENSG00000255397.1	AC022182.2	5.82	1.07e-08	0.0152	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45823744	chr8:60937705~60939871:-
HNSC	trans	rs9876781	0.507	rs1824362	ENSG00000235912.1	RP1-159A19.3	5.82	1.07e-08	0.0152	0.28	0.26	Longevity;	chr3:48360459	chr1:27649419~27649610:+
HNSC	trans	rs9425766	0.566	rs10912773	ENSG00000213331.4	RP11-713C19.2	5.82	1.07e-08	0.0152	0.31	0.26	Life satisfaction;	chr1:174374567	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.564	rs2437152	ENSG00000254340.1	RP11-10A14.3	-5.82	1.08e-08	0.0152	-0.3	-0.26	Retinal vascular caliber;	chr8:11377988	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs2736300	ENSG00000254340.1	RP11-10A14.3	-5.82	1.08e-08	0.0152	-0.3	-0.26	Retinal vascular caliber;	chr8:11378070	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.931	rs11211189	ENSG00000255397.1	AC022182.2	5.82	1.08e-08	0.0152	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45795912	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs34878803	ENSG00000253570.1	RNF5P1	5.82	1.08e-08	0.0152	0.6	0.26	Depression;	chr6:28282402	chr8:38600661~38601200:-
HNSC	trans	rs12145833	0.619	rs10927006	ENSG00000154608.12	CEP170P1	-5.82	1.08e-08	0.0153	-0.35	-0.26	Obesity (early onset extreme);	chr1:243394357	chr4:118467590~118554204:+
HNSC	trans	rs16953946	0.542	rs3114391	ENSG00000257497.2	RP11-585P4.5	5.82	1.08e-08	0.0153	0.52	0.26	Inflammatory bowel disease;	chr16:80708830	chr12:75483454~75489820:-
HNSC	trans	rs853679	1	rs10456362	ENSG00000271581.1	XXbac-BPG248L24.12	5.82	1.08e-08	0.0153	0.38	0.26	Depression;	chr6:28254038	chr6:31356647~31357637:+
HNSC	trans	rs8014204	0.935	rs3742786	ENSG00000181227.3	RP4-682C21.2	5.82	1.08e-08	0.0153	0.25	0.26	Caffeine consumption;	chr14:74906308	chr1:75743423~75744776:-
HNSC	trans	rs7520050	0.931	rs6686134	ENSG00000255397.1	AC022182.2	5.82	1.08e-08	0.0153	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45912596	chr8:60937705~60939871:-
HNSC	trans	rs16953946	0.542	rs8048249	ENSG00000257497.2	RP11-585P4.5	-5.82	1.09e-08	0.0153	-0.51	-0.26	Inflammatory bowel disease;	chr16:80709534	chr12:75483454~75489820:-
HNSC	trans	rs864643	0.513	rs1707956	ENSG00000183298.5	RP11-556K13.1	-5.82	1.09e-08	0.0154	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr3:39482025	chr1:101786340~101787219:-
HNSC	trans	rs1908814	0.541	rs7824267	ENSG00000173295.6	FAM86B3P	5.82	1.09e-08	0.0154	0.29	0.26	Neuroticism;	chr8:11936770	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-5.82	1.09e-08	0.0154	-0.33	-0.26	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-5.82	1.09e-08	0.0154	-0.33	-0.26	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-5.82	1.09e-08	0.0154	-0.33	-0.26	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-5.82	1.09e-08	0.0154	-0.33	-0.26	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
HNSC	trans	rs7824557	0.564	rs2572379	ENSG00000254340.1	RP11-10A14.3	-5.82	1.09e-08	0.0154	-0.31	-0.26	Retinal vascular caliber;	chr8:11379971	chr8:9141424~9145435:+
HNSC	trans	rs7121538	0.673	rs731274	ENSG00000236360.2	RP11-334A14.2	5.82	1.09e-08	0.0154	0.5	0.26	HDL cholesterol;	chr11:14252131	chr1:52993201~52993702:-
HNSC	trans	rs3826795	0.569	rs76909958	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46292542	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.53	rs7256047	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46292776	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs73059722	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46293161	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs73059723	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46293245	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs73059724	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46293510	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs73059725	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46293511	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs73059726	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46293937	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.53	rs117992292	ENSG00000269463.1	RP11-727F15.13	-5.82	1.09e-08	0.0154	-0.39	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46294038	chr11:62807682~62808063:-
HNSC	trans	rs7647973	0.626	rs6809879	ENSG00000197582.5	GPX1P1	-5.82	1.1e-08	0.0155	-0.43	-0.26	Menarche (age at onset);	chr3:49797138	chrX:13378735~13379340:-
HNSC	trans	rs4906172	0.838	rs2619092	ENSG00000181359.5	HSP90AA6P	5.82	1.1e-08	0.0155	0.35	0.26	Menopause (age at onset);	chr14:101959638	chr4:170581470~170605450:-
HNSC	trans	rs8014204	0.901	rs2080087	ENSG00000181227.3	RP4-682C21.2	-5.82	1.1e-08	0.0156	-0.26	-0.26	Caffeine consumption;	chr14:74898359	chr1:75743423~75744776:-
HNSC	trans	rs2950393	0.726	rs10459246	ENSG00000228224.3	NACAP1	-5.82	1.1e-08	0.0156	-0.29	-0.26	Platelet distribution width;	chr12:56776034	chr8:101361794~101372707:+
HNSC	trans	rs1816752	0.87	rs73469543	ENSG00000224976.2	PARP4P2	-5.82	1.11e-08	0.0156	-0.31	-0.26	Obesity-related traits;	chr13:24424832	chr13:19349137~19407962:+
HNSC	trans	rs10100465	0.889	rs7838659	ENSG00000224861.1	YBX1P1	5.82	1.11e-08	0.0157	0.27	0.26	Leprosy;	chr8:117672755	chr14:66012830~66013789:-
HNSC	trans	rs17301013	0.861	rs10912824	ENSG00000213331.4	RP11-713C19.2	5.82	1.11e-08	0.0157	0.31	0.26	Systemic lupus erythematosus;	chr1:174625846	chr4:187970273~187971284:+
HNSC	trans	rs17073641	0.553	rs34386993	ENSG00000214846.4	RP11-115L11.1	-5.82	1.12e-08	0.0157	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64720155	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.534	rs62098890	ENSG00000214846.4	RP11-115L11.1	-5.82	1.12e-08	0.0157	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64720844	chr4:15730962~15731627:-
HNSC	trans	rs853679	0.546	rs13214023	ENSG00000243753.4	HLA-L	5.82	1.12e-08	0.0158	0.53	0.26	Depression;	chr6:28364364	chr6:30259584~30293014:+
HNSC	trans	rs4713118	0.699	rs573179	ENSG00000204709.4	LINC01556	5.82	1.12e-08	0.0158	0.35	0.26	Parkinson's disease;	chr6:27881898	chr6:28943877~28944537:+
HNSC	trans	rs17073641	0.553	rs2048016	ENSG00000214846.4	RP11-115L11.1	-5.82	1.12e-08	0.0158	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64727942	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs12458071	ENSG00000214846.4	RP11-115L11.1	-5.82	1.12e-08	0.0158	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64728202	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs1506234	ENSG00000214846.4	RP11-115L11.1	-5.82	1.12e-08	0.0158	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64728572	chr4:15730962~15731627:-
HNSC	trans	rs673253	0.662	rs11210869	ENSG00000231007.5	CDC20P1	5.82	1.12e-08	0.0158	0.38	0.26	Intelligence (multi-trait analysis);	chr1:43560369	chr9:87011652~87013151:+
HNSC	trans	rs3779195	0.929	rs2906184	ENSG00000230273.1	AC087163.3	-5.82	1.12e-08	0.0158	-0.33	-0.26	Sex hormone-binding globulin levels;	chr7:98310675	chr17:17981192~17981572:-
HNSC	trans	rs11992162	0.967	rs10108320	ENSG00000173295.6	FAM86B3P	-5.82	1.12e-08	0.0158	-0.28	-0.26	Monocyte count;	chr8:11974754	chr8:8228595~8244865:+
HNSC	trans	rs12295638	0.571	rs12269966	ENSG00000269846.1	RP4-621N11.2	-5.82	1.12e-08	0.0158	-0.39	-0.26	Obesity (extreme);	chr11:26629600	chr20:37095785~37097178:+
HNSC	trans	rs17301013	0.861	rs7521870	ENSG00000213331.4	RP11-713C19.2	-5.82	1.13e-08	0.0159	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174497239	chr4:187970273~187971284:+
HNSC	trans	rs4713118	0.699	rs200978	ENSG00000204709.4	LINC01556	5.81	1.13e-08	0.0159	0.35	0.26	Parkinson's disease;	chr6:27885390	chr6:28943877~28944537:+
HNSC	trans	rs9329221	0.621	rs522483	ENSG00000173295.6	FAM86B3P	-5.81	1.13e-08	0.0159	-0.28	-0.26	Neuroticism;	chr8:9955459	chr8:8228595~8244865:+
HNSC	trans	rs864643	0.678	rs1707959	ENSG00000183298.5	RP11-556K13.1	5.81	1.13e-08	0.0159	0.42	0.26	Attention deficit hyperactivity disorder;	chr3:39481807	chr1:101786340~101787219:-
HNSC	trans	rs9650657	0.769	rs2116093	ENSG00000173295.6	FAM86B3P	-5.81	1.13e-08	0.016	-0.3	-0.26	Neuroticism;	chr8:10755789	chr8:8228595~8244865:+
HNSC	trans	rs17073641	0.571	rs12969595	ENSG00000214846.4	RP11-115L11.1	-5.81	1.13e-08	0.016	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64729088	chr4:15730962~15731627:-
HNSC	trans	rs3747547	0.892	rs17516779	ENSG00000229007.1	EXOSC3P1	5.81	1.13e-08	0.016	0.56	0.26	Metabolite levels (Dihydroxy docosatrienoic acid);	chr9:37955268	chr21:32496812~32497311:+
HNSC	trans	rs6831352	0.918	rs35784540	ENSG00000233859.2	ADH5P4	5.81	1.14e-08	0.016	0.32	0.26	Alcohol dependence;	chr4:99140541	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs34876213	ENSG00000233859.2	ADH5P4	5.81	1.14e-08	0.016	0.32	0.26	Alcohol dependence;	chr4:99141065	chr6:65836930~65838039:-
HNSC	trans	rs8014204	0.935	rs10141438	ENSG00000181227.3	RP4-682C21.2	5.81	1.14e-08	0.016	0.25	0.26	Caffeine consumption;	chr14:74887897	chr1:75743423~75744776:-
HNSC	trans	rs8014204	0.753	rs6574199	ENSG00000181227.3	RP4-682C21.2	5.81	1.14e-08	0.016	0.25	0.26	Caffeine consumption;	chr14:74889400	chr1:75743423~75744776:-
HNSC	trans	rs7520050	0.933	rs12565042	ENSG00000255397.1	AC022182.2	5.81	1.14e-08	0.016	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45833438	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs10789475	ENSG00000255397.1	AC022182.2	5.81	1.14e-08	0.016	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45838505	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.933	rs6666743	ENSG00000255397.1	AC022182.2	5.81	1.14e-08	0.016	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45845603	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.933	rs9787208	ENSG00000255397.1	AC022182.2	5.81	1.14e-08	0.016	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45848944	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.933	rs6680211	ENSG00000255397.1	AC022182.2	5.81	1.14e-08	0.016	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45849335	chr8:60937705~60939871:-
HNSC	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	5.81	1.14e-08	0.0161	0.31	0.26	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
HNSC	trans	rs3808502	0.503	rs2061830	ENSG00000253893.2	FAM85B	-5.81	1.14e-08	0.0161	-0.3	-0.26	Neuroticism;	chr8:11539948	chr8:8167819~8226614:-
HNSC	trans	rs7819412	0.749	rs11991118	ENSG00000254340.1	RP11-10A14.3	5.81	1.14e-08	0.0161	0.31	0.26	Triglycerides;	chr8:11081763	chr8:9141424~9145435:+
HNSC	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	5.81	1.15e-08	0.0161	0.3	0.26	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
HNSC	trans	rs11220237	0.92	rs11220263	ENSG00000236257.1	EI24P2	5.81	1.15e-08	0.0162	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125885375	chr1:158454198~158455273:+
HNSC	trans	rs9467711	0.606	rs2073529	ENSG00000253570.1	RNF5P1	-5.81	1.15e-08	0.0162	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26374931	chr8:38600661~38601200:-
HNSC	trans	rs6673267	0.807	rs3767499	ENSG00000244144.1	RP11-757F18.3	-5.81	1.15e-08	0.0162	-0.3	-0.26	Lobe attachment (rater-scored or self-reported);	chr1:201051723	chr3:112185480~112185998:-
HNSC	trans	rs722599	0.715	rs61978928	ENSG00000181227.3	RP4-682C21.2	5.81	1.15e-08	0.0162	0.27	0.26	IgG glycosylation;	chr14:74855011	chr1:75743423~75744776:-
HNSC	trans	rs6831352	0.918	rs2851246	ENSG00000233859.2	ADH5P4	-5.81	1.16e-08	0.0162	-0.32	-0.26	Alcohol dependence;	chr4:99124953	chr6:65836930~65838039:-
HNSC	trans	rs1568889	0.73	rs6484350	ENSG00000174912.7	METTL15P1	-5.81	1.16e-08	0.0163	-0.27	-0.26	Bipolar disorder;	chr11:28092111	chr3:156713884~156714928:-
HNSC	trans	rs16975963	0.644	rs12459013	ENSG00000247498.8	RP11-392P7.6	5.81	1.16e-08	0.0163	0.42	0.26	Longevity;	chr19:37638596	chr12:12927726~12984645:+
HNSC	trans	rs9467711	0.517	rs16901784	ENSG00000253570.1	RNF5P1	5.81	1.16e-08	0.0164	0.53	0.26	Autism spectrum disorder or schizophrenia;	chr6:26555205	chr8:38600661~38601200:-
HNSC	trans	rs2898290	0.622	rs4840567	ENSG00000173295.6	FAM86B3P	-5.81	1.17e-08	0.0164	-0.29	-0.26	Systolic blood pressure;	chr8:11490116	chr8:8228595~8244865:+
HNSC	trans	rs7113874	0.578	rs67067089	ENSG00000266891.1	RP11-692N5.2	5.81	1.17e-08	0.0164	0.4	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508480	chr18:9734882~9735602:-
HNSC	trans	rs7121538	0.673	rs11023164	ENSG00000236360.2	RP11-334A14.2	5.81	1.17e-08	0.0164	0.5	0.26	HDL cholesterol;	chr11:14261908	chr1:52993201~52993702:-
HNSC	trans	rs950169	0.92	rs2135551	ENSG00000229212.6	RP11-561C5.4	-5.81	1.17e-08	0.0164	-0.36	-0.26	Schizophrenia;	chr15:84039099	chr15:85205440~85234795:-
HNSC	trans	rs1473307	0.902	rs13020655	ENSG00000224295.2	AC087380.14	-5.81	1.17e-08	0.0164	-0.31	-0.26	Menopause (age at onset);	chr2:225286647	chr11:5518441~5524955:-
HNSC	trans	rs225245	0.541	rs321612	ENSG00000234130.2	RP13-88F20.1	5.81	1.17e-08	0.0164	0.3	0.26	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35554612	chrX:93222220~93225015:-
HNSC	trans	rs714543	1	rs10267576	ENSG00000226038.5	PPIAP21	-5.81	1.18e-08	0.0166	-0.31	-0.26	Plateletcrit;	chr7:44831334	chr20:43230760~43231260:+
HNSC	trans	rs714543	1	rs714543	ENSG00000226038.5	PPIAP21	-5.81	1.18e-08	0.0166	-0.31	-0.26	Plateletcrit;	chr7:44847477	chr20:43230760~43231260:+
HNSC	trans	rs714543	1	rs757693	ENSG00000226038.5	PPIAP21	-5.81	1.18e-08	0.0166	-0.31	-0.26	Plateletcrit;	chr7:44848430	chr20:43230760~43231260:+
HNSC	trans	rs714543	0.967	rs11762008	ENSG00000226038.5	PPIAP21	-5.81	1.18e-08	0.0166	-0.31	-0.26	Plateletcrit;	chr7:44864065	chr20:43230760~43231260:+
HNSC	trans	rs9733	0.519	rs7529194	ENSG00000180764.13	PIPSL	-5.81	1.18e-08	0.0166	-0.31	-0.26	Tonsillectomy;	chr1:150650144	chr10:93958191~93961540:-
HNSC	trans	rs546131	0.928	rs552171	ENSG00000225531.1	RP11-196I18.3	5.81	1.19e-08	0.0166	0.32	0.26	Lung disease severity in cystic fibrosis;	chr11:34809162	chr9:107116829~107117557:+
HNSC	trans	rs546131	0.928	rs550313	ENSG00000225531.1	RP11-196I18.3	5.81	1.19e-08	0.0166	0.32	0.26	Lung disease severity in cystic fibrosis;	chr11:34809372	chr9:107116829~107117557:+
HNSC	trans	rs6549438	0.524	rs4677087	ENSG00000280161.1	CTC-205M6.1	-5.81	1.19e-08	0.0166	-0.24	-0.26	Migraine - clinic-based;	chr3:72109292	chr5:180810401~180811384:+
HNSC	trans	rs8073060	0.518	rs225285	ENSG00000234130.2	RP13-88F20.1	-5.81	1.19e-08	0.0166	-0.33	-0.26	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35604065	chrX:93222220~93225015:-
HNSC	trans	rs853679	0.607	rs34950484	ENSG00000253570.1	RNF5P1	5.81	1.19e-08	0.0166	0.58	0.26	Depression;	chr6:28310911	chr8:38600661~38601200:-
HNSC	trans	rs722599	0.683	rs17102847	ENSG00000181227.3	RP4-682C21.2	5.81	1.19e-08	0.0166	0.27	0.26	IgG glycosylation;	chr14:74858077	chr1:75743423~75744776:-
HNSC	trans	rs7769051	0.522	rs10457596	ENSG00000227615.1	RP11-864N7.2	5.8	1.19e-08	0.0167	0.52	0.26	Type 2 diabetes nephropathy;	chr6:132848835	chr11:74745716~74746114:-
HNSC	trans	rs9650657	0.836	rs1073913	ENSG00000173295.6	FAM86B3P	-5.8	1.19e-08	0.0167	-0.3	-0.26	Neuroticism;	chr8:10754198	chr8:8228595~8244865:+
HNSC	trans	rs1821002	1	rs1821002	ENSG00000173295.6	FAM86B3P	-5.8	1.2e-08	0.0168	-0.29	-0.26	Systolic blood pressure;	chr8:10782555	chr8:8228595~8244865:+
HNSC	trans	rs4869931	0.929	rs12664686	ENSG00000262587.2	RP11-266L9.4	5.8	1.2e-08	0.0168	0.32	0.26	Systolic blood pressure in sickle cell anemia;	chr6:150660829	chr16:25031744~25058109:+
HNSC	trans	rs2456568	0.564	rs4608039	ENSG00000276509.1	CH17-353B19.1	-5.8	1.2e-08	0.0169	-0.28	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93891633	chr1:146235806~146237807:+
HNSC	trans	rs9425766	0.591	rs2049991	ENSG00000213331.4	RP11-713C19.2	5.8	1.2e-08	0.0169	0.31	0.26	Life satisfaction;	chr1:174356428	chr4:187970273~187971284:+
HNSC	trans	rs7829975	0.593	rs2921061	ENSG00000269918.1	AF131215.9	5.8	1.2e-08	0.0169	0.26	0.26	Mood instability;	chr8:8460105	chr8:11104691~11106704:-
HNSC	trans	rs853679	0.882	rs4713139	ENSG00000204622.9	HLA-J	-5.8	1.2e-08	0.0169	-0.48	-0.26	Depression;	chr6:28124907	chr6:30006583~30009956:+
HNSC	trans	rs5769765	0.671	rs138833	ENSG00000234751.1	AP002381.2	-5.8	1.21e-08	0.0169	-0.35	-0.26	Schizophrenia;	chr22:49785269	chr11:72940498~72941112:+
HNSC	trans	rs9467711	0.606	rs9393713	ENSG00000176998.4	HCG4	-5.8	1.21e-08	0.0169	-0.46	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26373450	chr6:29791753~29792750:-
HNSC	trans	rs11220237	1	rs56338707	ENSG00000236257.1	EI24P2	5.8	1.21e-08	0.017	0.39	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125883330	chr1:158454198~158455273:+
HNSC	trans	rs7829975	0.626	rs907183	ENSG00000269918.1	AF131215.9	-5.8	1.22e-08	0.017	-0.25	-0.26	Mood instability;	chr8:8872251	chr8:11104691~11106704:-
HNSC	trans	rs13016963	0.546	rs11898821	ENSG00000235105.1	RP11-329A14.1	5.8	1.22e-08	0.0171	0.31	0.26	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr1:48435967~48437223:+
HNSC	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-5.8	1.24e-08	0.0173	-0.33	-0.26	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
HNSC	trans	rs6831352	0.918	rs7694646	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99138581	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs7670638	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99138656	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs4699712	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99139339	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs4699713	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99139362	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs4699714	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99139387	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.84	rs17817868	ENSG00000233859.2	ADH5P4	5.8	1.24e-08	0.0173	0.31	0.26	Alcohol dependence;	chr4:99139472	chr6:65836930~65838039:-
HNSC	trans	rs2162440	0.528	rs17671611	ENSG00000213590.2	RP11-229P13.2	5.8	1.24e-08	0.0173	0.35	0.26	Telomere length;	chr18:37670895	chr9:136935840~136937161:+
HNSC	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-5.8	1.24e-08	0.0173	-0.33	-0.26	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
HNSC	trans	rs916888	0.61	rs199436	ENSG00000204650.12	CRHR1-IT1	-5.8	1.24e-08	0.0173	-0.29	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45620328~45648216:+
HNSC	trans	rs10506710	0.721	rs10879560	ENSG00000263266.2	RPS7P1	5.8	1.24e-08	0.0173	0.22	0.26	Systolic blood pressure;	chr12:73126811	chr17:28467822~28468406:+
HNSC	trans	rs11250098	0.547	rs2409764	ENSG00000173295.6	FAM86B3P	5.8	1.25e-08	0.0174	0.29	0.26	Morning vs. evening chronotype;	chr8:11423764	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-5.8	1.25e-08	0.0174	-0.33	-0.26	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
HNSC	trans	rs7873102	0.9	rs12380890	ENSG00000229007.1	EXOSC3P1	-5.8	1.25e-08	0.0175	-0.32	-0.26	Brain structure;	chr9:38002259	chr21:32496812~32497311:+
HNSC	trans	rs546131	1	rs546131	ENSG00000225531.1	RP11-196I18.3	5.79	1.26e-08	0.0176	0.32	0.26	Lung disease severity in cystic fibrosis;	chr11:34830213	chr9:107116829~107117557:+
HNSC	trans	rs7520050	0.966	rs7550746	ENSG00000255397.1	AC022182.2	5.79	1.26e-08	0.0176	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45886047	chr8:60937705~60939871:-
HNSC	trans	rs13416322	0.754	rs56890545	ENSG00000214286.2	PDCL3P3	5.79	1.27e-08	0.0177	0.39	0.26	Intelligence (multi-trait analysis);	chr2:100541138	chr3:17877455~17878169:-
HNSC	trans	rs7520050	0.966	rs11211199	ENSG00000255397.1	AC022182.2	5.79	1.27e-08	0.0177	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45822197	chr8:60937705~60939871:-
HNSC	trans	rs2250402	0.51	rs6492926	ENSG00000234106.3	RP11-288E14.2	5.79	1.27e-08	0.0177	0.58	0.26	Corneal curvature;	chr15:40033628	chr11:93535468~93535816:+
HNSC	trans	rs6011368	0.84	rs2427638	ENSG00000226210.3	WASH7P	5.79	1.27e-08	0.0177	0.29	0.26	Clozapine-induced cytotoxicity;	chr20:64269364	chr12:14522~32015:-
HNSC	trans	rs7520050	0.966	rs10890361	ENSG00000255397.1	AC022182.2	5.79	1.27e-08	0.0177	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:45880562	chr8:60937705~60939871:-
HNSC	trans	rs1908814	0.516	rs4841641	ENSG00000173295.6	FAM86B3P	5.79	1.27e-08	0.0178	0.28	0.26	Neuroticism;	chr8:11940718	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	5.79	1.28e-08	0.0178	0.33	0.26	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	5.79	1.28e-08	0.0178	0.33	0.26	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
HNSC	trans	rs11220082	0.787	rs34632138	ENSG00000236257.1	EI24P2	-5.79	1.28e-08	0.0178	-0.32	-0.26	Schizophrenia;	chr11:125428402	chr1:158454198~158455273:+
HNSC	trans	rs7824557	0.592	rs2572371	ENSG00000173295.6	FAM86B3P	5.79	1.28e-08	0.0178	0.27	0.26	Retinal vascular caliber;	chr8:11366284	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.778	rs35608615	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0178	0.53	0.26	Intelligence (multi-trait analysis);	chr6:27072623	chr8:38600661~38601200:-
HNSC	trans	rs9393777	0.778	rs35526527	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0178	0.53	0.26	Intelligence (multi-trait analysis);	chr6:27074508	chr8:38600661~38601200:-
HNSC	trans	rs7520050	0.966	rs6668284	ENSG00000255397.1	AC022182.2	5.79	1.28e-08	0.0178	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45888838	chr8:60937705~60939871:-
HNSC	trans	rs9425766	0.64	rs2067079	ENSG00000213331.4	RP11-713C19.2	5.79	1.28e-08	0.0178	0.35	0.26	Life satisfaction;	chr1:173866073	chr4:187970273~187971284:+
HNSC	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	5.79	1.28e-08	0.0179	0.33	0.26	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
HNSC	trans	rs7809615	0.515	rs10257273	ENSG00000228834.1	RP11-249L21.4	5.79	1.28e-08	0.0179	0.39	0.26	Blood metabolite ratios;	chr7:99590966	chr6:108907615~108907873:-
HNSC	trans	rs7824557	0.606	rs2736270	ENSG00000173295.6	FAM86B3P	5.79	1.29e-08	0.0179	0.29	0.26	Retinal vascular caliber;	chr8:11335084	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	5.79	1.29e-08	0.018	0.32	0.26	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
HNSC	trans	rs17073641	0.571	rs11659744	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726795	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs11662774	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726913	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs11151153	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726969	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs11151154	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64727251	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs2048017	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64727810	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.571	rs12955865	ENSG00000214846.4	RP11-115L11.1	-5.79	1.29e-08	0.018	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726354	chr4:15730962~15731627:-
HNSC	trans	rs17518584	0.934	rs1991872	ENSG00000263266.2	RPS7P1	5.79	1.29e-08	0.018	0.33	0.26	Cognitive function;Information processing speed;	chr3:85394643	chr17:28467822~28468406:+
HNSC	trans	rs6087990	0.735	rs2424906	ENSG00000253915.1	MAPRE1P1	5.79	1.31e-08	0.0182	0.31	0.26	Ulcerative colitis;	chr20:32771303	chr8:135625185~135625981:-
HNSC	trans	rs853679	1	rs9986596	ENSG00000253570.1	RNF5P1	5.79	1.31e-08	0.0182	0.44	0.26	Depression;	chr6:28251883	chr8:38600661~38601200:-
HNSC	trans	rs6831352	0.918	rs29001224	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99126222	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.84	rs29001223	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99126282	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs1126672	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99126661	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs6813415	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99127358	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs67311928	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99127848	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.877	rs28987101	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99128102	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs28987097	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99128428	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13112733	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129168	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13140423	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129249	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs13113166	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129377	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs34805407	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129635	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs35662508	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129823	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs34071486	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99129936	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs34360292	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99130152	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001216	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99130405	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs29001215	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99130571	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001214	ENSG00000233859.2	ADH5P4	5.79	1.31e-08	0.0182	0.31	0.26	Alcohol dependence;	chr4:99130582	chr6:65836930~65838039:-
HNSC	trans	rs12200782	0.872	rs10484440	ENSG00000242375.1	RP11-498P14.3	5.79	1.32e-08	0.0184	0.49	0.26	Small cell lung carcinoma;	chr6:26453514	chr9:97195351~97197687:-
HNSC	trans	rs190945449	1	rs190945449	ENSG00000176998.4	HCG4	-5.79	1.32e-08	0.0184	-0.49	-0.26	Urinary tract infection frequency;	chr6:26860580	chr6:29791753~29792750:-
HNSC	trans	rs1391708	0.834	rs34263825	ENSG00000121089.4	NACA3P	-5.79	1.32e-08	0.0184	-0.45	-0.26	Airway wall thickness;	chr12:56902465	chr4:164943290~164943937:+
HNSC	trans	rs6831352	0.918	rs1042365	ENSG00000233859.2	ADH5P4	5.79	1.33e-08	0.0184	0.32	0.26	Alcohol dependence;	chr4:99124349	chr6:65836930~65838039:-
HNSC	trans	rs9733	0.596	rs7418501	ENSG00000180764.13	PIPSL	-5.79	1.33e-08	0.0184	-0.3	-0.26	Tonsillectomy;	chr1:150739420	chr10:93958191~93961540:-
HNSC	trans	rs4730250	0.707	rs1981696	ENSG00000274012.1	RN7SL2	-5.78	1.33e-08	0.0185	-0.36	-0.26	Osteoarthritis;	chr7:107153655	chr14:49862550~49862849:-
HNSC	trans	rs3111637	1	rs1544781	ENSG00000216285.5	RP11-490H24.5	-5.78	1.33e-08	0.0185	-0.33	-0.26	Reticulocyte count;	chr5:54360538	chr12:104030779~104031543:+
HNSC	trans	rs6087990	0.842	rs4911105	ENSG00000253915.1	MAPRE1P1	5.78	1.33e-08	0.0185	0.3	0.26	Ulcerative colitis;	chr20:32742607	chr8:135625185~135625981:-
HNSC	trans	rs2898290	0.622	rs7822109	ENSG00000173295.6	FAM86B3P	-5.78	1.34e-08	0.0185	-0.29	-0.26	Systolic blood pressure;	chr8:11491638	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.564	rs2572389	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11378883	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs2736301	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11378904	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs2736302	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11378910	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs7821459	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11379172	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs7834572	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11379176	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs4631424	ENSG00000254340.1	RP11-10A14.3	-5.78	1.34e-08	0.0186	-0.3	-0.26	Retinal vascular caliber;	chr8:11379300	chr8:9141424~9145435:+
HNSC	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-5.78	1.34e-08	0.0186	-0.32	-0.26	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
HNSC	trans	rs9393777	0.844	rs72839477	ENSG00000243753.4	HLA-L	-5.78	1.34e-08	0.0186	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27359221	chr6:30259584~30293014:+
HNSC	trans	rs34421088	0.56	rs1478898	ENSG00000173295.6	FAM86B3P	-5.78	1.35e-08	0.0187	-0.29	-0.26	Neuroticism;	chr8:11537570	chr8:8228595~8244865:+
HNSC	trans	rs673253	0.686	rs943513	ENSG00000231007.5	CDC20P1	5.78	1.35e-08	0.0187	0.36	0.26	Intelligence (multi-trait analysis);	chr1:43569801	chr9:87011652~87013151:+
HNSC	trans	rs2950393	0.929	rs7980835	ENSG00000228224.3	NACAP1	5.78	1.35e-08	0.0187	0.28	0.26	Platelet distribution width;	chr12:56676847	chr8:101361794~101372707:+
HNSC	trans	rs2950393	0.929	rs10747769	ENSG00000228224.3	NACAP1	5.78	1.35e-08	0.0187	0.28	0.26	Platelet distribution width;	chr12:56677056	chr8:101361794~101372707:+
HNSC	trans	rs722599	0.683	rs8008475	ENSG00000181227.3	RP4-682C21.2	-5.78	1.35e-08	0.0188	-0.27	-0.26	IgG glycosylation;	chr14:74825197	chr1:75743423~75744776:-
HNSC	trans	rs17507216	0.588	rs28864981	ENSG00000235370.6	DNM1P51	-5.78	1.35e-08	0.0188	-0.4	-0.26	Excessive daytime sleepiness;	chr15:82695420	chr15:84398316~84411701:-
HNSC	trans	rs6831352	0.879	rs56272995	ENSG00000233859.2	ADH5P4	5.78	1.36e-08	0.0188	0.32	0.26	Alcohol dependence;	chr4:99139731	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.879	rs56295995	ENSG00000233859.2	ADH5P4	5.78	1.36e-08	0.0188	0.32	0.26	Alcohol dependence;	chr4:99139748	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs17218602	ENSG00000233859.2	ADH5P4	5.78	1.36e-08	0.0188	0.32	0.26	Alcohol dependence;	chr4:99139922	chr6:65836930~65838039:-
HNSC	trans	rs10435719	0.902	rs6601633	ENSG00000254340.1	RP11-10A14.3	-5.78	1.36e-08	0.0188	-0.31	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.564	rs13274106	ENSG00000254340.1	RP11-10A14.3	-5.78	1.36e-08	0.0188	-0.3	-0.26	Retinal vascular caliber;	chr8:11376449	chr8:9141424~9145435:+
HNSC	trans	rs950169	1	rs950169	ENSG00000229212.6	RP11-561C5.4	-5.78	1.36e-08	0.0188	-0.36	-0.26	Schizophrenia;	chr15:84037709	chr15:85205440~85234795:-
HNSC	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	5.78	1.36e-08	0.0189	0.33	0.26	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
HNSC	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-5.78	1.37e-08	0.019	-0.32	-0.26	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
HNSC	trans	rs3740713	0.669	rs113003553	ENSG00000214110.3	LDHAP4	5.78	1.37e-08	0.019	0.42	0.26	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr9:14921337~14922334:-
HNSC	trans	rs17040773	1	rs17040773	ENSG00000204745.3	AC083899.3	5.78	1.38e-08	0.0191	0.29	0.26	Bone mineral density;	chr2:111742458	chr2:87125390~87196647:+
HNSC	trans	rs7824557	0.628	rs2572387	ENSG00000254340.1	RP11-10A14.3	5.78	1.39e-08	0.0192	0.31	0.26	Retinal vascular caliber;	chr8:11346656	chr8:9141424~9145435:+
HNSC	trans	rs6831352	0.879	rs29001212	ENSG00000233859.2	ADH5P4	5.78	1.39e-08	0.0192	0.31	0.26	Alcohol dependence;	chr4:99130726	chr6:65836930~65838039:-
HNSC	trans	rs9650657	0.836	rs4841438	ENSG00000253893.2	FAM85B	5.78	1.39e-08	0.0193	0.31	0.26	Neuroticism;	chr8:10749246	chr8:8167819~8226614:-
HNSC	trans	rs9650657	0.836	rs11250067	ENSG00000253893.2	FAM85B	5.78	1.39e-08	0.0193	0.31	0.26	Neuroticism;	chr8:10749444	chr8:8167819~8226614:-
HNSC	trans	rs17102884	0.506	rs11845397	ENSG00000181227.3	RP4-682C21.2	5.78	1.4e-08	0.0193	0.26	0.26	Neuroticism;	chr14:74937884	chr1:75743423~75744776:-
HNSC	trans	rs1190596	0.567	rs7145061	ENSG00000181359.5	HSP90AA6P	-5.78	1.4e-08	0.0194	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102266330	chr4:170581470~170605450:-
HNSC	trans	rs1190596	0.567	rs12887648	ENSG00000181359.5	HSP90AA6P	-5.78	1.4e-08	0.0194	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102266873	chr4:170581470~170605450:-
HNSC	trans	rs7973618	1	rs7973618	ENSG00000257210.1	NACAP3	-5.78	1.4e-08	0.0194	-0.29	-0.26	Mean platelet volume;	chr12:56625659	chr12:93124063~93124543:-
HNSC	trans	rs8177876	0.822	rs7203546	ENSG00000224837.1	GCSHP5	-5.78	1.4e-08	0.0194	-0.41	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr1:168055901~168056422:-
HNSC	trans	rs1568889	0.838	rs11030187	ENSG00000174912.7	METTL15P1	5.78	1.4e-08	0.0194	0.27	0.26	Bipolar disorder;	chr11:28022844	chr3:156713884~156714928:-
HNSC	trans	rs2280018	0.963	rs12928424	ENSG00000250569.1	NTAN1P2	5.77	1.41e-08	0.0195	0.31	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr8:86481754~86483002:-
HNSC	trans	rs853679	0.546	rs35744819	ENSG00000204622.9	HLA-J	-5.77	1.42e-08	0.0196	-0.57	-0.26	Depression;	chr6:28350554	chr6:30006583~30009956:+
HNSC	trans	rs737008	0.922	rs28567501	ENSG00000277447.1	RP11-193E15.4	-5.77	1.42e-08	0.0196	-0.29	-0.26	Obesity-related traits;	chr16:11285071	chr18:3025069~3025387:-
HNSC	trans	rs10435719	0.834	rs11250176	ENSG00000173295.6	FAM86B3P	5.77	1.42e-08	0.0196	0.29	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:8228595~8244865:+
HNSC	trans	rs11871801	0.517	rs34855406	ENSG00000211800.3	TRAV20	5.77	1.43e-08	0.0197	0.26	0.26	Crohn's disease;	chr17:42579393	chr14:22040594~22041153:+
HNSC	trans	rs67340775	0.541	rs200979	ENSG00000204709.4	LINC01556	5.77	1.43e-08	0.0198	0.41	0.26	Lung cancer in ever smokers;	chr6:27884579	chr6:28943877~28944537:+
HNSC	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	5.77	1.45e-08	0.02	0.32	0.26	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
HNSC	trans	rs9329221	0.537	rs2062331	ENSG00000173295.6	FAM86B3P	-5.77	1.45e-08	0.02	-0.28	-0.26	Neuroticism;	chr8:10122482	chr8:8228595~8244865:+
HNSC	trans	rs62158211	1	rs62158211	ENSG00000203709.8	C1orf132	5.77	1.45e-08	0.02	0.32	0.26	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr1:207801518~207869150:-
HNSC	trans	rs902774	0.818	rs17120257	ENSG00000255815.3	KRT8P11	-5.77	1.45e-08	0.02	-0.48	-0.26	Prostate cancer;	chr12:52909547	chr9:99305176~99306611:+
HNSC	trans	rs1816752	0.638	rs9578730	ENSG00000224976.2	PARP4P2	-5.77	1.45e-08	0.02	-0.3	-0.26	Obesity-related traits;	chr13:24425545	chr13:19349137~19407962:+
HNSC	trans	rs916888	0.61	rs199438	ENSG00000204650.12	CRHR1-IT1	5.77	1.45e-08	0.02	0.29	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45620328~45648216:+
HNSC	trans	rs10435719	0.899	rs11250177	ENSG00000173295.6	FAM86B3P	5.77	1.45e-08	0.02	0.28	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.966	rs4545281	ENSG00000255397.1	AC022182.2	5.77	1.45e-08	0.02	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45894382	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs34218844	ENSG00000176998.4	HCG4	-5.77	1.46e-08	0.0202	-0.51	-0.26	Depression;	chr6:28322870	chr6:29791753~29792750:-
HNSC	trans	rs1190596	0.567	rs35308394	ENSG00000181359.5	HSP90AA6P	-5.77	1.46e-08	0.0202	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102256670	chr4:170581470~170605450:-
HNSC	trans	rs9393777	0.844	rs28360634	ENSG00000176998.4	HCG4	-5.77	1.46e-08	0.0202	-0.51	-0.26	Intelligence (multi-trait analysis);	chr6:27365112	chr6:29791753~29792750:-
HNSC	trans	rs4930561	1	rs10896298	ENSG00000155070.8	UNC93B2	-5.77	1.47e-08	0.0202	-0.3	-0.26	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68163992	chr7:6855485~6859830:-
HNSC	trans	rs916888	0.61	rs199453	ENSG00000204650.12	CRHR1-IT1	5.77	1.47e-08	0.0202	0.29	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45620328~45648216:+
HNSC	trans	rs17073641	0.611	rs62098925	ENSG00000214846.4	RP11-115L11.1	-5.77	1.47e-08	0.0203	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64737960	chr4:15730962~15731627:-
HNSC	trans	rs7819412	0.645	rs10156356	ENSG00000173295.6	FAM86B3P	-5.77	1.47e-08	0.0203	-0.3	-0.26	Triglycerides;	chr8:11188700	chr8:8228595~8244865:+
HNSC	trans	rs4343996	0.902	rs12540305	ENSG00000224750.5	RP11-94M14.2	5.77	1.47e-08	0.0203	0.27	0.26	Motion sickness;	chr7:3336440	chr10:90454170~90502968:+
HNSC	trans	rs4343996	0.934	rs6959232	ENSG00000224750.5	RP11-94M14.2	5.77	1.47e-08	0.0203	0.27	0.26	Motion sickness;	chr7:3336898	chr10:90454170~90502968:+
HNSC	trans	rs853679	0.607	rs34661125	ENSG00000228078.1	HLA-U	-5.77	1.48e-08	0.0203	-0.57	-0.26	Depression;	chr6:28314117	chr6:29934101~29934286:+
HNSC	trans	rs853679	0.607	rs13190888	ENSG00000228078.1	HLA-U	-5.77	1.48e-08	0.0203	-0.57	-0.26	Depression;	chr6:28318208	chr6:29934101~29934286:+
HNSC	trans	rs9393777	0.623	rs9358945	ENSG00000253570.1	RNF5P1	-5.77	1.48e-08	0.0204	-0.44	-0.26	Intelligence (multi-trait analysis);	chr6:26471886	chr8:38600661~38601200:-
HNSC	trans	rs3808502	0.526	rs36048422	ENSG00000173295.6	FAM86B3P	-5.77	1.49e-08	0.0204	-0.28	-0.26	Neuroticism;	chr8:11559635	chr8:8228595~8244865:+
HNSC	trans	rs3808502	0.526	rs11783065	ENSG00000173295.6	FAM86B3P	-5.77	1.49e-08	0.0204	-0.28	-0.26	Neuroticism;	chr8:11559748	chr8:8228595~8244865:+
HNSC	trans	rs67340775	0.541	rs200964	ENSG00000243753.4	HLA-L	-5.76	1.49e-08	0.0205	-0.42	-0.26	Lung cancer in ever smokers;	chr6:27899165	chr6:30259584~30293014:+
HNSC	trans	rs3808502	0.503	rs34190028	ENSG00000173295.6	FAM86B3P	-5.76	1.49e-08	0.0205	-0.28	-0.26	Neuroticism;	chr8:11559641	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.607	rs35749575	ENSG00000204622.9	HLA-J	-5.76	1.5e-08	0.0206	-0.59	-0.26	Depression;	chr6:28147040	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13205911	ENSG00000204622.9	HLA-J	-5.76	1.5e-08	0.0206	-0.59	-0.26	Depression;	chr6:28156336	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13197176	ENSG00000204622.9	HLA-J	-5.76	1.5e-08	0.0206	-0.59	-0.26	Depression;	chr6:28161454	chr6:30006583~30009956:+
HNSC	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	5.76	1.5e-08	0.0206	0.33	0.26	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs13208096	ENSG00000204622.9	HLA-J	-5.76	1.5e-08	0.0206	-0.55	-0.26	Depression;	chr6:28257533	chr6:30006583~30009956:+
HNSC	trans	rs6547537	0.954	rs7604649	ENSG00000242814.2	RP11-436H11.1	5.76	1.5e-08	0.0207	0.29	0.26	IgG glycosylation;	chr2:84259820	chr5:124808828~124809233:-
HNSC	trans	rs9467711	0.606	rs34104395	ENSG00000176998.4	HCG4	-5.76	1.5e-08	0.0207	-0.51	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:29791753~29792750:-
HNSC	trans	rs7297610	0.765	rs74575246	ENSG00000254512.1	RP11-472I20.2	5.76	1.51e-08	0.0207	0.63	0.26	Response to diuretic therapy;	chr12:69407386	chr11:43733759~43734564:+
HNSC	trans	rs1473307	0.902	rs10169158	ENSG00000224295.2	AC087380.14	5.76	1.51e-08	0.0207	0.31	0.26	Menopause (age at onset);	chr2:225330032	chr11:5518441~5524955:-
HNSC	trans	rs2274459	0.841	rs13204162	ENSG00000225246.1	RPS2P1	5.76	1.51e-08	0.0208	0.34	0.26	Obesity (extreme);	chr6:33728354	chr20:34122470~34123290:+
HNSC	trans	rs2274459	0.841	rs12661400	ENSG00000225246.1	RPS2P1	5.76	1.51e-08	0.0208	0.34	0.26	Obesity (extreme);	chr6:33728700	chr20:34122470~34123290:+
HNSC	trans	rs12138950	0.649	rs55815284	ENSG00000224237.1	MINOS1P3	5.76	1.51e-08	0.0208	0.54	0.26	Hypothyroidism;Thyroid volume;	chr1:19519787	chr3:27214816~27215018:-
HNSC	trans	rs11220237	0.62	rs11220184	ENSG00000236257.1	EI24P2	5.76	1.51e-08	0.0208	0.41	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125681713	chr1:158454198~158455273:+
HNSC	trans	rs2288327	0.818	rs13009158	ENSG00000269800.1	PLEKHA3P1	5.76	1.51e-08	0.0208	0.37	0.26	Atrial fibrillation;	chr2:178600227	chr19:41521043~41521989:-
HNSC	trans	rs1816752	0.633	rs9578729	ENSG00000224976.2	PARP4P2	-5.76	1.52e-08	0.0209	-0.3	-0.26	Obesity-related traits;	chr13:24425106	chr13:19349137~19407962:+
HNSC	trans	rs853679	1	rs2799079	ENSG00000204622.9	HLA-J	-5.76	1.52e-08	0.0209	-0.41	-0.26	Depression;	chr6:28267398	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13211507	ENSG00000243753.4	HLA-L	-5.76	1.52e-08	0.0209	-0.56	-0.26	Depression;	chr6:28289600	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs34691223	ENSG00000243753.4	HLA-L	-5.76	1.52e-08	0.0209	-0.56	-0.26	Depression;	chr6:28290431	chr6:30259584~30293014:+
HNSC	trans	rs860295	0.65	rs670523	ENSG00000241627.3	UBQLN4P1	5.76	1.52e-08	0.0209	0.29	0.26	Body mass index;	chr1:155908941	chr3:148985868~148987668:-
HNSC	trans	rs9393777	0.92	rs35869525	ENSG00000176998.4	HCG4	-5.76	1.52e-08	0.0209	-0.51	-0.26	Intelligence (multi-trait analysis);	chr6:26978908	chr6:29791753~29792750:-
HNSC	trans	rs17507216	0.591	rs7163848	ENSG00000259295.5	CSPG4P12	-5.76	1.52e-08	0.0209	-0.4	-0.26	Excessive daytime sleepiness;	chr15:82729563	chr15:85191438~85213905:+
HNSC	trans	rs17807624	0.964	rs13249843	ENSG00000253893.2	FAM85B	-5.76	1.53e-08	0.021	-0.31	-0.26	Systemic lupus erythematosus;	chr8:11601509	chr8:8167819~8226614:-
HNSC	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	5.76	1.53e-08	0.0211	0.33	0.26	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.545	rs35949109	ENSG00000253570.1	RNF5P1	5.76	1.54e-08	0.0211	0.51	0.26	Depression;	chr6:28058148	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.882	rs9468287	ENSG00000253570.1	RNF5P1	5.76	1.54e-08	0.0211	0.5	0.26	Depression;	chr6:28111963	chr8:38600661~38601200:-
HNSC	trans	rs2898290	0.694	rs2248909	ENSG00000173295.6	FAM86B3P	-5.76	1.54e-08	0.0211	-0.29	-0.26	Systolic blood pressure;	chr8:11534584	chr8:8228595~8244865:+
HNSC	trans	rs17073641	0.534	rs12954957	ENSG00000214846.4	RP11-115L11.1	-5.76	1.54e-08	0.0211	-0.32	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64726307	chr4:15730962~15731627:-
HNSC	trans	rs6921919	0.789	rs1119211	ENSG00000227766.1	HCG4P5	5.76	1.54e-08	0.0212	0.38	0.26	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:29942075~29943067:-
HNSC	trans	rs9650657	0.769	rs1968400	ENSG00000173295.6	FAM86B3P	-5.76	1.54e-08	0.0212	-0.29	-0.26	Neuroticism;	chr8:10757921	chr8:8228595~8244865:+
HNSC	trans	rs7113874	0.592	rs10840057	ENSG00000266891.1	RP11-692N5.2	5.76	1.55e-08	0.0212	0.4	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476681	chr18:9734882~9735602:-
HNSC	trans	rs330048	0.545	rs11781008	ENSG00000173295.6	FAM86B3P	5.76	1.55e-08	0.0212	0.3	0.26	Systemic lupus erythematosus;	chr8:9295729	chr8:8228595~8244865:+
HNSC	trans	rs860295	0.775	rs822509	ENSG00000241627.3	UBQLN4P1	5.76	1.55e-08	0.0213	0.28	0.26	Body mass index;	chr1:155881020	chr3:148985868~148987668:-
HNSC	trans	rs9393777	0.844	rs35909544	ENSG00000253570.1	RNF5P1	5.76	1.55e-08	0.0213	0.53	0.26	Intelligence (multi-trait analysis);	chr6:27195677	chr8:38600661~38601200:-
HNSC	trans	rs853679	1	rs7740487	ENSG00000253570.1	RNF5P1	5.76	1.56e-08	0.0213	0.44	0.26	Depression;	chr6:28248708	chr8:38600661~38601200:-
HNSC	trans	rs853679	1	rs68141011	ENSG00000253570.1	RNF5P1	5.76	1.56e-08	0.0213	0.44	0.26	Depression;	chr6:28250019	chr8:38600661~38601200:-
HNSC	trans	rs853679	1	rs13200462	ENSG00000253570.1	RNF5P1	5.76	1.56e-08	0.0213	0.44	0.26	Depression;	chr6:28250421	chr8:38600661~38601200:-
HNSC	trans	rs9329221	0.772	rs7824675	ENSG00000253893.2	FAM85B	5.76	1.56e-08	0.0213	0.3	0.26	Neuroticism;	chr8:10385908	chr8:8167819~8226614:-
HNSC	trans	rs6424115	0.546	rs35993651	ENSG00000228217.1	AL390877.1	5.76	1.56e-08	0.0213	0.32	0.26	Immature fraction of reticulocytes;	chr1:23854123	chr1:117778087~117778506:-
HNSC	trans	rs6424115	0.557	rs35904775	ENSG00000228217.1	AL390877.1	5.76	1.56e-08	0.0213	0.32	0.26	Immature fraction of reticulocytes;	chr1:23854133	chr1:117778087~117778506:-
HNSC	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-5.76	1.56e-08	0.0214	-0.32	-0.26	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
HNSC	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	5.76	1.56e-08	0.0214	0.33	0.26	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	5.76	1.56e-08	0.0214	0.33	0.26	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	5.76	1.56e-08	0.0214	0.33	0.26	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	5.76	1.56e-08	0.0214	0.33	0.26	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.824	rs34712084	ENSG00000204622.9	HLA-J	-5.76	1.56e-08	0.0214	-0.48	-0.26	Depression;	chr6:28076050	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.824	rs1321505	ENSG00000204622.9	HLA-J	-5.76	1.56e-08	0.0214	-0.48	-0.26	Depression;	chr6:28085045	chr6:30006583~30009956:+
HNSC	trans	rs860295	0.65	rs11264422	ENSG00000241627.3	UBQLN4P1	5.76	1.57e-08	0.0215	0.29	0.26	Body mass index;	chr1:155938032	chr3:148985868~148987668:-
HNSC	trans	rs9650657	0.74	rs2277130	ENSG00000173295.6	FAM86B3P	-5.76	1.57e-08	0.0215	-0.29	-0.26	Neuroticism;	chr8:10820091	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.767	rs6985460	ENSG00000173295.6	FAM86B3P	5.76	1.57e-08	0.0215	0.29	0.26	Retinal vascular caliber;	chr8:11313578	chr8:8228595~8244865:+
HNSC	trans	rs7746199	0.736	rs58616630	ENSG00000176998.4	HCG4	-5.76	1.57e-08	0.0215	-0.5	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:29791753~29792750:-
HNSC	trans	rs7520050	0.966	rs4660321	ENSG00000255397.1	AC022182.2	5.75	1.57e-08	0.0215	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45901088	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs6698247	ENSG00000255397.1	AC022182.2	5.75	1.57e-08	0.0215	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45905814	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6675946	ENSG00000255397.1	AC022182.2	5.75	1.57e-08	0.0215	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45906102	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs7526678	ENSG00000255397.1	AC022182.2	5.75	1.57e-08	0.0215	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45908487	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6695809	ENSG00000255397.1	AC022182.2	5.75	1.57e-08	0.0215	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45819789	chr8:60937705~60939871:-
HNSC	trans	rs8014204	0.566	rs12587457	ENSG00000230637.2	CTA-246H3.8	5.75	1.58e-08	0.0216	0.25	0.26	Caffeine consumption;	chr14:74697438	chr22:25327252~25339975:+
HNSC	trans	rs34421088	0.56	rs2245357	ENSG00000253893.2	FAM85B	5.75	1.58e-08	0.0216	0.3	0.26	Neuroticism;	chr8:11541975	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.546	rs13195291	ENSG00000243753.4	HLA-L	-5.75	1.58e-08	0.0217	-0.6	-0.26	Depression;	chr6:28201463	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.843	rs2736375	ENSG00000173295.6	FAM86B3P	-5.75	1.58e-08	0.0217	-0.29	-0.26	Retinal vascular caliber;	chr8:11258240	chr8:8228595~8244865:+
HNSC	trans	rs8014204	0.935	rs1799900	ENSG00000181227.3	RP4-682C21.2	5.75	1.59e-08	0.0217	0.25	0.26	Caffeine consumption;	chr14:74901037	chr1:75743423~75744776:-
HNSC	trans	rs8014204	0.935	rs2853779	ENSG00000181227.3	RP4-682C21.2	5.75	1.59e-08	0.0217	0.25	0.26	Caffeine consumption;	chr14:74901805	chr1:75743423~75744776:-
HNSC	trans	rs864643	1	rs816492	ENSG00000183298.5	RP11-556K13.1	5.75	1.59e-08	0.0217	0.41	0.26	Attention deficit hyperactivity disorder;	chr3:39514664	chr1:101786340~101787219:-
HNSC	trans	rs7520050	0.966	rs10890354	ENSG00000255397.1	AC022182.2	5.75	1.59e-08	0.0218	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45839675	chr8:60937705~60939871:-
HNSC	trans	rs2236178	0.515	rs804372	ENSG00000177640.14	CASC2	5.75	1.59e-08	0.0218	0.27	0.26	Lupus nephritis in systemic lupus erythematosus;	chr20:21425394	chr10:118046279~118210153:+
HNSC	trans	rs80264589	1	rs80264589	ENSG00000176998.4	HCG4	-5.75	1.59e-08	0.0218	-0.51	-0.26	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:29791753~29792750:-
HNSC	trans	rs853679	0.607	rs72846780	ENSG00000204622.9	HLA-J	-5.75	1.6e-08	0.0218	-0.59	-0.26	Depression;	chr6:28151277	chr6:30006583~30009956:+
HNSC	trans	rs2898290	0.622	rs13272061	ENSG00000173295.6	FAM86B3P	-5.75	1.6e-08	0.0219	-0.28	-0.26	Systolic blood pressure;	chr8:11494752	chr8:8228595~8244865:+
HNSC	trans	rs330071	0.686	rs4841139	ENSG00000253893.2	FAM85B	-5.75	1.61e-08	0.022	-0.31	-0.26	Acne (severe);	chr8:9391700	chr8:8167819~8226614:-
HNSC	trans	rs17073641	0.534	rs12954779	ENSG00000214846.4	RP11-115L11.1	-5.75	1.62e-08	0.0221	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64717911	chr4:15730962~15731627:-
HNSC	trans	rs7297610	0.765	rs79636486	ENSG00000254512.1	RP11-472I20.2	5.75	1.62e-08	0.0221	0.63	0.26	Response to diuretic therapy;	chr12:69405719	chr11:43733759~43734564:+
HNSC	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	5.75	1.62e-08	0.0222	0.33	0.26	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
HNSC	trans	rs7746199	0.736	rs10484399	ENSG00000176998.4	HCG4	-5.75	1.63e-08	0.0222	-0.49	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:29791753~29792750:-
HNSC	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	5.75	1.63e-08	0.0222	0.33	0.26	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
HNSC	trans	rs9329221	0.905	rs13252982	ENSG00000173295.6	FAM86B3P	-5.75	1.63e-08	0.0222	-0.29	-0.26	Neuroticism;	chr8:10397595	chr8:8228595~8244865:+
HNSC	trans	rs864643	1	rs1340224	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39508072	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1340222	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39508312	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs536454	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39508827	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.945	rs583083	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39508954	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs581691	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39509244	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs689352	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39509275	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1513213	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39509406	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1768261	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39510494	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1768262	ENSG00000183298.5	RP11-556K13.1	5.75	1.63e-08	0.0222	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39511785	chr1:101786340~101787219:-
HNSC	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	5.75	1.63e-08	0.0223	0.32	0.26	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
HNSC	trans	rs7520050	0.966	rs4376778	ENSG00000255397.1	AC022182.2	5.75	1.63e-08	0.0223	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45823174	chr8:60937705~60939871:-
HNSC	trans	rs9650657	0.504	rs7813802	ENSG00000173295.6	FAM86B3P	5.75	1.63e-08	0.0223	0.28	0.26	Neuroticism;	chr8:11176467	chr8:8228595~8244865:+
HNSC	trans	rs3781264	0.517	rs12780240	ENSG00000264070.1	DND1P1	5.75	1.63e-08	0.0223	0.38	0.26	Esophageal cancer and gastric cancer;	chr10:94300954	chr17:45585871~45586929:+
HNSC	trans	rs73108077	0.736	rs6060596	ENSG00000279352.1	RP11-411B10.7	5.75	1.64e-08	0.0223	0.46	0.26	Red blood cell density in sickle cell anemia;	chr20:31261457	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs6060617	ENSG00000279352.1	RP11-411B10.7	5.75	1.64e-08	0.0223	0.46	0.26	Red blood cell density in sickle cell anemia;	chr20:31261849	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs77855283	ENSG00000279352.1	RP11-411B10.7	5.75	1.64e-08	0.0223	0.46	0.26	Red blood cell density in sickle cell anemia;	chr20:31262576	chr18:14010054~14010917:+
HNSC	trans	rs950169	0.922	rs4842940	ENSG00000229212.6	RP11-561C5.4	5.75	1.64e-08	0.0224	0.36	0.26	Schizophrenia;	chr15:84162473	chr15:85205440~85234795:-
HNSC	trans	rs17073641	0.534	rs7506006	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64712375	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.517	rs12965114	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64712528	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.517	rs12969320	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64712987	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12956863	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64714580	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12606746	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64714864	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs11151151	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64714998	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.517	rs11151152	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64715034	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs17674259	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64715687	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.534	rs12954745	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64717152	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12953949	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64717186	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.534	rs12953886	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64717396	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12454737	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64718228	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs12454797	ENSG00000214846.4	RP11-115L11.1	-5.75	1.64e-08	0.0224	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64718354	chr4:15730962~15731627:-
HNSC	trans	rs3808502	0.549	rs7831039	ENSG00000173295.6	FAM86B3P	-5.75	1.64e-08	0.0224	-0.28	-0.26	Neuroticism;	chr8:11570128	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.966	rs7522601	ENSG00000255397.1	AC022182.2	5.75	1.64e-08	0.0224	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45953349	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs10789487	ENSG00000255397.1	AC022182.2	5.75	1.64e-08	0.0224	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45954549	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs34102169	ENSG00000255397.1	AC022182.2	5.75	1.64e-08	0.0224	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45959192	chr8:60937705~60939871:-
HNSC	trans	rs2288327	0.818	rs2303539	ENSG00000269800.1	PLEKHA3P1	5.75	1.65e-08	0.0224	0.37	0.26	Atrial fibrillation;	chr2:178538866	chr19:41521043~41521989:-
HNSC	trans	rs6756513	0.5	rs58206747	ENSG00000232654.1	FAM136BP	5.75	1.65e-08	0.0225	0.35	0.26	Breast cancer;Platelet count;	chr2:69899534	chr6:3045384~3045800:+
HNSC	trans	rs17073641	0.553	rs35890522	ENSG00000214846.4	RP11-115L11.1	-5.75	1.65e-08	0.0225	-0.31	-0.26	Age-related macular degeneration (smoking status interaction);	chr18:64719071	chr4:15730962~15731627:-
HNSC	trans	rs2288327	0.818	rs16866373	ENSG00000269800.1	PLEKHA3P1	5.75	1.65e-08	0.0225	0.37	0.26	Atrial fibrillation;	chr2:178527353	chr19:41521043~41521989:-
HNSC	trans	rs2950393	0.794	rs1563897	ENSG00000228224.3	NACAP1	5.75	1.65e-08	0.0225	0.28	0.26	Platelet distribution width;	chr12:56699316	chr8:101361794~101372707:+
HNSC	trans	rs3111637	1	rs1544780	ENSG00000216285.5	RP11-490H24.5	-5.74	1.66e-08	0.0226	-0.32	-0.26	Reticulocyte count;	chr5:54360347	chr12:104030779~104031543:+
HNSC	trans	rs7829975	0.511	rs2976906	ENSG00000255310.2	AF131215.2	5.74	1.67e-08	0.0227	0.25	0.26	Mood instability;	chr8:8484905	chr8:11107788~11109726:-
HNSC	trans	rs9650657	0.871	rs7814142	ENSG00000173295.6	FAM86B3P	-5.74	1.67e-08	0.0227	-0.29	-0.26	Neuroticism;	chr8:10780042	chr8:8228595~8244865:+
HNSC	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	5.74	1.67e-08	0.0228	0.32	0.26	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
HNSC	trans	rs860295	0.615	rs656737	ENSG00000241627.3	UBQLN4P1	5.74	1.67e-08	0.0228	0.28	0.26	Body mass index;	chr1:155908104	chr3:148985868~148987668:-
HNSC	trans	rs3826795	0.569	rs11671319	ENSG00000269463.1	RP11-727F15.13	-5.74	1.68e-08	0.0229	-0.38	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46291810	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs34128150	ENSG00000269463.1	RP11-727F15.13	-5.74	1.68e-08	0.0229	-0.38	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46291852	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.569	rs11671360	ENSG00000269463.1	RP11-727F15.13	-5.74	1.68e-08	0.0229	-0.38	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46291914	chr11:62807682~62808063:-
HNSC	trans	rs3826795	0.53	rs11667159	ENSG00000269463.1	RP11-727F15.13	-5.74	1.68e-08	0.0229	-0.38	-0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr19:46291989	chr11:62807682~62808063:-
HNSC	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-5.74	1.68e-08	0.0229	-0.32	-0.26	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
HNSC	trans	rs9733	0.818	rs7520022	ENSG00000180764.13	PIPSL	5.74	1.68e-08	0.0229	0.31	0.26	Tonsillectomy;	chr1:150686697	chr10:93958191~93961540:-
HNSC	trans	rs7746199	0.736	rs72845070	ENSG00000253570.1	RNF5P1	5.74	1.69e-08	0.0229	0.6	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr8:38600661~38601200:-
HNSC	trans	rs7937890	0.507	rs4463820	ENSG00000236360.2	RP11-334A14.2	5.74	1.69e-08	0.023	0.34	0.26	Mitochondrial DNA levels;	chr11:14534796	chr1:52993201~52993702:-
HNSC	trans	rs2456568	0.503	rs11020603	ENSG00000276509.1	CH17-353B19.1	-5.74	1.69e-08	0.023	-0.29	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93934273	chr1:146235806~146237807:+
HNSC	trans	rs7746199	0.736	rs13202295	ENSG00000243753.4	HLA-L	-5.74	1.69e-08	0.023	-0.57	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:30259584~30293014:+
HNSC	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	5.74	1.7e-08	0.0231	0.33	0.26	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
HNSC	trans	rs4343996	0.934	rs4320450	ENSG00000224750.5	RP11-94M14.2	5.74	1.7e-08	0.0231	0.27	0.26	Motion sickness;	chr7:3332676	chr10:90454170~90502968:+
HNSC	trans	rs445114	0.932	rs366991	ENSG00000263220.1	RP11-420A6.2	5.74	1.71e-08	0.0232	0.27	0.26	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127322000	chr17:5364315~5371626:-
HNSC	trans	rs11204666	0.5	rs77604525	ENSG00000180764.13	PIPSL	-5.74	1.71e-08	0.0232	-0.51	-0.26	Coronary artery disease;	chr1:150620915	chr10:93958191~93961540:-
HNSC	trans	rs3096299	0.685	rs4785571	ENSG00000215030.5	RPL13P12	-5.74	1.71e-08	0.0232	-0.25	-0.26	Multiple myeloma (IgH translocation);	chr16:89498761	chr17:17383377~17384012:-
HNSC	trans	rs13177918	1	rs13177918	ENSG00000226396.1	RP5-1056L3.3	5.74	1.71e-08	0.0232	0.23	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:19608114~19608568:+
HNSC	trans	rs6831352	0.918	rs13107558	ENSG00000233859.2	ADH5P4	5.74	1.71e-08	0.0233	0.31	0.26	Alcohol dependence;	chr4:99129049	chr6:65836930~65838039:-
HNSC	trans	rs860295	0.595	rs490498	ENSG00000241627.3	UBQLN4P1	5.74	1.71e-08	0.0233	0.29	0.26	Body mass index;	chr1:155911161	chr3:148985868~148987668:-
HNSC	trans	rs7520050	0.933	rs12045165	ENSG00000255397.1	AC022182.2	5.74	1.72e-08	0.0233	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45790350	chr8:60937705~60939871:-
HNSC	trans	rs9329221	0.905	rs28507213	ENSG00000173295.6	FAM86B3P	-5.74	1.72e-08	0.0234	-0.29	-0.26	Neuroticism;	chr8:10393339	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.675	rs2736265	ENSG00000254340.1	RP11-10A14.3	5.74	1.72e-08	0.0234	0.3	0.26	Retinal vascular caliber;	chr8:11329165	chr8:9141424~9145435:+
HNSC	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	5.74	1.72e-08	0.0234	0.32	0.26	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
HNSC	trans	rs7520050	0.966	rs6672898	ENSG00000255397.1	AC022182.2	5.74	1.72e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45824916	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.603	rs11250130	ENSG00000173295.6	FAM86B3P	-5.74	1.73e-08	0.0234	-0.28	-0.26	Retinal vascular caliber;	chr8:11356946	chr8:8228595~8244865:+
HNSC	trans	rs7520050	0.966	rs7539932	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45826682	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs61783200	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45831731	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6680380	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45834517	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs6697557	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45842137	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs6701614	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45843748	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.933	rs11211203	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.0234	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45849920	chr8:60937705~60939871:-
HNSC	trans	rs9393777	0.841	rs13191474	ENSG00000176998.4	HCG4	-5.74	1.73e-08	0.0234	-0.5	-0.26	Intelligence (multi-trait analysis);	chr6:27445566	chr6:29791753~29792750:-
HNSC	trans	rs8177876	0.822	rs7206814	ENSG00000224837.1	GCSHP5	-5.74	1.73e-08	0.0235	-0.41	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr1:168055901~168056422:-
HNSC	trans	rs9647570	0.702	rs10038819	ENSG00000225532.1	XX-C2158C6.3	-5.74	1.73e-08	0.0235	-0.34	-0.26	Menarche (age at onset);	chr5:167946270	chr6:170736173~170737777:-
HNSC	trans	rs2243480	1	rs4718270	ENSG00000273142.1	RP11-458F8.4	-5.74	1.73e-08	0.0235	-0.37	-0.26	Diabetic kidney disease;	chr7:65737415	chr7:66902857~66906297:+
HNSC	trans	rs2243480	0.901	rs2900904	ENSG00000273142.1	RP11-458F8.4	-5.74	1.73e-08	0.0235	-0.37	-0.26	Diabetic kidney disease;	chr7:65739282	chr7:66902857~66906297:+
HNSC	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	5.74	1.74e-08	0.0235	0.32	0.26	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
HNSC	trans	rs4713118	0.869	rs6901520	ENSG00000204709.4	LINC01556	5.74	1.74e-08	0.0236	0.34	0.26	Parkinson's disease;	chr6:27746796	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9283880	ENSG00000204709.4	LINC01556	5.74	1.74e-08	0.0236	0.34	0.26	Parkinson's disease;	chr6:27747464	chr6:28943877~28944537:+
HNSC	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-5.74	1.74e-08	0.0236	-0.33	-0.26	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
HNSC	trans	rs9650657	0.707	rs6984744	ENSG00000253893.2	FAM85B	5.74	1.75e-08	0.0237	0.3	0.26	Neuroticism;	chr8:10758755	chr8:8167819~8226614:-
HNSC	trans	rs9650657	0.675	rs2409658	ENSG00000253893.2	FAM85B	5.74	1.75e-08	0.0237	0.3	0.26	Neuroticism;	chr8:10811455	chr8:8167819~8226614:-
HNSC	trans	rs4343996	0.902	rs4719894	ENSG00000224750.5	RP11-94M14.2	5.74	1.75e-08	0.0237	0.27	0.26	Motion sickness;	chr7:3342157	chr10:90454170~90502968:+
HNSC	trans	rs4343996	0.869	rs4544975	ENSG00000224750.5	RP11-94M14.2	5.74	1.75e-08	0.0237	0.27	0.26	Motion sickness;	chr7:3345752	chr10:90454170~90502968:+
HNSC	trans	rs7520050	0.966	rs12564541	ENSG00000255397.1	AC022182.2	5.74	1.75e-08	0.0237	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45914565	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs61102033	ENSG00000255397.1	AC022182.2	5.74	1.75e-08	0.0237	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45916769	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs12405451	ENSG00000255397.1	AC022182.2	5.74	1.75e-08	0.0237	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45918654	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs11211224	ENSG00000255397.1	AC022182.2	5.74	1.75e-08	0.0237	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45918716	chr8:60937705~60939871:-
HNSC	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	5.73	1.76e-08	0.0238	0.32	0.26	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
HNSC	trans	rs722599	0.748	rs929579	ENSG00000181227.3	RP4-682C21.2	5.73	1.76e-08	0.0238	0.27	0.26	IgG glycosylation;	chr14:74863994	chr1:75743423~75744776:-
HNSC	trans	rs853679	0.607	rs56189111	ENSG00000204622.9	HLA-J	-5.73	1.76e-08	0.0238	-0.57	-0.26	Depression;	chr6:28304196	chr6:30006583~30009956:+
HNSC	trans	rs7824557	0.564	rs2572399	ENSG00000254340.1	RP11-10A14.3	-5.73	1.76e-08	0.0238	-0.3	-0.26	Retinal vascular caliber;	chr8:11377011	chr8:9141424~9145435:+
HNSC	trans	rs1190596	0.567	rs11846359	ENSG00000181359.5	HSP90AA6P	-5.73	1.77e-08	0.0239	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102275629	chr4:170581470~170605450:-
HNSC	trans	rs7819412	0.775	rs6601564	ENSG00000254340.1	RP11-10A14.3	-5.73	1.77e-08	0.024	-0.32	-0.26	Triglycerides;	chr8:11124541	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.933	rs4504835	ENSG00000255397.1	AC022182.2	5.73	1.77e-08	0.024	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45989899	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs34765154	ENSG00000243753.4	HLA-L	-5.73	1.78e-08	0.024	-0.59	-0.26	Depression;	chr6:28162672	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.556	rs67297533	ENSG00000243753.4	HLA-L	-5.73	1.78e-08	0.024	-0.59	-0.26	Depression;	chr6:28173475	chr6:30259584~30293014:+
HNSC	trans	rs7826238	0.601	rs2979206	ENSG00000269918.1	AF131215.9	5.73	1.78e-08	0.0241	0.26	0.26	Systolic blood pressure;	chr8:8488071	chr8:11104691~11106704:-
HNSC	trans	rs864643	0.678	rs1398668	ENSG00000183298.5	RP11-556K13.1	5.73	1.78e-08	0.0241	0.41	0.26	Attention deficit hyperactivity disorder;	chr3:39475753	chr1:101786340~101787219:-
HNSC	trans	rs7746199	0.736	rs35037868	ENSG00000243753.4	HLA-L	-5.73	1.79e-08	0.0242	-0.57	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:30259584~30293014:+
HNSC	trans	rs9329221	0.905	rs28712068	ENSG00000173295.6	FAM86B3P	-5.73	1.79e-08	0.0243	-0.29	-0.26	Neuroticism;	chr8:10393635	chr8:8228595~8244865:+
HNSC	trans	rs860295	0.65	rs12027412	ENSG00000241627.3	UBQLN4P1	5.73	1.8e-08	0.0243	0.28	0.26	Body mass index;	chr1:155939139	chr3:148985868~148987668:-
HNSC	trans	rs9467711	0.606	rs1977	ENSG00000176998.4	HCG4	-5.73	1.8e-08	0.0243	-0.45	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26377318	chr6:29791753~29792750:-
HNSC	trans	rs1568889	0.838	rs4614434	ENSG00000174912.7	METTL15P1	5.73	1.8e-08	0.0244	0.27	0.26	Bipolar disorder;	chr11:28280687	chr3:156713884~156714928:-
HNSC	trans	rs1568889	0.712	rs10835306	ENSG00000174912.7	METTL15P1	5.73	1.8e-08	0.0244	0.27	0.26	Bipolar disorder;	chr11:28280863	chr3:156713884~156714928:-
HNSC	trans	rs13177918	1	rs35007082	ENSG00000226396.1	RP5-1056L3.3	5.73	1.81e-08	0.0244	0.23	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:19608114~19608568:+
HNSC	trans	rs8014204	0.566	rs752857	ENSG00000230637.2	CTA-246H3.8	5.73	1.81e-08	0.0244	0.25	0.26	Caffeine consumption;	chr14:74664241	chr22:25327252~25339975:+
HNSC	trans	rs853679	0.607	rs35030260	ENSG00000204622.9	HLA-J	-5.73	1.81e-08	0.0245	-0.56	-0.26	Depression;	chr6:28337731	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs13217619	ENSG00000204622.9	HLA-J	-5.73	1.81e-08	0.0245	-0.56	-0.26	Depression;	chr6:28338894	chr6:30006583~30009956:+
HNSC	trans	rs4713118	0.869	rs6930992	ENSG00000204709.4	LINC01556	5.73	1.81e-08	0.0245	0.33	0.26	Parkinson's disease;	chr6:27744341	chr6:28943877~28944537:+
HNSC	trans	rs7520050	0.933	rs6656022	ENSG00000255397.1	AC022182.2	5.73	1.82e-08	0.0245	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45928643	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs4134386	ENSG00000255397.1	AC022182.2	5.73	1.82e-08	0.0245	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45929417	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs12561806	ENSG00000255397.1	AC022182.2	5.73	1.82e-08	0.0245	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45931104	chr8:60937705~60939871:-
HNSC	trans	rs3781264	0.617	rs34818536	ENSG00000264070.1	DND1P1	5.73	1.82e-08	0.0245	0.37	0.26	Esophageal cancer and gastric cancer;	chr10:94283136	chr17:45585871~45586929:+
HNSC	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	5.73	1.82e-08	0.0246	0.32	0.26	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
HNSC	trans	rs7121616	0.733	rs10892967	ENSG00000234176.1	HSPA8P1	5.73	1.82e-08	0.0246	0.33	0.26	Breast cancer;	chr11:123130350	chrX:121203182~121205014:-
HNSC	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-5.73	1.84e-08	0.0248	-0.32	-0.26	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-5.73	1.84e-08	0.0248	-0.32	-0.26	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
HNSC	trans	rs1568889	0.838	rs11030206	ENSG00000174912.7	METTL15P1	5.73	1.84e-08	0.0248	0.27	0.26	Bipolar disorder;	chr11:28078200	chr3:156713884~156714928:-
HNSC	trans	rs1243647	1	rs1243647	ENSG00000221716.1	SNORA11	5.73	1.84e-08	0.0249	0.33	0.26	Prostate cancer (SNP x SNP interaction);	chr14:20556460	chrX:54814370~54814497:+
HNSC	trans	rs9467711	0.606	rs2072806	ENSG00000176998.4	HCG4	-5.73	1.85e-08	0.0249	-0.47	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26384865	chr6:29791753~29792750:-
HNSC	trans	rs12714314	0.681	rs4853753	ENSG00000277383.1	CTD-3001H11.2	-5.72	1.85e-08	0.025	-0.3	-0.26	Type 2 diabetes (age of onset);	chr2:1937609	chr19:47607873~47608454:-
HNSC	trans	rs6601450	0.547	rs10105843	ENSG00000173295.6	FAM86B3P	5.72	1.85e-08	0.025	0.29	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10340353	chr8:8228595~8244865:+
HNSC	trans	rs12714314	0.756	rs10175420	ENSG00000277383.1	CTD-3001H11.2	-5.72	1.86e-08	0.025	-0.3	-0.26	Type 2 diabetes (age of onset);	chr2:1934366	chr19:47607873~47608454:-
HNSC	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-5.72	1.86e-08	0.0251	-0.32	-0.26	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	5.72	1.86e-08	0.0251	0.32	0.26	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
HNSC	trans	rs216303	0.642	rs216315	ENSG00000241717.1	VWFP1	5.72	1.86e-08	0.0251	0.45	0.26	Low vWF levels;	chr12:6027748	chr22:16690103~16704477:-
HNSC	trans	rs853679	0.607	rs33932084	ENSG00000204622.9	HLA-J	-5.72	1.87e-08	0.0251	-0.56	-0.26	Depression;	chr6:28301047	chr6:30006583~30009956:+
HNSC	trans	rs9650657	0.769	rs2116094	ENSG00000173295.6	FAM86B3P	-5.72	1.87e-08	0.0252	-0.29	-0.26	Neuroticism;	chr8:10741312	chr8:8228595~8244865:+
HNSC	trans	rs9467711	0.659	rs72844462	ENSG00000176998.4	HCG4	-5.72	1.87e-08	0.0252	-0.51	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:29791753~29792750:-
HNSC	trans	rs3779195	0.697	rs1688606	ENSG00000230273.1	AC087163.3	5.72	1.87e-08	0.0252	0.34	0.26	Sex hormone-binding globulin levels;	chr7:98345539	chr17:17981192~17981572:-
HNSC	trans	rs9876781	0.53	rs11708617	ENSG00000235912.1	RP1-159A19.3	-5.72	1.87e-08	0.0252	-0.26	-0.26	Longevity;	chr3:48354819	chr1:27649419~27649610:+
HNSC	trans	rs1996369	0.918	rs11033140	ENSG00000243256.1	RPL30P14	-5.72	1.87e-08	0.0252	-0.26	-0.26	Relative hand skill in reading disability;	chr11:35473339	chr18:61404858~61405205:-
HNSC	trans	rs9329221	0.537	rs12678797	ENSG00000173295.6	FAM86B3P	-5.72	1.87e-08	0.0252	-0.28	-0.26	Neuroticism;	chr8:10121409	chr8:8228595~8244865:+
HNSC	trans	rs9393777	0.841	rs67092078	ENSG00000176998.4	HCG4	-5.72	1.88e-08	0.0253	-0.53	-0.26	Intelligence (multi-trait analysis);	chr6:27086993	chr6:29791753~29792750:-
HNSC	trans	rs6831352	0.918	rs2602896	ENSG00000233859.2	ADH5P4	5.72	1.89e-08	0.0254	0.31	0.26	Alcohol dependence;	chr4:99125056	chr6:65836930~65838039:-
HNSC	trans	rs902774	0.818	rs56095813	ENSG00000224520.2	KRT8P45	-5.72	1.89e-08	0.0254	-0.46	-0.26	Prostate cancer;	chr12:52900963	chr1:157073257~157074703:+
HNSC	trans	rs2274459	0.841	rs12203688	ENSG00000225246.1	RPS2P1	-5.72	1.89e-08	0.0255	-0.34	-0.26	Obesity (extreme);	chr6:33725847	chr20:34122470~34123290:+
HNSC	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-5.72	1.9e-08	0.0256	-0.32	-0.26	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
HNSC	trans	rs34421088	0.576	rs2572437	ENSG00000173295.6	FAM86B3P	-5.72	1.91e-08	0.0257	-0.31	-0.26	Neuroticism;	chr8:11240932	chr8:8228595~8244865:+
HNSC	trans	rs702485	0.774	rs836516	ENSG00000249936.3	RAC1P2	5.72	1.91e-08	0.0257	0.3	0.26	HDL cholesterol levels;HDL cholesterol;	chr7:6422572	chr4:46723830~46724408:-
HNSC	trans	rs7647973	0.593	rs9870755	ENSG00000197582.5	GPX1P1	5.72	1.91e-08	0.0257	0.41	0.26	Menarche (age at onset);	chr3:49772408	chrX:13378735~13379340:-
HNSC	trans	rs9467773	0.55	rs4712987	ENSG00000242375.1	RP11-498P14.3	-5.72	1.91e-08	0.0257	-0.33	-0.26	Intelligence (multi-trait analysis);	chr6:26399387	chr9:97195351~97197687:-
HNSC	trans	rs10109025	0.67	rs7825690	ENSG00000173295.6	FAM86B3P	-5.72	1.91e-08	0.0257	-0.28	-0.26	Joint mobility (Beighton score);	chr8:11000747	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.707	rs10097283	ENSG00000253893.2	FAM85B	5.72	1.91e-08	0.0257	0.31	0.26	Neuroticism;	chr8:10801896	chr8:8167819~8226614:-
HNSC	trans	rs7335046	0.666	rs72645671	ENSG00000248925.1	CTD-2083E4.6	5.72	1.92e-08	0.0258	0.45	0.26	Basal cell carcinoma;	chr13:99164689	chr5:269858~271516:-
HNSC	trans	rs2302190	0.882	rs11650105	ENSG00000273445.1	RP11-1399P15.1	5.72	1.92e-08	0.0258	0.3	0.26	Vitamin D levels;	chr17:58510711	chr2:87477495~87478034:-
HNSC	trans	rs7121616	0.563	rs1461494	ENSG00000214144.3	RP11-488L18.1	5.72	1.92e-08	0.0258	0.32	0.26	Breast cancer;	chr11:123055777	chr1:247229940~247231880:+
HNSC	trans	rs673253	0.638	rs552638	ENSG00000231007.5	CDC20P1	5.72	1.92e-08	0.0258	0.36	0.26	Intelligence (multi-trait analysis);	chr1:43577721	chr9:87011652~87013151:+
HNSC	trans	rs2288327	0.818	rs3829747	ENSG00000269800.1	PLEKHA3P1	5.72	1.93e-08	0.0259	0.37	0.26	Atrial fibrillation;	chr2:178532834	chr19:41521043~41521989:-
HNSC	trans	rs2048656	0.54	rs55868514	ENSG00000269918.1	AF131215.9	-5.72	1.93e-08	0.0259	-0.26	-0.26	Schizophrenia;	chr8:9822890	chr8:11104691~11106704:-
HNSC	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	5.72	1.93e-08	0.0259	0.32	0.26	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
HNSC	trans	rs853679	1	rs853676	ENSG00000204622.9	HLA-J	-5.72	1.93e-08	0.026	-0.42	-0.26	Depression;	chr6:28331910	chr6:30006583~30009956:+
HNSC	trans	rs2096176	0.965	rs12569739	ENSG00000213801.4	ZNF816-ZNF321P	5.72	1.94e-08	0.026	0.28	0.26	Obesity-related traits;	chr10:26112662	chr19:52927135~52942601:-
HNSC	trans	rs7647973	0.592	rs6774202	ENSG00000197582.5	GPX1P1	5.72	1.94e-08	0.026	0.42	0.26	Menarche (age at onset);	chr3:49650346	chrX:13378735~13379340:-
HNSC	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-5.72	1.94e-08	0.0261	-0.33	-0.26	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
HNSC	trans	rs4784054	0.667	rs11864685	ENSG00000230849.2	GOT2P2	-5.72	1.95e-08	0.0261	-0.47	-0.26	Blood metabolite levels;	chr16:58771226	chr1:173141100~173142350:-
HNSC	trans	rs9467711	0.659	rs3823158	ENSG00000253570.1	RNF5P1	5.72	1.95e-08	0.0262	0.58	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr8:38600661~38601200:-
HNSC	trans	rs9467711	0.659	rs13195509	ENSG00000253570.1	RNF5P1	5.72	1.95e-08	0.0262	0.58	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr8:38600661~38601200:-
HNSC	trans	rs4713118	0.869	rs9283881	ENSG00000204709.4	LINC01556	5.72	1.95e-08	0.0262	0.34	0.26	Parkinson's disease;	chr6:27747476	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9283882	ENSG00000204709.4	LINC01556	5.72	1.95e-08	0.0262	0.34	0.26	Parkinson's disease;	chr6:27747479	chr6:28943877~28944537:+
HNSC	trans	rs13177918	0.906	rs12652032	ENSG00000226396.1	RP5-1056L3.3	5.71	1.97e-08	0.0264	0.23	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:19608114~19608568:+
HNSC	trans	rs4343996	0.902	rs4722693	ENSG00000224750.5	RP11-94M14.2	5.71	1.97e-08	0.0264	0.27	0.26	Motion sickness;	chr7:3334680	chr10:90454170~90502968:+
HNSC	trans	rs702485	0.84	rs836478	ENSG00000249936.3	RAC1P2	-5.71	1.97e-08	0.0265	-0.29	-0.26	HDL cholesterol levels;HDL cholesterol;	chr7:6392059	chr4:46723830~46724408:-
HNSC	trans	rs9329221	0.741	rs13264066	ENSG00000269918.1	AF131215.9	-5.71	1.98e-08	0.0265	-0.26	-0.26	Neuroticism;	chr8:9946565	chr8:11104691~11106704:-
HNSC	trans	rs9467711	0.606	rs1978	ENSG00000253570.1	RNF5P1	5.71	1.98e-08	0.0265	0.54	0.26	Autism spectrum disorder or schizophrenia;	chr6:26377345	chr8:38600661~38601200:-
HNSC	trans	rs7937890	0.559	rs6486193	ENSG00000236360.2	RP11-334A14.2	5.71	1.98e-08	0.0266	0.33	0.26	Mitochondrial DNA levels;	chr11:14416061	chr1:52993201~52993702:-
HNSC	trans	rs4343996	0.87	rs4722708	ENSG00000224750.5	RP11-94M14.2	5.71	1.99e-08	0.0266	0.27	0.26	Motion sickness;	chr7:3342931	chr10:90454170~90502968:+
HNSC	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0266	0.33	0.26	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
HNSC	trans	rs7819412	0.668	rs4841507	ENSG00000173295.6	FAM86B3P	-5.71	1.99e-08	0.0266	-0.28	-0.26	Triglycerides;	chr8:11188885	chr8:8228595~8244865:+
HNSC	trans	rs9329221	0.741	rs9650622	ENSG00000269918.1	AF131215.9	-5.71	2e-08	0.0268	-0.26	-0.26	Neuroticism;	chr8:9946782	chr8:11104691~11106704:-
HNSC	trans	rs864643	0.891	rs1624647	ENSG00000183298.5	RP11-556K13.1	5.71	2e-08	0.0268	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39533558	chr1:101786340~101787219:-
HNSC	trans	rs722599	0.748	rs11623342	ENSG00000181227.3	RP4-682C21.2	5.71	2e-08	0.0268	0.27	0.26	IgG glycosylation;	chr14:74881234	chr1:75743423~75744776:-
HNSC	trans	rs17607347	0.779	rs2967237	ENSG00000265201.1	MIR4677	5.71	2.01e-08	0.0269	0.33	0.26	Intelligence (multi-trait analysis);	chr16:72571687	chr1:243346176~243346255:+
HNSC	trans	rs2250402	0.51	rs8031319	ENSG00000234106.3	RP11-288E14.2	5.71	2.01e-08	0.0269	0.58	0.26	Corneal curvature;	chr15:40031491	chr11:93535468~93535816:+
HNSC	trans	rs7647973	0.769	rs6772452	ENSG00000197582.5	GPX1P1	5.71	2.01e-08	0.0269	0.37	0.26	Menarche (age at onset);	chr3:49003029	chrX:13378735~13379340:-
HNSC	trans	rs1473307	0.902	rs12997319	ENSG00000224295.2	AC087380.14	-5.71	2.01e-08	0.0269	-0.3	-0.26	Menopause (age at onset);	chr2:225286614	chr11:5518441~5524955:-
HNSC	trans	rs9650657	0.77	rs6601529	ENSG00000253893.2	FAM85B	5.71	2.02e-08	0.027	0.3	0.26	Neuroticism;	chr8:10813040	chr8:8167819~8226614:-
HNSC	trans	rs4343996	0.902	rs4336505	ENSG00000224750.5	RP11-94M14.2	5.71	2.02e-08	0.027	0.27	0.26	Motion sickness;	chr7:3334108	chr10:90454170~90502968:+
HNSC	trans	rs702485	0.84	rs836480	ENSG00000249936.3	RAC1P2	5.71	2.02e-08	0.027	0.29	0.26	HDL cholesterol levels;HDL cholesterol;	chr7:6391773	chr4:46723830~46724408:-
HNSC	trans	rs864643	1	rs1340223	ENSG00000183298.5	RP11-556K13.1	5.71	2.03e-08	0.0271	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39508208	chr1:101786340~101787219:-
HNSC	trans	rs9329221	0.905	rs6601451	ENSG00000253893.2	FAM85B	5.71	2.03e-08	0.0271	0.3	0.26	Neuroticism;	chr8:10386171	chr8:8167819~8226614:-
HNSC	trans	rs867371	1	rs8041924	ENSG00000259295.5	CSPG4P12	-5.71	2.03e-08	0.0271	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs2088858	ENSG00000259295.5	CSPG4P12	-5.71	2.03e-08	0.0271	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs4778982	ENSG00000259295.5	CSPG4P12	-5.71	2.03e-08	0.0271	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs2867579	ENSG00000259295.5	CSPG4P12	-5.71	2.03e-08	0.0271	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs881308	ENSG00000259295.5	CSPG4P12	-5.71	2.03e-08	0.0271	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:85191438~85213905:+
HNSC	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	5.71	2.03e-08	0.0272	0.32	0.26	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
HNSC	trans	rs792448	0.603	rs12024665	ENSG00000266126.1	RP11-209D14.4	5.71	2.03e-08	0.0272	0.32	0.26	White blood cell count (basophil);	chr1:212326553	chr17:19929372~19929737:-
HNSC	trans	rs34421088	0.576	rs2572432	ENSG00000173295.6	FAM86B3P	-5.71	2.04e-08	0.0273	-0.32	-0.26	Neuroticism;	chr8:11244214	chr8:8228595~8244865:+
HNSC	trans	rs75904417	0.673	rs75284091	ENSG00000248359.1	CTC-537E7.2	5.71	2.04e-08	0.0273	0.39	0.26	Interleukin-13 levels;Interleukin-7 levels;	chr2:167819805	chr5:68531690~68533530:-
HNSC	trans	rs7824557	0.564	rs1435275	ENSG00000254340.1	RP11-10A14.3	-5.71	2.04e-08	0.0273	-0.3	-0.26	Retinal vascular caliber;	chr8:11378226	chr8:9141424~9145435:+
HNSC	trans	rs4343996	0.902	rs9969270	ENSG00000224750.5	RP11-94M14.2	5.71	2.04e-08	0.0273	0.27	0.26	Motion sickness;	chr7:3329342	chr10:90454170~90502968:+
HNSC	trans	rs1190596	0.567	rs11846750	ENSG00000181359.5	HSP90AA6P	-5.71	2.04e-08	0.0273	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102279899	chr4:170581470~170605450:-
HNSC	trans	rs73108077	1	rs58925751	ENSG00000279352.1	RP11-411B10.7	5.71	2.05e-08	0.0274	0.53	0.26	Red blood cell density in sickle cell anemia;	chr20:31459409	chr18:14010054~14010917:+
HNSC	trans	rs17102884	0.506	rs4899540	ENSG00000181227.3	RP4-682C21.2	5.71	2.05e-08	0.0274	0.26	0.26	Neuroticism;	chr14:74936705	chr1:75743423~75744776:-
HNSC	trans	rs17102884	0.506	rs4899541	ENSG00000181227.3	RP4-682C21.2	5.71	2.05e-08	0.0274	0.26	0.26	Neuroticism;	chr14:74936734	chr1:75743423~75744776:-
HNSC	trans	rs902774	0.759	rs4919707	ENSG00000255815.3	KRT8P11	-5.71	2.06e-08	0.0275	-0.49	-0.26	Prostate cancer;	chr12:52895864	chr9:99305176~99306611:+
HNSC	trans	rs3806843	0.868	rs2531342	ENSG00000231043.3	AC007238.1	5.71	2.06e-08	0.0275	0.26	0.26	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr2:58460292~58462032:-
HNSC	trans	rs3806843	0.9	rs2563279	ENSG00000231043.3	AC007238.1	5.71	2.06e-08	0.0275	0.26	0.26	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr2:58460292~58462032:-
HNSC	trans	rs7873102	0.933	rs776010	ENSG00000229007.1	EXOSC3P1	-5.71	2.06e-08	0.0275	-0.32	-0.26	Brain structure;	chr9:37929841	chr21:32496812~32497311:+
HNSC	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-5.71	2.07e-08	0.0276	-0.32	-0.26	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
HNSC	trans	rs9329221	1	rs9329221	ENSG00000173295.6	FAM86B3P	5.71	2.07e-08	0.0276	0.28	0.26	Neuroticism;	chr8:10382692	chr8:8228595~8244865:+
HNSC	trans	rs3779195	0.697	rs13232861	ENSG00000230273.1	AC087163.3	5.71	2.07e-08	0.0276	0.33	0.26	Sex hormone-binding globulin levels;	chr7:98299769	chr17:17981192~17981572:-
HNSC	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	5.7	2.07e-08	0.0276	0.32	0.26	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	5.7	2.07e-08	0.0277	0.29	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
HNSC	trans	rs6831352	0.879	rs29001229	ENSG00000233859.2	ADH5P4	5.7	2.08e-08	0.0277	0.31	0.26	Alcohol dependence;	chr4:99125672	chr6:65836930~65838039:-
HNSC	trans	rs9393777	0.92	rs55834529	ENSG00000176998.4	HCG4	-5.7	2.08e-08	0.0277	-0.53	-0.26	Intelligence (multi-trait analysis);	chr6:27104763	chr6:29791753~29792750:-
HNSC	trans	rs6831352	0.801	rs2602897	ENSG00000233859.2	ADH5P4	-5.7	2.09e-08	0.0278	-0.31	-0.26	Alcohol dependence;	chr4:99125142	chr6:65836930~65838039:-
HNSC	trans	rs9329221	0.662	rs11249996	ENSG00000173295.6	FAM86B3P	-5.7	2.09e-08	0.0278	-0.3	-0.26	Neuroticism;	chr8:10387953	chr8:8228595~8244865:+
HNSC	trans	rs12145833	0.569	rs12049318	ENSG00000154608.12	CEP170P1	-5.7	2.09e-08	0.0279	-0.32	-0.26	Obesity (early onset extreme);	chr1:243430358	chr4:118467590~118554204:+
HNSC	trans	rs12439619	0.508	rs8023960	ENSG00000235370.6	DNM1P51	-5.7	2.09e-08	0.0279	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82206704	chr15:84398316~84411701:-
HNSC	trans	rs902774	0.818	rs4919742	ENSG00000255815.3	KRT8P11	-5.7	2.1e-08	0.028	-0.48	-0.26	Prostate cancer;	chr12:52879180	chr9:99305176~99306611:+
HNSC	trans	rs7826238	0.601	rs2976907	ENSG00000269918.1	AF131215.9	5.7	2.1e-08	0.028	0.26	0.26	Systolic blood pressure;	chr8:8487658	chr8:11104691~11106704:-
HNSC	trans	rs867371	0.896	rs6495647	ENSG00000259295.5	CSPG4P12	-5.7	2.11e-08	0.0281	-0.32	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:85191438~85213905:+
HNSC	trans	rs864643	1	rs1768127	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39523790	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs2542	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39525858	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.891	rs816518	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39527559	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1615844	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39532375	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1513216	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39532651	chr1:101786340~101787219:-
HNSC	trans	rs864643	1	rs1768134	ENSG00000183298.5	RP11-556K13.1	5.7	2.11e-08	0.0281	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39533080	chr1:101786340~101787219:-
HNSC	trans	rs714543	1	rs2898	ENSG00000226038.5	PPIAP21	-5.7	2.11e-08	0.0281	-0.31	-0.26	Plateletcrit;	chr7:44827034	chr20:43230760~43231260:+
HNSC	trans	rs9650657	0.737	rs4551304	ENSG00000253893.2	FAM85B	5.7	2.11e-08	0.0281	0.31	0.26	Neuroticism;	chr8:10807559	chr8:8167819~8226614:-
HNSC	trans	rs804280	0.509	rs13268030	ENSG00000253893.2	FAM85B	-5.7	2.12e-08	0.0282	-0.29	-0.26	Myopia (pathological);	chr8:11925564	chr8:8167819~8226614:-
HNSC	trans	rs902774	0.818	rs73110471	ENSG00000224520.2	KRT8P45	-5.7	2.12e-08	0.0282	-0.45	-0.26	Prostate cancer;	chr12:52923037	chr1:157073257~157074703:+
HNSC	trans	rs867371	1	rs7173339	ENSG00000259295.5	CSPG4P12	-5.7	2.12e-08	0.0283	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:85191438~85213905:+
HNSC	trans	rs2048656	0.6	rs1976671	ENSG00000269918.1	AF131215.9	5.7	2.13e-08	0.0283	0.26	0.26	Schizophrenia;	chr8:9822124	chr8:11104691~11106704:-
HNSC	trans	rs6831352	0.918	rs29001232	ENSG00000233859.2	ADH5P4	5.7	2.13e-08	0.0283	0.31	0.26	Alcohol dependence;	chr4:99125503	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs29001231	ENSG00000233859.2	ADH5P4	5.7	2.13e-08	0.0283	0.31	0.26	Alcohol dependence;	chr4:99125529	chr6:65836930~65838039:-
HNSC	trans	rs9329221	0.741	rs534523	ENSG00000253893.2	FAM85B	5.7	2.13e-08	0.0283	0.29	0.26	Neuroticism;	chr8:10027489	chr8:8167819~8226614:-
HNSC	trans	rs9467711	0.606	rs2073527	ENSG00000176998.4	HCG4	-5.7	2.13e-08	0.0283	-0.45	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26374750	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs2073530	ENSG00000176998.4	HCG4	-5.7	2.13e-08	0.0283	-0.45	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26375015	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs2073531	ENSG00000176998.4	HCG4	-5.7	2.13e-08	0.0283	-0.45	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26375028	chr6:29791753~29792750:-
HNSC	trans	rs7297610	0.92	rs75161052	ENSG00000254512.1	RP11-472I20.2	5.7	2.13e-08	0.0283	0.63	0.26	Response to diuretic therapy;	chr12:69414308	chr11:43733759~43734564:+
HNSC	trans	rs902774	0.818	rs11831919	ENSG00000255815.3	KRT8P11	-5.7	2.14e-08	0.0284	-0.47	-0.26	Prostate cancer;	chr12:52878231	chr9:99305176~99306611:+
HNSC	trans	rs9467711	0.606	rs9358938	ENSG00000176998.4	HCG4	-5.7	2.14e-08	0.0284	-0.47	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26387318	chr6:29791753~29792750:-
HNSC	trans	rs7520050	0.966	rs10890363	ENSG00000255397.1	AC022182.2	-5.7	2.15e-08	0.0286	-0.31	-0.25	Reticulocyte count;Red blood cell count;	chr1:45890476	chr8:60937705~60939871:-
HNSC	trans	rs4378355	1	rs4378355	ENSG00000225531.1	RP11-196I18.3	5.7	2.15e-08	0.0286	0.31	0.25	Prostate-specific antigen levels;	chr11:34761870	chr9:107116829~107117557:+
HNSC	trans	rs10435719	0.902	rs4840599	ENSG00000253893.2	FAM85B	5.7	2.15e-08	0.0286	0.29	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8167819~8226614:-
HNSC	trans	rs7520050	0.831	rs61783170	ENSG00000255397.1	AC022182.2	5.7	2.15e-08	0.0286	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45790657	chr8:60937705~60939871:-
HNSC	trans	rs7824557	0.675	rs2736265	ENSG00000173295.6	FAM86B3P	5.7	2.16e-08	0.0287	0.28	0.25	Retinal vascular caliber;	chr8:11329165	chr8:8228595~8244865:+
HNSC	trans	rs453301	0.624	rs330049	ENSG00000253893.2	FAM85B	-5.7	2.16e-08	0.0287	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9229789	chr8:8167819~8226614:-
HNSC	trans	rs3753275	0.624	rs7555126	ENSG00000265574.1	WDR45BP1	-5.7	2.16e-08	0.0287	-0.37	-0.25	Educational attainment;	chr1:8811426	chr17:32111562~32112590:-
HNSC	trans	rs2048656	0.535	rs2014514	ENSG00000269918.1	AF131215.9	5.7	2.16e-08	0.0287	0.25	0.25	Schizophrenia;	chr8:9789686	chr8:11104691~11106704:-
HNSC	trans	rs804280	1	rs804281	ENSG00000254340.1	RP11-10A14.3	5.7	2.16e-08	0.0288	0.3	0.25	Myopia (pathological);	chr8:11754356	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.902	rs4638056	ENSG00000255397.1	AC022182.2	5.7	2.16e-08	0.0288	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45992481	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.931	rs11576305	ENSG00000255397.1	AC022182.2	5.7	2.16e-08	0.0288	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45994374	chr8:60937705~60939871:-
HNSC	trans	rs113633047	1	rs113633047	ENSG00000231705.1	RP11-432J24.2	5.7	2.17e-08	0.0288	0.5	0.25	Iris color (L* coordinate);	chr5:134067204	chr10:132419083~132420953:+
HNSC	trans	rs853679	0.607	rs56075693	ENSG00000176998.4	HCG4	-5.7	2.17e-08	0.0288	-0.5	-0.25	Depression;	chr6:28322551	chr6:29791753~29792750:-
HNSC	trans	rs1933488	1	rs6901126	ENSG00000278974.1	RP11-756P10.6	5.7	2.17e-08	0.0288	0.34	0.25	Prostate cancer;	chr6:153118927	chr4:188740507~188741281:-
HNSC	trans	rs4713118	0.523	rs2179096	ENSG00000204709.4	LINC01556	5.7	2.17e-08	0.0288	0.3	0.25	Parkinson's disease;	chr6:27698141	chr6:28943877~28944537:+
HNSC	trans	rs453301	0.571	rs2929453	ENSG00000269918.1	AF131215.9	-5.7	2.18e-08	0.0289	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9226831	chr8:11104691~11106704:-
HNSC	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-5.7	2.18e-08	0.0289	-0.32	-0.25	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-5.7	2.18e-08	0.0289	-0.32	-0.25	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
HNSC	trans	rs916888	0.531	rs183211	ENSG00000204650.12	CRHR1-IT1	5.7	2.18e-08	0.0289	0.29	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45620328~45648216:+
HNSC	trans	rs7824557	0.564	rs2736295	ENSG00000254340.1	RP11-10A14.3	5.69	2.19e-08	0.0291	0.3	0.25	Retinal vascular caliber;	chr8:11377271	chr8:9141424~9145435:+
HNSC	trans	rs1473307	0.967	rs10185060	ENSG00000224295.2	AC087380.14	5.69	2.19e-08	0.0291	0.3	0.25	Menopause (age at onset);	chr2:225331222	chr11:5518441~5524955:-
HNSC	trans	rs12439619	0.508	rs8032033	ENSG00000235370.6	DNM1P51	-5.69	2.2e-08	0.0292	-0.31	-0.25	Intelligence (multi-trait analysis);	chr15:82165555	chr15:84398316~84411701:-
HNSC	trans	rs9467711	0.79	rs34107459	ENSG00000253570.1	RNF5P1	5.69	2.2e-08	0.0292	0.61	0.25	Autism spectrum disorder or schizophrenia;	chr6:26328125	chr8:38600661~38601200:-
HNSC	trans	rs13014235	0.562	rs2080325	ENSG00000235105.1	RP11-329A14.1	-5.69	2.2e-08	0.0292	-0.31	-0.25	Basal cell carcinoma;	chr2:201513640	chr1:48435967~48437223:+
HNSC	trans	rs9329221	0.502	rs11777364	ENSG00000173295.6	FAM86B3P	5.69	2.2e-08	0.0292	0.28	0.25	Neuroticism;	chr8:10431036	chr8:8228595~8244865:+
HNSC	trans	rs867371	1	rs8037224	ENSG00000259295.5	CSPG4P12	-5.69	2.21e-08	0.0293	-0.33	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:85191438~85213905:+
HNSC	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-5.69	2.21e-08	0.0293	-0.32	-0.25	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-5.69	2.21e-08	0.0293	-0.32	-0.25	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-5.69	2.21e-08	0.0293	-0.32	-0.25	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
HNSC	trans	rs73108077	0.736	rs6058546	ENSG00000279352.1	RP11-411B10.7	5.69	2.21e-08	0.0293	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31314582	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs1997741	ENSG00000279352.1	RP11-411B10.7	5.69	2.21e-08	0.0293	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31323198	chr18:14010054~14010917:+
HNSC	trans	rs867371	0.929	rs7176075	ENSG00000259295.5	CSPG4P12	-5.69	2.21e-08	0.0293	-0.33	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs8041868	ENSG00000259295.5	CSPG4P12	-5.69	2.21e-08	0.0293	-0.33	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:85191438~85213905:+
HNSC	trans	rs864643	0.513	rs1398666	ENSG00000183298.5	RP11-556K13.1	5.69	2.21e-08	0.0293	0.4	0.25	Attention deficit hyperactivity disorder;	chr3:39475540	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.513	rs1768202	ENSG00000183298.5	RP11-556K13.1	5.69	2.21e-08	0.0293	0.4	0.25	Attention deficit hyperactivity disorder;	chr3:39476053	chr1:101786340~101787219:-
HNSC	trans	rs7662987	1	rs11547772	ENSG00000228407.2	RP4-800M22.1	5.69	2.21e-08	0.0293	0.42	0.25	Smoking initiation;	chr4:99071642	chr1:52160261~52160600:-
HNSC	trans	rs6903823	0.508	rs1778484	ENSG00000227766.1	HCG4P5	-5.69	2.21e-08	0.0294	-0.34	-0.25	Pulmonary function;	chr6:28273021	chr6:29942075~29943067:-
HNSC	trans	rs10933436	0.702	rs9288685	ENSG00000205578.5	POM121B	-5.69	2.21e-08	0.0294	-0.27	-0.25	Coronary heart disease;	chr2:233122404	chr7:73293497~73301161:+
HNSC	trans	rs9467711	0.56	rs6900665	ENSG00000253570.1	RNF5P1	5.69	2.22e-08	0.0295	0.53	0.25	Autism spectrum disorder or schizophrenia;	chr6:26486941	chr8:38600661~38601200:-
HNSC	trans	rs7819412	0.525	rs10086521	ENSG00000173295.6	FAM86B3P	-5.69	2.23e-08	0.0295	-0.3	-0.25	Triglycerides;	chr8:10926259	chr8:8228595~8244865:+
HNSC	trans	rs864643	0.524	rs72869124	ENSG00000183298.5	RP11-556K13.1	5.69	2.23e-08	0.0296	0.48	0.25	Attention deficit hyperactivity disorder;	chr3:39469788	chr1:101786340~101787219:-
HNSC	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	5.69	2.24e-08	0.0296	0.33	0.25	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
HNSC	trans	rs4263408	0.935	rs62310123	ENSG00000237550.5	UBE2Q2P6	5.69	2.24e-08	0.0296	0.28	0.25	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39744462	chr15:82372196~82372912:-
HNSC	trans	rs7873102	0.967	rs776019	ENSG00000229007.1	EXOSC3P1	-5.69	2.24e-08	0.0297	-0.31	-0.25	Brain structure;	chr9:37939676	chr21:32496812~32497311:+
HNSC	trans	rs867371	1	rs7166570	ENSG00000259295.5	CSPG4P12	-5.69	2.24e-08	0.0297	-0.33	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:85191438~85213905:+
HNSC	trans	rs2524005	1	rs2524005	ENSG00000253570.1	RNF5P1	5.69	2.24e-08	0.0297	0.39	0.25	Bipolar disorder and schizophrenia;	chr6:29931900	chr8:38600661~38601200:-
HNSC	trans	rs4646450	0.838	rs10229569	ENSG00000228834.1	RP11-249L21.4	5.69	2.24e-08	0.0297	0.38	0.25	Blood metabolite levels;	chr7:99586081	chr6:108907615~108907873:-
HNSC	trans	rs9650657	0.836	rs6601523	ENSG00000173295.6	FAM86B3P	-5.69	2.25e-08	0.0298	-0.29	-0.25	Neuroticism;	chr8:10777631	chr8:8228595~8244865:+
HNSC	trans	rs722599	0.639	rs2193596	ENSG00000181227.3	RP4-682C21.2	-5.69	2.25e-08	0.0298	-0.27	-0.25	IgG glycosylation;	chr14:74767398	chr1:75743423~75744776:-
HNSC	trans	rs7824557	0.544	rs1865521	ENSG00000254340.1	RP11-10A14.3	5.69	2.26e-08	0.0298	0.3	0.25	Retinal vascular caliber;	chr8:11373740	chr8:9141424~9145435:+
HNSC	trans	rs9393777	0.778	rs74689501	ENSG00000253570.1	RNF5P1	5.69	2.26e-08	0.0299	0.57	0.25	Intelligence (multi-trait analysis);	chr6:26920042	chr8:38600661~38601200:-
HNSC	trans	rs6673267	0.709	rs4915475	ENSG00000244144.1	RP11-757F18.3	5.69	2.26e-08	0.0299	0.29	0.25	Lobe attachment (rater-scored or self-reported);	chr1:201060303	chr3:112185480~112185998:-
HNSC	trans	rs9733	0.65	rs11204668	ENSG00000180764.13	PIPSL	5.69	2.26e-08	0.0299	0.31	0.25	Tonsillectomy;	chr1:150571210	chr10:93958191~93961540:-
HNSC	trans	rs1584120	1	rs1584120	ENSG00000236617.2	RP11-46H11.12	5.69	2.27e-08	0.03	0.34	0.25	Pelvic organ prolapse (moderate/severe);	chr12:23446319	chr12:132887842~132888583:+
HNSC	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-5.69	2.27e-08	0.03	-0.32	-0.25	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-5.69	2.27e-08	0.03	-0.32	-0.25	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
HNSC	trans	rs9650315	0.706	rs11985751	ENSG00000243802.2	RP11-390K5.1	5.69	2.28e-08	0.0301	0.38	0.25	Height;	chr8:56224880	chr11:47191181~47191542:-
HNSC	trans	rs2325036	0.58	rs55829275	ENSG00000241218.1	RP11-446H18.1	5.69	2.28e-08	0.0301	0.31	0.25	Waist circumference;	chr3:85755482	chr3:107327830~107329197:-
HNSC	trans	rs7829975	0.633	rs2979181	ENSG00000255310.2	AF131215.2	5.69	2.28e-08	0.0302	0.25	0.25	Mood instability;	chr8:8465578	chr8:11107788~11109726:-
HNSC	trans	rs902774	0.818	rs56095813	ENSG00000255815.3	KRT8P11	-5.69	2.29e-08	0.0302	-0.48	-0.25	Prostate cancer;	chr12:52900963	chr9:99305176~99306611:+
HNSC	trans	rs1908814	0.51	rs57655799	ENSG00000253893.2	FAM85B	-5.69	2.29e-08	0.0302	-0.29	-0.25	Neuroticism;	chr8:11924908	chr8:8167819~8226614:-
HNSC	trans	rs9467711	0.659	rs36162392	ENSG00000176998.4	HCG4	-5.69	2.29e-08	0.0302	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs3823158	ENSG00000176998.4	HCG4	-5.69	2.29e-08	0.0302	-0.49	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs13195509	ENSG00000176998.4	HCG4	-5.69	2.29e-08	0.0302	-0.49	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:29791753~29792750:-
HNSC	trans	rs4713118	0.869	rs9366700	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27729172	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs6456802	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27730576	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9393851	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27731802	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9461400	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27732780	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9295742	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27735053	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs9461401	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27735512	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.869	rs6914924	ENSG00000204709.4	LINC01556	5.69	2.3e-08	0.0303	0.33	0.25	Parkinson's disease;	chr6:27743751	chr6:28943877~28944537:+
HNSC	trans	rs17507216	0.628	rs8032321	ENSG00000235370.6	DNM1P51	-5.69	2.3e-08	0.0304	-0.39	-0.25	Excessive daytime sleepiness;	chr15:82698956	chr15:84398316~84411701:-
HNSC	trans	rs17507216	0.628	rs8040488	ENSG00000235370.6	DNM1P51	-5.69	2.3e-08	0.0304	-0.39	-0.25	Excessive daytime sleepiness;	chr15:82699081	chr15:84398316~84411701:-
HNSC	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	5.69	2.3e-08	0.0304	0.32	0.25	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	5.69	2.3e-08	0.0304	0.32	0.25	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
HNSC	trans	rs7113874	0.534	rs2311392	ENSG00000266891.1	RP11-692N5.2	5.69	2.3e-08	0.0304	0.4	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8468889	chr18:9734882~9735602:-
HNSC	trans	rs7824557	0.569	rs35418978	ENSG00000173295.6	FAM86B3P	5.69	2.31e-08	0.0304	0.28	0.25	Retinal vascular caliber;	chr8:11328944	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.606	rs2736264	ENSG00000173295.6	FAM86B3P	5.69	2.31e-08	0.0304	0.28	0.25	Retinal vascular caliber;	chr8:11329130	chr8:8228595~8244865:+
HNSC	trans	rs1568889	0.775	rs35243076	ENSG00000174912.7	METTL15P1	5.68	2.31e-08	0.0305	0.27	0.25	Bipolar disorder;	chr11:28229071	chr3:156713884~156714928:-
HNSC	trans	rs7036656	0.583	rs2811710	ENSG00000279833.1	RP4-742C19.13	-5.68	2.31e-08	0.0305	-0.18	-0.25	White blood cell count;	chr9:21991924	chr22:39133090~39136760:+
HNSC	trans	rs9393777	0.92	rs66462181	ENSG00000176998.4	HCG4	-5.68	2.31e-08	0.0305	-0.53	-0.25	Intelligence (multi-trait analysis);	chr6:27123882	chr6:29791753~29792750:-
HNSC	trans	rs7520050	0.966	rs10789481	ENSG00000255397.1	AC022182.2	5.68	2.31e-08	0.0305	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45917911	chr8:60937705~60939871:-
HNSC	trans	rs13016963	0.526	rs6726823	ENSG00000235105.1	RP11-329A14.1	5.68	2.31e-08	0.0305	0.3	0.25	Esophageal squamous cell carcinoma;Melanoma;	chr2:201352193	chr1:48435967~48437223:+
HNSC	trans	rs7824557	0.778	rs6601572	ENSG00000254340.1	RP11-10A14.3	-5.68	2.32e-08	0.0306	-0.3	-0.25	Retinal vascular caliber;	chr8:11235828	chr8:9141424~9145435:+
HNSC	trans	rs6831352	0.918	rs17218560	ENSG00000233859.2	ADH5P4	-5.68	2.32e-08	0.0306	-0.31	-0.25	Alcohol dependence;	chr4:99139643	chr6:65836930~65838039:-
HNSC	trans	rs2288327	0.818	rs12618265	ENSG00000269800.1	PLEKHA3P1	5.68	2.32e-08	0.0306	0.36	0.25	Atrial fibrillation;	chr2:178518082	chr19:41521043~41521989:-
HNSC	trans	rs9393777	0.778	rs77666565	ENSG00000253570.1	RNF5P1	5.68	2.33e-08	0.0307	0.57	0.25	Intelligence (multi-trait analysis);	chr6:26883636	chr8:38600661~38601200:-
HNSC	trans	rs1510510	0.69	rs12996991	ENSG00000238290.1	RP11-431K24.1	-5.68	2.33e-08	0.0308	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641161	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs7599777	ENSG00000238290.1	RP11-431K24.1	-5.68	2.33e-08	0.0308	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641366	chr1:8026738~8122702:+
HNSC	trans	rs4713118	0.615	rs9295747	ENSG00000204709.4	LINC01556	-5.68	2.33e-08	0.0308	-0.3	-0.25	Parkinson's disease;	chr6:27769214	chr6:28943877~28944537:+
HNSC	trans	rs864643	0.524	rs80322842	ENSG00000183298.5	RP11-556K13.1	5.68	2.34e-08	0.0308	0.48	0.25	Attention deficit hyperactivity disorder;	chr3:39483682	chr1:101786340~101787219:-
HNSC	trans	rs9329221	0.537	rs6986911	ENSG00000173295.6	FAM86B3P	5.68	2.34e-08	0.0308	0.27	0.25	Neuroticism;	chr8:10121013	chr8:8228595~8244865:+
HNSC	trans	rs7824557	0.606	rs2736273	ENSG00000173295.6	FAM86B3P	5.68	2.34e-08	0.0308	0.28	0.25	Retinal vascular caliber;	chr8:11342429	chr8:8228595~8244865:+
HNSC	trans	rs4713118	0.699	rs200969	ENSG00000204709.4	LINC01556	5.68	2.34e-08	0.0308	0.35	0.25	Parkinson's disease;	chr6:27891675	chr6:28943877~28944537:+
HNSC	trans	rs9329221	0.905	rs4433149	ENSG00000173295.6	FAM86B3P	-5.68	2.35e-08	0.031	-0.28	-0.25	Neuroticism;	chr8:10391758	chr8:8228595~8244865:+
HNSC	trans	rs864643	1	rs816491	ENSG00000183298.5	RP11-556K13.1	-5.68	2.36e-08	0.031	-0.41	-0.25	Attention deficit hyperactivity disorder;	chr3:39514006	chr1:101786340~101787219:-
HNSC	trans	rs7191700	0.583	rs243314	ENSG00000277447.1	RP11-193E15.4	5.68	2.36e-08	0.0311	0.26	0.25	Multiple sclerosis;	chr16:11291247	chr18:3025069~3025387:-
HNSC	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-5.68	2.36e-08	0.0311	-0.32	-0.25	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
HNSC	trans	rs6921919	0.848	rs56131013	ENSG00000227766.1	HCG4P5	-5.68	2.36e-08	0.0311	-0.37	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:29942075~29943067:-
HNSC	trans	rs34816374	1	rs34816374	ENSG00000176998.4	HCG4	-5.68	2.37e-08	0.0312	-0.51	-0.25	Lung cancer in ever smokers;	chr6:26981893	chr6:29791753~29792750:-
HNSC	trans	rs9650657	0.711	rs7007318	ENSG00000173295.6	FAM86B3P	-5.68	2.37e-08	0.0312	-0.3	-0.25	Neuroticism;	chr8:10734768	chr8:8228595~8244865:+
HNSC	trans	rs7873102	0.933	rs4878178	ENSG00000229007.1	EXOSC3P1	5.68	2.37e-08	0.0312	0.31	0.25	Brain structure;	chr9:38037089	chr21:32496812~32497311:+
HNSC	trans	rs4713118	0.615	rs57252182	ENSG00000204709.4	LINC01556	5.68	2.37e-08	0.0312	0.31	0.25	Parkinson's disease;	chr6:27752470	chr6:28943877~28944537:+
HNSC	trans	rs34034915	1	rs34034915	ENSG00000204709.4	LINC01556	5.68	2.37e-08	0.0312	0.31	0.25	Hepatitis A;	chr6:27752924	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.527	rs36042294	ENSG00000204709.4	LINC01556	5.68	2.37e-08	0.0312	0.31	0.25	Parkinson's disease;	chr6:27752933	chr6:28943877~28944537:+
HNSC	trans	rs7335046	0.666	rs9513572	ENSG00000248925.1	CTD-2083E4.6	5.68	2.37e-08	0.0312	0.45	0.25	Basal cell carcinoma;	chr13:99163288	chr5:269858~271516:-
HNSC	trans	rs4732038	0.691	rs10239772	ENSG00000213606.3	AKR1B10P1	5.68	2.37e-08	0.0312	0.29	0.25	Longevity;	chr7:134561509	chr10:67750284~67751225:+
HNSC	trans	rs2302190	0.882	rs11650710	ENSG00000273445.1	RP11-1399P15.1	5.68	2.38e-08	0.0313	0.29	0.25	Vitamin D levels;	chr17:58506186	chr2:87477495~87478034:-
HNSC	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-5.68	2.38e-08	0.0313	-0.32	-0.25	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-5.68	2.38e-08	0.0313	-0.32	-0.25	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
HNSC	trans	rs8177876	0.822	rs804902	ENSG00000224837.1	GCSHP5	5.68	2.38e-08	0.0313	0.41	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr1:168055901~168056422:-
HNSC	trans	rs17507216	0.958	rs72751643	ENSG00000259295.5	CSPG4P12	-5.68	2.39e-08	0.0314	-0.37	-0.25	Excessive daytime sleepiness;	chr15:82559444	chr15:85191438~85213905:+
HNSC	trans	rs9733	0.65	rs12406712	ENSG00000180764.13	PIPSL	5.68	2.39e-08	0.0315	0.31	0.25	Tonsillectomy;	chr1:150572608	chr10:93958191~93961540:-
HNSC	trans	rs7833986	0.534	rs17813240	ENSG00000236862.1	RPS20P24	5.68	2.4e-08	0.0315	0.3	0.25	Height;	chr8:56013232	chr9:72655832~72656192:-
HNSC	trans	rs1038094	1	rs2127019	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73729281	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs2279154	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73730676	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs2279155	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73730796	chr22:20058030~20070569:-
HNSC	trans	rs1038094	0.929	rs28649098	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73731159	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs28627084	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73731297	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs4887036	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73731512	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs4887039	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73731523	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs4887045	ENSG00000236540.6	AC006547.13	-5.68	2.4e-08	0.0315	-0.36	-0.25	Bipolar disorder;	chr15:73731718	chr22:20058030~20070569:-
HNSC	trans	rs2687481	0.718	rs1719103	ENSG00000227542.1	AC092614.2	-5.68	2.4e-08	0.0315	-0.38	-0.25	Hearing function;	chr7:126278857	chr2:191229165~191246172:-
HNSC	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-5.68	2.4e-08	0.0316	-0.32	-0.25	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-5.68	2.4e-08	0.0316	-0.32	-0.25	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-5.68	2.4e-08	0.0316	-0.32	-0.25	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-5.68	2.4e-08	0.0316	-0.32	-0.25	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
HNSC	trans	rs261902	0.557	rs261898	ENSG00000180769.7	WDFY3-AS2	5.68	2.41e-08	0.0316	0.47	0.25	Normalized brain volume;	chr12:32312426	chr4:84965682~85011277:+
HNSC	trans	rs9650657	0.769	rs1968400	ENSG00000253893.2	FAM85B	5.68	2.42e-08	0.0317	0.3	0.25	Neuroticism;	chr8:10757921	chr8:8167819~8226614:-
HNSC	trans	rs3740713	0.748	rs35292478	ENSG00000214110.3	LDHAP4	5.68	2.43e-08	0.0319	0.4	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr9:14921337~14922334:-
HNSC	trans	rs4948102	0.924	rs13240915	ENSG00000215006.4	CHCHD2P2	-5.67	2.44e-08	0.032	-0.34	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56023059	chr5:69333929~69334249:+
HNSC	trans	rs916888	0.61	rs199454	ENSG00000204650.12	CRHR1-IT1	-5.67	2.44e-08	0.032	-0.29	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45620328~45648216:+
HNSC	trans	rs1991651	0.578	rs11778453	ENSG00000254340.1	RP11-10A14.3	-5.67	2.44e-08	0.0321	-0.31	-0.25	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.966	rs946529	ENSG00000255397.1	AC022182.2	5.67	2.45e-08	0.0322	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:46019876	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.966	rs2275426	ENSG00000255397.1	AC022182.2	5.67	2.45e-08	0.0322	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:46021880	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.902	rs4626927	ENSG00000255397.1	AC022182.2	5.67	2.46e-08	0.0322	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45782973	chr8:60937705~60939871:-
HNSC	trans	rs7520050	0.902	rs7514192	ENSG00000255397.1	AC022182.2	5.67	2.46e-08	0.0322	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45783305	chr8:60937705~60939871:-
HNSC	trans	rs2302190	0.882	rs7221464	ENSG00000273445.1	RP11-1399P15.1	5.67	2.46e-08	0.0322	0.29	0.25	Vitamin D levels;	chr17:58474992	chr2:87477495~87478034:-
HNSC	trans	rs702485	0.903	rs836526	ENSG00000249936.3	RAC1P2	5.67	2.46e-08	0.0323	0.3	0.25	HDL cholesterol levels;HDL cholesterol;	chr7:6426458	chr4:46723830~46724408:-
HNSC	trans	rs7873102	0.967	rs776017	ENSG00000229007.1	EXOSC3P1	-5.67	2.47e-08	0.0324	-0.31	-0.25	Brain structure;	chr9:37941306	chr21:32496812~32497311:+
HNSC	trans	rs17301013	0.861	rs10218528	ENSG00000213331.4	RP11-713C19.2	5.67	2.47e-08	0.0324	0.3	0.25	Systemic lupus erythematosus;	chr1:174478450	chr4:187970273~187971284:+
HNSC	trans	rs4869931	0.929	rs9480529	ENSG00000262587.2	RP11-266L9.4	-5.67	2.47e-08	0.0324	-0.32	-0.25	Systolic blood pressure in sickle cell anemia;	chr6:150681151	chr16:25031744~25058109:+
HNSC	trans	rs4730250	0.707	rs1981696	ENSG00000278771.1	Metazoa_SRP	-5.67	2.47e-08	0.0324	-0.35	-0.25	Osteoarthritis;	chr7:107153655	chr14:49853616~49853914:-
HNSC	trans	rs9329221	0.621	rs12156350	ENSG00000173295.6	FAM86B3P	-5.67	2.47e-08	0.0324	-0.28	-0.25	Neuroticism;	chr8:10411006	chr8:8228595~8244865:+
HNSC	trans	rs4784054	0.803	rs73553527	ENSG00000230849.2	GOT2P2	5.67	2.47e-08	0.0324	0.47	0.25	Blood metabolite levels;	chr16:58762002	chr1:173141100~173142350:-
HNSC	trans	rs4784054	0.667	rs8052824	ENSG00000230849.2	GOT2P2	5.67	2.47e-08	0.0324	0.47	0.25	Blood metabolite levels;	chr16:58762045	chr1:173141100~173142350:-
HNSC	trans	rs4784054	0.614	rs8046937	ENSG00000230849.2	GOT2P2	5.67	2.47e-08	0.0324	0.47	0.25	Blood metabolite levels;	chr16:58762282	chr1:173141100~173142350:-
HNSC	trans	rs4784054	0.803	rs4784980	ENSG00000230849.2	GOT2P2	5.67	2.47e-08	0.0324	0.47	0.25	Blood metabolite levels;	chr16:58763722	chr1:173141100~173142350:-
HNSC	trans	rs9650657	0.737	rs2409669	ENSG00000173295.6	FAM86B3P	-5.67	2.48e-08	0.0324	-0.29	-0.25	Neuroticism;	chr8:10766459	chr8:8228595~8244865:+
HNSC	trans	rs864643	0.678	rs1768203	ENSG00000183298.5	RP11-556K13.1	5.67	2.48e-08	0.0325	0.41	0.25	Attention deficit hyperactivity disorder;	chr3:39476377	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.678	rs1708100	ENSG00000183298.5	RP11-556K13.1	5.67	2.48e-08	0.0325	0.41	0.25	Attention deficit hyperactivity disorder;	chr3:39476400	chr1:101786340~101787219:-
HNSC	trans	rs9329221	0.617	rs615632	ENSG00000173295.6	FAM86B3P	-5.67	2.48e-08	0.0325	-0.28	-0.25	Neuroticism;	chr8:9938811	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.711	rs35091929	ENSG00000173295.6	FAM86B3P	-5.67	2.48e-08	0.0325	-0.29	-0.25	Neuroticism;	chr8:10835982	chr8:8228595~8244865:+
HNSC	trans	rs673253	0.686	rs11580258	ENSG00000231007.5	CDC20P1	5.67	2.48e-08	0.0325	0.37	0.25	Intelligence (multi-trait analysis);	chr1:43550344	chr9:87011652~87013151:+
HNSC	trans	rs67340775	0.748	rs13212651	ENSG00000253570.1	RNF5P1	5.67	2.49e-08	0.0326	0.57	0.25	Lung cancer in ever smokers;	chr6:27839207	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs71559070	ENSG00000204622.9	HLA-J	-5.67	2.49e-08	0.0326	-0.57	-0.25	Depression;	chr6:28071151	chr6:30006583~30009956:+
HNSC	trans	rs10435719	0.902	rs12681142	ENSG00000253893.2	FAM85B	-5.67	2.49e-08	0.0326	-0.3	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.546	rs35744819	ENSG00000228078.1	HLA-U	-5.67	2.5e-08	0.0327	-0.58	-0.25	Depression;	chr6:28350554	chr6:29934101~29934286:+
HNSC	trans	rs7113874	0.545	rs72855149	ENSG00000266891.1	RP11-692N5.2	5.67	2.5e-08	0.0327	0.39	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8586160	chr18:9734882~9735602:-
HNSC	trans	rs13016963	0.526	rs7577057	ENSG00000235105.1	RP11-329A14.1	5.67	2.5e-08	0.0327	0.3	0.25	Esophageal squamous cell carcinoma;Melanoma;	chr2:201343270	chr1:48435967~48437223:+
HNSC	trans	rs3740713	0.669	rs78098319	ENSG00000214110.3	LDHAP4	5.67	2.5e-08	0.0327	0.42	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr9:14921337~14922334:-
HNSC	trans	rs7824557	0.545	rs2572380	ENSG00000254340.1	RP11-10A14.3	-5.67	2.51e-08	0.0328	-0.3	-0.25	Retinal vascular caliber;	chr8:11379968	chr8:9141424~9145435:+
HNSC	trans	rs2687481	0.718	rs1673371	ENSG00000227542.1	AC092614.2	5.67	2.51e-08	0.0328	0.37	0.25	Hearing function;	chr7:126234016	chr2:191229165~191246172:-
HNSC	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	5.67	2.51e-08	0.0328	0.33	0.25	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
HNSC	trans	rs7178572	0.568	rs12443386	ENSG00000245275.6	SAP30L-AS1	5.67	2.52e-08	0.0329	0.33	0.25	Type 2 diabetes;	chr15:77199047	chr5:154329437~154445850:-
HNSC	trans	rs4343996	0.869	rs6949513	ENSG00000224750.5	RP11-94M14.2	-5.67	2.52e-08	0.033	-0.27	-0.25	Motion sickness;	chr7:3457099	chr10:90454170~90502968:+
HNSC	trans	rs12145833	0.679	rs12140432	ENSG00000154608.12	CEP170P1	-5.67	2.52e-08	0.033	-0.34	-0.25	Obesity (early onset extreme);	chr1:243432985	chr4:118467590~118554204:+
HNSC	trans	rs4276421	0.715	rs10043248	ENSG00000231752.4	EMBP1	5.67	2.53e-08	0.0331	0.32	0.25	P wave duration;	chr5:46025930	chr1:121519112~121571892:+
HNSC	trans	rs7121538	0.673	rs11023186	ENSG00000236360.2	RP11-334A14.2	-5.67	2.54e-08	0.0331	-0.51	-0.25	HDL cholesterol;	chr11:14321215	chr1:52993201~52993702:-
HNSC	trans	rs7121538	0.673	rs11023190	ENSG00000236360.2	RP11-334A14.2	-5.67	2.54e-08	0.0331	-0.51	-0.25	HDL cholesterol;	chr11:14337389	chr1:52993201~52993702:-
HNSC	trans	rs916888	0.61	rs142167	ENSG00000204650.12	CRHR1-IT1	-5.67	2.54e-08	0.0332	-0.28	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45620328~45648216:+
HNSC	trans	rs722599	0.715	rs2080086	ENSG00000181227.3	RP4-682C21.2	5.67	2.54e-08	0.0332	0.26	0.25	IgG glycosylation;	chr14:74871705	chr1:75743423~75744776:-
HNSC	trans	rs7824557	0.564	rs2572386	ENSG00000254340.1	RP11-10A14.3	-5.67	2.55e-08	0.0333	-0.3	-0.25	Retinal vascular caliber;	chr8:11379466	chr8:9141424~9145435:+
HNSC	trans	rs9425766	0.541	rs4652274	ENSG00000213331.4	RP11-713C19.2	5.67	2.55e-08	0.0333	0.31	0.25	Life satisfaction;	chr1:174249434	chr4:187970273~187971284:+
HNSC	trans	rs7121538	0.673	rs2303975	ENSG00000236360.2	RP11-334A14.2	-5.67	2.55e-08	0.0333	-0.5	-0.25	HDL cholesterol;	chr11:14255453	chr1:52993201~52993702:-
HNSC	trans	rs7121616	0.576	rs4936767	ENSG00000214144.3	RP11-488L18.1	5.67	2.55e-08	0.0333	0.32	0.25	Breast cancer;	chr11:123047451	chr1:247229940~247231880:+
HNSC	trans	rs853679	0.538	rs13199081	ENSG00000228078.1	HLA-U	-5.67	2.56e-08	0.0334	-0.35	-0.25	Depression;	chr6:28364057	chr6:29934101~29934286:+
HNSC	trans	rs10100465	0.765	rs1508559	ENSG00000224861.1	YBX1P1	-5.67	2.57e-08	0.0335	-0.26	-0.25	Leprosy;	chr8:117675153	chr14:66012830~66013789:-
HNSC	trans	rs7263120	1	rs8121173	ENSG00000228577.1	AC010731.2	-5.67	2.57e-08	0.0335	-0.34	-0.25	Blood protein levels;	chr20:23746311	chr2:206606497~206609812:-
HNSC	trans	rs73108077	0.736	rs6060436	ENSG00000279352.1	RP11-411B10.7	5.67	2.57e-08	0.0335	0.43	0.25	Red blood cell density in sickle cell anemia;	chr20:31258500	chr18:14010054~14010917:+
HNSC	trans	rs7819412	0.595	rs10106914	ENSG00000254340.1	RP11-10A14.3	-5.67	2.57e-08	0.0335	-0.31	-0.25	Triglycerides;	chr8:11130141	chr8:9141424~9145435:+
HNSC	trans	rs9467711	0.606	rs2073529	ENSG00000176998.4	HCG4	5.67	2.57e-08	0.0336	0.45	0.25	Autism spectrum disorder or schizophrenia;	chr6:26374931	chr6:29791753~29792750:-
HNSC	trans	rs9650657	0.707	rs4841452	ENSG00000253893.2	FAM85B	5.66	2.58e-08	0.0336	0.3	0.25	Neuroticism;	chr8:10829611	chr8:8167819~8226614:-
HNSC	trans	rs4869931	0.929	rs9478780	ENSG00000228501.2	RPL15P18	5.66	2.58e-08	0.0337	0.32	0.25	Systolic blood pressure in sickle cell anemia;	chr6:150687858	chr13:100150481~100151092:-
HNSC	trans	rs7746199	0.736	rs10484399	ENSG00000228078.1	HLA-U	-5.66	2.59e-08	0.0337	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:29934101~29934286:+
HNSC	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-5.66	2.59e-08	0.0337	-0.29	-0.25	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
HNSC	trans	rs7829975	0.511	rs2976902	ENSG00000255310.2	AF131215.2	5.66	2.59e-08	0.0337	0.25	0.25	Mood instability;	chr8:8483595	chr8:11107788~11109726:-
HNSC	trans	rs7824557	0.564	rs11781637	ENSG00000173295.6	FAM86B3P	-5.66	2.59e-08	0.0338	-0.28	-0.25	Retinal vascular caliber;	chr8:11357463	chr8:8228595~8244865:+
HNSC	trans	rs722599	0.651	rs12887044	ENSG00000181227.3	RP4-682C21.2	-5.66	2.59e-08	0.0338	-0.26	-0.25	IgG glycosylation;	chr14:74788956	chr1:75743423~75744776:-
HNSC	trans	rs860295	0.65	rs12024880	ENSG00000241627.3	UBQLN4P1	5.66	2.6e-08	0.0338	0.28	0.25	Body mass index;	chr1:155939119	chr3:148985868~148987668:-
HNSC	trans	rs6831352	0.918	rs2851248	ENSG00000233859.2	ADH5P4	-5.66	2.6e-08	0.0338	-0.31	-0.25	Alcohol dependence;	chr4:99124823	chr6:65836930~65838039:-
HNSC	trans	rs9329221	0.521	rs4841294	ENSG00000173295.6	FAM86B3P	-5.66	2.6e-08	0.0338	-0.28	-0.25	Neuroticism;	chr8:10247558	chr8:8228595~8244865:+
HNSC	trans	rs714543	1	rs8840	ENSG00000226038.5	PPIAP21	5.66	2.6e-08	0.0339	0.31	0.25	Plateletcrit;	chr7:44877441	chr20:43230760~43231260:+
HNSC	trans	rs4343996	0.869	rs4719944	ENSG00000224750.5	RP11-94M14.2	-5.66	2.61e-08	0.034	-0.27	-0.25	Motion sickness;	chr7:3456400	chr10:90454170~90502968:+
HNSC	trans	rs7647973	0.626	rs4855845	ENSG00000197582.5	GPX1P1	5.66	2.61e-08	0.0341	0.42	0.25	Menarche (age at onset);	chr3:49649610	chrX:13378735~13379340:-
HNSC	trans	rs9467711	0.606	rs66823108	ENSG00000176998.4	HCG4	-5.66	2.62e-08	0.0341	-0.46	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26377711	chr6:29791753~29792750:-
HNSC	trans	rs11110077	0.545	rs12369165	ENSG00000277589.1	RP11-333J10.3	5.66	2.62e-08	0.0341	0.58	0.25	Response to antipsychotic treatment in schizophrenia (working memory);	chr12:99990715	chr17:36998598~37000034:+
HNSC	trans	rs11110077	0.545	rs11110184	ENSG00000277589.1	RP11-333J10.3	5.66	2.62e-08	0.0341	0.58	0.25	Response to antipsychotic treatment in schizophrenia (working memory);	chr12:100009408	chr17:36998598~37000034:+
HNSC	trans	rs11110077	0.545	rs11110190	ENSG00000277589.1	RP11-333J10.3	5.66	2.62e-08	0.0341	0.58	0.25	Response to antipsychotic treatment in schizophrenia (working memory);	chr12:100010646	chr17:36998598~37000034:+
HNSC	trans	rs8177876	0.822	rs4889231	ENSG00000224837.1	GCSHP5	-5.66	2.62e-08	0.0341	-0.42	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr1:168055901~168056422:-
HNSC	trans	rs7520050	0.966	rs4073846	ENSG00000255397.1	AC022182.2	-5.66	2.62e-08	0.0341	-0.31	-0.25	Reticulocyte count;Red blood cell count;	chr1:45997209	chr8:60937705~60939871:-
HNSC	trans	rs853679	0.607	rs66886492	ENSG00000204622.9	HLA-J	-5.66	2.63e-08	0.0342	-0.57	-0.25	Depression;	chr6:28121953	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs35345226	ENSG00000204622.9	HLA-J	-5.66	2.63e-08	0.0342	-0.57	-0.25	Depression;	chr6:28123802	chr6:30006583~30009956:+
HNSC	trans	rs2302190	0.882	rs9903173	ENSG00000273445.1	RP11-1399P15.1	5.66	2.63e-08	0.0342	0.29	0.25	Vitamin D levels;	chr17:58529997	chr2:87477495~87478034:-
HNSC	trans	rs6981523	0.553	rs11989369	ENSG00000173295.6	FAM86B3P	5.66	2.63e-08	0.0342	0.3	0.25	Neuroticism;	chr8:11197876	chr8:8228595~8244865:+
HNSC	trans	rs9329221	0.617	rs483916	ENSG00000173295.6	FAM86B3P	-5.66	2.64e-08	0.0344	-0.27	-0.25	Neuroticism;	chr8:9936091	chr8:8228595~8244865:+
HNSC	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-5.66	2.65e-08	0.0344	-0.33	-0.25	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
HNSC	trans	rs722599	0.683	rs7160852	ENSG00000181227.3	RP4-682C21.2	-5.66	2.65e-08	0.0344	-0.26	-0.25	IgG glycosylation;	chr14:74772721	chr1:75743423~75744776:-
HNSC	trans	rs1274963	0.601	rs784503	ENSG00000214263.2	RPSAP53	-5.66	2.65e-08	0.0345	-0.38	-0.25	Chronic lymphocytic leukemia;	chr3:39156240	chr13:67266845~67267706:-
HNSC	trans	rs7819412	0.805	rs4333549	ENSG00000254340.1	RP11-10A14.3	-5.66	2.66e-08	0.0345	-0.31	-0.25	Triglycerides;	chr8:11122051	chr8:9141424~9145435:+
HNSC	trans	rs9467711	0.79	rs17598658	ENSG00000253570.1	RNF5P1	5.66	2.66e-08	0.0346	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26175638	chr8:38600661~38601200:-
HNSC	trans	rs860295	0.65	rs488079	ENSG00000241627.3	UBQLN4P1	5.66	2.66e-08	0.0346	0.28	0.25	Body mass index;	chr1:155920790	chr3:148985868~148987668:-
HNSC	trans	rs853679	0.607	rs13205211	ENSG00000204622.9	HLA-J	-5.66	2.67e-08	0.0346	-0.56	-0.25	Depression;	chr6:28235278	chr6:30006583~30009956:+
HNSC	trans	rs702485	0.967	rs836527	ENSG00000249936.3	RAC1P2	5.66	2.67e-08	0.0346	0.3	0.25	HDL cholesterol levels;HDL cholesterol;	chr7:6427040	chr4:46723830~46724408:-
HNSC	trans	rs9650657	0.801	rs7018334	ENSG00000253893.2	FAM85B	5.66	2.67e-08	0.0347	0.3	0.25	Neuroticism;	chr8:10754565	chr8:8167819~8226614:-
HNSC	trans	rs11779535	0.688	rs17423888	ENSG00000254495.1	AP000487.4	5.66	2.68e-08	0.0348	0.42	0.25	Lymphocyte counts;	chr8:100357573	chr11:70358198~70358677:-
HNSC	trans	rs2898290	0.694	rs2248909	ENSG00000253893.2	FAM85B	5.66	2.68e-08	0.0348	0.3	0.25	Systolic blood pressure;	chr8:11534584	chr8:8167819~8226614:-
HNSC	trans	rs9393777	0.841	rs13207082	ENSG00000243753.4	HLA-L	-5.66	2.68e-08	0.0348	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27283600	chr6:30259584~30293014:+
HNSC	trans	rs7520050	0.966	rs6661910	ENSG00000255397.1	AC022182.2	5.66	2.69e-08	0.0349	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45824960	chr8:60937705~60939871:-
HNSC	trans	rs8014204	0.967	rs4903266	ENSG00000181227.3	RP4-682C21.2	5.66	2.69e-08	0.0349	0.25	0.25	Caffeine consumption;	chr14:74878238	chr1:75743423~75744776:-
HNSC	trans	rs7829975	0.659	rs4382480	ENSG00000255310.2	AF131215.2	5.66	2.69e-08	0.0349	0.24	0.25	Mood instability;	chr8:8863963	chr8:11107788~11109726:-
HNSC	trans	rs9467711	0.659	rs35433030	ENSG00000176998.4	HCG4	-5.66	2.69e-08	0.035	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs66941101	ENSG00000176998.4	HCG4	-5.66	2.69e-08	0.035	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr6:29791753~29792750:-
HNSC	trans	rs1079467	1	rs1079467	ENSG00000275945.1	EIF3S5P1	-5.66	2.7e-08	0.035	-0.38	-0.25	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7948164	chr21:10330732~10331537:+
HNSC	trans	rs853679	0.76	rs9468317	ENSG00000204622.9	HLA-J	-5.66	2.7e-08	0.0351	-0.38	-0.25	Depression;	chr6:28230678	chr6:30006583~30009956:+
HNSC	trans	rs9467711	0.606	rs68072215	ENSG00000176998.4	HCG4	-5.66	2.7e-08	0.0351	-0.46	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26377699	chr6:29791753~29792750:-
HNSC	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	5.66	2.7e-08	0.0351	0.32	0.25	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
HNSC	trans	rs9650657	0.707	rs2005309	ENSG00000253893.2	FAM85B	5.66	2.7e-08	0.0351	0.3	0.25	Neuroticism;	chr8:10794660	chr8:8167819~8226614:-
HNSC	trans	rs7234719	0.579	rs1642550	ENSG00000272211.1	RP11-347P5.1	-5.66	2.71e-08	0.0351	-0.25	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr18:30657757	chr2:196151263~196154881:+
HNSC	trans	rs7234719	0.579	rs1788980	ENSG00000272211.1	RP11-347P5.1	-5.66	2.71e-08	0.0351	-0.25	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr18:30658755	chr2:196151263~196154881:+
HNSC	trans	rs9467711	0.659	rs13220261	ENSG00000176998.4	HCG4	-5.66	2.71e-08	0.0351	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs35555795	ENSG00000176998.4	HCG4	-5.66	2.71e-08	0.0351	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr6:29791753~29792750:-
HNSC	trans	rs3779195	0.929	rs4268041	ENSG00000230273.1	AC087163.3	-5.66	2.72e-08	0.0352	-0.32	-0.25	Sex hormone-binding globulin levels;	chr7:98376226	chr17:17981192~17981572:-
HNSC	trans	rs9393777	0.92	rs35120058	ENSG00000176998.4	HCG4	-5.66	2.72e-08	0.0352	-0.49	-0.25	Intelligence (multi-trait analysis);	chr6:27390387	chr6:29791753~29792750:-
HNSC	trans	rs1190596	0.567	rs56870778	ENSG00000181359.5	HSP90AA6P	-5.65	2.72e-08	0.0353	-0.36	-0.25	Behavioural disinhibition (generation interaction);	chr14:102241864	chr4:170581470~170605450:-
HNSC	trans	rs860295	0.65	rs625658	ENSG00000241627.3	UBQLN4P1	5.65	2.72e-08	0.0353	0.28	0.25	Body mass index;	chr1:155921254	chr3:148985868~148987668:-
HNSC	trans	rs9467711	0.606	rs9393708	ENSG00000176998.4	HCG4	5.65	2.72e-08	0.0353	0.46	0.25	Autism spectrum disorder or schizophrenia;	chr6:26362415	chr6:29791753~29792750:-
HNSC	trans	rs17073641	0.553	rs12457468	ENSG00000214846.4	RP11-115L11.1	-5.65	2.72e-08	0.0353	-0.31	-0.25	Age-related macular degeneration (smoking status interaction);	chr18:64718513	chr4:15730962~15731627:-
HNSC	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	5.65	2.72e-08	0.0353	0.31	0.25	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.607	rs34950484	ENSG00000228078.1	HLA-U	-5.65	2.72e-08	0.0353	-0.56	-0.25	Depression;	chr6:28310911	chr6:29934101~29934286:+
HNSC	trans	rs56114371	0.53	rs2056923	ENSG00000253570.1	RNF5P1	5.65	2.73e-08	0.0354	0.42	0.25	Breast cancer;	chr6:27722160	chr8:38600661~38601200:-
HNSC	trans	rs7824557	0.806	rs6601573	ENSG00000254340.1	RP11-10A14.3	-5.65	2.73e-08	0.0354	-0.31	-0.25	Retinal vascular caliber;	chr8:11237242	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.534	rs10092549	ENSG00000173295.6	FAM86B3P	-5.65	2.73e-08	0.0354	-0.29	-0.25	Retinal vascular caliber;	chr8:11231570	chr8:8228595~8244865:+
HNSC	trans	rs12145833	0.679	rs12029086	ENSG00000154608.12	CEP170P1	-5.65	2.73e-08	0.0354	-0.35	-0.25	Obesity (early onset extreme);	chr1:243401420	chr4:118467590~118554204:+
HNSC	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	5.65	2.74e-08	0.0354	0.32	0.25	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
HNSC	trans	rs9354654	0.826	rs7451539	ENSG00000251364.5	CTD-2516F10.2	-5.65	2.74e-08	0.0355	-0.23	-0.25	Classic bladder exstrophy;	chr6:67999752	chr11:7427266~7512515:-
HNSC	trans	rs6683419	0.967	rs2088825	ENSG00000224237.1	MINOS1P3	-5.65	2.74e-08	0.0355	-0.29	-0.25	Serum thyroid-stimulating hormone levels;	chr1:19495346	chr3:27214816~27215018:-
HNSC	trans	rs7952251	0.711	rs10750000	ENSG00000273321.1	RP11-621L6.3	-5.65	2.75e-08	0.0356	-0.25	-0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr11:112524595	chr18:24402153~24402714:+
HNSC	trans	rs853679	1	rs6901575	ENSG00000204622.9	HLA-J	-5.65	2.76e-08	0.0357	-0.43	-0.25	Depression;	chr6:28283207	chr6:30006583~30009956:+
HNSC	trans	rs9467711	0.606	rs12176317	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372558	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs12174623	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372858	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs12174639	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372893	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs12174631	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372922	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs13216828	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26373279	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs9393714	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26373512	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs9358937	ENSG00000176998.4	HCG4	-5.65	2.76e-08	0.0357	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26374046	chr6:29791753~29792750:-
HNSC	trans	rs9650657	0.623	rs10094497	ENSG00000253893.2	FAM85B	-5.65	2.76e-08	0.0358	-0.28	-0.25	Neuroticism;	chr8:10745319	chr8:8167819~8226614:-
HNSC	trans	rs6743068	0.6	rs1035140	ENSG00000235105.1	RP11-329A14.1	5.65	2.77e-08	0.0358	0.31	0.25	Lymphocyte percentage of white cells;	chr2:201287768	chr1:48435967~48437223:+
HNSC	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	5.65	2.77e-08	0.0358	0.32	0.25	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
HNSC	trans	rs4869931	0.929	rs4869927	ENSG00000262587.2	RP11-266L9.4	-5.65	2.77e-08	0.0359	-0.31	-0.25	Systolic blood pressure in sickle cell anemia;	chr6:150680102	chr16:25031744~25058109:+
HNSC	trans	rs7824557	0.806	rs7007394	ENSG00000254340.1	RP11-10A14.3	-5.65	2.77e-08	0.0359	-0.3	-0.25	Retinal vascular caliber;	chr8:11237057	chr8:9141424~9145435:+
HNSC	trans	rs7824557	0.806	rs6601574	ENSG00000254340.1	RP11-10A14.3	-5.65	2.77e-08	0.0359	-0.3	-0.25	Retinal vascular caliber;	chr8:11237376	chr8:9141424~9145435:+
HNSC	trans	rs860295	0.65	rs4661151	ENSG00000241627.3	UBQLN4P1	5.65	2.78e-08	0.0359	0.28	0.25	Body mass index;	chr1:155933617	chr3:148985868~148987668:-
HNSC	trans	rs17824247	0.584	rs7578553	ENSG00000250986.1	AC141928.1	5.65	2.78e-08	0.0359	0.29	0.25	Educational attainment (years of education);	chr2:143393592	chr4:3758748~3763390:-
HNSC	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-5.65	2.78e-08	0.0359	-0.32	-0.25	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
HNSC	trans	rs7829975	0.593	rs2921051	ENSG00000269918.1	AF131215.9	5.65	2.78e-08	0.0359	0.25	0.25	Mood instability;	chr8:8462594	chr8:11104691~11106704:-
HNSC	trans	rs9467711	0.606	rs4634439	ENSG00000253570.1	RNF5P1	-5.65	2.78e-08	0.0359	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26597776	chr8:38600661~38601200:-
HNSC	trans	rs2302190	1	rs2302190	ENSG00000273445.1	RP11-1399P15.1	5.65	2.78e-08	0.036	0.28	0.25	Vitamin D levels;	chr17:58507147	chr2:87477495~87478034:-
HNSC	trans	rs6831352	0.918	rs2213035	ENSG00000233859.2	ADH5P4	5.65	2.78e-08	0.036	0.31	0.25	Alcohol dependence;	chr4:99143082	chr6:65836930~65838039:-
HNSC	trans	rs6831352	0.918	rs3919370	ENSG00000233859.2	ADH5P4	5.65	2.78e-08	0.036	0.31	0.25	Alcohol dependence;	chr4:99143175	chr6:65836930~65838039:-
HNSC	trans	rs9650657	0.538	rs6984496	ENSG00000253893.2	FAM85B	5.65	2.79e-08	0.036	0.29	0.25	Neuroticism;	chr8:10938583	chr8:8167819~8226614:-
HNSC	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	5.65	2.79e-08	0.036	0.33	0.25	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-5.65	2.79e-08	0.0361	-0.32	-0.25	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-5.65	2.79e-08	0.0361	-0.32	-0.25	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
HNSC	trans	rs7647973	0.626	rs62262672	ENSG00000197582.5	GPX1P1	-5.65	2.8e-08	0.0362	-0.43	-0.25	Menarche (age at onset);	chr3:49618494	chrX:13378735~13379340:-
HNSC	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	5.65	2.8e-08	0.0362	0.33	0.25	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
HNSC	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	5.65	2.8e-08	0.0362	0.33	0.25	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	5.65	2.8e-08	0.0362	0.33	0.25	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
HNSC	trans	rs3779635	0.967	rs750538	ENSG00000255734.1	HNRNPABP1	-5.65	2.8e-08	0.0362	-0.28	-0.25	Neuroticism;	chr8:27418209	chr12:10111738~10112471:+
HNSC	trans	rs6903823	0.508	rs1150718	ENSG00000227766.1	HCG4P5	-5.65	2.8e-08	0.0362	-0.34	-0.25	Pulmonary function;	chr6:28289170	chr6:29942075~29943067:-
HNSC	trans	rs9425766	0.566	rs12079820	ENSG00000213331.4	RP11-713C19.2	5.65	2.8e-08	0.0362	0.3	0.25	Life satisfaction;	chr1:174240771	chr4:187970273~187971284:+
HNSC	trans	rs9393777	0.92	rs34953377	ENSG00000253570.1	RNF5P1	5.65	2.81e-08	0.0363	0.58	0.25	Intelligence (multi-trait analysis);	chr6:27413881	chr8:38600661~38601200:-
HNSC	trans	rs9393777	0.778	rs66841633	ENSG00000253570.1	RNF5P1	5.65	2.81e-08	0.0363	0.58	0.25	Intelligence (multi-trait analysis);	chr6:27414607	chr8:38600661~38601200:-
HNSC	trans	rs3779635	1	rs3779635	ENSG00000255734.1	HNRNPABP1	-5.65	2.82e-08	0.0364	-0.28	-0.25	Neuroticism;	chr8:27427175	chr12:10111738~10112471:+
HNSC	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	5.65	2.82e-08	0.0364	0.32	0.25	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	5.65	2.82e-08	0.0364	0.31	0.25	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
HNSC	trans	rs9650657	0.655	rs1991651	ENSG00000253893.2	FAM85B	-5.65	2.82e-08	0.0364	-0.3	-0.25	Neuroticism;	chr8:10848901	chr8:8167819~8226614:-
HNSC	trans	rs783540	0.542	rs62009945	ENSG00000259295.5	CSPG4P12	5.65	2.82e-08	0.0365	0.35	0.25	Schizophrenia;	chr15:82631205	chr15:85191438~85213905:+
HNSC	trans	rs867371	0.964	rs7169961	ENSG00000259295.5	CSPG4P12	-5.65	2.83e-08	0.0365	-0.32	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:85191438~85213905:+
HNSC	trans	rs867371	1	rs6495643	ENSG00000259295.5	CSPG4P12	-5.65	2.83e-08	0.0365	-0.32	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:85191438~85213905:+
HNSC	trans	rs13177918	1	rs13161334	ENSG00000226396.1	RP5-1056L3.3	5.65	2.83e-08	0.0365	0.23	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:19608114~19608568:+
HNSC	trans	rs2290492	0.714	rs62021050	ENSG00000205181.5	LINC00654	5.65	2.83e-08	0.0366	0.3	0.25	Fractures (vertebral);	chr15:92463658	chr20:5496067~5504613:-
HNSC	trans	rs4343996	0.869	rs6974577	ENSG00000224750.5	RP11-94M14.2	-5.65	2.84e-08	0.0367	-0.26	-0.25	Motion sickness;	chr7:3471718	chr10:90454170~90502968:+
HNSC	trans	rs941207	0.526	rs2950387	ENSG00000257210.1	NACAP3	-5.65	2.84e-08	0.0367	-0.28	-0.25	Platelet count;	chr12:56627222	chr12:93124063~93124543:-
HNSC	trans	rs1568889	0.838	rs6484359	ENSG00000174912.7	METTL15P1	5.65	2.85e-08	0.0367	0.26	0.25	Bipolar disorder;	chr11:28240781	chr3:156713884~156714928:-
HNSC	trans	rs1038094	1	rs1351161	ENSG00000236540.6	AC006547.13	-5.65	2.85e-08	0.0368	-0.36	-0.25	Bipolar disorder;	chr15:73724562	chr22:20058030~20070569:-
HNSC	trans	rs1038094	0.925	rs8042653	ENSG00000236540.6	AC006547.13	-5.65	2.85e-08	0.0368	-0.36	-0.25	Bipolar disorder;	chr15:73726821	chr22:20058030~20070569:-
HNSC	trans	rs7520050	0.645	rs1768809	ENSG00000255397.1	AC022182.2	5.65	2.86e-08	0.0369	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46037164	chr8:60937705~60939871:-
HNSC	trans	rs673253	0.662	rs11586016	ENSG00000231007.5	CDC20P1	5.65	2.86e-08	0.0369	0.36	0.25	Intelligence (multi-trait analysis);	chr1:43566122	chr9:87011652~87013151:+
HNSC	trans	rs4732038	0.715	rs1966139	ENSG00000213606.3	AKR1B10P1	5.65	2.86e-08	0.0369	0.28	0.25	Longevity;	chr7:134573523	chr10:67750284~67751225:+
HNSC	trans	rs11638815	0.859	rs11633991	ENSG00000235370.6	DNM1P51	-5.65	2.86e-08	0.0369	-0.35	-0.25	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82726588	chr15:84398316~84411701:-
HNSC	trans	rs9467711	0.72	rs35627490	ENSG00000253570.1	RNF5P1	5.65	2.87e-08	0.037	0.57	0.25	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr8:38600661~38601200:-
HNSC	trans	rs1568889	0.838	rs6484347	ENSG00000174912.7	METTL15P1	-5.64	2.87e-08	0.037	-0.26	-0.25	Bipolar disorder;	chr11:28019422	chr3:156713884~156714928:-
HNSC	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	5.64	2.87e-08	0.037	0.32	0.25	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	5.64	2.88e-08	0.0371	0.31	0.25	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
HNSC	trans	rs1550582	0.917	rs7831961	ENSG00000235064.1	SLC25A5P2	-5.64	2.88e-08	0.0371	-0.32	-0.25	Educational attainment;	chr8:134494817	chr2:33839782~33840678:-
HNSC	trans	rs7113874	0.578	rs34059271	ENSG00000266891.1	RP11-692N5.2	5.64	2.89e-08	0.0372	0.39	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8546311	chr18:9734882~9735602:-
HNSC	trans	rs7121538	0.673	rs7942990	ENSG00000236360.2	RP11-334A14.2	-5.64	2.89e-08	0.0372	-0.51	-0.25	HDL cholesterol;	chr11:14307132	chr1:52993201~52993702:-
HNSC	trans	rs1038094	0.925	rs11638072	ENSG00000236540.6	AC006547.13	-5.64	2.89e-08	0.0372	-0.36	-0.25	Bipolar disorder;	chr15:73728044	chr22:20058030~20070569:-
HNSC	trans	rs4343996	0.837	rs6462105	ENSG00000224750.5	RP11-94M14.2	-5.64	2.89e-08	0.0373	-0.27	-0.25	Motion sickness;	chr7:3474880	chr10:90454170~90502968:+
HNSC	trans	rs7824557	0.564	rs6601584	ENSG00000254340.1	RP11-10A14.3	-5.64	2.9e-08	0.0373	-0.3	-0.25	Retinal vascular caliber;	chr8:11374834	chr8:9141424~9145435:+
HNSC	trans	rs9329221	0.537	rs2062332	ENSG00000173295.6	FAM86B3P	5.64	2.9e-08	0.0373	0.28	0.25	Neuroticism;	chr8:10122514	chr8:8228595~8244865:+
HNSC	trans	rs4948102	0.924	rs13241866	ENSG00000215006.4	CHCHD2P2	-5.64	2.91e-08	0.0374	-0.34	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56023185	chr5:69333929~69334249:+
HNSC	trans	rs3779195	0.86	rs12704986	ENSG00000230273.1	AC087163.3	5.64	2.91e-08	0.0374	0.33	0.25	Sex hormone-binding globulin levels;	chr7:98357118	chr17:17981192~17981572:-
HNSC	trans	rs3779195	0.858	rs3779196	ENSG00000230273.1	AC087163.3	5.64	2.91e-08	0.0374	0.33	0.25	Sex hormone-binding globulin levels;	chr7:98360794	chr17:17981192~17981572:-
HNSC	trans	rs3779195	0.789	rs6965424	ENSG00000230273.1	AC087163.3	5.64	2.91e-08	0.0374	0.33	0.25	Sex hormone-binding globulin levels;	chr7:98361813	chr17:17981192~17981572:-
HNSC	trans	rs4713118	0.869	rs9295743	ENSG00000204709.4	LINC01556	5.64	2.91e-08	0.0374	0.33	0.25	Parkinson's disease;	chr6:27747323	chr6:28943877~28944537:+
HNSC	trans	rs950169	0.919	rs12915589	ENSG00000229212.6	RP11-561C5.4	-5.64	2.91e-08	0.0375	-0.35	-0.25	Schizophrenia;	chr15:84065712	chr15:85205440~85234795:-
HNSC	trans	rs950169	0.959	rs66801143	ENSG00000229212.6	RP11-561C5.4	-5.64	2.91e-08	0.0375	-0.35	-0.25	Schizophrenia;	chr15:84067905	chr15:85205440~85234795:-
HNSC	trans	rs950169	1	rs35648189	ENSG00000229212.6	RP11-561C5.4	-5.64	2.91e-08	0.0375	-0.35	-0.25	Schizophrenia;	chr15:84071996	chr15:85205440~85234795:-
HNSC	trans	rs950169	0.92	rs17300048	ENSG00000229212.6	RP11-561C5.4	-5.64	2.91e-08	0.0375	-0.35	-0.25	Schizophrenia;	chr15:84080725	chr15:85205440~85234795:-
HNSC	trans	rs7746199	0.736	rs13202291	ENSG00000176998.4	HCG4	-5.64	2.91e-08	0.0375	-0.49	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:29791753~29792750:-
HNSC	trans	rs7746199	0.736	rs17750424	ENSG00000176998.4	HCG4	-5.64	2.91e-08	0.0375	-0.49	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:29791753~29792750:-
HNSC	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-5.64	2.93e-08	0.0376	-0.32	-0.25	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
HNSC	trans	rs7746199	0.736	rs17749927	ENSG00000176998.4	HCG4	-5.64	2.93e-08	0.0376	-0.49	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:29791753~29792750:-
HNSC	trans	rs7746199	0.736	rs13192965	ENSG00000176998.4	HCG4	-5.64	2.93e-08	0.0376	-0.49	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:29791753~29792750:-
HNSC	trans	rs2302190	0.882	rs3809709	ENSG00000273445.1	RP11-1399P15.1	5.64	2.93e-08	0.0377	0.29	0.25	Vitamin D levels;	chr17:58513198	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs9901693	ENSG00000273445.1	RP11-1399P15.1	5.64	2.93e-08	0.0377	0.29	0.25	Vitamin D levels;	chr17:58529554	chr2:87477495~87478034:-
HNSC	trans	rs853679	1	rs1679732	ENSG00000253570.1	RNF5P1	-5.64	2.94e-08	0.0377	-0.43	-0.25	Depression;	chr6:28253486	chr8:38600661~38601200:-
HNSC	trans	rs6921919	0.562	rs13198809	ENSG00000204622.9	HLA-J	-5.64	2.95e-08	0.0379	-0.56	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:30006583~30009956:+
HNSC	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-5.64	2.95e-08	0.0379	-0.32	-0.25	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-5.64	2.95e-08	0.0379	-0.32	-0.25	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-5.64	2.95e-08	0.0379	-0.32	-0.25	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
HNSC	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-5.64	2.95e-08	0.0379	-0.32	-0.25	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
HNSC	trans	rs2687481	0.718	rs1719109	ENSG00000227542.1	AC092614.2	-5.64	2.95e-08	0.0379	-0.37	-0.25	Hearing function;	chr7:126285617	chr2:191229165~191246172:-
HNSC	trans	rs2687481	0.672	rs1719108	ENSG00000227542.1	AC092614.2	-5.64	2.95e-08	0.0379	-0.37	-0.25	Hearing function;	chr7:126286260	chr2:191229165~191246172:-
HNSC	trans	rs9650657	0.648	rs7833945	ENSG00000173295.6	FAM86B3P	-5.64	2.95e-08	0.0379	-0.28	-0.25	Neuroticism;	chr8:10842756	chr8:8228595~8244865:+
HNSC	trans	rs7746199	0.736	rs72845070	ENSG00000243753.4	HLA-L	-5.64	2.95e-08	0.0379	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:30259584~30293014:+
HNSC	trans	rs7819412	0.505	rs17726209	ENSG00000254340.1	RP11-10A14.3	5.64	2.95e-08	0.0379	0.31	0.25	Triglycerides;	chr8:11164675	chr8:9141424~9145435:+
HNSC	trans	rs9393777	0.72	rs56401801	ENSG00000176998.4	HCG4	-5.64	2.96e-08	0.038	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27333733	chr6:29791753~29792750:-
HNSC	trans	rs7824557	0.628	rs2572387	ENSG00000173295.6	FAM86B3P	5.64	2.96e-08	0.0381	0.28	0.25	Retinal vascular caliber;	chr8:11346656	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.707	rs6984744	ENSG00000173295.6	FAM86B3P	-5.64	2.97e-08	0.0381	-0.28	-0.25	Neuroticism;	chr8:10758755	chr8:8228595~8244865:+
HNSC	trans	rs1584120	0.953	rs1373585	ENSG00000236617.2	RP11-46H11.12	5.64	2.97e-08	0.0381	0.33	0.25	Pelvic organ prolapse (moderate/severe);	chr12:23446156	chr12:132887842~132888583:+
HNSC	trans	rs9329221	0.967	rs7005363	ENSG00000173295.6	FAM86B3P	-5.64	2.97e-08	0.0381	-0.28	-0.25	Neuroticism;	chr8:10426238	chr8:8228595~8244865:+
HNSC	trans	rs722599	0.683	rs7145246	ENSG00000181227.3	RP4-682C21.2	5.64	2.97e-08	0.0382	0.26	0.25	IgG glycosylation;	chr14:74775691	chr1:75743423~75744776:-
HNSC	trans	rs1510510	0.676	rs2878090	ENSG00000238290.1	RP11-431K24.1	-5.64	2.98e-08	0.0383	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238638496	chr1:8026738~8122702:+
HNSC	trans	rs330048	0.561	rs330088	ENSG00000173295.6	FAM86B3P	5.64	2.98e-08	0.0383	0.29	0.25	Systemic lupus erythematosus;	chr8:9292236	chr8:8228595~8244865:+
HNSC	trans	rs11220237	0.764	rs34125226	ENSG00000236257.1	EI24P2	5.64	2.99e-08	0.0384	0.44	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr11:125738705	chr1:158454198~158455273:+
HNSC	trans	rs916888	0.61	rs199452	ENSG00000204650.12	CRHR1-IT1	5.64	3e-08	0.0385	0.29	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45620328~45648216:+
HNSC	trans	rs61863408	0.925	rs4962510	ENSG00000271324.1	RP11-10C24.2	-5.64	3e-08	0.0385	-0.44	-0.25	Itch intensity from mosquito bite;	chr10:126161574	chr3:33793644~33794145:-
HNSC	trans	rs853679	0.882	rs9468300	ENSG00000253570.1	RNF5P1	5.64	3e-08	0.0385	0.49	0.25	Depression;	chr6:28159062	chr8:38600661~38601200:-
HNSC	trans	rs4646450	0.838	rs10257758	ENSG00000228834.1	RP11-249L21.4	5.64	3.01e-08	0.0385	0.38	0.25	Blood metabolite levels;	chr7:99591365	chr6:108907615~108907873:-
HNSC	trans	rs9650657	0.771	rs4240670	ENSG00000253893.2	FAM85B	5.64	3.01e-08	0.0386	0.3	0.25	Neuroticism;	chr8:10808338	chr8:8167819~8226614:-
HNSC	trans	rs17301013	0.861	rs12568655	ENSG00000213331.4	RP11-713C19.2	5.64	3.01e-08	0.0386	0.31	0.25	Systemic lupus erythematosus;	chr1:174465194	chr4:187970273~187971284:+
HNSC	trans	rs7824557	0.592	rs2736280	ENSG00000254340.1	RP11-10A14.3	5.64	3.01e-08	0.0386	0.29	0.25	Retinal vascular caliber;	chr8:11365513	chr8:9141424~9145435:+
HNSC	trans	rs722599	0.683	rs10144860	ENSG00000181227.3	RP4-682C21.2	-5.64	3.02e-08	0.0387	-0.26	-0.25	IgG glycosylation;	chr14:74819723	chr1:75743423~75744776:-
HNSC	trans	rs546131	0.928	rs546521	ENSG00000225531.1	RP11-196I18.3	5.64	3.02e-08	0.0387	0.31	0.25	Lung disease severity in cystic fibrosis;	chr11:34803226	chr9:107116829~107117557:+
HNSC	trans	rs1510510	0.69	rs7587609	ENSG00000238290.1	RP11-431K24.1	-5.64	3.03e-08	0.0388	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641255	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs7587615	ENSG00000238290.1	RP11-431K24.1	-5.64	3.03e-08	0.0388	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641260	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs7587686	ENSG00000238290.1	RP11-431K24.1	-5.64	3.03e-08	0.0388	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641292	chr1:8026738~8122702:+
HNSC	trans	rs853679	0.546	rs35819751	ENSG00000253570.1	RNF5P1	5.64	3.03e-08	0.0388	0.57	0.25	Depression;	chr6:27842791	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs13194781	ENSG00000253570.1	RNF5P1	5.64	3.03e-08	0.0388	0.57	0.25	Depression;	chr6:27847861	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs36116761	ENSG00000253570.1	RNF5P1	5.64	3.03e-08	0.0388	0.57	0.25	Depression;	chr6:27850704	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.546	rs34194357	ENSG00000253570.1	RNF5P1	5.64	3.03e-08	0.0388	0.57	0.25	Depression;	chr6:27850757	chr8:38600661~38601200:-
HNSC	trans	rs73108077	0.736	rs6058637	ENSG00000279352.1	RP11-411B10.7	5.63	3.03e-08	0.0389	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31325430	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs6057561	ENSG00000279352.1	RP11-411B10.7	5.63	3.03e-08	0.0389	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31327238	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs6119830	ENSG00000279352.1	RP11-411B10.7	5.63	3.03e-08	0.0389	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31327636	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.736	rs6119831	ENSG00000279352.1	RP11-411B10.7	5.63	3.03e-08	0.0389	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31328473	chr18:14010054~14010917:+
HNSC	trans	rs4948102	0.667	rs7811270	ENSG00000215006.4	CHCHD2P2	-5.63	3.04e-08	0.0389	-0.33	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr5:69333929~69334249:+
HNSC	trans	rs4732038	1	rs706202	ENSG00000213606.3	AKR1B10P1	-5.63	3.04e-08	0.039	-0.29	-0.25	Longevity;	chr7:134565952	chr10:67750284~67751225:+
HNSC	trans	rs7647973	0.593	rs62262730	ENSG00000197582.5	GPX1P1	-5.63	3.05e-08	0.039	-0.42	-0.25	Menarche (age at onset);	chr3:49770841	chrX:13378735~13379340:-
HNSC	trans	rs1908814	0.516	rs11996277	ENSG00000253893.2	FAM85B	-5.63	3.05e-08	0.039	-0.29	-0.25	Neuroticism;	chr8:11942522	chr8:8167819~8226614:-
HNSC	trans	rs7829975	0.564	rs2921057	ENSG00000269918.1	AF131215.9	5.63	3.06e-08	0.0391	0.25	0.25	Mood instability;	chr8:8461157	chr8:11104691~11106704:-
HNSC	trans	rs3808502	0.647	rs7821302	ENSG00000254340.1	RP11-10A14.3	-5.63	3.06e-08	0.0392	-0.3	-0.25	Neuroticism;	chr8:11379063	chr8:9141424~9145435:+
HNSC	trans	rs916888	0.647	rs199449	ENSG00000204650.12	CRHR1-IT1	5.63	3.07e-08	0.0393	0.28	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45620328~45648216:+
HNSC	trans	rs2687481	0.718	rs1379352	ENSG00000227542.1	AC092614.2	-5.63	3.07e-08	0.0393	-0.38	-0.25	Hearing function;	chr7:126301884	chr2:191229165~191246172:-
HNSC	trans	rs9650657	0.74	rs12676417	ENSG00000173295.6	FAM86B3P	5.63	3.07e-08	0.0393	0.28	0.25	Neuroticism;	chr8:10811124	chr8:8228595~8244865:+
HNSC	trans	rs864643	1	rs864643	ENSG00000183298.5	RP11-556K13.1	5.63	3.07e-08	0.0393	0.4	0.25	Attention deficit hyperactivity disorder;	chr3:39514089	chr1:101786340~101787219:-
HNSC	trans	rs9467711	0.659	rs34246779	ENSG00000176998.4	HCG4	-5.63	3.08e-08	0.0394	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs72845428	ENSG00000176998.4	HCG4	-5.63	3.08e-08	0.0394	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.659	rs35277236	ENSG00000176998.4	HCG4	-5.63	3.08e-08	0.0394	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr6:29791753~29792750:-
HNSC	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	5.63	3.08e-08	0.0394	0.32	0.25	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
HNSC	trans	rs860295	0.614	rs639398	ENSG00000241627.3	UBQLN4P1	5.63	3.08e-08	0.0394	0.28	0.25	Body mass index;	chr1:155920447	chr3:148985868~148987668:-
HNSC	trans	rs7520050	0.966	rs7556615	ENSG00000255397.1	AC022182.2	5.63	3.09e-08	0.0395	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45995697	chr8:60937705~60939871:-
HNSC	trans	rs902774	0.759	rs4919707	ENSG00000224520.2	KRT8P45	-5.63	3.09e-08	0.0395	-0.46	-0.25	Prostate cancer;	chr12:52895864	chr1:157073257~157074703:+
HNSC	trans	rs9300212	0.878	rs1384601	ENSG00000224652.1	LINC00885	-5.63	3.1e-08	0.0396	-0.31	-0.25	Cognitive test performance;	chr12:33561931	chr3:196142636~196160890:+
HNSC	trans	rs950169	0.922	rs4586394	ENSG00000229212.6	RP11-561C5.4	5.63	3.1e-08	0.0396	0.35	0.25	Schizophrenia;	chr15:84153633	chr15:85205440~85234795:-
HNSC	trans	rs853679	1	rs6905391	ENSG00000204622.9	HLA-J	-5.63	3.1e-08	0.0396	-0.42	-0.25	Depression;	chr6:28294909	chr6:30006583~30009956:+
HNSC	trans	rs7746199	0.736	rs13193542	ENSG00000204622.9	HLA-J	-5.63	3.11e-08	0.0397	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:30006583~30009956:+
HNSC	trans	rs7746199	0.736	rs13193480	ENSG00000204622.9	HLA-J	-5.63	3.11e-08	0.0397	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:30006583~30009956:+
HNSC	trans	rs1510510	0.69	rs13003781	ENSG00000238290.1	RP11-431K24.1	-5.63	3.11e-08	0.0397	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640544	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs13004019	ENSG00000238290.1	RP11-431K24.1	-5.63	3.11e-08	0.0397	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640671	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs13026799	ENSG00000238290.1	RP11-431K24.1	-5.63	3.11e-08	0.0397	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640693	chr1:8026738~8122702:+
HNSC	trans	rs950169	1	rs1818950	ENSG00000229212.6	RP11-561C5.4	-5.63	3.11e-08	0.0397	-0.35	-0.25	Schizophrenia;	chr15:84053769	chr15:85205440~85234795:-
HNSC	trans	rs546131	0.928	rs552627	ENSG00000225531.1	RP11-196I18.3	5.63	3.11e-08	0.0398	0.31	0.25	Lung disease severity in cystic fibrosis;	chr11:34805133	chr9:107116829~107117557:+
HNSC	trans	rs7824557	0.564	rs12550129	ENSG00000254340.1	RP11-10A14.3	-5.63	3.11e-08	0.0398	-0.3	-0.25	Retinal vascular caliber;	chr8:11376408	chr8:9141424~9145435:+
HNSC	trans	rs867371	1	rs1501372	ENSG00000259295.5	CSPG4P12	-5.63	3.11e-08	0.0398	-0.32	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:85191438~85213905:+
HNSC	trans	rs2302190	0.882	rs12939703	ENSG00000273445.1	RP11-1399P15.1	5.63	3.11e-08	0.0398	0.29	0.25	Vitamin D levels;	chr17:58533729	chr2:87477495~87478034:-
HNSC	trans	rs11250098	0.548	rs7837038	ENSG00000173295.6	FAM86B3P	-5.63	3.12e-08	0.0398	-0.28	-0.25	Morning vs. evening chronotype;	chr8:10925564	chr8:8228595~8244865:+
HNSC	trans	rs9354654	0.861	rs1913480	ENSG00000251364.5	CTD-2516F10.2	5.63	3.12e-08	0.0399	0.23	0.25	Classic bladder exstrophy;	chr6:67985109	chr11:7427266~7512515:-
HNSC	trans	rs10940346	0.506	rs11741135	ENSG00000261357.1	RP11-626G11.1	-5.63	3.13e-08	0.0399	-0.34	-0.25	Schizophrenia;	chr5:50579604	chr16:19065991~19066694:+
HNSC	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	5.63	3.13e-08	0.0399	0.32	0.25	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
HNSC	trans	rs7746199	0.736	rs58616630	ENSG00000253570.1	RNF5P1	5.63	3.13e-08	0.04	0.57	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr8:38600661~38601200:-
HNSC	trans	rs902774	0.818	rs55914512	ENSG00000255815.3	KRT8P11	-5.63	3.14e-08	0.04	-0.47	-0.25	Prostate cancer;	chr12:52888490	chr9:99305176~99306611:+
HNSC	trans	rs902774	0.818	rs73108466	ENSG00000255815.3	KRT8P11	-5.63	3.14e-08	0.04	-0.47	-0.25	Prostate cancer;	chr12:52889857	chr9:99305176~99306611:+
HNSC	trans	rs902774	0.818	rs55999178	ENSG00000255815.3	KRT8P11	-5.63	3.14e-08	0.04	-0.47	-0.25	Prostate cancer;	chr12:52890576	chr9:99305176~99306611:+
HNSC	trans	rs7824557	0.591	rs2572452	ENSG00000254340.1	RP11-10A14.3	-5.63	3.14e-08	0.0401	-0.29	-0.25	Retinal vascular caliber;	chr8:11370745	chr8:9141424~9145435:+
HNSC	trans	rs853679	0.545	rs35949109	ENSG00000243753.4	HLA-L	-5.63	3.14e-08	0.0401	-0.47	-0.25	Depression;	chr6:28058148	chr6:30259584~30293014:+
HNSC	trans	rs804280	0.509	rs13276433	ENSG00000253893.2	FAM85B	-5.63	3.15e-08	0.0402	-0.29	-0.25	Myopia (pathological);	chr8:11925527	chr8:8167819~8226614:-
HNSC	trans	rs9393777	0.764	rs35565446	ENSG00000176998.4	HCG4	-5.63	3.16e-08	0.0403	-0.52	-0.25	Intelligence (multi-trait analysis);	chr6:27177562	chr6:29791753~29792750:-
HNSC	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-5.63	3.16e-08	0.0403	-0.35	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
HNSC	trans	rs916888	0.61	rs199444	ENSG00000204650.12	CRHR1-IT1	5.63	3.17e-08	0.0404	0.28	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45620328~45648216:+
HNSC	trans	rs916888	0.61	rs199442	ENSG00000204650.12	CRHR1-IT1	5.63	3.17e-08	0.0404	0.28	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45620328~45648216:+
HNSC	trans	rs853679	0.599	rs13193295	ENSG00000243753.4	HLA-L	-5.63	3.18e-08	0.0405	-0.53	-0.25	Depression;	chr6:28035450	chr6:30259584~30293014:+
HNSC	trans	rs7824557	0.505	rs2572440	ENSG00000254340.1	RP11-10A14.3	5.63	3.18e-08	0.0405	0.3	0.25	Retinal vascular caliber;	chr8:11391501	chr8:9141424~9145435:+
HNSC	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	5.63	3.19e-08	0.0406	0.32	0.25	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
HNSC	trans	rs12145833	0.569	rs12136239	ENSG00000154608.12	CEP170P1	-5.63	3.19e-08	0.0406	-0.31	-0.25	Obesity (early onset extreme);	chr1:243429078	chr4:118467590~118554204:+
HNSC	trans	rs7824557	0.872	rs2572417	ENSG00000254340.1	RP11-10A14.3	-5.63	3.19e-08	0.0407	-0.29	-0.25	Retinal vascular caliber;	chr8:11253953	chr8:9141424~9145435:+
HNSC	trans	rs71537559	1	rs71537559	ENSG00000176998.4	HCG4	-5.62	3.2e-08	0.0408	-0.49	-0.25	Squamous cell lung carcinoma;	chr6:27342000	chr6:29791753~29792750:-
HNSC	trans	rs722599	0.715	rs11851433	ENSG00000181227.3	RP4-682C21.2	-5.62	3.2e-08	0.0408	-0.26	-0.25	IgG glycosylation;	chr14:74872747	chr1:75743423~75744776:-
HNSC	trans	rs9467711	0.606	rs4634439	ENSG00000227262.3	HCG4B	5.62	3.21e-08	0.0409	0.46	0.25	Autism spectrum disorder or schizophrenia;	chr6:26597776	chr6:29925983~29926973:-
HNSC	trans	rs12295638	0.571	rs12282129	ENSG00000269846.1	RP4-621N11.2	-5.62	3.21e-08	0.0409	-0.39	-0.25	Obesity (extreme);	chr11:26625990	chr20:37095785~37097178:+
HNSC	trans	rs12295638	0.571	rs7125967	ENSG00000269846.1	RP4-621N11.2	-5.62	3.21e-08	0.0409	-0.39	-0.25	Obesity (extreme);	chr11:26626210	chr20:37095785~37097178:+
HNSC	trans	rs12295638	0.571	rs1389454	ENSG00000269846.1	RP4-621N11.2	-5.62	3.21e-08	0.0409	-0.39	-0.25	Obesity (extreme);	chr11:26626863	chr20:37095785~37097178:+
HNSC	trans	rs12295638	0.571	rs11029653	ENSG00000269846.1	RP4-621N11.2	-5.62	3.21e-08	0.0409	-0.39	-0.25	Obesity (extreme);	chr11:26626995	chr20:37095785~37097178:+
HNSC	trans	rs867371	1	rs1846911	ENSG00000259295.5	CSPG4P12	-5.62	3.21e-08	0.0409	-0.32	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:85191438~85213905:+
HNSC	trans	rs740363	0.561	rs7909152	ENSG00000211820.1	TRAV41	-5.62	3.22e-08	0.0411	-0.21	-0.25	Heart failure;	chr10:116798872	chr14:22320188~22320691:+
HNSC	trans	rs3781264	0.583	rs4394764	ENSG00000264070.1	DND1P1	5.62	3.23e-08	0.0411	0.37	0.25	Esophageal cancer and gastric cancer;	chr10:94302036	chr17:45585871~45586929:+
HNSC	trans	rs714543	1	rs13245012	ENSG00000226038.5	PPIAP21	-5.62	3.23e-08	0.0412	-0.3	-0.25	Plateletcrit;	chr7:44826120	chr20:43230760~43231260:+
HNSC	trans	rs6852678	1	rs13136090	ENSG00000259972.2	AC009120.6	-5.62	3.24e-08	0.0413	-0.18	-0.25	Magnesium levels;	chr4:75609608	chr16:74305127~74335346:-
HNSC	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-5.62	3.25e-08	0.0413	-0.32	-0.25	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.567	rs3799499	ENSG00000228078.1	HLA-U	-5.62	3.25e-08	0.0413	-0.35	-0.25	Depression;	chr6:28386473	chr6:29934101~29934286:+
HNSC	trans	rs860295	0.65	rs539602	ENSG00000241627.3	UBQLN4P1	5.62	3.25e-08	0.0414	0.28	0.25	Body mass index;	chr1:155929229	chr3:148985868~148987668:-
HNSC	trans	rs853679	0.607	rs34396849	ENSG00000268140.1	PCGF7P	5.62	3.26e-08	0.0414	0.51	0.25	Depression;	chr6:28283178	chr19:22137931~22138981:+
HNSC	trans	rs8177876	0.731	rs4889227	ENSG00000224837.1	GCSHP5	-5.62	3.27e-08	0.0416	-0.41	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr1:168055901~168056422:-
HNSC	trans	rs6921919	1	rs6921919	ENSG00000227766.1	HCG4P5	-5.62	3.27e-08	0.0416	-0.38	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:29942075~29943067:-
HNSC	trans	rs1510510	0.676	rs2878089	ENSG00000238290.1	RP11-431K24.1	-5.62	3.29e-08	0.0418	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238638511	chr1:8026738~8122702:+
HNSC	trans	rs1473307	0.967	rs17409709	ENSG00000224295.2	AC087380.14	-5.62	3.3e-08	0.0419	-0.29	-0.25	Menopause (age at onset);	chr2:225313694	chr11:5518441~5524955:-
HNSC	trans	rs11615916	0.79	rs17661264	ENSG00000232774.6	FLJ22447	5.62	3.3e-08	0.0419	0.47	0.25	Pulmonary function decline;	chr12:62410299	chr14:61570540~61658696:+
HNSC	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	5.62	3.31e-08	0.042	0.35	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
HNSC	trans	rs7746199	0.673	rs72847313	ENSG00000253570.1	RNF5P1	5.62	3.32e-08	0.0421	0.58	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr8:38600661~38601200:-
HNSC	trans	rs7746199	0.611	rs17750747	ENSG00000253570.1	RNF5P1	5.62	3.32e-08	0.0421	0.58	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr8:38600661~38601200:-
HNSC	trans	rs3019286	0.644	rs2515219	ENSG00000260318.1	COX6CP1	-5.62	3.32e-08	0.0421	-0.34	-0.25	Suicide behavior;	chr8:98811822	chr16:11903923~11904137:-
HNSC	trans	rs853679	0.567	rs2232427	ENSG00000228078.1	HLA-U	-5.62	3.32e-08	0.0422	-0.35	-0.25	Depression;	chr6:28391932	chr6:29934101~29934286:+
HNSC	trans	rs11004008	0.74	rs17709865	ENSG00000251991.1	RNU7-49P	-5.62	3.32e-08	0.0422	-0.29	-0.25	Schizophrenia;	chr10:54008790	chr11:14478892~14478953:+
HNSC	trans	rs7824557	0.713	rs6601575	ENSG00000254340.1	RP11-10A14.3	5.62	3.33e-08	0.0423	0.31	0.25	Retinal vascular caliber;	chr8:11240295	chr8:9141424~9145435:+
HNSC	trans	rs9650657	0.74	rs12676417	ENSG00000253893.2	FAM85B	-5.62	3.33e-08	0.0423	-0.3	-0.25	Neuroticism;	chr8:10811124	chr8:8167819~8226614:-
HNSC	trans	rs67340775	0.541	rs200966	ENSG00000243753.4	HLA-L	-5.62	3.33e-08	0.0423	-0.41	-0.25	Lung cancer in ever smokers;	chr6:27894374	chr6:30259584~30293014:+
HNSC	trans	rs2288327	0.661	rs2129110	ENSG00000269800.1	PLEKHA3P1	5.62	3.34e-08	0.0424	0.36	0.25	Atrial fibrillation;	chr2:178726328	chr19:41521043~41521989:-
HNSC	trans	rs902774	0.818	rs4919763	ENSG00000255815.3	KRT8P11	-5.62	3.35e-08	0.0424	-0.47	-0.25	Prostate cancer;	chr12:52885839	chr9:99305176~99306611:+
HNSC	trans	rs9467711	0.606	rs72841536	ENSG00000176998.4	HCG4	-5.62	3.36e-08	0.0426	-0.46	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26378060	chr6:29791753~29792750:-
HNSC	trans	rs853679	0.607	rs13211507	ENSG00000268140.1	PCGF7P	5.62	3.36e-08	0.0426	0.51	0.25	Depression;	chr6:28289600	chr19:22137931~22138981:+
HNSC	trans	rs853679	0.607	rs34691223	ENSG00000268140.1	PCGF7P	5.62	3.36e-08	0.0426	0.51	0.25	Depression;	chr6:28290431	chr19:22137931~22138981:+
HNSC	trans	rs9650657	0.836	rs1073913	ENSG00000253893.2	FAM85B	5.62	3.37e-08	0.0427	0.3	0.25	Neuroticism;	chr8:10754198	chr8:8167819~8226614:-
HNSC	trans	rs7819412	0.561	rs2001328	ENSG00000254340.1	RP11-10A14.3	-5.62	3.37e-08	0.0427	-0.31	-0.25	Triglycerides;	chr8:11129689	chr8:9141424~9145435:+
HNSC	trans	rs10100465	0.889	rs6469700	ENSG00000224861.1	YBX1P1	-5.62	3.37e-08	0.0427	-0.26	-0.25	Leprosy;	chr8:117675604	chr14:66012830~66013789:-
HNSC	trans	rs11220082	0.761	rs1044314	ENSG00000236257.1	EI24P2	-5.62	3.38e-08	0.0428	-0.31	-0.25	Schizophrenia;	chr11:125431909	chr1:158454198~158455273:+
HNSC	trans	rs9393777	0.841	rs34332556	ENSG00000176998.4	HCG4	-5.61	3.38e-08	0.0428	-0.49	-0.25	Intelligence (multi-trait analysis);	chr6:27389635	chr6:29791753~29792750:-
HNSC	trans	rs6539288	0.803	rs10778517	ENSG00000257298.1	RP3-405J10.3	5.61	3.38e-08	0.0428	0.23	0.25	Total body bone mineral density;	chr12:106947886	chr12:50185580~50191363:-
HNSC	trans	rs853679	0.556	rs45509595	ENSG00000243753.4	HLA-L	-5.61	3.38e-08	0.0428	-0.56	-0.25	Depression;	chr6:27873148	chr6:30259584~30293014:+
HNSC	trans	rs9650657	0.74	rs34653170	ENSG00000253893.2	FAM85B	5.61	3.38e-08	0.0429	0.3	0.25	Neuroticism;	chr8:10819032	chr8:8167819~8226614:-
HNSC	trans	rs9650657	0.707	rs10098699	ENSG00000253893.2	FAM85B	5.61	3.38e-08	0.0429	0.3	0.25	Neuroticism;	chr8:10819246	chr8:8167819~8226614:-
HNSC	trans	rs902774	0.818	rs79377635	ENSG00000255815.3	KRT8P11	-5.61	3.39e-08	0.0429	-0.47	-0.25	Prostate cancer;	chr12:52883148	chr9:99305176~99306611:+
HNSC	trans	rs7824557	0.583	rs4448232	ENSG00000254340.1	RP11-10A14.3	5.61	3.39e-08	0.0429	0.3	0.25	Retinal vascular caliber;	chr8:11373845	chr8:9141424~9145435:+
HNSC	trans	rs34421088	0.56	rs2248325	ENSG00000253893.2	FAM85B	5.61	3.39e-08	0.043	0.29	0.25	Neuroticism;	chr8:11539365	chr8:8167819~8226614:-
HNSC	trans	rs34421088	0.56	rs2248316	ENSG00000253893.2	FAM85B	5.61	3.39e-08	0.043	0.29	0.25	Neuroticism;	chr8:11539564	chr8:8167819~8226614:-
HNSC	trans	rs10041657	0.857	rs10477931	ENSG00000277156.1	RP11-496I2.5	-5.61	3.39e-08	0.043	-0.34	-0.25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for body mass index;	chr5:108757828	chr14:19267115~19268164:+
HNSC	trans	rs9393777	0.92	rs41269265	ENSG00000176998.4	HCG4	-5.61	3.39e-08	0.043	-0.49	-0.25	Intelligence (multi-trait analysis);	chr6:27457570	chr6:29791753~29792750:-
HNSC	trans	rs9650657	0.769	rs2116094	ENSG00000253893.2	FAM85B	5.61	3.4e-08	0.043	0.3	0.25	Neuroticism;	chr8:10741312	chr8:8167819~8226614:-
HNSC	trans	rs804280	1	rs804280	ENSG00000253893.2	FAM85B	-5.61	3.4e-08	0.043	-0.29	-0.25	Myopia (pathological);	chr8:11755189	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.607	rs13204012	ENSG00000204622.9	HLA-J	-5.61	3.4e-08	0.0431	-0.57	-0.25	Depression;	chr6:28233753	chr6:30006583~30009956:+
HNSC	trans	rs4263408	1	rs7687557	ENSG00000237550.5	UBE2Q2P6	5.61	3.41e-08	0.0431	0.28	0.25	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39767640	chr15:82372196~82372912:-
HNSC	trans	rs1559759	1	rs1559759	ENSG00000260757.1	RP11-120K18.2	-5.61	3.41e-08	0.0431	-0.35	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr11:35101504	chr16:31402565~31404699:+
HNSC	trans	rs4713118	0.911	rs2394000	ENSG00000204709.4	LINC01556	5.61	3.41e-08	0.0431	0.34	0.25	Parkinson's disease;	chr6:27719212	chr6:28943877~28944537:+
HNSC	trans	rs4713118	0.955	rs9393847	ENSG00000204709.4	LINC01556	5.61	3.41e-08	0.0431	0.34	0.25	Parkinson's disease;	chr6:27720194	chr6:28943877~28944537:+
HNSC	trans	rs9329221	0.537	rs13264586	ENSG00000173295.6	FAM86B3P	5.61	3.41e-08	0.0432	0.27	0.25	Neuroticism;	chr8:10121875	chr8:8228595~8244865:+
HNSC	trans	rs216303	0.841	rs2283333	ENSG00000241717.1	VWFP1	5.61	3.41e-08	0.0432	0.41	0.25	Low vWF levels;	chr12:6053686	chr22:16690103~16704477:-
HNSC	trans	rs4254535	1	rs61649226	ENSG00000255760.1	RP11-428G5.5	5.61	3.42e-08	0.0432	0.24	0.25	Lung cancer;	chr2:68969706	chr12:31877079~31887203:-
HNSC	trans	rs3753275	0.684	rs1826583	ENSG00000265574.1	WDR45BP1	-5.61	3.42e-08	0.0433	-0.38	-0.25	Educational attainment;	chr1:8818422	chr17:32111562~32112590:-
HNSC	trans	rs7662987	1	rs7683704	ENSG00000228407.2	RP4-800M22.1	5.61	3.42e-08	0.0433	0.42	0.25	Smoking initiation;	chr4:99083075	chr1:52160261~52160600:-
HNSC	trans	rs7746199	0.736	rs13209332	ENSG00000243753.4	HLA-L	-5.61	3.42e-08	0.0433	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:30259584~30293014:+
HNSC	trans	rs546131	0.928	rs483976	ENSG00000225531.1	RP11-196I18.3	5.61	3.43e-08	0.0433	0.31	0.25	Lung disease severity in cystic fibrosis;	chr11:34818620	chr9:107116829~107117557:+
HNSC	trans	rs3740713	0.669	rs2896526	ENSG00000214110.3	LDHAP4	5.61	3.44e-08	0.0434	0.39	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr9:14921337~14922334:-
HNSC	trans	rs7829975	0.626	rs332040	ENSG00000269918.1	AF131215.9	5.61	3.44e-08	0.0435	0.25	0.25	Mood instability;	chr8:8872978	chr8:11104691~11106704:-
HNSC	trans	rs9650657	0.711	rs35091929	ENSG00000253893.2	FAM85B	5.61	3.44e-08	0.0435	0.3	0.25	Neuroticism;	chr8:10835982	chr8:8167819~8226614:-
HNSC	trans	rs673253	0.686	rs1887402	ENSG00000231007.5	CDC20P1	5.61	3.44e-08	0.0435	0.36	0.25	Intelligence (multi-trait analysis);	chr1:43570414	chr9:87011652~87013151:+
HNSC	trans	rs6940116	1	rs6940116	ENSG00000253570.1	RNF5P1	5.61	3.44e-08	0.0435	0.41	0.25	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr8:38600661~38601200:-
HNSC	trans	rs7121538	0.673	rs16913823	ENSG00000236360.2	RP11-334A14.2	-5.61	3.45e-08	0.0436	-0.5	-0.25	HDL cholesterol;	chr11:14321503	chr1:52993201~52993702:-
HNSC	trans	rs7873102	0.967	rs776009	ENSG00000229007.1	EXOSC3P1	-5.61	3.45e-08	0.0436	-0.31	-0.25	Brain structure;	chr9:37928491	chr21:32496812~32497311:+
HNSC	trans	rs73108077	0.607	rs6057566	ENSG00000279352.1	RP11-411B10.7	5.61	3.46e-08	0.0436	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31227621	chr18:14010054~14010917:+
HNSC	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-5.61	3.46e-08	0.0436	-0.32	-0.25	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
HNSC	trans	rs6424115	0.708	rs34570472	ENSG00000228217.1	AL390877.1	5.61	3.46e-08	0.0436	0.33	0.25	Immature fraction of reticulocytes;	chr1:23865230	chr1:117778087~117778506:-
HNSC	trans	rs7824557	1	rs7824557	ENSG00000254340.1	RP11-10A14.3	-5.61	3.46e-08	0.0436	-0.3	-0.25	Retinal vascular caliber;	chr8:11246602	chr8:9141424~9145435:+
HNSC	trans	rs864643	0.524	rs78956370	ENSG00000183298.5	RP11-556K13.1	5.61	3.46e-08	0.0436	0.47	0.25	Attention deficit hyperactivity disorder;	chr3:39463883	chr1:101786340~101787219:-
HNSC	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	5.61	3.47e-08	0.0437	0.37	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
HNSC	trans	rs3806843	0.868	rs2262573	ENSG00000231043.3	AC007238.1	5.61	3.47e-08	0.0437	0.25	0.25	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr2:58460292~58462032:-
HNSC	trans	rs2898290	0.506	rs2736311	ENSG00000253981.4	ALG1L13P	-5.61	3.47e-08	0.0437	-0.27	-0.25	Systolic blood pressure;	chr8:11394661	chr8:8236003~8244667:-
HNSC	trans	rs11004008	0.682	rs10509003	ENSG00000251991.1	RNU7-49P	-5.61	3.47e-08	0.0438	-0.29	-0.25	Schizophrenia;	chr10:54007862	chr11:14478892~14478953:+
HNSC	trans	rs853679	0.607	rs13205211	ENSG00000176998.4	HCG4	-5.61	3.47e-08	0.0438	-0.5	-0.25	Depression;	chr6:28235278	chr6:29791753~29792750:-
HNSC	trans	rs9650657	0.771	rs6601513	ENSG00000173295.6	FAM86B3P	-5.61	3.48e-08	0.0438	-0.28	-0.25	Neuroticism;	chr8:10737333	chr8:8228595~8244865:+
HNSC	trans	rs9348721	0.673	rs9358934	ENSG00000176998.4	HCG4	-5.61	3.48e-08	0.0438	-0.46	-0.25	Intelligence (multi-trait analysis);	chr6:26363527	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs12174602	ENSG00000176998.4	HCG4	-5.61	3.48e-08	0.0439	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372599	chr6:29791753~29792750:-
HNSC	trans	rs9393777	0.92	rs13196692	ENSG00000243753.4	HLA-L	-5.61	3.49e-08	0.0439	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr6:30259584~30293014:+
HNSC	trans	rs7824557	1	rs2736371	ENSG00000254340.1	RP11-10A14.3	-5.61	3.49e-08	0.044	-0.3	-0.25	Retinal vascular caliber;	chr8:11248020	chr8:9141424~9145435:+
HNSC	trans	rs2243480	1	rs4718269	ENSG00000273142.1	RP11-458F8.4	5.61	3.49e-08	0.044	0.35	0.25	Diabetic kidney disease;	chr7:65735810	chr7:66902857~66906297:+
HNSC	trans	rs9818758	0.607	rs56306491	ENSG00000197582.5	GPX1P1	-5.61	3.49e-08	0.044	-0.61	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chrX:13378735~13379340:-
HNSC	trans	rs10435719	0.902	rs7459983	ENSG00000253893.2	FAM85B	-5.61	3.5e-08	0.044	-0.3	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:8167819~8226614:-
HNSC	trans	rs2904524	0.609	rs2099373	ENSG00000235082.2	SUMO1P3	-5.61	3.5e-08	0.0441	-0.64	-0.25	Amyotrophic lateral sclerosis (age of onset);	chr12:70380680	chr1:160317403~160317706:+
HNSC	trans	rs7824557	0.564	rs13260727	ENSG00000254340.1	RP11-10A14.3	5.61	3.5e-08	0.0441	0.3	0.25	Retinal vascular caliber;	chr8:11375351	chr8:9141424~9145435:+
HNSC	trans	rs7819412	0.505	rs17782536	ENSG00000254340.1	RP11-10A14.3	-5.61	3.5e-08	0.0441	-0.32	-0.25	Triglycerides;	chr8:11164172	chr8:9141424~9145435:+
HNSC	trans	rs9393777	0.92	rs35768595	ENSG00000176998.4	HCG4	-5.61	3.5e-08	0.0441	-0.52	-0.25	Intelligence (multi-trait analysis);	chr6:27174125	chr6:29791753~29792750:-
HNSC	trans	rs902774	0.818	rs4919743	ENSG00000224520.2	KRT8P45	-5.61	3.52e-08	0.0443	-0.42	-0.25	Prostate cancer;	chr12:52915800	chr1:157073257~157074703:+
HNSC	trans	rs7097	1	rs9512760	ENSG00000203589.2	RP5-886K2.1	-5.61	3.52e-08	0.0443	-0.29	-0.25	Large B-cell lymphoma;	chr13:27599525	chr1:23705801~23706934:-
HNSC	trans	rs9329221	0.537	rs12678800	ENSG00000173295.6	FAM86B3P	5.61	3.52e-08	0.0443	0.27	0.25	Neuroticism;	chr8:10121430	chr8:8228595~8244865:+
HNSC	trans	rs9467711	0.606	rs9393718	ENSG00000253570.1	RNF5P1	5.61	3.52e-08	0.0444	0.54	0.25	Autism spectrum disorder or schizophrenia;	chr6:26407254	chr8:38600661~38601200:-
HNSC	trans	rs9876781	0.559	rs13073692	ENSG00000235912.1	RP1-159A19.3	-5.61	3.53e-08	0.0444	-0.26	-0.25	Longevity;	chr3:48361812	chr1:27649419~27649610:+
HNSC	trans	rs950169	1	rs35297609	ENSG00000229212.6	RP11-561C5.4	-5.61	3.53e-08	0.0444	-0.35	-0.25	Schizophrenia;	chr15:84104144	chr15:85205440~85234795:-
HNSC	trans	rs7824557	0.628	rs7820301	ENSG00000254340.1	RP11-10A14.3	5.61	3.53e-08	0.0444	0.29	0.25	Retinal vascular caliber;	chr8:11371163	chr8:9141424~9145435:+
HNSC	trans	rs7335046	0.61	rs72645668	ENSG00000248925.1	CTD-2083E4.6	5.61	3.54e-08	0.0445	0.43	0.25	Basal cell carcinoma;	chr13:99157192	chr5:269858~271516:-
HNSC	trans	rs67340775	0.541	rs200965	ENSG00000243753.4	HLA-L	-5.61	3.54e-08	0.0445	-0.41	-0.25	Lung cancer in ever smokers;	chr6:27898606	chr6:30259584~30293014:+
HNSC	trans	rs11250098	0.548	rs7843470	ENSG00000173295.6	FAM86B3P	-5.61	3.54e-08	0.0446	-0.28	-0.25	Morning vs. evening chronotype;	chr8:10926982	chr8:8228595~8244865:+
HNSC	trans	rs853679	0.546	rs35353359	ENSG00000176998.4	HCG4	-5.61	3.56e-08	0.0448	-0.5	-0.25	Depression;	chr6:28356601	chr6:29791753~29792750:-
HNSC	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-5.61	3.56e-08	0.0448	-0.32	-0.25	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
HNSC	trans	rs7769051	0.803	rs12193474	ENSG00000213303.3	CTC-398G3.2	5.61	3.56e-08	0.0448	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132865029	chr19:11523436~11523831:+
HNSC	trans	rs10936797	0.679	rs12494345	ENSG00000241983.3	RN7SL566P	5.61	3.56e-08	0.0448	0.25	0.25	Obesity-related traits;	chr3:174494483	chr19:39369153~39369448:+
HNSC	trans	rs10936797	0.679	rs10936798	ENSG00000241983.3	RN7SL566P	5.61	3.56e-08	0.0448	0.25	0.25	Obesity-related traits;	chr3:174494668	chr19:39369153~39369448:+
HNSC	trans	rs10936797	0.679	rs938441	ENSG00000241983.3	RN7SL566P	5.61	3.56e-08	0.0448	0.25	0.25	Obesity-related traits;	chr3:174495398	chr19:39369153~39369448:+
HNSC	trans	rs10936797	0.66	rs78480610	ENSG00000241983.3	RN7SL566P	5.61	3.56e-08	0.0448	0.25	0.25	Obesity-related traits;	chr3:174495762	chr19:39369153~39369448:+
HNSC	trans	rs8081395	0.627	rs12952730	ENSG00000226521.6	AC126365.1	5.61	3.56e-08	0.0448	0.27	0.25	White blood cell count;	chr17:59901475	chr17:20716481~20737127:+
HNSC	trans	rs1510510	0.742	rs12623067	ENSG00000238290.1	RP11-431K24.1	-5.61	3.57e-08	0.0448	-0.36	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238645780	chr1:8026738~8122702:+
HNSC	trans	rs73108077	0.79	rs73102048	ENSG00000279352.1	RP11-411B10.7	5.6	3.57e-08	0.0448	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31277508	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.704	rs7273922	ENSG00000279352.1	RP11-411B10.7	5.6	3.57e-08	0.0448	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31282601	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.79	rs73102082	ENSG00000279352.1	RP11-411B10.7	5.6	3.57e-08	0.0448	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31288687	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.79	rs73104050	ENSG00000279352.1	RP11-411B10.7	5.6	3.57e-08	0.0448	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31289961	chr18:14010054~14010917:+
HNSC	trans	rs73108077	0.79	rs73104055	ENSG00000279352.1	RP11-411B10.7	5.6	3.57e-08	0.0448	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31293082	chr18:14010054~14010917:+
HNSC	trans	rs7647973	0.593	rs7652179	ENSG00000197582.5	GPX1P1	-5.6	3.57e-08	0.0449	-0.43	-0.25	Menarche (age at onset);	chr3:49771185	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs7649428	ENSG00000197582.5	GPX1P1	-5.6	3.57e-08	0.0449	-0.41	-0.25	Menarche (age at onset);	chr3:49831443	chrX:13378735~13379340:-
HNSC	trans	rs7824557	0.524	rs7835318	ENSG00000254340.1	RP11-10A14.3	-5.6	3.58e-08	0.0449	-0.3	-0.25	Retinal vascular caliber;	chr8:11096364	chr8:9141424~9145435:+
HNSC	trans	rs950169	0.922	rs4842941	ENSG00000229212.6	RP11-561C5.4	5.6	3.58e-08	0.045	0.36	0.25	Schizophrenia;	chr15:84162560	chr15:85205440~85234795:-
HNSC	trans	rs950169	0.922	rs12911223	ENSG00000229212.6	RP11-561C5.4	5.6	3.58e-08	0.045	0.36	0.25	Schizophrenia;	chr15:84162919	chr15:85205440~85234795:-
HNSC	trans	rs950169	0.845	rs4106951	ENSG00000229212.6	RP11-561C5.4	-5.6	3.58e-08	0.045	-0.36	-0.25	Schizophrenia;	chr15:84164642	chr15:85205440~85234795:-
HNSC	trans	rs453301	0.522	rs2929309	ENSG00000269918.1	AF131215.9	-5.6	3.59e-08	0.0451	-0.24	-0.25	Joint mobility (Beighton score);	chr8:9226261	chr8:11104691~11106704:-
HNSC	trans	rs864643	0.524	rs12106854	ENSG00000183298.5	RP11-556K13.1	5.6	3.59e-08	0.0451	0.47	0.25	Attention deficit hyperactivity disorder;	chr3:39487321	chr1:101786340~101787219:-
HNSC	trans	rs864643	0.524	rs17038967	ENSG00000183298.5	RP11-556K13.1	5.6	3.59e-08	0.0451	0.47	0.25	Attention deficit hyperactivity disorder;	chr3:39489530	chr1:101786340~101787219:-
HNSC	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-5.6	3.6e-08	0.0451	-0.32	-0.25	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
HNSC	trans	rs853679	1	rs7740487	ENSG00000271581.1	XXbac-BPG248L24.12	-5.6	3.6e-08	0.0452	-0.38	-0.25	Depression;	chr6:28248708	chr6:31356647~31357637:+
HNSC	trans	rs853679	1	rs68141011	ENSG00000271581.1	XXbac-BPG248L24.12	-5.6	3.6e-08	0.0452	-0.38	-0.25	Depression;	chr6:28250019	chr6:31356647~31357637:+
HNSC	trans	rs853679	1	rs13200462	ENSG00000271581.1	XXbac-BPG248L24.12	-5.6	3.6e-08	0.0452	-0.38	-0.25	Depression;	chr6:28250421	chr6:31356647~31357637:+
HNSC	trans	rs6903823	0.508	rs1233660	ENSG00000227766.1	HCG4P5	-5.6	3.6e-08	0.0452	-0.34	-0.25	Pulmonary function;	chr6:28292472	chr6:29942075~29943067:-
HNSC	trans	rs7746199	0.736	rs17749927	ENSG00000253570.1	RNF5P1	5.6	3.61e-08	0.0452	0.57	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr8:38600661~38601200:-
HNSC	trans	rs7746199	0.736	rs13192965	ENSG00000253570.1	RNF5P1	5.6	3.61e-08	0.0452	0.57	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr8:38600661~38601200:-
HNSC	trans	rs10435719	0.899	rs11250177	ENSG00000253893.2	FAM85B	-5.6	3.61e-08	0.0453	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:8167819~8226614:-
HNSC	trans	rs2288327	0.818	rs3731751	ENSG00000269800.1	PLEKHA3P1	5.6	3.61e-08	0.0453	0.36	0.25	Atrial fibrillation;	chr2:178541158	chr19:41521043~41521989:-
HNSC	trans	rs2288327	0.818	rs3731749	ENSG00000269800.1	PLEKHA3P1	5.6	3.61e-08	0.0453	0.36	0.25	Atrial fibrillation;	chr2:178541464	chr19:41521043~41521989:-
HNSC	trans	rs6601450	0.522	rs7837979	ENSG00000173295.6	FAM86B3P	5.6	3.61e-08	0.0453	0.28	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:8228595~8244865:+
HNSC	trans	rs9650657	0.615	rs4840519	ENSG00000173295.6	FAM86B3P	-5.6	3.61e-08	0.0453	-0.28	-0.25	Neuroticism;	chr8:10835603	chr8:8228595~8244865:+
HNSC	trans	rs7243066	0.577	rs9946804	ENSG00000223959.7	AFG3L1P	5.6	3.61e-08	0.0453	0.38	0.25	Dental caries;	chr18:11296169	chr16:89972586~90002161:+
HNSC	trans	rs9650657	0.737	rs4504595	ENSG00000253893.2	FAM85B	5.6	3.62e-08	0.0454	0.3	0.25	Neuroticism;	chr8:10797995	chr8:8167819~8226614:-
HNSC	trans	rs3779195	0.929	rs10953259	ENSG00000230273.1	AC087163.3	-5.6	3.62e-08	0.0454	-0.33	-0.25	Sex hormone-binding globulin levels;	chr7:98383795	chr17:17981192~17981572:-
HNSC	trans	rs16975963	0.644	rs112666969	ENSG00000247498.8	RP11-392P7.6	5.6	3.62e-08	0.0454	0.4	0.25	Longevity;	chr19:37556743	chr12:12927726~12984645:+
HNSC	trans	rs9650657	0.737	rs4841436	ENSG00000173295.6	FAM86B3P	5.6	3.62e-08	0.0454	0.28	0.25	Neuroticism;	chr8:10736964	chr8:8228595~8244865:+
HNSC	trans	rs1038094	1	rs1871228	ENSG00000236540.6	AC006547.13	-5.6	3.62e-08	0.0454	-0.36	-0.25	Bipolar disorder;	chr15:73721449	chr22:20058030~20070569:-
HNSC	trans	rs1038094	1	rs922457	ENSG00000236540.6	AC006547.13	-5.6	3.62e-08	0.0454	-0.36	-0.25	Bipolar disorder;	chr15:73721871	chr22:20058030~20070569:-
HNSC	trans	rs6853410	0.667	rs499145	ENSG00000280331.1	RP11-545D22.1	5.6	3.63e-08	0.0455	0.38	0.25	Colorectal cancer;	chr4:81798074	chr11:36510361~36510537:+
HNSC	trans	rs1190596	0.567	rs8005884	ENSG00000181359.5	HSP90AA6P	-5.6	3.63e-08	0.0455	-0.37	-0.25	Behavioural disinhibition (generation interaction);	chr14:102226670	chr4:170581470~170605450:-
HNSC	trans	rs7746199	0.736	rs17749927	ENSG00000243753.4	HLA-L	-5.6	3.63e-08	0.0455	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:30259584~30293014:+
HNSC	trans	rs7746199	0.736	rs13192965	ENSG00000243753.4	HLA-L	-5.6	3.63e-08	0.0455	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:30259584~30293014:+
HNSC	trans	rs1996369	0.758	rs12799002	ENSG00000243256.1	RPL30P14	5.6	3.64e-08	0.0456	0.26	0.25	Relative hand skill in reading disability;	chr11:35474126	chr18:61404858~61405205:-
HNSC	trans	rs34421088	0.56	rs2618434	ENSG00000253893.2	FAM85B	5.6	3.64e-08	0.0456	0.29	0.25	Neuroticism;	chr8:11541356	chr8:8167819~8226614:-
HNSC	trans	rs16975963	0.644	rs11083427	ENSG00000247498.8	RP11-392P7.6	5.6	3.64e-08	0.0456	0.41	0.25	Longevity;	chr19:37583251	chr12:12927726~12984645:+
HNSC	trans	rs9467711	0.606	rs35076545	ENSG00000176998.4	HCG4	-5.6	3.65e-08	0.0457	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs13212985	ENSG00000176998.4	HCG4	-5.6	3.65e-08	0.0457	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:29791753~29792750:-
HNSC	trans	rs56114371	0.777	rs200482	ENSG00000227766.1	HCG4P5	-5.6	3.65e-08	0.0457	-0.49	-0.25	Breast cancer;	chr6:27806126	chr6:29942075~29943067:-
HNSC	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	5.6	3.67e-08	0.0459	0.28	0.25	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
HNSC	trans	rs17824247	0.584	rs6430030	ENSG00000250986.1	AC141928.1	5.6	3.67e-08	0.0459	0.29	0.25	Educational attainment (years of education);	chr2:143408954	chr4:3758748~3763390:-
HNSC	trans	rs2299116	1	rs2299116	ENSG00000269982.1	RP11-1020A11.2	5.6	3.67e-08	0.0459	0.26	0.25	Serum thyroid-stimulating hormone levels;	chr7:28775622	chr3:9958717~9962539:+
HNSC	trans	rs7200786	0.546	rs11642542	ENSG00000183935.5	HTR7P1	-5.6	3.67e-08	0.0459	-0.28	-0.25	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118197	chr12:13000420~13004830:+
HNSC	trans	rs804280	0.542	rs34117651	ENSG00000253893.2	FAM85B	-5.6	3.68e-08	0.046	-0.29	-0.25	Myopia (pathological);	chr8:11934108	chr8:8167819~8226614:-
HNSC	trans	rs2898290	0.54	rs35005793	ENSG00000173295.6	FAM86B3P	5.6	3.68e-08	0.046	0.29	0.25	Systolic blood pressure;	chr8:11592963	chr8:8228595~8244865:+
HNSC	trans	rs7617480	0.648	rs9859473	ENSG00000197582.5	GPX1P1	5.6	3.68e-08	0.046	0.38	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chrX:13378735~13379340:-
HNSC	trans	rs9393777	0.92	rs34071253	ENSG00000253570.1	RNF5P1	5.6	3.68e-08	0.0461	0.57	0.25	Intelligence (multi-trait analysis);	chr6:27424023	chr8:38600661~38601200:-
HNSC	trans	rs12145833	0.679	rs6429425	ENSG00000154608.12	CEP170P1	-5.6	3.69e-08	0.0462	-0.34	-0.25	Obesity (early onset extreme);	chr1:243427688	chr4:118467590~118554204:+
HNSC	trans	rs2302190	0.882	rs12942018	ENSG00000273445.1	RP11-1399P15.1	5.6	3.69e-08	0.0462	0.29	0.25	Vitamin D levels;	chr17:58535916	chr2:87477495~87478034:-
HNSC	trans	rs2302190	0.882	rs8073754	ENSG00000273445.1	RP11-1399P15.1	5.6	3.69e-08	0.0462	0.29	0.25	Vitamin D levels;	chr17:58540669	chr2:87477495~87478034:-
HNSC	trans	rs10940138	0.501	rs6872437	ENSG00000272288.4	RP11-140K17.3	5.6	3.7e-08	0.0463	0.22	0.25	Menarche (age at onset);	chr5:67944058	chr6:34696317~34697470:+
HNSC	trans	rs9467711	0.606	rs34781270	ENSG00000176998.4	HCG4	-5.6	3.7e-08	0.0463	-0.5	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:29791753~29792750:-
HNSC	trans	rs722599	0.683	rs8022046	ENSG00000181227.3	RP4-682C21.2	-5.6	3.7e-08	0.0463	-0.26	-0.25	IgG glycosylation;	chr14:74811599	chr1:75743423~75744776:-
HNSC	trans	rs4834770	1	rs878374	ENSG00000275858.1	RP11-291L22.8	5.6	3.71e-08	0.0464	0.3	0.25	Blood protein levels;	chr4:119316409	chr10:38450738~38451069:-
HNSC	trans	rs1996369	1	rs1996369	ENSG00000243256.1	RPL30P14	5.6	3.71e-08	0.0464	0.26	0.25	Relative hand skill in reading disability;	chr11:35473893	chr18:61404858~61405205:-
HNSC	trans	rs2302190	0.882	rs3744111	ENSG00000273445.1	RP11-1399P15.1	5.6	3.71e-08	0.0464	0.29	0.25	Vitamin D levels;	chr17:58530598	chr2:87477495~87478034:-
HNSC	trans	rs17807624	1	rs17807624	ENSG00000253893.2	FAM85B	5.6	3.72e-08	0.0465	0.3	0.25	Systemic lupus erythematosus;	chr8:11605506	chr8:8167819~8226614:-
HNSC	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	5.6	3.72e-08	0.0465	0.35	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
HNSC	trans	rs9393777	0.844	rs72839477	ENSG00000176998.4	HCG4	-5.6	3.72e-08	0.0465	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27359221	chr6:29791753~29792750:-
HNSC	trans	rs902774	0.818	rs73108429	ENSG00000255815.3	KRT8P11	-5.6	3.73e-08	0.0466	-0.47	-0.25	Prostate cancer;	chr12:52877887	chr9:99305176~99306611:+
HNSC	trans	rs12155039	1	rs12155039	ENSG00000226038.5	PPIAP21	-5.6	3.73e-08	0.0466	-0.3	-0.25	Mean platelet volume;	chr7:44833526	chr20:43230760~43231260:+
HNSC	trans	rs7263120	1	rs8114437	ENSG00000228577.1	AC010731.2	-5.6	3.73e-08	0.0466	-0.34	-0.25	Blood protein levels;	chr20:23746251	chr2:206606497~206609812:-
HNSC	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	5.6	3.74e-08	0.0466	0.31	0.25	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.769	rs17720293	ENSG00000204622.9	HLA-J	-5.6	3.74e-08	0.0467	-0.48	-0.25	Depression;	chr6:28246920	chr6:30006583~30009956:+
HNSC	trans	rs7819412	0.838	rs3021494	ENSG00000254340.1	RP11-10A14.3	-5.6	3.74e-08	0.0467	-0.31	-0.25	Triglycerides;	chr8:11126024	chr8:9141424~9145435:+
HNSC	trans	rs9467711	0.606	rs9393708	ENSG00000253570.1	RNF5P1	-5.6	3.74e-08	0.0467	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26362415	chr8:38600661~38601200:-
HNSC	trans	rs853679	0.607	rs35072899	ENSG00000176998.4	HCG4	-5.6	3.74e-08	0.0467	-0.5	-0.25	Depression;	chr6:28313764	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs13203358	ENSG00000253570.1	RNF5P1	5.6	3.74e-08	0.0467	0.52	0.25	Autism spectrum disorder or schizophrenia;	chr6:26590350	chr8:38600661~38601200:-
HNSC	trans	rs9393777	0.92	rs67859638	ENSG00000176998.4	HCG4	-5.6	3.75e-08	0.0468	-0.52	-0.25	Intelligence (multi-trait analysis);	chr6:27390199	chr6:29791753~29792750:-
HNSC	trans	rs9329221	0.537	rs6983332	ENSG00000173295.6	FAM86B3P	-5.6	3.75e-08	0.0468	-0.28	-0.25	Neuroticism;	chr8:10120408	chr8:8228595~8244865:+
HNSC	trans	rs722599	0.683	rs2302834	ENSG00000181227.3	RP4-682C21.2	-5.6	3.76e-08	0.0469	-0.26	-0.25	IgG glycosylation;	chr14:74812692	chr1:75743423~75744776:-
HNSC	trans	rs6011368	0.749	rs4809418	ENSG00000226210.3	WASH7P	-5.6	3.76e-08	0.0469	-0.28	-0.25	Clozapine-induced cytotoxicity;	chr20:64283878	chr12:14522~32015:-
HNSC	trans	rs4713118	0.715	rs200480	ENSG00000204709.4	LINC01556	5.6	3.76e-08	0.0469	0.3	0.25	Parkinson's disease;	chr6:27805886	chr6:28943877~28944537:+
HNSC	trans	rs3808502	0.527	rs2736374	ENSG00000254340.1	RP11-10A14.3	-5.59	3.77e-08	0.047	-0.32	-0.25	Neuroticism;	chr8:11256319	chr8:9141424~9145435:+
HNSC	trans	rs2400954	0.611	rs6539571	ENSG00000270083.1	RP1-257I20.14	5.59	3.77e-08	0.0471	0.24	0.25	Alcohol dependence;	chr12:81584247	chr22:42089630~42090028:-
HNSC	trans	rs2400954	0.548	rs4430586	ENSG00000270083.1	RP1-257I20.14	5.59	3.77e-08	0.0471	0.24	0.25	Alcohol dependence;	chr12:81587450	chr22:42089630~42090028:-
HNSC	trans	rs9467711	0.606	rs9379873	ENSG00000253570.1	RNF5P1	5.59	3.77e-08	0.0471	0.54	0.25	Autism spectrum disorder or schizophrenia;	chr6:26402489	chr8:38600661~38601200:-
HNSC	trans	rs9467773	0.511	rs17278688	ENSG00000242375.1	RP11-498P14.3	5.59	3.77e-08	0.0471	0.32	0.25	Intelligence (multi-trait analysis);	chr6:26922357	chr9:97195351~97197687:-
HNSC	trans	rs17073641	0.553	rs11151150	ENSG00000214846.4	RP11-115L11.1	-5.59	3.78e-08	0.0471	-0.31	-0.25	Age-related macular degeneration (smoking status interaction);	chr18:64711747	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.534	rs12968955	ENSG00000214846.4	RP11-115L11.1	-5.59	3.78e-08	0.0471	-0.31	-0.25	Age-related macular degeneration (smoking status interaction);	chr18:64711795	chr4:15730962~15731627:-
HNSC	trans	rs17073641	0.553	rs4414591	ENSG00000214846.4	RP11-115L11.1	-5.59	3.78e-08	0.0471	-0.31	-0.25	Age-related macular degeneration (smoking status interaction);	chr18:64712039	chr4:15730962~15731627:-
HNSC	trans	rs804280	0.542	rs35647515	ENSG00000253893.2	FAM85B	-5.59	3.78e-08	0.0472	-0.29	-0.25	Myopia (pathological);	chr8:11934120	chr8:8167819~8226614:-
HNSC	trans	rs45509595	0.841	rs17751184	ENSG00000253570.1	RNF5P1	5.59	3.78e-08	0.0472	0.56	0.25	Breast cancer;	chr6:27807250	chr8:38600661~38601200:-
HNSC	trans	rs190945449	1	rs190945449	ENSG00000253570.1	RNF5P1	5.59	3.78e-08	0.0472	0.55	0.25	Urinary tract infection frequency;	chr6:26860580	chr8:38600661~38601200:-
HNSC	trans	rs2302190	0.882	rs2270098	ENSG00000273445.1	RP11-1399P15.1	5.59	3.79e-08	0.0472	0.29	0.25	Vitamin D levels;	chr17:58494720	chr2:87477495~87478034:-
HNSC	trans	rs7263120	0.818	rs8119788	ENSG00000228577.1	AC010731.2	-5.59	3.8e-08	0.0473	-0.34	-0.25	Blood protein levels;	chr20:23741987	chr2:206606497~206609812:-
HNSC	trans	rs45509595	0.556	rs34409918	ENSG00000176998.4	HCG4	-5.59	3.8e-08	0.0474	-0.48	-0.25	Breast cancer;	chr6:27717569	chr6:29791753~29792750:-
HNSC	trans	rs7746199	0.736	rs13212318	ENSG00000176998.4	HCG4	-5.59	3.8e-08	0.0474	-0.48	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:29791753~29792750:-
HNSC	trans	rs9329221	0.538	rs9650651	ENSG00000173295.6	FAM86B3P	5.59	3.81e-08	0.0475	0.28	0.25	Neuroticism;	chr8:10410030	chr8:8228595~8244865:+
HNSC	trans	rs853679	1	rs2799077	ENSG00000204622.9	HLA-J	-5.59	3.81e-08	0.0475	-0.42	-0.25	Depression;	chr6:28266819	chr6:30006583~30009956:+
HNSC	trans	rs6853410	0.951	rs537421	ENSG00000280331.1	RP11-545D22.1	5.59	3.83e-08	0.0477	0.38	0.25	Colorectal cancer;	chr4:81796242	chr11:36510361~36510537:+
HNSC	trans	rs9650657	0.615	rs11986845	ENSG00000173295.6	FAM86B3P	-5.59	3.84e-08	0.0478	-0.28	-0.25	Neuroticism;	chr8:10833808	chr8:8228595~8244865:+
HNSC	trans	rs4869931	0.929	rs55646755	ENSG00000228501.2	RPL15P18	5.59	3.84e-08	0.0479	0.31	0.25	Systolic blood pressure in sickle cell anemia;	chr6:150686708	chr13:100150481~100151092:-
HNSC	trans	rs7662987	1	rs17595424	ENSG00000228407.2	RP4-800M22.1	5.59	3.85e-08	0.0479	0.42	0.25	Smoking initiation;	chr4:99072718	chr1:52160261~52160600:-
HNSC	trans	rs9467711	0.606	rs9379851	ENSG00000176998.4	HCG4	-5.59	3.85e-08	0.0479	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26354552	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.606	rs9366655	ENSG00000176998.4	HCG4	-5.59	3.85e-08	0.0479	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26377157	chr6:29791753~29792750:-
HNSC	trans	rs9467711	0.79	rs1979	ENSG00000176998.4	HCG4	-5.59	3.85e-08	0.0479	-0.45	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26377363	chr6:29791753~29792750:-
HNSC	trans	rs9393777	0.92	rs13196692	ENSG00000176998.4	HCG4	-5.59	3.85e-08	0.0479	-0.5	-0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr6:29791753~29792750:-
HNSC	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-5.59	3.86e-08	0.048	-0.32	-0.25	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
HNSC	trans	rs1510510	0.69	rs12987751	ENSG00000238290.1	RP11-431K24.1	-5.59	3.87e-08	0.0481	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643588	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs6749837	ENSG00000238290.1	RP11-431K24.1	-5.59	3.87e-08	0.0481	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643591	chr1:8026738~8122702:+
HNSC	trans	rs1510510	0.69	rs6746826	ENSG00000238290.1	RP11-431K24.1	-5.59	3.87e-08	0.0481	-0.37	-0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643776	chr1:8026738~8122702:+
HNSC	trans	rs2005199	1	rs9807825	ENSG00000231119.2	RP4-569M23.2	-5.59	3.87e-08	0.0481	-0.63	-0.25	Blood protein levels;Carotid intima media thickness;	chr19:51516693	chr20:47352561~47354633:+
HNSC	trans	rs2005199	0.85	rs12461433	ENSG00000231119.2	RP4-569M23.2	-5.59	3.87e-08	0.0481	-0.63	-0.25	Blood protein levels;Carotid intima media thickness;	chr19:51517439	chr20:47352561~47354633:+
HNSC	trans	rs2005199	1	rs17239287	ENSG00000231119.2	RP4-569M23.2	-5.59	3.87e-08	0.0481	-0.63	-0.25	Blood protein levels;Carotid intima media thickness;	chr19:51518779	chr20:47352561~47354633:+
HNSC	trans	rs2005199	1	rs73559130	ENSG00000231119.2	RP4-569M23.2	-5.59	3.87e-08	0.0481	-0.63	-0.25	Blood protein levels;Carotid intima media thickness;	chr19:51518915	chr20:47352561~47354633:+
HNSC	trans	rs2005199	1	rs62116204	ENSG00000231119.2	RP4-569M23.2	-5.59	3.87e-08	0.0481	-0.63	-0.25	Blood protein levels;Carotid intima media thickness;	chr19:51521121	chr20:47352561~47354633:+
HNSC	trans	rs3096299	0.503	rs4785677	ENSG00000215030.5	RPL13P12	-5.59	3.87e-08	0.0481	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89488693	chr17:17383377~17384012:-
HNSC	trans	rs853679	0.882	rs3757188	ENSG00000204622.9	HLA-J	-5.59	3.87e-08	0.0481	-0.46	-0.25	Depression;	chr6:28139579	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.556	rs45509595	ENSG00000204622.9	HLA-J	-5.59	3.87e-08	0.0481	-0.56	-0.25	Depression;	chr6:27873148	chr6:30006583~30009956:+
HNSC	trans	rs8177876	0.658	rs16954505	ENSG00000224837.1	GCSHP5	5.59	3.87e-08	0.0481	0.45	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr1:168055901~168056422:-
HNSC	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	5.59	3.88e-08	0.0482	0.31	0.25	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
HNSC	trans	rs13023575	0.55	rs1456576	ENSG00000213005.3	PTTG3P	-5.59	3.88e-08	0.0482	-0.24	-0.25	Gait speed in old age;	chr2:40875568	chr8:66767400~66768005:-
HNSC	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	5.59	3.88e-08	0.0482	0.32	0.25	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
HNSC	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	5.59	3.89e-08	0.0483	0.32	0.25	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
HNSC	trans	rs7819412	0.805	rs2409710	ENSG00000254340.1	RP11-10A14.3	-5.59	3.89e-08	0.0483	-0.31	-0.25	Triglycerides;	chr8:11122311	chr8:9141424~9145435:+
HNSC	trans	rs7520050	0.831	rs61783169	ENSG00000255397.1	AC022182.2	5.59	3.9e-08	0.0484	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45790655	chr8:60937705~60939871:-
HNSC	trans	rs11250098	0.583	rs66724331	ENSG00000173295.6	FAM86B3P	-5.59	3.9e-08	0.0484	-0.27	-0.25	Morning vs. evening chronotype;	chr8:10931835	chr8:8228595~8244865:+
HNSC	trans	rs4864809	0.536	rs1351056	ENSG00000200152.1	RNU6-216P	5.59	3.91e-08	0.0485	0.27	0.25	Beard thickness;	chr4:53676941	chr11:74968189~74968292:-
HNSC	trans	rs4864809	0.557	rs1351055	ENSG00000200152.1	RNU6-216P	5.59	3.91e-08	0.0485	0.27	0.25	Beard thickness;	chr4:53676945	chr11:74968189~74968292:-
HNSC	trans	rs9733	0.596	rs12089989	ENSG00000180764.13	PIPSL	-5.59	3.91e-08	0.0485	-0.3	-0.25	Tonsillectomy;	chr1:150743306	chr10:93958191~93961540:-
HNSC	trans	rs2274459	0.841	rs13214874	ENSG00000225246.1	RPS2P1	5.59	3.91e-08	0.0485	0.33	0.25	Obesity (extreme);	chr6:33718591	chr20:34122470~34123290:+
HNSC	trans	rs2687481	0.718	rs1719106	ENSG00000227542.1	AC092614.2	-5.59	3.91e-08	0.0485	-0.38	-0.25	Hearing function;	chr7:126292821	chr2:191229165~191246172:-
HNSC	trans	rs722599	0.683	rs11848876	ENSG00000181227.3	RP4-682C21.2	-5.59	3.91e-08	0.0485	-0.26	-0.25	IgG glycosylation;	chr14:74757923	chr1:75743423~75744776:-
HNSC	trans	rs11760067	0.858	rs113376209	ENSG00000274425.1	AC114271.2	5.59	3.91e-08	0.0485	0.51	0.25	Coronary artery calcification;	chr6:134756048	chr19:10333436~10336248:+
HNSC	trans	rs853679	0.607	rs13199906	ENSG00000204622.9	HLA-J	-5.59	3.91e-08	0.0485	-0.55	-0.25	Depression;	chr6:27866361	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs17763089	ENSG00000204622.9	HLA-J	-5.59	3.91e-08	0.0485	-0.55	-0.25	Depression;	chr6:27867440	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.546	rs17695758	ENSG00000204622.9	HLA-J	-5.59	3.91e-08	0.0485	-0.55	-0.25	Depression;	chr6:27869405	chr6:30006583~30009956:+
HNSC	trans	rs17073641	0.553	rs118091090	ENSG00000214846.4	RP11-115L11.1	-5.59	3.91e-08	0.0486	-0.31	-0.25	Age-related macular degeneration (smoking status interaction);	chr18:64709214	chr4:15730962~15731627:-
HNSC	trans	rs4343996	0.902	rs4722710	ENSG00000224750.5	RP11-94M14.2	5.59	3.91e-08	0.0486	0.26	0.25	Motion sickness;	chr7:3348622	chr10:90454170~90502968:+
HNSC	trans	rs4343996	0.87	rs6974075	ENSG00000224750.5	RP11-94M14.2	5.59	3.91e-08	0.0486	0.26	0.25	Motion sickness;	chr7:3352439	chr10:90454170~90502968:+
HNSC	trans	rs7824557	0.564	rs34964435	ENSG00000254340.1	RP11-10A14.3	-5.59	3.92e-08	0.0486	-0.29	-0.25	Retinal vascular caliber;	chr8:11372697	chr8:9141424~9145435:+
HNSC	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-5.59	3.93e-08	0.0487	-0.32	-0.25	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
HNSC	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-5.59	3.93e-08	0.0487	-0.32	-0.25	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
HNSC	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-5.59	3.93e-08	0.0487	-0.32	-0.25	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
HNSC	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-5.59	3.93e-08	0.0487	-0.32	-0.25	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
HNSC	trans	rs853679	0.769	rs17720293	ENSG00000271581.1	XXbac-BPG248L24.12	-5.59	3.94e-08	0.0488	-0.44	-0.25	Depression;	chr6:28246920	chr6:31356647~31357637:+
HNSC	trans	rs7200786	0.567	rs6498166	ENSG00000183935.5	HTR7P1	-5.59	3.94e-08	0.0488	-0.27	-0.25	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11120259	chr12:13000420~13004830:+
HNSC	trans	rs2950393	0.804	rs7295862	ENSG00000228224.3	NACAP1	-5.59	3.94e-08	0.0488	-0.28	-0.25	Platelet distribution width;	chr12:56775374	chr8:101361794~101372707:+
HNSC	trans	rs589756	1	rs676056	ENSG00000227260.1	AC116035.1	5.59	3.94e-08	0.0488	0.37	0.25	Obesity-related traits;	chr6:132321520	chr3:30524745~30527185:+
HNSC	trans	rs853679	0.607	rs13199772	ENSG00000204622.9	HLA-J	-5.59	3.95e-08	0.0489	-0.55	-0.25	Depression;	chr6:27866307	chr6:30006583~30009956:+
HNSC	trans	rs7200786	0.546	rs6498161	ENSG00000183935.5	HTR7P1	-5.59	3.96e-08	0.049	-0.28	-0.25	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118682	chr12:13000420~13004830:+
HNSC	trans	rs804280	0.543	rs13261205	ENSG00000253893.2	FAM85B	-5.59	3.96e-08	0.0491	-0.29	-0.25	Myopia (pathological);	chr8:11933707	chr8:8167819~8226614:-
HNSC	trans	rs10435719	0.867	rs34465618	ENSG00000253893.2	FAM85B	-5.59	3.96e-08	0.0491	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:8167819~8226614:-
HNSC	trans	rs10435719	0.867	rs34583868	ENSG00000253893.2	FAM85B	-5.59	3.96e-08	0.0491	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:8167819~8226614:-
HNSC	trans	rs804280	0.518	rs34266352	ENSG00000253893.2	FAM85B	-5.59	3.96e-08	0.0491	-0.29	-0.25	Myopia (pathological);	chr8:11933953	chr8:8167819~8226614:-
HNSC	trans	rs804280	0.542	rs36100659	ENSG00000253893.2	FAM85B	-5.59	3.96e-08	0.0491	-0.29	-0.25	Myopia (pathological);	chr8:11934144	chr8:8167819~8226614:-
HNSC	trans	rs853679	0.607	rs34243448	ENSG00000204622.9	HLA-J	-5.59	3.96e-08	0.0491	-0.56	-0.25	Depression;	chr6:28225324	chr6:30006583~30009956:+
HNSC	trans	rs853679	0.607	rs34788973	ENSG00000228078.1	HLA-U	-5.59	3.97e-08	0.0491	-0.56	-0.25	Depression;	chr6:27911422	chr6:29934101~29934286:+
HNSC	trans	rs853679	0.607	rs61742093	ENSG00000228078.1	HLA-U	-5.59	3.97e-08	0.0491	-0.56	-0.25	Depression;	chr6:27912204	chr6:29934101~29934286:+
HNSC	trans	rs3771317	0.941	rs1558471	ENSG00000226068.1	HNRNPA3P4	5.59	3.97e-08	0.0491	0.38	0.25	Primary biliary cholangitis;	chr2:190642047	chr6:48149203~48150005:-
HNSC	trans	rs9650657	0.707	rs4593498	ENSG00000253893.2	FAM85B	5.58	3.98e-08	0.0492	0.3	0.25	Neuroticism;	chr8:10797960	chr8:8167819~8226614:-
HNSC	trans	rs9647570	0.925	rs7730283	ENSG00000225532.1	XX-C2158C6.3	-5.58	3.98e-08	0.0493	-0.33	-0.25	Menarche (age at onset);	chr5:167946650	chr6:170736173~170737777:-
HNSC	trans	rs867371	0.929	rs7173852	ENSG00000259295.5	CSPG4P12	-5.58	3.98e-08	0.0493	-0.31	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:85191438~85213905:+
HNSC	trans	rs702485	0.712	rs836551	ENSG00000249936.3	RAC1P2	5.58	3.99e-08	0.0493	0.29	0.25	HDL cholesterol levels;HDL cholesterol;	chr7:6402168	chr4:46723830~46724408:-
HNSC	trans	rs73108077	0.736	rs56047717	ENSG00000279352.1	RP11-411B10.7	5.58	3.99e-08	0.0494	0.44	0.25	Red blood cell density in sickle cell anemia;	chr20:31279756	chr18:14010054~14010917:+
HNSC	trans	rs7647973	0.626	rs9824435	ENSG00000197582.5	GPX1P1	-5.58	3.99e-08	0.0494	-0.41	-0.25	Menarche (age at onset);	chr3:49636910	chrX:13378735~13379340:-
HNSC	trans	rs7647973	0.626	rs2131108	ENSG00000197582.5	GPX1P1	5.58	4e-08	0.0494	0.42	0.25	Menarche (age at onset);	chr3:49627957	chrX:13378735~13379340:-
HNSC	trans	rs6754640	0.582	rs7598402	ENSG00000276223.1	RP4-781B1.5	-5.58	4e-08	0.0495	-0.29	-0.25	Temperament;	chr2:50508805	chr20:44746642~44747201:+
HNSC	trans	rs9914988	0.887	rs2070265	ENSG00000243964.1	RP11-16F15.1	-5.58	4e-08	0.0495	-0.25	-0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28748405	chr11:9606142~9606609:+
HNSC	trans	rs722599	0.715	rs12147629	ENSG00000181227.3	RP4-682C21.2	5.58	4e-08	0.0495	0.26	0.25	IgG glycosylation;	chr14:74840885	chr1:75743423~75744776:-
HNSC	trans	rs853679	0.607	rs13201308	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28162311	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs34505829	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28165461	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs35098436	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28166443	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs72846794	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28169721	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.607	rs13217984	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28171932	chr6:30259584~30293014:+
HNSC	trans	rs853679	0.505	rs35781323	ENSG00000243753.4	HLA-L	-5.58	4e-08	0.0495	-0.58	-0.25	Depression;	chr6:28177054	chr6:30259584~30293014:+
HNSC	trans	rs4646450	0.838	rs1589739	ENSG00000228834.1	RP11-249L21.4	5.58	4e-08	0.0495	0.38	0.25	Blood metabolite levels;	chr7:99588124	chr6:108907615~108907873:-
HNSC	trans	rs864643	0.625	rs7613883	ENSG00000183298.5	RP11-556K13.1	5.58	4.01e-08	0.0495	0.4	0.25	Attention deficit hyperactivity disorder;	chr3:39476825	chr1:101786340~101787219:-
HNSC	trans	rs7520050	0.966	rs10890383	ENSG00000255397.1	AC022182.2	5.58	4.01e-08	0.0496	0.32	0.25	Reticulocyte count;Red blood cell count;	chr1:46122831	chr8:60937705~60939871:-
HNSC	trans	rs16975963	0.644	rs111694872	ENSG00000247498.8	RP11-392P7.6	5.58	4.02e-08	0.0497	0.41	0.25	Longevity;	chr19:37555429	chr12:12927726~12984645:+
HNSC	trans	rs3808502	0.527	rs2736389	ENSG00000173295.6	FAM86B3P	5.58	4.02e-08	0.0497	0.31	0.25	Neuroticism;	chr8:11303801	chr8:8228595~8244865:+
HNSC	trans	rs864643	0.513	rs481523	ENSG00000183298.5	RP11-556K13.1	5.58	4.02e-08	0.0497	0.4	0.25	Attention deficit hyperactivity disorder;	chr3:39477849	chr1:101786340~101787219:-
HNSC	trans	rs16975963	0.644	rs73031322	ENSG00000247498.8	RP11-392P7.6	5.58	4.02e-08	0.0497	0.41	0.25	Longevity;	chr19:37549977	chr12:12927726~12984645:+
HNSC	trans	rs16975963	0.644	rs73031326	ENSG00000247498.8	RP11-392P7.6	5.58	4.02e-08	0.0497	0.41	0.25	Longevity;	chr19:37552120	chr12:12927726~12984645:+
HNSC	trans	rs7113874	0.527	rs12790154	ENSG00000266891.1	RP11-692N5.2	5.58	4.02e-08	0.0497	0.38	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8383601	chr18:9734882~9735602:-
HNSC	trans	rs74902201	1	rs16960009	ENSG00000280434.1	RP4-671O14.6	5.58	4.03e-08	0.0498	0.49	0.25	Food addiction;	chr17:66684984	chr22:44139365~44153626:+
HNSC	trans	rs638893	0.636	rs583213	ENSG00000211683.3	KB-1572G7.3	-5.58	4.04e-08	0.05	-0.35	-0.25	Vitiligo;	chr11:118798469	chr22:23630618~23638941:-